1	1	T cell	[T cell]	955.2842105263157	2	959	706	190
2	2	transcription factor	[transcription factor]	834.825	2	837	696	320
3	3	NF-kappa b	[NF-kappa B]	498.4121621621622	2	501	383	148
4	4	nf-kappa b	[NF-kappa B]	429.54761904761904	2	432	309	126
5	5	cell	[cell]	419.6542857142858	1	4199	2838	1155
6	6	kappa b	[kappa B]	338.2162162162162	2	340	198	111
7	7	b cell	[B cell]	319.1	2	322	232	80
8	8	cell line	[cell line]	318.2307692307692	2	320	276	156
9	9	nuclear factor	[nuclear factor]	264.0657894736842	2	266	147	76
10	10	T lymphocyte	[T lymphocyte]	258.64516129032256	2	262	208	62
11	11	gene expression	[gene expression]	229.29166666666666	2	232	195	72
12	12	T	[T]	199.3246212121212	1	1997	991	264
13	13	human T	[human T]	196.44117647058823	2	198	53	34
14	14	mobility shift assay	[mobility shift assay]	189.2269118916536	3	126	119	18
15	15	tumor necrosis factor	[tumor necrosis factor]	176.88181508048103	3	114	84	35
16	16	protein kinase	[protein kinase]	175.84615384615384	2	178	168	78
17	17	gene	[gene]	174.52779329608938	1	1747	1233	716
18	18	transcription	[transcription]	162.53494809688584	1	1628	766	289
19	19	human immunodeficiency virus	[human immunodeficiency virus]	160.8510515017585	3	104	88	35
20	20	human monocyte	[human monocyte]	158.05555555555554	2	162	71	18
21	21	glucocorticoid receptor	[glucocorticoid receptor]	157.8695652173913	2	160	98	46
22	22	protein	[protein]	151.93080985915492	1	1521	961	568
23	23	expression	[expression]	151.10096774193548	1	1515	1237	310
24	24	tyrosine phosphorylation	[tyrosine phosphorylation]	150.53846153846155	2	153	128	52
25	25	Jurkat T cell	[Jurkat T cells]	148.09493366113304	3	96	41	16
26	26	blood mononuclear cell	[blood mononuclear cell]	144.6278281908055	3	95	90	24
27	27	human T cell	[Human T cell]	141.1182683677801	3	91	55	28
28	28	immunodeficiency virus type	[immunodeficiency virus type]	132.50286506028866	3	88	88	20
29	29	human immunodeficiency virus type	[human immunodeficiency virus type]	132.11794559582782	4	88	65	14
30	30	electrophoretic mobility shift assay	[electrophoretic mobility shift assay]	131.69597505992152	4	86	32	11
31	31	protein kinase c	[protein kinase C]	131.49528175625878	3	85	57	28
32	32	binding site	[binding site]	130.1864406779661	2	132	107	59
33	33	tumor necrosis	[tumor necrosis]	129.76666666666668	2	134	127	30
34	34	immunodeficiency virus	[immunodeficiency virus]	127.21739130434783	2	130	128	46
35	35	activation	[activation]	125.79333333333335	1	1262	976	240
36	36	DNA binding	[DNA binding]	121.18032786885246	2	123	111	61
37	37	peripheral blood mononuclear cell	[peripheral blood mononuclear cell]	119.94996205457711	4	78	58	25
38	38	T cell activation	[T cell activation]	117.62090136930688	3	76	34	19
39	39	binding	[binding]	117.0822966507177	1	1173	910	418
40	40	transcriptional activation	[transcriptional activation]	112.26923076923077	2	115	71	26
41	41	factor of T cell	[factor of T cells]	111.11421320845159	4	74	74	19
42	42	cell cycle	[cell cycle]	110.13157894736842	2	112	71	38
43	43	MHC class ii	[MHC class II]	109.92481859840278	3	71	51	31
44	44	immune response	[immune response]	109.30555555555556	2	111	61	36
45	45	b lymphocyte	[B lymphocyte]	107.57142857142857	2	110	68	28
46	46	nuclear extract	[nuclear extract]	106.80645161290323	2	109	68	31
47	47	b	[B]	105.03066666666666	1	1053	606	225
48	48	important role	[important role]	104.6842105263158	2	109	82	19
49	49	class ii	[class II]	104.55319148936171	2	106	68	47
50	50	nf-kappa b activation	[NF-kappa B activation]	104.524105968611	3	68	39	19
51	51	Jurkat T	[Jurkat T]	102.70588235294117	2	109	107	17
52	52	expression of gene	[expression of genes]	102.16582605999885	3	66	57	37
53	53	endothelial cell	[endothelial cell]	101.76923076923077	2	104	58	26
54	54	signal pathway	[signaling pathway]	98.52941176470588	2	100	75	51
55	55	human immunodeficiency	[human immunodeficiency]	98.5	2	101	20	8
56	56	high level	[high level]	97.33333333333333	2	101	88	24
57	57	T cell line	[T cell line]	97.23135340962479	3	63	43	26
58	58	phorbol ester	[phorbol ester]	97.11111111111111	2	99	51	27
59	59	Epstein-Barr virus	[Epstein-Barr virus]	91.07317073170732	2	93	79	41
60	60	effect	[effect]	90.20114068441065	1	905	786	263
61	61	human T lymphocyte	[human T lymphocyte]	89.00815727734071	3	58	35	19
62	62	receptor	[receptor]	87.93470437017996	1	881	643	389
63	63	signal transduction	[signal transduction]	85.83333333333333	2	88	65	30
64	64	monocytic cell	[monocytic cell]	83.91666666666667	2	88	49	12
65	65	transcriptional activity	[transcriptional activity]	83.15	2	86	57	20
66	66	MHC class	[MHC class]	82.58823529411765	2	85	82	34
67	67	cell surface	[cell surface]	82.52	2	84	74	50
68	68	human cell	[human cell]	82.36585365853658	2	84	67	41
69	69	nf-kappab activation	[NF-kappaB activation]	79.92	2	82	52	25
70	70	NF-kappa b activation	[NF-kappa B activation]	79.73580580551048	3	52	22	13
71	71	t-cell leukemia virus type	[T-cell leukemia virus type]	79.00428465133149	4	54	54	13
72	72	factor	[factor]	78.98355704697987	1	792	645	298
73	73	human b	[human B]	78.5	2	80	12	8
74	74	role	[role]	76.72769230769231	1	771	726	195
75	75	regulatory element	[regulatory element]	76.14285714285714	2	78	65	35
76	76	signal	[signaling]	75.83857677902623	1	760	431	267
77	77	tumor necrosis factor-alpha	[tumor necrosis factor-alpha]	75.48383909684507	3	50	38	16
78	78	NK cell	[NK cell]	75.1875	2	78	45	16
79	79	long terminal repeat	[long terminal repeat]	74.3263993759237	3	49	40	19
80	80	molecular mechanism	[molecular mechanism]	74.29411764705883	2	77	46	17
81	81	promoter	[promoter]	73.24290540540541	1	734	465	296
82	82	result	[result]	73.05254237288135	1	733	146	59
83	83	peripheral blood lymphocyte	[peripheral blood lymphocytes]	72.37995419959947	3	48	35	15
84	84	cell type	[cell type]	72.25	2	74	56	32
85	85	Jurkat cell	[Jurkat cell]	71.0	2	74	36	12
86	86	signal transduction pathway	[signal transduction pathway]	70.8830451711406	3	46	23	18
87	87	breast cancer	[breast cancer]	69.92857142857143	2	72	58	28
88	88	amino acid	[amino acid]	69.79310344827586	2	71	70	58
89	89	promoter activity	[promoter activity]	69.11538461538461	2	71	49	26
90	90	NF-kappa	[NF-kappa]	68.82758620689656	1	694	332	58
91	91	NF kappa b	[NF kappa B]	68.5760441978687	3	45	26	15
92	92	blood mononuclear	[blood mononuclear]	66.45454545454545	2	72	61	11
93	93	nuclear translocation	[nuclear translocation]	65.875	2	69	50	16
94	94	hiv-1 replication	[HIV-1 replication]	65.78571428571429	2	68	31	14
95	95	acute leukemia	[acute leukemia]	65.55882352941177	2	67	49	34
96	96	mobility shift	[mobility shift]	65.07142857142857	2	70	69	14
97	97	monocyte	[monocyte]	63.59159663865546	1	639	367	119
98	98	u937 cell	[U937 cell]	63.15384615384615	2	65	48	26
99	99	cytokine	[cytokine]	63.12011494252874	1	633	313	174
100	100	factor kappa b	[factor kappa B]	62.65263532262453	3	42	42	17
101	101	patient	[patient]	62.258241758241766	1	625	440	182
102	102	level	[level]	61.98676470588236	1	624	562	136
103	103	mononuclear leukocyte	[mononuclear leukocyte]	61.5	2	64	50	20
104	104	DNA	[DNA]	61.43262032085562	1	616	313	187
105	105	response	[response]	61.42700729927008	1	618	511	137
106	106	signal transducer	[signal transducer]	61.375	2	64	42	16
107	107	kappa	[kappa]	61.252040816326534	1	617	439	98
108	108	blot analysis	[blot analysis]	60.90909090909091	2	67	67	11
109	109	phorbol 12-myristate 13-acetate	[phorbol 12-myristate 13-acetate]	60.756895860977664	3	41	24	9
110	110	monocytic cell line	[monocytic cell line]	60.41504120395937	3	40	32	17
111	111	activity	[activity]	60.239226519337016	1	605	472	181
112	112	DNA binding activity	[DNA binding activity]	59.964414610617084	3	40	26	12
113	113	b cell line	[B cell line]	59.64464147450666	3	39	26	19
114	114	thp-1 cell	[THP-1 cells]	58.529411764705884	2	61	42	17
115	115	Northern blot analysis	[Northern blot analysis]	58.11529169310906	3	39	7	3
116	116	cell death	[cell death]	58.05263157894737	2	60	37	19
117	117	myeloid cell	[myeloid cell]	56.5	2	58	27	18
118	118	lymphoid cell	[lymphoid cell]	56.470588235294116	2	58	26	17
119	119	transcriptional regulation	[transcriptional regulation]	56.38461538461539	2	59	34	13
120	120	low level	[low level]	56.35	2	59	53	20
121	121	electrophoretic mobility	[electrophoretic mobility]	56.25	2	59	22	8
122	122	blood lymphocyte	[blood lymphocyte]	56.2	2	60	57	15
123	123	nuclear factor kappa b	[nuclear factor kappa B]	56.13408856720761	4	38	31	12
124	124	HeLa cell	[HeLa cells]	55.857142857142854	2	59	22	7
125	125	cell adhesion	[cell adhesion]	55.5	2	58	55	22
126	126	differentiation	[differentiation]	55.30472440944882	1	556	375	127
127	127	tumor necrosis factor alpha	[tumor necrosis factor alpha]	54.99819877502413	4	37	23	10
128	128	cytokine gene	[cytokine gene]	54.8	2	57	55	25
129	129	number of receptor	[number of receptors]	54.71894347727802	3	36	31	21
130	130	monocytic differentiation	[monocytic differentiation]	54.07142857142857	2	56	27	14
131	131	immune system	[immune system]	54.0	2	57	33	11
132	132	induction	[induction]	53.79772727272728	1	543	442	88
133	133	activation of NF-kappa b	[activation of NF-kappa B]	53.09624377415874	4	35	15	10
134	134	blood cell	[blood cell]	53.03703703703704	2	55	53	27
135	135	human b cell	[human B cell]	52.83208335737188	3	35	20	12
136	136	erythroid differentiation	[erythroid differentiation]	52.72727272727273	2	55	25	11
137	137	NF-kappa B	[NF-kappa B]	52.714285714285715	2	54	18	14
138	138	type ii	[type II]	51.89473684210526	2	53	21	19
139	139	cd4+ T cell	[CD4+ T cells]	51.82827377358181	3	35	23	10
140	140	blood monocyte	[blood monocyte]	51.1764705882353	2	54	48	17
141	141	IL-2 promoter	[IL-2 promoter]	51.125	2	55	31	8
142	142	peripheral blood monocyte	[peripheral blood monocytes]	51.07101391212615	3	35	25	9
143	143	mechanism	[mechanism]	50.75370370370371	1	510	399	162
144	144	human t-cell	[human T-cell]	50.63636363636363	2	52	15	11
145	145	promoter region	[promoter region]	50.57142857142857	2	52	30	21
146	146	nuclear factor of T cell	[nuclear factor of T cells]	50.125	5	52	30	16
147	147	reporter gene	[reporter gene]	50.0	2	52	40	20
148	148	factor-kappa b	[factor-kappa B]	49.55	2	52	49	20
149	149	terminal repeat	[terminal repeat]	49.46666666666667	2	53	53	15
150	150	lymphocyte	[lymphocyte]	49.41111111111111	1	496	289	153
151	151	adhesion molecule	[adhesion molecule]	49.18181818181818	2	51	40	22
152	152	stat protein	[Stat protein]	49.15	2	51	37	20
153	153	gene transcription	[gene transcription]	49.13636363636363	2	51	41	22
154	154	present study	[present study]	49.0	2	50	1	1
155	155	k562 cell	[K562 cell]	48.86666666666667	2	51	32	15
156	156	transcription of gene	[transcription of genes]	48.60551668878213	3	32	28	21
157	157	transgenic mouse	[transgenic mice]	48.4	2	50	24	15
158	158	nf-kappa b activity	[NF-kappa B activity]	48.158475983450515	3	32	21	13
159	159	nuclear protein	[nuclear protein]	47.75	2	49	30	24
160	160	t-cell activation	[T-cell activation]	47.625	2	49	22	16
161	161	inhibitory effect	[inhibitory effect]	47.36363636363637	2	51	40	11
162	162	nuclear factor-kappa b	[nuclear factor-kappa B]	46.65733361497904	3	31	25	16
163	163	blood	[blood]	46.35	1	466	220	88
164	164	dna-binding activity	[DNA-binding activity]	46.294117647058826	2	48	29	17
165	165	human t-cell leukemia virus type	[human T-cell leukemia virus type]	46.0	5	49	27	9
166	166	study	[study]	45.91294117647059	1	462	244	85
167	167	regulation	[regulation]	45.654216867469884	1	461	370	83
168	168	Electrophoretic mobility shift assay	[Electrophoretic mobility shift assay]	45.6469200207693	4	31	11	5
169	169	t-cell	[T-cell]	45.63037037037037	1	458	229	135
170	170	transcription start site	[transcription start site]	45.3695515831431	3	31	19	8
171	171	monoclonal antibody	[monoclonal antibody]	44.89655172413793	2	46	32	29
172	172	zinc finger	[zinc finger]	44.61538461538461	2	46	36	26
173	173	erythroid cell	[erythroid cells]	44.588235294117645	2	46	24	17
174	174	t-cell leukemia	[T-cell leukemia]	44.5625	2	47	39	16
175	175	tyrosine kinase	[tyrosine kinase]	44.5	2	46	33	22
176	176	cd4+ T	[CD4+ T]	44.294117647058826	2	47	46	17
177	177	growth factor	[growth factor]	43.80769230769231	2	45	31	26
178	178	retinoic acid	[retinoic acid]	43.69230769230769	2	46	30	13
179	179	immunodeficiency virus type hiv-1	[immunodeficiency virus type HIV-1]	43.674522242094085	4	31	31	9
180	180	activator of transcription	[activator of transcription]	43.51442501979901	3	29	17	11
181	181	cyclosporin a	[cyclosporin A]	43.42857142857143	2	45	22	14
182	182	il-2	[IL-2]	43.01634615384616	1	432	191	104
183	183	normal T cell	[normal T cell]	42.79398751947122	3	29	20	10
184	184	t-cell line	[T-cell line]	42.65384615384615	2	44	35	26
185	185	heat shock	[heat shock]	42.64	2	44	34	25
186	186	peripheral blood	[peripheral blood]	42.54545454545455	2	45	27	11
187	187	hiv-1	[HIV-1]	42.49619047619048	1	427	214	105
188	188	cell proliferation	[cell proliferation]	41.76923076923077	2	44	29	13
189	189	copyright Academic press.	[Copyright Academic Press.]	41.20902501875006	3	26	0	0
190	190	cytokine production	[cytokine production]	41.142857142857146	2	43	26	14
191	191	leukemic cell	[leukemic cell]	41.07142857142857	2	43	27	14
192	192	human immunodeficiency virus hiv	[human immunodeficiency virus HIV]	41.06493751868451	4	27	12	11
193	193	DNA sequence	[DNA sequence]	40.827586206896555	2	42	34	29
194	194	human cell line	[human cell line]	40.515603924684555	3	27	23	16
195	195	mrna	[mRNA]	40.45952380952381	1	406	295	210
196	196	T cell receptor	[T cell receptor]	40.41654376838949	3	27	18	12
197	197	cell growth	[cell growth]	40.333333333333336	2	42	30	18
198	198	estrogen receptor	[estrogen receptor]	40.05555555555556	2	42	35	18
199	199	tumor	[tumor]	39.6659793814433	1	399	227	97
200	200	blood T	[blood T]	39.55555555555556	2	44	40	9
201	201	U937 cell	[U937 cell]	39.54545454545455	2	42	27	11
202	202	human lymphocyte	[human lymphocyte]	39.27272727272727	2	41	19	11
203	203	protein tyrosine kinase	[protein tyrosine kinase]	39.058004482057065	3	26	19	14
204	204	nf-kappab	[NF-kappaB]	39.00973451327434	1	392	215	113
205	205	immunodeficiency virus hiv	[immunodeficiency virus HIV]	38.514588767524096	3	27	27	10
206	206	hematopoietic cell	[hematopoietic cell]	38.46153846153846	2	40	20	13
207	207	alpha	[alpha]	38.04329896907216	1	382	304	194
208	208	immunodeficiency virus type 1	[immunodeficiency virus type 1]	38.03910001730775	4	30	30	5
209	208	transcription factor ap-1	[transcription factor AP-1]	38.03910001730775	3	26	12	6
210	209	regulation of gene expression	[regulation of gene expression]	37.862993072783176	4	25	10	9
211	210	Epstein-Barr virus EBV	[Epstein-Barr virus EBV]	37.79525963258142	3	25	15	13
212	210	number of glucocorticoid receptor	[number of glucocorticoid receptors]	37.79525963258142	4	25	15	13
213	211	tyrosine	[tyrosine]	37.791818181818186	1	380	229	110
214	212	human monocytic cell	[human monocytic cells]	37.77493960052089	3	25	7	6
215	213	IL-2	[IL-2]	37.526760563380286	1	377	123	71
216	214	mechanism of action	[mechanism of action]	37.33467223920946	3	25	13	9
217	215	nf-kappa	[NF-kappa]	37.23548387096775	1	376	226	62
218	216	constitutive expression	[constitutive expression]	37.125	2	41	31	8
219	216	il-2 production	[IL-2 production]	37.125	2	39	30	16
220	217	transcriptional activator	[transcriptional activator]	36.529411764705884	2	38	25	17
221	218	long repeat	[long repeat]	36.357142857142854	2	39	37	14
222	219	leukemia cell	[leukemia cell]	36.333333333333336	2	38	35	21
223	220	ap-1	[AP-1]	35.98831168831169	1	362	163	77
224	221	T cell proliferation	[T cell proliferation]	35.82015251629814	3	24	14	10
225	222	apoptosis	[apoptosis]	35.1219512195122	1	353	146	82
226	223	lps	[LPS]	35.11358024691358	1	353	151	81
227	224	control	[control]	34.983695652173914	1	352	199	92
228	225	kappa b alpha	[kappa B alpha]	34.747254823502274	3	23	14	13
229	226	enhancer element	[enhancer element]	34.72727272727273	2	36	28	22
230	227	natural killer cell	[natural killer cell]	34.69306807134087	3	23	10	9
231	228	inhibition	[inhibition]	34.69130434782609	1	350	284	92
232	229	activation of T cell	[activation of T cells]	34.671054703275296	4	23	9	8
233	230	T cell response	[T cell response]	34.552182515721206	3	23	18	15
234	231	region	[region]	34.54093567251462	1	347	272	171
235	232	protein synthesis	[protein synthesis]	34.416666666666664	2	37	31	12
236	233	nf kappa b	[NF kappa B]	34.18990537269923	3	24	17	7
237	234	epithelial cell	[epithelial cell]	34.15384615384615	2	36	24	13
238	235	hl-60 cell	[HL-60 cells]	34.142857142857146	2	36	26	14
239	236	progenitor cell	[progenitor cell]	34.05882352941177	2	36	33	17
240	237	natural killer	[natural killer]	33.5	2	36	15	6
241	238	hiv replication	[HIV replication]	33.42857142857143	2	35	22	14
242	239	mrna level	[mRNA level]	33.375	2	35	26	16
243	240	critical role	[critical role]	33.333333333333336	2	36	32	12
244	241	peripheral blood cell	[peripheral blood cell]	32.78891173366892	3	22	21	16
245	242	induction of apoptosis	[induction of apoptosis]	32.57978473704599	3	22	13	9
246	243	intercellular adhesion molecule-1	[intercellular adhesion molecule-1]	32.563775014816486	3	22	16	11
247	244	polymerase chain reaction	[polymerase chain reaction]	32.4917312647837	3	22	15	10
248	245	human blood mononuclear cell	[human blood mononuclear cells]	32.35965105639028	4	22	19	12
249	246	datum	[data.]	32.244	1	324	39	25
250	247	least in part,	[least in part,]	32.17473876463947	3	22	17	10
251	248	all-tran retinoic acid	[all-trans retinoic acid]	32.05146390347227	3	22	16	9
252	249	cell types.	[cell types.]	31.9	2	35	31	10
253	250	cis-acting element	[cis-acting element]	31.772727272727273	2	33	27	22
254	251	transcription factor nf-kappa b	[transcription factor NF-kappa B]	31.699250014423125	4	21	5	5
255	251	phorbol myristate acetate	[phorbol myristate acetate]	31.699250014423125	3	23	9	3
256	251	western blot analysis	[Western blot analysis]	31.699250014423125	3	22	6	3
257	252	virus	[virus]	31.558333333333334	1	318	232	96
258	253	human mononuclear leukocyte	[human mononuclear leukocyte]	31.55516251435757	3	21	12	11
259	254	granulocyte-macrophage colony-stimulating factor	[granulocyte-macrophage colony-stimulating factor]	31.50112970183298	3	22	17	8
260	255	sequence	[sequence]	31.450694444444448	1	316	215	144
261	256	T cell development	[T cell development]	31.30300938924284	3	21	10	8
262	257	tumor cell	[tumor cell]	31.266666666666666	2	33	26	15
263	258	role in the regulation	[role in the regulation]	31.22376126420678	4	21	13	10
264	259	calcium ionophore	[calcium ionophore]	31.22222222222222	2	33	16	9
265	260	bone marrow	[bone marrow]	31.09090909090909	2	33	21	11
266	261	transcription initiation site	[transcription initiation site]	30.906768764062548	3	23	14	4
267	262	dna-binding protein	[DNA-binding protein]	30.866666666666667	2	32	17	15
268	263	increase	[increase]	30.823762376237624	1	311	279	101
269	264	Electrophoretic mobility	[Electrophoretic mobility]	30.75	2	39	33	4
270	265	transcription factor nf-kappab	[transcription factor NF-kappaB]	30.642608347275686	3	21	10	6
271	266	human leukocyte	[human leukocyte]	30.63157894736842	2	32	26	19
272	267	human blood monocyte	[human blood monocytes]	30.56713394247944	3	22	19	7
273	268	nuclear factor kappab	[nuclear factor kappaB]	30.431280013846198	3	21	18	10
274	268	peripheral blood T cell	[peripheral blood T cells]	30.431280013846198	4	22	14	5
275	269	hiv-1 terminal repeat	[HIV-1 terminal repeat]	30.258375013767527	3	21	21	11
276	270	long terminal repeat LTR	[long terminal repeat LTR]	30.11428751370197	4	22	15	5
277	271	normal cell	[normal cells]	29.928571428571427	2	31	15	14
278	272	leukemia cell line	[leukemia cell line]	29.58596668012825	3	20	20	15
279	273	mouse	[mouse]	29.52467532467533	1	297	135	77
280	274	suggest a role	[suggesting a role]	29.50468655188614	3	20	18	13
281	275	leukemia	[leukemia]	29.43975903614458	1	297	216	83
282	276	gel mobility shift assay	[gel mobility shift assay]	29.32180626334139	4	20	6	4
283	276	electrophoretic mobility shift	[electrophoretic mobility shift]	29.32180626334139	3	22	21	6
284	277	presence	[presence]	29.28461538461539	1	312	249	13
285	278	hiv	[HIV]	28.933333333333334	1	291	130	78
286	279	oxidative stress	[oxidative stress]	28.8	2	30	12	10
287	280	cell activation	[cell activation]	28.772727272727273	2	30	27	22
288	281	activation domain	[activation domain]	28.727272727272727	2	31	25	11
289	282	nuclear factor-kappaB	[nuclear factor-kappaB]	28.666666666666668	2	30	16	12
290	283	kappa b site	[kappa B site]	28.529325012980813	3	19	8	8
291	284	androgen receptor	[androgen receptor]	28.5	2	30	30	20
292	285	jurkat cell	[Jurkat cells]	28.333333333333332	2	30	15	9
293	286	element	[element]	28.331205673758866	1	285	238	141
294	287	two transcription factor	[two transcription factors]	28.331204700390668	3	19	18	16
295	288	stimulation	[stimulation]	28.292105263157897	1	286	234	76
296	289	alveolar macrophage	[alveolar macrophages]	28.285714285714285	2	30	12	7
297	290	lymphoblastoid cell line	[lymphoblastoid cell line]	28.26516459619395	3	19	14	12
298	291	transcriptional level	[transcriptional level]	28.25	2	30	7	4
299	292	level of expression	[level of expression]	28.17711112393167	3	19	11	9
300	293	hiv-1 LTR	[HIV-1 LTR]	28.166666666666668	2	30	11	6
301	294	human b lymphocyte	[human B lymphocytes]	28.076478584203343	3	19	9	7
302	295	induction of differentiation	[induction of differentiation]	28.053836262764467	3	19	13	10
303	295	NF-kappa b site	[NF-kappa B site]	28.053836262764467	3	19	13	10
304	296	protein tyrosine	[protein tyrosine]	27.923076923076923	2	30	27	13
305	297	vitamin d receptor	[vitamin D receptor]	27.895340012692355	3	19	14	10
306	298	previous study	[Previous studies]	27.857142857142858	2	29	8	7
307	298	adhesion molecule-1	[adhesion molecule-1]	27.857142857142858	2	30	30	14
308	299	kinase	[kinase]	27.847619047619048	1	280	224	147
309	300	control subject	[control subjects]	27.842105263157894	2	29	22	19
310	301	lipopolysaccharide lps	[lipopolysaccharide LPS]	27.77777777777778	2	30	20	9
311	302	amino acid sequence	[amino acid sequence]	27.736843762620236	3	19	12	8
312	303	signal molecule	[signaling molecule]	27.736842105263158	2	29	24	19
313	304	signal event	[signaling events]	27.72222222222222	2	29	23	18
314	305	activator protein-1	[activator protein-1]	27.647058823529413	2	29	23	17
315	306	DNA bind	[DNA binding]	27.444444444444443	2	29	28	18
316	307	blood mononuclear cell pbmc	[blood mononuclear cell PBMC]	27.340603137439945	4	23	23	4
317	308	regulatory region	[regulatory region]	27.333333333333332	2	29	25	15
318	309	NF-kappaB	[NF-kappaB]	27.22	1	274	90	50
319	310	vitro	[vitro]	27.136842105263156	1	274	50	19
320	311	key role	[key role]	27.0	2	30	18	6
321	311	viral replication	[viral replication]	27.0	2	28	9	9
322	312	base pair	[base pair]	26.96153846153846	2	28	27	26
323	313	human peripheral blood monocyte	[human peripheral blood monocytes]	26.94436251225966	4	18	5	5
324	313	family of transcription factor	[family of transcription factors]	26.94436251225966	4	18	5	5
325	313	human T cell line	[human T cell line]	26.94436251225966	4	18	10	10
326	313	acute promyelocytic leukemia	[acute promyelocytic leukemia]	26.94436251225966	3	20	9	3
327	313	human endothelial cell	[human endothelial cells]	26.94436251225966	3	18	8	8
328	314	PMA	[PMA]	26.9125	1	271	105	56
329	315	cDNA clone	[cDNA clone]	26.9	2	28	22	20
330	316	binding activity	[binding activity]	26.88888888888889	2	29	19	9
331	317	surface expression	[surface expression]	26.857142857142858	2	31	29	7
332	318	human neutrophil	[human neutrophil]	26.8	2	28	6	5
333	319	interaction	[interaction]	26.734482758620693	1	270	231	87
334	320	dna-binding domain	[DNA-binding domain]	26.733333333333334	2	28	19	15
335	321	tumor necrosis factor-alpha tnf-alpha	[tumor necrosis factor-alpha TNF-alpha]	26.680202095472797	4	18	7	6
336	322	include	[including]	26.678947368421053	1	268	138	114
337	323	retinoic acid receptor	[retinoic acid receptor]	26.656187512128536	3	18	13	11
338	324	stage of differentiation	[stage of differentiation]	26.60472769067655	3	18	17	14
339	325	breast cancer patient	[breast cancer patient]	26.592148623210512	3	18	11	9
340	326	positive regulatory element	[positive regulatory element]	26.54812188707937	3	18	10	8
341	327	high affinity	[high affinity]	26.333333333333332	2	28	10	6
342	328	open reading frame	[open reading frame]	26.151881261899078	3	18	12	8
343	329	acid receptor	[acid receptor]	26.1	2	29	29	10
344	330	primary T cell	[primary T cells]	25.953760949308933	3	18	13	8
345	331	Jurkat	[Jurkat]	25.84857142857143	1	261	88	35
346	332	enhancer	[enhancer]	25.770689655172415	1	259	150	116
347	333	site	[site]	25.7432	1	259	196	125
348	334	t-cell receptor	[T-cell receptor]	25.5	2	27	21	14
349	335	hiv infection	[HIV infection]	25.384615384615383	2	27	21	13
350	336	hiv-1 long terminal repeat	[HIV-1 long terminal repeat]	25.3594000115385	4	21	10	2
351	336	blood T cell	[blood T cells]	25.3594000115385	3	24	24	3
352	337	promyelocytic leukemia	[promyelocytic leukemia]	25.333333333333332	2	29	22	6
353	338	macrophage	[macrophage]	25.201886792452832	1	254	105	53
354	339	vitamin d	[vitamin D]	25.166666666666668	2	27	22	12
355	340	effect of dexamethasone	[effect of dexamethasone]	25.007186122489355	3	17	11	9
356	341	other gene	[other gene]	25.0	2	26	16	16
357	341	hl60 cell	[HL60 cells]	25.0	2	27	22	11
358	341	transcriptional factor	[transcriptional factor]	25.0	2	26	14	14
359	341	hiv-1 infection	[HIV-1 infection]	25.0	2	27	20	10
360	341	present study,	[present study,]	25.0	2	26	2	2
361	342	production of cytokine	[production of cytokines]	24.927137511341822	3	17	14	11
362	343	NF-kappa b complex	[NF-kappa B complex]	24.906553582761028	3	17	9	7
363	344	peripheral T	[peripheral T]	24.714285714285715	2	26	9	7
364	345	okadaic acid	[okadaic acid]	24.625	2	27	19	8
365	346	gene activation	[gene activation]	24.615384615384617	2	26	18	13
366	347	cell differentiation	[cell differentiation]	24.571428571428573	2	26	20	14
367	348	phorbol	[phorbol]	24.400000000000002	1	248	104	26
368	349	function	[function]	24.20842105263158	1	244	182	95
369	350	analysis	[analysis]	24.13604651162791	1	244	227	86
370	351	250 words)	[250 WORDS)]	24.0	2	24	0	0
371	351	transcription initiation	[transcription initiation]	24.0	2	26	24	12
372	351	healthy control	[healthy control]	24.0	2	25	12	12
373	352	Northern blot	[Northern blot]	23.857142857142858	2	26	15	7
374	353	IL-4	[IL-4]	23.846666666666668	1	240	69	45
375	354	phorbol 12-myristate 13-acetate PMA	[phorbol 12-myristate 13-acetate PMA]	23.774437510817343	4	16	2	2
376	354	naive T cell	[naive T cell]	23.774437510817343	3	16	7	7
377	354	tyrosine kinase activity	[tyrosine kinase activity]	23.774437510817343	3	16	3	3
378	355	treatment	[treatment]	23.75686274509804	1	241	175	51
379	356	RAR alpha	[RAR alpha]	23.75	2	25	15	12
380	357	TNF alpha	[TNF alpha]	23.7	2	25	13	10
381	358	b-cell line	[B-cell line]	23.625	2	25	22	16
382	359	growth	[growth]	23.609333333333336	1	238	143	75
383	360	inflammatory response	[inflammatory response]	23.6	2	25	7	5
384	361	several transcription factor	[several transcription factors]	23.598330566292773	3	16	10	9
385	361	myeloid cell line	[myeloid cell line]	23.598330566292773	3	16	10	9
386	362	activation of nf-kappab	[activation of NF-kappaB]	23.4222236217682	3	16	11	9
387	363	point mutation	[point mutation]	23.416666666666668	2	25	19	12
388	364	terminal repeat LTR	[terminal repeat LTR]	23.246116677243627	3	22	22	3
389	365	cell adhesion molecule	[cell adhesion molecule]	23.246116677243624	3	16	16	12
390	366	antigen receptor	[antigen receptor]	23.2	2	25	18	10
391	366	GM-CSF promoter	[GM-CSF promoter]	23.2	2	26	14	5
392	367	glucocorticoid receptor gr	[glucocorticoid receptor GR]	23.18007657304691	3	16	11	8
393	368	number	[number]	23.14761904761905	1	236	190	42
394	369	human immunodeficiency virus type hiv-1	[human immunodeficiency virus type HIV-1]	23.0	5	26	15	5
395	370	healthy subject	[healthy subjects]	22.9	2	24	11	10
396	371	protein kinase C	[protein kinase C]	22.89390278819448	3	16	14	9
397	372	two protein	[two protein]	22.857142857142858	2	24	16	14
398	373	flow cytometry	[flow cytometry]	22.8	2	24	6	5
399	374	expression pattern	[expression pattern]	22.75	2	24	15	12
400	374	killer cell	[killer cell]	22.75	2	26	26	8
401	375	CD4 T cell	[CD4 T cells]	22.642321438873662	3	16	12	7
402	376	mononuclear cell	[mononuclear cell]	22.571428571428573	2	24	20	14
403	377	cytoplasmic domain	[cytoplasmic domain]	22.555555555555557	2	24	13	9
404	378	human immunodeficiency virus type 1	[human immunodeficiency virus type 1]	22.5	5	26	14	4
405	379	membrane protein	[membrane protein]	22.466666666666665	2	24	23	15
406	380	tax	[Tax]	22.465000000000003	1	226	81	60
407	381	mutation	[mutation]	22.458333333333336	1	227	174	72
408	382	long repeat LTR	[long repeat LTR]	22.453635426883046	3	17	17	6
409	383	immunodeficiency	[immunodeficiency]	22.39130434782609	1	230	140	23
410	384	long terminal	[long terminal]	22.333333333333332	2	24	15	9
411	384	plasma cell	[plasma cell]	22.333333333333332	2	24	15	9
412	384	Recent study	[Recent studies]	22.333333333333332	2	24	5	3
413	384	molecular weight	[molecular weight]	22.333333333333332	2	24	15	9
414	384	nuclear localization	[nuclear localization]	22.333333333333332	2	24	15	9
415	385	domain	[domain]	22.327272727272728	1	225	190	110
416	386	myeloid leukemia	[myeloid leukemia]	22.285714285714285	2	25	19	7
417	386	Glucocorticoid receptor	[Glucocorticoid receptor]	22.285714285714285	2	25	19	7
418	387	reporter	[reporter]	22.239534883720932	1	224	138	86
419	388	myeloid differentiation	[myeloid differentiation]	22.2	2	24	9	5
420	389	human t-cell line	[human T-cell line]	22.18947501009619	3	15	10	10
421	389	other transcription factor	[other transcription factor]	22.18947501009619	3	15	10	10
422	389	human monocytic cell line	[human monocytic cell line]	22.18947501009619	4	16	8	4
423	389	expression of cytokine	[expression of cytokines]	22.18947501009619	3	15	13	13
424	390	patient with asthma	[patients with asthma]	22.030978760024073	3	15	11	10
425	391	activator	[activator]	22.02105263157895	1	223	159	57
426	392	T cell clone	[T cell clone]	22.013368065571616	3	15	10	9
427	393	monocyte differentiation	[monocyte differentiation]	22.0	2	24	14	7
428	394	gene product	[gene product]	21.95	2	23	21	20
429	395	c-fo	[c-fos]	21.927777777777777	1	221	93	54
430	396	cellular factor	[cellular factor]	21.9	2	23	11	10
431	397	acid	[acid]	21.893333333333334	1	221	155	75
432	398	tcr	[TCR]	21.837254901960787	1	220	83	51
433	399	cd8+ T	[CD8+ T]	21.81818181818182	2	24	24	11
434	400	response element	[response element]	21.705882352941178	2	23	22	17
435	401	locus control region	[locus control region]	21.66115417652247	3	15	8	6
436	402	hiv expression	[HIV expression]	21.625	2	24	19	8
437	403	erythroid progenitor	[erythroid progenitor]	21.6	2	23	14	10
438	404	early stage	[early stage]	21.571428571428573	2	24	17	7
439	405	protein kinase a	[protein kinase A]	21.555490009807723	3	15	7	5
440	405	peripheral blood leukocyte	[peripheral blood leukocyte]	21.555490009807723	3	15	7	5
441	406	il-2r alpha	[IL-2R alpha]	21.5	2	23	12	8
442	406	bind affinity	[binding affinity]	21.5	2	23	18	12
443	407	finding	[finding]	21.46785714285714	1	216	37	28
444	408	ifn-gamma	[IFN-gamma]	21.44901960784314	1	216	77	51
445	409	globin gene	[globin gene]	21.384615384615383	2	23	21	13
446	410	ap-1 activity	[AP-1 activity]	21.375	2	24	21	8
447	411	rheumatoid arthritis	[rheumatoid arthritis]	21.363636363636363	2	23	18	11
448	412	phorbol 12-myristate	[phorbol 12-myristate]	21.333333333333332	2	29	23	3
449	413	il-1 beta	[IL-1 beta]	21.3	2	23	17	10
450	414	peripheral T cell	[peripheral T cells]	21.00075313455532	3	16	11	4
451	415	tnf-alpha	[TNF-alpha]	20.905555555555555	1	211	105	54
452	416	helper T cell	[helper T cells]	20.86867292616189	3	15	11	6
453	417	dendritic cell	[dendritic cell]	20.857142857142858	2	22	16	14
454	417	inflammatory disease	[inflammatory disease]	20.857142857142858	2	22	16	14
455	418	mononuclear phagocyte	[mononuclear phagocyte]	20.833333333333332	2	22	7	6
456	419	cellular gene	[cellular gene]	20.818181818181817	2	22	13	11
457	420	phosphorylation	[phosphorylation]	20.67878787878788	1	209	146	66
458	421	molecular basis	[molecular basis]	20.666666666666664	2	29	25	3
459	422	expression of the gene	[expression of the gene]	20.60451250937503	4	14	9	9
460	422	response to lps	[response to LPS]	20.60451250937503	3	14	2	2
461	422	normal human monocyte	[normal human monocytes]	20.60451250937503	3	14	3	3
462	422	transient transfection assay	[transient transfection assay]	20.60451250937503	3	14	4	4
463	422	human b cell line	[human B cell line]	20.60451250937503	4	14	7	7
464	422	cell cycle progression	[cell cycle progression]	20.60451250937503	3	14	3	3
465	422	Electrophoretic mobility shift	[Electrophoretic mobility shift]	20.60451250937503	3	19	18	3
466	422	cytokine gene expression	[cytokine gene expression]	20.60451250937503	3	15	8	4
467	422	T cell antigen receptor	[T cell antigen receptor]	20.60451250937503	4	14	1	1
468	422	human umbilical vein	[human umbilical vein]	20.60451250937503	3	14	3	3
469	423	plasma cortisol	[plasma cortisol]	20.5	2	23	15	6
470	423	stem cell	[stem cell]	20.5	2	22	21	14
471	424	effect on the expression	[effect on the expression]	20.460425009309475	4	14	12	11
472	425	terminal differentiation	[terminal differentiation]	20.4	2	23	13	5
473	426	positive element	[positive element]	20.363636363636363	2	22	18	11
474	426	steroid hormone	[steroid hormone]	20.363636363636363	2	22	18	11
475	427	lymphoid cell line	[lymphoid cell line]	20.340352092588173	3	14	7	6
476	427	human vein cell	[human vein cells]	20.340352092588173	3	14	14	12
477	428	ability	[ability]	20.333333333333336	1	210	120	18
478	429	acute myeloid leukemia	[acute myeloid leukemia]	20.287520009230803	3	14	6	5
479	429	vascular cell adhesion	[vascular cell adhesion]	20.287520009230803	3	15	11	5
480	429	activation of nf-kappa b	[activation of NF-kappa B]	20.287520009230803	4	14	6	5
481	429	primary T lymphocyte	[primary T lymphocytes]	20.287520009230803	3	15	11	5
482	430	monocyte adhesion	[monocyte adhesion]	20.166666666666668	2	22	11	6
483	431	type	[type]	20.134065934065934	1	203	151	91
484	432	zinc finger protein	[zinc finger protein]	20.07619167580131	3	14	12	9
485	433	all-tran acid	[all-trans acid]	20.0	2	22	22	11
486	433	several gene	[several genes]	20.0	2	21	13	13
487	433	reporter construct	[reporter construct]	20.0	2	22	18	9
488	434	human vein endothelial cell	[human vein endothelial cells]	19.97052750908657	4	14	14	10
489	434	class ii gene	[class II gene]	19.97052750908657	3	14	7	5
490	434	human umbilical vein cell	[human umbilical vein cells]	19.97052750908657	4	14	14	10
491	435	cytokine receptor	[cytokine receptor]	19.933333333333334	2	21	16	15
492	436	promoter element	[promoter element]	19.823529411764707	2	21	20	17
493	437	inhibitor	[inhibitor]	19.76119402985075	1	200	160	67
494	438	enhancer activity	[enhancer activity]	19.7	2	21	13	10
495	439	ebv	[EBV]	19.679661016949154	1	198	71	59
496	440	th2 cell	[Th2 cell]	19.625	2	21	11	8
497	441	heterologous promoter	[heterologous promoter]	19.6	2	21	7	5
498	442	5' region	[5' region]	19.583333333333332	2	21	17	12
499	443	mrna expression	[mRNA expression]	19.5	2	22	15	6
500	444	30 minute	[30 min]	19.428571428571427	2	21	11	7
501	445	human blood lymphocyte	[human blood lymphocytes]	19.415790633834163	3	14	14	8
502	445	cell adhesion molecule-1	[cell adhesion molecule-1]	19.415790633834163	3	14	14	8
503	446	evidence	[evidence]	19.413513513513514	1	196	138	74
504	447	p sequence	[P sequence]	19.4	2	21	8	5
505	448	lymphocyte activation	[lymphocyte activation]	19.333333333333332	2	21	10	6
506	449	b activation	[B activation]	19.2	2	24	24	5
507	450	peripheral blood mononuclear cell pbmc	[peripheral blood mononuclear cell PBMC]	19.166666666666668	5	21	11	6
508	451	target gene	[target gene]	19.11111111111111	2	21	17	9
509	452	target	[target]	19.045238095238098	1	192	130	84
510	453	tissue	[tissue]	19.02166666666667	1	192	107	60
511	454	activation of transcription factor	[activation of transcription factors]	19.019550008653876	4	13	6	6
512	454	activation of NF-kappaB	[activation of NF-kappaB]	19.019550008653876	3	13	7	7
513	454	binding of transcription factor	[binding of transcription factors]	19.019550008653876	4	13	9	9
514	454	use mobility shift assay	[Using mobility shift assays]	19.019550008653876	4	16	16	4
515	454	human peripheral blood lymphocyte	[human peripheral blood lymphocytes]	19.019550008653876	4	13	6	6
516	454	ubiquitous transcription factor	[ubiquitous transcription factor]	19.019550008653876	3	13	4	4
517	454	hiv-1 gene expression	[HIV-1 gene expression]	19.019550008653876	3	13	5	5
518	454	hematopoietic cell line	[hematopoietic cell line]	19.019550008653876	3	13	8	8
519	454	expression of c-fo	[expression of c-fos]	19.019550008653876	3	13	10	10
520	455	c-jun	[c-jun]	19.015	1	192	74	40
521	456	other hand,	[other hand,]	19.0	2	20	3	3
522	457	pathway	[pathway]	18.94591836734694	1	191	151	98
523	458	RA	[RA]	18.93409090909091	1	191	73	44
524	459	human gene	[human gene]	18.928571428571427	2	20	15	14
525	460	tax protein	[Tax protein]	18.857142857142858	2	21	15	7
526	461	antibody	[antibody]	18.814285714285713	1	190	130	70
527	462	serum response	[serum response]	18.8	2	22	16	5
528	463	complex	[complex]	18.739285714285714	1	189	135	84
529	464	cd8+ T cell	[CD8+ T cell]	18.702557508509646	3	13	6	5
530	464	T lymphocyte activation	[T lymphocyte activation]	18.702557508509646	3	13	6	5
531	465	factor kappab	[factor kappaB]	18.666666666666668	2	21	21	9
532	466	cell types,	[cell types,]	18.615384615384617	2	20	18	13
533	467	addition,	[addition,]	18.583333333333336	1	187	7	6
534	468	activation of ap-1	[activation of AP-1]	18.5667035798764	3	13	9	7
535	469	dissociation constant	[dissociation constant]	18.545454545454547	2	20	16	11
536	470	regulatory protein	[regulatory protein]	18.5	2	20	18	12
537	471	nf-kappa b translocation	[NF-kappa B translocation]	18.491229175080157	3	13	8	6
538	472	antigen	[antigen]	18.46951219512195	1	186	107	82
539	473	hepatitis b	[hepatitis B]	18.46153846153846	2	20	20	13
540	474	acute lymphoblastic leukemia	[acute lymphoblastic leukemia]	18.42518907088344	3	13	11	8
541	475	protein-protein interaction	[protein-protein interaction]	18.25	2	20	7	4
542	476	least in part	[least in part]	18.227068758293296	3	13	9	6
543	477	nf-kappab activity	[NF-kappaB activity]	18.142857142857142	2	20	13	7
544	478	reactive oxygen species	[reactive oxygen species]	18.11385715109893	3	13	11	7
545	478	bone marrow cell	[bone marrow cells]	18.11385715109893	3	13	11	7
546	479	androgen receptor gene	[androgen receptor gene]	18.068572508221184	3	13	8	5
547	480	family	[family]	18.048979591836737	1	182	148	98
548	481	disease	[disease]	18.04342105263158	1	182	119	76
549	482	Epstein-Barr virus antigen	[Epstein-Barr virus antigen]	18.028948445703154	3	13	13	8
550	483	glucocorticoid	[glucocorticoid]	18.02857142857143	1	182	84	49
551	484	dose-dependent manner	[dose-dependent manner]	18.0	2	19	3	3
552	484	basal level	[basal level]	18.0	2	19	5	5
553	485	hla class ii	[HLA class II]	17.887433936710195	3	13	12	7
554	486	il-4	[IL-4]	17.86341463414634	1	180	56	41
555	487	other protein	[other proteins]	17.833333333333332	2	19	14	12
556	488	leukocyte	[leukocyte]	17.780645161290323	1	180	136	62
557	489	proliferation	[proliferation]	17.779166666666665	1	180	106	48
558	490	t-cell leukemia virus	[T-cell leukemia virus]	17.75158000807695	3	14	14	5
559	490	retinoid x receptor	[retinoid X receptor]	17.75158000807695	3	13	9	5
560	491	follow	[following]	17.66774193548387	1	178	123	93
561	492	class ii transactivator	[class II transactivator]	17.661010722321453	3	13	13	7
562	493	interleukin-2 il-2	[interleukin-2 IL-2]	17.6	2	19	14	10
563	494	regulatory mechanism	[regulatory mechanism]	17.583333333333332	2	19	17	12
564	495	repeat LTR	[repeat LTR]	17.5	2	21	21	6
565	496	transcription factor NF-kappa b	[transcription factor NF-kappa B]	17.43458750793272	4	12	6	6
566	496	NF-kappa b transcription factor	[NF-kappa B transcription factor]	17.43458750793272	4	12	2	2
567	496	activation of T lymphocyte	[activation of T lymphocytes]	17.43458750793272	4	12	3	3
568	496	transient expression assay	[transient expression assay]	17.43458750793272	3	12	3	3
569	496	activator protein-1 ap-1	[activator protein-1 AP-1]	17.43458750793272	3	12	6	6
570	496	ap-1 binding activity	[AP-1 binding activity]	17.43458750793272	3	13	6	3
571	496	nuclear transcription factor	[nuclear transcription factor]	17.43458750793272	3	12	9	9
572	497	inducible expression	[inducible expression]	17.4	2	20	13	5
573	498	early event	[early event]	17.375	2	19	13	8
574	499	translocation	[translocation]	17.365909090909092	1	177	147	44
575	500	mobility	[mobility]	17.31904761904762	1	180	143	21
576	501	transient transfection	[transient transfection]	17.285714285714285	2	19	12	7
577	502	cellular transcription factor	[cellular transcription factor]	17.276091257860603	3	12	11	10
578	503	class	[class]	17.19710144927536	1	174	140	69
579	504	nuclear expression	[nuclear expression]	17.166666666666668	2	20	17	6
580	504	immunoglobulin gene	[immunoglobulin gene]	17.166666666666668	2	19	11	6
581	505	neonatal T cell	[neonatal T cells]	17.117595007788488	3	12	6	5
582	505	differentiation of cell	[differentiation of cells]	17.117595007788488	3	12	12	10
583	506	viral gene expression	[viral gene expression]	17.038346882752432	3	12	5	4
584	507	central role	[central role]	17.0	2	19	8	4
585	507	CAT activity	[CAT activity]	17.0	2	19	16	8
586	507	potential role	[potential role]	17.0	2	20	18	6
587	508	lymph node	[lymph node]	16.923076923076923	2	18	14	13
588	509	expression of this gene	[expression of these genes]	16.906266674359	4	12	4	3
589	509	gel shift assay	[gel shift assay]	16.906266674359	3	12	4	3
590	509	hiv-1 long repeat	[HIV-1 long repeat]	16.906266674359	3	12	12	9
591	510	bind site	[binding site]	16.88888888888889	2	19	19	9
592	511	proinflammatory cytokine	[proinflammatory cytokine]	16.857142857142858	2	18	8	7
593	511	viral protein	[viral protein]	16.857142857142858	2	18	8	7
594	512	bcl-2 expression	[bcl-2 expression]	16.8	2	19	11	5
595	513	change	[change]	16.771875	1	170	146	64
596	514	camp response element	[cAMP response element]	16.75531786476651	3	12	10	7
597	515	progesterone receptor	[progesterone receptor]	16.75	2	18	10	8
598	516	DNA fragment	[DNA fragment]	16.666666666666668	2	18	12	9
599	517	umbilical vein endothelial cell	[umbilical vein endothelial cells]	16.64210625757214	4	14	14	4
600	517	umbilical vein cell	[umbilical vein cells]	16.64210625757214	3	14	14	4
601	517	vein endothelial cell	[vein endothelial cells]	16.64210625757214	3	14	14	4
602	518	acid RA	[acid RA]	16.625	2	19	19	8
603	519	IL-4 promoter	[IL-4 promoter]	16.6	2	20	17	5
604	519	cell survival	[cell survival]	16.6	2	18	7	5
605	520	CD40	[CD40]	16.55952380952381	1	167	59	42
606	521	lymphocyte proliferation	[lymphocyte proliferation]	16.5	2	18	12	8
607	522	Epstein-Barr virus nuclear antigen	[Epstein-Barr virus nuclear antigen]	16.483610007500026	4	12	8	5
608	522	class ii molecule	[class II molecule]	16.483610007500026	3	12	8	5
609	523	form	[form]	16.417721518987342	1	166	144	79
610	524	human peripheral blood mononuclear cell	[human peripheral blood mononuclear cells]	16.333333333333332	5	18	10	6
611	524	granulocytic differentiation	[granulocytic differentiation]	16.333333333333332	2	18	5	3
612	524	transactivation domain	[transactivation domain]	16.333333333333332	2	19	16	6
613	525	reading frame	[reading frame]	16.285714285714285	2	19	19	7
614	525	blood leukocyte	[blood leukocyte]	16.285714285714285	2	19	19	7
615	525	lymphoid tissue	[lymphoid tissue]	16.285714285714285	2	18	12	7
616	525	c-jun mrna	[c-jun mRNA]	16.285714285714285	2	18	12	7
617	526	p50 subunit	[p50 subunit]	16.25	2	19	11	4
618	527	DNA bind domain	[DNA binding domain]	16.24586563239185	3	12	7	4
619	528	inflammatory cytokine	[inflammatory cytokine]	16.166666666666668	2	18	11	6
620	529	transcriptional regulator	[transcriptional regulator]	16.0	2	17	11	11
621	529	Nuclear factor	[Nuclear factor]	16.0	2	19	15	5
622	529	crucial role	[crucial role]	16.0	2	18	10	5
623	529	activation of the transcription factor	[activation of the transcription factor]	16.0	5	17	8	8
624	529	normal subject	[normal subjects]	16.0	2	17	6	6
625	530	beta	[beta]	15.977528089887642	1	161	109	89
626	531	development	[development]	15.942424242424245	1	163	118	33
627	532	mineralocorticoid receptor	[mineralocorticoid receptor]	15.9	2	17	11	10
628	533	plasma membrane	[plasma membrane]	15.88888888888889	2	17	10	9
629	534	many gene	[many genes]	15.875	2	17	9	8
630	534	gel shift	[gel shift]	15.875	2	18	17	8
631	535	th1 cell	[Th1 cells]	15.857142857142858	2	17	8	7
632	536	protein kinase c pkc	[protein kinase C PKC]	15.849625007211563	4	11	5	5
633	536	T cell receptor tcr	[T cell receptor TCR]	15.849625007211563	4	11	5	5
634	536	expression in cell	[expression in cells]	15.849625007211563	3	11	11	11
635	536	late gene expression	[late gene expression]	15.849625007211563	3	11	4	4
636	536	normal human T cell	[normal human T cells]	15.849625007211563	4	11	2	2
637	536	adult t-cell leukemia	[adult T-cell leukemia]	15.849625007211563	3	14	8	2
638	536	protein kinase C PKC	[protein kinase C PKC]	15.849625007211563	4	11	5	5
639	536	activation of gene	[activation of genes]	15.849625007211563	3	11	10	10
640	536	group of patient	[group of patients]	15.849625007211563	3	11	9	9
641	536	human Jurkat T cell	[human Jurkat T cells]	15.849625007211563	4	11	4	4
642	536	T cell NFAT	[T cells NFAT]	15.849625007211563	3	13	9	3
643	536	granulocyte-macrophage colony-stimulating factor gm-csf	[Granulocyte-macrophage colony-stimulating factor GM-CSF]	15.849625007211563	4	10	0	0
644	536	myelomonocytic cell line	[myelomonocytic cell line]	15.849625007211563	3	11	5	5
645	536	level of transcription	[level of transcription]	15.849625007211563	3	11	7	7
646	536	mature b cell	[mature B cells]	15.849625007211563	3	12	2	1
647	537	protein expression	[protein expression]	15.833333333333334	2	17	7	6
648	538	neutrophil	[neutrophil]	15.831372549019608	1	160	86	51
649	539	cellular response	[cellular response]	15.8	2	18	11	5
650	540	CD28	[CD28]	15.771153846153846	1	159	67	52
651	541	plasma	[plasma]	15.751063829787235	1	159	70	47
652	542	cell receptor	[cell receptor]	15.75	2	17	15	12
653	542	gel mobility	[gel mobility]	15.75	2	21	21	4
654	543	depend on	[depending on]	15.666666666666666	2	17	12	9
655	544	member	[member]	15.666	1	159	117	50
656	545	effect of glucocorticoid	[effect of glucocorticoids]	15.65150469462142	3	11	9	8
657	546	colony-stimulating factor	[colony-stimulating factor]	15.636363636363637	2	17	15	11
658	547	chloramphenicol acetyltransferase CAT	[chloramphenicol acetyltransferase CAT]	15.623201792822828	3	11	8	7
659	548	granulocyte colony-stimulating factor	[granulocyte colony-stimulating factor]	15.585464590424705	3	11	7	6
660	549	ige synthesis	[IgE synthesis]	15.571428571428571	2	17	10	7
661	549	fusion protein	[fusion protein]	15.571428571428571	2	17	10	7
662	550	cell surface receptor	[cell surface receptor]	15.532632507067333	3	11	6	5
663	550	patient with breast cancer	[patients with breast cancer]	15.532632507067333	4	11	6	5
664	550	vascular cell adhesion molecule-1	[vascular cell adhesion molecule-1]	15.532632507067333	4	12	11	5
665	550	rest T cell	[resting T cells]	15.532632507067333	3	11	6	5
666	551	camp response	[cAMP response]	15.5	2	18	15	6
667	551	transfection assay	[transfection assay]	15.5	2	19	14	4
668	552	peptide	[peptide]	15.463235294117647	1	156	93	68
669	553	reactive oxygen intermediate	[reactive oxygen intermediates]	15.453384382031274	3	12	9	4
670	553	leukemic cell line	[leukemic cell line]	15.453384382031274	3	11	10	8
671	553	gel retardation assay	[gel retardation assay]	15.453384382031274	3	11	5	4
672	553	response to stimulus	[response to stimuli]	15.453384382031274	3	11	10	8
673	554	difference	[difference]	15.451785714285714	1	157	139	56
674	555	receptor gr	[receptor GR]	15.428571428571429	2	18	18	7
675	556	adhesion	[adhesion]	15.398076923076923	1	156	105	52
676	557	human t-cell leukemia	[human T-cell leukemia]	15.321304173637847	3	14	13	3
677	558	activity of transcription factor	[activity of transcription factors]	15.321304173637843	4	11	8	6
678	558	nuclear nf-kappa b	[nuclear NF-kappa B]	15.321304173637843	3	11	8	6
679	559	target cell	[target cell]	15.25	2	17	14	8
680	560	CD4 T	[CD4 T]	15.222222222222221	2	17	16	9
681	561	b cell development	[B cell development]	15.215640006923099	3	11	7	5
682	561	NF-kappa b transcription	[NF-kappa B transcription]	15.215640006923099	3	12	12	5
683	561	MHC class ii expression	[MHC class II expression]	15.215640006923099	4	11	7	5
684	562	vivo	[vivo]	15.175	1	154	27	12
685	563	c-fo expression	[c-fos expression]	15.166666666666666	2	17	11	6
686	564	histocompatibility complex class	[histocompatibility complex class]	15.057143756850985	3	12	10	4
687	565	other cytokine	[other cytokines]	15.0	2	16	8	8
688	565	major role	[major role]	15.0	2	17	8	4
689	565	use electrophoretic mobility shift assay	[Using electrophoretic mobility shift assays]	15.0	5	16	3	3
690	565	alternative splicing	[alternative splicing]	15.0	2	17	10	5
691	565	cellular proliferation	[cellular proliferation]	15.0	2	16	2	2
692	565	cytotoxic T	[cytotoxic T]	15.0	2	16	5	5
693	565	wild type	[wild type]	15.0	2	16	5	5
694	566	MHC class expression	[MHC class expression]	14.943932149656616	3	11	11	7
695	567	chronic leukemia	[chronic leukemia]	14.928571428571429	2	16	15	14
696	568	two site	[two sites]	14.90909090909091	2	16	12	11
697	568	signal cascade	[signal cascade]	14.90909090909091	2	16	12	11
698	569	peripheral T lymphocyte	[peripheral T lymphocytes]	14.89864750677887	3	11	8	5
699	570	bind	[bind]	14.857407407407408	1	150	77	54
700	571	p65	[p65]	14.842424242424244	1	150	52	33
701	572	regulatory sequence	[regulatory sequence]	14.833333333333334	2	16	14	12
702	572	gel retardation	[gel retardation]	14.833333333333334	2	17	13	6
703	572	nfat activation	[NFAT activation]	14.833333333333334	2	16	7	6
704	572	all-tran RA	[all-trans RA]	14.833333333333334	2	16	7	6
705	573	binding protein	[binding protein]	14.8	2	16	12	10
706	574	transcriptional start site	[transcriptional start site]	14.792983340064126	3	11	5	3
707	574	T cell function	[T cell function]	14.792983340064126	3	11	5	3
708	575	immune	[immune]	14.769565217391303	1	149	60	46
709	576	Janus kinase	[Janus kinase]	14.75	2	16	15	12
710	577	consensus sequence	[consensus sequence]	14.7	2	16	13	10
711	578	significant difference	[significant difference]	14.666666666666668	2	19	13	3
712	579	transcription factor gata-1	[transcription factor GATA-1]	14.660903131670695	3	11	7	4
713	579	peripheral blood T lymphocyte	[peripheral blood T lymphocytes]	14.660903131670695	4	11	7	4
714	579	t-cell antigen receptor	[T-cell antigen receptor]	14.660903131670695	3	11	7	4
715	579	estrogen receptor er	[estrogen receptor ER]	14.660903131670695	3	11	7	4
716	580	3 h	[3 h]	14.6	2	16	7	5
717	580	transcriptional control	[transcriptional control]	14.6	2	16	7	5
718	581	proliferative response	[proliferative response]	14.571428571428571	2	16	10	7
719	582	early gene	[early gene]	14.555555555555555	2	16	13	9
720	583	cell culture	[cell culture]	14.545454545454545	2	16	16	11
721	584	NK	[NK]	14.522222222222224	1	148	75	27
722	585	cytokine expression	[cytokine expression]	14.5	2	16	12	8
723	585	constitutive activation	[constitutive activation]	14.5	2	18	14	4
724	586	potent activator	[potent activator]	14.444444444444445	2	16	14	9
725	587	immediate early gene	[immediate early gene]	14.264662506490406	3	10	9	9
726	587	serum response factor	[serum response factor]	14.264662506490406	3	10	3	3
727	587	Epstein-Barr virus ebv	[Epstein-Barr virus EBV]	14.264662506490406	3	10	8	8
728	587	blood T lymphocyte	[blood T lymphocytes]	14.264662506490406	3	12	12	4
729	587	systemic lupus erythematosus	[systemic lupus erythematosus]	14.264662506490406	3	11	10	5
730	587	transcription factor Sp1	[transcription factor Sp1]	14.264662506490406	3	10	2	2
731	587	plasma cortisol concentration	[Plasma cortisol concentration]	14.264662506490406	3	10	3	3
732	587	factor-kappa b NF-kappa b	[factor-kappa B NF-kappa B]	14.264662506490406	4	12	12	4
733	587	retinoic acid RA	[retinoic acid RA]	14.264662506490406	3	11	8	4
734	587	mitogen-activated protein kinase	[mitogen-activated protein kinase]	14.264662506490406	3	10	6	6
735	587	human IL-4 promoter	[human IL-4 promoter]	14.264662506490406	3	10	4	4
736	587	human NK cell	[Human NK cell]	14.264662506490406	3	10	2	2
737	588	extract	[extract]	14.240000000000002	1	148	140	25
738	589	class gene	[class gene]	14.222222222222221	2	16	16	9
739	590	concentration	[concentration]	14.215151515151517	1	144	122	66
740	591	molecular mass	[molecular mass]	14.125	2	16	15	8
741	592	affinity	[affinity]	14.11451612903226	1	143	115	62
742	593	cell of the lineage	[cells of the lineage]	14.088555561965835	4	10	10	9
743	594	transactivation	[transactivation]	14.03404255319149	1	142	78	47
744	595	percentage of cell	[percentage of cells]	14.000502089703549	3	10	7	6
745	596	other factor	[other factor]	14.0	2	15	8	8
746	597	dexamethasone	[dexamethasone]	13.969444444444447	1	141	47	36
747	598	DNA binding protein	[DNA binding protein]	13.947670006346177	3	10	6	5
748	598	il-2 promoter activity	[IL-2 promoter activity]	13.947670006346177	3	10	6	5
749	599	gr	[GR]	13.938235294117646	1	141	55	34
750	600	phosphatidylinositol 3-kinase	[phosphatidylinositol 3-kinase]	13.88888888888889	2	15	10	9
751	601	human tissue	[human tissues]	13.875	2	15	9	8
752	602	nf-kappa b binding activity	[NF-kappa B binding activity]	13.868421881310118	4	10	5	4
753	602	T cell hybridoma	[T cell hybridoma]	13.868421881310118	3	10	5	4
754	603	tcr signal	[TCR signaling]	13.857142857142858	2	15	8	7
755	603	24 h	[24 h]	13.857142857142858	2	15	8	7
756	604	study,	[study,]	13.850000000000001	1	143	36	8
757	605	role in the pathogenesis	[role in the pathogenesis]	13.811816077712932	4	10	9	7
758	606	infection	[infection]	13.8	1	140	96	48
759	606	leukocyte adhesion	[leukocyte adhesion]	13.8	2	15	12	10
760	607	murine	[murine]	13.786274509803924	1	139	58	51
761	608	physical interaction	[physical interaction]	13.75	2	17	13	4
762	608	primary cell	[primary cell]	13.75	2	15	10	8
763	608	cellular activation	[cellular activation]	13.75	2	15	5	4
764	608	c-fo mrna	[c-fos mRNA]	13.75	2	16	9	4
765	609	human leukemia cell line	[human leukemia cell line]	13.736341672916687	4	10	8	6
766	609	latent membrane protein	[latent membrane protein]	13.736341672916687	3	10	8	6
767	610	NF-kappaB activation	[NF-kappaB activation]	13.714285714285714	2	15	9	7
768	611	stat1 alpha	[STAT1 alpha]	13.666666666666666	2	15	8	6
769	611	lps stimulation	[LPS stimulation]	13.666666666666666	2	16	7	3
770	611	germinal center	[germinal center]	13.666666666666666	2	15	4	3
771	612	addition	[addition]	13.635714285714286	1	141	130	28
772	613	stat	[STAT]	13.63095238095238	1	138	71	42
773	614	constitutive nf-kappa b	[constitutive NF-kappa B]	13.630677506201943	3	10	7	5
774	615	sh2 domain	[SH2 domain]	13.625	2	15	11	8
775	615	2 h	[2 h]	13.625	2	15	11	8
776	616	chloramphenicol acetyltransferase	[chloramphenicol acetyltransferase]	13.6	2	17	17	5
777	617	human leukemia cell	[human leukemia cell]	13.585392863324197	3	10	10	7
778	618	gamma interferon	[gamma interferon]	13.571428571428571	2	15	10	7
779	619	cell carcinoma	[cell carcinoma]	13.5	2	15	15	10
780	619	protein complex	[protein complex]	13.5	2	15	12	8
781	619	x chromosome	[X chromosome]	13.5	2	15	12	8
782	619	normal monocyte	[normal monocytes]	13.5	2	16	15	6
783	619	high concentration	[high concentration]	13.5	2	16	15	6
784	620	novel transcription factor	[novel transcription factor]	13.47218125612983	3	10	3	2
785	620	IL-2 gene expression	[IL-2 gene expression]	13.47218125612983	3	10	6	4
786	621	negative regulator	[negative regulator]	13.444444444444445	2	15	14	9
787	622	absence	[absence]	13.422222222222224	1	147	115	9
788	623	tissue factor	[tissue factor]	13.375	2	15	13	8
789	624	expression level	[expression level]	13.333333333333334	2	17	11	3
790	625	TNF	[TNF]	13.322857142857144	1	135	62	35
791	626	granulocyte-macrophage colony-stimumulatelany-stg factor	[granulocyte-macrophage colony-stimulating factor]	13.313685006057714	3	10	8	5
792	627	deletion	[deletion]	13.3	1	135	102	51
793	628	primary NK cell	[primary NK cells]	13.20802083934297	3	10	5	3
794	628	21 bp repeat	[21 bp repeat]	13.20802083934297	3	10	5	3
795	628	acid receptor alpha	[acid receptor alpha]	13.20802083934297	3	10	10	6
796	629	little effect	[little effect]	13.2	2	16	14	5
797	630	il-2 receptor	[IL-2 receptor]	13.166666666666666	2	15	11	6
798	631	tyrosine kinase inhibitor	[tyrosine kinase inhibitor]	13.075940630949539	3	10	7	4
799	631	peripheral blood T	[peripheral blood T]	13.075940630949539	3	10	7	4
800	632	production	[production]	13.064705882352943	1	134	114	34
801	633	IL-10	[IL-10]	13.063636363636363	1	132	30	22
802	634	membrane	[membrane]	13.058139534883722	1	132	61	43
803	635	transient expression	[transient expression]	13.0	2	16	12	4
804	635	western blotting	[Western blotting]	13.0	2	14	3	3
805	635	murine T	[murine T]	13.0	2	15	12	6
806	635	cellular protein	[cellular protein]	13.0	2	14	10	10
807	635	glucocorticoid resistance	[glucocorticoid resistance]	13.0	2	14	8	8
808	635	sequence element	[sequence element]	13.0	2	14	12	12
809	635	cell antigen	[cell antigen]	13.0	2	19	18	3
810	635	octamer motif	[octamer motif]	13.0	2	14	8	8
811	635	dna-binding complex	[DNA-binding complex]	13.0	2	14	11	11
812	635	low affinity	[low affinity]	13.0	2	14	9	9
813	635	pre-B cell	[pre-B cell]	13.0	2	14	5	5
814	636	transfection	[transfection]	12.92	1	132	84	30
815	637	hematopoietic progenitor	[hematopoietic progenitor]	12.857142857142858	2	14	8	7
816	637	thyroid hormone	[thyroid hormone]	12.857142857142858	2	14	8	7
817	638	event	[event]	12.854929577464787	1	130	103	71
818	639	I	[I]	12.852000000000002	1	130	74	50
819	640	several cytokine	[several cytokine]	12.833333333333334	2	14	7	6
820	640	virus replication	[virus replication]	12.833333333333334	2	14	7	6
821	641	accord to	[according to]	12.818181818181818	2	14	13	11
822	642	human vein	[human vein]	12.8	2	14	12	10
823	642	il-2 gene	[IL-2 gene]	12.8	2	15	11	5
824	643	human macrophage	[human macrophage]	12.777777777777779	2	14	11	9
825	643	u-937 cell	[U-937 cells]	12.777777777777779	2	14	11	9
826	644	sequence analysis	[Sequence analysis]	12.75	2	15	9	4
827	644	il-2 secretion	[IL-2 secretion]	12.75	2	14	5	4
828	644	vitamin D3	[vitamin D3]	12.75	2	14	10	8
829	644	tissue-specific expression	[tissue-specific expression]	12.75	2	15	9	4
830	645	LTR	[LTR]	12.73777777777778	1	129	73	45
831	646	human umbilical vein endothelial cell	[human umbilical vein endothelial cells]	12.714285714285714	5	14	9	7
832	647	significant correlation	[significant correlation]	12.7	2	14	13	10
833	647	hmg box	[HMG box]	12.7	2	14	13	10
834	648	gene in cell	[gene in cells]	12.67970000576925	3	9	9	9
835	648	monocytic cell adhesion	[monocytic cell adhesion]	12.67970000576925	3	10	6	3
836	648	normal b cell	[normal B cells]	12.67970000576925	3	11	9	3
837	648	kappa b enhancer	[kappa B enhancer]	12.67970000576925	3	9	3	3
838	648	b cell differentiation	[B cell differentiation]	12.67970000576925	3	9	4	4
839	648	nuclear factor kappab nf-kappab	[nuclear factor kappaB NF-kappaB]	12.67970000576925	4	9	2	2
840	648	acute promyelocytic leukemia APL	[acute promyelocytic leukemia APL]	12.67970000576925	4	9	1	1
841	648	regulate gene expression	[regulating gene expression]	12.67970000576925	3	9	7	7
842	648	tumor necrosis factor TNF	[tumor necrosis factor TNF]	12.67970000576925	4	9	2	2
843	648	early response gene	[early response genes]	12.67970000576925	3	10	8	4
844	648	aim of this study	[aim of this study]	12.67970000576925	4	9	1	1
845	648	primary human T cell	[primary human T cells]	12.67970000576925	4	9	2	2
846	648	cell line u937	[cell line U937]	12.67970000576925	3	10	10	5
847	648	DNA binding domain	[DNA binding domain]	12.67970000576925	3	9	4	4
848	648	chronic lymphocytic leukemia	[chronic lymphocytic leukemia]	12.67970000576925	3	9	6	6
849	648	ap-1 transcription factor	[AP-1 transcription factor]	12.67970000576925	3	9	2	2
850	648	transcriptional regulatory protein	[transcriptional regulatory protein]	12.67970000576925	3	9	4	4
851	648	receptor in lymphocyte	[receptors in lymphocytes]	12.67970000576925	3	10	10	5
852	648	retinoic acid receptor alpha	[retinoic acid receptor alpha]	12.67970000576925	4	9	7	7
853	649	umbilical vein	[umbilical vein]	12.666666666666668	2	18	16	3
854	650	helper T	[helper T]	12.666666666666666	2	15	14	6
855	650	nervous system	[nervous system]	12.666666666666666	2	16	10	3
856	650	monocyte-derived macrophage	[monocyte-derived macrophages]	12.666666666666666	2	14	4	3
857	650	control cell	[control cell]	12.666666666666666	2	14	8	6
858	651	mutant	[mutant]	12.664150943396228	1	128	72	53
859	652	nf-at	[NF-AT]	12.641176470588235	1	128	54	34
860	653	p50 homodimer	[p50 homodimer]	12.6	2	14	7	5
861	653	functional role	[functional role]	12.6	2	15	12	5
862	654	chromatin structure	[chromatin structure]	12.571428571428571	2	14	10	7
863	654	chromosomal translocation	[chromosomal translocation]	12.571428571428571	2	14	10	7
864	655	cortisol	[cortisol]	12.54186046511628	1	127	68	43
865	656	nuclear transcription	[nuclear transcription]	12.5	2	14	6	4
866	656	myelogenous leukemia	[myelogenous leukemia]	12.5	2	14	12	8
867	657	amino	[amino]	12.480952380952381	1	126	50	42
868	658	surface	[surface]	12.43913043478261	1	126	74	46
869	659	NFAT	[NFAT]	12.433333333333334	1	126	45	27
870	660	shift	[shift]	12.430769230769231	1	134	126	13
871	661	ap-1 site	[AP-1 site]	12.428571428571429	2	14	11	7
872	661	pi 3-kinase	[PI 3-kinase]	12.428571428571429	2	14	11	7
873	662	inflammatory mediator	[inflammatory mediators]	12.4	2	14	8	5
874	662	calcium	[calcium]	12.4	1	126	58	29
875	663	glucocorticoid receptor in lymphocyte	[glucocorticoid receptors in lymphocytes]	12.36270750562502	4	9	6	5
876	664	Epstein-Barr	[Epstein-Barr]	12.338461538461539	1	127	47	13
877	665	ap-1 transcription	[AP-1 transcription]	12.285714285714286	2	14	12	7
878	666	nuclear factor-kappa b activation	[nuclear factor-kappa B activation]	12.283459380588962	4	9	5	4
879	666	reporter gene activity	[reporter gene activity]	12.283459380588962	3	9	5	4
880	666	central nervous system	[central nervous system]	12.283459380588962	3	9	5	4
881	667	histocompatibility class	[histocompatibility class]	12.25	2	14	14	8
882	668	transcription factor factor	[transcription factor factor]	12.226853576991777	3	9	9	7
883	669	oxygen species	[oxygen species]	12.2	2	15	14	5
884	669	lymphoblastic leukemia	[lymphoblastic leukemia]	12.2	2	15	14	5
885	669	growth inhibition	[growth inhibition]	12.2	2	14	9	5
886	670	active form	[active form]	12.166666666666666	2	14	11	6
887	671	il-2 gene expression	[IL-2 gene expression]	12.151379172195533	3	9	4	3
888	671	t-cell acute leukemia	[T-cell acute leukemia]	12.151379172195533	3	9	8	6
889	671	expression of many gene	[expression of many genes]	12.151379172195533	4	9	4	3
890	671	protein kinase mapk	[protein kinase MAPK]	12.151379172195533	3	9	8	6
891	671	5' flank region	[5' flanking region]	12.151379172195533	3	9	4	3
892	672	monocytic thp-1 cell	[monocytic THP-1 cells]	12.151379172195531	3	10	7	3
893	672	myeloid leukemia cell	[myeloid leukemia cells]	12.151379172195531	3	10	7	3
894	673	MHC	[MHC]	12.146153846153847	1	123	40	26
895	674	action	[action]	12.089795918367347	1	123	103	49
896	675	CD4	[CD4]	12.073170731707318	1	122	52	41
897	676	gamma	[gamma]	12.048979591836735	1	122	74	49
898	677	interleukin-2	[interleukin-2]	12.027500000000002	1	122	69	40
899	678	essential role	[essential role]	12.0	2	15	12	4
900	678	protein level	[protein level]	12.0	2	13	3	3
901	678	viral gene	[viral gene]	12.0	2	13	8	8
902	678	1,25-dihydroxyvitamin D3	[1,25-dihydroxyvitamin D3]	12.0	2	13	9	9
903	678	antigen-presenting cell	[antigen-presenting cell]	12.0	2	13	5	5
904	678	complex formation	[complex formation]	12.0	2	13	10	10
905	678	human chromosome	[human chromosome]	12.0	2	13	7	7
906	678	tnf-alpha release	[TNF-alpha release]	12.0	2	14	12	6
907	678	proteasome inhibitor	[proteasome inhibitor]	12.0	2	13	8	8
908	678	tumor necrosis factor alpha tnf-alpha	[tumor necrosis factor alpha TNF-alpha]	12.0	5	12	0	0
909	679	il-6	[IL-6]	11.975000000000001	1	121	60	48
910	680	cell lineage	[cell lineage]	11.9	2	13	11	10
911	680	epstein-barr virus	[Epstein-Barr virus]	11.9	2	13	11	10
912	681	signal transducer of transcription	[signal transducer of transcription]	11.887218755408671	4	9	3	2
913	681	adhesion molecule expression	[adhesion molecule expression]	11.887218755408671	3	9	6	4
914	681	normal T lymphocyte	[normal T lymphocytes]	11.887218755408671	3	9	3	2
915	682	promoter sequence	[promoter sequence]	11.875	2	13	9	8
916	683	negative regulation	[negative regulation]	11.857142857142858	2	13	8	7
917	683	reporter plasmid	[reporter plasmid]	11.857142857142858	2	13	8	7
918	683	two gene	[two genes]	11.857142857142858	2	13	8	7
919	684	map kinase	[MAP kinase]	11.833333333333334	2	13	7	6
920	684	extracellular domain	[extracellular domain]	11.833333333333334	2	13	7	6
921	685	primary T	[primary T]	11.8	2	13	6	5
922	685	immune function	[immune function]	11.8	2	13	6	5
923	686	lipopolysaccharide	[lipopolysaccharide]	11.793333333333335	1	120	62	30
924	687	AP-1	[AP-1]	11.75909090909091	1	119	31	22
925	688	cell population	[cell population]	11.75	2	13	10	8
926	688	protein phosphatase	[protein phosphatase]	11.75	2	13	10	8
927	688	activation signal	[activation signal]	11.75	2	13	10	8
928	689	dominant negative mutant	[dominant negative mutant]	11.728722505336558	3	9	8	5
929	690	vitro transcription	[vitro transcription]	11.714285714285714	2	13	9	7
930	691	lps induction	[LPS induction]	11.666666666666668	2	16	13	3
931	692	glucocorticoid therapy	[glucocorticoid therapy]	11.666666666666666	2	13	8	6
932	692	hiv-1 expression	[HIV-1 expression]	11.666666666666666	2	13	8	6
933	692	immediate-early gene	[immediate-early gene]	11.666666666666666	2	13	8	6
934	693	interleukin-2 receptor	[interleukin-2 receptor]	11.625	2	13	11	8
935	694	electromobility shift assay	[electromobility shift assay]	11.623058338621812	3	9	5	3
936	695	decrease	[decrease]	11.575000000000001	1	118	108	48
937	696	nucleus	[nucleus]	11.57	1	120	43	10
938	697	class molecule	[class molecule]	11.555555555555555	2	13	13	9
939	698	c-jun expression	[c-jun expression]	11.5	2	13	9	6
940	698	specific binding	[specific binding]	11.5	2	13	9	6
941	698	DNA replication	[DNA replication]	11.5	2	13	9	6
942	698	cell membrane	[cell membrane]	11.5	2	13	6	4
943	698	15 minute	[15 min]	11.5	2	13	6	4
944	698	nitric oxide	[nitric oxide]	11.5	2	13	6	4
945	698	biological effect	[biological effect]	11.5	2	14	10	4
946	699	cell surface expression	[cell surface expression]	11.490978130228383	3	9	7	4
947	699	expression of adhesion molecule	[expression of adhesion molecules]	11.490978130228383	4	9	7	4
948	700	human herpesvirus	[human herpesvirus]	11.428571428571429	2	13	11	7
949	700	deletion mutant	[deletion mutant]	11.428571428571429	2	13	11	7
950	701	MHC class gene	[MHC class genes]	11.411730005192325	3	9	9	5
951	701	differentiation of k562 cell	[differentiation of K562 cells]	11.411730005192325	4	9	9	5
952	701	mobility shift assay EMSA	[mobility shift assay EMSA]	11.411730005192325	4	9	9	5
953	701	factor-kappa b activation	[factor-kappa B activation]	11.411730005192325	3	9	9	5
954	701	center b cell	[center B cells]	11.411730005192325	3	9	9	5
955	702	class transactivator	[class transactivator]	11.375	2	13	13	8
956	703	5'-flanking region	[5'-flanking region]	11.333333333333334	2	14	8	3
957	703	bacterial lipopolysaccharide	[bacterial lipopolysaccharide]	11.333333333333334	2	14	8	3
958	704	component	[component]	11.33157894736842	1	115	96	57
959	705	hiv-1 enhancer	[HIV-1 enhancer]	11.25	2	13	7	4
960	705	immunodeficiency virus type 1 hiv-1	[immunodeficiency virus type 1 HIV-1]	11.25	5	15	15	4
961	705	cells.	[cells.]	11.25	1	115	40	16
962	705	specific inhibitor	[specific inhibitor]	11.25	2	14	11	4
963	706	group	[group]	11.234693877551022	1	114	81	49
964	707	locus control	[locus control]	11.2	2	14	14	5
965	707	start site	[start site]	11.2	2	14	14	5
966	708	herpes simplex	[herpes simplex]	11.142857142857142	2	13	13	7
967	709	interferon regulatory factor	[interferon regulatory factor]	11.094737505048094	3	8	5	5
968	709	regulation of gene	[regulation of genes]	11.094737505048094	3	8	4	4
969	709	signal transduction event	[signal transduction events]	11.094737505048094	3	8	5	5
970	709	promoter of gene	[promoters of genes]	11.094737505048094	3	9	8	4
971	709	role in the control	[role in the control]	11.094737505048094	4	8	8	8
972	709	squamous cell carcinoma	[squamous cell carcinoma]	11.094737505048094	3	8	5	5
973	709	I kappa b alpha	[I kappa B alpha]	11.094737505048094	4	8	2	2
974	709	expression of c-jun	[expression of c-jun]	11.094737505048094	3	8	1	1
975	709	replication of hiv-1	[replication of HIV-1]	11.094737505048094	3	8	6	6
976	709	role in the development	[role in the development]	11.094737505048094	4	8	6	6
977	709	MHC class ii gene	[MHC class II genes]	11.094737505048094	4	8	3	3
978	709	hematopoietic progenitor cell	[hematopoietic progenitor cells]	11.094737505048094	3	8	6	6
979	709	human myeloid cell	[human myeloid cell]	11.094737505048094	3	8	4	4
980	709	basal promoter activity	[basal promoter activity]	11.094737505048094	3	8	3	3
981	709	human glucocorticoid receptor	[human glucocorticoid receptor]	11.094737505048094	3	8	3	3
982	709	expression of cytokine gene	[expression of cytokine genes]	11.094737505048094	4	8	4	4
983	709	role in regulation	[role in regulation]	11.094737505048094	3	8	6	6
984	709	use a assay	[using a assay]	11.094737505048094	3	8	8	8
985	709	bacterial lipopolysaccharide lps	[bacterial lipopolysaccharide LPS]	11.094737505048094	3	8	1	1
986	709	induction of gene	[induction of genes]	11.094737505048094	3	8	7	7
987	709	kappa b-binding activity	[kappa B-binding activity]	11.094737505048094	3	8	3	3
988	709	expression of transcription factor	[expression of transcription factors]	11.094737505048094	4	8	4	4
989	709	protein tyrosine kinase activity	[protein tyrosine kinase activity]	11.094737505048094	4	8	1	1
990	709	NF-kappaB transcription factor	[NF-kappaB transcription factor]	11.094737505048094	3	8	2	2
991	709	negative regulatory element	[negative regulatory element]	11.094737505048094	3	8	3	3
992	709	different transcription factor	[different transcription factors]	11.094737505048094	3	8	6	6
993	709	number of cell	[number of cells]	11.094737505048094	3	8	7	7
994	709	intracellular signal pathway	[intracellular signaling pathways]	11.094737505048094	3	8	6	6
995	709	proliferation of T cell	[proliferation of T cells]	11.094737505048094	4	8	3	3
996	709	patient with disease	[patients with diseases]	11.094737505048094	3	8	8	8
997	709	role in the activation	[role in the activation]	11.094737505048094	4	8	6	6
998	709	gel shift analysis	[gel shift analysis]	11.094737505048094	3	8	2	2
999	709	major depressive disorder	[major depressive disorder]	11.094737505048094	3	8	3	3
1000	709	induction of monocytic differentiation	[induction of monocytic differentiation]	11.094737505048094	4	8	3	3
1001	709	apoptotic cell death	[apoptotic cell death]	11.094737505048094	3	8	3	3
1002	709	hematopoietic transcription factor	[hematopoietic transcription factor]	11.094737505048094	3	8	6	6
1003	709	protein tyrosine phosphorylation	[protein tyrosine phosphorylation]	11.094737505048094	3	8	3	3
1004	709	patient with leukemia	[patient with leukemia]	11.094737505048094	3	8	8	8
1005	709	activation of pkc	[activation of PKC]	11.094737505048094	3	8	4	4
1006	710	cDNA	[cDNA]	11.072972972972973	1	112	47	37
1007	711	breast	[breast]	11.070588235294117	1	112	22	17
1008	712	nfat	[NFAT]	11.057142857142857	1	112	60	42
1009	713	human disease	[human disease]	11.0	2	12	7	7
1010	713	regulatory domain	[regulatory domain]	11.0	2	12	6	6
1011	713	24 P.	[24 h.]	11.0	2	12	3	3
1012	713	costimulatory signal	[costimulatory signal]	11.0	2	12	6	6
1013	713	fc gamma	[Fc gamma]	11.0	2	12	9	9
1014	713	sequence motif	[sequence motif]	11.0	2	12	9	9
1015	713	activation of protein kinase c	[activation of protein kinase C]	11.0	5	12	4	4
1016	713	transcriptional mechanism	[transcriptional mechanism]	11.0	2	12	3	3
1017	713	fasl expression	[FasL expression]	11.0	2	12	5	5
1018	713	similar effect	[similar effect]	11.0	2	12	5	5
1019	713	DNA-protein complex	[DNA-protein complex]	11.0	2	12	8	8
1020	713	transfection experiment	[transfection experiments]	11.0	2	13	10	5
1021	713	il-2 transcription	[IL-2 transcription]	11.0	2	12	7	7
1022	713	Northern analysis	[Northern analysis]	11.0	2	12	3	3
1023	713	polymorphonuclear leukocyte	[polymorphonuclear leukocyte]	11.0	2	12	5	5
1024	713	9-cis RA	[9-cis RA]	11.0	2	12	5	5
1025	713	sodium salicylate	[sodium salicylate]	11.0	2	12	2	2
1026	713	autoimmune disease	[autoimmune disease]	11.0	2	12	7	7
1027	713	mutational analysis	[mutational analysis]	11.0	2	13	4	2
1028	713	use antibody	[using antibodies]	11.0	2	12	11	11
1029	714	camp	[cAMP]	10.953333333333333	1	111	44	30
1030	715	regulatory factor	[regulatory factor]	10.9	2	12	11	10
1031	716	B-cell line	[B-cell line]	10.88888888888889	2	12	10	9
1032	716	trans-acting factor	[trans-acting factor]	10.88888888888889	2	12	10	9
1033	716	interleukin 2	[interleukin 2]	10.88888888888889	2	12	10	9
1034	717	gata site	[GATA site]	10.875	2	12	9	8
1035	717	gene regulation	[gene regulation]	10.875	2	12	9	8
1036	718	pattern of expression	[pattern of expression]	10.868314290659358	3	8	8	7
1037	718	T transcription factor	[T transcription factor]	10.868314290659358	3	8	8	7
1038	718	receptor in leukocyte	[receptor in leukocytes]	10.868314290659358	3	8	8	7
1039	718	activation of factor	[activation of factor]	10.868314290659358	3	8	8	7
1040	718	patient with disorder	[patients with disorder]	10.868314290659358	3	8	8	7
1041	719	cd4+	[CD4+]	10.861290322580645	1	110	43	31
1042	720	transfection study	[transfection studies]	10.857142857142858	2	12	8	7
1043	720	cytoplasmic inhibitor	[cytoplasmic inhibitor]	10.857142857142858	2	12	8	7
1044	721	potent inhibitor	[potent inhibitor]	10.833333333333334	2	13	13	6
1045	722	number of gene	[number of genes]	10.830577088261235	3	8	7	6
1046	722	t-cell-specific transcription factor	[T-cell-specific transcription factor]	10.830577088261235	3	8	7	6
1047	722	set of gene	[set of genes]	10.830577088261235	3	8	7	6
1048	722	stage of B-cell differentiation	[stage of B-cell differentiation]	10.830577088261235	4	8	7	6
1049	723	eosinophil	[eosinophil]	10.825000000000001	1	110	49	28
1050	724	estrogen	[estrogen]	10.824	1	110	44	25
1051	725	NF-kappaB site	[NF-kappaB site]	10.8	2	12	6	5
1052	725	transcriptional repressor	[transcriptional repressor]	10.8	2	12	6	5
1053	726	b-cell	[B-cell]	10.77948717948718	1	109	47	39
1054	727	il-4 gene expression	[IL-4 gene expression]	10.777745004903862	3	8	6	5
1055	727	transform growth factor-beta	[transforming growth factor-beta]	10.777745004903862	3	8	6	5
1056	727	myeloid cell differentiation	[myeloid cell differentiation]	10.777745004903862	3	8	6	5
1057	727	inhibition of apoptosis	[inhibition of apoptosis]	10.777745004903862	3	8	6	5
1058	727	cytokine gene transcription	[cytokine gene transcription]	10.777745004903862	3	8	6	5
1059	727	stimulation of cell	[Stimulation of cells]	10.777745004903862	3	8	6	5
1060	727	Sp1 binding site	[Sp1 binding site]	10.777745004903862	3	8	6	5
1061	728	AP-1 site	[AP-1 site]	10.75	2	13	9	4
1062	728	Sp1 site	[Sp1 site]	10.75	2	12	5	4
1063	728	severe immunodeficiency	[severe immunodeficiency]	10.75	2	12	10	8
1064	728	hiv enhancer	[HIV enhancer]	10.75	2	12	5	4
1065	729	agent	[agent]	10.741304347826087	1	109	73	46
1066	730	acute leukemia APL	[acute leukemia APL]	10.698496879867806	3	9	9	4
1067	730	factor kappab nf-kappab	[factor kappaB NF-kappaB]	10.698496879867806	3	9	9	4
1068	730	erythroid progenitor cell	[erythroid progenitor cells]	10.698496879867806	3	8	5	4
1069	730	ap-1 enhancer activity	[AP-1 enhancer activity]	10.698496879867806	3	8	5	4
1070	730	human mononuclear cell	[human mononuclear cells]	10.698496879867806	3	8	5	4
1071	730	pathogenesis of disease	[pathogenesis of diseases]	10.698496879867806	3	9	9	4
1072	730	1 alpha,25-dihydroxyvitamin D3	[1 alpha,25-dihydroxyvitamin D3]	10.698496879867806	3	8	5	4
1073	731	il-2r	[IL-2R]	10.690322580645162	1	109	65	31
1074	732	CRE site	[CRE site]	10.666666666666666	2	13	7	3
1075	732	further evidence	[further evidence]	10.666666666666666	2	12	8	6
1076	732	1 hour	[1 hr]	10.666666666666666	2	12	4	3
1077	732	N-terminal domain	[N-terminal domain]	10.666666666666666	2	12	8	6
1078	732	neutrophil adhesion	[neutrophil adhesion]	10.666666666666666	2	12	4	3
1079	732	molecular event	[molecular events]	10.666666666666666	2	12	4	3
1080	732	hiv-1 repeat	[HIV-1 repeat]	10.666666666666666	2	12	12	9
1081	732	M. tuberculosis	[M. tuberculosis]	10.666666666666666	2	12	4	3
1082	732	control group	[control group]	10.666666666666666	2	12	4	3
1083	733	model	[model]	10.663043478260871	1	108	63	46
1084	734	chain	[chain]	10.661111111111111	1	109	86	36
1085	735	Sp1	[Sp1]	10.644	1	108	39	25
1086	736	hydrogen peroxide	[hydrogen peroxide]	10.625	2	12	11	8
1087	737	nb4 cell	[NB4 cells]	10.6	2	12	7	5
1088	738	progenitor	[progenitor]	10.570967741935483	1	108	71	31
1089	739	primary human T lymphocyte	[primary human T lymphocytes]	10.566416671474375	4	8	4	3
1090	739	protein kinase pathway	[protein kinase pathway]	10.566416671474375	3	8	8	6
1091	739	b transcription factor	[B transcription factor]	10.566416671474375	3	8	8	6
1092	739	NF-kappa b binding site	[NF-kappa B binding site]	10.566416671474375	4	8	4	3
1093	739	putative transcription factor	[putative transcription factor]	10.566416671474375	3	8	8	6
1094	739	effect of RA	[effect of RA]	10.566416671474375	3	8	8	6
1095	739	t-cell acute lymphoblastic leukemia	[T-cell acute lymphoblastic leukemia]	10.566416671474375	4	8	4	3
1096	739	t-cell lymphoblastic leukemia	[T-cell lymphoblastic leukemia]	10.566416671474375	3	8	8	6
1097	739	human cd4+ T cell	[human CD4+ T cells]	10.566416671474375	4	8	4	3
1098	740	pbmc	[PBMC]	10.519354838709678	1	107	56	31
1099	741	IL-4 gene	[IL-4 gene]	10.5	2	12	9	6
1100	741	synthetic peptide	[synthetic peptide]	10.5	2	12	6	4
1101	741	vein cell	[vein cells]	10.5	2	14	14	4
1102	741	TATA box	[TATA box]	10.5	2	14	7	2
1103	741	lytic cycle	[lytic cycle]	10.5	2	12	6	4
1104	741	high expression	[high expression]	10.5	2	12	12	8
1105	742	murine T cell	[murine T cells]	10.46075250475963	3	8	7	5
1106	743	platelet	[platelet]	10.453846153846154	1	106	57	39
1107	744	lineage	[lineage]	10.434693877551021	1	106	81	49
1108	745	important regulator	[important regulator]	10.428571428571429	2	12	11	7
1109	746	il-2r beta	[IL-2R beta]	10.4	2	12	8	5
1110	747	calcineurin	[calcineurin]	10.368181818181819	1	105	29	22
1111	748	deletion analysis	[deletion analysis]	10.333333333333334	2	12	5	3
1112	749	T cell NF-AT	[T cells NF-AT]	10.302256254687515	3	10	7	2
1113	749	anergic T cell	[anergic T cells]	10.302256254687515	3	8	6	4
1114	749	nf-kappa b expression	[NF-kappa B expression]	10.302256254687515	3	8	3	2
1115	750	bp	[bp]	10.295000000000002	1	104	63	60
1116	751	b activity	[B activity]	10.285714285714286	2	12	12	7
1117	752	octamer site	[octamer site]	10.25	2	12	7	4
1118	753	peripheral leukocyte	[peripheral leukocytes]	10.2	2	12	9	5
1119	754	p	[P]	10.186206896551724	1	103	33	29
1120	755	mobility shift analysis	[mobility shift analysis]	10.143760004615402	3	8	8	5
1121	756	h	[h]	10.110204081632654	1	103	93	49
1122	757	(mhc) class ii	[(MHC) class II]	10.038095837900658	3	9	8	3
1123	758	erythroid transcription factor	[erythroid transcription factor]	10.038095837900656	3	8	5	3
1124	758	treatment of cell	[treatment of cells]	10.038095837900656	3	8	5	3
1125	759	kinase inhibitor	[kinase inhibitor]	10.0	2	11	7	7
1126	759	enf)-kappa b	[(NF)-kappa B]	10.0	2	12	8	4
1127	759	mnda expression	[MNDA expression]	10.0	2	12	8	4
1128	759	lymphocytic leukemia	[lymphocytic leukemia]	10.0	2	12	10	5
1129	759	u1 cell	[U1 cells]	10.0	2	11	5	5
1130	759	protein binding	[protein binding]	10.0	2	11	9	9
1131	759	anti-CD3 mab	[anti-CD3 mAb]	10.0	2	11	4	4
1132	759	mycobacterium tuberculosis	[Mycobacterium tuberculosis]	10.0	2	11	4	4
1133	759	tyrosine residue	[tyrosine residue]	10.0	2	11	3	3
1134	759	two element	[two elements]	10.0	2	11	9	9
1135	759	hiv transcription	[HIV transcription]	10.0	2	12	6	3
1136	759	t-cell clone	[T-cell clone]	10.0	2	11	7	7
1137	759	ifn-gamma production	[IFN-gamma production]	10.0	2	13	6	2
1138	759	family member	[family members,]	10.0	2	11	8	8
1139	759	inflammatory process	[inflammatory process]	10.0	2	11	3	3
1140	759	erythropoietin receptor	[erythropoietin receptor]	10.0	2	11	7	7
1141	759	b alpha	[B alpha]	10.0	2	12	6	3
1142	759	135eoh)2d3 receptor	[1,25(OH)2D3 receptor]	10.0	2	11	9	9
1143	759	chronic inflammation	[chronic inflammation]	10.0	2	11	3	3
1144	759	potent inducer	[potent inducer]	10.0	2	12	12	6
1145	759	t-cell proliferation	[T-cell proliferation]	10.0	2	11	6	6
1146	759	camp level	[cAMP levels]	10.0	2	11	6	6
1147	759	cis element	[cis element]	10.0	2	11	8	8
1148	760	stage	[stage]	9.895121951219513	1	101	84	41
1149	761	steroid	[steroid]	9.880645161290325	1	100	37	31
1150	762	NK activity	[NK activity]	9.875	2	11	9	8
1151	762	cell extract	[cell extract]	9.875	2	11	9	8
1152	763	er	[ER]	9.872727272727275	1	100	42	33
1153	764	regulator	[regulator]	9.863414634146343	1	101	97	41
1154	765	healthy woman	[healthy women]	9.857142857142858	2	11	8	7
1155	765	interleukin-1 beta	[interleukin-1 beta]	9.857142857142858	2	11	8	7
1156	766	case	[case]	9.841666666666669	1	100	76	48
1157	767	significant effect	[significant effect]	9.8	2	12	11	5
1158	767	enhancer region	[enhancer region]	9.8	2	11	6	5
1159	767	corticosteroid receptor	[corticosteroid receptor]	9.8	2	12	11	5
1160	767	gata-binding protein	[GATA-binding protein]	9.8	2	11	6	5
1161	768	chromosome	[chromosome]	9.77872340425532	1	99	57	47
1162	769	tumor suppressor	[tumor suppressor]	9.777777777777779	2	11	11	9
1163	770	GM-CSF	[GM-CSF]	9.762500000000001	1	99	22	16
1164	771	hormone	[hormone]	9.752777777777778	1	99	53	36
1165	772	hormone receptor	[hormone receptor]	9.75	2	11	10	8
1166	772	cDNA library	[cDNA library]	9.75	2	11	5	4
1167	772	sequence similarity	[sequence similarity]	9.75	2	11	10	8
1168	772	hiv-1 transcription	[HIV-1 transcription]	9.75	2	12	9	4
1169	772	direct effect	[direct effect]	9.75	2	11	10	8
1170	772	vcam-1 expression	[VCAM-1 expression]	9.75	2	11	5	4
1171	772	negative element	[negative element]	9.75	2	11	10	8
1172	772	granulocyte-macrophage colony-stimulating	[granulocyte-macrophage colony-stimulating]	9.75	2	13	13	4
1173	773	serum	[serum]	9.74848484848485	1	99	50	33
1174	774	pkc	[PKC]	9.74375	1	99	50	32
1175	775	membrane receptor	[membrane receptor]	9.714285714285714	2	11	9	7
1176	776	hla class	[HLA class]	9.666666666666668	2	14	13	3
1177	777	beta-globin promoter	[beta-globin promoter]	9.666666666666666	2	11	4	3
1178	777	neonatal T	[neonatal T]	9.666666666666666	2	11	4	3
1179	777	DRA promoter	[DRA promoter]	9.666666666666666	2	12	7	3
1180	777	GM-CSF gene	[GM-CSF gene]	9.666666666666666	2	11	4	3
1181	777	human eosinophil	[human eosinophils]	9.666666666666666	2	11	4	3
1182	777	significant decrease	[significant decrease]	9.666666666666666	2	13	10	3
1183	777	viral latency	[viral latency]	9.666666666666666	2	11	4	3
1184	778	combination	[combination]	9.655555555555557	1	101	80	18
1185	779	overexpression	[overexpression]	9.634615384615385	1	100	95	26
1186	780	oxygen intermediate	[oxygen intermediates]	9.6	2	12	12	5
1187	781	u937	[U937]	9.590909090909092	1	98	46	22
1188	782	subject	[subject]	9.577142857142858	1	98	78	35
1189	783	il-2 mrna	[IL-2 mRNA]	9.571428571428571	2	11	10	7
1190	783	activator protein	[activator protein]	9.571428571428571	2	11	10	7
1191	783	factor bind	[factor binding]	9.571428571428571	2	11	10	7
1192	784	blot	[blot]	9.55	1	100	81	18
1193	785	thp-1	[THP-1]	9.52608695652174	1	97	40	23
1194	786	RAW 264.7 cell	[RAW 264.7 cells]	9.509775004326938	3	7	3	3
1195	786	NF-kappa b p65	[NF-kappa B p65]	9.509775004326938	3	9	3	1
1196	786	phorbol ester PMA	[phorbol ester PMA]	9.509775004326938	3	7	1	1
1197	786	chloramphenicol acetyltransferase reporter gene	[chloramphenicol acetyltransferase reporter gene]	9.509775004326938	4	6	0	0
1198	786	hiv-1 terminal repeat LTR	[HIV-1 terminal repeat LTR]	9.509775004326938	4	9	9	3
1199	786	simian immunodeficiency virus	[simian immunodeficiency virus]	9.509775004326938	3	7	6	6
1200	786	thp-1 monocytic cell	[THP-1 monocytic cells]	9.509775004326938	3	7	2	2
1201	786	thyroid hormone receptor	[thyroid hormone receptor]	9.509775004326938	3	7	4	4
1202	786	level of gene transcription	[level of gene transcription]	9.509775004326938	4	7	1	1
1203	786	human blood T cell	[human blood T cells]	9.509775004326938	4	9	9	3
1204	786	NF-kappa b activity	[NF-kappa B activity]	9.509775004326938	3	7	5	5
1205	786	transcription factor nuclear factor	[transcription factor nuclear factor]	9.509775004326938	4	7	3	3
1206	786	JAK /stat pathway	[JAK /STAT pathway]	9.509775004326938	3	7	4	4
1207	786	hematopoietic stem cell	[hematopoietic stem cells]	9.509775004326938	3	7	3	3
1208	786	expression in T cell	[expression in T cells]	9.509775004326938	4	7	6	6
1209	786	gene expression in cell	[gene expression in cells]	9.509775004326938	4	7	7	7
1210	786	thromboxane receptor gene	[thromboxane receptor gene]	9.509775004326938	3	7	2	2
1211	786	hepatitis b virus	[hepatitis B virus]	9.509775004326938	3	7	5	5
1212	786	major transcription start site	[major transcription start site]	9.509775004326938	4	7	2	2
1213	786	major transcription initiation site	[major transcription initiation site]	9.509775004326938	4	7	2	2
1214	786	kappa b motif	[kappa B motif]	9.509775004326938	3	7	3	3
1215	786	transcription (stat) protein	[transcription (Stat) protein]	9.509775004326938	3	7	1	1
1216	786	T cell differentiation	[T cell differentiation]	9.509775004326938	3	7	3	3
1217	786	expression of NF-kappa b	[expression of NF-kappa B]	9.509775004326938	4	9	6	2
1218	786	early signal event	[early signaling events]	9.509775004326938	3	7	3	3
1219	786	binding of factor	[binding of factors]	9.509775004326938	3	7	7	7
1220	786	t-cell lymphotropic virus type	[T-cell lymphotropic virus type]	9.509775004326938	4	9	9	3
1221	786	NF-kappa b inhibitor	[NF-kappa B inhibitor]	9.509775004326938	3	7	3	3
1222	786	treatment of T cell	[Treatment of T cells]	9.509775004326938	4	7	2	2
1223	786	all-tran retinoic acid RA	[all-trans retinoic acid RA]	9.509775004326938	4	7	1	1
1224	786	phosphorylation of CREB	[phosphorylation of CREB]	9.509775004326938	3	7	1	1
1225	786	human alveolar macrophage	[human alveolar macrophages]	9.509775004326938	3	7	3	3
1226	786	CD28 response element	[CD28 response element]	9.509775004326938	3	7	3	3
1227	786	IL-4 gene expression	[IL-4 gene expression]	9.509775004326938	3	7	3	3
1228	786	tumour necrosis factor	[tumour necrosis factor]	9.509775004326938	3	8	8	4
1229	786	rabbit reticulocyte lysate	[rabbit reticulocyte lysate]	9.509775004326938	3	7	2	2
1230	786	b cell activation	[B cell activation]	9.509775004326938	3	7	4	4
1231	786	mouse T cell	[mouse T cells]	9.509775004326938	3	7	4	4
1232	786	effect on gene expression	[effect on gene expression]	9.509775004326938	4	7	7	7
1233	786	nf-kappa b binding	[NF-kappa B binding]	9.509775004326938	3	7	2	2
1234	786	expression of receptor	[expression of receptors]	9.509775004326938	3	7	5	5
1235	786	1 long terminal repeat	[1 long terminal repeat]	9.509775004326938	4	7	4	4
1236	786	several cytokine gene	[several cytokine genes]	9.509775004326938	3	7	3	3
1237	786	acidic activation domain	[acidic activation domain]	9.509775004326938	3	7	5	5
1238	786	class ii transactivator CIITA	[class II transactivator CIITA]	9.509775004326938	4	6	0	0
1239	786	intercellular adhesion molecule-1 icam-1	[intercellular adhesion molecule-1 ICAM-1]	9.509775004326938	4	7	4	4
1240	786	kappa b element	[kappa B element]	9.509775004326938	3	7	3	3
1241	786	endothelial cell activation	[endothelial cell activation]	9.509775004326938	3	7	4	4
1242	786	transient transfection experiment	[transient transfection experiments]	9.509775004326938	3	7	2	2
1243	786	heat shock protein	[heat shock protein]	9.509775004326938	3	7	5	5
1244	786	patient with sle	[patients with SLE]	9.509775004326938	3	7	4	4
1245	786	NF-kappa b binding activity	[NF-kappa B binding activity]	9.509775004326938	4	6	0	0
1246	786	regulation of expression	[regulation of expression]	9.509775004326938	3	7	6	6
1247	786	rest b cell	[resting B cells]	9.509775004326938	3	7	4	4
1248	786	eukaryotic transcription factor	[eukaryotic transcription factor]	9.509775004326938	3	7	5	5
1249	786	b-cell-specific transcription factor	[B-cell-specific transcription factor]	9.509775004326938	3	7	7	7
1250	786	increase in the level	[increase in the level]	9.509775004326938	4	7	6	6
1251	786	rna polymerase ii	[RNA polymerase II]	9.509775004326938	3	7	5	5
1252	786	memory T cell	[memory T cells]	9.509775004326938	3	8	2	1
1253	786	IL-4R alpha chain	[IL-4R alpha chain]	9.509775004326938	3	6	0	0
1254	787	adult T	[adult T]	9.5	2	12	5	2
1255	787	intracellular calcium	[intracellular calcium]	9.5	2	11	3	2
1256	787	CD4 promoter	[CD4 promoter]	9.5	2	11	6	4
1257	787	ets protein	[Ets protein]	9.5	2	11	6	4
1258	787	pkc activation	[PKC activation]	9.5	2	11	6	4
1259	788	observation	[observation]	9.371428571428572	1	95	18	14
1260	789	tpa	[TPA]	9.346153846153847	1	95	40	26
1261	790	potential mechanism	[potential mechanism]	9.333333333333334	2	11	5	3
1262	790	stat1	[STAT1]	9.333333333333334	1	95	45	27
1263	791	il-1	[IL-1]	9.317857142857143	1	95	51	28
1264	792	CsA	[CsA]	9.305882352941177	1	95	33	17
1265	793	replication	[replication]	9.263333333333334	1	95	71	30
1266	794	glial cell	[glial cells]	9.25	2	11	7	4
1267	794	pou domain	[POU domain]	9.25	2	11	7	4
1268	794	cathepsin g	[cathepsin G]	9.25	2	11	7	4
1269	795	lymphocyte glucocorticoid receptor	[Lymphocyte glucocorticoid receptor]	9.245614587540079	3	7	7	6
1270	795	1 terminal repeat	[1 terminal repeat]	9.245614587540079	3	7	7	6
1271	796	process	[process]	9.224324324324325	1	94	65	37
1272	797	ebv infection	[EBV infection]	9.2	2	11	9	5
1273	798	activation of gene expression	[activation of gene expression]	9.192782504182706	4	7	6	5
1274	798	transcriptional activation domain	[transcriptional activation domain]	9.192782504182706	3	7	6	5
1275	798	T cell-specific transcription factor	[T cell-specific transcription factor]	9.192782504182706	4	7	6	5
1276	798	gene in monocyte	[gene in monocytes]	9.192782504182706	3	7	6	5
1277	798	jurkat T cell	[Jurkat T cells]	9.192782504182706	3	7	6	5
1278	798	renal cell carcinoma	[renal cell carcinoma]	9.192782504182706	3	7	6	5
1279	798	class ii promoter	[class II promoter]	9.192782504182706	3	7	6	5
1280	798	histocompatibility class ii	[histocompatibility class II]	9.192782504182706	3	7	6	5
1281	798	transcription factor bind	[transcription factor binding]	9.192782504182706	3	7	6	5
1282	798	vascular cell adhesion molecule	[vascular cell adhesion molecule]	9.192782504182706	4	7	6	5
1283	798	lymphoid-specific transcription factor	[lymphoid-specific transcription factor]	9.192782504182706	3	7	6	5
1284	798	response to stimulation	[response to stimulation]	9.192782504182706	3	7	6	5
1285	799	response gene	[response genes]	9.166666666666666	2	11	11	6
1286	800	gata-1	[GATA-1]	9.13846153846154	1	93	42	26
1287	801	reporter gene construct	[reporter gene construct]	9.113534379146648	3	7	5	4
1288	801	macrophage colony-stimulating factor	[macrophage colony-stimulating factor]	9.113534379146648	3	7	5	4
1289	801	translocation of nf-kappa b	[translocation of NF-kappa B]	9.113534379146648	4	7	5	4
1290	801	two binding site	[two binding sites]	9.113534379146648	3	7	5	4
1291	801	DNA binding site	[DNA binding site]	9.113534379146648	3	7	5	4
1292	802	pattern	[pattern]	9.08974358974359	1	93	82	39
1293	803	ligand	[ligand]	9.079591836734695	1	92	59	49
1294	804	suppression	[suppression]	9.075675675675676	1	93	83	37
1295	805	involvement	[involvement]	9.041666666666668	1	94	86	24
1296	806	septic shock	[septic shock]	9.0	2	10	2	2
1297	806	specific antibody	[specific antibody]	9.0	2	10	5	5
1298	806	cellular transcription	[cellular transcription]	9.0	2	9	0	0
1299	806	two domain	[two domains]	9.0	2	10	7	7
1300	806	normal hematopoiesis	[normal hematopoiesis]	9.0	2	10	2	2
1301	806	differential expression	[differential expression]	9.0	2	12	9	3
1302	806	mature b	[mature B]	9.0	2	11	4	2
1303	806	c/ebp beta	[C/EBP beta]	9.0	2	11	10	5
1304	806	social support	[social support]	9.0	2	10	1	1
1305	806	DNA element	[DNA element]	9.0	2	10	9	9
1306	806	antisense oligonucleotide	[antisense oligonucleotide]	9.0	2	10	5	5
1307	806	mast cell	[mast cell]	9.0	2	10	2	2
1308	806	viral promoter	[viral promoter]	9.0	2	10	3	3
1309	806	expression assay	[expression assay]	9.0	2	12	12	4
1310	806	red cell	[red cell]	9.0	2	10	2	2
1311	806	three protein	[three proteins]	9.0	2	10	7	7
1312	806	possible mechanism	[possible mechanism]	9.0	2	10	6	6
1313	806	transcriptional induction	[transcriptional induction]	9.0	2	11	8	4
1314	806	IL-2 gene	[IL-2 gene]	9.0	2	12	6	2
1315	806	human leukemia	[human leukemia]	9.0	2	10	2	2
1316	806	interleukin (il)-2	[interleukin (IL)-2]	9.0	2	10	3	3
1317	806	mrna stability	[mRNA stability]	9.0	2	10	8	8
1318	806	G1 phase	[G1 phase]	9.0	2	10	7	7
1319	806	immediate gene	[immediate gene]	9.0	2	10	9	9
1320	806	t-cell antigen	[T-cell antigen]	9.0	2	11	8	4
1321	806	interferon-gamma ifn-gamma	[interferon-gamma IFN-gamma]	9.0	2	10	3	3
1322	806	monocytic lineage	[monocytic lineage]	9.0	2	10	4	4
1323	806	intracellular domain	[intracellular domain]	9.0	2	10	4	4
1324	806	e box	[E box]	9.0	2	10	9	9
1325	806	Retinoic acid	[Retinoic acid]	9.0	2	12	6	2
1326	806	memory T	[memory T]	9.0	2	11	10	5
1327	806	normal control	[normal control]	9.0	2	10	3	3
1328	806	B-cell differentiation	[B-cell differentiation]	9.0	2	10	2	2
1329	806	significant level	[significant level]	9.0	2	12	12	4
1330	807	cd4(+) T cell	[CD4(+) T cells]	8.981454170753219	3	7	4	3
1331	807	T cell nfat	[T cell NFAT]	8.981454170753219	3	8	7	3
1332	807	major histocompatibility class	[major histocompatibility class]	8.981454170753219	3	7	4	3
1333	807	extracellular signal-regulated kinase	[extracellular signal-regulated kinase]	8.981454170753219	3	7	4	3
1334	808	fusion	[fusion]	8.973809523809525	1	91	53	42
1335	809	molecule	[molecule]	8.96842105263158	1	91	75	57
1336	810	ca2+	[Ca2+]	8.958823529411765	1	91	48	34
1337	811	vitamin	[vitamin]	8.933333333333334	1	91	30	18
1338	812	bp upstream	[bp upstream]	8.88888888888889	2	10	10	9
1339	812	rna polymerase	[RNA polymerase]	8.88888888888889	2	10	10	9
1340	812	granulocyte-macrophage factor	[granulocyte-macrophage factor]	8.88888888888889	2	10	10	9
1341	812	fas ligand	[Fas ligand]	8.88888888888889	2	10	10	9
1342	813	activation of the factor	[activation of the factor]	8.875790004038475	4	7	7	5
1343	814	transcriptional element	[transcriptional element]	8.875	2	10	9	8
1344	814	receptor binding	[receptor binding]	8.875	2	10	9	8
1345	814	steroid receptor	[steroid receptor]	8.875	2	10	9	8
1346	814	upstream sequence	[upstream sequence]	8.875	2	10	9	8
1347	814	kda protein	[kDa protein]	8.875	2	10	9	8
1348	814	regulatory role	[regulatory role]	8.875	2	10	9	8
1349	815	VDR	[VDR]	8.860714285714286	1	90	39	28
1350	816	x box	[X box]	8.857142857142858	2	10	8	7
1351	817	accessory cell	[accessory cells]	8.833333333333334	2	10	7	6
1352	817	oestrogen receptor	[oestrogen receptor]	8.833333333333334	2	10	7	6
1353	818	HTLV-I	[HTLV-I]	8.83125	1	90	27	16
1354	819	ligand binding	[ligand binding]	8.8	2	10	6	5
1355	819	negative mutant	[negative mutant]	8.8	2	11	11	5
1356	819	serine phosphorylation	[serine phosphorylation]	8.8	2	11	11	5
1357	819	differentiation marker	[differentiation marker]	8.8	2	10	6	5
1358	819	tnf-alpha production	[TNF-alpha production]	8.8	2	10	6	5
1359	819	lupus erythematosus	[lupus erythematosus]	8.8	2	11	11	5
1360	819	N-terminal region	[N-terminal region]	8.8	2	10	6	5
1361	820	necrosis	[necrosis]	8.784615384615384	1	95	93	13
1362	821	interleukin	[interleukin]	8.76388888888889	1	89	49	36
1363	822	thymocyte	[thymocyte]	8.757575757575758	1	89	47	33
1364	823	cortisol level	[cortisol level]	8.75	2	10	5	4
1365	823	breast tumor	[breast tumor]	8.75	2	10	10	8
1366	824	luciferase reporter gene	[luciferase reporter gene]	8.71729375396636	3	7	3	2
1367	824	expression of cellular gene	[expression of cellular genes]	8.71729375396636	4	7	6	4
1368	824	stimulation of T cell	[Stimulation of T cells]	8.71729375396636	4	7	3	2
1369	824	binding of the factor	[binding of the factor]	8.71729375396636	4	7	6	4
1370	824	c-myc mrna expression	[c-myc mRNA expression]	8.71729375396636	3	7	6	4
1371	824	germinal center b cell	[germinal center B cells]	8.71729375396636	4	8	5	2
1372	824	myeloid leukemic cell	[myeloid leukemic cells]	8.71729375396636	3	7	3	2
1373	824	adult T cell	[adult T cells]	8.71729375396636	3	7	3	2
1374	824	intracellular signal transduction	[intracellular signal transduction]	8.71729375396636	3	7	3	2
1375	824	THP-1 cell line	[THP-1 cell line]	8.71729375396636	3	8	5	2
1376	825	follow activation	[following activation]	8.714285714285714	2	10	9	7
1377	825	receptor concentration	[receptor concentration]	8.714285714285714	2	10	9	7
1378	825	upstream region	[upstream region]	8.714285714285714	2	10	9	7
1379	826	anorexia nervosa	[anorexia nervosa]	8.666666666666666	2	12	10	3
1380	826	octamer sequence	[octamer sequence]	8.666666666666666	2	10	8	6
1381	826	effector cell	[effector cells]	8.666666666666666	2	10	8	6
1382	827	culture	[culture]	8.657142857142857	1	88	40	28
1383	828	stat3	[STAT3]	8.63846153846154	1	88	42	26
1384	829	NF	[NF]	8.635714285714286	1	89	37	14
1385	830	protein-DNA complex	[protein-DNA complex]	8.6	2	10	7	5
1386	831	characterization	[characterization]	8.58	1	90	63	15
1387	832	redox status	[redox status]	8.571428571428571	2	10	10	7
1388	832	potential target	[potential target]	8.571428571428571	2	10	10	7
1389	832	pkc activity	[PKC activity]	8.571428571428571	2	10	10	7
1390	832	mutant form	[mutant form]	8.571428571428571	2	10	10	7
1391	833	drug	[drug]	8.570731707317073	1	87	53	41
1392	834	degradation	[degradation]	8.516666666666667	1	87	55	30
1393	835	hour	[hr]	8.515217391304349	1	87	85	46
1394	836	further study	[further study]	8.5	2	10	3	2
1395	836	basal transcription	[basal transcription]	8.5	2	10	3	2
1396	836	human cytomegalovirus	[human cytomegalovirus]	8.5	2	10	6	4
1397	836	transendothelial migration	[transendothelial migration]	8.5	2	10	9	6
1398	836	dominant mutant	[dominant mutant]	8.5	2	10	9	6
1399	836	cyclosporin A	[cyclosporin A]	8.5	2	10	6	4
1400	836	leukemia virus	[leukemia virus]	8.5	2	11	10	4
1401	836	il-2 expression	[IL-2 expression]	8.5	2	10	6	4
1402	836	immune cell	[immune cells]	8.5	2	10	9	6
1403	836	stimulatory effect	[stimulatory effect]	8.5	2	11	10	4
1404	837	adhesion molecule-1 icam-1	[adhesion molecule-1 ICAM-1]	8.453133337179501	3	8	8	3
1405	838	chloramphenicol acetyl transferase	[chloramphenicol acetyl transferase]	8.4531333371795	3	7	5	3
1406	838	patient with sepsis	[patients with sepsis]	8.4531333371795	3	7	5	3
1407	838	plasma cortisol level	[plasma cortisol level]	8.4531333371795	3	7	5	3
1408	838	number of binding site	[number of binding sites]	8.4531333371795	4	7	5	3
1409	839	lead	[lead]	8.402702702702703	1	86	73	37
1410	840	bcl-6 protein	[BCL-6 protein]	8.4	2	10	8	5
1411	841	gm-csf	[GM-CSF]	8.384210526315789	1	86	41	19
1412	842	octamer	[octamer]	8.352631578947369	1	85	28	19
1413	843	significant increase	[significant increase]	8.333333333333334	2	12	11	3
1414	843	first demonstration	[first demonstration]	8.333333333333334	2	10	5	3
1415	843	mitogenic stimulation	[mitogenic stimulation]	8.333333333333334	2	10	5	3
1416	843	DNA fragmentation	[DNA fragmentation]	8.333333333333334	2	10	5	3
1417	844	hl-60	[HL-60]	8.33	1	85	34	20
1418	845	variety	[variety]	8.32857142857143	1	95	82	7
1419	846	cyclosporin	[cyclosporin]	8.294117647058824	1	85	35	17
1420	847	rna	[RNA]	8.279545454545454	1	84	53	44
1421	848	interferon	[interferon]	8.277142857142858	1	84	43	35
1422	849	bind activity	[binding activity]	8.25	2	11	11	4
1423	849	novel mechanism	[novel mechanism]	8.25	2	10	7	4
1424	850	repeat	[repeat]	8.226829268292683	1	84	71	41
1425	851	il-4 gene	[IL-4 gene]	8.2	2	10	9	5
1426	852	pu.1	[PU.1]	8.165000000000001	1	83	27	20
1427	853	gel	[gel]	8.161904761904763	1	84	50	21
1428	854	correlation	[correlation]	8.127500000000001	1	83	69	40
1429	855	time	[time]	8.060975609756097	1	82	57	41
1430	856	bone	[bone]	8.033333333333333	1	82	40	24
1431	857	inflammation	[inflammation]	8.005	1	82	39	20
1432	858	second messenger	[second messenger]	8.0	2	9	5	5
1433	858	human myeloid	[human myeloid]	8.0	2	10	4	2
1434	858	intracellular signal	[intracellular signaling]	8.0	2	9	4	4
1435	858	new insight	[new insights]	8.0	2	10	6	3
1436	858	human peripheral blood T cell	[human peripheral blood T cells]	8.0	5	9	1	1
1437	858	similar result	[similar result]	8.0	2	8	0	0
1438	858	expression vector	[expression vector]	8.0	2	9	7	7
1439	858	hematopoietic lineage	[hematopoietic lineage]	8.0	2	9	4	4
1440	858	gr mrna	[GR mRNA]	8.0	2	10	8	4
1441	858	simian virus	[simian virus]	8.0	2	10	4	2
1442	858	unstimulated cell	[unstimulated cells]	8.0	2	9	1	1
1443	858	mature T	[mature T]	8.0	2	9	1	1
1444	858	cell wall	[cell wall]	8.0	2	9	8	8
1445	858	biological function	[biological function]	8.0	2	9	6	6
1446	858	eukaryotic transcription	[eukaryotic transcription]	8.0	2	8	0	0
1447	858	two complex	[two complexes]	8.0	2	9	9	9
1448	858	western blot	[Western blot]	8.0	2	9	5	5
1449	858	Th1 cell	[Th1 cell]	8.0	2	9	6	6
1450	858	tcr stimulation	[TCR stimulation]	8.0	2	9	3	3
1451	858	viral transcription	[viral transcription]	8.0	2	9	4	4
1452	858	cell of the immune system	[cells of the immune system]	8.0	5	9	1	1
1453	858	oxidative signalling	[oxidative signalling]	8.0	2	9	1	1
1454	858	healthy volunteer	[healthy volunteer]	8.0	2	9	7	7
1455	858	basic protein	[basic protein]	8.0	2	9	8	8
1456	858	common pathway	[common pathway]	8.0	2	9	4	4
1457	858	mature cell	[mature cells]	8.0	2	9	8	8
1458	858	immunodeficiency syndrome	[immunodeficiency syndrome]	8.0	2	9	9	9
1459	858	interferon gamma	[interferon gamma]	8.0	2	9	4	4
1460	858	Burkitt' lymphoma	[Burkitt's lymphoma]	8.0	2	9	5	5
1461	858	DNA damage	[DNA damage]	8.0	2	9	6	6
1462	858	b gene	[B gene]	8.0	2	9	8	8
1463	858	neutrophil differentiation	[neutrophil differentiation]	8.0	2	9	3	3
1464	858	leukemic T	[leukemic T]	8.0	2	9	5	5
1465	858	intracellular receptor	[intracellular receptor]	8.0	2	9	8	8
1466	858	immature cell	[immature cells]	8.0	2	9	5	5
1467	858	chimeric receptor	[chimeric receptor]	8.0	2	9	7	7
1468	858	steel factor	[Steel factor]	8.0	2	9	3	3
1469	858	c/ebp protein	[C/EBP proteins]	8.0	2	9	3	3
1470	858	other cell	[other cell]	8.0	2	9	5	5
1471	858	human immunodeficiency virus type 1 hiv-1	[human immunodeficiency virus type 1 HIV-1]	8.0	6	9	1	1
1472	858	x inactivation	[X inactivation]	8.0	2	9	6	6
1473	858	model system	[model system]	8.0	2	9	5	5
1474	858	gel-shift assay	[gel-shift assay]	8.0	2	9	1	1
1475	858	fatty acid	[fatty acid]	8.0	2	9	4	4
1476	858	nuclear receptor	[nuclear receptor]	8.0	2	9	4	4
1477	858	tolerant cell	[tolerant cells]	8.0	2	9	2	2
1478	858	tnf alpha	[TNF alpha]	8.0	2	9	4	4
1479	858	adenovirus DNA	[adenovirus DNA]	8.0	2	10	6	3
1480	858	CD40 ligation	[CD40 ligation]	8.0	2	9	3	3
1481	858	t-cell gene	[T-cell gene]	8.0	2	9	8	8
1482	858	histone deacetylase	[histone deacetylase]	8.0	2	9	7	7
1483	859	reduction	[reduction]	7.976666666666667	1	82	67	30
1484	860	HeLa	[HeLa]	7.969230769230769	1	82	30	13
1485	861	IFN	[IFN]	7.958064516129032	1	81	44	31
1486	862	AP-1 transcription factor	[AP-1 transcription factor]	7.924812503605781	3	5	0	0
1487	862	novel regulatory element	[novel regulatory element]	7.924812503605781	3	6	4	4
1488	862	expression of this protein	[expression of these proteins]	7.924812503605781	4	6	3	3
1489	862	reporter gene expression	[reporter gene expression]	7.924812503605781	3	6	2	2
1490	862	herpes simplex virus	[herpes simplex virus]	7.924812503605781	3	6	4	4
1491	862	ap-1 transcriptional activity	[AP-1 transcriptional activity]	7.924812503605781	3	6	1	1
1492	862	human class ii	[human class II]	7.924812503605781	3	6	1	1
1493	862	reverse transcription-polymerase chain reaction	[reverse transcription-polymerase chain reaction]	7.924812503605781	4	6	2	2
1494	862	human myeloid leukemia cell	[human myeloid leukemia cells]	7.924812503605781	4	6	2	2
1495	862	presence of cycloheximide	[presence of cycloheximide]	7.924812503605781	3	6	1	1
1496	862	membrane protein 1	[membrane protein 1]	7.924812503605781	3	6	6	6
1497	862	transcription-polymerase chain reaction	[transcription-polymerase chain reaction]	7.924812503605781	3	7	6	3
1498	862	thymic epithelial cell	[thymic epithelial cells]	7.924812503605781	3	6	4	4
1499	862	transcription factor family	[transcription factor family]	7.924812503605781	3	6	5	5
1500	862	various cell type	[various cell types]	7.924812503605781	3	6	5	5
1501	862	human peripheral monocyte	[human peripheral monocytes]	7.924812503605781	3	5	0	0
1502	862	effect of ifn-gamma	[effects of IFN-gamma]	7.924812503605781	3	7	4	2
1503	862	differentiation of hl-60 cell	[differentiation of HL-60 cells]	7.924812503605781	4	6	5	5
1504	862	inhibitor of NF-kappa b	[inhibitor of NF-kappa B]	7.924812503605781	4	6	3	3
1505	862	treatment of disease	[treatment of diseases]	7.924812503605781	3	6	4	4
1506	862	patient with anorexia nervosa	[patients with anorexia nervosa]	7.924812503605781	4	6	3	3
1507	862	c-jun mrna expression	[c-jun mRNA expression]	7.924812503605781	3	6	2	2
1508	862	NF-kappa b induction	[NF-kappa B induction]	7.924812503605781	3	6	3	3
1509	862	human monocytic thp-1 cell	[human monocytic THP-1 cells]	7.924812503605781	4	5	0	0
1510	862	human blood cell	[human blood cells]	7.924812503605781	3	6	6	6
1511	862	expression of nf-kappa b	[expression of NF-kappa B]	7.924812503605781	4	6	4	4
1512	862	t-cell receptor tcr	[T-cell receptor TcR]	7.924812503605781	3	6	3	3
1513	862	phorbol ester treatment	[phorbol ester treatment]	7.924812503605781	3	7	4	2
1514	862	patient with acute leukemia	[patient with acute leukemia]	7.924812503605781	4	6	5	5
1515	862	normal human b cell	[normal human B cells]	7.924812503605781	4	6	1	1
1516	862	il-2 promoter activation	[IL-2 promoter activation]	7.924812503605781	3	6	3	3
1517	862	Jurkat T cell line	[Jurkat T cell line]	7.924812503605781	4	6	2	2
1518	862	transcription factor activation	[transcription factor activation]	7.924812503605781	3	6	3	3
1519	862	apoptosis of cell	[apoptosis of cells]	7.924812503605781	3	6	5	5
1520	862	h of stimulation	[h of stimulation]	7.924812503605781	3	6	6	6
1521	862	MHC class ii molecule	[MHC class II molecules]	7.924812503605781	4	6	4	4
1522	862	reactive oxygen intermediate ROI	[reactive oxygen intermediates ROI]	7.924812503605781	4	6	3	3
1523	862	cell cycle arrest	[cell cycle arrest]	7.924812503605781	3	6	1	1
1524	862	change in gene expression	[changes in gene expression]	7.924812503605781	4	6	1	1
1525	862	primary b cell	[primary B cells]	7.924812503605781	3	6	3	3
1526	862	granulocyte-macrophage colony-stimumulatelany-stg factor gm-csf	[granulocyte-macrophage colony-stimulating factor GM-CSF]	7.924812503605781	4	5	0	0
1527	862	role in activation	[role in activation]	7.924812503605781	3	6	6	6
1528	862	purpose of this study	[purpose of this study]	7.924812503605781	4	6	1	1
1529	862	trigger of hla-dr antigen	[triggering of HLA-DR antigens]	7.924812503605781	4	6	2	2
1530	862	viral long terminal repeat	[viral long terminal repeat]	7.924812503605781	4	7	4	2
1531	862	control of a promoter	[control of an promoter]	7.924812503605781	4	5	0	0
1532	862	two cell line	[two cell lines]	7.924812503605781	3	6	5	5
1533	862	understanding of the mechanism	[understanding of the mechanisms]	7.924812503605781	4	7	4	2
1534	862	transcription of the gene	[transcription of the gene]	7.924812503605781	4	6	5	5
1535	862	Cyclosporin A CsA	[Cyclosporin A CsA]	7.924812503605781	3	5	0	0
1536	862	effect on the activity	[effect on the activity]	7.924812503605781	4	6	6	6
1537	862	family of protein	[family of proteins]	7.924812503605781	3	6	6	6
1538	862	follow T cell activation	[following T cell activation]	7.924812503605781	4	6	2	2
1539	862	RNA polymerase ii	[RNA polymerase II]	7.924812503605781	3	6	2	2
1540	862	tcr alpha enhancer	[TCR alpha enhancer]	7.924812503605781	3	6	2	2
1541	862	activator of transcription stat	[activator of transcription STAT]	7.924812503605781	4	5	0	0
1542	862	T helper cell	[T helper cells]	7.924812503605781	3	6	4	4
1543	862	peripheral mononuclear leukocyte	[peripheral mononuclear leukocytes]	7.924812503605781	3	6	4	4
1544	862	major histocompatibility complex class	[major histocompatibility complex class]	7.924812503605781	4	6	1	1
1545	862	nf-kappab binding activity	[NF-kappaB binding activity]	7.924812503605781	3	6	3	3
1546	862	regulation of response	[regulation of responses]	7.924812503605781	3	6	6	6
1547	862	transcriptional regulatory element	[transcriptional regulatory element]	7.924812503605781	3	6	3	3
1548	862	blood of patient	[blood of patients]	7.924812503605781	3	6	5	5
1549	862	human blood T	[human blood T]	7.924812503605781	3	6	6	6
1550	862	increase in the amount	[increase in the amount]	7.924812503605781	4	6	1	1
1551	862	Oct-1 pou domain	[Oct-1 POU domain]	7.924812503605781	3	6	2	2
1552	862	level of receptor	[levels of receptors]	7.924812503605781	3	6	6	6
1553	862	T cell reactivity	[T cell reactivity]	7.924812503605781	3	6	1	1
1554	862	most cell line	[most cell lines]	7.924812503605781	3	6	5	5
1555	862	nf-kappa b protein	[NF-kappa B protein]	7.924812503605781	3	6	6	6
1556	862	antigen receptor signal	[antigen receptor signaling]	7.924812503605781	3	6	2	2
1557	862	distinct transcription factor	[distinct transcription factors]	7.924812503605781	3	6	5	5
1558	862	gene encode protein	[genes encoding proteins]	7.924812503605781	3	6	5	5
1559	862	kappa b binding activity	[kappa B binding activity]	7.924812503605781	4	5	0	0
1560	862	yeast two-hybrid screen	[yeast two-hybrid screen]	7.924812503605781	3	6	1	1
1561	862	normal human lymphocyte	[normal human lymphocytes]	7.924812503605781	3	6	2	2
1562	862	x-linked severe immunodeficiency	[X-linked severe immunodeficiency]	7.924812503605781	3	6	3	3
1563	862	all-tran retinoic acid atra	[all-trans retinoic acid ATRA]	7.924812503605781	4	5	0	0
1564	862	Cepsilon germline transcript	[Cepsilon germline transcripts]	7.924812503605781	3	6	3	3
1565	862	number of cytokine	[number of cytokines]	7.924812503605781	3	6	1	1
1566	862	ap-1 -binding activity	[AP-1 -binding activity]	7.924812503605781	3	6	4	4
1567	862	transcription of cytokine gene	[transcription of cytokine genes]	7.924812503605781	4	6	1	1
1568	862	nf-kappab DNA binding	[NF-kappaB DNA binding]	7.924812503605781	3	6	1	1
1569	862	histocompatibility complex class ii	[histocompatibility complex class II]	7.924812503605781	4	6	2	2
1570	862	number of gcr	[number of GCR]	7.924812503605781	3	6	1	1
1571	862	nuclear protein complex	[nuclear protein complex]	7.924812503605781	3	6	5	5
1572	862	bat box binding protein	[BAT box binding proteins]	7.924812503605781	4	5	0	0
1573	862	Jurkat cell line	[Jurkat cell line]	7.924812503605781	3	6	2	2
1574	862	Southern blot hybridization	[Southern blot hybridization]	7.924812503605781	3	5	0	0
1575	862	human t-cell leukemia virus	[human T-cell leukemia virus]	7.924812503605781	4	7	6	3
1576	862	zinc finger transcription factor	[zinc finger transcription factor]	7.924812503605781	4	6	3	3
1577	862	human tumor necrosis factor	[human tumor necrosis factor]	7.924812503605781	4	6	1	1
1578	862	regulate the expression	[regulating the expression]	7.924812503605781	3	7	6	3
1579	862	retinoid x receptor rxr	[retinoid X receptors RXRs]	7.924812503605781	4	5	0	0
1580	862	N-terminal amino acid	[N-terminal amino acids]	7.924812503605781	3	6	6	6
1581	862	Retinoic acid RA	[Retinoic acid RA]	7.924812503605781	3	6	3	3
1582	862	transcription factor AP-1	[transcription factor AP-1]	7.924812503605781	3	6	3	3
1583	862	reactive oxygen species ROS	[reactive oxygen species ROS]	7.924812503605781	4	6	2	2
1584	862	kappa b sequence	[kappa B sequence]	7.924812503605781	3	6	2	2
1585	862	induction of transcription factor	[induction of transcription factors]	7.924812503605781	4	6	1	1
1586	862	b cell proliferation	[B cell proliferation]	7.924812503605781	3	6	4	4
1587	862	phorbol myristate acetate PMA	[phorbol myristate acetate PMA]	7.924812503605781	4	6	1	1
1588	862	mature T cell	[mature T cells]	7.924812503605781	3	6	4	4
1589	863	system	[system]	7.920000000000001	1	81	63	35
1590	864	basis	[basis]	7.892	1	82	77	25
1591	865	il-10	[IL-10]	7.881481481481481	1	80	32	27
1592	866	important mediator	[important mediator]	7.875	2	9	9	8
1593	867	assay	[assay]	7.870212765957447	1	80	61	47
1594	868	normal development	[normal development]	7.857142857142858	2	9	8	7
1595	869	interleukin-2 IL-2	[interleukin-2 IL-2]	7.833333333333333	2	9	7	6
1596	869	serine residue	[serine residue]	7.833333333333333	2	9	7	6
1597	869	minimal promoter	[minimal promoter]	7.833333333333333	2	9	7	6
1598	869	interleukin-2 gene	[interleukin-2 gene]	7.833333333333333	2	9	7	6
1599	869	high activity	[high activity]	7.833333333333333	2	9	7	6
1600	870	manner	[manner]	7.823255813953489	1	80	76	43
1601	871	contrast,	[contrast,]	7.800000000000001	1	79	4	4
1602	872	ap-1 protein	[AP-1 protein]	7.8	2	9	6	5
1603	872	pyrrolidine dithiocarbamate	[pyrrolidine dithiocarbamate]	7.8	2	9	6	5
1604	872	rapid activation	[rapid activation]	7.8	2	9	6	5
1605	872	transcriptional protein	[transcriptional protein]	7.8	2	9	6	5
1606	873	association	[association]	7.786206896551724	1	80	62	29
1607	874	Oct-2	[Oct-2]	7.783333333333333	1	79	14	12
1608	875	clone	[clone]	7.782608695652174	1	79	54	46
1609	876	6tg1.1 cell	[6TG1.1 cells]	7.75	2	9	5	4
1610	876	(mhc) class	[(MHC) class]	7.75	2	10	9	4
1611	876	activation of factor kappa b	[activation of factor kappa B]	7.75	5	9	5	4
1612	876	inhibitory activity	[inhibitory activity]	7.75	2	9	5	4
1613	876	transcription stat	[transcription STAT]	7.75	2	10	9	4
1614	876	alpha-lipoic acid	[alpha-lipoic acid]	7.75	2	9	5	4
1615	877	p50	[p50]	7.746666666666667	1	79	23	15
1616	878	acid sequence	[acid sequence]	7.714285714285714	2	9	9	7
1617	878	four patient	[four patients]	7.714285714285714	2	9	9	7
1618	878	jurkat T	[Jurkat T]	7.714285714285714	2	9	9	7
1619	879	x	[X]	7.705	1	79	39	20
1620	880	part	[part]	7.692857142857143	1	79	58	28
1621	881	serine	[serine]	7.676666666666667	1	78	37	30
1622	882	plasma aldosterone	[plasma aldosterone]	7.666666666666667	2	9	4	3
1623	882	B-cell development	[B-cell development]	7.666666666666667	2	9	4	3
1624	882	monocyte activation	[monocyte activation]	7.666666666666667	2	9	4	3
1625	882	retinoblastoma protein	[retinoblastoma protein]	7.666666666666667	2	9	8	6
1626	882	HLA class	[HLA class]	7.666666666666667	2	9	4	3
1627	882	ca2+ ionophore	[Ca2+ ionophore]	7.666666666666667	2	9	4	3
1628	882	Southern blot	[Southern blot]	7.666666666666667	2	9	4	3
1629	882	cell hybrid	[cell hybrid]	7.666666666666667	2	9	8	6
1630	882	NF-kappaB pathway	[NF-kappaB pathway]	7.666666666666667	2	9	4	3
1631	883	subunit	[subunit]	7.665909090909091	1	78	59	44
1632	884	hiv-1 repeat LTR	[HIV-1 repeat LTR]	7.6078200034615495	3	6	6	5
1633	884	red blood cell	[red blood cells]	7.6078200034615495	3	6	6	5
1634	884	increase in the expression	[increase in the expression]	7.6078200034615495	4	6	6	5
1635	884	expression of mrna	[expression of mRNA]	7.6078200034615495	3	6	6	5
1636	884	MHC class molecule	[MHC class molecules]	7.6078200034615495	3	6	6	5
1637	884	cell line k562	[cell line K562]	7.6078200034615495	3	6	6	5
1638	885	gamma c	[gamma c]	7.6	2	9	7	5
1639	885	lymphokine gene	[lymphokine genes]	7.6	2	9	7	5
1640	885	mouse T	[mouse T]	7.6	2	9	7	5
1641	886	-binding	[-binding]	7.567924528301887	1	77	70	53
1642	887	stat5	[STAT5]	7.565217391304349	1	77	31	23
1643	888	serine /threonine kinase	[serine /threonine kinase]	7.528571878425493	3	6	5	4
1644	888	induction of expression	[induction of expression]	7.528571878425493	3	6	5	4
1645	888	activation of nuclear factor	[activation of nuclear factor]	7.528571878425493	4	6	5	4
1646	888	b cell-specific coactivator	[B cell-specific coactivator]	7.528571878425493	3	6	5	4
1647	888	exposure of cell	[exposure of cells]	7.528571878425493	3	6	5	4
1648	888	monoclonal antibody mab	[monoclonal antibody mAb]	7.528571878425493	3	6	5	4
1649	888	patient with bipolar disorder	[patients with bipolar disorder]	7.528571878425493	4	6	5	4
1650	888	monocyte cell line	[monocyte cell line]	7.528571878425493	3	6	5	4
1651	889	formation	[formation]	7.511764705882354	1	79	66	17
1652	890	urinary cortisol	[urinary cortisol]	7.5	2	9	6	4
1653	890	good understanding	[better understanding]	7.5	2	13	11	2
1654	890	mammalian cell	[mammalian cells]	7.5	2	9	3	2
1655	890	factor kappa b NF-kappa b	[factor kappa B NF-kappa B]	7.5	5	10	10	4
1656	890	human interleukin	[human interleukin]	7.5	2	9	3	2
1657	890	VDR mrna	[VDR mRNA]	7.5	2	9	6	4
1658	890	mechanism responsible	[mechanism responsible]	7.5	2	10	10	4
1659	890	proliferative activity	[proliferative activity]	7.5	2	9	6	4
1660	890	cell-free system	[cell-free system]	7.5	2	9	3	2
1661	890	central system	[central system]	7.5	2	9	9	6
1662	890	vivo footprinting	[vivo footprinting]	7.5	2	9	6	4
1663	890	surface receptor	[surface receptor]	7.5	2	9	6	4
1664	890	young subject	[young subjects]	7.5	2	9	3	2
1665	890	pertussis toxin	[pertussis toxin]	7.5	2	9	6	4
1666	890	lymphocyte infiltration	[lymphocyte infiltration]	7.5	2	9	6	4
1667	890	normal lymphocyte	[normal lymphocytes]	7.5	2	9	6	4
1668	890	novel element	[novel element]	7.5	2	9	9	6
1669	891	NF-AT	[NF-AT]	7.490909090909091	1	77	23	11
1670	892	IL-6	[IL-6]	7.472413793103448	1	76	37	29
1671	893	woman	[woman]	7.466666666666668	1	76	60	45
1672	894	CIITA	[CIITA]	7.453846153846154	1	76	19	13
1673	895	capacity	[capacity]	7.445454545454545	1	76	51	33
1674	896	individual	[individual]	7.413793103448277	1	76	54	29
1675	897	granzyme b	[granzyme B]	7.4	2	9	8	5
1676	897	alpha,25-dihydroxyvitamin D3	[alpha,25-dihydroxyvitamin D3]	7.4	2	9	8	5
1677	897	CBF beta	[CBF beta]	7.4	2	9	8	5
1678	897	different stage	[different stages]	7.4	2	9	8	5
1679	897	receptor number	[receptor number]	7.4	2	9	8	5
1680	898	b cell extract	[B cell extract]	7.396491670032063	3	6	4	3
1681	898	immunoglobulin gene expression	[immunoglobulin gene expression]	7.396491670032063	3	6	4	3
1682	898	differentiation of hl60 cell	[differentiation of HL60 cells]	7.396491670032063	4	6	4	3
1683	898	macrophage cell line	[macrophage cell line]	7.396491670032063	3	6	4	3
1684	898	active nf-kappa b	[active NF-kappa B]	7.396491670032063	3	6	4	3
1685	898	viral DNA replication	[viral DNA replication]	7.396491670032063	3	6	4	3
1686	899	cd4+ T lymphocyte	[CD4+ T lymphocytes]	7.396491670032062	3	7	7	3
1687	899	dominant negative form	[dominant negative form]	7.396491670032062	3	7	7	3
1688	899	all-tran acid RA	[all-trans acid RA]	7.396491670032062	3	7	7	3
1689	899	viral long repeat	[viral long repeat]	7.396491670032062	3	7	7	3
1690	899	viral terminal repeat	[viral terminal repeat]	7.396491670032062	3	7	7	3
1691	899	patient with lupus erythematosus	[patients with lupus erythematosus]	7.396491670032062	4	7	7	3
1692	900	consensus	[consensus]	7.38974358974359	1	75	43	39
1693	901	adult	[adult]	7.386666666666667	1	75	34	30
1694	902	marker	[marker]	7.363829787234043	1	75	64	47
1695	903	rap1 protein	[Rap1 protein]	7.333333333333333	2	9	5	3
1696	903	IL-6 promoter	[IL-6 promoter]	7.333333333333333	2	9	5	3
1697	903	actinomycin d	[actinomycin D]	7.333333333333333	2	9	5	3
1698	903	icam-1 expression	[ICAM-1 expression]	7.333333333333333	2	9	5	3
1699	903	lymphoid development	[lymphoid development]	7.333333333333333	2	9	5	3
1700	903	hiv LTR	[HIV LTR]	7.333333333333333	2	9	5	3
1701	904	loss	[loss]	7.320833333333333	1	76	67	24
1702	905	gc	[GC]	7.292307692307692	1	74	28	26
1703	906	contrast	[contrast]	7.28	1	80	72	10
1704	907	amount	[amount]	7.267857142857143	1	75	65	28
1705	908	icam-1	[ICAM-1]	7.2586206896551735	1	74	41	29
1706	909	erythroid precursor	[erythroid precursors]	7.25	2	9	7	4
1707	910	use	[use]	7.241666666666667	1	75	62	24
1708	911	exposure	[exposure]	7.231999999999999	1	75	67	25
1709	912	transduction	[transduction]	7.184210526315789	1	75	60	19
1710	913	NF-kappa b p50	[NF-kappa B p50]	7.132331253245203	3	6	3	2
1711	913	promyelocytic leukemia APL	[promyelocytic leukemia APL]	7.132331253245203	3	9	9	2
1712	913	other cell type	[other cell types]	7.132331253245203	3	7	5	2
1713	913	cell line thp-1	[cell line THP-1]	7.132331253245203	3	8	7	2
1714	913	monocytic cell line thp-1	[monocytic cell line THP-1]	7.132331253245203	4	8	7	2
1715	913	chronic myelogenous leukemia	[chronic myelogenous leukemia]	7.132331253245203	3	6	3	2
1716	913	T cell line Jurkat	[T cell line Jurkat]	7.132331253245203	4	6	3	2
1717	913	specific transcription factor	[specific transcription factor]	7.132331253245203	3	6	3	2
1718	913	minimal residual disease	[minimal residual disease]	7.132331253245203	3	6	3	2
1719	913	human immunodeficiency virus-1	[human immunodeficiency virus-1]	7.132331253245203	3	7	5	2
1720	913	chloramphenicol acetyltransferase gene	[chloramphenicol acetyltransferase gene]	7.132331253245203	3	6	3	2
1721	913	transcription factor binding	[transcription factor binding]	7.132331253245203	3	6	3	2
1722	913	transcription factor bsap	[transcription factor BSAP]	7.132331253245203	3	6	3	2
1723	913	globin gene expression	[globin gene expression]	7.132331253245203	3	6	3	2
1724	913	receptor in patient	[receptor in patients]	7.132331253245203	3	6	6	4
1725	913	hiv terminal repeat	[HIV terminal repeat]	7.132331253245203	3	6	6	4
1726	913	myeloid progenitor cell	[myeloid progenitor cells]	7.132331253245203	3	6	6	4
1727	914	lymphoma	[lymphoma]	7.130555555555556	1	73	61	36
1728	915	IL-12	[IL-12]	7.086666666666666	1	72	17	15
1729	916	enzyme	[enzyme]	7.08421052631579	1	72	44	38
1730	917	property	[property]	7.0687500000000005	1	72	63	48
1731	918	globin	[globin]	7.056521739130435	1	72	33	23
1732	919	vcam-1	[VCAM-1]	7.054166666666667	1	72	35	24
1733	920	CAT	[CAT]	7.053846153846154	1	72	38	26
1734	921	intact cell	[intact cell]	7.0	2	8	3	3
1735	921	specific receptor	[specific receptor]	7.0	2	8	6	6
1736	921	ccaat box	[CCAAT box]	7.0	2	8	6	6
1737	921	neutrophil maturation	[neutrophil maturation]	7.0	2	8	2	2
1738	921	T helper	[T helper]	7.0	2	8	7	7
1739	921	ap-1 complex	[AP-1 complex]	7.0	2	8	3	3
1740	921	U1 cell	[U1 cells]	7.0	2	8	4	4
1741	921	novel protein	[novel protein]	7.0	2	8	7	7
1742	921	inhibitory protein	[inhibitory protein]	7.0	2	8	3	3
1743	921	early growth	[early growth]	7.0	2	8	1	1
1744	921	regulatory pathway	[regulatory pathway]	7.0	2	8	8	8
1745	921	1 h	[1 h]	7.0	2	8	2	2
1746	921	asthmatic patient	[asthmatic patients]	7.0	2	8	5	5
1747	921	interleukin gene	[interleukin gene]	7.0	2	8	8	8
1748	921	JNK activation	[JNK activation]	7.0	2	8	4	4
1749	921	cyclic AMP	[cyclic AMP]	7.0	2	8	4	4
1750	921	previous work	[Previous work]	7.0	2	8	1	1
1751	921	anti-inflammatory drug	[anti-inflammatory drug]	7.0	2	8	6	6
1752	921	cd14 expression	[CD14 expression]	7.0	2	9	6	3
1753	921	therapeutic effect	[therapeutic effect]	7.0	2	9	6	3
1754	921	underlying mechanism	[underlying mechanism]	7.0	2	8	4	4
1755	921	gelatinase granule	[gelatinase granules]	7.0	2	8	4	4
1756	921	CD4 gene	[CD4 gene]	7.0	2	9	4	2
1757	921	kinase activity	[kinase activity]	7.0	2	8	6	6
1758	921	Escherichia coli	[Escherichia coli]	7.0	2	8	4	4
1759	921	erythroid lineage	[erythroid lineage]	7.0	2	7	0	0
1760	921	calcium mobilization	[calcium mobilization]	7.0	2	8	3	3
1761	921	platelet-activating factor	[platelet-activating factor]	7.0	2	8	5	5
1762	921	peripheral lymphocyte	[peripheral lymphocytes]	7.0	2	8	3	3
1763	921	binding capacity	[binding capacity]	7.0	2	8	6	6
1764	921	ATL cell	[ATL cells]	7.0	2	8	4	4
1765	921	inhibition of nf-kappa b activation	[inhibition of NF-kappa B activation]	7.0	5	8	4	4
1766	921	nfat activity	[NFAT activity]	7.0	2	8	5	5
1767	921	hiv-1 promoter	[HIV-1 promoter]	7.0	2	8	2	2
1768	921	tat protein	[Tat protein]	7.0	2	8	5	5
1769	921	myelomonocytic cell	[myelomonocytic cell]	7.0	2	8	6	6
1770	921	extracellular signal	[extracellular signal]	7.0	2	8	4	4
1771	921	granulocyte-macrophage colony-stimumulatelany-stg	[granulocyte-macrophage colony-stimulating]	7.0	2	9	8	4
1772	921	low-density lipoprotein	[low-density lipoprotein]	7.0	2	8	3	3
1773	921	key regulator	[key regulator]	7.0	2	9	8	4
1774	921	1 alpha,25-(OH)2D3	[1 alpha,25-(OH)2D3]	7.0	2	8	1	1
1775	921	normal woman	[normal women]	7.0	2	8	6	6
1776	921	two pathway	[two pathways]	7.0	2	8	7	7
1777	921	endothelial activation	[endothelial activation]	7.0	2	8	2	2
1778	921	tumour cell	[tumour cells]	7.0	2	9	6	3
1779	921	human receptor	[human receptor]	7.0	2	8	5	5
1780	921	supershift assay	[supershift assay]	7.0	2	8	2	2
1781	921	first time	[first time]	7.0	2	8	2	2
1782	921	biochemical event	[biochemical event]	7.0	2	8	6	6
1783	921	one mechanism	[one mechanism]	7.0	2	8	7	7
1784	921	interferon beta	[interferon beta]	7.0	2	8	6	6
1785	921	cytokine secretion	[cytokine secretion]	7.0	2	8	4	4
1786	921	viral genome	[viral genome]	7.0	2	9	2	1
1787	921	cytokine mrna	[cytokine mRNA]	7.0	2	8	7	7
1788	921	ca2+ signal	[Ca2+ signaling]	7.0	2	8	4	4
1789	921	present result	[present results]	7.0	2	7	0	0
1790	921	normal individual	[normal individuals]	7.0	2	11	4	1
1791	921	squirrel monkey	[squirrel monkey]	7.0	2	8	3	3
1792	921	primary monocyte	[primary monocytes]	7.0	2	8	4	4
1793	921	vascular cell	[vascular cell]	7.0	2	8	3	3
1794	921	type 1	[type 1]	7.0	2	8	4	4
1795	921	oligonucleotide probe	[oligonucleotide probe]	7.0	2	8	5	5
1796	921	bronchial asthma	[bronchial asthma]	7.0	2	8	4	4
1797	921	interferon alpha	[interferon alpha]	7.0	2	9	6	3
1798	921	soluble factor	[soluble factor]	7.0	2	8	1	1
1799	921	bat box	[BAT box]	7.0	2	10	6	2
1800	921	dose-dependent manner.	[dose-dependent manner.]	7.0	2	7	0	0
1801	921	bind protein	[binding protein]	7.0	2	8	6	6
1802	921	vascular cell adhesion molecule-1 vcam-1	[vascular cell adhesion molecule-1 VCAM-1]	7.0	5	8	1	1
1803	921	monocyte/macrophage lineage	[monocyte/macrophage lineage]	7.0	2	9	4	2
1804	921	allergic disease	[allergic disease.]	7.0	2	8	2	2
1805	921	tnf-alpha gene	[TNF-alpha gene]	7.0	2	8	4	4
1806	921	ut-7 cell	[UT-7 cells]	7.0	2	8	4	4
1807	922	effector	[effector]	6.993103448275862	1	71	31	29
1808	923	(p	[(P]	6.9904761904761905	1	71	23	21
1809	924	stimulus	[stimulus]	6.965789473684211	1	71	51	38
1810	925	tnf	[TNF]	6.96	1	71	42	30
1811	926	cAMP-dependent protein kinase	[cAMP-dependent protein kinase]	6.868170836458344	3	6	5	3
1812	926	inhibition of b activation	[inhibition of B activation]	6.868170836458344	4	6	5	3
1813	926	effect of il-10	[effect of IL-10]	6.868170836458344	3	6	5	3
1814	926	upstream regulatory element	[upstream regulatory element]	6.868170836458344	3	6	5	3
1815	926	very low level	[very low levels]	6.868170836458344	3	6	5	3
1816	926	T cell nf-at	[T cell NF-AT]	6.868170836458344	3	6	5	3
1817	927	c-myc	[c-myc]	6.858823529411765	1	70	24	17
1818	928	event lead	[event leading]	6.857142857142858	2	8	8	7
1819	928	lps response	[LPS response]	6.857142857142858	2	8	8	7
1820	928	two form	[two forms]	6.857142857142858	2	8	8	7
1821	928	protein-DNA interaction	[protein-DNA interaction]	6.857142857142858	2	8	8	7
1822	928	cell development	[cell development]	6.857142857142858	2	8	8	7
1823	929	EBV	[EBV]	6.854545454545455	1	70	32	22
1824	930	hela cell	[HeLa cells]	6.833333333333333	2	8	7	6
1825	930	c-Jun	[c-Jun]	6.833333333333333	1	70	20	12
1826	930	risk factor	[risk factor]	6.833333333333333	2	8	7	6
1827	930	nucleotide sequence	[nucleotide sequence]	6.833333333333333	2	8	7	6
1828	930	differentiation program	[differentiation program]	6.833333333333333	2	8	7	6
1829	930	nf-kappab transcription	[NF-kappaB transcription]	6.833333333333333	2	8	7	6
1830	930	interferon factor	[interferon factor]	6.833333333333333	2	8	7	6
1831	930	gene promoter	[gene promoter]	6.833333333333333	2	8	7	6
1832	930	upstream element	[upstream element]	6.833333333333333	2	8	7	6
1833	931	cortisol concentration	[cortisol concentration]	6.8	2	8	6	5
1834	931	inducible factor	[inducible factor]	6.8	2	8	6	5
1835	931	human blood	[human blood]	6.8	2	8	6	5
1836	931	host defense	[host defense]	6.8	2	8	6	5
1837	932	kda	[kDa]	6.787234042553192	1	69	53	47
1838	933	CD3	[CD3]	6.76	1	69	28	20
1839	933	LMP1	[LMP1]	6.76	1	69	28	20
1840	934	lymphoblastoid cell	[lymphoblastoid cells]	6.75	2	8	5	4
1841	934	ig gene	[Ig gene]	6.75	2	9	9	4
1842	934	pivotal role	[pivotal role]	6.75	2	8	5	4
1843	934	growth factor-beta	[growth factor-beta]	6.75	2	9	9	4
1844	934	hodgkin' disease	[Hodgkin's disease]	6.75	2	8	5	4
1845	934	genomic DNA	[genomic DNA]	6.75	2	8	5	4
1846	934	elderly subject	[elderly subjects]	6.75	2	8	5	4
1847	934	mobility-shift assay	[mobility-shift assay]	6.75	2	8	5	4
1848	935	progesterone	[progesterone]	6.740000000000001	1	69	16	10
1849	936	PKC	[PKC]	6.731578947368421	1	69	32	19
1850	937	day	[day]	6.675609756097561	1	68	51	41
1851	938	U937	[U937]	6.675000000000001	1	69	27	12
1852	939	methylation interference	[methylation interference]	6.666666666666667	2	8	4	3
1853	939	three patient	[three patient]	6.666666666666667	2	8	4	3
1854	939	ap-1 activation	[AP-1 activation]	6.666666666666667	2	8	4	3
1855	939	other member	[other members]	6.666666666666667	2	8	4	3
1856	939	major disorder	[major disorder]	6.666666666666667	2	8	8	6
1857	939	herpesvirus saimiry	[herpesvirus saimiri]	6.666666666666667	2	8	4	3
1858	939	b-cell-specific transcription	[B-cell-specific transcription]	6.666666666666667	2	8	4	3
1859	939	sequence homology	[sequence homology]	6.666666666666667	2	8	8	6
1860	939	fmol/10(7) cell	[fmol/10(7) cells]	6.666666666666667	2	8	8	6
1861	939	anti-inflammatory agent	[anti-inflammatory agent]	6.666666666666667	2	8	4	3
1862	939	ultra-violet irradiation	[UV irradiation]	6.666666666666667	2	8	4	3
1863	939	immunosuppressive agent	[immunosuppressive agent]	6.666666666666667	2	8	4	3
1864	939	cd4(+) T	[CD4(+) T]	6.666666666666667	2	8	8	6
1865	939	erythroid-specific gene	[erythroid-specific gene]	6.666666666666667	2	8	4	3
1866	939	24 hour	[24 hr]	6.666666666666667	2	8	4	3
1867	940	transcription start	[transcription start]	6.666666666666666	2	9	7	3
1868	940	ectopic expression	[ectopic expression]	6.666666666666666	2	10	10	3
1869	940	CD28 response	[CD28 response]	6.666666666666666	2	9	7	3
1870	941	oxidant stress	[oxidant stress]	6.6	2	8	7	5
1871	941	tax expression	[Tax expression]	6.6	2	8	7	5
1872	941	p65 subunit	[p65 subunit]	6.6	2	8	7	5
1873	941	receptor characteristic	[receptor characteristics]	6.6	2	8	7	5
1874	941	helix-loop-helix protein	[helix-loop-helix protein]	6.6	2	8	7	5
1875	942	anti-CD3	[anti-CD3]	6.588235294117647	1	67	19	17
1876	943	exon	[exon]	6.5725	1	67	51	40
1877	944	k562	[K562]	6.525	1	67	21	12
1878	945	RAR	[RAR]	6.5166666666666675	1	67	33	18
1879	946	various gene	[various gene]	6.5	2	8	3	2
1880	946	nf-at activity	[NF-AT activity]	6.5	2	8	3	2
1881	946	il-12 signal	[IL-12 signaling]	6.5	2	8	6	4
1882	946	proteolytic degradation	[proteolytic degradation]	6.5	2	8	3	2
1883	946	PMA treatment	[PMA treatment]	6.5	2	8	3	2
1884	946	8 hour	[8 hr]	6.5	2	8	3	2
1885	946	hiv-1 production	[HIV-1 production]	6.5	2	8	3	2
1886	946	nuclear export	[nuclear export]	6.5	2	8	3	2
1887	947	position	[position]	6.492000000000001	1	66	54	50
1888	948	motif	[motif]	6.477500000000001	1	66	49	40
1889	949	pathogenesis	[pathogenesis]	6.4625	1	71	51	8
1890	950	alteration	[alteration]	6.437142857142857	1	66	57	35
1891	951	minute	[min]	6.430555555555556	1	66	61	36
1892	952	c/ebp	[C/EBP]	6.423809523809524	1	66	37	21
1893	953	th cell	[Th cells]	6.4	2	8	8	5
1894	953	NF-kappaB complex	[NF-kappaB complex]	6.4	2	8	8	5
1895	953	residual disease	[residual disease]	6.4	2	8	8	5
1896	954	GATA-1	[GATA-1]	6.393750000000001	1	65	17	16
1897	955	core	[core]	6.391304347826087	1	65	25	23
1898	956	zinc	[zinc]	6.378947368421053	1	65	23	19
1899	957	precursor	[precursor]	6.348387096774194	1	65	47	31
1900	958	cell adhesion molecule-1 vcam-1	[cell adhesion molecule-1 VCAM-1]	6.339850002884625	4	8	8	2
1901	958	hiv long terminal repeat	[HIV long terminal repeat]	6.339850002884625	4	6	2	1
1902	958	J delta K cell	[J delta K cells]	6.339850002884625	4	4	0	0
1903	958	expression of protein	[expression of proteins]	6.339850002884625	3	5	4	4
1904	958	other cell types.	[other cell types.]	6.339850002884625	3	5	1	1
1905	958	several cell line	[several cell lines]	6.339850002884625	3	5	4	4
1906	958	neoplastic b cell	[neoplastic B cells]	6.339850002884625	3	4	0	0
1907	958	rheumatoid arthritis RA	[rheumatoid arthritis RA]	6.339850002884625	3	5	2	2
1908	958	DRA gene transcription	[DRA gene transcription]	6.339850002884625	3	5	1	1
1909	958	analysis of the promoter	[analysis of the promoter]	6.339850002884625	4	5	4	4
1910	958	neuroblastoma cell line	[neuroblastoma cell lines]	6.339850002884625	3	5	4	4
1911	958	oxygen intermediate ROI	[oxygen intermediates ROI]	6.339850002884625	3	6	6	3
1912	958	glucocorticoid receptor expression	[glucocorticoid receptor expression]	6.339850002884625	3	5	4	4
1913	958	other steroid hormone	[other steroid hormones]	6.339850002884625	3	5	2	2
1914	958	fetal blood cell	[fetal blood cells]	6.339850002884625	3	4	0	0
1915	958	nf-kappa b dna-binding activity	[NF-kappa B DNA-binding activity]	6.339850002884625	4	5	2	2
1916	958	site of inflammation	[sites of inflammation]	6.339850002884625	3	5	4	4
1917	958	1 tax protein	[1 tax protein]	6.339850002884625	3	4	0	0
1918	958	erythroid cell line	[erythroid cell line]	6.339850002884625	3	5	5	5
1919	958	Southern blot analysis	[Southern blot analysis]	6.339850002884625	3	5	1	1
1920	958	erythroleukemia cell line	[erythroleukemia cell line]	6.339850002884625	3	5	3	3
1921	958	growth of cell	[growth of cells]	6.339850002884625	3	5	5	5
1922	958	tyrosine phosphorylation of protein	[tyrosine phosphorylation of proteins]	6.339850002884625	4	5	5	5
1923	958	expression of several gene	[expression of several genes]	6.339850002884625	4	5	5	5
1924	958	IL-1 receptor antagonist	[IL-1 receptor antagonist]	6.339850002884625	3	4	0	0
1925	958	role in differentiation	[role in differentiation]	6.339850002884625	3	5	4	4
1926	958	nuclear localization sequence	[nuclear localization sequence]	6.339850002884625	3	5	3	3
1927	958	activation of NFkappaB	[activation of NFkappaB]	6.339850002884625	3	5	5	5
1928	958	adult erythroid cell	[adult erythroid cell]	6.339850002884625	3	5	2	2
1929	958	white blood cell	[white blood cell]	6.339850002884625	3	5	3	3
1930	958	nf-kappab DNA binding activity	[NF-kappaB DNA binding activity]	6.339850002884625	4	5	3	3
1931	958	NF-kappaB nuclear translocation	[NF-kappaB nuclear translocation]	6.339850002884625	3	5	2	2
1932	958	binding of NF-kappa b	[binding of NF-kappa B]	6.339850002884625	4	4	0	0
1933	958	result of activation	[result of activation]	6.339850002884625	3	5	3	3
1934	958	secondary lymphoid tissue	[secondary lymphoid tissues]	6.339850002884625	3	5	1	1
1935	958	mechanism of the effect	[mechanism of the effect]	6.339850002884625	4	5	4	4
1936	958	normal control subject	[normal control subjects]	6.339850002884625	3	5	2	2
1937	958	GM-CSF receptor alpha promoter	[GM-CSF receptor alpha promoter]	6.339850002884625	4	5	2	2
1938	958	cytotoxic T lymphocyte	[cytotoxic T lymphocyte]	6.339850002884625	3	5	3	3
1939	958	mammary epithelial cell	[mammary epithelial cells]	6.339850002884625	3	5	3	3
1940	958	variety of cell types,	[variety of cell types,]	6.339850002884625	4	4	0	0
1941	958	class ii transactivator ciita	[class II transactivator CIITA]	6.339850002884625	4	5	1	1
1942	958	mobility shift assay emsa	[mobility shift assay EMSA]	6.339850002884625	4	8	8	2
1943	958	peripheral blood of patient	[peripheral blood of patients]	6.339850002884625	4	5	4	4
1944	958	proportion of cell	[proportion of cells]	6.339850002884625	3	5	3	3
1945	958	adult globin gene	[adult globin gene]	6.339850002884625	3	5	2	2
1946	958	CD4 gene expression	[CD4 gene expression]	6.339850002884625	3	4	0	0
1947	958	inhibition of activation	[inhibition of activation]	6.339850002884625	3	5	3	3
1948	958	monocyte chemotactic protein-1	[monocyte chemotactic protein-1]	6.339850002884625	3	5	3	3
1949	958	flow cytometric analysis	[flow cytometric analysis]	6.339850002884625	3	4	0	0
1950	958	Mono Mac 6	[Mono Mac 6]	6.339850002884625	3	4	0	0
1951	958	level of protein	[level of proteins]	6.339850002884625	3	5	5	5
1952	958	number of gr	[number of GR]	6.339850002884625	3	6	2	1
1953	958	class ii histocompatibility gene	[class II histocompatibility gene]	6.339850002884625	4	5	5	5
1954	958	lps nf-kappab activation	[LPS NF-kappaB activation]	6.339850002884625	3	5	1	1
1955	958	new protein synthesis	[new protein synthesis]	6.339850002884625	3	4	0	0
1956	958	differentiation of monocyte	[differentiation of monocytes]	6.339850002884625	3	5	4	4
1957	958	hiv type 1	[HIV type 1]	6.339850002884625	3	5	2	2
1958	958	Burkitt' lymphoma cell	[Burkitt's lymphoma cells]	6.339850002884625	3	5	3	3
1959	958	multiple transcription factor	[multiple transcription factors]	6.339850002884625	3	5	3	3
1960	958	U S A	[U S A]	6.339850002884625	3	4	0	0
1961	958	human helper T cell	[human helper T cells]	6.339850002884625	4	5	2	2
1962	958	human immunodeficiency virus replication	[human immunodeficiency virus replication]	6.339850002884625	4	5	1	1
1963	958	zinc finger transcription	[zinc finger transcription]	6.339850002884625	3	7	6	2
1964	958	eosinophil granule protein	[eosinophil granule protein]	6.339850002884625	3	5	5	5
1965	958	GAL4 DNA binding domain	[GAL4 DNA binding domain]	6.339850002884625	4	4	0	0
1966	958	T cell blast	[T cell blasts]	6.339850002884625	3	5	3	3
1967	958	many cytokine gene	[many cytokine genes]	6.339850002884625	3	5	2	2
1968	958	beta-like globin gene	[beta-like globin genes]	6.339850002884625	3	5	3	3
1969	958	integral membrane protein	[integral membrane protein]	6.339850002884625	3	5	2	2
1970	958	B-lymphoblastoid cell line	[B-lymphoblastoid cell line]	6.339850002884625	3	5	5	5
1971	958	mononuclear leukocyte MNL	[mononuclear leukocytes MNL]	6.339850002884625	3	5	4	4
1972	958	type ii receptor	[type II receptor]	6.339850002884625	3	5	4	4
1973	958	cell-specific transcription factor	[cell-specific transcription factor]	6.339850002884625	3	5	5	5
1974	958	mechanism of transactivation	[mechanism of transactivation]	6.339850002884625	3	7	3	1
1975	958	stage of development	[stage of development]	6.339850002884625	3	5	5	5
1976	958	insight into the mechanism	[insight into the mechanisms]	6.339850002884625	4	5	4	4
1977	958	inducer of differentiation	[inducer of differentiation]	6.339850002884625	3	5	5	5
1978	958	M-CSF receptor promoter	[M-CSF receptor promoter]	6.339850002884625	3	4	0	0
1979	958	different cell type	[different cell types]	6.339850002884625	3	5	2	2
1980	958	response to IL-2	[response to IL-2]	6.339850002884625	3	5	1	1
1981	958	il-2 gene transcription	[IL-2 gene transcription]	6.339850002884625	3	5	3	3
1982	958	activation of nf-at	[activation of NF-AT]	6.339850002884625	3	5	4	4
1983	958	igh 3' enhancer	[IgH 3' enhancer]	6.339850002884625	3	5	1	1
1984	958	human peripheral blood T	[human peripheral blood T]	6.339850002884625	4	5	2	2
1985	958	adult t-cell leukemia ATL	[adult T-cell leukemia ATL]	6.339850002884625	4	5	1	1
1986	958	addition of lectin	[addition of lectin]	6.339850002884625	3	4	0	0
1987	958	activation of factor-kappaB	[activation of factor-kappaB]	6.339850002884625	3	5	5	5
1988	958	early stage of differentiation	[early stage of differentiation]	6.339850002884625	4	5	3	3
1989	958	inhibition of cytokine production	[inhibition of cytokine production]	6.339850002884625	4	5	4	4
1990	958	cytoplasm to the nucleus	[cytoplasm to the nucleus]	6.339850002884625	4	4	0	0
1991	958	Rel/ NF-kappa b protein	[Rel/ NF-kappa B proteins]	6.339850002884625	4	4	0	0
1992	958	glucocorticoid response element	[glucocorticoid response element]	6.339850002884625	3	5	4	4
1993	958	somatic cell hybrid	[somatic cell hybrid]	6.339850002884625	3	5	3	3
1994	958	upstream regulatory region	[upstream regulatory region]	6.339850002884625	3	5	1	1
1995	958	135eoh)2d3 receptor rna	[1,25(OH)2D3 receptor RNA]	6.339850002884625	3	8	4	1
1996	958	urinary free cortisol	[urinary free cortisol]	6.339850002884625	3	5	1	1
1997	958	intestinal epithelial cell	[intestinal epithelial cell]	6.339850002884625	3	5	1	1
1998	958	MHC class gene expression	[MHC class gene expression]	6.339850002884625	4	6	6	3
1999	958	class major histocompatibility gene	[class major histocompatibility gene]	6.339850002884625	4	5	5	5
2000	958	formation of a complex	[formation of a complex]	6.339850002884625	4	5	2	2
2001	958	activation of protein kinase	[activation of protein kinase]	6.339850002884625	4	5	4	4
2002	958	intracellular ca2+ concentration	[intracellular Ca2+ concentration]	6.339850002884625	3	5	2	2
2003	958	enzyme-linked immunosorbent assay	[enzyme-linked immunosorbent assay]	6.339850002884625	3	5	3	3
2004	958	patient with Takayasu arteritis	[patient with Takayasu arteritis]	6.339850002884625	4	4	0	0
2005	958	stat signal transducer	[Stat signal transducers]	6.339850002884625	3	4	0	0
2006	958	signal transduction molecule	[signal transduction molecule]	6.339850002884625	3	5	2	2
2007	958	apparent dissociation constant	[apparent dissociation constant]	6.339850002884625	3	7	6	2
2008	958	treatment of the cell	[treatment of the cells]	6.339850002884625	4	5	2	2
2009	958	number of mineralocorticoid receptor	[number of mineralocorticoid receptors]	6.339850002884625	4	5	3	3
2010	958	calcium ionophore a23187	[calcium ionophore A23187]	6.339850002884625	3	6	2	1
2011	958	majority of patient	[majority of patients]	6.339850002884625	3	5	2	2
2012	958	chloramphenicol acetyltransferase assay	[chloramphenicol acetyltransferase assay]	6.339850002884625	3	5	2	2
2013	958	gel mobility shift	[Gel mobility shift]	6.339850002884625	3	7	3	1
2014	958	natural killer (nk) cell	[natural killer (NK) cells]	6.339850002884625	4	5	2	2
2015	958	activation of the promoter	[activation of the promoter]	6.339850002884625	4	5	3	3
2016	958	regulator of gene	[regulator of genes]	6.339850002884625	3	5	5	5
2017	958	different cell types.	[different cell types.]	6.339850002884625	3	5	3	3
2018	958	human blood T lymphocyte	[human blood T lymphocytes]	6.339850002884625	4	6	6	3
2019	958	secretion of il-2	[secretion of IL-2]	6.339850002884625	3	5	2	2
2020	958	octamer transcription factor	[octamer transcription factor]	6.339850002884625	3	5	3	3
2021	958	cell of lineage	[cells of lineage]	6.339850002884625	3	5	5	5
2022	958	dendritic cell DC	[dendritic cells DC]	6.339850002884625	3	5	2	2
2023	958	role in the process	[role in the process]	6.339850002884625	4	5	5	5
2024	958	Mono Mac 6 cell	[Mono Mac 6 cells]	6.339850002884625	4	5	2	2
2025	958	normal myeloid cell	[normal myeloid cells]	6.339850002884625	3	5	5	5
2026	958	T cell activation signal	[T cell activation signals]	6.339850002884625	4	5	3	3
2027	958	expression of Egr-1	[expression of Egr-1]	6.339850002884625	3	4	0	0
2028	958	membrane receptor for aldosterone	[membrane receptor for aldosterone]	6.339850002884625	4	5	3	3
2029	958	use deletion mutant	[Using deletion mutants]	6.339850002884625	3	5	2	2
2030	958	hiv-1 LTR transcription	[HIV-1 LTR transcription]	6.339850002884625	3	7	3	1
2031	958	macrophage colony-stimumulatelany-stg factor	[macrophage colony-stimulating factor]	6.339850002884625	3	5	3	3
2032	958	specific DNA binding	[specific DNA binding]	6.339850002884625	3	5	2	2
2033	958	variety of gene	[variety of genes]	6.339850002884625	3	5	2	2
2034	958	inflammatory cytokine production	[inflammatory cytokine production]	6.339850002884625	3	5	5	5
2035	958	level of nf-kappa b	[level of NF-kappa B]	6.339850002884625	4	5	3	3
2036	958	er content in lymphocyte	[ER content in lymphocytes]	6.339850002884625	4	5	1	1
2037	958	hiv-1 long repeat LTR	[HIV-1 long repeat LTR]	6.339850002884625	4	6	6	3
2038	958	human gingival fibroblast	[human gingival fibroblasts]	6.339850002884625	3	5	2	2
2039	958	inhibition of proliferation	[inhibition of proliferation]	6.339850002884625	3	5	3	3
2040	958	extract of cell	[extract of cells]	6.339850002884625	3	5	4	4
2041	958	chloramphenicol acetyl transferase CAT	[chloramphenicol acetyl transferase CAT]	6.339850002884625	4	4	0	0
2042	958	cell of patient	[cells of patients]	6.339850002884625	3	5	5	5
2043	958	consensus binding site	[consensus binding sites]	6.339850002884625	3	5	4	4
2044	958	inhibition of nf-kappab activation	[inhibition of NF-kappaB activation]	6.339850002884625	4	5	3	3
2045	958	chronic hepatitis b	[chronic hepatitis B]	6.339850002884625	3	5	3	3
2046	958	alpha-globin promoter activity	[alpha-globin promoter activity]	6.339850002884625	3	5	3	3
2047	958	gene in human monocyte	[gene in human monocytes]	6.339850002884625	4	5	3	3
2048	958	vitamin d receptor VDR	[vitamin D receptor VDR]	6.339850002884625	4	6	2	1
2049	958	vitamin D3 receptor	[vitamin D3 receptor]	6.339850002884625	3	5	3	3
2050	958	control the expression	[controlling the expression]	6.339850002884625	3	5	5	5
2051	958	il-2 receptor expression	[IL-2 receptor expression]	6.339850002884625	3	5	3	3
2052	958	protein kinase c activity	[protein kinase C activity]	6.339850002884625	4	5	4	4
2053	958	cell cycle analysis	[cell cycle analysis]	6.339850002884625	3	5	1	1
2054	958	T cell stimulation	[T cell stimulation]	6.339850002884625	3	5	3	3
2055	958	level of glucocorticoid receptor	[levels of glucocorticoid receptors]	6.339850002884625	4	5	4	4
2056	958	chronic renal failure	[chronic renal failure]	6.339850002884625	3	5	2	2
2057	958	NF-AT binding site	[NF-AT binding site]	6.339850002884625	3	4	0	0
2058	958	class histocompatibility gene	[class histocompatibility gene]	6.339850002884625	3	5	5	5
2059	958	variety of cell type	[variety of cell types]	6.339850002884625	4	6	2	1
2060	958	polymerase chain reaction pcr	[polymerase chain reaction PCR]	6.339850002884625	4	5	1	1
2061	958	bare lymphocyte syndrome	[bare lymphocyte syndrome]	6.339850002884625	3	5	3	3
2062	958	formation of complex	[formation of complexes]	6.339850002884625	3	5	5	5
2063	958	inducible transcription factor	[inducible transcription factor]	6.339850002884625	3	5	4	4
2064	958	embryonic stem cell	[embryonic stem cells]	6.339850002884625	3	5	1	1
2065	958	retinoic acid receptor RAR	[retinoic acid receptor RAR]	6.339850002884625	4	5	2	2
2066	958	transcription factor binding site	[transcription factor binding sites]	6.339850002884625	4	5	4	4
2067	958	protein synthesis inhibitor cycloheximide	[protein synthesis inhibitor cycloheximide]	6.339850002884625	4	5	1	1
2068	958	basic helix-loop-helix protein	[basic helix-loop-helix protein]	6.339850002884625	3	5	4	4
2069	958	immediate early response gene	[immediate early response genes]	6.339850002884625	4	5	3	3
2070	958	cell cycle entry	[cell cycle entry]	6.339850002884625	3	6	4	2
2071	959	nuclear antigen	[nuclear antigen]	6.333333333333333	2	8	5	3
2072	959	il-2 promoter	[IL-2 promoter]	6.333333333333333	2	8	5	3
2073	959	myeloproliferative disorder	[myeloproliferative disorder]	6.333333333333333	2	8	5	3
2074	959	monocyte /macrophage	[monocytes /macrophages]	6.333333333333333	2	8	5	3
2075	960	asthma	[asthma]	6.305263157894737	1	65	37	19
2076	961	a	[A]	6.288095238095238	1	64	47	42
2077	962	host	[host]	6.272222222222222	1	64	23	18
2078	963	il-12	[IL-12]	6.255555555555556	1	64	26	18
2079	964	DC	[DC]	6.25	1	64	33	22
2080	964	initiation site	[initiation site]	6.25	2	8	7	4
2081	964	time course	[time course]	6.25	2	8	7	4
2082	964	culture supernatant	[culture supernatant]	6.25	2	8	7	4
2083	964	pregnant woman	[pregnant women]	6.25	2	8	7	4
2084	964	cortisol resistance	[cortisol resistance]	6.25	2	8	7	4
2085	964	dominant form	[dominant form]	6.25	2	8	7	4
2086	964	receptor antagonist	[receptor antagonist]	6.25	2	8	7	4
2087	964	transcription rate	[transcription rate]	6.25	2	8	7	4
2088	964	polymerase chain	[polymerase chain]	6.25	2	8	7	4
2089	964	nf-at transcription	[NF-AT transcription]	6.25	2	8	7	4
2090	965	aldosterone	[aldosterone]	6.236363636363637	1	64	36	22
2091	966	kappab	[kappaB]	6.176923076923077	1	63	32	26
2092	967	adenovirus	[adenovirus]	6.165217391304348	1	63	31	23
2093	968	oligonucleotide	[oligonucleotide]	6.075675675675676	1	62	46	37
2094	969	c-rel	[c-Rel]	6.036842105263158	1	62	31	19
2095	970	synthesis	[synthesis]	6.035294117647059	1	63	45	17
2096	971	U3 region	[U3 region]	6.0	2	7	3	3
2097	971	pkc inhibitor	[PKC inhibitor]	6.0	2	7	6	6
2098	971	hiv-1 tat	[HIV-1 tat]	6.0	2	7	4	4
2099	971	female patient	[female patient]	6.0	2	7	7	7
2100	971	multiple protein	[multiple proteins]	6.0	2	7	3	3
2101	971	activation pathway	[activation pathway]	6.0	2	7	6	6
2102	971	CD40 signal	[CD40 signaling]	6.0	2	7	5	5
2103	971	stat6 activation	[STAT6 activation]	6.0	2	7	2	2
2104	971	t-cell leukemia virus type 1	[T-cell leukemia virus type 1]	6.0	5	12	12	2
2105	971	specific complex	[specific complex]	6.0	2	7	5	5
2106	971	c-rel protein	[c-Rel protein]	6.0	2	7	1	1
2107	971	mm cell	[MM cells]	6.0	2	7	4	4
2108	971	peripheral cell	[peripheral cells]	6.0	2	7	6	6
2109	971	hiv promoter	[HIV promoter]	6.0	2	7	3	3
2110	971	IFN alpha	[IFN alpha]	6.0	2	7	4	4
2111	971	apoptotic cell	[apoptotic cells]	6.0	2	7	2	2
2112	971	chimeric protein	[chimeric protein]	6.0	2	7	3	3
2113	971	cellular function	[cellular function]	6.0	2	7	3	3
2114	971	lineage commitment	[lineage commitment]	6.0	2	7	6	6
2115	971	c-fo gene	[c-fos gene]	6.0	2	8	6	3
2116	971	47.10 cell	[47.10 cells]	6.0	2	7	4	4
2117	971	adherent monocyte	[adherent monocytes]	6.0	2	7	2	2
2118	971	early response	[early response]	6.0	2	7	4	4
2119	971	flank region	[flanking region]	6.0	2	9	9	3
2120	971	human cd34+	[human CD34+]	6.0	2	7	1	1
2121	971	macrophage differentiation	[macrophage differentiation]	6.0	2	7	2	2
2122	971	less extent	[lesser extent]	6.0	2	7	2	2
2123	971	two promoter	[two promoters]	6.0	2	7	4	4
2124	971	large number	[large number]	6.0	2	9	9	3
2125	971	essential component	[essential component]	6.0	2	8	6	3
2126	971	direct interaction	[direct interaction]	6.0	2	8	4	2
2127	971	hiv production	[HIV production]	6.0	2	7	6	6
2128	971	most cell	[most cells]	6.0	2	7	4	4
2129	971	cyclin-dependent kinase	[cyclin-dependent kinase]	6.0	2	7	1	1
2130	971	tcr gene	[TCR gene]	6.0	2	7	4	4
2131	971	lung injury	[lung injury]	6.0	2	7	5	5
2132	971	respiratory burst	[respiratory burst]	6.0	2	7	4	4
2133	971	AMP response	[AMP response]	6.0	2	8	8	4
2134	971	tissue damage	[tissue damage]	6.0	2	7	6	6
2135	971	reactive oxygen	[reactive oxygen]	6.0	2	7	4	4
2136	971	distinct role	[distinct role]	6.0	2	7	7	7
2137	971	complex class	[complex class]	6.0	2	8	6	3
2138	971	elderly individual	[elderly individuals]	6.0	2	7	4	4
2139	971	ebv-transformed b	[EBV-transformed B]	6.0	2	6	0	0
2140	971	naturally occur	[naturally occurring]	6.0	2	7	1	1
2141	971	many cytokine	[many cytokines]	6.0	2	7	2	2
2142	971	distinct complex	[distinct complex]	6.0	2	7	6	6
2143	971	growth arrest	[growth arrest]	6.0	2	7	2	2
2144	971	current study	[current study]	6.0	2	6	0	0
2145	971	135(oh)2d3 receptor	[1,25(OH)2D3 receptors]	6.0	2	7	3	3
2146	971	functional response	[functional responses]	6.0	2	7	4	4
2147	971	I receptor	[I receptors]	6.0	2	7	3	3
2148	971	protein product	[protein product]	6.0	2	8	2	1
2149	971	proximal promoter	[proximal promoter]	6.0	2	7	2	2
2150	971	cos-7 cell	[COS-7 cells]	6.0	2	7	4	4
2151	971	lymphoid organ	[lymphoid organ]	6.0	2	7	5	5
2152	971	repression domain	[repression domain]	6.0	2	7	4	4
2153	971	inactive form	[inactive form]	6.0	2	7	5	5
2154	971	CLL cell	[CLL cells]	6.0	2	7	2	2
2155	971	follow treatment	[following treatment]	6.0	2	7	4	4
2156	971	human thymocyte	[human thymocytes]	6.0	2	7	1	1
2157	971	PMA induction	[PMA induction]	6.0	2	8	6	3
2158	971	antibody specific	[antibody specific]	6.0	2	7	5	5
2159	971	DNA synthesis	[DNA synthesis]	6.0	2	7	5	5
2160	971	viral infection	[viral infection]	6.0	2	7	1	1
2161	971	phosphatase inhibitor	[phosphatase inhibitor]	6.0	2	7	5	5
2162	971	CAT reporter	[CAT reporter]	6.0	2	8	6	3
2163	971	differentiation pathway	[differentiation pathway]	6.0	2	7	5	5
2164	971	blood pressure	[blood pressure]	6.0	2	7	5	5
2165	971	tissue specificity	[tissue specificity]	6.0	2	8	4	2
2166	971	gc box	[GC box]	6.0	2	7	6	6
2167	971	signal-regulated kinase	[signal-regulated kinase]	6.0	2	8	8	4
2168	971	RAI therapy	[RAI therapy]	6.0	2	7	3	3
2169	971	previous observation	[previous observation]	6.0	2	7	5	5
2170	971	fas expression	[Fas expression]	6.0	2	7	3	3
2171	971	T cell-specific	[T cell-specific]	6.0	2	7	5	5
2172	971	IL-1 beta	[IL-1 beta]	6.0	2	9	3	1
2173	971	2 P.	[2 h.]	6.0	2	7	1	1
2174	971	healthy donor	[healthy donors]	6.0	2	7	2	2
2175	971	chemokine receptor	[chemokine receptor]	6.0	2	7	4	4
2176	971	3 hour	[3 hr]	6.0	2	7	2	2
2177	971	il-12 production	[IL-12 production]	6.0	2	7	4	4
2178	971	c-fo induction	[c-fos induction]	6.0	2	7	5	5
2179	971	lytic replication	[lytic replication]	6.0	2	7	2	2
2180	971	lymphoid malignancy	[lymphoid malignancies]	6.0	2	7	1	1
2181	971	repressor activity	[repressor activity]	6.0	2	7	3	3
2182	971	t-cell lymphoma	[T-cell lymphoma]	6.0	2	7	4	4
2183	971	thymic cell	[thymic cells]	6.0	2	7	7	7
2184	971	5' sequence	[5' sequence]	6.0	2	7	7	7
2185	971	hypertensive patient	[hypertensive patients]	6.0	2	6	0	0
2186	971	wide variety	[wide variety]	6.0	2	11	10	2
2187	971	nuclear import	[nuclear import]	6.0	2	8	6	3
2188	971	bipolar disorder	[bipolar disorder]	6.0	2	7	2	2
2189	971	interleukin-2 enhancer	[interleukin-2 enhancer]	6.0	2	7	4	4
2190	971	x-linked immunodeficiency	[X-linked immunodeficiency]	6.0	2	7	5	5
2191	971	stat3 activation	[Stat3 activation]	6.0	2	7	2	2
2192	971	CEM cell	[CEM cells]	6.0	2	8	6	3
2193	971	growth rate	[growth rate]	6.0	2	7	3	3
2194	971	4 hour	[4 hr]	6.0	2	7	3	3
2195	971	synthetic glucocorticoid	[synthetic glucocorticoid]	6.0	2	7	3	3
2196	971	precursor cell	[precursor cell]	6.0	2	7	4	4
2197	971	cytokine synthesis	[cytokine synthesis]	6.0	2	7	3	3
2198	971	b subunit	[B subunit]	6.0	2	7	5	5
2199	971	full length	[full length]	6.0	2	7	1	1
2200	971	nf-at complex	[NF-AT complex]	6.0	2	7	7	7
2201	971	octamer-binding protein	[octamer-binding protein]	6.0	2	7	3	3
2202	971	healthy individual	[healthy individual]	6.0	2	7	2	2
2203	972	antioxidant	[antioxidant]	5.9941176470588236	1	61	18	17
2204	973	rat	[rat]	5.9904761904761905	1	61	23	21
2205	974	initiation	[initiation]	5.977777777777778	1	62	40	18
2206	975	th2	[Th2]	5.969230769230769	1	61	34	26
2207	976	il-5	[IL-5]	5.966666666666667	1	61	24	18
2208	977	form of leukemia	[form of leukemia]	5.943609377704336	3	5	5	4
2209	977	endothelial cell adhesion	[endothelial cell adhesion]	5.943609377704336	3	5	5	4
2210	977	all-tran acid atra	[all-trans acid ATRA]	5.943609377704336	3	5	5	4
2211	977	cd4+ t-cell clone	[CD4+ T-cell clones]	5.943609377704336	3	5	5	4
2212	977	activation of factor-kappa b	[activation of factor-kappa B]	5.943609377704336	4	5	5	4
2213	977	immediate response gene	[immediate response genes]	5.943609377704336	3	5	5	4
2214	977	modulate the expression	[modulating the expression]	5.943609377704336	3	5	5	4
2215	977	acute leukemia cell	[acute leukemia cells]	5.943609377704336	3	5	5	4
2216	977	expression of a form	[expression of a form]	5.943609377704336	4	5	5	4
2217	977	lead to activation	[leading to activation]	5.943609377704336	3	5	5	4
2218	977	nf-kappa b transcription	[NF-kappa B transcription]	5.943609377704336	3	5	5	4
2219	977	transcription in T cell	[transcription in T cells]	5.943609377704336	4	5	5	4
2220	977	human vein cell HUVEC	[human vein cells HUVEC]	5.943609377704336	4	5	5	4
2221	977	Mono Mac cell	[Mono Mac cells]	5.943609377704336	3	5	5	4
2222	977	only in cell	[only in cells]	5.943609377704336	3	5	5	4
2223	977	tyrosine phosphorylation of substrate	[tyrosine phosphorylation of substrates]	5.943609377704336	4	5	5	4
2224	977	subunit of NF-kappa b	[subunit of NF-kappa B]	5.943609377704336	4	5	5	4
2225	977	effect of stress	[effect of stresses]	5.943609377704336	3	5	5	4
2226	978	stress	[stress]	5.920833333333334	1	61	43	24
2227	979	phenotype	[phenotype]	5.865517241379311	1	60	39	29
2228	980	androgen	[androgen]	5.8500000000000005	1	60	24	16
2229	981	p element	[P element]	5.833333333333333	2	7	7	6
2230	981	b coactivator	[B coactivator]	5.833333333333333	2	7	7	6
2231	981	homeobox gene	[homeobox gene]	5.833333333333333	2	7	7	6
2232	981	direct evidence	[direct evidence]	5.833333333333333	2	7	7	6
2233	981	class promoter	[class promoter]	5.833333333333333	2	7	7	6
2234	981	dioxin receptor	[dioxin receptor]	5.833333333333333	2	7	7	6
2235	981	binding factor	[binding factor]	5.833333333333333	2	7	7	6
2236	981	surface marker	[surface marker]	5.833333333333333	2	7	7	6
2237	981	potent agent	[potent agents]	5.833333333333333	2	7	7	6
2238	982	transcription factor belong	[transcription factor belonging]	5.811529169310907	3	5	4	3
2239	982	glucocorticoid receptor concentration	[glucocorticoid receptor concentration]	5.811529169310907	3	5	4	3
2240	982	NF-kappa b heterodimer	[NF-kappa B heterodimer]	5.811529169310907	3	5	4	3
2241	982	ets binding site	[Ets binding site]	5.811529169310907	3	5	4	3
2242	982	adhesion of monocyte	[adhesion of monocytes]	5.811529169310907	3	5	4	3
2243	982	low density lipoprotein	[low density lipoprotein]	5.811529169310907	3	5	4	3
2244	982	factor NF-kappa b	[factor NF-kappa B]	5.811529169310907	3	5	4	3
2245	982	glucocorticoid receptor number	[glucocorticoid receptor number]	5.811529169310907	3	5	4	3
2246	982	transcription factor nuclear factor-kappaB	[transcription factor nuclear factor-kappaB]	5.811529169310907	4	5	4	3
2247	982	cd34+ progenitor cell	[CD34+ progenitor cells]	5.811529169310907	3	5	4	3
2248	982	activation of nuclear factor-kappaB	[activation of nuclear factor-kappaB]	5.811529169310907	4	5	4	3
2249	982	potent transcriptional activator	[potent transcriptional activator]	5.811529169310907	3	5	4	3
2250	982	role in the expression	[role in the expression]	5.811529169310907	4	5	4	3
2251	982	protein (map) kinase	[protein (MAP) kinase]	5.811529169310907	3	5	4	3
2252	982	tissue factor tf	[Tissue factor TF]	5.811529169310907	3	5	4	3
2253	982	zinc finger gene	[zinc finger gene]	5.811529169310907	3	5	4	3
2254	983	ebv genome	[EBV genome]	5.8	2	7	6	5
2255	983	tax mutant	[Tax mutant]	5.8	2	7	6	5
2256	983	positive role	[positive role]	5.8	2	7	6	5
2257	983	different effect	[different effect]	5.8	2	7	6	5
2258	983	peripheral leucocyte	[peripheral leucocytes]	5.8	2	7	6	5
2259	983	cDNA sequence	[cDNA sequence]	5.8	2	7	6	5
2260	983	GATA site	[GATA site]	5.8	2	7	6	5
2261	983	death domain	[death domain]	5.8	2	7	6	5
2262	983	receptor expression	[receptor expression]	5.8	2	7	6	5
2263	983	cell-specific factor	[cell-specific factor]	5.8	2	7	6	5
2264	983	il-4 expression	[IL-4 expression]	5.8	2	7	6	5
2265	984	Oct-1	[Oct-1]	5.771428571428572	1	59	18	14
2266	985	human tumor	[human tumor]	5.75	2	7	5	4
2267	985	receptor complex	[receptor complex]	5.75	2	7	5	4
2268	985	NFAT complex	[NFAT complex]	5.75	2	7	5	4
2269	985	lps signal	[LPS signaling]	5.75	2	7	5	4
2270	985	CD28 costimulation	[CD28 costimulation]	5.75	2	7	5	4
2271	985	cp activity	[Cp activity]	5.75	2	7	5	4
2272	985	human t-cell lymphotropic virus type	[human T-cell lymphotropic virus type]	5.75	5	7	5	4
2273	985	cd19 gene	[CD19 gene]	5.75	2	7	5	4
2274	985	late stage	[late stage]	5.75	2	7	5	4
2275	985	one patient	[one patient]	5.75	2	7	5	4
2276	985	biological activity	[biological activity]	5.75	2	7	5	4
2277	985	cytoplasmic tail	[cytoplasmic tail]	5.75	2	7	5	4
2278	985	anti-CD3 stimulation	[anti-CD3 stimulation]	5.75	2	7	5	4
2279	985	novel factor	[novel factor]	5.75	2	7	5	4
2280	985	follow stimulation	[following stimulation]	5.75	2	7	5	4
2281	985	virus infection	[virus infection]	5.75	2	7	5	4
2282	985	functional interaction	[functional interaction]	5.75	2	7	5	4
2283	986	ige	[IgE]	5.747619047619048	1	59	32	21
2284	987	jurkat	[Jurkat]	5.745000000000001	1	59	31	20
2285	988	defect	[defect]	5.716	1	59	46	25
2286	989	nucleotide	[nucleotide]	5.6947368421052635	1	58	40	38
2287	990	ets	[Ets]	5.68421052631579	1	58	22	19
2288	991	incubation	[incubation]	5.68	1	59	44	20
2289	992	cells,	[cells,]	5.679166666666667	1	58	29	24
2290	993	transcript	[transcript]	5.6781250000000005	1	58	39	32
2291	994	variant	[variant]	5.676666666666667	1	58	37	30
2292	995	zebra protein	[ZEBRA protein]	5.666666666666667	2	7	4	3
2293	995	30 min.	[30 min.]	5.666666666666667	2	7	4	3
2294	995	stromal cell	[stromal cells]	5.666666666666667	2	7	4	3
2295	995	I HTLV-I	[I HTLV-I]	5.666666666666667	2	7	4	3
2296	995	distinct set	[distinct set]	5.666666666666667	2	7	4	3
2297	995	5' end	[5' end]	5.666666666666667	2	7	4	3
2298	995	Jak kinase	[Jak kinases]	5.666666666666667	2	7	4	3
2299	995	S phase	[S phase]	5.666666666666667	2	7	4	3
2300	995	transactivation function	[transactivation function]	5.666666666666667	2	7	4	3
2301	995	Functional study	[Functional studies]	5.666666666666667	2	7	4	3
2302	995	e2a protein	[E2A protein]	5.666666666666667	2	7	4	3
2303	995	transcriptional enhancer	[transcriptional enhancer]	5.666666666666667	2	7	4	3
2304	996	suppressive effect	[suppressive effect]	5.666666666666666	2	8	7	3
2305	996	nuclear appearance	[nuclear appearance]	5.666666666666666	2	8	7	3
2306	996	large amount	[large amount]	5.666666666666666	2	8	7	3
2307	997	dna-binding	[DNA-binding]	5.655882352941177	1	58	49	34
2308	998	repressor	[repressor]	5.648	1	58	38	25
2309	999	fas	[Fas]	5.641176470588236	1	58	27	17
2310	1000	vitro.	[vitro.]	5.6000000000000005	1	75	19	1
2311	1001	docking site	[docking site]	5.6	2	7	7	5
2312	1001	encode protein	[encoding proteins]	5.6	2	7	7	5
2313	1001	molecular analysis	[Molecular analysis]	5.6	2	7	7	5
2314	1001	20 patient	[20 patients]	5.6	2	7	7	5
2315	1001	early protein	[early protein]	5.6	2	7	7	5
2316	1002	killer	[killer]	5.57	1	60	43	10
2317	1003	other cell types,	[other cell types,]	5.547368752524047	3	5	3	2
2318	1003	blood mononuclear cell PBMC	[blood mononuclear cells PBMC]	5.547368752524047	4	7	7	2
2319	1003	glucocorticoid binding site	[glucocorticoid binding sites]	5.547368752524047	3	6	5	2
2320	1003	smooth muscle cell	[smooth muscle cells]	5.547368752524047	3	6	5	2
2321	1003	nf-kappab dna-binding activity	[NF-kappaB DNA-binding activity]	5.547368752524047	3	5	3	2
2322	1003	human thp-1 cell	[human THP-1 cells]	5.547368752524047	3	7	7	2
2323	1003	loss of heterozygosity	[loss of heterozygosity]	5.547368752524047	3	5	3	2
2324	1003	immunodeficiency virus terminal repeat	[immunodeficiency virus terminal repeat]	5.547368752524047	4	7	7	2
2325	1003	complex class ii	[complex class II]	5.547368752524047	3	5	3	2
2326	1003	patient with ss	[patients with SS]	5.547368752524047	3	5	3	2
2327	1003	degradation of IkappaBalpha	[degradation of IkappaBalpha]	5.547368752524047	3	5	3	2
2328	1003	patient with tuberculosis	[patients with tuberculosis]	5.547368752524047	3	5	3	2
2329	1003	lineage-restricted transcription factor	[lineage-restricted transcription factor]	5.547368752524047	3	5	3	2
2330	1003	treatment of leukemia	[treatment of leukemia]	5.547368752524047	3	5	3	2
2331	1003	Peripheral blood mononuclear cell	[Peripheral blood mononuclear cells]	5.547368752524047	4	5	3	2
2332	1003	recruitment of EKLF	[recruitment of EKLF]	5.547368752524047	3	6	5	2
2333	1003	high-affinity binding site	[high-affinity binding site]	5.547368752524047	3	5	3	2
2334	1003	downstream NF-kappa b site	[downstream NF-kappa B site]	5.547368752524047	4	5	3	2
2335	1003	even in the absence	[even in the absence]	5.547368752524047	4	5	3	2
2336	1004	TNF-alpha	[TNF-alpha]	5.546153846153846	1	57	20	13
2337	1005	fibroblast	[fibroblast]	5.5200000000000005	1	57	27	15
2338	1006	nuclei	[nuclei]	5.507142857142857	1	58	41	14
2339	1007	skin fibroblast	[skin fibroblast]	5.5	2	7	3	2
2340	1007	nonlymphoid cell	[nonlymphoid cells]	5.5	2	7	3	2
2341	1007	g1 phase	[G1 phase]	5.5	2	7	3	2
2342	1007	Ets family	[Ets family]	5.5	2	8	5	2
2343	1007	4 h	[4 h]	5.5	2	7	6	4
2344	1007	heat	[heat]	5.5	1	57	24	12
2345	1007	factor kappa b nf-kappa b	[factor kappa B NF-kappa B]	5.5	5	11	11	2
2346	1007	two type	[two types]	5.5	2	9	7	2
2347	1007	N terminus	[N terminus]	5.5	2	7	6	4
2348	1007	human fibroblast	[human fibroblasts]	5.5	2	7	3	2
2349	1007	receptor protein	[receptor protein]	5.5	2	7	6	4
2350	1007	phosphatase calcineurin	[phosphatase calcineurin]	5.5	2	7	6	4
2351	1007	IFN -mcp	[IFN -MCP]	5.5	2	7	3	2
2352	1007	cell transcription	[cell transcription]	5.5	2	7	6	4
2353	1007	virus production	[virus production]	5.5	2	7	3	2
2354	1007	positive regulation	[positive regulation]	5.5	2	7	3	2
2355	1007	recent study	[recent study]	5.5	2	7	3	2
2356	1007	hemopoietic cell	[hemopoietic cells]	5.5	2	8	5	2
2357	1007	cell lines,	[cell lines,]	5.5	2	7	6	4
2358	1007	respiratory epithelium	[respiratory epithelium]	5.5	2	7	6	4
2359	1007	possible role	[possible role]	5.5	2	7	6	4
2360	1007	nfat element	[NFAT element]	5.5	2	7	6	4
2361	1007	cd95 ligand	[CD95 ligand]	5.5	2	7	6	4
2362	1008	report	[report]	5.490909090909091	1	57	23	11
2363	1009	order	[order]	5.466666666666667	1	56	8	6
2364	1010	therapy	[therapy]	5.462068965517242	1	56	40	29
2365	1011	factor-kappa	[factor-kappa]	5.4375	1	58	29	8
2366	1011	identification	[identification]	5.4375	1	61	53	8
2367	1012	repression	[repression]	5.4105263157894745	1	56	36	19
2368	1013	feature	[feature]	5.385365853658537	1	55	47	41
2369	1014	tcr activation	[TCR activation]	5.333333333333334	2	8	8	3
2370	1015	Nuclear factor of T cell	[Nuclear factor of T cells]	5.333333333333333	5	7	5	3
2371	1015	human class	[human class]	5.333333333333333	2	7	5	3
2372	1015	culture medium	[culture medium]	5.333333333333333	2	7	5	3
2373	1015	creb protein	[CREB protein]	5.333333333333333	2	7	5	3
2374	1015	beta subunit	[beta subunit]	5.333333333333333	2	7	5	3
2375	1015	beta-globin locus	[beta-globin locus]	5.333333333333333	2	7	5	3
2376	1016	modulation	[modulation]	5.311764705882354	1	56	49	17
2377	1017	IL-1	[IL-1]	5.307142857142857	1	55	27	14
2378	1018	IL-13	[IL-13]	5.300000000000001	1	54	12	12
2379	1019	resistance	[resistance]	5.286956521739131	1	55	49	23
2380	1020	phosphatase	[phosphatase]	5.286206896551724	1	54	33	29
2381	1021	U937 cell line	[U937 cell line]	5.2832083357371875	3	5	5	3
2382	1021	class transactivator ciita	[class transactivator CIITA]	5.2832083357371875	3	5	5	3
2383	1021	human immunodeficiency virus type-1	[human immunodeficiency virus type-1]	5.2832083357371875	4	5	5	3
2384	1021	immunodeficiency virus replication	[immunodeficiency virus replication]	5.2832083357371875	3	5	5	3
2385	1021	leukemic T cell	[leukemic T cells]	5.2832083357371875	3	5	5	3
2386	1021	myeloid cell differentiation antigen	[myeloid cell differentiation antigen]	5.2832083357371875	4	5	5	3
2387	1021	restriction fragment length	[restriction fragment length]	5.2832083357371875	3	5	5	3
2388	1021	human cd4+ T	[human CD4+ T]	5.2832083357371875	3	5	5	3
2389	1021	blood lymphocyte of patient	[blood lymphocytes of patients]	5.2832083357371875	4	5	5	3
2390	1021	immunodeficiency virus type-1	[immunodeficiency virus type-1]	5.2832083357371875	3	5	5	3
2391	1021	transcription factor factor-kappaB	[transcription factor factor-kappaB]	5.2832083357371875	3	5	5	3
2392	1021	steady state level	[steady state levels]	5.2832083357371875	3	5	5	3
2393	1021	affinity of the receptor	[affinity of the receptor]	5.2832083357371875	4	5	5	3
2394	1021	killer (nk) cell	[killer (NK) cells]	5.2832083357371875	3	5	5	3
2395	1021	promyelocytic leukemia cell	[promyelocytic leukemia cells]	5.2832083357371875	3	5	5	3
2396	1021	only low level	[only low levels]	5.2832083357371875	3	5	5	3
2397	1021	response to signal	[response to signals]	5.2832083357371875	3	5	5	3
2398	1022	start	[start]	5.2700000000000005	1	56	33	10
2399	1023	disorder	[disorder]	5.263636363636364	1	54	45	33
2400	1024	B	[B]	5.2562500000000005	1	55	39	16
2401	1025	relative affinity	[relative affinity]	5.25	2	7	7	4
2402	1025	high dose	[high dose]	5.25	2	7	7	4
2403	1025	RAW cell	[RAW cells]	5.25	2	7	7	4
2404	1025	hiv type	[HIV type]	5.25	2	7	7	4
2405	1025	extracellular kinase	[extracellular kinase]	5.25	2	7	7	4
2406	1025	low dose	[low dose]	5.25	2	7	7	4
2407	1025	immunodeficiency virus-1	[immunodeficiency virus-1]	5.25	2	7	7	4
2408	1025	RNA polymerase	[RNA polymerase]	5.25	2	7	7	4
2409	1026	tf	[TF]	5.245454545454546	1	54	34	22
2410	1027	specificity	[specificity]	5.234615384615385	1	54	43	26
2411	1028	bcl-2	[bcl-2]	5.218181818181819	1	54	20	11
2412	1029	relationship	[relationship]	5.207692307692309	1	54	50	26
2413	1030	degree	[degree]	5.195652173913044	1	54	47	23
2414	1031	il-1beta	[IL-1beta]	5.194117647058824	1	53	18	17
2415	1032	il-8	[IL-8]	5.18125	1	53	19	16
2416	1033	sensitivity	[sensitivity]	5.18	1	54	44	20
2417	1034	ig	[Ig]	5.179166666666667	1	53	29	24
2418	1035	IL-5	[IL-5]	5.170000000000001	1	53	13	10
2419	1036	generation	[generation]	5.104761904761905	1	53	41	21
2420	1037	immunoglobulin	[immunoglobulin]	5.095000000000001	1	52	21	20
2421	1038	ciita	[CIITA]	5.089473684210526	1	52	21	19
2422	1039	phase	[phase]	5.077777777777778	1	52	44	36
2423	1040	condition	[condition]	5.075757575757576	1	52	41	33
2424	1041	Jun	[Jun]	5.07	1	52	13	10
2425	1042	CD2	[CD2]	5.050000000000001	1	52	24	16
2426	1043	dose	[dose]	5.041666666666667	1	52	38	24
2427	1044	accumulation	[accumulation]	5.01764705882353	1	53	48	17
2428	1045	transcription activation	[transcription activation]	5.0	2	6	3	3
2429	1045	competition experiment	[competition experiments]	5.0	2	6	1	1
2430	1045	hGR level	[hGR levels]	5.0	2	7	6	3
2431	1045	humoral immunity	[humoral immunity]	5.0	2	6	3	3
2432	1045	receptor affinity	[receptor affinity]	5.0	2	6	4	4
2433	1045	specific gene	[specific gene]	5.0	2	6	2	2
2434	1045	cotransfection experiment	[cotransfection experiments]	5.0	2	6	2	2
2435	1045	cellular differentiation	[cellular differentiation]	5.0	2	5	0	0
2436	1045	tnf-alpha release in human monocyte	[TNF-alpha release in human monocytes]	5.0	5	5	0	0
2437	1045	ATL patient	[ATL patients]	5.0	2	7	6	3
2438	1045	promoter construct	[promoter construct]	5.0	2	6	6	6
2439	1045	th2 cytokine	[Th2 cytokine]	5.0	2	6	6	6
2440	1045	disease progression	[disease progression]	5.0	2	6	3	3
2441	1045	two factor	[two factor]	5.0	2	6	4	4
2442	1045	Recent report	[Recent reports]	5.0	2	5	0	0
2443	1045	guanine nucleotide	[guanine nucleotide]	5.0	2	6	4	4
2444	1045	different protein	[different protein]	5.0	2	6	3	3
2445	1045	primer extension	[primer extension]	5.0	2	7	4	2
2446	1045	negative correlation	[negative correlation]	5.0	2	6	4	4
2447	1045	further analysis	[Further analysis]	5.0	2	7	4	2
2448	1045	protein factor	[protein factor]	5.0	2	6	5	5
2449	1045	early development	[early development]	5.0	2	6	5	5
2450	1045	fetal liver	[fetal liver]	5.0	2	6	2	2
2451	1045	pathway lead	[pathway leading]	5.0	2	6	5	5
2452	1045	immediate-early protein	[immediate-early protein]	5.0	2	6	6	6
2453	1045	ige production	[IgE production]	5.0	2	7	4	2
2454	1045	normal differentiation	[normal differentiation]	5.0	2	6	5	5
2455	1045	proximal element	[proximal element]	5.0	2	6	4	4
2456	1045	immunoglobulin promoter	[immunoglobulin promoter]	5.0	2	6	5	5
2457	1045	menstrual cycle	[menstrual cycle]	5.0	2	7	2	1
2458	1045	undifferentiated cell	[undifferentiated cells]	5.0	2	6	3	3
2459	1045	significant amount	[significant amount]	5.0	2	8	6	2
2460	1045	expression of the transcription factor	[expression of the transcription factor]	5.0	5	6	3	3
2461	1045	interleukin-2 promoter	[interleukin-2 promoter]	5.0	2	7	6	3
2462	1045	activation of the IL-2 promoter	[activation of the IL-2 promoter]	5.0	5	6	1	1
2463	1045	prostaglandin e2	[prostaglandin E2]	5.0	2	6	3	3
2464	1045	chronic disease	[chronic disease]	5.0	2	6	5	5
2465	1045	transcriptional response	[transcriptional response]	5.0	2	6	5	5
2466	1045	immunosuppressive drug	[immunosuppressive drug]	5.0	2	6	3	3
2467	1045	complementary DNA	[complementary DNA]	5.0	2	6	2	2
2468	1045	first evidence	[first evidence]	5.0	2	6	4	4
2469	1045	mechanical ventilation	[mechanical ventilation]	5.0	2	6	2	2
2470	1045	endogenous gene	[endogenous gene]	5.0	2	6	3	3
2471	1045	two region	[two regions]	5.0	2	6	5	5
2472	1045	healthy person	[healthy persons]	5.0	2	6	3	3
2473	1045	protein sequence	[protein sequence]	5.0	2	6	5	5
2474	1045	clinical significance	[clinical significance]	5.0	2	7	6	3
2475	1045	present report,	[present report,]	5.0	2	5	0	0
2476	1045	interleukin-1beta il-1beta	[interleukin-1beta IL-1beta]	5.0	2	6	3	3
2477	1045	ap-1 enhancer	[AP-1 enhancer]	5.0	2	6	4	4
2478	1045	normal tissue	[normal tissues]	5.0	2	6	2	2
2479	1045	first exon	[first exon]	5.0	2	6	3	3
2480	1045	tcr delta	[TCR delta]	5.0	2	6	6	6
2481	1045	catalytic subunit	[catalytic subunit]	5.0	2	6	3	3
2482	1045	effector function	[effector function]	5.0	2	7	6	3
2483	1045	kinase c	[kinase C]	5.0	2	6	5	5
2484	1045	nuclear differentiation	[nuclear differentiation]	5.0	2	7	2	1
2485	1045	two subunit	[two subunits]	5.0	2	6	5	5
2486	1045	mitogen stimulation	[mitogen stimulation]	5.0	2	6	3	3
2487	1045	six patient	[six patients]	5.0	2	6	2	2
2488	1045	nfkappab activation	[NFkappaB activation]	5.0	2	6	5	5
2489	1045	hypersensitive site	[hypersensitive site]	5.0	2	6	3	3
2490	1045	atopic asthma	[atopic asthma]	5.0	2	5	0	0
2491	1045	three site	[three sites]	5.0	2	6	5	5
2492	1045	low density	[low density]	5.0	2	5	0	0
2493	1045	immunosuppressive effect	[immunosuppressive effect]	5.0	2	9	4	1
2494	1045	il-5 gene	[IL-5 gene]	5.0	2	7	6	3
2495	1045	Fos kinase	[Fos kinase]	5.0	2	5	0	0
2496	1045	three region	[three regions]	5.0	2	6	3	3
2497	1045	effector mechanism	[effector mechanism]	5.0	2	6	6	6
2498	1045	little information	[little information]	5.0	2	6	4	4
2499	1045	ss RBC	[SS RBC]	5.0	2	6	6	6
2500	1045	tcr engagement	[TCR engagement]	5.0	2	6	3	3
2501	1045	macrophage colony-stimulating	[macrophage colony-stimulating]	5.0	2	9	8	2
2502	1045	physiological role	[physiological role]	5.0	2	6	4	4
2503	1045	region ii	[region II]	5.0	2	6	3	3
2504	1045	hiv-1 long terminal repeat LTR	[HIV-1 long terminal repeat LTR]	5.0	5	6	1	1
2505	1045	anergic T	[anergic T]	5.0	2	6	1	1
2506	1045	molecular level	[molecular level]	5.0	2	5	0	0
2507	1045	nuclear factor-kappa b NF-kappa b	[nuclear factor-kappa B NF-kappa B]	5.0	5	6	1	1
2508	1045	il-2r gamma	[IL-2R gamma]	5.0	2	6	2	2
2509	1045	center b	[center B]	5.0	2	9	8	2
2510	1045	receptor function	[receptor function]	5.0	2	7	4	2
2511	1045	disease-free survival	[disease-free survival]	5.0	2	6	1	1
2512	1045	core sequence	[core sequence]	5.0	2	6	4	4
2513	1045	ankyrin repeat	[ankyrin repeat]	5.0	2	6	5	5
2514	1045	functional domain	[functional domain]	5.0	2	7	6	3
2515	1045	enzyme activity	[enzyme activity]	5.0	2	6	3	3
2516	1045	viral peptide	[viral peptide]	5.0	2	6	3	3
2517	1045	core promoter	[core promoter]	5.0	2	6	4	4
2518	1045	cancer patient	[cancer patient]	5.0	2	6	5	5
2519	1045	site-directed mutagenesis	[site-directed mutagenesis]	5.0	2	6	1	1
2520	1045	reverse transcriptase -polymerase chain reaction	[reverse transcriptase -polymerase chain reaction]	5.0	5	6	4	4
2521	1045	such cell	[such cells]	5.0	2	6	2	2
2522	1045	patient with systemic lupus erythematosus	[patients with systemic lupus erythematosus]	5.0	5	7	4	2
2523	1045	hl-60 differentiation	[HL-60 differentiation]	5.0	2	6	4	4
2524	1045	synergistic activation	[synergistic activation]	5.0	2	8	6	2
2525	1045	HTLV-1 tax	[HTLV-1 Tax]	5.0	2	5	0	0
2526	1045	gene coding	[gene coding]	5.0	2	7	6	3
2527	1045	ap-1 binding	[AP-1 binding]	5.0	2	6	5	5
2528	1045	binding assay	[binding assay]	5.0	2	6	5	5
2529	1045	clinical parameter	[clinical parameters]	5.0	2	5	0	0
2530	1045	kappab site	[kappaB site]	5.0	2	6	5	5
2531	1045	lps activation	[LPS activation]	5.0	2	7	6	3
2532	1045	C-terminal domain	[C-terminal domain]	5.0	2	6	4	4
2533	1045	cord blood	[cord blood]	5.0	2	6	4	4
2534	1045	p45 mrna	[p45 mRNA]	5.0	2	6	1	1
2535	1045	tetanus toxoid	[tetanus toxoid]	5.0	2	6	5	5
2536	1045	anti-inflammatory effect	[anti-inflammatory effect]	5.0	2	5	0	0
2537	1045	epidermal growth	[epidermal growth]	5.0	2	6	2	2
2538	1045	CD40 ligand	[CD40 ligand]	5.0	2	6	4	4
2539	1045	patient with chronic hepatitis c	[patients with chronic hepatitis C]	5.0	5	5	0	0
2540	1045	htr beta	[hTR beta]	5.0	2	7	6	3
2541	1045	productive infection	[productive infection]	5.0	2	6	2	2
2542	1045	type receptor	[type receptor]	5.0	2	6	6	6
2543	1045	colony-stimumulatelany-stg factor	[colony-stimulating factor]	5.0	2	6	6	6
2544	1045	reverse transcriptase	[reverse transcriptase]	5.0	2	6	5	5
2545	1045	erythrocytic lineage	[erythrocytic lineage]	5.0	2	5	0	0
2546	1045	p38 mapk	[p38 MAPk]	5.0	2	7	4	2
2547	1045	ah receptor	[Ah receptor]	5.0	2	6	3	3
2548	1045	b-cell activation	[B-cell activation]	5.0	2	6	4	4
2549	1045	rel protein	[Rel proteins]	5.0	2	6	5	5
2550	1045	nf-kappab translocation	[NF-kappaB translocation]	5.0	2	6	5	5
2551	1045	37 degree	[37 degrees]	5.0	2	5	0	0
2552	1045	steroid treatment	[steroid treatment]	5.0	2	6	5	5
2553	1045	various stimulus	[various stimuli]	5.0	2	6	3	3
2554	1045	helper	[helper]	5.0	1	52	34	17
2555	1045	multiple element	[multiple elements]	5.0	2	6	6	6
2556	1045	proximal region	[proximal region]	5.0	2	6	6	6
2557	1045	gas element	[GAS element]	5.0	2	6	2	2
2558	1045	cell lines.	[cell lines.]	5.0	2	6	4	4
2559	1045	U-937 cell	[U-937 cells]	5.0	2	6	2	2
2560	1045	b-cell maturation	[B-cell maturation]	5.0	2	6	3	3
2561	1045	positive effect	[positive effect]	5.0	2	6	6	6
2562	1045	two isoform	[two isoforms]	5.0	2	6	4	4
2563	1045	phosphorothioate oligonucleotide	[phosphorothioate oligonucleotide]	5.0	2	6	5	5
2564	1045	early step	[early step]	5.0	2	7	6	3
2565	1045	transcriptional repression	[transcriptional repression]	5.0	2	6	3	3
2566	1045	CpG island	[CpG island]	5.0	2	6	2	2
2567	1045	neutral pH	[neutral pH]	5.0	2	7	2	1
2568	1045	three element	[three elements]	5.0	2	6	5	5
2569	1045	aml m4	[AML M4]	5.0	2	6	5	5
2570	1045	functional activity	[functional activity]	5.0	2	7	4	2
2571	1045	primary tumor	[primary tumor]	5.0	2	7	4	2
2572	1045	long term	[long term]	5.0	2	5	0	0
2573	1045	E2F activity	[E2F activity]	5.0	2	6	6	6
2574	1045	DNA binding,	[DNA binding,]	5.0	2	6	5	5
2575	1045	contain bp	[containing bp]	5.0	2	6	6	6
2576	1045	negative effect	[negative effect]	5.0	2	6	5	5
2577	1045	functional analysis	[functional analysis]	5.0	2	7	6	3
2578	1045	mature granulocyte	[mature granulocytes]	5.0	2	5	0	0
2579	1045	express cell	[expressing cells]	5.0	2	6	4	4
2580	1045	different pathway	[different pathway]	5.0	2	6	5	5
2581	1045	splenic T	[splenic T]	5.0	2	6	1	1
2582	1045	inflammatory reaction	[inflammatory reaction]	5.0	2	6	3	3
2583	1045	b beta	[B beta]	5.0	2	6	1	1
2584	1045	ulcerative colitis	[ulcerative colitis]	5.0	2	6	2	2
2585	1045	type 2	[type 2]	5.0	2	6	3	3
2586	1045	CD4 cell	[CD4 cells]	5.0	2	6	2	2
2587	1045	latent infection	[latent infection]	5.0	2	6	2	2
2588	1045	47 kda	[47 kDa]	5.0	2	5	0	0
2589	1045	provide evidence	[providing evidence]	5.0	2	6	5	5
2590	1045	CD4 molecule	[CD4 molecule]	5.0	2	5	0	0
2591	1045	Th1 development	[Th1 development]	5.0	2	6	3	3
2592	1045	il-2 enhancer	[IL-2 enhancer]	5.0	2	6	3	3
2593	1045	Recent evidence	[Recent evidence]	5.0	2	6	2	2
2594	1045	Jun kinase	[Jun kinase]	5.0	2	6	4	4
2595	1045	same cells.	[same cells.]	5.0	2	5	0	0
2596	1045	tandem repeat	[tandem repeat]	5.0	2	6	5	5
2597	1045	major protein	[major protein]	5.0	2	6	6	6
2598	1045	intracellular ca2+	[intracellular Ca2+]	5.0	2	6	1	1
2599	1045	luciferase reporter	[luciferase reporter]	5.0	2	6	4	4
2600	1045	tumor tissue	[tumor tissue]	5.0	2	6	2	2
2601	1045	gata element	[GATA element]	5.0	2	6	5	5
2602	1045	hematopoietic growth	[hematopoietic growth]	5.0	2	6	2	2
2603	1045	cytokine release	[cytokine release]	5.0	2	6	2	2
2604	1045	transfection analysis	[transfection analysis]	5.0	2	6	5	5
2605	1045	enhancer sequence	[enhancer sequence]	5.0	2	6	3	3
2606	1045	monocyte-to-macrophage differentiation	[monocyte-to-macrophage differentiation]	5.0	2	5	0	0
2607	1045	seven patient	[seven patients]	5.0	2	6	4	4
2608	1045	run-on assay	[run-on assay]	5.0	2	7	6	3
2609	1045	site b	[site B]	5.0	2	6	5	5
2610	1045	erythroid transcription	[erythroid transcription]	5.0	2	6	1	1
2611	1045	quiescent cell	[quiescent cells]	5.0	2	6	2	2
2612	1045	mitogenic stimulus	[mitogenic stimuli]	5.0	2	5	0	0
2613	1045	RA receptor	[RA receptor]	5.0	2	6	6	6
2614	1046	epo	[EPO]	4.993333333333333	1	51	16	15
2615	1047	up-regulation	[up-regulation]	4.992857142857144	1	53	43	14
2616	1048	importance	[importance]	4.9913043478260875	1	52	48	23
2617	1049	Bcl-2	[Bcl-2]	4.988888888888889	1	51	10	9
2618	1050	pha	[PHA]	4.98	1	51	18	15
2619	1051	sp1	[Sp1]	4.976190476190476	1	51	26	21
2620	1052	Egr-1	[Egr-1]	4.964285714285715	1	51	19	14
2621	1052	NFkappaB	[NFkappaB]	4.964285714285715	1	51	19	14
2622	1053	thyroid	[thyroid]	4.956250000000001	1	51	23	16
2623	1054	chloramphenicol	[chloramphenicol]	4.941666666666666	1	51	19	12
2624	1055	cytoplasm	[cytoplasm]	4.9	1	52	21	7
2625	1056	rest	[rest]	4.882352941176471	1	50	20	17
2626	1057	experiment	[experiments]	4.881818181818183	1	50	26	22
2627	1058	htlv-i	[HTLV-I]	4.876190476190477	1	50	26	21
2628	1059	lack	[lack]	4.86923076923077	1	52	43	13
2629	1060	transformation	[transformation]	4.862068965517242	1	50	40	29
2630	1061	stat6	[STAT6]	4.829411764705883	1	50	29	17
2631	1062	mediator	[mediator]	4.826923076923077	1	50	45	26
2632	1063	down-regulation	[down-regulation]	4.816666666666666	1	52	46	12
2633	1064	localization	[localization]	4.800000000000001	1	50	42	21
2634	1065	cd4+ lymphocyte	[CD4+ lymphocytes]	4.8	2	6	6	5
2635	1065	promoter site	[promoter site]	4.8	2	6	6	5
2636	1065	chromosome translocation	[chromosome translocation]	4.8	2	6	6	5
2637	1065	et transcription	[ets transcription]	4.8	2	6	6	5
2638	1065	phorbol 13-acetate	[phorbol 13-acetate]	4.8	2	6	6	5
2639	1065	glucocorticoid binding	[glucocorticoid binding]	4.8	2	6	6	5
2640	1065	serine protease	[serine protease]	4.8	2	6	6	5
2641	1065	platelet-activate factor	[platelet-activating factor]	4.8	2	6	6	5
2642	1065	first step	[first step]	4.8	2	6	6	5
2643	1065	transactivation activity	[transactivation activity]	4.8	2	6	6	5
2644	1065	factor responsible	[factor responsible]	4.8	2	6	6	5
2645	1065	density lipoprotein	[density lipoprotein]	4.8	2	6	6	5
2646	1065	time point	[time point]	4.8	2	6	6	5
2647	1065	virus expression	[virus expression]	4.8	2	6	6	5
2648	1065	hpa axis	[HPA axis]	4.8	2	6	6	5
2649	1066	granulocyte-macrophage	[granulocyte-macrophage]	4.7846153846153845	1	50	28	13
2650	1067	lung	[lung]	4.78421052631579	1	49	22	19
2651	1068	D3	[D3]	4.777272727272727	1	49	27	22
2652	1069	step	[step]	4.772972972972973	1	49	47	37
2653	1070	Tat	[Tat]	4.7727272727272725	1	49	14	11
2654	1071	oxygen	[oxygen]	4.757142857142857	1	51	24	7
2655	1072	nuclear translocation of NF-kappaB	[nuclear translocation of NF-kappaB]	4.754887502163469	4	3	0	0
2656	1072	induction of bcl-2 expression	[induction of bcl-2 expression]	4.754887502163469	4	4	3	3
2657	1072	region of the promoter	[region of the promoter]	4.754887502163469	4	4	3	3
2658	1072	human hematopoietic cell	[human hematopoietic cells]	4.754887502163469	3	4	1	1
2659	1072	inactivation of Rb	[inactivation of Rb]	4.754887502163469	3	3	0	0
2660	1072	contain the region	[containing the region]	4.754887502163469	3	4	4	4
2661	1072	regulator of transcription	[regulator of transcription]	4.754887502163469	3	4	4	4
2662	1072	1 mrna level	[1 mRNA levels]	4.754887502163469	3	4	1	1
2663	1072	regulation of the expression	[regulation of the expression]	4.754887502163469	4	3	0	0
2664	1072	binding to receptor	[Binding to receptor]	4.754887502163469	3	4	4	4
2665	1072	regulation of transcription	[regulation of transcription]	4.754887502163469	3	4	3	3
2666	1072	inflammatory bowel disease	[inflammatory bowel disease]	4.754887502163469	3	4	4	4
2667	1072	transcriptional activation of gene	[transcriptional activation of genes]	4.754887502163469	4	4	4	4
2668	1072	effector T cell	[effector T cells]	4.754887502163469	3	3	0	0
2669	1072	increase in the number	[increase in the number]	4.754887502163469	4	5	4	2
2670	1072	immunoglobulin heavy-chain enhancer	[immunoglobulin heavy-chain enhancer]	4.754887502163469	3	4	2	2
2671	1072	protein of kda	[protein of kDa]	4.754887502163469	3	4	4	4
2672	1072	tyrosine phosphorylation of Stat3	[tyrosine phosphorylation of Stat3]	4.754887502163469	4	4	1	1
2673	1072	antigen present cell	[antigen presenting cells]	4.754887502163469	3	4	2	2
2674	1072	involvement in the regulation	[involvement in the regulation]	4.754887502163469	4	4	4	4
2675	1072	activity of factor	[activity of factor]	4.754887502163469	3	4	4	4
2676	1072	glucocorticoid receptor binding	[glucocorticoid receptor binding]	4.754887502163469	3	4	2	2
2677	1072	activation of cell	[activation of cells]	4.754887502163469	3	4	4	4
2678	1072	CD2 adhesion molecule	[CD2 adhesion molecules]	4.754887502163469	3	4	2	2
2679	1072	CIITA activation domain	[CIITA activation domain]	4.754887502163469	3	3	0	0
2680	1072	two cell types.	[two cell types.]	4.754887502163469	3	4	1	1
2681	1072	lymphocyte cell line	[lymphocyte cell line]	4.754887502163469	3	4	2	2
2682	1072	tyrosine phosphorylation of Jak2	[tyrosine phosphorylation of Jak2]	4.754887502163469	4	4	1	1
2683	1072	primary cortisol resistance	[primary cortisol resistance]	4.754887502163469	3	4	1	1
2684	1072	human erythroleukemia cell	[human erythroleukemia cells]	4.754887502163469	3	4	2	2
2685	1072	specific DNA sequence	[specific DNA sequence]	4.754887502163469	3	3	0	0
2686	1072	responsiveness to ifn-gamma	[responsiveness to IFN-gamma]	4.754887502163469	3	3	0	0
2687	1072	cardiac transplant recipient	[cardiac transplant recipients]	4.754887502163469	3	4	1	1
2688	1072	cellular immune response	[cellular immune response]	4.754887502163469	3	4	2	2
2689	1072	PMA responsive element	[PMA responsive element]	4.754887502163469	3	3	0	0
2690	1072	MHC class ii promoter	[MHC class II promoters]	4.754887502163469	4	4	2	2
2691	1072	inducible expression of gene	[inducible expression of genes]	4.754887502163469	4	4	4	4
2692	1072	nucleus to the cytoplasm	[nucleus to the cytoplasm]	4.754887502163469	4	3	0	0
2693	1072	constitutively active form	[constitutively active form]	4.754887502163469	3	6	6	2
2694	1072	phosphorylation of mad3	[phosphorylation of MAD3]	4.754887502163469	3	3	0	0
2695	1072	signal transduction pathway lead	[signal transduction pathway leading]	4.754887502163469	4	3	0	0
2696	1072	expression of tcl1	[expression of TCL1]	4.754887502163469	3	4	1	1
2697	1072	CD28 -responsive element	[CD28 -responsive element]	4.754887502163469	3	4	1	1
2698	1072	cell line u1	[cell line U1]	4.754887502163469	3	4	4	4
2699	1072	adult T cell leukemia	[adult T cell leukemia]	4.754887502163469	4	4	1	1
2700	1072	several lymphokine gene	[several lymphokine genes]	4.754887502163469	3	3	0	0
2701	1072	nuclear factor-kappa b nf-kappab	[nuclear factor-kappa B NF-kappaB]	4.754887502163469	4	3	0	0
2702	1072	binding of nuclear protein	[binding of nuclear proteins]	4.754887502163469	4	4	2	2
2703	1072	b cell lymphoma line	[B cell lymphoma lines]	4.754887502163469	4	4	2	2
2704	1072	role for nf-kappab	[role for NF-kappaB]	4.754887502163469	3	4	3	3
2705	1072	ap-1 DNA binding activity	[AP-1 DNA binding activity]	4.754887502163469	4	4	1	1
2706	1072	kappab regulatory element	[kappaB regulatory elements]	4.754887502163469	3	3	0	0
2707	1072	increase in il-1 beta	[increase in IL-1 beta]	4.754887502163469	4	3	0	0
2708	1072	naive cd4+ T cell	[naive CD4+ T cells]	4.754887502163469	4	3	0	0
2709	1072	binding of ap-1	[binding of AP-1]	4.754887502163469	3	3	0	0
2710	1072	patient with diabetic nephropathy	[patients with diabetic nephropathy]	4.754887502163469	4	4	2	2
2711	1072	human estrogen receptor	[human estrogen receptor]	4.754887502163469	3	3	0	0
2712	1072	IL-2R alpha gene	[IL-2R alpha gene]	4.754887502163469	3	4	1	1
2713	1072	cd4+ cell count	[CD4+ cell counts]	4.754887502163469	3	4	2	2
2714	1072	member of this family	[member of this family]	4.754887502163469	4	4	2	2
2715	1072	TCF-1 alpha binding site	[TCF-1 alpha binding site]	4.754887502163469	4	3	0	0
2716	1072	CD40 cytoplasmic domain	[CD40 cytoplasmic domain]	4.754887502163469	3	3	0	0
2717	1072	expression of cd69	[expression of CD69]	4.754887502163469	3	4	1	1
2718	1072	stimulation of b lymphocyte	[stimulation of B lymphocytes]	4.754887502163469	4	4	3	3
2719	1072	effect of heat shock	[effect of heat shock]	4.754887502163469	4	4	3	3
2720	1072	transcription in cell	[transcription in cells]	4.754887502163469	3	4	4	4
2721	1072	nf-kappa b inhibitor	[NF-kappa B inhibitor]	4.754887502163469	3	4	3	3
2722	1072	activity of promoter	[activity of promoters]	4.754887502163469	3	4	3	3
2723	1072	inflammatory cytokine gene	[inflammatory cytokine genes]	4.754887502163469	3	4	2	2
2724	1072	result of this study	[Results of this study]	4.754887502163469	4	4	1	1
2725	1072	NF-kappa b family protein	[NF-kappa B family proteins]	4.754887502163469	4	3	0	0
2726	1072	mineralocorticoid effector mechanism	[Mineralocorticoid effector mechanism]	4.754887502163469	3	4	2	2
2727	1072	kappa b protein	[kappa B protein]	4.754887502163469	3	4	4	4
2728	1072	ets transcription factor	[Ets transcription factor]	4.754887502163469	3	4	3	3
2729	1072	human androgen receptor	[human androgen receptor]	4.754887502163469	3	4	3	3
2730	1072	Sp1 transcription factor	[Sp1 transcription factor]	4.754887502163469	3	4	1	1
2731	1072	regulation of cytokine gene	[regulation of cytokine genes]	4.754887502163469	4	5	4	2
2732	1072	activation of Jak1	[activation of Jak1]	4.754887502163469	3	3	0	0
2733	1072	okadaic acid a inhibitor	[okadaic acid an inhibitor]	4.754887502163469	4	4	1	1
2734	1072	c-jun gene expression	[c-jun gene expression]	4.754887502163469	3	3	0	0
2735	1072	hiv-1 LTR gene expression	[HIV-1 LTR gene expression]	4.754887502163469	4	4	3	3
2736	1072	protein tyrosine kinase ptk	[protein tyrosine kinase PTK]	4.754887502163469	4	4	3	3
2737	1072	nf kappab activation	[NF kappaB activation]	4.754887502163469	3	4	1	1
2738	1072	member of a set	[member of a set]	4.754887502163469	4	3	0	0
2739	1072	human lymphoid cell	[human lymphoid cells]	4.754887502163469	3	4	1	1
2740	1072	healthy pregnant woman	[healthy pregnant women]	4.754887502163469	3	4	2	2
2741	1072	acute lymphoblastic leukemia all	[acute lymphoblastic leukemia ALL]	4.754887502163469	4	3	0	0
2742	1072	tax gene product	[tax gene product]	4.754887502163469	3	4	2	2
2743	1072	effect of lps	[effect of LPS]	4.754887502163469	3	3	0	0
2744	1072	transendothelial migration of monocyte	[transendothelial migration of monocytes]	4.754887502163469	4	4	3	3
2745	1072	T cell signal	[T cell signaling]	4.754887502163469	3	4	2	2
2746	1072	natural killer gene complex	[natural killer gene complex]	4.754887502163469	4	3	0	0
2747	1072	IL-2 gene transcription	[IL-2 gene transcription]	4.754887502163469	3	4	1	1
2748	1072	various cell line	[various cell lines]	4.754887502163469	3	4	3	3
2749	1072	formation of this complex	[formation of this complex]	4.754887502163469	4	3	0	0
2750	1072	natural killer cell receptor	[natural killer cell receptors]	4.754887502163469	4	3	0	0
2751	1072	human t-cell clone	[human T-cell clone]	4.754887502163469	3	4	4	4
2752	1072	expression of immunoglobulin gene	[expression of immunoglobulin genes]	4.754887502163469	4	4	3	3
2753	1072	human beta-globin locus	[human beta-globin locus]	4.754887502163469	3	4	1	1
2754	1072	subset of leukemia	[subset of leukemias]	4.754887502163469	3	4	4	4
2755	1072	glucocorticoid receptor antagonist	[glucocorticoid receptor antagonist]	4.754887502163469	3	6	6	2
2756	1072	effect of cya	[effect of CyA]	4.754887502163469	3	4	4	4
2757	1072	serum response element	[serum response element]	4.754887502163469	3	4	2	2
2758	1072	NFAT transcription factor	[NFAT transcription factors]	4.754887502163469	3	3	0	0
2759	1072	membrane protein LMP1	[membrane protein LMP1]	4.754887502163469	3	4	4	4
2760	1072	normal peripheral blood	[normal peripheral blood]	4.754887502163469	3	4	2	2
2761	1072	protein synthesis inhibitor	[protein synthesis inhibitor]	4.754887502163469	3	6	3	1
2762	1072	protein kinase a pka	[protein kinase A PKA]	4.754887502163469	4	4	1	1
2763	1072	catalytic domain of pp56(lck)	[catalytic domain of pp56(lck)]	4.754887502163469	4	3	0	0
2764	1072	reporter gene assay	[reporter gene assays]	4.754887502163469	3	4	2	2
2765	1072	Abelson murine leukemia virus	[Abelson murine leukemia virus]	4.754887502163469	4	3	0	0
2766	1072	function of PAF	[function of PAF]	4.754887502163469	3	3	0	0
2767	1072	transformation of T cell	[transformation of T cells]	4.754887502163469	4	4	2	2
2768	1072	epithelial cell line	[epithelial cell line]	4.754887502163469	3	4	1	1
2769	1072	CD27 /cd70 interaction	[CD27 /CD70 interaction]	4.754887502163469	3	3	0	0
2770	1072	systemic lupus erythematosus SLE	[systemic lupus erythematosus SLE]	4.754887502163469	4	3	0	0
2771	1072	epstein-barr virus ebv	[Epstein-Barr virus EBV]	4.754887502163469	3	4	3	3
2772	1072	retinoblastoma gene product	[retinoblastoma gene product]	4.754887502163469	3	4	3	3
2773	1072	sensitivity to glucocorticoid	[sensitivity to glucocorticoids]	4.754887502163469	3	4	3	3
2774	1072	human k562 cell	[human K562 cells]	4.754887502163469	3	4	4	4
2775	1072	human leukemic cell	[human leukemic cells]	4.754887502163469	3	4	2	2
2776	1072	New World primate	[New World primate]	4.754887502163469	3	4	3	3
2777	1072	three cell line	[three cell lines]	4.754887502163469	3	4	2	2
2778	1072	promonocytic cell line	[promonocytic cell line]	4.754887502163469	3	4	4	4
2779	1072	expression of vcam-1	[expression of VCAM-1]	4.754887502163469	3	4	2	2
2780	1072	hla class ii molecule	[HLA class II molecules]	4.754887502163469	4	4	1	1
2781	1072	follow lps stimulation	[following LPS stimulation]	4.754887502163469	3	4	3	3
2782	1072	signal transduction mechanism	[signal transduction mechanism]	4.754887502163469	3	3	0	0
2783	1072	NK cell activity	[NK cell activity]	4.754887502163469	3	4	1	1
2784	1072	effect of cytokine	[effect of cytokines]	4.754887502163469	3	4	1	1
2785	1072	tumor necrosis factor (tnf)-alpha	[tumor necrosis factor (TNF)-alpha]	4.754887502163469	4	3	0	0
2786	1072	peripheral blood lymphocyte pbl	[peripheral blood lymphocytes PBLs]	4.754887502163469	4	4	1	1
2787	1072	induction of transcription	[induction of transcription]	4.754887502163469	3	4	2	2
2788	1072	transcription factor pu.1	[transcription factor PU.1]	4.754887502163469	3	4	3	3
2789	1072	difference in the number	[difference in the number]	4.754887502163469	4	4	2	2
2790	1072	normal myeloid progenitor cell	[normal myeloid progenitor cells]	4.754887502163469	4	4	1	1
2791	1072	Nuclear run-on assay	[Nuclear run-on assays]	4.754887502163469	3	3	0	0
2792	1072	naive b cell	[naive B cells]	4.754887502163469	3	4	3	3
2793	1072	lymphoid-specific transcription factor Oct-2a	[lymphoid-specific transcription factor Oct-2a]	4.754887502163469	4	3	0	0
2794	1072	g0/g1 switch gene	[G0/G1 switch gene]	4.754887502163469	3	4	4	4
2795	1072	cell surface molecule	[cell surface molecules]	4.754887502163469	3	5	4	2
2796	1072	erythroid transcription factor gata-1	[erythroid transcription factor GATA-1]	4.754887502163469	4	3	0	0
2797	1072	chronic rheumatoid arthritis	[chronic rheumatoid arthritis]	4.754887502163469	3	4	1	1
2798	1072	analysis of extract	[analysis of extracts]	4.754887502163469	3	4	4	4
2799	1072	tumor suppressor protein	[tumor suppressor protein]	4.754887502163469	3	4	1	1
2800	1072	activity of the enhancer	[activity of the enhancer]	4.754887502163469	4	4	2	2
2801	1072	T cell leukemia	[T cell leukemia]	4.754887502163469	3	4	3	3
2802	1072	squirrel monkey glucocorticoid receptor	[squirrel monkey glucocorticoid receptor]	4.754887502163469	4	3	0	0
2803	1072	cytoplasm of FDC	[cytoplasm of FDC]	4.754887502163469	3	3	0	0
2804	1072	rate of transcription	[rate of transcription]	4.754887502163469	3	3	0	0
2805	1072	class ii expression	[class II expression]	4.754887502163469	3	4	3	3
2806	1072	human androgen receptor gene	[human androgen receptor gene]	4.754887502163469	4	5	4	2
2807	1072	expression of c-fo mrna	[expression of c-fos mRNA]	4.754887502163469	4	3	0	0
2808	1072	cyclosporin a CsA	[cyclosporin A CsA]	4.754887502163469	3	4	2	2
2809	1072	adhesion of u937 cell	[adhesion of U937 cells]	4.754887502163469	4	4	4	4
2810	1072	wild-type HLF protein	[wild-type HLF protein]	4.754887502163469	3	3	0	0
2811	1072	aged long-distance runner	[aged long-distance runner]	4.754887502163469	3	4	1	1
2812	1072	nf-at transcription factor	[NF-AT transcription factor]	4.754887502163469	3	4	1	1
2813	1072	t-cell antigen receptor tcr	[T-cell antigen receptor TCR]	4.754887502163469	4	3	0	0
2814	1072	cell type specificity	[cell type specificity]	4.754887502163469	3	4	2	2
2815	1072	dna-binding activity of Oct-2	[DNA-binding activity of Oct-2]	4.754887502163469	4	3	0	0
2816	1072	use polyclonal antisera	[using polyclonal antisera]	4.754887502163469	3	4	2	2
2817	1072	immunosuppressant cyclosporin A CsA	[immunosuppressants cyclosporin A CsA]	4.754887502163469	4	3	0	0
2818	1072	response to activation	[response to activation]	4.754887502163469	3	4	3	3
2819	1072	chronic leukemia CLL	[chronic leukemia CLL]	4.754887502163469	3	4	4	4
2820	1072	use a combination	[Using a combination]	4.754887502163469	3	5	4	2
2821	1072	acute myeloid leukemia AML	[acute myeloid leukemia AML]	4.754887502163469	4	3	0	0
2822	1072	stimulation with lps	[stimulation with LPS]	4.754887502163469	3	4	1	1
2823	1072	expression of CD20	[expression of CD20]	4.754887502163469	3	4	4	4
2824	1072	interleukin 2 gene	[interleukin 2 gene]	4.754887502163469	3	4	3	3
2825	1072	human GM-CSF promoter	[human GM-CSF promoter]	4.754887502163469	3	3	0	0
2826	1072	interleukin-2 receptor alpha chain	[interleukin-2 receptor alpha chain]	4.754887502163469	4	4	2	2
2827	1072	Nuclear factor-kappa b	[Nuclear factor-kappa B]	4.754887502163469	3	6	3	1
2828	1072	variety of cytokine	[variety of cytokines]	4.754887502163469	3	4	2	2
2829	1072	human herpesvirus 6 hhv-6	[Human herpesvirus 6 HHV-6]	4.754887502163469	4	3	0	0
2830	1072	translocation to the nucleus	[translocation to the nucleus]	4.754887502163469	4	4	1	1
2831	1072	distal promoter element	[distal promoter element]	4.754887502163469	3	3	0	0
2832	1072	activation in T cell	[activation in T cells]	4.754887502163469	4	4	4	4
2833	1072	region of the gene	[region of the gene]	4.754887502163469	4	4	2	2
2834	1072	tumor necrosis factor-alpha promoter	[tumor necrosis factor-alpha promoter]	4.754887502163469	4	3	0	0
2835	1072	treatment of patient	[treatment of patients]	4.754887502163469	3	4	1	1
2836	1072	multipotent eml cell	[multipotent EML cells]	4.754887502163469	3	3	0	0
2837	1072	human leukemia u937 cell	[human leukemia U937 cells]	4.754887502163469	4	4	2	2
2838	1072	ap-1 binding site	[AP-1 binding site]	4.754887502163469	3	4	2	2
2839	1072	tnf-alpha gene transcription	[TNF-alpha gene transcription]	4.754887502163469	3	3	0	0
2840	1072	protein- tyrosine kinase	[protein- tyrosine kinases]	4.754887502163469	3	4	3	3
2841	1072	activation of the receptor	[activation of the receptor]	4.754887502163469	4	4	2	2
2842	1072	case of leukemia	[cases of leukemia]	4.754887502163469	3	4	4	4
2843	1072	three binding site	[three binding sites]	4.754887502163469	3	4	3	3
2844	1072	dpm mg-1 cytosol protein	[dpm mg-1 cytosol protein]	4.754887502163469	4	4	3	3
2845	1072	up-regulation of hb-egf mrna	[up-regulation of HB-EGF mRNA]	4.754887502163469	4	3	0	0
2846	1072	natural killer cell activity	[natural killer cell activity]	4.754887502163469	4	4	1	1
2847	1072	splenic T cell	[splenic T cells]	4.754887502163469	3	4	2	2
2848	1072	phorbol-12-myristate acetate PMA	[phorbol-12-myristate acetate PMA]	4.754887502163469	3	4	1	1
2849	1072	low level of expression	[low level of expression]	4.754887502163469	4	4	2	2
2850	1072	mature T cell phenotype	[mature T cell phenotype]	4.754887502163469	4	3	0	0
2851	1072	three transcription factor	[three transcription factors]	4.754887502163469	3	4	3	3
2852	1072	c-myc mrna level	[c-myc mRNA level]	4.754887502163469	3	4	2	2
2853	1072	transcription factor complex	[transcription factor complex]	4.754887502163469	3	4	4	4
2854	1072	antioxidant pyrrolidine dithiocarbamate pdtc	[antioxidant pyrrolidine dithiocarbamate PDTC]	4.754887502163469	4	3	0	0
2855	1072	immediate early protein	[immediate early protein]	4.754887502163469	3	4	2	2
2856	1072	acute promyelocytic leukemia cell	[acute promyelocytic leukemia cells]	4.754887502163469	4	4	1	1
2857	1072	processing of p105	[processing of p105]	4.754887502163469	3	4	1	1
2858	1072	effect in T cell	[effect in T cells]	4.754887502163469	4	4	4	4
2859	1072	stem cell factor	[stem cell factor]	4.754887502163469	3	5	4	2
2860	1072	acute promyelocytic leukaemia	[acute promyelocytic leukaemia]	4.754887502163469	3	3	0	0
2861	1072	signal transduction cascade	[signal transduction cascade]	4.754887502163469	3	4	2	2
2862	1072	fresh leukemic cell	[fresh leukemic cells]	4.754887502163469	3	4	4	4
2863	1072	hydrogen peroxide h2o2	[hydrogen peroxide H2O2]	4.754887502163469	3	3	0	0
2864	1072	granulocyte/macrophage colony-stimulating factor	[granulocyte/macrophage colony-stimulating factor]	4.754887502163469	3	4	2	2
2865	1072	regulation of cell growth	[regulation of cell growth]	4.754887502163469	4	3	0	0
2866	1072	patient with colitis	[patients with colitis]	4.754887502163469	3	4	4	4
2867	1072	stimulation of the cell	[stimulation of the cells]	4.754887502163469	4	3	0	0
2868	1072	cellular signal pathway	[cellular signaling pathway]	4.754887502163469	3	4	1	1
2869	1072	stimulation of NK cell	[stimulation of NK cells]	4.754887502163469	4	3	0	0
2870	1072	sp 1-binding site	[Sp 1-binding site]	4.754887502163469	3	4	3	3
2871	1072	expression of a gene	[expression of an gene]	4.754887502163469	4	4	3	3
2872	1072	hormone binding domain	[hormone binding domain]	4.754887502163469	3	4	1	1
2873	1072	member of a family	[member of a family]	4.754887502163469	4	3	0	0
2874	1072	retinoid x receptor RXR	[retinoid X receptor RXR]	4.754887502163469	4	3	0	0
2875	1072	Ets family member	[Ets family member]	4.754887502163469	3	4	2	2
2876	1072	Rel/NF-kappa b transcription factor	[Rel/NF-kappa B transcription factors]	4.754887502163469	4	3	0	0
2877	1072	expression of p65 mrna	[expression of p65 mRNA]	4.754887502163469	4	3	0	0
2878	1072	two cis-acting element	[two cis-acting elements]	4.754887502163469	3	4	4	4
2879	1072	pathogenesis of hiv-1 infection	[pathogenesis of HIV-1 infection]	4.754887502163469	4	3	0	0
2880	1072	human gm-csf gene	[human GM-CSF gene]	4.754887502163469	3	3	0	0
2881	1072	activation of NFAT	[activation of NFAT]	4.754887502163469	3	4	2	2
2882	1072	presence of lps	[presence of LPS]	4.754887502163469	3	5	2	1
2883	1072	early b-cell factor	[early B-cell factor]	4.754887502163469	3	4	4	4
2884	1072	inhibition of protein synthesis	[inhibition of protein synthesis]	4.754887502163469	4	4	1	1
2885	1072	NK cell activation	[NK cell activation]	4.754887502163469	3	4	1	1
2886	1072	NF kappa b activation	[NF kappa B activation]	4.754887502163469	4	3	0	0
2887	1072	type ii EBS	[type II EBS]	4.754887502163469	3	5	2	1
2888	1072	cytosolic phospholipase a2	[cytosolic phospholipase A2]	4.754887502163469	3	4	2	2
2889	1072	genital skin fibroblast	[genital skin fibroblast]	4.754887502163469	3	3	0	0
2890	1072	precursor b cell	[precursor B cells]	4.754887502163469	3	4	3	3
2891	1072	two regulatory element	[two regulatory elements]	4.754887502163469	3	4	3	3
2892	1072	primary T cell response	[primary T cell response]	4.754887502163469	4	4	1	1
2893	1072	nuclei of T cell	[nuclei of T cells]	4.754887502163469	4	3	0	0
2894	1072	bronchial epithelial cell	[bronchial epithelial cells]	4.754887502163469	3	4	1	1
2895	1072	pretreatment of cell	[Pretreatment of cells]	4.754887502163469	3	4	2	2
2896	1072	ipr cd4-8- T cell	[Ipr CD4-8- T cells]	4.754887502163469	4	4	1	1
2897	1072	kappa 3 element	[kappa 3 element]	4.754887502163469	3	3	0	0
2898	1072	deletion of this region	[deletion of this region]	4.754887502163469	4	4	1	1
2899	1072	hiv gene expression	[HIV gene expression]	4.754887502163469	3	4	2	2
2900	1072	response to mitogenic stimulus	[response to mitogenic stimuli]	4.754887502163469	4	3	0	0
2901	1072	intracellular signal molecule	[intracellular signaling molecules]	4.754887502163469	3	4	2	2
2902	1072	class transactivator CIITA	[class transactivator CIITA]	4.754887502163469	3	6	6	2
2903	1072	processing of the precursor	[processing of the precursors]	4.754887502163469	4	4	2	2
2904	1072	cdc2 mrna expression	[cdc2 mRNA expression]	4.754887502163469	3	4	1	1
2905	1072	only in T cell	[only in T cells]	4.754887502163469	4	3	0	0
2906	1072	transcription factor activator protein-1	[transcription factor activator protein-1]	4.754887502163469	4	3	0	0
2907	1072	regulation of sialoadhesin expression	[regulation of sialoadhesin expression]	4.754887502163469	4	3	0	0
2908	1072	cd8+ T lymphocyte	[CD8+ T lymphocytes]	4.754887502163469	3	4	3	3
2909	1072	J delta 1 segment	[J delta 1 segment]	4.754887502163469	4	3	0	0
2910	1072	hiv-1 long terminal	[HIV-1 long terminal]	4.754887502163469	3	6	3	1
2911	1072	patient with rheumatoid arthritis	[patient with rheumatoid arthritis]	4.754887502163469	4	4	4	4
2912	1072	inhibition of hiv-1 replication	[inhibition of HIV-1 replication]	4.754887502163469	4	4	3	3
2913	1072	NF-kappa b binding	[NF-kappa B binding]	4.754887502163469	3	4	2	2
2914	1072	phagocyte nadph oxidase	[phagocyte NADPH oxidase]	4.754887502163469	3	3	0	0
2915	1072	overexpression of p53 protein	[overexpression of p53 protein]	4.754887502163469	4	3	0	0
2916	1072	glucocorticoid binding in lymphocyte	[glucocorticoid binding in lymphocytes]	4.754887502163469	4	3	0	0
2917	1072	T cell factor	[T cell factor]	4.754887502163469	3	4	4	4
2918	1072	urinary cortisol excretion	[urinary cortisol excretion]	4.754887502163469	3	4	4	4
2919	1072	transcription factor e2f	[transcription factor E2F]	4.754887502163469	3	4	2	2
2920	1072	immortalization of T cell	[immortalization of T cells]	4.754887502163469	4	3	0	0
2921	1072	replication of immunodeficiency virus	[replication of immunodeficiency virus]	4.754887502163469	4	4	3	3
2922	1072	pathogenesis of inflammatory disease	[pathogenesis of inflammatory diseases]	4.754887502163469	4	4	2	2
2923	1072	glucocorticoid receptor antagonist ru38486	[glucocorticoid receptor antagonist RU38486]	4.754887502163469	4	3	0	0
2924	1072	cyclosporin A CsA	[cyclosporin A CsA]	4.754887502163469	3	4	2	2
2925	1072	nuclear run-on analysis	[nuclear run-on analysis]	4.754887502163469	3	3	0	0
2926	1072	beta-globin locus control region	[beta-globin locus control region]	4.754887502163469	4	4	3	3
2927	1072	Nuclear run-on experiment	[Nuclear run-on experiments]	4.754887502163469	3	3	0	0
2928	1072	several line of evidence	[Several lines of evidence]	4.754887502163469	4	3	0	0
2929	1072	molecular mass of kda	[molecular mass of kDa]	4.754887502163469	4	4	4	4
2930	1072	encode a protein	[encoding a protein]	4.754887502163469	3	4	4	4
2931	1072	glucocorticoid receptor in leukocyte	[glucocorticoid receptor in leukocytes]	4.754887502163469	4	4	4	4
2932	1072	stat transcription factor	[STAT transcription factor]	4.754887502163469	3	4	2	2
2933	1072	monocyte from II-2	[monocytes from II-2]	4.754887502163469	3	3	0	0
2934	1072	cell surface marker	[cell surface markers]	4.754887502163469	3	5	4	2
2935	1072	systemic lupus erythematosus sle	[systemic lupus erythematosus SLE]	4.754887502163469	4	3	0	0
2936	1072	presence of PMA	[presence of PMA]	4.754887502163469	3	3	0	0
2937	1072	regulation of gene transcription	[regulation of gene transcription]	4.754887502163469	4	3	0	0
2938	1072	interleukin 2 il-2	[interleukin 2 IL-2]	4.754887502163469	3	4	2	2
2939	1072	interaction with transcription factor	[interaction with transcription factor]	4.754887502163469	4	4	2	2
2940	1072	acute myelogenous leukemia	[acute myelogenous leukemia]	4.754887502163469	3	4	3	3
2941	1072	cell cycle control	[cell cycle control]	4.754887502163469	3	4	3	3
2942	1072	human peripheral leukocyte	[human peripheral leukocytes]	4.754887502163469	3	3	0	0
2943	1072	dissociation constant kd	[dissociation constant Kd]	4.754887502163469	3	4	3	3
2944	1072	colony-stimulating factor receptor	[colony-stimulating factor receptor]	4.754887502163469	3	4	3	3
2945	1072	follow t-cell activation	[following T-cell activation]	4.754887502163469	3	4	1	1
2946	1072	vascular muscle cell	[vascular muscle cells]	4.754887502163469	3	4	4	4
2947	1072	growth factor receptor	[growth factor receptor]	4.754887502163469	3	4	2	2
2948	1072	promonocytic cell line u937	[promonocytic cell line U937]	4.754887502163469	4	4	1	1
2949	1072	transcription factor nf-at	[transcription factor NF-AT]	4.754887502163469	3	4	2	2
2950	1072	proliferation of cell	[proliferation of cells]	4.754887502163469	3	4	4	4
2951	1072	glucocorticoid receptor GCR	[glucocorticoid receptors GCR]	4.754887502163469	3	4	3	3
2952	1072	nf-at -binding activity	[NF-AT -binding activity]	4.754887502163469	3	3	0	0
2953	1072	transcription factor ap-2	[transcription factor AP-2]	4.754887502163469	3	3	0	0
2954	1072	expression of pu.1	[expression of PU.1]	4.754887502163469	3	4	3	3
2955	1072	DNA binding assay	[DNA binding assays]	4.754887502163469	3	3	0	0
2956	1072	receptor in mononuclear leukocyte	[receptors in mononuclear leukocytes]	4.754887502163469	4	4	4	4
2957	1072	number of type	[number of Type]	4.754887502163469	3	4	3	3
2958	1072	notch signal pathway	[Notch signaling pathway]	4.754887502163469	3	3	0	0
2959	1072	role in development	[role in development]	4.754887502163469	3	4	4	4
2960	1072	respiratory distress syndrome	[respiratory distress syndrome]	4.754887502163469	3	4	3	3
2961	1072	role in lymphoid development	[role in lymphoid development]	4.754887502163469	4	4	4	4
2962	1072	nf-kappa b nuclear translocation	[NF-kappa B nuclear translocation]	4.754887502163469	4	3	0	0
2963	1072	estrogen binding site	[estrogen binding sites]	4.754887502163469	3	4	3	3
2964	1072	kappa b-like site	[kappa B-like site]	4.754887502163469	3	4	2	2
2965	1072	locus control region LCR	[locus control region LCR]	4.754887502163469	4	4	1	1
2966	1072	stimulatory effect of gp160	[stimulatory effect of gp160]	4.754887502163469	4	3	0	0
2967	1072	primary human T	[primary human T]	4.754887502163469	3	3	0	0
2968	1072	surface of cell	[surface of cells]	4.754887502163469	3	4	2	2
2969	1072	distinct signal pathway	[distinct signaling pathways]	4.754887502163469	3	4	2	2
2970	1072	human cd4+ lymphocyte	[human CD4+ lymphocytes]	4.754887502163469	3	3	0	0
2971	1072	patient with promyelocytic leukemia	[patient with promyelocytic leukemia]	4.754887502163469	4	4	4	4
2972	1072	viral protein tax	[viral protein Tax]	4.754887502163469	3	3	0	0
2973	1072	normal erythroid differentiation	[normal erythroid differentiation]	4.754887502163469	3	3	0	0
2974	1072	use a antibody	[Using a antibody]	4.754887502163469	3	4	4	4
2975	1072	number of cell types.	[number of cell types.]	4.754887502163469	4	3	0	0
2976	1072	such as ap-1	[such as AP-1]	4.754887502163469	3	3	0	0
2977	1072	CAT reporter gene	[CAT reporter gene]	4.754887502163469	3	4	2	2
2978	1072	agonist-induced monocytic cell adhesion	[agonist-induced monocytic cell adhesion]	4.754887502163469	4	4	1	1
2979	1072	level in cell	[levels in cells]	4.754887502163469	3	4	4	4
2980	1072	cell of origin	[cell of origin]	4.754887502163469	3	4	4	4
2981	1072	interleukin-2 receptor il-2r	[interleukin-2 receptor IL-2R]	4.754887502163469	3	3	0	0
2982	1072	presence of CsA	[presence of CsA]	4.754887502163469	3	3	0	0
2983	1072	nitric oxide no	[nitric oxide NO]	4.754887502163469	3	3	0	0
2984	1072	human peripheral T cell	[human peripheral T cells]	4.754887502163469	4	3	0	0
2985	1072	oxygen species ROS	[oxygen species ROS]	4.754887502163469	3	6	6	2
2986	1072	EBNA 2 -dependent enhancer	[EBNA 2 -dependent enhancer]	4.754887502163469	4	3	0	0
2987	1072	level of DNA binding	[level of DNA binding]	4.754887502163469	4	3	0	0
2988	1072	human interleukin gene	[human interleukin gene]	4.754887502163469	3	4	4	4
2989	1072	activator protein 1	[activator protein 1]	4.754887502163469	3	3	0	0
2990	1072	blood lymphocyte PBL	[blood lymphocytes PBL]	4.754887502163469	3	4	4	4
2991	1072	beta- globin gene	[beta- globin gene]	4.754887502163469	3	3	0	0
2992	1072	cell wall component	[cell wall component]	4.754887502163469	3	4	3	3
2993	1072	stem cell factor SCF	[stem cell factor SCF]	4.754887502163469	4	4	1	1
2994	1072	human cd34+ progenitor cell	[human CD34+ progenitor cells]	4.754887502163469	4	4	4	4
2995	1072	vitamin d receptor gene	[vitamin D receptor gene]	4.754887502163469	4	4	1	1
2996	1072	nuclear factor-kappaB NF-kappaB	[nuclear factor-kappaB NF-kappaB]	4.754887502163469	3	3	0	0
2997	1072	identification of transcription factor	[identification of transcription factors]	4.754887502163469	4	4	1	1
2998	1072	receptor for 135(oh)2d3	[receptor for 1,25(OH)2D3]	4.754887502163469	3	3	0	0
2999	1072	expression in b cell	[expression in B cells]	4.754887502163469	4	4	4	4
3000	1072	promoter in cell	[promoter in cells]	4.754887502163469	3	4	4	4
3001	1072	vascular smooth muscle cell	[vascular smooth muscle cells]	4.754887502163469	4	4	1	1
3002	1072	HTLV-I t-cell line	[HTLV-I T-cell line]	4.754887502163469	3	4	2	2
3003	1072	fetal thymic organ culture	[fetal thymic organ culture]	4.754887502163469	4	3	0	0
3004	1072	tumor cell line	[tumor cell lines]	4.754887502163469	3	4	1	1
3005	1072	human leukemic T cell	[human leukemic T cells]	4.754887502163469	4	3	0	0
3006	1072	mouse mammary tumor virus	[mouse mammary tumor virus]	4.754887502163469	4	4	1	1
3007	1072	T immune response	[T immune response]	4.754887502163469	3	4	3	3
3008	1072	level of transcription.	[level of transcription.]	4.754887502163469	3	4	1	1
3009	1072	casein kinase ii	[casein kinase II]	4.754887502163469	3	4	2	2
3010	1072	nf-kappa b transcription factor	[NF-kappa B transcription factor]	4.754887502163469	4	4	1	1
3011	1072	variant octamer motif	[variant octamer motif]	4.754887502163469	3	4	1	1
3012	1072	proximal promoter region	[proximal promoter region]	4.754887502163469	3	4	2	2
3013	1072	9-cis retinoic acid	[9-cis retinoic acid]	4.754887502163469	3	4	1	1
3014	1072	u-937 cell adhesion	[U-937 cell adhesion]	4.754887502163469	3	4	1	1
3015	1072	combination of il-12	[combination of IL-12]	4.754887502163469	3	3	0	0
3016	1072	HIV long terminal repeat	[HIV long terminal repeat]	4.754887502163469	4	4	1	1
3017	1072	mass of kda	[mass of kDa]	4.754887502163469	3	4	4	4
3018	1072	specific binding site	[specific binding sites]	4.754887502163469	3	4	3	3
3019	1072	change in glucocorticoid receptor	[changes in glucocorticoid receptors]	4.754887502163469	4	4	3	3
3020	1072	tyrosine phosphorylation of p80c-rel	[tyrosine phosphorylation of p80c-rel]	4.754887502163469	4	3	0	0
3021	1072	interleukin-2 promoter activity	[Interleukin-2 promoter activity]	4.754887502163469	3	4	1	1
3022	1072	rel T cell	[Rel T cells]	4.754887502163469	3	4	3	3
3023	1072	expression of il-2	[expression of IL-2]	4.754887502163469	3	4	2	2
3024	1072	proximal ap-1 site	[proximal AP-1 site]	4.754887502163469	3	4	1	1
3025	1072	effect of gdsp	[effect of GDSP]	4.754887502163469	3	4	2	2
3026	1072	human immunodeficiency virus-1 hiv-1	[human immunodeficiency virus-1 HIV-1]	4.754887502163469	4	3	0	0
3027	1072	kappa b alpha degradation	[kappa B alpha degradation]	4.754887502163469	4	3	0	0
3028	1072	amount of c-myb mrna	[amount of c-myb mRNA]	4.754887502163469	4	3	0	0
3029	1072	T cell area	[T cell area]	4.754887502163469	3	4	3	3
3030	1072	lack of response	[lack of response]	4.754887502163469	3	4	4	4
3031	1072	activation of kinase	[activation of kinases]	4.754887502163469	3	4	4	4
3032	1072	humoral immune response	[humoral immune response]	4.754887502163469	3	4	3	3
3033	1072	transcription factor NF-kappaB	[transcription factor NF-kappaB]	4.754887502163469	3	3	0	0
3034	1072	osteoblast-specific cis-acting element	[osteoblast-specific cis-acting element]	4.754887502163469	3	4	1	1
3035	1072	control of expression	[control of expression]	4.754887502163469	3	4	3	3
3036	1072	objective of this study	[objective of this study]	4.754887502163469	4	4	1	1
3037	1072	effect of NAC	[effect of NAC]	4.754887502163469	3	4	2	2
3038	1072	inducer of monocytic differentiation	[inducer of monocytic differentiation]	4.754887502163469	4	4	3	3
3039	1072	inhibitor of nf-kappab	[inhibitor of NF-kappaB]	4.754887502163469	3	4	3	3
3040	1072	G. vaginalis lysate	[G. vaginalis lysates]	4.754887502163469	3	3	0	0
3041	1072	amino acid residue	[amino acid residues]	4.754887502163469	3	4	3	3
3042	1072	nuclear factor-kappaB nf-kappab	[nuclear factor-kappaB NF-kappaB]	4.754887502163469	3	4	2	2
3043	1072	germline C epsilon transcription	[germline C epsilon transcription]	4.754887502163469	4	4	2	2
3044	1072	induction of NF-kappaB	[induction of NF-kappaB]	4.754887502163469	3	4	3	3
3045	1072	induction of gene expression	[induction of gene expression]	4.754887502163469	4	4	2	2
3046	1072	tax -express cell	[Tax -expressing cells]	4.754887502163469	3	3	0	0
3047	1072	pathogenesis of autoimmune disease	[pathogenesis of autoimmune diseases]	4.754887502163469	4	4	2	2
3048	1072	regulation of hiv-1 expression	[regulation of HIV-1 expression]	4.754887502163469	4	3	0	0
3049	1072	receptor binding site	[receptor binding sites]	4.754887502163469	3	4	3	3
3050	1072	retinoic acid receptor rar	[retinoic acid receptors RARs]	4.754887502163469	4	4	2	2
3051	1072	human immunodeficiency virus hiv-1	[human immunodeficiency virus HIV-1]	4.754887502163469	4	4	2	2
3052	1072	mononuclear cell culture	[mononuclear cell cultures]	4.754887502163469	3	3	0	0
3053	1072	induction of vcam-1	[induction of VCAM-1]	4.754887502163469	3	4	2	2
3054	1072	subset of gene	[subset of genes]	4.754887502163469	3	4	4	4
3055	1072	high risk woman	[high risk women]	4.754887502163469	3	4	3	3
3056	1072	expression of rrna	[expression of mRNAs]	4.754887502163469	3	4	2	2
3057	1072	drug cyclosporin a	[drugs cyclosporin A]	4.754887502163469	3	4	4	4
3058	1072	chronic hepatitis c	[chronic hepatitis C]	4.754887502163469	3	6	6	2
3059	1072	host transcription factor	[host transcription factor]	4.754887502163469	3	5	4	2
3060	1072	T cell extract	[T cell extracts]	4.754887502163469	3	4	1	1
3061	1072	T cell recognition	[T cell recognition]	4.754887502163469	3	4	4	4
3062	1072	human herpesvirus 6	[Human herpesvirus 6]	4.754887502163469	3	6	3	1
3063	1072	interaction with cell	[interaction with cells]	4.754887502163469	3	4	4	4
3064	1072	role of transcription factor	[role of transcription factors]	4.754887502163469	4	4	2	2
3065	1072	b lymphoid cell	[B lymphoid cells]	4.754887502163469	3	3	0	0
3066	1072	combination of phorbol ester	[combination of phorbol ester]	4.754887502163469	4	3	0	0
3067	1072	secretion of cytokine	[secretion of cytokines]	4.754887502163469	3	4	3	3
3068	1072	patient with ulcerative colitis	[patients with ulcerative colitis]	4.754887502163469	4	4	2	2
3069	1072	activity of ap-1	[activity of AP-1]	4.754887502163469	3	4	3	3
3070	1072	most potent agent	[most potent agents]	4.754887502163469	3	4	3	3
3071	1072	IL-2 cell line	[IL-2 cell lines]	4.754887502163469	3	4	4	4
3072	1072	induction of tyrosine phosphorylation	[induction of tyrosine phosphorylation]	4.754887502163469	4	4	2	2
3073	1072	antibody to CD3	[antibody to CD3]	4.754887502163469	3	4	1	1
3074	1072	NF kappa b site	[NF kappa B site]	4.754887502163469	4	4	1	1
3075	1072	THP-1 monocytic cell line	[THP-1 monocytic cell line]	4.754887502163469	4	4	1	1
3076	1072	ligand-induced tyrosine phosphorylation	[ligand-induced tyrosine phosphorylation]	4.754887502163469	3	5	4	2
3077	1072	cd4(-)cd8(-) T cell	[CD4(-)CD8(-) T cells]	4.754887502163469	3	4	1	1
3078	1072	inhibition of lymphocyte proliferation	[inhibition of lymphocyte proliferation]	4.754887502163469	4	4	3	3
3079	1072	induction of cell death	[induction of cell death]	4.754887502163469	4	4	1	1
3080	1072	T cell lineage	[T cell lineage]	4.754887502163469	3	3	0	0
3081	1072	expression of bcl-6 protein	[expression of bcl-6 protein]	4.754887502163469	4	4	2	2
3082	1072	expression of adhesion molecule-1	[expression of adhesion molecule-1]	4.754887502163469	4	4	4	4
3083	1072	kb of DNA	[kb of DNA]	4.754887502163469	3	4	4	4
3084	1072	negative regulatory sequence	[negative regulatory sequence]	4.754887502163469	3	3	0	0
3085	1072	beta interferon promoter	[beta interferon promoter]	4.754887502163469	3	4	2	2
3086	1072	erythroid-specific gene expression	[erythroid-specific gene expression]	4.754887502163469	3	3	0	0
3087	1072	specific gene expression	[specific gene expression]	4.754887502163469	3	4	4	4
3088	1072	nucleus of T cell	[nucleus of T cells]	4.754887502163469	4	3	0	0
3089	1072	calcineurin active site	[calcineurin active site]	4.754887502163469	3	4	1	1
3090	1072	nuclear localization signal	[nuclear localization signal]	4.754887502163469	3	4	2	2
3091	1072	cyclic AMP response	[cyclic AMP response]	4.754887502163469	3	4	4	4
3092	1072	effect of treatment	[effect of treatment]	4.754887502163469	3	4	2	2
3093	1072	Burkitt' lymphoma cell line	[Burkitt's lymphoma cell lines]	4.754887502163469	4	4	1	1
3094	1072	interleukin 2 promoter	[interleukin 2 promoter]	4.754887502163469	3	3	0	0
3095	1072	patient with RCC	[patients with RCCs]	4.754887502163469	3	4	2	2
3096	1072	human breast cancer	[human breast cancer]	4.754887502163469	3	4	2	2
3097	1072	T cell in vitro	[T cells in vitro]	4.754887502163469	4	4	3	3
3098	1072	TR2 orphan receptor	[TR2 orphan receptor]	4.754887502163469	3	3	0	0
3099	1072	control cell line	[control cell line]	4.754887502163469	3	4	1	1
3100	1072	nuclear nf kappa b	[nuclear NF kappa B]	4.754887502163469	4	4	2	2
3101	1072	transactivator protein tax	[transactivator protein Tax]	4.754887502163469	3	4	2	2
3102	1072	effect on lymphocyte	[effects on lymphocytes]	4.754887502163469	3	4	4	4
3103	1072	transient transfection study	[Transient transfection studies]	4.754887502163469	3	4	2	2
3104	1072	NK cell membrane extract	[NK cell membrane extracts]	4.754887502163469	4	3	0	0
3105	1072	T cell receptor signal	[T cell receptor signaling]	4.754887502163469	4	4	1	1
3106	1072	J Biol Chem	[J Biol Chem]	4.754887502163469	3	4	1	1
3107	1072	nadph oxidase activity	[NADPH oxidase activity]	4.754887502163469	3	3	0	0
3108	1072	ap-1 DNA binding	[AP-1 DNA binding]	4.754887502163469	3	3	0	0
3109	1072	differentiation of erythroid cell	[differentiation of erythroid cells]	4.754887502163469	4	4	3	3
3110	1072	healthy blood donor	[healthy blood donors]	4.754887502163469	3	3	0	0
3111	1073	cell fate	[cell fate]	4.75	2	6	5	4
3112	1073	tsp 1	[TSP 1]	4.75	2	6	5	4
3113	1073	vitro binding	[vitro binding]	4.75	2	6	5	4
3114	1073	initial stage	[initial stage]	4.75	2	6	5	4
3115	1073	nuclear component	[nuclear component]	4.75	2	6	5	4
3116	1073	major component	[major component]	4.75	2	6	5	4
3117	1073	interleukin il-2	[interleukin IL-2]	4.75	2	6	5	4
3118	1073	specific expression	[specific expression]	4.75	2	6	5	4
3119	1073	functional importance	[functional importance]	4.75	2	6	5	4
3120	1073	acute leukaemia	[acute leukaemia]	4.75	2	6	5	4
3121	1073	constitutive level	[constitutive level]	4.75	2	6	5	4
3122	1073	deletion construct	[deletion construct]	4.75	2	6	5	4
3123	1073	trans-activation domain	[trans-activation domain]	4.75	2	6	5	4
3124	1073	DR alpha	[DR alpha]	4.75	2	6	5	4
3125	1073	ca2+ mobilization	[Ca2+ mobilization]	4.75	2	6	5	4
3126	1073	basal activity	[basal activity]	4.75	2	6	5	4
3127	1074	IFN-gamma	[IFN-gamma]	4.7299999999999995	1	49	17	10
3128	1075	corticosteroid	[corticosteroid]	4.6947368421052635	1	48	20	19
3129	1076	and/or	[and/or]	4.693548387096775	1	48	33	31
3130	1077	tumour	[tumour]	4.688235294117647	1	48	19	17
3131	1078	fk506	[FK506]	4.6875	1	48	9	8
3132	1078	cis-acting	[cis-acting]	4.6875	1	48	18	16
3133	1079	kb	[kb]	4.6850000000000005	1	48	46	40
3134	1080	secretion	[secretion]	4.672727272727273	1	50	36	11
3135	1081	ultra-violet cross-linking	[UV cross-linking]	4.666666666666667	2	6	4	3
3136	1081	human platelet	[human platelets]	4.666666666666667	2	6	4	3
3137	1081	bronchial cell	[bronchial cells]	4.666666666666667	2	6	4	3
3138	1081	beta-globin gene	[beta-globin gene]	4.666666666666667	2	6	4	3
3139	1081	calcium signal	[calcium signaling]	4.666666666666667	2	6	4	3
3140	1081	important cytokine	[important cytokine]	4.666666666666667	2	6	4	3
3141	1081	tumor progression	[tumor progression]	4.666666666666667	2	6	4	3
3142	1081	different role	[different role]	4.666666666666667	2	6	4	3
3143	1081	Nuclear extract	[Nuclear extracts]	4.666666666666667	2	6	4	3
3144	1081	JNK	[JNK]	4.666666666666667	1	48	20	15
3145	1081	adult cell	[adult cells]	4.666666666666667	2	6	4	3
3146	1081	dna-binding specificity	[DNA-binding specificity]	4.666666666666667	2	6	4	3
3147	1081	hiv cell	[HIV cells]	4.666666666666667	2	6	4	3
3148	1081	12-o-tetradecanoylphorbol-13-acetate tpa	[12-O-tetradecanoylphorbol-13-acetate TPA]	4.666666666666667	2	6	4	3
3149	1081	minimal disease	[minimal disease]	4.666666666666667	2	6	4	3
3150	1081	immune complex	[immune complex]	4.666666666666667	2	6	4	3
3151	1081	direct correlation	[direct correlation]	4.666666666666667	2	6	4	3
3152	1081	IL-2 expression	[IL-2 expression]	4.666666666666667	2	6	4	3
3153	1081	specific granule	[specific granules]	4.666666666666667	2	6	4	3
3154	1081	alpha subunit	[alpha subunit]	4.666666666666667	2	6	4	3
3155	1081	ifn-gamma induction	[IFN-gamma induction]	4.666666666666667	2	6	4	3
3156	1081	junb mrna	[junB mRNA]	4.666666666666667	2	6	4	3
3157	1081	ets family	[Ets family]	4.666666666666667	2	6	4	3
3158	1081	proliferate cell	[proliferating cells]	4.666666666666667	2	6	4	3
3159	1081	cd14	[CD14]	4.666666666666667	1	48	12	9
3160	1081	adenylate cyclase	[adenylate cyclase]	4.666666666666667	2	6	4	3
3161	1081	intracellular level	[intracellular levels]	4.666666666666667	2	6	4	3
3162	1081	blast cell	[blast cells]	4.666666666666667	2	6	4	3
3163	1081	IL-2 production	[IL-2 production]	4.666666666666667	2	6	4	3
3164	1081	eosinophil apoptosis	[eosinophil apoptosis]	4.666666666666667	2	6	4	3
3165	1081	eosinophil lineage	[eosinophil lineage]	4.666666666666667	2	6	4	3
3166	1081	opposite effect	[opposite effects]	4.666666666666667	2	6	4	3
3167	1081	redox regulation	[redox regulation]	4.666666666666667	2	6	4	3
3168	1081	cushingd' disease	[Cushing's disease]	4.666666666666667	2	6	4	3
3169	1081	luciferase gene	[luciferase gene]	4.666666666666667	2	6	4	3
3170	1082	negative form	[negative form]	4.666666666666666	2	7	7	3
3171	1082	yeast screen	[yeast screen]	4.666666666666666	2	7	7	3
3172	1082	nf-kappab DNA	[NF-kappaB DNA]	4.666666666666666	2	7	7	3
3173	1082	several line	[several lines]	4.666666666666666	2	7	7	3
3174	1082	acid atra	[acid ATRA]	4.666666666666666	2	7	7	3
3175	1082	risk woman	[risk women]	4.666666666666666	2	7	7	3
3176	1082	er content	[ER content]	4.666666666666666	2	7	7	3
3177	1083	granulocyte	[granulocyte]	4.658333333333334	1	48	17	12
3178	1084	maturation	[maturation]	4.657894736842105	1	48	27	19
3179	1085	state	[state]	4.651851851851852	1	48	40	27
3180	1086	implication	[implication]	4.644444444444445	1	49	46	18
3181	1087	line	[line]	4.613636363636363	1	48	41	22
3182	1088	cancer	[cancer]	4.58421052631579	1	47	22	19
3183	1089	switch	[switch]	4.583333333333334	1	47	35	30
3184	1090	interferon-gamma	[interferon-gamma]	4.521428571428571	1	47	25	14
3185	1091	peripheral blood mononuclear cell PBMC	[peripheral blood mononuclear cells PBMC]	4.5	5	6	3	2
3186	1091	leukemia APL	[leukemia APL]	4.5	2	9	9	2
3187	1091	igh 3'	[IgH 3']	4.5	2	6	6	4
3188	1091	viral repeat	[viral repeat]	4.5	2	7	5	2
3189	1091	phospholipase a2	[phospholipase A2]	4.5	2	6	6	4
3190	1091	APL cell	[APL cells]	4.5	2	6	3	2
3191	1091	octamer transcription	[octamer transcription]	4.5	2	6	6	4
3192	1091	cytokine profile	[cytokine profile]	4.5	2	6	3	2
3193	1091	animal model	[animal models]	4.5	2	6	6	4
3194	1091	HS2 enhancer	[HS2 enhancer]	4.5	2	6	3	2
3195	1091	breast carcinoma	[breast carcinoma]	4.5	2	6	6	4
3196	1091	normal level	[normal level]	4.5	2	6	6	4
3197	1091	eosinophilic inflammation	[eosinophilic inflammation]	4.5	2	6	3	2
3198	1091	DNA methylation	[DNA methylation]	4.5	2	6	3	2
3199	1091	SCL protein	[SCL protein]	4.5	2	6	3	2
3200	1091	C-terminal region	[C-terminal region]	4.5	2	6	3	2
3201	1091	t-cell-specific factor	[T-cell-specific factor]	4.5	2	6	3	2
3202	1091	il-4 signal	[IL-4 signaling]	4.5	2	6	6	4
3203	1091	C/EBP beta	[C/EBP beta]	4.5	2	6	3	2
3204	1091	b transcription	[B transcription]	4.5	2	6	6	4
3205	1091	undergo apoptosis	[undergoing apoptosis]	4.5	2	6	6	4
3206	1091	transplant recipient	[transplant recipients]	4.5	2	6	6	4
3207	1091	c-myb expression	[c-myb expression]	4.5	2	6	3	2
3208	1091	stat transcription	[STAT transcription]	4.5	2	6	6	4
3209	1091	tumour necrosis	[tumour necrosis]	4.5	2	9	9	2
3210	1091	b translocation	[B translocation]	4.5	2	6	6	4
3211	1091	adult t-cell	[adult T-cell]	4.5	2	9	9	2
3212	1091	molecular target	[molecular target]	4.5	2	6	6	4
3213	1091	c-jun transcript	[c-jun transcripts]	4.5	2	7	5	2
3214	1091	PMA activation	[PMA activation]	4.5	2	6	3	2
3215	1091	gm-csf gene	[GM-CSF gene]	4.5	2	7	5	2
3216	1091	b-cll cell	[B-CLL cells]	4.5	2	6	3	2
3217	1092	potential	[potential]	4.483870967741935	1	46	36	31
3218	1093	hypothesis	[hypothesis]	4.483333333333333	1	46	14	12
3219	1094	retinoid	[retinoid]	4.45625	1	46	23	16
3220	1095	BSAP	[BSAP]	4.455555555555556	1	46	13	9
3221	1096	Stat3	[Stat3]	4.454545454545455	1	46	16	11
3222	1097	atra	[ATRA]	4.45	1	46	9	6
3223	1098	cytosol	[cytosol]	4.444444444444445	1	47	23	9
3224	1099	cd8+	[CD8+]	4.44	1	46	24	15
3225	1100	abnormality	[abnormality]	4.434782608695652	1	46	38	23
3226	1101	terminal	[terminal]	4.415	1	46	37	20
3227	1102	requirement	[requirement]	4.39	1	46	42	20
3228	1103	C	[C]	4.38	1	45	18	15
3229	1104	delta	[delta]	4.368181818181818	1	45	29	22
3230	1105	135eoh)2d3	[1,25(OH)2D3]	4.366666666666666	1	45	24	18
3231	1106	sodium	[sodium]	4.341176470588236	1	45	27	17
3232	1107	range	[range]	4.340740740740741	1	45	43	27
3233	1108	c-jun gene	[c-jun gene]	4.333333333333333	2	6	5	3
3234	1108	renal failure	[renal failure]	4.333333333333333	2	6	5	3
3235	1108	c-jun transcription	[c-jun transcription]	4.333333333333333	2	6	5	3
3236	1108	primary culture	[primary culture]	4.333333333333333	2	6	5	3
3237	1108	significant change	[significant change]	4.333333333333333	2	6	5	3
3238	1108	gata-1 gene	[GATA-1 gene]	4.333333333333333	2	6	5	3
3239	1108	tax -express	[Tax -expressing]	4.333333333333333	2	6	5	3
3240	1108	interleukin 1beta	[interleukin 1beta]	4.333333333333333	2	6	5	3
3241	1108	vivo footprint	[vivo footprint]	4.333333333333333	2	6	5	3
3242	1108	rapid increase	[rapid increase]	4.333333333333333	2	6	5	3
3243	1108	NF-kappaB transcription	[NF-kappaB transcription]	4.333333333333333	2	6	5	3
3244	1108	cd34+ cell	[CD34+ cells]	4.333333333333333	2	6	5	3
3245	1109	interleukin-1	[interleukin-1]	4.33125	1	45	27	16
3246	1110	product	[product]	4.325	1	45	35	20
3247	1111	ras	[Ras]	4.2894736842105265	1	44	21	19
3248	1112	nf	[NF]	4.2846153846153845	1	45	28	13
3249	1113	locus	[locus]	4.275	1	44	20	16
3250	1114	CRE	[CRE]	4.246153846153846	1	44	20	13
3251	1115	carcinoma cell line	[carcinoma cell line]	4.226566668589751	3	4	4	3
3252	1115	NF-kappaB signal pathway	[NF-kappaB signaling pathway]	4.226566668589751	3	4	4	3
3253	1115	nuclear factor bind	[nuclear factor binding]	4.226566668589751	3	4	4	3
3254	1115	granulocyte-macrophage factor gm-csf	[granulocyte-macrophage factor GM-CSF]	4.226566668589751	3	4	4	3
3255	1115	leukemia u937 cell	[leukemia U937 cells]	4.226566668589751	3	4	4	3
3256	1115	protein binding site	[protein binding sites]	4.226566668589751	3	4	4	3
3257	1115	human homeobox gene	[human homeobox gene]	4.226566668589751	3	4	4	3
3258	1115	change in receptor	[changes in receptors]	4.226566668589751	3	4	4	3
3259	1115	human u937 cell	[human U937 cells]	4.226566668589751	3	4	4	3
3260	1115	response element ISRE	[response element ISRE]	4.226566668589751	3	4	4	3
3261	1115	translocation of NF-kappa b	[translocation of NF-kappa B]	4.226566668589751	4	4	4	3
3262	1115	hiv long repeat	[HIV long repeat]	4.226566668589751	3	4	4	3
3263	1115	incubation of cell	[Incubation of cells]	4.226566668589751	3	4	4	3
3264	1115	killer cell activity	[killer cell activity]	4.226566668589751	3	4	4	3
3265	1115	ca(2+) -dependent pathway	[Ca(2+) -dependent pathways]	4.226566668589751	3	4	4	3
3266	1115	activation in response	[activation in response]	4.226566668589751	3	4	4	3
3267	1115	patient with nephropathy	[patients with nephropathy]	4.226566668589751	3	4	4	3
3268	1115	immunodeficiency virus hiv-1	[immunodeficiency virus HIV-1]	4.226566668589751	3	4	4	3
3269	1115	ring x chromosome	[ring X chromosome]	4.226566668589751	3	4	4	3
3270	1115	factor nf-kappa b	[factor NF-kappa B]	4.226566668589751	3	4	4	3
3271	1115	il-1 receptor antagonist	[IL-1 receptor antagonist]	4.226566668589751	3	4	4	3
3272	1115	human leukemia hl-60 cell	[human leukemia HL-60 cells]	4.226566668589751	4	4	4	3
3273	1115	receptor in peripheral leukocyte	[receptor in peripheral leukocytes]	4.226566668589751	4	4	4	3
3274	1115	peripheral mononuclear cell	[peripheral mononuclear cells]	4.226566668589751	3	4	4	3
3275	1115	leukocyte of patient	[leukocytes of patients]	4.226566668589751	3	4	4	3
3276	1115	patient with arthritis	[patient with arthritis]	4.226566668589751	3	4	4	3
3277	1115	response to retinoic acid	[response to retinoic acid]	4.226566668589751	4	4	4	3
3278	1115	translocation of p65	[translocation of p65]	4.226566668589751	3	4	4	3
3279	1115	binding of protein	[binding of proteins]	4.226566668589751	3	4	4	3
3280	1115	Effect of glucocorticoid	[Effects of glucocorticoids]	4.226566668589751	3	4	4	3
3281	1115	early growth response	[early growth response]	4.226566668589751	3	4	4	3
3282	1115	response to acid	[response to acid]	4.226566668589751	3	4	4	3
3283	1115	transcriptase polymerase chain reaction	[transcriptase polymerase chain reaction]	4.226566668589751	4	4	4	3
3284	1115	T cell phenotype	[T cell phenotype]	4.226566668589751	3	4	4	3
3285	1115	T cell from subject	[T cells from subjects]	4.226566668589751	4	4	4	3
3286	1115	glucocorticoid receptor level	[glucocorticoid receptor levels]	4.226566668589751	3	4	4	3
3287	1115	cell of the system	[cells of the system]	4.226566668589751	4	4	4	3
3288	1115	direct the expression	[directing the expression]	4.226566668589751	3	4	4	3
3289	1115	endothelial cell adhesion molecule	[endothelial cell adhesion molecules]	4.226566668589751	4	4	4	3
3290	1115	nf-kappab binding sequence	[NF-kappaB binding sequence]	4.226566668589751	3	4	4	3
3291	1115	primary blood mononuclear cell	[primary blood mononuclear cells]	4.226566668589751	4	4	4	3
3292	1115	form of calcineurin	[form of calcineurin]	4.226566668589751	3	4	4	3
3293	1115	component of NF-AT	[component of NF-AT]	4.226566668589751	3	4	4	3
3294	1115	hiv-1 infection of cell	[HIV-1 infection of cells]	4.226566668589751	4	4	4	3
3295	1115	monoamine oxidase b	[monoamine oxidase B]	4.226566668589751	3	4	4	3
3296	1115	presence of element	[presence of elements]	4.226566668589751	3	4	4	3
3297	1115	regulation during differentiation	[regulation during differentiation]	4.226566668589751	3	4	4	3
3298	1116	understanding	[understanding]	4.2	1	45	36	12
3299	1117	tat	[Tat]	4.188235294117647	1	43	19	17
3300	1118	gata	[GATA]	4.184615384615385	1	43	15	13
3301	1119	chemokine	[chemokine]	4.177777777777778	1	43	11	9
3302	1120	TNFalpha	[TNFalpha]	4.175	1	43	10	8
3303	1121	isoform	[isoform]	4.173913043478261	1	43	29	23
3304	1122	heterodimer	[heterodimer]	4.166666666666667	1	43	20	15
3305	1123	responsiveness	[responsiveness]	4.133333333333334	1	43	40	24
3306	1124	series	[series]	4.107142857142857	1	44	41	14
3307	1125	set	[set]	4.1000000000000005	1	43	36	18
3308	1125	base	[base]	4.1000000000000005	1	42	21	21
3309	1126	STAT3	[STAT3]	4.085714285714285	1	42	16	14
3310	1127	flow	[flow]	4.072727272727273	1	43	25	11
3311	1128	lymphoid	[lymphoid]	4.072222222222222	1	42	23	18
3312	1129	point	[point]	4.05625	1	42	23	16
3313	1130	recognition	[recognition]	4.052941176470589	1	42	25	17
3314	1131	c-Rel	[c-Rel]	4.05	1	42	9	6
3315	1132	IkappaBalpha	[IkappaBalpha]	4.0375000000000005	1	42	13	8
3316	1133	u-937	[U-937]	4.033333333333334	1	42	20	12
3317	1134	survival	[survival]	4.025	1	42	28	16
3318	1135	consequence	[consequence]	4.0200000000000005	1	42	36	20
3319	1136	rapid induction	[rapid induction]	4.0	2	6	4	2
3320	1136	fas ligation	[Fas ligation]	4.0	2	4	0	0
3321	1136	mouse gene	[mouse gene]	4.0	2	5	5	5
3322	1136	beneficial effect	[beneficial effect]	4.0	2	6	4	2
3323	1136	delta promoter	[delta promoter]	4.0	2	4	0	0
3324	1136	ciita construct	[CIITA construct]	4.0	2	6	4	2
3325	1136	aged subject	[aged subjects]	4.0	2	5	2	2
3326	1136	B29 gene	[B29 gene]	4.0	2	5	4	4
3327	1136	peripheral monocyte	[peripheral monocytes]	4.0	2	7	6	2
3328	1136	anti CD2	[anti CD2]	4.0	2	5	1	1
3329	1136	cDNA encoding	[cDNA encoding]	4.0	2	5	5	5
3330	1136	body mass	[body mass]	4.0	2	5	5	5
3331	1136	Ro 09-2210	[Ro 09-2210]	4.0	2	4	0	0
3332	1136	glucocorticoid hormone	[glucocorticoid hormone]	4.0	2	5	2	2
3333	1136	basal expression	[basal expression]	4.0	2	5	2	2
3334	1136	ICAM-1 promoter	[ICAM-1 promoter]	4.0	2	5	3	3
3335	1136	electrophoretic mobility shift assay emsa	[electrophoretic mobility shift assays EMSAs]	4.0	5	4	0	0
3336	1136	antigen recognition	[antigen recognition]	4.0	2	5	3	3
3337	1136	fas-mediated apoptosis	[Fas-mediated apoptosis]	4.0	2	5	2	2
3338	1136	differential regulation	[differential regulation]	4.0	2	5	2	2
3339	1136	interferon-gamma IFN-gamma	[interferon-gamma IFN-gamma]	4.0	2	4	0	0
3340	1136	structural motif	[structural motifs]	4.0	2	5	2	2
3341	1136	immunoblot analysis	[Immunoblot analysis]	4.0	2	5	1	1
3342	1136	b protein	[B protein]	4.0	2	5	4	4
3343	1136	Okadaic acid	[Okadaic acid]	4.0	2	5	1	1
3344	1136	genetic target	[genetic target]	4.0	2	6	4	2
3345	1136	aids patient	[AIDS patients]	4.0	2	5	3	3
3346	1136	present work	[present work]	4.0	2	4	0	0
3347	1136	serum cortisol	[Serum cortisol]	4.0	2	5	2	2
3348	1136	common element	[common element]	4.0	2	5	4	4
3349	1136	isotype switch	[isotype switching]	4.0	2	5	2	2
3350	1136	numerous gene	[numerous genes]	4.0	2	5	3	3
3351	1136	5'-untranslated region	[5'-untranslated region]	4.0	2	5	1	1
3352	1136	gata-binding site	[GATA-binding site]	4.0	2	5	4	4
3353	1136	first intron	[first intron]	4.0	2	5	2	2
3354	1136	eight patient	[eight patients]	4.0	2	5	4	4
3355	1136	other drug	[other drugs]	4.0	2	5	3	3
3356	1136	E2F site	[E2F sites]	4.0	2	5	4	4
3357	1136	IL-3 promoter	[IL-3 promoter]	4.0	2	5	3	3
3358	1136	105 kda	[105 kDa]	4.0	2	4	0	0
3359	1136	3' end	[3' end]	4.0	2	5	1	1
3360	1136	c/ebp epsilon	[C/EBP epsilon]	4.0	2	5	4	4
3361	1136	indirect immunofluorescence	[indirect immunofluorescence]	4.0	2	4	0	0
3362	1136	exogenous il-2	[exogenous IL-2]	4.0	2	5	1	1
3363	1136	t-cell leukemia virus type I	[T-cell leukemia virus type I]	4.0	5	7	6	2
3364	1136	gsh level	[GSH levels]	4.0	2	5	1	1
3365	1136	1 minute	[1 min]	4.0	2	5	4	4
3366	1136	subset	[subset]	4.0	1	43	33	11
3367	1136	chemotactic factor	[chemotactic factor]	4.0	2	5	2	2
3368	1136	five patient	[five patients]	4.0	2	5	3	3
3369	1136	rapid phosphorylation	[rapid phosphorylation]	4.0	2	5	3	3
3370	1136	c-fo protein	[c-Fos protein]	4.0	2	5	3	3
3371	1136	exact mechanism	[exact mechanism]	4.0	2	5	2	2
3372	1136	inducible phosphorylation	[inducible phosphorylation]	4.0	2	5	4	4
3373	1136	useful model	[useful model]	4.0	2	5	2	2
3374	1136	skeletal muscle	[skeletal muscle]	4.0	2	5	3	3
3375	1136	precise mechanism	[precise mechanism]	4.0	2	5	2	2
3376	1136	great ape	[great apes]	4.0	2	5	3	3
3377	1136	cerebral cortex	[cerebral cortex]	4.0	2	4	0	0
3378	1136	IL-2 growth	[IL-2 growth]	4.0	2	5	4	4
3379	1136	B-CLL cell	[B-CLL cells]	4.0	2	4	0	0
3380	1136	patient suffer	[patients suffering]	4.0	2	5	5	5
3381	1136	cell type-	[cell type-]	4.0	2	4	0	0
3382	1136	cell type.	[cell type.]	4.0	2	5	2	2
3383	1136	virus carrier	[virus carriers]	4.0	2	5	4	4
3384	1136	il-5 synthesis	[IL-5 synthesis]	4.0	2	5	3	3
3385	1136	thymic development	[thymic development]	4.0	2	4	0	0
3386	1136	chronic failure	[chronic failure]	4.0	2	5	4	4
3387	1136	follicular lymphoma	[follicular lymphoma]	4.0	2	5	1	1
3388	1136	6 h	[6 h]	4.0	2	5	2	2
3389	1136	atherosclerotic plaque	[atherosclerotic plaque]	4.0	2	5	4	4
3390	1136	untreated patient	[untreated patients]	4.0	2	5	5	5
3391	1136	macrophage activation	[macrophage activation]	4.0	2	6	4	2
3392	1136	supershift experiment	[supershift experiments]	4.0	2	5	1	1
3393	1136	fetal calf	[fetal calf]	4.0	2	4	0	0
3394	1136	t-cell lineage	[T-cell lineage]	4.0	2	5	2	2
3395	1136	signal mechanism	[signaling mechanisms]	4.0	2	5	4	4
3396	1136	hla-dr antigen	[HLA-DR antigens]	4.0	2	8	8	2
3397	1136	monocyte protein-1	[monocyte protein-1]	4.0	2	5	5	5
3398	1136	nfkappab activity	[NFkappaB activity]	4.0	2	5	3	3
3399	1136	synergistic effect	[synergistic effect]	4.0	2	6	6	3
3400	1136	immune responsiveness	[immune responsiveness]	4.0	2	5	4	4
3401	1136	thymocyte development	[thymocyte development]	4.0	2	5	3	3
3402	1136	beta 1	[beta 1]	4.0	2	5	4	4
3403	1136	hematopoietic transcription	[hematopoietic transcription]	4.0	2	4	0	0
3404	1136	cytokine il-2	[cytokine IL-2]	4.0	2	5	2	2
3405	1136	C/EBP alpha	[C/EBP alpha]	4.0	2	5	1	1
3406	1136	epo receptor	[Epo receptor]	4.0	2	5	4	4
3407	1136	anti-cd28 mab	[anti-CD28 mAb]	4.0	2	5	3	3
3408	1136	native peptide	[native peptide]	4.0	2	5	2	2
3409	1136	circulate monocyte	[circulating monocyte]	4.0	2	5	3	3
3410	1136	mapk activation	[MAPK activation]	4.0	2	4	0	0
3411	1136	6 P.	[6 h.]	4.0	2	4	0	0
3412	1136	mouse tissue	[mouse tissues]	4.0	2	5	4	4
3413	1136	cytokine signal	[cytokine signaling]	4.0	2	5	5	5
3414	1136	selective expression	[selective expression]	4.0	2	5	2	2
3415	1136	MHC class ii gene expression	[MHC class II gene expression]	4.0	5	5	1	1
3416	1136	tf activity	[TF activity]	4.0	2	6	4	2
3417	1136	nephrotic syndrome	[nephrotic syndrome]	4.0	2	4	0	0
3418	1136	Fos protein	[Fos proteins]	4.0	2	5	1	1
3419	1136	LMP1 expression	[LMP1 expression]	4.0	2	5	3	3
3420	1136	myeloid lineage	[myeloid lineage]	4.0	2	5	2	2
3421	1136	protease inhibitor	[protease inhibitors]	4.0	2	5	3	3
3422	1136	glucocorticoid-induced apoptosis	[glucocorticoid-induced apoptosis]	4.0	2	5	1	1
3423	1136	express level	[expressing levels]	4.0	2	5	5	5
3424	1136	x receptor	[X receptor]	4.0	2	5	4	4
3425	1136	cell-specific manner	[cell-specific manner]	4.0	2	5	1	1
3426	1136	physical exercise	[physical exercise]	4.0	2	5	3	3
3427	1136	previous datum	[previous data]	4.0	2	5	1	1
3428	1136	CD4 receptor	[CD4 receptor]	4.0	2	5	3	3
3429	1136	12 woman	[12 women]	4.0	2	5	3	3
3430	1136	transcriptional level.	[transcriptional level.]	4.0	2	4	0	0
3431	1136	50 kda	[50 kDa]	4.0	2	5	3	3
3432	1136	nuclear body	[nuclear body]	4.0	2	5	2	2
3433	1136	binding complex	[binding complex]	4.0	2	5	4	4
3434	1136	erythroid pathway	[erythroid pathway]	4.0	2	5	3	3
3435	1136	tal-1 gene	[tal-1 gene]	4.0	2	4	0	0
3436	1136	THP-1 cell	[THP-1 cells]	4.0	2	4	0	0
3437	1136	adherent cell	[adherent cells]	4.0	2	5	2	2
3438	1136	electrophoretic mobility shift assay EMSA	[electrophoretic mobility shift assay EMSA]	4.0	5	5	2	2
3439	1136	Interleukin-4 IL-4	[Interleukin-4 IL-4]	4.0	2	4	0	0
3440	1136	previous report	[previous report]	4.0	2	5	1	1
3441	1136	other study	[other studies]	4.0	2	4	0	0
3442	1136	tumor growth	[tumor growth]	4.0	2	4	0	0
3443	1136	positive autoregulation	[positive autoregulation]	4.0	2	5	3	3
3444	1136	cytokine interleukin	[cytokine interleukin]	4.0	2	5	5	5
3445	1136	non-B cell	[non-B cells]	4.0	2	6	2	1
3446	1136	protein fraction	[protein fraction]	4.0	2	5	5	5
3447	1136	molecular clone	[molecular clone]	4.0	2	5	5	5
3448	1136	FMS patient	[FMS patients]	4.0	2	5	2	2
3449	1136	transient increase	[transient increase]	4.0	2	7	6	2
3450	1136	cell morphology	[Cell morphology]	4.0	2	4	0	0
3451	1136	promonocytic cell	[promonocytic cells]	4.0	2	5	2	2
3452	1136	PI 3-kinase	[PI 3-kinase]	4.0	2	4	0	0
3453	1136	apoptotic process	[apoptotic process]	4.0	2	4	0	0
3454	1136	follow expression	[following expression]	4.0	2	5	5	5
3455	1136	recognition sequence	[recognition sequence]	4.0	2	5	2	2
3456	1136	various time	[various times]	4.0	2	4	0	0
3457	1136	present paper	[present paper]	4.0	2	4	0	0
3458	1136	consensus site	[consensus site]	4.0	2	5	5	5
3459	1136	switch region	[switch region]	4.0	2	5	4	4
3460	1136	stat1 protein	[STAT1 protein]	4.0	2	5	5	5
3461	1136	chromosome band	[chromosome band]	4.0	2	5	5	5
3462	1136	fresh cell	[fresh cells]	4.0	2	5	4	4
3463	1136	nf-kappa b DNA binding activity	[NF-kappa B DNA binding activity]	4.0	5	5	1	1
3464	1136	functional redundancy	[functional redundancy]	4.0	2	5	3	3
3465	1136	p50 protein	[p50 protein]	4.0	2	5	2	2
3466	1136	virus reactivation	[virus reactivation]	4.0	2	5	4	4
3467	1136	useful tool	[useful tool]	4.0	2	5	5	5
3468	1136	related gene	[related gene]	4.0	2	5	3	3
3469	1136	genetic defect	[genetic defect]	4.0	2	5	4	4
3470	1136	interleukin-4 IL-4	[interleukin-4 IL-4]	4.0	2	5	3	3
3471	1136	thromboxane receptor	[thromboxane receptor]	4.0	2	6	6	3
3472	1136	pml-rar alpha	[PML-RAR alpha]	4.0	2	5	4	4
3473	1136	x-chromosome inactivation	[X-chromosome inactivation]	4.0	2	5	5	5
3474	1136	cd23 expression	[CD23 expression]	4.0	2	5	1	1
3475	1136	erythroid gene	[erythroid genes]	4.0	2	5	3	3
3476	1136	carboxyl terminus	[carboxyl terminus]	4.0	2	5	2	2
3477	1136	blood sample	[blood samples]	4.0	2	5	3	3
3478	1136	activation of nuclear factor-kappa b	[activation of nuclear factor-kappa B]	4.0	5	5	3	3
3479	1136	Northern blotting	[Northern blotting]	4.0	2	5	1	1
3480	1136	diabetic nephropathy	[diabetic nephropathy]	4.0	2	5	1	1
3481	1136	novel gene	[novel gene]	4.0	2	5	2	2
3482	1136	7 patient	[7 patients]	4.0	2	4	0	0
3483	1136	distinct element	[distinct elements]	4.0	2	5	5	5
3484	1136	DNA motif	[DNA motifs]	4.0	2	5	4	4
3485	1136	glutathione gsh	[glutathione GSH]	4.0	2	5	4	4
3486	1136	ectopic pregnancy	[ectopic pregnancy]	4.0	2	4	0	0
3487	1136	affinity of the glucocorticoid receptor	[affinity of the glucocorticoid receptor]	4.0	5	5	2	2
3488	1136	irf-1 gene	[IRF-1 gene]	4.0	2	5	1	1
3489	1136	cushingd' syndrome	[Cushing's syndrome]	4.0	2	5	4	4
3490	1136	cell signal	[cell signaling]	4.0	2	5	5	5
3491	1136	specific manner	[specific manner]	4.0	2	5	5	5
3492	1136	late phase	[late phase]	4.0	2	5	2	2
3493	1136	same time	[same time]	4.0	2	6	2	1
3494	1136	th2 clone	[Th2 clones]	4.0	2	5	2	2
3495	1136	AP-1 complex	[AP-1 complex]	4.0	2	5	1	1
3496	1136	immunosuppressive activity	[immunosuppressive activity]	4.0	2	5	4	4
3497	1136	human peripheral blood T lymphocyte	[human peripheral blood T lymphocytes]	4.0	5	5	1	1
3498	1136	sem, n	[SEM, n]	4.0	2	4	0	0
3499	1136	LTR transcription	[LTR transcription]	4.0	2	5	2	2
3500	1136	cell-specific transcription	[cell-specific transcription]	4.0	2	6	2	1
3501	1136	different stimulus	[different stimuli]	4.0	2	5	5	5
3502	1136	oxidative signal	[oxidative signals]	4.0	2	5	1	1
3503	1136	lymphocyte development	[lymphocyte development]	4.0	2	5	2	2
3504	1136	transduce signal	[transducing signals]	4.0	2	5	4	4
3505	1136	alpha b	[alpha B]	4.0	2	5	2	2
3506	1136	sequence upstream	[sequence upstream]	4.0	2	5	4	4
3507	1136	two signal	[two signals]	4.0	2	5	3	3
3508	1136	host transcription	[host transcription]	4.0	2	5	2	2
3509	1136	dimethyl sulfoxide	[dimethyl sulfoxide]	4.0	2	5	3	3
3510	1136	cos cell	[COS cells]	4.0	2	5	3	3
3511	1136	ebv DNA	[EBV DNA]	4.0	2	6	4	2
3512	1136	signal requirement	[signal requirement]	4.0	2	5	4	4
3513	1136	type interferon	[type interferon]	4.0	2	5	5	5
3514	1136	octamer element	[octamer element]	4.0	2	5	4	4
3515	1136	apparent dissociation constant of glucocorticoid receptor	[apparent dissociation constant of glucocorticoid receptor]	4.0	6	4	0	0
3516	1136	transcriptional effect	[transcriptional effect]	4.0	2	5	3	3
3517	1136	stress response	[stress response]	4.0	2	5	5	5
3518	1136	I htlv-i	[I HTLV-I]	4.0	2	5	2	2
3519	1136	three groups.	[three groups.]	4.0	2	5	1	1
3520	1136	new approach	[new approach]	4.0	2	5	4	4
3521	1136	YJ cell	[YJ cells]	4.0	2	5	2	2
3522	1136	cognate ligand	[cognate ligand]	4.0	2	5	1	1
3523	1136	depressive disorder	[depressive disorder]	4.0	2	8	8	2
3524	1136	10(-7) m	[10(-7) M]	4.0	2	5	2	2
3525	1136	cortisol excretion	[cortisol excretion]	4.0	2	5	5	5
3526	1136	monocytic phenotype	[monocytic phenotype]	4.0	2	5	3	3
3527	1136	2 hour	[2 hr,]	4.0	2	5	1	1
3528	1136	uninfected cell	[uninfected cells]	4.0	2	5	1	1
3529	1136	transient assay	[transient assay]	4.0	2	5	2	2
3530	1136	Jurkat t-cell	[Jurkat T-cells]	4.0	2	5	1	1
3531	1136	transduction pathway	[transduction pathway]	4.0	2	5	4	4
3532	1136	immunosorbent assay	[immunosorbent assay]	4.0	2	6	6	3
3533	1136	composite element	[composite element]	4.0	2	5	3	3
3534	1136	NF-kappaB subunit	[NF-kappaB subunit]	4.0	2	6	6	3
3535	1136	gold compound	[gold compound]	4.0	2	5	4	4
3536	1136	signal from the antigen receptor	[signal from the antigen receptor]	4.0	5	4	0	0
3537	1136	CaM kinase	[CaM kinase]	4.0	2	5	5	5
3538	1136	IL-4 signal	[IL-4 signaling]	4.0	2	4	0	0
3539	1136	antiproliferative effect	[antiproliferative effect]	4.0	2	6	4	2
3540	1136	adrenal cortex	[adrenal cortex]	4.0	2	5	2	2
3541	1136	posttranslational modification	[posttranslational modification]	4.0	2	5	3	3
3542	1136	target tissue	[target tissues]	4.0	2	5	5	5
3543	1136	human il-4	[human IL-4]	4.0	2	4	0	0
3544	1136	gamma-globin promoter	[gamma-globin promoter]	4.0	2	5	4	4
3545	1136	nuclear envelope	[nuclear envelope]	4.0	2	4	0	0
3546	1136	eutopic endometrium	[eutopic endometrium]	4.0	2	5	2	2
3547	1136	activation of the transcription factor nf-kappab	[activation of the transcription factor NF-kappaB]	4.0	6	5	5	5
3548	1136	phorbol myristate	[phorbol myristate]	4.0	2	7	6	2
3549	1136	Interleukin-10 IL-10	[Interleukin-10 IL-10]	4.0	2	5	1	1
3550	1136	antibody mab	[antibody mAb]	4.0	2	6	6	3
3551	1136	c-fo promoter	[c-fos promoter]	4.0	2	5	3	3
3552	1136	p50/p65 heterodimer	[p50/p65 heterodimer]	4.0	2	5	3	3
3553	1136	t-cell activator	[T-cell activators]	4.0	2	5	3	3
3554	1136	previous studies,	[previous studies,]	4.0	2	4	0	0
3555	1136	experimental system	[experimental system]	4.0	2	5	3	3
3556	1136	mRNA level	[mRNA level]	4.0	2	5	1	1
3557	1136	nuclear fraction	[nuclear fraction]	4.0	2	5	2	2
3558	1136	c-myc allele	[c-myc allele]	4.0	2	5	4	4
3559	1136	signal protein	[signal proteins]	4.0	2	5	5	5
3560	1136	peritoneal macrophage	[peritoneal macrophages]	4.0	2	5	4	4
3561	1136	igm production	[IgM production]	4.0	2	5	1	1
3562	1136	glucocorticoid treatment	[glucocorticoid treatment]	4.0	2	5	4	4
3563	1136	anti- CD28	[anti- CD28]	4.0	2	5	3	3
3564	1136	human erythrocyte	[human erythrocyte]	4.0	2	5	2	2
3565	1136	lymphoid factor	[lymphoid factor]	4.0	2	5	5	5
3566	1136	mrna accumulation	[mRNA accumulation]	4.0	2	5	2	2
3567	1136	activation-induced apoptosis	[activation-induced apoptosis]	4.0	2	6	2	1
3568	1136	Gram-negative bacterium	[Gram-negative bacteria]	4.0	2	4	0	0
3569	1136	reverse transcription	[reverse transcription]	4.0	2	5	3	3
3570	1136	level expression	[level expression]	4.0	2	5	5	5
3571	1136	differanisole a	[differanisole A]	4.0	2	5	5	5
3572	1136	dose-dependent fashion	[dose-dependent fashion]	4.0	2	4	0	0
3573	1136	clinical relevance	[clinical relevance]	4.0	2	5	4	4
3574	1136	human homologue	[human homologue]	4.0	2	5	3	3
3575	1136	IL-2 secretion	[IL-2 secretion]	4.0	2	5	1	1
3576	1136	day 7	[day 7]	4.0	2	5	3	3
3577	1136	50% inhibition	[50% inhibition]	4.0	2	5	4	4
3578	1136	tnf gene	[TNF gene]	4.0	2	6	6	3
3579	1136	atopic dermatitis	[atopic dermatitis]	4.0	2	5	1	1
3580	1136	adult mouse	[adult mouse]	4.0	2	5	3	3
3581	1136	PMA stimulation	[PMA stimulation]	4.0	2	5	1	1
3582	1136	host cell	[host cell]	4.0	2	5	5	5
3583	1136	human ciita	[human CIITA]	4.0	2	5	2	2
3584	1136	7 day	[7 days)]	4.0	2	4	0	0
3585	1136	DNA repair	[DNA repair]	4.0	2	5	3	3
3586	1136	beta-casein promoter	[beta-casein promoter]	4.0	2	5	1	1
3587	1136	regulatory effect	[regulatory effect]	4.0	2	5	5	5
3588	1136	HL60 cell	[HL60 cells]	4.0	2	4	0	0
3589	1136	xenogeneic serum	[xenogeneic serum]	4.0	2	5	2	2
3590	1136	alkaline phosphatase	[alkaline phosphatase]	4.0	2	5	3	3
3591	1136	previous study,	[previous study,]	4.0	2	4	0	0
3592	1136	cis-acting sequence	[cis-acting sequence]	4.0	2	5	2	2
3593	1136	nf-at activation	[NF-AT activation]	4.0	2	5	3	3
3594	1136	maximal induction	[maximal induction]	4.0	2	5	5	5
3595	1136	inflammatory cascade	[inflammatory cascade]	4.0	2	4	0	0
3596	1136	monocyte binding	[monocyte binding]	4.0	2	5	4	4
3597	1136	cell clone	[cell clone]	4.0	2	5	4	4
3598	1136	eth1 cell	[eTh1 cells]	4.0	2	5	1	1
3599	1136	ultra-violet light	[UV light]	4.0	2	5	2	2
3600	1136	pu box	[Pu box]	4.0	2	5	3	3
3601	1136	TNF-alpha promoter	[TNF-alpha promoter]	4.0	2	5	4	4
3602	1136	therapeutic approach	[therapeutic approach]	4.0	2	5	3	3
3603	1136	nuclear expression of NF-kappa b	[nuclear expression of NF-kappa B]	4.0	5	5	2	2
3604	1136	developmental stage	[developmental stage]	4.0	2	5	4	4
3605	1136	mrna synthesis	[mRNA synthesis]	4.0	2	5	3	3
3606	1136	systemic effect	[systemic effects]	4.0	2	5	5	5
3607	1136	nuclear level	[nuclear level]	4.0	2	5	3	3
3608	1136	nasopharyngeal carcinoma	[nasopharyngeal carcinoma]	4.0	2	5	1	1
3609	1136	differentiation process	[differentiation process]	4.0	2	5	4	4
3610	1136	igh enhancer	[IgH enhancer]	4.0	2	7	3	1
3611	1136	binding affinity	[binding affinity]	4.0	2	5	5	5
3612	1136	low concentration	[lower concentration]	4.0	2	6	4	2
3613	1136	consensus motif	[consensus motif]	4.0	2	5	3	3
3614	1136	15 patient	[15 patients]	4.0	2	5	5	5
3615	1136	human beta-globin	[human beta-globin]	4.0	2	4	0	0
3616	1136	fold increase	[fold increase]	4.0	2	5	5	5
3617	1136	24 hr.	[24 hr.]	4.0	2	4	0	0
3618	1136	anti-CD3 antibody	[anti-CD3 antibody]	4.0	2	5	4	4
3619	1136	pAT 133	[pAT 133]	4.0	2	5	2	2
3620	1136	SR 31747a	[SR 31747A]	4.0	2	4	0	0
3621	1136	cytokine stimulation	[cytokine stimulation]	4.0	2	5	3	3
3622	1136	certain cell	[certain cells]	4.0	2	5	5	5
3623	1136	adenosine monophosphate	[adenosine monophosphate]	4.0	2	5	4	4
3624	1136	17 beta-estradiol	[17 beta-estradiol]	4.0	2	5	3	3
3625	1136	il-6 secretion	[IL-6 secretion]	4.0	2	5	3	3
3626	1136	gene therapy	[gene therapy]	4.0	2	5	3	3
3627	1136	prior study	[Prior studies]	4.0	2	4	0	0
3628	1136	regulatory function	[regulatory function]	4.0	2	5	4	4
3629	1136	IL-5 promoter	[IL-5 promoter]	4.0	2	6	4	2
3630	1136	RAR beta	[RAR beta]	4.0	2	5	4	4
3631	1136	vitro study	[vitro studies]	4.0	2	5	2	2
3632	1136	glucocorticoid apoptosis	[glucocorticoid apoptosis]	4.0	2	5	2	2
3633	1136	p21ras	[p21ras]	4.0	1	41	6	6
3634	1136	nuclear matrix	[nuclear matrix]	4.0	2	5	1	1
3635	1136	different cytokine	[different cytokines]	4.0	2	4	0	0
3636	1136	side effect	[side effects]	4.0	2	5	4	4
3637	1136	cd34(+) cell	[CD34(+) cells]	4.0	2	5	1	1
3638	1136	Electrophoretic mobility shift assay emsa	[Electrophoretic mobility shift assay EMSA]	4.0	5	4	0	0
3639	1136	NGFI-B/nur77 family	[NGFI-B/nur77 family]	4.0	2	5	1	1
3640	1136	wild-type ad	[wild-type Ad]	4.0	2	4	0	0
3641	1136	tnf production	[TNF production]	4.0	2	5	3	3
3642	1136	heavy chain	[heavy chain]	4.0	2	5	2	2
3643	1136	globin promoter	[globin promoter]	4.0	2	5	3	3
3644	1136	APL patient	[APL patients]	4.0	2	5	5	5
3645	1136	antigen stimulation	[antigen stimulation]	4.0	2	5	2	2
3646	1136	human serum	[human serum]	4.0	2	5	2	2
3647	1136	growth response	[growth response]	4.0	2	5	5	5
3648	1136	nuclear compartment	[nuclear compartment]	4.0	2	5	1	1
3649	1136	p65 mrna	[p65 mRNA]	4.0	2	6	2	1
3650	1136	DC differentiation	[DC differentiation]	4.0	2	5	2	2
3651	1136	t-cell-specific transcription	[T-cell-specific transcription]	4.0	2	5	1	1
3652	1136	resting cell	[resting cells]	4.0	2	5	1	1
3653	1136	CBF alpha	[CBF alpha]	4.0	2	5	3	3
3654	1136	Mono Mac	[Mono Mac]	4.0	2	7	6	2
3655	1136	significantly (p	[significantly (P]	4.0	2	5	3	3
3656	1136	th2 differentiation	[Th2 differentiation]	4.0	2	5	1	1
3657	1136	lipid peroxidation	[lipid peroxidation]	4.0	2	4	0	0
3658	1136	important role in the regulation	[important role in the regulation]	4.0	5	5	1	1
3659	1136	class ii major histocompatibility gene	[class II major histocompatibility gene]	4.0	5	5	3	3
3660	1136	chi b	[chi B]	4.0	2	5	4	4
3661	1136	mnda mrna	[MNDA mRNA]	4.0	2	5	4	4
3662	1136	expression gene	[expression genes]	4.0	2	5	5	5
3663	1136	CD11b promoter	[CD11b promoter]	4.0	2	6	2	1
3664	1136	liquid culture	[liquid culture]	4.0	2	4	0	0
3665	1136	human line	[human line]	4.0	2	5	5	5
3666	1136	several element	[several elements]	4.0	2	5	2	2
3667	1137	compound	[compound]	3.99	1	41	22	20
3668	1138	dissociation	[dissociation]	3.988888888888889	1	42	19	9
3669	1139	tcf-1	[TCF-1]	3.98421052631579	1	41	22	19
3670	1140	ionomycin	[ionomycin]	3.983333333333334	1	41	7	6
3671	1141	mab	[mAb]	3.980952380952381	1	41	25	21
3672	1142	creb	[CREB]	3.976470588235294	1	41	21	17
3673	1143	NAC	[NAC]	3.966666666666667	1	41	8	6
3674	1144	p38	[p38]	3.9636363636363634	1	41	15	11
3675	1145	u-937 leukemia cell	[U-937 leukemia cells]	3.9624062518028906	3	4	3	2
3676	1145	transcriptional initiation site	[transcriptional initiation site]	3.9624062518028906	3	4	3	2
3677	1145	vein cell HUVEC	[vein cells HUVEC]	3.9624062518028906	3	5	5	2
3678	1145	differential gene expression	[differential gene expression]	3.9624062518028906	3	5	5	2
3679	1145	umbilical vein cell HUVEC	[umbilical vein cells HUVEC]	3.9624062518028906	4	5	5	2
3680	1145	indicate the presence	[indicating the presence]	3.9624062518028906	3	5	5	2
3681	1145	activity of gata-1	[activity of GATA-1]	3.9624062518028906	3	4	3	2
3682	1145	immunodeficiency virus long repeat	[immunodeficiency virus long repeat]	3.9624062518028906	4	5	5	2
3683	1145	NIH 3t3 cell	[NIH 3T3 cells]	3.9624062518028906	3	4	3	2
3684	1145	tumour necrosis factor alpha	[tumour necrosis factor alpha]	3.9624062518028906	4	4	3	2
3685	1145	phosphorylation of serine	[phosphorylation of serine]	3.9624062518028906	3	4	3	2
3686	1145	mature T lymphocyte	[mature T lymphocytes]	3.9624062518028906	3	4	3	2
3687	1145	vein endothelial cell HUVEC	[vein endothelial cells HUVEC]	3.9624062518028906	4	5	5	2
3688	1145	hematopoietic growth factor	[hematopoietic growth factor]	3.9624062518028906	3	4	3	2
3689	1145	b cell nuclear extract	[B cell nuclear extract]	3.9624062518028906	4	4	3	2
3690	1145	protein kinase activation	[protein kinase activation]	3.9624062518028906	3	4	3	2
3691	1145	glucocorticoid receptor in patient	[glucocorticoid receptors in patients]	3.9624062518028906	4	4	3	2
3692	1145	p24 antigen production	[p24 antigen production]	3.9624062518028906	3	4	3	2
3693	1145	patient with AMI	[patients with AMI]	3.9624062518028906	3	4	3	2
3694	1145	zinc finger domain	[zinc finger domain]	3.9624062518028906	3	4	3	2
3695	1145	vitro effect of aldosterone	[vitro effect of aldosterone]	3.9624062518028906	4	4	3	2
3696	1145	primary b lymphocyte	[primary B lymphocytes]	3.9624062518028906	3	4	3	2
3697	1145	hiv-1 LTR activity	[HIV-1 LTR activity]	3.9624062518028906	3	4	3	2
3698	1145	Jurkat T lymphocyte	[Jurkat T lymphocytes]	3.9624062518028906	3	4	3	2
3699	1145	survival of cell	[survival of cells]	3.9624062518028906	3	4	3	2
3700	1145	patient with ss control	[patients with SS controls]	3.9624062518028906	4	4	3	2
3701	1145	preincubation of cell	[Preincubation of cells]	3.9624062518028906	3	4	3	2
3702	1145	t-cell line Jurkat	[T-cell line Jurkat]	3.9624062518028906	3	4	3	2
3703	1145	expression of erythroid-specific gene	[Expression of erythroid-specific genes]	3.9624062518028906	4	4	3	2
3704	1145	regulation of c-jun expression	[regulation of c-jun expression]	3.9624062518028906	4	4	3	2
3705	1145	immunodeficiency virus repeat	[immunodeficiency virus repeat]	3.9624062518028906	3	5	5	2
3706	1145	translation start site	[translation start site]	3.9624062518028906	3	4	3	2
3707	1145	form of acute leukemia	[form of acute leukemia]	3.9624062518028906	4	4	3	2
3708	1145	acid receptor RAR	[acid receptor RAR]	3.9624062518028906	3	5	5	2
3709	1145	resistance to glucocorticoid	[resistance to glucocorticoids]	3.9624062518028906	3	4	3	2
3710	1145	human t-cell lymphotropic	[human T-cell lymphotropic]	3.9624062518028906	3	4	3	2
3711	1145	2.3 fmol/10(7) cell	[2.3 fmol/10(7) cells]	3.9624062518028906	3	5	5	2
3712	1145	human erythroid precursor	[human erythroid precursors]	3.9624062518028906	3	4	3	2
3713	1145	tf gene transcription	[TF gene transcription]	3.9624062518028906	3	4	3	2
3714	1145	tonsillar b cell	[tonsillar B cells]	3.9624062518028906	3	4	3	2
3715	1145	range of concentration	[range of concentrations]	3.9624062518028906	3	4	3	2
3716	1146	structure	[structure]	3.9521739130434783	1	41	34	23
3717	1147	APL	[APL]	3.95	1	41	9	6
3718	1148	latency	[latency]	3.9333333333333336	1	41	25	15
3719	1149	polymerase	[polymerase]	3.91	1	41	19	10
3720	1150	E2F	[E2F]	3.9000000000000004	1	40	11	11
3721	1150	kinetic	[Kinetic]	3.9000000000000004	1	41	32	16
3722	1151	t-lymphocyte	[T-lymphocyte]	3.8937500000000003	1	40	17	16
3723	1152	h2o2	[H2O2]	3.8857142857142857	1	40	16	14
3724	1153	population	[population]	3.8827586206896556	1	40	34	29
3725	1154	aids	[AIDS]	3.877777777777778	1	40	11	9
3726	1155	homology	[homology]	3.8730769230769235	1	40	33	26
3727	1156	DRA	[DRA]	3.871428571428572	1	40	9	7
3728	1157	c-myb	[c-myb]	3.8700000000000006	1	40	13	10
3729	1158	yeast	[yeast]	3.8625000000000003	1	40	11	8
3730	1158	factor-kappaB	[factor-kappaB]	3.8625000000000003	1	41	38	16
3731	1159	erythropoietin	[erythropoietin]	3.8615384615384616	1	40	18	13
3732	1160	bcl-6	[BCL-6]	3.8533333333333335	1	40	22	15
3733	1161	mapk	[MAPK]	3.84	1	40	24	15
3734	1162	Janus	[Janus]	3.8200000000000003	1	40	18	10
3735	1163	mitogen	[mitogen]	3.8000000000000003	1	39	15	15
3736	1164	M-CSF	[M-CSF]	3.781818181818182	1	39	13	11
3737	1165	value	[value]	3.78	1	39	30	25
3738	1165	release	[release]	3.78	1	41	32	10
3739	1166	pretreatment	[pretreatment]	3.777777777777778	1	42	38	9
3740	1167	redox	[redox]	3.776923076923077	1	39	16	13
3741	1168	CBF	[CBF]	3.7733333333333334	1	39	19	15
3742	1169	thrombin	[thrombin]	3.772727272727273	1	39	14	11
3743	1169	messenger	[messenger]	3.772727272727273	1	39	28	22
3744	1170	possibility	[possibility]	3.757142857142857	1	39	20	14
3745	1171	effect.	[effect.]	3.755555555555556	1	39	13	9
3746	1172	stem	[stem]	3.7538461538461543	1	39	19	13
3747	1173	[3H]thymidine incorporation	[[3H]thymidine incorporation]	3.75	2	5	5	4
3748	1173	glutathione level	[glutathione level]	3.75	2	5	5	4
3749	1173	eosinophil granule	[eosinophil granule]	3.75	2	5	5	4
3750	1173	male patient	[male patient]	3.75	2	5	5	4
3751	1173	peptide binding	[peptide binding]	3.75	2	5	5	4
3752	1173	enzyme-linked assay	[enzyme-linked assay]	3.75	2	5	5	4
3753	1173	membrane protein-1	[membrane protein-1]	3.75	2	5	5	4
3754	1173	gr binding	[GR binding]	3.75	2	5	5	4
3755	1173	ca2+ concentration	[Ca2+ concentration]	3.75	2	5	5	4
3756	1173	kruppel-like factor	[Kruppel-like factor]	3.75	2	5	5	4
3757	1173	T expression	[T expression]	3.75	2	5	5	4
3758	1173	leukemia patient	[leukemia patients]	3.75	2	5	5	4
3759	1173	10 patient	[10 patients]	3.75	2	5	5	4
3760	1173	mrna transcript	[mRNA transcript]	3.75	2	5	5	4
3761	1173	gc resistance	[GC resistance]	3.75	2	5	5	4
3762	1173	tf gene	[TF gene]	3.75	2	5	5	4
3763	1173	cellular mechanism	[cellular mechanism]	3.75	2	5	5	4
3764	1173	state level	[state levels]	3.75	2	5	5	4
3765	1173	oxide synthase	[oxide synthase]	3.75	2	5	5	4
3766	1173	direct binding	[direct binding]	3.75	2	5	5	4
3767	1173	retinoblastoma gene	[retinoblastoma gene]	3.75	2	5	5	4
3768	1173	detailed analysis	[detailed analysis]	3.75	2	5	5	4
3769	1173	therapeutic target	[therapeutic target]	3.75	2	5	5	4
3770	1173	nf kappab	[NF kappaB]	3.75	2	5	5	4
3771	1173	clonality analysis	[Clonality analysis]	3.75	2	5	5	4
3772	1173	hiv-1 provirus	[HIV-1 provirus]	3.75	2	5	5	4
3773	1173	Cushing' disease	[Cushing's disease]	3.75	2	5	5	4
3774	1173	undetectable level	[undetectable levels]	3.75	2	5	5	4
3775	1173	CD28 surface	[CD28 surface]	3.75	2	5	5	4
3776	1173	interleukin-1 il-1	[interleukin-1 IL-1]	3.75	2	5	5	4
3777	1173	two class	[two class]	3.75	2	5	5	4
3778	1173	critical element	[critical element]	3.75	2	5	5	4
3779	1173	human vein endothelial cell HUVEC	[human vein endothelial cells HUVEC]	3.75	5	5	5	4
3780	1173	prostate cancer	[prostate cancer]	3.75	2	5	5	4
3781	1173	phosphorylation site	[phosphorylation site]	3.75	2	5	5	4
3782	1173	DNA target	[DNA target]	3.75	2	5	5	4
3783	1173	human homolog	[human homolog]	3.75	2	5	5	4
3784	1173	activate transcription	[activating transcription]	3.75	2	5	5	4
3785	1173	promoter function	[promoter function]	3.75	2	5	5	4
3786	1173	eml cell	[EML cells]	3.75	2	5	5	4
3787	1173	signal lead	[signal leading]	3.75	2	5	5	4
3788	1173	type EBS	[type EBS]	3.75	2	5	5	4
3789	1173	human umbilical vein cell HUVEC	[human umbilical vein cells HUVEC]	3.75	5	5	5	4
3790	1173	protein extract	[protein extracts]	3.75	2	5	5	4
3791	1173	fluticasone propionate	[fluticasone propionate]	3.75	2	5	5	4
3792	1173	transcription complex	[transcription complex]	3.75	2	5	5	4
3793	1173	adenovirus type	[adenovirus type]	3.75	2	5	5	4
3794	1173	control element	[control element]	3.75	2	5	5	4
3795	1173	acid treatment	[acid treatment]	3.75	2	5	5	4
3796	1173	important determinant	[important determinant]	3.75	2	5	5	4
3797	1173	induce apoptosis	[inducing apoptosis]	3.75	2	5	5	4
3798	1174	enhancement	[enhancement]	3.738095238095238	1	39	34	21
3799	1175	cycle	[cycle]	3.7375000000000003	1	39	26	16
3800	1176	hl60	[HL60]	3.7285714285714286	1	39	12	7
3801	1177	P.	[P.]	3.7	1	40	36	12
3802	1177	upregulation	[upregulation]	3.7	1	40	30	10
3803	1177	epsilon	[epsilon]	3.7	1	39	32	16
3804	1178	transactivator	[transactivator]	3.695652173913044	1	38	24	23
3805	1179	luciferase	[luciferase]	3.6950000000000003	1	38	21	20
3806	1180	nm	[nM]	3.6880000000000006	1	38	28	25
3807	1181	lymphokine	[lymphokine]	3.684615384615385	1	38	15	13
3808	1182	different mechanism	[different mechanisms]	3.666666666666667	2	5	4	3
3809	1182	monocyte/macrophage cell	[monocyte/macrophage cells]	3.666666666666667	2	5	4	3
3810	1182	replicative capacity	[replicative capacity]	3.666666666666667	2	5	4	3
3811	1182	germline C	[germline C]	3.666666666666667	2	5	4	3
3812	1182	specific function	[specific function]	3.666666666666667	2	5	4	3
3813	1182	related protein	[related protein]	3.666666666666667	2	5	4	3
3814	1182	cancer cell	[cancer cell]	3.666666666666667	2	5	4	3
3815	1182	whole blood	[whole blood]	3.666666666666667	2	5	4	3
3816	1182	activation of nuclear factor kappa b	[activation of nuclear factor kappa B]	3.666666666666667	6	5	4	3
3817	1182	cdc2 mrna	[cdc2 mRNA]	3.666666666666667	2	5	4	3
3818	1182	peri-kappa b	[peri-kappa B]	3.666666666666667	2	5	4	3
3819	1182	tnf-alpha secretion	[TNF-alpha secretion]	3.666666666666667	2	5	4	3
3820	1182	cytokine tnf-alpha	[cytokine TNF-alpha]	3.666666666666667	2	5	4	3
3821	1182	radiation therapy	[radiation therapy]	3.666666666666667	2	5	4	3
3822	1182	aldosterone receptor	[aldosterone receptors]	3.666666666666667	2	5	4	3
3823	1182	rev protein	[Rev protein]	3.666666666666667	2	5	4	3
3824	1182	full activation	[full activation]	3.666666666666667	2	5	4	3
3825	1182	wp activity	[Wp activity]	3.666666666666667	2	5	4	3
3826	1182	short arm	[short arm]	3.666666666666667	2	5	4	3
3827	1182	gata motif	[GATA motif]	3.666666666666667	2	5	4	3
3828	1182	egr-1 expression	[Egr-1 expression]	3.666666666666667	2	5	4	3
3829	1182	early activation	[early activation]	3.666666666666667	2	5	4	3
3830	1182	T cells.	[T cells.]	3.666666666666667	2	5	4	3
3831	1182	common mechanism	[common mechanism]	3.666666666666667	2	5	4	3
3832	1182	myocardial infarction	[myocardial infarction]	3.666666666666667	2	5	4	3
3833	1182	cn inhibition	[CN inhibition]	3.666666666666667	2	5	4	3
3834	1182	amino-terminal region	[amino-terminal region]	3.666666666666667	2	5	4	3
3835	1182	various concentration	[various concentrations]	3.666666666666667	2	5	4	3
3836	1183	cotransfection	[cotransfection]	3.6666666666666665	1	39	28	12
3837	1184	characteristic	[characteristic]	3.6653846153846157	1	38	35	26
3838	1185	N-terminal	[N-terminal]	3.655555555555556	1	38	13	9
3839	1186	modification	[modification]	3.638888888888889	1	38	29	18
3840	1187	thymus	[thymus]	3.6375	1	38	13	8
3841	1188	CREB	[CREB]	3.6285714285714286	1	38	12	7
3842	1189	SCL	[SCL]	3.6222222222222222	1	38	16	9
3843	1190	okadaic	[okadaic]	3.6142857142857148	1	38	13	7
3844	1191	Ca2+	[Ca2+]	3.6	1	37	11	11
3845	1192	construct	[construct]	3.5842105263157897	1	37	22	19
3846	1192	mcp-1	[MCP-1]	3.5842105263157897	1	37	22	19
3847	1193	CTL	[CTL]	3.583333333333334	1	37	21	18
3848	1193	p53	[p53]	3.583333333333334	1	37	7	6
3849	1194	nfatp	[NFATp]	3.5812500000000003	1	37	19	16
3850	1195	Ets	[Ets]	3.58	1	37	12	10
3851	1196	memory	[memory]	3.5666666666666664	1	37	20	15
3852	1197	germline	[germline]	3.564285714285715	1	37	19	14
3853	1198	recruitment	[recruitment]	3.5416666666666665	1	38	31	12
3854	1199	insight	[insight]	3.5250000000000004	1	38	33	12
3855	1200	dprl promoter	[dPRL promoter]	3.5	2	5	3	2
3856	1200	encode cytokine	[encoding cytokines]	3.5	2	5	3	2
3857	1200	new member	[new member]	3.5	2	5	3	2
3858	1200	RCC patient	[RCC patient]	3.5	2	6	5	2
3859	1200	activity of the transcription factor	[activity of the transcription factor]	3.5	5	5	3	2
3860	1200	cell lysis	[cell lysis]	3.5	2	5	3	2
3861	1200	vitro effect	[vitro effect]	3.5	2	6	5	2
3862	1200	HEL cell	[HEL cells]	3.5	2	5	3	2
3863	1200	intestinal cell	[intestinal cell]	3.5	2	5	3	2
3864	1200	antigenic peptide	[antigenic peptide]	3.5	2	5	3	2
3865	1200	ad vector	[Ad vector]	3.5	2	5	3	2
3866	1200	hiv-1 terminal	[HIV-1 terminal]	3.5	2	6	5	2
3867	1200	pdgf(b) mrna	[PDGF(B) mRNA]	3.5	2	5	3	2
3868	1200	Takayasu arteritis	[Takayasu arteritis]	3.5	2	6	5	2
3869	1200	tcf-1 protein	[TCF-1 protein]	3.5	2	5	3	2
3870	1200	transcriptional coactivator	[transcriptional coactivator]	3.5	2	5	3	2
3871	1200	ifn-gamma treatment	[IFN-gamma treatment]	3.5	2	5	3	2
3872	1200	nef protein	[Nef protein]	3.5	2	5	3	2
3873	1200	serine 727	[serine 727]	3.5	2	5	3	2
3874	1200	ebv latency	[EBV latency]	3.5	2	6	5	2
3875	1200	jak kinase	[JAK kinases]	3.5	2	6	5	2
3876	1200	gr expression	[GR expression]	3.5	2	5	3	2
3877	1200	ligand-binding domain	[ligand-binding domain]	3.5	2	6	5	2
3878	1200	sporadic case	[sporadic case]	3.5	2	5	3	2
3879	1200	cell DC	[cells DC]	3.5	2	7	7	2
3880	1200	lupus patient	[lupus patients]	3.5	2	5	3	2
3881	1200	binding study	[binding studies]	3.5	2	5	3	2
3882	1200	unstimulated T	[unstimulated T]	3.5	2	5	3	2
3883	1200	factor of T cell NF-AT	[factor of T cells NF-AT]	3.5	5	7	7	2
3884	1200	important component	[important component]	3.5	2	6	5	2
3885	1200	report,	[report,]	3.5	1	40	5	1
3886	1200	lymphocyte differentiation	[lymphocyte differentiation]	3.5	2	5	3	2
3887	1200	dose-dependent inhibition	[dose-dependent inhibition]	3.5	2	6	5	2
3888	1200	ebv cell	[EBV cells]	3.5	2	5	3	2
3889	1200	12-bp insert	[12-bp insert]	3.5	2	5	3	2
3890	1200	erythroleukemia cell	[erythroleukemia cells]	3.5	2	6	5	2
3891	1200	60 minute	[60 minutes]	3.5	2	5	3	2
3892	1200	context	[context]	3.5	1	38	27	9
3893	1200	coding region	[coding region]	3.5	2	5	3	2
3894	1200	2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	3.5	2	5	3	2
3895	1200	catalytic domain	[catalytic domain]	3.5	2	6	5	2
3896	1200	RA patient	[RA patients]	3.5	2	5	3	2
3897	1200	lipopolysaccharide induction	[lipopolysaccharide induction]	3.5	2	5	3	2
3898	1200	gingival fibroblast	[gingival fibroblasts]	3.5	2	6	5	2
3899	1200	several aspect	[several aspects]	3.5	2	6	5	2
3900	1200	X2 box	[X2 box]	3.5	2	5	3	2
3901	1200	basic domain	[basic domain]	3.5	2	5	3	2
3902	1200	gel-shift analysis	[Gel-shift analysis]	3.5	2	5	3	2
3903	1200	Scatchard analysis	[Scatchard analysis]	3.5	2	5	3	2
3904	1201	e2f	[E2F]	3.4923076923076923	1	36	14	13
3905	1202	hiv-2	[HIV-2]	3.488888888888889	1	36	10	9
3906	1203	approach	[approach]	3.488461538461539	1	36	29	26
3907	1204	part,	[part,]	3.4818181818181824	1	37	24	11
3908	1205	ifn-alpha	[IFN-alpha]	3.476923076923077	1	36	16	13
3909	1206	animal	[animal]	3.476470588235294	1	36	21	17
3910	1207	allele	[allele]	3.475	1	36	25	20
3911	1208	huvec	[HUVEC]	3.4529411764705884	1	36	25	17
3912	1209	center	[center]	3.4166666666666665	1	36	22	12
3913	1210	TCF-1	[TCF-1]	3.4142857142857146	1	36	13	7
3914	1211	PML	[PML]	3.4000000000000004	1	35	10	10
3915	1211	cycloheximide	[cycloheximide]	3.4000000000000004	1	35	6	6
3916	1212	residue	[residue]	3.3923076923076922	1	35	28	26
3917	1213	ec	[EC]	3.3916666666666666	1	35	13	12
3918	1214	e1a	[E1A]	3.384615384615385	1	35	15	13
3919	1215	epitope	[epitope]	3.38	1	35	24	20
3920	1216	peak	[peak]	3.377777777777778	1	35	22	18
3921	1217	chromatin	[chromatin]	3.376923076923077	1	35	16	13
3922	1218	plasmid	[plasmid]	3.3705882352941177	1	35	22	17
3923	1219	irf-1	[IRF-1]	3.3600000000000003	1	35	14	10
3924	1220	cd23	[CD23]	3.358333333333334	1	35	17	12
3925	1221	rate	[rate]	3.3454545454545457	1	36	28	11
3926	1222	th1	[Th1]	3.34	1	35	16	10
3927	1223	fc	[Fc]	3.333333333333334	1	35	20	12
3928	1224	comparable level	[comparable levels]	3.333333333333333	2	5	5	3
3929	1224	blood mononuclear cell from patient	[blood mononuclear cells from patients]	3.333333333333333	5	5	5	3
3930	1224	IkappaB alpha	[IkappaB alpha]	3.333333333333333	2	5	5	3
3931	1224	receptor level	[receptor level]	3.333333333333333	2	5	5	3
3932	1224	pax gene	[Pax genes]	3.333333333333333	2	5	5	3
3933	1224	kd value	[Kd value]	3.333333333333333	2	5	5	3
3934	1224	detectable activation	[detectable activation]	3.333333333333333	2	5	5	3
3935	1224	quantitative analysis	[quantitative analysis]	3.333333333333333	2	5	5	3
3936	1224	only level	[only levels]	3.333333333333333	2	5	5	3
3937	1224	RU 486	[RU 486]	3.333333333333333	2	5	5	3
3938	1224	contrast, treatment	[contrast, treatment]	3.333333333333333	2	5	5	3
3939	1224	tcf-1 alpha	[TCF-1 alpha]	3.333333333333333	2	5	5	3
3940	1224	drug cyclosporin	[drug cyclosporin]	3.333333333333333	2	5	5	3
3941	1224	different combination	[different combinations]	3.333333333333333	2	5	5	3
3942	1224	strong activity	[strong activity]	3.333333333333333	2	5	5	3
3943	1224	distinct subset	[distinct subset]	3.333333333333333	2	5	5	3
3944	1224	NF-kappaB translocation	[NF-kappaB translocation]	3.333333333333333	2	5	5	3
3945	1224	cell-specific gene	[cell-specific genes]	3.333333333333333	2	5	5	3
3946	1224	agent of adult t-cell leukemia	[agent of adult T-cell leukemia]	3.333333333333333	5	5	5	3
3947	1224	free cortisol	[free cortisol]	3.333333333333333	2	5	5	3
3948	1224	cytoplasmic level	[cytoplasmic levels]	3.333333333333333	2	5	5	3
3949	1224	mammary cell	[mammary cells]	3.333333333333333	2	5	5	3
3950	1224	distinct form	[distinct forms]	3.333333333333333	2	5	5	3
3951	1224	sequence requirement	[sequence requirements]	3.333333333333333	2	5	5	3
3952	1224	haemopoietic cell	[haemopoietic cells]	3.333333333333333	2	5	5	3
3953	1224	good correlation	[good correlation]	3.333333333333333	2	5	5	3
3954	1224	possible relationship	[possible relationship]	3.333333333333333	2	5	5	3
3955	1224	localization sequence	[localization sequence]	3.333333333333333	2	5	5	3
3956	1224	tnf receptor	[TNF receptor]	3.333333333333333	2	5	5	3
3957	1224	sequence specificity	[sequence specificity]	3.333333333333333	2	5	5	3
3958	1225	5'	[5']	3.3000000000000003	1	34	8	8
3959	1225	cloning	[cloning]	3.3000000000000003	1	38	30	6
3960	1225	oncogene	[oncogene]	3.3000000000000003	1	34	17	17
3961	1225	E1A	[E1A]	3.3000000000000003	1	34	12	12
3962	1226	CD30	[CD30]	3.292307692307692	1	34	14	13
3963	1227	aml	[AML]	3.2916666666666665	1	34	13	12
3964	1228	igh	[IgH]	3.2833333333333337	1	34	7	6
3965	1228	prb	[pRB]	3.2833333333333337	1	34	14	12
3966	1229	egr-1	[EGR-1]	3.2823529411764705	1	34	20	17
3967	1230	Jak3	[Jak3]	3.2750000000000004	1	34	10	8
3968	1231	comparison	[comparison]	3.272727272727273	1	35	25	11
3969	1232	appearance	[appearance]	3.271428571428572	1	37	30	7
3970	1233	myeloid	[myeloid]	3.2588235294117647	1	34	24	17
3971	1234	failure	[failure]	3.2583333333333337	1	34	17	12
3972	1235	hla	[HLA]	3.254545454545455	1	34	16	11
3973	1236	aspect	[aspect]	3.252380952380953	1	34	31	21
3974	1237	risk	[risk]	3.246153846153846	1	34	20	13
3975	1238	ultra-violet	[UV]	3.2454545454545456	1	34	17	11
3976	1239	supershift	[supershift]	3.238461538461539	1	34	21	13
3977	1240	mutagenesis	[mutagenesis]	3.214285714285715	1	34	26	14
3978	1241	Fos	[Fos]	3.2100000000000004	1	34	19	10
3979	1242	d	[D]	3.192857142857143	1	34	29	14
3980	1243	colony	[colony]	3.185714285714286	1	33	24	21
3981	1244	CEM	[CEM]	3.1833333333333336	1	33	7	6
3982	1245	map	[MAP]	3.177777777777778	1	34	20	9
3983	1246	PU.1	[PU.1]	3.1750000000000003	1	33	10	8
3984	1247	rapid tyrosine phosphorylation	[rapid tyrosine phosphorylation]	3.1699250014423126	3	10	8	1
3985	1247	t-cell transcription factor	[T-cell transcription factor]	3.1699250014423126	3	3	3	3
3986	1247	3 kb 5'-flanking DNA	[3 kb 5'-flanking DNA]	3.1699250014423126	4	3	1	1
3987	1247	peripheral blood of individual	[peripheral blood of individuals]	3.1699250014423126	4	3	2	2
3988	1247	western blotting analysis	[Western blotting analysis]	3.1699250014423126	3	2	0	0
3989	1247	DRA promoter occupancy	[DRA promoter occupancy]	3.1699250014423126	3	3	1	1
3990	1247	insulin receptor substrate	[insulin receptor substrate]	3.1699250014423126	3	3	3	3
3991	1247	six nuclear antigen	[six nuclear antigen]	3.1699250014423126	3	3	3	3
3992	1247	interleukin IL-2 gene	[interleukin IL-2 gene]	3.1699250014423126	3	3	3	3
3993	1247	all-tran retinoic acid ATRA	[all-trans retinoic acid ATRA]	3.1699250014423126	4	2	0	0
3994	1247	ability of cell	[ability of cells]	3.1699250014423126	3	3	3	3
3995	1247	sickle red blood cell	[sickle red blood cells]	3.1699250014423126	4	3	2	2
3996	1247	th1 cell development	[Th1 cell development]	3.1699250014423126	3	2	0	0
3997	1247	inhibition of binding	[inhibition of binding]	3.1699250014423126	3	3	1	1
3998	1247	primary mouse T cell	[primary mouse T cells]	3.1699250014423126	4	2	0	0
3999	1247	evidence for the involvement	[evidence for the involvement]	3.1699250014423126	4	3	2	2
4000	1247	thymic cell TEC	[thymic cells TEC]	3.1699250014423126	3	3	3	3
4001	1247	hiv-infected monocytic cell	[HIV-infected monocytic cells]	3.1699250014423126	3	3	1	1
4002	1247	T helper lymphocyte	[T helper lymphocytes]	3.1699250014423126	3	3	1	1
4003	1247	basal htlv-i transcription	[basal HTLV-I transcription]	3.1699250014423126	3	2	0	0
4004	1247	CD4 positive T cell	[CD4 positive T cells]	3.1699250014423126	4	3	1	1
4005	1247	human u-937 leukemia cell	[human U-937 leukemia cells]	3.1699250014423126	4	2	0	0
4006	1247	drip coactivator complex	[DRIP coactivator complex]	3.1699250014423126	3	2	0	0
4007	1247	degradation of ikappab-alpha	[degradation of IkappaB-alpha]	3.1699250014423126	3	3	2	2
4008	1247	beta-casein gene promoter	[beta-casein gene promoter]	3.1699250014423126	3	2	0	0
4009	1247	BCL-6 gene product	[BCL-6 gene product]	3.1699250014423126	3	2	0	0
4010	1247	receptor per cell	[receptors per cell]	3.1699250014423126	3	3	3	3
4011	1247	IL-2 promoter activation	[IL-2 promoter activation]	3.1699250014423126	3	2	0	0
4012	1247	body burden reference value	[body burden reference values]	3.1699250014423126	4	2	0	0
4013	1247	gata-3 promoter activity	[GATA-3 promoter activity]	3.1699250014423126	3	2	0	0
4014	1247	formation of oxygen intermediate	[formation of oxygen intermediates]	3.1699250014423126	4	3	3	3
4015	1247	il-2 gene activation	[IL-2 gene activation]	3.1699250014423126	3	3	2	2
4016	1247	zeta 2 globin gene	[zeta 2 globin gene]	3.1699250014423126	4	3	1	1
4017	1247	level in T cell	[level in T cells]	3.1699250014423126	4	3	3	3
4018	1247	mammalian pax gene	[mammalian Pax genes]	3.1699250014423126	3	3	1	1
4019	1247	cr of GR	[CR of GR]	3.1699250014423126	3	2	0	0
4020	1247	expression of nf-kappab	[expression of NF-kappaB]	3.1699250014423126	3	3	3	3
4021	1247	release of intracellular calcium	[release of intracellular calcium]	3.1699250014423126	4	2	0	0
4022	1247	ubiquitin -proteasome system	[ubiquitin -proteasome system]	3.1699250014423126	3	2	0	0
4023	1247	extract of T cell	[extracts of T cells]	3.1699250014423126	4	3	3	3
4024	1247	potential binding site	[potential binding sites]	3.1699250014423126	3	3	2	2
4025	1247	effect of tnf-alpha	[effect of TNF-alpha]	3.1699250014423126	3	3	2	2
4026	1247	lack of effect	[lack of effect]	3.1699250014423126	3	3	2	2
4027	1247	androgen receptor locus	[androgen receptor locus]	3.1699250014423126	3	2	0	0
4028	1247	appearance of transcription factor	[appearance of transcription factors]	3.1699250014423126	4	3	2	2
4029	1247	il-2 receptor il-2r	[IL-2 receptor IL-2R]	3.1699250014423126	3	2	0	0
4030	1247	nuclear translocation of p65	[nuclear translocation of p65]	3.1699250014423126	4	2	0	0
4031	1247	cell type-specific gene expression	[cell type-specific gene expression]	3.1699250014423126	4	2	0	0
4032	1247	monoclonal antibody specific	[monoclonal antibody specific]	3.1699250014423126	3	3	3	3
4033	1247	gene expression pattern	[gene expression pattern]	3.1699250014423126	3	3	2	2
4034	1247	camp response element CRE	[cAMP response element CRE]	3.1699250014423126	4	3	1	1
4035	1247	differentiation of human cell	[differentiation of human cells]	3.1699250014423126	4	3	3	3
4036	1247	b lineage cell	[B lineage cells]	3.1699250014423126	3	3	2	2
4037	1247	activation of jak kinase	[activation of JAK kinases]	3.1699250014423126	4	3	1	1
4038	1247	chloramphenicol acetyltransferase CAT gene	[chloramphenicol acetyltransferase CAT gene]	3.1699250014423126	4	2	0	0
4039	1247	monocyte chemoattractant protein-1 mcp-1	[monocyte chemoattractant protein-1 MCP-1]	3.1699250014423126	4	2	0	0
4040	1247	hypothalamic-pituitary-adrenal (hpa) axis	[hypothalamic-pituitary-adrenal (HPA) axis]	3.1699250014423126	3	3	1	1
4041	1247	tnf-alpha jurkat cell	[TNF-alpha Jurkat cells]	3.1699250014423126	3	2	0	0
4042	1247	chronic gut inflammation	[chronic gut inflammation]	3.1699250014423126	3	2	0	0
4043	1247	cytoplasmic tyrosine kinase	[cytoplasmic tyrosine kinase]	3.1699250014423126	3	3	1	1
4044	1247	intracellular calcium concentration	[intracellular calcium concentration]	3.1699250014423126	3	3	2	2
4045	1247	glutamic acid decarboxylase	[glutamic acid decarboxylase]	3.1699250014423126	3	2	0	0
4046	1247	constitutive DNA binding activity	[constitutive DNA binding activity]	3.1699250014423126	4	3	2	2
4047	1247	fraction of CHD	[fraction of CHD]	3.1699250014423126	3	2	0	0
4048	1247	infection of thymocyte	[Infection of thymocytes]	3.1699250014423126	3	2	0	0
4049	1247	transient transfection assays,	[transient transfection assays,]	3.1699250014423126	3	2	0	0
4050	1247	transcription factor gata-3	[transcription factor GATA-3]	3.1699250014423126	3	2	0	0
4051	1247	association with hsp90	[association with hsp90]	3.1699250014423126	3	2	0	0
4052	1247	kappa b binding	[kappa B binding]	3.1699250014423126	3	3	2	2
4053	1247	nuclear import of NF-ATc	[nuclear import of NF-ATc]	3.1699250014423126	4	2	0	0
4054	1247	5' upstream sequence	[5' upstream sequence]	3.1699250014423126	3	3	2	2
4055	1247	include tumor necrosis factor	[including tumor necrosis factor]	3.1699250014423126	4	3	3	3
4056	1247	c/ebp epsilon mrna	[C/EBP epsilon mRNA]	3.1699250014423126	3	8	6	1
4057	1247	variety of cell line	[variety of cell lines]	3.1699250014423126	4	2	0	0
4058	1247	tyrosine phosphorylation of Jak1	[tyrosine phosphorylation of Jak1]	3.1699250014423126	4	3	1	1
4059	1247	tyrosine phosphorylation of Jak3	[tyrosine phosphorylation of Jak3]	3.1699250014423126	4	3	2	2
4060	1247	interferon factor 1	[interferon factor 1]	3.1699250014423126	3	3	3	3
4061	1247	protein tyrosine kinase p56lck	[protein tyrosine kinases p56lck]	3.1699250014423126	4	2	0	0
4062	1247	major disorder MDD	[major disorder MDD]	3.1699250014423126	3	3	3	3
4063	1247	hypercalcemia of various granulomato	[hypercalcemia of various granulomatoses]	3.1699250014423126	4	2	0	0
4064	1247	wide range of concentration	[wide range of concentrations]	3.1699250014423126	4	2	0	0
4065	1247	early event lead	[early events leading]	3.1699250014423126	3	2	0	0
4066	1247	alpha 4 gene promoter	[alpha 4 gene promoter]	3.1699250014423126	4	2	0	0
4067	1247	representative adenoviral serotype	[representative adenoviral serotypes]	3.1699250014423126	3	2	0	0
4068	1247	role of p16	[role of p16]	3.1699250014423126	3	2	0	0
4069	1247	5' flank DNA	[5' flanking DNA]	3.1699250014423126	3	3	1	1
4070	1247	central nervous system CNS	[central nervous system CNS]	3.1699250014423126	4	3	1	1
4071	1247	level of replication	[levels of replication]	3.1699250014423126	3	3	2	2
4072	1247	susceptibility to hiv-1 infection	[susceptibility to HIV-1 infection]	3.1699250014423126	4	2	0	0
4073	1247	elevation of ca2+	[elevation of Ca2+]	3.1699250014423126	3	3	1	1
4074	1247	such as lps	[such as LPS]	3.1699250014423126	3	2	0	0
4075	1247	action of cyclosporin a	[action of cyclosporin A]	3.1699250014423126	4	2	0	0
4076	1247	amino acid change	[amino acid change]	3.1699250014423126	3	2	0	0
4077	1247	hla class antigen	[HLA class antigens]	3.1699250014423126	3	3	3	3
4078	1247	prenatal immune challenge	[Prenatal immune challenge]	3.1699250014423126	3	2	0	0
4079	1247	il-6 gene expression	[IL-6 gene expression]	3.1699250014423126	3	3	2	2
4080	1247	dephosphorylation of NFATp	[dephosphorylation of NFATp]	3.1699250014423126	3	2	0	0
4081	1247	gamma delta T	[gamma delta T]	3.1699250014423126	3	5	3	1
4082	1247	chronic myelogenous leukemia CML	[chronic myelogenous leukemia CML]	3.1699250014423126	4	2	0	0
4083	1247	tissue factor gene expression	[tissue factor gene expression]	3.1699250014423126	4	2	0	0
4084	1247	human aortic cell	[human aortic cells]	3.1699250014423126	3	3	3	3
4085	1247	patient with steroid-sensitive asthma	[patients with steroid-sensitive asthma]	3.1699250014423126	4	3	1	1
4086	1247	human natural killer cell	[human natural killer cells]	3.1699250014423126	4	3	2	2
4087	1247	EBNA2 responsive cis-element	[EBNA2 responsive cis-element]	3.1699250014423126	3	2	0	0
4088	1247	presence of c-fo	[presence of c-fos]	3.1699250014423126	3	2	0	0
4089	1247	member of the factor	[member of the factor]	3.1699250014423126	4	3	1	1
4090	1247	sequence-specific transcriptional repressor	[sequence-specific transcriptional repressor]	3.1699250014423126	3	2	0	0
4091	1247	non-antigen-selected human b cell	[non-antigen-selected human B cells]	3.1699250014423126	4	2	0	0
4092	1247	two dna-binding complex	[two DNA-binding complexes]	3.1699250014423126	3	3	3	3
4093	1247	tumour necrosis factor-alpha tnf-alpha	[tumour necrosis factor-alpha TNF-alpha]	3.1699250014423126	4	3	1	1
4094	1247	human interleukin 2	[human interleukin 2]	3.1699250014423126	3	3	2	2
4095	1247	release of cytokine	[release of cytokines]	3.1699250014423126	3	3	3	3
4096	1247	receptor antagonist RU	[receptor antagonist RU]	3.1699250014423126	3	3	3	3
4097	1247	constitutive NF-kappa b	[constitutive NF-kappa B]	3.1699250014423126	3	2	0	0
4098	1247	murine il-10 receptor	[murine IL-10 receptor]	3.1699250014423126	3	2	0	0
4099	1247	DNA consensus sequence	[DNA consensus sequence]	3.1699250014423126	3	2	0	0
4100	1247	control of gene expression	[control of gene expression]	3.1699250014423126	4	2	0	0
4101	1247	interaction with protein	[interaction with proteins]	3.1699250014423126	3	3	3	3
4102	1247	b cell transcription factor	[B cell transcription factor]	3.1699250014423126	4	3	2	2
4103	1247	addition of homocysteine	[addition of homocysteine]	3.1699250014423126	3	2	0	0
4104	1247	effect of il-4	[effect of IL-4]	3.1699250014423126	3	4	4	2
4105	1247	effect of il-2	[effects of IL-2]	3.1699250014423126	3	3	2	2
4106	1247	il-4 -inducible gene expression	[IL-4 -inducible gene expression]	3.1699250014423126	4	2	0	0
4107	1247	expression of IL-2	[expression of IL-2]	3.1699250014423126	3	2	0	0
4108	1247	b-cell-specific enhancer element	[B-cell-specific enhancer element]	3.1699250014423126	3	3	2	2
4109	1247	gamma interferon ifn-gamma	[gamma interferon IFN-gamma]	3.1699250014423126	3	3	1	1
4110	1247	transcription of class gene	[transcription of class genes]	3.1699250014423126	4	3	1	1
4111	1247	tcr delta enhancer	[TCR delta enhancer]	3.1699250014423126	3	2	0	0
4112	1247	patient with severe immunodeficiency	[patient with severe immunodeficiency]	3.1699250014423126	4	3	2	2
4113	1247	interleukin-1 beta production	[interleukin-1 beta production]	3.1699250014423126	3	3	2	2
4114	1247	effect of oxidative stress	[effect of oxidative stresses]	3.1699250014423126	4	3	1	1
4115	1247	subject with mild asthma	[subjects with mild asthma]	3.1699250014423126	4	2	0	0
4116	1247	activate protein-1 ap-1	[activating protein-1 AP-1]	3.1699250014423126	3	2	0	0
4117	1247	unprimed CD4 T cell	[unprimed CD4 T cells]	3.1699250014423126	4	2	0	0
4118	1247	DRE 1 regulatory sequence	[DRE 1 regulatory sequence]	3.1699250014423126	4	2	0	0
4119	1247	mature peripheral T lymphocyte	[mature peripheral T lymphocytes]	3.1699250014423126	4	2	0	0
4120	1247	use in vivo footprinting	[Using in vivo footprinting]	3.1699250014423126	4	3	1	1
4121	1247	cell culture system	[cell culture system]	3.1699250014423126	3	2	0	0
4122	1247	cell cycle regulator e2f	[cell cycle regulator E2F]	3.1699250014423126	4	2	0	0
4123	1247	follicular dendritic cell FDC	[follicular dendritic cells FDC]	3.1699250014423126	4	2	0	0
4124	1247	pwm B-cell mitogenesis	[PWM B-cell mitogenesis]	3.1699250014423126	3	2	0	0
4125	1247	induction of glutamine synthetase	[induction of glutamine synthetase]	3.1699250014423126	4	2	0	0
4126	1247	assembly of pr complex	[assembly of PR complexes]	3.1699250014423126	4	2	0	0
4127	1247	presence of a excess	[presence of a excess]	3.1699250014423126	4	2	0	0
4128	1247	human B29 gene	[human B29 gene]	3.1699250014423126	3	2	0	0
4129	1247	tsp 1 gene	[TSP 1 gene]	3.1699250014423126	3	3	2	2
4130	1247	adenovirus major late promoter	[adenovirus major late promoter]	3.1699250014423126	4	2	0	0
4131	1247	HSV-1 icp4 promoter	[HSV-1 ICP4 promoter]	3.1699250014423126	3	2	0	0
4132	1247	mechanism for the effect	[mechanism for the effects]	3.1699250014423126	4	3	3	3
4133	1247	Janus protein- tyrosine kinase	[Janus protein- tyrosine kinase]	3.1699250014423126	4	2	0	0
4134	1247	transcription factor nf-atc	[transcription factor NF-ATc]	3.1699250014423126	3	2	0	0
4135	1247	CMV Ie gene	[CMV IE genes]	3.1699250014423126	3	3	1	1
4136	1247	early stage of development.	[early stage of development.]	3.1699250014423126	4	2	0	0
4137	1247	expression of molecule	[expression of molecules]	3.1699250014423126	3	3	3	3
4138	1247	pkc enzymatic activity	[PKC enzymatic activity]	3.1699250014423126	3	3	3	3
4139	1247	c-Jun N-terminal kinase	[c-Jun N-terminal kinase]	3.1699250014423126	3	3	1	1
4140	1247	denature polyacrylamide gel electrophoresis	[denaturing polyacrylamide gel electrophoresis]	3.1699250014423126	4	2	0	0
4141	1247	2 receptor alpha-chain	[2 receptor alpha-chain]	3.1699250014423126	3	3	2	2
4142	1247	erythroid/megakaryocytic cell line	[erythroid/megakaryocytic cell lines]	3.1699250014423126	3	2	0	0
4143	1247	tat-i gene product	[tat-I gene product]	3.1699250014423126	3	2	0	0
4144	1247	pregnancy-induced hypertension PIH	[Pregnancy-induced hypertension PIH]	3.1699250014423126	3	2	0	0
4145	1247	use of immunohistochemistry	[use of immunohistochemistry]	3.1699250014423126	3	2	0	0
4146	1247	mutation of residue	[mutation of residues]	3.1699250014423126	3	2	0	0
4147	1247	lymphocyte of woman	[lymphocytes of women]	3.1699250014423126	3	3	3	3
4148	1247	normal human T lymphocyte	[normal human T lymphocytes]	3.1699250014423126	4	2	0	0
4149	1247	human MHC class	[human MHC class]	3.1699250014423126	3	3	3	3
4150	1247	monocytic cell differentiation	[monocytic cell differentiation]	3.1699250014423126	3	2	0	0
4151	1247	role of mineralocorticoid	[role of mineralocorticoids]	3.1699250014423126	3	3	1	1
4152	1247	induction of terminal differentiation	[induction of terminal differentiation]	3.1699250014423126	4	2	0	0
4153	1247	effect of agent	[effects of agents]	3.1699250014423126	3	3	3	3
4154	1247	p38 map kinase	[p38 MAP kinase]	3.1699250014423126	3	3	2	2
4155	1247	U2 snrna transcription	[U2 snRNA transcription]	3.1699250014423126	3	3	1	1
4156	1247	transcription factor egr1	[transcription factor EGR1]	3.1699250014423126	3	2	0	0
4157	1247	response to M-CSF	[response to M-CSF]	3.1699250014423126	3	2	0	0
4158	1247	interleukin-2 IL-2 promoter	[interleukin-2 IL-2 promoter]	3.1699250014423126	3	2	0	0
4159	1247	73 kda protein	[73 kDa protein]	3.1699250014423126	3	2	0	0
4160	1247	IFN gene expression	[IFN gene expression]	3.1699250014423126	3	2	0	0
4161	1247	polymerase chain reaction amplification	[polymerase chain reaction amplification]	3.1699250014423126	4	2	0	0
4162	1247	high-level nf-kappab activation	[high-level NF-kappaB activation]	3.1699250014423126	3	2	0	0
4163	1247	peripheral mononuclear leucocyte	[peripheral mononuclear leucocytes]	3.1699250014423126	3	2	0	0
4164	1247	T lymphocyte from patient	[T lymphocytes from patients]	3.1699250014423126	4	2	0	0
4165	1247	rnase protection assay	[RNase protection assay]	3.1699250014423126	3	2	0	0
4166	1247	I kappa b protein	[I kappa B proteins]	3.1699250014423126	4	2	0	0
4167	1247	human t-cell receptor delta	[human T-cell receptor delta]	3.1699250014423126	4	2	0	0
4168	1247	effect on the induction	[effect on the induction]	3.1699250014423126	4	3	3	3
4169	1247	nuclei of lymphocyte	[nuclei of lymphocytes]	3.1699250014423126	3	3	3	3
4170	1247	maltose binding protein mbp	[Maltose Binding Protein MBP]	3.1699250014423126	4	2	0	0
4171	1247	response to PMA	[response to PMA]	3.1699250014423126	3	3	1	1
4172	1247	ability of zap-70	[ability of ZAP-70]	3.1699250014423126	3	2	0	0
4173	1247	early invasive disease	[early invasive disease]	3.1699250014423126	3	2	0	0
4174	1247	unrearranged TcR delta gene	[unrearranged TcR delta gene]	3.1699250014423126	4	2	0	0
4175	1247	complete haematological remission CHR	[complete haematological remission CHR]	3.1699250014423126	4	2	0	0
4176	1247	T cell growth	[T cell growth]	3.1699250014423126	3	3	2	2
4177	1247	wild-type b cell	[wild-type B cells]	3.1699250014423126	3	3	2	2
4178	1247	analog of DHEA	[analog of DHEA]	3.1699250014423126	3	2	0	0
4179	1247	progression to aids	[progression to AIDS]	3.1699250014423126	3	2	0	0
4180	1247	sickle cell anaemia	[sickle cell anaemia]	3.1699250014423126	3	2	0	0
4181	1247	several inflammatory cytokine	[several inflammatory cytokines]	3.1699250014423126	3	3	1	1
4182	1247	4 beta 1	[4 beta 1]	3.1699250014423126	3	3	2	2
4183	1247	T lymphocyte response	[T lymphocyte response]	3.1699250014423126	3	3	3	3
4184	1247	many cellular gene	[many cellular genes]	3.1699250014423126	3	3	1	1
4185	1247	downstream signal event	[downstream signaling events]	3.1699250014423126	3	3	2	2
4186	1247	interferon regulatory factor-1 gene	[interferon regulatory factor-1 gene]	3.1699250014423126	4	3	2	2
4187	1247	human beta-globin gene locus	[human beta-globin gene locus]	3.1699250014423126	4	2	0	0
4188	1247	hormone receptor status	[hormone receptor status]	3.1699250014423126	3	2	0	0
4189	1247	tyrosine phosphorylation of HS1	[tyrosine phosphorylation of HS1]	3.1699250014423126	4	3	1	1
4190	1247	rel/ NF-kappa B family	[rel/ NF-kappa B family]	3.1699250014423126	4	2	0	0
4191	1247	response of cell	[response of cells]	3.1699250014423126	3	3	2	2
4192	1247	cell surface enzyme immunoassay	[cell surface enzyme immunoassays]	3.1699250014423126	4	2	0	0
4193	1247	activation of stat6	[activation of STAT6]	3.1699250014423126	3	3	2	2
4194	1247	oral hairy leukoplakia	[oral hairy leukoplakia]	3.1699250014423126	3	3	1	1
4195	1247	1 long repeat	[1 long repeat]	3.1699250014423126	3	3	3	3
4196	1247	surface marker analysis	[surface marker analysis]	3.1699250014423126	3	2	0	0
4197	1247	human il-5 gene promoter	[human IL-5 gene promoter]	3.1699250014423126	4	2	0	0
4198	1247	induction of this gene	[induction of these genes]	3.1699250014423126	4	4	2	1
4199	1247	protein kinase c PKC	[protein kinase C PKC]	3.1699250014423126	4	3	2	2
4200	1247	promoter of cytokine gene	[promoters of cytokine genes]	3.1699250014423126	4	2	0	0
4201	1247	immunoglobulin chain enhancer	[immunoglobulin chain enhancer]	3.1699250014423126	3	3	3	3
4202	1247	Oct-2 transcription factor	[Oct-2 transcription factor]	3.1699250014423126	3	2	0	0
4203	1247	T cell from donor	[T cells from donors]	3.1699250014423126	4	3	3	3
4204	1247	class gene expression	[class gene expression]	3.1699250014423126	3	3	3	3
4205	1247	response to epo	[response to EPO]	3.1699250014423126	3	2	0	0
4206	1247	strong inducible activity	[strongest inducible activity]	3.1699250014423126	3	2	0	0
4207	1247	il-2r alpha gene expression	[IL-2R alpha gene expression]	3.1699250014423126	4	3	1	1
4208	1247	arachidonic acid release	[arachidonic acid release]	3.1699250014423126	3	2	0	0
4209	1247	primary lymphoid cell	[primary lymphoid cells]	3.1699250014423126	3	2	0	0
4210	1247	expression of cd23	[expression of CD23]	3.1699250014423126	3	2	0	0
4211	1247	expression of cd14	[expression of CD14]	3.1699250014423126	3	3	3	3
4212	1247	-70 GATA site	[-70 GATA site]	3.1699250014423126	3	2	0	0
4213	1247	methylation interference analysis	[Methylation interference analysis]	3.1699250014423126	3	3	1	1
4214	1247	il-1 receptor antagonist il-1ra	[IL-1 receptor antagonist IL-1ra]	3.1699250014423126	4	2	0	0
4215	1247	activation of transcription	[activation of transcription]	3.1699250014423126	3	3	2	2
4216	1247	ZEBRA activation region	[ZEBRA activation region]	3.1699250014423126	3	2	0	0
4217	1247	ige isotype switch	[IgE isotype switching]	3.1699250014423126	3	4	2	1
4218	1247	Erythroid kruppel-like factor EKLF	[Erythroid Kruppel-like factor EKLF]	3.1699250014423126	4	2	0	0
4219	1247	Peripheral blood T cell	[Peripheral blood T cells]	3.1699250014423126	4	2	0	0
4220	1247	CAT reporter gene expression	[CAT reporter gene expression]	3.1699250014423126	4	2	0	0
4221	1247	ptk inhibitor herbimycin a	[PTK inhibitor herbimycin A]	3.1699250014423126	4	2	0	0
4222	1247	ultra-violet cross-linking study	[UV cross-linking studies]	3.1699250014423126	3	2	0	0
4223	1247	interference with transcription factor	[interference with transcription factors]	3.1699250014423126	4	3	3	3
4224	1247	DNase I footprinting	[DNase I footprinting]	3.1699250014423126	3	2	0	0
4225	1247	Ca(2+)-activated K+ channel	[Ca(2+)-activated K+ channel]	3.1699250014423126	3	2	0	0
4226	1247	DNA binding specificity	[DNA binding specificity]	3.1699250014423126	3	3	3	3
4227	1247	increase in mrna	[increase in mRNA]	3.1699250014423126	3	3	2	2
4228	1247	alpha, 25-dihydroxyvitamin D3	[alpha, 25-dihydroxyvitamin D3]	3.1699250014423126	3	3	3	3
4229	1247	interferon factor-1 gene	[interferon factor-1 gene]	3.1699250014423126	3	3	3	3
4230	1247	t-cell receptor complex	[T-cell receptor complex]	3.1699250014423126	3	2	0	0
4231	1247	decrease of the number	[decrease of the number]	3.1699250014423126	4	2	0	0
4232	1247	active v-abl protein	[active v-abl protein]	3.1699250014423126	3	2	0	0
4233	1247	t-cell by HTLV-1	[T-cells by HTLV-1]	3.1699250014423126	3	2	0	0
4234	1247	macrophage colony-stimulating factor m-csf	[macrophage colony-stimulating factor M-CSF]	3.1699250014423126	4	2	0	0
4235	1247	human RAR alpha	[human RAR alpha]	3.1699250014423126	3	3	1	1
4236	1247	phorbol ester-induced differentiation	[phorbol ester-induced differentiation]	3.1699250014423126	3	3	3	3
4237	1247	tcr zeta chain	[TCR zeta chain]	3.1699250014423126	3	2	0	0
4238	1247	RA receptor rar	[RA receptors RARs]	3.1699250014423126	3	3	2	2
4239	1247	GC in human monocyte	[GC in human monocytes]	3.1699250014423126	4	2	0	0
4240	1247	subunit of protein kinase	[subunit of protein kinase]	3.1699250014423126	4	3	3	3
4241	1247	such as cytokine	[such as cytokines]	3.1699250014423126	3	2	0	0
4242	1247	vivo protein-DNA interaction	[vivo protein-DNA interactions]	3.1699250014423126	3	2	0	0
4243	1247	platelet thromboxane receptor	[platelet thromboxane receptors]	3.1699250014423126	3	3	1	1
4244	1247	human peripheral-blood granulocyte	[human peripheral-blood granulocytes]	3.1699250014423126	3	2	0	0
4245	1247	protein kinase a pathway	[protein kinase A pathway]	3.1699250014423126	4	2	0	0
4246	1247	end of the month	[end of the month]	3.1699250014423126	4	2	0	0
4247	1247	cd45r0 T helper subset	[CD45R0 T helper subsets]	3.1699250014423126	4	2	0	0
4248	1247	array of cellular gene	[array of cellular genes]	3.1699250014423126	4	2	0	0
4249	1247	t-lymphocyte cell line	[T-lymphocyte cell line]	3.1699250014423126	3	3	3	3
4250	1247	several regulatory element	[several regulatory elements]	3.1699250014423126	3	3	2	2
4251	1247	analysis of nuclear extract	[analysis of nuclear extracts]	3.1699250014423126	4	3	2	2
4252	1247	cell with lps	[cells with LPS]	3.1699250014423126	3	3	2	2
4253	1247	unactivated T cell	[unactivated T cells]	3.1699250014423126	3	3	2	2
4254	1247	effect of Nef	[effects of Nef]	3.1699250014423126	3	3	2	2
4255	1247	primary biliary cirrhosis	[primary biliary cirrhosis]	3.1699250014423126	3	2	0	0
4256	1247	nuclear matrix attachment	[nuclear matrix attachment]	3.1699250014423126	3	3	1	1
4257	1247	ligand binding domain	[ligand binding domain]	3.1699250014423126	3	3	1	1
4258	1247	group of transcription factor	[group of transcription factors]	3.1699250014423126	4	3	1	1
4259	1247	follow phorbol ester treatment	[following phorbol ester treatment]	3.1699250014423126	4	2	0	0
4260	1247	untreated patient with disorder	[untreated patients with disorder]	3.1699250014423126	4	3	3	3
4261	1247	cytotoxic T cell	[cytotoxic T cells]	3.1699250014423126	3	3	1	1
4262	1247	expression of e2f1	[expression of E2F1]	3.1699250014423126	3	2	0	0
4263	1247	cell lack gamma(c)	[cells lacking gamma(c)]	3.1699250014423126	3	2	0	0
4264	1247	regulation of germline transcription	[regulation of germline transcription]	3.1699250014423126	4	3	1	1
4265	1247	nuclear factor-kappaB activation	[nuclear factor-kappaB activation]	3.1699250014423126	3	3	1	1
4266	1247	phorbol ester tpa	[phorbol ester TPA]	3.1699250014423126	3	2	0	0
4267	1247	response to anti-CD3	[response to anti-CD3]	3.1699250014423126	3	2	0	0
4268	1247	transcription of RALDH2	[transcription of RALDH2]	3.1699250014423126	3	2	0	0
4269	1247	response to phorbol ester	[response to phorbol esters]	3.1699250014423126	4	2	0	0
4270	1247	treatment of hl-60 cell	[treatment of HL-60 cells]	3.1699250014423126	4	3	3	3
4271	1247	novel serine /threonine kinase	[novel serine /threonine kinase]	3.1699250014423126	4	2	0	0
4272	1247	diameter of the pcv	[diameter of the PCVs]	3.1699250014423126	4	2	0	0
4273	1247	murine erythroleukemia cell	[murine erythroleukemia cells]	3.1699250014423126	3	2	0	0
4274	1247	cyclic protein kinase	[cyclic protein kinases]	3.1699250014423126	3	3	3	3
4275	1247	p50/p65 nf-kappa b	[p50/p65 NF-kappa B]	3.1699250014423126	3	2	0	0
4276	1247	tyrosine phosphorylation of JAK1	[tyrosine phosphorylation of JAK1]	3.1699250014423126	4	2	0	0
4277	1247	use a probe	[using a probe]	3.1699250014423126	3	3	3	3
4278	1247	lysosomal acid lipase	[lysosomal acid lipase]	3.1699250014423126	3	3	3	3
4279	1247	acute leukemia aml	[acute leukemia AML]	3.1699250014423126	3	3	3	3
4280	1247	binding of cellular factor	[binding of cellular factors]	3.1699250014423126	4	3	2	2
4281	1247	phagocytosis of apoptotic neutrophil	[phagocytosis of apoptotic neutrophils]	3.1699250014423126	4	2	0	0
4282	1247	T cell from patient	[T cells from patients]	3.1699250014423126	4	2	0	0
4283	1247	agonist-induced cell adhesion	[agonist-induced cell adhesion]	3.1699250014423126	3	4	4	2
4284	1247	nuclear stat protein	[nuclear STAT protein]	3.1699250014423126	3	2	0	0
4285	1247	androgen insensitivity syndrome	[androgen insensitivity syndrome]	3.1699250014423126	3	3	3	3
4286	1247	heme biosynthetic pathway	[heme biosynthetic pathway]	3.1699250014423126	3	2	0	0
4287	1247	expression of bcl-xl	[Expression of Bcl-xL]	3.1699250014423126	3	3	1	1
4288	1247	nuclear extract from monocyte	[nuclear extracts from monocytes]	3.1699250014423126	4	2	0	0
4289	1247	degree of inhibition	[degree of inhibition]	3.1699250014423126	3	3	1	1
4290	1247	healthy male volunteer	[healthy male volunteers]	3.1699250014423126	3	3	3	3
4291	1247	T cell by HTLV-I	[T cells by HTLV-I]	3.1699250014423126	4	2	0	0
4292	1247	interferon-stimulated response element	[interferon-stimulated response element]	3.1699250014423126	3	3	2	2
4293	1247	regulation of corticosteroid receptor	[regulation of corticosteroid receptors]	3.1699250014423126	4	2	0	0
4294	1247	HTLV-I basal transcription	[HTLV-I basal transcription]	3.1699250014423126	3	2	0	0
4295	1247	M. tuberculosis ManLAM	[M. tuberculosis ManLAM]	3.1699250014423126	3	2	0	0
4296	1247	reciprocal chromosomal translocation	[reciprocal chromosomal translocation]	3.1699250014423126	3	2	0	0
4297	1247	increase in the activity	[increase in the activity]	3.1699250014423126	4	3	3	3
4298	1247	transmission of signal	[transmission of signals]	3.1699250014423126	3	2	0	0
4299	1247	type ii IL-1R	[type II IL-1R]	3.1699250014423126	3	2	0	0
4300	1247	cyclin-dependent kinase inhibitor p27kip1	[cyclin-dependent kinase inhibitor p27Kip1]	3.1699250014423126	4	2	0	0
4301	1247	CD28 cell surface molecule	[CD28 cell surface molecule]	3.1699250014423126	4	2	0	0
4302	1247	level of c-fo	[levels of c-Fos]	3.1699250014423126	3	3	2	2
4303	1247	affinity for dexamethasone	[affinity for dexamethasone]	3.1699250014423126	3	3	2	2
4304	1247	LTR from SIVsmmPBj14	[LTR from SIVsmmPBj14]	3.1699250014423126	3	2	0	0
4305	1247	general transcription factor	[general transcription factor]	3.1699250014423126	3	3	3	3
4306	1247	effect of aldosterone	[effects of aldosterone]	3.1699250014423126	3	3	2	2
4307	1247	glucocorticoid receptor characteristic	[glucocorticoid receptor characteristics]	3.1699250014423126	3	4	2	1
4308	1247	implication for therapy	[implications for therapy]	3.1699250014423126	3	3	3	3
4309	1247	analysis of DNA	[analysis of DNA]	3.1699250014423126	3	2	0	0
4310	1247	effect of aspirin	[effect of aspirin]	3.1699250014423126	3	3	2	2
4311	1247	Epstein-Barr virus antigen 2	[Epstein-Barr virus antigen 2]	3.1699250014423126	4	4	4	2
4312	1247	HTLV-I tax expression	[HTLV-I Tax expression]	3.1699250014423126	3	2	0	0
4313	1247	human b-cell line	[human B-cell line]	3.1699250014423126	3	3	2	2
4314	1247	suggest the presence	[suggesting the presence]	3.1699250014423126	3	4	4	2
4315	1247	CsA -sensitive manner	[CsA -sensitive manner]	3.1699250014423126	3	2	0	0
4316	1247	ifn-gamma gene expression	[IFN-gamma gene expression]	3.1699250014423126	3	3	1	1
4317	1247	Ikaros binding site	[Ikaros binding site]	3.1699250014423126	3	2	0	0
4318	1247	restriction fragment length polymorphism	[restriction fragment length polymorphism]	3.1699250014423126	4	3	2	2
4319	1247	lymphoblastoid cell line LCLs	[lymphoblastoid cell lines LCLs]	3.1699250014423126	4	2	0	0
4320	1247	arsenic content in hair	[arsenic content in hair]	3.1699250014423126	4	2	0	0
4321	1247	many other cell types,	[many other cell types,]	3.1699250014423126	4	2	0	0
4322	1247	activity of nf-kappab	[activity of NF-kappaB]	3.1699250014423126	3	3	3	3
4323	1247	rest g0/g1 state	[resting G0/G1 state]	3.1699250014423126	3	2	0	0
4324	1247	proliferation of pbmc	[proliferation of PBMCs]	3.1699250014423126	3	2	0	0
4325	1247	absence of dm	[absence of DM]	3.1699250014423126	3	2	0	0
4326	1247	leukocyte adhesion molecule	[leukocyte adhesion molecule]	3.1699250014423126	3	3	2	2
4327	1247	human whole blood	[human whole blood]	3.1699250014423126	3	3	2	2
4328	1247	three 21 bp repeat	[three 21 bp repeats]	3.1699250014423126	4	2	0	0
4329	1247	variety of adhesion molecule	[variety of adhesion molecules]	3.1699250014423126	4	2	0	0
4330	1247	AP-1 transcription factor family	[AP-1 transcription factor family]	3.1699250014423126	4	2	0	0
4331	1247	induction of dna-binding protein	[induction of DNA-binding proteins]	3.1699250014423126	4	2	0	0
4332	1247	distal enhancer element	[distal enhancer element]	3.1699250014423126	3	2	0	0
4333	1247	inactive cytoplasmic complex	[inactive cytoplasmic complex]	3.1699250014423126	3	2	0	0
4334	1247	IL-2R gamma chain	[IL-2R gamma chain]	3.1699250014423126	3	2	0	0
4335	1247	immunosuppressive drug cyclosporin a	[immunosuppressive drugs cyclosporin A]	3.1699250014423126	4	3	1	1
4336	1247	patient with immunodeficiency	[patient with immunodeficiency]	3.1699250014423126	3	3	3	3
4337	1247	inhibition of growth	[inhibition of growth]	3.1699250014423126	3	3	1	1
4338	1247	factor of t-cell	[factor of T-cells]	3.1699250014423126	3	3	3	3
4339	1247	PML/RARalpha transgenic mouse	[PML/RARalpha transgenic mice]	3.1699250014423126	3	3	1	1
4340	1247	il-5 gene transcription	[IL-5 gene transcription]	3.1699250014423126	3	3	2	2
4341	1247	role of element	[role of elements]	3.1699250014423126	3	3	3	3
4342	1247	major depressive disorder MDD	[major depressive disorder MDD]	3.1699250014423126	4	3	2	2
4343	1247	Epstein-Barr virus latent	[Epstein-Barr virus latent]	3.1699250014423126	3	6	4	1
4344	1247	presence of il-4	[presence of IL-4]	3.1699250014423126	3	2	0	0
4345	1247	Tat -responsive element	[Tat -responsive element]	3.1699250014423126	3	2	0	0
4346	1247	RAR alpha gene	[RAR alpha gene]	3.1699250014423126	3	2	0	0
4347	1247	human mineralocorticoid receptor	[human mineralocorticoid receptor]	3.1699250014423126	3	4	2	1
4348	1247	more slowly migrate	[more slowly migrating]	3.1699250014423126	3	2	0	0
4349	1247	change in the activity	[changes in the activity]	3.1699250014423126	4	2	0	0
4350	1247	15 amino acid	[15 amino acids]	3.1699250014423126	3	3	2	2
4351	1247	vitro transcription study	[vitro transcription studies]	3.1699250014423126	3	2	0	0
4352	1247	anti- CD28 MoAb	[anti- CD28 MoAb]	3.1699250014423126	3	3	2	2
4353	1247	T cell receptor/CD3 complex	[T cell receptor/CD3 complex]	3.1699250014423126	4	2	0	0
4354	1247	RXR alpha expression	[RXR alpha expression]	3.1699250014423126	3	2	0	0
4355	1247	bursa of Fabricius	[bursa of Fabricius]	3.1699250014423126	3	2	0	0
4356	1247	NF-kappa b translocation	[NF-kappa B translocation]	3.1699250014423126	3	3	2	2
4357	1247	rest T lymphocyte	[resting T lymphocytes]	3.1699250014423126	3	3	1	1
4358	1247	NF-kappaB -dependent signal pathway	[NF-kappaB -dependent signaling pathway]	3.1699250014423126	4	3	1	1
4359	1247	DNA response element	[DNA response element]	3.1699250014423126	3	3	3	3
4360	1247	adenovirus e2 promoter	[adenovirus E2 promoter]	3.1699250014423126	3	2	0	0
4361	1247	infection of b lymphocyte	[infection of B lymphocytes]	3.1699250014423126	4	3	2	2
4362	1247	ifn-gamma stat activation	[IFN-gamma STAT activation]	3.1699250014423126	3	2	0	0
4363	1247	other stat protein	[other STAT protein]	3.1699250014423126	3	3	2	2
4364	1247	granulocyte colony-stimulating factor g-csf	[granulocyte colony-stimulating factor G-CSF]	3.1699250014423126	4	2	0	0
4365	1247	human immunodeficiency virus enhancer	[human immunodeficiency virus enhancer]	3.1699250014423126	4	2	0	0
4366	1247	high order nucleoprotein complex	[higher order nucleoprotein complex]	3.1699250014423126	4	2	0	0
4367	1247	hour time culture	[hours time culture]	3.1699250014423126	3	4	4	2
4368	1247	beta-casein gene by cytokine	[beta-casein gene by cytokines]	3.1699250014423126	4	2	0	0
4369	1247	B-cell lymphocytic leukemia	[B-cell lymphocytic leukemia]	3.1699250014423126	3	3	3	3
4370	1247	differentiate erythroid cell	[differentiating erythroid cells]	3.1699250014423126	3	2	0	0
4371	1247	transcription of several gene	[transcription of several genes]	3.1699250014423126	4	3	3	3
4372	1247	important transcription factor	[important transcription factor]	3.1699250014423126	3	3	1	1
4373	1247	coagulation protease cascade	[coagulation protease cascades]	3.1699250014423126	3	2	0	0
4374	1247	primary DNA breakage	[primary DNA breakage]	3.1699250014423126	3	2	0	0
4375	1247	DNA damage-induced apoptosis	[DNA damage-induced apoptosis]	3.1699250014423126	3	3	2	2
4376	1247	X chromosome inactivation	[X chromosome inactivation]	3.1699250014423126	3	3	2	2
4377	1247	study the mechanism	[studying the mechanisms]	3.1699250014423126	3	3	3	3
4378	1247	NF-kappa b -dependent gene	[NF-kappa B -dependent gene]	3.1699250014423126	4	2	0	0
4379	1247	winged-helix transcription factor Trident	[winged-helix transcription factor Trident]	3.1699250014423126	4	2	0	0
4380	1247	granulocyte-colony stimulate factor g-csf	[granulocyte-colony stimulating factor G-CSF]	3.1699250014423126	4	2	0	0
4381	1247	initiation of transcription	[initiation of transcription]	3.1699250014423126	3	3	1	1
4382	1247	AIR-1 locus defect	[AIR-1 locus defect]	3.1699250014423126	3	2	0	0
4383	1247	gr -dependent transcription	[GR -dependent transcription]	3.1699250014423126	3	3	2	2
4384	1247	treatment of b lymphocyte	[Treatment of B lymphocytes]	3.1699250014423126	4	3	2	2
4385	1247	ability of CD40	[ability of CD40]	3.1699250014423126	3	3	1	1
4386	1247	long term culture	[long term culture]	3.1699250014423126	3	2	0	0
4387	1247	response to cytokine	[response to cytokines]	3.1699250014423126	3	3	2	2
4388	1247	absence of tetracycline	[absence of tetracycline]	3.1699250014423126	3	2	0	0
4389	1247	induction of NF-kappa b	[induction of NF-kappa B]	3.1699250014423126	4	3	2	2
4390	1247	hla class molecule	[HLA class molecules]	3.1699250014423126	3	4	4	2
4391	1247	process of differentiation	[process of differentiation]	3.1699250014423126	3	3	3	3
4392	1247	induction of il-8 expression	[induction of IL-8 expression]	3.1699250014423126	4	3	1	1
4393	1247	calcineurin /nfat pathway	[calcineurin /NFAT pathway]	3.1699250014423126	3	2	0	0
4394	1247	alternative rna splicing	[alternative RNA splicing]	3.1699250014423126	3	2	0	0
4395	1247	mouse mammary tumor	[mouse mammary tumor]	3.1699250014423126	3	2	0	0
4396	1247	induction of the enhancer	[induction of the enhancer]	3.1699250014423126	4	2	0	0
4397	1247	level of p56lck	[levels of p56lck]	3.1699250014423126	3	2	0	0
4398	1247	treatment of rwleu-4 cell	[Treatment of RWLeu-4 cells]	3.1699250014423126	4	2	0	0
4399	1247	peri-kappa b site	[peri-kappa B site]	3.1699250014423126	3	3	1	1
4400	1247	expression of WT1	[expression of WT1]	3.1699250014423126	3	3	3	3
4401	1247	cell activation signal	[cell activation signals]	3.1699250014423126	3	3	2	2
4402	1247	mature b-cell line	[mature B-cell line]	3.1699250014423126	3	3	1	1
4403	1247	nf-kappa b /rel protein	[NF-kappa B /Rel proteins]	3.1699250014423126	4	2	0	0
4404	1247	viral lytic cycle	[viral lytic cycle]	3.1699250014423126	3	3	1	1
4405	1247	surface of T cell	[surface of T cells]	3.1699250014423126	4	2	0	0
4406	1247	splenic b cell	[splenic B cells]	3.1699250014423126	3	3	2	2
4407	1247	tiny ring x chromosome	[tiny ring X chromosome]	3.1699250014423126	4	3	1	1
4408	1247	t-cell nuclear extract	[T-cell nuclear extracts]	3.1699250014423126	3	3	2	2
4409	1247	Cushing' disease patient	[Cushing's disease patients]	3.1699250014423126	3	2	0	0
4410	1247	basic helix-loop-helix domain	[basic helix-loop-helix domain]	3.1699250014423126	3	2	0	0
4411	1247	variety of cell types.	[variety of cell types.]	3.1699250014423126	4	3	1	1
4412	1247	phosphorylation of pecam-1	[phosphorylation of PECAM-1]	3.1699250014423126	3	2	0	0
4413	1247	member of this family,	[member of this family,]	3.1699250014423126	4	3	2	2
4414	1247	inhibitor of nf-kappa b	[inhibitor of NF-kappa B]	3.1699250014423126	4	4	2	1
4415	1247	increase in transcription	[increase in transcription]	3.1699250014423126	3	3	2	2
4416	1247	mrna stability study	[mRNA stability studies]	3.1699250014423126	3	2	0	0
4417	1247	endothelial cell surface	[endothelial cell surface]	3.1699250014423126	3	2	0	0
4418	1247	C-JUN as oligonucleotide	[C-JUN AS oligonucleotides]	3.1699250014423126	3	3	3	3
4419	1247	B-cell chronic leukemia	[B-cell chronic leukemia]	3.1699250014423126	3	3	3	3
4420	1247	arm of chromosome	[arm of chromosome]	3.1699250014423126	3	3	3	3
4421	1247	however, in contrast	[However, in contrast]	3.1699250014423126	3	4	4	2
4422	1247	week of treatment	[week of treatment]	3.1699250014423126	3	3	3	3
4423	1247	X box region	[X box region]	3.1699250014423126	3	2	0	0
4424	1247	dna-binding specificity similar	[DNA-binding specificity similar]	3.1699250014423126	3	2	0	0
4425	1247	hepatitis b virus infection	[hepatitis B virus infection]	3.1699250014423126	4	3	3	3
4426	1247	alternative polyadenylation event	[Alternative polyadenylation events]	3.1699250014423126	3	2	0	0
4427	1247	inhibition of cell proliferation	[inhibition of cell proliferation]	3.1699250014423126	4	3	2	2
4428	1247	mature CD4 (+)	[mature CD4 (+)]	3.1699250014423126	3	2	0	0
4429	1247	progeny of stem cell	[progeny of stem cells]	3.1699250014423126	4	3	3	3
4430	1247	transdominant rev protein	[transdominant Rev protein]	3.1699250014423126	3	3	3	3
4431	1247	T cell precursor	[T cell precursors]	3.1699250014423126	3	2	0	0
4432	1247	human immunodeficiency virus promoter	[human immunodeficiency virus promoter]	3.1699250014423126	4	3	1	1
4433	1247	Bacterial lipopolysaccharide lps	[Bacterial lipopolysaccharide LPS]	3.1699250014423126	3	2	0	0
4434	1247	Epstein-Barr virus protein	[Epstein-Barr virus protein]	3.1699250014423126	3	3	3	3
4435	1247	functional synergy between IL-12	[functional synergy between IL-12]	3.1699250014423126	4	2	0	0
4436	1247	monoclonal antibody ki-67	[monoclonal antibody Ki-67]	3.1699250014423126	3	2	0	0
4437	1247	ap-1 -like factor	[AP-1 -like factors]	3.1699250014423126	3	2	0	0
4438	1247	Ig kappa b site	[Ig kappa B site]	3.1699250014423126	4	2	0	0
4439	1247	8 hour of infection.	[8 hr of infection.]	3.1699250014423126	4	2	0	0
4440	1247	non- b cell	[non- B cells]	3.1699250014423126	3	2	0	0
4441	1247	il-1 receptor antagonist secretion	[IL-1 receptor antagonist secretion]	3.1699250014423126	4	2	0	0
4442	1247	expression of rap1 protein	[expression of Rap1 protein]	3.1699250014423126	4	2	0	0
4443	1247	human IL-4 gene	[human IL-4 gene]	3.1699250014423126	3	3	1	1
4444	1247	anti-ig induction of c-fo	[anti-Ig induction of c-fos]	3.1699250014423126	4	2	0	0
4445	1247	DNA sequence analysis	[DNA sequence analysis]	3.1699250014423126	3	2	0	0
4446	1247	production of il-4	[production of IL-4]	3.1699250014423126	3	2	0	0
4447	1247	production of il-2	[production of IL-2]	3.1699250014423126	3	3	1	1
4448	1247	main transcription factor	[main transcription factor]	3.1699250014423126	3	2	0	0
4449	1247	anti- ro(ssa) antibody	[anti- Ro(SSA) antibodies]	3.1699250014423126	3	2	0	0
4450	1247	two reading frame orf	[two reading frames ORFs]	3.1699250014423126	4	3	3	3
4451	1247	transform growth factor-beta TGF-beta	[transforming growth factor-beta TGF-beta]	3.1699250014423126	4	2	0	0
4452	1247	hexamethylene bisacetamide hmba	[hexamethylene bisacetamide HMBA]	3.1699250014423126	3	2	0	0
4453	1247	electrophoretic mobility-shift assay	[electrophoretic mobility-shift assay]	3.1699250014423126	3	2	0	0
4454	1247	direct DNA sequencing	[direct DNA sequencing]	3.1699250014423126	3	2	0	0
4455	1247	persistent group c	[persistent group C]	3.1699250014423126	3	2	0	0
4456	1247	other hand, stimulation	[other hand, stimulation]	3.1699250014423126	3	2	0	0
4457	1247	change in mnda expression	[Changes in MNDA expression]	3.1699250014423126	4	2	0	0
4458	1247	heterologous activation domain	[heterologous activation domain]	3.1699250014423126	3	3	1	1
4459	1247	effect of SML cytosol	[effect of SML cytosol]	3.1699250014423126	4	2	0	0
4460	1247	high level of mineralocorticoid	[higher level of mineralocorticoids]	3.1699250014423126	4	2	0	0
4461	1247	multiple stat protein	[multiple STAT proteins]	3.1699250014423126	3	3	1	1
4462	1247	many cell types.	[many cell types.]	3.1699250014423126	3	3	1	1
4463	1247	four P-like element	[Four P-like elements]	3.1699250014423126	3	2	0	0
4464	1247	protein phosphatase inhibitor	[protein phosphatase inhibitor]	3.1699250014423126	3	3	2	2
4465	1247	Kruppel-related zinc finger gene	[Kruppel-related zinc finger genes]	3.1699250014423126	4	2	0	0
4466	1247	b cell culture	[B cell cultures]	3.1699250014423126	3	2	0	0
4467	1247	immunosuppressant cyclosporin a	[immunosuppressant cyclosporin A]	3.1699250014423126	3	3	1	1
4468	1247	expression of mcp-1	[expression of MCP-1]	3.1699250014423126	3	2	0	0
4469	1247	potential therapeutic target	[potential therapeutic target]	3.1699250014423126	3	3	2	2
4470	1247	nuclear hormone receptor	[nuclear hormone receptor]	3.1699250014423126	3	3	2	2
4471	1247	GM-CSFRalpha cytoplasmic domain	[GM-CSFRalpha cytoplasmic domain]	3.1699250014423126	3	2	0	0
4472	1247	erythroid gene expression	[erythroid gene expression]	3.1699250014423126	3	3	2	2
4473	1247	precursor of NF-kappa b	[precursor of NF-kappa B]	3.1699250014423126	4	2	0	0
4474	1247	include T cell	[including T cells]	3.1699250014423126	3	3	3	3
4475	1247	pathogenesis of aids	[pathogenesis of AIDS]	3.1699250014423126	3	2	0	0
4476	1247	DQ alpha gene	[DQ alpha gene]	3.1699250014423126	3	2	0	0
4477	1247	v-erb a oncogene	[v-erb A oncogene]	3.1699250014423126	3	2	0	0
4478	1247	T cell transcription factor	[T cells transcription factor]	3.1699250014423126	4	3	3	3
4479	1247	Oct2 transcription factor	[Oct2 transcription factor]	3.1699250014423126	3	2	0	0
4480	1247	anti- tnf-alpha antibody	[anti- TNF-alpha antibody]	3.1699250014423126	3	2	0	0
4481	1247	malignant tissue tumor	[malignant tissue tumors]	3.1699250014423126	3	3	3	3
4482	1247	mitogen-activated protein kinase cascade	[mitogen-activated protein kinase cascade]	3.1699250014423126	4	2	0	0
4483	1247	3/4 b-cell line	[3/4 B-cell lines]	3.1699250014423126	3	2	0	0
4484	1247	immunodeficiency virus promoter	[immunodeficiency virus promoter]	3.1699250014423126	3	3	3	3
4485	1247	include the enhancer	[including the enhancer]	3.1699250014423126	3	3	3	3
4486	1247	many inducible t-cell gene	[many inducible T-cell genes]	3.1699250014423126	4	2	0	0
4487	1247	t-cell receptor stimulation	[T-cell receptor stimulation]	3.1699250014423126	3	3	1	1
4488	1247	ebv type ebna-2	[EBV type EBNA-2]	3.1699250014423126	3	2	0	0
4489	1247	NF-kappa b precursor	[NF-kappa B precursor]	3.1699250014423126	3	2	0	0
4490	1247	amount of nf-kappa b	[amount of NF-kappa B]	3.1699250014423126	4	3	3	3
4491	1247	eosinophil cationic protein	[eosinophil cationic protein]	3.1699250014423126	3	3	1	1
4492	1247	AMP response element	[AMP response element]	3.1699250014423126	3	3	3	3
4493	1247	tyrosine phosphorylation of stat5a	[tyrosine phosphorylation of STAT5A]	3.1699250014423126	4	2	0	0
4494	1247	neutrophil tumor cell cytostasis	[neutrophil tumor cell cytostasis]	3.1699250014423126	4	2	0	0
4495	1247	requirement for induction	[requirements for induction]	3.1699250014423126	3	2	0	0
4496	1247	first A/R challenge	[first A/R challenge]	3.1699250014423126	3	2	0	0
4497	1247	physical interaction between calcineurin	[physical interaction between calcineurin]	3.1699250014423126	4	2	0	0
4498	1247	NF-kappa b gene	[NF-kappa B gene]	3.1699250014423126	3	3	2	2
4499	1247	inhibition of nf-kappab activity	[Inhibition of NF-kappaB activity]	3.1699250014423126	4	2	0	0
4500	1247	region of homology	[region of homology]	3.1699250014423126	3	3	2	2
4501	1247	effect of IL-4	[effect of IL-4]	3.1699250014423126	3	3	2	2
4502	1247	number of er	[number of ER]	3.1699250014423126	3	3	2	2
4503	1247	interaction of tax	[interaction of Tax]	3.1699250014423126	3	3	3	3
4504	1247	host-cell transcription factor	[host-cell transcription factors]	3.1699250014423126	3	2	0	0
4505	1247	latent membrane protein lmp1	[latent membrane protein LMP1]	3.1699250014423126	4	3	2	2
4506	1247	Moloney murine sarcoma virus	[Moloney murine sarcoma virus]	3.1699250014423126	4	2	0	0
4507	1247	consist of the domain	[consisting of the domain]	3.1699250014423126	4	3	3	3
4508	1247	late S phase	[late S phase]	3.1699250014423126	3	2	0	0
4509	1247	steroid receptor drug	[steroid receptor drugs]	3.1699250014423126	3	3	1	1
4510	1247	granzyme b promoter	[granzyme B promoter]	3.1699250014423126	3	3	1	1
4511	1247	interleukin-1 beta mrna	[interleukin-1 beta mRNA]	3.1699250014423126	3	3	3	3
4512	1247	NF-kappaB activation by LMP1	[NF-kappaB activation by LMP1]	3.1699250014423126	4	2	0	0
4513	1247	immunodeficiency syndrome AIDS	[immunodeficiency syndrome AIDS]	3.1699250014423126	3	3	1	1
4514	1247	nuclear protein-DNA complex	[nuclear protein-DNA complexes]	3.1699250014423126	3	2	0	0
4515	1247	line of mouse	[line of mice]	3.1699250014423126	3	3	3	3
4516	1247	nuclear factor NF-kappa b	[nuclear factor NF-kappa B]	3.1699250014423126	4	3	1	1
4517	1247	immune cell function	[immune cell function]	3.1699250014423126	3	2	0	0
4518	1247	correlation between infiltration	[correlation between infiltration]	3.1699250014423126	3	3	3	3
4519	1247	delta psi(m) collapse	[delta psi(m) collapse]	3.1699250014423126	3	3	1	1
4520	1247	il-2 deprivation apoptosis	[IL-2 deprivation apoptosis]	3.1699250014423126	3	2	0	0
4521	1247	5 nm D3	[5 nM D3]	3.1699250014423126	3	3	1	1
4522	1247	cytokine expression in monocyte	[cytokine expression in monocytes]	3.1699250014423126	4	3	1	1
4523	1247	nonsteroidal anti-inflammatory drug	[nonsteroidal anti-inflammatory drugs]	3.1699250014423126	3	3	3	3
4524	1247	transactivation domain of Stat6	[transactivation domain of Stat6]	3.1699250014423126	4	2	0	0
4525	1247	stimulation of CR1	[Stimulation of CR1]	3.1699250014423126	3	2	0	0
4526	1247	addition to role	[addition to role]	3.1699250014423126	3	3	1	1
4527	1247	use nuclear extract	[using nuclear extracts]	3.1699250014423126	3	3	2	2
4528	1247	mechanism of activation	[mechanism of activation]	3.1699250014423126	3	3	1	1
4529	1247	induction of cell proliferation	[induction of cell proliferation]	3.1699250014423126	4	2	0	0
4530	1247	activation in cell	[activation in cells]	3.1699250014423126	3	3	3	3
4531	1247	human il-4 promoter	[human IL-4 promoter]	3.1699250014423126	3	2	0	0
4532	1247	dose of lps	[dose of LPS]	3.1699250014423126	3	3	3	3
4533	1247	human malignant melanoma	[human malignant melanomas]	3.1699250014423126	3	3	3	3
4534	1247	concentration of D3	[concentrations of D3]	3.1699250014423126	3	2	0	0
4535	1247	transcriptional activator nf-kappa b	[transcriptional activator NF-kappa B]	3.1699250014423126	4	2	0	0
4536	1247	acetyl salicylic acid	[acetyl salicylic acid]	3.1699250014423126	3	3	2	2
4537	1247	protein tyrosine phosphatase ptpase	[protein tyrosine phosphatase PTPase]	3.1699250014423126	4	2	0	0
4538	1247	growth factor deprivation	[growth factor deprivation]	3.1699250014423126	3	2	0	0
4539	1247	mechanism of gene regulation	[mechanism of gene regulation]	3.1699250014423126	4	3	2	2
4540	1247	pathogenesis of atherosclerosis	[pathogenesis of atherosclerosis]	3.1699250014423126	3	2	0	0
4541	1247	effect on activation	[effect on activation]	3.1699250014423126	3	3	3	3
4542	1247	MHC class ii signal	[MHC class II signaling]	3.1699250014423126	4	2	0	0
4543	1247	classical mineralocorticoid antagonist	[classical mineralocorticoid antagonists]	3.1699250014423126	3	2	0	0
4544	1247	adherence of ss reticulocyte	[adherence of SS reticulocytes]	3.1699250014423126	4	2	0	0
4545	1247	generation of cytokine	[generation of cytokines]	3.1699250014423126	3	3	1	1
4546	1247	IL-2 promoter by Tpl-2	[IL-2 promoter by Tpl-2]	3.1699250014423126	4	2	0	0
4547	1247	malignant soft tissue tumor	[malignant soft tissue tumors]	3.1699250014423126	4	3	1	1
4548	1247	combination of anti-CD3	[combination of anti-CD3]	3.1699250014423126	3	2	0	0
4549	1247	normal bone marrow cell	[normal bone marrow cells]	3.1699250014423126	4	2	0	0
4550	1247	expression of marker	[expression of markers]	3.1699250014423126	3	3	3	3
4551	1247	NF-kappa b /rel family	[NF-kappa B /Rel family]	3.1699250014423126	4	2	0	0
4552	1247	gc -sensitive group	[GC -sensitive group]	3.1699250014423126	3	2	0	0
4553	1247	EBV lytic origin	[EBV lytic origin]	3.1699250014423126	3	3	1	1
4554	1247	nonhematopoietic cell line	[nonhematopoietic cell lines]	3.1699250014423126	3	3	1	1
4555	1247	downstream regulatory region	[downstream regulatory region]	3.1699250014423126	3	2	0	0
4556	1247	active form of calcineurin	[active form of calcineurin]	3.1699250014423126	4	3	1	1
4557	1247	expression of the enzyme	[expression of the enzyme]	3.1699250014423126	4	3	3	3
4558	1247	granulocyte colony-stimulating factor G-CSF	[granulocyte colony-stimulating factor G-CSF]	3.1699250014423126	4	2	0	0
4559	1247	expression of cd95 ligand	[expression of CD95 ligand]	3.1699250014423126	4	2	0	0
4560	1247	intracellular free calcium	[intracellular free calcium]	3.1699250014423126	3	2	0	0
4561	1247	1.955-kb viral segment	[1.955-kb viral segment]	3.1699250014423126	3	2	0	0
4562	1247	CMV Ie gene product	[CMV IE gene products]	3.1699250014423126	4	2	0	0
4563	1247	12-o-tetradecanoylphorbol 13-acetate tpa	[12-O-tetradecanoylphorbol 13-acetate TPA]	3.1699250014423126	3	3	1	1
4564	1247	receptor for il-2	[receptor for IL-2]	3.1699250014423126	3	2	0	0
4565	1247	ap-1 -dependent transcription	[AP-1 -dependent transcription]	3.1699250014423126	3	2	0	0
4566	1247	transcription factor NFkappaB	[transcription factor NFkappaB]	3.1699250014423126	3	2	0	0
4567	1247	sensitivity to RA	[sensitivity to RA]	3.1699250014423126	3	2	0	0
4568	1247	total cell lipid	[total cell lipids]	3.1699250014423126	3	2	0	0
4569	1247	bi- domain protein	[bi- domain protein]	3.1699250014423126	3	2	0	0
4570	1247	expression of fas ligand	[expression of Fas ligand]	3.1699250014423126	4	3	2	2
4571	1247	engagement of CD40	[engagement of CD40]	3.1699250014423126	3	2	0	0
4572	1247	es cell system	[ES cell system]	3.1699250014423126	3	2	0	0
4573	1247	recruitment of monocyte	[recruitment of monocytes]	3.1699250014423126	3	3	1	1
4574	1247	sequence of event	[sequence of events]	3.1699250014423126	3	3	2	2
4575	1247	sp family member	[Sp family members]	3.1699250014423126	3	4	2	1
4576	1247	blood of individual	[blood of individuals]	3.1699250014423126	3	3	3	3
4577	1247	NF-kappa b family	[NF-kappa B family]	3.1699250014423126	3	2	0	0
4578	1247	camp signal pathway	[cAMP signaling pathway]	3.1699250014423126	3	3	2	2
4579	1247	treatment of T lymphocyte	[treatment of T lymphocytes]	3.1699250014423126	4	3	2	2
4580	1247	differentiation of b cell	[differentiation of B cells]	3.1699250014423126	4	3	2	2
4581	1247	level of mrna	[level of mRNA]	3.1699250014423126	3	3	2	2
4582	1247	antibody to t-antigen	[antibodies to T-antigen]	3.1699250014423126	3	2	0	0
4583	1247	effect on regulation	[effect on regulation]	3.1699250014423126	3	3	3	3
4584	1247	statistically significant correlation	[statistically significant correlation]	3.1699250014423126	3	3	1	1
4585	1247	hla class ii antigen	[HLA class II antigens]	3.1699250014423126	4	3	2	2
4586	1247	human monocyte /macrophage	[human monocytes /macrophages]	3.1699250014423126	3	3	1	1
4587	1247	late time point	[later time point]	3.1699250014423126	3	3	1	1
4588	1247	binding of complex	[binding of complexes]	3.1699250014423126	3	3	3	3
4589	1247	pathogenesis of this disease	[pathogenesis of this disease.]	3.1699250014423126	4	2	0	0
4590	1247	inhibitory effect of dexamethasone	[inhibitory effect of dexamethasone]	3.1699250014423126	4	3	1	1
4591	1247	NF-kappaB activation pathway	[NF-kappaB activation pathway]	3.1699250014423126	3	2	0	0
4592	1247	Duffy blood group system	[Duffy blood group system]	3.1699250014423126	4	2	0	0
4593	1247	approximately 0.1 nm	[approximately 0.1 nM]	3.1699250014423126	3	2	0	0
4594	1247	tf gene expression	[TF gene expression]	3.1699250014423126	3	3	2	2
4595	1247	change in the level	[change in the level]	3.1699250014423126	4	3	2	2
4596	1247	Nuclear factor kappa b	[Nuclear factor kappa B]	3.1699250014423126	4	4	4	2
4597	1247	p21ras in T cell	[p21ras in T cells]	3.1699250014423126	4	2	0	0
4598	1247	polymerase chain reaction assay	[polymerase chain reaction assay]	3.1699250014423126	4	3	1	1
4599	1247	serious bacterial infection	[serious bacterial infections]	3.1699250014423126	3	2	0	0
4600	1247	IL-2 receptor alpha chain	[IL-2 receptor alpha chain]	3.1699250014423126	4	3	1	1
4601	1247	persistent hiv infection	[persistent HIV infection]	3.1699250014423126	3	3	2	2
4602	1247	interleukin-2 il-2 gene induction	[interleukin-2 IL-2 gene induction]	3.1699250014423126	4	2	0	0
4603	1247	rheumatoid arthritis patient	[rheumatoid arthritis patient]	3.1699250014423126	3	4	2	1
4604	1247	transgenic T cell	[transgenic T cells]	3.1699250014423126	3	2	0	0
4605	1247	human peripheral blood cell	[human peripheral blood cells]	3.1699250014423126	4	3	1	1
4606	1247	tcr alpha enhancer activity	[TCR alpha enhancer activity]	3.1699250014423126	4	2	0	0
4607	1247	human atherosclerotic lesion	[human atherosclerotic lesions]	3.1699250014423126	3	3	1	1
4608	1247	regulation during monocytic differentiation	[regulation during monocytic differentiation]	3.1699250014423126	4	4	4	2
4609	1247	tumor cell killing	[tumor cell killing]	3.1699250014423126	3	2	0	0
4610	1247	response of T cell	[response of T cells]	3.1699250014423126	4	3	2	2
4611	1247	primary cd4+ T cell	[primary CD4+ T cells]	3.1699250014423126	4	3	2	2
4612	1247	androgen receptor ar	[androgen receptor AR]	3.1699250014423126	3	3	1	1
4613	1247	form of nfatp	[form of NFATp]	3.1699250014423126	3	3	1	1
4614	1247	control of gene	[control of genes]	3.1699250014423126	3	3	3	3
4615	1247	zeta 2 globin promoter	[zeta 2 globin promoter]	3.1699250014423126	4	3	1	1
4616	1247	human primary haemopoietic cell	[human primary haemopoietic cells]	3.1699250014423126	4	3	1	1
4617	1247	distal 5' flank	[distal 5' flank]	3.1699250014423126	3	2	0	0
4618	1247	most potent antiinflammatory agent	[most potent antiinflammatory agents]	3.1699250014423126	4	2	0	0
4619	1247	oxygen radical scavenger	[oxygen radical scavenger]	3.1699250014423126	3	2	0	0
4620	1247	induction of a factor	[induction of a factor]	3.1699250014423126	4	3	3	3
4621	1247	analysis of the mechanism	[analysis of the mechanisms]	3.1699250014423126	4	2	0	0
4622	1247	different signal pathway	[different signaling pathways]	3.1699250014423126	3	3	3	3
4623	1247	naive th cell	[naive Th cells]	3.1699250014423126	3	3	1	1
4624	1247	IL-2 -independent growth	[IL-2 -independent growth]	3.1699250014423126	3	3	2	2
4625	1247	il-9 cell proliferation	[IL-9 cell proliferation]	3.1699250014423126	3	2	0	0
4626	1247	erythroid cell development	[erythroid cell development]	3.1699250014423126	3	3	2	2
4627	1247	effect on the number	[effect on the number]	3.1699250014423126	4	2	0	0
4628	1247	differentiation of u-937 cell	[Differentiation of U-937 cells]	3.1699250014423126	4	3	3	3
4629	1247	phorbol ester jurkat cell	[phorbol ester Jurkat cells]	3.1699250014423126	4	2	0	0
4630	1247	development of eosinophilia	[development of eosinophilia]	3.1699250014423126	3	2	0	0
4631	1247	IFN regulatory factor	[IFN regulatory factor]	3.1699250014423126	3	3	2	2
4632	1247	leukemia hl-60 cell	[leukemia HL-60 cells]	3.1699250014423126	3	4	4	2
4633	1247	cluster of gene	[Clusters of genes]	3.1699250014423126	3	3	1	1
4634	1247	electromobility shift assay EMSA	[electromobility shift assay EMSA]	3.1699250014423126	4	2	0	0
4635	1247	Granulocyte-macrophage colony-stimulating factor	[Granulocyte-macrophage colony-stimulating factor]	3.1699250014423126	3	2	0	0
4636	1247	anti-CD3 T cell	[anti-CD3 T cells]	3.1699250014423126	3	2	0	0
4637	1247	nf-kappa b site	[NF-kappa B site]	3.1699250014423126	3	3	2	2
4638	1247	bp deletion in exon	[bp deletion in exon]	3.1699250014423126	4	3	3	3
4639	1247	cellular redox status	[cellular redox status]	3.1699250014423126	3	3	1	1
4640	1247	kinetic of expression	[kinetics of expression]	3.1699250014423126	3	2	0	0
4641	1247	regulation of the gene	[regulation of the gene]	3.1699250014423126	4	3	2	2
4642	1247	granulocyte-macrophage colony-stimulating factor promoter	[granulocyte-macrophage colony-stimulating factor promoter]	3.1699250014423126	4	2	0	0
4643	1247	expression of LMP1	[Expression of LMP1]	3.1699250014423126	3	2	0	0
4644	1247	NF-kappa b sequence	[NF-kappa B sequence]	3.1699250014423126	3	2	0	0
4645	1247	base pair upstream	[base pairs upstream]	3.1699250014423126	3	3	3	3
4646	1247	purpose of this review	[purpose of this review]	3.1699250014423126	4	2	0	0
4647	1247	phosphorylation of protein	[phosphorylation of proteins]	3.1699250014423126	3	3	3	3
4648	1247	ability of tax	[ability of Tax]	3.1699250014423126	3	2	0	0
4649	1247	phosphatidylinositol 3-kinase pi 3-kinase	[phosphatidylinositol 3-kinase PI 3-kinase]	3.1699250014423126	4	3	2	2
4650	1247	primer extension analysis	[primer extension analysis]	3.1699250014423126	3	3	1	1
4651	1247	MHC class promoter	[MHC class promoters]	3.1699250014423126	3	4	4	2
4652	1247	interleukin 2 production.	[interleukin 2 production.]	3.1699250014423126	3	2	0	0
4653	1247	stimulation of monocyte	[stimulation of monocytes]	3.1699250014423126	3	3	3	3
4654	1247	transcriptional regulatory factor	[transcriptional regulatory factor]	3.1699250014423126	3	3	1	1
4655	1247	et transcription factor/oncoprotein family	[ets transcription factor/oncoprotein family]	3.1699250014423126	4	2	0	0
4656	1247	tar -independent transactivation	[TAR -independent transactivation]	3.1699250014423126	3	3	2	2
4657	1247	expression of tax	[expression of Tax]	3.1699250014423126	3	3	1	1
4658	1247	concentration of peptide	[concentrations of peptide]	3.1699250014423126	3	3	3	3
4659	1247	primary human monocyte	[primary human monocytes]	3.1699250014423126	3	3	2	2
4660	1247	lean body mass	[lean body mass]	3.1699250014423126	3	2	0	0
4661	1247	p75 tumor necrosis factor	[p75 tumor necrosis factor]	3.1699250014423126	4	2	0	0
4662	1247	activity in HeLa cell	[activity in HeLa cells]	3.1699250014423126	4	3	2	2
4663	1247	phorbol ester 12-o-tetradecanoylphorbol-13-acetate tpa	[phorbol ester 12-O-tetradecanoylphorbol-13-acetate TPA]	3.1699250014423126	4	3	1	1
4664	1247	neutrophil gelatinase-associated lipocalin NGAL	[Neutrophil gelatinase-associated lipocalin NGAL]	3.1699250014423126	4	2	0	0
4665	1247	DNA-protein binding study	[DNA-protein binding studies]	3.1699250014423126	3	2	0	0
4666	1247	normal peripheral blood lymphocyte	[normal peripheral blood lymphocytes]	3.1699250014423126	4	3	2	2
4667	1247	human intestinal receptor	[human intestinal receptor]	3.1699250014423126	3	2	0	0
4668	1247	pou domain transcription factor	[POU domain transcription factor]	3.1699250014423126	4	2	0	0
4669	1247	cyclic amp-dependent protein kinase	[cyclic AMP-dependent protein kinases]	3.1699250014423126	4	3	2	2
4670	1247	IL-2 gene promoter	[IL-2 gene promoter]	3.1699250014423126	3	2	0	0
4671	1247	active pulmonary tuberculosis	[active pulmonary tuberculosis]	3.1699250014423126	3	2	0	0
4672	1247	differentiation of hl-60	[differentiation of HL-60]	3.1699250014423126	3	3	3	3
4673	1247	enzyme-linked immunosorbent assay ELISA	[enzyme-linked immunosorbent assay ELISA]	3.1699250014423126	4	3	2	2
4674	1247	level of nf-kappab	[levels of NF-kappaB]	3.1699250014423126	3	3	3	3
4675	1247	normal erythroid development	[normal erythroid development]	3.1699250014423126	3	3	1	1
4676	1247	lack of expression	[lack of expression]	3.1699250014423126	3	2	0	0
4677	1247	lymphoma cell line	[lymphoma cell line]	3.1699250014423126	3	3	1	1
4678	1247	chemotaxis of pmn	[chemotaxis of PMNs]	3.1699250014423126	3	3	1	1
4679	1247	inducible, t-cell-specific factor	[inducible, T-cell-specific factor]	3.1699250014423126	3	2	0	0
4680	1247	aortic endothelial cell	[aortic endothelial cells]	3.1699250014423126	3	3	3	3
4681	1247	dephosphorylation of prb	[dephosphorylation of pRb]	3.1699250014423126	3	3	1	1
4682	1247	interleukin-6 gene expression	[interleukin-6 gene expression]	3.1699250014423126	3	2	0	0
4683	1247	th2 cell differentiation	[Th2 cell differentiation]	3.1699250014423126	3	3	2	2
4684	1247	dna-binding activity of e2f	[DNA-binding activity of E2F]	3.1699250014423126	4	2	0	0
4685	1247	CD28 surface molecule	[CD28 surface molecule]	3.1699250014423126	3	3	1	1
4686	1247	least 10 time	[least 10 times]	3.1699250014423126	3	2	0	0
4687	1247	naive CD4 T cell	[naive CD4 T cells]	3.1699250014423126	4	2	0	0
4688	1247	response to interleukin-2	[response to interleukin-2]	3.1699250014423126	3	3	1	1
4689	1247	small t allele mrna	[small t allele mRNA]	3.1699250014423126	4	2	0	0
4690	1247	mineralocorticoid in the pathophysiology	[mineralocorticoids in the pathophysiology]	3.1699250014423126	4	2	0	0
4691	1247	interaction of Tat	[interaction of Tat]	3.1699250014423126	3	2	0	0
4692	1247	cytoplasmic component of NF-AT	[cytoplasmic component of NF-AT]	3.1699250014423126	4	2	0	0
4693	1247	inhibition of transcription	[inhibition of transcription]	3.1699250014423126	3	3	1	1
4694	1247	retinoic acid treatment	[retinoic acid treatment]	3.1699250014423126	3	3	3	3
4695	1247	suggest a effect	[suggesting a effect]	3.1699250014423126	3	3	3	3
4696	1247	open reading frame orf	[open reading frames ORFs]	3.1699250014423126	4	3	3	3
4697	1247	number of cellular gene	[number of cellular genes]	3.1699250014423126	4	2	0	0
4698	1247	factor-kappa b activity	[factor-kappa B activity]	3.1699250014423126	3	3	3	3
4699	1247	difference in gene expression	[differences in gene expression]	3.1699250014423126	4	2	0	0
4700	1247	anti-il-1 beta antibody	[anti-IL-1 beta antibody]	3.1699250014423126	3	2	0	0
4701	1247	number of genes,	[number of genes,]	3.1699250014423126	3	3	3	3
4702	1247	transcriptional activation in vitro	[transcriptional activation in vitro]	3.1699250014423126	4	2	0	0
4703	1247	various cell types.	[various cell types.]	3.1699250014423126	3	2	0	0
4704	1247	human mononuclear leukocyte HML	[human mononuclear leukocytes HML]	3.1699250014423126	4	3	2	2
4705	1247	include chronic myeloid leukaemia	[including chronic myeloid leukaemia]	3.1699250014423126	4	2	0	0
4706	1247	acute promyelocytic leukemia patient	[acute promyelocytic leukemia patients]	3.1699250014423126	4	2	0	0
4707	1247	interaction with calcineurin	[interaction with calcineurin]	3.1699250014423126	3	3	3	3
4708	1247	reverse transcriptase assay	[reverse transcriptase assay]	3.1699250014423126	3	2	0	0
4709	1247	nf-at -dependent transcription	[NF-AT -dependent transcription]	3.1699250014423126	3	3	1	1
4710	1247	r7-57 reporter cell	[R7-57 reporter cells]	3.1699250014423126	3	2	0	0
4711	1247	antagonist of the response.	[antagonists of the response.]	3.1699250014423126	4	2	0	0
4712	1247	GATA-2 transcription factor	[GATA-2 transcription factor]	3.1699250014423126	3	2	0	0
4713	1247	zeta 2-globin promoter activity	[zeta 2-globin promoter activity]	3.1699250014423126	4	2	0	0
4714	1247	promonocytic thp-1 cell	[promonocytic THP-1 cells]	3.1699250014423126	3	3	1	1
4715	1247	interleukin-1 beta il-1 beta	[interleukin-1 beta IL-1 beta]	3.1699250014423126	4	4	2	1
4716	1247	primary amino acid sequence	[primary amino acid sequence]	3.1699250014423126	4	2	0	0
4717	1247	patient with ms	[patient with MS]	3.1699250014423126	3	2	0	0
4718	1247	GM-CSF proximal promoter	[GM-CSF proximal promoter]	3.1699250014423126	3	2	0	0
4719	1247	CD30 signal transduction	[CD30 signal transduction]	3.1699250014423126	3	2	0	0
4720	1247	increase in c-jun	[increase in c-jun]	3.1699250014423126	3	2	0	0
4721	1247	new transcription factor	[new transcription factor]	3.1699250014423126	3	3	3	3
4722	1247	sre sequence in lymphocyte	[SRE sequence in lymphocytes]	3.1699250014423126	4	2	0	0
4723	1247	IL-2 alpha gene	[IL-2 alpha genes]	3.1699250014423126	3	2	0	0
4724	1247	b cell-specific transcription factor	[B cell-specific transcription factor]	3.1699250014423126	4	3	2	2
4725	1247	gr in lymphocyte	[GR in lymphocytes]	3.1699250014423126	3	2	0	0
4726	1247	contrast to T cell	[contrast to T cells]	3.1699250014423126	4	2	0	0
4727	1247	use transgenic mouse	[using transgenic mice]	3.1699250014423126	3	2	0	0
4728	1247	display erythroid-specific expression	[displaying erythroid-specific expression]	3.1699250014423126	3	2	0	0
4729	1247	classical vitamin d receptor	[classical vitamin D receptor]	3.1699250014423126	4	2	0	0
4730	1247	NF-kappa B p50 subunit	[NF-kappa B p50 subunit]	3.1699250014423126	4	2	0	0
4731	1247	mrna expression pattern	[mRNA expression pattern]	3.1699250014423126	3	2	0	0
4732	1247	differentiation of leukemic cell	[differentiation of leukemic cells]	3.1699250014423126	4	3	3	3
4733	1247	patient with heart failure	[patient with heart failure]	3.1699250014423126	4	3	2	2
4734	1247	lineage-specific transcription factor	[lineage-specific transcription factor]	3.1699250014423126	3	3	2	2
4735	1247	cascade of event	[cascade of events]	3.1699250014423126	3	3	2	2
4736	1247	human t-cell virus type	[human T-cell virus type]	3.1699250014423126	4	3	3	3
4737	1247	degree of cn inhibition	[degree of CN inhibition]	3.1699250014423126	4	2	0	0
4738	1247	erythroblast cell line hd6	[erythroblast cell line HD6]	3.1699250014423126	4	2	0	0
4739	1247	cell of monocyte/macrophage lineage	[cells of monocyte/macrophage lineage]	3.1699250014423126	4	2	0	0
4740	1247	sickle cell anemia	[sickle cell anemia]	3.1699250014423126	3	2	0	0
4741	1247	human epithelial cell	[human epithelial cells]	3.1699250014423126	3	3	2	2
4742	1247	expression of CIITA	[expression of CIITA]	3.1699250014423126	3	3	1	1
4743	1247	first direct evidence	[first direct evidence]	3.1699250014423126	3	3	2	2
4744	1247	human immune system	[human immune system]	3.1699250014423126	3	2	0	0
4745	1247	phosphorylation of pkc substrate	[phosphorylation of PKC substrates]	3.1699250014423126	4	2	0	0
4746	1247	STAT3 tyrosine phosphorylation	[STAT3 tyrosine phosphorylation]	3.1699250014423126	3	2	0	0
4747	1247	member of the family	[member of the family]	3.1699250014423126	4	3	3	3
4748	1247	il-4 germline Cepsilon transcription	[IL-4 germline Cepsilon transcription]	3.1699250014423126	4	2	0	0
4749	1247	lymphocyte from CML patient	[lymphocytes from CML patients]	3.1699250014423126	4	4	2	1
4750	1247	b cell-specific manner	[B cell-specific manner]	3.1699250014423126	3	2	0	0
4751	1247	t-cell receptor activation	[T-cell receptor activation]	3.1699250014423126	3	2	0	0
4752	1247	various host transcription factor	[various host transcription factors]	3.1699250014423126	4	3	1	1
4753	1247	patient with syndrome	[patients with syndromes]	3.1699250014423126	3	3	3	3
4754	1247	kappa b gamma	[kappa B gamma]	3.1699250014423126	3	2	0	0
4755	1247	10(-6) m dm	[10(-6) M DM]	3.1699250014423126	3	2	0	0
4756	1247	aspirin-like drug ald	[Aspirin-like drugs ALD]	3.1699250014423126	3	2	0	0
4757	1247	production of proinflammatory cytokine	[production of proinflammatory cytokines]	3.1699250014423126	4	3	1	1
4758	1247	expression of both gene	[expression of both genes]	3.1699250014423126	4	2	0	0
4759	1247	ebv R protein	[EBV R protein]	3.1699250014423126	3	2	0	0
4760	1247	lps receptor complex	[LPS receptor complex]	3.1699250014423126	3	2	0	0
4761	1247	anti-cd40 monoclonal antibody	[anti-CD40 monoclonal antibody]	3.1699250014423126	3	2	0	0
4762	1247	il-2 mrna accumulation	[IL-2 mRNA accumulation]	3.1699250014423126	3	2	0	0
4763	1247	NF-kappa b antagonist	[NF-kappa B antagonists]	3.1699250014423126	3	2	0	0
4764	1247	inhibition of NF-kappaB	[inhibition of NF-kappaB]	3.1699250014423126	3	3	1	1
4765	1247	reactive lymph node	[reactive lymph nodes]	3.1699250014423126	3	3	2	2
4766	1247	number of protein	[number of proteins]	3.1699250014423126	3	3	3	3
4767	1247	nuclear factor kappab NF-kappaB	[nuclear factor kappaB NF-kappaB]	3.1699250014423126	4	2	0	0
4768	1247	continuous presence of lps	[continuous presence of LPS]	3.1699250014423126	4	2	0	0
4769	1247	class histocompatibility complex gene	[class histocompatibility complex gene]	3.1699250014423126	4	3	3	3
4770	1247	heterodimer with p50	[heterodimer with p50]	3.1699250014423126	3	2	0	0
4771	1247	response to ifn-gamma treatment	[response to IFN-gamma treatment]	3.1699250014423126	4	2	0	0
4772	1247	monocytic leukemia cell line	[monocytic leukemia cell line]	3.1699250014423126	4	3	2	2
4773	1247	peroxisome proliferator-activated receptor ppar	[peroxisome proliferator-activated receptor PPAR]	3.1699250014423126	4	3	1	1
4774	1247	induction of cytokine expression	[induction of cytokine expression]	3.1699250014423126	4	3	1	1
4775	1247	constitutive nf-kappa b activity	[constitutive NF-kappa B activity]	3.1699250014423126	4	2	0	0
4776	1247	microE5/kappa 2 motif	[microE5/kappa 2 motif]	3.1699250014423126	3	2	0	0
4777	1247	nf-at protein complex	[NF-AT protein complex]	3.1699250014423126	3	2	0	0
4778	1247	regulation of apoptosis	[regulation of apoptosis]	3.1699250014423126	3	2	0	0
4779	1247	mode of action	[mode of action]	3.1699250014423126	3	3	3	3
4780	1247	implication for the design	[implications for the design]	3.1699250014423126	4	3	3	3
4781	1247	JNK signal transduction pathway	[JNK signal transduction pathway]	3.1699250014423126	4	2	0	0
4782	1247	glucocorticoid -mediated apoptosis	[glucocorticoid -mediated apoptosis]	3.1699250014423126	3	2	0	0
4783	1247	contrast to cell	[contrast to cells]	3.1699250014423126	3	3	3	3
4784	1247	ifn-stimulated gene factor	[IFN-stimulated gene factor]	3.1699250014423126	3	2	0	0
4785	1247	major susceptibility gene	[major susceptibility gene]	3.1699250014423126	3	2	0	0
4786	1247	DNA target sequence	[DNA target sequence]	3.1699250014423126	3	3	1	1
4787	1247	protein of kD	[protein of kD]	3.1699250014423126	3	3	3	3
4788	1247	tcr alpha beta	[TCR alpha beta]	3.1699250014423126	3	2	0	0
4789	1247	decrease in the level	[decrease in the levels]	3.1699250014423126	4	3	2	2
4790	1247	beta globin gene	[beta globin gene]	3.1699250014423126	3	3	2	2
4791	1247	transcription factor function	[transcription factor function]	3.1699250014423126	3	3	1	1
4792	1247	T cell repertoire	[T cell repertoire]	3.1699250014423126	3	3	1	1
4793	1247	parental cell line	[parental cell line]	3.1699250014423126	3	3	1	1
4794	1247	early b-cell factor ebf	[early B-cell factor EBF]	3.1699250014423126	4	2	0	0
4795	1247	effective immune response	[effective immune response]	3.1699250014423126	3	3	1	1
4796	1247	second messenger cascade	[second messenger cascade]	3.1699250014423126	3	2	0	0
4797	1247	expression in monocyte	[expression in monocytes]	3.1699250014423126	3	3	3	3
4798	1247	PKC cellular response	[PKC cellular responses]	3.1699250014423126	3	2	0	0
4799	1247	major (mhc) class gene	[major (MHC) class genes]	3.1699250014423126	4	4	4	2
4800	1247	mcd14 lps uptake	[mCD14 LPS uptake]	3.1699250014423126	3	3	1	1
4801	1247	transactivation domain of c-Jun	[transactivation domain of c-Jun]	3.1699250014423126	4	2	0	0
4802	1247	interaction of the cell	[interaction of the cells]	3.1699250014423126	4	2	0	0
4803	1247	ACH-2 cell line	[ACH-2 cell line]	3.1699250014423126	3	2	0	0
4804	1247	ICAM-1 kappa b site	[ICAM-1 kappa B site]	3.1699250014423126	4	2	0	0
4805	1247	such as T cell	[such as T cells]	3.1699250014423126	4	2	0	0
4806	1247	rate of apoptosis	[rate of apoptosis]	3.1699250014423126	3	3	3	3
4807	1247	response to IL-6	[response to IL-6]	3.1699250014423126	3	2	0	0
4808	1247	kappa e3' enhancer	[kappa E3' enhancer]	3.1699250014423126	3	2	0	0
4809	1247	specific MHC molecule	[specific MHC molecules]	3.1699250014423126	3	2	0	0
4810	1247	nuclear translocation of stat6	[nuclear translocation of STAT6]	3.1699250014423126	4	2	0	0
4811	1247	production of IL-2	[production of IL-2]	3.1699250014423126	3	2	0	0
4812	1247	adhesion molecule-1 ICAM-1	[adhesion molecule-1 ICAM-1]	3.1699250014423126	3	3	3	3
4813	1247	control of apoptosis	[control of apoptosis]	3.1699250014423126	3	3	1	1
4814	1247	proliferation of progenitor	[proliferation of progenitors]	3.1699250014423126	3	3	3	3
4815	1247	regulator of differentiation	[regulator of differentiation]	3.1699250014423126	3	3	3	3
4816	1247	human leukocyte HML	[human leukocytes HML]	3.1699250014423126	3	3	3	3
4817	1247	interaction with DNA	[interaction with DNA]	3.1699250014423126	3	2	0	0
4818	1247	presence of p50	[presence of p50]	3.1699250014423126	3	3	1	1
4819	1247	U373 mg cell	[U373 MG cells]	3.1699250014423126	3	2	0	0
4820	1247	acute myeloid leukemia aml	[acute myeloid leukemia AML]	3.1699250014423126	4	2	0	0
4821	1247	form of the protein	[form of the protein]	3.1699250014423126	4	3	3	3
4822	1247	dyad symmetry element	[dyad symmetry element]	3.1699250014423126	3	3	2	2
4823	1247	decrease in pkc activity	[decrease in PKC activity]	3.1699250014423126	4	2	0	0
4824	1247	chronic kidney insufficiency	[chronic kidney insufficiency]	3.1699250014423126	3	2	0	0
4825	1247	very low level.	[very low level.]	3.1699250014423126	3	2	0	0
4826	1247	pathogenesis of type diabete	[pathogenesis of type diabetes]	3.1699250014423126	4	2	0	0
4827	1247	immunoglobulin (ig) gene	[immunoglobulin (Ig) gene]	3.1699250014423126	3	3	1	1
4828	1247	endothelial cell ECs	[endothelial cells ECs]	3.1699250014423126	3	3	2	2
4829	1247	induction of NF-MATp35	[Induction of NF-MATp35]	3.1699250014423126	3	2	0	0
4830	1247	sle disease activity	[SLE disease activity]	3.1699250014423126	3	2	0	0
4831	1247	gene in T cell	[gene in T cells]	3.1699250014423126	4	3	2	2
4832	1247	dominant negative c-fo	[dominant negative c-Fos]	3.1699250014423126	3	2	0	0
4833	1247	antigen-specific T cell	[antigen-specific T cells]	3.1699250014423126	3	2	0	0
4834	1247	il-1 receptor il-1r	[IL-1 receptor IL-1R]	3.1699250014423126	3	2	0	0
4835	1247	tnf alpha gene	[TNF alpha gene]	3.1699250014423126	3	2	0	0
4836	1247	T cell antigen	[T cell antigen]	3.1699250014423126	3	3	1	1
4837	1247	patient with diabete mellitus	[patients with diabetes mellitus]	3.1699250014423126	4	3	1	1
4838	1247	different T cell line	[different T cell line]	3.1699250014423126	4	3	1	1
4839	1247	GR binding parameter	[GR binding parameters]	3.1699250014423126	3	2	0	0
4840	1247	patient with APL	[patient with APL]	3.1699250014423126	3	3	2	2
4841	1247	distinct set of gene	[distinct set of genes]	3.1699250014423126	4	3	1	1
4842	1247	gata family protein	[GATA family protein]	3.1699250014423126	3	2	0	0
4843	1247	leukemia cell line thp-1	[leukemia cell line THP-1]	3.1699250014423126	4	4	4	2
4844	1247	sodium dodecyl sulfate-polyacrylamide gel	[sodium dodecyl sulfate-polyacrylamide gel]	3.1699250014423126	4	2	0	0
4845	1247	basal level expression	[basal level expression]	3.1699250014423126	3	3	2	2
4846	1247	effect of glucocorticoid hormone	[effect of glucocorticoid hormones]	3.1699250014423126	4	2	0	0
4847	1247	pbmc from patient	[PBMC from patients]	3.1699250014423126	3	3	2	2
4848	1247	DNA binding capacity	[DNA binding capacity]	3.1699250014423126	3	3	2	2
4849	1247	certain cell type	[certain cell types]	3.1699250014423126	3	3	3	3
4850	1247	cytokine in monocyte	[cytokines in monocytes]	3.1699250014423126	3	3	3	3
4851	1247	chimeric transcription factor	[chimeric transcription factor]	3.1699250014423126	3	2	0	0
4852	1247	IL-4 -inducible gene	[IL-4 -inducible gene]	3.1699250014423126	3	2	0	0
4853	1247	novel t-cell protein	[novel T-cell protein]	3.1699250014423126	3	2	0	0
4854	1247	stimulation with phorbol ester	[stimulation with phorbol esters]	3.1699250014423126	4	2	0	0
4855	1247	human cd19 gene	[human CD19 gene]	3.1699250014423126	3	2	0	0
4856	1247	calcineurin catalytic domain	[calcineurin catalytic domain]	3.1699250014423126	3	2	0	0
4857	1247	proliferation of T lymphocyte	[proliferation of T lymphocytes]	3.1699250014423126	4	3	1	1
4858	1247	infection of cell	[infection of cells]	3.1699250014423126	3	3	3	3
4859	1247	effect on the promoter	[effect on the promoter]	3.1699250014423126	4	3	2	2
4860	1247	cyclophilin b-binding protein	[cyclophilin B-binding protein]	3.1699250014423126	3	2	0	0
4861	1247	leukocyte integrin gene cd11c	[leukocyte integrin genes CD11C]	3.1699250014423126	4	2	0	0
4862	1247	response to infection	[response to infection]	3.1699250014423126	3	3	3	3
4863	1247	different cell line	[different cell lines]	3.1699250014423126	3	3	3	3
4864	1247	kb 5'-flanking DNA	[kb 5'-flanking DNA]	3.1699250014423126	3	4	4	2
4865	1247	concentration of plasma cortisol	[concentration of plasma cortisol]	3.1699250014423126	4	3	2	2
4866	1247	hiv-1 in vitro	[HIV-1 in vitro]	3.1699250014423126	3	2	0	0
4867	1247	reduction of symptom	[reduction of symptoms]	3.1699250014423126	3	3	2	2
4868	1247	PEBP2 alpha A1	[PEBP2 alpha A1]	3.1699250014423126	3	2	0	0
4869	1247	tumor suppressor gene	[tumor suppressor gene]	3.1699250014423126	3	3	2	2
4870	1247	pAT 133 gene	[pAT 133 gene]	3.1699250014423126	3	2	0	0
4871	1247	interaction of both subunit	[interaction of both subunits]	3.1699250014423126	4	2	0	0
4872	1247	cell antigen receptor	[cell antigen receptor]	3.1699250014423126	3	3	2	2
4873	1247	polymorphism at residue 57	[polymorphism at residue 57]	3.1699250014423126	4	2	0	0
4874	1247	c-jun mrna level	[c-jun mRNA levels]	3.1699250014423126	3	5	3	1
4875	1247	HIV terminal repeat	[HIV terminal repeat]	3.1699250014423126	3	4	4	2
4876	1247	Fc gamma R cross-linking	[Fc gamma R cross-linking]	3.1699250014423126	4	2	0	0
4877	1247	regulate cell growth	[regulating cell growth]	3.1699250014423126	3	2	0	0
4878	1247	irf-1 gene expression	[IRF-1 gene expression]	3.1699250014423126	3	4	2	1
4879	1247	histone h4 gene	[histone H4 gene]	3.1699250014423126	3	3	1	1
4880	1247	human virus type	[human virus type]	3.1699250014423126	3	3	3	3
4881	1247	individual stat protein	[individual STAT proteins]	3.1699250014423126	3	2	0	0
4882	1247	CaM kinase ii	[CaM kinase II]	3.1699250014423126	3	3	1	1
4883	1247	regulation of target gene	[regulation of target genes]	3.1699250014423126	4	2	0	0
4884	1247	B-cell chronic lymphocytic leukemia	[B-cell chronic lymphocytic leukemia]	3.1699250014423126	4	3	2	2
4885	1247	expression of il-2r beta	[expression of IL-2R beta]	3.1699250014423126	4	2	0	0
4886	1247	foam cell formation	[foam cell formation]	3.1699250014423126	3	3	2	2
4887	1247	renal cell carcinoma RCC	[renal cell carcinoma RCC]	3.1699250014423126	4	3	1	1
4888	1247	crude nuclear extract	[crude nuclear extracts]	3.1699250014423126	3	2	0	0
4889	1247	human aortic endothelial cell	[human aortic endothelial cells]	3.1699250014423126	4	3	2	2
4890	1247	polymorphonuclear leukocyte adhesion	[polymorphonuclear leukocyte adhesion]	3.1699250014423126	3	3	1	1
4891	1247	il-2r alpha gene	[IL-2R alpha gene]	3.1699250014423126	3	2	0	0
4892	1247	activity of nuclear factor	[activity of nuclear factor]	3.1699250014423126	4	3	2	2
4893	1247	population of cell	[population of cells]	3.1699250014423126	3	3	3	3
4894	1247	regulation of NF-kappa b	[Regulation of NF-kappa B]	3.1699250014423126	4	2	0	0
4895	1247	NF-kappa B /Rel family	[NF-kappa B /Rel family]	3.1699250014423126	4	3	1	1
4896	1247	mechanism of regulation	[mechanism of regulation]	3.1699250014423126	3	3	3	3
4897	1247	40 pediatric sample	[40 pediatric samples]	3.1699250014423126	3	2	0	0
4898	1247	long enhancer transcript	[long enhancer transcripts]	3.1699250014423126	3	3	2	2
4899	1247	induction of anergy	[induction of anergy]	3.1699250014423126	3	3	3	3
4900	1247	LP T cell	[LP T cells]	3.1699250014423126	3	2	0	0
4901	1247	electrophoretic mobility shift analysis	[electrophoretic mobility shift analysis]	3.1699250014423126	4	3	1	1
4902	1247	wild type p53	[wild type p53]	3.1699250014423126	3	3	1	1
4903	1247	human beta-globin gene	[human beta-globin gene]	3.1699250014423126	3	2	0	0
4904	1247	response to inducer	[response to inducers]	3.1699250014423126	3	2	0	0
4905	1247	new variant translocation	[new variant translocation]	3.1699250014423126	3	3	3	3
4906	1247	subset of T cell	[subsets of T cells]	3.1699250014423126	4	3	2	2
4907	1247	two distinct element	[two distinct elements]	3.1699250014423126	3	2	0	0
4908	1247	autoregulation of gr expression	[autoregulation of GR expression]	3.1699250014423126	4	3	3	3
4909	1247	differentiation of u937 cell	[differentiation of U937 cells]	3.1699250014423126	4	2	0	0
4910	1247	core SRF binding site	[core SRF binding site]	3.1699250014423126	4	2	0	0
4911	1247	cognate DNA sequence	[cognate DNA sequences]	3.1699250014423126	3	2	0	0
4912	1247	ligation of this receptor	[ligation of this receptor]	3.1699250014423126	4	2	0	0
4913	1247	primary human lymphocyte	[primary human lymphocytes]	3.1699250014423126	3	2	0	0
4914	1247	Rel homology domain	[Rel homology domain]	3.1699250014423126	3	2	0	0
4915	1247	protein kinase c activator	[protein kinase C activator]	3.1699250014423126	4	3	1	1
4916	1247	site of vascular injury	[sites of vascular injury]	3.1699250014423126	4	2	0	0
4917	1247	gene in b cell	[gene in B cells]	3.1699250014423126	4	3	1	1
4918	1247	human skin cancer	[human skin cancer]	3.1699250014423126	3	3	1	1
4919	1247	IL-2R alpha promoter	[IL-2R alpha promoter]	3.1699250014423126	3	4	2	1
4920	1247	indicate a role	[indicating a role]	3.1699250014423126	3	3	3	3
4921	1247	ligand of the cdr2-loop	[ligands of the CDR2-loop]	3.1699250014423126	4	2	0	0
4922	1247	activation of signal transducer	[activation of signal transducers]	3.1699250014423126	4	2	0	0
4923	1247	fetal calf serum	[fetal calf serum]	3.1699250014423126	3	3	3	3
4924	1247	pattern of gene expression	[pattern of gene expression]	3.1699250014423126	4	3	1	1
4925	1247	subset of cell	[subset of cells]	3.1699250014423126	3	3	2	2
4926	1247	NFkappaB nuclear translocation	[NFkappaB nuclear translocation]	3.1699250014423126	3	2	0	0
4927	1247	erythroid-specific chromatin structure reorganization	[erythroid-specific chromatin structure reorganization]	3.1699250014423126	4	2	0	0
4928	1247	thymic epithelial cell TEC	[thymic epithelial cells TEC]	3.1699250014423126	4	3	2	2
4929	1247	interferon regulatory factor 1	[interferon regulatory factor 1]	3.1699250014423126	4	3	2	2
4930	1247	cd4+ cd8+ T cell	[CD4+ CD8+ T cells]	3.1699250014423126	4	2	0	0
4931	1247	gcr in the patient	[GCR in the patients]	3.1699250014423126	4	2	0	0
4932	1247	same rapid time	[same rapid time]	3.1699250014423126	3	2	0	0
4933	1247	signal in T cell	[signal in T cells]	3.1699250014423126	4	3	3	3
4934	1247	region amino acid	[region amino acids]	3.1699250014423126	3	3	3	3
4935	1247	high mobility group	[high mobility group]	3.1699250014423126	3	3	3	3
4936	1247	CEM C7 cell	[CEM C7 cells]	3.1699250014423126	3	2	0	0
4937	1247	costimulation of T cell	[costimulation of T cells]	3.1699250014423126	4	2	0	0
4938	1247	class ii gene transcription	[class II gene transcription]	3.1699250014423126	4	3	1	1
4939	1247	measure [3h]dexamethasone binding	[measuring [3H]dexamethasone binding]	3.1699250014423126	3	2	0	0
4940	1247	Glucocorticoid receptor gr	[Glucocorticoid receptor GR]	3.1699250014423126	3	3	1	1
4941	1247	myosin light chain kinase	[myosin light chain kinase]	3.1699250014423126	4	3	1	1
4942	1247	latent membrane protein LMP1	[latent membrane protein LMP1]	3.1699250014423126	4	3	2	2
4943	1247	binding of this protein	[binding of these proteins]	3.1699250014423126	4	3	1	1
4944	1247	activation of PKC	[activation of PKC]	3.1699250014423126	3	3	2	2
4945	1247	arachidonic acid liberation	[arachidonic acid liberation]	3.1699250014423126	3	2	0	0
4946	1247	effect of cyclosporin a	[effect of cyclosporin A]	3.1699250014423126	4	3	3	3
4947	1247	IL-2 octamer motif	[IL-2 octamer motif]	3.1699250014423126	3	3	1	1
4948	1247	T cell-specific enhancer	[T cell-specific enhancer]	3.1699250014423126	3	3	2	2
4949	1247	tumor necrosis factor factor	[tumor necrosis factor factor]	3.1699250014423126	4	3	2	2
4950	1247	G1 phase transition	[G1 phase transition]	3.1699250014423126	3	2	0	0
4951	1247	two signal pathway	[two signaling pathways]	3.1699250014423126	3	3	1	1
4952	1247	monocytic cell line u937	[monocytic cell line U937]	3.1699250014423126	4	3	1	1
4953	1247	IL-2 T cell proliferation	[IL-2 T cell proliferation]	3.1699250014423126	4	2	0	0
4954	1247	expression of estrogen receptor	[expression of estrogen receptors]	3.1699250014423126	4	3	1	1
4955	1247	nf-kappa b DNA binding	[NF-kappa B DNA binding]	3.1699250014423126	4	2	0	0
4956	1247	control of cell proliferation	[control of cell proliferation]	3.1699250014423126	4	3	1	1
4957	1247	three bind site	[three binding sites]	3.1699250014423126	3	3	2	2
4958	1247	gamma c gene	[gamma c gene]	3.1699250014423126	3	3	1	1
4959	1247	resolution of inflammation	[resolution of inflammation]	3.1699250014423126	3	2	0	0
4960	1247	patient with granulomatous disease	[patients with granulomatous diseases]	3.1699250014423126	4	3	2	2
4961	1247	tumor necrosis factor receptor	[tumor necrosis factor receptor]	3.1699250014423126	4	3	2	2
4962	1247	release of CRM1	[release of CRM1]	3.1699250014423126	3	2	0	0
4963	1247	sp1 binding site	[Sp1 binding sites]	3.1699250014423126	3	3	1	1
4964	1247	decrease in the activity	[decrease in the activity]	3.1699250014423126	4	3	3	3
4965	1247	anti-CD3 mab okt3	[anti-CD3 mAB OKT3]	3.1699250014423126	3	2	0	0
4966	1247	nf of T cell	[NF of T cells]	3.1699250014423126	4	3	1	1
4967	1247	hl-60 cell differentiation	[HL-60 cell differentiation]	3.1699250014423126	3	3	1	1
4968	1247	first male patient	[first male patient]	3.1699250014423126	3	2	0	0
4969	1247	core binding factor	[core binding factor]	3.1699250014423126	3	3	2	2
4970	1247	monocyte protein-1 secretion	[monocyte protein-1 secretion]	3.1699250014423126	3	3	3	3
4971	1247	IFN regulatory factor-1 irf-1	[IFN regulatory factor-1 IRF-1]	3.1699250014423126	4	2	0	0
4972	1247	NF-ATp -deficient mouse	[NF-ATp -deficient mice]	3.1699250014423126	3	2	0	0
4973	1247	lytic cycle gene	[lytic cycle genes]	3.1699250014423126	3	3	2	2
4974	1247	haploinsufficiency of pax gene	[haploinsufficiency of Pax genes]	3.1699250014423126	4	3	1	1
4975	1247	tyrosine kinase-dependent pathway	[tyrosine kinase-dependent pathway]	3.1699250014423126	3	2	0	0
4976	1247	stat3 tyrosine phosphorylation	[STAT3 tyrosine phosphorylation]	3.1699250014423126	3	3	3	3
4977	1247	b-cell-specific transcription factor bsap	[B-cell-specific transcription factor BSAP]	3.1699250014423126	4	3	1	1
4978	1247	b-cell-specific activator protein-binding site	[B-cell-specific activator protein-binding site]	3.1699250014423126	4	2	0	0
4979	1247	sp1 transcription factor	[Sp1 transcription factor]	3.1699250014423126	3	3	1	1
4980	1247	carry cell line	[carrying cell lines]	3.1699250014423126	3	2	0	0
4981	1247	gm-csf gene transcription	[GM-CSF gene transcription]	3.1699250014423126	3	2	0	0
4982	1247	only in b cell	[only in B cells]	3.1699250014423126	4	2	0	0
4983	1247	intercellular adhesion molecule	[intercellular adhesion molecule]	3.1699250014423126	3	3	1	1
4984	1247	IkB alpha phosphorylation	[IkB alpha phosphorylation]	3.1699250014423126	3	3	1	1
4985	1247	human killer cell	[human killer cells]	3.1699250014423126	3	3	3	3
4986	1247	menopausal type ii diabete	[menopausal type II diabetes]	3.1699250014423126	4	2	0	0
4987	1247	binding of c-Rel/p65 heterodimer	[binding of c-Rel/p65 heterodimers]	3.1699250014423126	4	2	0	0
4988	1247	regulate the response	[regulating the response]	3.1699250014423126	3	3	3	3
4989	1247	type ii interferon	[type II interferon]	3.1699250014423126	3	3	2	2
4990	1247	constitutive nuclear nf-kappa b	[constitutive nuclear NF-kappa B]	3.1699250014423126	4	3	2	2
4991	1247	novel enhancer element	[novel enhancer element]	3.1699250014423126	3	3	2	2
4992	1247	variety of cells,	[variety of cells,]	3.1699250014423126	3	3	3	3
4993	1247	human myeloid differentiation	[Human myeloid differentiation]	3.1699250014423126	3	2	0	0
4994	1247	cellular redox state	[cellular redox state]	3.1699250014423126	3	2	0	0
4995	1247	reading frame orf	[reading frames ORFs]	3.1699250014423126	3	3	3	3
4996	1247	effect of okadaic acid	[effects of okadaic acid]	3.1699250014423126	4	2	0	0
4997	1247	p50 DNA binding subunit	[p50 DNA binding subunit]	3.1699250014423126	4	2	0	0
4998	1247	activation of STAT3	[activation of STAT3]	3.1699250014423126	3	3	2	2
4999	1247	igg fc receptor type	[IgG Fc receptor type]	3.1699250014423126	4	2	0	0
5000	1247	simian ebv lmp1	[simian EBV LMP1s]	3.1699250014423126	3	2	0	0
5001	1247	nuclear receptor superfamily	[nuclear receptor superfamily]	3.1699250014423126	3	3	1	1
5002	1247	stain for Bcl-6	[staining for Bcl-6]	3.1699250014423126	3	2	0	0
5003	1247	RANTES a chemokine	[RANTES a chemokine]	3.1699250014423126	3	2	0	0
5004	1247	Jurkat t-leukemia cell	[Jurkat T-leukemia cells]	3.1699250014423126	3	2	0	0
5005	1247	c-fo /c-jun heterodimer	[c-Fos /c-Jun heterodimers]	3.1699250014423126	3	2	0	0
5006	1247	vitellogenin gene b1 promoter	[vitellogenin gene B1 promoter]	3.1699250014423126	4	2	0	0
5007	1247	immune deficiency syndrome aids	[immune deficiency syndrome AIDS]	3.1699250014423126	4	2	0	0
5008	1247	class mutant cell line	[class mutant cell line]	3.1699250014423126	4	3	2	2
5009	1247	fatal adenoviral infection	[fatal adenoviral infection]	3.1699250014423126	3	2	0	0
5010	1247	pancreatic beta cell	[pancreatic beta cells]	3.1699250014423126	3	3	1	1
5011	1247	endothelium in shear flow	[endothelium in shear flow]	3.1699250014423126	4	2	0	0
5012	1247	Jurkat t-cell line	[Jurkat T-cell line]	3.1699250014423126	3	3	2	2
5013	1247	transcription from promoter	[transcription from promoters]	3.1699250014423126	3	3	1	1
5014	1247	vitro transcription assay	[vitro transcription assays]	3.1699250014423126	3	2	0	0
5015	1247	other inflammatory mediator	[other inflammatory mediators]	3.1699250014423126	3	2	0	0
5016	1247	molecular weight of nfatp	[molecular weight of NFATp]	3.1699250014423126	4	2	0	0
5017	1247	IL-2 receptor beta-chain	[IL-2 receptor beta-chain]	3.1699250014423126	3	2	0	0
5018	1247	innate immune system	[innate immune system]	3.1699250014423126	3	2	0	0
5019	1247	AP-1 binding site	[AP-1 binding sites]	3.1699250014423126	3	3	1	1
5020	1247	primary breast cancer	[primary breast cancer]	3.1699250014423126	3	3	2	2
5021	1247	human primary b-lymphocyte	[human primary B-lymphocytes]	3.1699250014423126	3	2	0	0
5022	1247	heterodimer complex formation	[heterodimer complex formation]	3.1699250014423126	3	2	0	0
5023	1247	kda heat shock protein	[kDa heat shock protein]	3.1699250014423126	4	3	3	3
5024	1247	fusion protein aml1/mds1/evi1	[fusion protein AML1/MDS1/EVI1]	3.1699250014423126	3	3	1	1
5025	1247	progesterone -dependent immunomodulation	[progesterone -dependent immunomodulation]	3.1699250014423126	3	2	0	0
5026	1247	adrenocorticotropic hormone test	[adrenocorticotropic hormone test]	3.1699250014423126	3	2	0	0
5027	1247	two set of primer	[Two sets of primers]	3.1699250014423126	4	2	0	0
5028	1247	X-SCID b cell	[X-SCID B cells]	3.1699250014423126	3	3	1	1
5029	1247	inducible interleukin-2 enhancer function	[inducible interleukin-2 enhancer function]	3.1699250014423126	4	2	0	0
5030	1247	form of NF-kappa b	[form of NF-kappa B]	3.1699250014423126	4	2	0	0
5031	1247	activation by stimulus	[Activation by stimuli]	3.1699250014423126	3	3	3	3
5032	1247	non- a-t individual	[non- A-T individuals]	3.1699250014423126	3	2	0	0
5033	1247	NF-kappa b system	[NF-kappa B system]	3.1699250014423126	3	2	0	0
5034	1247	strong transcriptional activity	[strong transcriptional activity]	3.1699250014423126	3	2	0	0
5035	1247	perforin gene expression	[perforin gene expression]	3.1699250014423126	3	2	0	0
5036	1247	fragment encompass end	[fragment encompassing ends]	3.1699250014423126	3	2	0	0
5037	1247	DNase i-hypersensitive site	[DNase I-hypersensitive site]	3.1699250014423126	3	2	0	0
5038	1247	receptor-interacting protein rip	[receptor-interacting protein RIP]	3.1699250014423126	3	2	0	0
5039	1247	blast in M7 case	[blasts in M7 cases]	3.1699250014423126	4	2	0	0
5040	1247	IL-6 mrna expression	[IL-6 mRNA expression]	3.1699250014423126	3	2	0	0
5041	1247	murine b lymphocyte	[murine B lymphocytes]	3.1699250014423126	3	3	1	1
5042	1247	alpha 4 integrin	[alpha 4 integrin]	3.1699250014423126	3	2	0	0
5043	1247	role of CD28	[role of CD28]	3.1699250014423126	3	3	1	1
5044	1247	activation of stat protein	[activation of STAT proteins]	3.1699250014423126	4	3	1	1
5045	1247	differentiation of progenitor cell	[differentiation of progenitor cells]	3.1699250014423126	4	3	3	3
5046	1247	mnda mrna level	[MNDA mRNA level]	3.1699250014423126	3	2	0	0
5047	1247	effect on hiv replication	[effect on HIV replication]	3.1699250014423126	4	3	2	2
5048	1247	cis-acting regulatory site	[cis-acting regulatory sites]	3.1699250014423126	3	3	2	2
5049	1247	post-gc, terminal b-cell differentiation	[post-GC, terminal B-cell differentiation]	3.1699250014423126	4	2	0	0
5050	1247	ability of the protein	[ability of the proteins]	3.1699250014423126	4	2	0	0
5051	1247	beta-globin reporter gene	[beta-globin reporter gene]	3.1699250014423126	3	3	2	2
5052	1247	role of NF-kappa b	[role of NF-kappa B]	3.1699250014423126	4	3	2	2
5053	1247	respect to pmn adhesion	[respect to PMN adhesion]	3.1699250014423126	4	2	0	0
5054	1247	PML nuclear body	[PML nuclear bodies]	3.1699250014423126	3	3	3	3
5055	1247	alternative splicing mechanism	[alternative splicing mechanism]	3.1699250014423126	3	2	0	0
5056	1247	constitutive tyrosine phosphorylation	[constitutive tyrosine phosphorylation]	3.1699250014423126	3	2	0	0
5057	1247	ap1 transcription factor	[AP1 transcription factor]	3.1699250014423126	3	2	0	0
5058	1247	effect of estrogen	[effect of estrogen]	3.1699250014423126	3	3	3	3
5059	1247	internucleosomal DNA fragmentation	[internucleosomal DNA fragmentation]	3.1699250014423126	3	3	2	2
5060	1247	Electrophoretic mobility-shift assay	[Electrophoretic mobility-shift assays]	3.1699250014423126	3	3	2	2
5061	1247	acute myocardial infarction	[acute myocardial infarction]	3.1699250014423126	3	3	1	1
5062	1247	mechanism for activation	[mechanism for activation]	3.1699250014423126	3	3	3	3
5063	1247	variety of protein	[variety of proteins]	3.1699250014423126	3	3	1	1
5064	1247	set of transcription factor	[set of transcription factors]	3.1699250014423126	4	3	2	2
5065	1247	transition of Epstein-Barr virus	[transition of Epstein-Barr virus]	3.1699250014423126	4	3	3	3
5066	1247	domain of pp56(lck)	[domain of pp56(lck)]	3.1699250014423126	3	4	4	2
5067	1247	stem secondary structure	[stem secondary structure]	3.1699250014423126	3	2	0	0
5068	1247	hepatitis b virus hbv	[hepatitis B virus HBV]	3.1699250014423126	4	3	2	2
5069	1247	protein kinase c inhibitor	[protein kinase C inhibitor]	3.1699250014423126	4	3	2	2
5070	1247	interleukin 2 il-2 gene	[interleukin 2 IL-2 gene]	3.1699250014423126	4	2	0	0
5071	1247	regulation of the response	[regulation of the response]	3.1699250014423126	4	5	3	1
5072	1247	regulation of cytokine	[Regulation of cytokine]	3.1699250014423126	3	3	2	2
5073	1247	monocytic differentiation marker	[monocytic differentiation markers]	3.1699250014423126	3	2	0	0
5074	1247	GAL4 dna-binding domain	[GAL4 DNA-binding domain]	3.1699250014423126	3	2	0	0
5075	1247	pu.1 DNA binding activity	[PU.1 DNA binding activity]	3.1699250014423126	4	2	0	0
5076	1247	human leukemia virus type	[human leukemia virus type]	3.1699250014423126	4	3	3	3
5077	1247	transcription factor for promoter	[transcription factor for promoters]	3.1699250014423126	4	2	0	0
5078	1247	suppression of il-5 transcription	[suppression of IL-5 transcription]	3.1699250014423126	4	2	0	0
5079	1247	low density lipoprotein ldl	[low density lipoprotein LDL]	3.1699250014423126	4	3	1	1
5080	1247	cell surface protein	[cell surface proteins]	3.1699250014423126	3	2	0	0
5081	1247	pocket protein- e2f complex	[pocket protein- E2F complexes]	3.1699250014423126	4	2	0	0
5082	1247	c/ebp epsilon mrna accumulation	[C/EBP epsilon mRNA accumulation]	3.1699250014423126	4	2	0	0
5083	1247	mouse, th cell	[mouse, Th cells]	3.1699250014423126	3	2	0	0
5084	1247	leukemia virus type	[leukemia virus type]	3.1699250014423126	3	3	3	3
5085	1247	human peripheral cell	[human peripheral cells]	3.1699250014423126	3	3	3	3
5086	1247	production of ro(ssa) antibody	[production of Ro(SSA) antibodies]	3.1699250014423126	4	2	0	0
5087	1247	Dendritic cell DC	[Dendritic cells DC]	3.1699250014423126	3	2	0	0
5088	1247	NF-kappaB binding activity	[NF-kappaB binding activity]	3.1699250014423126	3	3	1	1
5089	1247	(mhc) class gene	[(MHC) class genes]	3.1699250014423126	3	4	4	2
5090	1247	Physiological concentration of estradiol	[Physiological concentration of estradiol]	3.1699250014423126	4	2	0	0
5091	1247	human tonsillar t- lymphocyte	[human tonsillar T- lymphocytes]	3.1699250014423126	4	2	0	0
5092	1247	I alpha1 promoter	[I alpha1 promoter]	3.1699250014423126	3	2	0	0
5093	1247	activation of monocyte	[activation of monocytes]	3.1699250014423126	3	3	1	1
5094	1247	t-cell leukemia t-all	[T-cell leukemia T-ALL]	3.1699250014423126	3	3	3	3
5095	1247	zeta-globin mrna cap site	[zeta-globin mRNA cap site]	3.1699250014423126	4	2	0	0
5096	1247	10(-5) m Azeptin	[10(-5) M Azeptin]	3.1699250014423126	3	2	0	0
5097	1247	human ciita construct	[human CIITA constructs]	3.1699250014423126	3	3	2	2
5098	1247	t-cell cycle progression	[T-cell cycle progression]	3.1699250014423126	3	2	0	0
5099	1247	24-hour urinary cortisol excretion	[24-hour urinary cortisol excretion]	3.1699250014423126	4	3	2	2
5100	1247	tnf mrna accumulation	[TNF mRNA accumulation]	3.1699250014423126	3	2	0	0
5101	1247	novel nuclear factor	[novel nuclear factor]	3.1699250014423126	3	3	1	1
5102	1247	closely related gene	[closely related genes]	3.1699250014423126	3	2	0	0
5103	1247	MHC class ii compartment	[MHC class II compartment]	3.1699250014423126	4	2	0	0
5104	1247	transcription factor aml1	[transcription factor AML1]	3.1699250014423126	3	2	0	0
5105	1247	naive T cell subset	[naive T cell subsets]	3.1699250014423126	4	2	0	0
5106	1247	host defense mechanism	[host defense mechanisms]	3.1699250014423126	3	3	1	1
5107	1247	tyrosine kinase inhibitor herbimycin	[tyrosine kinase inhibitor herbimycin]	3.1699250014423126	4	2	0	0
5108	1247	neutrophil adhesion response	[neutrophil adhesion response]	3.1699250014423126	3	3	1	1
5109	1247	1,25-Dihydroxyvitamin D3 receptor	[1,25-Dihydroxyvitamin D3 receptors]	3.1699250014423126	3	2	0	0
5110	1247	T cell from individual	[T cells from individuals]	3.1699250014423126	4	4	4	2
5111	1247	reduction in the expression	[reduction in the expression]	3.1699250014423126	4	2	0	0
5112	1247	depletion of traf2	[depletion of TRAF2]	3.1699250014423126	3	3	3	3
5113	1247	role in hematopoiesis	[role in hematopoiesis]	3.1699250014423126	3	3	3	3
5114	1247	epsilon germline transcription	[epsilon germline transcription]	3.1699250014423126	3	3	2	2
5115	1247	immunosuppressant drug cyclosporin a	[immunosuppressant drug cyclosporin A]	3.1699250014423126	4	2	0	0
5116	1247	24-hour cortisol excretion	[24-hour cortisol excretion]	3.1699250014423126	3	3	3	3
5117	1247	ability of T cell	[ability of T cells]	3.1699250014423126	4	2	0	0
5118	1247	b cell-specific gene	[B cell-specific gene]	3.1699250014423126	3	3	2	2
5119	1247	effect of phorbol ester	[effects of phorbol ester]	3.1699250014423126	4	2	0	0
5120	1247	hiv-1 -infected cell	[HIV-1 -infected cells]	3.1699250014423126	3	3	1	1
5121	1247	lymphokine gene expression	[lymphokine gene expression]	3.1699250014423126	3	2	0	0
5122	1247	active NF-kappa b complex	[active NF-kappa B complex]	3.1699250014423126	4	2	0	0
5123	1247	simian virus 40	[simian virus 40]	3.1699250014423126	3	3	1	1
5124	1247	inflammatory cytokine tnf-alpha	[inflammatory cytokine TNF-alpha]	3.1699250014423126	3	2	0	0
5125	1247	DNA fragment of kb	[DNA fragment of kb]	3.1699250014423126	4	2	0	0
5126	1247	change in MBC	[change in MBC]	3.1699250014423126	3	2	0	0
5127	1247	ebv gene expression	[EBV gene expression]	3.1699250014423126	3	3	1	1
5128	1247	region of gene	[region of gene]	3.1699250014423126	3	3	3	3
5129	1247	serine phosphorylation of stat3	[serine phosphorylation of Stat3]	3.1699250014423126	4	3	1	1
5130	1247	human cd34(+) bone	[human CD34(+) bone]	3.1699250014423126	3	2	0	0
5131	1247	HTLV-I T cell	[HTLV-I T cells]	3.1699250014423126	3	3	1	1
5132	1247	murine T cell line	[murine T cell line]	3.1699250014423126	4	3	2	2
5133	1247	reduction of serum androgen	[reduction of serum androgens]	3.1699250014423126	4	2	0	0
5134	1247	promoter chromatin structure	[promoter chromatin structure]	3.1699250014423126	3	3	2	2
5135	1247	transcriptional factor nf-kappa b	[transcriptional factors NF-kappa B]	3.1699250014423126	4	2	0	0
5136	1247	precursor cell line	[precursor cell lines]	3.1699250014423126	3	3	3	3
5137	1247	regulate gene transcription	[regulating gene transcription]	3.1699250014423126	3	3	3	3
5138	1247	mitogen-activated protein kinase pathway	[mitogen-activated protein kinase pathway]	3.1699250014423126	4	3	2	2
5139	1247	heat shock gene	[heat shock genes]	3.1699250014423126	3	3	1	1
5140	1247	ebv b cell	[EBV B cells]	3.1699250014423126	3	2	0	0
5141	1247	gel shift experiment	[Gel shift experiments]	3.1699250014423126	3	2	0	0
5142	1247	pyrrolidine dithiocarbamate pdtc	[pyrrolidine dithiocarbamate PDTC]	3.1699250014423126	3	3	2	2
5143	1247	nuclear regulatory protein	[nuclear regulatory proteins]	3.1699250014423126	3	2	0	0
5144	1247	induction of nf-at activity	[induction of NF-AT activity]	3.1699250014423126	4	2	0	0
5145	1247	leukemic atll cell	[leukemic ATLL cells]	3.1699250014423126	3	2	0	0
5146	1247	similar degree of reduction	[similar degree of reduction]	3.1699250014423126	4	2	0	0
5147	1247	functional promoter activity	[functional promoter activity]	3.1699250014423126	3	3	1	1
5148	1247	CsA -sensitive mechanism	[CsA -sensitive mechanism]	3.1699250014423126	3	2	0	0
5149	1247	vitro kinase assay	[vitro kinase assay]	3.1699250014423126	3	2	0	0
5150	1247	human chromosome 11	[human chromosome 11]	3.1699250014423126	3	2	0	0
5151	1247	several positive regulatory element	[several positive regulatory elements]	3.1699250014423126	4	2	0	0
5152	1247	oct-1 DNA binding activity	[Oct-1 DNA binding activity]	3.1699250014423126	4	2	0	0
5153	1247	glucocorticoid receptor mrna expression	[glucocorticoid receptor mRNA expression]	3.1699250014423126	4	3	2	2
5154	1247	use this assay,	[Using this assay,]	3.1699250014423126	3	2	0	0
5155	1247	band 1pk activity	[band 1pk activity]	3.1699250014423126	3	2	0	0
5156	1247	activation of b cell	[activation of B cells]	3.1699250014423126	4	3	2	2
5157	1247	production of il-1beta protein	[production of IL-1beta protein]	3.1699250014423126	4	2	0	0
5158	1247	critical transcription factor	[critical transcription factor]	3.1699250014423126	3	3	2	2
5159	1247	nf-kappa b mobilization	[NF-kappa B mobilization]	3.1699250014423126	3	3	2	2
5160	1247	GAL4 DNA bind domain	[GAL4 DNA binding domain]	3.1699250014423126	4	2	0	0
5161	1247	t(8;21) acute leukemia	[t(8;21) acute leukemia]	3.1699250014423126	3	3	3	3
5162	1247	0.1-0.5 microm dmdtc	[0.1-0.5 microM DMDTC]	3.1699250014423126	3	2	0	0
5163	1247	mitogen-activated protein (map) kinase	[mitogen-activated protein (MAP) kinase]	3.1699250014423126	4	2	0	0
5164	1247	activity of NFAT	[activity of NFAT]	3.1699250014423126	3	3	2	2
5165	1247	high level gene expression	[high level gene expression]	3.1699250014423126	4	2	0	0
5166	1247	human primary T lymphocyte	[human primary T lymphocytes]	3.1699250014423126	4	2	0	0
5167	1247	induction of hiv expression	[induction of HIV expression]	3.1699250014423126	4	3	1	1
5168	1247	control of cell growth	[control of cell growth]	3.1699250014423126	4	2	0	0
5169	1247	presence of Epo	[presence of Epo]	3.1699250014423126	3	2	0	0
5170	1247	hsv-1 strain F	[HSV-1 strain F]	3.1699250014423126	3	2	0	0
5171	1247	latent membrane protein 1	[latent membrane protein 1]	3.1699250014423126	4	3	2	2
5172	1247	plzf-rar alpha fusion protein	[PLZF-RAR alpha fusion protein]	3.1699250014423126	4	2	0	0
5173	1247	chronic pulmonary heart disease	[chronic pulmonary heart disease]	3.1699250014423126	4	2	0	0
5174	1247	tyrosine kinase inhibitor genistein	[tyrosine kinase inhibitors genistein]	3.1699250014423126	4	2	0	0
5175	1247	differentiation inhibitory activity	[differentiation inhibitory activity]	3.1699250014423126	3	2	0	0
5176	1247	seek social support	[seeking social support]	3.1699250014423126	3	3	3	3
5177	1247	upstream promoter region	[upstream promoter region]	3.1699250014423126	3	3	2	2
5178	1247	risk develop prostate cancer	[risk developing prostate cancer]	3.1699250014423126	4	2	0	0
5179	1247	latent membrane protein-1	[latent membrane protein-1]	3.1699250014423126	3	3	2	2
5180	1247	NFAT complex with Fos	[NFAT complex with Fos]	3.1699250014423126	4	2	0	0
5181	1247	antisense cell line	[antisense cell lines]	3.1699250014423126	3	2	0	0
5182	1247	bone marrow progenitor	[bone marrow progenitor]	3.1699250014423126	3	3	1	1
5183	1247	pre-B cell stage	[pre-B cell stage]	3.1699250014423126	3	2	0	0
5184	1247	pu.1 binding site	[PU.1 binding site]	3.1699250014423126	3	3	2	2
5185	1247	p65 /p50 heterodimer	[p65 /p50 heterodimer]	3.1699250014423126	3	2	0	0
5186	1247	adult bone marrow	[adult bone marrow]	3.1699250014423126	3	3	1	1
5187	1247	inducible promoter activity	[inducible promoter activity]	3.1699250014423126	3	2	0	0
5188	1247	serum response factor SRF	[serum response factor SRF]	3.1699250014423126	4	2	0	0
5189	1247	calmodulin-dependent phosphatase calcineurin	[calmodulin-dependent phosphatase calcineurin]	3.1699250014423126	3	2	0	0
5190	1247	t-cell proliferative activity	[T-cell proliferative activity]	3.1699250014423126	3	2	0	0
5191	1247	angioimmunoblastic t-cell lymphoma	[angioimmunoblastic T-cell lymphoma]	3.1699250014423126	3	3	2	2
5192	1247	NF-kappaB/Rel family member	[NF-kappaB/Rel family members]	3.1699250014423126	3	2	0	0
5193	1247	hGR -Ile 729	[hGR -Ile 729]	3.1699250014423126	3	2	0	0
5194	1247	androgen receptor behavior	[androgen receptor behavior]	3.1699250014423126	3	2	0	0
5195	1247	1 nef protein	[1 Nef protein]	3.1699250014423126	3	2	0	0
5196	1247	peripheral blood t-lymphocyte	[peripheral blood T-lymphocytes]	3.1699250014423126	3	3	2	2
5197	1247	histocompatibility complex MHC	[histocompatibility complex MHC]	3.1699250014423126	3	3	2	2
5198	1247	role in expression	[role in expression]	3.1699250014423126	3	3	3	3
5199	1247	hiv long terminal	[HIV long terminal]	3.1699250014423126	3	3	1	1
5200	1247	impairment of cellular function	[impairment of cellular function]	3.1699250014423126	4	2	0	0
5201	1247	lymphocyte from normal subject	[lymphocytes from normal subjects]	3.1699250014423126	4	2	0	0
5202	1247	contain a site	[containing a site]	3.1699250014423126	3	3	3	3
5203	1247	subset of acute leukemia	[subset of acute leukemias]	3.1699250014423126	4	3	3	3
5204	1247	cell fate decision	[cell fate decisions]	3.1699250014423126	3	3	1	1
5205	1247	inhibitor of b activation	[inhibitor of B activation]	3.1699250014423126	4	3	3	3
5206	1247	nf-kappa b binding protein	[NF-kappa B binding proteins]	3.1699250014423126	4	2	0	0
5207	1247	NF-kappa b alone	[NF-kappa B alone]	3.1699250014423126	3	2	0	0
5208	1247	kappa b domain	[kappa B domain]	3.1699250014423126	3	3	2	2
5209	1247	two transactivation domain	[two transactivation domains]	3.1699250014423126	3	2	0	0
5210	1247	switch to ige	[switching to IgE]	3.1699250014423126	3	3	2	2
5211	1247	evidence for regulation	[evidence for regulation]	3.1699250014423126	3	3	2	2
5212	1247	Oct-2 -harbor tester strain	[Oct-2 -harboring tester strain]	3.1699250014423126	4	2	0	0
5213	1247	tyrosine phosphorylation of stat1	[tyrosine phosphorylation of STAT1]	3.1699250014423126	4	3	2	2
5214	1247	mucosal hGR level	[mucosal hGR levels]	3.1699250014423126	3	2	0	0
5215	1247	granulocytic differentiation pathway	[granulocytic differentiation pathway]	3.1699250014423126	3	2	0	0
5216	1247	Okadaic acid treatment	[Okadaic acid treatment]	3.1699250014423126	3	2	0	0
5217	1247	GATA binding site	[GATA binding site]	3.1699250014423126	3	3	2	2
5218	1247	human carcinoma cell line	[human carcinoma cell line]	3.1699250014423126	4	3	3	3
5219	1247	JAK -stat signal pathway	[JAK -STAT signaling pathway]	3.1699250014423126	4	2	0	0
5220	1247	human immunodeficiency virus transcription	[human immunodeficiency virus transcription]	3.1699250014423126	4	3	2	2
5221	1247	use monoclonal antibody mab	[using monoclonal antibodies mAb]	3.1699250014423126	4	2	0	0
5222	1247	tcr signal transduction	[TCR signal transduction]	3.1699250014423126	3	2	0	0
5223	1247	dexamethasone on [3H]thymidine incorporation	[dexamethasone on [3H]thymidine incorporation]	3.1699250014423126	4	2	0	0
5224	1247	all-trans-retinoic acid atra	[all-trans-retinoic acid ATRA]	3.1699250014423126	3	2	0	0
5225	1247	chronic lymphocytic leukemia CLL	[chronic lymphocytic leukemia CLL]	3.1699250014423126	4	3	1	1
5226	1247	blood cell pbmc	[blood cell PBMC]	3.1699250014423126	3	3	3	3
5227	1247	C-terminal sh2 domain	[C-terminal SH2 domain]	3.1699250014423126	3	2	0	0
5228	1247	transcription factor stat6	[transcription factor STAT6]	3.1699250014423126	3	3	2	2
5229	1247	wheat germ lysate	[wheat germ lysate]	3.1699250014423126	3	2	0	0
5230	1247	response to stimuli.	[response to stimuli.]	3.1699250014423126	3	3	3	3
5231	1247	mouse t-cell line	[mouse T-cell line]	3.1699250014423126	3	2	0	0
5232	1247	gamma delta cell	[gamma delta cells]	3.1699250014423126	3	2	0	0
5233	1247	porcine MHC class ii	[porcine MHC class II]	3.1699250014423126	4	3	2	2
5234	1247	v-abl protein tyrosine kinase	[v-abl protein tyrosine kinase]	3.1699250014423126	4	3	1	1
5235	1247	Electrophoretic mobility shift analysis	[Electrophoretic mobility shift analysis]	3.1699250014423126	4	3	1	1
5236	1247	glucocorticoid receptor antagonist RU	[glucocorticoid receptor antagonist RU]	3.1699250014423126	4	3	3	3
5237	1247	pleiotropic transcription factor	[pleiotropic transcription factor]	3.1699250014423126	3	3	2	2
5238	1247	kappa b enhancer element	[kappa B enhancer element]	3.1699250014423126	4	3	2	2
5239	1247	proliferator-activated receptor gamma	[proliferator-activated receptor gamma]	3.1699250014423126	3	3	3	3
5240	1247	sequence-specific dna-binding protein	[sequence-specific DNA-binding protein]	3.1699250014423126	3	3	2	2
5241	1247	entire dna-binding domain	[entire DNA-binding domain]	3.1699250014423126	3	2	0	0
5242	1247	beta globin promoter	[beta globin promoter]	3.1699250014423126	3	3	1	1
5243	1247	il-4 promoter activation	[IL-4 promoter activation]	3.1699250014423126	3	2	0	0
5244	1247	presence of phorbol ester	[presence of phorbol esters]	3.1699250014423126	4	2	0	0
5245	1247	percentage of apoptotic cell	[percentage of apoptotic cells]	3.1699250014423126	4	2	0	0
5246	1247	tnf-alpha gene expression	[TNF-alpha gene expression]	3.1699250014423126	3	3	1	1
5247	1247	optimal transcriptional activity	[optimal transcriptional activity]	3.1699250014423126	3	2	0	0
5248	1247	alpha RAR alpha	[alpha RAR alpha]	3.1699250014423126	3	2	0	0
5249	1247	major complex class	[major complex class]	3.1699250014423126	3	3	3	3
5250	1247	T cell mitogen	[T cell mitogens]	3.1699250014423126	3	3	2	2
5251	1247	use a whole-cell assay	[using a whole-cell assay]	3.1699250014423126	4	3	3	3
5252	1247	sickle blood cell	[sickle blood cells]	3.1699250014423126	3	3	3	3
5253	1247	multiple nuclear factor	[multiple nuclear factors]	3.1699250014423126	3	2	0	0
5254	1247	Xenogeneic human serum	[Xenogeneic human serum]	3.1699250014423126	3	2	0	0
5255	1247	human tsp 1	[human TSP 1]	3.1699250014423126	3	3	1	1
5256	1247	zebra activation domain	[ZEBRA activation domain]	3.1699250014423126	3	2	0	0
5257	1247	human jurkat T cell	[human Jurkat T cells]	3.1699250014423126	4	3	3	3
5258	1247	phorbol ester alone	[phorbol ester alone]	3.1699250014423126	3	2	0	0
5259	1247	immunoglobulin heavy chain enhancer	[immunoglobulin heavy chain enhancer]	3.1699250014423126	4	3	2	2
5260	1247	induction of il-2	[induction of IL-2]	3.1699250014423126	3	3	2	2
5261	1247	human hematopoietic cell line	[human hematopoietic cell line]	3.1699250014423126	4	2	0	0
5262	1247	guanine nucleotide exchange factor	[guanine nucleotide exchange factor]	3.1699250014423126	4	3	2	2
5263	1247	transcription factor requirement	[transcription factor requirement]	3.1699250014423126	3	2	0	0
5264	1247	case of acute leukemia	[cases of acute leukemia]	3.1699250014423126	4	3	3	3
5265	1247	pretreatment with actinomycin d	[Pretreatment with actinomycin D]	3.1699250014423126	4	2	0	0
5266	1247	resistance to defensin	[resistance to defensin]	3.1699250014423126	3	3	1	1
5267	1247	human tnf-alpha promoter	[human TNF-alpha promoter]	3.1699250014423126	3	3	1	1
5268	1247	herpes simplex virus type	[herpes simplex virus type]	3.1699250014423126	4	3	3	3
5269	1247	maximal il-2rbeta promoter activity	[maximal IL-2Rbeta promoter activity]	3.1699250014423126	4	2	0	0
5270	1247	suggest a possible role	[suggesting a possible role]	3.1699250014423126	4	3	3	3
5271	1247	hypomelanosis of Ito	[hypomelanosis of Ito]	3.1699250014423126	3	2	0	0
5272	1247	prior in vitro studies,	[prior in vitro studies,]	3.1699250014423126	4	2	0	0
5273	1247	component of the receptor	[component of the receptors]	3.1699250014423126	4	3	2	2
5274	1247	repeat of immunodeficiency virus	[repeat of immunodeficiency virus]	3.1699250014423126	4	3	3	3
5275	1247	nf-kappab -dependent activation	[NF-kappaB -dependent activation]	3.1699250014423126	3	3	2	2
5276	1247	activation of transcriptional factor	[activation of transcriptional factors]	3.1699250014423126	4	3	3	3
5277	1247	phorbol ester phorbol 12-myristate	[phorbol ester phorbol 12-myristate]	3.1699250014423126	4	2	0	0
5278	1247	human mineralocorticoid receptor hmr	[human mineralocorticoid receptor hMR]	3.1699250014423126	4	2	0	0
5279	1247	study in cell	[study in cells]	3.1699250014423126	3	3	2	2
5280	1247	proximal IL-4 promoter	[proximal IL-4 promoter]	3.1699250014423126	3	3	1	1
5281	1247	tcr signal pathway	[TCR signaling pathway]	3.1699250014423126	3	3	3	3
5282	1247	only from anf-e2 promoter	[only from aNF-E2 promoter]	3.1699250014423126	4	2	0	0
5283	1247	production of tnf-alpha	[production of TNF-alpha]	3.1699250014423126	3	3	1	1
5284	1247	ptdin 3-kinase activity	[PtdIns 3-kinase activity]	3.1699250014423126	3	2	0	0
5285	1247	variety of stimulus	[variety of stimuli]	3.1699250014423126	3	2	0	0
5286	1247	deletion in this element	[Deletions in this element]	3.1699250014423126	4	2	0	0
5287	1247	NFAT gene family member	[NFAT gene family member]	3.1699250014423126	4	2	0	0
5288	1247	second male patient	[second male patient]	3.1699250014423126	3	2	0	0
5289	1247	class ii gene expression	[class II gene expression]	3.1699250014423126	4	3	2	2
5290	1247	variety of stimuli,	[variety of stimuli,]	3.1699250014423126	3	3	2	2
5291	1247	site of adenoviral persistence	[site of adenoviral persistence]	3.1699250014423126	4	2	0	0
5292	1247	il-4 promoter activity	[IL-4 promoter activity]	3.1699250014423126	3	3	2	2
5293	1247	increase in the percentage	[increase in the percentage]	3.1699250014423126	4	3	2	2
5294	1247	Jak -stat pathway	[Jak -STAT pathway]	3.1699250014423126	3	2	0	0
5295	1247	human T cells.	[human T cells.]	3.1699250014423126	3	2	0	0
5296	1247	growth-inhibitory effect of tgf-beta1	[growth-inhibitory effect of TGF-beta1]	3.1699250014423126	4	2	0	0
5297	1247	insulin receptor substrate-2	[insulin receptor substrate-2]	3.1699250014423126	3	2	0	0
5298	1247	transcription factor activity	[transcription factor activity]	3.1699250014423126	3	3	1	1
5299	1247	transcription factor factor-kappa b	[transcription factor factor-kappa B]	3.1699250014423126	4	3	2	2
5300	1247	adult peripheral blood	[adult peripheral blood]	3.1699250014423126	3	3	1	1
5301	1247	proliferation in response	[proliferation in response]	3.1699250014423126	3	3	3	3
5302	1247	patient with primary ss	[patients with primary SS]	3.1699250014423126	4	2	0	0
5303	1247	CD28 costimulatory pathway	[CD28 costimulatory pathway]	3.1699250014423126	3	3	1	1
5304	1247	shift from the erythroid	[shift from the erythroid]	3.1699250014423126	4	2	0	0
5305	1247	transcriptase-polymerase chain reaction	[transcriptase-polymerase chain reaction]	3.1699250014423126	3	3	3	3
5306	1247	NF-kappa B site	[NF-kappa B site]	3.1699250014423126	3	2	0	0
5307	1247	T leukemia cell line	[T leukemia cell line]	3.1699250014423126	4	3	2	2
5308	1247	virtue of ability	[virtue of ability]	3.1699250014423126	3	3	1	1
5309	1247	YY1 binding site	[YY1 binding site]	3.1699250014423126	3	3	2	2
5310	1247	constitutive transcription factor	[constitutive transcription factor]	3.1699250014423126	3	3	2	2
5311	1247	variety of biological process	[variety of biological processes]	3.1699250014423126	4	2	0	0
5312	1247	treatment of hl60 cell	[Treatment of HL60 cells]	3.1699250014423126	4	3	2	2
5313	1247	intracellular glutathione level	[intracellular glutathione level]	3.1699250014423126	3	3	1	1
5314	1247	decrease in the expression	[decrease in the expression]	3.1699250014423126	4	3	1	1
5315	1247	signal pathway lead	[signaling pathway leading]	3.1699250014423126	3	3	2	2
5316	1247	hpa axis function	[HPA axis function]	3.1699250014423126	3	3	1	1
5317	1247	expression of il-6	[expression of IL-6]	3.1699250014423126	3	3	2	2
5318	1247	CD3 ligation by mAb	[CD3 ligation by mAb]	3.1699250014423126	4	2	0	0
5319	1247	cell surface activation marker	[cell surface activation markers]	3.1699250014423126	4	2	0	0
5320	1247	binding of nuclear factor	[binding of nuclear factors]	3.1699250014423126	4	3	3	3
5321	1247	expression of class gene	[expression of class genes]	3.1699250014423126	4	3	3	3
5322	1247	insulin gene promoter activity	[insulin gene promoter activity]	3.1699250014423126	4	2	0	0
5323	1247	nuclear export signal	[nuclear export signal]	3.1699250014423126	3	2	0	0
5324	1247	tyrosine kinase activation	[tyrosine kinase activation]	3.1699250014423126	3	3	3	3
5325	1247	activation of c-fo	[activation of c-fos]	3.1699250014423126	3	3	1	1
5326	1247	JAK -stat signal	[JAK -STAT signaling]	3.1699250014423126	3	2	0	0
5327	1247	-236 to -96 sequence	[-236 to -96 sequence]	3.1699250014423126	4	2	0	0
5328	1247	acquisition of antitumor function	[acquisition of antitumor function]	3.1699250014423126	4	2	0	0
5329	1247	lead to a increase	[leading to a increase]	3.1699250014423126	4	2	0	0
5330	1247	amino acid 729	[amino acid 729]	3.1699250014423126	3	2	0	0
5331	1247	hla-dra gene expression	[HLA-DRA gene expression]	3.1699250014423126	3	3	1	1
5332	1247	Flow cytometric analysis	[Flow cytometric analysis]	3.1699250014423126	3	2	0	0
5333	1247	patient with vkc	[patients with VKC]	3.1699250014423126	3	3	3	3
5334	1247	gene transcription in neutrophil	[gene transcription in neutrophils]	3.1699250014423126	4	2	0	0
5335	1247	result in activation	[resulting in activation]	3.1699250014423126	3	3	3	3
5336	1247	protein kinase c stimulation	[protein kinase C stimulation]	3.1699250014423126	4	3	1	1
5337	1247	primary sjogrens' syndrome	[primary Sjogrens' syndrome]	3.1699250014423126	3	2	0	0
5338	1247	NF kappa B	[NF kappa B]	3.1699250014423126	3	3	1	1
5339	1247	kappa b alpha protein	[kappa B alpha protein]	3.1699250014423126	4	2	0	0
5340	1247	cloning of murine tcf-1	[Cloning of murine TCF-1]	3.1699250014423126	4	2	0	0
5341	1247	patient with leukaemia	[patient with leukaemia]	3.1699250014423126	3	3	3	3
5342	1247	rna polymerase ii transcription	[RNA polymerase II transcription]	3.1699250014423126	4	3	2	2
5343	1247	circulate T cell	[circulating T cells]	3.1699250014423126	3	3	3	3
5344	1247	follicular dendritic cell	[follicular dendritic cells]	3.1699250014423126	3	3	3	3
5345	1247	dnase I hypersensitive site	[DNase I hypersensitive site]	3.1699250014423126	4	3	2	2
5346	1247	surface MHC class ii	[surface MHC class II]	3.1699250014423126	4	2	0	0
5347	1247	human transcription factor	[human transcription factor]	3.1699250014423126	3	3	3	3
5348	1247	igh gene expression	[IgH gene expression]	3.1699250014423126	3	3	2	2
5349	1247	thymoma cell line	[thymoma cell line]	3.1699250014423126	3	3	1	1
5350	1247	nucleotide exchange factor	[nucleotide exchange factor]	3.1699250014423126	3	3	3	3
5351	1247	activation of mapk pathway	[activation of MAPK pathway]	3.1699250014423126	4	2	0	0
5352	1247	T lymphoid cell	[T lymphoid cells]	3.1699250014423126	3	3	1	1
5353	1247	role in leukemogenesis	[role in leukemogenesis]	3.1699250014423126	3	3	2	2
5354	1247	development of th1 cell	[development of Th1 cells]	3.1699250014423126	4	2	0	0
5355	1247	latent transcription factor	[latent transcription factor]	3.1699250014423126	3	3	1	1
5356	1247	human cytomegalovirus hcmv	[human cytomegalovirus HCMV]	3.1699250014423126	3	3	1	1
5357	1247	multiple binding site	[multiple binding sites]	3.1699250014423126	3	3	2	2
5358	1247	level of il-2	[levels of IL-2]	3.1699250014423126	3	3	2	2
5359	1247	RANTES promoter region	[RANTES promoter region]	3.1699250014423126	3	2	0	0
5360	1247	gc -resistant group	[GC -resistant group]	3.1699250014423126	3	2	0	0
5361	1247	YJ cell line	[YJ cell line]	3.1699250014423126	3	2	0	0
5362	1247	nuclei of this cell	[nuclei of these cells]	3.1699250014423126	4	2	0	0
5363	1247	novel elastase inhibitor	[novel elastase inhibitor]	3.1699250014423126	3	3	3	3
5364	1247	modulation of gene expression	[modulation of gene expression]	3.1699250014423126	4	3	2	2
5365	1247	absence of protein synthesis	[absence of protein synthesis]	3.1699250014423126	4	2	0	0
5366	1247	spontaneous lymphocyte proliferation	[spontaneous lymphocyte proliferation]	3.1699250014423126	3	3	2	2
5367	1247	U937 promonocytic cell	[U937 promonocytic cells]	3.1699250014423126	3	4	2	1
5368	1247	p53 tumor suppressor gene	[p53 tumor suppressor gene]	3.1699250014423126	4	2	0	0
5369	1247	effect on the activation	[effect on the activation]	3.1699250014423126	4	3	3	3
5370	1247	kappa b-directed transcription	[kappa B-directed transcription]	3.1699250014423126	3	2	0	0
5371	1247	proximal ccaat box	[proximal CCAAT box]	3.1699250014423126	3	2	0	0
5372	1247	steroid receptor superfamily	[steroid receptor superfamily]	3.1699250014423126	3	3	1	1
5373	1247	15-lo promoter DNA	[15-LO promoter DNA]	3.1699250014423126	3	2	0	0
5374	1247	androgen binding site	[Androgen binding sites]	3.1699250014423126	3	4	2	1
5375	1247	NH2 regulatory domain	[NH2 regulatory domain]	3.1699250014423126	3	3	1	1
5376	1247	long cell line	[long-term cell lines]	3.1699250014423126	3	2	0	0
5377	1247	NF-kappa b level	[NF-kappa B level]	3.1699250014423126	3	3	1	1
5378	1247	TCR alpha enhancer complex	[TCR alpha enhancer complex]	3.1699250014423126	4	2	0	0
5379	1247	treatment with okadaic acid	[Treatment with okadaic acid]	3.1699250014423126	4	3	2	2
5380	1247	human cell carcinoma	[human cell carcinomas]	3.1699250014423126	3	3	2	2
5381	1247	NF-kappaB binding site	[NF-kappaB binding site]	3.1699250014423126	3	3	1	1
5382	1247	human b-lymphocyte precursor	[human B-lymphocyte precursors]	3.1699250014423126	3	3	1	1
5383	1247	normal bone marrow	[normal bone marrow]	3.1699250014423126	3	3	2	2
5384	1247	beta-globin gene expression	[beta-globin gene expression]	3.1699250014423126	3	3	2	2
5385	1247	corresponding plasma cortisol level	[corresponding plasma cortisol levels]	3.1699250014423126	4	2	0	0
5386	1247	NDP kinase expression	[NDP kinase expression]	3.1699250014423126	3	3	2	2
5387	1247	inducible degradation of p105	[inducible degradation of p105]	3.1699250014423126	4	2	0	0
5388	1247	reporter gene experiment	[Reporter gene experiments]	3.1699250014423126	3	2	0	0
5389	1247	hematopoietin receptor superfamily	[hematopoietin receptor superfamily]	3.1699250014423126	3	2	0	0
5390	1247	IFN alpha production	[IFN alpha production]	3.1699250014423126	3	3	2	2
5391	1247	large granular lymphocyte	[large granular lymphocytes]	3.1699250014423126	3	3	1	1
5392	1247	cellular activation by thrombin	[Cellular activation by thrombin]	3.1699250014423126	4	2	0	0
5393	1247	expression of a variety	[expression of a variety]	3.1699250014423126	4	3	1	1
5394	1247	nuclear envelope inner membrane	[nuclear envelope inner membrane]	3.1699250014423126	4	2	0	0
5395	1247	protein kinase inhibitor	[protein kinase inhibitor]	3.1699250014423126	3	3	3	3
5396	1247	erythroid kruppel-like factor	[erythroid Kruppel-like factor]	3.1699250014423126	3	3	2	2
5397	1247	JAK2 /stat5 pathway	[JAK2 /STAT5 pathway]	3.1699250014423126	3	2	0	0
5398	1247	normal immune system	[normal immune system]	3.1699250014423126	3	2	0	0
5399	1247	level of transcription factor	[level of transcription factor]	3.1699250014423126	4	3	3	3
5400	1247	low risk woman	[low risk women]	3.1699250014423126	3	3	1	1
5401	1247	kappa b binding site	[kappa B binding site]	3.1699250014423126	4	3	1	1
5402	1247	leukemic cell line k562	[leukemic cell line K562]	3.1699250014423126	4	3	1	1
5403	1247	antigen-specific T cell recognition	[antigen-specific T cell recognition]	3.1699250014423126	4	2	0	0
5404	1247	early B-cell development	[early B-cell development]	3.1699250014423126	3	2	0	0
5405	1247	steroid/thyroid hormone receptor family	[steroid/thyroid hormone receptor family]	3.1699250014423126	4	3	1	1
5406	1247	healthy subject (p	[healthy subjects (P]	3.1699250014423126	3	2	0	0
5407	1247	analysis of DNA binding	[Analysis of DNA binding]	3.1699250014423126	4	2	0	0
5408	1247	endothelial icam-1 expression	[endothelial ICAM-1 expression]	3.1699250014423126	3	2	0	0
5409	1247	thermosensitive sv40 T antigen	[thermosensitive SV40 T antigen]	3.1699250014423126	4	2	0	0
5410	1247	use cell line	[using cell lines]	3.1699250014423126	3	3	3	3
5411	1247	ii breast cancer patient	[II breast cancer patients]	3.1699250014423126	4	2	0	0
5412	1247	monocytic U937 cell line	[monocytic U937 cell line]	3.1699250014423126	4	2	0	0
5413	1247	contrast to neutrophil	[contrast to neutrophils]	3.1699250014423126	3	2	0	0
5414	1247	colon cancer cell line	[colon cancer cell lines]	3.1699250014423126	4	2	0	0
5415	1247	one such cytokine	[one such cytokine]	3.1699250014423126	3	2	0	0
5416	1247	differentiation of erythroid progenitor	[differentiation of erythroid progenitors]	3.1699250014423126	4	2	0	0
5417	1247	cd4+ t-cell line	[CD4+ T-cell lines]	3.1699250014423126	3	3	2	2
5418	1247	non-clonal progenitor cell	[non-clonal progenitor cells]	3.1699250014423126	3	2	0	0
5419	1247	hypersensitivity site 2	[hypersensitivity site 2]	3.1699250014423126	3	2	0	0
5420	1247	et gene family	[ets gene family]	3.1699250014423126	3	2	0	0
5421	1247	Jak/Stat signal pathway	[Jak/Stat signaling pathway]	3.1699250014423126	3	2	0	0
5422	1247	b-cell-specific activator protein BSAP	[B-cell-specific activator protein BSAP]	3.1699250014423126	4	2	0	0
5423	1247	expression of p21(waf1/cip1)	[expression of p21(WAF1/CIP1)]	3.1699250014423126	3	2	0	0
5424	1247	initial stage of infection	[initial stages of infection]	3.1699250014423126	4	3	1	1
5425	1247	benign uterus tumour leiomyoma	[benign uterus tumour leiomyoma]	3.1699250014423126	4	2	0	0
5426	1247	host cell transcription	[host cell transcription]	3.1699250014423126	3	2	0	0
5427	1247	23 healthy woman	[23 healthy women]	3.1699250014423126	3	2	0	0
5428	1247	specific progesterone receptor	[specific progesterone receptors]	3.1699250014423126	3	2	0	0
5429	1247	sensitivity of this cell	[sensitivity of these cells]	3.1699250014423126	4	3	1	1
5430	1247	analysis of gene expression	[analysis of gene expression]	3.1699250014423126	4	3	1	1
5431	1247	transcription factor important	[transcription factors important]	3.1699250014423126	3	2	0	0
5432	1247	myelo- monocytic cell	[myelo- monocytic cells]	3.1699250014423126	3	3	1	1
5433	1247	human b7.1 gene	[human B7.1 gene]	3.1699250014423126	3	2	0	0
5434	1247	role in gene expression	[role in gene expression]	3.1699250014423126	4	3	3	3
5435	1247	pathogenesis of hiv infection	[pathogenesis of HIV infection]	3.1699250014423126	4	2	0	0
5436	1247	development of a/r tolerance	[development of A/R tolerance]	3.1699250014423126	4	3	1	1
5437	1247	myogenic transcription factor	[myogenic transcription factors]	3.1699250014423126	3	2	0	0
5438	1247	number of report	[number of reports]	3.1699250014423126	3	2	0	0
5439	1247	patient with benign tumor	[patients with benign tumors]	3.1699250014423126	4	2	0	0
5440	1247	interleukin 2 IL-2	[interleukin 2 IL-2]	3.1699250014423126	3	3	3	3
5441	1247	lineage-restricted transcription factor gata-1	[lineage-restricted transcription factor GATA-1]	3.1699250014423126	4	2	0	0
5442	1247	enzyme-linked assay ELISA	[enzyme-linked assay ELISA]	3.1699250014423126	3	3	3	3
5443	1247	control of proliferation	[control of proliferation]	3.1699250014423126	3	3	1	1
5444	1247	untreated CML patient	[untreated CML patients]	3.1699250014423126	3	2	0	0
5445	1247	erythroid cell survival	[erythroid cell survival]	3.1699250014423126	3	3	1	1
5446	1247	human lox-1 gene	[human LOX-1 gene]	3.1699250014423126	3	3	1	1
5447	1247	several recent study	[Several recent studies]	3.1699250014423126	3	2	0	0
5448	1247	activity of protein	[activity of proteins]	3.1699250014423126	3	3	3	3
5449	1247	induction of Bcl-xL	[induction of Bcl-xL]	3.1699250014423126	3	2	0	0
5450	1247	interleukin 2 IL-2 gene	[interleukin 2 IL-2 gene]	3.1699250014423126	4	3	1	1
5451	1247	patient with hepatitis	[patients with hepatitis]	3.1699250014423126	3	3	3	3
5452	1247	murine erythroleukemia (mel) cell	[murine erythroleukemia (MEL) cells]	3.1699250014423126	4	3	1	1
5453	1247	ig gene transcription	[Ig gene transcription]	3.1699250014423126	3	3	2	2
5454	1247	histone deacetylase activity	[histone deacetylase activity]	3.1699250014423126	3	2	0	0
5455	1247	level of activity	[level of activity]	3.1699250014423126	3	3	2	2
5456	1247	effect on the proliferation	[effect on the proliferation]	3.1699250014423126	4	3	3	3
5457	1247	corresponding genomic sequence	[corresponding genomic sequence]	3.1699250014423126	3	2	0	0
5458	1247	macrophage scavenger receptor	[macrophage scavenger receptor]	3.1699250014423126	3	3	3	3
5459	1247	cellular glucocorticoid receptor level	[cellular glucocorticoid receptor levels]	3.1699250014423126	4	3	1	1
5460	1247	T cell-specific expression	[T cell-specific expression]	3.1699250014423126	3	3	1	1
5461	1247	human peripheral blood	[human peripheral blood]	3.1699250014423126	3	2	0	0
5462	1247	NF-kappa b signalling pathway	[NF-kappa B signalling pathway]	3.1699250014423126	4	2	0	0
5463	1247	HB9 rna transcript	[HB9 RNA transcripts]	3.1699250014423126	3	2	0	0
5464	1247	Recent biochemical study	[Recent biochemical studies]	3.1699250014423126	3	2	0	0
5465	1247	early progenitor cell	[early progenitor cells]	3.1699250014423126	3	3	3	3
5466	1247	activity of a promoter	[activity of a promoter]	3.1699250014423126	4	3	2	2
5467	1247	level of c-jun mrna	[level of c-jun mRNA]	3.1699250014423126	4	2	0	0
5468	1247	differentiation of leukemia cell	[differentiation of leukemia cells]	3.1699250014423126	4	3	2	2
5469	1247	tumour necrosis factor-alpha	[tumour necrosis factor-alpha]	3.1699250014423126	3	4	4	2
5470	1247	class iii snrna gene	[class III snRNA genes]	3.1699250014423126	4	2	0	0
5471	1247	component of the factor	[component of the factor]	3.1699250014423126	4	3	3	3
5472	1247	il-1beta mrna expression	[IL-1beta mRNA expression]	3.1699250014423126	3	2	0	0
5473	1247	phosphorylation of stat protein	[phosphorylation of STAT proteins]	3.1699250014423126	4	2	0	0
5474	1247	synovial T cell	[synovial T cells]	3.1699250014423126	3	3	1	1
5475	1247	human peripheral T lymphocyte	[human peripheral T lymphocytes]	3.1699250014423126	4	3	1	1
5476	1247	transcription factor sp1	[transcription factor SP1]	3.1699250014423126	3	3	1	1
5477	1247	erythroid differentiation program	[erythroid differentiation program]	3.1699250014423126	3	3	1	1
5478	1247	two other site	[Two other sites]	3.1699250014423126	3	2	0	0
5479	1247	set of protein	[set of proteins]	3.1699250014423126	3	3	3	3
5480	1247	role of this protein	[role of these proteins]	3.1699250014423126	4	3	2	2
5481	1247	nuclear factor-kappaB translocation	[nuclear factor-kappaB translocation]	3.1699250014423126	3	3	2	2
5482	1247	specific DNA binding protein	[specific DNA binding protein]	3.1699250014423126	4	3	1	1
5483	1247	tissue-specific transcription factor	[tissue-specific transcription factor]	3.1699250014423126	3	3	1	1
5484	1247	only a slight effect.	[only a slight effect.]	3.1699250014423126	4	2	0	0
5485	1247	NF-kappa b gene transcription	[NF-kappa B gene transcription]	3.1699250014423126	4	2	0	0
5486	1247	nuclear nf-kappa b expression	[nuclear NF-kappa B expression]	3.1699250014423126	4	2	0	0
5487	1247	ikappab-alpha protein level	[IkappaB-alpha protein levels]	3.1699250014423126	3	2	0	0
5488	1247	effect on hiv-1 transcription	[effect on HIV-1 transcription]	3.1699250014423126	4	2	0	0
5489	1247	presence of Cu2+	[presence of Cu2+]	3.1699250014423126	3	2	0	0
5490	1247	chemokine gene expression	[chemokine gene expression]	3.1699250014423126	3	2	0	0
5491	1247	lymphoblastic leukemia cell	[lymphoblastic leukemia cell]	3.1699250014423126	3	3	2	2
5492	1247	nf-kappa b -DNA interaction	[NF-kappa B -DNA interaction]	3.1699250014423126	4	3	2	2
5493	1247	level of unstimulated cell	[level of unstimulated cells]	3.1699250014423126	4	2	0	0
5494	1247	regulation of MHC class	[regulation of MHC class]	3.1699250014423126	4	2	0	0
5495	1247	ligation of CD3	[Ligation of CD3]	3.1699250014423126	3	2	0	0
5496	1247	TCR alpha enhancer	[TCR alpha enhancer]	3.1699250014423126	3	2	0	0
5497	1247	ability of IL-2	[ability of IL-2]	3.1699250014423126	3	2	0	0
5498	1247	monocyte/macrophage cell by lipopolysaccharide	[monocyte/macrophage cells by lipopolysaccharide]	3.1699250014423126	4	2	0	0
5499	1247	resting T cell	[resting T cells]	3.1699250014423126	3	3	1	1
5500	1247	upstream stimulatory factor	[upstream stimulatory factor]	3.1699250014423126	3	3	1	1
5501	1247	cd3+/cd4+ T cell	[CD3+/CD4+ T cells]	3.1699250014423126	3	3	2	2
5502	1247	expression of promoter	[expression of promoters]	3.1699250014423126	3	3	2	2
5503	1247	RNA polymerase ii promoter	[RNA polymerase II promoters]	3.1699250014423126	4	2	0	0
5504	1247	intracellular signal protein	[intracellular signaling proteins]	3.1699250014423126	3	3	3	3
5505	1247	switch to cp	[switch to Cp]	3.1699250014423126	3	2	0	0
5506	1247	such as lipopolysaccharide	[such as lipopolysaccharide]	3.1699250014423126	3	2	0	0
5507	1247	DNA mobility shift assay	[DNA mobility shift assay]	3.1699250014423126	4	4	2	1
5508	1247	induction of cytolytic resistance	[induction of cytolytic resistance]	3.1699250014423126	4	2	0	0
5509	1247	rna polymerase transcription	[RNA polymerase transcription]	3.1699250014423126	3	3	3	3
5510	1247	rest human b cell	[resting human B cells]	3.1699250014423126	4	2	0	0
5511	1247	activator of gene	[activator of genes]	3.1699250014423126	3	3	3	3
5512	1247	mouse GM-CSF promoter	[mouse GM-CSF promoter]	3.1699250014423126	3	2	0	0
5513	1247	alternative use of promoter	[alternative use of promoters]	3.1699250014423126	4	3	1	1
5514	1247	production of inflammatory cytokine	[production of inflammatory cytokines]	3.1699250014423126	4	2	0	0
5515	1247	adipocyte fatty acid	[adipocyte fatty acid]	3.1699250014423126	3	2	0	0
5516	1247	wild-type ciita activity	[wild-type CIITA activity]	3.1699250014423126	3	2	0	0
5517	1247	5' regulatory enhancer region	[5' regulatory enhancer region]	3.1699250014423126	4	2	0	0
5518	1247	histone h5 gene	[histone h5 gene]	3.1699250014423126	3	3	1	1
5519	1247	b-cell-specific activator protein	[B-cell-specific activator protein]	3.1699250014423126	3	3	3	3
5520	1247	plasma renin activity	[plasma renin activity]	3.1699250014423126	3	3	2	2
5521	1247	A-MYB transcription factor	[A-MYB transcription factor]	3.1699250014423126	3	2	0	0
5522	1247	understand the mechanism	[Understanding the mechanism]	3.1699250014423126	3	3	3	3
5523	1247	DNA bind activity	[DNA binding activity]	3.1699250014423126	3	3	1	1
5524	1247	cotton-top tamarin receptor	[cotton-top tamarin receptors]	3.1699250014423126	3	2	0	0
5525	1247	average number of peptide	[average number of peptides]	3.1699250014423126	4	2	0	0
5526	1247	AP-1 family member	[AP-1 family members]	3.1699250014423126	3	3	3	3
5527	1247	decrease in expression	[decrease in expression]	3.1699250014423126	3	3	2	2
5528	1247	expression of il-2 mrna	[expression of IL-2 mRNA]	3.1699250014423126	4	2	0	0
5529	1247	leukocyte alkaline phosphatase	[leukocyte alkaline phosphatase]	3.1699250014423126	3	2	0	0
5530	1247	tissue factor expression	[Tissue factor expression]	3.1699250014423126	3	3	3	3
5531	1247	paternal x chromosome	[paternal X chromosome]	3.1699250014423126	3	2	0	0
5532	1247	use a series	[using a series]	3.1699250014423126	3	3	1	1
5533	1247	expression of this genes.	[expression of these genes.]	3.1699250014423126	4	3	2	2
5534	1247	NK3.3 cell line	[NK3.3 cell line]	3.1699250014423126	3	2	0	0
5535	1247	normal human b lymphocyte	[normal human B lymphocytes]	3.1699250014423126	4	3	1	1
5536	1247	expression of ap-1	[expression of AP-1]	3.1699250014423126	3	2	0	0
5537	1247	normal comparison subject	[normal comparison subjects]	3.1699250014423126	3	2	0	0
5538	1247	repression of ap-1 activity	[repression of AP-1 activity]	3.1699250014423126	4	2	0	0
5539	1247	human myelomonocytic cell line	[human myelomonocytic cell line]	3.1699250014423126	4	3	1	1
5540	1247	low shear-induced vcam-1 expression	[low shear-induced VCAM-1 expression]	3.1699250014423126	4	2	0	0
5541	1247	chimeric oncoprotein e2a-hlf	[chimeric oncoprotein E2A-HLF]	3.1699250014423126	3	2	0	0
5542	1247	dex -resistant clone	[dex -resistant clones]	3.1699250014423126	3	3	1	1
5543	1247	effect of antioxidant	[effect of antioxidants]	3.1699250014423126	3	3	2	2
5544	1247	x-linked hypophosphatemic ricket	[X-linked hypophosphatemic rickets]	3.1699250014423126	3	2	0	0
5545	1247	response to glucocorticoid	[response to glucocorticoids]	3.1699250014423126	3	3	1	1
5546	1247	adenovirus type 2 genome	[adenovirus type 2 genome]	3.1699250014423126	4	2	0	0
5547	1247	inducible gene expression	[inducible gene expression]	3.1699250014423126	3	3	1	1
5548	1247	human inflammatory disease	[human inflammatory diseases]	3.1699250014423126	3	2	0	0
5549	1247	myeloid leukemia cell line	[myeloid leukemia cell lines]	3.1699250014423126	4	3	2	2
5550	1247	nfat DNA binding activity	[NFAT DNA binding activity]	3.1699250014423126	4	2	0	0
5551	1247	promoter of muscle-specific gene	[promoters of muscle-specific genes]	3.1699250014423126	4	2	0	0
5552	1247	10 nm RA	[10 nM RA]	3.1699250014423126	3	3	1	1
5553	1247	new aldosterone membrane receptor	[new aldosterone membrane receptor]	3.1699250014423126	4	2	0	0
5554	1247	translation initiation codon	[translation initiation codon]	3.1699250014423126	3	2	0	0
5555	1247	dominant-negative form of Stat3	[dominant-negative form of Stat3]	3.1699250014423126	4	2	0	0
5556	1247	Nuclear run-on analysis	[Nuclear run-on analysis]	3.1699250014423126	3	2	0	0
5557	1247	glucocorticoid on lymphocyte proliferation	[glucocorticoids on lymphocyte proliferation]	3.1699250014423126	4	2	0	0
5558	1247	putative x box	[putative X boxes]	3.1699250014423126	3	2	0	0
5559	1247	Jun kinase JNK	[Jun kinase JNK]	3.1699250014423126	3	3	3	3
5560	1247	activation of b	[activation of B]	3.1699250014423126	3	3	3	3
5561	1247	response to a number	[response to a number]	3.1699250014423126	4	2	0	0
5562	1247	kappab binding activity	[kappaB binding activity]	3.1699250014423126	3	3	1	1
5563	1247	classical genomic effects,	[classical genomic effects,]	3.1699250014423126	3	2	0	0
5564	1247	chromatin -dependent manner	[chromatin -dependent manner]	3.1699250014423126	3	2	0	0
5565	1247	dnase I site	[DNase I site]	3.1699250014423126	3	3	3	3
5566	1247	E2F transcriptional activity	[E2F transcriptional activity]	3.1699250014423126	3	3	2	2
5567	1247	erythroid cell-specific gene	[erythroid cell-specific genes]	3.1699250014423126	3	3	2	2
5568	1247	phosphorylation of serine 727	[phosphorylation of serine 727]	3.1699250014423126	4	2	0	0
5569	1247	bind site for protein(s)	[binding site for protein(s)]	3.1699250014423126	4	2	0	0
5570	1247	v-erb a protein	[v-erb A protein]	3.1699250014423126	3	3	1	1
5571	1247	ad 2/5 e1a sequence	[Ad 2/5 E1a sequences]	3.1699250014423126	4	3	2	2
5572	1247	120 bp upstream	[120 bp upstream]	3.1699250014423126	3	2	0	0
5573	1247	vitro mutagenesis experiment	[vitro mutagenesis experiments]	3.1699250014423126	3	2	0	0
5574	1247	migration of monocyte	[migration of monocytes]	3.1699250014423126	3	4	4	2
5575	1247	menopausal type ii	[menopausal type II]	3.1699250014423126	3	2	0	0
5576	1247	lymphoid cell-specific factor	[lymphoid cell-specific factor]	3.1699250014423126	3	3	2	2
5577	1247	core promoter activity	[core promoter activity]	3.1699250014423126	3	2	0	0
5578	1247	activator of transcription-6	[activator of transcription-6]	3.1699250014423126	3	2	0	0
5579	1247	transcriptional control element	[transcriptional control element]	3.1699250014423126	3	3	2	2
5580	1247	gene expression in monocyte	[gene expression in monocytes]	3.1699250014423126	4	3	3	3
5581	1247	kappa L chain	[kappa L chain]	3.1699250014423126	3	3	2	2
5582	1247	understanding of the regulation	[understanding of the regulation]	3.1699250014423126	4	3	3	3
5583	1247	hiv-1 nef protein	[HIV-1 Nef protein]	3.1699250014423126	3	2	0	0
5584	1247	patient with cancer	[patients with cancers]	3.1699250014423126	3	3	2	2
5585	1247	cytoplasm of T cell	[cytoplasm of T cells]	3.1699250014423126	4	2	0	0
5586	1247	vitamin d analog	[vitamin D analogs]	3.1699250014423126	3	2	0	0
5587	1247	AP-1 consensus sequence	[AP-1 consensus sequence]	3.1699250014423126	3	2	0	0
5588	1247	transcription (stat) family	[transcription (Stat) family]	3.1699250014423126	3	2	0	0
5589	1247	group of protein	[group of proteins]	3.1699250014423126	3	3	2	2
5590	1248	GR	[GR]	3.155555555555556	1	33	13	9
5591	1249	copy	[copy]	3.1500000000000004	1	33	30	20
5592	1250	carcinoma	[carcinoma]	3.1473684210526316	1	33	29	19
5593	1251	donor	[donor]	3.1437500000000003	1	33	25	16
5594	1252	Jak1	[Jak1]	3.141666666666667	1	33	19	12
5595	1253	inducer	[inducer]	3.1388888888888893	1	33	29	18
5596	1254	susceptibility	[susceptibility]	3.1375	1	33	26	16
5597	1255	herpesvirus	[herpesvirus]	3.1285714285714286	1	33	24	14
5598	1256	myristate	[myristate]	3.1142857142857143	1	36	34	7
5599	1257	GATA-3	[GATA-3]	3.1	1	32	9	9
5600	1258	proteasome	[proteasome]	3.0909090909090913	1	32	12	11
5601	1259	glutathione	[glutathione]	3.088888888888889	1	32	20	18
5602	1260	RXR	[RXR]	3.0846153846153848	1	32	15	13
5603	1261	synergy	[synergy]	3.077777777777778	1	33	20	9
5604	1262	protease	[protease]	3.075	1	32	25	20
5605	1263	human	[human]	3.0714285714285716	1	32	9	7
5606	1264	Jak	[Jak]	3.066666666666667	1	32	12	9
5607	1265	variation	[variation]	3.0631578947368423	1	32	26	19
5608	1266	reaction	[reaction]	3.0600000000000005	1	32	28	20
5609	1267	Rb	[Rb]	3.055555555555556	1	32	13	9
5610	1268	signalling	[signalling]	3.0500000000000003	1	32	24	16
5611	1269	liver	[liver]	3.033333333333333	1	32	20	12
5612	1270	cDNA cloning	[cDNA cloning]	3.0	2	4	1	1
5613	1270	second exon	[second exon]	3.0	2	4	1	1
5614	1270	four complex	[four complexes]	3.0	2	4	2	2
5615	1270	cl-01 cell	[CL-01 cells]	3.0	2	3	0	0
5616	1270	ifn-gamma gene	[IFN-gamma gene]	3.0	2	4	3	3
5617	1270	selective activation	[Selective activation]	3.0	2	5	4	2
5618	1270	gene segment	[gene segment]	3.0	2	4	4	4
5619	1270	il-4 production	[IL-4 production]	3.0	2	4	1	1
5620	1270	marrow	[marrow]	3.0	1	33	30	10
5621	1270	IFN -MCP	[IFN -MCP]	3.0	2	4	1	1
5622	1270	macrophage colony-stimumulatelany-stg	[macrophage colony-stimulating]	3.0	2	4	3	3
5623	1270	platelet aggregation	[platelet aggregation]	3.0	2	5	4	2
5624	1270	Ala peptide	[Ala peptide]	3.0	2	3	0	0
5625	1270	apoptotic neutrophil	[apoptotic neutrophils]	3.0	2	4	1	1
5626	1270	important role in the pathogenesis	[important role in the pathogenesis]	3.0	5	4	1	1
5627	1270	lymphoid lineage	[lymphoid lineage]	3.0	2	3	0	0
5628	1270	nuclear staining	[nuclear staining]	3.0	2	4	2	2
5629	1270	cholera toxin	[cholera toxin]	3.0	2	3	0	0
5630	1270	contain copy	[containing copies]	3.0	2	4	4	4
5631	1270	human b-cell	[human B-cell]	3.0	2	4	1	1
5632	1270	major mechanism	[major mechanism]	3.0	2	4	3	3
5633	1270	PMA /a23187	[PMA /A23187]	3.0	2	3	0	0
5634	1270	viral pathogenesis	[viral pathogenesis]	3.0	2	3	0	0
5635	1270	12 month	[12 months]	3.0	2	4	3	3
5636	1270	viral persistence	[viral persistence]	3.0	2	3	0	0
5637	1270	il-2 stimulation	[IL-2 stimulation]	3.0	2	4	2	2
5638	1270	myelomonocytic lineage	[myelomonocytic lineage]	3.0	2	4	2	2
5639	1270	tissue section	[tissue sections]	3.0	2	4	3	3
5640	1270	biological response	[biological response]	3.0	2	4	3	3
5641	1270	transient-transfection assay	[transient-transfection assay]	3.0	2	3	0	0
5642	1270	foam cell	[foam cell]	3.0	2	4	4	4
5643	1270	recombinant nfat1	[recombinant NFAT1]	3.0	2	3	0	0
5644	1270	same time,	[same time,]	3.0	2	3	0	0
5645	1270	inflammatory gene	[inflammatory genes]	3.0	2	4	3	3
5646	1270	common region	[common region]	3.0	2	3	0	0
5647	1270	qualitative difference	[qualitative difference]	3.0	2	4	3	3
5648	1270	optimal activation	[optimal activation]	3.0	2	6	6	2
5649	1270	b104 cell	[B104 cells]	3.0	2	4	2	2
5650	1270	adult lymphocyte	[adult lymphocytes]	3.0	2	4	2	2
5651	1270	synovial T	[synovial T]	3.0	2	3	0	0
5652	1270	nk3.3 cell	[NK3.3 cells]	3.0	2	4	2	2
5653	1270	receptor status	[receptor status]	3.0	2	4	4	4
5654	1270	present datum	[present data,]	3.0	2	4	1	1
5655	1270	human interleukin-2	[human interleukin-2]	3.0	2	4	3	3
5656	1270	I molecule	[I molecules]	3.0	2	3	0	0
5657	1270	mcp-1 expression	[MCP-1 expression]	3.0	2	4	3	3
5658	1270	HL-60 cell	[HL-60 cells]	3.0	2	4	1	1
5659	1270	t-cell costimulation	[T-cell costimulation]	3.0	2	3	0	0
5660	1270	active tuberculosis	[active tuberculosis]	3.0	2	4	2	2
5661	1270	regulation role	[Regulation role]	3.0	2	4	4	4
5662	1270	expression of cell adhesion molecule	[expression of cell adhesion molecule]	3.0	5	4	2	2
5663	1270	activation of transcription factor ap-1	[activation of transcription factor AP-1]	3.0	5	3	0	0
5664	1270	granulocytic maturation	[granulocytic maturation]	3.0	2	4	2	2
5665	1270	nf-kappab subunit	[NF-kappaB subunits]	3.0	2	4	4	4
5666	1270	beta-globin expression	[beta-globin expression]	3.0	2	4	3	3
5667	1270	cd68+ cell	[CD68+ cells]	3.0	2	4	2	2
5668	1270	S. cerevisiae	[S. cerevisiae]	3.0	2	4	3	3
5669	1270	rapid translocation	[rapid translocation]	3.0	2	4	2	2
5670	1270	1 week	[1 week]	3.0	2	4	2	2
5671	1270	IFN-gamma alone	[IFN-gamma alone]	3.0	2	3	0	0
5672	1270	Y chromosome	[Y chromosome]	3.0	2	4	3	3
5673	1270	vivo study	[vivo studies]	3.0	2	6	3	1
5674	1270	bacterial lps	[bacterial LPS]	3.0	2	4	2	2
5675	1270	13-acetate PMA	[13-acetate PMA]	3.0	2	8	5	1
5676	1270	kinase pathway	[kinase pathway]	3.0	2	4	4	4
5677	1270	transgene expression	[transgene expression]	3.0	2	4	1	1
5678	1270	first study	[first study]	3.0	2	4	1	1
5679	1270	C. albican	[C. albicans]	3.0	2	4	1	1
5680	1270	heart disease	[heart disease]	3.0	2	5	4	2
5681	1270	carboxy-terminal domain	[carboxy-terminal domain]	3.0	2	4	3	3
5682	1270	different gene	[different genes]	3.0	2	4	2	2
5683	1270	p105 precursor	[p105 precursor]	3.0	2	4	1	1
5684	1270	TCF-1 alpha	[TCF-1 alpha]	3.0	2	3	0	0
5685	1270	receptor alpha	[receptor alpha]	3.0	2	4	3	3
5686	1270	pleural effusion	[pleural effusion]	3.0	2	4	1	1
5687	1270	flanking sequence	[flanking sequence]	3.0	2	4	3	3
5688	1270	NFAT element	[NFAT elements]	3.0	2	4	3	3
5689	1270	inducible promoter	[inducible promoter]	3.0	2	4	2	2
5690	1270	tegument protein	[tegument protein]	3.0	2	4	4	4
5691	1270	il-1beta promoter	[IL-1beta promoter]	3.0	2	4	4	4
5692	1270	arginine residue	[arginine residues]	3.0	2	4	3	3
5693	1270	palindromic sequence	[palindromic sequence]	3.0	2	4	4	4
5694	1270	cell fusion	[cell fusion]	3.0	2	4	3	3
5695	1270	cell line.	[cell line.]	3.0	2	3	0	0
5696	1270	antiviral activity	[antiviral activity]	3.0	2	3	0	0
5697	1270	beta 2-m	[beta 2-m]	3.0	2	4	2	2
5698	1270	glucocorticoid response	[glucocorticoid response]	3.0	2	4	1	1
5699	1270	other cells.	[other cells.]	3.0	2	3	0	0
5700	1270	tcr-mediated apoptosis	[TCR-mediated apoptosis]	3.0	2	4	2	2
5701	1270	fmol/10(6) cell	[fmol/10(6) cells]	3.0	2	4	4	4
5702	1270	jun b	[jun B]	3.0	2	4	1	1
5703	1270	Jak1 expression	[Jak1 expression]	3.0	2	4	1	1
5704	1270	cryptococcus neoforman	[Cryptococcus neoformans]	3.0	2	4	1	1
5705	1270	autologous cell	[autologous cell]	3.0	2	4	4	4
5706	1270	lymphoid-specific transcription	[lymphoid-specific transcription]	3.0	2	3	0	0
5707	1270	saccharomy cerevisiae	[Saccharomyces cerevisiae]	3.0	2	4	2	2
5708	1270	NF-AT site	[NF-AT site]	3.0	2	4	2	2
5709	1270	extrinsic asthma	[extrinsic asthma]	3.0	2	3	0	0
5710	1270	5' flank	[5' flank]	3.0	2	5	2	1
5711	1270	inhibitory effect.	[inhibitory effect.]	3.0	2	3	0	0
5712	1270	icam-1 promoter	[ICAM-1 promoter]	3.0	2	4	2	2
5713	1270	lymphocytic infiltration	[lymphocytic infiltration]	3.0	2	4	2	2
5714	1270	interleukin-4 il-4	[interleukin-4 IL-4]	3.0	2	4	4	4
5715	1270	SRG3 protein	[SRG3 protein]	3.0	2	3	0	0
5716	1270	arsenic trioxide	[arsenic trioxide]	3.0	2	4	4	4
5717	1270	NF-kappaB activity	[NF-kappaB activity]	3.0	2	4	3	3
5718	1270	er mrna	[ER mRNA]	3.0	2	4	4	4
5719	1270	1 replication	[1 replication]	3.0	2	4	3	3
5720	1270	repressive function	[repressive function]	3.0	2	4	3	3
5721	1270	gliadin peptide	[gliadin peptide]	3.0	2	4	4	4
5722	1270	sp site	[Sp site]	3.0	2	4	4	4
5723	1270	relative level	[relative levels]	3.0	2	4	2	2
5724	1270	g0s gene	[G0S genes]	3.0	2	4	4	4
5725	1270	mature monocyte	[mature monocytes]	3.0	2	4	1	1
5726	1270	2 T	[2 T]	3.0	2	4	4	4
5727	1270	HTLV-I tax	[HTLV-I Tax]	3.0	2	4	1	1
5728	1270	neoplastic b	[neoplastic B]	3.0	2	3	0	0
5729	1270	two inhibitor	[two inhibitors]	3.0	2	4	4	4
5730	1270	second peak	[second peak]	3.0	2	4	1	1
5731	1270	inhibitor of nf-kappa b activation	[inhibitor of NF-kappa B activation]	3.0	5	4	2	2
5732	1270	5 m	[5 M]	3.0	2	4	2	2
5733	1270	VDR concentration	[VDR concentration]	3.0	2	4	2	2
5734	1270	humoral response	[humoral response]	3.0	2	4	3	3
5735	1270	interleukin-2 production	[interleukin-2 production]	3.0	2	4	2	2
5736	1270	human tcf-1	[human TCF-1]	3.0	2	4	1	1
5737	1270	signalling pathway	[signalling pathway]	3.0	2	4	4	4
5738	1270	limited number	[limited number]	3.0	2	5	4	2
5739	1270	10 nm	[10 nM]	3.0	2	4	2	2
5740	1270	8 h	[8 h]	3.0	2	4	1	1
5741	1270	leukocyte-platelet adhesion	[leukocyte-platelet adhesion]	3.0	2	4	1	1
5742	1270	Th1 clone	[Th1 clone]	3.0	2	4	2	2
5743	1270	mitogen activation	[mitogen activation]	3.0	2	5	4	2
5744	1270	t-cell leukemia virus type htlv-1	[T-cell leukemia virus type HTLV-1]	3.0	5	6	6	2
5745	1270	glucocorticoid action	[glucocorticoid action]	3.0	2	4	1	1
5746	1270	rex gene	[rex gene]	3.0	2	4	1	1
5747	1270	two mutation	[two mutations]	3.0	2	4	2	2
5748	1270	life span	[life span]	3.0	2	4	3	3
5749	1270	transmembrane domain	[transmembrane domain]	3.0	2	4	2	2
5750	1270	transcription activity	[transcription activity]	3.0	2	4	4	4
5751	1270	oleic acid	[oleic acid]	3.0	2	3	0	0
5752	1270	cotransfection assay	[cotransfection assay]	3.0	2	3	0	0
5753	1270	pafr transcript	[PAFR transcript]	3.0	2	4	3	3
5754	1270	nf-kappab inhibitor	[NF-kappaB inhibitor]	3.0	2	4	3	3
5755	1270	antigen presentation	[antigen presentation]	3.0	2	4	2	2
5756	1270	regulation of the immune response	[regulation of the immune response]	3.0	5	3	0	0
5757	1270	macrophage-like cell	[macrophage-like cell]	3.0	2	3	0	0
5758	1270	growth control	[growth control]	3.0	2	3	0	0
5759	1270	chronic bronchiti	[chronic bronchitis]	3.0	2	4	2	2
5760	1270	il-2 cell	[IL-2 cells]	3.0	2	4	3	3
5761	1270	possible involvement	[possible involvement]	3.0	2	5	4	2
5762	1270	human jurkat	[human Jurkat]	3.0	2	3	0	0
5763	1270	antigenic stimulation	[antigenic stimulation]	3.0	2	3	0	0
5764	1270	cytokine il-4	[cytokine IL-4]	3.0	2	4	4	4
5765	1270	level similar	[levels similar]	3.0	2	3	0	0
5766	1270	murine b	[murine B]	3.0	2	4	3	3
5767	1270	target sequence	[target sequence]	3.0	2	4	3	3
5768	1270	element-binding protein	[element-binding protein]	3.0	2	4	4	4
5769	1270	activation of the nuclear factor	[activation of the nuclear factors]	3.0	5	4	1	1
5770	1270	kappa b alpha /mad-3 gene transcription	[kappa B alpha /MAD-3 gene transcription]	3.0	6	3	0	0
5771	1270	g0/g1 switch	[G0/G1 switch]	3.0	2	4	4	4
5772	1270	lmp1 expression	[LMP1 expression]	3.0	2	4	2	2
5773	1270	germline promoter	[germline promoter]	3.0	2	4	3	3
5774	1270	small molecule	[small molecule]	3.0	2	4	2	2
5775	1270	NGAL gene	[NGAL gene]	3.0	2	3	0	0
5776	1270	vascular injury	[vascular injury]	3.0	2	3	0	0
5777	1270	fas apoptosis	[Fas apoptosis]	3.0	2	4	1	1
5778	1270	expression of the reporter gene	[expression of the reporter gene]	3.0	5	4	1	1
5779	1270	normal number	[normal number]	3.0	2	4	4	4
5780	1270	costimulatory molecule	[costimulatory molecule]	3.0	2	4	4	4
5781	1270	tata box	[TATA box]	3.0	2	4	3	3
5782	1270	ikappab alpha	[IkappaB alpha]	3.0	2	4	2	2
5783	1270	other agent	[other agents]	3.0	2	3	0	0
5784	1270	primary b	[primary B]	3.0	2	3	0	0
5785	1270	cell gene	[cell gene]	3.0	2	4	4	4
5786	1270	CXC chemokine	[CXC chemokine]	3.0	2	4	2	2
5787	1270	hiv-1 cell	[HIV-1 cells]	3.0	2	4	2	2
5788	1270	virus type	[virus type]	3.0	2	4	4	4
5789	1270	t-cell population	[T-cell population]	3.0	2	4	3	3
5790	1270	proinflammatory mediator	[proinflammatory mediator]	3.0	2	4	3	3
5791	1270	immunofluorescence study	[Immunofluorescence studies]	3.0	2	4	3	3
5792	1270	hm differentiation	[Hm differentiation]	3.0	2	4	3	3
5793	1270	factor of T cell NFAT	[factor of T cells NFAT]	3.0	5	6	6	2
5794	1270	positive correlation	[positive correlation]	3.0	2	4	4	4
5795	1270	NF-kappaB induction	[NF-kappaB induction]	3.0	2	4	2	2
5796	1270	t-cell hybridoma	[T-cell hybridomas]	3.0	2	3	0	0
5797	1270	viral production	[viral production]	3.0	2	4	1	1
5798	1270	32dcl3 cell	[32Dcl3 cells]	3.0	2	4	1	1
5799	1270	ROI production	[ROI production]	3.0	2	4	2	2
5800	1270	nuclear translocation of nf-kappa b	[nuclear translocation of NF-kappa B]	3.0	5	4	3	3
5801	1270	lavage cell	[lavage cells]	3.0	2	4	4	4
5802	1270	tissue-specific fashion	[tissue-specific fashion]	3.0	2	4	1	1
5803	1270	calyculin a	[calyculin A]	3.0	2	4	2	2
5804	1270	clinical course	[clinical course]	3.0	2	4	2	2
5805	1270	lymphocyte subset	[lymphocyte subsets]	3.0	2	4	3	3
5806	1270	one factor	[one factor]	3.0	2	4	3	3
5807	1270	second signal	[second signal]	3.0	2	3	0	0
5808	1270	ap-1 factor	[AP-1 factors]	3.0	2	4	4	4
5809	1270	T lymphocytic	[T lymphocytic]	3.0	2	4	1	1
5810	1270	mechanism lead	[mechanism leading]	3.0	2	4	4	4
5811	1270	distinct effect	[distinct effect]	3.0	2	4	3	3
5812	1270	additional factor	[additional factor]	3.0	2	4	3	3
5813	1270	mu enhancer	[mu enhancer]	3.0	2	4	2	2
5814	1270	protein bind	[proteins binding]	3.0	2	4	3	3
5815	1270	current study,	[current study,]	3.0	2	3	0	0
5816	1270	IL-6 production	[IL-6 production]	3.0	2	4	1	1
5817	1270	carboxyl-terminal region	[carboxyl-terminal region]	3.0	2	4	3	3
5818	1270	nm23 gene	[NM23 gene]	3.0	2	4	1	1
5819	1270	lytic infection	[lytic infection]	3.0	2	4	1	1
5820	1270	pro-B lymphocyte	[pro-B lymphocytes]	3.0	2	4	1	1
5821	1270	use rt-pcr	[Using RT-PCR]	3.0	2	3	0	0
5822	1270	IL-5 gene	[IL-5 gene]	3.0	2	4	1	1
5823	1270	biologic function	[biologic function]	3.0	2	4	3	3
5824	1270	ht-2 cell	[HT-2 cells]	3.0	2	4	3	3
5825	1270	cytolytic susceptibility	[cytolytic susceptibility]	3.0	2	4	2	2
5826	1270	HIV-1 LTR	[HIV-1 LTR]	3.0	2	4	1	1
5827	1270	regulate the expression of gene	[regulating the expression of genes]	3.0	5	4	2	2
5828	1270	factor-kappaB nf-kappab	[factor-kappaB NF-kappaB]	3.0	2	5	4	2
5829	1270	myeloid precursor	[myeloid precursor]	3.0	2	3	0	0
5830	1270	ebv replication	[EBV replication]	3.0	2	4	3	3
5831	1270	lymphoma b	[lymphoma B]	3.0	2	4	1	1
5832	1270	hiv-1 activation	[HIV-1 activation]	3.0	2	4	3	3
5833	1270	granulocytic pathway	[granulocytic pathway]	3.0	2	3	0	0
5834	1270	role of the transcription factor	[role of the transcription factor]	3.0	5	4	3	3
5835	1270	atopic patient	[atopic patients]	3.0	2	4	3	3
5836	1270	negative role	[negative role]	3.0	2	4	4	4
5837	1270	inverse relationship	[inverse relationship]	3.0	2	3	0	0
5838	1270	cell-mediated immunity	[cell-mediated immunity]	3.0	2	4	1	1
5839	1270	kappa b-alpha	[kappa B-alpha]	3.0	2	4	1	1
5840	1270	immunohistochemical staining	[immunohistochemical staining]	3.0	2	4	1	1
5841	1270	caat box	[CAAT box]	3.0	2	3	0	0
5842	1270	gata-1 expression	[GATA-1 expression]	3.0	2	4	2	2
5843	1270	granulocyte differentiation	[granulocyte differentiation]	3.0	2	4	1	1
5844	1270	novel target	[novel target]	3.0	2	4	4	4
5845	1270	catalase activity	[catalase activity]	3.0	2	3	0	0
5846	1270	circadian rhythm	[circadian rhythm]	3.0	2	4	2	2
5847	1270	human pcd/dcoh	[human PCD/DCoH]	3.0	2	3	0	0
5848	1270	t-cell malignancy	[T-cell malignancy]	3.0	2	4	2	2
5849	1270	unidentified factor	[unidentified factor]	3.0	2	4	3	3
5850	1270	cytokine interleukin-2	[cytokine interleukin-2]	3.0	2	4	4	4
5851	1270	IL-1alpha promoter	[IL-1alpha promoter]	3.0	2	4	2	2
5852	1270	endometrial stroma	[endometrial stroma]	3.0	2	4	1	1
5853	1270	good understanding of the mechanism	[better understanding of the mechanism]	3.0	5	3	0	0
5854	1270	glucocorticoid gc	[glucocorticoid GC]	3.0	2	4	1	1
5855	1270	several protein	[several proteins]	3.0	2	4	4	4
5856	1270	5 minute	[5 min]	3.0	2	4	1	1
5857	1270	ovarian carcinoma	[ovarian carcinoma]	3.0	2	4	3	3
5858	1270	vascular cell adhesion molecule vcam-1	[vascular cell adhesion molecule VCAM-1]	3.0	5	3	0	0
5859	1270	induction of the IL-2 promoter	[induction of the IL-2 promoter]	3.0	5	3	0	0
5860	1270	ach-2 cell	[ACH-2 cells]	3.0	2	4	3	3
5861	1270	ifn-alpha /beta	[IFN-alpha /beta]	3.0	2	4	1	1
5862	1270	BCL6 gene	[BCL6 gene]	3.0	2	3	0	0
5863	1270	nf-kappab binding	[NF-kappaB binding]	3.0	2	4	2	2
5864	1270	neutralize antibody	[neutralizing antibodies]	3.0	2	4	3	3
5865	1270	PML gene	[PML gene]	3.0	2	4	2	2
5866	1270	NFAT site	[NFAT site]	3.0	2	4	2	2
5867	1270	expression of intercellular adhesion molecule-1	[expression of intercellular adhesion molecule-1]	3.0	5	4	2	2
5868	1270	hiv repeat	[HIV repeat]	3.0	2	4	4	4
5869	1270	protein phosphorylation	[protein phosphorylation]	3.0	2	4	2	2
5870	1270	20-epi analogue	[20-epi analogue]	3.0	2	4	3	3
5871	1270	protein secretion	[protein secretion]	3.0	2	4	2	2
5872	1270	octamer-binding site	[octamer-binding site]	3.0	2	4	3	3
5873	1270	ikappab kinase	[IkappaB kinase]	3.0	2	4	3	3
5874	1270	cis-acting site	[cis-acting sites]	3.0	2	4	2	2
5875	1270	spontaneous abortion	[spontaneous abortion]	3.0	2	4	1	1
5876	1270	activation of helper T cell	[Activation of helper T cells]	3.0	5	3	0	0
5877	1270	message stability	[message stability]	3.0	2	3	0	0
5878	1270	t-cell type	[T-cell type]	3.0	2	4	3	3
5879	1270	mechanism distinct	[mechanism distinct]	3.0	2	4	3	3
5880	1270	multiple site	[multiple sites]	3.0	2	3	0	0
5881	1270	hematopoietic precursor	[hematopoietic precursor]	3.0	2	3	0	0
5882	1270	human adenoviruse	[human adenoviruses]	3.0	2	3	0	0
5883	1270	HTLV-I cell	[HTLV-I cells]	3.0	2	4	1	1
5884	1270	tnf-alpha apoptosis	[TNF-alpha apoptosis]	3.0	2	4	2	2
5885	1270	baseline level	[baseline levels]	3.0	2	3	0	0
5886	1270	positive cell	[positive cells]	3.0	2	4	2	2
5887	1270	much attention	[Much attention]	3.0	2	3	0	0
5888	1270	pmn	[PMN]	3.0	1	31	4	4
5889	1270	tiny ring	[tiny ring]	3.0	2	4	2	2
5890	1270	polymorphonuclear cell	[polymorphonuclear cells]	3.0	2	3	0	0
5891	1270	granulocytic lineage	[granulocytic lineage]	3.0	2	4	1	1
5892	1270	GATA-1 gene	[GATA-1 gene]	3.0	2	4	2	2
5893	1270	specific regulation	[specific regulation]	3.0	2	4	4	4
5894	1270	fas signal	[Fas signaling]	3.0	2	3	0	0
5895	1270	t-cell differentiation	[T-cell differentiation]	3.0	2	4	2	2
5896	1270	lmp promoter	[LMP promoter]	3.0	2	4	1	1
5897	1270	protein (map)	[protein (MAP)]	3.0	2	5	4	2
5898	1270	constitutive promoter	[constitutive promoter]	3.0	2	3	0	0
5899	1270	region upstream	[region upstream]	3.0	2	4	4	4
5900	1270	powerful enhancer	[powerful enhancer]	3.0	2	3	0	0
5901	1270	il-12 expression	[IL-12 expression]	3.0	2	3	0	0
5902	1270	72 h	[72 h]	3.0	2	4	2	2
5903	1270	erythroid colony	[erythroid colony]	3.0	2	4	2	2
5904	1270	enhancer activation	[enhancer activation]	3.0	2	4	3	3
5905	1270	Calphostin C	[Calphostin C]	3.0	2	4	1	1
5906	1270	10(-6) m	[10(-6) M]	3.0	2	4	3	3
5907	1270	human monocytic	[human monocytic]	3.0	2	3	0	0
5908	1270	Flow cytometry	[Flow cytometry]	3.0	2	4	1	1
5909	1270	nuclear factor-kappa b nf-kappa b	[nuclear factor-kappa B NF-kappa B]	3.0	5	3	0	0
5910	1270	DRA gene	[DRA gene]	3.0	2	4	2	2
5911	1270	tyrosine phosphatase	[tyrosine phosphatase]	3.0	2	4	3	3
5912	1270	interleukin (il)-10	[interleukin (IL)-10]	3.0	2	4	1	1
5913	1270	tr2re- sv40	[TR2RE- SV40]	3.0	2	3	0	0
5914	1270	gene encode	[gene encoding]	3.0	2	4	4	4
5915	1270	ligand activation	[ligand activation]	3.0	2	4	2	2
5916	1270	leucine zipper	[leucine zipper]	3.0	2	3	0	0
5917	1270	pancreatic beta-cell	[pancreatic beta-cell]	3.0	2	4	1	1
5918	1270	cellular transformation	[cellular transformation]	3.0	2	4	1	1
5919	1270	enhancer-binding protein	[enhancer-binding protein]	3.0	2	4	2	2
5920	1270	mutant mouse	[mutant mice]	3.0	2	4	2	2
5921	1270	ets-1 protein	[Ets-1 protein]	3.0	2	4	3	3
5922	1270	matrix attachment	[matrix attachment]	3.0	2	4	3	3
5923	1270	human breast	[human breast]	3.0	2	4	1	1
5924	1270	c-fos-positive lymphocyte	[c-fos-positive lymphocytes]	3.0	2	4	2	2
5925	1270	distinct pathway	[distinct pathways]	3.0	2	4	4	4
5926	1270	signal integration	[signal integration]	3.0	2	4	2	2
5927	1270	secondary tissue	[secondary tissues]	3.0	2	4	1	1
5928	1270	tcr alpha	[TCR alpha]	3.0	2	4	4	4
5929	1270	Nuclear factor of T cell NFAT	[Nuclear factor of T cells NFAT]	3.0	6	3	0	0
5930	1270	receptor mutant	[receptor mutant]	3.0	2	4	3	3
5931	1270	activator of transcription (stat) factor	[activator of transcription (STAT) factors]	3.0	5	3	0	0
5932	1270	receptor mrna	[receptor mRNA]	3.0	2	4	3	3
5933	1270	ROI formation	[ROI formation]	3.0	2	4	1	1
5934	1270	cellular event	[cellular event]	3.0	2	4	3	3
5935	1270	rwleu-4 cell	[RWLeu-4 cells]	3.0	2	5	4	2
5936	1270	Z/c-myb combination	[Z/c-myb combination]	3.0	2	3	0	0
5937	1270	binding site for transcription factor	[binding site for transcription factors]	3.0	5	4	2	2
5938	1270	aged runner	[aged runner]	3.0	2	5	2	1
5939	1270	cd11b promoter	[CD11b promoter]	3.0	2	4	1	1
5940	1270	Leukotriene B4	[Leukotriene B4]	3.0	2	4	1	1
5941	1270	rel T	[Rel T]	3.0	2	4	3	3
5942	1270	tcr affinity	[TCR affinities]	3.0	2	4	3	3
5943	1270	differentiation block	[differentiation block]	3.0	2	4	2	2
5944	1270	vascular inflammation	[vascular inflammation]	3.0	2	3	0	0
5945	1270	transcriptional event	[transcriptional events]	3.0	2	4	1	1
5946	1270	serum lipoprotein	[serum lipoproteins]	3.0	2	3	0	0
5947	1270	entire domain	[entire domain]	3.0	2	4	3	3
5948	1270	mature macrophage	[mature macrophages]	3.0	2	4	1	1
5949	1270	subsequent degradation	[subsequent degradation]	3.0	2	4	1	1
5950	1270	two isoforms,	[two isoforms,]	3.0	2	4	4	4
5951	1270	concentration-dependent manner	[concentration-dependent manner]	3.0	2	3	0	0
5952	1270	lps activation of thp-1 cell	[LPS activation of THP-1 cells]	3.0	5	3	0	0
5953	1270	clonal expansion	[clonal expansion]	3.0	2	3	0	0
5954	1270	5- increase	[5- increase]	3.0	2	4	4	4
5955	1270	herpesvirus 6	[herpesvirus 6]	3.0	2	6	6	2
5956	1270	cell volume	[cell volume]	3.0	2	3	0	0
5957	1270	human immunodeficiency virus type-1 hiv-1	[human immunodeficiency virus type-1 HIV-1]	3.0	5	3	0	0
5958	1270	translocation of the transcription factor	[translocation of the transcription factor]	3.0	5	4	3	3
5959	1270	Fabry disease	[Fabry disease]	3.0	2	4	2	2
5960	1270	important gene	[important gene]	3.0	2	4	4	4
5961	1270	p 0.05).	[p 0.05).]	3.0	2	3	0	0
5962	1270	elastase inhibitor	[elastase inhibitor]	3.0	2	4	4	4
5963	1270	CD38 expression	[CD38 expression]	3.0	2	4	3	3
5964	1270	core binding	[core binding]	3.0	2	4	4	4
5965	1270	androgen insensitivity	[androgen insensitivity]	3.0	2	4	3	3
5966	1270	viable cell	[viable cells]	3.0	2	4	3	3
5967	1270	sesquiterpene lactone	[sesquiterpene lactone]	3.0	2	4	2	2
5968	1270	viral transactivator	[viral transactivator]	3.0	2	4	4	4
5969	1270	mantle zone	[mantle zone]	3.0	2	4	3	3
5970	1270	Interleukin IL-2	[Interleukin IL-2]	3.0	2	3	0	0
5971	1270	steroid-sensitive asthma	[steroid-sensitive asthma]	3.0	2	3	0	0
5972	1270	nuclear complex	[nuclear complex]	3.0	2	4	2	2
5973	1270	acidic pH	[acidic pH]	3.0	2	4	1	1
5974	1270	clinical remission	[clinical remission]	3.0	2	4	2	2
5975	1270	culture system	[culture system]	3.0	2	4	2	2
5976	1270	Recent datum	[Recent data]	3.0	2	4	2	2
5977	1270	antigen processing	[antigen processing]	3.0	2	4	2	2
5978	1270	24 month	[24 months]	3.0	2	4	4	4
5979	1270	135eoh)2d3 synthesis	[1,25(OH)2D3 synthesis]	3.0	2	4	2	2
5980	1270	1 htlv-1	[1 HTLV-1]	3.0	2	4	1	1
5981	1270	72 P.	[72 h.]	3.0	2	3	0	0
5982	1270	cell survival.	[cell survival.]	3.0	2	4	2	2
5983	1270	lymphoid marker	[lymphoid markers]	3.0	2	3	0	0
5984	1270	endothelial cells.	[endothelial cells.]	3.0	2	4	1	1
5985	1270	distress syndrome	[distress syndrome]	3.0	2	4	4	4
5986	1270	fusion transcript	[fusion transcript]	3.0	2	4	3	3
5987	1270	human hematopoiesis	[human hematopoiesis]	3.0	2	3	0	0
5988	1270	kappab element	[kappaB element]	3.0	2	6	3	1
5989	1270	mn-sod expression	[Mn-SOD expression]	3.0	2	3	0	0
5990	1270	herbimycin a	[herbimycin A]	3.0	2	4	1	1
5991	1270	normal germinal center b cell	[normal germinal center B cells]	3.0	5	3	0	0
5992	1270	foreign antigen	[foreign antigen]	3.0	2	3	0	0
5993	1270	ifn-u937 cell	[IFN-U937 cells]	3.0	2	4	1	1
5994	1270	pre-T cell	[pre-T cells]	3.0	2	4	3	3
5995	1270	NS-Meg cell	[NS-Meg cells]	3.0	2	4	1	1
5996	1270	complex process	[complex process]	3.0	2	4	3	3
5997	1270	dense tubule	[dense tubules]	3.0	2	3	0	0
5998	1270	erythropoietin epo	[erythropoietin EPO]	3.0	2	4	3	3
5999	1270	therapeutic strategy	[therapeutic strategies]	3.0	2	4	3	3
6000	1270	conformational change	[conformational change]	3.0	2	4	3	3
6001	1270	ige synthesis in b cell	[IgE synthesis in B cells]	3.0	5	3	0	0
6002	1270	high risk	[high risk]	3.0	2	4	1	1
6003	1270	lymphoid neoplasm	[lymphoid neoplasms]	3.0	2	3	0	0
6004	1270	distinct domain	[distinct domain]	3.0	2	4	3	3
6005	1270	acidic sphingomyelinase	[acidic sphingomyelinase]	3.0	2	4	2	2
6006	1270	GM-CSF receptor	[GM-CSF receptor]	3.0	2	4	1	1
6007	1270	developmental control	[developmental control]	3.0	2	6	3	1
6008	1270	western analysis	[Western analysis]	3.0	2	3	0	0
6009	1270	same complex	[same complex.]	3.0	2	3	0	0
6010	1270	renal cell	[renal cell]	3.0	2	4	2	2
6011	1270	protein (s)	[protein (s)]	3.0	2	4	4	4
6012	1270	G0/G1 phase	[G0/G1 phase]	3.0	2	3	0	0
6013	1270	chicken IL2	[chicken IL2]	3.0	2	4	1	1
6014	1270	ebv antigen	[EBV antigen]	3.0	2	4	4	4
6015	1270	concentration range	[concentration range]	3.0	2	4	4	4
6016	1270	SLE patient	[SLE patients]	3.0	2	4	3	3
6017	1270	nonhuman primate	[nonhuman primates]	3.0	2	3	0	0
6018	1270	JNK activity	[JNK activity]	3.0	2	4	4	4
6019	1270	present work,	[present work,]	3.0	2	4	1	1
6020	1270	nuclear factor kappa b nf-kappa b	[nuclear factor kappa B NF-kappa B]	3.0	6	3	0	0
6021	1270	cytochalasin D	[cytochalasin D]	3.0	2	4	1	1
6022	1270	impaired activation	[impaired activation]	3.0	2	6	6	2
6023	1270	naive cell	[naive cells]	3.0	2	4	1	1
6024	1270	12-myristate 13-acetate	[12-myristate 13-acetate]	3.0	2	4	2	2
6025	1270	human myelomonocytic	[human myelomonocytic]	3.0	2	3	0	0
6026	1270	early study	[Early studies]	3.0	2	4	2	2
6027	1270	Interleukin-5 IL-5	[Interleukin-5 IL-5]	3.0	2	3	0	0
6028	1270	human t-lymphocyte	[human T-lymphocytes]	3.0	2	4	3	3
6029	1270	nuclear c-rel	[nuclear c-Rel]	3.0	2	4	1	1
6030	1270	membrane form	[membrane form]	3.0	2	4	3	3
6031	1270	P- lps	[P- LPS]	3.0	2	4	2	2
6032	1270	t-cell development	[T-cell development]	3.0	2	4	3	3
6033	1270	gene expression,	[gene expression,]	3.0	2	4	3	3
6034	1270	tpa differentiation	[TPA differentiation]	3.0	2	4	4	4
6035	1270	cross-link CD40 on b cell	[Cross-linking CD40 on B cells]	3.0	5	3	0	0
6036	1270	supershift analysis	[supershift analysis]	3.0	2	5	2	1
6037	1270	receptor down-regulation	[receptor down-regulation]	3.0	2	3	0	0
6038	1270	malignant transformation	[malignant transformation]	3.0	2	4	2	2
6039	1270	human promyelocytic leukemia hl-60 cell	[human promyelocytic leukemia HL-60 cells]	3.0	5	3	0	0
6040	1270	important implication	[important implications]	3.0	2	6	6	2
6041	1270	PPARalpha activator	[PPARalpha activators]	3.0	2	3	0	0
6042	1270	multiple copy	[multiple copies]	3.0	2	6	3	1
6043	1270	Nuclear factor-kappa b NF-kappa b	[Nuclear factor-kappa B NF-kappa B]	3.0	5	3	0	0
6044	1270	ets transcription	[Ets transcription]	3.0	2	4	4	4
6045	1270	monocyte adherence	[monocyte adherence]	3.0	2	4	2	2
6046	1270	matrix metalloproteinase	[matrix metalloproteinase]	3.0	2	4	4	4
6047	1270	phospholipase c	[phospholipase C]	3.0	2	4	4	4
6048	1270	cell lysate	[cell lysates]	3.0	2	4	3	3
6049	1270	several criterion	[several criteria]	3.0	2	3	0	0
6050	1270	second complex	[second complex]	3.0	2	4	1	1
6051	1270	control mouse	[control mice]	3.0	2	4	2	2
6052	1270	class expression	[class expression]	3.0	2	4	4	4
6053	1270	human t-cell leukemia virus type htlv-1	[Human T-cell leukemia virus type HTLV-1]	3.0	6	5	2	1
6054	1270	thymic selection	[thymic selection]	3.0	2	3	0	0
6055	1270	membrane potential	[membrane potential]	3.0	2	4	3	3
6056	1270	double-stranded rna	[double-stranded RNA]	3.0	2	4	2	2
6057	1270	human th1	[human Th1]	3.0	2	3	0	0
6058	1270	b-cell differentiation	[B-cell differentiation]	3.0	2	5	4	2
6059	1270	cd4+ cell	[CD4+ cells]	3.0	2	4	3	3
6060	1270	antigen-specific T	[antigen-specific T]	3.0	2	4	2	2
6061	1270	anti-AIM mab	[anti-AIM mAb]	3.0	2	4	1	1
6062	1270	NF-kappa b1	[NF-kappa B1]	3.0	2	4	2	2
6063	1270	mrna species	[mRNA species]	3.0	2	4	4	4
6064	1270	important molecule	[important molecule]	3.0	2	4	3	3
6065	1270	antigenic challenge	[antigenic challenge]	3.0	2	4	1	1
6066	1270	erythroid factor	[erythroid factor]	3.0	2	4	2	2
6067	1270	less extent,	[lesser extent,]	3.0	2	4	3	3
6068	1270	primary erythroblast	[primary erythroblasts]	3.0	2	4	3	3
6069	1270	Platelet-activating factor	[Platelet-activating factor]	3.0	2	4	1	1
6070	1270	biological process	[biological process]	3.0	2	4	2	2
6071	1270	s phase	[S phase]	3.0	2	4	3	3
6072	1270	cooh-terminal domain	[COOH-terminal domain]	3.0	2	4	2	2
6073	1270	3 day	[3 day]	3.0	2	4	2	2
6074	1270	tnf-alpha promoter	[TNF-alpha promoter]	3.0	2	5	4	2
6075	1270	granulomatous disease	[granulomatous disease]	3.0	2	4	2	2
6076	1270	inflammatory stimulus	[inflammatory stimuli]	3.0	2	4	2	2
6077	1270	tpa treatment	[TPA treatment]	3.0	2	4	2	2
6078	1270	AIDS NHL	[AIDS NHL]	3.0	2	4	3	3
6079	1270	variant translocation	[variant translocation]	3.0	2	4	4	4
6080	1270	atherosclerotic lesion	[atherosclerotic lesions]	3.0	2	6	3	1
6081	1270	relevant concentration	[relevant concentrations]	3.0	2	4	4	4
6082	1270	wild-type level	[wild-type level]	3.0	2	4	3	3
6083	1270	cytotoxic activity	[cytotoxic activity]	3.0	2	4	1	1
6084	1270	modulation of the immune response	[Modulation of the immune response]	3.0	5	3	0	0
6085	1270	agonist activity	[agonist activity]	3.0	2	4	1	1
6086	1270	nf-at factor	[NF-AT factor]	3.0	2	4	2	2
6087	1270	pu.1 site	[PU.1 site]	3.0	2	4	3	3
6088	1270	immunoregulatory cytokine	[immunoregulatory cytokine]	3.0	2	4	3	3
6089	1270	distinct protein	[distinct protein]	3.0	2	4	3	3
6090	1270	complete inhibition	[complete inhibition]	3.0	2	4	4	4
6091	1270	dexamethasone suppression	[dexamethasone suppression]	3.0	2	4	2	2
6092	1270	RXR alpha	[RXR alpha]	3.0	2	4	4	4
6093	1270	N-acetyl-L-cysteine NAC	[N-acetyl-L-cysteine NAC]	3.0	2	4	2	2
6094	1270	regulatory event	[regulatory events]	3.0	2	4	4	4
6095	1270	Candida albican	[Candida albicans]	3.0	2	4	1	1
6096	1270	thyroid gland	[thyroid gland]	3.0	2	4	2	2
6097	1270	factor present	[factor present]	3.0	2	4	4	4
6098	1270	ba/f3 cell	[Ba/F3 cells]	3.0	2	4	3	3
6099	1270	receptor gene	[receptor gene]	3.0	2	4	4	4
6100	1270	lymphocyte-specific protein	[lymphocyte-specific protein]	3.0	2	4	3	3
6101	1270	different aspect	[different aspects]	3.0	2	3	0	0
6102	1270	young donor	[young donors]	3.0	2	5	2	1
6103	1270	tcr beta	[TCR beta]	3.0	2	4	3	3
6104	1270	inducible protein	[inducible protein]	3.0	2	4	3	3
6105	1270	293 cell	[293 cells]	3.0	2	3	0	0
6106	1270	interleukin-6 il-6	[interleukin-6 IL-6]	3.0	2	4	1	1
6107	1270	genetic element	[genetic element]	3.0	2	4	3	3
6108	1270	Class ii	[Class II]	3.0	2	4	3	3
6109	1270	Mn sod	[Mn SOD]	3.0	2	4	2	2
6110	1270	serum-free media	[serum-free media]	3.0	2	3	0	0
6111	1270	steroid binding	[steroid binding]	3.0	2	4	4	4
6112	1270	level of c/ebp epsilon mrna	[levels of C/EBP epsilon mRNA]	3.0	5	3	0	0
6113	1270	[3H]dexamethasone binding	[[3H]dexamethasone binding]	3.0	2	4	3	3
6114	1270	kappa b-like	[kappa B-like]	3.0	2	4	4	4
6115	1270	positive selection	[positive selection]	3.0	2	4	3	3
6116	1270	hiv1 infection	[HIV1 infection]	3.0	2	4	3	3
6117	1270	disease activity	[disease activity]	3.0	2	4	1	1
6118	1270	nf-at induction	[NF-AT induction]	3.0	2	4	1	1
6119	1270	sea urchin	[sea urchin]	3.0	2	4	4	4
6120	1270	ig synthesis	[Ig synthesis]	3.0	2	4	3	3
6121	1270	negative selection	[negative selection]	3.0	2	4	1	1
6122	1270	important mechanism	[important mechanism]	3.0	2	4	4	4
6123	1270	rodent fibroblast	[rodent fibroblasts]	3.0	2	3	0	0
6124	1270	immunodominant epitope	[immunodominant epitope]	3.0	2	4	2	2
6125	1270	lymphoid differentiation	[lymphoid differentiation]	3.0	2	3	0	0
6126	1270	retroviral vector	[retroviral vector]	3.0	2	4	1	1
6127	1270	zap-70 function	[ZAP-70 function]	3.0	2	3	0	0
6128	1270	antiapoptotic effect	[antiapoptotic effect]	3.0	2	3	0	0
6129	1270	normal allele	[normal allele]	3.0	2	3	0	0
6130	1270	activation of a transcription factor	[activation of a transcription factor]	3.0	5	3	0	0
6131	1270	serine/threonine phosphatase	[serine/threonine phosphatase]	3.0	2	4	4	4
6132	1270	acidic domain	[acidic domain]	3.0	2	4	3	3
6133	1270	single site	[single site]	3.0	2	4	3	3
6134	1270	functional difference	[functional differences]	3.0	2	4	2	2
6135	1270	1 hiv-1	[1 HIV-1]	3.0	2	5	4	2
6136	1270	benign tumor	[benign tumor]	3.0	2	3	0	0
6137	1270	cell division	[cell division]	3.0	2	4	2	2
6138	1270	morphological differentiation	[morphological differentiation]	3.0	2	4	2	2
6139	1270	E2F complex	[E2F complex]	3.0	2	4	4	4
6140	1270	t-cell mitogen	[T-cell mitogen]	3.0	2	4	2	2
6141	1270	PuF site	[PuF site]	3.0	2	3	0	0
6142	1270	RAR gamma	[RAR gamma]	3.0	2	4	1	1
6143	1270	caccc-binding protein	[CACCC-binding proteins]	3.0	2	3	0	0
6144	1270	aim of the present study	[aim of the present study]	3.0	5	3	0	0
6145	1270	Epstein-Barr virus nuclear antigen 2	[Epstein-Barr virus nuclear antigen 2]	3.0	5	4	1	1
6146	1270	dibutyryl camp	[dibutyryl cAMP]	3.0	2	4	1	1
6147	1270	induce transcription	[inducing transcription]	3.0	2	4	4	4
6148	1270	K+ channel	[K+ channels]	3.0	2	6	6	2
6149	1270	il-6 production	[IL-6 production]	3.0	2	4	1	1
6150	1270	nre gamma	[NRE gamma]	3.0	2	4	2	2
6151	1270	differential activation	[differential activation]	3.0	2	4	2	2
6152	1270	T cell from RCC patient	[T cells from RCC patients]	3.0	5	3	0	0
6153	1270	oxidative species	[oxidative species]	3.0	2	4	3	3
6154	1270	TNF promoter	[TNF promoter]	3.0	2	4	1	1
6155	1270	other element	[other element]	3.0	2	4	3	3
6156	1270	mitogenic activation	[mitogenic activation]	3.0	2	4	1	1
6157	1270	significant homology	[significant homology]	3.0	2	4	2	2
6158	1270	untreated cell	[untreated cells]	3.0	2	3	0	0
6159	1270	atra treatment	[ATRA treatment]	3.0	2	4	2	2
6160	1270	molecular mimicry	[molecular mimicry]	3.0	2	4	3	3
6161	1270	e2a gene	[E2A gene]	3.0	2	4	2	2
6162	1270	use a gel mobility shift assay	[using a gel mobility shift assay]	3.0	6	3	0	0
6163	1270	corticosteroid treatment	[corticosteroid treatment]	3.0	2	4	2	2
6164	1270	transcription from the GM-CSF promoter	[transcription from the GM-CSF promoter]	3.0	5	3	0	0
6165	1270	differentiation response	[differentiation response]	3.0	2	4	2	2
6166	1270	use the electrophoretic mobility shift assay	[using the electrophoretic mobility shift assay]	3.0	6	3	0	0
6167	1270	expression plasmid	[expression plasmid]	3.0	2	4	3	3
6168	1270	few cell	[few cells]	3.0	2	4	3	3
6169	1270	5'-regulatory region	[5'-regulatory region]	3.0	2	4	1	1
6170	1270	gene rearrangement	[gene rearrangement]	3.0	2	4	3	3
6171	1270	optimal transcription	[optimal transcription]	3.0	2	4	4	4
6172	1270	primary human cd4+ T lymphocyte	[primary human CD4+ T lymphocytes]	3.0	5	3	0	0
6173	1270	NF-kappaB family	[NF-kappaB family]	3.0	2	5	4	2
6174	1270	term culture	[term culture]	3.0	2	4	3	3
6175	1270	ic50 value	[IC50 values]	3.0	2	4	3	3
6176	1270	non-hodgkin' lymphoma	[non-Hodgkin's lymphoma]	3.0	2	4	4	4
6177	1270	genomic clone	[genomic clone]	3.0	2	4	3	3
6178	1270	initial step	[initial step]	3.0	2	4	3	3
6179	1270	physiological condition	[physiological conditions]	3.0	2	4	3	3
6180	1270	vascular endothelium	[vascular endothelium]	3.0	2	3	0	0
6181	1270	blot hybridization	[blot hybridization]	3.0	2	6	6	2
6182	1270	tcr ligation	[TCR ligation]	3.0	2	4	3	3
6183	1270	autoregulatory loop	[autoregulatory loop]	3.0	2	4	1	1
6184	1270	potential regulator	[potential regulator]	3.0	2	4	3	3
6185	1270	20 h	[20 h]	3.0	2	4	3	3
6186	1270	cell of the monocytic lineage	[cells of the monocytic lineage]	3.0	5	4	2	2
6187	1270	intracellular substrate	[intracellular substrates]	3.0	2	4	4	4
6188	1270	id3 mrna	[Id3 mRNA]	3.0	2	4	1	1
6189	1270	number of glucocorticoid binding site	[number of glucocorticoid binding sites]	3.0	5	3	0	0
6190	1270	normal b	[normal B]	3.0	2	4	1	1
6191	1270	indirect evidence	[indirect evidence]	3.0	2	3	0	0
6192	1270	cell-surface receptor	[cell-surface receptor]	3.0	2	4	3	3
6193	1270	first report	[first report]	3.0	2	5	4	2
6194	1270	gene sry	[gene SRY]	3.0	2	4	4	4
6195	1270	70 kda	[70 kDa]	3.0	2	3	0	0
6196	1270	hiv-1 isolate	[HIV-1 isolate]	3.0	2	4	4	4
6197	1270	megakaryocytic differentiation	[megakaryocytic differentiation]	3.0	2	5	2	1
6198	1270	cellular change	[cellular changes]	3.0	2	4	1	1
6199	1270	clone 18	[clone 18]	3.0	2	3	0	0
6200	1270	dna-binding activity of transcription factor	[DNA-binding activity of transcription factors]	3.0	5	4	3	3
6201	1270	C26 element	[C26 element]	3.0	2	4	1	1
6202	1270	DBF site	[DBF site]	3.0	2	3	0	0
6203	1270	inhibitory subunit	[inhibitory subunit]	3.0	2	4	1	1
6204	1270	rhesus macaque	[rhesus macaques]	3.0	2	4	2	2
6205	1270	translation initiation	[translation initiation]	3.0	2	5	4	2
6206	1270	activation of the transcription factor factor-kappaB	[Activation of the transcription factor factor-kappaB]	3.0	6	3	0	0
6207	1270	chemotactic cytokine	[chemotactic cytokine]	3.0	2	4	1	1
6208	1270	id2 mrna	[Id2 mRNA]	3.0	2	5	4	2
6209	1270	immunoregulatory gene	[immunoregulatory gene]	3.0	2	4	4	4
6210	1270	B-cell lineage	[B-cell lineage]	3.0	2	3	0	0
6211	1270	80 kda	[80 kDa]	3.0	2	3	0	0
6212	1270	DNA clone	[DNA clone]	3.0	2	4	4	4
6213	1270	immunorecessive epitope	[immunorecessive epitopes]	3.0	2	3	0	0
6214	1270	cell growth,	[cell growth,]	3.0	2	4	3	3
6215	1270	lymphoid-specific expression	[lymphoid-specific expression]	3.0	2	3	0	0
6216	1270	p105 processing	[p105 processing]	3.0	2	4	2	2
6217	1270	eth2 cell	[eTh2 cells]	3.0	2	5	2	1
6218	1270	metastatic potential	[metastatic potential]	3.0	2	4	1	1
6219	1270	dose-dependent manner,	[dose-dependent manner,]	3.0	2	3	0	0
6220	1270	CTL response	[CTL response]	3.0	2	4	3	3
6221	1270	Interleukin-6 IL-6	[Interleukin-6 IL-6]	3.0	2	3	0	0
6222	1270	HIV individual	[HIV individuals]	3.0	2	4	2	2
6223	1270	NF-IL6 gene	[NF-IL6 gene]	3.0	2	4	1	1
6224	1270	progenitor proliferation	[progenitor proliferation]	3.0	2	4	4	4
6225	1270	1 microm	[1 microM]	3.0	2	4	1	1
6226	1270	tnf-alpha treatment	[TNF-alpha treatment]	3.0	2	3	0	0
6227	1270	ifn-gamma activation	[IFN-gamma activation]	3.0	2	4	3	3
6228	1270	major class	[major class]	3.0	2	4	3	3
6229	1270	viral protease	[viral protease]	3.0	2	3	0	0
6230	1270	cmat protein	[CMAT protein]	3.0	2	3	0	0
6231	1270	interleukin-4 gene	[interleukin-4 gene]	3.0	2	4	2	2
6232	1270	M-CSF receptor	[M-CSF receptor]	3.0	2	3	0	0
6233	1270	physical association	[physical association]	3.0	2	4	3	3
6234	1270	platelet function	[platelet function]	3.0	2	4	4	4
6235	1270	kappa B	[kappa B]	3.0	2	4	4	4
6236	1270	protein- tyrosine	[protein- tyrosine]	3.0	2	4	3	3
6237	1270	pleiotropic effect	[pleiotropic effects]	3.0	2	4	3	3
6238	1270	cytoplasmic form	[cytoplasmic form]	3.0	2	4	3	3
6239	1270	synovial cell	[synovial cells]	3.0	2	4	1	1
6240	1270	embryonic development	[embryonic development]	3.0	2	4	4	4
6241	1270	hl-60/vinc cell	[HL-60/vinc cells]	3.0	2	4	2	2
6242	1270	pkc isoenzyme	[PKC isoenzymes]	3.0	2	4	4	4
6243	1270	Tat protein	[Tat protein]	3.0	2	4	1	1
6244	1270	murine thymocyte	[murine thymocytes]	3.0	2	4	3	3
6245	1270	dna-binding factor	[DNA-binding factor]	3.0	2	4	4	4
6246	1270	RAR antagonist	[RAR antagonist]	3.0	2	4	2	2
6247	1270	myelodysplastic syndrome	[myelodysplastic syndrome]	3.0	2	4	3	3
6248	1270	steady-state level	[steady-state level]	3.0	2	5	2	1
6249	1270	human cd4+	[human CD4+]	3.0	2	3	0	0
6250	1270	human cd14	[human CD14]	3.0	2	4	1	1
6251	1270	erythroid differentiation of k562 cell	[erythroid differentiation of K562 cells]	3.0	5	4	2	2
6252	1270	chronic leukaemia	[chronic leukaemia]	3.0	2	4	4	4
6253	1270	hiv-1 gene	[HIV-1 gene]	3.0	2	4	3	3
6254	1270	etiologic agent	[etiologic agent]	3.0	2	6	3	1
6255	1270	igh locus	[IgH locus]	3.0	2	4	1	1
6256	1270	primary target	[primary target]	3.0	2	4	2	2
6257	1270	il-2 induction	[IL-2 induction]	3.0	2	4	3	3
6258	1270	cell cycle,	[cell cycle,]	3.0	2	3	0	0
6259	1270	natural killer (nk) cell activity	[natural killer (NK) cell activity]	3.0	5	3	0	0
6260	1270	high frequency	[high frequency]	3.0	2	4	3	3
6261	1270	increase evidence	[increasing evidence]	3.0	2	4	1	1
6262	1270	Chinese hamster	[Chinese hamster]	3.0	2	4	1	1
6263	1270	myeloid progenitor	[myeloid progenitor]	3.0	2	4	1	1
6264	1270	high potential	[high potential]	3.0	2	4	4	4
6265	1270	hiv-infected cell	[HIV-infected cells]	3.0	2	5	4	2
6266	1270	neuronal cell	[neuronal cells]	3.0	2	4	1	1
6267	1270	erythroid development	[erythroid development]	3.0	2	5	4	2
6268	1270	different region	[different regions]	3.0	2	5	4	2
6269	1270	ls mutation	[LS mutations]	3.0	2	4	2	2
6270	1270	climacteric syndrome	[climacteric syndrome]	3.0	2	3	0	0
6271	1270	1 transcription	[1 transcription]	3.0	2	4	3	3
6272	1270	intracellular camp	[intracellular cAMP]	3.0	2	3	0	0
6273	1270	C PKC	[C PKC]	3.0	2	4	3	3
6274	1270	il-10 production	[IL-10 production]	3.0	2	4	1	1
6275	1270	3 patient	[3 patients]	3.0	2	4	4	4
6276	1270	h-rs cell	[H-RS cells]	3.0	2	4	3	3
6277	1270	gc formation	[GC formation]	3.0	2	4	3	3
6278	1270	transcription of a reporter gene	[transcription of a reporter gene]	3.0	5	3	0	0
6279	1270	type-ii EBS	[type-II EBS]	3.0	2	4	1	1
6280	1270	apoptotic pathway	[apoptotic pathway]	3.0	2	4	2	2
6281	1270	differentiation arrest	[differentiation arrest]	3.0	2	4	3	3
6282	1270	inverse relation	[inverse relation]	3.0	2	4	4	4
6283	1270	calcium signalling	[calcium signalling]	3.0	2	4	3	3
6284	1271	weight	[weight]	2.991666666666667	1	32	25	12
6285	1272	ap1	[AP1]	2.990909090909091	1	31	12	11
6286	1272	p50/p65	[p50/p65]	2.990909090909091	1	31	12	11
6287	1273	phagocyte	[phagocyte]	2.99	1	32	21	10
6288	1273	substitution	[substitution]	2.99	1	31	22	20
6289	1274	activation.	[activation.]	2.9875000000000003	1	31	9	8
6290	1275	rela	[RelA]	2.9857142857142858	1	31	16	14
6291	1276	fasl	[FasL]	2.9846153846153847	1	31	15	13
6292	1277	CMV	[CMV]	2.9800000000000004	1	31	12	10
6293	1278	insulin	[insulin]	2.975	1	31	10	8
6294	1279	lesion	[lesion]	2.9722222222222223	1	31	23	18
6295	1280	megakaryocyte	[megakaryocyte]	2.966666666666667	1	31	8	6
6296	1280	substrate	[substrate]	2.966666666666667	1	31	20	15
6297	1281	Th1	[Th1]	2.9625000000000004	1	31	11	8
6298	1282	pcr	[PCR]	2.9600000000000004	1	31	21	15
6299	1282	block	[block]	2.9600000000000004	1	31	21	15
6300	1283	migration	[migration]	2.941666666666667	1	31	19	12
6301	1284	processing	[processing]	2.94	1	31	24	15
6302	1285	inactivation	[inactivation]	2.9214285714285717	1	31	25	14
6303	1286	differentiation.	[differentiation.]	2.9000000000000004	1	30	9	9
6304	1286	costimulation	[costimulation]	2.9000000000000004	1	31	22	11
6305	1286	zebra	[ZEBRA]	2.9000000000000004	1	30	14	14
6306	1286	detection	[detection]	2.9000000000000004	1	32	21	7
6307	1287	microm	[microM]	2.8894736842105266	1	30	21	19
6308	1288	PGE2	[PGE2]	2.8888888888888893	1	30	10	9
6309	1288	influence	[influence]	2.8888888888888893	1	32	28	9
6310	1289	gcr	[GCR]	2.8875	1	30	9	8
6311	1290	syndrome	[syndrome]	2.885714285714286	1	30	24	21
6312	1290	Spi-B	[Spi-B]	2.885714285714286	1	30	8	7
6313	1291	phenomenon	[phenomenon]	2.8800000000000003	1	30	12	10
6314	1292	spleen	[spleen]	2.871428571428572	1	30	9	7
6315	1293	IL-3	[IL-3]	2.866666666666667	1	30	4	3
6316	1294	extent	[extent]	2.8647058823529417	1	30	23	17
6317	1295	ad	[Ad]	2.8642857142857143	1	30	19	14
6318	1296	JAK3	[JAK3]	2.8571428571428577	1	30	10	7
6319	1297	selection	[selection]	2.8153846153846156	1	30	24	13
6320	1298	rheumatoid	[rheumatoid]	2.8125	1	30	15	8
6321	1299	work	[work]	2.8100000000000005	1	30	19	10
6322	1300	ICAM-1	[ICAM-1]	2.8000000000000003	1	29	11	11
6323	1300	IL-7	[IL-7]	2.8000000000000003	1	29	3	3
6324	1300	AML1	[AML1]	2.8000000000000003	1	29	8	8
6325	1301	body	[body]	2.7894736842105265	1	29	21	19
6326	1302	cysteine	[cysteine]	2.788888888888889	1	29	10	9
6327	1302	histone	[histone]	2.788888888888889	1	29	10	9
6328	1303	nfkappab	[NFkappaB]	2.785714285714286	1	29	16	14
6329	1304	rearrangement	[rearrangement]	2.78125	1	29	19	16
6330	1305	coactivator	[coactivator]	2.778947368421053	1	29	23	19
6331	1306	LPS	[LPS]	2.7750000000000004	1	29	5	4
6332	1307	corresponding	[corresponding]	2.7733333333333334	1	29	19	15
6333	1308	ar	[AR]	2.766666666666667	1	29	16	12
6334	1308	proteins.	[proteins.]	2.766666666666667	1	29	12	9
6335	1309	month	[month]	2.75625	1	29	23	16
6336	1310	hepatitis	[hepatitis]	2.75	1	29	9	6
6337	1311	htlv-1	[HTLV-1]	2.7454545454545456	1	29	17	11
6338	1312	ester	[ester]	2.7375000000000003	1	29	26	16
6339	1313	trigger	[trigger]	2.7333333333333334	1	30	24	9
6340	1314	hybrid	[hybrid]	2.7	1	28	13	13
6341	1315	antagonist	[antagonist]	2.6933333333333334	1	28	16	15
6342	1316	oxidant	[oxidant]	2.6923076923076925	1	28	14	13
6343	1317	glucocorticoid receptor in peripheral leukocyte	[glucocorticoid receptor in peripheral leukocytes]	2.666666666666667	5	4	4	3
6344	1317	malignant melanoma	[malignant melanoma]	2.666666666666667	2	4	4	3
6345	1317	mobility group	[mobility group]	2.666666666666667	2	4	4	3
6346	1317	major site	[major site]	2.666666666666667	2	4	4	3
6347	1317	core region	[core region]	2.666666666666667	2	4	4	3
6348	1317	non-T cell	[non-T cells]	2.666666666666667	2	4	4	3
6349	1317	bowel disease	[bowel disease]	2.666666666666667	2	4	4	3
6350	1317	phosphoinositide 3-kinase	[phosphoinositide 3-kinase]	2.666666666666667	2	4	4	3
6351	1317	airway cell	[airway cells]	2.666666666666667	2	4	4	3
6352	1317	activate signal	[activating signals]	2.666666666666667	2	4	4	3
6353	1317	human b-lymphocyte	[human B-lymphocyte]	2.666666666666667	2	4	4	3
6354	1317	-dependent manner	[-dependent manner]	2.666666666666667	2	4	4	3
6355	1317	es cell	[ES cells]	2.666666666666667	2	4	4	3
6356	1317	twofold increase	[twofold increase]	2.666666666666667	2	4	4	3
6357	1317	factor paf	[factor PAF]	2.666666666666667	2	4	4	3
6358	1317	growth hormone	[growth hormone]	2.666666666666667	2	4	4	3
6359	1317	circulate lymphocyte	[circulating lymphocytes]	2.666666666666667	2	4	4	3
6360	1317	ca(2+) pathway	[Ca(2+) pathways]	2.666666666666667	2	4	4	3
6361	1317	localization signal	[localization signal]	2.666666666666667	2	4	4	3
6362	1317	rna splicing	[RNA splicing]	2.666666666666667	2	4	4	3
6363	1317	apl cell	[APL cell]	2.666666666666667	2	4	4	3
6364	1317	er level	[ER level]	2.666666666666667	2	4	4	3
6365	1317	polycythemia vera	[polycythemia vera]	2.666666666666667	2	4	4	3
6366	1317	direct inhibition	[direct inhibition]	2.666666666666667	2	4	4	3
6367	1317	inverse correlation	[inverse correlation]	2.666666666666667	2	4	4	3
6368	1317	Ras	[Ras]	2.666666666666667	1	28	8	6
6369	1317	constitutive binding	[constitutive binding]	2.666666666666667	2	4	4	3
6370	1317	tuberculosis patient	[tuberculosis patients]	2.666666666666667	2	4	4	3
6371	1317	functional activation	[functional activation]	2.666666666666667	2	4	4	3
6372	1317	alpha beta	[alpha beta]	2.666666666666667	2	4	4	3
6373	1317	intron	[intron]	2.666666666666667	1	28	20	15
6374	1317	affinity binding	[affinity binding]	2.666666666666667	2	4	4	3
6375	1317	selective inhibition	[selective inhibition]	2.666666666666667	2	4	4	3
6376	1317	EBV origin	[EBV origin]	2.666666666666667	2	4	4	3
6377	1317	nadph oxidase	[NADPH oxidase]	2.666666666666667	2	4	4	3
6378	1317	repressive effect	[repressive effect]	2.666666666666667	2	4	4	3
6379	1317	cell function	[cell function]	2.666666666666667	2	4	4	3
6380	1317	b-cell factor	[B-cell factor]	2.666666666666667	2	4	4	3
6381	1317	factor-kappaB NF-kappaB	[factor-kappaB NF-kappaB]	2.666666666666667	2	4	4	3
6382	1317	vitro differentiation	[vitro differentiation]	2.666666666666667	2	4	4	3
6383	1317	body burden	[body burden]	2.666666666666667	2	4	4	3
6384	1317	leukemia factor	[leukemia factor]	2.666666666666667	2	4	4	3
6385	1317	calcium metabolism	[calcium metabolism]	2.666666666666667	2	4	4	3
6386	1317	physiological concentration	[physiological concentration]	2.666666666666667	2	4	4	3
6387	1317	e1a expression	[E1A expression]	2.666666666666667	2	4	4	3
6388	1317	CLL patient	[CLL patients]	2.666666666666667	2	4	4	3
6389	1317	multiple factor	[multiple factors]	2.666666666666667	2	4	4	3
6390	1317	carboxy terminus	[carboxy terminus]	2.666666666666667	2	4	4	3
6391	1317	protein/dna interaction	[protein/DNA interactions]	2.666666666666667	2	4	4	3
6392	1317	RelB	[RelB]	2.666666666666667	1	28	8	6
6393	1317	weak effect	[weak effect]	2.666666666666667	2	4	4	3
6394	1317	tax induction	[Tax induction]	2.666666666666667	2	4	4	3
6395	1317	enhancer function	[enhancer function]	2.666666666666667	2	4	4	3
6396	1317	cd45r0 T	[CD45R0 T]	2.666666666666667	2	4	4	3
6397	1317	x2 box	[X2 box]	2.666666666666667	2	4	4	3
6398	1317	granulocyte factor	[granulocyte factor]	2.666666666666667	2	4	4	3
6399	1317	il-12r beta	[IL-12R beta]	2.666666666666667	2	4	4	3
6400	1317	major target	[major target]	2.666666666666667	2	4	4	3
6401	1317	3' region	[3' region]	2.666666666666667	2	4	4	3
6402	1317	carcinoma cell	[carcinoma cells]	2.666666666666667	2	4	4	3
6403	1317	contain element	[containing elements]	2.666666666666667	2	4	4	3
6404	1317	factor gm-csf	[factor GM-CSF]	2.666666666666667	2	4	4	3
6405	1317	receptor GCR	[receptors GCR]	2.666666666666667	2	4	4	3
6406	1317	cell lymphoma	[cell lymphoma]	2.666666666666667	2	4	4	3
6407	1317	viral antigen	[viral antigen]	2.666666666666667	2	4	4	3
6408	1317	critical region	[critical region]	2.666666666666667	2	4	4	3
6409	1317	important insight	[important insight]	2.666666666666667	2	4	4	3
6410	1317	pro-B cell	[pro-B cells]	2.666666666666667	2	4	4	3
6411	1317	different form	[different forms]	2.666666666666667	2	4	4	3
6412	1317	3 kb	[3 kb]	2.666666666666667	2	4	4	3
6413	1317	factor-kappaB activation	[factor-kappaB activation]	2.666666666666667	2	4	4	3
6414	1317	beta cell	[beta cell]	2.666666666666667	2	4	4	3
6415	1317	differential effect	[differential effect]	2.666666666666667	2	4	4	3
6416	1317	different response	[different response]	2.666666666666667	2	4	4	3
6417	1317	World primate	[World primate]	2.666666666666667	2	4	4	3
6418	1317	ca2+ transport	[Ca2+ transport]	2.666666666666667	2	4	4	3
6419	1317	adult blood	[adult blood]	2.666666666666667	2	4	4	3
6420	1318	genome	[genome]	2.661538461538462	1	28	18	13
6421	1319	tandem	[tandem]	2.6571428571428575	1	28	10	7
6422	1320	ROI	[ROI]	2.655555555555556	1	28	13	9
6423	1321	fragment	[fragment]	2.6500000000000004	1	28	24	16
6424	1322	slp-76	[SLP-76]	2.6333333333333333	1	28	10	6
6425	1323	competition	[competition]	2.6272727272727274	1	28	19	11
6426	1324	HIV	[HIV]	2.6	1	27	7	7
6427	1324	Rel	[Rel]	2.6	1	27	6	6
6428	1324	NF-IL6	[NF-IL6]	2.6	1	27	6	6
6429	1324	progression	[progression]	2.6	1	28	16	8
6430	1324	conclusion,	[conclusion,]	2.6	1	26	0	0
6431	1325	band	[band]	2.594736842105263	1	27	20	19
6432	1326	coding	[coding]	2.59375	1	27	17	16
6433	1327	However,	[However,]	2.591304347826087	1	27	25	23
6434	1328	EBNA-2	[EBNA-2]	2.5909090909090913	1	27	12	11
6435	1329	il-3	[IL-3]	2.59	1	27	11	10
6436	1330	colony-stimulating	[colony-stimulating]	2.5875000000000004	1	29	25	8
6437	1331	hmg	[HMG]	2.5833333333333335	1	27	14	12
6438	1332	TATA	[TATA]	2.58	1	27	6	5
6439	1333	g1	[G1]	2.575	1	27	10	8
6440	1334	hGR	[hGR]	2.5727272727272728	1	27	14	11
6441	1335	CLL	[CLL]	2.566666666666667	1	27	4	3
6442	1335	Elf-1	[Elf-1]	2.566666666666667	1	27	8	6
6443	1336	majority	[majority]	2.5666666666666664	1	34	25	3
6444	1337	IkappaB	[IkappaB]	2.555555555555556	1	27	13	9
6445	1338	fraction	[fraction]	2.5500000000000003	1	27	24	16
6446	1339	significance	[significance]	2.5470588235294116	1	27	26	17
6447	1340	blotting	[blotting]	2.5300000000000002	1	28	27	10
6448	1341	proportion	[proportion]	2.521428571428572	1	27	25	14
6449	1342	mnda	[MNDA]	2.5142857142857142	1	27	13	7
6450	1343	factor of T cell nfat	[factor of T cells NFAT]	2.5	5	5	5	2
6451	1343	viral cycle	[viral cycle]	2.5	2	4	3	2
6452	1343	dep- pah	[DEP- PAHs]	2.5	2	4	3	2
6453	1343	dramatic decrease	[dramatic decrease]	2.5	2	4	3	2
6454	1343	responsive element	[responsive element]	2.5	2	4	3	2
6455	1343	CD40 antigen	[CD40 antigen]	2.5	2	4	3	2
6456	1343	hypothalamic-pituitary-adrenal system	[hypothalamic-pituitary-adrenal system]	2.5	2	4	3	2
6457	1343	AhR mrna	[AhR mRNA]	2.5	2	4	3	2
6458	1343	interleukin promoter	[interleukin promoter]	2.5	2	4	3	2
6459	1343	NF-kappa B/Rel	[NF-kappa B/Rel]	2.5	2	4	3	2
6460	1343	leukocyte MNL	[leukocytes MNL]	2.5	2	5	5	2
6461	1343	b-cell development	[B-cell development]	2.5	2	4	3	2
6462	1343	one member	[one member]	2.5	2	4	3	2
6463	1343	vitro model	[vitro model]	2.5	2	4	3	2
6464	1343	immunohistochemical study	[Immunohistochemical study]	2.5	2	4	3	2
6465	1343	immediate protein	[immediate protein]	2.5	2	4	3	2
6466	1343	interdomain b	[interdomain B]	2.5	2	4	3	2
6467	1343	potent stimulator	[potent stimulator]	2.5	2	5	5	2
6468	1343	high value	[high values]	2.5	2	4	3	2
6469	1343	a/r tolerance	[A/R tolerance]	2.5	2	4	3	2
6470	1343	nm23 protein	[nm23 proteins]	2.5	2	4	3	2
6471	1343	CREB/ATF family	[CREB/ATF family]	2.5	2	4	3	2
6472	1343	33 patient	[33 patients]	2.5	2	4	3	2
6473	1343	il-8 expression	[IL-8 expression]	2.5	2	5	5	2
6474	1343	Differential regulation	[Differential regulation]	2.5	2	5	5	2
6475	1343	surface immunoglobulin	[surface immunoglobulin]	2.5	2	4	3	2
6476	1343	cn activity	[CN activity]	2.5	2	4	3	2
6477	1343	C. sub.	[C. Sub.]	2.5	2	4	3	2
6478	1343	inhibitory action	[inhibitory action]	2.5	2	5	5	2
6479	1343	two group	[two groups]	2.5	2	5	5	2
6480	1343	25 woman	[25 women]	2.5	2	4	3	2
6481	1343	IL-6 mrna	[IL-6 mRNA]	2.5	2	4	3	2
6482	1343	activation status	[activation status]	2.5	2	4	3	2
6483	1343	stat complex	[STAT complexes]	2.5	2	4	3	2
6484	1343	follicular phase	[follicular phase]	2.5	2	4	3	2
6485	1343	human locus	[human locus]	2.5	2	4	3	2
6486	1343	tandem copy	[Tandem copies]	2.5	2	4	3	2
6487	1343	dual effect	[dual effect]	2.5	2	4	3	2
6488	1343	1a9-m cell	[1A9-M cells]	2.5	2	4	3	2
6489	1343	phosphatase activity	[phosphatase activity]	2.5	2	4	3	2
6490	1343	primary lymphocyte	[primary lymphocytes]	2.5	2	4	3	2
6491	1343	junb	[junB]	2.5	1	26	5	5
6492	1343	htlv-i transcription	[HTLV-I transcription]	2.5	2	4	3	2
6493	1343	suggest important	[suggesting important]	2.5	2	4	3	2
6494	1343	constitutive phosphorylation	[Constitutive phosphorylation]	2.5	2	4	3	2
6495	1343	critical component	[critical component]	2.5	2	5	5	2
6496	1343	protooncogene c-fo	[protooncogene c-fos]	2.5	2	4	3	2
6497	1343	il-1 receptor	[IL-1 receptor]	2.5	2	4	3	2
6498	1343	mrna transcription	[mRNA transcription]	2.5	2	4	3	2
6499	1343	stat3 phosphorylation	[Stat3 phosphorylation]	2.5	2	4	3	2
6500	1343	free calcium	[free calcium]	2.5	2	4	3	2
6501	1343	135(oh)2d3 production	[1,25(OH)2D3 production]	2.5	2	4	3	2
6502	1343	of binding	[of binding]	2.5	2	4	3	2
6503	1343	ifn-gamma promoter	[IFN-gamma promoter]	2.5	2	4	3	2
6504	1343	steroid-resistant asthma	[steroid-resistant asthma]	2.5	2	4	3	2
6505	1343	cd19	[CD19]	2.5	1	26	10	10
6506	1343	potent regulator	[potent regulator]	2.5	2	5	5	2
6507	1343	thiol antioxidant	[thiol antioxidant]	2.5	2	4	3	2
6508	1343	Wurzburg cell	[Wurzburg cells]	2.5	2	4	3	2
6509	1343	gamma chain	[gamma chain]	2.5	2	4	3	2
6510	1343	mononuclear leucocyte	[mononuclear leucocytes]	2.5	2	4	3	2
6511	1343	antiinflammatory agent	[antiinflammatory agent]	2.5	2	4	3	2
6512	1343	all-trans-retinoic acid	[all-trans-retinoic acid]	2.5	2	4	3	2
6513	1343	umbilical vein endothelial cell HUVEC	[umbilical vein endothelial cells HUVEC]	2.5	5	5	5	2
6514	1343	CD70 transfectant	[CD70 transfectants]	2.5	2	4	3	2
6515	1343	whole-cell assay	[whole-cell assay]	2.5	2	4	3	2
6516	1343	beta-casein gene	[beta-casein gene]	2.5	2	4	3	2
6517	1343	concomitant decrease	[concomitant decrease]	2.5	2	4	3	2
6518	1343	plzf-rar alpha	[PLZF-RAR alpha]	2.5	2	4	3	2
6519	1343	immune deficiency	[immune deficiency]	2.5	2	4	3	2
6520	1343	Interleukin-2 IL-2	[Interleukin-2 IL-2]	2.5	2	4	3	2
6521	1343	competitive inhibitor	[competitive inhibitor]	2.5	2	4	3	2
6522	1343	dna-binding subunit	[DNA-binding subunit]	2.5	2	4	3	2
6523	1343	factor binding	[factor binding]	2.5	2	4	3	2
6524	1343	pmn adhesion	[PMN adhesion]	2.5	2	4	3	2
6525	1343	novel approach	[novel approach]	2.5	2	4	3	2
6526	1343	activate	[activating]	2.5	1	26	8	8
6527	1343	tissue-specific regulation	[tissue-specific regulation]	2.5	2	4	3	2
6528	1343	tax activation	[tax activation]	2.5	2	4	3	2
6529	1343	g1 arrest	[G1 arrest]	2.5	2	4	3	2
6530	1343	developmental regulation	[developmental regulation]	2.5	2	4	3	2
6531	1343	run-on analysis	[run-on analysis]	2.5	2	5	5	2
6532	1343	complete loss	[complete loss]	2.5	2	4	3	2
6533	1343	human glucocorticoid	[human glucocorticoid]	2.5	2	4	3	2
6534	1343	transcription factors,	[transcription factors,]	2.5	2	4	3	2
6535	1343	sp1 site	[Sp1 sites]	2.5	2	4	3	2
6536	1343	clinical manifestation	[clinical manifestation]	2.5	2	4	3	2
6537	1343	protein-1 ap-1	[protein-1 AP-1]	2.5	2	4	3	2
6538	1343	functional synergy	[functional synergy]	2.5	2	5	5	2
6539	1343	minimal effect	[minimal effect]	2.5	2	5	5	2
6540	1343	dna-binding property	[DNA-binding properties]	2.5	2	4	3	2
6541	1343	lymphocyte syndrome	[lymphocyte syndrome]	2.5	2	5	5	2
6542	1343	other site	[other sites]	2.5	2	4	3	2
6543	1343	dual function	[dual function]	2.5	2	4	3	2
6544	1343	htlv-i infection	[HTLV-I infection]	2.5	2	4	3	2
6545	1343	novel mutation	[novel mutation]	2.5	2	4	3	2
6546	1343	CD28 pathway	[CD28 pathway]	2.5	2	4	3	2
6547	1344	occur	[occurring]	2.495	1	26	21	20
6548	1345	probe	[probe]	2.4947368421052634	1	26	20	19
6549	1346	activity.	[activity.]	2.490909090909091	1	26	12	11
6550	1347	tuberculosis	[tuberculosis]	2.4857142857142858	1	26	16	14
6551	1348	monocyte/macrophage	[monocyte/macrophage]	2.4833333333333334	1	26	7	6
6552	1348	cd11b	[CD11b]	2.4833333333333334	1	26	7	6
6553	1348	IL-8	[IL-8]	2.4833333333333334	1	26	14	12
6554	1349	erythroid	[erythroid]	2.481818181818182	1	26	13	11
6555	1349	matrix	[matrix]	2.481818181818182	1	26	13	11
6556	1350	staining	[staining]	2.477777777777778	1	26	22	18
6557	1351	gata-3	[GATA-3]	2.476923076923077	1	26	16	13
6558	1352	m	[M]	2.4733333333333336	1	26	19	15
6559	1353	ss	[SS]	2.4714285714285715	1	26	9	7
6560	1354	parameter	[parameter]	2.4692307692307693	1	26	17	13
6561	1355	nf-kb	[NF-kB]	2.463636363636364	1	26	15	11
6562	1356	age	[age]	2.4600000000000004	1	26	7	5
6563	1357	ATL	[ATL]	2.45	1	26	9	6
6564	1357	percentage	[percentage]	2.45	1	27	20	8
6565	1358	course	[course]	2.4444444444444446	1	27	23	9
6566	1359	e-selectin	[E-selectin]	2.4333333333333336	1	26	10	6
6567	1360	acetyltransferase	[acetyltransferase]	2.407692307692308	1	26	25	13
6568	1361	c	[C]	2.4000000000000004	1	25	12	12
6569	1361	il-13	[IL-13]	2.4000000000000004	1	25	3	3
6570	1361	aspirin	[aspirin]	2.4000000000000004	1	25	4	4
6571	1361	Ikaros	[Ikaros]	2.4000000000000004	1	25	9	9
6572	1362	TCR	[TCR]	2.388888888888889	1	25	10	9
6573	1363	b-lymphocyte	[B-lymphocyte]	2.3857142857142857	1	25	8	7
6574	1363	STAT	[STAT]	2.3857142857142857	1	25	8	7
6575	1364	polymorphism	[polymorphism]	2.38125	1	25	19	16
6576	1365	Glucocorticoid	[Glucocorticoid]	2.3800000000000003	1	28	21	5
6577	1366	incubation of endothelial cell	[Incubation of endothelial cells]	2.3774437510817346	4	3	3	2
6578	1366	T lymphocyte development	[T lymphocyte development]	2.3774437510817346	3	3	3	2
6579	1366	human peripheral leucocyte	[human peripheral leucocytes]	2.3774437510817346	3	3	3	2
6580	1366	gy of radiotherapy	[Gy of radiotherapy]	2.3774437510817346	3	3	3	2
6581	1366	acute leukemia AML	[acute leukemia AML]	2.3774437510817346	3	3	3	2
6582	1366	transcription of immunoglobulin gene	[transcription of immunoglobulin genes]	2.3774437510817346	4	3	3	2
6583	1366	disorder in down' syndrome	[disorder in Down's syndrome]	2.3774437510817346	4	3	3	2
6584	1366	AMP -responsive element	[AMP -responsive element]	2.3774437510817346	3	3	3	2
6585	1366	1 alpha, 25-dihydroxyvitamin D3	[1 alpha, 25-dihydroxyvitamin D3]	2.3774437510817346	4	3	3	2
6586	1366	activity of NF-kappa b	[activity of NF-kappa B]	2.3774437510817346	4	3	3	2
6587	1366	cord blood lymphocyte	[cord blood lymphocytes]	2.3774437510817346	3	3	3	2
6588	1366	regulation in b cell	[regulation in B cells]	2.3774437510817346	4	3	3	2
6589	1366	immunodeficiency virus-1 hiv-1	[immunodeficiency virus-1 HIV-1]	2.3774437510817346	3	3	3	2
6590	1366	protein kinase signal pathway	[protein kinase signaling pathway]	2.3774437510817346	4	3	3	2
6591	1366	il-1r gene expression	[IL-1R gene expression]	2.3774437510817346	3	3	3	2
6592	1366	differentiation of progenitor	[differentiation of progenitors]	2.3774437510817346	3	3	3	2
6593	1366	breast cancer cell line	[breast cancer cell line]	2.3774437510817346	4	3	3	2
6594	1366	acute leukemia all	[acute leukemia ALL]	2.3774437510817346	3	3	3	2
6595	1366	treatment of leukemia APL	[treatment of leukemia APL]	2.3774437510817346	4	3	3	2
6596	1366	depressive disorder MDD	[depressive disorder MDD]	2.3774437510817346	3	3	3	2
6597	1366	Jak -STAT pathway	[Jak -STAT pathway]	2.3774437510817346	3	3	3	2
6598	1366	(mhc) class antigen	[(MHC) class antigens]	2.3774437510817346	3	3	3	2
6599	1366	pulmonary heart disease	[pulmonary heart disease]	2.3774437510817346	3	3	3	2
6600	1366	selectivity for aldosterone	[selectivity for aldosterone]	2.3774437510817346	3	3	3	2
6601	1366	two ets binding site	[two Ets binding sites]	2.3774437510817346	4	3	3	2
6602	1366	accumulation of RelB	[accumulation of RelB]	2.3774437510817346	3	3	3	2
6603	1366	level of induction	[level of induction]	2.3774437510817346	3	3	3	2
6604	1366	production of il-8	[production of IL-8]	2.3774437510817346	3	3	3	2
6605	1366	patient with cell carcinoma	[patients with cell carcinoma]	2.3774437510817346	4	3	3	2
6606	1366	J delta segment	[J delta segment]	2.3774437510817346	3	3	3	2
6607	1366	gr binding capacity	[GR binding capacity]	2.3774437510817346	3	3	3	2
6608	1366	many cell types,	[many cell types,]	2.3774437510817346	3	3	3	2
6609	1366	use of promoter	[use of promoters]	2.3774437510817346	3	3	3	2
6610	1366	expression of a subset	[expression of a subset]	2.3774437510817346	4	3	3	2
6611	1366	airway epithelial cell	[airway epithelial cells]	2.3774437510817346	3	3	3	2
6612	1366	human haemopoietic cell	[human haemopoietic cells]	2.3774437510817346	3	3	3	2
6613	1366	domain of the receptor	[domain of the receptor]	2.3774437510817346	4	3	3	2
6614	1366	amp-dependent protein kinase	[AMP-dependent protein kinases]	2.3774437510817346	3	3	3	2
6615	1366	normal blood lymphocyte	[normal blood lymphocytes]	2.3774437510817346	3	3	3	2
6616	1366	kb from sox9	[kb from SOX9]	2.3774437510817346	3	3	3	2
6617	1366	use a bind assay	[using a binding assay]	2.3774437510817346	4	3	3	2
6618	1366	cell adhesion to cell	[cell adhesion to cells]	2.3774437510817346	4	3	3	2
6619	1366	promyelocyte cell line	[promyelocyte cell line]	2.3774437510817346	3	3	3	2
6620	1366	b dna-binding activity	[B DNA-binding activity]	2.3774437510817346	3	3	3	2
6621	1366	gene encode cytokine	[genes encoding cytokines]	2.3774437510817346	3	3	3	2
6622	1366	pathogenesis of leukemia	[pathogenesis of leukemia]	2.3774437510817346	3	3	3	2
6623	1366	soft tissue tumor	[soft tissue tumors]	2.3774437510817346	3	3	3	2
6624	1366	cyclic AMP -responsive element	[cyclic AMP -responsive element]	2.3774437510817346	4	3	3	2
6625	1366	stage of development.	[stage of development.]	2.3774437510817346	3	3	3	2
6626	1366	receptor in human leukocyte	[receptor in human leukocytes]	2.3774437510817346	4	3	3	2
6627	1366	tumor cell cytostasis	[tumor cell cytostasis]	2.3774437510817346	3	3	3	2
6628	1366	treatment of acute leukemia	[treatment of acute leukemia]	2.3774437510817346	4	3	3	2
6629	1366	expression of various gene	[expression of various genes]	2.3774437510817346	4	3	3	2
6630	1366	transcriptase -polymerase chain reaction	[transcriptase -polymerase chain reaction]	2.3774437510817346	4	3	3	2
6631	1366	immunosorbent assay ELISA	[immunosorbent assay ELISA]	2.3774437510817346	3	3	3	2
6632	1366	constitutively active mutant	[constitutively active mutant]	2.3774437510817346	3	3	3	2
6633	1366	class gene transcription	[class gene transcription]	2.3774437510817346	3	3	3	2
6634	1366	receptor mrna expression	[receptor mRNA expression]	2.3774437510817346	3	3	3	2
6635	1366	allele -specific regulation	[allele -specific regulation]	2.3774437510817346	3	3	3	2
6636	1366	amount of p65	[amount of P65]	2.3774437510817346	3	3	3	2
6637	1366	Peripheral blood lymphocyte	[Peripheral blood lymphocytes]	2.3774437510817346	3	3	3	2
6638	1366	unstimulated T cell	[unstimulated T cells]	2.3774437510817346	3	3	3	2
6639	1366	effect of hormone	[effect of hormones]	2.3774437510817346	3	3	3	2
6640	1366	only a subset	[only a subset]	2.3774437510817346	3	3	3	2
6641	1366	activation of the system	[activation of the system]	2.3774437510817346	4	3	3	2
6642	1366	hl60 leukemia cell	[HL60 leukemia cells]	2.3774437510817346	3	3	3	2
6643	1366	neutrophil gelatinase-associated lipocalin	[neutrophil gelatinase-associated lipocalin]	2.3774437510817346	3	3	3	2
6644	1366	hour of infection.	[hr of infection.]	2.3774437510817346	3	3	3	2
6645	1366	protein tyrosine phosphatase	[protein tyrosine phosphatase]	2.3774437510817346	3	3	3	2
6646	1366	porcine MHC class	[porcine MHC class]	2.3774437510817346	3	3	3	2
6647	1366	N-terminal activation domain	[N-terminal activation domain]	2.3774437510817346	3	3	3	2
6648	1366	primary haemopoietic cell	[primary haemopoietic cells]	2.3774437510817346	3	3	3	2
6649	1366	t-cell lymphoblastic leukemia t-all	[T-cell lymphoblastic leukemia T-ALL]	2.3774437510817346	4	3	3	2
6650	1366	peripheral blood cell pbmc	[peripheral blood cell PBMC]	2.3774437510817346	4	3	3	2
6651	1366	leukemia cell line hl-60	[leukemia cell line HL-60]	2.3774437510817346	4	3	3	2
6652	1366	peroxisome receptor ppar	[peroxisome receptor PPAR]	2.3774437510817346	3	3	3	2
6653	1366	phorbol ester 12-o-tetradecanoylphorbol-13-acetate	[phorbol ester 12-O-tetradecanoylphorbol-13-acetate]	2.3774437510817346	3	3	3	2
6654	1366	chloramphenicol acetyltransferase activity	[chloramphenicol acetyltransferase activity]	2.3774437510817346	3	3	3	2
6655	1366	primary blood lymphocyte	[primary blood lymphocytes]	2.3774437510817346	3	3	3	2
6656	1366	factor-kappa b nf-kappab	[factor-kappa B NF-kappaB]	2.3774437510817346	3	3	3	2
6657	1366	activation of expression	[activation of expression]	2.3774437510817346	3	3	3	2
6658	1366	mut-i kappa b	[mut-I kappa B]	2.3774437510817346	3	3	3	2
6659	1366	induce the expression	[inducing the expression]	2.3774437510817346	3	3	3	2
6660	1366	whole-cell bind assay	[whole-cell binding assay]	2.3774437510817346	3	3	3	2
6661	1366	inhibitor kappa b alpha	[inhibitor kappa B alpha]	2.3774437510817346	4	3	3	2
6662	1366	regulation of this gene	[regulation of this gene]	2.3774437510817346	4	3	3	2
6663	1366	mononuclear leukocyte of patient	[mononuclear leukocytes of patients]	2.3774437510817346	4	3	3	2
6664	1366	tissue factor gene	[tissue factor gene]	2.3774437510817346	3	3	3	2
6665	1366	treatment of promyelocytic leukemia	[treatment of promyelocytic leukemia]	2.3774437510817346	4	3	3	2
6666	1366	protein kinase cascade	[protein kinase cascade]	2.3774437510817346	3	3	3	2
6667	1366	circulate human lymphocyte	[circulating human lymphocytes]	2.3774437510817346	3	3	3	2
6668	1366	central system CNS	[central system CNS]	2.3774437510817346	3	3	3	2
6669	1366	degree of reduction	[degree of reduction]	2.3774437510817346	3	3	3	2
6670	1366	t-cell acute leukemia t-all	[T-cell acute leukemia T-ALL]	2.3774437510817346	4	3	3	2
6671	1366	high affinity binding	[high affinity binding]	2.3774437510817346	3	3	3	2
6672	1366	chronic inflammatory disease	[chronic inflammatory disease]	2.3774437510817346	3	3	3	2
6673	1366	set of primer	[set of primers]	2.3774437510817346	3	3	3	2
6674	1366	zeta globin promoter	[zeta globin promoter]	2.3774437510817346	3	3	3	2
6675	1366	two open reading frame	[two open reading frames]	2.3774437510817346	4	3	3	2
6676	1366	t-cell virus type	[T-cell virus type]	2.3774437510817346	3	3	3	2
6677	1366	use monoclonal antibody	[using monoclonal antibodies]	2.3774437510817346	3	3	3	2
6678	1366	mobility shift assay analysis	[mobility shift assay analysis]	2.3774437510817346	4	3	3	2
6679	1366	transcription factor Oct-2a	[transcription factor Oct-2a]	2.3774437510817346	3	3	3	2
6680	1366	migration of hl-60 cell	[migration of HL-60 cells]	2.3774437510817346	4	3	3	2
6681	1366	patient with tumor	[patients with tumors]	2.3774437510817346	3	3	3	2
6682	1366	immunodeficiency virus transcription	[immunodeficiency virus transcription]	2.3774437510817346	3	3	3	2
6683	1366	human jurkat T	[human Jurkat T]	2.3774437510817346	3	3	3	2
6684	1366	type ii diabete	[type II diabetes]	2.3774437510817346	3	3	3	2
6685	1366	phorbol 13-acetate PMA	[phorbol 13-acetate PMA]	2.3774437510817346	3	3	3	2
6686	1366	zeta globin gene	[zeta globin gene]	2.3774437510817346	3	3	3	2
6687	1366	interaction of nuclear factor	[interaction of nuclear factors]	2.3774437510817346	4	3	3	2
6688	1366	patient with hypertension	[patients with hypertension]	2.3774437510817346	3	3	3	2
6689	1366	increase in pdgf(b) mrna	[increase in PDGF(B) mRNA]	2.3774437510817346	4	3	3	2
6690	1366	T cell subset	[T cell subsets]	2.3774437510817346	3	3	3	2
6691	1366	stage of b-cell differentiation	[stage of B-cell differentiation]	2.3774437510817346	4	3	3	2
6692	1366	membrane protein lmp1	[membrane protein LMP1]	2.3774437510817346	3	3	3	2
6693	1366	interaction of factor	[interaction of factors]	2.3774437510817346	3	3	3	2
6694	1367	EKLF	[EKLF]	2.375	1	26	9	4
6695	1368	adherence	[adherence]	2.3666666666666667	1	25	16	12
6696	1369	lymphoblastoid	[lymphoblastoid]	2.3583333333333334	1	25	17	12
6697	1370	translation	[translation]	2.357142857142857	1	25	10	7
6698	1371	fashion	[fashion]	2.35625	1	25	23	16
6699	1372	e2a	[E2A]	2.3555555555555556	1	25	13	9
6700	1373	Study	[Studies]	2.35	1	26	20	8
6701	1374	end	[end]	2.3461538461538463	1	25	20	13
6702	1375	mammary	[mammary]	2.341666666666667	1	25	19	12
6703	1376	flank	[flank]	2.3333333333333335	1	25	10	6
6704	1377	splicing	[splicing]	2.325	1	26	22	8
6705	1378	disruption	[disruption]	2.316666666666667	1	27	23	6
6706	1379	hematopoiesis	[hematopoiesis]	2.31	1	25	19	10
6707	1380	t3	[T3]	2.3000000000000003	1	24	11	11
6708	1380	STAT1	[STAT1]	2.3000000000000003	1	24	7	7
6709	1380	turn	[turn]	2.3000000000000003	1	24	2	2
6710	1380	maintenance	[maintenance]	2.3000000000000003	1	25	18	9
6711	1380	pre-B	[pre-B]	2.3000000000000003	1	24	4	4
6712	1380	agonist	[agonist]	2.3000000000000003	1	24	16	16
6713	1381	cases,	[cases,]	2.29	1	24	11	10
6714	1381	cooperation	[cooperation]	2.29	1	25	21	10
6715	1382	kD	[kD]	2.2882352941176474	1	24	19	17
6716	1383	fos	[fos]	2.2875	1	24	9	8
6717	1383	tal1	[TAL1]	2.2875	1	24	9	8
6718	1384	phytohemagglutinin	[phytohemagglutinin]	2.285714285714286	1	24	8	7
6719	1384	RNA	[RNA]	2.285714285714286	1	24	8	7
6720	1384	rel	[Rel]	2.285714285714286	1	24	8	7
6721	1384	EBNA2	[EBNA2]	2.285714285714286	1	24	8	7
6722	1385	AMP	[AMP]	2.283333333333333	1	25	13	6
6723	1386	strategy	[strategy]	2.28125	1	24	19	16
6724	1387	cytotoxicity	[cytotoxicity]	2.2800000000000002	1	24	12	10
6725	1388	BCL-6	[BCL-6]	2.277777777777778	1	24	11	9
6726	1389	method	[method]	2.275	1	24	15	12
6727	1389	integrin	[integrin]	2.275	1	24	15	12
6728	1390	kd	[Kd]	2.272727272727273	1	24	14	11
6729	1391	portion	[portion]	2.272222222222222	1	24	23	18
6730	1392	9-cis	[9-cis]	2.271428571428572	1	24	9	7
6731	1393	erythroblast	[erythroblast]	2.2692307692307696	1	24	17	13
6732	1394	jun	[jun]	2.2571428571428576	1	24	10	7
6733	1394	retinoblastoma	[retinoblastoma]	2.2571428571428576	1	24	10	7
6734	1395	Burkitt'	[Burkitt's]	2.25	1	24	6	4
6735	1395	copyright	[Copyright]	2.25	1	30	30	4
6736	1395	Stat6	[Stat6]	2.25	1	24	9	6
6737	1396	demonstration	[demonstration]	2.2444444444444445	1	25	23	9
6738	1396	hla-dr	[HLA-DR]	2.2444444444444445	1	24	14	9
6739	1397	means	[means]	2.225	1	24	21	12
6740	1398	organ	[organ]	2.2222222222222223	1	24	16	9
6741	1398	phosphatidylinositol	[phosphatidylinositol]	2.2222222222222223	1	24	16	9
6742	1399	term	[term]	2.22	1	24	18	10
6743	1400	GC	[GC]	2.2	1	23	13	13
6744	1400	+/-	[+/-]	2.2	1	23	21	21
6745	1400	review	[review]	2.2	1	23	3	3
6746	1400	NF-kB	[NF-kB]	2.2	1	23	7	7
6747	1400	homodimer	[homodimer]	2.2	1	24	12	6
6748	1400	Stat1	[Stat1]	2.2	1	23	5	5
6749	1400	12-myristate	[12-myristate]	2.2	1	26	24	6
6750	1401	lymph	[lymph]	2.190909090909091	1	23	12	11
6751	1402	determinant	[determinant]	2.1904761904761907	1	23	23	21
6752	1403	protein-DNA	[protein-DNA]	2.188888888888889	1	23	10	9
6753	1404	M.	[M.]	2.18	1	23	6	5
6754	1405	dnase	[DNase]	2.177777777777778	1	23	11	9
6755	1405	cascade	[cascade]	2.177777777777778	1	24	20	9
6756	1406	rrna	[rRNA]	2.172727272727273	1	23	14	11
6757	1407	assembly	[assembly]	2.166666666666667	1	24	21	9
6758	1407	phospholipase	[phospholipase]	2.166666666666667	1	23	12	9
6759	1408	respect	[respect]	2.16	1	26	22	5
6760	1409	cp	[Cp]	2.1571428571428575	1	23	10	7
6761	1410	cord	[cord]	2.15	1	23	15	10
6762	1410	manner.	[manner.]	2.15	1	23	21	14
6763	1411	immunity	[immunity]	2.1384615384615384	1	23	21	13
6764	1412	RCC	[RCC]	2.1375	1	23	13	8
6765	1413	dephosphorylation	[dephosphorylation]	2.1333333333333333	1	24	16	6
6766	1413	C/EBP	[C/EBP]	2.1333333333333333	1	23	10	6
6767	1414	upstream	[upstream]	2.1272727272727274	1	23	19	11
6768	1415	ligation	[ligation]	2.125	1	27	23	4
6769	1415	hand,	[hand,]	2.125	1	26	19	4
6770	1416	OCA-B	[OCA-B]	2.1	1	22	2	2
6771	1416	vitro,	[vitro,]	2.1	1	31	10	1
6772	1416	PDTC	[PDTC]	2.1	1	22	3	3
6773	1416	October	[Oct]	2.1	1	22	11	11
6774	1416	cross-linking	[cross-linking]	2.1	1	23	18	9
6775	1416	Stat5	[Stat5]	2.1	1	22	5	5
6776	1416	IL-2R	[IL-2R]	2.1	1	23	8	4
6777	1417	sample	[sample]	2.09	1	22	11	10
6778	1418	consist	[consisting]	2.088888888888889	1	22	20	18
6779	1419	blast	[blast]	2.0875	1	22	9	8
6780	1420	nb4	[NB4]	2.085714285714286	1	22	8	7
6781	1421	female	[female]	2.0833333333333335	1	22	14	12
6782	1421	G-CSF	[G-CSF]	2.0833333333333335	1	22	7	6
6783	1422	death	[death]	2.075	1	22	10	8
6784	1422	lupus	[lupus]	2.075	1	22	5	4
6785	1422	granule	[granule]	2.075	1	22	15	12
6786	1422	cd34+	[CD34+]	2.075	1	22	10	8
6787	1422	mineralocorticoid	[mineralocorticoid]	2.075	1	22	10	8
6788	1423	similarity	[similarity]	2.0692307692307694	1	22	17	13
6789	1424	Ig	[Ig]	2.066666666666667	1	22	8	6
6790	1424	vivo,	[vivo,]	2.066666666666667	1	22	4	3
6791	1424	brain	[brain]	2.066666666666667	1	22	8	6
6792	1424	cd45	[CD45]	2.066666666666667	1	22	8	6
6793	1424	chicken	[chicken]	2.066666666666667	1	22	8	6
6794	1425	zap-70	[ZAP-70]	2.0625	1	22	11	8
6795	1426	rt-pcr	[RT-PCR]	2.06	1	23	12	5
6796	1426	NFATp	[NFATp]	2.06	1	22	7	5
6797	1427	genes.	[genes.]	2.055555555555556	1	22	13	9
6798	1427	contribution	[contribution]	2.055555555555556	1	23	22	9
6799	1428	metabolite	[metabolite]	2.0545454545454547	1	22	16	11
6800	1429	gas	[GAS]	2.0500000000000003	1	22	9	6
6801	1429	THP-1	[THP-1]	2.0500000000000003	1	22	3	2
6802	1429	ap-2	[AP-2]	2.0500000000000003	1	22	3	2
6803	1430	relevance	[relevance]	2.046153846153846	1	22	20	13
6804	1431	studies,	[studies,]	2.0454545454545454	1	22	17	11
6805	1432	S	[S]	2.0428571428571427	1	22	11	7
6806	1432	pi	[PI]	2.0428571428571427	1	22	11	7
6807	1432	squirrel	[squirrel]	2.0428571428571427	1	22	11	7
6808	1433	Jak2	[Jak2]	2.04	1	22	8	5
6809	1434	/rel	[/Rel]	2.033333333333333	1	22	20	12
6810	1435	support	[support]	2.0272727272727273	1	22	19	11
6811	1436	muscle	[muscle]	2.025	1	23	11	4
6812	1437	E-selectin mrna	[E-selectin mRNA]	2.0	2	2	0	0
6813	1437	primary b-cell	[primary B-cells]	2.0	2	3	2	2
6814	1437	TCF-1 a T cell-specific transcription factor	[TCF-1 a T cell-specific transcription factor]	2.0	6	2	0	0
6815	1437	dominant-negative form	[dominant-negative form]	2.0	2	4	4	2
6816	1437	induction of DNA binding activity	[Induction of DNA binding activity]	2.0	5	2	0	0
6817	1437	other antioxidant	[other antioxidants]	2.0	2	3	2	2
6818	1437	activation of the creb/atf pathway	[activation of the CREB/ATF pathway]	2.0	5	2	0	0
6819	1437	aids -gr	[AIDS -GR]	2.0	2	3	3	3
6820	1437	CD40 expression	[CD40 expression]	2.0	2	2	0	0
6821	1437	interaction of the transcription factor	[interaction of the transcription factors]	2.0	5	3	1	1
6822	1437	chain gene	[chain gene]	2.0	2	3	3	3
6823	1437	rna synthesis	[RNA synthesis]	2.0	2	3	1	1
6824	1437	respective factor	[respective factor]	2.0	2	2	0	0
6825	1437	induction of apoptosis by GC	[induction of apoptosis by GC]	2.0	5	2	0	0
6826	1437	poor prognosis	[poor prognosis]	2.0	2	2	0	0
6827	1437	gamma-globin mrna	[gamma-globin mRNA]	2.0	2	2	0	0
6828	1437	peptide vaccination	[peptide vaccination]	2.0	2	3	2	2
6829	1437	CML patient	[CML patients]	2.0	2	6	4	1
6830	1437	different activity	[different activities]	2.0	2	3	3	3
6831	1437	many protein	[many proteins]	2.0	2	2	0	0
6832	1437	gamma B*CaM-K	[gamma B*CaM-K]	2.0	2	3	1	1
6833	1437	tumour necrosis factor alpha tnf-alpha	[tumour necrosis factor alpha TNF-alpha]	2.0	5	2	0	0
6834	1437	histocompatibility complex	[histocompatibility complex]	2.0	2	3	3	3
6835	1437	gene fusion	[gene fusion]	2.0	2	3	2	2
6836	1437	cd69 gene	[CD69 gene]	2.0	2	2	0	0
6837	1437	TK activity	[TK activity]	2.0	2	2	0	0
6838	1437	viral reactivation	[viral reactivation]	2.0	2	3	1	1
6839	1437	b-lymphocyte activation	[B-lymphocyte activation]	2.0	2	3	1	1
6840	1437	low level)	[low level)]	2.0	2	2	0	0
6841	1437	XCI pattern	[XCI pattern]	2.0	2	3	1	1
6842	1437	Comparison of a full-length cDNA sequence	[Comparison of a full-length cDNA sequence]	2.0	6	2	0	0
6843	1437	gp 160	[gp 160]	2.0	2	2	0	0
6844	1437	absorptive hypercalciuria	[absorptive hypercalciuria]	2.0	2	3	1	1
6845	1437	differentiation-inducing activity	[differentiation-inducing activity]	2.0	2	3	3	3
6846	1437	adaptive immunity	[adaptive immunity]	2.0	2	2	0	0
6847	1437	erythroid proliferation	[erythroid proliferation]	2.0	2	3	1	1
6848	1437	structural feature	[structural feature]	2.0	2	3	1	1
6849	1437	healthy adult	[healthy adults]	2.0	2	2	0	0
6850	1437	knock-out mouse	[knock-out mice]	2.0	2	2	0	0
6851	1437	il-1 secretion	[IL-1 secretion]	2.0	2	2	0	0
6852	1437	T cell receptor tcr stimulation	[T cell receptor TCR stimulation]	2.0	5	2	0	0
6853	1437	phorbol-12-myristate acetate	[phorbol-12-myristate acetate]	2.0	2	4	4	2
6854	1437	TNFalpha release	[TNFalpha release]	2.0	2	3	1	1
6855	1437	sequence-specific manner	[sequence-specific manner]	2.0	2	2	0	0
6856	1437	cDNA expression	[cDNA expression]	2.0	2	3	3	3
6857	1437	NF-kappaB binding	[NF-kappaB binding]	2.0	2	3	1	1
6858	1437	reverse transcriptase -polymerase chain reaction rt-pcr	[reverse transcriptase -polymerase chain reaction RT-PCR]	2.0	6	3	2	2
6859	1437	surface expression of intercellular adhesion molecule-1	[surface expression of intercellular adhesion molecule-1]	2.0	6	3	2	2
6860	1437	Raji cell	[Raji cells]	2.0	2	3	1	1
6861	1437	immunoglobulin surrogate	[immunoglobulin surrogate]	2.0	2	2	0	0
6862	1437	single copy	[single copy]	2.0	2	2	0	0
6863	1437	contrast to a previous study,	[contrast to a previous study,]	2.0	5	2	0	0
6864	1437	cd8-positive lymphocyte	[CD8-positive lymphocytes]	2.0	2	2	0	0
6865	1437	Fas ligand	[Fas ligand]	2.0	2	3	2	2
6866	1437	mammalian homologue	[mammalian homologues]	2.0	2	2	0	0
6867	1437	cho-cd14 cell	[CHO-CD14 cells]	2.0	2	3	2	2
6868	1437	serious infection	[serious infections]	2.0	2	2	0	0
6869	1437	6 week	[6 weeks]	2.0	2	3	3	3
6870	1437	strong inhibition	[strong inhibition]	2.0	2	2	0	0
6871	1437	sre sequence	[SRE sequence]	2.0	2	4	2	1
6872	1437	autocrine loop	[autocrine loop]	2.0	2	2	0	0
6873	1437	nonstimulated cell	[nonstimulated cells]	2.0	2	2	0	0
6874	1437	activate stimulus	[activating stimulus]	2.0	2	2	0	0
6875	1437	CBF beta -myh11 fusion transcript	[CBF beta -MYH11 fusion transcripts]	2.0	5	2	0	0
6876	1437	exon 1	[exon 1]	2.0	2	2	0	0
6877	1437	exon 2	[exon 2]	2.0	2	3	1	1
6878	1437	ss control	[SS controls]	2.0	2	4	2	1
6879	1437	unique function	[unique function]	2.0	2	3	2	2
6880	1437	jun-B gene	[jun-B gene]	2.0	2	2	0	0
6881	1437	SMX -NHOH	[SMX -NHOH]	2.0	2	2	0	0
6882	1437	CAT assay	[CAT assay]	2.0	2	3	1	1
6883	1437	IL-9 gene	[IL-9 gene]	2.0	2	2	0	0
6884	1437	DNA binding of transcription factor	[DNA binding of transcription factors]	2.0	5	3	3	3
6885	1437	4 P.	[4 h.]	2.0	2	2	0	0
6886	1437	CD8 antigen	[CD8 antigen]	2.0	2	3	3	3
6887	1437	intravascular coagulation	[intravascular coagulation]	2.0	2	2	0	0
6888	1437	e1a oncoprotein	[E1A oncoprotein]	2.0	2	3	3	3
6889	1437	PAFR transcript	[PAFR transcript]	2.0	2	2	0	0
6890	1437	a-t patient	[A-T patients]	2.0	2	3	1	1
6891	1437	caev LTR	[CAEV LTR]	2.0	2	3	1	1
6892	1437	regulate human immunodeficiency virus hiv persistence	[regulating human immunodeficiency virus HIV persistence]	2.0	6	2	0	0
6893	1437	Bcl-2 promoter	[Bcl-2 promoter]	2.0	2	2	0	0
6894	1437	induction of the cd11b gene	[Induction of the CD11b gene]	2.0	5	2	0	0
6895	1437	human monocytic cell line thp-1	[Human monocytic cell line THP-1]	2.0	5	2	0	0
6896	1437	chromosome 16p13.3	[chromosome 16p13.3]	2.0	2	2	0	0
6897	1437	low activity	[low activity]	2.0	2	3	3	3
6898	1437	nfat-like element	[NFAT-like elements]	2.0	2	3	2	2
6899	1437	clinical disease	[clinical disease.]	2.0	2	2	0	0
6900	1437	20 patient with ss control	[20 patients with SS controls]	2.0	5	2	0	0
6901	1437	ionizing radiation	[ionizing radiation]	2.0	2	3	2	2
6902	1437	binding of the nuclear factor	[Binding of the nuclear factor]	2.0	5	2	0	0
6903	1437	similar increase	[similar increase]	2.0	2	3	3	3
6904	1437	tissue inhibitor	[tissue inhibitor]	2.0	2	3	3	3
6905	1437	sedentary group	[sedentary group]	2.0	2	2	0	0
6906	1437	normal range	[normal range]	2.0	2	3	2	2
6907	1437	co-transfection experiment	[co-transfection experiments]	2.0	2	3	1	1
6908	1437	Staphylococcal enterotoxin	[Staphylococcal enterotoxin]	2.0	2	3	1	1
6909	1437	functional motif	[functional motif]	2.0	2	3	1	1
6910	1437	important role regulate the expression	[important role regulating the expression]	2.0	5	2	0	0
6911	1437	positive signal	[positive signal]	2.0	2	3	3	3
6912	1437	gene expression in monocytic cell	[gene expression in monocytic cells]	2.0	5	3	2	2
6913	1437	interfollicular bcl-6	[interfollicular Bcl-6]	2.0	2	2	0	0
6914	1437	il-9 gene	[IL-9 gene]	2.0	2	2	0	0
6915	1437	protease treatment	[protease treatment]	2.0	2	3	3	3
6916	1437	intestinal mucosa	[intestinal mucosa]	2.0	2	2	0	0
6917	1437	nf-kappab suppression in T cell	[NF-kappaB suppression in T cells]	2.0	5	2	0	0
6918	1437	ikappab	[IkappaB]	2.0	1	21	13	13
6919	1437	DNA strand	[DNA strand]	2.0	2	3	3	3
6920	1437	mild asthma	[mild asthma]	2.0	2	2	0	0
6921	1437	vitro exposure	[vitro exposure]	2.0	2	3	2	2
6922	1437	simultaneous treatment	[simultaneous treatment]	2.0	2	3	3	3
6923	1437	human homeobox	[human homeobox]	2.0	2	3	1	1
6924	1437	HTLV-I enhancer	[HTLV-I enhancer]	2.0	2	5	3	1
6925	1437	Bcl-2 upregulation	[Bcl-2 upregulation]	2.0	2	2	0	0
6926	1437	tnf-alpha bioavailability	[TNF-alpha bioavailability]	2.0	2	3	1	1
6927	1437	asymptomatic carrier	[asymptomatic carriers]	2.0	2	2	0	0
6928	1437	cell regulation	[cell regulation]	2.0	2	3	2	2
6929	1437	NF-kappaB protein	[NF-kappaB proteins]	2.0	2	2	0	0
6930	1437	immunodeficiency virus type terminal repeat	[immunodeficiency virus type terminal repeat]	2.0	5	3	3	3
6931	1437	constitutive active version of c-Raf	[constitutive active version of c-Raf]	2.0	5	2	0	0
6932	1437	cytosolic component	[cytosolic component]	2.0	2	3	2	2
6933	1437	vitro response	[vitro response]	2.0	2	3	1	1
6934	1437	restriction enzyme	[Restriction enzyme]	2.0	2	3	3	3
6935	1437	cytoplasmic membrane	[cytoplasmic membranes]	2.0	2	2	0	0
6936	1437	perivascular DC	[perivascular DC]	2.0	2	2	0	0
6937	1437	ap-1 element	[AP-1 element]	2.0	2	3	1	1
6938	1437	tshr peptide	[TSHR peptides]	2.0	2	3	1	1
6939	1437	six case	[six cases]	2.0	2	3	2	2
6940	1437	are-containing gene	[ARE-containing genes]	2.0	2	2	0	0
6941	1437	chronic MPD	[chronic MPD]	2.0	2	2	0	0
6942	1437	binding activity.	[binding activity.]	2.0	2	2	0	0
6943	1437	normal counterpart	[normal counterpart]	2.0	2	3	2	2
6944	1437	0.2 kb	[0.2 kb]	2.0	2	3	2	2
6945	1437	metallothionein enhancer	[metallothionein enhancer]	2.0	2	2	0	0
6946	1437	early T	[early T]	2.0	2	3	1	1
6947	1437	hcd57-srei cell	[HCD57-SREI cells]	2.0	2	3	1	1
6948	1437	early b	[early B]	2.0	2	3	1	1
6949	1437	megakaryocytic marker	[megakaryocytic markers]	2.0	2	3	1	1
6950	1437	three isoform	[three isoforms]	2.0	2	3	3	3
6951	1437	stat6 activity	[STAT6 activity]	2.0	2	3	2	2
6952	1437	intracellular protein	[intracellular proteins]	2.0	2	3	1	1
6953	1437	clinical datum	[clinical data.]	2.0	2	3	1	1
6954	1437	binding site for the transcription factor	[binding sites for the transcription factors]	2.0	6	3	1	1
6955	1437	t-cell extract	[T-cell extracts]	2.0	2	3	2	2
6956	1437	IFN gamma	[IFN gamma]	2.0	2	2	0	0
6957	1437	member of the receptor superfamily	[member of the receptor superfamily]	2.0	5	3	1	1
6958	1437	gc b	[GC B]	2.0	2	3	3	3
6959	1437	sv40 T	[SV40 T]	2.0	2	2	0	0
6960	1437	electrophoretic DNA mobility shift assay	[electrophoretic DNA mobility shift assays]	2.0	5	2	0	0
6961	1437	downstream signal	[downstream signaling]	2.0	2	2	0	0
6962	1437	proviral DNA	[proviral DNA]	2.0	2	2	0	0
6963	1437	TNF production	[TNF production]	2.0	2	2	0	0
6964	1437	two subunit of NF-kappa b	[two subunits of NF-kappa B]	2.0	5	2	0	0
6965	1437	synovial fluid	[synovial fluid]	2.0	2	3	1	1
6966	1437	other tissues.	[other tissues.]	2.0	2	2	0	0
6967	1437	activation gene	[activation gene]	2.0	2	3	3	3
6968	1437	major importance	[major importance]	2.0	2	3	3	3
6969	1437	broad spectrum	[broad spectrum]	2.0	2	4	4	2
6970	1437	surface expression of adhesion molecule-1	[surface expression of adhesion molecule-1]	2.0	5	3	3	3
6971	1437	B2 promoter	[B2 promoter]	2.0	2	3	1	1
6972	1437	two subclone	[Two subclones]	2.0	2	2	0	0
6973	1437	concentration of the VDR mrna	[concentration of the VDR mRNA]	2.0	5	2	0	0
6974	1437	RXR agonist	[RXR agonist]	2.0	2	3	3	3
6975	1437	t-cell acute lymphoblastic leukemia t-all	[T-cell acute lymphoblastic leukemia T-ALL]	2.0	5	3	1	1
6976	1437	translocation of NF-kappa b p50/p65	[translocation of NF-kappa B p50/p65]	2.0	5	3	1	1
6977	1437	peak response	[peak responses]	2.0	2	2	0	0
6978	1437	sodium phenylacetate	[sodium phenylacetate]	2.0	2	3	2	2
6979	1437	adult tissue	[adult tissues]	2.0	2	2	0	0
6980	1437	PU-SF complex	[PU-SF complex]	2.0	2	3	1	1
6981	1437	experimental evidence	[Experimental evidence]	2.0	2	3	1	1
6982	1437	biochemical analysis	[biochemical analysis]	2.0	2	3	2	2
6983	1437	stable expression	[stable expression]	2.0	2	3	2	2
6984	1437	first gene	[first genes]	2.0	2	2	0	0
6985	1437	p105 mrna	[p105 mRNA]	2.0	2	2	0	0
6986	1437	depressed group	[depressed group]	2.0	2	3	1	1
6987	1437	differentiate cell	[differentiating cells]	2.0	2	3	2	2
6988	1437	positive regulator	[positive regulator]	2.0	2	6	4	1
6989	1437	high density	[high density]	2.0	2	3	1	1
6990	1437	plaque formation	[plaque formation]	2.0	2	3	2	2
6991	1437	respective receptor	[respective receptors]	2.0	2	2	0	0
6992	1437	unilineage differentiation	[unilineage differentiation]	2.0	2	3	3	3
6993	1437	c-myc expression	[c-myc expression]	2.0	2	5	3	1
6994	1437	atf-2 protein	[ATF-2 proteins]	2.0	2	2	0	0
6995	1437	wild-type hGR	[wild-type hGR]	2.0	2	2	0	0
6996	1437	expression of the il-4 gene	[expression of the IL-4 gene]	2.0	5	3	1	1
6997	1437	two signals,	[two signals,]	2.0	2	3	3	3
6998	1437	class ii molecule in cell	[class II molecules in cells]	2.0	5	2	0	0
6999	1437	several disease	[several diseases]	2.0	2	2	0	0
7000	1437	inhibitory molecule	[inhibitory molecule]	2.0	2	3	2	2
7001	1437	animal study	[animal studies]	2.0	2	2	0	0
7002	1437	important step	[important step]	2.0	2	3	3	3
7003	1437	patient population	[patient population]	2.0	2	3	1	1
7004	1437	toxic metabolite	[toxic metabolites]	2.0	2	2	0	0
7005	1437	reverse transcription-PCR	[reverse transcription-PCR]	2.0	2	3	1	1
7006	1437	lymphotoxin alpha	[lymphotoxin alpha]	2.0	2	2	0	0
7007	1437	lead to NF-kappa b activation	[leading to NF-kappa B activation]	2.0	5	3	1	1
7008	1437	EC1 antibody	[EC1 antibody]	2.0	2	2	0	0
7009	1437	transmembrane region	[transmembrane region]	2.0	2	2	0	0
7010	1437	compete ds-oligonucleotides	[competing ds-oligonucleotides]	2.0	2	2	0	0
7011	1437	leukemia gene	[leukemia gene]	2.0	2	3	3	3
7012	1437	CRF patient	[CRF patients]	2.0	2	3	2	2
7013	1437	IL-1 receptor	[IL-1 receptor]	2.0	2	2	0	0
7014	1437	hemoglobin synthesis	[hemoglobin synthesis]	2.0	2	3	2	2
7015	1437	current studies,	[current studies,]	2.0	2	2	0	0
7016	1437	Interleukin-3 IL-3	[Interleukin-3 IL-3]	2.0	2	2	0	0
7017	1437	VitD3 induction	[VitD3 induction]	2.0	2	3	1	1
7018	1437	transcription protein	[transcription protein]	2.0	2	3	2	2
7019	1437	available datum	[available data]	2.0	2	2	0	0
7020	1437	nuclear target	[nuclear targeting]	2.0	2	3	1	1
7021	1437	clinical significance.	[clinical significance.]	2.0	2	3	2	2
7022	1437	atrophy induction	[atrophy induction]	2.0	2	2	0	0
7023	1437	lymphocyte predominance	[lymphocyte predominance]	2.0	2	3	3	3
7024	1437	CMV infection	[CMV infection]	2.0	2	2	0	0
7025	1437	resting cells.	[resting cells.]	2.0	2	2	0	0
7026	1437	cd34 promoter	[CD34 promoter]	2.0	2	2	0	0
7027	1437	at box	[AT box]	2.0	2	3	1	1
7028	1437	tnf-alpha activation	[TNF-alpha activation]	2.0	2	3	3	3
7029	1437	wild-type mouse	[wild-type mouse]	2.0	2	3	1	1
7030	1437	little effect,	[little effect,]	2.0	2	2	0	0
7031	1437	little effect.	[little effect.]	2.0	2	2	0	0
7032	1437	regulate gene	[regulating genes]	2.0	2	2	0	0
7033	1437	NF-kappa b sensitive to nac	[NF-kappa B sensitive to NAC]	2.0	5	2	0	0
7034	1437	b-cell-specific enhancer	[B-cell-specific enhancer]	2.0	2	2	0	0
7035	1437	high amount	[highest amounts]	2.0	2	3	3	3
7036	1437	cross-link CD40	[Cross-linking CD40]	2.0	2	5	3	1
7037	1437	cellular immunity	[cellular immunity]	2.0	2	3	2	2
7038	1437	Sublethal level of oxidative stress	[Sublethal levels of oxidative stress]	2.0	5	2	0	0
7039	1437	different mechanisms.	[different mechanisms.]	2.0	2	2	0	0
7040	1437	predictor of killer cell activity	[predictors of killer cell activity]	2.0	5	2	0	0
7041	1437	CD38 antigen in myeloid cell	[CD38 antigen in myeloid cells]	2.0	5	2	0	0
7042	1437	ecv304 cell	[ECV304 cells]	2.0	2	3	2	2
7043	1437	SV40 promoter	[SV40 promoter]	2.0	2	3	1	1
7044	1437	use monocyte	[using monocytes]	2.0	2	3	3	3
7045	1437	glutathione disulfide	[glutathione disulfide]	2.0	2	3	3	3
7046	1437	encompass end of ebv DNA	[encompassing ends of EBV DNA]	2.0	5	2	0	0
7047	1437	hiv expression in monocytic cell	[HIV expression in monocytic cells]	2.0	5	2	0	0
7048	1437	leukemia CLL	[leukemia CLL]	2.0	2	4	4	2
7049	1437	immune dysfunction	[immune dysfunction]	2.0	2	3	1	1
7050	1437	htlv-i tax	[HTLV-I Tax]	2.0	2	2	0	0
7051	1437	anti-Fas-mediated apoptosis	[anti-Fas-mediated apoptosis]	2.0	2	2	0	0
7052	1437	rt-pcr assay	[RT-PCR assay]	2.0	2	3	1	1
7053	1437	zeta 2	[zeta 2]	2.0	2	3	2	2
7054	1437	cytoplasmic extract	[cytoplasmic extract]	2.0	2	3	3	3
7055	1437	48 h	[48 h]	2.0	2	3	3	3
7056	1437	20q deletion	[20q deletions]	2.0	2	2	0	0
7057	1437	wild-type cell	[wild-type cells]	2.0	2	2	0	0
7058	1437	10 min.	[10 min.]	2.0	2	3	1	1
7059	1437	promoter DNA	[promoter DNA]	2.0	2	3	2	2
7060	1437	low level of steroid receptor	[low level of steroid receptors]	2.0	5	2	0	0
7061	1437	role in T cell activation	[role in T cell activation]	2.0	5	3	2	2
7062	1437	high risk for breast cancer	[high risk for breast cancer]	2.0	5	2	0	0
7063	1437	cell harvester	[cell harvester]	2.0	2	2	0	0
7064	1437	membrane-bound DeltaE	[membrane-bound DeltaE]	2.0	2	2	0	0
7065	1437	Jak 2	[Jak 2]	2.0	2	3	1	1
7066	1437	wild-type virus	[wild-type virus]	2.0	2	2	0	0
7067	1437	5'-untranslated leader	[5'-untranslated leader]	2.0	2	3	1	1
7068	1437	hypercortisolemic patient	[hypercortisolemic patients]	2.0	2	3	1	1
7069	1437	human ccr-4	[human CCR-4]	2.0	2	2	0	0
7070	1437	ppargamma activation	[PPARgamma activation]	2.0	2	3	1	1
7071	1437	human transcription	[human transcription]	2.0	2	2	0	0
7072	1437	activation event	[activation events]	2.0	2	3	3	3
7073	1437	adenoviral persistence	[adenoviral persistence]	2.0	2	2	0	0
7074	1437	cell line,	[cell line,]	2.0	2	3	3	3
7075	1437	immunohistochemical technique	[immunohistochemical technique]	2.0	2	2	0	0
7076	1437	episomal maintenance	[episomal maintenance]	2.0	2	3	3	3
7077	1437	sequence-specific complex	[sequence-specific complexes]	2.0	2	3	2	2
7078	1437	8e51 cell	[8e51 cells]	2.0	2	2	0	0
7079	1437	transcription level	[transcription level]	2.0	2	2	0	0
7080	1437	inhibitor of protein kinase c	[inhibitors of protein kinase C]	2.0	5	3	1	1
7081	1437	different pattern	[different patterns]	2.0	2	4	4	2
7082	1437	human C	[human C]	2.0	2	2	0	0
7083	1437	sickle cell	[sickle cell]	2.0	2	3	3	3
7084	1437	u9-iiib cell	[U9-IIIB cells]	2.0	2	2	0	0
7085	1437	adrenocortical activity	[adrenocortical activity]	2.0	2	2	0	0
7086	1437	DRE 1	[DRE 1]	2.0	2	3	1	1
7087	1437	bacterial superantigen	[bacterial superantigen]	2.0	2	2	0	0
7088	1437	traf binding	[TRAF binding]	2.0	2	3	1	1
7089	1437	essential hypertension	[essential hypertension]	2.0	2	3	1	1
7090	1437	euthyroid patient	[euthyroid patients]	2.0	2	3	1	1
7091	1437	coordinate expression of a number	[coordinate expression of a number]	2.0	5	2	0	0
7092	1437	viral LTR	[viral LTR]	2.0	2	2	0	0
7093	1437	activation of the haematopoietic system	[activation of the haematopoietic system]	2.0	5	2	0	0
7094	1437	oncogenic protein	[oncogenic proteins]	2.0	2	2	0	0
7095	1437	human mzf-1	[human MZF-1]	2.0	2	2	0	0
7096	1437	granulocyte colony-stimulating	[granulocyte colony-stimulating]	2.0	2	4	2	1
7097	1437	cell proliferation.	[cell proliferation.]	2.0	2	3	3	3
7098	1437	inflammatory infiltrate	[inflammatory infiltrate]	2.0	2	3	1	1
7099	1437	10 minute	[10 minutes]	2.0	2	3	1	1
7100	1437	several pathway	[several pathways]	2.0	2	3	3	3
7101	1437	inhibition study	[Inhibition studies]	2.0	2	2	0	0
7102	1437	beta chain	[beta chain]	2.0	2	3	1	1
7103	1437	such as tumor necrosis factor-alpha	[such as tumor necrosis factor-alpha]	2.0	5	2	0	0
7104	1437	two repressor of translation initiation	[two repressors of translation initiation]	2.0	5	2	0	0
7105	1437	mature erythroblast	[mature erythroblasts]	2.0	2	2	0	0
7106	1437	t-lymphoid cell	[T-lymphoid cells]	2.0	2	3	1	1
7107	1437	human factor	[human factors]	2.0	2	2	0	0
7108	1437	schizosaccharome pombe	[Schizosaccharomyces pombe]	2.0	2	2	0	0
7109	1437	recruitment of EKLF to 5'HS2	[recruitment of EKLF to 5'HS2]	2.0	5	2	0	0
7110	1437	glucose uptake	[glucose uptake]	2.0	2	3	1	1
7111	1437	microbial lipoprotein	[microbial lipoproteins]	2.0	2	3	1	1
7112	1437	recombinant retrovirus	[recombinant retrovirus]	2.0	2	2	0	0
7113	1437	two agent	[two agents]	2.0	2	3	1	1
7114	1437	tf expression	[TF expression]	2.0	2	3	2	2
7115	1437	adaptor protein	[adaptor protein]	2.0	2	3	2	2
7116	1437	apoptosis by GC in monocyte	[apoptosis by GC in monocytes]	2.0	5	2	0	0
7117	1437	myeloid-cell-specific gene	[myeloid-cell-specific genes]	2.0	2	3	1	1
7118	1437	E. chaffeensis	[E. chaffeensis]	2.0	2	2	0	0
7119	1437	downstream event	[downstream events]	2.0	2	3	2	2
7120	1437	E2a- Pbx1	[E2a- Pbx1]	2.0	2	3	2	2
7121	1437	tal1 transcription	[TAL1 transcription]	2.0	2	3	2	2
7122	1437	SP-1 site	[SP-1 site]	2.0	2	3	2	2
7123	1437	AP-1 site at -150 bp	[AP-1 site at -150 bp]	2.0	5	2	0	0
7124	1437	cap site	[cap site]	2.0	2	5	3	1
7125	1437	glucocorticoid insensitivity	[glucocorticoid insensitivity]	2.0	2	3	2	2
7126	1437	comparative study	[comparative study]	2.0	2	3	2	2
7127	1437	same effect	[same effects]	2.0	2	3	3	3
7128	1437	nfat-family protein	[NFAT-family proteins]	2.0	2	3	2	2
7129	1437	p65 complex	[p65 complexes]	2.0	2	2	0	0
7130	1437	neutrophil surface	[neutrophil surface]	2.0	2	2	0	0
7131	1437	constitutive activity	[constitutive activity]	2.0	2	3	3	3
7132	1437	tnf-alpha induction	[TNF-alpha induction]	2.0	2	3	3	3
7133	1437	one allele	[one allele]	2.0	2	3	1	1
7134	1437	human immune	[human immune]	2.0	2	2	0	0
7135	1437	important factor	[important factor]	2.0	2	3	3	3
7136	1437	pkc stimulation	[PKC stimulation]	2.0	2	3	2	2
7137	1437	cd3+ cell	[CD3+ cells]	2.0	2	3	3	3
7138	1437	anti-cd2 antibody	[anti-CD2 antibodies]	2.0	2	3	2	2
7139	1437	patient with a disease-free survival	[patients with a disease-free survival]	2.0	5	2	0	0
7140	1437	element upstream	[element upstream]	2.0	2	3	3	3
7141	1437	wild-type ltr	[wild-type LTRs]	2.0	2	3	2	2
7142	1437	suggest involved.	[suggesting involved.]	2.0	2	2	0	0
7143	1437	T cell of young subject	[T cells of young subjects]	2.0	5	2	0	0
7144	1437	viral DNA	[viral DNA]	2.0	2	3	1	1
7145	1437	peroxidase-negative granule	[peroxidase-negative granules]	2.0	2	3	2	2
7146	1437	lymphocyte-specific transcription	[lymphocyte-specific transcription]	2.0	2	3	1	1
7147	1437	e2f regulation	[E2F regulation]	2.0	2	3	2	2
7148	1437	contrast, expression	[contrast, expression]	2.0	2	7	5	1
7149	1437	tissue distribution	[tissue distribution]	2.0	2	2	0	0
7150	1437	ineffectiveness of spironolactone as antagonist	[ineffectiveness of spironolactones as antagonists]	2.0	5	2	0	0
7151	1437	However, TG	[However, TG]	2.0	2	2	0	0
7152	1437	2 groups.	[2 groups.]	2.0	2	2	0	0
7153	1437	tachycardia cris	[tachycardia crises]	2.0	2	2	0	0
7154	1437	I interferon	[I interferon]	2.0	2	3	2	2
7155	1437	guinea pig	[guinea pig]	2.0	2	3	1	1
7156	1437	polyclonal antibody	[polyclonal antibody]	2.0	2	3	2	2
7157	1437	hiv-1 LTR -driven gene expression	[HIV-1 LTR -driven gene expression]	2.0	5	2	0	0
7158	1437	trigger of complement receptor CR1 cd35	[triggering of complement receptors CR1 CD35]	2.0	6	2	0	0
7159	1437	certain gene	[certain genes]	2.0	2	3	1	1
7160	1437	cDNA fragment	[cDNA fragments]	2.0	2	3	3	3
7161	1437	calcium flux	[calcium flux]	2.0	2	3	1	1
7162	1437	TNFalpha treatment	[TNFalpha treatment]	2.0	2	3	1	1
7163	1437	hepatic factor	[hepatic factor]	2.0	2	3	3	3
7164	1437	nucleosome-free region	[nucleosome-free region]	2.0	2	2	0	0
7165	1437	proliferative signal	[proliferative signaling]	2.0	2	3	1	1
7166	1437	protein kinase c signal pathway	[protein kinase C signaling pathway]	2.0	5	2	0	0
7167	1437	granulomatous reaction	[granulomatous reactions]	2.0	2	2	0	0
7168	1437	other leukemia	[other leukemias]	2.0	2	3	2	2
7169	1437	membrane-proximal region	[membrane-proximal region]	2.0	2	3	1	1
7170	1437	c/ebp site	[C/EBP sites]	2.0	2	3	1	1
7171	1437	human cd34+ hematopoietic stem cell	[human CD34+ hematopoietic stem cells]	2.0	5	2	0	0
7172	1437	DNA sequencing	[DNA sequencing]	2.0	2	4	2	1
7173	1437	her-2/neu expression	[HER-2/neu expression]	2.0	2	3	2	2
7174	1437	specific cytokine	[specific cytokines]	2.0	2	3	2	2
7175	1437	pokeweed mitogen	[pokeweed mitogen]	2.0	2	3	3	3
7176	1437	E(gre) motif	[E(gre) motifs]	2.0	2	3	1	1
7177	1437	active treatment	[active treatment]	2.0	2	2	0	0
7178	1437	low affinity,	[lower affinity,]	2.0	2	2	0	0
7179	1437	reverse-transcriptase polymerase chain reaction RT-PCR	[reverse-transcriptase polymerase chain reaction RT-PCR]	2.0	5	2	0	0
7180	1437	post-gc, terminal	[post-GC, terminal]	2.0	2	2	0	0
7181	1437	Electrophoretic mobility shift assay EMSA	[Electrophoretic mobility shift assay EMSA]	2.0	5	3	1	1
7182	1437	VDR expression	[VDR expression]	2.0	2	3	2	2
7183	1437	IL-12 expression	[IL-12 expression]	2.0	2	3	2	2
7184	1437	aged person	[aged persons]	2.0	2	3	1	1
7185	1437	dexamethasone treatment	[Dexamethasone treatment]	2.0	2	3	1	1
7186	1437	nonthyroidal disease	[nonthyroidal diseases]	2.0	2	2	0	0
7187	1437	transcription of the il-1beta gene	[transcription of the IL-1beta gene]	2.0	5	2	0	0
7188	1437	purine box	[purine box]	2.0	2	3	3	3
7189	1437	cytokine gene in T cell	[cytokine genes in T cells]	2.0	5	3	2	2
7190	1437	IRF-1 gas	[IRF-1 GAS]	2.0	2	3	3	3
7191	1437	cd23b promoter	[CD23b promoter]	2.0	2	2	0	0
7192	1437	normal blood	[normal blood]	2.0	2	4	4	2
7193	1437	Ca2+ ]i	[Ca2+ ]i]	2.0	2	3	3	3
7194	1437	24 h.	[24 h,]	2.0	2	2	0	0
7195	1437	three complex	[three complexes]	2.0	2	3	3	3
7196	1437	slowly migrate	[slowly migrating]	2.0	2	3	2	2
7197	1437	clinical symptom	[clinical symptoms]	2.0	2	3	1	1
7198	1437	cytotoxicity assay	[cytotoxicity assays]	2.0	2	3	1	1
7199	1437	normal person	[normal persons]	2.0	2	2	0	0
7200	1437	several lymphokine	[several lymphokines]	2.0	2	2	0	0
7201	1437	DNA apoptosis	[DNA apoptosis]	2.0	2	3	3	3
7202	1437	patient present	[patient presenting]	2.0	2	3	3	3
7203	1437	lncap cell	[LNCaP cell]	2.0	2	3	2	2
7204	1437	regulatory module	[regulatory module]	2.0	2	3	3	3
7205	1437	il-2 signal	[IL-2 signaling]	2.0	2	3	1	1
7206	1437	similar effects.	[similar effects.]	2.0	2	2	0	0
7207	1437	zeta-globin promoter	[zeta-globin promoter]	2.0	2	2	0	0
7208	1437	apoptosis resistance	[apoptosis resistance]	2.0	2	2	0	0
7209	1437	sequence in the adenovirus e1a gene	[sequences in the adenovirus E1A genes]	2.0	6	2	0	0
7210	1437	il-4r alpha	[IL-4R alpha]	2.0	2	3	2	2
7211	1437	vpr product	[vpr product]	2.0	2	2	0	0
7212	1437	1,25-Dihydroxyvitamin D3	[1,25-Dihydroxyvitamin D3]	2.0	2	3	2	2
7213	1437	metabolic activity	[metabolic activity]	2.0	2	2	0	0
7214	1437	two b cell-specific transcriptional coactivator	[two B cell-specific transcriptional coactivators]	2.0	5	2	0	0
7215	1437	high homology	[high homology]	2.0	2	6	4	1
7216	1437	mediate response	[mediating responses]	2.0	2	3	3	3
7217	1437	various granulomato	[various granulomatoses]	2.0	2	2	0	0
7218	1437	sequence tag	[sequence tag]	2.0	2	3	2	2
7219	1437	dp alpha	[DP alpha]	2.0	2	2	0	0
7220	1437	positive mechanism	[positive mechanisms]	2.0	2	3	3	3
7221	1437	casein kinase	[casein kinase]	2.0	2	4	4	2
7222	1437	cytokine gene during the response	[cytokine genes during the response]	2.0	5	2	0	0
7223	1437	lymphoid origin	[lymphoid origin]	2.0	2	2	0	0
7224	1437	quantitative assay	[quantitative assay]	2.0	2	2	0	0
7225	1437	Electrophoretic mobility shift assay analysis	[Electrophoretic mobility shift assay analysis]	2.0	5	3	1	1
7226	1437	Ets domain	[Ets domain]	2.0	2	3	1	1
7227	1437	non-hodgkin's lymphoma	[non-Hodgkin's lymphoma]	2.0	2	3	1	1
7228	1437	single element	[single element]	2.0	2	3	2	2
7229	1437	alternative mechanism	[alternative mechanism]	2.0	2	3	1	1
7230	1437	one cause of persistent inflammatory arthritis	[one cause of persistent inflammatory arthritis]	2.0	6	2	0	0
7231	1437	nonpregnancy lymphocyte	[nonpregnancy lymphocytes]	2.0	2	3	1	1
7232	1437	primary infection	[primary infection]	2.0	2	2	0	0
7233	1437	plc gamma	[PLC gamma]	2.0	2	4	4	2
7234	1437	normal cd34+ bone marrow cell	[normal CD34+ bone marrow cells]	2.0	5	2	0	0
7235	1437	malignant effusion	[malignant effusions]	2.0	2	3	1	1
7236	1437	two tyrosine	[two tyrosines]	2.0	2	3	2	2
7237	1437	nuclear extract-DNA	[nuclear extract-DNA]	2.0	2	2	0	0
7238	1437	human DR	[human DR]	2.0	2	2	0	0
7239	1437	rest lymphocyte	[resting lymphocytes]	2.0	2	3	1	1
7240	1437	human TF	[human TF]	2.0	2	2	0	0
7241	1437	protooncogene expression	[protooncogene expression]	2.0	2	2	0	0
7242	1437	4 day	[4 days]	2.0	2	3	2	2
7243	1437	IL-2 responsiveness	[IL-2 responsiveness]	2.0	2	3	1	1
7244	1437	stimulation of il-2 promoter transcription	[stimulation of IL-2 promoter transcription]	2.0	5	2	0	0
7245	1437	inhibit activation	[inhibiting activation]	2.0	2	4	4	2
7246	1437	basal value	[basal values]	2.0	2	2	0	0
7247	1437	calcium concentration	[calcium concentration]	2.0	2	3	3	3
7248	1437	hgata-3 T cell transcription factor	[hGATA-3 T cell transcription factor]	2.0	5	2	0	0
7249	1437	pou-specific homeodomain	[POU-specific homeodomain]	2.0	2	3	2	2
7250	1437	pmn infiltration	[PMN infiltration]	2.0	2	2	0	0
7251	1437	internal atg	[internal ATGs]	2.0	2	2	0	0
7252	1437	promoter activation	[promoter activation]	2.0	2	3	3	3
7253	1437	one gene	[One gene]	2.0	2	3	2	2
7254	1437	such as phorbol myristate acetate	[such as phorbol myristate acetate]	2.0	5	3	1	1
7255	1437	cd44 cross-linking	[CD44 cross-linking]	2.0	2	2	0	0
7256	1437	time- manner	[time- manner]	2.0	2	2	0	0
7257	1437	c-fe promoter	[c-fes promoter]	2.0	2	3	1	1
7258	1437	several study	[Several studies]	2.0	2	4	2	1
7259	1437	positive regulatory domain i-binding factor-1	[positive regulatory domain I-binding factor-1]	2.0	5	2	0	0
7260	1437	5 hour	[5 hr]	2.0	2	2	0	0
7261	1437	chronic phase	[chronic phase]	2.0	2	2	0	0
7262	1437	transcriptional initiation	[transcriptional initiation]	2.0	2	2	0	0
7263	1437	lymphocyte adhesion	[lymphocyte adhesion]	2.0	2	2	0	0
7264	1437	anergy induction	[anergy induction]	2.0	2	4	2	1
7265	1437	myelo- cell	[myelo- cells]	2.0	2	3	2	2
7266	1437	inactive calcineurin	[inactive calcineurin]	2.0	2	2	0	0
7267	1437	stat5 recruitment	[STAT5 recruitment]	2.0	2	2	0	0
7268	1437	human eotaxin	[human eotaxin]	2.0	2	2	0	0
7269	1437	breast-conservervest-cserveng therapy	[breast-conserving therapy]	2.0	2	2	0	0
7270	1437	stat1 activation	[STAT1 activation]	2.0	2	3	1	1
7271	1437	preliminary studies,	[preliminary studies,]	2.0	2	3	2	2
7272	1437	encode LBR a integral protein	[encoding LBR an integral protein]	2.0	5	2	0	0
7273	1437	viral enhancer	[viral enhancer]	2.0	2	3	2	2
7274	1437	efficient transcription	[efficient transcription]	2.0	2	3	3	3
7275	1437	pkc isoform	[PKC isoforms]	2.0	2	3	3	3
7276	1437	environmental estrogen	[environmental estrogens]	2.0	2	3	2	2
7277	1437	vd3 treatment	[VD3 treatment]	2.0	2	2	0	0
7278	1437	intronic sequence	[intronic sequence]	2.0	2	3	2	2
7279	1437	inducible transcription	[inducible transcription]	2.0	2	2	0	0
7280	1437	lavage cell from tuberculosis patient	[lavage cells from tuberculosis patients]	2.0	5	2	0	0
7281	1437	late activation	[later activation]	2.0	2	2	0	0
7282	1437	therapeutic potential	[therapeutic potential]	2.0	2	3	3	3
7283	1437	base substitution	[base substitution]	2.0	2	3	2	2
7284	1437	tar transactivation	[TAR transactivation]	2.0	2	3	3	3
7285	1437	RCC -S	[RCC -S]	2.0	2	3	1	1
7286	1437	TCF-1 mRNA	[TCF-1 mRNA]	2.0	2	2	0	0
7287	1437	tumor necrosis factor alpha TNF-alpha	[tumor necrosis factor alpha TNF-alpha]	2.0	5	3	1	1
7288	1437	nf-atp mouse	[NF-ATp mice]	2.0	2	3	3	3
7289	1437	cytokine il-6	[cytokine IL-6]	2.0	2	3	3	3
7290	1437	b inhibitor	[B inhibitor]	2.0	2	3	3	3
7291	1437	acid lipase	[acid lipase]	2.0	2	3	3	3
7292	1437	anti-inflammatory activity	[anti-inflammatory activity]	2.0	2	2	0	0
7293	1437	94-kd stat5a	[94-kD STAT5A]	2.0	2	2	0	0
7294	1437	spastic paraparesis	[spastic paraparesis]	2.0	2	3	3	3
7295	1437	reactivity	[reactivity]	2.0	1	22	20	10
7296	1437	differentiation stage	[differentiation stage]	2.0	2	3	2	2
7297	1437	CAT expression	[CAT expression]	2.0	2	3	1	1
7298	1437	hiv-1 dse	[HIV-1 DSE]	2.0	2	2	0	0
7299	1437	electrolyte balance	[electrolyte balance]	2.0	2	2	0	0
7300	1437	ebna-2 responsiveness	[EBNA-2 responsiveness]	2.0	2	2	0	0
7301	1437	such change	[Such changes]	2.0	2	3	1	1
7302	1437	effect on T cell proliferation	[effect on T cell proliferation]	2.0	5	3	2	2
7303	1437	b-cell-specific activator	[B-cell-specific activator]	2.0	2	2	0	0
7304	1437	b-cell-specific expression	[B-cell-specific expression]	2.0	2	2	0	0
7305	1437	AP-2 site	[AP-2 sites]	2.0	2	2	0	0
7306	1437	73 kda	[73 kDa]	2.0	2	2	0	0
7307	1437	stimuli-specific pathway	[stimuli-specific pathways]	2.0	2	2	0	0
7308	1437	CD8	[CD8]	2.0	1	21	4	4
7309	1437	2 receptor	[2 receptor]	2.0	2	3	1	1
7310	1437	control region	[control region]	2.0	2	3	3	3
7311	1437	linear correlation between the number	[linear correlation between the number]	2.0	5	2	0	0
7312	1437	cellular senescence	[cellular senescence]	2.0	2	3	1	1
7313	1437	two line	[two lines]	2.0	2	3	2	2
7314	1437	non-erythroid cell	[non-erythroid cells]	2.0	2	3	1	1
7315	1437	E3 transcript	[E3 transcripts]	2.0	2	2	0	0
7316	1437	expression of a subset of gene	[expression of a subset of genes]	2.0	6	3	2	2
7317	1437	cytokine induction	[cytokine induction]	2.0	2	2	0	0
7318	1437	C. sub. on ca2+ transport	[C. Sub. on Ca2+ transport]	2.0	5	2	0	0
7319	1437	nf-kappab/ntat protein	[NF-kappaB/NFAT proteins]	2.0	2	2	0	0
7320	1437	acute promyelocytic leukemia (apl) cell	[acute promyelocytic leukemia (APL) cells]	2.0	5	2	0	0
7321	1437	cemxl74 cell	[CEMxl74 cells]	2.0	2	3	2	2
7322	1437	remain patient	[remaining patients]	2.0	2	3	3	3
7323	1437	intrafollicular T	[intrafollicular T]	2.0	2	2	0	0
7324	1437	human lesion	[human lesions]	2.0	2	3	1	1
7325	1437	clonal analysis	[Clonal analysis]	2.0	2	2	0	0
7326	1437	hypoxic ECs	[hypoxic ECs]	2.0	2	3	1	1
7327	1437	cell death.	[cell death.]	2.0	2	3	1	1
7328	1437	adenovirus contain mut-i kappa b	[adenovirus containing mut-I kappa B]	2.0	5	2	0	0
7329	1437	vast majority	[vast majority]	2.0	2	4	4	2
7330	1437	ductal carcinoma	[ductal carcinomas]	2.0	2	3	1	1
7331	1437	BCP-ALL case	[BCP-ALL cases]	2.0	2	2	0	0
7332	1437	tax activity	[Tax activity]	2.0	2	3	2	2
7333	1437	synergistic action	[synergistic action]	2.0	2	3	2	2
7334	1437	gold ion	[gold ion]	2.0	2	3	2	2
7335	1437	A series	[A series]	2.0	2	3	3	3
7336	1437	pge2 production	[PGE2 production]	2.0	2	2	0	0
7337	1437	receptor superfamily	[receptor superfamily]	2.0	2	4	4	2
7338	1437	vivo effect	[vivo effect]	2.0	2	3	3	3
7339	1437	1 activation	[1 activation]	2.0	2	3	3	3
7340	1437	ets binding	[Ets binding]	2.0	2	3	2	2
7341	1437	truncation mutant	[truncation mutant]	2.0	2	3	3	3
7342	1437	6 h.	[6 h,]	2.0	2	3	1	1
7343	1437	distinct mechanisms.	[distinct mechanisms.]	2.0	2	3	1	1
7344	1437	b7 costimulation	[B7 costimulation]	2.0	2	3	2	2
7345	1437	cell cytokine	[cell cytokine]	2.0	2	3	2	2
7346	1437	gene important	[genes important]	2.0	2	3	3	3
7347	1437	i interferon	[I interferons]	2.0	2	3	3	3
7348	1437	TATA element	[TATA element]	2.0	2	3	3	3
7349	1437	molecular characterization	[Molecular characterization]	2.0	2	3	3	3
7350	1437	immunomodulatory agent	[immunomodulatory agent]	2.0	2	2	0	0
7351	1437	primary ss	[primary SS]	2.0	2	2	0	0
7352	1437	serine /threonine	[serine /threonine]	2.0	2	3	2	2
7353	1437	tumor necrosis factor alpha TNF alpha	[Tumor necrosis factor alpha TNF alpha]	2.0	6	2	0	0
7354	1437	NR2 hybrid	[NR2 hybrid]	2.0	2	2	0	0
7355	1437	human cd34+ hematopoietic progenitor cell	[human CD34+ hematopoietic progenitor cells]	2.0	5	2	0	0
7356	1437	porcine MHC class ii expression	[porcine MHC class II expression]	2.0	5	2	0	0
7357	1437	fas upregulation	[Fas upregulation]	2.0	2	3	2	2
7358	1437	SB 247464	[SB 247464]	2.0	2	2	0	0
7359	1437	receptor cross-linking	[receptor cross-linking]	2.0	2	2	0	0
7360	1437	importance of the internal atg	[importance of the internal ATGs]	2.0	5	2	0	0
7361	1437	manner similar	[manner similar]	2.0	2	2	0	0
7362	1437	Hashimoto patient	[Hashimoto patients]	2.0	2	3	3	3
7363	1437	peptide residue	[peptide residues]	2.0	2	3	2	2
7364	1437	histopathological analysis	[Histopathological analysis]	2.0	2	2	0	0
7365	1437	ets-like factor	[ETS-like factors]	2.0	2	3	2	2
7366	1437	lytic effect	[lytic effect]	2.0	2	3	3	3
7367	1437	ml-1 cell	[ML-1 cell]	2.0	2	3	3	3
7368	1437	SMX -NO	[SMX -NO]	2.0	2	3	1	1
7369	1437	10 year	[10 year]	2.0	2	3	2	2
7370	1437	granulocyte count	[granulocyte counts]	2.0	2	2	0	0
7371	1437	tpa transactivation	[TPA transactivation]	2.0	2	2	0	0
7372	1437	hepatic gr	[hepatic GR]	2.0	2	2	0	0
7373	1437	monocyte-derived DC	[monocyte-derived DC]	2.0	2	3	1	1
7374	1437	two molecule	[two molecules]	2.0	2	3	1	1
7375	1437	NIP region	[NIP region]	2.0	2	2	0	0
7376	1437	abnormal expression	[abnormal expression]	2.0	2	3	2	2
7377	1437	Cyclosporin A	[Cyclosporin A]	2.0	2	7	5	1
7378	1437	blk promoter	[blk promoter]	2.0	2	2	0	0
7379	1437	b95-8 cell	[B95-8 cells]	2.0	2	2	0	0
7380	1437	B-cell lymphoma	[B-cell lymphoma]	2.0	2	2	0	0
7381	1437	IL-4 receptor	[IL-4 receptor]	2.0	2	3	3	3
7382	1437	human peripheral blood T lymphoblast	[human peripheral blood T lymphoblasts]	2.0	5	2	0	0
7383	1437	human Toll	[human Toll]	2.0	2	2	0	0
7384	1437	normal donor	[normal donor]	2.0	2	2	0	0
7385	1437	new mechanism	[new mechanism]	2.0	2	3	2	2
7386	1437	bcl-6 expression	[BCL-6 expression]	2.0	2	3	2	2
7387	1437	b cell to plasma cell	[B cells to plasma cells]	2.0	5	2	0	0
7388	1437	h9 cell	[H9 cells]	2.0	2	3	1	1
7389	1437	expression of 135eoh)2d3 receptor rna	[expression of 1,25(OH)2D3 receptor RNA]	2.0	5	3	1	1
7390	1437	classical hd	[classical HD]	2.0	2	2	0	0
7391	1437	proto-oncogene product	[proto-oncogene product]	2.0	2	2	0	0
7392	1437	IL-2 mrna	[IL-2 mRNA]	2.0	2	3	2	2
7393	1437	Cushing' patient	[Cushing's patients]	2.0	2	2	0	0
7394	1437	activation of the protein kinase	[activation of the protein kinase]	2.0	5	3	2	2
7395	1437	allele loss	[allele loss]	2.0	2	3	1	1
7396	1437	IRF-2 gene	[IRF-2 gene]	2.0	2	2	0	0
7397	1437	lymphoma cell	[lymphoma cells]	2.0	2	3	1	1
7398	1437	bp repeat	[bp repeat]	2.0	2	12	10	1
7399	1437	lymphocyte culture	[lymphocyte culture]	2.0	2	3	2	2
7400	1437	gamma(c) subunit	[gamma(c) subunit]	2.0	2	2	0	0
7401	1437	symmetry element	[symmetry element]	2.0	2	3	3	3
7402	1437	24 hours.	[24 hours.]	2.0	2	2	0	0
7403	1437	monocyte-binding receptor	[monocyte-binding receptors]	2.0	2	3	1	1
7404	1437	immunoblot assay	[immunoblot assay]	2.0	2	3	1	1
7405	1437	hiv-1 regulation	[HIV-1 regulation]	2.0	2	2	0	0
7406	1437	second intron	[second intron]	2.0	2	2	0	0
7407	1437	resolution of the NF-kappa B complex	[Resolution of the NF-kappa B complex]	2.0	6	2	0	0
7408	1437	activate effect	[activating effect]	2.0	2	3	3	3
7409	1437	protective effect	[protective effect]	2.0	2	4	4	2
7410	1437	phorbol differentiation	[phorbol differentiation]	2.0	2	3	3	3
7411	1437	leukaemic clone	[leukaemic clone]	2.0	2	2	0	0
7412	1437	PyG box	[PyG box]	2.0	2	3	1	1
7413	1437	residue 57	[residue 57]	2.0	2	4	2	1
7414	1437	synovial macrophage	[synovial macrophages]	2.0	2	2	0	0
7415	1437	tnf cytotoxicity	[TNF cytotoxicity]	2.0	2	2	0	0
7416	1437	other finding	[other findings]	2.0	2	2	0	0
7417	1437	NGAL level	[NGAL levels]	2.0	2	2	0	0
7418	1437	sialoadhesin expression on rat macrophage	[sialoadhesin expression on rat macrophages]	2.0	5	2	0	0
7419	1437	core element	[core elements]	2.0	2	2	0	0
7420	1437	day 7 to day 14	[day 7 to day 14]	2.0	5	2	0	0
7421	1437	calcineurin activation	[calcineurin activation]	2.0	2	3	3	3
7422	1437	gr transcription	[GR transcription]	2.0	2	3	3	3
7423	1437	NF(P) a nuclear factor specific	[NF(P) a nuclear factor specific]	2.0	5	2	0	0
7424	1437	tcr repertoire	[TCR repertoire]	2.0	2	3	3	3
7425	1437	hypothalamic-pituitary-adrenal axis	[hypothalamic-pituitary-adrenal axis]	2.0	2	4	2	1
7426	1437	prognostic factor	[prognostic factor]	2.0	2	3	1	1
7427	1437	activator of transcription (stat) protein	[activator of transcription (Stat) protein]	2.0	5	2	0	0
7428	1437	phenotypic change	[phenotypic changes]	2.0	2	3	2	2
7429	1437	50 kD	[50 kD]	2.0	2	3	3	3
7430	1437	lymphoproliferative disorder	[lymphoproliferative disorders]	2.0	2	3	2	2
7431	1437	rat thymocyte	[rat thymocytes]	2.0	2	3	3	3
7432	1437	aml blast	[AML blasts]	2.0	2	2	0	0
7433	1437	gel electrophoretic mobility shift assay	[Gel electrophoretic mobility shift assay]	2.0	5	2	0	0
7434	1437	several sequence	[several sequences]	2.0	2	2	0	0
7435	1437	bq toxicity	[BQ toxicity]	2.0	2	2	0	0
7436	1437	liposomal mpl	[liposomal MPL]	2.0	2	3	1	1
7437	1437	mM nac	[mM NAC]	2.0	2	3	3	3
7438	1437	ag receptor	[Ag receptor]	2.0	2	3	2	2
7439	1437	E-selectin expression	[E-selectin expression]	2.0	2	3	2	2
7440	1437	several marker	[several markers]	2.0	2	3	3	3
7441	1437	intracellular mechanism	[intracellular mechanisms]	2.0	2	3	2	2
7442	1437	monoblastoid cell	[monoblastoid cells]	2.0	2	3	2	2
7443	1437	box 1	[box 1]	2.0	2	3	3	3
7444	1437	defensin resistance	[defensin resistance]	2.0	2	3	2	2
7445	1437	dose-dependent fashion,	[dose-dependent fashion,]	2.0	2	2	0	0
7446	1437	phenylarsine oxide	[phenylarsine oxide]	2.0	2	3	1	1
7447	1437	271c T	[271C T]	2.0	2	2	0	0
7448	1437	cushingoid feature	[cushingoid features]	2.0	2	3	1	1
7449	1437	p50/p50 homodimer	[p50/p50 homodimers]	2.0	2	2	0	0
7450	1437	kinase domain	[kinase domain]	2.0	2	3	3	3
7451	1437	three factor	[three factors]	2.0	2	2	0	0
7452	1437	rest peripheral blood T cell	[resting peripheral blood T cells]	2.0	5	2	0	0
7453	1437	C delta	[C delta]	2.0	2	2	0	0
7454	1437	novel member	[novel member]	2.0	2	2	0	0
7455	1437	Src homology	[Src homology]	2.0	2	2	0	0
7456	1437	pcr product	[PCR products]	2.0	2	3	3	3
7457	1437	IRE motif	[IRE motif]	2.0	2	2	0	0
7458	1437	group b	[group B]	2.0	2	3	1	1
7459	1437	D3 concentration	[D3 concentration]	2.0	2	2	0	0
7460	1437	large vessel	[large vessel]	2.0	2	2	0	0
7461	1437	absence in lymphocyte from CML patient	[absence in lymphocytes from CML patients]	2.0	6	2	0	0
7462	1437	Th2	[Th2]	2.0	1	21	4	4
7463	1437	two marker	[two markers]	2.0	2	3	1	1
7464	1437	IL1B promoter	[IL1B promoter]	2.0	2	2	0	0
7465	1437	FY*A allele	[FY*A alleles]	2.0	2	2	0	0
7466	1437	major inducer	[major inducer]	2.0	2	3	2	2
7467	1437	abnormal development	[abnormal development]	2.0	2	2	0	0
7468	1437	heterologous domain	[heterologous domain]	2.0	2	3	2	2
7469	1437	sequence-specific protein	[sequence-specific protein]	2.0	2	3	3	3
7470	1437	tissue specificity of this promoter	[tissue specificity of this promoter]	2.0	5	2	0	0
7471	1437	glutathione synthesis	[glutathione synthesis]	2.0	2	2	0	0
7472	1437	oncogene amplification	[Oncogene amplification]	2.0	2	2	0	0
7473	1437	paternal expression	[paternal expression]	2.0	2	3	3	3
7474	1437	human thymus	[human thymus]	2.0	2	2	0	0
7475	1437	proliferative advantage	[proliferative advantage]	2.0	2	2	0	0
7476	1437	VDR polymorphism	[VDR polymorphism]	2.0	2	2	0	0
7477	1437	regulatory molecule	[regulatory molecule]	2.0	2	3	2	2
7478	1437	pu.1 expression	[PU.1 expression]	2.0	2	3	2	2
7479	1437	BW 828	[BW 828]	2.0	2	2	0	0
7480	1437	four member	[four members]	2.0	2	2	0	0
7481	1437	substantial increase	[substantial increase]	2.0	2	3	2	2
7482	1437	rPRL promoter	[rPRL promoter]	2.0	2	2	0	0
7483	1437	two case	[two cases]	2.0	2	3	1	1
7484	1437	circulate leukocyte	[circulating leukocytes]	2.0	2	3	2	2
7485	1437	ec-mn adhesion	[EC-Mn adhesion]	2.0	2	3	1	1
7486	1437	xpb gene	[XPB gene]	2.0	2	2	0	0
7487	1437	ciita protein	[CIITA protein]	2.0	2	2	0	0
7488	1437	leukemic relapse follow autologous pbsct	[leukemic relapse following autologous PBSCT]	2.0	5	2	0	0
7489	1437	human megakaryocyte	[human megakaryocytes]	2.0	2	2	0	0
7490	1437	mammary gland	[mammary gland]	2.0	2	3	2	2
7491	1437	EL-4 cell	[EL-4 cells]	2.0	2	3	1	1
7492	1437	cationic protein	[cationic proteins]	2.0	2	2	0	0
7493	1437	35-kDa fragment	[35-kDa fragment]	2.0	2	2	0	0
7494	1437	DRA x2-box	[DRA X2-box]	2.0	2	2	0	0
7495	1437	enzymatic activity	[enzymatic activity]	2.0	2	3	1	1
7496	1437	29 bp truncation of mrna	[29 bp truncation of mRNA]	2.0	5	2	0	0
7497	1437	novel ets-related transcription factor Elf-1	[novel Ets-related transcription factor Elf-1]	2.0	5	2	0	0
7498	1437	same region	[same region]	2.0	2	2	0	0
7499	1437	child with ricket -like disease	[children with rickets -like diseases]	2.0	5	2	0	0
7500	1437	erythroid lineage-	[erythroid lineage-]	2.0	2	2	0	0
7501	1437	PML/RARalpha mouse	[PML/RARalpha mice]	2.0	2	3	3	3
7502	1437	M-CSF gene	[M-CSF gene]	2.0	2	3	1	1
7503	1437	two proto-oncogent	[two proto-oncogenes]	2.0	2	2	0	0
7504	1437	T cell from the elderly	[T cells from the elderly]	2.0	5	3	1	1
7505	1437	proto-oncogene c-fo	[proto-oncogene c-fos]	2.0	2	3	1	1
7506	1437	r-responsive element	[R-responsive element]	2.0	2	3	1	1
7507	1437	dna-binding site	[DNA-binding site]	2.0	2	3	2	2
7508	1437	essential element	[essential element]	2.0	2	3	3	3
7509	1437	increase in ap-1 enhancer activity	[increases in AP-1 enhancer activity]	2.0	5	2	0	0
7510	1437	include il-2	[including IL-2]	2.0	2	3	2	2
7511	1437	TCL1 gene	[TCL1 gene]	2.0	2	3	1	1
7512	1437	1 dayus-	[1 day,]	2.0	2	2	0	0
7513	1437	anti- stat	[anti- STAT]	2.0	2	3	1	1
7514	1437	interleukin-2 secretion	[interleukin-2 secretion]	2.0	2	3	2	2
7515	1437	insulin-induced hypoglycemia	[insulin-induced hypoglycemia]	2.0	2	2	0	0
7516	1437	factor in	[factor in]	2.0	2	3	2	2
7517	1437	tissue-specific splicing	[tissue-specific splicing]	2.0	2	3	2	2
7518	1437	pml expression	[PML expression]	2.0	2	3	3	3
7519	1437	serum osteocalcin	[Serum osteocalcin]	2.0	2	2	0	0
7520	1437	posttraumatic stress	[posttraumatic stress]	2.0	2	2	0	0
7521	1437	immunomagnetic separation	[immunomagnetic separation]	2.0	2	2	0	0
7522	1437	human multiple myeloma cell line	[human multiple myeloma cell lines]	2.0	5	2	0	0
7523	1437	Duffy-negative individual	[Duffy-negative individuals]	2.0	2	2	0	0
7524	1437	IFN-gamma stat1	[IFN-gamma STAT1]	2.0	2	2	0	0
7525	1437	skw6.4 cell	[SKW6.4 cells]	2.0	2	2	0	0
7526	1437	TF promoter	[TF promoter]	2.0	2	3	2	2
7527	1437	parental cell	[parental cells]	2.0	2	3	1	1
7528	1437	1 repeat	[1 repeat]	2.0	2	3	3	3
7529	1437	t-lymphocyte activation	[T-lymphocyte activation]	2.0	2	3	2	2
7530	1437	human cd3epsilon	[human CD3epsilon]	2.0	2	2	0	0
7531	1437	sites/cell respectively,	[sites/cell respectively,]	2.0	2	3	3	3
7532	1437	molecular basis of gc insensitivity	[molecular basis of GC insensitivity]	2.0	5	2	0	0
7533	1437	myeloid development	[myeloid development]	2.0	2	3	1	1
7534	1437	latent infection.	[latent infection.]	2.0	2	2	0	0
7535	1437	adult globin	[adult globin]	2.0	2	3	2	2
7536	1437	interaction of sp family member	[interaction of Sp family members]	2.0	5	2	0	0
7537	1437	A subunit	[A subunit]	2.0	2	2	0	0
7538	1437	antagonistic activity	[antagonistic activity]	2.0	2	2	0	0
7539	1437	ec activation	[EC activation]	2.0	2	3	2	2
7540	1437	amino acid 207 to 368	[amino acids 207 to 368]	2.0	5	2	0	0
7541	1437	human CD5	[human CD5]	2.0	2	2	0	0
7542	1437	serum withdrawal	[serum withdrawal]	2.0	2	3	1	1
7543	1437	aml m4eo	[AML M4Eo]	2.0	2	3	3	3
7544	1437	nf-kb activity	[NF-kB activity]	2.0	2	3	1	1
7545	1437	2 minute	[2 min]	2.0	2	2	0	0
7546	1437	synovial lining	[synovial lining]	2.0	2	3	1	1
7547	1437	adjuvant chemotherapy	[adjuvant chemotherapy]	2.0	2	3	3	3
7548	1437	NFAT protein	[NFAT protein]	2.0	2	2	0	0
7549	1437	immunodeficiency disease	[immunodeficiency disease]	2.0	2	3	3	3
7550	1437	cellular level.	[cellular level.]	2.0	2	2	0	0
7551	1437	causal relationship	[causal relationship]	2.0	2	3	2	2
7552	1437	switch recombination	[switch recombination]	2.0	2	3	2	2
7553	1437	serine 133	[serine 133]	2.0	2	2	0	0
7554	1437	cellular growth	[cellular growth]	2.0	2	2	0	0
7555	1437	role for this transcription factor	[role for this transcription factor]	2.0	5	3	2	2
7556	1437	human ECs	[human ECs]	2.0	2	3	1	1
7557	1437	lymphokine element	[lymphokine element]	2.0	2	3	3	3
7558	1437	healthy male	[healthy males]	2.0	2	3	1	1
7559	1437	Bacterial lipopolysaccharide	[Bacterial lipopolysaccharide]	2.0	2	4	2	1
7560	1437	hla-dq haplotype	[HLA-DQ haplotype]	2.0	2	3	2	2
7561	1437	collagenase expression	[collagenase expression]	2.0	2	3	3	3
7562	1437	Preliminary observation	[Preliminary observations]	2.0	2	2	0	0
7563	1437	hl-60-c15 cell	[HL-60-C15 cells]	2.0	2	3	3	3
7564	1437	Microtubule disruption	[Microtubule disruption]	2.0	2	2	0	0
7565	1437	EGR-1 promoter	[EGR-1 promoter]	2.0	2	2	0	0
7566	1437	human jurkat T leukemia cell	[human Jurkat T leukemia cells]	2.0	5	2	0	0
7567	1437	two motif	[two motifs]	2.0	2	3	3	3
7568	1437	Specific nuclear translocation of [3H]calcitriol/VDR	[Specific nuclear translocation of [3H]calcitriol/VDR]	2.0	5	2	0	0
7569	1437	biological effect of adrenocortical activity	[biological effects of adrenocortical activity]	2.0	5	2	0	0
7570	1437	anti-CD40 mab	[anti-CD40 mAb]	2.0	2	2	0	0
7571	1437	vivo modulation	[vivo modulation]	2.0	2	3	1	1
7572	1437	similar sequence	[similar sequence]	2.0	2	2	0	0
7573	1437	-insensitive pathway	[-insensitive pathway]	2.0	2	2	0	0
7574	1437	interleukin-2 receptor alpha chain expression	[interleukin-2 receptor alpha chain expression]	2.0	5	2	0	0
7575	1437	expression cloning	[Expression cloning]	2.0	2	3	2	2
7576	1437	gr heterocomplex	[GR heterocomplex]	2.0	2	3	2	2
7577	1437	NF-kappa b p50 /p65 heterodimer	[NF-kappa B p50 /p65 heterodimer]	2.0	5	2	0	0
7578	1437	100 microm	[100 microM]	2.0	2	2	0	0
7579	1437	monocyte/macrophage function	[monocyte/macrophage function]	2.0	2	3	2	2
7580	1437	patient with type iia hyperlipidemia	[patients with type IIa hyperlipidemia]	2.0	5	2	0	0
7581	1437	genetic variant	[genetic variant,]	2.0	2	2	0	0
7582	1437	leukemic relapse	[leukemic relapse]	2.0	2	2	0	0
7583	1437	srg3 protein	[SRG3 protein]	2.0	2	2	0	0
7584	1437	C/EBP site	[C/EBP site]	2.0	2	3	2	2
7585	1437	ga-binding protein	[GA-binding protein]	2.0	2	3	1	1
7586	1437	el4 cell	[El4 cells]	2.0	2	3	2	2
7587	1437	present report	[present report]	2.0	2	2	0	0
7588	1437	upstream factor	[upstream factor]	2.0	2	3	3	3
7589	1437	other promoter	[other promoters]	2.0	2	2	0	0
7590	1437	early precursor	[early precursors]	2.0	2	3	3	3
7591	1437	Rho-family gtpase	[Rho-family GTPases]	2.0	2	2	0	0
7592	1437	similar manner	[similar manner]	2.0	2	3	1	1
7593	1437	mouse thymus	[mouse thymus]	2.0	2	3	3	3
7594	1437	T enhancer	[T enhancer]	2.0	2	3	3	3
7595	1437	neoplastic cell	[neoplastic cell]	2.0	2	3	1	1
7596	1437	more recently circulate human lymphocyte	[more recently circulating human lymphocytes]	2.0	5	2	0	0
7597	1437	have affinity for this sre sequence	[having affinity for this SRE sequence]	2.0	6	2	0	0
7598	1437	il-6 gene	[IL-6 gene]	2.0	2	4	2	1
7599	1437	ciita function	[CIITA function]	2.0	2	2	0	0
7600	1437	CTL recognition	[CTL recognition]	2.0	2	3	1	1
7601	1437	apoptotic vsmc	[apoptotic VSMCs]	2.0	2	3	2	2
7602	1437	7-day pha-blast	[7-day PHA-blasts]	2.0	2	2	0	0
7603	1437	Janus family	[Janus family]	2.0	2	3	2	2
7604	1437	HMG I/Y	[HMG I/Y]	2.0	2	2	0	0
7605	1437	similar extent	[similar extent]	2.0	2	3	1	1
7606	1437	42 degree	[42 degrees]	2.0	2	3	2	2
7607	1437	apoptotic mechanism	[apoptotic mechanism]	2.0	2	3	2	2
7608	1437	group ii	[group II]	2.0	2	3	3	3
7609	1437	activation process	[activation process]	2.0	2	3	3	3
7610	1437	platelet factor	[platelet factor]	2.0	2	3	2	2
7611	1437	leukocyte protein	[leukocyte protein]	2.0	2	3	3	3
7612	1437	host response	[host response]	2.0	2	3	2	2
7613	1437	monocytes/ macrophage	[monocytes/ macrophages]	2.0	2	2	0	0
7614	1437	presence of a CRE site	[presence of an CRE site]	2.0	5	2	0	0
7615	1437	hypothalamic-hypophyseal-adrenocortical system	[hypothalamic-hypophyseal-adrenocortical system]	2.0	2	2	0	0
7616	1437	hs-40 enhancer	[HS-40 enhancer]	2.0	2	3	3	3
7617	1437	IL-7R complex	[IL-7R complex]	2.0	2	3	1	1
7618	1437	lymphocyte from untreated CML patient	[lymphocytes from untreated CML patients]	2.0	5	2	0	0
7619	1437	tcp succinate	[TCP succinate]	2.0	2	3	2	2
7620	1437	murine cDNA	[murine cDNA]	2.0	2	3	3	3
7621	1437	binding sequence	[binding sequences]	2.0	2	3	2	2
7622	1437	subendothelial space	[subendothelial space]	2.0	2	2	0	0
7623	1437	corticosteroid resistance in bronchial asthma	[corticosteroid resistance in bronchial asthma]	2.0	5	2	0	0
7624	1437	il-6 regulation	[IL-6 regulation]	2.0	2	2	0	0
7625	1437	heavy-chain enhancer	[heavy-chain enhancer]	2.0	2	4	4	2
7626	1437	acute ethanol	[acute ethanol]	2.0	2	2	0	0
7627	1437	oligonucleotide corresponding	[oligonucleotide corresponding]	2.0	2	3	3	3
7628	1437	insight into the molecular mechanism	[insight into the molecular mechanisms]	2.0	5	3	2	2
7629	1437	six intron	[six introns]	2.0	2	2	0	0
7630	1437	Recent finding	[Recent findings]	2.0	2	2	0	0
7631	1437	high order	[higher order]	2.0	2	2	0	0
7632	1437	acute inflammation	[acute inflammation]	2.0	2	3	1	1
7633	1437	vitro culture	[vitro culture]	2.0	2	3	2	2
7634	1437	hla -dr	[HLA -DR]	2.0	2	3	1	1
7635	1437	peak value	[peak value]	2.0	2	3	3	3
7636	1437	transient stimulation	[transient stimulation]	2.0	2	3	2	2
7637	1437	liposomal formulation	[liposomal formulation]	2.0	2	2	0	0
7638	1437	hepatic injury	[hepatic injury]	2.0	2	3	3	3
7639	1437	specific sequence	[specific sequence]	2.0	2	2	0	0
7640	1437	cag repeat	[CAG repeats]	2.0	2	3	2	2
7641	1437	computer enhancement	[computer enhancement]	2.0	2	2	0	0
7642	1437	mutation analysis	[Mutation analysis]	2.0	2	3	1	1
7643	1437	ifn-beta transcription	[IFN-beta transcription]	2.0	2	2	0	0
7644	1437	murine bone	[murine bone]	2.0	2	3	2	2
7645	1437	nuclear factor-IL-6beta	[nuclear factor-IL-6beta]	2.0	2	2	0	0
7646	1437	follow stimulation.	[following stimulation.]	2.0	2	3	3	3
7647	1437	human protein	[human protein]	2.0	2	3	1	1
7648	1437	complex effect	[complex effect]	2.0	2	3	1	1
7649	1437	transcription from the DRA promoter	[transcription from the DRA promoter]	2.0	5	2	0	0
7650	1437	use a whole-cell bind assay	[using a whole-cell binding assay]	2.0	5	3	1	1
7651	1437	c-Jun delta-domain	[c-Jun delta-domain]	2.0	2	2	0	0
7652	1437	distal promoter	[distal promoter]	2.0	2	2	0	0
7653	1437	gene target	[gene targeting]	2.0	2	3	1	1
7654	1437	human pbmc	[human PBMCs]	2.0	2	2	0	0
7655	1437	Negative regulation	[Negative regulation]	2.0	2	3	3	3
7656	1437	experimental condition	[experimental conditions]	2.0	2	2	0	0
7657	1437	g1 arrest of uf-1 cell	[G1 arrest of UF-1 cells]	2.0	5	2	0	0
7658	1437	NF-chi b	[NF-chi B]	2.0	2	3	3	3
7659	1437	regulate expression	[regulating expression]	2.0	2	3	2	2
7660	1437	intron 2	[intron 2]	2.0	2	3	2	2
7661	1437	p65 rela	[p65 RelA]	2.0	2	2	0	0
7662	1437	NK-kappa b	[NK-kappa B]	2.0	2	3	3	3
7663	1437	cyclin e	[cyclin E]	2.0	2	3	1	1
7664	1437	immunocompromised host	[immunocompromised hosts]	2.0	2	2	0	0
7665	1437	cancer lncap	[cancer LNCaP]	2.0	2	2	0	0
7666	1437	rna transcription	[RNA transcription]	2.0	2	3	2	2
7667	1437	mNFATc transcript	[mNFATc transcript]	2.0	2	2	0	0
7668	1437	same cis-element	[same cis-elements]	2.0	2	2	0	0
7669	1437	neutrophilic granulocyte	[neutrophilic granulocytes]	2.0	2	3	2	2
7670	1437	amino-terminal sequence	[amino-terminal sequence]	2.0	2	3	2	2
7671	1437	molecular interaction	[molecular interaction]	2.0	2	3	1	1
7672	1437	nuclear accumulation	[nuclear accumulation]	2.0	2	4	4	2
7673	1437	CD19 promoter	[CD19 promoter]	2.0	2	3	2	2
7674	1437	lymphocyte receptor	[lymphocyte receptors]	2.0	2	3	3	3
7675	1437	effective response	[effective response]	2.0	2	3	2	2
7676	1437	degree of leukemic cell contamination	[degree of leukemic cell contamination]	2.0	5	2	0	0
7677	1437	postmenopausal woman	[postmenopausal woman]	2.0	2	3	1	1
7678	1437	human u-937	[human U-937]	2.0	2	2	0	0
7679	1437	positive case	[positive cases]	2.0	2	3	1	1
7680	1437	ino expression	[iNOS expression]	2.0	2	3	1	1
7681	1437	octamer-dependent promoter	[octamer-dependent promoters]	2.0	2	2	0	0
7682	1437	therapeutic agent	[therapeutic agents]	2.0	2	3	2	2
7683	1437	LTR transactivation	[LTR transactivation]	2.0	2	3	1	1
7684	1437	thymic microenvironment	[thymic microenvironment]	2.0	2	2	0	0
7685	1437	specific depletion	[specific depletion]	2.0	2	2	0	0
7686	1437	T cell from young subject	[T cells from young subjects]	2.0	5	2	0	0
7687	1437	complex binding	[complex binding]	2.0	2	3	3	3
7688	1437	inducible pathway	[inducible pathway]	2.0	2	3	2	2
7689	1437	control mechanism	[control mechanisms]	2.0	2	3	3	3
7690	1437	parathyroid gland of uremic animal	[parathyroid glands of uremic animals]	2.0	5	2	0	0
7691	1437	major histocompatibility complex class ii	[major histocompatibility complex class II]	2.0	5	2	0	0
7692	1437	plb-iiib cell	[PLB-IIIB cells]	2.0	2	2	0	0
7693	1437	virus-infected cell	[virus-infected cells]	2.0	2	3	1	1
7694	1437	colorectal cancer	[colorectal cancer]	2.0	2	2	0	0
7695	1437	adhesion response	[adhesion response]	2.0	2	3	1	1
7696	1437	cell-specific activity	[cell-specific activity]	2.0	2	3	3	3
7697	1437	methylprednisolone treatment	[Methylprednisolone treatment]	2.0	2	2	0	0
7698	1437	kappab sequence	[kappaB sequence]	2.0	2	3	2	2
7699	1437	activation requirement	[activation requirements]	2.0	2	3	2	2
7700	1437	heterologous system	[heterologous system]	2.0	2	2	0	0
7701	1437	novel b	[novel B]	2.0	2	2	0	0
7702	1437	21-bp element	[21-bp element]	2.0	2	3	1	1
7703	1437	transcription machinery	[transcription machinery]	2.0	2	3	3	3
7704	1437	primitive cell	[primitive cells]	2.0	2	3	2	2
7705	1437	cell infiltration	[cell infiltration]	2.0	2	3	3	3
7706	1437	sarcoidosis patient	[sarcoidosis patients]	2.0	2	3	2	2
7707	1437	6 hour	[6 hr]	2.0	2	3	1	1
7708	1437	strong effect	[strong effect]	2.0	2	3	3	3
7709	1437	pha pbl	[PHA PBL]	2.0	2	3	1	1
7710	1437	steroid resistance	[steroid resistance]	2.0	2	3	2	2
7711	1437	regulatory network	[regulatory network]	2.0	2	3	2	2
7712	1437	such as tumor necrosis factor	[such as tumor necrosis factor]	2.0	5	2	0	0
7713	1437	several cases,	[several cases,]	2.0	2	2	0	0
7714	1437	hla-dra expression	[HLA-DRA expression]	2.0	2	3	2	2
7715	1437	neotropical primate	[neotropical primates]	2.0	2	3	2	2
7716	1437	functional defect	[functional defect]	2.0	2	3	1	1
7717	1437	IL-2 enhancer	[IL-2 enhancer]	2.0	2	2	0	0
7718	1437	seven exon	[seven exons]	2.0	2	3	1	1
7719	1437	constitutive MHC class ii expression	[constitutive MHC class II expression]	2.0	5	2	0	0
7720	1437	certain tissue	[certain tissues]	2.0	2	2	0	0
7721	1437	frameshift mutation	[frameshift mutation]	2.0	2	3	3	3
7722	1437	G-CSF receptor	[G-CSF receptor]	2.0	2	2	0	0
7723	1437	fusion partner	[fusion partner]	2.0	2	3	3	3
7724	1437	anti-IgM Ab	[anti-IgM Ab]	2.0	2	2	0	0
7725	1437	thermal activation	[thermal activation]	2.0	2	2	0	0
7726	1437	interstitial deletion	[interstitial deletion]	2.0	2	3	1	1
7727	1437	macrophage lineage	[macrophage lineage]	2.0	2	3	1	1
7728	1437	translocation breakpoint	[translocation breakpoint]	2.0	2	3	2	2
7729	1437	phosphate supplementation	[phosphate supplementation]	2.0	2	3	3	3
7730	1437	effective concentration	[effective concentration]	2.0	2	3	3	3
7731	1437	zinc-finger domain	[zinc-finger domain]	2.0	2	3	2	2
7732	1437	few hour	[few hours]	2.0	2	2	0	0
7733	1437	active role	[active role]	2.0	2	3	2	2
7734	1437	synthetic ligand	[synthetic ligands]	2.0	2	2	0	0
7735	1437	expression of tumor necrosis factor-alpha	[expression of tumor necrosis factor-alpha]	2.0	5	2	0	0
7736	1437	CaM-K ii	[CaM-K II]	2.0	2	3	1	1
7737	1437	CD28 signal	[CD28 signal]	2.0	2	3	2	2
7738	1437	t-cell specificity	[T-cell specificity]	2.0	2	2	0	0
7739	1437	accumulation of c/ebp epsilon mrna	[Accumulation of C/EBP epsilon mRNA]	2.0	5	2	0	0
7740	1437	expression of MHC class gene	[expression of MHC class genes]	2.0	5	3	1	1
7741	1437	aortic cell	[aortic cells]	2.0	2	3	3	3
7742	1437	plastic surface	[plastic surfaces]	2.0	2	3	1	1
7743	1437	CAEV LTR	[CAEV LTR]	2.0	2	3	1	1
7744	1437	factor responsible for the activation	[factor responsible for the activation]	2.0	5	2	0	0
7745	1437	receptor occupancy	[receptor occupancy]	2.0	2	3	2	2
7746	1437	Ferriman-Gallwey score	[Ferriman-Gallwey score]	2.0	2	2	0	0
7747	1437	genetic alteration	[genetic alterations]	2.0	2	3	1	1
7748	1437	110-kda protein	[110-kDa protein]	2.0	2	2	0	0
7749	1437	candidate gene	[candidate gene]	2.0	2	3	2	2
7750	1437	immunoglobulin secretion	[immunoglobulin secretion]	2.0	2	2	0	0
7751	1437	lymphoproliferative disease	[lymphoproliferative diseases]	2.0	2	3	1	1
7752	1437	paf-receptor antagonist	[PAF-receptor antagonist]	2.0	2	2	0	0
7753	1437	oncogene product	[oncogene product]	2.0	2	3	3	3
7754	1437	BCL-6 mutation	[BCL-6 mutations]	2.0	2	3	1	1
7755	1437	29-kDa protein	[29-kDa proteins]	2.0	2	2	0	0
7756	1437	lipopolysaccharide LPS	[lipopolysaccharide LPS]	2.0	2	2	0	0
7757	1437	RanQ69L preincubation	[RanQ69L preincubation]	2.0	2	2	0	0
7758	1437	cell differentiation,	[cell differentiation,]	2.0	2	3	2	2
7759	1437	TCL1 locus	[TCL1 locus]	2.0	2	3	2	2
7760	1437	terminal maturation	[terminal maturation]	2.0	2	3	2	2
7761	1437	specific peptide	[specific peptide]	2.0	2	3	1	1
7762	1437	GAL4 DNA	[GAL4 DNA]	2.0	2	4	4	2
7763	1437	vzv gE	[VZV gE]	2.0	2	3	2	2
7764	1437	granulocyte maturation	[granulocyte maturation]	2.0	2	2	0	0
7765	1437	time-dependent increase	[time-dependent increase]	2.0	2	3	1	1
7766	1437	beta-galactosidase activity	[beta-galactosidase activity]	2.0	2	2	0	0
7767	1437	mutant virus	[mutant virus]	2.0	2	3	1	1
7768	1437	neutrophil infiltration	[neutrophil infiltration]	2.0	2	2	0	0
7769	1437	signal complex	[signaling complex]	2.0	2	3	3	3
7770	1437	genomic change	[genomic changes]	2.0	2	2	0	0
7771	1437	MNP site	[MNP site]	2.0	2	2	0	0
7772	1437	critical role in the expression	[critical role in the expression]	2.0	5	2	0	0
7773	1437	nonpermissive temperature	[nonpermissive temperature]	2.0	2	2	0	0
7774	1437	p65/p50 subunit	[P65/p50 subunit]	2.0	2	2	0	0
7775	1437	cellular component	[cellular component]	2.0	2	3	3	3
7776	1437	numerous study	[numerous studies]	2.0	2	2	0	0
7777	1437	unknown mechanism	[unknown mechanism]	2.0	2	2	0	0
7778	1437	6-h increase in pdgf(b) mrna	[6-h increase in PDGF(B) mRNA]	2.0	5	2	0	0
7779	1437	IL-2 cell	[IL-2 cells]	2.0	2	3	1	1
7780	1437	Fy(a-b-) phenotype	[Fy(a-b-) phenotype]	2.0	2	2	0	0
7781	1437	major cytokine	[major cytokines]	2.0	2	2	0	0
7782	1437	peroxisome proliferator	[peroxisome proliferator]	2.0	2	3	2	2
7783	1437	two lineage	[two lineages]	2.0	2	2	0	0
7784	1437	ebv protein	[EBV proteins]	2.0	2	3	3	3
7785	1437	DNA response	[DNA response]	2.0	2	3	3	3
7786	1437	monitor the expression pattern of bcl-6	[monitoring the expression pattern of BCL-6]	2.0	6	2	0	0
7787	1437	healthy female	[healthy females]	2.0	2	3	3	3
7788	1437	induction of b dna-binding activity	[induction of B DNA-binding activity]	2.0	5	2	0	0
7789	1437	autocrine mechanism	[autocrine mechanism]	2.0	2	3	2	2
7790	1437	constitutive association	[constitutive association]	2.0	2	4	4	2
7791	1437	T cell receptor alpha enhancer	[T cell receptor alpha enhancer]	2.0	5	2	0	0
7792	1437	25 microM)	[25 microM)]	2.0	2	2	0	0
7793	1437	BR3 sequence	[BR3 sequence]	2.0	2	2	0	0
7794	1437	respiratory distress	[respiratory distress]	2.0	2	3	2	2
7795	1437	HS I	[HS I]	2.0	2	2	0	0
7796	1437	c-jun rna	[c-jun RNA]	2.0	2	3	3	3
7797	1437	base exchange	[base exchange]	2.0	2	3	3	3
7798	1437	regulatory system	[regulatory system]	2.0	2	3	1	1
7799	1437	ionomycin treatment	[ionomycin treatment]	2.0	2	3	1	1
7800	1437	E-box motif	[E-box motif]	2.0	2	2	0	0
7801	1437	only in primary NK cell	[only in primary NK cells]	2.0	5	2	0	0
7802	1437	signal transducer of transcription stat	[signal transducers of transcription STATs]	2.0	5	2	0	0
7803	1437	toll-like receptor	[Toll-like receptor]	2.0	2	3	2	2
7804	1437	ubiquitous molecule	[ubiquitous molecule]	2.0	2	2	0	0
7805	1437	selective effect	[selective effects]	2.0	2	3	2	2
7806	1437	secondary hyperparathyroidism	[secondary hyperparathyroidism]	2.0	2	3	1	1
7807	1437	normal volunteers.	[normal volunteers.]	2.0	2	2	0	0
7808	1437	proliferation factor	[proliferation factor]	2.0	2	2	0	0
7809	1437	owl monkey	[owl monkey]	2.0	2	3	2	2
7810	1437	member of the signal transducer	[member of the signal transducers]	2.0	5	3	1	1
7811	1437	nf-kappab site	[NF-kappaB sites]	2.0	2	3	2	2
7812	1437	most patient	[most patients]	2.0	2	3	2	2
7813	1437	sem, N	[SEM, N]	2.0	2	2	0	0
7814	1437	immunoelectron microscopy	[Immunoelectron microscopy]	2.0	2	2	0	0
7815	1437	BACKGROUND: IL-5	[BACKGROUND: IL-5]	2.0	2	2	0	0
7816	1437	agonistic activity	[agonistic activity]	2.0	2	3	2	2
7817	1437	lps induction of tf gene transcription	[LPS induction of TF gene transcription]	2.0	6	2	0	0
7818	1437	GATA-3 gene	[GATA-3 gene]	2.0	2	3	1	1
7819	1437	il-2 synthesis	[IL-2 synthesis]	2.0	2	3	2	2
7820	1437	virus transcription	[virus transcription]	2.0	2	3	1	1
7821	1437	ets-related protein	[ets-related protein]	2.0	2	3	2	2
7822	1437	CAT gene	[CAT gene]	2.0	2	4	4	2
7823	1437	cytotoxic function	[cytotoxic function]	2.0	2	2	0	0
7824	1437	unliganded c-erbA/TR	[unliganded c-erbA/TR]	2.0	2	2	0	0
7825	1437	L. donovani	[L. donovani]	2.0	2	3	2	2
7826	1437	src homology	[src homology]	2.0	2	3	2	2
7827	1437	one month	[one month]	2.0	2	3	1	1
7828	1437	granulocytic dysplasia	[granulocytic dysplasia]	2.0	2	2	0	0
7829	1437	myelomonocytic leukemia	[myelomonocytic leukemia]	2.0	2	3	1	1
7830	1437	cystic fibrosis	[cystic fibrosis]	2.0	2	3	1	1
7831	1437	bronchoalveolar lavage	[bronchoalveolar lavage]	2.0	2	2	0	0
7832	1437	stimulation with phorbol 12-myristate 13-acetate	[stimulation with phorbol 12-myristate 13-acetate]	2.0	5	2	0	0
7833	1437	ets-related transcription	[Ets-related transcription]	2.0	2	3	1	1
7834	1437	unexpected finding	[unexpected finding]	2.0	2	3	1	1
7835	1437	blood donor	[blood donor]	2.0	2	4	4	2
7836	1437	nonmyeloid cell	[nonmyeloid cells]	2.0	2	3	1	1
7837	1437	bind specificity	[binding specificity]	2.0	2	3	2	2
7838	1437	enhancer motif	[enhancer motif]	2.0	2	3	3	3
7839	1437	reverse transcriptase polymerase chain reaction	[reverse transcriptase polymerase chain reaction]	2.0	5	3	2	2
7840	1437	different element	[different elements]	2.0	2	2	0	0
7841	1437	E. coli	[E. coli]	2.0	2	3	2	2
7842	1437	persistent expression	[persistent expression]	2.0	2	3	2	2
7843	1437	camp response element binding protein	[cAMP response element binding protein]	2.0	5	3	1	1
7844	1437	rvlp particle	[RVLP particles]	2.0	2	2	0	0
7845	1437	14 patient	[14 patients]	2.0	2	3	1	1
7846	1437	unique expression	[unique expression]	2.0	2	2	0	0
7847	1437	IL-2R alpha	[IL-2R alpha]	2.0	2	2	0	0
7848	1437	nuclear phosphoprotein	[nuclear phosphoprotein]	2.0	2	2	0	0
7849	1437	vitro mutagenesis	[vitro mutagenesis]	2.0	2	3	1	1
7850	1437	novel evidence	[novel evidence]	2.0	2	2	0	0
7851	1437	sjogren' syndrome	[Sjogren's syndrome]	2.0	2	3	2	2
7852	1437	interleukin-1 beta il-1 beta mrna	[interleukin-1 beta IL-1 beta mRNA]	2.0	5	2	0	0
7853	1437	alpha 2	[alpha 2]	2.0	2	2	0	0
7854	1437	bcl-x promoter	[bcl-x promoter]	2.0	2	3	1	1
7855	1437	immediate-early transactivator	[immediate-early transactivator]	2.0	2	3	3	3
7856	1437	virus spread	[virus spread]	2.0	2	2	0	0
7857	1437	pol gene	[pol gene]	2.0	2	3	1	1
7858	1437	two exon	[two exons]	2.0	2	3	1	1
7859	1437	normal cells,	[normal cells,]	2.0	2	2	0	0
7860	1437	current finding	[current findings]	2.0	2	2	0	0
7861	1437	L. pneumophila	[L. pneumophila]	2.0	2	3	2	2
7862	1437	murine leukemia	[murine leukemia]	2.0	2	3	2	2
7863	1437	two patient	[two patients]	2.0	2	3	1	1
7864	1437	cell assay	[cell assay]	2.0	2	3	3	3
7865	1437	corresponding proteins.	[corresponding proteins.]	2.0	2	2	0	0
7866	1437	bcl-2 promoter	[bcl-2 promoter]	2.0	2	3	1	1
7867	1437	1 inhibitor	[1 inhibitors]	2.0	2	2	0	0
7868	1437	expression of a reporter gene	[expression of a reporter gene]	2.0	5	3	2	2
7869	1437	cell surface.	[cell surface.]	2.0	2	3	1	1
7870	1437	late stage of B-cell differentiation	[later stages of B-cell differentiation]	2.0	5	2	0	0
7871	1437	same cell	[same cells]	2.0	2	3	1	1
7872	1437	general factor	[general factor]	2.0	2	3	2	2
7873	1437	megakaryocytic cell	[megakaryocytic cells]	2.0	2	2	0	0
7874	1437	stat5 phosphorylation	[STAT5 phosphorylation]	2.0	2	2	0	0
7875	1437	B-1 lymphocyte	[B-1 lymphocytes]	2.0	2	2	0	0
7876	1437	dose-response curve	[dose-response curve]	2.0	2	2	0	0
7877	1437	activity of a transcription factor	[activity of an transcription factor]	2.0	5	2	0	0
7878	1437	binding of the glucocorticoid receptor	[binding of the glucocorticoid receptor]	2.0	5	2	0	0
7879	1437	tumor necrosis factor alpha TNFalpha	[Tumor necrosis factor alpha TNFalpha]	2.0	5	2	0	0
7880	1437	simian ebv	[simian EBV]	2.0	2	2	0	0
7881	1437	DFX treatment	[DFX treatment]	2.0	2	2	0	0
7882	1437	win 53071	[WIN 53071]	2.0	2	2	0	0
7883	1437	1 beta	[1 beta]	2.0	2	3	3	3
7884	1437	9-cis acid	[9-cis acid]	2.0	2	4	4	2
7885	1437	genomic mechanism	[genomic mechanisms]	2.0	2	2	0	0
7886	1437	mutant cell	[mutant cell]	2.0	2	3	2	2
7887	1437	CD40 pathway	[CD40 pathway]	2.0	2	2	0	0
7888	1437	130 kb	[130 kb]	2.0	2	3	3	3
7889	1437	activation cascade	[activation cascade]	2.0	2	3	1	1
7890	1437	monocyte apoptosis	[Monocyte apoptosis]	2.0	2	2	0	0
7891	1437	critical event	[critical event]	2.0	2	3	3	3
7892	1437	cell cycle s phase entry	[cell cycle S phase entry]	2.0	5	2	0	0
7893	1437	b-cell proliferation	[B-cell proliferation]	2.0	2	3	2	2
7894	1437	tnf mrna	[TNF mRNA]	2.0	2	4	2	1
7895	1437	dominant role	[dominant role]	2.0	2	3	1	1
7896	1437	immunodominant antigen	[immunodominant antigen]	2.0	2	3	2	2
7897	1437	mcp-1 secretion	[MCP-1 secretion]	2.0	2	3	1	1
7898	1437	helix loop	[helix loop]	2.0	2	3	1	1
7899	1437	human thp-1	[human THP-1]	2.0	2	2	0	0
7900	1437	other mechanism	[other mechanisms]	2.0	2	3	3	3
7901	1437	proliferative state	[proliferative state]	2.0	2	2	0	0
7902	1437	TNF signal	[TNF signaling]	2.0	2	2	0	0
7903	1437	thyroid function	[thyroid function]	2.0	2	3	2	2
7904	1437	phosphorylation status	[phosphorylation status]	2.0	2	3	2	2
7905	1437	Y box	[Y box]	2.0	2	3	1	1
7906	1437	t-cell determinant	[T-cell determinants]	2.0	2	3	2	2
7907	1437	GR mrna	[GR mRNA]	2.0	2	4	2	1
7908	1437	molecular approach	[molecular approach]	2.0	2	2	0	0
7909	1437	il-4 stimulation	[IL-4 stimulation]	2.0	2	3	2	2
7910	1437	chimeric oncoprotein	[chimeric oncoprotein]	2.0	2	2	0	0
7911	1437	tcl1 expression	[TCL1 expression]	2.0	2	3	2	2
7912	1437	htlv-ii tax	[HTLV-II Tax]	2.0	2	2	0	0
7913	1437	latency iii	[latency III]	2.0	2	2	0	0
7914	1437	SCL expression	[SCL expression]	2.0	2	3	2	2
7915	1437	expression of class ii gene	[expression of class II genes]	2.0	5	3	2	2
7916	1437	CD3 ligation	[CD3 ligation]	2.0	2	4	2	1
7917	1437	c-myc mrna	[c-myc mRNA]	2.0	2	3	2	2
7918	1437	heme-treated flc	[heme-treated FLCs]	2.0	2	2	0	0
7919	1437	C. neoforman	[C. neoformans]	2.0	2	3	3	3
7920	1437	ad 2/5	[Ad 2/5]	2.0	2	3	3	3
7921	1437	human melanoma	[human melanomas]	2.0	2	3	3	3
7922	1437	tal1 gene	[TAL1 gene]	2.0	2	4	4	2
7923	1437	human host	[human host]	2.0	2	2	0	0
7924	1437	Gram-positive bacterium	[Gram-positive bacteria]	2.0	2	2	0	0
7925	1437	resistant patient	[resistant patients]	2.0	2	3	2	2
7926	1437	receptor preparation	[receptor preparations]	2.0	2	2	0	0
7927	1437	granulocyte DNA	[granulocyte DNA]	2.0	2	3	1	1
7928	1437	carry mutation	[carrying mutations]	2.0	2	3	3	3
7929	1437	further evaluation.	[further evaluation.]	2.0	2	2	0	0
7930	1437	physical interaction between ets protein	[physical interaction between Ets proteins]	2.0	5	2	0	0
7931	1437	amino terminal	[amino terminal]	2.0	2	3	3	3
7932	1437	thiol-reducing compound	[thiol-reducing compounds]	2.0	2	2	0	0
7933	1437	step in the signal pathway	[step in the signaling pathways]	2.0	5	3	3	3
7934	1437	endometrial cell	[endometrial cells]	2.0	2	3	2	2
7935	1437	il-2 deprivation	[IL-2 deprivation]	2.0	2	3	2	2
7936	1437	vitro translation	[vitro translation]	2.0	2	2	0	0
7937	1437	dehydroepiandrosterone DHEA	[dehydroepiandrosterone DHEA]	2.0	2	2	0	0
7938	1437	myelomonocytic differentiation	[myelomonocytic differentiation]	2.0	2	3	2	2
7939	1437	protein(s) responsible	[protein(s) responsible]	2.0	2	2	0	0
7940	1437	MEL cell	[MEL cells]	2.0	2	3	2	2
7941	1437	interferon-gamma activation	[interferon-gamma activation]	2.0	2	3	3	3
7942	1437	intervene DNA	[intervening DNA]	2.0	2	2	0	0
7943	1437	endothelial adhesion	[endothelial adhesion]	2.0	2	3	2	2
7944	1437	use the protein truncation test ptt	[using the protein truncation test PTT]	2.0	6	2	0	0
7945	1437	il-2 activation	[IL-2 activation]	2.0	2	3	2	2
7946	1437	mature form	[mature forms]	2.0	2	3	2	2
7947	1437	Epstein-Barr virus latent membrane protein-1	[Epstein-Barr virus latent membrane protein-1]	2.0	5	2	0	0
7948	1437	N element	[N element]	2.0	2	3	1	1
7949	1437	abdominal subject	[abdominal subjects]	2.0	2	3	2	2
7950	1437	same level	[same level]	2.0	2	3	3	3
7951	1437	synthetic oligonucleotide	[synthetic oligonucleotides]	2.0	2	3	2	2
7952	1437	Band a	[Band A]	2.0	2	3	2	2
7953	1437	thrombin response	[thrombin response]	2.0	2	3	2	2
7954	1437	beta (25-35)	[beta (25-35)]	2.0	2	3	1	1
7955	1437	il-2r expression	[IL-2R expression]	2.0	2	3	1	1
7956	1437	inhibit effect	[inhibiting effect]	2.0	2	3	2	2
7957	1437	two potential ets binding site	[two potential Ets binding sites]	2.0	5	2	0	0
7958	1437	microsatellite instability	[microsatellite instability]	2.0	2	2	0	0
7959	1437	DNA segment	[DNA segment]	2.0	2	3	2	2
7960	1437	(hpa) axis	[(HPA) axis]	2.0	2	4	4	2
7961	1437	neighbor cell	[neighboring cells]	2.0	2	2	0	0
7962	1437	kD protein	[kD protein]	2.0	2	3	3	3
7963	1437	von willebrand	[von Willebrand]	2.0	2	3	3	3
7964	1437	ctcf expression	[CTCF expression]	2.0	2	2	0	0
7965	1437	untreated patient with bipolar disorder	[untreated patients with bipolar disorder]	2.0	5	3	2	2
7966	1437	tumor necrosis factor alpha release	[tumor necrosis factor alpha release]	2.0	5	2	0	0
7967	1437	bind motif	[binding motif]	2.0	2	3	3	3
7968	1437	p70(S6)-kinase activation	[p70(S6)-kinase activation]	2.0	2	2	0	0
7969	1437	dramatic increase	[dramatic increase]	2.0	2	6	4	1
7970	1437	tnf-induced vcam-1	[TNF-induced VCAM-1]	2.0	2	2	0	0
7971	1437	erythroid delta-aminolevulinate	[erythroid delta-aminolevulinate]	2.0	2	3	2	2
7972	1437	calf serum	[calf serum]	2.0	2	3	3	3
7973	1437	fetal hemoglobin	[fetal hemoglobin]	2.0	2	3	2	2
7974	1437	myeloblastic leukemia	[myeloblastic leukemia]	2.0	2	2	0	0
7975	1437	myeloid promoter	[myeloid promoters]	2.0	2	2	0	0
7976	1437	cd15 cross-linking	[CD15 cross-linking]	2.0	2	2	0	0
7977	1437	allele regulation	[allele regulation]	2.0	2	3	3	3
7978	1437	Egr-1 mrna	[Egr-1 mRNA]	2.0	2	3	2	2
7979	1437	identical sequence	[identical sequence]	2.0	2	3	3	3
7980	1437	55 kilometer	[55 kd]	2.0	2	3	2	2
7981	1437	transactivator protein	[transactivator protein]	2.0	2	3	2	2
7982	1437	immunocytochemical analysis	[Immunocytochemical analysis]	2.0	2	3	1	1
7983	1437	CBF site	[CBF site]	2.0	2	3	1	1
7984	1437	TGF-beta 1	[TGF-beta 1]	2.0	2	2	0	0
7985	1437	chromatin configuration	[chromatin configuration]	2.0	2	3	1	1
7986	1437	injury-induced apoptosis	[injury-induced apoptosis]	2.0	2	3	1	1
7987	1437	differential splicing	[differential splicing]	2.0	2	2	0	0
7988	1437	CR3 cd11b/cd18	[CR3 CD11b/CD18]	2.0	2	2	0	0
7989	1437	flank sequence	[flanking sequence]	2.0	2	3	3	3
7990	1437	surrogate receptor on non-T cell	[surrogate receptors on non-T cells]	2.0	5	2	0	0
7991	1437	native promoter	[native promoter]	2.0	2	3	2	2
7992	1437	5' DNA	[5' DNA]	2.0	2	3	3	3
7993	1437	binding site for factor kappa b	[binding sites for factor kappa B]	2.0	6	2	0	0
7994	1437	monocyte cytotoxicity	[monocyte cytotoxicity]	2.0	2	3	2	2
7995	1437	six flavonoid	[six flavonoids]	2.0	2	2	0	0
7996	1437	herpesvirus hhv-6	[herpesvirus HHV-6]	2.0	2	4	4	2
7997	1437	experimental model	[experimental model]	2.0	2	3	2	2
7998	1437	human leukemia cell line hl-60	[human leukemia cell lines HL-60]	2.0	5	2	0	0
7999	1437	critical factor	[critical factor]	2.0	2	3	3	3
8000	1437	third component	[third component]	2.0	2	2	0	0
8001	1437	acute injury	[Acute injury]	2.0	2	3	3	3
8002	1437	HIV LTR	[HIV LTR]	2.0	2	2	0	0
8003	1437	kda subunit	[kDa subunit]	2.0	2	3	3	3
8004	1437	therapeutic value	[therapeutic value]	2.0	2	3	3	3
8005	1437	t-cell response	[T-cell response]	2.0	2	3	2	2
8006	1437	control expression	[control expression]	2.0	2	3	3	3
8007	1437	Thus, Elf-1	[Thus, Elf-1]	2.0	2	2	0	0
8008	1437	tg receptor	[TG receptor]	2.0	2	3	3	3
8009	1437	nuclear factor-kappa	[nuclear factor-kappa]	2.0	2	3	1	1
8010	1437	bacterial endotoxin	[bacterial endotoxin]	2.0	2	3	3	3
8011	1437	hhv-6 transactivation	[HHV-6 transactivation]	2.0	2	3	2	2
8012	1437	1-2 hour of the addition	[1-2 hr of the addition]	2.0	5	2	0	0
8013	1437	two events.	[two events.]	2.0	2	2	0	0
8014	1437	thrombin receptor	[thrombin receptor]	2.0	2	3	3	3
8015	1437	HLA-DRA gene	[HLA-DRA gene]	2.0	2	2	0	0
8016	1437	v-erbA oncoprotein	[v-erbA oncoprotein]	2.0	2	3	1	1
8017	1437	elk-1 protein	[ELK-1 proteins]	2.0	2	2	0	0
8018	1437	molecular abnormality	[molecular abnormality]	2.0	2	3	1	1
8019	1437	E-selectin promoter	[E-selectin promoter]	2.0	2	2	0	0
8020	1437	Differential interaction of nuclear factor	[Differential interaction of nuclear factors]	2.0	5	2	0	0
8021	1437	colony formation	[colony formation]	2.0	2	3	3	3
8022	1437	leukemic cells.	[leukemic cells.]	2.0	2	2	0	0
8023	1437	human keratinocyte	[human keratinocyte]	2.0	2	3	1	1
8024	1437	reporter cell	[reporter cells]	2.0	2	3	2	2
8025	1437	block apoptosis	[blocking apoptosis]	2.0	2	2	0	0
8026	1437	Spi-B mrna	[Spi-B mRNA]	2.0	2	3	2	2
8027	1437	anti-inflammatory capacity	[anti-inflammatory capacity]	2.0	2	2	0	0
8028	1437	faster-migrating complex	[faster-migrating complex]	2.0	2	3	1	1
8029	1437	inducible enhancer	[inducible enhancer]	2.0	2	3	3	3
8030	1437	effector site	[effector sites]	2.0	2	3	1	1
8031	1437	interleukin (il)-6	[interleukin (IL)-6]	2.0	2	3	1	1
8032	1437	prb hyperphosphorylation	[pRb hyperphosphorylation]	2.0	2	2	0	0
8033	1437	various diseases,	[various diseases,]	2.0	2	2	0	0
8034	1437	hepatoma cell	[hepatoma cells]	2.0	2	2	0	0
8035	1437	nonhematopoietic cell	[nonhematopoietic cells]	2.0	2	3	1	1
8036	1437	nuclear grade	[nuclear grade]	2.0	2	3	1	1
8037	1437	human enhancer	[human enhancer]	2.0	2	3	1	1
8038	1437	CD28 activation	[CD28 activation]	2.0	2	3	1	1
8039	1437	t-cell signal	[T-cell signaling]	2.0	2	3	2	2
8040	1437	amino-terminal domain	[amino-terminal domain]	2.0	2	3	2	2
8041	1437	vcam-1 induction	[VCAM-1 induction]	2.0	2	3	2	2
8042	1437	mammalian gene	[mammalian gene]	2.0	2	3	3	3
8043	1437	cytopathic effect	[cytopathic effect]	2.0	2	3	2	2
8044	1437	phenotypic abnormality	[phenotypic abnormalities]	2.0	2	2	0	0
8045	1437	th2-specific cytokine	[Th2-specific cytokines]	2.0	2	2	0	0
8046	1437	receptor domain	[receptor domain]	2.0	2	3	3	3
8047	1437	HIV patient	[HIV patients]	2.0	2	2	0	0
8048	1437	fast kinetic	[fast kinetics]	2.0	2	3	2	2
8049	1437	tgf-beta 1 -mediated growth inhibition	[TGF-beta 1 -mediated growth inhibition]	2.0	5	2	0	0
8050	1437	most virus	[most viruses]	2.0	2	2	0	0
8051	1437	survival rate	[survival rate]	2.0	2	3	2	2
8052	1437	primary response	[primary response]	2.0	2	3	3	3
8053	1437	bacterial pathogen	[bacterial pathogens]	2.0	2	2	0	0
8054	1437	early differentiation	[early differentiation]	2.0	2	3	2	2
8055	1437	systemic symptom	[systemic symptoms]	2.0	2	2	0	0
8056	1437	natural cytotoxicity	[natural cytotoxicity]	2.0	2	3	1	1
8057	1437	c5mj2 cell	[C5MJ2 cells]	2.0	2	2	0	0
8058	1437	caenorhabditis elegan	[Caenorhabditis elegans]	2.0	2	3	2	2
8059	1437	low frequency	[low frequency]	2.0	2	3	1	1
8060	1437	dihydrolipoic acid	[dihydrolipoic acid]	2.0	2	2	0	0
8061	1437	IFN factor	[IFN factor]	2.0	2	3	3	3
8062	1437	receptor factor	[receptor factor]	2.0	2	3	1	1
8063	1437	biologic activity	[biologic activity]	2.0	2	3	1	1
8064	1437	fos family	[fos family]	2.0	2	3	3	3
8065	1437	ANG ii	[ANG II]	2.0	2	3	2	2
8066	1437	autosomal material	[autosomal material]	2.0	2	2	0	0
8067	1437	3-6 month	[3-6 months]	2.0	2	2	0	0
8068	1437	cryptococcal stimulation	[cryptococcal stimulation]	2.0	2	2	0	0
8069	1437	junb transcription	[junB transcription]	2.0	2	3	2	2
8070	1437	Epstein-Barr virus latent membrane protein	[Epstein-Barr virus latent membrane protein]	2.0	5	2	0	0
8071	1437	qp activity	[Qp activity]	2.0	2	3	1	1
8072	1437	leukemic cell from ATL patient	[leukemic cells from ATL patients]	2.0	5	3	1	1
8073	1437	3' sequence	[3' sequences]	2.0	2	3	2	2
8074	1437	IL-13 gene	[IL-13 gene]	2.0	2	3	3	3
8075	1437	mel cell	[MEL cells]	2.0	2	3	3	3
8076	1437	regulatory enhancer	[regulatory enhancer]	2.0	2	2	0	0
8077	1437	only a small amount of p65	[only a small amount of P65]	2.0	6	2	0	0
8078	1437	transcriptional activity of NF-kappa b	[transcriptional activity of NF-kappa B]	2.0	5	2	0	0
8079	1437	cd8(+) T	[CD8(+) T]	2.0	2	3	2	2
8080	1437	protein interaction	[protein interactions]	2.0	2	3	3	3
8081	1437	potential site	[potential sites]	2.0	2	4	4	2
8082	1437	structural requirement	[structural requirements]	2.0	2	4	4	2
8083	1437	differential sensitivity	[differential sensitivity]	2.0	2	2	0	0
8084	1437	CD28 element	[CD28 element]	2.0	2	4	4	2
8085	1437	other diseases.	[other diseases.]	2.0	2	2	0	0
8086	1437	Run-on analysis	[Run-on analysis]	2.0	2	2	0	0
8087	1437	hiv activation	[HIV activation]	2.0	2	3	1	1
8088	1437	b-cell-specific promoter	[B-cell-specific promoter]	2.0	2	2	0	0
8089	1437	six antigen	[six antigen]	2.0	2	3	3	3
8090	1437	enzyme inhibitor	[enzyme inhibitor]	2.0	2	3	3	3
8091	1437	uninduced cell	[uninduced cells]	2.0	2	3	1	1
8092	1437	other tissue	[other tissues]	2.0	2	3	3	3
8093	1437	distal element	[distal element]	2.0	2	3	2	2
8094	1437	non-genomic effect	[non-genomic effects]	2.0	2	3	3	3
8095	1437	cytokine tumor necrosis factor alpha	[cytokine tumor necrosis factor alpha]	2.0	5	2	0	0
8096	1437	biological significance	[biological significance]	2.0	2	3	3	3
8097	1437	human phagocyte	[human phagocytes]	2.0	2	3	2	2
8098	1437	anti-inflammatory property	[anti-inflammatory properties]	2.0	2	2	0	0
8099	1437	staphylococcal superantigen	[staphylococcal superantigens]	2.0	2	2	0	0
8100	1437	molecular level.	[molecular level.]	2.0	2	2	0	0
8101	1437	TNF mrna	[TNF mRNA]	2.0	2	2	0	0
8102	1437	tyrosine phosphorylation of intracellular substrate	[tyrosine phosphorylation of intracellular substrates]	2.0	5	3	3	3
8103	1437	certain disease	[certain diseases]	2.0	2	3	2	2
8104	1437	lai LTR	[LAI LTR]	2.0	2	2	0	0
8105	1437	binding motif	[binding motifs]	2.0	2	3	2	2
8106	1437	other molecule	[other molecules]	2.0	2	3	2	2
8107	1437	effect on NF-kappa b activation	[effect on NF-kappa B activation]	2.0	5	2	0	0
8108	1437	gas motif	[GAS motif]	2.0	2	3	3	3
8109	1437	hiv protease	[HIV protease]	2.0	2	3	3	3
8110	1437	Raji b	[Raji B]	2.0	2	3	3	3
8111	1437	CTL clone	[CTL clones]	2.0	2	3	1	1
8112	1437	expression of various cellular gene	[expression of various cellular genes]	2.0	5	2	0	0
8113	1437	multi-protein complex	[multi-protein complexes]	2.0	2	3	3	3
8114	1437	interleukin-8 production	[interleukin-8 production]	2.0	2	3	1	1
8115	1437	other condition	[other conditions]	2.0	2	3	2	2
8116	1437	blotting experiment	[blotting experiments]	2.0	2	3	3	3
8117	1437	ctll-r8 cell	[CTLL-R8 cells]	2.0	2	2	0	0
8118	1437	human il-2	[human IL-2]	2.0	2	3	1	1
8119	1437	c/ebp alpha	[C/EBP alpha]	2.0	2	3	1	1
8120	1437	many cell	[many cell]	2.0	2	3	2	2
8121	1437	thymic organ	[thymic organ]	2.0	2	3	1	1
8122	1437	human rdna	[Human cDNAs]	2.0	2	4	2	1
8123	1437	significant association between ngal expression	[significant association between NGAL expression]	2.0	5	2	0	0
8124	1437	20 day	[20 days]	2.0	2	2	0	0
8125	1437	IL-4 stat	[IL-4 Stat]	2.0	2	3	2	2
8126	1437	gene activity	[gene activity]	2.0	2	3	3	3
8127	1437	first patient	[first patient]	2.0	2	3	2	2
8128	1437	mouse strain	[mouse strains]	2.0	2	3	3	3
8129	1437	own promoter	[own promoter]	2.0	2	2	0	0
8130	1437	LIM domain	[LIM domain]	2.0	2	3	2	2
8131	1437	raw264.7 cell	[RAW264.7 cells]	2.0	2	3	2	2
8132	1437	NF-kappa b -dependent gene expression	[NF-kappa B -dependent gene expression]	2.0	5	2	0	0
8133	1437	pkc-zeta cell	[PKC-zeta cells]	2.0	2	2	0	0
8134	1437	extent similar	[extent similar]	2.0	2	2	0	0
8135	1437	increase in il-6 luciferase activity	[increase in IL-6 luciferase activity]	2.0	5	2	0	0
8136	1437	human il-1beta	[human IL-1beta]	2.0	2	2	0	0
8137	1437	early time	[early time]	2.0	2	3	1	1
8138	1437	suggest due, at least in part,	[suggesting due, at least in part,]	2.0	6	2	0	0
8139	1437	t-cell function	[T-cell function]	2.0	2	3	1	1
8140	1437	strong evidence	[strong evidence]	2.0	2	2	0	0
8141	1437	third intron	[third intron]	2.0	2	4	2	1
8142	1437	proinflammatory gene	[proinflammatory genes]	2.0	2	2	0	0
8143	1437	physiological significance	[physiological significance]	2.0	2	2	0	0
8144	1437	recent finding	[recent findings]	2.0	2	3	1	1
8145	1437	c-Jun kinase	[c-Jun kinase]	2.0	2	3	3	3
8146	1437	activation of the nf-kappab pathway	[activation of the NF-kappaB pathway]	2.0	5	2	0	0
8147	1437	important role in t-cell biology	[important role in T-cell biology]	2.0	5	2	0	0
8148	1437	platelet-like particle	[platelet-like particles]	2.0	2	2	0	0
8149	1437	synovial tissue	[synovial tissue]	2.0	2	3	2	2
8150	1437	IL-6 gene	[IL-6 gene]	2.0	2	3	2	2
8151	1437	epidermal cell	[epidermal cells]	2.0	2	3	3	3
8152	1437	autoinhibitory domain	[autoinhibitory domain]	2.0	2	2	0	0
8153	1437	peak level	[peak level]	2.0	2	3	1	1
8154	1437	ige isotype switch in b cell	[IgE isotype switching in B cells]	2.0	6	2	0	0
8155	1437	bronchial mucosa	[bronchial mucosa]	2.0	2	2	0	0
8156	1437	ap1 motif	[AP1 motif]	2.0	2	3	3	3
8157	1437	myelogenous leukaemia	[myelogenous leukaemia]	2.0	2	3	3	3
8158	1437	reporter assay	[reporter assay]	2.0	2	2	0	0
8159	1437	hydrolytic activity	[hydrolytic activity]	2.0	2	3	1	1
8160	1437	fetal thymocyte	[fetal thymocyte]	2.0	2	2	0	0
8161	1437	concentration-dependent manner.	[concentration-dependent manner.]	2.0	2	2	0	0
8162	1437	promoter context	[promoter context]	2.0	2	3	2	2
8163	1437	cell resistant	[cells resistant]	2.0	2	3	3	3
8164	1437	Burkitt' lymphoma (bl) cell line	[Burkitt's lymphoma (BL) cell lines]	2.0	5	2	0	0
8165	1437	regulatory gene	[regulatory gene]	2.0	2	3	1	1
8166	1437	dna-binding assay	[DNA-binding assays]	2.0	2	3	1	1
8167	1437	early region	[early region]	2.0	2	3	1	1
8168	1437	human genome	[human genome]	2.0	2	2	0	0
8169	1437	monoblastoid cell undergo tnf-alpha apoptosis	[monoblastoid cells undergoing TNF-alpha apoptosis]	2.0	5	2	0	0
8170	1437	NF-kappa B1	[NF-kappa B1]	2.0	2	2	0	0
8171	1437	chimeric animal	[chimeric animals]	2.0	2	3	1	1
8172	1437	E1a region	[E1a region]	2.0	2	3	1	1
8173	1437	normal human peripheral blood lymphocyte	[normal human peripheral blood lymphocytes]	2.0	5	2	0	0
8174	1437	high proportion	[high proportion]	2.0	2	3	2	2
8175	1437	cytokine promoter	[cytokine promoter]	2.0	2	3	2	2
8176	1437	il-1r gene expression by IFN-gamma	[IL-1R gene expression by IFN-gamma]	2.0	5	2	0	0
8177	1437	tumor sample	[tumor samples]	2.0	2	2	0	0
8178	1437	intron enhancer	[intron enhancer]	2.0	2	2	0	0
8179	1437	cytoplasmic protein	[cytoplasmic protein]	2.0	2	3	1	1
8180	1437	T activity	[T activity]	2.0	2	2	0	0
8181	1437	induction of hiv-1 LTR transcription	[Induction of HIV-1 LTR transcription]	2.0	5	2	0	0
8182	1437	metabolic substrate	[metabolic substrates]	2.0	2	2	0	0
8183	1437	model system,	[model system,]	2.0	2	2	0	0
8184	1437	class major histocompatibility complex gene	[class major histocompatibility complex gene]	2.0	5	3	3	3
8185	1437	k562 erythroblast	[K562 erythroblasts]	2.0	2	2	0	0
8186	1437	p65 homodimer	[p65 homodimer]	2.0	2	2	0	0
8187	1437	role of this transcription factor	[role of these transcription factors]	2.0	5	3	2	2
8188	1437	lung fibroblast	[lung fibroblasts]	2.0	2	3	2	2
8189	1437	negative autoregulation	[negative autoregulation]	2.0	2	2	0	0
8190	1437	e1c3 cell	[E1C3 cells]	2.0	2	2	0	0
8191	1437	egr-1 transcription	[EGR-1 transcription]	2.0	2	3	2	2
8192	1437	inducer of nf-kappa b activity	[inducers of NF-kappa B activity]	2.0	5	2	0	0
8193	1437	human ifngr1	[human IFNGR1]	2.0	2	2	0	0
8194	1437	vitro treatment	[vitro treatment]	2.0	2	3	1	1
8195	1437	lymphocyte of child with ricket	[lymphocytes of children with rickets]	2.0	5	2	0	0
8196	1437	necrosis factor	[necrosis factor]	2.0	2	3	3	3
8197	1437	monocytic/macrophage pathway	[monocytic/macrophage pathway]	2.0	2	3	1	1
8198	1437	histone acetyltransferase	[histone acetyltransferase]	2.0	2	3	3	3
8199	1437	follicular hyperplasia	[follicular hyperplasia]	2.0	2	3	3	3
8200	1437	potent effect	[potent effect]	2.0	2	3	3	3
8201	1437	natural ligand	[natural ligand]	2.0	2	3	2	2
8202	1437	erk activation	[ERK activation]	2.0	2	3	2	2
8203	1437	dm gene	[DM genes]	2.0	2	2	0	0
8204	1437	b7.1 expression	[B7.1 expression]	2.0	2	2	0	0
8205	1437	1 tax	[1 Tax]	2.0	2	2	0	0
8206	1437	hydrophobic domain	[hydrophobic domain]	2.0	2	3	2	2
8207	1437	erythroid maturation	[erythroid maturation]	2.0	2	3	2	2
8208	1437	intact domain	[intact domain]	2.0	2	3	1	1
8209	1437	p50-nf-kappa b	[p50-NF-kappa B]	2.0	2	2	0	0
8210	1437	impaired ability	[impaired ability]	2.0	2	2	0	0
8211	1437	gene transfer	[gene transfer]	2.0	2	3	2	2
8212	1437	T cell of RCC patient	[T cells of RCC patient]	2.0	5	2	0	0
8213	1437	untreated cells.	[untreated cells.]	2.0	2	2	0	0
8214	1437	htr beta 1 mrna level	[hTR beta 1 mRNA levels]	2.0	5	2	0	0
8215	1437	alpha-interferon therapy	[alpha-interferon therapy]	2.0	2	2	0	0
8216	1437	membrane glycoprotein	[membrane glycoprotein]	2.0	2	3	2	2
8217	1437	free solution,	[free solution,]	2.0	2	2	0	0
8218	1437	premenopausal patient	[premenopausal patients]	2.0	2	3	2	2
8219	1437	several mechanism	[several mechanisms]	2.0	2	3	1	1
8220	1437	heterologous enhancer/promoters	[heterologous enhancer/promoters]	2.0	2	3	1	1
8221	1437	oxygen radical	[oxygen radicals]	2.0	2	2	0	0
8222	1437	transcriptional synergy	[transcriptional synergy]	2.0	2	2	0	0
8223	1437	potential relevance	[potential relevance]	2.0	2	3	3	3
8224	1437	TP1 promoter	[TP1 promoter]	2.0	2	3	1	1
8225	1437	olfactory neuron	[olfactory neurons]	2.0	2	2	0	0
8226	1437	nuclear factor(	[nuclear factor(s)]	2.0	2	2	0	0
8227	1437	PML nbs	[PML NBs]	2.0	2	3	3	3
8228	1437	erythropoietin Epo	[erythropoietin Epo]	2.0	2	3	1	1
8229	1437	b-lymphoid cell	[B-lymphoid cells]	2.0	2	3	1	1
8230	1437	selective inhibitor	[selective inhibitor]	2.0	2	3	2	2
8231	1437	MHC class ii transactivator CIITA	[MHC class II transactivator CIITA]	2.0	5	2	0	0
8232	1437	low level of c-jun transcript	[Low levels of c-jun transcripts]	2.0	5	2	0	0
8233	1437	hsp70 expression	[Hsp70 expression]	2.0	2	2	0	0
8234	1437	various line	[various lines]	2.0	2	3	2	2
8235	1437	Northern experiment	[Northern experiments]	2.0	2	2	0	0
8236	1437	stage cell	[stage cells]	2.0	2	3	3	3
8237	1437	previous result	[previous results]	2.0	2	2	0	0
8238	1437	mineralocorticoid action	[mineralocorticoid action]	2.0	2	2	0	0
8239	1437	varicella-zoster virus	[varicella-zoster virus]	2.0	2	3	3	3
8240	1437	Nuclear factor-kappaB	[Nuclear factor-kappaB]	2.0	2	2	0	0
8241	1437	redox change	[redox changes]	2.0	2	3	1	1
8242	1437	peripheral blood T cell activation	[peripheral blood T cell activation]	2.0	5	2	0	0
8243	1437	second element	[second element]	2.0	2	3	2	2
8244	1437	drug therapy	[drug therapy]	2.0	2	3	1	1
8245	1437	m-csf receptor	[M-CSF receptor]	2.0	2	3	3	3
8246	1437	tnf-alpha mrna	[TNF-alpha mRNA]	2.0	2	3	3	3
8247	1437	maturation process	[maturation process]	2.0	2	3	2	2
8248	1437	c-rel homodimer	[c-Rel homodimer]	2.0	2	2	0	0
8249	1437	protein derivative	[protein derivative]	2.0	2	2	0	0
8250	1437	intercellular adhesion	[intercellular adhesion]	2.0	2	3	1	1
8251	1437	hiv-1 infection of myeloid cell	[HIV-1 infection of myeloid cells]	2.0	5	3	1	1
8252	1437	binding of the inducible factor	[binding of the inducible factor]	2.0	5	2	0	0
8253	1437	signal pathway in T lymphocyte	[signaling pathways in T lymphocytes]	2.0	5	2	0	0
8254	1437	24-hydroxylase mrna	[24-hydroxylase mRNA]	2.0	2	2	0	0
8255	1437	il-6 protein	[IL-6 protein]	2.0	2	3	2	2
8256	1437	pulmonary disease	[pulmonary diseases]	2.0	2	3	3	3
8257	1437	virus particle	[virus particle]	2.0	2	3	1	1
8258	1437	estrogen induction of survival of cell	[Estrogen induction of survival of cells]	2.0	6	2	0	0
8259	1437	Lipopolysaccharide LPS	[Lipopolysaccharide LPS]	2.0	2	2	0	0
8260	1437	adp aggregation	[ADP aggregation]	2.0	2	2	0	0
8261	1437	cytosolic extract	[cytosolic extracts]	2.0	2	3	2	2
8262	1437	late time	[later time]	2.0	2	3	1	1
8263	1437	transgenic animal	[transgenic animals]	2.0	2	3	1	1
8264	1437	nontransgenic mouse	[nontransgenic mice]	2.0	2	2	0	0
8265	1437	Furthermore, inhibition	[Furthermore, inhibition]	2.0	2	3	2	2
8266	1437	gc-insensitive asthma	[GC-insensitive asthma]	2.0	2	3	2	2
8267	1437	human lymphoblastoid	[human lymphoblastoid]	2.0	2	2	0	0
8268	1437	pro-inflammatory cytokine	[pro-inflammatory cytokine]	2.0	2	3	1	1
8269	1437	erythropoietic differentiation	[erythropoietic differentiation]	2.0	2	3	2	2
8270	1437	Drosophila Toll	[Drosophila Toll]	2.0	2	3	2	2
8271	1437	strong association	[strong association]	2.0	2	3	3	3
8272	1437	novel function	[novel function]	2.0	2	4	4	2
8273	1437	gamma mrna	[gamma mRNA]	2.0	2	2	0	0
8274	1437	Fcgamma receptor	[Fcgamma receptor]	2.0	2	2	0	0
8275	1437	inflammatory cell	[inflammatory cells]	2.0	2	2	0	0
8276	1437	suggest responsible	[suggesting responsible]	2.0	2	4	4	2
8277	1437	replicative senescence	[replicative senescence]	2.0	2	2	0	0
8278	1437	peripheral blood leukocyte in patient	[peripheral blood leukocytes in patients]	2.0	5	2	0	0
8279	1437	human apl	[human APL]	2.0	2	2	0	0
8280	1437	5 day	[5 days]	2.0	2	2	0	0
8281	1437	nuclear factor-kappa b NF-kappa b activation	[nuclear factor-kappa B NF-kappa B activation]	2.0	6	3	1	1
8282	1437	c-jun protein	[c-Jun protein]	2.0	2	3	2	2
8283	1437	activation of the tyrosine kinase lck	[activation of the tyrosine kinases lck]	2.0	6	2	0	0
8284	1437	cytokine therapy	[cytokine therapy]	2.0	2	3	2	2
8285	1437	persistent infection	[persistent infection]	2.0	2	3	1	1
8286	1437	small t	[small t]	2.0	2	2	0	0
8287	1437	il-4 receptor	[IL-4 receptor]	2.0	2	3	2	2
8288	1437	ifn-gamma mrna	[IFN-gamma mRNA]	2.0	2	3	1	1
8289	1437	mutant protein	[mutant protein]	2.0	2	2	0	0
8290	1437	maximal expression.	[maximal expression.]	2.0	2	2	0	0
8291	1437	apparent affinity	[apparent affinity]	2.0	2	3	3	3
8292	1437	antigen cell	[antigen cells]	2.0	2	3	3	3
8293	1437	Vitamin d	[Vitamin D]	2.0	2	3	2	2
8294	1437	concentration-dependent fashion	[concentration-dependent fashion]	2.0	2	2	0	0
8295	1437	immunological memory	[immunological memory]	2.0	2	2	0	0
8296	1437	spinal cord	[spinal cord]	2.0	2	2	0	0
8297	1437	unknown mechanism.	[unknown mechanism.]	2.0	2	2	0	0
8298	1437	unique mechanism	[unique mechanism]	2.0	2	3	3	3
8299	1437	otf-2 protein	[OTF-2 protein]	2.0	2	2	0	0
8300	1437	nf-atc isoform	[NF-ATc isoform]	2.0	2	3	2	2
8301	1437	ghost membrane	[ghost membrane]	2.0	2	3	2	2
8302	1437	BFU-E colony	[BFU-E colonies]	2.0	2	2	0	0
8303	1437	cysteamine treatment	[cysteamine treatment]	2.0	2	3	1	1
8304	1437	factor g-csf	[factor G-CSF]	2.0	2	3	3	3
8305	1437	distinct region	[distinct region]	2.0	2	3	2	2
8306	1437	pituitary transcription	[pituitary transcription]	2.0	2	2	0	0
8307	1437	airway inflammation	[airway inflammation]	2.0	2	3	1	1
8308	1437	resting	[resting]	2.0	1	21	5	5
8309	1437	ebna expression	[EBNA expression]	2.0	2	3	2	2
8310	1437	wild-type zap-70	[wild-type ZAP-70]	2.0	2	2	0	0
8311	1437	150 bp	[150 bp]	2.0	2	2	0	0
8312	1437	cytotoxic effect	[cytotoxic effect]	2.0	2	3	3	3
8313	1437	member of the C/EBP family	[member of the C/EBP family]	2.0	5	3	2	2
8314	1437	nuclear i(kappa)b(alpha)	[nuclear I(kappa)B(alpha)]	2.0	2	3	1	1
8315	1437	c-myc gene	[c-myc gene]	2.0	2	3	1	1
8316	1437	isg expression	[ISG expression]	2.0	2	2	0	0
8317	1437	transcriptional activator,	[transcriptional activator,]	2.0	2	3	1	1
8318	1437	Jak/Stat pathway	[Jak/Stat pathway]	2.0	2	3	2	2
8319	1437	nf-at site	[NF-AT site]	2.0	2	3	2	2
8320	1437	total rna	[Total RNA]	2.0	2	3	1	1
8321	1437	same sequence	[same sequence]	2.0	2	2	0	0
8322	1437	lps monocyte	[LPS monocytes]	2.0	2	3	1	1
8323	1437	nucleotide -137	[nucleotides -137]	2.0	2	2	0	0
8324	1437	control level	[control level]	2.0	2	3	3	3
8325	1437	ikk activity	[IKK activity]	2.0	2	3	2	2
8326	1437	include chronic myeloid leukaemia CML	[including chronic myeloid leukaemia CML]	2.0	5	2	0	0
8327	1437	il-8 expression in T cell	[IL-8 expression in T cells]	2.0	5	2	0	0
8328	1437	salivary gland	[salivary glands]	2.0	2	3	3	3
8329	1437	ubiquitous factor	[ubiquitous factor]	2.0	2	3	3	3
8330	1437	electron microscopy	[electron microscopy]	2.0	2	3	1	1
8331	1437	member of the chemokine superfamily	[member of the chemokine superfamily]	2.0	5	2	0	0
8332	1437	member of the Stat family	[members of the Stat family]	2.0	5	2	0	0
8333	1437	PHA/ PMA	[PHA/ PMA]	2.0	2	2	0	0
8334	1437	10 polymorphism	[10 polymorphism]	2.0	2	3	1	1
8335	1437	cell nucleus	[cell nucleus]	2.0	2	2	0	0
8336	1437	steroid-resistant patient	[steroid-resistant patients]	2.0	2	3	1	1
8337	1437	NFAT activation	[NFAT activation]	2.0	2	3	1	1
8338	1437	IL-4 Stat	[IL-4 Stat]	2.0	2	3	1	1
8339	1437	FK 506	[FK 506]	2.0	2	2	0	0
8340	1437	differential activity	[differential activity]	2.0	2	3	3	3
8341	1437	B-cell growth	[B-cell growth]	2.0	2	2	0	0
8342	1437	dna-protein binding	[DNA-protein binding]	2.0	2	3	2	2
8343	1437	Rel A	[Rel A]	2.0	2	3	2	2
8344	1437	Nuclear factor kappa b NF-kappa b	[Nuclear factor kappa B NF-kappa B]	2.0	6	3	1	1
8345	1437	MnlI-AluI fragment	[MnlI-AluI fragment]	2.0	2	2	0	0
8346	1437	signal defect	[signaling defect]	2.0	2	3	2	2
8347	1437	polymorphonuclear neutrophil	[polymorphonuclear neutrophil]	2.0	2	2	0	0
8348	1437	rapid degradation	[rapid degradation]	2.0	2	3	1	1
8349	1437	human promoter	[human promoter]	2.0	2	2	0	0
8350	1437	maximal level	[maximal levels]	2.0	2	2	0	0
8351	1437	muscle-specific gene	[muscle-specific genes]	2.0	2	2	0	0
8352	1437	-positive b	[-positive B]	2.0	2	3	2	2
8353	1437	aldosterone level	[Aldosterone levels]	2.0	2	2	0	0
8354	1437	disease process	[disease process]	2.0	2	2	0	0
8355	1437	IL-3 gene	[IL-3 gene]	2.0	2	3	1	1
8356	1437	cytoplasmic p62c-fo	[cytoplasmic p62c-fos]	2.0	2	2	0	0
8357	1437	ets site	[Ets site]	2.0	2	3	3	3
8358	1437	3-O-MG transport	[3-O-MG transport]	2.0	2	2	0	0
8359	1437	97 kda	[97 kDa]	2.0	2	2	0	0
8360	1437	cell-specific binding	[cell-specific binding]	2.0	2	3	1	1
8361	1437	respectively; p	[respectively; P]	2.0	2	3	2	2
8362	1437	rante expression	[RANTES expression]	2.0	2	4	4	2
8363	1437	Philadelphia chromosome-positive chronic myeloid leukemia	[Philadelphia chromosome-positive chronic myeloid leukemia]	2.0	5	2	0	0
8364	1437	cytoplasmic component	[cytoplasmic component]	2.0	2	4	2	1
8365	1437	il-3 gene	[IL-3 gene]	2.0	2	2	0	0
8366	1437	activation of the hiv-1 enhancer	[activation of the HIV-1 enhancer]	2.0	5	3	1	1
8367	1437	b expression	[B expression]	2.0	2	3	3	3
8368	1437	peptide synthesis	[peptide synthesis]	2.0	2	2	0	0
8369	1437	tcp acetate	[TCP acetate]	2.0	2	3	1	1
8370	1437	receptor site	[receptor sites]	2.0	2	3	3	3
8371	1437	short region	[short region]	2.0	2	3	1	1
8372	1437	mt-2 cell	[MT-2 cells]	2.0	2	3	2	2
8373	1437	29-kda protein	[29-kDa protein]	2.0	2	3	3	3
8374	1437	lps cell	[LPS cells]	2.0	2	3	2	2
8375	1437	chronic hepatitis	[chronic hepatitis]	2.0	2	2	0	0
8376	1437	nuclear extract from T cell	[nuclear extract from T cells]	2.0	5	2	0	0
8377	1437	amebic infection	[amebic infection]	2.0	2	3	2	2
8378	1437	phagocytosing neutrophil	[phagocytosing neutrophils]	2.0	2	2	0	0
8379	1437	immediate-early activation	[immediate-early activation]	2.0	2	2	0	0
8380	1437	receptor beta	[receptor beta]	2.0	2	3	3	3
8381	1437	chromosome abnormality	[chromosome abnormalities]	2.0	2	3	3	3
8382	1437	T lymphoid	[T lymphoid]	2.0	2	3	3	3
8383	1437	cd36 promoter	[CD36 promoter]	2.0	2	2	0	0
8384	1437	hiv-induced apoptosis	[HIV-induced apoptosis]	2.0	2	2	0	0
8385	1437	significant reduction	[significant reduction]	2.0	2	5	3	1
8386	1437	several hour	[several hours]	2.0	2	3	1	1
8387	1437	IL-2 proliferation	[IL-2 proliferation]	2.0	2	3	1	1
8388	1437	gata factor	[GATA factors]	2.0	2	3	2	2
8389	1437	gc receptor	[GC receptor]	2.0	2	3	2	2
8390	1437	cytoplasmic receptor	[cytoplasmic receptor]	2.0	2	2	0	0
8391	1437	vzv peptide	[VZV peptides]	2.0	2	3	3	3
8392	1437	il-4 level	[IL-4 level]	2.0	2	3	2	2
8393	1437	eosinophilic differentiation	[eosinophilic differentiation]	2.0	2	3	1	1
8394	1437	maximal activity	[maximal activity]	2.0	2	3	2	2
8395	1437	DQ molecule	[DQ molecules]	2.0	2	3	1	1
8396	1437	recruitment of ap-1 dna-binding activity	[recruitment of AP-1 DNA-binding activity]	2.0	5	2	0	0
8397	1437	CD18 promoter	[CD18 promoter]	2.0	2	2	0	0
8398	1437	abdominal obesity	[abdominal obesity]	2.0	2	2	0	0
8399	1437	signal-induced phosphorylation	[signal-induced phosphorylation]	2.0	2	3	2	2
8400	1437	immature thymocyte	[immature thymocytes]	2.0	2	3	1	1
8401	1437	competition analysis	[competition analysis]	2.0	2	3	1	1
8402	1437	unknown function	[unknown function]	2.0	2	2	0	0
8403	1437	radioreceptor assay	[radioreceptor assay]	2.0	2	3	2	2
8404	1437	t-cell biology	[T-cell biology]	2.0	2	2	0	0
8405	1437	HIV-2 LTR	[HIV-2 LTR]	2.0	2	2	0	0
8406	1437	beta- gene	[beta- gene]	2.0	2	3	2	2
8407	1437	mbp promoter	[MBP promoter]	2.0	2	3	1	1
8408	1437	low shear	[low shear]	2.0	2	2	0	0
8409	1437	5-day m	[5-day M]	2.0	2	3	1	1
8410	1437	target site	[target site]	2.0	2	3	3	3
8411	1437	use extract	[using extracts]	2.0	2	3	3	3
8412	1437	neutrophil function	[neutrophil function]	2.0	2	3	2	2
8413	1437	gammac chain	[gammac chain]	2.0	2	2	0	0
8414	1437	essential hypertension.	[essential hypertension.]	2.0	2	2	0	0
8415	1437	butyric acid	[butyric acid]	2.0	2	3	1	1
8416	1437	human proteasome	[human proteasome]	2.0	2	2	0	0
8417	1437	position 442	[position 442]	2.0	2	2	0	0
8418	1437	DNA binding activity of stat3	[DNA binding activity of STAT3]	2.0	5	2	0	0
8419	1437	G region	[G region]	2.0	2	3	2	2
8420	1437	malignant lymphocyte	[malignant lymphocytes]	2.0	2	3	1	1
8421	1437	biological effects,	[biological effects,]	2.0	2	2	0	0
8422	1437	various disease	[various diseases]	2.0	2	3	3	3
8423	1437	epsilon-globin-encoding gene	[epsilon-globin-encoding gene]	2.0	2	3	3	3
8424	1437	bp deletion	[bp deletion]	2.0	2	3	3	3
8425	1437	cyclin D2	[cyclin D2]	2.0	2	4	2	1
8426	1437	[change in leucocytic estrogen receptor level	[[Changes in leucocytic estrogen receptor levels]	2.0	6	2	0	0
8427	1437	expression of cell surface marker	[expression of cell surface markers]	2.0	5	2	0	0
8428	1437	kappa B-like	[kappa B-like]	2.0	2	3	3	3
8429	1437	putative factor	[putative factor]	2.0	2	2	0	0
8430	1437	bone density	[bone density]	2.0	2	3	2	2
8431	1437	th1 cytokine	[Th1 cytokine]	2.0	2	3	2	2
8432	1437	t(8;21) leukemia	[t(8;21) leukemia]	2.0	2	3	3	3
8433	1437	distal enhancer	[distal enhancer]	2.0	2	3	1	1
8434	1437	follow transfection	[following transfection]	2.0	2	3	1	1
8435	1437	multiple gene	[multiple genes]	2.0	2	3	1	1
8436	1437	A-myb expression	[A-myb expression]	2.0	2	3	1	1
8437	1437	at patient	[AT patient]	2.0	2	3	1	1
8438	1437	nonopsonic phagocytosis	[nonopsonic phagocytosis]	2.0	2	3	1	1
8439	1437	previous work,	[previous work,]	2.0	2	2	0	0
8440	1437	culture media	[culture media]	2.0	2	3	1	1
8441	1437	RA treatment	[RA treatment]	2.0	2	3	1	1
8442	1437	age-related change	[age-related changes]	2.0	2	2	0	0
8443	1437	fork head	[fork head]	2.0	2	3	3	3
8444	1437	ar protein	[AR protein]	2.0	2	2	0	0
8445	1437	analysis of the amino acid sequence	[Analysis of the amino acid sequence]	2.0	6	3	1	1
8446	1437	functional characterization	[functional characterization]	2.0	2	5	3	1
8447	1437	bcl-xl expression	[BCL-XL expression]	2.0	2	2	0	0
8448	1437	new isoform	[new isoform]	2.0	2	3	3	3
8449	1437	eukaryotic cell	[eukaryotic cells]	2.0	2	2	0	0
8450	1437	anti-TNF-alpha antibody	[anti-TNF-alpha antibody]	2.0	2	3	2	2
8451	1437	src-family kinase	[Src-family kinase]	2.0	2	2	0	0
8452	1437	vcam-1 mrna	[VCAM-1 mRNA]	2.0	2	3	2	2
8453	1437	intracellular pathway	[intracellular pathway]	2.0	2	3	2	2
8454	1437	6 case	[6 cases]	2.0	2	2	0	0
8455	1437	viral load	[viral load]	2.0	2	3	2	2
8456	1437	continuous presence	[continuous presence]	2.0	2	4	4	2
8457	1437	steroid sensitivity	[steroid sensitivity]	2.0	2	2	0	0
8458	1437	posttranscriptional mechanism	[posttranscriptional mechanism]	2.0	2	3	1	1
8459	1437	transcription unit	[transcription unit]	2.0	2	3	1	1
8460	1437	peroxisome receptor	[Peroxisome receptor]	2.0	2	4	4	2
8461	1437	hematopoietic development	[hematopoietic development]	2.0	2	2	0	0
8462	1437	high titer	[high titer]	2.0	2	2	0	0
8463	1437	B-cell leukemia	[B-cell leukemia]	2.0	2	3	3	3
8464	1437	polyclonal antisera	[polyclonal antisera]	2.0	2	4	4	2
8465	1437	wild-type promoter	[wild-type promoter]	2.0	2	2	0	0
8466	1437	use antisera	[using antisera]	2.0	2	4	4	2
8467	1437	47 day	[47 days]	2.0	2	2	0	0
8468	1437	lymphocyte growth	[lymphocyte growth]	2.0	2	3	2	2
8469	1437	stat activity	[STAT activity]	2.0	2	3	2	2
8470	1437	DNA reiteration	[DNA reiteration]	2.0	2	2	0	0
8471	1437	fetal brain	[fetal brain]	2.0	2	2	0	0
8472	1437	two process	[two processes]	2.0	2	3	1	1
8473	1437	surface protein	[surface protein]	2.0	2	3	2	2
8474	1437	LCR activity	[LCR activity]	2.0	2	2	0	0
8475	1437	new pathway	[new pathway]	2.0	2	3	1	1
8476	1437	rheumatic disease	[rheumatic disease]	2.0	2	3	2	2
8477	1437	ccaat enhancer binding protein alpha	[CCAAT enhancer binding protein alpha]	2.0	5	2	0	0
8478	1437	limited proteolysis	[limited proteolysis]	2.0	2	3	2	2
8479	1437	cytoplasmic compartment	[cytoplasmic compartment]	2.0	2	2	0	0
8480	1437	such as smooth muscle cell	[such as smooth muscle cells]	2.0	5	2	0	0
8481	1437	pre-B-cell stage	[pre-B-cell stage]	2.0	2	3	1	1
8482	1437	60 min,	[60 min,]	2.0	2	2	0	0
8483	1437	liver injury	[liver injury]	2.0	2	2	0	0
8484	1437	c-erb a	[c-erb A]	2.0	2	2	0	0
8485	1437	endogenous cortisol	[endogenous cortisol]	2.0	2	3	1	1
8486	1437	vitro stimulation	[vitro stimulation]	2.0	2	3	1	1
8487	1437	pu.1 binding	[PU.1 binding]	2.0	2	2	0	0
8488	1437	micromolar concentration	[micromolar concentrations]	2.0	2	4	4	2
8489	1437	immunoprecipitation analysis	[Immunoprecipitation analysis]	2.0	2	2	0	0
8490	1437	nuclear pore	[nuclear pore]	2.0	2	2	0	0
8491	1437	essential gata	[essential GATA]	2.0	2	2	0	0
8492	1437	internal AUG	[internal AUG]	2.0	2	2	0	0
8493	1437	same cell.	[same cell.]	2.0	2	2	0	0
8494	1437	Dendritic cell	[Dendritic cells]	2.0	2	4	2	1
8495	1437	effector molecule	[effector molecule]	2.0	2	3	2	2
8496	1437	leucocytic er	[leucocytic ER]	2.0	2	2	0	0
8497	1437	tissue injury	[tissue injury]	2.0	2	2	0	0
8498	1437	45 kda	[45 kDa]	2.0	2	2	0	0
8499	1437	mo7e cell	[MO7e cells]	2.0	2	3	1	1
8500	1437	cell systems.	[cell systems.]	2.0	2	3	3	3
8501	1437	normotensive volunteer	[normotensive volunteers]	2.0	2	2	0	0
8502	1437	general transcription	[general transcription]	2.0	2	2	0	0
8503	1437	erythroid differentiation of HEL cell	[erythroid differentiation of HEL cells]	2.0	5	2	0	0
8504	1437	ascorbic acid	[ascorbic acid]	2.0	2	3	1	1
8505	1437	DNA binding activity of factor	[DNA binding activity of factors]	2.0	5	2	0	0
8506	1437	pregnancy-induced hypertension	[pregnancy-induced hypertension]	2.0	2	3	2	2
8507	1437	several year	[several years]	2.0	2	2	0	0
8508	1437	reactive eosinophilias	[reactive eosinophilias]	2.0	2	2	0	0
8509	1437	other pathway	[other pathways]	2.0	2	3	2	2
8510	1437	transcriptional property	[transcriptional properties]	2.0	2	3	2	2
8511	1437	activation of transcription factor nf-kappab	[activation of transcription factor NF-kappaB]	2.0	5	3	1	1
8512	1437	unknown function.	[unknown function.]	2.0	2	3	1	1
8513	1437	gtp-binding protein	[GTP-binding proteins]	2.0	2	3	3	3
8514	1437	expression of cell adhesion molecule-1	[expression of cell adhesion molecule-1]	2.0	5	2	0	0
8515	1437	genomic pathway	[genomic pathway]	2.0	2	2	0	0
8516	1437	type I	[type I]	2.0	2	2	0	0
8517	1437	type a	[type A]	2.0	2	2	0	0
8518	1437	benzidine-positive cell	[benzidine-positive cells]	2.0	2	2	0	0
8519	1437	type i	[type I]	2.0	2	3	1	1
8520	1437	substantial decrease	[substantial decrease]	2.0	2	4	4	2
8521	1437	NK cytotoxicity	[NK cytotoxicity]	2.0	2	3	1	1
8522	1437	21 bp	[21 bp]	2.0	2	2	0	0
8523	1437	peptide ligand	[peptide ligand]	2.0	2	3	1	1
8524	1437	two ways.	[two ways.]	2.0	2	2	0	0
8525	1437	functional nf-kappab	[functional NF-kappaB]	2.0	2	2	0	0
8526	1437	ovarian cancer	[ovarian cancer]	2.0	2	2	0	0
8527	1437	detectable level	[detectable level]	2.0	2	7	5	1
8528	1437	important role in the pathophysiology	[important role in the pathophysiology]	2.0	5	2	0	0
8529	1437	luciferase activity	[luciferase activity]	2.0	2	2	0	0
8530	1437	ciita gene	[CIITA gene]	2.0	2	3	2	2
8531	1437	adenovirus e1a	[adenovirus E1A]	2.0	2	4	2	1
8532	1437	junb protein	[JunB protein]	2.0	2	3	2	2
8533	1437	intracellular sodium	[intracellular sodium]	2.0	2	3	1	1
8534	1437	tsc2 mutation	[TSC2 mutations]	2.0	2	3	2	2
8535	1437	functional study	[functional studies]	2.0	2	3	2	2
8536	1437	gata-1 activity	[GATA-1 activity]	2.0	2	3	2	2
8537	1437	Thus, IL-10	[Thus, IL-10]	2.0	2	2	0	0
8538	1437	nf-kappa b DNA binding protein	[NF-kappa B DNA binding proteins]	2.0	5	2	0	0
8539	1437	age-related difference	[age-related differences]	2.0	2	2	0	0
8540	1437	cell-to-cell contact	[Cell-to-cell contact]	2.0	2	3	1	1
8541	1437	GRalpha transactivation	[GRalpha transactivation]	2.0	2	3	2	2
8542	1437	one explanation	[one explanation]	2.0	2	3	3	3
8543	1437	transgenic T	[transgenic T]	2.0	2	2	0	0
8544	1437	CD28 receptor	[CD28 receptor]	2.0	2	3	3	3
8545	1437	wound healing	[wound healing]	2.0	2	4	2	1
8546	1437	pharmacological effect	[pharmacological effect]	2.0	2	2	0	0
8547	1437	other inducer	[other inducers]	2.0	2	2	0	0
8548	1437	recombinant protein	[recombinant protein]	2.0	2	3	2	2
8549	1437	il-10 secretion	[IL-10 secretion]	2.0	2	4	2	1
8550	1437	th2 lymphocyte	[Th2 lymphocytes]	2.0	2	2	0	0
8551	1437	up-regulation of lung vascular icam-1	[up-regulation of lung vascular ICAM-1]	2.0	5	2	0	0
8552	1437	gamma delta	[gamma delta]	2.0	2	3	3	3
8553	1437	one copy	[one copy]	2.0	2	4	4	2
8554	1437	optimal activation of T cell	[optimal activation of T cells]	2.0	5	2	0	0
8555	1437	notch receptor	[Notch receptors]	2.0	2	3	2	2
8556	1437	induce expression	[inducing expression]	2.0	2	3	3	3
8557	1437	spinal atrophy	[spinal atrophy]	2.0	2	3	2	2
8558	1437	specific mrna	[specific mRNA]	2.0	2	2	0	0
8559	1437	cellular extract	[cellular extracts]	2.0	2	3	2	2
8560	1437	insulin content	[insulin content]	2.0	2	2	0	0
8561	1437	normal T	[normal T]	2.0	2	3	1	1
8562	1437	dephosphorylated prb	[dephosphorylated pRB]	2.0	2	2	0	0
8563	1437	position-dependent manner	[position-dependent manner]	2.0	2	3	1	1
8564	1437	nuclear protooncogene	[nuclear protooncogenes]	2.0	2	3	2	2
8565	1437	megakaryocytic lineage	[megakaryocytic lineage]	2.0	2	3	1	1
8566	1437	im-9 cell	[IM-9 cells]	2.0	2	3	1	1
8567	1437	replication of human immunodeficiency virus	[replication of human immunodeficiency virus]	2.0	5	3	3	3
8568	1437	acute infection	[acute infection]	2.0	2	3	1	1
8569	1437	64.6 k.0	[64.6 kd,]	2.0	2	2	0	0
8570	1437	COS7 cell	[COS7 cells]	2.0	2	2	0	0
8571	1437	morphological change	[morphological changes]	2.0	2	3	2	2
8572	1437	ligand-activated c-erbA/TR	[ligand-activated c-erbA/TR]	2.0	2	2	0	0
8573	1437	mrna stabilization	[mRNA stabilization]	2.0	2	3	2	2
8574	1437	failure rate	[failure rate]	2.0	2	3	3	3
8575	1437	mrna production	[mRNA production]	2.0	2	2	0	0
8576	1437	bp relative	[bp relative]	2.0	2	3	2	2
8577	1437	VCAM-1 expression	[VCAM-1 expression]	2.0	2	2	0	0
8578	1437	chain enhancer	[chain enhancer]	2.0	2	3	2	2
8579	1437	Interleukin-12 IL-12	[Interleukin-12 IL-12]	2.0	2	3	1	1
8580	1437	ln cell	[LN cells]	2.0	2	3	3	3
8581	1437	new role	[new role]	2.0	2	3	3	3
8582	1437	class ii histocompatibility complex gene	[class II histocompatibility complex gene]	2.0	5	3	3	3
8583	1437	expression of many cellular gene	[expression of many cellular genes]	2.0	5	3	1	1
8584	1437	rna production	[RNA production]	2.0	2	3	3	3
8585	1437	histone h4	[histone H4]	2.0	2	3	2	2
8586	1437	transcriptional levels.	[transcriptional levels.]	2.0	2	2	0	0
8587	1437	clone 13	[clone 13]	2.0	2	2	0	0
8588	1437	only exception	[only exception]	2.0	2	2	0	0
8589	1437	receptor mr	[receptor MR]	2.0	2	3	3	3
8590	1437	oxidize agent	[Oxidizing agents]	2.0	2	2	0	0
8591	1437	primary hyperparathyroidism	[primary hyperparathyroidism]	2.0	2	3	1	1
8592	1437	receptor pr	[receptor PR]	2.0	2	2	0	0
8593	1437	hairy leukoplakia	[hairy leukoplakia]	2.0	2	3	3	3
8594	1437	Peripheral blood mononuclear cell pbmc	[Peripheral blood mononuclear cells PBMCs]	2.0	5	2	0	0
8595	1437	long period	[long period]	2.0	2	4	4	2
8596	1437	g protein	[G protein]	2.0	2	3	2	2
8597	1437	cd8+ cell	[CD8+ cells]	2.0	2	3	1	1
8598	1437	16 P.	[16 h.]	2.0	2	2	0	0
8599	1437	thrombin activation	[Thrombin activation]	2.0	2	3	1	1
8600	1437	interact protein	[interacting proteins]	2.0	2	3	3	3
8601	1437	interleukin-3 il-3	[interleukin-3 IL-3]	2.0	2	3	3	3
8602	1437	il-5 transcription in T cell	[IL-5 transcription in T cells]	2.0	5	2	0	0
8603	1437	85-kDa protein	[85-kDa protein]	2.0	2	2	0	0
8604	1437	protein capable	[proteins capable]	2.0	2	3	2	2
8605	1437	tsp gene	[TSP gene]	2.0	2	3	3	3
8606	1437	ICAM-I promoter	[ICAM-I promoter]	2.0	2	3	1	1
8607	1437	10 microm	[10 microM]	2.0	2	3	3	3
8608	1437	prolonged period	[prolonged period]	2.0	2	3	3	3
8609	1437	monocyte chemoattractant	[monocyte chemoattractant]	2.0	2	4	4	2
8610	1437	positive region	[positive region]	2.0	2	3	2	2
8611	1437	inducible form	[inducible form]	2.0	2	3	3	3
8612	1437	cytokine pattern	[cytokine pattern]	2.0	2	3	2	2
8613	1437	proliferative potential	[proliferative potential]	2.0	2	3	3	3
8614	1437	Ets protein	[Ets proteins]	2.0	2	2	0	0
8615	1437	gamma gene	[gamma genes]	2.0	2	2	0	0
8616	1437	human erythroleukemia	[human erythroleukemia]	2.0	2	2	0	0
8617	1437	normal resting	[normal resting]	2.0	2	2	0	0
8618	1437	steroid-resistant group	[steroid-resistant group]	2.0	2	2	0	0
8619	1437	39 case	[39 cases]	2.0	2	2	0	0
8620	1437	structural similarity	[structural similarity]	2.0	2	3	1	1
8621	1437	5' portion	[5' portion]	2.0	2	3	2	2
8622	1437	NK clone	[NK clones]	2.0	2	2	0	0
8623	1437	NF-kappa b /rel transcription factor	[NF-kappa B /Rel transcription factors]	2.0	5	2	0	0
8624	1437	alpha b1	[alpha B1]	2.0	2	3	1	1
8625	1437	molecular process	[molecular process]	2.0	2	2	0	0
8626	1437	nuclear factor of T cell NF-AT	[nuclear factor of T cells NF-AT]	2.0	6	2	0	0
8627	1437	cell activation.	[cell activation.]	2.0	2	3	2	2
8628	1437	bind assay	[binding assay]	2.0	2	4	4	2
8629	1437	glucocorticoid effect	[glucocorticoid effect]	2.0	2	2	0	0
8630	1437	pha proliferation	[PHA proliferation]	2.0	2	3	3	3
8631	1437	ptdin 3-kinase	[PtdIns 3-kinase]	2.0	2	3	2	2
8632	1437	tr alpha	[TR alpha]	2.0	2	3	3	3
8633	1437	hiv long terminal repeat LTR	[HIV long terminal repeat LTR]	2.0	5	2	0	0
8634	1437	activation of nf kappa b	[activation of NF kappa B]	2.0	5	3	1	1
8635	1437	t-lineage cell	[T-lineage cells]	2.0	2	3	1	1
8636	1437	Arp2/3 complex	[Arp2/3 complex]	2.0	2	2	0	0
8637	1437	nonsteroidal drug	[nonsteroidal drugs]	2.0	2	3	3	3
8638	1437	interleukin 2 receptor alpha-chain gene	[interleukin 2 receptor alpha-chain gene]	2.0	5	2	0	0
8639	1437	TF site	[TF site]	2.0	2	3	1	1
8640	1437	spleen cell	[spleen cells]	2.0	2	3	2	2
8641	1437	apoptotic stimulus	[apoptotic stimulus]	2.0	2	2	0	0
8642	1437	CACCC box	[CACCC box]	2.0	2	2	0	0
8643	1437	4-bp mutation	[4-bp mutation]	2.0	2	2	0	0
8644	1437	effect on the immune system	[effect on the immune system]	2.0	5	3	1	1
8645	1437	differentiation of myeloid leukemic cell	[differentiation of myeloid leukemic cells]	2.0	5	3	1	1
8646	1437	intracellular event	[intracellular events]	2.0	2	3	2	2
8647	1437	New World	[New World]	2.0	2	3	2	2
8648	1437	mouse macrophage	[mouse macrophage]	2.0	2	3	2	2
8649	1437	level of il-1 beta mrna	[level of IL-1 beta mRNA]	2.0	5	3	1	1
8650	1437	high turnover	[high turnover]	2.0	2	2	0	0
8651	1437	VDR cDNA	[VDR cDNA]	2.0	2	3	2	2
8652	1437	gata-1 transcription	[GATA-1 transcription]	2.0	2	3	3	3
8653	1437	mutation in the tsc2 gene	[Mutations in the TSC2 gene]	2.0	5	2	0	0
8654	1437	mutant strain	[mutant strain]	2.0	2	3	1	1
8655	1437	growth arrest,	[growth arrest,]	2.0	2	2	0	0
8656	1437	transcriptional regulation of cytokine gene	[transcriptional regulation of cytokine genes]	2.0	5	3	2	2
8657	1437	32 kda	[32 kDa]	2.0	2	2	0	0
8658	1437	additional function	[additional function]	2.0	2	2	0	0
8659	1437	erythrocyte	[erythrocyte]	2.0	1	21	9	9
8660	1437	PML body	[PML bodies]	2.0	2	3	3	3
8661	1437	tal-1 expression	[tal-1 expression]	2.0	2	3	1	1
8662	1437	tissue-specific activity	[Tissue-specific activity]	2.0	2	2	0	0
8663	1437	t(8;21) aml	[t(8;21) AML]	2.0	2	2	0	0
8664	1437	regulatory subunit	[regulatory subunit]	2.0	2	3	1	1
8665	1437	NFAT-1	[NFAT-1]	2.0	1	21	6	6
8666	1437	tyrosine phosphorylation of cellular protein	[tyrosine phosphorylation of cellular proteins]	2.0	5	3	2	2
8667	1437	CD40 molecule	[CD40 molecule]	2.0	2	3	3	3
8668	1437	predominant isoform	[predominant isoform]	2.0	2	2	0	0
8669	1437	alpha-globin promoter	[alpha-globin promoter]	2.0	2	2	0	0
8670	1437	nm23 expression	[NM23 expression]	2.0	2	2	0	0
8671	1437	anterior pituitary	[anterior pituitary]	2.0	2	2	0	0
8672	1437	transcription factor,	[transcription factor,]	2.0	2	3	2	2
8673	1437	p27(kip1) mrna	[p27(KIP1) mRNA]	2.0	2	2	0	0
8674	1437	two open reading frame orf	[two open reading frames ORFs]	2.0	5	3	2	2
8675	1437	mouse spleen	[mouse spleen]	2.0	2	3	2	2
8676	1437	myogenic transcription	[myogenic transcription]	2.0	2	2	0	0
8677	1437	human t-cell leukemia virus htlv-i	[human T-cell leukemia virus HTLV-I]	2.0	5	2	0	0
8678	1437	HTLV-I LTR	[HTLV-I LTR]	2.0	2	2	0	0
8679	1437	allergic reaction	[allergic reaction]	2.0	2	2	0	0
8680	1437	cytoplasmic ar	[Cytoplasmic AR]	2.0	2	2	0	0
8681	1437	human sequence	[human sequence]	2.0	2	3	3	3
8682	1437	one clone	[One clone]	2.0	2	3	3	3
8683	1437	persistent group c adenoviral infection	[persistent group C adenoviral infection]	2.0	5	2	0	0
8684	1437	elk-1 expression	[elk-1 expression]	2.0	2	3	2	2
8685	1437	cathepsin b	[cathepsin B]	2.0	2	3	2	2
8686	1437	characteristic feature	[characteristic feature]	2.0	2	4	4	2
8687	1437	direct repeat	[direct repeat]	2.0	2	3	1	1
8688	1437	cell transformation	[cell transformation]	2.0	2	3	3	3
8689	1437	H2 receptor	[H2 receptor]	2.0	2	2	0	0
8690	1437	transcription from a reporter construct	[transcription from a reporter construct]	2.0	5	2	0	0
8691	1437	DNA binding activity of p65	[DNA binding activity of p65]	2.0	5	2	0	0
8692	1437	epsilon germline	[epsilon germline]	2.0	2	3	3	3
8693	1437	interleukin-2 expression	[interleukin-2 expression]	2.0	2	3	2	2
8694	1437	whole cell	[whole cell]	2.0	2	2	0	0
8695	1437	five sequence	[five sequences]	2.0	2	2	0	0
8696	1437	expression study	[Expression studies]	2.0	2	3	1	1
8697	1437	RA response	[RA response]	2.0	2	3	1	1
8698	1437	kappa gene	[kappa genes]	2.0	2	3	2	2
8699	1437	inducible gene	[inducible genes]	2.0	2	3	2	2
8700	1437	suppressive activity	[suppressive activity]	2.0	2	2	0	0
8701	1437	-specific pcr	[-specific PCR]	2.0	2	2	0	0
8702	1437	tpa induction	[TPA induction]	2.0	2	3	1	1
8703	1437	human cd36	[human CD36]	2.0	2	2	0	0
8704	1437	DNA mobility	[DNA mobility]	2.0	2	4	4	2
8705	1437	downstream effector	[downstream effector]	2.0	2	3	3	3
8706	1437	cells/mm2, n	[cells/mm2, n]	2.0	2	2	0	0
8707	1437	cd69 expression	[CD69 expression]	2.0	2	3	1	1
8708	1437	rapid depletion	[rapid depletion]	2.0	2	3	2	2
8709	1437	interleukin 4	[interleukin 4]	2.0	2	2	0	0
8710	1437	ppar activator	[PPAR activators]	2.0	2	3	2	2
8711	1437	different isoform	[different isoforms]	2.0	2	3	3	3
8712	1437	thymic DC	[thymic DC]	2.0	2	2	0	0
8713	1437	cold exposure	[cold exposure]	2.0	2	2	0	0
8714	1437	subsequent nuclear translocation of stat3	[subsequent nuclear translocation of stat3]	2.0	5	2	0	0
8715	1437	enhancer shuffle	[enhancer shuffling]	2.0	2	2	0	0
8716	1437	control cells.	[control cells.]	2.0	2	2	0	0
8717	1437	Oct-1 protein	[Oct-1 protein]	2.0	2	3	2	2
8718	1437	same animal	[same animals]	2.0	2	2	0	0
8719	1437	benign polymorphism	[benign polymorphism]	2.0	2	2	0	0
8720	1437	influenza virus	[influenza virus]	2.0	2	3	2	2
8721	1437	senescent T	[senescent T]	2.0	2	3	1	1
8722	1437	genetic program	[genetic program]	2.0	2	3	1	1
8723	1437	codon-10-variant type	[codon-10-variant type]	2.0	2	2	0	0
8724	1437	two mechanism	[two mechanisms]	2.0	2	3	2	2
8725	1437	gata -1	[GATA -1]	2.0	2	2	0	0
8726	1437	6 month	[6 months]	2.0	2	3	3	3
8727	1437	murine-specific ifn-gamma	[murine-specific IFN-gamma]	2.0	2	2	0	0
8728	1437	factor-kappaB translocation	[factor-kappaB translocation]	2.0	2	3	3	3
8729	1437	M-CSF treatment	[M-CSF treatment]	2.0	2	2	0	0
8730	1437	interferon IFN	[interferon IFN]	2.0	2	3	3	3
8731	1437	synergistic induction	[synergistic induction]	2.0	2	4	4	2
8732	1437	alpha tnf-alpha	[alpha TNF-alpha]	2.0	2	2	0	0
8733	1437	polyomavirus reactivation	[polyomavirus reactivation]	2.0	2	3	2	2
8734	1437	type diabete	[type diabetes]	2.0	2	4	4	2
8735	1437	SML cytosol on gr binding	[SML cytosol on GR binding]	2.0	5	2	0	0
8736	1437	many disease	[many diseases]	2.0	2	3	2	2
8737	1437	key protein	[key protein]	2.0	2	3	3	3
8738	1437	indicate involved.	[indicating involved.]	2.0	2	2	0	0
8739	1437	leishmania donovani	[Leishmania donovani]	2.0	2	2	0	0
8740	1437	antiphosphotyrosine immunoblotting	[antiphosphotyrosine immunoblotting]	2.0	2	2	0	0
8741	1437	normal granulocyte	[normal granulocytes]	2.0	2	3	1	1
8742	1437	human b cell lymphoma line	[human B cell lymphoma lines]	2.0	5	2	0	0
8743	1437	E1A primer	[E1A primers]	2.0	2	2	0	0
8744	1437	chicken cytokine with t-cell activity	[chicken cytokine with T-cell activity]	2.0	5	2	0	0
8745	1437	b clone	[B clone]	2.0	2	3	3	3
8746	1437	proximal step	[proximal step]	2.0	2	3	3	3
8747	1437	fatal infection	[fatal infection]	2.0	2	2	0	0
8748	1437	depressed patient	[depressed patients]	2.0	2	3	3	3
8749	1437	single-copy gene	[single-copy gene]	2.0	2	3	1	1
8750	1437	cell surface expression of e-selectin	[cell surface expression of E-selectin]	2.0	5	2	0	0
8751	1437	high stability	[higher stability]	2.0	2	2	0	0
8752	1437	number of receptor in leukocyte	[number of receptors in leukocytes]	2.0	5	3	3	3
8753	1437	Pax-5 gene	[Pax-5 gene]	2.0	2	2	0	0
8754	1437	hiv-1 protease	[HIV-1 protease]	2.0	2	3	1	1
8755	1437	mouse b	[mouse B]	2.0	2	3	2	2
8756	1437	cell-type-specific fashion	[cell-type-specific fashion]	2.0	2	2	0	0
8757	1437	tissue-specific promoter	[tissue-specific promoter]	2.0	2	3	2	2
8758	1437	upstream kinase	[upstream kinase]	2.0	2	3	2	2
8759	1437	non- cell	[non- cells]	2.0	2	3	3	3
8760	1437	cholesterol synthesis	[cholesterol synthesis]	2.0	2	3	3	3
8761	1437	two mutant	[two mutants]	2.0	2	3	2	2
8762	1437	mcm6 gene	[MCM6 genes]	2.0	2	2	0	0
8763	1437	proximal site	[proximal site]	2.0	2	3	2	2
8764	1437	nude mouse	[nude mice]	2.0	2	2	0	0
8765	1437	2-4 hour	[2-4 hr,]	2.0	2	2	0	0
8766	1437	seek support	[seeking support]	2.0	2	3	3	3
8767	1437	family protein	[family proteins]	2.0	2	3	2	2
8768	1437	tuberculous patient	[tuberculous patients]	2.0	2	2	0	0
8769	1437	further increase	[further increase]	2.0	2	4	4	2
8770	1437	low shear-induced activation of nf-kappab	[low shear-induced activation of NF-kappaB]	2.0	5	2	0	0
8771	1437	alpha promoter	[alpha promoter]	2.0	2	2	0	0
8772	1437	pha activation	[PHA activation]	2.0	2	2	0	0
8773	1437	follicular cell	[follicular cells]	2.0	2	3	2	2
8774	1437	actin polymerization	[actin polymerization]	2.0	2	3	1	1
8775	1437	sialoadhesin expression	[sialoadhesin expression]	2.0	2	7	5	1
8776	1437	two groups,	[two groups,]	2.0	2	2	0	0
8777	1437	phospholipid surface	[phospholipid surface]	2.0	2	3	2	2
8778	1437	specific factor	[specific factors]	2.0	2	3	2	2
8779	1437	antiproliferative activity	[antiproliferative activity]	2.0	2	3	2	2
8780	1437	promyelocytic stage	[promyelocytic stage]	2.0	2	2	0	0
8781	1437	nfatp dephosphorylation	[NFATp dephosphorylation]	2.0	2	3	2	2
8782	1437	tal1 allele	[TAL1 allele]	2.0	2	3	2	2
8783	1437	ptpase inhibitor	[PTPase inhibitor]	2.0	2	3	2	2
8784	1437	same gene	[same gene]	2.0	2	3	1	1
8785	1437	p48 protein	[p48 protein]	2.0	2	2	0	0
8786	1437	pregnancy lymphocyte	[pregnancy lymphocytes]	2.0	2	4	4	2
8787	1437	G28-5 sFv	[G28-5 sFv]	2.0	2	2	0	0
8788	1437	immunomodulatory cytokine	[immunomodulatory cytokine]	2.0	2	2	0	0
8789	1437	m-csf gene	[M-CSF gene]	2.0	2	3	2	2
8790	1437	cd4-8- T	[CD4-8- T]	2.0	2	4	4	2
8791	1437	major groove	[major groove]	2.0	2	3	1	1
8792	1437	lak cell	[LAK cells]	2.0	2	4	2	1
8793	1437	glucocorticoid receptor.	[glucocorticoid receptor.]	2.0	2	2	0	0
8794	1437	anti-igm-induced apoptosis	[anti-IgM-induced apoptosis]	2.0	2	3	1	1
8795	1437	different endothelial cell adhesion molecule	[different endothelial cell adhesion molecules]	2.0	5	2	0	0
8796	1437	morphologic feature	[morphologic features,]	2.0	2	3	2	2
8797	1437	hs-72 cell	[HS-72 cells]	2.0	2	3	1	1
8798	1437	0.1 nm	[0.1 nM]	2.0	2	3	3	3
8799	1437	low number	[low number]	2.0	2	3	3	3
8800	1437	bandshift assay	[bandshift assays]	2.0	2	3	1	1
8801	1437	advanced stage	[advanced stage]	2.0	2	2	0	0
8802	1437	such increase	[such increase]	2.0	2	2	0	0
8803	1437	CLE0 sequence	[CLE0 sequence]	2.0	2	2	0	0
8804	1437	T cell from elderly individual	[T cells from elderly individuals]	2.0	5	3	1	1
8805	1437	use densitometry	[using densitometry]	2.0	2	2	0	0
8806	1437	ovarian tumor	[ovarian tumor]	2.0	2	2	0	0
8807	1437	IL-4 activation	[IL-4 activation]	2.0	2	3	3	3
8808	1437	gene family	[gene family]	2.0	2	3	3	3
8809	1437	immunoglobulin enhancer	[immunoglobulin enhancer]	2.0	2	3	1	1
8810	1437	mycoplasma fermentan	[Mycoplasma fermentans]	2.0	2	2	0	0
8811	1437	similar degree	[similar degree]	2.0	2	4	4	2
8812	1437	BALB/c mouse	[BALB/c mice]	2.0	2	3	2	2
8813	1437	x-inactivation pattern	[X-inactivation pattern]	2.0	2	3	2	2
8814	1437	viral expression	[viral expression]	2.0	2	2	0	0
8815	1437	Daudi cell	[Daudi cells]	2.0	2	3	3	3
8816	1438	BZLF1	[BZLF1]	1.9875	1	21	9	8
8817	1439	species	[species]	1.9866666666666668	1	21	17	15
8818	1440	sh2	[SH2]	1.9833333333333334	1	21	7	6
8819	1440	rapamycin	[rapamycin]	1.9833333333333334	1	21	7	6
8820	1441	lipoprotein	[lipoprotein]	1.9812500000000002	1	21	19	16
8821	1442	silencer	[silencer]	1.9800000000000002	1	21	6	5
8822	1443	m-csf	[M-CSF]	1.9777777777777779	1	21	11	9
8823	1444	DEX	[DEX]	1.975	1	21	5	4
8824	1444	rdna	[rDNA]	1.975	1	21	15	12
8825	1444	gsh	[GSH]	1.975	1	21	5	4
8826	1444	pou	[POU]	1.975	1	22	9	4
8827	1445	pbl	[PBL]	1.9727272727272727	1	21	14	11
8828	1446	interleukin-6	[interleukin-6]	1.97	1	21	13	10
8829	1447	herpes	[herpes]	1.9666666666666668	1	21	8	6
8830	1447	A-myb	[A-myb]	1.9666666666666668	1	21	4	3
8831	1448	A	[A]	1.9625000000000001	1	21	11	8
8832	1449	information	[information]	1.9615384615384617	1	21	18	13
8833	1450	PBMC	[PBMC]	1.9600000000000002	1	22	12	5
8834	1451	decline	[decline]	1.9583333333333333	1	21	17	12
8835	1452	HTLV-1	[HTLV-1]	1.9571428571428573	1	21	10	7
8836	1452	ldl	[LDL]	1.9571428571428573	1	21	10	7
8837	1453	Syk	[Syk]	1.9500000000000002	1	21	6	4
8838	1454	malignancy	[malignancy]	1.9454545454545453	1	21	17	11
8839	1455	lysis	[lysis]	1.9444444444444444	1	21	14	9
8840	1456	mode	[mode]	1.9416666666666669	1	21	19	12
8841	1457	distribution	[distribution]	1.9363636363636365	1	21	18	11
8842	1458	EMSA	[EMSA]	1.9333333333333333	1	22	16	6
8843	1458	origin	[origin]	1.9333333333333333	1	21	20	12
8844	1459	isolation	[isolation]	1.92	1	23	19	5
8845	1460	cyclin	[cyclin]	1.9125	1	21	15	8
8846	1461	G1	[G1]	1.9000000000000001	1	20	8	8
8847	1461	JAK	[JAK]	1.9000000000000001	1	20	7	7
8848	1461	Nef	[Nef]	1.9000000000000001	1	20	5	5
8849	1461	Oct2	[Oct2]	1.9000000000000001	1	20	8	8
8850	1461	apc	[APC]	1.9000000000000001	1	20	8	8
8851	1461	sle	[SLE]	1.9000000000000001	1	20	7	7
8852	1461	cd44	[CD44]	1.9000000000000001	1	20	6	6
8853	1461	IL-1beta	[IL-1beta]	1.9000000000000001	1	20	6	6
8854	1461	gamma(c)	[gamma(c)]	1.9000000000000001	1	20	3	3
8855	1461	relation	[relation]	1.9000000000000001	1	21	18	9
8856	1461	caspase	[caspase]	1.9000000000000001	1	20	9	9
8857	1462	year	[year]	1.8944444444444444	1	20	19	18
8858	1463	U1	[U1]	1.89	1	20	11	10
8859	1463	rise	[rise]	1.89	1	20	11	10
8860	1464	protein,	[protein,]	1.888888888888889	1	20	10	9
8861	1465	frequency	[frequency]	1.8875000000000002	1	21	17	8
8862	1466	myelomonocytic	[myelomonocytic]	1.885714285714286	1	20	8	7
8863	1467	Raji	[Raji]	1.8833333333333333	1	20	7	6
8864	1467	cytomegalovirus	[cytomegalovirus]	1.8833333333333333	1	20	14	12
8865	1468	candidate	[candidate]	1.8818181818181818	1	20	13	11
8866	1469	t-	[T-]	1.8800000000000001	1	20	6	5
8867	1469	LCR	[LCR]	1.8800000000000001	1	20	6	5
8868	1470	VCAM-1	[VCAM-1]	1.877777777777778	1	20	11	9
8869	1470	light	[light]	1.877777777777778	1	20	11	9
8870	1471	medium	[medium]	1.8769230769230771	1	20	16	13
8871	1472	none	[none]	1.866666666666667	1	26	22	3
8872	1473	g-csf	[G-CSF]	1.8625	1	20	11	8
8873	1473	interleukin-4	[interleukin-4]	1.8625	1	20	11	8
8874	1474	immunoprecipitation	[immunoprecipitation]	1.8571428571428574	1	20	10	7
8875	1475	skin	[skin]	1.85	1	20	9	6
8876	1475	pregnancy	[pregnancy]	1.85	1	20	12	8
8877	1476	min.	[min.]	1.846153846153846	1	20	20	13
8878	1477	link	[link]	1.8363636363636364	1	20	18	11
8879	1478	oestrogen	[oestrogen]	1.82	1	20	9	5
8880	1479	e	[E]	1.8	1	19	10	10
8881	1479	depletion	[depletion]	1.8	1	20	18	9
8882	1479	restriction	[restriction]	1.8	1	19	9	9
8883	1479	tgf-beta	[TGF-beta]	1.8	1	19	4	4
8884	1479	cofactor	[cofactor]	1.8	1	19	14	14
8885	1479	segment	[segment]	1.8	1	19	13	13
8886	1479	vector	[vector]	1.8	1	19	12	12
8887	1479	hypoxia	[hypoxia]	1.8	1	19	5	5
8888	1479	c-terminal	[C-terminal]	1.8	1	19	10	10
8889	1479	prl	[PRL]	1.8	1	19	3	3
8890	1479	CONCLUSIONS:	[CONCLUSIONS:]	1.8	1	19	6	6
8891	1479	hsp90	[hsp90]	1.8	1	19	6	6
8892	1480	mAb	[mAb]	1.790909090909091	1	19	12	11
8893	1481	adaptor	[adaptor]	1.788888888888889	1	19	10	9
8894	1481	calcitriol	[calcitriol]	1.788888888888889	1	19	10	9
8895	1482	th	[Th]	1.7875	1	19	9	8
8896	1482	removal	[removal]	1.7875	1	20	17	8
8897	1482	endotoxin	[endotoxin]	1.7875	1	19	9	8
8898	1482	nef	[Nef]	1.7875	1	19	9	8
8899	1483	Tax1	[Tax1]	1.7857142857142858	1	19	8	7
8900	1484	JAK2	[JAK2]	1.7833333333333332	1	19	7	6
8901	1484	suppressor	[suppressor]	1.7833333333333332	1	19	14	12
8902	1485	CML	[CML]	1.7800000000000002	1	19	6	5
8903	1486	stability	[stability]	1.7750000000000001	1	22	17	4
8904	1487	jak3	[JAK3]	1.7666666666666668	1	19	8	6
8905	1487	fibronectin	[fibronectin]	1.7666666666666668	1	19	12	9
8906	1488	erythroleukemia	[erythroleukemia]	1.7625000000000002	1	19	11	8
8907	1489	vd	[VD]	1.7600000000000002	1	19	7	5
8908	1489	inability	[inability]	1.7600000000000002	1	20	12	5
8909	1489	receptor.	[receptor.]	1.7600000000000002	1	19	7	5
8910	1490	existence	[existence]	1.75	1	22	18	4
8911	1490	histocompatibility	[histocompatibility]	1.75	1	19	3	2
8912	1491	HLA	[HLA]	1.7444444444444445	1	19	14	9
8913	1492	coexpression	[coexpression]	1.7333333333333334	1	24	20	3
8914	1492	Epo	[Epo]	1.7333333333333334	1	19	5	3
8915	1493	regard	[regard]	1.7142857142857144	1	19	13	7
8916	1494	period	[period]	1.7111111111111112	1	19	17	9
8917	1495	3'	[3']	1.7000000000000002	1	18	4	4
8918	1495	e2	[E2]	1.7000000000000002	1	18	9	9
8919	1495	C3a	[C3a]	1.7000000000000002	1	18	2	2
8920	1495	genes,	[genes,]	1.7000000000000002	1	18	9	9
8921	1495	FK506	[FK506]	1.7000000000000002	1	18	1	1
8922	1495	il-7	[IL-7]	1.7000000000000002	1	18	3	3
8923	1495	YY1	[YY1]	1.7000000000000002	1	18	4	4
8924	1495	ebf	[EBF]	1.7000000000000002	1	18	5	5
8925	1495	process.	[process.]	1.7000000000000002	1	18	2	2
8926	1495	nature	[nature]	1.7000000000000002	1	19	12	6
8927	1495	trans-activation	[trans-activation]	1.7000000000000002	1	19	8	4
8928	1495	TCL1	[TCL1]	1.7000000000000002	1	18	4	4
8929	1495	-express	[-expressing]	1.7000000000000002	1	18	15	15
8930	1495	recombinant	[recombinant]	1.7000000000000002	1	18	12	12
8931	1495	fact	[fact]	1.7000000000000002	1	18	3	3
8932	1496	Thus,	[Thus,]	1.6923076923076925	1	18	14	13
8933	1497	hybridization	[hybridization]	1.6916666666666669	1	18	13	12
8934	1497	subclone	[subclone]	1.6916666666666669	1	18	13	12
8935	1498	HLF	[HLF]	1.688888888888889	1	18	10	9
8936	1498	nf-e2	[NF-E2]	1.688888888888889	1	18	10	9
8937	1499	RB	[RB]	1.6875	1	18	9	8
8938	1499	(mean	[(mean]	1.6875	1	18	9	8
8939	1500	PBL	[PBL]	1.685714285714286	1	18	8	7
8940	1500	cd95	[CD95]	1.685714285714286	1	18	8	7
8941	1500	fluorescence	[fluorescence]	1.685714285714286	1	18	8	7
8942	1500	airway	[airway]	1.685714285714286	1	18	8	7
8943	1501	cd69	[CD69]	1.6833333333333333	1	18	7	6
8944	1502	-DNA	[-DNA]	1.6785714285714286	1	18	17	14
8945	1503	(stat)	[(STAT)]	1.675	1	19	18	8
8946	1504	endothelium	[endothelium]	1.6727272727272728	1	18	14	11
8947	1505	oxide	[oxide]	1.6714285714285717	1	19	16	7
8948	1506	ic50	[IC50]	1.666666666666667	1	18	8	6
8949	1506	CD20	[CD20]	1.666666666666667	1	18	4	3
8950	1507	uptake	[uptake]	1.6636363636363638	1	18	15	11
8951	1508	interference	[interference]	1.6600000000000001	1	18	14	10
8952	1508	dimerization	[dimerization]	1.6600000000000001	1	18	7	5
8953	1508	child	[child]	1.6600000000000001	1	18	14	10
8954	1509	elevation	[elevation]	1.6571428571428575	1	19	17	7
8955	1510	results:	[RESULTS:]	1.655555555555556	1	18	13	9
8956	1511	pr	[PR]	1.6500000000000001	1	18	6	4
8957	1511	immunofluorescence	[immunofluorescence]	1.6500000000000001	1	18	12	8
8958	1511	atherosclerosis	[atherosclerosis]	1.6500000000000001	1	18	3	2
8959	1511	arthritis	[arthritis]	1.6500000000000001	1	18	15	10
8960	1511	concert	[concert]	1.6500000000000001	1	19	5	2
8961	1512	hhv-6	[HHV-6]	1.64	1	18	8	5
8962	1513	leucocyte	[leucocyte]	1.6375000000000002	1	18	13	8
8963	1514	13-acetate	[13-acetate]	1.6285714285714286	1	18	12	7
8964	1515	TF	[TF]	1.6	1	17	8	8
8965	1515	mm	[MM]	1.6	1	17	8	8
8966	1515	ikappabalpha	[IkappaBalpha]	1.6	1	17	5	5
8967	1515	engagement	[engagement]	1.6	1	19	18	6
8968	1515	p56(lck)	[p56(lck)]	1.6	1	17	2	2
8969	1515	lmp-1	[LMP-1]	1.6	1	17	6	6
8970	1515	VitD3	[VitD3]	1.6	1	17	5	5
8971	1515	ebna2	[EBNA2]	1.6	1	17	7	7
8972	1515	reading	[reading]	1.6	1	22	6	1
8973	1515	p40	[p40]	1.6	1	17	8	8
8974	1515	cd36	[CD36]	1.6	1	17	3	3
8975	1515	transactivate	[transactivating]	1.6	1	17	4	4
8976	1515	AP-2	[AP-2]	1.6	1	17	3	3
8977	1515	mass	[mass]	1.6	1	18	16	8
8978	1515	controls.	[controls.]	1.6	1	17	4	4
8979	1515	anergy	[anergy]	1.6	1	17	4	4
8980	1515	IFN-alpha	[IFN-alpha]	1.6	1	17	3	3
8981	1515	beta-casein	[beta-casein]	1.6	1	17	4	4
8982	1516	technique	[technique]	1.5916666666666668	1	17	13	12
8983	1516	trans-activator	[trans-activator]	1.5916666666666668	1	17	13	12
8984	1517	stimulation,	[stimulation,]	1.588888888888889	1	17	10	9
8985	1518	hcmv	[HCMV]	1.5875000000000001	1	17	9	8
8986	1519	immunohistochemistry	[immunohistochemistry]	1.5857142857142859	1	17	8	7
8987	1520	analysis of tax mutant	[Analysis of Tax mutants]	1.5849625007211563	4	2	1	1
8988	1520	e2a basic helix-loop-helix protein	[E2A basic helix-loop-helix proteins]	1.5849625007211563	4	1	0	0
8989	1520	major histocompatibility complex fashion	[major histocompatibility complex fashion]	1.5849625007211563	4	1	0	0
8990	1520	several runt isoform	[several runt isoforms]	1.5849625007211563	3	1	0	0
8991	1520	pathophysiology of pih	[pathophysiology of PIH]	1.5849625007211563	3	1	0	0
8992	1520	dominant-negative ets-binding factor	[dominant-negative ets-binding factor]	1.5849625007211563	3	1	0	0
8993	1520	involvement of tyrosine phosphorylation	[Involvement of tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
8994	1520	HTLV-I transcriptional activator tax	[HTLV-I transcriptional activator tax]	1.5849625007211563	4	1	0	0
8995	1520	nonhuman primate model	[nonhuman primate model]	1.5849625007211563	3	1	0	0
8996	1520	competitive progesterone antagonist ru486	[competitive progesterone antagonist RU486]	1.5849625007211563	4	1	0	0
8997	1520	several diseases, include atherosclerosis	[several diseases, including atherosclerosis]	1.5849625007211563	4	1	0	0
8998	1520	potent monocyte/macrophage-specific stimulator	[potent monocyte/macrophage-specific stimulator]	1.5849625007211563	3	1	0	0
8999	1520	mutation in this site	[Mutations in this site]	1.5849625007211563	4	2	1	1
9000	1520	carboxyl-terminal portion of Stat3alpha	[carboxyl-terminal portion of Stat3alpha]	1.5849625007211563	4	1	0	0
9001	1520	IFN cytoprotection IFN -mcp	[IFN cytoprotection IFN -MCP]	1.5849625007211563	4	1	0	0
9002	1520	two inhibitory mechanims.	[two inhibitory mechanims.]	1.5849625007211563	3	1	0	0
9003	1520	ability of the analog	[ability of the analogs]	1.5849625007211563	4	1	0	0
9004	1520	aspect of erythroid differentiation	[aspects of erythroid differentiation]	1.5849625007211563	4	1	0	0
9005	1520	various key gene coding	[various key genes coding]	1.5849625007211563	4	1	0	0
9006	1520	stage include plasma cells,	[stages including plasma cells,]	1.5849625007211563	4	1	0	0
9007	1520	lipid-mediated DNA transfer	[lipid-mediated DNA transfer]	1.5849625007211563	3	1	0	0
9008	1520	factor 10 to 50.	[factor 10 to 50.]	1.5849625007211563	4	1	0	0
9009	1520	capacity of curcumin	[capacity of curcumin]	1.5849625007211563	3	1	0	0
9010	1520	150-200 kilometer fraction	[150-200 kd fractions]	1.5849625007211563	3	1	0	0
9011	1520	expression in the germ	[expression in the germ]	1.5849625007211563	4	1	0	0
9012	1520	cytoplasmic ikappab inhibitor	[cytoplasmic IkappaB inhibitor]	1.5849625007211563	3	1	0	0
9013	1520	blood of the animal	[blood of the animals]	1.5849625007211563	4	1	0	0
9014	1520	specific binding of [3h]dexamethasone	[specific binding of [3H]dexamethasone]	1.5849625007211563	4	1	0	0
9015	1520	effect of adt pretreatment	[effect of ADT pretreatment]	1.5849625007211563	4	1	0	0
9016	1520	myelogenous leukemia CML	[myelogenous leukemia CML]	1.5849625007211563	3	2	2	2
9017	1520	Epo stem cell factor	[Epo stem cell factor]	1.5849625007211563	4	1	0	0
9018	1520	combination of RA	[combination of RA]	1.5849625007211563	3	1	0	0
9019	1520	stimulation with PMA	[stimulation with PMA]	1.5849625007211563	3	2	1	1
9020	1520	up-regulation of the transcript	[up-regulation of the transcript]	1.5849625007211563	4	1	0	0
9021	1520	Mo T-lymphoid HTLV-II cell	[Mo T-lymphoid HTLV-II cells]	1.5849625007211563	4	1	0	0
9022	1520	dissociation constant capacity,	[dissociation constant capacity,]	1.5849625007211563	3	1	0	0
9023	1520	thus relieve repressive effect.	[thus relieving repressive effect.]	1.5849625007211563	4	1	0	0
9024	1520	proximal p element	[proximal P element]	1.5849625007211563	3	1	0	0
9025	1520	flank negative-acting element	[flanking negative-acting elements]	1.5849625007211563	3	1	0	0
9026	1520	human ige germline promoter	[human IgE germline promoter]	1.5849625007211563	4	1	0	0
9027	1520	core of base pair	[core of base pairs]	1.5849625007211563	4	1	0	0
9028	1520	combination of NE	[combination of NE]	1.5849625007211563	3	1	0	0
9029	1520	t(8;21) myeloid leukemia	[t(8;21) myeloid leukemia]	1.5849625007211563	3	2	1	1
9030	1520	IL-2 promoter region	[IL-2 promoter region]	1.5849625007211563	3	2	1	1
9031	1520	common gamma-chain gamma(c)	[common gamma-chain gamma(c)]	1.5849625007211563	3	1	0	0
9032	1520	unphysiologically high expression	[unphysiologically high expression]	1.5849625007211563	3	1	0	0
9033	1520	cell from patient	[cells from patients]	1.5849625007211563	3	2	1	1
9034	1520	central bp repeat	[central bp repeat]	1.5849625007211563	3	2	2	2
9035	1520	pkc T cell	[PKC T cells]	1.5849625007211563	3	1	0	0
9036	1520	pu.1 mrna expression	[PU.1 mRNA expression]	1.5849625007211563	3	1	0	0
9037	1520	tpa ap-1 /oap element	[TPA AP-1 /OAP element]	1.5849625007211563	4	1	0	0
9038	1520	nm, respectively; p	[nM, respectively; P]	1.5849625007211563	3	1	0	0
9039	1520	other steroid hormone receptor	[other steroid hormone receptors]	1.5849625007211563	4	1	0	0
9040	1520	presence of extracellular egta	[presence of extracellular EGTA]	1.5849625007211563	4	1	0	0
9041	1520	transcription factor JunB	[transcription factor JunB]	1.5849625007211563	3	1	0	0
9042	1520	100 microm pyrrolidine dithiocarbamate	[100 microM pyrrolidine dithiocarbamate]	1.5849625007211563	4	1	0	0
9043	1520	physical interaction between Tax	[physical interaction between Tax]	1.5849625007211563	4	1	0	0
9044	1520	antiviral action of S9a	[antiviral action of S9a]	1.5849625007211563	4	1	0	0
9045	1520	non-depressed control subject	[non-depressed control subjects]	1.5849625007211563	3	1	0	0
9046	1520	however, activation of stat6	[However, activation of STAT6]	1.5849625007211563	4	1	0	0
9047	1520	15-amino acid transactivation sequence	[15-amino acid transactivation sequence]	1.5849625007211563	4	1	0	0
9048	1520	gdp /gtp exchange	[GDP /GTP exchange]	1.5849625007211563	3	1	0	0
9049	1520	reactivity to glucocorticoid	[reactivity to glucocorticoids]	1.5849625007211563	3	1	0	0
9050	1520	similar adhesive response	[similar adhesive response]	1.5849625007211563	3	1	0	0
9051	1520	complex of protein	[complex of proteins]	1.5849625007211563	3	1	0	0
9052	1520	use this system,	[Using this system,]	1.5849625007211563	3	1	0	0
9053	1520	Ets transcription factor family	[Ets transcription factor family]	1.5849625007211563	4	1	0	0
9054	1520	htlv-1 transactivator protein tax	[HTLV-1 transactivator protein tax]	1.5849625007211563	4	1	0	0
9055	1520	low gcr on mnl	[lowest GCR on MNL]	1.5849625007211563	4	1	0	0
9056	1520	uncharted DNA sequence	[uncharted DNA sequences]	1.5849625007211563	3	1	0	0
9057	1520	x-y regulatory element	[X-Y regulatory elements]	1.5849625007211563	3	1	0	0
9058	1520	map kinase phosphatase-1 mkp-1	[map kinase phosphatase-1 MKP-1]	1.5849625007211563	4	1	0	0
9059	1520	also NF-kappa b molecules.	[also NF-kappa B molecules.]	1.5849625007211563	4	1	0	0
9060	1520	culture of normal cell	[cultures of normal cells]	1.5849625007211563	4	1	0	0
9061	1520	human csf-1 2M-1 cell	[human CSF-1 2M-1 cells]	1.5849625007211563	4	1	0	0
9062	1520	induction of icam-1	[Induction of ICAM-1]	1.5849625007211563	3	2	2	2
9063	1520	proliferation of pbmc cell	[proliferation of PBMC cells]	1.5849625007211563	4	1	0	0
9064	1520	human MCM gene promoter	[human MCM gene promoters]	1.5849625007211563	4	1	0	0
9065	1520	various kind of cell	[various kinds of cells]	1.5849625007211563	4	2	2	2
9066	1520	interferon gamma induction pathway	[interferon gamma induction pathway]	1.5849625007211563	4	1	0	0
9067	1520	serum 135eoh)2d3 of uremia	[serum 1,25(OH)2D3 of uremia]	1.5849625007211563	4	1	0	0
9068	1520	a/r -tolerant cell	[A/R -tolerant cells]	1.5849625007211563	3	1	0	0
9069	1520	antigenic er peptide	[antigenic ER peptides]	1.5849625007211563	3	1	0	0
9070	1520	loss of ref-1	[loss of REF-1]	1.5849625007211563	3	1	0	0
9071	1520	mediate growth inhibition	[mediating growth inhibition]	1.5849625007211563	3	2	2	2
9072	1520	platelet activating factor	[platelet activating factor]	1.5849625007211563	3	1	0	0
9073	1520	mechanism at the level	[mechanism at the level]	1.5849625007211563	4	2	2	2
9074	1520	human t-cell lymphotrophic	[human T-cell lymphotrophic]	1.5849625007211563	3	1	0	0
9075	1520	transfection with C/EBP alpha	[Transfection with C/EBP alpha]	1.5849625007211563	4	1	0	0
9076	1520	c-myb in T cell	[c-myb in T cells]	1.5849625007211563	4	1	0	0
9077	1520	ah receptor tcdd receptor	[Ah receptor TCDD receptor]	1.5849625007211563	4	2	2	2
9078	1520	monocytic differentiation marker,	[monocytic differentiation marker,]	1.5849625007211563	3	1	0	0
9079	1520	amount of ag	[amount of Ag]	1.5849625007211563	3	1	0	0
9080	1520	BOX1 consensus sequence	[BOX1 consensus sequence]	1.5849625007211563	3	1	0	0
9081	1520	cleavage domain of alphaIIbH	[cleavage domain of alphaIIbH]	1.5849625007211563	4	1	0	0
9082	1520	DNA strand break	[DNA strand breaks]	1.5849625007211563	3	1	0	0
9083	1520	regulation of E2F	[Regulation of E2F]	1.5849625007211563	3	1	0	0
9084	1520	two covalently p35	[two covalently p35]	1.5849625007211563	3	1	0	0
9085	1520	group of enhancer transcript	[group of enhancer transcripts]	1.5849625007211563	4	1	0	0
9086	1520	rel-/- T cell	[Rel-/- T cells]	1.5849625007211563	3	1	0	0
9087	1520	addition, vitamin d	[addition, vitamin D]	1.5849625007211563	3	1	0	0
9088	1520	other a viral target,	[other a viral target,]	1.5849625007211563	4	1	0	0
9089	1520	hiv-1 tat protein	[HIV-1 Tat protein]	1.5849625007211563	3	2	2	2
9090	1520	hiv-1 up to 10000-fold	[HIV-1 up to 10,000-fold]	1.5849625007211563	4	1	0	0
9091	1520	STAT3 binding motif ylpq	[STAT3 binding motif YLPQ]	1.5849625007211563	4	1	0	0
9092	1520	most immature cd34+thy-1+ subset	[most immature CD34+Thy-1+ subset]	1.5849625007211563	4	1	0	0
9093	1520	malignant mammary tumor	[malignant mammary tumors]	1.5849625007211563	3	1	0	0
9094	1520	dose of 400 microM.	[dose of 400 microM.]	1.5849625007211563	4	1	0	0
9095	1520	change in glucose transport	[changes in glucose transport]	1.5849625007211563	4	1	0	0
9096	1520	human delta-globin gene promoter	[human delta-globin gene promoter]	1.5849625007211563	4	1	0	0
9097	1520	promoter function analysis,	[promoter function analysis,]	1.5849625007211563	3	1	0	0
9098	1520	biallelic of 7 patient	[biallelic of 7 patients]	1.5849625007211563	4	1	0	0
9099	1520	viral transcription factor Tax1	[viral transcription factor Tax1]	1.5849625007211563	4	1	0	0
9100	1520	b-cell neoplasia particular bl	[B-cell neoplasias particular BL]	1.5849625007211563	4	1	0	0
9101	1520	murine bone marrow	[murine bone marrow]	1.5849625007211563	3	1	0	0
9102	1520	complex binding in vitro.	[complex binding in vitro.]	1.5849625007211563	4	1	0	0
9103	1520	activation domain of CIITA	[activation domain of CIITA]	1.5849625007211563	4	2	1	1
9104	1520	DNA-protein complex common	[DNA-protein complexes common]	1.5849625007211563	3	2	2	2
9105	1520	AP-1, Sp1, nf-kappab	[AP-1, Sp1, NF-kappaB]	1.5849625007211563	3	1	0	0
9106	1520	gammac basal promoter activity	[gammac basal promoter activity]	1.5849625007211563	4	1	0	0
9107	1520	role in b-cell development	[role in B-cell development]	1.5849625007211563	4	2	1	1
9108	1520	effect of toremifene therapy	[effect of toremifene therapy]	1.5849625007211563	4	1	0	0
9109	1520	GPIX Ets site	[GPIX Ets site]	1.5849625007211563	3	1	0	0
9110	1520	p93fe catalytic activity	[p93fes catalytic activity]	1.5849625007211563	3	1	0	0
9111	1520	RA on il-2 mrna	[RA on IL-2 mRNA]	1.5849625007211563	4	1	0	0
9112	1520	transcription factor in hematopoiesis	[transcription factors in hematopoiesis]	1.5849625007211563	4	1	0	0
9113	1520	alpha-tcp decrease in activation	[alpha-tcp decrease in activation]	1.5849625007211563	4	1	0	0
9114	1520	isoform lack exon 11	[isoform lacking exon 11]	1.5849625007211563	4	1	0	0
9115	1520	alpha2 integrin enhancer	[alpha2 integrin enhancer]	1.5849625007211563	3	1	0	0
9116	1520	sickle cell disease	[sickle cell disease]	1.5849625007211563	3	2	1	1
9117	1520	signal response domain	[signal response domain]	1.5849625007211563	3	2	2	2
9118	1520	ref 1-3 respectively),	[refs 1-3 respectively),]	1.5849625007211563	3	1	0	0
9119	1520	role of rpo	[role of rpoS]	1.5849625007211563	3	1	0	0
9120	1520	essential 40-kda protein tax	[essential 40-kDa protein Tax]	1.5849625007211563	4	1	0	0
9121	1520	U1 cellular clone	[U1 cellular clone]	1.5849625007211563	3	1	0	0
9122	1520	monocyte from patient	[monocytes from patients]	1.5849625007211563	3	2	1	1
9123	1520	inability of 135(oh)2d3	[inability of 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
9124	1520	mouse developmental mutant	[mouse developmental mutants]	1.5849625007211563	3	1	0	0
9125	1520	transcription factor Stat1alpha	[transcription factors Stat1alpha]	1.5849625007211563	3	1	0	0
9126	1520	soluble peptide inhibitor	[soluble peptide inhibitor]	1.5849625007211563	3	2	1	1
9127	1520	Ribophorin I -EVI1 fusion	[Ribophorin I -EVI1 fusion]	1.5849625007211563	4	1	0	0
9128	1520	lack dna-binding alf1	[lacking DNA-binding ALF1]	1.5849625007211563	3	1	0	0
9129	1520	level of rna coding	[Levels of RNA coding]	1.5849625007211563	4	1	0	0
9130	1520	stabilization of jak3 binding	[stabilization of JAK3 binding]	1.5849625007211563	4	1	0	0
9131	1520	defective il-12 response	[defective IL-12 responses]	1.5849625007211563	3	1	0	0
9132	1520	combination of ne	[combination of NE]	1.5849625007211563	3	1	0	0
9133	1520	two novel domain	[two novel domains]	1.5849625007211563	3	1	0	0
9134	1520	ciita expression plasmid	[CIITA expression plasmid]	1.5849625007211563	3	1	0	0
9135	1520	interleukin 2 cd28-responsive complex	[interleukin 2 CD28-responsive complex]	1.5849625007211563	4	1	0	0
9136	1520	production of IgA	[production of IgA]	1.5849625007211563	3	1	0	0
9137	1520	approximately 35 kda	[approximately 35 kDa]	1.5849625007211563	3	1	0	0
9138	1520	human motor activity	[human motor activity]	1.5849625007211563	3	2	1	1
9139	1520	spite of inflammatory activity	[spite of inflammatory activity]	1.5849625007211563	4	1	0	0
9140	1520	induction of nf-kappa b	[induction of NF-kappa B]	1.5849625007211563	4	1	0	0
9141	1520	stat1 gene in t-cell	[STAT1 genes in T-cells]	1.5849625007211563	4	1	0	0
9142	1520	testis of the mouse	[testis of the mouse]	1.5849625007211563	4	1	0	0
9143	1520	inhibition of raf-1	[inhibition of Raf-1]	1.5849625007211563	3	1	0	0
9144	1520	NF-kappa b -binding activity	[NF-kappa B -binding activity]	1.5849625007211563	4	1	0	0
9145	1520	glucocorticoid on eosinophil apoptosis	[glucocorticoids on eosinophil apoptosis]	1.5849625007211563	4	1	0	0
9146	1520	active globin gene promoter	[active globin gene promoters]	1.5849625007211563	4	1	0	0
9147	1520	bacterial endotoxin lipopolysaccharide	[bacterial endotoxin lipopolysaccharide]	1.5849625007211563	3	2	1	1
9148	1520	sex determine gene sry	[sex determining gene SRY]	1.5849625007211563	4	1	0	0
9149	1520	expression of cytosolic factor	[expression of cytosolic factors]	1.5849625007211563	4	1	0	0
9150	1520	presence of 8-bromo-cAMP	[presence of 8-bromo-cAMP]	1.5849625007211563	3	1	0	0
9151	1520	mechanism regulate the maintenance	[mechanisms regulating the maintenance]	1.5849625007211563	4	1	0	0
9152	1520	mrna transcript for c-jun	[mRNA transcripts for c-jun]	1.5849625007211563	4	1	0	0
9153	1520	lymphocyte of normal subject	[lymphocytes of normal subjects]	1.5849625007211563	4	1	0	0
9154	1520	two donor (d.e.	[two donors (D.E.]	1.5849625007211563	3	1	0	0
9155	1520	T/NK developmental checkpoint	[T/NK developmental checkpoint]	1.5849625007211563	3	1	0	0
9156	1520	transcriptional activation of nf-at	[transcriptional activation of NF-AT]	1.5849625007211563	4	1	0	0
9157	1520	systemic (pbmc) hGR level	[systemic (PBMC) hGR levels]	1.5849625007211563	4	1	0	0
9158	1520	thrombin-activated human platelet	[thrombin-activated human platelets]	1.5849625007211563	3	1	0	0
9159	1520	elevation of cytosolic calcium	[elevation of cytosolic calcium]	1.5849625007211563	4	2	1	1
9160	1520	complex with the class	[complexing with the class]	1.5849625007211563	4	1	0	0
9161	1520	importance of many	[importance of many]	1.5849625007211563	3	1	0	0
9162	1520	Per-Arnt-Sim (PAS) homology region	[Per-Arnt-Sim (PAS) homology region]	1.5849625007211563	4	1	0	0
9163	1520	5.5-kilobase genomic clone	[5.5-kilobase genomic clone]	1.5849625007211563	3	1	0	0
9164	1520	Yet, IL-2 proliferation	[Yet, IL-2 proliferation]	1.5849625007211563	3	1	0	0
9165	1520	protein kinase MAPK	[protein kinase MAPK]	1.5849625007211563	3	2	2	2
9166	1520	eb1-like gene family	[EB1-like gene family]	1.5849625007211563	3	1	0	0
9167	1520	fetus against antipaternal antibody	[fetus against antipaternal antibodies]	1.5849625007211563	4	1	0	0
9168	1520	c-erbA -dependent activation	[c-erbA -dependent activation]	1.5849625007211563	3	1	0	0
9169	1520	increase in episomal DNA	[increase in episomal DNA]	1.5849625007211563	4	1	0	0
9170	1520	29 patient with preeclampsia	[29 patients with preeclampsia]	1.5849625007211563	4	1	0	0
9171	1520	generation of b cell	[generation of B cell]	1.5849625007211563	4	1	0	0
9172	1520	finding with IkappaBbeta	[findings with IkappaBbeta]	1.5849625007211563	3	1	0	0
9173	1520	viability, erythroid cell	[viability, erythroid cells]	1.5849625007211563	3	1	0	0
9174	1520	certain developmental process	[certain developmental processes]	1.5849625007211563	3	1	0	0
9175	1520	bcl-6 protein expression	[BCL-6 protein expression]	1.5849625007211563	3	1	0	0
9176	1520	other dna-binding protein	[other DNA-binding proteins]	1.5849625007211563	3	2	1	1
9177	1520	least two cis-acting element	[least two cis-acting elements]	1.5849625007211563	4	1	0	0
9178	1520	lps il-1ra secretion	[LPS IL-1ra secretion]	1.5849625007211563	3	1	0	0
9179	1520	use a cell line	[Using a cell line]	1.5849625007211563	4	2	1	1
9180	1520	constitutive pkr activity	[Constitutive PKR activity]	1.5849625007211563	3	1	0	0
9181	1520	key VDR target gene	[key VDR target gene]	1.5849625007211563	4	1	0	0
9182	1520	role oppose macrophage differentiation	[role opposing macrophage differentiation]	1.5849625007211563	4	1	0	0
9183	1520	marker on 5q31.1	[markers on 5q31.1]	1.5849625007211563	3	1	0	0
9184	1520	il-2r beta chain expression	[IL-2R beta chain expression]	1.5849625007211563	4	1	0	0
9185	1520	programming of gene expression	[programming of gene expression]	1.5849625007211563	4	1	0	0
9186	1520	factor- bind element	[factor- binding elements]	1.5849625007211563	3	1	0	0
9187	1520	important immunoregulatory effect	[important immunoregulatory effects]	1.5849625007211563	3	1	0	0
9188	1520	317 base pair region	[317 base pair region]	1.5849625007211563	4	1	0	0
9189	1520	hiv infection in monocyte	[HIV infection in monocytes]	1.5849625007211563	4	2	1	1
9190	1520	AP-1 transcription factor complex	[AP-1 transcription factor complex]	1.5849625007211563	4	2	1	1
9191	1520	characterization of gene	[characterization of genes]	1.5849625007211563	3	1	0	0
9192	1520	potential ets binding site	[potential Ets binding sites]	1.5849625007211563	4	3	2	1
9193	1520	distinct subset of gene	[distinct subset of genes]	1.5849625007211563	4	2	1	1
9194	1520	pu.1 in cell	[PU.1 in cells]	1.5849625007211563	3	2	2	2
9195	1520	promoter activity of RANTES	[promoter activity of RANTES]	1.5849625007211563	4	1	0	0
9196	1520	inclusion of tnf-alpha	[inclusion of TNF-alpha]	1.5849625007211563	3	1	0	0
9197	1520	il-5 promoter activation	[IL-5 promoter activation]	1.5849625007211563	3	1	0	0
9198	1520	downstream signal pathway	[downstream signaling pathways]	1.5849625007211563	3	1	0	0
9199	1520	recombinant il-12 ril-12	[recombinant IL-12 rIL-12]	1.5849625007211563	3	1	0	0
9200	1520	downstream sequence element dse	[downstream sequence elements DSE]	1.5849625007211563	4	1	0	0
9201	1520	analysis of the extract	[Analysis of the extracts]	1.5849625007211563	4	2	2	2
9202	1520	bind the IL-1beta promoter	[binding the IL-1beta promoter]	1.5849625007211563	4	1	0	0
9203	1520	upregulation of cd23.	[upregulation of CD23.]	1.5849625007211563	3	1	0	0
9204	1520	absence of epo	[absence of EPO]	1.5849625007211563	3	1	0	0
9205	1520	follow ionomycin stimulation	[following ionomycin stimulation]	1.5849625007211563	3	1	0	0
9206	1520	interleukin-4 receptor alpha chain	[interleukin-4 receptor alpha chain]	1.5849625007211563	4	1	0	0
9207	1520	adenovirus nucleotide sequence	[adenovirus nucleotide sequences]	1.5849625007211563	3	1	0	0
9208	1520	clinical manifestation of thalassemia	[clinical manifestation of thalassemia]	1.5849625007211563	4	1	0	0
9209	1520	hemopoietic cell line	[hemopoietic cell lines]	1.5849625007211563	3	2	2	2
9210	1520	expression of activation marker	[expression of activation markers]	1.5849625007211563	4	1	0	0
9211	1520	(ap)-1 family protein	[(AP)-1 family proteins]	1.5849625007211563	3	1	0	0
9212	1520	transform growth factor beta	[transforming growth factor beta]	1.5849625007211563	4	2	2	2
9213	1520	RESULTS: cord lymphocyte	[RESULTS: Cord lymphocytes]	1.5849625007211563	3	1	0	0
9214	1520	clearance of plasma prednisolone	[clearance of plasma prednisolone]	1.5849625007211563	4	1	0	0
9215	1520	100 kD protein	[100 kD protein]	1.5849625007211563	3	1	0	0
9216	1520	origin of the cell	[origin of the cell]	1.5849625007211563	4	1	0	0
9217	1520	ability of this factor	[ability of these factors]	1.5849625007211563	4	1	0	0
9218	1520	indicate a translocation breakpoint	[indicating a translocation breakpoint]	1.5849625007211563	4	1	0	0
9219	1520	cytotoxic b activation	[cytotoxic B activation]	1.5849625007211563	3	1	0	0
9220	1520	second messenger pathway	[second messenger pathway]	1.5849625007211563	3	1	0	0
9221	1520	affect tissue inhibitor	[affecting tissue inhibitor]	1.5849625007211563	3	1	0	0
9222	1520	untransformed T cell clone	[untransformed T cell clone]	1.5849625007211563	4	1	0	0
9223	1520	use anti- ar antibody	[using anti- AR antibodies]	1.5849625007211563	4	1	0	0
9224	1520	hemoglobinopathybthybinobinybinybinybinybinie by transplantation	[hemoglobinopathies by transplantation]	1.5849625007211563	3	1	0	0
9225	1520	Northern (rna) blot	[Northern (RNA) blots]	1.5849625007211563	3	1	0	0
9226	1520	role determine the pattern	[role determining the patterns]	1.5849625007211563	4	1	0	0
9227	1520	NF-kappa b odn	[NF-kappa B ODNs]	1.5849625007211563	3	1	0	0
9228	1520	THP-1 cell extract	[THP-1 cell extracts]	1.5849625007211563	3	1	0	0
9229	1520	cell from joint	[cells from joints]	1.5849625007211563	3	1	0	0
9230	1520	presence of butyrate	[presence of butyrate]	1.5849625007211563	3	1	0	0
9231	1520	target gene for Oct-2	[target gene for Oct-2]	1.5849625007211563	4	1	0	0
9232	1520	mammalian sex-determining gene sry	[mammalian sex-determining gene Sry]	1.5849625007211563	4	1	0	0
9233	1520	overexpression of p65	[Overexpression of p65]	1.5849625007211563	3	1	0	0
9234	1520	expression pattern of lox-1	[expression pattern of LOX-1]	1.5849625007211563	4	1	0	0
9235	1520	intron 2 of RARA	[intron 2 of RARA]	1.5849625007211563	4	1	0	0
9236	1520	apoptosis sensitive cell line	[apoptosis sensitive cell lines]	1.5849625007211563	4	1	0	0
9237	1520	t-cell nuclear extract-DNA complex	[T-cell nuclear extract-DNA complexes]	1.5849625007211563	4	1	0	0
9238	1520	overexpression of p50	[overexpression of p50]	1.5849625007211563	3	1	0	0
9239	1520	certain subpopulation of lymphocyte	[Certain subpopulations of lymphocytes]	1.5849625007211563	4	1	0	0
9240	1520	two phosphorylation event	[two phosphorylation events]	1.5849625007211563	3	1	0	0
9241	1520	IFN -inducible gene promoter	[IFN -inducible gene promoters]	1.5849625007211563	4	1	0	0
9242	1520	combination of signal molecule	[combinations of signaling molecules]	1.5849625007211563	4	1	0	0
9243	1520	two new isoform	[Two new isoforms]	1.5849625007211563	3	2	1	1
9244	1520	other tissue-specific promoter	[other tissue-specific promoters]	1.5849625007211563	3	1	0	0
9245	1520	erythroid and/or megakaryocytic lineage	[erythroid and/or megakaryocytic lineages]	1.5849625007211563	4	1	0	0
9246	1520	designation myeloid/NK acute leukemia	[designation myeloid/NK acute leukemia]	1.5849625007211563	4	1	0	0
9247	1520	multiple oct2 isoform	[Multiple Oct2 isoforms]	1.5849625007211563	3	1	0	0
9248	1520	150 bp promoter fragment	[150 bp promoter fragment]	1.5849625007211563	4	1	0	0
9249	1520	high level of il-8	[high levels of IL-8]	1.5849625007211563	4	1	0	0
9250	1520	cDNA clone 15B-7	[cDNA clone 15B-7]	1.5849625007211563	3	1	0	0
9251	1520	antagonistic effect of gamma-ifn	[antagonistic effects of gamma-IFN]	1.5849625007211563	4	1	0	0
9252	1520	reactivity with antipeptide antibody	[reactivity with antipeptide antibodies]	1.5849625007211563	4	1	0	0
9253	1520	(day 0 hpc	[(day 0 HPCs]	1.5849625007211563	3	1	0	0
9254	1520	various level of expression	[Various levels of expression]	1.5849625007211563	4	1	0	0
9255	1520	other hematologic neoplasm	[other hematologic neoplasms]	1.5849625007211563	3	1	0	0
9256	1520	additional upstream gene segment	[Additional upstream gene segments]	1.5849625007211563	4	1	0	0
9257	1520	key role in hematopoiesis	[key role in hematopoiesis]	1.5849625007211563	4	2	2	2
9258	1520	NH2-terminal kinase activity	[NH2-terminal kinase activities]	1.5849625007211563	3	1	0	0
9259	1520	3 DNA recombination	[3 DNA recombination]	1.5849625007211563	3	1	0	0
9260	1520	development of nrd	[development of NRDS]	1.5849625007211563	3	1	0	0
9261	1520	promoter of cytokine	[promoters of cytokines]	1.5849625007211563	3	2	2	2
9262	1520	physiologic oxidative condition	[physiologic oxidative conditions]	1.5849625007211563	3	1	0	0
9263	1520	human microvessel cell	[human microvessel cells]	1.5849625007211563	3	2	2	2
9264	1520	effect on tpa activation	[effect on TPA activation]	1.5849625007211563	4	1	0	0
9265	1520	classical interferon-gamma-activated site	[classical interferon-gamma-activated site]	1.5849625007211563	3	1	0	0
9266	1520	substantial number of cell	[substantial number of cells]	1.5849625007211563	4	1	0	0
9267	1520	human il-4 receptor	[human IL-4 receptor]	1.5849625007211563	3	2	2	2
9268	1520	response to CSF	[response to CSF]	1.5849625007211563	3	1	0	0
9269	1520	most proximal region	[most proximal region]	1.5849625007211563	3	1	0	0
9270	1520	very low glycoprotein iib	[very low glycoprotein IIb]	1.5849625007211563	4	1	0	0
9271	1520	evaluation of signal pathway	[evaluation of signaling pathways]	1.5849625007211563	4	1	0	0
9272	1520	supramaximal dose of cerulein	[supramaximal dose of cerulein]	1.5849625007211563	4	1	0	0
9273	1520	reactive oxygen production	[reactive oxygen production]	1.5849625007211563	3	2	1	1
9274	1520	fetal murine thymus	[Fetal murine thymus]	1.5849625007211563	3	1	0	0
9275	1520	monoblastoid u937 cell	[monoblastoid U937 cells]	1.5849625007211563	3	1	0	0
9276	1520	expression of stat1 gene	[expression of STAT1 genes]	1.5849625007211563	4	1	0	0
9277	1520	adjacent promoter element	[adjacent promoter elements]	1.5849625007211563	3	1	0	0
9278	1520	comedo versus noncomedo status	[comedo versus noncomedo status]	1.5849625007211563	4	1	0	0
9279	1520	majority of the apc	[majority of the APCs]	1.5849625007211563	4	1	0	0
9280	1520	increase in dna-binding activity	[increase in DNA-binding activity]	1.5849625007211563	4	1	0	0
9281	1520	change in ion flux	[changes in ion fluxes]	1.5849625007211563	4	1	0	0
9282	1520	lack of overexpression	[lack of overexpression]	1.5849625007211563	3	1	0	0
9283	1520	translation of cytokine	[translation of cytokines]	1.5849625007211563	3	1	0	0
9284	1520	absence of ebna2 rrna	[absence of EBNA2 mRNAs]	1.5849625007211563	4	1	0	0
9285	1520	design of therapy	[design of therapies]	1.5849625007211563	3	2	2	2
9286	1520	gc of pharmacological dose	[GC of pharmacological doses]	1.5849625007211563	4	1	0	0
9287	1520	additional enhancer element	[additional enhancer elements]	1.5849625007211563	3	1	0	0
9288	1520	Ag receptor cross-linking	[Ag receptor cross-linking]	1.5849625007211563	3	1	0	0
9289	1520	specific inhibitor of erk	[specific inhibitor of ERK]	1.5849625007211563	4	1	0	0
9290	1520	isoform of NFATx NFATx1	[isoform of NFATx NFATx1]	1.5849625007211563	4	1	0	0
9291	1520	transcriptional activity in vivo	[transcriptional activity in vivo]	1.5849625007211563	4	1	0	0
9292	1520	untreated jurkat cell	[untreated Jurkat cells]	1.5849625007211563	3	1	0	0
9293	1520	macrophage inflammatory protein-2 mip-2	[macrophage inflammatory protein-2 MIP-2]	1.5849625007211563	4	1	0	0
9294	1520	transcription factor pertinent	[transcription factor pertinent]	1.5849625007211563	3	1	0	0
9295	1520	jun B rrna	[jun B mRNAs]	1.5849625007211563	3	1	0	0
9296	1520	novel gene in 3q21	[novel gene in 3q21]	1.5849625007211563	4	1	0	0
9297	1520	important role in activation	[important role in activation]	1.5849625007211563	4	2	2	2
9298	1520	nuclear translocation of STAT3	[nuclear translocation of STAT3]	1.5849625007211563	4	1	0	0
9299	1520	-141 base pair	[-141 base pairs]	1.5849625007211563	3	1	0	0
9300	1520	CD8 /hla class	[CD8 /HLA class]	1.5849625007211563	3	1	0	0
9301	1520	recruitment of T cell	[Recruitment of T cells]	1.5849625007211563	4	1	0	0
9302	1520	kit ligand cotreatment	[kit ligand cotreatment]	1.5849625007211563	3	1	0	0
9303	1520	activation of interleukin gene	[activation of interleukin gene]	1.5849625007211563	4	2	2	2
9304	1520	phagocytosis of apoptotic cell	[phagocytosis of apoptotic cells]	1.5849625007211563	4	1	0	0
9305	1520	interleukin-2 il-2 expression	[interleukin-2 IL-2 expression]	1.5849625007211563	3	1	0	0
9306	1520	T leukemic cell line	[T leukemic cell line]	1.5849625007211563	4	1	0	0
9307	1520	phosphorylation of stat1	[phosphorylation of Stat1]	1.5849625007211563	3	1	0	0
9308	1520	phosphorylation of stat3	[phosphorylation of STAT3]	1.5849625007211563	3	2	2	2
9309	1520	stimulus of T cell	[stimuli of T cells]	1.5849625007211563	4	2	2	2
9310	1520	IL-4 signal molecule	[IL-4 signaling molecules]	1.5849625007211563	3	1	0	0
9311	1520	purine-box regulator operate	[purine-box regulator operating]	1.5849625007211563	3	1	0	0
9312	1520	T cell-receptor engagement	[T cell-receptor engagement]	1.5849625007211563	3	1	0	0
9313	1520	signal pathway for tlr2	[signaling pathway for TLR2]	1.5849625007211563	4	1	0	0
9314	1520	range of precursor frequency	[range of precursor frequencies]	1.5849625007211563	4	1	0	0
9315	1520	activation of tissue-infiltrating macrophage	[activation of tissue-infiltrating macrophages]	1.5849625007211563	4	1	0	0
9316	1520	selective pkc inhibitor	[selective PKC inhibitor]	1.5849625007211563	3	1	0	0
9317	1520	induction of nf-kappab activity	[induction of NF-kappaB activity]	1.5849625007211563	4	1	0	0
9318	1520	target of SR 31747a	[target of SR 31747A]	1.5849625007211563	4	1	0	0
9319	1520	basis of this results,	[basis of these results,]	1.5849625007211563	4	1	0	0
9320	1520	addition, transcript from TSG101	[addition, transcripts from TSG101]	1.5849625007211563	4	1	0	0
9321	1520	inhibitor of pp70s6k activation	[inhibitor of pp70S6K activation]	1.5849625007211563	4	1	0	0
9322	1520	experiment in COS-1 cell	[Experiments in COS-1 cells]	1.5849625007211563	4	1	0	0
9323	1520	short bind motif	[short binding motif]	1.5849625007211563	3	1	0	0
9324	1520	autologous thymic cell	[autologous thymic cells]	1.5849625007211563	3	1	0	0
9325	1520	mature (Jurkat) t-cell line	[mature (Jurkat) T-cell lines]	1.5849625007211563	4	1	0	0
9326	1520	change in the occupancy	[changes in the occupancy]	1.5849625007211563	4	1	0	0
9327	1520	first biochemical event	[first biochemical events]	1.5849625007211563	3	1	0	0
9328	1520	level of e1a expression	[level of E1A expression]	1.5849625007211563	4	1	0	0
9329	1520	human interleukin -12	[human interleukin -12]	1.5849625007211563	3	1	0	0
9330	1520	follow placebo administration	[following placebo administration]	1.5849625007211563	3	1	0	0
9331	1520	result of supershift analysis	[results of supershift analysis]	1.5849625007211563	4	1	0	0
9332	1520	inducible lmp-1 mutant	[inducible LMP-1 mutant]	1.5849625007211563	3	1	0	0
9333	1520	membrane-proximal region of CD40	[membrane-proximal region of CD40]	1.5849625007211563	4	1	0	0
9334	1520	cd4+ spleen T cell	[CD4+ spleen T cells]	1.5849625007211563	4	1	0	0
9335	1520	pilot gene expression	[PILOT gene expression]	1.5849625007211563	3	1	0	0
9336	1520	positive-acting factor in	[positive-acting factor in]	1.5849625007211563	3	1	0	0
9337	1520	respectively, only j393/ cd43	[respectively, only J393/ CD43]	1.5849625007211563	4	1	0	0
9338	1520	effect on differentiation	[effect on differentiation]	1.5849625007211563	3	2	2	2
9339	1520	60% similar (46% identical)	[60% similar (46% identical)]	1.5849625007211563	4	1	0	0
9340	1520	severe immunodeficiency xscid	[severe immunodeficiency XSCID]	1.5849625007211563	3	2	1	1
9341	1520	binding of EBNA-2A	[binding of EBNA-2A]	1.5849625007211563	3	1	0	0
9342	1520	IL-2 transcriptional regulation	[IL-2 transcriptional regulation]	1.5849625007211563	3	1	0	0
9343	1520	pthrp alpha promoter	[PTHrP alpha promoters]	1.5849625007211563	3	1	0	0
9344	1520	rate of transcription initiation	[rate of transcription initiation]	1.5849625007211563	4	1	0	0
9345	1520	kappa b probe	[kappa B probe]	1.5849625007211563	3	1	0	0
9346	1520	regard to molecular weight	[regard to molecular weight]	1.5849625007211563	4	1	0	0
9347	1520	entire native mr	[entire native MR]	1.5849625007211563	3	1	0	0
9348	1520	combination of nf-kappa b	[combination of NF-kappa B]	1.5849625007211563	4	1	0	0
9349	1520	bear deletion (delta)	[bearing deletions (delta)]	1.5849625007211563	3	1	0	0
9350	1520	T lymphocyte gene regulation	[T lymphocyte gene regulation]	1.5849625007211563	4	1	0	0
9351	1520	trans-activator of HTLV-I	[trans-activator of HTLV-I]	1.5849625007211563	3	1	0	0
9352	1520	trans-activator protein-responsive promoter	[trans-activator protein-responsive promoter]	1.5849625007211563	3	1	0	0
9353	1520	role for N-terminal myristylation	[role for N-terminal myristylation]	1.5849625007211563	4	1	0	0
9354	1520	here, structure-function analysis	[here, structure-function analysis]	1.5849625007211563	3	1	0	0
9355	1520	intact p105 precursor,	[intact p105 precursor,]	1.5849625007211563	3	1	0	0
9356	1520	site at base pair	[site at base pair]	1.5849625007211563	4	1	0	0
9357	1520	29 (45%) individuals,	[29 (45%) individuals,]	1.5849625007211563	3	1	0	0
9358	1520	ii-negative bare lymphocyte syndrome	[II-negative bare lymphocyte syndrome]	1.5849625007211563	4	1	0	0
9359	1520	course of viral replication	[course of viral replication]	1.5849625007211563	4	1	0	0
9360	1520	Bcl-2 family member	[Bcl-2 family members]	1.5849625007211563	3	1	0	0
9361	1520	activation of PKC/Ras- pathway	[activation of PKC/Ras- pathways]	1.5849625007211563	4	1	0	0
9362	1520	amino acid polymorphism	[amino acid polymorphism]	1.5849625007211563	3	1	0	0
9363	1520	arachidonic acid oxygenation	[arachidonic acid oxygenation]	1.5849625007211563	3	1	0	0
9364	1520	prime by IFN-gamma	[Priming by IFN-gamma]	1.5849625007211563	3	1	0	0
9365	1520	fc gamma RI transcription	[Fc gamma RI transcription]	1.5849625007211563	4	1	0	0
9366	1520	asymptomatic infection to aids	[asymptomatic infection to AIDS]	1.5849625007211563	4	1	0	0
9367	1520	patient with b-cll cell	[patients with B-CLL cells]	1.5849625007211563	4	1	0	0
9368	1520	ability of a antibody	[ability of a antibody]	1.5849625007211563	4	1	0	0
9369	1520	treatment of mononuclear leucocyte	[treatment of mononuclear leucocytes]	1.5849625007211563	4	1	0	0
9370	1520	hematopoietic transcription factor belong	[hematopoietic transcription factor belonging]	1.5849625007211563	4	1	0	0
9371	1520	importance of this site	[importance of these sites]	1.5849625007211563	4	1	0	0
9372	1520	b-lymphoid cell line	[B-lymphoid cell lines]	1.5849625007211563	3	1	0	0
9373	1520	secondary tcr stimulation	[secondary TCR stimulation]	1.5849625007211563	3	1	0	0
9374	1520	development of lymphoid malignancy	[development of lymphoid malignancies]	1.5849625007211563	4	2	1	1
9375	1520	other signal transduction pathway	[other signal transduction pathways]	1.5849625007211563	4	1	0	0
9376	1520	nuclear dna-binding protein	[nuclear DNA-binding protein]	1.5849625007211563	3	1	0	0
9377	1520	Rb in nuclear extract	[Rb in nuclear extracts]	1.5849625007211563	4	1	0	0
9378	1520	high CsA blood concentration	[high CsA blood concentrations]	1.5849625007211563	4	1	0	0
9379	1520	long clonotype persistence,	[long-term clonotype persistence,]	1.5849625007211563	3	1	0	0
9380	1520	aim identify genetic target	[aim identifying genetic targets]	1.5849625007211563	4	1	0	0
9381	1520	activation of as gene	[activation of as genes]	1.5849625007211563	4	1	0	0
9382	1520	CD19-expressing b-cell line	[CD19-expressing B-cell line]	1.5849625007211563	3	1	0	0
9383	1520	5' end a site	[5' end a site]	1.5849625007211563	4	1	0	0
9384	1520	p65 antisense phosphorothioate oligodeoxynucleotide	[p65 antisense phosphorothioate oligodeoxynucleotide]	1.5849625007211563	4	1	0	0
9385	1520	mutant defective for transactivation	[mutant defective for transactivation]	1.5849625007211563	4	1	0	0
9386	1520	intracellular il-2 receptor expression	[intracellular IL-2 receptor expression]	1.5849625007211563	4	1	0	0
9387	1520	human a gamma-globin gene	[human A gamma-globin gene]	1.5849625007211563	4	1	0	0
9388	1520	proviral transcription in cell	[proviral transcription in cells]	1.5849625007211563	4	1	0	0
9389	1520	cellular receptor level	[cellular receptor levels]	1.5849625007211563	3	2	2	2
9390	1520	level of er content	[level of ER content]	1.5849625007211563	4	1	0	0
9391	1520	tobacco smoke ts exposure	[Tobacco smoke TS exposure]	1.5849625007211563	4	1	0	0
9392	1520	STP-C488 p10-->r mutant	[STP-C488 P10-->R mutant]	1.5849625007211563	3	1	0	0
9393	1520	differentiation process of cell	[differentiation process of cells]	1.5849625007211563	4	1	0	0
9394	1520	promoter of IL-4 gene	[promoters of IL-4 genes]	1.5849625007211563	4	1	0	0
9395	1520	core promoter between bp	[core promoter between bp]	1.5849625007211563	4	1	0	0
9396	1520	human T cell blast	[human T cell blasts]	1.5849625007211563	4	1	0	0
9397	1520	aiolo transcription factor	[Aiolos transcription factor]	1.5849625007211563	3	1	0	0
9398	1520	granulocytic maturation in NB4	[granulocytic maturation in NB4]	1.5849625007211563	4	1	0	0
9399	1520	role in the trapping	[role in the trapping]	1.5849625007211563	4	1	0	0
9400	1520	phosphorylation of this residue	[phosphorylation of this residue]	1.5849625007211563	4	1	0	0
9401	1520	carry a mutation	[carrying a mutation]	1.5849625007211563	3	1	0	0
9402	1520	astrocyte factor-dependent manner	[astrocyte factor-dependent manner]	1.5849625007211563	3	1	0	0
9403	1520	murine RA -inducible	[murine RA -inducible]	1.5849625007211563	3	1	0	0
9404	1520	regulation of NFAT	[Regulation of NFAT]	1.5849625007211563	3	1	0	0
9405	1520	cytotoxic effect of tnf-alpha	[cytotoxic effects of TNF-alpha]	1.5849625007211563	4	1	0	0
9406	1520	staining of PML body	[staining of PML bodies]	1.5849625007211563	4	1	0	0
9407	1520	post hiv-1 entry	[Post HIV-1 entry]	1.5849625007211563	3	1	0	0
9408	1520	purine -rich element	[purine -rich element]	1.5849625007211563	3	1	0	0
9409	1520	cotton top tamarin	[cotton top tamarin]	1.5849625007211563	3	1	0	0
9410	1520	rdna encode ebf	[cDNAs encoding EBF]	1.5849625007211563	3	1	0	0
9411	1520	aids iblp tissue sample	[AIDS IBLP tissue samples]	1.5849625007211563	4	1	0	0
9412	1520	tyrosine kinase -dependent	[Tyrosine kinase -dependent]	1.5849625007211563	3	1	0	0
9413	1520	expression of the factor	[expression of the factors]	1.5849625007211563	4	2	2	2
9414	1520	response to this cytokine	[response to these cytokines]	1.5849625007211563	4	1	0	0
9415	1520	27 kD mobility)	[27 kD mobility)]	1.5849625007211563	3	1	0	0
9416	1520	sexually active woman	[sexually active women]	1.5849625007211563	3	1	0	0
9417	1520	closely related kinase	[closely related kinase]	1.5849625007211563	3	1	0	0
9418	1520	(s) distinct from ISGF3	[(s) distinct from ISGF3]	1.5849625007211563	4	1	0	0
9419	1520	same biological effect	[same biological effects]	1.5849625007211563	3	1	0	0
9420	1520	strong homology to motif	[strong homology to motifs]	1.5849625007211563	4	1	0	0
9421	1520	negative effect of Ras	[negative effect of Ras]	1.5849625007211563	4	1	0	0
9422	1520	micromol/L, plasma arsenic	[micromol/L, plasma arsenic]	1.5849625007211563	3	1	0	0
9423	1520	functional syk kinase	[functional Syk kinases]	1.5849625007211563	3	1	0	0
9424	1520	metabolite 2-hydroxy-4-trifluoromethylbenzoic acid htb	[metabolite 2-hydroxy-4-trifluoromethylbenzoic acid HTB]	1.5849625007211563	4	1	0	0
9425	1520	distinct cytokine -production pattern	[distinct cytokine -production patterns]	1.5849625007211563	4	1	0	0
9426	1520	sequence of gene activation	[sequence of gene activation]	1.5849625007211563	4	1	0	0
9427	1520	regrettably, recent evidence	[Regrettably, recent evidence]	1.5849625007211563	3	1	0	0
9428	1520	expression of GrpL	[Expression of GrpL]	1.5849625007211563	3	1	0	0
9429	1520	strong negative regulator	[strong negative regulator]	1.5849625007211563	3	2	1	1
9430	1520	member of a subfamily	[member of a subfamily]	1.5849625007211563	4	1	0	0
9431	1520	SS Oct-1 dna-binding abnormality	[SS Oct-1 DNA-binding abnormality]	1.5849625007211563	4	1	0	0
9432	1520	Tat tar-independent loop	[Tat tar-independent loop]	1.5849625007211563	3	1	0	0
9433	1520	protein contain two domain	[protein containing two domains]	1.5849625007211563	4	1	0	0
9434	1520	heterologous minimal promoter	[heterologous minimal promoter]	1.5849625007211563	3	1	0	0
9435	1520	individual sequence element	[individual sequence elements]	1.5849625007211563	3	1	0	0
9436	1520	identification of sequence alteration	[Identification of sequence alterations]	1.5849625007211563	4	1	0	0
9437	1520	expression of ebv protein	[expression of EBV proteins]	1.5849625007211563	4	1	0	0
9438	1520	analysis of oct2-isoform expression	[Analysis of Oct2-isoform expression]	1.5849625007211563	4	1	0	0
9439	1520	ap-1 dna-binding activity	[AP-1 DNA-binding activity]	1.5849625007211563	3	3	2	1
9440	1520	thrombin receptor mrna expression	[thrombin receptor mRNA expression]	1.5849625007211563	4	1	0	0
9441	1520	different biochemical event	[different biochemical events]	1.5849625007211563	3	1	0	0
9442	1520	patient with basal lesion	[patients with basal lesions]	1.5849625007211563	4	1	0	0
9443	1520	mrna to approximately 50	[mRNA to approximately 50]	1.5849625007211563	4	1	0	0
9444	1520	TNF alpha concentration	[TNF alpha concentrations]	1.5849625007211563	3	1	0	0
9445	1520	prerequisite for erythroid differentiation	[prerequisite for erythroid differentiation]	1.5849625007211563	4	1	0	0
9446	1520	binding to glucocorticoid	[binding to glucocorticoid]	1.5849625007211563	3	1	0	0
9447	1520	intrinsic cellular apoptosis	[intrinsic cellular apoptosis]	1.5849625007211563	3	1	0	0
9448	1520	25 normal pregnant woman	[25 normal pregnant women]	1.5849625007211563	4	1	0	0
9449	1520	induction of c-jun transcription	[induction of c-jun transcription]	1.5849625007211563	4	1	0	0
9450	1520	intense mucocutaneous melanosis	[intense mucocutaneous melanosis]	1.5849625007211563	3	1	0	0
9451	1520	cr of gr	[CR of GR]	1.5849625007211563	3	2	1	1
9452	1520	functional threshold for activation	[functional thresholds for activation]	1.5849625007211563	4	1	0	0
9453	1520	single 68-amino-acid domain	[single 68-amino-acid domain]	1.5849625007211563	3	1	0	0
9454	1520	primary cd8+ t-pll cell	[primary CD8+ T-PLL cells]	1.5849625007211563	4	1	0	0
9455	1520	HTLV-I LTR gene expression	[HTLV-I LTR gene expression]	1.5849625007211563	4	1	0	0
9456	1520	tsc2 gene on chromosome	[TSC2 gene on chromosome]	1.5849625007211563	4	1	0	0
9457	1520	result in a pattern	[resulting in a pattern]	1.5849625007211563	4	1	0	0
9458	1520	additional 50% hcss	[additional 50% HCSs]	1.5849625007211563	3	1	0	0
9459	1520	kappa 3 binding factor	[kappa 3 binding factor]	1.5849625007211563	4	1	0	0
9460	1520	inhibition of interleukin-2 production	[inhibition of interleukin-2 production]	1.5849625007211563	4	1	0	0
9461	1520	splenocyte blastogenic response	[splenocyte blastogenic responses]	1.5849625007211563	3	1	0	0
9462	1520	effect of rapamycin o.,	[effects of rapamycin on,]	1.5849625007211563	4	1	0	0
9463	1520	advantage of a panel	[advantage of a panel]	1.5849625007211563	4	1	0	0
9464	1520	transcriptional activator META	[transcriptional activator META]	1.5849625007211563	3	1	0	0
9465	1520	same dose of staurosporine	[same dose of staurosporine]	1.5849625007211563	4	1	0	0
9466	1520	eosinophil gene expression	[eosinophil gene expression]	1.5849625007211563	3	1	0	0
9467	1520	case of th2 response	[case of Th2 responses]	1.5849625007211563	4	1	0	0
9468	1520	distinct regulatory signal	[distinct regulatory signals]	1.5849625007211563	3	1	0	0
9469	1520	proinflammatory cytokine release	[proinflammatory cytokine release]	1.5849625007211563	3	1	0	0
9470	1520	human cancer lncap cell	[human cancer LNCaP cells]	1.5849625007211563	4	2	1	1
9471	1520	concentration of each agent,	[concentrations of each agent,]	1.5849625007211563	4	1	0	0
9472	1520	possible t/nk-cell phenotype	[possible T/NK-cell phenotype]	1.5849625007211563	3	1	0	0
9473	1520	inhibit effect of IL-4	[inhibiting effect of IL-4]	1.5849625007211563	4	1	0	0
9474	1520	assess DNA synthesis	[assessing DNA synthesis]	1.5849625007211563	3	1	0	0
9475	1520	presence of 1 alpha,25(OH)2D3	[presence of 1 alpha,25(OH)2D3]	1.5849625007211563	4	1	0	0
9476	1520	homologous gene encode CD11a	[homologous genes encoding CD11a]	1.5849625007211563	4	1	0	0
9477	1520	encode the ciita trans-activator	[encoding the CIITA trans-activator]	1.5849625007211563	4	1	0	0
9478	1520	natural ligands, glucocorticosteroids	[natural ligands, glucocorticosteroids]	1.5849625007211563	3	1	0	0
9479	1520	particular allelic form	[particular allelic form]	1.5849625007211563	3	1	0	0
9480	1520	transfection of cell	[Transfection of cells]	1.5849625007211563	3	1	0	0
9481	1520	complex of signal molecule	[complex of signaling molecules]	1.5849625007211563	4	1	0	0
9482	1520	function of glutathione	[Functions of glutathione]	1.5849625007211563	3	1	0	0
9483	1520	patient upon DFX	[patients upon DFX]	1.5849625007211563	3	1	0	0
9484	1520	effect of e3330	[effect of E3330]	1.5849625007211563	3	2	2	2
9485	1520	potentially tissue-damaging granulocyte	[potentially tissue-damaging granulocytes]	1.5849625007211563	3	1	0	0
9486	1520	S-phase p107 complex	[S-phase p107 complex]	1.5849625007211563	3	1	0	0
9487	1520	native form of STAT-1	[native forms of STAT-1]	1.5849625007211563	4	1	0	0
9488	1520	inhibition of each event	[inhibition of each event]	1.5849625007211563	4	1	0	0
9489	1520	therapeutic benefit for individual	[therapeutic benefits for individuals]	1.5849625007211563	4	1	0	0
9490	1520	total number of colony	[total number of colonies]	1.5849625007211563	4	1	0	0
9491	1520	patient with pregnancy-induced hypertension	[patients with pregnancy-induced hypertension]	1.5849625007211563	4	1	0	0
9492	1520	mutation in tbp	[mutation in TBP]	1.5849625007211563	3	2	1	1
9493	1520	FKBP52 in SML	[FKBP52 in SML]	1.5849625007211563	3	1	0	0
9494	1520	process of signal-induced activation	[process of signal-induced activation]	1.5849625007211563	4	1	0	0
9495	1520	hypercalcemic effect for zk157202	[hypercalcemic effect for ZK157202]	1.5849625007211563	4	1	0	0
9496	1520	intermediate stage of differentiation	[intermediate stage of differentiation]	1.5849625007211563	4	2	2	2
9497	1520	other regulatory pathway	[other regulatory pathways]	1.5849625007211563	3	1	0	0
9498	1520	least 120 minute	[least 120 min]	1.5849625007211563	3	1	0	0
9499	1520	protein kinase activity	[protein kinase activities]	1.5849625007211563	3	2	2	2
9500	1520	-850 upstream of cp	[-850 upstream of Cp]	1.5849625007211563	4	1	0	0
9501	1520	overexpression of the gene,	[overexpression of the gene,]	1.5849625007211563	4	1	0	0
9502	1520	overexpression of the gene.	[overexpression of the gene.]	1.5849625007211563	4	1	0	0
9503	1520	b-cell-specific transcription factor pu.1/spi-1	[B-cell-specific transcription factor PU.1/Spi-1]	1.5849625007211563	4	1	0	0
9504	1520	other t-cell leukemia	[other T-cell leukemias]	1.5849625007211563	3	1	0	0
9505	1520	human impdh type	[human IMPDH type]	1.5849625007211563	3	1	0	0
9506	1520	putative pu.1 binding site	[putative PU.1 binding sites]	1.5849625007211563	4	1	0	0
9507	1520	novel effector of lmp-1	[novel effector of LMP-1]	1.5849625007211563	4	1	0	0
9508	1520	effect of CD4 trigger	[effect of CD4 triggering]	1.5849625007211563	4	1	0	0
9509	1520	combination of NF-kappa b	[combination of NF-kappa B]	1.5849625007211563	4	1	0	0
9510	1520	certain type of lymphoblast	[certain types of lymphoblasts]	1.5849625007211563	4	1	0	0
9511	1520	one female patient	[one female patient]	1.5849625007211563	3	1	0	0
9512	1520	12 nodular sclerosis	[12 nodular sclerosis]	1.5849625007211563	3	1	0	0
9513	1520	DNA methylation change	[DNA methylation changes]	1.5849625007211563	3	2	1	1
9514	1520	downregulation of les-induced ap-1	[Downregulation of LPS-induced AP-1]	1.5849625007211563	4	1	0	0
9515	1520	nf-kappab p50-p65 recruitment	[NF-kappaB p50-p65 recruitment]	1.5849625007211563	3	1	0	0
9516	1520	Addition of rIL-2	[Addition of rIL-2]	1.5849625007211563	3	1	0	0
9517	1520	up-regulation of il-1beta message	[up-regulation of IL-1beta message]	1.5849625007211563	4	1	0	0
9518	1520	Xq13 region carry XIC/XIST	[Xq13 region carrying XIC/XIST]	1.5849625007211563	4	1	0	0
9519	1520	induction of the NFkappaB	[induction of the NFkappaB]	1.5849625007211563	4	1	0	0
9520	1520	differentiation of t-helper lymphocyte	[Differentiation of T-helper lymphocytes]	1.5849625007211563	4	1	0	0
9521	1520	androgen receptor gene mutation	[androgen receptor gene mutations]	1.5849625007211563	4	1	0	0
9522	1520	kappa immunoglobulin germline promoter	[kappa immunoglobulin germline promoter]	1.5849625007211563	4	1	0	0
9523	1520	site of extravascular inflammation	[sites of extravascular inflammation]	1.5849625007211563	4	1	0	0
9524	1520	lt tnf-beta gene induction	[LT TNF-beta gene induction]	1.5849625007211563	4	1	0	0
9525	1520	loop length restriction	[loop length restriction]	1.5849625007211563	3	1	0	0
9526	1520	propagation of signal	[Propagation of signals]	1.5849625007211563	3	1	0	0
9527	1520	DRA promoter the x2-box	[DRA promoter the X2-box]	1.5849625007211563	4	1	0	0
9528	1520	regulation of NGAL	[regulation of NGAL]	1.5849625007211563	3	1	0	0
9529	1520	active suppression result	[active suppression resulting]	1.5849625007211563	3	1	0	0
9530	1520	presence of only p50	[presence of only p50]	1.5849625007211563	4	1	0	0
9531	1520	src kinase p56(lck)	[Src kinase p56(lck)]	1.5849625007211563	3	1	0	0
9532	1520	T cell at site	[T cells at sites]	1.5849625007211563	4	1	0	0
9533	1520	regulate interleukin-1 production	[regulating interleukin-1 production]	1.5849625007211563	3	1	0	0
9534	1520	CpG-rich island suggest expression	[CpG-rich island suggesting expression]	1.5849625007211563	4	1	0	0
9535	1520	monocyte activate signal	[monocyte activating signal]	1.5849625007211563	3	1	0	0
9536	1520	only x box region	[only X box region]	1.5849625007211563	4	1	0	0
9537	1520	CD40 ligand -positive	[CD40 ligand -positive]	1.5849625007211563	3	1	0	0
9538	1520	ebna-2 -positive cell extract	[EBNA-2 -positive cell extracts]	1.5849625007211563	4	1	0	0
9539	1520	critical cysteine residue	[critical cysteine residue]	1.5849625007211563	3	1	0	0
9540	1520	various cellular stimulus	[various cellular stimuli]	1.5849625007211563	3	2	1	1
9541	1520	mouse tnf-alpha gene	[mouse TNF-alpha gene]	1.5849625007211563	3	1	0	0
9542	1520	absence of NF-kappaB site	[absence of NF-kappaB sites]	1.5849625007211563	4	1	0	0
9543	1520	control beta-actin gene promoter	[control beta-actin gene promoter]	1.5849625007211563	4	1	0	0
9544	1520	inactive x chromosome	[inactive X chromosome]	1.5849625007211563	3	2	2	2
9545	1520	such proteasome activation	[Such proteasome activation]	1.5849625007211563	3	1	0	0
9546	1520	much broad range	[much broader range]	1.5849625007211563	3	1	0	0
9547	1520	Rel-deficient T cell	[Rel-deficient T cells]	1.5849625007211563	3	1	0	0
9548	1520	effect of protease inhibitor	[effects of protease inhibitors]	1.5849625007211563	4	1	0	0
9549	1520	immediate-early antigen bzlf1	[immediate-early antigen BZLF1]	1.5849625007211563	3	1	0	0
9550	1520	new mouse gene	[new mouse gene]	1.5849625007211563	3	2	1	1
9551	1520	CD4 cell activation	[CD4 cell activation]	1.5849625007211563	3	1	0	0
9552	1520	granulocyte macrophage colony-stimumulatelany-stg factor	[granulocyte macrophage colony-stimulating factor]	1.5849625007211563	4	1	0	0
9553	1520	human thymus lobule	[human thymus lobules]	1.5849625007211563	3	1	0	0
9554	1520	direct effect on hemoglobinization	[direct effect on hemoglobinization]	1.5849625007211563	4	1	0	0
9555	1520	T cell recognize antigen	[T cells recognizing antigens]	1.5849625007211563	4	1	0	0
9556	1520	phytohemagglutinin pha lymphocyte	[phytohemagglutinin PHA lymphocytes]	1.5849625007211563	3	1	0	0
9557	1520	even distribution between cytosol	[even distribution between cytosol]	1.5849625007211563	4	1	0	0
9558	1520	two CAGGTG e-box	[Two CAGGTG E-boxes]	1.5849625007211563	3	1	0	0
9559	1520	b-cell maturation pattern	[B-cell maturation pattern]	1.5849625007211563	3	1	0	0
9560	1520	effect on the rate	[effect on the rates]	1.5849625007211563	4	1	0	0
9561	1520	PMA dependent manner	[PMA dependent manner]	1.5849625007211563	3	1	0	0
9562	1520	putative peptide contact site	[putative peptide contact site]	1.5849625007211563	4	1	0	0
9563	1520	[3h]dexamethasone of gr mrna	[[3H]dexamethasone of GR mRNA]	1.5849625007211563	4	1	0	0
9564	1520	number of study	[number of studies]	1.5849625007211563	3	2	1	1
9565	1520	few week (>26	[few weeks (>26]	1.5849625007211563	3	1	0	0
9566	1520	mouse il-2r alpha gene	[mouse IL-2R alpha gene]	1.5849625007211563	4	1	0	0
9567	1520	transcriptional regulation of c-jun	[transcriptional regulation of c-jun]	1.5849625007211563	4	1	0	0
9568	1520	minute of stimulation	[min of stimulation]	1.5849625007211563	3	2	2	2
9569	1520	property of oka	[property of OKA]	1.5849625007211563	3	1	0	0
9570	1520	reactive follicular hyperplasias	[reactive follicular hyperplasias]	1.5849625007211563	3	2	1	1
9571	1520	response to GM-CSF	[response to GM-CSF]	1.5849625007211563	3	2	1	1
9572	1520	unusually high transcriptional activity	[unusually high transcriptional activity]	1.5849625007211563	4	1	0	0
9573	1520	synovium in rheumatoid arthritis	[synovium in rheumatoid arthritis]	1.5849625007211563	4	1	0	0
9574	1520	metastatic suppressor gene	[metastatic suppressor gene]	1.5849625007211563	3	2	1	1
9575	1520	(2) vzv gE	[(2) VZV gE]	1.5849625007211563	3	1	0	0
9576	1520	erythroid lineage cell	[erythroid lineage cells]	1.5849625007211563	3	1	0	0
9577	1520	transcriptional activity of ap1	[transcriptional activity of AP1]	1.5849625007211563	4	1	0	0
9578	1520	induction of ap-1 activity	[induction of AP-1 activity]	1.5849625007211563	4	1	0	0
9579	1520	many transcription factor	[Many transcription factors]	1.5849625007211563	3	1	0	0
9580	1520	e2f DNA binding site	[E2F DNA binding site]	1.5849625007211563	4	1	0	0
9581	1520	characterization of a cofactor	[Characterization of a cofactor]	1.5849625007211563	4	1	0	0
9582	1520	gamma globin gene	[gamma globin genes]	1.5849625007211563	3	1	0	0
9583	1520	first a/r challenge	[first A/R challenges]	1.5849625007211563	3	1	0	0
9584	1520	human hla-dq heterodimer	[human HLA-DQ heterodimer]	1.5849625007211563	3	1	0	0
9585	1520	exposure of monocyte	[exposure of monocytes]	1.5849625007211563	3	2	2	2
9586	1520	bona fide th2 cell	[bona fide Th2 cells]	1.5849625007211563	4	1	0	0
9587	1520	expression of either	[expression of either]	1.5849625007211563	3	1	0	0
9588	1520	stat (signal transducer	[STAT (signal transducers]	1.5849625007211563	3	2	1	1
9589	1520	oligomerized NFAT-1 bind motif	[oligomerized NFAT-1 binding motif]	1.5849625007211563	4	1	0	0
9590	1520	potential utility of agent	[potential utility of agents]	1.5849625007211563	4	1	0	0
9591	1520	use the catalytic subunit	[using the catalytic subunit]	1.5849625007211563	4	1	0	0
9592	1520	intact dna-binding domain	[intact DNA-binding domains]	1.5849625007211563	3	1	0	0
9593	1520	Finally, receptor cluster	[Finally, receptor clusters]	1.5849625007211563	3	1	0	0
9594	1520	various other genes,	[Various other genes,]	1.5849625007211563	3	1	0	0
9595	1520	important signal molecule capable	[important signaling molecule capable]	1.5849625007211563	4	1	0	0
9596	1520	transcription factor myod	[transcription factors MyoD]	1.5849625007211563	3	1	0	0
9597	1520	human leukemia hl60 cell	[Human leukemia HL60 cells]	1.5849625007211563	4	1	0	0
9598	1520	hiv provirus in monocyte	[HIV provirus in monocytes]	1.5849625007211563	4	1	0	0
9599	1520	several multicomponent cytokine receptor	[several multicomponent cytokine receptors]	1.5849625007211563	4	1	0	0
9600	1520	cell of low multinuclearity	[cells of low multinuclearity]	1.5849625007211563	4	1	0	0
9601	1520	il-2 -produce cell	[IL-2 -producing cells]	1.5849625007211563	3	2	2	2
9602	1520	low nuclear stat6 activity	[low nuclear STAT6 activity]	1.5849625007211563	4	1	0	0
9603	1520	RA receptor activation	[RA receptor activation]	1.5849625007211563	3	1	0	0
9604	1520	few inducible genes,	[few inducible genes,]	1.5849625007211563	3	1	0	0
9605	1520	expression of functional gene	[expression of functional genes]	1.5849625007211563	4	1	0	0
9606	1520	hla class expression	[HLA class expression]	1.5849625007211563	3	2	2	2
9607	1520	E2F -dependent activation	[E2F -dependent activation]	1.5849625007211563	3	1	0	0
9608	1520	antibody supershift experiment	[antibody supershift experiments]	1.5849625007211563	3	2	1	1
9609	1520	blood lactate concentration	[blood lactate concentrations]	1.5849625007211563	3	2	2	2
9610	1520	cell-cycle control of yeast	[cell-cycle control of yeast]	1.5849625007211563	4	1	0	0
9611	1520	cr group of patient	[CR group of patients]	1.5849625007211563	4	1	0	0
9612	1520	broad spectrum of antibody	[broad spectrum of antibodies]	1.5849625007211563	4	1	0	0
9613	1520	chromosome band 7q21-q22	[chromosome bands 7q21-q22]	1.5849625007211563	3	1	0	0
9614	1520	about a twofold increase	[about a twofold increase]	1.5849625007211563	4	1	0	0
9615	1520	second gcr gcrbeta	[second GCR GCRbeta]	1.5849625007211563	3	1	0	0
9616	1520	histogenesis of the lesion	[histogenesis of the lesion]	1.5849625007211563	4	1	0	0
9617	1520	plasma membrane receptor	[plasma membrane receptors]	1.5849625007211563	3	2	2	2
9618	1520	rapid transcriptional activation	[rapid transcriptional activation]	1.5849625007211563	3	2	2	2
9619	1520	lps (100 ng/ml)	[LPS (100 ng/ml)]	1.5849625007211563	3	1	0	0
9620	1520	first two footprint	[first two footprints]	1.5849625007211563	3	1	0	0
9621	1520	such repressive function	[Such repressive function]	1.5849625007211563	3	1	0	0
9622	1520	immunoregulatory property of prolactin	[immunoregulatory properties of prolactin]	1.5849625007211563	4	1	0	0
9623	1520	supplementation of selenium	[supplementation of selenium]	1.5849625007211563	3	1	0	0
9624	1520	factor to cognate site	[factor to cognate site]	1.5849625007211563	4	1	0	0
9625	1520	level of c-jun tre	[levels of c-jun TRE]	1.5849625007211563	4	1	0	0
9626	1520	adult globin gene expression	[adult globin gene expression]	1.5849625007211563	4	1	0	0
9627	1520	5' LCR regulatory region	[5' LCR regulatory region]	1.5849625007211563	4	1	0	0
9628	1520	ostensible immune stimulation	[ostensible immune stimulation]	1.5849625007211563	3	1	0	0
9629	1520	B29 sequence BCS	[B29 sequence BCS]	1.5849625007211563	3	1	0	0
9630	1520	trigger multiple signal pathway	[triggering multiple signaling pathways]	1.5849625007211563	4	1	0	0
9631	1520	inositol-1,4,5-trisphosphate /calcium pathway	[inositol-1,4,5-trisphosphate /calcium pathway]	1.5849625007211563	3	1	0	0
9632	1520	adherent population of cells,	[adherent population of cells,]	1.5849625007211563	4	1	0	0
9633	1520	site of regulation	[site of regulation]	1.5849625007211563	3	2	2	2
9634	1520	repression of LTR expression	[repression of LTR expression]	1.5849625007211563	4	1	0	0
9635	1520	anti-Tat single-chain intrabody	[anti-Tat single-chain intrabodies]	1.5849625007211563	3	1	0	0
9636	1520	filaria-induced lymphatic pathology LP	[filaria-induced lymphatic pathology LP]	1.5849625007211563	4	1	0	0
9637	1520	differentiation of cd34+ cell	[differentiation of CD34+ cells]	1.5849625007211563	4	2	2	2
9638	1520	(the hth recognition helix	[(the HTH recognition helix]	1.5849625007211563	4	1	0	0
9639	1520	RA (ligand)-binding domain	[RA (ligand)-binding domains]	1.5849625007211563	3	1	0	0
9640	1520	aids-related non-hodgkin' lymphoma	[AIDS-related non-Hodgkin's lymphoma]	1.5849625007211563	3	2	2	2
9641	1520	contribution of the domain	[contribution of the domains]	1.5849625007211563	4	2	2	2
9642	1520	finding under NF-kappaB control	[finding under NF-kappaB control]	1.5849625007211563	4	1	0	0
9643	1520	certain interaction between tbp	[Certain interactions between TBP]	1.5849625007211563	4	1	0	0
9644	1520	expression of Grf40	[Expression of Grf40]	1.5849625007211563	3	1	0	0
9645	1520	pathogenesis of neoplasia er	[pathogenesis of neoplasia ER]	1.5849625007211563	4	1	0	0
9646	1520	protein traf1 by proteolysis.	[protein TRAF1 by proteolysis.]	1.5849625007211563	4	1	0	0
9647	1520	nf-kappa b -related protein	[NF-kappa B -related proteins]	1.5849625007211563	4	1	0	0
9648	1520	C/EBP gene family	[C/EBP gene family]	1.5849625007211563	3	1	0	0
9649	1520	look at ganglioside	[Looking at gangliosides]	1.5849625007211563	3	1	0	0
9650	1520	half-life of c-jun transcript	[half-life of c-jun transcripts]	1.5849625007211563	4	1	0	0
9651	1520	membrane-proximal TRAF6 interaction domain	[membrane-proximal TRAF6 interaction domain]	1.5849625007211563	4	1	0	0
9652	1520	response to okadaic acid	[response to okadaic acid]	1.5849625007211563	4	1	0	0
9653	1520	number of myeloid promoter	[number of myeloid promoters]	1.5849625007211563	4	1	0	0
9654	1520	role of Egr-1	[role of Egr-1]	1.5849625007211563	3	1	0	0
9655	1520	selective pressures; activation	[selective pressures; activation]	1.5849625007211563	3	1	0	0
9656	1520	impact on the level	[impact on the level]	1.5849625007211563	4	1	0	0
9657	1520	major depressive disorder patient	[major depressive disorder patients]	1.5849625007211563	4	1	0	0
9658	1520	classical hla antigen	[classical HLA antigens]	1.5849625007211563	3	1	0	0
9659	1520	development of lymphocyte	[development of lymphocytes]	1.5849625007211563	3	1	0	0
9660	1520	Addition of KCl	[Addition of KCl]	1.5849625007211563	3	1	0	0
9661	1520	use of DNase	[use of DNase]	1.5849625007211563	3	1	0	0
9662	1520	putative human oncogene bcl-3	[putative human oncogene bcl-3]	1.5849625007211563	4	1	0	0
9663	1520	leukemic cell transformation	[leukemic cell transformation]	1.5849625007211563	3	1	0	0
9664	1520	determination of the level	[determination of the levels]	1.5849625007211563	4	1	0	0
9665	1520	IL-2 mrna production	[IL-2 mRNA production]	1.5849625007211563	3	1	0	0
9666	1520	putative AML1 -binding site	[putative AML1 -binding site]	1.5849625007211563	4	1	0	0
9667	1520	chloramphenicol acetyltransferase -express plasmid	[chloramphenicol acetyltransferase -expressing plasmid]	1.5849625007211563	4	1	0	0
9668	1520	structure of a gene	[structure of a gene]	1.5849625007211563	4	1	0	0
9669	1520	six viral antigen EBNAs	[six viral antigen EBNAs]	1.5849625007211563	4	2	2	2
9670	1520	nongenomic signal pathway	[nongenomic signaling pathways]	1.5849625007211563	3	2	1	1
9671	1520	expression of TCRzeta	[expression of TCRzeta]	1.5849625007211563	3	1	0	0
9672	1520	sea urchin protein tsap	[sea urchin protein TSAP]	1.5849625007211563	4	1	0	0
9673	1520	vitro production of mediator	[vitro production of mediators]	1.5849625007211563	4	1	0	0
9674	1520	involvement in transcription	[involvement in transcription]	1.5849625007211563	3	2	2	2
9675	1520	ie, gelatinase granule	[ie, gelatinase granules]	1.5849625007211563	3	1	0	0
9676	1520	analysis of the regulation	[Analysis of the regulation]	1.5849625007211563	4	2	1	1
9677	1520	two positive case	[two positive cases]	1.5849625007211563	3	1	0	0
9678	1520	Jak1 -dependent intracellular signal	[Jak1 -dependent intracellular signals]	1.5849625007211563	4	1	0	0
9679	1520	kinase 3 jak3	[kinase 3 JAK3]	1.5849625007211563	3	1	0	0
9680	1520	mrp14 promoter activity	[MRP14 promoter activity]	1.5849625007211563	3	1	0	0
9681	1520	induction of IL-1 beta	[induction of IL-1 beta]	1.5849625007211563	4	1	0	0
9682	1520	T cell specific-transcription	[T cell specific-transcription]	1.5849625007211563	3	1	0	0
9683	1520	inflammatory gene product	[inflammatory gene products]	1.5849625007211563	3	1	0	0
9684	1520	impaired immunoglobulin gene expression	[impaired immunoglobulin gene expression]	1.5849625007211563	4	1	0	0
9685	1520	heart to thyroid hormone	[heart to thyroid hormones]	1.5849625007211563	4	1	0	0
9686	1520	dephosphorylated form of nfatp	[dephosphorylated form of NFATp]	1.5849625007211563	4	1	0	0
9687	1520	several b-cell-specific gene	[several B-cell-specific genes]	1.5849625007211563	3	1	0	0
9688	1520	six antigen EBNAs	[six antigen EBNAs]	1.5849625007211563	3	2	2	2
9689	1520	1 transcription in vitro	[1 transcription in vitro]	1.5849625007211563	4	1	0	0
9690	1520	general approach for regulation	[general approach for regulation]	1.5849625007211563	4	1	0	0
9691	1520	potential regulatory sequence	[potential regulatory sequences]	1.5849625007211563	3	1	0	0
9692	1520	modulator of inflammation	[modulator of inflammation]	1.5849625007211563	3	1	0	0
9693	1520	ebna2 dependent transactivation	[EBNA2 dependent transactivation]	1.5849625007211563	3	1	0	0
9694	1520	hypothesis, light-chain gene structure	[hypothesis, light-chain gene structure]	1.5849625007211563	4	1	0	0
9695	1520	gene encode other protein	[genes encoding other proteins]	1.5849625007211563	4	2	1	1
9696	1520	mouse thioglycollate-activated peritoneal macrophage	[mouse thioglycollate-activated peritoneal macrophages]	1.5849625007211563	4	1	0	0
9697	1520	HTLV-1 human T lymphocyte	[HTLV-1 human T lymphocytes]	1.5849625007211563	4	1	0	0
9698	1520	CD4 T lymphocyte	[CD4 T lymphocytes]	1.5849625007211563	3	2	2	2
9699	1520	bound nfatp /ap-1-dna complex	[bound NFATp /AP-1-DNA complex]	1.5849625007211563	4	1	0	0
9700	1520	multiple response region	[multiple response region]	1.5849625007211563	3	1	0	0
9701	1520	exhibit intrinsic proliferative behavior	[exhibiting intrinsic proliferative behavior]	1.5849625007211563	4	1	0	0
9702	1520	GRalpha expression vector	[GRalpha expression vector]	1.5849625007211563	3	1	0	0
9703	1520	capability of C5a	[capability of C5a]	1.5849625007211563	3	1	0	0
9704	1520	control by META	[control by META]	1.5849625007211563	3	1	0	0
9705	1520	cytokine gene induction	[cytokine gene induction]	1.5849625007211563	3	1	0	0
9706	1520	functionality of the gr	[functionality of the GR]	1.5849625007211563	4	1	0	0
9707	1520	CD40 -cd40 ligand CD40L	[CD40 -CD40 ligand CD40L]	1.5849625007211563	4	1	0	0
9708	1520	ap-1 by antioxidant	[AP-1 by antioxidants]	1.5849625007211563	3	1	0	0
9709	1520	mean number of type	[mean number of type]	1.5849625007211563	4	2	1	1
9710	1520	transcription factor stat6 IL-4STAT	[transcription factor STAT6 IL-4STAT]	1.5849625007211563	4	1	0	0
9711	1520	case of myelogenous leukaemia	[cases of myelogenous leukaemia]	1.5849625007211563	4	2	2	2
9712	1520	nuclear translocation of nf-kappab	[nuclear translocation of NF-kappaB]	1.5849625007211563	4	1	0	0
9713	1520	harbor the GM2 sequence	[harboring the GM2 sequence]	1.5849625007211563	4	1	0	0
9714	1520	small lymphocytic lymphoma	[small lymphocytic lymphoma]	1.5849625007211563	3	1	0	0
9715	1520	process of macrophage differentiation	[process of macrophage differentiation]	1.5849625007211563	4	1	0	0
9716	1520	cd36 gene promoter	[CD36 gene promoter]	1.5849625007211563	3	2	1	1
9717	1520	follow stimulation, p-creb level	[Following stimulation, P-CREB levels]	1.5849625007211563	4	1	0	0
9718	1520	p24 gag protein	[p24 gag protein]	1.5849625007211563	3	1	0	0
9719	1520	cell-specific transcription factor nf-e2	[cell-specific transcription factor NF-E2]	1.5849625007211563	4	1	0	0
9720	1520	treatment of APL cell	[treatment of APL cells]	1.5849625007211563	4	1	0	0
9721	1520	effect of cysteine thiol	[effects of cysteine thiols]	1.5849625007211563	4	1	0	0
9722	1520	process of cross	[process of cross]	1.5849625007211563	3	1	0	0
9723	1520	ca2+ /calmodulin-dependent kinase	[Ca2+ /calmodulin-dependent kinases]	1.5849625007211563	3	1	0	0
9724	1520	full length cDNA	[full length cDNA]	1.5849625007211563	3	1	0	0
9725	1520	contrast to pu.1	[contrast to PU.1]	1.5849625007211563	3	1	0	0
9726	1520	nfat transcriptional activity	[NFAT transcriptional activity]	1.5849625007211563	3	2	2	2
9727	1520	TNF alpha gene induction	[TNF alpha gene induction]	1.5849625007211563	4	1	0	0
9728	1520	effect of differanisole a	[effect of differanisole A]	1.5849625007211563	4	1	0	0
9729	1520	chromatin structure level	[chromatin structure level]	1.5849625007211563	3	1	0	0
9730	1520	immunoglobulin m (igm)-, igd-,	[immunoglobulin M (IgM)-, IgD-,]	1.5849625007211563	4	1	0	0
9731	1520	many viral promoter	[many viral promoters]	1.5849625007211563	3	1	0	0
9732	1520	4 ATL cell line	[4 ATL cell lines]	1.5849625007211563	4	1	0	0
9733	1520	impaired ultra-violet response	[impaired UV responses]	1.5849625007211563	3	1	0	0
9734	1520	human gm-csf receptor alpha	[human GM-CSF receptor alpha]	1.5849625007211563	4	1	0	0
9735	1520	deranged cholesterol feedback mechanism	[deranged cholesterol feedback mechanism]	1.5849625007211563	4	1	0	0
9736	1520	bind reaction with probe.	[binding reaction with probe.]	1.5849625007211563	4	1	0	0
9737	1520	expression of BCL-2	[expression of BCL-2]	1.5849625007211563	3	1	0	0
9738	1520	patient carry b27 antigen	[patients carrying B27 antigen]	1.5849625007211563	4	1	0	0
9739	1520	monocyte-conditioned medium MCM	[monocyte-conditioned medium MCM]	1.5849625007211563	3	1	0	0
9740	1520	elaboration of il-8 antigen	[elaboration of IL-8 antigen]	1.5849625007211563	4	1	0	0
9741	1520	organism avirulent in survival	[organism avirulent in survival]	1.5849625007211563	4	1	0	0
9742	1520	newborn hemolytic disease	[newborn hemolytic disease]	1.5849625007211563	3	1	0	0
9743	1520	short analog 433-442a	[short analog 433-442A]	1.5849625007211563	3	1	0	0
9744	1520	b cell-specific otf-2	[B cell-specific OTF-2]	1.5849625007211563	3	1	0	0
9745	1520	possibly other transcription factor	[possibly other transcription factors]	1.5849625007211563	4	1	0	0
9746	1520	overexpression of exogenous c-fo	[overexpression of exogenous c-fos]	1.5849625007211563	4	1	0	0
9747	1520	express hiv-1 tat	[expressing HIV-1 tat]	1.5849625007211563	3	1	0	0
9748	1520	moreover, platelet-activating factor	[Moreover, platelet-activating factor]	1.5849625007211563	3	1	0	0
9749	1520	prevalence of biomarker abnormality	[prevalence of biomarker abnormalities]	1.5849625007211563	4	1	0	0
9750	1520	recombinant ebna-2 expression vector	[recombinant EBNA-2 expression vectors]	1.5849625007211563	4	1	0	0
9751	1520	high frequency (30%)	[highest frequency (30%)]	1.5849625007211563	3	1	0	0
9752	1520	glucocorticoid treatment (179.7	[glucocorticoid treatment (179.7]	1.5849625007211563	3	1	0	0
9753	1520	c-myb proto-oncogene product	[c-myb proto-oncogene product]	1.5849625007211563	3	1	0	0
9754	1520	different anti-cd mab	[different anti-CD4 mAb]	1.5849625007211563	3	1	0	0
9755	1520	activation of cp	[activation of Cp]	1.5849625007211563	3	1	0	0
9756	1520	AIM activation pathway	[AIM activation pathway]	1.5849625007211563	3	1	0	0
9757	1520	nf-kappa b -induce agent	[NF-kappa B -inducing agents]	1.5849625007211563	4	1	0	0
9758	1520	other signal pathway	[other signaling pathways]	1.5849625007211563	3	2	2	2
9759	1520	small number of thymocyte	[small numbers of thymocytes]	1.5849625007211563	4	1	0	0
9760	1520	bash b cell adaptor	[BASH B cell adaptor]	1.5849625007211563	4	1	0	0
9761	1520	delayed-early viral gene	[delayed-early viral genes]	1.5849625007211563	3	1	0	0
9762	1520	response to p40tax	[response to p40tax]	1.5849625007211563	3	2	1	1
9763	1520	relationship between glucocorticoid effect	[relationship between glucocorticoid effect]	1.5849625007211563	4	1	0	0
9764	1520	human malignant melanoma study	[human malignant melanoma study]	1.5849625007211563	4	1	0	0
9765	1520	two nonfunctional mutant	[two nonfunctional mutants]	1.5849625007211563	3	1	0	0
9766	1520	transcriptional activity of hnf1	[transcriptional activity of HNF1]	1.5849625007211563	4	1	0	0
9767	1520	number of transcription factor	[number of transcription factors]	1.5849625007211563	4	1	0	0
9768	1520	pag phop gene product	[pag phoP gene product]	1.5849625007211563	4	1	0	0
9769	1520	standard culture conditions,	[standard culture conditions,]	1.5849625007211563	3	1	0	0
9770	1520	endotoxic challenge during pregnancy	[endotoxic challenge during pregnancy]	1.5849625007211563	4	1	0	0
9771	1520	Tax1 -inducible transcriptional pathway	[Tax1 -inducible transcriptional pathway]	1.5849625007211563	4	1	0	0
9772	1520	CD5+) b cell	[CD5+) B cells]	1.5849625007211563	3	1	0	0
9773	1520	relapse of disease (55.3%	[relapse of disease (55.3%]	1.5849625007211563	4	1	0	0
9774	1520	direct vesicle trafficking	[direct vesicle trafficking]	1.5849625007211563	3	1	0	0
9775	1520	1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin D3 mc903	[1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin D3 MC903]	1.5849625007211563	3	1	0	0
9776	1520	4 h of treatment.	[4 h of treatment.]	1.5849625007211563	4	1	0	0
9777	1520	administration for 3 hour	[administration for 3 hours]	1.5849625007211563	4	1	0	0
9778	1520	preleukemic state in mouse	[preleukemic state in mice]	1.5849625007211563	4	1	0	0
9779	1520	cell count 2-6 mil.	[cell count 2-6 mil.]	1.5849625007211563	4	1	0	0
9780	1520	autopsy- human tissue	[autopsy- human tissues]	1.5849625007211563	3	1	0	0
9781	1520	5' upstream promoter	[5' upstream promoter]	1.5849625007211563	3	1	0	0
9782	1520	200 kD complex	[200 kD complex]	1.5849625007211563	3	1	0	0
9783	1520	production of type cytokine	[production of type cytokines]	1.5849625007211563	4	2	2	2
9784	1520	use a transfection technique,	[Using a transfection technique,]	1.5849625007211563	4	1	0	0
9785	1520	one October factor gene	[one Oct factor gene]	1.5849625007211563	4	1	0	0
9786	1520	BSAP cd19 gene transcription	[BSAP CD19 gene transcription]	1.5849625007211563	4	1	0	0
9787	1520	-176 to -96 sequence	[-176 to -96 sequence]	1.5849625007211563	4	1	0	0
9788	1520	-250 to +50 bp	[-250 to +50 bp]	1.5849625007211563	4	1	0	0
9789	1520	cytokine in human monocyte	[cytokines in human monocytes]	1.5849625007211563	4	2	2	2
9790	1520	T cell receptor engagement	[T cell receptor engagement]	1.5849625007211563	4	1	0	0
9791	1520	hiv terminal repeat transcription	[HIV terminal repeat transcription]	1.5849625007211563	4	2	2	2
9792	1520	phenotype of this cells.	[phenotype of these cells.]	1.5849625007211563	4	1	0	0
9793	1520	UP in mouse	[UP in mice]	1.5849625007211563	3	1	0	0
9794	1520	various growth factor	[various growth factors]	1.5849625007211563	3	1	0	0
9795	1520	NK cell-mediated ec activation	[NK cell-mediated EC activation]	1.5849625007211563	4	1	0	0
9796	1520	actin cytoskeleton independent	[actin cytoskeleton independent]	1.5849625007211563	3	1	0	0
9797	1520	level of IL2 transcription	[level of IL2 transcription]	1.5849625007211563	4	1	0	0
9798	1520	human T lymphoblastic	[human T lymphoblastic]	1.5849625007211563	3	1	0	0
9799	1520	only minor effects.	[only minor effects.]	1.5849625007211563	3	1	0	0
9800	1520	control il-2 production	[controlling IL-2 production]	1.5849625007211563	3	1	0	0
9801	1520	protein kinase kinase MEK	[protein kinase kinase MEK]	1.5849625007211563	4	2	1	1
9802	1520	calcineurin independent manner	[calcineurin independent manner]	1.5849625007211563	3	1	0	0
9803	1520	nuclear run-on assay	[nuclear run-on assay]	1.5849625007211563	3	2	1	1
9804	1520	10 to 120 min.	[10 to 120 min.]	1.5849625007211563	4	1	0	0
9805	1520	inducibility to reporter gene	[inducibility to reporter genes]	1.5849625007211563	4	1	0	0
9806	1520	clonal population of eosinophil	[clonal population of eosinophils]	1.5849625007211563	4	1	0	0
9807	1520	27-kDa unphosphorylated form	[27-kDa unphosphorylated form]	1.5849625007211563	3	1	0	0
9808	1520	fkbp12 /fk506 complex	[FKBP12 /FK506 complexes]	1.5849625007211563	3	1	0	0
9809	1520	Sp1 transcription factor binding	[Sp1 transcription factor binding]	1.5849625007211563	4	1	0	0
9810	1520	biologically active nf-kappa b	[biologically active NF-kappa B]	1.5849625007211563	4	1	0	0
9811	1520	basal level of transcription	[basal levels of transcription]	1.5849625007211563	4	1	0	0
9812	1520	phorbol ester-induced cell	[phorbol ester-induced cells]	1.5849625007211563	3	1	0	0
9813	1520	NFAT -1 regulatory element	[NFAT -1 regulatory elements]	1.5849625007211563	4	1	0	0
9814	1520	binding of stat 5a	[binding of Stat 5a]	1.5849625007211563	4	1	0	0
9815	1520	combination of pathway	[combination of pathways]	1.5849625007211563	3	1	0	0
9816	1520	enhancer element PRE-I	[enhancer element PRE-I]	1.5849625007211563	3	1	0	0
9817	1520	hepatoma cell line	[hepatoma cell line]	1.5849625007211563	3	1	0	0
9818	1520	nuclear pore complex	[nuclear pore complex]	1.5849625007211563	3	2	1	1
9819	1520	generality of this phenomenon	[generality of this phenomenon]	1.5849625007211563	4	1	0	0
9820	1520	recovery from stress,	[recovery from stress,]	1.5849625007211563	3	1	0	0
9821	1520	ebv-positive endemic bl	[EBV-positive endemic BL]	1.5849625007211563	3	1	0	0
9822	1520	gene in the gynecomastias	[genes in the gynecomastias]	1.5849625007211563	4	1	0	0
9823	1520	inhibition of hiv replication	[inhibition of HIV replication]	1.5849625007211563	4	2	1	1
9824	1520	precise differentiation stage	[precise differentiation stage]	1.5849625007211563	3	1	0	0
9825	1520	concentrate on role	[concentrating on roles]	1.5849625007211563	3	1	0	0
9826	1520	low level of c-fo	[low levels of c-Fos]	1.5849625007211563	4	1	0	0
9827	1520	nuclear translocation of p50/p65	[nuclear translocation of p50/p65]	1.5849625007211563	4	1	0	0
9828	1520	such as hemin	[such as hemin]	1.5849625007211563	3	1	0	0
9829	1520	k562 nuclear extract	[K562 nuclear extracts]	1.5849625007211563	3	1	0	0
9830	1520	role regulate differentiation	[role regulating differentiation]	1.5849625007211563	3	1	0	0
9831	1520	surface of mature macrophage	[surface of mature macrophages]	1.5849625007211563	4	1	0	0
9832	1520	proportion to affinity	[proportion to affinity]	1.5849625007211563	3	1	0	0
9833	1520	human pro-monocytic cell line	[human pro-monocytic cell line]	1.5849625007211563	4	1	0	0
9834	1520	number of signal molecule	[number of signaling molecules]	1.5849625007211563	4	2	2	2
9835	1520	adjacent 16 residue	[adjacent 16 residues]	1.5849625007211563	3	1	0	0
9836	1520	wild- type CD4	[wild- type CD4]	1.5849625007211563	3	1	0	0
9837	1520	difference in the pattern	[difference in the pattern]	1.5849625007211563	4	1	0	0
9838	1520	core Sp1 consensus element	[core Sp1 consensus element]	1.5849625007211563	4	1	0	0
9839	1520	physiology of T cell	[physiology of T cells]	1.5849625007211563	4	1	0	0
9840	1520	neomycin a inhibitor	[neomycin an inhibitor]	1.5849625007211563	3	1	0	0
9841	1520	phosphorylation of IkappaB alpha	[phosphorylation of IkappaB alpha]	1.5849625007211563	4	2	1	1
9842	1520	pretreatment with IFN-gamma	[Pretreatment with IFN-gamma]	1.5849625007211563	3	1	0	0
9843	1520	cell cycle control likely	[cell cycle control likely]	1.5849625007211563	4	1	0	0
9844	1520	independent transcriptional activation domain	[independent transcriptional activation domain]	1.5849625007211563	4	1	0	0
9845	1520	functional core of hs-40	[functional core of HS-40]	1.5849625007211563	4	1	0	0
9846	1520	heterotrimeric gtp-binding protein	[heterotrimeric GTP-binding proteins]	1.5849625007211563	3	1	0	0
9847	1520	m(r) of 70 kda	[M(r) of 70 kDa]	1.5849625007211563	4	1	0	0
9848	1520	negative regulatory event	[negative regulatory events]	1.5849625007211563	3	1	0	0
9849	1520	interleukin-2- dependent transcription	[interleukin-2- dependent transcription]	1.5849625007211563	3	1	0	0
9850	1520	high-affinity IFP53 GAS site.	[high-affinity IFP53 GAS site.]	1.5849625007211563	4	1	0	0
9851	1520	anti-cd14 monoclonal antibody	[anti-CD14 monoclonal antibodies]	1.5849625007211563	3	1	0	0
9852	1520	release of proinflammatory cytokine	[release of proinflammatory cytokines]	1.5849625007211563	4	1	0	0
9853	1520	encode LBR a protein	[encoding LBR an protein]	1.5849625007211563	4	2	2	2
9854	1520	astrocytoma cell line	[astrocytoma cell line]	1.5849625007211563	3	1	0	0
9855	1520	result of synthesis	[result of synthesis]	1.5849625007211563	3	1	0	0
9856	1520	th1 cytokine IL-2	[Th1 cytokines IL-2]	1.5849625007211563	3	1	0	0
9857	1520	neutrophil to endothelial cell	[neutrophils to endothelial cells]	1.5849625007211563	4	1	0	0
9858	1520	interferon consensus sequence	[Interferon Consensus Sequence]	1.5849625007211563	3	2	2	2
9859	1520	surface protein expression	[surface protein expression]	1.5849625007211563	3	1	0	0
9860	1520	high level of iron	[high levels of iron]	1.5849625007211563	4	1	0	0
9861	1520	ndp kinase activity	[NDP kinase activity]	1.5849625007211563	3	1	0	0
9862	1520	maximal induction by lps	[maximal induction by LPS]	1.5849625007211563	4	1	0	0
9863	1520	inducible pkc activity	[inducible PKC activity]	1.5849625007211563	3	1	0	0
9864	1520	herpes simplex virus-1	[herpes simplex virus-1]	1.5849625007211563	3	2	2	2
9865	1520	exception of genistein	[exception of genistein]	1.5849625007211563	3	1	0	0
9866	1520	GM2 sequence GGTAGTTCCC	[GM2 sequence GGTAGTTCCC]	1.5849625007211563	3	1	0	0
9867	1520	other patient with sle	[other patients with SLE]	1.5849625007211563	4	1	0	0
9868	1520	Fc gamma riia cross-linking	[Fc gamma RIIA cross-linking]	1.5849625007211563	4	1	0	0
9869	1520	site b palindrome	[site B palindrome]	1.5849625007211563	3	1	0	0
9870	1520	development of lymphoid neoplasm	[development of lymphoid neoplasms]	1.5849625007211563	4	1	0	0
9871	1520	lipid soluble antioxidant	[lipid soluble antioxidants]	1.5849625007211563	3	1	0	0
9872	1520	finding in mouse	[findings in mice]	1.5849625007211563	3	1	0	0
9873	1520	dose of staurosporine	[dose of staurosporine]	1.5849625007211563	3	2	2	2
9874	1520	reside in specific granule	[residing in specific granules]	1.5849625007211563	4	1	0	0
9875	1520	NF-AT-binding p element	[NF-AT-binding P elements]	1.5849625007211563	3	1	0	0
9876	1520	level during hiv-1 infection	[levels during HIV-1 infection]	1.5849625007211563	4	1	0	0
9877	1520	production of ROI	[production of ROIs]	1.5849625007211563	3	1	0	0
9878	1520	variety of factor	[variety of factors]	1.5849625007211563	3	1	0	0
9879	1520	substitution on viral replication	[substitutions on viral replication]	1.5849625007211563	4	1	0	0
9880	1520	plasma avp pmol/l; 0.5-2.5).	[plasma AVP pmol/l; 0.5-2.5).]	1.5849625007211563	4	1	0	0
9881	1520	kappa b/rel family protein	[kappa B/Rel family proteins]	1.5849625007211563	4	1	0	0
9882	1520	complex network of cytokine	[complex network of cytokines]	1.5849625007211563	4	1	0	0
9883	1520	20 patient with AMI	[20 patients with AMI]	1.5849625007211563	4	1	0	0
9884	1520	mature b cell proliferation	[mature B cell proliferation]	1.5849625007211563	4	1	0	0
9885	1520	tgf-beta1 in tgf-beta2	[TGF-beta1 in TGF-beta2]	1.5849625007211563	3	1	0	0
9886	1520	glucocorticoid in mononuclear	[glucocorticoids in mononuclear]	1.5849625007211563	3	1	0	0
9887	1520	subpopulation of lymphocyte	[subpopulations of lymphocytes]	1.5849625007211563	3	2	2	2
9888	1520	certain nonmyeloid cell type	[certain nonmyeloid cell types]	1.5849625007211563	4	1	0	0
9889	1520	virion-associated regulatory protein	[virion-associated regulatory protein]	1.5849625007211563	3	1	0	0
9890	1520	germinal center reaction	[germinal center reaction]	1.5849625007211563	3	1	0	0
9891	1520	increase in interferon-gamma production	[Increases in interferon-gamma production]	1.5849625007211563	4	1	0	0
9892	1520	activation domain in Oct-1	[activation domains in Oct-1]	1.5849625007211563	4	1	0	0
9893	1520	progression of htlv-1 disease	[progression of HTLV-1 diseases]	1.5849625007211563	4	1	0	0
9894	1520	additional putative regulatory sites.	[additional putative regulatory sites.]	1.5849625007211563	4	1	0	0
9895	1520	lymphocytic hemopoietic system	[lymphocytic hemopoietic systems]	1.5849625007211563	3	1	0	0
9896	1520	novel, approximately 320-kda species	[novel, approximately 320-kDa species]	1.5849625007211563	4	1	0	0
9897	1520	cases, peptide presentation	[cases, peptide presentation]	1.5849625007211563	3	1	0	0
9898	1520	immobilization of fusion protein	[Immobilization of fusion proteins]	1.5849625007211563	4	1	0	0
9899	1520	measurement of er	[measurement of ER]	1.5849625007211563	3	1	0	0
9900	1520	measurement of the number	[measurement of the number]	1.5849625007211563	4	1	0	0
9901	1520	expression of interleukin-1 il-1	[expression of interleukin-1 IL-1]	1.5849625007211563	4	1	0	0
9902	1520	anti- v3 loop	[anti- V3 loop]	1.5849625007211563	3	1	0	0
9903	1520	human RAR alpha expression	[Human RAR alpha expression]	1.5849625007211563	4	1	0	0
9904	1520	median time of observation	[median time of observation]	1.5849625007211563	4	1	0	0
9905	1520	mimetic molecule for hypoxia	[mimetic molecule for hypoxia]	1.5849625007211563	4	1	0	0
9906	1520	palindromic binding site	[palindromic binding sites]	1.5849625007211563	3	2	2	2
9907	1520	adhesion-dependent, ifn-gamma -independent manner	[adhesion-dependent, IFN-gamma -independent manner]	1.5849625007211563	4	1	0	0
9908	1520	anti-CD2-activated T cell	[anti-CD2-activated T cells]	1.5849625007211563	3	1	0	0
9909	1520	presence of IL-10	[presence of IL-10]	1.5849625007211563	3	2	1	1
9910	1520	contrast, expression of IL-4	[contrast, expression of IL-4]	1.5849625007211563	4	1	0	0
9911	1520	expression of cytotoxic cytokine	[expression of cytotoxic cytokines]	1.5849625007211563	4	1	0	0
9912	1520	intact gp130 cytoplasmic tail	[intact gp130 cytoplasmic tail]	1.5849625007211563	4	1	0	0
9913	1520	193-bp region 5'	[193-bp region 5']	1.5849625007211563	3	1	0	0
9914	1520	1 long terminal	[1 long terminal]	1.5849625007211563	3	2	1	1
9915	1520	protein kinase (camk) type	[protein kinase (CaMK) type]	1.5849625007211563	4	1	0	0
9916	1520	interleukin-1 beta precursor	[interleukin-1 beta precursor]	1.5849625007211563	3	1	0	0
9917	1520	interplay between this stimulus	[interplay between these stimuli]	1.5849625007211563	4	1	0	0
9918	1520	commitment of progenitor	[commitment of progenitors]	1.5849625007211563	3	2	1	1
9919	1520	NFAT transcriptional activation,	[NFAT transcriptional activation,]	1.5849625007211563	3	1	0	0
9920	1520	gamma c chain	[gamma c chain]	1.5849625007211563	3	1	0	0
9921	1520	emergence of virulent mutant	[emergence of virulent mutants]	1.5849625007211563	4	1	0	0
9922	1520	il-2 promoter/reporter construct	[IL-2 promoter/reporter constructs]	1.5849625007211563	3	1	0	0
9923	1520	il-10r activate stat protein	[IL-10R activating STAT proteins]	1.5849625007211563	4	1	0	0
9924	1520	most 47.10 cell	[most 47.10 cells]	1.5849625007211563	3	1	0	0
9925	1520	experiment involve gene transfection	[experiments involving gene transfection]	1.5849625007211563	4	1	0	0
9926	1520	peak level of micromol/L	[peak level of micromol/L]	1.5849625007211563	4	1	0	0
9927	1520	comparison with free drug	[comparison with free drug]	1.5849625007211563	4	1	0	0
9928	1520	putative e2f binding site	[putative E2F binding site]	1.5849625007211563	4	1	0	0
9929	1520	chimeric protein gal4-p65(286-551)	[chimeric protein GAL4-p65(286-551)]	1.5849625007211563	3	1	0	0
9930	1520	small rna gene	[small RNA genes]	1.5849625007211563	3	2	2	2
9931	1520	basis of this observations,	[basis of these observations,]	1.5849625007211563	4	1	0	0
9932	1520	IL-1 kinase IRAK	[IL-1 kinase IRAK]	1.5849625007211563	3	1	0	0
9933	1520	ability, CBF beta -148	[ability, CBF beta -148]	1.5849625007211563	4	1	0	0
9934	1520	NFAT homology domain	[NFAT homology domain]	1.5849625007211563	3	1	0	0
9935	1520	such as lymphokine production	[such as lymphokine production]	1.5849625007211563	4	1	0	0
9936	1520	two other domains,	[two other domains,]	1.5849625007211563	3	1	0	0
9937	1520	4 gy of radiotherapy	[4 Gy of radiotherapy]	1.5849625007211563	4	2	1	1
9938	1520	use transient transfection assay	[using transient transfection assays]	1.5849625007211563	4	1	0	0
9939	1520	chimeric oncoprotein e2a-pbx1	[chimeric oncoprotein E2a-Pbx1]	1.5849625007211563	3	1	0	0
9940	1520	inducible transcription factor ap-1	[inducible transcription factor AP-1]	1.5849625007211563	4	1	0	0
9941	1520	whole blood assay	[whole blood assays]	1.5849625007211563	3	1	0	0
9942	1520	receptor on leukocyte	[receptors on leukocytes]	1.5849625007211563	3	2	2	2
9943	1520	t-cell cycle entry, consistent	[T-cell cycle entry, consistent]	1.5849625007211563	4	1	0	0
9944	1520	numerous intracellular substrate	[numerous intracellular substrates]	1.5849625007211563	3	1	0	0
9945	1520	Partial amino acid sequence	[Partial amino acid sequences]	1.5849625007211563	4	1	0	0
9946	1520	morphology, surface antigen expression,	[morphology, surface antigen expression,]	1.5849625007211563	4	1	0	0
9947	1520	percentage of dead cell	[percentage of dead cells]	1.5849625007211563	4	1	0	0
9948	1520	potent inhibitory sequence	[potent inhibitory sequence]	1.5849625007211563	3	1	0	0
9949	1520	four variant of change	[Four variants of changes]	1.5849625007211563	4	1	0	0
9950	1520	common intracellular pathway	[common intracellular pathways]	1.5849625007211563	3	1	0	0
9951	1520	non- IL-2 -secreting cell	[non- IL-2 -secreting cells]	1.5849625007211563	4	1	0	0
9952	1520	C-terminal pou-specific homeodomain pouhd	[C-terminal POU-specific homeodomain POUHD]	1.5849625007211563	4	1	0	0
9953	1520	effect of tax	[effect of Tax]	1.5849625007211563	3	2	1	1
9954	1520	hallmark of b cell	[hallmark of B cells]	1.5849625007211563	4	2	2	2
9955	1520	recent discovery identical	[recent discovery identical]	1.5849625007211563	3	1	0	0
9956	1520	functional CRE site	[functional CRE site]	1.5849625007211563	3	1	0	0
9957	1520	stimulation of b cell	[stimulation of B cells]	1.5849625007211563	4	2	1	1
9958	1520	oncostatin m osm	[oncostatin M OSM]	1.5849625007211563	3	1	0	0
9959	1520	glucocorticoid receptor binding site	[glucocorticoid receptor binding sites]	1.5849625007211563	4	1	0	0
9960	1520	day 16 embryo	[day 16 embryos]	1.5849625007211563	3	1	0	0
9961	1520	MRP14 promoter in both,	[MRP14 promoter in both,]	1.5849625007211563	4	1	0	0
9962	1520	IL-2 promoter element	[IL-2 promoter elements]	1.5849625007211563	3	2	1	1
9963	1520	promonocytic leukemia cell u937	[promonocytic leukemia cells U937]	1.5849625007211563	4	1	0	0
9964	1520	circulate adrenal androgen level	[Circulating adrenal androgen levels]	1.5849625007211563	4	1	0	0
9965	1520	human microvessel endothelial cell	[human microvessel endothelial cells]	1.5849625007211563	4	2	2	2
9966	1520	NF-AT expression vector	[NF-AT expression vector]	1.5849625007211563	3	1	0	0
9967	1520	vivo footprinting experiment	[vivo footprinting experiments]	1.5849625007211563	3	1	0	0
9968	1520	NE by itself	[NE by itself]	1.5849625007211563	3	1	0	0
9969	1520	t-cell antigen receptor engagement	[T-cell antigen receptor engagement]	1.5849625007211563	4	1	0	0
9970	1520	antisense hmg i/y	[antisense HMG I/Y]	1.5849625007211563	3	1	0	0
9971	1520	immune costimulatory molecule b7.1	[immune costimulatory molecule B7.1]	1.5849625007211563	4	1	0	0
9972	1520	Grb2 family member	[Grb2 family member]	1.5849625007211563	3	2	2	2
9973	1520	UT-7 cell line	[UT-7 cell line]	1.5849625007211563	3	1	0	0
9974	1520	most human tissue	[most human tissues]	1.5849625007211563	3	1	0	0
9975	1520	il-4 among others.	[IL-4 among others.]	1.5849625007211563	3	1	0	0
9976	1520	However, B series cell	[However, B series cells]	1.5849625007211563	4	1	0	0
9977	1520	same conditions, delta cam-ai	[same conditions, delta CaM-AI]	1.5849625007211563	4	1	0	0
9978	1520	use 70z/3-derived pre-b-cell line	[using 70Z/3-derived pre-B-cell lines]	1.5849625007211563	4	1	0	0
9979	1520	PU.1 autoregulatory site	[PU.1 autoregulatory site]	1.5849625007211563	3	1	0	0
9980	1520	circulate dendritic cell DC	[Circulating dendritic cells DC]	1.5849625007211563	4	1	0	0
9981	1520	sig-crosslinking-induced protein tyrosine phosphorylation.	[sIg-crosslinking-induced protein tyrosine phosphorylation.]	1.5849625007211563	4	1	0	0
9982	1520	intact autophosphorylation site y518	[intact autophosphorylation site Y518]	1.5849625007211563	4	1	0	0
9983	1520	removal of pc4	[removal of PC4]	1.5849625007211563	3	2	2	2
9984	1520	most common cause	[most common cause]	1.5849625007211563	3	1	0	0
9985	1520	pre-B lymphocyte-specific mb-1 gene	[pre-B lymphocyte-specific mb-1 gene]	1.5849625007211563	4	1	0	0
9986	1520	expression of p50/rela(p65) heterodimer	[expression of p50/RelA(p65) heterodimers]	1.5849625007211563	4	1	0	0
9987	1520	many erythroid gene	[many erythroid genes]	1.5849625007211563	3	1	0	0
9988	1520	mature immunocompetent cell	[mature immunocompetent cells]	1.5849625007211563	3	1	0	0
9989	1520	human ifna2 gene	[human IFNA2 gene]	1.5849625007211563	3	1	0	0
9990	1520	pervanadate on tyrosine phosphorylation	[pervanadate on tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
9991	1520	use transfection gene assay	[Using transfection gene assays]	1.5849625007211563	4	1	0	0
9992	1520	such as the skin	[such as the skin]	1.5849625007211563	4	1	0	0
9993	1520	carboxyl-terminal 181 amino acid	[carboxyl-terminal 181 amino acids]	1.5849625007211563	4	1	0	0
9994	1520	allergen-specific t-cell clone	[allergen-specific T-cell clones]	1.5849625007211563	3	1	0	0
9995	1520	Epstein-Barr virus EBNA3C	[Epstein-Barr virus EBNA3C]	1.5849625007211563	3	1	0	0
9996	1520	little effect on nfat	[little effect on NFAT]	1.5849625007211563	4	1	0	0
9997	1520	membrane permeable ca2+ chelator	[membrane permeable Ca2+ chelator]	1.5849625007211563	4	1	0	0
9998	1520	early b-lymphoid progenitor	[early B-lymphoid progenitors]	1.5849625007211563	3	1	0	0
9999	1520	induction of hsf-1 activity	[induction of HSF-1 activity]	1.5849625007211563	4	1	0	0
10000	1520	role of jun	[role of jun]	1.5849625007211563	3	1	0	0
10001	1520	normal hematopoietic progenitor	[normal hematopoietic progenitors]	1.5849625007211563	3	1	0	0
10002	1520	Yin-Yang 1 YY1	[Yin-Yang 1 YY1]	1.5849625007211563	3	1	0	0
10003	1520	assay for determination	[assay for determination]	1.5849625007211563	3	1	0	0
10004	1520	heterodimer partner of RXR	[heterodimer partner of RXR]	1.5849625007211563	4	1	0	0
10005	1520	binding to a receptor	[binding to a receptor]	1.5849625007211563	4	2	2	2
10006	1520	absence of transactivator	[absence of transactivators]	1.5849625007211563	3	1	0	0
10007	1520	rat irf-1 gene	[rat IRF-1 gene]	1.5849625007211563	3	1	0	0
10008	1520	nf-kappa b -independent activity	[NF-kappa B -independent activity]	1.5849625007211563	4	1	0	0
10009	1520	molt4 c-myc mrna	[Molt4 c-myc mRNA]	1.5849625007211563	3	1	0	0
10010	1520	fluorescein-labeled amplicon (probe)	[fluorescein-labeled amplicon (probe)]	1.5849625007211563	3	1	0	0
10011	1520	pleiotropic effect of il-4	[pleiotropic effects of IL-4]	1.5849625007211563	4	1	0	0
10012	1520	four cysteine-rich domain	[four cysteine-rich domains]	1.5849625007211563	3	1	0	0
10013	1520	RAR beta tgase	[RAR beta TGase]	1.5849625007211563	3	1	0	0
10014	1520	sense, c-fo oligonucleotide	[sense, c-fos oligonucleotides]	1.5849625007211563	3	1	0	0
10015	1520	presence of jak3	[presence of JAK3]	1.5849625007211563	3	1	0	0
10016	1520	addition to PMA	[addition to PMA]	1.5849625007211563	3	1	0	0
10017	1520	target for nuclear factor	[target for nuclear factor]	1.5849625007211563	4	1	0	0
10018	1520	core tfiid complex	[core TFIID complex]	1.5849625007211563	3	1	0	0
10019	1520	CFU-GEMM/ bfu-e/cfu-m shift multipotent	[CFU-GEMM/ BFU-E/CFU-M shift multipotent]	1.5849625007211563	4	1	0	0
10020	1520	transcription of fasL	[transcription of fasL]	1.5849625007211563	3	1	0	0
10021	1520	endothelial cell adhesive property	[endothelial cell adhesive properties]	1.5849625007211563	4	1	0	0
10022	1520	effect on cd26	[effect on CD26]	1.5849625007211563	3	1	0	0
10023	1520	HNF-1 alpha DCoH	[HNF-1 alpha DCoH]	1.5849625007211563	3	1	0	0
10024	1520	individual b cell receptor	[individual B cell receptors]	1.5849625007211563	4	1	0	0
10025	1520	proliferation of memory	[proliferation of memory]	1.5849625007211563	3	1	0	0
10026	1520	form of rescue	[form of rescue]	1.5849625007211563	3	1	0	0
10027	1520	LTR size variation	[LTR size variation]	1.5849625007211563	3	1	0	0
10028	1520	exception of plasma cell	[exception of plasma cells]	1.5849625007211563	4	1	0	0
10029	1520	essential role in transformation	[essential role in transformation]	1.5849625007211563	4	1	0	0
10030	1520	marker of exposure	[marker of exposure]	1.5849625007211563	3	1	0	0
10031	1520	tartrate resistant acid phosphatase	[tartrate resistant acid phosphatase]	1.5849625007211563	4	1	0	0
10032	1520	blood leukocyte in runner	[blood leukocytes in runner]	1.5849625007211563	4	2	2	2
10033	1520	activator nf-kappa b	[activator NF-kappa B]	1.5849625007211563	3	2	2	2
10034	1520	use oligonucleotide primer	[using oligonucleotide primers]	1.5849625007211563	3	1	0	0
10035	1520	monocyte adherent to fibronectin	[monocytes adherent to fibronectin]	1.5849625007211563	4	1	0	0
10036	1520	pituitary-specific transcription factor	[pituitary-specific transcription factor]	1.5849625007211563	3	1	0	0
10037	1520	high dose of desferrioxamine	[high doses of desferrioxamine]	1.5849625007211563	4	1	0	0
10038	1520	p50p50 of NF-kappa b	[p50p50 of NF-kappa B]	1.5849625007211563	4	1	0	0
10039	1520	component with il-4r	[component with IL-4R]	1.5849625007211563	3	1	0	0
10040	1520	global tcr/cd3 -signaling defect	[global TCR/CD3 -signaling defect]	1.5849625007211563	4	1	0	0
10041	1520	inhibition of e-selectin induction.	[inhibition of E-selectin induction.]	1.5849625007211563	4	1	0	0
10042	1520	low level of transcription	[Low levels of transcription]	1.5849625007211563	4	2	1	1
10043	1520	signal growth inhibition	[signaling growth inhibition]	1.5849625007211563	3	1	0	0
10044	1520	action of transcription factor	[action of transcription factors]	1.5849625007211563	4	1	0	0
10045	1520	human interleukin-6 (il-6) gene	[human interleukin-6 (IL-6) gene]	1.5849625007211563	4	1	0	0
10046	1520	contribution of ligand binding	[contributions of ligand binding]	1.5849625007211563	4	1	0	0
10047	1520	use recombinant protein	[using recombinant proteins]	1.5849625007211563	3	1	0	0
10048	1520	elderly healthy subject	[elderly healthy subjects]	1.5849625007211563	3	1	0	0
10049	1520	response to steel	[response to Steel]	1.5849625007211563	3	1	0	0
10050	1520	approximately 120-kDa protein	[approximately 120-kDa protein]	1.5849625007211563	3	1	0	0
10051	1520	nitroblue tetrazolium nbt activity	[nitroblue tetrazolium NBT activity]	1.5849625007211563	4	1	0	0
10052	1520	three prominent isoform	[three prominent isoforms]	1.5849625007211563	3	1	0	0
10053	1520	contrast to mm cell	[contrast to MM cells]	1.5849625007211563	4	1	0	0
10054	1520	prevent nf-y binding	[preventing NF-Y binding]	1.5849625007211563	3	1	0	0
10055	1520	cotransfection of Sp3ilday	[Cotransfection of Sp3]	1.5849625007211563	3	1	0	0
10056	1520	modulation of ikappabalpha expression	[modulation of IkappaBalpha expression]	1.5849625007211563	4	1	0	0
10057	1520	complementation of this defect	[complementation of this defect]	1.5849625007211563	4	1	0	0
10058	1520	CD2 cross-link camp	[CD2 cross-linking cAMP]	1.5849625007211563	3	1	0	0
10059	1520	alpha b2 protein	[alpha B2 proteins]	1.5849625007211563	3	1	0	0
10060	1520	Jurkat cells, expression knock-out"	[Jurkat cells, expression knock-out"]	1.5849625007211563	4	1	0	0
10061	1520	implication of OCA-B	[implications of OCA-B]	1.5849625007211563	3	1	0	0
10062	1520	bona fide p50/p65 heterodimer	[bona fide p50/p65 heterodimers]	1.5849625007211563	4	1	0	0
10063	1520	Double-stranded GIRE sequence	[Double-stranded GIRE sequence]	1.5849625007211563	3	1	0	0
10064	1520	effect of rho	[effects of Rho]	1.5849625007211563	3	1	0	0
10065	1520	human interleukin 2 Il-2	[human Interleukin 2 Il-2]	1.5849625007211563	4	1	0	0
10066	1520	germ-line brca1 mutation	[germ-line BRCA1 mutation]	1.5849625007211563	3	1	0	0
10067	1520	physiology of thymic selection	[physiology of thymic selection]	1.5849625007211563	4	1	0	0
10068	1520	immunophenotype of IDC	[immunophenotype of IDC]	1.5849625007211563	3	1	0	0
10069	1520	hypersensitivity to thyroid hormone	[hypersensitivity to thyroid hormones]	1.5849625007211563	4	1	0	0
10070	1520	phosphatidylinositol 3-kinase pi3-k	[Phosphatidylinositol 3-kinase PI3-K]	1.5849625007211563	3	1	0	0
10071	1520	multiple cold-air exposure	[multiple cold-air exposures]	1.5849625007211563	3	1	0	0
10072	1520	obstacle to gene therapy	[obstacle to gene therapy]	1.5849625007211563	4	1	0	0
10073	1520	glutathione gsh level	[glutathione GSH level]	1.5849625007211563	3	2	2	2
10074	1520	human proximal sequence element	[human proximal sequence element]	1.5849625007211563	4	1	0	0
10075	1520	cross-talk among molecule	[cross-talk among molecules]	1.5849625007211563	3	1	0	0
10076	1520	alternative apoptotic "targets" eosinophil	[alternative apoptotic "targets" eosinophils]	1.5849625007211563	4	1	0	0
10077	1520	detection of ebv reactivation	[detection of EBV reactivation]	1.5849625007211563	4	1	0	0
10078	1520	oligomerization of tlr2	[oligomerization of TLR2]	1.5849625007211563	3	1	0	0
10079	1520	Additionally, overexpression of Vav	[Additionally, overexpression of Vav]	1.5849625007211563	4	1	0	0
10080	1520	lps CMV cell	[LPS CMV cells]	1.5849625007211563	3	1	0	0
10081	1520	identification of the pathway	[Identification of the pathways]	1.5849625007211563	4	1	0	0
10082	1520	incubation of nuclei	[incubation of nuclei]	1.5849625007211563	3	1	0	0
10083	1520	lack of transcription factor	[lack of transcription factors]	1.5849625007211563	4	1	0	0
10084	1520	2738 nucleotide 5'	[2,738 nucleotides 5']	1.5849625007211563	3	1	0	0
10085	1520	T cell NF-AT1	[T cells NF-AT1]	1.5849625007211563	3	1	0	0
10086	1520	PBMC from Graves' patient	[PBMC from Graves' patients]	1.5849625007211563	4	1	0	0
10087	1520	production of mitogen	[production of mitogens]	1.5849625007211563	3	1	0	0
10088	1520	il-4 stat6 phosphorylation	[IL-4 Stat6 phosphorylation]	1.5849625007211563	3	1	0	0
10089	1520	antisense myb rna expression.	[antisense myb RNA expression.]	1.5849625007211563	4	1	0	0
10090	1520	general correlation between induction	[general correlation between induction]	1.5849625007211563	4	1	0	0
10091	1520	proteinase in macrophage	[proteinase in macrophages]	1.5849625007211563	3	1	0	0
10092	1520	il-4 -specific signal	[IL-4 -specific signals]	1.5849625007211563	3	1	0	0
10093	1520	absence of glucocorticoid treatment	[absence of glucocorticoid treatment]	1.5849625007211563	4	1	0	0
10094	1520	hypergammaglobulinemia or, together	[hypergammaglobulinemia or, together]	1.5849625007211563	3	1	0	0
10095	1520	transcription factor NF-AT	[transcription factor NF-AT]	1.5849625007211563	3	1	0	0
10096	1520	presence of er variant	[presence of ER variants]	1.5849625007211563	4	1	0	0
10097	1520	latent membrane antigen lmp	[latent membrane antigens LMP]	1.5849625007211563	4	1	0	0
10098	1520	canonical DNA sequence canntg	[canonical DNA sequence CANNTG]	1.5849625007211563	4	1	0	0
10099	1520	cellular oxidant stress	[cellular oxidant stress]	1.5849625007211563	3	2	1	1
10100	1520	normal prickle cell	[normal prickle cells]	1.5849625007211563	3	1	0	0
10101	1520	endothelial medium e-cm	[endothelial medium E-CM]	1.5849625007211563	3	1	0	0
10102	1520	pretreatment of the endothelium	[Pretreatment of the endothelium]	1.5849625007211563	4	1	0	0
10103	1520	common endodermal origin	[common endodermal origin]	1.5849625007211563	3	1	0	0
10104	1520	NF-kappa b protein complex	[NF-kappa B protein complex]	1.5849625007211563	4	1	0	0
10105	1520	Latent membrane protein-1	[Latent membrane protein-1]	1.5849625007211563	3	1	0	0
10106	1520	NF-kappa b binding motif	[NF-kappa B binding motifs]	1.5849625007211563	4	1	0	0
10107	1520	infiltrate ductal carcinoma	[infiltrating ductal carcinomas]	1.5849625007211563	3	1	0	0
10108	1520	response to antigen presentation	[response to antigen presentation]	1.5849625007211563	4	1	0	0
10109	1520	NF-kappa b signal transduction	[NF-kappa B signal transduction]	1.5849625007211563	4	1	0	0
10110	1520	SE of fluorescence [channels]	[SE of fluorescence [channels]]	1.5849625007211563	4	1	0	0
10111	1520	use a cryostat,	[using a cryostat,]	1.5849625007211563	3	1	0	0
10112	1520	predominance of p50 homodimers.	[predominance of p50 homodimers.]	1.5849625007211563	4	1	0	0
10113	1520	TRAF2 dominant-negative mutant	[TRAF2 dominant-negative mutant]	1.5849625007211563	3	1	0	0
10114	1520	acute leukemia patient	[acute leukemia patients]	1.5849625007211563	3	3	2	1
10115	1520	major transcriptional initiation site	[major transcriptional initiation site]	1.5849625007211563	4	1	0	0
10116	1520	DNA repair enzyme	[DNA repair enzyme]	1.5849625007211563	3	2	2	2
10117	1520	HC11 mammary epithelial cell	[HC11 mammary epithelial cells]	1.5849625007211563	4	1	0	0
10118	1520	property of cell growth	[properties of cell growth]	1.5849625007211563	4	1	0	0
10119	1520	murine genomic DNA	[murine genomic DNA]	1.5849625007211563	3	1	0	0
10120	1520	activity of IL-1	[activity of IL-1]	1.5849625007211563	3	1	0	0
10121	1520	hdn alloimmune thrombocytopenia	[HDN alloimmune thrombocytopenia]	1.5849625007211563	3	1	0	0
10122	1520	apoptosis of cd34+ cell	[apoptosis of CD34+ cells]	1.5849625007211563	4	1	0	0
10123	1520	1.34 nmol/L; diethylstilbestrol	[1.34 nmol/L; diethylstilbestrol]	1.5849625007211563	3	1	0	0
10124	1520	result in depolarization	[resulting in depolarization]	1.5849625007211563	3	1	0	0
10125	1520	glycation reactive oxygen species	[glycation reactive oxygen species]	1.5849625007211563	4	1	0	0
10126	1520	single nucleotide polymorphism (snp)	[single nucleotide polymorphism (SNP)]	1.5849625007211563	4	1	0	0
10127	1520	contrast to cytoplasmic ar	[contrast to cytoplasmic AR]	1.5849625007211563	4	1	0	0
10128	1520	interaction with coregulators.	[interaction with coregulators.]	1.5849625007211563	3	1	0	0
10129	1520	mast cell proliferation	[mast cell proliferation]	1.5849625007211563	3	1	0	0
10130	1520	hiv-1 provirus sf-2 strain	[HIV-1 provirus SF-2 strain]	1.5849625007211563	4	1	0	0
10131	1520	human interleukin-4 IL-4 gene	[human interleukin-4 IL-4 gene]	1.5849625007211563	4	1	0	0
10132	1520	CD4 -express T lymphocyte	[CD4 -expressing T lymphocytes]	1.5849625007211563	4	1	0	0
10133	1520	local failure rate	[local failure rate]	1.5849625007211563	3	2	2	2
10134	1520	JAK /stat activation	[JAK /STAT activation]	1.5849625007211563	3	2	1	1
10135	1520	CD3 delta epsilon gamma	[CD3 delta epsilon gamma]	1.5849625007211563	4	1	0	0
10136	1520	initiate intracellular signal pathway	[initiating intracellular signaling pathways]	1.5849625007211563	4	1	0	0
10137	1520	induce the phosphorylation	[inducing the phosphorylation]	1.5849625007211563	3	1	0	0
10138	1520	inhibitor of type 1	[inhibitor of type 1]	1.5849625007211563	4	1	0	0
10139	1520	least one other,	[least one other,]	1.5849625007211563	3	1	0	0
10140	1520	number during pregnancy,	[number during pregnancy,]	1.5849625007211563	3	1	0	0
10141	1520	measurement of dexamethasone binding	[measurement of dexamethasone binding]	1.5849625007211563	4	1	0	0
10142	1520	corresponding stat protein	[corresponding Stat protein]	1.5849625007211563	3	1	0	0
10143	1520	induction of IL-2	[induction of IL-2]	1.5849625007211563	3	2	1	1
10144	1520	DNA bind nfkb2 p52	[DNA binding NFKB2 p52]	1.5849625007211563	4	1	0	0
10145	1520	beta-globin gene promoter	[beta-globin gene promoter]	1.5849625007211563	3	1	0	0
10146	1520	biology of monocyte	[biology of monocytes]	1.5849625007211563	3	1	0	0
10147	1520	apoptosis cycle arrest	[apoptosis cycle arrest]	1.5849625007211563	3	1	0	0
10148	1520	such as nef	[such as nef]	1.5849625007211563	3	1	0	0
10149	1520	NK cell cytotoxicity	[NK cell cytotoxicity]	1.5849625007211563	3	1	0	0
10150	1520	nfatp to calcineurin	[NFATp to calcineurin]	1.5849625007211563	3	1	0	0
10151	1520	single isolate AL1	[single isolate AL1]	1.5849625007211563	3	1	0	0
10152	1520	lead to hiv-1 replication	[leading to HIV-1 replication]	1.5849625007211563	4	2	1	1
10153	1520	mutation of both site	[Mutations of both sites]	1.5849625007211563	4	1	0	0
10154	1520	b-cell-derived nf-kappa b	[B-cell-derived NF-kappa B]	1.5849625007211563	3	1	0	0
10155	1520	include the globin gene	[including the globin genes]	1.5849625007211563	4	1	0	0
10156	1520	versatile cellular homeostatic switch	[versatile cellular homeostatic switch]	1.5849625007211563	4	1	0	0
10157	1520	asp -57-positive MHC molecule	[Asp -57-positive MHC molecules]	1.5849625007211563	4	1	0	0
10158	1520	NF kappa b mrna	[NF kappa B mRNA]	1.5849625007211563	4	1	0	0
10159	1520	infection with Theileria annulata	[Infection with Theileria annulata]	1.5849625007211563	4	1	0	0
10160	1520	confirmation of a model.	[Confirmation of a model.]	1.5849625007211563	4	1	0	0
10161	1520	costimulation requirement ap-1	[Costimulation requirement AP-1]	1.5849625007211563	3	1	0	0
10162	1520	b cell hybridoma 7td1	[B cell hybridoma 7TD1]	1.5849625007211563	4	1	0	0
10163	1520	protein of 75 kD	[proteins of 75 kD]	1.5849625007211563	4	2	2	2
10164	1520	ngal gene expression	[ngal gene expression]	1.5849625007211563	3	1	0	0
10165	1520	Ser616 to Ala	[Ser616 to Ala]	1.5849625007211563	3	1	0	0
10166	1520	concentration of androgen receptor	[concentration of androgen receptors]	1.5849625007211563	4	1	0	0
10167	1520	induction of hiv-1	[induction of HIV-1]	1.5849625007211563	3	1	0	0
10168	1520	maximum of binding sites/nucleus	[maximum of binding sites/nucleus]	1.5849625007211563	4	2	2	2
10169	1520	killing of k562 target	[killing of K562 targets]	1.5849625007211563	4	1	0	0
10170	1520	lymphoid-specific octamer-binding factor	[lymphoid-specific octamer-binding factor]	1.5849625007211563	3	1	0	0
10171	1520	positive transcription factor	[positive transcription factor]	1.5849625007211563	3	2	2	2
10172	1520	nf-kappa b -dependent gene	[NF-kappa B -dependent genes]	1.5849625007211563	4	1	0	0
10173	1520	southwestern blot analysis	[Southwestern blot analysis]	1.5849625007211563	3	1	0	0
10174	1520	concurrent follow-up NK activity	[concurrent follow-up NK activity]	1.5849625007211563	4	1	0	0
10175	1520	immunization with synthetic peptide	[immunization with synthetic peptides]	1.5849625007211563	4	1	0	0
10176	1520	only a copy	[only a copies]	1.5849625007211563	3	1	0	0
10177	1520	MHC-peptide ligand interaction	[MHC-peptide ligand interactions]	1.5849625007211563	3	1	0	0
10178	1520	significant age-related alteration	[significant age-related alterations]	1.5849625007211563	3	1	0	0
10179	1520	only the IL-2 promoter	[only the IL-2 promoter]	1.5849625007211563	4	1	0	0
10180	1520	many second messenger	[many second messengers]	1.5849625007211563	3	1	0	0
10181	1520	very different expression pattern	[very different expression patterns]	1.5849625007211563	4	1	0	0
10182	1520	same stat protein	[same Stat protein]	1.5849625007211563	3	1	0	0
10183	1520	z binding site	[Z binding site]	1.5849625007211563	3	1	0	0
10184	1520	leukemic hl60 cell	[leukemic HL60 cells]	1.5849625007211563	3	1	0	0
10185	1520	analysis of mouse	[analysis of mice]	1.5849625007211563	3	2	2	2
10186	1520	minute exposure time	[min exposure time]	1.5849625007211563	3	1	0	0
10187	1520	Addisonian picture (group 6.05	[Addisonian picture (group 6.05]	1.5849625007211563	4	1	0	0
10188	1520	72 h of virus	[72 h of virus]	1.5849625007211563	4	1	0	0
10189	1520	two latter signal	[two latter signals]	1.5849625007211563	3	1	0	0
10190	1520	expression of 642 fmol/mg	[expression of 642 fmol/mg]	1.5849625007211563	4	1	0	0
10191	1520	regulation of type p53	[regulation of type p53]	1.5849625007211563	4	1	0	0
10192	1520	background: Polyaromatic hydrocarbons pah	[BACKGROUND: Polyaromatic hydrocarbons PAHs]	1.5849625007211563	4	1	0	0
10193	1520	administration of such megadosis	[administration of such megadoses]	1.5849625007211563	4	1	0	0
10194	1520	site alpha -binding activity	[site alpha -binding activities]	1.5849625007211563	4	1	0	0
10195	1520	studies, stimulation experiment	[studies, stimulation experiments]	1.5849625007211563	3	1	0	0
10196	1520	patient present with IHES	[patient presenting with IHES]	1.5849625007211563	4	2	1	1
10197	1520	challenge cell with il-4	[challenging cells with IL-4]	1.5849625007211563	4	1	0	0
10198	1520	flow cytometry evaluation.	[flow cytometry evaluation.]	1.5849625007211563	3	1	0	0
10199	1520	human peripheral-blood monocyte	[human peripheral-blood monocytes]	1.5849625007211563	3	1	0	0
10200	1520	second repressor region	[second repressor region]	1.5849625007211563	3	1	0	0
10201	1520	mutation of the sp1	[mutations of the SP1]	1.5849625007211563	4	1	0	0
10202	1520	increase in the release	[increase in the release]	1.5849625007211563	4	1	0	0
10203	1520	src gene family p56lck	[src gene family p56lck]	1.5849625007211563	4	1	0	0
10204	1520	such as hypersensitivity	[such as hypersensitivity]	1.5849625007211563	3	1	0	0
10205	1520	induce VDR /drip interaction	[inducing VDR /DRIP interactions]	1.5849625007211563	4	1	0	0
10206	1520	minimal b cell-specific enhancer	[minimal B cell-specific enhancer]	1.5849625007211563	4	1	0	0
10207	1520	activator protein-1 transcription	[activator protein-1 transcription]	1.5849625007211563	3	2	2	2
10208	1520	immunosuppressive effect of oxldl	[immunosuppressive effect of oxLDLs]	1.5849625007211563	4	1	0	0
10209	1520	CD28 response element CD28RE	[CD28 response element CD28RE]	1.5849625007211563	4	1	0	0
10210	1520	enhancement of ige synthesis	[enhancement of IgE synthesis]	1.5849625007211563	4	1	0	0
10211	1520	chronic myelogenous leukaemia CML	[chronic myelogenous leukaemia CML]	1.5849625007211563	4	1	0	0
10212	1520	modulation of the level	[modulation of the level]	1.5849625007211563	4	1	0	0
10213	1520	involvement of several oncogene	[involvement of several oncogenes]	1.5849625007211563	4	1	0	0
10214	1520	variety of hematopoietic cell	[variety of hematopoietic cells]	1.5849625007211563	4	1	0	0
10215	1520	clinical immunosuppressive drug	[clinical immunosuppressive drug]	1.5849625007211563	3	1	0	0
10216	1520	acidic terminal segment vca	[acidic terminal segment VCA]	1.5849625007211563	4	1	0	0
10217	1520	NF-kappa B/Rel complex	[NF-kappa B/Rel complexes]	1.5849625007211563	3	2	1	1
10218	1520	virtually all tumour cell	[virtually all tumour cells]	1.5849625007211563	4	1	0	0
10219	1520	human b lymphoma	[human B lymphoma]	1.5849625007211563	3	1	0	0
10220	1520	il-2 gene a process	[IL-2 gene a process]	1.5849625007211563	4	1	0	0
10221	1520	owl monkey liver	[owl monkey liver]	1.5849625007211563	3	1	0	0
10222	1520	upregulation of cd11b	[upregulation of CD11b]	1.5849625007211563	3	1	0	0
10223	1520	interaction with epithelial cell	[interaction with epithelial cells]	1.5849625007211563	4	2	2	2
10224	1520	filarial inflammatory disease	[filarial inflammatory disease]	1.5849625007211563	3	1	0	0
10225	1520	hepatocyte in primary cultures.	[hepatocytes in primary cultures.]	1.5849625007211563	4	1	0	0
10226	1520	difference in gene regulation	[difference in gene regulation]	1.5849625007211563	4	1	0	0
10227	1520	regulation of mnda expression	[Regulation of MNDA expression]	1.5849625007211563	4	2	1	1
10228	1520	finding of the study	[findings of the study]	1.5849625007211563	4	1	0	0
10229	1520	rheumatoid arthritis pathogenesis	[rheumatoid arthritis pathogenesis]	1.5849625007211563	3	1	0	0
10230	1520	amount of tnf-alpha	[amounts of TNF-alpha]	1.5849625007211563	3	2	1	1
10231	1520	estrogen receptor status	[estrogen receptor status]	1.5849625007211563	3	2	2	2
10232	1520	however, transcriptional activation	[However, transcriptional activation]	1.5849625007211563	3	1	0	0
10233	1520	ribosomal protein gene promoter	[ribosomal protein gene promoters]	1.5849625007211563	4	1	0	0
10234	1520	addition of stromal cell	[addition of stromal cells]	1.5849625007211563	4	1	0	0
10235	1520	effect of deltorphin	[effect of deltorphin]	1.5849625007211563	3	1	0	0
10236	1520	extracellular generation of no	[Extracellular generation of NO]	1.5849625007211563	4	1	0	0
10237	1520	pathogenesis of breast cancer	[pathogenesis of breast cancer]	1.5849625007211563	4	1	0	0
10238	1520	SV40 core sequence	[SV40 core sequence]	1.5849625007211563	3	1	0	0
10239	1520	protein of mass	[proteins of mass]	1.5849625007211563	3	2	2	2
10240	1520	NK cell-mediated lysis	[NK cell-mediated lysis]	1.5849625007211563	3	1	0	0
10241	1520	nf-kappab activity in ec	[NF-kappaB activity in EC]	1.5849625007211563	4	1	0	0
10242	1520	Ikaros family member	[Ikaros family members]	1.5849625007211563	3	1	0	0
10243	1520	T helper-induced lymphocyte	[T helper-induced lymphocytes]	1.5849625007211563	3	1	0	0
10244	1520	gel shift assay distinct	[gel shift assays distinct]	1.5849625007211563	4	1	0	0
10245	1520	human lymphocyte proliferation	[human lymphocyte proliferation]	1.5849625007211563	3	2	1	1
10246	1520	hematopoiesis translocation involve aml1	[hematopoiesis translocations involving AML1]	1.5849625007211563	4	1	0	0
10247	1520	antifungal effect of CsA	[antifungal effects of CsA]	1.5849625007211563	4	1	0	0
10248	1520	macrophage colony-stimulating factor M-CSF	[macrophage colony-stimulating factor M-CSF]	1.5849625007211563	4	1	0	0
10249	1520	signal via the il-13r	[signaling via the IL-13R]	1.5849625007211563	4	1	0	0
10250	1520	regulation of promoter	[regulation of promoters]	1.5849625007211563	3	2	2	2
10251	1520	distinct biologic function	[distinct biologic functions]	1.5849625007211563	3	1	0	0
10252	1520	transfection of a cDNA	[Transfection of a cDNA]	1.5849625007211563	4	1	0	0
10253	1520	relatively high level	[relatively high level]	1.5849625007211563	3	1	0	0
10254	1520	antigen-induced il-2 secretion	[antigen-induced IL-2 secretion]	1.5849625007211563	3	1	0	0
10255	1520	release of H2O2	[release of H2O2]	1.5849625007211563	3	1	0	0
10256	1520	Jurkat crude extract	[Jurkat crude extract]	1.5849625007211563	3	1	0	0
10257	1520	2 long terminal repeat	[2 long terminal repeat]	1.5849625007211563	4	1	0	0
10258	1520	vitro clonal growth assay	[vitro clonal growth assays]	1.5849625007211563	4	1	0	0
10259	1520	closely related site	[closely related sites]	1.5849625007211563	3	1	0	0
10260	1520	aldosterone membrane receptor	[aldosterone membrane receptor]	1.5849625007211563	3	2	2	2
10261	1520	interleukin (il)-1 beta	[interleukin (IL)-1 beta]	1.5849625007211563	3	1	0	0
10262	1520	such sequence support replication	[such sequences supporting replication]	1.5849625007211563	4	1	0	0
10263	1520	assembly of STAT heterodimer	[assembly of STAT heterodimers]	1.5849625007211563	4	1	0	0
10264	1520	defect in proliferation	[defect in proliferation]	1.5849625007211563	3	1	0	0
10265	1520	complex array of protein	[complex array of proteins]	1.5849625007211563	4	2	1	1
10266	1520	possible long latency	[possible longer latency]	1.5849625007211563	3	1	0	0
10267	1520	enhancement by BDP	[enhancement by BDP]	1.5849625007211563	3	1	0	0
10268	1520	consequence of immaturity	[consequence of immaturity]	1.5849625007211563	3	1	0	0
10269	1520	activation/repression of transcription factor	[activation/repression of transcription factors]	1.5849625007211563	4	1	0	0
10270	1520	GM-kappa b motif	[GM-kappa B motif]	1.5849625007211563	3	1	0	0
10271	1520	T cell cytoskeleton	[T cell cytoskeleton]	1.5849625007211563	3	1	0	0
10272	1520	effect of trx	[effect of Trx]	1.5849625007211563	3	1	0	0
10273	1520	therefore, activation of nfat	[Therefore, activation of NFAT]	1.5849625007211563	4	1	0	0
10274	1520	important protective cellular	[important protective cellular]	1.5849625007211563	3	1	0	0
10275	1520	frequent polyomavirus reactivations.	[frequent polyomavirus reactivations.]	1.5849625007211563	3	1	0	0
10276	1520	terminal repeat hiv-1-ltr	[terminal repeat HIV-1-LTR]	1.5849625007211563	3	2	2	2
10277	1520	period of hours.	[period of hours.]	1.5849625007211563	3	1	0	0
10278	1520	sequence requirement for binding	[sequence requirements for binding]	1.5849625007211563	4	1	0	0
10279	1520	affect cellular proliferation	[affecting cellular proliferation]	1.5849625007211563	3	1	0	0
10280	1520	near physiological level	[near physiological levels]	1.5849625007211563	3	1	0	0
10281	1520	heterogeneity of clonal development	[Heterogeneity of clonal development]	1.5849625007211563	4	2	2	2
10282	1520	post-gc b cell	[post-GC B cells]	1.5849625007211563	3	1	0	0
10283	1520	effect of tpa	[effect of TPA]	1.5849625007211563	3	2	2	2
10284	1520	Latent membrane protein 1	[Latent membrane protein 1]	1.5849625007211563	4	2	2	2
10285	1520	variety of ligands.	[variety of ligands.]	1.5849625007211563	3	1	0	0
10286	1520	such as fibroblast	[such as fibroblasts]	1.5849625007211563	3	2	1	1
10287	1520	hormone binding specificity	[Hormone binding specificity]	1.5849625007211563	3	1	0	0
10288	1520	hla b8-restricted peptide rakfkqllq	[HLA B8-restricted peptide RAKFKQLLQ]	1.5849625007211563	4	1	0	0
10289	1520	0.1% bovine serum albumin	[0.1% bovine serum albumin]	1.5849625007211563	4	1	0	0
10290	1520	mutation in p50	[mutation in p50]	1.5849625007211563	3	1	0	0
10291	1520	anthropometric, metabolic parameter	[anthropometric, metabolic parameters]	1.5849625007211563	3	1	0	0
10292	1520	change in the expression	[changes in the expression]	1.5849625007211563	4	2	2	2
10293	1520	possible correlation between immune	[possible correlation between immune]	1.5849625007211563	4	1	0	0
10294	1520	chromatin -dependent process	[chromatin -dependent process]	1.5849625007211563	3	1	0	0
10295	1520	relb -ck1 gene expression.	[RelB -CK1 gene expression.]	1.5849625007211563	4	1	0	0
10296	1520	oxidant hydrogen peroxide	[oxidants hydrogen peroxide]	1.5849625007211563	3	1	0	0
10297	1520	day 6 (p	[day 6 (p]	1.5849625007211563	3	1	0	0
10298	1520	proliferation of cell types.	[proliferation of cell types.]	1.5849625007211563	4	1	0	0
10299	1520	administration of megakaryocyte growth	[Administration of megakaryocyte growth]	1.5849625007211563	4	1	0	0
10300	1520	E1a- adenovirus vector	[E1a- adenovirus vectors]	1.5849625007211563	3	1	0	0
10301	1520	direct link between ebv	[direct link between EBV]	1.5849625007211563	4	1	0	0
10302	1520	test ap-1 activity	[tested, AP-1 activity]	1.5849625007211563	3	1	0	0
10303	1520	human gata-1 gene	[human GATA-1 genes]	1.5849625007211563	3	1	0	0
10304	1520	good tolerance of exercise	[better tolerance of exercise]	1.5849625007211563	4	1	0	0
10305	1520	mitogenic stimulation of t-lymphocyte	[mitogenic stimulation of T-lymphocytes]	1.5849625007211563	4	1	0	0
10306	1520	CD2 antigen signal	[CD2 antigen signals]	1.5849625007211563	3	1	0	0
10307	1520	unknown gene in linkage	[unknown gene in linkage]	1.5849625007211563	4	1	0	0
10308	1520	informative female patient	[informative female patients]	1.5849625007211563	3	1	0	0
10309	1520	two mutants, iexc29	[two mutants, IEXC29S]	1.5849625007211563	3	1	0	0
10310	1520	number of thymocyte	[numbers of thymocytes]	1.5849625007211563	3	2	1	1
10311	1520	also in neutrophil	[also in neutrophils]	1.5849625007211563	3	1	0	0
10312	1520	tissue such as lung	[tissues such as lung]	1.5849625007211563	4	1	0	0
10313	1520	causal role in inflammation	[causal role in inflammation]	1.5849625007211563	4	1	0	0
10314	1520	antiproliferative effect of il-10	[antiproliferative effects of IL-10]	1.5849625007211563	4	1	0	0
10315	1520	inhibitory transcriptional activity	[inhibitory transcriptional activities]	1.5849625007211563	3	1	0	0
10316	1520	role of one	[role of one]	1.5849625007211563	3	1	0	0
10317	1520	hiv-1 -replicative cycle	[HIV-1 -replicative cycle]	1.5849625007211563	3	1	0	0
10318	1520	Electrophoretic mobility supershift assay	[Electrophoretic mobility supershift assays]	1.5849625007211563	4	1	0	0
10319	1520	show the cell selectivity	[showing the cell selectivity]	1.5849625007211563	4	1	0	0
10320	1520	induce jagged1 gene expression	[inducing jagged1 gene expression]	1.5849625007211563	4	1	0	0
10321	1520	proteasome inhibitor n-acetyl-leu-leu-norleucinal	[proteasome inhibitor N-acetyl-leu-leu-norleucinal]	1.5849625007211563	3	1	0	0
10322	1520	nuclei of some lymphocyte	[nuclei of some lymphocytes]	1.5849625007211563	4	1	0	0
10323	1520	BamHI C promoter	[BamHI C promoter]	1.5849625007211563	3	1	0	0
10324	1520	one ATF/CRE motif	[One ATF/CRE motif]	1.5849625007211563	3	1	0	0
10325	1520	mutation in region	[mutations in regions]	1.5849625007211563	3	1	0	0
10326	1520	one gliadin peptide	[one gliadin peptides]	1.5849625007211563	3	2	1	1
10327	1520	immunostaining on slide	[immunostaining on slides]	1.5849625007211563	3	1	0	0
10328	1520	important regulatory role	[important regulatory role]	1.5849625007211563	3	1	0	0
10329	1520	novel culture system,	[novel culture system,]	1.5849625007211563	3	1	0	0
10330	1520	mechanism of this activity	[mechanism of this activity]	1.5849625007211563	4	1	0	0
10331	1520	effect on erythropoiesis	[effects on erythropoiesis]	1.5849625007211563	3	1	0	0
10332	1520	class histocompatibility promoter	[class histocompatibility promoters]	1.5849625007211563	3	2	2	2
10333	1520	synthesis of reverse transcription	[synthesis of reverse transcription]	1.5849625007211563	4	1	0	0
10334	1520	transcription factor BSAP	[transcription factor BSAP]	1.5849625007211563	3	2	1	1
10335	1520	inability of il-4	[inability of IL-4]	1.5849625007211563	3	1	0	0
10336	1520	cell surface receptor epor	[cell surface receptor EpoR]	1.5849625007211563	4	1	0	0
10337	1520	other neuroblastoma cell line	[other neuroblastoma cell lines]	1.5849625007211563	4	1	0	0
10338	1520	light-chain gene rearrangement	[light-chain gene rearrangement]	1.5849625007211563	3	1	0	0
10339	1520	1,25 dihydroxyvitamin D3	[1,25 dihydroxyvitamin D3]	1.5849625007211563	3	1	0	0
10340	1520	several zebra -binding site	[several ZEBRA -binding sites]	1.5849625007211563	4	1	0	0
10341	1520	recombinant human nucleolin	[recombinant human nucleolin]	1.5849625007211563	3	1	0	0
10342	1520	expression of wild-type nfat1	[expression of wild-type NFAT1]	1.5849625007211563	4	1	0	0
10343	1520	ribosomal entry site	[ribosomal entry site]	1.5849625007211563	3	2	2	2
10344	1520	contrast, luciferase expression	[contrast, luciferase expression]	1.5849625007211563	3	1	0	0
10345	1520	-contain nf-kappa b	[-containing NF-kappa B]	1.5849625007211563	3	1	0	0
10346	1520	ebv zebra protein	[EBV ZEBRA protein]	1.5849625007211563	3	1	0	0
10347	1520	small maf family protein	[small Maf family protein]	1.5849625007211563	4	1	0	0
10348	1520	tsp gene family	[TSP gene family]	1.5849625007211563	3	1	0	0
10349	1520	IL-2 expression of beta-casein	[IL-2 expression of beta-casein]	1.5849625007211563	4	1	0	0
10350	1520	receptor binding studies.	[receptor binding studies.]	1.5849625007211563	3	1	0	0
10351	1520	site of positive regulation	[site of positive regulation]	1.5849625007211563	4	1	0	0
10352	1520	level of fkbp mrna	[level of FKBP mRNA]	1.5849625007211563	4	1	0	0
10353	1520	less extent, cd11c/cd18	[lesser extent, CD11c/CD18]	1.5849625007211563	3	1	0	0
10354	1520	determine the e2f-1 level	[determining the E2F-1 levels]	1.5849625007211563	4	1	0	0
10355	1520	(j774) monocytic cell line	[(J774) monocytic cell lines]	1.5849625007211563	4	1	0	0
10356	1520	major transcription factor	[major transcription factor]	1.5849625007211563	3	1	0	0
10357	1520	PDTC iron complex	[PDTC iron complex]	1.5849625007211563	3	1	0	0
10358	1520	Oct-2A expression vector	[Oct-2A expression vector]	1.5849625007211563	3	1	0	0
10359	1520	t-cell gene expression	[T-cell gene expression]	1.5849625007211563	3	2	2	2
10360	1520	metabolite of benzene	[metabolite of benzene]	1.5849625007211563	3	2	2	2
10361	1520	vp16 of hsv-2	[VP16 of HSV-2]	1.5849625007211563	3	2	1	1
10362	1520	novel pel cell line	[novel PEL cell lines]	1.5849625007211563	4	1	0	0
10363	1520	appearance of a factor	[appearance of a factor]	1.5849625007211563	4	2	2	2
10364	1520	apoptosis of T lymphocyte	[apoptosis of T lymphocytes]	1.5849625007211563	4	1	0	0
10365	1520	Indeed, erythroid gene expression	[Indeed, erythroid gene expression]	1.5849625007211563	4	1	0	0
10366	1520	analysis of the role	[Analysis of the role]	1.5849625007211563	4	1	0	0
10367	1520	causal relationship to MS	[causal relationship to MS]	1.5849625007211563	4	1	0	0
10368	1520	TcR delta locus	[TcR delta locus]	1.5849625007211563	3	1	0	0
10369	1520	three gata-binding protein	[three GATA-binding proteins]	1.5849625007211563	3	2	1	1
10370	1520	contrast, roll of monocyte	[contrast, rolling of monocytes]	1.5849625007211563	4	1	0	0
10371	1520	apparently nonfunctional sequence motif	[apparently nonfunctional sequence motifs]	1.5849625007211563	4	1	0	0
10372	1520	correlation between ic50 parameter	[correlation between IC50 parameters]	1.5849625007211563	4	1	0	0
10373	1520	cytokine signal pathway	[cytokine signaling pathway]	1.5849625007211563	3	2	1	1
10374	1520	such transdominant rev protein	[such transdominant Rev proteins]	1.5849625007211563	4	1	0	0
10375	1520	one set of phosphoprotein	[one set of phosphoproteins]	1.5849625007211563	4	1	0	0
10376	1520	42 amino acid	[42 amino acids]	1.5849625007211563	3	1	0	0
10377	1520	55 amino acid	[55 amino acids]	1.5849625007211563	3	2	1	1
10378	1520	granulocyte-colony stimulate factor	[granulocyte-colony stimulating factor]	1.5849625007211563	3	2	2	2
10379	1520	implication for c/ebpbeta activity	[implication for C/EBPbeta activity]	1.5849625007211563	4	1	0	0
10380	1520	lps signal cascade	[LPS signaling cascade]	1.5849625007211563	3	1	0	0
10381	1520	nucleus in macrophage	[nucleus in macrophages]	1.5849625007211563	3	1	0	0
10382	1520	cpo gene promoter	[CPO gene promoter]	1.5849625007211563	3	1	0	0
10383	1520	transcription stat binding site	[transcription Stat binding sites]	1.5849625007211563	4	1	0	0
10384	1520	phosphorylation of a peptide	[phosphorylation of a peptide]	1.5849625007211563	4	1	0	0
10385	1520	family of serine protease	[family of serine proteases]	1.5849625007211563	4	1	0	0
10386	1520	different T lymphocyte response	[different T lymphocyte responses]	1.5849625007211563	4	1	0	0
10387	1520	activation of JAK1	[activation of JAK1]	1.5849625007211563	3	1	0	0
10388	1520	activation of JAK2	[activation of JAK2]	1.5849625007211563	3	1	0	0
10389	1520	activation of JAK3	[Activation of JAK3]	1.5849625007211563	3	1	0	0
10390	1520	two latter gene	[two latter genes]	1.5849625007211563	3	1	0	0
10391	1520	promoter deletion construct	[promoter deletion constructs]	1.5849625007211563	3	2	1	1
10392	1520	MHC class ii protein	[MHC class II proteins]	1.5849625007211563	4	2	1	1
10393	1520	role of prb	[role of pRB]	1.5849625007211563	3	1	0	0
10394	1520	tcr activation of ap-1	[TCR activation of AP-1]	1.5849625007211563	4	1	0	0
10395	1520	recognition of a antigen	[recognition of an antigen]	1.5849625007211563	4	1	0	0
10396	1520	melanoma of patient	[melanomas of patients]	1.5849625007211563	3	1	0	0
10397	1520	x box element	[X box elements]	1.5849625007211563	3	1	0	0
10398	1520	intrapulmonary activation of NF-kappaB	[intrapulmonary activation of NF-kappaB]	1.5849625007211563	4	1	0	0
10399	1520	main factor responsible	[main factor responsible]	1.5849625007211563	3	1	0	0
10400	1520	positional effect of Nef	[positional effects of Nef]	1.5849625007211563	4	1	0	0
10401	1520	lymphocyte-specific protein 1 lsp1	[lymphocyte-specific protein 1 LSP1]	1.5849625007211563	4	1	0	0
10402	1520	p65 NF-kappa b gene	[p65 NF-kappa B gene]	1.5849625007211563	4	1	0	0
10403	1520	only TNF alpha	[only TNF alpha]	1.5849625007211563	3	1	0	0
10404	1520	B-CLL cell death	[B-CLL cell death]	1.5849625007211563	3	1	0	0
10405	1520	patient with hyperparathyroidism	[patients with hyperparathyroidism]	1.5849625007211563	3	2	2	2
10406	1520	human er mrna	[human ER mRNA]	1.5849625007211563	3	1	0	0
10407	1520	combination of dopamine	[combination of dopamine]	1.5849625007211563	3	1	0	0
10408	1520	10 patient with thalassaemia	[10 patients with thalassaemia]	1.5849625007211563	4	1	0	0
10409	1520	RARA in APL	[RARA in APL]	1.5849625007211563	3	1	0	0
10410	1520	express human CD80 cho-cd80	[expressing human CD80 CHO-CD80]	1.5849625007211563	4	1	0	0
10411	1520	tnf-alpha on gene expression	[TNF-alpha on gene expression]	1.5849625007211563	4	1	0	0
10412	1520	homozygous codeletion of p16	[homozygous codeletion of p16]	1.5849625007211563	4	1	0	0
10413	1520	minimal repression domain	[minimal repression domain]	1.5849625007211563	3	1	0	0
10414	1520	ligand transcription factor	[ligand transcription factors]	1.5849625007211563	3	1	0	0
10415	1520	metabolite of vitamin D3	[metabolite of vitamin D3]	1.5849625007211563	4	2	2	2
10416	1520	expression of sox9 allele	[expression of SOX9 alleles]	1.5849625007211563	4	1	0	0
10417	1520	myristate acetate PMA	[myristate acetate PMA]	1.5849625007211563	3	1	0	0
10418	1520	immune cell signal event	[immune cell signaling events]	1.5849625007211563	4	1	0	0
10419	1520	thioctic acid alpha-lipoic acid	[thioctic acid alpha-lipoic acid]	1.5849625007211563	4	1	0	0
10420	1520	first amino acid	[first amino acids]	1.5849625007211563	3	2	2	2
10421	1520	effect of TNFalpha	[effect of TNFalpha]	1.5849625007211563	3	1	0	0
10422	1520	tissue from both patient	[tissue from both patients]	1.5849625007211563	4	1	0	0
10423	1520	cell cycle machinery	[cell cycle machinery]	1.5849625007211563	3	1	0	0
10424	1520	HLF ancillary dna-binding domain	[HLF ancillary DNA-binding domain]	1.5849625007211563	4	1	0	0
10425	1520	individual dr unit	[individual DR units]	1.5849625007211563	3	1	0	0
10426	1520	Fibroblast growth factor-1 fgf-1	[Fibroblast growth factor-1 FGF-1]	1.5849625007211563	4	1	0	0
10427	1520	low passage clinical strains.	[low passage clinical strains.]	1.5849625007211563	4	1	0	0
10428	1520	mast cell line	[mast cell lines]	1.5849625007211563	3	1	0	0
10429	1520	contain the lacz gene	[containing the lacZ gene]	1.5849625007211563	4	1	0	0
10430	1520	maximum 40 minute	[maximum 40 min]	1.5849625007211563	3	1	0	0
10431	1520	detectable nf-at protein expression	[detectable NF-AT protein expression]	1.5849625007211563	4	1	0	0
10432	1520	Spi-B gene expression	[Spi-B gene expression]	1.5849625007211563	3	1	0	0
10433	1520	pro-B-cell acute lymphoblastic leukemia	[pro-B-cell acute lymphoblastic leukemia]	1.5849625007211563	4	1	0	0
10434	1520	primarily in T cell	[primarily in T cells]	1.5849625007211563	4	1	0	0
10435	1520	(stat) family, stat1alpha	[(STAT) family, Stat1alpha]	1.5849625007211563	3	1	0	0
10436	1520	constitutive version of c-Raf	[constitutive version of c-Raf]	1.5849625007211563	4	2	2	2
10437	1520	generation by mononuclear (mnc)	[generation by mononuclear (MNC)]	1.5849625007211563	4	1	0	0
10438	1520	four cell line	[four cell lines]	1.5849625007211563	3	2	1	1
10439	1520	mechanism other than ligand	[mechanisms other than ligand]	1.5849625007211563	4	1	0	0
10440	1520	family of 57- protein	[family of 57- proteins]	1.5849625007211563	4	1	0	0
10441	1520	strong repressor element	[strong repressor element]	1.5849625007211563	3	1	0	0
10442	1520	hbd of hmr	[HBD of hMR]	1.5849625007211563	3	1	0	0
10443	1520	cdc2 mrna transcript	[cdc2 mRNA transcripts]	1.5849625007211563	3	1	0	0
10444	1520	comparable level in U-937	[comparable levels in U-937]	1.5849625007211563	4	1	0	0
10445	1520	Lef/Tcf transcription factor family	[Lef/Tcf transcription factor family]	1.5849625007211563	4	1	0	0
10446	1520	extracellular domain consist	[extracellular domain consisting]	1.5849625007211563	3	1	0	0
10447	1520	elevation of camp	[elevation of cAMP]	1.5849625007211563	3	1	0	0
10448	1520	leukocyte-platelet conjugate in patient	[leukocyte-platelet conjugates in patients]	1.5849625007211563	4	1	0	0
10449	1520	parent compound by cysteine	[parent compound by cysteine]	1.5849625007211563	4	1	0	0
10450	1520	pathophysiology of inflammation	[pathophysiology of inflammation]	1.5849625007211563	3	1	0	0
10451	1520	thrombin receptor mrna	[thrombin receptor mRNA]	1.5849625007211563	3	1	0	0
10452	1520	mammary gland factor-Stat5	[mammary gland factor-Stat5]	1.5849625007211563	3	2	1	1
10453	1520	monocyte chemotactic activity	[monocyte chemotactic activity]	1.5849625007211563	3	2	1	1
10454	1520	dnase I footprint assay	[DNase I footprint assays]	1.5849625007211563	4	1	0	0
10455	1520	35s- tr alpha	[35S- TR alpha]	1.5849625007211563	3	2	2	2
10456	1520	expression of gata-1 gene	[expression of GATA-1 genes]	1.5849625007211563	4	1	0	0
10457	1520	result of functional redundancy	[result of functional redundancy]	1.5849625007211563	4	1	0	0
10458	1520	c-cerba/thyroid hormone receptor	[c-cerbA/thyroid hormone receptor]	1.5849625007211563	3	1	0	0
10459	1520	chemotherapy paclitaxel expression	[chemotherapy paclitaxel expression]	1.5849625007211563	3	1	0	0
10460	1520	transformation-related activity (colony formation	[transformation-related activity (colony formation]	1.5849625007211563	4	1	0	0
10461	1520	lysis of the cells.	[lysis of the cells.]	1.5849625007211563	4	1	0	0
10462	1520	pertussis-toxin-sensitive gi/go protein	[pertussis-toxin-sensitive Gi/Go protein]	1.5849625007211563	3	1	0	0
10463	1520	monocyte protein 1 mcp-1	[monocyte protein 1 MCP-1]	1.5849625007211563	4	1	0	0
10464	1520	familial ovarian cancer case	[familial ovarian cancer cases]	1.5849625007211563	4	1	0	0
10465	1520	utilize the transient transfection	[utilizing the transient transfection]	1.5849625007211563	4	1	0	0
10466	1520	receptor of the cell	[receptor of the cells]	1.5849625007211563	4	1	0	0
10467	1520	ad2 virus infection	[Ad2 virus infection]	1.5849625007211563	3	1	0	0
10468	1520	two biological process	[two biological processes]	1.5849625007211563	3	1	0	0
10469	1520	prominent increase in level	[prominent increase in levels]	1.5849625007211563	4	1	0	0
10470	1520	effect of the mab	[effect of the mAb]	1.5849625007211563	4	1	0	0
10471	1520	9-29 ppt i-te	[9-29 ppt I-TE]	1.5849625007211563	3	1	0	0
10472	1520	positive/negative regulation in vivo	[positive/negative regulation in vivo]	1.5849625007211563	4	1	0	0
10473	1520	amino acid sequence identity	[amino acid sequence identity]	1.5849625007211563	4	2	1	1
10474	1520	period of 30 days.	[period of 30 days.]	1.5849625007211563	4	1	0	0
10475	1520	primary response (myd) gene	[primary response (MyD) genes]	1.5849625007211563	4	1	0	0
10476	1520	ISG15-LTR-IFN hybrid gene	[ISG15-LTR-IFN hybrid gene]	1.5849625007211563	3	1	0	0
10477	1520	2 mM concentration	[2 mM concentration]	1.5849625007211563	3	1	0	0
10478	1520	RANKL nf-kappab activation	[RANKL NF-kappaB activation]	1.5849625007211563	3	1	0	0
10479	1520	family of regulatory protein	[family of regulatory proteins]	1.5849625007211563	4	2	2	2
10480	1520	IL-2 receptor alpha expression	[IL-2 receptor alpha expression]	1.5849625007211563	4	1	0	0
10481	1520	absence of estrogen	[absence of estrogen]	1.5849625007211563	3	1	0	0
10482	1520	nuclease- hypersensitive site	[nuclease- hypersensitive site]	1.5849625007211563	3	1	0	0
10483	1520	level of il-2 mrna	[levels of IL-2 mRNA]	1.5849625007211563	4	1	0	0
10484	1520	inhibitory effect of cysteamine	[inhibitory effect of cysteamine]	1.5849625007211563	4	1	0	0
10485	1520	production of erythroid cell	[production of erythroid cells]	1.5849625007211563	4	1	0	0
10486	1520	number of recent study	[number of recent studies]	1.5849625007211563	4	1	0	0
10487	1520	resistant icr27tk.3 cell	[resistant ICR27TK.3 cells]	1.5849625007211563	3	1	0	0
10488	1520	other lymphocyte-specific dna-binding protein	[other lymphocyte-specific DNA-binding proteins]	1.5849625007211563	4	1	0	0
10489	1520	many inherent problem	[many inherent problems.]	1.5849625007211563	3	1	0	0
10490	1520	b cell repertoire	[B cell repertoire]	1.5849625007211563	3	1	0	0
10491	1520	hemopoietic myeloid cell differentiation	[hemopoietic myeloid cell differentiation]	1.5849625007211563	4	1	0	0
10492	1520	optimal DNA sequence	[optimal DNA sequences]	1.5849625007211563	3	1	0	0
10493	1520	level of stat1	[levels of Stat1]	1.5849625007211563	3	2	2	2
10494	1520	two NF-kappaB-binding site	[two NF-kappaB-binding sites]	1.5849625007211563	3	1	0	0
10495	1520	X1 box-specific activity	[X1 box-specific activities]	1.5849625007211563	3	2	2	2
10496	1520	Consequently, cytosolic activation	[Consequently, cytosolic activation]	1.5849625007211563	3	1	0	0
10497	1520	insertion of oligonucleotide	[Insertion of oligonucleotides]	1.5849625007211563	3	1	0	0
10498	1520	respect to t1	[respect to T1]	1.5849625007211563	3	1	0	0
10499	1520	3'-azido-3'-deoxythymidine AZT a inhibitor	[3'-azido-3'-deoxythymidine AZT an inhibitor]	1.5849625007211563	4	1	0	0
10500	1520	pathogenesis of lupus erythematosus	[pathogenesis of lupus erythematosus]	1.5849625007211563	4	1	0	0
10501	1520	ap-1 regulation of c-jun	[AP-1 regulation of c-jun]	1.5849625007211563	4	1	0	0
10502	1520	expression of interleukin-3	[expression of interleukin-3]	1.5849625007211563	3	2	2	2
10503	1520	downstream activation event	[downstream activation events]	1.5849625007211563	3	1	0	0
10504	1520	human promyelocytic leukemia cell	[human promyelocytic leukemia cells]	1.5849625007211563	4	1	0	0
10505	1520	basal LTR function	[basal LTR function]	1.5849625007211563	3	1	0	0
10506	1520	tal1 express endogeneous tal1	[TAL1 expressing endogeneous TAL1]	1.5849625007211563	4	1	0	0
10507	1520	expression of interleukin 2	[expression of interleukin 2]	1.5849625007211563	4	1	0	0
10508	1520	competition with other gene	[competition with other genes]	1.5849625007211563	4	1	0	0
10509	1520	increase in pha proliferation	[increase in PHA proliferation]	1.5849625007211563	4	1	0	0
10510	1520	respiratory burst activity	[respiratory burst activity]	1.5849625007211563	3	1	0	0
10511	1520	peripheral blood monocytes.	[peripheral blood monocytes.]	1.5849625007211563	3	2	1	1
10512	1520	almost identical reaction	[almost identical reaction]	1.5849625007211563	3	1	0	0
10513	1520	PMA nuclear factors,	[PMA nuclear factors,]	1.5849625007211563	3	1	0	0
10514	1520	site of ubiquitinylation	[sites of ubiquitinylation]	1.5849625007211563	3	1	0	0
10515	1520	tgf-alpha production by eosinophil	[TGF-alpha production by eosinophils]	1.5849625007211563	4	1	0	0
10516	1520	suppression of cd11b/cd18 expression	[suppression of CD11b/CD18 expression]	1.5849625007211563	4	1	0	0
10517	1520	redox homeostasis of cell	[redox homeostasis of cells]	1.5849625007211563	4	1	0	0
10518	1520	240 minute (phase 2)	[240 minutes (phase 2)]	1.5849625007211563	4	1	0	0
10519	1520	chimeric promoter construction	[chimeric promoter constructions]	1.5849625007211563	3	1	0	0
10520	1520	pathway regulate gene expression	[pathway regulating gene expression]	1.5849625007211563	4	2	2	2
10521	1520	dual stimulation with ionomycin	[dual stimulation with ionomycin]	1.5849625007211563	4	1	0	0
10522	1520	respect to gr	[respect to GR]	1.5849625007211563	3	1	0	0
10523	1520	nonreceptor tyrosine kinase jak2	[nonreceptor tyrosine kinases JAK2]	1.5849625007211563	4	1	0	0
10524	1520	bronchoalveolar lavage (bal) cell	[Bronchoalveolar lavage (BAL) cells]	1.5849625007211563	4	2	1	1
10525	1520	induction of ebv antigen	[induction of EBV antigens]	1.5849625007211563	4	1	0	0
10526	1520	il-2 transcription in pbl	[IL-2 transcription in PBL]	1.5849625007211563	4	1	0	0
10527	1520	even in cell	[even in cells]	1.5849625007211563	3	1	0	0
10528	1520	IL-1 beta mrna accumulation	[IL-1 beta mRNA accumulation]	1.5849625007211563	4	1	0	0
10529	1520	canonical tata element	[canonical TATA elements]	1.5849625007211563	3	1	0	0
10530	1520	T lymphocyte protein	[T lymphocyte protein]	1.5849625007211563	3	2	1	1
10531	1520	CD3 complex expression	[CD3 complex expression]	1.5849625007211563	3	1	0	0
10532	1520	first formal demonstration	[first formal demonstration]	1.5849625007211563	3	1	0	0
10533	1520	level of cortisol	[levels of cortisol]	1.5849625007211563	3	2	2	2
10534	1520	acute myocardial infarction AMI	[acute myocardial infarction AMI]	1.5849625007211563	4	1	0	0
10535	1520	intermediate size range (33-39	[intermediate size range (33-39]	1.5849625007211563	4	1	0	0
10536	1520	18.5% cd68+ cell	[18.5% CD68+ cells]	1.5849625007211563	3	1	0	0
10537	1520	severe fura toxicity secondary	[severe FUra toxicity secondary]	1.5849625007211563	4	1	0	0
10538	1520	initiation signal downstream	[initiation signaling downstream]	1.5849625007211563	3	1	0	0
10539	1520	analysis of SJO extract	[analysis of SJO extracts]	1.5849625007211563	4	1	0	0
10540	1520	regulatory domain of pp56(lck)	[regulatory domains of pp56(lck)]	1.5849625007211563	4	1	0	0
10541	1520	vcam-1 a 110-kDa member	[VCAM-1 a 110-kDa member]	1.5849625007211563	4	1	0	0
10542	1520	zdevd-fmk a inhibitor specific	[zDEVD-fmk an inhibitor specific]	1.5849625007211563	4	1	0	0
10543	1520	index of lymphocytic infiltration	[index of lymphocytic infiltration]	1.5849625007211563	4	1	0	0
10544	1520	American Society of Hematology	[American Society of Hematology]	1.5849625007211563	4	1	0	0
10545	1520	Sp1 bind motif	[Sp1 binding motif]	1.5849625007211563	3	1	0	0
10546	1520	expression of tissue factor	[expression of tissue factor]	1.5849625007211563	4	2	1	1
10547	1520	kappa b binding protein	[Kappa B binding proteins]	1.5849625007211563	4	1	0	0
10548	1520	other nonsteroidal anti-inflammatory drug	[other nonsteroidal anti-inflammatory drugs]	1.5849625007211563	4	2	2	2
10549	1520	3 to 15 years)	[3 to 15 years)]	1.5849625007211563	4	1	0	0
10550	1520	strong transactivation domain present	[strong transactivation domain present]	1.5849625007211563	4	1	0	0
10551	1520	persistence of T cell	[persistence of T cells]	1.5849625007211563	4	1	0	0
10552	1520	cd8+ T cell clone	[CD8+ T cell clones]	1.5849625007211563	4	1	0	0
10553	1520	normal peripheral blood monocyte	[normal peripheral blood monocytes]	1.5849625007211563	4	1	0	0
10554	1520	lps tumor necrosis factor	[LPS tumor necrosis factor]	1.5849625007211563	4	1	0	0
10555	1520	activation of phospholipase a2	[activation of phospholipase A2]	1.5849625007211563	4	1	0	0
10556	1520	E2F-4 /p130 complex	[E2F-4 /p130 complex]	1.5849625007211563	3	1	0	0
10557	1520	host cell activation	[host cell activation]	1.5849625007211563	3	2	2	2
10558	1520	cluster of amino acid	[clusters of amino acids]	1.5849625007211563	4	1	0	0
10559	1520	proinflammatory cytokine il-6	[proinflammatory cytokines IL-6]	1.5849625007211563	3	1	0	0
10560	1520	maximal reaction velocity (vmax)	[maximal reaction velocity (Vmax)]	1.5849625007211563	4	1	0	0
10561	1520	peak inhibitory activity	[Peak inhibitory activity]	1.5849625007211563	3	1	0	0
10562	1520	nuclear extract of HUVEC	[nuclear extracts of HUVEC]	1.5849625007211563	4	1	0	0
10563	1520	primary target of AML1/ETO	[primary target of AML1/ETO]	1.5849625007211563	4	1	0	0
10564	1520	addition of ctla4ig	[addition of CTLA4Ig]	1.5849625007211563	3	1	0	0
10565	1520	pathogenesis of rheumatoid arthritis	[pathogenesis of rheumatoid arthritis]	1.5849625007211563	4	1	0	0
10566	1520	cDNA clone b4-2	[cDNA clone B4-2]	1.5849625007211563	3	1	0	0
10567	1520	25-mer pml/ rar-alpha	[25-mer pml/ RAR-alpha]	1.5849625007211563	3	1	0	0
10568	1520	transcription in pre-B	[transcription in pre-B]	1.5849625007211563	3	1	0	0
10569	1520	active raf-1 mek1 expression	[active Raf-1 MEK1 expression]	1.5849625007211563	4	1	0	0
10570	1520	IL-13R alpha chain	[IL-13R alpha chain]	1.5849625007211563	3	1	0	0
10571	1520	4.55 0.67 nm,	[4.55 0.67 nM,]	1.5849625007211563	3	1	0	0
10572	1520	adrenal pituitary axis	[adrenal pituitary axis]	1.5849625007211563	3	1	0	0
10573	1520	GATA consensus site	[GATA consensus site]	1.5849625007211563	3	1	0	0
10574	1520	epitope mapping within e1b	[epitope mapping within E1B]	1.5849625007211563	4	1	0	0
10575	1520	DNA divide cells, fludarabine	[DNA dividing cells, fludarabine]	1.5849625007211563	4	1	0	0
10576	1520	subsequent squelching of transcription.	[subsequent squelching of transcription.]	1.5849625007211563	4	1	0	0
10577	1520	inhibitory activity of cyclosporine	[inhibitory activity of cyclosporine]	1.5849625007211563	4	1	0	0
10578	1520	nfat family protein	[NFAT family proteins]	1.5849625007211563	3	1	0	0
10579	1520	mutation of this site	[Mutations of this site]	1.5849625007211563	4	1	0	0
10580	1520	c6.1b/mtcp1 A1 transcript at-Xq28	[c6.1B/MTCP1 A1 transcript at-Xq28]	1.5849625007211563	4	1	0	0
10581	1520	0.82 to 1.0 unit	[0.82 to 1.0 units]	1.5849625007211563	4	1	0	0
10582	1520	lymphoid system GrpL	[lymphoid system GrpL]	1.5849625007211563	3	1	0	0
10583	1520	ut-7 cell (2400	[UT-7 cells (2400]	1.5849625007211563	3	1	0	0
10584	1520	islet cell antibody	[islet cell antibodies]	1.5849625007211563	3	1	0	0
10585	1520	32p-labeled ht-2 cell	[32P-labeled HT-2 cells]	1.5849625007211563	3	1	0	0
10586	1520	chicken NF-M transcription factor	[Chicken NF-M transcription factor]	1.5849625007211563	4	1	0	0
10587	1520	pml-rar a aberrant form	[PML-RAR an aberrant form]	1.5849625007211563	4	1	0	0
10588	1520	ebna3c on reporter plasmid	[EBNA3C on reporter plasmids]	1.5849625007211563	4	1	0	0
10589	1520	detection of residual disease	[Detection of residual disease]	1.5849625007211563	4	2	2	2
10590	1520	[change in plasma interleukin-1	[[Changes in plasma interleukin-1]	1.5849625007211563	4	1	0	0
10591	1520	follow-up of three patient	[Follow-up of three patient]	1.5849625007211563	4	1	0	0
10592	1520	three human tissue	[three human tissues]	1.5849625007211563	3	1	0	0
10593	1520	late (3-5 day	[late (3-5 days)]	1.5849625007211563	3	1	0	0
10594	1520	nf kappab family protein	[NF kappaB family proteins]	1.5849625007211563	4	1	0	0
10595	1520	Jak3 JH2 domain	[Jak3 JH2 domain]	1.5849625007211563	3	1	0	0
10596	1520	LFA-I beta chain CD18	[LFA-I beta chain CD18]	1.5849625007211563	4	1	0	0
10597	1520	primary pathogenic role	[primary pathogenic role]	1.5849625007211563	3	1	0	0
10598	1520	approximately 30-40 torr),	[approximately 30-40 Torr),]	1.5849625007211563	3	1	0	0
10599	1520	complex tissue-specific structure	[complex tissue-specific structure]	1.5849625007211563	3	1	0	0
10600	1520	bipolar disorder (52 euthymic,	[bipolar disorder (52 euthymic,]	1.5849625007211563	4	1	0	0
10601	1520	nuclear antigen ebna-5	[nuclear antigen EBNA-5]	1.5849625007211563	3	1	0	0
10602	1520	GM-CSF promoter region (position	[GM-CSF promoter region (positions]	1.5849625007211563	4	1	0	0
10603	1520	subsequent interferon alpha	[subsequent interferon alpha]	1.5849625007211563	3	1	0	0
10604	1520	Nuclear factor nf-kb	[Nuclear factor NF-kB]	1.5849625007211563	3	1	0	0
10605	1520	hypotetraploid DNA (4C) content	[hypotetraploid DNA (4C) content]	1.5849625007211563	4	1	0	0
10606	1520	murine cDNA probe	[murine cDNA probe]	1.5849625007211563	3	1	0	0
10607	1520	beta-galactosidase mrna level	[beta-galactosidase mRNA levels]	1.5849625007211563	3	1	0	0
10608	1520	basic helix-loop-helix protein e2a	[basic helix-loop-helix proteins E2A]	1.5849625007211563	4	1	0	0
10609	1520	ca2+ /calmodulin-dependent protein phosphatase	[Ca2+ /calmodulin-dependent protein phosphatase]	1.5849625007211563	4	2	1	1
10610	1520	several area include Sp1	[several areas including Sp1]	1.5849625007211563	4	1	0	0
10611	1520	TNF-alpha induction of apoptosis	[TNF-alpha induction of apoptosis]	1.5849625007211563	4	1	0	0
10612	1520	change in the dissociation	[changes in the dissociation]	1.5849625007211563	4	1	0	0
10613	1520	T cell stimulus	[T cell stimuli]	1.5849625007211563	3	2	2	2
10614	1520	c-fo content of ap-1	[c-Fos content of AP-1]	1.5849625007211563	4	1	0	0
10615	1520	STAT6 binding site	[STAT6 binding site]	1.5849625007211563	3	1	0	0
10616	1520	nf-kappab -dependent transcriptional activation	[NF-kappaB -dependent transcriptional activation]	1.5849625007211563	4	1	0	0
10617	1520	helper (th) cell	[helper (Th) cells]	1.5849625007211563	3	1	0	0
10618	1520	large amount of tnf-alpha	[large amounts of TNF-alpha]	1.5849625007211563	4	1	0	0
10619	1520	presence of a virus	[presence of a virus]	1.5849625007211563	4	1	0	0
10620	1520	relation circulate cortisol concentration	[relation circulating cortisol concentrations]	1.5849625007211563	4	1	0	0
10621	1520	Glucocorticoid receptor GcR	[Glucocorticoid receptors GcR]	1.5849625007211563	3	1	0	0
10622	1520	human lymphoid tumor	[human lymphoid tumors]	1.5849625007211563	3	1	0	0
10623	1520	signal to the development	[signaling to the development]	1.5849625007211563	4	1	0	0
10624	1520	naive memory T lymphocyte	[naive memory T lymphocytes]	1.5849625007211563	4	1	0	0
10625	1520	Kruppel-like zinc finger protein	[Kruppel-like zinc finger proteins]	1.5849625007211563	4	1	0	0
10626	1520	only differentiate to monocyte	[only differentiating to monocytes]	1.5849625007211563	4	1	0	0
10627	1520	other systems, fragmentation	[other systems, fragmentation]	1.5849625007211563	3	1	0	0
10628	1520	CTL response in vivo	[CTL responses in vivo]	1.5849625007211563	4	2	1	1
10629	1520	secretion of myeloid cytokine	[Secretion of myeloid cytokines]	1.5849625007211563	4	1	0	0
10630	1520	induce CAT activity	[inducing CAT activity]	1.5849625007211563	3	2	2	2
10631	1520	target of the cell.	[target of the cell.]	1.5849625007211563	4	1	0	0
10632	1520	interleukin-6 kappa b-related motif	[interleukin-6 kappa B-related motifs]	1.5849625007211563	4	1	0	0
10633	1520	interferon beta ifn-beta promoter	[interferon beta IFN-beta promoter]	1.5849625007211563	4	1	0	0
10634	1520	one octamer motif October	[one octamer motif Oct]	1.5849625007211563	4	1	0	0
10635	1520	human irf-2 gene	[human IRF-2 gene]	1.5849625007211563	3	2	1	1
10636	1520	therapeutic effect of aspirin	[therapeutic effects of aspirin]	1.5849625007211563	4	1	0	0
10637	1520	normal wild type er	[normal wild type ER]	1.5849625007211563	4	1	0	0
10638	1520	decrease in tyrosine phosphorylation	[decrease in tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
10639	1520	human vein cell huvec	[human vein cells HUVECs]	1.5849625007211563	4	2	2	2
10640	1520	human mouse T cell	[human mouse T cells]	1.5849625007211563	4	2	1	1
10641	1520	differentiation in k562 cell	[differentiation in K562 cells]	1.5849625007211563	4	1	0	0
10642	1520	location of Sp140	[location of Sp140]	1.5849625007211563	3	1	0	0
10643	1520	stage of maturation,	[stages of maturation,]	1.5849625007211563	3	2	2	2
10644	1520	activation of protein-1	[activation of protein-1]	1.5849625007211563	3	1	0	0
10645	1520	absence of junb	[absence of JunB]	1.5849625007211563	3	1	0	0
10646	1520	nf-at gene expression	[NF-AT gene expression]	1.5849625007211563	3	1	0	0
10647	1520	cell surface hla-dr antigen	[cell surface HLA-DR antigens]	1.5849625007211563	4	1	0	0
10648	1520	mature, rest b cell	[mature, resting B cells]	1.5849625007211563	4	1	0	0
10649	1520	hiv-1 replication in om10.1	[HIV-1 replication in OM10.1]	1.5849625007211563	4	1	0	0
10650	1520	use pure recombinant p21ras	[using pure recombinant p21ras]	1.5849625007211563	4	1	0	0
10651	1520	engagement of leukocyte integrin	[engagement of leukocyte integrins]	1.5849625007211563	4	1	0	0
10652	1520	numerous inflammatory process	[numerous inflammatory processes]	1.5849625007211563	3	1	0	0
10653	1520	express wild-type human CD40	[expressing wild-type human CD40]	1.5849625007211563	4	1	0	0
10654	1520	pretreatment with tnf-alpha	[pretreatment with TNF-alpha]	1.5849625007211563	3	1	0	0
10655	1520	two b coactivator	[two B coactivators]	1.5849625007211563	3	2	2	2
10656	1520	analysis of gene	[Analysis of genes]	1.5849625007211563	3	2	2	2
10657	1520	surface of target cell	[surface of target cells]	1.5849625007211563	4	1	0	0
10658	1520	hla-dr on the surface	[HLA-DR on the surface]	1.5849625007211563	4	1	0	0
10659	1520	induction of CD20 mrna	[induction of CD20 mRNA]	1.5849625007211563	4	1	0	0
10660	1520	Jak Janus kinase	[Jak Janus kinases]	1.5849625007211563	3	1	0	0
10661	1520	dna-binding property of HIV-TF1	[DNA-binding properties of HIV-TF1]	1.5849625007211563	4	1	0	0
10662	1520	IL-4 p0 element	[IL-4 P0 element]	1.5849625007211563	3	1	0	0
10663	1520	sexual dimorphism of autoimmunity	[sexual dimorphism of autoimmunity]	1.5849625007211563	4	1	0	0
10664	1520	remarkable b cell hyperreactivity	[remarkable B cell hyperreactivity]	1.5849625007211563	4	1	0	0
10665	1520	inhalation of oxygen	[inhalation of oxygen]	1.5849625007211563	3	1	0	0
10666	1520	release of proteolytic activity	[release of proteolytic activities]	1.5849625007211563	4	1	0	0
10667	1520	same parental cell	[same parental cells]	1.5849625007211563	3	1	0	0
10668	1520	purine-rich cd3r element	[purine-rich CD3R element]	1.5849625007211563	3	1	0	0
10669	1520	transactivation by ETS1	[Transactivation by ETS1]	1.5849625007211563	3	1	0	0
10670	1520	Jak/Stat signal transducer pathway	[Jak/Stat signal transducer pathway]	1.5849625007211563	4	1	0	0
10671	1520	physical interaction between AML1	[physical interactions between AML1]	1.5849625007211563	4	1	0	0
10672	1520	medium without serum	[medium without serum]	1.5849625007211563	3	1	0	0
10673	1520	growth of erythroid cell	[growth of erythroid cells]	1.5849625007211563	4	1	0	0
10674	1520	month of bed rest	[month of bed rest]	1.5849625007211563	4	2	2	2
10675	1520	decrease in gr binding	[decrease in GR binding]	1.5849625007211563	4	1	0	0
10676	1520	receptor complex binding	[receptor complex binding]	1.5849625007211563	3	1	0	0
10677	1520	dual signal pathway	[dual signal pathway]	1.5849625007211563	3	1	0	0
10678	1520	level of transcriptional control	[level of transcriptional control]	1.5849625007211563	4	2	1	1
10679	1520	acute ethanol treatment	[acute ethanol treatment]	1.5849625007211563	3	2	1	1
10680	1520	component of the body	[component of the body]	1.5849625007211563	4	2	2	2
10681	1520	different cell surface event	[different cell surface events]	1.5849625007211563	4	1	0	0
10682	1520	erythroleukemic cell line k562	[erythroleukemic cell line K562]	1.5849625007211563	4	1	0	0
10683	1520	response to TNF	[response to TNF]	1.5849625007211563	3	1	0	0
10684	1520	silent normal c-myc allele	[silent normal c-myc allele]	1.5849625007211563	4	1	0	0
10685	1520	cyclosporin a -resistant pathway	[cyclosporin A -resistant pathway]	1.5849625007211563	4	1	0	0
10686	1520	CK-1 /CD28RE region	[CK-1 /CD28RE region]	1.5849625007211563	3	1	0	0
10687	1520	expression of mhc-class antigen	[expression of MHC-class antigens]	1.5849625007211563	4	1	0	0
10688	1520	mutant ciita construct	[mutant CIITA constructs]	1.5849625007211563	3	1	0	0
10689	1520	I tax activation	[I Tax activation]	1.5849625007211563	3	1	0	0
10690	1520	cross-linking of CD28 CD2	[cross-linking of CD28 CD2]	1.5849625007211563	4	1	0	0
10691	1520	blood cell formation.	[blood cell formation.]	1.5849625007211563	3	1	0	0
10692	1520	tip of herpesvirus saimiry	[tip of herpesvirus saimiri]	1.5849625007211563	4	1	0	0
10693	1520	head during radiation therapy	[head during radiation therapy]	1.5849625007211563	4	1	0	0
10694	1520	2-day incubation in LDL	[2-day incubation in LDL]	1.5849625007211563	4	1	0	0
10695	1520	addition increase understanding	[addition increasing understanding]	1.5849625007211563	3	1	0	0
10696	1520	left adnexal region	[left adnexal region]	1.5849625007211563	3	1	0	0
10697	1520	t-cell-specific transcription factor athat	[T-cell-specific transcription factor athat]	1.5849625007211563	4	1	0	0
10698	1520	population of this cell	[population of these cells]	1.5849625007211563	4	1	0	0
10699	1520	nuclei in cd1a+ cell	[nuclei in CD1a+ cells]	1.5849625007211563	4	1	0	0
10700	1520	eligible high risk woman	[Eligible high risk women]	1.5849625007211563	4	1	0	0
10701	1520	adherence in the presence	[adherence in the presence]	1.5849625007211563	4	1	0	0
10702	1520	RGD -adherent monocyte	[RGD -adherent monocytes]	1.5849625007211563	3	1	0	0
10703	1520	encode the N-terminal portion	[encoding the N-terminal portion]	1.5849625007211563	4	1	0	0
10704	1520	apoptotic effect of triptolide	[apoptotic effect of triptolide]	1.5849625007211563	4	1	0	0
10705	1520	aids dementia complex	[AIDS dementia complex]	1.5849625007211563	3	1	0	0
10706	1520	decrease in cell proliferation	[decrease in cell proliferation]	1.5849625007211563	4	2	1	1
10707	1520	yeast saccharomy cerevisiae	[yeast Saccharomyces cerevisiae]	1.5849625007211563	3	1	0	0
10708	1520	infectious hiv-1 molecular clone	[infectious HIV-1 molecular clone]	1.5849625007211563	4	1	0	0
10709	1520	regulator of acid liberation	[regulator of acid liberation]	1.5849625007211563	4	1	0	0
10710	1520	inhibition in human monocyte	[inhibition in human monocytes]	1.5849625007211563	4	1	0	0
10711	1520	15 normal woman	[15 normal women]	1.5849625007211563	3	1	0	0
10712	1520	Northern blot hybridization	[Northern blot hybridization]	1.5849625007211563	3	1	0	0
10713	1520	loss of C/EBPalpha	[loss of C/EBPalpha]	1.5849625007211563	3	1	0	0
10714	1520	expression of marker specific	[expression of markers specific]	1.5849625007211563	4	1	0	0
10715	1520	role in response	[role in responses]	1.5849625007211563	3	2	2	2
10716	1520	b-cell-specific transcription factor otf-2	[B-cell-specific transcription factor OTF-2]	1.5849625007211563	4	1	0	0
10717	1520	decrease in transcription activity	[decrease in transcription activity]	1.5849625007211563	4	1	0	0
10718	1520	factor in bovine colostrum	[factor in bovine colostrum]	1.5849625007211563	4	2	1	1
10719	1520	participate in the activation	[participating in the activation]	1.5849625007211563	4	1	0	0
10720	1520	addition, bronchoalveolar lavage level	[addition, bronchoalveolar lavage levels]	1.5849625007211563	4	1	0	0
10721	1520	I trans-activator tax1 antigen	[I trans-activator tax1 antigen]	1.5849625007211563	4	1	0	0
10722	1520	b-cell line to apoptosis	[B-cell lines to apoptosis]	1.5849625007211563	4	1	0	0
10723	1520	leukemic myeloid cell	[leukemic myeloid cells]	1.5849625007211563	3	1	0	0
10724	1520	more periodontal research	[more periodontal research]	1.5849625007211563	3	1	0	0
10725	1520	I kappa b -alpha	[I kappa B -alpha]	1.5849625007211563	4	1	0	0
10726	1520	even in the presence	[even in the presence]	1.5849625007211563	4	5	4	1
10727	1520	response of the cell	[response of the cells]	1.5849625007211563	4	1	0	0
10728	1520	result in expression	[resulting in expression]	1.5849625007211563	3	2	2	2
10729	1520	cyclin/cdk activation by CAK	[cyclin/cdks activation by CAK]	1.5849625007211563	4	1	0	0
10730	1520	cell with substrate.	[cells with substrate.]	1.5849625007211563	3	1	0	0
10731	1520	endogenous cholesterol synthesis	[endogenous cholesterol synthesis]	1.5849625007211563	3	2	1	1
10732	1520	pathway of tpa	[pathway of TPA]	1.5849625007211563	3	1	0	0
10733	1520	regulation of calcium homeostasis	[regulation of calcium homeostasis]	1.5849625007211563	4	1	0	0
10734	1520	negative correlation between hyperthermia	[negative correlation between hyperthermia]	1.5849625007211563	4	1	0	0
10735	1520	non- il-2 -produce cell	[non- IL-2 -producing cells]	1.5849625007211563	4	1	0	0
10736	1520	wt1 in k562	[WT1 in K562]	1.5849625007211563	3	1	0	0
10737	1520	gld T cell	[gld T cells]	1.5849625007211563	3	1	0	0
10738	1520	correlation with inflammation	[correlation with inflammation]	1.5849625007211563	3	1	0	0
10739	1520	pld action on phospholipid	[PLD action on phospholipids]	1.5849625007211563	4	1	0	0
10740	1520	phorbol myristate acetate effect	[phorbol myristate acetate effect]	1.5849625007211563	4	1	0	0
10741	1520	receptor-1 cell surface protein	[receptor-1 cell surface protein]	1.5849625007211563	4	1	0	0
10742	1520	onset of abnormality	[onset of abnormalities]	1.5849625007211563	3	1	0	0
10743	1520	poorly virulent mycobacteria	[poorly virulent mycobacteria]	1.5849625007211563	3	1	0	0
10744	1520	nfatc mrna accumulation	[NFATc mRNA accumulation]	1.5849625007211563	3	1	0	0
10745	1520	least 23 P.	[least 23 h.]	1.5849625007211563	3	1	0	0
10746	1520	absence of PhoP	[absence of PhoP]	1.5849625007211563	3	1	0	0
10747	1520	anti-CD3 antibody mab	[anti-CD3 antibody mAb]	1.5849625007211563	3	2	2	2
10748	1520	cd14 a glycosylphosphatidylinositol-linked antigen	[CD14 a glycosylphosphatidylinositol-linked antigen]	1.5849625007211563	4	1	0	0
10749	1520	regulate nf-kappa b activation	[regulating NF-kappa B activation]	1.5849625007211563	4	1	0	0
10750	1520	familial (fh) subject	[familial (FH) subjects]	1.5849625007211563	3	1	0	0
10751	1520	human peripheral blood neutrophil	[human peripheral blood neutrophils]	1.5849625007211563	4	1	0	0
10752	1520	immature myeloid cell	[immature myeloid cells]	1.5849625007211563	3	2	2	2
10753	1520	serine/threonine protein kinase c	[serine/threonine protein kinase C]	1.5849625007211563	4	1	0	0
10754	1520	diverse physiologic role	[diverse physiologic roles]	1.5849625007211563	3	1	0	0
10755	1520	chimeric e2a- HLF protein	[chimeric E2A- HLF proteins]	1.5849625007211563	4	1	0	0
10756	1520	various NF-kappaB subunit	[various NF-kappaB subunits]	1.5849625007211563	3	1	0	0
10757	1520	p50 steady-state protein level	[p50 steady-state protein levels]	1.5849625007211563	4	1	0	0
10758	1520	loss of bcl-2 expression	[loss of bcl-2 expression]	1.5849625007211563	4	1	0	0
10759	1520	rapid turnover rate	[rapid turnover rate]	1.5849625007211563	3	1	0	0
10760	1520	glucocorticoid receptor regulation	[glucocorticoid receptor regulation]	1.5849625007211563	3	1	0	0
10761	1520	content of membrane protein	[content of membrane proteins]	1.5849625007211563	4	1	0	0
10762	1520	underlying molecular mechanism	[underlying molecular mechanism]	1.5849625007211563	3	2	1	1
10763	1520	ectopic expression of spi-1	[ectopic expression of spi-1]	1.5849625007211563	4	1	0	0
10764	1520	persistent inflammatory arthritis	[persistent inflammatory arthritis]	1.5849625007211563	3	3	2	1
10765	1520	detection of fusion transcript	[detection of fusion transcripts]	1.5849625007211563	4	1	0	0
10766	1520	retinoblastoma gene product Rb	[retinoblastoma gene product Rb]	1.5849625007211563	4	1	0	0
10767	1520	C-terminal regulatory module	[C-terminal regulatory module]	1.5849625007211563	3	1	0	0
10768	1520	preleukemic clonal cell	[preleukemic clonal cells]	1.5849625007211563	3	1	0	0
10769	1520	transcriptional activation in cell	[transcriptional activation in cells]	1.5849625007211563	4	1	0	0
10770	1520	hiv-1 expression in monocytes/macrophages	[HIV-1 expression in monocytes/macrophages]	1.5849625007211563	4	1	0	0
10771	1520	B lymphoid lineage	[B lymphoid lineages]	1.5849625007211563	3	1	0	0
10772	1520	use a variety	[using a variety]	1.5849625007211563	3	2	1	1
10773	1520	early T cell differentiation	[early T cell differentiation]	1.5849625007211563	4	1	0	0
10774	1520	regulation of IRF-1	[regulation of IRF-1]	1.5849625007211563	3	1	0	0
10775	1520	9-cis RA (5	[9-cis RA (5]	1.5849625007211563	3	1	0	0
10776	1520	long regulatory mechanism	[long-term regulatory mechanisms]	1.5849625007211563	3	1	0	0
10777	1520	ikappab-alpha inhibitor hydrolysis	[IkappaB-alpha inhibitor hydrolysis]	1.5849625007211563	3	1	0	0
10778	1520	magnitude of intracellular ROI	[magnitude of intracellular ROI]	1.5849625007211563	4	1	0	0
10779	1520	Study with motheaten mouse	[Studies with motheaten mice]	1.5849625007211563	4	1	0	0
10780	1520	cd11b+ bone marrow cell	[CD11b+ bone marrow cells]	1.5849625007211563	4	1	0	0
10781	1520	strong expression of sla-dr	[strong expression of SLA-DR]	1.5849625007211563	4	1	0	0
10782	1520	role of receptor	[role of receptors]	1.5849625007211563	3	2	2	2
10783	1520	Chimeric oncoprotein e2a-pbx1	[Chimeric oncoprotein E2a-Pbx1]	1.5849625007211563	3	1	0	0
10784	1520	LN T cell	[LN T cells]	1.5849625007211563	3	1	0	0
10785	1520	macrophage of healthy smoker	[macrophages of healthy smokers]	1.5849625007211563	4	1	0	0
10786	1520	src-family tyrosine kinase gene	[src-family tyrosine kinase genes]	1.5849625007211563	4	1	0	0
10787	1520	use Jurkat CD4	[using Jurkat CD4]	1.5849625007211563	3	1	0	0
10788	1520	lymphoblast express high level	[lymphoblasts expressing high levels]	1.5849625007211563	4	1	0	0
10789	1520	adult male progeny	[adult male progeny]	1.5849625007211563	3	1	0	0
10790	1520	lncap cell variant	[LNCaP cell variant]	1.5849625007211563	3	1	0	0
10791	1520	secretion of il-1beta protein	[secretion of IL-1beta protein]	1.5849625007211563	4	1	0	0
10792	1520	immortalization of erythrocytic progenitor	[immortalization of erythrocytic progenitors]	1.5849625007211563	4	1	0	0
10793	1520	aldosterone (1.4 nmol/l)	[aldosterone (1.4 nmol/l)]	1.5849625007211563	3	1	0	0
10794	1520	use supercoiled, template	[Using supercoiled, templates,]	1.5849625007211563	3	1	0	0
10795	1520	ability of TNF-alpha	[ability of TNF-alpha]	1.5849625007211563	3	1	0	0
10796	1520	Chronic myelogenous leukemia	[Chronic myelogenous leukemia]	1.5849625007211563	3	1	0	0
10797	1520	human granulocyte-macrophage colony-stimumulatelany-stg	[human granulocyte-macrophage colony-stimulating]	1.5849625007211563	3	1	0	0
10798	1520	bind affinity for dexamethasone	[binding affinity for dexamethasone]	1.5849625007211563	4	2	1	1
10799	1520	specificity of Id3	[specificity of Id3]	1.5849625007211563	3	1	0	0
10800	1520	mrna expression level	[mRNA expression levels]	1.5849625007211563	3	1	0	0
10801	1520	glucocorticoid therapy in asthma.	[glucocorticoid therapy in asthma.]	1.5849625007211563	4	1	0	0
10802	1520	suppression of expression	[suppression of expression]	1.5849625007211563	3	1	0	0
10803	1520	Addition of TFE-3	[Addition of TFE-3]	1.5849625007211563	3	1	0	0
10804	1520	transduce a signal	[transducing a signal]	1.5849625007211563	3	2	2	2
10805	1520	acinar epithelial cell	[acinar epithelial cells]	1.5849625007211563	3	1	0	0
10806	1520	A series cell	[A series cells]	1.5849625007211563	3	1	0	0
10807	1520	relation to the mechanism	[relation to the mechanism]	1.5849625007211563	4	1	0	0
10808	1520	latent, cytosolic signal transducer	[latent, cytosolic signal transducers]	1.5849625007211563	4	1	0	0
10809	1520	regulation of nuclear factor	[regulation of nuclear factor]	1.5849625007211563	4	2	1	1
10810	1520	NLS of STAT1	[NLS of STAT1]	1.5849625007211563	3	1	0	0
10811	1520	putative function of bhrf1	[putative function of BHRF1]	1.5849625007211563	4	1	0	0
10812	1520	posttraumatic stress disorder.	[posttraumatic stress disorder.]	1.5849625007211563	3	1	0	0
10813	1520	complex gp ib alpha	[complex GP Ib alpha]	1.5849625007211563	4	1	0	0
10814	1520	case of myeloid leukemia	[cases of myeloid leukemia]	1.5849625007211563	4	2	2	2
10815	1520	immunofluorescence with beta-	[immunofluorescence with beta-]	1.5849625007211563	3	1	0	0
10816	1520	Gene transcription through activation	[Gene transcription through activation]	1.5849625007211563	4	1	0	0
10817	1520	inhibition of this activities,	[inhibition of these activities,]	1.5849625007211563	4	1	0	0
10818	1520	radioreceptor assay in leukocyte	[radioreceptor assay in leukocytes]	1.5849625007211563	4	1	0	0
10819	1520	differentiation of this cell	[differentiation of these cells]	1.5849625007211563	4	2	1	1
10820	1520	kappa b sequence gggactttcc	[kappa B sequence GGGACTTTCC]	1.5849625007211563	4	1	0	0
10821	1520	reconstitution of Jak1 expression	[Reconstitution of Jak1 expression]	1.5849625007211563	4	1	0	0
10822	1520	1 to 4 hour	[1 to 4 hours]	1.5849625007211563	4	1	0	0
10823	1520	implication for viral latency.	[implications for viral latency.]	1.5849625007211563	4	1	0	0
10824	1520	putative mammalian sex-determine gene	[putative mammalian sex-determining gene]	1.5849625007211563	4	1	0	0
10825	1520	use LTR -cat assay	[using LTR -CAT assays]	1.5849625007211563	4	1	0	0
10826	1520	suppression by dexamethasone	[suppression by dexamethasone]	1.5849625007211563	3	1	0	0
10827	1520	presence of ciprofloxacin micrograms/ml)	[presence of ciprofloxacin micrograms/ml)]	1.5849625007211563	4	1	0	0
10828	1520	number of stain lymphocyte	[number of staining lymphocytes]	1.5849625007211563	4	1	0	0
10829	1520	response to antigen stimulation	[response to antigen stimulation]	1.5849625007211563	4	1	0	0
10830	1520	inhibition of p38alpha MAPk	[Inhibition of p38alpha MAPk]	1.5849625007211563	4	1	0	0
10831	1520	otherwise cytoplasmic protein	[otherwise cytoplasmic protein]	1.5849625007211563	3	1	0	0
10832	1520	tcr nf-at response	[TCR NF-AT responses]	1.5849625007211563	3	1	0	0
10833	1520	cysteine protease inhibitor	[cysteine protease inhibitor]	1.5849625007211563	3	1	0	0
10834	1520	analysis of ltr	[Analysis of LTRs]	1.5849625007211563	3	1	0	0
10835	1520	interaction between pu.1	[Interaction between PU.1]	1.5849625007211563	3	1	0	0
10836	1520	local thrombin activation	[local thrombin activation]	1.5849625007211563	3	1	0	0
10837	1520	nf-kappa b induction	[NF-kappa B induction]	1.5849625007211563	3	2	1	1
10838	1520	epithelial cell-specific fashion	[epithelial cell-specific fashion]	1.5849625007211563	3	1	0	0
10839	1520	human CD4 T cell	[human CD4 T cells]	1.5849625007211563	4	1	0	0
10840	1520	pathogenesis of gynecomastia	[pathogenesis of gynecomastia]	1.5849625007211563	3	1	0	0
10841	1520	wild type cell line	[wild type cell line]	1.5849625007211563	4	1	0	0
10842	1520	expression of Spi-1	[expression of Spi-1]	1.5849625007211563	3	2	2	2
10843	1520	immunoglobulin kappa 3' enhancer	[immunoglobulin kappa 3' enhancer]	1.5849625007211563	4	2	1	1
10844	1520	dna-binding transcription factor	[DNA-binding transcription factors]	1.5849625007211563	3	2	2	2
10845	1520	transcriptional activity of A-MYB	[transcriptional activity of A-MYB]	1.5849625007211563	4	1	0	0
10846	1520	serial 5'-deletion mutation	[serial 5'-deletion mutations]	1.5849625007211563	3	1	0	0
10847	1520	prototypic nuclear factor kappab	[prototypic nuclear factor kappaB]	1.5849625007211563	4	1	0	0
10848	1520	overexpression of gabp factor	[overexpression of GABP factors]	1.5849625007211563	4	1	0	0
10849	1520	HLA-DRA promoter activity	[HLA-DRA promoter activity]	1.5849625007211563	3	1	0	0
10850	1520	unspliced viral mrna	[unspliced viral mRNA]	1.5849625007211563	3	1	0	0
10851	1520	activator protein-1 transcriptional activity	[activator protein-1 transcriptional activity]	1.5849625007211563	4	1	0	0
10852	1520	inhibit 135eoh)2d3 synthesis	[inhibiting 1,25(OH)2D3 synthesis]	1.5849625007211563	3	1	0	0
10853	1520	use of chemical agent	[use of chemical agents]	1.5849625007211563	4	1	0	0
10854	1520	U937 cell line U9-IIIB	[U937 cell line U9-IIIB]	1.5849625007211563	4	1	0	0
10855	1520	use anti-TNF-alpha antibody	[using anti-TNF-alpha antibody]	1.5849625007211563	3	1	0	0
10856	1520	inducibility of elk-1 expression	[inducibility of elk-1 expression]	1.5849625007211563	4	1	0	0
10857	1520	measurement of gr mrna	[measurements of GR mRNA]	1.5849625007211563	4	1	0	0
10858	1520	chimeric tcr gene	[chimeric TCR gene]	1.5849625007211563	3	1	0	0
10859	1520	variable tcr affinity	[variable TCR affinities]	1.5849625007211563	3	1	0	0
10860	1520	[3h]aldosterone mbp-hbd complex	[[3H]aldosterone MBP-HBD complex]	1.5849625007211563	3	1	0	0
10861	1520	lambda phosphatase treatment	[lambda phosphatase treatment]	1.5849625007211563	3	1	0	0
10862	1520	nuclear factor nf-kappab	[nuclear factor NF-kappaB]	1.5849625007211563	3	1	0	0
10863	1520	Monoallelic expression of TAL1	[Monoallelic expression of TAL1]	1.5849625007211563	4	1	0	0
10864	1520	GATA-1 nuclear body	[GATA-1 nuclear bodies]	1.5849625007211563	3	1	0	0
10865	1520	late time point,	[later time point,]	1.5849625007211563	3	1	0	0
10866	1520	growth factor-beta tgf-beta	[growth factor-beta TGF-beta]	1.5849625007211563	3	2	2	2
10867	1520	nine mammalian pax gene	[nine mammalian Pax genes]	1.5849625007211563	4	1	0	0
10868	1520	probably as a homodimer.	[probably as a homodimer.]	1.5849625007211563	4	1	0	0
10869	1520	stage of differentiation;	[stage of differentiation;]	1.5849625007211563	3	1	0	0
10870	1520	approximately 50-kda protein nfkb1(p50)	[approximately 50-kDa protein NFKB1(p50)]	1.5849625007211563	4	1	0	0
10871	1520	chromosome 14 rearrangement	[chromosome 14 rearrangements]	1.5849625007211563	3	1	0	0
10872	1520	unique DNA-protein complex	[unique DNA-protein complex]	1.5849625007211563	3	1	0	0
10873	1520	stage of differentiation.	[stage of differentiation.]	1.5849625007211563	3	2	1	1
10874	1520	appropriate cellular receptors.	[appropriate cellular receptors.]	1.5849625007211563	3	1	0	0
10875	1520	TRE -DNA affinity chromatography	[TRE -DNA affinity chromatography]	1.5849625007211563	4	1	0	0
10876	1520	mrna cap site	[mRNA cap site]	1.5849625007211563	3	2	2	2
10877	1520	change in c-fo expression	[Changes in c-fos expression]	1.5849625007211563	4	1	0	0
10878	1520	result of ebv serology	[results of EBV serology]	1.5849625007211563	4	1	0	0
10879	1520	cell for destruction	[cells for destruction]	1.5849625007211563	3	1	0	0
10880	1520	protein phosphatase pp1	[protein phosphatase PP1]	1.5849625007211563	3	2	2	2
10881	1520	HUVECs at least 75%	[HUVECs at least 75%]	1.5849625007211563	4	1	0	0
10882	1520	inhibit the switch	[inhibiting the switch]	1.5849625007211563	3	1	0	0
10883	1520	GAL4 binding site	[GAL4 binding sites]	1.5849625007211563	3	1	0	0
10884	1520	activation of Rap1	[activation of Rap1]	1.5849625007211563	3	1	0	0
10885	1520	vitro binding site	[vitro binding site]	1.5849625007211563	3	1	0	0
10886	1520	regulatory sequence similar	[regulatory sequences similar]	1.5849625007211563	3	2	2	2
10887	1520	insulin tolerance test ITT	[insulin tolerance test ITT]	1.5849625007211563	4	1	0	0
10888	1520	position -206 to -195	[positions -206 to -195]	1.5849625007211563	4	1	0	0
10889	1520	high hybridization accessibility	[higher hybridization accessibility]	1.5849625007211563	3	1	0	0
10890	1520	canonical tata box	[canonical TATA box]	1.5849625007211563	3	1	0	0
10891	1520	absence of tar	[absence of TAR]	1.5849625007211563	3	1	0	0
10892	1520	late result of inhibition	[later result of inhibition]	1.5849625007211563	4	1	0	0
10893	1520	blood-thyroid hormone concentration	[blood-thyroid hormone concentration]	1.5849625007211563	3	1	0	0
10894	1520	platelet of bipolar patient	[platelets of bipolar patients]	1.5849625007211563	4	1	0	0
10895	1520	several cis-acting regulatory site	[Several cis-acting regulatory sites]	1.5849625007211563	4	1	0	0
10896	1520	region of the repeat	[region of the repeat]	1.5849625007211563	4	2	2	2
10897	1520	response to h2o2	[response to H2O2]	1.5849625007211563	3	1	0	0
10898	1520	part of the intron	[part of the intron]	1.5849625007211563	4	1	0	0
10899	1520	sea urchin pax-258 protein	[sea urchin Pax-258 proteins]	1.5849625007211563	4	1	0	0
10900	1520	tre tax -response element	[TRE Tax -response element]	1.5849625007211563	4	1	0	0
10901	1520	generation of guanine nucleotide	[generation of guanine nucleotides]	1.5849625007211563	4	1	0	0
10902	1520	translocation of hsf3	[translocation of HSF3]	1.5849625007211563	3	1	0	0
10903	1520	mol/L for hydrocortisone	[mol/L for hydrocortisone]	1.5849625007211563	3	2	2	2
10904	1520	normal circulate granulocyte	[normal circulating granulocytes]	1.5849625007211563	3	1	0	0
10905	1520	polymorphonuclear leukocyte chemotaxis	[polymorphonuclear leukocyte chemotaxis]	1.5849625007211563	3	1	0	0
10906	1520	nuclear protein binding	[nuclear proteins binding]	1.5849625007211563	3	1	0	0
10907	1520	state in patient	[state in patients]	1.5849625007211563	3	2	2	2
10908	1520	il-8 gene expression	[IL-8 gene expression]	1.5849625007211563	3	2	1	1
10909	1520	nontuberculous pulmonary condition	[nontuberculous pulmonary conditions]	1.5849625007211563	3	1	0	0
10910	1520	surface of endothelial cell	[surface of endothelial cells]	1.5849625007211563	4	2	2	2
10911	1520	interleukin (il)-2 gene induction	[interleukin (IL)-2 gene induction]	1.5849625007211563	4	1	0	0
10912	1520	GATA transcription factor	[GATA transcription factors]	1.5849625007211563	3	1	0	0
10913	1520	second exon of Tat	[second exon of Tat]	1.5849625007211563	4	1	0	0
10914	1520	summary, platelet-activating factor	[summary, platelet-activating factor]	1.5849625007211563	3	1	0	0
10915	1520	microB-dependent enhancer activity	[microB-dependent enhancer activity]	1.5849625007211563	3	1	0	0
10916	1520	adjacent long repeat region	[adjacent long repeat region]	1.5849625007211563	4	1	0	0
10917	1520	change in the ratio	[changes in the ratio]	1.5849625007211563	4	1	0	0
10918	1520	Jun phosphorylation by JNK	[Jun phosphorylation by JNK]	1.5849625007211563	4	1	0	0
10919	1520	contrast, NF-kappa b	[contrast, NF-kappa B]	1.5849625007211563	3	1	0	0
10920	1520	follow g-csf stimulation activation	[following G-CSF stimulation activation]	1.5849625007211563	4	1	0	0
10921	1520	human lymphoblastoid cell	[human lymphoblastoid cells]	1.5849625007211563	3	2	2	2
10922	1520	146 healthy female	[146 healthy females]	1.5849625007211563	3	1	0	0
10923	1520	stat signal pathway	[STAT signaling pathways]	1.5849625007211563	3	1	0	0
10924	1520	murine m phi	[murine M phi]	1.5849625007211563	3	1	0	0
10925	1520	lack of involvement signal	[lack of involvement signaling]	1.5849625007211563	4	1	0	0
10926	1520	alternative polyadenylylation site	[alternative polyadenylylation sites]	1.5849625007211563	3	1	0	0
10927	1520	subpopulation of b lymphocyte	[subpopulation of B lymphocytes]	1.5849625007211563	4	1	0	0
10928	1520	three patient with gynecomastia	[three patients with gynecomastia]	1.5849625007211563	4	1	0	0
10929	1520	functional nf-e2 complex	[functional NF-E2 complex]	1.5849625007211563	3	1	0	0
10930	1520	enhancer function of one	[enhancer function of one]	1.5849625007211563	4	1	0	0
10931	1520	human VDR CDNA	[human VDR CDNA]	1.5849625007211563	3	1	0	0
10932	1520	S194 plasma cell	[S194 plasma cells]	1.5849625007211563	3	1	0	0
10933	1520	b cell growth regulation	[B cell growth regulation]	1.5849625007211563	4	1	0	0
10934	1520	number of monocyte	[number of monocytes]	1.5849625007211563	3	1	0	0
10935	1520	inflammatory cell infiltration score	[inflammatory cell infiltration score]	1.5849625007211563	4	1	0	0
10936	1520	vacuolar H+-ATPase b2 subunit	[vacuolar H+-ATPase B2 subunit]	1.5849625007211563	4	1	0	0
10937	1520	DNA receptor gr	[DNA receptors GR]	1.5849625007211563	3	1	0	0
10938	1520	normal intergenic splicing	[normal intergenic splicing]	1.5849625007211563	3	1	0	0
10939	1520	kappab alpha degradation	[kappaB alpha degradation]	1.5849625007211563	3	1	0	0
10940	1520	latent component of isgf3	[latent component of ISGF3]	1.5849625007211563	4	1	0	0
10941	1520	oligo stimulation in patient	[oligo stimulation in patients]	1.5849625007211563	4	1	0	0
10942	1520	cell originate from case	[Cells originating from cases]	1.5849625007211563	4	1	0	0
10943	1520	chronic eosinophilic inflammation	[chronic eosinophilic inflammation]	1.5849625007211563	3	1	0	0
10944	1520	nfkappab activity on apoptosis	[NFkappaB activity on apoptosis]	1.5849625007211563	4	1	0	0
10945	1520	expression of A-myb	[expression of A-myb]	1.5849625007211563	3	1	0	0
10946	1520	NF-kappaB- reporter construct	[NF-kappaB- reporter construct]	1.5849625007211563	3	1	0	0
10947	1520	expression of bzlf1	[expression of BZLF1]	1.5849625007211563	3	2	1	1
10948	1520	mainly kappa b alpha	[mainly kappa B alpha]	1.5849625007211563	4	1	0	0
10949	1520	tissue-specific expression of interleukin-3	[tissue-specific expression of interleukin-3]	1.5849625007211563	4	2	1	1
10950	1520	CD5 structural gene	[CD5 structural gene]	1.5849625007211563	3	1	0	0
10951	1520	high level in monocyte	[highest levels in monocytes]	1.5849625007211563	4	2	1	1
10952	1520	indistinct mantle zone	[indistinct mantle zones]	1.5849625007211563	3	1	0	0
10953	1520	course of myeloid differentiation	[course of myeloid differentiation]	1.5849625007211563	4	1	0	0
10954	1520	however, b cell	[However, B cells]	1.5849625007211563	3	1	0	0
10955	1520	beta cell glucose toxicity	[beta cell glucose toxicity]	1.5849625007211563	4	1	0	0
10956	1520	action of dexamethasone	[action of dexamethasone]	1.5849625007211563	3	2	1	1
10957	1520	Taq I polymorphism	[Taq I polymorphism]	1.5849625007211563	3	1	0	0
10958	1520	change in bind affinity	[change in binding affinity]	1.5849625007211563	4	1	0	0
10959	1520	expression of Egr-1 mrna	[expression of Egr-1 mRNA]	1.5849625007211563	4	1	0	0
10960	1520	copy of CIITA	[copies of CIITA]	1.5849625007211563	3	1	0	0
10961	1520	minimal constitutive virus expression	[minimal constitutive virus expression]	1.5849625007211563	4	1	0	0
10962	1520	A series cells.	[A series cells.]	1.5849625007211563	3	1	0	0
10963	1520	PMLRAR alpha transgenic mouse	[PMLRAR alpha transgenic mice]	1.5849625007211563	4	1	0	0
10964	1520	short promoter region	[short promoter region]	1.5849625007211563	3	1	0	0
10965	1520	DNA band-shift analysis	[DNA band-shift analysis]	1.5849625007211563	3	1	0	0
10966	1520	acute myeloid leukaemia AML	[acute myeloid leukaemia AML]	1.5849625007211563	4	1	0	0
10967	1520	EBNA2 dependent cis-acting element	[EBNA2 dependent cis-acting element]	1.5849625007211563	4	1	0	0
10968	1520	new gene TINUR	[new gene TINUR]	1.5849625007211563	3	1	0	0
10969	1520	form of latency	[form of latency]	1.5849625007211563	3	1	0	0
10970	1520	intracellular calcium signal	[intracellular calcium signaling]	1.5849625007211563	3	1	0	0
10971	1520	potential overlap core recognition	[potential overlapping core recognition]	1.5849625007211563	4	1	0	0
10972	1520	Oct-2 c-terminal domain	[Oct-2 C-terminal domain]	1.5849625007211563	3	1	0	0
10973	1520	basis for nf-kappab activation	[basis for NF-kappaB activation]	1.5849625007211563	4	1	0	0
10974	1520	effect of icp0	[effect of ICP0]	1.5849625007211563	3	1	0	0
10975	1520	buffy coat preparation	[buffy coat preparations]	1.5849625007211563	3	1	0	0
10976	1520	absence of activity	[absence of activity]	1.5849625007211563	3	2	2	2
10977	1520	human interleukin 2 IL-2	[human interleukin 2 IL-2]	1.5849625007211563	4	1	0	0
10978	1520	proliferation of aortic endothelial	[proliferation of aortic endothelial]	1.5849625007211563	4	1	0	0
10979	1520	exposure to hydrogen peroxide	[exposure to hydrogen peroxide]	1.5849625007211563	4	2	2	2
10980	1520	catalytic cleft of VIIa	[catalytic cleft of VIIa]	1.5849625007211563	4	1	0	0
10981	1520	isolated hilar adenopathy	[isolated hilar adenopathy]	1.5849625007211563	3	1	0	0
10982	1520	NF-kappa b prototypic probe	[NF-kappa B prototypic probe]	1.5849625007211563	4	1	0	0
10983	1520	HTLV-1 T lymphocyte	[HTLV-1 T lymphocytes]	1.5849625007211563	3	2	1	1
10984	1520	addition to Zap-70	[addition to Zap-70]	1.5849625007211563	3	1	0	0
10985	1520	stable Jurkat cell clone	[stable Jurkat cell clones]	1.5849625007211563	4	1	0	0
10986	1520	3 amino acid	[3 amino acids]	1.5849625007211563	3	1	0	0
10987	1520	biologic function of il-13	[biologic function of IL-13]	1.5849625007211563	4	1	0	0
10988	1520	change in il-2 expression	[changes in IL-2 expression]	1.5849625007211563	4	1	0	0
10989	1520	b cell lineage	[B cell lineage]	1.5849625007211563	3	1	0	0
10990	1520	coactivator of NF-kappa b	[coactivators of NF-kappa B]	1.5849625007211563	4	1	0	0
10991	1520	T cell to Ags	[T cells to Ags]	1.5849625007211563	4	1	0	0
10992	1520	use cDNA microarray technology	[using cDNA microarray technology]	1.5849625007211563	4	1	0	0
10993	1520	addition of il-6 receptor	[addition of IL-6 receptor]	1.5849625007211563	4	1	0	0
10994	1520	Epstein-Barr virus (EBV) infection	[Epstein-Barr virus (EBV) infection]	1.5849625007211563	4	1	0	0
10995	1520	hiv-long terminal repeat	[HIV-long terminal repeat]	1.5849625007211563	3	1	0	0
10996	1520	nuclei of il-4-	[nuclei of IL-4-]	1.5849625007211563	3	1	0	0
10997	1520	stimulation of a progression	[stimulation of a progression]	1.5849625007211563	4	1	0	0
10998	1520	five element homologous	[five elements homologous]	1.5849625007211563	3	1	0	0
10999	1520	stat6 -dependent gene expression	[STAT6 -dependent gene expression]	1.5849625007211563	4	1	0	0
11000	1520	precursor b lymphocyte	[precursor B lymphocytes]	1.5849625007211563	3	1	0	0
11001	1520	g-->t transversion in exon	[G-->T transversion in exon]	1.5849625007211563	4	1	0	0
11002	1520	frame with a homeodomain	[frame with a homeodomain]	1.5849625007211563	4	1	0	0
11003	1520	type 0, type	[type 0, type]	1.5849625007211563	3	1	0	0
11004	1520	additional regulatory factor	[additional regulatory factors]	1.5849625007211563	3	1	0	0
11005	1520	(cfu-gm) myeloid progenitor	[(CFU-GM) myeloid progenitors]	1.5849625007211563	3	1	0	0
11006	1520	panel of E2A-HLF mutant	[panel of E2A-HLF mutants]	1.5849625007211563	4	1	0	0
11007	1520	immunoblot assay eightfold.	[immunoblot assay eightfold.]	1.5849625007211563	3	1	0	0
11008	1520	addition of phytohemagglutinin	[addition of phytohemagglutinin]	1.5849625007211563	3	1	0	0
11009	1520	certain T cell line	[certain T cell lines]	1.5849625007211563	4	1	0	0
11010	1520	recruiting the signal pathway	[recruiting the signaling pathways]	1.5849625007211563	4	1	0	0
11011	1520	vitro effect of beta-estradiol	[vitro effect of beta-estradiol]	1.5849625007211563	4	1	0	0
11012	1520	NF-kappaB DNA binding	[NF-kappaB DNA binding]	1.5849625007211563	3	1	0	0
11013	1520	Mono b protein complex	[Mono B protein complexes]	1.5849625007211563	4	1	0	0
11014	1520	numerous cellular gene	[numerous cellular genes]	1.5849625007211563	3	1	0	0
11015	1520	conjunction with anti-AIM mab	[conjunction with anti-AIM mAb]	1.5849625007211563	4	1	0	0
11016	1520	endogenous ecto-5'-NT mrna	[endogenous ecto-5'-NT mRNA]	1.5849625007211563	3	1	0	0
11017	1520	cis-linked CAT gene	[cis-linked CAT gene]	1.5849625007211563	3	2	1	1
11018	1520	IL-2 NF-chi b probe	[IL-2 NF-chi B probe]	1.5849625007211563	4	1	0	0
11019	1520	tcr T cell	[TCR T cells]	1.5849625007211563	3	1	0	0
11020	1520	immature human DC	[immature human DC]	1.5849625007211563	3	1	0	0
11021	1520	RA -responsive reporter gene	[RA -responsive reporter gene]	1.5849625007211563	4	1	0	0
11022	1520	MHC class ii induction	[MHC class II induction]	1.5849625007211563	4	1	0	0
11023	1520	c-fo serum response element	[c-fos serum response element]	1.5849625007211563	4	2	1	1
11024	1520	protein level, tax	[protein level, Tax]	1.5849625007211563	3	1	0	0
11025	1520	further characterization of FKHRL1	[Further characterization of FKHRL1]	1.5849625007211563	4	1	0	0
11026	1520	nf- kappa b	[NF- kappa B]	1.5849625007211563	3	1	0	0
11027	1520	same sequence specificity	[same sequence specificity]	1.5849625007211563	3	1	0	0
11028	1520	Jurkat-tat cell line	[Jurkat-tat cell lines]	1.5849625007211563	3	1	0	0
11029	1520	ubiquitous octamer-binding protein (s)	[ubiquitous octamer-binding protein (s)]	1.5849625007211563	4	1	0	0
11030	1520	autocrine activation by interferon-gamma	[Autocrine activation by interferon-gamma]	1.5849625007211563	4	1	0	0
11031	1520	leukocyte differentiation antigen	[leukocyte differentiation antigen]	1.5849625007211563	3	1	0	0
11032	1520	mechanism of control	[mechanism of control]	1.5849625007211563	3	2	2	2
11033	1520	specific nuclear binding site	[specific nuclear binding sites]	1.5849625007211563	4	1	0	0
11034	1520	evolutionary x2 box	[evolutionary X2 box]	1.5849625007211563	3	1	0	0
11035	1520	expression of the class	[expression of the class]	1.5849625007211563	4	2	1	1
11036	1520	total human leukocyte	[total human leukocytes]	1.5849625007211563	3	1	0	0
11037	1520	nuclear oncogene c-fo	[nuclear oncogene c-fos]	1.5849625007211563	3	1	0	0
11038	1520	c-fo mrna induction	[c-fos mRNA induction]	1.5849625007211563	3	2	1	1
11039	1520	addition find hlh-2 expression	[addition finding hLH-2 expression]	1.5849625007211563	4	1	0	0
11040	1520	membrane protein gene	[membrane protein gene]	1.5849625007211563	3	2	2	2
11041	1520	certain virus-infected cell	[certain virus-infected cells]	1.5849625007211563	3	1	0	0
11042	1520	fatty acid metabolite	[fatty acid metabolites]	1.5849625007211563	3	1	0	0
11043	1520	four distinct gene	[four distinct genes]	1.5849625007211563	3	1	0	0
11044	1520	/i kappa b component	[/I kappa B components]	1.5849625007211563	4	1	0	0
11045	1520	104-bp minimal promoter region	[104-bp minimal promoter region]	1.5849625007211563	4	1	0	0
11046	1520	cd20+ b cell	[CD20+ B cells]	1.5849625007211563	3	1	0	0
11047	1520	response to G(Anh)MTetra	[responses to G(Anh)MTetra]	1.5849625007211563	3	1	0	0
11048	1520	level of p50	[levels of p50]	1.5849625007211563	3	1	0	0
11049	1520	T cell pathway	[T cell pathway]	1.5849625007211563	3	1	0	0
11050	1520	significant inverse correlation	[significant inverse correlation]	1.5849625007211563	3	1	0	0
11051	1520	different stage of b-lymphocyte	[different stages of B-lymphocyte]	1.5849625007211563	4	1	0	0
11052	1520	E2F-1 expression in megakaryocyte	[E2F-1 expression in megakaryocytes]	1.5849625007211563	4	1	0	0
11053	1520	inv(14)(q11;q32) chromosome inversion	[inv(14)(q11;q32) chromosome inversion]	1.5849625007211563	3	1	0	0
11054	1520	endotoxin lps with	[endotoxin LPS with]	1.5849625007211563	3	1	0	0
11055	1520	amino-terminal region y145	[amino-terminal region Y145]	1.5849625007211563	3	1	0	0
11056	1520	murine igh enhancer	[murine IgH enhancer]	1.5849625007211563	3	1	0	0
11057	1520	fourth g76:gpltplpv aes1/2 (128-135)	[fourth G76:GPLTPLPV AES1/2 (128-135)]	1.5849625007211563	4	1	0	0
11058	1520	function of this enzyme	[function of this enzyme]	1.5849625007211563	4	1	0	0
11059	1520	EBNA2-deficient Epstein-Barr virus strain	[EBNA2-deficient Epstein-Barr virus strain]	1.5849625007211563	4	1	0	0
11060	1520	promoter for human inducible	[promoters for human inducible]	1.5849625007211563	4	1	0	0
11061	1520	isoform in T cell	[isoforms in T cells]	1.5849625007211563	4	2	2	2
11062	1520	transgenic mouse overexpress icsat	[transgenic mice overexpressing ICSAT]	1.5849625007211563	4	2	1	1
11063	1520	mutation in pagc	[mutations in pagC]	1.5849625007211563	3	1	0	0
11064	1520	majority of the cells.	[majority of the cells.]	1.5849625007211563	4	1	0	0
11065	1520	functional antagonism between VitD3	[functional antagonism between VitD3]	1.5849625007211563	4	1	0	0
11066	1520	several patient with asthma	[several patients with asthma]	1.5849625007211563	4	1	0	0
11067	1520	normal thymic epithelial cell	[normal thymic epithelial cells]	1.5849625007211563	4	1	0	0
11068	1520	more t-cell determinant	[more T-cell determinants]	1.5849625007211563	3	1	0	0
11069	1520	macrophage transcription factor	[macrophage transcription factor]	1.5849625007211563	3	2	1	1
11070	1520	il-2 -gene regulation	[IL-2 -gene regulation]	1.5849625007211563	3	1	0	0
11071	1520	Pan/ e2a protein expression	[Pan/ E2A protein expression]	1.5849625007211563	4	1	0	0
11072	1520	functional role of c-Jun	[functional role of c-Jun]	1.5849625007211563	4	1	0	0
11073	1520	sp-1 -like element	[SP-1 -like element]	1.5849625007211563	3	2	2	2
11074	1520	human aml1 gene	[human AML1 gene]	1.5849625007211563	3	1	0	0
11075	1520	human genome evolution	[human genome evolution]	1.5849625007211563	3	1	0	0
11076	1520	ngfi-b/nur77-related transcription factor	[NGFI-B/nur77-related transcription factor]	1.5849625007211563	3	1	0	0
11077	1520	patient with pulmonary disease	[patients with pulmonary diseases]	1.5849625007211563	4	2	2	2
11078	1520	different cell systems.	[different cell systems.]	1.5849625007211563	3	1	0	0
11079	1520	PLZF-RAR alpha expression	[PLZF-RAR alpha expression]	1.5849625007211563	3	1	0	0
11080	1520	stimulation of hiv-1 transcription	[stimulation of HIV-1 transcription]	1.5849625007211563	4	1	0	0
11081	1520	new, distinct histopathological entity	[new, distinct histopathological entity]	1.5849625007211563	4	1	0	0
11082	1520	naturally occur frameshift mutation	[naturally occurring frameshift mutation]	1.5849625007211563	4	1	0	0
11083	1520	activation of icam-1 promoter	[activation of ICAM-1 promoter]	1.5849625007211563	4	1	0	0
11084	1520	regulation of response gene	[regulation of response genes]	1.5849625007211563	4	1	0	0
11085	1520	generality of this finding	[generality of this finding]	1.5849625007211563	4	1	0	0
11086	1520	dimethyl sulfoxide-induced mel cell	[dimethyl sulfoxide-induced MEL cells]	1.5849625007211563	4	1	0	0
11087	1520	glucocorticoid in vitro.	[glucocorticoids in vitro.]	1.5849625007211563	3	1	0	0
11088	1520	role in tnf-alpha activation	[role in TNF-alpha activation]	1.5849625007211563	4	1	0	0
11089	1520	distinct cell type-specific complex	[distinct cell type-specific complexes]	1.5849625007211563	4	1	0	0
11090	1520	methods: lymphocyte sample	[METHODS: Lymphocyte samples]	1.5849625007211563	3	1	0	0
11091	1520	nuclear factor-kappaB NFkappaB	[nuclear factor-kappaB NFkappaB]	1.5849625007211563	3	2	1	1
11092	1520	IL-2 growth hormone	[IL-2 growth hormone]	1.5849625007211563	3	1	0	0
11093	1520	physical separation from XIC/XIST	[physical separation from XIC/XIST]	1.5849625007211563	4	1	0	0
11094	1520	c-myc translocation in BL	[c-myc translocation in BL]	1.5849625007211563	4	1	0	0
11095	1520	peripheral T cells.	[peripheral T cells.]	1.5849625007211563	3	1	0	0
11096	1520	addition to TNF	[addition to TNF]	1.5849625007211563	3	1	0	0
11097	1520	various cis-act regulatory element	[various cis-acting regulatory elements]	1.5849625007211563	4	1	0	0
11098	1520	nf-kappab mediate dopamine responsiveness	[NF-kappaB mediating dopamine responsiveness]	1.5849625007211563	4	1	0	0
11099	1520	significant systemic effect	[significant systemic effects]	1.5849625007211563	3	2	2	2
11100	1520	human dendritic cell-based assay	[human dendritic cell-based assay]	1.5849625007211563	4	1	0	0
11101	1520	igg+ plasma cell	[IgG+ plasma cells]	1.5849625007211563	3	1	0	0
11102	1520	gr mrna expression	[GR mRNA expression]	1.5849625007211563	3	2	1	1
11103	1520	many pathological situations,	[many pathological situations,]	1.5849625007211563	3	1	0	0
11104	1520	unusual transcription element tar	[unusual transcription element TAR]	1.5849625007211563	4	1	0	0
11105	1520	use cd45- negative variant	[Using CD45- negative variants]	1.5849625007211563	4	1	0	0
11106	1520	peak (0:00) value	[peak (0:00) values]	1.5849625007211563	3	1	0	0
11107	1520	hiv-1 expression by dopamine	[HIV-1 expression by dopamine]	1.5849625007211563	4	1	0	0
11108	1520	anti-inflammatory drug nsaid	[anti-inflammatory drugs NSAIDs]	1.5849625007211563	3	2	2	2
11109	1520	activity of SB 247464	[activity of SB 247464]	1.5849625007211563	4	1	0	0
11110	1520	prototype class ii gene	[prototype class II gene]	1.5849625007211563	4	1	0	0
11111	1520	assay use monocyte	[Assays using monocytes]	1.5849625007211563	3	1	0	0
11112	1520	interference with the phosphorylation	[interference with the phosphorylation]	1.5849625007211563	4	1	0	0
11113	1520	activator in b lymphocyte	[activator in B lymphocytes]	1.5849625007211563	4	1	0	0
11114	1520	other four family	[other four families]	1.5849625007211563	3	1	0	0
11115	1520	case of aml	[cases of AML]	1.5849625007211563	3	1	0	0
11116	1520	lmp promoter -binding protein	[LMP promoter -binding proteins]	1.5849625007211563	4	1	0	0
11117	1520	high population of thymocyte	[higher population of thymocytes]	1.5849625007211563	4	1	0	0
11118	1520	Naive ecd45ra+) T lymphocyte	[Naive (CD45RA+) T lymphocytes]	1.5849625007211563	4	1	0	0
11119	1520	T helper 2-type cytokine	[T helper 2-type cytokines]	1.5849625007211563	4	1	0	0
11120	1520	decoy oligodeoxynucleotides for nf-kappab	[decoy oligodeoxynucleotides for NF-kappaB]	1.5849625007211563	4	1	0	0
11121	1520	IRF-2 promoter region	[IRF-2 promoter region]	1.5849625007211563	3	1	0	0
11122	1520	follow atra treatment	[following ATRA treatment]	1.5849625007211563	3	1	0	0
11123	1520	immunosuppressive effect of glucocorticoid	[immunosuppressive effects of glucocorticoids]	1.5849625007211563	4	1	0	0
11124	1520	therefore, activation of Stat3	[Therefore, activation of Stat3]	1.5849625007211563	4	1	0	0
11125	1520	lymphoid cell by glucocorticoid	[lymphoid cells by glucocorticoids]	1.5849625007211563	4	1	0	0
11126	1520	yeast two-hybrid system	[yeast two-hybrid system]	1.5849625007211563	3	2	1	1
11127	1520	camp /pka pathway	[cAMP /PKA pathway]	1.5849625007211563	3	1	0	0
11128	1520	contact with endothelium	[contact with endothelium]	1.5849625007211563	3	1	0	0
11129	1520	distribution of atypical pkc-zeta	[distribution of atypical PKC-zeta]	1.5849625007211563	4	1	0	0
11130	1520	example, kappa b-related sequence	[example, kappa B-related sequences]	1.5849625007211563	4	1	0	0
11131	1520	contain fetal-calf serum	[containing fetal-calf serum]	1.5849625007211563	3	1	0	0
11132	1520	two different AUG codon	[two different AUG codons]	1.5849625007211563	4	1	0	0
11133	1520	subset of CAM vcam-1	[subset of CAMs VCAM-1]	1.5849625007211563	4	1	0	0
11134	1520	Conversely, several cytokine	[Conversely, several cytokines]	1.5849625007211563	3	1	0	0
11135	1520	TSH-R expression level	[TSH-R expression levels]	1.5849625007211563	3	1	0	0
11136	1520	term of requirement	[terms of requirements]	1.5849625007211563	3	1	0	0
11137	1520	EBV reactivation process	[EBV reactivation process]	1.5849625007211563	3	1	0	0
11138	1520	use Fe2+ /cu2+ ion	[using Fe2+ /Cu2+ ions]	1.5849625007211563	4	1	0	0
11139	1520	p45 subunit of NF-E2	[p45 subunit of NF-E2]	1.5849625007211563	4	1	0	0
11140	1520	viral replicative pathway	[viral replicative pathway]	1.5849625007211563	3	1	0	0
11141	1520	double-stranded (ds) phosphorothioate oligonucleotide	[double-stranded (ds) phosphorothioate oligonucleotides]	1.5849625007211563	4	1	0	0
11142	1520	transcription factor Oct-1	[transcription factor Oct-1]	1.5849625007211563	3	2	2	2
11143	1520	BLIN-1 pre-B cell line	[BLIN-1 pre-B cell line]	1.5849625007211563	4	1	0	0
11144	1520	two different cytosolic protein	[two different cytosolic protein]	1.5849625007211563	4	1	0	0
11145	1520	step of kidney insufficiency	[step of kidney insufficiency]	1.5849625007211563	4	1	0	0
11146	1520	protein phosphatase 1	[Protein phosphatases 1]	1.5849625007211563	3	2	1	1
11147	1520	differential signal of BW	[differential signaling of BW]	1.5849625007211563	4	1	0	0
11148	1520	four complex to CRE	[four complexes to CRE]	1.5849625007211563	4	1	0	0
11149	1520	LT-kappa b site	[LT-kappa B site]	1.5849625007211563	3	1	0	0
11150	1520	human gammac promoter	[human gammac promoter]	1.5849625007211563	3	1	0	0
11151	1520	transcription signal pathway	[transcription signaling pathways]	1.5849625007211563	3	1	0	0
11152	1520	moreover, kappa 1-kappa 3	[Moreover, kappa 1-kappa 3]	1.5849625007211563	4	1	0	0
11153	1520	failure of granulopoiesis	[failure of granulopoiesis]	1.5849625007211563	3	1	0	0
11154	1520	calcium ca2+ ionophore ionomycin	[calcium Ca2+ ionophore ionomycin]	1.5849625007211563	4	1	0	0
11155	1520	hmg box contain protein	[HMG box containing proteins]	1.5849625007211563	4	1	0	0
11156	1520	full-length sp1 transcription factor	[full-length Sp1 transcription factor]	1.5849625007211563	4	1	0	0
11157	1520	Jak1 -binding Box1 region	[Jak1 -binding Box1 region]	1.5849625007211563	4	1	0	0
11158	1520	alteration in pyrimidine catabolism	[alteration in pyrimidine catabolism]	1.5849625007211563	4	1	0	0
11159	1520	primary murine thymocyte	[primary murine thymocytes]	1.5849625007211563	3	1	0	0
11160	1520	stably cd4+ cell capable	[stably CD4+ cells capable]	1.5849625007211563	4	1	0	0
11161	1520	name tnf-alpha factor LITAF	[name TNF-alpha factor LITAF]	1.5849625007211563	4	1	0	0
11162	1520	2-kb VDR cDNA insert	[2-kb VDR cDNA insert]	1.5849625007211563	4	1	0	0
11163	1520	human beta-globin gene cluster	[human beta-globin gene cluster]	1.5849625007211563	4	1	0	0
11164	1520	primary tool for diagnosis	[primary tool for diagnosis]	1.5849625007211563	4	1	0	0
11165	1520	cardiac infarction patient	[cardiac infarction patients]	1.5849625007211563	3	1	0	0
11166	1520	Sendai virus extract	[Sendai virus extracts]	1.5849625007211563	3	1	0	0
11167	1520	cell vulnerable to cytolysis	[cells vulnerable to cytolysis]	1.5849625007211563	4	1	0	0
11168	1520	kinase as ser	[kinase as Ser]	1.5849625007211563	3	1	0	0
11169	1520	transcription of proinflammatory gene	[transcription of proinflammatory genes]	1.5849625007211563	4	1	0	0
11170	1520	immunohistochemistry in the diagnosis	[immunohistochemistry in the diagnosis]	1.5849625007211563	4	1	0	0
11171	1520	major transactivation region	[major transactivation region]	1.5849625007211563	3	1	0	0
11172	1520	plasmacytoma cell extracts.	[plasmacytoma cell extracts.]	1.5849625007211563	3	1	0	0
11173	1520	action of tepoxalin	[action of tepoxalin]	1.5849625007211563	3	1	0	0
11174	1520	block in granulocyte differentiation	[block in granulocyte differentiation]	1.5849625007211563	4	1	0	0
11175	1520	octamer-binding ioct) protein	[octamer-binding (Oct) proteins]	1.5849625007211563	3	1	0	0
11176	1520	such as TNF	[such as TNF]	1.5849625007211563	3	1	0	0
11177	1520	GRE binding in pbmc	[GRE binding in PBMCs]	1.5849625007211563	4	1	0	0
11178	1520	immunolabeling of Rap1	[immunolabeling of Rap1]	1.5849625007211563	3	1	0	0
11179	1520	reversal by IL-2	[reversal by IL-2]	1.5849625007211563	3	1	0	0
11180	1520	rapid activation in response	[rapid activation in response]	1.5849625007211563	4	2	2	2
11181	1520	beta-globin gene in mouse	[beta-globin gene in mice]	1.5849625007211563	4	1	0	0
11182	1520	cis-acting regulatory element	[cis-acting regulatory element]	1.5849625007211563	3	2	2	2
11183	1520	Furthermore, blockade of prostaglandin	[Furthermore, blockade of prostaglandin]	1.5849625007211563	4	1	0	0
11184	1520	efficacy of local immunosuppression	[efficacy of local immunosuppression]	1.5849625007211563	4	1	0	0
11185	1520	10(-10) m; control	[10(-10) M; controls]	1.5849625007211563	3	1	0	0
11186	1520	Kcat of the domain	[Kcat of the domain]	1.5849625007211563	4	1	0	0
11187	1520	nf-kappa b p50 homodimer	[NF-kappa B p50 homodimers]	1.5849625007211563	4	1	0	0
11188	1520	element in the region	[element in the region]	1.5849625007211563	4	2	2	2
11189	1520	33 patient with SLE	[33 patients with SLE]	1.5849625007211563	4	1	0	0
11190	1520	T cell maturation	[T cell maturation]	1.5849625007211563	3	1	0	0
11191	1520	POUHD solution structure	[POUHD solution structure]	1.5849625007211563	3	1	0	0
11192	1520	ability of endothelial cell	[ability of endothelial cells]	1.5849625007211563	4	1	0	0
11193	1520	drastic effect in vivo,	[drastic effect in vivo,]	1.5849625007211563	4	1	0	0
11194	1520	NF-kappaB /Rel family	[NF-kappaB /Rel family]	1.5849625007211563	3	2	1	1
11195	1520	family of cytokine	[family of cytokines]	1.5849625007211563	3	2	2	2
11196	1520	novel immunosuppressive agent	[novel immunosuppressive agent]	1.5849625007211563	3	1	0	0
11197	1520	decline of cortisol concentration	[decline of cortisol concentrations]	1.5849625007211563	4	1	0	0
11198	1520	expression of p21ras	[expression of p21ras]	1.5849625007211563	3	1	0	0
11199	1520	UAS2 -352 to -264	[UAS2 -352 to -264]	1.5849625007211563	4	1	0	0
11200	1520	rna processing Spl	[RNA processing Spl]	1.5849625007211563	3	1	0	0
11201	1520	modification of a protocol	[modification of a protocol]	1.5849625007211563	4	1	0	0
11202	1520	delay of 24 P.	[delay of 24 h.]	1.5849625007211563	4	1	0	0
11203	1520	absence of pou	[absence of POUs]	1.5849625007211563	3	1	0	0
11204	1520	clustering of monocyte-binding receptor	[clustering of monocyte-binding receptors]	1.5849625007211563	4	1	0	0
11205	1520	background: platelet tether	[BACKGROUND: platelets tether]	1.5849625007211563	3	1	0	0
11206	1520	-regulation of asm expression	[-regulation of ASM expression]	1.5849625007211563	4	1	0	0
11207	1520	basal cell epithelioma	[basal cell epitheliomas]	1.5849625007211563	3	2	1	1
11208	1520	ratio of around 10%.	[ratio of around 10%.]	1.5849625007211563	4	1	0	0
11209	1520	induction by PMA	[induction by PMA]	1.5849625007211563	3	1	0	0
11210	1520	calcium -signal transduction pathway	[calcium -signal transduction pathway]	1.5849625007211563	4	1	0	0
11211	1520	region between -3134	[region between -3134]	1.5849625007211563	3	1	0	0
11212	1520	only at low level	[only at low levels]	1.5849625007211563	4	1	0	0
11213	1520	Calcium/calmodulin-dependent protein kinase ii	[Calcium/calmodulin-dependent protein kinase II]	1.5849625007211563	4	1	0	0
11214	1520	ICP36 family of phosphoprotein	[ICP36 family of phosphoprotein]	1.5849625007211563	4	1	0	0
11215	1520	cleavage stimulation factor CstF-64	[cleavage stimulation factor CstF-64]	1.5849625007211563	4	1	0	0
11216	1520	human chromosomal il-16 gene	[human chromosomal IL-16 gene]	1.5849625007211563	4	1	0	0
11217	1520	ERG2 gene product	[ERG2 gene product]	1.5849625007211563	3	1	0	0
11218	1520	interleukin-5 /receptor interaction	[interleukin-5 /receptor interaction]	1.5849625007211563	3	1	0	0
11219	1520	c-fo expression by tpa	[c-fos expression by TPA]	1.5849625007211563	4	1	0	0
11220	1520	mutant e6 motif	[mutant E6 motif]	1.5849625007211563	3	1	0	0
11221	1520	expression of msr protein	[expression of MSR protein]	1.5849625007211563	4	1	0	0
11222	1520	transcription of some gene	[transcription of some genes]	1.5849625007211563	4	1	0	0
11223	1520	indicate a function	[indicating a function]	1.5849625007211563	3	2	2	2
11224	1520	caspase inhibitor z-vad-fmk	[caspase inhibitor Z-VAD-fmk]	1.5849625007211563	3	1	0	0
11225	1520	PKC -dependent fas expression	[PKC -dependent Fas expression]	1.5849625007211563	4	1	0	0
11226	1520	cd23 expression by IL-4	[CD23 expression by IL-4]	1.5849625007211563	4	1	0	0
11227	1520	TG myristate acetate PMA	[TG myristate acetate PMA]	1.5849625007211563	4	1	0	0
11228	1520	calcineurin catalytic (a) subunit	[calcineurin catalytic (A) subunit]	1.5849625007211563	4	1	0	0
11229	1520	CD28 -responsive complex	[CD28 -responsive complex]	1.5849625007211563	3	1	0	0
11230	1520	role in binding	[role in binding]	1.5849625007211563	3	2	2	2
11231	1520	stress fiber assembly	[stress fiber assembly]	1.5849625007211563	3	1	0	0
11232	1520	0.15 nm for (+)-pentazocine	[0.15 nM for (+)-pentazocine]	1.5849625007211563	4	1	0	0
11233	1520	important nf-kappab binding activity	[important NF-kappaB binding activity]	1.5849625007211563	4	1	0	0
11234	1520	variety of cell lines,	[variety of cell lines,]	1.5849625007211563	4	1	0	0
11235	1520	control from patient	[controls from patients]	1.5849625007211563	3	1	0	0
11236	1520	nf-at DNA binding	[NF-AT DNA binding]	1.5849625007211563	3	1	0	0
11237	1520	allergy, parasitic infection	[allergy, parasitic infection]	1.5849625007211563	3	1	0	0
11238	1520	actively divide lymphocyte	[actively dividing lymphocytes]	1.5849625007211563	3	1	0	0
11239	1520	result on the recognition	[results on the recognition]	1.5849625007211563	4	1	0	0
11240	1520	mammalian histone deacetylase related	[mammalian histone deacetylase related]	1.5849625007211563	4	1	0	0
11241	1520	panel of malignant lymphocyte	[panel of malignant lymphocytes]	1.5849625007211563	4	1	0	0
11242	1520	t3 -responsive reporter gene	[T3 -responsive reporter gene]	1.5849625007211563	4	1	0	0
11243	1520	ebv lytic cycle	[EBV lytic cycle]	1.5849625007211563	3	2	1	1
11244	1520	stat5- related protein	[STAT5- related proteins]	1.5849625007211563	3	1	0	0
11245	1520	lymphoid cell-specific factor otf2	[lymphoid cell-specific factor OTF2]	1.5849625007211563	4	1	0	0
11246	1520	TNF alpha activation	[TNF alpha activation]	1.5849625007211563	3	1	0	0
11247	1520	basal transcription machinery	[basal transcription machinery]	1.5849625007211563	3	1	0	0
11248	1520	x-linked immunodeficiency disease XCID	[X-linked immunodeficiency disease XCID]	1.5849625007211563	4	1	0	0
11249	1520	149 pmol/L; control	[149 pmol/L; controls]	1.5849625007211563	3	1	0	0
11250	1520	untreated hl-60 leukemic cell	[untreated HL-60 leukemic cells]	1.5849625007211563	4	1	0	0
11251	1520	serine phosphorylation of stat	[serine phosphorylation of STATs]	1.5849625007211563	4	1	0	0
11252	1520	only 11 amino acid	[only 11 amino acids]	1.5849625007211563	4	1	0	0
11253	1520	slowly migrate isoform, Stat3alpha	[slowly migrating isoform, Stat3alpha]	1.5849625007211563	4	1	0	0
11254	1520	intracellular il-2 production	[intracellular IL-2 production]	1.5849625007211563	3	1	0	0
11255	1520	arachidonic acid from membrane	[arachidonic acid from membranes]	1.5849625007211563	4	1	0	0
11256	1520	Nuclear localization of RelB	[Nuclear localization of RelB]	1.5849625007211563	4	1	0	0
11257	1520	Sp binding motif	[Sp binding motifs]	1.5849625007211563	3	1	0	0
11258	1520	include 15-deoxy-delta12,14-prostaglandin J2	[including 15-deoxy-delta12,14-prostaglandin J2]	1.5849625007211563	3	1	0	0
11259	1520	secretion of bioactive macrophage	[secretion of bioactive macrophage]	1.5849625007211563	4	1	0	0
11260	1520	mature b- cell stage	[mature B- cell stages]	1.5849625007211563	4	1	0	0
11261	1520	increase of type EBS	[increase of type EBS]	1.5849625007211563	4	1	0	0
11262	1520	only FMS patient	[Only FMS patients]	1.5849625007211563	3	1	0	0
11263	1520	h of treatment.	[h of treatment.]	1.5849625007211563	3	2	2	2
11264	1520	hpa axis in ptsd	[HPA axis in PTSD]	1.5849625007211563	4	1	0	0
11265	1520	cases, raralpha translocate	[cases, RARalpha translocates]	1.5849625007211563	3	1	0	0
11266	1520	factor with the characteristic	[factor with the characteristics]	1.5849625007211563	4	1	0	0
11267	1520	time course of infection.	[time course of infection.]	1.5849625007211563	4	1	0	0
11268	1520	enhancer positive regulatory element	[enhancer positive regulatory element]	1.5849625007211563	4	1	0	0
11269	1520	>10 mm, respectively).	[>10 mM, respectively).]	1.5849625007211563	3	1	0	0
11270	1520	presence of structure	[presence of structures]	1.5849625007211563	3	1	0	0
11271	1520	rrna for th2-type lymphokine	[mRNAs for Th2-type lymphokines]	1.5849625007211563	4	1	0	0
11272	1520	-contain dna-binding activity	[-containing DNA-binding activity]	1.5849625007211563	3	1	0	0
11273	1520	NFAT composite element	[NFAT composite elements]	1.5849625007211563	3	2	1	1
11274	1520	tyrosine kinase csk	[tyrosine kinase csk]	1.5849625007211563	3	1	0	0
11275	1520	important hematopoietic gene	[important hematopoietic genes]	1.5849625007211563	3	1	0	0
11276	1520	developmentally related interaction	[developmentally related interaction]	1.5849625007211563	3	1	0	0
11277	1520	target for DNA methylation	[target for DNA methylation]	1.5849625007211563	4	1	0	0
11278	1520	T cell nfatp	[T cells NFATp]	1.5849625007211563	3	1	0	0
11279	1520	kd value for aldosterone	[Kd value for aldosterone]	1.5849625007211563	4	1	0	0
11280	1520	genomic DNA of lymphocyte	[genomic DNA of lymphocytes]	1.5849625007211563	4	1	0	0
11281	1520	hematopoietic human erythroleukemia cell	[hematopoietic human erythroleukemia cells]	1.5849625007211563	4	1	0	0
11282	1520	ligand-binding domain amino acid	[ligand-binding domain amino acids]	1.5849625007211563	4	1	0	0
11283	1520	T. parva-transformed T cell	[T. parva-transformed T cells]	1.5849625007211563	4	2	1	1
11284	1520	lipid kinase activity	[lipid kinase activity]	1.5849625007211563	3	1	0	0
11285	1520	differential cDNA hybridization	[differential cDNA hybridization]	1.5849625007211563	3	1	0	0
11286	1520	other inflammatory lung disease	[other inflammatory lung diseases]	1.5849625007211563	4	1	0	0
11287	1520	TG il-2r alpha	[TG IL-2R alpha]	1.5849625007211563	3	1	0	0
11288	1520	up-regulated surface expression	[up-regulated surface expression]	1.5849625007211563	3	1	0	0
11289	1520	immature class ii	[immature class II]	1.5849625007211563	3	1	0	0
11290	1520	stem cell proliferation	[stem cell proliferation]	1.5849625007211563	3	1	0	0
11291	1520	CD4 T cell line	[CD4 T cell lines]	1.5849625007211563	4	2	2	2
11292	1520	classical p50/p65 heterodimer	[classical p50/p65 heterodimer]	1.5849625007211563	3	1	0	0
11293	1520	complex of two proteins,	[complex of two proteins,]	1.5849625007211563	4	1	0	0
11294	1520	major risk factor	[major risk factor]	1.5849625007211563	3	2	2	2
11295	1520	pediatric age range;	[pediatric age range;]	1.5849625007211563	3	1	0	0
11296	1520	constitutive expression c-fo	[Constitutive expression c-fos]	1.5849625007211563	3	1	0	0
11297	1520	kappa b phosphorylation	[kappa B phosphorylation]	1.5849625007211563	3	1	0	0
11298	1520	Ig heavy chain promoter,	[Ig heavy chain promoter,]	1.5849625007211563	4	1	0	0
11299	1520	cell express level	[cells expressing levels]	1.5849625007211563	3	2	1	1
11300	1520	adeno-associated virus p5 promoter	[adeno-associated virus P5 promoter]	1.5849625007211563	4	1	0	0
11301	1520	m-csf receptor promoter activity	[M-CSF receptor promoter activity]	1.5849625007211563	4	1	0	0
11302	1520	T cell signal transduction	[T cell signal transduction]	1.5849625007211563	4	1	0	0
11303	1520	localisation of other factor	[localisation of other factors]	1.5849625007211563	4	1	0	0
11304	1520	various cellular protein	[various cellular proteins]	1.5849625007211563	3	1	0	0
11305	1520	c-jun as oligonucleotide	[c-jun AS oligonucleotides]	1.5849625007211563	3	2	1	1
11306	1520	hence in the activation	[hence in the activation]	1.5849625007211563	4	1	0	0
11307	1520	transactivation and/or DNA binding	[transactivation and/or DNA binding]	1.5849625007211563	4	1	0	0
11308	1520	cd16 in NK cell	[CD16 in NK cells]	1.5849625007211563	4	1	0	0
11309	1520	two NF-IL-6 motif	[two NF-IL-6 motifs]	1.5849625007211563	3	1	0	0
11310	1520	3 pediatric patient	[3 pediatric patients]	1.5849625007211563	3	1	0	0
11311	1520	novel homeobox gene	[novel homeobox gene]	1.5849625007211563	3	2	2	2
11312	1520	STAT3 expression in particular	[STAT3 expression in particular]	1.5849625007211563	4	1	0	0
11313	1520	concert with Tat	[concert with Tat]	1.5849625007211563	3	1	0	0
11314	1520	c-Jun n-terminal kinase	[c-Jun N-terminal kinase]	1.5849625007211563	3	2	2	2
11315	1520	DNase I site	[DNase I site]	1.5849625007211563	3	2	1	1
11316	1520	normal cell growth,	[normal cell growth,]	1.5849625007211563	3	1	0	0
11317	1520	inactive camkiv on activation	[inactive CaMKIV on activation]	1.5849625007211563	4	1	0	0
11318	1520	chloramphenicol acetyltransferase CAT activity	[Chloramphenicol acetyltransferase CAT activities]	1.5849625007211563	4	1	0	0
11319	1520	RA start at concentration	[RA starting at concentrations]	1.5849625007211563	4	1	0	0
11320	1520	translocation of stat5	[translocation of STAT5]	1.5849625007211563	3	1	0	0
11321	1520	prior to cytokine stimulation	[prior to cytokine stimulation]	1.5849625007211563	4	1	0	0
11322	1520	v/v) in HL60	[v/v) in HL60]	1.5849625007211563	3	1	0	0
11323	1520	tnf-alpha with AZT	[TNF-alpha with AZT]	1.5849625007211563	3	1	0	0
11324	1520	anti- apoptosis protein	[anti- apoptosis protein]	1.5849625007211563	3	1	0	0
11325	1520	major isoflavone metabolite	[major isoflavone metabolites]	1.5849625007211563	3	1	0	0
11326	1520	asparagine bond rearrangement	[asparagine bond rearrangement]	1.5849625007211563	3	1	0	0
11327	1520	b lymphocyte cell line	[B lymphocyte cell line]	1.5849625007211563	4	2	1	1
11328	1520	cd4+ cd8int/- cell population	[CD4+ CD8int/- cell population]	1.5849625007211563	4	1	0	0
11329	1520	retinoblastoma prb 105	[retinoblastoma pRb 105]	1.5849625007211563	3	1	0	0
11330	1520	presence of SOCS-3	[presence of SOCS-3]	1.5849625007211563	3	1	0	0
11331	1520	decrease with age	[decrease with age]	1.5849625007211563	3	1	0	0
11332	1520	il-2 response element	[IL-2 response element]	1.5849625007211563	3	1	0	0
11333	1520	A.Rickinson, cell 1991).	[A.Rickinson, Cell 1991).]	1.5849625007211563	3	1	0	0
11334	1520	resultant cell line DH42	[resultant cell line DH42]	1.5849625007211563	4	1	0	0
11335	1520	patient with advanced tuberculosis,	[patients with advanced tuberculosis,]	1.5849625007211563	4	1	0	0
11336	1520	depletion of apolipoprotein a1,	[depletion of apolipoprotein A1,]	1.5849625007211563	4	1	0	0
11337	1520	anti-rabbit hsp90 monoclonal antibody	[anti-rabbit hsp90 monoclonal antibody]	1.5849625007211563	4	1	0	0
11338	1520	effect on transcription factor	[effect on transcription factors]	1.5849625007211563	4	2	2	2
11339	1520	double-stranded phosphorothioate oligonucleotide	[double-stranded phosphorothioate oligonucleotides]	1.5849625007211563	3	1	0	0
11340	1520	activation of tolerant cell	[activation of tolerant cells]	1.5849625007211563	4	1	0	0
11341	1520	Granulocyte/macrophage colony-stimulating factor	[Granulocyte/macrophage colony-stimulating factor]	1.5849625007211563	3	1	0	0
11342	1520	J.M.Hardwick, j.virol.64:313-321, 1990).	[J.M.Hardwick, J.Virol.64:313-321, 1990).]	1.5849625007211563	3	1	0	0
11343	1520	protein sequence of b1	[protein sequence of B1]	1.5849625007211563	4	1	0	0
11344	1520	pathogen Shigella flexneri	[pathogen Shigella flexneri]	1.5849625007211563	3	1	0	0
11345	1520	transactivation domain of stat5	[transactivation domains of Stat5]	1.5849625007211563	4	1	0	0
11346	1520	depend on intracellular localization	[depending on intracellular localization]	1.5849625007211563	4	1	0	0
11347	1520	fetal/adult alpha globin gene	[fetal/adult alpha globin genes]	1.5849625007211563	4	1	0	0
11348	1520	ifn-gamma -produce T	[IFN-gamma -producing T]	1.5849625007211563	3	1	0	0
11349	1520	molecular pathogenesis of x-scid	[molecular pathogenesis of X-SCID]	1.5849625007211563	4	1	0	0
11350	1520	total of nine patient	[total of nine patients]	1.5849625007211563	4	1	0	0
11351	1520	mechanism responsible for induction	[mechanisms responsible for induction]	1.5849625007211563	4	1	0	0
11352	1520	rearrangement of BCL6	[rearrangement of BCL6]	1.5849625007211563	3	1	0	0
11353	1520	anti-VLA-5 human fibronectin receptor	[anti-VLA-5 human fibronectin receptor]	1.5849625007211563	4	1	0	0
11354	1520	remote il-2 enhancer	[remote IL-2 enhancer]	1.5849625007211563	3	1	0	0
11355	1520	IkappaB kinase IKKalpha	[IkappaB kinases IKKalpha]	1.5849625007211563	3	1	0	0
11356	1520	htlv-1-transformed T cell	[HTLV-1-transformed T cells]	1.5849625007211563	3	1	0	0
11357	1520	stimulation through CD28	[stimulation through CD28]	1.5849625007211563	3	1	0	0
11358	1520	serum immunoglobulin iga	[serum immunoglobulin IgA]	1.5849625007211563	3	1	0	0
11359	1520	CD40 surface expression	[CD40 surface expression]	1.5849625007211563	3	1	0	0
11360	1520	intact octamer element	[intact octamer element]	1.5849625007211563	3	1	0	0
11361	1520	absence of p56	[absence of p56]	1.5849625007211563	3	1	0	0
11362	1520	use flow cytometry,	[Using flow cytometry,]	1.5849625007211563	3	1	0	0
11363	1520	Epstein-Barr virus EBV antigen	[Epstein-Barr virus EBV antigen]	1.5849625007211563	4	2	2	2
11364	1520	inflammatory cytokine il-1	[inflammatory cytokines IL-1]	1.5849625007211563	3	1	0	0
11365	1520	ets ap-1 transcription factor	[Ets AP-1 transcription factors]	1.5849625007211563	4	1	0	0
11366	1520	contain gal4 site	[containing GAL4 sites]	1.5849625007211563	3	1	0	0
11367	1520	p27(kip1 a inhibitory protein	[p27(Kip1 an inhibitory protein]	1.5849625007211563	4	1	0	0
11368	1520	HLA-DM -do complex	[HLA-DM -DO complexes]	1.5849625007211563	3	1	0	0
11369	1520	E1A cytolytic susceptibility	[E1A cytolytic susceptibility]	1.5849625007211563	3	1	0	0
11370	1520	functional molecular clone	[functional molecular clone]	1.5849625007211563	3	1	0	0
11371	1520	activin a growth arrest	[activin A growth arrest]	1.5849625007211563	4	1	0	0
11372	1520	human gm-csf hgm-csf	[human GM-CSF hGM-CSF]	1.5849625007211563	3	1	0	0
11373	1520	patient with essential hypertension	[patients with essential hypertension]	1.5849625007211563	4	2	1	1
11374	1520	follow estrogen replacement therapy	[following estrogen replacement therapy]	1.5849625007211563	4	1	0	0
11375	1520	p95vav nfat activation	[p95vav NFAT activation]	1.5849625007211563	3	1	0	0
11376	1520	such as leukemia	[such as leukemia]	1.5849625007211563	3	1	0	0
11377	1520	cessation of cell proliferation	[cessation of cell proliferation]	1.5849625007211563	4	1	0	0
11378	1520	anti- CD4 monoclonal antibody	[anti- CD4 monoclonal antibodies]	1.5849625007211563	4	1	0	0
11379	1520	dexamethasone (ic50 1 nm,	[dexamethasone (IC50 1 nM,]	1.5849625007211563	4	1	0	0
11380	1520	early model of apoptosis	[earliest models of apoptosis]	1.5849625007211563	4	1	0	0
11381	1520	1 alpha,25-dihydroxyvitamin D3 receptor	[1 alpha,25-dihydroxyvitamin D3 receptor]	1.5849625007211563	4	1	0	0
11382	1520	lipopolysaccharide tyrosine kinase activation	[lipopolysaccharide tyrosine kinase activation]	1.5849625007211563	4	1	0	0
11383	1520	other ifn-inducible gene product	[other IFN-inducible gene products]	1.5849625007211563	4	1	0	0
11384	1520	novel role for GATA-3	[novel role for GATA-3]	1.5849625007211563	4	1	0	0
11385	1520	NF-kappa(b) EGR-1 transcription factor	[NF-kappa(B) EGR-1 transcription factors]	1.5849625007211563	4	1	0	0
11386	1520	regulation during t-cell development	[regulation during T-cell development]	1.5849625007211563	4	1	0	0
11387	1520	thyroid hormone response element	[thyroid hormone response element]	1.5849625007211563	4	2	1	1
11388	1520	use recombinant p50	[Using recombinant p50]	1.5849625007211563	3	1	0	0
11389	1520	action of this cytokine	[actions of these cytokines]	1.5849625007211563	4	1	0	0
11390	1520	divergent reaction with er	[divergent reaction with ER]	1.5849625007211563	4	1	0	0
11391	1520	Janus kinase-1-deficient cell line	[Janus kinase-1-deficient cell line]	1.5849625007211563	4	1	0	0
11392	1520	component of Band a	[component of Band A]	1.5849625007211563	4	1	0	0
11393	1520	ligation of MHC-I	[ligation of MHC-I]	1.5849625007211563	3	1	0	0
11394	1520	inhibition of PI3K	[Inhibition of PI3K]	1.5849625007211563	3	1	0	0
11395	1520	lps signal receptor	[LPS signaling receptor]	1.5849625007211563	3	1	0	0
11396	1520	production of this cytokine	[production of these cytokines]	1.5849625007211563	4	1	0	0
11397	1520	nuclear factor (nf)-kappab activation	[nuclear factor (NF)-kappaB activation]	1.5849625007211563	4	1	0	0
11398	1520	DNase-I-hypersensitive (HS) region	[DNase-I-hypersensitive (HS) regions]	1.5849625007211563	3	1	0	0
11399	1520	mosaic for the mutation.	[mosaic for the mutation.]	1.5849625007211563	4	1	0	0
11400	1520	different glucocorticoid hormone gch	[Different glucocorticoid hormones GCH]	1.5849625007211563	4	1	0	0
11401	1520	lack of activation	[Lack of activation]	1.5849625007211563	3	2	2	2
11402	1520	liver of patient	[liver of patients]	1.5849625007211563	3	1	0	0
11403	1520	restriction enzyme analysis	[Restriction enzyme analysis]	1.5849625007211563	3	1	0	0
11404	1520	p21ras effector pathway	[p21ras effector pathway]	1.5849625007211563	3	2	2	2
11405	1520	phorbol monocytic differentiation	[phorbol monocytic differentiation]	1.5849625007211563	3	2	2	2
11406	1520	first 280 bp upstream	[first 280 bp upstream]	1.5849625007211563	4	1	0	0
11407	1520	patient without renal complication	[patients without renal complications]	1.5849625007211563	4	1	0	0
11408	1520	most T cell line	[most T cell lines]	1.5849625007211563	4	1	0	0
11409	1520	consist of Raf-1 function	[consisting of Raf-1 functions]	1.5849625007211563	4	1	0	0
11410	1520	host defence response	[host defence response]	1.5849625007211563	3	2	1	1
11411	1520	NF-kappaB -responsive reporter gene	[NF-kappaB -responsive reporter gene]	1.5849625007211563	4	1	0	0
11412	1520	moreover, ectopic id1	[Moreover, ectopic Id1]	1.5849625007211563	3	1	0	0
11413	1520	expression of this component	[expression of these components]	1.5849625007211563	4	1	0	0
11414	1520	yeast transactivator gal4	[yeast transactivator GAL4]	1.5849625007211563	3	1	0	0
11415	1520	nuclear body NB	[nuclear body NB]	1.5849625007211563	3	1	0	0
11416	1520	role as a regulator	[role as a regulator]	1.5849625007211563	4	2	2	2
11417	1520	C5a reporter gene expression	[C5a reporter gene expression]	1.5849625007211563	4	1	0	0
11418	1520	MRD in PBSC harvest	[MRD in PBSC harvests]	1.5849625007211563	4	1	0	0
11419	1520	include the STAT family	[including the STAT family]	1.5849625007211563	4	1	0	0
11420	1520	interaction between viral factor	[interactions between viral factors]	1.5849625007211563	4	1	0	0
11421	1520	therefore, activation of stat5a	[Therefore, activation of STAT5A]	1.5849625007211563	4	1	0	0
11422	1520	increase in nf-kappa b	[increase in NF-kappa B]	1.5849625007211563	4	1	0	0
11423	1520	dna-binding homeodomain of Pbx1	[DNA-binding homeodomain of Pbx1]	1.5849625007211563	4	1	0	0
11424	1520	human PAX-5 gene	[human PAX-5 gene]	1.5849625007211563	3	1	0	0
11425	1520	erythropoietin receptor epo-r gene	[erythropoietin receptor Epo-R gene]	1.5849625007211563	4	1	0	0
11426	1520	endogenous thymocyte-specific gene	[endogenous thymocyte-specific gene]	1.5849625007211563	3	1	0	0
11427	1520	used, icsat expression	[used, ICSAT expression]	1.5849625007211563	3	1	0	0
11428	1520	second pathway lead	[second pathway leading]	1.5849625007211563	3	1	0	0
11429	1520	normal lung parenchyma	[normal lung parenchyma]	1.5849625007211563	3	1	0	0
11430	1520	most lymphoblastoid cell	[most lymphoblastoid cells]	1.5849625007211563	3	1	0	0
11431	1520	promoter region between -173	[promoter region between -173]	1.5849625007211563	4	1	0	0
11432	1520	binding to enhancer	[binding to enhancers]	1.5849625007211563	3	1	0	0
11433	1520	(3) expression of gene	[(3) expression of genes]	1.5849625007211563	4	1	0	0
11434	1520	gene on chromosome 16p13.3	[gene on chromosome 16p13.3]	1.5849625007211563	4	1	0	0
11435	1520	cytokine of neutrophil pmn	[cytokines of neutrophils PMN]	1.5849625007211563	4	1	0	0
11436	1520	2 microm concentration,	[2 microM concentration,]	1.5849625007211563	3	1	0	0
11437	1520	Study of the mechanism	[Studies of the mechanisms]	1.5849625007211563	4	1	0	0
11438	1520	cytoplasmic retention of rela	[cytoplasmic retention of RelA]	1.5849625007211563	4	1	0	0
11439	1520	caspase 3-like protease	[caspase 3-like proteases]	1.5849625007211563	3	2	2	2
11440	1520	insertion of multiple copy	[insertion of multiple copies]	1.5849625007211563	4	1	0	0
11441	1520	universal ras effector molecule	[universal Ras effector molecules]	1.5849625007211563	4	1	0	0
11442	1520	sucrose gradient analysis	[sucrose gradient analysis]	1.5849625007211563	3	1	0	0
11443	1520	dexamethasone-treated rat thymocyte	[dexamethasone-treated rat thymocytes]	1.5849625007211563	3	1	0	0
11444	1520	carboxylesterase upstream sequence	[carboxylesterase upstream sequence]	1.5849625007211563	3	1	0	0
11445	1520	three major 29-kda protein	[three major 29-kDa proteins]	1.5849625007211563	4	1	0	0
11446	1520	culture medium of J.Jhan	[culture medium of J.Jhan]	1.5849625007211563	4	1	0	0
11447	1520	dexamethasone-induced transcription in cell	[dexamethasone-induced transcription in cells]	1.5849625007211563	4	1	0	0
11448	1520	normal child-bearing-age woman	[normal child-bearing-age women]	1.5849625007211563	3	2	1	1
11449	1520	differentiation of native monocyte	[differentiation of native monocytes]	1.5849625007211563	4	1	0	0
11450	1520	phagocytosis by this cells.	[phagocytosis by these cells.]	1.5849625007211563	4	1	0	0
11451	1520	stage of T	[stage of T]	1.5849625007211563	3	1	0	0
11452	1520	also strongly BCL-6	[also strongly BCL-6]	1.5849625007211563	3	1	0	0
11453	1520	untreated ht-2 cell	[untreated HT-2 cells]	1.5849625007211563	3	1	0	0
11454	1520	minute after stimulation.	[min after stimulation.]	1.5849625007211563	3	2	2	2
11455	1520	STAT /DNA binding	[STAT /DNA binding]	1.5849625007211563	3	1	0	0
11456	1520	variety of construct	[variety of constructs]	1.5849625007211563	3	1	0	0
11457	1520	example, rheumatoid synovitis,	[example, rheumatoid synovitis,]	1.5849625007211563	3	1	0	0
11458	1520	degree of negative autoregulation	[degree of negative autoregulation]	1.5849625007211563	4	1	0	0
11459	1520	one specific band	[one specific band]	1.5849625007211563	3	1	0	0
11460	1520	single point assay	[single point assay]	1.5849625007211563	3	2	1	1
11461	1520	Ad-infected human cell	[Ad-infected human cells]	1.5849625007211563	3	1	0	0
11462	1520	monocyte from tuberculous patient	[monocytes from tuberculous patients]	1.5849625007211563	4	1	0	0
11463	1520	only after incubation (90-120	[only after incubation (90-120]	1.5849625007211563	4	1	0	0
11464	1520	binding of Jun pfo	[binding of Jun /Fos]	1.5849625007211563	4	1	0	0
11465	1520	low salt concentration	[lower salt concentration]	1.5849625007211563	3	1	0	0
11466	1520	response to LPS	[response to LPS]	1.5849625007211563	3	1	0	0
11467	1520	renin -angiotensin system	[renin -angiotensin system]	1.5849625007211563	3	1	0	0
11468	1520	induction of tnf-alpha	[induction of TNF-alpha]	1.5849625007211563	3	2	2	2
11469	1520	new antiinflammatory therapy	[new antiinflammatory therapy]	1.5849625007211563	3	1	0	0
11470	1520	unrelated antioxidants, n-acetylcysteine nac	[unrelated antioxidants, N-acetylcysteine NAC]	1.5849625007211563	4	1	0	0
11471	1520	regulation of Bcl-2 expression	[regulation of Bcl-2 expression]	1.5849625007211563	4	1	0	0
11472	1520	10 bp apart,	[10 bp apart,]	1.5849625007211563	3	1	0	0
11473	1520	TBP-associated factor tafii32	[TBP-associated factor TAFII32]	1.5849625007211563	3	1	0	0
11474	1520	severe systemic anaphylaxis	[severe systemic anaphylaxis]	1.5849625007211563	3	1	0	0
11475	1520	most cell types, activation	[most cell types, activation]	1.5849625007211563	4	1	0	0
11476	1520	novel human homeobox gene	[novel human homeobox gene]	1.5849625007211563	4	2	2	2
11477	1520	transcription factor as target	[transcription factors as targets]	1.5849625007211563	4	2	2	2
11478	1520	GR binding characteristic	[GR binding characteristics]	1.5849625007211563	3	1	0	0
11479	1520	RXR agonist activity	[RXR agonist activity]	1.5849625007211563	3	1	0	0
11480	1520	nasopharyngeal carcinoma (npc) cell	[nasopharyngeal carcinoma (NPC) cells]	1.5849625007211563	4	1	0	0
11481	1520	murine bcl6 (mbcl6) cDNA	[murine BCL6 (mBCL6) cDNA]	1.5849625007211563	4	1	0	0
11482	1520	host NK cell response	[host NK cell response]	1.5849625007211563	4	1	0	0
11483	1520	gata zinc finger domain	[GATA zinc finger domain]	1.5849625007211563	4	1	0	0
11484	1520	bear htlv-i retroviruse	[bearing HTLV-I retroviruses]	1.5849625007211563	3	1	0	0
11485	1520	two nuclear factor-IL6 motif	[two nuclear factor-IL6 motifs]	1.5849625007211563	4	1	0	0
11486	1520	superinduction of c-jun transcripts.	[superinduction of c-jun transcripts.]	1.5849625007211563	4	1	0	0
11487	1520	p less than 0.01	[P less than 0.01]	1.5849625007211563	4	2	1	1
11488	1520	inflammatory bowel disease IBD	[inflammatory bowel disease IBD]	1.5849625007211563	4	1	0	0
11489	1520	gene expression by FICZ	[gene expression by FICZ]	1.5849625007211563	4	1	0	0
11490	1520	direct effect of glucocorticoid	[direct effects of glucocorticoids]	1.5849625007211563	4	1	0	0
11491	1520	progesterone receptor in tumor.	[progesterone receptors in tumor.]	1.5849625007211563	4	1	0	0
11492	1520	J Virol feb;72(2):1709]	[J Virol Feb;72(2):1709]]	1.5849625007211563	3	1	0	0
11493	1520	mutation of the C-site	[Mutation of the C-site]	1.5849625007211563	4	1	0	0
11494	1520	up-regulation of cytokine	[up-regulation of cytokines]	1.5849625007211563	3	1	0	0
11495	1520	IL-10 on Teflon	[IL-10 on Teflon]	1.5849625007211563	3	1	0	0
11496	1520	regulation of pak activation	[Regulation of PAK activation]	1.5849625007211563	4	1	0	0
11497	1520	activity of the enzyme	[activity of the enzyme]	1.5849625007211563	4	2	2	2
11498	1520	limit dilution assay	[limiting dilution assays]	1.5849625007211563	3	1	0	0
11499	1520	ultra-violet signal transduction	[UV signal transduction]	1.5849625007211563	3	1	0	0
11500	1520	several NF-kappaB family member	[several NF-kappaB family members,]	1.5849625007211563	4	1	0	0
11501	1520	transport of class molecule	[transport of class molecules]	1.5849625007211563	4	2	2	2
11502	1520	three tandem copy	[three tandem copies]	1.5849625007211563	3	1	0	0
11503	1520	aged adrenal cortex	[aged adrenal cortex]	1.5849625007211563	3	1	0	0
11504	1520	addition of camp	[addition of cAMP]	1.5849625007211563	3	1	0	0
11505	1520	peptide by pbmc	[peptides by PBMC]	1.5849625007211563	3	1	0	0
11506	1520	growth factor cell proliferation	[growth factor cell proliferation]	1.5849625007211563	4	1	0	0
11507	1520	creb/atf pathway by tax	[CREB/ATF pathway by Tax]	1.5849625007211563	4	1	0	0
11508	1520	outcome of many disease	[outcome of many diseases]	1.5849625007211563	4	1	0	0
11509	1520	cytosol of monocyte	[cytosol of monocytes]	1.5849625007211563	3	1	0	0
11510	1520	cytotoxic property of monocyte	[cytotoxic properties of monocytes]	1.5849625007211563	4	1	0	0
11511	1520	namely, by il-2	[namely, by IL-2]	1.5849625007211563	3	1	0	0
11512	1520	transcription factor nfat	[transcription factor NFAT]	1.5849625007211563	3	2	1	1
11513	1520	heb e2a protein	[HEB E2A proteins]	1.5849625007211563	3	1	0	0
11514	1520	course of asthma	[course of asthma]	1.5849625007211563	3	1	0	0
11515	1520	change in fev1	[changes in FEV1]	1.5849625007211563	3	1	0	0
11516	1520	half-life of both inhibitor	[half-life of both inhibitors]	1.5849625007211563	4	1	0	0
11517	1520	TCR-associated ptk zap-70	[TCR-associated PTK ZAP-70]	1.5849625007211563	3	1	0	0
11518	1520	protein kinase kinase	[protein kinase kinase]	1.5849625007211563	3	2	2	2
11519	1520	period of latency	[period of latency]	1.5849625007211563	3	2	2	2
11520	1520	definitive erythroid colony	[definitive erythroid colonies]	1.5849625007211563	3	1	0	0
11521	1520	interferon-stimulated response element ISRE	[interferon-stimulated response element ISRE]	1.5849625007211563	4	2	1	1
11522	1520	intact x chromosome	[intact X chromosome]	1.5849625007211563	3	1	0	0
11523	1520	equally high il-2 level	[equally high IL-2 levels]	1.5849625007211563	4	1	0	0
11524	1520	camp response element site	[camp response element site]	1.5849625007211563	4	1	0	0
11525	1520	c-myb oncogene product	[c-myb oncogene product]	1.5849625007211563	3	1	0	0
11526	1520	review of the mechanism	[review of the mechanism]	1.5849625007211563	4	1	0	0
11527	1520	immunodeficiency virus hodgkin' disease	[immunodeficiency virus Hodgkin's disease]	1.5849625007211563	4	2	2	2
11528	1520	regulation of elk-1 transcription	[regulation of elk-1 transcription]	1.5849625007211563	4	1	0	0
11529	1520	il-13 promoter activity	[IL-13 promoter activity]	1.5849625007211563	3	1	0	0
11530	1520	various stress condition	[various stress conditions]	1.5849625007211563	3	1	0	0
11531	1520	transcriptional activator protein	[transcriptional activator protein]	1.5849625007211563	3	1	0	0
11532	1520	bone marrow transplantation	[bone marrow transplantation]	1.5849625007211563	3	2	2	2
11533	1520	alteration of transcription factor	[alterations of transcription factors]	1.5849625007211563	4	1	0	0
11534	1520	important role of polyamine	[important role of polyamines]	1.5849625007211563	4	1	0	0
11535	1520	downregulation of l-selectin	[downregulation of L-selectin]	1.5849625007211563	3	1	0	0
11536	1520	NFAT oligonucleotide carry mutation	[NFAT oligonucleotide carrying mutations]	1.5849625007211563	4	1	0	0
11537	1520	1 alphav5 dihydroxyvitamin D3	[1 alpha,25 dihydroxyvitamin D3]	1.5849625007211563	4	1	0	0
11538	1520	several cellular transcription factor	[several cellular transcription factors]	1.5849625007211563	4	1	0	0
11539	1520	specific receptor c-mpl	[specific receptor c-Mpl]	1.5849625007211563	3	1	0	0
11540	1520	start site of transcription	[start site of transcription]	1.5849625007211563	4	1	0	0
11541	1520	T cell receptor-CD3 complex	[T cell receptor-CD3 complex]	1.5849625007211563	4	1	0	0
11542	1520	activation protein ap-1	[activation protein AP-1]	1.5849625007211563	3	1	0	0
11543	1520	inhibition of c-myc expression	[inhibition of c-myc expression]	1.5849625007211563	4	1	0	0
11544	1520	intracellular glutathione gsh	[intracellular glutathione GSH]	1.5849625007211563	3	1	0	0
11545	1520	IkappaBalpha phosphorylation in	[IkappaBalpha phosphorylation in]	1.5849625007211563	3	1	0	0
11546	1520	CD4 cytoplasmic tail	[CD4 cytoplasmic tail]	1.5849625007211563	3	2	1	1
11547	1520	cell of preosteoclast phenotype	[cells of preosteoclast phenotype]	1.5849625007211563	4	1	0	0
11548	1520	supposedly normal population,	[supposedly normal population,]	1.5849625007211563	3	1	0	0
11549	1520	cell from donor	[cells from donors]	1.5849625007211563	3	2	2	2
11550	1520	specificity towards the hbd	[specificity towards the HBD]	1.5849625007211563	4	1	0	0
11551	1520	nuclei of cd1a+	[nuclei of CD1a+]	1.5849625007211563	3	1	0	0
11552	1520	4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl) 1h-imidazole sb	[4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl) 1H-imidazole SB]	1.5849625007211563	3	1	0	0
11553	1520	analysis of this region	[analysis of this region]	1.5849625007211563	4	1	0	0
11554	1520	sensitivity to cortisol	[sensitivity to cortisol]	1.5849625007211563	3	1	0	0
11555	1520	tcr-mediated gene transcription	[TCR-mediated gene transcription]	1.5849625007211563	3	1	0	0
11556	1520	primary rat microglia	[primary rat microglia]	1.5849625007211563	3	1	0	0
11557	1520	transcription factor in pbmc	[transcription factors in PBMC]	1.5849625007211563	4	1	0	0
11558	1520	lymphocytic transformation by htlv-i	[lymphocytic transformation by HTLV-I]	1.5849625007211563	4	1	0	0
11559	1520	negative transcription regulation.	[negative transcription regulation.]	1.5849625007211563	3	1	0	0
11560	1520	calmodulin- dependent phosphatase calcineurin	[calmodulin- dependent phosphatase calcineurin]	1.5849625007211563	4	1	0	0
11561	1520	macrophage cell line u937	[macrophage cell line U937]	1.5849625007211563	4	1	0	0
11562	1520	vivo; however, deletion	[vivo; however, deletion]	1.5849625007211563	3	1	0	0
11563	1520	set of g0s gene	[set of G0S genes]	1.5849625007211563	4	1	0	0
11564	1520	CD11c gene promoter	[CD11c gene promoters]	1.5849625007211563	3	1	0	0
11565	1520	contrast, egr-1 expression	[contrast, Egr-1 expression]	1.5849625007211563	3	1	0	0
11566	1520	increase use of antiestrogen	[increasing use of antiestrogens]	1.5849625007211563	4	1	0	0
11567	1520	approach to the study	[approach to the study]	1.5849625007211563	4	2	2	2
11568	1520	pebp2 site-binding protein (s)	[PEBP2 site-binding protein (s)]	1.5849625007211563	4	1	0	0
11569	1520	production of soluble il-1rii	[production of soluble IL-1RII]	1.5849625007211563	4	1	0	0
11570	1520	response to cellular differentiation.	[response to cellular differentiation.]	1.5849625007211563	4	1	0	0
11571	1520	activity of this phosphatase	[activities of these phosphatases]	1.5849625007211563	4	1	0	0
11572	1520	nuclear signal mechanism	[nuclear signaling mechanisms]	1.5849625007211563	3	1	0	0
11573	1520	difference in basal transcription	[differences in basal transcription]	1.5849625007211563	4	1	0	0
11574	1520	contrast, anergic T cell	[contrast, anergic T cells]	1.5849625007211563	4	1	0	0
11575	1520	form of inheritance	[form of inheritance]	1.5849625007211563	3	2	2	2
11576	1520	position effect of translocation	[Position effect of translocations]	1.5849625007211563	4	1	0	0
11577	1520	one phagocyte system	[one phagocyte system]	1.5849625007211563	3	1	0	0
11578	1520	ATRA /9-cis RA	[ATRA /9-cis RA]	1.5849625007211563	3	1	0	0
11579	1520	synthesis of rel protein	[synthesis of Rel proteins]	1.5849625007211563	4	1	0	0
11580	1520	repressive chromatin organization	[repressive chromatin organization]	1.5849625007211563	3	1	0	0
11581	1520	Epstein-Barr virus EBV infection	[Epstein-Barr virus EBV infection]	1.5849625007211563	4	2	2	2
11582	1520	activation infiltrate T cell	[activation infiltrating T cells]	1.5849625007211563	4	1	0	0
11583	1520	gene expression of gene	[gene expression of genes]	1.5849625007211563	4	2	2	2
11584	1520	growth response gene	[growth response gene]	1.5849625007211563	3	2	2	2
11585	1520	monocyte cell line thp-1	[monocyte cell line THP-1]	1.5849625007211563	4	2	1	1
11586	1520	dna-binding protein gata-1	[DNA-binding protein GATA-1]	1.5849625007211563	3	1	0	0
11587	1520	set of t-cell malignancy	[set of T-cell malignancies]	1.5849625007211563	4	1	0	0
11588	1520	503-amino-acid-long acidic protein	[503-amino-acid-long acidic protein]	1.5849625007211563	3	1	0	0
11589	1520	lymphocyte subpopulation of worker	[lymphocyte subpopulations of workers]	1.5849625007211563	4	1	0	0
11590	1520	g1 cell cycle progression	[G1 cell cycle progression]	1.5849625007211563	4	1	0	0
11591	1520	bind motif for hla-cw*0702	[binding motif for HLA-Cw*0702]	1.5849625007211563	4	1	0	0
11592	1520	binding of repressor	[binding of repressors]	1.5849625007211563	3	1	0	0
11593	1520	numerous Heinz body	[numerous Heinz bodies]	1.5849625007211563	3	1	0	0
11594	1520	concert with slp-76	[concert with SLP-76]	1.5849625007211563	3	1	0	0
11595	1520	gssg /gsh ratio	[GSSG /GSH ratio]	1.5849625007211563	3	1	0	0
11596	1520	/i kappa b dissociation	[/I kappa B dissociation]	1.5849625007211563	4	1	0	0
11597	1520	high order nf-atp complex	[higher order NF-ATp complex]	1.5849625007211563	4	1	0	0
11598	1520	NF-kappa b element	[NF-kappa B element]	1.5849625007211563	3	4	3	1
11599	1520	hs-40 enhancer function	[HS-40 enhancer function]	1.5849625007211563	3	1	0	0
11600	1520	heterologous promoter follow transfection	[heterologous promoter following transfection]	1.5849625007211563	4	1	0	0
11601	1520	several downstream kinase	[several downstream kinases]	1.5849625007211563	3	1	0	0
11602	1520	Y chromosome gene sequence	[Y chromosome) gene sequence]	1.5849625007211563	4	1	0	0
11603	1520	participation of cyclic AMP	[participation of cyclic AMP]	1.5849625007211563	4	1	0	0
11604	1520	role in erythroid differentiation	[role in erythroid differentiation]	1.5849625007211563	4	2	1	1
11605	1520	line of transgenic mouse	[lines of transgenic mice]	1.5849625007211563	4	2	1	1
11606	1520	respective gene Oct-2	[respective genes Oct-2]	1.5849625007211563	3	1	0	0
11607	1520	PML/RAR alpha fusion transcript	[PML/RAR alpha fusion transcript]	1.5849625007211563	4	1	0	0
11608	1520	transfection of el-4 cell	[Transfection of EL-4 cells]	1.5849625007211563	4	1	0	0
11609	1520	nf-kappab -induce kinase	[NF-kappaB -inducing kinase]	1.5849625007211563	3	2	1	1
11610	1520	other pp2a inhibitor	[other PP2A inhibitors]	1.5849625007211563	3	1	0	0
11611	1520	self peptide rskfrqiv	[self peptide RSKFRQIV]	1.5849625007211563	3	1	0	0
11612	1520	recombinant vascular-cell adhesion molecule-1	[recombinant vascular-cell adhesion molecule-1]	1.5849625007211563	4	1	0	0
11613	1520	block in myeloid differentiation	[block in myeloid differentiation]	1.5849625007211563	4	1	0	0
11614	1520	body, include epithelia	[body, including epithelia]	1.5849625007211563	3	1	0	0
11615	1520	inactive cytoplasmic form	[inactive cytoplasmic form]	1.5849625007211563	3	1	0	0
11616	1520	activation of lung nf-kappab	[activation of lung NF-kappaB]	1.5849625007211563	4	1	0	0
11617	1520	next 3 hr.	[next 3 hr.]	1.5849625007211563	3	1	0	0
11618	1520	b lymphocyte differentiation	[B lymphocyte differentiation]	1.5849625007211563	3	2	1	1
11619	1520	Hox11 null mouse embryo	[Hox11 null mouse embryos]	1.5849625007211563	4	1	0	0
11620	1520	relatively high levels,	[relatively high levels,]	1.5849625007211563	3	1	0	0
11621	1520	CBF beta myh11 transcript	[CBF beta MYH11 transcripts]	1.5849625007211563	4	1	0	0
11622	1520	friend leukemia cell	[Friend leukemia cells]	1.5849625007211563	3	2	2	2
11623	1520	tal-1 promoter 1b	[tal-1 promoter 1b]	1.5849625007211563	3	1	0	0
11624	1520	1,25-dihydroxyvitamin D3 135eoh)2d3 ]receptor	[1,25-dihydroxyvitamin D3 1,25(OH)2D3 ]receptor]	1.5849625007211563	4	1	0	0
11625	1520	hiv-infected human monocytic cell	[HIV-infected human monocytic cells]	1.5849625007211563	4	1	0	0
11626	1520	ability of e1a	[ability of E1A]	1.5849625007211563	3	1	0	0
11627	1520	alpha beta lineage	[alpha beta lineage]	1.5849625007211563	3	1	0	0
11628	1520	parallel signal transduction pathway	[parallel signal transduction pathways]	1.5849625007211563	4	1	0	0
11629	1520	immunosuppressive drug cyclosporine CsA	[immunosuppressive drug cyclosporine CsA]	1.5849625007211563	4	1	0	0
11630	1520	tcr -signal transduction	[TCR -signal transduction]	1.5849625007211563	3	1	0	0
11631	1520	il-1beta in epithelial cell	[IL-1beta in epithelial cells]	1.5849625007211563	4	1	0	0
11632	1520	Fc gamma R	[Fc gamma R]	1.5849625007211563	3	1	0	0
11633	1520	leukocyte-mediated tissue damage	[leukocyte-mediated tissue damage]	1.5849625007211563	3	1	0	0
11634	1520	pkc NF-kappa b	[PKC NF-kappa B]	1.5849625007211563	3	1	0	0
11635	1520	granuloma in animal model	[granulomas in animal models]	1.5849625007211563	4	1	0	0
11636	1520	addition, amino acid	[addition, amino acids]	1.5849625007211563	3	1	0	0
11637	1520	induce socs-1 gene expression	[inducing SOCS-1 gene expression]	1.5849625007211563	4	1	0	0
11638	1520	1-2 microm as2o3	[1-2 microM As2O3]	1.5849625007211563	3	1	0	0
11639	1520	cis-acting sequence necessary	[cis-acting sequences necessary]	1.5849625007211563	3	1	0	0
11640	1520	level of bcl-2 mrna	[Levels of bcl-2 mRNA]	1.5849625007211563	4	1	0	0
11641	1520	express a stat3	[expressing a STAT3]	1.5849625007211563	3	1	0	0
11642	1520	cd14 receptor system	[CD14 receptor system]	1.5849625007211563	3	1	0	0
11643	1520	viral gene transactivation	[viral gene transactivation]	1.5849625007211563	3	1	0	0
11644	1520	follow activation with pha	[following activation with PHA]	1.5849625007211563	4	1	0	0
11645	1520	uptake of apoptotic neutrophil	[uptake of apoptotic neutrophils]	1.5849625007211563	4	2	1	1
11646	1520	selection in response	[selection in response]	1.5849625007211563	3	2	2	2
11647	1520	low-dose ionizing radiation	[low-dose ionizing radiation]	1.5849625007211563	3	1	0	0
11648	1520	binding site for sp1	[binding sites for Sp1]	1.5849625007211563	4	2	2	2
11649	1520	complex sialylated tetra-	[complex sialylated tetra-]	1.5849625007211563	3	1	0	0
11650	1520	Northern blotting experiment	[Northern blotting experiments]	1.5849625007211563	3	1	0	0
11651	1520	human acute myeloid leukemia	[human acute myeloid leukemia]	1.5849625007211563	4	1	0	0
11652	1520	response to il-2 binding	[response to IL-2 binding]	1.5849625007211563	4	1	0	0
11653	1520	rare cd3+/cd4+ T cell	[rare CD3+/CD4+ T cells]	1.5849625007211563	4	1	0	0
11654	1520	phosphorylation of substrate	[phosphorylation of substrates]	1.5849625007211563	3	2	1	1
11655	1520	generation of monoclonal antibody	[generation of monoclonal antibodies]	1.5849625007211563	4	1	0	0
11656	1520	EMS supershift analysis	[EMS supershift analyses]	1.5849625007211563	3	1	0	0
11657	1520	cortisol clearance in patient	[cortisol clearance in patients]	1.5849625007211563	4	1	0	0
11658	1520	sle Disease activity index	[SLE Disease Activity Index]	1.5849625007211563	4	1	0	0
11659	1520	contain the cellular SRF	[containing the cellular SRF]	1.5849625007211563	4	1	0	0
11660	1520	12 healthy control	[12 healthy controls]	1.5849625007211563	3	1	0	0
11661	1520	positive regulatory factor	[positive regulatory factors]	1.5849625007211563	3	1	0	0
11662	1520	rnase protection analysis	[RNase protection analysis]	1.5849625007211563	3	1	0	0
11663	1520	promoter regulate the synthesis	[promoter regulating the synthesis]	1.5849625007211563	4	1	0	0
11664	1520	hormone-binding domain HBD	[hormone-binding domain HBD]	1.5849625007211563	3	1	0	0
11665	1520	new protein family	[new protein family]	1.5849625007211563	3	1	0	0
11666	1520	proliferation of normal b	[proliferation of normal B]	1.5849625007211563	4	1	0	0
11667	1520	rearrangement at PML locus	[rearrangement at PML locus]	1.5849625007211563	4	1	0	0
11668	1520	expression of new enzyme,	[expression of new enzyme,]	1.5849625007211563	4	1	0	0
11669	1520	stimulation of both pathway	[stimulation of both pathways]	1.5849625007211563	4	1	0	0
11670	1520	nucleus of cells,	[nucleus of cells,]	1.5849625007211563	3	1	0	0
11671	1520	potent synergist hx630	[potent synergist HX630]	1.5849625007211563	3	1	0	0
11672	1520	intracellular il-2 signal	[intracellular IL-2 signaling]	1.5849625007211563	3	1	0	0
11673	1520	bipotent myeloid progenitor	[bipotent myeloid progenitors]	1.5849625007211563	3	1	0	0
11674	1520	specific immune modulation	[specific immune modulation]	1.5849625007211563	3	1	0	0
11675	1520	human B-lymphocyte cell cycle	[human B-lymphocyte cell cycle]	1.5849625007211563	4	1	0	0
11676	1520	only hiv gene	[only HIV genes]	1.5849625007211563	3	1	0	0
11677	1520	intracellular tail gp130	[intracellular tail gp130]	1.5849625007211563	3	1	0	0
11678	1520	dyad symmetry element dse	[dyad symmetry element DSE]	1.5849625007211563	4	1	0	0
11679	1520	activation of p56(lck)	[activation of p56(lck)]	1.5849625007211563	3	1	0	0
11680	1520	mutant form of notch1	[mutant forms of NOTCH1]	1.5849625007211563	4	1	0	0
11681	1520	mechanism of il-10 regulation	[mechanism of IL-10 regulation]	1.5849625007211563	4	1	0	0
11682	1520	human gata-3 protein	[human GATA-3 proteins]	1.5849625007211563	3	1	0	0
11683	1520	ability of this receptor	[ability of these receptors]	1.5849625007211563	4	1	0	0
11684	1520	canonical Egr-1 binding site	[canonical Egr-1 binding site]	1.5849625007211563	4	1	0	0
11685	1520	R24 signal pathway.	[R24 signaling pathway.]	1.5849625007211563	3	1	0	0
11686	1520	requirement for the secretion	[requirements for the secretion]	1.5849625007211563	4	1	0	0
11687	1520	role in il-8 expression	[role in IL-8 expression]	1.5849625007211563	4	1	0	0
11688	1520	region outside E1	[region outside E1]	1.5849625007211563	3	1	0	0
11689	1520	multiple host defense gene	[multiple host defense genes]	1.5849625007211563	4	1	0	0
11690	1520	acquisition of different feature	[acquisition of different features]	1.5849625007211563	4	1	0	0
11691	1520	0.5 molecule per cell.	[0.5 molecules per cell.]	1.5849625007211563	4	1	0	0
11692	1520	most 400 kb	[most 400 kb]	1.5849625007211563	3	1	0	0
11693	1520	infiltrate T lymphocytes,	[infiltrating T lymphocytes,]	1.5849625007211563	3	1	0	0
11694	1520	tnf-alpha to this construct	[TNF-alpha to this construct]	1.5849625007211563	4	1	0	0
11695	1520	pretreatment with dexamethasone	[Pretreatment with dexamethasone]	1.5849625007211563	3	1	0	0
11696	1520	protein partner of beta-catenin	[protein partners of beta-catenin]	1.5849625007211563	4	1	0	0
11697	1520	apc-independent T cell response	[APC-independent T cell responses]	1.5849625007211563	4	1	0	0
11698	1520	Egr-1 gene expression	[Egr-1 gene expression]	1.5849625007211563	3	1	0	0
11699	1520	target for redox regulation	[target for redox regulation]	1.5849625007211563	4	1	0	0
11700	1520	renal cell carcinoma patient	[renal cell carcinoma patients]	1.5849625007211563	4	1	0	0
11701	1520	specific inhibitor of pi3-kinase	[specific inhibitor of PI3-kinase]	1.5849625007211563	4	1	0	0
11702	1520	second lymphoid-specific enhancer element	[second lymphoid-specific enhancer element]	1.5849625007211563	4	1	0	0
11703	1520	peripheral-blood mononuclear cell pbmc	[peripheral-blood mononuclear cells PBMC]	1.5849625007211563	4	1	0	0
11704	1520	nfkappab induction in TNF-alpha	[NFkappaB induction in TNF-alpha]	1.5849625007211563	4	1	0	0
11705	1520	transcription of a number	[transcription of a number]	1.5849625007211563	4	3	2	1
11706	1520	early fetal thymus	[early fetal thymus]	1.5849625007211563	3	1	0	0
11707	1520	down-regulation of stat1 protein	[down-regulation of Stat1 protein]	1.5849625007211563	4	1	0	0
11708	1520	new ets-1-containg complex c	[new Ets-1-containing complex c]	1.5849625007211563	4	1	0	0
11709	1520	24 to 72 hours,	[24 to 72 hours,]	1.5849625007211563	4	1	0	0
11710	1520	context of polyomavirus reactivation	[context of polyomavirus reactivations]	1.5849625007211563	4	1	0	0
11711	1520	dna-binding protein isgf3 gamma	[DNA-binding protein ISGF3 gamma]	1.5849625007211563	4	1	0	0
11712	1520	contrast to IL-12	[contrast to IL-12]	1.5849625007211563	3	1	0	0
11713	1520	virus infection in macrophage	[virus infection in macrophages]	1.5849625007211563	4	1	0	0
11714	1520	generation of inflammatory mediator	[generation of inflammatory mediators]	1.5849625007211563	4	1	0	0
11715	1520	primary hiv-1 isolate	[primary HIV-1 isolate]	1.5849625007211563	3	1	0	0
11716	1520	implication for regulation	[implications for regulation]	1.5849625007211563	3	2	2	2
11717	1520	murine thymoma cell	[murine thymoma cells]	1.5849625007211563	3	1	0	0
11718	1520	primary human malignant melanoma	[primary human malignant melanomas]	1.5849625007211563	4	1	0	0
11719	1520	Irish control population	[Irish control populations]	1.5849625007211563	3	1	0	0
11720	1520	b-lymphoblastoid cell line	[B-lymphoblastoid cell lines]	1.5849625007211563	3	1	0	0
11721	1520	processing in vitro	[processing in vitro]	1.5849625007211563	3	1	0	0
11722	1520	occur at tissue site	[occurring at tissue sites]	1.5849625007211563	4	1	0	0
11723	1520	half-life of c-jun rna	[half-life of c-jun RNA]	1.5849625007211563	4	2	1	1
11724	1520	primary event lead	[primary event leading]	1.5849625007211563	3	1	0	0
11725	1520	cysteamine in vitro	[cysteamine in vitro]	1.5849625007211563	3	1	0	0
11726	1520	cytoplasm of effector cell	[cytoplasm of effector cells]	1.5849625007211563	4	1	0	0
11727	1520	ethyl-methanesulfonate-treated CEM subclone	[ethyl-methanesulfonate-treated CEM subclones]	1.5849625007211563	3	1	0	0
11728	1520	hla-dr-constitutive b cell	[HLA-DR-constitutive B cells]	1.5849625007211563	3	1	0	0
11729	1520	several gene encode cytokine	[several genes encoding cytokines]	1.5849625007211563	4	1	0	0
11730	1520	study x inactivation status	[studying X inactivation status]	1.5849625007211563	4	1	0	0
11731	1520	change in hs1 phosphorylation	[changes in HS1 phosphorylation]	1.5849625007211563	4	1	0	0
11732	1520	heterologous viral transcription-activateactivateactivateactivating domain	[heterologous viral transcription-activating domain]	1.5849625007211563	4	1	0	0
11733	1520	p38 mapk isoform	[p38 MAPk isoforms]	1.5849625007211563	3	2	1	1
11734	1520	expression of VCAM-1	[expression of VCAM-1]	1.5849625007211563	3	1	0	0
11735	1520	interferon gamma- gene	[interferon gamma- genes]	1.5849625007211563	3	1	0	0
11736	1520	p65 protein level	[p65 protein levels]	1.5849625007211563	3	1	0	0
11737	1520	such interaction for function.	[such interactions for function.]	1.5849625007211563	4	1	0	0
11738	1520	new mouse gene SRG3	[new mouse gene SRG3]	1.5849625007211563	4	1	0	0
11739	1520	cytoplasmic factor IkappaBalpha	[cytoplasmic factor IkappaBalpha]	1.5849625007211563	3	1	0	0
11740	1520	binding site for NF-Y	[binding site for NF-Y]	1.5849625007211563	4	1	0	0
11741	1520	c group; p 0.01).	[C group; P 0.01).]	1.5849625007211563	4	1	0	0
11742	1520	day 7 erythroid precursor	[day 7 erythroid precursors]	1.5849625007211563	4	1	0	0
11743	1520	part of dimeric complex	[part of dimeric complexes]	1.5849625007211563	4	1	0	0
11744	1520	expression of cyclin	[expression of cyclins]	1.5849625007211563	3	1	0	0
11745	1520	enhance( hiv-1 promoter transcription	[enhance(s) HIV-1 promoter transcription]	1.5849625007211563	4	1	0	0
11746	1520	pair of anti-cd2 antibody	[pair of anti-CD2 antibodies]	1.5849625007211563	4	1	0	0
11747	1520	IL-2 promoter activity	[IL-2 promoter activity]	1.5849625007211563	3	2	1	1
11748	1520	exogenous e2f expression	[exogenous E2F expression]	1.5849625007211563	3	1	0	0
11749	1520	NF-E2 binding site	[NF-E2 binding site]	1.5849625007211563	3	1	0	0
11750	1520	factor-induced nf-kappab binding	[factor-induced NF-kappaB binding]	1.5849625007211563	3	1	0	0
11751	1520	extracellular regulatory event	[extracellular regulatory events]	1.5849625007211563	3	1	0	0
11752	1520	GC-rich 5' untranslated sequence	[GC-rich 5' untranslated sequence]	1.5849625007211563	4	1	0	0
11753	1520	use limiting-dilution analysis	[Using limiting-dilution analysis]	1.5849625007211563	3	1	0	0
11754	1520	pattern of cytokine expression	[patterns of cytokine expression]	1.5849625007211563	4	1	0	0
11755	1520	compare the level	[comparing the level]	1.5849625007211563	3	1	0	0
11756	1520	infection of b cell	[infection of B cells]	1.5849625007211563	4	2	1	1
11757	1520	vd -responsive gene	[VD -responsive genes]	1.5849625007211563	3	1	0	0
11758	1520	germline Cepsilon gene	[germline Cepsilon gene]	1.5849625007211563	3	1	0	0
11759	1520	antibody to DNA factor	[antibodies to DNA factors]	1.5849625007211563	4	1	0	0
11760	1520	novel death-inducing protein	[novel death-inducing protein]	1.5849625007211563	3	1	0	0
11761	1520	intranuclear environment capable	[intranuclear environment capable]	1.5849625007211563	3	1	0	0
11762	1520	potential recognition site	[potential recognition sites]	1.5849625007211563	3	1	0	0
11763	1520	expression of hormone receptor	[expression of hormone receptors]	1.5849625007211563	4	1	0	0
11764	1520	two closely related lineage	[two closely related lineages]	1.5849625007211563	4	1	0	0
11765	1520	result of this expression	[result of this expression]	1.5849625007211563	4	1	0	0
11766	1520	gd3 T cell proliferation	[GD3 T cell proliferation]	1.5849625007211563	4	1	0	0
11767	1520	lymphokine element 0	[lymphokine element 0]	1.5849625007211563	3	2	2	2
11768	1520	il-1ri-associated protein kinase	[IL-1RI-associated protein kinase]	1.5849625007211563	3	1	0	0
11769	1520	propenoic acid e3330	[propenoic acid E3330]	1.5849625007211563	3	1	0	0
11770	1520	ability of ebv	[ability of EBV]	1.5849625007211563	3	1	0	0
11771	1520	effect on IL-2	[effect on IL-2]	1.5849625007211563	3	1	0	0
11772	1520	target of antioxidant agent	[target of antioxidant agents]	1.5849625007211563	4	1	0	0
11773	1520	inhibit cell proliferation	[inhibiting cell proliferation]	1.5849625007211563	3	1	0	0
11774	1520	helper T cell revert	[helper T cells reverting]	1.5849625007211563	4	1	0	0
11775	1520	Duffy blood group antigen	[Duffy blood group antigen]	1.5849625007211563	4	1	0	0
11776	1520	most patient with t-all	[most patients with T-ALL]	1.5849625007211563	4	1	0	0
11777	1520	reporter construct span portion	[Reporter constructs spanning portions]	1.5849625007211563	4	1	0	0
11778	1520	mediator of lipopolysaccharide effect	[mediator of lipopolysaccharide effects]	1.5849625007211563	4	1	0	0
11779	1520	pathophysiology of the disease	[pathophysiology of the disease]	1.5849625007211563	4	1	0	0
11780	1520	response to PMA stimulation	[response to PMA stimulation]	1.5849625007211563	4	1	0	0
11781	1520	only from patient F.R.	[only from patients F.R.]	1.5849625007211563	4	1	0	0
11782	1520	constitutive sp1 factor	[constitutive Sp1 factor]	1.5849625007211563	3	1	0	0
11783	1520	il-6 luciferase assay	[IL-6 luciferase assays]	1.5849625007211563	3	1	0	0
11784	1520	8.20; control: 46.26	[8.20; control: 46.26]	1.5849625007211563	3	1	0	0
11785	1520	TCR signal event	[TCR signaling events]	1.5849625007211563	3	1	0	0
11786	1520	5.54 micromol/L to 7.30	[5.54 micromol/L to 7.30]	1.5849625007211563	4	1	0	0
11787	1520	50-kDa NF-kappa b	[50-kDa NF-kappa B]	1.5849625007211563	3	1	0	0
11788	1520	PMA alone however, camp	[PMA alone; however, cAMP]	1.5849625007211563	4	1	0	0
11789	1520	allergen provocation 1000	[allergen provocation 1000,]	1.5849625007211563	3	1	0	0
11790	1520	combination of Ctx	[combination of Ctx]	1.5849625007211563	3	1	0	0
11791	1520	ro5-3335 hiv-1 tat inhibitor	[Ro5-3335 HIV-1 Tat inhibitor]	1.5849625007211563	4	1	0	0
11792	1520	b-lymphotropic herpesvirus closely related	[B-lymphotropic herpesvirus closely related]	1.5849625007211563	4	1	0	0
11793	1520	intensity of p65 labeling	[intensity of p65 labeling]	1.5849625007211563	4	1	0	0
11794	1520	nuclear factor activation	[nuclear factor activation]	1.5849625007211563	3	2	2	2
11795	1520	protein- tre -DNA complex	[protein- TRE -DNA complex]	1.5849625007211563	4	1	0	0
11796	1520	octamer DNA motif	[octamer DNA motif]	1.5849625007211563	3	2	1	1
11797	1520	Ets binding site	[Ets binding site]	1.5849625007211563	3	2	2	2
11798	1520	Jak3 messenger RNA	[Jak3 messenger RNA]	1.5849625007211563	3	1	0	0
11799	1520	growth of ad5e1a-expressing tumor	[growth of Ad5E1A-expressing tumors]	1.5849625007211563	4	1	0	0
11800	1520	single genetic locus	[single genetic locus]	1.5849625007211563	3	1	0	0
11801	1520	binding of this complex	[binding of this complex]	1.5849625007211563	4	1	0	0
11802	1520	turn, icam-1 level	[turn, ICAM-1 levels]	1.5849625007211563	3	1	0	0
11803	1520	effect of activator	[effects of activators]	1.5849625007211563	3	1	0	0
11804	1520	EBNA gene promoter	[EBNA gene promoters]	1.5849625007211563	3	1	0	0
11805	1520	change in nf-kappab translocation	[changes in NF-kappaB translocation]	1.5849625007211563	4	1	0	0
11806	1520	b-cell-specific transcription coactivator oca-b	[B-cell-specific transcription coactivator OCA-B]	1.5849625007211563	4	1	0	0
11807	1520	viral immediate-early protein	[viral immediate-early protein]	1.5849625007211563	3	2	2	2
11808	1520	decrease in nuclear translocation	[decrease in nuclear translocation]	1.5849625007211563	4	1	0	0
11809	1520	involvement of oxygen species	[involvement of oxygen species]	1.5849625007211563	4	2	2	2
11810	1520	inducibility of expression construct	[inducibility of expression constructs]	1.5849625007211563	4	1	0	0
11811	1520	domain of chromatin structure	[domains of chromatin structure]	1.5849625007211563	4	2	1	1
11812	1520	11 cell line	[11 cell lines]	1.5849625007211563	3	1	0	0
11813	1520	level of stat3 phosphorylation	[level of STAT3 phosphorylation]	1.5849625007211563	4	1	0	0
11814	1520	mutation at position	[mutation at position]	1.5849625007211563	3	2	1	1
11815	1520	maternal expression in placentae	[maternal expression in placentae]	1.5849625007211563	4	2	1	1
11816	1520	Ad5 e1a gene	[Ad5 E1A gene]	1.5849625007211563	3	1	0	0
11817	1520	difference in the capacity	[differences in the capacity]	1.5849625007211563	4	2	1	1
11818	1520	day of treatment	[days of treatment]	1.5849625007211563	3	2	2	2
11819	1520	Pax-5 -deficient pro-B cell	[Pax-5 -deficient pro-B cells]	1.5849625007211563	4	1	0	0
11820	1520	specific stat protein	[specific Stat protein]	1.5849625007211563	3	2	1	1
11821	1520	Epstein-Barr virus (ebv)-infected cell	[Epstein-Barr virus (EBV)-infected cells]	1.5849625007211563	4	1	0	0
11822	1520	use TGF -specific elisa	[using TGF -specific ELISAs]	1.5849625007211563	4	1	0	0
11823	1520	leukemia cell line u937	[leukemia cell line U937]	1.5849625007211563	4	2	2	2
11824	1520	N-acetyl-L-cysteine NAC a antioxidant	[N-acetyl-L-cysteine NAC a antioxidant]	1.5849625007211563	4	2	1	1
11825	1520	three alpha-helice each	[three alpha-helices each]	1.5849625007211563	3	1	0	0
11826	1520	induction of c-jun mrna	[induction of c-jun mRNA]	1.5849625007211563	4	1	0	0
11827	1520	purpose investigate the nature	[purpose investigating the nature]	1.5849625007211563	4	1	0	0
11828	1520	role regulate the response	[role regulating the response]	1.5849625007211563	4	2	2	2
11829	1520	vitro in macrophage	[vitro in macrophages]	1.5849625007211563	3	1	0	0
11830	1520	least one first- relative;	[least one first- relative;]	1.5849625007211563	4	1	0	0
11831	1520	surface expression of il-2r	[surface expression of IL-2R]	1.5849625007211563	4	1	0	0
11832	1520	apoptosis in this cell	[apoptosis in these cells]	1.5849625007211563	4	1	0	0
11833	1520	therefore, regulate gene transcription	[therefore, regulating gene transcription]	1.5849625007211563	4	1	0	0
11834	1520	reduction of nuclear translocation	[reduction of nuclear translocation]	1.5849625007211563	4	1	0	0
11835	1520	phosphorylation of Jak3	[phosphorylation of Jak3]	1.5849625007211563	3	2	2	2
11836	1520	three sp1 virus	[three Sp1 virus]	1.5849625007211563	3	1	0	0
11837	1520	specific functional program	[specific functional programs]	1.5849625007211563	3	1	0	0
11838	1520	one small intron	[one small intron]	1.5849625007211563	3	1	0	0
11839	1520	c-fo expression by il-4	[c-fos expression by IL-4]	1.5849625007211563	4	1	0	0
11840	1520	cell of species	[cells of species]	1.5849625007211563	3	2	2	2
11841	1520	surrogate thyroglobulin receptor	[Surrogate thyroglobulin receptors]	1.5849625007211563	3	1	0	0
11842	1520	degree, lymphocytic infiltration	[degree, lymphocytic infiltration]	1.5849625007211563	3	1	0	0
11843	1520	cooh-terminal domain of N-WASP	[COOH-terminal domain of N-WASP]	1.5849625007211563	4	1	0	0
11844	1520	plasma membrane rich fraction	[plasma membrane rich fractions]	1.5849625007211563	4	2	2	2
11845	1520	first, previous study	[First, previous studies]	1.5849625007211563	3	1	0	0
11846	1520	events, antibody to t-antigen	[events, antibodies to T-antigen]	1.5849625007211563	4	1	0	0
11847	1520	RALDH2 transcript in T-all	[RALDH2 transcripts in T-ALL]	1.5849625007211563	4	1	0	0
11848	1520	tcr with anti-CD3	[TCR with anti-CD3]	1.5849625007211563	3	1	0	0
11849	1520	intravenous pcr injection	[Intravenous PCr injection]	1.5849625007211563	3	1	0	0
11850	1520	regulation of the balance	[Regulation of the balance]	1.5849625007211563	4	1	0	0
11851	1520	signal pathway molecule Jak1	[signaling pathway molecules Jak1]	1.5849625007211563	4	1	0	0
11852	1520	cell with fk506 consistent	[cells with FK506 consistent]	1.5849625007211563	4	1	0	0
11853	1520	expression of LAZ3/BCL6	[expression of LAZ3/BCL6]	1.5849625007211563	3	2	1	1
11854	1520	understanding of lps- signal	[understanding of LPS- signaling]	1.5849625007211563	4	1	0	0
11855	1520	cell-specific translational regulation	[cell-specific translational regulation]	1.5849625007211563	3	1	0	0
11856	1520	cytokine pathway lead	[cytokine pathway leading]	1.5849625007211563	3	1	0	0
11857	1520	loss of conventional responsiveness	[loss of conventional responsiveness]	1.5849625007211563	4	1	0	0
11858	1520	protein (residue 32	[protein (residues 32]	1.5849625007211563	3	1	0	0
11859	1520	380 bp upstream	[380 bp upstream]	1.5849625007211563	3	1	0	0
11860	1520	proliferation and/or differentiation	[proliferation and/or differentiation]	1.5849625007211563	3	1	0	0
11861	1520	catalytically inactive form	[catalytically inactive form]	1.5849625007211563	3	2	2	2
11862	1520	p50 -p65 heterodimer	[p50 -p65 heterodimers]	1.5849625007211563	3	1	0	0
11863	1520	replicative capacity of hiv	[replicative capacity of HIV]	1.5849625007211563	4	1	0	0
11864	1520	EBNA-2 expression vector	[EBNA-2 expression vector]	1.5849625007211563	3	1	0	0
11865	1520	property of hsf1	[properties of HSF1]	1.5849625007211563	3	1	0	0
11866	1520	mass-spectrometric analysis MS	[mass-spectrometric analysis MS]	1.5849625007211563	3	1	0	0
11867	1520	only in lymphocyte	[only in lymphocytes]	1.5849625007211563	3	1	0	0
11868	1520	sry-related gene sox9	[SRY-related gene SOX9]	1.5849625007211563	3	1	0	0
11869	1520	untransformed steroid receptor complex	[untransformed steroid receptor complexes]	1.5849625007211563	4	1	0	0
11870	1520	stimulate interleukin-2 il-2	[stimulating interleukin-2 IL-2]	1.5849625007211563	3	1	0	0
11871	1520	four female patient	[four female patients]	1.5849625007211563	3	1	0	0
11872	1520	NF-kappa b mobilization	[NF-kappa B mobilization]	1.5849625007211563	3	1	0	0
11873	1520	non-irradiated ht29 cell	[non-irradiated HT29 cells]	1.5849625007211563	3	1	0	0
11874	1520	human granulocyte apoptosis	[human granulocyte apoptosis]	1.5849625007211563	3	2	1	1
11875	1520	NF-kappaB subunit c-rel	[NF-kappaB subunits c-Rel]	1.5849625007211563	3	1	0	0
11876	1520	squirrel monkey receptor	[squirrel monkey receptor]	1.5849625007211563	3	1	0	0
11877	1520	other PKC subfamily	[other PKC subfamilies]	1.5849625007211563	3	1	0	0
11878	1520	several autoimmune disease	[several autoimmune diseases]	1.5849625007211563	3	1	0	0
11879	1520	interaction of rela	[interaction of RelA]	1.5849625007211563	3	1	0	0
11880	1520	patient without phosphate supplementation	[Patients without phosphate supplementation]	1.5849625007211563	4	1	0	0
11881	1520	discovery of a family	[discovery of a family]	1.5849625007211563	4	1	0	0
11882	1520	only U alpha S	[only U alpha S]	1.5849625007211563	4	1	0	0
11883	1520	deletion of N-terminal domain	[deletions of N-terminal domain]	1.5849625007211563	4	1	0	0
11884	1520	adherence of proliferation	[adherence of proliferation]	1.5849625007211563	3	1	0	0
11885	1520	month of therapy	[months of therapy]	1.5849625007211563	3	2	2	2
11886	1520	severe pathological condition	[severe pathological conditions]	1.5849625007211563	3	1	0	0
11887	1520	biologic effect of RA	[biologic effects of RA]	1.5849625007211563	4	1	0	0
11888	1520	tax /rex mrna	[tax /rex mRNA]	1.5849625007211563	3	1	0	0
11889	1520	expression of bhrf1	[Expression of BHRF1]	1.5849625007211563	3	2	2	2
11890	1520	ifn-gamma-treated human cell	[IFN-gamma-treated human cells]	1.5849625007211563	3	1	0	0
11891	1520	ligation of CD80 b7-1	[Ligation of CD80 B7-1]	1.5849625007211563	4	1	0	0
11892	1520	cell to cytokine	[cells to cytokines]	1.5849625007211563	3	1	0	0
11893	1520	suggest also necessary	[suggesting also necessary]	1.5849625007211563	3	1	0	0
11894	1520	positive control (40-48%	[positive control (40-48%]	1.5849625007211563	3	1	0	0
11895	1520	cis-acting element necessary	[cis-acting elements necessary]	1.5849625007211563	3	1	0	0
11896	1520	new immunosuppressive agent	[new immunosuppressive agents]	1.5849625007211563	3	1	0	0
11897	1520	induction of dna-mobility shift	[induction of DNA-mobility shift]	1.5849625007211563	4	1	0	0
11898	1520	Benzene toxicity towards lymphocyte	[Benzene toxicity towards lymphocytes]	1.5849625007211563	4	1	0	0
11899	1520	strong expression of vimentin	[strong expression of vimentin]	1.5849625007211563	4	1	0	0
11900	1520	NF-kappa B /I	[NF-kappa B /I]	1.5849625007211563	3	1	0	0
11901	1520	several gene include IL-2	[several genes including IL-2]	1.5849625007211563	4	1	0	0
11902	1520	growth transform infection	[growth transforming infection]	1.5849625007211563	3	1	0	0
11903	1520	169 base pair	[169 base pairs]	1.5849625007211563	3	1	0	0
11904	1520	human DR alpha gene	[human DR alpha gene]	1.5849625007211563	4	1	0	0
11905	1520	breast carcinoma --correlation	[breast carcinomas --correlation]	1.5849625007211563	3	1	0	0
11906	1520	single nucleotide mutation	[single nucleotide mutations]	1.5849625007211563	3	1	0	0
11907	1520	NF-kappa b2 gene	[NF-kappa B2 gene]	1.5849625007211563	3	1	0	0
11908	1520	effect of alpha-tocopherol tcp	[effects of alpha-tocopherol TCP]	1.5849625007211563	4	1	0	0
11909	1520	GP Ib-IX-V complex	[GP Ib-IX-V complex]	1.5849625007211563	3	1	0	0
11910	1520	jun gene family	[jun gene family]	1.5849625007211563	3	1	0	0
11911	1520	IL-1 receptor complex	[IL-1 receptor complex]	1.5849625007211563	3	2	1	1
11912	1520	use of a inhibitor	[use of a inhibitor]	1.5849625007211563	4	1	0	0
11913	1520	difference in structure	[differences in structure]	1.5849625007211563	3	1	0	0
11914	1520	model of CD28 costimulation	[model of CD28 costimulation]	1.5849625007211563	4	1	0	0
11915	1520	i footprinting analysis	[I footprinting analysis]	1.5849625007211563	3	1	0	0
11916	1520	non-abortive maternal infection	[non-abortive maternal infections]	1.5849625007211563	3	1	0	0
11917	1520	addition, immunoprecipitation analysis	[addition, immunoprecipitation analyses]	1.5849625007211563	3	1	0	0
11918	1520	condition for transient transfection	[conditions for transient transfection]	1.5849625007211563	4	1	0	0
11919	1520	requirement for ap1 activation	[requirement for AP1 activation]	1.5849625007211563	4	1	0	0
11920	1520	defect in this subclone	[defect in these subclones.]	1.5849625007211563	4	1	0	0
11921	1520	good therapeutic option	[better therapeutic options]	1.5849625007211563	3	1	0	0
11922	1520	addition of great magnitude.	[addition of greater magnitude.]	1.5849625007211563	4	1	0	0
11923	1520	use normal human monocyte	[using normal human monocytes]	1.5849625007211563	4	1	0	0
11924	1520	ligand bind avidity	[ligand binding avidity]	1.5849625007211563	3	1	0	0
11925	1520	phorbol ester in combination	[phorbol esters in combination]	1.5849625007211563	4	1	0	0
11926	1520	normal B-cell development	[normal B-cell development]	1.5849625007211563	3	1	0	0
11927	1520	reactive cd3+/cd4+ T cell	[reactive CD3+/CD4+ T cells]	1.5849625007211563	4	1	0	0
11928	1520	concomitant overexpression of AML1b	[concomitant overexpression of AML1b]	1.5849625007211563	4	1	0	0
11929	1520	cytokine mrna accumulation	[cytokine mRNA accumulation]	1.5849625007211563	3	1	0	0
11930	1520	cytotoxicity of viral growth	[cytotoxicity of viral growth]	1.5849625007211563	4	1	0	0
11931	1520	baseline lymphocyte gcii site	[baseline lymphocyte GCII sites]	1.5849625007211563	4	1	0	0
11932	1520	polyclonal CTL line	[polyclonal CTL lines]	1.5849625007211563	3	1	0	0
11933	1520	formation of multiprotein complex	[formation of multiprotein complexes]	1.5849625007211563	4	1	0	0
11934	1520	high nf-kappab binding activity	[higher NF-kappaB binding activity]	1.5849625007211563	4	1	0	0
11935	1520	promyelocytic leukemia gene pml	[promyelocytic leukemia gene PML]	1.5849625007211563	4	1	0	0
11936	1520	thp-1 monocyte/macrophage cell	[THP-1 monocyte/macrophage cells]	1.5849625007211563	3	1	0	0
11937	1520	use a reporter construct	[using a reporter construct]	1.5849625007211563	4	1	0	0
11938	1520	development after transplantation	[development after transplantation]	1.5849625007211563	3	2	2	2
11939	1520	contain the sh2 domain	[containing the SH2 domains]	1.5849625007211563	4	1	0	0
11940	1520	porcine MHC class expression	[porcine MHC class expression]	1.5849625007211563	4	2	2	2
11941	1520	gsh gssg ratio	[GSH GSSG ratio]	1.5849625007211563	3	1	0	0
11942	1520	RA -resistant subclone hl60r	[RA -resistant subclone HL60R]	1.5849625007211563	4	1	0	0
11943	1520	hiv-1 protease during infection	[HIV-1 protease during infection]	1.5849625007211563	4	1	0	0
11944	1520	expression of cd102	[expression of CD102]	1.5849625007211563	3	1	0	0
11945	1520	development of granulocytic lineage	[development of granulocytic lineages]	1.5849625007211563	4	1	0	0
11946	1520	x-chromosome inactivation (xci) pattern	[X-chromosome inactivation (XCI) patterns]	1.5849625007211563	4	1	0	0
11947	1520	patient with extrinsic asthma	[patients with extrinsic asthma]	1.5849625007211563	4	2	1	1
11948	1520	cell of each volunteer	[cells of each volunteer]	1.5849625007211563	4	1	0	0
11949	1520	activation of Stat-3	[Activation of Stat-3]	1.5849625007211563	3	1	0	0
11950	1520	surfactant protein a	[Surfactant protein A]	1.5849625007211563	3	1	0	0
11951	1520	use deletion construct	[Using deletion constructs]	1.5849625007211563	3	1	0	0
11952	1520	pan anti gamma/delta antibody	[pan anti gamma/delta antibody]	1.5849625007211563	4	1	0	0
11953	1520	interaction of il-2	[interaction of IL-2]	1.5849625007211563	3	1	0	0
11954	1520	IL-4 gene transcription	[IL-4 gene transcription]	1.5849625007211563	3	2	1	1
11955	1520	kappa immunoglobulin light	[kappa immunoglobulin light]	1.5849625007211563	3	1	0	0
11956	1520	characterize the mechanism	[characterizing the mechanisms]	1.5849625007211563	3	1	0	0
11957	1520	NK cell NFAT	[NK cell NFAT]	1.5849625007211563	3	1	0	0
11958	1520	acute megakaryoblastic leukaemia	[acute megakaryoblastic leukaemia]	1.5849625007211563	3	2	1	1
11959	1520	aldosterone-specific membrane receptor	[Aldosterone-specific membrane receptors]	1.5849625007211563	3	1	0	0
11960	1520	zymogen plasma factor x	[zymogen plasma factor X]	1.5849625007211563	4	1	0	0
11961	1520	pulmonary granulomatous disease	[pulmonary granulomatous diseases]	1.5849625007211563	3	2	1	1
11962	1520	T cell from young	[T cells from young]	1.5849625007211563	4	1	0	0
11963	1520	hgata-3 transcriptional activation domain	[hGATA-3 transcriptional activation domain]	1.5849625007211563	4	1	0	0
11964	1520	substrate for upstream kinase	[substrate for upstream kinase]	1.5849625007211563	4	1	0	0
11965	1520	expression of proinflammatory cytokine	[expression of proinflammatory cytokines]	1.5849625007211563	4	2	2	2
11966	1520	novel DNA sequence element	[novel DNA sequence element]	1.5849625007211563	4	1	0	0
11967	1520	sigma 1 receptor	[sigma 1 receptor]	1.5849625007211563	3	2	2	2
11968	1520	human b cell growth	[human B cell growth]	1.5849625007211563	4	1	0	0
11969	1520	trans-activating effect of tax	[trans-activating effects of Tax]	1.5849625007211563	4	1	0	0
11970	1520	b cell of human	[B cells of humans]	1.5849625007211563	4	1	0	0
11971	1520	occupancy of this sites.	[occupancy of these sites.]	1.5849625007211563	4	1	0	0
11972	1520	amplicon (target) during hybridization	[amplicon (target) during hybridization]	1.5849625007211563	4	1	0	0
11973	1520	high affinity (dissociation constant	[high affinity (dissociation constant]	1.5849625007211563	4	1	0	0
11974	1520	(mean ige 285+/-100	[(mean IgE 285+/-100]	1.5849625007211563	3	1	0	0
11975	1520	human t-cell leukemia line	[human T-cell leukemia line]	1.5849625007211563	4	1	0	0
11976	1520	active mitogen-activated kinase	[active mitogen-activated kinase]	1.5849625007211563	3	1	0	0
11977	1520	interleukin 2 alpha-chain receptor	[interleukin 2 alpha-chain receptor]	1.5849625007211563	4	1	0	0
11978	1520	multiple cellular gene	[multiple cellular genes]	1.5849625007211563	3	1	0	0
11979	1520	specific anti-hla antibody	[specific anti-HLA antibodies]	1.5849625007211563	3	1	0	0
11980	1520	Intrafollicular cd57+ cell	[Intrafollicular CD57+ cells]	1.5849625007211563	3	2	1	1
11981	1520	ratio of gssg	[ratio of GSSG]	1.5849625007211563	3	1	0	0
11982	1520	"physiologic" cell lineage	["physiologic" cell lineage]	1.5849625007211563	3	1	0	0
11983	1520	concert with secretory vesicle	[concert with secretory vesicles]	1.5849625007211563	4	1	0	0
11984	1520	patient with hepatitis b	[patients with hepatitis B]	1.5849625007211563	4	2	1	1
11985	1520	cooperation with il-4 signaling,	[cooperation with IL-4 signaling,]	1.5849625007211563	4	1	0	0
11986	1520	cell line model	[cell line model]	1.5849625007211563	3	2	2	2
11987	1520	phosphorylation of a number	[phosphorylation of a number]	1.5849625007211563	4	1	0	0
11988	1520	expression of cd11b	[expression of CD11b]	1.5849625007211563	3	2	1	1
11989	1520	physiologically, high level	[physiologically, high levels]	1.5849625007211563	3	1	0	0
11990	1520	U3 region of DNA	[U3 regions of DNA]	1.5849625007211563	4	1	0	0
11991	1520	patient with a MPD	[patients with a MPD]	1.5849625007211563	4	2	2	2
11992	1520	prototypic class ii	[prototypic class II]	1.5849625007211563	3	1	0	0
11993	1520	immediate-early protein ie62	[immediate-early protein IE62]	1.5849625007211563	3	1	0	0
11994	1520	retroviral counterpart of c-Fos	[retroviral counterpart of c-Fos]	1.5849625007211563	4	1	0	0
11995	1520	effect of the lectins	[effect of the lectins]	1.5849625007211563	4	1	0	0
11996	1520	pretreatment with this cytokine	[pretreatment with these cytokines]	1.5849625007211563	4	1	0	0
11997	1520	point in cell cycle	[point in cell cycle]	1.5849625007211563	4	1	0	0
11998	1520	mip-1 alpha gene expression	[MIP-1 alpha gene expression]	1.5849625007211563	4	1	0	0
11999	1520	scavenger of h2o2 N-acetyl-L-cysteine	[scavenger of H2O2 N-acetyl-L-cysteine]	1.5849625007211563	4	1	0	0
12000	1520	TPA translocation of cpkc-alpha	[TPA translocation of cPKC-alpha]	1.5849625007211563	4	1	0	0
12001	1520	tsh receptor TSHR	[TSH receptor TSHR]	1.5849625007211563	3	1	0	0
12002	1520	other nf-kappa b	[other NF-kappa B]	1.5849625007211563	3	1	0	0
12003	1520	stem cell disorder	[stem cell disorders]	1.5849625007211563	3	1	0	0
12004	1520	overproduction of endothelial protein	[overproduction of endothelial proteins]	1.5849625007211563	4	1	0	0
12005	1520	Retinoic acid RA maturation	[Retinoic acid RA maturation]	1.5849625007211563	4	1	0	0
12006	1520	phosphorylation of protein product	[phosphorylation of protein products]	1.5849625007211563	4	1	0	0
12007	1520	inducible nuclear component	[inducible nuclear component]	1.5849625007211563	3	2	2	2
12008	1520	difference in the prevalence	[difference in the prevalence]	1.5849625007211563	4	1	0	0
12009	1520	IL-6 transcription rate	[IL-6 transcription rate]	1.5849625007211563	3	1	0	0
12010	1520	b cell neoplasm	[B cell neoplasms]	1.5849625007211563	3	2	1	1
12011	1520	er in the patient	[ER in the patients]	1.5849625007211563	4	1	0	0
12012	1520	presence of PML-RAR	[presence of PML-RAR]	1.5849625007211563	3	1	0	0
12013	1520	mouse th1 development	[mouse Th1 development]	1.5849625007211563	3	1	0	0
12014	1520	90% suppression constitutive sla-dr	[90% suppression constitutive SLA-DR]	1.5849625007211563	4	1	0	0
12015	1520	drosophila Toll protein signal	[Drosophila Toll protein signals]	1.5849625007211563	4	1	0	0
12016	1520	activity against ec	[Activity against EC]	1.5849625007211563	3	2	2	2
12017	1520	eutopic endometrium in endometriosis	[eutopic endometrium in endometriosis]	1.5849625007211563	4	1	0	0
12018	1520	modification of this protein	[modifications of these proteins]	1.5849625007211563	4	1	0	0
12019	1520	NAD(P)H:quinone reductase qr	[NAD(P)H:quinone reductase QR]	1.5849625007211563	3	1	0	0
12020	1520	severe gut inflammation	[severe gut inflammation]	1.5849625007211563	3	1	0	0
12021	1520	specific set of gene	[specific sets of genes]	1.5849625007211563	4	1	0	0
12022	1520	common signal transducer	[common signal transducer]	1.5849625007211563	3	1	0	0
12023	1520	ovary (stage I),	[ovary (stage I),]	1.5849625007211563	3	1	0	0
12024	1520	ig gene without promoter	[Ig genes without promoter]	1.5849625007211563	4	1	0	0
12025	1520	position -97 to -91	[positions -97 to -91]	1.5849625007211563	4	1	0	0
12026	1520	recognition by lymphocyte OVTAL	[recognition by lymphocyte OVTAL]	1.5849625007211563	4	1	0	0
12027	1520	secondary lymphoid organs.	[secondary lymphoid organs.]	1.5849625007211563	3	1	0	0
12028	1520	take into consideration	[taking into consideration]	1.5849625007211563	3	1	0	0
12029	1520	normal epidermal cell	[normal epidermal cells]	1.5849625007211563	3	1	0	0
12030	1520	chronic bronchiti subject	[chronic bronchitis subjects]	1.5849625007211563	3	1	0	0
12031	1520	tonsil b cell	[tonsil B cells]	1.5849625007211563	3	1	0	0
12032	1520	mode of peptide delivery	[mode of peptide delivery]	1.5849625007211563	4	1	0	0
12033	1520	atf-1 as a dimer	[ATF-1 as a dimer]	1.5849625007211563	4	1	0	0
12034	1520	p75 tnf receptor	[p75 TNF receptor]	1.5849625007211563	3	1	0	0
12035	1520	increase in b activity	[increase in B activity]	1.5849625007211563	4	1	0	0
12036	1520	level of nuclear translocation	[level of nuclear translocation]	1.5849625007211563	4	1	0	0
12037	1520	SH-SY5Y neuroblastoma cell line	[SH-SY5Y neuroblastoma cell line]	1.5849625007211563	4	1	0	0
12038	1520	open chromatin configuration	[open chromatin configuration]	1.5849625007211563	3	1	0	0
12039	1520	response to gcs	[response to GCs]	1.5849625007211563	3	1	0	0
12040	1520	characteristic of the monocyte,	[characteristic of the monocyte,]	1.5849625007211563	4	1	0	0
12041	1520	Mol cell biol	[Mol Cell Biol]	1.5849625007211563	3	1	0	0
12042	1520	low level of il-5	[low levels of IL-5]	1.5849625007211563	4	1	0	0
12043	1520	c-rel nf-kappab subunit	[c-Rel NF-kappaB subunits]	1.5849625007211563	3	1	0	0
12044	1520	substrate for calcineurin	[substrate for calcineurin]	1.5849625007211563	3	1	0	0
12045	1520	reporter gene analysis	[Reporter gene analysis]	1.5849625007211563	3	2	1	1
12046	1520	c-Myc overexpress fibroblast	[c-Myc overexpressing fibroblasts]	1.5849625007211563	3	1	0	0
12047	1520	delta promoter fragment	[delta promoter fragment]	1.5849625007211563	3	1	0	0
12048	1520	low affinity than atra	[lower affinity than ATRA]	1.5849625007211563	4	1	0	0
12049	1520	early killing effect	[early killing effect]	1.5849625007211563	3	1	0	0
12050	1520	T lymphoid cell line	[T lymphoid cell line]	1.5849625007211563	4	2	2	2
12051	1520	nonatopic control subject	[nonatopic control subjects]	1.5849625007211563	3	2	2	2
12052	1520	development of mature erythrocytes.	[development of mature erythrocytes.]	1.5849625007211563	4	1	0	0
12053	1520	vitamin d-dependent ricket VDDR-II	[vitamin D-dependent rickets VDDR-II]	1.5849625007211563	4	1	0	0
12054	1520	pool of random oligonucleotide	[pool of random oligonucleotides]	1.5849625007211563	4	1	0	0
12055	1520	membrane glycoprotein cd36	[membrane glycoprotein CD36]	1.5849625007211563	3	2	2	2
12056	1520	p70 kappa b protein	[p70 kappa B protein]	1.5849625007211563	4	1	0	0
12057	1520	Bcl-2 gene product	[Bcl-2 gene products]	1.5849625007211563	3	1	0	0
12058	1520	b cell line cess	[B cell line CESS]	1.5849625007211563	4	1	0	0
12059	1520	amount of tfiih	[amounts of TFIIH]	1.5849625007211563	3	1	0	0
12060	1520	persistent nf-kappa b activation	[persistent NF-kappa B activation]	1.5849625007211563	4	1	0	0
12061	1520	investigation of potential antagonism	[investigation of potential antagonism]	1.5849625007211563	4	1	0	0
12062	1520	extract from normal cells.	[extracts from normal cells.]	1.5849625007211563	4	1	0	0
12063	1520	increase of c-fo immunoreactivity	[increase of c-Fos immunoreactivity]	1.5849625007211563	4	1	0	0
12064	1520	give 50% inhibition	[giving 50% inhibition]	1.5849625007211563	3	1	0	0
12065	1520	animal with advanced malignancy	[animals with advanced malignancy]	1.5849625007211563	4	1	0	0
12066	1520	myeloid cell differentiation,	[myeloid cell differentiation,]	1.5849625007211563	3	1	0	0
12067	1520	2 class of compound	[2 classes of compounds]	1.5849625007211563	4	1	0	0
12068	1520	advanced renal carcinoma	[advanced renal carcinoma]	1.5849625007211563	3	1	0	0
12069	1520	important proximal step	[important proximal step]	1.5849625007211563	3	1	0	0
12070	1520	use immunomagnetic bead	[using immunomagnetic beads]	1.5849625007211563	3	1	0	0
12071	1520	class ii trans-activator	[class II trans-activator]	1.5849625007211563	3	2	2	2
12072	1520	purification of tcf-1 alpha	[Purification of TCF-1 alpha]	1.5849625007211563	4	1	0	0
12073	1520	CD4(+) T helper	[CD4(+) T helper]	1.5849625007211563	3	1	0	0
12074	1520	presence of sodium acetate	[presence of sodium acetate]	1.5849625007211563	4	1	0	0
12075	1520	-79 to -52 region	[-79 to -52 region]	1.5849625007211563	4	1	0	0
12076	1520	peripheral blood (PB) granulocyte	[peripheral blood (PB) granulocytes]	1.5849625007211563	4	1	0	0
12077	1520	CD40 -cd40l interaction	[CD40 -CD40L interactions]	1.5849625007211563	3	1	0	0
12078	1520	role in nf-kappab activation	[role in NF-kappaB activation]	1.5849625007211563	4	2	1	1
12079	1520	anti-allergy agent azelastine hydrochloride	[anti-allergy agent azelastine hydrochloride]	1.5849625007211563	4	1	0	0
12080	1520	long-lived state of nonresponsiveness	[long-lived state of nonresponsiveness]	1.5849625007211563	4	1	0	0
12081	1520	intact IL-2 promoter	[intact IL-2 promoter]	1.5849625007211563	3	2	1	1
12082	1520	increase in pmn adhesion	[increase in PMN adhesion]	1.5849625007211563	4	1	0	0
12083	1520	primary human astrocyte	[primary human astrocytes]	1.5849625007211563	3	1	0	0
12084	1520	expression of p105 transcript	[expression of p105 transcripts]	1.5849625007211563	4	1	0	0
12085	1520	e1a domain responsible	[E1A domain responsible]	1.5849625007211563	3	1	0	0
12086	1520	regulation of gene expression,	[regulation of gene expression,]	1.5849625007211563	4	1	0	0
12087	1520	chronic airway inflammation	[chronic airway inflammation]	1.5849625007211563	3	1	0	0
12088	1520	absence of binding	[absence of binding]	1.5849625007211563	3	1	0	0
12089	1520	response-specific pattern of deactivation	[response-specific patterns of deactivation]	1.5849625007211563	4	1	0	0
12090	1520	accumulation of hemoglobin	[accumulation of hemoglobin]	1.5849625007211563	3	1	0	0
12091	1520	12-O-tetradecanoyl phorbol 13-acetate	[12-O-tetradecanoyl phorbol 13-acetate]	1.5849625007211563	3	1	0	0
12092	1520	dprl promoter in cell	[dPRL promoter in cells]	1.5849625007211563	4	1	0	0
12093	1520	-107 bp upstream	[-107 bp upstream]	1.5849625007211563	3	1	0	0
12094	1520	derivative of Raji	[derivative of Raji]	1.5849625007211563	3	1	0	0
12095	1520	Nef express cell	[Nef expressing cells]	1.5849625007211563	3	1	0	0
12096	1520	RAR -specific antagonist	[RAR -specific antagonists]	1.5849625007211563	3	1	0	0
12097	1520	DR alpha promoter	[DR alpha promoter]	1.5849625007211563	3	2	1	1
12098	1520	autocrine and/or paracrine factor	[autocrine and/or paracrine factor]	1.5849625007211563	4	1	0	0
12099	1520	thereby inhibit protein synthesis	[thereby inhibiting protein synthesis]	1.5849625007211563	4	1	0	0
12100	1520	different physiological condition	[different physiological conditions]	1.5849625007211563	3	1	0	0
12101	1520	impaired tyrosine phosphorylation	[impaired tyrosine phosphorylation]	1.5849625007211563	3	2	1	1
12102	1520	effect of Vpr	[effects of Vpr]	1.5849625007211563	3	2	1	1
12103	1520	hiv enhancer activity	[HIV enhancer activity]	1.5849625007211563	3	2	1	1
12104	1520	redefin the identity	[redefining the identity]	1.5849625007211563	3	1	0	0
12105	1520	glycosphingolipid lactosylceramide present	[glycosphingolipid lactosylceramide present]	1.5849625007211563	3	1	0	0
12106	1520	cd8(+) T cell specific	[CD8(+) T cells specific]	1.5849625007211563	4	1	0	0
12107	1520	regulation of egr-1 expression	[regulation of EGR-1 expression]	1.5849625007211563	4	1	0	0
12108	1520	etiology of preeclampsia	[etiology of preeclampsia]	1.5849625007211563	3	1	0	0
12109	1520	intracellular redox status	[intracellular redox status]	1.5849625007211563	3	2	1	1
12110	1520	chloramphenicol acetyl-transferase vector	[chloramphenicol acetyl-transferase vectors]	1.5849625007211563	3	1	0	0
12111	1520	AP-1 mutant construct	[AP-1 mutant constructs]	1.5849625007211563	3	1	0	0
12112	1520	early th development	[early Th development]	1.5849625007211563	3	1	0	0
12113	1520	activation of hiv replication	[activation of HIV replication]	1.5849625007211563	4	1	0	0
12114	1520	responsiveness to ifn-gamma varies,	[responsiveness to IFN-gamma varies,]	1.5849625007211563	4	1	0	0
12115	1520	soluble factor independent	[soluble factor independent]	1.5849625007211563	3	1	0	0
12116	1520	investigation of interferon-gamma activation	[investigation of interferon-gamma activation]	1.5849625007211563	4	1	0	0
12117	1520	influence of b expression	[influence of B expression]	1.5849625007211563	4	1	0	0
12118	1520	protein kinase inhibitor h-7	[Protein kinase inhibitor H-7]	1.5849625007211563	4	2	1	1
12119	1520	activation pathway in CD4	[activation pathways in CD4]	1.5849625007211563	4	1	0	0
12120	1520	basis distinguish heterozygous carrier	[basis distinguishing heterozygous carriers]	1.5849625007211563	4	1	0	0
12121	1520	Ca2+ signal-dependent regulatory element	[Ca2+ signal-dependent regulatory element]	1.5849625007211563	4	1	0	0
12122	1520	(apparent molecular mass,	[(apparent molecular mass,]	1.5849625007211563	3	1	0	0
12123	1520	functional consequence downstream	[functional consequences downstream]	1.5849625007211563	3	1	0	0
12124	1520	only b cell	[only B cells]	1.5849625007211563	3	1	0	0
12125	1520	peripheral lung inflammation	[peripheral lung inflammation]	1.5849625007211563	3	1	0	0
12126	1520	Wnt signal pathway	[Wnt signaling pathway]	1.5849625007211563	3	1	0	0
12127	1520	October 1 transcription factor	[Oct 1 transcription factor]	1.5849625007211563	4	1	0	0
12128	1520	T cell response occur	[T cell responses occurring]	1.5849625007211563	4	1	0	0
12129	1520	two pyrrole-imidazole polyamide	[Two pyrrole-imidazole polyamides]	1.5849625007211563	3	1	0	0
12130	1520	control value of 100	[control value of 100]	1.5849625007211563	4	1	0	0
12131	1520	cellular expression of rar	[cellular expression of RARs]	1.5849625007211563	4	1	0	0
12132	1520	ccaat box ccaac	[CCAAT box CCAAC]	1.5849625007211563	3	1	0	0
12133	1520	multiple positive element	[multiple positive elements]	1.5849625007211563	3	1	0	0
12134	1520	decrease of free e2f	[decrease of free E2F]	1.5849625007211563	4	1	0	0
12135	1520	model for Rex trans-activation	[model for Rex trans-activation]	1.5849625007211563	4	1	0	0
12136	1520	element-binding protein (creb) factor	[element-binding protein (CREB) factors]	1.5849625007211563	4	1	0	0
12137	1520	interaction of trans-acting factor	[interaction of trans-acting factors]	1.5849625007211563	4	1	0	0
12138	1520	GM-CSF gene through pkc-	[GM-CSF gene through PKC-]	1.5849625007211563	4	1	0	0
12139	1520	hiv-1 long repeat transcription	[HIV-1 long repeat transcription]	1.5849625007211563	4	2	2	2
12140	1520	potentiation of aggregation.	[potentiation of aggregation.]	1.5849625007211563	3	1	0	0
12141	1520	level of control	[level of control]	1.5849625007211563	3	2	2	2
12142	1520	mannose receptor-mediated endocytosis	[mannose receptor-mediated endocytosis]	1.5849625007211563	3	1	0	0
12143	1520	involution of receptor synthesis	[involution of receptor synthesis]	1.5849625007211563	4	1	0	0
12144	1520	presence of RA	[presence of RA]	1.5849625007211563	3	1	0	0
12145	1520	one gene product,	[One gene product,]	1.5849625007211563	3	1	0	0
12146	1520	normal level of gm-csf	[normal levels of GM-CSF]	1.5849625007211563	4	1	0	0
12147	1520	transactivation domain of pu.1	[transactivation domains of PU.1]	1.5849625007211563	4	1	0	0
12148	1520	site-specific transcriptional property	[site-specific transcriptional properties]	1.5849625007211563	3	1	0	0
12149	1520	kappab -dependent transcription	[kappaB -dependent transcription]	1.5849625007211563	3	2	2	2
12150	1520	339 amino acid	[339 amino acids]	1.5849625007211563	3	1	0	0
12151	1520	heterodimer with NF-kappa b1	[heterodimers with NF-kappa B1]	1.5849625007211563	4	1	0	0
12152	1520	ZII domain of Zp	[ZII domain of Zp]	1.5849625007211563	4	1	0	0
12153	1520	expression of nfatc mrna	[expression of NFATc mRNA]	1.5849625007211563	4	1	0	0
12154	1520	(but all) b-lymphoid line	[(but all) B-lymphoid lines]	1.5849625007211563	4	1	0	0
12155	1520	tissue-specific gata-binding site	[tissue-specific GATA-binding site]	1.5849625007211563	3	1	0	0
12156	1520	activation of stat3	[activation of STAT3]	1.5849625007211563	3	1	0	0
12157	1520	virtually all B-cell line	[Virtually all B-cell lines]	1.5849625007211563	4	1	0	0
12158	1520	constitutively active calcineurin	[constitutively active calcineurin]	1.5849625007211563	3	2	1	1
12159	1520	activation of stat1	[activation of STAT1]	1.5849625007211563	3	2	1	1
12160	1520	inhibition of alpha interferon	[Inhibition of alpha interferon]	1.5849625007211563	4	1	0	0
12161	1520	Conversely, SCL expression	[Conversely, SCL expression]	1.5849625007211563	3	1	0	0
12162	1520	proximal 5' flank region	[proximal 5' flanking region]	1.5849625007211563	4	1	0	0
12163	1520	kilodalton heat shock protein	[kilodalton heat shock proteins]	1.5849625007211563	4	1	0	0
12164	1520	abundant tcl1 expression	[abundant TCL1 expression]	1.5849625007211563	3	1	0	0
12165	1520	loss of body mass	[loss of body mass]	1.5849625007211563	4	1	0	0
12166	1520	one possible mechanism	[one possible mechanism]	1.5849625007211563	3	2	2	2
12167	1520	complex development pathway	[complex development pathways]	1.5849625007211563	3	1	0	0
12168	1520	-bound receptor complex	[-bound receptor complexes]	1.5849625007211563	3	1	0	0
12169	1520	most malignant lymphocytic cell	[most malignant lymphocytic cells]	1.5849625007211563	4	1	0	0
12170	1520	fp 250 microg	[FP 250 microg]	1.5849625007211563	3	1	0	0
12171	1520	gene expression of mediator	[gene expression of mediators]	1.5849625007211563	4	2	2	2
12172	1520	such as JunB	[such as JunB]	1.5849625007211563	3	1	0	0
12173	1520	such as JunD	[such as JunD]	1.5849625007211563	3	1	0	0
12174	1520	h-7-sensitive kinase pathway	[H-7-sensitive kinase pathways]	1.5849625007211563	3	1	0	0
12175	1520	unstimulated NK cell	[unstimulated NK cells]	1.5849625007211563	3	2	1	1
12176	1520	contain n-terminal (1-60) peptide	[containing N-terminal (1-60) peptide]	1.5849625007211563	4	1	0	0
12177	1520	gr in MNL	[GR in MNL]	1.5849625007211563	3	2	1	1
12178	1520	histochemical staining with Fast-Green/Neutral-Red	[histochemical staining with Fast-Green/Neutral-Red]	1.5849625007211563	4	1	0	0
12179	1520	NB a 140-kDa sp140	[NB a 140-kDa Sp140]	1.5849625007211563	4	1	0	0
12180	1520	capacity of the receptor	[capacity of the receptor]	1.5849625007211563	4	1	0	0
12181	1520	variety of phagocyte function	[variety of phagocyte functions]	1.5849625007211563	4	1	0	0
12182	1520	presence of HS	[presence of HS]	1.5849625007211563	3	1	0	0
12183	1520	cell in AITL /gc	[cells in AITL /GC]	1.5849625007211563	4	1	0	0
12184	1520	isre binding of ISGF3gamma.	[ISRE binding of ISGF3gamma.]	1.5849625007211563	4	1	0	0
12185	1520	cell surface paf receptor	[cell surface PAF receptors]	1.5849625007211563	4	1	0	0
12186	1520	prevalence of aneuploidy	[Prevalence of aneuploidy]	1.5849625007211563	3	2	1	1
12187	1520	tumor necrosis factor-a	[tumor necrosis factor-a]	1.5849625007211563	3	1	0	0
12188	1520	Epstein-Barr virus LMP1 domain	[Epstein-Barr virus LMP1 domain]	1.5849625007211563	4	1	0	0
12189	1520	immunoglobulin light-chain gene rearrangement	[immunoglobulin light-chain gene rearrangement]	1.5849625007211563	4	1	0	0
12190	1520	potential use of dtc	[potential use of DTCs]	1.5849625007211563	4	1	0	0
12191	1520	326 amino acid	[326 amino acids]	1.5849625007211563	3	1	0	0
12192	1520	JAK2 tyrosine kinase	[JAK2 tyrosine kinase]	1.5849625007211563	3	1	0	0
12193	1520	detection of NF-ATc.alpha mrna	[Detection of NF-ATc.alpha mRNA]	1.5849625007211563	4	1	0	0
12194	1520	dual color confocal microscopy	[dual color confocal microscopy]	1.5849625007211563	4	1	0	0
12195	1520	activation of hiv production	[activation of HIV production]	1.5849625007211563	4	1	0	0
12196	1520	only slightly on cell	[only slightly on cells]	1.5849625007211563	4	1	0	0
12197	1520	supershift with antibody	[Supershift with antibodies]	1.5849625007211563	3	2	2	2
12198	1520	three stimuli, disparate stimulus-	[three stimuli, disparate stimulus-]	1.5849625007211563	4	1	0	0
12199	1520	carboxyl-terminal amino acid	[carboxyl-terminal amino acids]	1.5849625007211563	3	2	2	2
12200	1520	b- lymphocyte development	[B- lymphocyte development]	1.5849625007211563	3	1	0	0
12201	1520	tnf-alpha bioavailability ep<0.05)	[TNF-alpha bioavailability (P<0.05)]	1.5849625007211563	3	1	0	0
12202	1520	-ii; (2) t-cell	[-II; (2) T-cells]	1.5849625007211563	3	1	0	0
12203	1520	T cell reporter construct.	[T cells reporter construct.]	1.5849625007211563	4	1	0	0
12204	1520	antibody to stat protein	[antibodies to Stat proteins]	1.5849625007211563	4	2	1	1
12205	1520	many lps response	[many LPS responses]	1.5849625007211563	3	1	0	0
12206	1520	cloning of p27kip1 gene	[cloning of p27Kip1 gene]	1.5849625007211563	4	1	0	0
12207	1520	discrete nuclear structure	[discrete nuclear structures]	1.5849625007211563	3	1	0	0
12208	1520	nmol/L), mcp-1 expression	[nmol/L), MCP-1 expression]	1.5849625007211563	3	1	0	0
12209	1520	CD28 surface expression	[CD28 surface expression]	1.5849625007211563	3	1	0	0
12210	1520	proximal tsp 1	[proximal TSP 1]	1.5849625007211563	3	1	0	0
12211	1520	Conversely, calcium-independent anti-cd28 ab	[Conversely, calcium-independent anti-CD28 Ab]	1.5849625007211563	4	1	0	0
12212	1520	breast cancer for dfs	[breast cancer for DFS]	1.5849625007211563	4	1	0	0
12213	1520	4-phorbol 12-myristate 13-acetate PMA	[4-phorbol 12-myristate 13-acetate PMA]	1.5849625007211563	4	1	0	0
12214	1520	Bacterial vaginosis bv	[Bacterial vaginosis BV]	1.5849625007211563	3	1	0	0
12215	1520	nf-at transcriptional activity	[NF-AT transcriptional activity]	1.5849625007211563	3	2	1	1
12216	1520	cd14 distal sp1-binding site	[CD14 distal Sp1-binding site]	1.5849625007211563	4	1	0	0
12217	1520	property of nf-atc	[properties of NF-ATc]	1.5849625007211563	3	1	0	0
12218	1520	chloramphenicol acetyltransferase CAT reporter	[chloramphenicol acetyltransferase CAT reporter]	1.5849625007211563	4	1	0	0
12219	1520	Thy-1 gene promoter	[Thy-1 gene promoter]	1.5849625007211563	3	1	0	0
12220	1520	activator in b cell	[activators in B cells]	1.5849625007211563	4	1	0	0
12221	1520	such as sensation	[such as sensation]	1.5849625007211563	3	1	0	0
12222	1520	lymphocyte g0/g1 switch gene	[lymphocyte G0/G1 switch gene]	1.5849625007211563	4	2	2	2
12223	1520	5 all-tran RA	[5 all-trans RA]	1.5849625007211563	3	1	0	0
12224	1520	present study, structure/function analysis	[present study, structure/function analyses]	1.5849625007211563	4	1	0	0
12225	1520	overlapping biological effect	[overlapping biological effects]	1.5849625007211563	3	1	0	0
12226	1520	much less work	[much less work]	1.5849625007211563	3	1	0	0
12227	1520	direct in vivo evidence	[direct in vivo evidence]	1.5849625007211563	4	1	0	0
12228	1520	mutation in any one	[mutations in any one]	1.5849625007211563	4	1	0	0
12229	1520	b- cell marker	[B- cell markers]	1.5849625007211563	3	1	0	0
12230	1520	plasmid pnf-kappa bluc	[plasmid pNF-kappa BLUC]	1.5849625007211563	3	1	0	0
12231	1520	response to tnf-alpha treatment	[response to TNF-alpha treatment]	1.5849625007211563	4	1	0	0
12232	1520	serum response element sre	[serum response element SRE]	1.5849625007211563	4	1	0	0
12233	1520	positive-pressure mechanical ventilation	[Positive-pressure mechanical ventilation]	1.5849625007211563	3	1	0	0
12234	1520	immunosuppression on cytokine production	[immunosuppression on cytokine production]	1.5849625007211563	4	1	0	0
12235	1520	boundary of the concentration	[boundaries of the concentrations]	1.5849625007211563	4	1	0	0
12236	1520	vertebrate t-cell-specific transcriptional regulation	[vertebrate T-cell-specific transcriptional regulation]	1.5849625007211563	4	1	0	0
12237	1520	two apoptotic signal	[two apoptotic signals]	1.5849625007211563	3	1	0	0
12238	1520	encode a 97-kDa protein	[encoding a 97-kDa protein]	1.5849625007211563	4	1	0	0
12239	1520	hsp90 in reticulocyte lysate	[hsp90 in reticulocyte lysate]	1.5849625007211563	4	1	0	0
12240	1520	pathway of signal transmission	[pathway of signal transmission]	1.5849625007211563	4	1	0	0
12241	1520	sh2 domain of slp-76	[SH2 domain of SLP-76]	1.5849625007211563	4	1	0	0
12242	1520	multiple TRAF binding site	[multiple TRAF binding sites]	1.5849625007211563	4	1	0	0
12243	1520	ap-1 transcriptional factor	[AP-1 transcriptional factors]	1.5849625007211563	3	1	0	0
12244	1520	dominant-negative form of calcineurin	[dominant-negative form of calcineurin]	1.5849625007211563	4	1	0	0
12245	1520	transcription (rt)-pcr analysis	[transcription (RT)-PCR analysis]	1.5849625007211563	3	1	0	0
12246	1520	four cis-acting element	[four cis-acting elements]	1.5849625007211563	3	2	2	2
12247	1520	threshold concentration (Renesto, p.,	[threshold concentration (Renesto, P.,]	1.5849625007211563	4	1	0	0
12248	1520	efficient transcription in cell	[efficient transcription in cells]	1.5849625007211563	4	1	0	0
12249	1520	group ii cid cell	[group II CID cells]	1.5849625007211563	4	1	0	0
12250	1520	only with Oct-2	[only with Oct-2]	1.5849625007211563	3	1	0	0
12251	1520	p65 protein expression.	[p65 protein expression.]	1.5849625007211563	3	1	0	0
12252	1520	high titer igg autoantibody	[high titer IgG autoantibodies]	1.5849625007211563	4	1	0	0
12253	1520	molecular weight variant	[molecular weight variant]	1.5849625007211563	3	2	2	2
12254	1520	arterial endothelial cells.	[arterial endothelial cells.]	1.5849625007211563	3	1	0	0
12255	1520	dyad symmetry region	[dyad symmetry region]	1.5849625007211563	3	1	0	0
12256	1520	such 'constitutive' nf-kappa b	[such 'constitutive' NF-kappa B]	1.5849625007211563	4	1	0	0
12257	1520	potential TATA element	[potential TATA element]	1.5849625007211563	3	1	0	0
12258	1520	contrast, in a state	[contrast, in a state]	1.5849625007211563	4	1	0	0
12259	1520	state mrna level	[state mRNA levels]	1.5849625007211563	3	2	2	2
12260	1520	occupancy of both site	[occupancy of both sites]	1.5849625007211563	4	1	0	0
12261	1520	cis-acting negative regulatory element	[cis-acting negative regulatory element]	1.5849625007211563	4	1	0	0
12262	1520	Indeed, IL-10 like IFN-gamma	[Indeed, IL-10 like IFN-gamma]	1.5849625007211563	4	1	0	0
12263	1520	nf-kappa b level	[NF-kappa B levels]	1.5849625007211563	3	1	0	0
12264	1520	transform growth factor-beta family	[transforming growth factor-beta family]	1.5849625007211563	4	1	0	0
12265	1520	immunoglobulin gene superfamily	[immunoglobulin gene superfamily]	1.5849625007211563	3	1	0	0
12266	1520	specific antigenic stimulus	[specific antigenic stimulus]	1.5849625007211563	3	1	0	0
12267	1520	Bcl-2 family of protein	[Bcl-2 family of proteins]	1.5849625007211563	4	1	0	0
12268	1520	first exon of E1A	[first exon of E1A]	1.5849625007211563	4	2	1	1
12269	1520	C/EBP-epsilon expression plasmid	[C/EBP-epsilon expression plasmid]	1.5849625007211563	3	1	0	0
12270	1520	single cytokine receptor	[single cytokine receptor]	1.5849625007211563	3	1	0	0
12271	1520	level circulate immune complex	[levels circulating immune complexes]	1.5849625007211563	4	1	0	0
12272	1520	t- cell type	[T- cell types]	1.5849625007211563	3	1	0	0
12273	1520	effect of progesterone	[effect of progesterone]	1.5849625007211563	3	2	1	1
12274	1520	lymphocyte of each sample	[lymphocytes of each sample]	1.5849625007211563	4	1	0	0
12275	1520	impaired myelopoiesis in vivo	[Impaired myelopoiesis in vivo]	1.5849625007211563	4	1	0	0
12276	1520	dominant promoter element	[dominant promoter elements]	1.5849625007211563	3	1	0	0
12277	1520	NFkappaB binding activity	[NFkappaB binding activity]	1.5849625007211563	3	1	0	0
12278	1520	down-regulation of the level	[down-regulation of the levels]	1.5849625007211563	4	1	0	0
12279	1520	CAAT/enhancer binding protein c/ebp	[CAAT/enhancer binding proteins C/EBPs]	1.5849625007211563	4	1	0	0
12280	1520	cotransfection with pzvb70	[cotransfection with pZVB70]	1.5849625007211563	3	1	0	0
12281	1520	phosphorylation-defective form of Rb	[phosphorylation-defective form of Rb]	1.5849625007211563	4	1	0	0
12282	1520	high degree of conservation	[high degree of conservation]	1.5849625007211563	4	1	0	0
12283	1520	great number of cancer	[great number of cancers]	1.5849625007211563	4	1	0	0
12284	1520	negative effect of udg	[negative effect of UDG]	1.5849625007211563	4	1	0	0
12285	1520	human endothelial cell activation	[human endothelial cell activation]	1.5849625007211563	4	1	0	0
12286	1520	Positive regulatory element	[Positive regulatory element]	1.5849625007211563	3	1	0	0
12287	1520	p50/c-Rel in medullary thymocyte	[p50/c-Rel in medullary thymocytes]	1.5849625007211563	4	1	0	0
12288	1520	gynecomastia (rs of leucocyte	[gynecomastia (Rs of leucocytes]	1.5849625007211563	4	1	0	0
12289	1520	normal ductal epithelium	[normal ductal epithelium]	1.5849625007211563	3	1	0	0
12290	1520	same dna-binding site specificity	[same DNA-binding site specificity]	1.5849625007211563	4	1	0	0
12291	1520	parasite-induced constitutive nf-kappab activation	[parasite-induced constitutive NF-kappaB activation]	1.5849625007211563	4	1	0	0
12292	1520	injury/activation of endothelium	[injury/activation of endothelium]	1.5849625007211563	3	1	0	0
12293	1520	maximal translational suppression	[maximal translational suppression]	1.5849625007211563	3	1	0	0
12294	1520	cell-permeable camp analogue dbcamp	[cell-permeable cAMP analogue dbcAMP]	1.5849625007211563	4	1	0	0
12295	1520	Functional DC characteristic	[Functional DC characteristics]	1.5849625007211563	3	1	0	0
12296	1520	infectious molecular clone	[infectious molecular clone]	1.5849625007211563	3	2	2	2
12297	1520	il-2 -induced, activation	[IL-2 -induced, activation]	1.5849625007211563	3	1	0	0
12298	1520	high c-erb b-2 expression.	[high c-erb B-2 expression.]	1.5849625007211563	4	1	0	0
12299	1520	box 1 pdp motif	[box 1 PDP motif]	1.5849625007211563	4	1	0	0
12300	1520	ongoing protein synthesis	[ongoing protein synthesis]	1.5849625007211563	3	1	0	0
12301	1520	ap-1 protein c-jun	[AP-1 protein c-Jun]	1.5849625007211563	3	1	0	0
12302	1520	17-bp gas homology	[17-bp GAS homology]	1.5849625007211563	3	1	0	0
12303	1520	p50/p65 NF-kappa b	[p50/p65 NF-kappa B]	1.5849625007211563	3	1	0	0
12304	1520	human pro-interleukin 1beta gene	[human pro-interleukin 1beta gene]	1.5849625007211563	4	1	0	0
12305	1520	presence of bone metastase	[presence of bone metastases]	1.5849625007211563	4	1	0	0
12306	1520	increase mrna stability	[increasing mRNA stability]	1.5849625007211563	3	1	0	0
12307	1520	RXR -specific agonist	[RXR -specific agonist]	1.5849625007211563	3	1	0	0
12308	1520	myd88 th1-developing cell	[MyD88 Th1-developing cells]	1.5849625007211563	3	1	0	0
12309	1520	half-maximal induction of IL-2	[half-maximal induction of IL-2]	1.5849625007211563	4	1	0	0
12310	1520	cellular immune pathway result	[Cellular immune pathways resulting]	1.5849625007211563	4	1	0	0
12311	1520	myeloid-specific expression of cd11b	[myeloid-specific expression of CD11b]	1.5849625007211563	4	1	0	0
12312	1520	stage of the disease	[stage of the disease]	1.5849625007211563	4	2	1	1
12313	1520	regulation of cell proliferation	[regulation of cell proliferation]	1.5849625007211563	4	1	0	0
12314	1520	erythroid colony growth	[erythroid colony growth]	1.5849625007211563	3	1	0	0
12315	1520	gdsp on pancreatic weight	[GDSP on pancreatic weight]	1.5849625007211563	4	1	0	0
12316	1520	cell-specific gene expression	[cell-specific gene expression]	1.5849625007211563	3	1	0	0
12317	1520	presence of alpha-helice	[presence of alpha-helices]	1.5849625007211563	3	2	2	2
12318	1520	rna polymerase iii	[RNA polymerase III]	1.5849625007211563	3	1	0	0
12319	1520	human tsh receptor tsh-r	[human TSH receptor TSH-R]	1.5849625007211563	4	1	0	0
12320	1520	transformation-competent EBNA-2 deletion mutant	[transformation-competent EBNA-2 deletion mutant]	1.5849625007211563	4	1	0	0
12321	1520	downstream target gene	[downstream target genes]	1.5849625007211563	3	2	1	1
12322	1520	vitro binding of aldosterone	[vitro binding of aldosterone]	1.5849625007211563	4	1	0	0
12323	1520	particular fusion partner	[particular fusion partner]	1.5849625007211563	3	1	0	0
12324	1520	dna-binding activity of gata-1	[DNA-binding activity of GATA-1]	1.5849625007211563	4	2	1	1
12325	1520	human fetal (gamma)	[human fetal (gamma)]	1.5849625007211563	3	1	0	0
12326	1520	region contain the element	[region containing the elements]	1.5849625007211563	4	1	0	0
12327	1520	expression of factor	[expression of factors]	1.5849625007211563	3	2	1	1
12328	1520	breakpoint on chromosome	[breakpoint on chromosome]	1.5849625007211563	3	2	2	2
12329	1520	impaired activation of nf-kappab	[impaired activation of NF-kappaB]	1.5849625007211563	4	1	0	0
12330	1520	level of progesterone receptor	[level of progesterone receptors]	1.5849625007211563	4	1	0	0
12331	1520	transcription of a cytokine	[transcription of a cytokine]	1.5849625007211563	4	2	2	2
12332	1520	expression of cd62	[expression of CD62]	1.5849625007211563	3	1	0	0
12333	1520	expression of cd44	[expression of CD44]	1.5849625007211563	3	1	0	0
12334	1520	expression of cd45	[expression of CD45]	1.5849625007211563	3	1	0	0
12335	1520	two isolate belong	[two isolates belonging]	1.5849625007211563	3	1	0	0
12336	1520	gamma-ifn of 135(oh)2d3 action	[gamma-IFN of 1,25(OH)2D3 action]	1.5849625007211563	4	1	0	0
12337	1520	furthermore, IL-18 activation	[Furthermore, IL-18 activation]	1.5849625007211563	3	1	0	0
12338	1520	structure of steroid receptors,	[structure of steroid receptors,]	1.5849625007211563	4	1	0	0
12339	1520	studies, the first	[studies, the first]	1.5849625007211563	3	1	0	0
12340	1520	means of control.	[means of control.]	1.5849625007211563	3	1	0	0
12341	1520	30 minute of stimulation	[30 min of stimulation]	1.5849625007211563	4	1	0	0
12342	1520	expression of cd25	[expression of CD25]	1.5849625007211563	3	1	0	0
12343	1520	respectively, t-cell antigen	[respectively, T-cell antigens]	1.5849625007211563	3	1	0	0
12344	1520	p38 kinase activity	[p38 kinase activity]	1.5849625007211563	3	1	0	0
12345	1520	novel b-cell oncogene	[novel B-cell oncogene]	1.5849625007211563	3	1	0	0
12346	1520	gcr of target cell	[GcR of target cells]	1.5849625007211563	4	1	0	0
12347	1520	information on memory	[information on memory]	1.5849625007211563	3	1	0	0
12348	1520	pure b cell line	[pure B cell line]	1.5849625007211563	4	1	0	0
12349	1520	redox-sensitive transcription factor	[redox-sensitive transcription factor]	1.5849625007211563	3	1	0	0
12350	1520	nuclear receptor er	[nuclear receptor ER]	1.5849625007211563	3	1	0	0
12351	1520	effect of receptor activation	[effects of receptor activation]	1.5849625007211563	4	1	0	0
12352	1520	impdh type ii	[IMPDH type II]	1.5849625007211563	3	2	2	2
12353	1520	loss of il-13 regulation	[loss of IL-13 regulation]	1.5849625007211563	4	1	0	0
12354	1520	wild type ikk2	[wild type IKK2]	1.5849625007211563	3	1	0	0
12355	1520	tyrosine phosphorylation of cd19	[tyrosine phosphorylation of CD19]	1.5849625007211563	4	1	0	0
12356	1520	TCF-1 alpha mrna	[TCF-1 alpha mRNA]	1.5849625007211563	3	1	0	0
12357	1520	multiple DNA bind homo-	[multiple DNA binding homo-]	1.5849625007211563	4	1	0	0
12358	1520	basis of th1/th2 differentiation	[basis of Th1/Th2 differentiation]	1.5849625007211563	4	1	0	0
12359	1520	kinetic in cemxl74 cell	[kinetics in CEMxl74 cells]	1.5849625007211563	4	2	2	2
12360	1520	mitogen-activated protein kinase mapk	[mitogen-activated protein kinase MAPK]	1.5849625007211563	4	1	0	0
12361	1520	stat1 -like factor	[STAT1 -like factor]	1.5849625007211563	3	1	0	0
12362	1520	CAAX site on V14Rho	[CAAX site on V14Rho]	1.5849625007211563	4	1	0	0
12363	1520	catalytic subunit of pka	[catalytic subunit of PKA]	1.5849625007211563	4	1	0	0
12364	1520	instead in conjunction	[instead in conjunction]	1.5849625007211563	3	1	0	0
12365	1520	general coping strategy	[general coping strategy]	1.5849625007211563	3	1	0	0
12366	1520	cotreatment with RA	[cotreatment with RA]	1.5849625007211563	3	1	0	0
12367	1520	human T helper cell	[human T helper cells]	1.5849625007211563	4	2	1	1
12368	1520	HeLa nonpituitary cell	[HeLa nonpituitary cells]	1.5849625007211563	3	1	0	0
12369	1520	formation in cell types.	[formation in cell types.]	1.5849625007211563	4	1	0	0
12370	1520	various disease include leukemia	[various diseases including leukemia]	1.5849625007211563	4	1	0	0
12371	1520	(from hour 72	[(from hours 72]	1.5849625007211563	3	1	0	0
12372	1520	CIITA -express cell	[CIITA -expressing cells]	1.5849625007211563	3	1	0	0
12373	1520	presence of m Azeptin	[presence of M Azeptin]	1.5849625007211563	4	1	0	0
12374	1520	nuclear factor-kappa beta	[nuclear factor-kappa beta]	1.5849625007211563	3	2	2	2
12375	1520	variety of ligand	[variety of ligands]	1.5849625007211563	3	1	0	0
12376	1520	nuclear translocation of NFkappaB	[nuclear translocation of NFkappaB]	1.5849625007211563	4	2	1	1
12377	1520	(2) genomic configuration	[(2) genomic configuration]	1.5849625007211563	3	1	0	0
12378	1520	initial receptor binding	[initial receptor binding]	1.5849625007211563	3	1	0	0
12379	1520	ICAM-1 promoter ICAM-1 pire	[ICAM-1 promoter ICAM-1 pIRE]	1.5849625007211563	4	1	0	0
12380	1520	undergo apoptotic cell death	[undergoing apoptotic cell death]	1.5849625007211563	4	1	0	0
12381	1520	activity of this enzyme	[activity of this enzyme]	1.5849625007211563	4	2	1	1
12382	1520	SIV long terminal repeat	[SIV long terminal repeat]	1.5849625007211563	4	1	0	0
12383	1520	series of in vivo	[series of in vivo]	1.5849625007211563	4	1	0	0
12384	1520	effect on this cells.	[effect on these cells.]	1.5849625007211563	4	1	0	0
12385	1520	U937 cell by ML-9	[U937 cells by ML-9]	1.5849625007211563	4	1	0	0
12386	1520	down-regulation of il-12 production	[down-regulation of IL-12 production]	1.5849625007211563	4	1	0	0
12387	1520	retinoid in APL patient	[retinoids in APL patients]	1.5849625007211563	4	1	0	0
12388	1520	identification of regulatory element	[Identification of regulatory elements]	1.5849625007211563	4	2	2	2
12389	1520	series of biochemical events.	[series of biochemical events.]	1.5849625007211563	4	1	0	0
12390	1520	activity of nuclear protein	[activity of nuclear proteins]	1.5849625007211563	4	1	0	0
12391	1520	nf-kappa b by cycloheximide	[NF-kappa B by cycloheximide]	1.5849625007211563	4	1	0	0
12392	1520	level of il-8 release	[level of IL-8 release]	1.5849625007211563	4	1	0	0
12393	1520	similarity in expression	[similarity in expression]	1.5849625007211563	3	1	0	0
12394	1520	delay in cell death	[delay in cell death]	1.5849625007211563	4	1	0	0
12395	1520	frequency of the cell	[frequency of the cells]	1.5849625007211563	4	1	0	0
12396	1520	dominant susceptibility to infection	[dominant susceptibility to infections]	1.5849625007211563	4	1	0	0
12397	1520	signal transduction by dioxin	[signal transduction by dioxin]	1.5849625007211563	4	1	0	0
12398	1520	respect to the phenotype	[respect to the phenotype]	1.5849625007211563	4	1	0	0
12399	1520	Electrophoretic mobility-shift assay EMSA	[Electrophoretic mobility-shift assays EMSA]	1.5849625007211563	4	1	0	0
12400	1520	tnf-alpha-induced hiv-1 expression.	[TNF-alpha-induced HIV-1 expression.]	1.5849625007211563	3	1	0	0
12401	1520	cellular camp level	[cellular cAMP levels]	1.5849625007211563	3	1	0	0
12402	1520	130 base pair (bp)	[130 base pairs (bp)]	1.5849625007211563	4	1	0	0
12403	1520	role in transcription	[role in transcription]	1.5849625007211563	3	1	0	0
12404	1520	reduction of mmp-9 activity	[reduction of MMP-9 activity]	1.5849625007211563	4	1	0	0
12405	1520	gene for cytokine	[genes for cytokines]	1.5849625007211563	3	2	2	2
12406	1520	overproduction by disease-activated macrophage	[overproduction by disease-activated macrophages]	1.5849625007211563	4	1	0	0
12407	1520	nuclear factor kappab activation	[nuclear factor kappaB activation]	1.5849625007211563	4	2	1	1
12408	1520	C5a kappab binding activity	[C5a kappaB binding activity]	1.5849625007211563	4	1	0	0
12409	1520	ap-1 in bovine leucocyte	[AP-1 in bovine leucocytes]	1.5849625007211563	4	1	0	0
12410	1520	nf-kappab-controlled beta-globin reporter gene	[NF-kappaB-controlled beta-globin reporter gene]	1.5849625007211563	4	1	0	0
12411	1520	downstream PKC/Ras pathway	[downstream PKC/Ras pathway]	1.5849625007211563	3	1	0	0
12412	1520	further 1-2 hour	[further 1-2 hr]	1.5849625007211563	3	1	0	0
12413	1520	normal retinoid signal	[normal retinoid signaling]	1.5849625007211563	3	1	0	0
12414	1520	42 degree c,	[42 degrees C,]	1.5849625007211563	3	1	0	0
12415	1520	redundancy of transactivation function	[redundancy of transactivation function]	1.5849625007211563	4	1	0	0
12416	1520	also significantly (p low	[also significantly (P lower]	1.5849625007211563	4	1	0	0
12417	1520	develop Th1 cell	[developing Th1 cells]	1.5849625007211563	3	1	0	0
12418	1520	interleukin (il)-2 gene expression	[interleukin (IL)-2 gene expression]	1.5849625007211563	4	1	0	0
12419	1520	wild-type, unfused ebna3c	[wild-type, unfused EBNA3C]	1.5849625007211563	3	1	0	0
12420	1520	treatment with eosinophil apoptosis	[treatment with eosinophil apoptosis]	1.5849625007211563	4	1	0	0
12421	1520	mutant T cell line	[mutant T cell line]	1.5849625007211563	4	1	0	0
12422	1520	x2 box protein-DNA interaction	[X2 box protein-DNA interactions]	1.5849625007211563	4	1	0	0
12423	1520	(b) level of tnf-alpha	[(b) levels of TNF-alpha]	1.5849625007211563	4	1	0	0
12424	1520	absence of ATP	[absence of ATP]	1.5849625007211563	3	1	0	0
12425	1520	Ca2+ -free medium	[Ca2+ -free medium]	1.5849625007211563	3	1	0	0
12426	1520	mineralocorticoid antagonist spironolactone	[mineralocorticoid antagonist spironolactone]	1.5849625007211563	3	1	0	0
12427	1520	cis-act DNA site	[cis-acting DNA site]	1.5849625007211563	3	1	0	0
12428	1520	expression of cd41a	[expression of CD41a]	1.5849625007211563	3	1	0	0
12429	1520	such as cancer	[such as cancer]	1.5849625007211563	3	1	0	0
12430	1520	different e1a domain	[different E1A domains]	1.5849625007211563	3	1	0	0
12431	1520	symptom of inflammation	[symptoms of inflammation]	1.5849625007211563	3	1	0	0
12432	1520	various tumor cell type	[various tumor cell types]	1.5849625007211563	4	1	0	0
12433	1520	human renal cell carcinoma	[human renal cell carcinoma]	1.5849625007211563	4	2	1	1
12434	1520	dominant-act repressor molecule	[dominant-acting repressor molecule]	1.5849625007211563	3	1	0	0
12435	1520	contrast, ifn-gamma priming	[contrast, IFN-gamma priming]	1.5849625007211563	3	1	0	0
12436	1520	loss of enhancer function	[loss of enhancer function]	1.5849625007211563	4	1	0	0
12437	1520	11 abdominal obese subject	[11 abdominal obese subjects]	1.5849625007211563	4	1	0	0
12438	1520	expression in monocytic cell	[expression in monocytic cells]	1.5849625007211563	4	2	2	2
12439	1520	Lewis X antigen cd15	[Lewis X antigen CD15]	1.5849625007211563	4	1	0	0
12440	1520	three hsv/vzv recombinant	[Three HSV/VZV recombinants]	1.5849625007211563	3	1	0	0
12441	1520	extracellular kinase ERK	[extracellular kinase ERK]	1.5849625007211563	3	2	2	2
12442	1520	etoposide (0.15 microM)	[etoposide (0.15 microM)]	1.5849625007211563	3	1	0	0
12443	1520	history of exposure	[history of exposure]	1.5849625007211563	3	1	0	0
12444	1520	low weight variant	[lower weight variant]	1.5849625007211563	3	2	2	2
12445	1520	tnf-alpha mrna expression	[TNF-alpha mRNA expression]	1.5849625007211563	3	1	0	0
12446	1520	glutathione disulfide gssg level	[glutathione disulfide GSSG levels]	1.5849625007211563	4	1	0	0
12447	1520	first year of life,	[first year of life,]	1.5849625007211563	4	1	0	0
12448	1520	EMBO j.16:332-342, 1997).	[EMBO J.16:332-342, 1997).]	1.5849625007211563	3	1	0	0
12449	1520	immune system include autoimmunity	[immune system including autoimmunity]	1.5849625007211563	4	1	0	0
12450	1520	uptake by cho-cd14 cell	[uptake by CHO-CD14 cells]	1.5849625007211563	4	1	0	0
12451	1520	major sialoglycoprotein of leukocyte	[major sialoglycoprotein of leukocytes]	1.5849625007211563	4	1	0	0
12452	1520	tumor promoter PMA	[tumor promoter PMA]	1.5849625007211563	3	2	1	1
12453	1520	symmetric NF-kappa b site	[symmetric NF-kappa B site]	1.5849625007211563	4	1	0	0
12454	1520	study of lymphocyte infiltration	[study of lymphocyte infiltration]	1.5849625007211563	4	1	0	0
12455	1520	contrast, other viral product	[contrast, other viral products]	1.5849625007211563	4	1	0	0
12456	1520	many hematopoietin receptor	[many hematopoietin receptors]	1.5849625007211563	3	1	0	0
12457	1520	cell cycle perturbation	[cell cycle perturbation]	1.5849625007211563	3	1	0	0
12458	1520	primary murine T cell	[primary murine T cells]	1.5849625007211563	4	1	0	0
12459	1520	turnover of ikappabbeta	[turnover Of IkappaBbeta]	1.5849625007211563	3	1	0	0
12460	1520	regulation in the human	[regulation in the human]	1.5849625007211563	4	1	0	0
12461	1520	IL-1 beta gene expression	[IL-1 beta gene expression]	1.5849625007211563	4	1	0	0
12462	1520	confocal fluorescence microscopy	[confocal fluorescence microscopy]	1.5849625007211563	3	1	0	0
12463	1520	total of 7 patient	[total of 7 patients]	1.5849625007211563	4	1	0	0
12464	1520	important immunologic mediator	[important immunologic mediator]	1.5849625007211563	3	1	0	0
12465	1520	pcr-based humara method	[PCR-based HUMARA method]	1.5849625007211563	3	1	0	0
12466	1520	evidence for different theory	[evidence for different theories]	1.5849625007211563	4	1	0	0
12467	1520	CRE kappab3) site	[CRE kappaB3) sites]	1.5849625007211563	3	1	0	0
12468	1520	rela in nuclear extract	[RelA in nuclear extracts]	1.5849625007211563	4	1	0	0
12469	1520	alteration in T cell	[alterations in T cells]	1.5849625007211563	4	2	2	2
12470	1520	interleukin-6 from 10(-5) m	[interleukin-6 from 10(-5) M]	1.5849625007211563	4	1	0	0
12471	1520	cd19 reporter construct activity	[CD19 reporter construct activity]	1.5849625007211563	4	1	0	0
12472	1520	differentiation process of erythrocyte	[differentiation processes of erythrocytes]	1.5849625007211563	4	1	0	0
12473	1520	hierarchy of cellular permissivity	[hierarchy of cellular permissivity]	1.5849625007211563	4	1	0	0
12474	1520	two purine-rich binding site	[two purine-rich binding sites]	1.5849625007211563	4	1	0	0
12475	1520	cysteine residue (s)	[cysteine residue (s)]	1.5849625007211563	3	1	0	0
12476	1520	diurnal variation in GR	[diurnal variations in GR]	1.5849625007211563	4	1	0	0
12477	1520	nf-kappa b inducer	[NF-kappa B inducer]	1.5849625007211563	3	2	2	2
12478	1520	time in culture.	[time in culture.]	1.5849625007211563	3	1	0	0
12479	1520	monocyte tf activation	[monocyte TF activation]	1.5849625007211563	3	1	0	0
12480	1520	vivo hla-dr promoter occupancy	[vivo HLA-DR promoter occupancy]	1.5849625007211563	4	1	0	0
12481	1520	ciita -specific transcript	[CIITA -specific transcripts]	1.5849625007211563	3	1	0	0
12482	1520	alveolar macrophage-depleted rat	[alveolar macrophage-depleted rats]	1.5849625007211563	3	1	0	0
12483	1520	hypochlorous acid HOCl	[hypochlorous acid HOCl]	1.5849625007211563	3	1	0	0
12484	1520	establishment with the induction	[establishment with the induction]	1.5849625007211563	4	1	0	0
12485	1520	production of il-10	[production of IL-10]	1.5849625007211563	3	1	0	0
12486	1520	decrease in b-cell proliferation	[decrease in B-cell proliferation]	1.5849625007211563	4	1	0	0
12487	1520	production of il-12	[production of IL-12]	1.5849625007211563	3	2	2	2
12488	1520	DNA-protein crosslinking study	[DNA-protein crosslinking studies]	1.5849625007211563	3	1	0	0
12489	1520	nfat-controlled luciferase gene system	[NFAT-controlled luciferase gene system]	1.5849625007211563	4	1	0	0
12490	1520	integratory secondary messenger	[integratory secondary messenger]	1.5849625007211563	3	1	0	0
12491	1520	glycoprotein hormone erythropoietin Epo	[glycoprotein hormone erythropoietin Epo]	1.5849625007211563	4	1	0	0
12492	1520	cooh-terminal SH3-deleted Grf40 mutant	[COOH-terminal SH3-deleted Grf40 mutant]	1.5849625007211563	4	1	0	0
12493	1520	cd34+thy-1+ single cell	[CD34+Thy-1+ single cells]	1.5849625007211563	3	1	0	0
12494	1520	interaction with histone acetyltransferase	[interaction with histone acetyltransferases]	1.5849625007211563	4	1	0	0
12495	1520	alpha 2,6 sialyltransferase isozyme	[alpha 2,6 sialyltransferase isozyme]	1.5849625007211563	4	1	0	0
12496	1520	multiple myeloma mm	[multiple myeloma MM]	1.5849625007211563	3	1	0	0
12497	1520	expression within the hs	[expression within the HS]	1.5849625007211563	4	1	0	0
12498	1520	response in T cell	[response in T cells]	1.5849625007211563	4	2	2	2
12499	1520	membrane expression of antigen	[membrane expression of antigens]	1.5849625007211563	4	1	0	0
12500	1520	four C delta exon	[four C delta exons]	1.5849625007211563	4	1	0	0
12501	1520	alpha globin element	[alpha globin element]	1.5849625007211563	3	2	2	2
12502	1520	differ genetic defect	[differing genetic defects]	1.5849625007211563	3	1	0	0
12503	1520	cell of monocytic lineage	[cells of monocytic lineage]	1.5849625007211563	4	1	0	0
12504	1520	wild-type es cell	[wild-type ES cells]	1.5849625007211563	3	2	1	1
12505	1520	WGATAR consensus motif	[WGATAR consensus motifs]	1.5849625007211563	3	1	0	0
12506	1520	TACI activation of NF-AT	[TACI activation of NF-AT]	1.5849625007211563	4	1	0	0
12507	1520	domain analysis of NFATx1	[domain analysis of NFATx1]	1.5849625007211563	4	1	0	0
12508	1520	suggest a mechanism	[suggesting a mechanism]	1.5849625007211563	3	2	2	2
12509	1520	late-myeloblast-like cell line	[late-myeloblast-like cell lines]	1.5849625007211563	3	1	0	0
12510	1520	(3) expression of il-3	[(3) expression of IL-3]	1.5849625007211563	4	1	0	0
12511	1520	BCL-6 mrna level	[BCL-6 mRNA levels]	1.5849625007211563	3	1	0	0
12512	1520	TK inhibitor herbimycin a	[TK inhibitors herbimycin A]	1.5849625007211563	4	1	0	0
12513	1520	small human tissue sample	[small human tissue samples]	1.5849625007211563	4	1	0	0
12514	1520	NF kappa b promoter	[NF kappa B promoter]	1.5849625007211563	4	1	0	0
12515	1520	composition of il-2r	[composition of IL-2Rs]	1.5849625007211563	3	1	0	0
12516	1520	proximal gc box	[proximal GC box]	1.5849625007211563	3	1	0	0
12517	1520	belong to the Ets-family	[belonging to the Ets-family]	1.5849625007211563	4	1	0	0
12518	1520	Thus, htlv-i tax	[Thus, HTLV-I Tax]	1.5849625007211563	3	1	0	0
12519	1520	deletion of the region	[Deletion of the regions]	1.5849625007211563	4	2	2	2
12520	1520	lack the sugar moiety	[lacking the sugar moiety]	1.5849625007211563	4	1	0	0
12521	1520	human cell differentiation	[human cell differentiation]	1.5849625007211563	3	2	2	2
12522	1520	unusual heterologous syncytia	[unusual heterologous syncytia]	1.5849625007211563	3	1	0	0
12523	1520	rag gene transcription	[RAG gene transcription]	1.5849625007211563	3	1	0	0
12524	1520	transendothelial migration of t-cell	[transendothelial migration of T-cells]	1.5849625007211563	4	1	0	0
12525	1520	monocyte involve hiv	[monocytes involving HIV]	1.5849625007211563	3	1	0	0
12526	1520	precipitation of alpha-globin chain	[precipitation of alpha-globin chains]	1.5849625007211563	4	1	0	0
12527	1520	Kruppel-related zinc finger protein	[Kruppel-related zinc finger proteins]	1.5849625007211563	4	2	2	2
12528	1520	membrane-related rapid response	[membrane-related rapid responses]	1.5849625007211563	3	1	0	0
12529	1520	transactivation potential of Stat6	[transactivation potential of Stat6]	1.5849625007211563	4	1	0	0
12530	1520	inhibit steady state ep<0.05)	[inhibiting steady state (P<0.05)]	1.5849625007211563	4	1	0	0
12531	1520	second gene, mtcp1	[second gene, MTCP1]	1.5849625007211563	3	1	0	0
12532	1520	400-base pair META region	[400-base pair META region]	1.5849625007211563	4	1	0	0
12533	1520	cofactor for gata-binding protein	[cofactor for GATA-binding proteins]	1.5849625007211563	4	1	0	0
12534	1520	il-2ralpha expression on culture	[IL-2Ralpha expression on culture]	1.5849625007211563	4	1	0	0
12535	1520	proliferative response of cd4+	[proliferative responses of CD4+]	1.5849625007211563	4	1	0	0
12536	1520	bm of ST patient	[BM of ST patients]	1.5849625007211563	4	1	0	0
12537	1520	osteoclast -like cell	[osteoclast -like cells]	1.5849625007211563	3	1	0	0
12538	1520	six viral antigen	[six viral antigen]	1.5849625007211563	3	2	2	2
12539	1520	alpha (tnf-alpha) monoclonal antibody	[alpha (TNF-alpha) monoclonal antibody]	1.5849625007211563	4	1	0	0
12540	1520	4 day of costimulation	[4 days of costimulation]	1.5849625007211563	4	1	0	0
12541	1520	nuclear extract with antibody	[nuclear extracts with antibodies]	1.5849625007211563	4	1	0	0
12542	1520	VDR overexpression vector	[VDR overexpression vector]	1.5849625007211563	3	1	0	0
12543	1520	enigma for many	[enigma for many]	1.5849625007211563	3	1	0	0
12544	1520	fetal hb synthesis	[fetal Hb synthesis]	1.5849625007211563	3	1	0	0
12545	1520	signal through cd11b/cd18	[signaling through CD11b/CD18]	1.5849625007211563	3	1	0	0
12546	1520	5, band q34	[5, band q34]	1.5849625007211563	3	1	0	0
12547	1520	VDR retention in pulse	[VDR retention in pulse]	1.5849625007211563	4	1	0	0
12548	1520	human neutrophil elastase	[Human neutrophil elastase]	1.5849625007211563	3	1	0	0
12549	1520	fraction of blood cell	[fraction of blood cells]	1.5849625007211563	4	2	2	2
12550	1520	combination, at noncytoxic concentration	[combination, at noncytoxic concentrations]	1.5849625007211563	4	1	0	0
12551	1520	complete activation programme.	[complete activation programme.]	1.5849625007211563	3	1	0	0
12552	1520	apparent complete remission.	[apparent complete remission.]	1.5849625007211563	3	1	0	0
12553	1520	cytosol of the cells.	[cytosol of the cells.]	1.5849625007211563	4	1	0	0
12554	1520	induction of NF-AT	[induction of NF-AT]	1.5849625007211563	3	1	0	0
12555	1520	affinity for glucocorticosteroids gcs	[affinity for glucocorticosteroids GCS]	1.5849625007211563	4	1	0	0
12556	1520	tumor-draining lymph node LN	[tumor-draining lymph node LN]	1.5849625007211563	4	1	0	0
12557	1520	c-fo to c-jun mrna	[c-fos to c-jun mRNA]	1.5849625007211563	4	1	0	0
12558	1520	p105 nf-kappa b	[p105 NF-kappa B]	1.5849625007211563	3	1	0	0
12559	1520	sampling of venous blood	[sampling of venous blood]	1.5849625007211563	4	1	0	0
12560	1520	CD8 antigen expression	[CD8 antigen expression]	1.5849625007211563	3	1	0	0
12561	1520	Functional myc-max heterodimer	[Functional Myc-Max heterodimer]	1.5849625007211563	3	1	0	0
12562	1520	ability of ifn-beta	[ability of IFN-beta]	1.5849625007211563	3	1	0	0
12563	1520	Bcl-2 expression via Aiolos	[Bcl-2 expression via Aiolos]	1.5849625007211563	4	1	0	0
12564	1520	appearance of NFAT-1 activity	[appearance of NFAT-1 activity]	1.5849625007211563	4	1	0	0
12565	1520	identification of are-containing gene	[identification of ARE-containing genes]	1.5849625007211563	4	1	0	0
12566	1520	population of thymocyte	[population of thymocytes]	1.5849625007211563	3	2	2	2
12567	1520	ms -like disease	[MS -like disease]	1.5849625007211563	3	1	0	0
12568	1520	factor in b cell	[factor in B cells]	1.5849625007211563	4	2	1	1
12569	1520	ets protein Spi-B	[Ets protein Spi-B]	1.5849625007211563	3	1	0	0
12570	1520	combination of gm-csf il-4	[combination of GM-CSF IL-4]	1.5849625007211563	4	1	0	0
12571	1520	inhibit the expression	[inhibiting the expression]	1.5849625007211563	3	2	2	2
12572	1520	oligomerization of CD4	[oligomerization of CD4]	1.5849625007211563	3	1	0	0
12573	1520	second subnuclear domain	[second subnuclear domain]	1.5849625007211563	3	1	0	0
12574	1520	natural thiol antioxidant	[natural thiol antioxidant]	1.5849625007211563	3	2	1	1
12575	1520	vitro dna-binding study	[vitro DNA-binding studies]	1.5849625007211563	3	1	0	0
12576	1520	il-6 promoter activity	[IL-6 promoter activity]	1.5849625007211563	3	2	1	1
12577	1520	complete coding sequence	[complete coding sequence]	1.5849625007211563	3	2	2	2
12578	1520	model for study	[model for studies]	1.5849625007211563	3	2	2	2
12579	1520	physical interaction between tax	[physical interaction between Tax]	1.5849625007211563	4	1	0	0
12580	1520	costimulatory receptor CD28	[costimulatory receptor CD28]	1.5849625007211563	3	1	0	0
12581	1520	hpa abnormality in ptsd	[HPA abnormalities in PTSD]	1.5849625007211563	4	1	0	0
12582	1520	3' utr of VDR	[3' UTR of VDR]	1.5849625007211563	4	1	0	0
12583	1520	density of glucocorticoid receptor	[density of glucocorticoid receptors]	1.5849625007211563	4	1	0	0
12584	1520	V region promoter	[V region promoters]	1.5849625007211563	3	2	1	1
12585	1520	progression to subsequent event	[progression to subsequent events]	1.5849625007211563	4	1	0	0
12586	1520	clinical prognostic factor	[clinical prognostic factors]	1.5849625007211563	3	1	0	0
12587	1520	CArG motif C C[AT]6GG	[CArG motif C C[AT]6GG]	1.5849625007211563	4	1	0	0
12588	1520	more intense T lymphocyte	[more intense T lymphocyte]	1.5849625007211563	4	1	0	0
12589	1520	Epstein-Barr viral DNA	[Epstein-Barr viral DNA]	1.5849625007211563	3	2	2	2
12590	1520	classic MAP- Erk cascade	[classic MAP- Erk cascade]	1.5849625007211563	4	1	0	0
12591	1520	-binding transcription factor	[-binding transcription factor]	1.5849625007211563	3	1	0	0
12592	1520	human polymorphonuclear leukocyte	[human polymorphonuclear leukocytes]	1.5849625007211563	3	1	0	0
12593	1520	MTS1 tumor suppressor gene	[MTS1 tumor suppressor gene]	1.5849625007211563	4	1	0	0
12594	1520	fetal bovine serum-contain medium	[fetal bovine serum-containing medium]	1.5849625007211563	4	1	0	0
12595	1520	cognate ligand of TF	[cognate ligands of TF]	1.5849625007211563	4	1	0	0
12596	1520	various concentration of cortivazol	[various concentrations of cortivazol]	1.5849625007211563	4	1	0	0
12597	1520	PLAP reporter gene	[PLAP reporter gene]	1.5849625007211563	3	1	0	0
12598	1520	activation-induced fas upregulation	[activation-induced Fas upregulation]	1.5849625007211563	3	1	0	0
12599	1520	inhibit nf-kappa b activation	[inhibiting NF-kappa B activation]	1.5849625007211563	4	1	0	0
12600	1520	cell receptor c	[cell receptor C]	1.5849625007211563	3	1	0	0
12601	1520	suggest a potential mechanism	[suggesting a potential mechanism]	1.5849625007211563	4	1	0	0
12602	1520	mitogen-activated protein p38 kinase	[mitogen-activated protein p38 kinase]	1.5849625007211563	4	1	0	0
12603	1520	IL-8 gene induction	[IL-8 gene induction]	1.5849625007211563	3	1	0	0
12604	1520	important respiratory pathogen	[important respiratory pathogen]	1.5849625007211563	3	1	0	0
12605	1520	Recombinant mzf-1 protein	[Recombinant MZF-1 protein]	1.5849625007211563	3	1	0	0
12606	1520	hiv-2 LTR cell activation	[HIV-2 LTR cell activation]	1.5849625007211563	4	1	0	0
12607	1520	healthy human volunteer	[healthy human volunteer]	1.5849625007211563	3	1	0	0
12608	1520	significant negative correlation	[significant negative correlation]	1.5849625007211563	3	2	1	1
12609	1520	alpha 4 line	[alpha 4 lines]	1.5849625007211563	3	1	0	0
12610	1520	other nonhematopoietic cell	[other nonhematopoietic cells]	1.5849625007211563	3	1	0	0
12611	1520	kinetic of immunomodulating activity	[kinetics of immunomodulating activity]	1.5849625007211563	4	1	0	0
12612	1520	Interleukin 2 signal	[Interleukin 2 signaling]	1.5849625007211563	3	1	0	0
12613	1520	response to ro(ssa)	[response to Ro(SSA)]	1.5849625007211563	3	1	0	0
12614	1520	induction of NF-kB	[Induction of NF-kB]	1.5849625007211563	3	1	0	0
12615	1520	major difficulty in determination	[major difficulty in determination]	1.5849625007211563	4	1	0	0
12616	1520	specific nfat binding activity	[specific NFAT binding activity]	1.5849625007211563	4	1	0	0
12617	1520	IL-4 luciferase reporter gene	[IL-4 luciferase reporter gene]	1.5849625007211563	4	1	0	0
12618	1520	quality of support,	[quality of support,]	1.5849625007211563	3	1	0	0
12619	1520	CD28 activation in isolation.	[CD28 activation in isolation.]	1.5849625007211563	4	1	0	0
12620	1520	dominant negative nf-il6 mutant	[dominant negative NF-IL6 mutant]	1.5849625007211563	4	1	0	0
12621	1520	Sephadex LH-20 column	[Sephadex LH-20 column]	1.5849625007211563	3	1	0	0
12622	1520	annexin V protein level	[annexin V protein level]	1.5849625007211563	4	1	0	0
12623	1520	tentative leucine-zipper structure	[tentative leucine-zipper structure]	1.5849625007211563	3	1	0	0
12624	1520	engagement of the molecule	[engagement of the molecules]	1.5849625007211563	4	1	0	0
12625	1520	ca2+ ionophore with PMA	[Ca2+ ionophore with PMA]	1.5849625007211563	4	1	0	0
12626	1520	heat activation step	[heat activation step]	1.5849625007211563	3	1	0	0
12627	1520	CaMKIV/ gr signal	[CaMKIV/ Gr signaling]	1.5849625007211563	3	1	0	0
12628	1520	two transcriptional control element	[two transcriptional control elements]	1.5849625007211563	4	1	0	0
12629	1520	human tcf-1 gene	[human TCF-1 gene]	1.5849625007211563	3	1	0	0
12630	1520	immature b cell	[immature B cells]	1.5849625007211563	3	2	1	1
12631	1520	two DNA sequence	[two DNA sequences]	1.5849625007211563	3	1	0	0
12632	1520	viral transcriptional pattern similar	[viral transcriptional pattern similar]	1.5849625007211563	4	1	0	0
12633	1520	significantly (p 0.05).	[significantly (P 0.05).]	1.5849625007211563	3	1	0	0
12634	1520	autocrine IFN synthesis	[autocrine IFN synthesis]	1.5849625007211563	3	1	0	0
12635	1520	ability of hiv-1	[ability of HIV-1]	1.5849625007211563	3	1	0	0
12636	1520	mammalian protein BSAP	[mammalian protein BSAP]	1.5849625007211563	3	1	0	0
12637	1520	nuclear nf-kappa b activity	[nuclear NF-kappa B activity]	1.5849625007211563	4	2	2	2
12638	1520	regulation of c-myb expression	[regulation of c-myb expression]	1.5849625007211563	4	1	0	0
12639	1520	prb of b cell	[pRB of B cells]	1.5849625007211563	4	1	0	0
12640	1520	early biochemical event	[early biochemical event]	1.5849625007211563	3	1	0	0
12641	1520	objective: many study	[OBJECTIVE: Many studies]	1.5849625007211563	3	1	0	0
12642	1520	human placental cDNA	[human placental cDNA]	1.5849625007211563	3	1	0	0
12643	1520	fibrinous provisional matrix	[fibrinous provisional matrix]	1.5849625007211563	3	1	0	0
12644	1520	presence of other inducers,	[presence of other inducers,]	1.5849625007211563	4	1	0	0
12645	1520	RU-486 (10 microM),	[RU-486 (10 microM),]	1.5849625007211563	3	1	0	0
12646	1520	cytokine with actions.	[cytokines with actions.]	1.5849625007211563	3	1	0	0
12647	1520	fragment span nucleotide -158	[fragment spanning nucleotides -158]	1.5849625007211563	4	1	0	0
12648	1520	response to glucocorticoid therapy	[response to glucocorticoid therapy]	1.5849625007211563	4	2	2	2
12649	1520	tg epsilon26 thymocyte	[tg epsilon26 thymocytes]	1.5849625007211563	3	1	0	0
12650	1520	such as CD80	[such as CD80]	1.5849625007211563	3	1	0	0
12651	1520	regulator of il-5 expression	[regulators of IL-5 expression]	1.5849625007211563	4	1	0	0
12652	1520	naturally occur GRE	[naturally occurring GRE]	1.5849625007211563	3	1	0	0
12653	1520	clinical responsiveness to ifn-alpha	[clinical responsiveness to IFN-alpha]	1.5849625007211563	4	1	0	0
12654	1520	Kinetic study use cytosol	[Kinetic studies using cytosol]	1.5849625007211563	4	1	0	0
12655	1520	hcss in some cases,	[HCSs in some cases,]	1.5849625007211563	4	1	0	0
12656	1520	NF kappa b2 motif	[NF kappa B2 motif]	1.5849625007211563	4	1	0	0
12657	1520	incubation of CLL cell	[incubation of CLL cells]	1.5849625007211563	4	1	0	0
12658	1520	paracrine manner in	[paracrine manner in]	1.5849625007211563	3	1	0	0
12659	1520	mature peripheral T cell	[mature peripheral T cells]	1.5849625007211563	4	2	1	1
12660	1520	halflife of 30 minute	[halflife of 30 min]	1.5849625007211563	4	1	0	0
12661	1520	only slight decreases.	[only slight decreases.]	1.5849625007211563	3	1	0	0
12662	1520	corresponding laboratory mutant	[corresponding laboratory mutants]	1.5849625007211563	3	1	0	0
12663	1520	phosphorylation of creb	[phosphorylation of CREB]	1.5849625007211563	3	2	1	1
12664	1520	9011 500 (post) sites/cell,	[9011 500 (post) sites/cell,]	1.5849625007211563	4	1	0	0
12665	1520	promoter construct with mutation	[Promoter constructs with mutations]	1.5849625007211563	4	1	0	0
12666	1520	tcr signal via NFAT	[TCR signals via NFAT]	1.5849625007211563	4	1	0	0
12667	1520	CRE -contain promoter	[CRE -containing promoter]	1.5849625007211563	3	1	0	0
12668	1520	antibody to PECAM-1	[antibody to PECAM-1]	1.5849625007211563	3	1	0	0
12669	1520	commitment of multipotential progenitor	[commitment of multipotential progenitors]	1.5849625007211563	4	1	0	0
12670	1520	PMA /Iono-stimulated il-2 transcription	[PMA /Iono-stimulated IL-2 transcription]	1.5849625007211563	4	1	0	0
12671	1520	comparable amount of activity	[comparable amounts of activity]	1.5849625007211563	4	1	0	0
12672	1520	protein-DNA interaction important	[protein-DNA interactions important]	1.5849625007211563	3	1	0	0
12673	1520	core binding motif (ayt)gataeatarr	[core binding motif (A/T)GATA(A/G)]	1.5849625007211563	4	1	0	0
12674	1520	metabolite in vitro.	[metabolites in vitro.]	1.5849625007211563	3	1	0	0
12675	1520	three unexpected finding	[three unexpected findings]	1.5849625007211563	3	1	0	0
12676	1520	two molecule of nfatp	[two molecules of NFATp]	1.5849625007211563	4	1	0	0
12677	1520	zap-70 signal function lead	[ZAP-70 signaling function leading]	1.5849625007211563	4	1	0	0
12678	1520	lack of ebna2 mrna	[lack of EBNA2 mRNA]	1.5849625007211563	4	1	0	0
12679	1520	human peripheral T	[human peripheral T]	1.5849625007211563	3	1	0	0
12680	1520	selective ability of c-ErbB	[selective ability of c-ErbB]	1.5849625007211563	4	1	0	0
12681	1520	induction of NF-KB	[Induction of NF-KB]	1.5849625007211563	3	2	1	1
12682	1520	one b element	[one B elements]	1.5849625007211563	3	1	0	0
12683	1520	role of oxidative signalling	[role of oxidative signalling]	1.5849625007211563	4	1	0	0
12684	1520	such as CD48	[such as CD48]	1.5849625007211563	3	1	0	0
12685	1520	DEX condition in	[DEX condition in]	1.5849625007211563	3	1	0	0
12686	1520	presence of estrogen	[presence of estrogen]	1.5849625007211563	3	1	0	0
12687	1520	generation of inflammatory infiltrate	[generation of inflammatory infiltrate]	1.5849625007211563	4	1	0	0
12688	1520	Furthermore, cross-linking of CD30	[Furthermore, cross-linking of CD30]	1.5849625007211563	4	1	0	0
12689	1520	b cell follicle	[B cell follicles]	1.5849625007211563	3	1	0	0
12690	1520	more than 130 kb	[more than 130 kb]	1.5849625007211563	4	2	1	1
12691	1520	stimulation by lipopolysaccharide	[stimulation by lipopolysaccharide]	1.5849625007211563	3	2	1	1
12692	1520	activate the BMRF1 promoter	[activating the BMRF1 promoter]	1.5849625007211563	4	1	0	0
12693	1520	ISRE binding factor	[ISRE binding factors]	1.5849625007211563	3	1	0	0
12694	1520	rpo in L. pneumophila	[rpoS in L. pneumophila]	1.5849625007211563	4	1	0	0
12695	1520	AIDS iblp tumor	[AIDS IBLP tumors]	1.5849625007211563	3	1	0	0
12696	1520	reduction in lymphocyte proliferation	[reduction in lymphocyte proliferation]	1.5849625007211563	4	1	0	0
12697	1520	RA synovial cell	[RA synovial cells]	1.5849625007211563	3	2	1	1
12698	1520	10 control subject	[10 control subjects]	1.5849625007211563	3	2	2	2
12699	1520	human genomic clone	[human genomic clones]	1.5849625007211563	3	1	0	0
12700	1520	hematopoietin/cytokine receptor superfamily	[hematopoietin/cytokine receptor superfamily]	1.5849625007211563	3	1	0	0
12701	1520	addition of anti-cd28 mab	[addition of anti-CD28 mAb]	1.5849625007211563	4	2	1	1
12702	1520	STAT transcription factor	[STAT transcription factor]	1.5849625007211563	3	2	2	2
12703	1520	impairment of function	[impairment of function]	1.5849625007211563	3	2	2	2
12704	1520	X box dna-binding protein	[X box DNA-binding proteins]	1.5849625007211563	4	1	0	0
12705	1520	expression of the /cd25	[expression of the /CD25]	1.5849625007211563	4	1	0	0
12706	1520	contain the DPA promoter	[containing the DPA promoter]	1.5849625007211563	4	1	0	0
12707	1520	normal skin sample	[normal skin samples]	1.5849625007211563	3	1	0	0
12708	1520	LR1 -DNA binding activity	[LR1 -DNA binding activity]	1.5849625007211563	4	2	1	1
12709	1520	megakaryocytic marker glycoprotein iib	[megakaryocytic markers glycoprotein IIb]	1.5849625007211563	4	1	0	0
12710	1520	inhibit protein synthesis	[inhibiting protein synthesis]	1.5849625007211563	3	2	1	1
12711	1520	EKLF-/- adult erythrocyte	[EKLF-/- adult erythrocytes]	1.5849625007211563	3	1	0	0
12712	1520	such as t-prolymphocytic t-pll	[such as T-prolymphocytic T-PLL]	1.5849625007211563	4	1	0	0
12713	1520	kinase in cell extract	[kinase in cell extracts]	1.5849625007211563	4	1	0	0
12714	1520	I-kappa b mrna expression	[I-kappa B mRNA expression]	1.5849625007211563	4	1	0	0
12715	1520	translation-dependent degradation mechanism	[translation-dependent degradation mechanism]	1.5849625007211563	3	1	0	0
12716	1520	mouse erythroleukemia MEL	[mouse erythroleukemia MEL]	1.5849625007211563	3	1	0	0
12717	1520	IL1B promoter fragment	[IL1B promoter fragment]	1.5849625007211563	3	1	0	0
12718	1520	X chromosome inactivation pattern	[X chromosome inactivation patterns]	1.5849625007211563	4	2	1	1
12719	1520	cd19 promoter construct	[CD19 promoter constructs]	1.5849625007211563	3	1	0	0
12720	1520	binding to tafii32	[binding to TAFII32]	1.5849625007211563	3	1	0	0
12721	1520	68.5-kb genomic segment	[68.5-kb genomic segment]	1.5849625007211563	3	1	0	0
12722	1520	include cd3-epsilon knockout mouse	[including CD3-epsilon knockout mice]	1.5849625007211563	4	1	0	0
12723	1520	early activation of nfatp	[early activation of NFATp]	1.5849625007211563	4	1	0	0
12724	1520	nuclei of PAEC	[nuclei of PAEC]	1.5849625007211563	3	1	0	0
12725	1520	phagocytosis of pseudomonas aeruginosa	[phagocytosis of Pseudomonas aeruginosa]	1.5849625007211563	4	2	2	2
12726	1520	normal pbl sample	[normal PBL samples]	1.5849625007211563	3	1	0	0
12727	1520	hormone binding domain,	[hormone binding domain,]	1.5849625007211563	3	1	0	0
12728	1520	TCL1 genomic locus	[TCL1 genomic locus]	1.5849625007211563	3	1	0	0
12729	1520	gene in lymphoid cell	[genes in lymphoid cells]	1.5849625007211563	4	2	1	1
12730	1520	inducible transcriptional activator	[inducible transcriptional activator]	1.5849625007211563	3	2	2	2
12731	1520	nuclear NF-kappa b activity	[nuclear NF-kappa B activity]	1.5849625007211563	4	1	0	0
12732	1520	repression of gata-1 activity	[repression of GATA-1 activity]	1.5849625007211563	4	1	0	0
12733	1520	Syk-deficient dt-40 b cell	[Syk-deficient DT-40 B cells]	1.5849625007211563	4	1	0	0
12734	1520	blood T cell activation	[blood T cell activation]	1.5849625007211563	4	2	2	2
12735	1520	tcp tcp acetate	[TCP TCP acetate]	1.5849625007211563	3	1	0	0
12736	1520	employ ap-1 consensus oligonucleotide	[employing AP-1 consensus oligonucleotides]	1.5849625007211563	4	1	0	0
12737	1520	study of NF-kappaB	[study of NF-kappaB]	1.5849625007211563	3	1	0	0
12738	1520	alteration by E2A-HLF	[alteration by E2A-HLF]	1.5849625007211563	3	1	0	0
12739	1520	hematopoietic progenitor cell line	[hematopoietic progenitor cell line]	1.5849625007211563	4	1	0	0
12740	1520	NF-Y -binding site	[NF-Y -binding site]	1.5849625007211563	3	1	0	0
12741	1520	amplification of cdk4	[amplification of CDK4]	1.5849625007211563	3	1	0	0
12742	1520	phorbol ester-induced monocytic differentiation	[phorbol ester-induced monocytic differentiation]	1.5849625007211563	4	2	1	1
12743	1520	octamer DNA motif present	[octamer DNA motif present]	1.5849625007211563	4	1	0	0
12744	1520	IL3 promoter contain ap-2	[IL3 promoter containing AP-2]	1.5849625007211563	4	1	0	0
12745	1520	normal mouse il-2 enhancer	[normal mouse IL-2 enhancer]	1.5849625007211563	4	1	0	0
12746	1520	effect of PGE2	[effects of PGE2]	1.5849625007211563	3	1	0	0
12747	1520	Furthermore, timp-1 upregulation	[Furthermore, TIMP-1 upregulation]	1.5849625007211563	3	1	0	0
12748	1520	metal response element	[metal response element]	1.5849625007211563	3	1	0	0
12749	1520	Egr-2 (Krox-20); Egr-3	[Egr-2 (Krox-20); Egr-3]	1.5849625007211563	3	1	0	0
12750	1520	vitro primary immune response	[vitro primary immune response]	1.5849625007211563	4	1	0	0
12751	1520	expression in placentae	[expression in placentae]	1.5849625007211563	3	2	2	2
12752	1520	gene expression of tnf-alpha	[gene expression of TNF-alpha]	1.5849625007211563	4	1	0	0
12753	1520	use blot analysis	[using blot analysis]	1.5849625007211563	3	2	2	2
12754	1520	tyrosine phosphorylation of tyk2	[tyrosine phosphorylation of tyk2]	1.5849625007211563	4	2	1	1
12755	1520	phosphatidyl inositol turnover	[phosphatidyl inositol turnover]	1.5849625007211563	3	1	0	0
12756	1520	level of IL-2 event	[level of IL-2 events]	1.5849625007211563	4	1	0	0
12757	1520	direct participation of c-fo	[direct participation of c-Fos]	1.5849625007211563	4	1	0	0
12758	1520	stable replication of episome	[stable replication of episomes]	1.5849625007211563	4	1	0	0
12759	1520	radioligand binding method.	[radioligand binding method.]	1.5849625007211563	3	1	0	0
12760	1520	translocation event per se	[translocation event per se]	1.5849625007211563	4	1	0	0
12761	1520	advance in gene technology	[Advances in gene technology]	1.5849625007211563	4	1	0	0
12762	1520	effect of PMA	[effects of PMA]	1.5849625007211563	3	2	1	1
12763	1520	-bear Jurkat T cell	[-bearing Jurkat T cells]	1.5849625007211563	4	1	0	0
12764	1520	jun1 tumor promoter-responsive element	[jun1 tumor promoter-responsive element]	1.5849625007211563	4	1	0	0
12765	1520	fc epsilonRII cd23	[Fc epsilonRII CD23]	1.5849625007211563	3	1	0	0
12766	1520	saturable binding of [3h]aldosterone	[saturable binding of [3H]aldosterone]	1.5849625007211563	4	1	0	0
12767	1520	bone marrow depression	[bone marrow depression]	1.5849625007211563	3	1	0	0
12768	1520	zymogen plasma factor	[zymogen plasma factor]	1.5849625007211563	3	2	2	2
12769	1520	subset of DNA sequence	[subset of DNA sequences]	1.5849625007211563	4	1	0	0
12770	1520	function of the hGR	[function of the hGR]	1.5849625007211563	4	1	0	0
12771	1520	significant il-2 upon stimulation,	[significant IL-2 upon stimulation,]	1.5849625007211563	4	1	0	0
12772	1520	acute nonlymphocytic leukemia	[acute nonlymphocytic leukemias]	1.5849625007211563	3	1	0	0
12773	1520	immunosuppressive agent cyclosporin a	[immunosuppressive agent cyclosporin A]	1.5849625007211563	4	1	0	0
12774	1520	inefficient DNA replication	[Inefficient DNA replication]	1.5849625007211563	3	1	0	0
12775	1520	transcription of gene important	[transcription of genes important]	1.5849625007211563	4	1	0	0
12776	1520	promoter of some gene	[promoters of some genes]	1.5849625007211563	4	1	0	0
12777	1520	human promonocytic u937 cell	[human promonocytic U937 cells]	1.5849625007211563	4	2	1	1
12778	1520	immune response to adenoviruse	[Immune responses to adenoviruses]	1.5849625007211563	4	1	0	0
12779	1520	nfatp induction of NFATc	[NFATp induction of NFATc]	1.5849625007211563	4	1	0	0
12780	1520	binding of STAT1 homodimer	[binding of STAT1 homodimers]	1.5849625007211563	4	1	0	0
12781	1520	minimal DNA sequence	[minimal DNA sequence]	1.5849625007211563	3	1	0	0
12782	1520	factor kappab NFkappaB	[factor kappaB NFkappaB]	1.5849625007211563	3	2	2	2
12783	1520	interleukin-4-dependent transcription factor	[interleukin-4-dependent transcription factor]	1.5849625007211563	3	1	0	0
12784	1520	(nf-at) target sequence	[(NF-AT) target sequence]	1.5849625007211563	3	1	0	0
12785	1520	increase transcript level	[increasing transcript levels]	1.5849625007211563	3	1	0	0
12786	1520	amount of jak3 present	[amount of JAK3 present]	1.5849625007211563	4	1	0	0
12787	1520	function, m-csf responsiveness	[function, M-CSF responsiveness]	1.5849625007211563	3	1	0	0
12788	1520	use in vitro footprinting	[Using in vitro footprinting]	1.5849625007211563	4	1	0	0
12789	1520	il-10 gene in vitro	[IL-10 genes in vitro]	1.5849625007211563	4	1	0	0
12790	1520	large region 255 nucleotide	[large region 255 nucleotides]	1.5849625007211563	4	1	0	0
12791	1520	release of TNF	[release of TNF]	1.5849625007211563	3	1	0	0
12792	1520	hemoglobin switch in human	[Hemoglobin switching in humans]	1.5849625007211563	4	1	0	0
12793	1520	expression of other gene	[expression of other genes]	1.5849625007211563	4	2	2	2
12794	1520	several neuroendocrine-immune interaction	[Several neuroendocrine-immune interactions]	1.5849625007211563	3	1	0	0
12795	1520	affinity to glucocorticoid	[affinity to glucocorticoids]	1.5849625007211563	3	2	2	2
12796	1520	hl-60 cell line	[HL-60 cell line]	1.5849625007211563	3	1	0	0
12797	1520	component of NF-kappa b	[components of NF-kappa B]	1.5849625007211563	4	2	2	2
12798	1520	receptor concentration in leukocyte	[receptor concentration in leukocytes]	1.5849625007211563	4	2	2	2
12799	1520	h2o2 in human lymphocyte	[H2O2 in human lymphocytes]	1.5849625007211563	4	1	0	0
12800	1520	effect of mitogenic lectins	[effect of mitogenic lectins]	1.5849625007211563	4	1	0	0
12801	1520	tgf-beta growth inhibition	[TGF-beta growth inhibition]	1.5849625007211563	3	2	2	2
12802	1520	loss of tnfrp55 function	[loss of TNFRp55 function]	1.5849625007211563	4	1	0	0
12803	1520	consensus kappa b site	[consensus kappa B site]	1.5849625007211563	4	1	0	0
12804	1520	corticosteroid receptor function	[corticosteroid receptor function]	1.5849625007211563	3	1	0	0
12805	1520	transcriptional activator of gene	[transcriptional activator of genes]	1.5849625007211563	4	2	2	2
12806	1520	exception of LEF1	[exception of LEF1]	1.5849625007211563	3	1	0	0
12807	1520	simultaneous sequential) presence	[simultaneous sequential) presence]	1.5849625007211563	3	1	0	0
12808	1520	il-4 stat6 activity	[IL-4 STAT6 activity]	1.5849625007211563	3	1	0	0
12809	1520	relatively long life span	[relatively longer life span]	1.5849625007211563	4	1	0	0
12810	1520	ccaat/enhancer binding protein	[CCAAT/enhancer binding protein]	1.5849625007211563	3	1	0	0
12811	1520	NFAT family of protein	[NFAT family of proteins]	1.5849625007211563	4	1	0	0
12812	1520	lead to adhesion	[leading to adhesion]	1.5849625007211563	3	2	2	2
12813	1520	series from control	[series from controls]	1.5849625007211563	3	1	0	0
12814	1520	dominant negative regulator	[dominant negative regulator]	1.5849625007211563	3	2	1	1
12815	1520	reduction of cell adhesion	[reduction of cell adhesion]	1.5849625007211563	4	1	0	0
12816	1520	independently up-regulated tgf-beta1 mrna	[independently up-regulated TGF-beta1 mRNA]	1.5849625007211563	4	1	0	0
12817	1520	other epitope in D1	[other epitopes in D1]	1.5849625007211563	4	1	0	0
12818	1520	core-binding factor CBF	[core-binding factor CBF]	1.5849625007211563	3	1	0	0
12819	1520	specific cell-surface receptor	[specific cell-surface receptors]	1.5849625007211563	3	1	0	0
12820	1520	transient ca2+ signal	[transient Ca2+ signals]	1.5849625007211563	3	1	0	0
12821	1520	forkhead protein family	[forkhead protein family]	1.5849625007211563	3	1	0	0
12822	1520	oxidative stress-induced signal	[oxidative stress-induced signals]	1.5849625007211563	3	1	0	0
12823	1520	alpha2 integrin gene	[alpha2 integrin gene]	1.5849625007211563	3	3	2	1
12824	1520	chronic inflammatory condition	[chronic inflammatory conditions]	1.5849625007211563	3	1	0	0
12825	1520	killer (lak) activity	[killer (LAK) activity]	1.5849625007211563	3	1	0	0
12826	1520	suppress hiv replication	[suppressing HIV replication]	1.5849625007211563	3	1	0	0
12827	1520	IL-8 AP-1 B-like site	[IL-8 AP-1 B-like sites]	1.5849625007211563	4	1	0	0
12828	1520	mechanism of alternative rna	[mechanism of alternative RNA]	1.5849625007211563	4	1	0	0
12829	1520	response element for NF-AT	[response element for NF-AT]	1.5849625007211563	4	1	0	0
12830	1520	IL-4 -independent fashion	[IL-4 -independent fashion]	1.5849625007211563	3	1	0	0
12831	1520	10(-7) to 10(-6) mol/L	[10(-7) to 10(-6) mol/L]	1.5849625007211563	4	1	0	0
12832	1520	light zone of center	[light zone of centers]	1.5849625007211563	4	1	0	0
12833	1520	similar, heat labile activity	[similar, heat labile activity]	1.5849625007211563	4	1	0	0
12834	1520	dissociation from cytoplasmic inhibitor	[dissociation from cytoplasmic inhibitor]	1.5849625007211563	4	1	0	0
12835	1520	membrane from Jurkat	[membranes from Jurkat]	1.5849625007211563	3	1	0	0
12836	1520	reduction in susceptibility	[reduction in susceptibility]	1.5849625007211563	3	1	0	0
12837	1520	transcription factor ap-1, nf-kappab	[transcription factors AP-1, NF-kappaB]	1.5849625007211563	4	1	0	0
12838	1520	surrogate" antigen receptor	[surrogate" antigen receptor]	1.5849625007211563	3	1	0	0
12839	1520	autocrine mechanism of growth	[autocrine mechanism of growth]	1.5849625007211563	4	1	0	0
12840	1520	16 CBF beta-myh11 fusion	[16 CBF beta-MYH11 fusion]	1.5849625007211563	4	1	0	0
12841	1520	tcr gene rearrangement	[TCR gene rearrangement]	1.5849625007211563	3	2	2	2
12842	1520	cell from unbound ligand.	[cells from unbound ligand.]	1.5849625007211563	4	1	0	0
12843	1520	developmental stage-specificity of PYBF	[developmental stage-specificity of PYBF]	1.5849625007211563	4	1	0	0
12844	1520	suppression of sla-dr expression	[suppression of SLA-DR expression]	1.5849625007211563	4	1	0	0
12845	1520	certain cns-derived cell	[certain CNS-derived cells]	1.5849625007211563	3	1	0	0
12846	1520	lack interdomain b	[lacking interdomain B]	1.5849625007211563	3	1	0	0
12847	1520	rapid production of il-8	[rapid production of IL-8]	1.5849625007211563	4	1	0	0
12848	1520	synthesis of new protein,	[synthesis of new protein,]	1.5849625007211563	4	1	0	0
12849	1520	presence of interleukin (il)-4	[presence of interleukin (IL)-4]	1.5849625007211563	4	1	0	0
12850	1520	presence of interleukin (il)-2	[presence of interleukin (IL)-2]	1.5849625007211563	4	1	0	0
12851	1520	contain putative ap-2	[containing putative AP-2]	1.5849625007211563	3	1	0	0
12852	1520	second week of treatment	[second week of treatment]	1.5849625007211563	4	1	0	0
12853	1520	expression of fasl protein	[expression of FasL protein]	1.5849625007211563	4	1	0	0
12854	1520	transactivation of nf-at-1	[transactivation of NF-AT-1]	1.5849625007211563	3	1	0	0
12855	1520	DNA binding site GRE	[DNA binding sites GRE]	1.5849625007211563	4	1	0	0
12856	1520	cell-mediated immune response	[cell-mediated immune responses]	1.5849625007211563	3	2	1	1
12857	1520	IL-2 receptor alpha-chain	[IL-2 receptor alpha-chain]	1.5849625007211563	3	1	0	0
12858	1520	CD14 Sp1 site oligonucleotide	[CD14 Sp1 site oligonucleotides]	1.5849625007211563	4	1	0	0
12859	1520	human helper T	[human helper T]	1.5849625007211563	3	1	0	0
12860	1520	such as c-jun expression	[such as c-jun expression]	1.5849625007211563	4	1	0	0
12861	1520	degree of albuminuria	[degree of albuminuria]	1.5849625007211563	3	1	0	0
12862	1520	transactivation domain of e2a	[transactivation domains of E2A]	1.5849625007211563	4	1	0	0
12863	1520	TR beta 1	[TR beta 1]	1.5849625007211563	3	1	0	0
12864	1520	reduction in the binding	[reduction in the binding]	1.5849625007211563	4	1	0	0
12865	1520	immunological marker MHC	[immunological markers MHC]	1.5849625007211563	3	1	0	0
12866	1520	Recently, several group	[Recently, several groups]	1.5849625007211563	3	1	0	0
12867	1520	ets gene family	[ets gene family]	1.5849625007211563	3	1	0	0
12868	1520	binding to corticosteroid receptor	[binding to corticosteroid receptors]	1.5849625007211563	4	1	0	0
12869	1520	observation in the pathophysiology	[observations in the pathophysiology]	1.5849625007211563	4	1	0	0
12870	1520	recombinant full length tf	[recombinant full length TF]	1.5849625007211563	4	1	0	0
12871	1520	tumor necrosis factor-alpha TNF-alpha	[tumor necrosis factor-alpha TNF-alpha]	1.5849625007211563	4	2	2	2
12872	1520	major source of il-4	[major source of IL-4]	1.5849625007211563	4	1	0	0
12873	1520	nuclei of resting	[nuclei of resting]	1.5849625007211563	3	1	0	0
12874	1520	three t-cell proliferation	[three T-cell proliferations]	1.5849625007211563	3	1	0	0
12875	1520	role of receptor motif	[role of receptor motifs]	1.5849625007211563	4	1	0	0
12876	1520	b-cell-specific coactivator oca-b Bob-1	[B-cell-specific coactivator OCA-B Bob-1]	1.5849625007211563	4	1	0	0
12877	1520	estrogen responsive element	[estrogen responsive elements]	1.5849625007211563	3	1	0	0
12878	1520	cascade of molecular event	[cascade of molecular events]	1.5849625007211563	4	1	0	0
12879	1520	seven so-called ankyrin repeat	[seven so-called ankyrin repeats]	1.5849625007211563	4	1	0	0
12880	1520	47 kda sterol	[47 kDa sterol]	1.5849625007211563	3	1	0	0
12881	1520	intracellular receptor ERalpha	[intracellular receptors ERalpha]	1.5849625007211563	3	1	0	0
12882	1520	lack bcl-6 function	[lacking BCL-6 function]	1.5849625007211563	3	1	0	0
12883	1520	delineation of signal pathway	[delineation of signaling pathways]	1.5849625007211563	4	1	0	0
12884	1520	natural immunoglobulin promoter	[natural immunoglobulin promoter]	1.5849625007211563	3	1	0	0
12885	1520	MHC-I signal transduction	[MHC-I signal transduction]	1.5849625007211563	3	1	0	0
12886	1520	three proximal cis-acting element	[three proximal cis-acting elements]	1.5849625007211563	4	1	0	0
12887	1520	model for 135-(oh)2d3 regulation	[model for 1,25-(OH)2D3 regulation]	1.5849625007211563	4	1	0	0
12888	1520	Neutral smase activity	[Neutral SMase activity]	1.5849625007211563	3	1	0	0
12889	1520	nf-kappab activation in Jurkat	[NF-kappaB activation in Jurkat]	1.5849625007211563	4	1	0	0
12890	1520	c-fo protein synthesis	[c-Fos protein synthesis]	1.5849625007211563	3	1	0	0
12891	1520	AP-1 binding protein	[AP-1 binding proteins]	1.5849625007211563	3	1	0	0
12892	1520	particular that encode cytokine	[particular those encoding cytokines]	1.5849625007211563	4	1	0	0
12893	1520	cd95 ligand a step	[CD95 ligand a step]	1.5849625007211563	4	1	0	0
12894	1520	tolerant blood monocyte	[tolerant blood monocytes]	1.5849625007211563	3	1	0	0
12895	1520	subset of lupus patient	[subset of lupus patients]	1.5849625007211563	4	1	0	0
12896	1520	healthy elderly subject	[healthy elderly subjects]	1.5849625007211563	3	1	0	0
12897	1520	Ter erythroid cell	[Ter erythroid cells]	1.5849625007211563	3	2	2	2
12898	1520	functional pafr transcript 1	[functional PAFR transcript 1]	1.5849625007211563	4	1	0	0
12899	1520	putative transcription factor pilot	[putative transcription factor PILOT]	1.5849625007211563	4	1	0	0
12900	1520	rip for nf-kappab activation	[RIP for NF-kappaB activation]	1.5849625007211563	4	1	0	0
12901	1520	absence of nf-y activity	[absence of NF-Y activity]	1.5849625007211563	4	1	0	0
12902	1520	cytokine gene in monocyte	[cytokine genes in monocytes]	1.5849625007211563	4	1	0	0
12903	1520	addition, EL-4 cell	[addition, EL-4 cells]	1.5849625007211563	3	1	0	0
12904	1520	protein with structural similarity	[protein with structural similarities]	1.5849625007211563	4	1	0	0
12905	1520	form of Raf-1	[form of Raf-1]	1.5849625007211563	3	2	2	2
12906	1520	upregulation of Bcl-2	[upregulation of Bcl-2]	1.5849625007211563	3	1	0	0
12907	1520	tyrosine phosphorylation of IFN-gammaR	[Tyrosine phosphorylation of IFN-gammaR]	1.5849625007211563	4	1	0	0
12908	1520	cleavage of caspase-3 substrate	[cleavage of caspase-3 substrates]	1.5849625007211563	4	1	0	0
12909	1520	portion of e2a protein	[portion of E2A proteins]	1.5849625007211563	4	1	0	0
12910	1520	inhibition of IL-12 expression	[inhibition of IL-12 expression]	1.5849625007211563	4	1	0	0
12911	1520	tyrosine kinase Tyk2	[tyrosine kinase Tyk2]	1.5849625007211563	3	1	0	0
12912	1520	gata-3 gene expression	[GATA-3 gene expression]	1.5849625007211563	3	1	0	0
12913	1520	21-66 year (mean	[21-66 yr (mean]	1.5849625007211563	3	1	0	0
12914	1520	specify hematopoietic cell type	[specifying hematopoietic cell types]	1.5849625007211563	4	1	0	0
12915	1520	Epstein-Barr virus gene expression	[Epstein-Barr virus gene expression]	1.5849625007211563	4	2	2	2
12916	1520	antibody against cd45	[antibodies against CD45]	1.5849625007211563	3	1	0	0
12917	1520	two dna-binding motif	[two DNA-binding motifs]	1.5849625007211563	3	1	0	0
12918	1520	manner indistinguishable from tsap	[manner indistinguishable from TSAP]	1.5849625007211563	4	1	0	0
12919	1520	macrophage-differentiation of NB4	[Macrophage-differentiation of NB4]	1.5849625007211563	3	1	0	0
12920	1520	use this approach,	[Using this approach,]	1.5849625007211563	3	1	0	0
12921	1520	IL-5 gene-nonexpress t-cell line	[IL-5 gene-nonexpressing T-cell line]	1.5849625007211563	4	1	0	0
12922	1520	adenovirus E1B 19K gene	[adenovirus E1B 19K gene]	1.5849625007211563	4	1	0	0
12923	1520	reconstitution of functional Rb	[reconstitution of functional Rb]	1.5849625007211563	4	1	0	0
12924	1520	lesion in dlcl pathogenesis	[lesions in DLCL pathogenesis]	1.5849625007211563	4	1	0	0
12925	1520	CCAAT box at bp	[CCAAT box at bp]	1.5849625007211563	4	1	0	0
12926	1520	HIV-2 transcriptional enhancer	[HIV-2 transcriptional enhancer]	1.5849625007211563	3	1	0	0
12927	1520	other immune cell	[other immune cells]	1.5849625007211563	3	1	0	0
12928	1520	induction of NF-IL6 mrna	[induction of NF-IL6 mRNA]	1.5849625007211563	4	1	0	0
12929	1520	expression of gene characteristic	[expression of genes characteristic]	1.5849625007211563	4	1	0	0
12930	1520	present in-vitro experiment	[present in-vitro experiments]	1.5849625007211563	3	1	0	0
12931	1520	TATA box promoter element	[TATA box promoter element]	1.5849625007211563	4	1	0	0
12932	1520	dexamethasone to the gcr	[dexamethasone to the GCR]	1.5849625007211563	4	1	0	0
12933	1520	chronic inflammatory autoimmune disease	[chronic inflammatory autoimmune diseases]	1.5849625007211563	4	1	0	0
12934	1520	detectable involvement of jak1	[detectable involvement of JAK1]	1.5849625007211563	4	1	0	0
12935	1520	local tumor control	[local tumor control]	1.5849625007211563	3	1	0	0
12936	1520	intracellular gsh pool	[intracellular GSH pool]	1.5849625007211563	3	1	0	0
12937	1520	non-malignant reactive lymph node	[non-malignant reactive lymph nodes]	1.5849625007211563	4	1	0	0
12938	1520	complex of fk506	[complex of FK506]	1.5849625007211563	3	1	0	0
12939	1520	serine /threonine protein phosphatase	[serine /threonine protein phosphatases]	1.5849625007211563	4	1	0	0
12940	1520	elevation of intracellular ca2+	[elevation of intracellular Ca2+]	1.5849625007211563	4	1	0	0
12941	1520	E2A- HLF chimera	[E2A- HLF chimeras]	1.5849625007211563	3	1	0	0
12942	1520	il-2 receptor RAR	[IL-2 receptors RAR]	1.5849625007211563	3	1	0	0
12943	1520	monomer in solution.	[monomer in solution.]	1.5849625007211563	3	1	0	0
12944	1520	mutation in one allele	[mutation in one allele]	1.5849625007211563	4	1	0	0
12945	1520	small molecule S9a	[small molecule S9a]	1.5849625007211563	3	1	0	0
12946	1520	time course of appearance	[time course of appearance]	1.5849625007211563	4	1	0	0
12947	1520	huvec to A/R	[HUVECs to A/R]	1.5849625007211563	3	1	0	0
12948	1520	PML-RAR alpha expression	[PML-RAR alpha expression]	1.5849625007211563	3	1	0	0
12949	1520	expression of stat protein	[expression of STAT proteins]	1.5849625007211563	4	1	0	0
12950	1520	gene expression of m-csf	[gene expression of M-CSF]	1.5849625007211563	4	1	0	0
12951	1520	expression of a factor	[expression of a factor]	1.5849625007211563	4	2	2	2
12952	1520	high mobility complex	[higher mobility complex]	1.5849625007211563	3	1	0	0
12953	1520	10.5 4.2 nmol/L	[10.5 4.2 nmol/L]	1.5849625007211563	3	1	0	0
12954	1520	interaction during thymocyte maturation	[interactions during thymocyte maturation]	1.5849625007211563	4	1	0	0
12955	1520	death domain protein tradd	[death domain protein TRADD]	1.5849625007211563	4	1	0	0
12956	1520	nucleus of signal transducer	[nucleus of signal transducers]	1.5849625007211563	4	1	0	0
12957	1520	rapid mitotic rate epithelia	[rapid mitotic rate epithelia]	1.5849625007211563	4	1	0	0
12958	1520	myeloma cell line	[myeloma cell lines]	1.5849625007211563	3	5	4	1
12959	1520	include normal plasma cells,	[including normal plasma cells,]	1.5849625007211563	4	1	0	0
12960	1520	most T lymphocytic cell	[most T lymphocytic cells]	1.5849625007211563	4	1	0	0
12961	1520	line with this conclusion,	[line with this conclusion,]	1.5849625007211563	4	1	0	0
12962	1520	severity of disease,	[severity of disease,]	1.5849625007211563	3	1	0	0
12963	1520	fuse lymphoblastoid cell	[fusing lymphoblastoid cells]	1.5849625007211563	3	1	0	0
12964	1520	gata motif implication	[GATA motifs implications]	1.5849625007211563	3	1	0	0
12965	1520	mature human monocytic cell	[mature human monocytic cells]	1.5849625007211563	4	1	0	0
12966	1520	Recently, cyclin e-cdk2-	[Recently, cyclin E-Cdk2-]	1.5849625007211563	3	1	0	0
12967	1520	diffuse nucleoplasmic localization	[diffuse nucleoplasmic localization]	1.5849625007211563	3	1	0	0
12968	1520	common pathological finding	[common pathological finding]	1.5849625007211563	3	1	0	0
12969	1520	t-cell transformation by HTLV-I	[T-cell transformation by HTLV-I]	1.5849625007211563	4	1	0	0
12970	1520	weak octamer-binding site	[weak octamer-binding site]	1.5849625007211563	3	1	0	0
12971	1520	core promoter region	[core promoter region]	1.5849625007211563	3	1	0	0
12972	1520	addition, electrophoretic mobility shift	[addition, electrophoretic mobility shift]	1.5849625007211563	4	1	0	0
12973	1520	hypothalamo-pituitary-adrenal axis function	[hypothalamo-pituitary-adrenal axis function]	1.5849625007211563	3	1	0	0
12974	1520	order of magnitude	[orders of magnitude]	1.5849625007211563	3	2	2	2
12975	1520	biopsy enter lytic	[biopsies entering lytic]	1.5849625007211563	3	1	0	0
12976	1520	Src kinase inhibitor PP1	[Src kinase inhibitor PP1]	1.5849625007211563	4	1	0	0
12977	1520	appropriate site on DNA.	[appropriate site on DNA.]	1.5849625007211563	4	1	0	0
12978	1520	taci transmembrane activator	[TACI transmembrane activator]	1.5849625007211563	3	1	0	0
12979	1520	more than 3 weeks.	[more than 3 weeks.]	1.5849625007211563	4	1	0	0
12980	1520	six PTT shift	[Six PTT shifts]	1.5849625007211563	3	1	0	0
12981	1520	immunoreceptor tyrosine-based inhibition motif.	[immunoreceptor tyrosine-based inhibition motif.]	1.5849625007211563	4	1	0	0
12982	1520	induce cd14 expression	[inducing CD14 expression]	1.5849625007211563	3	1	0	0
12983	1520	32 healthy aged person	[32 healthy aged persons]	1.5849625007211563	4	1	0	0
12984	1520	other target cells.	[other target cells.]	1.5849625007211563	3	1	0	0
12985	1520	zap-70- dependent signal pathway	[zap-70- dependent signaling pathways]	1.5849625007211563	4	1	0	0
12986	1520	ifn-gamma -produce cell	[IFN-gamma -producing cells]	1.5849625007211563	3	1	0	0
12987	1520	region of high homology	[region of high homology]	1.5849625007211563	4	1	0	0
12988	1520	interferon gamma IFN-gamma	[interferon gamma IFN-gamma]	1.5849625007211563	3	1	0	0
12989	1520	Daidzein glucuronide in vitro	[Daidzein glucuronides in vitro]	1.5849625007211563	4	1	0	0
12990	1520	result of competition experiment	[results of competition experiments]	1.5849625007211563	4	1	0	0
12991	1520	novel immunosuppressive therapy	[novel immunosuppressive therapies]	1.5849625007211563	3	1	0	0
12992	1520	fetal-to-adult globin gene switch	[fetal-to-adult globin gene switching]	1.5849625007211563	4	1	0	0
12993	1520	induction by ultra-violet light	[induction by UV light]	1.5849625007211563	4	1	0	0
12994	1520	means of Northern blot	[means of Northern blots]	1.5849625007211563	4	1	0	0
12995	1520	IL-2 NF-chi b site	[IL-2 NF-chi B site]	1.5849625007211563	4	1	0	0
12996	1520	histone h2b promoter	[histone H2B promoter]	1.5849625007211563	3	1	0	0
12997	1520	Further, M. tuberculosis	[Further, M. tuberculosis]	1.5849625007211563	3	1	0	0
12998	1520	endogenous corticosterone in plasma	[endogenous corticosterone in plasma]	1.5849625007211563	4	1	0	0
12999	1520	series of observation	[series of observations]	1.5849625007211563	3	1	0	0
13000	1520	cd19 ig alpha	[CD19 Ig alpha]	1.5849625007211563	3	1	0	0
13001	1520	protein in lymphoid development	[proteins in lymphoid development]	1.5849625007211563	4	1	0	0
13002	1520	core ets binding site	[core ETS binding site]	1.5849625007211563	4	1	0	0
13003	1520	shp1 on tcr signal	[SHP1 on TCR signaling]	1.5849625007211563	4	1	0	0
13004	1520	chronic kidney failure	[chronic kidney failure]	1.5849625007211563	3	1	0	0
13005	1520	mip-1 alpha expression	[MIP-1 alpha expression]	1.5849625007211563	3	1	0	0
13006	1520	t- cell line	[T- cell lines]	1.5849625007211563	3	2	1	1
13007	1520	stimulation of CD2 activation	[Stimulation of CD2 activation]	1.5849625007211563	4	1	0	0
13008	1520	Neutral sphingomyelinase smase	[Neutral sphingomyelinase SMase]	1.5849625007211563	3	1	0	0
13009	1520	neutralize anti-m-csf antibody	[neutralizing anti-M-CSF antibody]	1.5849625007211563	3	1	0	0
13010	1520	maximal enhancer activity	[maximal enhancer activity]	1.5849625007211563	3	1	0	0
13011	1520	almost identical zinc-finger domain	[almost identical zinc-finger domains]	1.5849625007211563	4	1	0	0
13012	1520	data regard the process	[Data regarding the processes]	1.5849625007211563	4	1	0	0
13013	1520	contrast, c-fo mrna	[contrast, c-fos mRNA]	1.5849625007211563	3	1	0	0
13014	1520	resistance in disorder	[resistance in disorder]	1.5849625007211563	3	2	2	2
13015	1520	cell line, ut-7 epo.	[cell line, UT-7 Epo.]	1.5849625007211563	4	1	0	0
13016	1520	control of hsv infection	[control of HSV infection]	1.5849625007211563	4	1	0	0
13017	1520	2.0-kb region 3'	[2.0-kb region 3']	1.5849625007211563	3	1	0	0
13018	1520	immunodeficiency virus type-1 genome	[immunodeficiency virus type-1 genome]	1.5849625007211563	4	1	0	0
13019	1520	non-erythroid cell type	[non-erythroid cell types]	1.5849625007211563	3	1	0	0
13020	1520	dnase I footprint	[DNAse I footprints]	1.5849625007211563	3	1	0	0
13021	1520	factor present in extract	[factor present in extracts]	1.5849625007211563	4	2	2	2
13022	1520	cell within each category	[Cells within each category]	1.5849625007211563	4	1	0	0
13023	1520	NFAT chloramphenicol acetyltransferase construct	[NFAT chloramphenicol acetyltransferase construct]	1.5849625007211563	4	1	0	0
13024	1520	c-myc -like functional characteristic	[c-myc -like functional characteristics]	1.5849625007211563	4	1	0	0
13025	1520	trend toward intense staining	[trend toward intense staining]	1.5849625007211563	4	1	0	0
13026	1520	capacity of T cell	[capacity of T cells]	1.5849625007211563	4	2	2	2
13027	1520	cyclin a transcription	[Cyclin A transcription]	1.5849625007211563	3	1	0	0
13028	1520	-30 promoter region	[-30 promoter region]	1.5849625007211563	3	1	0	0
13029	1520	very low proliferative activity	[very low proliferative activity]	1.5849625007211563	4	1	0	0
13030	1520	phenotype in this patient,	[phenotype in this patient,]	1.5849625007211563	4	1	0	0
13031	1520	Colinear triplex formation	[Colinear triplex formation]	1.5849625007211563	3	1	0	0
13032	1520	such closely related protein	[such closely related proteins]	1.5849625007211563	4	1	0	0
13033	1520	presence of erythropoietin	[presence of erythropoietin]	1.5849625007211563	3	2	1	1
13034	1520	DNA binding activity,	[DNA binding activity,]	1.5849625007211563	3	1	0	0
13035	1520	DNA binding activity.	[DNA binding activity.]	1.5849625007211563	3	1	0	0
13036	1520	formation of heterokaryon	[formation of heterokaryons]	1.5849625007211563	3	1	0	0
13037	1520	acinar cell damage	[acinar cell damage]	1.5849625007211563	3	1	0	0
13038	1520	nucleus of cell	[nucleus of cells]	1.5849625007211563	3	2	2	2
13039	1520	cell lineage-independent manner	[cell lineage-independent manner]	1.5849625007211563	3	1	0	0
13040	1520	corticosteroid treatment (per cent	[corticosteroid treatment (per cent]	1.5849625007211563	4	1	0	0
13041	1520	glucocorticoid -insensitive asthma	[glucocorticoid -insensitive asthma]	1.5849625007211563	3	1	0	0
13042	1520	minimal lox promoter fragment	[minimal lox promoter fragment]	1.5849625007211563	4	1	0	0
13043	1520	demonstrate the bovine homologue	[demonstrating the bovine homologue]	1.5849625007211563	4	1	0	0
13044	1520	ltr-driven proviral transcription unit	[LTR-driven proviral transcription unit]	1.5849625007211563	4	1	0	0
13045	1520	gene-proximal regulatory element	[gene-proximal regulatory elements]	1.5849625007211563	3	1	0	0
13046	1520	such as myeloid leukemia	[such as myeloid leukemia]	1.5849625007211563	4	1	0	0
13047	1520	protective effect on hepatocyte	[protective effect on hepatocytes]	1.5849625007211563	4	1	0	0
13048	1520	various t(17;19)-bearing leukemia	[various t(17;19)-bearing leukemias]	1.5849625007211563	3	1	0	0
13049	1520	AML1b the domain) protein	[AML1b the domain) proteins]	1.5849625007211563	4	1	0	0
13050	1520	thyroid hormone t3 alone	[Thyroid hormone T3 alone]	1.5849625007211563	4	1	0	0
13051	1520	panoply of cellular change	[panoply of cellular changes]	1.5849625007211563	4	1	0	0
13052	1520	level of degradation.	[level of degradation.]	1.5849625007211563	3	1	0	0
13053	1520	transcription in cells,	[transcription in cells,]	1.5849625007211563	3	1	0	0
13054	1520	host cell genome	[host cell genome]	1.5849625007211563	3	1	0	0
13055	1520	expression of allergy	[expression of allergies]	1.5849625007211563	3	1	0	0
13056	1520	TNF translational regulation	[TNF translational regulation]	1.5849625007211563	3	1	0	0
13057	1520	latter region from cell	[latter region from cells]	1.5849625007211563	4	1	0	0
13058	1520	1.54 0.06 nm (mean	[1.54 0.06 nM (mean]	1.5849625007211563	4	1	0	0
13059	1520	late secretory phase	[late secretory phase]	1.5849625007211563	3	1	0	0
13060	1520	activation domain in yeast	[activation domain in yeast]	1.5849625007211563	4	1	0	0
13061	1520	presence of Aldh1 mrna	[presence of Aldh1 mRNA]	1.5849625007211563	4	1	0	0
13062	1520	nf-at -binding factor	[NF-AT -binding factor]	1.5849625007211563	3	2	2	2
13063	1520	epo -independent, apoptosis subclone	[EPO -independent, apoptosis subclone]	1.5849625007211563	4	1	0	0
13064	1520	hormonal form of 135(oh)2d3	[hormonal form of 1,25(OH)2D3]	1.5849625007211563	4	1	0	0
13065	1520	candidate oncogene bcl-3	[candidate oncogene bcl-3]	1.5849625007211563	3	1	0	0
13066	1520	cognate viral peptide	[cognate viral peptide]	1.5849625007211563	3	1	0	0
13067	1520	separation of specific granule	[separation of specific granules]	1.5849625007211563	4	2	1	1
13068	1520	epitope-tagged nucleolin expression construct	[epitope-tagged nucleolin expression constructs]	1.5849625007211563	4	1	0	0
13069	1520	activity of various protease	[activity of various proteases]	1.5849625007211563	4	1	0	0
13070	1520	evidence for the presence	[evidence for the presence]	1.5849625007211563	4	2	2	2
13071	1520	LMP-1 EBNA-2 response element	[LMP-1 EBNA-2 response element]	1.5849625007211563	4	1	0	0
13072	1520	pyrrolidine dtc pdtc	[pyrrolidine DTC PDTC]	1.5849625007211563	3	1	0	0
13073	1520	fc gamma riiia	[Fc gamma RIIIA]	1.5849625007211563	3	2	2	2
13074	1520	interleukin-2 gene in b-lymphocyte	[interleukin-2 gene in B-lymphocytes]	1.5849625007211563	4	1	0	0
13075	1520	human interferon factor	[Human interferon factor]	1.5849625007211563	3	2	2	2
13076	1520	tolerant murine p388 macrophage	[tolerant murine P388 macrophages]	1.5849625007211563	4	1	0	0
13077	1520	least 30 days.	[least 30 days.]	1.5849625007211563	3	1	0	0
13078	1520	specific cytokine-produce-pduce-pduce-prine-prine-prine-pri effector cell	[specific cytokine-producing effector cells]	1.5849625007211563	4	1	0	0
13079	1520	analysis by Northern blotting	[analysis by Northern blotting]	1.5849625007211563	4	1	0	0
13080	1520	human gamma-globin chain	[human gamma-globin chains]	1.5849625007211563	3	1	0	0
13081	1520	survey of promoter	[survey of promoters]	1.5849625007211563	3	1	0	0
13082	1520	interfere with the shut-down	[interfering with the shut-down]	1.5849625007211563	4	1	0	0
13083	1520	novel class of self-antigen	[novel class of self-antigens]	1.5849625007211563	4	1	0	0
13084	1520	patient of 8)	[patients of 8)]	1.5849625007211563	3	1	0	0
13085	1520	Anti- HBx antibody titer	[Anti- HBx antibody titers]	1.5849625007211563	4	1	0	0
13086	1520	mRNA expression of Smad6	[mRNA expression of Smad6]	1.5849625007211563	4	1	0	0
13087	1520	AP-2 consensus binding sequence	[AP-2 consensus binding sequences]	1.5849625007211563	4	1	0	0
13088	1520	common target of CsA	[common target of CsA]	1.5849625007211563	4	1	0	0
13089	1520	gene encode IL-2	[genes encoding IL-2]	1.5849625007211563	3	1	0	0
13090	1520	decay of vimentin mrna	[decay of vimentin mRNA]	1.5849625007211563	4	1	0	0
13091	1520	NF-kappaB /rel binding site	[NF-kappaB /Rel binding site]	1.5849625007211563	4	1	0	0
13092	1520	autologous de LCL	[autologous DE LCL]	1.5849625007211563	3	1	0	0
13093	1520	identical kinetics, p84	[identical kinetics, p84]	1.5849625007211563	3	1	0	0
13094	1520	cell cycling of cell	[cell cycling of cells]	1.5849625007211563	4	1	0	0
13095	1520	bcl-6 (+)/ syn-1 phenotype	[BCL-6 (+)/ syn-1 phenotype]	1.5849625007211563	4	1	0	0
13096	1520	SH2-deleted Grf40 mutant	[SH2-deleted Grf40 mutant]	1.5849625007211563	3	1	0	0
13097	1520	co-operativity between 9-cis RA	[co-operativity between 9-cis RA]	1.5849625007211563	4	1	0	0
13098	1520	immune function in vitro	[immune functions in vitro]	1.5849625007211563	4	1	0	0
13099	1520	type b ebv	[type B EBV]	1.5849625007211563	3	2	1	1
13100	1520	tegument-specific CD4 t-cell clone	[tegument-specific CD4 T-cell clones]	1.5849625007211563	4	1	0	0
13101	1520	chain- specific mab	[chain- specific mAbs]	1.5849625007211563	3	1	0	0
13102	1520	daughter cell analysis	[daughter cell analysis]	1.5849625007211563	3	1	0	0
13103	1520	risk of myocardial infarction	[risk of myocardial infarction]	1.5849625007211563	4	1	0	0
13104	1520	activation of NK-kappa b	[Activation of NK-kappa B]	1.5849625007211563	4	1	0	0
13105	1520	full gene activity	[full gene activity]	1.5849625007211563	3	1	0	0
13106	1520	effect via phosphorylation	[effects via phosphorylation]	1.5849625007211563	3	2	1	1
13107	1520	stat except Stat2	[STATs except Stat2]	1.5849625007211563	3	1	0	0
13108	1520	induction during monocyte differentiation	[Induction during monocyte differentiation]	1.5849625007211563	4	2	2	2
13109	1520	function of gata-1	[function of GATA-1]	1.5849625007211563	3	2	1	1
13110	1520	addition of CD70 transfectant	[addition of CD70 transfectants]	1.5849625007211563	4	1	0	0
13111	1520	number of laboratory	[number of laboratories]	1.5849625007211563	3	1	0	0
13112	1520	activity of JNK1	[activity of JNK1]	1.5849625007211563	3	1	0	0
13113	1520	tcf-1 alpha activity	[TCF-1 alpha activity]	1.5849625007211563	3	1	0	0
13114	1520	kappay element reporter gene	[kappaY element reporter gene]	1.5849625007211563	4	1	0	0
13115	1520	integrin -dependent adhesive function	[integrin -dependent adhesive function]	1.5849625007211563	4	1	0	0
13116	1520	role of caspase	[role of caspases]	1.5849625007211563	3	1	0	0
13117	1520	corresponding bone marrow	[corresponding bone marrow]	1.5849625007211563	3	1	0	0
13118	1520	METHODS: T cell	[METHODS: T cells]	1.5849625007211563	3	1	0	0
13119	1520	deletion mutant of EBF	[deletion mutants of EBF]	1.5849625007211563	4	1	0	0
13120	1520	action of glucocorticoid	[action of glucocorticoids]	1.5849625007211563	3	2	2	2
13121	1520	autoregulation of receptor expression	[autoregulation of receptor expression]	1.5849625007211563	4	2	2	2
13122	1520	leukemia breakpoint region	[leukemia breakpoint region]	1.5849625007211563	3	1	0	0
13123	1520	putative function of CD28	[putative function of CD28]	1.5849625007211563	4	1	0	0
13124	1520	immunological disease include allergy	[immunological diseases including allergy]	1.5849625007211563	4	1	0	0
13125	1520	elevation of c-jun mrna	[elevation of c-jun mRNA]	1.5849625007211563	4	1	0	0
13126	1520	visceral tsc2 expression	[Visceral TSC2 expression]	1.5849625007211563	3	1	0	0
13127	1520	glucocorticoid resistance in disorder	[glucocorticoid resistance in disorder]	1.5849625007211563	4	2	2	2
13128	1520	human rhabdomyosarcoma cell	[Human rhabdomyosarcoma cells]	1.5849625007211563	3	1	0	0
13129	1520	il-2r beta gamma	[IL-2R beta gamma]	1.5849625007211563	3	1	0	0
13130	1520	46.6% (39.9% of cd3+	[46.6% (39.9% of CD3+]	1.5849625007211563	4	1	0	0
13131	1520	background: Platelet/endothelium interaction	[BACKGROUND: Platelet/endothelium interaction]	1.5849625007211563	3	1	0	0
13132	1520	defective transcription factor	[defective transcription factor]	1.5849625007211563	3	1	0	0
13133	1520	inhibitor of pkc activation	[inhibitors of PKC activation]	1.5849625007211563	4	1	0	0
13134	1520	use selective inhibitor	[Using selective inhibitors]	1.5849625007211563	3	1	0	0
13135	1520	several htlv-i(+) t-cell line	[several HTLV-I(+) T-cell lines]	1.5849625007211563	4	1	0	0
13136	1520	tyrosine phosphorylation of Syk	[tyrosine phosphorylation of Syk]	1.5849625007211563	4	1	0	0
13137	1520	absence of tata motif	[absence of TATA motifs]	1.5849625007211563	4	1	0	0
13138	1520	rapamycin e2f response	[rapamycin E2F responses]	1.5849625007211563	3	1	0	0
13139	1520	similar structural protein sequence	[similar structural protein sequences]	1.5849625007211563	4	1	0	0
13140	1520	k562 erythroleukemia cell	[K562 erythroleukemia cells]	1.5849625007211563	3	2	2	2
13141	1520	inactivation of the	[inactivation of the]	1.5849625007211563	3	1	0	0
13142	1520	different nuclear subvolumes:	[different nuclear subvolumes:]	1.5849625007211563	3	1	0	0
13143	1520	modification of c-myc expression	[modification of c-myc expression]	1.5849625007211563	4	1	0	0
13144	1520	contain the ap-1 -tre	[containing the AP-1 -TRE]	1.5849625007211563	4	1	0	0
13145	1520	fusion with the domain	[fusion with the domain]	1.5849625007211563	4	1	0	0
13146	1520	estradiol in human plasma	[estradiol in human plasma]	1.5849625007211563	4	1	0	0
13147	1520	monocyte stimulus lipopolysaccharide	[monocyte stimulus lipopolysaccharide]	1.5849625007211563	3	1	0	0
13148	1520	rank cytoplasmic tail	[RANK cytoplasmic tail]	1.5849625007211563	3	1	0	0
13149	1520	mouse Th2 clone d10	[mouse Th2 clone D10]	1.5849625007211563	4	1	0	0
13150	1520	induction of hiv-2 transcription	[induction of HIV-2 transcription]	1.5849625007211563	4	1	0	0
13151	1520	mean survival of 9.6	[mean survival of 9.6]	1.5849625007211563	4	1	0	0
13152	1520	gene expression per cell	[gene expression per cell]	1.5849625007211563	4	1	0	0
13153	1520	neutrophil il-8 release	[neutrophil IL-8 release]	1.5849625007211563	3	2	1	1
13154	1520	one constitutive, C2	[one constitutive, C2]	1.5849625007211563	3	1	0	0
13155	1520	one palindrome alone	[one palindrome alone]	1.5849625007211563	3	1	0	0
13156	1520	stimulation with retinoic acid	[stimulation with retinoic acid]	1.5849625007211563	4	2	1	1
13157	1520	circulate des-arg form	[circulating des-Arg form]	1.5849625007211563	3	1	0	0
13158	1520	wnt signal between fibroblast	[Wnt signaling between fibroblasts]	1.5849625007211563	4	1	0	0
13159	1520	-specific genomic phage clone	[-specific genomic phage clones]	1.5849625007211563	4	1	0	0
13160	1520	rapid mutational analysis	[rapid mutational analysis]	1.5849625007211563	3	1	0	0
13161	1520	vitamin d receptor expression	[vitamin D receptor expression]	1.5849625007211563	4	2	1	1
13162	1520	specific expression of CD20	[specific expression of CD20]	1.5849625007211563	4	1	0	0
13163	1520	different stage of differentiation.	[different stages of differentiation.]	1.5849625007211563	4	1	0	0
13164	1520	adenylyl cyclase (ac) cascade	[adenylyl cyclase (AC) cascade]	1.5849625007211563	4	1	0	0
13165	1520	positively control the expression	[positively controlling the expression]	1.5849625007211563	4	1	0	0
13166	1520	virus production by iHIV-1	[virus production by iHIV-1]	1.5849625007211563	4	1	0	0
13167	1520	other NFATp -binding site	[other NFATp -binding sites]	1.5849625007211563	4	2	1	1
13168	1520	lysosomal enzyme activity	[lysosomal enzyme activities]	1.5849625007211563	3	1	0	0
13169	1520	receptor-1 cell-surface protein	[receptor-1 cell-surface protein]	1.5849625007211563	3	1	0	0
13170	1520	absence of GATA-3	[absence of GATA-3]	1.5849625007211563	3	1	0	0
13171	1520	Janus kinase JAK2	[Janus kinase JAK2]	1.5849625007211563	3	2	1	1
13172	1520	Janus kinase JAK3	[Janus kinase JAK3]	1.5849625007211563	3	1	0	0
13173	1520	erythropoietin receptor gene	[erythropoietin receptor gene]	1.5849625007211563	3	2	2	2
13174	1520	I tax protein	[I Tax protein]	1.5849625007211563	3	1	0	0
13175	1520	Janus kinase JAK1	[Janus kinases JAK1]	1.5849625007211563	3	2	1	1
13176	1520	stat protein during growth	[STAT proteins during growth]	1.5849625007211563	4	1	0	0
13177	1520	other transcription factor change	[other transcription factor changes]	1.5849625007211563	4	1	0	0
13178	1520	ic50 of alpha-tcp	[IC50 of alpha-tcp]	1.5849625007211563	3	1	0	0
13179	1520	so-called glucose toxicity	[so-called glucose toxicity]	1.5849625007211563	3	1	0	0
13180	1520	CRE binding protein creb	[CRE binding protein CREB]	1.5849625007211563	4	1	0	0
13181	1520	two ligand for CD28	[two ligands for CD28]	1.5849625007211563	4	2	1	1
13182	1520	up-regulation in T cell	[up-regulation in T cells]	1.5849625007211563	4	2	2	2
13183	1520	total human DNA	[total human DNA]	1.5849625007211563	3	1	0	0
13184	1520	lymphocyte-specific negative regulation	[lymphocyte-specific negative regulation]	1.5849625007211563	3	1	0	0
13185	1520	lipoprotein of treponema pallidum	[lipoproteins of Treponema pallidum]	1.5849625007211563	4	1	0	0
13186	1520	mature b lymphocyte	[mature B lymphocytes]	1.5849625007211563	3	2	1	1
13187	1520	induction of nf-kb-related factor	[induction of NF-KB-related factors]	1.5849625007211563	4	1	0	0
13188	1520	bind activity of ap-1	[binding activity of AP-1]	1.5849625007211563	4	1	0	0
13189	1520	RB -defective cell	[RB -defective cells]	1.5849625007211563	3	1	0	0
13190	1520	71 receptor per cell),	[71 receptors per cell),]	1.5849625007211563	4	1	0	0
13191	1520	Janus kinase -stat pathway	[Janus kinase -STAT pathway]	1.5849625007211563	4	1	0	0
13192	1520	peak content of arsenic	[peak content of arsenic]	1.5849625007211563	4	1	0	0
13193	1520	serine protease xa	[serine protease Xa]	1.5849625007211563	3	1	0	0
13194	1520	4-trifluoromethyl derivative of salicylate	[4-trifluoromethyl derivatives of salicylate]	1.5849625007211563	4	1	0	0
13195	1520	strikingly high frequency.	[strikingly high frequency.]	1.5849625007211563	3	1	0	0
13196	1520	such target gene	[such target genes]	1.5849625007211563	3	1	0	0
13197	1520	level of ikappabalpha	[level of IkappaBalpha]	1.5849625007211563	3	1	0	0
13198	1520	MTCP1 locus configuration	[MTCP1 locus configuration]	1.5849625007211563	3	1	0	0
13199	1520	contrast, U-937 cell	[contrast, U-937 cells]	1.5849625007211563	3	1	0	0
13200	1520	late time (12-24 h)	[later times (12-24 h)]	1.5849625007211563	4	1	0	0
13201	1520	icam-1 mrna expression	[ICAM-1 mRNA expression]	1.5849625007211563	3	2	1	1
13202	1520	functional interaction between PML	[functional interaction between PML]	1.5849625007211563	4	1	0	0
13203	1520	certain growth factor	[certain growth factors]	1.5849625007211563	3	2	1	1
13204	1520	same promoter element	[same promoter element]	1.5849625007211563	3	1	0	0
13205	1520	jurkat t-cell in b-cell	[Jurkat T-cells in B-cells]	1.5849625007211563	4	1	0	0
13206	1520	interaction of holo- TFIIA	[interaction of holo- TFIIA]	1.5849625007211563	4	1	0	0
13207	1520	androgen receptor mrna	[Androgen receptor mRNA]	1.5849625007211563	3	1	0	0
13208	1520	expression of endothelial icam-1	[expression of endothelial ICAM-1]	1.5849625007211563	4	1	0	0
13209	1520	screen cDNA library	[screening cDNA libraries]	1.5849625007211563	3	1	0	0
13210	1520	active treatment period	[active treatment period]	1.5849625007211563	3	1	0	0
13211	1520	I kappa b	[I kappa B]	1.5849625007211563	3	1	0	0
13212	1520	expression of c-myc	[expression of c-myc]	1.5849625007211563	3	2	1	1
13213	1520	C-terminal acidic domain	[C-terminal acidic domain]	1.5849625007211563	3	2	1	1
13214	1520	upstream beta globin sequence	[upstream beta globin sequence]	1.5849625007211563	4	1	0	0
13215	1520	genome [Noteborn J.	[genome [Noteborn J.]	1.5849625007211563	3	1	0	0
13216	1520	C-terminal TA1 transactivation domain	[C-terminal TA1 transactivation domain]	1.5849625007211563	4	1	0	0
13217	1520	use protein fraction	[using protein fractions]	1.5849625007211563	3	1	0	0
13218	1520	nuclear matrix preparation	[nuclear matrix preparations]	1.5849625007211563	3	2	1	1
13219	1520	induction of p27(kip1) protein	[induction of p27(KIP1) protein]	1.5849625007211563	4	1	0	0
13220	1520	regulation of Ca2+	[Regulation of Ca2+]	1.5849625007211563	3	1	0	0
13221	1520	il-2r alpha by TG	[IL-2R alpha by TG]	1.5849625007211563	4	1	0	0
13222	1520	least two X1-specific factor	[least two X1-specific factors]	1.5849625007211563	4	1	0	0
13223	1520	IL-2 mrna induction	[IL-2 mRNA induction]	1.5849625007211563	3	1	0	0
13224	1520	mechanism of corticosteroid resistance	[mechanism of corticosteroid resistance]	1.5849625007211563	4	1	0	0
13225	1520	response to treatment.	[response to treatment.]	1.5849625007211563	3	1	0	0
13226	1520	increase in vimentin level	[increase in vimentin levels]	1.5849625007211563	4	1	0	0
13227	1520	level of amplification	[levels of amplification]	1.5849625007211563	3	2	2	2
13228	1520	contribute to the phenotype	[contributing to the phenotype]	1.5849625007211563	4	1	0	0
13229	1520	VDR creatinine value	[VDR creatinine values]	1.5849625007211563	3	1	0	0
13230	1520	8.3 kilobasis 5'	[8.3 kilobases 5']	1.5849625007211563	3	1	0	0
13231	1520	NFAT-1 nuclear protein complex	[NFAT-1 nuclear protein complexes]	1.5849625007211563	4	1	0	0
13232	1520	stimulation with mitogen	[stimulation with mitogens]	1.5849625007211563	3	2	1	1
13233	1520	HIV1 tat gene	[HIV1 tat gene]	1.5849625007211563	3	1	0	0
13234	1520	contrast to culture	[contrast to cultures]	1.5849625007211563	3	1	0	0
13235	1520	interleukin-1 receptor il-1r	[interleukin-1 receptor IL-1R]	1.5849625007211563	3	1	0	0
13236	1520	1 to 14 years.	[1 to 14 years.]	1.5849625007211563	4	1	0	0
13237	1520	LEF-1 hmg protein	[LEF-1 HMG protein]	1.5849625007211563	3	1	0	0
13238	1520	c/ebpalpha -dependent transcription,	[C/EBPalpha -dependent transcription,]	1.5849625007211563	3	1	0	0
13239	1520	b cell activation marker	[B cell activation markers]	1.5849625007211563	4	1	0	0
13240	1520	follow biological stimulation.	[following biological stimulation.]	1.5849625007211563	3	1	0	0
13241	1520	il-4 DNA synthesis	[IL-4 DNA synthesis]	1.5849625007211563	3	1	0	0
13242	1520	hiv-2 gene expression	[HIV-2 gene expression]	1.5849625007211563	3	2	1	1
13243	1520	onset of proliferation, level	[onset of proliferation, levels]	1.5849625007211563	4	1	0	0
13244	1520	NF-kappa b -binding complex	[NF-kappa B -binding complexes]	1.5849625007211563	4	1	0	0
13245	1520	process generate the diversity	[processes generating the diversity]	1.5849625007211563	4	1	0	0
13246	1520	cell with nuclear staining	[cells with nuclear staining]	1.5849625007211563	4	1	0	0
13247	1520	tax induction of nf-kappab	[Tax induction of NF-kappaB]	1.5849625007211563	4	2	1	1
13248	1520	cytoplasmic subunit of nf-at	[cytoplasmic subunit of NF-AT]	1.5849625007211563	4	1	0	0
13249	1520	NF-kappa b elevation	[NF-kappa B elevation]	1.5849625007211563	3	1	0	0
13250	1520	il-4 signal for generation	[IL-4 signal for generation]	1.5849625007211563	4	1	0	0
13251	1520	disorder of the water	[disorders of the water]	1.5849625007211563	4	2	2	2
13252	1520	only in monocyte	[only in monocytes]	1.5849625007211563	3	1	0	0
13253	1520	cellular response to serum	[cellular response to serum]	1.5849625007211563	4	1	0	0
13254	1520	CKII site in SM	[CKII site in SM]	1.5849625007211563	4	1	0	0
13255	1520	expression from the down-regulation,	[expression from the down-regulation,]	1.5849625007211563	4	1	0	0
13256	1520	positive regulatory region	[positive regulatory region]	1.5849625007211563	3	2	2	2
13257	1520	Tat mutant contain ltr	[Tat mutants containing LTRs]	1.5849625007211563	4	1	0	0
13258	1520	interleukin-1 beta mrna level	[interleukin-1 beta mRNA levels]	1.5849625007211563	4	1	0	0
13259	1520	human b cell function	[human B cell functions]	1.5849625007211563	4	1	0	0
13260	1520	beta-like globin cluster	[beta-like globin cluster]	1.5849625007211563	3	1	0	0
13261	1520	(high affinity, low capacity)	[(high affinity, low capacity)]	1.5849625007211563	4	1	0	0
13262	1520	immediate early gene c-jun	[immediate early gene c-jun]	1.5849625007211563	4	1	0	0
13263	1520	one gt motif,	[one GT motif,]	1.5849625007211563	3	1	0	0
13264	1520	tumor necrosis factor-alpha production	[tumor necrosis factor-alpha production]	1.5849625007211563	4	1	0	0
13265	1520	normal adult peripheral blood	[normal adult peripheral blood]	1.5849625007211563	4	1	0	0
13266	1520	adenovirus 5 ad5 infection	[adenovirus 5 Ad5 infection]	1.5849625007211563	4	1	0	0
13267	1520	role of cytokine	[roles of cytokines]	1.5849625007211563	3	1	0	0
13268	1520	tre -DNA fragment	[TRE -DNA fragment]	1.5849625007211563	3	1	0	0
13269	1520	morphologically apoptotic change	[morphologically apoptotic changes]	1.5849625007211563	3	1	0	0
13270	1520	cytosolic component of NF-ATc	[cytosolic component of NF-ATc]	1.5849625007211563	4	1	0	0
13271	1520	variant with exon	[Variants with exon]	1.5849625007211563	3	2	2	2
13272	1520	octamer site 4X NF-AT-Oct	[octamer site 4X NF-AT-Oct]	1.5849625007211563	4	1	0	0
13273	1520	26S proteasome complex	[26S proteasome complex]	1.5849625007211563	3	1	0	0
13274	1520	peripheral blood lymphocyte PBL	[peripheral blood lymphocytes PBL]	1.5849625007211563	4	2	1	1
13275	1520	upstream NF-kappaB site	[upstream NF-kappaB site]	1.5849625007211563	3	1	0	0
13276	1520	heterodimeric binding partner,	[heterodimeric binding partner,]	1.5849625007211563	3	1	0	0
13277	1520	vivo regulatory mechanism	[vivo regulatory mechanisms]	1.5849625007211563	3	1	0	0
13278	1520	first 12 amino acid	[first 12 amino acids]	1.5849625007211563	4	1	0	0
13279	1520	significant proportion of control	[significant proportion of controls]	1.5849625007211563	4	1	0	0
13280	1520	period of 5 years.	[period of 5 years.]	1.5849625007211563	4	1	0	0
13281	1520	different set of epitope	[different set of epitopes]	1.5849625007211563	4	1	0	0
13282	1520	constitutive nuclear factor	[constitutive nuclear factor]	1.5849625007211563	3	1	0	0
13283	1520	promoter for several marker	[promoters for several markers]	1.5849625007211563	4	2	2	2
13284	1520	present studies, rat lung	[present studies, rat lungs]	1.5849625007211563	4	1	0	0
13285	1520	adhesion molecule in ECs	[adhesion molecules in ECs]	1.5849625007211563	4	1	0	0
13286	1520	tnf-alpha signal pathway lead	[TNF-alpha signaling pathways leading]	1.5849625007211563	4	1	0	0
13287	1520	other tyrosine kinase receptor	[other tyrosine kinase receptors]	1.5849625007211563	4	1	0	0
13288	1520	role of kappab-responsive element	[role of kappaB-responsive elements]	1.5849625007211563	4	1	0	0
13289	1520	several new 4,19-substituted steroid	[Several new 4,19-substituted steroids]	1.5849625007211563	4	1	0	0
13290	1520	CD4 transduction pathway	[CD4 transduction pathway]	1.5849625007211563	3	1	0	0
13291	1520	role of nf-kappab	[role of NF-kappaB]	1.5849625007211563	3	2	2	2
13292	1520	PyG box mutation	[PyG box mutation]	1.5849625007211563	3	1	0	0
13293	1520	cdc42 -like fashion	[Cdc42 -like fashion]	1.5849625007211563	3	1	0	0
13294	1520	action of Sp1urday	[action of Sp1-]	1.5849625007211563	3	1	0	0
13295	1520	child with severe immunodeficiency	[child with severe immunodeficiency]	1.5849625007211563	4	1	0	0
13296	1520	novel il-10 stat protein	[novel IL-10 STAT protein]	1.5849625007211563	4	1	0	0
13297	1520	formation of complex a	[Formation of complex a]	1.5849625007211563	4	1	0	0
13298	1520	cd44 markedly vcam-1 expression	[CD44 markedly VCAM-1 expression]	1.5849625007211563	4	1	0	0
13299	1520	kind of cell	[kinds of cells]	1.5849625007211563	3	2	2	2
13300	1520	activator of NF-kappaB	[activator of NF-kappaB]	1.5849625007211563	3	2	2	2
13301	1520	individual reactivity of choice;	[individual reactivity of choice;]	1.5849625007211563	4	1	0	0
13302	1520	contribution of this alteration	[contribution of these alterations]	1.5849625007211563	4	1	0	0
13303	1520	inducible no synthase	[inducible NO synthase]	1.5849625007211563	3	1	0	0
13304	1520	other model system	[other model systems]	1.5849625007211563	3	1	0	0
13305	1520	soluble il-6 receptor	[soluble IL-6 receptor]	1.5849625007211563	3	1	0	0
13306	1520	nuclear body in erythroblast	[nuclear bodies in erythroblasts]	1.5849625007211563	4	1	0	0
13307	1520	molecular weight 49	[molecular weight 49]	1.5849625007211563	3	1	0	0
13308	1520	cooperativity between 9-cis RA	[cooperativities between 9-cis RA]	1.5849625007211563	4	1	0	0
13309	1520	observations, reticulocyte lysate	[observations, reticulocyte lysate]	1.5849625007211563	3	1	0	0
13310	1520	endogenous 1,25-dihydroxyvitamin d	[endogenous 1,25-dihydroxyvitamin D]	1.5849625007211563	3	1	0	0
13311	1520	human DPA gene	[human DPA gene]	1.5849625007211563	3	1	0	0
13312	1520	normal protein mds1/evi1	[normal protein MDS1/EVI1]	1.5849625007211563	3	2	1	1
13313	1520	transcription of the interleukin-2	[transcription of the interleukin-2]	1.5849625007211563	4	1	0	0
13314	1520	two megakaryocytic-specific gene	[two megakaryocytic-specific genes]	1.5849625007211563	3	1	0	0
13315	1520	vitality of lymphoid cell	[vitality of lymphoid cells]	1.5849625007211563	4	1	0	0
13316	1520	positive reaction for HER-2/neu	[positive reactions for HER-2/neu]	1.5849625007211563	4	1	0	0
13317	1520	mrna of pAT 225/EGR1	[mRNA of pAT 225/EGR1]	1.5849625007211563	4	1	0	0
13318	1520	cis-acting element p sequence	[cis-acting element P sequence]	1.5849625007211563	4	1	0	0
13319	1520	less extent fra-1	[lesser extent Fra-1]	1.5849625007211563	3	1	0	0
13320	1520	tyrosine phosphorylation of Vav	[tyrosine phosphorylation of Vav]	1.5849625007211563	4	1	0	0
13321	1520	such as atherosclerosis	[such as atherosclerosis]	1.5849625007211563	3	2	2	2
13322	1520	new isoform, nfatc.beta	[new isoform, NFATc.beta]	1.5849625007211563	3	1	0	0
13323	1520	p50/p50 kbf1 factor	[p50/p50 KBF1 factor]	1.5849625007211563	3	1	0	0
13324	1520	use luciferase reporter construct	[using luciferase reporter constructs]	1.5849625007211563	4	1	0	0
13325	1520	expression of this oncogene	[expression of these oncogenes]	1.5849625007211563	4	1	0	0
13326	1520	divergent effect of LSF	[divergent effects of LSF]	1.5849625007211563	4	1	0	0
13327	1520	potent immunosuppressive agent	[potent immunosuppressive agents]	1.5849625007211563	3	2	1	1
13328	1520	induction by virus	[induction by virus]	1.5849625007211563	3	1	0	0
13329	1520	degree of immunodeficiency	[degree of immunodeficiency]	1.5849625007211563	3	1	0	0
13330	1520	one group of individual	[one group of individuals]	1.5849625007211563	4	1	0	0
13331	1520	human il-2r alpha promoter	[human IL-2R alpha promoter]	1.5849625007211563	4	1	0	0
13332	1520	t-cell receptor gene activation	[T-cell receptor gene activation]	1.5849625007211563	4	1	0	0
13333	1520	nuclear appearance of NF-MATp35	[nuclear appearance of NF-MATp35]	1.5849625007211563	4	1	0	0
13334	1520	distinct sequence-specific protein	[distinct sequence-specific proteins]	1.5849625007211563	3	1	0	0
13335	1520	other cell surface interaction	[other cell surface interactions]	1.5849625007211563	4	1	0	0
13336	1520	stable integration into chromatin	[stable integration into chromatin]	1.5849625007211563	4	1	0	0
13337	1520	proteasome inhibitor mg-132	[proteasome inhibitor MG-132]	1.5849625007211563	3	1	0	0
13338	1520	nf-kappa b [g.nabel	[NF-kappa B [G.Nabel]	1.5849625007211563	3	1	0	0
13339	1520	hiv plasmid construct	[HIV plasmid constructs]	1.5849625007211563	3	1	0	0
13340	1520	IL-1 beta gene	[IL-1 beta gene]	1.5849625007211563	3	2	1	1
13341	1520	Ikaros gene in development	[Ikaros gene in development]	1.5849625007211563	4	1	0	0
13342	1520	key transcription factor	[key transcription factor]	1.5849625007211563	3	2	1	1
13343	1520	use neutralize anti-TNF-alpha antibody	[using neutralizing anti-TNF-alpha antibodies]	1.5849625007211563	4	1	0	0
13344	1520	octanucleotide promoter element ATGCAAAT	[octanucleotide promoter element ATGCAAAT]	1.5849625007211563	4	1	0	0
13345	1520	autoimmune rheumatic disease	[autoimmune rheumatic disease]	1.5849625007211563	3	1	0	0
13346	1520	rakfkqllq -specific CTL	[RAKFKQLLQ -specific CTL]	1.5849625007211563	3	1	0	0
13347	1520	pro-B cell stage	[pro-B cell stage]	1.5849625007211563	3	2	1	1
13348	1520	egr-1 expression vector	[egr-1 expression vector]	1.5849625007211563	3	1	0	0
13349	1520	mixture of tumor cell	[mixture of tumor cells]	1.5849625007211563	4	1	0	0
13350	1520	loss in viability,	[loss in viability,]	1.5849625007211563	3	1	0	0
13351	1520	immunodeficiency syndrome patient	[immunodeficiency syndrome patients]	1.5849625007211563	3	1	0	0
13352	1520	closely related, cell	[closely related, cells]	1.5849625007211563	3	1	0	0
13353	1520	site near the C-terminus	[site near the C-terminus]	1.5849625007211563	4	1	0	0
13354	1520	cr of plasma cortisol	[CR of plasma cortisol]	1.5849625007211563	4	1	0	0
13355	1520	0.84 nmol/l, control	[0.84 nmol/l, control]	1.5849625007211563	3	1	0	0
13356	1520	nf-il-6 binding activity	[NF-IL-6 binding activity]	1.5849625007211563	3	1	0	0
13357	1520	S1T cell line	[S1T cell lines]	1.5849625007211563	3	1	0	0
13358	1520	common gamma chain gene	[common gamma chain gene]	1.5849625007211563	4	1	0	0
13359	1520	Addition of tpa	[Addition of TPA]	1.5849625007211563	3	1	0	0
13360	1520	reactivity toward stat-specific antisera	[reactivities toward Stat-specific antisera]	1.5849625007211563	4	1	0	0
13361	1520	ebv lmp-1 protein	[EBV LMP-1 protein]	1.5849625007211563	3	1	0	0
13362	1520	vitro bandshift assay	[vitro bandshift assays]	1.5849625007211563	3	1	0	0
13363	1520	virtue of the presence	[virtue of the presence]	1.5849625007211563	4	1	0	0
13364	1520	many viral gene	[many viral genes]	1.5849625007211563	3	1	0	0
13365	1520	addition to transcriptional activation	[addition to transcriptional activation]	1.5849625007211563	4	1	0	0
13366	1520	functional domain of HS-40	[functional domains of HS-40]	1.5849625007211563	4	1	0	0
13367	1520	incubation of nuclear extract	[incubation of nuclear extracts]	1.5849625007211563	4	2	1	1
13368	1520	p80c-rel a proto-oncogene belong	[p80c-rel a proto-oncogene belonging]	1.5849625007211563	4	1	0	0
13369	1520	transcriptional activity of NFAT	[transcriptional activities of NFAT]	1.5849625007211563	4	1	0	0
13370	1520	pbmc from healthy subject	[PBMC from healthy subjects]	1.5849625007211563	4	1	0	0
13371	1520	potent activator of NF-kappaB	[potent activators of NF-kappaB]	1.5849625007211563	4	1	0	0
13372	1520	cellular uptake of lps	[cellular uptake of LPS]	1.5849625007211563	4	1	0	0
13373	1520	DNaseI footprinting assay	[DNaseI footprinting assays]	1.5849625007211563	3	1	0	0
13374	1520	(hsf2) DNA binding activity	[(HSF2) DNA binding activity]	1.5849625007211563	4	1	0	0
13375	1520	infection by oncogenic herpesviruse	[infections by oncogenic herpesviruses]	1.5849625007211563	4	1	0	0
13376	1520	consequence of myeloid differentiation	[consequence of myeloid differentiation]	1.5849625007211563	4	1	0	0
13377	1520	eosinophil in all donors.	[eosinophils in all donors.]	1.5849625007211563	4	1	0	0
13378	1520	modulation of this event	[Modulation of these events]	1.5849625007211563	4	1	0	0
13379	1520	multiple gata-binding protein	[multiple GATA-binding proteins]	1.5849625007211563	3	1	0	0
13380	1520	effect RAR beta	[effect RAR beta]	1.5849625007211563	3	1	0	0
13381	1520	recombinant human nm23 -h1	[recombinant human nm23 -H1]	1.5849625007211563	4	1	0	0
13382	1520	RJ 2.2.5 cell	[RJ 2.2.5 cells]	1.5849625007211563	3	1	0	0
13383	1520	strand conformation polymorphism analysis	[strand conformation polymorphism analysis]	1.5849625007211563	4	2	2	2
13384	1520	expression of cdk inhibitor	[expression of cdk inhibitors]	1.5849625007211563	4	1	0	0
13385	1520	estrogen receptor-related protein"	[estrogen receptor-related protein"]	1.5849625007211563	3	1	0	0
13386	1520	serum-independent HL60 cell line	[serum-independent HL60 cell line]	1.5849625007211563	4	1	0	0
13387	1520	nonlymphoid tumor like KS	[nonlymphoid tumors like KS]	1.5849625007211563	4	1	0	0
13388	1520	pc4 usa-derived component	[PC4 USA-derived component]	1.5849625007211563	3	1	0	0
13389	1520	determine T cell development	[determining T cell development]	1.5849625007211563	4	1	0	0
13390	1520	12-o-tetradecanoyl-phorbol-13-acetate tpa ca(2+) signal	[12-O-tetradecanoyl-phorbol-13-acetate TPA Ca(2+) signals]	1.5849625007211563	4	1	0	0
13391	1520	effectiveness of this approach	[effectiveness of this approach]	1.5849625007211563	4	1	0	0
13392	1520	human intestinal xenograft	[human intestinal xenografts]	1.5849625007211563	3	1	0	0
13393	1520	oncogenic E2A-HLF fusion protein	[oncogenic E2A-HLF fusion protein]	1.5849625007211563	4	1	0	0
13394	1520	human lcr/gamma-globin gene	[human LCR/gamma-globin gene]	1.5849625007211563	3	1	0	0
13395	1520	highly cell-specific manner,	[highly cell-specific manner,]	1.5849625007211563	3	1	0	0
13396	1520	fmol/mg of cytosolic protein	[fmol/mg of cytosolic protein]	1.5849625007211563	4	1	0	0
13397	1520	downstream effector of p21ras	[downstream effector of p21ras]	1.5849625007211563	4	1	0	0
13398	1520	DNA precursor pathway enzyme	[DNA precursor pathway enzyme]	1.5849625007211563	4	1	0	0
13399	1520	pretreatment with IL-10	[pretreatment with IL-10]	1.5849625007211563	3	1	0	0
13400	1520	addition, mild detergent treatment	[addition, mild detergent treatment]	1.5849625007211563	4	1	0	0
13401	1520	central role for CaMKIV/Gr	[central role for CaMKIV/Gr]	1.5849625007211563	4	1	0	0
13402	1520	xeroderma pigmentosum group b	[xeroderma pigmentosum group B]	1.5849625007211563	4	2	1	1
13403	1520	particular, proinflammatory cytokine	[particular, proinflammatory cytokines]	1.5849625007211563	3	1	0	0
13404	1520	infectivity of human erythrocyte	[infectivity of human erythrocytes]	1.5849625007211563	4	2	1	1
13405	1520	have zinc finger motif	[having zinc finger motifs]	1.5849625007211563	4	1	0	0
13406	1520	t-cell transcription factor nfat	[T-cell transcription factor NFAT]	1.5849625007211563	4	1	0	0
13407	1520	basic domain-helix-loop-helix protein	[basic domain-helix-loop-helix protein]	1.5849625007211563	3	1	0	0
13408	1520	other open-reading frame	[other open-reading frames]	1.5849625007211563	3	1	0	0
13409	1520	human il-4r alpha	[human IL-4R alpha]	1.5849625007211563	3	1	0	0
13410	1520	antiglucocorticoid property of RU486	[antiglucocorticoid properties of RU486]	1.5849625007211563	4	1	0	0
13411	1520	prior to the injection	[prior to the injection]	1.5849625007211563	4	1	0	0
13412	1520	human thrombospondin 1 gene	[human thrombospondin 1 gene]	1.5849625007211563	4	1	0	0
13413	1520	other CNS disease state	[other CNS disease states]	1.5849625007211563	4	1	0	0
13414	1520	first demonstration in vivo	[first demonstration in vivo]	1.5849625007211563	4	1	0	0
13415	1520	enhancer/ promoter combination	[enhancer/ promoter combination]	1.5849625007211563	3	1	0	0
13416	1520	mode of inheritance	[mode of inheritance]	1.5849625007211563	3	1	0	0
13417	1520	five reactive lymph node	[five reactive lymph nodes]	1.5849625007211563	4	1	0	0
13418	1520	preeminent antiinflammatory agent	[preeminent antiinflammatory agents]	1.5849625007211563	3	1	0	0
13419	1520	normal artery specimen	[Normal artery specimens]	1.5849625007211563	3	1	0	0
13420	1520	exhibit fast growth rate	[exhibiting faster growth rates]	1.5849625007211563	4	1	0	0
13421	1520	gpix promoter expression	[GPIX promoter expression]	1.5849625007211563	3	1	0	0
13422	1520	Similarly, D3 monocyte differentiation	[Similarly, D3 monocyte differentiation]	1.5849625007211563	4	1	0	0
13423	1520	low level of activation	[low level of activation]	1.5849625007211563	4	2	1	1
13424	1520	gm-csf-responsive bone marrow cell	[GM-CSF-responsive bone marrow cells]	1.5849625007211563	4	1	0	0
13425	1520	fetal beta-globin (hbb)-like gene	[fetal beta-globin (HBB)-like genes]	1.5849625007211563	4	1	0	0
13426	1520	lymphoid CEM line	[lymphoid CEM line]	1.5849625007211563	3	1	0	0
13427	1520	calcineurin -nfat interaction	[calcineurin -NFAT interaction]	1.5849625007211563	3	1	0	0
13428	1520	120 h versus 18	[120 h vs 18]	1.5849625007211563	4	1	0	0
13429	1520	a stat3 phosphorylation	[A STAT3 phosphorylation]	1.5849625007211563	3	1	0	0
13430	1520	secretion of inflammatory mediator	[secretion of inflammatory mediators]	1.5849625007211563	4	2	1	1
13431	1520	various adult mouse tissue	[various adult mouse tissues]	1.5849625007211563	4	1	0	0
13432	1520	usf-related transcription factor hiv-tf1	[USF-related transcription factor HIV-TF1]	1.5849625007211563	4	1	0	0
13433	1520	regulate lps gene induction	[regulating LPS gene induction]	1.5849625007211563	4	1	0	0
13434	1520	study implicate IL-4R	[studies implicating IL-4R]	1.5849625007211563	3	1	0	0
13435	1520	six 5' upstream	[six 5' upstream]	1.5849625007211563	3	1	0	0
13436	1520	frequently the immunodominant target	[frequently the immunodominant targets]	1.5849625007211563	4	1	0	0
13437	1520	activator of transcription 5a	[activator of transcription 5a]	1.5849625007211563	4	1	0	0
13438	1520	regulation of myeloid differentiation	[regulation of myeloid differentiation]	1.5849625007211563	4	1	0	0
13439	1520	replicative gene expression	[replicative gene expression]	1.5849625007211563	3	2	2	2
13440	1520	Thr729 to Leu765	[Thr729 to Leu765]	1.5849625007211563	3	1	0	0
13441	1520	m-csf gene by IL-2	[M-CSF gene by IL-2]	1.5849625007211563	4	1	0	0
13442	1520	NF-kappaB1 p105/p50 level	[NF-kappaB1 p105/p50 levels]	1.5849625007211563	3	1	0	0
13443	1520	percentage of asymmetric molecule	[percentage of asymmetric molecules]	1.5849625007211563	4	1	0	0
13444	1520	inflammatory mediator lipopolysaccharide lps	[inflammatory mediators lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
13445	1520	presence of a silencer	[presence of a silencer]	1.5849625007211563	4	1	0	0
13446	1520	23 cases, 19	[23 cases, 19]	1.5849625007211563	3	1	0	0
13447	1520	day of monocyte cultivation	[days of monocyte cultivation]	1.5849625007211563	4	1	0	0
13448	1520	use of IFN-U937 cell	[use of IFN-U937 cells]	1.5849625007211563	4	1	0	0
13449	1520	human beta-globin gene expression	[human beta-globin gene expression]	1.5849625007211563	4	1	0	0
13450	1520	well-studied costimulatory molecule	[well-studied costimulatory molecules]	1.5849625007211563	3	1	0	0
13451	1520	transcription from homologous region	[transcription from homologous regions]	1.5849625007211563	4	1	0	0
13452	1520	cell with pertussis toxin	[cells with pertussis toxin]	1.5849625007211563	4	1	0	0
13453	1520	human interleukin-4 gene	[human interleukin-4 gene]	1.5849625007211563	3	2	1	1
13454	1520	multiple cis-acting regulatory site	[multiple cis-acting regulatory sites]	1.5849625007211563	4	1	0	0
13455	1520	clonal anergy induction	[clonal anergy induction]	1.5849625007211563	3	1	0	0
13456	1520	fully lymphoblastoid phenotype	[fully lymphoblastoid phenotype]	1.5849625007211563	3	1	0	0
13457	1520	regulation of fasl expression	[regulation of FasL expression]	1.5849625007211563	4	1	0	0
13458	1520	tumor endocrine status	[tumor endocrine status]	1.5849625007211563	3	1	0	0
13459	1520	transcription from reporter plasmid	[transcription from reporter plasmids]	1.5849625007211563	4	1	0	0
13460	1520	analogy htlv-ii p24rex	[analogy HTLV-II p24rex]	1.5849625007211563	3	1	0	0
13461	1520	t-cell receptor stimulation.	[T-cell receptor stimulation.]	1.5849625007211563	3	1	0	0
13462	1520	generation of inflammatory cytokine	[generation of inflammatory cytokines]	1.5849625007211563	4	1	0	0
13463	1520	such clone by transfection.	[such clones by transfection.]	1.5849625007211563	4	1	0	0
13464	1520	antisense oligomer to p65	[antisense oligomers to p65]	1.5849625007211563	4	1	0	0
13465	1520	k562 cell to HMBA	[K562 cells to HMBA]	1.5849625007211563	4	1	0	0
13466	1520	eosinophil-specific granule protein gene	[eosinophil-specific granule protein gene]	1.5849625007211563	4	1	0	0
13467	1520	viral protein epitope in	[viral protein epitopes in]	1.5849625007211563	4	1	0	0
13468	1520	vitro, in liquid culture	[vitro, in liquid culture]	1.5849625007211563	4	1	0	0
13469	1520	tissue transglutaminase ttg reaction	[tissue transglutaminase tTG reaction]	1.5849625007211563	4	1	0	0
13470	1520	ap-1 dna-binding activity,	[AP-1 DNA-binding activity,]	1.5849625007211563	3	1	0	0
13471	1520	activation of death-inducing receptor	[activation of death-inducing receptors]	1.5849625007211563	4	1	0	0
13472	1520	proliferation in transgenic megakaryocyte	[proliferation in transgenic megakaryocytes]	1.5849625007211563	4	1	0	0
13473	1520	platelet peroxidase activity	[platelet peroxidase activity]	1.5849625007211563	3	1	0	0
13474	1520	AML1 beta gene	[AML1 beta genes]	1.5849625007211563	3	1	0	0
13475	1520	extrathymic t-cell development	[extrathymic T-cell development]	1.5849625007211563	3	1	0	0
13476	1520	10 elderly subject	[10 elderly subjects]	1.5849625007211563	3	1	0	0
13477	1520	effect on T cell	[effect on T cells]	1.5849625007211563	4	2	2	2
13478	1520	sparingly in the adult	[sparingly in the adult]	1.5849625007211563	4	1	0	0
13479	1520	monocyte-derived macrophage mdm	[monocyte-derived macrophages MDMs]	1.5849625007211563	3	2	1	1
13480	1520	gtp -bound p21ras	[GTP -bound p21ras]	1.5849625007211563	3	1	0	0
13481	1520	context of cell process	[context of cell processes]	1.5849625007211563	4	1	0	0
13482	1520	coincubation of oleate	[coincubation of oleate]	1.5849625007211563	3	1	0	0
13483	1520	such as IkappaBalpha	[such as IkappaBalpha]	1.5849625007211563	3	1	0	0
13484	1520	IL-4 response element il-4re	[IL-4 response element IL-4RE]	1.5849625007211563	4	1	0	0
13485	1520	c-myc PuF site	[c-myc PuF site]	1.5849625007211563	3	1	0	0
13486	1520	cellular factor HEB-1	[cellular factors HEB-1]	1.5849625007211563	3	1	0	0
13487	1520	activation of Elf-1 transcription	[activation of Elf-1 transcription]	1.5849625007211563	4	1	0	0
13488	1520	increase of promoter-enhancer induction	[increase of promoter-enhancer induction]	1.5849625007211563	4	1	0	0
13489	1520	ccaat binding factor nf-y	[CCAAT binding factor NF-Y]	1.5849625007211563	4	1	0	0
13490	1520	low mrna level	[lower mRNA levels]	1.5849625007211563	3	1	0	0
13491	1520	familial hypercholesterolemic (fh) subject	[familial hypercholesterolemic (FH) subjects]	1.5849625007211563	4	1	0	0
13492	1520	minimal CD4 promoter	[minimal CD4 promoter]	1.5849625007211563	3	1	0	0
13493	1520	glutathione s-transferase gst	[glutathione S-transferase GST]	1.5849625007211563	3	1	0	0
13494	1520	concentration of NF-AT	[concentration of NF-AT]	1.5849625007211563	3	1	0	0
13495	1520	tyrosine by a cysteine	[tyrosine by a cysteine]	1.5849625007211563	4	1	0	0
13496	1520	class ii trans-activator ciita	[class II trans-activator CIITA]	1.5849625007211563	4	1	0	0
13497	1520	inhibition of IkappaBalpha	[inhibition of IkappaBalpha]	1.5849625007211563	3	1	0	0
13498	1520	ig integrin ligand	[Ig integrin ligand]	1.5849625007211563	3	1	0	0
13499	1520	150 nucleotide upstream	[150 nucleotides upstream]	1.5849625007211563	3	1	0	0
13500	1520	consensus DNA sequence	[consensus DNA sequence]	1.5849625007211563	3	1	0	0
13501	1520	response to dexamethasone	[response to dexamethasone]	1.5849625007211563	3	1	0	0
13502	1520	low dissociation constant	[lower dissociation constant]	1.5849625007211563	3	2	1	1
13503	1520	previous observation in man	[previous observations in men]	1.5849625007211563	4	1	0	0
13504	1520	understanding of mechanism	[understanding of mechanisms]	1.5849625007211563	3	2	2	2
13505	1520	other cell line	[other cell lines]	1.5849625007211563	3	2	2	2
13506	1520	lytic viral replication	[lytic viral replication]	1.5849625007211563	3	1	0	0
13507	1520	14 pr patient respectively.	[14 PR patients respectively.]	1.5849625007211563	4	1	0	0
13508	1520	expression of co-stimulatory molecule	[expression of co-stimulatory molecules]	1.5849625007211563	4	1	0	0
13509	1520	human peripheral blood leukocyte	[human peripheral blood leukocytes]	1.5849625007211563	4	1	0	0
13510	1520	level of nuclear protein	[level of nuclear proteins]	1.5849625007211563	4	2	2	2
13511	1520	aberrant cd4(-)cd8(-) T cell	[aberrant CD4(-)CD8(-) T cells]	1.5849625007211563	4	1	0	0
13512	1520	predominantly in b lymphocyte	[predominantly in B lymphocytes]	1.5849625007211563	4	1	0	0
13513	1520	human b lymphocyte culture	[human B lymphocyte cultures]	1.5849625007211563	4	1	0	0
13514	1520	camp accumulation in monocyte	[cAMP accumulation in monocytes]	1.5849625007211563	4	1	0	0
13515	1520	il-1rii mrna level	[IL-1RII mRNA levels]	1.5849625007211563	3	1	0	0
13516	1520	CYP1A1 mrna level	[CYP1A1 mRNA level]	1.5849625007211563	3	1	0	0
13517	1520	Surprisingly, G28-5 sFv	[Surprisingly, G28-5 sFv]	1.5849625007211563	3	1	0	0
13518	1520	tcr zeta subunit	[TCR zeta subunits]	1.5849625007211563	3	1	0	0
13519	1520	treatment with calcium ionophore	[Treatment with calcium ionophore]	1.5849625007211563	4	1	0	0
13520	1520	functionally important subunit,	[functionally important subunit,]	1.5849625007211563	3	1	0	0
13521	1520	proliferation of differentiation-blocked erythroblast	[proliferation of differentiation-blocked erythroblasts]	1.5849625007211563	4	1	0	0
13522	1520	tcr-beta/tcr-delta double knockout mouse	[TCR-beta/TCR-delta double knockout mice]	1.5849625007211563	4	1	0	0
13523	1520	regulate IL-4 transcription,	[regulating IL-4 transcription,]	1.5849625007211563	3	1	0	0
13524	1520	patient with resistance	[patient with resistance]	1.5849625007211563	3	2	2	2
13525	1520	cryptic splice site	[cryptic splice site]	1.5849625007211563	3	2	2	2
13526	1520	CCACC site at -240	[CCACC site at -240]	1.5849625007211563	4	1	0	0
13527	1520	High NK activity	[Higher NK activity]	1.5849625007211563	3	1	0	0
13528	1520	late feedback "talking"	[later feedback "talking"]	1.5849625007211563	3	1	0	0
13529	1520	nitric oxide synthase	[nitric oxide synthase]	1.5849625007211563	3	2	2	2
13530	1520	hot aqueous phenol extraction	[hot aqueous phenol extraction]	1.5849625007211563	4	1	0	0
13531	1520	tnf pma- hiv replication	[TNF PMA- HIV replication]	1.5849625007211563	4	1	0	0
13532	1520	human monoblastic cell line	[human monoblastic cell line]	1.5849625007211563	4	1	0	0
13533	1520	thp-1 leukemia cell	[THP-1 leukemia cells]	1.5849625007211563	3	2	2	2
13534	1520	T cell functional response	[T cell functional responses]	1.5849625007211563	4	1	0	0
13535	1520	CD3 activation of stat3	[CD3 activation of Stat3]	1.5849625007211563	4	1	0	0
13536	1520	expression of cdc2 mrna	[expression of cdc2 mRNA]	1.5849625007211563	4	1	0	0
13537	1520	human t-cell receptor tcr	[human T-cell receptor TCR]	1.5849625007211563	4	1	0	0
13538	1520	antiserum against the mouse	[antiserum against the mouse]	1.5849625007211563	4	1	0	0
13539	1520	Simon unpublished observations).	[Simon unpublished observations).]	1.5849625007211563	3	1	0	0
13540	1520	NF-kappa b in PBL	[NF-kappa B in PBL]	1.5849625007211563	4	1	0	0
13541	1520	insulin-like growth factor	[insulin-like growth factor]	1.5849625007211563	3	1	0	0
13542	1520	silent fy*b allele	[silent FY*B allele]	1.5849625007211563	3	1	0	0
13543	1520	increase in specific binding	[increase in specific binding]	1.5849625007211563	4	1	0	0
13544	1520	heat shock factor	[heat shock factor]	1.5849625007211563	3	2	2	2
13545	1520	low molecular weight variant	[lower molecular weight variant]	1.5849625007211563	4	2	2	2
13546	1520	response to G-CSF	[responses to G-CSF]	1.5849625007211563	3	1	0	0
13547	1520	UT-7 epo cell	[UT-7 Epo cells]	1.5849625007211563	3	1	0	0
13548	1520	co-stimulatory activity by apc	[co-stimulatory activity by APCs]	1.5849625007211563	4	1	0	0
13549	1520	early crucial step	[earliest crucial steps]	1.5849625007211563	3	1	0	0
13550	1520	follow CD19 cross-linking	[following CD19 cross-linking]	1.5849625007211563	3	1	0	0
13551	1520	transglutaminase type ii	[transglutaminase type II]	1.5849625007211563	3	1	0	0
13552	1520	physiological role of darc	[physiological roles of DARC]	1.5849625007211563	4	1	0	0
13553	1520	cell toward granulocyte	[cells toward granulocytes]	1.5849625007211563	3	1	0	0
13554	1520	identify segment in Ag	[identifying segments in Ag]	1.5849625007211563	4	1	0	0
13555	1520	other promoter site	[other promoter sites]	1.5849625007211563	3	1	0	0
13556	1520	c-jun gene 1.4-fold.	[c-jun gene 1.4-fold.]	1.5849625007211563	3	1	0	0
13557	1520	granulocytic-neutrophilic differentiation program	[granulocytic-neutrophilic differentiation program]	1.5849625007211563	3	1	0	0
13558	1520	B2 site, concomitant	[B2 site, concomitant]	1.5849625007211563	3	1	0	0
13559	1520	13-myristate acetate PMA	[13-myristate acetate PMA]	1.5849625007211563	3	1	0	0
13560	1520	inducible autoregulatory pathway	[inducible autoregulatory pathway]	1.5849625007211563	3	2	1	1
13561	1520	effect of iNO	[effects of iNO]	1.5849625007211563	3	2	2	2
13562	1520	nuclei of monocyte	[nuclei of monocytes]	1.5849625007211563	3	2	1	1
13563	1520	other translocation case	[other translocation cases]	1.5849625007211563	3	1	0	0
13564	1520	igg fc gamma riiia	[IgG Fc gamma RIIIA]	1.5849625007211563	4	1	0	0
13565	1520	corticosteroid-resistant (cr) asthmatic subject	[corticosteroid-resistant (CR) asthmatic subjects]	1.5849625007211563	4	1	0	0
13566	1520	development of this neoplasm	[development of these neoplasms]	1.5849625007211563	4	1	0	0
13567	1520	antibody to slp-76	[antibodies to SLP-76]	1.5849625007211563	3	1	0	0
13568	1520	position -295 to -286	[positions -295 to -286]	1.5849625007211563	4	1	0	0
13569	1520	NF-kappa b /kbf1 p50	[NF-kappa B /KBF1 p50]	1.5849625007211563	4	1	0	0
13570	1520	form of CBF beta	[form of CBF beta]	1.5849625007211563	4	1	0	0
13571	1520	dna-bound Oct-1 pou domain	[DNA-bound Oct-1 POU domain]	1.5849625007211563	4	1	0	0
13572	1520	transcription of early gene	[transcription of early genes]	1.5849625007211563	4	1	0	0
13573	1520	region contain this domain	[region containing these domains]	1.5849625007211563	4	1	0	0
13574	1520	initial activation of nf-kappab	[initial activation of NF-kappaB]	1.5849625007211563	4	1	0	0
13575	1520	control of cellular protein	[control of cellular proteins]	1.5849625007211563	4	1	0	0
13576	1520	complex regulatory function in	[complex regulatory functions in]	1.5849625007211563	4	1	0	0
13577	1520	results: in preliminary studies,	[RESULTS: In preliminary studies,]	1.5849625007211563	4	1	0	0
13578	1520	hiv LTR CAT	[HIV LTR CAT]	1.5849625007211563	3	1	0	0
13579	1520	transcriptional transactivation function	[transcriptional transactivation functions]	1.5849625007211563	3	1	0	0
13580	1520	binding of the mAECA	[binding of the mAECA]	1.5849625007211563	4	1	0	0
13581	1520	NF-kappaB element present	[NF-kappaB element present]	1.5849625007211563	3	1	0	0
13582	1520	however, k562 cell	[however, K562 cells]	1.5849625007211563	3	1	0	0
13583	1520	DNase i footprinting assay	[DNase I footprinting assays]	1.5849625007211563	4	1	0	0
13584	1520	three 21 bp element	[three 21 bp elements]	1.5849625007211563	4	1	0	0
13585	1520	regulation of il-2 synthesis	[regulation of IL-2 synthesis]	1.5849625007211563	4	1	0	0
13586	1520	mechanism(s) regulate this activation	[mechanism(s) regulating this activation]	1.5849625007211563	4	1	0	0
13587	1520	cell-surface ifngamma receptor	[cell-surface IFNgamma receptors]	1.5849625007211563	3	1	0	0
13588	1520	lymphocyte for the effect	[lymphocytes for the effect]	1.5849625007211563	4	1	0	0
13589	1520	Raf1/MEK1/ ERK1/2 pathway	[Raf1/MEK1/ ERK1/2 pathway]	1.5849625007211563	3	1	0	0
13590	1520	seven xpa through XPG	[seven XPA through XPG]	1.5849625007211563	4	1	0	0
13591	1520	E74 site independent	[E74 site independent]	1.5849625007211563	3	1	0	0
13592	1520	one possible immunological variable	[one possible immunological variable]	1.5849625007211563	4	1	0	0
13593	1520	e1b 19k mutant	[E1B 19K mutants]	1.5849625007211563	3	1	0	0
13594	1520	fresh ATL sample	[fresh ATL samples]	1.5849625007211563	3	1	0	0
13595	1520	Autosome/ xi translocation	[Autosome/ Xi translocations]	1.5849625007211563	3	1	0	0
13596	1520	Differential monocyte adhesion	[Differential monocyte adhesion]	1.5849625007211563	3	1	0	0
13597	1520	such as member	[such as members]	1.5849625007211563	3	1	0	0
13598	1520	lymphocyte of non-pregnant woman	[Lymphocytes of non-pregnant women]	1.5849625007211563	4	1	0	0
13599	1520	effect on il-1beta production	[effects on IL-1beta production]	1.5849625007211563	4	1	0	0
13600	1520	5'-regulatory region of BCL-6	[5'-regulatory region of BCL-6]	1.5849625007211563	4	1	0	0
13601	1520	immunoglobulin kappa enhancer	[immunoglobulin kappa enhancer]	1.5849625007211563	3	1	0	0
13602	1520	alternative approach in all	[alternative approaches in ALL]	1.5849625007211563	4	1	0	0
13603	1520	activation of mkk3	[activation of MKK3]	1.5849625007211563	3	1	0	0
13604	1520	phosphorothioate oligonucleotide complementary	[phosphorothioate oligonucleotides complementary]	1.5849625007211563	3	1	0	0
13605	1520	PKC -independent mechanism	[PKC -independent mechanism]	1.5849625007211563	3	1	0	0
13606	1520	inhibitor of serine protease	[inhibitors of serine proteases]	1.5849625007211563	4	1	0	0
13607	1520	induction of cd23	[induction of CD23]	1.5849625007211563	3	1	0	0
13608	1520	complex with extract	[complex with extract]	1.5849625007211563	3	2	2	2
13609	1520	induction of cd36	[induction of CD36]	1.5849625007211563	3	1	0	0
13610	1520	B /Rel transcription	[B /Rel transcription]	1.5849625007211563	3	1	0	0
13611	1520	new approach in favour	[new approach in favour]	1.5849625007211563	4	1	0	0
13612	1520	induction of cd44	[induction of CD44]	1.5849625007211563	3	1	0	0
13613	1520	viral protein secretion	[viral protein secretion]	1.5849625007211563	3	1	0	0
13614	1520	1,25-Dihydroxy vitamin D3	[1,25-Dihydroxy vitamin D3]	1.5849625007211563	3	1	0	0
13615	1520	SH2 domain of vav	[SH2 domain of Vav]	1.5849625007211563	4	1	0	0
13616	1520	specific t(15;17) translocation	[specific t(15;17) translocation]	1.5849625007211563	3	1	0	0
13617	1520	action of Eed	[action of Eed]	1.5849625007211563	3	1	0	0
13618	1520	dominant negative IkappaBalpha construct	[dominant negative IkappaBalpha construct]	1.5849625007211563	4	1	0	0
13619	1520	complex contain STAT3 alpha	[complexes containing STAT3 alpha]	1.5849625007211563	4	1	0	0
13620	1520	cd95 ligand expression	[CD95 ligand expression]	1.5849625007211563	3	1	0	0
13621	1520	early transient activation	[early transient activation]	1.5849625007211563	3	1	0	0
13622	1520	immunodeficiency virus infection	[immunodeficiency virus infection]	1.5849625007211563	3	2	2	2
13623	1520	rest normal human pbl	[resting normal human PBL]	1.5849625007211563	4	1	0	0
13624	1520	state of activation	[state of activation]	1.5849625007211563	3	2	2	2
13625	1520	box contain gene pax-5	[box containing gene Pax-5]	1.5849625007211563	4	1	0	0
13626	1520	presence of protein synthesis	[presence of protein synthesis]	1.5849625007211563	4	1	0	0
13627	1520	regulation of tnf-alpha synthesis	[regulation of TNF-alpha synthesis]	1.5849625007211563	4	1	0	0
13628	1520	IgH enhancer pi site	[IgH enhancer pi site]	1.5849625007211563	4	1	0	0
13629	1520	human monocyte-derived macrophage	[human monocyte-derived macrophages]	1.5849625007211563	3	2	2	2
13630	1520	Epstein-Barr virus DR promoter	[Epstein-Barr virus DR promoter]	1.5849625007211563	4	1	0	0
13631	1520	gene in erythroid cell	[gene in erythroid cells]	1.5849625007211563	4	2	2	2
13632	1520	affinity (3.93+/-0.89 nm	[affinity (3.93+/-0.89 nM]	1.5849625007211563	3	1	0	0
13633	1520	perpetuation of virus infection	[perpetuation of virus infection]	1.5849625007211563	4	1	0	0
13634	1520	blood cell from patient	[blood cells from patients]	1.5849625007211563	4	2	2	2
13635	1520	hiv-1 express ikappab-alphas32/36a	[HIV-1 expressing IkappaB-alphaS32/36A]	1.5849625007211563	3	1	0	0
13636	1520	plasma cell line	[plasma cell lines]	1.5849625007211563	3	1	0	0
13637	1520	C-terminal hsp70 peptide	[C-terminal Hsp70 peptide]	1.5849625007211563	3	1	0	0
13638	1520	enhancer activity of own.	[enhancer activity of own.]	1.5849625007211563	4	1	0	0
13639	1520	moreover, cotransfection with c-fo	[Moreover, cotransfections with c-fos]	1.5849625007211563	4	1	0	0
13640	1520	CD3 receptor cross-linking	[CD3 receptor cross-linking]	1.5849625007211563	3	1	0	0
13641	1520	plasmid express taxi	[plasmid expressing TaxI]	1.5849625007211563	3	1	0	0
13642	1520	heat shock transcription	[heat shock transcription]	1.5849625007211563	3	2	2	2
13643	1520	effect of acid RA	[effect of acids RA]	1.5849625007211563	4	2	2	2
13644	1520	bind the transactivator e2f-i	[binding the transactivator E2F-I]	1.5849625007211563	4	1	0	0
13645	1520	study, use a assay	[study, using a assay]	1.5849625007211563	4	1	0	0
13646	1520	dermal microvessel cell	[dermal microvessel cells]	1.5849625007211563	3	2	2	2
13647	1520	cytoplasm of all lymphocyte	[cytoplasm of all lymphocytes]	1.5849625007211563	4	1	0	0
13648	1520	Recent study from group	[Recent studies from group]	1.5849625007211563	4	1	0	0
13649	1520	Jurkat cell overexpress IkappaB-alpha	[Jurkat cells overexpressing IkappaB-alpha]	1.5849625007211563	4	1	0	0
13650	1520	CD19 GC box	[CD19 GC box]	1.5849625007211563	3	1	0	0
13651	1520	3' flank region	[3' flanking region]	1.5849625007211563	3	1	0	0
13652	1520	ability of PRL	[ability of PRL]	1.5849625007211563	3	1	0	0
13653	1520	several radical-generating system	[several radical-generating systems]	1.5849625007211563	3	1	0	0
13654	1520	distinct protein heterodimer	[distinct protein heterodimers]	1.5849625007211563	3	1	0	0
13655	1520	tnf-alpha activation of nf-kappab	[TNF-alpha activation of NF-kappaB]	1.5849625007211563	4	1	0	0
13656	1520	anti- ar antibody	[anti- AR antibodies]	1.5849625007211563	3	2	1	1
13657	1520	homeotic gene expression	[homeotic gene expression]	1.5849625007211563	3	1	0	0
13658	1520	existence of tyrosine motif	[existence of tyrosine motifs]	1.5849625007211563	4	1	0	0
13659	1520	various steroid ligands.	[various steroid ligands.]	1.5849625007211563	3	1	0	0
13660	1520	protein in human platelet	[proteins in human platelets]	1.5849625007211563	4	2	2	2
13661	1520	u1 monocytoid cells;	[U1 monocytoid cells;]	1.5849625007211563	3	1	0	0
13662	1520	specific trans-activating factor	[specific trans-activating factors]	1.5849625007211563	3	1	0	0
13663	1520	bcl-2 expression take place.	[Bcl-2 expression take place.]	1.5849625007211563	4	1	0	0
13664	1520	HLA Class ii dependency	[HLA Class II dependency]	1.5849625007211563	4	1	0	0
13665	1520	function of this element	[function of these elements]	1.5849625007211563	4	2	2	2
13666	1520	T lymphocyte activation.	[T lymphocyte activation.]	1.5849625007211563	3	1	0	0
13667	1520	b cell in patient	[B cells in patients]	1.5849625007211563	4	1	0	0
13668	1520	survey of gata motif	[survey of GATA motifs]	1.5849625007211563	4	1	0	0
13669	1520	c-Rel protein complex	[c-Rel protein complexes]	1.5849625007211563	3	1	0	0
13670	1520	T-cell lineage express Oct-2	[T-cell lineage express Oct-2]	1.5849625007211563	4	1	0	0
13671	1520	cross-linking of CD30	[Cross-linking of CD30]	1.5849625007211563	3	2	1	1
13672	1520	leukaemic T cell	[leukaemic T cells]	1.5849625007211563	3	2	1	1
13673	1520	multifunctional YY1 transcription factor	[multifunctional YY1 transcription factor]	1.5849625007211563	4	1	0	0
13674	1520	two lineage-restricted transcription factor	[two lineage-restricted transcription factors]	1.5849625007211563	4	1	0	0
13675	1520	hormone-induced tax activation	[Hormone-induced Tax activation]	1.5849625007211563	3	1	0	0
13676	1520	respectively in the presence	[respectively in the presence]	1.5849625007211563	4	1	0	0
13677	1520	CAT reporter construction	[CAT reporter constructions]	1.5849625007211563	3	1	0	0
13678	1520	c-jun b mrna expression	[c-jun B mRNA expression]	1.5849625007211563	4	1	0	0
13679	1520	marker of tumour differentiation	[markers of tumour differentiation]	1.5849625007211563	4	1	0	0
13680	1520	two new findings.	[two new findings.]	1.5849625007211563	3	1	0	0
13681	1520	lack the amino terminal	[lacking the amino terminal]	1.5849625007211563	4	1	0	0
13682	1520	normal second messenger system	[normal second messenger systems]	1.5849625007211563	4	1	0	0
13683	1520	mouse osteocalcin gene	[mouse osteocalcin gene]	1.5849625007211563	3	1	0	0
13684	1520	adenosine deaminase ada	[adenosine deaminase ADA]	1.5849625007211563	3	1	0	0
13685	1520	study of different aspect	[study of different aspects]	1.5849625007211563	4	1	0	0
13686	1520	ic50 of 87 nm	[IC50s of 87 nM]	1.5849625007211563	4	1	0	0
13687	1520	association of 20q deletion	[association of 20q deletions]	1.5849625007211563	4	1	0	0
13688	1520	vzv glycoprotein e gE	[VZV glycoprotein E gE]	1.5849625007211563	4	1	0	0
13689	1520	induction of IFN-beta synthesis	[induction of IFN-beta synthesis]	1.5849625007211563	4	1	0	0
13690	1520	binding of ap-1 factor	[binding of AP-1 factors]	1.5849625007211563	4	2	1	1
13691	1520	nearly wild-type level	[nearly wild-type levels]	1.5849625007211563	3	2	1	1
13692	1520	lps 0.2 ng/ml	[LPS 0.2 ng/ml]	1.5849625007211563	3	1	0	0
13693	1520	p65-rela protein expression	[p65-RelA protein expression]	1.5849625007211563	3	1	0	0
13694	1520	apoptosis by monomer	[apoptosis by monomer]	1.5849625007211563	3	1	0	0
13695	1520	transfection in transgenic thymocyte	[transfections in transgenic thymocytes]	1.5849625007211563	4	1	0	0
13696	1520	target for the development	[target for the development]	1.5849625007211563	4	2	2	2
13697	1520	cyclic AMP signal pathway	[cyclic AMP signaling pathway]	1.5849625007211563	4	1	0	0
13698	1520	ifn-alpha binding of stat1	[IFN-alpha binding of STAT1]	1.5849625007211563	4	1	0	0
13699	1520	change in the number	[change in the number]	1.5849625007211563	4	1	0	0
13700	1520	X1 box dna-binding protein	[X1 box DNA-binding protein]	1.5849625007211563	4	1	0	0
13701	1520	Separate epitope in vp22	[Separate epitopes in VP22]	1.5849625007211563	4	1	0	0
13702	1520	individual homodimeric rel-related protein	[individual homodimeric Rel-related proteins]	1.5849625007211563	4	1	0	0
13703	1520	2 mol/L for budesonide	[2 mol/L for budesonide]	1.5849625007211563	4	2	1	1
13704	1520	signal control proliferation	[signals controlling proliferation]	1.5849625007211563	3	1	0	0
13705	1520	SCMV mie enhancer	[SCMV MIE enhancer]	1.5849625007211563	3	1	0	0
13706	1520	distinct monocytic differentiation pathway	[distinct monocytic differentiation pathways]	1.5849625007211563	4	1	0	0
13707	1520	gc b cell	[GC B cells]	1.5849625007211563	3	2	2	2
13708	1520	express the nef	[expressing the nef]	1.5849625007211563	3	1	0	0
13709	1520	role in the commitment	[role in the commitment]	1.5849625007211563	4	2	1	1
13710	1520	non-voltage-gated ca2+ channel	[non-voltage-gated Ca2+ channels]	1.5849625007211563	3	1	0	0
13711	1520	affect viral replication	[affecting viral replication]	1.5849625007211563	3	1	0	0
13712	1520	anti- STAT-1 Ab	[anti- STAT-1 Ab]	1.5849625007211563	3	1	0	0
13713	1520	contrast to MEL cell	[contrast to MEL cells]	1.5849625007211563	4	1	0	0
13714	1520	cd45 tyrosine phosphatase	[CD45 tyrosine phosphatase]	1.5849625007211563	3	1	0	0
13715	1520	respect to arginine residue	[respect to arginine residues]	1.5849625007211563	4	1	0	0
13716	1520	nonoptimal binding site	[nonoptimal binding sites]	1.5849625007211563	3	1	0	0
13717	1520	rel /nf-kappa b activity	[Rel /NF-kappa B activity]	1.5849625007211563	4	1	0	0
13718	1520	splenic cDNA library	[splenic cDNA library]	1.5849625007211563	3	1	0	0
13719	1520	CD38 antigen in cell	[CD38 antigen in cells]	1.5849625007211563	4	2	2	2
13720	1520	other unidentified factor	[other unidentified factors]	1.5849625007211563	3	2	2	2
13721	1520	functionally distinct role	[functionally distinct roles]	1.5849625007211563	3	1	0	0
13722	1520	p50 subunit of nf-kappab	[p50 subunit of NF-kappaB]	1.5849625007211563	4	1	0	0
13723	1520	CD2 receptor activation	[CD2 receptor activation]	1.5849625007211563	3	1	0	0
13724	1520	three independent site	[three independent sites]	1.5849625007211563	3	1	0	0
13725	1520	use interspecy hybrids,	[Using interspecies hybrids,]	1.5849625007211563	3	1	0	0
13726	1520	novel cis-acting element	[novel cis-acting element]	1.5849625007211563	3	1	0	0
13727	1520	activation transform growth factor-beta	[activation transforming growth factor-beta]	1.5849625007211563	4	1	0	0
13728	1520	American Society of Hematology.	[American Society of Hematology.]	1.5849625007211563	4	1	0	0
13729	1520	risk of prostate cancer	[risk of prostate cancer]	1.5849625007211563	4	1	0	0
13730	1520	vitro-cultured T cell	[vitro-cultured T cells]	1.5849625007211563	3	1	0	0
13731	1520	beta 2 subunit	[beta 2 subunit]	1.5849625007211563	3	2	1	1
13732	1520	Ig class switch	[Ig class switching]	1.5849625007211563	3	1	0	0
13733	1520	follow CD40 stimulation	[following CD40 stimulation]	1.5849625007211563	3	2	1	1
13734	1520	vivo hiv-1 replication	[vivo HIV-1 replication]	1.5849625007211563	3	1	0	0
13735	1520	novel heterodimeric cytokine	[novel heterodimeric cytokine]	1.5849625007211563	3	1	0	0
13736	1520	promoter sequence analysis	[promoter sequence analysis]	1.5849625007211563	3	1	0	0
13737	1520	p50 subunit of NF-kappaB	[p50 subunit of NF-kappaB]	1.5849625007211563	4	2	1	1
13738	1520	involvement in the activation	[Involvement in the activation]	1.5849625007211563	4	2	2	2
13739	1520	also role in leukemogenesis	[also role in leukemogenesis]	1.5849625007211563	4	1	0	0
13740	1520	lps cellular signal	[LPS cellular signaling]	1.5849625007211563	3	1	0	0
13741	1520	longer-ter potentiation by methylprednisolone	[longer-term potentiation by methylprednisolone]	1.5849625007211563	4	1	0	0
13742	1520	low binding capacity	[low binding capacity]	1.5849625007211563	3	1	0	0
13743	1520	MTIIa mrna level	[MTIIa mRNA levels]	1.5849625007211563	3	1	0	0
13744	1520	retinoic-acid receptor type alpha	[retinoic-acid receptors type alpha]	1.5849625007211563	4	2	2	2
13745	1520	tyrosine phosphorylation stat1	[Tyrosine phosphorylation STAT1]	1.5849625007211563	3	1	0	0
13746	1520	human c-fe gene	[human c-fes gene]	1.5849625007211563	3	2	1	1
13747	1520	non-erythroid cell line	[non-erythroid cell lines]	1.5849625007211563	3	1	0	0
13748	1520	cell-associated recognition molecule	[cell-associated recognition molecule]	1.5849625007211563	3	1	0	0
13749	1520	ligand activation of c-ErbB	[Ligand activation of c-ErbB]	1.5849625007211563	4	1	0	0
13750	1520	absence of Sp1	[absence of Sp1]	1.5849625007211563	3	1	0	0
13751	1520	target of pentoxifylline inhibition	[target of pentoxifylline inhibition]	1.5849625007211563	4	1	0	0
13752	1520	level of gata-1 mrna	[level of GATA-1 mRNA]	1.5849625007211563	4	2	1	1
13753	1520	interleukin-2 receptor alpha-chain gene	[interleukin-2 receptor alpha-chain gene]	1.5849625007211563	4	1	0	0
13754	1520	activation of hiv-1	[activation of HIV-1]	1.5849625007211563	3	2	2	2
13755	1520	Bak gene expression	[Bak gene expression]	1.5849625007211563	3	1	0	0
13756	1520	obligate carrier of XCID	[obligate carriers of XCID]	1.5849625007211563	4	1	0	0
13757	1520	hiv-1 tat affinity column	[HIV-1 Tat affinity column]	1.5849625007211563	4	1	0	0
13758	1520	absence of karyotypic abnormality	[absence of karyotypic abnormalities]	1.5849625007211563	4	1	0	0
13759	1520	second-messenger ca2+ ion	[second-messenger Ca2+ ions]	1.5849625007211563	3	1	0	0
13760	1520	immune/inflammatory effector cell	[immune/inflammatory effector cells]	1.5849625007211563	3	1	0	0
13761	1520	two transcriptional regulatory factor	[two transcriptional regulatory factors]	1.5849625007211563	4	1	0	0
13762	1520	native NF-GM2 complex	[native NF-GM2 complex]	1.5849625007211563	3	1	0	0
13763	1520	mutation of RB gene	[mutations of RB gene]	1.5849625007211563	4	1	0	0
13764	1520	anti CD28 alone	[anti CD28 alone]	1.5849625007211563	3	1	0	0
13765	1520	six adenoviral group A-F	[six adenoviral groups A-F]	1.5849625007211563	4	1	0	0
13766	1520	dominant negative mutant mek1s218/222a	[dominant negative mutant MEK1S218/222A]	1.5849625007211563	4	1	0	0
13767	1520	reinfusion of pbsc	[reinfusion of PBSC]	1.5849625007211563	3	1	0	0
13768	1520	master gata1 gene	[master GATA1 gene]	1.5849625007211563	3	1	0	0
13769	1520	production of c/ebp beta	[production of C/EBP beta]	1.5849625007211563	4	1	0	0
13770	1520	7 residue SFLLRNP	[7 residues SFLLRNP]	1.5849625007211563	3	1	0	0
13771	1520	most b lymphocyte line	[Most B lymphocyte lines]	1.5849625007211563	4	1	0	0
13772	1520	modulation of nf-kappab activity	[modulation of NF-kappaB activity]	1.5849625007211563	4	1	0	0
13773	1520	G-CSF-R /IL-7R alpha	[G-CSF-R /IL-7R alpha]	1.5849625007211563	3	1	0	0
13774	1520	second stage development,	[second stage, development,]	1.5849625007211563	3	1	0	0
13775	1520	ability of PMA	[ability of PMA]	1.5849625007211563	3	1	0	0
13776	1520	increase of related steroid	[increase of related steroids]	1.5849625007211563	4	1	0	0
13777	1520	potential "stress" buffer,	[potential "stress" buffer,]	1.5849625007211563	3	1	0	0
13778	1520	proteasome -mediated degradation	[proteasome -mediated degradation]	1.5849625007211563	3	1	0	0
13779	1520	ets-1 binding site	[ets-1 binding site]	1.5849625007211563	3	2	1	1
13780	1520	unaffected twin sister	[unaffected twin sister]	1.5849625007211563	3	1	0	0
13781	1520	cytokine-stimulated endothelial cell	[cytokine-stimulated endothelial cells]	1.5849625007211563	3	1	0	0
13782	1520	rabbit 59-kda protein	[rabbit 59-kDa protein]	1.5849625007211563	3	1	0	0
13783	1520	T cell in conjunction	[T cells in conjunction]	1.5849625007211563	4	1	0	0
13784	1520	vitro, human b lymphocyte	[vitro, human B lymphocytes]	1.5849625007211563	4	1	0	0
13785	1520	strike a effect	[striking an effect]	1.5849625007211563	3	1	0	0
13786	1520	other chronic inflammatory disease	[other chronic inflammatory diseases]	1.5849625007211563	4	1	0	0
13787	1520	fmol/microgram of lymphocyte DNA	[fmol/micrograms of lymphocyte DNA]	1.5849625007211563	4	1	0	0
13788	1520	study of respective roles.	[study of respective roles.]	1.5849625007211563	4	1	0	0
13789	1520	alteration in the development	[alterations in the development]	1.5849625007211563	4	1	0	0
13790	1520	physical interaction between elf-1	[physical interactions between Elf-1]	1.5849625007211563	4	1	0	0
13791	1520	most lymphocytic cell	[most lymphocytic cells]	1.5849625007211563	3	2	2	2
13792	1520	more than one point.	[more than one point.]	1.5849625007211563	4	1	0	0
13793	1520	tandem ap-1-binding site	[tandem AP-1-binding sites]	1.5849625007211563	3	1	0	0
13794	1520	unrearranged igh gene	[unrearranged IgH genes]	1.5849625007211563	3	1	0	0
13795	1520	uniformly of monoclonal origin,	[uniformly of monoclonal origin,]	1.5849625007211563	4	1	0	0
13796	1520	actively fuse cell	[actively fusing cells]	1.5849625007211563	3	1	0	0
13797	1520	beta 2-integrin gene cd11a	[beta 2-integrin genes CD11a]	1.5849625007211563	4	1	0	0
13798	1520	complex, promoter specificity	[complex, promoter specificity]	1.5849625007211563	3	1	0	0
13799	1520	activation of ca(2+) pathway	[Activation of Ca(2+) pathways]	1.5849625007211563	4	2	2	2
13800	1520	activation by h2o2	[activation by H2O2]	1.5849625007211563	3	1	0	0
13801	1520	CD28 auxiliary receptor	[CD28 auxiliary receptor]	1.5849625007211563	3	1	0	0
13802	1520	pathogenesis of some disease	[pathogenesis of some diseases]	1.5849625007211563	4	1	0	0
13803	1520	dexamethasone suppression mg	[dexamethasone suppression mg]	1.5849625007211563	3	1	0	0
13804	1520	hematopoietic transcription factor gata-1	[hematopoietic transcription factors GATA-1]	1.5849625007211563	4	1	0	0
13805	1520	expression of the protein	[expression of the protein]	1.5849625007211563	4	2	2	2
13806	1520	increase in the form	[increase in the form]	1.5849625007211563	4	1	0	0
13807	1520	mutation at position 12	[mutation at position 12]	1.5849625007211563	4	1	0	0
13808	1520	hiv-1 proviral latency	[HIV-1 proviral latency]	1.5849625007211563	3	1	0	0
13809	1520	antibody to Duffy antigen	[Antibodies to Duffy antigens]	1.5849625007211563	4	1	0	0
13810	1520	pol gene of hiv-1	[pol gene of HIV-1]	1.5849625007211563	4	1	0	0
13811	1520	female family member	[Female family members]	1.5849625007211563	3	1	0	0
13812	1520	regulation of collagenase expression	[regulation of collagenase expression]	1.5849625007211563	4	1	0	0
13813	1520	stage selector element SSE	[stage selector element SSE]	1.5849625007211563	4	1	0	0
13814	1520	phosphorylation-dependent signal on c-Jun	[phosphorylation-dependent signal on c-Jun]	1.5849625007211563	4	1	0	0
13815	1520	sequence element upstream	[sequence elements upstream]	1.5849625007211563	3	1	0	0
13816	1520	lymphocyte from normal patient	[lymphocytes from normal patients]	1.5849625007211563	4	1	0	0
13817	1520	monocytoid (u937vhl-1) cell line	[monocytoid (U937,THP-1) cell lines]	1.5849625007211563	4	1	0	0
13818	1520	multiple serine-specific protein kinase	[multiple serine-specific protein kinases]	1.5849625007211563	4	1	0	0
13819	1520	NF-kappaB1 p105 precursor protein	[NF-kappaB1 p105 precursor protein]	1.5849625007211563	4	1	0	0
13820	1520	Nuclear matrix-bound RB	[Nuclear matrix-bound RB]	1.5849625007211563	3	1	0	0
13821	1520	function of oriP	[function of oriP]	1.5849625007211563	3	1	0	0
13822	1520	specific ebv promoter	[specific EBV promoters]	1.5849625007211563	3	1	0	0
13823	1520	stimulation of bcl-2 expression	[stimulation of Bcl-2 expression]	1.5849625007211563	4	1	0	0
13824	1520	DNA binding study	[DNA binding studies]	1.5849625007211563	3	2	1	1
13825	1520	contribute to the regulation	[contributing to the regulation]	1.5849625007211563	4	1	0	0
13826	1520	sensitivity of cell	[sensitivity of cells]	1.5849625007211563	3	2	1	1
13827	1520	specific kappa b site	[specific kappa B sites]	1.5849625007211563	4	1	0	0
13828	1520	granulocyte-macrophage colony-stimulating factor gene	[granulocyte-macrophage colony-stimulating factor gene]	1.5849625007211563	4	1	0	0
13829	1520	potent inducer of ap-1	[potent inducer of AP-1]	1.5849625007211563	4	1	0	0
13830	1520	human dermal microvessel cell	[human dermal microvessel cells]	1.5849625007211563	4	2	2	2
13831	1520	most immature dn thymocyte	[most immature DN thymocytes]	1.5849625007211563	4	1	0	0
13832	1520	expression of AP-1	[expression of AP-1]	1.5849625007211563	3	1	0	0
13833	1520	observation in T cell	[observation in T cells]	1.5849625007211563	4	1	0	0
13834	1520	cytokine interleukin il-6	[cytokine interleukin IL-6]	1.5849625007211563	3	1	0	0
13835	1520	induction of G(S)alpha expression	[induction of G(S)alpha expression]	1.5849625007211563	4	2	1	1
13836	1520	control of the wild-type,	[control of the wild-type,]	1.5849625007211563	4	1	0	0
13837	1520	dexamethasone in control	[dexamethasone in controls]	1.5849625007211563	3	1	0	0
13838	1520	PMA T cell line	[PMA T cell lines]	1.5849625007211563	4	1	0	0
13839	1520	synergy on downstream target	[synergy on downstream targets]	1.5849625007211563	4	1	0	0
13840	1520	extracellular signal-regulated kinase ERK	[extracellular signal-regulated kinase ERK]	1.5849625007211563	4	2	1	1
13841	1520	size of this signals.	[size of this signals.]	1.5849625007211563	4	1	0	0
13842	1520	human toll-like receptor tlr2	[Human Toll-like receptor TLR2]	1.5849625007211563	4	1	0	0
13843	1520	ag in cell culture	[Ag in cell cultures]	1.5849625007211563	4	1	0	0
13844	1520	deletion of NFAT-1	[deletion of NFAT-1]	1.5849625007211563	3	2	1	1
13845	1520	AML1 /eto transcript	[AML1 /ETO transcripts]	1.5849625007211563	3	2	1	1
13846	1520	transcription by lps	[transcription by LPS]	1.5849625007211563	3	1	0	0
13847	1520	growth factor deprivation apoptosis	[growth factor deprivation apoptosis]	1.5849625007211563	4	1	0	0
13848	1520	Chronic myeloproliferative disease mpd	[Chronic myeloproliferative diseases MPDs]	1.5849625007211563	4	1	0	0
13849	1520	fibrosarcoma cell line	[fibrosarcoma cell lines]	1.5849625007211563	3	1	0	0
13850	1520	phase of neutrophil adhesion	[phases of neutrophil adhesion]	1.5849625007211563	4	1	0	0
13851	1520	cellular protein synthesis	[cellular protein synthesis]	1.5849625007211563	3	1	0	0
13852	1520	Elf-1 -dependent transcription	[Elf-1 -dependent transcription]	1.5849625007211563	3	1	0	0
13853	1520	ability of Id3	[ability of Id3]	1.5849625007211563	3	1	0	0
13854	1520	10(2.9) pfu/animal, on day	[10(2.9) pfu/animal, on days]	1.5849625007211563	4	1	0	0
13855	1520	hiv proviral DNA	[HIV proviral DNA]	1.5849625007211563	3	1	0	0
13856	1520	nf-e1 messenger rna	[NF-E1 messenger RNA]	1.5849625007211563	3	1	0	0
13857	1520	dual specificity phosphatase	[dual specificity phosphatase]	1.5849625007211563	3	1	0	0
13858	1520	anti-tumor CTL response	[anti-tumor CTL responses]	1.5849625007211563	3	1	0	0
13859	1520	lymphokine element cle0	[lymphokine element CLE0]	1.5849625007211563	3	2	1	1
13860	1520	cytoplasmic free calcium	[cytoplasmic free calcium]	1.5849625007211563	3	1	0	0
13861	1520	such as the system	[such as the system]	1.5849625007211563	4	1	0	0
13862	1520	induction of surface receptor	[induction of surface receptors]	1.5849625007211563	4	1	0	0
13863	1520	undergo in vitro differentiation	[undergoing in vitro differentiation]	1.5849625007211563	4	1	0	0
13864	1520	increase in the transcription	[increase in the transcription]	1.5849625007211563	4	1	0	0
13865	1520	Recombinant caspase Mch	[Recombinant caspase Mch]	1.5849625007211563	3	1	0	0
13866	1520	il-2r regulation gene	[IL-2R regulation gene]	1.5849625007211563	3	1	0	0
13867	1520	glucocorticoid receptor change	[glucocorticoid receptor changes]	1.5849625007211563	3	1	0	0
13868	1520	il-2 alpha gene	[IL-2 alpha genes]	1.5849625007211563	3	1	0	0
13869	1520	role of chromatin degradation	[role of chromatin degradation]	1.5849625007211563	4	1	0	0
13870	1520	inhibitory effect of c-Rel	[inhibitory effects of c-Rel]	1.5849625007211563	4	1	0	0
13871	1520	various hiv-1 isolate	[various HIV-1 isolates]	1.5849625007211563	3	1	0	0
13872	1520	even at dose	[even at doses]	1.5849625007211563	3	1	0	0
13873	1520	acute lung injury	[acute lung injury]	1.5849625007211563	3	2	1	1
13874	1520	nontuberculous lung disease	[nontuberculous lung diseases]	1.5849625007211563	3	1	0	0
13875	1520	two Sp1 binding site	[two Sp1 binding sites]	1.5849625007211563	4	2	1	1
13876	1520	suggest sufficient for proliferation	[suggesting sufficient for proliferation]	1.5849625007211563	4	1	0	0
13877	1520	er content of lymphocyte	[ER content of lymphocytes]	1.5849625007211563	4	1	0	0
13878	1520	regulation in T cell	[regulation in T cells]	1.5849625007211563	4	2	2	2
13879	1520	different gch compound	[different GCH compounds]	1.5849625007211563	3	1	0	0
13880	1520	distinct cytokine profile	[distinct cytokine profiles]	1.5849625007211563	3	1	0	0
13881	1520	intestinal epithelial cell apoptosis	[intestinal epithelial cell apoptosis]	1.5849625007211563	4	1	0	0
13882	1520	late stage cell	[late stage cells]	1.5849625007211563	3	2	1	1
13883	1520	er-alpha protein expression	[ER-alpha protein expression]	1.5849625007211563	3	1	0	0
13884	1520	various fundamental cellular processes,	[various fundamental cellular processes,]	1.5849625007211563	4	1	0	0
13885	1520	fusion protein to g-csf	[fusion protein to G-CSF]	1.5849625007211563	4	1	0	0
13886	1520	cell surface cd4(-)cd8(-)cd3(-) cell	[cell surface CD4(-)CD8(-)CD3(-) cells]	1.5849625007211563	4	1	0	0
13887	1520	human carotid artery ECs	[human carotid artery ECs]	1.5849625007211563	4	1	0	0
13888	1520	compare the nucleotide sequence	[comparing the nucleotide sequence]	1.5849625007211563	4	1	0	0
13889	1520	other regulatory element	[other regulatory element]	1.5849625007211563	3	1	0	0
13890	1520	such as IkappaB alpha	[such as IkappaB alpha]	1.5849625007211563	4	1	0	0
13891	1520	two transcriptional coactivator	[two transcriptional coactivators]	1.5849625007211563	3	2	2	2
13892	1520	corresponding human I gamma	[corresponding human I gamma]	1.5849625007211563	4	1	0	0
13893	1520	activity of copy	[activity of copies]	1.5849625007211563	3	1	0	0
13894	1520	monocytic cell line U937	[monocytic cell line U937]	1.5849625007211563	4	1	0	0
13895	1520	amino enhancer of protein	[amino enhancer of protein]	1.5849625007211563	4	1	0	0
13896	1520	carboxyl-terminal region amino acid	[carboxyl-terminal region amino acids]	1.5849625007211563	4	2	2	2
13897	1520	acute phase protein	[acute phase proteins]	1.5849625007211563	3	2	1	1
13898	1520	constitutive dna-binding activity	[constitutive DNA-binding activity]	1.5849625007211563	3	1	0	0
13899	1520	platelet from 14 white	[Platelets from 14 white]	1.5849625007211563	4	1	0	0
13900	1520	use a short pulse	[using a short pulse]	1.5849625007211563	4	1	0	0
13901	1520	whole cell assay patient	[whole cell assay patients]	1.5849625007211563	4	1	0	0
13902	1520	international-toxicity equivalency I-TE	[International-Toxicity Equivalencies I-TE]	1.5849625007211563	3	1	0	0
13903	1520	production of blood cell	[production of blood cells]	1.5849625007211563	4	1	0	0
13904	1520	T cell receptor cross-linking	[T cell receptor cross-linking]	1.5849625007211563	4	1	0	0
13905	1520	chronicity of the disease,	[chronicity of the disease,]	1.5849625007211563	4	1	0	0
13906	1520	normal non-viral oncogene-expressing	[normal non-viral oncogene-expressing]	1.5849625007211563	3	1	0	0
13907	1520	suggest caspase -dependent	[suggesting caspase -dependent]	1.5849625007211563	3	1	0	0
13908	1520	urinary cortisol level	[urinary cortisol levels]	1.5849625007211563	3	1	0	0
13909	1520	effect on inducibility	[effect on inducibility]	1.5849625007211563	3	1	0	0
13910	1520	combination of m-csf	[combination of M-CSF]	1.5849625007211563	3	1	0	0
13911	1520	Burkitt lymphoma Raji cell	[Burkitt lymphoma Raji cell]	1.5849625007211563	4	1	0	0
13912	1520	advantage of monoclonal model	[advantage of monoclonal model]	1.5849625007211563	4	1	0	0
13913	1520	mangabey cell lysate	[mangabey cell lysates]	1.5849625007211563	3	1	0	0
13914	1520	senescent cd8+ T cell	[senescent CD8+ T cells]	1.5849625007211563	4	1	0	0
13915	1520	variance, in PAEC	[variance, in PAEC]	1.5849625007211563	3	1	0	0
13916	1520	proximal IL-5 promoter	[proximal IL-5 promoter]	1.5849625007211563	3	1	0	0
13917	1520	stimulation by RA	[Stimulation by RA]	1.5849625007211563	3	1	0	0
13918	1520	CRE oligonucleotide probe	[CRE oligonucleotide probe]	1.5849625007211563	3	1	0	0
13919	1520	CIS rapidly tyrosine	[CIS rapidly tyrosine]	1.5849625007211563	3	1	0	0
13920	1520	site of chronic inflammation	[sites of chronic inflammation]	1.5849625007211563	4	2	1	1
13921	1520	lineage transcription factor	[lineage transcription factor]	1.5849625007211563	3	2	1	1
13922	1520	involvement of signal transducer	[involvement of signal transducers]	1.5849625007211563	4	1	0	0
13923	1520	CD40 -inducible molecule	[CD40 -inducible molecule]	1.5849625007211563	3	1	0	0
13924	1520	presence of TGF-beta	[presence of TGF-beta]	1.5849625007211563	3	1	0	0
13925	1520	precursor frequency for t-lymphocyte	[precursor frequencies for T-lymphocytes]	1.5849625007211563	4	1	0	0
13926	1520	class of inducible factor	[class of inducible factors]	1.5849625007211563	4	1	0	0
13927	1520	number of peptide	[number of peptides]	1.5849625007211563	3	3	2	1
13928	1520	Kaposi's sarcoma herpesvirus KSHV	[Kaposi's sarcoma herpesvirus KSHV]	1.5849625007211563	4	1	0	0
13929	1520	RARalpha /pml fusion protein	[RARalpha /PML fusion proteins]	1.5849625007211563	4	1	0	0
13930	1520	gene expression in lymphocyte	[gene expression in lymphocytes]	1.5849625007211563	4	2	2	2
13931	1520	Intercellular adhesion molecule-1	[Intercellular adhesion molecule-1]	1.5849625007211563	3	1	0	0
13932	1520	murine b cell line	[murine B cell line]	1.5849625007211563	4	1	0	0
13933	1520	isolation of multiple rdna	[isolation of multiple cDNAs]	1.5849625007211563	4	1	0	0
13934	1520	contain the GM-kappa b/gc-box	[containing the GM-kappa B/GC-box]	1.5849625007211563	4	1	0	0
13935	1520	disturbance in serum concentration	[disturbances in serum concentration]	1.5849625007211563	4	1	0	0
13936	1520	result of transform ability	[result of transforming abilities]	1.5849625007211563	4	1	0	0
13937	1520	absence of ec	[absence of EC]	1.5849625007211563	3	1	0	0
13938	1520	camp -dependent second-messenger pathway	[cAMP -dependent second-messenger pathway]	1.5849625007211563	4	1	0	0
13939	1520	possibly tcr beta	[possibly TCR beta]	1.5849625007211563	3	1	0	0
13940	1520	rate of er content	[rate of ER content]	1.5849625007211563	4	1	0	0
13941	1520	age of the donor,	[age of the donor,]	1.5849625007211563	4	1	0	0
13942	1520	role limit the duration	[role limiting the duration]	1.5849625007211563	4	1	0	0
13943	1520	IL-4 gene -311ctcccttct-303 NRE-I	[IL-4 gene -311CTCCCTTCT-303 NRE-I]	1.5849625007211563	4	1	0	0
13944	1520	heat shock response	[heat shock response]	1.5849625007211563	3	1	0	0
13945	1520	hypersensitivity of the heart	[hypersensitivity of the heart]	1.5849625007211563	4	1	0	0
13946	1520	ability of ascorbate	[ability of ascorbate]	1.5849625007211563	3	1	0	0
13947	1520	sequence within the repeat	[sequence within the repeat]	1.5849625007211563	4	1	0	0
13948	1520	inducible egr-1 protein	[inducible EGR-1 protein]	1.5849625007211563	3	1	0	0
13949	1520	androgen receptor (humara) locus	[androgen receptor (HUMARA) locus]	1.5849625007211563	4	1	0	0
13950	1520	chloramphenicol acetyltransferase reporter construct	[chloramphenicol acetyltransferase reporter construct]	1.5849625007211563	4	1	0	0
13951	1520	constitutive MHC class expression	[constitutive MHC class expression]	1.5849625007211563	4	2	2	2
13952	1520	include virus-induced tumorigenesis.	[including virus-induced tumorigenesis.]	1.5849625007211563	3	1	0	0
13953	1520	direct-repeat palindrome tgcgcatgcgca	[direct-repeat palindrome TGCGCATGCGCA]	1.5849625007211563	3	1	0	0
13954	1520	abnormality of/or influence nf-at	[abnormality of/or influencing NF-AT]	1.5849625007211563	4	1	0	0
13955	1520	position -502 to -413	[positions -502 to -413]	1.5849625007211563	4	1	0	0
13956	1520	protect to cell death	[protecting to cell death]	1.5849625007211563	4	1	0	0
13957	1520	ability -express human cell	[abilities -expressing human cells]	1.5849625007211563	4	2	2	2
13958	1520	causal role in oncogenesis	[causal role in oncogenesis]	1.5849625007211563	4	1	0	0
13959	1520	however, sodium supplementation	[however, sodium supplementation]	1.5849625007211563	3	1	0	0
13960	1520	absence of NE	[absence of NE]	1.5849625007211563	3	1	0	0
13961	1520	qualitatively similar cellular response	[qualitatively similar cellular responses]	1.5849625007211563	4	1	0	0
13962	1520	evidence of wild-type reversion	[evidence of wild-type reversion]	1.5849625007211563	4	1	0	0
13963	1520	2 hashimoto disease	[2 Hashimoto's disease]	1.5849625007211563	3	1	0	0
13964	1520	variety by means	[variety by means]	1.5849625007211563	3	1	0	0
13965	1520	cell to radiation-induced apoptosis	[cells to radiation-induced apoptosis]	1.5849625007211563	4	1	0	0
13966	1520	suppress toxic/septic shock	[suppressing toxic/septic shock]	1.5849625007211563	3	1	0	0
13967	1520	anti-CD3 monoclonal antibody mab	[anti-CD3 monoclonal antibody mAb]	1.5849625007211563	4	2	1	1
13968	1520	class of AIDS NHL	[class of AIDS NHL]	1.5849625007211563	4	2	2	2
13969	1520	relative level of TCRzeta	[relative levels of TCRzeta]	1.5849625007211563	4	1	0	0
13970	1520	15 day of treatment	[15 days of treatment]	1.5849625007211563	4	1	0	0
13971	1520	adenovirus (ad) infection	[Adenovirus (Ad) infection]	1.5849625007211563	3	1	0	0
13972	1520	simian immunodeficiency virus SIV	[simian immunodeficiency virus SIV]	1.5849625007211563	4	1	0	0
13973	1520	mouse perforin gene	[mouse perforin gene]	1.5849625007211563	3	2	1	1
13974	1520	number of pbmc respond	[number of PBMC responding]	1.5849625007211563	4	1	0	0
13975	1520	augmentation of growth	[augmentation of growth]	1.5849625007211563	3	1	0	0
13976	1520	purine-box/antigen receptor response element	[purine-box/antigen receptor response element]	1.5849625007211563	4	1	0	0
13977	1520	express a pattern	[expressing a pattern]	1.5849625007211563	3	2	2	2
13978	1520	two tandem Ap1 site	[two tandem Ap1 sites]	1.5849625007211563	4	1	0	0
13979	1520	cross-linked anti-cd3epsilon mab okt3	[cross-linked anti-CD3epsilon mAb OKT3]	1.5849625007211563	4	1	0	0
13980	1520	result in two infant	[Results in two infants]	1.5849625007211563	4	1	0	0
13981	1520	cell from young donor	[cells from young donors]	1.5849625007211563	4	1	0	0
13982	1520	upregulation by interleukin-4 il-4	[upregulation by interleukin-4 IL-4]	1.5849625007211563	4	1	0	0
13983	1520	Phosphatidyl inositol 3-kinase PI3K	[Phosphatidyl inositol 3-kinase PI3K]	1.5849625007211563	4	1	0	0
13984	1520	four genomic anonymous probe	[four genomic anonymous probes]	1.5849625007211563	4	1	0	0
13985	1520	neoplastic cell in AITL	[neoplastic cells in AITL]	1.5849625007211563	4	1	0	0
13986	1520	corneal endothelium by dexamethasone	[corneal endothelium by dexamethasone]	1.5849625007211563	4	1	0	0
13987	1520	CD40 ligand cd40l expression	[CD40 ligand CD40L expression]	1.5849625007211563	4	1	0	0
13988	1520	intermediate T cell proliferation	[intermediate T cell proliferation]	1.5849625007211563	4	1	0	0
13989	1520	several hundred basis	[several hundred bases]	1.5849625007211563	3	1	0	0
13990	1520	x box-dependent transcriptional pathway	[X box-dependent transcriptional pathway]	1.5849625007211563	4	1	0	0
13991	1520	addition of calf serum	[addition of calf serum]	1.5849625007211563	4	1	0	0
13992	1520	functional parameter tsh-r	[functional parameters TSH-R]	1.5849625007211563	3	1	0	0
13993	1520	dna-binding regulatory factor	[DNA-binding regulatory factor]	1.5849625007211563	3	1	0	0
13994	1520	role of salicylate	[role of salicylate]	1.5849625007211563	3	1	0	0
13995	1520	inhibit the calcium-	[inhibiting the calcium-]	1.5849625007211563	3	1	0	0
13996	1520	calcitriol action in gut	[calcitriol action in gut]	1.5849625007211563	4	1	0	0
13997	1520	(47 repeats), 66%	[(47 repeats), 66%]	1.5849625007211563	3	1	0	0
13998	1520	u-937 cell line	[U-937 cell line]	1.5849625007211563	3	1	0	0
13999	1520	hsp70 mrna species	[HSP70 mRNA species]	1.5849625007211563	3	1	0	0
14000	1520	prolong xenograft survival	[prolonging xenograft survival]	1.5849625007211563	3	1	0	0
14001	1520	group of subject	[group of subjects]	1.5849625007211563	3	2	2	2
14002	1520	expression of that gene	[expression of those genes]	1.5849625007211563	4	1	0	0
14003	1520	molecular mass of kilodalton	[molecular mass of kilodaltons]	1.5849625007211563	4	2	2	2
14004	1520	contrast, factor in addition	[contrast, factors in addition]	1.5849625007211563	4	1	0	0
14005	1520	expression of thyroid peroxidase	[expression of thyroid peroxidase]	1.5849625007211563	4	1	0	0
14006	1520	binding of the protein	[binding of the protein]	1.5849625007211563	4	2	2	2
14007	1520	morphologic risk factor	[morphologic risk factors]	1.5849625007211563	3	1	0	0
14008	1520	kappa b-like sequence	[kappa B-like sequence]	1.5849625007211563	3	1	0	0
14009	1520	surround interfollicular zone	[surrounding interfollicular zones]	1.5849625007211563	3	1	0	0
14010	1520	experimental expression in mouse	[Experimental expression in mice]	1.5849625007211563	4	1	0	0
14011	1520	degradation by the proteasome	[degradation by the proteasome]	1.5849625007211563	4	1	0	0
14012	1520	16-96 h post-PMA	[16-96 h post-PMA]	1.5849625007211563	3	1	0	0
14013	1520	serum-starved mm patient cell	[serum-starved MM patient cells]	1.5849625007211563	4	1	0	0
14014	1520	ionomycin myristate acetate PMA	[ionomycin myristate acetate PMA]	1.5849625007211563	4	1	0	0
14015	1520	interleukin 9 il-9	[interleukin 9 IL-9]	1.5849625007211563	3	1	0	0
14016	1520	p42/44 (erk) mapk cascade	[p42/44 (ERK) MAPk cascade]	1.5849625007211563	4	1	0	0
14017	1520	different great ape	[different great apes]	1.5849625007211563	3	1	0	0
14018	1520	DNA binding component	[DNA binding component]	1.5849625007211563	3	1	0	0
14019	1520	Namalwa b lymphoid cell	[Namalwa B lymphoid cells]	1.5849625007211563	4	1	0	0
14020	1520	deregulation of the pathway	[Deregulation of the pathway]	1.5849625007211563	4	1	0	0
14021	1520	intact gpix ets site	[intact GPIX Ets site]	1.5849625007211563	4	1	0	0
14022	1520	precursor for steroid hormone	[precursor for steroid hormones]	1.5849625007211563	4	1	0	0
14023	1520	receptor alpha subunit	[receptor alpha subunit]	1.5849625007211563	3	2	2	2
14024	1520	mechanism responsible for expression	[mechanisms responsible for expression]	1.5849625007211563	4	2	1	1
14025	1520	mrna of 2061 bp	[mRNA of 2061 bp]	1.5849625007211563	4	1	0	0
14026	1520	differentiation of human,	[differentiation of human,]	1.5849625007211563	3	1	0	0
14027	1520	reduction of the percentage	[reduction of the percentage]	1.5849625007211563	4	1	0	0
14028	1520	significant e2a protein expression	[significant E2A protein expression]	1.5849625007211563	4	1	0	0
14029	1520	certain elderly individual	[certain elderly individuals]	1.5849625007211563	3	1	0	0
14030	1520	nuclei of thymocyte	[nuclei of thymocytes]	1.5849625007211563	3	1	0	0
14031	1520	b cell ig secretion	[B cell Ig secretion]	1.5849625007211563	4	2	1	1
14032	1520	thus with the completion	[thus with the completion]	1.5849625007211563	4	1	0	0
14033	1520	least three exon	[least three exons]	1.5849625007211563	3	1	0	0
14034	1520	rampant virus replication	[rampant virus replication]	1.5849625007211563	3	1	0	0
14035	1520	mast cell activation signal	[mast cell activation signals]	1.5849625007211563	4	1	0	0
14036	1520	individual latent protein	[individual latent proteins]	1.5849625007211563	3	1	0	0
14037	1520	nm in group	[nM in group]	1.5849625007211563	3	2	2	2
14038	1520	tcf-1 knock-out mouse	[TCF-1 knock-out mice]	1.5849625007211563	3	2	1	1
14039	1520	inflammatory protein-1alpha mip-1alpha	[inflammatory protein-1alpha MIP-1alpha]	1.5849625007211563	3	1	0	0
14040	1520	cell in phase s	[cells in phase S]	1.5849625007211563	4	1	0	0
14041	1520	t-cell receptor (tcr)	[T-cell receptor (TCR)]	1.5849625007211563	3	1	0	0
14042	1520	function of this proteins.	[function of these proteins.]	1.5849625007211563	4	1	0	0
14043	1520	serine phosphorylation of STAT1	[Serine phosphorylation of STAT1]	1.5849625007211563	4	1	0	0
14044	1520	nuclear factor-chi b	[nuclear factor-chi B]	1.5849625007211563	3	1	0	0
14045	1520	kappa b dna-binding proteins.	[kappa B DNA-binding proteins.]	1.5849625007211563	4	1	0	0
14046	1520	T cell product il-2	[T cell products IL-2]	1.5849625007211563	4	1	0	0
14047	1520	biological function of Spi-B	[biological function of Spi-B]	1.5849625007211563	4	1	0	0
14048	1520	DRA promoter construct	[DRA promoter construct]	1.5849625007211563	3	1	0	0
14049	1520	chronic renal failure patient	[chronic renal failure patients]	1.5849625007211563	4	1	0	0
14050	1520	65 +/- 7	[65 +/- 7]	1.5849625007211563	3	1	0	0
14051	1520	similarity in structural motif	[similarities in structural motifs]	1.5849625007211563	4	1	0	0
14052	1520	h of incubation,	[h of incubation,]	1.5849625007211563	3	1	0	0
14053	1520	SH with renal transplant	[SH with renal transplant]	1.5849625007211563	4	1	0	0
14054	1520	pathway lead to activation	[pathways leading to activation]	1.5849625007211563	4	1	0	0
14055	1520	transcription from nucleosomal DNA	[transcription from nucleosomal DNA]	1.5849625007211563	4	1	0	0
14056	1520	mechanism for upregulation	[mechanism for upregulation]	1.5849625007211563	3	1	0	0
14057	1520	DNA change 2418delA	[DNA change 2418delA]	1.5849625007211563	3	1	0	0
14058	1520	high NK activity	[higher NK activity]	1.5849625007211563	3	1	0	0
14059	1520	lck gene expression	[lck gene expression]	1.5849625007211563	3	1	0	0
14060	1520	form of c-myb	[form of c-myb]	1.5849625007211563	3	1	0	0
14061	1520	maximal il-1 beta	[maximal IL-1 beta]	1.5849625007211563	3	1	0	0
14062	1520	synthetic analog of OspA	[synthetic analogs of OspA]	1.5849625007211563	4	1	0	0
14063	1520	many inflammatory disease	[many inflammatory diseases]	1.5849625007211563	3	1	0	0
14064	1520	TA-rich sequence present	[TA-rich sequence present]	1.5849625007211563	3	1	0	0
14065	1520	control of nfat	[control of NFAT]	1.5849625007211563	3	1	0	0
14066	1520	HeLa cell line	[HeLa cell lines]	1.5849625007211563	3	1	0	0
14067	1520	XY sex-reversed female	[XY sex-reversed female]	1.5849625007211563	3	1	0	0
14068	1520	competitive model of switch	[competitive model of switching]	1.5849625007211563	4	1	0	0
14069	1520	Precise alignment of site	[Precise alignment of sites]	1.5849625007211563	4	1	0	0
14070	1520	many immunologically important gene	[many immunologically important genes]	1.5849625007211563	4	1	0	0
14071	1520	early event in atherogenesis	[early event in atherogenesis]	1.5849625007211563	4	2	1	1
14072	1520	approximately 1.8 kb 5'	[approximately 1.8 kb 5']	1.5849625007211563	4	1	0	0
14073	1520	enable efficient transcriptional activation	[enabling efficient transcriptional activation]	1.5849625007211563	4	1	0	0
14074	1520	less extent, in cell	[lesser extent, in cells]	1.5849625007211563	4	1	0	0
14075	1520	exposure to dimethyl sulfoxide	[exposure to dimethyl sulfoxide]	1.5849625007211563	4	1	0	0
14076	1520	serum concentration of calcitriol	[serum concentration of calcitriol]	1.5849625007211563	4	1	0	0
14077	1520	transcriptional hierarchy of hnf	[transcriptional hierarchy of HNFs]	1.5849625007211563	4	1	0	0
14078	1520	cellular activation signals,	[cellular activation signals,]	1.5849625007211563	3	1	0	0
14079	1520	Cytokine-stimulated cell surface expression	[Cytokine-stimulated cell surface expression]	1.5849625007211563	4	1	0	0
14080	1520	vivo dnase i footprint	[vivo DNAse I footprint]	1.5849625007211563	4	1	0	0
14081	1520	several hemopoietic cell line	[several hemopoietic cell lines]	1.5849625007211563	4	1	0	0
14082	1520	cd8(+)-t-cell response to hcmv	[CD8(+)-T-cell response to HCMV]	1.5849625007211563	4	1	0	0
14083	1520	b cell line Raji	[B cell line Raji]	1.5849625007211563	4	1	0	0
14084	1520	transcription in vitro.	[transcription in vitro.]	1.5849625007211563	3	1	0	0
14085	1520	C; kinetic analysis	[C; kinetic analysis]	1.5849625007211563	3	1	0	0
14086	1520	high dose of staurosporine	[high doses of staurosporine]	1.5849625007211563	4	1	0	0
14087	1520	three zinc finger	[three zinc fingers]	1.5849625007211563	3	2	1	1
14088	1520	transfection of decoy oligodeoxynucleotides	[transfection of decoy oligodeoxynucleotides]	1.5849625007211563	4	1	0	0
14089	1520	preleukaemic clone cell	[preleukaemic clone cells]	1.5849625007211563	3	1	0	0
14090	1520	activation of IL-5 gene	[activation of IL-5 genes]	1.5849625007211563	4	1	0	0
14091	1520	modification of the expression	[modification of the expression]	1.5849625007211563	4	1	0	0
14092	1520	term of host interaction	[terms of host interaction]	1.5849625007211563	4	1	0	0
14093	1520	human androgen receptor humara	[human androgen receptor HUMARA]	1.5849625007211563	4	1	0	0
14094	1520	nonmonocytic cell line HeLa	[nonmonocytic cell lines HeLa]	1.5849625007211563	4	1	0	0
14095	1520	NFAT family protein	[NFAT family proteins]	1.5849625007211563	3	1	0	0
14096	1520	member of the class	[member of the class]	1.5849625007211563	4	1	0	0
14097	1520	peroxidase-negative granule contain gelatinase	[peroxidase-negative granules containing gelatinase]	1.5849625007211563	4	1	0	0
14098	1520	respect to PAEC	[respect to PAEC]	1.5849625007211563	3	1	0	0
14099	1520	viability of DC	[viability of DC]	1.5849625007211563	3	1	0	0
14100	1520	nf-kappa b element	[NF-kappa B elements]	1.5849625007211563	3	2	2	2
14101	1520	receptor subunit gamma c	[receptor subunit gamma c]	1.5849625007211563	4	1	0	0
14102	1520	h in PBL	[h in PBL]	1.5849625007211563	3	2	2	2
14103	1520	human granzyme b promoter	[human granzyme B promoter]	1.5849625007211563	4	1	0	0
14104	1520	follow interferon-gamma treatment	[following interferon-gamma treatment]	1.5849625007211563	3	1	0	0
14105	1520	adenovirus e1b 19k	[adenovirus E1B 19K]	1.5849625007211563	3	1	0	0
14106	1520	increase in the intensity	[increase in the intensity]	1.5849625007211563	4	1	0	0
14107	1520	consensus binding motif	[consensus binding motif]	1.5849625007211563	3	1	0	0
14108	1520	reaction of the host	[reactions of the host]	1.5849625007211563	4	1	0	0
14109	1520	htlv-1 T cell	[HTLV-1 T cells]	1.5849625007211563	3	1	0	0
14110	1520	hetero-oligomeric mr form	[hetero-oligomeric MR form]	1.5849625007211563	3	1	0	0
14111	1520	use lps 1.0	[using LPS 1.0]	1.5849625007211563	3	1	0	0
14112	1520	change in plasma acth	[changes in plasma ACTH]	1.5849625007211563	4	1	0	0
14113	1520	syk tyrosine kinase	[Syk tyrosine kinase]	1.5849625007211563	3	1	0	0
14114	1520	PML/RAR alpha mrna	[PML/RAR alpha mRNA]	1.5849625007211563	3	1	0	0
14115	1520	impaired activation of nfkappab	[impaired activation of NFkappaB]	1.5849625007211563	4	1	0	0
14116	1520	ball1 b cell	[BALL1 B cell]	1.5849625007211563	3	1	0	0
14117	1520	adherent human igg	[adherent human IgG]	1.5849625007211563	3	1	0	0
14118	1520	inheritance of a defect	[inheritance of a defect]	1.5849625007211563	4	1	0	0
14119	1520	ebv lytic antigen	[EBV lytic antigen]	1.5849625007211563	3	1	0	0
14120	1520	x chromosome inactivation pattern	[X chromosome inactivation pattern]	1.5849625007211563	4	1	0	0
14121	1520	effectively, low responder	[effectively, low responders]	1.5849625007211563	3	1	0	0
14122	1520	digital image analysis	[digital image analysis]	1.5849625007211563	3	1	0	0
14123	1520	Mono Mac-6 cell	[Mono Mac-6 cells]	1.5849625007211563	3	1	0	0
14124	1520	exposure to tpa	[exposure to TPA]	1.5849625007211563	3	2	1	1
14125	1520	allergic eosinophilic disease	[allergic eosinophilic disease.]	1.5849625007211563	3	1	0	0
14126	1520	assay volume 0.25 millileter	[assay volume 0.25 ml]	1.5849625007211563	4	1	0	0
14127	1520	level of bcl-2 protein	[levels of BCL-2 protein]	1.5849625007211563	4	1	0	0
14128	1520	antioxidant on the basis	[antioxidants on the basis]	1.5849625007211563	4	1	0	0
14129	1520	integration of opposing signal	[integration of opposing signals]	1.5849625007211563	4	1	0	0
14130	1520	immunoblotting of nuclear fraction	[immunoblotting of nuclear fractions]	1.5849625007211563	4	1	0	0
14131	1520	plasma aldosterone level	[plasma aldosterone levels]	1.5849625007211563	3	1	0	0
14132	1520	human il-4 gene	[human IL-4 gene]	1.5849625007211563	3	1	0	0
14133	1520	IFN beta promoter deletion	[IFN beta promoter deletions]	1.5849625007211563	4	1	0	0
14134	1520	phosphorylation of serine residue	[phosphorylation of serine residues]	1.5849625007211563	4	1	0	0
14135	1520	upstream enhancer region	[upstream enhancer region]	1.5849625007211563	3	1	0	0
14136	1520	interleukin-10 (il-10) receptor	[interleukin-10 (IL-10) receptor]	1.5849625007211563	3	1	0	0
14137	1520	overexpression of egfr 35%,	[overexpression of EGFR 35%,]	1.5849625007211563	4	1	0	0
14138	1520	normal human thymocytes.	[normal human thymocytes.]	1.5849625007211563	3	1	0	0
14139	1520	59-kda protein [tai,	[59-kDa protein [Tai,]	1.5849625007211563	3	1	0	0
14140	1520	humara loci in eosinophil	[HUMARA loci in eosinophils]	1.5849625007211563	4	1	0	0
14141	1520	p40 mrna expression	[p40 mRNA expression]	1.5849625007211563	3	1	0	0
14142	1520	pattern in T cell	[pattern in T cells]	1.5849625007211563	4	2	2	2
14143	1520	DC lineage commitment	[DC lineage commitment]	1.5849625007211563	3	1	0	0
14144	1520	light chain gene	[light chain genes]	1.5849625007211563	3	1	0	0
14145	1520	chronic myeloid leukaemia	[chronic myeloid leukaemia]	1.5849625007211563	3	1	0	0
14146	1520	level of phospholipase a2	[level of phospholipase A2]	1.5849625007211563	4	1	0	0
14147	1520	presence of androgen receptor	[presence of androgen receptors]	1.5849625007211563	4	1	0	0
14148	1520	1.6 micromol/L; dg	[1.6 micromol/L; DG]	1.5849625007211563	3	1	0	0
14149	1520	continuous viral replication	[continuous viral replication]	1.5849625007211563	3	1	0	0
14150	1520	IFNalpha- inducible gene	[IFNalpha- inducible genes]	1.5849625007211563	3	1	0	0
14151	1520	diverse cell lineage	[diverse cell lineages]	1.5849625007211563	3	1	0	0
14152	1520	role in megakaryopoiesis/ thrombopoiesis	[role in megakaryopoiesis/ thrombopoiesis]	1.5849625007211563	4	1	0	0
14153	1520	preference for gene activation	[preference for gene activation]	1.5849625007211563	4	1	0	0
14154	1520	dramatic cell aggregation.	[dramatic cell aggregation.]	1.5849625007211563	3	1	0	0
14155	1520	ifn-alpha growth arrest	[IFN-alpha growth arrest]	1.5849625007211563	3	1	0	0
14156	1520	use of combination	[use of combinations]	1.5849625007211563	3	2	2	2
14157	1520	majority of nasopharyngeal carcinoma	[majority of nasopharyngeal carcinomas]	1.5849625007211563	4	1	0	0
14158	1520	synergy between this factor	[synergy between these factors]	1.5849625007211563	4	1	0	0
14159	1520	indicate activated, proliferated,	[indicating activated, proliferated,]	1.5849625007211563	3	1	0	0
14160	1520	von Willebrand receptor GPIb-V-IX	[von Willebrand receptor GPIb-V-IX]	1.5849625007211563	4	1	0	0
14161	1520	several sequence motif	[several sequence motifs]	1.5849625007211563	3	2	1	1
14162	1520	PTK inhibition with Gen	[PTK inhibition with Gen]	1.5849625007211563	4	1	0	0
14163	1520	monocytoid U937 cell line	[monocytoid U937 cell line]	1.5849625007211563	4	1	0	0
14164	1520	dephosphorylation of 4E-BP1	[Dephosphorylation of 4E-BP1]	1.5849625007211563	3	1	0	0
14165	1520	phosphorylation of peptide	[phosphorylation of peptides]	1.5849625007211563	3	1	0	0
14166	1520	human IL-13 gene	[human IL-13 gene]	1.5849625007211563	3	1	0	0
14167	1520	pattern of pml expression	[pattern of PML expression]	1.5849625007211563	4	1	0	0
14168	1520	activation of myeloid lineage	[activation of myeloid lineages]	1.5849625007211563	4	1	0	0
14169	1520	other immunological function	[other immunological functions]	1.5849625007211563	3	1	0	0
14170	1520	role of ap-2	[role of AP-2]	1.5849625007211563	3	1	0	0
14171	1520	presence of il-2	[presence of IL-2]	1.5849625007211563	3	1	0	0
14172	1520	sensitive (ic50 381 ng/ml)	[sensitive (IC50 381 ng/mL)]	1.5849625007211563	4	1	0	0
14173	1520	reactive metabolite of oxygen	[reactive metabolites of oxygen]	1.5849625007211563	4	2	1	1
14174	1520	lytic ebv expression	[lytic EBV expression]	1.5849625007211563	3	1	0	0
14175	1520	increase of cortisol	[increase of cortisol]	1.5849625007211563	3	1	0	0
14176	1520	sea urchin function	[sea urchin functions]	1.5849625007211563	3	1	0	0
14177	1520	human thromboxane receptor gene	[human thromboxane receptor gene]	1.5849625007211563	4	1	0	0
14178	1520	two different transcription factor	[two different transcription factors]	1.5849625007211563	4	2	1	1
14179	1520	N terminus of EBNA2	[N terminus of EBNA2]	1.5849625007211563	4	1	0	0
14180	1520	CD40 -positive immunogenic MMs	[CD40 -positive immunogenic MMs]	1.5849625007211563	4	1	0	0
14181	1520	pip pu.1 -interaction partner	[Pip PU.1 -interaction partner]	1.5849625007211563	4	1	0	0
14182	1520	pkc- dependent signal system	[PKC- dependent signaling systems]	1.5849625007211563	4	1	0	0
14183	1520	effect on ZAP-70	[effect on ZAP-70]	1.5849625007211563	3	1	0	0
14184	1520	expression of level	[expression of levels]	1.5849625007211563	3	2	2	2
14185	1520	octamer site contain gene	[octamer sites containing genes]	1.5849625007211563	4	1	0	0
14186	1520	also a inhibitor	[also an inhibitor]	1.5849625007211563	3	2	2	2
14187	1520	NF-M the chicken homolog	[NF-M the chicken homolog]	1.5849625007211563	4	1	0	0
14188	1520	p42/p44 protein kinase	[p42/p44 protein kinase]	1.5849625007211563	3	1	0	0
14189	1520	contain zinc finger	[containing zinc fingers]	1.5849625007211563	3	2	2	2
14190	1520	combination of lps	[combination of LPS]	1.5849625007211563	3	1	0	0
14191	1520	t-cell accumulation in tissue.	[T-cell accumulation in tissue.]	1.5849625007211563	4	1	0	0
14192	1520	cotreatment with actinomycin d	[cotreatment with actinomycin D]	1.5849625007211563	4	1	0	0
14193	1520	intracellular adhesion molecule (icam)-1	[intracellular adhesion molecule (ICAM)-1]	1.5849625007211563	4	1	0	0
14194	1520	mutation of IkappaBbeta	[mutation Of IkappaBbeta]	1.5849625007211563	3	1	0	0
14195	1520	chimeric gal4 -hsf3 protein	[chimeric GAL4 -HSF3 protein]	1.5849625007211563	4	1	0	0
14196	1520	non-genomic aldosterone effects.	[non-genomic aldosterone effects.]	1.5849625007211563	3	1	0	0
14197	1520	cockayne' syndrome CS	[Cockayne's syndrome CS]	1.5849625007211563	3	1	0	0
14198	1520	lytic gene cascade	[lytic gene cascade]	1.5849625007211563	3	1	0	0
14199	1520	normal human neutrophil	[normal human neutrophils]	1.5849625007211563	3	1	0	0
14200	1520	reporter gene encode	[reporter gene encoding]	1.5849625007211563	3	1	0	0
14201	1520	induction of calcium flux	[induction of calcium fluxes]	1.5849625007211563	4	1	0	0
14202	1520	Ala618 to Ser	[Ala618 to Ser]	1.5849625007211563	3	1	0	0
14203	1520	production of this molecule,	[production of this molecule,]	1.5849625007211563	4	1	0	0
14204	1520	eutopic implantation site	[eutopic implantation sites]	1.5849625007211563	3	1	0	0
14205	1520	Jun family member	[Jun family members]	1.5849625007211563	3	2	2	2
14206	1520	sequence-specific hmg box	[sequence-specific HMG box]	1.5849625007211563	3	2	1	1
14207	1520	determine the mrna level	[determining the mRNA levels]	1.5849625007211563	4	1	0	0
14208	1520	various signal system lead	[various signaling systems leading]	1.5849625007211563	4	1	0	0
14209	1520	human neutrophil gene expression	[human neutrophil gene expression]	1.5849625007211563	4	1	0	0
14210	1520	undefined serine kinase	[undefined serine kinase]	1.5849625007211563	3	1	0	0
14211	1520	response to bacterial pathogen	[response to bacterial pathogens]	1.5849625007211563	4	1	0	0
14212	1520	follow such genetic alteration	[following such genetic alterations]	1.5849625007211563	4	1	0	0
14213	1520	two opposite phenotype	[Two opposite phenotypes]	1.5849625007211563	3	1	0	0
14214	1520	progesterone receptor pr	[progesterone receptor PR]	1.5849625007211563	3	2	1	1
14215	1520	steroid -binding region	[steroid -binding region]	1.5849625007211563	3	1	0	0
14216	1520	use RNase protection assay	[using RNase protection assays]	1.5849625007211563	4	1	0	0
14217	1520	immunoglobulin heavy chain	[immunoglobulin heavy chain]	1.5849625007211563	3	2	2	2
14218	1520	pair of CD2 antibody	[pairs of CD2 antibodies]	1.5849625007211563	4	1	0	0
14219	1520	anti-inflammatory activity of glucocorticoid	[anti-inflammatory activity of glucocorticoids]	1.5849625007211563	4	1	0	0
14220	1520	other t-cell activator	[other T-cell activators]	1.5849625007211563	3	1	0	0
14221	1520	retinoic acid (ra)-induced differentiation	[retinoic acid (RA)-induced differentiation]	1.5849625007211563	4	1	0	0
14222	1520	nuclei of monocytes.	[nuclei of monocytes.]	1.5849625007211563	3	1	0	0
14223	1520	increase of AhR mrna	[increase of AhR mRNA]	1.5849625007211563	4	2	2	2
14224	1520	patient with gc resistance	[patient with GC resistance]	1.5849625007211563	4	1	0	0
14225	1520	accord to current model	[According to current models]	1.5849625007211563	4	1	0	0
14226	1520	B104 cell death	[B104 cell death]	1.5849625007211563	3	1	0	0
14227	1520	human IL-5 promoter/enhancer	[human IL-5 promoter/enhancer]	1.5849625007211563	3	1	0	0
14228	1520	response to 24 h	[response to 24 h]	1.5849625007211563	4	1	0	0
14229	1520	promonocyte cell line	[promonocyte cell line]	1.5849625007211563	3	1	0	0
14230	1520	characterization of this protein	[characterization of these proteins]	1.5849625007211563	4	1	0	0
14231	1520	enter the cell cycle	[entering the cell cycle]	1.5849625007211563	4	1	0	0
14232	1520	mapk activity by Bcl-2	[MAPK activity by Bcl-2]	1.5849625007211563	4	1	0	0
14233	1520	CD28 with antibody	[CD28 with antibodies]	1.5849625007211563	3	1	0	0
14234	1520	basis of the effect	[basis of the effect]	1.5849625007211563	4	2	2	2
14235	1520	interferon beta expression	[interferon beta expression]	1.5849625007211563	3	1	0	0
14236	1520	authentic kappa b site	[authentic kappa B site]	1.5849625007211563	4	1	0	0
14237	1520	entire IL-2 promoter-enhancer	[entire IL-2 promoter-enhancer]	1.5849625007211563	3	1	0	0
14238	1520	affinity between depressed patient	[affinity between depressed patients]	1.5849625007211563	4	1	0	0
14239	1520	cytotoxic T cell response	[cytotoxic T cell responses]	1.5849625007211563	4	1	0	0
14240	1520	antimouse alpha A1 antibody	[antimouse alpha A1 antibodies]	1.5849625007211563	4	1	0	0
14241	1520	human herpesvirus type-8 hhv-8	[human herpesvirus type-8 HHV-8]	1.5849625007211563	4	1	0	0
14242	1520	igh 3' enhancer activity	[IgH 3' enhancer activity]	1.5849625007211563	4	2	2	2
14243	1520	closely related (if	[closely related (if]	1.5849625007211563	3	1	0	0
14244	1520	activation of cellular gene	[activation of cellular genes]	1.5849625007211563	4	1	0	0
14245	1520	anti- topoisomerase drug	[anti- topoisomerase drugs]	1.5849625007211563	3	1	0	0
14246	1520	functional reporter-gene assay	[functional reporter-gene assays]	1.5849625007211563	3	1	0	0
14247	1520	binding activity in extract	[binding activity in extracts]	1.5849625007211563	4	2	2	2
14248	1520	induction of the gene	[induction of the gene]	1.5849625007211563	4	1	0	0
14249	1520	adhesion to matrice	[adhesion to matrices]	1.5849625007211563	3	2	2	2
14250	1520	obtain consent, biopsy	[obtaining consent, biopsies]	1.5849625007211563	3	1	0	0
14251	1520	macrophage in lymphoid tissue	[macrophages in lymphoid tissues]	1.5849625007211563	4	1	0	0
14252	1520	low gcr number	[lower GCR number]	1.5849625007211563	3	1	0	0
14253	1520	phase of the disease	[phase of the disease.]	1.5849625007211563	4	2	2	2
14254	1520	gut-associated lymphoid organ	[gut-associated lymphoid organ]	1.5849625007211563	3	1	0	0
14255	1520	less than 24 month	[less than 24 months]	1.5849625007211563	4	2	1	1
14256	1520	cellular cd23 gene expression	[cellular CD23 gene expression]	1.5849625007211563	4	1	0	0
14257	1520	inhibition process dependent	[inhibition processes dependent]	1.5849625007211563	3	1	0	0
14258	1520	prenatal steroid treatment	[prenatal steroid treatment]	1.5849625007211563	3	1	0	0
14259	1520	IL-2 promoter repression	[IL-2 promoter repression]	1.5849625007211563	3	1	0	0
14260	1520	kinetic of activation	[kinetics of activation]	1.5849625007211563	3	1	0	0
14261	1520	increase RA concentration	[Increasing RA concentrations]	1.5849625007211563	3	1	0	0
14262	1520	IL-2 superinduction by Tat	[IL-2 superinduction by Tat]	1.5849625007211563	4	1	0	0
14263	1520	IL-2 beta-casein expression	[IL-2 beta-casein expression]	1.5849625007211563	3	1	0	0
14264	1520	cell type-specific enhancer region	[cell type-specific enhancer region]	1.5849625007211563	4	1	0	0
14265	1520	Thus, nf-at induction	[Thus, NF-AT induction]	1.5849625007211563	3	1	0	0
14266	1520	subgroup of CRF	[subgroups of CRF]	1.5849625007211563	3	1	0	0
14267	1520	variety of sources. here	[variety of sources. Here]	1.5849625007211563	4	1	0	0
14268	1520	New immunosuppressive drug pnu156804	[New immunosuppressive drug PNU156804]	1.5849625007211563	4	1	0	0
14269	1520	Jun n-terminal kinase	[Jun N-terminal kinase]	1.5849625007211563	3	1	0	0
14270	1520	N-Oct protein to Oct-1	[N-Oct proteins to Oct-1]	1.5849625007211563	4	1	0	0
14271	1520	transient transfection system	[transient transfection system]	1.5849625007211563	3	1	0	0
14272	1520	camp elevate agent	[cAMP elevating agents]	1.5849625007211563	3	1	0	0
14273	1520	HL-60/vinc revertant hl-60/vinc/r line	[HL-60/vinc revertant HL-60/vinc/R line]	1.5849625007211563	4	1	0	0
14274	1520	sequence to receptor sequence	[sequence to receptor sequences]	1.5849625007211563	4	1	0	0
14275	1520	rel oncogene family capable	[rel oncogene family capable]	1.5849625007211563	4	1	0	0
14276	1520	gc resistance in MDD	[GC resistance in MDD]	1.5849625007211563	4	1	0	0
14277	1520	induction phase of anergy	[induction phase of anergy]	1.5849625007211563	4	1	0	0
14278	1520	interaction between cd95 ligand	[interaction between CD95 ligand]	1.5849625007211563	4	1	0	0
14279	1520	Tpl-2 nfat activation	[Tpl-2 NFAT activation]	1.5849625007211563	3	1	0	0
14280	1520	six adenoviral group	[six adenoviral groups]	1.5849625007211563	3	2	1	1
14281	1520	nuclear transcriptional factor ap-1	[nuclear transcriptional factors AP-1]	1.5849625007211563	4	1	0	0
14282	1520	exposure to nsaid	[Exposure to NSAIDs]	1.5849625007211563	3	2	1	1
14283	1520	release of e2f	[release of E2F]	1.5849625007211563	3	1	0	0
14284	1520	rhythm of receptor	[rhythm of receptor]	1.5849625007211563	3	2	2	2
14285	1520	inducible nuclear factor bind	[inducible nuclear factor binding]	1.5849625007211563	4	1	0	0
14286	1520	only limited side effect	[only limited side effects]	1.5849625007211563	4	1	0	0
14287	1520	wild-type rev activity	[wild-type Rev activity]	1.5849625007211563	3	1	0	0
14288	1520	many clinical application	[many clinical applications]	1.5849625007211563	3	1	0	0
14289	1520	-76 base pair (bp)	[-76 base pairs (bp)]	1.5849625007211563	4	1	0	0
14290	1520	specific property of cell	[specific property of cells]	1.5849625007211563	4	1	0	0
14291	1520	transient CAT assay	[transient CAT assay]	1.5849625007211563	3	1	0	0
14292	1520	reporter gene transcription	[reporter gene transcription]	1.5849625007211563	3	2	1	1
14293	1520	strong transcriptional repressor	[strong transcriptional repressors]	1.5849625007211563	3	1	0	0
14294	1520	phenomenon of activation-induced apoptosis	[phenomenon of activation-induced apoptosis]	1.5849625007211563	4	1	0	0
14295	1520	antioxidant defence mechanism	[antioxidant defence mechanisms]	1.5849625007211563	3	1	0	0
14296	1520	T cell by mitogen	[T cells by mitogens]	1.5849625007211563	4	1	0	0
14297	1520	growth of mononuclear phagocyte	[growth of mononuclear phagocytes]	1.5849625007211563	4	1	0	0
14298	1520	variety of agents.	[variety of agents.]	1.5849625007211563	3	1	0	0
14299	1520	tissue-specific stage-specific dna-binding protein	[tissue-specific stage-specific DNA-binding protein]	1.5849625007211563	4	1	0	0
14300	1520	tnf-alpha protein presence	[TNF-alpha protein presence]	1.5849625007211563	3	1	0	0
14301	1520	mmhg, extracellular dehydration	[mmHg, extracellular dehydration]	1.5849625007211563	3	1	0	0
14302	1520	patient with non-hodgkin's lymphoma	[patient with non-Hodgkin's lymphoma]	1.5849625007211563	4	1	0	0
14303	1520	least several important gene	[least several important genes]	1.5849625007211563	4	1	0	0
14304	1520	immediate-early g1 phase gene	[immediate-early G1 phase gene]	1.5849625007211563	4	1	0	0
14305	1520	full activation of NF-kappaB	[full activation of NF-kappaB]	1.5849625007211563	4	1	0	0
14306	1520	most hiv-1 isolate	[most HIV-1 isolates]	1.5849625007211563	3	1	0	0
14307	1520	precise congruence between pbmc	[precise congruence between PBMC]	1.5849625007211563	4	1	0	0
14308	1520	consideration of gcr treatment	[consideration of GCR treatment]	1.5849625007211563	4	1	0	0
14309	1520	retrovirus-transduced oncogenic version	[retrovirus-transduced oncogenic version]	1.5849625007211563	3	1	0	0
14310	1520	use a proliferation	[using a proliferation]	1.5849625007211563	3	1	0	0
14311	1520	lymphoid-specific transcription factor oct-2a	[lymphoid-specific transcription factor oct-2A]	1.5849625007211563	4	1	0	0
14312	1520	b-cell-restricted transcription factor	[B-cell-restricted transcription factors]	1.5849625007211563	3	1	0	0
14313	1520	RBP-Jkappa -binding site	[RBP-Jkappa -binding site]	1.5849625007211563	3	2	2	2
14314	1520	ganglioside on the expression	[gangliosides on the expression]	1.5849625007211563	4	1	0	0
14315	1520	nonlymphoid cell line	[nonlymphoid cell lines]	1.5849625007211563	3	2	1	1
14316	1520	permanent nf-kappab translocation	[permanent NF-kappaB translocation]	1.5849625007211563	3	1	0	0
14317	1520	transcription of specific genes.	[transcription of specific genes.]	1.5849625007211563	4	1	0	0
14318	1520	activation of this cell	[activation of these cells]	1.5849625007211563	4	2	1	1
14319	1520	mutation of site	[Mutations of sites]	1.5849625007211563	3	1	0	0
14320	1520	results: in FH adenopathy	[RESULTS: In FH adenopathy]	1.5849625007211563	4	1	0	0
14321	1520	differentiation of promonocytic cells,	[differentiation of promonocytic cells,]	1.5849625007211563	4	1	0	0
14322	1520	N-terminus of Oct-2a	[N-terminus of Oct-2a]	1.5849625007211563	3	1	0	0
14323	1520	10 mM n-acetylcysteine	[10 mM N-acetylcysteine]	1.5849625007211563	3	1	0	0
14324	1520	classical nfkappab site	[classical NFkappaB sites]	1.5849625007211563	3	1	0	0
14325	1520	full th2 level	[full Th2 levels]	1.5849625007211563	3	1	0	0
14326	1520	nf-kappab activation in cell	[NF-kappaB activation in cells]	1.5849625007211563	4	2	2	2
14327	1520	kinase c activation	[kinase C activation]	1.5849625007211563	3	2	1	1
14328	1520	asymptomatic (mf) individual	[asymptomatic (MF) individuals]	1.5849625007211563	3	1	0	0
14329	1520	regulation of hiv-1 replication	[regulation of HIV-1 replication]	1.5849625007211563	4	1	0	0
14330	1520	lyso- platelet-activating factor	[lyso- platelet-activating factor]	1.5849625007211563	3	1	0	0
14331	1520	yeast cell wall derivative	[yeast cell wall derivative]	1.5849625007211563	4	1	0	0
14332	1520	such as NF-kappa b	[such as NF-kappa B]	1.5849625007211563	4	2	1	1
14333	1520	decrease in the intensity	[decrease in the intensity]	1.5849625007211563	4	1	0	0
14334	1520	erythropoietin epo receptor	[erythropoietin EPO receptor]	1.5849625007211563	3	1	0	0
14335	1520	response to CD80	[response to CD80]	1.5849625007211563	3	1	0	0
14336	1520	activation of adaptive immunity	[activation of adaptive immunity]	1.5849625007211563	4	2	1	1
14337	1520	interest in the dynamic	[interest in the dynamics]	1.5849625007211563	4	1	0	0
14338	1520	potential effect of stress	[potential effects of stress]	1.5849625007211563	4	1	0	0
14339	1520	large prospective trial	[large prospective trial]	1.5849625007211563	3	1	0	0
14340	1520	polycystic ovary syndrome	[polycystic ovary syndrome]	1.5849625007211563	3	2	2	2
14341	1520	multiple protein kinase	[multiple protein kinases]	1.5849625007211563	3	1	0	0
14342	1520	group of sequence-related gene	[group of sequence-related genes]	1.5849625007211563	4	1	0	0
14343	1520	interleukin 2 IL2 production	[interleukin 2 IL2 production]	1.5849625007211563	4	1	0	0
14344	1520	cellular proliferation control	[cellular proliferation control]	1.5849625007211563	3	1	0	0
14345	1520	stability of VDR mrna	[stability of VDR mRNA]	1.5849625007211563	4	1	0	0
14346	1520	functional activity of monocyte	[functional activity of monocytes]	1.5849625007211563	4	1	0	0
14347	1520	fluoroquinolone antibiotic ciprofloxacin	[fluoroquinolone antibiotic ciprofloxacin]	1.5849625007211563	3	2	1	1
14348	1520	only low level activity	[only low level activity]	1.5849625007211563	4	1	0	0
14349	1520	t-cell surface molecule	[T-cell surface molecule]	1.5849625007211563	3	1	0	0
14350	1520	six viral nuclear antigen	[six viral nuclear antigen]	1.5849625007211563	4	2	2	2
14351	1520	indicator of the function	[indicator of the function]	1.5849625007211563	4	1	0	0
14352	1520	Oct-1 coregulator vp16	[Oct-1 coregulator VP16]	1.5849625007211563	3	1	0	0
14353	1520	extra-renal 135(oh)2d3 production	[extra-renal 1,25(OH)2D3 production]	1.5849625007211563	3	1	0	0
14354	1520	Ki-67 cell cycle	[Ki-67 cell cycle]	1.5849625007211563	3	1	0	0
14355	1520	role in the transcription	[role in the transcription]	1.5849625007211563	4	2	2	2
14356	1520	response to paf	[response to PAF]	1.5849625007211563	3	1	0	0
14357	1520	heterozygosity at distal marker	[heterozygosity at distal markers]	1.5849625007211563	4	1	0	0
14358	1520	high concentration of nf-atc	[high concentrations of NF-ATc]	1.5849625007211563	4	1	0	0
14359	1520	p53-dependent cyclin kinase inhibitor	[p53-dependent cyclin kinase inhibitor]	1.5849625007211563	4	1	0	0
14360	1520	long terminal repeat region	[long terminal repeat region]	1.5849625007211563	4	2	2	2
14361	1520	okadaic il-6 gene expression	[okadaic IL-6 gene expression]	1.5849625007211563	4	1	0	0
14362	1520	analysis of the element	[analysis of the elements]	1.5849625007211563	4	1	0	0
14363	1520	preosteoclast/ osteoclast phenotypic property	[preosteoclast/ osteoclast phenotypic properties]	1.5849625007211563	4	1	0	0
14364	1520	block of differentiation.	[block of differentiation.]	1.5849625007211563	3	1	0	0
14365	1520	tumour cell of A-T	[tumour cells of A-T]	1.5849625007211563	4	1	0	0
14366	1520	ability of monocyte	[ability of monocytes]	1.5849625007211563	3	1	0	0
14367	1520	objective of the study	[objective of the study]	1.5849625007211563	4	2	2	2
14368	1520	hiv replication in monocyte	[HIV replication in monocytes]	1.5849625007211563	4	1	0	0
14369	1520	recruitment to 5'HS2	[recruitment to 5'HS2]	1.5849625007211563	3	3	2	1
14370	1520	recruitment to 5'HS3	[recruitment to 5'HS3]	1.5849625007211563	3	1	0	0
14371	1520	minimal CD4 silencer	[minimal CD4 silencer]	1.5849625007211563	3	1	0	0
14372	1520	SH3 domain of Grb2	[SH3 domains of Grb2]	1.5849625007211563	4	1	0	0
14373	1520	apparently novel, faster-migrating complex	[apparently novel, faster-migrating complex]	1.5849625007211563	4	1	0	0
14374	1520	RP1 a new member	[RP1 a new member]	1.5849625007211563	4	1	0	0
14375	1520	respective virus in	[respective viruses in]	1.5849625007211563	3	1	0	0
14376	1520	interleukin-2 il-2 gene	[interleukin-2 IL-2 gene]	1.5849625007211563	3	1	0	0
14377	1520	production of leukocyte-derived oxidant	[production of leukocyte-derived oxidants]	1.5849625007211563	4	1	0	0
14378	1520	untreated hl-60 cell	[untreated HL-60 cells]	1.5849625007211563	3	2	1	1
14379	1520	nf-kappa b in t-lymphocyte	[NF-kappa B in T-lymphocytes]	1.5849625007211563	4	1	0	0
14380	1520	effect on human lymphocyte	[effects on human lymphocytes]	1.5849625007211563	4	1	0	0
14381	1520	bat box sequence	[BAT box sequence]	1.5849625007211563	3	1	0	0
14382	1520	presence of significant number	[presence of significant numbers]	1.5849625007211563	4	1	0	0
14383	1520	1.3 kilobasis upstream	[1.3 kilobases upstream]	1.5849625007211563	3	1	0	0
14384	1520	cause a il-2 transcription	[causing an IL-2 transcription]	1.5849625007211563	4	1	0	0
14385	1520	nuclear receptor VDR	[nuclear receptor VDR]	1.5849625007211563	3	1	0	0
14386	1520	high-affinity bsap-binding site	[high-affinity BSAP-binding site]	1.5849625007211563	3	1	0	0
14387	1520	rise of the number	[rise of the number]	1.5849625007211563	4	1	0	0
14388	1520	CIITA gene expression	[CIITA gene expression]	1.5849625007211563	3	1	0	0
14389	1520	ace inhibitor captopril	[ACE inhibitor captopril]	1.5849625007211563	3	1	0	0
14390	1520	EBV episomal vector pmep4	[EBV episomal vector pMEP4]	1.5849625007211563	4	1	0	0
14391	1520	co-expression of Ras	[Co-expression of Ras]	1.5849625007211563	3	1	0	0
14392	1520	pao -sensitive phosphatase	[PAO -sensitive phosphatase]	1.5849625007211563	3	1	0	0
14393	1520	linear ebv DNA molecule	[linear EBV DNA molecule]	1.5849625007211563	4	1	0	0
14394	1520	murine nf-at complex	[murine NF-AT complex]	1.5849625007211563	3	1	0	0
14395	1520	mosaic 45,X/46,X,X) karyotype	[mosaic 45,X/46,X,r(X) karyotype]	1.5849625007211563	3	1	0	0
14396	1520	human primary cd34(+) cell	[human primary CD34(+) cells]	1.5849625007211563	4	1	0	0
14397	1520	monocyte/macrophage-like cell line u1	[monocyte/macrophage-like cell line U1]	1.5849625007211563	4	1	0	0
14398	1520	transient 3bp2 overexpression	[Transient 3BP2 overexpression]	1.5849625007211563	3	1	0	0
14399	1520	weak staining comparable	[weak staining comparable]	1.5849625007211563	3	1	0	0
14400	1520	b7.1 -positive b cell	[B7.1 -positive B cells]	1.5849625007211563	4	1	0	0
14401	1520	5 m all-tran RA	[5 M all-trans RA]	1.5849625007211563	4	1	0	0
14402	1520	currently under clinical investigation.	[currently under clinical investigation.]	1.5849625007211563	4	1	0	0
14403	1520	hiv by retinoic acid	[HIV by retinoic acid]	1.5849625007211563	4	1	0	0
14404	1520	number of variation	[number of variations]	1.5849625007211563	3	1	0	0
14405	1520	conversely, aids-gr patient	[conversely, AIDS-GR patients]	1.5849625007211563	3	1	0	0
14406	1520	htlv-i gene expression	[HTLV-I gene expression]	1.5849625007211563	3	2	1	1
14407	1520	double-stranded kappab phosphorothioate oligonucleotide	[double-stranded kappaB phosphorothioate oligonucleotide]	1.5849625007211563	4	1	0	0
14408	1520	chronic sodium depletion	[chronic sodium depletion]	1.5849625007211563	3	1	0	0
14409	1520	virus replication i.stefanescu, D.V.Ablashi,	[virus replication I.Stefanescu, D.V.Ablashi,]	1.5849625007211563	4	1	0	0
14410	1520	reactive oxygen intermediate production	[reactive oxygen intermediate production]	1.5849625007211563	4	1	0	0
14411	1520	difference in LTR sequence	[Differences in LTR sequence]	1.5849625007211563	4	1	0	0
14412	1520	CsA -sensitive T	[CsA -sensitive T]	1.5849625007211563	3	1	0	0
14413	1520	band contain VDR-RXR	[band containing VDR-RXR]	1.5849625007211563	3	1	0	0
14414	1520	mainly posttranscriptionally by DOX	[mainly posttranscriptionally by DOX]	1.5849625007211563	4	1	0	0
14415	1520	interact receptor-ligand pair	[interacting receptor-ligand pair]	1.5849625007211563	3	1	0	0
14416	1520	inducible oct-2 gene expression	[inducible Oct-2 gene expression]	1.5849625007211563	4	1	0	0
14417	1520	18 nuclear protein	[18 nuclear proteins]	1.5849625007211563	3	1	0	0
14418	1520	probable regulatory point	[probable regulatory point]	1.5849625007211563	3	1	0	0
14419	1520	PB1 element alone	[PB1 element alone]	1.5849625007211563	3	1	0	0
14420	1520	3' region of gene	[3' regions of genes]	1.5849625007211563	4	1	0	0
14421	1520	glucocorticoid-responsive element reporter gene	[glucocorticoid-responsive element reporter gene]	1.5849625007211563	4	1	0	0
14422	1520	pu.1 in nonlymphoid cell	[PU.1 in nonlymphoid cells]	1.5849625007211563	4	1	0	0
14423	1520	expression in the absence	[expression in the absence]	1.5849625007211563	4	2	2	2
14424	1520	tax -responsive element 1	[Tax -responsive element 1]	1.5849625007211563	4	2	1	1
14425	1520	mature t-cell line Jurkat	[mature T-cell lines Jurkat]	1.5849625007211563	4	1	0	0
14426	1520	serum of patient	[serum of patients]	1.5849625007211563	3	1	0	0
14427	1520	cis- regulatory element	[cis- regulatory elements]	1.5849625007211563	3	1	0	0
14428	1520	polyclonal activator phytohemagglutinin pha	[polyclonal activator phytohemagglutinin PHA]	1.5849625007211563	4	1	0	0
14429	1520	exception of beta h1-globin	[exception of beta h1-globin]	1.5849625007211563	4	1	0	0
14430	1520	inhibitor protein i-kb	[inhibitor protein I-kB]	1.5849625007211563	3	1	0	0
14431	1520	asymmetric cell division	[asymmetric cell division]	1.5849625007211563	3	1	0	0
14432	1520	two binding complex	[two binding complexes]	1.5849625007211563	3	1	0	0
14433	1520	cooperation with other factor	[cooperation with other factors]	1.5849625007211563	4	1	0	0
14434	1520	vitro differentiation of monocyte	[vitro differentiation of monocytes]	1.5849625007211563	4	1	0	0
14435	1520	surface plasmon resonance	[surface plasmon resonance]	1.5849625007211563	3	2	1	1
14436	1520	promoter by transfection assay	[promoter by transfection assays]	1.5849625007211563	4	1	0	0
14437	1520	increase in tr75 expression	[increase in TR75 expression]	1.5849625007211563	4	1	0	0
14438	1520	family of proteins.	[family of proteins.]	1.5849625007211563	3	1	0	0
14439	1520	immunoglobulin heavy-chain igh enhancer	[immunoglobulin heavy-chain IgH enhancer]	1.5849625007211563	4	1	0	0
14440	1520	pathophysiology of acute asthma	[pathophysiology of acute asthma]	1.5849625007211563	4	1	0	0
14441	1520	transition from IL-2	[transition from IL-2]	1.5849625007211563	3	1	0	0
14442	1520	form of the factor.	[form of the factor.]	1.5849625007211563	4	1	0	0
14443	1520	activity of cell	[activity of cells]	1.5849625007211563	3	2	1	1
14444	1520	amino acid level	[amino acid level]	1.5849625007211563	3	1	0	0
14445	1520	NF-AT -binding site	[NF-AT -binding site]	1.5849625007211563	3	1	0	0
14446	1520	effect of ebna3c	[effect of EBNA3C]	1.5849625007211563	3	1	0	0
14447	1520	rapid induction of rap1	[rapid induction of Rap1]	1.5849625007211563	4	1	0	0
14448	1520	severe acute disease	[severe acute disease]	1.5849625007211563	3	1	0	0
14449	1520	acquisition of molecular marker	[acquisition of molecular markers]	1.5849625007211563	4	1	0	0
14450	1520	almost the same degree,	[almost the same degree,]	1.5849625007211563	4	1	0	0
14451	1520	three new epitope	[Three new epitopes]	1.5849625007211563	3	1	0	0
14452	1520	dominant c/ebp protein LIP	[dominant C/EBP protein LIP]	1.5849625007211563	4	1	0	0
14453	1520	role of Pit-1	[role of Pit-1]	1.5849625007211563	3	1	0	0
14454	1520	level of glutathione	[levels of glutathione]	1.5849625007211563	3	2	1	1
14455	1520	disease such as atherosclerosis	[diseases such as atherosclerosis]	1.5849625007211563	4	1	0	0
14456	1520	enter the cell,	[entering the cell,]	1.5849625007211563	3	1	0	0
14457	1520	association with the precursor	[Association with the precursors]	1.5849625007211563	4	1	0	0
14458	1520	genetic target for ebf	[genetic target for EBF]	1.5849625007211563	4	2	1	1
14459	1520	RXR mutant devoid	[RXR mutants devoid]	1.5849625007211563	3	1	0	0
14460	1520	important transcriptional factor	[important transcriptional factor]	1.5849625007211563	3	1	0	0
14461	1520	high extent than aspirin	[higher extent than aspirin]	1.5849625007211563	4	1	0	0
14462	1520	v-erbA oncogene a version	[v-erbA oncogene a version]	1.5849625007211563	4	1	0	0
14463	1520	early agonist-induced signalling	[early agonist-induced signalling]	1.5849625007211563	3	1	0	0
14464	1520	mechanism lead to disruption	[mechanisms leading to disruption]	1.5849625007211563	4	1	0	0
14465	1520	7 graves' disease	[7 Graves' disease]	1.5849625007211563	3	1	0	0
14466	1520	high level of id2	[high levels of Id2]	1.5849625007211563	4	1	0	0
14467	1520	class ii-negative t-cell line	[class II-negative T-cell lines]	1.5849625007211563	4	1	0	0
14468	1520	action of estrogen	[action of estrogens]	1.5849625007211563	3	1	0	0
14469	1520	role in T cell	[Role in T cells]	1.5849625007211563	4	2	1	1
14470	1520	human CLEO hcleo element	[human CLEO hCLEO element]	1.5849625007211563	4	1	0	0
14471	1520	proliferation of u937 cell	[proliferation of U937 cells]	1.5849625007211563	4	1	0	0
14472	1520	new family of molecule	[new family of molecules]	1.5849625007211563	4	1	0	0
14473	1520	mature human lymphocyte	[Mature human lymphocytes]	1.5849625007211563	3	1	0	0
14474	1520	T cell upon activation	[T cells upon activation]	1.5849625007211563	4	1	0	0
14475	1520	lps response in monocyte	[LPS response in monocytes]	1.5849625007211563	4	1	0	0
14476	1520	atmospheric urban pollution	[atmospheric urban pollution]	1.5849625007211563	3	1	0	0
14477	1520	transactivation of target	[transactivation of target]	1.5849625007211563	3	1	0	0
14478	1520	ability of HTB	[ability of HTB]	1.5849625007211563	3	1	0	0
14479	1520	link between the hpa	[link between the HPA]	1.5849625007211563	4	1	0	0
14480	1520	inactive phorbol ester	[inactive phorbol esters]	1.5849625007211563	3	1	0	0
14481	1520	gata-1 transcription factor	[GATA-1 transcription factor]	1.5849625007211563	3	2	1	1
14482	1520	protein with a size	[protein with an size]	1.5849625007211563	4	1	0	0
14483	1520	therefore candidate gene	[therefore candidate genes]	1.5849625007211563	3	1	0	0
14484	1520	Syk tyrosine kinase	[Syk tyrosine kinase]	1.5849625007211563	3	1	0	0
14485	1520	NF-kappa b -binding site	[NF-kappa B -binding site]	1.5849625007211563	4	2	2	2
14486	1520	expression of the Tax1	[expression of the Tax1]	1.5849625007211563	4	1	0	0
14487	1520	open reading frame brlf1	[open reading frame BRLF1]	1.5849625007211563	4	1	0	0
14488	1520	large stimulatory effect.	[large stimulatory effect.]	1.5849625007211563	3	1	0	0
14489	1520	different: hck expression	[different: hck expression]	1.5849625007211563	3	1	0	0
14490	1520	b cell specific activity	[B cell specific activity]	1.5849625007211563	4	1	0	0
14491	1520	interaction in b-cell line	[interactions in B-cell lines]	1.5849625007211563	4	1	0	0
14492	1520	distinct Stat3-like protein	[distinct Stat3-like protein]	1.5849625007211563	3	1	0	0
14493	1520	insulin a putative glycolipid	[insulin a putative glycolipid]	1.5849625007211563	4	1	0	0
14494	1520	b cell coactivator obf-1/bob1/oca-b	[B cell coactivator OBF-1/Bob1/OCA-B]	1.5849625007211563	4	1	0	0
14495	1520	many other systems,	[many other systems,]	1.5849625007211563	3	1	0	0
14496	1520	only by expression	[only by expression]	1.5849625007211563	3	1	0	0
14497	1520	expression of LITAF	[expression of LITAF]	1.5849625007211563	3	1	0	0
14498	1520	recognition of pml/rar-alpha peptide	[recognition of pml/RAR-alpha peptides]	1.5849625007211563	4	1	0	0
14499	1520	80-kDa tyrosine -phosphorylated protein	[80-kDa tyrosine -phosphorylated protein]	1.5849625007211563	4	1	0	0
14500	1520	function of Stat6	[function of Stat6]	1.5849625007211563	3	1	0	0
14501	1520	tumor necrosis factor-alpha secretion	[tumor necrosis factor-alpha secretion]	1.5849625007211563	4	1	0	0
14502	1520	rapid aldosterone effect	[rapid aldosterone effects]	1.5849625007211563	3	1	0	0
14503	1520	effect of atp	[effects of ATP]	1.5849625007211563	3	1	0	0
14504	1520	Clinical efficacy in patient	[Clinical efficacy in patients]	1.5849625007211563	4	1	0	0
14505	1520	transient nf-kappab response	[transient NF-kappaB response]	1.5849625007211563	3	1	0	0
14506	1520	suggest a association	[suggesting a association]	1.5849625007211563	3	2	2	2
14507	1520	C26 element alone,	[C26 element alone,]	1.5849625007211563	3	1	0	0
14508	1520	selectively block MKK activity	[selectively blocking MKK activity]	1.5849625007211563	4	1	0	0
14509	1520	ICAM-1 kappa b-reporter construct	[ICAM-1 kappa B-reporter construct]	1.5849625007211563	4	1	0	0
14510	1520	additional transcription factor	[additional transcription factor]	1.5849625007211563	3	2	2	2
14511	1520	peptide-affinity specific manner	[peptide-affinity specific manner]	1.5849625007211563	3	1	0	0
14512	1520	factor J kappa	[factors J kappa]	1.5849625007211563	3	1	0	0
14513	1520	transcript from homologue mtcp1/c6.1b	[transcripts from homologue MTCP1/c6.1B]	1.5849625007211563	4	1	0	0
14514	1520	normal vaginal floram	[normal vaginal flora,]	1.5849625007211563	3	1	0	0
14515	1520	gp41 envelope protein	[gp41 envelope protein]	1.5849625007211563	3	1	0	0
14516	1520	sequence homology with c-myb	[sequence homology with c-myb]	1.5849625007211563	4	1	0	0
14517	1520	15-amino acid sequence	[15-amino acid sequence]	1.5849625007211563	3	2	2	2
14518	1520	cluster of c-Myb site	[cluster of c-Myb sites]	1.5849625007211563	4	1	0	0
14519	1520	absence of IL-3	[absence of IL-3]	1.5849625007211563	3	1	0	0
14520	1520	methylation interference study	[methylation interference studies]	1.5849625007211563	3	1	0	0
14521	1520	calcineurin- dependent pathway	[calcineurin- dependent pathways]	1.5849625007211563	3	1	0	0
14522	1520	8 aml m5	[8 AML M5]	1.5849625007211563	3	1	0	0
14523	1520	HLP-1 binding activity	[HLP-1 binding activities]	1.5849625007211563	3	1	0	0
14524	1520	unbalanced inactivation in fibroblast	[unbalanced inactivation in fibroblasts]	1.5849625007211563	4	1	0	0
14525	1520	noncanonical octamer motif	[noncanonical octamer motif]	1.5849625007211563	3	1	0	0
14526	1520	hemin-mediated erythroid differentiation	[hemin-mediated erythroid differentiation]	1.5849625007211563	3	2	1	1
14527	1520	sensitivity to exogenous 135eoh)2d3	[sensitivity to exogenous 1,25(OH)2D3]	1.5849625007211563	4	1	0	0
14528	1520	Oxidants, transcription factor	[Oxidants, transcription factors]	1.5849625007211563	3	1	0	0
14529	1520	substrate in intact	[substrates in intact]	1.5849625007211563	3	1	0	0
14530	1520	GcR in hMNL	[GcR in hMNL]	1.5849625007211563	3	1	0	0
14531	1520	beta-like globin locus	[beta-like globin locus]	1.5849625007211563	3	1	0	0
14532	1520	C/EBP family of transcription	[C/EBP family of transcription]	1.5849625007211563	4	1	0	0
14533	1520	transcription of another	[transcription of another]	1.5849625007211563	3	1	0	0
14534	1520	complex regulatory mechanism	[complex regulatory mechanisms]	1.5849625007211563	3	1	0	0
14535	1520	vascular protective property	[vascular protective properties]	1.5849625007211563	3	1	0	0
14536	1520	promoter for HLA-DRA	[promoter for HLA-DRA]	1.5849625007211563	3	1	0	0
14537	1520	endogenous IFN activity	[endogenous IFN activity]	1.5849625007211563	3	1	0	0
14538	1520	effect of age	[effects of age]	1.5849625007211563	3	1	0	0
14539	1520	aim/cd69 cell-surface expression	[AIM/CD69 cell-surface expression]	1.5849625007211563	3	1	0	0
14540	1520	Janus tyrosine kinase-3 JAK3	[Janus tyrosine kinase-3 JAK3]	1.5849625007211563	4	1	0	0
14541	1520	myocyte within each muscle	[myocytes within each muscle]	1.5849625007211563	4	1	0	0
14542	1520	rephosphorylation with protein kinase	[rephosphorylation with protein kinase]	1.5849625007211563	4	1	0	0
14543	1520	duplication of the part	[duplication of the part]	1.5849625007211563	4	1	0	0
14544	1520	presence of il-4 signal	[presence of IL-4 signaling]	1.5849625007211563	4	1	0	0
14545	1520	IL-4 -secret th2 cells.	[IL-4 -secreting Th2 cells.]	1.5849625007211563	4	1	0	0
14546	1520	result of translocation	[result of translocation]	1.5849625007211563	3	1	0	0
14547	1520	(HIV) terminal repeat	[(HIV) terminal repeat]	1.5849625007211563	3	2	2	2
14548	1520	specific cellular activation signal	[specific cellular activation signals]	1.5849625007211563	4	1	0	0
14549	1520	ability of this enzyme	[ability of this enzyme]	1.5849625007211563	4	1	0	0
14550	1520	lone c/ebp motif	[lone C/EBP motif]	1.5849625007211563	3	1	0	0
14551	1520	TNF nf-kappa b activation	[TNF NF-kappa B activation]	1.5849625007211563	4	2	1	1
14552	1520	human gene encode LBR	[human gene encoding LBR]	1.5849625007211563	4	2	1	1
14553	1520	CD2/CD4-positive, cd8-negative subtype	[CD2/CD4-positive, CD8-negative subtype]	1.5849625007211563	3	1	0	0
14554	1520	expression of il-16	[expression of IL-16]	1.5849625007211563	3	1	0	0
14555	1520	normal Rh(D) positive cell	[normal Rh(D) positive cells]	1.5849625007211563	4	1	0	0
14556	1520	2.7 kb fragment	[2.7 kb fragment]	1.5849625007211563	3	1	0	0
14557	1520	patient with essential hypertension.	[patients with essential hypertension.]	1.5849625007211563	4	1	0	0
14558	1520	array of transcription factor	[array of transcription factors]	1.5849625007211563	4	1	0	0
14559	1520	maintenance of the phenotype	[maintenance of the phenotype]	1.5849625007211563	4	1	0	0
14560	1520	epsilon germline expression	[epsilon germline expression]	1.5849625007211563	3	1	0	0
14561	1520	differentiation therapy of leukemia	[differentiation therapy of leukemias]	1.5849625007211563	4	1	0	0
14562	1520	hiv-1 terminal repeat transcription	[HIV-1 terminal repeat transcription]	1.5849625007211563	4	2	2	2
14563	1520	IL-2 promoter factor	[IL-2 promoter factor]	1.5849625007211563	3	2	1	1
14564	1520	large palindromic sequence	[larger palindromic sequences]	1.5849625007211563	3	1	0	0
14565	1520	slightly different mobility.	[slightly different mobility.]	1.5849625007211563	3	1	0	0
14566	1520	ad in BALB/c mouse	[Ad in BALB/c mice]	1.5849625007211563	4	1	0	0
14567	1520	particular, of Hsp70	[particular, of Hsp70]	1.5849625007211563	3	1	0	0
14568	1520	13 man with gynecomastia	[13 men with gynecomastia]	1.5849625007211563	4	1	0	0
14569	1520	season, on the age	[season, on the age]	1.5849625007211563	4	1	0	0
14570	1520	peripheral blood cell culture	[peripheral blood cell cultures]	1.5849625007211563	4	2	2	2
14571	1520	high failure rate	[high failure rate]	1.5849625007211563	3	2	2	2
14572	1520	transcription factor IFN factor-1	[transcription factor IFN factor-1]	1.5849625007211563	4	1	0	0
14573	1520	positive c-jun expression	[positive c-jun expression]	1.5849625007211563	3	1	0	0
14574	1520	3 endemic goiter	[3 endemic goiter]	1.5849625007211563	3	1	0	0
14575	1520	significance of quantitative analysis	[Significance of quantitative analysis]	1.5849625007211563	4	1	0	0
14576	1520	contrast, lipopolysaccharide stimulation	[contrast, lipopolysaccharide stimulation]	1.5849625007211563	3	1	0	0
14577	1520	cell line kg-1 myeloblast	[cell lines KG-1 myeloblasts]	1.5849625007211563	4	1	0	0
14578	1520	healthy person with hypertension	[healthy persons with hypertension]	1.5849625007211563	4	1	0	0
14579	1520	human lymphoblastoid cell line	[human lymphoblastoid cell line]	1.5849625007211563	4	2	1	1
14580	1520	equivalent level than ZEBRA	[equivalent levels than ZEBRA]	1.5849625007211563	4	1	0	0
14581	1520	CD28 -mediated signal transduction	[CD28 -mediated signal transduction]	1.5849625007211563	4	1	0	0
14582	1520	HTLV-I cell line	[HTLV-I cell lines]	1.5849625007211563	3	1	0	0
14583	1520	include exogenous cytokine	[including exogenous cytokines]	1.5849625007211563	3	1	0	0
14584	1520	effector phase of inflammation	[effector phase of inflammation]	1.5849625007211563	4	1	0	0
14585	1520	different concentration of [3h]testosterone	[different concentrations of [3H]testosterone]	1.5849625007211563	4	1	0	0
14586	1520	macrophage cell line RAW264	[macrophage cell line RAW264]	1.5849625007211563	4	1	0	0
14587	1520	gc -sensitive asthmatics	[GC -sensitive asthmatics]	1.5849625007211563	3	1	0	0
14588	1520	various csf by IL-2	[various CSFs by IL-2]	1.5849625007211563	4	1	0	0
14589	1520	effectiveness of glucocorticoid therapy	[effectiveness of glucocorticoid therapy]	1.5849625007211563	4	2	1	1
14590	1520	murine c-fo promoter	[murine c-fos promoter]	1.5849625007211563	3	1	0	0
14591	1520	down-regulation of c-myc transcript	[down-regulation of c-myc transcripts]	1.5849625007211563	4	1	0	0
14592	1520	amount of hemoglobin,	[amount of hemoglobin,]	1.5849625007211563	3	1	0	0
14593	1520	normal human hematopoietic cell	[normal human hematopoietic cells]	1.5849625007211563	4	1	0	0
14594	1520	incidence of HLA antigen	[Incidence of HLA antigens]	1.5849625007211563	4	1	0	0
14595	1520	stimulation of proliferation	[stimulation of proliferation]	1.5849625007211563	3	1	0	0
14596	1520	erythroid colony development	[erythroid colony development]	1.5849625007211563	3	1	0	0
14597	1520	erythroid differentiation in culture,	[erythroid differentiation in culture,]	1.5849625007211563	4	1	0	0
14598	1520	anti- CD18 antibody	[anti- CD18 antibody]	1.5849625007211563	3	1	0	0
14599	1520	y731eam to y731eac	[Y731EAM to Y731EAC]	1.5849625007211563	3	1	0	0
14600	1520	Nef-expressing t-cell line	[Nef-expressing T-cell lines]	1.5849625007211563	3	1	0	0
14601	1520	different T cell subset	[different T cell subsets]	1.5849625007211563	4	1	0	0
14602	1520	hematopoietic cytokine interleukin-2 il-2	[hematopoietic cytokine interleukin-2 IL-2]	1.5849625007211563	4	1	0	0
14603	1520	interaction between epithelial cell	[interaction between epithelial cells]	1.5849625007211563	4	1	0	0
14604	1520	identification of 253 nucleotide	[identification of 253 nucleotides]	1.5849625007211563	4	1	0	0
14605	1520	same transcription factor nf-il4	[same transcription factor NF-IL4]	1.5849625007211563	4	1	0	0
14606	1520	progesterone at concentration	[progesterone at concentrations]	1.5849625007211563	3	1	0	0
14607	1520	factor in nf-kappab activation	[factor in NF-kappaB activation]	1.5849625007211563	4	2	2	2
14608	1520	b-cell from B-CLL patient	[B-cells from B-CLL patients]	1.5849625007211563	4	2	1	1
14609	1520	chromosome 1 alteration	[chromosome 1 alterations]	1.5849625007211563	3	1	0	0
14610	1520	mouse il-10r construct	[mouse IL-10R constructs]	1.5849625007211563	3	1	0	0
14611	1520	differentiation of tissue	[differentiation of tissues]	1.5849625007211563	3	1	0	0
14612	1520	antigen receptor costimulation	[antigen receptor costimulation]	1.5849625007211563	3	1	0	0
14613	1520	D3 in human monocyte	[D3 in human monocytes]	1.5849625007211563	4	2	2	2
14614	1520	induction of translocation	[induction of translocation]	1.5849625007211563	3	1	0	0
14615	1520	tissue-specific regulatory region	[tissue-specific regulatory region]	1.5849625007211563	3	1	0	0
14616	1520	transcription stat transcription factor	[transcription STAT transcription factors]	1.5849625007211563	4	1	0	0
14617	1520	IL-7R alpha chain	[IL-7R alpha chains]	1.5849625007211563	3	1	0	0
14618	1520	most potent inducer	[most potent inducers]	1.5849625007211563	3	1	0	0
14619	1520	nuclear factor include NFAT-1	[nuclear factors including NFAT-1]	1.5849625007211563	4	1	0	0
14620	1520	vitro transfection assay	[vitro transfection assays]	1.5849625007211563	3	1	0	0
14621	1520	CD28 T cell	[CD28 T cells]	1.5849625007211563	3	2	1	1
14622	1520	intracellular 25(oh)d3 transport	[intracellular 25(OH)D3 transport]	1.5849625007211563	3	1	0	0
14623	1520	two stages, capacitance	[two stages, capacitance]	1.5849625007211563	3	1	0	0
14624	1520	factor for the expression	[factor for the expression]	1.5849625007211563	4	2	2	2
14625	1520	human leukemic k562 cell	[human leukemic K562 cells]	1.5849625007211563	4	1	0	0
14626	1520	Jak2 tyrosine kinase	[Jak2 tyrosine kinases]	1.5849625007211563	3	1	0	0
14627	1520	il-2 t-cell proliferation	[IL-2 T-cell proliferation]	1.5849625007211563	3	2	1	1
14628	1520	receptor on mononuclear leukocyte	[receptors on mononuclear leukocytes]	1.5849625007211563	4	2	2	2
14629	1520	protein kinase c activation	[protein kinase C activation]	1.5849625007211563	4	2	1	1
14630	1520	staphylococcal enterotoxin a sea	[staphylococcal enterotoxin A SEA]	1.5849625007211563	4	1	0	0
14631	1520	cytomegalovirus (CMV) infection	[Cytomegalovirus (CMV) infection]	1.5849625007211563	3	1	0	0
14632	1520	composite element capable	[composite element capable]	1.5849625007211563	3	1	0	0
14633	1520	HLA-A3 /peptide complex	[HLA-A3 /peptide complex]	1.5849625007211563	3	1	0	0
14634	1520	link the tcr	[linking the TCR]	1.5849625007211563	3	1	0	0
14635	1520	jpx-9 cell a subclone	[JPX-9 cells a subclone]	1.5849625007211563	4	1	0	0
14636	1520	c-terminal 196 amino acid	[C-terminal 196 amino acids]	1.5849625007211563	4	1	0	0
14637	1520	develop b cell	[developing B cells]	1.5849625007211563	3	1	0	0
14638	1520	4 non-hodgkin' lymphoma NHL	[4 non-Hodgkin's lymphoma NHL]	1.5849625007211563	4	1	0	0
14639	1520	category iii cell	[Category III cells]	1.5849625007211563	3	1	0	0
14640	1520	several positive regulatory mechanism	[several positive regulatory mechanisms]	1.5849625007211563	4	1	0	0
14641	1520	growth of lymphocyte	[growth of lymphocytes]	1.5849625007211563	3	1	0	0
14642	1520	central 21 bp repeat	[central 21 bp repeat]	1.5849625007211563	4	2	1	1
14643	1520	sjogren' syndrome ss	[Sjogren's syndrome SS]	1.5849625007211563	3	2	1	1
14644	1520	sv40 gene expression	[SV40 gene expression]	1.5849625007211563	3	1	0	0
14645	1520	25 risk control	[25 risk controls]	1.5849625007211563	3	1	0	0
14646	1520	heterogeneous group of neoplasm	[heterogeneous group of neoplasms]	1.5849625007211563	4	1	0	0
14647	1520	AP-1 consensus site	[AP-1 consensus site]	1.5849625007211563	3	1	0	0
14648	1520	Rap binding domain RBD	[Rap binding domain RBD]	1.5849625007211563	4	1	0	0
14649	1520	patient with churg-strauss syndrome	[patient with Churg-Strauss syndrome]	1.5849625007211563	4	1	0	0
14650	1520	transcription factor of T	[Transcription factors of T]	1.5849625007211563	4	1	0	0
14651	1520	25 healthy pregnant woman	[25 healthy pregnant women]	1.5849625007211563	4	1	0	0
14652	1520	ligand on accessory cell	[ligands on accessory cells]	1.5849625007211563	4	1	0	0
14653	1520	affinity of receptor	[affinity of receptors]	1.5849625007211563	3	1	0	0
14654	1520	several cell type	[several cell types]	1.5849625007211563	3	2	2	2
14655	1520	ultimately to cell death	[ultimately to cell death]	1.5849625007211563	4	1	0	0
14656	1520	GATA-3 binding site	[GATA-3 binding site]	1.5849625007211563	3	1	0	0
14657	1520	tpa monocytic differentiation	[TPA monocytic differentiation]	1.5849625007211563	3	2	1	1
14658	1520	frequency of oct2-positive clone	[frequency of Oct2-positive clones]	1.5849625007211563	4	1	0	0
14659	1520	D3 receptor rna	[D3 receptor RNA]	1.5849625007211563	3	1	0	0
14660	1520	p65 activation domain	[p65 activation domain]	1.5849625007211563	3	1	0	0
14661	1520	CD40 molecule in monocyte	[CD40 molecules in monocytes]	1.5849625007211563	4	1	0	0
14662	1520	distribution in the pathogenesis	[distribution in the pathogenesis]	1.5849625007211563	4	1	0	0
14663	1520	pretreatment with 2'-deoxy-3'-adenosine monophosphate	[pretreatment with 2'-deoxy-3'-adenosine monophosphate]	1.5849625007211563	4	1	0	0
14664	1520	MTCP1 /a1 transcript	[MTCP1 /A1 transcript]	1.5849625007211563	3	1	0	0
14665	1520	endoplasmic reticulum immunize cell	[endoplasmic reticulum immunizing cells]	1.5849625007211563	4	1	0	0
14666	1520	very complicated assay	[very complicated assay]	1.5849625007211563	3	1	0	0
14667	1520	binding of ligand,	[binding of ligand,]	1.5849625007211563	3	1	0	0
14668	1520	immediate gene c-fo	[immediate gene c-fos]	1.5849625007211563	3	2	2	2
14669	1520	similar DNA motif	[similar DNA motifs]	1.5849625007211563	3	1	0	0
14670	1520	transient increase in mrna	[transient increases in mRNA]	1.5849625007211563	4	1	0	0
14671	1520	HTLV-I tax mutant	[HTLV-I Tax mutants]	1.5849625007211563	3	1	0	0
14672	1520	use a mutant	[Using a mutant]	1.5849625007211563	3	1	0	0
14673	1520	Platelet-activating factor paf	[Platelet-activating factor PAF]	1.5849625007211563	3	1	0	0
14674	1520	residual disease MRD	[residual disease MRD]	1.5849625007211563	3	2	2	2
14675	1520	hitherto unknown mineralocorticoid	[hitherto unknown mineralocorticoid]	1.5849625007211563	3	1	0	0
14676	1520	binding of trans-factor	[binding of trans-factors]	1.5849625007211563	3	1	0	0
14677	1520	responsive cell type	[responsive cell types]	1.5849625007211563	3	1	0	0
14678	1520	namely, 11 copy	[namely, 11 copies]	1.5849625007211563	3	1	0	0
14679	1520	preincubation with lps	[preincubation with LPS]	1.5849625007211563	3	1	0	0
14680	1520	action of Sp1	[action of Sp1]	1.5849625007211563	3	1	0	0
14681	1520	binding of c-jun/c-fo heterodimer	[binding of c-Jun/c-Fos heterodimers]	1.5849625007211563	4	1	0	0
14682	1520	follow ebv infection	[Following EBV infection]	1.5849625007211563	3	1	0	0
14683	1520	tcr alpha gene	[TCR alpha gene]	1.5849625007211563	3	1	0	0
14684	1520	induction of the tf	[induction of the TF]	1.5849625007211563	4	1	0	0
14685	1520	evidence a transcription factor	[evidence a transcription factor]	1.5849625007211563	4	1	0	0
14686	1520	endothelial adhesion molecule	[endothelial adhesion molecules]	1.5849625007211563	3	3	2	1
14687	1520	molecule for proteolysis	[molecule for proteolysis]	1.5849625007211563	3	1	0	0
14688	1520	stimulation with anti-CD3	[stimulation with anti-CD3]	1.5849625007211563	3	1	0	0
14689	1520	chronic hiv infection	[chronic HIV infection]	1.5849625007211563	3	2	1	1
14690	1520	polymorphic trinucleotide repeat	[polymorphic trinucleotide repeat]	1.5849625007211563	3	1	0	0
14691	1520	mechanism for rapid activation	[mechanism for rapid activation]	1.5849625007211563	4	1	0	0
14692	1520	such as phosphonoacetic acid	[such as phosphonoacetic acid]	1.5849625007211563	4	1	0	0
14693	1520	cell of hematopoietic lineage	[cells of hematopoietic lineage]	1.5849625007211563	4	2	2	2
14694	1520	only SRI responder	[Only SRI responders]	1.5849625007211563	3	1	0	0
14695	1520	fork head cDNA	[fork head cDNA]	1.5849625007211563	3	1	0	0
14696	1520	level of the octamer	[Levels of the octamer]	1.5849625007211563	4	2	1	1
14697	1520	absence of bsap	[absence of BSAP]	1.5849625007211563	3	1	0	0
14698	1520	antibody, ultra-violet cross-linking	[antibody, UV cross-linking]	1.5849625007211563	3	1	0	0
14699	1520	Bmax in this subject	[Bmax in these subjects]	1.5849625007211563	4	1	0	0
14700	1520	reactivity to 1 alpha,25(OH)2D3	[reactivity to 1 alpha,25(OH)2D3]	1.5849625007211563	4	1	0	0
14701	1520	feasibility engineering a vaccine	[feasibility engineering a vaccine]	1.5849625007211563	4	1	0	0
14702	1520	two form of stat3	[two forms of STAT3]	1.5849625007211563	4	1	0	0
14703	1520	same degradation machinery	[same degradation machinery]	1.5849625007211563	3	1	0	0
14704	1520	32dcl3 cell by AML1/ETO(MTG8)	[32Dcl3 cells by AML1/ETO(MTG8)]	1.5849625007211563	4	1	0	0
14705	1520	in-situ detection of DNA	[In-situ detection of DNA]	1.5849625007211563	4	1	0	0
14706	1520	percentage of hemoglobin-positive cell	[percentage of hemoglobin-positive cells]	1.5849625007211563	4	1	0	0
14707	1520	proliferative effect of csf-1	[proliferative effects of CSF-1]	1.5849625007211563	4	1	0	0
14708	1520	proto-enhancer activity of TCEd	[proto-enhancer activity of TCEd]	1.5849625007211563	4	1	0	0
14709	1520	tcr -signalling event	[TCR -signalling events]	1.5849625007211563	3	1	0	0
14710	1520	murine gata-3 factor	[Murine GATA-3 factors]	1.5849625007211563	3	1	0	0
14711	1520	down-regulation of the activity	[down-regulation of the activity]	1.5849625007211563	4	1	0	0
14712	1520	overexpression of b subunit	[overexpression of B subunit]	1.5849625007211563	4	1	0	0
14713	1520	human il-13 gene	[human IL-13 gene]	1.5849625007211563	3	1	0	0
14714	1520	principal IL-2 -inducible component	[principal IL-2 -inducible component]	1.5849625007211563	4	1	0	0
14715	1520	element specific for transcription	[elements specific for transcription]	1.5849625007211563	4	1	0	0
14716	1520	plasma cortisol concentration in	[plasma cortisol concentrations in]	1.5849625007211563	4	1	0	0
14717	1520	response to tcr	[response to TCR]	1.5849625007211563	3	1	0	0
14718	1520	tissue-specific core promoter structure	[tissue-specific core promoter structure]	1.5849625007211563	4	1	0	0
14719	1520	surprisingly, the bHLH domain	[surprisingly, the bHLH domain]	1.5849625007211563	4	1	0	0
14720	1520	9 nucleotide IP9	[9 nucleotides IP9]	1.5849625007211563	3	1	0	0
14721	1520	octamer, nf-kappa b	[octamer, NF-kappa B]	1.5849625007211563	3	1	0	0
14722	1520	readout for monocyte activation	[readout for monocyte activation]	1.5849625007211563	4	1	0	0
14723	1520	ikappab-alpha a inhibitor	[IkappaB-alpha an inhibitor]	1.5849625007211563	3	1	0	0
14724	1520	stimulation of most cell	[stimulation of most cells]	1.5849625007211563	4	1	0	0
14725	1520	SIV TATA box	[SIV TATA box]	1.5849625007211563	3	1	0	0
14726	1520	response to tpa	[response to TPA]	1.5849625007211563	3	1	0	0
14727	1520	4/5 t-cell line	[4/5 T-cell lines]	1.5849625007211563	3	1	0	0
14728	1520	antiinflammatory effect of corticosteroid	[antiinflammatory effects of corticosteroids]	1.5849625007211563	4	1	0	0
14729	1520	other signal activity	[other signaling activities]	1.5849625007211563	3	1	0	0
14730	1520	constitutive association with tradd	[constitutive association with TRADD]	1.5849625007211563	4	1	0	0
14731	1520	recent clinical therapeutic initiative	[recent clinical therapeutic initiative]	1.5849625007211563	4	1	0	0
14732	1520	(HIV) long repeat	[(HIV) long repeat]	1.5849625007211563	3	2	2	2
14733	1520	total ige (p 0.01).	[total IgE (p 0.01).]	1.5849625007211563	4	1	0	0
14734	1520	other DNA element present	[Other DNA elements present]	1.5849625007211563	4	1	0	0
14735	1520	cell in the lining	[cells in the lining]	1.5849625007211563	4	2	2	2
14736	1520	novel function for cd44	[novel function for CD44]	1.5849625007211563	4	1	0	0
14737	1520	pathogenesis of climacteric syndrome	[pathogenesis of climacteric syndrome]	1.5849625007211563	4	1	0	0
14738	1520	hyperproliferative disorder include psoriasis	[hyperproliferative disorders including psoriasis]	1.5849625007211563	4	1	0	0
14739	1520	rna join BSLF2	[RNA joining BSLF2]	1.5849625007211563	3	1	0	0
14740	1520	surface expression of CD3	[surface expression of CD3]	1.5849625007211563	4	1	0	0
14741	1520	normal, healthy carrier	[normal, healthy carriers]	1.5849625007211563	3	1	0	0
14742	1520	Akv MLV transcriptional activity	[Akv MLV transcriptional activity]	1.5849625007211563	4	1	0	0
14743	1520	transgenic mouse to infection	[transgenic mice to infection]	1.5849625007211563	4	1	0	0
14744	1520	AP-1 NF-kappa b pathway	[AP-1 NF-kappa B pathway]	1.5849625007211563	4	1	0	0
14745	1520	late diabetic complication	[late diabetic complications]	1.5849625007211563	3	1	0	0
14746	1520	different region of Stat3	[different regions of Stat3]	1.5849625007211563	4	1	0	0
14747	1520	set of plasmid	[set of plasmids]	1.5849625007211563	3	1	0	0
14748	1520	p38 mapk activation	[p38 MAPk activation]	1.5849625007211563	3	2	1	1
14749	1520	rapidly inducible transcriptional activator	[rapidly inducible transcriptional activator]	1.5849625007211563	4	1	0	0
14750	1520	open binding site	[open binding site]	1.5849625007211563	3	1	0	0
14751	1520	peripheral lymphoid tissue	[peripheral lymphoid tissues]	1.5849625007211563	3	1	0	0
14752	1520	different adhesion molecule	[different adhesion molecules]	1.5849625007211563	3	1	0	0
14753	1520	role of protein kinase	[role of protein kinase]	1.5849625007211563	4	1	0	0
14754	1520	cytokine interleukin-2 il-2	[cytokine interleukin-2 IL-2]	1.5849625007211563	3	2	1	1
14755	1520	undifferentiated pma-differentiated u937 cell	[undifferentiated PMA-differentiated U937 cells]	1.5849625007211563	4	1	0	0
14756	1520	modulate cell activation	[modulating cell activation]	1.5849625007211563	3	1	0	0
14757	1520	lack of pu.1 expression	[lack of PU.1 expression]	1.5849625007211563	4	1	0	0
14758	1520	free t4 FT4	[free T4 FT4]	1.5849625007211563	3	1	0	0
14759	1520	p .001 versus lps	[p .001 versus LPS]	1.5849625007211563	4	1	0	0
14760	1520	ectopic expression of Smad6	[ectopic expressions of Smad6]	1.5849625007211563	4	1	0	0
14761	1520	ectopic expression of Smad7	[ectopic expression of Smad7]	1.5849625007211563	4	1	0	0
14762	1520	ras protein activity	[ras protein activity]	1.5849625007211563	3	1	0	0
14763	1520	value of plasma aldosterone	[values of plasma aldosterone]	1.5849625007211563	4	1	0	0
14764	1520	stimulus-dependent cd44 transcription	[stimulus-dependent CD44 transcription]	1.5849625007211563	3	1	0	0
14765	1520	GC induction of sialoadhesin	[GC induction of sialoadhesin]	1.5849625007211563	4	1	0	0
14766	1520	family of domain protein	[family of domain proteins]	1.5849625007211563	4	1	0	0
14767	1520	supershift with specific antibody	[Supershift with specific antibodies]	1.5849625007211563	4	1	0	0
14768	1520	certain lymphoid-derived disease	[certain lymphoid-derived diseases]	1.5849625007211563	3	1	0	0
14769	1520	blood monocyte monocyte	[blood monocyte monocyte]	1.5849625007211563	3	1	0	0
14770	1520	24 to 48 h	[24 to 48 h]	1.5849625007211563	4	1	0	0
14771	1520	inhibitor of phosphatase	[inhibitor of phosphatases]	1.5849625007211563	3	2	1	1
14772	1520	accumulation of the ifn-gamma	[accumulation of the IFN-gamma]	1.5849625007211563	4	1	0	0
14773	1520	most primitive cell cd34(2+)/cd38-	[most primitive cells CD34(2+)/CD38-]	1.5849625007211563	4	1	0	0
14774	1520	phosphorylation of JAK1	[phosphorylation of JAK1]	1.5849625007211563	3	1	0	0
14775	1520	low affinity binding	[lower affinity binding]	1.5849625007211563	3	1	0	0
14776	1520	response to immunization	[response to immunization]	1.5849625007211563	3	1	0	0
14777	1520	chloramphenicol acetyltransferase construct	[chloramphenicol acetyltransferase constructs]	1.5849625007211563	3	1	0	0
14778	1520	HLA DR alpha promoter	[HLA DR alpha promoter]	1.5849625007211563	4	1	0	0
14779	1520	intracellular signalling molecules.	[intracellular signalling molecules.]	1.5849625007211563	3	1	0	0
14780	1520	overall promoter activity	[overall promoter activity]	1.5849625007211563	3	2	1	1
14781	1520	induce the differentiation	[inducing the differentiation]	1.5849625007211563	3	1	0	0
14782	1520	coactivator creb binding protein/p300	[coactivator CREB binding protein/p300]	1.5849625007211563	4	1	0	0
14783	1520	transcription of gene responsive	[transcription of genes responsive]	1.5849625007211563	4	1	0	0
14784	1520	peripheral blood lymphoid organ	[peripheral blood lymphoid organs]	1.5849625007211563	4	1	0	0
14785	1520	(via e1a n-terminal	[(via E1A N-terminal]	1.5849625007211563	3	1	0	0
14786	1520	level of p27(kip1) transcript	[levels of p27(KIP1) transcript]	1.5849625007211563	4	1	0	0
14787	1520	-66 to -59 region	[-66 to -59 region]	1.5849625007211563	4	2	1	1
14788	1520	gcr regulation in hMNL	[GcR regulation in hMNL]	1.5849625007211563	4	1	0	0
14789	1520	use thp-1 cell	[using THP-1 cells]	1.5849625007211563	3	1	0	0
14790	1520	result, inhibited, growth	[result, inhibited, growth]	1.5849625007211563	3	1	0	0
14791	1520	inhibitor of ap-1	[inhibitor of AP-1]	1.5849625007211563	3	1	0	0
14792	1520	immunization with varicella vaccine	[immunization with varicella vaccine]	1.5849625007211563	4	1	0	0
14793	1520	viral reactivation from latency	[Viral reactivation from latency]	1.5849625007211563	4	1	0	0
14794	1520	series of event	[series of events]	1.5849625007211563	3	2	1	1
14795	1520	B cell progenitor	[B cell progenitors]	1.5849625007211563	3	2	1	1
14796	1520	exposure to il-4	[exposure to IL-4]	1.5849625007211563	3	1	0	0
14797	1520	different type of stimulus	[different types of stimuli]	1.5849625007211563	4	1	0	0
14798	1520	immunocytochemistry 60 minute	[Immunocytochemistry 60 minutes]	1.5849625007211563	3	1	0	0
14799	1520	include the activation	[including the activation]	1.5849625007211563	3	2	2	2
14800	1520	generation of second messenger	[generation of second messengers]	1.5849625007211563	4	1	0	0
14801	1520	GATA-1 -red cell	[GATA-1 -red cells]	1.5849625007211563	3	1	0	0
14802	1520	NK cell line nk92	[NK cell line NK92]	1.5849625007211563	4	1	0	0
14803	1520	cloning of NF-ATc	[Cloning of NF-ATc]	1.5849625007211563	3	1	0	0
14804	1520	gp91phox gene expression	[gp91phox gene expression]	1.5849625007211563	3	2	1	1
14805	1520	activate signal through sigm	[activating signals through sIgM]	1.5849625007211563	4	1	0	0
14806	1520	role of this kinase	[role of this kinase]	1.5849625007211563	4	2	1	1
14807	1520	stress-activated protein (sap) kinase	[stress-activated protein (SAP) kinases]	1.5849625007211563	4	1	0	0
14808	1520	long-term inositol phosphate release	[Long-term inositol phosphate release]	1.5849625007211563	4	1	0	0
14809	1520	similar tyrosine -phosphorylated motif	[similar tyrosine -phosphorylated motifs]	1.5849625007211563	4	1	0	0
14810	1520	patient positive for c-jun	[patients positive for c-Jun]	1.5849625007211563	4	1	0	0
14811	1520	(NF) kappa b	[(NF) kappa B]	1.5849625007211563	3	1	0	0
14812	1520	g-csf receptor mrna	[G-CSF receptor mRNA]	1.5849625007211563	3	1	0	0
14813	1520	parallel signal pathway	[parallel signaling pathways]	1.5849625007211563	3	1	0	0
14814	1520	3 transcription factor complex	[3 transcription factor complex]	1.5849625007211563	4	1	0	0
14815	1520	SP-1 consensus sequence	[SP-1 consensus sequence]	1.5849625007211563	3	1	0	0
14816	1520	several DNA clone	[Several DNA clones]	1.5849625007211563	3	1	0	0
14817	1520	Functional specificity for repression	[Functional specificity for repression]	1.5849625007211563	4	1	0	0
14818	1520	1 mt-2 cell	[1 MT-2 cells]	1.5849625007211563	3	1	0	0
14819	1520	repopulate stem cell	[repopulating stem cells]	1.5849625007211563	3	1	0	0
14820	1520	key signal intermediate calcineurin	[key signalling intermediate calcineurin]	1.5849625007211563	4	1	0	0
14821	1520	well-characterized morphology, immunophenotype,	[well-characterized morphology, immunophenotype,]	1.5849625007211563	3	1	0	0
14822	1520	after cellular activation,	[After cellular activation,]	1.5849625007211563	3	1	0	0
14823	1520	4X NF-AT-Oct construct	[4X NF-AT-Oct construct]	1.5849625007211563	3	1	0	0
14824	1520	apoptosis cell cycle progression	[apoptosis cell cycle progression]	1.5849625007211563	4	1	0	0
14825	1520	E74 target sequence	[E74 target sequence]	1.5849625007211563	3	1	0	0
14826	1520	robust tyrosine phosphorylation	[robust tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
14827	1520	protein kinase c -alpha	[protein kinase C -alpha]	1.5849625007211563	4	1	0	0
14828	1520	HLA-DMA gene expression	[HLA-DMA gene expression]	1.5849625007211563	3	1	0	0
14829	1520	mostly of p50/c-Rel	[mostly of p50/c-Rel]	1.5849625007211563	3	1	0	0
14830	1520	expression of the protooncogene	[expression of the protooncogenes]	1.5849625007211563	4	1	0	0
14831	1520	hcmv CMV mie enhancer	[HCMV CMV MIE enhancers]	1.5849625007211563	4	1	0	0
14832	1520	leave nf-at transcription responsive	[leaving NF-AT transcription responsive]	1.5849625007211563	4	1	0	0
14833	1520	triplex formation by GM3	[Triplex formation by GM3]	1.5849625007211563	4	1	0	0
14834	1520	Iepsilon promoter by IL-4	[Iepsilon promoter by IL-4]	1.5849625007211563	4	1	0	0
14835	1520	T. parva-infected cell	[T. parva-infected cells]	1.5849625007211563	3	1	0	0
14836	1520	stimulation of the pathway	[stimulation of the pathway]	1.5849625007211563	4	1	0	0
14837	1520	alternative La mRNA	[alternative La mRNA]	1.5849625007211563	3	1	0	0
14838	1520	nuclear antigens, particularly u1rnp	[nuclear antigens, particularly U1RNP]	1.5849625007211563	4	1	0	0
14839	1520	NF-kappaB subunit p50	[NF-kappaB subunits p50]	1.5849625007211563	3	1	0	0
14840	1520	responsive element for PMA	[responsive element for PMA]	1.5849625007211563	4	2	1	1
14841	1520	regulate expression in platelet	[regulating expression in platelets]	1.5849625007211563	4	1	0	0
14842	1520	pathologic sign of cachexia	[pathologic signs of cachexia]	1.5849625007211563	4	1	0	0
14843	1520	context-dependent activation domain	[context-dependent activation domains]	1.5849625007211563	3	1	0	0
14844	1520	subsequent isolation of nuclei	[subsequent isolation of nuclei]	1.5849625007211563	4	1	0	0
14845	1520	increase in mobility	[increase in mobility]	1.5849625007211563	3	2	1	1
14846	1520	functional caev LTR	[functional CAEV LTR]	1.5849625007211563	3	1	0	0
14847	1520	nf-kappa b complex	[NF-kappa B complex]	1.5849625007211563	3	2	2	2
14848	1520	lambda5 promoter/enhancer region	[lambda5 promoter/enhancer region]	1.5849625007211563	3	1	0	0
14849	1520	respectively, bind protein	[respectively, bind proteins]	1.5849625007211563	3	1	0	0
14850	1520	myeloid cell line u937	[myeloid cell lines U937]	1.5849625007211563	4	1	0	0
14851	1520	significant improvement in airflow	[significant improvements in airflow]	1.5849625007211563	4	1	0	0
14852	1520	nuclear receptor ppargamma	[nuclear receptor PPARgamma]	1.5849625007211563	3	1	0	0
14853	1520	hla-dra expression in response	[HLA-DRA expression in response]	1.5849625007211563	4	1	0	0
14854	1520	woman with bv	[women with BV]	1.5849625007211563	3	1	0	0
14855	1520	interaction 1 tax transactivator	[Interaction 1 tax transactivator]	1.5849625007211563	4	1	0	0
14856	1520	Intestinal epithelial cell	[Intestinal epithelial cells]	1.5849625007211563	3	2	1	1
14857	1520	murine bone marrow cell	[murine bone marrow cells]	1.5849625007211563	4	2	2	2
14858	1520	early rheumatoid arthritis	[early rheumatoid arthritis]	1.5849625007211563	3	1	0	0
14859	1520	large cytogenetic clone	[large cytogenetic clones]	1.5849625007211563	3	1	0	0
14860	1520	production of progeny virion	[production of progeny virions]	1.5849625007211563	4	1	0	0
14861	1520	activation by Tpl-2	[activation by Tpl-2]	1.5849625007211563	3	2	1	1
14862	1520	vivo with cbp	[vivo with CBP]	1.5849625007211563	3	1	0	0
14863	1520	approximately 204 bp	[approximately 204 bp]	1.5849625007211563	3	1	0	0
14864	1520	presence of multimer	[presence of multimers]	1.5849625007211563	3	1	0	0
14865	1520	major increase in avp	[major increase in AVP]	1.5849625007211563	4	1	0	0
14866	1520	expression of various promoter	[expression of various promoters]	1.5849625007211563	4	1	0	0
14867	1520	october sequence Oct-1	[october sequence Oct-1]	1.5849625007211563	3	1	0	0
14868	1520	expression of GCRbeta	[expression of GCRbeta]	1.5849625007211563	3	2	1	1
14869	1520	great deal of attention	[great deal of attention]	1.5849625007211563	4	1	0	0
14870	1520	IL-2 IL-6 mrna expression	[IL-2 IL-6 mRNA expression]	1.5849625007211563	4	1	0	0
14871	1520	other hematopoietic cell	[other hematopoietic cells]	1.5849625007211563	3	1	0	0
14872	1520	c-fo gene of mrna	[c-fos gene of mRNA]	1.5849625007211563	4	1	0	0
14873	1520	mutually exclusive fashion.	[mutually exclusive fashion.]	1.5849625007211563	3	1	0	0
14874	1520	composite nf-at/ element	[composite NF-AT/ element]	1.5849625007211563	3	1	0	0
14875	1520	various transiently cell line	[various transiently cell lines]	1.5849625007211563	4	1	0	0
14876	1520	exposure to lps	[Exposure to LPS]	1.5849625007211563	3	1	0	0
14877	1520	trans-activation domain of e2a	[trans-activation domain of E2A]	1.5849625007211563	4	1	0	0
14878	1520	active functional state	[active functional state]	1.5849625007211563	3	1	0	0
14879	1520	CD43/leukosialin pathway induce apoptosis	[CD43/leukosialin pathway inducing apoptosis]	1.5849625007211563	4	1	0	0
14880	1520	b cell surface igm	[B cell surface IgM]	1.5849625007211563	4	1	0	0
14881	1520	transcriptional control activity	[transcriptional control activity]	1.5849625007211563	3	1	0	0
14882	1520	percentage of er monocyte	[percentage of ER monocytes]	1.5849625007211563	4	1	0	0
14883	1520	expression of gamma-globin mrna	[expression of gamma-globin mRNA]	1.5849625007211563	4	1	0	0
14884	1520	naive cd4(+) T cell	[naive CD4(+) T cells]	1.5849625007211563	4	1	0	0
14885	1520	development of a response	[development of an response]	1.5849625007211563	4	1	0	0
14886	1520	novel matrix attachment region	[novel matrix attachment region]	1.5849625007211563	4	1	0	0
14887	1520	DNA regulatory motif	[DNA regulatory motifs]	1.5849625007211563	3	1	0	0
14888	1520	high gssg level	[high GSSG levels]	1.5849625007211563	3	1	0	0
14889	1520	granulopoietic pathway (rather	[granulopoietic pathway (rather]	1.5849625007211563	3	1	0	0
14890	1520	particular loci for rearrangement	[particular loci for rearrangement]	1.5849625007211563	4	1	0	0
14891	1520	GR -responsive element GRE	[GR -responsive element GRE]	1.5849625007211563	4	1	0	0
14892	1520	transcription of several cytokine	[transcription of several cytokines]	1.5849625007211563	4	1	0	0
14893	1520	resting t-cell nuclear extract	[Resting T-cell nuclear extracts]	1.5849625007211563	4	1	0	0
14894	1520	Stat protein binding site	[Stat protein binding site]	1.5849625007211563	4	1	0	0
14895	1520	mutation in the gene	[mutations in the genes]	1.5849625007211563	4	2	1	1
14896	1520	p50 DNA binding domain	[p50 DNA binding domain]	1.5849625007211563	4	1	0	0
14897	1520	concomitantly, the tyrosine phosphorylation	[concomitantly, the tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
14898	1520	therapeutic effect of glucocorticoid	[therapeutic effects of glucocorticoids]	1.5849625007211563	4	1	0	0
14899	1520	anti-inflammatory drug sodium salicylate	[anti-inflammatory drugs sodium salicylate]	1.5849625007211563	4	1	0	0
14900	1520	gamma delta T cell	[gamma delta T cells]	1.5849625007211563	4	2	1	1
14901	1520	interleukin-2 receptor alpha-chain	[interleukin-2 receptor alpha-chain]	1.5849625007211563	3	2	1	1
14902	1520	avian erythroblast cell line	[avian erythroblast cell line]	1.5849625007211563	4	1	0	0
14903	1520	CD3 -epsilon expression	[CD3 -epsilon expression]	1.5849625007211563	3	1	0	0
14904	1520	hemin-induced DNA binding activity	[hemin-induced DNA binding activity]	1.5849625007211563	4	1	0	0
14905	1520	myeloid cell precursor	[myeloid cell precursors]	1.5849625007211563	3	1	0	0
14906	1520	trinucleotide repeat expansion	[trinucleotide repeat expansions]	1.5849625007211563	3	1	0	0
14907	1520	cellular immunoreaction MLR	[cellular immunoreactions MLR]	1.5849625007211563	3	1	0	0
14908	1520	nf-kappab in thp-1 cell	[NF-kappaB in THP-1 cells]	1.5849625007211563	4	1	0	0
14909	1520	group of gene	[group of gene]	1.5849625007211563	3	2	2	2
14910	1520	monocyte differentiation in vivo	[monocyte differentiation in vivo]	1.5849625007211563	4	1	0	0
14911	1520	SLP-76 function in separate,	[SLP-76 function in separate,]	1.5849625007211563	4	1	0	0
14912	1520	patient with steroid-resistant asthma	[patients with steroid-resistant asthma]	1.5849625007211563	4	2	1	1
14913	1520	proximal signal transduction defect	[proximal signal transduction defect]	1.5849625007211563	4	1	0	0
14914	1520	new combination isoform	[new combination isoform]	1.5849625007211563	3	1	0	0
14915	1520	early erythroid precursor	[early erythroid precursors]	1.5849625007211563	3	1	0	0
14916	1520	hiv-1 mutant virus	[HIV-1 mutant virus]	1.5849625007211563	3	1	0	0
14917	1520	express the tax	[expressing the Tax]	1.5849625007211563	3	2	2	2
14918	1520	vasoactive peptide ANG ii	[vasoactive peptide ANG II]	1.5849625007211563	4	1	0	0
14919	1520	different stage of differentiation	[different stages of differentiation]	1.5849625007211563	4	2	1	1
14920	1520	full length e2a cDNA	[full length E2A cDNA]	1.5849625007211563	4	1	0	0
14921	1520	presence of tgf-beta	[presence of TGF-beta]	1.5849625007211563	3	1	0	0
14922	1520	neuronal nos nno	[neuronal NOS nNOS]	1.5849625007211563	3	1	0	0
14923	1520	palindromic sequence with homology	[palindromic sequence with homology]	1.5849625007211563	4	1	0	0
14924	1520	1 interferon IFN	[1 interferon IFN]	1.5849625007211563	3	1	0	0
14925	1520	fusion complementary DNA	[fusion complementary DNA]	1.5849625007211563	3	1	0	0
14926	1520	decrease in the weight	[decrease in the weight]	1.5849625007211563	4	1	0	0
14927	1520	long form, Stat3alpha	[longer form, Stat3alpha]	1.5849625007211563	3	1	0	0
14928	1520	junb gene expression	[junB gene expression]	1.5849625007211563	3	1	0	0
14929	1520	mixture of cell	[mixture of cells]	1.5849625007211563	3	1	0	0
14930	1520	NFkappaB in human monocyte	[NFkappaB in human monocytes]	1.5849625007211563	4	1	0	0
14931	1520	phospholipase c /protein	[phospholipase C /protein]	1.5849625007211563	3	1	0	0
14932	1520	fourth cell line	[fourth cell line]	1.5849625007211563	3	1	0	0
14933	1520	redox control mechanism	[redox control mechanism]	1.5849625007211563	3	1	0	0
14934	1520	blast sensitivity to glucocorticoid	[Blast sensitivity to glucocorticoids]	1.5849625007211563	4	1	0	0
14935	1520	TCR beta analysis	[TCR beta analysis]	1.5849625007211563	3	1	0	0
14936	1520	cyclic adenosine monophosphate	[cyclic adenosine monophosphate]	1.5849625007211563	3	1	0	0
14937	1520	p65 p50 motif	[p65 p50 motifs]	1.5849625007211563	3	1	0	0
14938	1520	CD3/T cell receptor tcr	[CD3/T cell receptor TcR]	1.5849625007211563	4	1	0	0
14939	1520	lack of b29 transcript	[lack of B29 transcripts]	1.5849625007211563	4	1	0	0
14940	1520	logarithmic growth phase	[logarithmic growth phase]	1.5849625007211563	3	1	0	0
14941	1520	5-fold low affinity	[5-fold lower affinity]	1.5849625007211563	3	1	0	0
14942	1520	b cell co-culture	[B cell co-cultures]	1.5849625007211563	3	1	0	0
14943	1520	72-hr period of activation,	[72-hr period of activation,]	1.5849625007211563	4	1	0	0
14944	1520	alpha-galactosidase a gene	[alpha-galactosidase A gene]	1.5849625007211563	3	2	1	1
14945	1520	two patient with ss	[two patients with SS]	1.5849625007211563	4	1	0	0
14946	1520	permanent nf-kappa b translocation	[permanent NF-kappa B translocation]	1.5849625007211563	4	1	0	0
14947	1520	macrophage at transcriptional	[macrophages at transcriptional]	1.5849625007211563	3	1	0	0
14948	1520	human class ii trans-activator	[human class II trans-activator]	1.5849625007211563	4	1	0	0
14949	1520	Spi-B transcription factor	[Spi-B transcription factor]	1.5849625007211563	3	1	0	0
14950	1520	stimulation of bone growth	[stimulation of bone growth]	1.5849625007211563	4	1	0	0
14951	1520	proliferation of hematopoietic progenitor	[proliferation of hematopoietic progenitors]	1.5849625007211563	4	1	0	0
14952	1520	fetal developmental stage.	[fetal developmental stage.]	1.5849625007211563	3	1	0	0
14953	1520	immunosuppressant cyclosporin a CsA	[immunosuppressants cyclosporin A CsA]	1.5849625007211563	4	1	0	0
14954	1520	different traf protein	[different TRAF proteins]	1.5849625007211563	3	1	0	0
14955	1520	use of glucocorticoid	[use of glucocorticoids]	1.5849625007211563	3	2	2	2
14956	1520	th2 cytokine gene expression	[Th2 cytokine gene expression]	1.5849625007211563	4	1	0	0
14957	1520	erythrocyte in this colony	[erythrocytes in these colonies]	1.5849625007211563	4	1	0	0
14958	1520	acute myeloid leukaemia	[acute myeloid leukaemia]	1.5849625007211563	3	1	0	0
14959	1520	epsilon- globin gene	[epsilon- globin gene]	1.5849625007211563	3	2	1	1
14960	1520	(m/z) of 793	[(m/z) of 793]	1.5849625007211563	3	1	0	0
14961	1520	monocyte maturation/differentiation cd11b	[monocyte maturation/differentiation CD11b]	1.5849625007211563	3	1	0	0
14962	1520	use a set	[using a set]	1.5849625007211563	3	1	0	0
14963	1520	one hand, activation	[one hand, activation]	1.5849625007211563	3	1	0	0
14964	1520	range of cytokine	[range of cytokines]	1.5849625007211563	3	2	2	2
14965	1520	receptor for interleukin il-10r	[receptor for interleukin IL-10R]	1.5849625007211563	4	1	0	0
14966	1520	synergistic promoter activation	[synergistic promoter activation]	1.5849625007211563	3	1	0	0
14967	1520	nuclear component of NF-AT	[nuclear component of NF-AT]	1.5849625007211563	4	1	0	0
14968	1520	primary human breast tumor	[primary human breast tumors]	1.5849625007211563	4	1	0	0
14969	1520	thymocyte by immunoprecipitation	[thymocytes by immunoprecipitation]	1.5849625007211563	3	1	0	0
14970	1520	apoptosis -resistant T cell	[Apoptosis -resistant T cells]	1.5849625007211563	4	1	0	0
14971	1520	hepatic injury in mouse	[hepatic injury in mice]	1.5849625007211563	4	1	0	0
14972	1520	24 h of exposure	[24 h of exposure]	1.5849625007211563	4	1	0	0
14973	1520	activity of NF-kappaB promoter	[activity of NF-kappaB promoter]	1.5849625007211563	4	1	0	0
14974	1520	tyrosine phosphorylation of hs1	[tyrosine phosphorylation of HS1]	1.5849625007211563	4	1	0	0
14975	1520	production of viral antigen	[production of viral antigens]	1.5849625007211563	4	1	0	0
14976	1520	retinoid-mediated gene expression	[retinoid-mediated gene expression]	1.5849625007211563	3	1	0	0
14977	1520	tyrosine phosphorylation of hsi	[tyrosine phosphorylation of HSI]	1.5849625007211563	4	1	0	0
14978	1520	secretion of interleukin 2	[secretion of interleukin 2]	1.5849625007211563	4	1	0	0
14979	1520	primary murine b lymphocyte	[primary murine B lymphocytes]	1.5849625007211563	4	1	0	0
14980	1520	cell to plastic surface	[cells to plastic surfaces]	1.5849625007211563	4	1	0	0
14981	1520	peripheral blood lymphocyte culture	[peripheral blood lymphocyte cultures]	1.5849625007211563	4	2	2	2
14982	1520	encode a transdominant mutant	[encoding a transdominant mutant]	1.5849625007211563	4	1	0	0
14983	1520	tnf gene induction	[TNF gene induction]	1.5849625007211563	3	1	0	0
14984	1520	gene expression by selenium	[gene expression by selenium]	1.5849625007211563	4	1	0	0
14985	1520	CD40-stimulated human b lymphocyte	[CD40-stimulated human B lymphocytes]	1.5849625007211563	4	1	0	0
14986	1520	I kappa b-like protein	[I kappa B-like protein]	1.5849625007211563	4	1	0	0
14987	1520	include c-fo il-2r alpha	[including c-fos IL-2R alpha]	1.5849625007211563	4	1	0	0
14988	1520	such as chemotaxis	[such as chemotaxis]	1.5849625007211563	3	1	0	0
14989	1520	e box -binding activity	[E box -binding activity]	1.5849625007211563	4	1	0	0
14990	1520	possibility of a modification	[possibility of a modification]	1.5849625007211563	4	1	0	0
14991	1520	moreover, mrna for IL-2	[Moreover, mRNA for IL-2]	1.5849625007211563	4	1	0	0
14992	1520	addition of antibody	[addition of antibody]	1.5849625007211563	3	2	2	2
14993	1520	receptor in cell	[receptors in cells]	1.5849625007211563	3	2	2	2
14994	1520	CD40 signal pathway	[CD40 signaling pathway]	1.5849625007211563	3	2	2	2
14995	1520	mechanism of nonopsonic phagocytosis	[mechanism of nonopsonic phagocytosis]	1.5849625007211563	4	1	0	0
14996	1520	level of NF(kappa)B	[level of NF(kappa)B]	1.5849625007211563	3	1	0	0
14997	1520	t-cell transcription factor nf-at	[T-cell transcription factor NF-AT]	1.5849625007211563	4	1	0	0
14998	1520	undetectable basal level	[undetectable basal levels]	1.5849625007211563	3	1	0	0
14999	1520	extracellular matrix protein tenascin	[extracellular matrix protein tenascin]	1.5849625007211563	4	1	0	0
15000	1520	primarily to b lymphocyte	[primarily to B lymphocytes]	1.5849625007211563	4	1	0	0
15001	1520	nuclei of hla-dr+ cell	[nuclei of HLA-DR+ cells]	1.5849625007211563	4	1	0	0
15002	1520	I corticosteroid receptor	[I corticosteroid receptors]	1.5849625007211563	3	1	0	0
15003	1520	myeloid-committed cd34+thy-l-cd45ra+ subset	[myeloid-committed CD34+Thy-l-CD45RA+ subset]	1.5849625007211563	3	1	0	0
15004	1520	transcription of this proto-oncogent	[transcription of these proto-oncogenes]	1.5849625007211563	4	1	0	0
15005	1520	nuclear factor-DNA complex	[nuclear factor-DNA complexes]	1.5849625007211563	3	2	2	2
15006	1520	Egr-1 c-fo mrna expression	[Egr-1 c-fos mRNA expression]	1.5849625007211563	4	1	0	0
15007	1520	viral control element	[viral control elements]	1.5849625007211563	3	1	0	0
15008	1520	glucocorticoid gc insensitivity	[glucocorticoid GC insensitivity]	1.5849625007211563	3	1	0	0
15009	1520	GrpL -SLP-76 complex	[GrpL -SLP-76 complex]	1.5849625007211563	3	1	0	0
15010	1520	binding of v3 loop	[binding of V3 loop]	1.5849625007211563	4	1	0	0
15011	1520	patient T lymphocyte	[patient's T lymphocytes]	1.5849625007211563	3	1	0	0
15012	1520	gene activation identical	[gene activation identical]	1.5849625007211563	3	1	0	0
15013	1520	infectious progeny virion	[infectious progeny virions]	1.5849625007211563	3	1	0	0
15014	1520	human pro-interleukin-1beta gene	[human pro-interleukin-1beta gene]	1.5849625007211563	3	1	0	0
15015	1520	produce select outcomes,	[producing select outcomes,]	1.5849625007211563	3	1	0	0
15016	1520	zinc-finger transcription factor	[zinc-finger transcription factor]	1.5849625007211563	3	2	2	2
15017	1520	activation of gene isg	[activation of genes ISGs]	1.5849625007211563	4	2	2	2
15018	1520	regression analysis of datum	[Regression analysis of data]	1.5849625007211563	4	1	0	0
15019	1520	proportion of oleate	[proportions of oleate]	1.5849625007211563	3	1	0	0
15020	1520	efficiently kill target	[efficiently killing targets]	1.5849625007211563	3	1	0	0
15021	1520	otf1 from HeLa cell	[OTF1 from HeLa cells]	1.5849625007211563	4	1	0	0
15022	1520	histogenesis of hd	[histogenesis of HD]	1.5849625007211563	3	1	0	0
15023	1520	addition, only a subset	[addition, only a subset]	1.5849625007211563	4	1	0	0
15024	1520	rela (p65) protein	[RelA (p65) proteins]	1.5849625007211563	3	1	0	0
15025	1520	murine macrophage 12/15-lipoxygenase activity	[murine macrophage 12/15-lipoxygenase activity]	1.5849625007211563	4	1	0	0
15026	1520	half-life of e-selectin	[half-life of E-selectin]	1.5849625007211563	3	1	0	0
15027	1520	use semiquantitative rt- pcr	[Using semiquantitative RT- PCR]	1.5849625007211563	4	1	0	0
15028	1520	HTLV-II by immunofluorescence	[HTLV-II by immunofluorescence]	1.5849625007211563	3	1	0	0
15029	1520	transient expression of LSF	[transient expression of LSF]	1.5849625007211563	4	1	0	0
15030	1520	ap-1 enhancer activity result	[AP-1 enhancer activity resulting]	1.5849625007211563	4	1	0	0
15031	1520	various cellular activation agent	[various cellular activation agents]	1.5849625007211563	4	1	0	0
15032	1520	hiv-2 enhancer activation	[HIV-2 enhancer activation]	1.5849625007211563	3	1	0	0
15033	1520	friend virus erythroblast	[Friend virus erythroblasts]	1.5849625007211563	3	1	0	0
15034	1520	t- cell mitogen	[T- cell mitogens]	1.5849625007211563	3	1	0	0
15035	1520	explanation for many	[explanation for many]	1.5849625007211563	3	1	0	0
15036	1520	IL-7 /il-7r system	[IL-7 /IL-7R system]	1.5849625007211563	3	1	0	0
15037	1520	extracellular matrix proteins,	[extracellular matrix proteins,]	1.5849625007211563	3	1	0	0
15038	1520	signal transduction culminate	[signal transduction culminating]	1.5849625007211563	3	1	0	0
15039	1520	deletion of b lymphocyte	[deletion of B lymphocytes]	1.5849625007211563	4	1	0	0
15040	1520	oestrogen receptor er	[Oestrogen receptor ER]	1.5849625007211563	3	2	1	1
15041	1520	5-bromo-2'-deoxyuridine incorporation into DNA	[5-bromo-2'-deoxyuridine incorporation into DNA]	1.5849625007211563	4	1	0	0
15042	1520	tax mutant IEXL320G	[Tax mutant IEXL320G]	1.5849625007211563	3	1	0	0
15043	1520	and/or specific compound tested.	[and/or specific compound tested.]	1.5849625007211563	4	1	0	0
15044	1520	expression of cyclin D2	[expression of cyclin D2]	1.5849625007211563	4	1	0	0
15045	1520	lymphocytic receptor concentration	[lymphocytic receptor concentrations]	1.5849625007211563	3	1	0	0
15046	1520	cytokine cell cycle analysis	[cytokines cell cycle analysis]	1.5849625007211563	4	1	0	0
15047	1520	kinetic of induction	[kinetics of induction]	1.5849625007211563	3	2	1	1
15048	1520	[regulation of transcription	[[Regulation of transcription]	1.5849625007211563	3	1	0	0
15049	1520	hiv-infected T cell	[HIV-infected T cells]	1.5849625007211563	3	2	1	1
15050	1520	binding site for NF-AT	[binding site for NF-AT]	1.5849625007211563	4	1	0	0
15051	1520	DNA sequence proximal	[DNA sequences proximal]	1.5849625007211563	3	1	0	0
15052	1520	host with breast cancer	[host with breast cancer]	1.5849625007211563	4	1	0	0
15053	1520	CD28 responsive complex cd28rc	[CD28 responsive complex CD28RC]	1.5849625007211563	4	1	0	0
15054	1520	Sp140 in the NB	[Sp140 in the NB]	1.5849625007211563	4	1	0	0
15055	1520	stimulation through this protein	[stimulation through this protein]	1.5849625007211563	4	1	0	0
15056	1520	bind activity, phosphorylation event	[binding activity, phosphorylation events]	1.5849625007211563	4	1	0	0
15057	1520	ap-1 protein c-fo	[AP-1 proteins c-Fos]	1.5849625007211563	3	1	0	0
15058	1520	igm-secreting plasma cell	[IgM-secreting plasma cells]	1.5849625007211563	3	1	0	0
15059	1520	promoter context-specific manner;	[promoter context-specific manner;]	1.5849625007211563	3	1	0	0
15060	1520	1 beta il-1 beta	[1 beta IL-1 beta]	1.5849625007211563	4	2	1	1
15061	1520	I epsilon exon	[I epsilon exon]	1.5849625007211563	3	2	1	1
15062	1520	Janus tyrosine kinase	[Janus tyrosine kinase]	1.5849625007211563	3	2	2	2
15063	1520	gene transcription in response	[gene transcription in response]	1.5849625007211563	4	1	0	0
15064	1520	Rheumatoid arthritis RA	[Rheumatoid arthritis RA]	1.5849625007211563	3	1	0	0
15065	1520	reduction of tcrzeta expression	[reduction of TCRzeta expression]	1.5849625007211563	4	1	0	0
15066	1520	b cell OCA-B	[B cells OCA-B]	1.5849625007211563	3	1	0	0
15067	1520	homodimer (two p50	[homodimer (two p50s]	1.5849625007211563	3	1	0	0
15068	1520	Rel transcription factor family	[Rel transcription factor family]	1.5849625007211563	4	1	0	0
15069	1520	ferritin h-chain gene	[ferritin H-chain gene]	1.5849625007211563	3	1	0	0
15070	1520	W box promoter element	[W box promoter element]	1.5849625007211563	4	1	0	0
15071	1520	sequence specificity of nf-at	[sequence specificity of NF-AT]	1.5849625007211563	4	1	0	0
15072	1520	face of progressive infection.	[face of progressive infection.]	1.5849625007211563	4	1	0	0
15073	1520	anti-oxidative effect of BHA	[anti-oxidative effect of BHA]	1.5849625007211563	4	1	0	0
15074	1520	varicella-zoster virus peptide	[varicella-zoster virus peptides]	1.5849625007211563	3	2	1	1
15075	1520	full length wild-type form	[full length wild-type form]	1.5849625007211563	4	1	0	0
15076	1520	zap-70 tyrosine kinase	[ZAP-70 tyrosine kinase]	1.5849625007211563	3	1	0	0
15077	1520	T24 Ha-ras oncogene	[T24 Ha-ras oncogene]	1.5849625007211563	3	1	0	0
15078	1520	cell redox status.	[cell redox status.]	1.5849625007211563	3	1	0	0
15079	1520	design future therapeutic strategy	[designing future therapeutic strategies]	1.5849625007211563	4	1	0	0
15080	1520	stimulation of any one	[stimulation of any one]	1.5849625007211563	4	1	0	0
15081	1520	chemotactic activity for neutrophil	[chemotactic activity for neutrophils]	1.5849625007211563	4	1	0	0
15082	1520	inhibit NF-kappa b	[inhibiting NF-kappa B]	1.5849625007211563	3	1	0	0
15083	1520	bind protein CREB	[binding protein CREB]	1.5849625007211563	3	1	0	0
15084	1520	human interleukin-5 hil-5	[human interleukin-5 hIL-5]	1.5849625007211563	3	1	0	0
15085	1520	domain of the protein	[domains of the protein]	1.5849625007211563	4	2	2	2
15086	1520	N-terminal poz domain	[N-terminal POZ domain]	1.5849625007211563	3	1	0	0
15087	1520	growth of sense	[growth of sense]	1.5849625007211563	3	1	0	0
15088	1520	stat1-containing dna-binding complex	[STAT1-containing DNA-binding complex]	1.5849625007211563	3	1	0	0
15089	1520	differential activation property	[differential activation properties]	1.5849625007211563	3	1	0	0
15090	1520	Rex protein production	[Rex protein production]	1.5849625007211563	3	1	0	0
15091	1520	different CD4 epitope	[different CD4 epitopes]	1.5849625007211563	3	2	1	1
15092	1520	induction of elk-1 expression	[induction of elk-1 expression]	1.5849625007211563	4	1	0	0
15093	1520	immediate-early trans-activator protein bzlf1	[immediate-early trans-activator protein BZLF1]	1.5849625007211563	4	1	0	0
15094	1520	inhibitor of the activation	[inhibitors of the activation]	1.5849625007211563	4	1	0	0
15095	1520	initiation of the reaction	[initiation of the reaction]	1.5849625007211563	4	1	0	0
15096	1520	correlation between the uptake	[correlation between the uptake]	1.5849625007211563	4	1	0	0
15097	1520	contain wild-type ltr	[containing wild-type LTRs]	1.5849625007211563	3	1	0	0
15098	1520	ut-7 epo cell	[UT-7 Epo cells]	1.5849625007211563	3	1	0	0
15099	1520	same electrophoretic mobility	[same electrophoretic mobility]	1.5849625007211563	3	2	1	1
15100	1520	construct in tpa	[constructs in TPA]	1.5849625007211563	3	1	0	0
15101	1520	NF-E2 another trans-acting factor	[NF-E2 another trans-acting factor]	1.5849625007211563	4	1	0	0
15102	1520	two adjacent site	[two adjacent sites]	1.5849625007211563	3	2	1	1
15103	1520	Epstein-Barr virus antigen EBNA2	[Epstein-Barr virus antigen EBNA2]	1.5849625007211563	4	2	2	2
15104	1520	nonleukemogenic virus Akv	[nonleukemogenic virus Akv]	1.5849625007211563	3	1	0	0
15105	1520	Jak -STAT signal pathway	[Jak -STAT signaling pathway]	1.5849625007211563	4	1	0	0
15106	1520	furthermore, in T cell	[Furthermore, in T cells]	1.5849625007211563	4	2	1	1
15107	1520	primary peripheral blood lymphocyte	[primary peripheral blood lymphocytes]	1.5849625007211563	4	2	1	1
15108	1520	ifn-gamma priming of monocyte	[IFN-gamma priming of monocytes]	1.5849625007211563	4	1	0	0
15109	1520	number of bhlh factor	[number of bHLH factors]	1.5849625007211563	4	1	0	0
15110	1520	high expression of il-6	[high expression of IL-6]	1.5849625007211563	4	1	0	0
15111	1520	il-2 activation in initiation	[IL-2 activation in initiation]	1.5849625007211563	4	1	0	0
15112	1520	130 kb from sox9	[130 kb from SOX9]	1.5849625007211563	4	2	2	2
15113	1520	activation of the integrin	[activation of the integrin]	1.5849625007211563	4	1	0	0
15114	1520	neoplastic lymphoid cell	[neoplastic lymphoid cells]	1.5849625007211563	3	2	1	1
15115	1520	nonconsensus binding site	[nonconsensus binding sites]	1.5849625007211563	3	1	0	0
15116	1520	peptide corresponding to residue	[Peptides corresponding to residues]	1.5849625007211563	4	1	0	0
15117	1520	ccaat-box binding factor	[CCAAT-box binding factor]	1.5849625007211563	3	2	2	2
15118	1520	hla binding characteristic	[HLA binding characteristics]	1.5849625007211563	3	1	0	0
15119	1520	analysis by Northern hybridization	[analysis by Northern hybridization]	1.5849625007211563	4	1	0	0
15120	1520	cell type-specific October factor	[cell type-specific Oct factors]	1.5849625007211563	4	1	0	0
15121	1520	leukemic cell of patient	[leukemic cells of patients]	1.5849625007211563	4	2	1	1
15122	1520	significantly high CAT activity	[significantly high CAT activity]	1.5849625007211563	4	1	0	0
15123	1520	survey in lymphoid malignancy	[survey in lymphoid malignancies]	1.5849625007211563	4	1	0	0
15124	1520	(nk) progenitor cell	[(NK) progenitor cells]	1.5849625007211563	3	1	0	0
15125	1520	1.42 m-1 m-1)	[1.42 M-1 M-1)]	1.5849625007211563	3	1	0	0
15126	1520	group of SLE patient	[group of SLE patients]	1.5849625007211563	4	1	0	0
15127	1520	lymphoblastoid t-cell-line-expressing CD4 receptor	[lymphoblastoid T-cell-line-expressing CD4 receptors]	1.5849625007211563	4	1	0	0
15128	1520	nf-kappa b transcription factors.	[NF-kappa B transcription factors.]	1.5849625007211563	4	1	0	0
15129	1520	increase of tnf-alpha mrna	[increase of TNF-alpha mRNA]	1.5849625007211563	4	1	0	0
15130	1520	degradation in T cell	[degradation in T cells]	1.5849625007211563	4	2	2	2
15131	1520	genomic LMP1 DNA fragment	[genomic LMP1 DNA fragments]	1.5849625007211563	4	1	0	0
15132	1520	cp in lcl	[Cp in LCLs]	1.5849625007211563	3	1	0	0
15133	1520	IL3 gene expression	[IL3 gene expression]	1.5849625007211563	3	2	1	1
15134	1520	Mol cell Biol	[Mol Cell Biol]	1.5849625007211563	3	2	1	1
15135	1520	interleukin gene expression	[interleukin gene expression]	1.5849625007211563	3	2	2	2
15136	1520	lt biologic activity	[LT biologic activity]	1.5849625007211563	3	2	1	1
15137	1520	duration of mrna accumulation	[duration of mRNA accumulation]	1.5849625007211563	4	1	0	0
15138	1520	regard to capacity	[regard to capacity]	1.5849625007211563	3	1	0	0
15139	1520	useful marker for diagnosis	[useful marker for diagnosis]	1.5849625007211563	4	1	0	0
15140	1520	bind affinity nmol/L)	[binding affinity nmol/L)]	1.5849625007211563	3	1	0	0
15141	1520	low vcam-1 expression	[low VCAM-1 expression]	1.5849625007211563	3	2	2	2
15142	1520	entirely miss the nf-kappab	[entirely missing the NF-kappaB]	1.5849625007211563	4	1	0	0
15143	1520	lack the kinase activity	[lacking the kinase activity]	1.5849625007211563	4	1	0	0
15144	1520	time of adherence	[time of adherence]	1.5849625007211563	3	1	0	0
15145	1520	prototypic class ii promoter	[prototypic class II promoter]	1.5849625007211563	4	1	0	0
15146	1520	cooperation with soluble tnf-alpha	[cooperation with soluble TNF-alpha]	1.5849625007211563	4	1	0	0
15147	1520	endobronchial biopsy specimen	[endobronchial biopsy specimens]	1.5849625007211563	3	1	0	0
15148	1520	methylation interference assay	[methylation interference assays]	1.5849625007211563	3	1	0	0
15149	1520	interferon-gamma activation site-like sequence	[interferon-gamma activation site-like sequence]	1.5849625007211563	4	1	0	0
15150	1520	fk506 -binding protein fkbp	[FK506 -binding protein FKBP]	1.5849625007211563	4	1	0	0
15151	1520	classic target tissue	[classic target tissues]	1.5849625007211563	3	1	0	0
15152	1520	AP1 family member	[AP1 family members]	1.5849625007211563	3	1	0	0
15153	1520	p3hr-1 strain of virus	[P3HR-1 strain of virus]	1.5849625007211563	4	1	0	0
15154	1520	Antisera to Fos	[Antisera to Fos]	1.5849625007211563	3	1	0	0
15155	1520	(3) asymmetric division	[(3) asymmetric divisions]	1.5849625007211563	3	1	0	0
15156	1520	complex in haemopoietic cell	[complexes in haemopoietic cells]	1.5849625007211563	4	1	0	0
15157	1520	human cell lysate	[human cell lysates]	1.5849625007211563	3	1	0	0
15158	1520	cystatin C CST3	[cystatin C CST3]	1.5849625007211563	3	1	0	0
15159	1520	wash the cells,	[washing the cells,]	1.5849625007211563	3	1	0	0
15160	1520	model, kda value	[model, kDa values]	1.5849625007211563	3	1	0	0
15161	1520	context of a promoter	[context of an promoter]	1.5849625007211563	4	1	0	0
15162	1520	ige production of anti-CD40	[IgE production of anti-CD40]	1.5849625007211563	4	1	0	0
15163	1520	binding of pac-1	[binding of PAC-1]	1.5849625007211563	3	2	2	2
15164	1520	twentyfold increase in phosphorylation	[twentyfold increase in phosphorylation]	1.5849625007211563	4	1	0	0
15165	1520	human lim-hox gene hlh-2	[human LIM-Hox gene hLH-2]	1.5849625007211563	4	1	0	0
15166	1520	least three transcription factor	[least three transcription factors]	1.5849625007211563	4	2	1	1
15167	1520	Rel/ NF-kappaB family	[Rel/ NF-kappaB family]	1.5849625007211563	3	1	0	0
15168	1520	vitro system consist	[vitro system consisting]	1.5849625007211563	3	1	0	0
15169	1520	several cell surface molecule	[several cell surface molecules]	1.5849625007211563	4	1	0	0
15170	1520	moreover, cell line	[Moreover, cell lines]	1.5849625007211563	3	1	0	0
15171	1520	include the Janus kinase	[including the Janus kinases]	1.5849625007211563	4	2	2	2
15172	1520	IL-8 gene expression	[IL-8 gene expression]	1.5849625007211563	3	2	1	1
15173	1520	cell to glucocorticoid	[cells to glucocorticoids]	1.5849625007211563	3	1	0	0
15174	1520	agonist of monocyte adhesion	[agonists of monocyte adhesion]	1.5849625007211563	4	1	0	0
15175	1520	gr with one-site kinetic	[GR with one-site kinetics]	1.5849625007211563	4	1	0	0
15176	1520	cell from primate	[cells from primates]	1.5849625007211563	3	2	2	2
15177	1520	age-related T cell response	[age-related T cell responses]	1.5849625007211563	4	1	0	0
15178	1520	induce the surface expression	[inducing the surface expression]	1.5849625007211563	4	1	0	0
15179	1520	mmol/l); hyperkalemia (7.6	[mmol/l); hyperkalemia (7.6]	1.5849625007211563	3	1	0	0
15180	1520	three-layer Percoll density gradient	[three-layer Percoll density gradient]	1.5849625007211563	4	1	0	0
15181	1520	kinase in IL-2	[kinase in IL-2]	1.5849625007211563	3	1	0	0
15182	1520	incubation in culture medium	[incubation in culture medium]	1.5849625007211563	4	1	0	0
15183	1520	apoptotic lymphocyte from individual	[apoptotic lymphocytes from individuals]	1.5849625007211563	4	1	0	0
15184	1520	epstein-barr virus oncoprotein latent	[Epstein-Barr virus oncoprotein latent]	1.5849625007211563	4	1	0	0
15185	1520	control of inflammatory process	[control of inflammatory processes]	1.5849625007211563	4	1	0	0
15186	1520	stress response of cell	[stress response of cells]	1.5849625007211563	4	1	0	0
15187	1520	Epstein-Barr virus antigen ebna-2	[Epstein-Barr virus antigen EBNA-2]	1.5849625007211563	4	2	2	2
15188	1520	lps il-1ra synthesis	[LPS IL-1ra synthesis]	1.5849625007211563	3	1	0	0
15189	1520	stromal cell line	[stromal cell line]	1.5849625007211563	3	2	2	2
15190	1520	rat peritoneal neutrophil	[rat peritoneal neutrophils]	1.5849625007211563	3	1	0	0
15191	1520	pathogenesis of tumor progression	[pathogenesis of tumor progression]	1.5849625007211563	4	1	0	0
15192	1520	insight into different role	[insight into different roles]	1.5849625007211563	4	1	0	0
15193	1520	immunoblot flow cytometry analysis	[Immunoblot flow cytometry analysis]	1.5849625007211563	4	1	0	0
15194	1520	major functional importance	[major functional importance]	1.5849625007211563	3	1	0	0
15195	1520	responsiveness of this cell	[responsiveness of these cells]	1.5849625007211563	4	1	0	0
15196	1520	effect of this substitution	[effects of these substitutions]	1.5849625007211563	4	1	0	0
15197	1520	two infant brother	[two infant brothers]	1.5849625007211563	3	1	0	0
15198	1520	response to PDTC	[response to PDTC]	1.5849625007211563	3	1	0	0
15199	1520	10(-7) mol/L phorbol	[10(-7) mol/L phorbol]	1.5849625007211563	3	1	0	0
15200	1520	repression of survival factor	[repression of survival factors]	1.5849625007211563	4	1	0	0
15201	1520	express nuclear nf-kappa b	[expressing nuclear NF-kappa B]	1.5849625007211563	4	1	0	0
15202	1520	RA nuclear receptor	[RA nuclear receptors]	1.5849625007211563	3	1	0	0
15203	1520	increase in illness	[increase in illness]	1.5849625007211563	3	1	0	0
15204	1520	JNK c-Jun NH2-terminal kinase	[JNK c-Jun NH2-terminal kinase]	1.5849625007211563	4	1	0	0
15205	1520	two unique phosphopeptide	[two unique phosphopeptides]	1.5849625007211563	3	1	0	0
15206	1520	weak effect on proliferation.	[weak effects on proliferation.]	1.5849625007211563	4	1	0	0
15207	1520	enhancer binding protein	[enhancer binding proteins]	1.5849625007211563	3	1	0	0
15208	1520	promoter-luciferase reporter plasmid	[promoter-luciferase reporter plasmids]	1.5849625007211563	3	1	0	0
15209	1520	characterization of chromosome breakpoint	[characterizations of chromosome breakpoints]	1.5849625007211563	4	1	0	0
15210	1520	high weight dextran sulfate	[High weight dextran sulfate]	1.5849625007211563	4	2	2	2
15211	1520	rb-related protein p107	[Rb-related protein p107]	1.5849625007211563	3	1	0	0
15212	1520	unseparated lavage cell	[unseparated lavage cells]	1.5849625007211563	3	1	0	0
15213	1520	agonist-induced monocyte adhesion	[agonist-induced monocyte adhesion]	1.5849625007211563	3	1	0	0
15214	1520	homology between nucleolin	[Homology between nucleolin]	1.5849625007211563	3	1	0	0
15215	1520	predominance of p50p50	[predominance of p50p50]	1.5849625007211563	3	1	0	0
15216	1520	level of hes-1 transcript	[levels of HES-1 transcripts]	1.5849625007211563	4	1	0	0
15217	1520	CD8+CD28null T cell	[CD8+CD28null T cells]	1.5849625007211563	3	1	0	0
15218	1520	physiological role in binding	[physiological role in binding]	1.5849625007211563	4	1	0	0
15219	1520	NF-kappaB in TL-Om1	[NF-kappaB in TL-Om1]	1.5849625007211563	3	1	0	0
15220	1520	spontaneous expression of il-2r	[spontaneous expression of IL-2R]	1.5849625007211563	4	1	0	0
15221	1520	threshold for apoptosis	[threshold for apoptosis]	1.5849625007211563	3	1	0	0
15222	1520	human bactericidal/permeability-increasing protein bpi	[human bactericidal/permeability-increasing protein BPI]	1.5849625007211563	4	1	0	0
15223	1520	markedly anionic domain	[markedly anionic domain]	1.5849625007211563	3	1	0	0
15224	1520	okt8+ suppressor/cytotoxic T cell	[OKT8+ suppressor/cytotoxic T cells]	1.5849625007211563	4	1	0	0
15225	1520	genetic predisposition for atopy	[genetic predisposition for atopy]	1.5849625007211563	4	1	0	0
15226	1520	bacterial protein icsa	[bacterial protein IcsA]	1.5849625007211563	3	1	0	0
15227	1520	progesterone receptor-specific monoclonal antibody	[progesterone receptor-specific monoclonal antibody]	1.5849625007211563	4	1	0	0
15228	1520	two different mechanims:	[two different mechanims:]	1.5849625007211563	3	1	0	0
15229	1520	demonstrate a early event.	[demonstrating an early event.]	1.5849625007211563	4	1	0	0
15230	1520	recurrence of glial tumor	[recurrence of glial tumors]	1.5849625007211563	4	1	0	0
15231	1520	patient with carcinoma	[patients with carcinoma]	1.5849625007211563	3	2	2	2
15232	1520	response to receptor cross-linking	[response to receptor cross-linking]	1.5849625007211563	4	1	0	0
15233	1520	many chronic disorder	[many chronic disorders]	1.5849625007211563	3	1	0	0
15234	1520	p105/ nf-kappa b1	[p105/ NF-kappa B1]	1.5849625007211563	3	1	0	0
15235	1520	31834500), 3610 (range, 2594-3979)	[3183-4450), 3610 (range, 2594-3979)]	1.5849625007211563	4	1	0	0
15236	1520	C/EBPalpha -deficient hematopoietic cell	[C/EBPalpha -deficient hematopoietic cells]	1.5849625007211563	4	1	0	0
15237	1520	competent stat transcription	[competent STAT transcription]	1.5849625007211563	3	1	0	0
15238	1520	number of model systems,	[number of model systems,]	1.5849625007211563	4	1	0	0
15239	1520	1.46 nmol/L; daidzein	[1.46 nmol/L; daidzein]	1.5849625007211563	3	1	0	0
15240	1520	human TNF promoter GGGGCTGTCCC	[human TNF promoter GGGGCTGTCCC]	1.5849625007211563	4	1	0	0
15241	1520	cd95 APO-1/Fas ligand cd95l	[CD95 APO-1/Fas ligand CD95L]	1.5849625007211563	4	1	0	0
15242	1520	c-fo sense mrna expression	[c-fos sense mRNA expression]	1.5849625007211563	4	1	0	0
15243	1520	IL-2 promoter region nfat	[IL-2 promoter region NFAT]	1.5849625007211563	4	1	0	0
15244	1520	plasmacytoma b cell hybrid	[plasmacytoma B cell hybrids]	1.5849625007211563	4	1	0	0
15245	1520	T cell infiltrate joint	[T cells infiltrating joints]	1.5849625007211563	4	1	0	0
15246	1520	activation by heme	[activation by heme]	1.5849625007211563	3	1	0	0
15247	1520	tyrosine phosphorylation tyr-705	[tyrosine phosphorylation Tyr-705]	1.5849625007211563	3	1	0	0
15248	1520	induction during experimental anemia	[induction during experimental anemia]	1.5849625007211563	4	1	0	0
15249	1520	latent cytoplasmic form	[latent cytoplasmic form]	1.5849625007211563	3	1	0	0
15250	1520	rest pbl in vitro,	[resting PBL in vitro,]	1.5849625007211563	4	1	0	0
15251	1520	et transcription factor	[ets transcription factor]	1.5849625007211563	3	2	2	2
15252	1520	gata-1 binding transcription factor	[GATA-1 binding transcription factor]	1.5849625007211563	4	1	0	0
15253	1520	Finally, gel shift analysis	[Finally, gel shift analysis]	1.5849625007211563	4	1	0	0
15254	1520	erythroid cell viability	[erythroid cell viability]	1.5849625007211563	3	1	0	0
15255	1520	cyclosporin a-treated human b	[cyclosporin A-treated human B]	1.5849625007211563	4	1	0	0
15256	1520	RESULTS: Hypercortisolaemia, in vitro,	[RESULTS: Hypercortisolaemia, in vitro,]	1.5849625007211563	4	1	0	0
15257	1520	treatment of child	[treatment of children]	1.5849625007211563	3	1	0	0
15258	1520	branch site critical	[branch site critical]	1.5849625007211563	3	1	0	0
15259	1520	oestrogen receptor gene polymorphism	[Oestrogen receptor gene polymorphisms]	1.5849625007211563	4	1	0	0
15260	1520	adjuvant chemotherapy with CMF	[adjuvant chemotherapy with CMF]	1.5849625007211563	4	1	0	0
15261	1520	nitric oxide synthetase activity	[nitric oxide synthetase activity]	1.5849625007211563	4	1	0	0
15262	1520	level of mrna stability	[level of mRNA stability]	1.5849625007211563	4	1	0	0
15263	1520	binding by il-2 stimulation	[binding by IL-2 stimulation]	1.5849625007211563	4	1	0	0
15264	1520	unique function of mzf-2	[unique function of MZF-2]	1.5849625007211563	4	1	0	0
15265	1520	phop/phoq two-component virulence regulon	[phoP/phoQ two-component virulence regulon]	1.5849625007211563	4	1	0	0
15266	1520	viral survival-promoting protein	[viral survival-promoting proteins]	1.5849625007211563	3	1	0	0
15267	1520	CD40 ig sIg receptor	[CD40 Ig sIg receptors]	1.5849625007211563	4	1	0	0
15268	1520	cell type specific	[cell type specific]	1.5849625007211563	3	1	0	0
15269	1520	Th2 cytokine profile	[Th2 cytokine profile]	1.5849625007211563	3	1	0	0
15270	1520	effect of ptpase inhibitor	[effect of PTPase inhibitors]	1.5849625007211563	4	1	0	0
15271	1520	glia from mouse	[glia from mice]	1.5849625007211563	3	1	0	0
15272	1520	antisense oligodeoxynucleotides odn	[antisense oligodeoxynucleotides ODNs]	1.5849625007211563	3	1	0	0
15273	1520	immune function datum	[immune function data]	1.5849625007211563	3	1	0	0
15274	1520	activation of the LTR	[Activation of the LTR]	1.5849625007211563	4	1	0	0
15275	1520	sequence element microa	[sequence element microA]	1.5849625007211563	3	1	0	0
15276	1520	monocyte/macrophage-like cell line	[monocyte/macrophage-like cell line]	1.5849625007211563	3	2	1	1
15277	1520	GR mrna level	[GR mRNA levels]	1.5849625007211563	3	1	0	0
15278	1520	expression of NF-kappa B	[expression of NF-kappa B]	1.5849625007211563	4	1	0	0
15279	1520	activation of kinase activity	[activation of kinase activity]	1.5849625007211563	4	1	0	0
15280	1520	several problem in vectors,	[several problems in vectors,]	1.5849625007211563	4	1	0	0
15281	1520	cyclin d-associated kinase activity	[cyclin D-associated kinase activity]	1.5849625007211563	4	1	0	0
15282	1520	inhibition of NF-kappa b	[inhibition of NF-kappa B]	1.5849625007211563	4	1	0	0
15283	1520	single ala asp amino	[single Ala Asp amino]	1.5849625007211563	4	1	0	0
15284	1520	il-2- dependent transcription	[IL-2- dependent transcription]	1.5849625007211563	3	1	0	0
15285	1520	camp-response element CRE	[cAMP-response element CRE]	1.5849625007211563	3	2	2	2
15286	1520	total cellular 25(oh)d3 uptake	[total cellular 25(OH)D3 uptake]	1.5849625007211563	4	1	0	0
15287	1520	U937 monocytic cell	[U937 monocytic cells]	1.5849625007211563	3	2	1	1
15288	1520	monocyte /macrophage by ifn-gamma	[monocytes /macrophages by IFN-gamma]	1.5849625007211563	4	1	0	0
15289	1520	immunoglobulin heavy-chain (igh) gene	[immunoglobulin heavy-chain (IgH) gene]	1.5849625007211563	4	1	0	0
15290	1520	analysis of deletion mutant	[analysis of deletion mutants]	1.5849625007211563	4	2	2	2
15291	1520	B-cell line represent stage	[B-cell lines representing stages]	1.5849625007211563	4	2	2	2
15292	1520	variety of cell	[variety of cells]	1.5849625007211563	3	2	2	2
15293	1520	metallothionein promoter induction	[metallothionein promoter induction]	1.5849625007211563	3	1	0	0
15294	1520	il-4 of CD40	[IL-4 of CD40]	1.5849625007211563	3	1	0	0
15295	1520	measurement of il-6 secretion	[measurement of IL-6 secretion]	1.5849625007211563	4	1	0	0
15296	1520	reversible airway obstruction	[reversible airways obstruction]	1.5849625007211563	3	1	0	0
15297	1520	inhibition of NF-kappa B	[Inhibition of NF-kappa B]	1.5849625007211563	4	1	0	0
15298	1520	cyclophilin a /csa	[cyclophilin A /CsA]	1.5849625007211563	3	1	0	0
15299	1520	regulation of this genes.	[regulation of these genes.]	1.5849625007211563	4	1	0	0
15300	1520	region/leucine zipper bzip	[region/leucine zipper bZIP]	1.5849625007211563	3	2	1	1
15301	1520	avian sarcoma/leukemia virus ltr	[avian sarcoma/leukemia virus LTRs]	1.5849625007211563	4	1	0	0
15302	1520	vivo Th1 response	[vivo Th1 response]	1.5849625007211563	3	1	0	0
15303	1520	-3 DNA binding	[-3 DNA binding]	1.5849625007211563	3	1	0	0
15304	1520	non-antigen-selected b cell	[non-antigen-selected B cells]	1.5849625007211563	3	2	2	2
15305	1520	regulation of factor	[regulation of factor]	1.5849625007211563	3	2	2	2
15306	1520	tissue pattern of expression	[tissue pattern of expression]	1.5849625007211563	4	1	0	0
15307	1520	TNF mrna accumulation	[TNF mRNA accumulation]	1.5849625007211563	3	1	0	0
15308	1520	isolated lung cell	[isolated lung cells]	1.5849625007211563	3	1	0	0
15309	1520	only in the context	[only in the context]	1.5849625007211563	4	2	1	1
15310	1520	contrast to early hypotheses,	[contrast to earlier hypotheses,]	1.5849625007211563	4	1	0	0
15311	1520	reflect a program	[reflecting a program]	1.5849625007211563	3	1	0	0
15312	1520	examine the gene expression	[examining the gene expression]	1.5849625007211563	4	1	0	0
15313	1520	amino-terminal portion of E2A	[amino-terminal portion of E2A]	1.5849625007211563	4	1	0	0
15314	1520	slight flow with dysmenorrhoea	[slight flow with dysmenorrhoea]	1.5849625007211563	4	1	0	0
15315	1520	low renin activity,	[low renin activity,]	1.5849625007211563	3	1	0	0
15316	1520	extract of cos cell	[extracts of COS cells]	1.5849625007211563	4	1	0	0
15317	1520	0.1 to 10 microm	[0.1 to 10 microM]	1.5849625007211563	4	1	0	0
15318	1520	expression of multiple gene	[expression of multiple genes]	1.5849625007211563	4	2	1	1
15319	1520	viral production in vivo,	[viral production in vivo,]	1.5849625007211563	4	1	0	0
15320	1520	dominant inhibitory IkappaB mutant	[dominant inhibitory IkappaB mutant]	1.5849625007211563	4	1	0	0
15321	1520	use the dioxin receptor	[using the dioxin receptor]	1.5849625007211563	4	1	0	0
15322	1520	identification of element	[Identification of elements]	1.5849625007211563	3	2	2	2
15323	1520	heterodimer with atf-2	[heterodimer with ATF-2]	1.5849625007211563	3	1	0	0
15324	1520	induction by both organism	[induction by both organisms]	1.5849625007211563	4	1	0	0
15325	1520	survival of b-cell progenitor	[survival of B-cell progenitors]	1.5849625007211563	4	1	0	0
15326	1520	glucocorticoid receptor beta	[glucocorticoid receptor beta]	1.5849625007211563	3	2	2	2
15327	1520	translocation of this factor	[translocation of these factors]	1.5849625007211563	4	1	0	0
15328	1520	level of c-maf protein	[levels of c-Maf protein]	1.5849625007211563	4	1	0	0
15329	1520	gene encode the homolog	[gene encoding the homolog]	1.5849625007211563	4	1	0	0
15330	1520	aged group of patient	[aged group of patients]	1.5849625007211563	4	1	0	0
15331	1520	processing rate of p105	[processing rate of p105]	1.5849625007211563	4	1	0	0
15332	1520	binding of this stat	[binding of these STATs]	1.5849625007211563	4	1	0	0
15333	1520	decrease of this value	[decrease of these values]	1.5849625007211563	4	1	0	0
15334	1520	inhibition of protein phosphatase	[Inhibition of protein phosphatases]	1.5849625007211563	4	1	0	0
15335	1520	Th2 type cytokine	[Th2 type cytokines]	1.5849625007211563	3	1	0	0
15336	1520	oncogenic protein fli-1	[oncogenic protein Fli-1]	1.5849625007211563	3	1	0	0
15337	1520	late G1-to- phase transition	[late G1-to-S phase transition]	1.5849625007211563	4	1	0	0
15338	1520	time of heat shock	[time of heat shock]	1.5849625007211563	4	1	0	0
15339	1520	eicosanoid profile of tissue	[eicosanoid profile of tissue]	1.5849625007211563	4	1	0	0
15340	1520	comparison to k562	[comparison to K562]	1.5849625007211563	3	1	0	0
15341	1520	hcd57 erythroid cell	[HCD57 erythroid cells]	1.5849625007211563	3	1	0	0
15342	1520	memory th2 cell	[memory Th2 cells]	1.5849625007211563	3	1	0	0
15343	1520	cell apoptosis in response	[cell apoptosis in response]	1.5849625007211563	4	1	0	0
15344	1520	human adenovirus type	[human adenovirus type]	1.5849625007211563	3	2	1	1
15345	1520	cytoplasm in unstimulated cell	[cytoplasm in unstimulated cells]	1.5849625007211563	4	1	0	0
15346	1520	cis-trans prolyl isomerase	[cis-trans prolyl isomerases]	1.5849625007211563	3	1	0	0
15347	1520	84 kda protein	[84 kDa protein]	1.5849625007211563	3	1	0	0
15348	1520	potent lipid proinflammatory mediator	[potent lipid proinflammatory mediator]	1.5849625007211563	4	1	0	0
15349	1520	effect block a target	[effects blocking a target]	1.5849625007211563	4	1	0	0
15350	1520	effect of CD70 transfectant	[effect of CD70 transfectants]	1.5849625007211563	4	1	0	0
15351	1520	mrna represent pAT 591/EGR2	[mRNA representing pAT 591/EGR2]	1.5849625007211563	4	1	0	0
15352	1520	transcriptional activation of il-2	[transcriptional activation of IL-2]	1.5849625007211563	4	1	0	0
15353	1520	human peripheral b cell	[Human peripheral B cells]	1.5849625007211563	4	2	1	1
15354	1520	variety of ets-binding site	[variety of ets-binding sites]	1.5849625007211563	4	1	0	0
15355	1520	variety of lymphoid extract	[variety of lymphoid extracts]	1.5849625007211563	4	1	0	0
15356	1520	morphologic feature of apoptosis	[morphologic features of apoptosis]	1.5849625007211563	4	1	0	0
15357	1520	individual viable cell	[individual viable cells]	1.5849625007211563	3	1	0	0
15358	1520	latent, cytoplasmic transcription factor	[latent, cytoplasmic transcription factors]	1.5849625007211563	4	1	0	0
15359	1520	R7-57 reporter line	[R7-57 reporter line]	1.5849625007211563	3	1	0	0
15360	1520	two erythroid cell line	[two erythroid cell lines]	1.5849625007211563	4	1	0	0
15361	1520	fmol/mg protein, mean	[fmol/mg protein, mean]	1.5849625007211563	3	1	0	0
15362	1520	5x ap-1 /cat activity	[5X AP-1 /CAT activity]	1.5849625007211563	4	1	0	0
15363	1520	cellular cysteine supply	[cellular cysteine supply]	1.5849625007211563	3	1	0	0
15364	1520	presence of pkc inhibitor	[presence of PKC inhibitors]	1.5849625007211563	4	1	0	0
15365	1520	insulin gene promoter	[insulin gene promoter]	1.5849625007211563	3	1	0	0
15366	1520	other elderly individual	[other elderly individuals]	1.5849625007211563	3	1	0	0
15367	1520	glucocorticosteroid receptor density	[glucocorticosteroid receptor density]	1.5849625007211563	3	1	0	0
15368	1520	differential therapeutic strategy	[differential therapeutic strategies]	1.5849625007211563	3	1	0	0
15369	1520	b29 minimal promoter activity	[B29 minimal promoter activity]	1.5849625007211563	4	1	0	0
15370	1520	NF-kappaB binding element	[NF-kappaB binding elements]	1.5849625007211563	3	1	0	0
15371	1520	level of hiv-1 transactivation	[levels of HIV-1 transactivation]	1.5849625007211563	4	1	0	0
15372	1520	management of allergic disease	[management of allergic diseases]	1.5849625007211563	4	1	0	0
15373	1520	increase in neutrophil adhesion	[increase in neutrophil adhesion]	1.5849625007211563	4	2	2	2
15374	1520	BACKGROUND: myeloid cell development	[BACKGROUND: Myeloid cell development]	1.5849625007211563	4	1	0	0
15375	1520	level of p21(waf1/cip1)	[levels of p21(WAF1/CIP1)]	1.5849625007211563	3	1	0	0
15376	1520	dna-binding nuclear factor	[DNA-binding nuclear factors]	1.5849625007211563	3	1	0	0
15377	1520	type of enhancer present	[type of enhancer present]	1.5849625007211563	4	1	0	0
15378	1520	effect of E2a-Pbx1	[effects of E2a-Pbx1]	1.5849625007211563	3	1	0	0
15379	1520	NF-kappa bp65 binding	[NF-kappa Bp65 binding]	1.5849625007211563	3	1	0	0
15380	1520	allele ratio 3:1)	[allele ratio 3:1)]	1.5849625007211563	3	1	0	0
15381	1520	c-jun proto-oncogene product	[c-jun proto-oncogene product]	1.5849625007211563	3	1	0	0
15382	1520	design of treatment approach	[design of treatment approaches]	1.5849625007211563	4	1	0	0
15383	1520	pathogenesis of asthma	[pathogenesis of asthma]	1.5849625007211563	3	2	1	1
15384	1520	response in cell	[response in cells]	1.5849625007211563	3	2	2	2
15385	1520	contain the fosb gene	[containing the FOSB gene]	1.5849625007211563	4	1	0	0
15386	1520	difference from wild-type 70z/3	[difference from wild-type 70Z/3]	1.5849625007211563	4	1	0	0
15387	1520	u937 cell (p	[U937 cells (P]	1.5849625007211563	3	1	0	0
15388	1520	absence of hiv-1 Tat	[absence of HIV-1 Tat]	1.5849625007211563	4	1	0	0
15389	1520	enhancer in hiv-1	[enhancer in HIV-1]	1.5849625007211563	3	1	0	0
15390	1520	CsA -resistant nfat complex	[CsA -resistant NFAT complex]	1.5849625007211563	4	1	0	0
15391	1520	only a few cell	[Only a few cells]	1.5849625007211563	4	1	0	0
15392	1520	mrna encode the form	[mRNA encoding the form]	1.5849625007211563	4	1	0	0
15393	1520	ZEBRA /EBV biological system	[ZEBRA /EBV biological system]	1.5849625007211563	4	1	0	0
15394	1520	B29 atg start codon	[B29 ATG start codon]	1.5849625007211563	4	1	0	0
15395	1520	interaction between Cbl-b	[interaction between Cbl-b]	1.5849625007211563	3	1	0	0
15396	1520	tnf-alpha induction of NFkappaB	[TNF-alpha induction of NFkappaB]	1.5849625007211563	4	1	0	0
15397	1520	adenosine receptor agonist neca	[adenosine receptor agonist NECA]	1.5849625007211563	4	1	0	0
15398	1520	lack of binding.	[lack of binding.]	1.5849625007211563	3	1	0	0
15399	1520	human tfiid polypeptide	[human TFIID polypeptide]	1.5849625007211563	3	1	0	0
15400	1520	cohort of patient	[cohort of patients]	1.5849625007211563	3	2	2	2
15401	1520	lps kappab -dependent transcription	[LPS kappaB -dependent transcription]	1.5849625007211563	4	1	0	0
15402	1520	reveal predominant expression	[revealing predominant expression]	1.5849625007211563	3	1	0	0
15403	1520	hiv LTR transactivation	[HIV LTR transactivation]	1.5849625007211563	3	1	0	0
15404	1520	nitroblue tetrazolium staining	[nitroblue tetrazolium staining]	1.5849625007211563	3	1	0	0
15405	1520	activation by Sp3ilday	[activation by Sp3]	1.5849625007211563	3	1	0	0
15406	1520	preincubation with lysopc	[Preincubation with lysoPC]	1.5849625007211563	3	1	0	0
15407	1520	rhombotin gene family	[rhombotin gene family]	1.5849625007211563	3	1	0	0
15408	1520	creb binding (38%)	[CREB binding (38%)]	1.5849625007211563	3	1	0	0
15409	1520	nuclear regulatory factor-kappa beta	[nuclear regulatory factor-kappa beta]	1.5849625007211563	4	2	2	2
15410	1520	TCF-1 alpha binding motif	[TCF-1 alpha binding motif]	1.5849625007211563	4	1	0	0
15411	1520	chloramphenicol acetyltransferase reporter vector	[chloramphenicol acetyltransferase reporter vectors]	1.5849625007211563	4	1	0	0
15412	1520	NF-kappa b nuclear translocation	[NF-kappa B nuclear translocation]	1.5849625007211563	4	1	0	0
15413	1520	(bcr)- signal threshold	[(BCR)- signaling thresholds]	1.5849625007211563	3	1	0	0
15414	1520	cell type responsible,	[cell types responsible,]	1.5849625007211563	3	1	0	0
15415	1520	T cell okt3	[T cells OKT3]	1.5849625007211563	3	1	0	0
15416	1520	c-rel protooncogene product	[c-rel protooncogene product]	1.5849625007211563	3	1	0	0
15417	1520	potent transactivator protein tax	[potent transactivator protein Tax]	1.5849625007211563	4	1	0	0
15418	1520	specific binding complex relative	[specific binding complexes relative]	1.5849625007211563	4	1	0	0
15419	1520	individual granulocyte colony	[individual granulocyte colonies]	1.5849625007211563	3	1	0	0
15420	1520	include inhibition of increase	[including inhibition of increases]	1.5849625007211563	4	1	0	0
15421	1520	functioning in el4 cell	[functioning in El4 cells]	1.5849625007211563	4	1	0	0
15422	1520	human taf subunit	[human TAF subunits]	1.5849625007211563	3	1	0	0
15423	1520	p38 mitogen-activated protein kinase	[p38 mitogen-activated protein kinase]	1.5849625007211563	4	2	1	1
15424	1520	two b cell-specific coactivator	[two B cell-specific coactivators]	1.5849625007211563	4	2	1	1
15425	1520	human CD4 lymphocyte	[Human CD4 lymphocytes]	1.5849625007211563	3	1	0	0
15426	1520	Partial cortisol receptor resistance	[Partial cortisol receptor resistance]	1.5849625007211563	4	1	0	0
15427	1520	other signal molecule	[other signaling molecules]	1.5849625007211563	3	1	0	0
15428	1520	activation in fibroblast	[activation in fibroblasts]	1.5849625007211563	3	2	2	2
15429	1520	il-9 epo (100%).	[IL-9 Epo (100%).]	1.5849625007211563	3	1	0	0
15430	1520	extinction of il-12 signal	[extinction of IL-12 signaling]	1.5849625007211563	4	1	0	0
15431	1520	addition, extracellular factor	[addition, extracellular factor]	1.5849625007211563	3	1	0	0
15432	1520	novel gene pml	[novel gene PML]	1.5849625007211563	3	1	0	0
15433	1520	putative cd peptide	[putative CD peptides]	1.5849625007211563	3	1	0	0
15434	1520	marrow-derived stromal cell line	[marrow-derived stromal cell line]	1.5849625007211563	4	1	0	0
15435	1520	inhibition of replication	[inhibition of replication]	1.5849625007211563	3	2	2	2
15436	1520	variety of antibody	[variety of antibodies]	1.5849625007211563	3	1	0	0
15437	1520	recognition of fetal antigen	[recognition of fetal antigens]	1.5849625007211563	4	1	0	0
15438	1520	receptor in vitro repression	[receptor in vitro repression]	1.5849625007211563	4	1	0	0
15439	1520	tyrosine phosphorylation of p38	[Tyrosine phosphorylation of p38]	1.5849625007211563	4	1	0	0
15440	1520	monocyte by [3H]dexamethasone binding	[monocytes by [3H]dexamethasone binding]	1.5849625007211563	4	1	0	0
15441	1520	domain of il-9ralpha	[domain of IL-9Ralpha]	1.5849625007211563	3	2	2	2
15442	1520	level of this transcripts.	[levels of these transcripts.]	1.5849625007211563	4	1	0	0
15443	1520	steroid hormone activation	[steroid hormone activation]	1.5849625007211563	3	1	0	0
15444	1520	binding to dna-cellulose	[binding to DNA-cellulose]	1.5849625007211563	3	1	0	0
15445	1520	curcumin in rat thymocyte	[curcumin in rat thymocytes]	1.5849625007211563	4	1	0	0
15446	1520	activation of the axis	[Activation of the axis]	1.5849625007211563	4	2	2	2
15447	1520	gp91phox mrna expression	[gp91phox mRNA expression]	1.5849625007211563	3	1	0	0
15448	1520	upstream regulatory sequence	[upstream regulatory sequences]	1.5849625007211563	3	2	1	1
15449	1520	number of division	[number of divisions]	1.5849625007211563	3	1	0	0
15450	1520	individual pkc isotype	[individual PKC isotypes]	1.5849625007211563	3	1	0	0
15451	1520	activation of CD40	[Activation of CD40]	1.5849625007211563	3	1	0	0
15452	1520	presence of enhancer sequence	[presence of enhancer sequences]	1.5849625007211563	4	1	0	0
15453	1520	two Ad12 E1A domain	[two Ad12 E1A domains]	1.5849625007211563	4	1	0	0
15454	1520	vascular endothelial cell	[vascular endothelial cells]	1.5849625007211563	3	1	0	0
15455	1520	essential gene for differentiation	[essential genes for differentiation]	1.5849625007211563	4	1	0	0
15456	1520	present study, analysis	[present study, analysis]	1.5849625007211563	3	1	0	0
15457	1520	first, anti- cd45 antibody	[First, anti- CD45 antibodies]	1.5849625007211563	4	1	0	0
15458	1520	subject with cortisol resistance	[subject with cortisol resistance]	1.5849625007211563	4	1	0	0
15459	1520	suggest a dichotomy	[suggesting a dichotomy]	1.5849625007211563	3	1	0	0
15460	1520	function of gamma c	[functions of gamma c]	1.5849625007211563	4	1	0	0
15461	1520	dna-binding activity complex	[DNA-binding activity complex]	1.5849625007211563	3	2	1	1
15462	1520	htlv-i t-cell line	[HTLV-I T-cell lines]	1.5849625007211563	3	1	0	0
15463	1520	internal entry site	[internal entry site]	1.5849625007211563	3	2	2	2
15464	1520	MIBP1 gene for studies,	[MIBP1 gene for studies,]	1.5849625007211563	4	1	0	0
15465	1520	4-week-old adult mouse	[4-week-old adult mice]	1.5849625007211563	3	1	0	0
15466	1520	pleiotropic regulator of immunoregulatory	[pleiotropic regulators of immunoregulatory]	1.5849625007211563	4	1	0	0
15467	1520	stat from the cytoplasm	[STAT from the cytoplasm]	1.5849625007211563	4	1	0	0
15468	1520	pbl of a patient	[PBLs of an patient]	1.5849625007211563	4	1	0	0
15469	1520	use specific antibody	[using specific antibodies]	1.5849625007211563	3	2	2	2
15470	1520	less than 0.05, p	[less than 0.05, P]	1.5849625007211563	4	1	0	0
15471	1520	result from T cell	[resulting from T cell]	1.5849625007211563	4	1	0	0
15472	1520	obligatory heterodimerization with Max	[obligatory heterodimerization with Max]	1.5849625007211563	4	1	0	0
15473	1520	rather, tyrosine phosphorylation	[Rather, tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
15474	1520	80-kd stat5a molecule	[80-kD STAT5A molecule]	1.5849625007211563	3	1	0	0
15475	1520	patient 8.98 +/- 1.07	[patients 8.98 +/- 1.07]	1.5849625007211563	4	1	0	0
15476	1520	relation to staging, infiltration	[relation to staging, infiltration]	1.5849625007211563	4	1	0	0
15477	1520	restimulation of T cell	[Restimulation of T cell]	1.5849625007211563	4	1	0	0
15478	1520	therapy with dexamethasone	[Therapy with dexamethasone]	1.5849625007211563	3	1	0	0
15479	1520	transfection of Jurkat cell	[Transfection of Jurkat cells]	1.5849625007211563	4	1	0	0
15480	1520	T cell activation.	[T cell activation.]	1.5849625007211563	3	3	2	1
15481	1520	viability of the cell	[viability of the cells]	1.5849625007211563	4	1	0	0
15482	1520	transcriptional activity relative	[transcriptional activity relative]	1.5849625007211563	3	1	0	0
15483	1520	101 control in Germany.	[101 controls in Germany.]	1.5849625007211563	4	1	0	0
15484	1520	costimulation of T lymphocyte	[costimulation of T lymphocytes]	1.5849625007211563	4	1	0	0
15485	1520	nuclear transcription factor ap-1	[nuclear transcription factors AP-1]	1.5849625007211563	4	1	0	0
15486	1520	protein kinase c-zeta	[Protein kinase C-zeta]	1.5849625007211563	3	1	0	0
15487	1520	regulate the ICAM-1 promoter	[regulating the ICAM-1 promoter]	1.5849625007211563	4	1	0	0
15488	1520	HLA-DR alpha (dra) promoter	[HLA-DR alpha (DRA) promoter]	1.5849625007211563	4	1	0	0
15489	1520	cos cell with ionomycin	[COS cells with ionomycin]	1.5849625007211563	4	1	0	0
15490	1520	function in the context	[function in the context]	1.5849625007211563	4	2	1	1
15491	1520	contrast, prostaglandin I2 PGI2	[contrast, prostaglandin I2 PGI2]	1.5849625007211563	4	1	0	0
15492	1520	sequence in the promoter	[sequences in the promoter]	1.5849625007211563	4	1	0	0
15493	1520	irradiation with gamma-ray	[irradiation with gamma-rays]	1.5849625007211563	3	1	0	0
15494	1520	default pathway lead	[default pathway leading]	1.5849625007211563	3	1	0	0
15495	1520	Glycation-dependent reactive oxygen	[Glycation-dependent reactive oxygen]	1.5849625007211563	3	1	0	0
15496	1520	rapid apoptotic cell death	[rapid apoptotic cell death]	1.5849625007211563	4	1	0	0
15497	1520	expression of BCL2	[expression of BCL2]	1.5849625007211563	3	1	0	0
15498	1520	prior to stimulation.	[prior to stimulation.]	1.5849625007211563	3	1	0	0
15499	1520	mechanism involve retinoblastoma protein	[mechanism involving retinoblastoma protein]	1.5849625007211563	4	1	0	0
15500	1520	variety of isoform	[variety of isoforms]	1.5849625007211563	3	1	0	0
15501	1520	exon of 132, 112	[exons of 132, 112]	1.5849625007211563	4	1	0	0
15502	1520	difference in the level	[differences in the level]	1.5849625007211563	4	1	0	0
15503	1520	onset of apoptosis	[onset of apoptosis]	1.5849625007211563	3	1	0	0
15504	1520	addition, in contrast	[addition, in contrast]	1.5849625007211563	3	1	0	0
15505	1520	5'-cc(a consensus sequence characteristic	[5'-CC(A consensus sequence characteristic]	1.5849625007211563	4	1	0	0
15506	1520	late stage of erythropoiesis	[later stages of erythropoiesis]	1.5849625007211563	4	1	0	0
15507	1520	specific lineage maturation.	[specific lineage maturation.]	1.5849625007211563	3	1	0	0
15508	1520	putative stat3 serine kinase	[putative STAT3 serine kinase]	1.5849625007211563	4	1	0	0
15509	1520	human glial cell	[human glial cells]	1.5849625007211563	3	1	0	0
15510	1520	ap3-like motif ap3-l	[AP3-like motif AP3-L]	1.5849625007211563	3	1	0	0
15511	1520	CD40 -traf2 interaction	[CD40 -TRAF2 interaction]	1.5849625007211563	3	1	0	0
15512	1520	25 pregnant woman	[25 pregnant women]	1.5849625007211563	3	2	2	2
15513	1520	luciferase reporter plasmid	[luciferase reporter plasmids]	1.5849625007211563	3	1	0	0
15514	1520	uptake of neutrophil	[uptake of neutrophils]	1.5849625007211563	3	2	2	2
15515	1520	coincubation of cd36 cell	[coincubation of CD36 cells]	1.5849625007211563	4	1	0	0
15516	1520	logarithmic phase of growth	[logarithmic phase of growth]	1.5849625007211563	4	1	0	0
15517	1520	breast cancer mcf-7	[breast cancer MCF-7]	1.5849625007211563	3	1	0	0
15518	1520	endothelial cell line	[endothelial cell line]	1.5849625007211563	3	1	0	0
15519	1520	breast tissue biomarker	[Breast tissue biomarkers]	1.5849625007211563	3	1	0	0
15520	1520	151 amino acid	[151 amino acids]	1.5849625007211563	3	1	0	0
15521	1520	early event detectable (Martin	[earliest events detectable (Martin]	1.5849625007211563	4	1	0	0
15522	1520	Drosophila segment polarity gene	[Drosophila segment polarity gene]	1.5849625007211563	4	1	0	0
15523	1520	cotransfection with plasmid	[cotransfection with plasmids]	1.5849625007211563	3	1	0	0
15524	1520	include ARDS after HS	[including ARDS after HS]	1.5849625007211563	4	1	0	0
15525	1520	class ii-restricted antigen processing	[class II-restricted antigen processing]	1.5849625007211563	4	1	0	0
15526	1520	Indeed, addition of inhibitor	[Indeed, addition of inhibitors]	1.5849625007211563	4	1	0	0
15527	1520	unstimulated jurkat cell	[unstimulated Jurkat cells]	1.5849625007211563	3	1	0	0
15528	1520	NFKB family member Rel-A	[NFKB family members Rel-A]	1.5849625007211563	4	1	0	0
15529	1520	sequence of the region	[sequences of the region]	1.5849625007211563	4	2	2	2
15530	1520	transcriptional repressor activity	[transcriptional repressor activity]	1.5849625007211563	3	2	1	1
15531	1520	formation of protein-DNA complex	[formation of protein-DNA complexes]	1.5849625007211563	4	1	0	0
15532	1520	immunophenotype of intraductal carcinoma	[Immunophenotype of intraductal carcinoma]	1.5849625007211563	4	1	0	0
15533	1520	action of MM-LDL	[actions of MM-LDL]	1.5849625007211563	3	1	0	0
15534	1520	synthesis of fetal hemoglobin	[synthesis of fetal hemoglobin]	1.5849625007211563	4	1	0	0
15535	1520	such as glut1	[such as GLUT1]	1.5849625007211563	3	1	0	0
15536	1520	N-terminal regulatory serine	[N-terminal regulatory serines]	1.5849625007211563	3	1	0	0
15537	1520	finding, Northern experiment	[finding, Northern experiments]	1.5849625007211563	3	1	0	0
15538	1520	complex of lps	[complex of LPS]	1.5849625007211563	3	1	0	0
15539	1520	function of il-4r	[function of IL-4R]	1.5849625007211563	3	1	0	0
15540	1520	plc gamma 1	[PLC gamma 1]	1.5849625007211563	3	2	1	1
15541	1520	traf interaction domain	[TRAF interaction domain]	1.5849625007211563	3	1	0	0
15542	1520	CD40 like sIg	[CD40 like sIg]	1.5849625007211563	3	1	0	0
15543	1520	overall enzyme activity	[overall enzyme activity]	1.5849625007211563	3	1	0	0
15544	1520	molecular mechanism responsible	[molecular mechanism responsible]	1.5849625007211563	3	2	2	2
15545	1520	Fas Ligand fasl	[Fas Ligand FasL]	1.5849625007211563	3	1	0	0
15546	1520	method of choice.	[method of choice.]	1.5849625007211563	3	1	0	0
15547	1520	prototypical NF-kappa b complex	[prototypical NF-kappa B complex]	1.5849625007211563	4	1	0	0
15548	1520	ets-1 protein from cell	[Ets-1 protein from cells]	1.5849625007211563	4	1	0	0
15549	1520	ability of this complex	[ability of these complexes]	1.5849625007211563	4	1	0	0
15550	1520	human IL-3 proximal promoter	[human IL-3 proximal promoter]	1.5849625007211563	4	1	0	0
15551	1520	stabilization of IL-2 mrna	[stabilization of IL-2 mRNA]	1.5849625007211563	4	1	0	0
15552	1520	transcription in vitro	[transcription in vitro]	1.5849625007211563	3	2	1	1
15553	1520	numerous inflammatory gene	[numerous inflammatory genes]	1.5849625007211563	3	1	0	0
15554	1520	genomic clone pgd41	[genomic clone pGD41]	1.5849625007211563	3	1	0	0
15555	1520	N terminal transactivation domain	[N terminal transactivation domain]	1.5849625007211563	4	1	0	0
15556	1520	mrna level for fkhrl1	[mRNA levels for fkhrl1]	1.5849625007211563	4	1	0	0
15557	1520	optimal enhancer function	[optimal enhancer function]	1.5849625007211563	3	1	0	0
15558	1520	association of TRAF1	[Association of TRAF1]	1.5849625007211563	3	1	0	0
15559	1520	long primary transcript	[long primary transcripts]	1.5849625007211563	3	1	0	0
15560	1520	architecture of transcription complex	[architecture of transcription complexes]	1.5849625007211563	4	1	0	0
15561	1520	erythroblast of blood island	[erythroblasts of blood islands]	1.5849625007211563	4	1	0	0
15562	1520	tnf-alpha degradation of IkappaB-alpha	[TNF-alpha degradation of IkappaB-alpha]	1.5849625007211563	4	1	0	0
15563	1520	fusion with HeLa cell	[fusion with HeLa cells]	1.5849625007211563	4	1	0	0
15564	1520	transport of 3-o-methyl-d-glucose	[transport of 3-O-methyl-D-glucose]	1.5849625007211563	3	1	0	0
15565	1520	hiv-1 infection in	[HIV-1 infection in]	1.5849625007211563	3	1	0	0
15566	1520	absence of DNA binding	[absence of DNA binding]	1.5849625007211563	4	1	0	0
15567	1520	Oct-1 pou domain erratum	[Oct-1 POU domain erratum]	1.5849625007211563	4	1	0	0
15568	1520	hiv-2 tat gene	[HIV-2 tat gene]	1.5849625007211563	3	1	0	0
15569	1520	expression of Gs(alpha)	[expression of Gs(alpha)]	1.5849625007211563	3	1	0	0
15570	1520	i.e. hhv-8 +/ebv- pel	[i.e. HHV-8 +/EBV- PEL]	1.5849625007211563	4	1	0	0
15571	1520	approximately one half	[approximately one half]	1.5849625007211563	3	1	0	0
15572	1520	two osteoblast-specific cis-acting element	[two osteoblast-specific cis-acting elements]	1.5849625007211563	4	1	0	0
15573	1520	removal of the stimulus	[removal of the stimulus]	1.5849625007211563	4	1	0	0
15574	1520	determinant of the threshold	[determinants of the threshold]	1.5849625007211563	4	1	0	0
15575	1520	significant difference in stability.	[significant difference in stability.]	1.5849625007211563	4	1	0	0
15576	1520	response to il-1	[response to IL-1]	1.5849625007211563	3	1	0	0
15577	1520	response to il-2	[response to IL-2]	1.5849625007211563	3	1	0	0
15578	1520	open the chromatin	[opening the chromatin]	1.5849625007211563	3	1	0	0
15579	1520	transcription of a variety	[transcription of a variety]	1.5849625007211563	4	2	1	1
15580	1520	vivo transgenic model	[vivo transgenic model]	1.5849625007211563	3	1	0	0
15581	1520	early to mo)	[early to mo)]	1.5849625007211563	3	1	0	0
15582	1520	somewhat surprising finding	[somewhat surprising finding]	1.5849625007211563	3	1	0	0
15583	1520	growth of most virus	[growth of most viruses]	1.5849625007211563	4	1	0	0
15584	1520	other b gene	[other B genes]	1.5849625007211563	3	2	2	2
15585	1520	knowledge, of regulatory element	[knowledge, of regulatory elements]	1.5849625007211563	4	1	0	0
15586	1520	17 beta-estradiol e2	[17 beta-estradiol E2]	1.5849625007211563	3	1	0	0
15587	1520	pathogenesis of alzheimer's disease	[pathogenesis of Alzheimer's disease]	1.5849625007211563	4	1	0	0
15588	1520	putative target of calcineurin	[putative targets of calcineurin]	1.5849625007211563	4	1	0	0
15589	1520	various T cell line	[various T cell lines]	1.5849625007211563	4	1	0	0
15590	1520	growth, development, apoptosis	[growth, development, apoptosis]	1.5849625007211563	3	1	0	0
15591	1520	abnormal fast feedback	[Abnormal fast feedback]	1.5849625007211563	3	1	0	0
15592	1520	monocyte neutrophil binding	[monocyte neutrophil binding]	1.5849625007211563	3	1	0	0
15593	1520	only upon hiv1 infection	[only upon HIV1 infection]	1.5849625007211563	4	1	0	0
15594	1520	Egr-1 -express Ramos cell	[Egr-1 -expressing Ramos cells]	1.5849625007211563	4	1	0	0
15595	1520	order of ghost membrane	[order of ghost membrane]	1.5849625007211563	4	2	2	2
15596	1520	Northern blot experiment	[Northern blot experiments]	1.5849625007211563	3	1	0	0
15597	1520	response to MM-LDL	[response to MM-LDL]	1.5849625007211563	3	1	0	0
15598	1520	tgf-beta -mediated growth inhibition	[TGF-beta -mediated growth inhibition]	1.5849625007211563	4	2	2	2
15599	1520	sequence similarity to c-fo	[sequence similarity to c-Fos]	1.5849625007211563	4	1	0	0
15600	1520	stimulation of T	[stimulation of T]	1.5849625007211563	3	2	1	1
15601	1520	proximal region between -46	[proximal region between -46]	1.5849625007211563	4	1	0	0
15602	1520	corresponding cell nuclei	[corresponding cell nuclei]	1.5849625007211563	3	1	0	0
15603	1520	intermediate phenotype, similar	[intermediate phenotype, similar]	1.5849625007211563	3	1	0	0
15604	1520	high level of ligand	[high levels of ligand]	1.5849625007211563	4	1	0	0
15605	1520	co-stimulatory agent phorbol	[co-stimulatory agent phorbol]	1.5849625007211563	3	1	0	0
15606	1520	fos family include c-fo	[fos family including c-fos]	1.5849625007211563	4	1	0	0
15607	1520	analysis of the expression	[Analysis of the expression]	1.5849625007211563	4	2	2	2
15608	1520	pathogenesis of disorder	[pathogenesis of disorder]	1.5849625007211563	3	2	2	2
15609	1520	implication for pathophysiological condition	[implications for pathophysiological conditions]	1.5849625007211563	4	1	0	0
15610	1520	rapid signal-transduction pathway	[rapid signal-transduction pathway]	1.5849625007211563	3	1	0	0
15611	1520	hmg box family	[HMG box family]	1.5849625007211563	3	1	0	0
15612	1520	two Jurkat cell clone	[Two Jurkat cell clones]	1.5849625007211563	4	1	0	0
15613	1520	HLA-DM gene transcription	[HLA-DM gene transcription]	1.5849625007211563	3	1	0	0
15614	1520	cleavage of cholesteryl ester	[cleavage of cholesteryl esters]	1.5849625007211563	4	1	0	0
15615	1520	B29 immunoglobulin beta-chain gene	[B29 immunoglobulin beta-chain gene]	1.5849625007211563	4	1	0	0
15616	1520	competent vector for expression	[competent vector for expression]	1.5849625007211563	4	1	0	0
15617	1520	female somatic cell	[female somatic cells]	1.5849625007211563	3	1	0	0
15618	1520	control of gene transactivation	[control of gene transactivation]	1.5849625007211563	4	1	0	0
15619	1520	transcription factor gene	[transcription factor genes]	1.5849625007211563	3	2	2	2
15620	1520	phosphorylation of Stat3	[phosphorylation of Stat3]	1.5849625007211563	3	1	0	0
15621	1520	high initial level	[high initial levels]	1.5849625007211563	3	1	0	0
15622	1520	mechanism of gr level	[mechanism of GR levels]	1.5849625007211563	4	1	0	0
15623	1520	irf-1 promoter region act	[IRF-1 promoter region act]	1.5849625007211563	4	1	0	0
15624	1520	right adnexal mass	[right adnexal mass]	1.5849625007211563	3	1	0	0
15625	1520	viral load in vivo	[viral load in vivo]	1.5849625007211563	4	1	0	0
15626	1520	two mechanisms: protein stabilization	[two mechanisms: protein stabilization]	1.5849625007211563	4	1	0	0
15627	1520	unique subunit association	[unique subunit associations]	1.5849625007211563	3	1	0	0
15628	1520	caenorhabditis elegan cell death	[Caenorhabditis elegans cell death]	1.5849625007211563	4	1	0	0
15629	1520	autoantibody-producing b cell	[autoantibody-producing B cells]	1.5849625007211563	3	1	0	0
15630	1520	T cell activation-induced apoptosis	[T cell activation-induced apoptosis]	1.5849625007211563	4	1	0	0
15631	1520	RelB knockout mouse	[RelB knockout mice]	1.5849625007211563	3	2	1	1
15632	1520	change in ikappabalpha level	[Changes in IkappaBalpha levels]	1.5849625007211563	4	1	0	0
15633	1520	production of il-6	[production of IL-6]	1.5849625007211563	3	1	0	0
15634	1520	production of il-3	[production of IL-3]	1.5849625007211563	3	1	0	0
15635	1520	group of related gene	[group of related gene]	1.5849625007211563	4	1	0	0
15636	1520	leukocyte -endothelial cell interaction	[leukocyte -endothelial cell interaction]	1.5849625007211563	4	1	0	0
15637	1520	functional Ets binding site	[functional Ets binding site]	1.5849625007211563	4	1	0	0
15638	1520	exposure to glucocorticoid	[exposure to glucocorticoid]	1.5849625007211563	3	1	0	0
15639	1520	human impdh type ii	[human IMPDH type II]	1.5849625007211563	4	1	0	0
15640	1520	expression by western blotting	[expression by Western blotting]	1.5849625007211563	4	1	0	0
15641	1520	interaction of antigen-presenting cell	[interaction of antigen-presenting cells]	1.5849625007211563	4	1	0	0
15642	1520	interleukin 4 IL-4 promoter	[interleukin 4 IL-4 promoter]	1.5849625007211563	4	1	0	0
15643	1520	erythroid cell differentiation	[erythroid cell differentiation]	1.5849625007211563	3	1	0	0
15644	1520	early B-cell factor	[early B-cell factor]	1.5849625007211563	3	1	0	0
15645	1520	stat6 signal molecule	[Stat6 signaling molecules]	1.5849625007211563	3	1	0	0
15646	1520	immunoglobulin heavy-chain igh locus	[immunoglobulin heavy-chain IgH locus]	1.5849625007211563	4	1	0	0
15647	1520	intron downstream exon	[intron downstream exon]	1.5849625007211563	3	1	0	0
15648	1520	EBV- b cell	[EBV- B cells]	1.5849625007211563	3	1	0	0
15649	1520	costimulatory molecule CD28	[costimulatory molecule CD28]	1.5849625007211563	3	1	0	0
15650	1520	enhancement of ICAM-1	[enhancement of ICAM-1]	1.5849625007211563	3	1	0	0
15651	1520	New world primate	[New World primates]	1.5849625007211563	3	1	0	0
15652	1520	sequence analysis of pcd41	[Sequence analyses of pCD41]	1.5849625007211563	4	1	0	0
15653	1520	ets-related transcriptional regulator	[ets-related transcriptional regulators]	1.5849625007211563	3	1	0	0
15654	1520	glucocorticoid receptor gr number	[glucocorticoid receptor GR number]	1.5849625007211563	4	1	0	0
15655	1520	T cell activation determined.	[T cell activation determined.]	1.5849625007211563	4	1	0	0
15656	1520	ciita second look.	[CIITA second look.]	1.5849625007211563	3	1	0	0
15657	1520	ccaat binding protein nf-y	[CCAAT binding protein NF-Y]	1.5849625007211563	4	1	0	0
15658	1520	foundation determine the regulation	[foundation determining the regulation]	1.5849625007211563	4	1	0	0
15659	1520	small gtp -binding protein	[small GTP -binding proteins]	1.5849625007211563	4	1	0	0
15660	1520	initial attack of asthma	[initial attack of asthma]	1.5849625007211563	4	1	0	0
15661	1520	circadian modification of GR	[circadian modification of GR]	1.5849625007211563	4	1	0	0
15662	1520	vitamin D3 receptor VDR	[vitamin D3 receptor VDR]	1.5849625007211563	4	2	1	1
15663	1520	gamma response region	[gamma response region]	1.5849625007211563	3	2	1	1
15664	1520	DHEA receptor in monocyte	[DHEA receptor in monocytes]	1.5849625007211563	4	1	0	0
15665	1520	many immunoregulatory gene	[many immunoregulatory genes]	1.5849625007211563	3	1	0	0
15666	1520	unstimulated (ifn)-activated NK cell	[unstimulated (IFN)-activated NK cells]	1.5849625007211563	4	1	0	0
15667	1520	representational difference analysis	[representational difference analysis]	1.5849625007211563	3	1	0	0
15668	1520	lymphocyte homeostasis by apoptosis	[lymphocyte homeostasis by apoptosis]	1.5849625007211563	4	1	0	0
15669	1520	3' R-3-hydroxymyristate position	[3' R-3-hydroxymyristate position]	1.5849625007211563	3	1	0	0
15670	1520	effect of mp	[effects of MP]	1.5849625007211563	3	1	0	0
15671	1520	transcription in conjunction	[transcription in conjunction]	1.5849625007211563	3	1	0	0
15672	1520	childhood b lineage leukemia	[childhood B lineage leukemia]	1.5849625007211563	4	1	0	0
15673	1520	somatic cell hybrid panel	[somatic cell hybrid panels]	1.5849625007211563	4	1	0	0
15674	1520	dimerization among transcription factor	[Dimerization among transcription factors]	1.5849625007211563	4	1	0	0
15675	1520	hormone-mediated survival against apoptosis	[hormone-mediated survival against apoptosis]	1.5849625007211563	4	1	0	0
15676	1520	erythroid Kruppel-like factor eklf	[erythroid Kruppel-like factor EKLF]	1.5849625007211563	4	1	0	0
15677	1520	Th1 cell development	[Th1 cell development]	1.5849625007211563	3	1	0	0
15678	1520	two separate exon	[two separate exons]	1.5849625007211563	3	1	0	0
15679	1520	acute promelocytic leukemia	[acute promelocytic leukemia]	1.5849625007211563	3	1	0	0
15680	1520	pathogenesis of cushingd' syndrome	[pathogenesis of Cushing's syndrome]	1.5849625007211563	4	1	0	0
15681	1520	novel protein motif	[novel protein motif]	1.5849625007211563	3	1	0	0
15682	1520	choice between T lymphocyte	[choice between T lymphocytes]	1.5849625007211563	4	1	0	0
15683	1520	inosine-5'-monophosphate dehydrogenase type ii	[inosine-5'-monophosphate dehydrogenase type II]	1.5849625007211563	4	1	0	0
15684	1520	il-9ralpha other than stat3	[IL-9Ralpha other than STAT3]	1.5849625007211563	4	1	0	0
15685	1520	use a chromogenic assay	[using a chromogenic assay]	1.5849625007211563	4	1	0	0
15686	1520	colony-stimumulatelany-stg factor 1 csf-1	[colony-stimulating factor 1 CSF-1]	1.5849625007211563	4	1	0	0
15687	1520	spontaneous il-1ra production	[spontaneous IL-1ra production]	1.5849625007211563	3	1	0	0
15688	1520	3 sequence motif	[3 sequence motifs]	1.5849625007211563	3	1	0	0
15689	1520	level of the rrna	[level of the mRNAs]	1.5849625007211563	4	1	0	0
15690	1520	mechanical ventilation in vitro.	[mechanical ventilation in vitro.]	1.5849625007211563	4	1	0	0
15691	1520	interferon receptor family,	[interferon receptor family,]	1.5849625007211563	3	1	0	0
15692	1520	function of this protein	[function of this protein]	1.5849625007211563	4	2	1	1
15693	1520	several similar effects,	[several similar effects,]	1.5849625007211563	3	1	0	0
15694	1520	several other gene	[several other genes]	1.5849625007211563	3	2	1	1
15695	1520	human autosome 11	[human autosome 11]	1.5849625007211563	3	1	0	0
15696	1520	show glutamine synthetase induction	[showing glutamine synthetase induction]	1.5849625007211563	4	1	0	0
15697	1520	ovarian cancer patient	[ovarian cancer patient]	1.5849625007211563	3	2	2	2
15698	1520	b cell nfat complex	[B cell NFAT complex]	1.5849625007211563	4	1	0	0
15699	1520	use defensin np-1	[using defensins NP-1]	1.5849625007211563	3	1	0	0
15700	1520	kappa B-dependent manner	[kappa B-dependent manner]	1.5849625007211563	3	1	0	0
15701	1520	T lymphocyte to glucocorticoid	[T lymphocytes to glucocorticoids]	1.5849625007211563	4	1	0	0
15702	1520	typical ap-1 site	[typical AP-1 site]	1.5849625007211563	3	1	0	0
15703	1520	expression of all member	[expression of all members]	1.5849625007211563	4	1	0	0
15704	1520	prior breast cancer	[prior breast cancer]	1.5849625007211563	3	1	0	0
15705	1520	low apparent affinity	[lower apparent affinity]	1.5849625007211563	3	1	0	0
15706	1520	blood pressure pattern	[blood pressure patterns]	1.5849625007211563	3	1	0	0
15707	1520	exposure to dmso	[exposure to DMSO]	1.5849625007211563	3	1	0	0
15708	1520	phosphatidylinositol 3-kinase inhibitor wortmannin	[phosphatidylinositol 3-kinase inhibitor wortmannin]	1.5849625007211563	4	1	0	0
15709	1520	1,25-dihydroxyvitamin D3 -responsive protein	[1,25-dihydroxyvitamin D3 -responsive protein]	1.5849625007211563	4	1	0	0
15710	1520	alteration in oncogene	[alterations in oncogenes]	1.5849625007211563	3	1	0	0
15711	1520	translocation of pkc activity	[translocation of PKC activity]	1.5849625007211563	4	1	0	0
15712	1520	eosinophilic phenotype yj	[eosinophilic phenotype YJ]	1.5849625007211563	3	1	0	0
15713	1520	T cell hypoactivity	[T cell hypoactivity]	1.5849625007211563	3	1	0	0
15714	1520	kappa b DNA motif	[kappa B DNA motifs]	1.5849625007211563	4	1	0	0
15715	1520	gene encode gamma c	[genes encoding gamma c]	1.5849625007211563	4	1	0	0
15716	1520	Jurkat cell to hormone	[Jurkat cells to hormone]	1.5849625007211563	4	1	0	0
15717	1520	stationary-phase sigma factor rpose	[stationary-phase sigma factor RpoS]	1.5849625007211563	4	1	0	0
15718	1520	suppression of translation efficiency	[suppression of translation efficiency]	1.5849625007211563	4	1	0	0
15719	1520	several gata protein	[several GATA proteins]	1.5849625007211563	3	1	0	0
15720	1520	inhibitor of this phosphatase	[inhibitors of these phosphatases]	1.5849625007211563	4	1	0	0
15721	1520	other receptor c-kit/epo-r	[other receptors c-Kit/Epo-R]	1.5849625007211563	3	1	0	0
15722	1520	only weakly by NFATx2	[only weakly by NFATx2]	1.5849625007211563	4	1	0	0
15723	1520	basic amino acid	[basic amino acids]	1.5849625007211563	3	1	0	0
15724	1520	zeta-globin promoter activity	[zeta-globin promoter activity]	1.5849625007211563	3	1	0	0
15725	1520	difference in regulation	[difference in regulation]	1.5849625007211563	3	1	0	0
15726	1520	Jak kinase specific antibody	[Jak kinase specific antibodies]	1.5849625007211563	4	1	0	0
15727	1520	15 control subject	[15 control subjects]	1.5849625007211563	3	1	0	0
15728	1520	1.7-kb irf- CAT construct	[1.7-kb IRF- CAT construct]	1.5849625007211563	4	1	0	0
15729	1520	activation of leukocyte function	[activation of leukocyte functions]	1.5849625007211563	4	1	0	0
15730	1520	IL2 regulatory region	[IL2 regulatory region]	1.5849625007211563	3	2	1	1
15731	1520	human ghost membrane	[human ghost membrane]	1.5849625007211563	3	2	1	1
15732	1520	design of antioxidant-based therapy	[design of antioxidant-based therapies]	1.5849625007211563	4	1	0	0
15733	1520	induction of e2f activity	[induction of E2F activity]	1.5849625007211563	4	1	0	0
15734	1520	Egr-1 -overexpress transfectant	[Egr-1 -overexpressing transfectants]	1.5849625007211563	3	1	0	0
15735	1520	octamer-binding protein oct-2a	[octamer-binding protein Oct-2A]	1.5849625007211563	3	1	0	0
15736	1520	number of cd8+ leukocyte	[numbers of CD8+ leukocytes]	1.5849625007211563	4	1	0	0
15737	1520	degradation of IkappaBs	[degradation of IkappaBs]	1.5849625007211563	3	1	0	0
15738	1520	action of prolactin	[actions of prolactin]	1.5849625007211563	3	2	2	2
15739	1520	natural endogenous gene	[natural endogenous gene]	1.5849625007211563	3	1	0	0
15740	1520	squirrel monkey GR	[squirrel monkey GR]	1.5849625007211563	3	1	0	0
15741	1520	weight of kD	[weight of kD]	1.5849625007211563	3	2	2	2
15742	1520	restriction enzyme digestion	[restriction enzyme digestion]	1.5849625007211563	3	1	0	0
15743	1520	vary time interval	[varying time intervals]	1.5849625007211563	3	1	0	0
15744	1520	viral trans-activator tax protein	[viral trans-activator Tax protein]	1.5849625007211563	4	1	0	0
15745	1520	use DC as APC	[using DC as APC]	1.5849625007211563	4	1	0	0
15746	1520	half-life of 2.5 h.	[half-life of 2.5 h,]	1.5849625007211563	4	1	0	0
15747	1520	tat protein of hiv1	[Tat protein of HIV1]	1.5849625007211563	4	1	0	0
15748	1520	induce il-2 production	[inducing IL-2 production]	1.5849625007211563	3	1	0	0
15749	1520	thapsigargin sensitive, ca2+ dependent	[thapsigargin sensitive, Ca2+ dependent]	1.5849625007211563	4	1	0	0
15750	1520	ras -dependent manner	[Ras -dependent manner]	1.5849625007211563	3	1	0	0
15751	1520	regulation of the transcription	[regulation of the transcription]	1.5849625007211563	4	1	0	0
15752	1520	different functional response	[different functional responses]	1.5849625007211563	3	1	0	0
15753	1520	developmental control gene	[developmental control gene]	1.5849625007211563	3	1	0	0
15754	1520	729-6 b cell line	[729-6 B cell line]	1.5849625007211563	4	1	0	0
15755	1520	human lymphoid line	[human lymphoid lines]	1.5849625007211563	3	1	0	0
15756	1520	structure-function mutagenesis approach,	[structure-function mutagenesis approach,]	1.5849625007211563	3	1	0	0
15757	1520	interleukin-2 (il-2) secretion	[interleukin-2 (IL-2) secretion]	1.5849625007211563	3	1	0	0
15758	1520	small non-polyadenylated rna	[small non-polyadenylated RNAs]	1.5849625007211563	3	1	0	0
15759	1520	25% mature cells).	[25% mature cells).]	1.5849625007211563	3	1	0	0
15760	1520	signal transduction of il-4	[signal transduction of IL-4]	1.5849625007211563	4	1	0	0
15761	1520	(viability great to 90%).	[(viability greater to 90%).]	1.5849625007211563	4	1	0	0
15762	1520	tam for type-ii EBS	[TAM for type-II EBS]	1.5849625007211563	4	1	0	0
15763	1520	surface igm sigm	[surface IgM sIgM]	1.5849625007211563	3	1	0	0
15764	1520	hybrid drand_ reporter construct	[hybrid DRA/DQB reporter constructs]	1.5849625007211563	4	1	0	0
15765	1520	ribonuclease protection analysis	[ribonuclease protection analyses]	1.5849625007211563	3	1	0	0
15766	1520	p56 Src family	[p56 Src family]	1.5849625007211563	3	1	0	0
15767	1520	presence of anti-hgh mab	[presence of anti-hGH mAb]	1.5849625007211563	4	1	0	0
15768	1520	antigen-specific t-cell receptor	[antigen-specific T-cell receptor]	1.5849625007211563	3	1	0	0
15769	1520	biologic action of GM-CSF	[biologic actions of GM-CSF]	1.5849625007211563	4	1	0	0
15770	1520	CD40 signal component upstream	[CD40 signaling components upstream]	1.5849625007211563	4	1	0	0
15771	1520	human germinal center	[human germinal centers]	1.5849625007211563	3	1	0	0
15772	1520	erythroid burst-forming unit BFU-E	[erythroid burst-forming units BFU-E]	1.5849625007211563	4	1	0	0
15773	1520	host-derived mcd14 ligand	[host-derived mCD14 ligands]	1.5849625007211563	3	1	0	0
15774	1520	hiv-1 envelope glycoprotein	[HIV-1 envelope glycoproteins]	1.5849625007211563	3	1	0	0
15775	1520	return to the distribution	[return to the distribution]	1.5849625007211563	4	1	0	0
15776	1520	intrapulmonary accumulation of neutrophil	[intrapulmonary accumulation of neutrophils]	1.5849625007211563	4	1	0	0
15777	1520	tcf-1 alpha protein	[TCF-1 alpha protein]	1.5849625007211563	3	1	0	0
15778	1520	5-day m phi uptake	[5-day M phi uptake]	1.5849625007211563	4	2	2	2
15779	1520	effect on the differentiation	[effect on the differentiation]	1.5849625007211563	4	2	2	2
15780	1520	anlage of a spleen	[anlage of a spleen]	1.5849625007211563	4	1	0	0
15781	1520	b cell NHL	[B cell NHL]	1.5849625007211563	3	1	0	0
15782	1520	composite kappa 3/cre site	[composite kappa 3/CRE site]	1.5849625007211563	4	1	0	0
15783	1520	contain the il-2 promoter	[containing the IL-2 promoter]	1.5849625007211563	4	2	1	1
15784	1520	type of leukemia	[type of leukemia]	1.5849625007211563	3	2	1	1
15785	1520	carboxyl-terminus of the TRs	[carboxyl-terminus of the TRs]	1.5849625007211563	4	1	0	0
15786	1520	distinct complex involve GrpL	[distinct complexes involving GrpL]	1.5849625007211563	4	1	0	0
15787	1520	follow induction for differentiation	[following induction for differentiation]	1.5849625007211563	4	1	0	0
15788	1520	binding of ets-like factor	[binding of ETS-like factors]	1.5849625007211563	4	1	0	0
15789	1520	CD4 (+) subpopulation	[CD4 (+) subpopulations]	1.5849625007211563	3	1	0	0
15790	1520	homologous peptide 430-444,442A	[homologous peptide 430-444,442A]	1.5849625007211563	3	1	0	0
15791	1520	overexpression of hsf2-alpha result	[overexpression of HSF2-alpha results]	1.5849625007211563	4	1	0	0
15792	1520	29 bp truncation	[29 bp truncation]	1.5849625007211563	3	2	2	2
15793	1520	epithelial cell fusion partner	[epithelial cell fusion partner]	1.5849625007211563	4	1	0	0
15794	1520	three new isoforms, pax-5b	[three new isoforms, Pax-5b]	1.5849625007211563	4	1	0	0
15795	1520	expression of TAL1	[expression of TAL1]	1.5849625007211563	3	2	2	2
15796	1520	hour of exposure	[hr of exposure]	1.5849625007211563	3	2	2	2
15797	1520	additional signal molecule	[Additional signaling molecules]	1.5849625007211563	3	1	0	0
15798	1520	I IFN receptor	[I IFN receptors]	1.5849625007211563	3	1	0	0
15799	1520	IL-4R alpha cytoplasmic domain	[IL-4R alpha cytoplasmic domain]	1.5849625007211563	4	1	0	0
15800	1520	consequence of the activation	[consequence of the activation]	1.5849625007211563	4	2	1	1
15801	1520	nontransformed t-lineage cell population	[nontransformed T-lineage cell populations]	1.5849625007211563	4	1	0	0
15802	1520	nuclear level of gata-1	[nuclear levels of GATA-1]	1.5849625007211563	4	1	0	0
15803	1520	site-directed mutagenesis study	[site-directed mutagenesis studies]	1.5849625007211563	3	1	0	0
15804	1520	various aspect of senescence.	[various aspects of senescence.]	1.5849625007211563	4	1	0	0
15805	1520	constitutive PI3-kinase /pkb/akt pathway	[constitutive PI3-kinase /PKB/Akt pathway]	1.5849625007211563	4	1	0	0
15806	1520	rhizome of tumeric	[rhizome of tumeric]	1.5849625007211563	3	1	0	0
15807	1520	replication, cell survival	[replication, cell survival]	1.5849625007211563	3	1	0	0
15808	1520	strong deoxidizing activity, d-ribose	[strong deoxidizing activity, D-ribose]	1.5849625007211563	4	1	0	0
15809	1520	nineteen healthy woman aged	[nineteen healthy women aged]	1.5849625007211563	4	1	0	0
15810	1520	SMX -no than neutrophil	[SMX -NO than neutrophils]	1.5849625007211563	4	1	0	0
15811	1520	contrast, AP-1 generation	[contrast, AP-1 generation]	1.5849625007211563	3	1	0	0
15812	1520	intact pu.1 site adjacent	[intact PU.1 site adjacent]	1.5849625007211563	4	1	0	0
15813	1520	antiestrogen in cancer therapy	[antiestrogens in cancer therapy]	1.5849625007211563	4	1	0	0
15814	1520	phorbol myristate acetate,	[phorbol myristate acetate,]	1.5849625007211563	3	1	0	0
15815	1520	exclusively t-cell lymphoma	[exclusively T-cell lymphomas]	1.5849625007211563	3	1	0	0
15816	1520	potential AML1 -binding site	[potential AML1 -binding sites]	1.5849625007211563	4	1	0	0
15817	1520	subtractive pcr method	[subtractive PCR method]	1.5849625007211563	3	1	0	0
15818	1520	ikkbeta cellular kinase	[IKKbeta cellular kinases]	1.5849625007211563	3	1	0	0
15819	1520	stromal cell line bms2.4	[stromal cell line BMS2.4]	1.5849625007211563	4	1	0	0
15820	1520	Zalani, E. Holley-Guthrie, USA	[Zalani, E. Holley-Guthrie, USA]	1.5849625007211563	4	1	0	0
15821	1520	characterization of protein	[Characterization of proteins]	1.5849625007211563	3	2	2	2
15822	1520	lower-affinity site for rela	[lower-affinity site for RelA]	1.5849625007211563	4	1	0	0
15823	1520	most efficient competitors,	[most efficient competitors,]	1.5849625007211563	3	1	0	0
15824	1520	ets binding motif	[ETS binding motifs]	1.5849625007211563	3	2	1	1
15825	1520	inhibitory effect of cortisol	[inhibitory effect of cortisol]	1.5849625007211563	4	1	0	0
15826	1520	tumor cell for minute	[tumor cells for min]	1.5849625007211563	4	1	0	0
15827	1520	regulation of il-6	[regulation of IL-6]	1.5849625007211563	3	1	0	0
15828	1520	suggest a function	[suggesting a function]	1.5849625007211563	3	2	2	2
15829	1520	6 control donor	[6 control donors]	1.5849625007211563	3	1	0	0
15830	1520	key subdominant reactivities.	[key subdominant reactivities.]	1.5849625007211563	3	1	0	0
15831	1520	two motifs, site alpha	[two motifs, site alpha]	1.5849625007211563	4	1	0	0
15832	1520	immature hematopoietic ba/f3 cell	[immature hematopoietic Ba/F3 cells]	1.5849625007211563	4	1	0	0
15833	1520	Furthermore, inhibition by IFN	[Furthermore, inhibition by IFN]	1.5849625007211563	4	1	0	0
15834	1520	encode a component	[encoding a component]	1.5849625007211563	3	2	2	2
15835	1520	cell contact-delivered signals.	[cell contact-delivered signals.]	1.5849625007211563	3	1	0	0
15836	1520	high level of fosb/g0s3	[high levels of FOSB/G0S3]	1.5849625007211563	4	1	0	0
15837	1520	kappa b enhancer element,	[kappa B enhancer element,]	1.5849625007211563	4	1	0	0
15838	1520	least a mechanism	[least a mechanism]	1.5849625007211563	3	1	0	0
15839	1520	mmp-9 gelatinolytic activity	[MMP-9 gelatinolytic activity]	1.5849625007211563	3	1	0	0
15840	1520	proportion of lymphocyte	[proportion of lymphocytes]	1.5849625007211563	3	1	0	0
15841	1520	patient with chronic hepatitis	[patients with chronic hepatitis]	1.5849625007211563	4	2	1	1
15842	1520	above cytotoxic markers,	[above cytotoxic markers,]	1.5849625007211563	3	1	0	0
15843	1520	nuclear extract of pbmc	[nuclear extracts of PBMC]	1.5849625007211563	4	1	0	0
15844	1520	tal-1 transgenic mouse	[tal-1 transgenic mice]	1.5849625007211563	3	1	0	0
15845	1520	-70 to -65 region	[-70 to -65 region]	1.5849625007211563	4	2	1	1
15846	1520	cell transcription factor	[cell transcription factor]	1.5849625007211563	3	2	2	2
15847	1520	dephosphorylated form of Ets-1	[dephosphorylated form of Ets-1]	1.5849625007211563	4	1	0	0
15848	1520	possible signal role	[possible signaling role]	1.5849625007211563	3	1	0	0
15849	1520	successful antituberculous immune response	[successful antituberculous immune response]	1.5849625007211563	4	1	0	0
15850	1520	steroid receptor agonist cortisol	[steroid receptor agonist cortisol]	1.5849625007211563	4	1	0	0
15851	1520	erythroid progenitor cell differentiation	[erythroid progenitor cell differentiation]	1.5849625007211563	4	1	0	0
15852	1520	nfat activator protein-1 ap-1	[NFAT activator protein-1 AP-1]	1.5849625007211563	4	1	0	0
15853	1520	transcription factor nf-kb indicator	[transcription factor NF-kB indicators]	1.5849625007211563	4	1	0	0
15854	1520	other hematopoietic gene	[other hematopoietic genes]	1.5849625007211563	3	1	0	0
15855	1520	novel aldosterone membrane receptor	[novel aldosterone membrane receptor]	1.5849625007211563	4	1	0	0
15856	1520	IL4 transcription initiation site	[IL4 transcription initiation site]	1.5849625007211563	4	1	0	0
15857	1520	Th2-type cytokine IL-4	[Th2-type cytokines IL-4]	1.5849625007211563	3	1	0	0
15858	1520	human jurkat t-cell	[human Jurkat T-cells]	1.5849625007211563	3	1	0	0
15859	1520	short-term cellular response	[short-term cellular responses]	1.5849625007211563	3	1	0	0
15860	1520	control of viral latency	[control of viral latency]	1.5849625007211563	4	1	0	0
15861	1520	inflammatory cytokine expression erratum	[inflammatory cytokine expression erratum]	1.5849625007211563	4	1	0	0
15862	1520	novel ets protein	[novel Ets protein]	1.5849625007211563	3	2	1	1
15863	1520	correlation with the status	[correlation with the status]	1.5849625007211563	4	1	0	0
15864	1520	t-cell-specific transcription factor necessary	[T-cell-specific transcription factor necessary]	1.5849625007211563	4	1	0	0
15865	1520	influence of platelet-activate factor	[influence of platelet-activating factor]	1.5849625007211563	4	1	0	0
15866	1520	t-lymphoid cell line	[T-lymphoid cell lines]	1.5849625007211563	3	1	0	0
15867	1520	contrast to inhibitory effect	[contrast to inhibitory effects]	1.5849625007211563	4	1	0	0
15868	1520	EGR1 -express subclone	[EGR1 -expressing subclone]	1.5849625007211563	3	1	0	0
15869	1520	identical five amino-acid motif	[identical five amino-acid motif]	1.5849625007211563	4	1	0	0
15870	1520	potential agonistic activity	[potential agonistic activity]	1.5849625007211563	3	1	0	0
15871	1520	down-regulation of ar level	[down-regulation of AR levels]	1.5849625007211563	4	1	0	0
15872	1520	direct cytotoxic effect	[direct cytotoxic effects]	1.5849625007211563	3	1	0	0
15873	1520	bcl-2 u937 cell	[bcl-2 U937 cells]	1.5849625007211563	3	1	0	0
15874	1520	Elf-1 binding site	[Elf-1 binding sites]	1.5849625007211563	3	1	0	0
15875	1520	nuclear pool of I(kappa)B(alpha)	[nuclear pool of I(kappa)B(alpha)]	1.5849625007211563	4	1	0	0
15876	1520	significant intracellular thiol decrease,	[significant intracellular thiol decrease,]	1.5849625007211563	4	1	0	0
15877	1520	prerequisite for the progression	[prerequisite for the progression]	1.5849625007211563	4	1	0	0
15878	1520	HTLV-I tax production	[HTLV-I Tax production]	1.5849625007211563	3	1	0	0
15879	1520	poor binding peptide	[poorest binding peptide]	1.5849625007211563	3	1	0	0
15880	1520	early b lymphopoiesis	[early B lymphopoiesis]	1.5849625007211563	3	1	0	0
15881	1520	new binding site	[new binding sites]	1.5849625007211563	3	1	0	0
15882	1520	signal-regulated kinase ERK	[signal-regulated kinase ERK]	1.5849625007211563	3	2	2	2
15883	1520	addition of PMA	[addition of PMA]	1.5849625007211563	3	1	0	0
15884	1520	er -positive mcf-7	[ER -positive MCF-7]	1.5849625007211563	3	1	0	0
15885	1520	incubation with dexamethasone	[incubation with dexamethasone]	1.5849625007211563	3	2	2	2
15886	1520	pyruvate kinase erythroid-specific promoter	[pyruvate kinase erythroid-specific promoter]	1.5849625007211563	4	1	0	0
15887	1520	th2-associated cytokine il-4	[Th2-associated cytokines IL-4]	1.5849625007211563	3	1	0	0
15888	1520	13-kb human c-fe locus	[13-kb human c-fes locus]	1.5849625007211563	4	1	0	0
15889	1520	region critical for dimerization	[region critical for dimerization]	1.5849625007211563	4	1	0	0
15890	1520	about 50 kD	[about 50 kD]	1.5849625007211563	3	1	0	0
15891	1520	change in NF-kappaB component	[change in NF-kappaB components]	1.5849625007211563	4	1	0	0
15892	1520	tax protein of HTLV-I	[Tax protein of HTLV-I]	1.5849625007211563	4	2	1	1
15893	1520	whole arm x;17 translocation	[whole arm X;17 translocation]	1.5849625007211563	4	1	0	0
15894	1520	use human b-	[Using human B-]	1.5849625007211563	3	1	0	0
15895	1520	more mature cell	[more mature cells]	1.5849625007211563	3	2	1	1
15896	1520	examination of the induction	[examination of the induction]	1.5849625007211563	4	1	0	0
15897	1520	host's defense against microorganism	[host's defense against microorganisms]	1.5849625007211563	4	1	0	0
15898	1520	K46 b cell	[K46 B cells]	1.5849625007211563	3	1	0	0
15899	1520	promoter of cell growth	[promoters of cell growth]	1.5849625007211563	4	1	0	0
15900	1520	two gas-binding protein	[two GAS-binding proteins]	1.5849625007211563	3	1	0	0
15901	1520	135-(oh)2d3 suppression of synthesis,	[1,25-(OH)2D3 suppression of synthesis,]	1.5849625007211563	4	1	0	0
15902	1520	collective name for flowerhead	[collective name for flowerheads]	1.5849625007211563	4	1	0	0
15903	1520	intense physical exercise	[intense physical exercise]	1.5849625007211563	3	2	1	1
15904	1520	investigation of this factor	[Investigation of these factors]	1.5849625007211563	4	1	0	0
15905	1520	lysate of 1d4	[lysates of 1D4]	1.5849625007211563	3	1	0	0
15906	1520	STLV-I -bearing T	[STLV-I -bearing T]	1.5849625007211563	3	1	0	0
15907	1520	difference of binding factor	[difference of binding factors]	1.5849625007211563	4	1	0	0
15908	1520	SCL protein size	[SCL protein size]	1.5849625007211563	3	1	0	0
15909	1520	ras -dependent signal pathway	[Ras -dependent signaling pathways]	1.5849625007211563	4	1	0	0
15910	1520	cell of macrophage lineage	[cells of macrophage lineage]	1.5849625007211563	4	1	0	0
15911	1520	elevation in intracellular calcium	[elevation in intracellular calcium]	1.5849625007211563	4	1	0	0
15912	1520	tar transactivation responsive	[TAR transactivation responsive]	1.5849625007211563	3	1	0	0
15913	1520	JNK map kinase	[JNK MAP kinase]	1.5849625007211563	3	1	0	0
15914	1520	human b cell differentiation	[human B cell differentiation]	1.5849625007211563	4	1	0	0
15915	1520	coinfected human T cell	[coinfected human T cells]	1.5849625007211563	4	1	0	0
15916	1520	useful diagnostic tool	[useful diagnostic tools]	1.5849625007211563	3	1	0	0
15917	1520	CD3 CD28 T cell	[CD3 CD28 T cells]	1.5849625007211563	4	1	0	0
15918	1520	mean dissociation constant kd	[mean dissociation constant Kd]	1.5849625007211563	4	1	0	0
15919	1520	replication in monocyte	[replication in monocytes]	1.5849625007211563	3	2	2	2
15920	1520	4.3 0.2 nmol/l,	[4.3 0.2 nmol/L,]	1.5849625007211563	3	1	0	0
15921	1520	human fkbp cDNA	[human FKBP cDNA]	1.5849625007211563	3	1	0	0
15922	1520	susceptibility of a individual	[susceptibility of an individual]	1.5849625007211563	4	1	0	0
15923	1520	potent monocyte regulatory cytokine	[potent monocyte regulatory cytokine]	1.5849625007211563	4	1	0	0
15924	1520	breast cancer target susceptibility	[breast cancer target susceptibility]	1.5849625007211563	4	1	0	0
15925	1520	negative regulator, slap-130	[negative regulator, SLAP-130]	1.5849625007211563	3	1	0	0
15926	1520	six hgata-3 binding site	[six hGATA-3 binding sites]	1.5849625007211563	4	1	0	0
15927	1520	hiv -inductive cytokine	[HIV -inductive cytokines]	1.5849625007211563	3	1	0	0
15928	1520	association of JAK1	[association of JAK1]	1.5849625007211563	3	2	1	1
15929	1520	three additional agent endotoxin	[Three additional agents endotoxin]	1.5849625007211563	4	1	0	0
15930	1520	corresponding control cell	[corresponding control cells]	1.5849625007211563	3	1	0	0
15931	1520	GPIIb the alpha subunit	[GPIIb the alpha subunit]	1.5849625007211563	4	1	0	0
15932	1520	self-renewing, cd5+ b cell	[self-renewing, CD5+ B cells]	1.5849625007211563	4	1	0	0
15933	1520	phosphorylation of tyrosine kinase	[phosphorylation of tyrosine kinases]	1.5849625007211563	4	1	0	0
15934	1520	imbalance in understanding	[imbalance in understanding]	1.5849625007211563	3	1	0	0
15935	1520	more severe leukopenia	[more severe leukopenia]	1.5849625007211563	3	1	0	0
15936	1520	14 kda id-3 protein	[14 kDa Id-3 protein]	1.5849625007211563	4	1	0	0
15937	1520	antigen receptor agonism	[antigen receptor agonism]	1.5849625007211563	3	1	0	0
15938	1520	membrane binding of aldosterone	[membrane binding of aldosterone]	1.5849625007211563	4	1	0	0
15939	1520	cognate enhancer element	[cognate enhancer elements]	1.5849625007211563	3	1	0	0
15940	1520	pre-incubation with clomiphene	[Pre-incubation with clomiphene]	1.5849625007211563	3	1	0	0
15941	1520	difference in plasma cortisol	[difference in plasma cortisol]	1.5849625007211563	4	1	0	0
15942	1520	bcl-2 expression vector	[bcl-2 expression vector]	1.5849625007211563	3	1	0	0
15943	1520	serine phosphorylation response	[serine phosphorylation responses]	1.5849625007211563	3	1	0	0
15944	1520	microb binding protein	[microB binding protein]	1.5849625007211563	3	1	0	0
15945	1520	contrast, SCL mrna level	[contrast, SCL mRNA levels]	1.5849625007211563	4	1	0	0
15946	1520	10 healthy control	[10 healthy controls]	1.5849625007211563	3	1	0	0
15947	1520	remain eight patient	[remaining eight patients]	1.5849625007211563	3	1	0	0
15948	1520	mitogen phytohemagglutinin pha	[mitogen phytohemagglutinin PHA]	1.5849625007211563	3	1	0	0
15949	1520	effect of insulin	[effect of insulin]	1.5849625007211563	3	2	2	2
15950	1520	signal for abrogation protein	[signal for abrogation proteins]	1.5849625007211563	4	1	0	0
15951	1520	cell separation experiment	[Cell separation experiments]	1.5849625007211563	3	1	0	0
15952	1520	comparable enhancer element	[comparable enhancer element]	1.5849625007211563	3	1	0	0
15953	1520	development of T lymphocyte	[development of T lymphocytes]	1.5849625007211563	4	1	0	0
15954	1520	enhancement of hiv-1 replication	[Enhancement of HIV-1 replication]	1.5849625007211563	4	1	0	0
15955	1520	use a pbr 322-relaxation-assay	[using a PBR 322-relaxation-assay]	1.5849625007211563	4	1	0	0
15956	1520	Kmone for daidzein	[Km for daidzein]	1.5849625007211563	3	1	0	0
15957	1520	possible immune factor	[possible immune factors]	1.5849625007211563	3	1	0	0
15958	1520	follow anti-CD3 stimulation	[following anti-CD3 stimulation]	1.5849625007211563	3	1	0	0
15959	1520	immune dysregulation accompany aging	[immune dysregulation accompanying aging]	1.5849625007211563	4	1	0	0
15960	1520	cell with endocrine function	[cells with endocrine functions]	1.5849625007211563	4	1	0	0
15961	1520	development of the vasculopathy	[development of the vasculopathy]	1.5849625007211563	4	1	0	0
15962	1520	one clone DEG5	[One clone DEG5]	1.5849625007211563	3	1	0	0
15963	1520	TRs with NE	[TRs with NE]	1.5849625007211563	3	1	0	0
15964	1520	origin of the basophil	[origin of the basophils]	1.5849625007211563	4	1	0	0
15965	1520	completely bare promoter	[completely bare promoter]	1.5849625007211563	3	1	0	0
15966	1520	bacterial chloramphenicol acetyltransferase gene	[bacterial chloramphenicol acetyltransferase gene]	1.5849625007211563	4	1	0	0
15967	1520	patient before surgery	[patients before surgery]	1.5849625007211563	3	1	0	0
15968	1520	synthetic nf-kappab -dependent promoter	[synthetic NF-kappaB -dependent promoter]	1.5849625007211563	4	1	0	0
15969	1520	follow anti-CD3 activation	[following anti-CD3 activation]	1.5849625007211563	3	1	0	0
15970	1520	order of addition	[Order of addition]	1.5849625007211563	3	1	0	0
15971	1520	stat5 to all elements.	[STAT5 to all elements.]	1.5849625007211563	4	1	0	0
15972	1520	early T cell activation	[early T cell activation]	1.5849625007211563	4	1	0	0
15973	1520	acute leukemia cell line	[acute leukemia cell line]	1.5849625007211563	4	2	2	2
15974	1520	derivative 9 chromosome	[derivative 9 chromosome]	1.5849625007211563	3	1	0	0
15975	1520	t-cell receptor c	[T-cell receptor C]	1.5849625007211563	3	1	0	0
15976	1520	neuroendocrine promoter activity	[neuroendocrine promoter activity]	1.5849625007211563	3	1	0	0
15977	1520	Oct-2 gene expression	[Oct-2 gene expression]	1.5849625007211563	3	1	0	0
15978	1520	er mrna expression	[ER mRNA expression]	1.5849625007211563	3	1	0	0
15979	1520	light-regulated biological rhythm	[light-regulated biological rhythms]	1.5849625007211563	3	1	0	0
15980	1520	class ii protein	[class II proteins]	1.5849625007211563	3	1	0	0
15981	1520	inhibition of il-2 production	[inhibition of IL-2 production]	1.5849625007211563	4	1	0	0
15982	1520	low cd3+cd28-induced interleukin-2 production	[Low CD3+CD28-induced interleukin-2 production]	1.5849625007211563	4	1	0	0
15983	1520	two zinc finger domain	[two zinc finger domains]	1.5849625007211563	4	1	0	0
15984	1520	transactivator (ie-2) gene	[transactivator (IE-2) gene]	1.5849625007211563	3	1	0	0
15985	1520	CD2 signal pathway	[CD2 signalling pathway]	1.5849625007211563	3	1	0	0
15986	1520	terminal granulocyte differentiation	[terminal granulocyte differentiation]	1.5849625007211563	3	1	0	0
15987	1520	growth of hematopoietic cell	[growth of hematopoietic cells]	1.5849625007211563	4	2	2	2
15988	1520	recovery of tax response	[recovery of Tax responses]	1.5849625007211563	4	1	0	0
15989	1520	growth cell line	[growth cell lines]	1.5849625007211563	3	2	2	2
15990	1520	3' locus control region	[3' locus control region]	1.5849625007211563	4	1	0	0
15991	1520	cellular distribution of Aiolos	[cellular distribution of Aiolos]	1.5849625007211563	4	1	0	0
15992	1520	E2 er+ cell	[E2 ER+ cells]	1.5849625007211563	3	1	0	0
15993	1520	hnf-1 alpha dimer	[HNF-1 alpha dimers]	1.5849625007211563	3	1	0	0
15994	1520	biological effect of RA	[biological effects of RA]	1.5849625007211563	4	1	0	0
15995	1520	low molecular isoform	[lower molecular isoforms]	1.5849625007211563	3	1	0	0
15996	1520	human 105k precursor	[human 105K precursor]	1.5849625007211563	3	1	0	0
15997	1520	hiv- hd phenotype	[HIV- HD phenotype]	1.5849625007211563	3	1	0	0
15998	1520	NF-kappaB protein in cell	[NF-kappaB proteins in cells]	1.5849625007211563	4	1	0	0
15999	1520	inhibitory, p50 /p50	[inhibitory, p50 /p50]	1.5849625007211563	3	1	0	0
16000	1520	putative NFAT-1 region	[putative NFAT-1 region]	1.5849625007211563	3	1	0	0
16001	1520	Addisonian picture weakness	[Addisonian picture weakness]	1.5849625007211563	3	1	0	0
16002	1520	rapamycin like fk506	[rapamycin like FK506]	1.5849625007211563	3	1	0	0
16003	1520	contain DRA promoter (wild-type	[containing DRA promoter (wild-type]	1.5849625007211563	4	1	0	0
16004	1520	primary human blood lymphocyte	[primary human blood lymphocytes]	1.5849625007211563	4	2	1	1
16005	1520	IL-10 inhibitory activity	[IL-10 inhibitory activity]	1.5849625007211563	3	1	0	0
16006	1520	interleukin (il)-1 activation	[interleukin (IL)-1 activation]	1.5849625007211563	3	1	0	0
16007	1520	base of the brain	[base of the brain]	1.5849625007211563	4	1	0	0
16008	1520	detection of minimal disease	[Detection of minimal disease]	1.5849625007211563	4	2	2	2
16009	1520	activator in s49 cell	[activator in S49 cells]	1.5849625007211563	4	1	0	0
16010	1520	induction of this promoter	[induction of this promoter]	1.5849625007211563	4	1	0	0
16011	1520	first 40 residue	[first 40 residues]	1.5849625007211563	3	1	0	0
16012	1520	result of removal	[result of removal]	1.5849625007211563	3	1	0	0
16013	1520	least three different form	[least three different forms]	1.5849625007211563	4	1	0	0
16014	1520	stable chromatin-integrated yeast cell	[stable chromatin-integrated yeast cells]	1.5849625007211563	4	1	0	0
16015	1520	cd8+ cytotoxic T lymphocyte	[CD8+ cytotoxic T lymphocytes]	1.5849625007211563	4	1	0	0
16016	1520	putative ikappabalpha kinase p90(rsk)	[putative IkappaBalpha kinase p90(rsk)]	1.5849625007211563	4	1	0	0
16017	1520	several specific genes.	[several specific genes.]	1.5849625007211563	3	1	0	0
16018	1520	level of JNK activation.	[level of JNK activation.]	1.5849625007211563	4	1	0	0
16019	1520	transfection of c-jun	[transfection of c-jun]	1.5849625007211563	3	1	0	0
16020	1520	ap-1 complex junb	[AP-1 complex junB]	1.5849625007211563	3	1	0	0
16021	1520	mediate murine thymocyte apoptosis,	[mediating murine thymocyte apoptosis,]	1.5849625007211563	4	1	0	0
16022	1520	only in cd68- cell	[only in CD68- cells]	1.5849625007211563	4	1	0	0
16023	1520	up-regulation of VDR message	[up-regulation of VDR message]	1.5849625007211563	4	1	0	0
16024	1520	40 nucleotide 5'	[40 nucleotides 5']	1.5849625007211563	3	1	0	0
16025	1520	definitive hematopoiesis in vivo,	[definitive hematopoiesis in vivo,]	1.5849625007211563	4	1	0	0
16026	1520	strength of ligand signal	[strength of ligand signal]	1.5849625007211563	4	1	0	0
16027	1520	short 40-bp region	[short 40-bp region]	1.5849625007211563	3	1	0	0
16028	1520	occasional lymphoid aggregate formation	[occasional lymphoid aggregate formation]	1.5849625007211563	4	1	0	0
16029	1520	b cell 110-kda protein	[B cell 110-kDa protein]	1.5849625007211563	4	1	0	0
16030	1520	expression of Rta	[expression of Rta]	1.5849625007211563	3	1	0	0
16031	1520	protein of 51659 daltons.	[protein of 51,659 daltons.]	1.5849625007211563	4	1	0	0
16032	1520	four at case	[four AT cases]	1.5849625007211563	3	1	0	0
16033	1520	understanding of dlcl pathogenesis	[understanding of DLCL pathogenesis]	1.5849625007211563	4	1	0	0
16034	1520	indicate a involvement	[indicating a involvement]	1.5849625007211563	3	2	2	2
16035	1520	stat1 p91 p92	[STAT1 p91 p92]	1.5849625007211563	3	1	0	0
16036	1520	cytokine-induced vcam-1 mrna expression	[cytokine-induced VCAM-1 mRNA expression]	1.5849625007211563	4	1	0	0
16037	1520	4 normal subject	[4 normal subjects]	1.5849625007211563	3	1	0	0
16038	1520	phosphorylation on serine	[phosphorylation on serine]	1.5849625007211563	3	2	2	2
16039	1520	PWM egr-1 transcription	[PWM EGR-1 transcription]	1.5849625007211563	3	1	0	0
16040	1520	effect of cell adhesion	[effect of cell adhesion]	1.5849625007211563	4	1	0	0
16041	1520	metastatic capacity of tumor	[metastatic capacity of tumors]	1.5849625007211563	4	1	0	0
16042	1520	particular, naturally occur	[particular, naturally occurring]	1.5849625007211563	3	1	0	0
16043	1520	HTLV-1 tax gene	[HTLV-1 tax gene]	1.5849625007211563	3	1	0	0
16044	1520	ecotropic insertion site	[ecotropic insertion site]	1.5849625007211563	3	2	2	2
16045	1520	absence of IL-12	[absence of IL-12]	1.5849625007211563	3	1	0	0
16046	1520	number of high-affinity il-2r	[number of high-affinity IL-2Rs]	1.5849625007211563	4	1	0	0
16047	1520	FDC in gc	[FDC in GC]	1.5849625007211563	3	1	0	0
16048	1520	approximately 6-fold high (KD	[approximately 6-fold higher (KD]	1.5849625007211563	4	1	0	0
16049	1520	response of type ii	[response of Type II]	1.5849625007211563	4	1	0	0
16050	1520	mutants, include one strain	[mutants, including one strain]	1.5849625007211563	4	1	0	0
16051	1520	soluble cd40l fusion protein	[soluble CD40L fusion protein]	1.5849625007211563	4	1	0	0
16052	1520	second from clinic population	[second from clinic population]	1.5849625007211563	4	1	0	0
16053	1520	kda stat5 isoform	[kDa STAT5 isoform]	1.5849625007211563	3	2	2	2
16054	1520	response to costimulatory signal	[response to costimulatory signals]	1.5849625007211563	4	1	0	0
16055	1520	binding of NF-E1	[binding of NF-E1]	1.5849625007211563	3	2	1	1
16056	1520	4-fold increase in transcription	[4-fold increase in transcription]	1.5849625007211563	4	1	0	0
16057	1520	binding of NF-E2	[binding of NF-E2]	1.5849625007211563	3	1	0	0
16058	1520	reduction in splenic lymphocyte	[reduction in splenic lymphocytes]	1.5849625007211563	4	1	0	0
16059	1520	novel ets-related protein elf-1	[novel Ets-related protein Elf-1]	1.5849625007211563	4	1	0	0
16060	1520	consider the abovesaid	[Considering the abovesaid]	1.5849625007211563	3	1	0	0
16061	1520	promoter of growth hormone	[promoters of growth hormone]	1.5849625007211563	4	1	0	0
16062	1520	absolute htr beta	[Absolute hTR beta]	1.5849625007211563	3	1	0	0
16063	1520	ROS generation inhibition	[ROS generation inhibition]	1.5849625007211563	3	1	0	0
16064	1520	TNF alpha U/ml), one	[TNF alpha U/ml), one]	1.5849625007211563	4	1	0	0
16065	1520	p26rex /p24rex in HTLV-I	[p26rex /p24rex in HTLV-I]	1.5849625007211563	4	1	0	0
16066	1520	activate cell proliferation	[activating cell proliferation]	1.5849625007211563	3	1	0	0
16067	1520	binding of NF-AT	[binding of NF-AT]	1.5849625007211563	3	1	0	0
16068	1520	addition of beta-estradiol	[addition of beta-estradiol]	1.5849625007211563	3	1	0	0
16069	1520	hml of hypertensive patient	[HML of hypertensive patients]	1.5849625007211563	4	1	0	0
16070	1520	other T cell-deficient mouse	[other T cell-deficient mice]	1.5849625007211563	4	1	0	0
16071	1520	Aggarwal, J. biol.	[Aggarwal, J. Biol.]	1.5849625007211563	3	1	0	0
16072	1520	p47phox -deficient patient	[p47phox -deficient patients]	1.5849625007211563	3	1	0	0
16073	1520	regulate ige synthesis	[regulating IgE synthesis]	1.5849625007211563	3	2	2	2
16074	1520	epidermal growth factor	[epidermal growth factor]	1.5849625007211563	3	2	1	1
16075	1520	use of transgenic animal	[use of transgenic animals]	1.5849625007211563	4	1	0	0
16076	1520	multigene family, cGATA-3	[multigene family, cGATA-3]	1.5849625007211563	3	1	0	0
16077	1520	ecotropic viral insertion site	[ecotropic viral insertion site]	1.5849625007211563	4	2	1	1
16078	1520	point of departure	[point of departure]	1.5849625007211563	3	1	0	0
16079	1520	receptor affinity to glucocorticoid	[receptor affinity to glucocorticoids]	1.5849625007211563	4	2	2	2
16080	1520	association of isgf3 components.	[association of ISGF3 components.]	1.5849625007211563	4	1	0	0
16081	1520	cbf1/rbp-jkappa binding site	[CBF1/RBP-Jkappa binding site]	1.5849625007211563	3	1	0	0
16082	1520	expression of SCL	[expression of SCL]	1.5849625007211563	3	1	0	0
16083	1520	activator of ap-1	[activator of AP-1]	1.5849625007211563	3	1	0	0
16084	1520	imply a role	[implying a role]	1.5849625007211563	3	2	2	2
16085	1520	nfkb-like transcription factor	[NFkB-like transcription factors]	1.5849625007211563	3	1	0	0
16086	1520	represent the whole spectrum	[representing the whole spectrum]	1.5849625007211563	4	1	0	0
16087	1520	expression of wild-type RXR	[expression of wild-type RXR]	1.5849625007211563	4	1	0	0
16088	1520	respiratory epithelium of normal	[respiratory epithelium of normals]	1.5849625007211563	4	2	1	1
16089	1520	C2H2 zinc finger gene	[C2H2 zinc finger gene]	1.5849625007211563	4	1	0	0
16090	1520	upstream of cp	[upstream of Cp]	1.5849625007211563	3	2	1	1
16091	1520	effective antigen-presenting cell function	[effective antigen-presenting cell function]	1.5849625007211563	4	1	0	0
16092	1520	four nonatopic control subject	[four nonatopic control subjects]	1.5849625007211563	4	1	0	0
16093	1520	Ig-expressing (rare) hybrid	[Ig-expressing (rare) hybrids]	1.5849625007211563	3	1	0	0
16094	1520	B cell lineage cell	[B cell lineage cells]	1.5849625007211563	4	1	0	0
16095	1520	patient with renin value	[Patients with renin values]	1.5849625007211563	4	2	2	2
16096	1520	lineage-restricted ets transcription factor	[lineage-restricted Ets transcription factor]	1.5849625007211563	4	1	0	0
16097	1520	problem of frequent emergence	[problem of frequent emergence]	1.5849625007211563	4	1	0	0
16098	1520	il-2-r alpha for il-2	[IL-2-R alpha for IL-2]	1.5849625007211563	4	1	0	0
16099	1520	include change in morphology	[including changes in morphology]	1.5849625007211563	4	1	0	0
16100	1520	v-rel oncogene product	[v-rel oncogene product]	1.5849625007211563	3	2	1	1
16101	1520	late granulocytic maturation	[late granulocytic maturation]	1.5849625007211563	3	1	0	0
16102	1520	monoclonal anti-endothelial cell antibody	[Monoclonal anti-endothelial cell antibodies]	1.5849625007211563	4	2	2	2
16103	1520	E1a copy number	[E1a copy number]	1.5849625007211563	3	2	1	1
16104	1520	ish for ebv	[ISH for EBV]	1.5849625007211563	3	1	0	0
16105	1520	kappab -dependent transcriptional activity	[kappaB -dependent transcriptional activity]	1.5849625007211563	4	1	0	0
16106	1520	outgrowth of bone	[outgrowth of bone]	1.5849625007211563	3	1	0	0
16107	1520	defense of the organism.	[defense of the organism.]	1.5849625007211563	4	1	0	0
16108	1520	increase in il-2 level	[increase in IL-2 levels]	1.5849625007211563	4	1	0	0
16109	1520	form of immunodeficiency	[form of immunodeficiency]	1.5849625007211563	3	2	2	2
16110	1520	monocyte tethering by p-selectin	[Monocyte tethering by P-selectin]	1.5849625007211563	4	1	0	0
16111	1520	vitamin d-mediated gene regulation	[vitamin D-mediated gene regulation]	1.5849625007211563	4	1	0	0
16112	1520	U937 monocytic line	[U937 monocytic line]	1.5849625007211563	3	1	0	0
16113	1520	in vitro reconstitution assay	[in vitro reconstitution assay]	1.5849625007211563	4	1	0	0
16114	1520	response to interleukin (il)-2	[response to interleukin (IL)-2]	1.5849625007211563	4	1	0	0
16115	1520	insight into the maturation	[insight into the maturation]	1.5849625007211563	4	1	0	0
16116	1520	promoter of several gene	[promoters of several genes]	1.5849625007211563	4	1	0	0
16117	1520	fraction of cell	[fractions of cells]	1.5849625007211563	3	1	0	0
16118	1520	mitogen-activated protein kinase erk1	[mitogen-activated protein kinases erk1]	1.5849625007211563	4	1	0	0
16119	1520	factor responsible for expression	[factors responsible for expression]	1.5849625007211563	4	1	0	0
16120	1520	surfactant inflammatory cytokine production	[surfactant inflammatory cytokine production]	1.5849625007211563	4	1	0	0
16121	1520	myeloid integrin cd11b	[myeloid integrin CD11b]	1.5849625007211563	3	1	0	0
16122	1520	cytokine tgf-beta in cell	[cytokine TGF-beta in cells]	1.5849625007211563	4	2	2	2
16123	1520	implication for tumorigenesis	[implications for tumorigenesis]	1.5849625007211563	3	1	0	0
16124	1520	dephosphorylation of dp1	[dephosphorylation of DP1]	1.5849625007211563	3	1	0	0
16125	1520	terminal complement complex	[terminal complement complexes]	1.5849625007211563	3	2	1	1
16126	1520	gr apparent bind affinity	[GR apparent binding affinity]	1.5849625007211563	4	1	0	0
16127	1520	40-kda protein tax	[40-kDa protein Tax]	1.5849625007211563	3	2	1	1
16128	1520	absence of hla -dr	[absence of HLA -DR]	1.5849625007211563	4	1	0	0
16129	1520	patient with atopic dermatitis	[patients with atopic dermatitis]	1.5849625007211563	4	2	1	1
16130	1520	example, against keratin	[example, against keratin]	1.5849625007211563	3	1	0	0
16131	1520	1 hour of treatment.	[1 hour of treatment.]	1.5849625007211563	4	1	0	0
16132	1520	such as bcl-2+	[such as BCL-2+]	1.5849625007211563	3	1	0	0
16133	1520	precise mode of action	[precise mode of action]	1.5849625007211563	4	1	0	0
16134	1520	natural ppargamma agonist	[natural PPARgamma agonists]	1.5849625007211563	3	1	0	0
16135	1520	mibp1 to nre gamma	[MIBP1 to NRE gamma]	1.5849625007211563	4	1	0	0
16136	1520	lack the binding site	[lacking the binding sites]	1.5849625007211563	4	2	2	2
16137	1520	fusion of HeLa cell	[fusion of HeLa cells]	1.5849625007211563	4	1	0	0
16138	1520	GAL4 DNA binding site	[GAL4 DNA binding site]	1.5849625007211563	4	2	1	1
16139	1520	regard to tyk2 dephosphorylation	[regard to Tyk2 dephosphorylation]	1.5849625007211563	4	1	0	0
16140	1520	analysis of preclinical	[analysis of preclinical]	1.5849625007211563	3	1	0	0
16141	1520	immune response in	[immune response in]	1.5849625007211563	3	1	0	0
16142	1520	cell of category Va	[cells of Categories Va]	1.5849625007211563	4	1	0	0
16143	1520	nucleotide excision repair ner	[nucleotide excision repair NER]	1.5849625007211563	4	1	0	0
16144	1520	part of the effect	[part of the effect]	1.5849625007211563	4	2	2	2
16145	1520	transcription factor TFIIA	[transcription factor TFIIA]	1.5849625007211563	3	1	0	0
16146	1520	implication for vaccine development	[implications for vaccine development]	1.5849625007211563	4	1	0	0
16147	1520	follow CD28 coligation.	[following CD28 coligation.]	1.5849625007211563	3	1	0	0
16148	1520	il-1 beta mrna	[IL-1 beta mRNA]	1.5849625007211563	3	4	3	1
16149	1520	infection of human monocyte	[Infection of human monocytes]	1.5849625007211563	4	1	0	0
16150	1520	67-bp MnlI-AluI fragment	[67-bp MnlI-AluI fragment]	1.5849625007211563	3	1	0	0
16151	1520	Correspondingly, transfection of p50	[Correspondingly, transfection of p50]	1.5849625007211563	4	1	0	0
16152	1520	Central nervous system cell	[Central nervous system cells]	1.5849625007211563	4	1	0	0
16153	1520	additional mapping study	[Additional mapping studies]	1.5849625007211563	3	1	0	0
16154	1520	responsiveness to tnf-alpha induction	[responsiveness to TNF-alpha induction]	1.5849625007211563	4	1	0	0
16155	1520	same T cell clone	[same T cell clone]	1.5849625007211563	4	1	0	0
16156	1520	red cell viability	[red cell viability]	1.5849625007211563	3	1	0	0
16157	1520	activity of a subset	[activity of a subset]	1.5849625007211563	4	1	0	0
16158	1520	patient with x-linked immunodeficiency	[patients with X-linked immunodeficiency]	1.5849625007211563	4	2	2	2
16159	1520	simian immunodeficiency virus isolate	[simian immunodeficiency virus isolates]	1.5849625007211563	4	1	0	0
16160	1520	4 h in HL60	[4 h in HL60]	1.5849625007211563	4	1	0	0
16161	1520	suggest a primary inducer	[suggesting a primary inducer]	1.5849625007211563	4	1	0	0
16162	1520	precursor of macrophage	[precursors of macrophages]	1.5849625007211563	3	1	0	0
16163	1520	cytokine stimulation good	[cytokine stimulation better]	1.5849625007211563	3	1	0	0
16164	1520	ebv-positive b cell	[EBV-positive B cells]	1.5849625007211563	3	1	0	0
16165	1520	potent activator, transcription	[potent activator, transcription]	1.5849625007211563	3	1	0	0
16166	1520	oxidant stress-induced signal	[oxidant stress-induced signaling]	1.5849625007211563	3	1	0	0
16167	1520	different relative affinity	[different relative affinities]	1.5849625007211563	3	1	0	0
16168	1520	two transcription factor Sp1	[two transcription factors Sp1]	1.5849625007211563	4	1	0	0
16169	1520	increase in the synthesis	[increases in the synthesis]	1.5849625007211563	4	1	0	0
16170	1520	variant of Spi-B	[variant of Spi-B]	1.5849625007211563	3	1	0	0
16171	1520	interaction(s) between ebv	[interaction(s) between EBV]	1.5849625007211563	3	1	0	0
16172	1520	computer algorithm capable	[computer algorithm capable]	1.5849625007211563	3	1	0	0
16173	1520	mechanism of inflammation	[mechanisms of inflammation]	1.5849625007211563	3	1	0	0
16174	1520	NF-kappa b p50 /p65	[NF-kappa B p50 /p65]	1.5849625007211563	4	1	0	0
16175	1520	presence of this protein	[presence of these proteins]	1.5849625007211563	4	2	1	1
16176	1520	heterologous activation region	[heterologous activation regions]	1.5849625007211563	3	1	0	0
16177	1520	LTR sequence change	[LTR sequence changes]	1.5849625007211563	3	1	0	0
16178	1520	jnk1 protein level	[JNK1 protein levels]	1.5849625007211563	3	1	0	0
16179	1520	human carboxylesterase gene	[human carboxylesterase gene]	1.5849625007211563	3	1	0	0
16180	1520	three healthy child	[three healthy children]	1.5849625007211563	3	1	0	0
16181	1520	second, T cell	[Second, T cells]	1.5849625007211563	3	1	0	0
16182	1520	80 amino acid	[80 amino acids]	1.5849625007211563	3	1	0	0
16183	1520	mediate the effect	[mediating the effect]	1.5849625007211563	3	2	2	2
16184	1520	identical concentration of hormone	[identical concentrations of hormone]	1.5849625007211563	4	1	0	0
16185	1520	site for protein	[site for proteins]	1.5849625007211563	3	2	2	2
16186	1520	additive combination of "adult"	[additive combination of "adult"]	1.5849625007211563	4	1	0	0
16187	1520	ap-1 -dependent expression	[AP-1 -dependent expression]	1.5849625007211563	3	1	0	0
16188	1520	induction in T cell	[induction in T cells]	1.5849625007211563	4	2	2	2
16189	1520	typical aml m4eo	[typical AML M4Eo]	1.5849625007211563	3	2	1	1
16190	1520	three chromatographic step	[three chromatographic steps]	1.5849625007211563	3	1	0	0
16191	1520	activation via CD40	[activation via CD40]	1.5849625007211563	3	1	0	0
16192	1520	composite pu.1 pip site	[composite PU.1 Pip site]	1.5849625007211563	4	1	0	0
16193	1520	ebv receptor cr2/cd21	[EBV receptor CR2/CD21]	1.5849625007211563	3	1	0	0
16194	1520	salt bridge structure	[salt bridge structure]	1.5849625007211563	3	1	0	0
16195	1520	expression in mouse	[expression in mice]	1.5849625007211563	3	2	2	2
16196	1520	i collagen fibril	[I collagen fibrils]	1.5849625007211563	3	1	0	0
16197	1520	thalassaemia major patient	[thalassaemia major patients]	1.5849625007211563	3	1	0	0
16198	1520	expression of CD40 antigen	[expression of CD40 antigen]	1.5849625007211563	4	1	0	0
16199	1520	average, plasma cysteine	[average, plasma cysteine]	1.5849625007211563	3	1	0	0
16200	1520	preservation of immunologic tolerance,	[preservation of immunologic tolerance,]	1.5849625007211563	4	1	0	0
16201	1520	cross-linked anti-CD3 abs	[cross-linked anti-CD3 Abs]	1.5849625007211563	3	1	0	0
16202	1520	distinct regulation of expression	[distinct regulation of expression]	1.5849625007211563	4	1	0	0
16203	1520	glucocorticoid receptor characteristics,	[glucocorticoid receptor characteristics,]	1.5849625007211563	3	1	0	0
16204	1520	two signals, one	[two signals, one]	1.5849625007211563	3	2	1	1
16205	1520	lymphocytic cell origin	[lymphocytic cell origin]	1.5849625007211563	3	1	0	0
16206	1520	express squirrel monkey fkbp51	[expressing squirrel monkey FKBP51]	1.5849625007211563	4	1	0	0
16207	1520	other leukocyte undergo apoptosis	[other leukocytes undergoing apoptosis]	1.5849625007211563	4	1	0	0
16208	1520	interleukin 2 lymphocyte proliferation	[interleukin 2 lymphocyte proliferation]	1.5849625007211563	4	1	0	0
16209	1520	feature in patient	[features in patients]	1.5849625007211563	3	2	2	2
16210	1520	Study of cell line	[Studies of cell lines]	1.5849625007211563	4	1	0	0
16211	1520	gcs -untreated patient	[GCS -untreated patients]	1.5849625007211563	3	1	0	0
16212	1520	structural (amino acid)	[structural (amino acid)]	1.5849625007211563	3	1	0	0
16213	1520	core binding factor CBF	[Core binding factor CBF]	1.5849625007211563	4	1	0	0
16214	1520	primarily by IL-1	[primarily by IL-1]	1.5849625007211563	3	1	0	0
16215	1520	distal enhancer hs-40	[distal enhancer HS-40]	1.5849625007211563	3	1	0	0
16216	1520	peripheral leucocyte in woman	[peripheral leucocytes in women]	1.5849625007211563	4	2	2	2
16217	1520	interleukin 2 il-2 synthesis	[interleukin 2 IL-2 synthesis]	1.5849625007211563	4	1	0	0
16218	1520	nucleus in mnc in	[nucleus in MNC in]	1.5849625007211563	4	1	0	0
16219	1520	secretable cytokine il-6	[secretable cytokines IL-6]	1.5849625007211563	3	1	0	0
16220	1520	function of C3a	[functions of C3a]	1.5849625007211563	3	1	0	0
16221	1520	respect to the augmentation	[respect to the augmentation]	1.5849625007211563	4	1	0	0
16222	1520	zinc finger of Sp1	[zinc fingers of Sp1]	1.5849625007211563	4	1	0	0
16223	1520	presence of ras mutation	[presence of ras mutations]	1.5849625007211563	4	1	0	0
16224	1520	defective gamma(c) chain	[defective gamma(c) chain]	1.5849625007211563	3	1	0	0
16225	1520	immediate/early gene family	[immediate/early gene family]	1.5849625007211563	3	1	0	0
16226	1520	other pathogenic infections.	[other pathogenic infections.]	1.5849625007211563	3	1	0	0
16227	1520	1,25(OH)2D3 receptor of S-LB1	[1,25(OH)2D3 receptor of S-LB1]	1.5849625007211563	4	1	0	0
16228	1520	unidentified ligand pair	[unidentified ligand pair]	1.5849625007211563	3	1	0	0
16229	1520	e1b 19K protein	[E1B 19K protein]	1.5849625007211563	3	1	0	0
16230	1520	hematopoietic cell line K562	[hematopoietic cell lines K562]	1.5849625007211563	4	1	0	0
16231	1520	single c motif-1/lymphotactin promoter	[single C motif-1/lymphotactin promoter]	1.5849625007211563	4	1	0	0
16232	1520	dysregulation of cytokine	[Dysregulation of cytokines]	1.5849625007211563	3	1	0	0
16233	1520	amino-terminal region of PU.1	[amino-terminal region of PU.1]	1.5849625007211563	4	1	0	0
16234	1520	lps binding protein	[LPS binding protein]	1.5849625007211563	3	1	0	0
16235	1520	ap-1 nf-kappa b	[AP-1 NF-kappa B]	1.5849625007211563	3	1	0	0
16236	1520	Jurkat human leukaemic t-cell	[Jurkat human leukaemic T-cells]	1.5849625007211563	4	1	0	0
16237	1520	response to different stimulus	[response to different stimuli]	1.5849625007211563	4	2	2	2
16238	1520	expression level of AML1	[expression level of AML1]	1.5849625007211563	4	1	0	0
16239	1520	Syk T cell	[Syk T cell]	1.5849625007211563	3	1	0	0
16240	1520	expression of BLR1	[expression of BLR1]	1.5849625007211563	3	1	0	0
16241	1520	thrombin -generation curve (auc)	[thrombin -generation curve (AUC)]	1.5849625007211563	4	1	0	0
16242	1520	host natural killer	[host natural killer]	1.5849625007211563	3	1	0	0
16243	1520	involvement of transcription factor	[Involvement of transcription factor]	1.5849625007211563	4	2	2	2
16244	1520	increase unresponsiveness of patient	[increasing unresponsiveness of patients]	1.5849625007211563	4	1	0	0
16245	1520	hl60 promyelocytic leukemia cell	[HL60 promyelocytic leukemia cells]	1.5849625007211563	4	1	0	0
16246	1520	encompass seven exon	[encompassing seven exons]	1.5849625007211563	3	1	0	0
16247	1520	adjunct to cancer chemotherapy	[adjunct to cancer chemotherapy]	1.5849625007211563	4	1	0	0
16248	1520	persistent latency of HTLV-I	[persistent latency of HTLV-I]	1.5849625007211563	4	1	0	0
16249	1520	two distinct domain	[two distinct domains]	1.5849625007211563	3	2	2	2
16250	1520	TCR alpha beta lineage	[TCR alpha beta lineage]	1.5849625007211563	4	1	0	0
16251	1520	terminal neutrophilic maturation	[terminal neutrophilic maturation]	1.5849625007211563	3	1	0	0
16252	1520	slightly few gr	[slightly fewer GR]	1.5849625007211563	3	1	0	0
16253	1520	four map kinase mapk	[four MAP kinase MAPK]	1.5849625007211563	4	1	0	0
16254	1520	significant quantity of nf-at	[significant quantities of NF-AT]	1.5849625007211563	4	1	0	0
16255	1520	role of nfatp	[role of NFATp]	1.5849625007211563	3	1	0	0
16256	1520	growth-inhibitory effect of DES	[growth-inhibitory effect of DES]	1.5849625007211563	4	1	0	0
16257	1520	40 kb upstream	[40 kb upstream]	1.5849625007211563	3	1	0	0
16258	1520	physiologically relevant promoter	[physiologically relevant promoter]	1.5849625007211563	3	1	0	0
16259	1520	e box recognition sequence	[E box recognition sequence]	1.5849625007211563	4	1	0	0
16260	1520	under-representation of 1p36	[under-representation of 1p36]	1.5849625007211563	3	1	0	0
16261	1520	important role in expression	[important role in expression]	1.5849625007211563	4	2	2	2
16262	1520	1 healthy thyroid gland	[1 healthy thyroid gland]	1.5849625007211563	4	1	0	0
16263	1520	T alpha 1 creb	[T alpha 1 CREB]	1.5849625007211563	4	1	0	0
16264	1520	ligand binding affinity	[ligand binding affinity]	1.5849625007211563	3	2	2	2
16265	1520	gamma delta lineage	[gamma delta lineage]	1.5849625007211563	3	1	0	0
16266	1520	experiment with u937 cell	[experiments with U937 cells]	1.5849625007211563	4	1	0	0
16267	1520	potent activator of transcription	[potent activator of transcription]	1.5849625007211563	4	1	0	0
16268	1520	binding to nuclear receptor	[binding to nuclear receptors]	1.5849625007211563	4	1	0	0
16269	1520	most cell line tested;	[most cell lines tested;]	1.5849625007211563	4	1	0	0
16270	1520	aspect of hiv-1 replication	[aspects of HIV-1 replication]	1.5849625007211563	4	1	0	0
16271	1520	short-term systemic effect	[short-term systemic effects]	1.5849625007211563	3	2	1	1
16272	1520	effect for this class	[effects for this class]	1.5849625007211563	4	1	0	0
16273	1520	IFNA -produce cell	[IFNA -producing cells]	1.5849625007211563	3	1	0	0
16274	1520	human chronic lymphocytic leukemia	[human chronic lymphocytic leukemias]	1.5849625007211563	4	1	0	0
16275	1520	0.5 nm for hydrocortisone	[0.5 nM for hydrocortisone]	1.5849625007211563	4	1	0	0
16276	1520	high dose of lps	[high dose of LPS]	1.5849625007211563	4	1	0	0
16277	1520	primary human monocyte thp-1	[primary human monocytes THP-1]	1.5849625007211563	4	1	0	0
16278	1520	human myeloid cell line	[human myeloid cell lines]	1.5849625007211563	4	2	1	1
16279	1520	contain NF kappa b	[containing NF kappa B]	1.5849625007211563	4	1	0	0
16280	1520	SDS gel electrophoresis	[SDS gel electrophoresis]	1.5849625007211563	3	1	0	0
16281	1520	immune response to ad	[immune response to Ad]	1.5849625007211563	4	1	0	0
16282	1520	antigen receptor trigger	[antigen receptor triggering]	1.5849625007211563	3	1	0	0
16283	1520	LIM-only protein gene lmo	[LIM-only protein gene LMO]	1.5849625007211563	4	1	0	0
16284	1520	cortisol receptor resistance	[Cortisol receptor resistance]	1.5849625007211563	3	2	2	2
16285	1520	ifn-gamma -independent component	[IFN-gamma -independent component]	1.5849625007211563	3	1	0	0
16286	1520	cyclin D2 expression	[cyclin D2 expression]	1.5849625007211563	3	1	0	0
16287	1520	vitamin D3 vitd3	[vitamin D3 VitD3]	1.5849625007211563	3	1	0	0
16288	1520	promoter-distal site META(D+)	[promoter-distal site META(D+)]	1.5849625007211563	3	1	0	0
16289	1520	Jurkat t-cell line zap-70	[Jurkat T-cell line ZAP-70]	1.5849625007211563	4	1	0	0
16290	1520	inactivation of the inhibition	[inactivation of the inhibition]	1.5849625007211563	4	1	0	0
16291	1520	up-regulation of tnf-alpha receptor	[up-regulation of TNF-alpha receptors]	1.5849625007211563	4	1	0	0
16292	1520	contrast to the decrease	[contrast to the decrease]	1.5849625007211563	4	1	0	0
16293	1520	excess of fk506	[excess of FK506]	1.5849625007211563	3	1	0	0
16294	1520	cellular glucocorticoid receptor	[cellular glucocorticoid receptors]	1.5849625007211563	3	1	0	0
16295	1520	calcium-dependent PMA pathway	[calcium-dependent PMA pathway]	1.5849625007211563	3	1	0	0
16296	1520	rest human t-cell	[resting human T-cells]	1.5849625007211563	3	1	0	0
16297	1520	switch in vitro.	[switching in vitro.]	1.5849625007211563	3	1	0	0
16298	1520	such as tnfr1	[such as TNFR1]	1.5849625007211563	3	1	0	0
16299	1520	increase in c-jun transcript	[increase in c-jun transcripts]	1.5849625007211563	4	1	0	0
16300	1520	immunological feature indistinguishable	[immunological features indistinguishable]	1.5849625007211563	3	1	0	0
16301	1520	prolactin -inducible target gene	[prolactin -inducible target genes]	1.5849625007211563	4	1	0	0
16302	1520	MOPC immunoglobulin heavy-chain gene	[MOPC immunoglobulin heavy-chain gene]	1.5849625007211563	4	1	0	0
16303	1520	interaction with the region	[interactions with the region]	1.5849625007211563	4	2	2	2
16304	1520	three additional small region	[Three additional smaller regions]	1.5849625007211563	4	1	0	0
16305	1520	monocyte chemoattractant protein-1	[monocyte chemoattractant protein-1]	1.5849625007211563	3	3	2	1
16306	1520	include 1 secondary aml	[including 1 secondary AML]	1.5849625007211563	4	1	0	0
16307	1520	promoter of the p27kip1	[promoter of the p27Kip1]	1.5849625007211563	4	1	0	0
16308	1520	result in a increase	[resulting in an increase]	1.5849625007211563	4	2	2	2
16309	1520	c-fo gene 7-fold	[c-fos gene 7-fold]	1.5849625007211563	3	1	0	0
16310	1520	pretreatment with soluble CD4	[pretreatment with soluble CD4]	1.5849625007211563	4	1	0	0
16311	1520	ikappab alpha kinase IKKalpha	[IkappaB alpha kinases IKKalpha]	1.5849625007211563	4	1	0	0
16312	1520	multiple allelic form	[multiple allelic forms]	1.5849625007211563	3	1	0	0
16313	1520	anti-apoptotic protein eib19k	[anti-apoptotic protein EIB19K]	1.5849625007211563	3	1	0	0
16314	1520	signal transduction by DR3	[Signal transduction by DR3]	1.5849625007211563	4	1	0	0
16315	1520	development of the tissue	[development of the tissues]	1.5849625007211563	4	1	0	0
16316	1520	transcription factor closely related	[transcription factor closely related]	1.5849625007211563	4	1	0	0
16317	1520	latter two complex	[latter two complexes]	1.5849625007211563	3	1	0	0
16318	1520	constitutive tnf mrna expression	[constitutive TNF mRNA expression]	1.5849625007211563	4	1	0	0
16319	1520	il-4 in th2 cell	[IL-4 in Th2 cells]	1.5849625007211563	4	1	0	0
16320	1520	XP-B lymphoblastoid cell	[XP-B lymphoblastoid cells]	1.5849625007211563	3	1	0	0
16321	1520	important signal molecule	[important signaling molecule]	1.5849625007211563	3	2	2	2
16322	1520	cd4+ cell depletion	[CD4+ cell depletion]	1.5849625007211563	3	1	0	0
16323	1520	nuclear hormone receptor retinoid	[nuclear hormone receptor retinoid]	1.5849625007211563	4	1	0	0
16324	1520	component of nf-at	[component of NF-AT]	1.5849625007211563	3	2	1	1
16325	1520	germinal center reaction,	[germinal center reaction,]	1.5849625007211563	3	1	0	0
16326	1520	effect of GH	[effect of GH]	1.5849625007211563	3	1	0	0
16327	1520	effect of D3	[effect of D3]	1.5849625007211563	3	2	2	2
16328	1520	less pronounced, of c-rel	[less pronounced, of c-Rel]	1.5849625007211563	4	1	0	0
16329	1520	three distinct complex	[three distinct complexes]	1.5849625007211563	3	2	2	2
16330	1520	immunopathogenesis of disease	[immunopathogenesis of diseases]	1.5849625007211563	3	1	0	0
16331	1520	immunosuppressant pg490 triptolide	[Immunosuppressant PG490 triptolide]	1.5849625007211563	3	1	0	0
16332	1520	J393/ cd43 ligation	[J393/ CD43 ligation]	1.5849625007211563	3	1	0	0
16333	1520	cell-specific nuclear factor	[cell-specific nuclear factor]	1.5849625007211563	3	2	2	2
16334	1520	VLA-5 fibronectin receptor	[VLA-5 fibronectin receptor]	1.5849625007211563	3	1	0	0
16335	1520	dense lymphocyte infiltration	[dense lymphocyte infiltration]	1.5849625007211563	3	2	2	2
16336	1520	carboxy- terminal sequence	[carboxy- terminal sequences]	1.5849625007211563	3	1	0	0
16337	1520	molecular action of prolactin	[Molecular actions of prolactin]	1.5849625007211563	4	2	1	1
16338	1520	differentiation along the macrophage	[differentiation along the macrophage]	1.5849625007211563	4	1	0	0
16339	1520	modulation by heparin	[modulation by heparin]	1.5849625007211563	3	1	0	0
16340	1520	hypermethylation within the promoter	[Hypermethylation within the promoters]	1.5849625007211563	4	2	1	1
16341	1520	necessary cytokines: tnf	[necessary cytokines: TNF]	1.5849625007211563	3	1	0	0
16342	1520	NF-AT site p sequence	[NF-AT site P sequence]	1.5849625007211563	4	1	0	0
16343	1520	half-live of this rrna	[half-lives of these mRNAs]	1.5849625007211563	4	1	0	0
16344	1520	hematopoietic-specific transcription factor	[hematopoietic-specific transcription factors]	1.5849625007211563	3	1	0	0
16345	1520	il-2 secret cell	[IL-2 secreting cells]	1.5849625007211563	3	1	0	0
16346	1520	N-terminal acidic domain	[N-terminal acidic domain]	1.5849625007211563	3	2	2	2
16347	1520	subendothelium of blood vessel	[subendothelium of blood vessels]	1.5849625007211563	4	1	0	0
16348	1520	five normal human tonsil	[five normal human tonsils]	1.5849625007211563	4	1	0	0
16349	1520	Ca(2+) -dependent factor NF-ATp	[Ca(2+) -dependent factor NF-ATp]	1.5849625007211563	4	1	0	0
16350	1520	N-terminal half of MZF-2	[N-terminal half of MZF-2]	1.5849625007211563	4	2	1	1
16351	1520	antigen-dependent T cell activation	[antigen-dependent T cell activation]	1.5849625007211563	4	1	0	0
16352	1520	Proximal signal transduction event	[Proximal signal transduction events]	1.5849625007211563	4	1	0	0
16353	1520	effect on translocation	[effect on translocation]	1.5849625007211563	3	1	0	0
16354	1520	membrane proximal proline-rich domain	[membrane proximal proline-rich domain]	1.5849625007211563	4	1	0	0
16355	1520	il-5 -produce t-cell clone	[IL-5 -producing T-cell clones]	1.5849625007211563	4	1	0	0
16356	1520	cerulein-induced acute pancreatitis	[cerulein-induced acute pancreatitis]	1.5849625007211563	3	1	0	0
16357	1520	erythroid terminal maturation	[erythroid terminal maturation]	1.5849625007211563	3	1	0	0
16358	1520	fate on cell activation.	[fate on cell activation.]	1.5849625007211563	4	1	0	0
16359	1520	effect on junb mrna	[effect on junB mRNA]	1.5849625007211563	4	1	0	0
16360	1520	other immunoregulatory gene	[other immunoregulatory genes]	1.5849625007211563	3	1	0	0
16361	1520	functional 135-(oh)2d3 receptors; 2)	[functional 1,25-(OH)2D3 receptors; 2)]	1.5849625007211563	4	1	0	0
16362	1520	addition, in vitro differentiation	[addition, in vitro differentiation]	1.5849625007211563	4	1	0	0
16363	1520	role of thrombin	[role of thrombin]	1.5849625007211563	3	1	0	0
16364	1520	use Northern blotting	[Using Northern blotting]	1.5849625007211563	3	1	0	0
16365	1520	gamma response region GRR	[gamma response region GRR]	1.5849625007211563	4	1	0	0
16366	1520	IL3 5'-flanking sequence	[IL3 5'-flanking sequence]	1.5849625007211563	3	1	0	0
16367	1520	level of gr mrna	[levels of GR mRNA]	1.5849625007211563	4	1	0	0
16368	1520	nfatx1 transactivation activity	[NFATx1 transactivation activity]	1.5849625007211563	3	1	0	0
16369	1520	few immunodominant epitope	[few immunodominant epitopes]	1.5849625007211563	3	1	0	0
16370	1520	cd14 5' upstream sequence	[CD14 5' upstream sequence]	1.5849625007211563	4	1	0	0
16371	1520	stimulation of viral transcription	[stimulation of viral transcription]	1.5849625007211563	4	1	0	0
16372	1520	upstream delta-globin region	[upstream delta-globin region]	1.5849625007211563	3	1	0	0
16373	1520	glucocorticoid receptor/progesterone receptor pr	[glucocorticoid receptor/progesterone receptor PR]	1.5849625007211563	4	1	0	0
16374	1520	major myeloid lineage	[major myeloid lineages]	1.5849625007211563	3	1	0	0
16375	1520	human transcription factor tcf-1	[human transcription factor TCF-1]	1.5849625007211563	4	1	0	0
16376	1520	258 x chromosome-containing sperm	[258 X chromosome-containing sperm]	1.5849625007211563	4	1	0	0
16377	1520	effect of IL-7	[effect of IL-7]	1.5849625007211563	3	2	1	1
16378	1520	specific cis-active sequence	[specific cis-active sequences]	1.5849625007211563	3	1	0	0
16379	1520	series of event result	[series of events resulting]	1.5849625007211563	4	1	0	0
16380	1520	transcriptional induction of isg	[transcriptional induction of ISGs]	1.5849625007211563	4	1	0	0
16381	1520	pathophysiology of patient	[pathophysiology of patients]	1.5849625007211563	3	1	0	0
16382	1520	expression of the proto-oncogent	[expression of the proto-oncogenes]	1.5849625007211563	4	1	0	0
16383	1520	addition of il-10	[addition of IL-10]	1.5849625007211563	3	1	0	0
16384	1520	none of the construct	[None of the constructs]	1.5849625007211563	4	1	0	0
16385	1520	nonlymphoid hela cell	[nonlymphoid HeLa cells]	1.5849625007211563	3	1	0	0
16386	1520	addition of activation region	[addition of activation regions]	1.5849625007211563	4	1	0	0
16387	1520	many cytokine signal	[many cytokine signals]	1.5849625007211563	3	1	0	0
16388	1520	expression of Fas	[expression of Fas]	1.5849625007211563	3	1	0	0
16389	1520	Oct2 -deficient b cell	[Oct2 -deficient B cells]	1.5849625007211563	4	1	0	0
16390	1520	growth-inhibitory effect of as2o3	[growth-inhibitory effects of As2O3]	1.5849625007211563	4	1	0	0
16391	1520	physiological function of NF-kappaB	[physiological functions of NF-kappaB]	1.5849625007211563	4	1	0	0
16392	1520	gamma-gene 5'-untranslated region UTR	[gamma-gene 5'-untranslated region UTR]	1.5849625007211563	4	1	0	0
16393	1520	calcineurin -dependent activation	[calcineurin -dependent activation]	1.5849625007211563	3	1	0	0
16394	1520	evidence from several system	[Evidence from several systems]	1.5849625007211563	4	1	0	0
16395	1520	germinal center cell origin	[germinal center cell origin]	1.5849625007211563	4	1	0	0
16396	1520	IL-6 mrna level	[IL-6 mRNA levels]	1.5849625007211563	3	1	0	0
16397	1520	also in th2 cell	[also in Th2 cells]	1.5849625007211563	4	1	0	0
16398	1520	immunoprecipitation of cell extract	[Immunoprecipitation of cell extract]	1.5849625007211563	4	1	0	0
16399	1520	nuclear estrogen receptor content	[nuclear estrogen receptor content]	1.5849625007211563	4	1	0	0
16400	1520	four nucleotide dr+4	[four nucleotides DR+4]	1.5849625007211563	3	1	0	0
16401	1520	cytokine to leukemic cells.	[cytokines to leukemic cells.]	1.5849625007211563	4	1	0	0
16402	1520	cellular morphological change	[cellular morphological changes]	1.5849625007211563	3	1	0	0
16403	1520	vivo protein binding	[vivo protein binding]	1.5849625007211563	3	1	0	0
16404	1520	initiation of proliferation	[Initiation of proliferation]	1.5849625007211563	3	1	0	0
16405	1520	important role for abnormality	[important role for abnormalities]	1.5849625007211563	4	1	0	0
16406	1520	gene structure of LOX-1	[gene structure of LOX-1]	1.5849625007211563	4	1	0	0
16407	1520	first 2 h	[first 2 h]	1.5849625007211563	3	1	0	0
16408	1520	latent membrane protein lmp2	[latent membrane protein LMP2]	1.5849625007211563	4	1	0	0
16409	1520	distinct pattern of chromosome	[distinct patterns of chromosome]	1.5849625007211563	4	1	0	0
16410	1520	platelet low-affinity igg receptor	[platelet low-affinity IgG receptor]	1.5849625007211563	4	1	0	0
16411	1520	novel c/ebp-epsilon transcription factor	[novel C/EBP-epsilon transcription factor]	1.5849625007211563	4	1	0	0
16412	1520	wide variety of genes.	[wide variety of genes.]	1.5849625007211563	4	1	0	0
16413	1520	T a function	[T a function]	1.5849625007211563	3	1	0	0
16414	1520	predominantly megakaryoblastic phenotype	[predominantly megakaryoblastic phenotype]	1.5849625007211563	3	1	0	0
16415	1520	full-length protein as p97	[full-length protein as p97]	1.5849625007211563	4	1	0	0
16416	1520	hiv promoter in vivo.	[HIV promoter in vivo.]	1.5849625007211563	4	1	0	0
16417	1520	difference to the transactivation	[difference to the transactivation]	1.5849625007211563	4	1	0	0
16418	1520	other hand, in culture	[other hand, in cultures]	1.5849625007211563	4	1	0	0
16419	1520	chronic myelogenous leukaemia	[chronic myelogenous leukaemia]	1.5849625007211563	3	2	1	1
16420	1520	other composite element	[other composite elements]	1.5849625007211563	3	1	0	0
16421	1520	redundancy in the function	[redundancy in the function]	1.5849625007211563	4	1	0	0
16422	1520	red cell development	[red cell development]	1.5849625007211563	3	1	0	0
16423	1520	expression of hiv-1	[expression of HIV-1]	1.5849625007211563	3	1	0	0
16424	1520	common allelic variant	[common allelic variants]	1.5849625007211563	3	1	0	0
16425	1520	role of ptdin 3-kinase	[role of PtdIns 3-kinase]	1.5849625007211563	4	1	0	0
16426	1520	mammalian type-C retroviruse	[mammalian type-C retroviruses]	1.5849625007211563	3	1	0	0
16427	1520	oestrogen receptor codon	[oestrogen receptor codon]	1.5849625007211563	3	1	0	0
16428	1520	receptor agonist collagen	[receptor agonist collagen]	1.5849625007211563	3	1	0	0
16429	1520	other N-Oct factor	[other N-Oct factors]	1.5849625007211563	3	1	0	0
16430	1520	RAR alpha during myelopoiesis	[RAR alpha during myelopoiesis]	1.5849625007211563	4	1	0	0
16431	1520	inducible dna-binding protein	[inducible DNA-binding protein]	1.5849625007211563	3	1	0	0
16432	1520	preleukemic T cell	[preleukemic T cells]	1.5849625007211563	3	1	0	0
16433	1520	T-lymphocytic ach-2 cell	[T-lymphocytic ACH-2 cells]	1.5849625007211563	3	1	0	0
16434	1520	eukaryotic vector suitable	[eukaryotic vectors suitable]	1.5849625007211563	3	1	0	0
16435	1520	sometimes contain follicular DC	[sometimes containing follicular DC]	1.5849625007211563	4	1	0	0
16436	1520	expression of FOG	[Expression of FOG]	1.5849625007211563	3	1	0	0
16437	1520	luciferase reporter construct	[luciferase reporter construct]	1.5849625007211563	3	2	2	2
16438	1520	il-12 -nonresponsive th cell	[IL-12 -nonresponsive Th cells]	1.5849625007211563	4	1	0	0
16439	1520	Similarly, STAT1 -stat3 heterocomplex	[Similarly, STAT1 -STAT3 heterocomplexes]	1.5849625007211563	4	1	0	0
16440	1520	three cell lines.	[three cell lines.]	1.5849625007211563	3	1	0	0
16441	1520	engagement of surface immunoglobulin	[Engagement of surface immunoglobulin]	1.5849625007211563	4	1	0	0
16442	1520	peak of a infection	[peak of an infection]	1.5849625007211563	4	1	0	0
16443	1520	30 patient with fibroadenomas	[30 patients with fibroadenomas]	1.5849625007211563	4	1	0	0
16444	1520	growth of granulocytes,	[growth of granulocytes,]	1.5849625007211563	3	1	0	0
16445	1520	specific glucocorticoid binding	[specific glucocorticoid binding]	1.5849625007211563	3	2	1	1
16446	1520	shut-down of pax-5 transcription	[shut-down of PAX-5 transcription]	1.5849625007211563	4	1	0	0
16447	1520	anti-CD3 in murine thymocyte	[anti-CD3 in murine thymocytes]	1.5849625007211563	4	1	0	0
16448	1520	corneal endothelial cell	[corneal endothelial cells]	1.5849625007211563	3	2	1	1
16449	1520	ester response element	[ester response elements]	1.5849625007211563	3	1	0	0
16450	1520	model for monocyte differentiation	[model for monocyte differentiation]	1.5849625007211563	4	1	0	0
16451	1520	il-2r alpha mrna	[IL-2R alpha mRNA]	1.5849625007211563	3	1	0	0
16452	1520	gc cell death.	[GC cell death.]	1.5849625007211563	3	1	0	0
16453	1520	turn on il-2 expression	[turning on IL-2 expression]	1.5849625007211563	4	1	0	0
16454	1520	promoter of lymphokine gene	[promoter of lymphokine genes]	1.5849625007211563	4	1	0	0
16455	1520	C57BL/10 (b10) mouse	[C57BL/10 (B10) mice]	1.5849625007211563	3	1	0	0
16456	1520	target bhlh specificity	[target bHLH specificity]	1.5849625007211563	3	1	0	0
16457	1520	similarity between IL-4	[similarities between IL-4]	1.5849625007211563	3	1	0	0
16458	1520	vaginal host defense:	[vaginal host defense:]	1.5849625007211563	3	1	0	0
16459	1520	wild-type (wt) cell	[Wild-type (wt) cells]	1.5849625007211563	3	1	0	0
16460	1520	such as delayed-type hypersensitivity	[such as delayed-type hypersensitivity]	1.5849625007211563	4	1	0	0
16461	1520	prevalence of er overexpression	[prevalence of ER overexpression]	1.5849625007211563	4	1	0	0
16462	1520	subpopulation of peroxidase-negative granule	[subpopulation of peroxidase-negative granules]	1.5849625007211563	4	1	0	0
16463	1520	endothelial-RAW264.7 coculture system	[endothelial-RAW264.7 coculture system]	1.5849625007211563	3	1	0	0
16464	1520	zap-70 /Syk-deficient jurkat cell	[ZAP-70 /Syk-deficient Jurkat cells]	1.5849625007211563	4	1	0	0
16465	1520	transformation of b cell	[transformation of B cells]	1.5849625007211563	4	2	2	2
16466	1520	suppressive transcriptional effect	[suppressive transcriptional effect]	1.5849625007211563	3	1	0	0
16467	1520	primary T cell consistent	[primary T cells consistent]	1.5849625007211563	4	1	0	0
16468	1520	number of GR	[number of GR]	1.5849625007211563	3	2	1	1
16469	1520	posttraumatic stress disorder ptsd	[posttraumatic stress disorder PTSD]	1.5849625007211563	4	1	0	0
16470	1520	GATA-1 binding site	[GATA-1 binding sites]	1.5849625007211563	3	1	0	0
16471	1520	set of band range	[set of bands ranging]	1.5849625007211563	4	1	0	0
16472	1520	about 65-75 kda	[about 65-75 kDa]	1.5849625007211563	3	1	0	0
16473	1520	presence of amino acid	[presence of amino acids]	1.5849625007211563	4	1	0	0
16474	1520	stimulation with calcium ionophore	[stimulation with calcium ionophore]	1.5849625007211563	4	1	0	0
16475	1520	presence of variant	[presence of variants]	1.5849625007211563	3	1	0	0
16476	1520	such as adhesion molecule	[such as adhesion molecule]	1.5849625007211563	4	1	0	0
16477	1520	proliferation after stimulation	[proliferation after stimulation]	1.5849625007211563	3	1	0	0
16478	1520	control of a combination	[control of a combination]	1.5849625007211563	4	1	0	0
16479	1520	different techniques: western blot	[different techniques: Western blot]	1.5849625007211563	4	1	0	0
16480	1520	p -like element	[P -like elements]	1.5849625007211563	3	1	0	0
16481	1520	patient under adjuvant treatment	[patients under adjuvant treatment]	1.5849625007211563	4	1	0	0
16482	1520	results: gel-shift analysis	[RESULTS: Gel-shift analyses]	1.5849625007211563	3	1	0	0
16483	1520	suggest a critical role	[suggesting a critical role]	1.5849625007211563	4	1	0	0
16484	1520	efficient c-fo induction	[efficient c-fos induction]	1.5849625007211563	3	1	0	0
16485	1520	powerful microbicidal pathway	[powerful microbicidal pathway]	1.5849625007211563	3	1	0	0
16486	1520	regulation of immunoglobulin gene	[regulation of immunoglobulin genes]	1.5849625007211563	4	2	1	1
16487	1520	presence of progesterone	[presence of progesterone]	1.5849625007211563	3	1	0	0
16488	1520	erythroid-enriched nf-e2 factor	[erythroid-enriched NF-E2 factor]	1.5849625007211563	3	1	0	0
16489	1520	viable alternative to promoter	[viable alternatives to promoters]	1.5849625007211563	4	1	0	0
16490	1520	domain i-binding factor-1	[domain I-binding factor-1]	1.5849625007211563	3	2	2	2
16491	1520	M-TAT/EPO cell culture	[M-TAT/EPO cell culture]	1.5849625007211563	3	1	0	0
16492	1520	decrease follow hydrocortisone injection	[decrease following hydrocortisone injection]	1.5849625007211563	4	1	0	0
16493	1520	3 band q26	[3 band q26]	1.5849625007211563	3	1	0	0
16494	1520	GATA-3 transcriptional initiation site	[GATA-3 transcriptional initiation site]	1.5849625007211563	4	1	0	0
16495	1520	several E-protein family member	[several E-protein family members]	1.5849625007211563	4	1	0	0
16496	1520	inability of this chromosome	[inability of these chromosomes]	1.5849625007211563	4	1	0	0
16497	1520	ability of qp	[ability of Qp]	1.5849625007211563	3	1	0	0
16498	1520	mature b-cell line bal-17	[mature B-cell line BAL-17]	1.5849625007211563	4	1	0	0
16499	1520	[Cortisone-resistant bronchial asthma]	[[Cortisone-resistant bronchial asthma]]	1.5849625007211563	3	1	0	0
16500	1520	ets dna-binding domain common	[ETS DNA-binding domain common]	1.5849625007211563	4	1	0	0
16501	1520	complex role for VitD3	[complex role for VitD3]	1.5849625007211563	4	1	0	0
16502	1520	persistent hepatitis b infection	[persistent hepatitis B infection]	1.5849625007211563	4	1	0	0
16503	1520	nuclear receptor protein	[nuclear receptor proteins]	1.5849625007211563	3	2	1	1
16504	1520	BZLF 1 trans-activator Zta	[BZLF 1 trans-activator Zta]	1.5849625007211563	4	1	0	0
16505	1520	Functional study in cell	[Functional studies in cells]	1.5849625007211563	4	2	2	2
16506	1520	rrna encode GATA-1	[mRNAs encoding GATA-1]	1.5849625007211563	3	1	0	0
16507	1520	map kinase-specific phosphatase mkp-1	[MAP kinase-specific phosphatase MKP-1]	1.5849625007211563	4	1	0	0
16508	1520	maximal il-2 promoter activity	[maximal IL-2 promoter activity]	1.5849625007211563	4	1	0	0
16509	1520	Charcot-Leyden crystal (clc) protein	[Charcot-Leyden crystal (CLC) protein]	1.5849625007211563	4	1	0	0
16510	1520	"two-handed" zinc finger protein	["two-handed" zinc finger protein]	1.5849625007211563	4	1	0	0
16511	1520	plasmacytoma cell line	[plasmacytoma cell lines]	1.5849625007211563	3	1	0	0
16512	1520	hiv-1 strain iiib	[HIV-1 strain IIIB]	1.5849625007211563	3	1	0	0
16513	1520	gastric epithelial cell	[gastric epithelial cells]	1.5849625007211563	3	1	0	0
16514	1520	level of nuclear p62c-fo	[levels of nuclear p62c-fos]	1.5849625007211563	4	1	0	0
16515	1520	follow the differentiation	[following the differentiation]	1.5849625007211563	3	2	1	1
16516	1520	gc b-cell phenotype	[GC B-cell phenotype]	1.5849625007211563	3	1	0	0
16517	1520	maximum activity of CBF	[maximum activity of CBF]	1.5849625007211563	4	1	0	0
16518	1520	normal erythroid progenitor	[normal erythroid progenitors]	1.5849625007211563	3	2	1	1
16519	1520	increase in tetrahydrocortisone mg/24h;	[increase in tetrahydrocortisone mg/24h;]	1.5849625007211563	4	1	0	0
16520	1520	plasma ANH level	[plasma ANH level]	1.5849625007211563	3	1	0	0
16521	1520	deletion of autoreactive thymocyte	[deletion of autoreactive thymocytes]	1.5849625007211563	4	1	0	0
16522	1520	induction of a number	[induction of a number]	1.5849625007211563	4	1	0	0
16523	1520	bcl-2 gene a repressor	[bcl-2 gene a repressor]	1.5849625007211563	4	1	0	0
16524	1520	restoration of terminal differentiation	[Restoration of terminal differentiation]	1.5849625007211563	4	1	0	0
16525	1520	control, htlv-i(-) t-cell line	[control, HTLV-I(-) T-cell lines]	1.5849625007211563	4	1	0	0
16526	1520	absence of gata-1	[absence of GATA-1]	1.5849625007211563	3	1	0	0
16527	1520	three ig gene	[three Ig genes]	1.5849625007211563	3	1	0	0
16528	1520	kappa 1-kappa 3	[kappa 1-kappa 3]	1.5849625007211563	3	2	2	2
16529	1520	synthetic dna-binding ligand	[synthetic DNA-binding ligands]	1.5849625007211563	3	1	0	0
16530	1520	element conferr DNA binding	[element conferring DNA binding]	1.5849625007211563	4	1	0	0
16531	1520	NFATp -binding site	[NFATp -binding sites]	1.5849625007211563	3	2	2	2
16532	1520	gr in blood leukocyte	[GR in blood leukocytes]	1.5849625007211563	4	2	2	2
16533	1520	60 to 90 minute	[60 to 90 minutes]	1.5849625007211563	4	1	0	0
16534	1520	1 -mediated growth	[1 -mediated growth]	1.5849625007211563	3	2	1	1
16535	1520	acetyl salicylic acid asa	[acetyl salicylic acid ASA]	1.5849625007211563	4	1	0	0
16536	1520	developmental event in yeast	[developmental events in yeast]	1.5849625007211563	4	1	0	0
16537	1520	intrinsic transcriptional activation domain	[intrinsic transcriptional activation domain]	1.5849625007211563	4	1	0	0
16538	1520	concentration 100-fold low	[concentration 100-fold lower]	1.5849625007211563	3	1	0	0
16539	1520	nuclear extract-DNA complex	[nuclear extract-DNA complexes]	1.5849625007211563	3	2	2	2
16540	1520	role in maturation	[role in maturation]	1.5849625007211563	3	2	2	2
16541	1520	musculin expression in embryo	[musculin expression in embryos]	1.5849625007211563	4	1	0	0
16542	1520	important immunoregulatory gene	[important immunoregulatory gene]	1.5849625007211563	3	1	0	0
16543	1520	rante gene expression	[RANTES gene expression]	1.5849625007211563	3	2	1	1
16544	1520	native il-2 enhancer	[native IL-2 enhancer]	1.5849625007211563	3	1	0	0
16545	1520	overall topographical distribution	[overall topographical distributions]	1.5849625007211563	3	1	0	0
16546	1520	Th2 type response	[Th2 type response]	1.5849625007211563	3	1	0	0
16547	1520	primarily by transcriptional means	[primarily by transcriptional means]	1.5849625007211563	4	1	0	0
16548	1520	other octamer factor variant	[other octamer factor variants]	1.5849625007211563	4	1	0	0
16549	1520	C/EBP family of regulator	[C/EBP family of regulators]	1.5849625007211563	4	1	0	0
16550	1520	significant anti inflammatory activity	[significant anti inflammatory activity]	1.5849625007211563	4	1	0	0
16551	1520	regulation of c-fo	[regulation of c-fos]	1.5849625007211563	3	2	2	2
16552	1520	vitamin d-responsive cell line	[vitamin D-responsive cell line]	1.5849625007211563	4	1	0	0
16553	1520	atra -responsive true APL	[ATRA -responsive true APL]	1.5849625007211563	4	1	0	0
16554	1520	inhibition of PKC	[inhibition of PKC]	1.5849625007211563	3	2	1	1
16555	1520	human cytomegalovirus ie2 protein	[human cytomegalovirus IE2 protein]	1.5849625007211563	4	1	0	0
16556	1520	lps stimulation in monocyte	[LPS stimulation in monocytes]	1.5849625007211563	4	2	2	2
16557	1520	high-level zeta 2	[high-level zeta 2]	1.5849625007211563	3	1	0	0
16558	1520	integration of signal	[integration of signals]	1.5849625007211563	3	2	2	2
16559	1520	human hla-dq class ii	[human HLA-DQ class II]	1.5849625007211563	4	1	0	0
16560	1520	raw264.7 macrophage-like cell	[RAW264.7 macrophage-like cells]	1.5849625007211563	3	1	0	0
16561	1520	constitutive nf-kappab dna-binding activity	[constitutive NF-kappaB DNA-binding activity]	1.5849625007211563	4	1	0	0
16562	1520	SCL protein production	[SCL protein production]	1.5849625007211563	3	1	0	0
16563	1520	differentiation of T cell	[differentiation of T cells]	1.5849625007211563	4	2	1	1
16564	1520	cho-cd80 like anti-CD28 mab	[CHO-CD80 like anti-CD28 mAb]	1.5849625007211563	4	1	0	0
16565	1520	clonally expand population	[clonally expanding populations]	1.5849625007211563	3	1	0	0
16566	1520	LIM domain of rhombotin	[LIM domain of rhombotin]	1.5849625007211563	4	1	0	0
16567	1520	mu enhancer activation	[mu enhancer activation]	1.5849625007211563	3	1	0	0
16568	1520	E1a reiteration mutant	[E1a reiteration mutants]	1.5849625007211563	3	1	0	0
16569	1520	three splice alternative	[three splice alternatives]	1.5849625007211563	3	1	0	0
16570	1520	Fos kinase phosphorylate c-fo	[Fos kinase phosphorylates c-Fos]	1.5849625007211563	4	1	0	0
16571	1520	rotamase activity of fkbp	[rotamase activity of FKBP]	1.5849625007211563	4	2	1	1
16572	1520	activity of a element	[activity of a element]	1.5849625007211563	4	1	0	0
16573	1520	interleukin (il)-2 promoter activity	[interleukin (IL)-2 promoter activity]	1.5849625007211563	4	1	0	0
16574	1520	expression in megakaryocyte	[expression in megakaryocytes]	1.5849625007211563	3	1	0	0
16575	1520	human dermal cell	[human dermal cells]	1.5849625007211563	3	1	0	0
16576	1520	specificity of HePTP	[specificity of HePTP]	1.5849625007211563	3	1	0	0
16577	1520	8 cases, constitutive DNA	[8 cases, constitutive DNA]	1.5849625007211563	4	1	0	0
16578	1520	cause of morbidity	[cause of morbidity]	1.5849625007211563	3	2	2	2
16579	1520	sterile culture media	[sterile culture media]	1.5849625007211563	3	1	0	0
16580	1520	15 minute of stimulation.	[15 min of stimulation.]	1.5849625007211563	4	1	0	0
16581	1520	intracellular localization of Nef	[intracellular localization of Nef]	1.5849625007211563	4	1	0	0
16582	1520	patient with cushingd' disease	[patients with Cushing's disease]	1.5849625007211563	4	2	2	2
16583	1520	wide range of gene	[wide range of genes]	1.5849625007211563	4	1	0	0
16584	1520	anoxia /reoxygenation A/R	[anoxia /reoxygenation A/R]	1.5849625007211563	3	1	0	0
16585	1520	development of the disease,	[development of the disease,]	1.5849625007211563	4	1	0	0
16586	1520	regulation of differentiation	[regulation of differentiation]	1.5849625007211563	3	2	2	2
16587	1520	role of this channel	[role of these channels]	1.5849625007211563	4	1	0	0
16588	1520	E2A- HLF protein	[E2A- HLF proteins]	1.5849625007211563	3	1	0	0
16589	1520	part of the armamentarium	[part of the armamentarium]	1.5849625007211563	4	1	0	0
16590	1520	cell type include lymphocyte	[cell types including lymphocytes]	1.5849625007211563	4	1	0	0
16591	1520	activation of distinct set	[activation of distinct sets]	1.5849625007211563	4	1	0	0
16592	1520	neutrophil -to-tumor cell binding	[neutrophil -to-tumor cell binding]	1.5849625007211563	4	1	0	0
16593	1520	treatment with retinoic acid	[treatment with retinoic acid]	1.5849625007211563	4	2	1	1
16594	1520	differentiation of myeloid precursor	[differentiation of myeloid precursors]	1.5849625007211563	4	1	0	0
16595	1520	contain a CpG-rich island	[containing a CpG-rich island]	1.5849625007211563	4	1	0	0
16596	1520	status of the site	[status of the site]	1.5849625007211563	4	1	0	0
16597	1520	suggest essential for oncogenesis	[suggesting essential for oncogenesis]	1.5849625007211563	4	1	0	0
16598	1520	t-lymphocyte-depleted spleen cell	[T-lymphocyte-depleted spleen cells]	1.5849625007211563	3	1	0	0
16599	1520	action of gcs	[action of GCS]	1.5849625007211563	3	1	0	0
16600	1520	M10 -express cell line	[M10 -expressing cell lines]	1.5849625007211563	4	1	0	0
16601	1520	three motifs, a	[three motifs, A]	1.5849625007211563	3	1	0	0
16602	1520	stability of rela(p65) mrna	[stability of RelA(p65) mRNA]	1.5849625007211563	4	1	0	0
16603	1520	one site (-213)	[one site (-213)]	1.5849625007211563	3	1	0	0
16604	1520	cd14 gene regulation	[CD14 gene regulation]	1.5849625007211563	3	1	0	0
16605	1520	site of infection	[site of infection]	1.5849625007211563	3	2	2	2
16606	1520	significant internucleosomal DNA fragmentation	[significant internucleosomal DNA fragmentation]	1.5849625007211563	4	1	0	0
16607	1520	only weakly with Jak3	[only weakly with Jak3]	1.5849625007211563	4	1	0	0
16608	1520	sensitization of T cell	[sensitization of T cells]	1.5849625007211563	4	2	1	1
16609	1520	interleukin-1 il-1 stimulation	[interleukin-1 IL-1 stimulation]	1.5849625007211563	3	1	0	0
16610	1520	interleukin-2 receptor alpha-chain enhancer	[interleukin-2 receptor alpha-chain enhancer]	1.5849625007211563	4	1	0	0
16611	1520	deficient b-cell line	[deficient B-cell lines]	1.5849625007211563	3	1	0	0
16612	1520	cytosol of T cell	[cytosols of T cells]	1.5849625007211563	4	1	0	0
16613	1520	2 h of treatment.	[2 h of treatment.]	1.5849625007211563	4	1	0	0
16614	1520	B-lymphoid cell line	[B-lymphoid cell lines]	1.5849625007211563	3	1	0	0
16615	1520	p24rex of HTLV-II	[p24rex of HTLV-II]	1.5849625007211563	3	1	0	0
16616	1520	fact, mAb l243	[fact, mAb L243]	1.5849625007211563	3	1	0	0
16617	1520	double point mutation	[double point mutation]	1.5849625007211563	3	1	0	0
16618	1520	multiple cytokine gene	[multiple cytokine genes]	1.5849625007211563	3	1	0	0
16619	1520	two isoforms, hsf2-alpha	[two isoforms, HSF2-alpha]	1.5849625007211563	3	1	0	0
16620	1520	high amount of stat1	[higher amounts of STAT1]	1.5849625007211563	4	1	0	0
16621	1520	also in neural development	[also in neural development]	1.5849625007211563	4	1	0	0
16622	1520	significant level of il-2	[significant levels of IL-2]	1.5849625007211563	4	1	0	0
16623	1520	il-4 signal in patient	[IL-4 signaling in patients]	1.5849625007211563	4	1	0	0
16624	1520	down-regulation of nf-kappab complex	[down-regulation of NF-kappaB complexes]	1.5849625007211563	4	1	0	0
16625	1520	nf-kappa b2 (p100)	[NF-kappa B2 (p100)]	1.5849625007211563	3	1	0	0
16626	1520	mother of baby	[mothers of babies]	1.5849625007211563	3	1	0	0
16627	1520	estrogen receptor concentration	[estrogen receptor concentration]	1.5849625007211563	3	2	1	1
16628	1520	primary target of Dex	[primary target of Dex]	1.5849625007211563	4	1	0	0
16629	1520	induce hiv-1 replication	[inducing HIV-1 replication]	1.5849625007211563	3	1	0	0
16630	1520	CTL from BALB/c mouse	[CTLs from BALB/c mice]	1.5849625007211563	4	1	0	0
16631	1520	viral latent gene	[viral latent genes]	1.5849625007211563	3	1	0	0
16632	1520	707-base pair silencer	[707-base pair silencer]	1.5849625007211563	3	1	0	0
16633	1520	several leukemia cell line	[Several leukemia cell lines]	1.5849625007211563	4	2	2	2
16634	1520	mature human monocyte	[mature human monocytes]	1.5849625007211563	3	1	0	0
16635	1520	astrocyte from wild-type mouse	[astrocytes from wild-type mice]	1.5849625007211563	4	1	0	0
16636	1520	transcription from various globin	[transcription from various globin]	1.5849625007211563	4	1	0	0
16637	1520	hygromycin resistance gene	[hygromycin resistance gene]	1.5849625007211563	3	1	0	0
16638	1520	binding to epo receptor	[binding to EPO receptor]	1.5849625007211563	4	1	0	0
16639	1520	tumour suppressor gene	[tumour suppressor genes]	1.5849625007211563	3	1	0	0
16640	1520	molecule -t cell interaction	[molecule -T cell interactions]	1.5849625007211563	4	1	0	0
16641	1520	common occurrence in t(3;3)	[common occurrence in t(3;3)]	1.5849625007211563	4	1	0	0
16642	1520	imbalance exists, haptenation	[imbalance exists, haptenation]	1.5849625007211563	3	1	0	0
16643	1520	human TF promoter	[human TF promoter]	1.5849625007211563	3	1	0	0
16644	1520	impairment of nkl cytotoxicity	[impairment of NKL cytotoxicity]	1.5849625007211563	4	1	0	0
16645	1520	transcription factor kappa b	[transcription factor kappa B]	1.5849625007211563	4	2	2	2
16646	1520	action of glucocorticoid therapy	[action of glucocorticoid therapy]	1.5849625007211563	4	1	0	0
16647	1520	blood cell platelet	[blood cells platelets]	1.5849625007211563	3	1	0	0
16648	1520	effect of p21ras	[effects of p21ras]	1.5849625007211563	3	1	0	0
16649	1520	critical role control level	[critical role controlling levels]	1.5849625007211563	4	1	0	0
16650	1520	patient with chronic disease	[patients with chronic diseases]	1.5849625007211563	4	2	2	2
16651	1520	wildtype aes sequence	[wildtype AES sequence]	1.5849625007211563	3	1	0	0
16652	1520	cell from nonhuman primate	[cells from nonhuman primates]	1.5849625007211563	4	1	0	0
16653	1520	-47 to -40 upstream	[-47 to -40 upstream]	1.5849625007211563	4	1	0	0
16654	1520	limit dilution cloning	[limiting dilution cloning]	1.5849625007211563	3	1	0	0
16655	1520	fluticasone propionate fp	[fluticasone propionate FP]	1.5849625007211563	3	2	1	1
16656	1520	several signal pathway	[several signaling pathways]	1.5849625007211563	3	1	0	0
16657	1520	cell line UT-7	[cell line UT-7]	1.5849625007211563	3	2	2	2
16658	1520	T-leukemia cell line	[T-leukemia cell line]	1.5849625007211563	3	1	0	0
16659	1520	human mononuclear leukocyte hml	[human mononuclear leukocytes HML]	1.5849625007211563	4	1	0	0
16660	1520	nf- il-6 activity	[NF- IL-6 activity]	1.5849625007211563	3	1	0	0
16661	1520	2/6 sarcoidosis patient	[2/6 sarcoidosis patients]	1.5849625007211563	3	1	0	0
16662	1520	kappa light chain locus	[kappa light chain locus]	1.5849625007211563	4	1	0	0
16663	1520	other human tissue	[other human tissues]	1.5849625007211563	3	1	0	0
16664	1520	form of stat1	[form of STAT1]	1.5849625007211563	3	1	0	0
16665	1520	potential antiviral effect	[potential antiviral effects]	1.5849625007211563	3	1	0	0
16666	1520	form of stat3	[form of STAT3]	1.5849625007211563	3	2	1	1
16667	1520	transcriptional factor AP-1	[transcriptional factors AP-1]	1.5849625007211563	3	1	0	0
16668	1520	parental hl60 cell	[parental HL60 cells]	1.5849625007211563	3	1	0	0
16669	1520	difference in the intensity	[differences in the intensity]	1.5849625007211563	4	1	0	0
16670	1520	60 male subject	[60 male subjects]	1.5849625007211563	3	1	0	0
16671	1520	adult t-cell lymphoma/leukemia ATLL	[adult T-cell lymphoma/leukemia ATLL]	1.5849625007211563	4	1	0	0
16672	1520	3.5 fmol/10(6) cells).	[3.5 fmol/10(6) cells).]	1.5849625007211563	3	1	0	0
16673	1520	aldosterone on sodium	[aldosterone on sodium]	1.5849625007211563	3	2	2	2
16674	1520	206 high risk woman	[206 high risk women]	1.5849625007211563	4	1	0	0
16675	1520	bcl-2 family protein	[Bcl-2 family proteins]	1.5849625007211563	3	1	0	0
16676	1520	concentration of viral protein	[concentrations of viral proteins]	1.5849625007211563	4	1	0	0
16677	1520	observations, coexpression of form	[observations, coexpression of forms]	1.5849625007211563	4	1	0	0
16678	1520	coincubate the monocyte	[coincubating the monocytes]	1.5849625007211563	3	1	0	0
16679	1520	G(Anh)MTetra il-6 mrna expression	[G(Anh)MTetra IL-6 mRNA expression]	1.5849625007211563	4	1	0	0
16680	1520	TNF/neuron growth factor	[TNF/neuron growth factor]	1.5849625007211563	3	1	0	0
16681	1520	basal plasma corticosterone level	[basal plasma corticosterone levels]	1.5849625007211563	4	1	0	0
16682	1520	b cell-specific complex	[B cell-specific complex]	1.5849625007211563	3	1	0	0
16683	1520	Glucocorticoid receptor characteristic	[Glucocorticoid receptor characteristics]	1.5849625007211563	3	2	1	1
16684	1520	vitamin d-responsive element vdre	[vitamin D-responsive element VDRE]	1.5849625007211563	4	1	0	0
16685	1520	expression of htlv-1 tax	[Expression of HTLV-1 tax]	1.5849625007211563	4	1	0	0
16686	1520	small animal model	[small animal models]	1.5849625007211563	3	1	0	0
16687	1520	57- to 53-kd protein	[57- to 53-kD proteins]	1.5849625007211563	4	1	0	0
16688	1520	IL-6 production, expression level	[IL-6 production, expression level]	1.5849625007211563	4	1	0	0
16689	1520	inhibitor of b activity	[inhibitor of B activity]	1.5849625007211563	4	1	0	0
16690	1520	cooperation between R	[cooperation between R]	1.5849625007211563	3	1	0	0
16691	1520	mediator of the response	[mediator of the response]	1.5849625007211563	4	2	2	2
16692	1520	phosphorylation at one	[phosphorylation at one]	1.5849625007211563	3	1	0	0
16693	1520	thrombin receptor agonist peptide	[Thrombin receptor agonist peptide]	1.5849625007211563	4	2	1	1
16694	1520	cell against bq cytotoxicity	[cells against BQ cytotoxicity]	1.5849625007211563	4	1	0	0
16695	1520	behavior of cell	[behavior of cells]	1.5849625007211563	3	1	0	0
16696	1520	wild-type ifngr1 allele	[wild-type IFNGR1 allele]	1.5849625007211563	3	1	0	0
16697	1520	dominant negative inhibitor	[dominant negative inhibitor]	1.5849625007211563	3	2	1	1
16698	1520	slow rate in cell	[slow rate in cells]	1.5849625007211563	4	1	0	0
16699	1520	normal t-lineage lymphocyte	[normal T-lineage lymphocytes]	1.5849625007211563	3	1	0	0
16700	1520	inhibitory kappaB-alpha IkappaB-alpha	[inhibitory kappaB-alpha IkappaB-alpha]	1.5849625007211563	3	1	0	0
16701	1520	cytotoxic cytokine synthesis	[cytotoxic cytokine synthesis]	1.5849625007211563	3	1	0	0
16702	1520	activity of t3	[activity of T3]	1.5849625007211563	3	1	0	0
16703	1520	several cytokine receptor	[several cytokine receptors]	1.5849625007211563	3	2	2	2
16704	1520	U alpha S	[U alpha S]	1.5849625007211563	3	2	1	1
16705	1520	adhesion of cell	[adhesion of cells]	1.5849625007211563	3	2	2	2
16706	1520	sensitivity of antigen recognition	[sensitivity of antigen recognition]	1.5849625007211563	4	1	0	0
16707	1520	primary lymphocyte culture	[Primary lymphocyte cultures]	1.5849625007211563	3	1	0	0
16708	1520	multiple hematopoietic lineage	[multiple hematopoietic lineages]	1.5849625007211563	3	1	0	0
16709	1520	natural calcineurin docking site	[natural calcineurin docking site]	1.5849625007211563	4	1	0	0
16710	1520	regulate leukocyte gene expression	[regulating leukocytes gene expression]	1.5849625007211563	4	1	0	0
16711	1520	staurosporine -sensitive kinase	[staurosporine -sensitive kinase]	1.5849625007211563	3	1	0	0
16712	1520	ubiquitin carrier enzyme e214k	[ubiquitin carrier enzymes E214K]	1.5849625007211563	4	1	0	0
16713	1520	overlapping Sp1/ Egr-1 site	[overlapping Sp1/ Egr-1 site]	1.5849625007211563	4	1	0	0
16714	1520	critical role for Sp1	[critical role for Sp1]	1.5849625007211563	4	1	0	0
16715	1520	U alpha A	[U alpha A]	1.5849625007211563	3	1	0	0
16716	1520	Ter positive cell	[Ter positive cells]	1.5849625007211563	3	2	2	2
16717	1520	product of distinct genes,	[products of distinct genes,]	1.5849625007211563	4	1	0	0
16718	1520	tumor-specific immune response	[tumor-specific immune responses]	1.5849625007211563	3	1	0	0
16719	1520	nuclear appearance of RelB	[nuclear appearance of RelB]	1.5849625007211563	4	1	0	0
16720	1520	J region gene segment	[J region gene segments]	1.5849625007211563	4	1	0	0
16721	1520	expansion of choriocarcinoma	[expansion of choriocarcinoma]	1.5849625007211563	3	1	0	0
16722	1520	monitor residual disease	[monitoring residual disease]	1.5849625007211563	3	1	0	0
16723	1520	nf-kappa B/Rel nuclear activity	[NF-kappa B/Rel nuclear activity]	1.5849625007211563	4	1	0	0
16724	1520	CD95-dependent cold shock pathway	[CD95-dependent cold shock pathways]	1.5849625007211563	4	1	0	0
16725	1520	use ig enhancer	[using Ig enhancer]	1.5849625007211563	3	1	0	0
16726	1520	respect to follicular phase	[respect to follicular phases]	1.5849625007211563	4	1	0	0
16727	1520	property of OCA-B	[properties of OCA-B]	1.5849625007211563	3	1	0	0
16728	1520	14 active sle	[14 active SLE]	1.5849625007211563	3	1	0	0
16729	1520	epithelium of normal	[epithelium of normals]	1.5849625007211563	3	2	2	2
16730	1520	presence of the DCR	[presence of the DCR]	1.5849625007211563	4	1	0	0
16731	1520	underlying regulatory mechanism	[underlying regulatory mechanism]	1.5849625007211563	3	1	0	0
16732	1520	tat- LTR transcription	[Tat- LTR transcription]	1.5849625007211563	3	1	0	0
16733	1520	p50 nf-kappa b	[p50 NF-kappa B]	1.5849625007211563	3	1	0	0
16734	1520	regulator of gene expression	[regulator of gene expression]	1.5849625007211563	4	2	2	2
16735	1520	response to tpa treatment	[response to TPA treatment]	1.5849625007211563	4	1	0	0
16736	1520	early transcription factor	[early transcription factor]	1.5849625007211563	3	1	0	0
16737	1520	structure of this integrin	[structure of this integrin]	1.5849625007211563	4	1	0	0
16738	1520	different gene important	[different genes important]	1.5849625007211563	3	1	0	0
16739	1520	use a monoclonal antibody	[using a monoclonal antibody]	1.5849625007211563	4	2	2	2
16740	1520	functional retinoblastoma protein	[functional retinoblastoma protein]	1.5849625007211563	3	1	0	0
16741	1520	addition, anti-cd29 integrin beta	[addition, anti-CD29 integrin beta]	1.5849625007211563	4	1	0	0
16742	1520	response to tcr activation	[response to TCR activation]	1.5849625007211563	4	1	0	0
16743	1520	cyclic amp-responsive element modulator	[cyclic AMP-responsive element modulator]	1.5849625007211563	4	1	0	0
16744	1520	mature erythrocyte compartment	[mature erythrocyte compartment]	1.5849625007211563	3	1	0	0
16745	1520	abundance of rrna	[abundance of mRNAs]	1.5849625007211563	3	1	0	0
16746	1520	perpetuation of hiv infection	[perpetuation of HIV infection]	1.5849625007211563	4	1	0	0
16747	1520	mechanism of limited proteolysis	[mechanism of limited proteolysis]	1.5849625007211563	4	1	0	0
16748	1520	potassium concentration of hml	[potassium concentrations of HML]	1.5849625007211563	4	1	0	0
16749	1520	novel, proteasome -dependent stimulus	[novel, proteasome -dependent stimulus]	1.5849625007211563	4	1	0	0
16750	1520	receptor to cell lysis	[receptor to cell lysis]	1.5849625007211563	4	1	0	0
16751	1520	ifn-gamma cytoplasmic mrna	[IFN-gamma cytoplasmic mRNA]	1.5849625007211563	3	1	0	0
16752	1520	cognate catalytic cofactor	[cognate catalytic cofactor]	1.5849625007211563	3	1	0	0
16753	1520	kappa b synthesis	[kappa B synthesis]	1.5849625007211563	3	1	0	0
16754	1520	reversion of blast Tcells	[reversion of blast Tcells]	1.5849625007211563	4	1	0	0
16755	1520	unprimed eosinophil phenotype	[unprimed eosinophil phenotype]	1.5849625007211563	3	1	0	0
16756	1520	0.5 ng to 50	[0.5 ng to 50]	1.5849625007211563	4	1	0	0
16757	1520	moderate body mass	[Moderate body mass]	1.5849625007211563	3	1	0	0
16758	1520	membrane to the nucleus	[membrane to the nucleus]	1.5849625007211563	4	1	0	0
16759	1520	ifn-gamma activation of Stat1alpha	[IFN-gamma activation of Stat1alpha]	1.5849625007211563	4	1	0	0
16760	1520	b cell necessary	[B cells necessary]	1.5849625007211563	3	1	0	0
16761	1520	hl60 human leukemia cell	[HL60 human leukemia cells]	1.5849625007211563	4	1	0	0
16762	1520	RAR beta /rxr heterodimer	[RAR beta /RXR heterodimers]	1.5849625007211563	4	1	0	0
16763	1520	potentially important role	[potentially important role]	1.5849625007211563	3	1	0	0
16764	1520	use T cell	[using T cells]	1.5849625007211563	3	2	2	2
16765	1520	effect on thrombin responsiveness	[effect on thrombin responsiveness]	1.5849625007211563	4	1	0	0
16766	1520	nf-kappab activation of monocyte	[NF-kappaB activation of monocytes]	1.5849625007211563	4	1	0	0
16767	1520	47 kda factor	[47 kDa factor]	1.5849625007211563	3	2	1	1
16768	1520	NK activity by E2	[NK activity by E2]	1.5849625007211563	4	1	0	0
16769	1520	proximal 5'-flanking region	[proximal 5'-flanking region]	1.5849625007211563	3	1	0	0
16770	1520	leucocyte in patient	[leucocytes in patients]	1.5849625007211563	3	2	2	2
16771	1520	huvec by 30%	[HUVEC by 30%]	1.5849625007211563	3	1	0	0
16772	1520	i interferon ifi	[I interferons IFNs]	1.5849625007211563	3	1	0	0
16773	1520	growth response to IL-2	[growth response to IL-2]	1.5849625007211563	4	1	0	0
16774	1520	increase in the kinetic	[increase in the kinetics]	1.5849625007211563	4	1	0	0
16775	1520	progenitor of erythroid lineage	[progenitors of erythroid lineages]	1.5849625007211563	4	1	0	0
16776	1520	prior in vitro	[prior in vitro]	1.5849625007211563	3	1	0	0
16777	1520	interleukin-1 (il-1)-responsive cell	[interleukin-1 (IL-1)-responsive cells]	1.5849625007211563	3	1	0	0
16778	1520	T cell transcriptional event	[T cell transcriptional events]	1.5849625007211563	4	1	0	0
16779	1520	CAEV LTR by IFN-gamma	[CAEV LTR by IFN-gamma]	1.5849625007211563	4	1	0	0
16780	1520	gr per cell	[GR per cell]	1.5849625007211563	3	1	0	0
16781	1520	basal nfat activation	[basal NFAT activation]	1.5849625007211563	3	1	0	0
16782	1520	consensus ap-1 site	[consensus AP-1 site]	1.5849625007211563	3	1	0	0
16783	1520	physiological concentration of gc	[physiological concentration of GC]	1.5849625007211563	4	1	0	0
16784	1520	level of p-creb	[levels of P-CREB]	1.5849625007211563	3	1	0	0
16785	1520	peak value of GR	[peak value of GR]	1.5849625007211563	4	1	0	0
16786	1520	transgenic mouse model	[transgenic mouse model]	1.5849625007211563	3	1	0	0
16787	1520	other cell receptor	[other cell receptors]	1.5849625007211563	3	1	0	0
16788	1520	herbimycin A sensitive pathway	[herbimycin A sensitive pathway]	1.5849625007211563	4	1	0	0
16789	1520	-to-oxidized glutathione gssg	[-to-oxidized glutathione GSSG]	1.5849625007211563	3	1	0	0
16790	1520	evidence for a pathway	[evidence for an pathway]	1.5849625007211563	4	2	2	2
16791	1520	overexpression of slp-76	[Overexpression of SLP-76]	1.5849625007211563	3	1	0	0
16792	1520	full length c-jun promoter	[full length c-jun promoter]	1.5849625007211563	4	1	0	0
16793	1520	tcr alpha enhancer complex	[TCR alpha enhancer complex]	1.5849625007211563	4	1	0	0
16794	1520	level of dp 1	[levels of DP 1]	1.5849625007211563	4	1	0	0
16795	1520	non- octamer motif	[non- octamer motif]	1.5849625007211563	3	1	0	0
16796	1520	immature thymocyte in vitro.	[immature thymocytes in vitro.]	1.5849625007211563	4	1	0	0
16797	1520	ed50 between 9	[ED50 between 9]	1.5849625007211563	3	1	0	0
16798	1520	role in gc resistance	[role in GC resistance]	1.5849625007211563	4	1	0	0
16799	1520	putative nuclear localization sequence	[putative nuclear localization sequences]	1.5849625007211563	4	1	0	0
16800	1520	mantle cell lymphoma	[mantle cell lymphoma]	1.5849625007211563	3	2	1	1
16801	1520	region downstream of -90	[region downstream of -90]	1.5849625007211563	4	1	0	0
16802	1520	two tyrosine residue Tyr427	[two tyrosine residues Tyr427]	1.5849625007211563	4	1	0	0
16803	1520	reactive nitrogen intermediate release	[reactive nitrogen intermediate release]	1.5849625007211563	4	1	0	0
16804	1520	molecular weight of kD	[molecular weight of kD]	1.5849625007211563	4	2	2	2
16805	1520	limit of detection	[limit of detection]	1.5849625007211563	3	1	0	0
16806	1520	result of a duplication	[result of a duplication]	1.5849625007211563	4	1	0	0
16807	1520	background: Study from laboratory	[BACKGROUND: Studies from laboratory]	1.5849625007211563	4	1	0	0
16808	1520	3-day pha treatment	[3-day PHA treatment]	1.5849625007211563	3	1	0	0
16809	1520	panel of B-cell line	[panel of B-cell lines]	1.5849625007211563	4	2	1	1
16810	1520	consensus octamer motif	[consensus octamer motif]	1.5849625007211563	3	1	0	0
16811	1520	fully functional il-2r	[fully functional IL-2r]	1.5849625007211563	3	1	0	0
16812	1520	use NF kappa b	[using NF kappa B]	1.5849625007211563	4	1	0	0
16813	1520	adult globin developmental program	[adult globin developmental program]	1.5849625007211563	4	1	0	0
16814	1520	erythroblast express exogenous gata-2	[erythroblasts expressing exogenous GATA-2]	1.5849625007211563	4	1	0	0
16815	1520	Fli-1 protein in lysate	[Fli-1 protein in lysates]	1.5849625007211563	4	1	0	0
16816	1520	activity of the kinase	[activity of the kinase]	1.5849625007211563	4	1	0	0
16817	1520	possibly through the activation	[possibly through the activation]	1.5849625007211563	4	1	0	0
16818	1520	increase in intracellular calcium	[increase in intracellular calcium]	1.5849625007211563	4	1	0	0
16819	1520	high dose of IL-2	[high doses of IL-2]	1.5849625007211563	4	1	0	0
16820	1520	NF-kappaB inhibitory subunit IkappaB	[NF-kappaB inhibitory subunits IkappaB]	1.5849625007211563	4	1	0	0
16821	1520	Jurkat T cell transcription	[Jurkat T cells transcription]	1.5849625007211563	4	1	0	0
16822	1520	myeloid cell model	[myeloid cell models]	1.5849625007211563	3	1	0	0
16823	1520	lead to CD40 activation	[leading to CD40 activation]	1.5849625007211563	4	1	0	0
16824	1520	down-regulation of c-myc expression	[down-regulation of c-myc expression]	1.5849625007211563	4	1	0	0
16825	1520	transactivate region of E2A	[transactivating regions of E2A]	1.5849625007211563	4	1	0	0
16826	1520	level of CD8 contribution	[level of CD8 contribution]	1.5849625007211563	4	1	0	0
16827	1520	expression within the thymus	[expression within the thymus]	1.5849625007211563	4	1	0	0
16828	1520	pp-2a -oppose kinase	[PP-2A -opposing kinases]	1.5849625007211563	3	1	0	0
16829	1520	upstream of MAPK	[upstream of MAPK]	1.5849625007211563	3	1	0	0
16830	1520	precondition for selection.	[precondition for selection.]	1.5849625007211563	3	1	0	0
16831	1520	proliferation of this cells.	[proliferation of these cells.]	1.5849625007211563	4	1	0	0
16832	1520	expression of M10	[Expression of M10]	1.5849625007211563	3	1	0	0
16833	1520	Ca(2+)-dependent K+ channel	[Ca(2+)-dependent K+ channels]	1.5849625007211563	3	1	0	0
16834	1520	MRD +/lt patient	[MRD +/LT patients]	1.5849625007211563	3	1	0	0
16835	1520	activation by hgata-3	[activation by hGATA-3]	1.5849625007211563	3	1	0	0
16836	1520	high-level lymphoid-specific responsiveness	[high-level lymphoid-specific responsiveness]	1.5849625007211563	3	1	0	0
16837	1520	human class ii isotype	[human class II isotypes]	1.5849625007211563	4	1	0	0
16838	1520	multiple myeloma cell line	[multiple myeloma cell lines]	1.5849625007211563	4	4	3	1
16839	1520	critical cell cycle checkpoint	[critical cell cycle checkpoint]	1.5849625007211563	4	1	0	0
16840	1520	protein binding characteristic	[protein binding characteristics]	1.5849625007211563	3	1	0	0
16841	1520	specificity of DNA binding	[specificity of DNA binding]	1.5849625007211563	4	1	0	0
16842	1520	vitro apoptosis induction	[vitro apoptosis induction]	1.5849625007211563	3	1	0	0
16843	1520	tata-less blr1 core promoter	[TATA-less blr1 core promoter]	1.5849625007211563	4	1	0	0
16844	1520	cytoplasm of lymphocyte	[cytoplasm of lymphocytes]	1.5849625007211563	3	2	2	2
16845	1520	1,25-dihydroxyvitamin D3 calcitriol	[1,25-dihydroxyvitamin D3 calcitriol]	1.5849625007211563	3	2	2	2
16846	1520	b104 cell death	[B104 cell death]	1.5849625007211563	3	1	0	0
16847	1520	imbalance of beta-	[imbalance of beta-]	1.5849625007211563	3	1	0	0
16848	1520	binding pattern of ap-1	[binding patterns of AP-1]	1.5849625007211563	4	1	0	0
16849	1520	ikappabbeta protein expression	[IkappaBbeta protein expression]	1.5849625007211563	3	1	0	0
16850	1520	cellular gene activation	[cellular gene activation]	1.5849625007211563	3	2	2	2
16851	1520	MHC class ii transcription	[MHC class II transcription]	1.5849625007211563	4	1	0	0
16852	1520	alpha CD3 /il-2	[alpha CD3 /IL-2]	1.5849625007211563	3	1	0	0
16853	1520	initial a/r challenge	[initial A/R challenge]	1.5849625007211563	3	1	0	0
16854	1520	human crh gene promoter	[human CRH gene promoter]	1.5849625007211563	4	1	0	0
16855	1520	glutaminyl-ttg substrate in vivo,	[glutaminyl-tTG substrates in vivo,]	1.5849625007211563	4	1	0	0
16856	1520	IL-2mRNA synthesis in condition	[IL-2mRNA synthesis in conditions]	1.5849625007211563	4	1	0	0
16857	1520	e box enhancer element	[E box enhancer elements]	1.5849625007211563	4	1	0	0
16858	1520	cd27 ligand (cd70) transfectant	[CD27 ligand (CD70) transfectants]	1.5849625007211563	4	1	0	0
16859	1520	secondary lymphoid tissue development	[secondary lymphoid tissue development]	1.5849625007211563	4	1	0	0
16860	1520	nf-kappab n-terminal kinase JNK	[NF-kappaB N-terminal kinase JNK]	1.5849625007211563	4	1	0	0
16861	1520	total plasma sialyltransferase	[total plasma sialyltransferase]	1.5849625007211563	3	1	0	0
16862	1520	primary leukemic cell	[primary leukemic cells]	1.5849625007211563	3	2	2	2
16863	1520	least three signal	[least three signals]	1.5849625007211563	3	1	0	0
16864	1520	Stable transfectant of HB24	[Stable transfectants of HB24]	1.5849625007211563	4	1	0	0
16865	1520	group of inhibitory protein	[group of inhibitory proteins]	1.5849625007211563	4	1	0	0
16866	1520	overexpression in T cell	[overexpression in T cells]	1.5849625007211563	4	2	1	1
16867	1520	group ii type ii	[group II type II]	1.5849625007211563	4	1	0	0
16868	1520	inhibition of granulocytic differentiation	[inhibition of granulocytic differentiation]	1.5849625007211563	4	1	0	0
16869	1520	addition of exogenous il-6	[addition of exogenous IL-6]	1.5849625007211563	4	1	0	0
16870	1520	specific DNA binding,	[specific DNA binding,]	1.5849625007211563	3	1	0	0
16871	1520	hypoxic lung tissue	[hypoxic lung tissue]	1.5849625007211563	3	1	0	0
16872	1520	negative control region	[negative control region]	1.5849625007211563	3	1	0	0
16873	1520	signal through PKC	[signaling through PKC]	1.5849625007211563	3	1	0	0
16874	1520	ability of hgm-csf	[ability of hGM-CSF]	1.5849625007211563	3	1	0	0
16875	1520	Sp binding site	[Sp binding site]	1.5849625007211563	3	1	0	0
16876	1520	hla DQ 2,7 individual	[HLA DQ 2,7 individual]	1.5849625007211563	4	1	0	0
16877	1520	actually the result	[actually the result]	1.5849625007211563	3	1	0	0
16878	1520	h-rs cell in tissue	[H-RS cells in tissue]	1.5849625007211563	4	1	0	0
16879	1520	body of evidence	[body of evidence]	1.5849625007211563	3	2	2	2
16880	1520	EBNA-2 -responsive element	[EBNA-2 -responsive element]	1.5849625007211563	3	1	0	0
16881	1520	direct free-radical scavenging property	[direct free-radical scavenging properties]	1.5849625007211563	4	1	0	0
16882	1520	synergy of signal pathway	[synergy of signaling pathways]	1.5849625007211563	4	1	0	0
16883	1520	pgn in mouse raw264.7	[PGN in mouse RAW264.7]	1.5849625007211563	4	1	0	0
16884	1520	almost all stat protein	[almost all Stat proteins]	1.5849625007211563	4	1	0	0
16885	1520	lymphocyte by anti-hla class	[lymphocytes by anti-HLA class]	1.5849625007211563	4	1	0	0
16886	1520	increase in a subset	[increase in a subset]	1.5849625007211563	4	1	0	0
16887	1520	increase in electrophoretic mobility	[increase in electrophoretic mobility]	1.5849625007211563	4	1	0	0
16888	1520	peripheral blood lymphocytes, expression	[peripheral blood lymphocytes, expression]	1.5849625007211563	4	1	0	0
16889	1520	PU.1- family member	[PU.1- family members]	1.5849625007211563	3	1	0	0
16890	1520	IL-1RII mrna level	[IL-1RII mRNA levels]	1.5849625007211563	3	2	1	1
16891	1520	endogenous 5-lipoxygenase activity	[endogenous 5-lipoxygenase activity]	1.5849625007211563	3	1	0	0
16892	1520	basal transcription complex	[basal transcription complex]	1.5849625007211563	3	1	0	0
16893	1520	interleukin 2 IL2 promoter	[interleukin 2 IL2 promoter]	1.5849625007211563	4	1	0	0
16894	1520	positively stain lymphocyte	[positively staining lymphocytes]	1.5849625007211563	3	1	0	0
16895	1520	one intronic DHS	[one intronic DHS]	1.5849625007211563	3	1	0	0
16896	1520	cell surface of hdmec	[cell surface of HDMEC]	1.5849625007211563	4	1	0	0
16897	1520	widespread use of glucocorticoid	[widespread use of glucocorticoids]	1.5849625007211563	4	1	0	0
16898	1520	ikk kinase activity,	[IKK kinase activity,]	1.5849625007211563	3	1	0	0
16899	1520	CD28RE /ap-1-specific complex	[CD28RE /AP-1-specific complex]	1.5849625007211563	3	1	0	0
16900	1520	Jurkat cell lysates.	[Jurkat cell lysates.]	1.5849625007211563	3	1	0	0
16901	1520	Interestingly, residue c-235	[Interestingly, residue C-235]	1.5849625007211563	3	1	0	0
16902	1520	contain a enhancerless promoter,	[containing an enhancerless promoter,]	1.5849625007211563	4	1	0	0
16903	1520	dna- receptor complex formation	[DNA- receptor complex formation]	1.5849625007211563	4	1	0	0
16904	1520	undifferentiated human monocytic cell	[undifferentiated human monocytic cells]	1.5849625007211563	4	1	0	0
16905	1520	n- terminal residue	[N- terminal residues]	1.5849625007211563	3	1	0	0
16906	1520	such as blood transfusion	[such as blood transfusion]	1.5849625007211563	4	1	0	0
16907	1520	upstream promoter sequence	[upstream promoter sequences]	1.5849625007211563	3	2	1	1
16908	1520	development of asthma	[development of asthma]	1.5849625007211563	3	1	0	0
16909	1520	human tcr delta	[human TCR delta]	1.5849625007211563	3	1	0	0
16910	1520	pkc inhibitor gf	[PKC inhibitor GF]	1.5849625007211563	3	1	0	0
16911	1520	calcineurin a calcium-calmodulin-dependent phosphatase	[calcineurin a calcium-calmodulin-dependent phosphatase]	1.5849625007211563	4	1	0	0
16912	1520	human interleukin-4 promoter activity	[human interleukin-4 promoter activity]	1.5849625007211563	4	1	0	0
16913	1520	life-threatening disease progression	[life-threatening disease progression]	1.5849625007211563	3	1	0	0
16914	1520	majority of case	[majority of cases]	1.5849625007211563	3	1	0	0
16915	1520	result in a supershift	[resulting in a supershift]	1.5849625007211563	4	1	0	0
16916	1520	presence of phospholipid surface	[presence of phospholipid surfaces]	1.5849625007211563	4	1	0	0
16917	1520	antiserum to this enzyme	[antiserum to this enzyme]	1.5849625007211563	4	1	0	0
16918	1520	Strikingly, western blotting	[Strikingly, Western blotting]	1.5849625007211563	3	1	0	0
16919	1520	human epsilon-globin-encoding gene	[human epsilon-globin-encoding gene]	1.5849625007211563	3	2	1	1
16920	1520	plasma cell pathway	[plasma cell pathway]	1.5849625007211563	3	1	0	0
16921	1520	NF-kappa b region	[NF-kappa B region]	1.5849625007211563	3	1	0	0
16922	1520	-encode pebp2 alpha gene	[-encoding PEBP2 alpha genes]	1.5849625007211563	4	1	0	0
16923	1520	interaction between SLP-76	[interaction between SLP-76]	1.5849625007211563	3	1	0	0
16924	1520	resistant asthmatic patient	[resistant asthmatic patients]	1.5849625007211563	3	1	0	0
16925	1520	tata box binding protein	[TATA box binding protein]	1.5849625007211563	4	2	1	1
16926	1520	21 bp repeat element	[21 bp repeat elements]	1.5849625007211563	4	1	0	0
16927	1520	extensive upstream sequence	[extensive upstream sequences]	1.5849625007211563	3	1	0	0
16928	1520	FK506.FKBP12 drug-immunophilin complex	[FK506.FKBP12 drug-immunophilin complexes]	1.5849625007211563	3	1	0	0
16929	1520	inducibility of endogenous ifn-beta	[Inducibility of endogenous IFN-beta]	1.5849625007211563	4	1	0	0
16930	1520	sequence analysis in lymphocyte	[Sequence analysis in lymphocytes]	1.5849625007211563	4	1	0	0
16931	1520	H5sub304 a deletion/substitution mutant	[H5sub304 a deletion/substitution mutant]	1.5849625007211563	4	1	0	0
16932	1520	tetrahexamer binding protein	[tetrahexamer binding proteins]	1.5849625007211563	3	1	0	0
16933	1520	presence of human serum	[presence of human serum]	1.5849625007211563	4	1	0	0
16934	1520	clone 13 CIITA allele	[clone 13 CIITA alleles]	1.5849625007211563	4	1	0	0
16935	1520	response to interferon-gamma	[response to interferon-gamma]	1.5849625007211563	3	1	0	0
16936	1520	complex protein-DNA interaction	[complex protein-DNA interactions]	1.5849625007211563	3	1	0	0
16937	1520	acute hepatic injury	[Acute hepatic injury]	1.5849625007211563	3	2	1	1
16938	1520	upregulation of d cyclin	[upregulation of D cyclins]	1.5849625007211563	4	1	0	0
16939	1520	result of preliminary studies,	[Results of preliminary studies,]	1.5849625007211563	4	1	0	0
16940	1520	familial ovarian cancer patient	[familial ovarian cancer patient]	1.5849625007211563	4	1	0	0
16941	1520	presence of nuclear i(kappa)b(alpha)	[presence of nuclear I(kappa)B(alpha)]	1.5849625007211563	4	1	0	0
16942	1520	human jurkat lymphoblastoid cell	[human Jurkat lymphoblastoid cells]	1.5849625007211563	4	1	0	0
16943	1520	interaction with the domain	[interaction with the domain]	1.5849625007211563	4	1	0	0
16944	1520	il-1beta receptor type 1,	[IL-1beta receptor type 1,]	1.5849625007211563	4	1	0	0
16945	1520	transcriptional regulator in lymphocyte	[transcriptional regulators in lymphocytes]	1.5849625007211563	4	1	0	0
16946	1520	follow PMA /ionomycin treatment	[following PMA /ionomycin treatment]	1.5849625007211563	4	1	0	0
16947	1520	cytosolic component of NFAT	[cytosolic component of NFAT]	1.5849625007211563	4	1	0	0
16948	1520	normal human blood lymphocyte	[normal human blood lymphocytes]	1.5849625007211563	4	2	2	2
16949	1520	il-12 phosphorylation of stat4	[IL-12 phosphorylation of STAT4]	1.5849625007211563	4	1	0	0
16950	1520	t-cell leukemia-specific translocation	[T-cell leukemia-specific translocations]	1.5849625007211563	3	1	0	0
16951	1520	role of bsap	[role of BSAP]	1.5849625007211563	3	2	2	2
16952	1520	terminal repeat region	[terminal repeat region]	1.5849625007211563	3	2	2	2
16953	1520	clinical perspective for gastroenterology	[clinical perspectives for gastroenterology]	1.5849625007211563	4	1	0	0
16954	1520	peptide binding affinity	[Peptide binding affinity]	1.5849625007211563	3	1	0	0
16955	1520	positive plasma cell	[positive plasma cells]	1.5849625007211563	3	1	0	0
16956	1520	binding of each factor	[binding of each factor]	1.5849625007211563	4	1	0	0
16957	1520	loss-of-function signal defect	[loss-of-function signaling defect]	1.5849625007211563	3	1	0	0
16958	1520	strong positive effect	[strong positive effect]	1.5849625007211563	3	2	2	2
16959	1520	patient positive for gst-pi	[patients positive for GST-pi]	1.5849625007211563	4	1	0	0
16960	1520	only in G1	[only in G1]	1.5849625007211563	3	1	0	0
16961	1520	expression of il-2r alpha	[expression of IL-2R alpha]	1.5849625007211563	4	2	1	1
16962	1520	two distinct molecules, nfatp	[Two distinct molecules, NFATp]	1.5849625007211563	4	1	0	0
16963	1520	il-6 protein expression	[IL-6 protein expression]	1.5849625007211563	3	1	0	0
16964	1520	O-side chain-specific mAb	[O-side chain-specific mAb]	1.5849625007211563	3	1	0	0
16965	1520	several nuclear protein	[several nuclear proteins]	1.5849625007211563	3	1	0	0
16966	1520	binding of HMG-I(Y)	[Binding of HMG-I(Y)]	1.5849625007211563	3	1	0	0
16967	1520	two hsp90 complex	[two hsp90 complexes]	1.5849625007211563	3	1	0	0
16968	1520	productively u937 cell	[productively U937 cells]	1.5849625007211563	3	1	0	0
16969	1520	type i interferon ifn-alpha/beta	[type I interferons IFN-alpha/beta]	1.5849625007211563	4	1	0	0
16970	1520	1,25-Dihydroxyvitamin D3 135eoh)2d3	[1,25-Dihydroxyvitamin D3 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
16971	1520	immunodominant antigen in e1a	[immunodominant antigen in E1A]	1.5849625007211563	4	1	0	0
16972	1520	chemokine family related	[chemokine family related]	1.5849625007211563	3	1	0	0
16973	1520	elastase inhibitor elastatinal	[elastase inhibitor elastatinal]	1.5849625007211563	3	1	0	0
16974	1520	immediate-early activation gene	[immediate-early activation gene]	1.5849625007211563	3	2	1	1
16975	1520	syndrome (cushing disease	[syndrome (Cushing's disease)]	1.5849625007211563	3	1	0	0
16976	1520	expression by lymphoid cell	[expression by lymphoid cells]	1.5849625007211563	4	1	0	0
16977	1520	expression of EBNA-2	[expression of EBNA-2]	1.5849625007211563	3	1	0	0
16978	1520	T-lymphocyte cell lineage	[T-lymphocyte cell lineage]	1.5849625007211563	3	1	0	0
16979	1520	b cell activation event	[B cell activation events]	1.5849625007211563	4	1	0	0
16980	1520	repeat number equal	[repeat number equal]	1.5849625007211563	3	1	0	0
16981	1520	comparison with vd	[comparison with VD]	1.5849625007211563	3	1	0	0
16982	1520	shortly after lineage commitment	[shortly after lineage commitment]	1.5849625007211563	4	1	0	0
16983	1520	alpha-naphthyl butyrate esterase staining	[alpha-naphthyl butyrate esterase staining]	1.5849625007211563	4	1	0	0
16984	1520	proximal TNF-alpha promoter	[proximal TNF-alpha promoter]	1.5849625007211563	3	1	0	0
16985	1520	peak at h.	[peaks at h,]	1.5849625007211563	3	2	2	2
16986	1520	characteristic dna-binding domain	[characteristic DNA-binding domain]	1.5849625007211563	3	1	0	0
16987	1520	ELISA of IL-2 release	[ELISA of IL-2 release]	1.5849625007211563	4	1	0	0
16988	1520	pattern of x-inactivation	[pattern of X-inactivation]	1.5849625007211563	3	2	2	2
16989	1520	activity with mutation	[activity with mutation]	1.5849625007211563	3	1	0	0
16990	1520	oxidant-rich purulent airway secretion	[oxidant-rich purulent airway secretions]	1.5849625007211563	4	1	0	0
16991	1520	pfp5a contain -795 bp	[PFP5a containing -795 bp]	1.5849625007211563	4	1	0	0
16992	1520	cascade of genetic change	[cascade of genetic changes]	1.5849625007211563	4	1	0	0
16993	1520	two nfat-binding element P0	[two NFAT-binding elements P0]	1.5849625007211563	4	1	0	0
16994	1520	U937 human monoblastic cell	[U937 human monoblastic cells]	1.5849625007211563	4	1	0	0
16995	1520	nonspecific protein kinase inhibition	[Nonspecific protein kinase inhibition]	1.5849625007211563	4	1	0	0
16996	1520	degradation of inhibitor-kappaB alpha	[degradation of inhibitor-kappaB alpha]	1.5849625007211563	4	1	0	0
16997	1520	presence of the scavenger	[presence of the scavenger]	1.5849625007211563	4	1	0	0
16998	1520	human b cell proliferation	[human B cell proliferation]	1.5849625007211563	4	1	0	0
16999	1520	induction of NFkappaB	[Induction of NFkappaB]	1.5849625007211563	3	1	0	0
17000	1520	IL-2R alpha expression	[IL-2R alpha expression]	1.5849625007211563	3	1	0	0
17001	1520	mouse overexpress icsat	[mice overexpressing ICSAT]	1.5849625007211563	3	2	2	2
17002	1520	N-terminal 151 amino acid	[N-terminal 151 amino acids]	1.5849625007211563	4	1	0	0
17003	1520	position in cell	[position in cells]	1.5849625007211563	3	1	0	0
17004	1520	candidate influence inflammatory disease	[candidates influencing inflammatory disease]	1.5849625007211563	4	1	0	0
17005	1520	replication of mutant hiv-1	[replication of mutant HIV-1]	1.5849625007211563	4	1	0	0
17006	1520	lymphoid-specific transcription factor Oct-2A	[lymphoid-specific transcription factor Oct-2A]	1.5849625007211563	4	1	0	0
17007	1520	lymphoblastoid t-cell line	[lymphoblastoid T-cell line]	1.5849625007211563	3	2	2	2
17008	1520	one pax-5 allele	[one PAX-5 allele]	1.5849625007211563	3	1	0	0
17009	1520	healthy virus carrier	[healthy virus carriers]	1.5849625007211563	3	1	0	0
17010	1520	non-Hodgkin' lymphoma cell Ri-I	[non-Hodgkin's lymphoma cells Ri-I]	1.5849625007211563	4	1	0	0
17011	1520	colony-forming unit-granulocyte-macrophage progenitor cell	[colony-forming unit-granulocyte-macrophage progenitor cells]	1.5849625007211563	4	1	0	0
17012	1520	expression of EBNA 2	[expression of EBNA 2]	1.5849625007211563	4	1	0	0
17013	1520	tax protein transcription	[Tax protein transcription]	1.5849625007211563	3	1	0	0
17014	1520	unique mechanism involve NF-ATp	[unique mechanism involving NF-ATp]	1.5849625007211563	4	1	0	0
17015	1520	15-lipoxygenase (lox) gene	[15-lipoxygenase (lox) gene]	1.5849625007211563	3	1	0	0
17016	1520	important role in oncogenesis	[important role in oncogenesis]	1.5849625007211563	4	1	0	0
17017	1520	chimeric ebna2 protein	[chimeric EBNA2 protein]	1.5849625007211563	3	2	1	1
17018	1520	human osteosarcoma Saos-2 cell	[human osteosarcoma Saos-2 cells]	1.5849625007211563	4	1	0	0
17019	1520	concentration of RA	[concentrations of RA]	1.5849625007211563	3	2	2	2
17020	1520	arsenic trioxide as2o3	[Arsenic trioxide As2O3]	1.5849625007211563	3	2	1	1
17021	1520	effect of this motif	[effects of these motifs]	1.5849625007211563	4	1	0	0
17022	1520	cysteine -rich LIM domain	[cysteine -rich LIM domains]	1.5849625007211563	4	1	0	0
17023	1520	cf lung disease	[CF lung disease]	1.5849625007211563	3	1	0	0
17024	1520	NF-kappaB activation response	[NF-kappaB activation response]	1.5849625007211563	3	1	0	0
17025	1520	active transcriptional activation domain,	[active transcriptional activation domain,]	1.5849625007211563	4	1	0	0
17026	1520	amino acid residue c-terminal	[amino acid residues C-terminal]	1.5849625007211563	4	1	0	0
17027	1520	regulatory DNA element	[regulatory DNA element]	1.5849625007211563	3	2	1	1
17028	1520	surface of thymus-derived lymphocyte	[surface of thymus-derived lymphocytes]	1.5849625007211563	4	1	0	0
17029	1520	cell cycle entry event	[cell cycle entry events]	1.5849625007211563	4	1	0	0
17030	1520	multiple signal defect	[multiple signaling defects]	1.5849625007211563	3	1	0	0
17031	1520	IL-8 kappa b-like site	[IL-8 kappa B-like site]	1.5849625007211563	4	1	0	0
17032	1520	3H-thymidine uptake procedure	[3H-thymidine uptake procedure]	1.5849625007211563	3	1	0	0
17033	1520	les-induced ap-1 binding activity	[LPS-induced AP-1 binding activity]	1.5849625007211563	4	1	0	0
17034	1520	lipopolysaccharide b cell	[lipopolysaccharide B cells]	1.5849625007211563	3	1	0	0
17035	1520	total of 880 comparison	[total of 880 comparisons]	1.5849625007211563	4	1	0	0
17036	1520	two NF-E2/AP1 motif together	[two NF-E2/AP1 motifs together]	1.5849625007211563	4	1	0	0
17037	1520	exogenous IL-6 dephosphorylated prb	[exogenous IL-6 dephosphorylated pRB]	1.5849625007211563	4	1	0	0
17038	1520	10 XLH patient	[10 XLH patients]	1.5849625007211563	3	1	0	0
17039	1520	class ii antibody	[class II antibodies]	1.5849625007211563	3	2	2	2
17040	1520	glucose transporter isoform	[glucose transporter isoforms]	1.5849625007211563	3	1	0	0
17041	1520	restoration of the capacity	[Restoration of the capacity]	1.5849625007211563	4	1	0	0
17042	1520	colostrum inhibitory factor CIF	[colostrum inhibitory factor CIF]	1.5849625007211563	4	1	0	0
17043	1520	consequence of a increase	[consequence of a increase]	1.5849625007211563	4	1	0	0
17044	1520	three specific protein-DNA complex	[three specific protein-DNA complexes]	1.5849625007211563	4	1	0	0
17045	1520	soluble, heparin gag	[soluble, heparin GAGs]	1.5849625007211563	3	1	0	0
17046	1520	signal transduce adaptor molecule	[signal transducing adaptor molecule]	1.5849625007211563	4	1	0	0
17047	1520	Epstein-Barr virus latency	[Epstein-Barr virus latency]	1.5849625007211563	3	2	2	2
17048	1520	affect total 135eoh)2d3 uptake	[affecting total 1,25(OH)2D3 uptake]	1.5849625007211563	4	1	0	0
17049	1520	mechanism of gene expression	[mechanisms of gene expression]	1.5849625007211563	4	1	0	0
17050	1520	tyrosine -phosphorylated substrate	[tyrosine -phosphorylated substrates]	1.5849625007211563	3	1	0	0
17051	1520	effect of tamoxifen tam	[effects of tamoxifen TAM]	1.5849625007211563	4	1	0	0
17052	1520	sh2 domain of 3bp2	[SH2 domains of 3BP2]	1.5849625007211563	4	1	0	0
17053	1520	nf-kappab in T cell	[NF-kappaB in T cells]	1.5849625007211563	4	1	0	0
17054	1520	variation of creb	[variations of CREB]	1.5849625007211563	3	1	0	0
17055	1520	RESULTS: secretion of IL-8	[RESULTS: Secretion of IL-8]	1.5849625007211563	4	1	0	0
17056	1520	background: arsenic trioxide as2o3	[BACKGROUND: Arsenic trioxide As2O3]	1.5849625007211563	4	1	0	0
17057	1520	potent transactivator in HTLV-I	[potent transactivator in HTLV-I]	1.5849625007211563	4	1	0	0
17058	1520	same factor(s), protease treatment	[same factor(s), protease treatment]	1.5849625007211563	4	1	0	0
17059	1520	G. vaginalis on hiv	[G. vaginalis on HIV]	1.5849625007211563	4	1	0	0
17060	1520	response to chemotherapy	[response to chemotherapy]	1.5849625007211563	3	1	0	0
17061	1520	specific DNA-protein complex	[specific DNA-protein complex]	1.5849625007211563	3	2	1	1
17062	1520	two distinct nucleoprotein complex	[two distinct nucleoprotein complexes]	1.5849625007211563	4	1	0	0
17063	1520	only in hs	[only in HS]	1.5849625007211563	3	1	0	0
17064	1520	successive gc therapy	[successive GC therapy]	1.5849625007211563	3	1	0	0
17065	1520	effect of agonist	[effects of agonists]	1.5849625007211563	3	1	0	0
17066	1520	protein of amino acid	[protein of amino acids]	1.5849625007211563	4	2	2	2
17067	1520	cytokine pleiotropy by IL-2	[cytokine pleiotropy by IL-2]	1.5849625007211563	4	1	0	0
17068	1520	myelomocytic cell line HL60	[myelomocytic cell line HL60]	1.5849625007211563	4	1	0	0
17069	1520	immunodominant native peptide	[immunodominant native peptide]	1.5849625007211563	3	1	0	0
17070	1520	control of growth	[control of growth]	1.5849625007211563	3	1	0	0
17071	1520	il-2r beta membrane expression	[IL-2R beta membrane expression]	1.5849625007211563	4	1	0	0
17072	1520	Egr-1 antisense oligomer	[Egr-1 antisense oligomers]	1.5849625007211563	3	1	0	0
17073	1520	level of il-8 mrna	[levels of IL-8 mRNA]	1.5849625007211563	4	1	0	0
17074	1520	lymphocyte-specific protein tyrosine kinase	[lymphocyte-specific protein tyrosine kinase]	1.5849625007211563	4	1	0	0
17075	1520	yeast one-hybrid screen	[yeast one-hybrid screening]	1.5849625007211563	3	1	0	0
17076	1520	lymphocyte infiltration of tumor	[Lymphocyte infiltration of tumor]	1.5849625007211563	4	1	0	0
17077	1520	growth-promoting effect of IL-7	[growth-promoting effects of IL-7]	1.5849625007211563	4	1	0	0
17078	1520	binding of gliadin peptide	[binding of gliadin peptides]	1.5849625007211563	4	1	0	0
17079	1520	phosphorylation of the erk1/2	[phosphorylation of the ERK1/2]	1.5849625007211563	4	1	0	0
17080	1520	1,25-Dihydroxyvitamin D3 135(oh)2d3	[1,25-Dihydroxyvitamin D3 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
17081	1520	cognate cDNA sequence	[cognate cDNA sequence]	1.5849625007211563	3	1	0	0
17082	1520	transcription factor expression plasmid	[transcription factor expression plasmids]	1.5849625007211563	4	1	0	0
17083	1520	regulatory module of promoter	[regulatory modules of promoters]	1.5849625007211563	4	1	0	0
17084	1520	receptor gamma ppargamma	[receptor gamma PPARgamma]	1.5849625007211563	3	2	2	2
17085	1520	level of estrogen receptor	[levels of estrogen receptor]	1.5849625007211563	4	2	2	2
17086	1520	thymic T cell	[thymic T cells]	1.5849625007211563	3	2	2	2
17087	1520	ras upstream of PKC	[ras upstream of PKC]	1.5849625007211563	4	1	0	0
17088	1520	new principle search Ag	[new principle searching Ag]	1.5849625007211563	4	1	0	0
17089	1520	dissociation from Ras	[dissociation from Ras]	1.5849625007211563	3	1	0	0
17090	1520	differentiation- specific expression	[differentiation- specific expression]	1.5849625007211563	3	1	0	0
17091	1520	low anabolic/catabolic balance	[lower anabolic/catabolic balance]	1.5849625007211563	3	1	0	0
17092	1520	anti-mhc class ii antibody	[anti-MHC class II antibodies]	1.5849625007211563	4	2	1	1
17093	1520	target gene expression.	[target gene expression.]	1.5849625007211563	3	1	0	0
17094	1520	approximately 18-fold-lower affinity	[approximately 18-fold-lower affinity]	1.5849625007211563	3	1	0	0
17095	1520	amino-terminal acidic region	[amino-terminal acidic region]	1.5849625007211563	3	1	0	0
17096	1520	systemic effect of glucocorticoid	[systemic effects of glucocorticoids]	1.5849625007211563	4	2	2	2
17097	1520	undergo a mammary reduction	[undergoing a mammary reduction]	1.5849625007211563	4	1	0	0
17098	1520	cellular immune function	[cellular immune functions]	1.5849625007211563	3	1	0	0
17099	1520	discrimination between a mixture	[discrimination between a mixture]	1.5849625007211563	4	1	0	0
17100	1520	other nf-kappa b induction	[other NF-kappa B induction]	1.5849625007211563	4	1	0	0
17101	1520	most potent therapeutic agent	[most potent therapeutic agents]	1.5849625007211563	4	1	0	0
17102	1520	process of activation	[process of activation]	1.5849625007211563	3	2	1	1
17103	1520	ligand testosterone -bsa-fitc	[ligand testosterone -BSA-FITC]	1.5849625007211563	3	1	0	0
17104	1520	affinity to dexamethasone	[affinity to dexamethasone]	1.5849625007211563	3	1	0	0
17105	1520	multiple prolactin-responsive element	[Multiple prolactin-responsive elements]	1.5849625007211563	3	1	0	0
17106	1520	specific inhibitor of caspase	[specific inhibitor of caspases]	1.5849625007211563	4	1	0	0
17107	1520	insulin gene transcription	[insulin gene transcription]	1.5849625007211563	3	2	1	1
17108	1520	control ifn-gamma expression	[controlling IFN-gamma expression]	1.5849625007211563	3	1	0	0
17109	1520	PMA induction of differentiation	[PMA induction of differentiation]	1.5849625007211563	4	1	0	0
17110	1520	lifer with ilf	[livers with ILFs]	1.5849625007211563	3	1	0	0
17111	1520	glucocorticoid receptor function	[glucocorticoid receptor function]	1.5849625007211563	3	3	2	1
17112	1520	vitro transcription /translation	[vitro transcription /translation]	1.5849625007211563	3	1	0	0
17113	1520	binding of Rel,	[binding of Rel,]	1.5849625007211563	3	1	0	0
17114	1520	mzf1 transcription factor	[MZF1 transcription factors]	1.5849625007211563	3	1	0	0
17115	1520	kd similar to 433-442	[Kd similar to 433-442]	1.5849625007211563	4	1	0	0
17116	1520	germline IgE promoter	[germline IgE promoter]	1.5849625007211563	3	1	0	0
17117	1520	result from stimulation	[resulting from stimulation]	1.5849625007211563	3	1	0	0
17118	1520	activation of two kinase	[activation of two kinases]	1.5849625007211563	4	1	0	0
17119	1520	saturable capacity (184	[saturable capacity (184]	1.5849625007211563	3	1	0	0
17120	1520	PD98059 a specific inhibitor	[PD98059 a specific inhibitor]	1.5849625007211563	4	2	1	1
17121	1520	hml of patient	[HML of patients]	1.5849625007211563	3	2	2	2
17122	1520	peptide binding interaction	[peptide binding interactions]	1.5849625007211563	3	1	0	0
17123	1520	HIV long repeat	[HIV long repeat]	1.5849625007211563	3	2	2	2
17124	1520	endogenous gene for ice	[endogenous gene for ICE]	1.5849625007211563	4	1	0	0
17125	1520	variation of MHC concentration	[variation of MHC concentration]	1.5849625007211563	4	1	0	0
17126	1520	antigen receptor agonism,	[antigen receptor agonism,]	1.5849625007211563	3	1	0	0
17127	1520	deletion mutant contain 1.3	[Deletion mutants containing 1.3]	1.5849625007211563	4	1	0	0
17128	1520	response to E2	[response to E2]	1.5849625007211563	3	1	0	0
17129	1520	normal human igg	[normal human IgG]	1.5849625007211563	3	1	0	0
17130	1520	several cell types, activation	[several cell types, activation]	1.5849625007211563	4	1	0	0
17131	1520	quiescence to proliferation	[quiescence to proliferation]	1.5849625007211563	3	1	0	0
17132	1520	fat/lean body mass ratio	[fat/lean body mass ratio]	1.5849625007211563	4	1	0	0
17133	1520	e box around -260	[E box around -260]	1.5849625007211563	4	1	0	0
17134	1520	half-life of c-jun mrna	[half-life of c-jun mRNA]	1.5849625007211563	4	1	0	0
17135	1520	early T cell development	[early T cell development]	1.5849625007211563	4	1	0	0
17136	1520	transcription of a genes,	[transcription of a genes,]	1.5849625007211563	4	1	0	0
17137	1520	cell-type specific transcription factor	[cell-type specific transcription factor]	1.5849625007211563	4	1	0	0
17138	1520	varicella-zoster virus vzv	[varicella-zoster virus VZV]	1.5849625007211563	3	1	0	0
17139	1520	inhibitory effect of insulin	[inhibitory effect of insulin]	1.5849625007211563	4	1	0	0
17140	1520	various stage of maturation,	[various stages of maturation,]	1.5849625007211563	4	1	0	0
17141	1520	neighbour sequence analysis	[Neighbouring sequence analysis]	1.5849625007211563	3	1	0	0
17142	1520	JunD pc-fo heterodimer	[JunD /c-Fos heterodimers]	1.5849625007211563	3	1	0	0
17143	1520	Finally, infectious virus stock	[Finally, infectious virus stocks]	1.5849625007211563	4	1	0	0
17144	1520	substitution in the receptor,	[substitutions in the receptor,]	1.5849625007211563	4	1	0	0
17145	1520	c5b-7 at 10 min,	[C5b-7 at 10 min,]	1.5849625007211563	4	1	0	0
17146	1520	TAL-1 gene product	[TAL-1 gene product]	1.5849625007211563	3	1	0	0
17147	1520	contain cytoplasmic domain	[containing cytoplasmic domains]	1.5849625007211563	3	1	0	0
17148	1520	novel NF-kappa b complex	[novel NF-kappa B complex]	1.5849625007211563	4	1	0	0
17149	1520	pma-induced il-2 production	[PMA-induced IL-2 production]	1.5849625007211563	3	1	0	0
17150	1520	particular serine protease	[particular serine proteases]	1.5849625007211563	3	2	1	1
17151	1520	efficacy of this agent	[efficacy of these agents]	1.5849625007211563	4	1	0	0
17152	1520	monocyte of aids -gr	[monocytes of AIDS -GR]	1.5849625007211563	4	1	0	0
17153	1520	active phorbol ester	[active phorbol ester]	1.5849625007211563	3	1	0	0
17154	1520	c-terminal ankyrin motif domain	[C-terminal ankyrin motif domain]	1.5849625007211563	4	1	0	0
17155	1520	[3H]dexamethasone binding use cytosol	[[3H]dexamethasone binding using cytosol]	1.5849625007211563	4	1	0	0
17156	1520	frequently traffic together	[frequently traffic together]	1.5849625007211563	3	1	0	0
17157	1520	factor of good prognosis	[factors of good prognosis]	1.5849625007211563	4	1	0	0
17158	1520	nonmitogenic T cell stimulation	[Nonmitogenic T cell stimulation]	1.5849625007211563	4	1	0	0
17159	1520	cellular factor cbf1/rbp-jkappa	[cellular factor CBF1/RBP-Jkappa]	1.5849625007211563	3	1	0	0
17160	1520	highly specific protein inhibitor	[highly specific protein inhibitor]	1.5849625007211563	4	1	0	0
17161	1520	differential mzf-1 modification	[differential MZF-1 modifications]	1.5849625007211563	3	1	0	0
17162	1520	presence of ifn-gamma	[presence of IFN-gamma]	1.5849625007211563	3	1	0	0
17163	1520	Phosphoamino acid analysis	[Phosphoamino acid analysis]	1.5849625007211563	3	1	0	0
17164	1520	MAPk kinase MKK	[MAPk kinase MKK]	1.5849625007211563	3	1	0	0
17165	1520	glucocorticoid-induced cell death	[glucocorticoid-induced cell death]	1.5849625007211563	3	2	1	1
17166	1520	s phase gene	[S phase gene]	1.5849625007211563	3	2	2	2
17167	1520	response to PMA/anti-CD28 mab	[response to PMA/anti-CD28 mAb]	1.5849625007211563	4	1	0	0
17168	1520	expression in fibroblast	[expression in fibroblasts]	1.5849625007211563	3	2	2	2
17169	1520	level of transcriptional activity	[level of transcriptional activity]	1.5849625007211563	4	1	0	0
17170	1520	inhibitor b alpha	[inhibitor B alpha]	1.5849625007211563	3	2	2	2
17171	1520	occurrence of a silencer	[Occurrence of a silencer]	1.5849625007211563	4	1	0	0
17172	1520	condition link the expression	[condition linking the expression]	1.5849625007211563	4	1	0	0
17173	1520	inhibition of lysozyme release	[inhibition of lysozyme release]	1.5849625007211563	4	1	0	0
17174	1520	b cell-specific activity	[B cell-specific activity]	1.5849625007211563	3	2	1	1
17175	1520	propidium iodide staining	[propidium iodide staining]	1.5849625007211563	3	1	0	0
17176	1520	transcription of a promoter	[transcription of a promoter]	1.5849625007211563	4	2	1	1
17177	1520	effector T cells.	[effector T cells.]	1.5849625007211563	3	1	0	0
17178	1520	human cytomegalovirus ul44	[human cytomegalovirus UL44]	1.5849625007211563	3	1	0	0
17179	1520	GM-kappa b sequence	[GM-kappa B sequence]	1.5849625007211563	3	1	0	0
17180	1520	surface of antigen cell	[surface of antigen cells]	1.5849625007211563	4	1	0	0
17181	1520	addition, competitive single-cell	[addition, competitive single-cell]	1.5849625007211563	3	1	0	0
17182	1520	positive selection of lymphocyte	[positive selection of lymphocytes]	1.5849625007211563	4	1	0	0
17183	1520	whole cell assay	[whole cell assay]	1.5849625007211563	3	2	2	2
17184	1520	enhancement of ifna synthesis	[Enhancement of IFNA synthesis]	1.5849625007211563	4	1	0	0
17185	1520	fluoroquinolone antibiotic ciprofloxacin cipro	[fluoroquinolone antibiotic ciprofloxacin cipro]	1.5849625007211563	4	1	0	0
17186	1520	initiation of resuscitation.	[initiation of resuscitation.]	1.5849625007211563	3	1	0	0
17187	1520	cell-specific pattern of synergy	[cell-specific patterns of synergy]	1.5849625007211563	4	1	0	0
17188	1520	cd8+ T cell supernatant	[CD8+ T cell supernatants]	1.5849625007211563	4	1	0	0
17189	1520	contrast to phorbol ester	[contrast to phorbol esters]	1.5849625007211563	4	1	0	0
17190	1520	multiple ap2 binding site	[multiple AP2 binding sites]	1.5849625007211563	4	1	0	0
17191	1520	study of apoptosis	[studies of apoptosis]	1.5849625007211563	3	1	0	0
17192	1520	nuclear export in cell	[nuclear export in cells]	1.5849625007211563	4	1	0	0
17193	1520	novel target specificity	[novel target specificity]	1.5849625007211563	3	1	0	0
17194	1520	conjunction with TPA	[conjunction with TPA]	1.5849625007211563	3	1	0	0
17195	1520	4-month interval during treatment.	[4-month intervals during treatment.]	1.5849625007211563	4	1	0	0
17196	1520	consensus sequence ctcacntnc	[consensus sequence CTCACNTNC]	1.5849625007211563	3	1	0	0
17197	1520	key regulator of hematopoiesis	[key regulators of hematopoiesis]	1.5849625007211563	4	1	0	0
17198	1520	Sp family member	[Sp family members]	1.5849625007211563	3	1	0	0
17199	1520	modulation of transcription factor	[Modulation of transcription factor]	1.5849625007211563	4	1	0	0
17200	1520	aids -gr group	[AIDS -GR group]	1.5849625007211563	3	1	0	0
17201	1520	response to FMLP	[response to FMLP]	1.5849625007211563	3	1	0	0
17202	1520	pp2b cyclosporine a	[PP2B cyclosporine A]	1.5849625007211563	3	1	0	0
17203	1520	ablate the expression	[ablating the expression]	1.5849625007211563	3	1	0	0
17204	1520	phosphatase 2a-sensitive site	[phosphatase 2A-sensitive sites]	1.5849625007211563	3	1	0	0
17205	1520	enhancer region just upstream	[enhancer region just upstream]	1.5849625007211563	4	1	0	0
17206	1520	incubation with oleate	[incubation with oleate]	1.5849625007211563	3	2	2	2
17207	1520	defect in gammac	[defect in gammac]	1.5849625007211563	3	1	0	0
17208	1520	(gamma(c))-like molecule il-13r alpha1	[(gamma(c))-like molecule IL-13R alpha1]	1.5849625007211563	4	1	0	0
17209	1520	multiple positive transcriptional element	[multiple positive transcriptional elements]	1.5849625007211563	4	1	0	0
17210	1520	GR binding capacity	[GR binding capacity]	1.5849625007211563	3	2	1	1
17211	1520	consensus response element present	[consensus response elements present]	1.5849625007211563	4	1	0	0
17212	1520	t-lymphocyte cell line Jurkat	[T-lymphocyte cell line Jurkat]	1.5849625007211563	4	1	0	0
17213	1520	use Scatchard analysis	[using Scatchard analysis]	1.5849625007211563	3	1	0	0
17214	1520	proliferation in T cell	[proliferation in T cells]	1.5849625007211563	4	1	0	0
17215	1520	Zta of qp function	[Zta of Qp function]	1.5849625007211563	4	1	0	0
17216	1520	acylation of OspA	[Acylation of OspA]	1.5849625007211563	3	1	0	0
17217	1520	transcription of c-fo gene	[transcription of c-fos genes]	1.5849625007211563	4	1	0	0
17218	1520	least two dna-binding complex	[least two DNA-binding complexes]	1.5849625007211563	4	1	0	0
17219	1520	PD98059 a inhibitor	[PD98059 a inhibitor]	1.5849625007211563	3	2	2	2
17220	1520	renal cell carcinomas.	[renal cell carcinomas.]	1.5849625007211563	3	1	0	0
17221	1520	mildly oxldl (50	[Mildly oxLDLs (50]	1.5849625007211563	3	1	0	0
17222	1520	human blood-derived Mo	[human blood-derived Mo]	1.5849625007211563	3	1	0	0
17223	1520	nuclear t3 receptor nt3r	[nuclear T3 receptor NT3R]	1.5849625007211563	4	1	0	0
17224	1520	proliferation of primitive hpc	[proliferation of primitive HPCs]	1.5849625007211563	4	1	0	0
17225	1520	However, presentation of ie1	[However, presentation of IE1]	1.5849625007211563	4	1	0	0
17226	1520	inducer of cd11b/cd18 expression	[inducer of CD11b/CD18 expression]	1.5849625007211563	4	1	0	0
17227	1520	cell surface immunoglobulin ig	[cell surface immunoglobulin Ig]	1.5849625007211563	4	1	0	0
17228	1520	inhibition of gene expression	[inhibition of gene expression]	1.5849625007211563	4	2	2	2
17229	1520	number adhere pmn	[number adhering PMN]	1.5849625007211563	3	1	0	0
17230	1520	regulation of ctcf activity	[regulation of CTCF activity]	1.5849625007211563	4	1	0	0
17231	1520	lytic expression program	[lytic expression program]	1.5849625007211563	3	1	0	0
17232	1520	consistency of translocation	[consistency of translocations]	1.5849625007211563	3	1	0	0
17233	1520	threshold of cathepsin g	[threshold of cathepsin G]	1.5849625007211563	4	2	1	1
17234	1520	luman of breast duct	[lumen of breast ducts]	1.5849625007211563	4	1	0	0
17235	1520	lymphocyte glucocorticoid receptor number	[Lymphocyte glucocorticoid receptor number]	1.5849625007211563	4	1	0	0
17236	1520	mapk pathway by tcc	[MAPK pathway by TCC]	1.5849625007211563	4	1	0	0
17237	1520	(abdominal obese: 31.90	[(abdominal obese: 31.90]	1.5849625007211563	3	1	0	0
17238	1520	type 2 response il-4	[type 2 responses IL-4]	1.5849625007211563	4	1	0	0
17239	1520	t-cell cDNA library	[T-cell cDNA library]	1.5849625007211563	3	1	0	0
17240	1520	STAT3 DNA binding	[STAT3 DNA binding]	1.5849625007211563	3	1	0	0
17241	1520	relation between the functionality	[relation between the functionality]	1.5849625007211563	4	1	0	0
17242	1520	long beta-globin gene silencing	[long-term beta-globin gene silencing]	1.5849625007211563	4	1	0	0
17243	1520	conclusion about pathogenesis	[conclusions about pathogenesis]	1.5849625007211563	3	1	0	0
17244	1520	morphology, hemoglobin accumulation	[morphology, hemoglobin accumulation]	1.5849625007211563	3	1	0	0
17245	1520	follicular small cell lymphoma	[follicular small cell lymphomas]	1.5849625007211563	4	1	0	0
17246	1520	BCL2 -responsive checkpoint eventuate	[BCL2 -responsive checkpoint eventuating]	1.5849625007211563	4	1	0	0
17247	1520	CD2 T lymphocyte	[CD2 T lymphocyte]	1.5849625007211563	3	1	0	0
17248	1520	higher-affinity site for NF-ATp	[higher-affinity site for NF-ATp]	1.5849625007211563	4	1	0	0
17249	1520	lymphocyte of patient	[Lymphocytes of patients]	1.5849625007211563	3	2	2	2
17250	1520	peripheral blood pb	[peripheral blood PB]	1.5849625007211563	3	2	1	1
17251	1520	use mrna differential display	[using mRNA differential display]	1.5849625007211563	4	2	1	1
17252	1520	stability of IL-8 mrna	[stability of IL-8 mRNA]	1.5849625007211563	4	1	0	0
17253	1520	asparagine side chain	[asparagine side chain]	1.5849625007211563	3	1	0	0
17254	1520	preincubation with the lysophospholipid.	[preincubation with the lysophospholipid.]	1.5849625007211563	4	1	0	0
17255	1520	generation by Azeptin	[generation by Azeptin]	1.5849625007211563	3	1	0	0
17256	1520	least two contacts,	[least two contacts,]	1.5849625007211563	3	1	0	0
17257	1520	protein tyrosine kinase inhibitor	[protein tyrosine kinase inhibitors]	1.5849625007211563	4	1	0	0
17258	1520	plasma cell differentiation	[plasma cell differentiation]	1.5849625007211563	3	1	0	0
17259	1520	T cell nuclear extract	[T cell nuclear extracts]	1.5849625007211563	4	1	0	0
17260	1520	T cell factor-1 tcf-1	[T cell factor-1 TCF-1]	1.5849625007211563	4	1	0	0
17261	1520	I gene expression	[I gene expression]	1.5849625007211563	3	2	2	2
17262	1520	several cell lines.	[several cell lines.]	1.5849625007211563	3	1	0	0
17263	1520	lectin to control level	[lectin to control levels]	1.5849625007211563	4	1	0	0
17264	1520	pre-B cell line	[pre-B cell line]	1.5849625007211563	3	2	1	1
17265	1520	stimulation by IL-1	[stimulation by IL-1]	1.5849625007211563	3	1	0	0
17266	1520	nf-kappa b p65 mutant	[NF-kappa B p65 mutants]	1.5849625007211563	4	1	0	0
17267	1520	number of early-response gene	[number of early-response genes]	1.5849625007211563	4	1	0	0
17268	1520	variation between the sequences,	[variations between the sequences,]	1.5849625007211563	4	1	0	0
17269	1520	two potential alpha-helical domain	[two potential alpha-helical domains]	1.5849625007211563	4	1	0	0
17270	1520	oxidation of ldl lipid	[oxidation of LDL lipids]	1.5849625007211563	4	1	0	0
17271	1520	monocytic (U937) cell line	[monocytic (U937) cell lines]	1.5849625007211563	4	1	0	0
17272	1520	hiv-infected patient with affinity	[HIV-infected patients with affinity]	1.5849625007211563	4	2	2	2
17273	1520	mode of cell death	[mode of cell death]	1.5849625007211563	4	1	0	0
17274	1520	Finally, cd27 cross-linking	[Finally, CD27 cross-linking]	1.5849625007211563	3	1	0	0
17275	1520	role of Cbl-b	[role of Cbl-b]	1.5849625007211563	3	1	0	0
17276	1520	context of bind site	[context of binding site]	1.5849625007211563	4	1	0	0
17277	1520	ivs1-10t-->c to the other.	[IVS1-10T-->C to the other.]	1.5849625007211563	4	1	0	0
17278	1520	JAK3 -dependent pathway	[JAK3 -dependent pathways]	1.5849625007211563	3	1	0	0
17279	1520	ifn-gamma for 9 hour	[IFN-gamma for 9 hr]	1.5849625007211563	4	1	0	0
17280	1520	role for NF-kappaB	[role for NF-kappaB]	1.5849625007211563	3	2	2	2
17281	1520	various Jurkat mutant deficient	[various Jurkat mutants deficient]	1.5849625007211563	4	1	0	0
17282	1520	nuclear factor NF-kB	[nuclear factor NF-kB]	1.5849625007211563	3	1	0	0
17283	1520	antithyroid drug treatment	[antithyroid drug treatment]	1.5849625007211563	3	1	0	0
17284	1520	Vmax of the SERCA	[Vmax of the SERCA]	1.5849625007211563	4	1	0	0
17285	1520	novel transcriptional enhancer element	[novel transcriptional enhancer element]	1.5849625007211563	4	1	0	0
17286	1520	il-4-producing th2 cell	[IL-4-producing Th2 cells]	1.5849625007211563	3	1	0	0
17287	1520	amino acid domain	[amino acid domain]	1.5849625007211563	3	2	1	1
17288	1520	important role of bsap	[important role of BSAP]	1.5849625007211563	4	2	2	2
17289	1520	nadph-oxidase component cytochrome b558	[NADPH-oxidase component cytochrome b558]	1.5849625007211563	4	1	0	0
17290	1520	common marmoset T lymphocyte	[common marmoset T lymphocytes]	1.5849625007211563	4	1	0	0
17291	1520	hydrolysis of inositol phosphate	[hydrolysis of inositol phosphates]	1.5849625007211563	4	1	0	0
17292	1520	intrinsic dna-binding activity	[intrinsic DNA-binding activity]	1.5849625007211563	3	1	0	0
17293	1520	secondary hyperaldosteronism pseudohyperaldosteronism	[secondary hyperaldosteronism pseudohyperaldosteronism]	1.5849625007211563	3	1	0	0
17294	1520	high gcr binding affinity	[high GCR binding affinities]	1.5849625007211563	4	1	0	0
17295	1520	transform growth factor-beta tgf-beta	[transforming growth factor-beta TGF-beta]	1.5849625007211563	4	2	1	1
17296	1520	(up to 1.8 +/-	[(up to 1.8 +/-]	1.5849625007211563	4	1	0	0
17297	1520	immune response toward Th1	[immune response toward Th1]	1.5849625007211563	4	1	0	0
17298	1520	1 alpha mip-1 alpha	[1 alpha MIP-1 alpha]	1.5849625007211563	4	1	0	0
17299	1520	blast in M7	[blasts in M7]	1.5849625007211563	3	1	0	0
17300	1520	addition to c-kit receptor	[addition to c-kit receptors]	1.5849625007211563	4	1	0	0
17301	1520	rela -p100 cytoplasmic complex	[RelA -p100 cytoplasmic complexes]	1.5849625007211563	4	1	0	0
17302	1520	expression of tnf-alpha beta	[expression of TNF-alpha beta]	1.5849625007211563	4	1	0	0
17303	1520	ligand for CD28	[ligands for CD28]	1.5849625007211563	3	2	2	2
17304	1520	benefit reduce platelet transfusion	[benefit reducing platelet transfusion]	1.5849625007211563	4	1	0	0
17305	1520	Ig kappa 3' enhancer	[Ig kappa 3' enhancer]	1.5849625007211563	4	1	0	0
17306	1520	few transcription factor	[few transcription factors]	1.5849625007211563	3	1	0	0
17307	1520	process of apoptosis	[process of apoptosis]	1.5849625007211563	3	2	1	1
17308	1520	single complex contain nf-atp	[single complex containing NF-ATp]	1.5849625007211563	4	1	0	0
17309	1520	Conversely, glucocorticoid receptor affinity	[Conversely, glucocorticoid receptor affinity]	1.5849625007211563	4	1	0	0
17310	1520	model of megakaryocytic differentiation	[model of megakaryocytic differentiation]	1.5849625007211563	4	1	0	0
17311	1520	mononuclear phagocyte activation	[mononuclear phagocyte activation]	1.5849625007211563	3	1	0	0
17312	1520	T helper differentiation	[T helper differentiation]	1.5849625007211563	3	1	0	0
17313	1520	P0 -compatible nfat activity	[P0 -compatible NFAT activity]	1.5849625007211563	4	1	0	0
17314	1520	myelomonocytic lineage specific gene	[myelomonocytic lineage specific gene]	1.5849625007211563	4	1	0	0
17315	1520	unexplained, persistent eosinophilia	[unexplained, persistent eosinophilia]	1.5849625007211563	3	1	0	0
17316	1520	kappa intron enhancer	[kappa intron enhancer]	1.5849625007211563	3	1	0	0
17317	1520	functional consequence, adhesion	[functional consequence, adhesion]	1.5849625007211563	3	1	0	0
17318	1520	human il-2r beta asn240-leu335	[human IL-2R beta Asn240-Leu335]	1.5849625007211563	4	1	0	0
17319	1520	deactivation of mononuclear phagocyte	[Deactivation of mononuclear phagocytes]	1.5849625007211563	4	1	0	0
17320	1520	intracellular glutathione gsh level	[intracellular glutathione GSH level]	1.5849625007211563	4	1	0	0
17321	1520	CBP a histone acetyltransferase	[CBP a histone acetyltransferase]	1.5849625007211563	4	1	0	0
17322	1520	non- T cell	[non- T cells]	1.5849625007211563	3	2	1	1
17323	1520	intraductal carcinoma IDC	[intraductal carcinoma IDC]	1.5849625007211563	3	1	0	0
17324	1520	lac-Z reporter gene	[lac-Z reporter gene]	1.5849625007211563	3	1	0	0
17325	1520	AAGTGA tetrahexamer sequence	[AAGTGA tetrahexamer sequence]	1.5849625007211563	3	1	0	0
17326	1520	observation inactive in c81-66-45	[observation inactive in C81-66-45]	1.5849625007211563	4	1	0	0
17327	1520	anti- CR3 abs	[anti- CR3 Abs]	1.5849625007211563	3	1	0	0
17328	1520	response to mitogen	[response to mitogens]	1.5849625007211563	3	2	1	1
17329	1520	clonal rearrangement of gene	[clonal rearrangement of genes]	1.5849625007211563	4	1	0	0
17330	1520	reactivity towards antisera	[reactivity towards antisera]	1.5849625007211563	3	1	0	0
17331	1520	Zta dna-binding activity	[Zta DNA-binding activity]	1.5849625007211563	3	1	0	0
17332	1520	none of the substitution	[None of the substitutions]	1.5849625007211563	4	1	0	0
17333	1520	(for lymphoid enhancer factor	[(for lymphoid enhancer factor]	1.5849625007211563	4	1	0	0
17334	1520	contribution of phosphatase inhibitor	[contribution of phosphatase inhibitors]	1.5849625007211563	4	1	0	0
17335	1520	distinct sequence motif	[distinct sequence motif]	1.5849625007211563	3	1	0	0
17336	1520	contrast to PBMo	[contrast to PBMo]	1.5849625007211563	3	1	0	0
17337	1520	NF-kappa b-inducible early gene	[NF-kappa B-inducible early genes]	1.5849625007211563	4	1	0	0
17338	1520	selective regulation by member	[selective regulation by members]	1.5849625007211563	4	1	0	0
17339	1520	p24 antigen level	[p24 antigen level]	1.5849625007211563	3	1	0	0
17340	1520	nonrelated cell as	[nonrelated cells as]	1.5849625007211563	3	1	0	0
17341	1520	p24 antigen measurement	[p24 antigen measurement]	1.5849625007211563	3	1	0	0
17342	1520	embryonic skeletal muscle lineage	[embryonic skeletal muscle lineage]	1.5849625007211563	4	1	0	0
17343	1520	E2a- Pbx1 apoptosis	[E2a- Pbx1 apoptosis]	1.5849625007211563	3	1	0	0
17344	1520	increase of caspase activity	[increase of caspase activity]	1.5849625007211563	4	2	1	1
17345	1520	series of reporter plasmid	[series of reporter plasmids]	1.5849625007211563	4	1	0	0
17346	1520	novel nuclear factor ms-2	[novel nuclear factor MS-2]	1.5849625007211563	4	1	0	0
17347	1520	capacity of anti- Jun	[capacity of anti- Jun]	1.5849625007211563	4	1	0	0
17348	1520	basis of change	[basis of changes]	1.5849625007211563	3	1	0	0
17349	1520	il-6 thp-1 macrophage	[IL-6 THP-1 macrophages]	1.5849625007211563	3	1	0	0
17350	1520	addition activate transcription	[addition activating transcription]	1.5849625007211563	3	1	0	0
17351	1520	103-amino-acid basic protein	[103-amino-acid basic protein]	1.5849625007211563	3	1	0	0
17352	1520	virtually no information	[Virtually no information]	1.5849625007211563	3	1	0	0
17353	1520	GM-CSF promoter-driven reporter plasmid	[GM-CSF promoter-driven reporter plasmid]	1.5849625007211563	4	1	0	0
17354	1520	37.5% reduction in dose	[37.5% reduction in dose]	1.5849625007211563	4	1	0	0
17355	1520	increase in the Kmone	[increase in the Km]	1.5849625007211563	4	1	0	0
17356	1520	intrinsic tyrosine kinase activity	[intrinsic tyrosine kinase activity]	1.5849625007211563	4	1	0	0
17357	1520	h2o2 scavenger pyrrolidine dithiocarbamate	[H2O2 scavenger pyrrolidine dithiocarbamate]	1.5849625007211563	4	1	0	0
17358	1520	inhibitory effect on NFAT	[inhibitory effects on NFAT]	1.5849625007211563	4	1	0	0
17359	1520	interplay of promoter element	[interplay of promoter elements]	1.5849625007211563	4	1	0	0
17360	1520	series of signal event	[series of signaling events]	1.5849625007211563	4	1	0	0
17361	1520	heptamer motif aacaaag	[heptamer motif AACAAAG]	1.5849625007211563	3	1	0	0
17362	1520	single hmg box	[single HMG box]	1.5849625007211563	3	2	1	1
17363	1520	resynthesis of the protein.	[resynthesis of the protein.]	1.5849625007211563	4	1	0	0
17364	1520	disruption of microtubular assembly	[disruption of microtubular assembly]	1.5849625007211563	4	1	0	0
17365	1520	E2F -dependent regulation	[E2F -dependent regulation]	1.5849625007211563	3	1	0	0
17366	1520	age of subject	[age of subjects]	1.5849625007211563	3	1	0	0
17367	1520	2 complex translocations,	[2 complex translocations,]	1.5849625007211563	3	1	0	0
17368	1520	other X1 box-specific activity	[other X1 box-specific activities]	1.5849625007211563	4	1	0	0
17369	1520	mitotic recombination event	[mitotic recombination events]	1.5849625007211563	3	1	0	0
17370	1520	biosynthesis of il-2	[biosynthesis of IL-2]	1.5849625007211563	3	1	0	0
17371	1520	octamer-binding transcription factor	[octamer-binding transcription factors]	1.5849625007211563	3	2	2	2
17372	1520	nuclear localization of gr	[nuclear localization of GR]	1.5849625007211563	4	1	0	0
17373	1520	CD34 promoter by MZF-1	[CD34 promoter by MZF-1]	1.5849625007211563	4	1	0	0
17374	1520	VCAM- NF-kappa b oligomer	[VCAM- NF-kappa B oligomer]	1.5849625007211563	4	1	0	0
17375	1520	development of clinical disease	[development of clinical disease.]	1.5849625007211563	4	1	0	0
17376	1520	binding of Oct-1	[binding of Oct-1]	1.5849625007211563	3	1	0	0
17377	1520	gc -receptor (gc-r) parameter	[GC -receptor (GC-R) parameters]	1.5849625007211563	4	1	0	0
17378	1520	induction of erythroid differentiation	[induction of erythroid differentiation]	1.5849625007211563	4	2	1	1
17379	1520	Instead, regulation of activation	[Instead, regulation of activation]	1.5849625007211563	4	1	0	0
17380	1520	chloramphenicol acetyltransferase reporter plasmid	[chloramphenicol acetyltransferase reporter plasmid]	1.5849625007211563	4	1	0	0
17381	1520	palindromic site site b	[palindromic site site B]	1.5849625007211563	4	1	0	0
17382	1520	adhesion of platelet	[adhesion of platelets]	1.5849625007211563	3	1	0	0
17383	1520	follow stimulation of CR1	[following stimulation of CR1]	1.5849625007211563	4	1	0	0
17384	1520	induction of nf-kb factor	[induction of NF-KB factor]	1.5849625007211563	4	1	0	0
17385	1520	RAW264.7 macrophage cell	[RAW264.7 macrophage cells]	1.5849625007211563	3	1	0	0
17386	1520	(CB) progenitor cell	[(CB) progenitor cells]	1.5849625007211563	3	1	0	0
17387	1520	plc gamma 1 overexpression	[PLC gamma 1 overexpression]	1.5849625007211563	4	1	0	0
17388	1520	inability of cell	[inability of cells]	1.5849625007211563	3	1	0	0
17389	1520	NF-kappa b regulation	[NF-kappa B regulation]	1.5849625007211563	3	1	0	0
17390	1520	pim-1 gene expression	[pim-1 gene expression]	1.5849625007211563	3	1	0	0
17391	1520	purine-box/arre/nf-at target DNA sequence	[purine-box/ARRE/NF-AT target DNA sequences]	1.5849625007211563	4	1	0	0
17392	1520	hence, th1/th2 balance	[hence, TH1/TH2 balance]	1.5849625007211563	3	1	0	0
17393	1520	unusually persistent transcription	[unusually persistent transcription]	1.5849625007211563	3	1	0	0
17394	1520	cytokine such as il-2	[cytokines such as IL-2]	1.5849625007211563	4	1	0	0
17395	1520	lymphocyte of pregnant woman	[lymphocytes of pregnant women]	1.5849625007211563	4	2	1	1
17396	1520	similarly, substantial evidence	[Similarly, substantial evidence]	1.5849625007211563	3	1	0	0
17397	1520	unique domain of stat6	[unique domains of STAT6]	1.5849625007211563	4	1	0	0
17398	1520	use several hbd subfragment	[using several HBD subfragments]	1.5849625007211563	4	1	0	0
17399	1520	T cell include ETS1	[T cells including ETS1]	1.5849625007211563	4	1	0	0
17400	1520	96 -chaperoned antigenic peptide	[96 -chaperoned antigenic peptides]	1.5849625007211563	4	1	0	0
17401	1520	T cell-specific manner	[T cell-specific manner]	1.5849625007211563	3	1	0	0
17402	1520	new transcription factor np-tcii	[new transcription factor NP-TCII]	1.5849625007211563	4	1	0	0
17403	1520	primary murine erythroblast	[primary murine erythroblasts]	1.5849625007211563	3	1	0	0
17404	1520	monoclonal anti- CR1	[monoclonal anti- CR1]	1.5849625007211563	3	1	0	0
17405	1520	sp1 binding site present	[Sp1 binding sites present]	1.5849625007211563	4	1	0	0
17406	1520	sry-related protein sox-4	[SRY-related protein Sox-4]	1.5849625007211563	3	1	0	0
17407	1520	NF-kappa B p65 subunit	[NF-kappa B p65 subunit]	1.5849625007211563	4	1	0	0
17408	1520	cd4+ macrophage in tissue	[CD4+ macrophages in tissues]	1.5849625007211563	4	1	0	0
17409	1520	atypical pkc isoenzyme	[atypical PKC isoenzymes]	1.5849625007211563	3	2	1	1
17410	1520	hepatic leukemic factor	[hepatic leukemic factor]	1.5849625007211563	3	2	1	1
17411	1520	protein nuclear factor (nf)-kb	[protein nuclear factor (NF)-kB]	1.5849625007211563	4	1	0	0
17412	1520	22-bp duplication in SIVsmmPBj14	[22-bp duplication in SIVsmmPBj14]	1.5849625007211563	4	1	0	0
17413	1520	contrast, protease treatment	[contrast, protease treatment]	1.5849625007211563	3	1	0	0
17414	1520	subsequent nuclear translocation	[subsequent nuclear translocation]	1.5849625007211563	3	3	2	1
17415	1520	GATA-1 mrna level	[GATA-1 mRNA levels]	1.5849625007211563	3	1	0	0
17416	1520	response to medium cm	[response to medium CM]	1.5849625007211563	4	1	0	0
17417	1520	state level of mrna	[state levels of mRNA]	1.5849625007211563	4	2	2	2
17418	1520	Furthermore, cyclosporin A	[Furthermore, cyclosporin A]	1.5849625007211563	3	1	0	0
17419	1520	partial differentiation of hl-60	[partial differentiation of HL-60]	1.5849625007211563	4	1	0	0
17420	1520	Furthermore, cyclosporin a	[Furthermore, cyclosporin A]	1.5849625007211563	3	1	0	0
17421	1520	partially substitute for tpa	[partially substitute for TPA]	1.5849625007211563	4	1	0	0
17422	1520	cytokine signal network	[Cytokine signal networks]	1.5849625007211563	3	1	0	0
17423	1520	accord to diagnosis	[according to diagnosis]	1.5849625007211563	3	1	0	0
17424	1520	therapeutic concentrations, triflusal	[therapeutic concentrations, triflusal]	1.5849625007211563	3	1	0	0
17425	1520	adherence to fibronectin	[Adherence to fibronectin]	1.5849625007211563	3	1	0	0
17426	1520	binding of AP-2	[Binding of AP-2]	1.5849625007211563	3	1	0	0
17427	1520	approximately 70 residue	[approximately 70 residues]	1.5849625007211563	3	1	0	0
17428	1520	immature bone marrow cell	[immature bone marrow cells]	1.5849625007211563	4	1	0	0
17429	1520	stimulatory activity of hsf3	[stimulatory activity of HSF3]	1.5849625007211563	4	1	0	0
17430	1520	late stage of differentiation	[later stages of differentiation]	1.5849625007211563	4	2	2	2
17431	1520	Correspondingly, rnase treatment	[Correspondingly, RNase treatment]	1.5849625007211563	3	1	0	0
17432	1520	absence of the SSE	[absence of the SSE]	1.5849625007211563	4	1	0	0
17433	1520	one cell line	[one cell line]	1.5849625007211563	3	1	0	0
17434	1520	induction during differentiation	[induction during differentiation]	1.5849625007211563	3	2	2	2
17435	1520	calcium/calmodulin-dependent protein kinase	[calcium/calmodulin-dependent protein kinase]	1.5849625007211563	3	2	2	2
17436	1520	majority of the granulocyte	[majority of the granulocytes]	1.5849625007211563	4	1	0	0
17437	1520	antiviral, antiproliferative, function	[antiviral, antiproliferative, functions]	1.5849625007211563	3	1	0	0
17438	1520	butyric-acid yy-1 yyabu	[butyric-acid YY-1 YY-Bu]	1.5849625007211563	3	1	0	0
17439	1520	treatment with glucocorticoid	[treatment with glucocorticoids]	1.5849625007211563	3	1	0	0
17440	1520	thromboxane receptor gene expression	[thromboxane receptor gene expression]	1.5849625007211563	4	1	0	0
17441	1520	t-derived lymphoid cell	[T-derived lymphoid cells]	1.5849625007211563	3	1	0	0
17442	1520	gene product of interest	[gene product of interest]	1.5849625007211563	4	1	0	0
17443	1520	DNA element present	[DNA element present]	1.5849625007211563	3	2	2	2
17444	1520	acute t-cell malignancy	[acute T-cell malignancy]	1.5849625007211563	3	1	0	0
17445	1520	maintenance of proper microarchitecture	[maintenance of proper microarchitecture]	1.5849625007211563	4	1	0	0
17446	1520	herpes simplex virus-1 vector	[herpes simplex virus-1 vector]	1.5849625007211563	4	1	0	0
17447	1520	lps on hiv-1 replication	[LPS on HIV-1 replication]	1.5849625007211563	4	1	0	0
17448	1520	second signal critical	[second signal critical]	1.5849625007211563	3	1	0	0
17449	1520	DRA gene regulatory sequence	[DRA gene regulatory sequences]	1.5849625007211563	4	1	0	0
17450	1520	2 -stat 1	[2 -STAT 1]	1.5849625007211563	3	1	0	0
17451	1520	repressor of lymphocyte death	[repressor of lymphocyte death]	1.5849625007211563	4	2	1	1
17452	1520	protein (map) kinase Erk	[protein (MAP) kinases Erk]	1.5849625007211563	4	1	0	0
17453	1520	two groups, 17 sr	[two groups, 17 SR]	1.5849625007211563	4	1	0	0
17454	1520	STAT6 response element	[STAT6 response element]	1.5849625007211563	3	1	0	0
17455	1520	5-hydroxyeicosatetraenoic acid production.	[5-hydroxyeicosatetraenoic acid production.]	1.5849625007211563	3	1	0	0
17456	1520	certain adhesion molecule	[certain adhesion molecules]	1.5849625007211563	3	1	0	0
17457	1520	seal the culture	[sealing the culture]	1.5849625007211563	3	1	0	0
17458	1520	effect of oxldl	[effect of oxLDLs]	1.5849625007211563	3	2	1	1
17459	1520	Specific family of receptor	[Specific families of receptors]	1.5849625007211563	4	1	0	0
17460	1520	only on pbmc	[only on PBMC]	1.5849625007211563	3	1	0	0
17461	1520	dioxin receptor system	[dioxin receptor system]	1.5849625007211563	3	1	0	0
17462	1520	Currently, adenovirus ad	[Currently, adenovirus Ad]	1.5849625007211563	3	1	0	0
17463	1520	transcriptional induction of collagenase-1	[transcriptional induction of collagenase-1]	1.5849625007211563	4	1	0	0
17464	1520	downstream regulatory element	[downstream regulatory element]	1.5849625007211563	3	1	0	0
17465	1520	alpha-lipoic acid dihydrolipoic acid	[alpha-lipoic acid dihydrolipoic acid]	1.5849625007211563	4	1	0	0
17466	1520	structure of this tissue	[structure of these tissues]	1.5849625007211563	4	1	0	0
17467	1520	rele related polypeptide	[rel related polypeptides]	1.5849625007211563	3	1	0	0
17468	1520	nf-kappa b /rel homodimer	[NF-kappa B /Rel homodimer]	1.5849625007211563	4	1	0	0
17469	1520	human erythrocyte membrane	[human erythrocyte membranes]	1.5849625007211563	3	1	0	0
17470	1520	arachidonic acid aggregation	[arachidonic acid aggregation]	1.5849625007211563	3	1	0	0
17471	1520	nuclear factor NF-AT	[nuclear factor NF-AT]	1.5849625007211563	3	2	2	2
17472	1520	c-Jun NH2-terminal kinase JNK	[c-Jun NH2-terminal kinase JNK]	1.5849625007211563	4	1	0	0
17473	1520	state of functional unresponsiveness	[state of functional unresponsiveness]	1.5849625007211563	4	1	0	0
17474	1520	ectopic endometrial fragment	[ectopic endometrial fragments]	1.5849625007211563	3	1	0	0
17475	1520	complex process of selection.	[complex process of selection.]	1.5849625007211563	4	1	0	0
17476	1520	T cell nf-at activation	[T cell NF-AT activation]	1.5849625007211563	4	1	0	0
17477	1520	protein in binding activity	[proteins in binding activity]	1.5849625007211563	4	1	0	0
17478	1520	DNase i footprinting	[DNase I footprinting]	1.5849625007211563	3	2	1	1
17479	1520	IL-5 -produce t-cell clone	[IL-5 -producing T-cell clones]	1.5849625007211563	4	1	0	0
17480	1520	effect on the inhibition	[effect on the inhibition]	1.5849625007211563	4	2	1	1
17481	1520	effect in Ramos	[effect in Ramos]	1.5849625007211563	3	1	0	0
17482	1520	pretreatment of MCM	[pretreatment of MCM]	1.5849625007211563	3	1	0	0
17483	1520	presence of various concentration	[presence of various concentrations]	1.5849625007211563	4	1	0	0
17484	1520	TT T cell line	[TT T cell line]	1.5849625007211563	4	1	0	0
17485	1520	amino acid sequence similarity	[amino acid sequence similarity]	1.5849625007211563	4	1	0	0
17486	1520	protein-tyrosine kinase inhibitor genistein	[protein-tyrosine kinase inhibitors genistein]	1.5849625007211563	4	1	0	0
17487	1520	nuclear receptor superfamily responsible	[nuclear receptor superfamily responsible]	1.5849625007211563	4	1	0	0
17488	1520	cd23 nf-kappab activation	[CD23 NF-kappaB activation]	1.5849625007211563	3	1	0	0
17489	1520	21 repeat element	[21 repeat elements]	1.5849625007211563	3	1	0	0
17490	1520	inhibition of tnf-alpha production	[Inhibition of TNF-alpha production]	1.5849625007211563	4	2	1	1
17491	1520	Scatchard plot analysis	[Scatchard plot analysis]	1.5849625007211563	3	2	1	1
17492	1520	activation of Jak 2	[activation of Jak 2]	1.5849625007211563	4	1	0	0
17493	1520	coligation of CD28	[Coligation of CD28]	1.5849625007211563	3	1	0	0
17494	1520	express a bcr1 type	[expressing a bcr1 type]	1.5849625007211563	4	1	0	0
17495	1520	viral DNA synthesis	[Viral DNA synthesis]	1.5849625007211563	3	1	0	0
17496	1520	hlh-2 to the breakpoint	[hLH-2 to the breakpoint]	1.5849625007211563	4	1	0	0
17497	1520	rate of hiv transmission	[rate of HIV transmission]	1.5849625007211563	4	1	0	0
17498	1520	previously unrecognized element,	[previously unrecognized element,]	1.5849625007211563	3	1	0	0
17499	1520	expression of p13mtcp1	[Expression of p13MTCP1]	1.5849625007211563	3	2	1	1
17500	1520	platelet on cytokine production	[platelets on cytokine production]	1.5849625007211563	4	1	0	0
17501	1520	more mature cell line	[more mature cell lines]	1.5849625007211563	4	1	0	0
17502	1520	200-bp enhancer domain	[200-bp enhancer domain]	1.5849625007211563	3	1	0	0
17503	1520	expression of hiv plasmid	[expression of HIV plasmid]	1.5849625007211563	4	1	0	0
17504	1520	novel function of ebna2	[novel function of EBNA2]	1.5849625007211563	4	1	0	0
17505	1520	responsiveness to D3	[responsiveness to D3]	1.5849625007211563	3	1	0	0
17506	1520	receptor for interleukin (il)-10	[Receptors for interleukin (IL)-10]	1.5849625007211563	4	1	0	0
17507	1520	transcriptional activation of c-fo	[transcriptional activation of c-fos]	1.5849625007211563	4	1	0	0
17508	1520	other cell functions.	[other cell functions.]	1.5849625007211563	3	1	0	0
17509	1520	regulate normal hematopoietic differentiation	[regulating normal hematopoietic differentiation]	1.5849625007211563	4	1	0	0
17510	1520	TCR zeta chain	[TCR zeta chain]	1.5849625007211563	3	1	0	0
17511	1520	core traf binding motif	[core TRAF binding motif]	1.5849625007211563	4	1	0	0
17512	1520	ifn-gamma necrosis factor-alpha	[IFN-gamma necrosis factor-alpha]	1.5849625007211563	3	1	0	0
17513	1520	portion of the domain	[portion of the domain]	1.5849625007211563	4	2	2	2
17514	1520	join gene segment	[joining gene segments]	1.5849625007211563	3	2	2	2
17515	1520	transient expression experiment	[Transient expression experiments]	1.5849625007211563	3	2	1	1
17516	1520	responsiveness to gc	[responsiveness to GC]	1.5849625007211563	3	1	0	0
17517	1520	presence of four domain	[presence of four domains]	1.5849625007211563	4	1	0	0
17518	1520	mechanism of this effect	[mechanism of this effect]	1.5849625007211563	4	1	0	0
17519	1520	zpcat reporter gene construct	[ZpCat reporter gene constructs]	1.5849625007211563	4	1	0	0
17520	1520	alter the activity	[altering the activity]	1.5849625007211563	3	1	0	0
17521	1520	early step of activation	[early step of activation]	1.5849625007211563	4	1	0	0
17522	1520	level of nf-matp35 induction	[level of NF-MATp35 induction]	1.5849625007211563	4	1	0	0
17523	1520	50-kda nf-kappa b dimer	[50-kDa NF-kappa B dimer]	1.5849625007211563	4	1	0	0
17524	1520	same specific trans-acting factor	[same specific trans-acting factors]	1.5849625007211563	4	1	0	0
17525	1520	medium from monocyte	[medium from monocytes]	1.5849625007211563	3	1	0	0
17526	1520	inhibition of Rho activity	[Inhibition of Rho activity]	1.5849625007211563	4	1	0	0
17527	1520	effect on the kinetic	[effect on the kinetics]	1.5849625007211563	4	1	0	0
17528	1520	ability of IL-10	[ability of IL-10]	1.5849625007211563	3	1	0	0
17529	1520	direct link between change	[direct link between changes]	1.5849625007211563	4	1	0	0
17530	1520	random fine needle aspiration	[random fine needle aspirations]	1.5849625007211563	4	1	0	0
17531	1520	methylation-sensitive HpaII site	[methylation-sensitive HpaII site]	1.5849625007211563	3	1	0	0
17532	1520	cdr2-loop in domain	[CDR2-loop in domain]	1.5849625007211563	3	2	2	2
17533	1520	expression in human fibroblast	[expression in human fibroblasts]	1.5849625007211563	4	2	2	2
17534	1520	reactive follicular hyperplasia	[reactive follicular hyperplasia]	1.5849625007211563	3	2	2	2
17535	1520	act as tumor vaccine	[acting as tumor vaccines]	1.5849625007211563	4	1	0	0
17536	1520	expression of Btk	[expression of Btk]	1.5849625007211563	3	1	0	0
17537	1520	characteristic of pml-rar	[characteristic of PML-RAR]	1.5849625007211563	3	1	0	0
17538	1520	tyrosine phosphorylation of erk	[tyrosine phosphorylation of ERK]	1.5849625007211563	4	1	0	0
17539	1520	adult beta-like globin gene	[adult beta-like globin genes]	1.5849625007211563	4	2	2	2
17540	1520	phosphorylation of Oct-1	[phosphorylation of Oct-1]	1.5849625007211563	3	1	0	0
17541	1520	T cell growth factor	[T cell growth factor]	1.5849625007211563	4	2	1	1
17542	1520	T cell tropic strain	[T cell tropic strain]	1.5849625007211563	4	1	0	0
17543	1520	premature cell death	[premature cell death]	1.5849625007211563	3	1	0	0
17544	1520	whole tshr molecule.	[whole TSHR molecule.]	1.5849625007211563	3	1	0	0
17545	1520	lymphocyte from patient	[lymphocytes from patients]	1.5849625007211563	3	2	1	1
17546	1520	lead to the phosphorylation	[leading to the phosphorylation]	1.5849625007211563	4	1	0	0
17547	1520	immunodeficiency virus nef protein	[immunodeficiency virus Nef protein]	1.5849625007211563	4	1	0	0
17548	1520	rate of sexual transmission	[rate of sexual transmission]	1.5849625007211563	4	1	0	0
17549	1520	median (interquartile range).	[median (interquartile range).]	1.5849625007211563	3	1	0	0
17550	1520	helix (bhlh) transcription	[helix (bHLH) transcription]	1.5849625007211563	3	1	0	0
17551	1520	DNA bind motif	[DNA binding motif]	1.5849625007211563	3	2	1	1
17552	1520	tandem ap1 binding site	[tandem AP1 binding sites]	1.5849625007211563	4	2	2	2
17553	1520	level of cytokine rrna	[levels of cytokine mRNAs]	1.5849625007211563	4	1	0	0
17554	1520	adherence of blood cell	[adherence of blood cells]	1.5849625007211563	4	2	1	1
17555	1520	chronic myelogenous leukemia patient	[chronic myelogenous leukemia patients]	1.5849625007211563	4	2	1	1
17556	1520	il-4 signal transduction	[IL-4 signal transduction]	1.5849625007211563	3	1	0	0
17557	1520	granulocyte-macrophage colony-stimulating factor (gm-csf)-	[granulocyte-macrophage colony-stimulating factor (GM-CSF)-]	1.5849625007211563	4	1	0	0
17558	1520	stably express the il-10r	[stably expressing the IL-10R]	1.5849625007211563	4	1	0	0
17559	1520	stage i-iii breast cancer	[stage I-III breast cancer]	1.5849625007211563	4	1	0	0
17560	1520	ad e1a sequence	[Ad E1a sequences]	1.5849625007211563	3	2	2	2
17561	1520	target for transcription factor	[targets for transcription factors]	1.5849625007211563	4	1	0	0
17562	1520	transcription of inflammatory gene	[transcription of inflammatory genes]	1.5849625007211563	4	2	1	1
17563	1520	transactivation by bmlf1 protein	[transactivation by BMLF1 proteins]	1.5849625007211563	4	1	0	0
17564	1520	human alpha-globin gene	[human alpha-globin gene]	1.5849625007211563	3	1	0	0
17565	1520	related protein bcl-2	[related proteins bcl-2]	1.5849625007211563	3	1	0	0
17566	1520	follow cell fusion	[following cell fusion]	1.5849625007211563	3	1	0	0
17567	1520	form of aml1	[form of AML1]	1.5849625007211563	3	2	2	2
17568	1520	two 20-epi analogue	[two 20-epi analogues]	1.5849625007211563	3	1	0	0
17569	1520	thus, autoreactive t-cell	[Thus, autoreactive T-cells]	1.5849625007211563	3	1	0	0
17570	1520	okadaic acid -sensitive phosphatase	[okadaic acid -sensitive phosphatases]	1.5849625007211563	4	1	0	0
17571	1520	signal in b cell	[signaling in B cells]	1.5849625007211563	4	2	2	2
17572	1520	pathogenesis of bipolar disorder	[pathogenesis of bipolar disorder]	1.5849625007211563	4	1	0	0
17573	1520	3 nucleotide DR3	[3 nucleotides DR3]	1.5849625007211563	3	1	0	0
17574	1520	single tumor cell	[single tumor cells]	1.5849625007211563	3	2	1	1
17575	1520	317 base pair	[317 base pair]	1.5849625007211563	3	2	1	1
17576	1520	binding activity of NF1	[binding activities of NF1]	1.5849625007211563	4	1	0	0
17577	1520	+/- 0.49 nM; mean	[+/- 0.49 nM; mean]	1.5849625007211563	4	1	0	0
17578	1520	cytoplasmic level of RelA	[cytoplasmic levels of RelA]	1.5849625007211563	4	1	0	0
17579	1520	embryonic and/or fetal	[embryonic and/or fetal]	1.5849625007211563	3	1	0	0
17580	1520	alpha chain cd25	[alpha chain CD25]	1.5849625007211563	3	1	0	0
17581	1520	ability of slp-76	[ability of SLP-76]	1.5849625007211563	3	1	0	0
17582	1520	use a DNA sequence	[using a DNA sequence]	1.5849625007211563	4	1	0	0
17583	1520	tyrosine phosphorylation of fak	[tyrosine phosphorylation of FAK]	1.5849625007211563	4	1	0	0
17584	1520	NH(2)-terminal domain of N-WASP	[NH(2)-terminal domain of N-WASP]	1.5849625007211563	4	1	0	0
17585	1520	endothelial adhesion molecule induction	[endothelial adhesion molecule induction]	1.5849625007211563	4	1	0	0
17586	1520	stat6 activation by IL-4	[STAT6 activation by IL-4]	1.5849625007211563	4	1	0	0
17587	1520	nf-kappa b by h2o2	[NF-kappa B by H2O2]	1.5849625007211563	4	1	0	0
17588	1520	translation of the mrna	[translation of the mRNA]	1.5849625007211563	4	1	0	0
17589	1520	activity significantly great	[activity significantly greater]	1.5849625007211563	3	1	0	0
17590	1520	macrophage tnf synthesis	[macrophage TNF synthesis]	1.5849625007211563	3	1	0	0
17591	1520	76 breast carcinoma	[76 breast carcinomas]	1.5849625007211563	3	1	0	0
17592	1520	c/ebp ccaat/enhancer-binding protein	[C/EBP CCAAT/enhancer-binding protein]	1.5849625007211563	3	1	0	0
17593	1520	contain the y292	[containing the Y292]	1.5849625007211563	3	1	0	0
17594	1520	inefficient nf-kappab activation	[inefficient NF-kappaB activation]	1.5849625007211563	3	1	0	0
17595	1520	lps response element	[LPS response element]	1.5849625007211563	3	2	1	1
17596	1520	intense self-perpetuated transcription	[intense self-perpetuated transcription]	1.5849625007211563	3	1	0	0
17597	1520	subset of CAM	[subset of CAMs]	1.5849625007211563	3	2	1	1
17598	1520	target for tumor-eradicate CTL	[target for tumor-eradicating CTL]	1.5849625007211563	4	1	0	0
17599	1520	eklf binding site	[EKLF binding site]	1.5849625007211563	3	1	0	0
17600	1520	stimulation of virus replication	[stimulation of virus replication]	1.5849625007211563	4	1	0	0
17601	1520	GATA-1 DNA binding activity	[GATA-1 DNA binding activity]	1.5849625007211563	4	1	0	0
17602	1520	three internal peptide	[three internal peptides]	1.5849625007211563	3	1	0	0
17603	1520	patient with hiv infection	[Patients with HIV infections]	1.5849625007211563	4	1	0	0
17604	1520	1, g1 arrest	[1, G1 arrest]	1.5849625007211563	3	1	0	0
17605	1520	contrast to the type	[contrast to the type]	1.5849625007211563	4	1	0	0
17606	1520	human p40 promoter region	[human p40 promoter regions]	1.5849625007211563	4	1	0	0
17607	1520	L gene erythroid promoter	[L gene erythroid promoter]	1.5849625007211563	4	1	0	0
17608	1520	ebv sm protein	[EBV SM protein]	1.5849625007211563	3	1	0	0
17609	1520	LR1 -DNA complex	[LR1 -DNA complex]	1.5849625007211563	3	1	0	0
17610	1520	protein tyrosine kinase activation	[protein tyrosine kinase activation]	1.5849625007211563	4	1	0	0
17611	1520	association of Epstein-Barr virus	[association of Epstein-Barr virus]	1.5849625007211563	4	1	0	0
17612	1520	fetal globin express cell	[fetal globin expressing cells]	1.5849625007211563	4	1	0	0
17613	1520	loop region Ser23-Ala49	[loop regions Ser23-Ala49]	1.5849625007211563	3	1	0	0
17614	1520	nuclear matrix-associated Site IV	[nuclear matrix-associated Site IV]	1.5849625007211563	4	1	0	0
17615	1520	(day 5 culture	[(day 5 culture)]	1.5849625007211563	3	1	0	0
17616	1520	9-cis granulocytic differentiation	[9-cis granulocytic differentiation]	1.5849625007211563	3	1	0	0
17617	1520	cellular phenotype, t-cell receptor	[cellular phenotype, T-cell receptor]	1.5849625007211563	4	1	0	0
17618	1520	immediate early transactivator	[immediate early transactivator]	1.5849625007211563	3	1	0	0
17619	1520	herpesvirus saimiry HVS	[herpesvirus saimiri HVS]	1.5849625007211563	3	2	1	1
17620	1520	survival, disease site	[survival, disease sites]	1.5849625007211563	3	1	0	0
17621	1520	use promoter- plap plasmid	[using promoter- PLAP plasmids]	1.5849625007211563	4	1	0	0
17622	1520	pathogenesis of APL	[pathogenesis of APL]	1.5849625007211563	3	2	1	1
17623	1520	cellular response gene inducibility	[cellular response gene inducibility]	1.5849625007211563	4	1	0	0
17624	1520	atra -dependent growth inhibition	[ATRA -dependent growth inhibition]	1.5849625007211563	4	1	0	0
17625	1520	specific intracellular signal pathway	[specific intracellular signaling pathways]	1.5849625007211563	4	1	0	0
17626	1520	study with isogenic mutant	[studies with isogenic mutants]	1.5849625007211563	4	1	0	0
17627	1520	c-rel/ p65 heterodimer	[c-Rel/ p65 heterodimers]	1.5849625007211563	3	2	2	2
17628	1520	abnormality in patient	[abnormalities in patients]	1.5849625007211563	3	1	0	0
17629	1520	synthesis of a protein	[synthesis of a protein]	1.5849625007211563	4	1	0	0
17630	1520	even with physiotherapy	[even with physiotherapy]	1.5849625007211563	3	1	0	0
17631	1520	use gel shift assay	[Using gel shift assay]	1.5849625007211563	4	1	0	0
17632	1520	(hiv-1) replication in thymocyte	[(HIV-1) replication in thymocytes]	1.5849625007211563	4	1	0	0
17633	1520	ectopic expression of gata-3	[ectopic expression of GATA-3]	1.5849625007211563	4	1	0	0
17634	1520	specific protein-DNA complex	[specific protein-DNA complexes]	1.5849625007211563	3	2	2	2
17635	1520	upstream sequence in promoter	[upstream sequences in promoters]	1.5849625007211563	4	1	0	0
17636	1520	typical apoptotic features.	[typical apoptotic features.]	1.5849625007211563	3	1	0	0
17637	1520	Comparison of this sequence	[Comparison of these sequences]	1.5849625007211563	4	1	0	0
17638	1520	c-Jun N-terminal transactivation domain	[c-Jun N-terminal transactivation domain]	1.5849625007211563	4	1	0	0
17639	1520	allogeneic lymphocyte culture	[allogeneic lymphocyte cultures]	1.5849625007211563	3	1	0	0
17640	1520	high-affinity serum-inducible element hsie	[high-affinity serum-inducible element hSIE]	1.5849625007211563	4	1	0	0
17641	1520	family of polypeptide	[family of polypeptides]	1.5849625007211563	3	1	0	0
17642	1520	0.2-kb irf- CAT construct	[0.2-kb IRF- CAT construct]	1.5849625007211563	4	1	0	0
17643	1520	childrens' T cell	[childrens' T cells]	1.5849625007211563	3	1	0	0
17644	1520	CD40-activated human b lymphocyte	[CD40-activated human B lymphocytes]	1.5849625007211563	4	1	0	0
17645	1520	two major component	[two major components]	1.5849625007211563	3	1	0	0
17646	1520	regulation of inflammatory response	[regulation of inflammatory responses]	1.5849625007211563	4	1	0	0
17647	1520	unique model system	[unique model system]	1.5849625007211563	3	1	0	0
17648	1520	role in disease pathogenesis	[role in disease pathogenesis]	1.5849625007211563	4	1	0	0
17649	1520	tuberous sclerosis complex TSC	[tuberous sclerosis complex TSC]	1.5849625007211563	4	1	0	0
17650	1520	nfat -binding site	[NFAT -binding site]	1.5849625007211563	3	1	0	0
17651	1520	transcription factor EKLF	[transcription factors EKLF]	1.5849625007211563	3	1	0	0
17652	1520	mnda expression for cell	[MNDA expression for cells]	1.5849625007211563	4	1	0	0
17653	1520	expression of DR3	[Expression of DR3]	1.5849625007211563	3	1	0	0
17654	1520	presence of factor	[presence of factor]	1.5849625007211563	3	2	2	2
17655	1520	presence of c-Rel	[presence of c-Rel]	1.5849625007211563	3	1	0	0
17656	1520	gc box (-20)	[GC box (-20)]	1.5849625007211563	3	1	0	0
17657	1520	small population of cell	[small population of cells]	1.5849625007211563	4	1	0	0
17658	1520	t47d mammary tumor cell	[T47D mammary tumor cells]	1.5849625007211563	4	1	0	0
17659	1520	protein kinase c mechanism	[protein kinase C mechanism]	1.5849625007211563	4	1	0	0
17660	1520	small, Ras-like gtpase	[small, Ras-like GTPase]	1.5849625007211563	3	1	0	0
17661	1520	nuclei of rest eosinophil	[nuclei of resting eosinophils]	1.5849625007211563	4	1	0	0
17662	1520	human im-9 lymphocyte	[human IM-9 lymphocytes]	1.5849625007211563	3	1	0	0
17663	1520	insertion mutation in phop	[insertion mutations in phoP]	1.5849625007211563	4	1	0	0
17664	1520	granulocyte monocyte differentiation	[granulocyte monocyte differentiation]	1.5849625007211563	3	1	0	0
17665	1520	correlation of biochemical method	[correlation of biochemical methods]	1.5849625007211563	4	1	0	0
17666	1520	established: r59z activator cell	[established: R59Z activator cells]	1.5849625007211563	4	1	0	0
17667	1520	maintenance of aspect	[maintenance of aspects]	1.5849625007211563	3	1	0	0
17668	1520	gene fusion to AML1	[gene fusion to AML1]	1.5849625007211563	4	1	0	0
17669	1520	potential ap-1 binding site	[potential AP-1 binding site]	1.5849625007211563	4	1	0	0
17670	1520	successful production of no	[successful production of NO]	1.5849625007211563	4	1	0	0
17671	1520	lysate of T cell	[lysates of T cells]	1.5849625007211563	4	1	0	0
17672	1520	p50 gene coding	[p50 gene coding]	1.5849625007211563	3	1	0	0
17673	1520	addition, sodium salicylate	[addition, sodium salicylate]	1.5849625007211563	3	1	0	0
17674	1520	autoantibody in iddm	[autoantibodies in IDDM]	1.5849625007211563	3	1	0	0
17675	1520	tramp cell death	[TRAMP cell death]	1.5849625007211563	3	1	0	0
17676	1520	such as factor	[such as factor]	1.5849625007211563	3	1	0	0
17677	1520	intracellular biochemical event	[intracellular biochemical events]	1.5849625007211563	3	2	1	1
17678	1520	Janus kinase -stat	[Janus kinase -STAT]	1.5849625007211563	3	1	0	0
17679	1520	efficiency of the system	[efficiency of the system]	1.5849625007211563	4	1	0	0
17680	1520	effect of glucocorticoid therapy	[effect of glucocorticoid therapy]	1.5849625007211563	4	1	0	0
17681	1520	ERK -activate stimulus	[ERK -activating stimuli]	1.5849625007211563	3	1	0	0
17682	1520	intracellular binding protein CsA	[intracellular binding proteins CsA]	1.5849625007211563	4	1	0	0
17683	1520	IL-5 t-cell clone	[IL-5 T-cell clones]	1.5849625007211563	3	2	2	2
17684	1520	wide variety of organisms.	[wide variety of organisms.]	1.5849625007211563	4	1	0	0
17685	1520	short osteocalcin promoter	[short osteocalcin promoter]	1.5849625007211563	3	1	0	0
17686	1520	specific T cell line	[specific T cell lines]	1.5849625007211563	4	1	0	0
17687	1520	mitogen-activated T lymphocyte	[mitogen-activated T lymphocytes]	1.5849625007211563	3	2	1	1
17688	1520	low concentration of steroid	[lower concentrations of steroid]	1.5849625007211563	4	1	0	0
17689	1520	use the TUNEL assay	[using the TUNEL assay]	1.5849625007211563	4	1	0	0
17690	1520	infection by human adenoviruse	[infection by human adenoviruses]	1.5849625007211563	4	1	0	0
17691	1520	PML/RARalpha fusion protein	[PML/RARalpha fusion protein]	1.5849625007211563	3	1	0	0
17692	1520	tyrosine kinase p56(lck)	[tyrosine kinase p56(lck)]	1.5849625007211563	3	1	0	0
17693	1520	chemokine receptor BLR1	[chemokine receptor BLR1]	1.5849625007211563	3	1	0	0
17694	1520	inducible footprint between -183	[inducible footprint between -183]	1.5849625007211563	4	1	0	0
17695	1520	in vitro model	[in vitro model]	1.5849625007211563	3	1	0	0
17696	1520	constitutive factor A1	[constitutive factors A1]	1.5849625007211563	3	1	0	0
17697	1520	intravascular coagulation activation	[intravascular coagulation activation]	1.5849625007211563	3	1	0	0
17698	1520	differentiation of myelomonoblastic cell	[differentiation of myelomonoblastic cells]	1.5849625007211563	4	1	0	0
17699	1520	c-Rel -express cell monolayer	[c-Rel -expressing cell monolayers]	1.5849625007211563	4	1	0	0
17700	1520	other neuroendocrine cell characteristic	[other neuroendocrine cell characteristics]	1.5849625007211563	4	1	0	0
17701	1520	contain transcription factor	[containing transcription factor]	1.5849625007211563	3	2	2	2
17702	1520	onset of clinical symptom	[onset of clinical symptoms]	1.5849625007211563	4	1	0	0
17703	1520	antisense oligonucleotide ao	[antisense oligonucleotides AO]	1.5849625007211563	3	1	0	0
17704	1520	human herpesvirus type-8	[human herpesvirus type-8]	1.5849625007211563	3	2	2	2
17705	1520	basis of cross-linking result	[basis of cross-linking results]	1.5849625007211563	4	1	0	0
17706	1520	IL-2R alpha enhancer	[IL-2R alpha enhancer]	1.5849625007211563	3	1	0	0
17707	1520	elimination of self-reactive cell	[elimination of self-reactive cells]	1.5849625007211563	4	1	0	0
17708	1520	NF kappa b family	[NF kappa B family]	1.5849625007211563	4	1	0	0
17709	1520	high-level ebv replication	[high-level EBV replication]	1.5849625007211563	3	1	0	0
17710	1520	information on the effect	[information on the effects]	1.5849625007211563	4	1	0	0
17711	1520	serum ige level	[serum IgE levels]	1.5849625007211563	3	3	2	1
17712	1520	industrial compound 4-octylphenol	[industrial compound 4-octylphenol]	1.5849625007211563	3	1	0	0
17713	1520	as2o3 atp depletion	[As2O3 ATP depletion]	1.5849625007211563	3	1	0	0
17714	1520	stat3 -independent bcl2 downregulation	[Stat3 -independent BCL2 downregulation]	1.5849625007211563	4	1	0	0
17715	1520	variety of tissues.	[variety of tissues.]	1.5849625007211563	3	1	0	0
17716	1520	addition to the onset	[addition to the onset]	1.5849625007211563	4	1	0	0
17717	1520	growth-inhibitory effect of estrogen	[growth-inhibitory effect of estrogen]	1.5849625007211563	4	1	0	0
17718	1520	(within 1 min)	[(within 1 min)]	1.5849625007211563	3	1	0	0
17719	1520	composition of nf-at protein	[composition of NF-AT protein]	1.5849625007211563	4	1	0	0
17720	1520	suppressive effect of v3-bh10	[suppressive effect of V3-BH10]	1.5849625007211563	4	1	0	0
17721	1520	cysteine -rich region	[cysteine -rich regions]	1.5849625007211563	3	2	2	2
17722	1520	analysis of function	[analysis of function]	1.5849625007211563	3	1	0	0
17723	1520	precursor interleukin-1 alpha cytokine	[precursor interleukin-1 alpha cytokine]	1.5849625007211563	4	1	0	0
17724	1520	response to dm	[response to DM]	1.5849625007211563	3	1	0	0
17725	1520	6 normally menstruate woman	[6 normally menstruating women]	1.5849625007211563	4	1	0	0
17726	1520	exposure to VitD3	[Exposure to VitD3]	1.5849625007211563	3	1	0	0
17727	1520	phosphorylation status of traf2	[phosphorylation status of TRAF2]	1.5849625007211563	4	1	0	0
17728	1520	role of hiv1 infection	[role of HIV1 infection]	1.5849625007211563	4	1	0	0
17729	1520	b cell source	[B cell source]	1.5849625007211563	3	1	0	0
17730	1520	interleukin-8 gene expression	[interleukin-8 gene expression]	1.5849625007211563	3	2	2	2
17731	1520	response to e2	[response to E2]	1.5849625007211563	3	1	0	0
17732	1520	endogenous gene isg	[endogenous genes ISGs]	1.5849625007211563	3	1	0	0
17733	1520	hormone datum in parents,	[hormone data in parents,]	1.5849625007211563	4	1	0	0
17734	1520	define a subfamily	[defining a subfamily]	1.5849625007211563	3	1	0	0
17735	1520	family, dimethyldithiocarbamate DMDTC	[family, dimethyldithiocarbamate DMDTC]	1.5849625007211563	3	1	0	0
17736	1520	NF-muNR enhancer repressor	[NF-muNR enhancer repressor]	1.5849625007211563	3	1	0	0
17737	1520	B-cell line BJAB	[B-cell line BJAB]	1.5849625007211563	3	1	0	0
17738	1520	suggest a ap1 motif	[suggesting an AP1 motif]	1.5849625007211563	4	1	0	0
17739	1520	decrease Jun protein level	[decrease Jun protein levels]	1.5849625007211563	4	1	0	0
17740	1520	nf kappa b activity	[NF kappa B activity]	1.5849625007211563	4	1	0	0
17741	1520	present study, corticosteroid type	[present study, corticosteroid Type]	1.5849625007211563	4	1	0	0
17742	1520	pattern of gene activation	[pattern of gene activation]	1.5849625007211563	4	1	0	0
17743	1520	transcription of USF- promoter	[transcription of USF- promoters]	1.5849625007211563	4	1	0	0
17744	1520	type 2 cytokine il-4	[type 2 cytokines IL-4]	1.5849625007211563	4	1	0	0
17745	1520	vivo study in rat	[vivo studies in rats]	1.5849625007211563	4	1	0	0
17746	1520	response to a second	[response to a second]	1.5849625007211563	4	1	0	0
17747	1520	DNA consensus binding site	[DNA consensus binding site]	1.5849625007211563	4	1	0	0
17748	1520	mass of kilodalton	[mass of kilodaltons]	1.5849625007211563	3	2	2	2
17749	1520	hiv-1-encoded nef protein	[HIV-1-encoded Nef protein]	1.5849625007211563	3	1	0	0
17750	1520	site selection analysis	[site selection analysis]	1.5849625007211563	3	1	0	0
17751	1520	lung vascular adhesion molecule	[lung vascular adhesion molecule]	1.5849625007211563	4	1	0	0
17752	1520	long repeat region	[long repeat region]	1.5849625007211563	3	2	2	2
17753	1520	phosphorylation of traf2	[Phosphorylation of TRAF2]	1.5849625007211563	3	1	0	0
17754	1520	posttranscriptional effect of antioxidant	[posttranscriptional effect of antioxidants]	1.5849625007211563	4	1	0	0
17755	1520	IL-1 protein kinase IRAK	[IL-1 protein kinase IRAK]	1.5849625007211563	4	1	0	0
17756	1520	p40 gene promoter	[p40 gene promoter]	1.5849625007211563	3	1	0	0
17757	1520	various cellular organelle	[various cellular organelles]	1.5849625007211563	3	1	0	0
17758	1520	primary human leukocyte	[primary human leukocytes]	1.5849625007211563	3	1	0	0
17759	1520	degradative action of dexamethasone	[degradative action of dexamethasone]	1.5849625007211563	4	1	0	0
17760	1520	intracellular signal component	[intracellular signaling components]	1.5849625007211563	3	1	0	0
17761	1520	cause of cortisol resistance	[cause of cortisol resistance]	1.5849625007211563	4	2	1	1
17762	1520	monocyte adherence to fibronectin	[monocyte adherence to fibronectin]	1.5849625007211563	4	1	0	0
17763	1520	new protein-DNA complex	[new protein-DNA complex]	1.5849625007211563	3	1	0	0
17764	1520	mutation of this motif	[Mutation of this motif]	1.5849625007211563	4	1	0	0
17765	1520	osteoblast nuclear extract-DNA complex	[osteoblast nuclear extract-DNA complexes]	1.5849625007211563	4	1	0	0
17766	1520	other microbial product	[other microbial products]	1.5849625007211563	3	1	0	0
17767	1520	gm-csf RA 27%).	[GM-CSF RA 27%).]	1.5849625007211563	3	1	0	0
17768	1520	cotransfect jurkat cell	[cotransfecting Jurkat cells]	1.5849625007211563	3	1	0	0
17769	1520	activity in transient transfection	[activity in transient transfections]	1.5849625007211563	4	1	0	0
17770	1520	new biologic marker	[new biologic markers]	1.5849625007211563	3	1	0	0
17771	1520	study of tat function	[study of Tat function]	1.5849625007211563	4	1	0	0
17772	1520	encode the raz	[encoding the RAZ]	1.5849625007211563	3	1	0	0
17773	1520	peripheral venous blood sample	[peripheral venous blood samples]	1.5849625007211563	4	1	0	0
17774	1520	STAT3 nuclear translocation	[STAT3 nuclear translocation]	1.5849625007211563	3	1	0	0
17775	1520	use a slide assay	[using a slide assay]	1.5849625007211563	4	1	0	0
17776	1520	even so, medullary thymocyte	[Even so, medullary thymocytes]	1.5849625007211563	4	1	0	0
17777	1520	mouse embryonic globin gene	[mouse embryonic globin genes]	1.5849625007211563	4	1	0	0
17778	1520	dominant-negative cdk2 construct	[dominant-negative cdk2 construct]	1.5849625007211563	3	1	0	0
17779	1520	1alpha,25(OH)2-d5-previtamin D3 HF JN	[1alpha,25(OH)2-d5-previtamin D3 HF JN]	1.5849625007211563	4	1	0	0
17780	1520	(ebna2)-oestrogen receptor fusion protein	[(EBNA2)-oestrogen receptor fusion proteins]	1.5849625007211563	4	1	0	0
17781	1520	lead to the precipitation	[leading to the precipitation]	1.5849625007211563	4	1	0	0
17782	1520	alternative promoter site	[alternative promoter site]	1.5849625007211563	3	1	0	0
17783	1520	resistance to lysis	[resistance to lysis]	1.5849625007211563	3	1	0	0
17784	1520	platelet integrin alphaiibbeta3	[platelet integrin alphaIIbbeta3]	1.5849625007211563	3	1	0	0
17785	1520	octamer sequence by OCA-B	[octamer sequence by OCA-B]	1.5849625007211563	4	1	0	0
17786	1520	first 12 rdna HZF	[first 12 cDNAs HZF]	1.5849625007211563	4	1	0	0
17787	1520	interleukin (il)-2 in vitro.	[interleukin (IL)-2 in vitro.]	1.5849625007211563	4	1	0	0
17788	1520	IL-1beta /sv40 promoter /cat	[IL-1beta /SV40 promoter /CAT]	1.5849625007211563	4	1	0	0
17789	1520	absence of serum	[absence of serum]	1.5849625007211563	3	1	0	0
17790	1520	production of interferon-gamma ifn-gamma	[production of interferon-gamma IFN-gamma]	1.5849625007211563	4	1	0	0
17791	1520	moreover, camp activator	[Moreover, cAMP activators]	1.5849625007211563	3	1	0	0
17792	1520	phorbol 12-myristate 13-acetate activation	[phorbol 12-myristate 13-acetate activation]	1.5849625007211563	4	1	0	0
17793	1520	ifn-gamma response element IRE	[IFN-gamma response element IRE]	1.5849625007211563	4	1	0	0
17794	1520	identification of bcl-6 lesion	[identification of BCL-6 lesions]	1.5849625007211563	4	1	0	0
17795	1520	NF-M -estrogen receptor	[NF-M -estrogen receptor]	1.5849625007211563	3	1	0	0
17796	1520	two GATA-1 factor	[two GATA-1 factor]	1.5849625007211563	3	1	0	0
17797	1520	thp-1 cell by superantigen	[THP-1 cells by superantigens]	1.5849625007211563	4	1	0	0
17798	1520	major inducer in cell	[major inducer in cells]	1.5849625007211563	4	1	0	0
17799	1520	specific expression of pu.1	[specific expression of PU.1]	1.5849625007211563	4	1	0	0
17800	1520	acute myelogenous leukaemia	[acute myelogenous leukaemia]	1.5849625007211563	3	1	0	0
17801	1520	mechanism of immune modulation	[mechanisms of immune modulation]	1.5849625007211563	4	1	0	0
17802	1520	s107 plasmacytoma cell	[S107 plasmacytoma cells]	1.5849625007211563	3	1	0	0
17803	1520	transcriptional trans-activator tax	[transcriptional trans-activator Tax]	1.5849625007211563	3	1	0	0
17804	1520	signal mechanism of activator	[signaling mechanisms of activator]	1.5849625007211563	4	1	0	0
17805	1520	tumor-draining ln T cell	[tumor-draining LN T cells]	1.5849625007211563	4	2	1	1
17806	1520	N-terminal coactivator domain	[N-terminal coactivator domain]	1.5849625007211563	3	1	0	0
17807	1520	formation of NF-kappaB complex	[formation of NF-kappaB complexes]	1.5849625007211563	4	1	0	0
17808	1520	plasma sialyltransferase activity	[plasma sialyltransferase activity]	1.5849625007211563	3	1	0	0
17809	1520	dominant-negative mutant approach	[dominant-negative mutant approach]	1.5849625007211563	3	1	0	0
17810	1520	cell surface of cd45	[cell surface of CD45]	1.5849625007211563	4	1	0	0
17811	1520	basis for hyporesponsiveness	[basis for hyporesponsiveness]	1.5849625007211563	3	1	0	0
17812	1520	m-csf receptor c-fm	[M-CSF receptor C-FMS]	1.5849625007211563	3	1	0	0
17813	1520	ikappab kinase alpha ikkalpha	[IkappaB kinase alpha IKKalpha]	1.5849625007211563	4	1	0	0
17814	1520	signal transduction for cytokine	[signal transduction for cytokines]	1.5849625007211563	4	1	0	0
17815	1520	NFAT transcriptional complex	[NFAT transcriptional complex]	1.5849625007211563	3	2	2	2
17816	1520	megakaryocyte differentiation thrombopoietin	[megakaryocyte differentiation thrombopoietin]	1.5849625007211563	3	1	0	0
17817	1520	contain 13 zinc finger	[containing 13 zinc fingers]	1.5849625007211563	4	1	0	0
17818	1520	Sephacryl G-200 ultrafiltration	[Sephacryl G-200 ultrafiltration]	1.5849625007211563	3	1	0	0
17819	1520	intracellular free calcium level	[intracellular free calcium levels]	1.5849625007211563	4	1	0	0
17820	1520	skw 6.4 cell	[SKW 6.4 cells]	1.5849625007211563	3	2	2	2
17821	1520	I kappa b family	[I kappa B family]	1.5849625007211563	4	1	0	0
17822	1520	tumor necrosis factor, interleukin-1,	[tumor necrosis factor, interleukin-1,]	1.5849625007211563	4	1	0	0
17823	1520	pattern similar to PBMC	[pattern similar to PBMC]	1.5849625007211563	4	1	0	0
17824	1520	release in the hypothalamus.	[release in the hypothalamus.]	1.5849625007211563	4	1	0	0
17825	1520	control of prl expression	[control of PRL expression]	1.5849625007211563	4	1	0	0
17826	1520	thymic maturation for factor	[thymic maturation for factors]	1.5849625007211563	4	1	0	0
17827	1520	mature erythroid cell	[mature erythroid cells]	1.5849625007211563	3	2	1	1
17828	1520	promoter between basis -186	[promoter between bases -186]	1.5849625007211563	4	1	0	0
17829	1520	high local failure rate	[high local failure rate]	1.5849625007211563	4	2	1	1
17830	1520	positive transcriptional element	[positive transcriptional element]	1.5849625007211563	3	2	1	1
17831	1520	tissue culture cell	[tissue culture cells]	1.5849625007211563	3	2	2	2
17832	1520	limit amount of cbp	[limiting amounts of CBP]	1.5849625007211563	4	1	0	0
17833	1520	calcineurin autoinhibitory domain	[calcineurin autoinhibitory domain]	1.5849625007211563	3	1	0	0
17834	1520	htlv-1 tax for IkappaBalpha	[HTLV-1 Tax for IkappaBalpha]	1.5849625007211563	4	1	0	0
17835	1520	stress response system	[stress response system]	1.5849625007211563	3	1	0	0
17836	1520	rele family protein c-rel	[rel family proteins c-Rel]	1.5849625007211563	4	1	0	0
17837	1520	pml-rar alpha alpha	[PML-RAR alpha alpha]	1.5849625007211563	3	1	0	0
17838	1520	cellular survivalepromot protein	[cellular survival-promoting proteins]	1.5849625007211563	3	1	0	0
17839	1520	R.C.Gallo, Nature 349:533-535,	[R.C.Gallo, Nature 349:533-535,]	1.5849625007211563	3	1	0	0
17840	1520	program for recognition	[program for recognition]	1.5849625007211563	3	1	0	0
17841	1520	intracellular transcriptional factor	[intracellular transcriptional factors]	1.5849625007211563	3	1	0	0
17842	1520	p65 the two subunit	[p65 the two subunits]	1.5849625007211563	4	1	0	0
17843	1520	fusion protein e2a-hlf	[fusion protein E2A-HLF]	1.5849625007211563	3	1	0	0
17844	1520	mzf-2 in neutrophil development	[MZF-2 in neutrophil development]	1.5849625007211563	4	1	0	0
17845	1520	control of process	[control of processes]	1.5849625007211563	3	2	2	2
17846	1520	type ii interferon ifn-gamma	[type II interferon IFN-gamma]	1.5849625007211563	4	1	0	0
17847	1520	chronic leukemia CML	[chronic leukemia CML]	1.5849625007211563	3	2	2	2
17848	1520	increase concentration of tetracycline	[increasing concentrations of tetracyclines]	1.5849625007211563	4	1	0	0
17849	1520	suggest activity of nf-kappab	[suggesting activity of NF-kappaB]	1.5849625007211563	4	1	0	0
17850	1520	one such example	[One such example]	1.5849625007211563	3	1	0	0
17851	1520	activation of transcription factor,	[activation of transcription factor,]	1.5849625007211563	4	1	0	0
17852	1520	protein very similar	[protein very similar]	1.5849625007211563	3	1	0	0
17853	1520	signal transduction system	[signal transduction systems]	1.5849625007211563	3	1	0	0
17854	1520	murine monoclonal antibody	[murine monoclonal antibody]	1.5849625007211563	3	2	1	1
17855	1520	in vitro cortisol inhibition	[in vitro cortisol inhibition]	1.5849625007211563	4	1	0	0
17856	1520	HTLV-I -positive mt-2 cell	[HTLV-I -positive MT-2 cells]	1.5849625007211563	4	1	0	0
17857	1520	IARC 301 cell	[IARC 301 cells]	1.5849625007211563	3	1	0	0
17858	1520	compound for PKC	[compound for PKC]	1.5849625007211563	3	1	0	0
17859	1520	stat2 by transfection	[STAT2 by transfection]	1.5849625007211563	3	1	0	0
17860	1520	human NK cell line	[human NK cell line]	1.5849625007211563	4	1	0	0
17861	1520	human immunoglobulin gene enhancer	[human immunoglobulin gene enhancer]	1.5849625007211563	4	1	0	0
17862	1520	mitogen-stimulated T cell	[mitogen-stimulated T cells]	1.5849625007211563	3	1	0	0
17863	1520	glucocorticoid receptor affinity	[glucocorticoid receptor affinity]	1.5849625007211563	3	2	1	1
17864	1520	surface ganglioside gd3 erratum	[surface ganglioside GD3 erratum]	1.5849625007211563	4	1	0	0
17865	1520	regulation of the production	[regulation of the production]	1.5849625007211563	4	1	0	0
17866	1520	low t3 syndrome	[low T3 syndrome]	1.5849625007211563	3	1	0	0
17867	1520	nef of primate lentiviruse	[Nef of primate lentiviruses]	1.5849625007211563	4	1	0	0
17868	1520	envelope glycoprotein of hiv	[envelope glycoprotein of HIV]	1.5849625007211563	4	2	2	2
17869	1520	long period of latency	[long period of latency]	1.5849625007211563	4	2	2	2
17870	1520	function of component	[function of components]	1.5849625007211563	3	1	0	0
17871	1520	cd69 surface expression	[CD69 surface expression]	1.5849625007211563	3	1	0	0
17872	1520	il-6 -type cytokine receptor	[IL-6 -type cytokine receptors]	1.5849625007211563	4	1	0	0
17873	1520	respect to comedo	[respect to comedo]	1.5849625007211563	3	1	0	0
17874	1520	differentiation of hematopoietic cell	[differentiation of hematopoietic cells]	1.5849625007211563	4	1	0	0
17875	1520	spi-1 expression vector	[spi-1 expression vector]	1.5849625007211563	3	1	0	0
17876	1520	nuclear factor KB NF-KB	[nuclear factor KB NF-KB]	1.5849625007211563	4	1	0	0
17877	1520	RESULTS: BZLF1 zebra	[RESULTS: BZLF1 ZEBRA]	1.5849625007211563	3	1	0	0
17878	1520	occurrence of leukocyte-platelet conjugate	[occurrence of leukocyte-platelet conjugates]	1.5849625007211563	4	1	0	0
17879	1520	fibroblast collagenase expression	[fibroblast collagenase expression]	1.5849625007211563	3	1	0	0
17880	1520	differential modification in monocyte	[differential modification in monocytes]	1.5849625007211563	4	1	0	0
17881	1520	age-associated immune dysfunction	[age-associated immune dysfunction]	1.5849625007211563	3	1	0	0
17882	1520	ME1a1 G3AG4AG3 motif	[ME1a1 G3AG4AG3 motif]	1.5849625007211563	3	1	0	0
17883	1520	DNA bind region	[DNA binding region]	1.5849625007211563	3	2	2	2
17884	1520	AP-1 type heterodimeric complex	[AP-1 type heterodimeric complexes]	1.5849625007211563	4	1	0	0
17885	1520	inhibition effect versus time	[Inhibition effects versus time]	1.5849625007211563	4	1	0	0
17886	1520	IL-9 promoter activity	[IL-9 promoter activity]	1.5849625007211563	3	1	0	0
17887	1520	HTLV-II tax protein	[HTLV-II Tax proteins]	1.5849625007211563	3	1	0	0
17888	1520	preference of the il-10r	[preference of the IL-10R]	1.5849625007211563	4	1	0	0
17889	1520	5 steroid hormone	[5 steroid hormones]	1.5849625007211563	3	1	0	0
17890	1520	stimulation with paf	[Stimulation with PAF]	1.5849625007211563	3	1	0	0
17891	1520	treatment of PAEC	[Treatment of PAEC]	1.5849625007211563	3	1	0	0
17892	1520	modulation of differentiation	[Modulation of differentiation]	1.5849625007211563	3	2	2	2
17893	1520	1 posttranscriptional trans-activator	[1 posttranscriptional trans-activator]	1.5849625007211563	3	1	0	0
17894	1520	ltr-modified tat mutant	[LTR-modified tat mutants]	1.5849625007211563	3	1	0	0
17895	1520	bacterial cell wall	[bacterial cell wall]	1.5849625007211563	3	2	1	1
17896	1520	rate of transendothelial migration	[rate of transendothelial migration]	1.5849625007211563	4	1	0	0
17897	1520	gene in hl-60-c15 cell	[gene in HL-60-C15 cells]	1.5849625007211563	4	1	0	0
17898	1520	deactivate cytokine interleukin il-10	[deactivating cytokine interleukin IL-10]	1.5849625007211563	4	1	0	0
17899	1520	methyl tertiary-butyl ether	[methyl tertiary-butyl ether]	1.5849625007211563	3	1	0	0
17900	1520	apoptotic human vsmc	[apoptotic human VSMCs]	1.5849625007211563	3	1	0	0
17901	1520	Gal4- eed fusion protein	[Gal4- Eed fusion protein]	1.5849625007211563	4	1	0	0
17902	1520	previous cotransfection experiment	[Previous cotransfection experiments]	1.5849625007211563	3	1	0	0
17903	1520	h2o2 treatment of cell	[H2O2 treatment of cells]	1.5849625007211563	4	1	0	0
17904	1520	cytosol of bl-2 cell	[cytosol of BL-2 cells]	1.5849625007211563	4	1	0	0
17905	1520	cell gene cd21	[cell gene CD21]	1.5849625007211563	3	1	0	0
17906	1520	T cell to dexamethasone	[T cells to dexamethasone]	1.5849625007211563	4	1	0	0
17907	1520	DNA ladder formation	[DNA ladder formation]	1.5849625007211563	3	1	0	0
17908	1520	elimination of apl cell	[elimination of APL cells]	1.5849625007211563	4	1	0	0
17909	1520	results: in patient	[RESULTS: In patients]	1.5849625007211563	3	1	0	0
17910	1520	IL-2R alpha transcription	[IL-2R alpha transcription]	1.5849625007211563	3	1	0	0
17911	1520	heterozygosity in granulocyte DNA	[heterozygosity in granulocyte DNA]	1.5849625007211563	4	1	0	0
17912	1520	reactive nitrogen intermediate	[reactive nitrogen intermediates]	1.5849625007211563	3	1	0	0
17913	1520	nf-kappab -induce kinase NIK	[NF-kappaB -inducing kinase NIK]	1.5849625007211563	4	1	0	0
17914	1520	enhance il-2 gene	[enhancing IL-2 gene]	1.5849625007211563	3	1	0	0
17915	1520	IL-12 activation of T	[IL-12 activation of T]	1.5849625007211563	4	1	0	0
17916	1520	stimulatory mab BW 828	[stimulatory mAb BW 828]	1.5849625007211563	4	1	0	0
17917	1520	antagonization of NFkappaB activity	[antagonization of NFkappaB activity]	1.5849625007211563	4	1	0	0
17918	1520	human interleukin-3 promoter	[human interleukin-3 promoter]	1.5849625007211563	3	1	0	0
17919	1520	pma-differentiated u937 cell	[PMA-differentiated U937 cells]	1.5849625007211563	3	2	1	1
17920	1520	nuclear localization of Delta19	[nuclear localization of Delta19]	1.5849625007211563	4	1	0	0
17921	1520	mechanism of stat5 activation	[mechanisms of STAT5 activation]	1.5849625007211563	4	1	0	0
17922	1520	vertebral bone density	[vertebral bone density]	1.5849625007211563	3	1	0	0
17923	1520	response to extracellular signal	[response to extracellular signals]	1.5849625007211563	4	2	1	1
17924	1520	cytokine gene regulation	[cytokine gene regulation]	1.5849625007211563	3	2	1	1
17925	1520	endothelial cell (ec) surface	[endothelial cell (EC) surface]	1.5849625007211563	4	1	0	0
17926	1520	prolonged period of immunosuppression	[prolonged period of immunosuppression]	1.5849625007211563	4	1	0	0
17927	1520	treatment of asthma	[treatment of asthma]	1.5849625007211563	3	3	2	1
17928	1520	TNF alpha NF-kappa b	[TNF alpha NF-kappa B]	1.5849625007211563	4	1	0	0
17929	1520	modulate nf-kappa b activation	[modulating NF-kappa B activation]	1.5849625007211563	4	1	0	0
17930	1520	potent PKC activator	[potent PKC activator]	1.5849625007211563	3	1	0	0
17931	1520	level of this inhibitor	[level of this inhibitor]	1.5849625007211563	4	1	0	0
17932	1520	context of cell signal	[context of cell signaling]	1.5849625007211563	4	1	0	0
17933	1520	joint from monocyte-derived cytokine	[joint from monocyte-derived cytokines]	1.5849625007211563	4	1	0	0
17934	1520	major stat complex	[major STAT complexes]	1.5849625007211563	3	2	1	1
17935	1520	regulation by IL-4	[regulation by IL-4]	1.5849625007211563	3	1	0	0
17936	1520	kappa light chain gene	[kappa light chain gene]	1.5849625007211563	4	1	0	0
17937	1520	growth growth factor	[growth growth factor]	1.5849625007211563	3	2	2	2
17938	1520	patient with lupus nephritis	[patients with lupus nephritis]	1.5849625007211563	4	2	1	1
17939	1520	15N resonance assignment	[15N resonance assignment]	1.5849625007211563	3	1	0	0
17940	1520	loss of activity	[loss of activity]	1.5849625007211563	3	2	1	1
17941	1520	article hybrid gene	[article) hybrid gene]	1.5849625007211563	3	1	0	0
17942	1520	transcription factor downstream	[transcription factors downstream]	1.5849625007211563	3	1	0	0
17943	1520	tumor cell differentiation	[tumor cell differentiation]	1.5849625007211563	3	1	0	0
17944	1520	myristoyl fatty acid	[myristoyl fatty acid]	1.5849625007211563	3	2	2	2
17945	1520	degree of lymphocyte infiltration	[degree of lymphocyte infiltration]	1.5849625007211563	4	1	0	0
17946	1520	pcr of rna	[PCR of RNA]	1.5849625007211563	3	1	0	0
17947	1520	study of human disorder	[study of human disorders]	1.5849625007211563	4	1	0	0
17948	1520	cell proliferative signal	[cell proliferative signals]	1.5849625007211563	3	1	0	0
17949	1520	haemopoietic (nf-e2) transcription factor	[haemopoietic (NF-E2) transcription factors]	1.5849625007211563	4	1	0	0
17950	1520	kinase in tpa-treated u-937	[kinase in TPA-treated U-937]	1.5849625007211563	4	1	0	0
17951	1520	ebv -specific memory response	[EBV -specific memory response]	1.5849625007211563	4	1	0	0
17952	1520	level of gata-1	[levels of GATA-1]	1.5849625007211563	3	2	1	1
17953	1520	inactive, long enhancer transcript	[inactive, long enhancer transcripts]	1.5849625007211563	4	1	0	0
17954	1520	growth of b104 cell	[growth of B104 cells]	1.5849625007211563	4	1	0	0
17955	1520	much low extent.	[much lower extent.]	1.5849625007211563	3	1	0	0
17956	1520	wild type 430-444	[wild type 430-444]	1.5849625007211563	3	1	0	0
17957	1520	end growth of filament	[end growth of filaments]	1.5849625007211563	4	1	0	0
17958	1520	IFNgamma response region	[IFNgamma response region]	1.5849625007211563	3	1	0	0
17959	1520	requirement of x-chromosome-specific element	[requirement of X-chromosome-specific elements]	1.5849625007211563	4	1	0	0
17960	1520	interleukin-10 receptor intracellular domain	[interleukin-10 receptor intracellular domain]	1.5849625007211563	4	1	0	0
17961	1520	Sp3ilday -dependent expression	[Sp3 -dependent expression]	1.5849625007211563	3	1	0	0
17962	1520	pou transcription factor	[POU transcription factors]	1.5849625007211563	3	1	0	0
17963	1520	primary response gene,	[primary response gene,]	1.5849625007211563	3	1	0	0
17964	1520	TNF alpha promoter activation	[TNF alpha promoter activation]	1.5849625007211563	4	1	0	0
17965	1520	large case-control study	[large case-control studies]	1.5849625007211563	3	2	2	2
17966	1520	stat1 binding activity	[STAT1 binding activity]	1.5849625007211563	3	2	1	1
17967	1520	single-strand conformation polymorphism analysis	[single-strand conformation polymorphism analysis]	1.5849625007211563	4	1	0	0
17968	1520	fourth C delta exon	[fourth C delta exon]	1.5849625007211563	4	1	0	0
17969	1520	contrast to control cell	[contrast to control cells]	1.5849625007211563	4	1	0	0
17970	1520	several other antioxidant	[several other antioxidants]	1.5849625007211563	3	1	0	0
17971	1520	endogenous glucocorticoid peripheral function	[endogenous glucocorticoid peripheral function]	1.5849625007211563	4	1	0	0
17972	1520	E1A oncogene expression	[E1A oncogene expression]	1.5849625007211563	3	1	0	0
17973	1520	50-kda form in combination	[50-kDa forms in combination]	1.5849625007211563	4	1	0	0
17974	1520	Rb protein in erythropoiesis	[Rb proteins in erythropoiesis]	1.5849625007211563	4	1	0	0
17975	1520	dna-binding activity primarily consist	[DNA-binding activity primarily consisting]	1.5849625007211563	4	1	0	0
17976	1520	immunosuppressive effect of CyA	[immunosuppressive effect of CyA]	1.5849625007211563	4	1	0	0
17977	1520	product of this gene	[product of this gene]	1.5849625007211563	4	1	0	0
17978	1520	T lymphocyte function	[T lymphocyte function]	1.5849625007211563	3	2	1	1
17979	1520	IL-7 receptor alpha chain	[IL-7 receptor alpha chain]	1.5849625007211563	4	1	0	0
17980	1520	change in plasma interleukin-1	[changes in plasma interleukin-1]	1.5849625007211563	4	1	0	0
17981	1520	presence of IFNgamma	[presence of IFNgamma]	1.5849625007211563	3	1	0	0
17982	1520	DNA binding, transcriptional activation	[DNA binding, transcriptional activation]	1.5849625007211563	4	1	0	0
17983	1520	b7-positive (B cells)	[B7-positive (B cells)]	1.5849625007211563	3	1	0	0
17984	1520	12-o-tetradecanoylphorbol-13-acetate tpa response element	[12-O-tetradecanoylphorbol-13-acetate TPA response elements]	1.5849625007211563	4	1	0	0
17985	1520	basis for selective expression	[basis for selective expression]	1.5849625007211563	4	1	0	0
17986	1520	block JNK activity	[blocking JNK activity]	1.5849625007211563	3	1	0	0
17987	1520	different host cell types.	[different host cell types.]	1.5849625007211563	4	1	0	0
17988	1520	HIV kappa b site	[HIV kappa B site]	1.5849625007211563	4	1	0	0
17989	1520	Also, NF-kappa b activity	[Also, NF-kappa B activity]	1.5849625007211563	4	1	0	0
17990	1520	candidate oxygen reactive species	[candidate oxygen reactive species]	1.5849625007211563	4	1	0	0
17991	1520	ultra-violet cyp1a1 gene expression	[UV CYP1A1 gene expression]	1.5849625007211563	4	1	0	0
17992	1520	effect on lps	[effect on LPS]	1.5849625007211563	3	2	2	2
17993	1520	change of nuclear protein	[changes of nuclear proteins]	1.5849625007211563	4	1	0	0
17994	1520	PHA kappab-dependent reporter activity	[PHA kappaB-dependent reporter activity]	1.5849625007211563	4	1	0	0
17995	1520	gene coding for interleukin-2	[gene coding for interleukin-2]	1.5849625007211563	4	1	0	0
17996	1520	G(Anh)MTetra il-1 beta	[G(Anh)MTetra IL-1 beta]	1.5849625007211563	3	1	0	0
17997	1520	produce virus upon stimulation	[producing virus upon stimulation]	1.5849625007211563	4	1	0	0
17998	1520	flow cytometry study	[flow cytometry studies]	1.5849625007211563	3	1	0	0
17999	1520	proteolytic degradation of IkappaBalpha	[proteolytic degradation of IkappaBalpha]	1.5849625007211563	4	1	0	0
18000	1520	IL-4 NAF complex	[IL-4 NAF complex]	1.5849625007211563	3	1	0	0
18001	1520	regulation of cellular activation	[regulation of cellular activation]	1.5849625007211563	4	1	0	0
18002	1520	lipopolysaccharide-stimulated rel macrophage	[lipopolysaccharide-stimulated Rel macrophages]	1.5849625007211563	3	1	0	0
18003	1520	open-label study, adolescent	[open-label study, adolescents]	1.5849625007211563	3	1	0	0
18004	1520	promyelocytic leukemia gene	[promyelocytic leukemia gene]	1.5849625007211563	3	2	2	2
18005	1520	gata element at -24	[GATA element at -24]	1.5849625007211563	4	1	0	0
18006	1520	primary invasive breast cancer	[primary invasive breast cancer]	1.5849625007211563	4	1	0	0
18007	1520	separation of granule	[separation of granules]	1.5849625007211563	3	2	2	2
18008	1520	most Duffy-negative black	[most Duffy-negative blacks]	1.5849625007211563	3	1	0	0
18009	1520	DNA binding form	[DNA binding form]	1.5849625007211563	3	2	2	2
18010	1520	range of acute leukemia	[range of acute leukemias]	1.5849625007211563	4	1	0	0
18011	1520	age chromosome inactivation pattern	[age chromosome inactivation pattern]	1.5849625007211563	4	1	0	0
18012	1520	long disease-free survival	[long-term disease-free survival]	1.5849625007211563	3	1	0	0
18013	1520	thus implicate a number	[thus implicating a number]	1.5849625007211563	4	1	0	0
18014	1520	potent immunosuppressive property	[potent immunosuppressive properties]	1.5849625007211563	3	1	0	0
18015	1520	mitogen-stimulated human t-cell	[mitogen-stimulated human T-cells]	1.5849625007211563	3	1	0	0
18016	1520	t3-responsive pituitary (gh3) cell	[T3-responsive pituitary (GH3) cells]	1.5849625007211563	4	1	0	0
18017	1520	specific nuclear translocation mechanism	[specific nuclear translocation mechanism]	1.5849625007211563	4	1	0	0
18018	1520	t(8;21) acute myelogenous leukemia	[t(8;21) acute myelogenous leukemia]	1.5849625007211563	4	2	1	1
18019	1520	two tyrosine of SLP-76	[two tyrosines of SLP-76]	1.5849625007211563	4	1	0	0
18020	1520	hybrid cd8- nef protein	[hybrid CD8- Nef protein]	1.5849625007211563	4	1	0	0
18021	1520	provide a basis	[providing a basis]	1.5849625007211563	3	2	2	2
18022	1520	block in ciita inducibility	[block in CIITA inducibility]	1.5849625007211563	4	1	0	0
18023	1520	density centrifugation method	[density centrifugation methods]	1.5849625007211563	3	1	0	0
18024	1520	induction of change	[induction of changes]	1.5849625007211563	3	1	0	0
18025	1520	effect of herbimycin	[effect of herbimycin]	1.5849625007211563	3	1	0	0
18026	1520	anti-cd3 monoclonal antibody	[anti-CD3 monoclonal antibodies]	1.5849625007211563	3	1	0	0
18027	1520	binding to lef-1	[binding to LEF-1]	1.5849625007211563	3	1	0	0
18028	1520	sequence motif occur	[sequence motif occurring]	1.5849625007211563	3	1	0	0
18029	1520	own high-affinity receptor	[own high-affinity receptor]	1.5849625007211563	3	1	0	0
18030	1520	apparent lack of response	[apparent lack of response]	1.5849625007211563	4	1	0	0
18031	1520	flowerhead from Arnica Montana	[flowerheads from Arnica montana]	1.5849625007211563	4	1	0	0
18032	1520	normal silent c-myc allele	[normal silent c-myc allele]	1.5849625007211563	4	1	0	0
18033	1520	DNA triplex formation	[DNA triplex formation]	1.5849625007211563	3	1	0	0
18034	1520	4 hour follow stimulation.	[4 hours following stimulation.]	1.5849625007211563	4	1	0	0
18035	1520	alpha TNF alpha	[alpha TNF alpha]	1.5849625007211563	3	1	0	0
18036	1520	two such cluster	[Two such clusters]	1.5849625007211563	3	1	0	0
18037	1520	intracellular gsh level	[intracellular GSH levels]	1.5849625007211563	3	1	0	0
18038	1520	breakpoint in two	[breakpoints in two]	1.5849625007211563	3	1	0	0
18039	1520	VDR abnormality of VDR	[VDR abnormalities of VDR]	1.5849625007211563	4	1	0	0
18040	1520	loop of the IRE	[loop of the IRE]	1.5849625007211563	4	1	0	0
18041	1520	sequence-specific dna-bound complex	[sequence-specific DNA-bound complexes]	1.5849625007211563	3	1	0	0
18042	1520	65-kilodalton transactivate subunit	[65-kilodalton transactivating subunit]	1.5849625007211563	3	1	0	0
18043	1520	regard signal transduction event	[regarding signal transduction events]	1.5849625007211563	4	1	0	0
18044	1520	MIP-1 alpha promoter	[MIP-1 alpha promoter]	1.5849625007211563	3	1	0	0
18045	1520	epsilon germline promoter	[epsilon germline promoter]	1.5849625007211563	3	1	0	0
18046	1520	positive receptor status	[positive receptor status]	1.5849625007211563	3	1	0	0
18047	1520	E3 a hematopoietic-specific transcript	[E3 a hematopoietic-specific transcript]	1.5849625007211563	4	1	0	0
18048	1520	most primitive ones.	[most primitive ones.]	1.5849625007211563	3	1	0	0
18049	1520	activation with anti-CD3	[activation with anti-CD3]	1.5849625007211563	3	1	0	0
18050	1520	tyrosine phosphatase activity	[tyrosine phosphatase activity]	1.5849625007211563	3	1	0	0
18051	1520	sensitivity to signal	[sensitivity to signals]	1.5849625007211563	3	1	0	0
18052	1520	basis for differentiation therapy	[basis for differentiation therapy]	1.5849625007211563	4	1	0	0
18053	1520	chromosome 14 region	[chromosome 14 region]	1.5849625007211563	3	1	0	0
18054	1520	association between nuclear i(kappa)b(alpha)	[association between nuclear I(kappa)B(alpha)]	1.5849625007211563	4	1	0	0
18055	1520	transcriptional induction of NF-ATc	[transcriptional induction of NF-ATc]	1.5849625007211563	4	1	0	0
18056	1520	hetero dimer formation	[hetero dimer formation]	1.5849625007211563	3	1	0	0
18057	1520	loss of electrolyte	[loss of electrolytes]	1.5849625007211563	3	1	0	0
18058	1520	target for efficient down-regulation	[target for efficient down-regulation]	1.5849625007211563	4	1	0	0
18059	1520	indicate a direct involvement	[indicating a direct involvement]	1.5849625007211563	4	1	0	0
18060	1520	activation of hormone-receptor interaction	[activation of hormone-receptor interactions]	1.5849625007211563	4	1	0	0
18061	1520	cytokine induce transcription	[cytokines inducing transcription]	1.5849625007211563	3	1	0	0
18062	1520	inhibitor of type	[inhibitor of type]	1.5849625007211563	3	2	1	1
18063	1520	NF-kappa b transactivator rela	[NF-kappa B transactivator RelA]	1.5849625007211563	4	1	0	0
18064	1520	bp truncation of mrna	[bp truncation of mRNA]	1.5849625007211563	4	2	2	2
18065	1520	implication of this finding	[implication of these findings]	1.5849625007211563	4	1	0	0
18066	1520	transient transfection analysis	[Transient transfection analysis]	1.5849625007211563	3	2	1	1
18067	1520	furthermore, hmg-i(y) expression	[Furthermore, HMG-I(Y) expression]	1.5849625007211563	3	1	0	0
18068	1520	antioxidant in T lymphocyte	[antioxidants in T lymphocytes]	1.5849625007211563	4	1	0	0
18069	1520	dual function of immunocyte	[dual function of immunocytes]	1.5849625007211563	4	1	0	0
18070	1520	32 B-cell line	[32 B-cell lines]	1.5849625007211563	3	1	0	0
18071	1520	il-12 namely, mip-1alpha	[IL-12 namely, MIP-1alpha]	1.5849625007211563	3	1	0	0
18072	1520	gg at 0.1-10	[GG at 0.1-10]	1.5849625007211563	3	1	0	0
18073	1520	such as stage	[such as stage]	1.5849625007211563	3	1	0	0
18074	1520	different family members.	[different family members.]	1.5849625007211563	3	1	0	0
18075	1520	gene such as cytokine	[genes such as cytokines]	1.5849625007211563	4	1	0	0
18076	1520	92-kDa DNA binding protein	[92-kDa DNA binding protein]	1.5849625007211563	4	1	0	0
18077	1520	elongation of transcription.	[elongation of transcription.]	1.5849625007211563	3	1	0	0
18078	1520	A6H cd8+ T cell	[A6H CD8+ T cells]	1.5849625007211563	4	1	0	0
18079	1520	proteins, include cyclophilin	[proteins, including cyclophilin]	1.5849625007211563	3	1	0	0
18080	1520	predominantly in form 1,	[predominantly in Form 1,]	1.5849625007211563	4	1	0	0
18081	1520	little internucleosomal DNA fragmentation	[little internucleosomal DNA fragmentation]	1.5849625007211563	4	1	0	0
18082	1520	impaired nuclear translocation	[impaired nuclear translocation]	1.5849625007211563	3	1	0	0
18083	1520	pretreatment of NK cell	[Pretreatment of NK cells]	1.5849625007211563	4	1	0	0
18084	1520	growth of this cell	[growth of these cells]	1.5849625007211563	4	1	0	0
18085	1520	ICAM-1 kappa b	[ICAM-1 kappa B]	1.5849625007211563	3	1	0	0
18086	1520	patient peripheral leucocyte	[patient's peripheral leucocytes]	1.5849625007211563	3	1	0	0
18087	1520	cotransfection of this LTR	[cotransfection of this LTR]	1.5849625007211563	4	1	0	0
18088	1520	background of normal cell	[background of normal cells]	1.5849625007211563	4	1	0	0
18089	1520	capacity of Syk	[capacity of Syk]	1.5849625007211563	3	1	0	0
18090	1520	kinase inhibitor p27kip1	[kinase inhibitor p27Kip1]	1.5849625007211563	3	2	2	2
18091	1520	different cytokine production	[different cytokine production]	1.5849625007211563	3	1	0	0
18092	1520	T cell population	[T cell population]	1.5849625007211563	3	2	1	1
18093	1520	CD14 a monocyte/macrophage receptor	[CD14 a monocyte/macrophage receptor]	1.5849625007211563	4	1	0	0
18094	1520	down-regulation of transcriptional activity	[down-regulation of transcriptional activity]	1.5849625007211563	4	1	0	0
18095	1520	uncontrolled cell proliferation	[uncontrolled cell proliferation]	1.5849625007211563	3	1	0	0
18096	1520	high activation level	[higher activation levels]	1.5849625007211563	3	1	0	0
18097	1520	unique deleterious mechanism	[unique deleterious mechanism]	1.5849625007211563	3	1	0	0
18098	1520	reactive oxygen formation	[reactive oxygen formation]	1.5849625007211563	3	2	2	2
18099	1520	t-cell-specific transcription factor nfatp	[T-cell-specific transcription factor NFATp]	1.5849625007211563	4	1	0	0
18100	1520	GR expression level	[GR expression levels]	1.5849625007211563	3	1	0	0
18101	1520	low receptor affinity (Kd)	[low receptor affinity (Kd)]	1.5849625007211563	4	1	0	0
18102	1520	steroid binding test	[steroid binding test]	1.5849625007211563	3	1	0	0
18103	1520	two retinoid response pathway	[two retinoid response pathways]	1.5849625007211563	4	1	0	0
18104	1520	IL-6 promoter by LTB4	[IL-6 promoter by LTB4]	1.5849625007211563	4	1	0	0
18105	1520	resting b-cell preparation	[resting B-cell preparation]	1.5849625007211563	3	1	0	0
18106	1520	octamer transcription factor OTF1	[octamer transcription factors OTF1]	1.5849625007211563	4	1	0	0
18107	1520	length variation in sperm	[length variation in sperm]	1.5849625007211563	4	1	0	0
18108	1520	human chromosomal band	[human chromosomal bands]	1.5849625007211563	3	1	0	0
18109	1520	Jurkat T lymphocyte resistant	[Jurkat T lymphocytes resistant]	1.5849625007211563	4	1	0	0
18110	1520	cell with nuclear p50	[Cells with nuclear p50]	1.5849625007211563	4	1	0	0
18111	1520	lectin switch of lymphocyte	[lectin switch of lymphocytes]	1.5849625007211563	4	1	0	0
18112	1520	decrease in nfkappab induction	[decrease in NFkappaB induction]	1.5849625007211563	4	1	0	0
18113	1520	thromboxane receptor promoter activity	[Thromboxane receptor promoter activity]	1.5849625007211563	4	1	0	0
18114	1520	production of ige	[production of IgE]	1.5849625007211563	3	1	0	0
18115	1520	inactive sle (0.2979	[inactive SLE (0.2979]	1.5849625007211563	3	1	0	0
18116	1520	tax1 a transactivate protein	[tax1 a transactivating protein]	1.5849625007211563	4	1	0	0
18117	1520	rearrangement of tcr beta	[rearrangement of TCR beta]	1.5849625007211563	4	1	0	0
18118	1520	calcium -signal dependence	[calcium -signaling dependence]	1.5849625007211563	3	1	0	0
18119	1520	[125i]- aldosterone -derivative	[[125I]- aldosterone -derivative]	1.5849625007211563	3	1	0	0
18120	1520	true erythroid environment, experiment	[true erythroid environment, experiments]	1.5849625007211563	4	1	0	0
18121	1520	inhibition of mcp-1 production	[inhibition of MCP-1 production]	1.5849625007211563	4	1	0	0
18122	1520	ATF/CRE binding site	[ATF/CRE binding site]	1.5849625007211563	3	1	0	0
18123	1520	docking site for Grb2	[docking site for Grb2]	1.5849625007211563	4	1	0	0
18124	1520	function of the protein	[function of the proteins]	1.5849625007211563	4	2	2	2
18125	1520	abundant chromosomal protein hmg-1	[abundant chromosomal protein HMG-1]	1.5849625007211563	4	1	0	0
18126	1520	NFAT EMSA binding complex	[NFAT EMSA binding complex]	1.5849625007211563	4	1	0	0
18127	1520	CD40-stimulated b lymphocyte	[CD40-stimulated B lymphocytes]	1.5849625007211563	3	2	1	1
18128	1520	DR3 signal transduction	[DR3 signal transduction]	1.5849625007211563	3	1	0	0
18129	1520	cd1+relb+ dendritic cell DC	[CD1+relB+ dendritic cells DC]	1.5849625007211563	4	1	0	0
18130	1520	cytokine tumor necrosis factor-alpha	[cytokine tumor necrosis factor-alpha]	1.5849625007211563	4	2	1	1
18131	1520	role as a precursor	[role as a precursor]	1.5849625007211563	4	1	0	0
18132	1520	binding of the drug	[Binding of the drug]	1.5849625007211563	4	1	0	0
18133	1520	question the validity	[question the validity]	1.5849625007211563	3	1	0	0
18134	1520	bp -128 to -70	[bp -128 to -70]	1.5849625007211563	4	1	0	0
18135	1520	recognize specific component	[recognizing specific components]	1.5849625007211563	3	1	0	0
18136	1520	overlap palindrome 5'-ttgtcccgtggacaaatgtcc-3'	[overlapping palindromes 5'-TTGTCCcgtGGACAAaTGTCC-3']	1.5849625007211563	3	1	0	0
18137	1520	shed form of l-selectin	[shed form of L-selectin]	1.5849625007211563	4	1	0	0
18138	1520	normal, self-renewing b-1 cell	[normal, self-renewing B-1 cells]	1.5849625007211563	4	1	0	0
18139	1520	monocytic THP-1 cell line	[monocytic THP-1 cell line]	1.5849625007211563	4	1	0	0
18140	1520	ability of h2o2	[ability of H2O2]	1.5849625007211563	3	1	0	0
18141	1520	t-cell-receptor-mediated trans activation	[T-cell-receptor-mediated trans activation]	1.5849625007211563	3	1	0	0
18142	1520	other th2 cytokine gene	[other Th2 cytokine genes]	1.5849625007211563	4	1	0	0
18143	1520	low dose of ifn-gamma	[low doses of IFN-gamma]	1.5849625007211563	4	1	0	0
18144	1520	role for histone deacetylase	[role for histone deacetylase]	1.5849625007211563	4	1	0	0
18145	1520	splenic T lymphocyte	[splenic T lymphocytes]	1.5849625007211563	3	1	0	0
18146	1520	aldosterone on intracellular sodium	[aldosterone on intracellular sodium]	1.5849625007211563	4	1	0	0
18147	1520	tyrosine phosphorylation of CD28	[tyrosine phosphorylation of CD28]	1.5849625007211563	4	1	0	0
18148	1520	study of lineage	[study of lineage]	1.5849625007211563	3	1	0	0
18149	1520	lymphocyte proliferation in man	[lymphocyte proliferation in man]	1.5849625007211563	4	1	0	0
18150	1520	ebv-encoded antigen EBNA	[EBV-encoded antigen EBNA]	1.5849625007211563	3	2	2	2
18151	1520	lytic effect of dexamethasone	[lytic effects of dexamethasone]	1.5849625007211563	4	1	0	0
18152	1520	normal human alveolar macrophage	[normal human alveolar macrophages]	1.5849625007211563	4	2	2	2
18153	1520	aids-related non-hodgkin's lymphoma	[AIDS-related non-Hodgkin's lymphoma]	1.5849625007211563	3	1	0	0
18154	1520	Stat transcription factor family	[Stat transcription factor family]	1.5849625007211563	4	1	0	0
18155	1520	expression of RAG-1 rna	[expression of RAG-1 RNAs]	1.5849625007211563	4	1	0	0
18156	1520	friend murine erythroleukemia	[Friend murine erythroleukemia]	1.5849625007211563	3	1	0	0
18157	1520	ebv -negative b-cell line	[EBV -negative B-cell lines]	1.5849625007211563	4	1	0	0
18158	1520	similar chromosomal rearrangement	[Similar chromosomal rearrangements]	1.5849625007211563	3	1	0	0
18159	1520	globin chain alpha	[Globin chains alpha]	1.5849625007211563	3	1	0	0
18160	1520	bronchial patency disorder	[bronchial patency disorders]	1.5849625007211563	3	1	0	0
18161	1520	il-1 production of il-6	[IL-1 production of IL-6]	1.5849625007211563	4	1	0	0
18162	1520	insulin gene transcription factor	[insulin gene transcription factor]	1.5849625007211563	4	1	0	0
18163	1520	three third trimester),	[three third trimester),]	1.5849625007211563	3	1	0	0
18164	1520	p105 precursor protein	[p105 precursor proteins]	1.5849625007211563	3	1	0	0
18165	1520	result of the interaction	[result of the interaction]	1.5849625007211563	4	1	0	0
18166	1520	type of apoptosis	[type of apoptosis]	1.5849625007211563	3	1	0	0
18167	1520	process of retrodifferentiation	[process of retrodifferentiation]	1.5849625007211563	3	1	0	0
18168	1520	tropical spastic paraparesis	[tropical spastic paraparesis]	1.5849625007211563	3	2	1	1
18169	1520	regulation of jun	[Regulation of jun]	1.5849625007211563	3	1	0	0
18170	1520	only ebv trans-activator	[only EBV trans-activator]	1.5849625007211563	3	1	0	0
18171	1520	recurrent chromosomal translocation	[recurrent chromosomal translocation]	1.5849625007211563	3	1	0	0
18172	1520	activity of src-family kinase	[activities of Src-family kinases]	1.5849625007211563	4	1	0	0
18173	1520	nuclear factor Evi-1	[nuclear factors Evi-1]	1.5849625007211563	3	1	0	0
18174	1520	globin gene switching.	[Globin gene switching.]	1.5849625007211563	3	1	0	0
18175	1520	different glucocorticoid hormone compound	[different glucocorticoid hormone compounds]	1.5849625007211563	4	1	0	0
18176	1520	cell survival mechanism	[cell survival mechanisms]	1.5849625007211563	3	1	0	0
18177	1520	activity nf-kappa b dimer	[activity NF-kappa B dimers]	1.5849625007211563	4	1	0	0
18178	1520	induction of synthesis	[induction of synthesis]	1.5849625007211563	3	2	2	2
18179	1520	distinct signal transduction pathway	[distinct signal transduction pathways]	1.5849625007211563	4	1	0	0
18180	1520	Ca2+/calmodulin-dependent protein kinase iv	[Ca2+/calmodulin-dependent protein kinase IV]	1.5849625007211563	4	2	1	1
18181	1520	NF-kappaB -binding site	[NF-kappaB -binding site]	1.5849625007211563	3	2	1	1
18182	1520	x-linked spinal atrophy	[X-linked spinal atrophy]	1.5849625007211563	3	2	1	1
18183	1520	signal pathway involve ca2+	[signaling pathways involving Ca2+]	1.5849625007211563	4	1	0	0
18184	1520	alphabeta tcr phenotype	[alphabeta TCR phenotype]	1.5849625007211563	3	1	0	0
18185	1520	Escherichia coli tester strain	[Escherichia coli tester strain]	1.5849625007211563	4	1	0	0
18186	1520	molecular basis for specificity	[molecular basis for specificity]	1.5849625007211563	4	1	0	0
18187	1520	only one signal PMA	[only one signal PMA]	1.5849625007211563	4	1	0	0
18188	1520	dexamethasone a glucocorticoid	[dexamethasone a glucocorticoid]	1.5849625007211563	3	2	1	1
18189	1520	peripheral human lymphocyte	[peripheral human lymphocytes]	1.5849625007211563	3	1	0	0
18190	1520	heterogeneous transcription start site	[heterogeneous transcription start sites]	1.5849625007211563	4	1	0	0
18191	1520	difference in the susceptibility	[difference in the susceptibility]	1.5849625007211563	4	1	0	0
18192	1520	induction of phosphatidylinositol turnover	[Induction of phosphatidylinositol turnover]	1.5849625007211563	4	1	0	0
18193	1520	lead to a reduction	[leading to a reduction]	1.5849625007211563	4	1	0	0
18194	1520	t- lymphocyte proliferation	[T- lymphocyte proliferation]	1.5849625007211563	3	1	0	0
18195	1520	one type, eay	[One type, EA/S]	1.5849625007211563	3	1	0	0
18196	1520	differentiation inhibitory factor i-factor	[differentiation inhibitory factor I-factor]	1.5849625007211563	4	1	0	0
18197	1520	immature erythroid tissue	[immature erythroid tissues]	1.5849625007211563	3	1	0	0
18198	1520	effect on p53	[effect on p53]	1.5849625007211563	3	1	0	0
18199	1520	weak oxidative stress	[weak oxidative stress]	1.5849625007211563	3	1	0	0
18200	1520	short life span	[short life span]	1.5849625007211563	3	1	0	0
18201	1520	rather, squirrel monkey	[Rather, squirrel monkeys]	1.5849625007211563	3	1	0	0
18202	1520	background: fibrin deposition	[BACKGROUND: Fibrin deposition]	1.5849625007211563	3	1	0	0
18203	1520	leukemia inhibitory factor LIF	[leukemia inhibitory factor LIF]	1.5849625007211563	4	1	0	0
18204	1520	presence of Lymphotoxin-alpha LTalpha	[presence of Lymphotoxin-alpha LTalpha]	1.5849625007211563	4	1	0	0
18205	1520	cell of hyperlipidemic patient	[cells of hyperlipidemic patients]	1.5849625007211563	4	1	0	0
18206	1520	non- aids iblp	[non- AIDS IBLP]	1.5849625007211563	3	1	0	0
18207	1520	include tissue factor tf	[including tissue factor TF]	1.5849625007211563	4	1	0	0
18208	1520	such as CACCC motif	[such as CACCC motifs]	1.5849625007211563	4	1	0	0
18209	1520	nuclear level of c-Jun	[nuclear levels of c-Jun]	1.5849625007211563	4	1	0	0
18210	1520	change in the ability	[change in the ability]	1.5849625007211563	4	1	0	0
18211	1520	14 asymptomatic family member	[14 asymptomatic family members]	1.5849625007211563	4	1	0	0
18212	1520	induction of CREB	[induction of CREB]	1.5849625007211563	3	1	0	0
18213	1520	anti-endothelial cell antibody	[anti-endothelial cell antibodies]	1.5849625007211563	3	2	2	2
18214	1520	several other enhancer element	[several other enhancer elements]	1.5849625007211563	4	1	0	0
18215	1520	level of a number	[level of a number]	1.5849625007211563	4	1	0	0
18216	1520	change in the production	[changes in the production]	1.5849625007211563	4	1	0	0
18217	1520	furthermore, E1A mutant protein	[Furthermore, E1A mutant proteins]	1.5849625007211563	4	1	0	0
18218	1520	contrast, tissue macrophage	[contrast, tissue macrophages]	1.5849625007211563	3	1	0	0
18219	1520	expression of nf-kappab gene	[expression of NF-kappaB genes]	1.5849625007211563	4	1	0	0
18220	1520	thrombomodulin plasma concentration	[thrombomodulin plasma concentrations]	1.5849625007211563	3	1	0	0
18221	1520	region of Stat3alpha	[region of Stat3alpha]	1.5849625007211563	3	1	0	0
18222	1520	cell undergo megakaryocytic differentiation	[cells undergoing megakaryocytic differentiation]	1.5849625007211563	4	1	0	0
18223	1520	interferon-gamma activation sequence gas	[interferon-gamma activation sequence GAS]	1.5849625007211563	4	1	0	0
18224	1520	novel analog rad	[novel analog RAD]	1.5849625007211563	3	1	0	0
18225	1520	promoter 5' flanking sequence	[promoter 5' flanking sequences]	1.5849625007211563	4	1	0	0
18226	1520	novel nf-at -binding factor	[novel NF-AT -binding factor]	1.5849625007211563	4	1	0	0
18227	1520	various allele of HLA-DR4	[various alleles of HLA-DR4]	1.5849625007211563	4	1	0	0
18228	1520	enhancer comprise the October	[enhancer comprising the Oct]	1.5849625007211563	4	1	0	0
18229	1520	level of viral replication	[levels of viral replication]	1.5849625007211563	4	2	1	1
18230	1520	novel palindromic octamer sequence	[novel palindromic octamer sequence]	1.5849625007211563	4	2	2	2
18231	1520	expression in cell line	[expression in cell lines]	1.5849625007211563	4	2	2	2
18232	1520	binding of subunit	[binding of subunits]	1.5849625007211563	3	1	0	0
18233	1520	AP-1 family protein	[AP-1 family proteins]	1.5849625007211563	3	1	0	0
18234	1520	minimal tissue-specific promoter region	[minimal tissue-specific promoter region]	1.5849625007211563	4	1	0	0
18235	1520	response to hepo	[response to hEpo]	1.5849625007211563	3	1	0	0
18236	1520	follow il-2 stimulation	[following IL-2 stimulation]	1.5849625007211563	3	1	0	0
18237	1520	nucleotide excision repair	[nucleotide excision repair]	1.5849625007211563	3	2	2	2
18238	1520	differentiation of th effector	[differentiation of Th effectors]	1.5849625007211563	4	1	0	0
18239	1520	otherwise normal menstrual	[otherwise normal menstrual]	1.5849625007211563	3	1	0	0
18240	1520	subsequently hiv transcription	[subsequently HIV transcription]	1.5849625007211563	3	1	0	0
18241	1520	human erythroid ALAS gene	[human erythroid ALAS gene]	1.5849625007211563	4	1	0	0
18242	1520	normal induction of il-2	[normal induction of IL-2]	1.5849625007211563	4	1	0	0
18243	1520	only two band	[only two bands]	1.5849625007211563	3	1	0	0
18244	1520	phosphorylation of rap1 protein	[phosphorylation of Rap1 protein]	1.5849625007211563	4	1	0	0
18245	1520	p53 (wild type), prb	[p53 (wild type), pRb]	1.5849625007211563	4	1	0	0
18246	1520	drop in proliferation	[drop in proliferation]	1.5849625007211563	3	1	0	0
18247	1520	consequence of a hypersensitivity	[consequence of a hypersensitivity]	1.5849625007211563	4	1	0	0
18248	1520	'perfect' NF-kB binding site	['perfect' NF-kB binding site]	1.5849625007211563	4	1	0	0
18249	1520	effect of interferon alpha	[effect of interferon alpha]	1.5849625007211563	4	1	0	0
18250	1520	Jun protein complex	[Jun protein complex]	1.5849625007211563	3	1	0	0
18251	1520	down-regulation of c-fo protein	[down-regulation of c-fos protein]	1.5849625007211563	4	1	0	0
18252	1520	analysis of role	[analysis of role]	1.5849625007211563	3	1	0	0
18253	1520	circular dichroism analysis	[Circular dichroism analysis]	1.5849625007211563	3	1	0	0
18254	1520	lack of sensitivity	[lack of sensitivity]	1.5849625007211563	3	1	0	0
18255	1520	t-cell receptor (tcr)/cd3 engagement	[T-cell receptor (TCR)/CD3 engagement]	1.5849625007211563	4	1	0	0
18256	1520	cytopathic virus infections.	[cytopathic virus infections.]	1.5849625007211563	3	1	0	0
18257	1520	one base pair change	[One base pair change]	1.5849625007211563	4	1	0	0
18258	1520	two NF-ATc isoform	[two NF-ATc isoforms]	1.5849625007211563	3	1	0	0
18259	1520	upregulation of Fas Ligand	[upregulation of Fas Ligand]	1.5849625007211563	4	1	0	0
18260	1520	fos-related gene fra-1	[fos-related gene fra-1]	1.5849625007211563	3	1	0	0
18261	1520	presence of platelet	[presence of platelets]	1.5849625007211563	3	2	1	1
18262	1520	cell type-specific regulation	[cell type-specific regulation]	1.5849625007211563	3	2	1	1
18263	1520	three DNA region	[three DNA regions]	1.5849625007211563	3	1	0	0
18264	1520	distinct expression pattern	[distinct expression patterns]	1.5849625007211563	3	1	0	0
18265	1520	cooperation with RA	[cooperation with RA]	1.5849625007211563	3	1	0	0
18266	1520	process of transcription initiation	[process of transcription initiation]	1.5849625007211563	4	1	0	0
18267	1520	mouse mpc11 plasmacytoma cell	[mouse MPC11 plasmacytoma cells]	1.5849625007211563	4	1	0	0
18268	1520	class ii transcription	[class II transcription]	1.5849625007211563	3	1	0	0
18269	1520	mutation of any one	[mutation of any one]	1.5849625007211563	4	1	0	0
18270	1520	estrogen responsive unit	[estrogen responsive unit]	1.5849625007211563	3	1	0	0
18271	1520	expression the first	[expression the first]	1.5849625007211563	3	1	0	0
18272	1520	chromosome 16 abnormality	[chromosome 16 abnormalities]	1.5849625007211563	3	2	2	2
18273	1520	Jurkat cell extract	[Jurkat cell extract]	1.5849625007211563	3	1	0	0
18274	1520	plasmid contain bp	[plasmids containing bp]	1.5849625007211563	3	2	2	2
18275	1520	HLF consensus binding site	[HLF consensus binding site]	1.5849625007211563	4	2	1	1
18276	1520	sIgD in b104 cell	[sIgD in B104 cells]	1.5849625007211563	4	1	0	0
18277	1520	p16 in this regulation	[p16 in this regulation]	1.5849625007211563	4	1	0	0
18278	1520	expression of mip-1alpha-r mrna	[Expression of MIP-1alpha-R mRNA]	1.5849625007211563	4	1	0	0
18279	1520	/i kappa b molecule	[/I kappa B molecules]	1.5849625007211563	4	1	0	0
18280	1520	lps endothelial cell	[LPS endothelial cells]	1.5849625007211563	3	1	0	0
18281	1520	several viral oncoprotein	[several viral oncoproteins]	1.5849625007211563	3	1	0	0
18282	1520	YY1 consensus sequence	[YY1 consensus sequence]	1.5849625007211563	3	1	0	0
18283	1520	short enhancer element	[short enhancer element]	1.5849625007211563	3	1	0	0
18284	1520	ets transcription factor family	[ets transcription factor family]	1.5849625007211563	4	1	0	0
18285	1520	class of protein	[class of proteins]	1.5849625007211563	3	2	2	2
18286	1520	expression of tgf-alpha	[expression of TGF-alpha]	1.5849625007211563	3	1	0	0
18287	1520	alpha-globin hs-40 enhancer	[alpha-globin HS-40 enhancer]	1.5849625007211563	3	1	0	0
18288	1520	translocation of protein	[translocation of proteins]	1.5849625007211563	3	2	2	2
18289	1520	promonocytic leukemia cell	[promonocytic leukemia cells]	1.5849625007211563	3	2	2	2
18290	1520	Recent study from laboratory	[Recent studies from laboratory]	1.5849625007211563	4	1	0	0
18291	1520	different pattern of p50	[different patterns of p50]	1.5849625007211563	4	1	0	0
18292	1520	classic model for study	[classic models for study]	1.5849625007211563	4	1	0	0
18293	1520	homeodomain from HB24	[homeodomain from HB24]	1.5849625007211563	3	1	0	0
18294	1520	expression of surface receptor	[expression of surface receptors]	1.5849625007211563	4	1	0	0
18295	1520	transcriptional regulatory domain	[transcriptional regulatory domain]	1.5849625007211563	3	1	0	0
18296	1520	nuclear level pcna	[nuclear level PCNA]	1.5849625007211563	3	1	0	0
18297	1520	overlapping Egr-1/ Sp1 site	[overlapping Egr-1/ Sp1 site]	1.5849625007211563	4	1	0	0
18298	1520	regulate bcl-2 expression	[regulating Bcl-2 expression]	1.5849625007211563	3	1	0	0
18299	1520	hcmv DNA replication	[HCMV DNA replication]	1.5849625007211563	3	1	0	0
18300	1520	negative regulatory element nre	[negative regulatory element NRE]	1.5849625007211563	4	1	0	0
18301	1520	predominant e2f component	[predominant E2F components]	1.5849625007211563	3	1	0	0
18302	1520	differentiation of the lineage	[differentiation of the lineages]	1.5849625007211563	4	1	0	0
18303	1520	one major site.	[one major site.]	1.5849625007211563	3	1	0	0
18304	1520	primary ebv infection	[primary EBV infection]	1.5849625007211563	3	1	0	0
18305	1520	CD4 accessory function	[CD4 accessory function]	1.5849625007211563	3	1	0	0
18306	1520	nuclear factor kappab NFkappaB	[nuclear factor kappaB NFkappaB]	1.5849625007211563	4	2	1	1
18307	1520	intestinal calcium absorption	[intestinal calcium absorption]	1.5849625007211563	3	1	0	0
18308	1520	IFN-gamma- stat molecule	[IFN-gamma- STAT molecules]	1.5849625007211563	3	1	0	0
18309	1520	epstein-barr virus EBV	[Epstein-Barr virus EBV]	1.5849625007211563	3	1	0	0
18310	1520	Wnt signal transduction pathway	[Wnt signal transduction pathway]	1.5849625007211563	4	1	0	0
18311	1520	cell of system	[cells of systems]	1.5849625007211563	3	2	2	2
18312	1520	hybridoma cell line	[hybridoma cell line]	1.5849625007211563	3	1	0	0
18313	1520	decrease in the amount	[decrease in the amount]	1.5849625007211563	4	1	0	0
18314	1520	specifically in monocyte	[specifically in monocytes]	1.5849625007211563	3	1	0	0
18315	1520	synthesis of zebra	[synthesis of ZEBRA]	1.5849625007211563	3	1	0	0
18316	1520	regulator of cytokine signal	[regulators of cytokine signaling]	1.5849625007211563	4	1	0	0
18317	1520	two second messenger	[two second messengers]	1.5849625007211563	3	1	0	0
18318	1520	NFAT nuclear translocation	[NFAT nuclear translocation]	1.5849625007211563	3	1	0	0
18319	1520	DR enhancer b domain	[DR enhancer B domain]	1.5849625007211563	4	1	0	0
18320	1520	function of the eosinophil	[functions of the eosinophils]	1.5849625007211563	4	1	0	0
18321	1520	expression of il-2 receptor	[expression of IL-2 receptors]	1.5849625007211563	4	1	0	0
18322	1520	regulate nf-kappa b	[regulating NF-kappa B]	1.5849625007211563	3	1	0	0
18323	1520	cDNA encoding htafii105	[cDNA encoding hTAFII105]	1.5849625007211563	3	1	0	0
18324	1520	125d3 signal pathway	[1,25D3 signaling pathway]	1.5849625007211563	3	1	0	0
18325	1520	PI3-kinase inhibitor LY294002	[PI3-kinase inhibitor LY294002]	1.5849625007211563	3	1	0	0
18326	1520	Peripheral leucocyte genomic dna	[Peripheral leucocyte genomic DNAs]	1.5849625007211563	4	1	0	0
18327	1520	treatment of lymphoid neoplasm	[treatment of lymphoid neoplasms]	1.5849625007211563	4	1	0	0
18328	1520	bal fluid content	[BAL fluid content]	1.5849625007211563	3	1	0	0
18329	1520	expression of each protein	[expression of each protein]	1.5849625007211563	4	1	0	0
18330	1520	b-cell lineage of differentiation	[B-cell lineage of differentiation]	1.5849625007211563	4	1	0	0
18331	1520	retinoblastoma gene product prb	[retinoblastoma gene product pRB]	1.5849625007211563	4	1	0	0
18332	1520	apoptosis of the cells.	[apoptosis of the cells.]	1.5849625007211563	4	1	0	0
18333	1520	rheumatoid arthritis synovial fluid	[Rheumatoid arthritis synovial fluid]	1.5849625007211563	4	1	0	0
18334	1520	moderate ubiquitous activation	[Moderate ubiquitous activation]	1.5849625007211563	3	1	0	0
18335	1520	neutralize anti- IL-6 abs	[neutralizing anti- IL-6 Abs]	1.5849625007211563	4	1	0	0
18336	1520	endothelial mcp-1 secretion	[endothelial MCP-1 secretion]	1.5849625007211563	3	1	0	0
18337	1520	prior incubation with dexamethasone	[prior incubation with dexamethasone]	1.5849625007211563	4	1	0	0
18338	1520	transient transfection experiments,	[transient transfection experiments,]	1.5849625007211563	3	1	0	0
18339	1520	contrast, expression of C/EBPbeta	[contrast, expressions of C/EBPbeta]	1.5849625007211563	4	1	0	0
18340	1520	transient transfection experiments.	[transient transfection experiments.]	1.5849625007211563	3	1	0	0
18341	1520	long isoforms, b	[longer isoforms, B]	1.5849625007211563	3	1	0	0
18342	1520	regulation of hiv	[regulation of HIV]	1.5849625007211563	3	2	2	2
18343	1520	significant effect of bdp	[significant effect of BDP]	1.5849625007211563	4	1	0	0
18344	1520	activation of Statl	[activation of Statl]	1.5849625007211563	3	1	0	0
18345	1520	dominant negative gsk-3beta	[dominant negative GSK-3beta]	1.5849625007211563	3	1	0	0
18346	1520	regulation of activation	[regulation of activation]	1.5849625007211563	3	2	2	2
18347	1520	histone deacetylase complex	[histone deacetylase complexes]	1.5849625007211563	3	2	1	1
18348	1520	similar RA binding affinities;	[similar RA binding affinities;]	1.5849625007211563	4	1	0	0
18349	1520	only in cell line	[only in cell lines]	1.5849625007211563	4	2	2	2
18350	1520	activation of Stat4	[activation of Stat4]	1.5849625007211563	3	1	0	0
18351	1520	activation of Stat3	[activation of Stat3]	1.5849625007211563	3	2	1	1
18352	1520	activation of Stat6	[activation of Stat6]	1.5849625007211563	3	1	0	0
18353	1520	activation of Stat5	[activation of Stat5]	1.5849625007211563	3	1	0	0
18354	1520	activity of neutrophil	[activity of neutrophils]	1.5849625007211563	3	1	0	0
18355	1520	different receptor concentration	[different receptor concentrations]	1.5849625007211563	3	1	0	0
18356	1520	short isoform a	[short isoform A]	1.5849625007211563	3	1	0	0
18357	1520	cell-type specific regulation	[cell-type specific regulation]	1.5849625007211563	3	1	0	0
18358	1520	level of gene amplification	[Level of gene amplification]	1.5849625007211563	4	1	0	0
18359	1520	mitogen-activated protein kinase MAPK	[mitogen-activated protein kinase MAPK]	1.5849625007211563	4	1	0	0
18360	1520	use of anchor residue	[use of anchor residues]	1.5849625007211563	4	1	0	0
18361	1520	early regulatory protein	[early regulatory protein]	1.5849625007211563	3	1	0	0
18362	1520	rare interfollicular zone cell	[rare interfollicular zone cells]	1.5849625007211563	4	1	0	0
18363	1520	identical signal cascade	[identical signaling cascades]	1.5849625007211563	3	1	0	0
18364	1520	adult beta globin gene	[adult beta globin gene]	1.5849625007211563	4	1	0	0
18365	1520	monocyte to macrophage differentiation	[monocyte to macrophage differentiation]	1.5849625007211563	4	1	0	0
18366	1520	several independent assay	[several independent assays]	1.5849625007211563	3	1	0	0
18367	1520	course of hiv disease	[course of HIV disease]	1.5849625007211563	4	1	0	0
18368	1520	b-cell line bl41-p3hr1	[B-cell line BL41-P3HR1]	1.5849625007211563	3	1	0	0
18369	1520	haplotype contain hla dqa1*0501	[Haplotypes containing HLA DQA1*0501]	1.5849625007211563	4	1	0	0
18370	1520	presence of testosterone	[presence of testosterone]	1.5849625007211563	3	1	0	0
18371	1520	hbv mrna sequence	[HBV mRNA sequence]	1.5849625007211563	3	1	0	0
18372	1520	anti-inflammatory /hypereosinophilic agent	[anti-inflammatory /hypereosinophilic agents]	1.5849625007211563	3	1	0	0
18373	1520	B-cell line wehi-231	[B-cell line WEHI-231]	1.5849625007211563	3	1	0	0
18374	1520	dose-dependent manner parallel	[dose-dependent manner parallel]	1.5849625007211563	3	1	0	0
18375	1520	intestinal hyperabsorption of calcium	[intestinal hyperabsorption of calcium]	1.5849625007211563	4	1	0	0
18376	1520	DNA cotransfection experiment	[DNA cotransfection experiments]	1.5849625007211563	3	1	0	0
18377	1520	importance of this sites.	[importance of these sites.]	1.5849625007211563	4	1	0	0
18378	1520	human immunodeficiency virus infection	[human immunodeficiency virus infection]	1.5849625007211563	4	2	1	1
18379	1520	calcium ionophore pdbu	[calcium ionophore PDBu]	1.5849625007211563	3	1	0	0
18380	1520	I (p55) ii (p75)	[I (p55) II (p75)]	1.5849625007211563	4	1	0	0
18381	1520	PBMC of 11 woman	[PBMC of 11 women]	1.5849625007211563	4	1	0	0
18382	1520	only virulence characteristic	[only virulence characteristic]	1.5849625007211563	3	1	0	0
18383	1520	general initiation factor	[general initiation factors]	1.5849625007211563	3	2	2	2
18384	1520	interaction of interleukin (il)-5	[interaction of interleukin (IL)-5]	1.5849625007211563	4	1	0	0
18385	1520	entry of the virus,	[entry of the virus,]	1.5849625007211563	4	1	0	0
18386	1520	human arteritis-SCID chimera	[human arteritis-SCID chimeras]	1.5849625007211563	3	1	0	0
18387	1520	low-grade clonal disorder	[low-grade clonal disorder]	1.5849625007211563	3	1	0	0
18388	1520	product (band 1 pk)	[products (band 1 pk)]	1.5849625007211563	4	1	0	0
18389	1520	atheogenic lipoprotein ldl	[atheogenic lipoprotein LDL]	1.5849625007211563	3	1	0	0
18390	1520	patient with acute,	[patients with acute,]	1.5849625007211563	3	1	0	0
18391	1520	disruption of the spacing	[Disruption of the spacing]	1.5849625007211563	4	1	0	0
18392	1520	accord to relative affinities.	[according to relative affinities.]	1.5849625007211563	4	1	0	0
18393	1520	promoter of several cytokine	[promoters of several cytokines]	1.5849625007211563	4	2	1	1
18394	1520	20 healthy subject	[20 healthy subjects]	1.5849625007211563	3	1	0	0
18395	1520	CD40 -dependent signal	[CD40 -dependent signals]	1.5849625007211563	3	2	2	2
18396	1520	2 aml -m1	[2 AML -M1]	1.5849625007211563	3	1	0	0
18397	1520	immunoglobulin molecule fcr	[immunoglobulin molecules FcR]	1.5849625007211563	3	1	0	0
18398	1520	intracellular electrolyte from aldosterone	[intracellular electrolytes from aldosterone]	1.5849625007211563	4	1	0	0
18399	1520	relatively young (18-	[relatively young (18-]	1.5849625007211563	3	1	0	0
18400	1520	element-binding protein creb	[element-binding protein CREB]	1.5849625007211563	3	1	0	0
18401	1520	ras-induced ap1 activation	[ras-induced AP1 activation]	1.5849625007211563	3	1	0	0
18402	1520	immunodeficiency virus type hiv-2	[immunodeficiency virus type HIV-2]	1.5849625007211563	4	2	2	2
18403	1520	monocyte 135eoh)2d3 synthesis	[monocyte 1,25(OH)2D3 synthesis]	1.5849625007211563	3	1	0	0
18404	1520	normal b cell population	[normal B cell population]	1.5849625007211563	4	1	0	0
18405	1520	four representative mutant	[four representative mutants]	1.5849625007211563	3	1	0	0
18406	1520	Ab supershift assay	[Ab supershift assays]	1.5849625007211563	3	1	0	0
18407	1520	Duffy chemokine receptor gene	[Duffy chemokine receptor gene]	1.5849625007211563	4	1	0	0
18408	1520	cell surface t-cell receptor	[cell surface T-cell receptor]	1.5849625007211563	4	1	0	0
18409	1520	mass spectrometry study	[Mass spectrometry studies]	1.5849625007211563	3	1	0	0
18410	1520	antibody mib-1 ki-67 antigen	[antibody MIB-1 Ki-67 antigen]	1.5849625007211563	4	1	0	0
18411	1520	inability of PKC-zeta (mut)	[inability of PKC-zeta (mut)]	1.5849625007211563	4	1	0	0
18412	1520	stimulation of neutrophil	[Stimulation of neutrophils]	1.5849625007211563	3	2	2	2
18413	1520	IL-4 -inducible gene expression	[IL-4 -inducible gene expression]	1.5849625007211563	4	2	1	1
18414	1520	high concentration (10(-6)	[high concentration (10(-6)]	1.5849625007211563	3	1	0	0
18415	1520	(37.8 30.5) patient	[(37.8 30.5) patients]	1.5849625007211563	3	1	0	0
18416	1520	evidence show physical interaction	[evidence showing physical interactions]	1.5849625007211563	4	1	0	0
18417	1520	apoptosis -induce ligand	[apoptosis -inducing ligand]	1.5849625007211563	3	2	1	1
18418	1520	4-6 fold increase	[4-6 fold increase]	1.5849625007211563	3	1	0	0
18419	1520	potent costimulatory factor	[potent costimulatory factor]	1.5849625007211563	3	1	0	0
18420	1520	TCR-stimulated protein tyrosine kinase	[TCR-stimulated protein tyrosine kinases]	1.5849625007211563	4	1	0	0
18421	1520	sequence within the element	[sequences within the elements]	1.5849625007211563	4	2	2	2
18422	1520	progression of lymphoid malignancy	[progression of lymphoid malignancies]	1.5849625007211563	4	2	1	1
18423	1520	control of transcription	[control of transcription]	1.5849625007211563	3	2	2	2
18424	1520	10 (90%) patient	[10 (90%) patients]	1.5849625007211563	3	1	0	0
18425	1520	context of a model	[context of a model]	1.5849625007211563	4	1	0	0
18426	1520	senescent T cell	[senescent T cells]	1.5849625007211563	3	2	2	2
18427	1520	lymphoblastic leukemia cell line	[lymphoblastic leukemia cell line]	1.5849625007211563	4	1	0	0
18428	1520	ability of BHRF1	[ability of BHRF1]	1.5849625007211563	3	1	0	0
18429	1520	subsequent protein conjugation	[subsequent protein conjugation]	1.5849625007211563	3	1	0	0
18430	1520	Tax1 -inducible transcription factor	[Tax1 -inducible transcription factors]	1.5849625007211563	4	1	0	0
18431	1520	T helper cell subset	[T helper cell subsets]	1.5849625007211563	4	1	0	0
18432	1520	vitro treatment with calcineurin	[vitro treatment with calcineurin]	1.5849625007211563	4	1	0	0
18433	1520	inhibit the transactivation function	[inhibiting the transactivation functions]	1.5849625007211563	4	1	0	0
18434	1520	early hematopoietic differentiation	[early hematopoietic differentiation]	1.5849625007211563	3	1	0	0
18435	1520	binding activity of il-10-	[binding activity of IL-10-]	1.5849625007211563	4	1	0	0
18436	1520	kinetic of nuclear translocation	[Kinetics of nuclear translocation]	1.5849625007211563	4	1	0	0
18437	1520	lymphokine-activated killer cell	[lymphokine-activated killer cells]	1.5849625007211563	3	2	1	1
18438	1520	superoxide anion radical	[superoxide anion radical]	1.5849625007211563	3	1	0	0
18439	1520	cells' redox status	[cells' redox status]	1.5849625007211563	3	1	0	0
18440	1520	caspase inhibitor zvad-fmk	[caspase inhibitor zVAD-fmk]	1.5849625007211563	3	1	0	0
18441	1520	zinc finger type	[zinc finger type]	1.5849625007211563	3	1	0	0
18442	1520	administration of rbpi21	[administration of rBPI21]	1.5849625007211563	3	1	0	0
18443	1520	high transactivate ability	[highest transactivating ability]	1.5849625007211563	3	1	0	0
18444	1520	normal LTR transcription	[normal LTR transcription]	1.5849625007211563	3	1	0	0
18445	1520	patient with perennial rhinitis.	[patients with perennial rhinitis.]	1.5849625007211563	4	1	0	0
18446	1520	early growth response gene	[early growth response gene]	1.5849625007211563	4	2	2	2
18447	1520	part of this process	[Part of this process]	1.5849625007211563	4	1	0	0
18448	1520	TNF promoter region	[TNF promoter region]	1.5849625007211563	3	1	0	0
18449	1520	cell line exhibit property	[cell lines exhibiting properties]	1.5849625007211563	4	1	0	0
18450	1520	thyroid hormone receptor alpha	[thyroid hormone receptor alpha]	1.5849625007211563	4	2	1	1
18451	1520	role of alteration	[role of alterations]	1.5849625007211563	3	1	0	0
18452	1520	viral integral membrane protein	[viral integral membrane protein]	1.5849625007211563	4	1	0	0
18453	1520	ebv-encoded nuclear antigen	[EBV-encoded nuclear antigen]	1.5849625007211563	3	2	2	2
18454	1520	NF kappab gene	[NF kappaB genes]	1.5849625007211563	3	1	0	0
18455	1520	B-lymphoblastoid cell line LCLs	[B-lymphoblastoid cell lines LCLs]	1.5849625007211563	4	1	0	0
18456	1520	vivo DNA footprinting	[vivo DNA footprinting]	1.5849625007211563	3	1	0	0
18457	1520	ADT (0.1 mm)	[ADT (0.1 mM)]	1.5849625007211563	3	1	0	0
18458	1520	steroid ligands, agonist	[steroid ligands, agonists]	1.5849625007211563	3	1	0	0
18459	1520	myeloid-cell-specific c-fe promoter	[myeloid-cell-specific c-fes promoter]	1.5849625007211563	3	1	0	0
18460	1520	vitro CD4 cross-linking	[vitro CD4 cross-linking]	1.5849625007211563	3	2	1	1
18461	1520	enhancer of ig gene	[enhancer of Ig genes]	1.5849625007211563	4	1	0	0
18462	1520	subset of osteoclast cell	[subset of osteoclast cells]	1.5849625007211563	4	1	0	0
18463	1520	upregulation of pml protein	[upregulation of PML proteins]	1.5849625007211563	4	1	0	0
18464	1520	coculture,n induce nf-kappab activity	[coculture, induce NF-kappaB activity]	1.5849625007211563	4	1	0	0
18465	1520	recombinant human il-10	[recombinant human IL-10]	1.5849625007211563	3	1	0	0
18466	1520	human gm-csf promoter	[human GM-CSF promoter]	1.5849625007211563	3	1	0	0
18467	1520	nuclei in IL-4-	[nuclei in IL-4-]	1.5849625007211563	3	1	0	0
18468	1520	interleukin 2 production	[interleukin 2 production]	1.5849625007211563	3	1	0	0
18469	1520	high value of acth	[high values of ACTH]	1.5849625007211563	4	1	0	0
18470	1520	such as 12-o-tetradecanoylphorbol-13-acetate	[such as 12-O-tetradecanoylphorbol-13-acetate]	1.5849625007211563	3	1	0	0
18471	1520	cho-cd80 in the presence	[CHO-CD80 in the presence]	1.5849625007211563	4	1	0	0
18472	1520	trans-acting factor common	[trans-acting factor common]	1.5849625007211563	3	1	0	0
18473	1520	14.7 micromol/L; genistein	[14.7 micromol/L; genistein]	1.5849625007211563	3	1	0	0
18474	1520	nf-kappab -dependent promoter activity	[NF-kappaB -dependent promoter activity]	1.5849625007211563	4	1	0	0
18475	1520	medium (100 ng/ml)	[medium (100 ng/ml)]	1.5849625007211563	3	1	0	0
18476	1520	iron-sulfur center of ferredoxin	[iron-sulfur centers of ferredoxins]	1.5849625007211563	4	1	0	0
18477	1520	unique significance of zinc	[unique significance of zinc]	1.5849625007211563	4	1	0	0
18478	1520	b cell-specific promoter	[B cell-specific promoter]	1.5849625007211563	3	1	0	0
18479	1520	histamine Ca2+ rise	[histamine Ca2+ rise]	1.5849625007211563	3	1	0	0
18480	1520	detection of monocyte activation	[detection of monocyte activation]	1.5849625007211563	4	1	0	0
18481	1520	quiescent endothelial cell	[quiescent endothelial cells]	1.5849625007211563	3	1	0	0
18482	1520	NF-YA subunit in flc	[NF-YA subunit in FLCs]	1.5849625007211563	4	1	0	0
18483	1520	receptor activator of NF-kappaB	[receptor activator of NF-kappaB]	1.5849625007211563	4	2	2	2
18484	1520	proinflammatory cytokine tnf-alpha	[proinflammatory cytokines TNF-alpha]	1.5849625007211563	3	1	0	0
18485	1520	tandem dinucleotide repeat (ct)19/(ca)16	[tandem dinucleotide repeats (CT)19/(CA)16]	1.5849625007211563	4	1	0	0
18486	1520	immunologically relevant protein	[immunologically relevant proteins]	1.5849625007211563	3	1	0	0
18487	1520	transcriptional activity in myelopoiesis	[transcriptional activity in myelopoiesis]	1.5849625007211563	4	1	0	0
18488	1520	functional difference th1	[functional differences Th1]	1.5849625007211563	3	1	0	0
18489	1520	balance of cytokine production	[balance of cytokine production]	1.5849625007211563	4	1	0	0
18490	1520	nf-kappa b dimer	[NF-kappa B dimers]	1.5849625007211563	3	2	2	2
18491	1520	different receptor binding specificity	[different receptor binding specificity]	1.5849625007211563	4	1	0	0
18492	1520	step for apoptosis	[step for apoptosis]	1.5849625007211563	3	1	0	0
18493	1520	concentration of receptor	[concentration of receptors]	1.5849625007211563	3	2	2	2
18494	1520	ca(2+)-dependent signal-transduction pathway emanate	[Ca(2+)-dependent signal-transduction pathway emanating]	1.5849625007211563	4	1	0	0
18495	1520	rate of nuclear staining	[rate of nuclear staining]	1.5849625007211563	4	1	0	0
18496	1520	extent of processing	[extent of processing]	1.5849625007211563	3	1	0	0
18497	1520	plasmid contain 446 bp	[plasmids containing 446 bp]	1.5849625007211563	4	1	0	0
18498	1520	potent inhibitor of transcription	[potent inhibitor of transcription]	1.5849625007211563	4	1	0	0
18499	1520	exclude other possible targets,	[excluding other possible targets,]	1.5849625007211563	4	1	0	0
18500	1520	CsA on endothelial cell	[CsA on endothelial cells]	1.5849625007211563	4	1	0	0
18501	1520	constitutive elk-1 expression	[constitutive Elk-1 expression]	1.5849625007211563	3	1	0	0
18502	1520	kappa light chain	[kappa light chain]	1.5849625007211563	3	1	0	0
18503	1520	p40 promoter region	[p40 promoter region]	1.5849625007211563	3	2	1	1
18504	1520	Egr-1 mrna expression	[Egr-1 mRNA expression]	1.5849625007211563	3	1	0	0
18505	1520	expression of tcrzeta	[expression of TCRzeta]	1.5849625007211563	3	1	0	0
18506	1520	onset of morphological differentiation	[onset of morphological differentiation]	1.5849625007211563	4	1	0	0
18507	1520	(starting 1 day	[(starting 1 day]	1.5849625007211563	3	1	0	0
18508	1520	resolution of viral infection	[resolution of viral infections]	1.5849625007211563	4	1	0	0
18509	1520	differentiation of myeloid cell	[differentiation of myeloid cells]	1.5849625007211563	4	2	2	2
18510	1520	inactive cytoplasmic state	[inactive cytoplasmic state]	1.5849625007211563	3	1	0	0
18511	1520	subline region, in rheumatoid	[sublining region, in rheumatoid]	1.5849625007211563	4	1	0	0
18512	1520	granzyme b promoter activity	[granzyme B promoter activity]	1.5849625007211563	4	1	0	0
18513	1520	diurnal variation of GR	[diurnal variation of GR]	1.5849625007211563	4	1	0	0
18514	1520	intensity of the complex	[intensity of the complex]	1.5849625007211563	4	1	0	0
18515	1520	globin gene promoter	[globin gene promoters]	1.5849625007211563	3	2	2	2
18516	1520	stimulation with anti-CD3 antibody	[stimulation with anti-CD3 antibodies]	1.5849625007211563	4	1	0	0
18517	1520	regulator of monocyte/macrophage function	[regulator of monocyte/macrophage function]	1.5849625007211563	4	2	2	2
18518	1520	additional b cofactor	[additional B cofactors]	1.5849625007211563	3	1	0	0
18519	1520	adult t-cell leukemia /lymphoma	[adult T-cell leukemia /lymphoma]	1.5849625007211563	4	1	0	0
18520	1520	murine cell line	[murine cell line]	1.5849625007211563	3	2	2	2
18521	1520	cellular transcriptional coactivator	[cellular transcriptional coactivator]	1.5849625007211563	3	1	0	0
18522	1520	one receptor allele	[one receptor allele]	1.5849625007211563	3	1	0	0
18523	1520	Zebra promoter zp	[Zebra promoter Zp]	1.5849625007211563	3	1	0	0
18524	1520	transcription factor Nm23H2	[transcription factor Nm23H2]	1.5849625007211563	3	1	0	0
18525	1520	downmodulate the MIP-1alpha gene	[downmodulating the MIP-1alpha gene]	1.5849625007211563	4	1	0	0
18526	1520	regulatory immediate-early gene	[regulatory immediate-early genes]	1.5849625007211563	3	1	0	0
18527	1520	patient with thalassaemia	[patients with thalassaemia]	1.5849625007211563	3	2	2	2
18528	1520	tax 12-myristate 13-acetate PMA	[Tax 12-myristate 13-acetate PMA]	1.5849625007211563	4	1	0	0
18529	1520	cytoplasmic domain of CD30	[cytoplasmic domain of CD30]	1.5849625007211563	4	1	0	0
18530	1520	two signals, PMA	[two signals, PMA]	1.5849625007211563	3	1	0	0
18531	1520	reversal of apoptosis	[Reversal of apoptosis]	1.5849625007211563	3	2	1	1
18532	1520	-specific DNA binding activity	[-specific DNA binding activity]	1.5849625007211563	4	1	0	0
18533	1520	nonhistone chromosomal protein	[nonhistone chromosomal proteins]	1.5849625007211563	3	1	0	0
18534	1520	erythroleukemia k562 cell	[erythroleukemia K562 cells]	1.5849625007211563	3	1	0	0
18535	1520	other activation-inducible protein	[other activation-inducible proteins]	1.5849625007211563	3	1	0	0
18536	1520	NFAT minimal promoter	[NFAT minimal promoter]	1.5849625007211563	3	2	1	1
18537	1520	anti-mhc class antibody	[anti-MHC class antibodies]	1.5849625007211563	3	2	2	2
18538	1520	bending/flexure of the dna.	[bending/flexure of the DNA.]	1.5849625007211563	4	1	0	0
18539	1520	17 beta-hydroxysteroid dehydrogenase	[17 beta-hydroxysteroid dehydrogenase]	1.5849625007211563	3	2	2	2
18540	1520	very potent ah-receptor agonist	[very potent Ah-receptor agonists]	1.5849625007211563	4	1	0	0
18541	1520	il-4r alpha-chain il-4ralpha gene	[IL-4R alpha-chain IL-4Ralpha gene]	1.5849625007211563	4	1	0	0
18542	1520	endothelial cell ec activation	[endothelial cell EC activation]	1.5849625007211563	4	1	0	0
18543	1520	PMA-stimulated u937 cell	[PMA-stimulated U937 cells]	1.5849625007211563	3	1	0	0
18544	1520	Interestingly, apoptosis in contrast	[Interestingly, apoptosis in contrast]	1.5849625007211563	4	1	0	0
18545	1520	contrast, T cell activation	[contrast, T cell activation]	1.5849625007211563	4	1	0	0
18546	1520	viral insertion site	[viral insertion site]	1.5849625007211563	3	2	2	2
18547	1520	TCL1 protein expression	[TCL1 protein expression]	1.5849625007211563	3	1	0	0
18548	1520	putative role in functionality	[putative roles in functionality]	1.5849625007211563	4	1	0	0
18549	1520	C-terminal amino acid	[C-terminal amino acids]	1.5849625007211563	3	2	2	2
18550	1520	relatively low fat level	[relatively low fat level]	1.5849625007211563	4	1	0	0
18551	1520	uncultured leukemic cell	[uncultured leukemic cells]	1.5849625007211563	3	1	0	0
18552	1520	responsive DNA element	[responsive DNA element]	1.5849625007211563	3	1	0	0
18553	1520	Jun NH(2)-terminal kinase JNK	[Jun NH(2)-terminal kinase JNK]	1.5849625007211563	4	1	0	0
18554	1520	treatment with PMA agent	[treatment with PMA agents]	1.5849625007211563	4	1	0	0
18555	1520	novel et transcription factor	[novel ets transcription factor]	1.5849625007211563	4	1	0	0
18556	1520	modulate dioxin receptor function	[modulating dioxin receptor function]	1.5849625007211563	4	2	1	1
18557	1520	antigenic property indistinguishable	[antigenic properties indistinguishable]	1.5849625007211563	3	1	0	0
18558	1520	subpopulation of macrophage	[subpopulation of macrophages]	1.5849625007211563	3	1	0	0
18559	1520	ige immune complex	[IgE immune complexes]	1.5849625007211563	3	1	0	0
18560	1520	suppression of basophil	[suppression of basophils]	1.5849625007211563	3	1	0	0
18561	1520	VP16 a tegument protein	[VP16 a tegument protein]	1.5849625007211563	4	1	0	0
18562	1520	endogenous glucocorticoid function	[endogenous glucocorticoid function]	1.5849625007211563	3	1	0	0
18563	1520	signal-transduce receptor subunit	[signal-transducing receptor subunits]	1.5849625007211563	3	1	0	0
18564	1520	various cellular process	[various cellular processes]	1.5849625007211563	3	1	0	0
18565	1520	two separate transduction pathway	[two separate transduction pathways]	1.5849625007211563	4	1	0	0
18566	1520	22 patient allergic	[22 patients allergic]	1.5849625007211563	3	1	0	0
18567	1520	separable domain for activation	[separable domains for activation]	1.5849625007211563	4	1	0	0
18568	1520	much high incidence	[much higher incidence]	1.5849625007211563	3	1	0	0
18569	1520	proportion of patient	[proportion of patients]	1.5849625007211563	3	2	2	2
18570	1520	functionally related gene	[functionally related gene]	1.5849625007211563	3	1	0	0
18571	1520	accumulation of steady-state level	[accumulation of steady-state levels]	1.5849625007211563	4	1	0	0
18572	1520	effect on any	[effect on any]	1.5849625007211563	3	1	0	0
18573	1520	mitogen-stimulated rel T cell	[mitogen-stimulated Rel T cells]	1.5849625007211563	4	1	0	0
18574	1520	erythroid differentiation of hel	[erythroid differentiation of HEL]	1.5849625007211563	4	1	0	0
18575	1520	pathway of signal transduction	[pathways of signal transduction]	1.5849625007211563	4	2	1	1
18576	1520	duplication of activation domain	[duplication of activation domains]	1.5849625007211563	4	1	0	0
18577	1520	closely related protein	[closely related protein]	1.5849625007211563	3	2	1	1
18578	1520	control subject (59.6	[control subjects (59.6]	1.5849625007211563	3	1	0	0
18579	1520	monocyte-derived DC in vitro.	[monocyte-derived DC in vitro.]	1.5849625007211563	4	1	0	0
18580	1520	lps express e-selectin	[LPS express E-selectin]	1.5849625007211563	3	1	0	0
18581	1520	production of several cytokine	[production of several cytokines]	1.5849625007211563	4	2	1	1
18582	1520	wild type cell	[wild type cell]	1.5849625007211563	3	1	0	0
18583	1520	class ii-peptide complex	[class II-peptide complex]	1.5849625007211563	3	1	0	0
18584	1520	anti-rheumatic compound aurothioglucose	[Anti-rheumatic compound aurothioglucose]	1.5849625007211563	3	1	0	0
18585	1520	expression of own	[expression of own]	1.5849625007211563	3	1	0	0
18586	1520	copyright 1999 Wiley-Liss, Inc.	[Copyright 1999 Wiley-Liss, Inc.]	1.5849625007211563	4	1	0	0
18587	1520	follow serum stimulation	[following serum stimulation]	1.5849625007211563	3	1	0	0
18588	1520	specific hla-dr-restricted T lymphocyte	[specific HLA-DR-restricted T lymphocytes]	1.5849625007211563	4	1	0	0
18589	1520	hiv p24 antigen release	[HIV p24 antigen release]	1.5849625007211563	4	1	0	0
18590	1520	binding to Vav	[binding to Vav]	1.5849625007211563	3	1	0	0
18591	1520	ap1 binding site	[AP1 binding site]	1.5849625007211563	3	1	0	0
18592	1520	control of bcl-2 expression	[control of bcl-2 expression]	1.5849625007211563	4	1	0	0
18593	1520	regulatory factor-kappa beta	[regulatory factor-kappa beta]	1.5849625007211563	3	2	2	2
18594	1520	abnormality of chromosome 20	[abnormalities of chromosome 20]	1.5849625007211563	4	1	0	0
18595	1520	cell with 135eoh)2d3	[cells with 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
18596	1520	peptidylprolyl cis-tran isomerase	[peptidylprolyl cis-trans isomerase]	1.5849625007211563	3	2	2	2
18597	1520	several cellular gene	[several cellular genes]	1.5849625007211563	3	2	1	1
18598	1520	PDBu hl-60 cell	[PDBu HL-60 cells]	1.5849625007211563	3	1	0	0
18599	1520	AP-1 independent pma-mediated transactivation	[AP-1 independent PMA-mediated transactivation]	1.5849625007211563	4	1	0	0
18600	1520	lymphocyte from the g0	[lymphocytes from the G0]	1.5849625007211563	4	1	0	0
18601	1520	aberrant pml gene product	[aberrant PML gene products]	1.5849625007211563	4	1	0	0
18602	1520	contain a bind site	[containing a binding site]	1.5849625007211563	4	2	2	2
18603	1520	vitro, hiv cell	[vitro, HIV cells]	1.5849625007211563	3	1	0	0
18604	1520	consist of HeLa extract	[consisting of HeLa extracts]	1.5849625007211563	4	1	0	0
18605	1520	use in polypeptide	[Using in polypeptides]	1.5849625007211563	3	1	0	0
18606	1520	patient with Cushing' disease	[patients with Cushing's disease]	1.5849625007211563	4	1	0	0
18607	1520	CREB family of protein	[CREB family of proteins]	1.5849625007211563	4	1	0	0
18608	1520	activation of the fos	[activation of the fos]	1.5849625007211563	4	1	0	0
18609	1520	CMV immediate early cell	[CMV immediate early cells]	1.5849625007211563	4	1	0	0
18610	1520	il-4 gene by NFAT	[IL-4 gene by NFAT]	1.5849625007211563	4	1	0	0
18611	1520	nfat -1 regulatory element	[NFAT -1 regulatory element]	1.5849625007211563	4	1	0	0
18612	1520	NF-kappa b1 dimer	[NF-kappa B1 dimers]	1.5849625007211563	3	1	0	0
18613	1520	discrete cell basis	[discrete cell basis]	1.5849625007211563	3	1	0	0
18614	1520	activate specific stat protein	[activating specific STAT proteins]	1.5849625007211563	4	1	0	0
18615	1520	human neutrophil pmn	[human neutrophils PMN]	1.5849625007211563	3	1	0	0
18616	1520	differentiation toward neutrophil respectively.	[differentiation toward neutrophils respectively.]	1.5849625007211563	4	1	0	0
18617	1520	detection in nuclear extract	[detection in nuclear extracts]	1.5849625007211563	4	1	0	0
18618	1520	eukaryotic origin of replication	[eukaryotic origin of replication]	1.5849625007211563	4	1	0	0
18619	1520	increase of c-fo	[increases of c-fos]	1.5849625007211563	3	1	0	0
18620	1520	effect of pi 3-kinase	[effects of PI 3-kinase]	1.5849625007211563	4	1	0	0
18621	1520	k-ra protein (encompassing	[K-RAS protein (encompassing]	1.5849625007211563	3	1	0	0
18622	1520	monocyte mcp-1 expression	[monocyte MCP-1 expression]	1.5849625007211563	3	1	0	0
18623	1520	lymphoid-specific element microb	[lymphoid-specific element microB]	1.5849625007211563	3	1	0	0
18624	1520	group of 28 patient	[group of 28 patients]	1.5849625007211563	4	1	0	0
18625	1520	change in membrane potential	[change in membrane potential]	1.5849625007211563	4	1	0	0
18626	1520	follow the response.	[following the response.]	1.5849625007211563	3	1	0	0
18627	1520	various Oct-2a effector region	[various Oct-2a effector regions]	1.5849625007211563	4	1	0	0
18628	1520	phosphorylation of tyrosine residue	[phosphorylation of tyrosine residues]	1.5849625007211563	4	1	0	0
18629	1520	block in JNK activity	[block in JNK activity]	1.5849625007211563	4	1	0	0
18630	1520	IL-6 kappa b motif	[IL-6 kappa B motif]	1.5849625007211563	4	1	0	0
18631	1520	hbsag -reactive cell	[HBsAg -reactive cells]	1.5849625007211563	3	1	0	0
18632	1520	immunodeficiency virus entry	[immunodeficiency virus entry]	1.5849625007211563	3	2	2	2
18633	1520	signal in eosinophil	[signaling in eosinophils]	1.5849625007211563	3	2	2	2
18634	1520	activation, T lymphocyte	[activation, T lymphocytes]	1.5849625007211563	3	1	0	0
18635	1520	murine lck gene	[murine lck gene]	1.5849625007211563	3	1	0	0
18636	1520	agent, cell type,	[agent, cell type,]	1.5849625007211563	3	1	0	0
18637	1520	follicular expression pattern	[follicular expression pattern]	1.5849625007211563	3	1	0	0
18638	1520	high level of transcription	[high levels of transcription]	1.5849625007211563	4	1	0	0
18639	1520	resolution of this controversy	[resolution of this controversy]	1.5849625007211563	4	1	0	0
18640	1520	12 normal child-bearing-age woman	[12 normal child-bearing-age women]	1.5849625007211563	4	1	0	0
18641	1520	two repression domain	[two repression domains]	1.5849625007211563	3	1	0	0
18642	1520	expression of differentiation-related antigen	[expression of differentiation-related antigens]	1.5849625007211563	4	1	0	0
18643	1520	mouse-repopulating stem cell	[mouse-repopulating stem cells]	1.5849625007211563	3	1	0	0
18644	1520	suppress cellular infiltration	[suppressing cellular infiltration]	1.5849625007211563	3	1	0	0
18645	1520	developmental stage- specific manner	[developmental stage- specific manner]	1.5849625007211563	4	1	0	0
18646	1520	blood urea nitrogen bun	[blood urea nitrogen BUN]	1.5849625007211563	4	1	0	0
18647	1520	sequence specificity of BSAP	[sequence specificity of BSAP]	1.5849625007211563	4	1	0	0
18648	1520	decline in proteasome activity	[decline in proteasome activity]	1.5849625007211563	4	1	0	0
18649	1520	CD3 epsilon enhancer	[CD3 epsilon enhancer]	1.5849625007211563	3	1	0	0
18650	1520	supernatant from HUVEC	[supernatants from HUVEC]	1.5849625007211563	3	1	0	0
18651	1520	receptor intracellular domain	[receptor intracellular domain]	1.5849625007211563	3	2	1	1
18652	1520	32-kDa nuclear phosphoprotein	[32-kDa nuclear phosphoprotein]	1.5849625007211563	3	1	0	0
18653	1520	oncogene express fibroblast	[oncogene expressing fibroblasts]	1.5849625007211563	3	1	0	0
18654	1520	substance in serum	[substances in serum]	1.5849625007211563	3	1	0	0
18655	1520	all-tran retinoic acid treatment	[all-trans retinoic acid treatment]	1.5849625007211563	4	2	1	1
18656	1520	nature of the factor	[nature of the factors]	1.5849625007211563	4	2	2	2
18657	1520	gene on chromosome	[gene on chromosome]	1.5849625007211563	3	2	2	2
18658	1520	glucocorticoid receptor per cell	[glucocorticoid receptors per cell]	1.5849625007211563	4	2	1	1
18659	1520	binding of NF-E1 YY1	[binding of NF-E1 YY1]	1.5849625007211563	4	1	0	0
18660	1520	use of length tf	[use of length TF]	1.5849625007211563	4	1	0	0
18661	1520	linear ebv genome	[linear EBV genome]	1.5849625007211563	3	1	0	0
18662	1520	many b cell	[many B cell]	1.5849625007211563	3	1	0	0
18663	1520	adaptor protein cbl-b	[adaptor protein Cbl-b]	1.5849625007211563	3	1	0	0
18664	1520	IL-4 promoter activity	[IL-4 promoter activity]	1.5849625007211563	3	1	0	0
18665	1520	mutation of JAK3	[mutations of JAK3]	1.5849625007211563	3	1	0	0
18666	1520	genome of T cell	[genome of T cell]	1.5849625007211563	4	1	0	0
18667	1520	extremely low level	[extremely low levels]	1.5849625007211563	3	2	2	2
18668	1520	more than 4 weeks.	[more than 4 weeks.]	1.5849625007211563	4	1	0	0
18669	1520	leucine transport selection	[leucine transport selection]	1.5849625007211563	3	1	0	0
18670	1520	monocytic lineage hl60	[monocytic lineage HL60]	1.5849625007211563	3	1	0	0
18671	1520	case of undesirable overexpression	[cases of undesirable overexpression]	1.5849625007211563	4	1	0	0
18672	1520	N-terminal region amino acid	[N-terminal region amino acids]	1.5849625007211563	4	1	0	0
18673	1520	multiple organ dysfunction	[multiple organ dysfunction]	1.5849625007211563	3	1	0	0
18674	1520	T cell nfat domain	[T cell NFAT domain]	1.5849625007211563	4	1	0	0
18675	1520	cd14+ adherent human monocyte	[CD14+ adherent human monocytes]	1.5849625007211563	4	1	0	0
18676	1520	experiment use inhibitor	[Experiments using inhibitors]	1.5849625007211563	3	1	0	0
18677	1520	c-jun mrna inducibility	[c-jun mRNA inducibility]	1.5849625007211563	3	1	0	0
18678	1520	c/ebp epsilon promoter/enhancer	[C/EBP epsilon promoter/enhancer]	1.5849625007211563	3	1	0	0
18679	1520	exposure of human monocyte	[exposure of human monocytes]	1.5849625007211563	4	1	0	0
18680	1520	low affinity BSAP site	[low affinity BSAP site]	1.5849625007211563	4	1	0	0
18681	1520	mature t-cell phenotype	[mature T-cell phenotype]	1.5849625007211563	3	1	0	0
18682	1520	T-lymphocyte activation mechanism	[T-lymphocyte activation mechanisms]	1.5849625007211563	3	1	0	0
18683	1520	involvement of nf-kappab	[involvement of NF-kappaB]	1.5849625007211563	3	2	1	1
18684	1520	AP-1- binding site	[AP-1- binding sites]	1.5849625007211563	3	2	1	1
18685	1520	effect of tpck	[effect of TPCK]	1.5849625007211563	3	2	1	1
18686	1520	Ad5 E1A DNA	[Ad5 E1A DNA]	1.5849625007211563	3	1	0	0
18687	1520	i interferon ifn-alpha	[I interferons IFN-alpha]	1.5849625007211563	3	1	0	0
18688	1520	activation-dependent cell surface marker	[activation-dependent cell surface markers]	1.5849625007211563	4	1	0	0
18689	1520	20 gy of radiotherapy	[20 Gy of radiotherapy]	1.5849625007211563	4	1	0	0
18690	1520	replication of monocyte-	[replication of monocyte-]	1.5849625007211563	3	1	0	0
18691	1520	hence, for viral replication	[hence, for viral replication]	1.5849625007211563	4	1	0	0
18692	1520	ability of huaec	[ability of HUAECs]	1.5849625007211563	3	1	0	0
18693	1520	few viral protein	[few viral proteins]	1.5849625007211563	3	1	0	0
18694	1520	promote cell-cell interaction	[promoting cell-cell interactions]	1.5849625007211563	3	1	0	0
18695	1520	lymphoblastic cell line	[lymphoblastic cell lines]	1.5849625007211563	3	2	2	2
18696	1520	leukemia factor HLF	[leukemia factor HLF]	1.5849625007211563	3	2	2	2
18697	1520	several key transcription factor	[several key transcription factors]	1.5849625007211563	4	1	0	0
18698	1520	dioxin receptor with hsp90	[dioxin receptor with hsp90]	1.5849625007211563	4	1	0	0
18699	1520	normocalcemic patient with sarcoidosis	[normocalcemic patients with sarcoidosis]	1.5849625007211563	4	1	0	0
18700	1520	quiescent human-peripheral-blood T cell	[quiescent human-peripheral-blood T cells]	1.5849625007211563	4	1	0	0
18701	1520	response to the tcr	[response to the TCR]	1.5849625007211563	4	1	0	0
18702	1520	MHC immune deficiency	[MHC immune deficiency]	1.5849625007211563	3	1	0	0
18703	1520	CD28 -mediated costimulation	[CD28 -mediated costimulation]	1.5849625007211563	3	1	0	0
18704	1520	lymphoid lineage commitment	[lymphoid lineage commitment]	1.5849625007211563	3	1	0	0
18705	1520	granulocyte-macrophage colony-stimulating factor production	[granulocyte-macrophage colony-stimulating factor production]	1.5849625007211563	4	1	0	0
18706	1520	regulation of a promoter	[regulation of a promoter]	1.5849625007211563	4	1	0	0
18707	1520	protective t-cell-mediated immunity	[protective T-cell-mediated immunity]	1.5849625007211563	3	1	0	0
18708	1520	b cell Daudi	[B cells Daudi]	1.5849625007211563	3	1	0	0
18709	1520	constellation of congenital malformation	[constellation of congenital malformations]	1.5849625007211563	4	1	0	0
18710	1520	b cell receptor	[B cell receptor]	1.5849625007211563	3	2	1	1
18711	1520	coexpression of bcl-2	[coexpression of Bcl-2]	1.5849625007211563	3	1	0	0
18712	1520	distal Sp1-binding site	[distal Sp1-binding site]	1.5849625007211563	3	1	0	0
18713	1520	specific nuclear factor in	[specific nuclear factors in]	1.5849625007211563	4	1	0	0
18714	1520	other intracellular signal	[other intracellular signals]	1.5849625007211563	3	1	0	0
18715	1520	molecular mechanism govern proliferation	[molecular mechanisms governing proliferation]	1.5849625007211563	4	1	0	0
18716	1520	epidermal growth growth factor	[epidermal growth growth factor]	1.5849625007211563	4	2	2	2
18717	1520	gp160 NF-kappa b complex	[gp160 NF-kappa B complex]	1.5849625007211563	4	1	0	0
18718	1520	regulation of a subset	[regulation of a subset]	1.5849625007211563	4	1	0	0
18719	1520	nfat composite element	[NFAT composite elements]	1.5849625007211563	3	2	2	2
18720	1520	LIF hiv replication	[LIF HIV replication]	1.5849625007211563	3	1	0	0
18721	1520	several immediate-early cytokine gene	[several immediate-early cytokine genes]	1.5849625007211563	4	1	0	0
18722	1520	lysis of lymphoblast	[lysis of lymphoblasts]	1.5849625007211563	3	1	0	0
18723	1520	role for transcription factor	[role for transcription factors]	1.5849625007211563	4	1	0	0
18724	1520	cd4(+) T helper cell	[CD4(+) T helper cells]	1.5849625007211563	4	1	0	0
18725	1520	Active raf-1 phosphorylate	[Active Raf-1 phosphorylates]	1.5849625007211563	3	1	0	0
18726	1520	human tr2 orphan	[human TR2 orphan]	1.5849625007211563	3	1	0	0
18727	1520	nonmyeloid cell type	[nonmyeloid cell types]	1.5849625007211563	3	2	1	1
18728	1520	degree of squamous differentiation.	[degree of squamous differentiation.]	1.5849625007211563	4	1	0	0
18729	1520	twice daily resistant sr	[twice daily resistant SR]	1.5849625007211563	4	1	0	0
18730	1520	concentration between 10 nm	[concentrations between 10 nM]	1.5849625007211563	4	1	0	0
18731	1520	series of density-gradient centrifugation	[series of density-gradient centrifugations]	1.5849625007211563	4	1	0	0
18732	1520	mouse b cell	[mouse B cells]	1.5849625007211563	3	2	2	2
18733	1520	dependence on disease conditions.	[dependence on disease conditions.]	1.5849625007211563	4	1	0	0
18734	1520	NF-kB to corresponding site	[NF-kB to corresponding sites]	1.5849625007211563	4	1	0	0
18735	1520	normal tnf-alpha activation	[normal TNF-alpha activation]	1.5849625007211563	3	1	0	0
18736	1520	maintenance of homeostasis	[maintenance of homeostasis]	1.5849625007211563	3	2	1	1
18737	1520	three tetraproline repeat	[three tetraproline repeats]	1.5849625007211563	3	1	0	0
18738	1520	several aspect of TCF-1	[several aspects of TCF-1]	1.5849625007211563	4	1	0	0
18739	1520	promyelocytic leukemia (pml) gene	[promyelocytic leukemia (PML) gene]	1.5849625007211563	4	1	0	0
18740	1520	patient with autoimmune/inflammatory disease	[patients with autoimmune/inflammatory diseases]	1.5849625007211563	4	1	0	0
18741	1520	amino acid substitution	[amino acid substitutions]	1.5849625007211563	3	1	0	0
18742	1520	regulation of globin gene	[regulation of globin genes]	1.5849625007211563	4	1	0	0
18743	1520	most lymphokine gene	[most lymphokine genes]	1.5849625007211563	3	1	0	0
18744	1520	nucleotide excision repair (ner)	[nucleotide excision repair (NER)]	1.5849625007211563	4	1	0	0
18745	1520	activation of NF-kB	[activation of NF-kB]	1.5849625007211563	3	2	2	2
18746	1520	c-jun gene transcription	[c-jun gene transcription]	1.5849625007211563	3	2	1	1
18747	1520	non-depressed psychiatric control	[non-depressed psychiatric controls]	1.5849625007211563	3	1	0	0
18748	1520	IL-3 promoter between nucleotide	[IL-3 promoter between nucleotides]	1.5849625007211563	4	1	0	0
18749	1520	tpa ionophore to tcr	[TPA ionophore to TCR]	1.5849625007211563	4	1	0	0
18750	1520	murine E3 promoter	[murine E3 promoter]	1.5849625007211563	3	1	0	0
18751	1520	interleukin-7 receptor alpha chain	[interleukin-7 receptor alpha chain]	1.5849625007211563	4	1	0	0
18752	1520	increase of the form	[increase of the form]	1.5849625007211563	4	1	0	0
18753	1520	transcription activity of xp-b	[transcription activity of XP-B]	1.5849625007211563	4	1	0	0
18754	1520	cytokine in T cell	[cytokines in T cells]	1.5849625007211563	4	1	0	0
18755	1520	majority of this gene	[majority of these genes]	1.5849625007211563	4	1	0	0
18756	1520	therefore a effective strategy	[therefore an effective strategy]	1.5849625007211563	4	1	0	0
18757	1520	SS RBC oxidant stress	[SS RBC oxidant stress]	1.5849625007211563	4	1	0	0
18758	1520	b cell receptor stimulation	[B cell receptor stimulation]	1.5849625007211563	4	1	0	0
18759	1520	more likely, Stat4	[more likely, Stat4]	1.5849625007211563	3	1	0	0
18760	1520	pattern of A-myb expression	[pattern of A-myb expression]	1.5849625007211563	4	1	0	0
18761	1520	con A proliferate thymocyte	[Con A proliferating thymocytes]	1.5849625007211563	4	1	0	0
18762	1520	32dc13 myeloid cell	[32Dc13 myeloid cells]	1.5849625007211563	3	1	0	0
18763	1520	microtubule mediate cellular	[Microtubules mediate cellular]	1.5849625007211563	3	1	0	0
18764	1520	small basic protein	[small basic protein]	1.5849625007211563	3	1	0	0
18765	1520	large clonal t-cell population	[large clonal T-cell population]	1.5849625007211563	4	1	0	0
18766	1520	protein in the group	[Proteins in the group]	1.5849625007211563	4	2	2	2
18767	1520	neutrophil lineage by treatment	[neutrophil lineage by treatment]	1.5849625007211563	4	1	0	0
18768	1520	other EBV gene	[other EBV genes]	1.5849625007211563	3	1	0	0
18769	1520	tandem pair of ets	[tandem pairs of Ets]	1.5849625007211563	4	1	0	0
18770	1520	E2F -contain dna-binding complex	[E2F -containing DNA-binding complexes]	1.5849625007211563	4	1	0	0
18771	1520	hypercortisolaemia in anorexia nervosa	[hypercortisolaemia in anorexia nervosa]	1.5849625007211563	4	1	0	0
18772	1520	two cell-specific coactivator	[two cell-specific coactivators]	1.5849625007211563	3	2	2	2
18773	1520	two common haplotype bat	[two common haplotypes BAt]	1.5849625007211563	4	1	0	0
18774	1520	contain level of nf-kappab	[containing levels of NF-kappaB]	1.5849625007211563	4	2	2	2
18775	1520	condition of kidney insufficiency	[conditions of kidney insufficiency]	1.5849625007211563	4	2	1	1
18776	1520	lymphoid cell-specific nuclear factor	[lymphoid cell-specific nuclear factor]	1.5849625007211563	4	2	2	2
18777	1520	various mutant probe	[various mutant probes]	1.5849625007211563	3	1	0	0
18778	1520	phorbol myristate-induced signal	[phorbol myristate-induced signal]	1.5849625007211563	3	1	0	0
18779	1520	24 hour of infection.	[24 hr of infection.]	1.5849625007211563	4	1	0	0
18780	1520	lipid transfer protein	[lipid transfer protein]	1.5849625007211563	3	1	0	0
18781	1520	monoblastic leukemia u937 cell	[monoblastic leukemia U937 cells]	1.5849625007211563	4	2	2	2
18782	1520	Clone pAT 133	[Clone pAT 133]	1.5849625007211563	3	1	0	0
18783	1520	normal b-cell-specific transcription	[normal B-cell-specific transcription]	1.5849625007211563	3	1	0	0
18784	1520	thus, intact microtubule	[Thus, intact microtubules]	1.5849625007211563	3	1	0	0
18785	1520	TCRalpha enhancer function	[TCRalpha enhancer function]	1.5849625007211563	3	1	0	0
18786	1520	several BSAP -binding site	[several BSAP -binding sites]	1.5849625007211563	4	1	0	0
18787	1520	purpose of comparison,	[purposes of comparison,]	1.5849625007211563	3	1	0	0
18788	1520	effect on viral replication	[effects on viral replication]	1.5849625007211563	4	1	0	0
18789	1520	five t-cell clone specific	[Five T-cell clones specific]	1.5849625007211563	4	1	0	0
18790	1520	antibody recognize double-stranded DNA	[Antibodies recognizing double-stranded DNA]	1.5849625007211563	4	1	0	0
18791	1520	molecular weight of great	[molecular weight of greater]	1.5849625007211563	4	1	0	0
18792	1520	stabilize the c-jun mrna	[stabilizing the c-jun mRNA]	1.5849625007211563	4	1	0	0
18793	1520	cytotoxic T lymphocyte response	[cytotoxic T lymphocyte response]	1.5849625007211563	4	2	2	2
18794	1520	IL-2 a feature	[IL-2 a feature]	1.5849625007211563	3	1	0	0
18795	1520	Janus kinase 3 jak3	[Janus kinase 3 JAK3]	1.5849625007211563	4	1	0	0
18796	1520	oestrogen receptor expression	[oestrogen receptor expression]	1.5849625007211563	3	1	0	0
18797	1520	nuclear factor-kappa b mobilization	[nuclear factor-kappa B mobilization]	1.5849625007211563	4	2	1	1
18798	1520	constitutive stat5 activity	[Constitutive STAT5 activity]	1.5849625007211563	3	1	0	0
18799	1520	selectively regulate cytokine production	[selectively regulating cytokine production]	1.5849625007211563	4	1	0	0
18800	1520	fifth cell line	[fifth cell line]	1.5849625007211563	3	1	0	0
18801	1520	signal event responsible	[signaling events responsible]	1.5849625007211563	3	1	0	0
18802	1520	100 u/ml IFN gamma	[100 U/ml IFN gamma]	1.5849625007211563	4	1	0	0
18803	1520	ig gene silencing	[Ig gene silencing]	1.5849625007211563	3	1	0	0
18804	1520	cortisol -resistant aids	[cortisol -resistant AIDS]	1.5849625007211563	3	1	0	0
18805	1520	three main approaches.	[three main approaches.]	1.5849625007211563	3	1	0	0
18806	1520	response to a variety	[response to a variety]	1.5849625007211563	4	1	0	0
18807	1520	NF-kappaB transcription factor family	[NF-kappaB transcription factor family]	1.5849625007211563	4	1	0	0
18808	1520	thymocyte-thymic epithelial cell interaction	[Thymocyte-thymic epithelial cell interaction]	1.5849625007211563	4	1	0	0
18809	1520	nutritionally relevant concentrations.	[nutritionally relevant concentrations.]	1.5849625007211563	3	1	0	0
18810	1520	hmg box protein	[HMG box proteins]	1.5849625007211563	3	2	1	1
18811	1520	expression of the clone	[expression of the clone]	1.5849625007211563	4	1	0	0
18812	1520	expression of CREB	[expression of CREB]	1.5849625007211563	3	1	0	0
18813	1520	presence of a factor	[presence of a factor]	1.5849625007211563	4	2	1	1
18814	1520	monoclonal antibody 60b	[monoclonal antibody 60b]	1.5849625007211563	3	1	0	0
18815	1520	weak effect on vWf	[weak effect on vWf]	1.5849625007211563	4	1	0	0
18816	1520	complex with nuclear extract	[complex with nuclear extract]	1.5849625007211563	4	2	2	2
18817	1520	major positive element	[major positive element]	1.5849625007211563	3	2	1	1
18818	1520	function of id2	[function of Id2]	1.5849625007211563	3	1	0	0
18819	1520	n.engl.j. med.324:308-317, s.m.schnittman,	[N.Engl.J. Med.324:308-317, S.M.Schnittman,]	1.5849625007211563	3	1	0	0
18820	1520	t-lymphocyte nfat-1 activity	[T-lymphocytes NFAT-1 activity]	1.5849625007211563	3	1	0	0
18821	1520	il-2r jak/stat pathway	[IL-2R Jak/STAT pathway]	1.5849625007211563	3	1	0	0
18822	1520	activate protein-1 binding	[activating protein-1 binding]	1.5849625007211563	3	1	0	0
18823	1520	48 h of activation.	[48 h of activation.]	1.5849625007211563	4	1	0	0
18824	1520	p85 phosphoinositide 3-kinase	[p85 phosphoinositide 3-kinase]	1.5849625007211563	3	1	0	0
18825	1520	part of leucocyte	[part of leucocytes]	1.5849625007211563	3	1	0	0
18826	1520	composite kappa 3/CRE site	[composite kappa 3/CRE site]	1.5849625007211563	4	1	0	0
18827	1520	low-level IFN production	[low-level IFN production]	1.5849625007211563	3	1	0	0
18828	1520	hl-60 monocytic differentiation	[HL-60 monocytic differentiation]	1.5849625007211563	3	1	0	0
18829	1520	expression, DNA binding,	[expression, DNA binding,]	1.5849625007211563	3	1	0	0
18830	1520	ion channel in b	[ion channels in B]	1.5849625007211563	4	1	0	0
18831	1520	two nf-kappa b inhibitor	[two NF-kappa B inhibitors]	1.5849625007211563	4	1	0	0
18832	1520	follicular b cell	[follicular B cells]	1.5849625007211563	3	1	0	0
18833	1520	structure function analysis	[Structure function analysis]	1.5849625007211563	3	1	0	0
18834	1520	octamer-binding protein otf-2	[octamer-binding protein OTF-2]	1.5849625007211563	3	1	0	0
18835	1520	ras signal pathway	[Ras signaling pathway]	1.5849625007211563	3	1	0	0
18836	1520	response to CD28 costimulation,	[response to CD28 costimulation,]	1.5849625007211563	4	1	0	0
18837	1520	antisense phosphorothioate oligodeoxynucleotides complementary	[antisense phosphorothioate oligodeoxynucleotides complementary]	1.5849625007211563	4	1	0	0
18838	1520	expression of set	[expression of sets]	1.5849625007211563	3	2	2	2
18839	1520	stimulation with IL-13	[stimulation with IL-13]	1.5849625007211563	3	1	0	0
18840	1520	hemodynamic phase of sepsis	[hemodynamic phase of sepsis]	1.5849625007211563	4	2	1	1
18841	1520	triple helix formation	[triple helix formation]	1.5849625007211563	3	1	0	0
18842	1520	constitutively express tax	[constitutively expressing Tax]	1.5849625007211563	3	1	0	0
18843	1520	activation of NF-AT	[activation of NF-AT]	1.5849625007211563	3	2	1	1
18844	1520	CD38 protein level	[CD38 protein levels]	1.5849625007211563	3	1	0	0
18845	1520	pml protein expression	[PML protein expression]	1.5849625007211563	3	1	0	0
18846	1520	mechanism independent of calcineurin	[mechanism independent of calcineurin]	1.5849625007211563	4	1	0	0
18847	1520	ebna2 rrna compatible	[EBNA2 mRNAs compatible]	1.5849625007211563	3	1	0	0
18848	1520	tissue-specific regulatory region 5'	[tissue-specific regulatory region 5']	1.5849625007211563	4	1	0	0
18849	1520	activity of glucocorticoid	[activity of glucocorticoids]	1.5849625007211563	3	2	2	2
18850	1520	IL-2Rbeta DNA binding motif	[IL-2Rbeta DNA binding motif]	1.5849625007211563	4	1	0	0
18851	1520	study of control	[study of control]	1.5849625007211563	3	1	0	0
18852	1520	other amino acid sequence	[other amino acid sequences]	1.5849625007211563	4	1	0	0
18853	1520	reporter gene construct,	[reporter gene construct,]	1.5849625007211563	3	1	0	0
18854	1520	CD4+ T cell subset	[CD4+ T cell subsets]	1.5849625007211563	4	1	0	0
18855	1520	large amount of p50	[large amounts of p50]	1.5849625007211563	4	1	0	0
18856	1520	5- to 10-fold increase	[5- to 10-fold increase]	1.5849625007211563	4	2	1	1
18857	1520	BRLF1 product Rta	[BRLF1 product Rta]	1.5849625007211563	3	1	0	0
18858	1520	IL-2 -gene transcription rate	[IL-2 -gene transcription rate]	1.5849625007211563	4	1	0	0
18859	1520	interleukin-2 gene transcription	[interleukin-2 gene transcription]	1.5849625007211563	3	1	0	0
18860	1520	pulmonary infiltrate and/or cavity	[pulmonary infiltrates and/or cavities]	1.5849625007211563	4	1	0	0
18861	1520	pattern of Pan expression	[Patterns of Pan expression]	1.5849625007211563	4	1	0	0
18862	1520	nuclear factor nf-kappa b	[nuclear factor NF-kappa B]	1.5849625007211563	4	1	0	0
18863	1520	Study with 20-epi analogue	[Studies with 20-epi analogues]	1.5849625007211563	4	1	0	0
18864	1520	free cortisol excretion	[free cortisol excretion]	1.5849625007211563	3	2	1	1
18865	1520	72-hour incubation with oleate	[72-hour incubation with oleate]	1.5849625007211563	4	1	0	0
18866	1520	Peripheral blood resting cell	[Peripheral blood resting cells]	1.5849625007211563	4	1	0	0
18867	1520	multiple cytokine production deficiency	[multiple cytokine production deficiency]	1.5849625007211563	4	1	0	0
18868	1520	x-chromosome inactivation x inactivation	[X-chromosome inactivation X inactivation]	1.5849625007211563	4	1	0	0
18869	1520	STAT5A -STAT5B heterodimer	[STAT5A -STAT5B heterodimers]	1.5849625007211563	3	1	0	0
18870	1520	ascorbic acid ascorbate	[Ascorbic acid ascorbate]	1.5849625007211563	3	1	0	0
18871	1520	T cell p56(lck) activation	[T cells p56(lck) activation]	1.5849625007211563	4	1	0	0
18872	1520	glucocorticoid hormone in undernutrition	[glucocorticoid hormones in undernutrition]	1.5849625007211563	4	1	0	0
18873	1520	rapid depletion of traf2	[rapid depletion of TRAF2]	1.5849625007211563	4	1	0	0
18874	1520	quantitative Southern blotting	[quantitative Southern blotting]	1.5849625007211563	3	1	0	0
18875	1520	function of activation domain	[function of activation domains]	1.5849625007211563	4	2	1	1
18876	1520	E2F DNA site	[E2F DNA site]	1.5849625007211563	3	1	0	0
18877	1520	adaptor protein cbl	[adaptor protein Cbl]	1.5849625007211563	3	1	0	0
18878	1520	intact GR dna-binding domain	[intact GR DNA-binding domain]	1.5849625007211563	4	1	0	0
18879	1520	human immunodeficiency virus transmission	[human immunodeficiency virus transmission]	1.5849625007211563	4	1	0	0
18880	1520	gene encode proinflammatory cytokine	[genes encoding proinflammatory cytokines]	1.5849625007211563	4	1	0	0
18881	1520	T cell unresponsiveness	[T cell unresponsiveness]	1.5849625007211563	3	1	0	0
18882	1520	human thp-1 macrophage cell	[human THP-1 macrophage cells]	1.5849625007211563	4	1	0	0
18883	1520	effect of interleukin-13 IL-13	[effects of interleukin-13 IL-13]	1.5849625007211563	4	1	0	0
18884	1520	ets bind motif	[Ets binding motifs]	1.5849625007211563	3	1	0	0
18885	1520	apparent chromosome 16 abnormality	[apparent chromosome 16 abnormalities]	1.5849625007211563	4	1	0	0
18886	1520	many pathogenic signal	[many pathogenic signals]	1.5849625007211563	3	1	0	0
18887	1520	use recombinant hbxag protein	[Using recombinant HBxAg protein]	1.5849625007211563	4	1	0	0
18888	1520	potency induce apoptosis	[potencies inducing apoptosis]	1.5849625007211563	3	1	0	0
18889	1520	transcription factor pax-5	[transcription factor Pax-5]	1.5849625007211563	3	1	0	0
18890	1520	human malignant melanoma MMs	[human malignant melanomas MMs]	1.5849625007211563	4	1	0	0
18891	1520	normal platelet function	[normal platelet function]	1.5849625007211563	3	1	0	0
18892	1520	polycystic ovary syndrome pco	[polycystic ovary syndrome PCOS]	1.5849625007211563	4	1	0	0
18893	1520	b-cell, iggk phenotype	[B-cell, IgGk phenotype]	1.5849625007211563	3	1	0	0
18894	1520	recruitment of granulocytic hpc	[recruitment of granulocytic HPCs]	1.5849625007211563	4	1	0	0
18895	1520	peripheral blood monocyte PBM	[peripheral blood monocytes PBM]	1.5849625007211563	4	1	0	0
18896	1520	membrane-mediated signal event	[membrane-mediated signaling events]	1.5849625007211563	3	1	0	0
18897	1520	homotypic aggregation of Ri-I	[homotypic aggregation of Ri-I]	1.5849625007211563	4	1	0	0
18898	1520	pre-exist nf-at -binding factor	[pre-existing NF-AT -binding factor]	1.5849625007211563	4	1	0	0
18899	1520	combination with dexamethasone	[combination with dexamethasone]	1.5849625007211563	3	1	0	0
18900	1520	STAT 5 activity	[STAT 5 activity]	1.5849625007211563	3	1	0	0
18901	1520	part of the promoter	[part of the promoter]	1.5849625007211563	4	1	0	0
18902	1520	calcium /calcineurin signal	[calcium /calcineurin signals]	1.5849625007211563	3	2	1	1
18903	1520	Con A stimulation	[Con A stimulation]	1.5849625007211563	3	1	0	0
18904	1520	full-length cDNA clone	[full-length cDNA clone]	1.5849625007211563	3	2	2	2
18905	1520	mechanism of gc resistance	[mechanism of GC resistance]	1.5849625007211563	4	1	0	0
18906	1520	anti- TNF alpha antibody	[anti- TNF alpha antibody]	1.5849625007211563	4	2	1	1
18907	1520	small 95-bp fragment	[small 95-bp fragment]	1.5849625007211563	3	1	0	0
18908	1520	patient with chronic leukemia	[patients with chronic leukemia]	1.5849625007211563	4	2	2	2
18909	1520	nonerythroid nih3t3 cell	[nonerythroid NIH3T3 cells]	1.5849625007211563	3	1	0	0
18910	1520	distinct set of genes.	[distinct sets of genes.]	1.5849625007211563	4	1	0	0
18911	1520	additional c/ebpalpha target gene	[additional C/EBPalpha target genes]	1.5849625007211563	4	1	0	0
18912	1520	conjunction with datum	[conjunction with data]	1.5849625007211563	3	1	0	0
18913	1520	42-nucleotide repeat element	[42-nucleotide repeat element]	1.5849625007211563	3	1	0	0
18914	1520	activation of specific gene	[activation of specific genes]	1.5849625007211563	4	1	0	0
18915	1520	b cell line implication	[B cell lines implication]	1.5849625007211563	4	1	0	0
18916	1520	Specific NF-kappa b subunit	[Specific NF-kappa B subunits]	1.5849625007211563	4	1	0	0
18917	1520	result of il-2 transcription	[result of IL-2 transcription]	1.5849625007211563	4	1	0	0
18918	1520	NF(P) DNA binding protein	[NF(P) DNA binding protein]	1.5849625007211563	4	1	0	0
18919	1520	two DNA binding sites.	[two DNA binding sites.]	1.5849625007211563	4	1	0	0
18920	1520	bat box-deleted cd20-cat construct	[BAT box-deleted CD20-CAT construct]	1.5849625007211563	4	1	0	0
18921	1520	multiple ets in vitro	[multiple Ets in vitro]	1.5849625007211563	4	1	0	0
18922	1520	such as hydrogen peroxide	[such as hydrogen peroxide]	1.5849625007211563	4	2	2	2
18923	1520	use reporter gene construct	[Using reporter gene constructs]	1.5849625007211563	4	1	0	0
18924	1520	serum cortisol concentration	[serum cortisol concentrations]	1.5849625007211563	3	2	2	2
18925	1520	NF-kappa B/Sp1 enhancer	[NF-kappa B/Sp1 enhancer]	1.5849625007211563	3	1	0	0
18926	1520	steroid dose sparing	[Steroid dose sparing]	1.5849625007211563	3	1	0	0
18927	1520	pathologic picture in ischemia/reperfusion	[pathologic picture in ischemia/reperfusion]	1.5849625007211563	4	1	0	0
18928	1520	calycin protein superfamily	[calycin protein superfamily]	1.5849625007211563	3	1	0	0
18929	1520	caspase 7 Mch	[caspase 7 Mch]	1.5849625007211563	3	1	0	0
18930	1520	interact protein tradd	[interacting protein TRADD]	1.5849625007211563	3	1	0	0
18931	1520	protein in relation	[proteins in relation]	1.5849625007211563	3	1	0	0
18932	1520	level of IkappaB alpha	[levels of IkappaB alpha]	1.5849625007211563	4	1	0	0
18933	1520	AITL /GC, gcs	[AITL /GC, GCs]	1.5849625007211563	3	1	0	0
18934	1520	response element GRE	[response elements GRE]	1.5849625007211563	3	1	0	0
18935	1520	1,25 alpha-Dihydroxicholecalciferol vitd3	[1,25 alpha-Dihydroxicholecalciferol VitD3]	1.5849625007211563	3	1	0	0
18936	1520	interaction with fibronectin	[interaction with fibronectin]	1.5849625007211563	3	1	0	0
18937	1520	determination of phosphorylation site	[determination of phosphorylation sites]	1.5849625007211563	4	1	0	0
18938	1520	number of eicosanoid metabolite	[number of eicosanoid metabolites]	1.5849625007211563	4	1	0	0
18939	1520	er -negative phenotype	[ER -negative phenotype]	1.5849625007211563	3	1	0	0
18940	1520	access to this site	[Access to this site]	1.5849625007211563	4	1	0	0
18941	1520	decrease in SCL protein	[decrease in SCL protein]	1.5849625007211563	4	1	0	0
18942	1520	nuclei of u1 cell	[nuclei of U1 cells]	1.5849625007211563	4	1	0	0
18943	1520	addition to biophysical properties	[addition to biophysical properties,]	1.5849625007211563	4	1	0	0
18944	1520	nm23 gene family	[nm23 gene family]	1.5849625007211563	3	1	0	0
18945	1520	immunosuppression by glucocorticoid	[Immunosuppression by glucocorticoids]	1.5849625007211563	3	1	0	0
18946	1520	separate specific function	[separate specific functions]	1.5849625007211563	3	1	0	0
18947	1520	invariant chain-derived peptide	[invariant chain-derived peptides]	1.5849625007211563	3	1	0	0
18948	1520	inhibitory effect of il-10	[inhibitory effect of IL-10]	1.5849625007211563	4	1	0	0
18949	1520	BamHI-Q promoter Qp	[BamHI-Q promoter Qp]	1.5849625007211563	3	1	0	0
18950	1520	ifn-gamma receptor beta-chain	[IFN-gamma receptor beta-chain]	1.5849625007211563	3	1	0	0
18951	1520	hormonal receptor presence	[hormonal receptor presence]	1.5849625007211563	3	1	0	0
18952	1520	ca2+ ionophore a23187.	[Ca2+ ionophore A23187.]	1.5849625007211563	3	1	0	0
18953	1520	simple activation of rxr	[Simple activation of RXRs]	1.5849625007211563	4	1	0	0
18954	1520	MHC class ii w-x-y	[MHC class II W-X-Y]	1.5849625007211563	4	1	0	0
18955	1520	small percentage of normal	[small percentage of normals]	1.5849625007211563	4	1	0	0
18956	1520	block tnf-alpha transcription	[blocking TNF-alpha transcription]	1.5849625007211563	3	1	0	0
18957	1520	(mean S.D. (range): php	[(mean S.D. (range): PHP]	1.5849625007211563	4	1	0	0
18958	1520	germ-line mutation in brca1	[germ-line mutations in BRCA1]	1.5849625007211563	4	1	0	0
18959	1520	differential mrna display analysis	[differential mRNA display analysis]	1.5849625007211563	4	1	0	0
18960	1520	sequence between -1.7 kb	[sequence between -1.7 kb]	1.5849625007211563	4	1	0	0
18961	1520	effect on induction	[effect on induction]	1.5849625007211563	3	2	1	1
18962	1520	bmt allo drug	[BMT allo drug]	1.5849625007211563	3	1	0	0
18963	1520	binding to RBD	[Binding to RBD]	1.5849625007211563	3	1	0	0
18964	1520	ets nf-kappab interaction	[Ets NF-kappaB interaction]	1.5849625007211563	3	1	0	0
18965	1520	certain genomic region	[certain genomic regions]	1.5849625007211563	3	1	0	0
18966	1520	contain NF-kappa b site	[containing NF-kappa B sites]	1.5849625007211563	4	1	0	0
18967	1520	foreign body giant cell	[foreign body giant cells]	1.5849625007211563	4	1	0	0
18968	1520	regulatory pair phop	[regulatory pair phoP]	1.5849625007211563	3	1	0	0
18969	1520	ic50 parameter in CRF	[IC50 parameters in CRF]	1.5849625007211563	4	1	0	0
18970	1520	ssb reactivity in control	[SSB reactivity in controls]	1.5849625007211563	4	1	0	0
18971	1520	up-regulation of CD80 ag	[up-regulation of CD80 Ag]	1.5849625007211563	4	1	0	0
18972	1520	factor with the mobility	[factor with the mobility]	1.5849625007211563	4	1	0	0
18973	1520	ad vector lack E1A	[Ad vectors lacking E1A]	1.5849625007211563	4	1	0	0
18974	1520	(5 Hashimoto patient	[(5 Hashimoto patients]	1.5849625007211563	3	1	0	0
18975	1520	regulation of allergic response	[regulation of allergic responses]	1.5849625007211563	4	1	0	0
18976	1520	transfection of the cDNA	[transfection of the cDNA]	1.5849625007211563	4	1	0	0
18977	1520	incorporation of fkbp51	[incorporation of FKBP51]	1.5849625007211563	3	2	1	1
18978	1520	herbimycin a block	[herbimycin A block]	1.5849625007211563	3	1	0	0
18979	1520	expression of nf-at rdna	[expression of NF-AT cDNAs]	1.5849625007211563	4	1	0	0
18980	1520	Tamoxifen a oestrogen antagonist	[Tamoxifen an oestrogen antagonist]	1.5849625007211563	4	1	0	0
18981	1520	kappa immunoglobulin intron enhancer	[kappa immunoglobulin intron enhancer]	1.5849625007211563	4	1	0	0
18982	1520	prototypical nf-kappa b	[prototypical NF-kappa B]	1.5849625007211563	3	2	1	1
18983	1520	ubiquitous repressor ZEB	[ubiquitous repressor ZEB]	1.5849625007211563	3	1	0	0
18984	1520	human hepatitis b virus	[human hepatitis B virus]	1.5849625007211563	4	2	1	1
18985	1520	lymphoid enhancer-binding factor lef-1	[Lymphoid enhancer-binding factor LEF-1]	1.5849625007211563	4	1	0	0
18986	1520	unmanipulated conventional (b-2) lymphocyte	[unmanipulated conventional (B-2) lymphocytes]	1.5849625007211563	4	1	0	0
18987	1520	cytomegalovirus Ie gene product	[Cytomegalovirus IE gene products]	1.5849625007211563	4	1	0	0
18988	1520	process of gcr regulation	[process of GcR regulation]	1.5849625007211563	4	1	0	0
18989	1520	Ovarian cytotoxic T lymphocyte	[Ovarian cytotoxic T lymphocytes]	1.5849625007211563	4	1	0	0
18990	1520	'converted' tced motif	['converted' TCEd motifs]	1.5849625007211563	3	1	0	0
18991	1520	patient with various disease	[patients with various diseases]	1.5849625007211563	4	2	2	2
18992	1520	transcriptionally active p50/p65 heterodimer	[transcriptionally active p50/p65 heterodimers]	1.5849625007211563	4	1	0	0
18993	1520	control cells, class molecule	[control cells, class molecules]	1.5849625007211563	4	1	0	0
18994	1520	turnover of IkappaBalpha	[turnover of IkappaBalpha]	1.5849625007211563	3	1	0	0
18995	1520	granzyme b mrna transcript	[granzyme B mRNA transcript]	1.5849625007211563	4	1	0	0
18996	1520	129 primary breast cancer	[129 primary breast cancers]	1.5849625007211563	4	1	0	0
18997	1520	inhibitor of nf-kappab activation	[inhibitors of NF-kappaB activation]	1.5849625007211563	4	2	2	2
18998	1520	different nonerythroid cell	[different nonerythroid cells]	1.5849625007211563	3	1	0	0
18999	1520	suggest one possible mechanism	[suggesting one possible mechanism]	1.5849625007211563	4	1	0	0
19000	1520	protein latency expression	[Protein latency expression]	1.5849625007211563	3	1	0	0
19001	1520	relation to the position	[relation to the position]	1.5849625007211563	4	1	0	0
19002	1520	second subunit, CBF beta	[second subunit, CBF beta]	1.5849625007211563	4	1	0	0
19003	1520	eukaryotic transcription regulatory factor	[eukaryotic transcription regulatory factor]	1.5849625007211563	4	1	0	0
19004	1520	high proline content	[high proline content]	1.5849625007211563	3	2	1	1
19005	1520	suppression by antioxidant	[suppression by antioxidants]	1.5849625007211563	3	1	0	0
19006	1520	incidence of skewing	[incidence of skewing]	1.5849625007211563	3	1	0	0
19007	1520	role of interleukin-1 il-1	[role of interleukin-1 IL-1]	1.5849625007211563	4	1	0	0
19008	1520	predictor of euthyroidism	[predictor of euthyroidism]	1.5849625007211563	3	1	0	0
19009	1520	lytic viral life cycle	[lytic viral life cycle]	1.5849625007211563	4	1	0	0
19010	1520	c-myc mrna accumulation	[c-myc mRNA accumulation]	1.5849625007211563	3	1	0	0
19011	1520	c-rel nf-kappa b protein	[c-Rel NF-kappa B proteins]	1.5849625007211563	4	1	0	0
19012	1520	position -158 to -49	[positions -158 to -49]	1.5849625007211563	4	1	0	0
19013	1520	expression of epor	[expression of EpoR]	1.5849625007211563	3	1	0	0
19014	1520	expression in mature cell	[expression in mature cells]	1.5849625007211563	4	1	0	0
19015	1520	peptide with intermediate affinity	[peptide with intermediate affinity]	1.5849625007211563	4	1	0	0
19016	1520	number of cell type	[number of cell types]	1.5849625007211563	4	1	0	0
19017	1520	four patient (22%)	[Four patients (22%)]	1.5849625007211563	3	1	0	0
19018	1520	inappropriate binding of cortisol	[inappropriate binding of cortisol]	1.5849625007211563	4	1	0	0
19019	1520	level of proliferation	[levels of proliferation]	1.5849625007211563	3	1	0	0
19020	1520	context of the genome.	[context of the genome.]	1.5849625007211563	4	1	0	0
19021	1520	eventual cell death	[eventual cell death]	1.5849625007211563	3	1	0	0
19022	1520	five cellular protein p52	[Five cellular proteins p52]	1.5849625007211563	4	1	0	0
19023	1520	downstream intronic sequence	[downstream intronic sequence]	1.5849625007211563	3	1	0	0
19024	1520	4 month of flutamide	[4 months of flutamide]	1.5849625007211563	4	1	0	0
19025	1520	apparent affinity between ligand	[apparent affinity between ligand]	1.5849625007211563	4	1	0	0
19026	1520	second class ii-like molecule	[second class II-like molecule]	1.5849625007211563	4	1	0	0
19027	1520	regulate bcl-xL expression	[regulating bcl-xL expression]	1.5849625007211563	3	1	0	0
19028	1520	alternative splice/polyadenylation event	[alternative splice/polyadenylation events]	1.5849625007211563	3	1	0	0
19029	1520	expression of a number	[expression of a number]	1.5849625007211563	4	4	3	1
19030	1520	putative new retrovirus (es)	[putative new retrovirus (es)]	1.5849625007211563	4	1	0	0
19031	1520	malignant breast tumor	[malignant breast tumor]	1.5849625007211563	3	1	0	0
19032	1520	freely exchangeable ca2+	[freely exchangeable Ca2+]	1.5849625007211563	3	2	2	2
19033	1520	interfollicular bcl-6 +/cd3+ cell	[interfollicular Bcl-6 +/CD3+ cells]	1.5849625007211563	4	1	0	0
19034	1520	ANG ii like TNFalpha	[ANG II like TNFalpha]	1.5849625007211563	4	1	0	0
19035	1520	guanylate binding protein	[guanylate binding protein]	1.5849625007211563	3	1	0	0
19036	1520	potential nfat target gene	[potential NFAT target genes]	1.5849625007211563	4	1	0	0
19037	1520	respectively the fusion point	[respectively the fusion point]	1.5849625007211563	4	1	0	0
19038	1520	divergent T cell signal	[divergent T cell signals]	1.5849625007211563	4	1	0	0
19039	1520	T cell by progesterone	[T cells by progesterone]	1.5849625007211563	4	1	0	0
19040	1520	NF-kappa b suppression	[NF-kappa B suppression]	1.5849625007211563	3	2	1	1
19041	1520	phosphate-supplemented patient (58.3 2.7)	[phosphate-supplemented patients (58.3 2.7)]	1.5849625007211563	4	1	0	0
19042	1520	multiple enhanson domain	[multiple enhanson domains]	1.5849625007211563	3	1	0	0
19043	1520	HLA-DRA gene promoter	[HLA-DRA gene promoter]	1.5849625007211563	3	1	0	0
19044	1520	dex -resistant cell	[dex -resistant cells]	1.5849625007211563	3	2	1	1
19045	1520	excess alpha-globin chain	[excess alpha-globin chains]	1.5849625007211563	3	1	0	0
19046	1520	possibly other cytokine receptors,	[possibly other cytokine receptors,]	1.5849625007211563	4	1	0	0
19047	1520	four Spl binding element	[four Spl binding elements]	1.5849625007211563	4	1	0	0
19048	1520	level of fkbp51	[level of FKBP51]	1.5849625007211563	3	1	0	0
19049	1520	kappab site deleted,	[kappaB sites deleted,]	1.5849625007211563	3	1	0	0
19050	1520	dexamethasone by preincubation	[dexamethasone by preincubation]	1.5849625007211563	3	1	0	0
19051	1520	activity of this element.	[activity of this element.]	1.5849625007211563	4	1	0	0
19052	1520	tax -express t-cell line	[Tax -expressing T-cell lines]	1.5849625007211563	4	1	0	0
19053	1520	time of initiation	[time of initiation]	1.5849625007211563	3	1	0	0
19054	1520	granule exocytosis pathway	[granule exocytosis pathway]	1.5849625007211563	3	1	0	0
19055	1520	early myeloid cell line	[early myeloid cell lines]	1.5849625007211563	4	1	0	0
19056	1520	two bind protein	[Two binding proteins]	1.5849625007211563	3	1	0	0
19057	1520	NF-E1 YY-1 delta	[NF-E1 YY-1 delta]	1.5849625007211563	3	1	0	0
19058	1520	human Ramos b cell	[human Ramos B cells]	1.5849625007211563	4	1	0	0
19059	1520	course of malignant disease	[course of malignant diseases]	1.5849625007211563	4	1	0	0
19060	1520	female steroid receptor	[female steroid receptors]	1.5849625007211563	3	1	0	0
19061	1520	two alpha-helical segment	[two alpha-helical segments]	1.5849625007211563	3	1	0	0
19062	1520	second junb mrna peak	[second junB mRNA peak]	1.5849625007211563	4	1	0	0
19063	1520	contact with nuclear factor	[contacts with nuclear factors]	1.5849625007211563	4	1	0	0
19064	1520	extracellular domain (egf) receptor	[extracellular domain (EGF) receptor]	1.5849625007211563	4	1	0	0
19065	1520	patient with cd8+ t-pll	[patient with CD8+ T-PLL]	1.5849625007211563	4	1	0	0
19066	1520	AP1 by okadaic acid	[AP1 by okadaic acid]	1.5849625007211563	4	1	0	0
19067	1520	least one mutant line	[least one mutant line]	1.5849625007211563	4	1	0	0
19068	1520	tax -response element DNA	[Tax -response element DNA]	1.5849625007211563	4	1	0	0
19069	1520	degenerate oligonucleotide encode sequence	[degenerate oligonucleotides encoding sequences]	1.5849625007211563	4	1	0	0
19070	1520	androgen-responsive prostate tumour cell	[androgen-responsive prostate tumour cells]	1.5849625007211563	4	1	0	0
19071	1520	glycoprotein c (gC) gene	[glycoprotein C (gC) gene]	1.5849625007211563	4	1	0	0
19072	1520	genes, include glucocorticoid receptor	[genes, including glucocorticoid receptor]	1.5849625007211563	4	1	0	0
19073	1520	novel tre dr+2	[novel TRE DR+2]	1.5849625007211563	3	1	0	0
19074	1520	T roset cd4+	[T rosetting CD4+]	1.5849625007211563	3	1	0	0
19075	1520	ubiquitous protein oct-1	[ubiquitous protein Oct-1]	1.5849625007211563	3	1	0	0
19076	1520	fas promoter activity	[fas promoter activity]	1.5849625007211563	3	1	0	0
19077	1520	MHC class ii antigen	[MHC class II antigens]	1.5849625007211563	4	1	0	0
19078	1520	kappa b binding motif	[kappa B binding motif]	1.5849625007211563	4	1	0	0
19079	1520	T cell clone ar-5	[T cell clone Ar-5]	1.5849625007211563	4	1	0	0
19080	1520	epsilon BP ige-binding protein	[epsilon BP IgE-binding protein]	1.5849625007211563	4	1	0	0
19081	1520	stat6 signal transducer	[STAT6 signal transducer]	1.5849625007211563	3	1	0	0
19082	1520	inducible tnf-alpha expression	[inducible TNF-alpha expression]	1.5849625007211563	3	1	0	0
19083	1520	novel specific elastase inhibitor	[novel specific elastase inhibitor]	1.5849625007211563	4	1	0	0
19084	1520	other hypereosinophilic disease	[other hypereosinophilic diseases]	1.5849625007211563	3	1	0	0
19085	1520	spatial expression pattern	[spatial expression pattern]	1.5849625007211563	3	1	0	0
19086	1520	mechanism of action,	[mechanism of action,]	1.5849625007211563	3	2	1	1
19087	1520	mechanism of action.	[mechanisms of action.]	1.5849625007211563	3	2	2	2
19088	1520	maximal binding capacity nmax	[maximal binding capacity Nmax]	1.5849625007211563	4	1	0	0
19089	1520	positive regulatory activity	[positive regulatory activity]	1.5849625007211563	3	1	0	0
19090	1520	variety of contexts,	[variety of contexts,]	1.5849625007211563	3	1	0	0
19091	1520	progesterone on pregnancy lymphocyte	[progesterone on pregnancy lymphocytes]	1.5849625007211563	4	1	0	0
19092	1520	latency breaking activity,	[Latency breaking activity,]	1.5849625007211563	3	1	0	0
19093	1520	difference in bone mineralization	[differences in bone mineralization]	1.5849625007211563	4	1	0	0
19094	1520	bovine ganglioside G(m1)	[bovine gangliosides G(m1)]	1.5849625007211563	3	1	0	0
19095	1520	nongenomic response to testosterone	[nongenomic response to testosterone]	1.5849625007211563	4	1	0	0
19096	1520	estrogen receptor alpha eer-alpha)	[estrogen receptor alpha (ER-alpha)]	1.5849625007211563	4	1	0	0
19097	1520	circulate lymphocyte in hyperthyroidism	[circulating lymphocytes in hyperthyroidism]	1.5849625007211563	4	1	0	0
19098	1520	approximately 40-fold high activity	[approximately 40-fold higher activity]	1.5849625007211563	4	1	0	0
19099	1520	CAT plasmid reporter construct	[CAT plasmid reporter construct]	1.5849625007211563	4	1	0	0
19100	1520	crux of transcriptional activation	[crux of transcriptional activation]	1.5849625007211563	4	1	0	0
19101	1520	vertebrate t-cell-specific regulation	[vertebrate T-cell-specific regulation]	1.5849625007211563	3	1	0	0
19102	1520	amount of b	[amount of B]	1.5849625007211563	3	2	2	2
19103	1520	slight expression of c-fo	[slight expression of c-fos]	1.5849625007211563	4	1	0	0
19104	1520	source of polypeptide	[source of polypeptides]	1.5849625007211563	3	1	0	0
19105	1520	interaction of ss RBC	[interaction of SS RBC]	1.5849625007211563	4	2	2	2
19106	1520	heavy light chain enhancer	[heavy light chain enhancers]	1.5849625007211563	4	1	0	0
19107	1520	role in immune response	[role in immune responses]	1.5849625007211563	4	2	2	2
19108	1520	small proportion of patient	[small proportion of patients]	1.5849625007211563	4	1	0	0
19109	1520	antiinflammatory activity as potent	[antiinflammatory activity as potent]	1.5849625007211563	4	1	0	0
19110	1520	cortisol level of patient	[cortisol levels of patients]	1.5849625007211563	4	1	0	0
19111	1520	overall study group	[overall study group]	1.5849625007211563	3	1	0	0
19112	1520	adaptation to the presence	[adaptation to the presence]	1.5849625007211563	4	1	0	0
19113	1520	-72 to -63) motif	[-72 to -63) motifs]	1.5849625007211563	4	1	0	0
19114	1520	transcription factor rbp-jkappa	[transcription factor RBP-Jkappa]	1.5849625007211563	3	1	0	0
19115	1520	glucocorticoid receptor gr functionality	[glucocorticoid receptor GR functionality]	1.5849625007211563	4	1	0	0
19116	1520	GT (caccc) motif	[GT (CACCC) motifs]	1.5849625007211563	3	1	0	0
19117	1520	quiescent human b-lymphocyte	[quiescent human B-lymphocytes]	1.5849625007211563	3	1	0	0
19118	1520	GAL4 reporter construct	[GAL4 reporter construct]	1.5849625007211563	3	1	0	0
19119	1520	consist of two chain	[consisting of two chains]	1.5849625007211563	4	1	0	0
19120	1520	positive role for PGE2	[positive role for PGE2]	1.5849625007211563	4	1	0	0
19121	1520	non-insulin-dependent diabete mellitus patient	[non-insulin-dependent diabetes mellitus patients]	1.5849625007211563	4	1	0	0
19122	1520	well-characterized, thiol-containing antioxidant	[well-characterized, thiol-containing antioxidant]	1.5849625007211563	3	1	0	0
19123	1520	nonspecific esterase activity	[nonspecific esterase activity]	1.5849625007211563	3	1	0	0
19124	1520	IgE/allergen immune complex	[IgE/allergen immune complexes]	1.5849625007211563	3	1	0	0
19125	1520	gel-mobility shift assay	[gel-mobility shift assays]	1.5849625007211563	3	1	0	0
19126	1520	NF-kappa b subunit	[NF-kappa B subunits]	1.5849625007211563	3	2	2	2
19127	1520	increase in haemoglobin production	[increase in haemoglobin production]	1.5849625007211563	4	1	0	0
19128	1520	particular, with up-regulation	[particular, with up-regulation]	1.5849625007211563	3	1	0	0
19129	1520	first 12 month	[first 12 months]	1.5849625007211563	3	1	0	0
19130	1520	effect on il-10 secretion	[effect on IL-10 secretion]	1.5849625007211563	4	1	0	0
19131	1520	uncharacterized transcription factor	[uncharacterized transcription factor]	1.5849625007211563	3	1	0	0
19132	1520	eight pair of oligonucleotide	[eight pairs of oligonucleotides]	1.5849625007211563	4	1	0	0
19133	1520	corresponding nuclear binding factor	[corresponding nuclear binding factors]	1.5849625007211563	4	1	0	0
19134	1520	p3hr1 virus genome	[P3HR1 virus genome]	1.5849625007211563	3	1	0	0
19135	1520	mutant ebv strain	[mutant EBV strain]	1.5849625007211563	3	1	0	0
19136	1520	form of creb protein	[form of CREB protein]	1.5849625007211563	4	1	0	0
19137	1520	resistance in chronic asthma	[resistance in chronic asthma]	1.5849625007211563	4	2	2	2
19138	1520	human il4 promoter transcription	[Human IL4 promoter transcription]	1.5849625007211563	4	1	0	0
19139	1520	PRDII regulatory element	[PRDII regulatory element]	1.5849625007211563	3	1	0	0
19140	1520	affect stat tyrosine phosphorylation	[affecting STAT tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
19141	1520	approximately 28 kda	[approximately 28 kDa]	1.5849625007211563	3	1	0	0
19142	1520	site HS2 enhancer	[site HS2 enhancer]	1.5849625007211563	3	2	2	2
19143	1520	lymphocyte gr binding parameter	[lymphocyte GR binding parameters]	1.5849625007211563	4	1	0	0
19144	1520	pml nuclear protein	[PML nuclear protein]	1.5849625007211563	3	1	0	0
19145	1520	development of sepsis.	[development of sepsis.]	1.5849625007211563	3	1	0	0
19146	1520	BCL-2 -deficient T cell	[BCL-2 -deficient T cells]	1.5849625007211563	4	1	0	0
19147	1520	TCR delta enhancer Edelta	[TCR delta enhancer Edelta]	1.5849625007211563	4	1	0	0
19148	1520	human immunodeficiency virus monocyte	[human immunodeficiency virus monocytes]	1.5849625007211563	4	1	0	0
19149	1520	expression of LAL -mRNA	[expression of LAL -mRNA]	1.5849625007211563	4	1	0	0
19150	1520	reservoir of cell	[reservoir of cells]	1.5849625007211563	3	1	0	0
19151	1520	state of knowledge	[state of knowledge]	1.5849625007211563	3	2	2	2
19152	1520	immediate 5' upstream region	[immediate 5' upstream region]	1.5849625007211563	4	1	0	0
19153	1520	patient with preeclampsia	[patients with preeclampsia]	1.5849625007211563	3	2	2	2
19154	1520	MRD -/lt) patient	[MRD -/LT) patients]	1.5849625007211563	3	1	0	0
19155	1520	ebv antibody titre	[EBV antibody titres]	1.5849625007211563	3	2	2	2
19156	1520	4-exon structure characteristic	[4-exon structure characteristic]	1.5849625007211563	3	1	0	0
19157	1520	hepatic pcd/dcoh protein level	[hepatic PCD/DCoH protein level]	1.5849625007211563	4	1	0	0
19158	1520	radio-ligand binding method	[radio-ligand binding method]	1.5849625007211563	3	1	0	0
19159	1520	only intercellular adhesion molecule-1	[only intercellular adhesion molecule-1]	1.5849625007211563	4	1	0	0
19160	1520	approximately 30 minute	[approximately 30 min]	1.5849625007211563	3	1	0	0
19161	1520	reactive oxygen species ROS)	[reactive oxygen species ROS)]	1.5849625007211563	4	1	0	0
19162	1520	calcium signalling pathway	[calcium signalling pathways]	1.5849625007211563	3	1	0	0
19163	1520	utilize transient transfection assay	[Utilizing transient transfection assays]	1.5849625007211563	4	1	0	0
19164	1520	association of Nmi	[association of Nmi]	1.5849625007211563	3	2	2	2
19165	1520	steel factor erythroid proliferation	[Steel factor erythroid proliferation]	1.5849625007211563	4	1	0	0
19166	1520	viral rna production	[viral RNA production]	1.5849625007211563	3	2	2	2
19167	1520	monovalent gold compound autg	[monovalent gold compound AuTG]	1.5849625007211563	4	1	0	0
19168	1520	stimulation by PMA	[stimulation by PMA]	1.5849625007211563	3	1	0	0
19169	1520	Nuclear transcription factor	[Nuclear transcription factor]	1.5849625007211563	3	2	1	1
19170	1520	activation, normal T cell	[activation, normal T cell]	1.5849625007211563	4	1	0	0
19171	1520	mouse b29 promoter	[mouse B29 promoter]	1.5849625007211563	3	1	0	0
19172	1520	murine haemopoietic cell	[murine haemopoietic cells]	1.5849625007211563	3	1	0	0
19173	1520	expression of wt1	[expression of WT1]	1.5849625007211563	3	2	2	2
19174	1520	H/C link sequence	[H/C link sequence]	1.5849625007211563	3	1	0	0
19175	1520	reconstitution of receptor function	[reconstitution of receptor functions]	1.5849625007211563	4	1	0	0
19176	1520	lack of cooperation	[lack of cooperation]	1.5849625007211563	3	1	0	0
19177	1520	deletion mutation analysis	[Deletion mutation analysis]	1.5849625007211563	3	1	0	0
19178	1520	most prominent factor,	[most prominent factor,]	1.5849625007211563	3	1	0	0
19179	1520	nf-kappa b in monocyte	[NF-kappa B in monocytes]	1.5849625007211563	4	1	0	0
19180	1520	strong lps responsiveness	[strong LPS responsiveness]	1.5849625007211563	3	1	0	0
19181	1520	cd95 ligand expression,	[CD95 ligand expression,]	1.5849625007211563	3	1	0	0
19182	1520	coordination of effector function	[coordination of effector functions]	1.5849625007211563	4	1	0	0
19183	1520	MZF-1 expression vector	[MZF-1 expression vectors]	1.5849625007211563	3	1	0	0
19184	1520	cysteine deficiency in individual	[cysteine deficiency in individuals]	1.5849625007211563	4	1	0	0
19185	1520	two consensus sequences, capable	[Two consensus sequences, capable]	1.5849625007211563	4	1	0	0
19186	1520	mediate the gm-csf production	[mediating the GM-CSF production]	1.5849625007211563	4	1	0	0
19187	1520	adenovirus e1a sequence relevant	[adenovirus E1a sequences relevant]	1.5849625007211563	4	1	0	0
19188	1520	cell supernatant by ELISA	[cell supernatants by ELISA]	1.5849625007211563	4	1	0	0
19189	1520	(il-2rbeta)/il-4ralpha cytokine receptor chimera	[(IL-2Rbeta)/IL-4Ralpha cytokine receptor chimera]	1.5849625007211563	4	1	0	0
19190	1520	ligand, to the culture	[ligand, to the cultures]	1.5849625007211563	4	1	0	0
19191	1520	immediate-early ebv zebra gene	[immediate-early EBV Zebra gene]	1.5849625007211563	4	1	0	0
19192	1520	transcription factor gene family	[transcription factor gene families]	1.5849625007211563	4	1	0	0
19193	1520	U937 monocytic cell line	[U937 monocytic cell line]	1.5849625007211563	4	1	0	0
19194	1520	neutrophil polymorphonuclear leukocyte	[neutrophils polymorphonuclear leukocytes]	1.5849625007211563	3	1	0	0
19195	1520	about 300 amino acid	[about 300 amino acids]	1.5849625007211563	4	1	0	0
19196	1520	peripheral blood human monocyte	[peripheral blood human monocytes]	1.5849625007211563	4	1	0	0
19197	1520	nf-at /DNA binding defect	[NF-AT /DNA binding defect]	1.5849625007211563	4	1	0	0
19198	1520	multiple traf3 binding site	[Multiple TRAF3 binding sites]	1.5849625007211563	4	1	0	0
19199	1520	cd56+ endometrial lymphocyte (egls)	[CD56+ endometrial lymphocytes (eGLs)]	1.5849625007211563	4	1	0	0
19200	1520	protein range between 70	[proteins ranging between 70]	1.5849625007211563	4	1	0	0
19201	1520	transcription factor E2F-1	[transcription factor E2F-1]	1.5849625007211563	3	1	0	0
19202	1520	immune responsiveness to Ag	[immune responsiveness to Ag]	1.5849625007211563	4	1	0	0
19203	1520	one LYSP100 cDNA isoform	[one LYSP100 cDNA isoform]	1.5849625007211563	4	1	0	0
19204	1520	il-2 in T lymphocyte	[IL-2 in T lymphocytes]	1.5849625007211563	4	1	0	0
19205	1520	phenolic, lipid-soluble, chain-break antioxidant	[phenolic, lipid-soluble, chain-breaking antioxidant]	1.5849625007211563	4	1	0	0
19206	1520	absence of BRCA1 mrna	[absence of BRCA1 mRNA]	1.5849625007211563	4	1	0	0
19207	1520	P3HR-1 defective genome	[P3HR-1 defective genome]	1.5849625007211563	3	1	0	0
19208	1520	extensive clinical application.	[extensive clinical application.]	1.5849625007211563	3	1	0	0
19209	1520	connective tissue turnover,	[connective tissue turnover,]	1.5849625007211563	3	1	0	0
19210	1520	hiv promoter activity	[HIV promoter activity]	1.5849625007211563	3	2	1	1
19211	1520	essentially identical deletions.	[essentially identical deletions.]	1.5849625007211563	3	1	0	0
19212	1520	globin locus control region	[globin locus control region]	1.5849625007211563	4	1	0	0
19213	1520	calcineurin a chain	[calcineurin A chain]	1.5849625007211563	3	1	0	0
19214	1520	two distinct transcription factor	[Two distinct transcription factors]	1.5849625007211563	4	1	0	0
19215	1520	expression cloning strategy	[expression cloning strategy]	1.5849625007211563	3	1	0	0
19216	1520	study with pyrrolidinedithiocarbamate	[studies with pyrrolidinedithiocarbamate]	1.5849625007211563	3	1	0	0
19217	1520	il-12p40 mrna expression	[IL-12p40 mRNA expression]	1.5849625007211563	3	1	0	0
19218	1520	transcription of hiv repeat	[transcription of HIV repeat]	1.5849625007211563	4	1	0	0
19219	1520	modulation of the proliferation	[modulation of the proliferation]	1.5849625007211563	4	1	0	0
19220	1520	human plasma cell	[human plasma cells]	1.5849625007211563	3	2	1	1
19221	1520	patient own autoimmune serum	[patients own autoimmune serum]	1.5849625007211563	4	1	0	0
19222	1520	one pattern dominant	[one pattern dominant]	1.5849625007211563	3	1	0	0
19223	1520	cell surface antigene cd33	[cell surface antigenes CD33]	1.5849625007211563	4	1	0	0
19224	1520	ouabain resistant, atp hydroly	[ouabain resistant, ATP hydrolyses]	1.5849625007211563	4	1	0	0
19225	1520	proximity of hlh-2	[proximity of hLH-2]	1.5849625007211563	3	1	0	0
19226	1520	particular, two interleukin ILs	[particular, two interleukins ILs]	1.5849625007211563	4	1	0	0
19227	1520	ionomycin p/i pharmacological mimic	[ionomycin P/I pharmacological mimics]	1.5849625007211563	4	1	0	0
19228	1520	eosinophil specific beta-chemokine	[eosinophil specific beta-chemokine]	1.5849625007211563	3	1	0	0
19229	1520	activity of erk1	[activity of ERK1]	1.5849625007211563	3	1	0	0
19230	1520	Gln at 551	[Gln at 551]	1.5849625007211563	3	1	0	0
19231	1520	dominant-negative form of TRAF2	[dominant-negative form of TRAF2]	1.5849625007211563	4	1	0	0
19232	1520	treatment of inflammation	[treatment of inflammation]	1.5849625007211563	3	1	0	0
19233	1520	variety of immune response	[variety of immune responses]	1.5849625007211563	4	1	0	0
19234	1520	high ligand binding affinity	[high ligand binding affinity]	1.5849625007211563	4	1	0	0
19235	1520	tyrosine phosphorylation of proteins.	[tyrosine phosphorylation of proteins.]	1.5849625007211563	4	1	0	0
19236	1520	increase in bcl-2 expression	[increase in bcl-2 expression]	1.5849625007211563	4	1	0	0
19237	1520	U-937 monoblastic cell line	[U-937 monoblastic cell line]	1.5849625007211563	4	1	0	0
19238	1520	interleukin-2 receptor-alpha il-2r alpha	[interleukin-2 receptor-alpha IL-2R alpha]	1.5849625007211563	4	1	0	0
19239	1520	induction of promoter dependent	[induction of promoters dependent]	1.5849625007211563	4	1	0	0
19240	1520	eosinophilia in asthma	[eosinophilia in asthma]	1.5849625007211563	3	1	0	0
19241	1520	remain cd4+ T cell	[remaining CD4+ T cells]	1.5849625007211563	4	1	0	0
19242	1520	primitive erythroid environment	[primitive erythroid environment]	1.5849625007211563	3	1	0	0
19243	1520	role of p95vav	[role of p95vav]	1.5849625007211563	3	1	0	0
19244	1520	diverse biochemical signal	[diverse biochemical signals]	1.5849625007211563	3	1	0	0
19245	1520	cell antigen receptor signal	[cell antigen receptor signals]	1.5849625007211563	4	1	0	0
19246	1520	murine adult hpc	[murine adult HPCs]	1.5849625007211563	3	1	0	0
19247	1520	-inducing kinase nik	[-inducing kinase NIK]	1.5849625007211563	3	1	0	0
19248	1520	activation of receptor	[activation of receptors]	1.5849625007211563	3	2	2	2
19249	1520	several line of investigation	[several lines of investigation]	1.5849625007211563	4	2	1	1
19250	1520	beneficial effect in process	[beneficial effects in processes]	1.5849625007211563	4	1	0	0
19251	1520	59 amino acid c-terminal	[59 amino acids C-terminal]	1.5849625007211563	4	1	0	0
19252	1520	presence of tepoxalin	[presence of tepoxalin]	1.5849625007211563	3	1	0	0
19253	1520	stability of pbgd rrna	[stability of PBGD mRNAs]	1.5849625007211563	4	1	0	0
19254	1520	cellular nf-kappa b activity	[cellular NF-kappa B activity]	1.5849625007211563	4	2	1	1
19255	1520	position -102 to -73,	[positions -102 to -73,]	1.5849625007211563	4	1	0	0
19256	1520	vivo genomic footprinting	[vivo genomic footprinting]	1.5849625007211563	3	2	1	1
19257	1520	several other human sequence	[several other human sequences]	1.5849625007211563	4	1	0	0
19258	1520	furthermore, the ability	[Furthermore, the ability]	1.5849625007211563	3	1	0	0
19259	1520	downstream enhancer domain	[downstream enhancer domain]	1.5849625007211563	3	1	0	0
19260	1520	exposure of nb4 cell	[exposure of NB4 cells]	1.5849625007211563	4	1	0	0
19261	1520	CIITA -independent mechanism	[CIITA -independent mechanism]	1.5849625007211563	3	1	0	0
19262	1520	difference in activation	[differences in activation]	1.5849625007211563	3	2	2	2
19263	1520	bind to this site	[binding to this site]	1.5849625007211563	4	1	0	0
19264	1520	Epstein-Barr virus dutpase	[Epstein-Barr virus dUTPase]	1.5849625007211563	3	2	2	2
19265	1520	intracellular il-2 protein	[intracellular IL-2 protein]	1.5849625007211563	3	1	0	0
19266	1520	LT-producing C81-66-45 cell line	[LT-producing C81-66-45 cell line]	1.5849625007211563	4	1	0	0
19267	1520	IL-2 pi 3-kinase pathway	[IL-2 PI 3-kinase pathways]	1.5849625007211563	4	1	0	0
19268	1520	role for hsp27	[role for HSP27]	1.5849625007211563	3	1	0	0
19269	1520	protein of function	[protein of function]	1.5849625007211563	3	2	2	2
19270	1520	cellular response during infection	[cellular responses during infection]	1.5849625007211563	4	1	0	0
19271	1520	abnormal glucocorticoid clearance	[abnormal glucocorticoid clearance]	1.5849625007211563	3	1	0	0
19272	1520	primary structure analysis	[Primary structure analysis]	1.5849625007211563	3	1	0	0
19273	1520	activation of gene transcription	[activation of gene transcription]	1.5849625007211563	4	1	0	0
19274	1520	analysis at the phenotype	[Analysis at the phenotype]	1.5849625007211563	4	1	0	0
19275	1520	nuclear factor-activated T cell	[nuclear factor-activated T cells]	1.5849625007211563	4	1	0	0
19276	1520	two serine proteinase	[two serine proteinases]	1.5849625007211563	3	1	0	0
19277	1520	phop -phoq two-component system	[phoP -phoQ two-component system]	1.5849625007211563	4	1	0	0
19278	1520	regulation of migration	[regulation of migration]	1.5849625007211563	3	1	0	0
19279	1520	normal tissue histiocyte	[normal tissue histiocytes]	1.5849625007211563	3	1	0	0
19280	1520	NFAT family member	[NFAT family member]	1.5849625007211563	3	2	2	2
19281	1520	macrophage scavenger receptor msr	[macrophage scavenger receptor MSR]	1.5849625007211563	4	1	0	0
19282	1520	human retinoblastoma gene	[human retinoblastoma gene]	1.5849625007211563	3	1	0	0
19283	1520	marginal amount of jun-b	[marginal amounts of Jun-B]	1.5849625007211563	4	1	0	0
19284	1520	serine-threonine phosphatase pp2a	[serine-threonine phosphatase PP2A]	1.5849625007211563	3	1	0	0
19285	1520	inhibitor of ice-like protease	[inhibitor of ICE-like proteases]	1.5849625007211563	4	1	0	0
19286	1520	generation of ap-1 activity	[generation of AP-1 activity]	1.5849625007211563	4	1	0	0
19287	1520	activator of transcription-3 STAT3	[activator of transcription-3 STAT3]	1.5849625007211563	4	1	0	0
19288	1520	acidic transcriptional activation domain	[acidic transcriptional activation domain]	1.5849625007211563	4	2	1	1
19289	1520	one hiv-1 variant	[One HIV-1 variant]	1.5849625007211563	3	1	0	0
19290	1520	similar glucocorticoid-mediated potentiation	[Similar glucocorticoid-mediated potentiation]	1.5849625007211563	3	1	0	0
19291	1520	detection of disease	[Detection of disease]	1.5849625007211563	3	2	2	2
19292	1520	interleukin 2 (il-2)	[interleukin 2 (IL-2)]	1.5849625007211563	3	1	0	0
19293	1520	activate pml -dependent pathway	[activating PML -dependent pathways]	1.5849625007211563	4	1	0	0
19294	1520	convergence of the mapk	[convergence of the MAPK]	1.5849625007211563	4	1	0	0
19295	1520	pattern of signal event	[pattern of signaling events]	1.5849625007211563	4	2	2	2
19296	1520	addition, over-expression of stat2	[addition, over-expression of STAT2]	1.5849625007211563	4	1	0	0
19297	1520	least dense peroxidase-negative granule	[least dense peroxidase-negative granules]	1.5849625007211563	4	1	0	0
19298	1520	form of this structure	[forms of these structures]	1.5849625007211563	4	1	0	0
19299	1520	specificity of some	[specificities of some]	1.5849625007211563	3	1	0	0
19300	1520	provide the modulate activity.	[providing the modulating activity.]	1.5849625007211563	4	1	0	0
19301	1520	hiv-1 steady-state mrna level	[HIV-1 steady-state mRNA levels]	1.5849625007211563	4	1	0	0
19302	1520	various inflammatory disease	[various inflammatory diseases]	1.5849625007211563	3	1	0	0
19303	1520	cDNA encode a receptor	[cDNA encoding a receptor]	1.5849625007211563	4	1	0	0
19304	1520	-encode gene chimera	[-encoding gene chimeras]	1.5849625007211563	3	1	0	0
19305	1520	pkc isoform alpha	[PKC isoforms alpha]	1.5849625007211563	3	1	0	0
19306	1520	hybrid molecule pml/rar alpha	[hybrid molecule pml/RAR alpha]	1.5849625007211563	4	1	0	0
19307	1520	even with a therapy	[Even with a therapy]	1.5849625007211563	4	1	0	0
19308	1520	certain leukocyte subset	[certain leukocyte subsets]	1.5849625007211563	3	1	0	0
19309	1520	identical sequence CCGAAACTGAAAAGG E6	[identical sequence CCGAAACTGAAAAGG E6]	1.5849625007211563	4	1	0	0
19310	1520	mitogen stimulation of t-cell	[Mitogen stimulation of T-cells]	1.5849625007211563	4	1	0	0
19311	1520	arrest of kit225 cell	[arrest of Kit225 cells]	1.5849625007211563	4	1	0	0
19312	1520	lymphoma model use antibody	[lymphoma model using antibodies]	1.5849625007211563	4	1	0	0
19313	1520	Fc gamma riia	[Fc gamma RIIA]	1.5849625007211563	3	1	0	0
19314	1520	bacterial cell wall component	[bacterial cell wall components]	1.5849625007211563	4	1	0	0
19315	1520	predetermine DNA sequence	[predetermined DNA sequences]	1.5849625007211563	3	1	0	0
19316	1520	cycle of chemotherapy.	[cycles of chemotherapy.]	1.5849625007211563	3	1	0	0
19317	1520	serum ig level	[Serum Ig levels]	1.5849625007211563	3	1	0	0
19318	1520	variety of specific cytokine	[variety of specific cytokines]	1.5849625007211563	4	1	0	0
19319	1520	transfection of EBNA-LP alone	[Transfection of EBNA-LP alone]	1.5849625007211563	4	1	0	0
19320	1520	3-o-methyl-d glucose 3-o-mg	[3-O-methyl-D glucose 3-O-MG]	1.5849625007211563	3	1	0	0
19321	1520	9 healthy volunteer	[9 healthy volunteers]	1.5849625007211563	3	1	0	0
19322	1520	hiv-1 myeloid cell	[HIV-1 myeloid cells]	1.5849625007211563	3	1	0	0
19323	1520	MEK inhibitor pd98059	[MEK inhibitor PD98059]	1.5849625007211563	3	1	0	0
19324	1520	immunoglobulin g immune complex	[immunoglobulin G immune complexes]	1.5849625007211563	4	1	0	0
19325	1520	lymphotropic herpesvirus capable	[lymphotropic herpesvirus capable]	1.5849625007211563	3	1	0	0
19326	1520	particularly strong transcription	[particularly strong transcription]	1.5849625007211563	3	1	0	0
19327	1520	expression of id3	[expression of Id3]	1.5849625007211563	3	1	0	0
19328	1520	anti-human aortic ec activity	[anti-human aortic EC activity]	1.5849625007211563	4	1	0	0
19329	1520	different regulatory pathway	[different regulatory pathways]	1.5849625007211563	3	2	2	2
19330	1520	B alpha complex	[B alpha complex]	1.5849625007211563	3	1	0	0
19331	1520	pyrrolidine dithiocarbamate a inhibitor	[Pyrrolidine dithiocarbamate an inhibitor]	1.5849625007211563	4	2	1	1
19332	1520	low renin value	[lower renin values]	1.5849625007211563	3	1	0	0
19333	1520	disease with inflammatory pathogenesis	[diseases with inflammatory pathogenesis]	1.5849625007211563	4	1	0	0
19334	1520	vitamin d 1,25-dihydroxyvitamin D3	[vitamin D 1,25-dihydroxyvitamin D3]	1.5849625007211563	4	1	0	0
19335	1520	human b cell mutant	[human B cell mutant]	1.5849625007211563	4	1	0	0
19336	1520	use the t-cell line	[using the T-cell line]	1.5849625007211563	4	2	2	2
19337	1520	inducible virus expression	[inducible virus expression]	1.5849625007211563	3	1	0	0
19338	1520	nuclear localization sequence NLS	[nuclear localization sequence NLS]	1.5849625007211563	4	1	0	0
19339	1520	precise molecular abnormality	[precise molecular abnormalities]	1.5849625007211563	3	1	0	0
19340	1520	cooperative nf-kappa b	[cooperative NF-kappa B]	1.5849625007211563	3	1	0	0
19341	1520	N-terminal half of IBR/F	[N-terminal half of IBR/F]	1.5849625007211563	4	1	0	0
19342	1520	human CD4 gene	[human CD4 gene]	1.5849625007211563	3	1	0	0
19343	1520	outside of embryonic development	[outside of embryonic development]	1.5849625007211563	4	1	0	0
19344	1520	IL-6 promoter activity	[IL-6 promoter activity]	1.5849625007211563	3	2	1	1
19345	1520	high g c content	[high G C content]	1.5849625007211563	4	1	0	0
19346	1520	processing in a system	[processing in a system]	1.5849625007211563	4	1	0	0
19347	1520	high relative level	[higher relative levels]	1.5849625007211563	3	1	0	0
19348	1520	electrophoretic mobility supershift assay	[electrophoretic mobility supershift assay]	1.5849625007211563	4	1	0	0
19349	1520	myeloblastic leukemic ml-1 cell	[myeloblastic leukemic ML-1 cell]	1.5849625007211563	4	1	0	0
19350	1520	regard, anti-inflammatory cytokine lps	[regard, anti-inflammatory cytokines LPS]	1.5849625007211563	4	1	0	0
19351	1520	give rise to protein	[giving rise to proteins]	1.5849625007211563	4	1	0	0
19352	1520	pre-B cell IL-4	[pre-B cells IL-4]	1.5849625007211563	3	1	0	0
19353	1520	Anergic cd4+ th cell	[Anergic CD4+ Th cells]	1.5849625007211563	4	1	0	0
19354	1520	(threshold of cathepsin g	[(threshold of cathepsin G]	1.5849625007211563	4	1	0	0
19355	1520	emphasis on: transcriptional regulation	[emphasis on: transcriptional regulation]	1.5849625007211563	4	1	0	0
19356	1520	migration of leukocyte	[migration of leukocytes]	1.5849625007211563	3	2	2	2
19357	1520	trans-act dominant negative regulator	[trans-acting dominant negative regulator]	1.5849625007211563	4	1	0	0
19358	1520	relative molecular mass	[relative molecular mass]	1.5849625007211563	3	2	2	2
19359	1520	carboxyl-terminal region of Stat6	[carboxyl-terminal region of Stat6]	1.5849625007211563	4	1	0	0
19360	1520	nuclear appearance of p50/p65-nf-kappab	[nuclear appearance of p50/p65-NF-kappaB]	1.5849625007211563	4	1	0	0
19361	1520	pre-exist nf-at complex	[pre-existing NF-AT complex]	1.5849625007211563	3	1	0	0
19362	1520	cd3+ T cell	[CD3+ T cells]	1.5849625007211563	3	2	2	2
19363	1520	histocompatibility complex (mhc) class	[histocompatibility complex (MHC) class]	1.5849625007211563	4	1	0	0
19364	1520	creb binding protein	[CREB binding protein]	1.5849625007211563	3	1	0	0
19365	1520	fas -regulatory gene TDAG51	[Fas -regulatory gene TDAG51]	1.5849625007211563	4	1	0	0
19366	1520	control of protein	[control of proteins]	1.5849625007211563	3	2	2	2
19367	1520	phosphoprotein in ebv cell	[phosphoprotein in EBV cells]	1.5849625007211563	4	1	0	0
19368	1520	mature cell culture	[maturing cell cultures]	1.5849625007211563	3	1	0	0
19369	1520	limited gene rearrangement	[limited gene rearrangement]	1.5849625007211563	3	1	0	0
19370	1520	loss of RB	[loss of RB]	1.5849625007211563	3	1	0	0
19371	1520	nuclear protein Ets-1	[nuclear protein Ets-1]	1.5849625007211563	3	1	0	0
19372	1520	affect subcellular distribution.	[affecting subcellular distribution.]	1.5849625007211563	3	1	0	0
19373	1520	HHV-6 variant b BA92	[HHV-6 variant B BA92]	1.5849625007211563	4	1	0	0
19374	1520	presence of b cell	[presence of B cells]	1.5849625007211563	4	1	0	0
19375	1520	several aspect of calcium	[several aspects of calcium]	1.5849625007211563	4	1	0	0
19376	1520	thr alpha- ppar heterodimer	[THR alpha- PPAR heterodimer]	1.5849625007211563	4	1	0	0
19377	1520	extracellular cysteine supply	[extracellular cysteine supply]	1.5849625007211563	3	1	0	0
19378	1520	separate prl -responsive element	[separate PRL -responsive elements]	1.5849625007211563	4	1	0	0
19379	1520	context-dependent apoptosis regulator	[context-dependent apoptosis regulator]	1.5849625007211563	3	1	0	0
19380	1520	Granulocyte-macrophage colony-stimumulatelany-stg factor gm-csf	[Granulocyte-macrophage colony-stimulating factor GM-CSF]	1.5849625007211563	4	1	0	0
19381	1520	loss-of-function mutation in Cbl-b	[loss-of-function mutation in Cbl-b]	1.5849625007211563	4	1	0	0
19382	1520	dysfunction of this gene	[dysfunction of these genes]	1.5849625007211563	4	1	0	0
19383	1520	effect of IL-10	[effect of IL-10]	1.5849625007211563	3	1	0	0
19384	1520	ldl MM-LDL endothelial cell	[LDL MM-LDL endothelial cells]	1.5849625007211563	4	1	0	0
19385	1520	line differ in capacity	[lines differing in capacity]	1.5849625007211563	4	1	0	0
19386	1520	150 bp hEpoR promoter	[150 bp hEpoR promoter]	1.5849625007211563	4	1	0	0
19387	1520	gene control of cell	[gene control of cells]	1.5849625007211563	4	1	0	0
19388	1520	cytoplasmic CAT mrna	[cytoplasmic CAT mRNA]	1.5849625007211563	3	1	0	0
19389	1520	gp120 human astrocyte	[gp120 human astrocytes]	1.5849625007211563	3	1	0	0
19390	1520	fab fragment immunoglobulin g	[Fab fragment immunoglobulin G]	1.5849625007211563	4	1	0	0
19391	1520	class ii MHC gene	[class II MHC genes]	1.5849625007211563	4	1	0	0
19392	1520	sequence of one	[sequence of one]	1.5849625007211563	3	1	0	0
19393	1520	post-germinal centre b cell	[post-germinal centre B cell]	1.5849625007211563	4	1	0	0
19394	1520	cell survival signal	[cell survival signals]	1.5849625007211563	3	1	0	0
19395	1520	low pkc enzymatic activity	[low PKC enzymatic activity]	1.5849625007211563	4	1	0	0
19396	1520	nonmyeloid cell line	[nonmyeloid cell lines]	1.5849625007211563	3	1	0	0
19397	1520	effect of selenium	[effects of selenium]	1.5849625007211563	3	2	1	1
19398	1520	association with the p65	[association with the p65]	1.5849625007211563	4	1	0	0
19399	1520	human nm23-h2 gene product	[human nm23-H2 gene product]	1.5849625007211563	4	1	0	0
19400	1520	neomycin resistance gene	[neomycin resistance gene]	1.5849625007211563	3	1	0	0
19401	1520	herpes virus transactivator vp16	[herpes virus transactivator VP16]	1.5849625007211563	4	1	0	0
19402	1520	Furthermore, biologic function	[Furthermore, biologic functions]	1.5849625007211563	3	1	0	0
19403	1520	b-cell-specific transcription factor Oct-2	[B-cell-specific transcription factor Oct-2]	1.5849625007211563	4	1	0	0
19404	1520	pluripotent endocrine culture	[pluripotent endocrine cultures]	1.5849625007211563	3	1	0	0
19405	1520	evidence for a mechanism	[evidence for an mechanism]	1.5849625007211563	4	2	2	2
19406	1520	ppargamma in human atherosclerosis	[PPARgamma in human atherosclerosis]	1.5849625007211563	4	1	0	0
19407	1520	viral DNA fragment	[Viral DNA fragments]	1.5849625007211563	3	1	0	0
19408	1520	absorption of sodium	[absorption of sodium]	1.5849625007211563	3	1	0	0
19409	1520	mediate tyrosine phosphorylation	[mediating tyrosine phosphorylation]	1.5849625007211563	3	2	2	2
19410	1520	concentration of immunodominant peptide	[concentrations of immunodominant peptide]	1.5849625007211563	4	2	2	2
19411	1520	peripheral b lymphocyte	[peripheral B lymphocytes]	1.5849625007211563	3	1	0	0
19412	1520	tgf-beta in glial cell	[TGF-beta in glial cells]	1.5849625007211563	4	1	0	0
19413	1520	group of protooncogene	[group of protooncogenes]	1.5849625007211563	3	1	0	0
19414	1520	human toll-like receptor-2 htlr2	[human Toll-like receptor-2 hTLR2]	1.5849625007211563	4	1	0	0
19415	1520	cdna-transfected tf-1 tf-h5r alpha	[cDNA-transfected TF-1 TF-h5R alpha]	1.5849625007211563	4	1	0	0
19416	1520	il-12 signal through Stat4	[IL-12 signaling through Stat4]	1.5849625007211563	4	1	0	0
19417	1520	lymphoid-specific otf-2 factor	[lymphoid-specific OTF-2 factor]	1.5849625007211563	3	1	0	0
19418	1520	HTLV-I -bear cell line	[HTLV-I -bearing cell lines]	1.5849625007211563	4	2	1	1
19419	1520	control of immune response	[control of immune responses]	1.5849625007211563	4	1	0	0
19420	1520	transfection of Rta	[transfection of Rta]	1.5849625007211563	3	1	0	0
19421	1520	responsiveness to tpa	[responsiveness to TPA]	1.5849625007211563	3	1	0	0
19422	1520	hmg box transcription factor	[HMG box transcription factors]	1.5849625007211563	4	2	1	1
19423	1520	prevent fc gamma endocytosis	[preventing Fc gamma endocytosis]	1.5849625007211563	4	1	0	0
19424	1520	two granule population	[two granule populations]	1.5849625007211563	3	1	0	0
19425	1520	sis-inducible element probe	[sis-inducible element probe]	1.5849625007211563	3	1	0	0
19426	1520	time-dependent differentiation into macrophage	[time-dependent differentiation into macrophages]	1.5849625007211563	4	1	0	0
19427	1520	phospholipase c gamma	[phospholipase C gamma]	1.5849625007211563	3	2	2	2
19428	1520	absence of other upstream	[absence of other upstream]	1.5849625007211563	4	1	0	0
19429	1520	receptor level in leukocyte	[receptor levels in leukocytes]	1.5849625007211563	4	2	2	2
19430	1520	interleukin-1 receptor type	[interleukin-1 receptor type]	1.5849625007211563	3	1	0	0
19431	1520	two gas motif	[two GAS motifs]	1.5849625007211563	3	1	0	0
19432	1520	activation-dependent scm-1 promoter activity	[activation-dependent SCM-1 promoter activity]	1.5849625007211563	4	1	0	0
19433	1520	stage of development,	[stages of development,]	1.5849625007211563	3	1	0	0
19434	1520	human cd34+ cord	[human CD34+ cord]	1.5849625007211563	3	1	0	0
19435	1520	deficient il-2 production	[deficient IL-2 production]	1.5849625007211563	3	1	0	0
19436	1520	Bipotential t/natural killer	[Bipotential T/natural killer]	1.5849625007211563	3	1	0	0
19437	1520	methods: allergen-specific t-cell clone	[METHODS: Allergen-specific T-cell clones]	1.5849625007211563	4	1	0	0
19438	1520	addition, new technology	[addition, new technology]	1.5849625007211563	3	1	0	0
19439	1520	identification of nucleotide sequence	[Identification of nucleotide sequences]	1.5849625007211563	4	1	0	0
19440	1520	important role in initiation	[important role in initiation]	1.5849625007211563	4	1	0	0
19441	1520	12-myristate 13 acetate differentiation	[12-myristate 13 acetate differentiation]	1.5849625007211563	4	1	0	0
19442	1520	cellular, humoral, non-specific action	[cellular, humoral, non-specific actions]	1.5849625007211563	4	1	0	0
19443	1520	human g-csfr nfs-60 cell	[human G-CSFR NFS-60 cells]	1.5849625007211563	4	1	0	0
19444	1520	nuclear factor-kappaB nf-kappab regulation	[nuclear factor-kappaB NF-kappaB regulation]	1.5849625007211563	4	1	0	0
19445	1520	interesting therapeutic potential.	[interesting therapeutic potential.]	1.5849625007211563	3	1	0	0
19446	1520	nf-x2 contain c-fo	[NF-X2 containing c-Fos]	1.5849625007211563	3	1	0	0
19447	1520	loss of creb binding	[loss of CREB binding]	1.5849625007211563	4	1	0	0
19448	1520	Phytohemagglutinin pha proliferation	[Phytohemagglutinin PHA proliferation]	1.5849625007211563	3	1	0	0
19449	1520	expression status of bcl-6	[Expression status of BCL-6]	1.5849625007211563	4	1	0	0
19450	1520	R7-57 reporter cell	[R7-57 reporter cells]	1.5849625007211563	3	1	0	0
19451	1520	correlation between promoter activity	[correlation between promoter activity]	1.5849625007211563	4	1	0	0
19452	1520	infectivity of erythrocyte	[infectivity of erythrocytes]	1.5849625007211563	3	2	2	2
19453	1520	physiological inhibitor of nf-kappab	[physiological inhibitor of NF-kappaB]	1.5849625007211563	4	1	0	0
19454	1520	include response to therapy	[including response to therapy]	1.5849625007211563	4	1	0	0
19455	1520	activation of gamma-promoter activity	[activation of gamma-promoter activity]	1.5849625007211563	4	1	0	0
19456	1520	primary adult erythroid cell	[primary adult erythroid cells]	1.5849625007211563	4	1	0	0
19457	1520	assembly of actin filament	[assembly of actin filaments]	1.5849625007211563	4	1	0	0
19458	1520	32 kda subunit	[32 kDa subunit]	1.5849625007211563	3	1	0	0
19459	1520	nf.kappa b activation	[NF.kappa B activation]	1.5849625007211563	3	1	0	0
19460	1520	fact, 8e51 cell	[fact, 8e51 cells]	1.5849625007211563	3	1	0	0
19461	1520	induction of CD20	[induction of CD20]	1.5849625007211563	3	2	1	1
19462	1520	specific cd4(+) t-cell clone	[specific CD4(+) T-cell clones]	1.5849625007211563	4	1	0	0
19463	1520	Jurkat cell model	[Jurkat cell model]	1.5849625007211563	3	1	0	0
19464	1520	regulatory promoter element	[regulatory promoter elements]	1.5849625007211563	3	1	0	0
19465	1520	activity of p105	[activity of p105]	1.5849625007211563	3	1	0	0
19466	1520	human fas promoter	[human Fas promoter]	1.5849625007211563	3	2	1	1
19467	1520	Lyn tyrosine kinase	[Lyn tyrosine kinase]	1.5849625007211563	3	1	0	0
19468	1520	receptor signal pathway	[receptor signaling pathways]	1.5849625007211563	3	2	1	1
19469	1520	synthesis of interleukin (il)-6	[synthesis of interleukin (IL)-6]	1.5849625007211563	4	1	0	0
19470	1520	vcam- nf-kappa b	[VCAM- NF-kappa B]	1.5849625007211563	3	1	0	0
19471	1520	mature th cell line	[mature Th cell lines]	1.5849625007211563	4	1	0	0
19472	1520	viral replication rate	[viral replication rate]	1.5849625007211563	3	1	0	0
19473	1520	androgen-dependent lncap cell line	[androgen-dependent LNCaP cell line]	1.5849625007211563	4	1	0	0
19474	1520	IL-2 receptor alpha subunit	[IL-2 receptor alpha subunit]	1.5849625007211563	4	1	0	0
19475	1520	related family member	[related family members]	1.5849625007211563	3	1	0	0
19476	1520	one C/EBP site	[one C/EBP site]	1.5849625007211563	3	1	0	0
19477	1520	p65 subunit complex	[p65 subunit complex]	1.5849625007211563	3	1	0	0
19478	1520	significant reduction in transcription	[significant reduction in transcription]	1.5849625007211563	4	1	0	0
19479	1520	lps tf expression	[LPS TF expression]	1.5849625007211563	3	2	1	1
19480	1520	100% of the cells.	[100% of the cells.]	1.5849625007211563	4	1	0	0
19481	1520	T cell-tropic hiv-1 entry	[T cell-tropic HIV-1 entry]	1.5849625007211563	4	1	0	0
19482	1520	potential as a screen	[potential as a screen]	1.5849625007211563	4	1	0	0
19483	1520	t3 sulfate t3so4	[T3 sulfate T3SO4]	1.5849625007211563	3	1	0	0
19484	1520	spread of hiv infection	[spread of HIV infection]	1.5849625007211563	4	1	0	0
19485	1520	squirrel monkey cell	[squirrel monkey cells]	1.5849625007211563	3	1	0	0
19486	1520	region upstream of Cp	[region upstream of Cp]	1.5849625007211563	4	1	0	0
19487	1520	several small molecules,	[Several small molecules,]	1.5849625007211563	3	1	0	0
19488	1520	certain bone marrow-derived cell	[certain bone marrow-derived cells]	1.5849625007211563	4	1	0	0
19489	1520	bind to TRE1	[binding to TRE1]	1.5849625007211563	3	1	0	0
19490	1520	nuclear cell extract	[nuclear cell extracts]	1.5849625007211563	3	2	2	2
19491	1520	receptor on T cell	[receptor on T cells]	1.5849625007211563	4	2	1	1
19492	1520	morning plasma cortisol value	[morning plasma cortisol values]	1.5849625007211563	4	1	0	0
19493	1520	similar cleavage product	[similar cleavage products]	1.5849625007211563	3	1	0	0
19494	1520	patient in megakaryoblastic transformation	[patient in megakaryoblastic transformation]	1.5849625007211563	4	1	0	0
19495	1520	transcription of oncogenic gene	[transcription of oncogenic genes]	1.5849625007211563	4	1	0	0
19496	1520	direct phosphorylation of IkappaBalpha	[direct phosphorylation of IkappaBalpha]	1.5849625007211563	4	1	0	0
19497	1520	viral ligand binding	[viral ligand binding]	1.5849625007211563	3	1	0	0
19498	1520	stimulation of T lymphocyte	[Stimulation of T lymphocytes]	1.5849625007211563	4	2	1	1
19499	1520	IkappaBalpha promoter region	[IkappaBalpha promoter regions]	1.5849625007211563	3	1	0	0
19500	1520	hiv-1 LTR reporter construct	[HIV-1 LTR reporter constructs]	1.5849625007211563	4	1	0	0
19501	1520	tyrosine phosphoryl group	[tyrosine phosphoryl groups]	1.5849625007211563	3	1	0	0
19502	1520	L.Chene, M.Nugeyre, F.Barre-Sinoussi,	[L.Chene, M.Nugeyre, F.Barre-Sinoussi,]	1.5849625007211563	3	1	0	0
19503	1520	RA response element	[RA response elements]	1.5849625007211563	3	1	0	0
19504	1520	bare lymphocyte syndrome BLS	[bare lymphocyte syndrome BLS]	1.5849625007211563	4	1	0	0
19505	1520	activation of immunoglobulin promoter	[activation of immunoglobulin promoters]	1.5849625007211563	4	1	0	0
19506	1520	major start site	[major start site]	1.5849625007211563	3	2	2	2
19507	1520	hormone-receptor interaction in hypertension	[hormone-receptor interactions in hypertension]	1.5849625007211563	4	1	0	0
19508	1520	therefore, transcription factor	[therefore, transcription factor]	1.5849625007211563	3	1	0	0
19509	1520	nfat -dependent transcriptional activation	[NFAT -dependent transcriptional activation]	1.5849625007211563	4	1	0	0
19510	1520	blood pressure of 80/60	[blood pressure of 80/60]	1.5849625007211563	4	1	0	0
19511	1520	trace amount in lung	[trace amounts in lung]	1.5849625007211563	4	1	0	0
19512	1520	inhibitory action on ChtM	[inhibitory action on ChtM]	1.5849625007211563	4	1	0	0
19513	1520	biological impact of EBNA-2	[biological impact of EBNA-2]	1.5849625007211563	4	1	0	0
19514	1520	cd11b/cd18 expression by tepoxalin	[CD11b/CD18 expression by tepoxalin]	1.5849625007211563	4	1	0	0
19515	1520	recombinant fusion protein	[recombinant fusion protein]	1.5849625007211563	3	1	0	0
19516	1520	specific transcriptional regulatory protein	[specific transcriptional regulatory proteins]	1.5849625007211563	4	1	0	0
19517	1520	cd4+ t-lymphocyte in sarcoidosis	[CD4+ T-lymphocytes in sarcoidosis]	1.5849625007211563	4	1	0	0
19518	1520	promyelocyte cell line om10.1	[promyelocyte cell line OM10.1]	1.5849625007211563	4	1	0	0
19519	1520	cell with expression	[cells with expression]	1.5849625007211563	3	1	0	0
19520	1520	use the e1 oligonucleotide	[using the E1 oligonucleotide]	1.5849625007211563	4	1	0	0
19521	1520	increase in SCL protein	[increase in SCL protein]	1.5849625007211563	4	1	0	0
19522	1520	prodigiosin family of immunosuppressant	[prodigiosin family of immunosuppressants]	1.5849625007211563	4	1	0	0
19523	1520	incubation post- ultra-violet irradiation.	[incubation post- UV irradiation.]	1.5849625007211563	4	1	0	0
19524	1520	level of tax activation	[level of tax activation]	1.5849625007211563	4	1	0	0
19525	1520	52-kDa form of G(S)alpha	[52-kDa form of G(S)alpha]	1.5849625007211563	4	1	0	0
19526	1520	anatomy of interaction	[anatomy of interaction]	1.5849625007211563	3	1	0	0
19527	1520	presence of N-terminal peptide	[presence of N-terminal peptides]	1.5849625007211563	4	1	0	0
19528	1520	chimeric cd8alpha/il-4ralpha receptor	[chimeric CD8alpha/IL-4Ralpha receptor]	1.5849625007211563	3	1	0	0
19529	1520	I kappa B alpha	[I kappa B alpha]	1.5849625007211563	4	1	0	0
19530	1520	TRAF /rank interaction	[TRAF /RANK interaction]	1.5849625007211563	3	1	0	0
19531	1520	complete loss of responsiveness	[complete loss of responsiveness]	1.5849625007211563	4	1	0	0
19532	1520	novel positive regulatory element	[novel positive regulatory element]	1.5849625007211563	4	1	0	0
19533	1520	RelA a member	[RelA a member]	1.5849625007211563	3	1	0	0
19534	1520	glucocorticoid-sensitive 6tg1.1 icr27tk.3	[glucocorticoid-sensitive 6TG1.1 ICR27TK.3]	1.5849625007211563	3	1	0	0
19535	1520	cholesterol feedback mechanism	[cholesterol feedback mechanism]	1.5849625007211563	3	2	1	1
19536	1520	stimulation by anti CD2	[stimulation by anti CD2]	1.5849625007211563	4	1	0	0
19537	1520	regulation of TNF	[regulation of TNF]	1.5849625007211563	3	2	2	2
19538	1520	involvement signal pathway	[involvement signaling pathways]	1.5849625007211563	3	1	0	0
19539	1520	macrophage by bacterial endotoxin	[macrophages by bacterial endotoxin]	1.5849625007211563	4	1	0	0
19540	1520	new signal transduction pathway	[new signal transduction pathway]	1.5849625007211563	4	1	0	0
19541	1520	myeloid progenitor proliferation	[myeloid progenitor proliferation]	1.5849625007211563	3	1	0	0
19542	1520	recognition motif of TCF-1	[recognition motif of TCF-1]	1.5849625007211563	4	1	0	0
19543	1520	kappa binding factor	[kappa binding factor]	1.5849625007211563	3	2	2	2
19544	1520	gel retardation analysis,	[gel retardation analysis,]	1.5849625007211563	3	1	0	0
19545	1520	constitutive expression of e2a-pbx1	[constitutive expression of E2a-Pbx1]	1.5849625007211563	4	1	0	0
19546	1520	role for this lesion	[role for these lesions]	1.5849625007211563	4	1	0	0
19547	1520	functional activation antigen	[functional activation antigen]	1.5849625007211563	3	1	0	0
19548	1520	6 gram of salt	[6 g of salt]	1.5849625007211563	4	1	0	0
19549	1520	mispair event during replication	[mispairing events during replication]	1.5849625007211563	4	1	0	0
19550	1520	icam-1 promoter reporter	[ICAM-1 promoter reporter]	1.5849625007211563	3	1	0	0
19551	1520	antisense oligonucleotide to c-fo	[antisense oligonucleotides to c-fos]	1.5849625007211563	4	1	0	0
19552	1520	cell with several chemoattract	[cells with several chemoattractants]	1.5849625007211563	4	1	0	0
19553	1520	constitutive level of activity	[constitutive level of activity]	1.5849625007211563	4	1	0	0
19554	1520	immunoglobulin heavy-chain promoter	[immunoglobulin heavy-chain promoter]	1.5849625007211563	3	1	0	0
19555	1520	anti-viral therapeutic effect	[anti-viral therapeutic effects]	1.5849625007211563	3	1	0	0
19556	1520	initial expression of il-4	[initial expression of IL-4]	1.5849625007211563	4	1	0	0
19557	1520	multiple endothelial gene product	[multiple endothelial gene products]	1.5849625007211563	4	1	0	0
19558	1520	augmentation of nuclear c-rel	[augmentation of nuclear c-Rel]	1.5849625007211563	4	1	0	0
19559	1520	biologically active molecules.	[biologically active molecules.]	1.5849625007211563	3	1	0	0
19560	1520	one normal blood donor	[one normal blood donor]	1.5849625007211563	4	1	0	0
19561	1520	human il-2r beta	[human IL-2R beta]	1.5849625007211563	3	2	1	1
19562	1520	other reactive follicular hyperplasias	[other reactive follicular hyperplasias]	1.5849625007211563	4	1	0	0
19563	1520	non- erythroid cell	[non- erythroid cells]	1.5849625007211563	3	1	0	0
19564	1520	contrast, soluble factor	[contrast, soluble factors]	1.5849625007211563	3	1	0	0
19565	1520	many t-cell gene	[many T-cell genes]	1.5849625007211563	3	2	2	2
19566	1520	same pattern of inhibition	[same pattern of inhibition]	1.5849625007211563	4	1	0	0
19567	1520	total serum ige level	[total serum IgE levels]	1.5849625007211563	4	2	1	1
19568	1520	steroid binding activity per	[steroid binding activity per]	1.5849625007211563	4	1	0	0
19569	1520	signalsome protein ikk-alpha	[signalsome proteins IKK-alpha]	1.5849625007211563	3	1	0	0
19570	1520	bzip domain defective	[bZIP domain defective]	1.5849625007211563	3	1	0	0
19571	1520	two protein-binding site	[two protein-binding sites]	1.5849625007211563	3	2	1	1
19572	1520	development of secondary hyperparathyroidism	[development of secondary hyperparathyroidism]	1.5849625007211563	4	1	0	0
19573	1520	aids -gr monocyte	[AIDS -GR monocytes]	1.5849625007211563	3	1	0	0
19574	1520	CD28 receptor ligation	[CD28 receptor ligation]	1.5849625007211563	3	1	0	0
19575	1520	dna-binding domain of bsap	[DNA-binding domain of BSAP]	1.5849625007211563	4	1	0	0
19576	1520	new monoclonal antibody	[new monoclonal antibody]	1.5849625007211563	3	2	1	1
19577	1520	activity of calcineurin,	[activity of calcineurin,]	1.5849625007211563	3	1	0	0
19578	1520	lymphocyte of the cases.	[lymphocytes of the cases.]	1.5849625007211563	4	1	0	0
19579	1520	expression of IFN-gamma	[expression of IFN-gamma]	1.5849625007211563	3	1	0	0
19580	1520	human NK/ T cell	[human NK/ T cells]	1.5849625007211563	4	1	0	0
19581	1520	antenatal steroid treatment	[antenatal steroid treatment]	1.5849625007211563	3	1	0	0
19582	1520	murine pre-B cell line	[murine pre-B cell line]	1.5849625007211563	4	1	0	0
19583	1520	amount of protein	[amount of protein]	1.5849625007211563	3	1	0	0
19584	1520	gel shift mobility assay	[Gel shift mobility assay]	1.5849625007211563	4	1	0	0
19585	1520	about 10(-6) m	[about 10(-6) M]	1.5849625007211563	3	1	0	0
19586	1520	trans class ii	[trans class II]	1.5849625007211563	3	1	0	0
19587	1520	level of TCRzeta	[levels of TCRzeta]	1.5849625007211563	3	2	1	1
19588	1520	androgen receptor status,	[androgen receptor status,]	1.5849625007211563	3	1	0	0
19589	1520	t, N, grade, multifocality	[T, N, grade, multifocality]	1.5849625007211563	4	1	0	0
19590	1520	exception of ETS1	[exception of ETS1]	1.5849625007211563	3	1	0	0
19591	1520	(ii) lineage-dependent maintenance	[(ii) lineage-dependent maintenance]	1.5849625007211563	3	1	0	0
19592	1520	survival of 24 month	[survival of 24 months]	1.5849625007211563	4	2	2	2
19593	1520	signal in human eosinophil	[signaling in human eosinophils]	1.5849625007211563	4	2	2	2
19594	1520	octamer binding site	[octamer binding sites]	1.5849625007211563	3	1	0	0
19595	1520	NK activity of YT-N17	[NK activity of YT-N17]	1.5849625007211563	4	1	0	0
19596	1520	continuous administration of As2O3	[continuous administration of As2O3]	1.5849625007211563	4	1	0	0
19597	1520	1-2 h after stimulation.	[1-2 h after stimulation.]	1.5849625007211563	4	1	0	0
19598	1520	such genetic element	[such genetic elements]	1.5849625007211563	3	1	0	0
19599	1520	potential therapeutic measure	[potential therapeutic measures]	1.5849625007211563	3	1	0	0
19600	1520	endogenous no regulation	[endogenous NO regulation]	1.5849625007211563	3	1	0	0
19601	1520	bioassay for glucocorticoid action	[bioassay for glucocorticoid action]	1.5849625007211563	4	1	0	0
19602	1520	dna-binding regulatory protein	[DNA-binding regulatory proteins]	1.5849625007211563	3	1	0	0
19603	1520	host of tnf-alpha	[host of TNF-alpha]	1.5849625007211563	3	1	0	0
19604	1520	mononuclear phagocyte in vitro	[mononuclear phagocytes in vitro]	1.5849625007211563	4	1	0	0
19605	1520	CXC chemokine interleukin-8	[CXC chemokine interleukin-8]	1.5849625007211563	3	1	0	0
19606	1520	cell growth inhibition	[cell growth inhibition]	1.5849625007211563	3	1	0	0
19607	1520	stat5 to the nucleus	[STAT5 to the nucleus]	1.5849625007211563	4	1	0	0
19608	1520	U937 cell undergo apoptosis	[U937 cells undergoing apoptosis]	1.5849625007211563	4	1	0	0
19609	1520	detectable level of beta-	[detectable levels of beta-]	1.5849625007211563	4	1	0	0
19610	1520	presence of cis element	[presence of cis elements]	1.5849625007211563	4	2	1	1
19611	1520	major initiation site	[major initiation site]	1.5849625007211563	3	2	1	1
19612	1520	single c motif-1	[Single C motif-1]	1.5849625007211563	3	1	0	0
19613	1520	result in Jurkat cell	[results in Jurkat cells]	1.5849625007211563	4	1	0	0
19614	1520	various key gene	[various key genes]	1.5849625007211563	3	1	0	0
19615	1520	p50 NF-kappa b1	[p50 NF-kappa B1]	1.5849625007211563	3	1	0	0
19616	1520	METHODS: E. histolytica infection	[METHODS: E. histolytica infection]	1.5849625007211563	4	1	0	0
19617	1520	delayed-type hypersensitivity response	[delayed-type hypersensitivity response]	1.5849625007211563	3	1	0	0
19618	1520	novel ca2+ dependent step	[novel Ca2+ dependent step]	1.5849625007211563	4	1	0	0
19619	1520	ebv-transformed b clone	[EBV-transformed B clones]	1.5849625007211563	3	1	0	0
19620	1520	high v-abl kinase activity	[high v-abl kinase activity]	1.5849625007211563	4	1	0	0
19621	1520	proliferation of T and,	[proliferation of T and,]	1.5849625007211563	4	1	0	0
19622	1520	prerequisite of transcription initiation	[prerequisite of transcription initiation]	1.5849625007211563	4	1	0	0
19623	1520	exception of exon 2	[exceptions of exon 2]	1.5849625007211563	4	1	0	0
19624	1520	ATGCAAAT octamer sequence	[ATGCAAAT octamer sequence]	1.5849625007211563	3	1	0	0
19625	1520	sp1 -binding site	[Sp1 -binding sites]	1.5849625007211563	3	1	0	0
19626	1520	much less degree,	[much lesser degree,]	1.5849625007211563	3	1	0	0
19627	1520	role of AP-1	[Role of AP-1]	1.5849625007211563	3	1	0	0
19628	1520	T cell in ATL	[T cells in ATL]	1.5849625007211563	4	1	0	0
19629	1520	approach to the problem	[approach to the problem]	1.5849625007211563	4	1	0	0
19630	1520	use a construct	[using a construct]	1.5849625007211563	3	1	0	0
19631	1520	lps-responsive enhancer element	[LPS-responsive enhancer element]	1.5849625007211563	3	1	0	0
19632	1520	dsm-iii-r criterion for MDD	[DSM-III-R criteria for MDD]	1.5849625007211563	4	1	0	0
19633	1520	e.g. between menopausal status	[e.g. between menopausal status]	1.5849625007211563	4	1	0	0
19634	1520	T-tropic primary isolate	[T-tropic primary isolate]	1.5849625007211563	3	1	0	0
19635	1520	nuclear factor recruitment	[nuclear factor recruitment]	1.5849625007211563	3	1	0	0
19636	1520	heterologous dc-t-cell syncytia	[heterologous DC-T-cell syncytia]	1.5849625007211563	3	1	0	0
19637	1520	(human growth hormone	[(human growth hormone)]	1.5849625007211563	3	1	0	0
19638	1520	6 b cell differentiation	[6 B cell differentiation]	1.5849625007211563	4	1	0	0
19639	1520	dna-binding domain of ZEBRA	[DNA-binding domain of ZEBRA]	1.5849625007211563	4	1	0	0
19640	1520	over-expression of gene	[Over-expression of genes]	1.5849625007211563	3	1	0	0
19641	1520	regulation of translation	[regulation of translation]	1.5849625007211563	3	1	0	0
19642	1520	dephosphorylation of Tyk2	[dephosphorylation of Tyk2]	1.5849625007211563	3	1	0	0
19643	1520	presence of adp-activated platelet	[presence of ADP-activated platelets]	1.5849625007211563	4	1	0	0
19644	1520	sickle cell anemia patient	[sickle cell anemia patients]	1.5849625007211563	4	1	0	0
19645	1520	il-2 -dependent function	[IL-2 -dependent functions]	1.5849625007211563	3	1	0	0
19646	1520	single mhc/peptide complex	[single MHC/peptide complex]	1.5849625007211563	3	1	0	0
19647	1520	hiv-1 transcription anti-tnf-alpha antibody	[HIV-1 transcription Anti-TNF-alpha antibody]	1.5849625007211563	4	1	0	0
19648	1520	lymphokine element 0 cle0	[lymphokine element 0 CLE0]	1.5849625007211563	4	1	0	0
19649	1520	addition of oestrogen	[addition of oestrogen]	1.5849625007211563	3	1	0	0
19650	1520	high affinity site	[high affinity site]	1.5849625007211563	3	2	1	1
19651	1520	limit activate transcription factor	[limiting activating transcription factors]	1.5849625007211563	4	1	0	0
19652	1520	transform growth factor	[transforming growth factor]	1.5849625007211563	3	2	1	1
19653	1520	human cd14 gene	[human CD14 gene]	1.5849625007211563	3	1	0	0
19654	1520	follicle in the liver	[follicles in the liver]	1.5849625007211563	4	2	1	1
19655	1520	x-linked severe immunodeficiency x-scid	[X-linked severe immunodeficiency X-SCID]	1.5849625007211563	4	1	0	0
19656	1520	Ter 119 positive cell	[Ter 119 positive cells]	1.5849625007211563	4	2	2	2
19657	1520	normal pattern in parent	[normal pattern in parents]	1.5849625007211563	4	1	0	0
19658	1520	pma-treated thp-1 cell	[PMA-treated THP-1 cells]	1.5849625007211563	3	1	0	0
19659	1520	different combination of factor	[different combinations of factors]	1.5849625007211563	4	1	0	0
19660	1520	PEBP2 alpha/AML-1 family	[PEBP2 alpha/AML-1 family]	1.5849625007211563	3	1	0	0
19661	1520	very little information	[Very little information]	1.5849625007211563	3	2	1	1
19662	1520	partial loss of sensitivity	[partial loss of sensitivity]	1.5849625007211563	4	1	0	0
19663	1520	human coactivator Bob1 hbob1	[human coactivator Bob1 hBob1]	1.5849625007211563	4	1	0	0
19664	1520	physiological receptor-mediated agonist gm-csf	[physiological receptor-mediated agonists GM-CSF]	1.5849625007211563	4	1	0	0
19665	1520	cytokine -dependent upregulation	[cytokine -dependent upregulation]	1.5849625007211563	3	1	0	0
19666	1520	inhibition of protein	[inhibition of proteins]	1.5849625007211563	3	2	2	2
19667	1520	reporter gene for scd8	[reporter gene for sCD8]	1.5849625007211563	4	1	0	0
19668	1520	E1B- specific CTL	[E1B- specific CTLs]	1.5849625007211563	3	1	0	0
19669	1520	production of different cytokine	[production of different cytokines]	1.5849625007211563	4	1	0	0
19670	1520	ligand for protein	[ligand for proteins]	1.5849625007211563	3	1	0	0
19671	1520	aspect of microarchitecture as	[aspects of microarchitecture as]	1.5849625007211563	4	1	0	0
19672	1520	tumor cell infiltration	[tumor cell infiltration]	1.5849625007211563	3	2	1	1
19673	1520	b cell-specific expression	[B cell-specific expression]	1.5849625007211563	3	2	2	2
19674	1520	gr receptor mr	[GR receptor MR]	1.5849625007211563	3	1	0	0
19675	1520	human cd36 gene promoter	[human CD36 gene promoter]	1.5849625007211563	4	1	0	0
19676	1520	100 microm cadmium chloride	[100 microM cadmium chloride]	1.5849625007211563	4	1	0	0
19677	1520	b29 promoter activity	[B29 promoter activity]	1.5849625007211563	3	2	1	1
19678	1520	few apoptotic cell body	[Fewer apoptotic cell bodies]	1.5849625007211563	4	1	0	0
19679	1520	G1 phase arrest	[G1 phase arrest]	1.5849625007211563	3	1	0	0
19680	1520	survival of serum-starved cell	[survival of serum-starved cells]	1.5849625007211563	4	1	0	0
19681	1520	other globin cis-element	[other globin cis-elements]	1.5849625007211563	3	1	0	0
19682	1520	interferon beta prdii site	[interferon beta PRDII site]	1.5849625007211563	4	1	0	0
19683	1520	level of protein/dna interaction	[level of protein/DNA interactions]	1.5849625007211563	4	1	0	0
19684	1520	rapid calcineurin -dependent translocation	[rapid calcineurin -dependent translocation]	1.5849625007211563	4	1	0	0
19685	1520	PU.1 site between position	[PU.1 site between positions]	1.5849625007211563	4	1	0	0
19686	1520	T helper 1-type cytokine	[T helper 1-type cytokine]	1.5849625007211563	4	1	0	0
19687	1520	sideroblast in erythroid colony	[sideroblasts in erythroid colonies]	1.5849625007211563	4	1	0	0
19688	1520	number of leucocytic er	[numbers of leucocytic ER]	1.5849625007211563	4	1	0	0
19689	1520	heat shock om10.1	[heat shock OM10.1]	1.5849625007211563	3	1	0	0
19690	1520	atf1 protein present	[ATF1 proteins present]	1.5849625007211563	3	1	0	0
19691	1520	b7-negative (endothelial) accessory cells,	[B7-negative (endothelial) accessory cells,]	1.5849625007211563	4	1	0	0
19692	1520	expression of the msr	[expression of the MSR]	1.5849625007211563	4	1	0	0
19693	1520	use a immunosorbent assay	[using an immunosorbent assay]	1.5849625007211563	4	1	0	0
19694	1520	small panel of antibody	[small panel of antibodies]	1.5849625007211563	4	1	0	0
19695	1520	human hematopoietic neoplasm	[human hematopoietic neoplasms]	1.5849625007211563	3	1	0	0
19696	1520	specifically in T cell	[specifically in T cells]	1.5849625007211563	4	2	1	1
19697	1520	presence of C/EBP beta	[presence of C/EBP beta]	1.5849625007211563	4	1	0	0
19698	1520	cd4+ cell count (17	[CD4+ cell counts (17]	1.5849625007211563	4	1	0	0
19699	1520	such as lipopolysaccharide lps	[such as lipopolysaccharide LPS]	1.5849625007211563	4	2	2	2
19700	1520	tnf-alpha production (297+/-54;	[TNF-alpha production (297+/-54;]	1.5849625007211563	3	1	0	0
19701	1520	cytoplasmic level of c-Rel	[cytoplasmic levels of c-Rel]	1.5849625007211563	4	1	0	0
19702	1520	stimulation of the transcription	[stimulation of the transcription]	1.5849625007211563	4	1	0	0
19703	1520	etv6- evi1 fusion	[ETV6- EVI1 fusions]	1.5849625007211563	3	1	0	0
19704	1520	PRE-I binding factor	[PRE-I binding factor]	1.5849625007211563	3	1	0	0
19705	1520	development of alteration	[development of alterations]	1.5849625007211563	3	2	1	1
19706	1520	protein kinase mapk pathway	[protein kinase MAPK pathway]	1.5849625007211563	4	2	1	1
19707	1520	cell of immune system	[cells of immune system]	1.5849625007211563	4	1	0	0
19708	1520	level of adult hpc	[level of adult HPC]	1.5849625007211563	4	1	0	0
19709	1520	plasma interleukin-1 il-1	[plasma interleukin-1 IL-1]	1.5849625007211563	3	1	0	0
19710	1520	ability of mutant	[ability of mutants]	1.5849625007211563	3	1	0	0
19711	1520	beta interferon promoter GGGAAATTCC	[beta interferon promoter GGGAAATTCC]	1.5849625007211563	4	1	0	0
19712	1520	factor of T lymphocyte	[factor of T lymphocytes]	1.5849625007211563	4	2	2	2
19713	1520	formation of LCR HS4	[formation of LCR HS4]	1.5849625007211563	4	1	0	0
19714	1520	five normal tonsil	[five normal tonsils]	1.5849625007211563	3	1	0	0
19715	1520	involvement of Jak 2	[involvement of Jak 2]	1.5849625007211563	4	1	0	0
19716	1520	novel inhibitor of tnf-alpha	[novel inhibitor of TNF-alpha]	1.5849625007211563	4	1	0	0
19717	1520	signal through HLA class	[Signaling through HLA class]	1.5849625007211563	4	1	0	0
19718	1520	interaction with member	[interactions with members]	1.5849625007211563	3	1	0	0
19719	1520	il-10r for stat3	[IL-10R for STAT3]	1.5849625007211563	3	1	0	0
19720	1520	high affinity b	[high affinity B]	1.5849625007211563	3	1	0	0
19721	1520	IRF-1 reporter construct	[IRF-1 reporter construct]	1.5849625007211563	3	1	0	0
19722	1520	however, receptor level	[however, receptor levels]	1.5849625007211563	3	1	0	0
19723	1520	virtual absence of mutation	[virtual absence of mutation]	1.5849625007211563	4	1	0	0
19724	1520	nasal t/nk-cell lymphoma	[Nasal T/NK-cell lymphomas]	1.5849625007211563	3	1	0	0
19725	1520	sensitivity of cem-c7 cell	[sensitivity of CEM-C7 cells]	1.5849625007211563	4	1	0	0
19726	1520	activity of b95-8	[activity of B95-8]	1.5849625007211563	3	1	0	0
19727	1520	such as atopic dermatitis	[such as atopic dermatitis]	1.5849625007211563	4	1	0	0
19728	1520	hiv-1 tat cDNA	[HIV-1 tat cDNA]	1.5849625007211563	3	1	0	0
19729	1520	regulate hbv gene expression	[regulating HBV gene expression]	1.5849625007211563	4	1	0	0
19730	1520	affinity for sequence-specific complex	[affinity for sequence-specific complexes]	1.5849625007211563	4	1	0	0
19731	1520	adjacent ap-1 site	[adjacent AP-1 site]	1.5849625007211563	3	1	0	0
19732	1520	also TRE sites,	[also TRE sites,]	1.5849625007211563	3	1	0	0
19733	1520	value with intraarterial measurement	[values with intraarterial measurements]	1.5849625007211563	4	1	0	0
19734	1520	protein result in expression	[proteins resulting in expression]	1.5849625007211563	4	1	0	0
19735	1520	ig kappa enhancer	[Ig kappa enhancer]	1.5849625007211563	3	1	0	0
19736	1520	little amino acid identity	[little amino acid identity]	1.5849625007211563	4	1	0	0
19737	1520	expression of CD4 antigen	[expression of CD4 antigen]	1.5849625007211563	4	1	0	0
19738	1520	expression of p53	[expression of P53]	1.5849625007211563	3	1	0	0
19739	1520	anergic murine T cell	[anergic murine T cells]	1.5849625007211563	4	2	1	1
19740	1520	deletion by subtractive cloning	[deletion by subtractive cloning]	1.5849625007211563	4	1	0	0
19741	1520	single tissue-specific element	[single tissue-specific element]	1.5849625007211563	3	1	0	0
19742	1520	inhibition in monocyte	[inhibition in monocytes]	1.5849625007211563	3	2	2	2
19743	1520	Janus protein kinase (jak)1	[Janus protein kinase (JAK)1]	1.5849625007211563	4	1	0	0
19744	1520	establishment of a infection	[establishment of a infection]	1.5849625007211563	4	1	0	0
19745	1520	expression of p65	[expression of p65]	1.5849625007211563	3	1	0	0
19746	1520	retinoid receptor x protein	[retinoid receptor X proteins]	1.5849625007211563	4	1	0	0
19747	1520	none of this phenomena.	[none of these phenomena.]	1.5849625007211563	4	1	0	0
19748	1520	VDR messenger RNA	[VDR messenger RNA]	1.5849625007211563	3	1	0	0
19749	1520	dephosphorylated prb -e2f complex	[dephosphorylated pRB -E2F complexes]	1.5849625007211563	4	1	0	0
19750	1520	immunosuppressive effect of tpck	[immunosuppressive effects of TPCK]	1.5849625007211563	4	1	0	0
19751	1520	specific protein factor	[specific protein factors]	1.5849625007211563	3	1	0	0
19752	1520	variety of transcription factor	[variety of transcription factors]	1.5849625007211563	4	1	0	0
19753	1520	hla class ii gene	[HLA class II genes]	1.5849625007211563	4	1	0	0
19754	1520	18 h of autoinduction.	[18 h of autoinduction.]	1.5849625007211563	4	1	0	0
19755	1520	activity in cell	[activity in cells]	1.5849625007211563	3	2	2	2
19756	1520	epitope of hla-dr antigen	[epitopes of HLA-DR antigens]	1.5849625007211563	4	1	0	0
19757	1520	alpha isozyme of pkc	[alpha isozymes of PKC]	1.5849625007211563	4	1	0	0
19758	1520	platelet cytoadhesin gpiin-iiia	[platelet cytoadhesin GPIIb-IIIa]	1.5849625007211563	3	1	0	0
19759	1520	target organ responsiveness	[target organ responsiveness]	1.5849625007211563	3	1	0	0
19760	1520	treatment of k562 cell	[treatment of K562 cells]	1.5849625007211563	4	1	0	0
19761	1520	contain the beta-galactosidase gene	[containing the beta-galactosidase gene]	1.5849625007211563	4	1	0	0
19762	1520	methods: peripheral eosinophil	[METHODS: peripheral eosinophils]	1.5849625007211563	3	1	0	0
19763	1520	proil-1 beta enhancer	[proIL-1 beta enhancer]	1.5849625007211563	3	1	0	0
19764	1520	murine Ba/F3 cell	[murine Ba/F3 cells]	1.5849625007211563	3	1	0	0
19765	1520	hypertension in pregnancy	[Hypertension in pregnancy]	1.5849625007211563	3	1	0	0
19766	1520	various mouse tissue	[various mouse tissues]	1.5849625007211563	3	2	2	2
19767	1520	about 150 kD	[about 150 kD]	1.5849625007211563	3	1	0	0
19768	1520	240 minute 2).	[240 minutes 2).]	1.5849625007211563	3	1	0	0
19769	1520	progressively enlarge vulvar mass	[progressively enlarging vulvar mass]	1.5849625007211563	4	1	0	0
19770	1520	vdre of the osteocalcin	[VDREs of the osteocalcin]	1.5849625007211563	4	1	0	0
19771	1520	ability of defensin NP-1	[ability of defensins NP-1]	1.5849625007211563	4	1	0	0
19772	1520	constitutive expression of ifn-alpha5	[Constitutive expression of IFN-alpha5]	1.5849625007211563	4	1	0	0
19773	1520	action of glucocorticosteroids	[action of glucocorticosteroids]	1.5849625007211563	3	1	0	0
19774	1520	0.7 micromol/(mg protein. min),	[0.7 micromol/(mg protein. min),]	1.5849625007211563	4	1	0	0
19775	1520	just a few instances.	[just a few instances.]	1.5849625007211563	4	1	0	0
19776	1520	use of intracellular staining	[use of intracellular staining]	1.5849625007211563	4	1	0	0
19777	1520	patient with gd	[patients with GD]	1.5849625007211563	3	2	2	2
19778	1520	signal in nk3.3 cell	[signaling in NK3.3 cells]	1.5849625007211563	4	1	0	0
19779	1520	thereby increase mrna level	[thereby increasing mRNA levels]	1.5849625007211563	4	1	0	0
19780	1520	gc inhibition of il-1beta	[GC inhibition of IL-1beta]	1.5849625007211563	4	1	0	0
19781	1520	corresponding cytokine receptor	[corresponding cytokine receptor]	1.5849625007211563	3	1	0	0
19782	1520	nucleolin component of LR1	[nucleolin component of LR1]	1.5849625007211563	4	1	0	0
19783	1520	gamma interferon signal transduction	[gamma interferon signal transduction]	1.5849625007211563	4	1	0	0
19784	1520	ifn-stimulated gene isg15	[IFN-stimulated gene ISG15]	1.5849625007211563	3	1	0	0
19785	1520	recombinant ptf beta	[recombinant PTF beta]	1.5849625007211563	3	1	0	0
19786	1520	capacity of platelet	[capacity of platelets]	1.5849625007211563	3	1	0	0
19787	1520	vitro kinase activity	[vitro kinase activity]	1.5849625007211563	3	1	0	0
19788	1520	VCAM-1 gene transcription	[VCAM-1 gene transcription]	1.5849625007211563	3	3	2	1
19789	1520	study the effect	[studying the effects]	1.5849625007211563	3	2	2	2
19790	1520	cle0 binding protein	[CLE0 binding protein]	1.5849625007211563	3	1	0	0
19791	1520	macrophage colony-stimulating factor gene	[macrophage colony-stimulating factor gene]	1.5849625007211563	4	1	0	0
19792	1520	cyclosporin a pretreatment	[cyclosporin A pretreatment]	1.5849625007211563	3	1	0	0
19793	1520	pathway in T cell	[pathway in T cells]	1.5849625007211563	4	1	0	0
19794	1520	dist kappa b element	[distal, kappa B element]	1.5849625007211563	4	1	0	0
19795	1520	cell-permeable proteasome inhibitor	[cell-permeable proteasome inhibitors]	1.5849625007211563	3	1	0	0
19796	1520	HTLV-I human lymphocyte line	[HTLV-I human lymphocyte line]	1.5849625007211563	4	1	0	0
19797	1520	Nuclear accumulation of NFAT4	[Nuclear accumulation of NFAT4]	1.5849625007211563	4	1	0	0
19798	1520	clonal cell growth	[clonal cell growth]	1.5849625007211563	3	2	2	2
19799	1520	CD14 5' upstream sequence	[CD14 5' upstream sequence]	1.5849625007211563	4	1	0	0
19800	1520	only the Y-box element	[only the Y-box element]	1.5849625007211563	4	1	0	0
19801	1520	amino- terminal domain	[amino- terminal domains]	1.5849625007211563	3	1	0	0
19802	1520	endogenous wild-type Itk	[endogenous wild-type Itk]	1.5849625007211563	3	1	0	0
19803	1520	monoclonal anti-D antibody	[Monoclonal anti-D antibodies]	1.5849625007211563	3	1	0	0
19804	1520	marrow progenitor cell	[marrow progenitor cells]	1.5849625007211563	3	1	0	0
19805	1520	severe immunodeficiency disease (scid)	[severe immunodeficiency disease (SCID)]	1.5849625007211563	4	1	0	0
19806	1520	depend on promoter element	[depending on promoter elements]	1.5849625007211563	4	1	0	0
19807	1520	cooperation of signal molecule	[cooperation of signaling molecules]	1.5849625007211563	4	1	0	0
19808	1520	cl-01 b cell	[CL-01 B cells]	1.5849625007211563	3	1	0	0
19809	1520	first strand hGR rdna	[first strand hGR cDNAs]	1.5849625007211563	4	1	0	0
19810	1520	homologue of stat5	[homologues of STAT5]	1.5849625007211563	3	1	0	0
19811	1520	3 binding site	[3 binding sites]	1.5849625007211563	3	1	0	0
19812	1520	adhesion molecule important	[adhesion molecule important]	1.5849625007211563	3	1	0	0
19813	1520	drop in glutathione gsh	[drop in glutathione GSH]	1.5849625007211563	4	1	0	0
19814	1520	expression of expression	[expression of expression]	1.5849625007211563	3	2	1	1
19815	1520	protein kinase c -dependent	[protein kinase C -dependent]	1.5849625007211563	4	1	0	0
19816	1520	low-density lipoprotein ox ldl	[low-density lipoprotein Ox LDL]	1.5849625007211563	4	1	0	0
19817	1520	mean il-4 level	[mean IL-4 level]	1.5849625007211563	3	1	0	0
19818	1520	induction of ifn-gamma production	[induction of IFN-gamma production]	1.5849625007211563	4	1	0	0
19819	1520	dysregulation of the machinery	[dysregulation of the machinery]	1.5849625007211563	4	1	0	0
19820	1520	.3; pt of 172	[.3; PT of 172]	1.5849625007211563	4	1	0	0
19821	1520	hyperplastic gcs aitl/gc	[hyperplastic GCs AITL/GC]	1.5849625007211563	3	1	0	0
19822	1520	IL-4 -specific gene expression	[IL-4 -specific gene expression]	1.5849625007211563	4	1	0	0
19823	1520	multiple sclerosis patient	[multiple sclerosis patients]	1.5849625007211563	3	1	0	0
19824	1520	certain genetic makaume mtbe	[certain genetic makeup, MTBE]	1.5849625007211563	4	1	0	0
19825	1520	PRE-I enhancer element	[PRE-I enhancer element]	1.5849625007211563	3	1	0	0
19826	1520	level of factor	[level of factor]	1.5849625007211563	3	2	2	2
19827	1520	sensitivity to fas-mediated apoptosis	[sensitivity to Fas-mediated apoptosis]	1.5849625007211563	4	1	0	0
19828	1520	carboxylic acid moiety	[carboxylic acid moiety]	1.5849625007211563	3	1	0	0
19829	1520	unknown inducible factor	[unknown inducible factor]	1.5849625007211563	3	1	0	0
19830	1520	induction of ciita	[Induction of CIITA]	1.5849625007211563	3	1	0	0
19831	1520	treatment of several diseases,	[treatment of several diseases,]	1.5849625007211563	4	1	0	0
19832	1520	commitment to fetal program	[commitment to fetal program]	1.5849625007211563	4	1	0	0
19833	1520	last 13 amino acid	[last 13 amino acids]	1.5849625007211563	4	1	0	0
19834	1520	overexpression of c-fo	[overexpression of c-fos]	1.5849625007211563	3	2	2	2
19835	1520	two caat box-like motif	[two CAAT box-like motifs]	1.5849625007211563	4	1	0	0
19836	1520	cyclin/cdk cyclin-dependent kinase complex	[cyclin/cdks cyclin-dependent kinase complexes]	1.5849625007211563	4	1	0	0
19837	1520	leukocyte clearance mechanism	[leukocyte clearance mechanism]	1.5849625007211563	3	1	0	0
19838	1520	stably express AML1/ETO	[stably expressing AML1/ETO]	1.5849625007211563	3	1	0	0
19839	1520	bind efficiency for antagonist	[binding efficiency for antagonists]	1.5849625007211563	4	1	0	0
19840	1520	protein kinase c signal	[protein kinase C signaling]	1.5849625007211563	4	2	1	1
19841	1520	interleukin 2 gene enhancer	[interleukin 2 gene enhancer]	1.5849625007211563	4	1	0	0
19842	1520	immunoglobulin kappa ggaaagtccc	[immunoglobulin kappa GGAAAGTCCC]	1.5849625007211563	3	1	0	0
19843	1520	acth growth hormone	[ACTH growth hormone]	1.5849625007211563	3	1	0	0
19844	1520	anti-CD3-activated T lymphocyte	[anti-CD3-activated T lymphocytes]	1.5849625007211563	3	2	2	2
19845	1520	other DNA element	[other DNA element]	1.5849625007211563	3	2	1	1
19846	1520	transcriptional activation of hiv-1	[transcriptional activation of HIV-1]	1.5849625007211563	4	1	0	0
19847	1520	CCAAT binding protein nf-y	[CCAAT binding protein NF-Y]	1.5849625007211563	4	1	0	0
19848	1520	control of virus reactivation	[control of virus reactivation]	1.5849625007211563	4	1	0	0
19849	1520	murine leukemia virus promoter	[murine leukemia virus promoters]	1.5849625007211563	4	1	0	0
19850	1520	steroid-induced monokine gene expression	[steroid-induced monokine gene expression]	1.5849625007211563	4	1	0	0
19851	1520	several dna-binding complex	[Several DNA-binding complexes]	1.5849625007211563	3	1	0	0
19852	1520	gata binding site	[GATA binding site]	1.5849625007211563	3	2	1	1
19853	1520	proliferation of hematopoietic cell	[proliferation of hematopoietic cells]	1.5849625007211563	4	1	0	0
19854	1520	human gasd element	[human GASd element]	1.5849625007211563	3	1	0	0
19855	1520	Escherichia coli lipopolysaccharide	[Escherichia coli lipopolysaccharide]	1.5849625007211563	3	2	1	1
19856	1520	hiv-1 laboratory isolate HTLV-IIIB	[HIV-1 laboratory isolates HTLV-IIIB]	1.5849625007211563	4	1	0	0
19857	1520	thereby increase the amount	[thereby increasing the amount]	1.5849625007211563	4	1	0	0
19858	1520	toxic shock syndrome toxin-I	[toxic shock syndrome toxin-I]	1.5849625007211563	4	1	0	0
19859	1520	natural surfactant Survanta	[natural surfactant Survanta]	1.5849625007211563	3	1	0	0
19860	1520	identification of carrier	[identification of carriers]	1.5849625007211563	3	1	0	0
19861	1520	four distinct site	[four distinct sites]	1.5849625007211563	3	1	0	0
19862	1520	5' upstream region	[5' upstream region]	1.5849625007211563	3	2	1	1
19863	1520	significant level of c-rel	[significant levels of c-Rel]	1.5849625007211563	4	1	0	0
19864	1520	human p sequence	[human P sequence]	1.5849625007211563	3	1	0	0
19865	1520	variety of signal pathway	[variety of signaling pathways]	1.5849625007211563	4	1	0	0
19866	1520	follow t-cell-receptor-mediated t-cell activation	[following T-cell-receptor-mediated T-cell activation]	1.5849625007211563	4	1	0	0
19867	1520	only in the hybrid	[only in the hybrids]	1.5849625007211563	4	1	0	0
19868	1520	expression vector contain orf2	[expression vector containing ORF2]	1.5849625007211563	4	1	0	0
19869	1520	many infectious pathogen	[many infectious pathogens]	1.5849625007211563	3	1	0	0
19870	1520	mutation of either	[Mutation of either]	1.5849625007211563	3	1	0	0
19871	1520	uptake of dexamethasone	[uptake of dexamethasone]	1.5849625007211563	3	1	0	0
19872	1520	down-regulation of glucocorticoid receptor	[down-regulation of glucocorticoid receptors]	1.5849625007211563	4	1	0	0
19873	1520	connection between fgf-1 signal	[connection between FGF-1 signaling]	1.5849625007211563	4	1	0	0
19874	1520	expression of beta-galactosidase	[expression of beta-galactosidase]	1.5849625007211563	3	1	0	0
19875	1520	GATA-1 site at -230	[GATA-1 site at -230]	1.5849625007211563	4	1	0	0
19876	1520	highly synergistic manner.	[highly synergistic manner.]	1.5849625007211563	3	1	0	0
19877	1520	AP-1 components, Fos	[AP-1 components, Fos]	1.5849625007211563	3	1	0	0
19878	1520	tsc2 messenger rna expression	[TSC2 messenger RNA expression]	1.5849625007211563	4	1	0	0
19879	1520	interaction between Cbl	[interaction between Cbl]	1.5849625007211563	3	1	0	0
19880	1520	ebv nuclear protein	[EBV nuclear proteins]	1.5849625007211563	3	2	1	1
19881	1520	Furthermore, recombinant timp-1	[Furthermore, recombinant TIMP-1]	1.5849625007211563	3	1	0	0
19882	1520	involvement of Janus kinase	[involvement of Janus kinase]	1.5849625007211563	4	1	0	0
19883	1520	kappaB- sp1 element	[kappaB- Sp1 element]	1.5849625007211563	3	1	0	0
19884	1520	almost all treatment regimen	[almost all treatment regimens]	1.5849625007211563	4	1	0	0
19885	1520	activation of gs	[activation of Gs]	1.5849625007211563	3	1	0	0
19886	1520	up-regulation of differentiation marker	[up-regulation of differentiation markers]	1.5849625007211563	4	1	0	0
19887	1520	receptor binding characteristic	[receptor binding characteristics]	1.5849625007211563	3	2	2	2
19888	1520	il-1 beta in monocyte	[IL-1 beta in monocytes]	1.5849625007211563	4	1	0	0
19889	1520	several other sequence	[several other sequences]	1.5849625007211563	3	1	0	0
19890	1520	TGF-beta 1 -mediated modulation	[TGF-beta 1 -mediated modulation]	1.5849625007211563	4	1	0	0
19891	1520	same effect in fibroblast	[same effects in fibroblasts]	1.5849625007211563	4	1	0	0
19892	1520	lpr cd4-cd8- T lymphocyte	[lpr CD4-CD8- T lymphocytes]	1.5849625007211563	4	1	0	0
19893	1520	PMA cell adhesion	[PMA cell adhesion]	1.5849625007211563	3	1	0	0
19894	1520	HBx -specific peptide elisa	[HBx -specific peptide ELISAs]	1.5849625007211563	4	1	0	0
19895	1520	antigen-stimulated b-cell-mediated immune response	[antigen-stimulated B-cell-mediated immune responses]	1.5849625007211563	4	1	0	0
19896	1520	timp-1 in tissue homeostasis	[TIMP-1 in tissue homeostasis]	1.5849625007211563	4	1	0	0
19897	1520	resemble the pattern	[resembling the pattern]	1.5849625007211563	3	1	0	0
19898	1520	minimal mu enhancer	[minimal mu enhancer]	1.5849625007211563	3	1	0	0
19899	1520	differentiation of thymocyte	[differentiation of thymocytes]	1.5849625007211563	3	2	2	2
19900	1520	increase in adhesion	[increase in adhesion]	1.5849625007211563	3	2	2	2
19901	1520	99-bp (delta99) sequence	[99-bp (delta99) sequences]	1.5849625007211563	3	1	0	0
19902	1520	activation of nf	[activation of NF]	1.5849625007211563	3	1	0	0
19903	1520	early-onset type 2	[early-onset type 2]	1.5849625007211563	3	1	0	0
19904	1520	monocytic/myeloic gene mrp14	[monocytic/myeloic gene MRP14]	1.5849625007211563	3	1	0	0
19905	1520	free radical scavenger	[free radical scavenger]	1.5849625007211563	3	1	0	0
19906	1520	cell at low levels,	[cells at low levels,]	1.5849625007211563	4	1	0	0
19907	1520	immunoglobulin kappa light	[immunoglobulin kappa light]	1.5849625007211563	3	1	0	0
19908	1520	importance for gene regulation	[importance for gene regulation]	1.5849625007211563	4	1	0	0
19909	1520	role of phosphorylation	[role of phosphorylation]	1.5849625007211563	3	1	0	0
19910	1520	various hematopoietic cell line	[various hematopoietic cell lines]	1.5849625007211563	4	1	0	0
19911	1520	phosphorylation of slp-76	[phosphorylation of SLP-76]	1.5849625007211563	3	1	0	0
19912	1520	t-cell interleukin-2 expression	[T-cell interleukin-2 expression]	1.5849625007211563	3	1	0	0
19913	1520	alpha-tocopheryl succinate tcp succinate	[alpha-tocopheryl succinate TCP succinate]	1.5849625007211563	4	1	0	0
19914	1520	level of h-7 used.	[level of H-7 used.]	1.5849625007211563	4	1	0	0
19915	1520	cell line lack p56	[cell lines lacking p56]	1.5849625007211563	4	1	0	0
19916	1520	status of the twin	[status of the twins]	1.5849625007211563	4	2	1	1
19917	1520	High-dose estrogen administration	[High-dose estrogen administration]	1.5849625007211563	3	1	0	0
19918	1520	tcr -CD8 complex condition	[TCR -CD8 complex conditions]	1.5849625007211563	4	1	0	0
19919	1520	impact of ganglioside	[impact of gangliosides]	1.5849625007211563	3	1	0	0
19920	1520	effect in p19 cell	[effect in P19 cells]	1.5849625007211563	4	1	0	0
19921	1520	two signal requirement	[two signals requirements]	1.5849625007211563	3	1	0	0
19922	1520	monocyte /macrophage activation	[monocyte /macrophage activation]	1.5849625007211563	3	1	0	0
19923	1520	inflammatory synovial fluid sf	[inflammatory synovial fluids SFs]	1.5849625007211563	4	1	0	0
19924	1520	N-terminal transactivation domain	[N-terminal transactivation domain]	1.5849625007211563	3	1	0	0
19925	1520	various hematopoietic cell type	[various hematopoietic cell types]	1.5849625007211563	4	1	0	0
19926	1520	prebed rest level	[prebed rest levels]	1.5849625007211563	3	1	0	0
19927	1520	erythropoietin-dependent erythroid progenitor	[erythropoietin-dependent erythroid progenitors]	1.5849625007211563	3	1	0	0
19928	1520	pmn chemotaxis to fmlp	[PMNs chemotaxis to FMLP]	1.5849625007211563	4	1	0	0
19929	1520	importance of NF-kappaB site	[importance of NF-kappaB sites]	1.5849625007211563	4	1	0	0
19930	1520	such as Fos b	[such as Fos B]	1.5849625007211563	4	1	0	0
19931	1520	high affinity sites; 3)	[higher affinity sites; 3)]	1.5849625007211563	4	1	0	0
19932	1520	two specific complex	[two specific complexes]	1.5849625007211563	3	1	0	0
19933	1520	reverse the position	[Reversing the position]	1.5849625007211563	3	1	0	0
19934	1520	addition of sodium molybdate	[addition of sodium molybdate]	1.5849625007211563	4	1	0	0
19935	1520	design of effective therapy	[design of effective therapy]	1.5849625007211563	4	1	0	0
19936	1520	complication after lung transplantation	[Complications after lung transplantation]	1.5849625007211563	4	1	0	0
19937	1520	plzf-rar alpha apl	[PLZF-RAR alpha APLs]	1.5849625007211563	3	1	0	0
19938	1520	pulmonary granulomatous disease tuberculosis	[pulmonary granulomatous diseases tuberculosis]	1.5849625007211563	4	1	0	0
19939	1520	others, such as IL-2	[others, such as IL-2]	1.5849625007211563	4	1	0	0
19940	1520	T-lymphocytes gene expression	[T-lymphocytes gene expression]	1.5849625007211563	3	1	0	0
19941	1520	TF antigen expression	[TF antigen expression]	1.5849625007211563	3	1	0	0
19942	1520	Fos peptide c-fo phosphorylation.	[Fos peptide c-Fos phosphorylation.]	1.5849625007211563	4	1	0	0
19943	1520	surface expression on huvec	[Surface expression on HUVECs]	1.5849625007211563	4	2	2	2
19944	1520	epidermal growth factor receptor	[epidermal growth factor receptor]	1.5849625007211563	4	2	1	1
19945	1520	second cell line	[second cell line]	1.5849625007211563	3	1	0	0
19946	1520	water-soluble emulsion of alpha-tocopherol	[water-soluble emulsion of alpha-tocopherol]	1.5849625007211563	4	1	0	0
19947	1520	main reservoir of hiv	[main reservoirs of HIV]	1.5849625007211563	4	1	0	0
19948	1520	dna-protein binding analysis	[DNA-protein binding analysis]	1.5849625007211563	3	1	0	0
19949	1520	results: during menopause	[RESULTS: During menopause]	1.5849625007211563	3	1	0	0
19950	1520	response in lymphoid cell	[response in lymphoid cells]	1.5849625007211563	4	1	0	0
19951	1520	support of this model,	[support of this model,]	1.5849625007211563	4	1	0	0
19952	1520	control patient SE	[control patients SE]	1.5849625007211563	3	1	0	0
19953	1520	human ciita gene	[human CIITA gene]	1.5849625007211563	3	2	1	1
19954	1520	protein mediate signal transduction	[proteins mediating signal transduction]	1.5849625007211563	4	1	0	0
19955	1520	induction of cyclooxygenase-2	[induction of cyclooxygenase-2]	1.5849625007211563	3	1	0	0
19956	1520	Geist, L. J.,	[Geist, L. J.,]	1.5849625007211563	3	1	0	0
19957	1520	include fcepsilonriib cd23 15-lipoxygenase	[including FcepsilonRIIb CD23 15-lipoxygenase]	1.5849625007211563	4	1	0	0
19958	1520	ets family member	[Ets family member]	1.5849625007211563	3	2	2	2
19959	1520	inflammatory mediator expression	[inflammatory mediator expression]	1.5849625007211563	3	1	0	0
19960	1520	vivo testing of tam	[vivo testing of TAM]	1.5849625007211563	4	1	0	0
19961	1520	pos -binding protein	[POS -binding protein]	1.5849625007211563	3	1	0	0
19962	1520	PECAM-1 promoter segment	[PECAM-1 promoter segments]	1.5849625007211563	3	1	0	0
19963	1520	short immunodominant antigenic region	[short immunodominant antigenic region]	1.5849625007211563	4	1	0	0
19964	1520	vitro binding study	[vitro binding studies]	1.5849625007211563	3	1	0	0
19965	1520	blocker of the ar	[blocker of the AR]	1.5849625007211563	4	1	0	0
19966	1520	c-erbB2 gene sequence	[c-erbB2 gene sequences]	1.5849625007211563	3	1	0	0
19967	1520	effect of cya upon	[effects of CyA upon]	1.5849625007211563	4	1	0	0
19968	1520	NF-kappa b inhibitor pyrrolidinedithiocarbamate	[NF-kappa B inhibitors pyrrolidinedithiocarbamate]	1.5849625007211563	4	1	0	0
19969	1520	change in cytokine production	[changes in cytokine production]	1.5849625007211563	4	1	0	0
19970	1520	migration of human leukocyte	[migration of human leukocytes]	1.5849625007211563	4	2	2	2
19971	1520	human peripheral granurocyte	[human peripheral granurocytes]	1.5849625007211563	3	1	0	0
19972	1520	monocytic differentiation by stimulation	[monocytic differentiation by stimulation]	1.5849625007211563	4	1	0	0
19973	1520	nf-kappa b production	[NF-kappa B production]	1.5849625007211563	3	1	0	0
19974	1520	individual cell cycle phase	[individual cell cycle phases]	1.5849625007211563	4	1	0	0
19975	1520	molecular level for rearrangement	[molecular level for rearrangement]	1.5849625007211563	4	1	0	0
19976	1520	level of leukotriene b4	[levels of leukotriene B4]	1.5849625007211563	4	1	0	0
19977	1520	other ebv gene	[other EBV genes]	1.5849625007211563	3	1	0	0
19978	1520	differentiation-linked gene expression	[differentiation-linked gene expression]	1.5849625007211563	3	1	0	0
19979	1520	harbour human herpesvirus type-8	[harbouring human herpesvirus type-8]	1.5849625007211563	4	1	0	0
19980	1520	function of adrenal cortex	[function of adrenal cortex]	1.5849625007211563	4	1	0	0
19981	1520	activity of the gene	[activity of the gene]	1.5849625007211563	4	2	2	2
19982	1520	monocyte tf expression	[monocyte TF expression]	1.5849625007211563	3	2	1	1
19983	1520	naturally occur mutation	[naturally occurring mutation]	1.5849625007211563	3	1	0	0
19984	1520	social factor namely,	[social factors namely,]	1.5849625007211563	3	1	0	0
19985	1520	oxidative burst response	[oxidative burst response]	1.5849625007211563	3	2	1	1
19986	1520	nm23 .h1 gene	[NM23 .H1 gene]	1.5849625007211563	3	1	0	0
19987	1520	murine pu.1 promoter	[murine PU.1 promoter]	1.5849625007211563	3	1	0	0
19988	1520	photoproduct of tryptophan	[photoproducts of tryptophan]	1.5849625007211563	3	1	0	0
19989	1520	few viral regulatory protein	[few viral regulatory proteins]	1.5849625007211563	4	1	0	0
19990	1520	gc formation in patient	[GC formation in patients]	1.5849625007211563	4	1	0	0
19991	1520	surface igd sIgD	[surface IgD sIgD]	1.5849625007211563	3	1	0	0
19992	1520	5'HS3 of the LCR	[5'HS3 of the LCR]	1.5849625007211563	4	1	0	0
19993	1520	progenitor cell line	[progenitor cell line]	1.5849625007211563	3	2	2	2
19994	1520	AP-1/octamer composite element	[AP-1/octamer composite element]	1.5849625007211563	3	1	0	0
19995	1520	apparent non-cell-type-specific expression	[apparent non-cell-type-specific expression]	1.5849625007211563	3	1	0	0
19996	1520	(median follow-up, 71 months)	[(median follow-up, 71 months)]	1.5849625007211563	4	1	0	0
19997	1520	normal with cf	[normals with CF]	1.5849625007211563	3	2	1	1
19998	1520	myeloid "stem cell" disorder	[myeloid "stem cell" disorders]	1.5849625007211563	4	1	0	0
19999	1520	oxidative suppression of NF-AT	[oxidative suppression of NF-AT]	1.5849625007211563	4	1	0	0
20000	1520	responsiveness to the ag	[responsiveness to the Ag]	1.5849625007211563	4	1	0	0
20001	1520	effect of antioxidant treatment	[effect of antioxidant treatment]	1.5849625007211563	4	2	1	1
20002	1520	mediate apoptosis of lymphocyte	[mediating apoptosis of lymphocytes]	1.5849625007211563	4	1	0	0
20003	1520	transcription of target gene	[transcription of target genes]	1.5849625007211563	4	1	0	0
20004	1520	one brca1 allele	[one BRCA1 allele]	1.5849625007211563	3	1	0	0
20005	1520	plasma membrane cd14	[plasma membrane CD14]	1.5849625007211563	3	1	0	0
20006	1520	family of factor	[family of factors]	1.5849625007211563	3	2	1	1
20007	1520	xist gene in development	[XIST gene in development]	1.5849625007211563	4	1	0	0
20008	1520	monocyte surface marker	[monocyte surface markers]	1.5849625007211563	3	1	0	0
20009	1520	genuine splice site sequence	[genuine splice site sequences]	1.5849625007211563	4	1	0	0
20010	1520	assembly of this complex	[assembly of this complex]	1.5849625007211563	4	2	2	2
20011	1520	camp signal transduction pathway	[cAMP signal transduction pathway]	1.5849625007211563	4	1	0	0
20012	1520	dna-binding of nf-kappab	[DNA-binding of NF-kappaB]	1.5849625007211563	3	1	0	0
20013	1520	addition of mifepristone	[addition of mifepristone]	1.5849625007211563	3	1	0	0
20014	1520	inactive metabolite tetrahydrocortisol	[inactive metabolite tetrahydrocortisol]	1.5849625007211563	3	1	0	0
20015	1520	immunosuppressive drug rapamycin	[immunosuppressive drug rapamycin]	1.5849625007211563	3	1	0	0
20016	1520	ap-1 enhancer activity,	[AP-1 enhancer activity,]	1.5849625007211563	3	1	0	0
20017	1520	human gingival fibroblast HF	[human gingival fibroblasts HF]	1.5849625007211563	4	1	0	0
20018	1520	specificity of mnda expression	[specificity of MNDA expression]	1.5849625007211563	4	1	0	0
20019	1520	characteristic of the receptor	[characteristics of the receptor]	1.5849625007211563	4	1	0	0
20020	1520	cord adult sample	[cord adult samples]	1.5849625007211563	3	1	0	0
20021	1520	proximal hil-5 promoter	[proximal hIL-5 promoter]	1.5849625007211563	3	1	0	0
20022	1520	62 healthy subject	[62 healthy subjects]	1.5849625007211563	3	1	0	0
20023	1520	level of cytokine message	[levels of cytokine messages]	1.5849625007211563	4	1	0	0
20024	1520	transcription factor factor kappab	[transcription factor factor kappaB]	1.5849625007211563	4	2	1	1
20025	1520	alteration in the composition	[alteration in the composition]	1.5849625007211563	4	1	0	0
20026	1520	series of reporter construct	[series of reporter constructs]	1.5849625007211563	4	1	0	0
20027	1520	inhibition 1 replication	[Inhibition 1 replication]	1.5849625007211563	3	2	2	2
20028	1520	oppose effect of glucocorticoid	[Opposing effects of glucocorticoids]	1.5849625007211563	4	1	0	0
20029	1520	macrophage colony-stimulating factor receptor	[macrophage colony-stimulating factor receptor]	1.5849625007211563	4	1	0	0
20030	1520	specific inhibitor of ptpase	[specific inhibitor of PTPase]	1.5849625007211563	4	1	0	0
20031	1520	RA -responsive gene	[RA -responsive genes]	1.5849625007211563	3	1	0	0
20032	1520	monocytic lineage in response	[monocytic lineages in response]	1.5849625007211563	4	1	0	0
20033	1520	effect of b95-8.	[effect of B95-8.]	1.5849625007211563	3	1	0	0
20034	1520	further blur the distinction	[further blurring the distinction]	1.5849625007211563	4	1	0	0
20035	1520	inhibition of nf-kappa b	[Inhibition of NF-kappa B]	1.5849625007211563	4	2	2	2
20036	1520	healthy aged subject	[healthy aged subjects]	1.5849625007211563	3	2	1	1
20037	1520	merge point of pathway	[merging point of pathways]	1.5849625007211563	4	1	0	0
20038	1520	vivo transient transfection study	[vivo transient transfection studies]	1.5849625007211563	4	1	0	0
20039	1520	defect in il-2 production	[defect in IL-2 production]	1.5849625007211563	4	1	0	0
20040	1520	marrow-derived macrophage bind activity	[marrow-derived macrophages binding activity]	1.5849625007211563	4	1	0	0
20041	1520	ultrastructural analysis of megakaryocyte	[Ultrastructural analysis of megakaryocytes]	1.5849625007211563	4	1	0	0
20042	1520	MRD -negative MRD lt	[MRD -negative MRD LT]	1.5849625007211563	4	1	0	0
20043	1520	TCR-dependent signal transduction pathway	[TCR-dependent signal transduction pathway]	1.5849625007211563	4	1	0	0
20044	1520	signal from the tcr	[signals from the TCR]	1.5849625007211563	4	1	0	0
20045	1520	much less degree, 11alpha,13-dihydrohelenalin	[much lesser degree, 11alpha,13-dihydrohelenalin]	1.5849625007211563	4	1	0	0
20046	1520	yy1 class transcription factor	[YY1 class transcription factors]	1.5849625007211563	4	1	0	0
20047	1520	composition of subunits, p50	[composition of subunits, p50]	1.5849625007211563	4	1	0	0
20048	1520	microb motif alone	[microB motif alone]	1.5849625007211563	3	1	0	0
20049	1520	myeloid cell feature	[myeloid cell features]	1.5849625007211563	3	1	0	0
20050	1520	breast tumor sample	[breast tumor samples]	1.5849625007211563	3	2	1	1
20051	1520	short nf-atc isoform	[shorter NF-ATc isoform]	1.5849625007211563	3	1	0	0
20052	1520	evidence a member	[evidence a member]	1.5849625007211563	3	1	0	0
20053	1520	CRO-AP/3 cell line	[CRO-AP/3 cell lines]	1.5849625007211563	3	1	0	0
20054	1520	result in significant reduction	[resulting in significant reduction]	1.5849625007211563	4	1	0	0
20055	1520	[3H]dexamethasone binding in cytosol	[[3H]dexamethasone binding in cytosol]	1.5849625007211563	4	1	0	0
20056	1520	viral self peptide	[viral self peptides]	1.5849625007211563	3	1	0	0
20057	1520	specific genotoxic stimulus	[specific genotoxic stimuli]	1.5849625007211563	3	1	0	0
20058	1520	prostaglandin e2 PGE2	[prostaglandin E2 PGE2]	1.5849625007211563	3	2	1	1
20059	1520	5'-untranslated coding region	[5'-untranslated coding regions]	1.5849625007211563	3	1	0	0
20060	1520	c-maf transcription factor	[c-Maf transcription factors]	1.5849625007211563	3	1	0	0
20061	1520	various non-irradiated cell line	[various non-irradiated cell lines]	1.5849625007211563	4	1	0	0
20062	1520	deranged cellular cholesterol homeostasis	[Deranged cellular cholesterol homeostasis]	1.5849625007211563	4	1	0	0
20063	1520	requirement for synergy	[requirements for synergy]	1.5849625007211563	3	2	1	1
20064	1520	effect of alpha-tocopherol	[effect of alpha-tocopherol]	1.5849625007211563	3	2	2	2
20065	1520	presence of a polymorphism	[presence of a polymorphism]	1.5849625007211563	4	1	0	0
20066	1520	response to interleukin-2 il-2	[response to interleukin-2 IL-2]	1.5849625007211563	4	1	0	0
20067	1520	human lymphocyte line	[human lymphocyte line]	1.5849625007211563	3	1	0	0
20068	1520	normal b lymphocyte	[normal B lymphocytes]	1.5849625007211563	3	4	3	1
20069	1520	naive human T cell	[naive human T cells]	1.5849625007211563	4	1	0	0
20070	1520	cd8(-) CD3 (+) thymocyte	[CD8(-) CD3 (+) thymocytes]	1.5849625007211563	4	2	1	1
20071	1520	regulation by Egr-1	[Regulation by Egr-1]	1.5849625007211563	3	1	0	0
20072	1520	segregate this two pathway	[segregating these two pathways]	1.5849625007211563	4	1	0	0
20073	1520	control of il-5 production	[Control of IL-5 production]	1.5849625007211563	4	1	0	0
20074	1520	msr promoter ap-1/et element	[MSR promoter AP-1/ets elements]	1.5849625007211563	4	1	0	0
20075	1520	context of spontaneous abortion	[context of spontaneous abortion]	1.5849625007211563	4	1	0	0
20076	1520	such as l-cystine	[such as L-cystine]	1.5849625007211563	3	1	0	0
20077	1520	transmission electron microscopy	[transmission electron microscopy]	1.5849625007211563	3	2	2	2
20078	1520	raise the possibility	[raising the possibility]	1.5849625007211563	3	2	1	1
20079	1520	normal tonsil- b cell	[normal tonsil- B cells]	1.5849625007211563	4	1	0	0
20080	1520	35-kDa (alpha) subunit	[35-kDa (alpha) subunit]	1.5849625007211563	3	1	0	0
20081	1520	b lymphocyte monoclonicity	[B lymphocyte monoclonicity]	1.5849625007211563	3	1	0	0
20082	1520	different genetic defect	[different genetic defects]	1.5849625007211563	3	1	0	0
20083	1520	Functional synergy between Raf	[Functional synergy between Raf]	1.5849625007211563	4	1	0	0
20084	1520	specific promoter sequence	[specific promoter sequences]	1.5849625007211563	3	1	0	0
20085	1520	indicate a lymphoid-related	[indicating a lymphoid-related]	1.5849625007211563	3	1	0	0
20086	1520	signal via HLA class	[signaling via HLA class]	1.5849625007211563	4	1	0	0
20087	1520	use a p50-	[Using a p50-]	1.5849625007211563	3	1	0	0
20088	1520	transcription factor spi-1/pu.1	[transcription factor Spi-1/PU.1]	1.5849625007211563	3	1	0	0
20089	1520	target of pge2 action	[target of PGE2 action]	1.5849625007211563	4	1	0	0
20090	1520	Furthermore, b cell	[Furthermore, B cells]	1.5849625007211563	3	1	0	0
20091	1520	ratio of c-fo	[ratio of c-fos]	1.5849625007211563	3	1	0	0
20092	1520	expression of elam-1	[expression of ELAM-1]	1.5849625007211563	3	2	2	2
20093	1520	hla-dr alpha promoter construct	[HLA-DR alpha promoter constructs]	1.5849625007211563	4	1	0	0
20094	1520	line, tg epsilon26,	[line, tg epsilon26,]	1.5849625007211563	3	1	0	0
20095	1520	anti- fas killing	[anti- Fas killing]	1.5849625007211563	3	1	0	0
20096	1520	sequence-specific transcription factor	[sequence-specific transcription factors]	1.5849625007211563	3	2	1	1
20097	1520	activation of p38 mapk	[Activation of p38 MAPK]	1.5849625007211563	4	1	0	0
20098	1520	ep4 receptor subtype	[EP4 receptor subtype]	1.5849625007211563	3	1	0	0
20099	1520	human B-cell development	[human B-cell development]	1.5849625007211563	3	1	0	0
20100	1520	18-20 residue-long peptide fragment	[18-20 residue-long peptide fragments]	1.5849625007211563	4	1	0	0
20101	1520	apoptosis suppressor protein bcl-2	[apoptosis suppressor protein Bcl-2]	1.5849625007211563	4	1	0	0
20102	1520	several lymphokine receptor gene	[several lymphokine receptor genes]	1.5849625007211563	4	1	0	0
20103	1520	suppression of splenocyte proliferation	[suppression of splenocyte proliferation]	1.5849625007211563	4	1	0	0
20104	1520	human peripheral blood monocytes.	[human peripheral blood monocytes.]	1.5849625007211563	4	1	0	0
20105	1520	two- to threefold rise	[two- to threefold rise]	1.5849625007211563	4	1	0	0
20106	1520	strong c-myc mrna expression	[Stronger c-myc mRNA expression]	1.5849625007211563	4	1	0	0
20107	1520	immunotherapy of APL	[immunotherapy of APL]	1.5849625007211563	3	1	0	0
20108	1520	basis of cytotoxicity pattern	[basis of cytotoxicity patterns]	1.5849625007211563	4	1	0	0
20109	1520	5-lipoxygenase inhibitor zileuton	[5-lipoxygenase inhibitor zileuton]	1.5849625007211563	3	1	0	0
20110	1520	gcr of healthy control	[GCR of healthy controls]	1.5849625007211563	4	1	0	0
20111	1520	activation pathway by p21(ras)	[activation pathway by p21(ras)]	1.5849625007211563	4	1	0	0
20112	1520	reduction of 4.3-fold.	[reduction of 4.3-fold.]	1.5849625007211563	3	1	0	0
20113	1520	normal pancreatic beta-cell function	[normal pancreatic beta-cell function]	1.5849625007211563	4	1	0	0
20114	1520	role in gene transcription	[role in gene transcription]	1.5849625007211563	4	2	2	2
20115	1520	number of androgen receptor	[number of androgen receptors]	1.5849625007211563	4	1	0	0
20116	1520	accumulation of the mrna	[accumulation of the mRNA]	1.5849625007211563	4	2	2	2
20117	1520	recombinant ori lyt element	[recombinant ori Lyt element]	1.5849625007211563	4	1	0	0
20118	1520	use a lmp-1 allele	[Using a LMP-1 allele]	1.5849625007211563	4	1	0	0
20119	1520	AML1 runt dna-binding domain	[AML1 runt DNA-binding domain]	1.5849625007211563	4	1	0	0
20120	1520	age of corticosteroid receptor	[age of corticosteroid receptors]	1.5849625007211563	4	1	0	0
20121	1520	immunoglobulin heavy-chain gene expression	[immunoglobulin heavy-chain gene expression]	1.5849625007211563	4	1	0	0
20122	1520	B-cell receptor complex,	[B-cell receptor complex,]	1.5849625007211563	3	1	0	0
20123	1520	only perforin-expressing lymphocyte	[only perforin-expressing lymphocytes]	1.5849625007211563	3	1	0	0
20124	1520	class II-deficient b cell	[class II-deficient B cells]	1.5849625007211563	4	1	0	0
20125	1520	chimera PMLRAR alpha	[chimera PMLRAR alpha]	1.5849625007211563	3	1	0	0
20126	1520	gr by cognate ligand	[GR by cognate ligand]	1.5849625007211563	4	1	0	0
20127	1520	c-terminal segment of alpha-helix	[C-terminal segment of alpha-helix]	1.5849625007211563	4	1	0	0
20128	1520	hypothesis a calcineurin substrate	[hypothesis a calcineurin substrate]	1.5849625007211563	4	1	0	0
20129	1520	central pathogenic role,	[central pathogenic role,]	1.5849625007211563	3	1	0	0
20130	1520	inflammation of the tubulointerstitium	[inflammation of the tubulointerstitium]	1.5849625007211563	4	1	0	0
20131	1520	Ile50 -bear pbmc	[Ile50 -bearing PBMC]	1.5849625007211563	3	1	0	0
20132	1520	level of GATA-2 mrna	[levels of GATA-2 mRNA]	1.5849625007211563	4	1	0	0
20133	1520	c-Jun delta-domain function	[c-Jun delta-domain functions]	1.5849625007211563	3	1	0	0
20134	1520	T cell leukemia/lymphoma development	[T cell leukemia/lymphoma development]	1.5849625007211563	4	1	0	0
20135	1520	down-regulation of rante expression	[down-regulation of RANTES expression]	1.5849625007211563	4	1	0	0
20136	1520	METHODS: Stable transfectant	[METHODS: Stable transfectants]	1.5849625007211563	3	1	0	0
20137	1520	technique for the measurement	[technique for the measurement]	1.5849625007211563	4	2	2	2
20138	1520	persistent infection ad5	[persistent infection Ad5]	1.5849625007211563	3	1	0	0
20139	1520	mutant of NIK	[mutant of NIK]	1.5849625007211563	3	2	2	2
20140	1520	same tnf-alpha -dose dependency	[same TNF-alpha -dose dependency]	1.5849625007211563	4	1	0	0
20141	1520	gene (-276 to -250	[genes (-276 to -250]	1.5849625007211563	4	1	0	0
20142	1520	receptor antagonist ru-38486	[receptor antagonist RU-38486]	1.5849625007211563	3	1	0	0
20143	1520	transactivation activity of mef2c	[transactivation activity of MEF2C]	1.5849625007211563	4	1	0	0
20144	1520	normal proliferative response	[normal proliferative responses]	1.5849625007211563	3	1	0	0
20145	1520	hyperphosphorylation of e2f-4	[hyperphosphorylation of E2F-4]	1.5849625007211563	3	1	0	0
20146	1520	glucocorticoid in inflammation	[glucocorticoids in inflammation]	1.5849625007211563	3	1	0	0
20147	1520	NFAT transcriptional activation	[NFAT transcriptional activation]	1.5849625007211563	3	1	0	0
20148	1520	localization of the protein	[localization of the protein]	1.5849625007211563	4	1	0	0
20149	1520	fetal globin gene	[fetal globin genes]	1.5849625007211563	3	1	0	0
20150	1520	t-cell receptor signal pathway	[T-cell receptor signaling pathway]	1.5849625007211563	4	2	2	2
20151	1520	potent immunoregulatory molecule	[potent immunoregulatory molecule]	1.5849625007211563	3	1	0	0
20152	1520	il-4 level in asthma	[IL-4 levels in asthma]	1.5849625007211563	4	1	0	0
20153	1520	intact human IL-4 promoter	[intact human IL-4 promoter]	1.5849625007211563	4	1	0	0
20154	1520	binding result from interaction	[binding results from interactions]	1.5849625007211563	4	1	0	0
20155	1520	IL-5 promoter to camp	[IL-5 promoter to cAMP]	1.5849625007211563	4	1	0	0
20156	1520	specifically in b cell	[specifically in B cells]	1.5849625007211563	4	1	0	0
20157	1520	more day post-stimulation	[more days) post-stimulation]	1.5849625007211563	3	1	0	0
20158	1520	onset of both process	[onset of both processes]	1.5849625007211563	4	1	0	0
20159	1520	strong accumulation of RelB	[strong accumulation of RelB]	1.5849625007211563	4	1	0	0
20160	1520	novel dyad symmetrical sequence	[novel dyad symmetrical sequence]	1.5849625007211563	4	1	0	0
20161	1520	selective eosinophil-activating factor	[selective eosinophil-activating factor]	1.5849625007211563	3	1	0	0
20162	1520	control of the form	[control of the forms]	1.5849625007211563	4	1	0	0
20163	1520	binding of P. aeruginosa	[binding of P. aeruginosa]	1.5849625007211563	4	2	1	1
20164	1520	gain in transcriptional signal	[gain in transcriptional signal]	1.5849625007211563	4	1	0	0
20165	1520	one such cofactor BOB.1/OBF.1	[One such cofactor BOB.1/OBF.1]	1.5849625007211563	4	1	0	0
20166	1520	expose huvec to A/R	[Exposing HUVECs to A/R]	1.5849625007211563	4	1	0	0
20167	1520	use library screening	[using library screenings]	1.5849625007211563	3	1	0	0
20168	1520	addition, DNA methylation	[addition, DNA methylation]	1.5849625007211563	3	1	0	0
20169	1520	undetectable level of galectin-3	[undetectable levels of galectin-3]	1.5849625007211563	4	1	0	0
20170	1520	alveolar type ii-like cell	[alveolar type II-like cells]	1.5849625007211563	4	1	0	0
20171	1520	nuclear factor ATF-2	[nuclear factors ATF-2]	1.5849625007211563	3	1	0	0
20172	1520	IL-2Rgamma (gammac) chain	[IL-2Rgamma (gammac) chain]	1.5849625007211563	3	1	0	0
20173	1520	TCR Vbeta 8.1 promoter	[TCR Vbeta 8.1 promoter]	1.5849625007211563	4	1	0	0
20174	1520	important immunoregulatory cytokine	[important immunoregulatory cytokine]	1.5849625007211563	3	1	0	0
20175	1520	c-fo sre cross	[c-fos SRE cross]	1.5849625007211563	3	1	0	0
20176	1520	presence a inhibitor	[presence an inhibitor]	1.5849625007211563	3	2	2	2
20177	1520	high order complex	[higher order complex]	1.5849625007211563	3	2	2	2
20178	1520	four nuclear protein	[four nuclear proteins]	1.5849625007211563	3	1	0	0
20179	1520	short arm of chromosome	[short arm of chromosome]	1.5849625007211563	4	2	2	2
20180	1520	absence of exogenous hgf	[absence of exogenous HGFs]	1.5849625007211563	4	1	0	0
20181	1520	inducible protein complex	[inducible protein complex]	1.5849625007211563	3	2	2	2
20182	1520	important activity of DEN	[important activity of DEN]	1.5849625007211563	4	1	0	0
20183	1520	consensus heat shock element	[consensus heat shock element]	1.5849625007211563	4	1	0	0
20184	1520	several factors, include ap-1	[several factors, including AP-1]	1.5849625007211563	4	1	0	0
20185	1520	A series 4c cell	[A series 4C cells]	1.5849625007211563	4	1	0	0
20186	1520	offspring of nonalcoholic	[offspring of nonalcoholics]	1.5849625007211563	3	1	0	0
20187	1520	Interleukin-10 IL-10 like IL-4	[Interleukin-10 IL-10 like IL-4]	1.5849625007211563	4	1	0	0
20188	1520	recent sib-pair analysis	[recent sib-pair analysis]	1.5849625007211563	3	1	0	0
20189	1520	examination of activation-induced phosphorylation	[Examination of activation-induced phosphorylation]	1.5849625007211563	4	1	0	0
20190	1520	ikk complex protein	[IKK complex protein]	1.5849625007211563	3	1	0	0
20191	1520	inflammatory synovial microenvironment	[inflammatory synovial microenvironment]	1.5849625007211563	3	1	0	0
20192	1520	presence of cell important	[presence of cells important]	1.5849625007211563	4	1	0	0
20193	1520	C-terminal portion of p105	[C-terminal portion of p105]	1.5849625007211563	4	1	0	0
20194	1520	synthetic double-stranded oligonucleotide	[synthetic double-stranded oligonucleotides]	1.5849625007211563	3	1	0	0
20195	1520	protein of a mass	[protein of a mass]	1.5849625007211563	4	1	0	0
20196	1520	transcriptional up-regulation of p50	[transcriptional up-regulation of p50]	1.5849625007211563	4	1	0	0
20197	1520	dehydratase in the regeneration	[dehydratase in the regeneration]	1.5849625007211563	4	1	0	0
20198	1520	40 early promoter	[40 early promoter]	1.5849625007211563	3	1	0	0
20199	1520	untreated euthymic patient	[untreated euthymic patients]	1.5849625007211563	3	2	2	2
20200	1520	DNA binding function	[DNA binding function]	1.5849625007211563	3	1	0	0
20201	1520	biological effect of il-2	[biological effects of IL-2]	1.5849625007211563	4	1	0	0
20202	1520	transcription factor in neutrophil	[transcription factor in neutrophils]	1.5849625007211563	4	2	2	2
20203	1520	naive T cell proliferation	[naive T cell proliferation]	1.5849625007211563	4	1	0	0
20204	1520	very early developmental stage	[very early developmental stage]	1.5849625007211563	4	1	0	0
20205	1520	7 hiv adenopathy	[7 HIV adenopathy]	1.5849625007211563	3	1	0	0
20206	1520	il-2 binding to receptor	[IL-2 binding to receptor]	1.5849625007211563	4	1	0	0
20207	1520	calcium -dependent protease	[calcium -dependent protease]	1.5849625007211563	3	1	0	0
20208	1520	combination of hypoxia	[combinations of hypoxia]	1.5849625007211563	3	2	1	1
20209	1520	herpes simplex virus gene	[herpes simplex virus genes]	1.5849625007211563	4	1	0	0
20210	1520	other class ii promoter	[other class II promoters]	1.5849625007211563	4	1	0	0
20211	1520	use cd4+ T cell	[using CD4+ T cells]	1.5849625007211563	4	2	2	2
20212	1520	activation of immune cell	[activation of immune cells]	1.5849625007211563	4	1	0	0
20213	1520	four other herpesviruse	[four other herpesviruses]	1.5849625007211563	3	1	0	0
20214	1520	mnda -express cell	[MNDA -expressing cells]	1.5849625007211563	3	1	0	0
20215	1520	cell to this agent	[cells to these agents]	1.5849625007211563	4	1	0	0
20216	1520	IL-7 -signaling pathway	[IL-7 -signaling pathway]	1.5849625007211563	3	1	0	0
20217	1520	related antiapoptotic molecule a1/bfl-1	[related antiapoptotic molecule A1/Bfl-1]	1.5849625007211563	4	1	0	0
20218	1520	monocytic differentiation of cell	[monocytic differentiation of cells]	1.5849625007211563	4	2	2	2
20219	1520	colon cancer cell	[colon cancer cells]	1.5849625007211563	3	1	0	0
20220	1520	cellular transcription factor e2f	[cellular transcription factor E2F]	1.5849625007211563	4	1	0	0
20221	1520	EMSA electromobility shift assay	[EMSA electromobility shift assay]	1.5849625007211563	4	1	0	0
20222	1520	proinflammatory cytokine gamma-ifn	[proinflammatory cytokine gamma-IFN]	1.5849625007211563	3	1	0	0
20223	1520	entire ligand binding domain	[entire ligand binding domain]	1.5849625007211563	4	1	0	0
20224	1520	combination, for capacity	[combination, for capacity]	1.5849625007211563	3	1	0	0
20225	1520	one p21ras effector pathway	[One p21ras effector pathway]	1.5849625007211563	4	1	0	0
20226	1520	72-kilodalton major immediate-early protein	[72-kilodalton major immediate-early protein]	1.5849625007211563	4	1	0	0
20227	1520	T cell priming	[T cell priming]	1.5849625007211563	3	1	0	0
20228	1520	great stat5 activation	[greater STAT5 activation]	1.5849625007211563	3	1	0	0
20229	1520	redox status of 1.3E2	[redox status of 1.3E2]	1.5849625007211563	4	1	0	0
20230	1520	N-terminal acidic activation domain	[N-terminal acidic activation domain]	1.5849625007211563	4	1	0	0
20231	1520	one case of CLL	[one case of CLL]	1.5849625007211563	4	1	0	0
20232	1520	enhancer core of SL3	[enhancer core of SL3]	1.5849625007211563	4	1	0	0
20233	1520	androgen receptor gene transcription	[androgen receptor gene transcription]	1.5849625007211563	4	1	0	0
20234	1520	medulla of the thymus	[medulla of the thymus]	1.5849625007211563	4	1	0	0
20235	1520	cellular protein include Cbl	[cellular proteins including Cbl]	1.5849625007211563	4	1	0	0
20236	1520	only a domain	[only a domain]	1.5849625007211563	3	1	0	0
20237	1520	anti-cd3-induced tyrosine phosphorylation	[anti-CD3-induced tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
20238	1520	lymphoid lineage-determinetermining factor	[lymphoid lineage-determining factors]	1.5849625007211563	3	1	0	0
20239	1520	presence of wild-type ebv	[presence of wild-type EBV]	1.5849625007211563	4	1	0	0
20240	1520	vitro by nf-kappa b	[vitro by NF-kappa B]	1.5849625007211563	4	1	0	0
20241	1520	ras-related gtp-binding protein	[Ras-related GTP-binding proteins]	1.5849625007211563	3	1	0	0
20242	1520	RAR gamma-specific ligand	[RAR gamma-specific ligands]	1.5849625007211563	3	1	0	0
20243	1520	activate cell types.	[activating cell types.]	1.5849625007211563	3	1	0	0
20244	1520	fungal metabolite gliotoxin	[fungal metabolite gliotoxin]	1.5849625007211563	3	1	0	0
20245	1520	Src homology domain association	[Src homology domain association]	1.5849625007211563	4	1	0	0
20246	1520	potent t-cell-specific enhancer in	[potent T-cell-specific enhancer in]	1.5849625007211563	4	1	0	0
20247	1520	extremely high concentrations.	[extremely high concentrations.]	1.5849625007211563	3	1	0	0
20248	1520	nonactivated, noncycling b cell	[nonactivated, noncycling B cells]	1.5849625007211563	4	1	0	0
20249	1520	kappa b response element	[kappa B response elements]	1.5849625007211563	4	1	0	0
20250	1520	ag-induced T cell activation	[Ag-induced T cell activation]	1.5849625007211563	4	1	0	0
20251	1520	produce ebv- b cell	[producing EBV- B cells]	1.5849625007211563	4	1	0	0
20252	1520	t-cell receptor tcr apoptosis	[T-cell receptor TCR apoptosis]	1.5849625007211563	4	1	0	0
20253	1520	inflammatory response of monocytes/macrophages	[inflammatory responses of monocytes/macrophages]	1.5849625007211563	4	1	0	0
20254	1520	NF-kappa b domain	[NF-kappa B domain]	1.5849625007211563	3	1	0	0
20255	1520	seven other gene	[seven other genes]	1.5849625007211563	3	1	0	0
20256	1520	maintain ctl-specific expression	[maintaining CTL-specific expression]	1.5849625007211563	3	1	0	0
20257	1520	p50 of nf-gm2	[p50 of NF-GM2]	1.5849625007211563	3	1	0	0
20258	1520	hiv-1 in laboratory isolate	[HIV-1 in laboratory isolates]	1.5849625007211563	4	1	0	0
20259	1520	monocyte follow lps stimulation	[monocytes following LPS stimulation]	1.5849625007211563	4	1	0	0
20260	1520	phosphoinositide 3-kinase pi 3-kinase	[Phosphoinositide 3-kinase PI 3-kinase]	1.5849625007211563	4	1	0	0
20261	1520	IL-1 nf-kappa b activation	[IL-1 NF-kappa B activation]	1.5849625007211563	4	1	0	0
20262	1520	(7-16 P; early),	[(7-16 h; early),]	1.5849625007211563	3	1	0	0
20263	1520	b DNA binding activity	[B DNA binding activity]	1.5849625007211563	4	2	2	2
20264	1520	Interleukin (il) 6 level	[Interleukin (IL) 6 levels]	1.5849625007211563	4	1	0	0
20265	1520	octamer element atttgcat	[octamer element ATTTGCAT]	1.5849625007211563	3	1	0	0
20266	1520	two NF-kappaB motif	[two NF-kappaB motifs]	1.5849625007211563	3	1	0	0
20267	1520	polyomavirus protein 2/core-binding factor	[polyomavirus protein 2/core-binding factor]	1.5849625007211563	4	2	2	2
20268	1520	plasma bicarbonate level	[plasma bicarbonates level]	1.5849625007211563	3	1	0	0
20269	1520	currently under investigation.	[currently under investigation.]	1.5849625007211563	3	2	1	1
20270	1520	activation of monocyte-endothelial interactions.	[activation of monocyte-endothelial interactions.]	1.5849625007211563	4	1	0	0
20271	1520	granulocyte-macrophage lineage in report	[granulocyte-macrophage lineage in reports.]	1.5849625007211563	4	1	0	0
20272	1520	transient chloramphenicol acetyltransferase assay	[Transient chloramphenicol acetyltransferase assay]	1.5849625007211563	4	1	0	0
20273	1520	basis of blotting experiment	[basis of blotting experiments]	1.5849625007211563	4	1	0	0
20274	1520	transcription activate subunit	[transcription activating subunit]	1.5849625007211563	3	1	0	0
20275	1520	Cbl-b activation of NFAT	[Cbl-b activation of NFAT]	1.5849625007211563	4	1	0	0
20276	1520	translation of picornavirus rrna	[translation of picornavirus mRNAs]	1.5849625007211563	4	1	0	0
20277	1520	normal breast parenchyma	[normal breast parenchyma]	1.5849625007211563	3	1	0	0
20278	1520	human interleukin-2 (il-2)	[human interleukin-2 (IL-2)]	1.5849625007211563	3	1	0	0
20279	1520	response to priming.	[response to priming.]	1.5849625007211563	3	1	0	0
20280	1520	IL2R gamma c	[IL2R gamma c]	1.5849625007211563	3	1	0	0
20281	1520	use various construct	[Using various constructs]	1.5849625007211563	3	1	0	0
20282	1520	single nucleotide insertion result	[single nucleotide insertion resulting]	1.5849625007211563	4	1	0	0
20283	1520	(0.8 0.5 fmol/10(7) cell	[(0.8 0.5 fmol/10(7) cells]	1.5849625007211563	4	1	0	0
20284	1520	myeloid blast cell	[myeloid blast cells]	1.5849625007211563	3	1	0	0
20285	1520	mitogen-activated rel T cell	[mitogen-activated Rel T cells]	1.5849625007211563	4	1	0	0
20286	1520	monocytic cell by superantigen	[monocytic cells by superantigens]	1.5849625007211563	4	1	0	0
20287	1520	stimulation with agonist	[stimulation with agonists]	1.5849625007211563	3	1	0	0
20288	1520	actual hla binding	[actual HLA binding]	1.5849625007211563	3	1	0	0
20289	1520	Locus control region lcr	[Locus control regions LCRs]	1.5849625007211563	4	1	0	0
20290	1520	HLA-A2-restricted, melana/mart-1-specific CTL clone	[HLA-A2-restricted, MelanA/MART-1-specific CTL clone]	1.5849625007211563	4	1	0	0
20291	1520	cell from apoptosis	[cells from apoptosis]	1.5849625007211563	3	1	0	0
20292	1520	quantitate corticosteroid response	[quantitating corticosteroid responses]	1.5849625007211563	3	1	0	0
20293	1520	number of interfollicular bcl-6	[number of interfollicular Bcl-6]	1.5849625007211563	4	1	0	0
20294	1520	translocation nf-kappa b	[translocation NF-kappa B]	1.5849625007211563	3	2	2	2
20295	1520	activation of immunity	[activation of immunity]	1.5849625007211563	3	2	2	2
20296	1520	protein kinase raf-1	[protein kinase Raf-1]	1.5849625007211563	3	1	0	0
20297	1520	addition, lytic cycle	[addition, lytic cycle]	1.5849625007211563	3	1	0	0
20298	1520	cyclic AMP factor	[cyclic AMP factors]	1.5849625007211563	3	1	0	0
20299	1520	serine /threonine phosphorylation	[serine /threonine phosphorylation]	1.5849625007211563	3	1	0	0
20300	1520	marrow-derived erythroid progenitor cell	[marrow-derived erythroid progenitor cells]	1.5849625007211563	4	1	0	0
20301	1520	s-lb1 htlv-1-transfected T lymphocyte	[S-LB1 HTLV-1-transfected T lymphocytes]	1.5849625007211563	4	1	0	0
20302	1520	granulomonocytic colony formation	[granulomonocytic colony formation]	1.5849625007211563	3	1	0	0
20303	1520	phosphorylation of retinoblastoma protein	[phosphorylation of retinoblastoma protein]	1.5849625007211563	4	1	0	0
20304	1520	yt cell line	[YT cell line]	1.5849625007211563	3	1	0	0
20305	1520	nf-kappa b p50-p65 heterodimer	[NF-kappa B p50-p65 heterodimer]	1.5849625007211563	4	1	0	0
20306	1520	Cotransfection of Zta	[Cotransfection of Zta]	1.5849625007211563	3	1	0	0
20307	1520	anti- ro(ssa) response	[anti- Ro(SSA) response]	1.5849625007211563	3	1	0	0
20308	1520	response to interferon	[responses to interferons]	1.5849625007211563	3	1	0	0
20309	1520	NF kappa b sequence	[NF kappa B sequence]	1.5849625007211563	4	1	0	0
20310	1520	hyponatremia suggest pha related	[hyponatremia suggesting PHA related]	1.5849625007211563	4	1	0	0
20311	1520	RXR -specific effects.	[RXR -specific effects.]	1.5849625007211563	3	1	0	0
20312	1520	complex regulatory protein network	[complex regulatory protein network]	1.5849625007211563	4	1	0	0
20313	1520	strong myeloid-cell-specific promoter	[strong myeloid-cell-specific promoter]	1.5849625007211563	3	1	0	0
20314	1520	phosphorylation of p105	[phosphorylation of p105]	1.5849625007211563	3	1	0	0
20315	1520	possibility transcriptionally inactive	[possibility transcriptionally inactive]	1.5849625007211563	3	1	0	0
20316	1520	0.2 kb 5'-flanking DNA	[0.2 kb 5'-flanking DNA]	1.5849625007211563	4	1	0	0
20317	1520	dissociation constant of fk506	[dissociation constant of FK506]	1.5849625007211563	4	1	0	0
20318	1520	apoptosis in T lymphocyte	[apoptosis in T lymphocytes]	1.5849625007211563	4	2	2	2
20319	1520	activation structure for interaction	[activation structure for interaction]	1.5849625007211563	4	1	0	0
20320	1520	primary tcr activation	[primary TCR activation]	1.5849625007211563	3	1	0	0
20321	1520	plzf-rar alpha expression	[PLZF-RAR alpha expression]	1.5849625007211563	3	1	0	0
20322	1520	HeLa cDNA library	[HeLa cDNA library]	1.5849625007211563	3	1	0	0
20323	1520	subset of myeloid-cell-specific gene	[subset of myeloid-cell-specific genes]	1.5849625007211563	4	1	0	0
20324	1520	sign of hypothyroidism	[signs of hypothyroidism]	1.5849625007211563	3	2	2	2
20325	1520	IL-4 gene regulation	[IL-4 gene regulation]	1.5849625007211563	3	2	1	1
20326	1520	mouse ets-1 cDNA clone	[mouse ets-1 cDNA clone]	1.5849625007211563	4	1	0	0
20327	1520	transgenic mouse express e2a-hlf	[transgenic mice expressing E2A-HLF]	1.5849625007211563	4	1	0	0
20328	1520	production of oxygen intermediate	[production of oxygen intermediates]	1.5849625007211563	4	1	0	0
20329	1520	T cell by htlv-1	[T cells by HTLV-1]	1.5849625007211563	4	1	0	0
20330	1520	chromosome band 14q32.1	[chromosome band 14q32.1]	1.5849625007211563	3	1	0	0
20331	1520	nuclear factor e1-binding site	[nuclear factor E1-binding site]	1.5849625007211563	4	1	0	0
20332	1520	hiv-1 genome expression	[HIV-1 genome expression]	1.5849625007211563	3	1	0	0
20333	1520	prognosis in breast cancer	[prognosis in breast cancer]	1.5849625007211563	4	2	1	1
20334	1520	thymoma cell line s49.1	[thymoma cell line S49.1]	1.5849625007211563	4	1	0	0
20335	1520	role signal pathway	[role signaling pathway]	1.5849625007211563	3	2	2	2
20336	1520	common component of AP-1	[common component of AP-1]	1.5849625007211563	4	1	0	0
20337	1520	domain of N-WASP	[domain of N-WASP]	1.5849625007211563	3	2	2	2
20338	1520	pu.1 ggaa core sequence	[PU.1 GGAA core sequence]	1.5849625007211563	4	1	0	0
20339	1520	optimal dna-binding motif	[optimal DNA-binding motifs]	1.5849625007211563	3	1	0	0
20340	1520	x receptor rxr 25-6603).	[X receptors RXRs 25-6603).]	1.5849625007211563	4	1	0	0
20341	1520	two stat-related protein	[two Stat-related proteins]	1.5849625007211563	3	1	0	0
20342	1520	production of il-2 receptor	[production of IL-2 receptors]	1.5849625007211563	4	1	0	0
20343	1520	role of this subunit	[role of this subunit]	1.5849625007211563	4	1	0	0
20344	1520	endogenous corticosteroid cushingd' syndrome	[endogenous corticosteroids Cushing's syndrome]	1.5849625007211563	4	1	0	0
20345	1520	cell specific fashion	[cell specific fashion]	1.5849625007211563	3	1	0	0
20346	1520	specific receptor ahr	[specific receptor AhR]	1.5849625007211563	3	1	0	0
20347	1520	tyrosine phosphatase inhibitor pervanadate	[tyrosine phosphatase inhibitor pervanadate]	1.5849625007211563	4	2	1	1
20348	1520	heat shock promoter	[heat shock promoters]	1.5849625007211563	3	1	0	0
20349	1520	(band 1 pk)	[(band 1 pk)]	1.5849625007211563	3	1	0	0
20350	1520	putative gtp -binding motif	[putative GTP -binding motif]	1.5849625007211563	4	1	0	0
20351	1520	induction of a state	[induction of a state]	1.5849625007211563	4	1	0	0
20352	1520	ATF family member	[ATF family members]	1.5849625007211563	3	1	0	0
20353	1520	lps-lp binding protein complex	[LPS-LPS binding protein complexes]	1.5849625007211563	4	1	0	0
20354	1520	aromatic amino acid hydroxylase	[aromatic amino acid hydroxylases]	1.5849625007211563	4	1	0	0
20355	1520	pu.1 -binding site	[PU.1 -binding site]	1.5849625007211563	3	2	1	1
20356	1520	beta-globin minimal promoter	[beta-globin minimal promoter]	1.5849625007211563	3	1	0	0
20357	1520	JunD a component	[JunD a component]	1.5849625007211563	3	1	0	0
20358	1520	down-regulation of GcR	[down-regulation of GcR]	1.5849625007211563	3	1	0	0
20359	1520	protect against apoptosis	[protecting against apoptosis]	1.5849625007211563	3	1	0	0
20360	1520	hyperproduction of interleukin il-2	[hyperproduction of interleukin IL-2]	1.5849625007211563	4	1	0	0
20361	1520	upstream prl response element	[upstream PRL response elements]	1.5849625007211563	4	1	0	0
20362	1520	hiv-1 peripheral blood	[HIV-1 peripheral blood]	1.5849625007211563	3	1	0	0
20363	1520	bypass the tcr	[bypassing the TCR]	1.5849625007211563	3	1	0	0
20364	1520	novel gene GR6	[novel gene GR6]	1.5849625007211563	3	1	0	0
20365	1520	expression of tnf mrna	[expression of TNF mRNA]	1.5849625007211563	4	1	0	0
20366	1520	five Sp1 site	[five Sp1 sites]	1.5849625007211563	3	1	0	0
20367	1520	activation in thp-1 cell	[activation in THP-1 cells]	1.5849625007211563	4	2	2	2
20368	1520	pre-existing, T cytoplasmic factor	[pre-existing, T cytoplasmic factor]	1.5849625007211563	4	1	0	0
20369	1520	protein synthesis with cycloheximide	[protein synthesis with cycloheximide]	1.5849625007211563	4	1	0	0
20370	1520	expression of cat	[expression of cat]	1.5849625007211563	3	1	0	0
20371	1520	ATL cell line	[ATL cell lines]	1.5849625007211563	3	2	2	2
20372	1520	minimal promoter region	[minimal promoter region]	1.5849625007211563	3	2	2	2
20373	1520	T helper 1 cell	[T helper 1 cells]	1.5849625007211563	4	2	2	2
20374	1520	STAT family member	[STAT family member]	1.5849625007211563	3	2	1	1
20375	1520	cell-type-specific differential response creb	[cell-type-specific differential response CREB]	1.5849625007211563	4	1	0	0
20376	1520	analysis of hybrid cell	[Analyses of hybrid cells]	1.5849625007211563	4	1	0	0
20377	1520	number circulate T lymphocyte	[numbers circulating T lymphocytes]	1.5849625007211563	4	1	0	0
20378	1520	mean dissociation constant (kd)	[mean dissociation constant (KD)]	1.5849625007211563	4	1	0	0
20379	1520	other such as THP1	[others such as THP1]	1.5849625007211563	4	1	0	0
20380	1520	mutant collagenase-1 promoter	[mutant collagenase-1 promoter]	1.5849625007211563	3	1	0	0
20381	1520	all-tran acid treatment	[all-trans acid treatment]	1.5849625007211563	3	2	2	2
20382	1520	maintenance of the clone	[maintenance of the clones]	1.5849625007211563	4	1	0	0
20383	1520	H-RS cell in tissue	[H-RS cells in tissues]	1.5849625007211563	4	1	0	0
20384	1520	human acid receptor alpha	[human acid receptor alpha]	1.5849625007211563	4	2	2	2
20385	1520	low back pain	[low back pain]	1.5849625007211563	3	2	1	1
20386	1520	inducible proto-enhancer element	[inducible proto-enhancer element]	1.5849625007211563	3	1	0	0
20387	1520	uptake and/or binding	[uptake and/or binding]	1.5849625007211563	3	1	0	0
20388	1520	three jun gene	[three jun genes]	1.5849625007211563	3	1	0	0
20389	1520	two anti-MHC class ii	[Two anti-MHC class II]	1.5849625007211563	4	1	0	0
20390	1520	gal4 activation domain gad	[GAL4 activation domain GAD]	1.5849625007211563	4	1	0	0
20391	1520	ligation of kit/il-4r alpha	[ligation of kit/IL-4R alpha]	1.5849625007211563	4	1	0	0
20392	1520	response to insulin-induced hypoglycemia	[response to insulin-induced hypoglycemia]	1.5849625007211563	4	1	0	0
20393	1520	release of MCP-1	[release of MCP-1]	1.5849625007211563	3	1	0	0
20394	1520	Sp1 -related factor Sp3ilday	[Sp1 -related factor Sp3]	1.5849625007211563	4	1	0	0
20395	1520	impaired nfkappab activity	[impaired NFkappaB activity]	1.5849625007211563	3	1	0	0
20396	1520	heterologous thymidine kinase promoter	[heterologous thymidine kinase promoter]	1.5849625007211563	4	1	0	0
20397	1520	decrease in gene expression	[decreases in gene expression]	1.5849625007211563	4	1	0	0
20398	1520	range for normal person	[range for normal persons]	1.5849625007211563	4	1	0	0
20399	1520	three rflp TaqI	[Three RFLPs TaqI]	1.5849625007211563	3	1	0	0
20400	1520	Ets related pu.1 site	[Ets related PU.1 site]	1.5849625007211563	4	1	0	0
20401	1520	kappa b site -206	[kappa B sites -206]	1.5849625007211563	4	1	0	0
20402	1520	unstimulated HeLa cell	[unstimulated HeLa cells]	1.5849625007211563	3	1	0	0
20403	1520	promonocytic u937 cell	[promonocytic U937 cells]	1.5849625007211563	3	3	2	1
20404	1520	ap-1 enhancer factor activity	[AP-1 enhancer factor activity]	1.5849625007211563	4	1	0	0
20405	1520	receptor complex for IL	[receptor complexes for IL]	1.5849625007211563	4	1	0	0
20406	1520	macrophage to foam cell	[macrophages to foam cells]	1.5849625007211563	4	1	0	0
20407	1520	lymph node interdigitate DC	[lymph node interdigitating DC]	1.5849625007211563	4	1	0	0
20408	1520	DNA binding experiment	[DNA binding experiments]	1.5849625007211563	3	1	0	0
20409	1520	use a pathological model	[using a pathological model]	1.5849625007211563	4	1	0	0
20410	1520	5' deletion construct	[5' deletion constructs]	1.5849625007211563	3	2	1	1
20411	1520	specific dna-protein complex	[specific DNA-protein complex]	1.5849625007211563	3	1	0	0
20412	1520	GRbeta expression vector alone	[GRbeta expression vector alone]	1.5849625007211563	4	1	0	0
20413	1520	significantly great amount	[significantly greater amounts]	1.5849625007211563	3	1	0	0
20414	1520	-gamma delta chain	[-gamma delta chains]	1.5849625007211563	3	1	0	0
20415	1520	monocyte chemoattractant protein gene	[monocyte chemoattractant protein gene]	1.5849625007211563	4	1	0	0
20416	1520	bound [3H] DHEA	[Bound [3H] DHEA]	1.5849625007211563	3	1	0	0
20417	1520	trigger through CD2	[Triggering through CD2]	1.5849625007211563	3	1	0	0
20418	1520	impaired uv-induced tyrosine phosphorylation	[impaired UV-induced tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
20419	1520	viscosity of cf sputum	[viscosity of CF sputum]	1.5849625007211563	4	1	0	0
20420	1520	natural host cell	[natural host cell]	1.5849625007211563	3	1	0	0
20421	1520	contain the nf-chi b	[containing the NF-chi B]	1.5849625007211563	4	1	0	0
20422	1520	differanisole a 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid	[Differanisole A 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid]	1.5849625007211563	4	1	0	0
20423	1520	effect on the binding	[effect on the binding]	1.5849625007211563	4	2	2	2
20424	1520	response to viral stimulus	[response to viral stimuli]	1.5849625007211563	4	1	0	0
20425	1520	human t-cell-leukemia virus type	[human T-cell-leukemia virus type]	1.5849625007211563	4	2	2	2
20426	1520	kappaB- Sp1 composite site	[kappaB- Sp1 composite site]	1.5849625007211563	4	1	0	0
20427	1520	lymphocyte in RA patient	[lymphocytes in RA patients]	1.5849625007211563	4	1	0	0
20428	1520	two splice alternative	[Two splice alternatives]	1.5849625007211563	3	1	0	0
20429	1520	corticosteroid receptor in lymphocyte	[Corticosteroid receptors in lymphocytes]	1.5849625007211563	4	2	1	1
20430	1520	human breast tumor	[human breast tumors]	1.5849625007211563	3	2	1	1
20431	1520	most YJ cell	[most YJ cells]	1.5849625007211563	3	1	0	0
20432	1520	same effect as gdsp	[same effects as GDSP]	1.5849625007211563	4	1	0	0
20433	1520	vitro tyrosine kinase activity	[vitro tyrosine kinase activity]	1.5849625007211563	4	1	0	0
20434	1520	library of human rdna	[library of human cDNAs]	1.5849625007211563	4	1	0	0
20435	1520	b lymphocyte-specific gene expression	[B lymphocyte-specific gene expression]	1.5849625007211563	4	1	0	0
20436	1520	only in lymphoid cell	[only in lymphoid cells]	1.5849625007211563	4	1	0	0
20437	1520	heterologous enhancer element	[heterologous enhancer elements]	1.5849625007211563	3	1	0	0
20438	1520	addition, expression of Fli-1	[addition, expression of Fli-1]	1.5849625007211563	4	1	0	0
20439	1520	induction of acid sphingomyelinase	[induction of acid sphingomyelinase]	1.5849625007211563	4	1	0	0
20440	1520	Irreversible terminal differentiation	[Irreversible terminal differentiation]	1.5849625007211563	3	1	0	0
20441	1520	CsA -resistant pathway	[CsA -resistant pathway]	1.5849625007211563	3	1	0	0
20442	1520	adult human tissue	[adult human tissues]	1.5849625007211563	3	1	0	0
20443	1520	inhibition of nfkappab activation	[inhibition of NFkappaB activation]	1.5849625007211563	4	1	0	0
20444	1520	modulation of mrna expression	[Modulation of mRNA expression]	1.5849625007211563	4	1	0	0
20445	1520	electrophoretic shift assay EMSA	[electrophoretic shift assay EMSA]	1.5849625007211563	4	1	0	0
20446	1520	1.8 kilobase (kb) fragment	[1.8 kilobase (kb) fragment]	1.5849625007211563	4	1	0	0
20447	1520	positive regulatory signal	[positive regulatory signals]	1.5849625007211563	3	1	0	0
20448	1520	motif of Bcl-3	[motifs of Bcl-3]	1.5849625007211563	3	1	0	0
20449	1520	phorbol myristake acetate-A23187 stimulation	[phorbol myristake acetate-A23187 stimulation]	1.5849625007211563	4	1	0	0
20450	1520	such as the uterus	[such as the uterus]	1.5849625007211563	4	2	1	1
20451	1520	diagnosis of t-pll	[diagnosis of T-PLL]	1.5849625007211563	3	1	0	0
20452	1520	ligand binding to c-Mpl	[ligand binding to c-Mpl]	1.5849625007211563	4	1	0	0
20453	1520	rat mammary carcinoma	[rat mammary carcinomas]	1.5849625007211563	3	2	2	2
20454	1520	presence of a flagellum	[presence of a flagellum]	1.5849625007211563	4	1	0	0
20455	1520	productive replication cycle	[productive replication cycle]	1.5849625007211563	3	1	0	0
20456	1520	TF kappa B-like site	[TF kappa B-like site]	1.5849625007211563	4	1	0	0
20457	1520	sequence of tbp7	[sequence of TBP7]	1.5849625007211563	3	1	0	0
20458	1520	sera of patient	[sera of patients]	1.5849625007211563	3	2	1	1
20459	1520	pathogenesis of allergic disease	[pathogenesis of allergic diseases]	1.5849625007211563	4	2	1	1
20460	1520	phorbol myristate acetate lymphocyte	[phorbol myristate acetate lymphocytes]	1.5849625007211563	4	1	0	0
20461	1520	micromolar concentration of HOCl	[micromolar concentrations of HOCl]	1.5849625007211563	4	1	0	0
20462	1520	result suggest the absence	[results suggesting the absence]	1.5849625007211563	4	1	0	0
20463	1520	binding of steroid	[binding of steroids]	1.5849625007211563	3	1	0	0
20464	1520	potentially autoreactive thymocyte	[potentially autoreactive thymocytes]	1.5849625007211563	3	1	0	0
20465	1520	viral evasion mechanism	[viral evasion mechanisms]	1.5849625007211563	3	1	0	0
20466	1520	fresh blood mononuclear cell	[fresh blood mononuclear cells]	1.5849625007211563	4	2	2	2
20467	1520	er in the monocyte	[ER in the monocytes]	1.5849625007211563	4	1	0	0
20468	1520	contrast to peptide vaccination	[contrast to peptide vaccination]	1.5849625007211563	4	1	0	0
20469	1520	human pro-interleukin 1beta	[human pro-interleukin 1beta]	1.5849625007211563	3	1	0	0
20470	1520	human TATA binding factor	[human TATA binding factor]	1.5849625007211563	4	1	0	0
20471	1520	dna-binding activity of nf-kappab	[DNA-binding activity of NF-kappaB]	1.5849625007211563	4	1	0	0
20472	1520	strong tcl1 protein expression	[strong TCL1 protein expression]	1.5849625007211563	4	1	0	0
20473	1520	patient with various diseases.	[patients with various diseases.]	1.5849625007211563	4	1	0	0
20474	1520	intracellular signal complex	[intracellular signaling complex]	1.5849625007211563	3	1	0	0
20475	1520	viral cellular gene	[viral cellular genes]	1.5849625007211563	3	1	0	0
20476	1520	detection of p50 homodimer	[detection of p50 homodimers]	1.5849625007211563	4	1	0	0
20477	1520	four CMPD1 translocation case	[four CMPD1 translocation cases]	1.5849625007211563	4	1	0	0
20478	1520	ca2+ protein phosphatase	[Ca2+ protein phosphatase]	1.5849625007211563	3	2	2	2
20479	1520	order nucleoprotein complex	[order nucleoprotein complex]	1.5849625007211563	3	2	2	2
20480	1520	fork head domain protein	[fork head domain protein]	1.5849625007211563	4	1	0	0
20481	1520	Ad12 E1A cell line	[Ad12 E1A cell lines]	1.5849625007211563	4	1	0	0
20482	1520	extreme evolutionary conservation.	[extreme evolutionary conservation.]	1.5849625007211563	3	1	0	0
20483	1520	apoptotic cell death program	[apoptotic cell death program]	1.5849625007211563	4	1	0	0
20484	1520	response of mammalian cell	[response of mammalian cells]	1.5849625007211563	4	1	0	0
20485	1520	lps -inducible response	[LPS -inducible responses]	1.5849625007211563	3	1	0	0
20486	1520	induction of egr-1 expression	[induction of EGR-1 expression]	1.5849625007211563	4	1	0	0
20487	1520	inhibitor of PKC	[inhibitor of PKC]	1.5849625007211563	3	2	2	2
20488	1520	microorganism into the body	[microorganisms into the body]	1.5849625007211563	4	1	0	0
20489	1520	Pancreatic islet expression study	[Pancreatic islet expression studies]	1.5849625007211563	4	1	0	0
20490	1520	tata-box binding protein	[TATA-box binding protein]	1.5849625007211563	3	2	1	1
20491	1520	ebv antigen by lymphocyte	[EBV antigens by lymphocytes]	1.5849625007211563	4	1	0	0
20492	1520	patient with rheumatic disease	[patients with rheumatic diseases]	1.5849625007211563	4	2	1	1
20493	1520	pilot study with Urapidil	[pilot study with Urapidil]	1.5849625007211563	4	1	0	0
20494	1520	predominance of p50 homodimer	[predominance of p50 homodimers]	1.5849625007211563	4	1	0	0
20495	1520	tgf-beta1 mrna synthesis	[TGF-beta1 mRNA synthesis]	1.5849625007211563	3	1	0	0
20496	1520	P- signal-transducing mechanism	[P- signal-transducing mechanism]	1.5849625007211563	3	1	0	0
20497	1520	number of lymphoblast	[number of lymphoblasts]	1.5849625007211563	3	1	0	0
20498	1520	cell with complement-opsonized particle	[cells with complement-opsonized particles]	1.5849625007211563	4	1	0	0
20499	1520	population of black people	[populations of black people]	1.5849625007211563	4	1	0	0
20500	1520	finding, transient co-transfection	[finding, transient co-transfection]	1.5849625007211563	3	1	0	0
20501	1520	target for oxidative signalling	[targets for oxidative signalling]	1.5849625007211563	4	2	1	1
20502	1520	NF-M chicken c/ebp beta	[NF-M chicken C/EBP beta]	1.5849625007211563	4	1	0	0
20503	1520	circulate filarial antigen-specific t-cell	[circulating filarial antigen-specific T-cells]	1.5849625007211563	4	1	0	0
20504	1520	vzv ie62 protein	[VZV IE62 protein]	1.5849625007211563	3	1	0	0
20505	1520	calcineurin -dependent signal	[calcineurin -dependent signaling]	1.5849625007211563	3	1	0	0
20506	1520	integrin cell adhesion	[integrin cell adhesion]	1.5849625007211563	3	2	2	2
20507	1520	T lymphocyte development coincident	[T lymphocyte development coincident]	1.5849625007211563	4	1	0	0
20508	1520	cytokine such as gm-csf	[cytokines such as GM-CSF]	1.5849625007211563	4	1	0	0
20509	1520	two male infant	[two male infants]	1.5849625007211563	3	1	0	0
20510	1520	patient with ptsd	[patients with PTSD]	1.5849625007211563	3	2	1	1
20511	1520	gm-csf receptor alpha subunit	[GM-CSF receptor alpha subunits]	1.5849625007211563	4	1	0	0
20512	1520	follow SE stimulation	[following SE stimulation]	1.5849625007211563	3	1	0	0
20513	1520	improvement in fev1 value	[improvement in FEV1 values]	1.5849625007211563	4	1	0	0
20514	1520	moderate level of ap-1	[moderate levels of AP-1]	1.5849625007211563	4	1	0	0
20515	1520	measurement of corticosteroid receptor	[measurement of corticosteroid receptors]	1.5849625007211563	4	1	0	0
20516	1520	premature stop codon	[premature stop codon]	1.5849625007211563	3	1	0	0
20517	1520	adenovirus e1b 19K protein	[Adenovirus E1B 19K protein]	1.5849625007211563	4	1	0	0
20518	1520	range of cell types.	[range of cell types.]	1.5849625007211563	4	2	1	1
20519	1520	predominantly inhibitory effect	[predominantly inhibitory effect]	1.5849625007211563	3	1	0	0
20520	1520	anti-cd3 mAb-stimulated T cell	[anti-CD3 mAb-stimulated T cells]	1.5849625007211563	4	1	0	0
20521	1520	family of transcriptional activator	[family of transcriptional activators]	1.5849625007211563	4	1	0	0
20522	1520	treatment with As2O3	[treatment with As2O3]	1.5849625007211563	3	1	0	0
20523	1520	prolactin receptor signal transduction	[prolactin receptor signal transduction]	1.5849625007211563	4	1	0	0
20524	1520	certain subclone of thp-1	[certain subclones of THP-1]	1.5849625007211563	4	1	0	0
20525	1520	hormone/receptor complex of nuclei	[hormone/receptor complexes of nuclei]	1.5849625007211563	4	1	0	0
20526	1520	suppression by azelastine hydrochloride	[Suppression by azelastine hydrochloride]	1.5849625007211563	4	1	0	0
20527	1520	repression of cp activity	[Repression of Cp activity]	1.5849625007211563	4	1	0	0
20528	1520	transrepressive effect of glucocorticoid	[transrepressive effect of glucocorticoids]	1.5849625007211563	4	1	0	0
20529	1520	lymphoid progenitor cell	[lymphoid progenitor cells]	1.5849625007211563	3	2	1	1
20530	1520	cooperation of transcription factor	[cooperation of transcription factors]	1.5849625007211563	4	2	2	2
20531	1520	expression of other	[expression of others]	1.5849625007211563	3	1	0	0
20532	1520	sulfhydryl agent dithiothreitol	[sulfhydryl agent dithiothreitol]	1.5849625007211563	3	1	0	0
20533	1520	previously unrecognized binding site	[previously unrecognized binding site]	1.5849625007211563	4	1	0	0
20534	1520	PhoP -PhoQ regulon	[PhoP -PhoQ regulon]	1.5849625007211563	3	1	0	0
20535	1520	dominantly negative fashion,	[dominantly negative fashion,]	1.5849625007211563	3	1	0	0
20536	1520	positive c-fo expression	[positive c-fos expression]	1.5849625007211563	3	1	0	0
20537	1520	presence of p21(ras)	[presence of p21(ras)]	1.5849625007211563	3	1	0	0
20538	1520	function of cis-acting element	[function of cis-acting elements]	1.5849625007211563	4	1	0	0
20539	1520	cd3/t-cell antigen receptor tcr	[CD3/T-cell antigen receptor TCR]	1.5849625007211563	4	1	0	0
20540	1520	vivo chronic response,	[vivo chronic response,]	1.5849625007211563	3	1	0	0
20541	1520	fas pfa ligand	[Fas /Fas ligand]	1.5849625007211563	3	1	0	0
20542	1520	hindrance of p65 phosphorylation	[hindrance of p65 phosphorylation]	1.5849625007211563	4	1	0	0
20543	1520	cytotoxic T lymphocyte CTL	[cytotoxic T lymphocytes CTL]	1.5849625007211563	4	1	0	0
20544	1520	IL2R alpha expression	[IL2R alpha expression]	1.5849625007211563	3	1	0	0
20545	1520	proliferator-activated receptor gamma ppargamma	[proliferator-activated receptor gamma PPARgamma]	1.5849625007211563	4	2	2	2
20546	1520	effect of nsaid	[effects of NSAIDs]	1.5849625007211563	3	1	0	0
20547	1520	early replication of gene	[early replication of genes]	1.5849625007211563	4	1	0	0
20548	1520	expression of ebf	[expression of EBF]	1.5849625007211563	3	2	2	2
20549	1520	discrepancy in the degree	[discrepancy in the degree]	1.5849625007211563	4	1	0	0
20550	1520	physiologic mechanism control reactvation	[physiologic mechanisms controlling reactvation]	1.5849625007211563	4	1	0	0
20551	1520	use this assay system	[Using this assay system]	1.5849625007211563	4	1	0	0
20552	1520	phosphorylation of IkappaBalpha	[phosphorylation of IkappaBalpha]	1.5849625007211563	3	2	2	2
20553	1520	cDNA encoding ptf beta	[cDNA encoding PTF beta]	1.5849625007211563	4	1	0	0
20554	1520	human umbilical vein ec	[human umbilical vein EC]	1.5849625007211563	4	1	0	0
20555	1520	maximal oxygen uptake)	[maximal oxygen uptake)]	1.5849625007211563	3	1	0	0
20556	1520	low dose of lps	[low dose of LPS]	1.5849625007211563	4	2	1	1
20557	1520	subsequent synthesis of galectin-3	[subsequent synthesis of galectin-3]	1.5849625007211563	4	1	0	0
20558	1520	differentiation with phorbol ester	[differentiation with phorbol ester]	1.5849625007211563	4	1	0	0
20559	1520	effect of ethanol	[effects of ethanol]	1.5849625007211563	3	1	0	0
20560	1520	gata/er chimeric factor	[GATA/ER chimeric factors]	1.5849625007211563	3	1	0	0
20561	1520	source for ROI	[sources for ROIs]	1.5849625007211563	3	1	0	0
20562	1520	modulation of the expression	[Modulation of the expression]	1.5849625007211563	4	1	0	0
20563	1520	phenotypic conversion of group	[phenotypic conversion of group]	1.5849625007211563	4	1	0	0
20564	1520	exposure to IL-2	[exposure to IL-2]	1.5849625007211563	3	1	0	0
20565	1520	latter three protein	[latter three proteins]	1.5849625007211563	3	1	0	0
20566	1520	AP-2 site mutation	[AP-2 site mutation]	1.5849625007211563	3	1	0	0
20567	1520	three zinc-finger gene	[three zinc-finger genes]	1.5849625007211563	3	1	0	0
20568	1520	T cell responses,	[T cell responses,]	1.5849625007211563	3	1	0	0
20569	1520	processing in T cell	[processing in T cells]	1.5849625007211563	4	1	0	0
20570	1520	low level of cd45	[lower levels of CD45]	1.5849625007211563	4	1	0	0
20571	1520	human mononuclear leukocyte MNL	[human mononuclear leukocytes MNL]	1.5849625007211563	4	1	0	0
20572	1520	epo factor gm-csf	[EPO factor GM-CSF]	1.5849625007211563	3	2	2	2
20573	1520	age of 20-30 year	[age of 20-30 yr]	1.5849625007211563	4	1	0	0
20574	1520	french-american-british acute myeloid leukemia-M3	[French-American-British acute myeloid leukemia-M3]	1.5849625007211563	4	1	0	0
20575	1520	nuclear transcription factor-kappa b	[nuclear transcription factor-kappa B]	1.5849625007211563	4	1	0	0
20576	1520	great selectivity of pf	[greater selectivity of PF]	1.5849625007211563	4	1	0	0
20577	1520	differentiate thp-1 cell	[differentiating THP-1 cells]	1.5849625007211563	3	1	0	0
20578	1520	production of other cytokine	[production of other cytokines]	1.5849625007211563	4	2	1	1
20579	1520	expression of p21(ras)	[expression of p21(ras)]	1.5849625007211563	3	1	0	0
20580	1520	role of b activation	[role of B activation]	1.5849625007211563	4	1	0	0
20581	1520	drosophila toll protein Toll	[Drosophila toll protein Toll]	1.5849625007211563	4	1	0	0
20582	1520	inhibitory, "dominant-negative," form	[inhibitory, "dominant-negative," form]	1.5849625007211563	3	1	0	0
20583	1520	western blot analysis, immunostaining,	[Western blot analysis, immunostaining,]	1.5849625007211563	4	1	0	0
20584	1520	D3 VDR RAR alpha	[D3 VDR RAR alpha]	1.5849625007211563	4	1	0	0
20585	1520	AML1a k562 cell	[AML1a K562 cells]	1.5849625007211563	3	1	0	0
20586	1520	level of induction.	[level of induction.]	1.5849625007211563	3	1	0	0
20587	1520	stimulation of c-jun	[stimulation of c-jun]	1.5849625007211563	3	2	2	2
20588	1520	presence of es reticulocyte	[presence of ES reticulocytes]	1.5849625007211563	4	1	0	0
20589	1520	3 kb upstream,	[3 kb upstream,]	1.5849625007211563	3	1	0	0
20590	1520	lck gene product	[lck gene product]	1.5849625007211563	3	1	0	0
20591	1520	E(gre) -binding protein complex	[E(gre) -binding protein complexes]	1.5849625007211563	4	1	0	0
20592	1520	Erythroid colony growth	[Erythroid colony growth]	1.5849625007211563	3	1	0	0
20593	1520	etiology of celiac disease	[etiology of celiac disease]	1.5849625007211563	4	1	0	0
20594	1520	physiological regulation of cytokine	[physiological regulation of cytokines]	1.5849625007211563	4	1	0	0
20595	1520	RpoN sigma factor	[RpoN sigma factor]	1.5849625007211563	3	1	0	0
20596	1520	binding-protein 2 pebp2	[binding-protein 2 PEBP2]	1.5849625007211563	3	1	0	0
20597	1520	normal profile of p16	[normal profile of p16]	1.5849625007211563	4	1	0	0
20598	1520	CD40 ligand CD40L	[CD40 ligand CD40L]	1.5849625007211563	3	1	0	0
20599	1520	subcellular distribution (cytoplasmic	[subcellular distribution (cytoplasmic]	1.5849625007211563	3	1	0	0
20600	1520	hiv-1 enhancer t-cell stimulation	[HIV-1 enhancer T-cell stimulation]	1.5849625007211563	4	1	0	0
20601	1520	protein kinase calpha pkcalpha	[protein kinase Calpha PKCalpha]	1.5849625007211563	4	1	0	0
20602	1520	approximately 2000-3000 sites/cell,	[approximately 2000-3000 sites/cell,]	1.5849625007211563	3	1	0	0
20603	1520	several E2F site	[several E2F sites]	1.5849625007211563	3	1	0	0
20604	1520	product expression by eosinophil	[product expression by eosinophils]	1.5849625007211563	4	1	0	0
20605	1520	ductal breast carcinoma	[ductal breast carcinoma]	1.5849625007211563	3	1	0	0
20606	1520	regulation of cellular response	[regulation of cellular responses]	1.5849625007211563	4	1	0	0
20607	1520	association of dioxin receptor	[association of dioxin receptor]	1.5849625007211563	4	1	0	0
20608	1520	effect as a regulator,	[effects as a regulator,]	1.5849625007211563	4	1	0	0
20609	1520	15 patient in ST	[15 patients in ST]	1.5849625007211563	4	1	0	0
20610	1520	intracellular signal-transduce protein stat6	[intracellular signal-transducing protein Stat6]	1.5849625007211563	4	1	0	0
20611	1520	NF-kappa b -responsive complex	[NF-kappa B -responsive complex]	1.5849625007211563	4	1	0	0
20612	1520	age-related immune deficiency	[age-related immune deficiency]	1.5849625007211563	3	1	0	0
20613	1520	clonality in lesional tissue	[clonality in lesional tissue]	1.5849625007211563	4	1	0	0
20614	1520	STAT-1 signal pathway	[STAT-1 signaling pathway]	1.5849625007211563	3	1	0	0
20615	1520	role in lymphocyte maturation	[role in lymphocyte maturation]	1.5849625007211563	4	1	0	0
20616	1520	complete remission CR	[complete remission CR]	1.5849625007211563	3	1	0	0
20617	1520	cd16 ligand binding	[CD16 ligand binding]	1.5849625007211563	3	2	1	1
20618	1520	other putative regulatory site	[other putative regulatory sites]	1.5849625007211563	4	1	0	0
20619	1520	cell overexpress Bcl-2	[cells overexpressing Bcl-2]	1.5849625007211563	3	1	0	0
20620	1520	quiescent cd4(+) T cell	[quiescent CD4(+) T cells]	1.5849625007211563	4	1	0	0
20621	1520	uninfected t-cell line	[uninfected T-cell line]	1.5849625007211563	3	1	0	0
20622	1520	mature myelomonocytic cell lines.	[mature myelomonocytic cell lines.]	1.5849625007211563	4	1	0	0
20623	1520	high salt concentration	[high salt concentrations]	1.5849625007211563	3	2	1	1
20624	1520	il-1 receptor-associated protein kinase	[IL-1 receptor-associated protein kinase]	1.5849625007211563	4	1	0	0
20625	1520	feature of RA resistance	[features of RA resistance]	1.5849625007211563	4	1	0	0
20626	1520	DEX (1.0 mg orally)	[DEX (1.0 mg orally)]	1.5849625007211563	4	1	0	0
20627	1520	NFeB p65 rel-a	[NFeB p65 Rel-A]	1.5849625007211563	3	1	0	0
20628	1520	moreover, integrin -ligand interaction	[Moreover, integrin -ligand interactions]	1.5849625007211563	4	1	0	0
20629	1520	NF-AT/AP-1 transcription factor	[NF-AT/AP-1 transcription factor]	1.5849625007211563	3	1	0	0
20630	1520	Fc epsilon ri-gamma chain	[Fc epsilon RI-gamma chains]	1.5849625007211563	4	1	0	0
20631	1520	Finally, GATA-1 protein level	[Finally, GATA-1 protein level]	1.5849625007211563	4	1	0	0
20632	1520	early lytic cycle	[early lytic cycle]	1.5849625007211563	3	1	0	0
20633	1520	type of donors,	[types of donors,]	1.5849625007211563	3	1	0	0
20634	1520	human CIITA gene	[human CIITA gene]	1.5849625007211563	3	1	0	0
20635	1520	EBNA-1 gene in thymocyte	[EBNA-1 gene in thymocytes]	1.5849625007211563	4	1	0	0
20636	1520	contact with protein	[contact with proteins]	1.5849625007211563	3	1	0	0
20637	1520	difference in conformation	[Differences in conformation]	1.5849625007211563	3	1	0	0
20638	1520	child with bronchial asthma	[children with bronchial asthma]	1.5849625007211563	4	1	0	0
20639	1520	effect on the half-life	[effect on the half-life]	1.5849625007211563	4	1	0	0
20640	1520	immunoglobulin gene in b-lymphocyte	[immunoglobulin genes in B-lymphocytes]	1.5849625007211563	4	1	0	0
20641	1520	specific protein interaction	[specific protein interactions]	1.5849625007211563	3	2	2	2
20642	1520	ag-pulsed accessory cell	[Ag-pulsed accessory cells]	1.5849625007211563	3	1	0	0
20643	1520	possibly T cell	[possibly T cells]	1.5849625007211563	3	1	0	0
20644	1520	reverse transcription pcr assay	[reverse transcription PCR assay]	1.5849625007211563	4	1	0	0
20645	1520	x box region	[X box region]	1.5849625007211563	3	2	1	1
20646	1520	estrogen replacement therapy	[estrogen replacement therapy]	1.5849625007211563	3	2	1	1
20647	1520	remote enhancer position	[remote enhancer position]	1.5849625007211563	3	1	0	0
20648	1520	EB1 -binding site zre-b	[EB1 -binding site ZRE-B]	1.5849625007211563	4	1	0	0
20649	1520	tegument protein vp22	[tegument protein VP22]	1.5849625007211563	3	1	0	0
20650	1520	efficacy of il-10	[efficacy of IL-10]	1.5849625007211563	3	1	0	0
20651	1520	result in the degradation	[resulting in the degradation]	1.5849625007211563	4	1	0	0
20652	1520	promote tumor progression	[promoting tumor progression]	1.5849625007211563	3	1	0	0
20653	1520	relation to future prognosis	[relation to future prognosis]	1.5849625007211563	4	1	0	0
20654	1520	igh enhancer regulation	[IgH enhancer regulation]	1.5849625007211563	3	1	0	0
20655	1520	activity of leukocyte	[activity of leukocytes]	1.5849625007211563	3	1	0	0
20656	1520	neutrophil by bacterial lps	[neutrophils by bacterial LPS]	1.5849625007211563	4	1	0	0
20657	1520	disease-free survival of month	[disease-free survival of months]	1.5849625007211563	4	2	2	2
20658	1520	macrophage- pu.1 transcription factor	[macrophage- PU.1 transcription factor]	1.5849625007211563	4	1	0	0
20659	1520	select for cell	[selecting for cells]	1.5849625007211563	3	1	0	0
20660	1520	octamer DNA sequence	[octamer DNA sequence]	1.5849625007211563	3	1	0	0
20661	1520	band-shift assay indistinguishable	[band-shift assay indistinguishable]	1.5849625007211563	3	1	0	0
20662	1520	new CMPD1 /sra1 patient	[new CMPD1 /SRA1 patient]	1.5849625007211563	4	1	0	0
20663	1520	stimulation with natural ligand	[stimulation with natural ligand]	1.5849625007211563	4	1	0	0
20664	1520	VDR interact proteins: RXR	[VDR interacting proteins: RXR]	1.5849625007211563	4	1	0	0
20665	1520	so-called AU-rich element AREs	[so-called AU-rich elements AREs]	1.5849625007211563	4	1	0	0
20666	1520	A6H monoclonal antibody (mAb)	[A6H monoclonal antibody (mAb)]	1.5849625007211563	4	1	0	0
20667	1520	ketoconazole in Cushing' disease	[ketoconazole in Cushing's disease]	1.5849625007211563	4	1	0	0
20668	1520	role of this tissue	[role of these tissues]	1.5849625007211563	4	1	0	0
20669	1520	expression of egr-1	[expression of Egr-1]	1.5849625007211563	3	1	0	0
20670	1520	express antisense egr-1 rna	[expressing antisense Egr-1 RNA]	1.5849625007211563	4	1	0	0
20671	1520	expression of egr-2	[expression of egr-2]	1.5849625007211563	3	1	0	0
20672	1520	increase in p53 level	[increase in p53 levels]	1.5849625007211563	4	1	0	0
20673	1520	past few years,	[past few years,]	1.5849625007211563	3	1	0	0
20674	1520	NF kappa B/Rel family	[NF kappa B/Rel family]	1.5849625007211563	4	1	0	0
20675	1520	vitro transformation with ebv	[vitro transformation with EBV]	1.5849625007211563	4	1	0	0
20676	1520	two nf-at complex	[two NF-AT complexes]	1.5849625007211563	3	2	2	2
20677	1520	role in transcriptional activation	[role in transcriptional activation]	1.5849625007211563	4	2	1	1
20678	1520	VZV gE-HSV TK	[VZV gE-HSV TK]	1.5849625007211563	3	1	0	0
20679	1520	>50% of total rap1	[>50% of total Rap1]	1.5849625007211563	4	1	0	0
20680	1520	nf-kappa b /ap-1	[NF-kappa B /AP-1]	1.5849625007211563	3	1	0	0
20681	1520	il-4 b-cell activation	[IL-4 B-cell activation]	1.5849625007211563	3	1	0	0
20682	1520	vivo footprint analysis	[vivo footprint analysis]	1.5849625007211563	3	2	1	1
20683	1520	secretion of IL-1beta	[secretion of IL-1beta]	1.5849625007211563	3	1	0	0
20684	1520	form of hsp27	[forms of HSP27]	1.5849625007211563	3	2	1	1
20685	1520	CD2 receptor signalling	[CD2 receptor signalling]	1.5849625007211563	3	1	0	0
20686	1520	increase in the effect	[increase in the effect]	1.5849625007211563	4	1	0	0
20687	1520	(chi2=6.25, 1 df, p=.01)	[(chi2=6.25, 1 df, P=.01)]	1.5849625007211563	4	1	0	0
20688	1520	bound tripartite complex	[bound tripartite complex]	1.5849625007211563	3	1	0	0
20689	1520	107 amino-acid protein p13mtcp1	[107 amino-acid protein p13MTCP1]	1.5849625007211563	4	1	0	0
20690	1520	induction of tax expression	[induction of Tax expression]	1.5849625007211563	4	1	0	0
20691	1520	episomal maintenance without integration	[episomal maintenance without integration]	1.5849625007211563	4	1	0	0
20692	1520	potentiation of platelet aggregation	[potentiation of platelet aggregation]	1.5849625007211563	4	1	0	0
20693	1520	signal transduction element	[signal transduction elements]	1.5849625007211563	3	2	2	2
20694	1520	co-transfect the Trx-expressing plasmid	[co-transfecting the Trx-expressing plasmid]	1.5849625007211563	4	1	0	0
20695	1520	transcription factor factor (nf)-kappab	[transcription factor factor (NF)-kappaB]	1.5849625007211563	4	1	0	0
20696	1520	ongoing immune response	[ongoing immune response]	1.5849625007211563	3	2	1	1
20697	1520	cellular response to injury.	[cellular response to injury.]	1.5849625007211563	4	1	0	0
20698	1520	ionomycin-evoked ca2+ release	[ionomycin-evoked Ca2+ release]	1.5849625007211563	3	1	0	0
20699	1520	multiple USA component	[multiple USA components]	1.5849625007211563	3	1	0	0
20700	1520	dexamethasone on il-10 secretion	[dexamethasone on IL-10 secretion]	1.5849625007211563	4	1	0	0
20701	1520	activity on T cell	[activities on T cells]	1.5849625007211563	4	2	2	2
20702	1520	native IFN-gamma locus	[native IFN-gamma locus]	1.5849625007211563	3	1	0	0
20703	1520	1.6 0.35 nm	[1.6 0.35 nM]	1.5849625007211563	3	1	0	0
20704	1520	synthetic lipid a	[synthetic lipid A]	1.5849625007211563	3	1	0	0
20705	1520	activation of rel/stat complex	[activation of Rel/STAT complexes]	1.5849625007211563	4	1	0	0
20706	1520	AP1 transcriptional regulator	[AP1 transcriptional regulator]	1.5849625007211563	3	1	0	0
20707	1520	spite of the difference	[spite of the difference]	1.5849625007211563	4	1	0	0
20708	1520	glucocorticoid in vitro	[glucocorticoids in vitro]	1.5849625007211563	3	1	0	0
20709	1520	phosphorylation of IkB alpha	[phosphorylation of IkB alpha]	1.5849625007211563	4	1	0	0
20710	1520	wild-type par protein	[wild-type PAR proteins]	1.5849625007211563	3	1	0	0
20711	1520	expression of cd45ra	[expression of CD45RA]	1.5849625007211563	3	1	0	0
20712	1520	influence of the mesenchyme	[influence of the mesenchyme]	1.5849625007211563	4	1	0	0
20713	1520	infection of monocyte	[Infection of monocytes]	1.5849625007211563	3	2	1	1
20714	1520	cell membrane phospholipid	[cell membrane phospholipids]	1.5849625007211563	3	1	0	0
20715	1520	human basal brain	[human basal brain]	1.5849625007211563	3	1	0	0
20716	1520	60-kDa protein binding	[60-kDa protein binding]	1.5849625007211563	3	1	0	0
20717	1520	activation-induced fas expression	[activation-induced Fas expression]	1.5849625007211563	3	1	0	0
20718	1520	dexamethasone (apparent kd, 5.9	[dexamethasone (apparent Kd, 5.9]	1.5849625007211563	4	1	0	0
20719	1520	genuine nf-e2 complex	[genuine NF-E2 complex]	1.5849625007211563	3	1	0	0
20720	1520	135(oh)2d3 overproduction in granulomato	[1,25(OH)2D3 overproduction in granulomatoses]	1.5849625007211563	4	1	0	0
20721	1520	approximately 1.5 time	[approximately 1.5 times]	1.5849625007211563	3	1	0	0
20722	1520	biallelic mode of transcription	[biallelic mode of transcription]	1.5849625007211563	4	1	0	0
20723	1520	concentration range of microm	[concentration range of microM]	1.5849625007211563	4	1	0	0
20724	1520	viability and/or proliferation.	[viability and/or proliferation.]	1.5849625007211563	3	1	0	0
20725	1520	age-related decline in induction	[age-related decline in induction]	1.5849625007211563	4	1	0	0
20726	1520	tyrosine phosphorylation by src	[tyrosine phosphorylation by src]	1.5849625007211563	4	1	0	0
20727	1520	concentration of c-fo	[concentration of c-fos]	1.5849625007211563	3	1	0	0
20728	1520	less extent, stat1	[lesser extent, Stat1]	1.5849625007211563	3	1	0	0
20729	1520	laminar flow (1.5	[laminar flow (1.5]	1.5849625007211563	3	1	0	0
20730	1520	mobilization of factor-kappaB	[Mobilization of factor-kappaB]	1.5849625007211563	3	2	2	2
20731	1520	same cell line	[same cell lines]	1.5849625007211563	3	1	0	0
20732	1520	contain the M47 mutation	[containing the M47 mutation]	1.5849625007211563	4	1	0	0
20733	1520	potential regulatory role	[potential regulatory role]	1.5849625007211563	3	1	0	0
20734	1520	21-base-pair (bp) core element	[21-base-pair (bp) core element]	1.5849625007211563	4	1	0	0
20735	1520	activity of Oct-1	[activity of Oct-1]	1.5849625007211563	3	1	0	0
20736	1520	il-12r beta 2 expression	[IL-12R beta 2 expression]	1.5849625007211563	4	1	0	0
20737	1520	human swi2 protein	[human SWI2 protein]	1.5849625007211563	3	1	0	0
20738	1520	HS-40 enhancer activity	[HS-40 enhancer activity]	1.5849625007211563	3	1	0	0
20739	1520	rapidak protein synthesis-independent appearance	[rapid, protein synthesis-independent appearance]	1.5849625007211563	4	1	0	0
20740	1520	balance between the activity	[balance between the activities]	1.5849625007211563	4	1	0	0
20741	1520	structure of this promoter	[structure of this promoter]	1.5849625007211563	4	1	0	0
20742	1520	several cell adhesion molecule	[several cell adhesion molecules]	1.5849625007211563	4	1	0	0
20743	1520	lps control cell	[LPS control cells]	1.5849625007211563	3	1	0	0
20744	1520	potential transcriptional regulator	[potential transcriptional regulators]	1.5849625007211563	3	1	0	0
20745	1520	c-fo protein expression	[c-Fos protein expression]	1.5849625007211563	3	2	1	1
20746	1520	9 young rat	[9 young rats]	1.5849625007211563	3	1	0	0
20747	1520	family of transcription-regulategulate protein	[family of transcription-regulating proteins]	1.5849625007211563	4	1	0	0
20748	1520	elevation of c-reactive protein	[elevation of C-reactive protein]	1.5849625007211563	4	1	0	0
20749	1520	mutant ap-1 element	[mutant AP-1 element]	1.5849625007211563	3	1	0	0
20750	1520	early b-cell progenitor	[early B-cell progenitors]	1.5849625007211563	3	1	0	0
20751	1520	969-base pair (bp) fragment	[969-base pair (bp) fragment]	1.5849625007211563	4	1	0	0
20752	1520	genesis of myelodysplasia	[genesis of myelodysplasia]	1.5849625007211563	3	1	0	0
20753	1520	total cell lysate	[total cell lysates]	1.5849625007211563	3	1	0	0
20754	1520	B-cell stimulatory factor	[B-cell stimulatory factor]	1.5849625007211563	3	1	0	0
20755	1520	index of DNA synthesis.	[index of DNA synthesis.]	1.5849625007211563	4	1	0	0
20756	1520	deletion of the allele	[deletion of the allele]	1.5849625007211563	4	2	1	1
20757	1520	expression of differentiation marker	[expression of differentiation markers]	1.5849625007211563	4	2	1	1
20758	1520	receptor of interleukin-2 il-2	[receptors of interleukin-2 IL-2]	1.5849625007211563	4	1	0	0
20759	1520	cross-link the ig receptor	[cross-linking the Ig receptor]	1.5849625007211563	4	1	0	0
20760	1520	t3 /100 microgram dna).	[T3 /100 micrograms DNA).]	1.5849625007211563	4	1	0	0
20761	1520	human primary T	[human primary T]	1.5849625007211563	3	1	0	0
20762	1520	mouse MHC class	[mouse MHC class]	1.5849625007211563	3	2	1	1
20763	1520	InterleUkin 2 expression	[InterleUkin 2 expression]	1.5849625007211563	3	1	0	0
20764	1520	nuclear translocation signal	[nuclear translocation signals]	1.5849625007211563	3	1	0	0
20765	1520	Importantly, jagged1 transcript	[Importantly, jagged1 transcripts]	1.5849625007211563	3	1	0	0
20766	1520	stat3 phosphorylation in cell	[Stat3 phosphorylation in cells]	1.5849625007211563	4	1	0	0
20767	1520	hla-dq -specific immune response	[HLA-DQ -specific immune response]	1.5849625007211563	4	1	0	0
20768	1520	signal from patient	[signalling from patients]	1.5849625007211563	3	2	2	2
20769	1520	coordination of cell proliferation	[coordination of cell proliferation]	1.5849625007211563	4	1	0	0
20770	1520	induction of stat activity	[induction of STAT activity]	1.5849625007211563	4	1	0	0
20771	1520	monocyte tissue factor activation	[monocyte tissue factor activation]	1.5849625007211563	4	1	0	0
20772	1520	primary reservoir of infection	[primary reservoir of infection]	1.5849625007211563	4	1	0	0
20773	1520	number of cytokine gene	[number of cytokine genes]	1.5849625007211563	4	1	0	0
20774	1520	contrary, other steroid hormone	[contrary, other steroid hormones]	1.5849625007211563	4	1	0	0
20775	1520	mid-age hypertensive patient	[mid-age hypertensive patients]	1.5849625007211563	3	1	0	0
20776	1520	import of nf-kappa b	[import of NF-kappa B]	1.5849625007211563	4	2	2	2
20777	1520	two activation domain	[two activation domains]	1.5849625007211563	3	2	2	2
20778	1520	cellular tyrosine hydroxylase gene	[cellular tyrosine hydroxylase gene]	1.5849625007211563	4	1	0	0
20779	1520	such as failure	[such as failure]	1.5849625007211563	3	1	0	0
20780	1520	increase of er level	[increase of ER levels]	1.5849625007211563	4	1	0	0
20781	1520	kappa b-like site 5'-cggagtttcc-3'	[kappa B-like site 5'-CGGAGTTTCC-3']	1.5849625007211563	4	1	0	0
20782	1520	physiologically relevant concentration	[physiologically relevant concentrations]	1.5849625007211563	3	2	2	2
20783	1520	12 normal woman	[12 normal women]	1.5849625007211563	3	2	2	2
20784	1520	C5a interleukin-8 gene expression	[C5a interleukin-8 gene expression]	1.5849625007211563	4	1	0	0
20785	1520	soluble tat protein	[soluble Tat protein]	1.5849625007211563	3	1	0	0
20786	1520	regulatory tat protein	[regulatory Tat protein]	1.5849625007211563	3	1	0	0
20787	1520	expression in blood lymphocyte	[Expression in blood lymphocytes]	1.5849625007211563	4	2	2	2
20788	1520	1 gene product	[1 gene product]	1.5849625007211563	3	2	2	2
20789	1520	agent, beta- estradiol	[agent, beta- estradiol]	1.5849625007211563	3	1	0	0
20790	1520	monocytic camp level	[monocytic cAMP levels]	1.5849625007211563	3	1	0	0
20791	1520	autosomal dominant neurocutaneous disorder	[autosomal dominant neurocutaneous disorder]	1.5849625007211563	4	1	0	0
20792	1520	approximately 2100 binding sites/nucleus	[approximately 2100 binding sites/nucleus]	1.5849625007211563	4	1	0	0
20793	1520	peripheral blood sample	[peripheral blood samples]	1.5849625007211563	3	2	2	2
20794	1520	such as ip-10	[such as IP-10]	1.5849625007211563	3	1	0	0
20795	1520	isolation of murine fra-1	[Isolation of murine fra-1]	1.5849625007211563	4	1	0	0
20796	1520	Oct-2 mrna level	[Oct-2 mRNA levels]	1.5849625007211563	3	1	0	0
20797	1520	finally, soluble CD4 scd4	[Finally, soluble CD4 sCD4]	1.5849625007211563	4	1	0	0
20798	1520	low serum condition	[low serum conditions]	1.5849625007211563	3	1	0	0
20799	1520	inhibitory effect of DZA	[inhibitory effect of DZA]	1.5849625007211563	4	1	0	0
20800	1520	T cell in patient	[T cells in patients]	1.5849625007211563	4	2	2	2
20801	1520	cell receptor alpha	[cell receptor alpha]	1.5849625007211563	3	1	0	0
20802	1520	kinase inhibitor h7	[kinase inhibitor H7]	1.5849625007211563	3	1	0	0
20803	1520	cooperation with E1A	[cooperation with E1A]	1.5849625007211563	3	1	0	0
20804	1520	kd value of microm	[Kd value of microM]	1.5849625007211563	4	1	0	0
20805	1520	receptor in peripheral lymphocyte	[receptors in peripheral lymphocytes]	1.5849625007211563	4	2	2	2
20806	1520	50% effective concentration	[50% effective concentrations]	1.5849625007211563	3	1	0	0
20807	1520	antigen-presenting cell APC	[antigen-presenting cells APC]	1.5849625007211563	3	1	0	0
20808	1520	inhibition of IFN -MCP	[inhibition of IFN -MCP]	1.5849625007211563	4	1	0	0
20809	1520	species despite the functions.	[species despite the functions.]	1.5849625007211563	4	1	0	0
20810	1520	arrangement of binding site	[arrangement of binding sites]	1.5849625007211563	4	2	2	2
20811	1520	pattern of distribution	[pattern of distribution]	1.5849625007211563	3	1	0	0
20812	1520	disruption of one	[disruption of one]	1.5849625007211563	3	1	0	0
20813	1520	possibly other lymphoid organ	[possibly other lymphoid organs]	1.5849625007211563	4	1	0	0
20814	1520	ability of E2A-HLF	[ability of E2A-HLF]	1.5849625007211563	3	1	0	0
20815	1520	vitro responsiveness to glucocorticoid	[vitro responsiveness to glucocorticoids]	1.5849625007211563	4	1	0	0
20816	1520	critical role in inflammation	[critical role in inflammation]	1.5849625007211563	4	1	0	0
20817	1520	constitutive nf-kappab -binding activity	[constitutive NF-kappaB -binding activity]	1.5849625007211563	4	1	0	0
20818	1520	lead to transcriptional repression	[leading to transcriptional repression]	1.5849625007211563	4	1	0	0
20819	1520	human c/ebp epsilon	[Human C/EBP epsilon]	1.5849625007211563	3	1	0	0
20820	1520	inhibitor of ptpase	[inhibitor of PTPase]	1.5849625007211563	3	2	2	2
20821	1520	overall increase in transcription	[overall increase in transcription]	1.5849625007211563	4	1	0	0
20822	1520	lps dose-dependent fashion	[LPS dose-dependent fashion]	1.5849625007211563	3	1	0	0
20823	1520	recombinant kappa B-alpha( mad-3	[Recombinant kappa B-alpha( MAD-3]	1.5849625007211563	4	1	0	0
20824	1520	b6d2f1 mouse uterine cytosol	[B6D2F1 mouse uterine cytosol]	1.5849625007211563	4	1	0	0
20825	1520	lat -contain signal complex	[LAT -containing signaling complex]	1.5849625007211563	4	1	0	0
20826	1520	Furthermore, ethanol a inhibitor	[Furthermore, ethanol an inhibitor]	1.5849625007211563	4	1	0	0
20827	1520	target site specificity,	[target site specificity,]	1.5849625007211563	3	1	0	0
20828	1520	presence of il-10 receptor	[presence of IL-10 receptors]	1.5849625007211563	4	1	0	0
20829	1520	full-length, Jun/Fos heterodimer	[full-length, Jun/Fos heterodimers]	1.5849625007211563	3	1	0	0
20830	1520	TRAF3 signal transduction pathway	[TRAF3 signal transduction pathway]	1.5849625007211563	4	1	0	0
20831	1520	germline c epsilon transcription	[germline C epsilon transcription]	1.5849625007211563	4	1	0	0
20832	1520	follow culture with atra	[Following culture with ATRA]	1.5849625007211563	4	1	0	0
20833	1520	myelopathy/tropical spastic paraparesis	[myelopathy/tropical spastic paraparesis]	1.5849625007211563	3	1	0	0
20834	1520	lack the 19-bp site	[lacking the 19-bp site]	1.5849625007211563	4	1	0	0
20835	1520	IL-2 receptor signal transduction	[IL-2 receptor signal transduction]	1.5849625007211563	4	1	0	0
20836	1520	notch receptor protein	[Notch receptor protein]	1.5849625007211563	3	1	0	0
20837	1520	accumulation of effector cell	[accumulation of effector cells]	1.5849625007211563	4	1	0	0
20838	1520	lymphoid-specific oct2b protein	[lymphoid-specific Oct2B protein]	1.5849625007211563	3	1	0	0
20839	1520	child with hormone deficiency	[children with hormone deficiency]	1.5849625007211563	4	2	2	2
20840	1520	cd4(+) human T cell	[CD4(+) human T cells]	1.5849625007211563	4	1	0	0
20841	1520	cytoplasmic cellular extract	[cytoplasmic cellular extracts]	1.5849625007211563	3	1	0	0
20842	1520	extent of cellular proliferation	[extent of cellular proliferation]	1.5849625007211563	4	1	0	0
20843	1520	activation of nf-at1	[activation of NF-AT1]	1.5849625007211563	3	2	2	2
20844	1520	two HUMARA allele	[two HUMARA alleles]	1.5849625007211563	3	1	0	0
20845	1520	several gc box	[several GC boxes]	1.5849625007211563	3	1	0	0
20846	1520	human interleukin (il)-1 receptor	[human interleukin (IL)-1 receptor]	1.5849625007211563	4	1	0	0
20847	1520	primary anaplastic astrocytomas /glioblastomas	[primary anaplastic astrocytomas /glioblastomas]	1.5849625007211563	4	1	0	0
20848	1520	adult t-cell leukemia cell	[adult T-cell leukemia cells]	1.5849625007211563	4	2	1	1
20849	1520	sublethal level of H2O2	[sublethal levels of H2O2]	1.5849625007211563	4	1	0	0
20850	1520	expression of the beta-chain	[Expression of the beta-chain]	1.5849625007211563	4	1	0	0
20851	1520	NF-kappaB site at -59	[NF-kappaB site at -59]	1.5849625007211563	4	1	0	0
20852	1520	BLS complementation group	[BLS complementation group]	1.5849625007211563	3	2	2	2
20853	1520	matter of debate	[matter of debate]	1.5849625007211563	3	1	0	0
20854	1520	human adenoviruse in human	[human adenoviruses in humans]	1.5849625007211563	4	1	0	0
20855	1520	aspect of viral pathogenesis	[aspects of viral pathogenesis]	1.5849625007211563	4	1	0	0
20856	1520	nf-kappab nuclear translocation	[NF-kappaB nuclear translocation]	1.5849625007211563	3	2	2	2
20857	1520	enhancement of CAT protein	[enhancement of CAT protein]	1.5849625007211563	4	1	0	0
20858	1520	two cDNA clone	[Two cDNA clones]	1.5849625007211563	3	1	0	0
20859	1520	contain ankyrin motif	[containing ankyrin motifs]	1.5849625007211563	3	1	0	0
20860	1520	response to thrombopoietin	[response to thrombopoietin]	1.5849625007211563	3	1	0	0
20861	1520	T cell activation pathway	[T cell activation pathways]	1.5849625007211563	4	1	0	0
20862	1520	jurkat t-leukemia cell	[Jurkat T-leukemia cells]	1.5849625007211563	3	1	0	0
20863	1520	dprl promoter/reporter gene construct	[dPRL promoter/reporter gene constructs]	1.5849625007211563	4	1	0	0
20864	1520	135eoh)2d3 receptor status	[1,25(OH)2D3 receptor status]	1.5849625007211563	3	1	0	0
20865	1520	Glucocorticoid receptor density	[Glucocorticoid receptor density]	1.5849625007211563	3	1	0	0
20866	1520	eight putative transmembrane segment	[eight putative transmembrane segments]	1.5849625007211563	4	1	0	0
20867	1520	less than 60 residue	[less than 60 residues]	1.5849625007211563	4	1	0	0
20868	1520	cellular factor from non-transformed	[cellular factors from non-transformed]	1.5849625007211563	4	1	0	0
20869	1520	additional role for transrepression	[additional role for transrepression]	1.5849625007211563	4	1	0	0
20870	1520	receptor alpha promoter	[receptor alpha promoter]	1.5849625007211563	3	1	0	0
20871	1520	active viral infection	[active viral infection]	1.5849625007211563	3	1	0	0
20872	1520	mycobacterial cell wall component	[mycobacterial cell wall component]	1.5849625007211563	4	1	0	0
20873	1520	transcription repressor evi1	[transcription repressor EVI1]	1.5849625007211563	3	2	1	1
20874	1520	subtractive hybridisation method	[subtractive hybridisation method]	1.5849625007211563	3	1	0	0
20875	1520	aldosterone in human lymphocyte	[aldosterone in human lymphocytes]	1.5849625007211563	4	1	0	0
20876	1520	various cell function	[various cell functions]	1.5849625007211563	3	1	0	0
20877	1520	dominant-negative version of STAT5b	[dominant-negative version of STAT5b]	1.5849625007211563	4	1	0	0
20878	1520	tumor necrosis factor-alpha TNFalpha	[tumor necrosis factor-alpha TNFalpha]	1.5849625007211563	4	1	0	0
20879	1520	development of resistance	[development of resistance]	1.5849625007211563	3	1	0	0
20880	1520	acute megakaryoblastic leukaemia m7	[Acute megakaryoblastic leukaemia M7]	1.5849625007211563	4	1	0	0
20881	1520	previous clinical observation	[previous clinical observations]	1.5849625007211563	3	1	0	0
20882	1520	T-all cell line hpb-all	[T-ALL cell line HPB-ALL]	1.5849625007211563	4	1	0	0
20883	1520	zinc-finger dna-binding transcription activator	[zinc-finger DNA-binding transcription activator]	1.5849625007211563	4	1	0	0
20884	1520	less than 3 kda.	[less than 3 kDa.]	1.5849625007211563	4	1	0	0
20885	1520	HIV-2 hiv-1 tat gene	[HIV-2 HIV-1 tat genes]	1.5849625007211563	4	1	0	0
20886	1520	number of protein ag	[number of protein Ag]	1.5849625007211563	4	1	0	0
20887	1520	constitutive viral enhancer	[constitutive viral enhancer]	1.5849625007211563	3	1	0	0
20888	1520	course of breast cancer	[course of breast cancer]	1.5849625007211563	4	1	0	0
20889	1520	murine gm-csf promoter	[murine GM-CSF promoter]	1.5849625007211563	3	1	0	0
20890	1520	long form, CBF beta	[longest form, CBF beta]	1.5849625007211563	4	1	0	0
20891	1520	absence of tcr activation	[absence of TCR activation]	1.5849625007211563	4	1	0	0
20892	1520	protein RNA complex	[protein RNA complex]	1.5849625007211563	3	1	0	0
20893	1520	symptom due to treatment	[symptoms due to treatment]	1.5849625007211563	4	1	0	0
20894	1520	om10.1 ach2 cell	[OM10.1 Ach2 cells]	1.5849625007211563	3	1	0	0
20895	1520	P0 nfat-binding element	[P0 NFAT-binding elements]	1.5849625007211563	3	1	0	0
20896	1520	rapid time course,	[rapid time course,]	1.5849625007211563	3	1	0	0
20897	1520	kappa b DNA element	[kappa B DNA elements]	1.5849625007211563	4	1	0	0
20898	1520	transcription of inflammatory effector	[transcription of inflammatory effector]	1.5849625007211563	4	1	0	0
20899	1520	mini- ebv plasmid	[mini- EBV plasmid]	1.5849625007211563	3	1	0	0
20900	1520	component(s) of NF-AT	[component(s) of NF-AT]	1.5849625007211563	3	1	0	0
20901	1520	congestive heart failure	[congestive heart failure]	1.5849625007211563	3	1	0	0
20902	1520	creb DNA binding	[CREB DNA binding]	1.5849625007211563	3	1	0	0
20903	1520	IL-2 mrna response	[IL-2 mRNA response]	1.5849625007211563	3	1	0	0
20904	1520	gst- EBNA-2 fusion protein	[gst- EBNA-2 fusion protein]	1.5849625007211563	4	1	0	0
20905	1520	classical 135eoh)2d3 receptor	[classical 1,25(OH)2D3 receptor]	1.5849625007211563	3	2	2	2
20906	1520	Thus, CD30 -cd30l interaction	[Thus, CD30 -CD30L interactions]	1.5849625007211563	4	1	0	0
20907	1520	sequence element in repeat	[sequence elements in repeats]	1.5849625007211563	4	1	0	0
20908	1520	stat transcription factor stat5	[STAT transcription factor STAT5]	1.5849625007211563	4	1	0	0
20909	1520	combinatorial peptide library	[combinatorial peptide libraries]	1.5849625007211563	3	1	0	0
20910	1520	mitogen-activated protein kinase activation	[mitogen-activated protein kinase activation]	1.5849625007211563	4	2	1	1
20911	1520	stability of c-fo	[stability of c-Fos]	1.5849625007211563	3	1	0	0
20912	1520	DEX IkappaBalpha induction	[DEX IkappaBalpha induction]	1.5849625007211563	3	1	0	0
20913	1520	T lymphocyte from 6	[T lymphocytes from 6]	1.5849625007211563	4	1	0	0
20914	1520	DNA synthesis by pretreatment	[DNA synthesis by pretreatment]	1.5849625007211563	4	1	0	0
20915	1520	importance of antigen presentation	[importance of antigen presentation]	1.5849625007211563	4	1	0	0
20916	1520	lupus T cell	[lupus T cells]	1.5849625007211563	3	1	0	0
20917	1520	human T cell activation	[human T cell activation]	1.5849625007211563	4	2	1	1
20918	1520	presence of 135(oh)2d3	[presence of 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
20919	1520	vehicle for intracytoplasmic delivery	[vehicle for intracytoplasmic delivery]	1.5849625007211563	4	1	0	0
20920	1520	HPC differentiation program	[HPC differentiation program]	1.5849625007211563	3	1	0	0
20921	1520	MOPC 141 promoter	[MOPC 141 promoter]	1.5849625007211563	3	1	0	0
20922	1520	certain lymphoid malignancy	[certain lymphoid malignancies]	1.5849625007211563	3	1	0	0
20923	1520	function of this receptor	[function of this receptor]	1.5849625007211563	4	1	0	0
20924	1520	such as nf-kappab	[such as NF-kappaB]	1.5849625007211563	3	1	0	0
20925	1520	region of il-2r beta	[region of IL-2R beta]	1.5849625007211563	4	2	2	2
20926	1520	dexamethasone suppression test dst	[dexamethasone suppression test DST]	1.5849625007211563	4	1	0	0
20927	1520	DNA binding trans-activation activity	[DNA binding trans-activation activity]	1.5849625007211563	4	1	0	0
20928	1520	basis for the expression	[basis for the expression]	1.5849625007211563	4	2	2	2
20929	1520	resultant DNA demethylation	[resultant DNA demethylation]	1.5849625007211563	3	1	0	0
20930	1520	Recently, fibromyalgia fms	[Recently, fibromyalgia FMS]	1.5849625007211563	3	1	0	0
20931	1520	various other agents.	[various other agents.]	1.5849625007211563	3	1	0	0
20932	1520	novel mutation present	[novel mutation present]	1.5849625007211563	3	1	0	0
20933	1520	human cd4(+) T cell	[human CD4(+) T cells]	1.5849625007211563	4	1	0	0
20934	1520	monocytes/macrophages via cd14 one	[monocytes/macrophages via CD14 one]	1.5849625007211563	4	1	0	0
20935	1520	human udg promoter sequence	[human UDG promoter sequences]	1.5849625007211563	4	1	0	0
20936	1520	ability of small molecule	[ability of small molecules]	1.5849625007211563	4	1	0	0
20937	1520	Bcl-x a antiapoptotic molecule	[Bcl-x a antiapoptotic molecule]	1.5849625007211563	4	1	0	0
20938	1520	induction of il-2 mrna	[induction of IL-2 mRNA]	1.5849625007211563	4	1	0	0
20939	1520	least three member	[least three members]	1.5849625007211563	3	1	0	0
20940	1520	regulatory effect of insulin	[regulatory effect of insulin]	1.5849625007211563	4	1	0	0
20941	1520	patient with receptor affinity	[patients with receptor affinity]	1.5849625007211563	4	2	2	2
20942	1520	continuous blood pressure measurement	[continuous blood pressure measurements]	1.5849625007211563	4	1	0	0
20943	1520	Tyrosine phosphorylation of SOCS-3	[Tyrosine phosphorylation of SOCS-3]	1.5849625007211563	4	1	0	0
20944	1520	anergized T cell	[anergized T cells]	1.5849625007211563	3	1	0	0
20945	1520	use western blot analysis	[using Western blot analysis]	1.5849625007211563	4	2	1	1
20946	1520	full agonist activity,	[full agonist activity,]	1.5849625007211563	3	1	0	0
20947	1520	number of housekeeping gene	[number of housekeeping genes]	1.5849625007211563	4	1	0	0
20948	1520	splenic erythroblast from mouse	[splenic erythroblasts from mice]	1.5849625007211563	4	1	0	0
20949	1520	autologous antigen-present cell apc	[autologous antigen-presenting cell APC]	1.5849625007211563	4	1	0	0
20950	1520	DNA binding motif	[DNA binding motif]	1.5849625007211563	3	1	0	0
20951	1520	form of e2f-4	[forms of E2F-4]	1.5849625007211563	3	1	0	0
20952	1520	certain develop tissue	[certain developing tissues]	1.5849625007211563	3	1	0	0
20953	1520	intracellular ca2+ mobilization	[intracellular Ca2+ mobilization]	1.5849625007211563	3	2	1	1
20954	1520	analyzed, spi-1 overexpression	[analyzed, spi-1 overexpression]	1.5849625007211563	3	1	0	0
20955	1520	adult cd4+cd45ro- T cell	[adult CD4+CD45RO- T cells]	1.5849625007211563	4	1	0	0
20956	1520	distal ccaat box apparent	[distal CCAAT box apparent]	1.5849625007211563	4	1	0	0
20957	1520	activity on calcium metabolism	[activity on calcium metabolism]	1.5849625007211563	4	1	0	0
20958	1520	dna-binding domain amino acid	[DNA-binding domain amino acids]	1.5849625007211563	4	1	0	0
20959	1520	certain number of hybrid	[certain number of hybrids]	1.5849625007211563	4	1	0	0
20960	1520	nucleolin cDNA expression construct	[nucleolin cDNA expression construct]	1.5849625007211563	4	1	0	0
20961	1520	human cytomegalovirus CMV	[human cytomegalovirus CMV]	1.5849625007211563	3	2	1	1
20962	1520	yeast reporter strain	[yeast reporter strain]	1.5849625007211563	3	1	0	0
20963	1520	novel kappa b-like site	[novel kappa B-like site]	1.5849625007211563	4	1	0	0
20964	1520	mediate transcription initiation	[mediating transcription initiation]	1.5849625007211563	3	1	0	0
20965	1520	limit dilution analysis	[limiting dilution analysis]	1.5849625007211563	3	1	0	0
20966	1520	contrast, STAT3 activation	[contrast, STAT3 activation]	1.5849625007211563	3	1	0	0
20967	1520	core sequence taat	[core sequence TAAT]	1.5849625007211563	3	1	0	0
20968	1520	contrast, caspase 1	[contrast, caspase 1]	1.5849625007211563	3	1	0	0
20969	1520	differentiation of t-helper cell	[differentiation of T-helper cells]	1.5849625007211563	4	1	0	0
20970	1520	Furthermore, GR number	[Furthermore, GR number]	1.5849625007211563	3	1	0	0
20971	1520	contrast to ionomycin treatment	[contrast to ionomycin treatment]	1.5849625007211563	4	1	0	0
20972	1520	cd11c promoter -luciferase construct	[CD11c promoter -luciferase constructs]	1.5849625007211563	4	1	0	0
20973	1520	increase in c-fo	[increases in c-fos]	1.5849625007211563	3	2	1	1
20974	1520	survey of gene	[survey of genes]	1.5849625007211563	3	1	0	0
20975	1520	retinoblastoma protein RB	[Retinoblastoma protein RB]	1.5849625007211563	3	1	0	0
20976	1520	exogenous il-2 growth factor	[exogenous IL-2 growth factor]	1.5849625007211563	4	1	0	0
20977	1520	150 bp fragment	[150 bp fragment]	1.5849625007211563	3	1	0	0
20978	1520	T. T cell	[T. T cells]	1.5849625007211563	3	2	2	2
20979	1520	cyclic AMP camp	[cyclic AMP cAMP]	1.5849625007211563	3	2	1	1
20980	1520	significant loss in activity.	[significant loss in activity.]	1.5849625007211563	4	1	0	0
20981	1520	identification of allelic nucleotide	[identification of allelic nucleotides]	1.5849625007211563	4	1	0	0
20982	1520	three S6 peptide	[three S6 peptides]	1.5849625007211563	3	1	0	0
20983	1520	human cd95l promoter	[human CD95L promoter]	1.5849625007211563	3	1	0	0
20984	1520	approximately 560 bp	[approximately 560 bp]	1.5849625007211563	3	1	0	0
20985	1520	administration of recombinant thioredoxin	[administration of recombinant thioredoxin]	1.5849625007211563	4	1	0	0
20986	1520	endothelial-leukocyte adhesion molecule	[endothelial-leukocyte adhesion molecule]	1.5849625007211563	3	2	2	2
20987	1520	regulation of early change	[regulation of early changes]	1.5849625007211563	4	1	0	0
20988	1520	early diagnosis of relapse	[early diagnosis of relapse]	1.5849625007211563	4	1	0	0
20989	1520	congenital immunodeficiency disease	[congenital immunodeficiency disease]	1.5849625007211563	3	1	0	0
20990	1520	glucocorticoid receptor gr expression	[glucocorticoid receptor GR expression]	1.5849625007211563	4	1	0	0
20991	1520	LT-kappa b construct M1-CAT	[LT-kappa B construct M1-CAT]	1.5849625007211563	4	1	0	0
20992	1520	level of transcript	[levels of transcripts]	1.5849625007211563	3	2	2	2
20993	1520	follow autologous pbsct	[following autologous PBSCT]	1.5849625007211563	3	3	2	1
20994	1520	ets proto-oncogene family	[ets proto-oncogene family]	1.5849625007211563	3	1	0	0
20995	1520	event of leukemogenesis	[events of leukemogenesis]	1.5849625007211563	3	1	0	0
20996	1520	use this T cell	[Using these T cells]	1.5849625007211563	4	1	0	0
20997	1520	breakpoint in the exon	[breakpoints in the exon]	1.5849625007211563	4	1	0	0
20998	1520	IL-5 -nonproduce clone	[IL-5 -nonproducing clones]	1.5849625007211563	3	1	0	0
20999	1520	different cell cycle kinetic	[different cell cycle kinetics]	1.5849625007211563	4	1	0	0
21000	1520	RNase protection assay	[RNase protection assay]	1.5849625007211563	3	2	1	1
21001	1520	herpes simplex virus hsv	[herpes simplex virus HSV]	1.5849625007211563	4	2	1	1
21002	1520	GATA-1.05 mutant female	[GATA-1.05 mutant females]	1.5849625007211563	3	1	0	0
21003	1520	t(8;21) acute myeloid leukemia	[t(8;21) acute myeloid leukemia]	1.5849625007211563	4	1	0	0
21004	1520	intact T cell	[intact T cells]	1.5849625007211563	3	2	1	1
21005	1520	isolated human membrane system	[isolated human membrane system]	1.5849625007211563	4	1	0	0
21006	1520	approximately 1 P;	[approximately 1 h;]	1.5849625007211563	3	1	0	0
21007	1520	transcription of c-fo	[transcription of c-fos]	1.5849625007211563	3	1	0	0
21008	1520	promoter element kappa	[promoter element kappa]	1.5849625007211563	3	2	1	1
21009	1520	impaired glucocorticoid induction	[impaired glucocorticoid induction]	1.5849625007211563	3	1	0	0
21010	1520	develop th2 cell	[developing Th2 cells]	1.5849625007211563	3	1	0	0
21011	1520	suppression of vcam-1	[suppression of VCAM-1]	1.5849625007211563	3	1	0	0
21012	1520	conditions, interleukin-2 synthesis	[conditions, interleukin-2 synthesis]	1.5849625007211563	3	1	0	0
21013	1520	human tsp gene	[human TSP gene]	1.5849625007211563	3	2	2	2
21014	1520	autofluoresence use flow cytometric	[autofluoresence using flow cytometric]	1.5849625007211563	4	1	0	0
21015	1520	Locus Control Region LCR	[Locus Control Region LCR]	1.5849625007211563	4	1	0	0
21016	1520	1 h of stimulation	[1 h of stimulation]	1.5849625007211563	4	1	0	0
21017	1520	normal polyclonal granulocyte	[normal polyclonal granulocytes]	1.5849625007211563	3	1	0	0
21018	1520	anti-cd95 ab treatment	[anti-CD95 Ab treatment]	1.5849625007211563	3	1	0	0
21019	1520	down-regulation of surface il-4r	[down-regulation of surface IL-4R]	1.5849625007211563	4	1	0	0
21020	1520	viral immediate-early protein BRLF1	[viral immediate-early protein BRLF1]	1.5849625007211563	4	1	0	0
21021	1520	subsequent cross-linking of cd15	[Subsequent cross-linking of CD15]	1.5849625007211563	4	1	0	0
21022	1520	woman with breast cancer	[women with breast cancer]	1.5849625007211563	4	1	0	0
21023	1520	contain myeloid-cell-specific c-mim	[containing myeloid-cell-specific c-mim]	1.5849625007211563	3	1	0	0
21024	1520	variety of other cells.	[variety of other cells.]	1.5849625007211563	4	1	0	0
21025	1520	nuclear factor-kappaB phenomenon	[nuclear factor-kappaB phenomenon]	1.5849625007211563	3	1	0	0
21026	1520	terminal repeat activity	[terminal repeat activity]	1.5849625007211563	3	2	2	2
21027	1520	cytokine on NK cell	[cytokines on NK cells]	1.5849625007211563	4	1	0	0
21028	1520	role mediate growth inhibition	[role mediating growth inhibition]	1.5849625007211563	4	1	0	0
21029	1520	tpa response element	[TPA response elements]	1.5849625007211563	3	1	0	0
21030	1520	CD40 -positive mm	[CD40 -positive MM]	1.5849625007211563	3	1	0	0
21031	1520	novel ap-2 transcription factor	[novel AP-2 transcription factor]	1.5849625007211563	4	1	0	0
21032	1520	rapid phosphorylation in	[rapid phosphorylation in]	1.5849625007211563	3	1	0	0
21033	1520	cell in cycle	[cells in cycle]	1.5849625007211563	3	1	0	0
21034	1520	normal human epidermal keratinocyte	[normal human epidermal keratinocytes]	1.5849625007211563	4	1	0	0
21035	1520	DNA position tax	[DNA positions Tax]	1.5849625007211563	3	1	0	0
21036	1520	difficulty obtain quiescent monocyte	[difficulty obtaining quiescent monocytes]	1.5849625007211563	4	1	0	0
21037	1520	cross-linking of CD2	[cross-linking of CD2]	1.5849625007211563	3	1	0	0
21038	1520	concentration of DEX	[concentrations of DEX]	1.5849625007211563	3	2	2	2
21039	1520	tnf-alpha mrna transcript	[TNF-alpha mRNA transcripts]	1.5849625007211563	3	1	0	0
21040	1520	role of ascorbate	[Role of ascorbate]	1.5849625007211563	3	2	2	2
21041	1520	laser scanning confocal microscopy	[laser scanning confocal microscopy]	1.5849625007211563	4	1	0	0
21042	1520	inhibition of RANTES expression	[Inhibition of RANTES expression]	1.5849625007211563	4	1	0	0
21043	1520	mononuclear leukocyte in aging.	[mononuclear leukocytes in aging.]	1.5849625007211563	4	1	0	0
21044	1520	most signal pathway	[most signaling pathways]	1.5849625007211563	3	1	0	0
21045	1520	vitamin d receptor mrna	[vitamin D receptor mRNA]	1.5849625007211563	4	2	1	1
21046	1520	adrenal cortex function	[adrenal cortex function]	1.5849625007211563	3	1	0	0
21047	1520	activity of pi 3-kinase	[activity of PI 3-kinase]	1.5849625007211563	4	1	0	0
21048	1520	action of this inhibitor.	[action of this inhibitor.]	1.5849625007211563	4	1	0	0
21049	1520	half-life of icam-1 message	[half-life of ICAM-1 message]	1.5849625007211563	4	1	0	0
21050	1520	response element by monomer	[response element by monomer]	1.5849625007211563	4	1	0	0
21051	1520	CCAAT/enhancer -binding protein c/ebp	[CCAAT/enhancer -binding protein C/EBP]	1.5849625007211563	4	1	0	0
21052	1520	sh2-deleted Grb2 mutant	[SH2-deleted Grb2 mutant]	1.5849625007211563	3	1	0	0
21053	1520	b lymphoid origin	[B lymphoid origin]	1.5849625007211563	3	1	0	0
21054	1520	latter class of event	[latter class of events]	1.5849625007211563	4	1	0	0
21055	1520	cyclic-AMP -responsive element bind	[cyclic-AMP -responsive element binding]	1.5849625007211563	4	1	0	0
21056	1520	source of the fragment	[source of the fragment]	1.5849625007211563	4	1	0	0
21057	1520	DNA sequence at -120	[DNA sequence at -120]	1.5849625007211563	4	1	0	0
21058	1520	activator of gene expression	[activator of gene expression]	1.5849625007211563	4	2	1	1
21059	1520	CD40 -ligand+ T cell	[CD40 -ligand+ T cells]	1.5849625007211563	4	1	0	0
21060	1520	-70 gata site	[-70 GATA site]	1.5849625007211563	3	2	1	1
21061	1520	compared, suggest highly selective	[compared, suggesting highly selective]	1.5849625007211563	4	1	0	0
21062	1520	Addition of phosphorothioate oligonucleotide	[Addition of phosphorothioate oligonucleotides]	1.5849625007211563	4	1	0	0
21063	1520	"pure" early hematopoietic progenitor	["pure" early hematopoietic progenitors]	1.5849625007211563	4	1	0	0
21064	1520	C-terminal two-third of proteins.	[C-terminal two-thirds of proteins.]	1.5849625007211563	4	1	0	0
21065	1520	regulatory subunit (type I	[regulatory subunits (type I]	1.5849625007211563	4	1	0	0
21066	1520	interleukin-2 receptor-gamma il-2r gamma	[interleukin-2 receptor-gamma IL-2R gamma]	1.5849625007211563	4	1	0	0
21067	1520	search for a treatment,	[search for a treatment,]	1.5849625007211563	4	1	0	0
21068	1520	protein with proline content	[protein with proline content]	1.5849625007211563	4	1	0	0
21069	1520	change in total level	[change in total level]	1.5849625007211563	4	1	0	0
21070	1520	part by nuclear import	[part by nuclear import]	1.5849625007211563	4	1	0	0
21071	1520	favor VDR /rxr binding	[favoring VDR /RXR binding]	1.5849625007211563	4	1	0	0
21072	1520	adjacent BRLF-1 locus	[adjacent BRLF-1 locus]	1.5849625007211563	3	1	0	0
21073	1520	relationship between leukocyte population	[relationship between leukocyte populations]	1.5849625007211563	4	1	0	0
21074	1520	in vitro system	[in vitro system]	1.5849625007211563	3	1	0	0
21075	1520	TCR CD3/CD28 signal	[TCR CD3/CD28 signaling]	1.5849625007211563	3	1	0	0
21076	1520	key inducer of differentiation	[key inducer of differentiation]	1.5849625007211563	4	1	0	0
21077	1520	addition, stimulation with MBP	[addition, stimulation with MBP]	1.5849625007211563	4	1	0	0
21078	1520	atherosclerotic fatty streak	[atherosclerotic fatty streak]	1.5849625007211563	3	1	0	0
21079	1520	expression of certain transcription	[expression of certain transcription]	1.5849625007211563	4	1	0	0
21080	1520	expression of Egr -1	[expression of Egr -1]	1.5849625007211563	4	1	0	0
21081	1520	cytoplasm into the nucleus	[cytoplasm into the nucleus]	1.5849625007211563	4	1	0	0
21082	1520	results: Nuclear factor (nf)-kappab	[RESULTS: Nuclear factor (NF)-kappaB]	1.5849625007211563	4	1	0	0
21083	1520	HIV nf-kappa b activation	[HIV NF-kappa B activation]	1.5849625007211563	4	1	0	0
21084	1520	protein of this class,	[proteins of this class,]	1.5849625007211563	4	1	0	0
21085	1520	intracellular parasite Theileria parva	[intracellular parasite Theileria parva]	1.5849625007211563	4	1	0	0
21086	1520	development of lineage	[development of lineages]	1.5849625007211563	3	2	2	2
21087	1520	two zinc finger protein	[two zinc finger proteins]	1.5849625007211563	4	1	0	0
21088	1520	average, abnormally high level	[average, abnormally high levels]	1.5849625007211563	4	1	0	0
21089	1520	immunoglobulin isotype class switch	[immunoglobulin isotype class switching]	1.5849625007211563	4	1	0	0
21090	1520	62 kda subunit	[62 kDa subunit]	1.5849625007211563	3	1	0	0
21091	1520	Epstein-Barr virus latent infection	[Epstein-Barr virus latent infection]	1.5849625007211563	4	1	0	0
21092	1520	different atopic disorder	[different atopic disorders]	1.5849625007211563	3	1	0	0
21093	1520	link between oxidative signalling	[link between oxidative signalling]	1.5849625007211563	4	1	0	0
21094	1520	DSL family of ligand	[DSL family of ligands]	1.5849625007211563	4	1	0	0
21095	1520	namely the epipodophyllotoxin etoposide	[namely the epipodophyllotoxin etoposide]	1.5849625007211563	4	1	0	0
21096	1520	expression of many cytokine	[expression of many cytokines]	1.5849625007211563	4	2	1	1
21097	1520	interact with Vav	[interacting with Vav]	1.5849625007211563	3	1	0	0
21098	1520	two distinct promoter	[two distinct promoters]	1.5849625007211563	3	2	2	2
21099	1520	such as ICAM-1	[such as ICAM-1]	1.5849625007211563	3	1	0	0
21100	1520	20 healthy control	[20 healthy controls]	1.5849625007211563	3	1	0	0
21101	1520	only a partial inhibition	[only a partial inhibition]	1.5849625007211563	4	1	0	0
21102	1520	sequence within the promoter	[sequences within the promoter]	1.5849625007211563	4	2	1	1
21103	1520	myeloid cell extract	[myeloid cell extracts]	1.5849625007211563	3	1	0	0
21104	1520	phosphatidylinositol-3-kinase pi-3 kinase	[phosphatidylinositol-3-kinase PI-3 kinase]	1.5849625007211563	3	1	0	0
21105	1520	major histocompatibility complex molecule	[major histocompatibility complex molecules]	1.5849625007211563	4	1	0	0
21106	1520	functional selection maintain variation	[functional selection maintaining variation]	1.5849625007211563	4	1	0	0
21107	1520	nf-kappab -DNA binding	[NF-kappaB -DNA binding]	1.5849625007211563	3	1	0	0
21108	1520	filaria-induced lymphatic pathology	[filaria-induced lymphatic pathology]	1.5849625007211563	3	1	0	0
21109	1520	low basal il-2 production	[low basal IL-2 production]	1.5849625007211563	4	1	0	0
21110	1520	autologous dendritic cell	[autologous dendritic cells]	1.5849625007211563	3	1	0	0
21111	1520	other thyroid autoantigen	[other thyroid autoantigens]	1.5849625007211563	3	1	0	0
21112	1520	nuclear translocation of stat3	[nuclear translocation of stat3]	1.5849625007211563	4	3	2	1
21113	1520	calmodulin -binding domain	[calmodulin -binding domain]	1.5849625007211563	3	1	0	0
21114	1520	leucine-rich repeat lrr domain	[leucine-rich repeat LRR domain]	1.5849625007211563	4	1	0	0
21115	1520	major side effect	[major side effects]	1.5849625007211563	3	1	0	0
21116	1520	binding site selection	[Binding site selection]	1.5849625007211563	3	1	0	0
21117	1520	upregulation of transcript	[upregulation of transcripts]	1.5849625007211563	3	1	0	0
21118	1520	ICK-1 binding site	[ICK-1 binding site]	1.5849625007211563	3	1	0	0
21119	1520	binding of STAT5	[binding of STAT5]	1.5849625007211563	3	1	0	0
21120	1520	vitro DNA mobility	[vitro DNA mobility]	1.5849625007211563	3	1	0	0
21121	1520	NK cell by 80%	[NK cells by 80%]	1.5849625007211563	4	1	0	0
21122	1520	number of woman	[number of women]	1.5849625007211563	3	1	0	0
21123	1520	potentiation of the induction	[potentiation of the induction]	1.5849625007211563	4	1	0	0
21124	1520	activation and/or expression	[activation and/or expression]	1.5849625007211563	3	1	0	0
21125	1520	injection of ad5e1a-peptide	[injection of Ad5E1A-peptide]	1.5849625007211563	3	1	0	0
21126	1520	cell culture experiment	[Cell culture experiments]	1.5849625007211563	3	1	0	0
21127	1520	cell receptor alpha/delta	[cell receptor alpha/delta]	1.5849625007211563	3	1	0	0
21128	1520	Anti- CD28 MoAb costimulation	[Anti- CD28 MoAb costimulation]	1.5849625007211563	4	1	0	0
21129	1520	consist of Jun	[consisting of Jun]	1.5849625007211563	3	1	0	0
21130	1520	include the il-2 gene	[including the IL-2 genes]	1.5849625007211563	4	1	0	0
21131	1520	adhesiveness of endothelial cell	[adhesiveness of endothelial cells]	1.5849625007211563	4	1	0	0
21132	1520	functional inhibition of stat3	[functional inhibition of STAT3]	1.5849625007211563	4	1	0	0
21133	1520	ah receptor ligand	[Ah receptor ligand]	1.5849625007211563	3	1	0	0
21134	1520	follow this lead,	[Following this lead,]	1.5849625007211563	3	1	0	0
21135	1520	induction of endogenous tnf-alpha	[induction of endogenous TNF-alpha]	1.5849625007211563	4	1	0	0
21136	1520	induction in response	[induction in responses]	1.5849625007211563	3	2	2	2
21137	1520	case of a woman	[case of a woman]	1.5849625007211563	4	2	2	2
21138	1520	indicate in part	[indicating in part]	1.5849625007211563	3	1	0	0
21139	1520	tata-less interferon-regulated gene	[TATA-less interferon-regulated gene]	1.5849625007211563	3	1	0	0
21140	1520	hemorrhagic shock HS	[Hemorrhagic shock HS]	1.5849625007211563	3	1	0	0
21141	1520	CsA with cyclophilin a	[CsA with cyclophilin A]	1.5849625007211563	4	1	0	0
21142	1520	IL-5 proximal promoter region	[IL-5 proximal promoter region]	1.5849625007211563	4	1	0	0
21143	1520	endothelial adhesion molecule-1 cd62e	[endothelial adhesion molecule-1 CD62E]	1.5849625007211563	4	1	0	0
21144	1520	identification of a element	[Identification of a element]	1.5849625007211563	4	2	1	1
21145	1520	deletion of NFAT-1 alone	[deletion of NFAT-1 alone]	1.5849625007211563	4	1	0	0
21146	1520	natural compound sarcophytol a	[natural compound sarcophytol A]	1.5849625007211563	4	1	0	0
21147	1520	immunoglobulin heavy chain expression	[immunoglobulin heavy chain expression]	1.5849625007211563	4	1	0	0
21148	1520	impaired glucose-stimulated insulin secretion	[impaired glucose-stimulated insulin secretion]	1.5849625007211563	4	1	0	0
21149	1520	patient with CLL	[patients with CLL]	1.5849625007211563	3	2	2	2
21150	1520	METHODS: bovine corneal endothelium	[METHODS: bovine corneal endothelium]	1.5849625007211563	4	1	0	0
21151	1520	productive (lytic) infection	[productive (lytic) infections]	1.5849625007211563	3	1	0	0
21152	1520	pathogenesis of immune disorder	[pathogenesis of immune disorders]	1.5849625007211563	4	1	0	0
21153	1520	megakaryocytic cell line	[megakaryocytic cell line]	1.5849625007211563	3	2	1	1
21154	1520	temporal artery-SCID chimera	[temporal artery-SCID chimeras]	1.5849625007211563	3	1	0	0
21155	1520	NK: EC co-culture	[NK: EC co-cultures]	1.5849625007211563	3	1	0	0
21156	1520	GM-CSF transcription initiation site	[GM-CSF transcription initiation site]	1.5849625007211563	4	1	0	0
21157	1520	PHA-activated peripheral mononuclear cell	[PHA-activated peripheral mononuclear cells]	1.5849625007211563	4	1	0	0
21158	1520	anti-CD3 monoclonal antibody	[anti-CD3 monoclonal antibody]	1.5849625007211563	3	2	2	2
21159	1520	assay CAT enzyme activity	[assaying CAT enzyme activity]	1.5849625007211563	4	1	0	0
21160	1520	kappa b regulatory element	[kappa B regulatory element]	1.5849625007211563	4	1	0	0
21161	1520	interleukin 2 receptor	[interleukin 2 receptor]	1.5849625007211563	3	1	0	0
21162	1520	effect on monocyte	[effect on monocytes]	1.5849625007211563	3	1	0	0
21163	1520	latency type ii	[latency type II]	1.5849625007211563	3	1	0	0
21164	1520	classic androgen receptor	[classic androgen receptors]	1.5849625007211563	3	1	0	0
21165	1520	interleukin-2 gene expression	[interleukin-2 gene expression]	1.5849625007211563	3	1	0	0
21166	1520	2 early lytic transcript	[2 early lytic transcripts]	1.5849625007211563	4	1	0	0
21167	1520	site of active transcription	[sites of active transcription]	1.5849625007211563	4	1	0	0
21168	1520	many all Junuary	[many all Jun-]	1.5849625007211563	3	1	0	0
21169	1520	characterization of transcription factor	[characterization of transcription factors]	1.5849625007211563	4	1	0	0
21170	1520	endocrine exocrine precursor cell	[endocrine exocrine precursor cells]	1.5849625007211563	4	1	0	0
21171	1520	tf expression circulate monocyte	[TF expression circulating monocytes]	1.5849625007211563	4	1	0	0
21172	1520	interaction with slp-76	[interaction with SLP-76]	1.5849625007211563	3	2	1	1
21173	1520	protein from E. coli	[protein from E. coli]	1.5849625007211563	4	1	0	0
21174	1520	ability of Hsp70	[ability of Hsp70]	1.5849625007211563	3	1	0	0
21175	1520	endothelial leukocyte adhesion molecule-1	[endothelial leukocyte adhesion molecule-1]	1.5849625007211563	4	1	0	0
21176	1520	addition of interferon gamma	[addition of interferon gamma]	1.5849625007211563	4	1	0	0
21177	1520	involvement of g protein	[Involvement of G protein]	1.5849625007211563	4	1	0	0
21178	1520	il-4 expression of 12/15-lipoxygenase	[IL-4 expression of 12/15-lipoxygenase]	1.5849625007211563	4	1	0	0
21179	1520	transcription in b cell	[transcription in B cells]	1.5849625007211563	4	1	0	0
21180	1520	multiple myeloma (mm) cell	[multiple myeloma (MM) cells]	1.5849625007211563	4	1	0	0
21181	1520	transcriptional factor FcRFgamma	[transcriptional factor FcRFgamma]	1.5849625007211563	3	1	0	0
21182	1520	step elucidate the background	[step elucidating the background]	1.5849625007211563	4	1	0	0
21183	1520	nuclear factor nf-il6	[nuclear factor NF-IL6]	1.5849625007211563	3	2	1	1
21184	1520	gene' transcriptional start site	[gene's transcriptional start site]	1.5849625007211563	4	1	0	0
21185	1520	ability of factor	[ability of factors]	1.5849625007211563	3	2	2	2
21186	1520	overexpression of the subunit	[overexpression of the subunit]	1.5849625007211563	4	2	2	2
21187	1520	nuclear exclusion of NFAT4	[nuclear exclusion of NFAT4]	1.5849625007211563	4	1	0	0
21188	1520	reactivity to tshr peptide	[Reactivity to TSHR peptides]	1.5849625007211563	4	1	0	0
21189	1520	expression in patient	[expression in patients]	1.5849625007211563	3	2	2	2
21190	1520	hyperdemarcation of cytoplasmic membrane	[hyperdemarcation of cytoplasmic membranes]	1.5849625007211563	4	1	0	0
21191	1520	other polychlorinated dibenzo-p-dioxin pcdd/pcdf	[other polychlorinated dibenzo-p-dioxins PCDD/PCDF]	1.5849625007211563	4	1	0	0
21192	1520	same four genes, suggest	[same four genes, suggesting]	1.5849625007211563	4	1	0	0
21193	1520	stimulatory g protein G(S)alpha	[stimulatory G protein G(S)alpha]	1.5849625007211563	4	1	0	0
21194	1520	Janus kinase function	[Janus kinase function]	1.5849625007211563	3	1	0	0
21195	1520	T helper cell differentiation	[T helper cell differentiation]	1.5849625007211563	4	2	1	1
21196	1520	nuclear translocation of RelB	[nuclear translocation of RelB]	1.5849625007211563	4	1	0	0
21197	1520	observation period of month	[observation period of months]	1.5849625007211563	4	1	0	0
21198	1520	humoral immunity to VZV	[humoral immunity to VZV]	1.5849625007211563	4	1	0	0
21199	1520	antibody competition experiment	[antibody competition experiments]	1.5849625007211563	3	1	0	0
21200	1520	marker for the process.	[marker for the process.]	1.5849625007211563	4	1	0	0
21201	1520	17 beta- estradiol	[17 beta- estradiol]	1.5849625007211563	3	2	1	1
21202	1520	rate of decay	[rate of decay]	1.5849625007211563	3	1	0	0
21203	1520	ifn-gamma induction of CIITA	[IFN-gamma induction of CIITA]	1.5849625007211563	4	1	0	0
21204	1520	more proximal polyA site	[more proximal polyA site]	1.5849625007211563	4	1	0	0
21205	1520	generation of p50	[generation of p50]	1.5849625007211563	3	2	1	1
21206	1520	active CRE site	[active CRE site]	1.5849625007211563	3	1	0	0
21207	1520	anti- tcf-1 antibody	[anti- TCF-1 antibodies]	1.5849625007211563	3	1	0	0
21208	1520	retinoid-resistant promyelocytic cell line	[retinoid-resistant promyelocytic cell line]	1.5849625007211563	4	1	0	0
21209	1520	leukocyte microbicidal activity	[leukocyte microbicidal activity]	1.5849625007211563	3	1	0	0
21210	1520	tata-less promoter by Oct-2	[TATA-less promoter by Oct-2]	1.5849625007211563	4	1	0	0
21211	1520	removal of T cell	[removal of T cells]	1.5849625007211563	4	1	0	0
21212	1520	concentration of microM.	[concentration of microM.]	1.5849625007211563	3	2	2	2
21213	1520	lymphoid-restricted gene lysp100	[lymphoid-restricted gene LYSP100]	1.5849625007211563	3	1	0	0
21214	1520	mean gr count	[mean GR count]	1.5849625007211563	3	1	0	0
21215	1520	stroma cell line pa6-neo	[stroma cell line PA6-neo]	1.5849625007211563	4	1	0	0
21216	1520	L- MPL rat return	[L- MPL rats returning]	1.5849625007211563	4	1	0	0
21217	1520	NF-kappa b transcriptional activity	[NF-kappa B transcriptional activity]	1.5849625007211563	4	1	0	0
21218	1520	free radical production/oxidative stress	[free radical production/oxidative stress]	1.5849625007211563	4	1	0	0
21219	1520	transcriptional activity of c-jun,	[transcriptional activity of c-Jun,]	1.5849625007211563	4	1	0	0
21220	1520	688 amino acid residue	[688 amino acid residues]	1.5849625007211563	4	1	0	0
21221	1520	requisite bacterial ligand	[requisite bacterial ligands]	1.5849625007211563	3	1	0	0
21222	1520	most lymphoblastoid t-cell line	[most lymphoblastoid T-cell lines]	1.5849625007211563	4	1	0	0
21223	1520	large granular lymphocyte LGL	[large granular lymphocytes LGL]	1.5849625007211563	4	1	0	0
21224	1520	stimulation of hiv-1 production	[stimulation of HIV-1 production]	1.5849625007211563	4	1	0	0
21225	1520	most frequent molecular lesion	[most frequent molecular lesion]	1.5849625007211563	4	1	0	0
21226	1520	binding of normal lifer	[binding of normal livers]	1.5849625007211563	4	1	0	0
21227	1520	inhibitory capacity of I(kappa)B(alpha)	[inhibitory capacity of I(kappa)B(alpha)]	1.5849625007211563	4	1	0	0
21228	1520	reporter construct contain both	[reporter construct containing both]	1.5849625007211563	4	1	0	0
21229	1520	carboxyl-terminal end of NFATx1	[carboxyl-terminal end of NFATx1]	1.5849625007211563	4	1	0	0
21230	1520	overexpression of her-2/neu protein	[overexpression of HER-2/neu protein]	1.5849625007211563	4	1	0	0
21231	1520	inhibition by RA	[inhibition by RA]	1.5849625007211563	3	1	0	0
21232	1520	abundance of fkbp51	[abundance of FKBP51]	1.5849625007211563	3	1	0	0
21233	1520	tcrg mrna level	[TCRG mRNA levels]	1.5849625007211563	3	1	0	0
21234	1520	normal (17 subject	[normal (17 subjects]	1.5849625007211563	3	1	0	0
21235	1520	antiproliferative activity of 135(oh)2d3	[antiproliferative activities of 1,25(OH)2D3]	1.5849625007211563	4	1	0	0
21236	1520	common DNA binding site	[common DNA binding site]	1.5849625007211563	4	1	0	0
21237	1520	manner in the nuclei	[manner in the nuclei]	1.5849625007211563	4	1	0	0
21238	1520	inactive nuclear factor-kappaB	[inactive nuclear factor-kappaB]	1.5849625007211563	3	1	0	0
21239	1520	tandem e-box domain	[tandem E-box domains]	1.5849625007211563	3	1	0	0
21240	1520	more accurate picture,	[more accurate picture,]	1.5849625007211563	3	1	0	0
21241	1520	requirement for protein synthesis	[requirement for protein synthesis]	1.5849625007211563	4	1	0	0
21242	1520	about 15000 receptors/cell,	[about 15,000 receptors/cell,]	1.5849625007211563	3	1	0	0
21243	1520	il-1 -specific induction	[IL-1 -specific induction]	1.5849625007211563	3	1	0	0
21244	1520	growth of NS-Meg cell	[growth of NS-Meg cells]	1.5849625007211563	4	1	0	0
21245	1520	interleukin 1beta protein production	[interleukin 1beta protein production]	1.5849625007211563	4	1	0	0
21246	1520	protein tyrosine kinase-	[protein tyrosine kinase-]	1.5849625007211563	3	1	0	0
21247	1520	least 3 weeks.	[least 3 weeks.]	1.5849625007211563	3	1	0	0
21248	1520	kappa b transcription	[kappa B transcription]	1.5849625007211563	3	1	0	0
21249	1520	cluster of myb site	[cluster of Myb sites]	1.5849625007211563	4	1	0	0
21250	1520	estrogen receptor beta ERbeta	[estrogen receptor beta ERbeta]	1.5849625007211563	4	1	0	0
21251	1520	level of mrna expression	[level of mRNA expression]	1.5849625007211563	4	1	0	0
21252	1520	nmol/L; p 0.01).	[nmol/L; P 0.01).]	1.5849625007211563	3	1	0	0
21253	1520	IL-4 a product	[IL-4 a product]	1.5849625007211563	3	1	0	0
21254	1520	rel-related complementary DNA	[rel-related complementary DNA]	1.5849625007211563	3	1	0	0
21255	1520	influx of extracellular ca2+	[influx of extracellular Ca2+]	1.5849625007211563	4	1	0	0
21256	1520	carry a AIR-1 locus	[carrying an AIR-1 locus]	1.5849625007211563	4	1	0	0
21257	1520	msr promoter-reporter gene construct	[MSR promoter-reporter gene construct]	1.5849625007211563	4	1	0	0
21258	1520	TNF alpha antibody	[TNF alpha antibody]	1.5849625007211563	3	2	2	2
21259	1520	tcr -like signal	[TCR -like signals]	1.5849625007211563	3	1	0	0
21260	1520	-557 zeta- luciferase construct	[-557 zeta- luciferase constructs]	1.5849625007211563	4	1	0	0
21261	1520	least a mechanism dependent	[least a mechanism dependent]	1.5849625007211563	4	1	0	0
21262	1520	gene for inflammatory cytokine	[genes for inflammatory cytokines]	1.5849625007211563	4	1	0	0
21263	1520	contain gold ion	[containing gold ion]	1.5849625007211563	3	2	2	2
21264	1520	hsp expression in ec	[Hsp expression in EC]	1.5849625007211563	4	1	0	0
21265	1520	normal myeloid development	[normal myeloid development]	1.5849625007211563	3	1	0	0
21266	1520	alphaIIb subunit chain	[alphaIIb subunit chain]	1.5849625007211563	3	2	2	2
21267	1520	least six discrete subregion	[least six discrete subregions]	1.5849625007211563	4	1	0	0
21268	1520	mouse thymocyte cell line	[mouse thymocyte cell line]	1.5849625007211563	4	1	0	0
21269	1520	vitro level in plasma	[vitro levels in plasma]	1.5849625007211563	4	1	0	0
21270	1520	erythroid k562 cell	[erythroid K562 cells]	1.5849625007211563	3	2	1	1
21271	1520	use tnf-alpha-activity neutralize antibody	[Using TNF-alpha-activity neutralizing antibodies]	1.5849625007211563	4	1	0	0
21272	1520	13 protein coding exon	[13 protein coding exons]	1.5849625007211563	4	1	0	0
21273	1520	delivery of activation signal	[delivery of activation signals]	1.5849625007211563	4	1	0	0
21274	1520	small mitochondrial protein	[small mitochondrial protein]	1.5849625007211563	3	1	0	0
21275	1520	expression of TNF-alpha	[expression of TNF-alpha]	1.5849625007211563	3	1	0	0
21276	1520	augment uptake through CR1	[augmenting uptake through CR1]	1.5849625007211563	4	1	0	0
21277	1520	Thus, EBNA-2 transactivation	[Thus, EBNA-2 transactivation]	1.5849625007211563	3	2	1	1
21278	1520	apparently "nonresponsive" clone	[apparently "nonresponsive" clones]	1.5849625007211563	3	1	0	0
21279	1520	functional promoter region	[functional promoter region]	1.5849625007211563	3	2	2	2
21280	1520	fas ligand cd95l	[Fas ligand CD95L]	1.5849625007211563	3	1	0	0
21281	1520	th1 immune response	[Th1 immune responses]	1.5849625007211563	3	2	2	2
21282	1520	naive t-helper (th) cell	[naive T-helper (Th) cells]	1.5849625007211563	4	1	0	0
21283	1520	activation of pkc.	[activation of PKC.]	1.5849625007211563	3	1	0	0
21284	1520	presence of cellular stimulation	[presence of cellular stimulation]	1.5849625007211563	4	1	0	0
21285	1520	support to previous report	[support to previous reports]	1.5849625007211563	4	1	0	0
21286	1520	absence of this protein	[absence of this protein]	1.5849625007211563	4	1	0	0
21287	1520	transfection of e3 construct	[Transfections of E3 constructs]	1.5849625007211563	4	1	0	0
21288	1520	NGAL -express tumor	[NGAL -expressing tumors]	1.5849625007211563	3	1	0	0
21289	1520	histogenetically distinct, b-cell-derived subtype	[histogenetically distinct, B-cell-derived subtype]	1.5849625007211563	4	1	0	0
21290	1520	immediate early gene egr-1	[immediate early gene egr-1]	1.5849625007211563	4	1	0	0
21291	1520	treatment with pdbu	[treatment with PDBu]	1.5849625007211563	3	1	0	0
21292	1520	osteocalcine in blood serum	[osteocalcine in blood serum]	1.5849625007211563	4	1	0	0
21293	1520	mcr high histologic grade	[MCR high histologic grade]	1.5849625007211563	4	1	0	0
21294	1520	activation of adenylate cyclase	[activation of adenylate cyclase]	1.5849625007211563	4	1	0	0
21295	1520	contain the 5'-flanking region	[containing the 5'-flanking region]	1.5849625007211563	4	1	0	0
21296	1520	fc gamma receptor	[Fc gamma receptor]	1.5849625007211563	3	2	1	1
21297	1520	mobilization of nuclear factor-kappaB	[Mobilization of nuclear factor-kappaB]	1.5849625007211563	4	2	1	1
21298	1520	functional trans-activation domain	[functional trans-activation domain]	1.5849625007211563	3	1	0	0
21299	1520	consequence of cell dysregulation	[consequence of cell dysregulation]	1.5849625007211563	4	1	0	0
21300	1520	cycling of Rat-1 fibroblast	[cycling of Rat-1 fibroblasts]	1.5849625007211563	4	1	0	0
21301	1520	late junb transcription wave	[late junB transcription waves]	1.5849625007211563	4	1	0	0
21302	1520	reporter luciferase gene vector	[Reporter luciferase gene vectors]	1.5849625007211563	4	1	0	0
21303	1520	carboxy-terminal leucin-zipper region	[carboxy-terminal leucin-zipper region]	1.5849625007211563	3	1	0	0
21304	1520	respectively by 13-cis RA	[respectively by 13-cis RA]	1.5849625007211563	4	1	0	0
21305	1520	b cell growth	[B cell growth]	1.5849625007211563	3	2	1	1
21306	1520	evidence for a decrease	[evidence for a decrease]	1.5849625007211563	4	1	0	0
21307	1520	regimen of Kidney-tonifying	[regimen of Kidney-tonifying]	1.5849625007211563	3	1	0	0
21308	1520	les-induced il-6 mrna	[LPS-induced IL-6 mRNA]	1.5849625007211563	3	1	0	0
21309	1520	GM-CSF promoter activity	[GM-CSF promoter activity]	1.5849625007211563	3	1	0	0
21310	1520	upstream of -141	[upstream of -141]	1.5849625007211563	3	1	0	0
21311	1520	sem by Exosurf	[SEM by Exosurf]	1.5849625007211563	3	1	0	0
21312	1520	il-4 gene transcription	[IL-4 gene transcription]	1.5849625007211563	3	1	0	0
21313	1520	inhibitor of phosphoinositide hydrolysis	[inhibitor of phosphoinositide hydrolysis]	1.5849625007211563	4	1	0	0
21314	1520	incubation of extract	[incubation of extracts]	1.5849625007211563	3	2	2	2
21315	1520	vast majority of patient	[vast majority of patients]	1.5849625007211563	4	1	0	0
21316	1520	closely related species,	[closely related species,]	1.5849625007211563	3	1	0	0
21317	1520	percentage of cd4+cd45r0+ cell	[percentage of CD4+CD45R0+ cells]	1.5849625007211563	4	1	0	0
21318	1520	CONCLUSIONS: level of Rap1	[CONCLUSIONS: Levels of Rap1]	1.5849625007211563	4	1	0	0
21319	1520	mitogen-activated protein kinase family	[mitogen-activated protein kinase family]	1.5849625007211563	4	2	1	1
21320	1520	Addisonian picture (group 16.2	[Addisonian picture (group 16.2]	1.5849625007211563	4	1	0	0
21321	1520	example of mammalian development	[examples of mammalian development]	1.5849625007211563	4	1	0	0
21322	1520	ca. two- reduction	[ca. two- reduction]	1.5849625007211563	3	1	0	0
21323	1520	binding of c-Rel	[binding of c-Rel]	1.5849625007211563	3	2	1	1
21324	1520	deletion of this sequence	[Deletion of this sequence]	1.5849625007211563	4	1	0	0
21325	1520	cd45r0 T cell	[CD45R0 T cells]	1.5849625007211563	3	2	2	2
21326	1520	17 kda variant	[17 kDa variant]	1.5849625007211563	3	1	0	0
21327	1520	aberrant tcl1 expression	[Aberrant TCL1 expression]	1.5849625007211563	3	1	0	0
21328	1520	huvec surface vcam-1	[HUVEC surface VCAM-1]	1.5849625007211563	3	1	0	0
21329	1520	normal t-cell activation	[normal T-cell activation]	1.5849625007211563	3	2	2	2
21330	1520	platelet of patient	[platelets of patients]	1.5849625007211563	3	2	2	2
21331	1520	form of ferrous chloride	[form of ferrous chloride]	1.5849625007211563	4	1	0	0
21332	1520	brlf1 Coxriber J.Leahy,	[BRLF1 Cox, J.Leahy,]	1.5849625007211563	3	1	0	0
21333	1520	NF-kappa b/rel inhibition	[NF-kappa B/Rel inhibition]	1.5849625007211563	3	1	0	0
21334	1520	nf-kappa b p65	[NF-kappa B P65]	1.5849625007211563	3	2	1	1
21335	1520	IFN alpha a cytokine	[IFN alpha a cytokine]	1.5849625007211563	4	1	0	0
21336	1520	569 receptor per cell).	[569 receptors per cell).]	1.5849625007211563	4	1	0	0
21337	1520	adult globin program	[adult globin program]	1.5849625007211563	3	2	1	1
21338	1520	allogeneic organ transplant	[allogeneic organ transplants]	1.5849625007211563	3	1	0	0
21339	1520	b-cell-specific promoter of CIITA	[B-cell-specific promoter of CIITA]	1.5849625007211563	4	1	0	0
21340	1520	inhibition of stat6 activity	[Inhibition of STAT6 activity]	1.5849625007211563	4	1	0	0
21341	1520	adult globin express cell	[adult globin expressing cells]	1.5849625007211563	4	1	0	0
21342	1520	immunoglobulin heavy-chain gene	[immunoglobulin heavy-chain gene]	1.5849625007211563	3	1	0	0
21343	1520	patient with lesion	[patients with lesions]	1.5849625007211563	3	2	2	2
21344	1520	conjugation of p53	[conjugation of p53]	1.5849625007211563	3	1	0	0
21345	1520	dominant-active inhibitor of NF-kappaB	[dominant-active inhibitor of NF-kappaB]	1.5849625007211563	4	1	0	0
21346	1520	administration of dexamethasone DEX	[administration of dexamethasone DEX]	1.5849625007211563	4	1	0	0
21347	1520	nf-at binding site	[NF-AT binding site]	1.5849625007211563	3	1	0	0
21348	1520	oligonucleotide contain CRE	[oligonucleotides containing CRE]	1.5849625007211563	3	1	0	0
21349	1520	gene for transcription factor	[genes for transcription factors]	1.5849625007211563	4	1	0	0
21350	1520	only with Rel	[only with Rel]	1.5849625007211563	3	1	0	0
21351	1520	glutathione disulfide in immunology	[glutathione disulfide in immunology]	1.5849625007211563	4	1	0	0
21352	1520	presence of two exon	[presence of two exons]	1.5849625007211563	4	1	0	0
21353	1520	ca2+ -modulate cyclophilin ligand	[Ca2+ -modulating cyclophilin ligand]	1.5849625007211563	4	2	1	1
21354	1520	nuclear transcription factor AP-1	[nuclear transcription factors AP-1]	1.5849625007211563	4	1	0	0
21355	1520	result of gene target	[results of gene targeting]	1.5849625007211563	4	1	0	0
21356	1520	1.9 (1.3-7.6) fmol/10(7) cell	[1.9 (1.3-7.6) fmol/10(7) cells]	1.5849625007211563	4	1	0	0
21357	1520	androgen receptor bind assay	[androgen receptor binding assay]	1.5849625007211563	4	1	0	0
21358	1520	quiescent haemopoietic cell	[quiescent haemopoietic cells]	1.5849625007211563	3	1	0	0
21359	1520	immunoglobulin e production	[immunoglobulin E production]	1.5849625007211563	3	1	0	0
21360	1520	phosphotyrosine antibody 4g10	[phosphotyrosine antibody 4G10]	1.5849625007211563	3	1	0	0
21361	1520	membrane receptor expression	[membrane receptor expression]	1.5849625007211563	3	1	0	0
21362	1520	tnf gene expression	[TNF gene expression]	1.5849625007211563	3	2	1	1
21363	1520	constitutive expression in monocyte	[constitutive expression in monocytes]	1.5849625007211563	4	2	1	1
21364	1520	two 4-trifluoromethyl salicylate derivative	[two 4-trifluoromethyl salicylate derivatives]	1.5849625007211563	4	1	0	0
21365	1520	x chromosome in cell	[X chromosome in cells]	1.5849625007211563	4	2	1	1
21366	1520	30-kd protein product	[30-kD protein product]	1.5849625007211563	3	1	0	0
21367	1520	variable VDR expression	[variable VDR expression]	1.5849625007211563	3	1	0	0
21368	1520	transcription (stat) factor	[transcription (STAT) factors]	1.5849625007211563	3	4	3	1
21369	1520	virus contain mutation	[viruses containing mutations]	1.5849625007211563	3	2	1	1
21370	1520	one function of c-Rel	[one function of c-Rel]	1.5849625007211563	4	1	0	0
21371	1520	other human gene	[other human genes]	1.5849625007211563	3	1	0	0
21372	1520	intermediate filament protein vimentin	[intermediate filament protein vimentin]	1.5849625007211563	4	1	0	0
21373	1520	HTLV-1 t-cell line	[HTLV-1 T-cell lines]	1.5849625007211563	3	1	0	0
21374	1520	specific binding activity	[specific binding activity]	1.5849625007211563	3	2	2	2
21375	1520	nuclear factor binding	[nuclear factor binding]	1.5849625007211563	3	2	1	1
21376	1520	complex of high m(r)	[complex of higher M(r)]	1.5849625007211563	4	1	0	0
21377	1520	myb-like DNA binding domain	[myb-like DNA binding domain]	1.5849625007211563	4	1	0	0
21378	1520	investigation of the role	[investigation of the role]	1.5849625007211563	4	1	0	0
21379	1520	important regulatory domain	[important regulatory domains]	1.5849625007211563	3	1	0	0
21380	1520	exposure to TNFalpha	[exposure to TNFalpha]	1.5849625007211563	3	1	0	0
21381	1520	glucocorticoid resistance aids -c	[glucocorticoid resistance AIDS -C]	1.5849625007211563	4	1	0	0
21382	1520	late hexon ad protein	[late hexon Ad proteins]	1.5849625007211563	4	1	0	0
21383	1520	cell to cell adhesion	[cell to cell adhesion]	1.5849625007211563	4	1	0	0
21384	1520	intracellular prooxidant state	[intracellular prooxidant state]	1.5849625007211563	3	1	0	0
21385	1520	IgH 3' LCR	[IgH 3' LCR]	1.5849625007211563	3	1	0	0
21386	1520	early stage of development	[early stage of development]	1.5849625007211563	4	2	2	2
21387	1520	T cell receptor complex	[T cell receptor complex]	1.5849625007211563	4	1	0	0
21388	1520	change in fkbp51	[changes in FKBP51]	1.5849625007211563	3	1	0	0
21389	1520	210 7%, respectively,	[210 7%, respectively,]	1.5849625007211563	3	1	0	0
21390	1520	underlying suppression by CsA	[underlying suppression by CsA]	1.5849625007211563	4	1	0	0
21391	1520	control of the region	[control of the region]	1.5849625007211563	4	1	0	0
21392	1520	fp treatment (36.6	[FP treatment (36.6]	1.5849625007211563	3	1	0	0
21393	1520	progesterone receptor gene	[progesterone receptor gene]	1.5849625007211563	3	1	0	0
21394	1520	relief of cyclin	[Relief of cyclin]	1.5849625007211563	3	1	0	0
21395	1520	b- all case	[B- ALL cases]	1.5849625007211563	3	1	0	0
21396	1520	epo -independent hcd57-srei cell	[EPO -independent HCD57-SREI cells]	1.5849625007211563	4	1	0	0
21397	1520	eighteen different kox gene	[eighteen different KOX genes]	1.5849625007211563	4	1	0	0
21398	1520	response to mitogen stimulation	[response to mitogen stimulation]	1.5849625007211563	4	1	0	0
21399	1520	human blood T lymphoblast	[human blood T lymphoblasts]	1.5849625007211563	4	2	2	2
21400	1520	osteocalcin promoter activity	[osteocalcin promoter activity]	1.5849625007211563	3	1	0	0
21401	1520	statistically significant effect	[statistically significant effect]	1.5849625007211563	3	1	0	0
21402	1520	galectin-3 promoter induction	[galectin-3 promoter induction]	1.5849625007211563	3	1	0	0
21403	1520	similar DNA binding activity	[Similar DNA binding activity]	1.5849625007211563	4	1	0	0
21404	1520	NK cell functions,	[NK cell functions,]	1.5849625007211563	3	1	0	0
21405	1520	T cell line ach-2	[T cell line ACH-2]	1.5849625007211563	4	1	0	0
21406	1520	erythropoietin -dependent manner	[erythropoietin -dependent manner]	1.5849625007211563	3	1	0	0
21407	1520	promising tool for diagnosis.	[promising tool for diagnosis.]	1.5849625007211563	4	1	0	0
21408	1520	hypercholesterolemia by glucocorticoid	[hypercholesterolemia by glucocorticoids]	1.5849625007211563	3	1	0	0
21409	1520	T cell-receptor-induced fasl upregulation	[T cell-receptor-induced FasL upregulation]	1.5849625007211563	4	1	0	0
21410	1520	production of the cytokine	[production of the cytokines]	1.5849625007211563	4	1	0	0
21411	1520	phosphorylation site of NFATp	[phosphorylation sites of NFATp]	1.5849625007211563	4	1	0	0
21412	1520	putative AP-1 recognition sequence	[putative AP-1 recognition sequence]	1.5849625007211563	4	1	0	0
21413	1520	inward rectifier K+ channel	[inward rectifier K+ channel]	1.5849625007211563	4	1	0	0
21414	1520	stage-specific expression of CD20	[stage-specific expression of CD20]	1.5849625007211563	4	1	0	0
21415	1520	formalin-fixed paraffin section	[Formalin-fixed paraffin sections]	1.5849625007211563	3	1	0	0
21416	1520	other nonsteroidal drug	[other nonsteroidal drugs]	1.5849625007211563	3	2	2	2
21417	1520	induction of nf-at	[induction of NF-AT]	1.5849625007211563	3	1	0	0
21418	1520	neuronal ceroid-lypofuscinosis NCL	[neuronal ceroid-lypofuscinosis NCL]	1.5849625007211563	3	1	0	0
21419	1520	dimer of Jun/Jun	[dimer of Jun/Jun]	1.5849625007211563	3	1	0	0
21420	1520	chemotaxis of pmn (10(-10)	[chemotaxis of PMNs (10(-10)]	1.5849625007211563	4	1	0	0
21421	1520	similar age distribution	[similar age distribution]	1.5849625007211563	3	1	0	0
21422	1520	hybrid clone, nr2	[hybrid clone, NR2]	1.5849625007211563	3	1	0	0
21423	1520	suggest a intervention	[suggesting an intervention]	1.5849625007211563	3	1	0	0
21424	1520	Nuclear factor-kappaB induction	[Nuclear factor-kappaB induction]	1.5849625007211563	3	2	2	2
21425	1520	human interleukin-3 il-3 gene	[human interleukin-3 IL-3 gene]	1.5849625007211563	4	1	0	0
21426	1520	upstream of -224	[upstream of -224,]	1.5849625007211563	3	1	0	0
21427	1520	prevalence of DNA aneuploidy	[prevalence of DNA aneuploidy]	1.5849625007211563	4	1	0	0
21428	1520	cell-specific activate protein bsap/pax5	[cell-specific activating protein BSAP/PAX5]	1.5849625007211563	4	1	0	0
21429	1520	(hla-b8)-positive virus carrier	[(HLA-B8)-positive virus carriers]	1.5849625007211563	3	1	0	0
21430	1520	NF-Y binding activity	[NF-Y binding activity]	1.5849625007211563	3	1	0	0
21431	1520	cocultivation of rd cell	[cocultivation of RD cells]	1.5849625007211563	4	1	0	0
21432	1520	two b transcriptional coactivator	[two B transcriptional coactivators]	1.5849625007211563	4	2	2	2
21433	1520	double-stranded DNA target	[double-stranded DNA target]	1.5849625007211563	3	1	0	0
21434	1520	acth in aids patient	[ACTH in AIDS patients]	1.5849625007211563	4	1	0	0
21435	1520	223-amino acid protein	[223-amino acid protein]	1.5849625007211563	3	1	0	0
21436	1520	adult erythroid-specific genomic footprint	[adult erythroid-specific genomic footprint]	1.5849625007211563	4	1	0	0
21437	1520	guanine nucleotide binding factor	[guanine nucleotide binding factor]	1.5849625007211563	4	1	0	0
21438	1520	spleen of mouse	[spleens of mice]	1.5849625007211563	3	2	2	2
21439	1520	difference in function,	[differences in function,]	1.5849625007211563	3	1	0	0
21440	1520	fmol/million cells; p	[fmol/million cells; P]	1.5849625007211563	3	2	2	2
21441	1520	different U2 enhancer construction	[different U2 enhancer constructions]	1.5849625007211563	4	1	0	0
21442	1520	human ifngr1 small deletion	[human IFNGR1 small deletions]	1.5849625007211563	4	1	0	0
21443	1520	only by cycloheximide	[only by cycloheximide]	1.5849625007211563	3	1	0	0
21444	1520	common sequence variant	[common sequence variants]	1.5849625007211563	3	1	0	0
21445	1520	800-base pair proximal promoter	[800-base pair proximal promoter]	1.5849625007211563	4	1	0	0
21446	1520	thyroid hormone receptor thr	[thyroid hormone receptor THR]	1.5849625007211563	4	1	0	0
21447	1520	immune response by Ras	[immune response by Ras]	1.5849625007211563	4	1	0	0
21448	1520	major inducible protein complex	[major inducible protein complex]	1.5849625007211563	4	1	0	0
21449	1520	nuclear factor-kappa b activity	[nuclear factor-kappa B activity]	1.5849625007211563	4	2	1	1
21450	1520	sensitive pcr-based technique	[sensitive PCR-based techniques]	1.5849625007211563	3	1	0	0
21451	1520	absence of insulin	[absence of insulin]	1.5849625007211563	3	1	0	0
21452	1520	T cell activation signals.	[T cell activation signals.]	1.5849625007211563	4	1	0	0
21453	1520	T cell activation signals,	[T cell activation signals,]	1.5849625007211563	4	1	0	0
21454	1520	erk1 kinase activity,	[ERK1 kinase activity,]	1.5849625007211563	3	1	0	0
21455	1520	exactly the same phenomenon	[exactly the same phenomenon]	1.5849625007211563	4	1	0	0
21456	1520	terminal T cell differentiation	[terminal T cell differentiation]	1.5849625007211563	4	1	0	0
21457	1520	high grbeta expression	[high GRbeta expression]	1.5849625007211563	3	1	0	0
21458	1520	upstream activator of PKB/Akt	[upstream activator of PKB/Akt]	1.5849625007211563	4	1	0	0
21459	1520	activation of promoter	[activation of promoters]	1.5849625007211563	3	2	2	2
21460	1520	synthesis of rrna	[synthesis of mRNAs]	1.5849625007211563	3	1	0	0
21461	1520	phorbol ester -dependent differentiation	[phorbol ester -dependent differentiation]	1.5849625007211563	4	1	0	0
21462	1520	transcription factor ets-1	[transcription factors Ets-1]	1.5849625007211563	3	1	0	0
21463	1520	tumor suppressor p16(ink4a)	[tumor suppressor p16(INK4A)]	1.5849625007211563	3	1	0	0
21464	1520	immature hematopoietic cell	[immature hematopoietic cells]	1.5849625007211563	3	1	0	0
21465	1520	addition block abs	[addition blocking Abs]	1.5849625007211563	3	1	0	0
21466	1520	novel negative regulatory element	[novel negative regulatory element]	1.5849625007211563	4	1	0	0
21467	1520	bovine papilloma virus bpv	[bovine papilloma virus BPV]	1.5849625007211563	4	1	0	0
21468	1520	tal-1 oncogenic potential	[tal-1 oncogenic potential]	1.5849625007211563	3	1	0	0
21469	1520	interplay between metabolic stimulus	[interplay between metabolic stimuli]	1.5849625007211563	4	1	0	0
21470	1520	synthetic peptide Arg-Gly-Asp RGD	[synthetic peptide Arg-Gly-Asp RGD]	1.5849625007211563	4	1	0	0
21471	1520	electrophoretic mobility of complex	[electrophoretic mobility of complexes]	1.5849625007211563	4	1	0	0
21472	1520	activated, glucocorticoid receptor	[activated, glucocorticoid receptors]	1.5849625007211563	3	1	0	0
21473	1520	other mechanism of action.	[other mechanisms of action.]	1.5849625007211563	4	1	0	0
21474	1520	effect of ultra-violet light	[effect of UV light]	1.5849625007211563	4	1	0	0
21475	1520	69-bp proximal promoter fragment	[69-bp proximal promoter fragment]	1.5849625007211563	4	1	0	0
21476	1520	target the inhibitory molecule	[targeting the inhibitory molecule]	1.5849625007211563	4	1	0	0
21477	1520	pattern of bind activity	[pattern of binding activity]	1.5849625007211563	4	1	0	0
21478	1520	traf3 binding site	[TRAF3 binding sites]	1.5849625007211563	3	2	2	2
21479	1520	cellular macromolecular synthesis	[cellular macromolecular synthesis]	1.5849625007211563	3	1	0	0
21480	1520	5 e1a-region Ad5E1A234-243	[5 E1A-region Ad5E1A234-243]	1.5849625007211563	3	1	0	0
21481	1520	low level activity	[low level activity]	1.5849625007211563	3	2	2	2
21482	1520	regulator of numerous gene	[regulator of numerous genes]	1.5849625007211563	4	2	2	2
21483	1520	variety of genes.	[variety of genes.]	1.5849625007211563	3	2	1	1
21484	1520	mechanism of trophoblast invasion	[mechanism of trophoblast invasion]	1.5849625007211563	4	1	0	0
21485	1520	West African African population	[West African African populations]	1.5849625007211563	4	1	0	0
21486	1520	response to granulocyte-macrophage CSF	[response to granulocyte-macrophage CSF]	1.5849625007211563	4	1	0	0
21487	1520	induction of 24-hydroxylase message	[induction of 24-hydroxylase message]	1.5849625007211563	4	1	0	0
21488	1520	il-6 luciferase construct	[IL-6 luciferase constructs]	1.5849625007211563	3	1	0	0
21489	1520	early b lymphocyte	[early B lymphocytes]	1.5849625007211563	3	1	0	0
21490	1520	ebv nuclear antigen EBNA	[EBV nuclear antigen EBNA]	1.5849625007211563	4	1	0	0
21491	1520	m-tat/scf cell respectively.	[M-TAT/SCF cells respectively.]	1.5849625007211563	3	1	0	0
21492	1520	observation of AGS patient	[observations of AGS patients]	1.5849625007211563	4	1	0	0
21493	1520	join BSLF2 to BMLF1	[joining BSLF2 to BMLF1]	1.5849625007211563	4	1	0	0
21494	1520	molt 4 T cell	[Molt 4 T cells]	1.5849625007211563	4	1	0	0
21495	1520	epithelial fusion partner	[epithelial fusion partner]	1.5849625007211563	3	1	0	0
21496	1520	interaction of LMP1	[interaction of LMP1]	1.5849625007211563	3	1	0	0
21497	1520	signal 1 tcr signal	[signal 1 TCR signal]	1.5849625007211563	4	1	0	0
21498	1520	inhibition of IL-2 production	[inhibition of IL-2 production]	1.5849625007211563	4	1	0	0
21499	1520	include up-regulation of cd23	[including up-regulation of CD23]	1.5849625007211563	4	1	0	0
21500	1520	normal cellular function	[normal cellular function]	1.5849625007211563	3	1	0	0
21501	1520	actinomycin d pulse experiment	[actinomycin D pulse experiments]	1.5849625007211563	4	1	0	0
21502	1520	expression of tnfrp55	[expression of TNFRp55]	1.5849625007211563	3	1	0	0
21503	1520	factor with property	[factor with properties]	1.5849625007211563	3	2	2	2
21504	1520	expression of oct-2 mrna	[expression of Oct-2 mRNA]	1.5849625007211563	4	1	0	0
21505	1520	most b cell clone	[most B cell clones]	1.5849625007211563	4	1	0	0
21506	1520	DU-145 cell line	[DU-145 cell lines]	1.5849625007211563	3	1	0	0
21507	1520	synergistic induction by interferon-gamma	[synergistic induction by interferon-gamma]	1.5849625007211563	4	1	0	0
21508	1520	normal control group (4462	[normal control group (4462]	1.5849625007211563	4	1	0	0
21509	1520	distinct regulatory element	[distinct regulatory elements]	1.5849625007211563	3	2	1	1
21510	1520	t-cell-leukemia virus type	[T-cell-leukemia virus type]	1.5849625007211563	3	2	2	2
21511	1520	10 microm kn-62	[10 microM KN-62]	1.5849625007211563	3	1	0	0
21512	1520	level of c-Fos	[levels of c-Fos]	1.5849625007211563	3	1	0	0
21513	1520	human ets-1 protein	[human ets-1 protein]	1.5849625007211563	3	1	0	0
21514	1520	human cd4+ t-cell clone	[human CD4+ T-cell clones]	1.5849625007211563	4	2	2	2
21515	1520	tandem CRE motif	[tandem CRE motifs]	1.5849625007211563	3	1	0	0
21516	1520	cell cycle exit	[cell cycle exit]	1.5849625007211563	3	1	0	0
21517	1520	9-cis RA RXR alpha	[9-CIS RA RXR alpha]	1.5849625007211563	4	1	0	0
21518	1520	absence of exogenous cytokine	[absence of exogenous cytokines]	1.5849625007211563	4	1	0	0
21519	1520	level of the cell	[level of the cell]	1.5849625007211563	4	1	0	0
21520	1520	b lymphocyte immortalization	[B lymphocyte immortalization]	1.5849625007211563	3	1	0	0
21521	1520	Nef -express cell	[Nef -expressing cells]	1.5849625007211563	3	1	0	0
21522	1520	role in the release	[role in the release]	1.5849625007211563	4	2	2	2
21523	1520	lymphoid-related DC in vivo	[lymphoid-related DC in vivo]	1.5849625007211563	4	1	0	0
21524	1520	expression of nf-il-6	[expression of NF-IL-6]	1.5849625007211563	3	1	0	0
21525	1520	T cell zone	[T cell zone]	1.5849625007211563	3	2	1	1
21526	1520	individual with spinal atrophy	[individual with spinal atrophy]	1.5849625007211563	4	1	0	0
21527	1520	3.8-kb genomic fragment	[3.8-kb genomic fragment]	1.5849625007211563	3	1	0	0
21528	1520	nre gamma site	[NRE gamma site]	1.5849625007211563	3	1	0	0
21529	1520	second inducible inhibitory pathway	[second inducible inhibitory pathway]	1.5849625007211563	4	1	0	0
21530	1520	cell overexpress hsf2-beta	[cells overexpressing HSF2-beta]	1.5849625007211563	3	1	0	0
21531	1520	activity of each element	[activity of each element]	1.5849625007211563	4	1	0	0
21532	1520	IL-1 beta expression	[IL-1 beta expression]	1.5849625007211563	3	1	0	0
21533	1520	region of LMP1	[region of LMP1]	1.5849625007211563	3	1	0	0
21534	1520	range of stimulation conditions.	[range of stimulation conditions.]	1.5849625007211563	4	1	0	0
21535	1520	parallel plate flow chamber	[parallel plate flow chamber]	1.5849625007211563	4	1	0	0
21536	1520	tumor necrosis factor tnf-alpha	[tumor necrosis factor TNF-alpha]	1.5849625007211563	4	1	0	0
21537	1520	development of neutrophilic granulocyte	[development of neutrophilic granulocytes]	1.5849625007211563	4	1	0	0
21538	1520	cellular activation and/or differentiation	[cellular activation and/or differentiation]	1.5849625007211563	4	1	0	0
21539	1520	presentation of peptide	[Presentation of peptide]	1.5849625007211563	3	2	2	2
21540	1520	antioxidant treatment on lipopolysaccharide	[antioxidant treatment on lipopolysaccharide]	1.5849625007211563	4	1	0	0
21541	1520	ca2+ transport in platelet	[Ca2+ transport in platelets]	1.5849625007211563	4	1	0	0
21542	1520	DNA fragmentation study	[DNA fragmentation studies]	1.5849625007211563	3	1	0	0
21543	1520	stage selector activity	[stage selector activity]	1.5849625007211563	3	1	0	0
21544	1520	hla-dr alpha mrna	[HLA-DR alpha mRNA]	1.5849625007211563	3	1	0	0
21545	1520	cotransfection into non-T cell	[cotransfection into non-T cells]	1.5849625007211563	4	1	0	0
21546	1520	phosphorylation of c-Jun	[phosphorylation of c-Jun]	1.5849625007211563	3	2	1	1
21547	1520	contrast, dominant negative rac	[contrast, dominant negative Rac]	1.5849625007211563	4	1	0	0
21548	1520	role of RelB	[role of RelB]	1.5849625007211563	3	1	0	0
21549	1520	aldosterone on intracellular electrolyte	[aldosterone on intracellular electrolytes]	1.5849625007211563	4	1	0	0
21550	1520	endothelium from blood	[endothelium from blood]	1.5849625007211563	3	1	0	0
21551	1520	cis -acting element	[cis -acting elements]	1.5849625007211563	3	1	0	0
21552	1520	cell-specific difference in factors,	[cell-specific differences in factors,]	1.5849625007211563	4	1	0	0
21553	1520	salivary gland of patient	[salivary glands of patients]	1.5849625007211563	4	2	2	2
21554	1520	reside primarily within RelB	[residing primarily within RelB]	1.5849625007211563	4	1	0	0
21555	1520	background: Retinoic acid RA	[BACKGROUND: Retinoic acid RA]	1.5849625007211563	4	1	0	0
21556	1520	70-bp ifn-gamma response element	[70-bp IFN-gamma response element]	1.5849625007211563	4	1	0	0
21557	1520	multiple minor susceptibility gene	[multiple minor susceptibility genes]	1.5849625007211563	4	1	0	0
21558	1520	alter mrna half-life	[altering mRNA half-life]	1.5849625007211563	3	1	0	0
21559	1520	promoter on the recruitment	[promoter on the recruitment]	1.5849625007211563	4	1	0	0
21560	1520	germline cepsilon transcription	[germline Cepsilon transcription]	1.5849625007211563	3	2	1	1
21561	1520	well-documented biological phenomenon	[well-documented biological phenomenon]	1.5849625007211563	3	1	0	0
21562	1520	immature erythroid cell	[immature erythroid cells]	1.5849625007211563	3	1	0	0
21563	1520	adhesion of ss RBC	[adhesion of SS RBC]	1.5849625007211563	4	1	0	0
21564	1520	different effect on lps	[different effects on LPS]	1.5849625007211563	4	1	0	0
21565	1520	coexpression with p65 Rel	[coexpression with p65 Rel]	1.5849625007211563	4	1	0	0
21566	1520	chromosome (Chr) 20	[Chromosome (Chr) 20]	1.5849625007211563	3	1	0	0
21567	1520	modulation of transcriptional activity	[modulation of transcriptional activity]	1.5849625007211563	4	1	0	0
21568	1520	functional significance of mutation	[functional significance of mutations]	1.5849625007211563	4	1	0	0
21569	1520	spread of hiv-1	[spread of HIV-1]	1.5849625007211563	3	1	0	0
21570	1520	VCAM-1 gene promoter	[VCAM-1 gene promoter]	1.5849625007211563	3	1	0	0
21571	1520	constitutive sla-dr expression	[constitutive SLA-DR expression]	1.5849625007211563	3	1	0	0
21572	1520	base on this experiments,	[Basing on these experiments,]	1.5849625007211563	4	1	0	0
21573	1520	increase in mrna accumulation	[increase in mRNA accumulation]	1.5849625007211563	4	1	0	0
21574	1520	novel inducible protein	[novel inducible protein]	1.5849625007211563	3	1	0	0
21575	1520	human myeloid leukemic cell	[human myeloid leukemic cells]	1.5849625007211563	4	1	0	0
21576	1520	bind site for protein	[binding site for proteins]	1.5849625007211563	4	2	1	1
21577	1520	single-chain Fv sFv	[single-chain Fv sFv]	1.5849625007211563	3	1	0	0
21578	1520	induce continuous proliferation	[inducing continuous proliferation]	1.5849625007211563	3	1	0	0
21579	1520	anti-ig inducibility of zp	[anti-Ig inducibility of Zp]	1.5849625007211563	4	1	0	0
21580	1520	15-base oligonucleotide GM3	[15-base oligonucleotide GM3]	1.5849625007211563	3	1	0	0
21581	1520	accumulation of isgf3 gamma	[accumulation of ISGF3 gamma]	1.5849625007211563	4	1	0	0
21582	1520	novel t-cell trans-activator	[novel T-cell trans-activator]	1.5849625007211563	3	1	0	0
21583	1520	two distinct stimuli, lipopolysaccharide	[two distinct stimuli, lipopolysaccharide]	1.5849625007211563	4	1	0	0
21584	1520	inhibitor of pa phosphohydrolase	[inhibitor of PA phosphohydrolase]	1.5849625007211563	4	1	0	0
21585	1520	way to study	[way to studies]	1.5849625007211563	3	1	0	0
21586	1520	mite-specific helper T cell	[mite-specific helper T cells]	1.5849625007211563	4	1	0	0
21587	1520	conditional tyrosine kinase oncogene	[conditional tyrosine kinase oncogene]	1.5849625007211563	4	1	0	0
21588	1520	potential regulatory sequence similar	[potential regulatory sequences similar]	1.5849625007211563	4	1	0	0
21589	1520	work from laboratory,	[work from laboratory,]	1.5849625007211563	3	1	0	0
21590	1520	somatic hypermutation mechanism active	[somatic hypermutation mechanism active]	1.5849625007211563	4	1	0	0
21591	1520	term of kinetic	[terms of kinetics]	1.5849625007211563	3	1	0	0
21592	1520	gamma chain gene	[gamma chain gene]	1.5849625007211563	3	2	1	1
21593	1520	21 adult control (21-50	[21 adult controls (21-50]	1.5849625007211563	4	1	0	0
21594	1520	cytomegalovirus transactivator gene	[cytomegalovirus transactivator gene]	1.5849625007211563	3	1	0	0
21595	1520	appearance of a smear	[appearance of a smear]	1.5849625007211563	4	1	0	0
21596	1520	DNA sequence information	[DNA sequence information]	1.5849625007211563	3	1	0	0
21597	1520	lymphoblastoid cell outgrowth	[lymphoblastoid cell outgrowth]	1.5849625007211563	3	2	1	1
21598	1520	immediate-early transcriptional transactivator	[immediate-early transcriptional transactivators]	1.5849625007211563	3	1	0	0
21599	1520	pattern of differential expression	[pattern of differential expression]	1.5849625007211563	4	1	0	0
21600	1520	TCF-1 -specific hybridoma	[TCF-1 -specific hybridomas]	1.5849625007211563	3	1	0	0
21601	1520	nucleosome-assembled DNA in vitro.	[nucleosome-assembled DNA in vitro.]	1.5849625007211563	4	1	0	0
21602	1520	deletion of exon 2	[deletions of exons 2]	1.5849625007211563	4	1	0	0
21603	1520	nuclear protein binding site	[nuclear protein binding sites]	1.5849625007211563	4	2	1	1
21604	1520	300 base pair	[300 base pairs]	1.5849625007211563	3	1	0	0
21605	1520	widespread inactivation of gene	[widespread inactivation of genes]	1.5849625007211563	4	1	0	0
21606	1520	unicellular culture system	[unicellular culture systems]	1.5849625007211563	3	1	0	0
21607	1520	family of anti-inflammatory agent	[family of anti-inflammatory agents]	1.5849625007211563	4	1	0	0
21608	1520	Nef jurkat cell	[Nef Jurkat cells]	1.5849625007211563	3	1	0	0
21609	1520	tumor necrosis factor-alpha induction	[tumor necrosis factor-alpha induction]	1.5849625007211563	4	1	0	0
21610	1520	5.33 fmol/10(6) cell	[5.33 fmol/10(6) cells]	1.5849625007211563	3	1	0	0
21611	1520	murine acute promyelocytic leukemia	[murine acute promyelocytic leukemia]	1.5849625007211563	4	1	0	0
21612	1520	number of b lymphocyte	[number of B lymphocytes]	1.5849625007211563	4	1	0	0
21613	1520	high-affinity ibr/f binding site	[high-affinity IBR/F binding sites]	1.5849625007211563	4	1	0	0
21614	1520	endogenous il-2 gene	[endogenous IL-2 gene]	1.5849625007211563	3	1	0	0
21615	1520	epo receptor expression	[Epo receptor expression]	1.5849625007211563	3	1	0	0
21616	1520	fmol/microgram of DNA,	[fmol/micrograms of DNA,]	1.5849625007211563	3	1	0	0
21617	1520	binding of nfkb2 p49	[binding of NFKB2 p49]	1.5849625007211563	4	1	0	0
21618	1520	hiv-1 in vitro.	[HIV-1 in vitro.]	1.5849625007211563	3	1	0	0
21619	1520	chromosome 1 abnormality	[Chromosome 1 abnormalities]	1.5849625007211563	3	2	2	2
21620	1520	other experimental strategy	[Other experimental strategies]	1.5849625007211563	3	1	0	0
21621	1520	adult globin gene program	[adult globin gene program]	1.5849625007211563	4	1	0	0
21622	1520	on, ikappab-alpha degradation	[on, IkappaB-alpha degradation]	1.5849625007211563	3	1	0	0
21623	1520	globin gene transcription	[globin gene transcription]	1.5849625007211563	3	1	0	0
21624	1520	direct reporter gene expression	[directing reporter gene expression]	1.5849625007211563	4	1	0	0
21625	1520	CD19 promoter use	[CD19 promoter using]	1.5849625007211563	3	1	0	0
21626	1520	antiinflammatory, antiallergic, activity in	[antiinflammatory, antiallergic, activities in]	1.5849625007211563	4	1	0	0
21627	1520	camp -dependent signal pathway	[cAMP -dependent signaling pathway]	1.5849625007211563	4	2	1	1
21628	1520	immune function particularly,	[immune functions particularly,]	1.5849625007211563	3	1	0	0
21629	1520	transcription of some genes,	[transcription of some genes,]	1.5849625007211563	4	1	0	0
21630	1520	high eukaryotic gene	[higher eukaryotic gene]	1.5849625007211563	3	1	0	0
21631	1520	b-cell-specific transcription coactivator	[B-cell-specific transcription coactivator]	1.5849625007211563	3	1	0	0
21632	1520	single point mutation	[single point mutation]	1.5849625007211563	3	2	1	1
21633	1520	T cell receptor stimulation	[T cell receptor stimulation]	1.5849625007211563	4	3	2	1
21634	1520	surface expression of CD23	[Surface expression of CD23]	1.5849625007211563	4	1	0	0
21635	1520	seven resistant patient	[seven resistant patients]	1.5849625007211563	3	1	0	0
21636	1520	suggest a interaction	[suggesting a interaction]	1.5849625007211563	3	2	2	2
21637	1520	thus, human erythroid precursor	[Thus, human erythroid precursors]	1.5849625007211563	4	1	0	0
21638	1520	control of the repeat	[control of the repeat]	1.5849625007211563	4	1	0	0
21639	1520	platelet from woman	[platelets from women]	1.5849625007211563	3	2	1	1
21640	1520	dephosphorylation of nfatp	[dephosphorylation of NFATp]	1.5849625007211563	3	1	0	0
21641	1520	272 carboxy-terminal amino acid	[272 carboxy-terminal amino acids]	1.5849625007211563	4	1	0	0
21642	1520	RB -defective lines.	[RB -defective lines.]	1.5849625007211563	3	1	0	0
21643	1520	importance of NF-kappaB complex	[importance of NF-kappaB complexes]	1.5849625007211563	4	1	0	0
21644	1520	matrix metalloproteinase 9	[matrix metalloproteinase 9]	1.5849625007211563	3	2	1	1
21645	1520	involvement of RXR alpha	[involvement of RXR alpha]	1.5849625007211563	4	1	0	0
21646	1520	nuclear export receptor crm1	[nuclear export receptor CRM1]	1.5849625007211563	4	1	0	0
21647	1520	small number of controls.	[small number of controls.]	1.5849625007211563	4	1	0	0
21648	1520	oxidative species capable	[oxidative species capable]	1.5849625007211563	3	1	0	0
21649	1520	transcriptional regulation of hiv-1	[transcriptional regulation of HIV-1]	1.5849625007211563	4	1	0	0
21650	1520	decrease in cox-2 expression	[decrease in COX-2 expression]	1.5849625007211563	4	1	0	0
21651	1520	YY1 LSF erratum	[YY1 LSF erratum]	1.5849625007211563	3	1	0	0
21652	1520	new mechanism for regulation	[new mechanism for regulation]	1.5849625007211563	4	1	0	0
21653	1520	activation of Raf-1	[activation of Raf-1]	1.5849625007211563	3	1	0	0
21654	1520	so-far-unrecognized SP-1 site	[so-far-unrecognized SP-1 site]	1.5849625007211563	3	1	0	0
21655	1520	biologically active lipid	[biologically active lipids]	1.5849625007211563	3	1	0	0
21656	1520	rate of lymphocyte infiltration	[rate of lymphocyte infiltration]	1.5849625007211563	4	1	0	0
21657	1520	ad5 e1a deletion mutant	[Ad5 E1A deletion mutant]	1.5849625007211563	4	1	0	0
21658	1520	minute (phase 1)	[minutes (phase 1)]	1.5849625007211563	3	2	2	2
21659	1520	early b-lymphocyte development	[early B-lymphocyte development]	1.5849625007211563	3	1	0	0
21660	1520	I HTLV-I ATL-1k	[I HTLV-I ATL-1k]	1.5849625007211563	3	1	0	0
21661	1520	60 minute of induction.	[60 min of induction.]	1.5849625007211563	4	1	0	0
21662	1520	next 6 hr.	[next 6 hr.]	1.5849625007211563	3	1	0	0
21663	1520	b cell maturation	[B cell maturation]	1.5849625007211563	3	2	1	1
21664	1520	activation status of cell	[activation status of cells]	1.5849625007211563	4	1	0	0
21665	1520	siv-infected rhesus macaque	[SIV-infected rhesus macaques]	1.5849625007211563	3	1	0	0
21666	1520	A. Rosen, Exp.Cell	[A. Rosen, Exp.Cell]	1.5849625007211563	3	1	0	0
21667	1520	chloramphenicol acetyltransferase reporter	[chloramphenicol acetyltransferase reporter]	1.5849625007211563	3	2	2	2
21668	1520	UCSD-AML1 cell line	[UCSD-AML1 cell line]	1.5849625007211563	3	1	0	0
21669	1520	low amount of il-2	[low amounts of IL-2]	1.5849625007211563	4	1	0	0
21670	1520	use lps-free condition	[Using LPS-free conditions]	1.5849625007211563	3	1	0	0
21671	1520	surgery), proliferation of pbmc	[surgery), proliferation of PBMCs]	1.5849625007211563	4	1	0	0
21672	1520	sterol regulatory element SRE	[Sterol regulatory element SRE]	1.5849625007211563	4	2	1	1
21673	1520	bacterial actin -based motility	[bacterial actin -based motility]	1.5849625007211563	4	1	0	0
21674	1520	bioactive il-12 production	[bioactive IL-12 production]	1.5849625007211563	3	1	0	0
21675	1520	oxygen intermediate formation	[oxygen intermediate formation]	1.5849625007211563	3	2	2	2
21676	1520	such as disease	[such as disease]	1.5849625007211563	3	2	1	1
21677	1520	il-10 on cytokine production	[IL-10 on cytokine production]	1.5849625007211563	4	1	0	0
21678	1520	il-2 -dependent line	[IL-2 -dependent lines]	1.5849625007211563	3	1	0	0
21679	1520	abundant cytosolic receptor	[abundant cytosolic receptors]	1.5849625007211563	3	1	0	0
21680	1520	CD20 +/cd10-/cd5- b cell	[CD20 +/CD10-/CD5- B cells]	1.5849625007211563	4	1	0	0
21681	1520	redox change in vivo	[redox changes in vivo]	1.5849625007211563	4	1	0	0
21682	1520	CD28 minimal promoter	[CD28 minimal promoter]	1.5849625007211563	3	1	0	0
21683	1520	promoter of housekeeping gene	[promoters of housekeeping genes]	1.5849625007211563	4	1	0	0
21684	1520	ap-1 (-186 to -176)	[AP-1 (-186 to -176)]	1.5849625007211563	4	1	0	0
21685	1520	subset of patient	[subset of patients]	1.5849625007211563	3	1	0	0
21686	1520	growth of apl cell	[growth of APL cells]	1.5849625007211563	4	1	0	0
21687	1520	Janus kinase 3	[Janus kinase 3]	1.5849625007211563	3	2	1	1
21688	1520	mechanism of monocytic differentiation	[mechanisms of monocytic differentiation]	1.5849625007211563	4	2	2	2
21689	1520	p24 Ag assay	[p24 Ag assay]	1.5849625007211563	3	1	0	0
21690	1520	eventuate in parp inactivation	[eventuating in PARP inactivation]	1.5849625007211563	4	1	0	0
21691	1520	lead to the activation	[leading to the activation]	1.5849625007211563	4	2	1	1
21692	1520	mrna level in liver	[mRNA level in liver]	1.5849625007211563	4	1	0	0
21693	1520	analogous pattern in brain	[analogous pattern in brain]	1.5849625007211563	4	1	0	0
21694	1520	group of age-	[group of age-]	1.5849625007211563	3	1	0	0
21695	1520	stress-responsive hsp70 protein	[stress-responsive HSP70 protein]	1.5849625007211563	3	1	0	0
21696	1520	down-regulation of qp	[down-regulation of Qp]	1.5849625007211563	3	1	0	0
21697	1520	hut-78 T cell	[Hut-78 T cells]	1.5849625007211563	3	1	0	0
21698	1520	surface antigenic profile	[surface antigenic profile]	1.5849625007211563	3	1	0	0
21699	1520	parasite-induced nf-kappab activation	[parasite-induced NF-kappaB activation]	1.5849625007211563	3	2	1	1
21700	1520	vicinity of tcr alpha/delta	[vicinity of TCR alpha/delta]	1.5849625007211563	4	1	0	0
21701	1520	minority of gene	[minority of genes]	1.5849625007211563	3	1	0	0
21702	1520	innate immune response	[innate immune response]	1.5849625007211563	3	2	1	1
21703	1520	immunoprecipitation shift analysis	[Immunoprecipitation shift analysis]	1.5849625007211563	3	1	0	0
21704	1520	antibody on aldosterone	[antibody on aldosterone]	1.5849625007211563	3	1	0	0
21705	1520	seventeen microsatellite marker	[Seventeen microsatellite markers]	1.5849625007211563	3	1	0	0
21706	1520	down regulation of c-fo	[down regulation of c-fos]	1.5849625007211563	4	1	0	0
21707	1520	same extent as ifn-alpha	[same extent as IFN-alpha]	1.5849625007211563	4	1	0	0
21708	1520	patient have g3 tumor	[patients having G3 tumors]	1.5849625007211563	4	1	0	0
21709	1520	corticosteroid derivative in leukocyte	[corticosteroid derivatives in leukocytes]	1.5849625007211563	4	1	0	0
21710	1520	systemic lupus erythematosus patient	[systemic lupus erythematosus patients]	1.5849625007211563	4	1	0	0
21711	1520	cyclosporin-sensitive promoter element	[cyclosporin-sensitive promoter element]	1.5849625007211563	3	1	0	0
21712	1520	identification of LCD motif	[identification of LCD motifs]	1.5849625007211563	4	1	0	0
21713	1520	80-kd stat5a isoform	[80-kD STAT5A isoform]	1.5849625007211563	3	1	0	0
21714	1520	pbmc of 12 woman	[PBMC of 12 women]	1.5849625007211563	4	1	0	0
21715	1520	patient with renal insufficiency	[patients with renal insufficiency]	1.5849625007211563	4	1	0	0
21716	1520	severity of depression	[severity of depression]	1.5849625007211563	3	1	0	0
21717	1520	tolerance to lipopolysaccharide	[Tolerance to lipopolysaccharide]	1.5849625007211563	3	1	0	0
21718	1520	full-length human ciita construct	[full-length human CIITA constructs]	1.5849625007211563	4	1	0	0
21719	1520	two NF-IL6 site	[two NF-IL6 sites]	1.5849625007211563	3	1	0	0
21720	1520	complex to platelet morphogenesis	[complex to platelet morphogenesis]	1.5849625007211563	4	1	0	0
21721	1520	role in ebv-associated malignancy	[role in EBV-associated malignancies]	1.5849625007211563	4	1	0	0
21722	1520	HL60 cell variant	[HL60 cell variants]	1.5849625007211563	3	1	0	0
21723	1520	cognate e box	[cognate E box]	1.5849625007211563	3	1	0	0
21724	1520	constitutive Ca(2+)-independent activity	[constitutive Ca(2+)-independent activity]	1.5849625007211563	3	1	0	0
21725	1520	cytokine receptor dimerization	[cytokine receptor dimerization]	1.5849625007211563	3	1	0	0
21726	1520	pretreatment with cycloheximide	[pretreatment with cycloheximide]	1.5849625007211563	3	1	0	0
21727	1520	NF-kappa b precursor activation	[NF-kappa B precursor activation]	1.5849625007211563	4	1	0	0
21728	1520	form of Rb	[form of Rb]	1.5849625007211563	3	2	2	2
21729	1520	interferon gamma ifn-gamma	[interferon gamma IFN-gamma]	1.5849625007211563	3	1	0	0
21730	1520	Ca2+ activation of Rap1	[Ca2+ activation of Rap1]	1.5849625007211563	4	1	0	0
21731	1520	membrane of erythrocyte ghost	[membrane of erythrocyte ghosts]	1.5849625007211563	4	1	0	0
21732	1520	CD28 costimulatory receptor	[CD28 costimulatory receptor]	1.5849625007211563	3	1	0	0
21733	1520	ten healthy control	[ten healthy controls]	1.5849625007211563	3	1	0	0
21734	1520	normal myeloid promyelocytic cell	[normal myeloid promyelocytic cells]	1.5849625007211563	4	1	0	0
21735	1520	absence of synthesis	[absence of synthesis]	1.5849625007211563	3	1	0	0
21736	1520	regulation of ap-1 activity	[regulation of AP-1 activity]	1.5849625007211563	4	1	0	0
21737	1520	viral transcription initiation	[viral transcription initiation]	1.5849625007211563	3	1	0	0
21738	1520	long acting responses.	[longer acting responses.]	1.5849625007211563	3	1	0	0
21739	1520	U-937 human promonocytic cell	[U-937 human promonocytic cells]	1.5849625007211563	4	1	0	0
21740	1520	apl blast from patient	[APL blasts from patients]	1.5849625007211563	4	1	0	0
21741	1520	isolate of hiv-2	[isolates of HIV-2]	1.5849625007211563	3	1	0	0
21742	1520	isolate of hiv-1	[isolate of HIV-1]	1.5849625007211563	3	1	0	0
21743	1520	human il-1beta gene expression	[human IL-1beta gene expression]	1.5849625007211563	4	1	0	0
21744	1520	other glucocorticoid tested, methylprednisolone	[other glucocorticoids tested, methylprednisolone]	1.5849625007211563	4	1	0	0
21745	1520	further activation requirement	[further activation requirements]	1.5849625007211563	3	1	0	0
21746	1520	inositol phosphate response	[inositol phosphate response]	1.5849625007211563	3	1	0	0
21747	1520	range of peptide length	[range of peptide lengths]	1.5849625007211563	4	1	0	0
21748	1520	temperature-sensitive v-abl mutant	[temperature-sensitive v-Abl mutant]	1.5849625007211563	3	1	0	0
21749	1520	even weak T	[even weaker T]	1.5849625007211563	3	1	0	0
21750	1520	loss of responsiveness	[loss of responsiveness]	1.5849625007211563	3	2	2	2
21751	1520	Ii-expressing t-cell line H9	[Ii-expressing T-cell line H9]	1.5849625007211563	4	1	0	0
21752	1520	gene in mouse	[gene in mice]	1.5849625007211563	3	2	2	2
21753	1520	five-fold to 35-fold decrease	[five-fold to 35-fold decrease]	1.5849625007211563	4	1	0	0
21754	1520	first, deletion analysis	[First, deletion analysis]	1.5849625007211563	3	1	0	0
21755	1520	cis-acting element with nfkappab	[Cis-acting elements with NFkappaB]	1.5849625007211563	4	1	0	0
21756	1520	prolongation in the half-life	[prolongation in the half-life]	1.5849625007211563	4	1	0	0
21757	1520	specifically in cell	[specifically in cells]	1.5849625007211563	3	2	2	2
21758	1520	consensus nf-kappa b site	[consensus NF-kappa B site]	1.5849625007211563	4	1	0	0
21759	1520	immunosuppressive activity of heparin	[immunosuppressive activity of heparin]	1.5849625007211563	4	1	0	0
21760	1520	fc gammaRI promoter element	[Fc gammaRI promoter elements]	1.5849625007211563	4	1	0	0
21761	1520	control of lymphocyte development	[Control of lymphocyte development]	1.5849625007211563	4	1	0	0
21762	1520	accompany active proliferation	[accompanying active proliferation]	1.5849625007211563	3	1	0	0
21763	1520	cell undergo apoptosis	[cells undergoing apoptosis]	1.5849625007211563	3	2	2	2
21764	1520	fetal calf serum fcs	[fetal calf serum FCS]	1.5849625007211563	4	2	2	2
21765	1520	tcr transduction mechanism	[TcR transduction mechanisms]	1.5849625007211563	3	1	0	0
21766	1520	multiple docking site	[multiple docking sites]	1.5849625007211563	3	1	0	0
21767	1520	clonal derivative alpha g2s	[clonal derivative alpha G2S]	1.5849625007211563	4	1	0	0
21768	1520	form of altruistic suicide	[form of altruistic suicide]	1.5849625007211563	4	1	0	0
21769	1520	lymphoma precursor cell	[lymphoma precursor cells]	1.5849625007211563	3	1	0	0
21770	1520	activation of c-jun	[activation of c-jun]	1.5849625007211563	3	2	1	1
21771	1520	human CMV hcmv	[human CMV HCMV]	1.5849625007211563	3	1	0	0
21772	1520	nitroblue tetrazolium (nbt)-positive cell	[nitroblue tetrazolium (NBT)-positive cells]	1.5849625007211563	4	1	0	0
21773	1520	role in the establishment	[role in the establishment]	1.5849625007211563	4	2	2	2
21774	1520	inhibitory effect of cepharanthine	[inhibitory effects of cepharanthine]	1.5849625007211563	4	2	1	1
21775	1520	LTR in recombinant siv	[LTR in recombinant SIVs]	1.5849625007211563	4	1	0	0
21776	1520	cell-type specific; bacterial lps	[cell-type specific; bacterial LPS]	1.5849625007211563	4	1	0	0
21777	1520	Nuclear run-on transcription assay	[Nuclear run-on transcription assays]	1.5849625007211563	4	1	0	0
21778	1520	study of hd histogenesis.	[study of HD histogenesis.]	1.5849625007211563	4	1	0	0
21779	1520	other cellular factor	[other cellular factors]	1.5849625007211563	3	1	0	0
21780	1520	ifn-alpha-stimulated gene isg	[IFN-alpha-stimulated genes ISGs]	1.5849625007211563	3	1	0	0
21781	1520	t-cell receptor beta-chain	[T-cell receptor beta-chain]	1.5849625007211563	3	1	0	0
21782	1520	major class gene	[major class genes]	1.5849625007211563	3	2	2	2
21783	1520	lead to il-8 secretion	[leading to IL-8 secretion]	1.5849625007211563	4	1	0	0
21784	1520	estrogen receptor negativity	[estrogen receptor negativity]	1.5849625007211563	3	1	0	0
21785	1520	lmp-1 -express b cell	[LMP-1 -expressing B cells]	1.5849625007211563	4	1	0	0
21786	1520	patient with gc-insensitive asthma	[patients with GC-insensitive asthma]	1.5849625007211563	4	1	0	0
21787	1520	partial sensitivity to vincristine	[partial sensitivity to vincristine]	1.5849625007211563	4	1	0	0
21788	1520	blood transfusion recipient	[blood transfusion recipients]	1.5849625007211563	3	1	0	0
21789	1520	activation by PMA+ ionomycin	[activation by PMA+ ionomycin]	1.5849625007211563	4	1	0	0
21790	1520	thereby inhibit the activation	[thereby inhibiting the activation]	1.5849625007211563	4	1	0	0
21791	1520	ability of monocytic cell	[ability of monocytic cells]	1.5849625007211563	4	1	0	0
21792	1520	ecreb)/cctivating transcription factor atf-1	[(CREB)/activating transcription factor ATF-1]	1.5849625007211563	4	1	0	0
21793	1520	strong negative association	[strong negative association]	1.5849625007211563	3	1	0	0
21794	1520	macrophage inflammatory protein-1alpha	[macrophage inflammatory protein-1alpha]	1.5849625007211563	3	2	1	1
21795	1520	binding to a element	[Binding to a element]	1.5849625007211563	4	2	2	2
21796	1520	defect in pyrimidine catabolism	[defect in pyrimidine catabolism]	1.5849625007211563	4	1	0	0
21797	1520	systemic glucocorticoid resistance	[systemic glucocorticoid resistance]	1.5849625007211563	3	1	0	0
21798	1520	selective activity of c-ErbB	[selective activity of c-ErbB]	1.5849625007211563	4	1	0	0
21799	1520	apoptosis effector Bax	[apoptosis effector Bax]	1.5849625007211563	3	1	0	0
21800	1520	novel Grb2-like adaptor molecule	[novel Grb2-like adaptor molecule]	1.5849625007211563	4	1	0	0
21801	1520	transient expression analysis,	[transient expression analysis,]	1.5849625007211563	3	1	0	0
21802	1520	presence of CD28 MoAb	[presence of CD28 MoAb]	1.5849625007211563	4	1	0	0
21803	1520	part of this pathway,	[part of this pathway,]	1.5849625007211563	4	1	0	0
21804	1520	expression of endogenous gene	[expression of endogenous genes]	1.5849625007211563	4	1	0	0
21805	1520	concentration, Ro 13-7410	[concentration, Ro 13-7410]	1.5849625007211563	3	1	0	0
21806	1520	optimal conditions, reagents,	[optimal conditions, reagents,]	1.5849625007211563	3	1	0	0
21807	1520	il-6 mm cell growth	[IL-6 MM cell growth]	1.5849625007211563	4	1	0	0
21808	1520	nucleus of human cell	[nucleus of human cells]	1.5849625007211563	4	1	0	0
21809	1520	serum-free medium, cem-c7 cell	[serum-free medium, CEM-C7 cells]	1.5849625007211563	4	1	0	0
21810	1520	standard gel retardation assay	[standard gel retardation assay]	1.5849625007211563	4	1	0	0
21811	1520	level of mrna transcription	[level of mRNA transcription]	1.5849625007211563	4	1	0	0
21812	1520	NF-AT transcription factor	[NF-AT transcription factors]	1.5849625007211563	3	1	0	0
21813	1520	woman with pre-term delivery,	[women with pre-term delivery,]	1.5849625007211563	4	1	0	0
21814	1520	/nerve growth factor	[/nerve growth factor]	1.5849625007211563	3	1	0	0
21815	1520	critical inflammatory mediator	[critical inflammatory mediators]	1.5849625007211563	3	1	0	0
21816	1520	DNA binding activity indistinguishable	[DNA binding activity indistinguishable]	1.5849625007211563	4	1	0	0
21817	1520	use protein-DNA interaction assay	[Using protein-DNA interaction assays]	1.5849625007211563	4	1	0	0
21818	1520	differential lymphokine expression	[differential lymphokine expression]	1.5849625007211563	3	1	0	0
21819	1520	several binding site	[several binding sites]	1.5849625007211563	3	2	1	1
21820	1520	cell types, include lymphocyte	[cell types, including lymphocytes]	1.5849625007211563	4	1	0	0
21821	1520	NF-kappa b p65 subunit	[NF-kappa B p65 subunit]	1.5849625007211563	4	1	0	0
21822	1520	individual rel-related protein	[individual Rel-related proteins]	1.5849625007211563	3	2	1	1
21823	1520	zinc-finger protein the ets	[zinc-finger proteins the Ets]	1.5849625007211563	4	1	0	0
21824	1520	induction of cytokine production	[induction of cytokine production]	1.5849625007211563	4	1	0	0
21825	1520	monoclonal antibody alphacd3	[monoclonal antibody alphaCD3]	1.5849625007211563	3	1	0	0
21826	1520	regulation of ca2+ transport	[regulation of Ca2+ transport]	1.5849625007211563	4	1	0	0
21827	1520	human activation antigen cd69	[human activation antigen CD69]	1.5849625007211563	4	1	0	0
21828	1520	RAR alpha agonist	[RAR alpha agonist]	1.5849625007211563	3	1	0	0
21829	1520	hematopoietic control mechanism	[hematopoietic control mechanisms]	1.5849625007211563	3	1	0	0
21830	1520	however, despite ability	[However, despite ability]	1.5849625007211563	3	1	0	0
21831	1520	subclone of Jurkat cell	[subclone of Jurkat cells]	1.5849625007211563	4	1	0	0
21832	1520	analysis of ap-1 activity	[Analysis of AP-1 activity]	1.5849625007211563	4	1	0	0
21833	1520	novel activity for timp-1	[novel activity for TIMP-1]	1.5849625007211563	4	1	0	0
21834	1520	preserve IkappaB-alpha protein level	[preserving IkappaB-alpha protein levels]	1.5849625007211563	4	1	0	0
21835	1520	eukaryotic dna-binding protein	[eukaryotic DNA-binding proteins]	1.5849625007211563	3	1	0	0
21836	1520	estrogen receptor gene	[estrogen receptor gene]	1.5849625007211563	3	2	1	1
21837	1520	kappa b-alpha mad-3	[kappa B-alpha MAD-3]	1.5849625007211563	3	1	0	0
21838	1520	control of cell survival	[control of cell survival]	1.5849625007211563	4	1	0	0
21839	1520	CD2 -based signal pathway	[CD2 -based signaling pathway]	1.5849625007211563	4	1	0	0
21840	1520	bhlh heterodimer-dependent gene expression	[bHLH heterodimer-dependent gene expression]	1.5849625007211563	4	1	0	0
21841	1520	ca2+ -chelating agent	[Ca2+ -chelating agent]	1.5849625007211563	3	1	0	0
21842	1520	primary isolate KMT	[primary isolates KMT]	1.5849625007211563	3	1	0	0
21843	1520	continued, high-level bcl-6 expression	[continued, high-level BCL-6 expression]	1.5849625007211563	4	1	0	0
21844	1520	type of viral latency	[type of viral latency]	1.5849625007211563	4	1	0	0
21845	1520	CML cytoplasmic protein	[CML cytoplasmic proteins]	1.5849625007211563	3	1	0	0
21846	1520	partial ecori chromosome	[partial EcoRI chromosome]	1.5849625007211563	3	1	0	0
21847	1520	bp -90 to -82	[bp -90 to -82]	1.5849625007211563	4	1	0	0
21848	1520	rodent central nervous system	[rodent central nervous system]	1.5849625007211563	4	1	0	0
21849	1520	lymphoid nuclear factor	[lymphoid nuclear factor]	1.5849625007211563	3	2	2	2
21850	1520	1 hour 30 minute	[1 hr 30 min]	1.5849625007211563	4	1	0	0
21851	1520	normal subject (2.0	[normal subjects (2.0]	1.5849625007211563	3	1	0	0
21852	1520	tax -mediated apoptosis	[Tax -mediated apoptosis]	1.5849625007211563	3	1	0	0
21853	1520	mouse lung tissue	[mouse lung tissue]	1.5849625007211563	3	1	0	0
21854	1520	protein of molecular mass	[proteins of molecular mass]	1.5849625007211563	4	2	2	2
21855	1520	multiple biochemical pathway	[multiple biochemical pathways]	1.5849625007211563	3	1	0	0
21856	1520	high level of interleukin-1alpha	[high levels of interleukin-1alpha]	1.5849625007211563	4	1	0	0
21857	1520	chicken anemia virus	[chicken anemia virus]	1.5849625007211563	3	2	2	2
21858	1520	cdr2-loop in domain 1	[CDR2-loop in domain 1]	1.5849625007211563	4	2	2	2
21859	1520	intracellular signalling agent	[intracellular signalling agents]	1.5849625007211563	3	1	0	0
21860	1520	expression cDNA cloning	[expression cDNA cloning]	1.5849625007211563	3	1	0	0
21861	1520	E2F binding site	[E2F binding site]	1.5849625007211563	3	3	2	1
21862	1520	tnfalpha phosphorylation of p65	[TNFalpha phosphorylation of p65]	1.5849625007211563	4	1	0	0
21863	1520	12-myristate -13- acetate PMA	[12-myristate -13- acetate PMA]	1.5849625007211563	4	1	0	0
21864	1520	5 early region e1a	[5 early regions E1A]	1.5849625007211563	4	1	0	0
21865	1520	negative regulatory circuit	[negative regulatory circuits]	1.5849625007211563	3	1	0	0
21866	1520	comparison to untreated cell	[comparison to untreated cells]	1.5849625007211563	4	1	0	0
21867	1520	retinoid include all-trans-retinoic acid	[Retinoids including all-trans-retinoic acid]	1.5849625007211563	4	1	0	0
21868	1520	effect on the estrogen	[effects on the estrogen]	1.5849625007211563	4	1	0	0
21869	1520	knowledge about the molecule	[knowledge about the molecules]	1.5849625007211563	4	1	0	0
21870	1520	Germ line c transcript	[Germ line C transcripts]	1.5849625007211563	4	1	0	0
21871	1520	recently, many investigator	[Recently, many investigators]	1.5849625007211563	3	1	0	0
21872	1520	single transcription initiation site	[single transcription initiation site]	1.5849625007211563	4	1	0	0
21873	1520	two DNA motif homologous	[two DNA motifs homologous]	1.5849625007211563	4	1	0	0
21874	1520	actively bind RFX species	[actively binding RFX species]	1.5849625007211563	4	1	0	0
21875	1520	six hematopoietic cell line	[six hematopoietic cell lines]	1.5849625007211563	4	1	0	0
21876	1520	endogenous intracellular receptor	[endogenous intracellular receptors]	1.5849625007211563	3	1	0	0
21877	1520	lymphotropic virus type	[lymphotropic virus type]	1.5849625007211563	3	2	2	2
21878	1520	response to the combination	[response to the combination]	1.5849625007211563	4	1	0	0
21879	1520	significant implication for autoimmunity	[significant implications for autoimmunity]	1.5849625007211563	4	1	0	0
21880	1520	mechanism(s) of action	[mechanism(s) of action]	1.5849625007211563	3	2	2	2
21881	1520	NOTCH1 ankyrin repeat region	[NOTCH1 ankyrin repeat region]	1.5849625007211563	4	1	0	0
21882	1520	addition, nuclear extract	[addition, nuclear extracts]	1.5849625007211563	3	1	0	0
21883	1520	pivotal promoter element	[pivotal promoter element]	1.5849625007211563	3	1	0	0
21884	1520	role of stat protein	[role of STAT proteins]	1.5849625007211563	4	1	0	0
21885	1520	mutant Escherichia coli endotoxin	[mutant Escherichia coli endotoxin]	1.5849625007211563	4	1	0	0
21886	1520	homodimer of e2a protein	[homodimer of E2A proteins]	1.5849625007211563	4	1	0	0
21887	1520	therefore, for virus replication.	[therefore, for virus replication.]	1.5849625007211563	4	1	0	0
21888	1520	related 16-bp see motif	[related 16-bp SEE motif]	1.5849625007211563	4	1	0	0
21889	1520	exert antiproliferative effects,	[exerting antiproliferative effects,]	1.5849625007211563	3	1	0	0
21890	1520	absence of bind competition	[absence of binding competition]	1.5849625007211563	4	1	0	0
21891	1520	lead to cellular response	[leading to cellular responses]	1.5849625007211563	4	1	0	0
21892	1520	es-derived embryoid body	[ES-derived embryoid bodies]	1.5849625007211563	3	1	0	0
21893	1520	adjacent regulatory motif	[adjacent regulatory motif]	1.5849625007211563	3	1	0	0
21894	1520	gene therapy vector	[gene therapy vector]	1.5849625007211563	3	1	0	0
21895	1520	significant difference in activation	[significant differences in activation]	1.5849625007211563	4	1	0	0
21896	1520	Retinoic acid (ra) resistance	[Retinoic acid (RA) resistance]	1.5849625007211563	4	1	0	0
21897	1520	other protein- tyrosine kinase	[other protein- tyrosine kinases]	1.5849625007211563	4	1	0	0
21898	1520	human tissue examined, breast	[human tissues examined, breast]	1.5849625007211563	4	1	0	0
21899	1520	TNF gene expression	[TNF gene expression]	1.5849625007211563	3	2	1	1
21900	1520	CD40 fra-1 induction	[CD40 fra-1 induction]	1.5849625007211563	3	1	0	0
21901	1520	il-10 in biological activity	[IL-10 in biological activity]	1.5849625007211563	4	1	0	0
21902	1520	atherosclerosis-promoting effect of cya	[atherosclerosis-promoting effect of CyA]	1.5849625007211563	4	1	0	0
21903	1520	DNA affinity-purified protein	[DNA affinity-purified protein]	1.5849625007211563	3	1	0	0
21904	1520	CD28 enhances, il-2 production	[CD28 enhances, IL-2 production]	1.5849625007211563	4	1	0	0
21905	1520	GT box in PFP9a20	[GT box in PFP9a20]	1.5849625007211563	4	1	0	0
21906	1520	different inhibitory activity	[different inhibitory activities]	1.5849625007211563	3	1	0	0
21907	1520	porcine b-cell line L23	[porcine B-cell line L23]	1.5849625007211563	4	1	0	0
21908	1520	antigen of pathogen	[antigen of pathogens]	1.5849625007211563	3	1	0	0
21909	1520	exploration of the role	[exploration of the role]	1.5849625007211563	4	1	0	0
21910	1520	Ad5E1A -specific CTL activity	[Ad5E1A -specific CTL activity]	1.5849625007211563	4	1	0	0
21911	1520	peptide-specific t-cell line	[peptide-specific T-cell line]	1.5849625007211563	3	1	0	0
21912	1520	entire interleukin-2 enhancer	[entire interleukin-2 enhancer]	1.5849625007211563	3	1	0	0
21913	1520	two distinct mechanisms.	[two distinct mechanisms.]	1.5849625007211563	3	1	0	0
21914	1520	cytokine -produce effector cell	[cytokine -producing effector cells]	1.5849625007211563	4	1	0	0
21915	1520	use standard immunofluorescence method	[using standard immunofluorescence method]	1.5849625007211563	4	1	0	0
21916	1520	number of t-cell enhancer	[number of T-cell enhancers]	1.5849625007211563	4	1	0	0
21917	1520	expression of b7.1 molecule	[expression of B7.1 molecules]	1.5849625007211563	4	1	0	0
21918	1520	critical signal response domain	[critical signal response domain]	1.5849625007211563	4	1	0	0
21919	1520	ebv b cell clone	[EBV B cell clones]	1.5849625007211563	4	1	0	0
21920	1520	immunomodulatory property of heparin	[immunomodulatory properties of heparin]	1.5849625007211563	4	1	0	0
21921	1520	increase in isgf3 activity	[increase in ISGF3 activity]	1.5849625007211563	4	1	0	0
21922	1520	respectively, treatment with CsA	[respectively, treatment with CsA]	1.5849625007211563	4	1	0	0
21923	1520	human cell line k562	[human cell line K562]	1.5849625007211563	4	2	1	1
21924	1520	il-1beta gene transcription	[IL-1beta gene transcription]	1.5849625007211563	3	1	0	0
21925	1520	evidence for a role	[evidence for a role]	1.5849625007211563	4	2	1	1
21926	1520	expression of il-1alpha	[expression of IL-1alpha]	1.5849625007211563	3	2	1	1
21927	1520	involvement of a cellular	[Involvement of a cellular]	1.5849625007211563	4	1	0	0
21928	1520	Ig heavy chain enhancer	[Ig heavy chain enhancer]	1.5849625007211563	4	1	0	0
21929	1520	STAT3 serine phosphorylation	[STAT3 serine phosphorylation]	1.5849625007211563	3	1	0	0
21930	1520	cyclic nucleotide-dependent kinases.	[cyclic nucleotide-dependent kinases.]	1.5849625007211563	3	1	0	0
21931	1520	especially in lymphoid organ	[especially in lymphoid organs]	1.5849625007211563	4	1	0	0
21932	1520	different anchor residue	[different anchor residues]	1.5849625007211563	3	1	0	0
21933	1520	infectious proviral construct	[infectious proviral constructs]	1.5849625007211563	3	1	0	0
21934	1520	mature organ develops,	[mature organ develops,]	1.5849625007211563	3	1	0	0
21935	1520	protein in platelet	[proteins in platelets]	1.5849625007211563	3	2	2	2
21936	1520	immunoglobulin eig)-secreting plasmacytoma	[immunoglobulin (Ig)-secreting plasmacytomas]	1.5849625007211563	3	1	0	0
21937	1520	position -98 to -108	[positions -98 to -108]	1.5849625007211563	4	1	0	0
21938	1520	p65 antisense oligomer	[p65 antisense oligomer]	1.5849625007211563	3	1	0	0
21939	1520	starting point for study	[starting point for studies]	1.5849625007211563	4	1	0	0
21940	1520	dependence of ligand stimulation.	[dependence of ligand stimulation.]	1.5849625007211563	4	1	0	0
21941	1520	murine erythroid leukemia cell	[murine erythroid leukemia cells]	1.5849625007211563	4	2	1	1
21942	1520	proinflammatory cytokine pathway	[proinflammatory cytokine pathways]	1.5849625007211563	3	1	0	0
21943	1520	cross-linking of surface immunoglobulin	[cross-linking of surface immunoglobulin]	1.5849625007211563	4	1	0	0
21944	1520	receptor contain a region.	[receptor containing a region.]	1.5849625007211563	4	1	0	0
21945	1520	MHC class DRA promoter	[MHC class DRA promoter]	1.5849625007211563	4	1	0	0
21946	1520	tpa expression of c-jun	[TPA expression of c-jun]	1.5849625007211563	4	1	0	0
21947	1520	oscillatory ca2+ signal	[oscillatory Ca2+ signals]	1.5849625007211563	3	1	0	0
21948	1520	post- pha stimulation c-fo	[post- PHA stimulation c-fos]	1.5849625007211563	4	1	0	0
21949	1520	appropriate spatial alignment	[appropriate spatial alignment]	1.5849625007211563	3	1	0	0
21950	1520	cell division (cdc),	[cell division (cdc),]	1.5849625007211563	3	1	0	0
21951	1520	gata transcription factor	[GATA transcription factors]	1.5849625007211563	3	2	2	2
21952	1520	differentiation from b cell	[differentiation from B cells]	1.5849625007211563	4	1	0	0
21953	1520	only in amino-terminal sequence	[only in amino-terminal sequence]	1.5849625007211563	4	1	0	0
21954	1520	functional conservation across species	[functional conservation across species]	1.5849625007211563	4	1	0	0
21955	1520	element-bind protein nuclear complex	[element-binding protein nuclear complexes]	1.5849625007211563	4	1	0	0
21956	1520	promoter of IL-3	[promoters of IL-3]	1.5849625007211563	3	1	0	0
21957	1520	tyrosine kinase JAK1	[tyrosine kinases JAK1]	1.5849625007211563	3	2	1	1
21958	1520	1 activation of b	[1 activation of B]	1.5849625007211563	4	1	0	0
21959	1520	kinetic of this translocation	[kinetics of this translocation]	1.5849625007211563	4	1	0	0
21960	1520	kinetic of il-1 activation	[kinetics of IL-1 activation]	1.5849625007211563	4	1	0	0
21961	1520	transfection of the cell	[transfection of the cells]	1.5849625007211563	4	1	0	0
21962	1520	biochemical change by tcdd	[biochemical changes by TCDD]	1.5849625007211563	4	1	0	0
21963	1520	soluble tnf receptor	[soluble TNF receptor]	1.5849625007211563	3	2	1	1
21964	1520	intercellular signal network	[intercellular signal networks]	1.5849625007211563	3	1	0	0
21965	1520	egr-1 gene expression	[EGR-1 gene expression]	1.5849625007211563	3	1	0	0
21966	1520	normal level of gr	[normal levels of GR]	1.5849625007211563	4	1	0	0
21967	1520	surface expression of hla-dr	[surface expression of HLA-DR]	1.5849625007211563	4	1	0	0
21968	1520	adenylyl cyclase signal	[adenylyl cyclase signal]	1.5849625007211563	3	1	0	0
21969	1520	5 virus carrier	[5 virus carriers]	1.5849625007211563	3	1	0	0
21970	1520	two type of hybrid	[two types of hybrids]	1.5849625007211563	4	1	0	0
21971	1520	cloning of the gene	[cloning of the genes]	1.5849625007211563	4	1	0	0
21972	1520	epithelial hela cell	[epithelial HeLa cells]	1.5849625007211563	3	1	0	0
21973	1520	heterogeneity of antigen molecule	[Heterogeneity of antigen molecules]	1.5849625007211563	4	1	0	0
21974	1520	production of DNA breakage	[production of DNA breakage]	1.5849625007211563	4	1	0	0
21975	1520	estrogen receptor (er) transcript	[estrogen receptor (ER) transcripts]	1.5849625007211563	4	1	0	0
21976	1520	ubiquitin- proteasome pathway	[ubiquitin- proteasome pathway]	1.5849625007211563	3	1	0	0
21977	1520	capacity of cell	[capacity of cells]	1.5849625007211563	3	2	2	2
21978	1520	specifically in T lymphocyte	[specifically in T lymphocytes]	1.5849625007211563	4	1	0	0
21979	1520	PHA-activated mononuclear cell	[PHA-activated mononuclear cells]	1.5849625007211563	3	2	1	1
21980	1520	GRbeta antiglucocorticoid activity	[GRbeta antiglucocorticoid activity]	1.5849625007211563	3	1	0	0
21981	1520	form of mu	[forms of mu]	1.5849625007211563	3	1	0	0
21982	1520	c-fo mrna expression	[c-fos mRNA expression]	1.5849625007211563	3	2	2	2
21983	1520	1,2-bis(o-aminophenoxy)-ethane-n,n,n',n'-tetraacetic acid bapta-am	[1,2-bis(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid BAPTA-AM]	1.5849625007211563	3	1	0	0
21984	1520	nf-kappa b target gene	[NF-kappa B target genes]	1.5849625007211563	4	1	0	0
21985	1520	vicinity of NGAL tumor	[vicinity of NGAL tumors]	1.5849625007211563	4	1	0	0
21986	1520	serum-free culture system	[serum-free culture system]	1.5849625007211563	3	1	0	0
21987	1520	35 to 50 kD	[35 to 50 kD]	1.5849625007211563	4	1	0	0
21988	1520	level of this proto-oncogene	[levels of this proto-oncogene]	1.5849625007211563	4	1	0	0
21989	1520	understand the monocyte-specific function	[Understanding the monocyte-specific function]	1.5849625007211563	4	1	0	0
21990	1520	SH2 domain of Grb2	[SH2 domain of Grb2]	1.5849625007211563	4	1	0	0
21991	1520	NFATp family member	[NFATp family members]	1.5849625007211563	3	1	0	0
21992	1520	efficient hiv replication	[efficient HIV replication]	1.5849625007211563	3	2	1	1
21993	1520	lef/tcf transcription factor	[LEF/TCF transcription factors]	1.5849625007211563	3	1	0	0
21994	1520	proper lymphoid development	[proper lymphoid development]	1.5849625007211563	3	1	0	0
21995	1520	oct2 target gene	[Oct2 target genes]	1.5849625007211563	3	2	1	1
21996	1520	calcium stimulation ionophore	[calcium stimulation ionophore]	1.5849625007211563	3	1	0	0
21997	1520	co-cultivated T cell	[co-cultivated T cells]	1.5849625007211563	3	1	0	0
21998	1520	HRF heme-responsive factor	[HRF heme-responsive factor]	1.5849625007211563	3	1	0	0
21999	1520	viral gene regulation	[viral gene regulation]	1.5849625007211563	3	1	0	0
22000	1520	classic glucocorticoid prednisolone	[classic glucocorticoid prednisolone]	1.5849625007211563	3	1	0	0
22001	1520	increase in gtp p21ras	[increase in GTP p21ras]	1.5849625007211563	4	1	0	0
22002	1520	more severe phenotype	[more severe phenotype]	1.5849625007211563	3	1	0	0
22003	1520	presence of G-CSF	[presence of G-CSF]	1.5849625007211563	3	1	0	0
22004	1520	early signal transduction pathway	[early signal transduction pathways]	1.5849625007211563	4	1	0	0
22005	1520	general transcription factor tfiih	[general transcription factor TFIIH]	1.5849625007211563	4	1	0	0
22006	1520	pathogenesis of rheumatoid arthritis.	[pathogenesis of rheumatoid arthritis.]	1.5849625007211563	4	1	0	0
22007	1520	inhibition of viral replication	[inhibition of viral replication]	1.5849625007211563	4	1	0	0
22008	1520	absence the area responsive	[absence the area responsive]	1.5849625007211563	4	1	0	0
22009	1520	human lymphoid cell line	[human lymphoid cell line]	1.5849625007211563	4	2	2	2
22010	1520	vitro supershift study	[vitro supershift studies]	1.5849625007211563	3	1	0	0
22011	1520	proportion of beta-globin promoter	[proportion of beta-globin promoters]	1.5849625007211563	4	1	0	0
22012	1520	increase in Oct-2 protein	[increase in Oct-2 protein]	1.5849625007211563	4	1	0	0
22013	1520	antisense myb rna expression	[antisense myb RNA expression]	1.5849625007211563	4	1	0	0
22014	1520	'octamer' sequence ATGCAAAT	['octamer' sequence ATGCAAAT]	1.5849625007211563	3	1	0	0
22015	1520	rna polymerase transcription system	[RNA polymerase transcription systems]	1.5849625007211563	4	2	2	2
22016	1520	tnf-alpha neutrophil apoptosis	[TNF-alpha neutrophil apoptosis]	1.5849625007211563	3	1	0	0
22017	1520	multiple lymphokine deficiency	[multiple lymphokine deficiency]	1.5849625007211563	3	2	2	2
22018	1520	gr site per cell	[GR sites per cell]	1.5849625007211563	4	1	0	0
22019	1520	combination of differential splicing	[combination of differential splicing]	1.5849625007211563	4	1	0	0
22020	1520	blood mononuclear leukocyte	[blood mononuclear leukocytes]	1.5849625007211563	3	2	2	2
22021	1520	cell surface glycoprotein	[cell surface glycoprotein]	1.5849625007211563	3	2	1	1
22022	1520	tnf receptor-associated factor	[TNF receptor-associated factor]	1.5849625007211563	3	1	0	0
22023	1520	human transcriptional activator	[human transcriptional activators]	1.5849625007211563	3	1	0	0
22024	1520	woman with ectopic pregnancy	[women with ectopic pregnancy]	1.5849625007211563	4	1	0	0
22025	1520	exact mechanism of action	[exact mechanism of action]	1.5849625007211563	4	1	0	0
22026	1520	c/ebp epsilon mrna expression	[C/EBP epsilon mRNA expression]	1.5849625007211563	4	1	0	0
22027	1520	bind affinity of dexamethasone	[binding affinity of dexamethasone]	1.5849625007211563	4	1	0	0
22028	1520	proximal region in PFP9a20	[proximal region in PFP9a20]	1.5849625007211563	4	1	0	0
22029	1520	polymorphonuclear leucocyte PMNL	[polymorphonuclear leucocytes PMNL]	1.5849625007211563	3	1	0	0
22030	1520	breast cancer sample	[breast cancer samples]	1.5849625007211563	3	2	1	1
22031	1520	lytic regulatory gene	[lytic regulatory gene]	1.5849625007211563	3	1	0	0
22032	1520	short period in patient	[shorter period in patients]	1.5849625007211563	4	1	0	0
22033	1520	dexamethasone -crh test	[dexamethasone -CRH test]	1.5849625007211563	3	1	0	0
22034	1520	il-6 in vitro	[IL-6 in vitro]	1.5849625007211563	3	1	0	0
22035	1520	cell of diverse species	[cells of diverse species]	1.5849625007211563	4	1	0	0
22036	1520	same ibr sites.	[same IBR sites.]	1.5849625007211563	3	1	0	0
22037	1520	various chronic disease	[various chronic diseases]	1.5849625007211563	3	1	0	0
22038	1520	stat5a DNA binding activity	[STAT5a DNA binding activity]	1.5849625007211563	4	1	0	0
22039	1520	105-kDa Sp1 species	[105-kDa Sp1 species]	1.5849625007211563	3	1	0	0
22040	1520	prolong mp plasma concentration	[prolonging MP plasma concentrations]	1.5849625007211563	4	1	0	0
22041	1520	manner analogous to promoter	[manner analogous to promoters]	1.5849625007211563	4	1	0	0
22042	1520	binding to OSE2	[binding to OSE2]	1.5849625007211563	3	1	0	0
22043	1520	constitutive virus expression	[constitutive virus expression]	1.5849625007211563	3	2	2	2
22044	1520	complex of four subunit	[complex of four subunits]	1.5849625007211563	4	1	0	0
22045	1520	presence of tnf	[presence of TNF]	1.5849625007211563	3	1	0	0
22046	1520	yeast artificial chromosome contig	[yeast artificial chromosome contig]	1.5849625007211563	4	1	0	0
22047	1520	experimentally B cell progenitor	[Experimentally B cell progenitors]	1.5849625007211563	4	1	0	0
22048	1520	TSC2 messenger RNA	[TSC2 messenger RNA]	1.5849625007211563	3	1	0	0
22049	1520	naive T lymphocyte	[naive T lymphocytes]	1.5849625007211563	3	2	1	1
22050	1520	dominant-negative acting Stat-3 isoform	[dominant-negative acting Stat-3 isoform]	1.5849625007211563	4	1	0	0
22051	1520	eight patient in LT	[eight patients in LT]	1.5849625007211563	4	1	0	0
22052	1520	apparent mass of kda	[apparent mass of kDa]	1.5849625007211563	4	2	2	2
22053	1520	ap-1 -dependent reporter construct	[AP-1 -dependent reporter constructs]	1.5849625007211563	4	1	0	0
22054	1520	response to a antigen	[response to an antigen]	1.5849625007211563	4	1	0	0
22055	1520	enhance beta-globin expression	[enhancing beta-globin expression]	1.5849625007211563	3	1	0	0
22056	1520	so-called PML nuclear body	[so-called PML nuclear bodies]	1.5849625007211563	4	1	0	0
22057	1520	radioligand with a kd	[radioligand with an Kd]	1.5849625007211563	4	1	0	0
22058	1520	virus reservoir in vivo,	[virus reservoir in vivo,]	1.5849625007211563	4	1	0	0
22059	1520	chronic MPD 71 (82%)	[chronic MPD 71 (82%)]	1.5849625007211563	4	1	0	0
22060	1520	characteristic pattern of infiltration	[characteristic pattern of infiltration]	1.5849625007211563	4	1	0	0
22061	1520	Epstein-Barr virus protein EBNA2	[Epstein-Barr virus protein EBNA2]	1.5849625007211563	4	1	0	0
22062	1520	patient' T lymphocyte	[patient's T lymphocytes]	1.5849625007211563	3	1	0	0
22063	1520	subject with clinical malaria	[subjects with clinical malaria]	1.5849625007211563	4	1	0	0
22064	1520	major cell reservoir	[major cell reservoir]	1.5849625007211563	3	1	0	0
22065	1520	camp phorbol ester enhancer	[cAMP phorbol ester enhancer]	1.5849625007211563	4	1	0	0
22066	1520	reason for this change	[reasons for these changes]	1.5849625007211563	4	1	0	0
22067	1520	47 kda protein factor	[47 kDa protein factor]	1.5849625007211563	4	3	2	1
22068	1520	treatment of chronic asthma	[treatment of chronic asthma]	1.5849625007211563	4	1	0	0
22069	1520	glucocorticoid gc resistance	[glucocorticoid GC resistance]	1.5849625007211563	3	1	0	0
22070	1520	novel element distinct	[novel elements distinct]	1.5849625007211563	3	1	0	0
22071	1520	protein levels, ap-1 binding	[protein levels, AP-1 binding]	1.5849625007211563	4	1	0	0
22072	1520	human il-4 receptor alpha-chain	[human IL-4 receptor alpha-chain]	1.5849625007211563	4	1	0	0
22073	1520	presence of 125d3	[presence of 1,25D3]	1.5849625007211563	3	2	1	1
22074	1520	transcription factor gene expression	[transcription factor gene expression]	1.5849625007211563	4	1	0	0
22075	1520	Peripheral blood eosinophil	[Peripheral blood eosinophils]	1.5849625007211563	3	1	0	0
22076	1520	(approximately 80% inhibition	[(approximately 80% inhibition]	1.5849625007211563	3	1	0	0
22077	1520	distinct stage of maturation.	[distinct stage of maturation.]	1.5849625007211563	4	1	0	0
22078	1520	specific dor1 agonist	[specific DOR1 agonist]	1.5849625007211563	3	1	0	0
22079	1520	antigenic site, absent	[antigenic site, absent]	1.5849625007211563	3	1	0	0
22080	1520	characterization of 5' end	[Characterization of 5' end]	1.5849625007211563	4	1	0	0
22081	1520	Syk kinases-interacting protein skip	[Syk kinases-interacting proteins SKIPs]	1.5849625007211563	4	1	0	0
22082	1520	g0/g1 switch regulatory gene	[G0/G1 switch regulatory genes]	1.5849625007211563	4	2	2	2
22083	1520	regulation of eosinophil apoptosis	[regulation of eosinophil apoptosis]	1.5849625007211563	4	1	0	0
22084	1520	unresponsiveness to YY1 inhibition	[unresponsiveness to YY1 inhibition]	1.5849625007211563	4	1	0	0
22085	1520	protein tyrosine kinase zap-70	[protein tyrosine kinase ZAP-70]	1.5849625007211563	4	1	0	0
22086	1520	ifn-gamma-primed lung fibroblast	[IFN-gamma-primed lung fibroblasts]	1.5849625007211563	3	1	0	0
22087	1520	SCL 5' regulatory region	[SCL 5' regulatory region]	1.5849625007211563	4	1	0	0
22088	1520	nearly full-length cDNA sequence	[nearly full-length cDNA sequence]	1.5849625007211563	4	1	0	0
22089	1520	capacity of intact c3a	[capacity of intact C3a]	1.5849625007211563	4	1	0	0
22090	1520	glucocorticoid in patient groups,	[glucocorticoids in patient groups,]	1.5849625007211563	4	1	0	0
22091	1520	gentle elution conditions,	[gentle elution conditions,]	1.5849625007211563	3	1	0	0
22092	1520	Retroviral induction of timp-1	[Retroviral induction of TIMP-1]	1.5849625007211563	4	1	0	0
22093	1520	various STAT 5 isoform	[various STAT 5 isoforms]	1.5849625007211563	4	1	0	0
22094	1520	continuum of replicative capacity	[continuum of replicative capacities]	1.5849625007211563	4	1	0	0
22095	1520	Nuclear t3r in lymphocyte	[Nuclear T3R in lymphocytes]	1.5849625007211563	4	1	0	0
22096	1520	inhibition in protein synthesis	[inhibition in protein synthesis]	1.5849625007211563	4	1	0	0
22097	1520	glucocorticoid receptor determination	[glucocorticoid receptor determination]	1.5849625007211563	3	2	2	2
22098	1520	proviral genome of HTLV-I	[proviral genome of HTLV-I]	1.5849625007211563	4	1	0	0
22099	1520	date about the regulation	[date about the regulation]	1.5849625007211563	4	1	0	0
22100	1520	15 minute (phase 1)	[15 minutes (phase 1)]	1.5849625007211563	4	1	0	0
22101	1520	mouse hepa-1 cell	[mouse Hepa-1 cells]	1.5849625007211563	3	1	0	0
22102	1520	response to TNF alpha	[response to TNF alpha]	1.5849625007211563	4	1	0	0
22103	1520	only triflusal animal	[only triflusal animals]	1.5849625007211563	3	1	0	0
22104	1520	discussion of several method	[discussion of several methods]	1.5849625007211563	4	1	0	0
22105	1520	presence of tax	[presence of Tax]	1.5849625007211563	3	1	0	0
22106	1520	Addition of exogenous il-2	[Addition of exogenous IL-2]	1.5849625007211563	4	1	0	0
22107	1520	mediate CD40 -dependent signal	[mediating CD40 -dependent signals]	1.5849625007211563	4	1	0	0
22108	1520	coexpression with Jak1	[coexpression with Jak1]	1.5849625007211563	3	1	0	0
22109	1520	upstream stimulatory factor USF	[upstream stimulatory factor USF]	1.5849625007211563	4	1	0	0
22110	1520	consensus DNA binding sequence	[consensus DNA binding sequence]	1.5849625007211563	4	1	0	0
22111	1520	cd4+cd45ro+ T cell	[CD4+CD45RO+ T cells]	1.5849625007211563	3	1	0	0
22112	1520	dead cell from 24%	[dead cells from 24%]	1.5849625007211563	4	1	0	0
22113	1520	cause degradation of protein	[causing degradation of protein]	1.5849625007211563	4	1	0	0
22114	1520	general factor Sp1	[general factor Sp1]	1.5849625007211563	3	1	0	0
22115	1520	reporter transgenic mouse	[reporter transgenic mice]	1.5849625007211563	3	1	0	0
22116	1520	SM protein sequence	[SM protein sequence]	1.5849625007211563	3	1	0	0
22117	1520	block of apoptosis	[block of apoptosis]	1.5849625007211563	3	1	0	0
22118	1520	nfatp in transcriptional activation	[NFATp in transcriptional activation]	1.5849625007211563	4	1	0	0
22119	1520	bind characteristic for dexamethasone	[binding characteristics for dexamethasone]	1.5849625007211563	4	1	0	0
22120	1520	only on Th1 cell	[only on Th1 cells]	1.5849625007211563	4	1	0	0
22121	1520	malignant cell growth,	[malignant cell growth,]	1.5849625007211563	3	1	0	0
22122	1520	APL cell with am580	[APL cells with AM580]	1.5849625007211563	4	1	0	0
22123	1520	kappa b epsilon	[kappa B epsilon]	1.5849625007211563	3	1	0	0
22124	1520	heterozygosity rate approach 90%.	[heterozygosity rate approaching 90%.]	1.5849625007211563	4	1	0	0
22125	1520	small increase in anh	[small increase in ANH]	1.5849625007211563	4	1	0	0
22126	1520	calcineurin in turn,	[calcineurin in turn,]	1.5849625007211563	3	1	0	0
22127	1520	B-cell fc gamma RII	[B-cell Fc gamma RII]	1.5849625007211563	4	1	0	0
22128	1520	maximum in expression	[maximum in expression]	1.5849625007211563	3	1	0	0
22129	1520	gene in k562 cell	[genes in K562 cells]	1.5849625007211563	4	1	0	0
22130	1520	previous 6 month	[previous 6 months]	1.5849625007211563	3	1	0	0
22131	1520	hiv-1 transcriptional enhancer	[HIV-1 transcriptional enhancer]	1.5849625007211563	3	1	0	0
22132	1520	stage of B-cell maturation	[stage of B-cell maturation]	1.5849625007211563	4	1	0	0
22133	1520	IL-5 signal transduction mechanism	[IL-5 signal transduction mechanism]	1.5849625007211563	4	1	0	0
22134	1520	response to tgf-beta1	[response to TGF-beta1]	1.5849625007211563	3	1	0	0
22135	1520	immediate-early protein BZLF1	[immediate-early protein BZLF1]	1.5849625007211563	3	1	0	0
22136	1520	p50 nf-kappa b1	[p50 NF-kappa B1]	1.5849625007211563	3	1	0	0
22137	1520	pgn phosphorylation of c-jun	[PGN phosphorylation of c-Jun]	1.5849625007211563	4	1	0	0
22138	1520	event at the time	[events at the time]	1.5849625007211563	4	1	0	0
22139	1520	C/EBP transcriptional activator	[C/EBP transcriptional activators]	1.5849625007211563	3	1	0	0
22140	1520	epstein-barr virus zebra protein	[Epstein-Barr virus ZEBRA protein]	1.5849625007211563	4	1	0	0
22141	1520	different cytokine receptor	[different cytokine receptors]	1.5849625007211563	3	1	0	0
22142	1520	powerful ptpase inhibitor pervanadate	[powerful PTPase inhibitor pervanadate]	1.5849625007211563	4	1	0	0
22143	1520	10 U/ml, 6 h)	[10 U/ml, 6 h)]	1.5849625007211563	4	1	0	0
22144	1520	brushing, e1a sequence	[brushing, E1a sequences]	1.5849625007211563	3	1	0	0
22145	1520	vivo substrate of calcineurin	[vivo substrate of calcineurin]	1.5849625007211563	4	1	0	0
22146	1520	glucocorticoid receptor hGR	[glucocorticoid receptor hGR]	1.5849625007211563	3	2	1	1
22147	1520	result of transduction	[result of transduction]	1.5849625007211563	3	1	0	0
22148	1520	degree of cell damage	[degree of cell damage]	1.5849625007211563	4	1	0	0
22149	1520	Mol cell Biol apr;18(4):2430]	[Mol Cell Biol Apr;18(4):2430]]	1.5849625007211563	4	1	0	0
22150	1520	NFkappaB gene expression	[NFkappaB gene expression]	1.5849625007211563	3	1	0	0
22151	1520	glucocorticoid receptor gcr	[glucocorticoid receptor GCR]	1.5849625007211563	3	2	2	2
22152	1520	inactivation in human cell	[inactivation in human cells]	1.5849625007211563	4	1	0	0
22153	1520	more potent competitor	[more potent competitor]	1.5849625007211563	3	1	0	0
22154	1520	regulation of il-4 expression	[Regulation of IL-4 expression]	1.5849625007211563	4	1	0	0
22155	1520	combination of mapkk-1	[combination of MAPKK-1]	1.5849625007211563	3	1	0	0
22156	1520	peripheral blood monocyte pbm	[peripheral blood monocytes PBM]	1.5849625007211563	4	1	0	0
22157	1520	dioxin receptor function	[dioxin receptor function]	1.5849625007211563	3	3	2	1
22158	1520	(2.5 ng/mL), interleukin-3 ng/mL),	[(2.5 ng/mL), interleukin-3 ng/mL),]	1.5849625007211563	4	1	0	0
22159	1520	pattern of cytokine	[pattern of cytokines]	1.5849625007211563	3	2	2	2
22160	1520	3-carboranyl-substituted compound 8	[3-carboranyl-substituted compounds 8]	1.5849625007211563	3	1	0	0
22161	1520	result of IFN production	[result of IFN production]	1.5849625007211563	4	1	0	0
22162	1520	yeast transcriptional regulator Rpd3p	[yeast transcriptional regulator Rpd3p]	1.5849625007211563	4	1	0	0
22163	1520	antibody to IL-4 stat	[antibodies to IL-4 Stat]	1.5849625007211563	4	1	0	0
22164	1520	leader protein ebna-lp	[leader protein EBNA-LP]	1.5849625007211563	3	1	0	0
22165	1520	cellular gene expression	[cellular gene expression]	1.5849625007211563	3	2	1	1
22166	1520	clonal derivative alpha b5a	[clonal derivative alpha B5A]	1.5849625007211563	4	1	0	0
22167	1520	PMA ap-1 transcriptional activation	[PMA AP-1 transcriptional activation]	1.5849625007211563	4	1	0	0
22168	1520	cytoplasmic domain common	[cytoplasmic domain common]	1.5849625007211563	3	1	0	0
22169	1520	dominant-negative CAML mutant	[dominant-negative CAML mutant]	1.5849625007211563	3	1	0	0
22170	1520	cell differentiation, proliferation,	[cell differentiation, proliferation,]	1.5849625007211563	3	1	0	0
22171	1520	abnormality of chromosome	[abnormalities of chromosome]	1.5849625007211563	3	1	0	0
22172	1520	human inflammatory pathology	[human inflammatory pathologies]	1.5849625007211563	3	2	1	1
22173	1520	IFN regulatory factor-1	[IFN regulatory factor-1]	1.5849625007211563	3	3	2	1
22174	1520	case of thymic selection	[case of thymic selection]	1.5849625007211563	4	1	0	0
22175	1520	proportion of HIV individual	[proportion of HIV individuals]	1.5849625007211563	4	1	0	0
22176	1520	fos family of proto-oncogent	[fos family of proto-oncogenes]	1.5849625007211563	4	1	0	0
22177	1520	role for gsh	[role for GSH]	1.5849625007211563	3	1	0	0
22178	1520	induction of hiv transcription	[induction of HIV transcription]	1.5849625007211563	4	2	1	1
22179	1520	CAII reporter construct	[CAII reporter construct]	1.5849625007211563	3	1	0	0
22180	1520	DQ cis- dimer availability	[DQ cis- dimer availability]	1.5849625007211563	4	1	0	0
22181	1520	murine il-2 promoter	[murine IL-2 promoter]	1.5849625007211563	3	1	0	0
22182	1520	previously unrecognized form	[previously unrecognized form]	1.5849625007211563	3	2	2	2
22183	1520	pbmc of patient	[PBMC of patients]	1.5849625007211563	3	2	2	2
22184	1520	three to 6 month	[Three to 6 months]	1.5849625007211563	4	1	0	0
22185	1520	suggest the existence	[suggesting the existence]	1.5849625007211563	3	2	1	1
22186	1520	age, sex, course, duration	[age, sex, course, duration]	1.5849625007211563	4	1	0	0
22187	1520	high affinity for testosterone	[high affinity for testosterone]	1.5849625007211563	4	1	0	0
22188	1520	part to the suppression	[part to the suppression]	1.5849625007211563	4	1	0	0
22189	1520	increase in mrna level	[increase in mRNA levels]	1.5849625007211563	4	2	2	2
22190	1520	nf-at -binding site	[NF-AT -binding site]	1.5849625007211563	3	1	0	0
22191	1520	therapeutic agent for aids	[therapeutic agents for AIDS]	1.5849625007211563	4	1	0	0
22192	1520	structure of cytokine receptor	[structure of cytokine receptors]	1.5849625007211563	4	1	0	0
22193	1520	man in postmenopausal woman	[men in postmenopausal women]	1.5849625007211563	4	1	0	0
22194	1520	term of anti-proliferative activity	[terms of anti-proliferative activity]	1.5849625007211563	4	1	0	0
22195	1520	functional activity of member	[functional activity of members]	1.5849625007211563	4	1	0	0
22196	1520	SL3 enhancer factor 1	[SL3 enhancer factor 1]	1.5849625007211563	4	1	0	0
22197	1520	endogenous murine protein, exogenous	[endogenous murine protein, exogenous]	1.5849625007211563	4	1	0	0
22198	1520	histone deacetylase inhibitor	[histone deacetylase inhibitors]	1.5849625007211563	3	1	0	0
22199	1520	complete sequence of pp65	[complete sequence of pp65]	1.5849625007211563	4	1	0	0
22200	1520	lymphocyte nuclear t3 receptor	[lymphocyte nuclear T3 receptor]	1.5849625007211563	4	1	0	0
22201	1520	regard to content	[regard to content]	1.5849625007211563	3	1	0	0
22202	1520	line represent stage	[lines representing stages]	1.5849625007211563	3	2	2	2
22203	1520	direct th2-specific activity	[directing Th2-specific activity]	1.5849625007211563	3	1	0	0
22204	1520	ERP a new member	[ERP a new member]	1.5849625007211563	4	1	0	0
22205	1520	other b cell component	[other B cell components]	1.5849625007211563	4	1	0	0
22206	1520	stat serine phosphorylation	[STAT serine phosphorylation]	1.5849625007211563	3	2	1	1
22207	1520	period of pkc activation	[periods of PKC activation]	1.5849625007211563	4	1	0	0
22208	1520	genomic configuration of gm-csf	[genomic configuration of GM-CSF]	1.5849625007211563	4	1	0	0
22209	1520	comparison with healthy donor	[comparison with healthy donors]	1.5849625007211563	4	1	0	0
22210	1520	Shigella flexneri icsa protein	[Shigella flexneri IcsA protein]	1.5849625007211563	4	1	0	0
22211	1520	conclusion, e(gre) motif	[conclusion, E(gre) motifs]	1.5849625007211563	3	1	0	0
22212	1520	dexamethasone of further glucocorticoid	[dexamethasone of further glucocorticoids]	1.5849625007211563	4	1	0	0
22213	1520	PRL receptor activation	[PRL receptor activation]	1.5849625007211563	3	1	0	0
22214	1520	direct transcriptional target gene	[direct transcriptional target genes]	1.5849625007211563	4	1	0	0
22215	1520	only from T cell	[only from T cells]	1.5849625007211563	4	1	0	0
22216	1520	Sjogren' syndrome patient	[Sjogren's syndrome patients]	1.5849625007211563	3	1	0	0
22217	1520	stimulus of hiv replication	[stimulus of HIV replication]	1.5849625007211563	4	1	0	0
22218	1520	human platelet/endothelial cell adhesion	[human platelet/endothelial cell adhesion]	1.5849625007211563	4	1	0	0
22219	1520	-230 GATA-1 site	[-230 GATA-1 site]	1.5849625007211563	3	1	0	0
22220	1520	-ggaa- to -GGAT-	[-GGAA- to -GGAT-]	1.5849625007211563	3	1	0	0
22221	1520	differentiation of p21 Waf1	[differentiation of p21 Waf1]	1.5849625007211563	4	1	0	0
22222	1520	predominantly on megakaryocytopoiesis	[predominantly on megakaryocytopoiesis]	1.5849625007211563	3	1	0	0
22223	1520	role of this factor	[roles of these factor]	1.5849625007211563	4	2	2	2
22224	1520	two gata-associated site CACCC	[two GATA-associated sites CACCC]	1.5849625007211563	4	1	0	0
22225	1520	low growth fraction	[low growth fraction]	1.5849625007211563	3	1	0	0
22226	1520	clinical spectra of disease	[clinical spectra of diseases]	1.5849625007211563	4	1	0	0
22227	1520	eosinophilic tissue infiltration	[eosinophilic tissue infiltration]	1.5849625007211563	3	1	0	0
22228	1520	pma/ca2+ ionophore stimulation	[PMA/Ca2+ ionophore stimulation]	1.5849625007211563	3	1	0	0
22229	1520	rel-related transcription factor	[Rel-related transcription factors]	1.5849625007211563	3	1	0	0
22230	1520	however, stimulation with mbp	[However, stimulation with MBP]	1.5849625007211563	4	1	0	0
22231	1520	c-terminal to the phosphotyrosine	[C-terminal to the phosphotyrosine]	1.5849625007211563	4	1	0	0
22232	1520	various inflammatory gene	[various inflammatory genes]	1.5849625007211563	3	1	0	0
22233	1520	third intron of tnf-alpha	[third intron of TNF-alpha]	1.5849625007211563	4	1	0	0
22234	1520	obvious sequence homology between	[obvious sequence homology between]	1.5849625007211563	4	1	0	0
22235	1520	transcription of nuclear protooncogene	[transcription of nuclear protooncogenes]	1.5849625007211563	4	1	0	0
22236	1520	presence of ap1	[presence of AP1]	1.5849625007211563	3	1	0	0
22237	1520	viral activation process	[viral activation process]	1.5849625007211563	3	1	0	0
22238	1520	other nuclear protein	[other nuclear proteins]	1.5849625007211563	3	1	0	0
22239	1520	intact NF-kappa b	[intact NF-kappa B]	1.5849625007211563	3	1	0	0
22240	1520	expression of the IL-2	[expression of the IL-2]	1.5849625007211563	4	1	0	0
22241	1520	heterologous beta-globin reporter gene	[heterologous beta-globin reporter gene]	1.5849625007211563	4	1	0	0
22242	1520	certain stat enhancer	[certain STAT enhancers]	1.5849625007211563	3	1	0	0
22243	1520	conditional ebv mutant	[conditional EBV mutants]	1.5849625007211563	3	1	0	0
22244	1520	IL-6 gene by ifn-gamma	[IL-6 gene by IFN-gamma]	1.5849625007211563	4	1	0	0
22245	1520	mode of synthesis.	[mode of synthesis.]	1.5849625007211563	3	1	0	0
22246	1520	secondary pathogenic infection	[secondary pathogenic infections]	1.5849625007211563	3	1	0	0
22247	1520	three protein binding site	[three protein binding sites]	1.5849625007211563	4	1	0	0
22248	1520	requirement of gata-1	[Requirement of GATA-1]	1.5849625007211563	3	2	1	1
22249	1520	nuclear runoff experiments,	[nuclear runoff experiments,]	1.5849625007211563	3	1	0	0
22250	1520	1 to 3 minute	[1 to 3 min]	1.5849625007211563	4	1	0	0
22251	1520	linker protein slp-76	[linker protein SLP-76]	1.5849625007211563	3	1	0	0
22252	1520	Y chromosomal rearrangement	[Y chromosomal rearrangements]	1.5849625007211563	3	1	0	0
22253	1520	severely defective replicative phenotype.	[severely defective replicative phenotype.]	1.5849625007211563	4	1	0	0
22254	1520	importance of NF-kappaB induction	[importance of NF-kappaB induction]	1.5849625007211563	4	1	0	0
22255	1520	signal of eosinophil	[signaling of eosinophils]	1.5849625007211563	3	1	0	0
22256	1520	replate on 2M-1 cell	[replating on 2M-1 cells]	1.5849625007211563	4	1	0	0
22257	1520	primary b-lymphocyte growth transformation	[primary B-lymphocyte growth transformation]	1.5849625007211563	4	1	0	0
22258	1520	miss in b cell	[missing in B cells]	1.5849625007211563	4	1	0	0
22259	1520	anti-tax1 monoclonal antibody lt-4	[anti-tax1 monoclonal antibody Lt-4]	1.5849625007211563	4	1	0	0
22260	1520	c-fo in T lymphocyte	[c-fos in T lymphocytes]	1.5849625007211563	4	1	0	0
22261	1520	other pax gene	[other Pax genes]	1.5849625007211563	3	2	1	1
22262	1520	glucocorticoid receptor -dependent transcription	[glucocorticoid receptor -dependent transcription]	1.5849625007211563	4	1	0	0
22263	1520	refractory risk breast cancer	[refractory risk breast cancer]	1.5849625007211563	4	1	0	0
22264	1520	slow migrating form	[slower migrating forms]	1.5849625007211563	3	2	1	1
22265	1520	3 kb 5'-flanking region	[3 kb 5'-flanking region]	1.5849625007211563	4	1	0	0
22266	1520	late erythroblast stage	[late erythroblast stage]	1.5849625007211563	3	1	0	0
22267	1520	NFAT binding site	[NFAT binding site]	1.5849625007211563	3	1	0	0
22268	1520	interleukin 3 il-3	[interleukin 3 IL-3]	1.5849625007211563	3	1	0	0
22269	1520	1,25-dihydroxyvitamin D3 125d3	[1,25-dihydroxyvitamin D3 1,25D3]	1.5849625007211563	3	1	0	0
22270	1520	specific response of NF-kappaB	[specific response of NF-kappaB]	1.5849625007211563	4	1	0	0
22271	1520	interaction between the receptor	[interaction between the receptor]	1.5849625007211563	4	2	2	2
22272	1520	rheumatoid synovial cell	[rheumatoid synovial cells]	1.5849625007211563	3	2	2	2
22273	1520	difference in phosphorylation	[Differences in phosphorylation]	1.5849625007211563	3	1	0	0
22274	1520	intronic sequence at +265	[intronic sequence at +265]	1.5849625007211563	4	1	0	0
22275	1520	breast cancer development	[breast cancer development]	1.5849625007211563	3	2	1	1
22276	1520	KBF1 by itself	[KBF1 by itself]	1.5849625007211563	3	1	0	0
22277	1520	putative helix-loop-helix motif	[putative helix-loop-helix motifs]	1.5849625007211563	3	1	0	0
22278	1520	point in activation	[point in activation]	1.5849625007211563	3	1	0	0
22279	1520	CD28 response element cd28re	[CD28 response element CD28RE]	1.5849625007211563	4	1	0	0
22280	1520	downstream, function-related gene	[downstream, function-related genes]	1.5849625007211563	3	1	0	0
22281	1520	AML1 -binding site	[AML1 -binding site]	1.5849625007211563	3	2	2	2
22282	1520	one protein, nf-gm2	[One protein, NF-GM2]	1.5849625007211563	3	1	0	0
22283	1520	clinical use, CsA treatment	[clinical use, CsA treatment]	1.5849625007211563	4	1	0	0
22284	1520	GATA1 erythroid transcription factor	[GATA1 erythroid transcription factor]	1.5849625007211563	4	1	0	0
22285	1520	T cell p50	[T cell p50]	1.5849625007211563	3	1	0	0
22286	1520	viral episomal maintenance	[viral episomal maintenance]	1.5849625007211563	3	1	0	0
22287	1520	infection of myeloid cell	[infection of myeloid cells]	1.5849625007211563	4	2	2	2
22288	1520	squirrel monkey lymphocyte SML	[squirrel monkey lymphocytes SML]	1.5849625007211563	4	1	0	0
22289	1520	collagen receptor on platelet	[collagen receptor on platelets]	1.5849625007211563	4	1	0	0
22290	1520	nkl natural cytotoxicity	[NKL natural cytotoxicity]	1.5849625007211563	3	1	0	0
22291	1520	t-cell-specific promoter sequence	[T-cell-specific promoter sequences]	1.5849625007211563	3	1	0	0
22292	1520	region between -108	[region between -108]	1.5849625007211563	3	1	0	0
22293	1520	tax the viral protein	[Tax the viral protein]	1.5849625007211563	4	1	0	0
22294	1520	certain NF-AT(Rel) family member	[certain NF-AT(Rel) family members]	1.5849625007211563	4	1	0	0
22295	1520	region between -105	[region between -105]	1.5849625007211563	3	1	0	0
22296	1520	partially overlapping CD40L	[partially overlapping CD40L]	1.5849625007211563	3	1	0	0
22297	1520	classical intracellular ar	[classical intracellular AR]	1.5849625007211563	3	1	0	0
22298	1520	three induction condition	[three induction conditions]	1.5849625007211563	3	1	0	0
22299	1520	overexpression of p95vav	[overexpression of p95vav]	1.5849625007211563	3	2	2	2
22300	1520	suppression of il-2 production	[suppression of IL-2 production]	1.5849625007211563	4	1	0	0
22301	1520	human erythroleukemic cell	[human erythroleukemic cells]	1.5849625007211563	3	1	0	0
22302	1520	thymus from day embryo	[thymuses from day embryos]	1.5849625007211563	4	1	0	0
22303	1520	induction of collagenase-1	[induction of collagenase-1]	1.5849625007211563	3	2	2	2
22304	1520	similar DNA binding domain	[similar DNA binding domains]	1.5849625007211563	4	1	0	0
22305	1520	cluster of c-myb site	[cluster of c-Myb sites]	1.5849625007211563	4	1	0	0
22306	1520	presumably other MCM member	[presumably other MCM members,]	1.5849625007211563	4	1	0	0
22307	1520	high-grade b cell tumor	[high-grade B cell tumors]	1.5849625007211563	4	1	0	0
22308	1520	level in macrophage	[level in macrophages]	1.5849625007211563	3	2	2	2
22309	1520	effect of il-13	[effect of IL-13]	1.5849625007211563	3	2	2	2
22310	1520	initiate the apoptotic pathway	[initiating the apoptotic pathway]	1.5849625007211563	4	1	0	0
22311	1520	B29 gene expression	[B29 gene expression]	1.5849625007211563	3	1	0	0
22312	1520	biomarker of effect	[biomarker of effects]	1.5849625007211563	3	1	0	0
22313	1520	1 df, p=.01)	[1 df, P=.01)]	1.5849625007211563	3	1	0	0
22314	1520	cd40: cd40l engagement	[CD40: CD40L engagement]	1.5849625007211563	3	1	0	0
22315	1520	response to several stimuli.	[response to several stimuli.]	1.5849625007211563	4	1	0	0
22316	1520	progression of lymphoproliferative disease	[progression of lymphoproliferative diseases]	1.5849625007211563	4	1	0	0
22317	1520	addition to Egr-3	[addition to Egr-3]	1.5849625007211563	3	1	0	0
22318	1520	release of chemokine	[release of chemokine]	1.5849625007211563	3	1	0	0
22319	1520	rate of ifn-gamma transcription	[rate of IFN-gamma transcription]	1.5849625007211563	4	1	0	0
22320	1520	10(-7) m dexamethasone (207.9+/-31.5	[10(-7) M dexamethasone (207.9+/-31.5]	1.5849625007211563	4	1	0	0
22321	1520	stat tyrosine phosphorylation	[STAT tyrosine phosphorylation]	1.5849625007211563	3	2	2	2
22322	1520	different cytokine production profile	[different cytokine production profiles]	1.5849625007211563	4	1	0	0
22323	1520	C-terminal 607 amino acid	[C-terminal 607 amino acids]	1.5849625007211563	4	1	0	0
22324	1520	specific interaction with pu.1	[specific interaction with PU.1]	1.5849625007211563	4	1	0	0
22325	1520	il-2 -dependent cell	[IL-2 -dependent cells]	1.5849625007211563	3	1	0	0
22326	1520	bcl6+/cd3+/cd20-/cd57- T cell	[Bcl6+/CD3+/CD20-/CD57- T cells]	1.5849625007211563	3	1	0	0
22327	1520	leukocyte anti-infective activity	[leukocyte anti-infective activity]	1.5849625007211563	3	1	0	0
22328	1520	lymphoid/myeloid somatic hybrid	[lymphoid/myeloid somatic hybrid]	1.5849625007211563	3	1	0	0
22329	1520	adjuvant treatment with tamoxifen	[adjuvant treatment with tamoxifen]	1.5849625007211563	4	1	0	0
22330	1520	structural analog0 rapamycin	[structural analog, rapamycin]	1.5849625007211563	3	1	0	0
22331	1520	use flow cytometry analysis,	[Using flow cytometry analysis,]	1.5849625007211563	4	1	0	0
22332	1520	full-length mzf-1 coding region	[full-length MZF-1 coding region]	1.5849625007211563	4	1	0	0
22333	1520	apoptotic vsmc-myc cell	[apoptotic VSMC-myc cells]	1.5849625007211563	3	1	0	0
22334	1520	adjacent binding site	[adjacent binding sites]	1.5849625007211563	3	2	1	1
22335	1520	increase of plasma cortisol	[increase of plasma cortisol]	1.5849625007211563	4	1	0	0
22336	1520	homeobox gene HB24	[homeobox gene HB24]	1.5849625007211563	3	2	1	1
22337	1520	role as a target	[role as a target]	1.5849625007211563	4	1	0	0
22338	1520	other cytotoxic protein	[other cytotoxic proteins]	1.5849625007211563	3	1	0	0
22339	1520	mrna of TNF-alpha	[mRNA of TNF-alpha]	1.5849625007211563	3	1	0	0
22340	1520	human interferon regulatory factor	[Human interferon regulatory factor]	1.5849625007211563	4	2	2	2
22341	1520	release of inflammatory mediator	[release of inflammatory mediators]	1.5849625007211563	4	1	0	0
22342	1520	135(oh)2d3 receptor rna	[1,25(OH)2D3 receptor RNA]	1.5849625007211563	3	3	2	1
22343	1520	tcr constant region	[TCR constant region]	1.5849625007211563	3	1	0	0
22344	1520	ability of such cell	[ability of such cells]	1.5849625007211563	4	1	0	0
22345	1520	promoter proximal repeat	[promoter proximal repeat]	1.5849625007211563	3	1	0	0
22346	1520	pro- b-cell line	[pro- B-cell lines]	1.5849625007211563	3	1	0	0
22347	1520	effect on the na(+)-h(+)-antiport	[effect on the Na(+)-H(+)-antiport]	1.5849625007211563	4	1	0	0
22348	1520	four important functional region	[four important functional regions]	1.5849625007211563	4	1	0	0
22349	1520	extracellular-regulated kinase 1/2	[Extracellular-regulated kinase 1/2]	1.5849625007211563	3	1	0	0
22350	1520	diesel exhaust emission	[diesel exhaust emission]	1.5849625007211563	3	1	0	0
22351	1520	indicate a requirement	[indicating a requirement]	1.5849625007211563	3	2	1	1
22352	1520	JNK enzymatic activity	[JNK enzymatic activity]	1.5849625007211563	3	1	0	0
22353	1520	human erythropoietin receptor gene	[human erythropoietin receptor gene]	1.5849625007211563	4	1	0	0
22354	1520	second a/r insult	[second A/R insult]	1.5849625007211563	3	1	0	0
22355	1520	maintain cellular homeostasis	[maintaining cellular homeostasis]	1.5849625007211563	3	1	0	0
22356	1520	variety of viral pathogens,	[variety of viral pathogens,]	1.5849625007211563	4	1	0	0
22357	1520	a/r tolerance with respect	[A/R tolerance with respect]	1.5849625007211563	4	1	0	0
22358	1520	autocrine effect of tnf-alpha	[autocrine effect of TNF-alpha]	1.5849625007211563	4	1	0	0
22359	1520	lymphocyte in vitro	[lymphocytes in vitro]	1.5849625007211563	3	1	0	0
22360	1520	CD40 antigen expression	[CD40 antigen expression]	1.5849625007211563	3	2	2	2
22361	1520	NLSs of NF-kappa b	[NLSs of NF-kappa B]	1.5849625007211563	4	1	0	0
22362	1520	"giant" platelet a condition	["giant" platelets a condition]	1.5849625007211563	4	1	0	0
22363	1520	one gene of interest	[One gene of interest]	1.5849625007211563	4	1	0	0
22364	1520	Comparison of the sequence	[Comparison of the sequences]	1.5849625007211563	4	1	0	0
22365	1520	CIITA mrna induction level	[CIITA mRNA induction levels]	1.5849625007211563	4	1	0	0
22366	1520	immediate-early gene product Egr-1	[immediate-early gene product Egr-1]	1.5849625007211563	4	1	0	0
22367	1520	JNK /sapk activation upstream	[JNK /SAPK activation upstream]	1.5849625007211563	4	1	0	0
22368	1520	two DNA binding domain	[two DNA binding domains]	1.5849625007211563	4	1	0	0
22369	1520	result in the abrogation	[resulting in the abrogation]	1.5849625007211563	4	1	0	0
22370	1520	loss of bcl-2	[loss of bcl-2]	1.5849625007211563	3	1	0	0
22371	1520	phosphorylation and/or degradation	[phosphorylation and/or degradation]	1.5849625007211563	3	1	0	0
22372	1520	RPMI 1640 medium	[RPMI 1640 medium]	1.5849625007211563	3	1	0	0
22373	1520	type ii il-1r	[type II IL-1R]	1.5849625007211563	3	1	0	0
22374	1520	C196 T cell line	[C196 T cell lines]	1.5849625007211563	4	1	0	0
22375	1520	normal adult hematopoiesis	[normal adult hematopoiesis]	1.5849625007211563	3	1	0	0
22376	1520	CD40 survival signal	[CD40 survival signaling]	1.5849625007211563	3	1	0	0
22377	1520	expression of c-fo gene	[expression of c-fos genes]	1.5849625007211563	4	1	0	0
22378	1520	expression during differentiation	[Expression during differentiation]	1.5849625007211563	3	2	2	2
22379	1520	same nuclear extract	[same nuclear extracts]	1.5849625007211563	3	1	0	0
22380	1520	secondary virus infection	[secondary virus infection]	1.5849625007211563	3	1	0	0
22381	1520	drosophila morphogen dorsal	[Drosophila morphogen dorsal]	1.5849625007211563	3	1	0	0
22382	1520	TRAF1 /TRAF2 heteroaggregate	[TRAF1 /TRAF2 heteroaggregates]	1.5849625007211563	3	1	0	0
22383	1520	binding of [3H]VD3	[Binding of [3H]VD3]	1.5849625007211563	3	1	0	0
22384	1520	b cell tumor	[B cell tumors]	1.5849625007211563	3	2	1	1
22385	1520	varicella-zoster virus glycoprotein e	[varicella-zoster virus glycoprotein E]	1.5849625007211563	4	1	0	0
22386	1520	biologically important mechanism	[biologically important mechanism]	1.5849625007211563	3	1	0	0
22387	1520	role of CaM-K ii	[role of CaM-K II]	1.5849625007211563	4	1	0	0
22388	1520	lipopolysaccharide lps release	[lipopolysaccharide LPS release]	1.5849625007211563	3	1	0	0
22389	1520	effect of cepharanthine	[effects of cepharanthine]	1.5849625007211563	3	2	2	2
22390	1520	activation of Syk	[activation of Syk]	1.5849625007211563	3	1	0	0
22391	1520	challenge with allergen.	[challenge with allergen.]	1.5849625007211563	3	1	0	0
22392	1520	10 follicular lymphoma	[10 follicular lymphoma]	1.5849625007211563	3	1	0	0
22393	1520	regulator of hematopoiesis	[regulators of hematopoiesis]	1.5849625007211563	3	2	2	2
22394	1520	expression in hematopoietic cell	[expression in hematopoietic cells]	1.5849625007211563	4	2	1	1
22395	1520	hiv-1 proviral DNA	[HIV-1 proviral DNA]	1.5849625007211563	3	1	0	0
22396	1520	constitutively active calcineurin cn	[constitutively active calcineurin CN]	1.5849625007211563	4	1	0	0
22397	1520	five lymph node	[five lymph nodes]	1.5849625007211563	3	2	2	2
22398	1520	leukocyte-specific pp52 promoter	[leukocyte-specific pp52 promoter]	1.5849625007211563	3	1	0	0
22399	1520	addition act on IkappaBalpha	[addition acting on IkappaBalpha]	1.5849625007211563	4	1	0	0
22400	1520	exogenous p27(kip1) expression	[exogenous p27(KIP1) expression]	1.5849625007211563	3	1	0	0
22401	1520	only the upstream sequence	[only the upstream sequences]	1.5849625007211563	4	1	0	0
22402	1520	effect in lymphocyte development	[effects in lymphocyte development]	1.5849625007211563	4	1	0	0
22403	1520	JAK -stat pathway	[JAK -STAT pathway]	1.5849625007211563	3	2	1	1
22404	1520	NF-kappaB pathway of activation	[NF-kappaB pathway of activation]	1.5849625007211563	4	1	0	0
22405	1520	approximately 20 kda.	[approximately 20 kDa.]	1.5849625007211563	3	1	0	0
22406	1520	IFN receptor family	[IFN receptor family]	1.5849625007211563	3	1	0	0
22407	1520	uninduced virus HeLa extract	[Uninduced virus HeLa extracts]	1.5849625007211563	4	1	0	0
22408	1520	lymphoid src kinase pp56(lck)	[lymphoid src kinase pp56(lck)]	1.5849625007211563	4	1	0	0
22409	1520	cytokine receptor superfamily	[cytokine receptor superfamily]	1.5849625007211563	3	1	0	0
22410	1520	first degree relative	[first degree relative]	1.5849625007211563	3	1	0	0
22411	1520	promoter proximal region	[promoter proximal region]	1.5849625007211563	3	1	0	0
22412	1520	pleckstrin homology domain	[pleckstrin homology domains]	1.5849625007211563	3	1	0	0
22413	1520	use herbimycin a	[using herbimycin A]	1.5849625007211563	3	1	0	0
22414	1520	fusion with hela cell	[fusion with HeLa cells]	1.5849625007211563	4	1	0	0
22415	1520	transduction pathway lead	[transduction pathway leading]	1.5849625007211563	3	1	0	0
22416	1520	G75:AES1/2 128-135 G60: Aes1/2	[G75:AES1/2 128-135 G60: AES1/2]	1.5849625007211563	4	1	0	0
22417	1520	most eukaryotic gene	[most eukaryotic genes]	1.5849625007211563	3	1	0	0
22418	1520	such as the inability	[such as the inability]	1.5849625007211563	4	1	0	0
22419	1520	human intestinal epithelial cell	[human intestinal epithelial cells]	1.5849625007211563	4	1	0	0
22420	1520	human tnf-alpha gene	[human TNF-alpha gene]	1.5849625007211563	3	1	0	0
22421	1520	human papillomavirus e6	[human papillomavirus E6]	1.5849625007211563	3	1	0	0
22422	1520	vivo footprinting by pcr	[vivo footprinting by PCR]	1.5849625007211563	4	1	0	0
22423	1520	sequence between -155	[sequence between -155]	1.5849625007211563	3	1	0	0
22424	1520	cytokine the peptide hormone	[Cytokines the peptide hormones]	1.5849625007211563	4	1	0	0
22425	1520	leucocytic estrogen receptor	[leucocytic estrogen receptor]	1.5849625007211563	3	1	0	0
22426	1520	such as ctla-4	[such as CTLA-4]	1.5849625007211563	3	1	0	0
22427	1520	14 ppb for benzene	[14 PPB for benzene]	1.5849625007211563	4	1	0	0
22428	1520	-130 ap-1-like site	[-130 AP-1-like site]	1.5849625007211563	3	1	0	0
22429	1520	function of the axis	[function of the axis]	1.5849625007211563	4	1	0	0
22430	1520	different nf-kappa b subunit	[different NF-kappa B subunits]	1.5849625007211563	4	1	0	0
22431	1520	mab against the dUTPase	[MAbs against the dUTPase]	1.5849625007211563	4	1	0	0
22432	1520	abnormal nfkappab activation	[abnormal NFkappaB activation]	1.5849625007211563	3	2	2	2
22433	1520	PGE2 -dependent up-regulating effect	[PGE2 -dependent up-regulating effect]	1.5849625007211563	4	1	0	0
22434	1520	impact of this compound	[impact of these compounds]	1.5849625007211563	4	1	0	0
22435	1520	enhancer by cooperation	[enhancer by cooperation]	1.5849625007211563	3	1	0	0
22436	1520	hormonal state in patient	[hormonal state in patients]	1.5849625007211563	4	1	0	0
22437	1520	lack of nf-ya protein	[lack of NF-YA protein]	1.5849625007211563	4	1	0	0
22438	1520	common pathway to induction	[common pathway to induction]	1.5849625007211563	4	1	0	0
22439	1520	tumour suppressor p53	[tumour suppressor p53]	1.5849625007211563	3	1	0	0
22440	1520	regulation of inflammatory responses,	[regulation of inflammatory responses,]	1.5849625007211563	4	1	0	0
22441	1520	mainly in b lymphocyte	[mainly in B lymphocytes]	1.5849625007211563	4	1	0	0
22442	1520	respective pathogenetic role	[respective pathogenetic roles]	1.5849625007211563	3	1	0	0
22443	1520	facilitate antibody in patient	[facilitating antibody in patients]	1.5849625007211563	4	1	0	0
22444	1520	VDR antisense transfection	[VDR antisense transfection]	1.5849625007211563	3	1	0	0
22445	1520	xp-d lymphoblastoid cell	[XP-D lymphoblastoid cells]	1.5849625007211563	3	1	0	0
22446	1520	use differential display rt-pcr	[using differential display RT-PCR]	1.5849625007211563	4	1	0	0
22447	1520	Jurkat hb24 transfectant	[Jurkat HB24 transfectants]	1.5849625007211563	3	1	0	0
22448	1520	All-trans-retinoic acid atra	[All-trans-retinoic acid ATRA]	1.5849625007211563	3	1	0	0
22449	1520	relative 1p36 under-representation	[Relative 1p36 under-representation]	1.5849625007211563	3	1	0	0
22450	1520	immunmodulatory effect in vitro.	[immunmodulatory effects in vitro.]	1.5849625007211563	4	1	0	0
22451	1520	12.1% positive cells)	[12.1% positive cells)]	1.5849625007211563	3	1	0	0
22452	1520	treatment of disorder	[treatment of disorders]	1.5849625007211563	3	2	2	2
22453	1520	10 base pair	[10 base pairs]	1.5849625007211563	3	1	0	0
22454	1520	fc-derived non-hodgkin lymphoma	[FC-derived non-Hodgkin lymphomas]	1.5849625007211563	3	1	0	0
22455	1520	IL-2 promoter response element	[IL-2 promoter response element]	1.5849625007211563	4	1	0	0
22456	1520	production of functional il-12	[Production of functional IL-12]	1.5849625007211563	4	1	0	0
22457	1520	anti- timp-1 antibody	[anti- TIMP-1 antibodies]	1.5849625007211563	3	1	0	0
22458	1520	p100 the product	[p100 the product]	1.5849625007211563	3	1	0	0
22459	1520	Conversely, classic hd CHD	[Conversely, classic HD CHD]	1.5849625007211563	4	1	0	0
22460	1520	(include anti- zebra activity	[(including anti- ZEBRA activity]	1.5849625007211563	4	1	0	0
22461	1520	dominant negative activity	[dominant negative activity]	1.5849625007211563	3	1	0	0
22462	1520	live, replicate hiv-1	[live, replicating HIV-1]	1.5849625007211563	3	1	0	0
22463	1520	cd4-positive lymphocyte cell line	[CD4-positive lymphocyte cell line]	1.5849625007211563	4	1	0	0
22464	1520	different VDR genotype	[different VDR genotypes]	1.5849625007211563	3	1	0	0
22465	1520	poly( adp -ribose polymerase	[poly( ADP -ribose) polymerase]	1.5849625007211563	4	1	0	0
22466	1520	two undifferentiated spindle-shaped carcinoma	[two undifferentiated spindle-shaped carcinomas]	1.5849625007211563	4	1	0	0
22467	1520	insight into the pathogenesis	[insight into the pathogenesis]	1.5849625007211563	4	2	2	2
22468	1520	bfu-e colony growth	[BFU-E colony growth]	1.5849625007211563	3	1	0	0
22469	1520	apoptotic leukocyte by phagocyte	[apoptotic leukocytes by phagocytes]	1.5849625007211563	4	1	0	0
22470	1520	lymphoma cell at presentation.	[lymphoma cells at presentation.]	1.5849625007211563	4	1	0	0
22471	1520	derepression of beta-promoter activity	[derepression of beta-promoter activity]	1.5849625007211563	4	1	0	0
22472	1520	extracellular domain DeltaE	[extracellular domain DeltaE]	1.5849625007211563	3	1	0	0
22473	1520	human t- lymphocyte	[human T- lymphocytes]	1.5849625007211563	3	2	2	2
22474	1520	RESULTS: Dose-dependent inhibition	[RESULTS: Dose-dependent inhibition]	1.5849625007211563	3	1	0	0
22475	1520	pure differentiate hematopoietic progenitor	[pure differentiating hematopoietic progenitors]	1.5849625007211563	4	1	0	0
22476	1520	several HMG box protein	[several HMG box proteins]	1.5849625007211563	4	1	0	0
22477	1520	PKA transduction pathway	[PKA transduction pathway]	1.5849625007211563	3	1	0	0
22478	1520	antibody in the serum	[antibodies in the serum]	1.5849625007211563	4	1	0	0
22479	1520	2 receptor alpha	[2 receptor alpha]	1.5849625007211563	3	2	1	1
22480	1520	lck promoter et site	[lck promoter ets site]	1.5849625007211563	4	1	0	0
22481	1520	PML gene product	[PML gene product]	1.5849625007211563	3	1	0	0
22482	1520	gp ib alpha	[GP Ib alpha]	1.5849625007211563	3	2	1	1
22483	1520	0.006) control subject	[0.006) control subjects]	1.5849625007211563	3	1	0	0
22484	1520	gamma 3 region	[gamma 3 region]	1.5849625007211563	3	1	0	0
22485	1520	T cell immunity	[T cell immunity]	1.5849625007211563	3	3	2	1
22486	1520	most potent regulator	[most potent regulators]	1.5849625007211563	3	1	0	0
22487	1520	cell-specific gene transcription	[cell-specific gene transcription]	1.5849625007211563	3	1	0	0
22488	1520	second NFAT site	[second NFAT site]	1.5849625007211563	3	1	0	0
22489	1520	sufficient endogenous TRs	[sufficient endogenous TRs]	1.5849625007211563	3	1	0	0
22490	1520	RA target gene	[RA target genes]	1.5849625007211563	3	1	0	0
22491	1520	response to mitogenic stimuli.	[response to mitogenic stimuli.]	1.5849625007211563	4	1	0	0
22492	1520	nf-kappa b in cell	[NF-kappa B in cells]	1.5849625007211563	4	2	1	1
22493	1520	nuclear binding factor	[nuclear binding factor]	1.5849625007211563	3	2	2	2
22494	1520	activation of Rta	[activation of Rta]	1.5849625007211563	3	1	0	0
22495	1520	titrate the oestrogen concentration	[titrating the oestrogen concentration]	1.5849625007211563	4	1	0	0
22496	1520	tyrosine phosphorylation of slp-76	[tyrosine phosphorylation of SLP-76]	1.5849625007211563	4	1	0	0
22497	1520	pretreatment with B.pertussis	[Pretreatment with B.pertussis]	1.5849625007211563	3	1	0	0
22498	1520	strongly suggest platelet production	[strongly suggesting platelet production]	1.5849625007211563	4	1	0	0
22499	1520	pattern of stat activation	[pattern of STAT activation]	1.5849625007211563	4	1	0	0
22500	1520	follow pcr administration	[Following PCr administration]	1.5849625007211563	3	1	0	0
22501	1520	E1A gene expression	[E1A gene expression]	1.5849625007211563	3	1	0	0
22502	1520	stimulation with mycobacteria	[stimulation with mycobacteria]	1.5849625007211563	3	1	0	0
22503	1520	S-X-Y regulatory region	[S-X-Y regulatory region]	1.5849625007211563	3	1	0	0
22504	1520	76 ppb for MTBE	[76 PPB for MTBE]	1.5849625007211563	4	1	0	0
22505	1520	CD28 MoAb costimulation	[CD28 MoAb costimulation]	1.5849625007211563	3	2	2	2
22506	1520	human leukocyte membrane	[human leukocyte membranes]	1.5849625007211563	3	1	0	0
22507	1520	distinct change in p-glycoprotein	[distinct changes in P-glycoprotein]	1.5849625007211563	4	1	0	0
22508	1520	proteasome for processing.	[proteasome for processing.]	1.5849625007211563	3	1	0	0
22509	1520	mechanism of steroid resistance	[mechanism of steroid resistance]	1.5849625007211563	4	1	0	0
22510	1520	cyclic AMP response element	[cyclic AMP response element]	1.5849625007211563	4	3	2	1
22511	1520	variation in transcriptional regulation	[variation in transcriptional regulation]	1.5849625007211563	4	1	0	0
22512	1520	frameshift mutation TFIIHmut	[frameshift mutation TFIIHmut]	1.5849625007211563	3	1	0	0
22513	1520	intracytoplasmic delivery of protein	[intracytoplasmic delivery of proteins]	1.5849625007211563	4	1	0	0
22514	1520	role of the promoter	[role of the promoter]	1.5849625007211563	4	1	0	0
22515	1520	large dose of prednisone	[large doses of prednisone]	1.5849625007211563	4	1	0	0
22516	1520	gene expression for molecule	[gene expression for molecules]	1.5849625007211563	4	1	0	0
22517	1520	formation of this domain	[formation of these domains]	1.5849625007211563	4	1	0	0
22518	1520	regulation of macrophage activation	[regulation of macrophage activation]	1.5849625007211563	4	1	0	0
22519	1520	36 amino acids.	[36 amino acids.]	1.5849625007211563	3	1	0	0
22520	1520	t-cell-specific elf-1 factor	[T-cell-specific Elf-1 factor]	1.5849625007211563	3	1	0	0
22521	1520	mediator of the phenomena.	[mediators of the phenomena.]	1.5849625007211563	4	1	0	0
22522	1520	only a constitutive complex	[only a constitutive complex]	1.5849625007211563	4	1	0	0
22523	1520	absence of accessory cell	[absence of accessory cells]	1.5849625007211563	4	1	0	0
22524	1520	SRE- binding site	[SRE- binding site]	1.5849625007211563	3	1	0	0
22525	1520	suggest functionally important.	[suggesting functionally important.]	1.5849625007211563	3	1	0	0
22526	1520	arginine element RRLPIF	[arginine element RRLPIF]	1.5849625007211563	3	1	0	0
22527	1520	silencer of the gene	[silencer of the gene]	1.5849625007211563	4	1	0	0
22528	1520	binding in the nucleus	[binding in the nucleus]	1.5849625007211563	4	1	0	0
22529	1520	early Th2 development	[early Th2 development]	1.5849625007211563	3	1	0	0
22530	1520	means of alternative splicing	[means of alternative splicing]	1.5849625007211563	4	1	0	0
22531	1520	protein activity of nf-kappab	[protein activity of NF-kappaB]	1.5849625007211563	4	1	0	0
22532	1520	level of c-fo mrna	[level of c-fos mRNA]	1.5849625007211563	4	1	0	0
22533	1520	none of the gene	[none of the genes]	1.5849625007211563	4	2	1	1
22534	1520	gene during lymphocyte differentiation	[genes during lymphocyte differentiation]	1.5849625007211563	4	1	0	0
22535	1520	total of 80 exposures.	[total of 80 exposures.]	1.5849625007211563	4	1	0	0
22536	1520	activation of this kinase	[activation of this kinase]	1.5849625007211563	4	2	1	1
22537	1520	CD4 -positive lymphocyte cytotoxicity	[CD4 -positive lymphocyte cytotoxicity]	1.5849625007211563	4	1	0	0
22538	1520	non-hodgkin' lymphoma NHL	[non-Hodgkin's lymphoma NHL]	1.5849625007211563	3	2	2	2
22539	1520	five CIITA mutant construction	[Five CIITA mutant constructions]	1.5849625007211563	4	1	0	0
22540	1520	anti- CD2 mab capable	[anti- CD2 mAbs capable]	1.5849625007211563	4	1	0	0
22541	1520	beta- globin gene promoter	[beta- globin gene promoters]	1.5849625007211563	4	1	0	0
22542	1520	display gc phenotype	[displaying GC phenotype]	1.5849625007211563	3	1	0	0
22543	1520	reinsertion of this sequence	[Reinsertion of these sequences]	1.5849625007211563	4	1	0	0
22544	1520	human IL-16 gene	[human IL-16 gene]	1.5849625007211563	3	1	0	0
22545	1520	Rel/NF-kappaB -responsive gene	[Rel/NF-kappaB -responsive gene]	1.5849625007211563	3	1	0	0
22546	1520	tat protein Tat1-72	[Tat protein Tat1-72]	1.5849625007211563	3	1	0	0
22547	1520	other activation antigen	[other activation antigens]	1.5849625007211563	3	1	0	0
22548	1520	mechanism of the gene	[mechanism of the genes]	1.5849625007211563	4	1	0	0
22549	1520	retinoblastoma control element present	[retinoblastoma control element present]	1.5849625007211563	4	1	0	0
22550	1520	kappa B-dependent pathway	[kappa B-dependent pathway]	1.5849625007211563	3	1	0	0
22551	1520	absence follow induction	[absence following induction]	1.5849625007211563	3	1	0	0
22552	1520	stimulatory effect of pha	[stimulatory effect of PHA]	1.5849625007211563	4	1	0	0
22553	1520	transcription from nfat site	[transcription from NFAT sites]	1.5849625007211563	4	1	0	0
22554	1520	two kinases, ikk1	[two kinases, IKK1]	1.5849625007211563	3	1	0	0
22555	1520	exposure of whole cell	[exposure of whole cells]	1.5849625007211563	4	1	0	0
22556	1520	understanding of neutrophil biology	[understanding of neutrophil biology]	1.5849625007211563	4	1	0	0
22557	1520	p47phox a activator	[p47phox an activator]	1.5849625007211563	3	1	0	0
22558	1520	human cell line model	[human cell line model]	1.5849625007211563	4	2	1	1
22559	1520	detectable quantity of eicosanoid	[detectable quantities of eicosanoids]	1.5849625007211563	4	1	0	0
22560	1520	protein phosphatase 1 pp1	[protein phosphatases 1 PP1]	1.5849625007211563	4	1	0	0
22561	1520	5' flank genomic clone	[5' flanking genomic clone]	1.5849625007211563	4	1	0	0
22562	1520	small proportion 0.01-5%)	[small proportion 0.01-5%)]	1.5849625007211563	3	1	0	0
22563	1520	treatment of calcium metabolism	[treatment of calcium metabolism]	1.5849625007211563	4	1	0	0
22564	1520	recombinant c/ebpbeta protein	[recombinant C/EBPbeta protein]	1.5849625007211563	3	1	0	0
22565	1520	exogenous provision of NFkB	[Exogenous provision of NFkB]	1.5849625007211563	4	1	0	0
22566	1520	comparison of association profile	[comparison of association profiles]	1.5849625007211563	4	1	0	0
22567	1520	vitro transcription analysis	[vitro transcription analysis]	1.5849625007211563	3	1	0	0
22568	1520	approximately 3 time	[Approximately 3 times]	1.5849625007211563	3	1	0	0
22569	1520	ability of megakaryocyte	[ability of megakaryocytes]	1.5849625007211563	3	1	0	0
22570	1520	interaction between cell	[interaction between cells]	1.5849625007211563	3	2	2	2
22571	1520	cytokine il-2 ifn-gamma	[cytokines IL-2 IFN-gamma]	1.5849625007211563	3	1	0	0
22572	1520	leukocyte integrin gene	[leukocyte integrin genes]	1.5849625007211563	3	2	2	2
22573	1520	human ciita cDNA	[human CIITA cDNA]	1.5849625007211563	3	1	0	0
22574	1520	T cell apoptosis	[T cell apoptosis]	1.5849625007211563	3	2	1	1
22575	1520	rapid expression of cytokine	[rapid expression of cytokines]	1.5849625007211563	4	1	0	0
22576	1520	healthy, sedentary control person	[healthy, sedentary control persons]	1.5849625007211563	4	1	0	0
22577	1520	rate of progression	[rate of progression]	1.5849625007211563	3	1	0	0
22578	1520	HTLV-I(+) t-cell line	[HTLV-I(+) T-cell lines]	1.5849625007211563	3	1	0	0
22579	1520	heterologous dna-binding domain	[heterologous DNA-binding domain]	1.5849625007211563	3	1	0	0
22580	1520	gene to tcr activation	[gene to TCR activation]	1.5849625007211563	4	1	0	0
22581	1520	nuclear extract from cd16-	[nuclear extracts from CD16-]	1.5849625007211563	4	1	0	0
22582	1520	IL-4 and/or IL-13	[IL-4 and/or IL-13]	1.5849625007211563	3	1	0	0
22583	1520	ramification of cd19 signaling,	[ramifications of CD19 signaling,]	1.5849625007211563	4	1	0	0
22584	1520	TCR activation of NF-kappaB	[TCR activation of NF-kappaB]	1.5849625007211563	4	1	0	0
22585	1520	low binding affinity	[low binding affinity]	1.5849625007211563	3	2	2	2
22586	1520	activation of NK cell	[activation of NK cells]	1.5849625007211563	4	2	1	1
22587	1520	accumulation of NFAT4	[accumulation of NFAT4]	1.5849625007211563	3	2	2	2
22588	1520	myeloid differentiation to monocyte	[myeloid differentiation to monocytes]	1.5849625007211563	4	1	0	0
22589	1520	rar-specific ligand am80	[RAR-specific ligand Am80]	1.5849625007211563	3	1	0	0
22590	1520	mechanism for differential regulation	[mechanism for differential regulation]	1.5849625007211563	4	1	0	0
22591	1520	presence in the nucleus	[presence in the nucleus]	1.5849625007211563	4	1	0	0
22592	1520	response to gm-csf	[response to GM-CSF]	1.5849625007211563	3	1	0	0
22593	1520	kappa b domain capable	[kappa B domain capable]	1.5849625007211563	4	1	0	0
22594	1520	expression of icam-1	[expression of ICAM-1]	1.5849625007211563	3	2	2	2
22595	1520	nuclear translocation of b	[nuclear translocation of B]	1.5849625007211563	4	2	2	2
22596	1520	thiobarbituric acid-reactive substance tbar	[thiobarbituric acid-reactive substances TBARS]	1.5849625007211563	4	1	0	0
22597	1520	NF-kappaB -dependent up-regulation	[NF-kappaB -dependent up-regulation]	1.5849625007211563	3	1	0	0
22598	1520	resistance to differentiation induction	[resistance to differentiation induction]	1.5849625007211563	4	1	0	0
22599	1520	icam-1 alpha promoter	[ICAM-1 alpha promoter]	1.5849625007211563	3	1	0	0
22600	1520	protein immunologically indistinguishable	[protein immunologically indistinguishable]	1.5849625007211563	3	1	0	0
22601	1520	block in differentiation	[block in differentiation]	1.5849625007211563	3	2	2	2
22602	1520	S phase progression	[S phase progression]	1.5849625007211563	3	1	0	0
22603	1520	term of ability	[terms of ability]	1.5849625007211563	3	1	0	0
22604	1520	binding of nuclear extract	[binding of nuclear extracts]	1.5849625007211563	4	1	0	0
22605	1520	level of gc enhancement	[level of GC enhancement]	1.5849625007211563	4	1	0	0
22606	1520	considerable tissue-specific variation	[considerable tissue-specific variation]	1.5849625007211563	3	1	0	0
22607	1520	site of action.	[site of action.]	1.5849625007211563	3	1	0	0
22608	1520	stably express the tax	[stably expressing the tax]	1.5849625007211563	4	1	0	0
22609	1520	octamer-binding protein Oct-1	[octamer-binding proteins Oct-1]	1.5849625007211563	3	1	0	0
22610	1520	ap-1 consensus sequence	[AP-1 consensus sequences]	1.5849625007211563	3	1	0	0
22611	1520	receptor tyrosine kinase c-erbb	[receptor tyrosine kinase c-ErbB]	1.5849625007211563	4	1	0	0
22612	1520	cytokine interleukin (IL)-4	[cytokines interleukin (IL)-4]	1.5849625007211563	3	1	0	0
22613	1520	platelet aggregation assay	[platelet aggregation assays]	1.5849625007211563	3	1	0	0
22614	1520	myeloid lineage-associated cytokine receptor	[myeloid lineage-associated cytokine receptors]	1.5849625007211563	4	1	0	0
22615	1520	ap-1 transcriptional activation	[AP-1 transcriptional activation]	1.5849625007211563	3	1	0	0
22616	1520	novel cellular protein Bik	[novel cellular protein Bik]	1.5849625007211563	4	1	0	0
22617	1520	use of gene disruption	[use of gene disruption]	1.5849625007211563	4	1	0	0
22618	1520	IL-13 p element site	[IL-13 P element site]	1.5849625007211563	4	1	0	0
22619	1520	consensus sequence for binding	[consensus sequence for binding]	1.5849625007211563	4	1	0	0
22620	1520	mechanism of il-5 synthesis	[mechanisms of IL-5 synthesis]	1.5849625007211563	4	2	2	2
22621	1520	two cell-specific transcriptional coactivator	[two cell-specific transcriptional coactivators]	1.5849625007211563	4	2	2	2
22622	1520	pre-B-cell variant line 1a9-m	[pre-B-cell variant line 1A9-M]	1.5849625007211563	4	1	0	0
22623	1520	considerable significance with respect	[considerable significance with respect]	1.5849625007211563	4	1	0	0
22624	1520	effect of 9-cis RA	[effects of 9-cis RA]	1.5849625007211563	4	1	0	0
22625	1520	24 h incubation	[24 h incubation]	1.5849625007211563	3	2	1	1
22626	1520	close to 600 gene	[close to 600 genes]	1.5849625007211563	4	1	0	0
22627	1520	constitutively active SHP1 -DeltaSH2	[Constitutively active SHP1 -DeltaSH2]	1.5849625007211563	4	1	0	0
22628	1520	Pd-C hydrogenation of diacetate	[Pd-C hydrogenation of diacetate]	1.5849625007211563	4	1	0	0
22629	1520	activation with lps	[activation with LPS]	1.5849625007211563	3	1	0	0
22630	1520	cytokine such as IL-5	[cytokines such as IL-5]	1.5849625007211563	4	1	0	0
22631	1520	HTLV-I rex gene	[HTLV-I rex gene]	1.5849625007211563	3	1	0	0
22632	1520	two other compartments.	[two other compartments.]	1.5849625007211563	3	1	0	0
22633	1520	acute megakaryoblastic leukemia aml-m7	[Acute megakaryoblastic leukemia AML-M7]	1.5849625007211563	4	1	0	0
22634	1520	inflammatory response in AMI	[inflammatory responses in AMI]	1.5849625007211563	4	1	0	0
22635	1520	lethal dosage of lipopolysaccharide	[lethal dosages of lipopolysaccharides]	1.5849625007211563	4	1	0	0
22636	1520	same MTHC line	[same MTHC lines]	1.5849625007211563	3	1	0	0
22637	1520	amino acid sequence comparison	[Amino acid sequence comparison]	1.5849625007211563	4	1	0	0
22638	1520	mature lymphoid cell	[mature lymphoid cells]	1.5849625007211563	3	1	0	0
22639	1520	inhibition of gata-3 activity	[Inhibition of GATA-3 activity]	1.5849625007211563	4	1	0	0
22640	1520	lymphocyte from FDC	[lymphocytes from FDC]	1.5849625007211563	3	1	0	0
22641	1520	liposome-encapsulated dichloromethylene diphosphonate	[liposome-encapsulated dichloromethylene diphosphonate]	1.5849625007211563	3	1	0	0
22642	1520	immunotoxicity of one member	[immunotoxicity of one member]	1.5849625007211563	4	1	0	0
22643	1520	human monocyte nuclear factor-kappaB	[human monocyte nuclear factor-kappaB]	1.5849625007211563	4	1	0	0
22644	1520	L. monocytogent infection	[L. monocytogenes infection]	1.5849625007211563	3	1	0	0
22645	1520	role of retinoic acid.	[role of retinoic acid.]	1.5849625007211563	4	1	0	0
22646	1520	relatively small cis-acting element	[relatively small cis-acting element]	1.5849625007211563	4	1	0	0
22647	1520	activator of transcription stat5	[activator of transcription STAT5]	1.5849625007211563	4	1	0	0
22648	1520	underphosphorylated form of Rb	[underphosphorylated form of Rb]	1.5849625007211563	4	1	0	0
22649	1520	six cc(a/t)6gg (carg) motif	[six CC(A/T)6GG (CArG) motifs]	1.5849625007211563	4	1	0	0
22650	1520	intact n-terminal half	[intact N-terminal half]	1.5849625007211563	3	1	0	0
22651	1520	identical rbtn-2 binding region	[identical RBTN-2 binding regions]	1.5849625007211563	4	1	0	0
22652	1520	virus-specific cd4+ clone	[virus-specific CD4+ clone]	1.5849625007211563	3	1	0	0
22653	1520	Nuclear nuclear extract	[Nuclear nuclear extracts]	1.5849625007211563	3	1	0	0
22654	1520	notable participant in inflammation	[notable participant in inflammation]	1.5849625007211563	4	1	0	0
22655	1520	many biochemical change	[many biochemical changes]	1.5849625007211563	3	1	0	0
22656	1520	embryonic hb synthesis	[embryonic Hb synthesis]	1.5849625007211563	3	1	0	0
22657	1520	alternative reading frame	[alternative reading frame]	1.5849625007211563	3	1	0	0
22658	1520	ss rbc adhesion inhibitable	[SS RBC adhesion inhibitable]	1.5849625007211563	4	1	0	0
22659	1520	safe live-attenuated hiv	[safer live-attenuated HIVs]	1.5849625007211563	3	1	0	0
22660	1520	activator protein-1 ap-1 activation	[activator protein-1 AP-1 activation]	1.5849625007211563	4	1	0	0
22661	1520	decrease in gr mrna	[decrease in GR mRNA]	1.5849625007211563	4	1	0	0
22662	1520	anaerobic threshold at	[Anaerobic threshold AT]	1.5849625007211563	3	1	0	0
22663	1520	igh gene regulation	[IgH gene regulation]	1.5849625007211563	3	1	0	0
22664	1520	active hiv-1 replication	[active HIV-1 replication]	1.5849625007211563	3	1	0	0
22665	1520	detection of T cell	[detection of T cells]	1.5849625007211563	4	1	0	0
22666	1520	proliferation of erythroid progenitor	[proliferation of erythroid progenitors]	1.5849625007211563	4	2	1	1
22667	1520	time of diagnosis	[time of diagnosis]	1.5849625007211563	3	1	0	0
22668	1520	NK cell line	[NK cell line]	1.5849625007211563	3	2	1	1
22669	1520	nuclei of the b	[nuclei of the B]	1.5849625007211563	4	1	0	0
22670	1520	transcription of e-selectin	[transcription of E-selectin]	1.5849625007211563	3	1	0	0
22671	1520	STAT family member stat4	[STAT family member STAT4]	1.5849625007211563	4	1	0	0
22672	1520	case of cro-ap/5	[case of CRO-AP/5]	1.5849625007211563	3	1	0	0
22673	1520	case of cro-ap/3	[case of CRO-AP/3]	1.5849625007211563	3	1	0	0
22674	1520	pathophysiology of hiv-1 infection	[pathophysiology of HIV-1 infection]	1.5849625007211563	4	1	0	0
22675	1520	uninduced tf gene expression	[uninduced TF gene expression]	1.5849625007211563	4	1	0	0
22676	1520	v3 loop of gp120	[V3 loop of gp120]	1.5849625007211563	4	1	0	0
22677	1520	integration of the signal	[Integration of the signals]	1.5849625007211563	4	1	0	0
22678	1520	concept actually the result	[concept actually the result]	1.5849625007211563	4	1	0	0
22679	1520	novel role for IK	[novel role for IK]	1.5849625007211563	4	1	0	0
22680	1520	GATA-1 heterozygous mutant mouse	[GATA-1 heterozygous mutant mouse]	1.5849625007211563	4	1	0	0
22681	1520	putative gas element	[putative GAS element]	1.5849625007211563	3	1	0	0
22682	1520	response to heat shock	[response to heat shock]	1.5849625007211563	4	1	0	0
22683	1520	concentration of m	[concentrations of M]	1.5849625007211563	3	2	2	2
22684	1520	alpha-tocopherol vitamin e	[alpha-tocopherol vitamin E]	1.5849625007211563	3	1	0	0
22685	1520	normal gamma c expression	[normal gamma c expression]	1.5849625007211563	4	1	0	0
22686	1520	suppression of cytokine	[suppression of cytokine]	1.5849625007211563	3	1	0	0
22687	1520	massive megakaryocyte accumulation	[massive megakaryocyte accumulation]	1.5849625007211563	3	1	0	0
22688	1520	12 normal control	[12 normal controls]	1.5849625007211563	3	1	0	0
22689	1520	nf-kb binding activity	[NF-kB binding activity]	1.5849625007211563	3	1	0	0
22690	1520	effect of the antioxidant.	[effect of the antioxidant.]	1.5849625007211563	4	1	0	0
22691	1520	recognition of antigen	[recognition of antigens]	1.5849625007211563	3	2	1	1
22692	1520	labeling of this protein	[labeling of these proteins]	1.5849625007211563	4	1	0	0
22693	1520	pha proliferation of pbmc	[PHA proliferation of PBMCs]	1.5849625007211563	4	1	0	0
22694	1520	high affinity for aldosterone	[high affinity for aldosterone]	1.5849625007211563	4	1	0	0
22695	1520	MLL/ AF10 fusion	[MLL/ AF10 fusion]	1.5849625007211563	3	1	0	0
22696	1520	th2 cytokine pattern	[TH2 cytokine pattern]	1.5849625007211563	3	1	0	0
22697	1520	R24 increase in proliferation	[R24 increase in proliferation]	1.5849625007211563	4	1	0	0
22698	1520	cytokine secretion study	[cytokine secretion studies]	1.5849625007211563	3	1	0	0
22699	1520	murine baf3 cell	[murine BAF3 cells]	1.5849625007211563	3	1	0	0
22700	1520	cell growth molt-4	[cell growth MOLT-4]	1.5849625007211563	3	1	0	0
22701	1520	activate protein-1 binding activity	[activating protein-1 binding activity]	1.5849625007211563	4	1	0	0
22702	1520	average, plasma cyst(e)ine	[average, plasma cyst(e)ine]	1.5849625007211563	3	1	0	0
22703	1520	normal alveolar macrophage	[normal alveolar macrophages]	1.5849625007211563	3	2	2	2
22704	1520	r-responsive enhancer region	[R-responsive enhancer region]	1.5849625007211563	3	1	0	0
22705	1520	cathepsin g platelet aggregation	[cathepsin G platelet aggregation]	1.5849625007211563	4	2	1	1
22706	1520	productive infection with hiv-1	[productive infection with HIV-1]	1.5849625007211563	4	1	0	0
22707	1520	ligand-activated transcription factor	[ligand-activated transcription factor]	1.5849625007211563	3	1	0	0
22708	1520	c-Rel /p65 dimer	[c-Rel /p65 dimers]	1.5849625007211563	3	1	0	0
22709	1520	E3 regulation in lymphocyte	[E3 regulation in lymphocytes]	1.5849625007211563	4	1	0	0
22710	1520	Jak kinase Jak1	[Jak kinases Jak1]	1.5849625007211563	3	1	0	0
22711	1520	contrast, memory cells,	[contrast, memory cells,]	1.5849625007211563	3	1	0	0
22712	1520	ig gene extinction	[Ig gene extinction]	1.5849625007211563	3	2	1	1
22713	1520	extensive intraductal component eic	[extensive intraductal component EIC]	1.5849625007211563	4	1	0	0
22714	1520	only after stimulation.	[only after stimulation.]	1.5849625007211563	3	1	0	0
22715	1520	adhesion molecule on neutrophil	[adhesion molecules on neutrophils]	1.5849625007211563	4	2	1	1
22716	1520	several no donor	[several NO donors]	1.5849625007211563	3	1	0	0
22717	1520	two VDR 3'-utr haplotype	[two VDR 3'-UTR haplotypes]	1.5849625007211563	4	1	0	0
22718	1520	isoform of NFATx	[isoform of NFATx]	1.5849625007211563	3	2	2	2
22719	1520	support of humoral response	[support of humoral responses]	1.5849625007211563	4	1	0	0
22720	1520	th2 cytokine gene	[Th2 cytokine gene]	1.5849625007211563	3	2	2	2
22721	1520	role in normal development	[role in normal development]	1.5849625007211563	4	2	2	2
22722	1520	OKA a selective inhibitor	[OKA a selective inhibitor]	1.5849625007211563	4	1	0	0
22723	1520	TNF alpha mrna	[TNF alpha mRNA]	1.5849625007211563	3	2	1	1
22724	1520	24 healthy laboratory employees.	[24 healthy laboratory employees.]	1.5849625007211563	4	1	0	0
22725	1520	induction with dexamethasone	[induction with dexamethasone]	1.5849625007211563	3	1	0	0
22726	1520	conventional b lymphocyte	[conventional B lymphocytes]	1.5849625007211563	3	1	0	0
22727	1520	virus-host cell protein interaction	[virus-host cell protein interaction]	1.5849625007211563	4	1	0	0
22728	1520	different combination of olp	[different combinations of /LPS]	1.5849625007211563	4	1	0	0
22729	1520	4-carboranyl-substituted compound 7	[4-carboranyl-substituted compounds 7]	1.5849625007211563	3	1	0	0
22730	1520	gene activation pathway	[gene activation pathway]	1.5849625007211563	3	1	0	0
22731	1520	STAT protein heterocomplex	[STAT protein heterocomplexes]	1.5849625007211563	3	1	0	0
22732	1520	TRAF2 dominant-negative mutant.	[TRAF2 dominant-negative mutant.]	1.5849625007211563	3	1	0	0
22733	1520	few binding site	[fewer binding sites]	1.5849625007211563	3	1	0	0
22734	1520	proliferation of rat thymocyte	[proliferation of rat thymocytes]	1.5849625007211563	4	1	0	0
22735	1520	combination cytokine therapy	[combination cytokine therapy]	1.5849625007211563	3	1	0	0
22736	1520	action of alpha-tcp	[action of alpha-tcp]	1.5849625007211563	3	1	0	0
22737	1520	monocyte-like hl-60 cell	[monocyte-like HL-60 cells]	1.5849625007211563	3	3	2	1
22738	1520	T lymphoid lineage	[T lymphoid lineage]	1.5849625007211563	3	1	0	0
22739	1520	chronic autoimmune inflammatory disease	[chronic autoimmune inflammatory disease]	1.5849625007211563	4	1	0	0
22740	1520	more than 1 week	[more than 1 week]	1.5849625007211563	4	1	0	0
22741	1520	component of the complex	[component of the complex.]	1.5849625007211563	4	2	2	2
22742	1520	one copy of brca1	[one copy of BRCA1]	1.5849625007211563	4	1	0	0
22743	1520	gene expression level	[gene expression level]	1.5849625007211563	3	1	0	0
22744	1520	trigger with alpha CD3	[triggering with alpha CD3]	1.5849625007211563	4	1	0	0
22745	1520	two et site	[two ets sites]	1.5849625007211563	3	1	0	0
22746	1520	preformed, heterodimeric nfkb2 p49	[preformed, heterodimeric NFKB2 p49]	1.5849625007211563	4	1	0	0
22747	1520	addition, translation of NFATc	[addition, translation of NFATc]	1.5849625007211563	4	1	0	0
22748	1520	4s salt-transformed receptor	[4S salt-transformed receptors]	1.5849625007211563	3	1	0	0
22749	1520	role in up-regulation	[Role in up-regulation]	1.5849625007211563	3	2	2	2
22750	1520	fas ligand transcription	[Fas ligand transcription]	1.5849625007211563	3	2	1	1
22751	1520	activation of cd34 expression	[Activation of CD34 expression]	1.5849625007211563	4	1	0	0
22752	1520	Fos-B expression vector	[Fos-B expression vectors]	1.5849625007211563	3	1	0	0
22753	1520	two 21 bp repeat	[two 21 bp repeats]	1.5849625007211563	4	1	0	0
22754	1520	cell cycle-associated gene	[cell cycle-associated gene]	1.5849625007211563	3	2	1	1
22755	1520	lps TK activity	[LPS TK activity]	1.5849625007211563	3	1	0	0
22756	1520	Cross competition experiment	[Cross competition experiments]	1.5849625007211563	3	1	0	0
22757	1520	most prominent E2F activity	[most prominent E2F activity]	1.5849625007211563	4	1	0	0
22758	1520	MHC class signal	[MHC class signaling]	1.5849625007211563	3	2	2	2
22759	1520	mechanism direct the expression	[mechanisms directing the expression]	1.5849625007211563	4	1	0	0
22760	1520	cd44 CD4 stage	[CD44 CD4 stage]	1.5849625007211563	3	1	0	0
22761	1520	lps such as tnf-alpha	[LPS such as TNF-alpha]	1.5849625007211563	4	1	0	0
22762	1520	implantation of trophoblast cell	[implantation of trophoblast cells]	1.5849625007211563	4	1	0	0
22763	1520	four factor binding site	[four factor binding sites]	1.5849625007211563	4	1	0	0
22764	1520	lack the N-terminal domain	[lacking the N-terminal domain]	1.5849625007211563	4	1	0	0
22765	1520	two mrna species 2.7	[two mRNA species 2.7]	1.5849625007211563	4	1	0	0
22766	1520	phosphorothioate antisense oligodeoxynucleotide	[phosphorothioate antisense oligodeoxynucleotide]	1.5849625007211563	3	1	0	0
22767	1520	T lymphocytic cell	[T lymphocytic cells]	1.5849625007211563	3	2	2	2
22768	1520	distinct e2f dna-binding protein	[distinct E2F DNA-binding protein]	1.5849625007211563	4	1	0	0
22769	1520	constitutive activation of PKB/Akt	[Constitutive activations of PKB/Akt]	1.5849625007211563	4	1	0	0
22770	1520	IL-2 regulatory region	[IL-2 regulatory region]	1.5849625007211563	3	1	0	0
22771	1520	preferential transcriptional activity	[preferential transcriptional activity]	1.5849625007211563	3	1	0	0
22772	1520	ym268 glucose uptake	[YM268 glucose uptake]	1.5849625007211563	3	1	0	0
22773	1520	initiation of DNA replication	[Initiation of DNA replication]	1.5849625007211563	4	1	0	0
22774	1520	blot of cellular extract	[blots of cellular extracts]	1.5849625007211563	4	1	0	0
22775	1520	influence of positive- element	[influence of positive- elements]	1.5849625007211563	4	1	0	0
22776	1520	CD28 -responsive element present	[CD28 -responsive element present]	1.5849625007211563	4	1	0	0
22777	1520	index of corticosteroid action	[index of corticosteroid action]	1.5849625007211563	4	1	0	0
22778	1520	remix of T cell	[Remixing of T cells]	1.5849625007211563	4	1	0	0
22779	1520	p50 nf-kappa b moiety	[p50 NF-kappa B moieties]	1.5849625007211563	4	1	0	0
22780	1520	IFN NK cell	[IFN NK cells]	1.5849625007211563	3	2	1	1
22781	1520	lambda L chain expression	[lambda L chain expression]	1.5849625007211563	4	1	0	0
22782	1520	Positive regulation of granulocyte-macrophage	[Positive regulation of granulocyte-macrophage]	1.5849625007211563	4	1	0	0
22783	1520	IK stably clone	[IK stably clones]	1.5849625007211563	3	1	0	0
22784	1520	erk2 a key element	[erk2 a key element]	1.5849625007211563	4	1	0	0
22785	1520	increase in rrna	[increases in mRNAs]	1.5849625007211563	3	1	0	0
22786	1520	regulation of hiv expression	[regulation of HIV expression]	1.5849625007211563	4	1	0	0
22787	1520	subsequent proliferation activity	[subsequent proliferation activity]	1.5849625007211563	3	1	0	0
22788	1520	plasma estradiol level	[plasma estradiol levels]	1.5849625007211563	3	1	0	0
22789	1520	mechanism of pg490 inhibition	[mechanism of PG490 inhibition]	1.5849625007211563	4	1	0	0
22790	1520	silent DRA reporter	[silent DRA reporter]	1.5849625007211563	3	1	0	0
22791	1520	immature class ii heterodimer	[immature class II heterodimers]	1.5849625007211563	4	1	0	0
22792	1520	rest tonsillar b cell	[resting tonsillar B cells]	1.5849625007211563	4	2	1	1
22793	1520	nonhuman primate siv infection	[nonhuman primate SIV infection]	1.5849625007211563	4	1	0	0
22794	1520	importance of resolution	[importance of resolution]	1.5849625007211563	3	1	0	0
22795	1520	AU-motif-directed differential display	[AU-motif-directed differential display]	1.5849625007211563	3	1	0	0
22796	1520	ability of erythroid factor	[ability of erythroid factors]	1.5849625007211563	4	1	0	0
22797	1520	mutant of m22	[mutant of M22]	1.5849625007211563	3	1	0	0
22798	1520	target for pkc	[target for PKC]	1.5849625007211563	3	1	0	0
22799	1520	DNA damage agent	[DNA damaging agents]	1.5849625007211563	3	2	1	1
22800	1520	recruitment to the tcr	[recruitment to the TCR]	1.5849625007211563	4	1	0	0
22801	1520	stable adhesion with monocyte	[stable adhesions with monocytes]	1.5849625007211563	4	1	0	0
22802	1520	efficient viral transcription	[efficient viral transcription]	1.5849625007211563	3	1	0	0
22803	1520	intercellular adhesion molecule-1 ICAM-1	[intercellular adhesion molecule-1 ICAM-1]	1.5849625007211563	4	2	1	1
22804	1520	cooperative DNA binding,	[cooperative DNA binding,]	1.5849625007211563	3	1	0	0
22805	1520	MAZ transcription factor	[MAZ transcription factor]	1.5849625007211563	3	1	0	0
22806	1520	monoclonal antibody Yae	[monoclonal antibody Yae]	1.5849625007211563	3	1	0	0
22807	1520	constitutive nf-kappab activity	[constitutive NF-kappaB activity]	1.5849625007211563	3	1	0	0
22808	1520	none of the patient	[none of the patients]	1.5849625007211563	4	1	0	0
22809	1520	nf-kappab transcriptional activation	[NF-kappaB transcriptional activation]	1.5849625007211563	3	2	1	1
22810	1520	alpha1 -positive thp-1 cell	[alpha1 -positive THP-1 cells]	1.5849625007211563	4	1	0	0
22811	1520	1,25(OH)2D3 intracellular receptor	[1,25(OH)2D3 intracellular receptor]	1.5849625007211563	3	1	0	0
22812	1520	other active signal pathway	[other active signaling pathways]	1.5849625007211563	4	1	0	0
22813	1520	subclinical marker of response,	[subclinical markers of response,]	1.5849625007211563	4	1	0	0
22814	1520	IkappaB -alpha proteolysis	[IkappaB -alpha proteolysis]	1.5849625007211563	3	1	0	0
22815	1520	effect of the nature	[effect of the nature]	1.5849625007211563	4	1	0	0
22816	1520	NF-kappa B/Rel protein	[NF-kappa B/Rel proteins]	1.5849625007211563	3	1	0	0
22817	1520	similarity in the action	[similarities in the actions]	1.5849625007211563	4	1	0	0
22818	1520	inducibility/cell type specificity	[inducibility/cell type specificity]	1.5849625007211563	3	1	0	0
22819	1520	T cell functional phenotype	[T cell functional phenotype]	1.5849625007211563	4	1	0	0
22820	1520	HIV- hd histogenesis	[HIV- HD histogenesis]	1.5849625007211563	3	1	0	0
22821	1520	DRA reporter plasmid expression	[DRA reporter plasmid expression]	1.5849625007211563	4	1	0	0
22822	1520	STAT-6 binding site	[STAT-6 binding sites]	1.5849625007211563	3	1	0	0
22823	1520	prepartal treatment of PIH	[prepartal treatment of PIH]	1.5849625007211563	4	1	0	0
22824	1520	neutralize anti- il-1beta antibody	[neutralizing anti- IL-1beta antibody]	1.5849625007211563	4	1	0	0
22825	1520	further evidence in support	[further evidence in support]	1.5849625007211563	4	1	0	0
22826	1520	sterol regulatory element	[Sterol regulatory element]	1.5849625007211563	3	2	2	2
22827	1520	lymphoid/ DC precursor	[lymphoid/ DC precursors]	1.5849625007211563	3	1	0	0
22828	1520	high gata-1 binding activity	[high GATA-1 binding activity]	1.5849625007211563	4	1	0	0
22829	1520	NF-kappa b -activate	[NF-kappa B -activating]	1.5849625007211563	3	1	0	0
22830	1520	interaction with TEC	[interaction with TEC]	1.5849625007211563	3	1	0	0
22831	1520	functional vitamin d receptor	[functional vitamin D receptor]	1.5849625007211563	4	1	0	0
22832	1520	corresponding set of peptide	[corresponding set of peptides]	1.5849625007211563	4	1	0	0
22833	1520	insight into the regulation	[insight into the regulation]	1.5849625007211563	4	1	0	0
22834	1520	cell surface antigen a6h	[cell surface antigen A6H]	1.5849625007211563	4	1	0	0
22835	1520	bacterial lipopolysaccharide-activated human blood	[bacterial lipopolysaccharide-activated human blood]	1.5849625007211563	4	1	0	0
22836	1520	functional receptor number	[functional receptor number]	1.5849625007211563	3	1	0	0
22837	1520	regulation through the phosphorylation	[regulation through the phosphorylation]	1.5849625007211563	4	1	0	0
22838	1520	(38.9 +/- 13.9)	[(38.9 +/- 13.9)]	1.5849625007211563	3	1	0	0
22839	1520	encode the alpha subunit	[encoding the alpha subunit]	1.5849625007211563	4	2	1	1
22840	1520	stimulation with lipopolysaccharide lps	[stimulation with lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
22841	1520	nonresident vascular wall cell	[nonresident vascular wall cells]	1.5849625007211563	4	1	0	0
22842	1520	DNA protein interaction	[DNA protein interactions]	1.5849625007211563	3	1	0	0
22843	1520	I kappa b gamma-1	[I kappa B gamma-1]	1.5849625007211563	4	1	0	0
22844	1520	wild-type receptor in repression	[wild-type receptor in repression]	1.5849625007211563	4	1	0	0
22845	1520	nuclease S1 protection analysis	[nuclease S1 protection analysis]	1.5849625007211563	4	1	0	0
22846	1520	failure of eth1 cell	[failure of eTh1 cells]	1.5849625007211563	4	1	0	0
22847	1520	contrast to IL-2	[contrast to IL-2]	1.5849625007211563	3	1	0	0
22848	1520	mimick tcr ligation	[mimicking TCR ligation]	1.5849625007211563	3	1	0	0
22849	1520	contrast to IL-4	[contrast to IL-4]	1.5849625007211563	3	1	0	0
22850	1520	Dexter-type long culture	[Dexter-type long-term culture]	1.5849625007211563	3	1	0	0
22851	1520	monocyte on tnf-alpha endothelium	[monocytes on TNF-alpha endothelium]	1.5849625007211563	4	1	0	0
22852	1520	role in cell adhesion	[role in cell adhesion]	1.5849625007211563	4	1	0	0
22853	1520	surgery in stage	[surgery in stage]	1.5849625007211563	3	1	0	0
22854	1520	activation of glucocorticoid receptor	[activation of glucocorticoid receptor]	1.5849625007211563	4	1	0	0
22855	1520	Aiolos -binding site	[Aiolos -binding sites]	1.5849625007211563	3	2	2	2
22856	1520	displacement of a repressor	[Displacement of an repressor]	1.5849625007211563	4	2	2	2
22857	1520	human homolog baf155	[human homolog BAF155]	1.5849625007211563	3	1	0	0
22858	1520	two myeloid cell line	[two myeloid cell lines]	1.5849625007211563	4	2	1	1
22859	1520	expression of E2F-1	[expression of E2F-1]	1.5849625007211563	3	1	0	0
22860	1520	sequence element present	[sequence element present]	1.5849625007211563	3	1	0	0
22861	1520	NF-kappa b /rel site	[NF-kappa B /Rel sites]	1.5849625007211563	4	1	0	0
22862	1520	inflammatory liver disease	[inflammatory liver disease]	1.5849625007211563	3	1	0	0
22863	1520	HTLV-I human t-cell line	[HTLV-I human T-cell line]	1.5849625007211563	4	1	0	0
22864	1520	GT box of pfp5a	[GT box of PFP5a]	1.5849625007211563	4	1	0	0
22865	1520	high phorbol ester concentration,	[high phorbol ester concentration,]	1.5849625007211563	4	1	0	0
22866	1520	putative cell-specific transcription factor	[putative cell-specific transcription factor]	1.5849625007211563	4	1	0	0
22867	1520	mechanism underlie the development	[mechanisms underlying the development]	1.5849625007211563	4	1	0	0
22868	1520	consequence of complex formation	[consequence of complex formation]	1.5849625007211563	4	1	0	0
22869	1520	hepatitis b patient	[hepatitis B patients]	1.5849625007211563	3	2	1	1
22870	1520	cell of hematopoietic origin	[cells of hematopoietic origin]	1.5849625007211563	4	2	2	2
22871	1520	two distinct subunit	[two distinct subunits]	1.5849625007211563	3	1	0	0
22872	1520	tumorigenesis of non-hodgkin lymphoma	[tumorigenesis of non-Hodgkin lymphoma]	1.5849625007211563	4	1	0	0
22873	1520	express human recombinant alphaiibbeta3	[expressing human recombinant alphaIIbbeta3]	1.5849625007211563	4	1	0	0
22874	1520	complex interaction of stat5	[complex interaction of STAT5]	1.5849625007211563	4	1	0	0
22875	1520	explanation for the chronicity	[explanation for the chronicity]	1.5849625007211563	4	1	0	0
22876	1520	Finally, recombinant ghf-1	[Finally, recombinant GHF-1]	1.5849625007211563	3	1	0	0
22877	1520	regulation of expression.	[regulation of expression.]	1.5849625007211563	3	1	0	0
22878	1520	murine leukemia virus transcription	[murine leukemia virus transcription]	1.5849625007211563	4	1	0	0
22879	1520	Oct-2 expression vector	[Oct-2 expression vector]	1.5849625007211563	3	1	0	0
22880	1520	kappa b alpha /mad-3	[kappa B alpha /MAD-3]	1.5849625007211563	4	1	0	0
22881	1520	expression of certain gene	[expression of certain genes]	1.5849625007211563	4	1	0	0
22882	1520	chimeric cytokine receptor	[chimeric cytokine receptor]	1.5849625007211563	3	1	0	0
22883	1520	tumour cell of Arnhl	[tumour cells of ARNHL]	1.5849625007211563	4	1	0	0
22884	1520	long a puzzle	[long a puzzle]	1.5849625007211563	3	1	0	0
22885	1520	hepatocyte nuclear factor	[hepatocyte nuclear factor]	1.5849625007211563	3	2	2	2
22886	1520	ifn-gamma for 72 h.	[IFN-gamma for 72 h,]	1.5849625007211563	4	1	0	0
22887	1520	reactive oxygen intermediate release	[reactive oxygen intermediate release]	1.5849625007211563	4	1	0	0
22888	1520	response to treatment	[response to treatment]	1.5849625007211563	3	2	2	2
22889	1520	Conclusions: sexual hormone	[CONCLUSIONS: Sexual hormones]	1.5849625007211563	3	1	0	0
22890	1520	high-mobility group hmg	[high-mobility group HMG]	1.5849625007211563	3	1	0	0
22891	1520	maximal mrna level	[maximal mRNA levels]	1.5849625007211563	3	1	0	0
22892	1520	absence of other region	[absence of other regions]	1.5849625007211563	4	1	0	0
22893	1520	more mature monocytic phenotype	[more mature monocytic phenotype]	1.5849625007211563	4	1	0	0
22894	1520	use enhancer with spacings.	[using enhancers with spacings.]	1.5849625007211563	4	1	0	0
22895	1520	corresponding binding factor	[corresponding binding factors]	1.5849625007211563	3	2	1	1
22896	1520	1,25-dihydroxyvitamin D2 vd	[1,25-dihydroxyvitamin D2 VD]	1.5849625007211563	3	1	0	0
22897	1520	proliferative response to erythropoietin	[proliferative response to erythropoietin]	1.5849625007211563	4	1	0	0
22898	1520	inhibition of il-1ra secretion	[inhibition of IL-1ra secretion]	1.5849625007211563	4	1	0	0
22899	1520	inducer of hsp60 expression	[inducer of Hsp60 expression]	1.5849625007211563	4	1	0	0
22900	1520	target cell genome	[target cell genome]	1.5849625007211563	3	1	0	0
22901	1520	heterogeneity of development	[Heterogeneity of development]	1.5849625007211563	3	2	2	2
22902	1520	mouse IL-4 promoter	[mouse IL-4 promoter]	1.5849625007211563	3	1	0	0
22903	1520	autocrine tumor cell growth	[autocrine tumor cell growth]	1.5849625007211563	4	1	0	0
22904	1520	human interleukin 2 gene	[human interleukin 2 gene]	1.5849625007211563	4	2	1	1
22905	1520	early second messenger generation	[early second messenger generation]	1.5849625007211563	4	1	0	0
22906	1520	most characteristic histological feature	[most characteristic histological features]	1.5849625007211563	4	1	0	0
22907	1520	report of pathogenicity	[reports of pathogenicity]	1.5849625007211563	3	1	0	0
22908	1520	octamer sequence ATGCAAAT	[octamer sequence ATGCAAAT]	1.5849625007211563	3	1	0	0
22909	1520	disease with a epitope	[disease with an epitope]	1.5849625007211563	4	1	0	0
22910	1520	activity of tad-a	[activity of TAD-A]	1.5849625007211563	3	1	0	0
22911	1520	two group of subject	[two groups of subjects]	1.5849625007211563	4	1	0	0
22912	1520	activity of tad-b	[activity of TAD-B]	1.5849625007211563	3	1	0	0
22913	1520	precursor of 135eoh)2d3	[Precursors of 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
22914	1520	specific hormone receptors,	[specific hormone receptors,]	1.5849625007211563	3	1	0	0
22915	1520	human alpha-globin promoter activity	[human alpha-globin promoter activity]	1.5849625007211563	4	1	0	0
22916	1520	one nuclear factor	[one nuclear factor]	1.5849625007211563	3	2	2	2
22917	1520	dissect the mechanism	[dissecting the mechanisms]	1.5849625007211563	3	1	0	0
22918	1520	costimulus to tcr engagement	[costimulus to TCR engagement]	1.5849625007211563	4	1	0	0
22919	1520	adjacent normal kidney tissue	[adjacent normal kidney tissue]	1.5849625007211563	4	1	0	0
22920	1520	entire IL2 regulatory region	[entire IL2 regulatory region]	1.5849625007211563	4	1	0	0
22921	1520	function of aml1	[function of AML1]	1.5849625007211563	3	1	0	0
22922	1520	normal human myeloid cell	[normal human myeloid cells]	1.5849625007211563	4	2	2	2
22923	1520	several Oct2 isoform	[several Oct2 isoforms]	1.5849625007211563	3	1	0	0
22924	1520	vitro administration of glucocorticoid	[vitro administration of glucocorticoids]	1.5849625007211563	4	1	0	0
22925	1520	normal pregnant woman	[normal pregnant women]	1.5849625007211563	3	2	1	1
22926	1520	cd36 -produce cho cell	[CD36 -producing CHO cells]	1.5849625007211563	4	1	0	0
22927	1520	level of hiv expression	[levels of HIV expression]	1.5849625007211563	4	2	2	2
22928	1520	trigger in monocyte	[triggering in monocytes]	1.5849625007211563	3	1	0	0
22929	1520	Genomic sequence upstream	[Genomic sequence upstream]	1.5849625007211563	3	1	0	0
22930	1520	result of immortalization	[result of immortalization]	1.5849625007211563	3	1	0	0
22931	1520	cyclin E-dependent kinase activity	[cyclin E-dependent kinase activity]	1.5849625007211563	4	1	0	0
22932	1520	platelet ca2+ transport	[platelet Ca2+ transport]	1.5849625007211563	3	1	0	0
22933	1520	system from protein	[systems from proteins]	1.5849625007211563	3	1	0	0
22934	1520	activation of several kinase	[activation of several kinases]	1.5849625007211563	4	2	1	1
22935	1520	defect in maturation	[defect in maturation]	1.5849625007211563	3	1	0	0
22936	1520	-activate phorbol ester	[-activating phorbol esters]	1.5849625007211563	3	1	0	0
22937	1520	long-lasting csf-1 -dependent proliferation	[long-lasting CSF-1 -dependent proliferation]	1.5849625007211563	4	1	0	0
22938	1520	adult mouse thymus	[adult mouse thymus]	1.5849625007211563	3	1	0	0
22939	1520	nf-kappa b motif	[NF-kappa B motif]	1.5849625007211563	3	2	2	2
22940	1520	nfat -1-linked lac-Z transfectant	[NFAT -1-linked lac-Z transfectants]	1.5849625007211563	4	1	0	0
22941	1520	decidual prl gene	[decidual PRL gene]	1.5849625007211563	3	1	0	0
22942	1520	weakly in skeletal muscle	[weakly in skeletal muscle]	1.5849625007211563	4	1	0	0
22943	1520	renal cell carcinoma-derived ganglioside	[Renal cell carcinoma-derived gangliosides]	1.5849625007211563	4	1	0	0
22944	1520	c-fo c-jun mrna expression	[c-fos c-jun mRNA expression]	1.5849625007211563	4	1	0	0
22945	1520	antigen receptor engagement	[antigen receptor engagement]	1.5849625007211563	3	1	0	0
22946	1520	thymic locus control region	[thymic locus control region]	1.5849625007211563	4	1	0	0
22947	1520	decrease of intracellular sodium	[decrease of intracellular sodium]	1.5849625007211563	4	1	0	0
22948	1520	production of ifn-gamma	[production of IFN-gamma]	1.5849625007211563	3	1	0	0
22949	1520	single cell type.	[single cell type.]	1.5849625007211563	3	1	0	0
22950	1520	transcription of cellular gene	[transcription of cellular genes]	1.5849625007211563	4	2	2	2
22951	1520	undifferentiated basal cell epithelioma	[undifferentiated basal cell epitheliomas]	1.5849625007211563	4	1	0	0
22952	1520	survival of monoblastoid cell	[survival of monoblastoid cells]	1.5849625007211563	4	2	1	1
22953	1520	pathogenesis of inflammatory synovitis	[pathogenesis of inflammatory synovitis]	1.5849625007211563	4	1	0	0
22954	1520	nucleus of il-2-	[nucleus of IL-2-]	1.5849625007211563	3	1	0	0
22955	1520	adenovirus antigen stimulation	[adenovirus antigen stimulation]	1.5849625007211563	3	1	0	0
22956	1520	transcription factor elk-1	[transcription factor Elk-1]	1.5849625007211563	3	1	0	0
22957	1520	Eur J Immunol jul;27(7):1830]	[Eur J Immunol Jul;27(7):1830]]	1.5849625007211563	4	1	0	0
22958	1520	regulation of immune function	[regulation of immune function]	1.5849625007211563	4	1	0	0
22959	1520	nf-il-6 the inhibitor	[NF-IL-6 the inhibitor]	1.5849625007211563	3	1	0	0
22960	1520	RANTES mrna expression dose	[RANTES mRNA expression dose]	1.5849625007211563	4	1	0	0
22961	1520	oxidant stress similar	[oxidant stress similar]	1.5849625007211563	3	1	0	0
22962	1520	human tonsil b lymphocyte	[human tonsil B lymphocytes]	1.5849625007211563	4	1	0	0
22963	1520	two NF-E2/AP1 motif	[two NF-E2/AP1 motifs]	1.5849625007211563	3	2	2	2
22964	1520	follow g-csf stimulation	[following G-CSF stimulation]	1.5849625007211563	3	2	2	2
22965	1520	monoclonal antibody pmi-1	[monoclonal antibody PMI-1]	1.5849625007211563	3	1	0	0
22966	1520	two 65k subunit	[two 65K subunits]	1.5849625007211563	3	1	0	0
22967	1520	binding of ifi	[binding of IFNs]	1.5849625007211563	3	1	0	0
22968	1520	multiple initiation site	[multiple initiation sites]	1.5849625007211563	3	1	0	0
22969	1520	result from Northern blot	[Results from Northern blot]	1.5849625007211563	4	1	0	0
22970	1520	interfere with signal process	[interfering with signaling processes]	1.5849625007211563	4	1	0	0
22971	1520	multipotent progenitor cell line	[multipotent progenitor cell line]	1.5849625007211563	4	1	0	0
22972	1520	mechanism of overexpression	[mechanism of overexpression]	1.5849625007211563	3	1	0	0
22973	1520	relevance to host defense	[relevance to host defense]	1.5849625007211563	4	1	0	0
22974	1520	dexamethasone on 3-o-methyl-d-glucose uptake	[dexamethasone on 3-O-methyl-D-glucose uptake]	1.5849625007211563	4	1	0	0
22975	1520	evidence for differential regulation	[evidence for differential regulation]	1.5849625007211563	4	2	1	1
22976	1520	bcl-xL gene expression	[bcl-xL gene expression]	1.5849625007211563	3	1	0	0
22977	1520	specific intracellular receptor	[specific intracellular receptors]	1.5849625007211563	3	1	0	0
22978	1520	HMG protein family	[HMG protein family]	1.5849625007211563	3	1	0	0
22979	1520	number of receptor-containing cell	[number of receptor-containing cells]	1.5849625007211563	4	1	0	0
22980	1520	recruitment of fetal progenitor	[recruitment of fetal progenitors]	1.5849625007211563	4	1	0	0
22981	1520	serine/threonine kinase Raf-1	[serine/threonine kinase Raf-1]	1.5849625007211563	3	1	0	0
22982	1520	ah receptor ligand,	[Ah receptor ligand,]	1.5849625007211563	3	1	0	0
22983	1520	10 case aml	[10 cases AML]	1.5849625007211563	3	1	0	0
22984	1520	AP-1 transcription complex JunB	[AP-1 transcription complex JunB]	1.5849625007211563	4	1	0	0
22985	1520	kappa B alpha	[kappa B alpha]	1.5849625007211563	3	1	0	0
22986	1520	glutathione disulfide level	[glutathione disulfide levels]	1.5849625007211563	3	2	2	2
22987	1520	further characterization of protein	[further characterization of proteins]	1.5849625007211563	4	1	0	0
22988	1520	tnf tumor necrosis factor	[TNF tumor necrosis factor]	1.5849625007211563	4	1	0	0
22989	1520	80 kda stat5 isoform	[80 kDa STAT5 isoform]	1.5849625007211563	4	1	0	0
22990	1520	number of receptor available	[number of receptors available]	1.5849625007211563	4	1	0	0
22991	1520	downregulation of c-fo expression	[downregulation of c-fos expression]	1.5849625007211563	4	1	0	0
22992	1520	kappab -dependent manner	[kappaB -dependent manner]	1.5849625007211563	3	1	0	0
22993	1520	low transcription rate	[lower transcription rate]	1.5849625007211563	3	1	0	0
22994	1520	homologous competition curve	[homologous competition curves]	1.5849625007211563	3	1	0	0
22995	1520	addition of gp41	[addition of gp41]	1.5849625007211563	3	1	0	0
22996	1520	6 week of treatment	[6 weeks of treatment]	1.5849625007211563	4	1	0	0
22997	1520	efficient gene activation	[Efficient gene activation]	1.5849625007211563	3	1	0	0
22998	1520	site of proteolysis	[site of proteolysis]	1.5849625007211563	3	1	0	0
22999	1520	T helper type	[T helper type]	1.5849625007211563	3	1	0	0
23000	1520	regulator of the response	[regulator of the response]	1.5849625007211563	4	2	1	1
23001	1520	incubation with gamma interferon	[incubation with gamma interferon]	1.5849625007211563	4	1	0	0
23002	1520	bzip domain of HLF	[bZIP domain of HLF]	1.5849625007211563	4	1	0	0
23003	1520	use dnase I footprinting	[using DNase I footprinting]	1.5849625007211563	4	1	0	0
23004	1520	presence of novel duplication	[presence of novel duplications]	1.5849625007211563	4	1	0	0
23005	1520	effect of drug	[effects of drugs]	1.5849625007211563	3	2	2	2
23006	1520	design of therapeutic approach	[design of therapeutic approaches]	1.5849625007211563	4	1	0	0
23007	1520	low calcemic effect in	[lower calcemic effects in]	1.5849625007211563	4	1	0	0
23008	1520	closely related factor Spi-B	[closely related factor Spi-B]	1.5849625007211563	4	1	0	0
23009	1520	er upstream regulatory region	[ER upstream regulatory region]	1.5849625007211563	4	1	0	0
23010	1520	response to sris	[response to SRIs]	1.5849625007211563	3	1	0	0
23011	1520	antioxidant dimethyl sulfoxide dmso	[antioxidant dimethyl sulfoxide DMSO]	1.5849625007211563	4	1	0	0
23012	1520	anti-apoptotic transcription factor	[anti-apoptotic transcription factor]	1.5849625007211563	3	1	0	0
23013	1520	normal aging process	[normal aging process]	1.5849625007211563	3	1	0	0
23014	1520	overexpression of IkappaB alpha	[overexpression of IkappaB alpha]	1.5849625007211563	4	1	0	0
23015	1520	cytokine-inducible sh2-containing protein CIS	[cytokine-inducible SH2-containing protein CIS]	1.5849625007211563	4	1	0	0
23016	1520	ligand for notch receptor	[ligand for Notch receptors]	1.5849625007211563	4	1	0	0
23017	1520	availability of ligand	[availability of ligand]	1.5849625007211563	3	1	0	0
23018	1520	kappa b gamma-1	[kappa B gamma-1]	1.5849625007211563	3	1	0	0
23019	1520	kappa b gamma-2	[kappa B gamma-2]	1.5849625007211563	3	2	1	1
23020	1520	second gcr gcr-beta	[second GCR GCR-beta]	1.5849625007211563	3	1	0	0
23021	1520	of rest b cell	[of resting B cells]	1.5849625007211563	4	1	0	0
23022	1520	population of cell stably	[population of cells stably]	1.5849625007211563	4	1	0	0
23023	1520	Th1 cell during differentiation.	[Th1 cells during differentiation.]	1.5849625007211563	4	1	0	0
23024	1520	affinity of glucocorticoid receptor	[affinity of glucocorticoid receptors]	1.5849625007211563	4	1	0	0
23025	1520	p65 mrna level	[p65 mRNA levels]	1.5849625007211563	3	1	0	0
23026	1520	Ig gene superfamily	[Ig gene superfamily]	1.5849625007211563	3	1	0	0
23027	1520	Concomitant stimulation by VitD3	[Concomitant stimulation by VitD3]	1.5849625007211563	4	1	0	0
23028	1520	extract from nonstimulated cell	[extracts from nonstimulated cells]	1.5849625007211563	4	1	0	0
23029	1520	CBF alpha 2-451	[CBF alpha 2-451]	1.5849625007211563	3	2	2	2
23030	1520	immunoglobulin variable region promoter	[immunoglobulin variable region promoters]	1.5849625007211563	4	1	0	0
23031	1520	potent activator of monocyte	[potent activator of monocytes]	1.5849625007211563	4	1	0	0
23032	1520	plasma membrane redox system	[plasma membrane redox system]	1.5849625007211563	4	1	0	0
23033	1520	IKAROS/LYF-1 transcription factor motif	[IKAROS/LYF-1 transcription factor motifs]	1.5849625007211563	4	1	0	0
23034	1520	neutrophil in tissue damage	[neutrophils in tissue damage]	1.5849625007211563	4	1	0	0
23035	1520	corticosteroid-treated ibd patient	[corticosteroid-treated IBD patients]	1.5849625007211563	3	1	0	0
23036	1520	nuclear, DNA binding state	[nuclear, DNA binding state]	1.5849625007211563	4	1	0	0
23037	1520	tar primary sequence	[TAR primary sequence]	1.5849625007211563	3	1	0	0
23038	1520	response to pro-inflammatory stimuli,	[response to pro-inflammatory stimuli,]	1.5849625007211563	4	1	0	0
23039	1520	reporter plasmid p[(TRE)3-tk-Luc]	[reporter plasmid p[(TRE)3-tk-Luc]]	1.5849625007211563	3	1	0	0
23040	1520	other platelet activator	[other platelet activators]	1.5849625007211563	3	1	0	0
23041	1520	stat6 tyrosine phosphorylation	[Stat6 tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
23042	1520	severe phenotype of female	[severe phenotype of females]	1.5849625007211563	4	1	0	0
23043	1520	certain ppar activator	[certain PPAR activators]	1.5849625007211563	3	1	0	0
23044	1520	species via TNFRI	[species via TNFRI]	1.5849625007211563	3	1	0	0
23045	1520	early adult hpc	[early adult HPC]	1.5849625007211563	3	1	0	0
23046	1520	DNA band-shift assay	[DNA band-shift assays]	1.5849625007211563	3	1	0	0
23047	1520	development of the breast	[development of the breast]	1.5849625007211563	4	1	0	0
23048	1520	protein of 92 kda	[protein of 92 kDa]	1.5849625007211563	4	1	0	0
23049	1520	LBR a protein	[LBR an protein]	1.5849625007211563	3	2	2	2
23050	1520	membrane tyrosine phosphatase	[membrane tyrosine phosphatase]	1.5849625007211563	3	1	0	0
23051	1520	change circulate hormone concentration	[changes circulating hormone concentrations]	1.5849625007211563	4	1	0	0
23052	1520	cyclosporin a a immunosuppressant	[cyclosporin A an immunosuppressant]	1.5849625007211563	4	1	0	0
23053	1520	retinoic acid signalling	[retinoic acid signalling]	1.5849625007211563	3	1	0	0
23054	1520	physiological role for camp	[physiological role for cAMP]	1.5849625007211563	4	2	2	2
23055	1520	transcription factor nfat1	[transcription factor NFAT1]	1.5849625007211563	3	1	0	0
23056	1520	IL-2 NF-AT site	[IL-2 NF-AT sites]	1.5849625007211563	3	1	0	0
23057	1520	current protocol of immunotherapy	[current protocols of immunotherapy]	1.5849625007211563	4	1	0	0
23058	1520	involvement of rapamycin pathway	[involvement of rapamycin pathways]	1.5849625007211563	4	1	0	0
23059	1520	gpc91-phox gene expression	[gpc91-phox gene expression]	1.5849625007211563	3	1	0	0
23060	1520	two cytokine gene	[two cytokine genes]	1.5849625007211563	3	1	0	0
23061	1520	trans-activating domain of E2A	[trans-activating domains of E2A]	1.5849625007211563	4	1	0	0
23062	1520	NFAT DNA binding	[NFAT DNA binding]	1.5849625007211563	3	1	0	0
23063	1520	mechanism of binding	[mechanism of binding]	1.5849625007211563	3	1	0	0
23064	1520	smoking menopausal patient	[smoking menopausal patients]	1.5849625007211563	3	1	0	0
23065	1520	proapoptotic nip-2 protein	[proapoptotic Nip-2 protein]	1.5849625007211563	3	1	0	0
23066	1520	autonomous transrepressor domain	[autonomous transrepressor domain]	1.5849625007211563	3	1	0	0
23067	1520	tumor specific antigen	[tumor specific antigens]	1.5849625007211563	3	1	0	0
23068	1520	5% human serum	[5% human serum]	1.5849625007211563	3	1	0	0
23069	1520	position of nucleotide -124	[position of nucleotides -124]	1.5849625007211563	4	1	0	0
23070	1520	transcription factor nfatc	[transcription factor NFATc]	1.5849625007211563	3	1	0	0
23071	1520	new Grb2 family member	[new Grb2 family member]	1.5849625007211563	4	1	0	0
23072	1520	such nf-atp mouse	[Such NF-ATp mice]	1.5849625007211563	3	1	0	0
23073	1520	binding of p50p50	[binding of p50p50]	1.5849625007211563	3	2	2	2
23074	1520	transcription factor nfatp	[transcription factor NFATp]	1.5849625007211563	3	2	2	2
23075	1520	detectable tax expression	[detectable Tax expression]	1.5849625007211563	3	1	0	0
23076	1520	borrelia burgdorferi lipoprotein	[Borrelia burgdorferi lipoproteins]	1.5849625007211563	3	1	0	0
23077	1520	interleukin receptor alpha-chain	[interleukin receptor alpha-chain]	1.5849625007211563	3	2	2	2
23078	1520	contrast to result	[contrast to results]	1.5849625007211563	3	2	2	2
23079	1520	cis- acting element	[cis- acting elements]	1.5849625007211563	3	1	0	0
23080	1520	homeobox gene essential	[homeobox gene essential]	1.5849625007211563	3	1	0	0
23081	1520	such as interleukin-5	[such as interleukin-5]	1.5849625007211563	3	1	0	0
23082	1520	T cell consistent	[T cells consistent]	1.5849625007211563	3	2	2	2
23083	1520	prototype class ii	[prototype class II]	1.5849625007211563	3	1	0	0
23084	1520	activation of Janus kinase	[activation of Janus kinase]	1.5849625007211563	4	1	0	0
23085	1520	binding of ox ldl	[binding of Ox LDL]	1.5849625007211563	4	1	0	0
23086	1520	interleukin-2 t-cell line ctll-2	[interleukin-2 T-cell line CTLL-2]	1.5849625007211563	4	1	0	0
23087	1520	tissues, gr expression	[tissues, GR expression]	1.5849625007211563	3	1	0	0
23088	1520	CD28 augmentation of signal	[CD28 augmentation of signaling]	1.5849625007211563	4	1	0	0
23089	1520	short tandem repeat	[short tandem repeat]	1.5849625007211563	3	2	2	2
23090	1520	bear point mutation	[bearing point mutations]	1.5849625007211563	3	1	0	0
23091	1520	only rbp binding	[only RBP binding]	1.5849625007211563	3	1	0	0
23092	1520	cortisol resistance in monocyte	[cortisol resistance in monocytes]	1.5849625007211563	4	1	0	0
23093	1520	expression of pcna	[expression of PCNA]	1.5849625007211563	3	1	0	0
23094	1520	absence of transcriptional activity	[absence of transcriptional activity]	1.5849625007211563	4	1	0	0
23095	1520	cysteine -rich lim-domain oncogene	[cysteine -rich LIM-domain oncogenes]	1.5849625007211563	4	1	0	0
23096	1520	major inducer of NF-kappaB	[major inducer of NF-kappaB]	1.5849625007211563	4	1	0	0
23097	1520	IL-4 a finding	[IL-4 a finding]	1.5849625007211563	3	1	0	0
23098	1520	formation of transcription factor	[formation of transcription factors]	1.5849625007211563	4	1	0	0
23099	1520	Ipr cd4-8- T cell	[Ipr CD4-8- T cells]	1.5849625007211563	4	2	1	1
23100	1520	full transactivation function,	[full transactivation function,]	1.5849625007211563	3	1	0	0
23101	1520	four distinct complementation group	[Four distinct complementation groups]	1.5849625007211563	4	1	0	0
23102	1520	97 kda ca(2+)-atpase	[97 kDa Ca(2+)-ATPase]	1.5849625007211563	3	1	0	0
23103	1520	primary erythroid cell	[primary erythroid cells]	1.5849625007211563	3	2	1	1
23104	1520	understanding of alternative mechanism	[understanding of alternative mechanisms]	1.5849625007211563	4	1	0	0
23105	1520	hsv-1-activated cellular factor icp0	[HSV-1-activated cellular factor ICP0]	1.5849625007211563	4	1	0	0
23106	1520	particular, tgf beta 1	[particular, TGF beta 1]	1.5849625007211563	4	1	0	0
23107	1520	transcriptional activity of NFAT-1	[transcriptional activity of NFAT-1]	1.5849625007211563	4	1	0	0
23108	1520	presentation of viral peptide	[Presentation of viral peptide]	1.5849625007211563	4	1	0	0
23109	1520	38 consecutive glutamine residue	[38 consecutive glutamine residues]	1.5849625007211563	4	1	0	0
23110	1520	many alteration in function	[many alterations in function]	1.5849625007211563	4	1	0	0
23111	1520	ligation of glucocorticoid receptor	[ligation of glucocorticoid receptors]	1.5849625007211563	4	1	0	0
23112	1520	receptor protein from membrane	[receptor protein from membranes]	1.5849625007211563	4	1	0	0
23113	1520	I gamma 3 ECS	[I gamma 3 ECS]	1.5849625007211563	4	1	0	0
23114	1520	two specific region	[two specific regions]	1.5849625007211563	3	1	0	0
23115	1520	three cell types,	[three cell types,]	1.5849625007211563	3	1	0	0
23116	1520	particularly the gata element	[particularly the GATA elements]	1.5849625007211563	4	1	0	0
23117	1520	early embryonic development	[early embryonic development]	1.5849625007211563	3	2	1	1
23118	1520	most likely other components.	[most likely other components.]	1.5849625007211563	4	1	0	0
23119	1520	overexpression of tramp	[Overexpression of TRAMP]	1.5849625007211563	3	1	0	0
23120	1520	day of surgery	[day of surgery]	1.5849625007211563	3	1	0	0
23121	1520	continuous blood pressure	[continuous blood pressure]	1.5849625007211563	3	1	0	0
23122	1520	several molecular pathway	[several molecular pathways]	1.5849625007211563	3	1	0	0
23123	1520	risk of hiv transmission	[risk of HIV transmission]	1.5849625007211563	4	1	0	0
23124	1520	gr mrna level	[GR mRNA levels]	1.5849625007211563	3	1	0	0
23125	1520	protein 2 EBNA-2	[protein 2 EBNA-2]	1.5849625007211563	3	1	0	0
23126	1520	classical 135eoh)2d3 receptor similar	[classical 1,25(OH)2D3 receptor similar]	1.5849625007211563	4	1	0	0
23127	1520	ebv transcription factor R	[EBV transcription factors R]	1.5849625007211563	4	1	0	0
23128	1520	dibutyryl camp bt2camp	[dibutyryl cAMP Bt2cAMP]	1.5849625007211563	3	1	0	0
23129	1520	human cd4+ T lymphocyte	[human CD4+ T lymphocytes]	1.5849625007211563	4	4	3	1
23130	1520	free cytosolic calcium	[free cytosolic calcium]	1.5849625007211563	3	1	0	0
23131	1520	synthesis in macrophage	[synthesis in macrophages]	1.5849625007211563	3	1	0	0
23132	1520	ligation of histocompatibility class	[ligation of histocompatibility class]	1.5849625007211563	4	2	2	2
23133	1520	detail about the protein	[detail about the proteins]	1.5849625007211563	4	1	0	0
23134	1520	monocyte arrest on endothelium	[Monocyte arrest on endothelium]	1.5849625007211563	4	1	0	0
23135	1520	CD3 zeta tyrosine phosphorylation	[CD3 zeta tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
23136	1520	(pt) of 154 nmol/L.	[(PT) of 154 nmol/L.]	1.5849625007211563	4	1	0	0
23137	1520	morphology of apoptosis	[morphology of apoptosis]	1.5849625007211563	3	1	0	0
23138	1520	one to three days'	[one to three days']	1.5849625007211563	4	1	0	0
23139	1520	expression of rar-beta	[expression of RAR-beta]	1.5849625007211563	3	1	0	0
23140	1520	coherent expression pattern	[coherent expression patterns]	1.5849625007211563	3	1	0	0
23141	1520	inhibitory kappa b protein	[inhibitory kappa B proteins]	1.5849625007211563	4	1	0	0
23142	1520	activin a-induced growth arrest	[activin A-induced growth arrest]	1.5849625007211563	4	1	0	0
23143	1520	role in growth	[role in growth]	1.5849625007211563	3	2	2	2
23144	1520	sensitivity to anti-CD3 stimulation	[sensitivity to anti-CD3 stimulation]	1.5849625007211563	4	1	0	0
23145	1520	lps thp-1 cell	[LPS THP-1 cells]	1.5849625007211563	3	1	0	0
23146	1520	0 to 72 hours,	[0 to 72 hours,]	1.5849625007211563	4	1	0	0
23147	1520	level of il-1beta	[levels of IL-1beta]	1.5849625007211563	3	1	0	0
23148	1520	125d3 -resistant variant	[1,25D3 -resistant variants]	1.5849625007211563	3	1	0	0
23149	1520	six healthy male volunteer	[six healthy male volunteers]	1.5849625007211563	4	1	0	0
23150	1520	Interleukin-1 beta IL-1beta	[Interleukin-1 beta IL-1beta]	1.5849625007211563	3	1	0	0
23151	1520	novel mouse model	[novel mouse model]	1.5849625007211563	3	1	0	0
23152	1520	calcium ionophore (cai)	[calcium ionophore (CaI)]	1.5849625007211563	3	1	0	0
23153	1520	murine peritoneal macrophage	[murine peritoneal macrophages]	1.5849625007211563	3	2	1	1
23154	1520	locus on chromosome unlikely.	[locus on chromosome unlikely.]	1.5849625007211563	4	1	0	0
23155	1520	need for the expression	[need for the expression]	1.5849625007211563	4	1	0	0
23156	1520	1 nm 12-o-tetradecanoylphorbol-13-acetate	[1 nM 12-O-tetradecanoylphorbol-13-acetate]	1.5849625007211563	3	1	0	0
23157	1520	lineage-specific effector function	[lineage-specific effector functions]	1.5849625007211563	3	1	0	0
23158	1520	relevance of the regulation	[relevance of the regulation]	1.5849625007211563	4	1	0	0
23159	1520	human b-cell line im-9	[human B-cell line IM-9]	1.5849625007211563	4	1	0	0
23160	1520	prior to tcr rearrangement	[prior to TCR rearrangement]	1.5849625007211563	4	1	0	0
23161	1520	vaccination with synthetic peptide	[Vaccination with synthetic peptides]	1.5849625007211563	4	1	0	0
23162	1520	28 lbp patient (25:3)	[28 LBP patients (25:3)]	1.5849625007211563	4	1	0	0
23163	1520	background: alveolar macrophage	[BACKGROUND: Alveolar macrophages]	1.5849625007211563	3	1	0	0
23164	1520	purine-rich IL-2 promoter element	[purine-rich IL-2 promoter elements]	1.5849625007211563	4	1	0	0
23165	1520	antioxidant (ao) thiol	[antioxidant (AO) thiols]	1.5849625007211563	3	1	0	0
23166	1520	apoptosis kinase activation	[apoptosis kinase activation]	1.5849625007211563	3	1	0	0
23167	1520	TRAF binding domain	[TRAF binding domains]	1.5849625007211563	3	1	0	0
23168	1520	human gata-3 gene	[human GATA-3 gene]	1.5849625007211563	3	1	0	0
23169	1520	lymphocyte cytosolic glucocorticoid receptor	[lymphocyte cytosolic glucocorticoid receptors]	1.5849625007211563	4	1	0	0
23170	1520	internal methionine codon	[internal methionine codons]	1.5849625007211563	3	1	0	0
23171	1520	long 5' utr	[longer 5' UTR]	1.5849625007211563	3	1	0	0
23172	1520	human il-10 (10	[human IL-10 (10]	1.5849625007211563	3	1	0	0
23173	1520	CCAAT/enhancer-binding protein (C/EBP) family	[CCAAT/enhancer-binding protein (C/EBP) family]	1.5849625007211563	4	1	0	0
23174	1520	recurrent hsv infection	[recurrent HSV infection]	1.5849625007211563	3	1	0	0
23175	1520	PMA il-2r alpha	[PMA IL-2R alpha]	1.5849625007211563	3	1	0	0
23176	1520	translocation of pkc	[translocation of PKC]	1.5849625007211563	3	1	0	0
23177	1520	cord lymphocyte proliferation rate	[cord lymphocyte proliferation rates]	1.5849625007211563	4	1	0	0
23178	1520	use tax mutant	[Using Tax mutants]	1.5849625007211563	3	1	0	0
23179	1520	serum hormone level	[serum hormone levels]	1.5849625007211563	3	1	0	0
23180	1520	mobility supershift assay	[mobility supershift assay]	1.5849625007211563	3	2	2	2
23181	1520	stable plasmid replication	[stable plasmid replication]	1.5849625007211563	3	1	0	0
23182	1520	NF kappa B1 site	[NF kappa B1 site]	1.5849625007211563	4	1	0	0
23183	1520	PMA -dependent il-5 production	[PMA -dependent IL-5 production]	1.5849625007211563	4	1	0	0
23184	1520	induction of CAT activity	[induction of CAT activity]	1.5849625007211563	4	1	0	0
23185	1520	adult erythroid mel cell	[adult erythroid MEL cells]	1.5849625007211563	4	1	0	0
23186	1520	similar molecular mechanism	[similar molecular mechanisms]	1.5849625007211563	3	1	0	0
23187	1520	mechanism of ec activation	[mechanism of EC activation]	1.5849625007211563	4	1	0	0
23188	1520	broad spectrum in binding	[broader spectrum in binding]	1.5849625007211563	4	1	0	0
23189	1520	use ltr- chloramphenicol acetyltransferase	[using LTR- chloramphenicol acetyltransferase]	1.5849625007211563	4	1	0	0
23190	1520	cellular response to lps	[cellular responses to LPS]	1.5849625007211563	4	1	0	0
23191	1520	lps stimulation of neutrophil	[LPS stimulation of neutrophils]	1.5849625007211563	4	1	0	0
23192	1520	nuclear nf-kappab dna-binding activity	[nuclear NF-kappaB DNA-binding activity]	1.5849625007211563	4	1	0	0
23193	1520	decrease in hiv-1 replication	[decreases in HIV-1 replication]	1.5849625007211563	4	1	0	0
23194	1520	CD19 signal transduction	[CD19 signal transduction]	1.5849625007211563	3	1	0	0
23195	1520	cDNA of cck(b) receptor	[cDNA of CCK(B) receptor]	1.5849625007211563	4	1	0	0
23196	1520	human mammary cell	[human mammary cells]	1.5849625007211563	3	2	2	2
23197	1520	reassembly with the signalsome,	[reassembly with the signalsome,]	1.5849625007211563	4	1	0	0
23198	1520	disruption of ebv	[disruption of EBV]	1.5849625007211563	3	1	0	0
23199	1520	nucleus of the cells,	[nucleus of the cells,]	1.5849625007211563	4	1	0	0
23200	1520	pafr transcript 2 tissue-type	[PAFR transcript 2 tissue-type]	1.5849625007211563	4	1	0	0
23201	1520	level of hiv mrna	[levels of HIV mRNA]	1.5849625007211563	4	2	1	1
23202	1520	incorporation of phosphate	[incorporation of phosphate]	1.5849625007211563	3	1	0	0
23203	1520	host immune-response gene	[host immune-response genes]	1.5849625007211563	3	1	0	0
23204	1520	mononuclear cell to DFX	[mononuclear cells to DFX]	1.5849625007211563	4	1	0	0
23205	1520	expression of tnf alpha	[expression of TNF alpha]	1.5849625007211563	4	1	0	0
23206	1520	PGG-Glucan binding moiety	[PGG-Glucan binding moiety]	1.5849625007211563	3	1	0	0
23207	1520	approximately 10 P.	[approximately 10 h.]	1.5849625007211563	3	1	0	0
23208	1520	oxldl on blast differentiation	[oxLDLs on blast differentiation]	1.5849625007211563	4	1	0	0
23209	1520	Beres Drops Plus BDP	[Beres Drops Plus BDP]	1.5849625007211563	4	1	0	0
23210	1520	management of difficult-to-control asthma	[management of difficult-to-control asthma]	1.5849625007211563	4	1	0	0
23211	1520	potent repressor of transcription	[potent repressor of transcription]	1.5849625007211563	4	1	0	0
23212	1520	number of regulatory protein	[number of regulatory proteins]	1.5849625007211563	4	2	2	2
23213	1520	megakaryoblastic/erythroid cell line	[megakaryoblastic/erythroid cell line]	1.5849625007211563	3	1	0	0
23214	1520	patient with her-2/neu overexpression	[patients with HER-2/neu overexpression]	1.5849625007211563	4	1	0	0
23215	1520	minimal Thy-1 promoter	[minimal Thy-1 promoter]	1.5849625007211563	3	1	0	0
23216	1520	4 h in cell	[4 h in cells]	1.5849625007211563	4	2	2	2
23217	1520	monoblastoid U937 cell line	[monoblastoid U937 cell line]	1.5849625007211563	4	1	0	0
23218	1520	important immunomodulatory role	[important immunomodulatory role]	1.5849625007211563	3	1	0	0
23219	1520	CD19 gc box	[CD19 GC box]	1.5849625007211563	3	1	0	0
23220	1520	activity against macrovascular ec	[Activity against macrovascular EC]	1.5849625007211563	4	2	2	2
23221	1520	activation of Jak	[activation of Jak]	1.5849625007211563	3	2	1	1
23222	1520	increase in il-2ralpha expression	[increase in IL-2Ralpha expression]	1.5849625007211563	4	1	0	0
23223	1520	acute phase response	[acute phase response]	1.5849625007211563	3	1	0	0
23224	1520	11 typical aml m4eo	[11 typical AML M4Eo]	1.5849625007211563	4	1	0	0
23225	1520	two isoforms, GRalpha	[two isoforms, GRalpha]	1.5849625007211563	3	1	0	0
23226	1520	tcr /cd3 signal	[TCR /CD3 signal]	1.5849625007211563	3	1	0	0
23227	1520	apoptotic peer cell	[apoptotic PEER cells]	1.5849625007211563	3	1	0	0
23228	1520	Finally, Scatchard plot analysis	[Finally, Scatchard plot analysis]	1.5849625007211563	4	1	0	0
23229	1520	steroid to glucocorticoid receptor	[steroids to glucocorticoid receptors]	1.5849625007211563	4	1	0	0
23230	1520	patient with retinoblastoma	[patients with retinoblastoma]	1.5849625007211563	3	1	0	0
23231	1520	fy(b-) phenotype among Jew	[Fy(b-) phenotypes among Jews]	1.5849625007211563	4	1	0	0
23232	1520	fcs- liquid-suspension culture	[FCS- liquid-suspension culture]	1.5849625007211563	3	1	0	0
23233	1520	STAT 4 transcription factor	[STAT 4 transcription factor]	1.5849625007211563	4	1	0	0
23234	1520	pathway of nf-kappab activation	[pathways of NF-kappaB activation]	1.5849625007211563	4	1	0	0
23235	1520	(a beta) peptide	[(A beta) peptides]	1.5849625007211563	3	1	0	0
23236	1520	polymerase chain reaction rt-pcr	[polymerase chain reaction RT-PCR]	1.5849625007211563	4	1	0	0
23237	1520	cell with megakaryocytic feature	[cells with megakaryocytic features]	1.5849625007211563	4	1	0	0
23238	1520	chloramphenicol acetyltransferase plasmid	[chloramphenicol acetyltransferase plasmid]	1.5849625007211563	3	2	2	2
23239	1520	mechanism distinct from loss-of-function	[mechanisms distinct from loss-of-function]	1.5849625007211563	4	1	0	0
23240	1520	normal progenitor cell	[normal progenitor cells]	1.5849625007211563	3	5	4	1
23241	1520	hpv-18 e7 oncoprotein	[HPV-18 E7 oncoprotein]	1.5849625007211563	3	1	0	0
23242	1520	peripheral cell PBMC	[peripheral cells PBMC]	1.5849625007211563	3	2	2	2
23243	1520	constitutive activation of Stat1alpha	[constitutive activation of Stat1alpha]	1.5849625007211563	4	1	0	0
23244	1520	macrophage inflammatory protein-2	[macrophage inflammatory protein-2]	1.5849625007211563	3	2	1	1
23245	1520	33 absorptive hypercalciuric patient	[33 absorptive hypercalciuric patients]	1.5849625007211563	4	1	0	0
23246	1520	serum-activated cell line	[serum-activated cell lines]	1.5849625007211563	3	1	0	0
23247	1520	cellular response to ldl	[cellular responses to LDL]	1.5849625007211563	4	1	0	0
23248	1520	t-cell receptor tcr stimulation	[T-cell receptor TcR stimulation]	1.5849625007211563	4	1	0	0
23249	1520	nuclear NF-kappa b	[nuclear NF-kappa B]	1.5849625007211563	3	1	0	0
23250	1520	carboxyl terminus of CIITA	[carboxyl terminus of CIITA]	1.5849625007211563	4	1	0	0
23251	1520	female patient with eosinophilia	[female patients with eosinophilia]	1.5849625007211563	4	1	0	0
23252	1520	perpetuate hiv-1 replication	[perpetuating HIV-1 replication]	1.5849625007211563	3	1	0	0
23253	1520	NF-kappaB -dependent pathway	[NF-kappaB -dependent pathway]	1.5849625007211563	3	1	0	0
23254	1520	contrast to this findings,	[contrast to these findings,]	1.5849625007211563	4	1	0	0
23255	1520	10(-7) mol/L 135(oh)2d3	[10(-7) mol/L 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
23256	1520	approximately 35 kilobasis	[approximately 35 kilobases]	1.5849625007211563	3	1	0	0
23257	1520	IL-2 gene promoter region	[IL-2 gene promoter region]	1.5849625007211563	4	1	0	0
23258	1520	certain autoimmune disease	[certain autoimmune diseases]	1.5849625007211563	3	1	0	0
23259	1520	inhibitor of pp1 tautomycin	[inhibitors of PP1 tautomycin]	1.5849625007211563	4	1	0	0
23260	1520	prototype octamer element	[prototype octamer element]	1.5849625007211563	3	1	0	0
23261	1520	CD2 interleukin-2 production	[CD2 interleukin-2 production]	1.5849625007211563	3	1	0	0
23262	1520	mammalian oncogenic virus	[mammalian oncogenic viruses]	1.5849625007211563	3	1	0	0
23263	1520	activation of JNK	[activation of JNK]	1.5849625007211563	3	2	2	2
23264	1520	interaction with hemopoietic cell	[interaction with hemopoietic cells]	1.5849625007211563	4	1	0	0
23265	1520	childhood acute T	[childhood acute T]	1.5849625007211563	3	1	0	0
23266	1520	second alteration, at threonine	[second alteration, at threonine]	1.5849625007211563	4	1	0	0
23267	1520	human il-16 gene	[human IL-16 gene]	1.5849625007211563	3	2	1	1
23268	1520	response to jun-B	[Responses to jun-B]	1.5849625007211563	3	1	0	0
23269	1520	Cepsilon gene transcription	[Cepsilon gene transcription]	1.5849625007211563	3	1	0	0
23270	1520	novel class of protein	[novel class of proteins]	1.5849625007211563	4	1	0	0
23271	1520	binding of all-tran RA	[binding of all-trans RA]	1.5849625007211563	4	1	0	0
23272	1520	wide variety of cytokine	[wide variety of cytokines]	1.5849625007211563	4	1	0	0
23273	1520	ebna2 -oestrogen receptor fusion	[EBNA2 -oestrogen receptor fusion]	1.5849625007211563	4	1	0	0
23274	1520	stage of commitment	[stages of commitment]	1.5849625007211563	3	2	2	2
23275	1520	cytoplasmic hela extract	[cytoplasmic HeLa extract]	1.5849625007211563	3	1	0	0
23276	1520	novel b-cell-specific enhancer element	[novel B-cell-specific enhancer element]	1.5849625007211563	4	1	0	0
23277	1520	pml/rar alpha hybrid protein	[pml/RAR alpha hybrid protein]	1.5849625007211563	4	1	0	0
23278	1520	target for ebf	[target for EBF]	1.5849625007211563	3	2	2	2
23279	1520	approximately 4 kilobasis 5'	[approximately 4 kilobases 5']	1.5849625007211563	4	1	0	0
23280	1520	dominant negative effect	[dominant negative effect]	1.5849625007211563	3	2	2	2
23281	1520	human tcr zeta-chain	[human TCR zeta-chain]	1.5849625007211563	3	1	0	0
23282	1520	suppression of hiv-1 replication	[suppression of HIV-1 replication]	1.5849625007211563	4	2	1	1
23283	1520	nf-kappa b/rel activity	[NF-kappa B/Rel activity]	1.5849625007211563	3	2	2	2
23284	1520	Drosophila Toll a type	[Drosophila Toll a type]	1.5849625007211563	4	1	0	0
23285	1520	determinant for peptide binding	[determinant for peptide binding]	1.5849625007211563	4	1	0	0
23286	1520	Granzyme B gene transcription	[Granzyme B gene transcription]	1.5849625007211563	4	1	0	0
23287	1520	immortalization of b cell	[immortalization of B cells]	1.5849625007211563	4	1	0	0
23288	1520	competition ems analysis	[Competition EMS analyses]	1.5849625007211563	3	1	0	0
23289	1520	-326 to -615 region	[-326 to -615 region]	1.5849625007211563	4	1	0	0
23290	1520	il-2 gene promoter activity	[IL-2 gene promoter activity]	1.5849625007211563	4	1	0	0
23291	1520	okadaic acid OKA	[okadaic acid OKA]	1.5849625007211563	3	1	0	0
23292	1520	lead to the induction	[leading to the induction]	1.5849625007211563	4	2	1	1
23293	1520	BCL-2 family of proteins,	[BCL-2 family of proteins,]	1.5849625007211563	4	1	0	0
23294	1520	regulator in vitro.	[regulator in vitro.]	1.5849625007211563	3	2	2	2
23295	1520	immunodominant lytic cycle epitope	[immunodominant lytic cycle epitopes]	1.5849625007211563	4	1	0	0
23296	1520	non- mcd14 lps uptake	[non- mCD14 LPS uptake]	1.5849625007211563	4	1	0	0
23297	1520	NF-kappa b inhibitor alone	[NF-kappa B inhibitors alone]	1.5849625007211563	4	1	0	0
23298	1520	negative growth regulatory signal	[negative growth regulatory signals]	1.5849625007211563	4	1	0	0
23299	1520	response to lipopolysaccharide	[response to lipopolysaccharide]	1.5849625007211563	3	2	1	1
23300	1520	great sensitivity to mpl	[greater sensitivity to MPL]	1.5849625007211563	4	1	0	0
23301	1520	anti-CD3-stimulated ap-1 enhancer activity	[anti-CD3-stimulated AP-1 enhancer activity]	1.5849625007211563	4	1	0	0
23302	1520	electrophoresis mobility shift assay	[Electrophoresis mobility shift assays]	1.5849625007211563	4	2	1	1
23303	1520	itself, a mutant p53	[itself, a mutant p53]	1.5849625007211563	4	1	0	0
23304	1520	new role for nf-kappab	[new role for NF-kappaB]	1.5849625007211563	4	1	0	0
23305	1520	iron-responsive element (ire) motif	[iron-responsive element (IRE) motif]	1.5849625007211563	4	1	0	0
23306	1520	expression of Oct-1	[expression of Oct-1]	1.5849625007211563	3	1	0	0
23307	1520	multiple hmg box	[multiple HMG boxes]	1.5849625007211563	3	1	0	0
23308	1520	b104 growth inhibition	[B104 growth inhibition]	1.5849625007211563	3	1	0	0
23309	1520	activation in killer cell	[activation in killer cells]	1.5849625007211563	4	2	2	2
23310	1520	treat eosinophlic inflammation	[treating eosinophlic inflammation]	1.5849625007211563	3	1	0	0
23311	1520	inhibition of gata1 induction	[inhibition of GATA1 induction]	1.5849625007211563	4	1	0	0
23312	1520	very early B-cell differentiation	[very early B-cell differentiation]	1.5849625007211563	4	1	0	0
23313	1520	lineage-specific determinant of cell	[lineage-specific determinants of cell]	1.5849625007211563	4	1	0	0
23314	1520	il-1beta promoter activity	[IL-1beta promoter activity]	1.5849625007211563	3	3	2	1
23315	1520	instead on the transcription	[instead on the transcription]	1.5849625007211563	4	1	0	0
23316	1520	BZLF1 immediate-early transcript	[BZLF1 immediate-early transcripts]	1.5849625007211563	3	1	0	0
23317	1520	major transcriptional start site	[major transcriptional start site]	1.5849625007211563	4	2	1	1
23318	1520	interleukin 1 signal pathway	[interleukin 1 signaling pathways]	1.5849625007211563	4	1	0	0
23319	1520	thus suggest dependent	[thus suggesting dependent]	1.5849625007211563	3	1	0	0
23320	1520	ability of wild-type cbl	[ability of wild-type Cbl]	1.5849625007211563	4	1	0	0
23321	1520	DNA binding characteristic	[DNA binding characteristics]	1.5849625007211563	3	1	0	0
23322	1520	2100 binding sites/nucleus	[2100 binding sites/nucleus]	1.5849625007211563	3	1	0	0
23323	1520	early g1 protein p27(kip1)	[early G1 proteins p27(Kip1)]	1.5849625007211563	4	1	0	0
23324	1520	up-regulation of irf-1	[up-regulation of IRF-1]	1.5849625007211563	3	1	0	0
23325	1520	ebv transactivate factor	[EBV transactivating factors]	1.5849625007211563	3	1	0	0
23326	1520	human megakaryocytic cell line	[human megakaryocytic cell line]	1.5849625007211563	4	1	0	0
23327	1520	b cell immunopoiesis	[B cell immunopoiesis]	1.5849625007211563	3	2	1	1
23328	1520	agreement with this, decrease	[agreement with this, decrease]	1.5849625007211563	4	1	0	0
23329	1520	keep with this finding,	[keeping with this finding,]	1.5849625007211563	4	1	0	0
23330	1520	patient with acute leukaemia	[patient with acute leukaemia]	1.5849625007211563	4	2	2	2
23331	1520	Cdc42 machinery responsible	[Cdc42 machinery responsible]	1.5849625007211563	3	1	0	0
23332	1520	high c-erb b-2	[high c-erb B-2]	1.5849625007211563	3	2	1	1
23333	1520	enzymatic activation of jak3	[enzymatic activation of JAK3]	1.5849625007211563	4	1	0	0
23334	1520	novel fusion transcript RAZ	[novel fusion transcript RAZ]	1.5849625007211563	4	1	0	0
23335	1520	hiv replication by cytokine	[HIV replication by cytokines]	1.5849625007211563	4	1	0	0
23336	1520	deregulation of bcl-6 expression	[deregulation of BCL-6 expression]	1.5849625007211563	4	1	0	0
23337	1520	promoter of human gene	[promoters of human genes]	1.5849625007211563	4	1	0	0
23338	1520	T cell line lead	[T cell lines leading]	1.5849625007211563	4	1	0	0
23339	1520	Wilms' tumor gene	[Wilms' tumor gene]	1.5849625007211563	3	2	2	2
23340	1520	complexity of il-16 expression	[complexity of IL-16 expression]	1.5849625007211563	4	1	0	0
23341	1520	trypan blue exclusion	[trypan blue exclusion]	1.5849625007211563	3	1	0	0
23342	1520	expression of laz3/bcl6	[Expression of LAZ3/BCL6]	1.5849625007211563	3	2	1	1
23343	1520	own ligand, il-2	[own ligand, IL-2]	1.5849625007211563	3	1	0	0
23344	1520	transcriptional cooperativity between TNFalpha	[transcriptional cooperativity between TNFalpha]	1.5849625007211563	4	1	0	0
23345	1520	binding of 17beta-(3H) estradiol	[binding of 17beta-(3H) estradiol]	1.5849625007211563	4	1	0	0
23346	1520	diagnosis of lymphoid malignancy	[diagnosis of lymphoid malignancies]	1.5849625007211563	4	1	0	0
23347	1520	Philadelphia myeloid leukemia	[Philadelphia myeloid leukemia]	1.5849625007211563	3	2	2	2
23348	1520	report of a case.	[report of a case.]	1.5849625007211563	4	1	0	0
23349	1520	three UAS1 binding site	[three UAS1 binding sites]	1.5849625007211563	4	1	0	0
23350	1520	carboxyl-terminal cytoplasmic tail	[carboxyl-terminal cytoplasmic tail]	1.5849625007211563	3	1	0	0
23351	1520	chromosomal translocation with one	[chromosomal translocations with one]	1.5849625007211563	4	1	0	0
23352	1520	cis-cloned synthetic oligodeoxyribonudleotides	[cis-cloned synthetic oligodeoxyribonucleotides]	1.5849625007211563	3	1	0	0
23353	1520	expression of il-1beta	[expression of IL-1beta]	1.5849625007211563	3	1	0	0
23354	1520	functional 135eoh)2d3 receptor	[functional 1,25(OH)2D3 receptor]	1.5849625007211563	3	1	0	0
23355	1520	expression of p45 mrna	[expression of p45 mRNA]	1.5849625007211563	4	1	0	0
23356	1520	activity, of IkappaB	[activity, of IkappaB]	1.5849625007211563	3	1	0	0
23357	1520	two polyadenylation site	[Two polyadenylation sites]	1.5849625007211563	3	1	0	0
23358	1520	primarily in the thymus	[primarily in the thymus]	1.5849625007211563	4	1	0	0
23359	1520	down-modulation of site beta	[down-modulation of site beta]	1.5849625007211563	4	1	0	0
23360	1520	nuclear factor enf)-kappa b	[nuclear factor (NF)-kappa B]	1.5849625007211563	4	1	0	0
23361	1520	Philadelphia chronic leukemia	[Philadelphia chronic leukemia]	1.5849625007211563	3	2	2	2
23362	1520	chemotactic factor for eosinophil	[chemotactic factor for eosinophils]	1.5849625007211563	4	1	0	0
23363	1520	maturation defect occur	[maturation defects occurring]	1.5849625007211563	3	1	0	0
23364	1520	patient with gynecomastia	[patients with gynecomastia]	1.5849625007211563	3	2	1	1
23365	1520	antibody to Stat6	[Antibodies to Stat6]	1.5849625007211563	3	1	0	0
23366	1520	nuclear extract from cell	[nuclear extracts from cells]	1.5849625007211563	4	1	0	0
23367	1520	normal erythroid proliferation	[normal erythroid proliferation]	1.5849625007211563	3	1	0	0
23368	1520	invariant (ii) chain	[invariant (Ii) chains]	1.5849625007211563	3	1	0	0
23369	1520	question of the regulation	[question of the regulation]	1.5849625007211563	4	1	0	0
23370	1520	lps nf-kappa b	[LPS NF-kappa B]	1.5849625007211563	3	1	0	0
23371	1520	transcriptional activation of RE/AP	[transcriptional activation of RE/AP]	1.5849625007211563	4	1	0	0
23372	1520	sensitivity of the cell	[sensitivity of the cell]	1.5849625007211563	4	1	0	0
23373	1520	study define crucial signal	[studies defining crucial signals]	1.5849625007211563	4	1	0	0
23374	1520	10 healthy woman (controls)	[10 healthy women (controls)]	1.5849625007211563	4	1	0	0
23375	1520	co-activation of pkc	[co-activation of PKC]	1.5849625007211563	3	1	0	0
23376	1520	hiv-1 enhancer region	[HIV-1 enhancer region]	1.5849625007211563	3	1	0	0
23377	1520	heat shock factor-1 hsf-1	[heat shock factor-1 HSF-1]	1.5849625007211563	4	1	0	0
23378	1520	level in monocyte	[levels in monocytes]	1.5849625007211563	3	2	2	2
23379	1520	lipoprotein in pathophysiologic amounts,	[lipoprotein in pathophysiologic amounts,]	1.5849625007211563	4	1	0	0
23380	1520	affect T cell function	[affecting T cell function]	1.5849625007211563	4	1	0	0
23381	1520	transcription factor ap2	[transcription factors AP2]	1.5849625007211563	3	1	0	0
23382	1520	il-2 -mRNA accumulation	[IL-2 -mRNA accumulation]	1.5849625007211563	3	1	0	0
23383	1520	specific nuclear factor	[specific nuclear factors]	1.5849625007211563	3	1	0	0
23384	1520	okt8+ T cell 0.04)	[OKT8+ T cells 0.04)]	1.5849625007211563	4	1	0	0
23385	1520	transcription factor ap1	[transcription factor AP1]	1.5849625007211563	3	1	0	0
23386	1520	coordination of nf-kappab	[coordination of NF-kappaB]	1.5849625007211563	3	1	0	0
23387	1520	oestrogen target organ	[oestrogen target organs]	1.5849625007211563	3	2	2	2
23388	1520	role of Jak1	[role of Jak1]	1.5849625007211563	3	1	0	0
23389	1520	tax -express jurkat cell	[Tax -expressing Jurkat cells]	1.5849625007211563	4	1	0	0
23390	1520	17 alpha- estradiol	[17 alpha- estradiol]	1.5849625007211563	3	1	0	0
23391	1520	cyclin-dependent kinase (cdk)4	[cyclin-dependent kinase (cdk)4]	1.5849625007211563	3	1	0	0
23392	1520	factor to the nucleus	[factors to the nucleus]	1.5849625007211563	4	1	0	0
23393	1520	29-kDa proteolysist fragment	[29-kDa proteolysis-resisting fragment]	1.5849625007211563	3	1	0	0
23394	1520	hematopoietic cell type	[hematopoietic cell types]	1.5849625007211563	3	2	2	2
23395	1520	other nf-kappab protein p52	[other NF-kappaB proteins p52]	1.5849625007211563	4	1	0	0
23396	1520	ISRE oligonucleotide probe	[ISRE oligonucleotide probe]	1.5849625007211563	3	1	0	0
23397	1520	-76 nucleotide relative	[-76 nucleotides relative]	1.5849625007211563	3	1	0	0
23398	1520	mechanism for the inhibition	[mechanism for the inhibition]	1.5849625007211563	4	2	1	1
23399	1520	early pro-B cell stage	[early pro-B cell stage]	1.5849625007211563	4	1	0	0
23400	1520	absence of ascorbate nac	[absence of ascorbate NAC]	1.5849625007211563	4	1	0	0
23401	1520	304g a substitution	[304G A substitution]	1.5849625007211563	3	1	0	0
23402	1520	primary sjogren' syndrome ss	[Primary Sjogren's syndrome SS]	1.5849625007211563	4	1	0	0
23403	1520	several other myeloid-cell-specific gene	[several other myeloid-cell-specific genes]	1.5849625007211563	4	1	0	0
23404	1520	closely related cell type	[closely related cell types]	1.5849625007211563	4	1	0	0
23405	1520	cytokine synthesis inhibitory activity	[cytokine synthesis inhibitory activity]	1.5849625007211563	4	1	0	0
23406	1520	latent membrane protein LMP	[latent membrane proteins LMP]	1.5849625007211563	4	1	0	0
23407	1520	cytoplasm of htlv-infected cell	[cytoplasm of HTLV-infected cells]	1.5849625007211563	4	1	0	0
23408	1520	other human LCR HSs	[other human LCR HSs]	1.5849625007211563	4	1	0	0
23409	1520	related factor Ets1	[related factor Ets1]	1.5849625007211563	3	1	0	0
23410	1520	factor kappab p50/p65 heterodimer	[factor kappaB p50/p65 heterodimer]	1.5849625007211563	4	1	0	0
23411	1520	normal human subject	[normal human subjects]	1.5849625007211563	3	1	0	0
23412	1520	activation of the cell	[activation of the cells]	1.5849625007211563	4	1	0	0
23413	1520	high-affinity calcineurin -binding peptide	[high-affinity calcineurin -binding peptide]	1.5849625007211563	4	1	0	0
23414	1520	cell specific expression	[Cell specific expression]	1.5849625007211563	3	1	0	0
23415	1520	nf-kappa b with DNA	[NF-kappa B with DNA]	1.5849625007211563	4	1	0	0
23416	1520	discontinuous Percoll gradient	[discontinuous Percoll gradients]	1.5849625007211563	3	1	0	0
23417	1520	cortisol -dependent BA	[cortisol -dependent BA]	1.5849625007211563	3	1	0	0
23418	1520	day 7 cells,	[day 7 cells,]	1.5849625007211563	3	1	0	0
23419	1520	primary blood monocyte	[primary blood monocytes]	1.5849625007211563	3	1	0	0
23420	1520	coexpression of pebp2betamyh11	[Coexpression of PEBP2betaMYH11]	1.5849625007211563	3	1	0	0
23421	1520	mek1 kinase activity	[MEK1 kinase activity]	1.5849625007211563	3	1	0	0
23422	1520	37 chronic, severe,	[37 chronic, severe,]	1.5849625007211563	3	1	0	0
23423	1520	role transduce signal	[role transducing signals]	1.5849625007211563	3	2	2	2
23424	1520	mouse cell line	[mouse cell line]	1.5849625007211563	3	2	2	2
23425	1520	(+/- sem) for control	[(+/- SEM) for controls]	1.5849625007211563	4	1	0	0
23426	1520	N-terminal Thr729-Leu765 region	[N-terminal Thr729-Leu765 region]	1.5849625007211563	3	1	0	0
23427	1520	four nfat-like element	[Four NFAT-like elements]	1.5849625007211563	3	1	0	0
23428	1520	human cytokine il-4	[human cytokine IL-4]	1.5849625007211563	3	1	0	0
23429	1520	biphasic increase in adhesion	[biphasic increase in adhesion]	1.5849625007211563	4	2	2	2
23430	1520	immunomodulatory activity in vivo	[immunomodulatory activity in vivo]	1.5849625007211563	4	1	0	0
23431	1520	contrast, ifn-alpha /beta	[contrast, IFN-alpha /beta]	1.5849625007211563	3	1	0	0
23432	1520	binding of dexamethasone	[binding of dexamethasone]	1.5849625007211563	3	1	0	0
23433	1520	include protein kinase c	[including protein kinase C]	1.5849625007211563	4	2	1	1
23434	1520	include protein kinase a	[including protein kinase A]	1.5849625007211563	4	1	0	0
23435	1520	tyrosine phosphorylation event(s)	[tyrosine phosphorylation event(s)]	1.5849625007211563	3	1	0	0
23436	1520	transcription 6 stat6	[transcription 6 STAT6]	1.5849625007211563	3	2	2	2
23437	1520	Interferon-alpha induction of stat	[Interferon-alpha induction of STATs]	1.5849625007211563	4	1	0	0
23438	1520	binding to plasma membrane	[binding to plasma membranes]	1.5849625007211563	4	2	2	2
23439	1520	absence of hormone.	[absence of hormone.]	1.5849625007211563	3	1	0	0
23440	1520	exposure to IFN-gamma	[exposure to IFN-gamma]	1.5849625007211563	3	1	0	0
23441	1520	analysis of intron-exon structure	[Analysis of intron-exon structure]	1.5849625007211563	4	1	0	0
23442	1520	interleukin (il)-1beta CD40 trigger	[interleukin (IL)-1beta CD40 triggering]	1.5849625007211563	4	1	0	0
23443	1520	induction by okadaic acid	[induction by okadaic acid]	1.5849625007211563	4	2	2	2
23444	1520	red cell-specific transcriptional activator	[red cell-specific transcriptional activator]	1.5849625007211563	4	1	0	0
23445	1520	affinity for functional motif	[affinity for functional motifs]	1.5849625007211563	4	1	0	0
23446	1520	relative low binding affinity	[relative low binding affinity]	1.5849625007211563	4	1	0	0
23447	1520	tr75 surface expression	[TR75 surface expression]	1.5849625007211563	3	1	0	0
23448	1520	1 week of treatment	[1 week of treatment]	1.5849625007211563	4	1	0	0
23449	1520	Jak- Stat1 pathway	[Jak- Stat1 pathway]	1.5849625007211563	3	1	0	0
23450	1520	macrophage transcription factor pu.1	[macrophage transcription factor PU.1]	1.5849625007211563	4	1	0	0
23451	1520	identical sequence of biotin-	[identical sequences of biotin-]	1.5849625007211563	4	1	0	0
23452	1520	factor 6 traf6	[factor 6 TRAF6]	1.5849625007211563	3	1	0	0
23453	1520	multidrug-resistant hl-60 cell hl-60/vinc,	[multidrug-resistant HL-60 cells HL-60/vinc,]	1.5849625007211563	4	1	0	0
23454	1520	understanding of the development	[understanding of the development]	1.5849625007211563	4	1	0	0
23455	1520	PKC -dependent pathway	[PKC -dependent pathways]	1.5849625007211563	3	2	1	1
23456	1520	germinal center cell	[germinal center cells]	1.5849625007211563	3	1	0	0
23457	1520	multispecific immune response	[multispecific immune response]	1.5849625007211563	3	1	0	0
23458	1520	predominant STAT transcription factor	[predominant STAT transcription factor]	1.5849625007211563	4	1	0	0
23459	1520	NF-kappa B1 precursor p105	[NF-kappa B1 precursor p105]	1.5849625007211563	4	1	0	0
23460	1520	precursor of 105 kda	[precursor of 105 kDa]	1.5849625007211563	4	1	0	0
23461	1520	sequence of peptide g76	[sequence of peptide G76]	1.5849625007211563	4	1	0	0
23462	1520	lymphoid cell in growth	[lymphoid cells in growth]	1.5849625007211563	4	1	0	0
23463	1520	IRE transcript from ferritin	[IRE transcripts from ferritin]	1.5849625007211563	4	1	0	0
23464	1520	combination with cytosol	[combination with cytosol]	1.5849625007211563	3	1	0	0
23465	1520	dendritic antigen-presenting cell	[dendritic antigen-presenting cells]	1.5849625007211563	3	1	0	0
23466	1520	conversion into macrophage	[conversion into macrophages]	1.5849625007211563	3	1	0	0
23467	1520	1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	1.5849625007211563	4	2	2	2
23468	1520	basis of nuclear localization	[basis of nuclear localization]	1.5849625007211563	4	1	0	0
23469	1520	change of dissociation	[changes of dissociation]	1.5849625007211563	3	1	0	0
23470	1520	mrna -encoding member	[mRNA -encoding members]	1.5849625007211563	3	1	0	0
23471	1520	information concern the signal	[information concerning the signals]	1.5849625007211563	4	1	0	0
23472	1520	transformation activity of c-Jun	[transformation activity of c-Jun]	1.5849625007211563	4	1	0	0
23473	1520	immunodeficiency virus type repeat	[immunodeficiency virus type repeats]	1.5849625007211563	4	2	2	2
23474	1520	clinical picture of hypercorticism	[clinical picture of hypercorticism]	1.5849625007211563	4	1	0	0
23475	1520	maximum transactivation activity	[maximum transactivation activity]	1.5849625007211563	3	1	0	0
23476	1520	potentially influence own expression	[potentially influencing own expression]	1.5849625007211563	4	1	0	0
23477	1520	more rapidly migrate	[more rapidly migrating]	1.5849625007211563	3	1	0	0
23478	1520	cognate octamer motif ATGCAAAT	[cognate octamer motif ATGCAAAT]	1.5849625007211563	4	1	0	0
23479	1520	human nur77 beta cDNA	[human nur77 beta cDNA]	1.5849625007211563	4	1	0	0
23480	1520	NB4 cell line	[NB4 cell line]	1.5849625007211563	3	1	0	0
23481	1520	il-5 eosinophil lineage	[IL-5 eosinophil lineage]	1.5849625007211563	3	1	0	0
23482	1520	comparable level by ar	[comparable levels by AR]	1.5849625007211563	4	1	0	0
23483	1520	cDNA clone dr-nm23	[cDNA clone DR-nm23]	1.5849625007211563	3	1	0	0
23484	1520	successfully colonize hosts.	[successfully colonizing hosts.]	1.5849625007211563	3	1	0	0
23485	1520	PMA superoxide release	[PMA superoxide release]	1.5849625007211563	3	1	0	0
23486	1520	recovery of protein	[recovery of proteins]	1.5849625007211563	3	1	0	0
23487	1520	different restriction enzyme	[different restriction enzymes]	1.5849625007211563	3	1	0	0
23488	1520	response of the gene	[response of the gene]	1.5849625007211563	4	1	0	0
23489	1520	activation marker cd44	[activation markers CD44]	1.5849625007211563	3	1	0	0
23490	1520	lack of t-cell-mediated recognition	[Lack of T-cell-mediated recognition]	1.5849625007211563	4	1	0	0
23491	1520	myeloid-cell-specific gene expression	[myeloid-cell-specific gene expression]	1.5849625007211563	3	1	0	0
23492	1520	c/ebp-epsilon amino acid 1	[C/EBP-epsilon amino acids 1]	1.5849625007211563	4	1	0	0
23493	1520	decrease in binding	[decrease in binding]	1.5849625007211563	3	1	0	0
23494	1520	early b lymphocyte differentiation	[early B lymphocyte differentiation]	1.5849625007211563	4	1	0	0
23495	1520	serum phosphate (p	[serum phosphate (P]	1.5849625007211563	3	1	0	0
23496	1520	auxiliary receptor CD28	[auxiliary receptor CD28]	1.5849625007211563	3	1	0	0
23497	1520	various expression vector	[various expression vectors]	1.5849625007211563	3	1	0	0
23498	1520	follow CD30 ligation	[following CD30 ligation]	1.5849625007211563	3	1	0	0
23499	1520	induce cell proliferation.	[inducing cell proliferation.]	1.5849625007211563	3	1	0	0
23500	1520	complex formation with nf-at	[complex formation with NF-AT]	1.5849625007211563	4	1	0	0
23501	1520	high level of er	[high levels of ER]	1.5849625007211563	4	1	0	0
23502	1520	tar loop sequence	[TAR loop sequences]	1.5849625007211563	3	1	0	0
23503	1520	response to calcium signal	[response to calcium signals]	1.5849625007211563	4	1	0	0
23504	1520	cell with phorbol ester	[cells with phorbol ester]	1.5849625007211563	4	1	0	0
23505	1520	release of the inhibitor	[release of the inhibitor]	1.5849625007211563	4	1	0	0
23506	1520	such as il-2	[such as IL-2]	1.5849625007211563	3	1	0	0
23507	1520	Furthermore, activation of pkc	[Furthermore, activation of PKC]	1.5849625007211563	4	1	0	0
23508	1520	exception of indomethacin	[exception of indomethacin]	1.5849625007211563	3	1	0	0
23509	1520	Interdomain B in ZAP-70	[Interdomain B in ZAP-70]	1.5849625007211563	4	1	0	0
23510	1520	otherwise unresponsive cell	[otherwise unresponsive cells]	1.5849625007211563	3	1	0	0
23511	1520	transformation effector site	[transformation effector site]	1.5849625007211563	3	2	2	2
23512	1520	only weak cross-reactivity	[only weak cross-reactivity]	1.5849625007211563	3	1	0	0
23513	1520	interleukin 8 expression	[interleukin 8 expression]	1.5849625007211563	3	1	0	0
23514	1520	trapping of growth factor	[trapping of growth factors]	1.5849625007211563	4	1	0	0
23515	1520	lps whole-blood cell culture	[LPS whole-blood cell cultures]	1.5849625007211563	4	1	0	0
23516	1520	pretreatment of calcineurin	[pretreatment of calcineurin]	1.5849625007211563	3	1	0	0
23517	1520	importance of tnf-alpha release	[importance of TNF-alpha release]	1.5849625007211563	4	1	0	0
23518	1520	CBF alpha 2-451 twofold	[CBF alpha 2-451 twofold]	1.5849625007211563	4	1	0	0
23519	1520	activation of stat5 homologue	[activation of STAT5 homologues]	1.5849625007211563	4	2	2	2
23520	1520	mutant of tax	[mutant of Tax]	1.5849625007211563	3	1	0	0
23521	1520	il-6 -type cytokine	[IL-6 -type cytokines]	1.5849625007211563	3	1	0	0
23522	1520	effect of ml-9	[effect of ML-9]	1.5849625007211563	3	1	0	0
23523	1520	rela -overexpress cell	[RelA -overexpressing cells]	1.5849625007211563	3	1	0	0
23524	1520	29-kDa phosphoprotein species	[29-kDa phosphoprotein species]	1.5849625007211563	3	1	0	0
23525	1520	accumulation of CRM1	[accumulation of CRM1]	1.5849625007211563	3	1	0	0
23526	1520	b-cell maturation arrest	[B-cell maturation arrest]	1.5849625007211563	3	2	1	1
23527	1520	stat dna-binding activity	[STAT DNA-binding activity]	1.5849625007211563	3	1	0	0
23528	1520	calcium ionophore-induced c-myc suppression	[calcium ionophore-induced c-myc suppression]	1.5849625007211563	4	1	0	0
23529	1520	model study the mechanism	[model studying the mechanism]	1.5849625007211563	4	1	0	0
23530	1520	NL of both subtype	[NL of both subtypes]	1.5849625007211563	4	1	0	0
23531	1520	development of this DC	[development of these DC]	1.5849625007211563	4	1	0	0
23532	1520	transcription factor Stat-3	[transcription factor Stat-3]	1.5849625007211563	3	1	0	0
23533	1520	hiv-1 viral particle	[HIV-1 viral particle]	1.5849625007211563	3	1	0	0
23534	1520	binding of c-Jun pc-fo	[binding of c-Jun /c-Fos]	1.5849625007211563	4	1	0	0
23535	1520	expression of equivalent level	[expression of equivalent levels]	1.5849625007211563	4	1	0	0
23536	1520	antioncogenic transcription factor	[antioncogenic transcription factor]	1.5849625007211563	3	1	0	0
23537	1520	study of thrombogenesis	[study of thrombogenesis]	1.5849625007211563	3	1	0	0
23538	1520	underlie monocytic differentiation	[underlying monocytic differentiation]	1.5849625007211563	3	2	2	2
23539	1520	human class ii transactivator	[human class II transactivator]	1.5849625007211563	4	1	0	0
23540	1520	sequela plaque rupture	[sequela plaque rupture]	1.5849625007211563	3	1	0	0
23541	1520	mammal pyruvate kinase	[Mammal pyruvate kinases]	1.5849625007211563	3	1	0	0
23542	1520	ccaat-box binding factor nf-y	[CCAAT-box binding factor NF-Y]	1.5849625007211563	4	1	0	0
23543	1520	t-cell nuclear protein complex	[T-cell nuclear protein complex]	1.5849625007211563	4	1	0	0
23544	1520	AP-1/c-jun expression vector	[AP-1/c-jun expression vector]	1.5849625007211563	3	1	0	0
23545	1520	5' NF-kappaB site	[5' NF-kappaB site]	1.5849625007211563	3	1	0	0
23546	1520	modulation of x1 interaction	[modulation of X1 interactions]	1.5849625007211563	4	1	0	0
23547	1520	bulk of protein-DNA interaction	[bulk of protein-DNA interactions]	1.5849625007211563	4	1	0	0
23548	1520	erythroid maturation, GPA	[erythroid maturation, GPA]	1.5849625007211563	3	1	0	0
23549	1520	Boyden chamber method	[Boyden chamber method]	1.5849625007211563	3	1	0	0
23550	1520	interaction between TAFII32	[interactions between TAFII32]	1.5849625007211563	3	1	0	0
23551	1520	mouse cpo gene	[mouse CPO gene]	1.5849625007211563	3	1	0	0
23552	1520	class switch recombination.	[class switch recombination.]	1.5849625007211563	3	1	0	0
23553	1520	ubiquitously active transcription factor	[ubiquitously active transcription factor]	1.5849625007211563	4	1	0	0
23554	1520	two decoy oligodeoxynucleotides	[two decoy oligodeoxynucleotides]	1.5849625007211563	3	1	0	0
23555	1520	relationship of this protein	[relationship of this protein]	1.5849625007211563	4	1	0	0
23556	1520	lymphoid-specific transcription factor oct2	[lymphoid-specific transcription factor Oct2]	1.5849625007211563	4	1	0	0
23557	1520	synthesis of a component	[synthesis of a component]	1.5849625007211563	4	1	0	0
23558	1520	chloramphenicol acetyl transferase gene	[chloramphenicol acetyl transferase gene]	1.5849625007211563	4	1	0	0
23559	1520	Janus family tyrosine kinase	[Janus family tyrosine kinase]	1.5849625007211563	4	1	0	0
23560	1520	capacity of ifn-gamma	[capacity of IFN-gamma]	1.5849625007211563	3	1	0	0
23561	1520	severe heart failure	[severe heart failure]	1.5849625007211563	3	1	0	0
23562	1520	stage of atherosclerosis	[stages of atherosclerosis]	1.5849625007211563	3	2	1	1
23563	1520	inhibitor of pkc	[inhibitor of PKC]	1.5849625007211563	3	1	0	0
23564	1520	excessive fecal sodium loss	[excessive fecal sodium losses]	1.5849625007211563	4	1	0	0
23565	1520	extrathymic development of T	[extrathymic development of T]	1.5849625007211563	4	1	0	0
23566	1520	human immunodeficiency virus 1	[human immunodeficiency virus 1]	1.5849625007211563	4	1	0	0
23567	1520	phosphorylation on serine 32	[phosphorylation on serines 32]	1.5849625007211563	4	1	0	0
23568	1520	use fluorogenic peptide assay	[using fluorogenic peptide assays]	1.5849625007211563	4	1	0	0
23569	1520	substantial proportion of patient	[substantial proportion of patients]	1.5849625007211563	4	1	0	0
23570	1520	NF-kappaB binding complex	[NF-kappaB binding complex]	1.5849625007211563	3	1	0	0
23571	1520	cell line u-937	[cell lines U-937]	1.5849625007211563	3	2	2	2
23572	1520	population of immature thymocyte	[population of immature thymocytes]	1.5849625007211563	4	1	0	0
23573	1520	autopresentation of native peptide	[autopresentation of native peptide]	1.5849625007211563	4	1	0	0
23574	1520	lack intrinsic kinase activity	[lacking intrinsic kinase activity]	1.5849625007211563	4	1	0	0
23575	1520	Epstein-Barr virus sm protein	[Epstein-Barr virus SM protein]	1.5849625007211563	4	1	0	0
23576	1520	nadph oxidase p47(phox)	[NADPH oxidase p47(phox)]	1.5849625007211563	3	1	0	0
23577	1520	suggest phosphorylation antecedent activation	[suggesting phosphorylation antecedent activation]	1.5849625007211563	4	1	0	0
23578	1520	retrievable alveolar macrophage	[retrievable alveolar macrophages]	1.5849625007211563	3	1	0	0
23579	1520	familial tuberous sclerosis	[familial tuberous sclerosis]	1.5849625007211563	3	1	0	0
23580	1520	transcription factor C/EBPbeta NF-IL6	[transcription factors C/EBPbeta NF-IL6]	1.5849625007211563	4	1	0	0
23581	1520	different th cell subsets.	[different Th cell subsets.]	1.5849625007211563	4	1	0	0
23582	1520	t-cell-specific response element TCE	[T-cell-specific response element TCE]	1.5849625007211563	4	1	0	0
23583	1520	VitD3 receptor VDR	[VitD3 receptor VDR]	1.5849625007211563	3	1	0	0
23584	1520	quiescent cd4(+) t-cell activation	[quiescent CD4(+) T-cell activation]	1.5849625007211563	4	1	0	0
23585	1520	effect of 18c7	[effect of 18C7]	1.5849625007211563	3	1	0	0
23586	1520	promyelocyte stage cell	[promyelocyte stage cells]	1.5849625007211563	3	1	0	0
23587	1520	sensitize target cell lysis,	[sensitizing target cell lysis,]	1.5849625007211563	4	1	0	0
23588	1520	NF kappa B2 effect	[NF kappa B2 effect]	1.5849625007211563	4	1	0	0
23589	1520	prior steroid treatment	[prior steroid treatments]	1.5849625007211563	3	1	0	0
23590	1520	induction of STAT3	[Induction of STAT3]	1.5849625007211563	3	1	0	0
23591	1520	condition, binding characteristic	[condition, binding characteristics]	1.5849625007211563	3	1	0	0
23592	1520	induction of endotoxin tolerance	[induction of endotoxin tolerance]	1.5849625007211563	4	1	0	0
23593	1520	lysis of CEM cell	[lysis of CEM cells]	1.5849625007211563	4	1	0	0
23594	1520	e29.1 T cell hybridoma	[E29.1 T cell hybridoma]	1.5849625007211563	4	1	0	0
23595	1520	monoclonal antibody against c-fos.	[monoclonal antibody against c-fos.]	1.5849625007211563	4	1	0	0
23596	1520	NF-kappa b protein	[NF-kappa B proteins]	1.5849625007211563	3	2	1	1
23597	1520	live k562 cell	[living K562 cells]	1.5849625007211563	3	1	0	0
23598	1520	mu enhancer DNA	[mu enhancer DNA]	1.5849625007211563	3	1	0	0
23599	1520	steroid hormone receptor family	[steroid hormone receptor family]	1.5849625007211563	4	1	0	0
23600	1520	gamma-globin-expressing k562 cell	[gamma-globin-expressing K562 cells]	1.5849625007211563	3	1	0	0
23601	1520	measurement of plasma aldosterone	[measurement of plasma aldosterone]	1.5849625007211563	4	1	0	0
23602	1520	hiv infection in cell	[HIV infection in cells]	1.5849625007211563	4	1	0	0
23603	1520	interferon consensus sequence icss	[interferon consensus sequences ICSs]	1.5849625007211563	4	1	0	0
23604	1520	30 minute after stimulation.	[30 min after stimulation.]	1.5849625007211563	4	1	0	0
23605	1520	development of pre-T cell	[development of pre-T cells]	1.5849625007211563	4	1	0	0
23606	1520	progression of leukemia	[progression of leukemias]	1.5849625007211563	3	1	0	0
23607	1520	50 kda subunit	[50 kDa subunit]	1.5849625007211563	3	1	0	0
23608	1520	combination of inhibitors,	[combination of inhibitors,]	1.5849625007211563	3	1	0	0
23609	1520	response to self antigens.	[response to self antigens.]	1.5849625007211563	4	1	0	0
23610	1520	hormone for 3 h	[hormone for 3 h]	1.5849625007211563	4	1	0	0
23611	1520	cystic fibrosis (cf) patient	[Cystic fibrosis (CF) patients]	1.5849625007211563	4	1	0	0
23612	1520	exposure to phorbol ester	[exposure to phorbol esters]	1.5849625007211563	4	1	0	0
23613	1520	increase body of evidence	[increasing body of evidence]	1.5849625007211563	4	1	0	0
23614	1520	kappab -dependent reporter assay	[kappaB -dependent reporter assays]	1.5849625007211563	4	1	0	0
23615	1520	binding of repressor protein	[binding of repressor proteins]	1.5849625007211563	4	1	0	0
23616	1520	region of DNA	[region of DNA]	1.5849625007211563	3	1	0	0
23617	1520	several spxx motif	[several SPXX motifs]	1.5849625007211563	3	1	0	0
23618	1520	expression of gcr-beta	[expression of GCR-beta]	1.5849625007211563	3	1	0	0
23619	1520	human b cell precursor	[human B cell precursor]	1.5849625007211563	4	1	0	0
23620	1520	other ATL cell	[other ATL cells]	1.5849625007211563	3	1	0	0
23621	1520	intracellular free calcium concentration	[intracellular free calcium concentration]	1.5849625007211563	4	2	1	1
23622	1520	vitro binding assay.	[vitro binding assay.]	1.5849625007211563	3	1	0	0
23623	1520	affect nf-kappab binding activity,	[affecting NF-kappaB binding activity,]	1.5849625007211563	4	1	0	0
23624	1520	b cell membrane	[B cell membrane]	1.5849625007211563	3	2	1	1
23625	1520	express b cell	[expressing B cells]	1.5849625007211563	3	1	0	0
23626	1520	CD3 receptor in Jurkat	[CD3 receptors in Jurkat]	1.5849625007211563	4	1	0	0
23627	1520	transcription factor egr-1 activity	[Transcription factor Egr-1 activity]	1.5849625007211563	4	1	0	0
23628	1520	contain this two domain	[containing these two domains]	1.5849625007211563	4	1	0	0
23629	1520	activation of STAT6	[activation of STAT6]	1.5849625007211563	3	2	1	1
23630	1520	nature of the subunit	[nature of the subunit]	1.5849625007211563	4	1	0	0
23631	1520	introduction of point mutation	[Introduction of point mutations]	1.5849625007211563	4	1	0	0
23632	1520	cell/monocyte surface antigen	[cell/monocyte surface antigen]	1.5849625007211563	3	1	0	0
23633	1520	imply a functional defect	[implying a functional defect]	1.5849625007211563	4	1	0	0
23634	1520	spontaneous m2 blast cell	[spontaneous M2 blast cells]	1.5849625007211563	4	1	0	0
23635	1520	response to mitogenic stimulation	[response to mitogenic stimulation]	1.5849625007211563	4	2	1	1
23636	1520	IL-1 -dependent manner	[IL-1 -dependent manner]	1.5849625007211563	3	1	0	0
23637	1520	receptor dimerization process and/or	[receptor dimerization process and/or]	1.5849625007211563	4	1	0	0
23638	1520	key immediate-early protein	[key immediate-early protein]	1.5849625007211563	3	1	0	0
23639	1520	contain the hiv-1 enhancer	[containing the HIV-1 enhancer]	1.5849625007211563	4	1	0	0
23640	1520	retinoic acid receptor action	[retinoic acid receptor action]	1.5849625007211563	4	1	0	0
23641	1520	evening exposure to mp	[evening exposure to MP]	1.5849625007211563	4	1	0	0
23642	1520	important secretory/transport functions.	[important secretory/transport functions.]	1.5849625007211563	3	1	0	0
23643	1520	cyclin kinase inhibitor p21/cip1	[cyclin kinase inhibitor p21/Cip1]	1.5849625007211563	4	1	0	0
23644	1520	novel ventilatory strategy	[novel ventilatory strategies]	1.5849625007211563	3	1	0	0
23645	1520	RA (100 nm)	[RA (100 nM)]	1.5849625007211563	3	1	0	0
23646	1520	variety of signal	[variety of signals]	1.5849625007211563	3	2	1	1
23647	1520	U1 promonocytic cell	[U1 promonocytic cells]	1.5849625007211563	3	1	0	0
23648	1520	ne of cathepsin g	[NE of cathepsin G]	1.5849625007211563	4	1	0	0
23649	1520	p130 form 3	[p130 Form 3]	1.5849625007211563	3	2	1	1
23650	1520	pou domain of Oct1	[POU domains of Oct1]	1.5849625007211563	4	1	0	0
23651	1520	use tetanus toxoid	[using tetanus toxoid]	1.5849625007211563	3	1	0	0
23652	1520	selection of stable lmp1	[selection of stable LMP1]	1.5849625007211563	4	1	0	0
23653	1520	NK cell-target cell interaction	[NK cell-target cell interaction]	1.5849625007211563	4	1	0	0
23654	1520	general transcription machinery	[general transcription machinery]	1.5849625007211563	3	1	0	0
23655	1520	vitro administration of il-2	[vitro administration of IL-2]	1.5849625007211563	4	1	0	0
23656	1520	model system of induction	[model system of induction]	1.5849625007211563	4	1	0	0
23657	1520	t-cell-specific transcriptional regulator	[T-cell-specific transcriptional regulator]	1.5849625007211563	3	1	0	0
23658	1520	similar set of gene	[similar sets of genes]	1.5849625007211563	4	1	0	0
23659	1520	accumulation of icam-1 mrna	[accumulation of ICAM-1 mRNA]	1.5849625007211563	4	1	0	0
23660	1520	14.6 +/- 3.7%	[14.6 +/- 3.7%]	1.5849625007211563	3	1	0	0
23661	1520	GATA-3 -dependent enhancer activity	[GATA-3 -dependent enhancer activity]	1.5849625007211563	4	1	0	0
23662	1520	cytotoxicity assay use t-lymphocyte	[cytotoxicity assays using T-lymphocytes]	1.5849625007211563	4	1	0	0
23663	1520	absence of neutrophil differentiation	[absence of neutrophil differentiation]	1.5849625007211563	4	1	0	0
23664	1520	t-cell clone specific	[T-cell clone specific]	1.5849625007211563	3	2	1	1
23665	1520	four isoform of WT1	[four isoforms of WT1]	1.5849625007211563	4	1	0	0
23666	1520	tradd mutant consist	[TRADD mutant consisting]	1.5849625007211563	3	1	0	0
23667	1520	CD40 -dependent b	[CD40 -dependent B]	1.5849625007211563	3	1	0	0
23668	1520	herpes simplex tegument protein	[herpes simplex tegument proteins]	1.5849625007211563	4	1	0	0
23669	1520	non-rheumatoid arthritis example, osteoarthritis	[non-rheumatoid arthritis example, osteoarthritis]	1.5849625007211563	4	1	0	0
23670	1520	mutationally active pkc -alpha	[mutationally active PKC -alpha]	1.5849625007211563	4	1	0	0
23671	1520	opioid effect on lymphocyte	[opioid effects on lymphocytes]	1.5849625007211563	4	1	0	0
23672	1520	anti-CD3-activated human T lymphocyte	[anti-CD3-activated human T lymphocytes]	1.5849625007211563	4	2	2	2
23673	1520	response to C. neoforman	[response to C. neoformans]	1.5849625007211563	4	1	0	0
23674	1520	transient assay in monocyte	[transient assays in monocyte]	1.5849625007211563	4	1	0	0
23675	1520	elderly (mean 78 years)	[elderly (mean 78 years)]	1.5849625007211563	4	1	0	0
23676	1520	negative feedback of cortisol	[negative feedback of cortisol]	1.5849625007211563	4	1	0	0
23677	1520	response to trigger	[response to triggering]	1.5849625007211563	3	1	0	0
23678	1520	icenko- cushingd' syndrome	[Icenko- Cushing's syndrome]	1.5849625007211563	3	2	2	2
23679	1520	>10(-10) mol/L for pbmc	[>10(-10) mol/L for PBMC]	1.5849625007211563	4	1	0	0
23680	1520	3 transcription initiation	[3 transcription initiation]	1.5849625007211563	3	1	0	0
23681	1520	light of the evidence	[light of the evidence]	1.5849625007211563	4	1	0	0
23682	1520	identification of this gene	[identification of this gene]	1.5849625007211563	4	1	0	0
23683	1520	effect of Bcl-2	[effects of Bcl-2]	1.5849625007211563	3	1	0	0
23684	1520	respond to any peptide	[responding to any peptide]	1.5849625007211563	4	2	2	2
23685	1520	contrast, T cell	[contrast, T cells]	1.5849625007211563	3	2	2	2
23686	1520	further mapping purposes,	[further mapping purposes,]	1.5849625007211563	3	1	0	0
23687	1520	ability of the receptor	[ability of the receptor]	1.5849625007211563	4	2	1	1
23688	1520	important immunoregulatory hormone	[important immunoregulatory hormone]	1.5849625007211563	3	1	0	0
23689	1520	tumor estrogen/progesterone receptor status	[tumor estrogen/progesterone receptor status]	1.5849625007211563	4	1	0	0
23690	1520	actively secret prl	[actively secreting PRL]	1.5849625007211563	3	1	0	0
23691	1520	b-cell-specific coactivator oca-b	[B-cell-specific coactivator OCA-B]	1.5849625007211563	3	2	1	1
23692	1520	integral role in pathogenesis.	[integral role in pathogenesis.]	1.5849625007211563	4	1	0	0
23693	1520	sign of renal dysplasia	[signs of renal dysplasia]	1.5849625007211563	4	1	0	0
23694	1520	region of E2A	[region of E2A]	1.5849625007211563	3	2	2	2
23695	1520	contain trace element preparation	[containing trace element preparation]	1.5849625007211563	4	1	0	0
23696	1520	variety of lymphoid cell	[variety of lymphoid cells]	1.5849625007211563	4	1	0	0
23697	1520	activity, a enzyme	[activity, an enzyme]	1.5849625007211563	3	1	0	0
23698	1520	cd28re /ap-1-specific complex	[CD28RE /AP-1-specific complex]	1.5849625007211563	3	1	0	0
23699	1520	IL-2 receptor complex	[IL-2 receptor complex]	1.5849625007211563	3	1	0	0
23700	1520	cytokine gene cluster	[cytokine gene cluster]	1.5849625007211563	3	1	0	0
23701	1520	endothelial cell EC	[Endothelial cells EC]	1.5849625007211563	3	1	0	0
23702	1520	5' flanking sequence	[5' flanking sequence]	1.5849625007211563	3	2	1	1
23703	1520	treatment of cystic fibrosis	[treatment of cystic fibrosis]	1.5849625007211563	4	1	0	0
23704	1520	hence, integration of signal	[Hence, integration of signals]	1.5849625007211563	4	1	0	0
23705	1520	unilateral x inactivation	[unilateral X inactivation]	1.5849625007211563	3	1	0	0
23706	1520	ability of ErbB	[ability of ErbB]	1.5849625007211563	3	1	0	0
23707	1520	activation of a pathway	[activation of an pathway]	1.5849625007211563	4	2	1	1
23708	1520	Oct-2 -dependent transactivation	[Oct-2 -dependent transactivation]	1.5849625007211563	3	1	0	0
23709	1520	transcriptional level by dexamethasone	[transcriptional level by dexamethasone]	1.5849625007211563	4	1	0	0
23710	1520	ifn-gamma responsive element GIRE	[IFN-gamma responsive element GIRE]	1.5849625007211563	4	1	0	0
23711	1520	mrna level in monocyte	[mRNA level in monocytes]	1.5849625007211563	4	1	0	0
23712	1520	binding property to dna-cellulose	[Binding properties to DNA-cellulose]	1.5849625007211563	4	1	0	0
23713	1520	cell express wild-type tdag51	[cells expressing wild-type TDAG51]	1.5849625007211563	4	1	0	0
23714	1520	human cd44 promoter	[human CD44 promoter]	1.5849625007211563	3	1	0	0
23715	1520	stat family member	[STAT family member]	1.5849625007211563	3	2	2	2
23716	1520	E1 ad vector	[E1 Ad vectors]	1.5849625007211563	3	1	0	0
23717	1520	nuclear CaM kinase ii	[nuclear CaM kinase II]	1.5849625007211563	4	1	0	0
23718	1520	protein phosphorylation pattern	[protein phosphorylation pattern]	1.5849625007211563	3	2	1	1
23719	1520	moreover, anti- STAT3 antibody	[Moreover, anti- STAT3 antibodies]	1.5849625007211563	4	1	0	0
23720	1520	induce gene transcription	[inducing gene transcription]	1.5849625007211563	3	1	0	0
23721	1520	activation of macrophage	[Activation of macrophages]	1.5849625007211563	3	2	2	2
23722	1520	sustain the expression	[sustaining the expression]	1.5849625007211563	3	1	0	0
23723	1520	several dna-binding protein	[Several DNA-binding proteins]	1.5849625007211563	3	1	0	0
23724	1520	nf-kb activation in thymocyte	[NF-kB activation in thymocytes]	1.5849625007211563	4	1	0	0
23725	1520	pathogenesis of sepsis syndrome	[pathogenesis of sepsis syndrome]	1.5849625007211563	4	1	0	0
23726	1520	gamma chain of fc	[gamma chain of Fc]	1.5849625007211563	4	1	0	0
23727	1520	mutation of y113	[mutation of Y113]	1.5849625007211563	3	1	0	0
23728	1520	carboxy-terminal domain of Oct2	[carboxy-terminal domain of Oct2]	1.5849625007211563	4	1	0	0
23729	1520	mycobacterium tuberculosis lipoarabinomannan	[Mycobacterium tuberculosis lipoarabinomannan]	1.5849625007211563	3	1	0	0
23730	1520	early disease onset,	[early disease onset,]	1.5849625007211563	3	1	0	0
23731	1520	gamma-globin expression upon repression,	[gamma-globin expression upon repression,]	1.5849625007211563	4	1	0	0
23732	1520	capsid antigen vca	[capsid antigen VCA]	1.5849625007211563	3	2	2	2
23733	1520	proteasome inhibitor psi	[proteasome inhibitor PSI]	1.5849625007211563	3	1	0	0
23734	1520	highly active ocim1 cell	[highly active OCIM1 cells]	1.5849625007211563	4	1	0	0
23735	1520	mouse hematopoietic tissue	[mouse hematopoietic tissues]	1.5849625007211563	3	1	0	0
23736	1520	monocytic specific promoter activity	[monocytic specific promoter activity]	1.5849625007211563	4	1	0	0
23737	1520	two ATL patient	[two ATL patients]	1.5849625007211563	3	1	0	0
23738	1520	HUVEC adhesion molecule	[HUVEC adhesion molecules]	1.5849625007211563	3	1	0	0
23739	1520	control in T cell	[control in T cells]	1.5849625007211563	4	2	1	1
23740	1520	expression of a protein	[expression of an protein]	1.5849625007211563	4	2	2	2
23741	1520	autokinase activity of jak3	[autokinase activity of JAK3]	1.5849625007211563	4	1	0	0
23742	1520	episode of bacterial infection	[episodes of bacterial infections]	1.5849625007211563	4	1	0	0
23743	1520	inhibit hiv replication	[inhibiting HIV replication]	1.5849625007211563	3	1	0	0
23744	1520	tfiia expression vector	[TFIIA expression vectors]	1.5849625007211563	3	1	0	0
23745	1520	normal T cell development	[normal T cell development]	1.5849625007211563	4	1	0	0
23746	1520	mantle zone b cell	[mantle zone B cells]	1.5849625007211563	4	2	1	1
23747	1520	2 intron of 1211	[2 introns of 1211]	1.5849625007211563	4	1	0	0
23748	1520	human il-1beta promoter	[human IL-1beta promoter]	1.5849625007211563	3	2	1	1
23749	1520	NF-kappa b/rel/nfat transcription factor	[NF-kappa B/Rel/NFAT transcription factors]	1.5849625007211563	4	1	0	0
23750	1520	EB1 -responsive element	[EB1 -responsive element]	1.5849625007211563	3	2	2	2
23751	1520	effect on the transcription	[effect on the transcription]	1.5849625007211563	4	2	2	2
23752	1520	degree of the defect	[degree of the defect]	1.5849625007211563	4	1	0	0
23753	1520	2 h in PBL	[2 h in PBL]	1.5849625007211563	4	1	0	0
23754	1520	prior to atrophy	[prior to atrophy]	1.5849625007211563	3	1	0	0
23755	1520	symptom of ptsd	[symptoms of PTSD]	1.5849625007211563	3	1	0	0
23756	1520	normal b cell differentiation	[normal B cell differentiation]	1.5849625007211563	4	1	0	0
23757	1520	hemopoietic growth factor	[hemopoietic growth factor]	1.5849625007211563	3	2	1	1
23758	1520	CsA -sensitive transcription	[CsA -sensitive transcription]	1.5849625007211563	3	1	0	0
23759	1520	putative p13mtcp1 protein	[putative p13MTCP1 protein]	1.5849625007211563	3	1	0	0
23760	1520	only sigm -crosslinking	[only sIgM -crosslinking]	1.5849625007211563	3	1	0	0
23761	1520	consensus sequence 5'-gttacgtaat-3'	[consensus sequence 5'-GTTACGTAAT-3']	1.5849625007211563	3	1	0	0
23762	1520	induction of sp1 phosphorylation	[Induction of Sp1 phosphorylation]	1.5849625007211563	4	1	0	0
23763	1520	plasmodium vivax malaria parasite	[Plasmodium vivax malaria parasite]	1.5849625007211563	4	1	0	0
23764	1520	insulin receptor substrate (irs)-1	[insulin receptor substrate (IRS)-1]	1.5849625007211563	4	1	0	0
23765	1520	ability of b cell	[ability of B cells]	1.5849625007211563	4	1	0	0
23766	1520	non- lymphoid cell	[non- lymphoid cells]	1.5849625007211563	3	1	0	0
23767	1520	weak RBP-Jkappa -binding site	[weak RBP-Jkappa -binding site]	1.5849625007211563	4	1	0	0
23768	1520	two allele t1	[two alleles T1]	1.5849625007211563	3	1	0	0
23769	1520	viral lytic cycle promoter	[viral lytic cycle promoters]	1.5849625007211563	4	1	0	0
23770	1520	growth regulation during differentiation	[Growth regulation during differentiation]	1.5849625007211563	4	1	0	0
23771	1520	disease susceptibility markers,	[disease susceptibility markers,]	1.5849625007211563	3	1	0	0
23772	1520	interferon-gamma-treated u937 IFN-U937 cell	[interferon-gamma-treated U937 IFN-U937 cells]	1.5849625007211563	4	1	0	0
23773	1520	gcr bind affinity	[GCR binding affinity]	1.5849625007211563	3	1	0	0
23774	1520	Peripheral blood t-cell	[Peripheral blood T-cells]	1.5849625007211563	3	1	0	0
23775	1520	b- cell line	[B- cell lines]	1.5849625007211563	3	1	0	0
23776	1520	rdna encode octamer-binding protein	[cDNAs encoding octamer-binding proteins]	1.5849625007211563	4	1	0	0
23777	1520	presence of e1a sequences.	[presence of E1a sequences.]	1.5849625007211563	4	1	0	0
23778	1520	incidence of leukemic relapse	[incidence of leukemic relapse]	1.5849625007211563	4	2	1	1
23779	1520	estrogen receptor antagonists,	[estrogen receptor antagonists,]	1.5849625007211563	3	1	0	0
23780	1520	level of nfkappab	[levels of NFkappaB]	1.5849625007211563	3	1	0	0
23781	1520	loss of stat1 analogous	[loss of STAT1 analogous]	1.5849625007211563	4	1	0	0
23782	1520	NB4 APL cell line	[NB4 APL cell line]	1.5849625007211563	4	1	0	0
23783	1520	incubation of human blood	[Incubation of human blood]	1.5849625007211563	4	2	2	2
23784	1520	Rac-1 signal pathway	[Rac-1 signaling pathways]	1.5849625007211563	3	2	1	1
23785	1520	sensitive target k562	[sensitive target K562]	1.5849625007211563	3	1	0	0
23786	1520	two distinct stimuli, tcr	[two distinct stimuli, TCR]	1.5849625007211563	4	1	0	0
23787	1520	marker of erythroid differentiation	[marker of erythroid differentiation]	1.5849625007211563	4	1	0	0
23788	1520	affect calcineurin phosphatase activity	[affecting calcineurin phosphatase activity]	1.5849625007211563	4	1	0	0
23789	1520	changes, include the induction	[changes, including the induction]	1.5849625007211563	4	1	0	0
23790	1520	cellular protein tyrosine kinase	[cellular protein tyrosine kinases]	1.5849625007211563	4	1	0	0
23791	1520	phorbol ester response	[phorbol ester response]	1.5849625007211563	3	1	0	0
23792	1520	dose of 4,	[doses of 4,]	1.5849625007211563	3	1	0	0
23793	1520	transcription specific difference	[Transcription specific differences]	1.5849625007211563	3	1	0	0
23794	1520	even in serum	[even in serum]	1.5849625007211563	3	1	0	0
23795	1520	transcriptional regulator in turn	[transcriptional regulators in turn]	1.5849625007211563	4	1	0	0
23796	1520	transcriptional activation by BSAP	[transcriptional activation by BSAP]	1.5849625007211563	4	1	0	0
23797	1520	DNA response element tr2re-sv40	[DNA response element TR2RE-SV40]	1.5849625007211563	4	1	0	0
23798	1520	treatment with lps	[treatment with LPS]	1.5849625007211563	3	1	0	0
23799	1520	late) after activation.	[late) after activation.]	1.5849625007211563	3	1	0	0
23800	1520	addition of cycloheximide	[addition of cycloheximide]	1.5849625007211563	3	1	0	0
23801	1520	two distinct subgroups, protein	[two distinct subgroups, proteins]	1.5849625007211563	4	1	0	0
23802	1520	eosinophil in hematopoietic cell	[eosinophils in hematopoietic cells]	1.5849625007211563	4	1	0	0
23803	1520	Wnt signal cascade	[Wnt signaling cascade]	1.5849625007211563	3	1	0	0
23804	1520	type of tnf receptor	[types of TNF receptors]	1.5849625007211563	4	1	0	0
23805	1520	two anti-CD3 mab	[two anti-CD3 mAbs]	1.5849625007211563	3	1	0	0
23806	1520	p53 protein expression	[p53 protein expression]	1.5849625007211563	3	1	0	0
23807	1520	anti-tumor immune response	[anti-tumor immune response]	1.5849625007211563	3	1	0	0
23808	1520	translocation of hGR	[translocation of hGR]	1.5849625007211563	3	1	0	0
23809	1520	hsv-specific T cell clone	[HSV-specific T cell clone]	1.5849625007211563	4	1	0	0
23810	1520	nre via repression	[NRE via repression]	1.5849625007211563	3	1	0	0
23811	1520	highly productive infection	[highly productive infection]	1.5849625007211563	3	1	0	0
23812	1520	include the coup protein	[including the COUP protein]	1.5849625007211563	4	1	0	0
23813	1520	erythroid alas precursor protein	[erythroid ALAS precursor protein]	1.5849625007211563	4	1	0	0
23814	1520	proliferation of cd34+ cell	[proliferation of CD34+ cells]	1.5849625007211563	4	1	0	0
23815	1520	lack of PMA induction	[lack of PMA induction]	1.5849625007211563	4	1	0	0
23816	1520	improvement of antiinflammatory therapy	[improvement of antiinflammatory therapies]	1.5849625007211563	4	1	0	0
23817	1520	human tsp 1 gene	[human TSP 1 gene]	1.5849625007211563	4	2	1	1
23818	1520	Phenylarsine oxide pao	[Phenylarsine oxide PAO]	1.5849625007211563	3	1	0	0
23819	1520	two messenger Ca2+	[two messengers Ca2+]	1.5849625007211563	3	1	0	0
23820	1520	diverse biologic effect	[diverse biologic effects]	1.5849625007211563	3	1	0	0
23821	1520	hla binding motif	[HLA binding motifs]	1.5849625007211563	3	1	0	0
23822	1520	thereby release growth arrest;	[thereby releasing growth arrest;]	1.5849625007211563	4	1	0	0
23823	1520	human GATA-3 gene	[human GATA-3 gene]	1.5849625007211563	3	1	0	0
23824	1520	form, mcp-1 secretion	[form, MCP-1 secretion]	1.5849625007211563	3	1	0	0
23825	1520	monoclonal antibody pg-b6	[monoclonal antibodies PG-B6]	1.5849625007211563	3	1	0	0
23826	1520	contrast, virus reactivation	[contrast, virus reactivation]	1.5849625007211563	3	1	0	0
23827	1520	interleukin gene promoter	[interleukin gene promoter]	1.5849625007211563	3	2	2	2
23828	1520	icsat overexpression in lymphocyte	[ICSAT overexpression in lymphocytes]	1.5849625007211563	4	1	0	0
23829	1520	tyrosine auto/transphosphorylation of JAK3	[tyrosine auto/transphosphorylation of JAK3]	1.5849625007211563	4	1	0	0
23830	1520	immunomodulatory cytokine il-4	[immunomodulatory cytokine IL-4]	1.5849625007211563	3	1	0	0
23831	1520	G1 to S phase	[G1 to S phase]	1.5849625007211563	4	2	1	1
23832	1520	IL-3 CK-1/CK-2 element	[IL-3 CK-1/CK-2 elements]	1.5849625007211563	3	1	0	0
23833	1520	relationship of IBR	[relationship of IBR]	1.5849625007211563	3	1	0	0
23834	1520	other monocytic gene tnf-alpha	[other monocytic genes TNF-alpha]	1.5849625007211563	4	1	0	0
23835	1520	pre-B leukemia cell Nalm-6	[pre-B leukemia cells Nalm-6]	1.5849625007211563	4	1	0	0
23836	1520	human myeloperoxidase promoter	[human myeloperoxidase promoters]	1.5849625007211563	3	1	0	0
23837	1520	rheumatoid arthritis RA patient	[rheumatoid arthritis RA patients]	1.5849625007211563	4	1	0	0
23838	1520	role of ap-1-	[Role of AP-1-]	1.5849625007211563	3	1	0	0
23839	1520	transcription factor sp-1	[transcription factor SP-1]	1.5849625007211563	3	1	0	0
23840	1520	ALG-4F a transcript	[ALG-4F a transcript]	1.5849625007211563	3	1	0	0
23841	1520	structurally related retroviruse	[structurally related retroviruses]	1.5849625007211563	3	1	0	0
23842	1520	increase in the proteins.	[increase in the proteins.]	1.5849625007211563	4	1	0	0
23843	1520	antagonistic anti-tr55 antibody	[antagonistic anti-TR55 antibody]	1.5849625007211563	3	1	0	0
23844	1520	use of recombinant retroviruse	[use of recombinant retroviruses]	1.5849625007211563	4	1	0	0
23845	1520	nf kappab activity	[NF kappaB activity]	1.5849625007211563	3	1	0	0
23846	1520	administer mp in doses.	[administering MP in doses.]	1.5849625007211563	4	1	0	0
23847	1520	include peripheral blood monocyte	[including peripheral blood monocytes]	1.5849625007211563	4	1	0	0
23848	1520	patient with hiv-1 infection.	[patients with HIV-1 infection.]	1.5849625007211563	4	1	0	0
23849	1520	normal RAR alpha	[normal RAR alpha]	1.5849625007211563	3	1	0	0
23850	1520	common progenitor cell,	[common progenitor cell,]	1.5849625007211563	3	1	0	0
23851	1520	presence of tryptophan	[presence of tryptophan]	1.5849625007211563	3	1	0	0
23852	1520	kinetic relative to p65	[kinetics relative to p65]	1.5849625007211563	4	1	0	0
23853	1520	interferon-gamma activation sequence	[interferon-gamma activation sequence]	1.5849625007211563	3	2	1	1
23854	1520	aldosterone on electrolyte	[aldosterone on electrolytes]	1.5849625007211563	3	2	2	2
23855	1520	use the available mab	[using the available mAb]	1.5849625007211563	4	1	0	0
23856	1520	employ the -605 motif	[employing the -605 motif]	1.5849625007211563	4	1	0	0
23857	1520	myristic acetate PMA	[myristic acetate PMA]	1.5849625007211563	3	1	0	0
23858	1520	M0/M1 leukemic cell	[M0/M1 leukemic cells]	1.5849625007211563	3	1	0	0
23859	1520	constitutive inducible expression	[constitutive inducible expression]	1.5849625007211563	3	1	0	0
23860	1520	overnight 1-mg dexamethasone test	[overnight 1-mg dexamethasone test]	1.5849625007211563	4	1	0	0
23861	1520	anti-cd3-induced c-rel expression	[anti-CD3-induced c-Rel expression]	1.5849625007211563	3	1	0	0
23862	1520	nervous system cell	[nervous system cells]	1.5849625007211563	3	2	2	2
23863	1520	patient suffer from depression	[patients suffering from depression]	1.5849625007211563	4	1	0	0
23864	1520	leukemic cell differentiation	[leukemic cell differentiation]	1.5849625007211563	3	1	0	0
23865	1520	variety of animal model	[variety of animal models]	1.5849625007211563	4	1	0	0
23866	1520	adhesion molecule-1 on cell	[adhesion molecule-1 on cells]	1.5849625007211563	4	2	2	2
23867	1520	inflammatory response of ECs	[inflammatory responses of ECs]	1.5849625007211563	4	1	0	0
23868	1520	organizer of gene expression	[organizer of gene expression]	1.5849625007211563	4	1	0	0
23869	1520	correlation in cushingd' disease	[correlation in Cushing's disease]	1.5849625007211563	4	1	0	0
23870	1520	have no effect.	[having no effect.]	1.5849625007211563	3	1	0	0
23871	1520	age of 25	[ages of 25]	1.5849625007211563	3	1	0	0
23872	1520	ebv producer cell line	[EBV producer cell line]	1.5849625007211563	4	1	0	0
23873	1520	class ii- clip complex	[class II- CLIP complexes]	1.5849625007211563	4	1	0	0
23874	1520	human lymphotropic virus type	[human lymphotropic virus type]	1.5849625007211563	4	2	2	2
23875	1520	lack thereof) to gliadin	[lack thereof) to gliadins]	1.5849625007211563	4	1	0	0
23876	1520	different jak kinase	[different JAK kinases]	1.5849625007211563	3	1	0	0
23877	1520	DR alpha proximal promoter	[DR alpha proximal promoter]	1.5849625007211563	4	1	0	0
23878	1520	nf-il-6 DNA binding activity	[NF-IL-6 DNA binding activity]	1.5849625007211563	4	1	0	0
23879	1520	NF-kappa b )/rel protein	[NF-kappa B )/Rel proteins]	1.5849625007211563	4	1	0	0
23880	1520	growth of nb4 cell	[growth of NB4 cells]	1.5849625007211563	4	1	0	0
23881	1520	dimerization of the receptor.	[dimerization of the receptor.]	1.5849625007211563	4	1	0	0
23882	1520	RelA.p50 NF-kappa b heterodimer	[RelA.p50 NF-kappa B heterodimer]	1.5849625007211563	4	1	0	0
23883	1520	promyelocyte (mpro) stage	[promyelocyte (MPRO) stages]	1.5849625007211563	3	1	0	0
23884	1520	part due to enzyme	[part due to enzymes]	1.5849625007211563	4	1	0	0
23885	1520	T cell -bind factor	[T cells -binding factor]	1.5849625007211563	4	1	0	0
23886	1520	activator of transcription) protein	[activators of transcription) proteins]	1.5849625007211563	4	1	0	0
23887	1520	ribonuclease protection assay	[ribonuclease protection assay]	1.5849625007211563	3	1	0	0
23888	1520	independency of the cr	[independency of the CR]	1.5849625007211563	4	1	0	0
23889	1520	phosphorylation on Rex function	[phosphorylation on Rex function]	1.5849625007211563	4	1	0	0
23890	1520	target for signalling	[targets for signalling]	1.5849625007211563	3	2	2	2
23891	1520	gd of hsv-2	[gD of HSV-2]	1.5849625007211563	3	1	0	0
23892	1520	supershift with anti-STAT antibody	[Supershifts with anti-STAT antibodies]	1.5849625007211563	4	1	0	0
23893	1520	hydroxylamine of dapsone	[hydroxylamine of dapsone]	1.5849625007211563	3	1	0	0
23894	1520	effect on transcriptional activation	[effect on transcriptional activation]	1.5849625007211563	4	2	1	1
23895	1520	binding to oligonucleotide	[binding to oligonucleotides]	1.5849625007211563	3	1	0	0
23896	1520	interaction with inactive calcineurin	[interaction with inactive calcineurin]	1.5849625007211563	4	1	0	0
23897	1520	erbA target gene caii	[erbA target gene CAII]	1.5849625007211563	4	1	0	0
23898	1520	beta subunit transcription factor	[beta subunit transcription factor]	1.5849625007211563	4	1	0	0
23899	1520	express the epor	[expressing the EPOR]	1.5849625007211563	3	2	2	2
23900	1520	consensus ckii site	[consensus CKII sites]	1.5849625007211563	3	1	0	0
23901	1520	panel of human tissue	[panel of human tissues]	1.5849625007211563	4	1	0	0
23902	1520	CREB gene transcript	[CREB gene transcript]	1.5849625007211563	3	1	0	0
23903	1520	constitutive p21ras activity	[constitutive p21ras activity]	1.5849625007211563	3	1	0	0
23904	1520	transduction of activation signal	[transduction of activation signals]	1.5849625007211563	4	1	0	0
23905	1520	use this antibody,	[Using this antibody,]	1.5849625007211563	3	1	0	0
23906	1520	ii-negative human T cell	[II-negative human T cells]	1.5849625007211563	4	1	0	0
23907	1520	trophoblast, fetal antigen	[trophoblast, fetal antigens]	1.5849625007211563	3	1	0	0
23908	1520	okadaic acid treatment	[okadaic acid treatment]	1.5849625007211563	3	1	0	0
23909	1520	addition to activation	[addition to activation]	1.5849625007211563	3	2	2	2
23910	1520	induction of c-jun activation	[induction of c-Jun activation]	1.5849625007211563	4	1	0	0
23911	1520	cd23 mrna by IFN-gamma	[CD23 mRNA by IFN-gamma]	1.5849625007211563	4	1	0	0
23912	1520	influence of nfkappab activity	[influence of NFkappaB activity]	1.5849625007211563	4	1	0	0
23913	1520	development of granulocyte	[development of granulocytes]	1.5849625007211563	3	2	1	1
23914	1520	generation of ap-1 complex	[generation of AP-1 complexes]	1.5849625007211563	4	1	0	0
23915	1520	lymphoid cell line SupT1	[lymphoid cell lines SupT1]	1.5849625007211563	4	1	0	0
23916	1520	change in trans-acting factor	[changes in trans-acting factors]	1.5849625007211563	4	1	0	0
23917	1520	human th2-type lymphocyte	[human Th2-type lymphocytes]	1.5849625007211563	3	1	0	0
23918	1520	nf-kb nuclear translocation	[NF-kB nuclear translocation]	1.5849625007211563	3	1	0	0
23919	1520	retroviral particle transduce tat	[retroviral particles transducing tat]	1.5849625007211563	4	1	0	0
23920	1520	serum- cell culture system	[serum- cell culture system]	1.5849625007211563	4	1	0	0
23921	1520	specific binding to wild-type	[specific binding to wild-type]	1.5849625007211563	4	1	0	0
23922	1520	herpes simplex virus HSV	[herpes simplex virus HSV]	1.5849625007211563	4	1	0	0
23923	1520	cell of hematopoietic	[cells of hematopoietic]	1.5849625007211563	3	1	0	0
23924	1520	RJ2.2.5 DQB gene	[RJ2.2.5 DQB gene]	1.5849625007211563	3	1	0	0
23925	1520	GH inhibitory effect	[GH inhibitory effect]	1.5849625007211563	3	1	0	0
23926	1520	tumor tissue hormone sensitivity	[tumor tissue hormone sensitivity]	1.5849625007211563	4	1	0	0
23927	1520	group of cytokine	[group of cytokines]	1.5849625007211563	3	2	1	1
23928	1520	such as thymidine kinase	[such as thymidine kinase]	1.5849625007211563	4	1	0	0
23929	1520	murine transcription factor PEBP2	[murine transcription factor PEBP2]	1.5849625007211563	4	1	0	0
23930	1520	dephosphorylation of nuclear extract	[dephosphorylation of nuclear extracts]	1.5849625007211563	4	1	0	0
23931	1520	ah receptor complex	[Ah receptor complex]	1.5849625007211563	3	1	0	0
23932	1520	CD40 -inducible gene	[CD40 -inducible gene]	1.5849625007211563	3	1	0	0
23933	1520	lectin-like, gliadin peptide	[lectin-like, gliadin peptides]	1.5849625007211563	3	1	0	0
23934	1520	effector domain of Oct-2a	[effector domains of Oct-2a]	1.5849625007211563	4	1	0	0
23935	1520	VDR /rxr dna-binding complex	[VDR /RXR DNA-binding complexes]	1.5849625007211563	4	1	0	0
23936	1520	dominant control region	[dominant control region]	1.5849625007211563	3	2	2	2
23937	1520	RA regulation of differentiation	[RA regulation of differentiation]	1.5849625007211563	4	1	0	0
23938	1520	pI of 9.5.	[pI of 9.5.]	1.5849625007211563	3	1	0	0
23939	1520	endothelial nos protein	[endothelial NOS protein]	1.5849625007211563	3	1	0	0
23940	1520	experiment in this report	[experiments in this report]	1.5849625007211563	4	1	0	0
23941	1520	monocyte chemoattractant protein-1 secretion	[monocyte chemoattractant protein-1 secretion]	1.5849625007211563	4	1	0	0
23942	1520	previous localization of 15-lo	[previous localization of 15-LO]	1.5849625007211563	4	1	0	0
23943	1520	intracellular domain of IL-4Ralpha	[intracellular domain of IL-4Ralpha]	1.5849625007211563	4	1	0	0
23944	1520	coexpression of tax	[coexpression of Tax]	1.5849625007211563	3	1	0	0
23945	1520	human mammary epithelial cell	[human mammary epithelial cells]	1.5849625007211563	4	2	1	1
23946	1520	il-6 b-cell differentiation	[IL-6 B-cell differentiation]	1.5849625007211563	3	1	0	0
23947	1520	9-cis-retinoic acid 9-cis-ra	[9-cis-retinoic acid 9-cis-RA]	1.5849625007211563	3	1	0	0
23948	1520	intermediary link bcr signal	[intermediary linking BCR signals]	1.5849625007211563	4	1	0	0
23949	1520	same extracellular signal	[same extracellular signal]	1.5849625007211563	3	1	0	0
23950	1520	extracellular hiv-1 tat protein	[extracellular HIV-1 Tat protein]	1.5849625007211563	4	1	0	0
23951	1520	interleukin 2 gene promoter	[interleukin 2 gene promoter]	1.5849625007211563	4	2	2	2
23952	1520	all-tran RA m,	[all-trans RA M,]	1.5849625007211563	3	2	2	2
23953	1520	LMP1 of other lymphycryptoviruss	[LMP1 of other lymphycryptoviruses]	1.5849625007211563	4	1	0	0
23954	1520	basis of cDNA hybridization	[basis of cDNA hybridization]	1.5849625007211563	4	1	0	0
23955	1520	IL-13 activation of STAT6	[IL-13 activation of STAT6]	1.5849625007211563	4	1	0	0
23956	1520	accumulation of mrna	[accumulation of mRNA]	1.5849625007211563	3	2	2	2
23957	1520	X-inactivation pattern circulate pmnc	[X-inactivation patterns circulating PMNCs]	1.5849625007211563	4	1	0	0
23958	1520	expression of anti-sense rna	[expression of anti-sense RNA]	1.5849625007211563	4	1	0	0
23959	1520	Indeed, usa-derived pc2	[Indeed, USA-derived PC2]	1.5849625007211563	3	1	0	0
23960	1520	two DNA-protein complex	[two DNA-protein complexes]	1.5849625007211563	3	1	0	0
23961	1520	early erythroid progenitor cell	[early erythroid progenitor cells]	1.5849625007211563	4	1	0	0
23962	1520	lack the immunodominant antigen	[lacking the immunodominant antigen]	1.5849625007211563	4	1	0	0
23963	1520	disulfide-linked homodimeric glycoprotein	[disulfide-linked homodimeric glycoprotein]	1.5849625007211563	3	1	0	0
23964	1520	augmentation of promoter activity	[augmentation of promoter activity]	1.5849625007211563	4	1	0	0
23965	1520	duration of latency	[duration of latency]	1.5849625007211563	3	1	0	0
23966	1520	immediate-early trans-activator protein	[immediate-early trans-activator protein]	1.5849625007211563	3	2	2	2
23967	1520	metabolic substrate necessary	[metabolic substrates necessary]	1.5849625007211563	3	1	0	0
23968	1520	potential ttg substrate	[potential tTG substrate]	1.5849625007211563	3	1	0	0
23969	1520	histamine Ca2+ ]i rise	[histamine Ca2+ ]i rise]	1.5849625007211563	4	1	0	0
23970	1520	AML1 expression level	[AML1 expression level]	1.5849625007211563	3	1	0	0
23971	1520	early phase of pregnancy	[early phase of pregnancy]	1.5849625007211563	4	1	0	0
23972	1520	sequence of all element	[sequences of all elements]	1.5849625007211563	4	1	0	0
23973	1520	introduction of the mutation	[introduction of the mutation]	1.5849625007211563	4	1	0	0
23974	1520	self-distructed immune response	[self-distructed immune response]	1.5849625007211563	3	1	0	0
23975	1520	FN il-1beta response	[FN IL-1beta response]	1.5849625007211563	3	1	0	0
23976	1520	several other nervous tissue	[several other nervous tissues]	1.5849625007211563	4	1	0	0
23977	1520	von willebrand factor	[von Willebrand factor]	1.5849625007211563	3	2	2	2
23978	1520	contain unmodified asparagine	[containing unmodified asparagine]	1.5849625007211563	3	1	0	0
23979	1520	NF kappa b2 site	[NF kappa B2 site]	1.5849625007211563	4	1	0	0
23980	1520	potent protein phosphatase inhibitor	[potent protein phosphatase inhibitor]	1.5849625007211563	4	1	0	0
23981	1520	major phosphorylation site	[major phosphorylation sites]	1.5849625007211563	3	1	0	0
23982	1520	significant upregulation of binding	[significant upregulation of binding]	1.5849625007211563	4	1	0	0
23983	1520	isotonic nacl solution	[isotonic NaCl solution]	1.5849625007211563	3	1	0	0
23984	1520	nonpituitary prl gene expression	[nonpituitary PRL gene expression]	1.5849625007211563	4	1	0	0
23985	1520	AP-1 factor family	[AP-1 factor family]	1.5849625007211563	3	2	1	1
23986	1520	sublining), cell type,	[sublining), cell type,]	1.5849625007211563	3	1	0	0
23987	1520	GC monocyte apoptosis	[GC monocyte apoptosis]	1.5849625007211563	3	1	0	0
23988	1520	regulation of interleukin-1beta transcription	[Regulation of interleukin-1beta transcription]	1.5849625007211563	4	1	0	0
23989	1520	four specific protein-DNA complex	[Four specific protein-DNA complexes]	1.5849625007211563	4	1	0	0
23990	1520	oncogenicity of human papillomavirus-	[Oncogenicity of human papillomavirus-]	1.5849625007211563	4	1	0	0
23991	1520	primary t-all cell	[primary T-ALL cells]	1.5849625007211563	3	1	0	0
23992	1520	t-cell nucleus nfat regulation	[T-cell nucleus NFAT regulation]	1.5849625007211563	4	1	0	0
23993	1520	21-base pair sequence	[21-base pair sequence]	1.5849625007211563	3	1	0	0
23994	1520	active form of nf-at1	[active form of NF-AT1]	1.5849625007211563	4	1	0	0
23995	1520	plasma for both treatment	[plasma for both treatments]	1.5849625007211563	4	1	0	0
23996	1520	TNF alpha effect	[TNF alpha effect]	1.5849625007211563	3	1	0	0
23997	1520	kappa b-alpha protein	[kappa B-alpha protein]	1.5849625007211563	3	1	0	0
23998	1520	mineralocorticoid in pih	[mineralocorticoids in PIH]	1.5849625007211563	3	1	0	0
23999	1520	proline -rich domain	[proline -rich domain]	1.5849625007211563	3	1	0	0
24000	1520	terminal cell differentiation	[terminal cell differentiation]	1.5849625007211563	3	1	0	0
24001	1520	T lymphocytic phagocytic lineage	[T lymphocytic phagocytic lineage]	1.5849625007211563	4	1	0	0
24002	1520	leukemia zinc finger/	[leukemia zinc finger/]	1.5849625007211563	3	1	0	0
24003	1520	interaction with gcr	[interaction with GcR]	1.5849625007211563	3	1	0	0
24004	1520	proliferation of 47.10 cell	[Proliferation of 47.10 cells]	1.5849625007211563	4	1	0	0
24005	1520	NFAT regulatory domain	[NFAT regulatory domain]	1.5849625007211563	3	1	0	0
24006	1520	egl from non-pregnant endometrium	[eGLs from non-pregnant endometrium]	1.5849625007211563	4	1	0	0
24007	1520	blood estrogen level	[blood estrogen levels]	1.5849625007211563	3	1	0	0
24008	1520	internal ribosomal entry site	[internal ribosomal entry site]	1.5849625007211563	4	2	2	2
24009	1520	putative transactivation domain	[putative transactivation domain]	1.5849625007211563	3	1	0	0
24010	1520	cis-acting DNA element	[cis-acting DNA elements]	1.5849625007211563	3	2	2	2
24011	1520	cell regulatory property	[cell regulatory properties]	1.5849625007211563	3	1	0	0
24012	1520	activity of octamer-dependent promoter	[activity of octamer-dependent promoters]	1.5849625007211563	4	1	0	0
24013	1520	ptdin 3-kinase signal	[PtdIns 3-kinase signals]	1.5849625007211563	3	1	0	0
24014	1520	HLF bzip domain	[HLF bZIP domain]	1.5849625007211563	3	1	0	0
24015	1520	amount of the protein	[amounts of the protein]	1.5849625007211563	4	2	1	1
24016	1520	adhesion to extracellular matrice	[Adhesion to extracellular matrices]	1.5849625007211563	4	1	0	0
24017	1520	stimulation of progesterone	[stimulation of progesterone]	1.5849625007211563	3	1	0	0
24018	1520	govern lineage switch	[governing lineage switching]	1.5849625007211563	3	1	0	0
24019	1520	elucidate the pathophysiological background	[elucidating the pathophysiological background]	1.5849625007211563	4	1	0	0
24020	1520	human full-length il-1beta promoter	[human full-length IL-1beta promoter]	1.5849625007211563	4	1	0	0
24021	1520	life cycle of hcmv	[life cycle of HCMV]	1.5849625007211563	4	1	0	0
24022	1520	translocation into the alpha-locus	[translocation into the alpha-locus]	1.5849625007211563	4	1	0	0
24023	1520	transactivation by CIITA	[Transactivation by CIITA]	1.5849625007211563	3	2	1	1
24024	1520	less infiltrate tumour	[less infiltrating tumours]	1.5849625007211563	3	1	0	0
24025	1520	consequent activation of 4e-bp1	[consequent activation of 4E-BP1]	1.5849625007211563	4	1	0	0
24026	1520	cell cycle regulate protein	[cell cycle regulating proteins]	1.5849625007211563	4	2	1	1
24027	1520	105000- prb form	[105,000- pRB forms]	1.5849625007211563	3	1	0	0
24028	1520	tumorigenic T cell line	[tumorigenic T cell lines]	1.5849625007211563	4	1	0	0
24029	1520	b-acute lymphoblastic leukemia	[B-acute lymphoblastic leukemia]	1.5849625007211563	3	1	0	0
24030	1520	positive correlation 3-o-mg transport	[positive correlation 3-O-MG transport]	1.5849625007211563	4	1	0	0
24031	1520	human fetal progenitor	[human fetal progenitors]	1.5849625007211563	3	1	0	0
24032	1520	nongenomic activity of 125d3	[nongenomic activities of 1,25D3]	1.5849625007211563	4	1	0	0
24033	1520	BamHI W (wp)	[BamHI W (Wp)]	1.5849625007211563	3	1	0	0
24034	1520	inhibitor of th2 proliferation	[inhibitor of Th2 proliferation]	1.5849625007211563	4	1	0	0
24035	1520	transcription factor atf2	[transcription factor ATF2]	1.5849625007211563	3	1	0	0
24036	1520	pattern of band migration	[pattern of band migration]	1.5849625007211563	4	1	0	0
24037	1520	p39c-jun ap-1 activity	[p39c-jun AP-1 activity]	1.5849625007211563	3	1	0	0
24038	1520	Philadelphia chromosome-positive leukemia	[Philadelphia chromosome-positive leukemia]	1.5849625007211563	3	2	2	2
24039	1520	peripheral lymphoid organ	[peripheral lymphoid organs]	1.5849625007211563	3	1	0	0
24040	1520	differentiation of human monocyte	[differentiation of human monocytes]	1.5849625007211563	4	1	0	0
24041	1520	inhibition of stat1 signal	[inhibition of STAT1 signaling]	1.5849625007211563	4	1	0	0
24042	1520	NF-kappaB -dependent gene expression	[NF-kappaB -dependent gene expression]	1.5849625007211563	4	1	0	0
24043	1520	effective biologic inhibitory concentration	[effective biologic inhibitory concentrations]	1.5849625007211563	4	1	0	0
24044	1520	human cell activation	[human cell activation]	1.5849625007211563	3	1	0	0
24045	1520	fragment extend from -643	[fragment extending from -643]	1.5849625007211563	4	1	0	0
24046	1520	role in rdna transcription	[role in rDNA transcription]	1.5849625007211563	4	1	0	0
24047	1520	glutamine-rich activation domain present	[glutamine-rich activation domain present]	1.5849625007211563	4	1	0	0
24048	1520	fk506 binding protein fkbp	[FK506 binding protein FKBP]	1.5849625007211563	4	1	0	0
24049	1520	use of other inhibitors.	[use of other inhibitors.]	1.5849625007211563	4	1	0	0
24050	1520	potential NF-kappaB -binding sequence	[potential NF-kappaB -binding sequence]	1.5849625007211563	4	1	0	0
24051	1520	j biol chem	[J Biol Chem]	1.5849625007211563	3	1	0	0
24052	1520	parent peptide contain asparagine	[parent peptide containing asparagine]	1.5849625007211563	4	1	0	0
24053	1520	addition of differentiation inducer	[addition of differentiation inducers]	1.5849625007211563	4	1	0	0
24054	1520	activation of Egr-1	[activation of Egr-1]	1.5849625007211563	3	1	0	0
24055	1520	Th1 effector function	[Th1 effector functions]	1.5849625007211563	3	1	0	0
24056	1520	increase in stat3 activation	[increase in Stat3 activation]	1.5849625007211563	4	1	0	0
24057	1520	heterodimerization of stat5 isoform	[heterodimerization of STAT5 isoforms]	1.5849625007211563	4	1	0	0
24058	1520	t-cell antigen receptor element	[T-cell antigen receptor element]	1.5849625007211563	4	1	0	0
24059	1520	Negative regulation by HLA-DO	[Negative regulation by HLA-DO]	1.5849625007211563	4	1	0	0
24060	1520	three A1 constitutive protein	[three A1 constitutive proteins]	1.5849625007211563	4	1	0	0
24061	1520	relation to age activity	[relation to age activity]	1.5849625007211563	4	1	0	0
24062	1520	Jun NH2-terminal kinase JNK	[Jun NH2-terminal kinase JNK]	1.5849625007211563	4	1	0	0
24063	1520	clonal pattern of x-inactivation	[clonal pattern of X-inactivation]	1.5849625007211563	4	1	0	0
24064	1520	distinct regulatory domain	[distinct regulatory domains]	1.5849625007211563	3	1	0	0
24065	1520	suppressive action of MPL	[suppressive action of MPL]	1.5849625007211563	4	1	0	0
24066	1520	common DNA sequence	[common DNA sequence]	1.5849625007211563	3	1	0	0
24067	1520	murine gammac promoter gene	[murine gammac promoter gene]	1.5849625007211563	4	1	0	0
24068	1520	human histiocytic u937 cell	[human histiocytic U937 cells]	1.5849625007211563	4	1	0	0
24069	1520	performance in transfection analysis	[performance in transfection analyses]	1.5849625007211563	4	1	0	0
24070	1520	mononuclear cell priming culture	[mononuclear cell priming cultures]	1.5849625007211563	4	1	0	0
24071	1520	inducible c1 protein	[inducible C1 protein]	1.5849625007211563	3	1	0	0
24072	1520	B-cell chronic lymphocytic leukaemias	[B-cell chronic lymphocytic leukaemias]	1.5849625007211563	4	1	0	0
24073	1520	alpha 4 expression	[alpha 4 expression]	1.5849625007211563	3	1	0	0
24074	1520	mediator of inflammatory response,	[mediator of inflammatory response,]	1.5849625007211563	4	1	0	0
24075	1520	only signal molecule	[only signaling molecule]	1.5849625007211563	3	2	1	1
24076	1520	supernatant from alveolar macrophage	[supernatants from alveolar macrophages]	1.5849625007211563	4	1	0	0
24077	1520	mechanism underlie the expression	[mechanisms underlying the expression]	1.5849625007211563	4	1	0	0
24078	1520	major class ii gene	[major class II genes]	1.5849625007211563	4	2	2	2
24079	1520	patient with hie asthma.	[patients with HIE asthma.]	1.5849625007211563	4	1	0	0
24080	1520	serum-free hl60 cell	[serum-free HL60 cells]	1.5849625007211563	3	2	1	1
24081	1520	augmentation of p39c-jun expression	[augmentation of p39c-jun expression]	1.5849625007211563	4	1	0	0
24082	1520	adult mouse tissue	[adult mouse tissues]	1.5849625007211563	3	2	2	2
24083	1520	perennial allergic rhinitis	[perennial allergic rhinitis]	1.5849625007211563	3	2	1	1
24084	1520	intracellular protein expression	[intracellular protein expression]	1.5849625007211563	3	1	0	0
24085	1520	level of hiv-1 expression	[levels of HIV-1 expression]	1.5849625007211563	4	2	1	1
24086	1520	complex with wild-type tlr2	[complexes with wild-type TLR2]	1.5849625007211563	4	1	0	0
24087	1520	identical experiment with intact	[identical experiments with intact]	1.5849625007211563	4	1	0	0
24088	1520	dimeric gata-1 binding site	[dimeric GATA-1 binding site]	1.5849625007211563	4	1	0	0
24089	1520	tcr repertoire selection	[TCR repertoire selection]	1.5849625007211563	3	1	0	0
24090	1520	protein synthesis independent,	[protein synthesis independent,]	1.5849625007211563	3	1	0	0
24091	1520	erythroid factor gata-1	[erythroid factor GATA-1]	1.5849625007211563	3	1	0	0
24092	1520	myocyte-enhancer factor (mef2) group	[myocyte-enhancer factor (MEF2) group]	1.5849625007211563	4	1	0	0
24093	1520	I kappa b-alpha mrna	[I kappa B-alpha mRNA]	1.5849625007211563	4	1	0	0
24094	1520	member of this group	[Members of this group]	1.5849625007211563	4	1	0	0
24095	1520	MHC class I-restricted peptide	[MHC class I-restricted peptide]	1.5849625007211563	4	1	0	0
24096	1520	leukocyte adhesion to cell	[leukocyte adhesion to cells]	1.5849625007211563	4	2	2	2
24097	1520	cd138/ syndecan-1 a proteoglycan	[CD138/ syndecan-1 a proteoglycan]	1.5849625007211563	4	1	0	0
24098	1520	hiv promoter construct	[HIV promoter construct]	1.5849625007211563	3	1	0	0
24099	1520	inhibit interleukin-2 secretion	[inhibiting interleukin-2 secretion]	1.5849625007211563	3	1	0	0
24100	1520	abundant pybf activity	[abundant PYBF activity]	1.5849625007211563	3	1	0	0
24101	1520	plc gamma 1 expression	[PLC gamma 1 expression]	1.5849625007211563	4	1	0	0
24102	1520	48 to 72 h	[48 to 72 h]	1.5849625007211563	4	1	0	0
24103	1520	2 enhancer by ap-1	[2 enhancer by AP-1]	1.5849625007211563	4	1	0	0
24104	1520	dominant negative RhoA mutant	[dominant negative RhoA mutant]	1.5849625007211563	4	1	0	0
24105	1520	high level of beta-globin	[high levels of beta-globin]	1.5849625007211563	4	1	0	0
24106	1520	role of transcriptional regulation	[Role of transcriptional regulation]	1.5849625007211563	4	1	0	0
24107	1520	only positive mechanism	[only positive mechanisms]	1.5849625007211563	3	1	0	0
24108	1520	human tnf gene	[human TNF genes]	1.5849625007211563	3	1	0	0
24109	1520	relative expression of SERCA	[Relative expressions of SERCA]	1.5849625007211563	4	1	0	0
24110	1520	conventional mechanical ventilation	[conventional mechanical ventilation]	1.5849625007211563	3	1	0	0
24111	1520	one 12-bp insert	[one 12-bp insert]	1.5849625007211563	3	1	0	0
24112	1520	competitive antagonist ru38486	[competitive antagonist RU38486]	1.5849625007211563	3	1	0	0
24113	1520	non-syntenic trans-active locus	[non-syntenic trans-active locus]	1.5849625007211563	3	1	0	0
24114	1520	EBV origin of replication	[EBV origin of replication]	1.5849625007211563	4	1	0	0
24115	1520	nf-kappa b -like factor	[NF-kappa B -like factor]	1.5849625007211563	4	2	1	1
24116	1520	chromosome translocation involve sequence	[chromosome translocation involving sequences]	1.5849625007211563	4	1	0	0
24117	1520	transcriptional activation in PBMC	[transcriptional activation in PBMC]	1.5849625007211563	4	1	0	0
24118	1520	E1A -express cell	[E1A -expressing cells]	1.5849625007211563	3	1	0	0
24119	1520	insight into mechanism	[insight into mechanisms]	1.5849625007211563	3	1	0	0
24120	1520	two serine residue present	[two serine residues present]	1.5849625007211563	4	1	0	0
24121	1520	interaction with monocyte	[interaction with monocytes]	1.5849625007211563	3	1	0	0
24122	1520	36-kDa transcription factor yb-1	[36-kDa transcription factor YB-1]	1.5849625007211563	4	1	0	0
24123	1520	pathogenesis of t-pll conditions.	[pathogenesis of T-PLL conditions.]	1.5849625007211563	4	1	0	0
24124	1520	presence of the component	[presence of the component]	1.5849625007211563	4	1	0	0
24125	1520	protein family, highly homologous	[protein family, highly homologous]	1.5849625007211563	4	1	0	0
24126	1520	mzf-1 transcriptional regulatory function	[MZF-1 transcriptional regulatory function]	1.5849625007211563	4	1	0	0
24127	1520	c-rel mrna synthesis	[c-rel mRNA synthesis]	1.5849625007211563	3	1	0	0
24128	1520	additional major protein-DNA interaction	[Additional major protein-DNA interactions]	1.5849625007211563	4	1	0	0
24129	1520	contrast, JNK activation	[contrast, JNK activation]	1.5849625007211563	3	2	1	1
24130	1520	four other transcription factor	[four other transcription factors]	1.5849625007211563	4	1	0	0
24131	1520	several cellular block	[several cellular blocks]	1.5849625007211563	3	1	0	0
24132	1520	RA u937 cell	[RA U937 cells]	1.5849625007211563	3	1	0	0
24133	1520	high lymphocytic infiltration	[high lymphocytic infiltration]	1.5849625007211563	3	1	0	0
24134	1520	inducible cytoplasmic form	[inducible cytoplasmic form]	1.5849625007211563	3	1	0	0
24135	1520	human tfiid protein	[human TFIID protein]	1.5849625007211563	3	2	1	1
24136	1520	gel-shift analysis in HUVECs	[Gel-shift analysis in HUVECs]	1.5849625007211563	4	1	0	0
24137	1520	maximal hiv-1 expression,	[maximal HIV-1 expression,]	1.5849625007211563	3	1	0	0
24138	1520	other bacterial toxin	[Other bacterial toxins]	1.5849625007211563	3	1	0	0
24139	1520	viral gene product	[viral gene products]	1.5849625007211563	3	2	1	1
24140	1520	corresponding messenger rna	[corresponding messenger RNAs]	1.5849625007211563	3	1	0	0
24141	1520	use on section	[Using on sections]	1.5849625007211563	3	1	0	0
24142	1520	ap-1 -DNA binding activity	[AP-1 -DNA binding activity]	1.5849625007211563	4	1	0	0
24143	1520	ilf with gc formation	[ILFs with GC formation]	1.5849625007211563	4	1	0	0
24144	1520	molecular weight dextran sulfate	[molecular weight dextran sulfate]	1.5849625007211563	4	2	2	2
24145	1520	progesterone receptor (pr) rrna	[progesterone receptor (PR) mRNAs]	1.5849625007211563	4	1	0	0
24146	1520	sr-bp 50-fold high	[SR-BP 50-fold higher]	1.5849625007211563	3	1	0	0
24147	1520	use NFATp- specific antibody	[using NFATp- specific antibodies]	1.5849625007211563	4	1	0	0
24148	1520	cd8+), 51.6% cd56+ cell	[CD8+), 51.6% CD56+ cells]	1.5849625007211563	4	1	0	0
24149	1520	consist of p50 homodimer	[consisting of p50 homodimers]	1.5849625007211563	4	1	0	0
24150	1520	1 minute after stimulation.	[1 min after stimulation.]	1.5849625007211563	4	1	0	0
24151	1520	level of the receptor	[level of the receptor]	1.5849625007211563	4	1	0	0
24152	1520	positive regulatory mechanism	[positive regulatory mechanisms]	1.5849625007211563	3	2	1	1
24153	1520	migration of t-cell	[migration of T-cells]	1.5849625007211563	3	2	2	2
24154	1520	t- lymphocyte differentiation.	[T- lymphocyte differentiation.]	1.5849625007211563	3	1	0	0
24155	1520	Differential binding affinity	[Differential binding affinities]	1.5849625007211563	3	1	0	0
24156	1520	early b-cell factor EBF	[Early B-cell factor EBF]	1.5849625007211563	4	1	0	0
24157	1520	contrast to hematopoietic cell	[contrast to hematopoietic cells]	1.5849625007211563	4	1	0	0
24158	1520	2-week captopril treatment	[2-week captopril treatment]	1.5849625007211563	3	1	0	0
24159	1520	characterisation of NF-kappaB subunit	[characterisation of NF-kappaB subunits]	1.5849625007211563	4	1	0	0
24160	1520	limbic brain structure critical	[limbic brain structure critical]	1.5849625007211563	4	1	0	0
24161	1520	role of CD30	[role of CD30]	1.5849625007211563	3	1	0	0
24162	1520	recombinant p38 mapk	[recombinant p38 MAPk]	1.5849625007211563	3	1	0	0
24163	1520	5 micrograms/mL phytohemagglutinin	[5 micrograms/mL phytohemagglutinin]	1.5849625007211563	3	1	0	0
24164	1520	multipotential cell line	[multipotential cell line]	1.5849625007211563	3	1	0	0
24165	1520	Nuclease Protection Assay	[Nuclease Protection Assay]	1.5849625007211563	3	1	0	0
24166	1520	helix-loop-helix (hlh) protein	[helix-loop-helix (HLH) proteins]	1.5849625007211563	3	1	0	0
24167	1520	immune response in vivo	[immune response in vivo]	1.5849625007211563	4	1	0	0
24168	1520	transendothelial migration in vitro.	[transendothelial migration in vitro.]	1.5849625007211563	4	1	0	0
24169	1520	mouse plasmacytoma cell line	[mouse plasmacytoma cell line]	1.5849625007211563	4	1	0	0
24170	1520	biphasic junb transcription	[biphasic junB transcription]	1.5849625007211563	3	1	0	0
24171	1520	canonical tfiid binding site	[canonical TFIID binding site]	1.5849625007211563	4	1	0	0
24172	1520	5-lox -dependent nf-kappab activation	[5-LOX -dependent NF-kappaB activation]	1.5849625007211563	4	1	0	0
24173	1520	steady-state mrna level	[steady-state mRNA levels]	1.5849625007211563	3	2	1	1
24174	1520	anti-intercellular adhesion molecule-1 icam-1	[Anti-intercellular adhesion molecule-1 ICAM-1]	1.5849625007211563	4	1	0	0
24175	1520	agent in differentiation therapy	[agents in differentiation therapy]	1.5849625007211563	4	1	0	0
24176	1520	percentage of infectable cell	[percentage of infectable cells]	1.5849625007211563	4	1	0	0
24177	1520	immortalize potential of lmp-1	[immortalizing potential of LMP-1]	1.5849625007211563	4	1	0	0
24178	1520	15 healthy control	[15 healthy controls]	1.5849625007211563	3	1	0	0
24179	1520	plasma tpo level	[Plasma TPO levels]	1.5849625007211563	3	1	0	0
24180	1520	absence of a system	[absence of an system]	1.5849625007211563	4	1	0	0
24181	1520	mammalian stress response	[mammalian stress responses]	1.5849625007211563	3	1	0	0
24182	1520	cross-linking of surface igm	[cross-linking of surface IgM]	1.5849625007211563	4	1	0	0
24183	1520	monocyte gene expression	[monocyte gene expression]	1.5849625007211563	3	1	0	0
24184	1520	unusual persistent expression	[unusual persistent expression]	1.5849625007211563	3	1	0	0
24185	1520	intrahepatic lymphoid follicle	[Intrahepatic lymphoid follicle]	1.5849625007211563	3	2	2	2
24186	1520	Furthermore, sodium salicylate	[Furthermore, sodium salicylate]	1.5849625007211563	3	1	0	0
24187	1520	presence of tnf-alpha	[presence of TNF-alpha]	1.5849625007211563	3	2	1	1
24188	1520	viability of pdbu cell	[viability of PDBu cells]	1.5849625007211563	4	1	0	0
24189	1520	nf-kappa b functional activity	[NF-kappa B functional activity]	1.5849625007211563	4	1	0	0
24190	1520	exercise during ppe	[exercise during PPE]	1.5849625007211563	3	1	0	0
24191	1520	MCM on cellular proliferation	[MCM on cellular proliferation]	1.5849625007211563	4	1	0	0
24192	1520	endogenous IL-6 -responsive gene	[endogenous IL-6 -responsive genes]	1.5849625007211563	4	1	0	0
24193	1520	regulation of tissue-specific gene	[regulation of tissue-specific genes]	1.5849625007211563	4	1	0	0
24194	1520	number of receptor site	[number of receptor sites]	1.5849625007211563	4	1	0	0
24195	1520	identification of target gene	[Identification of target genes]	1.5849625007211563	4	1	0	0
24196	1520	two distinct promoter promoter	[two distinct promoters promoter]	1.5849625007211563	4	1	0	0
24197	1520	chronic allergic disease	[chronic allergic diseases]	1.5849625007211563	3	1	0	0
24198	1520	such as glucocorticoid	[such as glucocorticoid]	1.5849625007211563	3	1	0	0
24199	1520	phosphorylation of c-jun y-peptide	[phosphorylation of c-Jun Y-peptide]	1.5849625007211563	4	1	0	0
24200	1520	increase hiv promoter activity	[increasing HIV promoter activity]	1.5849625007211563	4	1	0	0
24201	1520	cell types, activation	[cell types, activation]	1.5849625007211563	3	2	2	2
24202	1520	augmentation of lps response	[augmentation of LPS responses]	1.5849625007211563	4	1	0	0
24203	1520	level of cd95 expression	[levels of CD95 expression]	1.5849625007211563	4	1	0	0
24204	1520	nf-kappab activation in PBM	[NF-kappaB activation in PBM]	1.5849625007211563	4	1	0	0
24205	1520	agreement with the result	[agreement with the results]	1.5849625007211563	4	1	0	0
24206	1520	trans-cellular activation of ebv	[trans-cellular activation of EBV]	1.5849625007211563	4	1	0	0
24207	1520	second line of mouse	[second line of mice]	1.5849625007211563	4	1	0	0
24208	1520	promote the differentiation	[promoting the differentiation]	1.5849625007211563	3	2	2	2
24209	1520	hematopoietic system, RA	[hematopoietic system, RA]	1.5849625007211563	3	1	0	0
24210	1520	trigger of epitope	[triggering of epitopes]	1.5849625007211563	3	1	0	0
24211	1520	regulation of calcium signal	[regulation of calcium signals]	1.5849625007211563	4	1	0	0
24212	1520	combination of neca	[combination of NECA]	1.5849625007211563	3	1	0	0
24213	1520	transgenic mouse spleen in	[transgenic mice spleen in]	1.5849625007211563	4	1	0	0
24214	1520	zeta- luciferase construct	[zeta- luciferase constructs]	1.5849625007211563	3	2	2	2
24215	1520	value approximately equal	[value approximately equal]	1.5849625007211563	3	1	0	0
24216	1520	major immediate-early promoter	[major immediate-early promoters]	1.5849625007211563	3	1	0	0
24217	1520	binding at neutral pH	[binding at neutral pH]	1.5849625007211563	4	1	0	0
24218	1520	basis of a ability	[basis of an ability]	1.5849625007211563	4	1	0	0
24219	1520	staphylococcus aureus Cowan strain	[Staphylococcus aureus Cowan strain]	1.5849625007211563	4	1	0	0
24220	1520	mouse fibroblastic cell line	[mouse fibroblastic cell line]	1.5849625007211563	4	1	0	0
24221	1520	nik in unstimulated cell	[NIK in unstimulated cells]	1.5849625007211563	4	1	0	0
24222	1520	Epstein-Barr viral latency	[Epstein-Barr viral latency]	1.5849625007211563	3	1	0	0
24223	1520	induce nf-kappa b activation	[inducing NF-kappa B activation]	1.5849625007211563	4	1	0	0
24224	1520	modulation of irf-1 level	[modulation of IRF-1 levels]	1.5849625007211563	4	1	0	0
24225	1520	early 1 gene product	[early 1 gene product]	1.5849625007211563	4	1	0	0
24226	1520	well-defined, regular borders.	[well-defined, regular borders.]	1.5849625007211563	3	1	0	0
24227	1520	number of both sites.	[number of both sites.]	1.5849625007211563	4	1	0	0
24228	1520	proviral DNA present	[proviral DNA present]	1.5849625007211563	3	1	0	0
24229	1520	NFAT -luc assay	[NFAT -luc assay]	1.5849625007211563	3	1	0	0
24230	1520	Proinflammatory neutrophil stimulus	[Proinflammatory neutrophil stimuli]	1.5849625007211563	3	1	0	0
24231	1520	AP-1 site at -146	[AP-1 site at -146]	1.5849625007211563	4	1	0	0
24232	1520	effect of oestrogen	[effect of oestrogens]	1.5849625007211563	3	1	0	0
24233	1520	Irish/German population (p	[Irish/German population (P]	1.5849625007211563	3	1	0	0
24234	1520	nuclear receptor family	[nuclear receptor family]	1.5849625007211563	3	1	0	0
24235	1520	mouse tis11 gene	[mouse TIS11 genes]	1.5849625007211563	3	1	0	0
24236	1520	considerable proportion of cell	[considerable proportion of cells]	1.5849625007211563	4	1	0	0
24237	1520	Hyperplastic lymph node	[Hyperplastic lymph node]	1.5849625007211563	3	1	0	0
24238	1520	terminal step of transport	[terminal step of transport]	1.5849625007211563	4	1	0	0
24239	1520	certain pro-inflammatory mediator	[certain pro-inflammatory mediators]	1.5849625007211563	3	1	0	0
24240	1520	guamerin-derived synthetic peptide gdsp	[guamerin-derived synthetic peptide GDSP]	1.5849625007211563	4	1	0	0
24241	1520	ATF/CREB family member	[ATF/CREB family members]	1.5849625007211563	3	1	0	0
24242	1520	activity of interferon-regulated gene	[activity of interferon-regulated genes]	1.5849625007211563	4	1	0	0
24243	1520	other leukaemias /lymphomas	[other leukaemias /lymphomas]	1.5849625007211563	3	1	0	0
24244	1520	interferon-alpha ifn-alpha treatment	[interferon-alpha IFN-alpha treatment]	1.5849625007211563	3	1	0	0
24245	1520	biphasic time-dependent expression	[biphasic time-dependent expression]	1.5849625007211563	3	1	0	0
24246	1520	host cytotoxic t-cell surveillance	[host cytotoxic T-cell surveillance]	1.5849625007211563	4	1	0	0
24247	1520	course of immunodeficiency syndrome	[course of immunodeficiency syndrome]	1.5849625007211563	4	1	0	0
24248	1520	bacillus calmette-guerin (bcg) infection	[bacillus Calmette-Guerin (BCG) infection]	1.5849625007211563	4	1	0	0
24249	1520	Burkitt lymphoma line Raji	[Burkitt lymphoma line Raji]	1.5849625007211563	4	1	0	0
24250	1520	T cell with phytohemagglutinin	[T cells with phytohemagglutinin]	1.5849625007211563	4	1	0	0
24251	1520	serve as common messenger	[serving as common messengers]	1.5849625007211563	4	1	0	0
24252	1520	nuclear factor STAT-1 p91	[nuclear factor STAT-1 p91]	1.5849625007211563	4	1	0	0
24253	1520	up-regulation of icam-1	[up-regulation of ICAM-1]	1.5849625007211563	3	1	0	0
24254	1520	loss of Rel	[loss of Rel]	1.5849625007211563	3	1	0	0
24255	1520	use mrna display	[using mRNA display]	1.5849625007211563	3	2	2	2
24256	1520	cell express p85 mutant	[cells expressing p85 mutants]	1.5849625007211563	4	1	0	0
24257	1520	monocyte by mycobacterium tuberculosis	[monocytes by Mycobacterium tuberculosis]	1.5849625007211563	4	1	0	0
24258	1520	pkc /calmodulin-dependent protein kinase	[PKC /calmodulin-dependent protein kinase]	1.5849625007211563	4	1	0	0
24259	1520	k562 stem cell	[K562 stem cells]	1.5849625007211563	3	1	0	0
24260	1520	expression of some gene	[expression of some genes]	1.5849625007211563	4	2	1	1
24261	1520	fresh human epstein-barr virus	[fresh human Epstein-Barr virus]	1.5849625007211563	4	1	0	0
24262	1520	antigen-specific T cell stimulation	[antigen-specific T cell stimulation]	1.5849625007211563	4	1	0	0
24263	1520	fmol/10(7) pbmc in male	[fmol/10(7) PBMC in males]	1.5849625007211563	4	1	0	0
24264	1520	consequence, b-lymphoid tissue	[consequence, B-lymphoid tissues]	1.5849625007211563	3	1	0	0
24265	1520	nuclear protein REF-1	[nuclear protein REF-1]	1.5849625007211563	3	1	0	0
24266	1520	heterozygosity on chromosome 20q	[heterozygosity on chromosome 20q]	1.5849625007211563	4	1	0	0
24267	1520	identical pan/e2a complex	[identical Pan/E2A complexes]	1.5849625007211563	3	1	0	0
24268	1520	mechanism of apoptosis	[mechanism of apoptosis]	1.5849625007211563	3	1	0	0
24269	1520	major likely factor	[major likely factor]	1.5849625007211563	3	1	0	0
24270	1520	response to t-cell activation	[response to T-cell activation]	1.5849625007211563	4	1	0	0
24271	1520	synthetic metalloproteinase inhibitor bb-94	[synthetic metalloproteinase inhibitor BB-94]	1.5849625007211563	4	1	0	0
24272	1520	transcription start site.	[transcription start site.]	1.5849625007211563	3	1	0	0
24273	1520	role of genetic variation	[role of genetic variation]	1.5849625007211563	4	1	0	0
24274	1520	binding of each	[binding of each]	1.5849625007211563	3	1	0	0
24275	1520	new regulatory pathway	[new regulatory pathways]	1.5849625007211563	3	1	0	0
24276	1520	functional il-12 signal	[functional IL-12 signaling]	1.5849625007211563	3	1	0	0
24277	1520	splenic cell of rat	[splenic cells of rats]	1.5849625007211563	4	1	0	0
24278	1520	TNF-alpha- dependent mechanism	[TNF-alpha- dependent mechanism]	1.5849625007211563	3	1	0	0
24279	1520	benign clinical course	[benign clinical course]	1.5849625007211563	3	1	0	0
24280	1520	presence of LMO	[presence of LMO]	1.5849625007211563	3	1	0	0
24281	1520	prerequisite for full activation	[prerequisite for full activation]	1.5849625007211563	4	1	0	0
24282	1520	range of 36-41 kd.	[range of 36-41 kd.]	1.5849625007211563	4	1	0	0
24283	1520	SM by CKII	[SM by CKII]	1.5849625007211563	3	1	0	0
24284	1520	increase in the ratio	[increase in the ratio]	1.5849625007211563	4	1	0	0
24285	1520	abrogation of oral tolerance	[abrogation of oral tolerance]	1.5849625007211563	4	1	0	0
24286	1520	Stat3 -independent signal	[Stat3 -independent signals]	1.5849625007211563	3	1	0	0
24287	1520	human TF gene	[human TF gene]	1.5849625007211563	3	1	0	0
24288	1520	combination of monoclonal antibody	[combination of monoclonal antibodies]	1.5849625007211563	4	1	0	0
24289	1520	mononuclear phagocyte upon stimulation	[mononuclear phagocytes upon stimulation]	1.5849625007211563	4	1	0	0
24290	1520	transient rise of ca2+	[transient rise of Ca2+]	1.5849625007211563	4	1	0	0
24291	1520	murine macrophage 12-lipoxygenase	[murine macrophage 12-lipoxygenase]	1.5849625007211563	3	1	0	0
24292	1520	less extent, of nf-il6	[lesser extent, of NF-IL6]	1.5849625007211563	4	1	0	0
24293	1520	fluorescence-activated cell sorter	[fluorescence-activated cell sorter]	1.5849625007211563	3	1	0	0
24294	1520	highly malignant lymphoma	[highly malignant lymphomas]	1.5849625007211563	3	1	0	0
24295	1520	normal cell counterpart	[normal cell counterparts]	1.5849625007211563	3	1	0	0
24296	1520	Finally, co-immunoprecipitation analysis	[Finally, co-immunoprecipitation analysis]	1.5849625007211563	3	1	0	0
24297	1520	octamer motif in activation	[octamer motif in activation]	1.5849625007211563	4	1	0	0
24298	1520	peripheral tissue resistance	[peripheral tissue resistance]	1.5849625007211563	3	1	0	0
24299	1520	tetanus toxoid tt	[tetanus toxoid TT]	1.5849625007211563	3	1	0	0
24300	1520	mechanism for effect	[mechanism for effects]	1.5849625007211563	3	2	2	2
24301	1520	transcription of tal-1	[transcription of tal-1]	1.5849625007211563	3	1	0	0
24302	1520	subfamily of pax protein	[subfamily of Pax proteins]	1.5849625007211563	4	1	0	0
24303	1520	er+ er- cell	[ER+ ER- cells]	1.5849625007211563	3	1	0	0
24304	1520	various stage of differentiation	[various stages of differentiation]	1.5849625007211563	4	1	0	0
24305	1520	antigen-processing pathway during infection	[antigen-processing pathway during infection]	1.5849625007211563	4	1	0	0
24306	1520	multiple regulatory element	[multiple regulatory elements]	1.5849625007211563	3	2	2	2
24307	1520	include ebv genome negative	[including EBV genome negative]	1.5849625007211563	4	1	0	0
24308	1520	DNA variation 233g-->a	[DNA variation 233G-->A]	1.5849625007211563	3	1	0	0
24309	1520	involvement of member	[involvement of members]	1.5849625007211563	3	1	0	0
24310	1520	specific dna-binding activity	[specific DNA-binding activity]	1.5849625007211563	3	1	0	0
24311	1520	activation of the sodium/proton-exchanger	[activation of the sodium/proton-exchanger]	1.5849625007211563	4	1	0	0
24312	1520	primary glucocorticoid resistance	[primary glucocorticoid resistance]	1.5849625007211563	3	1	0	0
24313	1520	excess of mineralocorticoid (primary	[excess of mineralocorticoids (primary]	1.5849625007211563	4	1	0	0
24314	1520	expression pattern of bcl-2	[expression pattern of BCL-2]	1.5849625007211563	4	1	0	0
24315	1520	production of ltb4	[production of LTB4]	1.5849625007211563	3	1	0	0
24316	1520	influence of cold exposure	[influence of cold exposure]	1.5849625007211563	4	1	0	0
24317	1520	tcr alpha/delta locus	[TCR alpha/delta locus]	1.5849625007211563	3	1	0	0
24318	1520	PRRIII /cat reporter construct	[PRRIII /CAT reporter constructs]	1.5849625007211563	4	1	0	0
24319	1520	transient expression system	[transient expression system]	1.5849625007211563	3	1	0	0
24320	1520	tax transgenic mouse model	[tax transgenic mouse model]	1.5849625007211563	4	1	0	0
24321	1520	also of CD1+relB+DC	[also of CD1+relB+DC]	1.5849625007211563	3	1	0	0
24322	1520	result of supershift assay	[results of supershift assays]	1.5849625007211563	4	1	0	0
24323	1520	nucleotide +13 to +15	[nucleotides +13 to +15]	1.5849625007211563	4	1	0	0
24324	1520	305 +/- 17 nmol	[305 +/- 17 nmol]	1.5849625007211563	4	1	0	0
24325	1520	many lymphoproliferative disease	[many lymphoproliferative diseases]	1.5849625007211563	3	1	0	0
24326	1520	absence of activation	[absence of activation]	1.5849625007211563	3	1	0	0
24327	1520	Furthermore, transient-cotransfection assay	[Furthermore, transient-cotransfection assay]	1.5849625007211563	3	1	0	0
24328	1520	classical Oct2a Oct2b isoform	[classical Oct2a Oct2b isoforms]	1.5849625007211563	4	1	0	0
24329	1520	b lymphocyte activation	[B lymphocyte activation]	1.5849625007211563	3	1	0	0
24330	1520	B-cell specific gene expression	[B-cell specific gene expression]	1.5849625007211563	4	1	0	0
24331	1520	clinical trial with il-10	[clinical trials with IL-10]	1.5849625007211563	4	1	0	0
24332	1520	datum on c-Raf phosphorylation	[data on c-Raf phosphorylation]	1.5849625007211563	4	1	0	0
24333	1520	glyocophorin a GPA	[glyocophorin A GPA]	1.5849625007211563	3	1	0	0
24334	1520	result of transcriptional activation	[result of transcriptional activation]	1.5849625007211563	4	2	1	1
24335	1520	Brief exposure to fludarabine	[Brief exposure to fludarabine]	1.5849625007211563	4	1	0	0
24336	1520	transcription factor mibp1	[transcription factor MIBP1]	1.5849625007211563	3	1	0	0
24337	1520	binding of a factor	[binding of a factor]	1.5849625007211563	4	2	2	2
24338	1520	IFN NK cell killing	[IFN NK cell killing]	1.5849625007211563	4	1	0	0
24339	1520	slightly high promoter activity	[slightly higher promoter activity]	1.5849625007211563	4	1	0	0
24340	1520	monocytic cell line u1	[monocytic cell line U1]	1.5849625007211563	4	2	1	1
24341	1520	allergen-specific cd4+ t-cell clone	[allergen-specific CD4+ T-cell clones]	1.5849625007211563	4	1	0	0
24342	1520	survival in serum-free medium	[survival in serum-free medium]	1.5849625007211563	4	1	0	0
24343	1520	tyrosine phosphorylation of STAT1alpha	[tyrosine phosphorylation of STAT1alpha]	1.5849625007211563	4	1	0	0
24344	1520	purine-box/nuclear factor of t-cell	[purine-box/nuclear factor of T-cells]	1.5849625007211563	4	1	0	0
24345	1520	allergic airway disease	[allergic airway disease]	1.5849625007211563	3	1	0	0
24346	1520	estrogen receptor er status	[estrogen receptor ER status]	1.5849625007211563	4	1	0	0
24347	1520	mutation of microB site	[mutation of microB sites]	1.5849625007211563	4	1	0	0
24348	1520	consistent genetic alterations.	[consistent genetic alterations.]	1.5849625007211563	3	1	0	0
24349	1520	unfractionated nuclear extract	[unfractionated nuclear extract]	1.5849625007211563	3	1	0	0
24350	1520	protein kinase inhibitor gf109203x	[protein kinase inhibitor GF109203X]	1.5849625007211563	4	1	0	0
24351	1520	binding kappa b/mad-3	[binding kappa B/MAD-3]	1.5849625007211563	3	1	0	0
24352	1520	EBNA2 expression vector	[EBNA2 expression vector]	1.5849625007211563	3	1	0	0
24353	1520	Potential cis-acting element	[Potential cis-acting elements]	1.5849625007211563	3	1	0	0
24354	1520	IARC 301 T cell	[IARC 301 T cells]	1.5849625007211563	4	1	0	0
24355	1520	expression of 135(oh)2d3 receptor	[Expression of 1,25(OH)2D3 receptors]	1.5849625007211563	4	2	1	1
24356	1520	cytotoxic NK cell granule	[cytotoxic NK cell granules]	1.5849625007211563	4	1	0	0
24357	1520	adenomatous polyposis coli	[adenomatous polyposis coli]	1.5849625007211563	3	1	0	0
24358	1520	precise role of pebp2	[precise role of PEBP2]	1.5849625007211563	4	1	0	0
24359	1520	CD3-stimulated T lymphocyte	[CD3-stimulated T lymphocytes]	1.5849625007211563	3	2	1	1
24360	1520	IL-1RI protein kinase	[IL-1RI protein kinase]	1.5849625007211563	3	1	0	0
24361	1520	expression of il-1-ra	[expression of IL-1-RA]	1.5849625007211563	3	1	0	0
24362	1520	generation of a response	[generation of a response]	1.5849625007211563	4	2	1	1
24363	1520	significance of this region	[significance of this region]	1.5849625007211563	4	1	0	0
24364	1520	expression of membrane-associated elam-1	[expression of membrane-associated ELAM-1]	1.5849625007211563	4	1	0	0
24365	1520	positive cis-acting element	[positive cis-acting elements]	1.5849625007211563	3	1	0	0
24366	1520	IFN alpha level	[IFN alpha levels]	1.5849625007211563	3	2	1	1
24367	1520	CD3 HSI phosphorylation	[CD3 HSI phosphorylation]	1.5849625007211563	3	1	0	0
24368	1520	ebv (or lmp-1 cell	[EBV (or LMP-1 cells]	1.5849625007211563	4	1	0	0
24369	1520	other, nearby polymorphism	[other, nearby polymorphisms]	1.5849625007211563	3	1	0	0
24370	1520	linker scanning analysis	[linker scanning analysis]	1.5849625007211563	3	1	0	0
24371	1520	insensitivity to tpa differentiation	[insensitivity to TPA differentiation]	1.5849625007211563	4	1	0	0
24372	1520	steroid-resistant bronchial asthmatic subject	[steroid-resistant bronchial asthmatic subjects]	1.5849625007211563	4	1	0	0
24373	1520	peripheral blood leucocyte	[peripheral blood leucocyte]	1.5849625007211563	3	2	2	2
24374	1520	VZV ie62ohsv gc	[VZV IE62-HSV gC]	1.5849625007211563	3	1	0	0
24375	1520	CN a subunit	[CN A subunit]	1.5849625007211563	3	1	0	0
24376	1520	adjacent regulatory region	[adjacent regulatory region]	1.5849625007211563	3	1	0	0
24377	1520	tcr-mediated il-2 production	[TCR-mediated IL-2 production]	1.5849625007211563	3	1	0	0
24378	1520	infect T cell	[infecting T cells]	1.5849625007211563	3	1	0	0
24379	1520	other pebp2 alpha factor	[other PEBP2 alpha factors]	1.5849625007211563	4	1	0	0
24380	1520	general transcription apparatus	[general transcription apparatus]	1.5849625007211563	3	1	0	0
24381	1520	T lymphocyte subset	[T lymphocyte subsets]	1.5849625007211563	3	2	2	2
24382	1520	sequence at threonine 78	[sequence at threonine 78]	1.5849625007211563	4	1	0	0
24383	1520	lymphocyte of the patient	[lymphocytes of the patients]	1.5849625007211563	4	1	0	0
24384	1520	monocyte to macrophage maturation	[monocyte to macrophage maturation]	1.5849625007211563	4	2	1	1
24385	1520	level of tnf-alpha	[levels of TNF-alpha]	1.5849625007211563	3	2	2	2
24386	1520	constitutive nf-kappa b translocation	[constitutive NF-kappa B translocation]	1.5849625007211563	4	1	0	0
24387	1520	blood cell culture	[blood cell cultures]	1.5849625007211563	3	2	2	2
24388	1520	curcumin a curry pigment	[curcumin a curry pigment]	1.5849625007211563	4	1	0	0
24389	1520	regulation of cytoskeletal structure	[regulation of cytoskeletal structure]	1.5849625007211563	4	1	0	0
24390	1520	provide a model	[providing a model]	1.5849625007211563	3	1	0	0
24391	1520	six different specific band	[six different specific bands]	1.5849625007211563	4	1	0	0
24392	1520	RNAase protection assay	[RNAase protection assays]	1.5849625007211563	3	1	0	0
24393	1520	two nuclear rna EBERs	[two nuclear RNAs EBERs]	1.5849625007211563	4	1	0	0
24394	1520	IL-4 upregulation of CD40	[IL-4 upregulation of CD40]	1.5849625007211563	4	1	0	0
24395	1520	case of hodgkin' disease	[cases of Hodgkin's disease]	1.5849625007211563	4	2	2	2
24396	1520	stabilization of IkappaB-alpha	[stabilization of IkappaB-alpha]	1.5849625007211563	3	1	0	0
24397	1520	NH2-terminal transactivation domain	[NH2-terminal transactivation domain]	1.5849625007211563	3	1	0	0
24398	1520	p less than 0.001).	[P less than 0.001).]	1.5849625007211563	4	1	0	0
24399	1520	cell antigen receptor tcr	[cell antigen receptor TCR]	1.5849625007211563	4	1	0	0
24400	1520	m phi uptake	[M phi uptake]	1.5849625007211563	3	2	2	2
24401	1520	ubiquitous environmental contaminant	[ubiquitous environmental contaminant]	1.5849625007211563	3	1	0	0
24402	1520	NF-kappa B/Rel family member	[NF-kappa B/Rel family members]	1.5849625007211563	4	1	0	0
24403	1520	promyelocyte cell line nb4	[promyelocyte cell line NB4]	1.5849625007211563	4	1	0	0
24404	1520	clue understand the involvement	[clues understanding the involvement]	1.5849625007211563	4	1	0	0
24405	1520	NK cell cytolytic program	[NK cell cytolytic programs]	1.5849625007211563	4	1	0	0
24406	1520	propranolol a beta-adrenoreceptor antagonist	[propranolol a beta-adrenoreceptor antagonist]	1.5849625007211563	4	1	0	0
24407	1520	CMAT binding complex	[CMAT binding complex]	1.5849625007211563	3	1	0	0
24408	1520	homodimeric stat1 protein	[homodimeric STAT1 protein]	1.5849625007211563	3	1	0	0
24409	1520	mechanism regulate gene expression	[mechanisms regulating gene expression]	1.5849625007211563	4	1	0	0
24410	1520	ICAM-1 surface expression	[ICAM-1 surface expression]	1.5849625007211563	3	1	0	0
24411	1520	NF-kappaB nuclear activation	[NF-kappaB nuclear activation]	1.5849625007211563	3	1	0	0
24412	1520	inflammatory lung disease	[inflammatory lung disease]	1.5849625007211563	3	2	2	2
24413	1520	early immune response	[early immune response]	1.5849625007211563	3	1	0	0
24414	1520	35S-TR: TREp complex	[35S-TR: TREp complex]	1.5849625007211563	3	1	0	0
24415	1520	development of Th1 response	[development of Th1 responses]	1.5849625007211563	4	1	0	0
24416	1520	physiologically relevant concentrations.	[physiologically relevant concentrations.]	1.5849625007211563	3	1	0	0
24417	1520	such as soluble e-selectin	[such as soluble E-selectin]	1.5849625007211563	4	1	0	0
24418	1520	addition of rCTLA4Ig	[addition of rCTLA4Ig]	1.5849625007211563	3	1	0	0
24419	1520	dose-dependent manner between 2	[dose-dependent manner between 2]	1.5849625007211563	4	1	0	0
24420	1520	physiologically relevant concentrations;	[physiologically relevant concentrations;]	1.5849625007211563	3	1	0	0
24421	1520	unrearranged kappa locus	[unrearranged kappa locus]	1.5849625007211563	3	1	0	0
24422	1520	dominant control region DCR	[dominant control region DCR]	1.5849625007211563	4	1	0	0
24423	1520	T delta 7 element	[T delta 7 element]	1.5849625007211563	4	1	0	0
24424	1520	treatment of T disease	[treatment of T diseases]	1.5849625007211563	4	1	0	0
24425	1520	mm patient (31/33	[MM patients (31/33]	1.5849625007211563	3	1	0	0
24426	1520	subsequent cell activation	[subsequent cell activation]	1.5849625007211563	3	1	0	0
24427	1520	accumulation of the form	[accumulation of the forms]	1.5849625007211563	4	1	0	0
24428	1520	somatic cell hybridization approach	[somatic cell hybridization approach]	1.5849625007211563	4	1	0	0
24429	1520	various combination of retinoid	[various combinations of retinoids]	1.5849625007211563	4	1	0	0
24430	1520	abnormality of this gene	[abnormality of this gene]	1.5849625007211563	4	1	0	0
24431	1520	bone marrow of mouse	[bone marrow of mice]	1.5849625007211563	4	1	0	0
24432	1520	cd34+ cb subset	[CD34+ CB subsets]	1.5849625007211563	3	1	0	0
24433	1520	presence of indomethacin	[presence of indomethacin]	1.5849625007211563	3	1	0	0
24434	1520	promoter sequence polymorphism	[promoter sequence polymorphisms]	1.5849625007211563	3	1	0	0
24435	1520	membrane phospholipid metabolism	[membrane phospholipid metabolism]	1.5849625007211563	3	1	0	0
24436	1520	IL-13 receptor complex	[IL-13 receptor complex]	1.5849625007211563	3	2	1	1
24437	1520	activation by antigen	[activation by antigens]	1.5849625007211563	3	1	0	0
24438	1520	sequencing of brca1	[Sequencing of BRCA1]	1.5849625007211563	3	1	0	0
24439	1520	human aortic ec	[human aortic EC]	1.5849625007211563	3	1	0	0
24440	1520	cell line from patient	[cell lines from patients]	1.5849625007211563	4	1	0	0
24441	1520	least two signals.	[least two signals.]	1.5849625007211563	3	1	0	0
24442	1520	least two signals,	[least two signals,]	1.5849625007211563	3	2	1	1
24443	1520	conjunction with Oct-1	[conjunction with Oct-1]	1.5849625007211563	3	1	0	0
24444	1520	plasmid carry multiple copy	[plasmids carrying multiple copies]	1.5849625007211563	4	1	0	0
24445	1520	Representational difference analysis	[Representational difference analysis]	1.5849625007211563	3	1	0	0
24446	1520	incubation with 40% MCM	[Incubation with 40% MCM]	1.5849625007211563	4	1	0	0
24447	1520	presence of tissue-specific regulators/adapter	[presence of tissue-specific regulators/adapters]	1.5849625007211563	4	1	0	0
24448	1520	quieiescent patient (23.1%, p	[quieiescent patients (23.1%, P]	1.5849625007211563	4	1	0	0
24449	1520	precise mechanism of action	[precise mechanism of action]	1.5849625007211563	4	1	0	0
24450	1520	pge2 -dependent activate effect	[PGE2 -dependent activating effect]	1.5849625007211563	4	1	0	0
24451	1520	chronic inflammatory reaction	[chronic inflammatory reaction]	1.5849625007211563	3	1	0	0
24452	1520	Moreover, ANG ii	[Moreover, ANG II]	1.5849625007211563	3	1	0	0
24453	1520	hs-40 enhancer- zeta	[HS-40 enhancer- zeta]	1.5849625007211563	3	1	0	0
24454	1520	cle0 ap-1 /nf-at	[CLE0 AP-1 /NF-AT]	1.5849625007211563	3	1	0	0
24455	1520	treatment of rhinitis	[treatment of rhinitis]	1.5849625007211563	3	1	0	0
24456	1520	most distal site (-579)	[most distal site (-579)]	1.5849625007211563	4	1	0	0
24457	1520	21 bp repeat c1-c3	[21 bp repeats C1-C3]	1.5849625007211563	4	1	0	0
24458	1520	il-4 gene expression level	[IL-4 gene expression levels]	1.5849625007211563	4	1	0	0
24459	1520	pi 3-kinase nf-at induction	[PI 3-kinase NF-AT induction]	1.5849625007211563	4	1	0	0
24460	1520	absence of presentation	[absence of presentation]	1.5849625007211563	3	1	0	0
24461	1520	il-1 -dependent nfkappab activity	[IL-1 -dependent NFkappaB activity]	1.5849625007211563	4	1	0	0
24462	1520	clonal immune response specific	[clonal immune response specific]	1.5849625007211563	4	1	0	0
24463	1520	3 day intervention study	[3 day intervention study]	1.5849625007211563	4	1	0	0
24464	1520	cellular inhibitor kappab alpha	[cellular inhibitor kappaB alpha]	1.5849625007211563	4	1	0	0
24465	1520	treatment with ru38486	[treatment with RU38486]	1.5849625007211563	3	1	0	0
24466	1520	activation of hemopoietic cell	[activation of hemopoietic cells]	1.5849625007211563	4	2	1	1
24467	1520	hie level of ige	[HIE levels of IgE]	1.5849625007211563	4	1	0	0
24468	1520	gene encode transcription factor	[genes encoding transcription factors]	1.5849625007211563	4	1	0	0
24469	1520	protein tumor necrosis factor-alpha	[protein tumor necrosis factor-alpha]	1.5849625007211563	4	1	0	0
24470	1520	NF-kappaB up-regulation of Bcl-x	[NF-kappaB up-regulation of Bcl-x]	1.5849625007211563	4	1	0	0
24471	1520	several AP-2 response element	[several AP-2 response elements]	1.5849625007211563	4	1	0	0
24472	1520	estrogen target organ	[estrogen target organ]	1.5849625007211563	3	1	0	0
24473	1520	protein- tyrosine phosphatases,	[protein- tyrosine phosphatases,]	1.5849625007211563	3	1	0	0
24474	1520	ankyrin repeat 7	[ankyrin repeat 7]	1.5849625007211563	3	1	0	0
24475	1520	very potent inducer	[very potent inducer]	1.5849625007211563	3	1	0	0
24476	1520	Y x2 box	[Y X2 boxes]	1.5849625007211563	3	1	0	0
24477	1520	manipulation of cytokine network	[manipulation of cytokine networks]	1.5849625007211563	4	1	0	0
24478	1520	clinical benefit of salicylate	[clinical benefits of salicylates]	1.5849625007211563	4	1	0	0
24479	1520	efficient DNA replication	[efficient DNA replication]	1.5849625007211563	3	2	2	2
24480	1520	viral protein vp16	[viral protein VP16]	1.5849625007211563	3	1	0	0
24481	1520	combination with allergy-driven overproduction	[combination with allergy-driven overproduction]	1.5849625007211563	4	1	0	0
24482	1520	alignment of the sequence	[Alignment of the sequences]	1.5849625007211563	4	1	0	0
24483	1520	depend on tre structure	[depending on TRE structure]	1.5849625007211563	4	1	0	0
24484	1520	new immunotherapeutic target	[new immunotherapeutic targets]	1.5849625007211563	3	1	0	0
24485	1520	significant response to stimulus	[significant response to stimuli]	1.5849625007211563	4	1	0	0
24486	1520	also many other cytokine	[also many other cytokines]	1.5849625007211563	4	1	0	0
24487	1520	transcriptional activation by AML1b	[transcriptional activation by AML1b]	1.5849625007211563	4	1	0	0
24488	1520	les-induced phosphotyrosine residue	[LPS-induced phosphotyrosine residues]	1.5849625007211563	3	1	0	0
24489	1520	different lymphocyte population	[different lymphocyte populations]	1.5849625007211563	3	1	0	0
24490	1520	growth factor-like growth factor	[growth factor-like growth factor]	1.5849625007211563	4	2	2	2
24491	1520	NF-kappa b p50 subunit	[NF-kappa B p50 subunit]	1.5849625007211563	4	2	1	1
24492	1520	Activation, normal T	[Activation, Normal T]	1.5849625007211563	3	1	0	0
24493	1520	viremia to aids	[viremia to AIDS]	1.5849625007211563	3	1	0	0
24494	1520	major positive regulatory region	[major positive regulatory region]	1.5849625007211563	4	1	0	0
24495	1520	Third Monoclonal International Workshop	[Third Monoclonal International Workshop]	1.5849625007211563	4	1	0	0
24496	1520	two other transcription factor	[two other transcription factors]	1.5849625007211563	4	1	0	0
24497	1520	hiv-1 latency reactivation	[HIV-1 latency reactivation]	1.5849625007211563	3	2	2	2
24498	1520	mense of one days'	[menses of one days']	1.5849625007211563	4	1	0	0
24499	1520	differential stimulation of CD3	[differential stimulation of CD3]	1.5849625007211563	4	1	0	0
24500	1520	affect erythroid cell fate	[affecting erythroid cell fate]	1.5849625007211563	4	1	0	0
24501	1520	il-2ralpha gene expression	[IL-2Ralpha gene expression]	1.5849625007211563	3	1	0	0
24502	1520	eight patient with dermatomyositis/polymyositis	[Eight patients with dermatomyositis/polymyositis]	1.5849625007211563	4	1	0	0
24503	1520	hybridization pattern at all.	[hybridization pattern at all.]	1.5849625007211563	4	1	0	0
24504	1520	50-kDa species cross-react	[50-kDa species cross-reacting]	1.5849625007211563	3	1	0	0
24505	1520	fetal brain development	[fetal brain development]	1.5849625007211563	3	2	1	1
24506	1520	gC2- specific cd4+ clone	[gC2- specific CD4+ clones]	1.5849625007211563	4	1	0	0
24507	1520	range of 36-41	[range of 36-41]	1.5849625007211563	3	1	0	0
24508	1520	hemopoietic lineage restriction	[hemopoietic lineage restriction]	1.5849625007211563	3	1	0	0
24509	1520	supernatant from this culture	[Supernatants from these cultures]	1.5849625007211563	4	1	0	0
24510	1520	lack of CD5 expression	[lack of CD5 expression]	1.5849625007211563	4	1	0	0
24511	1520	monocyte/macrophage tumor necrosis factor	[monocyte/macrophage tumor necrosis factor]	1.5849625007211563	4	1	0	0
24512	1520	progress in the understanding	[progress in the understanding]	1.5849625007211563	4	2	1	1
24513	1520	several aids-related neoplasm	[several AIDS-related neoplasms]	1.5849625007211563	3	1	0	0
24514	1520	induction of monocyte binding	[induction of monocyte binding]	1.5849625007211563	4	1	0	0
24515	1520	contain gata-responsive element	[containing GATA-responsive elements]	1.5849625007211563	3	1	0	0
24516	1520	one transcription factor	[one transcription factor]	1.5849625007211563	3	2	1	1
24517	1520	genetic familial disorder	[genetic familial disorders]	1.5849625007211563	3	1	0	0
24518	1520	concomitant down-regulation of Bcl-xL	[concomitant down-regulation of Bcl-xL]	1.5849625007211563	4	1	0	0
24519	1520	TFG-beta 2 promoter	[TFG-beta 2 promoter]	1.5849625007211563	3	1	0	0
24520	1520	pre-treatment with cytochalasin D	[pre-treatment with cytochalasin D]	1.5849625007211563	4	1	0	0
24521	1520	chrysotile b fr 101	[Chrysotile B FR 101]	1.5849625007211563	4	1	0	0
24522	1520	IL-3 gm-csf receptor beta-subunit	[IL-3 GM-CSF receptor beta-subunit]	1.5849625007211563	4	1	0	0
24523	1520	hGR glucocorticoid-binding domain	[hGR glucocorticoid-binding domain]	1.5849625007211563	3	1	0	0
24524	1520	p130 complex e2f-4	[p130 complexes E2F-4]	1.5849625007211563	3	1	0	0
24525	1520	receptor from OKT3	[receptor from OKT3]	1.5849625007211563	3	1	0	0
24526	1520	glucocorticoid receptor complex	[glucocorticoid receptor complexes]	1.5849625007211563	3	2	2	2
24527	1520	IFN stimulus response element	[IFN stimulus response element]	1.5849625007211563	4	2	1	1
24528	1520	antibody ablation/supershift assay	[antibody ablation/supershift assays]	1.5849625007211563	3	1	0	0
24529	1520	hiv-1 LTR alpha promoters,	[HIV-1 LTR alpha promoters,]	1.5849625007211563	4	1	0	0
24530	1520	manipulation of molecular interaction	[manipulation of molecular interactions]	1.5849625007211563	4	1	0	0
24531	1520	hiv-1 in monocyte-derived macrophage	[HIV-1 in monocyte-derived macrophages]	1.5849625007211563	4	1	0	0
24532	1520	immediate upstream region	[immediate upstream region]	1.5849625007211563	3	1	0	0
24533	1520	IL-2 -independent t-cell transformation	[IL-2 -independent T-cell transformation]	1.5849625007211563	4	1	0	0
24534	1520	early untreated RA	[early untreated RA]	1.5849625007211563	3	1	0	0
24535	1520	cysteine-rich protein 3 crisp-3	[cysteine-rich protein 3 CRISP-3]	1.5849625007211563	4	1	0	0
24536	1520	hypersensitive site HS2 enhancer	[hypersensitive site HS2 enhancer]	1.5849625007211563	4	2	1	1
24537	1520	m2-type leukemic blast cell	[M2-type leukemic blast cells]	1.5849625007211563	4	1	0	0
24538	1520	benign clinical behavior	[benign clinical behavior]	1.5849625007211563	3	1	0	0
24539	1520	transcription factor c-myb	[transcription factors c-myb]	1.5849625007211563	3	1	0	0
24540	1520	elderly interferon-gamma ifn-gamma	[elderly interferon-gamma IFN-gamma]	1.5849625007211563	3	1	0	0
24541	1520	down-regulation of CD28	[down-regulation of CD28]	1.5849625007211563	3	1	0	0
24542	1520	binding of STAT1 alpha	[binding of STAT1 alpha]	1.5849625007211563	4	1	0	0
24543	1520	understanding of regulation	[understanding of regulation]	1.5849625007211563	3	2	2	2
24544	1520	7-day exposure to tpo	[7-day exposure to TPO]	1.5849625007211563	4	1	0	0
24545	1520	vitamin d -binding protein	[vitamin D -binding protein]	1.5849625007211563	4	1	0	0
24546	1520	cytokine factor receptor engagement	[Cytokine factor receptor engagement]	1.5849625007211563	4	1	0	0
24547	1520	Jurkat ESb-L T lymphocyte	[Jurkat ESb-L T lymphocytes]	1.5849625007211563	4	1	0	0
24548	1520	nucleus of HeLa cell	[nucleus of HeLa cells]	1.5849625007211563	4	1	0	0
24549	1520	induction of factor	[Induction of factor]	1.5849625007211563	3	2	2	2
24550	1520	lck electrophoretic mobility	[Lck electrophoretic mobility]	1.5849625007211563	3	1	0	0
24551	1520	regulation of immune response	[regulation of immune responses]	1.5849625007211563	4	2	2	2
24552	1520	microb DNA motif	[microB DNA motif]	1.5849625007211563	3	2	1	1
24553	1520	poly(A)+ rna from brain	[poly(A)+ RNAs from brain]	1.5849625007211563	4	1	0	0
24554	1520	dissociation constant Kd	[dissociation constant Kd]	1.5849625007211563	3	1	0	0
24555	1520	course of several month	[course of several months]	1.5849625007211563	4	1	0	0
24556	1520	CD3 -dependent signal transduction	[CD3 -dependent signal transduction]	1.5849625007211563	4	1	0	0
24557	1520	dominant inhibitory ras mutant	[dominant inhibitory ras mutant]	1.5849625007211563	4	1	0	0
24558	1520	amount of circular DNA	[amount of circular DNA]	1.5849625007211563	4	1	0	0
24559	1520	different X1 box activity	[different X1 box activities]	1.5849625007211563	4	1	0	0
24560	1520	composite pu.1 site	[composite PU.1 site]	1.5849625007211563	3	1	0	0
24561	1520	18-bp DNA segment	[18-bp DNA segment]	1.5849625007211563	3	1	0	0
24562	1520	BCL-6 coding domain	[BCL-6 coding domain]	1.5849625007211563	3	1	0	0
24563	1520	attack of asthma	[attack of asthma]	1.5849625007211563	3	2	1	1
24564	1520	p45 nf-e2 protein	[p45 NF-E2 proteins]	1.5849625007211563	3	2	1	1
24565	1520	appropriate hydrophobic group	[appropriate hydrophobic group]	1.5849625007211563	3	1	0	0
24566	1520	primarily in the nucleus	[primarily in the nucleus]	1.5849625007211563	4	1	0	0
24567	1520	aim gain insight	[aim gaining insight]	1.5849625007211563	3	1	0	0
24568	1520	Escherichia coli lipopolysaccharide lps	[Escherichia coli lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
24569	1520	human monocyte nf-kappab activation	[human monocyte NF-kappaB activation]	1.5849625007211563	4	1	0	0
24570	1520	Conversely, diurnal rhythmicity	[Conversely, diurnal rhythmicity]	1.5849625007211563	3	1	0	0
24571	1520	effect of CD28	[effects of CD28]	1.5849625007211563	3	1	0	0
24572	1520	adhesion of ss rbc	[adhesion of SS RBC]	1.5849625007211563	4	1	0	0
24573	1520	enhance cell survival.	[enhancing cell survival.]	1.5849625007211563	3	1	0	0
24574	1520	more central position	[more central positions]	1.5849625007211563	3	1	0	0
24575	1520	balance between type 1	[balance between type 1]	1.5849625007211563	4	1	0	0
24576	1520	Staphylococcal enterotoxin SE	[Staphylococcal enterotoxins SE]	1.5849625007211563	3	1	0	0
24577	1520	upstream c/ebp-beta site	[upstream C/EBP-beta site]	1.5849625007211563	3	1	0	0
24578	1520	sp1 binding motif	[Sp1 binding motifs]	1.5849625007211563	3	1	0	0
24579	1520	lipid-laden foam cell	[lipid-laden foam cells]	1.5849625007211563	3	1	0	0
24580	1520	nuclear protein extract	[nuclear protein extracts]	1.5849625007211563	3	1	0	0
24581	1520	cytoplasmic domain of gamma(c)	[cytoplasmic domain of gamma(c)]	1.5849625007211563	4	1	0	0
24582	1520	receptor agonist thrombin	[receptor agonist thrombin]	1.5849625007211563	3	1	0	0
24583	1520	IL-5 -nonproduce t-cell clone	[IL-5 -nonproducing T-cell clones]	1.5849625007211563	4	1	0	0
24584	1520	protease treatment hydrophobicity	[protease treatment hydrophobicity]	1.5849625007211563	3	1	0	0
24585	1520	possibility get some insight	[possibility getting some insights]	1.5849625007211563	4	1	0	0
24586	1520	lps in fact,	[LPS in fact,]	1.5849625007211563	3	1	0	0
24587	1520	response to therapy	[response to therapy]	1.5849625007211563	3	2	2	2
24588	1520	early fetal development	[early fetal development]	1.5849625007211563	3	1	0	0
24589	1520	patient to patient	[patient to patient]	1.5849625007211563	3	1	0	0
24590	1520	absence of DNA.	[absence of DNA.]	1.5849625007211563	3	1	0	0
24591	1520	impaired expression of c-fo	[impaired expression of c-Fos]	1.5849625007211563	4	1	0	0
24592	1520	degradation of IL-6 mrna	[degradation of IL-6 mRNA]	1.5849625007211563	4	1	0	0
24593	1520	gamma 3 ECS responsiveness	[gamma 3 ECS responsiveness]	1.5849625007211563	4	1	0	0
24594	1520	high level il-2 production	[high level IL-2 production]	1.5849625007211563	4	1	0	0
24595	1520	ifn-gamma in the mouse,	[IFN-gamma in the mouse,]	1.5849625007211563	4	1	0	0
24596	1520	immunologically relevant gene	[immunologically relevant genes]	1.5849625007211563	3	1	0	0
24597	1520	gr bind affinity	[GR binding affinity]	1.5849625007211563	3	2	1	1
24598	1520	nucleus in b cell	[nucleus in B cells]	1.5849625007211563	4	1	0	0
24599	1520	DQA1*0501/DQB1*0302 trans class heterodimer	[DQA1*0501/DQB1*0302 trans class heterodimer]	1.5849625007211563	4	1	0	0
24600	1520	functional NK cell-mediated cytotoxicity	[functional NK cell-mediated cytotoxicity]	1.5849625007211563	4	1	0	0
24601	1520	-dq beta transcription	[-DQ beta transcription]	1.5849625007211563	3	1	0	0
24602	1520	SDS-polyacrylamide gel electrophoresis gel	[SDS-polyacrylamide gel electrophoresis gels]	1.5849625007211563	4	1	0	0
24603	1520	show the bcl-6 cd40l	[showing the BCL-6 CD40L]	1.5849625007211563	4	1	0	0
24604	1520	expression of the gr	[expression of the GR]	1.5849625007211563	4	1	0	0
24605	1520	function of profilin	[function of profilin]	1.5849625007211563	3	1	0	0
24606	1520	expression of p105 mrna	[expression of p105 mRNA]	1.5849625007211563	4	1	0	0
24607	1520	transcription factor nf-kb	[transcription factor NF-kB]	1.5849625007211563	3	2	2	2
24608	1520	interleukin 8 promoter activity	[interleukin 8 promoter activity]	1.5849625007211563	4	1	0	0
24609	1520	IL-6 1a9-m cell	[IL-6 1A9-M cells]	1.5849625007211563	3	1	0	0
24610	1520	cytosol of nonstimulated cell	[cytosol of nonstimulated cells]	1.5849625007211563	4	1	0	0
24611	1520	splenic lymphocyte depletion	[splenic lymphocyte depletion]	1.5849625007211563	3	1	0	0
24612	1520	PEBP2 alpha/aml-1-related factor	[PEBP2 alpha/AML-1-related factor]	1.5849625007211563	3	1	0	0
24613	1520	subsequent cloning of TCF-1	[Subsequent cloning of TCF-1]	1.5849625007211563	4	1	0	0
24614	1520	0.75 yeast colonies, four	[0.75 yeast colonies, four]	1.5849625007211563	4	1	0	0
24615	1520	cellular transactivation factor nf-kb	[cellular transactivation factor NF-KB]	1.5849625007211563	4	1	0	0
24616	1520	contrast, E1A -positive cell	[contrast, E1A -positive cells]	1.5849625007211563	4	1	0	0
24617	1520	969-bp promoter fragment	[969-bp promoter fragments]	1.5849625007211563	3	1	0	0
24618	1520	low proliferative activity	[low proliferative activity]	1.5849625007211563	3	2	2	2
24619	1520	phorbol myristate production	[phorbol myristate production]	1.5849625007211563	3	1	0	0
24620	1520	b lymphoid development	[B lymphoid development]	1.5849625007211563	3	1	0	0
24621	1520	human epsilon germline transcription	[human epsilon germline transcription]	1.5849625007211563	4	2	2	2
24622	1520	however, the result	[However, the result]	1.5849625007211563	3	1	0	0
24623	1520	mutation of this elements,	[mutation of these elements,]	1.5849625007211563	4	1	0	0
24624	1520	effect of MM-LDL	[effects of MM-LDL]	1.5849625007211563	3	1	0	0
24625	1520	PMA -dependent activation	[PMA -dependent activation]	1.5849625007211563	3	1	0	0
24626	1520	constitutive transcriptional activity	[constitutive transcriptional activity]	1.5849625007211563	3	1	0	0
24627	1520	human tonsillar b cell	[human tonsillar B cells]	1.5849625007211563	4	2	1	1
24628	1520	chimeric promoter ISG15 LTR	[chimeric promoter ISG15 LTR]	1.5849625007211563	4	1	0	0
24629	1520	importance of ifn-alpha	[importance of IFN-alpha]	1.5849625007211563	3	1	0	0
24630	1520	selective inhibition by IL-10	[selective inhibition by IL-10]	1.5849625007211563	4	1	0	0
24631	1520	gene encode hnf-3alpha	[genes encoding HNF-3alpha]	1.5849625007211563	3	1	0	0
24632	1520	significantly high glutathione level	[significantly higher glutathione levels]	1.5849625007211563	4	1	0	0
24633	1520	strong ap-1 inhibition	[strong AP-1 inhibition]	1.5849625007211563	3	1	0	0
24634	1520	ptdin mcd14 binding	[PtdIns mCD14 binding]	1.5849625007211563	3	1	0	0
24635	1520	Tandem ap-1-binding site	[Tandem AP-1-binding sites]	1.5849625007211563	3	1	0	0
24636	1520	fos content of ap-1	[Fos content of AP-1]	1.5849625007211563	4	1	0	0
24637	1520	Epstein-Barr virus oncoprotein latent	[Epstein-Barr virus oncoprotein latent]	1.5849625007211563	4	1	0	0
24638	1520	translocation of the heterodimer	[translocation of the heterodimer]	1.5849625007211563	4	1	0	0
24639	1520	early stage of atherosclerosis	[earliest stages of atherosclerosis]	1.5849625007211563	4	1	0	0
24640	1520	apoptosis of u937 cell	[apoptosis of U937 cells]	1.5849625007211563	4	1	0	0
24641	1520	growth factor-dependent cell line	[growth factor-dependent cell lines]	1.5849625007211563	4	2	2	2
24642	1520	same T cell	[same T cells]	1.5849625007211563	3	1	0	0
24643	1520	activation of Erk2	[activation of Erk2]	1.5849625007211563	3	1	0	0
24644	1520	early productive cycle	[early productive cycle]	1.5849625007211563	3	1	0	0
24645	1520	mean serum cortisol level	[mean serum cortisol level]	1.5849625007211563	4	1	0	0
24646	1520	NF-kappa b transcription factor,	[NF-kappa B transcription factor,]	1.5849625007211563	4	1	0	0
24647	1520	common octamer motif	[common octamer motif]	1.5849625007211563	3	1	0	0
24648	1520	PMA /a23187 stimulation	[PMA /A23187 stimulation]	1.5849625007211563	3	1	0	0
24649	1520	severe runting, skin defect	[severe runting, skin defects]	1.5849625007211563	4	1	0	0
24650	1520	model of leukaemogenesis	[model of leukaemogenesis]	1.5849625007211563	3	1	0	0
24651	1520	addition of interferon alpha	[addition of interferon alpha]	1.5849625007211563	4	1	0	0
24652	1520	episomal maintenance during latency	[episomal maintenance during latency]	1.5849625007211563	4	1	0	0
24653	1520	swi3 of saccharomy cerevisiae	[SWI3 of Saccharomyces cerevisiae]	1.5849625007211563	4	1	0	0
24654	1520	maintenance of self-tolerance.	[maintenance of self-tolerance.]	1.5849625007211563	3	1	0	0
24655	1520	inducible camp early repressor	[inducible cAMP early repressor]	1.5849625007211563	4	1	0	0
24656	1520	effect of ldl oxldl	[effects of LDL oxLDL]	1.5849625007211563	4	1	0	0
24657	1520	platelet glycoprotein gp	[Platelet glycoprotein GP]	1.5849625007211563	3	1	0	0
24658	1520	other arginine mutation	[other arginine mutations]	1.5849625007211563	3	1	0	0
24659	1520	mutational mobility shift analysis	[mutational mobility shift analyses]	1.5849625007211563	4	1	0	0
24660	1520	nf-kappab with monocyte differentiation	[NF-kappaB with monocyte differentiation]	1.5849625007211563	4	1	0	0
24661	1520	region between -95	[region between -95]	1.5849625007211563	3	1	0	0
24662	1520	gene expression under control	[gene expression under control]	1.5849625007211563	4	1	0	0
24663	1520	region between -73	[region between -73]	1.5849625007211563	3	1	0	0
24664	1520	region between -85	[region between -85]	1.5849625007211563	3	1	0	0
24665	1520	antibody against NFAT	[antibody against NFAT]	1.5849625007211563	3	1	0	0
24666	1520	mechanism of glucocorticosteroid action	[mechanism of glucocorticosteroid action]	1.5849625007211563	4	1	0	0
24667	1520	several short sequence motif	[several short sequence motifs]	1.5849625007211563	4	1	0	0
24668	1520	induce c-jun transcription	[inducing c-jun transcription]	1.5849625007211563	3	1	0	0
24669	1520	mutation of this site.	[mutation of this site.]	1.5849625007211563	4	1	0	0
24670	1520	unique transcription factor	[unique transcription factor]	1.5849625007211563	3	1	0	0
24671	1520	include erythroid precursor	[including erythroid precursors]	1.5849625007211563	3	1	0	0
24672	1520	jurkat cell t-cell line	[Jurkat cells T-cell line]	1.5849625007211563	4	1	0	0
24673	1520	cord blood culture	[Cord blood cultures]	1.5849625007211563	3	1	0	0
24674	1520	transcription factor tcf-1	[transcription factor TCF-1]	1.5849625007211563	3	2	2	2
24675	1520	previous experiment by others,	[previous experiments by others,]	1.5849625007211563	4	1	0	0
24676	1520	control of monoblastic differentiation	[control of monoblastic differentiation]	1.5849625007211563	4	1	0	0
24677	1520	transcription factor nf-e2	[transcription factor NF-E2]	1.5849625007211563	3	2	1	1
24678	1520	offspring of alcoholics	[offspring of alcoholics]	1.5849625007211563	3	1	0	0
24679	1520	hcmv binding to monocyte	[HCMV binding to monocytes]	1.5849625007211563	4	1	0	0
24680	1520	tradd activation activation	[TRADD activation activation]	1.5849625007211563	3	1	0	0
24681	1520	human monoblastic cell THP-1	[human monoblastic cells THP-1]	1.5849625007211563	4	1	0	0
24682	1520	group b type 35	[group B type 35]	1.5849625007211563	4	1	0	0
24683	1520	immune hyporesponsiveness accompany aging.	[immune hyporesponsiveness accompanying aging.]	1.5849625007211563	4	1	0	0
24684	1520	decidual prl gene expression	[decidual PRL gene expression]	1.5849625007211563	4	1	0	0
24685	1520	activation of pp90rsk	[Activation of pp90rsk]	1.5849625007211563	3	2	1	1
24686	1520	activity in vivo	[activity in vivo]	1.5849625007211563	3	2	2	2
24687	1520	rxr-specific ligand ro47-5944	[RXR-specific ligand Ro47-5944]	1.5849625007211563	3	1	0	0
24688	1520	mrna 141 bp	[mRNA 141 bp]	1.5849625007211563	3	1	0	0
24689	1520	IL-13 mrna expression	[IL-13 mRNA expression]	1.5849625007211563	3	1	0	0
24690	1520	Genetic inactivation of JAK3	[Genetic inactivation of JAK3]	1.5849625007211563	4	1	0	0
24691	1520	il-4 in human monocyte	[IL-4 in human monocytes]	1.5849625007211563	4	1	0	0
24692	1520	CONCLUSION: in IBD	[CONCLUSION: In IBD]	1.5849625007211563	3	1	0	0
24693	1520	gene in human cell	[genes in human cells]	1.5849625007211563	4	2	1	1
24694	1520	ten-day exposure to Epo	[Ten-day exposure to Epo]	1.5849625007211563	4	1	0	0
24695	1520	normal tcrzeta level	[normal TCRzeta levels]	1.5849625007211563	3	1	0	0
24696	1520	whole-blood cell culture (p	[whole-blood cell cultures (P]	1.5849625007211563	4	1	0	0
24697	1520	IL-3 -dependent pro-B cell	[IL-3 -dependent pro-B cells]	1.5849625007211563	4	1	0	0
24698	1520	genomic sterol regulatory sequence	[genomic sterol regulatory sequence]	1.5849625007211563	4	1	0	0
24699	1520	NF-kappa b expression	[NF-kappa B expression]	1.5849625007211563	3	1	0	0
24700	1520	such as egr-1	[such as egr-1]	1.5849625007211563	3	1	0	0
24701	1520	block abs to il-2	[blocking Abs to IL-2]	1.5849625007211563	4	1	0	0
24702	1520	induction with M. tuberculosis	[induction with M. tuberculosis]	1.5849625007211563	4	1	0	0
24703	1520	initiation of the cycle	[initiation of the cycle]	1.5849625007211563	4	1	0	0
24704	1520	base pair -55	[base pair -55]	1.5849625007211563	3	1	0	0
24705	1520	activation of Jun kinase	[activation of Jun kinase]	1.5849625007211563	4	2	1	1
24706	1520	recombinant adeno-associated virus aav	[recombinant adeno-associated virus AAV]	1.5849625007211563	4	1	0	0
24707	1520	human type ii	[human type II]	1.5849625007211563	3	1	0	0
24708	1520	cag repeat in SBMA	[CAG repeats in SBMA]	1.5849625007211563	4	1	0	0
24709	1520	endometrial stromal cell	[endometrial stromal cells]	1.5849625007211563	3	2	1	1
24710	1520	cytotoxic drug doxorubicin	[cytotoxic drug doxorubicin]	1.5849625007211563	3	1	0	0
24711	1520	c-myc gene amplification	[c-myc gene amplification]	1.5849625007211563	3	1	0	0
24712	1520	markedly impaired binding	[Markedly impaired binding]	1.5849625007211563	3	1	0	0
24713	1520	5 micrograms/ml each transferrin	[5 micrograms/ml each transferrin]	1.5849625007211563	4	1	0	0
24714	1520	osteoblast nuclear extract	[osteoblast nuclear extracts]	1.5849625007211563	3	1	0	0
24715	1520	soluble fas ligand cd95	[soluble Fas ligand CD95]	1.5849625007211563	4	1	0	0
24716	1520	predominantly RAR alpha	[predominantly RAR alpha]	1.5849625007211563	3	1	0	0
24717	1520	constitutive b cell	[constitutive B cells]	1.5849625007211563	3	1	0	0
24718	1520	calcium-dependent phosphatase calcineurin	[calcium-dependent phosphatase calcineurin]	1.5849625007211563	3	1	0	0
24719	1520	calcineurin responsiveness of NFAT	[calcineurin responsiveness of NFAT]	1.5849625007211563	4	1	0	0
24720	1520	unspliced viral gag-pol mrna	[unspliced viral gag-pol mRNA]	1.5849625007211563	4	1	0	0
24721	1520	27-amino acid regulatory motif	[27-amino acid regulatory motif]	1.5849625007211563	4	1	0	0
24722	1520	understanding of the function	[understanding of the function]	1.5849625007211563	4	1	0	0
24723	1520	multiple p21ras effector pathway	[Multiple p21ras effector pathways]	1.5849625007211563	4	1	0	0
24724	1520	use atl-16t cell	[Using ATL-16T cells]	1.5849625007211563	3	1	0	0
24725	1520	significant gr mrna induction.	[significant GR mRNA induction.]	1.5849625007211563	4	1	0	0
24726	1520	viral transcriptional transactivator	[viral transcriptional transactivator]	1.5849625007211563	3	1	0	0
24727	1520	effect on hybridization pattern	[effect on hybridization pattern]	1.5849625007211563	4	1	0	0
24728	1520	IFN-gamma mrna level	[IFN-gamma mRNA levels]	1.5849625007211563	3	1	0	0
24729	1520	brief overview of bcl-2	[brief overview of bcl-2]	1.5849625007211563	4	1	0	0
24730	1520	human CD5 gene	[human CD5 gene]	1.5849625007211563	3	1	0	0
24731	1520	human alpha-like globin gene	[human alpha-like globin genes]	1.5849625007211563	4	1	0	0
24732	1520	N-terminal signal sequence	[N-terminal signal sequences]	1.5849625007211563	3	1	0	0
24733	1520	AML1 gene product,	[AML1 gene product,]	1.5849625007211563	3	1	0	0
24734	1520	Spi-1 and/or fli-1 gene	[Spi-1 and/or Fli-1 genes]	1.5849625007211563	4	1	0	0
24735	1520	LMP1 signal through tradd	[LMP1 signaling through TRADD]	1.5849625007211563	4	1	0	0
24736	1520	contrast with endometriosis	[contrast with endometriosis]	1.5849625007211563	3	1	0	0
24737	1520	separate heterocomplex with stat1	[separate heterocomplexes with STAT1]	1.5849625007211563	4	1	0	0
24738	1520	status of IL-2 secretion	[status of IL-2 secretion]	1.5849625007211563	4	1	0	0
24739	1520	polarization to eth1	[polarization to eTh1]	1.5849625007211563	3	1	0	0
24740	1520	other immediate response gene	[other immediate response genes]	1.5849625007211563	4	1	0	0
24741	1520	asp to Ala	[Asp to Ala]	1.5849625007211563	3	1	0	0
24742	1520	implication for immunity	[Implications for immunity]	1.5849625007211563	3	1	0	0
24743	1520	cross-link cell surface CD3	[cross-linking cell surface CD3]	1.5849625007211563	4	1	0	0
24744	1520	correlative LTR transactivation	[correlative LTR transactivation]	1.5849625007211563	3	1	0	0
24745	1520	co-stimulatory molecule b7.1	[co-stimulatory molecule B7.1]	1.5849625007211563	3	1	0	0
24746	1520	panel of transcription factor	[panel of transcription factors]	1.5849625007211563	4	1	0	0
24747	1520	aim identify segment	[aim identifying segments]	1.5849625007211563	3	1	0	0
24748	1520	normal lymphoid tissue structure	[normal lymphoid tissue structure]	1.5849625007211563	4	1	0	0
24749	1520	data from cell culture	[Data from cell culture]	1.5849625007211563	4	1	0	0
24750	1520	understanding of this molecule	[understanding of these molecules]	1.5849625007211563	4	1	0	0
24751	1520	s49 cell apoptosis	[S49 cell apoptosis]	1.5849625007211563	3	1	0	0
24752	1520	MLV transcriptional regulation	[MLV transcriptional regulation]	1.5849625007211563	3	1	0	0
24753	1520	female embryonic development	[female embryonic development]	1.5849625007211563	3	1	0	0
24754	1520	effect on IL-10 secretion	[effect on IL-10 secretion]	1.5849625007211563	4	1	0	0
24755	1520	maternal immune system	[maternal immune system]	1.5849625007211563	3	1	0	0
24756	1520	gene activation of cytokine	[gene activation of cytokines]	1.5849625007211563	4	2	1	1
24757	1520	3 kinase /pkb	[3 kinase /PKB]	1.5849625007211563	3	1	0	0
24758	1520	major e2f complex	[major E2F complex]	1.5849625007211563	3	1	0	0
24759	1520	distinct tissue-specific constraint	[distinct tissue-specific constraints]	1.5849625007211563	3	1	0	0
24760	1520	nuclear receptor occupancy	[nuclear receptor occupancy]	1.5849625007211563	3	1	0	0
24761	1520	critical cell function,	[critical cell function,]	1.5849625007211563	3	1	0	0
24762	1520	Study in mouse	[Studies in mice]	1.5849625007211563	3	1	0	0
24763	1520	block CD8 interaction	[blocking CD8 interaction]	1.5849625007211563	3	1	0	0
24764	1520	gene expression in erythroid	[gene expression in erythroid]	1.5849625007211563	4	1	0	0
24765	1520	binding of Sp1	[binding of Sp1]	1.5849625007211563	3	2	2	2
24766	1520	product of the tic	[product of the t(3;21),]	1.5849625007211563	4	1	0	0
24767	1520	hypothalamic-pituitary-adrenocortical (hpa) axis functioning	[hypothalamic-pituitary-adrenocortical (HPA) axis functioning]	1.5849625007211563	4	1	0	0
24768	1520	rel family member	[Rel family members]	1.5849625007211563	3	1	0	0
24769	1520	encode fos-related Ag 1	[encoding Fos-related Ag 1]	1.5849625007211563	4	1	0	0
24770	1520	different proximal mechanism	[different proximal mechanisms]	1.5849625007211563	3	1	0	0
24771	1520	RXR RAR -specific agonist	[RXR RAR -specific agonists]	1.5849625007211563	4	1	0	0
24772	1520	malignant progression of astrocytomas	[malignant progression of astrocytomas]	1.5849625007211563	4	1	0	0
24773	1520	Interleukin-2 IL-2 promoter activity	[Interleukin-2 IL-2 promoter activity]	1.5849625007211563	4	1	0	0
24774	1520	transcription control element	[transcription control elements]	1.5849625007211563	3	1	0	0
24775	1520	gst pull-down experiment	[GST pull-down experiments]	1.5849625007211563	3	1	0	0
24776	1520	ebf -binding site	[EBF -binding site]	1.5849625007211563	3	2	2	2
24777	1520	loss of il-1- function	[loss of IL-1- function]	1.5849625007211563	4	1	0	0
24778	1520	tumor additional immunohistochemical study	[tumor additional immunohistochemical studies]	1.5849625007211563	4	1	0	0
24779	1520	Sp1 binding site adjacent	[Sp1 binding site adjacent]	1.5849625007211563	4	1	0	0
24780	1520	AM580 a derivative	[AM580 a derivative]	1.5849625007211563	3	2	2	2
24781	1520	beta-chain of the receptor	[beta-chain of the receptor]	1.5849625007211563	4	1	0	0
24782	1520	subset of b lymphocyte	[subset of B lymphocytes]	1.5849625007211563	4	1	0	0
24783	1520	Epstein-Barr virus bzlf1 transactivator	[Epstein-Barr virus BZLF1 transactivator]	1.5849625007211563	4	1	0	0
24784	1520	c-Rel/ p65 heterodimer	[c-Rel/ p65 heterodimers]	1.5849625007211563	3	2	1	1
24785	1520	ets family of protein	[Ets family of proteins]	1.5849625007211563	4	1	0	0
24786	1520	retinoblastoma protein expression	[Retinoblastoma protein expression]	1.5849625007211563	3	1	0	0
24787	1520	similar electrophoretic mobility	[similar electrophoretic mobilities]	1.5849625007211563	3	1	0	0
24788	1520	normal 135eoh)2d3 synthesis	[normal 1,25(OH)2D3 synthesis]	1.5849625007211563	3	1	0	0
24789	1520	ubiquitous otf-1 factor	[ubiquitous OTF-1 factor]	1.5849625007211563	3	1	0	0
24790	1520	sensitivity to megakaryocytic differentiation	[sensitivity to megakaryocytic differentiation]	1.5849625007211563	4	1	0	0
24791	1520	association of pi3-k	[association of PI3-K]	1.5849625007211563	3	1	0	0
24792	1520	calcium ionophore (a23187)	[calcium ionophore (A23187)]	1.5849625007211563	3	1	0	0
24793	1520	leukemic clone CEM c1	[leukemic clone CEM C1]	1.5849625007211563	4	1	0	0
24794	1520	agreement with the concept	[agreement with the concept]	1.5849625007211563	4	1	0	0
24795	1520	Strikingly, costimulation with ec	[Strikingly, costimulation with EC]	1.5849625007211563	4	1	0	0
24796	1520	TCP succinate (200 microM,	[TCP succinate (200 microM,]	1.5849625007211563	4	1	0	0
24797	1520	1 h lag,	[1 h lag,]	1.5849625007211563	3	1	0	0
24798	1520	il-4-induced tyrosine phosphorylation	[IL-4-induced tyrosine phosphorylation]	1.5849625007211563	3	2	2	2
24799	1520	such as cell-free extract	[such as cell-free extracts]	1.5849625007211563	4	1	0	0
24800	1520	phorbol ester stimulation	[phorbol ester stimulation]	1.5849625007211563	3	2	1	1
24801	1520	investigation of the factor	[investigation of the factors]	1.5849625007211563	4	1	0	0
24802	1520	concentration of VDR	[concentration of VDR]	1.5849625007211563	3	1	0	0
24803	1520	trans-activation domain of e2	[trans-activation domain of E2]	1.5849625007211563	4	1	0	0
24804	1520	very low proliferative activity,	[very low proliferative activity,]	1.5849625007211563	4	1	0	0
24805	1520	infiltration of cd4+ lymphocyte	[infiltration of CD4+ lymphocytes]	1.5849625007211563	4	1	0	0
24806	1520	expression of inflammatory cytokine	[expression of inflammatory cytokines]	1.5849625007211563	4	2	2	2
24807	1520	mean kd (affinity)	[mean Kd (affinity)]	1.5849625007211563	3	1	0	0
24808	1520	number of alpha granule	[numbers of alpha granules]	1.5849625007211563	4	1	0	0
24809	1520	very close homologue, KIAA0144	[very close homologue, KIAA0144]	1.5849625007211563	4	1	0	0
24810	1520	E-selectin hl60 cell binding	[E-selectin HL60 cell binding]	1.5849625007211563	4	1	0	0
24811	1520	21 base pair repeat	[21 base pair repeats]	1.5849625007211563	4	1	0	0
24812	1520	two distinct complex	[two distinct complexes]	1.5849625007211563	3	1	0	0
24813	1520	signal control the expression	[signals controlling the expression]	1.5849625007211563	4	1	0	0
24814	1520	electrophoretic mobility shift assays,	[electrophoretic mobility shift assays,]	1.5849625007211563	4	1	0	0
24815	1520	role in the induction	[role in the induction]	1.5849625007211563	4	2	1	1
24816	1520	difference in (Ca2+)i requirement	[differences in (Ca2+)i requirement]	1.5849625007211563	4	1	0	0
24817	1520	reticulocyte lysate system	[Reticulocyte Lysate System]	1.5849625007211563	3	1	0	0
24818	1520	two E(gre) motif equally,	[two E(gre) motifs equally,]	1.5849625007211563	4	1	0	0
24819	1520	expression of interleukin-4 gene	[expression of interleukin-4 genes]	1.5849625007211563	4	1	0	0
24820	1520	NF-kappa b p65 heterodimer	[NF-kappa B P65 heterodimer]	1.5849625007211563	4	1	0	0
24821	1520	effectiveness of such approaches.	[effectiveness of such approaches.]	1.5849625007211563	4	1	0	0
24822	1520	absence of abnormality	[absence of abnormalities]	1.5849625007211563	3	2	2	2
24823	1520	kinetic of the development	[kinetics of the development]	1.5849625007211563	4	1	0	0
24824	1520	CRE -binding protein	[CRE -binding protein]	1.5849625007211563	3	1	0	0
24825	1520	elk-1 transcription differentiate monocyte	[elk-1 transcription differentiating monocytes]	1.5849625007211563	4	1	0	0
24826	1520	intracellular signalling pathway	[intracellular signalling pathways]	1.5849625007211563	3	1	0	0
24827	1520	immunostained tumor cell	[Immunostained tumor cells]	1.5849625007211563	3	1	0	0
24828	1520	high affinity ige receptor	[high affinity IgE receptor]	1.5849625007211563	4	1	0	0
24829	1520	nf-kappa b/c-rel protein	[NF-kappa B/c-Rel proteins]	1.5849625007211563	3	1	0	0
24830	1520	absence of lck expression	[absence of Lck expression]	1.5849625007211563	4	1	0	0
24831	1520	Study of this female	[Studies of these females]	1.5849625007211563	4	1	0	0
24832	1520	Rheumatoid arthritis synovial tissue	[Rheumatoid arthritis synovial tissue]	1.5849625007211563	4	1	0	0
24833	1520	hiv-2 enhancer in monocyte	[HIV-2 enhancer in monocytes]	1.5849625007211563	4	1	0	0
24834	1520	two alternative promoter Palpha	[two alternative promoters Palpha]	1.5849625007211563	4	1	0	0
24835	1520	presence of Tat	[presence of Tat]	1.5849625007211563	3	1	0	0
24836	1520	regulation by glucocorticoid	[regulation by glucocorticoids]	1.5849625007211563	3	1	0	0
24837	1520	parental u937 cell	[parental U937 cells]	1.5849625007211563	3	2	2	2
24838	1520	STAT1 alpha protein	[STAT1 alpha protein]	1.5849625007211563	3	1	0	0
24839	1520	inhibition of cyclooxygenase activity	[inhibition of cyclooxygenase activity]	1.5849625007211563	4	1	0	0
24840	1520	flt-3 ligand FL	[Flt-3 ligand FL]	1.5849625007211563	3	1	0	0
24841	1520	8 to 16 hour	[8 to 16 hours]	1.5849625007211563	4	1	0	0
24842	1520	progesterone receptor complex	[progesterone receptor complexes]	1.5849625007211563	3	1	0	0
24843	1520	activation-induced fasl promoter activity	[activation-induced FasL promoter activity]	1.5849625007211563	4	1	0	0
24844	1520	effect on expression	[effect on expression]	1.5849625007211563	3	2	2	2
24845	1520	chimeric g-csf-r /il-7r alpha	[chimeric G-CSF-R /IL-7R alpha]	1.5849625007211563	4	1	0	0
24846	1520	3' enhancer inactivity	[3' enhancer inactivity]	1.5849625007211563	3	1	0	0
24847	1520	goat anti-mouse igg ab	[goat anti-mouse IgG Ab]	1.5849625007211563	4	1	0	0
24848	1520	two B-lymphoblastoid cell line	[two B-lymphoblastoid cell lines]	1.5849625007211563	4	1	0	0
24849	1520	preincubation of the cell	[preincubation of the cells]	1.5849625007211563	4	1	0	0
24850	1520	two common haplotype	[two common haplotypes]	1.5849625007211563	3	2	1	1
24851	1520	same gene segment	[same gene segment]	1.5849625007211563	3	1	0	0
24852	1520	lymphocyte glucocorticoid receptor predictor	[Lymphocyte glucocorticoid receptor predictor]	1.5849625007211563	4	1	0	0
24853	1520	inability of prolonged stimulation	[inability of prolonged stimulation]	1.5849625007211563	4	1	0	0
24854	1520	effect of cryptococcus neoforman	[effect of Cryptococcus neoformans]	1.5849625007211563	4	1	0	0
24855	1520	phosphorylation of hiv-tf1	[phosphorylation of HIV-TF1]	1.5849625007211563	3	1	0	0
24856	1520	human cd3epsilon transgenic mouse	[human CD3epsilon transgenic mice]	1.5849625007211563	4	1	0	0
24857	1520	period of g0/g1 prolongation	[period of G0/G1 prolongation]	1.5849625007211563	4	1	0	0
24858	1520	Fc gamma RI gene	[Fc gamma RI gene]	1.5849625007211563	4	1	0	0
24859	1520	essential nature of GATA-1	[essential nature of GATA-1]	1.5849625007211563	4	1	0	0
24860	1520	type 2 diabete	[type 2 diabetes]	1.5849625007211563	3	1	0	0
24861	1520	-dependent transcription in vivo	[-dependent transcription in vivo]	1.5849625007211563	4	1	0	0
24862	1520	presence of nf-kappa b	[presence of NF-kappa B]	1.5849625007211563	4	1	0	0
24863	1520	absence of exogenous tnf-alpha	[absence of exogenous TNF-alpha]	1.5849625007211563	4	1	0	0
24864	1520	parent cell line u937	[parent cell line U937]	1.5849625007211563	4	1	0	0
24865	1520	interleukin-1 beta gene	[interleukin-1 beta gene]	1.5849625007211563	3	2	1	1
24866	1520	equivalent degree of inhibition.	[equivalent degree of inhibition.]	1.5849625007211563	4	1	0	0
24867	1520	inhibitor of nf kappab	[inhibitor of NF kappaB]	1.5849625007211563	4	1	0	0
24868	1520	rate of lysosomal degradation	[rate of lysosomal degradation]	1.5849625007211563	4	1	0	0
24869	1520	mapping of new probe	[mapping of new probes]	1.5849625007211563	4	1	0	0
24870	1520	absence of ciita	[absence of CIITA]	1.5849625007211563	3	1	0	0
24871	1520	control of T gene	[control of T genes]	1.5849625007211563	4	1	0	0
24872	1520	vitro globin gene	[vitro globin gene]	1.5849625007211563	3	1	0	0
24873	1520	one group of mutant	[One group of mutants]	1.5849625007211563	4	1	0	0
24874	1520	variety of cytokine gene	[variety of cytokine genes]	1.5849625007211563	4	1	0	0
24875	1520	8 month of therapy	[8 months of therapy]	1.5849625007211563	4	1	0	0
24876	1520	region of intracellular homology	[region of intracellular homology]	1.5849625007211563	4	1	0	0
24877	1520	target IFN synthesis	[targeting IFN synthesis]	1.5849625007211563	3	1	0	0
24878	1520	stringent cut-off values.	[stringent cut-off values.]	1.5849625007211563	3	1	0	0
24879	1520	b lymphocyte ig secretion	[B lymphocyte Ig secretion]	1.5849625007211563	4	1	0	0
24880	1520	only in nuclear extract	[only in nuclear extracts]	1.5849625007211563	4	1	0	0
24881	1520	human x box	[human X box]	1.5849625007211563	3	1	0	0
24882	1520	absence of vanadate	[absence of vanadate]	1.5849625007211563	3	1	0	0
24883	1520	amount of p80c-rel	[amount of p80c-rel]	1.5849625007211563	3	1	0	0
24884	1520	human papillomaviruse hpv	[human papillomaviruses HPV]	1.5849625007211563	3	1	0	0
24885	1520	kit ligand-dependent proliferation	[Kit ligand-dependent proliferation]	1.5849625007211563	3	1	0	0
24886	1520	major immediate-early protein ie1	[major immediate-early protein IE1]	1.5849625007211563	4	1	0	0
24887	1520	different lymphocyte tropism	[different lymphocyte tropisms]	1.5849625007211563	3	1	0	0
24888	1520	basal serum cortisol concentration	[basal serum cortisol concentrations]	1.5849625007211563	4	1	0	0
24889	1520	GM-CSF gene essential	[GM-CSF gene essential]	1.5849625007211563	3	1	0	0
24890	1520	inhibition of mapk activity	[inhibition of MAPK activity]	1.5849625007211563	4	1	0	0
24891	1520	inhibit nf-kappab -mediated transcription	[inhibiting NF-kappaB -mediated transcription]	1.5849625007211563	4	1	0	0
24892	1520	double-immunogold labeling of PML	[double-immunogold labeling of PML]	1.5849625007211563	4	1	0	0
24893	1520	pattern of protein binding	[pattern of protein binding]	1.5849625007211563	4	1	0	0
24894	1520	bind site of g28-5	[binding site of G28-5]	1.5849625007211563	4	1	0	0
24895	1520	resistance in asthma	[resistance in asthma]	1.5849625007211563	3	2	2	2
24896	1520	regulate human granulocyte apoptosis	[regulating human granulocyte apoptosis]	1.5849625007211563	4	1	0	0
24897	1520	reason for the prevalence	[reasons for the prevalence]	1.5849625007211563	4	1	0	0
24898	1520	Src family kinase Lck	[Src family kinases Lck]	1.5849625007211563	4	1	0	0
24899	1520	detectable cell toxicity.	[detectable cell toxicity.]	1.5849625007211563	3	1	0	0
24900	1520	several indirect observations,	[several indirect observations,]	1.5849625007211563	3	1	0	0
24901	1520	two clinically distinct stages:	[two clinically distinct stages:]	1.5849625007211563	4	1	0	0
24902	1520	characterization of line	[Characterization of line]	1.5849625007211563	3	1	0	0
24903	1520	transcriptional activator capable	[transcriptional activator capable]	1.5849625007211563	3	1	0	0
24904	1520	two inhibitor in monocyte	[two inhibitors in monocytes]	1.5849625007211563	4	1	0	0
24905	1520	mammalian cell to stress	[mammalian cells to stress]	1.5849625007211563	4	1	0	0
24906	1520	follow transcription factor	[following transcription factors]	1.5849625007211563	3	1	0	0
24907	1520	contrast, C3H mouse	[contrast, C3H mice]	1.5849625007211563	3	1	0	0
24908	1520	complex sedimenting at 8.3s	[complex sedimenting at 8.3S]	1.5849625007211563	4	1	0	0
24909	1520	association a activator	[Association an activator]	1.5849625007211563	3	1	0	0
24910	1520	tumor cell of CHD	[tumor cells of CHD]	1.5849625007211563	4	2	1	1
24911	1520	pbmc from hiv-1 patient	[PBMCs from HIV-1 patients]	1.5849625007211563	4	1	0	0
24912	1520	network of protein-protein interaction	[network of protein-protein interactions]	1.5849625007211563	4	1	0	0
24913	1520	nucleotide sequence requirement	[nucleotide sequence requirements]	1.5849625007211563	3	2	1	1
24914	1520	new b-cell-specific enhancer element	[new B-cell-specific enhancer element]	1.5849625007211563	4	1	0	0
24915	1520	c/ebpbeta GATA-1 expression vector	[C/EBPbeta GATA-1 expression vectors]	1.5849625007211563	4	1	0	0
24916	1520	receptor from the nonresponder	[receptors from the nonresponders]	1.5849625007211563	4	2	2	2
24917	1520	reach a maximum	[reaching a maximum]	1.5849625007211563	3	2	2	2
24918	1520	SCL with erythroid proliferation	[SCL with erythroid proliferation]	1.5849625007211563	4	1	0	0
24919	1520	relationship with germinal centers.	[relationship with germinal centers.]	1.5849625007211563	4	1	0	0
24920	1520	antigen handling cell	[antigen handling cells]	1.5849625007211563	3	1	0	0
24921	1520	Takayasu arteritis patient	[Takayasu arteritis patient]	1.5849625007211563	3	1	0	0
24922	1520	non-hodgkin lymphoma NHL	[non-Hodgkin lymphoma NHL]	1.5849625007211563	3	1	0	0
24923	1520	u-373 mg cell	[U-373 MG cells]	1.5849625007211563	3	1	0	0
24924	1520	nf-kappab component p50	[NF-kappaB components p50]	1.5849625007211563	3	1	0	0
24925	1520	two serine residue	[two serine residues]	1.5849625007211563	3	2	1	1
24926	1520	11 beta-methyl analog	[11 beta-methyl analog]	1.5849625007211563	3	1	0	0
24927	1520	number of adherent leukocyte	[number of adherent leukocytes]	1.5849625007211563	4	1	0	0
24928	1520	high reporter gene activity	[higher reporter gene activity]	1.5849625007211563	4	1	0	0
24929	1520	profile of adhesion molecule	[profile of adhesion molecules]	1.5849625007211563	4	1	0	0
24930	1520	EBNA-2 transactivation of LMP1	[EBNA-2 transactivation of LMP1]	1.5849625007211563	4	1	0	0
24931	1520	BCL-6 a poz/zinc-finger protein	[BCL-6 a POZ/zinc-finger protein]	1.5849625007211563	4	1	0	0
24932	1520	enhancer of [E(spl)] gene	[Enhancer of [E(spl)] genes]	1.5849625007211563	4	1	0	0
24933	1520	panel of mAECA	[panel of mAECA]	1.5849625007211563	3	1	0	0
24934	1520	increase of p21(waf1/cip1) transcript	[increase of p21(WAF1/CIP1) transcript]	1.5849625007211563	4	1	0	0
24935	1520	six B-cell line	[six B-cell lines]	1.5849625007211563	3	1	0	0
24936	1520	synthesis of proinflammatory cytokine	[synthesis of proinflammatory cytokines]	1.5849625007211563	4	1	0	0
24937	1520	identification of a ionomycin	[Identification of an ionomycin]	1.5849625007211563	4	1	0	0
24938	1520	myeloid surface marker cd11b	[myeloid surface markers CD11b]	1.5849625007211563	4	1	0	0
24939	1520	presence of synthetic oligonucleotide	[presence of synthetic oligonucleotides]	1.5849625007211563	4	1	0	0
24940	1520	downstream TATA element	[downstream TATA element]	1.5849625007211563	3	1	0	0
24941	1520	cell surface molecule(s)	[cell surface molecule(s)]	1.5849625007211563	3	1	0	0
24942	1520	transient expression of NFATc.beta	[Transient expression of NFATc.beta]	1.5849625007211563	4	1	0	0
24943	1520	single c-Myb binding site	[single c-Myb binding site]	1.5849625007211563	4	1	0	0
24944	1520	dna-binding factor contain stat1	[DNA-binding factor containing STAT1]	1.5849625007211563	4	1	0	0
24945	1520	cascade of gene activation	[cascade of gene activation]	1.5849625007211563	4	1	0	0
24946	1520	low dose dexamethasone therapy	[Low dose dexamethasone therapy]	1.5849625007211563	4	1	0	0
24947	1520	thus, tyrosine phosphorylation	[Thus, tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
24948	1520	glucocorticoid receptor together	[glucocorticoid receptor together]	1.5849625007211563	3	1	0	0
24949	1520	high level of amplification	[high levels of amplification]	1.5849625007211563	4	2	2	2
24950	1520	expression of egr-1 mrna	[expression of Egr-1 mRNA]	1.5849625007211563	4	1	0	0
24951	1520	substitution per se	[substitutions per se]	1.5849625007211563	3	1	0	0
24952	1520	glucocorticoid receptor abnormality	[glucocorticoid receptor abnormality]	1.5849625007211563	3	1	0	0
24953	1520	1) rheumatoid synovial cell	[1) rheumatoid synovial cells]	1.5849625007211563	4	1	0	0
24954	1520	various synthetic glucocorticoid	[various synthetic glucocorticoids]	1.5849625007211563	3	1	0	0
24955	1520	rel-related 65-kd protein	[rel-related 65-kD protein]	1.5849625007211563	3	1	0	0
24956	1520	treatment with arsenic trioxide	[treatment with arsenic trioxide]	1.5849625007211563	4	1	0	0
24957	1520	b cell function	[B cell functions]	1.5849625007211563	3	2	2	2
24958	1520	chromosome 1 lp	[chromosome 1 lp]	1.5849625007211563	3	1	0	0
24959	1520	human MHC class ii	[Human MHC class II]	1.5849625007211563	4	2	1	1
24960	1520	steady state mrna level	[steady state mRNA levels]	1.5849625007211563	4	2	1	1
24961	1520	transcriptional activity of nf-kappab	[transcriptional activity of NF-kappaB]	1.5849625007211563	4	1	0	0
24962	1520	three group of patient	[three groups of patients]	1.5849625007211563	4	1	0	0
24963	1520	accord to the criterion	[according to the criteria]	1.5849625007211563	4	1	0	0
24964	1520	IL-2 the IL-2R alpha-chain	[IL-2 the IL-2R alpha-chain]	1.5849625007211563	4	1	0	0
24965	1520	other g0s gene	[other G0S genes]	1.5849625007211563	3	1	0	0
24966	1520	processing of pro-il-16	[processing of pro-IL-16]	1.5849625007211563	3	1	0	0
24967	1520	vitamin d -resistant	[vitamin D -resistant]	1.5849625007211563	3	1	0	0
24968	1520	tpa erk2 activity.	[TPA ERK2 activity.]	1.5849625007211563	3	1	0	0
24969	1520	TCR -inducible gene expression	[TCR -inducible gene expression]	1.5849625007211563	4	1	0	0
24970	1520	context-dependent transcriptional activation	[context-dependent transcriptional activation]	1.5849625007211563	3	1	0	0
24971	1520	oxidative signalling process	[oxidative signalling processes]	1.5849625007211563	3	2	1	1
24972	1520	Leukotriene B4 LTB4	[Leukotriene B4 LTB4]	1.5849625007211563	3	1	0	0
24973	1520	LNCaP cell line	[LNCaP cell line]	1.5849625007211563	3	1	0	0
24974	1520	gtp-binding protein function	[GTP-binding protein function]	1.5849625007211563	3	1	0	0
24975	1520	amino acid 279	[amino acid 279]	1.5849625007211563	3	1	0	0
24976	1520	PMA -inducible factor PIF	[PMA -inducible factor PIF]	1.5849625007211563	4	1	0	0
24977	1520	NF kappa b protein	[NF kappa B protein]	1.5849625007211563	4	1	0	0
24978	1520	long virus exposure	[long-term virus exposure]	1.5849625007211563	3	1	0	0
24979	1520	sialoadhesin expression in vitro	[sialoadhesin expression in vitro]	1.5849625007211563	4	1	0	0
24980	1520	new controversies, one	[new controversies, one]	1.5849625007211563	3	1	0	0
24981	1520	protein-tyrosine kinase activation	[Protein-tyrosine kinase activation]	1.5849625007211563	3	1	0	0
24982	1520	concentration of 1-10 microM.	[concentration of 1-10 microM.]	1.5849625007211563	4	1	0	0
24983	1520	functional rbp binding site	[functional RBP binding site]	1.5849625007211563	4	1	0	0
24984	1520	suggest a similar function	[suggesting a similar function]	1.5849625007211563	4	1	0	0
24985	1520	implication for the detection	[implications for the detection]	1.5849625007211563	4	1	0	0
24986	1520	promoter of CIS	[promoters of CIS]	1.5849625007211563	3	1	0	0
24987	1520	Effect of dep- pah	[Effects of DEP- PAHs]	1.5849625007211563	4	1	0	0
24988	1520	surrogate tg receptor	[surrogate TG receptor]	1.5849625007211563	3	2	1	1
24989	1520	stromal cell rescue	[stromal cell rescue]	1.5849625007211563	3	2	1	1
24990	1520	amino acid 201	[amino acids 201]	1.5849625007211563	3	1	0	0
24991	1520	physical association with targets.	[physical association with targets.]	1.5849625007211563	4	1	0	0
24992	1520	association between Elf-1	[association between Elf-1]	1.5849625007211563	3	1	0	0
24993	1520	adenosine receptor stimulation	[adenosine receptor stimulation]	1.5849625007211563	3	1	0	0
24994	1520	calcium ionophore ionomycin	[calcium ionophore ionomycin]	1.5849625007211563	3	2	1	1
24995	1520	tf mrna accumulation	[TF mRNA accumulation]	1.5849625007211563	3	1	0	0
24996	1520	murine melanoma cell line	[murine melanoma cell lines]	1.5849625007211563	4	1	0	0
24997	1520	Fc gamma RIC gene	[Fc gamma RIC gene]	1.5849625007211563	4	1	0	0
24998	1520	membrane il-2r alpha	[membrane IL-2R alpha]	1.5849625007211563	3	1	0	0
24999	1520	gel retardation analysis	[gel retardation analysis]	1.5849625007211563	3	1	0	0
25000	1520	synthesis of the isoform	[synthesis of the isoforms]	1.5849625007211563	4	1	0	0
25001	1520	lack the domain	[lacking the domain]	1.5849625007211563	3	2	2	2
25002	1520	DNA bind ets domain	[DNA binding Ets domain]	1.5849625007211563	4	1	0	0
25003	1520	jun-D expression vector	[jun-D expression vectors]	1.5849625007211563	3	1	0	0
25004	1520	hiv-1 replication in tnf-alpha-	[HIV-1 replication in TNF-alpha-]	1.5849625007211563	4	1	0	0
25005	1520	decidual gammadelta T cell	[Decidual gammadelta T cells]	1.5849625007211563	4	1	0	0
25006	1520	"natural" ppar activator	["natural" PPAR activator]	1.5849625007211563	3	1	0	0
25007	1520	glucocorticoid-sensitive T cell	[glucocorticoid-sensitive T cells]	1.5849625007211563	3	1	0	0
25008	1520	follow viral binding	[following viral binding]	1.5849625007211563	3	2	1	1
25009	1520	treatment of jurkat cell	[Treatment of Jurkat cells]	1.5849625007211563	4	1	0	0
25010	1520	10 healthy control subject	[10 healthy control subjects]	1.5849625007211563	4	2	1	1
25011	1520	study on the number	[study on the number]	1.5849625007211563	4	1	0	0
25012	1520	vivo activation of nf-kappab	[vivo activation of NF-kappaB]	1.5849625007211563	4	1	0	0
25013	1520	long-last activation of NF-kappaB	[long-lasting activation of NF-kappaB]	1.5849625007211563	4	1	0	0
25014	1520	PML/ RARalpha transgenic mouse	[PML/ RARalpha transgenic mice]	1.5849625007211563	4	1	0	0
25015	1520	proximal upstream element	[proximal upstream elements]	1.5849625007211563	3	1	0	0
25016	1520	unique profilin-like functional fashion.	[unique profilin-like functional fashion.]	1.5849625007211563	4	1	0	0
25017	1520	low-affinity il-12r beta1 subunit	[low-affinity IL-12R beta1 subunit]	1.5849625007211563	4	1	0	0
25018	1520	equivalent levels: 3	[equivalent levels: 3]	1.5849625007211563	3	1	0	0
25019	1520	Alagille syndrome AGS	[Alagille syndrome AGS]	1.5849625007211563	3	1	0	0
25020	1520	transgene expression in cell	[transgene expression in cells]	1.5849625007211563	4	1	0	0
25021	1520	entirety in MDS1/EVI1	[entirety in MDS1/EVI1]	1.5849625007211563	3	1	0	0
25022	1520	inv(16)(p13;q22) on myelopoiesis	[inv(16)(p13;q22) on myelopoiesis]	1.5849625007211563	3	1	0	0
25023	1520	macrophage-tropic strain of hiv	[macrophage-tropic strains of HIV]	1.5849625007211563	4	2	1	1
25024	1520	prolactin receptor a member	[prolactin receptor a member]	1.5849625007211563	4	1	0	0
25025	1520	addition, adp- platelet	[addition, ADP- platelets]	1.5849625007211563	3	1	0	0
25026	1520	T cell progenitor	[T cell progenitors]	1.5849625007211563	3	2	1	1
25027	1520	intensive care unit	[intensive care unit]	1.5849625007211563	3	1	0	0
25028	1520	influence on interleukin (il)-2	[influence on interleukin (IL)-2]	1.5849625007211563	4	1	0	0
25029	1520	hiv inhibition by ascorbate	[HIV inhibition by ascorbate]	1.5849625007211563	4	1	0	0
25030	1520	pregnancy, lymphocyte progesterone act	[pregnancy, lymphocyte progesterone acts]	1.5849625007211563	4	1	0	0
25031	1520	estrogen -dependent manner	[estrogen -dependent manner]	1.5849625007211563	3	1	0	0
25032	1520	transgenic mouse express PML/RARalpha	[transgenic mice expressing PML/RARalpha]	1.5849625007211563	4	1	0	0
25033	1520	ISGF3 -independent response	[ISGF3 -independent response]	1.5849625007211563	3	1	0	0
25034	1520	lead to anergy	[leading to anergy]	1.5849625007211563	3	1	0	0
25035	1520	function test in MS	[Function tests in MS]	1.5849625007211563	4	1	0	0
25036	1520	primarily at the level	[primarily at the level]	1.5849625007211563	4	2	2	2
25037	1520	ebf -deficient mouse	[EBF -deficient mice]	1.5849625007211563	3	1	0	0
25038	1520	novel screen system	[novel screening system]	1.5849625007211563	3	1	0	0
25039	1520	carboxyl portion of Sp140	[carboxyl portion of Sp140]	1.5849625007211563	4	1	0	0
25040	1520	latter four agents.	[latter four agents.]	1.5849625007211563	3	1	0	0
25041	1520	partial resistance to glucocorticoid	[partial resistance to glucocorticoids]	1.5849625007211563	4	1	0	0
25042	1520	three prominent isoforms.	[three prominent isoforms.]	1.5849625007211563	3	1	0	0
25043	1520	balance between Th1 subset	[balance between Th1 subsets]	1.5849625007211563	4	1	0	0
25044	1520	1200001400000 mw antigen	[120,000-140,000 MW antigen]	1.5849625007211563	3	1	0	0
25045	1520	nonstructured basal promoter	[nonstructured basal promoters]	1.5849625007211563	3	1	0	0
25046	1520	scavenger macrophage from GC	[scavenger macrophages from GC]	1.5849625007211563	4	1	0	0
25047	1520	gata-binding family protein	[GATA-binding family proteins]	1.5849625007211563	3	1	0	0
25048	1520	variability of clinical presentation	[variability of clinical presentation]	1.5849625007211563	4	1	0	0
25049	1520	chronic myeloproliferative disorder	[chronic myeloproliferative disorders]	1.5849625007211563	3	1	0	0
25050	1520	inhibitory nls peptide	[inhibitory NLS peptide]	1.5849625007211563	3	1	0	0
25051	1520	5' hiv ltr	[5' HIV LTRs]	1.5849625007211563	3	1	0	0
25052	1520	mechanism of sensitization	[mechanisms of sensitization]	1.5849625007211563	3	1	0	0
25053	1520	long terminal repeat transcription	[long terminal repeat transcription]	1.5849625007211563	4	1	0	0
25054	1520	s phase gene inducible	[S phase gene inducible]	1.5849625007211563	4	1	0	0
25055	1520	continuous t-leukemia cell line	[continuous T-leukemia cell lines]	1.5849625007211563	4	1	0	0
25056	1520	il-10r unlike other member	[IL-10R unlike other members]	1.5849625007211563	4	1	0	0
25057	1520	native RFX activity	[native RFX activity]	1.5849625007211563	3	1	0	0
25058	1520	various synthetic agonist	[various synthetic agonists]	1.5849625007211563	3	1	0	0
25059	1520	coexpression of NF-kappa b	[Coexpression of NF-kappa B]	1.5849625007211563	4	1	0	0
25060	1520	result in the use	[resulting in the use]	1.5849625007211563	4	1	0	0
25061	1520	downstream 3' region act	[downstream 3' regions acting]	1.5849625007211563	4	1	0	0
25062	1520	immune response during pregnancy	[immune response during pregnancy]	1.5849625007211563	4	1	0	0
25063	1520	ELISA assay system	[ELISA assay system]	1.5849625007211563	3	1	0	0
25064	1520	xenoreactive natural antibody	[xenoreactive natural antibodies]	1.5849625007211563	3	1	0	0
25065	1520	tl20/12r sun lamp emit	[TL20/12RS sun lamps emitting]	1.5849625007211563	4	1	0	0
25066	1520	prominent protein kinase cascade	[Prominent protein kinase cascades]	1.5849625007211563	4	1	0	0
25067	1520	current study, binding activity	[current study, binding activity]	1.5849625007211563	4	1	0	0
25068	1520	role in tumorigenesis	[role in tumorigenesis]	1.5849625007211563	3	1	0	0
25069	1520	BCL-6 coding region	[BCL-6 coding region]	1.5849625007211563	3	1	0	0
25070	1520	receptor alpha chain promoter	[receptor alpha chain promoters]	1.5849625007211563	4	1	0	0
25071	1520	increase in myb:maf complex	[increases in Myb:Maf complexes]	1.5849625007211563	4	1	0	0
25072	1520	plasmid contain the il-2	[plasmids containing the IL-2]	1.5849625007211563	4	1	0	0
25073	1520	mouse T cells.	[mouse T cells.]	1.5849625007211563	3	1	0	0
25074	1520	c-jun NH2-terminal mapk jnk	[c-jun NH2-terminal MAPk JNKs]	1.5849625007211563	4	1	0	0
25075	1520	poor prognosis, include estrogen	[poor prognosis, including estrogen]	1.5849625007211563	4	1	0	0
25076	1520	gamma- chain expression	[gamma- chain expression]	1.5849625007211563	3	1	0	0
25077	1520	E47 binding site	[E47 binding sites]	1.5849625007211563	3	1	0	0
25078	1520	event in the process	[event in the process]	1.5849625007211563	4	2	2	2
25079	1520	decrease in extracellular pH	[decreases in extracellular pH]	1.5849625007211563	4	1	0	0
25080	1520	EGR1 binding motif	[EGR1 binding motif]	1.5849625007211563	3	2	1	1
25081	1520	negatively regulate e2f	[negatively regulating E2F]	1.5849625007211563	3	1	0	0
25082	1520	initiation of the culture	[initiation of the cultures]	1.5849625007211563	4	1	0	0
25083	1520	other adherence-associated gene	[other adherence-associated genes]	1.5849625007211563	3	1	0	0
25084	1520	vitro monocyte-derived macrophage	[vitro monocyte-derived macrophages]	1.5849625007211563	3	2	1	1
25085	1520	GABP by supershift	[GABP by supershift]	1.5849625007211563	3	1	0	0
25086	1520	1 (th1) cell	[1 (TH1) cells]	1.5849625007211563	3	1	0	0
25087	1520	contain kappab site	[containing kappaB sites]	1.5849625007211563	3	2	2	2
25088	1520	culture with exogeneous il-2	[culture with exogeneous IL-2]	1.5849625007211563	4	1	0	0
25089	1520	1 major gene	[1 major gene]	1.5849625007211563	3	1	0	0
25090	1520	human thp-1 promonocytic cell	[human THP-1 promonocytic cells]	1.5849625007211563	4	1	0	0
25091	1520	activation inducer molecule	[activation inducer molecule]	1.5849625007211563	3	1	0	0
25092	1520	presence of a element	[presence of a element]	1.5849625007211563	4	2	2	2
25093	1520	stat protein pair	[STAT protein pairs]	1.5849625007211563	3	1	0	0
25094	1520	acute adenovirus infection	[acute adenovirus infections]	1.5849625007211563	3	1	0	0
25095	1520	involvement of cell	[involvement of cells]	1.5849625007211563	3	2	2	2
25096	1520	co-stimulation with lps	[co-stimulation with LPS]	1.5849625007211563	3	1	0	0
25097	1520	55 kilometer tumor	[55 kd tumor]	1.5849625007211563	3	1	0	0
25098	1520	addition of tpa	[addition of TPA]	1.5849625007211563	3	2	1	1
25099	1520	patient receive 5-fluorouracil FUra	[patient receiving 5-fluorouracil FUra]	1.5849625007211563	4	1	0	0
25100	1520	unoccupied receptor site capable	[unoccupied receptor sites capable]	1.5849625007211563	4	1	0	0
25101	1520	addition to nf-kappab	[addition to NF-kappaB]	1.5849625007211563	3	1	0	0
25102	1520	depletion of cd4+ cell	[depletion of CD4+ cells]	1.5849625007211563	4	1	0	0
25103	1520	tight regulatory control.	[tight regulatory control.]	1.5849625007211563	3	1	0	0
25104	1520	U373 mg astrocytoma cell	[U373 MG astrocytoma cells]	1.5849625007211563	4	1	0	0
25105	1520	receptor-mediated ap-1 induction	[receptor-mediated AP-1 induction]	1.5849625007211563	3	1	0	0
25106	1520	further, like PMA	[Further, like PMA]	1.5849625007211563	3	1	0	0
25107	1520	TF with VIIa	[TF with VIIa]	1.5849625007211563	3	1	0	0
25108	1520	patient with tuberculosis.	[patients with tuberculosis.]	1.5849625007211563	3	2	2	2
25109	1520	two tandem ap1 site	[two tandem AP1 sites]	1.5849625007211563	4	1	0	0
25110	1520	however, the second enhancer	[however, the second enhancer]	1.5849625007211563	4	1	0	0
25111	1520	over 10-fold less il-10	[over 10-fold less IL-10]	1.5849625007211563	4	1	0	0
25112	1520	subset of thymocyte	[subset of thymocytes]	1.5849625007211563	3	2	1	1
25113	1520	even at time point	[even at time points]	1.5849625007211563	4	1	0	0
25114	1520	viable u937 cell	[viable U937 cells]	1.5849625007211563	3	1	0	0
25115	1520	critical component of C1-C3	[critical components of C1-C3]	1.5849625007211563	4	1	0	0
25116	1520	novel cell line	[novel cell line]	1.5849625007211563	3	2	2	2
25117	1520	MEK1/MEK2 inhibitor pd098059	[MEK1/MEK2 inhibitor PD098059]	1.5849625007211563	3	1	0	0
25118	1520	blood concentration of hormone	[blood concentrations of hormones]	1.5849625007211563	4	1	0	0
25119	1520	addition of TNF alpha	[addition of TNF alpha]	1.5849625007211563	4	1	0	0
25120	1520	two heat shock factor	[two heat shock factors]	1.5849625007211563	4	1	0	0
25121	1520	complete loss of dnase	[complete loss of DNase]	1.5849625007211563	4	1	0	0
25122	1520	different kinases, include PKC	[different kinases, including PKC]	1.5849625007211563	4	1	0	0
25123	1520	interfere with a signal	[interfering with a signal]	1.5849625007211563	4	1	0	0
25124	1520	complex with a protein	[complex with an protein]	1.5849625007211563	4	1	0	0
25125	1520	pediatric oncology group study	[pediatric oncology group study]	1.5849625007211563	4	1	0	0
25126	1520	combination of impaired recycling	[combination of impaired recycling]	1.5849625007211563	4	1	0	0
25127	1520	response to growth factor	[response to growth factors]	1.5849625007211563	4	2	2	2
25128	1520	32dc13 murine myeloid cell	[32Dc13 murine myeloid cells]	1.5849625007211563	4	1	0	0
25129	1520	most erythroleukemic cell line	[Most erythroleukemic cell lines]	1.5849625007211563	4	1	0	0
25130	1520	new amino acid	[new amino acid]	1.5849625007211563	3	1	0	0
25131	1520	zinc finger region	[zinc finger region]	1.5849625007211563	3	2	1	1
25132	1520	cytokine message induction	[cytokine message induction]	1.5849625007211563	3	1	0	0
25133	1520	suggest a important modulator	[suggesting an important modulator]	1.5849625007211563	4	1	0	0
25134	1520	transient overexpression of p16	[transient overexpression of p16]	1.5849625007211563	4	1	0	0
25135	1520	carboxy terminal insert exon	[carboxy terminal insert exon]	1.5849625007211563	4	1	0	0
25136	1520	N-terminal region of Oct-2a	[N-terminal region of Oct-2a]	1.5849625007211563	4	1	0	0
25137	1520	treatment of hematologic malignancy	[treatment of hematologic malignancies]	1.5849625007211563	4	1	0	0
25138	1520	semiquantitative rt- pcr	[semiquantitative RT- PCR]	1.5849625007211563	3	2	1	1
25139	1520	high-grade vulvar leiomyosarcoma	[high-grade vulvar leiomyosarcoma]	1.5849625007211563	3	1	0	0
25140	1520	lymphocytic cell line	[lymphocytic cell lines]	1.5849625007211563	3	1	0	0
25141	1520	control of il-2 expression	[control of IL-2 expression]	1.5849625007211563	4	1	0	0
25142	1520	nuclear accumulation of NFAT4	[nuclear accumulation of NFAT4]	1.5849625007211563	4	1	0	0
25143	1520	such as 1-beta-d-arabino-furanosylcytosine	[such as 1-beta-D-arabino-furanosylcytosine]	1.5849625007211563	3	1	0	0
25144	1520	neuroblastoma cell differentiation	[neuroblastoma cell differentiation]	1.5849625007211563	3	1	0	0
25145	1520	nuclear glucocorticoid receptor	[nuclear glucocorticoid receptors]	1.5849625007211563	3	1	0	0
25146	1520	lytic viral DNA replication	[lytic viral DNA replication]	1.5849625007211563	4	1	0	0
25147	1520	variety of diseases.	[variety of diseases.]	1.5849625007211563	3	1	0	0
25148	1520	multiple signal transduction pathway	[multiple signal transduction pathways]	1.5849625007211563	4	1	0	0
25149	1520	peripheral CD8 T lymphocyte	[peripheral CD8 T lymphocytes]	1.5849625007211563	4	1	0	0
25150	1520	impair translation and/or	[impairing translation and/or]	1.5849625007211563	3	1	0	0
25151	1520	function of each protein	[function of each protein]	1.5849625007211563	4	1	0	0
25152	1520	Fes tyrosine kinase	[Fes tyrosine kinases]	1.5849625007211563	3	1	0	0
25153	1520	contrast to myeloid-related DC	[contrast to myeloid-related DC]	1.5849625007211563	4	1	0	0
25154	1520	majority of samples.	[majority of samples.]	1.5849625007211563	3	1	0	0
25155	1520	new perspective about mechanism	[new perspectives about mechanisms]	1.5849625007211563	4	1	0	0
25156	1520	suppression of monocyte adhesion	[suppression of monocyte adhesion]	1.5849625007211563	4	1	0	0
25157	1520	tsc2 notably sscp	[TSC2 notably SSCP]	1.5849625007211563	3	1	0	0
25158	1520	0.2 mmol/L diamide	[0.2 mmol/L diamide]	1.5849625007211563	3	1	0	0
25159	1520	C-terminal Tax1 mutant	[C-terminal Tax1 mutants]	1.5849625007211563	3	1	0	0
25160	1520	TCF-1 knock-out mouse	[TCF-1 knock-out mice]	1.5849625007211563	3	1	0	0
25161	1520	IL-4 regulatory element	[IL-4 regulatory elements]	1.5849625007211563	3	1	0	0
25162	1520	carry a lac operon	[carrying a lac operon]	1.5849625007211563	4	1	0	0
25163	1520	cytoplasm of quiescent cell	[cytoplasm of quiescent cells]	1.5849625007211563	4	1	0	0
25164	1520	unstimulated patient T cell	[unstimulated patient T cells]	1.5849625007211563	4	1	0	0
25165	1520	gene for pro-inflammatory cytokine	[genes for pro-inflammatory cytokines]	1.5849625007211563	4	1	0	0
25166	1520	disease such as leukemia	[diseases such as leukemia]	1.5849625007211563	4	1	0	0
25167	1520	mice lack Rel	[Mice lacking Rel]	1.5849625007211563	3	1	0	0
25168	1520	secondary response pathway	[secondary response pathways]	1.5849625007211563	3	1	0	0
25169	1520	human type ii interleukin-1	[human type II interleukin-1]	1.5849625007211563	4	1	0	0
25170	1520	zinc for immune function	[zinc for immune function]	1.5849625007211563	4	1	0	0
25171	1520	viral p24 antigen	[viral p24 antigen]	1.5849625007211563	3	1	0	0
25172	1520	three regulatory element	[three regulatory elements]	1.5849625007211563	3	1	0	0
25173	1520	tissue-specific manner by element	[tissue-specific manner by elements]	1.5849625007211563	4	1	0	0
25174	1520	use anti-human lt	[using anti-human LT]	1.5849625007211563	3	1	0	0
25175	1520	human interleukin-2 enhancer	[human interleukin-2 enhancers]	1.5849625007211563	3	1	0	0
25176	1520	examination of CIITA mrna	[Examination of CIITA mRNA]	1.5849625007211563	4	1	0	0
25177	1520	G-rich switch region	[G-rich switch regions]	1.5849625007211563	3	1	0	0
25178	1520	discussion of the use	[discussion of the use]	1.5849625007211563	4	1	0	0
25179	1520	novel therapeutic target	[novel therapeutic target]	1.5849625007211563	3	1	0	0
25180	1520	receptor binding study	[receptor binding studies]	1.5849625007211563	3	2	2	2
25181	1520	variety of adult tissue	[variety of adult tissues]	1.5849625007211563	4	1	0	0
25182	1520	regulation of granulomatous reaction	[regulation of granulomatous reactions]	1.5849625007211563	4	1	0	0
25183	1520	t(17;19) translocation in leukemia	[t(17;19) translocation in leukemias]	1.5849625007211563	4	2	2	2
25184	1520	barely hybridization signal	[barely hybridization signals]	1.5849625007211563	3	1	0	0
25185	1520	presumably by activation	[presumably by activation]	1.5849625007211563	3	1	0	0
25186	1520	cleavage of Bcl-2	[cleavage of Bcl-2]	1.5849625007211563	3	1	0	0
25187	1520	glucocorticoid -repressible gene	[glucocorticoid -repressible genes]	1.5849625007211563	3	1	0	0
25188	1520	SBMA sperm type result	[SBMA sperm typing results]	1.5849625007211563	4	1	0	0
25189	1520	t-cell-specific ets protein elf-1	[T-cell-specific Ets protein Elf-1]	1.5849625007211563	4	1	0	0
25190	1520	homolog of mouse	[homologs of mouse]	1.5849625007211563	3	1	0	0
25191	1520	IL-2 alpha promoter	[IL-2 alpha promoters]	1.5849625007211563	3	1	0	0
25192	1520	gene encode tissue-specific component	[genes encoding tissue-specific components]	1.5849625007211563	4	1	0	0
25193	1520	form of ig mrna	[form of Ig mRNA]	1.5849625007211563	4	1	0	0
25194	1520	cell from malignant effusion	[cells from malignant effusions]	1.5849625007211563	4	1	0	0
25195	1520	use specific polyclonal antisera	[using specific polyclonal antisera]	1.5849625007211563	4	1	0	0
25196	1520	effect of random replacement	[effects of random replacement]	1.5849625007211563	4	1	0	0
25197	1520	Defining therapeutic target	[Defining therapeutic targets]	1.5849625007211563	3	1	0	0
25198	1520	urinary cortisol concentration	[urinary cortisol concentrations]	1.5849625007211563	3	1	0	0
25199	1520	activation by phytohemagglutinin	[activation by phytohemagglutinin]	1.5849625007211563	3	1	0	0
25200	1520	host blastocyst-derived erythrocyte	[host blastocyst-derived erythrocytes]	1.5849625007211563	3	1	0	0
25201	1520	four dihydro derivative 5,	[four dihydro derivatives 5,]	1.5849625007211563	4	1	0	0
25202	1520	expression of ecto-5'-NT mrna	[expression of ecto-5'-NT mRNA]	1.5849625007211563	4	1	0	0
25203	1520	demonstrate independent of il-2	[demonstrating independent of IL-2]	1.5849625007211563	4	1	0	0
25204	1520	intravenous administration of pcr	[Intravenous administration of PCr]	1.5849625007211563	4	1	0	0
25205	1520	normal x allele	[normal X allele]	1.5849625007211563	3	1	0	0
25206	1520	specificity of the element.	[specificity of the element.]	1.5849625007211563	4	1	0	0
25207	1520	JM T cell	[JM T cells]	1.5849625007211563	3	1	0	0
25208	1520	7 mol/L for hydrocortisone	[7 mol/L for hydrocortisone]	1.5849625007211563	4	1	0	0
25209	1520	structurally related progesterone	[structurally related progesterone]	1.5849625007211563	3	1	0	0
25210	1520	various cell lineages.	[various cell lineages.]	1.5849625007211563	3	1	0	0
25211	1520	kinetic of JNK activation	[kinetics of JNK activation]	1.5849625007211563	4	1	0	0
25212	1520	level in uninfected cell	[levels in uninfected cells]	1.5849625007211563	4	1	0	0
25213	1520	991.9 224 ng/mL, respectively).	[991.9 224 ng/mL, respectively).]	1.5849625007211563	4	1	0	0
25214	1520	cross-priming of CTL response	[Cross-priming of CTL responses]	1.5849625007211563	4	2	1	1
25215	1520	fertile adult male	[fertile adult males]	1.5849625007211563	3	1	0	0
25216	1520	pertussis toxin treatment	[Pertussis toxin treatment]	1.5849625007211563	3	1	0	0
25217	1520	treatment of individual	[treatment of individuals]	1.5849625007211563	3	1	0	0
25218	1520	ability of il-4	[ability of IL-4]	1.5849625007211563	3	2	1	1
25219	1520	membrane binding site	[membrane binding sites]	1.5849625007211563	3	1	0	0
25220	1520	binding of platelet	[binding of platelets]	1.5849625007211563	3	2	1	1
25221	1520	such as endothelial cell	[such as endothelial cells]	1.5849625007211563	4	1	0	0
25222	1520	replication in cell lines.	[replication in cell lines.]	1.5849625007211563	4	1	0	0
25223	1520	early antigen EA-D	[early antigen EA-D]	1.5849625007211563	3	1	0	0
25224	1520	61 stage i	[61 Stage I]	1.5849625007211563	3	1	0	0
25225	1520	novel T lymphocyte protein	[novel T lymphocyte protein]	1.5849625007211563	4	1	0	0
25226	1520	13 young adult	[13 young adults]	1.5849625007211563	3	1	0	0
25227	1520	specific cd8+ CTL line	[specific CD8+ CTL line]	1.5849625007211563	4	1	0	0
25228	1520	expression of EBNA2	[Expression of EBNA2]	1.5849625007211563	3	1	0	0
25229	1520	specific receptor for calcitriol	[specific receptors for calcitriol]	1.5849625007211563	4	1	0	0
25230	1520	affinity 10-fold low	[affinity 10-fold lower]	1.5849625007211563	3	1	0	0
25231	1520	important cross-talk mechanism	[important cross-talk mechanism]	1.5849625007211563	3	1	0	0
25232	1520	express the fetal	[expressing the fetal]	1.5849625007211563	3	3	2	1
25233	1520	(4) Intrafollicular cd57+ cell	[(4) Intrafollicular CD57+ cells]	1.5849625007211563	4	1	0	0
25234	1520	elevation of calcium	[elevation of calcium]	1.5849625007211563	3	2	2	2
25235	1520	kinase with the receptor.	[kinase with the receptor.]	1.5849625007211563	4	1	0	0
25236	1520	affect the expression	[affecting the expression]	1.5849625007211563	3	2	1	1
25237	1520	fgf-1 -responsive T cell	[FGF-1 -responsive T cells]	1.5849625007211563	4	1	0	0
25238	1520	use to a site	[use to a site]	1.5849625007211563	4	1	0	0
25239	1520	untransformed steroid receptor	[untransformed steroid receptors]	1.5849625007211563	3	1	0	0
25240	1520	clinical symptom in xp-b	[clinical symptoms in XP-B]	1.5849625007211563	4	1	0	0
25241	1520	th2-type cytokine interleukin-4 il-4	[Th2-type cytokines interleukin-4 IL-4]	1.5849625007211563	4	1	0	0
25242	1520	presence of anti-CD3 mab	[presence of anti-CD3 mAb]	1.5849625007211563	4	1	0	0
25243	1520	icam-1 cytokine tnf	[ICAM-1 cytokines TNF]	1.5849625007211563	3	1	0	0
25244	1520	GCR on MNL	[GCR on MNL]	1.5849625007211563	3	2	1	1
25245	1520	upper range ppt	[upper range ppt]	1.5849625007211563	3	1	0	0
25246	1520	strong positive-acting element	[strong positive-acting element]	1.5849625007211563	3	1	0	0
25247	1520	treatment with DMSO	[Treatment with DMSO]	1.5849625007211563	3	1	0	0
25248	1520	glucocorticoid response element binding	[glucocorticoid response element binding]	1.5849625007211563	4	1	0	0
25249	1520	hematopoietic gene expression	[hematopoietic gene expression]	1.5849625007211563	3	1	0	0
25250	1520	JAK phosphorylation by IL-12	[JAK phosphorylation by IL-12]	1.5849625007211563	4	1	0	0
25251	1520	chromosome from a patient	[chromosome from a patient]	1.5849625007211563	4	1	0	0
25252	1520	tcc -inducible mitotic signal	[TCC -inducible mitotic signaling]	1.5849625007211563	4	1	0	0
25253	1520	purine box 1 pb1	[purine box 1 PB1]	1.5849625007211563	4	1	0	0
25254	1520	er antagonist ICI 182780	[ER antagonist ICI 182,780]	1.5849625007211563	4	1	0	0
25255	1520	regulation of nf-y expression	[regulation of NF-Y expression]	1.5849625007211563	4	1	0	0
25256	1520	expression of interferon-stimulated gene	[expression of interferon-stimulated genes]	1.5849625007211563	4	1	0	0
25257	1520	coculture with autologous tec	[coculture with autologous TEC]	1.5849625007211563	4	1	0	0
25258	1520	wild-type CEM cell	[wild-type CEM cells]	1.5849625007211563	3	1	0	0
25259	1520	interrelationship between cd45	[interrelationships between CD45]	1.5849625007211563	3	1	0	0
25260	1520	-alpha gene transcription	[-alpha gene transcription]	1.5849625007211563	3	1	0	0
25261	1520	IL-1 beta message induction	[IL-1 beta message induction]	1.5849625007211563	4	1	0	0
25262	1520	rna from lymphocyte	[RNA from lymphocytes]	1.5849625007211563	3	1	0	0
25263	1520	il-12r beta 2 subunit	[IL-12R beta 2 subunit]	1.5849625007211563	4	1	0	0
25264	1520	surface MHC class	[surface MHC class]	1.5849625007211563	3	2	2	2
25265	1520	unstimulated b cell	[unstimulated B cells]	1.5849625007211563	3	2	2	2
25266	1520	mast cell lineage	[mast cell lineages]	1.5849625007211563	3	1	0	0
25267	1520	g-protein-coupled serpentine receptor	[G-protein-coupled serpentine receptors]	1.5849625007211563	3	1	0	0
25268	1520	induction of specific gene	[induction of specific genes]	1.5849625007211563	4	2	1	1
25269	1520	100% of the experiments.	[100% of the experiments.]	1.5849625007211563	4	1	0	0
25270	1520	human chromosome 17p13.3	[human chromosome 17p13.3]	1.5849625007211563	3	1	0	0
25271	1520	IL-4 promoter-reporter construct	[IL-4 promoter-reporter constructs]	1.5849625007211563	3	1	0	0
25272	1520	inactivation of Rb function	[inactivation of Rb function]	1.5849625007211563	4	1	0	0
25273	1520	appropriate activation signal	[appropriate activation signal]	1.5849625007211563	3	1	0	0
25274	1520	anionic phospholipid surface	[anionic phospholipid surface]	1.5849625007211563	3	1	0	0
25275	1520	accumulation of globin	[accumulation of globin]	1.5849625007211563	3	1	0	0
25276	1520	inhibitor of Tat b	[inhibitors of Tat B]	1.5849625007211563	4	1	0	0
25277	1520	severe immunodeficiency SCID	[severe immunodeficiency SCID]	1.5849625007211563	3	2	2	2
25278	1520	contrast, many study	[contrast, many studies]	1.5849625007211563	3	1	0	0
25279	1520	T cell receptor alpha	[T cell receptor alpha]	1.5849625007211563	4	2	1	1
25280	1520	number of gamma-positive cell	[number of gamma-positive cells]	1.5849625007211563	4	1	0	0
25281	1520	repression by Ikaros protein	[Repression by Ikaros proteins]	1.5849625007211563	4	1	0	0
25282	1520	both, cell apc	[both, cells APC]	1.5849625007211563	3	1	0	0
25283	1520	IL-3 promoter construct	[IL-3 promoter constructs]	1.5849625007211563	3	1	0	0
25284	1520	human chromosome 4	[human chromosome 4]	1.5849625007211563	3	1	0	0
25285	1520	purity of >90%	[purity of >90%]	1.5849625007211563	3	1	0	0
25286	1520	differentiation of skeletal muscle	[differentiation of skeletal muscle]	1.5849625007211563	4	1	0	0
25287	1520	stimulation of the gene.	[stimulation of the gene.]	1.5849625007211563	4	1	0	0
25288	1520	nucleotide -124 to -117	[nucleotides -124 to -117]	1.5849625007211563	4	1	0	0
25289	1520	b cell immunoglobulin production	[B cell immunoglobulin production]	1.5849625007211563	4	1	0	0
25290	1520	Addition of thp-1 cell	[Addition of THP-1 cells]	1.5849625007211563	4	2	1	1
25291	1520	polyclonal reactive process	[polyclonal reactive process]	1.5849625007211563	3	1	0	0
25292	1520	primary human t-lymphocyte	[primary human T-lymphocytes]	1.5849625007211563	3	1	0	0
25293	1520	putative NFAT-1 site enhancer	[putative NFAT-1 site enhancer]	1.5849625007211563	4	1	0	0
25294	1520	IL-12 signal transduction pathway	[IL-12 signal transduction pathway]	1.5849625007211563	4	1	0	0
25295	1520	reduce il-4 promoter activity	[reducing IL-4 promoter activity]	1.5849625007211563	4	1	0	0
25296	1520	various extracellular signal	[Various extracellular signals]	1.5849625007211563	3	2	1	1
25297	1520	infected human cell	[infected human cells]	1.5849625007211563	3	1	0	0
25298	1520	macrophage inflammatory protein (mip)-1alpha	[macrophage inflammatory protein (MIP)-1alpha]	1.5849625007211563	4	1	0	0
25299	1520	(2) synergism between TNF-alpha	[(2) synergism between TNF-alpha]	1.5849625007211563	4	1	0	0
25300	1520	qualitative, difference between signal	[qualitative, differences between signaling]	1.5849625007211563	4	1	0	0
25301	1520	aim of this research	[aim of this research]	1.5849625007211563	4	1	0	0
25302	1520	different costimulatory signal	[different costimulatory signals]	1.5849625007211563	3	1	0	0
25303	1520	synergy in c-fo induction	[synergy in c-fos induction]	1.5849625007211563	4	1	0	0
25304	1520	use of promoter construct	[use of promoter constructs]	1.5849625007211563	4	1	0	0
25305	1520	far-upstream alpha-globin enhancer hs-40	[far-upstream alpha-globin enhancer HS-40]	1.5849625007211563	4	1	0	0
25306	1520	precursor cell common	[precursor cell common]	1.5849625007211563	3	1	0	0
25307	1520	stat protein form	[Stat proteins form]	1.5849625007211563	3	1	0	0
25308	1520	single kappa b site	[single kappa B site]	1.5849625007211563	4	1	0	0
25309	1520	cathepsin k protein	[cathepsin K protein]	1.5849625007211563	3	1	0	0
25310	1520	NF-kappaB transcriptional activation	[NF-kappaB transcriptional activation]	1.5849625007211563	3	2	1	1
25311	1520	seven healthy volunteers.	[seven healthy volunteers.]	1.5849625007211563	3	1	0	0
25312	1520	class b cell line	[class B cell lines]	1.5849625007211563	4	2	2	2
25313	1520	challenging clinical problem	[challenging clinical problem]	1.5849625007211563	3	2	1	1
25314	1520	novel cDNA clone	[novel cDNA clone]	1.5849625007211563	3	2	1	1
25315	1520	interleukin-2 promoter/reporter gene construct	[interleukin-2 promoter/reporter gene construct]	1.5849625007211563	4	1	0	0
25316	1520	viral capsid antigen vca	[viral capsid antigen VCA]	1.5849625007211563	4	1	0	0
25317	1520	human t-cell line Jurkat	[human T-cell line Jurkat]	1.5849625007211563	4	2	1	1
25318	1520	EBS motif GASd/EBSd	[EBS motif GASd/EBSd]	1.5849625007211563	3	1	0	0
25319	1520	significant il-2 production	[significant IL-2 production]	1.5849625007211563	3	1	0	0
25320	1520	CD4 CD8 -double-negative	[CD4 CD8 -double-negative]	1.5849625007211563	3	1	0	0
25321	1520	gamma interferon class ii	[gamma interferon class II]	1.5849625007211563	4	1	0	0
25322	1520	southwestern blotting experiment	[Southwestern blotting experiments]	1.5849625007211563	3	1	0	0
25323	1520	3'-most site alone	[3'-most site alone]	1.5849625007211563	3	1	0	0
25324	1520	base pair (bp)	[base pairs (bp)]	1.5849625007211563	3	2	2	2
25325	1520	certain camp -dependent gene	[certain cAMP -dependent genes]	1.5849625007211563	4	1	0	0
25326	1520	activin a- signal	[activin A- signaling]	1.5849625007211563	3	1	0	0
25327	1520	RB sense, oligonucleotide ODN	[RB sense, oligonucleotide ODN]	1.5849625007211563	4	1	0	0
25328	1520	lyn mrna production	[lyn mRNA production]	1.5849625007211563	3	1	0	0
25329	1520	T helper cell level	[T helper cell level]	1.5849625007211563	4	1	0	0
25330	1520	consensus, gata site	[consensus, GATA sites]	1.5849625007211563	3	1	0	0
25331	1520	kappa b-binding, protein	[kappa B-binding, protein]	1.5849625007211563	3	1	0	0
25332	1520	express cell surface mu/kappa	[expressing cell surface mu/kappa]	1.5849625007211563	4	1	0	0
25333	1520	regulation of e2f activity	[regulation of E2F activity]	1.5849625007211563	4	1	0	0
25334	1520	coactivator CREB binding protein/p300	[coactivator CREB binding protein/p300]	1.5849625007211563	4	1	0	0
25335	1520	neutrophil undergo the phagocytosis	[neutrophils undergoing the phagocytosis]	1.5849625007211563	4	1	0	0
25336	1520	b lymphocyte function	[B lymphocyte function]	1.5849625007211563	3	1	0	0
25337	1520	(20 microM, 72 h),	[(20 microM, 72 h),]	1.5849625007211563	4	1	0	0
25338	1520	inositol phosphate release	[inositol phosphate release]	1.5849625007211563	3	2	1	1
25339	1520	very versatile molecules:	[very versatile molecules:]	1.5849625007211563	3	1	0	0
25340	1520	proline in B4-2	[prolines in B4-2]	1.5849625007211563	3	1	0	0
25341	1520	i htlv-i transcription	[I HTLV-I transcription]	1.5849625007211563	3	1	0	0
25342	1520	multiple cellular promoter	[multiple cellular promoters]	1.5849625007211563	3	1	0	0
25343	1520	E3 sequence motif	[E3 sequence motif]	1.5849625007211563	3	1	0	0
25344	1520	minimal disease MRD	[minimal disease MRD]	1.5849625007211563	3	2	2	2
25345	1520	periodic acid-Schiff ppas) staining	[periodic acid-Schiff (PAS) staining]	1.5849625007211563	4	1	0	0
25346	1520	nuclear factor-IL-6beta -ig/ebp-1 heterodimer	[nuclear factor-IL-6beta -Ig/EBP-1 heterodimer]	1.5849625007211563	4	1	0	0
25347	1520	protective effect of ald	[protective effect of ALD]	1.5849625007211563	4	1	0	0
25348	1520	patient with climacteric syndrome	[patients with climacteric syndrome]	1.5849625007211563	4	1	0	0
25349	1520	inhibit neutrophil apoptosis	[inhibiting neutrophil apoptosis]	1.5849625007211563	3	1	0	0
25350	1520	monoclonal antibody kn	[monoclonal antibody KN]	1.5849625007211563	3	1	0	0
25351	1520	NF-kappa b by PDTC	[NF-kappa B by PDTC]	1.5849625007211563	4	1	0	0
25352	1520	T cell of hiv	[T cells of HIV]	1.5849625007211563	4	1	0	0
25353	1520	adverse environmental condition	[adverse environmental conditions]	1.5849625007211563	3	1	0	0
25354	1520	several cell types.	[several cell types.]	1.5849625007211563	3	1	0	0
25355	1520	template contain the region	[template containing the region]	1.5849625007211563	4	1	0	0
25356	1520	nuclear triiodothyronine receptor	[nuclear triiodothyronine receptors]	1.5849625007211563	3	1	0	0
25357	1520	hrar alpha hrar alpha-lbd	[hRAR alpha hRAR alpha-LBD]	1.5849625007211563	4	1	0	0
25358	1520	NK cell with il-2	[NK cells with IL-2]	1.5849625007211563	4	1	0	0
25359	1520	particularly polycythemia vera	[particularly polycythemia vera]	1.5849625007211563	3	1	0	0
25360	1520	myeloid cell lines,	[myeloid cell lines,]	1.5849625007211563	3	2	1	1
25361	1520	515 base pair	[515 base pair]	1.5849625007211563	3	1	0	0
25362	1520	calcineurin docking motif	[calcineurin docking motif]	1.5849625007211563	3	1	0	0
25363	1520	ability of NFkappaB	[ability of NFkappaB]	1.5849625007211563	3	1	0	0
25364	1520	blast-crisis cDNA library,	[blast-crisis cDNA library,]	1.5849625007211563	3	1	0	0
25365	1520	noncode control regions,	[noncoding control regions,]	1.5849625007211563	3	1	0	0
25366	1520	ifn-gamma activation sequence gas	[IFN-gamma activation sequence GAS]	1.5849625007211563	4	1	0	0
25367	1520	disappearance of the epitope	[disappearance of the epitope]	1.5849625007211563	4	1	0	0
25368	1520	receptor for interferon-alpha ifn-alpha	[receptors for interferon-alpha IFN-alpha]	1.5849625007211563	4	1	0	0
25369	1520	constitutively active type	[constitutively active type]	1.5849625007211563	3	1	0	0
25370	1520	secondarily by dihydrotestosterone	[secondarily by dihydrotestosterone]	1.5849625007211563	3	1	0	0
25371	1520	particular signal pathway,	[particular signaling pathway,]	1.5849625007211563	3	1	0	0
25372	1520	sense sequence sequence	[sense sequence sequence]	1.5849625007211563	3	1	0	0
25373	1520	dose-dependence study use histamine	[Dose-dependence studies using histamine]	1.5849625007211563	4	1	0	0
25374	1520	additional VDR 3'-utr polymorphism	[additional VDR 3'-UTR polymorphisms]	1.5849625007211563	4	1	0	0
25375	1520	absence of 1 alpha,25-(OH)2D3	[absence of 1 alpha,25-(OH)2D3]	1.5849625007211563	4	1	0	0
25376	1520	1 htlv-1 transcription	[1 HTLV-1 transcription]	1.5849625007211563	3	1	0	0
25377	1520	peptide-pulsed lymphoblastic cell line	[peptide-pulsed lymphoblastic cell lines]	1.5849625007211563	4	1	0	0
25378	1520	possibility of cis-activation	[possibility of cis-activation]	1.5849625007211563	3	1	0	0
25379	1520	accordance with this notion.	[accordance with this notion.]	1.5849625007211563	4	1	0	0
25380	1520	ca2+-dependent signal cascade	[Ca2+-dependent signal cascades]	1.5849625007211563	3	1	0	0
25381	1520	promotion of neutrophil differentiation	[promotion of neutrophil differentiation]	1.5849625007211563	4	1	0	0
25382	1520	PMA -unresponsive subline kg1a	[PMA -unresponsive subline KG1a]	1.5849625007211563	4	1	0	0
25383	1520	attention in molecular biology	[attention in molecular biology]	1.5849625007211563	4	1	0	0
25384	1520	il-2 pbmc proliferation	[IL-2 PBMC proliferation]	1.5849625007211563	3	1	0	0
25385	1520	map kinase erk-2	[MAP kinase ERK-2]	1.5849625007211563	3	1	0	0
25386	1520	T cell activity	[T cells activity]	1.5849625007211563	3	2	2	2
25387	1520	single polypeptide chain	[single polypeptide chain]	1.5849625007211563	3	1	0	0
25388	1520	ca2+ signal similar	[Ca2+ signals similar]	1.5849625007211563	3	1	0	0
25389	1520	cd45ro+ (memory) T lymphocyte	[CD45RO+ (memory) T lymphocytes]	1.5849625007211563	4	1	0	0
25390	1520	control p less	[controls P less]	1.5849625007211563	3	2	1	1
25391	1520	multivalent guanylhydrazone cni-1493	[multivalent guanylhydrazone CNI-1493]	1.5849625007211563	3	1	0	0
25392	1520	homozygous stat6 -deficient mouse	[homozygous STAT6 -deficient mice]	1.5849625007211563	4	1	0	0
25393	1520	Ig heavy chain locus	[Ig heavy chain locus]	1.5849625007211563	4	1	0	0
25394	1520	increase in lamin a	[increases in lamin A]	1.5849625007211563	4	1	0	0
25395	1520	difference in functional response	[differences in functional responses]	1.5849625007211563	4	1	0	0
25396	1520	inhibition with monoclonal antibody	[Inhibition with monoclonal antibodies]	1.5849625007211563	4	1	0	0
25397	1520	beta towards microglia	[beta towards microglia]	1.5849625007211563	3	1	0	0
25398	1520	CD28 trigger molecule	[CD28 trigger molecules]	1.5849625007211563	3	1	0	0
25399	1520	CONCLUSIONS: human ECs	[CONCLUSIONS: Human ECs]	1.5849625007211563	3	1	0	0
25400	1520	new aspect to knowledge	[new aspect to knowledge]	1.5849625007211563	4	1	0	0
25401	1520	effect on function	[effect on functions]	1.5849625007211563	3	2	2	2
25402	1520	activate function of p95vav	[activating function of p95vav]	1.5849625007211563	4	1	0	0
25403	1520	decrease the activity	[decreasing the activity]	1.5849625007211563	3	1	0	0
25404	1520	sequence of TAL1	[sequences of TAL1]	1.5849625007211563	3	1	0	0
25405	1520	exchange of a tyrosine	[exchange of a tyrosine]	1.5849625007211563	4	1	0	0
25406	1520	Sox-4 hmg box	[Sox-4 HMG box]	1.5849625007211563	3	1	0	0
25407	1520	replicative gene product	[replicative gene products]	1.5849625007211563	3	1	0	0
25408	1520	bacterial endotoxin lipopolysaccharide lps	[bacterial endotoxin lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
25409	1520	biologically active prolactin	[biologically active prolactin]	1.5849625007211563	3	1	0	0
25410	1520	significant difference between patient	[significant difference between patients]	1.5849625007211563	4	1	0	0
25411	1520	activation of Jak kinase	[activation of Jak kinases]	1.5849625007211563	4	1	0	0
25412	1520	octamer (octa)-nucleotide motif	[octamer (OCTA)-nucleotide motif]	1.5849625007211563	3	1	0	0
25413	1520	requirement for precise spacing	[requirement for precise spacing]	1.5849625007211563	4	1	0	0
25414	1520	RA c/ebpalpha mrna expression	[RA C/EBPalpha mRNA expression]	1.5849625007211563	4	1	0	0
25415	1520	approximately 50 kD	[approximately 50 kD]	1.5849625007211563	3	1	0	0
25416	1520	NF-AT/AP-1-binding promoter element	[NF-AT/AP-1-binding promoter element]	1.5849625007211563	3	1	0	0
25417	1520	respective binding site	[respective binding sites]	1.5849625007211563	3	1	0	0
25418	1520	constitutive binding protein	[constitutive binding protein]	1.5849625007211563	3	1	0	0
25419	1520	N-terminal 36 amino acid	[N-terminal 36 amino acids]	1.5849625007211563	4	1	0	0
25420	1520	myelogenous leukemia cell line	[myelogenous leukemia cell line]	1.5849625007211563	4	1	0	0
25421	1520	primarily to defect	[primarily to defects]	1.5849625007211563	3	1	0	0
25422	1520	focus-form virus-induced murine erythroleukemias	[focus-forming virus-induced murine erythroleukemias]	1.5849625007211563	4	1	0	0
25423	1520	serine protease granzyme B	[serine protease granzyme B]	1.5849625007211563	4	1	0	0
25424	1520	crosslinking of sigm	[crosslinking of sIgM]	1.5849625007211563	3	1	0	0
25425	1520	chronic renal failure CRF	[chronic renal failure CRF]	1.5849625007211563	4	1	0	0
25426	1520	mechanism of this effect.	[mechanism of this effect.]	1.5849625007211563	4	1	0	0
25427	1520	fc gamma RIC gene	[Fc gamma RIC gene]	1.5849625007211563	4	1	0	0
25428	1520	several cellular substrate	[several cellular substrates]	1.5849625007211563	3	1	0	0
25429	1520	various receptor gene	[various receptor gene]	1.5849625007211563	3	1	0	0
25430	1520	nucleus of FDC	[nucleus of FDC]	1.5849625007211563	3	1	0	0
25431	1520	such transcription factor	[Such transcription factors]	1.5849625007211563	3	1	0	0
25432	1520	HIV-TF1 -binding site	[HIV-TF1 -binding site]	1.5849625007211563	3	2	1	1
25433	1520	means successfully colonize hosts.	[means successfully colonizing hosts.]	1.5849625007211563	4	1	0	0
25434	1520	Ig heavy chain	[Ig heavy chain]	1.5849625007211563	3	1	0	0
25435	1520	group of chemotactic cytokine	[group of chemotactic cytokines]	1.5849625007211563	4	1	0	0
25436	1520	EPO -independent cell	[EPO -independent cells]	1.5849625007211563	3	1	0	0
25437	1520	stimulation with erythropoietin	[stimulation with erythropoietin]	1.5849625007211563	3	1	0	0
25438	1520	binding motif for SRF	[binding motifs for SRF]	1.5849625007211563	4	1	0	0
25439	1520	other nuclear oncoprotein	[other nuclear oncoproteins]	1.5849625007211563	3	1	0	0
25440	1520	reduction of the TIMP-1	[reduction of the TIMP-1]	1.5849625007211563	4	1	0	0
25441	1520	induction of cd14 expression	[induction of CD14 expression]	1.5849625007211563	4	1	0	0
25442	1520	use in vivo	[Using in vivo]	1.5849625007211563	3	1	0	0
25443	1520	stability of the c-fo	[Stability of the c-fos]	1.5849625007211563	4	1	0	0
25444	1520	lead to tyrosine phosphorylation	[leading to tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
25445	1520	induction of nf-atc	[induction of NF-ATc]	1.5849625007211563	3	1	0	0
25446	1520	increase the ap-1 component	[increasing the AP-1 component]	1.5849625007211563	4	1	0	0
25447	1520	lymphocyte-specific transcription factor	[lymphocyte-specific transcription factor]	1.5849625007211563	3	2	2	2
25448	1520	autosome of the position	[autosomes of the position]	1.5849625007211563	4	1	0	0
25449	1520	effect of 383-bp (delta383)	[effect of 383-bp (delta383)]	1.5849625007211563	4	1	0	0
25450	1520	transcriptional regulator of gene	[transcriptional regulator of genes]	1.5849625007211563	4	2	2	2
25451	1520	combination of il-4 signal	[combination of IL-4 signaling]	1.5849625007211563	4	1	0	0
25452	1520	T cell transformation	[T cell transformation]	1.5849625007211563	3	1	0	0
25453	1520	reduction of corticosteroid receptor	[reductions of corticosteroid receptors]	1.5849625007211563	4	1	0	0
25454	1520	MNDA mrna level	[MNDA mRNA level]	1.5849625007211563	3	3	2	1
25455	1520	preincubation of alpha-lipoic acid	[preincubation of alpha-lipoic acid]	1.5849625007211563	4	1	0	0
25456	1520	IL-2 cytokine production	[IL-2 cytokine production]	1.5849625007211563	3	1	0	0
25457	1520	ldl receptor gene expression	[LDL receptor gene expression]	1.5849625007211563	4	1	0	0
25458	1520	important signal ag	[important signaling Ag]	1.5849625007211563	3	1	0	0
25459	1520	bulk of wp activity	[bulk of Wp activity]	1.5849625007211563	4	1	0	0
25460	1520	pathway induce apoptosis	[pathway inducing apoptosis]	1.5849625007211563	3	1	0	0
25461	1520	proto-oncogene c-erbA in erythropoiesis	[proto-oncogene c-erbA in erythropoiesis]	1.5849625007211563	4	1	0	0
25462	1520	amount of ikappab alpha	[amount of IkappaB alpha]	1.5849625007211563	4	1	0	0
25463	1520	hpp- 47.10 cell	[HPP- 47.10 cells]	1.5849625007211563	3	1	0	0
25464	1520	D3 in monocyte	[D3 in monocytes]	1.5849625007211563	3	2	2	2
25465	1520	low-dose il-3 /gm-csf	[low-dose IL-3 /GM-CSF]	1.5849625007211563	3	1	0	0
25466	1520	clear difference between stimuli,	[clear difference between stimuli,]	1.5849625007211563	4	1	0	0
25467	1520	three immunophilin fkbp54	[three immunophilins FKBP54]	1.5849625007211563	3	1	0	0
25468	1520	androgen -bound from antiandrogen	[androgen -bound from antiandrogen]	1.5849625007211563	4	1	0	0
25469	1520	signal-coupled depletion of traf2	[signal-coupled depletion of TRAF2]	1.5849625007211563	4	1	0	0
25470	1520	retinoic acid-response element	[retinoic acid-response element]	1.5849625007211563	3	1	0	0
25471	1520	RAR alpha cell	[RAR alpha cells]	1.5849625007211563	3	1	0	0
25472	1520	approximately 50000 Dalton	[approximately 50000 Dalton]	1.5849625007211563	3	1	0	0
25473	1520	cd34+ stem cell	[CD34+ stem cells]	1.5849625007211563	3	2	2	2
25474	1520	presence of mrna	[presence of mRNA]	1.5849625007211563	3	1	0	0
25475	1520	suspension on plastic surface	[suspension on plastic surfaces]	1.5849625007211563	4	1	0	0
25476	1520	protein-tyrosine kinase zap-70	[protein-tyrosine kinase ZAP-70]	1.5849625007211563	3	1	0	0
25477	1520	PU.1 binding site	[PU.1 binding sites]	1.5849625007211563	3	1	0	0
25478	1520	c/ebp-epsilon transcription factor	[C/EBP-epsilon transcription factor]	1.5849625007211563	3	2	2	2
25479	1520	caspase 3 cleavage site	[caspase 3 cleavage site]	1.5849625007211563	4	1	0	0
25480	1520	oncogenic potential of lmp-1	[oncogenic potential of LMP-1]	1.5849625007211563	4	1	0	0
25481	1520	two week of discharge.	[two weeks of discharge.]	1.5849625007211563	4	1	0	0
25482	1520	different stage of maturation,	[different stages of maturation,]	1.5849625007211563	4	1	0	0
25483	1520	cellular cytotoxic assay	[cellular cytotoxic assays]	1.5849625007211563	3	1	0	0
25484	1520	astrocytic glial cell	[astrocytic glial cells]	1.5849625007211563	3	1	0	0
25485	1520	other viral strain	[other viral strains]	1.5849625007211563	3	1	0	0
25486	1520	CD27- b cell	[CD27- B cells]	1.5849625007211563	3	1	0	0
25487	1520	parameter of thyroid function	[parameters of thyroid function]	1.5849625007211563	4	1	0	0
25488	1520	viral immediate-early transactivator zebra	[viral immediate-early transactivator ZEBRA]	1.5849625007211563	4	1	0	0
25489	1520	presence of protein capable	[presence of proteins capable]	1.5849625007211563	4	1	0	0
25490	1520	all-trans-retinoic acid RA	[all-trans-retinoic acid RA]	1.5849625007211563	3	1	0	0
25491	1520	differentiate hematopoietic progenitor	[differentiating hematopoietic progenitors]	1.5849625007211563	3	2	2	2
25492	1520	development of immunosuppressant	[development of immunosuppressants]	1.5849625007211563	3	1	0	0
25493	1520	antigen present cell APC	[antigen presenting cells APC]	1.5849625007211563	4	1	0	0
25494	1520	target for factor	[target for factor]	1.5849625007211563	3	2	2	2
25495	1520	detection in extract	[detection in extracts]	1.5849625007211563	3	2	2	2
25496	1520	effect of anti-inflammatory glucocorticoid	[effects of anti-inflammatory glucocorticoids]	1.5849625007211563	4	1	0	0
25497	1520	express tafii105 mrna	[express TAFII105 mRNA]	1.5849625007211563	3	1	0	0
25498	1520	glucocorticoid-dependent stimulation of neoglucogenesis	[glucocorticoid-dependent stimulation of neoglucogenesis]	1.5849625007211563	4	1	0	0
25499	1520	aml /pebp2/cbf family	[AML /PEBP2/CBF family]	1.5849625007211563	3	1	0	0
25500	1520	IL-1 beta level	[IL-1 beta levels]	1.5849625007211563	3	1	0	0
25501	1520	overlapping host range	[overlapping host range,]	1.5849625007211563	3	1	0	0
25502	1520	NF-kappaB induction by HOCl	[NF-kappaB induction by HOCl]	1.5849625007211563	4	1	0	0
25503	1520	change in susceptibility	[changes in susceptibility]	1.5849625007211563	3	1	0	0
25504	1520	female monozygotic twin pair	[female monozygotic twin pair]	1.5849625007211563	4	1	0	0
25505	1520	serine phosphorylation of stat1	[serine phosphorylation of STAT1]	1.5849625007211563	4	2	1	1
25506	1520	co-cultivated b cell	[co-cultivated B cells]	1.5849625007211563	3	1	0	0
25507	1520	polymorphonuclear leukocyte pmn	[polymorphonuclear leukocyte PMN]	1.5849625007211563	3	2	1	1
25508	1520	mcp-1 expression of icam-1	[MCP-1 expression of ICAM-1]	1.5849625007211563	4	1	0	0
25509	1520	host cell types.	[host cell types.]	1.5849625007211563	3	2	2	2
25510	1520	typical native receptor characteristics.	[typical native receptor characteristics.]	1.5849625007211563	4	1	0	0
25511	1520	appropriate germline promoter	[appropriate germline promoter]	1.5849625007211563	3	1	0	0
25512	1520	Northern blot analysis,	[Northern blot analysis,]	1.5849625007211563	3	1	0	0
25513	1520	nfat promoter activity	[NFAT promoter activity]	1.5849625007211563	3	2	1	1
25514	1520	appearance of the leukemia	[appearance of the leukemia]	1.5849625007211563	4	1	0	0
25515	1520	cortisol -resistant patient	[cortisol -resistant patients]	1.5849625007211563	3	1	0	0
25516	1520	monocyte/b-cell-specific transcription factor	[monocyte/B-cell-specific transcription factor]	1.5849625007211563	3	2	1	1
25517	1520	a 187 to 231	[aa 187 to 231]	1.5849625007211563	4	1	0	0
25518	1520	various environmental estrogen	[various environmental estrogens]	1.5849625007211563	3	1	0	0
25519	1520	STAT5- related factor	[STAT5- related factors]	1.5849625007211563	3	1	0	0
25520	1520	other ifn-alpha-activated protein	[other IFN-alpha-activated proteins]	1.5849625007211563	3	1	0	0
25521	1520	negative estrogen receptor status	[negative estrogen receptor status]	1.5849625007211563	4	1	0	0
25522	1520	cellular level of component	[cellular levels of components]	1.5849625007211563	4	1	0	0
25523	1520	muscle cDNA library	[muscle cDNA library]	1.5849625007211563	3	1	0	0
25524	1520	deletion in this promoter	[Deletions in this promoter]	1.5849625007211563	4	1	0	0
25525	1520	-C-C family of chemokine	[-C-C family of chemokines]	1.5849625007211563	4	1	0	0
25526	1520	2) induction of apoptosis	[2) induction of apoptosis]	1.5849625007211563	4	1	0	0
25527	1520	coexpression of c-fo	[coexpression of c-Fos]	1.5849625007211563	3	1	0	0
25528	1520	AP-1 B-like site	[AP-1 B-like sites]	1.5849625007211563	3	1	0	0
25529	1520	number of stimulus	[number of stimuli]	1.5849625007211563	3	1	0	0
25530	1520	extract from HeLa cell	[extracts from HeLa cells]	1.5849625007211563	4	1	0	0
25531	1520	different cell types,	[different cell types,]	1.5849625007211563	3	1	0	0
25532	1520	IkappaB kinase complex activation	[IkappaB kinase complex activation]	1.5849625007211563	4	1	0	0
25533	1520	HTLV-II -bearing cell line	[HTLV-II -bearing cell line]	1.5849625007211563	4	1	0	0
25534	1520	pattern of transcription factor	[pattern of transcription factors]	1.5849625007211563	4	2	2	2
25535	1520	functional lymphoid tissues,	[functional lymphoid tissues,]	1.5849625007211563	3	1	0	0
25536	1520	other protein-protein interaction	[other protein-protein interactions]	1.5849625007211563	3	1	0	0
25537	1520	mcd14 -express cell	[mCD14 -expressing cells]	1.5849625007211563	3	1	0	0
25538	1520	fusion of cell line	[fusion of cell lines]	1.5849625007211563	4	1	0	0
25539	1520	major positive cis element	[major positive cis elements]	1.5849625007211563	4	1	0	0
25540	1520	NF-IL6 mrna level	[NF-IL6 mRNA levels]	1.5849625007211563	3	1	0	0
25541	1520	b-cell-specific interferon-inducible fashion	[B-cell-specific interferon-inducible fashion]	1.5849625007211563	3	1	0	0
25542	1520	il-2 mrna expression	[IL-2 mRNA expression]	1.5849625007211563	3	2	1	1
25543	1520	ebv oncogenicity in cell	[EBV oncogenicity in cells]	1.5849625007211563	4	1	0	0
25544	1520	nuclear factor-kappaB NF-kappaB activity	[nuclear factor-kappaB NF-kappaB activity]	1.5849625007211563	4	1	0	0
25545	1520	suppression of signal	[Suppression of signals]	1.5849625007211563	3	1	0	0
25546	1520	lymphoblastoid t-cell line a2.01	[lymphoblastoid T-cell line A2.01]	1.5849625007211563	4	1	0	0
25547	1520	percent-age of il-2+ cell	[percent-age of IL-2+ cells]	1.5849625007211563	4	1	0	0
25548	1520	kb-like sequence gggatttcacc	[kB-like sequence GGGATTTCACC]	1.5849625007211563	3	1	0	0
25549	1520	irs-2 in 1d4	[IRS-2 in 1D4]	1.5849625007211563	3	1	0	0
25550	1520	Tax1 a transcriptional trans-activator	[Tax1 a transcriptional trans-activator]	1.5849625007211563	4	1	0	0
25551	1520	NF-kappa b -DNA complex	[NF-kappa B -DNA complex]	1.5849625007211563	4	1	0	0
25552	1520	proliferation-specific transcription factor e2f1	[proliferation-specific transcription factor E2F1]	1.5849625007211563	4	1	0	0
25553	1520	level of activation	[level of activation]	1.5849625007211563	3	2	2	2
25554	1520	capacity of the e1a	[capacities of the E1A]	1.5849625007211563	4	1	0	0
25555	1520	Chen, U. (1989) Genes	[Chen, U. (1989) Genes]	1.5849625007211563	4	1	0	0
25556	1520	specific T cell recognition	[specific T cell recognition]	1.5849625007211563	4	1	0	0
25557	1520	mutation in critical site	[mutations in critical sites]	1.5849625007211563	4	1	0	0
25558	1520	endogenous tnf alpha/beta	[endogenous TNF alpha/beta]	1.5849625007211563	3	1	0	0
25559	1520	expression of IL-1 beta	[expression of IL-1 beta]	1.5849625007211563	4	1	0	0
25560	1520	bind the ap-1 tre	[binding the AP-1 TRE]	1.5849625007211563	4	1	0	0
25561	1520	blast crisis phase	[blast crisis phase]	1.5849625007211563	3	1	0	0
25562	1520	U937 lymphoid cell	[U937 lymphoid cells]	1.5849625007211563	3	1	0	0
25563	1520	peripheral blood mononuclear leukocyte	[peripheral blood mononuclear leukocytes]	1.5849625007211563	4	2	1	1
25564	1520	role of interleukin-11 IL-11	[role of interleukin-11 IL-11]	1.5849625007211563	4	1	0	0
25565	1520	human hematopoietic progenitor cell	[human hematopoietic progenitor cells]	1.5849625007211563	4	1	0	0
25566	1520	patient with CLL disease	[patients with CLL disease]	1.5849625007211563	4	1	0	0
25567	1520	about two fold	[about two fold]	1.5849625007211563	3	1	0	0
25568	1520	presence of binding activity	[presence of binding activity]	1.5849625007211563	4	1	0	0
25569	1520	fas Fas ligand expression	[Fas Fas ligand expression]	1.5849625007211563	4	1	0	0
25570	1520	expression of b gene	[expression of B genes]	1.5849625007211563	4	2	2	2
25571	1520	free radical-induced tissue damage	[free radical-induced tissue damage]	1.5849625007211563	4	1	0	0
25572	1520	CK-1 /cd28re of GM-CSF	[CK-1 /CD28RE of GM-CSF]	1.5849625007211563	4	1	0	0
25573	1520	contrast, overexpression of Vav	[contrast, overexpression of Vav]	1.5849625007211563	4	1	0	0
25574	1520	nmol/l, respectively; p	[nmol/L, respectively; P]	1.5849625007211563	3	1	0	0
25575	1520	concentration of VDR secondary	[concentration of VDR secondary]	1.5849625007211563	4	1	0	0
25576	1520	level of apoptosis	[level of apoptosis]	1.5849625007211563	3	1	0	0
25577	1520	4 megakaryocytic transcript	[4 megakaryocytic transcripts]	1.5849625007211563	3	1	0	0
25578	1520	total of patient	[total of patients]	1.5849625007211563	3	2	2	2
25579	1520	functional synergy between IL-2	[functional synergy between IL-2]	1.5849625007211563	4	1	0	0
25580	1520	identify the thymocyte subpopulation	[identifying the thymocyte subpopulation]	1.5849625007211563	4	1	0	0
25581	1520	site of the tumor	[site of the tumor]	1.5849625007211563	4	1	0	0
25582	1520	PML nbs sp100	[PML NBs SP100]	1.5849625007211563	3	1	0	0
25583	1520	lung transplant patient	[lung transplant patients]	1.5849625007211563	3	1	0	0
25584	1520	constitutively active mapkk-1	[Constitutively active MAPKK-1]	1.5849625007211563	3	1	0	0
25585	1520	other cellular protein	[other cellular proteins]	1.5849625007211563	3	1	0	0
25586	1520	composition of NF-kappa b	[composition of NF-kappa B]	1.5849625007211563	4	1	0	0
25587	1520	combination of as2o3	[combination of As2O3]	1.5849625007211563	3	1	0	0
25588	1520	other iron salt	[other iron salts]	1.5849625007211563	3	1	0	0
25589	1520	differentiation-inducing effect of D3	[differentiation-inducing effects of D3]	1.5849625007211563	4	1	0	0
25590	1520	selective transcriptional repressor	[selective transcriptional repressor]	1.5849625007211563	3	1	0	0
25591	1520	TcR delta gene	[TcR delta gene]	1.5849625007211563	3	2	2	2
25592	1520	however, tyrosine -phosphorylated p80c-rel	[however, tyrosine -phosphorylated p80c-rel]	1.5849625007211563	4	1	0	0
25593	1520	jurkat-derived T cell line	[Jurkat-derived T cell line]	1.5849625007211563	4	1	0	0
25594	1520	vitro transcription activity	[vitro transcription activity]	1.5849625007211563	3	1	0	0
25595	1520	response to the secosterol	[response to the secosterol]	1.5849625007211563	4	1	0	0
25596	1520	proline -rich region	[proline -rich region]	1.5849625007211563	3	2	2	2
25597	1520	difference in the signal	[differences in the signals]	1.5849625007211563	4	1	0	0
25598	1520	response to IL-13	[response to IL-13]	1.5849625007211563	3	2	1	1
25599	1520	12-o-tetradecanoylphorbol-13-acetate tpa mononuclear differentiation	[12-O-tetradecanoylphorbol-13-acetate TPA mononuclear differentiation]	1.5849625007211563	4	1	0	0
25600	1520	response to IL-18	[response to IL-18]	1.5849625007211563	3	1	0	0
25601	1520	intracellular ca2+ store	[intracellular Ca2+ stores]	1.5849625007211563	3	1	0	0
25602	1520	simian virus 40 enhancer	[simian virus 40 enhancer]	1.5849625007211563	4	1	0	0
25603	1520	individual with cystic fibrosis	[individuals with cystic fibrosis]	1.5849625007211563	4	1	0	0
25604	1520	DU528 a t-cell line	[DU528 a T-cell line]	1.5849625007211563	4	1	0	0
25605	1520	level of spi-1 mrna	[levels of spi-1 mRNA]	1.5849625007211563	4	1	0	0
25606	1520	expression of g(s)alpha	[expression of G(S)alpha]	1.5849625007211563	3	1	0	0
25607	1520	gal4-binding DNA element	[Gal4-binding DNA elements]	1.5849625007211563	3	1	0	0
25608	1520	mutation of either site	[Mutation of either site]	1.5849625007211563	4	1	0	0
25609	1520	retinoid -dependent regulation	[retinoid -dependent regulation]	1.5849625007211563	3	1	0	0
25610	1520	use expression cloning,	[Using expression cloning,]	1.5849625007211563	3	1	0	0
25611	1520	use Scatchard analysis,	[Using Scatchard analysis,]	1.5849625007211563	3	1	0	0
25612	1520	chronic leukemia cell	[chronic leukemia cells]	1.5849625007211563	3	2	2	2
25613	1520	presence of il-11	[presence of IL-11]	1.5849625007211563	3	1	0	0
25614	1520	presence of il-10	[presence of IL-10]	1.5849625007211563	3	2	1	1
25615	1520	least 10 epitopes.	[least 10 epitopes.]	1.5849625007211563	3	1	0	0
25616	1520	human immuno-deficiency virus hiv	[human immuno-deficiency virus HIV]	1.5849625007211563	4	1	0	0
25617	1520	intracellular calcium level	[intracellular calcium levels]	1.5849625007211563	3	2	1	1
25618	1520	majority of cell line	[majority of cell lines]	1.5849625007211563	4	1	0	0
25619	1520	Jurkat T leukemia cell	[Jurkat T leukemia cells]	1.5849625007211563	4	1	0	0
25620	1520	pro-opiomelanocortin (pomc) gene	[pro-opiomelanocortin (POMC) gene]	1.5849625007211563	3	1	0	0
25621	1520	silencer between bp -92	[silencer between bp -92]	1.5849625007211563	4	1	0	0
25622	1520	proportion of protein	[proportion of protein]	1.5849625007211563	3	1	0	0
25623	1520	TaqI restriction site	[TaqI restriction site]	1.5849625007211563	3	2	2	2
25624	1520	induction of stat1s1	[induction of STAT1s1]	1.5849625007211563	3	1	0	0
25625	1520	two nuclear complex	[two nuclear complexes]	1.5849625007211563	3	1	0	0
25626	1520	gene disruption of il-7	[gene disruption of IL-7]	1.5849625007211563	4	1	0	0
25627	1520	activation of primary t-lymphocyte	[Activation of primary T-lymphocytes]	1.5849625007211563	4	2	2	2
25628	1520	number of binding complex	[number of binding complexes]	1.5849625007211563	4	1	0	0
25629	1520	NF-kappa B/Rel protein family	[NF-kappa B/Rel protein family]	1.5849625007211563	4	1	0	0
25630	1520	current study, cysteamine	[current study, cysteamine]	1.5849625007211563	3	1	0	0
25631	1520	binding site for Oct-1	[binding site for Oct-1]	1.5849625007211563	4	1	0	0
25632	1520	clone of U937 cell	[clone of U937 cells]	1.5849625007211563	4	1	0	0
25633	1520	multicolor flow cytometric assay	[Multicolor flow cytometric assays]	1.5849625007211563	4	1	0	0
25634	1520	POU dna-binding motif	[POU DNA-binding motif]	1.5849625007211563	3	1	0	0
25635	1520	novel genetic system	[novel genetic system]	1.5849625007211563	3	1	0	0
25636	1520	course of the cycle	[course of the cycle]	1.5849625007211563	4	1	0	0
25637	1520	benzene contaminate water	[benzene contaminating water]	1.5849625007211563	3	1	0	0
25638	1520	specific t-cell tolerance induction	[specific T-cell tolerance induction]	1.5849625007211563	4	1	0	0
25639	1520	activation of tyrosine kinase	[activation of tyrosine kinases]	1.5849625007211563	4	2	2	2
25640	1520	rest Jurkat cell	[resting Jurkat cells]	1.5849625007211563	3	1	0	0
25641	1520	one gata-1 motif,	[one GATA-1 motif,]	1.5849625007211563	3	1	0	0
25642	1520	CMV transactivator in combination	[CMV transactivator in combination]	1.5849625007211563	4	1	0	0
25643	1520	cell activation, displacement	[cell activation, displacement]	1.5849625007211563	3	1	0	0
25644	1520	Jurkat t-cell clone	[Jurkat T-cell clones]	1.5849625007211563	3	1	0	0
25645	1520	domain in N terminus	[domain in N terminus]	1.5849625007211563	4	1	0	0
25646	1520	Hodgkin' disease marker CD30	[Hodgkin's disease marker CD30]	1.5849625007211563	4	1	0	0
25647	1520	leukemia/B lymphoma cell line	[leukemia/B lymphoma cell lines]	1.5849625007211563	4	1	0	0
25648	1520	six G-rich motif	[six G-rich motifs]	1.5849625007211563	3	1	0	0
25649	1520	difference between the distribution	[difference between the distribution]	1.5849625007211563	4	1	0	0
25650	1520	RFX -deficient b cell	[RFX -deficient B cells]	1.5849625007211563	4	1	0	0
25651	1520	receptor in human lymphocyte	[receptors in human lymphocytes]	1.5849625007211563	4	2	2	2
25652	1520	cd36 -ox ldl interaction	[CD36 -Ox LDL interaction]	1.5849625007211563	4	1	0	0
25653	1520	type of immune cell	[type of immune cells]	1.5849625007211563	4	1	0	0
25654	1520	transplantation of bone marrow	[transplantation of bone marrow]	1.5849625007211563	4	1	0	0
25655	1520	mutant tsap -binding site	[mutant TSAP -binding site]	1.5849625007211563	4	1	0	0
25656	1520	partial responsiveness to p40tax	[partial responsiveness to p40tax]	1.5849625007211563	4	1	0	0
25657	1520	difference in signal	[difference in signals]	1.5849625007211563	3	1	0	0
25658	1520	corresponding h&e-stained section	[corresponding H&E-stained sections]	1.5849625007211563	3	1	0	0
25659	1520	monocytic u937 cell	[monocytic U937 cells]	1.5849625007211563	3	2	1	1
25660	1520	virus-induced cellular transformation	[virus-induced cellular transformation]	1.5849625007211563	3	1	0	0
25661	1520	addition of iron salt	[addition of iron salts]	1.5849625007211563	4	1	0	0
25662	1520	gamma- specific antibody	[gamma- specific antibodies]	1.5849625007211563	3	1	0	0
25663	1520	transform growth factor beta1	[transforming growth factor beta1]	1.5849625007211563	4	1	0	0
25664	1520	effector function of CTL	[effector function of CTL]	1.5849625007211563	4	1	0	0
25665	1520	response to inductive stimulation	[response to inductive stimulations]	1.5849625007211563	4	1	0	0
25666	1520	loss of gata-3 expression	[loss of GATA-3 expression]	1.5849625007211563	4	1	0	0
25667	1520	primary myelodysplastic syndrome	[primary myelodysplastic syndromes]	1.5849625007211563	3	2	2	2
25668	1520	v-abl kinase activity	[v-abl kinase activity]	1.5849625007211563	3	2	2	2
25669	1520	increase gata-1 level	[increasing GATA-1 levels]	1.5849625007211563	3	2	2	2
25670	1520	isolated case of ige	[isolated cases of IgE]	1.5849625007211563	4	1	0	0
25671	1520	hypo-acetylation of core histone	[hypo-acetylation of core histones]	1.5849625007211563	4	1	0	0
25672	1520	other macrophage marker CD14	[other macrophage markers CD14]	1.5849625007211563	4	1	0	0
25673	1520	High-dose pulse glucocorticoid therapy	[High-dose pulse glucocorticoid therapy]	1.5849625007211563	4	1	0	0
25674	1520	cd40l expression vector	[CD40L expression vector]	1.5849625007211563	3	1	0	0
25675	1520	upstream positive regulatory element	[upstream positive regulatory elements]	1.5849625007211563	4	1	0	0
25676	1520	reduction in gene expression	[reduction in gene expression]	1.5849625007211563	4	1	0	0
25677	1520	ebv infection of b-cell	[EBV infection of B-cells]	1.5849625007211563	4	1	0	0
25678	1520	(the leucine zipper-like	[(the leucine zipper-like]	1.5849625007211563	3	1	0	0
25679	1520	interleukin 10 il-10 receptor	[interleukin 10 IL-10 receptor]	1.5849625007211563	4	1	0	0
25680	1520	E2A gene product	[E2A gene products]	1.5849625007211563	3	1	0	0
25681	1520	Cyclin A locus	[Cyclin A locus]	1.5849625007211563	3	1	0	0
25682	1520	(respective mean values: 385	[(respective mean values: 385]	1.5849625007211563	4	1	0	0
25683	1520	tumor cell of nlphd	[tumor cells of NLPHD]	1.5849625007211563	4	1	0	0
25684	1520	large body of evidence	[large body of evidence]	1.5849625007211563	4	1	0	0
25685	1520	equimolar heterodimerization of jak1	[equimolar heterodimerization of JAK1]	1.5849625007211563	4	1	0	0
25686	1520	arterial endothelial cell	[arterial endothelial cells]	1.5849625007211563	3	2	2	2
25687	1520	concentration of binding site	[concentration of binding sites]	1.5849625007211563	4	2	2	2
25688	1520	together, substitution of Arg551	[together, substitution of Arg551]	1.5849625007211563	4	1	0	0
25689	1520	level of tf activity	[levels of TF activity]	1.5849625007211563	4	1	0	0
25690	1520	very severe forms, granulocyte	[very severe forms, granulocytes]	1.5849625007211563	4	1	0	0
25691	1520	contrast, pma-induced JNK activation	[contrast, PMA-induced JNK activation]	1.5849625007211563	4	1	0	0
25692	1520	only very low level	[only very low levels]	1.5849625007211563	4	1	0	0
25693	1520	temporal control of c-Jun	[temporal control of c-Jun]	1.5849625007211563	4	1	0	0
25694	1520	role for the regulation	[role for the regulation]	1.5849625007211563	4	1	0	0
25695	1520	specific CD4 promoter mutant	[specific CD4 promoter mutants]	1.5849625007211563	4	1	0	0
25696	1520	same chimeric animal	[same chimeric animals]	1.5849625007211563	3	1	0	0
25697	1520	aminoenhancer of (ars) protein	[Aminoenhancer of (AES) protein]	1.5849625007211563	4	1	0	0
25698	1520	chromatinized viral episome	[chromatinized viral episome]	1.5849625007211563	3	1	0	0
25699	1520	case of cathepsin g	[case of cathepsin G]	1.5849625007211563	4	1	0	0
25700	1520	disruption of ebv latency	[disruption of EBV latency]	1.5849625007211563	4	2	1	1
25701	1520	induction of nuclear nfkappab	[induction of nuclear NFkappaB]	1.5849625007211563	4	1	0	0
25702	1520	68-kDa cleavage product,	[68-kDa cleavage product,]	1.5849625007211563	3	1	0	0
25703	1520	85-kDa cytosolic phospholipase a2	[85-kDa cytosolic phospholipase A2]	1.5849625007211563	4	1	0	0
25704	1520	utility of MTHC	[utility of MTHC]	1.5849625007211563	3	1	0	0
25705	1520	diagnosis of gct	[diagnosis of GCT]	1.5849625007211563	3	1	0	0
25706	1520	control at 14.7118.7, 3.8-7.0	[control at 14.7-18.7, 3.8-7.0]	1.5849625007211563	4	1	0	0
25707	1520	identification of genetic target	[identification of genetic targets]	1.5849625007211563	4	1	0	0
25708	1520	flutamide on clinical parameter	[flutamide on clinical parameters]	1.5849625007211563	4	1	0	0
25709	1520	human cell line u937	[human cell line U937]	1.5849625007211563	4	2	2	2
25710	1520	T-lymphocytic cell line	[T-lymphocytic cell line]	1.5849625007211563	3	3	2	1
25711	1520	absence of gamma(c)	[absence of gamma(c)]	1.5849625007211563	3	1	0	0
25712	1520	circulate level of cortisol	[circulating levels of cortisol]	1.5849625007211563	4	1	0	0
25713	1520	trans- activation region	[trans- activation region]	1.5849625007211563	3	1	0	0
25714	1520	modulation of CD28 expression	[Modulation of CD28 expression]	1.5849625007211563	4	1	0	0
25715	1520	upstream enhancer element	[upstream enhancer element]	1.5849625007211563	3	1	0	0
25716	1520	model for cell-type regulation	[model for cell-type regulation]	1.5849625007211563	4	1	0	0
25717	1520	expression of RANTES	[expression of RANTES]	1.5849625007211563	3	1	0	0
25718	1520	expression of several lymphokine	[expression of several lymphokines]	1.5849625007211563	4	1	0	0
25719	1520	major cause of morbidity	[major cause of morbidity]	1.5849625007211563	4	1	0	0
25720	1520	mechanism largely unknown,	[mechanisms largely unknown,]	1.5849625007211563	3	1	0	0
25721	1520	cytokine tnf alpha	[cytokines TNF alpha]	1.5849625007211563	3	1	0	0
25722	1520	cellular thiol level	[cellular thiol level]	1.5849625007211563	3	1	0	0
25723	1520	two ap-1 site	[two AP-1 sites]	1.5849625007211563	3	1	0	0
25724	1520	successful T cell activation	[successful T cell activation]	1.5849625007211563	4	1	0	0
25725	1520	N-terminal domain of PKCalpha	[N-terminal domain of PKCalpha]	1.5849625007211563	4	1	0	0
25726	1520	growth-related activity-alpha gro-alpha	[growth-related activity-alpha GRO-alpha]	1.5849625007211563	3	1	0	0
25727	1520	permanent overexpression of IRAK	[permanent overexpression of IRAK]	1.5849625007211563	4	1	0	0
25728	1520	m(r) of kda	[M(r) of kDa]	1.5849625007211563	3	2	2	2
25729	1520	HIV1 gene product	[HIV1 gene products]	1.5849625007211563	3	1	0	0
25730	1520	series of gene	[series of genes]	1.5849625007211563	3	1	0	0
25731	1520	sensitivity to hormone treatment	[sensitivity to hormone treatment]	1.5849625007211563	4	1	0	0
25732	1520	fifty synthetic retinoid	[fifty synthetic retinoids]	1.5849625007211563	3	1	0	0
25733	1520	regulatory region of IL2	[regulatory region of IL2]	1.5849625007211563	4	1	0	0
25734	1520	disease involve immune	[diseases involving immune]	1.5849625007211563	3	1	0	0
25735	1520	nfat binding to calcineurin	[NFAT binding to calcineurin]	1.5849625007211563	4	1	0	0
25736	1520	mechanism of hm differentiation	[mechanism of Hm differentiation]	1.5849625007211563	4	1	0	0
25737	1520	tgf-beta gene promoter	[TGF-beta gene promoters]	1.5849625007211563	3	2	1	1
25738	1520	fc gamma RI	[Fc gamma RI]	1.5849625007211563	3	2	1	1
25739	1520	putative nuclear target sequence	[putative nuclear targeting sequence]	1.5849625007211563	4	1	0	0
25740	1520	virus-immortalized lymphoblastoid cell line	[virus-immortalized lymphoblastoid cell lines]	1.5849625007211563	4	1	0	0
25741	1520	normal cellular equivalent c-myb	[normal cellular equivalent c-myb]	1.5849625007211563	4	1	0	0
25742	1520	mechanism for regulation	[mechanism for regulation]	1.5849625007211563	3	2	2	2
25743	1520	B2 site of proenkephalin	[B2 site of proenkephalin]	1.5849625007211563	4	1	0	0
25744	1520	vitro erythroid differentiation	[vitro erythroid differentiation]	1.5849625007211563	3	1	0	0
25745	1520	orf 50 transactivator	[ORF 50 transactivator]	1.5849625007211563	3	1	0	0
25746	1520	cell express the fetal	[cells expressing the fetal]	1.5849625007211563	4	2	1	1
25747	1520	only partial receptor occupancy	[Only partial receptor occupancy]	1.5849625007211563	4	1	0	0
25748	1520	absence of progesterone	[absence of progesterone]	1.5849625007211563	3	1	0	0
25749	1520	endothelial activation, inflammation	[endothelial activation, inflammation]	1.5849625007211563	3	1	0	0
25750	1520	interference with Oct-2 function	[interference with Oct-2 function]	1.5849625007211563	4	1	0	0
25751	1520	approximately 30 min.	[approximately 30 min.]	1.5849625007211563	3	1	0	0
25752	1520	one lps event	[one LPS event]	1.5849625007211563	3	1	0	0
25753	1520	pathway of induction	[pathway of induction]	1.5849625007211563	3	1	0	0
25754	1520	T cell-independent culture system	[T cell-independent culture system]	1.5849625007211563	4	1	0	0
25755	1520	little detectable cytokine	[little detectable cytokines]	1.5849625007211563	3	1	0	0
25756	1520	regulation of ferritin expression	[regulation of ferritin expression]	1.5849625007211563	4	1	0	0
25757	1520	serum immunoglobulin level	[serum immunoglobulin levels]	1.5849625007211563	3	1	0	0
25758	1520	distinct NF-kappaB activation mechanism	[distinct NF-kappaB activation mechanism]	1.5849625007211563	4	1	0	0
25759	1520	level of beta-actin mrna	[levels of beta-actin mRNA]	1.5849625007211563	4	1	0	0
25760	1520	inactive analog methylthiogliotoxin	[inactive analog methylthiogliotoxin]	1.5849625007211563	3	1	0	0
25761	1520	direct transcriptional control	[direct transcriptional control]	1.5849625007211563	3	1	0	0
25762	1520	importance of this observation	[importance of these observations]	1.5849625007211563	4	1	0	0
25763	1520	simian immunodeficiency virus sivsmmpbj14	[simian immunodeficiency virus SIVsmmPBj14]	1.5849625007211563	4	1	0	0
25764	1520	box 1 pax1	[box 1 PAX1]	1.5849625007211563	3	1	0	0
25765	1520	NFATp/c- binding site	[NFATp/c- binding sites]	1.5849625007211563	3	1	0	0
25766	1520	bind activity specific	[binding activity specific]	1.5849625007211563	3	1	0	0
25767	1520	eukaryotic rna polymerase ii	[eukaryotic RNA polymerase II]	1.5849625007211563	4	1	0	0
25768	1520	function of transcription factor	[function of transcription factors]	1.5849625007211563	4	1	0	0
25769	1520	vitro phosphorylation of SM	[vitro phosphorylation of SM]	1.5849625007211563	4	1	0	0
25770	1520	pml-rar -contain leukemic cell	[PML-RAR -containing leukemic cells]	1.5849625007211563	4	1	0	0
25771	1520	pkc-zeta pkc-zeta mut	[PKC-zeta PKC-zeta mut]	1.5849625007211563	3	1	0	0
25772	1520	corresponding mononuclear leukocyte	[corresponding mononuclear leukocytes]	1.5849625007211563	3	1	0	0
25773	1520	Putative steroid binding domain	[Putative steroid binding domain]	1.5849625007211563	4	1	0	0
25774	1520	proliferation of b cell	[proliferation of B cells]	1.5849625007211563	4	1	0	0
25775	1520	activation of human t-lymphocyte	[Activation of human T-lymphocytes]	1.5849625007211563	4	2	2	2
25776	1520	Ca(2+)- dependent pathway	[Ca(2+)- dependent pathways]	1.5849625007211563	3	1	0	0
25777	1520	two transcriptional activation domain	[two transcriptional activation domains]	1.5849625007211563	4	1	0	0
25778	1520	regulation of replicative function	[Regulation of replicative functions]	1.5849625007211563	4	1	0	0
25779	1520	CTL against immunorecessive epitope	[CTLs against immunorecessive epitopes]	1.5849625007211563	4	1	0	0
25780	1520	genuine hugata-3 by sds-page	[genuine huGATA-3 by SDS-PAGE]	1.5849625007211563	4	1	0	0
25781	1520	alone combination with lps	[alone combination with LPS]	1.5849625007211563	4	1	0	0
25782	1520	sequence-specific dna-binding small molecule	[Sequence-specific DNA-binding small molecules]	1.5849625007211563	4	1	0	0
25783	1520	b beta level	[B beta levels]	1.5849625007211563	3	1	0	0
25784	1520	Gal4- k protein	[Gal4- K protein]	1.5849625007211563	3	1	0	0
25785	1520	involve mainly the pancrea	[involving mainly the pancreas]	1.5849625007211563	4	1	0	0
25786	1520	E. coli rpo mutation	[E. coli rpoS mutation]	1.5849625007211563	4	1	0	0
25787	1520	response to 135(oh)2d3	[response to 1,25(OH)2D3]	1.5849625007211563	3	2	1	1
25788	1520	expression of cd14 mrna	[expression of CD14 mRNA]	1.5849625007211563	4	1	0	0
25789	1520	three cis-acting element	[three cis-acting elements]	1.5849625007211563	3	2	1	1
25790	1520	two transcription factor AP-1	[two transcription factors AP-1]	1.5849625007211563	4	1	0	0
25791	1520	PKC inhibitor staurosporine	[PKC inhibitor staurosporine]	1.5849625007211563	3	1	0	0
25792	1520	follow transient transfection	[following transient transfection]	1.5849625007211563	3	1	0	0
25793	1520	plasma RIA value	[plasma RIA values]	1.5849625007211563	3	1	0	0
25794	1520	treatment of leukemia (apl):	[treatment of leukemia (APL):]	1.5849625007211563	4	1	0	0
25795	1520	other, putatively non-cross-resisting agent	[other, putatively non-cross-resisting agents]	1.5849625007211563	4	1	0	0
25796	1520	signal via receptor	[signaling via receptors]	1.5849625007211563	3	1	0	0
25797	1520	however, terminally cell	[However, terminally cells]	1.5849625007211563	3	1	0	0
25798	1520	biphasic expression of irf-1	[biphasic expression of IRF-1]	1.5849625007211563	4	1	0	0
25799	1520	kappa gene promoter	[kappa gene promoter]	1.5849625007211563	3	1	0	0
25800	1520	il-2 T cell proliferation	[IL-2 T cell proliferation]	1.5849625007211563	4	2	1	1
25801	1520	induction of differentiation.	[induction of differentiation.]	1.5849625007211563	3	1	0	0
25802	1520	induction of differentiation,	[induction of differentiation,]	1.5849625007211563	3	1	0	0
25803	1520	rate of c-jun transcription	[rates of c-jun transcription]	1.5849625007211563	4	1	0	0
25804	1520	specific dexamethasone binding	[specific dexamethasone binding]	1.5849625007211563	3	1	0	0
25805	1520	human chromosome 5.	[human chromosome 5.]	1.5849625007211563	3	1	0	0
25806	1520	kappa b-related sequence	[kappa B-related sequences]	1.5849625007211563	3	2	1	1
25807	1520	level of this protein.	[levels of this protein.]	1.5849625007211563	4	1	0	0
25808	1520	high concentration of compound	[High concentrations of compound]	1.5849625007211563	4	1	0	0
25809	1520	similarity to NF-kappa b	[similarity to NF-kappa B]	1.5849625007211563	4	1	0	0
25810	1520	VZV -susceptible donor	[VZV -susceptible donors]	1.5849625007211563	3	1	0	0
25811	1520	signal from cytokine receptor	[signals from cytokine receptors]	1.5849625007211563	4	1	0	0
25812	1520	proximal 0.2-kb region	[proximal 0.2-kb region]	1.5849625007211563	3	1	0	0
25813	1520	active renin (869 pg/ml;	[active renin (869 pg/ml;]	1.5849625007211563	4	1	0	0
25814	1520	p65 rel-a phosphorylation	[p65 Rel-A phosphorylation]	1.5849625007211563	3	1	0	0
25815	1520	fc gamma RIC gire	[Fc gamma RIC GIRE]	1.5849625007211563	4	1	0	0
25816	1520	transcription factor ctf/nf-1	[transcription factors CTF/NF-1]	1.5849625007211563	3	1	0	0
25817	1520	distribution of pkc	[distribution of PKC]	1.5849625007211563	3	1	0	0
25818	1520	collagen acid aggregation	[collagen acid aggregation]	1.5849625007211563	3	1	0	0
25819	1520	il-2 receptors, pi 3-kinase	[IL-2 receptors, PI 3-kinase]	1.5849625007211563	4	1	0	0
25820	1520	(HIV) long terminal repeat	[(HIV) long terminal repeat]	1.5849625007211563	4	2	1	1
25821	1520	recruitment of inflammatory cell	[recruitment of inflammatory cells]	1.5849625007211563	4	1	0	0
25822	1520	two ribosomal protein sequence	[two ribosomal protein sequences]	1.5849625007211563	4	1	0	0
25823	1520	endogenous gata-1 gene	[endogenous GATA-1 gene]	1.5849625007211563	3	1	0	0
25824	1520	signal upon infection	[signals upon infection]	1.5849625007211563	3	1	0	0
25825	1520	determination of cell lineage	[determination of cell lineage]	1.5849625007211563	4	1	0	0
25826	1520	2 (th2) cell	[2 (Th2) cells]	1.5849625007211563	3	2	1	1
25827	1520	predominant producer of IL-2	[predominant producers of IL-2]	1.5849625007211563	4	1	0	0
25828	1520	human gm-csf promoter-	[human GM-CSF promoter-]	1.5849625007211563	3	1	0	0
25829	1520	FK-506 CsA -sensitive enzyme	[FK-506 CsA -sensitive enzyme]	1.5849625007211563	4	1	0	0
25830	1520	great than 90% inhibition	[greater than 90% inhibition]	1.5849625007211563	4	1	0	0
25831	1520	effect on the stabilization	[effect on the stabilization]	1.5849625007211563	4	1	0	0
25832	1520	ten control subject	[ten control subjects]	1.5849625007211563	3	1	0	0
25833	1520	inhibition of differentiation	[inhibition of differentiation]	1.5849625007211563	3	2	1	1
25834	1520	increase in c-jun rna	[increase in c-jun RNA]	1.5849625007211563	4	1	0	0
25835	1520	monoclonal anti-mbp antibody	[monoclonal anti-MBP antibody]	1.5849625007211563	3	1	0	0
25836	1520	calmodulin to calcineurin	[calmodulin to calcineurin]	1.5849625007211563	3	1	0	0
25837	1520	calcineurin in this regulation.	[calcineurin in this regulation.]	1.5849625007211563	4	1	0	0
25838	1520	repressor of level expression	[repressor of level expression]	1.5849625007211563	4	1	0	0
25839	1520	age, size, lymph-node involvement	[age, size, lymph-node involvement]	1.5849625007211563	4	1	0	0
25840	1520	inflammatory cytokine -mRNA level	[inflammatory cytokine -mRNA level]	1.5849625007211563	4	1	0	0
25841	1520	culminate in t-lymphocyte activation	[culminating in T-lymphocyte activation]	1.5849625007211563	4	1	0	0
25842	1520	study use antibody	[study using antibodies]	1.5849625007211563	3	2	2	2
25843	1520	activity of c-Myb	[activity of c-Myb]	1.5849625007211563	3	1	0	0
25844	1520	inhibition of one	[inhibition of one]	1.5849625007211563	3	1	0	0
25845	1520	vitro binding activity	[vitro binding activity]	1.5849625007211563	3	1	0	0
25846	1520	effect of this synergism	[effect of this synergism]	1.5849625007211563	4	1	0	0
25847	1520	effect of R	[effect of R]	1.5849625007211563	3	1	0	0
25848	1520	xp/ cs clinical entity	[XP/ CS clinical entity]	1.5849625007211563	4	1	0	0
25849	1520	receptor to the nucleus	[receptors to the nucleus]	1.5849625007211563	4	1	0	0
25850	1520	RNA protection assay	[RNA protection assays]	1.5849625007211563	3	1	0	0
25851	1520	permanently hiv enhancer activity	[permanently HIV enhancer activity]	1.5849625007211563	4	1	0	0
25852	1520	chronic myeloproliferative disease	[chronic myeloproliferative diseases]	1.5849625007211563	3	1	0	0
25853	1520	immunoblotting for tyrosine phosphorylation	[immunoblotting for tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
25854	1520	high abundance in liver	[highest abundance in liver]	1.5849625007211563	4	1	0	0
25855	1520	such as Jurkat	[such as Jurkat]	1.5849625007211563	3	1	0	0
25856	1520	TF-specific kappab site	[TF-specific kappaB site]	1.5849625007211563	3	1	0	0
25857	1520	tissue factor tf gene	[Tissue Factor TF gene]	1.5849625007211563	4	1	0	0
25858	1520	four animal 20	[four animals 20]	1.5849625007211563	3	1	0	0
25859	1520	il-2r beta mrna level	[IL-2R beta mRNA levels]	1.5849625007211563	4	1	0	0
25860	1520	multiple polypeptide subunit	[multiple polypeptide subunits]	1.5849625007211563	3	1	0	0
25861	1520	Raji b cell line	[Raji B cell line]	1.5849625007211563	4	3	2	1
25862	1520	inositol 1,4,5-trisphosphate /calcium pathway	[inositol 1,4,5-trisphosphate /calcium pathway]	1.5849625007211563	4	1	0	0
25863	1520	most potent anti-inflammatory agent	[most potent anti-inflammatory agents]	1.5849625007211563	4	1	0	0
25864	1520	1.3-1.5 kb in	[1.3-1.5 kb in]	1.5849625007211563	3	1	0	0
25865	1520	3 kD molecule	[3 kD molecule]	1.5849625007211563	3	1	0	0
25866	1520	NFAT nuclear factor element	[NFAT nuclear factor element]	1.5849625007211563	4	1	0	0
25867	1520	competitive reverse transcription-PCR	[competitive reverse transcription-PCR]	1.5849625007211563	3	1	0	0
25868	1520	flow cytometry analysis	[flow cytometry analysis]	1.5849625007211563	3	1	0	0
25869	1520	myb-transformed hemopoi-etic cell mthc	[myb-transformed hemopoi-etic cells MTHC]	1.5849625007211563	4	1	0	0
25870	1520	protein kinase c dependent	[protein kinase C dependent]	1.5849625007211563	4	1	0	0
25871	1520	MNL from this patient	[MNL from these patients]	1.5849625007211563	4	1	0	0
25872	1520	lymphoid cell line BJA-B	[lymphoid cell line BJA-B]	1.5849625007211563	4	1	0	0
25873	1520	characteristic in vivo footprint	[characteristic in vivo footprint]	1.5849625007211563	4	1	0	0
25874	1520	implication for c-fo control	[implication for c-fos control]	1.5849625007211563	4	1	0	0
25875	1520	proliferation of a phenotype	[proliferation of a phenotype]	1.5849625007211563	4	1	0	0
25876	1520	human sr 31747a-binding protein	[human SR 31747A-binding protein]	1.5849625007211563	4	1	0	0
25877	1520	human tcr beta gene	[human TCR beta gene]	1.5849625007211563	4	1	0	0
25878	1520	kappa immunoglobulin enhancer	[kappa immunoglobulin enhancer]	1.5849625007211563	3	1	0	0
25879	1520	inhibition of activity	[inhibition of activity]	1.5849625007211563	3	2	1	1
25880	1520	synergistic effect of Dexamethasone	[synergistic effect of Dexamethasone]	1.5849625007211563	4	1	0	0
25881	1520	immediate-early gene mie	[immediate-early gene MIE]	1.5849625007211563	3	1	0	0
25882	1520	study, transient cotransfection	[study, transient cotransfection]	1.5849625007211563	3	1	0	0
25883	1520	amino acid 86-265	[amino acids 86-265]	1.5849625007211563	3	1	0	0
25884	1520	globin gene activation	[globin gene activation]	1.5849625007211563	3	1	0	0
25885	1520	genomic tnf gene	[genomic TNF gene]	1.5849625007211563	3	1	0	0
25886	1520	B29 promoter reporter	[B29 promoter reporter]	1.5849625007211563	3	1	0	0
25887	1520	expression of E2a-Pbx1	[expression of E2a-Pbx1]	1.5849625007211563	3	1	0	0
25888	1520	more 3' sequence	[more 3' sequences]	1.5849625007211563	3	1	0	0
25889	1520	calcium ionophore alone	[calcium ionophore alone]	1.5849625007211563	3	1	0	0
25890	1520	difference between wild-type receptor	[differences between wild-type receptors]	1.5849625007211563	4	1	0	0
25891	1520	accessory cell by immunohistochemistry	[accessory cells by immunohistochemistry]	1.5849625007211563	4	1	0	0
25892	1520	transcriptional factor NF-kappa b	[transcriptional factor NF-kappa B]	1.5849625007211563	4	1	0	0
25893	1520	GR N terminus	[GR N terminus]	1.5849625007211563	3	1	0	0
25894	1520	salient difference between solution	[salient difference between solution]	1.5849625007211563	4	1	0	0
25895	1520	GATA3 a member	[GATA3 a member]	1.5849625007211563	3	1	0	0
25896	1520	defective DNA binding	[defective DNA binding]	1.5849625007211563	3	1	0	0
25897	1520	contrast to pth cell	[contrast to pTh cells]	1.5849625007211563	4	1	0	0
25898	1520	exclusion of amino acid	[exclusion of amino acids]	1.5849625007211563	4	1	0	0
25899	1520	class of compounds.	[class of compounds.]	1.5849625007211563	3	1	0	0
25900	1520	cell adhesion molecule-1 expression	[cell adhesion molecule-1 expression]	1.5849625007211563	4	2	2	2
25901	1520	clone of CEM cell	[clone of CEM cells]	1.5849625007211563	4	1	0	0
25902	1520	adult t-cell lymphoma/leukemia	[adult T-cell lymphoma/leukemia]	1.5849625007211563	3	2	2	2
25903	1520	nucleus of this cells.	[nucleus of these cells.]	1.5849625007211563	4	1	0	0
25904	1520	vivo protein-DNA contact	[vivo protein-DNA contacts]	1.5849625007211563	3	1	0	0
25905	1520	inhibition by membrane extract	[inhibition by membrane extracts]	1.5849625007211563	4	1	0	0
25906	1520	ubiquitin -carrier protein e2-f1	[ubiquitin -carrier protein E2-F1]	1.5849625007211563	4	1	0	0
25907	1520	co-transfection of HeLa cell	[co-transfection of HeLa cells]	1.5849625007211563	4	1	0	0
25908	1520	interleukin-2 gene in naive	[interleukin-2 gene in naive]	1.5849625007211563	4	1	0	0
25909	1520	human 15-LO promoter region	[human 15-LO promoter region]	1.5849625007211563	4	1	0	0
25910	1520	proteolytic processing of p105	[proteolytic processing of p105]	1.5849625007211563	4	1	0	0
25911	1520	IFN alpha-stimulated tyrosine phosphorylation	[IFN alpha-stimulated tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
25912	1520	follow gene transfer	[following gene transfer]	1.5849625007211563	3	1	0	0
25913	1520	inhibition of ige production	[inhibition of IgE production]	1.5849625007211563	4	2	1	1
25914	1520	11 kb 5'	[11 kb 5']	1.5849625007211563	3	1	0	0
25915	1520	b-cell lymphoma/leukemia-2 gene product	[B-cell lymphoma/leukemia-2 gene product]	1.5849625007211563	4	1	0	0
25916	1520	secretion of il-6	[secretion of IL-6]	1.5849625007211563	3	1	0	0
25917	1520	response to lipopolysaccharide lps	[response to lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
25918	1520	tcr of calcineurin	[TCR of calcineurin]	1.5849625007211563	3	1	0	0
25919	1520	erythroid progenitor express Gal/ER	[erythroid progenitors expressing Gal/ER]	1.5849625007211563	4	1	0	0
25920	1520	documented clinical significance	[documented) clinical significance]	1.5849625007211563	3	1	0	0
25921	1520	intracellular dioxin receptor	[intracellular dioxin receptor]	1.5849625007211563	3	1	0	0
25922	1520	distinct signal complex	[distinct signaling complexes]	1.5849625007211563	3	1	0	0
25923	1520	STAT3 signal transducer	[STAT3 signal transducer]	1.5849625007211563	3	1	0	0
25924	1520	up-regulation of asm expression	[up-regulation of ASM expression]	1.5849625007211563	4	1	0	0
25925	1520	tata-binding protein tbp	[TATA-binding protein TBP]	1.5849625007211563	3	2	1	1
25926	1520	Jakdstat inhibitory gene socs-1	[JAK/STAT inhibitory gene SOCS-1]	1.5849625007211563	4	1	0	0
25927	1520	IL-2-R alpha gene	[IL-2-R alpha genes]	1.5849625007211563	3	1	0	0
25928	1520	cell response to IL-10	[cell response to IL-10]	1.5849625007211563	4	1	0	0
25929	1520	wild type CEM	[wild type CEM]	1.5849625007211563	3	1	0	0
25930	1520	anti-CD2 T cells.	[anti-CD2 T cells.]	1.5849625007211563	3	1	0	0
25931	1520	follow stable expression	[following stable expression]	1.5849625007211563	3	2	2	2
25932	1520	recombinant nf-kappab protein bind	[recombinant NF-kappaB proteins binding]	1.5849625007211563	4	1	0	0
25933	1520	possibly use rbp	[possibly using RBP]	1.5849625007211563	3	1	0	0
25934	1520	purpose, lncap cell	[purpose, LNCaP cells]	1.5849625007211563	3	1	0	0
25935	1520	SML lymphocyte HL	[SML lymphocytes HL]	1.5849625007211563	3	1	0	0
25936	1520	non-cultured peripheral lymphocyte	[non-cultured peripheral lymphocytes]	1.5849625007211563	3	1	0	0
25937	1520	activation of a element	[activation of an element]	1.5849625007211563	4	2	2	2
25938	1520	essential cis-acting enhancer motif	[essential cis-acting enhancer motif]	1.5849625007211563	4	1	0	0
25939	1520	Conclusions: Intestinal epithelial cell	[CONCLUSIONS: Intestinal epithelial cells]	1.5849625007211563	4	1	0	0
25940	1520	glucocorticoid in human monocyte	[glucocorticoids in human monocytes]	1.5849625007211563	4	1	0	0
25941	1520	POU-dependent conformational change	[POU-dependent conformational change]	1.5849625007211563	3	1	0	0
25942	1520	human monocyte hm	[human monocytes HM]	1.5849625007211563	3	1	0	0
25943	1520	contrast, induction of differentiation	[contrast, induction of differentiation]	1.5849625007211563	4	1	0	0
25944	1520	cytoplasmic NLS receptor complex	[cytoplasmic NLS receptor complex]	1.5849625007211563	4	1	0	0
25945	1520	NF-kappaB -dependent transcriptional activation	[NF-kappaB -dependent transcriptional activation]	1.5849625007211563	4	1	0	0
25946	1520	human dermal fibroblast	[human dermal fibroblasts]	1.5849625007211563	3	1	0	0
25947	1520	dissociation constant of rapamycin	[dissociation constant of rapamycin]	1.5849625007211563	4	1	0	0
25948	1520	contain the s element	[containing the S element]	1.5849625007211563	4	1	0	0
25949	1520	gamma-globin 5-aminolevulinate synthetase transcript	[gamma-globin 5-aminolevulinate synthetase transcripts]	1.5849625007211563	4	1	0	0
25950	1520	most important cytokine	[most important cytokines]	1.5849625007211563	3	1	0	0
25951	1520	formation of staT3-containing complex	[formation of STAT3-containing complexes]	1.5849625007211563	4	1	0	0
25952	1520	Qp -cat reporter	[Qp -CAT reporter]	1.5849625007211563	3	1	0	0
25953	1520	line represent different stage	[lines representing different stages]	1.5849625007211563	4	2	2	2
25954	1520	protein with function	[proteins with functions]	1.5849625007211563	3	1	0	0
25955	1520	represent different stage	[representing different stages]	1.5849625007211563	3	2	2	2
25956	1520	model for the regulation	[model for the regulation]	1.5849625007211563	4	1	0	0
25957	1520	molecular cloning of gene	[molecular cloning of genes]	1.5849625007211563	4	1	0	0
25958	1520	interferon-alpha IFN alpha production	[interferon-alpha IFN alpha production]	1.5849625007211563	4	1	0	0
25959	1520	pretreatment with anti- il-8	[pretreatment with anti- IL-8]	1.5849625007211563	4	1	0	0
25960	1520	signal transduction cascade downstream	[signal transduction cascade downstream]	1.5849625007211563	4	1	0	0
25961	1520	normal cell for lysis	[normal cells for lysis]	1.5849625007211563	4	1	0	0
25962	1520	coexpression of protein	[Coexpression of proteins]	1.5849625007211563	3	1	0	0
25963	1520	present cell apc	[presenting cells APCs]	1.5849625007211563	3	1	0	0
25964	1520	analogous region of HLA-DQB	[analogous regions of HLA-DQB]	1.5849625007211563	4	1	0	0
25965	1520	basis for ATL cell	[basis for ATL cells]	1.5849625007211563	4	1	0	0
25966	1520	Ets consensus sequence	[Ets consensus sequence]	1.5849625007211563	3	1	0	0
25967	1520	5'-most CArG element	[5'-most CArG element]	1.5849625007211563	3	1	0	0
25968	1520	increase ap-1 complex	[increasing AP-1 complexes]	1.5849625007211563	3	1	0	0
25969	1520	interestingly, phase 1	[Interestingly, phase 1]	1.5849625007211563	3	1	0	0
25970	1520	60 minute of anoxia	[60 minutes of anoxia]	1.5849625007211563	4	1	0	0
25971	1520	biological effect of cyclosporine	[biological effect of cyclosporine]	1.5849625007211563	4	1	0	0
25972	1520	protein factor present	[protein factor present]	1.5849625007211563	3	1	0	0
25973	1520	N-terminal SH2 domain	[N-terminal SH2 domain]	1.5849625007211563	3	1	0	0
25974	1520	12.91 fmol/10(6) cell, min,	[12.91 fmol/10(6) cell, min,]	1.5849625007211563	4	1	0	0
25975	1520	cell growth in leukemia	[cell growth in leukemia]	1.5849625007211563	4	2	2	2
25976	1520	-a23187 PMA -pha combination	[-A23187 PMA -PHA combinations]	1.5849625007211563	4	1	0	0
25977	1520	rare -dependent transcription	[RARE -dependent transcription]	1.5849625007211563	3	1	0	0
25978	1520	il-2r jak/stat protein	[IL-2R JAK/STAT proteins]	1.5849625007211563	3	1	0	0
25979	1520	aml1-related transcription factor pebp2	[AML1-related transcription factor PEBP2]	1.5849625007211563	4	1	0	0
25980	1520	kappa b/mad3 a inhibitor	[kappa B/MAD3 an inhibitor]	1.5849625007211563	4	1	0	0
25981	1520	227.0 90.8 dpm mg-1	[227.0 90.8 dpm mg-1]	1.5849625007211563	4	1	0	0
25982	1520	adapter molecule myd88	[adapter molecule MyD88]	1.5849625007211563	3	1	0	0
25983	1520	hla class ii expression	[HLA class II expression]	1.5849625007211563	4	2	1	1
25984	1520	influence of vitamin d	[influence of vitamin D]	1.5849625007211563	4	1	0	0
25985	1520	patient with advanced RCC	[patients with advanced RCC]	1.5849625007211563	4	1	0	0
25986	1520	J393/ cd43 apoptosis	[J393/ CD43 apoptosis]	1.5849625007211563	3	1	0	0
25987	1520	few T cell	[fewer T cells]	1.5849625007211563	3	1	0	0
25988	1520	human normal b cell	[human normal B cells]	1.5849625007211563	4	1	0	0
25989	1520	blk promoter transcription	[blk promoter transcription]	1.5849625007211563	3	1	0	0
25990	1520	term cord blood	[term cord bloods]	1.5849625007211563	3	1	0	0
25991	1520	cytosolic nf-kappa b inhibitor	[cytosolic NF-kappa B inhibitors]	1.5849625007211563	4	1	0	0
25992	1520	b-cell-specific b29 gene b29	[B-cell-specific B29 gene B29]	1.5849625007211563	4	1	0	0
25993	1520	(on average by 5.8%)	[(on average by 5.8%)]	1.5849625007211563	4	1	0	0
25994	1520	c-Jun protein level	[c-Jun protein levels]	1.5849625007211563	3	1	0	0
25995	1520	region base pair (bp))	[region base pairs (bp))]	1.5849625007211563	4	1	0	0
25996	1520	47-kd mature glycoprotein	[47-kD mature glycoprotein]	1.5849625007211563	3	1	0	0
25997	1520	peripheral blood stem cell	[peripheral blood stem cells]	1.5849625007211563	4	2	2	2
25998	1520	range of G(S)alpha expression	[range of G(S)alpha expression]	1.5849625007211563	4	1	0	0
25999	1520	N9 microglial cell line	[N9 microglial cell line]	1.5849625007211563	4	1	0	0
26000	1520	dnase footprinting analysis	[DNase footprinting analysis]	1.5849625007211563	3	1	0	0
26001	1520	effect of the inv(16)(p13;q22)	[effect of the inv(16)(p13;q22)]	1.5849625007211563	4	1	0	0
26002	1520	overexpression of cjun	[Overexpression of cJun]	1.5849625007211563	3	1	0	0
26003	1520	ability of hiv-1 replication	[ability of HIV-1 replication]	1.5849625007211563	4	1	0	0
26004	1520	HMG-I(Y) binding site	[HMG-I(Y) binding site]	1.5849625007211563	3	1	0	0
26005	1520	subsequent 24 month	[subsequent 24 months]	1.5849625007211563	3	1	0	0
26006	1520	(11 aml m4eo	[(11 AML M4Eo]	1.5849625007211563	3	1	0	0
26007	1520	approximately 11 kb	[approximately 11 kb]	1.5849625007211563	3	1	0	0
26008	1520	additional hhv-6 orf	[additional HHV-6 ORFs]	1.5849625007211563	3	1	0	0
26009	1520	p3hr-1-infected Burkitt' lymphoma cell	[P3HR-1-infected Burkitt's lymphoma cells]	1.5849625007211563	4	1	0	0
26010	1520	effect of hiv-1 infection	[effect of HIV-1 infection]	1.5849625007211563	4	1	0	0
26011	1520	novel heterodimerization partner	[novel heterodimerization partner]	1.5849625007211563	3	1	0	0
26012	1520	emergence of leukemic clone	[emergence of leukemic clones]	1.5849625007211563	4	1	0	0
26013	1520	type of phenotypic differentiation	[type of phenotypic differentiation]	1.5849625007211563	4	1	0	0
26014	1520	4.8%) pregerminal center	[4.8%) pregerminal center]	1.5849625007211563	3	1	0	0
26015	1520	defect in Jak3	[defects in Jak3]	1.5849625007211563	3	1	0	0
26016	1520	P1 a element	[P1 an element]	1.5849625007211563	3	1	0	0
26017	1520	taci -specific antibody	[TACI -specific antibodies]	1.5849625007211563	3	1	0	0
26018	1520	transcription factor E2F	[transcription factor E2F]	1.5849625007211563	3	1	0	0
26019	1520	platelet activate factor	[platelet activating factor]	1.5849625007211563	3	2	2	2
26020	1520	relation to the result	[relation to the results]	1.5849625007211563	4	1	0	0
26021	1520	t-cell stimulation defect	[T-cell stimulation defects]	1.5849625007211563	3	1	0	0
26022	1520	ubiquitously express nuclear protein	[ubiquitously expressed, nuclear protein]	1.5849625007211563	4	1	0	0
26023	1520	NF kappa b -binding	[NF kappa B -binding]	1.5849625007211563	4	1	0	0
26024	1520	antioxidant on nf-kappab activation	[antioxidants on NF-kappaB activation]	1.5849625007211563	4	1	0	0
26025	1520	human coronary atherosclerotic plaque	[human coronary atherosclerotic plaques]	1.5849625007211563	4	1	0	0
26026	1520	cell express osteoclast marker	[cells expressing osteoclast markers]	1.5849625007211563	4	1	0	0
26027	1520	biochemical sign of hypothyroidism	[biochemical signs of hypothyroidism]	1.5849625007211563	4	2	2	2
26028	1520	NF-kappa b /rel protein	[NF-kappa B /Rel protein]	1.5849625007211563	4	1	0	0
26029	1520	receptor on lymphocyte	[receptors on lymphocytes]	1.5849625007211563	3	2	2	2
26030	1520	less extent, c-jun complex	[lesser extent, c-Jun complexes]	1.5849625007211563	4	1	0	0
26031	1520	approximately 320-kda species	[approximately 320-kDa species]	1.5849625007211563	3	1	0	0
26032	1520	igm+ igd+ cl-01 cell	[IgM+ IgD+ CL-01 cells]	1.5849625007211563	4	1	0	0
26033	1520	rap1 protein in platelet	[Rap1 protein in platelets]	1.5849625007211563	4	1	0	0
26034	1520	4.5 kb transcript	[4.5 kb transcript]	1.5849625007211563	3	1	0	0
26035	1520	sucrose density gradient analysis	[sucrose density gradient analysis]	1.5849625007211563	4	1	0	0
26036	1520	dnase i hypersensitive site	[DNase I hypersensitive site]	1.5849625007211563	4	1	0	0
26037	1520	pathogenicity of hiv-2	[pathogenicity of HIV-2]	1.5849625007211563	3	1	0	0
26038	1520	retinoic acid receptor-alpha	[retinoic acid receptor-alpha]	1.5849625007211563	3	1	0	0
26039	1520	similar downstream signalling,	[similar downstream signalling,]	1.5849625007211563	3	1	0	0
26040	1520	Ile761 to Leu	[Ile761 to Leu]	1.5849625007211563	3	1	0	0
26041	1520	b cell in	[B cells in]	1.5849625007211563	3	1	0	0
26042	1520	for cloning labile rrna	[for cloning labile mRNAs]	1.5849625007211563	4	1	0	0
26043	1520	inhibition of factor	[inhibition of factor]	1.5849625007211563	3	2	2	2
26044	1520	immediate-early brlf1 protein	[immediate-early BRLF1 protein]	1.5849625007211563	3	1	0	0
26045	1520	basis detect cytokine	[basis detecting cytokine]	1.5849625007211563	3	1	0	0
26046	1520	CONCLUSION: IL-5 synthesis	[CONCLUSION: IL-5 synthesis]	1.5849625007211563	3	1	0	0
26047	1520	htlv-i-transformed T cell	[HTLV-I-transformed T cells]	1.5849625007211563	3	1	0	0
26048	1520	embryonic skeletal muscle	[embryonic skeletal muscle]	1.5849625007211563	3	1	0	0
26049	1520	ebv-mediated B-cell immortalization	[EBV-mediated B-cell immortalization]	1.5849625007211563	3	1	0	0
26050	1520	type 1 interferon IFN	[type 1 interferon IFN]	1.5849625007211563	4	1	0	0
26051	1520	Bcl-6 gene rearrangement	[Bcl-6 gene rearrangement]	1.5849625007211563	3	1	0	0
26052	1520	retinoic acid 9cisra	[retinoic acid 9cisRA]	1.5849625007211563	3	1	0	0
26053	1520	erythroid-specific reporter expression	[erythroid-specific reporter expression]	1.5849625007211563	3	1	0	0
26054	1520	stat-related transcription factor	[STAT-related transcription factors]	1.5849625007211563	3	1	0	0
26055	1520	high turnover rate,	[high turnover rate,]	1.5849625007211563	3	1	0	0
26056	1520	ifn-alpha/beta-induced transcription complex isgf3	[IFN-alpha/beta-induced transcription complex ISGF3]	1.5849625007211563	4	1	0	0
26057	1520	rrna for immediate-early gene	[mRNAs for immediate-early genes]	1.5849625007211563	4	1	0	0
26058	1520	glucocorticoid recognition sequence	[glucocorticoid recognition sequences]	1.5849625007211563	3	1	0	0
26059	1520	rapamycin -resistant p70(s6k)	[rapamycin -resistant p70(s6k)]	1.5849625007211563	3	1	0	0
26060	1520	-132/+170)-reporter gene construct	[-132/+170)-reporter gene constructs]	1.5849625007211563	3	1	0	0
26061	1520	human growth hormone hgh	[human growth hormone hGH]	1.5849625007211563	4	1	0	0
26062	1520	structure of IL-12	[structure of IL-12]	1.5849625007211563	3	1	0	0
26063	1520	surround the globin gene	[surrounding the globin genes]	1.5849625007211563	4	1	0	0
26064	1520	mapping by complementation analysis	[mapping by complementation analysis]	1.5849625007211563	4	1	0	0
26065	1520	corticosteroid -resistant bronchial asthma	[corticosteroid -resistant bronchial asthma]	1.5849625007211563	4	1	0	0
26066	1520	treatment with corticosteroid	[treatment with corticosteroids]	1.5849625007211563	3	1	0	0
26067	1520	single viral gene ORF	[single viral gene ORF]	1.5849625007211563	4	1	0	0
26068	1520	C T base exchange	[C T base exchange]	1.5849625007211563	4	1	0	0
26069	1520	moreover, EGF treatment	[Moreover, EGF treatment]	1.5849625007211563	3	1	0	0
26070	1520	variety of pharmacological effect	[variety of pharmacological effects]	1.5849625007211563	4	1	0	0
26071	1520	promoter for the combination	[promoter for the combinations]	1.5849625007211563	4	1	0	0
26072	1520	VDR of reactivity	[VDR of reactivity]	1.5849625007211563	3	1	0	0
26073	1520	coinducer of nf-at activation	[coinducer of NF-AT activation]	1.5849625007211563	4	1	0	0
26074	1520	active sle (0.9356	[active SLE (0.9356]	1.5849625007211563	3	1	0	0
26075	1520	sensitivity of this assay	[sensitivity of this assay]	1.5849625007211563	4	1	0	0
26076	1520	series of deletion mutant	[series of deletion mutants]	1.5849625007211563	4	1	0	0
26077	1520	monocyte versus T cell	[monocytes versus T cells]	1.5849625007211563	4	1	0	0
26078	1520	several round of subcloning	[several round of subcloning]	1.5849625007211563	4	1	0	0
26079	1520	regard to the mechanism	[regard to the mechanisms]	1.5849625007211563	4	1	0	0
26080	1520	increase in transcription rate	[increase in transcription rate]	1.5849625007211563	4	1	0	0
26081	1520	mechanism underlie beneficial effect	[mechanisms underlying beneficial effects]	1.5849625007211563	4	1	0	0
26082	1520	large, immature cell	[large, immature cells]	1.5849625007211563	3	1	0	0
26083	1520	human erythroid alas mrna	[human erythroid ALAS mRNA]	1.5849625007211563	4	1	0	0
26084	1520	tumor cell in cases.	[tumor cells in cases.]	1.5849625007211563	4	1	0	0
26085	1520	split (ars) protein	[split (AES) protein]	1.5849625007211563	3	1	0	0
26086	1520	b cell line studied,	[B cell lines studied,]	1.5849625007211563	4	1	0	0
26087	1520	lymphoid cell differentiation	[Lymphoid cell differentiation]	1.5849625007211563	3	1	0	0
26088	1520	various markers, include p53	[various markers, including p53]	1.5849625007211563	4	1	0	0
26089	1520	nuclear factor include nfat	[nuclear factors including NFAT]	1.5849625007211563	4	1	0	0
26090	1520	g0 to g1 transition	[G0 to G1 transition]	1.5849625007211563	4	1	0	0
26091	1520	similar concentration of 125d3	[similar concentrations of 1,25D3]	1.5849625007211563	4	1	0	0
26092	1520	transactivation in vitro,	[transactivation in vitro,]	1.5849625007211563	3	1	0	0
26093	1520	interferon-alpha /beta-induced tyrosine phosphorylation	[interferon-alpha /beta-induced tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
26094	1520	nf-kappa benefit activation	[NF-kappa b activation]	1.5849625007211563	3	1	0	0
26095	1520	gene encode LBR	[gene encoding LBR]	1.5849625007211563	3	2	2	2
26096	1520	lymphoid cell express e2a-hlf	[lymphoid cells expressing E2A-HLF]	1.5849625007211563	4	1	0	0
26097	1520	"normal" lymphokine of cytokine	["normal" lymphokines of cytokines]	1.5849625007211563	4	1	0	0
26098	1520	transcription initiation site TIS	[transcription initiation site TIS]	1.5849625007211563	4	1	0	0
26099	1520	ability of exogenous 135eoh)2d3	[ability of exogenous 1,25(OH)2D3]	1.5849625007211563	4	1	0	0
26100	1520	identification of regulatory protein	[identification of regulatory proteins]	1.5849625007211563	4	1	0	0
26101	1520	GR within the nucleus	[GR within the nucleus]	1.5849625007211563	4	1	0	0
26102	1520	succinimide intermediate of peptide	[succinimide intermediates of peptides]	1.5849625007211563	4	1	0	0
26103	1520	normal receptor status	[normal receptor status]	1.5849625007211563	3	1	0	0
26104	1520	exhibit the t(14;14) translocation	[exhibiting the t(14;14) translocation]	1.5849625007211563	4	1	0	0
26105	1520	human gm-csf element	[human GM-CSF element]	1.5849625007211563	3	1	0	0
26106	1520	nonphlogistic degradation of neutrophil	[nonphlogistic degradation of neutrophils]	1.5849625007211563	4	1	0	0
26107	1520	event in atherogenesis	[event in atherogenesis]	1.5849625007211563	3	2	2	2
26108	1520	number of GCR	[number of GCR]	1.5849625007211563	3	2	1	1
26109	1520	TNFRp55 -deficient mouse	[TNFRp55 -deficient mice]	1.5849625007211563	3	1	0	0
26110	1520	aminothiol compound with antioxidant	[aminothiol compound with antioxidant]	1.5849625007211563	4	1	0	0
26111	1520	viral inducer il-1 beta	[viral inducer IL-1 beta]	1.5849625007211563	4	1	0	0
26112	1520	Ramos b cell	[Ramos B cells]	1.5849625007211563	3	2	2	2
26113	1520	effect of early replication	[effect of early replication]	1.5849625007211563	4	1	0	0
26114	1520	5.13 fmol/10(6) cell	[5.13 fmol/10(6) cells]	1.5849625007211563	3	1	0	0
26115	1520	CD3 tcr signal transduction	[CD3 TCR signal transduction]	1.5849625007211563	4	1	0	0
26116	1520	significant defect in transport	[significant defect in transport]	1.5849625007211563	4	1	0	0
26117	1520	healthy control kd:2.92	[healthy controls Kd:2.92]	1.5849625007211563	3	1	0	0
26118	1520	htlv-1 tax trans-activator	[HTLV-1 Tax trans-activator]	1.5849625007211563	3	1	0	0
26119	1520	lighting regimen (12d:12l; light	[lighting regimen (12D:12L; lights]	1.5849625007211563	4	1	0	0
26120	1520	level of rxr-alpha respectively.	[levels of RXR-alpha respectively.]	1.5849625007211563	4	1	0	0
26121	1520	expression of id2 mrna	[expression of Id2 mRNA]	1.5849625007211563	4	3	2	1
26122	1520	subsequent tnf-alpha release	[subsequent TNF-alpha release]	1.5849625007211563	3	1	0	0
26123	1520	18 healthy subject	[18 healthy subjects]	1.5849625007211563	3	1	0	0
26124	1520	various chain of receptor	[various chains of receptor]	1.5849625007211563	4	1	0	0
26125	1520	similar molecular weight	[similar molecular weights]	1.5849625007211563	3	1	0	0
26126	1520	human CD5 antigen	[human CD5 antigen]	1.5849625007211563	3	1	0	0
26127	1520	Ikaros regulatory element	[Ikaros regulatory elements]	1.5849625007211563	3	1	0	0
26128	1520	L. pneumophila RpoS	[L. pneumophila RpoS]	1.5849625007211563	3	1	0	0
26129	1520	patient with hodgkin' disease	[patients with Hodgkin's disease]	1.5849625007211563	4	1	0	0
26130	1520	erythroid to differentiation pathway	[erythroid to differentiation pathway]	1.5849625007211563	4	1	0	0
26131	1520	RB -defective tumor line	[RB -defective tumor lines]	1.5849625007211563	4	1	0	0
26132	1520	E1a- replication-deficient vector replicate	[E1a- replication-deficient vector replicating]	1.5849625007211563	4	1	0	0
26133	1520	cd4+ memory T cell	[CD4+ memory T cells]	1.5849625007211563	4	2	2	2
26134	1520	contain different nfat-family protein	[containing different NFAT-family proteins]	1.5849625007211563	4	1	0	0
26135	1520	half of the molecule	[half of the molecule]	1.5849625007211563	4	1	0	0
26136	1520	eosinophil granule protein EPO	[eosinophil granule proteins EPO]	1.5849625007211563	4	1	0	0
26137	1520	extracellular matrix gene	[extracellular matrix genes]	1.5849625007211563	3	1	0	0
26138	1520	peptide sequence of ORF2	[peptide sequence of ORF2]	1.5849625007211563	4	1	0	0
26139	1520	putative transcriptional activation domain	[putative transcriptional activation domain]	1.5849625007211563	4	1	0	0
26140	1520	maintenance of viral persistence	[maintenance of viral persistence]	1.5849625007211563	4	1	0	0
26141	1520	antigen-driven t-cell activation	[antigen-driven T-cell activation]	1.5849625007211563	3	1	0	0
26142	1520	major transactivation sequence	[major transactivation sequence]	1.5849625007211563	3	1	0	0
26143	1520	patient with lymphoproliferative disorder	[patients with lymphoproliferative disorders]	1.5849625007211563	4	1	0	0
26144	1520	lead to transmigration	[leading to transmigration]	1.5849625007211563	3	1	0	0
26145	1520	target of hhv-6 transactivation	[target of HHV-6 transactivation]	1.5849625007211563	4	1	0	0
26146	1520	T lineage-specific expression	[T lineage-specific expression]	1.5849625007211563	3	1	0	0
26147	1520	nf-kappa b /rel	[NF-kappa B /Rel]	1.5849625007211563	3	2	1	1
26148	1520	gene expression, hemin induction	[gene expression, hemin induction]	1.5849625007211563	4	1	0	0
26149	1520	frequent polyomavirus reactivation	[frequent polyomavirus reactivations]	1.5849625007211563	3	1	0	0
26150	1520	human bcl-2 gene	[human BCL-2 gene]	1.5849625007211563	3	1	0	0
26151	1520	cytostasis in the presence	[cytostasis in the presence]	1.5849625007211563	4	1	0	0
26152	1520	HIV glycoprotein 120	[HIV glycoprotein 120]	1.5849625007211563	3	1	0	0
26153	1520	death domain protein	[death domain protein]	1.5849625007211563	3	2	1	1
26154	1520	v-Abl kinase inactivation	[v-Abl kinase inactivation]	1.5849625007211563	3	1	0	0
26155	1520	megakaryocytic glycoprotein ix promoter	[megakaryocytic glycoprotein IX promoter]	1.5849625007211563	4	1	0	0
26156	1520	T cell undergo activation	[T cells undergoing activation]	1.5849625007211563	4	1	0	0
26157	1520	cancer lncap cell	[cancer LNCaP cells]	1.5849625007211563	3	2	2	2
26158	1520	signal by htoll	[Signaling by hToll]	1.5849625007211563	3	1	0	0
26159	1520	human interleukin-1beta gene	[human interleukin-1beta gene]	1.5849625007211563	3	1	0	0
26160	1520	jagged1 gene expression	[jagged1 gene expression]	1.5849625007211563	3	2	1	1
26161	1520	T cell activator	[T cell activators]	1.5849625007211563	3	1	0	0
26162	1520	initiation of this growth	[initiation of this growth]	1.5849625007211563	4	1	0	0
26163	1520	concentration of microg/10(6) cells.	[concentration of microg/10(6) cells.]	1.5849625007211563	4	1	0	0
26164	1520	alpha thf/thf ratio	[alpha THF/THF ratios]	1.5849625007211563	3	1	0	0
26165	1520	study on death	[studies on death]	1.5849625007211563	3	1	0	0
26166	1520	ec50 value of 1.8	[EC50 values of 1.8]	1.5849625007211563	4	1	0	0
26167	1520	binding of HRF	[binding of HRF]	1.5849625007211563	3	1	0	0
26168	1520	DR alpha gene	[DR alpha gene]	1.5849625007211563	3	2	1	1
26169	1520	mouse pro-B lymphocyte	[mouse pro-B lymphocytes]	1.5849625007211563	3	1	0	0
26170	1520	only after PMA treatment	[only after PMA treatment]	1.5849625007211563	4	1	0	0
26171	1520	broad mantle zone;	[broad mantle zone;]	1.5849625007211563	3	1	0	0
26172	1520	eosinophil-derived neurotoxin edn	[eosinophil-derived neurotoxin EDN]	1.5849625007211563	3	1	0	0
26173	1520	Jak3 in HTLV-1	[Jak3 in HTLV-1]	1.5849625007211563	3	1	0	0
26174	1520	co-treatment of IL-4 induced,	[Co-treatment of IL-4 induced,]	1.5849625007211563	4	1	0	0
26175	1520	mode of signaling.	[mode of signaling.]	1.5849625007211563	3	1	0	0
26176	1520	il-4 expression in	[IL-4 expression in]	1.5849625007211563	3	1	0	0
26177	1520	syk kinases-interact protein 3bp2	[Syk kinases-interacting protein 3BP2]	1.5849625007211563	4	1	0	0
26178	1520	basal level gr expression	[basal level GR expression]	1.5849625007211563	4	2	1	1
26179	1520	NFAT docking site peptide	[NFAT docking site peptide]	1.5849625007211563	4	1	0	0
26180	1520	presence of ebs1	[presence of EBS1]	1.5849625007211563	3	1	0	0
26181	1520	sera of individual	[sera of individuals]	1.5849625007211563	3	1	0	0
26182	1520	subject with ptsd	[subjects with PTSD]	1.5849625007211563	3	1	0	0
26183	1520	mature red blood cell	[mature red blood cells]	1.5849625007211563	4	1	0	0
26184	1520	p38 protein kinase	[p38 protein kinase]	1.5849625007211563	3	2	2	2
26185	1520	lymphocyte in vitro level	[lymphocytes in vitro levels]	1.5849625007211563	4	1	0	0
26186	1520	human vacuolar h(+)-atpase v-atpase	[human vacuolar H(+)-ATPase V-ATPase]	1.5849625007211563	4	1	0	0
26187	1520	human peripheral blood precursor	[human peripheral blood precursors]	1.5849625007211563	4	1	0	0
26188	1520	X2 box 5'-tgcgtca-3'	[X2 box 5'-TGCGTCA-3']	1.5849625007211563	3	1	0	0
26189	1520	medication, include corticosteroid	[medication, including corticosteroids]	1.5849625007211563	3	1	0	0
26190	1520	instead of T cell	[instead of T cells]	1.5849625007211563	4	1	0	0
26191	1520	binding to region	[binding to regions]	1.5849625007211563	3	2	2	2
26192	1520	NIP repressor site	[NIP repressor site]	1.5849625007211563	3	1	0	0
26193	1520	course of this response	[course of this response]	1.5849625007211563	4	1	0	0
26194	1520	use a tre1 probe	[using a TRE1 probe]	1.5849625007211563	4	1	0	0
26195	1520	furthermore, P- lps expression	[Furthermore, P- LPS expression]	1.5849625007211563	4	1	0	0
26196	1520	proil-1beta gene in cell	[proIL-1beta gene in cells]	1.5849625007211563	4	1	0	0
26197	1520	tcr delta gene segment	[TCR delta gene segments]	1.5849625007211563	4	1	0	0
26198	1520	von willebrand factor vWF	[von Willebrand factor vWF]	1.5849625007211563	4	1	0	0
26199	1520	combination with ifn-gamma	[combination with IFN-gamma]	1.5849625007211563	3	1	0	0
26200	1520	target of phosphatase activity	[target of phosphatase activity]	1.5849625007211563	4	1	0	0
26201	1520	phosphorylation of stat1 alpha	[phosphorylation of Stat1 alpha]	1.5849625007211563	4	1	0	0
26202	1520	von willebrand factor vWf	[von Willebrand factor vWf]	1.5849625007211563	4	1	0	0
26203	1520	erythroid-specific transcription factor NF-E1	[erythroid-specific transcription factor NF-E1]	1.5849625007211563	4	1	0	0
26204	1520	repression of il-12 signal	[repression of IL-12 signaling]	1.5849625007211563	4	1	0	0
26205	1520	translocation of PKC	[translocation of PKC]	1.5849625007211563	3	1	0	0
26206	1520	stat1 c-terminal residue	[Stat1 C-terminal residues]	1.5849625007211563	3	1	0	0
26207	1520	CD30 Hodgkin' disease marker	[CD30 Hodgkin's disease marker]	1.5849625007211563	4	1	0	0
26208	1520	diversity of tcr repertoire	[diversity of TCR repertoire]	1.5849625007211563	4	1	0	0
26209	1520	therapeutic approach for disease	[therapeutic approach for disease]	1.5849625007211563	4	1	0	0
26210	1520	transcription of the c-jun	[transcription of the c-jun]	1.5849625007211563	4	1	0	0
26211	1520	finding of tax mutant	[finding of Tax mutants]	1.5849625007211563	4	1	0	0
26212	1520	p50 subunit factor-kappa b	[p50 subunit factor-kappa B]	1.5849625007211563	4	1	0	0
26213	1520	highly tissue specific,	[highly tissue specific,]	1.5849625007211563	3	1	0	0
26214	1520	lack of sequence homology,	[lack of sequence homology,]	1.5849625007211563	4	1	0	0
26215	1520	beta protein production	[beta protein production]	1.5849625007211563	3	1	0	0
26216	1520	monocyte to endothelial cell	[monocytes to endothelial cells]	1.5849625007211563	4	1	0	0
26217	1520	various hormone condition	[various hormone conditions]	1.5849625007211563	3	1	0	0
26218	1520	tcr gamma loci	[TCR gamma loci]	1.5849625007211563	3	1	0	0
26219	1520	c-fo sre binding complex	[c-fos SRE binding complexes]	1.5849625007211563	4	1	0	0
26220	1520	Protein kinase C PKC	[Protein kinase C PKC]	1.5849625007211563	4	1	0	0
26221	1520	promotion of ikappabalpha degradation	[promotion of IkappaBalpha degradation]	1.5849625007211563	4	1	0	0
26222	1520	nfatp DNA binding activity	[NFATp DNA binding activity]	1.5849625007211563	4	1	0	0
26223	1520	early gene product EA-R	[early gene products EA-R]	1.5849625007211563	4	1	0	0
26224	1520	host immunologic destruction	[host immunologic destruction]	1.5849625007211563	3	1	0	0
26225	1520	lps -mcd14 binding	[LPS -mCD14 binding]	1.5849625007211563	3	2	1	1
26226	1520	NFkappaB /ikappab system	[NFkappaB /IkappaB system]	1.5849625007211563	3	1	0	0
26227	1520	retention of rel/nf-kappab protein	[retention of Rel/NF-kappaB proteins]	1.5849625007211563	4	1	0	0
26228	1520	NFAT- p0 complex formation	[NFAT- P0 complex formation]	1.5849625007211563	4	1	0	0
26229	1520	wild-type id3 protein	[wild-type Id3 protein]	1.5849625007211563	3	1	0	0
26230	1520	directly phosphorylate nfatp	[directly phosphorylating NFATp]	1.5849625007211563	3	1	0	0
26231	1520	cell-specific regulation of transcription	[cell-specific regulation of transcription]	1.5849625007211563	4	1	0	0
26232	1520	ability of il-7r	[ability of IL-7R]	1.5849625007211563	3	1	0	0
26233	1520	dna-binding site for LEF-1	[DNA-binding sites for LEF-1]	1.5849625007211563	4	1	0	0
26234	1520	proximal polyA site	[proximal polyA site]	1.5849625007211563	3	2	2	2
26235	1520	ability of PtdIns 3-kinase	[ability of PtdIns 3-kinase]	1.5849625007211563	4	1	0	0
26236	1520	PU.1 spi-1 a member	[PU.1 spi-1 a member]	1.5849625007211563	4	1	0	0
26237	1520	tnf alpha mrna level	[TNF alpha mRNA levels]	1.5849625007211563	4	1	0	0
26238	1520	defect in the reactivity	[defects in the reactivity]	1.5849625007211563	4	1	0	0
26239	1520	B-lymphoblastoid cell line B-LCL	[B-lymphoblastoid cell line B-LCL]	1.5849625007211563	4	1	0	0
26240	1520	hormone on the level	[hormone on the levels]	1.5849625007211563	4	1	0	0
26241	1520	pc-3 145 prostate cancer	[PC-3 145 prostate cancers]	1.5849625007211563	4	1	0	0
26242	1520	peripheral murine monocyte	[peripheral murine monocytes]	1.5849625007211563	3	1	0	0
26243	1520	Jurkat leukemic t-cell line	[Jurkat leukemic T-cell line]	1.5849625007211563	4	1	0	0
26244	1520	dimerization domain of protein	[dimerization domains of proteins]	1.5849625007211563	4	1	0	0
26245	1520	pancreatic endocrine beta-cell	[pancreatic endocrine beta-cells]	1.5849625007211563	3	1	0	0
26246	1520	b cell-specific transcriptional activity	[B cell-specific transcriptional activity]	1.5849625007211563	4	1	0	0
26247	1520	transcription start site 465	[transcription start site 465]	1.5849625007211563	4	1	0	0
26248	1520	single hmg motif	[single HMG motif]	1.5849625007211563	3	1	0	0
26249	1520	pituitary endocrine cell	[pituitary endocrine cells]	1.5849625007211563	3	1	0	0
26250	1520	pdtc -insensitive pathway	[PDTC -insensitive pathways]	1.5849625007211563	3	1	0	0
26251	1520	identical dna-binding specificity	[identical DNA-binding specificities]	1.5849625007211563	3	1	0	0
26252	1520	other inducible gene	[other inducible genes]	1.5849625007211563	3	1	0	0
26253	1520	ability of il-10	[ability of IL-10]	1.5849625007211563	3	1	0	0
26254	1520	exposure to mtbe	[exposure to MTBE]	1.5849625007211563	3	1	0	0
26255	1520	human mcm6 promoter	[human MCM6 promoter]	1.5849625007211563	3	1	0	0
26256	1520	immunoglobulin promoter activity	[immunoglobulin promoter activity]	1.5849625007211563	3	1	0	0
26257	1520	most hematopoietic lineage	[most hematopoietic lineages]	1.5849625007211563	3	1	0	0
26258	1520	as, h after lps	[as, h after, LPS]	1.5849625007211563	4	1	0	0
26259	1520	combination of this processes.	[combination of these processes.]	1.5849625007211563	4	1	0	0
26260	1520	Stat3 in pbl	[Stat3 in PBL]	1.5849625007211563	3	1	0	0
26261	1520	series of sequence element	[series of sequence elements]	1.5849625007211563	4	1	0	0
26262	1520	213 amino acid	[213 amino acids]	1.5849625007211563	3	1	0	0
26263	1520	(57.3 +/- 11.0%).	[(57.3 +/- 11.0%).]	1.5849625007211563	3	1	0	0
26264	1520	other kappa b protein	[Other kappa B proteins]	1.5849625007211563	4	1	0	0
26265	1520	five point mutation	[five point mutations]	1.5849625007211563	3	1	0	0
26266	1520	mouse gata3 gene	[mouse GATA3 gene]	1.5849625007211563	3	1	0	0
26267	1520	transcription initiation complex assembly	[transcription initiation complex assembly]	1.5849625007211563	4	1	0	0
26268	1520	human genomic library	[human genomic library]	1.5849625007211563	3	1	0	0
26269	1520	variant of immunodeficiency virus	[variant of immunodeficiency virus]	1.5849625007211563	4	1	0	0
26270	1520	vitro protein-DNA binding study	[vitro protein-DNA binding studies]	1.5849625007211563	4	1	0	0
26271	1520	vascular-specific gene expression	[vascular-specific gene expression]	1.5849625007211563	3	1	0	0
26272	1520	ventilatory response from linearity	[ventilatory response from linearity]	1.5849625007211563	4	1	0	0
26273	1520	other screen method	[other screening methods]	1.5849625007211563	3	1	0	0
26274	1520	unique transcriptional mechanism distinct	[unique transcriptional mechanism distinct]	1.5849625007211563	4	1	0	0
26275	1520	resolution of immune response	[resolution of immune responses]	1.5849625007211563	4	1	0	0
26276	1520	IL-1 beta mrna appearance	[IL-1 beta mRNA appearance]	1.5849625007211563	4	1	0	0
26277	1520	type of cell line	[types of cell lines]	1.5849625007211563	4	2	2	2
26278	1520	patient relative to controls.	[patient relative to controls.]	1.5849625007211563	4	1	0	0
26279	1520	stromal-derived cytokine interleukin-7 il-7	[stromal-derived cytokine interleukin-7 IL-7]	1.5849625007211563	4	1	0	0
26280	1520	expression of several cytoskeleton	[expression of several cytoskeleton]	1.5849625007211563	4	1	0	0
26281	1520	Diamide thiol/disulfide imbalance	[Diamide thiol/disulfide imbalance]	1.5849625007211563	3	1	0	0
26282	1520	activation of ikk2	[activation of IKK2]	1.5849625007211563	3	1	0	0
26283	1520	prominent member of family	[prominent members of family]	1.5849625007211563	4	1	0	0
26284	1520	results: in all cell	[RESULTS: In all cells]	1.5849625007211563	4	1	0	0
26285	1520	high level of bcl-2	[high level of bcl-2]	1.5849625007211563	4	2	1	1
26286	1520	neutrophil-specific gene expression	[neutrophil-specific gene expression]	1.5849625007211563	3	1	0	0
26287	1520	interassay coefficient of variation	[interassay coefficient of variation]	1.5849625007211563	4	1	0	0
26288	1520	rescue from apoptosis	[rescue from apoptosis]	1.5849625007211563	3	1	0	0
26289	1520	consecutive healthy control	[consecutive healthy controls]	1.5849625007211563	3	1	0	0
26290	1520	mitotic arrest assay	[mitotic arrest assay]	1.5849625007211563	3	1	0	0
26291	1520	rapidity of NK lysis	[rapidity of NK lysis]	1.5849625007211563	4	1	0	0
26292	1520	definitive erythroid cell	[definitive erythroid cells]	1.5849625007211563	3	2	2	2
26293	1520	addition, integrin ligation	[addition, integrin ligation]	1.5849625007211563	3	1	0	0
26294	1520	stress-induced vimentin increase	[stress-induced vimentin increase]	1.5849625007211563	3	1	0	0
26295	1520	context of this studies.	[context of these studies.]	1.5849625007211563	4	1	0	0
26296	1520	heterologous reporter gene	[heterologous reporter gene]	1.5849625007211563	3	2	1	1
26297	1520	undetected viral gene product	[undetected viral gene products]	1.5849625007211563	4	1	0	0
26298	1520	form of 135(oh)2d3	[form of 1,25(OH)2D3]	1.5849625007211563	3	1	0	0
26299	1520	[Jalaguier, Mesnier, Leger	[[Jalaguier, Mesnier, Leger]	1.5849625007211563	3	1	0	0
26300	1520	progesterone antagonist RU 486	[progesterone antagonist RU 486]	1.5849625007211563	4	1	0	0
26301	1520	nonrandom in T	[nonrandom in T]	1.5849625007211563	3	1	0	0
26302	1520	very diverse function	[very diverse functions]	1.5849625007211563	3	1	0	0
26303	1520	molecular event lead	[molecular events leading]	1.5849625007211563	3	2	2	2
26304	1520	end-labelled reverse primer adjacent	[end-labelled reverse primer adjacent]	1.5849625007211563	4	1	0	0
26305	1520	trep -contain DNA fragment	[TREp -containing DNA fragment]	1.5849625007211563	4	1	0	0
26306	1520	B cell differentiation	[B cell differentiation]	1.5849625007211563	3	1	0	0
26307	1520	mutant es cell	[mutant ES cells]	1.5849625007211563	3	1	0	0
26308	1520	T cell-dependent pathway	[T cell-dependent pathway]	1.5849625007211563	3	1	0	0
26309	1520	fraction of t-lymphoid cell	[fraction of T-lymphoid cells]	1.5849625007211563	4	1	0	0
26310	1520	University of Toronto,	[University of Toronto,]	1.5849625007211563	3	1	0	0
26311	1520	regulatory p sequence 5'-cgaaaatttcc-3'	[regulatory P sequence 5'-CGAAAATTTCC-3']	1.5849625007211563	4	1	0	0
26312	1520	treat Jurkat T cell	[treating Jurkat T cells]	1.5849625007211563	4	1	0	0
26313	1520	production of adrenal androgen	[production of adrenal androgens]	1.5849625007211563	4	1	0	0
26314	1520	(1.7 fmol/10(7) cell	[(1.7 fmol/10(7) cells]	1.5849625007211563	3	1	0	0
26315	1520	b lymphocyte development	[B lymphocyte development]	1.5849625007211563	3	1	0	0
26316	1520	presence of the enzyme	[presence of the enzyme]	1.5849625007211563	4	1	0	0
26317	1520	several distinct cell type	[several distinct cell types]	1.5849625007211563	4	1	0	0
26318	1520	enhancer/promoter region of hiv-2	[enhancer/promoter region of HIV-2]	1.5849625007211563	4	1	0	0
26319	1520	subject with stat1alpha expression	[subjects with STAT1alpha expression]	1.5849625007211563	4	1	0	0
26320	1520	direct temporal correlation	[direct temporal correlation]	1.5849625007211563	3	1	0	0
26321	1520	-512 LMP1 DNA	[-512 LMP1 DNA]	1.5849625007211563	3	1	0	0
26322	1520	protein kinase p56(lck)	[protein kinases p56(lck)]	1.5849625007211563	3	1	0	0
26323	1520	isgf3 ifn-stimulated gene factor	[ISGF3 IFN-stimulated gene factor]	1.5849625007211563	4	1	0	0
26324	1520	appearance of NF-MATp35	[appearance of NF-MATp35]	1.5849625007211563	3	2	1	1
26325	1520	monocyte of this group	[monocytes of these groups]	1.5849625007211563	4	1	0	0
26326	1520	murine pu.1 (spi-1) promoter	[murine PU.1 (spi-1) promoter]	1.5849625007211563	4	1	0	0
26327	1520	primary site of cancer	[primary site of cancer]	1.5849625007211563	4	1	0	0
26328	1520	induction of E2F activity	[induction of E2F activity]	1.5849625007211563	4	1	0	0
26329	1520	two immediate early protein	[two immediate early proteins]	1.5849625007211563	4	1	0	0
26330	1520	subsequent antigenic challenge	[subsequent antigenic challenges]	1.5849625007211563	3	1	0	0
26331	1520	other motor neuron	[other motor neurons]	1.5849625007211563	3	1	0	0
26332	1520	functional receptor protein	[functional receptor proteins]	1.5849625007211563	3	1	0	0
26333	1520	isolate prb -null clone	[isolating pRB -null clones]	1.5849625007211563	4	1	0	0
26334	1520	level of purine-box/nuclear factor	[level of purine-box/nuclear factor]	1.5849625007211563	4	1	0	0
26335	1520	inhibition of spontaneous cytotoxicity	[inhibition of spontaneous cytotoxicity]	1.5849625007211563	4	1	0	0
26336	1520	ifn-gamma and/or tnf-alpha action,	[IFN-gamma and/or TNF-alpha action,]	1.5849625007211563	4	1	0	0
26337	1520	neutrophil elastase NE	[Neutrophil elastase NE]	1.5849625007211563	3	1	0	0
26338	1520	TF cognate catalytic cofactor	[TF cognate catalytic cofactor]	1.5849625007211563	4	1	0	0
26339	1520	3 h to hormone	[3 h to hormone]	1.5849625007211563	4	1	0	0
26340	1520	costimulation of interleukin-2	[costimulation of interleukin-2]	1.5849625007211563	3	1	0	0
26341	1520	T cell ICSAT	[T cells ICSAT]	1.5849625007211563	3	1	0	0
26342	1520	induction of c-fos/c-jun ap-1	[induction of c-Fos/c-Jun AP-1]	1.5849625007211563	4	1	0	0
26343	1520	hiv-1 provirus DNA	[HIV-1 provirus DNA]	1.5849625007211563	3	1	0	0
26344	1520	IL-4 transcriptional control	[IL-4 transcriptional control]	1.5849625007211563	3	1	0	0
26345	1520	thereby form complex	[thereby forming complexes]	1.5849625007211563	3	1	0	0
26346	1520	contrast, NF-kappa b activity	[contrast, NF-kappa B activity]	1.5849625007211563	4	1	0	0
26347	1520	normal nonpregnant value	[normal nonpregnant values]	1.5849625007211563	3	1	0	0
26348	1520	short-term, in vitro exposure	[short-term, in vitro exposure]	1.5849625007211563	4	1	0	0
26349	1520	target cell apoptosis	[target cell apoptosis]	1.5849625007211563	3	1	0	0
26350	1520	chi b site	[chi B site]	1.5849625007211563	3	1	0	0
26351	1520	position between -54	[positions between -54]	1.5849625007211563	3	1	0	0
26352	1520	combination of CD3 mab	[combination of CD3 mAbs]	1.5849625007211563	4	1	0	0
26353	1520	fas ligand FasL	[Fas ligand FasL]	1.5849625007211563	3	2	1	1
26354	1520	tumor (l&h) cell	[tumor (L&H) cells]	1.5849625007211563	3	1	0	0
26355	1520	major apoptotic mechanism	[major apoptotic mechanism]	1.5849625007211563	3	1	0	0
26356	1520	Ikaros gene family	[Ikaros gene family]	1.5849625007211563	3	1	0	0
26357	1520	carry the t(12;15) translocation	[carrying the t(12;15) translocation]	1.5849625007211563	4	1	0	0
26358	1520	bcl-6 mrna level	[BCL-6 mRNA levels]	1.5849625007211563	3	1	0	0
26359	1520	second A/R challenge,	[second A/R challenge,]	1.5849625007211563	3	1	0	0
26360	1520	position between -95	[positions between -95]	1.5849625007211563	3	1	0	0
26361	1520	presence of EBV	[presence of EBV]	1.5849625007211563	3	1	0	0
26362	1520	new, fast assay	[new, faster assay]	1.5849625007211563	3	1	0	0
26363	1520	consequent differential activation	[consequent differential activation]	1.5849625007211563	3	1	0	0
26364	1520	co-localization with nuclear antigen	[co-localization with nuclear antigens]	1.5849625007211563	4	1	0	0
26365	1520	rar-rxr rxr-rxr dimers,	[RAR-RXR RXR-RXR dimers,]	1.5849625007211563	3	1	0	0
26366	1520	548 bp il-2 promoter	[548 bp IL-2 promoter]	1.5849625007211563	4	1	0	0
26367	1520	antiviral drug acyclovir	[antiviral drug acyclovir]	1.5849625007211563	3	1	0	0
26368	1520	positive activator region	[positive activator region]	1.5849625007211563	3	1	0	0
26369	1520	small peptidyl substrate	[small peptidyl substrates]	1.5849625007211563	3	1	0	0
26370	1520	extrathymic t-cell differentiation	[extrathymic T-cell differentiation]	1.5849625007211563	3	1	0	0
26371	1520	NF-kappa B B/MAD-3	[NF-kappa B B/MAD-3]	1.5849625007211563	3	1	0	0
26372	1520	cell cycle- control gene	[cell cycle- controlling genes]	1.5849625007211563	4	1	0	0
26373	1520	novel cellular protein	[novel cellular protein]	1.5849625007211563	3	2	1	1
26374	1520	glucocorticoid in the membrane	[glucocorticoids in the membrane]	1.5849625007211563	4	1	0	0
26375	1520	process require phosphorylation	[process requiring phosphorylation]	1.5849625007211563	3	1	0	0
26376	1520	activate the transcription factor	[activating the transcription factors]	1.5849625007211563	4	2	2	2
26377	1520	condition for optimal expression	[conditions for optimal expression]	1.5849625007211563	4	1	0	0
26378	1520	chromosome 17 breakpoint	[chromosome 17 breakpoint]	1.5849625007211563	3	1	0	0
26379	1520	monocytic cell line (Singh	[monocytic cell line (Singh]	1.5849625007211563	4	1	0	0
26380	1520	predisposition to leukaemia/lymphoma	[predisposition to leukaemia/lymphoma]	1.5849625007211563	3	1	0	0
26381	1520	myocyte-enhancer factor 2	[myocyte-enhancer factor 2]	1.5849625007211563	3	1	0	0
26382	1520	mechanism underlie this activity	[mechanism underlying this activity]	1.5849625007211563	4	1	0	0
26383	1520	normally function thyroid gland	[normally functioning thyroid gland]	1.5849625007211563	4	1	0	0
26384	1520	leukemia-specific t(15;17) chromosomal translocation	[leukemia-specific t(15;17) chromosomal translocation]	1.5849625007211563	4	1	0	0
26385	1520	stably associate with rip	[stably associates with RIP]	1.5849625007211563	4	1	0	0
26386	1520	455-bp U3 region	[455-bp U3 region]	1.5849625007211563	3	1	0	0
26387	1520	specific nuclear factor-DNA complex	[specific nuclear factor-DNA complexes]	1.5849625007211563	4	1	0	0
26388	1520	sublytic tcc ras	[sublytic TCC Ras]	1.5849625007211563	3	1	0	0
26389	1520	mouse il-4 gene	[mouse IL-4 gene]	1.5849625007211563	3	1	0	0
26390	1520	interaction with promoter-proximal element	[interaction with promoter-proximal elements]	1.5849625007211563	4	1	0	0
26391	1520	important hiv transcription factor	[important HIV transcription factors]	1.5849625007211563	4	1	0	0
26392	1520	different human t-cell type	[different human T-cell types]	1.5849625007211563	4	1	0	0
26393	1520	polyanionic glycosaminoglycan gag	[polyanionic glycosaminoglycan GAG]	1.5849625007211563	3	1	0	0
26394	1520	r59z activator cell	[R59Z activator cells]	1.5849625007211563	3	2	2	2
26395	1520	response to various stimulus	[responses to various stimuli]	1.5849625007211563	4	1	0	0
26396	1520	addition, after novelty stress	[addition, after novelty stress]	1.5849625007211563	4	1	0	0
26397	1520	endogenous ikk enzymatic activity	[endogenous IKK enzymatic activity]	1.5849625007211563	4	1	0	0
26398	1520	RXR alpha protein	[RXR alpha protein]	1.5849625007211563	3	1	0	0
26399	1520	activation domain of lef-1	[activation domains of LEF-1]	1.5849625007211563	4	1	0	0
26400	1520	technique of clonal analysis	[technique of clonal analysis]	1.5849625007211563	4	1	0	0
26401	1520	conversion of the tced	[conversion of the TCEd]	1.5849625007211563	4	1	0	0
26402	1520	tyrosine phosphorylation, nuclear translocation	[tyrosine phosphorylation, nuclear translocation]	1.5849625007211563	4	1	0	0
26403	1520	express high level	[expressing high levels]	1.5849625007211563	3	2	2	2
26404	1520	cytoplasmic carboxyl terminus ct	[cytoplasmic carboxyl terminus CT]	1.5849625007211563	4	1	0	0
26405	1520	il-1beta promoter construct	[IL-1beta promoter construct]	1.5849625007211563	3	1	0	0
26406	1520	latency type ii pattern	[latency type II pattern]	1.5849625007211563	4	1	0	0
26407	1520	primary rest T lymphocyte	[Primary resting T lymphocytes]	1.5849625007211563	4	1	0	0
26408	1520	increase the amount	[increasing the amount]	1.5849625007211563	3	2	2	2
26409	1520	human IP-10 promoter region	[human IP-10 promoter region]	1.5849625007211563	4	1	0	0
26410	1520	LEF-1 -beta-catenin complex	[LEF-1 -beta-catenin complexes]	1.5849625007211563	3	1	0	0
26411	1520	Janus kinase/STAT signal pathway	[Janus kinase/STAT signaling pathways]	1.5849625007211563	4	1	0	0
26412	1520	formation of tissue structure	[formation of tissue structure]	1.5849625007211563	4	1	0	0
26413	1520	requirement for a region	[requirement for an region]	1.5849625007211563	4	1	0	0
26414	1520	stimulation of the cells,	[stimulation of the cells,]	1.5849625007211563	4	1	0	0
26415	1520	DNA response element corresponding	[DNA response elements corresponding]	1.5849625007211563	4	1	0	0
26416	1520	intensity of the staining	[intensity of the staining]	1.5849625007211563	4	1	0	0
26417	1520	expression of c/ebp beta	[expression of C/EBP beta]	1.5849625007211563	4	1	0	0
26418	1520	oncoprotein such as aml1/eto	[oncoproteins such as AML1/ETO]	1.5849625007211563	4	1	0	0
26419	1520	clinically achievable concentrations.	[clinically achievable concentrations.]	1.5849625007211563	3	1	0	0
26420	1520	48-hr media-stimulated t-cell	[48-hr media-stimulated T-cells]	1.5849625007211563	3	1	0	0
26421	1520	active v-abl kinase	[active v-Abl kinase]	1.5849625007211563	3	1	0	0
26422	1520	cytomegalovirus immediate early gene	[Cytomegalovirus immediate early genes]	1.5849625007211563	4	1	0	0
26423	1520	stem cell to monocyte	[stem cells to monocytes]	1.5849625007211563	4	1	0	0
26424	1520	inability of this mutant	[inability of these mutants]	1.5849625007211563	4	1	0	0
26425	1520	platelet from patient	[platelets from patients]	1.5849625007211563	3	2	1	1
26426	1520	step after DNA binding	[step after DNA binding]	1.5849625007211563	4	1	0	0
26427	1520	maintenance of x-chromosome inactivation	[maintenance of X-chromosome inactivation]	1.5849625007211563	4	1	0	0
26428	1520	ataxia telangiectasia clonal proliferation	[ataxia telangiectasia clonal proliferation]	1.5849625007211563	4	1	0	0
26429	1520	nuclear binding protein	[nuclear binding proteins]	1.5849625007211563	3	2	2	2
26430	1520	vitro peptide sensitization	[vitro peptide sensitization]	1.5849625007211563	3	1	0	0
26431	1520	property of cell	[property of cells]	1.5849625007211563	3	2	2	2
26432	1520	basal inducible cd23 expression	[basal inducible CD23 expression]	1.5849625007211563	4	1	0	0
26433	1520	human elk-1 promoter	[human elk-1 promoter]	1.5849625007211563	3	2	1	1
26434	1520	DNA sequence element	[DNA sequence element]	1.5849625007211563	3	2	2	2
26435	1520	heteromeric complex formation	[heteromeric complex formation]	1.5849625007211563	3	1	0	0
26436	1520	stimulation of ln cell	[Stimulation of LN cells]	1.5849625007211563	4	1	0	0
26437	1520	htr beta 1	[hTR beta 1]	1.5849625007211563	3	2	1	1
26438	1520	body mass index	[body mass index]	1.5849625007211563	3	1	0	0
26439	1520	infection in one	[infection in one]	1.5849625007211563	3	1	0	0
26440	1520	Sp1 binding site mutant	[Sp1 binding site mutants]	1.5849625007211563	4	1	0	0
26441	1520	interaction between transcription factor	[interactions between transcription factors]	1.5849625007211563	4	2	1	1
26442	1520	human IL-1beta promoter	[human IL-1beta promoter]	1.5849625007211563	3	1	0	0
26443	1520	deletion of prdi element	[deletion of PRDI elements]	1.5849625007211563	4	1	0	0
26444	1520	six different transcription factor	[six different transcription factors]	1.5849625007211563	4	1	0	0
26445	1520	900 amino acid capable	[900 amino acids capable]	1.5849625007211563	4	1	0	0
26446	1520	microvessel endothelial cell	[microvessel endothelial cells]	1.5849625007211563	3	2	2	2
26447	1520	androgen receptor agonist attack	[androgen receptor agonist attack]	1.5849625007211563	4	1	0	0
26448	1520	class ii trans-activator CIITA	[class II trans-activator CIITA]	1.5849625007211563	4	1	0	0
26449	1520	prolonged cyclic pressure-stretch load	[prolonged cyclic pressure-stretching load]	1.5849625007211563	4	1	0	0
26450	1520	measurable il-2 production	[measurable IL-2 production]	1.5849625007211563	3	1	0	0
26451	1520	second messenger up-regulation	[Second messenger up-regulation]	1.5849625007211563	3	1	0	0
26452	1520	transcriptional factor activator protein-1	[transcriptional factor activator protein-1]	1.5849625007211563	4	1	0	0
26453	1520	pou domain of Oct-1	[POU domains of Oct-1]	1.5849625007211563	4	1	0	0
26454	1520	majority of T lymphocyte	[majority of T lymphocytes]	1.5849625007211563	4	1	0	0
26455	1520	down-regulation of nf-kappab activation	[Down-regulation of NF-kappaB activation]	1.5849625007211563	4	1	0	0
26456	1520	infectious mononucleosis patient	[infectious mononucleosis patients]	1.5849625007211563	3	1	0	0
26457	1520	one such phagocyte system	[one such phagocyte system]	1.5849625007211563	4	1	0	0
26458	1520	subclassify a IDC	[subclassifying an IDC]	1.5849625007211563	3	1	0	0
26459	1520	phorbol myristate acetate induction	[phorbol myristate acetate induction]	1.5849625007211563	4	1	0	0
26460	1520	estrogen receptor in monocyte	[estrogen receptor in monocytes]	1.5849625007211563	4	2	2	2
26461	1520	single-cell rt-pcr analysis,	[single-cell RT-PCR analysis,]	1.5849625007211563	3	1	0	0
26462	1520	aids -c group (2.9	[AIDS -C group (2.9]	1.5849625007211563	4	1	0	0
26463	1520	different signal transduction element	[different signal transduction elements]	1.5849625007211563	4	1	0	0
26464	1520	development of bronchiolitis obliteran	[development of bronchiolitis obliterans]	1.5849625007211563	4	2	1	1
26465	1520	radio-ligand binding analysis	[radio-ligand binding analysis]	1.5849625007211563	3	1	0	0
26466	1520	optimal transcriptional activation	[optimal transcriptional activation]	1.5849625007211563	3	1	0	0
26467	1520	Concanavalin a stimulation	[Concanavalin A stimulation]	1.5849625007211563	3	1	0	0
26468	1520	sensitivity to M-CSF	[sensitivity to M-CSF]	1.5849625007211563	3	1	0	0
26469	1520	Reverse transcription-PCR analysis	[Reverse transcription-PCR analysis]	1.5849625007211563	3	1	0	0
26470	1520	mechanism underlie this association	[mechanism underlying this association]	1.5849625007211563	4	1	0	0
26471	1520	leukocyte from 2 woman	[leukocytes from 2 women]	1.5849625007211563	4	1	0	0
26472	1520	monoclonal cell antibody	[Monoclonal cell antibodies]	1.5849625007211563	3	2	2	2
26473	1520	factor in naive cell	[factor in naive cells]	1.5849625007211563	4	1	0	0
26474	1520	155 residue beyond TES1	[155 residues beyond TES1]	1.5849625007211563	4	1	0	0
26475	1520	transactivation response element tar	[transactivation response element TAR]	1.5849625007211563	4	1	0	0
26476	1520	IFN regulatory factor irf-1	[IFN regulatory factor IRF-1]	1.5849625007211563	4	1	0	0
26477	1520	binding of DNA	[binding of DNA]	1.5849625007211563	3	1	0	0
26478	1520	foreign cell rat fibroblast	[foreign cells rat fibroblasts]	1.5849625007211563	4	1	0	0
26479	1520	downstream T lymphocyte-specific	[downstream T lymphocyte-specific]	1.5849625007211563	3	1	0	0
26480	1520	C beta 2 gene	[C beta 2 gene]	1.5849625007211563	4	1	0	0
26481	1520	giant cell arteritis GCA	[Giant cell arteritis GCA]	1.5849625007211563	4	1	0	0
26482	1520	B-cell nuclear extract	[B-cell nuclear extracts]	1.5849625007211563	3	1	0	0
26483	1520	endothelial cell with ifn-gamma	[endothelial cells with IFN-gamma]	1.5849625007211563	4	1	0	0
26484	1520	GH4C1 pituitary cell	[GH4C1 pituitary cells]	1.5849625007211563	3	1	0	0
26485	1520	sequence at bp -60	[sequence at bp -60]	1.5849625007211563	4	1	0	0
26486	1520	inhibition of il-1ri	[Inhibition of IL-1RI]	1.5849625007211563	3	1	0	0
26487	1520	circumvention of tolerance	[Circumvention of tolerance]	1.5849625007211563	3	1	0	0
26488	1520	block gene transcription	[blocking gene transcription]	1.5849625007211563	3	1	0	0
26489	1520	20 case (6%)	[20 cases (6%)]	1.5849625007211563	3	1	0	0
26490	1520	icam-1 by LMP1	[ICAM-1 by LMP1]	1.5849625007211563	3	1	0	0
26491	1520	various immune gene	[various immune genes]	1.5849625007211563	3	1	0	0
26492	1520	erythroid differentiation marker	[erythroid differentiation markers]	1.5849625007211563	3	1	0	0
26493	1520	course of infection.	[course of infection.]	1.5849625007211563	3	1	0	0
26494	1520	htlv-1-infected t-cell line	[HTLV-1-infected T-cell lines]	1.5849625007211563	3	1	0	0
26495	1520	reference to the biology	[reference to the biology]	1.5849625007211563	4	1	0	0
26496	1520	transcription protein, stat-1	[transcription protein, STAT-1]	1.5849625007211563	3	1	0	0
26497	1520	liver of ATL patient	[liver of ATL patients]	1.5849625007211563	4	1	0	0
26498	1520	inhibition of the binding	[inhibition of the binding]	1.5849625007211563	4	1	0	0
26499	1520	yeast two-hybrid interaction system	[yeast two-hybrid interaction system]	1.5849625007211563	4	1	0	0
26500	1520	CCAAT motif present	[CCAAT motif present]	1.5849625007211563	3	1	0	0
26501	1520	only upon exposure	[only upon exposure]	1.5849625007211563	3	2	2	2
26502	1520	72-kDa major immediate-early protein	[72-kDa major immediate-early protein]	1.5849625007211563	4	1	0	0
26503	1520	limiting-component transcription assay	[limiting-component transcription assays]	1.5849625007211563	3	1	0	0
26504	1520	rante expression by glucocorticoid	[RANTES expression by glucocorticoids]	1.5849625007211563	4	1	0	0
26505	1520	two model ags	[two model Ags]	1.5849625007211563	3	1	0	0
26506	1520	stat nuclear protein	[STAT nuclear proteins]	1.5849625007211563	3	1	0	0
26507	1520	multisubunit adhesion receptor	[multisubunit adhesion receptor]	1.5849625007211563	3	1	0	0
26508	1520	mode of lymphocyte activation	[mode of lymphocyte activation]	1.5849625007211563	4	1	0	0
26509	1520	early phase of apoptosis	[early phases of apoptosis]	1.5849625007211563	4	1	0	0
26510	1520	synthesis of protein factor	[synthesis of protein factors]	1.5849625007211563	4	2	2	2
26511	1520	induction of the synthesis	[induction of the synthesis]	1.5849625007211563	4	1	0	0
26512	1520	breakpoint of myeloid leukemia	[breakpoints of myeloid leukemias]	1.5849625007211563	4	1	0	0
26513	1520	expression of hsp60	[expression of Hsp60]	1.5849625007211563	3	2	1	1
26514	1520	hiv-1 long repeat promoter	[HIV-1 long repeat promoter]	1.5849625007211563	4	1	0	0
26515	1520	cdk2 inhibitor Olomoucine	[cdk2 inhibitor Olomoucine]	1.5849625007211563	3	1	0	0
26516	1520	IL-2 stat3 activation	[IL-2 Stat3 activation]	1.5849625007211563	3	1	0	0
26517	1520	M2 leukemic blast cell	[M2 leukemic blast cells]	1.5849625007211563	4	1	0	0
26518	1520	tyrosine phosphorylation of member	[tyrosine phosphorylation of members]	1.5849625007211563	4	1	0	0
26519	1520	outer nuclear volume,	[outer nuclear volume,]	1.5849625007211563	3	1	0	0
26520	1520	diverse set of receptor	[diverse set of receptors]	1.5849625007211563	4	1	0	0
26521	1520	stress-activated protein kinase SAPK	[stress-activated protein kinases SAPK]	1.5849625007211563	4	1	0	0
26522	1520	HTLV-I gene include tax	[HTLV-I genes including Tax]	1.5849625007211563	4	1	0	0
26523	1520	il-12 signal transduction	[IL-12 signal transduction]	1.5849625007211563	3	1	0	0
26524	1520	use human T lymphocyte	[Using human T lymphocytes]	1.5849625007211563	4	1	0	0
26525	1520	action of Stat6	[action of Stat6]	1.5849625007211563	3	1	0	0
26526	1520	casein kinase ii CKII	[casein kinase II CKII]	1.5849625007211563	4	1	0	0
26527	1520	monoblastoid cell line u937	[monoblastoid cell line U937]	1.5849625007211563	4	1	0	0
26528	1520	factor, distinct from CIITA	[factor, distinct from CIITA]	1.5849625007211563	4	1	0	0
26529	1520	understand the function	[Understanding the function]	1.5849625007211563	3	2	2	2
26530	1520	ic50 of 6 microM.	[IC50 of 6 microM.]	1.5849625007211563	4	1	0	0
26531	1520	expression of the c-fo	[expression of the c-fos]	1.5849625007211563	4	1	0	0
26532	1520	induction by glucocorticoid	[Induction by glucocorticoids]	1.5849625007211563	3	2	2	2
26533	1520	differentiate erythroid progeny	[differentiating erythroid progeny]	1.5849625007211563	3	1	0	0
26534	1520	22 case of Arnhl	[22 cases of ARNHL]	1.5849625007211563	4	1	0	0
26535	1520	total plasma cortisol concentration	[total plasma cortisol concentrations]	1.5849625007211563	4	1	0	0
26536	1520	intrinsic differentiate stimulus	[intrinsic differentiating stimulus]	1.5849625007211563	3	1	0	0
26537	1520	ester on monocyte adhesion	[esters on monocyte adhesion]	1.5849625007211563	4	1	0	0
26538	1520	difference in p-creb level	[differences in P-CREB levels]	1.5849625007211563	4	1	0	0
26539	1520	two transcription initiation site	[two transcription initiation sites]	1.5849625007211563	4	2	2	2
26540	1520	activator protein-2 ap-2	[activator protein-2 AP-2]	1.5849625007211563	3	1	0	0
26541	1520	fk506 a immunosuppressant	[FK506 an immunosuppressant]	1.5849625007211563	3	1	0	0
26542	1520	MEK /erk pathway	[MEK /ERK pathway]	1.5849625007211563	3	1	0	0
26543	1520	seven EBV-B cell clone	[seven EBV-B cell clones]	1.5849625007211563	4	1	0	0
26544	1520	Oct-1 -binding phenotype	[Oct-1 -binding phenotype]	1.5849625007211563	3	1	0	0
26545	1520	especially elderly, patient	[especially elderly, patients]	1.5849625007211563	3	1	0	0
26546	1520	MEK /erk signal pathway	[MEK /ERK signaling pathway]	1.5849625007211563	4	1	0	0
26547	1520	mitogen phorbol ester	[mitogens phorbol esters]	1.5849625007211563	3	1	0	0
26548	1520	germline Cepsilon transcription	[germline Cepsilon transcription]	1.5849625007211563	3	2	2	2
26549	1520	clonality analysis of granulocyte	[Clonality analysis of granulocytes]	1.5849625007211563	4	1	0	0
26550	1520	zinc finger/homeodomain protein	[zinc finger/homeodomain proteins]	1.5849625007211563	3	1	0	0
26551	1520	expression of il-12r beta	[expression of IL-12R beta]	1.5849625007211563	4	1	0	0
26552	1520	1 Jak1 activation	[1 Jak1 activation]	1.5849625007211563	3	1	0	0
26553	1520	consequence of chromosome translocation	[consequence of chromosome translocation]	1.5849625007211563	4	1	0	0
26554	1520	expression of p16(ink4a)	[expression of p16(INK4A)]	1.5849625007211563	3	1	0	0
26555	1520	T cell line HSB-2	[T cell line HSB-2]	1.5849625007211563	4	1	0	0
26556	1520	differentiation arrest a feature	[differentiation arrest a feature]	1.5849625007211563	4	1	0	0
26557	1520	activator protein 3	[activator protein 3]	1.5849625007211563	3	1	0	0
26558	1520	Latent membrane protein	[Latent membrane protein]	1.5849625007211563	3	3	2	1
26559	1520	10 year period	[10 year period]	1.5849625007211563	3	1	0	0
26560	1520	analysis of the accumulation	[Analysis of the accumulation]	1.5849625007211563	4	1	0	0
26561	1520	upstream kinase zap-70	[upstream kinase Zap-70]	1.5849625007211563	3	1	0	0
26562	1520	DRA gene expression	[DRA gene expression]	1.5849625007211563	3	1	0	0
26563	1520	presence of CD4	[presence of CD4]	1.5849625007211563	3	1	0	0
26564	1520	specific rna target	[specific RNA target]	1.5849625007211563	3	1	0	0
26565	1520	t-cell clone reactive	[T-cell clone reactive]	1.5849625007211563	3	2	2	2
26566	1520	alteration at the level	[alterations at the level]	1.5849625007211563	4	1	0	0
26567	1520	Zebra gene transcription	[Zebra gene transcription]	1.5849625007211563	3	1	0	0
26568	1520	glioblastoma cell line	[glioblastoma cell line]	1.5849625007211563	3	1	0	0
26569	1520	stat -dependent transcription	[STAT -dependent transcription]	1.5849625007211563	3	1	0	0
26570	1520	consistent cytogenetic abnormality	[consistent cytogenetic abnormalities]	1.5849625007211563	3	1	0	0
26571	1520	wild-type b cell line	[wild-type B cell line]	1.5849625007211563	4	1	0	0
26572	1520	high level, tissue-specific expression	[high level, tissue-specific expression]	1.5849625007211563	4	1	0	0
26573	1520	common structural element	[common structural elements]	1.5849625007211563	3	1	0	0
26574	1520	early lymphoid cell	[early lymphoid cells]	1.5849625007211563	3	1	0	0
26575	1520	region (CR) 3	[region (CR) 3]	1.5849625007211563	3	1	0	0
26576	1520	Hsp70 induction by TS	[Hsp70 induction by TS]	1.5849625007211563	4	1	0	0
26577	1520	3 h of culture.	[3 h of culture.]	1.5849625007211563	4	1	0	0
26578	1520	confirm early findings.	[confirming earlier findings.]	1.5849625007211563	3	1	0	0
26579	1520	early b cell development	[early B cell development]	1.5849625007211563	4	1	0	0
26580	1520	binding of both form	[binding of both forms]	1.5849625007211563	4	1	0	0
26581	1520	E2A-HLF fusion gene	[E2A-HLF fusion gene]	1.5849625007211563	3	1	0	0
26582	1520	clinical response to atra	[clinical response to ATRA]	1.5849625007211563	4	1	0	0
26583	1520	autophosphorylation in vitro	[autophosphorylation in vitro]	1.5849625007211563	3	1	0	0
26584	1520	gastric carcinoma cell	[gastric carcinoma cells]	1.5849625007211563	3	1	0	0
26585	1520	autoregulatory mechanism for transcription	[autoregulatory mechanism for transcription]	1.5849625007211563	4	1	0	0
26586	1520	several BSAP recognition sequence	[several BSAP recognition sequences]	1.5849625007211563	4	1	0	0
26587	1520	mitochondrial transmembrane potential delta	[Mitochondrial transmembrane potential delta]	1.5849625007211563	4	1	0	0
26588	1520	injury in the brain	[injury in the brain]	1.5849625007211563	4	1	0	0
26589	1520	Jurkat T cells.	[Jurkat T cells.]	1.5849625007211563	3	1	0	0
26590	1520	important role in lymphocyte	[important role in lymphocytes]	1.5849625007211563	4	1	0	0
26591	1520	c-jun early response gene	[c-jun early response gene]	1.5849625007211563	4	1	0	0
26592	1520	mutation of Ser184	[Mutation of Ser184]	1.5849625007211563	3	1	0	0
26593	1520	cellular gene like cd23	[cellular genes like CD23]	1.5849625007211563	4	1	0	0
26594	1520	tf promotor in monocyte	[TF promotor in monocytes]	1.5849625007211563	4	1	0	0
26595	1520	induction of gr mrna	[induction of GR mRNA]	1.5849625007211563	4	2	1	1
26596	1520	id2 mrna decrease	[Id2 mRNA decrease]	1.5849625007211563	3	1	0	0
26597	1520	function of protein	[function of proteins]	1.5849625007211563	3	2	2	2
26598	1520	possible t-cell killer T/NK	[possible T-cell killer T/NK]	1.5849625007211563	4	1	0	0
26599	1520	timp-1 -negative bl line	[TIMP-1 -negative BL lines]	1.5849625007211563	4	1	0	0
26600	1520	develop of this abnormality	[developing of these abnormalities]	1.5849625007211563	4	1	0	0
26601	1520	human eotaxin gene	[human eotaxin gene]	1.5849625007211563	3	2	1	1
26602	1520	human ige germline gene	[human IgE germline gene]	1.5849625007211563	4	1	0	0
26603	1520	"N-end rule" ligase	["N-end rule" ligase]	1.5849625007211563	3	1	0	0
26604	1520	double repeat-KB enhancer sequence	[double repeat-KB enhancer sequence]	1.5849625007211563	4	1	0	0
26605	1520	NF-kappaB/ IkappaB complex	[NF-kappaB/ IkappaB complex]	1.5849625007211563	3	1	0	0
26606	1520	expression of the p450ia1	[expression of the P450IA1]	1.5849625007211563	4	1	0	0
26607	1520	signal pathway of apoptosis	[signaling pathway of apoptosis]	1.5849625007211563	4	2	1	1
26608	1520	mgf-stat5-like transcription factor	[MGF-STAT5-like transcription factor]	1.5849625007211563	3	1	0	0
26609	1520	nf-kappa b /rel subunit	[NF-kappa B /Rel subunits]	1.5849625007211563	4	2	2	2
26610	1520	many different cell types.	[many different cell types.]	1.5849625007211563	4	1	0	0
26611	1520	il-4 in lps-treated cell	[IL-4 in LPS-treated cells]	1.5849625007211563	4	1	0	0
26612	1520	similar level of mnda	[similar levels of MNDA]	1.5849625007211563	4	1	0	0
26613	1520	use of a motif	[use of an motif]	1.5849625007211563	4	1	0	0
26614	1520	role in b-cell activation	[role in B-cell activation]	1.5849625007211563	4	2	2	2
26615	1520	kappa B-specific binding factor	[kappa B-specific binding factors]	1.5849625007211563	4	1	0	0
26616	1520	other nf-kappab inhibitor	[other NF-kappaB inhibitors]	1.5849625007211563	3	1	0	0
26617	1520	peak at 30 min.	[peaking at 30 min.]	1.5849625007211563	4	1	0	0
26618	1520	cotransfection of c-Rel	[cotransfection of c-Rel]	1.5849625007211563	3	1	0	0
26619	1520	Thus, gata-3 expression	[Thus, GATA-3 expression]	1.5849625007211563	3	1	0	0
26620	1520	EBNA2 specific monoclonal antibody	[EBNA2 specific monoclonal antibodies]	1.5849625007211563	4	1	0	0
26621	1520	three sp 1-binding site	[three Sp 1-binding sites]	1.5849625007211563	4	1	0	0
26622	1520	respond beta chain	[responding beta chains]	1.5849625007211563	3	1	0	0
26623	1520	human blood platelet	[human blood platelets]	1.5849625007211563	3	1	0	0
26624	1520	constitutively active pkc	[constitutively active PKCs]	1.5849625007211563	3	1	0	0
26625	1520	androgen receptor blockade	[Androgen receptor blockade]	1.5849625007211563	3	1	0	0
26626	1520	tissue-specific promoter activity	[tissue-specific promoter activity]	1.5849625007211563	3	1	0	0
26627	1520	intact mzf-1 binding site	[intact MZF-1 binding sites]	1.5849625007211563	4	1	0	0
26628	1520	N-terminal domain of NFATx1	[N-terminal domain of NFATx1]	1.5849625007211563	4	1	0	0
26629	1520	mnp protein (s) binding	[MNP protein (s) binding]	1.5849625007211563	4	1	0	0
26630	1520	plasmid contain various length	[plasmids containing various lengths]	1.5849625007211563	4	1	0	0
26631	1520	il-2r alpha promoter construct	[IL-2R alpha promoter constructs]	1.5849625007211563	4	1	0	0
26632	1520	progesterone receptor in pregnancy	[progesterone receptor in pregnancy]	1.5849625007211563	4	1	0	0
26633	1520	patient with aids-related cancer	[patients with AIDS-related cancers]	1.5849625007211563	4	1	0	0
26634	1520	death receptor 3 DR3	[death receptor 3 DR3]	1.5849625007211563	4	1	0	0
26635	1520	GATA-3 transcription factor	[GATA-3 transcription factor]	1.5849625007211563	3	1	0	0
26636	1520	novel E2F complex	[novel E2F complexes]	1.5849625007211563	3	1	0	0
26637	1520	type-ii estrogen binding site	[Type-II estrogen binding sites]	1.5849625007211563	4	1	0	0
26638	1520	hl60 cell with 3-methylcholanthrene	[HL60 cells with 3-methylcholanthrene]	1.5849625007211563	4	1	0	0
26639	1520	removal of this region	[removal of this region]	1.5849625007211563	4	1	0	0
26640	1520	patient with one type	[Patients with one type]	1.5849625007211563	4	1	0	0
26641	1520	soluble nuclear matrix preparation	[soluble nuclear matrix preparations]	1.5849625007211563	4	1	0	0
26642	1520	mature HeLa cell mrna	[mature HeLa cell mRNA]	1.5849625007211563	4	1	0	0
26643	1520	depletion of intracellular glutathione	[depletion of intracellular glutathione]	1.5849625007211563	4	1	0	0
26644	1520	3 h in PBL	[3 h in PBL]	1.5849625007211563	4	1	0	0
26645	1520	core sp1 consensus element	[core Sp1 consensus element]	1.5849625007211563	4	1	0	0
26646	1520	previous protein-DNA binding study	[Previous protein-DNA binding studies]	1.5849625007211563	4	1	0	0
26647	1520	hormone-dependent regulator of transcription	[hormone-dependent regulator of transcription]	1.5849625007211563	4	1	0	0
26648	1520	avian erythroid progenitor	[avian erythroid progenitors]	1.5849625007211563	3	1	0	0
26649	1520	primary human lymphocyte activation	[primary human lymphocyte activation]	1.5849625007211563	4	1	0	0
26650	1520	nno in astrocyte	[nNOS in astrocytes]	1.5849625007211563	3	1	0	0
26651	1520	kappa B-like site	[kappa B-like sites]	1.5849625007211563	3	2	1	1
26652	1520	pattern of ebna expression	[pattern of EBNA expression]	1.5849625007211563	4	1	0	0
26653	1520	contrast to previous result	[contrast to previous results]	1.5849625007211563	4	1	0	0
26654	1520	MYH11 genomic rearrangement	[MYH11 genomic rearrangement]	1.5849625007211563	3	1	0	0
26655	1520	possibly p50 homodimer	[possibly p50 homodimers]	1.5849625007211563	3	1	0	0
26656	1520	14 normal healthy subject	[14 normal healthy subjects]	1.5849625007211563	4	1	0	0
26657	1520	relation between stat3 activation	[relation between Stat3 activation]	1.5849625007211563	4	1	0	0
26658	1520	uptake of density lipoprotein	[uptake of density lipoprotein]	1.5849625007211563	4	2	2	2
26659	1520	dna-binding domain relative	[DNA-binding domain relative]	1.5849625007211563	3	1	0	0
26660	1520	pleiotropic cytokine affect growth	[pleiotropic cytokine affecting growth]	1.5849625007211563	4	1	0	0
26661	1520	N-terminal 218 amino acid	[N-terminal 218 amino acids]	1.5849625007211563	4	1	0	0
26662	1520	administration of dexamethasone	[Administration of dexamethasone]	1.5849625007211563	3	2	2	2
26663	1520	incidence of relapse	[incidence of relapse]	1.5849625007211563	3	2	2	2
26664	1520	PHA-activated T cell	[PHA-activated T cells]	1.5849625007211563	3	1	0	0
26665	1520	murine TNF promoter GGGGGCTTTCCC	[murine TNF promoter GGGGGCTTTCCC]	1.5849625007211563	4	1	0	0
26666	1520	nf-kappab transcription factor	[NF-kappaB transcription factors]	1.5849625007211563	3	1	0	0
26667	1520	transcription factor z bzlf1	[transcription factor Z BZLF1]	1.5849625007211563	4	1	0	0
26668	1520	ebna2 response element	[EBNA2 response element]	1.5849625007211563	3	1	0	0
26669	1520	overexpression of BASH	[Overexpression of BASH]	1.5849625007211563	3	1	0	0
26670	1520	response to TNF,	[response to TNF,]	1.5849625007211563	3	1	0	0
26671	1520	great variety of gene	[great variety of genes]	1.5849625007211563	4	1	0	0
26672	1520	constitutively active ras	[constitutively active Ras]	1.5849625007211563	3	1	0	0
26673	1520	syk-family tyrosine kinase	[Syk-family tyrosine kinases]	1.5849625007211563	3	1	0	0
26674	1520	3-o-methyl-d-glucose uptake by glucocorticoid	[3-O-methyl-D-glucose uptake by glucocorticoids]	1.5849625007211563	4	1	0	0
26675	1520	measure platelet-activating factor	[measuring platelet-activating factor]	1.5849625007211563	3	1	0	0
26676	1520	CsA -sensitive transcription factor	[CsA -sensitive transcription factors]	1.5849625007211563	4	1	0	0
26677	1520	EBV -replicative lesion	[EBV -replicative lesions]	1.5849625007211563	3	1	0	0
26678	1520	amino acid contain cysteine	[amino acids containing cysteine]	1.5849625007211563	4	1	0	0
26679	1520	il-4 phosphorylation of jak1	[IL-4 phosphorylation of JAK1]	1.5849625007211563	4	1	0	0
26680	1520	proliferation to tetanus toxoid	[Proliferation to tetanus toxoid]	1.5849625007211563	4	1	0	0
26681	1520	presence of oestrogen	[presence of oestrogen]	1.5849625007211563	3	2	1	1
26682	1520	certain T cell malignancy	[certain T cell malignancies]	1.5849625007211563	4	1	0	0
26683	1520	exposure to oxidative stress	[exposure to oxidative stress]	1.5849625007211563	4	2	1	1
26684	1520	death-inducing ligand dil	[Death-inducing ligands DILs]	1.5849625007211563	3	1	0	0
26685	1520	glucocorticoid in T cell	[glucocorticoids in T cells]	1.5849625007211563	4	1	0	0
26686	1520	loss of p16	[loss of p16]	1.5849625007211563	3	1	0	0
26687	1520	contrast, treatment of cell	[contrast, treatment of cells]	1.5849625007211563	4	1	0	0
26688	1520	kappa b alpha evidence	[kappa B alpha evidence]	1.5849625007211563	4	1	0	0
26689	1520	IL-2 promoter CD28 response	[IL-2 promoter CD28 response]	1.5849625007211563	4	1	0	0
26690	1520	4) mutation on any	[4) mutation on any]	1.5849625007211563	4	1	0	0
26691	1520	response to challenge	[response to challenge]	1.5849625007211563	3	2	2	2
26692	1520	bhlh-pas partner factor arnt	[bHLH-PAS partner factor Arnt]	1.5849625007211563	4	1	0	0
26693	1520	degree of stability	[degree of stability]	1.5849625007211563	3	1	0	0
26694	1520	transient heterokaryon system	[transient heterokaryon system]	1.5849625007211563	3	1	0	0
26695	1520	Inorganic lead pb	[Inorganic lead Pb]	1.5849625007211563	3	1	0	0
26696	1520	promyelomonocytic leukemic hl-60 cell	[promyelomonocytic leukemic HL-60 cells]	1.5849625007211563	4	1	0	0
26697	1520	inability of osf2	[inability of OSF2]	1.5849625007211563	3	1	0	0
26698	1520	high level of transcription.	[high level of transcription.]	1.5849625007211563	4	1	0	0
26699	1520	host immune factors,	[host immune factors,]	1.5849625007211563	3	1	0	0
26700	1520	comparison of the value	[comparison of the values]	1.5849625007211563	4	1	0	0
26701	1520	tyrosine phosphorylation of stat6	[tyrosine phosphorylation of STAT6]	1.5849625007211563	4	1	0	0
26702	1520	tyrosine phosphorylation of stat5	[Tyrosine phosphorylation of STAT5]	1.5849625007211563	4	1	0	0
26703	1520	tyrosine phosphorylation of stat4	[tyrosine phosphorylation of STAT4]	1.5849625007211563	4	2	2	2
26704	1520	validity of that model	[validity of those models]	1.5849625007211563	4	1	0	0
26705	1520	effect of prednisone PDN	[effects of prednisone PDN]	1.5849625007211563	4	1	0	0
26706	1520	activation-driven fas upregulation	[activation-driven fas upregulation]	1.5849625007211563	3	1	0	0
26707	1520	about 5 ng/ml	[about 5 ng/ml]	1.5849625007211563	3	1	0	0
26708	1520	suppressive effect of progesterone	[suppressive effect of progesterone]	1.5849625007211563	4	1	0	0
26709	1520	pi 3-kinase activation	[PI 3-kinase activation]	1.5849625007211563	3	1	0	0
26710	1520	pretreatment with TNFalpha diminished,	[Pretreatment with TNFalpha diminished,]	1.5849625007211563	4	1	0	0
26711	1520	initiation of prednisolone therapy	[initiation of prednisolone therapy]	1.5849625007211563	4	1	0	0
26712	1520	increase in p50 homodimer	[increase in p50 homodimers]	1.5849625007211563	4	1	0	0
26713	1520	ribosome salt wash fraction	[ribosome salt wash fraction]	1.5849625007211563	4	1	0	0
26714	1520	gut hyperabsorption of calcium	[gut hyperabsorption of calcium]	1.5849625007211563	4	1	0	0
26715	1520	SCL mrna level	[SCL mRNA levels]	1.5849625007211563	3	2	1	1
26716	1520	dominant mutant of IkappaBalpha	[dominant mutant of IkappaBalpha]	1.5849625007211563	4	1	0	0
26717	1520	plasmid contain kappab site	[plasmid containing kappaB sites]	1.5849625007211563	4	1	0	0
26718	1520	initiation of virus replication	[initiation of virus replication]	1.5849625007211563	4	1	0	0
26719	1520	EBV cell line	[EBV cell line]	1.5849625007211563	3	2	1	1
26720	1520	IgG immune complex model	[IgG immune complex model]	1.5849625007211563	4	1	0	0
26721	1520	CREB binding protein cbp	[CREB binding protein CBP]	1.5849625007211563	4	1	0	0
26722	1520	interleukin 3 colony-stimulating factor	[interleukin 3 colony-stimulating factor]	1.5849625007211563	4	1	0	0
26723	1520	Jun family protein	[Jun family proteins]	1.5849625007211563	3	1	0	0
26724	1520	coactivator protein recruitment	[coactivator protein recruitment]	1.5849625007211563	3	1	0	0
26725	1520	susceptibility to specific lysis	[susceptibility to specific lysis]	1.5849625007211563	4	1	0	0
26726	1520	interleukin (il)-2 gene	[interleukin (IL)-2 gene]	1.5849625007211563	3	1	0	0
26727	1520	absence of hla-dr synthesis	[absence of HLA-DR synthesis]	1.5849625007211563	4	1	0	0
26728	1520	virus-induced nf-kappa b activation	[virus-induced NF-kappa B activation]	1.5849625007211563	4	1	0	0
26729	1520	lps in monocyte	[LPS in monocytes]	1.5849625007211563	3	1	0	0
26730	1520	cellular senescence in vitro	[cellular senescence in vitro]	1.5849625007211563	4	1	0	0
26731	1520	expression of gene product	[expression of gene products]	1.5849625007211563	4	2	2	2
26732	1520	octamer-binding transcription factor Oct-1	[octamer-binding transcription factors Oct-1]	1.5849625007211563	4	1	0	0
26733	1520	less stat1 alpha activation	[less STAT1 alpha activation]	1.5849625007211563	4	1	0	0
26734	1520	nsaid on gene expression	[NSAIDs on gene expression]	1.5849625007211563	4	1	0	0
26735	1520	short term priming.	[short term priming.]	1.5849625007211563	3	1	0	0
26736	1520	tsh-r transcript level	[TSH-R transcript levels]	1.5849625007211563	3	2	1	1
26737	1520	hiv-1 tat gene expression	[HIV-1 tat gene expression]	1.5849625007211563	4	1	0	0
26738	1520	granulocyte-macrophage colony-stimumulatelany-stg factor gene	[granulocyte-macrophage colony-stimulating factor gene]	1.5849625007211563	4	1	0	0
26739	1520	pu.1 include T cell	[PU.1 including T cells]	1.5849625007211563	4	1	0	0
26740	1520	lmp-2a loci in thymocyte	[LMP-2A loci in thymocytes]	1.5849625007211563	4	1	0	0
26741	1520	regulatory element upstream	[regulatory element upstream]	1.5849625007211563	3	1	0	0
26742	1520	magnitude of the fos	[magnitude of the Fos]	1.5849625007211563	4	1	0	0
26743	1520	5'-utr of the gamma-gene	[5'-UTR of the gamma-gene]	1.5849625007211563	4	1	0	0
26744	1520	neutralize mab to IL-10	[Neutralizing mAbs to IL-10]	1.5849625007211563	4	1	0	0
26745	1520	six nuclear antigen EBNAs	[six nuclear antigen EBNAs]	1.5849625007211563	4	2	2	2
26746	1520	step in the initiation	[step in the initiation]	1.5849625007211563	4	2	2	2
26747	1520	onset of b lymphopoiesis	[onset of B lymphopoiesis]	1.5849625007211563	4	1	0	0
26748	1520	peripheral blood from transgenic	[peripheral blood from transgenic]	1.5849625007211563	4	1	0	0
26749	1520	ifn-stimulated response element ISRE	[IFN-stimulated response element ISRE]	1.5849625007211563	4	1	0	0
26750	1520	activator of viral gene	[activator of viral genes]	1.5849625007211563	4	2	2	2
26751	1520	reduction of nf-kappa b	[reduction of NF-kappa B]	1.5849625007211563	4	1	0	0
26752	1520	conclusion a important component	[conclusion an important component]	1.5849625007211563	4	1	0	0
26753	1520	function, cytokine production	[function, cytokine production]	1.5849625007211563	3	1	0	0
26754	1520	absence of 9-cis-ra	[absence of 9-cis-RA]	1.5849625007211563	3	1	0	0
26755	1520	allergic inflammatory response	[allergic inflammatory response]	1.5849625007211563	3	1	0	0
26756	1520	transactivation by Oct-2	[transactivation by Oct-2]	1.5849625007211563	3	1	0	0
26757	1520	hepatic HTC cell	[hepatic HTC cells]	1.5849625007211563	3	1	0	0
26758	1520	requirement for TNF	[requirement for TNF]	1.5849625007211563	3	1	0	0
26759	1520	10.4s sedimenting complex	[10.4S sedimenting complex]	1.5849625007211563	3	1	0	0
26760	1520	1100 amino acid	[1,100 amino acids]	1.5849625007211563	3	1	0	0
26761	1520	denature gradient gel electrophoresis	[denaturing gradient gel electrophoresis]	1.5849625007211563	4	1	0	0
26762	1520	fetal hematopoietic population	[fetal hematopoietic populations]	1.5849625007211563	3	1	0	0
26763	1520	progesterone binding structure	[progesterone binding structures]	1.5849625007211563	3	1	0	0
26764	1520	control of developmental expression	[control of developmental expression]	1.5849625007211563	4	1	0	0
26765	1520	other hand, interleukin	[other hand, interleukin]	1.5849625007211563	3	1	0	0
26766	1520	MCP-1 rna level	[MCP-1 RNA level]	1.5849625007211563	3	1	0	0
26767	1520	role in embryogenesis	[role in embryogenesis]	1.5849625007211563	3	1	0	0
26768	1520	cd14- phosphorylation- dependent event	[CD14- phosphorylation- dependent event]	1.5849625007211563	4	1	0	0
26769	1520	kappa b tyrosine phosphorylation	[kappa B tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
26770	1520	include activation of monocyte	[including activation of monocytes]	1.5849625007211563	4	1	0	0
26771	1520	progenitor cell CD34+/CD38(2+)	[progenitors cells CD34+/CD38(2+)]	1.5849625007211563	3	1	0	0
26772	1520	leucine zipper class	[leucine zipper class]	1.5849625007211563	3	1	0	0
26773	1520	hybrid promoter construct	[hybrid promoter constructs]	1.5849625007211563	3	1	0	0
26774	1520	tissue-specific alternative splicing	[tissue-specific alternative splicing]	1.5849625007211563	3	2	1	1
26775	1520	degradation of p105	[degradation of p105]	1.5849625007211563	3	3	2	1
26776	1520	development of a disease	[development of an disease]	1.5849625007211563	4	1	0	0
26777	1520	murine macrophage-like cell raw264.7	[murine macrophage-like cells RAW264.7]	1.5849625007211563	4	1	0	0
26778	1520	activator of transcription STAT1alpha	[activator of transcription STAT1alpha]	1.5849625007211563	4	1	0	0
26779	1520	important role in function	[important role in functions]	1.5849625007211563	4	1	0	0
26780	1520	Zta up-regulation of p53	[Zta up-regulation of p53]	1.5849625007211563	4	1	0	0
26781	1520	NFAT nuclear factor	[NFAT nuclear factor]	1.5849625007211563	3	1	0	0
26782	1520	comparison to variant present	[comparison to variants present]	1.5849625007211563	4	1	0	0
26783	1520	normal control (60.7	[normal controls (60.7]	1.5849625007211563	3	1	0	0
26784	1520	induction of IL-16 promoter	[induction of IL-16 promoter]	1.5849625007211563	4	1	0	0
26785	1520	important immunoregulatory protein	[important immunoregulatory protein]	1.5849625007211563	3	1	0	0
26786	1520	normal control group	[normal control group]	1.5849625007211563	3	1	0	0
26787	1520	vitamin D3 vd	[vitamin D3 VD]	1.5849625007211563	3	1	0	0
26788	1520	conditional gata-2/estrogen receptor chimera	[conditional GATA-2/estrogen receptor chimera]	1.5849625007211563	4	1	0	0
26789	1520	detectable 135eoh)2d3 receptor	[detectable 1,25(OH)2D3 receptors]	1.5849625007211563	3	1	0	0
26790	1520	aids patient with hypercortisolism	[AIDS patients with hypercortisolism]	1.5849625007211563	4	1	0	0
26791	1520	pkc downstream event	[PKC downstream events]	1.5849625007211563	3	1	0	0
26792	1520	ability of tnf-alpha	[ability of TNF-alpha]	1.5849625007211563	3	1	0	0
26793	1520	comparison with lymphocyte	[comparison with lymphocytes]	1.5849625007211563	3	1	0	0
26794	1520	12-O-tetradecanoyl phorbol-13-acetate tpa	[12-O-tetradecanoyl phorbol-13-acetate TPA]	1.5849625007211563	3	1	0	0
26795	1520	Burkitt' lymphoma BL	[Burkitt's lymphoma BL]	1.5849625007211563	3	2	1	1
26796	1520	high affinity il-2r	[high affinity IL-2R]	1.5849625007211563	3	1	0	0
26797	1520	bcl-6 protein level	[BCL-6 protein levels]	1.5849625007211563	3	1	0	0
26798	1520	affinity of exogenous peptide	[affinity of exogenous peptide]	1.5849625007211563	4	1	0	0
26799	1520	immune cell of patient	[immune cells of patients]	1.5849625007211563	4	1	0	0
26800	1520	ensue production of tnf-alpha	[ensuing production of TNF-alpha]	1.5849625007211563	4	1	0	0
26801	1520	increase in adherence	[increase in adherence]	1.5849625007211563	3	2	2	2
26802	1520	increase in leukocyte adhesion	[increase in leukocyte adhesion]	1.5849625007211563	4	1	0	0
26803	1520	1 tax1 protein	[1 Tax1 protein]	1.5849625007211563	3	1	0	0
26804	1520	contrast to Zap	[contrast to Zap]	1.5849625007211563	3	1	0	0
26805	1520	minimally by PAF	[minimally by PAF]	1.5849625007211563	3	1	0	0
26806	1520	multiple human tissue	[multiple human tissues]	1.5849625007211563	3	1	0	0
26807	1520	pathogenesis of allergic disorder	[pathogenesis of allergic disorders]	1.5849625007211563	4	1	0	0
26808	1520	E14 T lymphoma cell	[E14 T lymphoma cells]	1.5849625007211563	4	1	0	0
26809	1520	dna-protein binding complex formation	[DNA-protein binding complex formation]	1.5849625007211563	4	1	0	0
26810	1520	Cbl homologue Cbl -b	[Cbl homologue Cbl -b]	1.5849625007211563	4	1	0	0
26811	1520	il-5 in eosinophil	[IL-5 in eosinophils]	1.5849625007211563	3	1	0	0
26812	1520	distinct stat6-dna binding complex	[distinct STAT6-DNA binding complexes]	1.5849625007211563	4	1	0	0
26813	1520	partially inhibit the expression	[partially inhibiting the expression]	1.5849625007211563	4	1	0	0
26814	1520	instance of microsatellite instability	[instance of microsatellite instability]	1.5849625007211563	4	1	0	0
26815	1520	expression of subunit	[expression of subunits]	1.5849625007211563	3	2	2	2
26816	1520	certain tumor characteristic	[certain tumor characteristics]	1.5849625007211563	3	1	0	0
26817	1520	mediate biological response	[mediating biological responses]	1.5849625007211563	3	1	0	0
26818	1520	transcription from immunoglobulin gene	[transcription from immunoglobulin genes]	1.5849625007211563	4	1	0	0
26819	1520	lps-stimulated Raw 264.7 cell	[LPS-stimulated Raw 264.7 cells]	1.5849625007211563	4	1	0	0
26820	1520	false positive prediction	[false positive predictions]	1.5849625007211563	3	1	0	0
26821	1520	neutrophil adhesion to huvec	[neutrophil adhesion to HUVECs]	1.5849625007211563	4	1	0	0
26822	1520	merit of ddpcr relative	[merits of DDPCR relative]	1.5849625007211563	4	1	0	0
26823	1520	two protein 50 kda	[two proteins 50 kDa]	1.5849625007211563	4	1	0	0
26824	1520	gene of T cell	[genes of T cells]	1.5849625007211563	4	1	0	0
26825	1520	ebv-transformed b cell	[EBV-transformed B cells]	1.5849625007211563	3	2	1	1
26826	1520	specific steroid binding site	[specific steroid binding sites]	1.5849625007211563	4	1	0	0
26827	1520	c-sis/platelet-derived growth factor-B promoter	[c-sis/platelet-derived growth factor-B promoter]	1.5849625007211563	4	1	0	0
26828	1520	AP1 consensus motif	[AP1 consensus motif]	1.5849625007211563	3	1	0	0
26829	1520	14 breast cancer patient	[14 breast cancer patients]	1.5849625007211563	4	1	0	0
26830	1520	different cell line three	[different cell lines three]	1.5849625007211563	4	1	0	0
26831	1520	two cytokine systems, il-2	[two cytokine systems, IL-2]	1.5849625007211563	4	1	0	0
26832	1520	human gamma-globin gene	[human gamma-globin gene]	1.5849625007211563	3	1	0	0
26833	1520	ability of nuclear factor	[ability of nuclear factors]	1.5849625007211563	4	1	0	0
26834	1520	isolation of CEM subclone	[isolation of CEM subclones]	1.5849625007211563	4	1	0	0
26835	1520	basal transcriptional machinery.	[basal transcriptional machinery.]	1.5849625007211563	3	1	0	0
26836	1520	slope factor for alpha-zearalenol	[slope factors for alpha-zearalenol]	1.5849625007211563	4	1	0	0
26837	1520	5' end noncoding sequence	[5' end noncoding sequence]	1.5849625007211563	4	1	0	0
26838	1520	results: interleukin-6 protein	[RESULTS: Interleukin-6 protein]	1.5849625007211563	3	1	0	0
26839	1520	other, control expression	[other, control expression]	1.5849625007211563	3	1	0	0
26840	1520	DEX isoproterenol ISO	[DEX isoproterenol ISO]	1.5849625007211563	3	1	0	0
26841	1520	il-1 il-2 production	[IL-1 IL-2 production]	1.5849625007211563	3	1	0	0
26842	1520	distinct silencer mechanism	[distinct silencer mechanism]	1.5849625007211563	3	1	0	0
26843	1520	different restriction point	[different restriction points]	1.5849625007211563	3	1	0	0
26844	1520	cyclic amp-responsive element-binding protein	[cyclic AMP-responsive element-binding protein]	1.5849625007211563	4	1	0	0
26845	1520	Southern hybridization analysis	[Southern hybridization analyses]	1.5849625007211563	3	1	0	0
26846	1520	apparent tal1 gene	[apparent TAL1 gene]	1.5849625007211563	3	1	0	0
26847	1520	hiv transmission in woman	[HIV transmission in women]	1.5849625007211563	4	1	0	0
26848	1520	difference in virus production	[difference in virus production]	1.5849625007211563	4	2	2	2
26849	1520	number of response	[number of responses]	1.5849625007211563	3	2	1	1
26850	1520	gm-csf neutrophil lineage	[GM-CSF neutrophil lineage]	1.5849625007211563	3	1	0	0
26851	1520	mouse Ig heavy-chain enhancer	[mouse Ig heavy-chain enhancer]	1.5849625007211563	4	1	0	0
26852	1520	contain the luciferase gene	[containing the luciferase gene]	1.5849625007211563	4	1	0	0
26853	1520	ciprofloxacin (5-80 micrograms/ml)	[ciprofloxacin (5-80 micrograms/ml)]	1.5849625007211563	3	1	0	0
26854	1520	residue position p1	[Residues position P1]	1.5849625007211563	3	1	0	0
26855	1520	overexpression of BCL2	[overexpression of BCL2]	1.5849625007211563	3	1	0	0
26856	1520	Raf -signaling pathway	[Raf -signaling pathways]	1.5849625007211563	3	1	0	0
26857	1520	role of NF-ATp	[role of NF-ATp]	1.5849625007211563	3	1	0	0
26858	1520	expression of member	[expression of members]	1.5849625007211563	3	1	0	0
26859	1520	i-factor /nm23 protein	[I-factor /nm23 protein]	1.5849625007211563	3	1	0	0
26860	1520	nuclear extract of cell	[nuclear extract of cells]	1.5849625007211563	4	2	2	2
26861	1520	MHC -diverse human population	[MHC -diverse human population]	1.5849625007211563	4	1	0	0
26862	1520	origin of abnormal cytokine	[origin of abnormal cytokine]	1.5849625007211563	4	1	0	0
26863	1520	lack a TATA sequence	[lacking a TATA sequence]	1.5849625007211563	4	1	0	0
26864	1520	interleukin 1 production	[interleukin 1 production]	1.5849625007211563	3	1	0	0
26865	1520	increase in mrna expression	[increase in mRNA expression]	1.5849625007211563	4	2	1	1
26866	1520	tnf-alpha-induced hiv-1 expression	[TNF-alpha-induced HIV-1 expression]	1.5849625007211563	3	1	0	0
26867	1520	critical signal pathway	[critical signaling pathway]	1.5849625007211563	3	1	0	0
26868	1520	addition of IFNgamma	[addition of IFNgamma]	1.5849625007211563	3	1	0	0
26869	1520	fibroblast medium FCM	[fibroblast medium FCM]	1.5849625007211563	3	1	0	0
26870	1520	expression of interferon alpha-	[expression of interferon alpha-]	1.5849625007211563	4	1	0	0
26871	1520	transformation of t-cell	[transformation of T-cells]	1.5849625007211563	3	1	0	0
26872	1520	T tumor cell line	[T tumor cell line]	1.5849625007211563	4	2	1	1
26873	1520	decrease in VDR concentration	[decrease in VDR concentration]	1.5849625007211563	4	1	0	0
26874	1520	antibody super-shift reaction	[antibody super-shift reaction]	1.5849625007211563	3	1	0	0
26875	1520	early blood island	[early blood islands]	1.5849625007211563	3	1	0	0
26876	1520	normal CEM cell	[normal CEM cells]	1.5849625007211563	3	1	0	0
26877	1520	mycobacterial infection [see comments]	[mycobacterial infection [see comments]]	1.5849625007211563	4	1	0	0
26878	1520	eklf-/- es cell	[EKLF-/- ES cells]	1.5849625007211563	3	1	0	0
26879	1520	full-length chimeric receptor	[full-length chimeric receptor]	1.5849625007211563	3	1	0	0
26880	1520	concanavalin a con a	[concanavalin A Con A]	1.5849625007211563	4	1	0	0
26881	1520	two different cell line	[two different cell lines]	1.5849625007211563	4	1	0	0
26882	1520	dr-nm23 in normal hematopoiesis	[DR-nm23 in normal hematopoiesis]	1.5849625007211563	4	1	0	0
26883	1520	high expression of myf3	[high expression of myf3]	1.5849625007211563	4	1	0	0
26884	1520	Tcf transcription lithium	[Tcf transcription lithium]	1.5849625007211563	3	1	0	0
26885	1520	activation of signal	[activation of signals]	1.5849625007211563	3	1	0	0
26886	1520	10 pituitary-dependent cushingd'	[10 pituitary-dependent Cushing's]	1.5849625007211563	3	1	0	0
26887	1520	IL-1alpha gene transcription	[IL-1alpha gene transcription]	1.5849625007211563	3	1	0	0
26888	1520	significantly affect erk1	[significantly affecting ERK1]	1.5849625007211563	3	1	0	0
26889	1520	t-cell-mediated autoimmune disease	[T-cell-mediated autoimmune diseases]	1.5849625007211563	3	1	0	0
26890	1520	serum response element SRE	[serum response element SRE]	1.5849625007211563	4	1	0	0
26891	1520	PMA CD4 down-modulation	[PMA CD4 down-modulation]	1.5849625007211563	3	1	0	0
26892	1520	reverse transcription pcr	[reverse transcription PCR]	1.5849625007211563	3	2	1	1
26893	1520	transactivator of megakaryocyte-specific promoter	[transactivators of megakaryocyte-specific promoters]	1.5849625007211563	4	1	0	0
26894	1520	b cell responses.	[B cell responses.]	1.5849625007211563	3	1	0	0
26895	1520	use the yeast system	[using the yeast system]	1.5849625007211563	4	2	2	2
26896	1520	beta 2 subunit binding	[beta 2 subunit binding]	1.5849625007211563	4	1	0	0
26897	1520	196 base pair	[196 base pair]	1.5849625007211563	3	1	0	0
26898	1520	exception of a region	[exception of a region]	1.5849625007211563	4	1	0	0
26899	1520	result from this study	[Results from this study]	1.5849625007211563	4	1	0	0
26900	1520	quiescent non-proliferative state	[quiescent non-proliferative state]	1.5849625007211563	3	1	0	0
26901	1520	fk506 with fkbp12	[FK506 with FKBP12]	1.5849625007211563	3	1	0	0
26902	1520	similar number of cell	[similar numbers of cells]	1.5849625007211563	4	1	0	0
26903	1520	However, p38 mapk	[However, p38 MAPK]	1.5849625007211563	3	1	0	0
26904	1520	binding of [3h]1,25(oh)2d3	[binding of [3H]1,25(OH)2D3]	1.5849625007211563	3	1	0	0
26905	1520	minority of tumor cell	[minority of tumor cells]	1.5849625007211563	4	1	0	0
26906	1520	DMSO treatment, HL-60 cell	[DMSO treatment, HL-60 cells]	1.5849625007211563	4	1	0	0
26907	1520	primary cd45r0 T cell	[primary CD45R0 T cells]	1.5849625007211563	4	1	0	0
26908	1520	phenotype of the cell	[phenotype of the cells]	1.5849625007211563	4	2	1	1
26909	1520	hil-5 promoter activity	[hIL-5 promoter activity]	1.5849625007211563	3	2	1	1
26910	1520	G61: Aes1/2 125-133	[G61: AES1/2 125-133]	1.5849625007211563	3	1	0	0
26911	1520	neutrophilic differentiation in colony	[neutrophilic differentiation in colonies]	1.5849625007211563	4	1	0	0
26912	1520	t-cell activation c-jun	[T-cell activation c-jun]	1.5849625007211563	3	1	0	0
26913	1520	1,25-dihydroxy vitamin D3	[1,25-dihydroxy vitamin D3]	1.5849625007211563	3	1	0	0
26914	1520	use a zinc-inducible vector.	[using a zinc-inducible vector.]	1.5849625007211563	4	1	0	0
26915	1520	normal human cells,	[normal human cells,]	1.5849625007211563	3	1	0	0
26916	1520	identification of a region	[Identification of a region]	1.5849625007211563	4	1	0	0
26917	1520	downregulation of transcription factor	[downregulation of transcription factors]	1.5849625007211563	4	2	2	2
26918	1520	ATF NF-kappaB-dependent promoter	[ATF NF-kappaB-dependent promoters]	1.5849625007211563	3	1	0	0
26919	1520	constitutive nuclear appearance	[Constitutive nuclear appearance]	1.5849625007211563	3	1	0	0
26920	1520	sensitive 6tg1.1 cell	[sensitive 6TG1.1 cells]	1.5849625007211563	3	1	0	0
26921	1520	ferritin H-gene promoter	[ferritin H-gene promoter]	1.5849625007211563	3	1	0	0
26922	1520	effect on the development	[effect on the development]	1.5849625007211563	4	2	2	2
26923	1520	GC -resistance of CRF	[GC -resistance of CRF]	1.5849625007211563	4	1	0	0
26924	1520	result of a set	[result of a set]	1.5849625007211563	4	1	0	0
26925	1520	repressor from that site.	[repressor from that site.]	1.5849625007211563	4	1	0	0
26926	1520	increase in globin mrna	[increase in globin mRNA]	1.5849625007211563	4	1	0	0
26927	1520	full length promoter construct	[full length promoter construct]	1.5849625007211563	4	1	0	0
26928	1520	higher-ord protein complex	[higher-order protein complex]	1.5849625007211563	3	1	0	0
26929	1520	overexpression of a form	[overexpression of an form]	1.5849625007211563	4	2	2	2
26930	1520	murine leukemia virus family	[murine leukemia virus family]	1.5849625007211563	4	1	0	0
26931	1520	transcription factor protein	[transcription factor proteins]	1.5849625007211563	3	2	1	1
26932	1520	various type of cells.	[various type of cells.]	1.5849625007211563	4	1	0	0
26933	1520	large amount early e1b	[large amounts early E1B]	1.5849625007211563	4	1	0	0
26934	1520	a6h mab CD80	[A6H mAb CD80]	1.5849625007211563	3	1	0	0
26935	1520	conditional allele of gata-1	[conditional alleles of GATA-1]	1.5849625007211563	4	1	0	0
26936	1520	polypyrimidine tract-binding protein	[polypyrimidine tract-binding protein]	1.5849625007211563	3	1	0	0
26937	1520	number of VDR	[numbers of VDR]	1.5849625007211563	3	2	1	1
26938	1520	prior to fixation.	[prior to fixation.]	1.5849625007211563	3	1	0	0
26939	1520	antisense gata-3 rna	[antisense GATA-3 RNA]	1.5849625007211563	3	1	0	0
26940	1520	increase in tgf-beta mrna	[increase in TGF-beta mRNA]	1.5849625007211563	4	1	0	0
26941	1520	fasl paclitaxel apoptosis	[FasL paclitaxel apoptosis]	1.5849625007211563	3	1	0	0
26942	1520	A-MYB N-terminal domain	[A-MYB N-terminal domain]	1.5849625007211563	3	1	0	0
26943	1520	new protein-DNA interaction	[new protein-DNA interaction]	1.5849625007211563	3	1	0	0
26944	1520	Random migration RM	[Random migration RM]	1.5849625007211563	3	1	0	0
26945	1520	gene-modified T cell	[gene-modified T cells]	1.5849625007211563	3	1	0	0
26946	1520	lectins on c-Fos	[lectins on c-Fos]	1.5849625007211563	3	1	0	0
26947	1520	vaginal fluid of agent(s)	[vaginal fluid of agent(s)]	1.5849625007211563	4	1	0	0
26948	1520	additional significant finding	[additional significant finding]	1.5849625007211563	3	1	0	0
26949	1520	promoter by this complexes.	[promoters by these complexes.]	1.5849625007211563	4	1	0	0
26950	1520	DNA processivity factor	[DNA processivity factor]	1.5849625007211563	3	1	0	0
26951	1520	very early activator protein	[very early activator protein]	1.5849625007211563	4	1	0	0
26952	1520	expression in human monocyte	[expression in human monocytes]	1.5849625007211563	4	2	2	2
26953	1520	transcription factor RFX1	[transcription factors RFX1]	1.5849625007211563	3	1	0	0
26954	1520	fas/ fasl interaction	[Fas/ FasL interaction]	1.5849625007211563	3	1	0	0
26955	1520	dissociation between the ability	[dissociation between the ability]	1.5849625007211563	4	1	0	0
26956	1520	human hl60 leukemia cell	[human HL60 leukemia cells]	1.5849625007211563	4	1	0	0
26957	1520	12-o-tetradecanoylphorbol-13-acetate tpa mitogen tnf-alpha	[12-O-tetradecanoylphorbol-13-acetate TPA mitogen TNF-alpha]	1.5849625007211563	4	1	0	0
26958	1520	Internal ribosome binding	[Internal ribosome binding]	1.5849625007211563	3	1	0	0
26959	1520	hs transcription factor HSF	[HS transcription factor HSF]	1.5849625007211563	4	1	0	0
26960	1520	suggest pretranslational control mechanism	[suggesting pretranslational control mechanisms]	1.5849625007211563	4	1	0	0
26961	1520	octamer bind protein	[octamer binding protein]	1.5849625007211563	3	1	0	0
26962	1520	binding of 125i-il-4	[binding of 125I-IL-4]	1.5849625007211563	3	1	0	0
26963	1520	authors' previous observation	[authors' previous observations]	1.5849625007211563	3	1	0	0
26964	1520	mmp9 mrna level	[MMP9 mRNA levels]	1.5849625007211563	3	1	0	0
26965	1520	bind the consensus site	[binding the consensus site]	1.5849625007211563	4	1	0	0
26966	1520	membrane potential change secondary	[membrane potential changes secondary]	1.5849625007211563	4	1	0	0
26967	1520	Internal ribosomal binding	[Internal ribosomal binding]	1.5849625007211563	3	1	0	0
26968	1520	less extent, b cell	[lesser extent, B cells]	1.5849625007211563	4	1	0	0
26969	1520	NF-chi B TCEd	[NF-chi B TCEd]	1.5849625007211563	3	1	0	0
26970	1520	appearance of early marker	[appearance of early markers]	1.5849625007211563	4	1	0	0
26971	1520	im-9 cell cytosol	[IM-9 cell cytosol]	1.5849625007211563	3	1	0	0
26972	1520	anti- Itk immunoprecipitate	[anti- Itk immunoprecipitate]	1.5849625007211563	3	1	0	0
26973	1520	action of protein tyrosine	[action of protein tyrosine]	1.5849625007211563	4	1	0	0
26974	1520	promonocytic cell line u1	[promonocytic cell line U1]	1.5849625007211563	4	1	0	0
26975	1520	involve nuclear factor	[involving nuclear factor]	1.5849625007211563	3	2	2	2
26976	1520	cd4+ T cell response	[CD4+ T cell responses]	1.5849625007211563	4	1	0	0
26977	1520	immunologic nos iNOS	[immunologic NOS iNOS]	1.5849625007211563	3	1	0	0
26978	1520	dimerize with proapoptotic member	[dimerizing with proapoptotic members]	1.5849625007211563	4	1	0	0
26979	1520	DNA bind subunit	[DNA binding subunit]	1.5849625007211563	3	1	0	0
26980	1520	such as aml1/eto	[such as AML1/ETO]	1.5849625007211563	3	1	0	0
26981	1520	erythroblastic HEL cell	[erythroblastic HEL cells]	1.5849625007211563	3	1	0	0
26982	1520	chimeric gene, aml1/eto (mtg8)	[chimeric gene, AML1/ETO (MTG8)]	1.5849625007211563	4	1	0	0
26983	1520	effect of the hormone	[effect of the hormone]	1.5849625007211563	4	1	0	0
26984	1520	analysis of interaction	[Analysis of interactions]	1.5849625007211563	3	1	0	0
26985	1520	40 mM nac	[40 mM NAC]	1.5849625007211563	3	1	0	0
26986	1520	POZ/Zinc finger transcriptional repressor	[POZ/Zinc finger transcriptional repressor]	1.5849625007211563	4	1	0	0
26987	1520	blood monocyte number	[blood monocyte number]	1.5849625007211563	3	2	1	1
26988	1520	beneficial effect of ketoconazole	[beneficial effects of ketoconazole]	1.5849625007211563	4	1	0	0
26989	1520	approximately 120-amino-acid n-terminal motif	[approximately 120-amino-acid N-terminal motif]	1.5849625007211563	4	1	0	0
26990	1520	(TNF) receptor family tramp	[(TNF) receptor family TRAMP]	1.5849625007211563	4	1	0	0
26991	1520	caspase-3 inhibitor devd-cho	[caspase-3 inhibitor DEVD-CHO]	1.5849625007211563	3	1	0	0
26992	1520	normal center b cell	[normal center B cells]	1.5849625007211563	4	4	3	1
26993	1520	role of MARs	[role of MARs]	1.5849625007211563	3	1	0	0
26994	1520	A-myb transcription factor	[A-myb transcription factor]	1.5849625007211563	3	1	0	0
26995	1520	low amount of IFN.	[low amounts of IFN.]	1.5849625007211563	4	1	0	0
26996	1520	viral structural protein	[viral structural proteins]	1.5849625007211563	3	1	0	0
26997	1520	difference in cell surface	[differences in cell surface]	1.5849625007211563	4	1	0	0
26998	1520	second AIDS retrovirus hiv-2	[second AIDS retrovirus HIV-2]	1.5849625007211563	4	1	0	0
26999	1520	effect of the drug	[effects of the drug]	1.5849625007211563	4	2	1	1
27000	1520	one class compounds, 20-epi	[one class compounds, 20-epi]	1.5849625007211563	4	1	0	0
27001	1520	leucocyte in 5 patient	[leucocytes in 5 patients]	1.5849625007211563	4	1	0	0
27002	1520	apoptosis follow activation.	[apoptosis following activation.]	1.5849625007211563	3	1	0	0
27003	1520	oligomerize receptor chain	[oligomerizing receptor chains]	1.5849625007211563	3	1	0	0
27004	1520	5-60 mg of prednisolone	[5-60 mg of prednisolone]	1.5849625007211563	4	1	0	0
27005	1520	tyrosine serine /threonine kinase	[tyrosine serine /threonine kinases]	1.5849625007211563	4	1	0	0
27006	1520	several NF-kappaB complex	[several NF-kappaB complexes]	1.5849625007211563	3	1	0	0
27007	1520	different t-cell type	[different T-cell types]	1.5849625007211563	3	2	1	1
27008	1520	aberrant double-negative lpr	[aberrant double-negative lpr]	1.5849625007211563	3	1	0	0
27009	1520	variety of cellular activities,	[variety of cellular activities,]	1.5849625007211563	4	1	0	0
27010	1520	one molecule of mrna	[one molecule of mRNA]	1.5849625007211563	4	1	0	0
27011	1520	interaction with general factor	[interaction with general factors]	1.5849625007211563	4	1	0	0
27012	1520	factor kappa b activation	[factor kappa B activation]	1.5849625007211563	4	2	2	2
27013	1520	B-cell transcription factor	[B-cell transcription factor]	1.5849625007211563	3	2	2	2
27014	1520	stimulus in T cell	[stimuli in T cells]	1.5849625007211563	4	1	0	0
27015	1520	sv40 promoter specific protein-1	[SV40 promoter specific protein-1]	1.5849625007211563	4	1	0	0
27016	1520	basis of binding	[basis of binding]	1.5849625007211563	3	1	0	0
27017	1520	X2 NF-X2 binds.	[X2 NF-X2 binds.]	1.5849625007211563	3	1	0	0
27018	1520	addition to normal role	[addition to normal role]	1.5849625007211563	4	1	0	0
27019	1520	nf-kappa b /rel factor	[NF-kappa B /Rel factors]	1.5849625007211563	4	1	0	0
27020	1520	growth factor suramin	[growth factors suramin]	1.5849625007211563	3	1	0	0
27021	1520	element for PMA	[element for PMA]	1.5849625007211563	3	2	2	2
27022	1520	LTR from a pathogenic	[LTR from a pathogenic]	1.5849625007211563	4	1	0	0
27023	1520	relationship of this parameter	[relationship of these parameters]	1.5849625007211563	4	1	0	0
27024	1520	novel function of iNO	[novel function of iNO]	1.5849625007211563	4	1	0	0
27025	1520	analysis of mouse strain	[analysis of mouse strains]	1.5849625007211563	4	2	2	2
27026	1520	loss of a complex	[loss of a complex]	1.5849625007211563	4	1	0	0
27027	1520	antigen stimulation, precursor	[antigen stimulation, precursor]	1.5849625007211563	3	1	0	0
27028	1520	serine protease factor VIIa	[serine protease factor VIIa]	1.5849625007211563	4	1	0	0
27029	1520	peptide/glycoprotein 96 complex	[peptide/glycoprotein 96 complexes]	1.5849625007211563	3	1	0	0
27030	1520	small nuclear rna gene	[small nuclear RNA genes]	1.5849625007211563	4	2	2	2
27031	1520	stimulus include anti-CD3 PMA	[stimuli including anti-CD3 PMA]	1.5849625007211563	4	1	0	0
27032	1520	normal phagocyte function	[normal phagocyte functions]	1.5849625007211563	3	1	0	0
27033	1520	perforin- cell line	[perforin-expressing cell lines]	1.5849625007211563	3	1	0	0
27034	1520	human lymphocyte activation	[human lymphocyte activation]	1.5849625007211563	3	2	1	1
27035	1520	abort the potential	[aborting the potential]	1.5849625007211563	3	1	0	0
27036	1520	process of hypermutation	[process of hypermutation]	1.5849625007211563	3	2	1	1
27037	1520	immunologically related octamer-binding protein	[immunologically related octamer-binding protein]	1.5849625007211563	4	1	0	0
27038	1520	human vein cell HUVECs	[human vein cells HUVECs]	1.5849625007211563	4	2	2	2
27039	1520	Finally, functional activation	[Finally, functional activation]	1.5849625007211563	3	1	0	0
27040	1520	transcription factor stat1	[transcription factor Stat1]	1.5849625007211563	3	2	1	1
27041	1520	PU.1 (the Spi-1 oncogene	[PU.1 (the Spi-1 oncogene]	1.5849625007211563	4	1	0	0
27042	1520	rest g0/g1 configuration	[resting G0/G1 configuration]	1.5849625007211563	3	1	0	0
27043	1520	antioxidant pyrrolidine dithiocarbarmate pdtc	[antioxidant pyrrolidine dithiocarbarmate PDTC]	1.5849625007211563	4	1	0	0
27044	1520	specific cell target	[specific cell targets]	1.5849625007211563	3	1	0	0
27045	1520	human retinoid-X receptor alpha	[human retinoid-X receptor alpha]	1.5849625007211563	4	1	0	0
27046	1520	anion exchange chromatography	[anion exchange chromatography]	1.5849625007211563	3	1	0	0
27047	1520	lymphoma of low malignancy	[lymphomas of low malignancy]	1.5849625007211563	4	1	0	0
27048	1520	mitogen T cell proliferation	[mitogen T cell proliferation]	1.5849625007211563	4	1	0	0
27049	1520	1 bp insertion result	[1 bp insertion resulting]	1.5849625007211563	4	1	0	0
27050	1520	cell development by type	[cell development by type]	1.5849625007211563	4	1	0	0
27051	1520	lipopolysaccharide-induced expression c-jun	[lipopolysaccharide-induced expression c-jun]	1.5849625007211563	3	1	0	0
27052	1520	315 base pair	[315 base pairs]	1.5849625007211563	3	1	0	0
27053	1520	Effect of tpa	[Effects of TPA]	1.5849625007211563	3	1	0	0
27054	1520	CsA serum concentration	[CsA serum concentrations]	1.5849625007211563	3	1	0	0
27055	1520	box 3 motif	[box 3 motifs]	1.5849625007211563	3	1	0	0
27056	1520	inhibitor of macrophage activation	[inhibitor of macrophage activation]	1.5849625007211563	4	1	0	0
27057	1520	process of monocyte differentiation	[process of monocyte differentiation]	1.5849625007211563	4	1	0	0
27058	1520	loss of STAT1	[loss of STAT1]	1.5849625007211563	3	1	0	0
27059	1520	immediate early gene transcription	[immediate early gene transcription]	1.5849625007211563	4	1	0	0
27060	1520	complex with dna,	[complex with DNA,]	1.5849625007211563	3	1	0	0
27061	1520	serine /threonine kinase akt/pkb	[serine /threonine kinase Akt/PKB]	1.5849625007211563	4	1	0	0
27062	1520	antibody to il-1	[antibodies to IL-1]	1.5849625007211563	3	1	0	0
27063	1520	specific extracellular matrix process	[specific extracellular matrix processes]	1.5849625007211563	4	1	0	0
27064	1520	low constitutive level	[low constitutive level]	1.5849625007211563	3	2	1	1
27065	1520	entire hGR cDNA	[entire hGR cDNA]	1.5849625007211563	3	1	0	0
27066	1520	large crossreacting protein	[larger crossreacting protein]	1.5849625007211563	3	1	0	0
27067	1520	as whole blood histamine	[as whole blood histamine]	1.5849625007211563	4	1	0	0
27068	1520	kinase-specific phosphatase mkp-1	[kinase-specific phosphatase MKP-1]	1.5849625007211563	3	1	0	0
27069	1520	induction of activity	[induction of activity]	1.5849625007211563	3	2	2	2
27070	1520	high-level e1a oncoprotein expression	[high-level E1A oncoprotein expression]	1.5849625007211563	4	1	0	0
27071	1520	phosphatidylinositol 3-kinase with CD28	[phosphatidylinositol 3-kinase with CD28]	1.5849625007211563	4	1	0	0
27072	1520	molecular mechanism underlie immunosenescence	[molecular mechanisms underlying immunosenescence]	1.5849625007211563	4	1	0	0
27073	1520	promonocytic cell line U1	[promonocytic cell line U1]	1.5849625007211563	4	1	0	0
27074	1520	bear mc38 colon adenocarcinoma	[bearing MC38 colon adenocarcinoma]	1.5849625007211563	4	1	0	0
27075	1520	ltr-modified Tat mutant	[LTR-modified Tat mutants]	1.5849625007211563	3	1	0	0
27076	1520	fos proto-oncogene family	[fos proto-oncogene family]	1.5849625007211563	3	1	0	0
27077	1520	stimulation-dependent signal transduction	[stimulation-dependent signal transduction]	1.5849625007211563	3	1	0	0
27078	1520	respective biological function	[respective biological functions]	1.5849625007211563	3	1	0	0
27079	1520	presence of colimycin	[presence of colimycin]	1.5849625007211563	3	1	0	0
27080	1520	disrupt a binding site	[disrupting a binding site]	1.5849625007211563	4	1	0	0
27081	1520	development of 20-methyl derivative	[development of 20-methyl derivatives]	1.5849625007211563	4	1	0	0
27082	1520	pattern of c-myb	[pattern of c-myb]	1.5849625007211563	3	1	0	0
27083	1520	interleukin 6-induced differentiation	[Interleukin 6-induced differentiation]	1.5849625007211563	3	1	0	0
27084	1520	reporter plasmid dependent	[reporter plasmid dependent]	1.5849625007211563	3	1	0	0
27085	1520	high level of tnf-alpha	[higher levels of TNF-alpha]	1.5849625007211563	4	1	0	0
27086	1520	U937 promonocytic cell line	[U937 promonocytic cell line]	1.5849625007211563	4	1	0	0
27087	1520	plasma membrane by ascorbate	[plasma membrane by ascorbate]	1.5849625007211563	4	1	0	0
27088	1520	thus identify a mechanism	[thus identifying a mechanism]	1.5849625007211563	4	1	0	0
27089	1520	clinically unaffected family member	[clinically unaffected family members]	1.5849625007211563	4	1	0	0
27090	1520	patient with pseudohypoaldosteronism	[patients with pseudohypoaldosteronism]	1.5849625007211563	3	2	2	2
27091	1520	EBV early promoter bmrf1	[EBV early promoter BMRF1]	1.5849625007211563	4	1	0	0
27092	1520	factor- specific coactivator	[factor- specific coactivator]	1.5849625007211563	3	1	0	0
27093	1520	control subject 125.6	[control subjects 125.6]	1.5849625007211563	3	1	0	0
27094	1520	thrombin-induced Ca2+ ]i rise	[thrombin-induced Ca2+ ]i rise]	1.5849625007211563	4	1	0	0
27095	1520	prevention of the development	[prevention of the development]	1.5849625007211563	4	1	0	0
27096	1520	NF-kappa b1 gene	[NF-kappa B1 gene]	1.5849625007211563	3	1	0	0
27097	1520	second week of treatment.	[second week of treatment.]	1.5849625007211563	4	1	0	0
27098	1520	nuclear import process	[nuclear import process]	1.5849625007211563	3	1	0	0
27099	1520	p53 -independent pathway (s)	[p53 -independent pathway (s)]	1.5849625007211563	4	1	0	0
27100	1520	peripheral blood neutrophil count	[peripheral blood neutrophil counts]	1.5849625007211563	4	1	0	0
27101	1520	nuclei of adherent monocyte	[nuclei of adherent monocytes]	1.5849625007211563	4	1	0	0
27102	1520	follow lymphocyte activation	[following lymphocyte activation]	1.5849625007211563	3	1	0	0
27103	1520	GSH:oxidized gsh gssg ratio	[GSH:oxidized GSH GSSG ratio]	1.5849625007211563	4	1	0	0
27104	1520	result of the influence	[result of the influence]	1.5849625007211563	4	1	0	0
27105	1520	recruitment of transcriptional factor	[recruitment of transcriptional factors]	1.5849625007211563	4	1	0	0
27106	1520	presence of EBNA2 antibody	[presence of EBNA2 antibodies]	1.5849625007211563	4	1	0	0
27107	1520	cDNA clone CHEMR1	[cDNA clone CHEMR1]	1.5849625007211563	3	1	0	0
27108	1520	increase in the proportion	[increase in the proportion]	1.5849625007211563	4	1	0	0
27109	1520	development of rejection	[development of rejection]	1.5849625007211563	3	2	1	1
27110	1520	PEBP2betaMYH11 transgenic mouse	[PEBP2betaMYH11 transgenic mice]	1.5849625007211563	3	1	0	0
27111	1520	dominant negative creb	[dominant negative CREB]	1.5849625007211563	3	1	0	0
27112	1520	nuclear nf-kappa b binding	[nuclear NF-kappa B binding]	1.5849625007211563	4	1	0	0
27113	1520	5' -flanking sequence	[5' -flanking sequence]	1.5849625007211563	3	1	0	0
27114	1520	hepatic leukemia factor	[hepatic leukemia factor]	1.5849625007211563	3	2	2	2
27115	1520	novel th protein	[novel TH protein]	1.5849625007211563	3	1	0	0
27116	1520	glucocorticoid receptor activation	[glucocorticoid receptor activation]	1.5849625007211563	3	1	0	0
27117	1520	previously unidentified target gene	[previously unidentified target genes]	1.5849625007211563	4	1	0	0
27118	1520	transformation of bone marrow	[Transformation of bone marrow]	1.5849625007211563	4	1	0	0
27119	1520	endothelium with leukocyte adhesion	[endothelium with leukocyte adhesion]	1.5849625007211563	4	1	0	0
27120	1520	form of the product	[form of the product]	1.5849625007211563	4	1	0	0
27121	1520	IL-2 receptor beta	[IL-2 receptor beta]	1.5849625007211563	3	1	0	0
27122	1520	conversion in the blood	[conversion in the blood]	1.5849625007211563	4	1	0	0
27123	1520	marker of differentiation	[marker of differentiation]	1.5849625007211563	3	2	2	2
27124	1520	CD4 cell proliferation	[CD4 cell proliferation]	1.5849625007211563	3	1	0	0
27125	1520	serotonin reuptake inhibitor sris	[serotonin reuptake inhibitors SRIs]	1.5849625007211563	4	1	0	0
27126	1520	arterial intima beneath ec	[arterial intima beneath EC]	1.5849625007211563	4	1	0	0
27127	1520	two fibrinogen-binding integrin	[two fibrinogen-binding integrins]	1.5849625007211563	3	1	0	0
27128	1520	activation of hormone receptors,	[activation of hormone receptors,]	1.5849625007211563	4	1	0	0
27129	1520	requirement for PMA	[requirement for PMA]	1.5849625007211563	3	1	0	0
27130	1520	important negative regulator	[important negative regulators]	1.5849625007211563	3	1	0	0
27131	1520	dimer of Fos	[dimers of Fos]	1.5849625007211563	3	1	0	0
27132	1520	activation-dependent fas promoter induction	[activation-dependent fas promoter induction]	1.5849625007211563	4	1	0	0
27133	1520	only one tumor.	[only one tumor.]	1.5849625007211563	3	1	0	0
27134	1520	diverse phenotype of Nef	[diverse phenotypes of Nef]	1.5849625007211563	4	1	0	0
27135	1520	hybrid of the chromosome	[hybrids of the chromosomes]	1.5849625007211563	4	1	0	0
27136	1520	Peripheral blood monocyte	[Peripheral blood monocytes]	1.5849625007211563	3	1	0	0
27137	1520	critical immunoregulatory cytokine	[critical immunoregulatory cytokine]	1.5849625007211563	3	1	0	0
27138	1520	Spi-B binding site	[Spi-B binding site]	1.5849625007211563	3	1	0	0
27139	1520	response to stimuli,	[response to stimuli,]	1.5849625007211563	3	2	2	2
27140	1520	ATL leukemic cell	[ATL leukemic cells]	1.5849625007211563	3	1	0	0
27141	1520	evidence for autoregulation	[evidence for autoregulation]	1.5849625007211563	3	1	0	0
27142	1520	endogenous steroid hormone	[Endogenous steroid hormones]	1.5849625007211563	3	1	0	0
27143	1520	repression by this fusion	[repression by these fusions]	1.5849625007211563	4	1	0	0
27144	1520	Stat6 -express Jurkat cell	[Stat6 -expressing Jurkat cells]	1.5849625007211563	4	1	0	0
27145	1520	state of chronic activation	[state of chronic activation]	1.5849625007211563	4	1	0	0
27146	1520	cd3-cd16+ natural killer( NK	[CD3-CD16+ natural killer( NK]	1.5849625007211563	4	1	0	0
27147	1520	gr level in relation	[GR levels in relation]	1.5849625007211563	4	1	0	0
27148	1520	epithelial cell-initiated inflammation	[Epithelial cell-initiated inflammation]	1.5849625007211563	3	1	0	0
27149	1520	extinction of ig gene	[extinction of Ig genes]	1.5849625007211563	4	1	0	0
27150	1520	several t-cell epitope	[several T-cell epitopes]	1.5849625007211563	3	1	0	0
27151	1520	cd8(+) T cell	[CD8(+) T cells]	1.5849625007211563	3	3	2	1
27152	1520	block ca2+ flux	[blocking Ca2+ flux]	1.5849625007211563	3	1	0	0
27153	1520	other related result	[other related results]	1.5849625007211563	3	1	0	0
27154	1520	human cDNA clone	[human cDNA clone]	1.5849625007211563	3	2	1	1
27155	1520	common gamma chain	[common gamma chain]	1.5849625007211563	3	2	1	1
27156	1520	protein of unknown function	[protein of unknown function]	1.5849625007211563	4	1	0	0
27157	1520	expression of functional icam-1	[expression of functional ICAM-1]	1.5849625007211563	4	1	0	0
27158	1520	quantitative immunofluorescence p	[quantitative immunofluorescence P]	1.5849625007211563	3	1	0	0
27159	1520	combination of this agent	[combinations of these agents]	1.5849625007211563	4	1	0	0
27160	1520	specific promoter site	[specific promoter sites]	1.5849625007211563	3	1	0	0
27161	1520	hiv-1 dse bind heterodimer	[HIV-1 DSE bind heterodimers]	1.5849625007211563	4	1	0	0
27162	1520	modulation by cyclosporin a	[modulation by cyclosporin A]	1.5849625007211563	4	1	0	0
27163	1520	th1 cell-mediated immune response	[Th1 cell-mediated immune responses]	1.5849625007211563	4	1	0	0
27164	1520	specific cell fate development	[specific cell fate development]	1.5849625007211563	4	1	0	0
27165	1520	200 to 580 kb.	[200 to 580 kb.]	1.5849625007211563	4	1	0	0
27166	1520	gene product esc	[gene product Esc]	1.5849625007211563	3	1	0	0
27167	1520	stat in CLL cell	[STAT in CLL cells]	1.5849625007211563	4	1	0	0
27168	1520	two distinct enhancer element	[two distinct enhancer elements]	1.5849625007211563	4	1	0	0
27169	1520	transient cotransfection experiment	[transient cotransfection experiments]	1.5849625007211563	3	1	0	0
27170	1520	NF-Y -responsive DQbeta promoter	[NF-Y -responsive DQbeta promoter]	1.5849625007211563	4	1	0	0
27171	1520	untreated thp-1 cell	[untreated THP-1 cells]	1.5849625007211563	3	2	1	1
27172	1520	group b type 35.	[group B type 35.]	1.5849625007211563	4	1	0	0
27173	1520	TNF resistance in vitro	[TNF resistance in vitro]	1.5849625007211563	4	1	0	0
27174	1520	number of diseases,	[number of diseases,]	1.5849625007211563	3	1	0	0
27175	1520	suppression of ap-1 activity	[suppression of AP-1 activity]	1.5849625007211563	4	2	2	2
27176	1520	normal lymphoid cell	[normal lymphoid cells]	1.5849625007211563	3	1	0	0
27177	1520	nk-derived polya+ rna	[NK-derived polyA+ RNA]	1.5849625007211563	3	1	0	0
27178	1520	KB-enhancer target sequence	[KB-enhancer target sequence]	1.5849625007211563	3	1	0	0
27179	1520	cyclosporin a CsA factor	[cyclosporin A CsA factor]	1.5849625007211563	4	1	0	0
27180	1520	rest go t-cell	[resting Go T-cells]	1.5849625007211563	3	1	0	0
27181	1520	prolonged cyclic pressure-stretch strain	[prolonged cyclic pressure-stretching strain]	1.5849625007211563	4	1	0	0
27182	1520	pre-exist cytoplasmic subunit	[pre-existing cytoplasmic subunit]	1.5849625007211563	3	1	0	0
27183	1520	type of samples.	[types of samples.]	1.5849625007211563	3	1	0	0
27184	1520	B2 subunit promoter region	[B2 subunit promoter region]	1.5849625007211563	4	1	0	0
27185	1520	human leucocyte in woman	[human leucocytes in women]	1.5849625007211563	4	2	2	2
27186	1520	vitro binding assay	[vitro binding assays]	1.5849625007211563	3	1	0	0
27187	1520	function of LEF-1	[function of LEF-1]	1.5849625007211563	3	1	0	0
27188	1520	clone in each group	[clones in each group]	1.5849625007211563	4	1	0	0
27189	1520	alter phosphatidyl inositol level	[altering phosphatidyl inositol levels]	1.5849625007211563	4	1	0	0
27190	1520	calcium dependent activation	[Calcium dependent activation]	1.5849625007211563	3	1	0	0
27191	1520	Interleukin-9 receptor (il-9r) complex	[Interleukin-9 receptor (IL-9R) complex]	1.5849625007211563	4	1	0	0
27192	1520	nervous system-derived (n-oct) protein	[nervous system-derived (N-Oct) proteins]	1.5849625007211563	4	1	0	0
27193	1520	G76 128-135 L128G	[G76 128-135 L128G]	1.5849625007211563	3	1	0	0
27194	1520	T cell-specific fashion	[T cell-specific fashion]	1.5849625007211563	3	1	0	0
27195	1520	two explanation for hyporesponsiveness	[Two explanations for hyporesponsiveness]	1.5849625007211563	4	1	0	0
27196	1520	c-fo for degradation,	[c-Fos for degradation,]	1.5849625007211563	3	1	0	0
27197	1520	bHLH- hsp90 interaction	[bHLH- hsp90 interaction]	1.5849625007211563	3	1	0	0
27198	1520	PMA RA u937 cell	[PMA RA U937 cells]	1.5849625007211563	4	1	0	0
27199	1520	62 18% loss	[62 18% loss]	1.5849625007211563	3	1	0	0
27200	1520	a (hmg-coa) reductase	[A (HMG-CoA) reductase]	1.5849625007211563	3	1	0	0
27201	1520	gr kappa b	[GR kappa B]	1.5849625007211563	3	1	0	0
27202	1520	treatment with PDTC	[treatment with PDTC]	1.5849625007211563	3	1	0	0
27203	1520	more immature b-cell line	[more immature B-cell line]	1.5849625007211563	4	1	0	0
27204	1520	block to rna elongation	[block to RNA elongation]	1.5849625007211563	4	1	0	0
27205	1520	multimerized octamer enhancer element	[multimerized octamer enhancer element]	1.5849625007211563	4	1	0	0
27206	1520	three patient with php	[three patients with PHP]	1.5849625007211563	4	1	0	0
27207	1520	diurnal rhythm of acth	[diurnal rhythm of ACTH]	1.5849625007211563	4	1	0	0
27208	1520	patient with bronchial asthma	[patients with bronchial asthma]	1.5849625007211563	4	1	0	0
27209	1520	cell of most lineage	[cells of most lineages]	1.5849625007211563	4	2	2	2
27210	1520	inhibition of c-fo expression	[inhibition of c-fos expression]	1.5849625007211563	4	1	0	0
27211	1520	vitro protein truncation	[vitro protein truncation]	1.5849625007211563	3	1	0	0
27212	1520	Ets bind motif 93	[Ets binding motifs 93]	1.5849625007211563	4	1	0	0
27213	1520	intracellular accumulation of cholesterol	[intracellular accumulation of cholesterol]	1.5849625007211563	4	1	0	0
27214	1520	involvement of p50	[involvement of p50]	1.5849625007211563	3	1	0	0
27215	1520	long term glucocorticoid treatment	[long term glucocorticoid treatment]	1.5849625007211563	4	1	0	0
27216	1520	thp-1 monocytic leukemia cell	[THP-1 monocytic leukemia cells]	1.5849625007211563	4	2	1	1
27217	1520	approximately 310 binding sites/nucleus	[approximately 310 binding sites/nucleus]	1.5849625007211563	4	1	0	0
27218	1520	major proinflammatory cytokine	[major proinflammatory cytokines]	1.5849625007211563	3	2	1	1
27219	1520	interleukin-2 il-2 secretion	[interleukin-2 IL-2 secretion]	1.5849625007211563	3	1	0	0
27220	1520	NF-kappa B1 gene	[NF-kappa B1 gene]	1.5849625007211563	3	1	0	0
27221	1520	transient overexpression of htafii105	[Transient overexpression of hTAFII105]	1.5849625007211563	4	1	0	0
27222	1520	antibody for p65	[antibodies for p65]	1.5849625007211563	3	1	0	0
27223	1520	activity of the promoter	[activity of the promoter]	1.5849625007211563	4	2	1	1
27224	1520	alternative tat function	[alternative Tat function]	1.5849625007211563	3	1	0	0
27225	1520	mediator of beta-casein expression	[mediator of beta-casein expression]	1.5849625007211563	4	1	0	0
27226	1520	field gel electrophoresis analysis	[field gel electrophoresis analysis]	1.5849625007211563	4	1	0	0
27227	1520	role in il-2 production	[role in IL-2 production]	1.5849625007211563	4	1	0	0
27228	1520	tax -responsive element	[Tax -responsive element]	1.5849625007211563	3	2	2	2
27229	1520	peak at min.	[peaking at min.]	1.5849625007211563	3	2	2	2
27230	1520	Peripheral blood lymphocyte PBL	[Peripheral blood lymphocytes PBL]	1.5849625007211563	4	2	1	1
27231	1520	lymphoblastoid T J.Jhan	[lymphoblastoid T J.Jhan]	1.5849625007211563	3	1	0	0
27232	1520	expression cloning of c-Jun	[Expression cloning of c-Jun]	1.5849625007211563	4	1	0	0
27233	1520	primary leukemia cell	[primary leukemia cells]	1.5849625007211563	3	2	1	1
27234	1520	b cell activator Oct-2	[B cell activator Oct-2]	1.5849625007211563	4	1	0	0
27235	1520	only one (2%)	[only one (2%)]	1.5849625007211563	3	1	0	0
27236	1520	lineage choice between T	[lineage choice between T]	1.5849625007211563	4	1	0	0
27237	1520	basal nf kappab activation	[basal NF kappaB activation]	1.5849625007211563	4	1	0	0
27238	1520	recombinant herpes simplex virus-1	[recombinant herpes simplex virus-1]	1.5849625007211563	4	1	0	0
27239	1520	hematopoietic cell other	[hematopoietic cells other]	1.5849625007211563	3	1	0	0
27240	1520	long clinical effect	[long-term clinical effects]	1.5849625007211563	3	1	0	0
27241	1520	different transactivation property	[different transactivation properties]	1.5849625007211563	3	1	0	0
27242	1520	kappa b consensus sequence	[kappa B consensus sequences]	1.5849625007211563	4	1	0	0
27243	1520	early RA addition	[early RA addition]	1.5849625007211563	3	1	0	0
27244	1520	origin of a subset	[origin of a subset]	1.5849625007211563	4	1	0	0
27245	1520	ap-1 -dependent transcriptional activity	[AP-1 -dependent transcriptional activity]	1.5849625007211563	4	1	0	0
27246	1520	tissue-specific transcriptional activator ebf	[tissue-specific transcriptional activator EBF]	1.5849625007211563	4	1	0	0
27247	1520	dominant negative phenotype	[dominant negative phenotype]	1.5849625007211563	3	1	0	0
27248	1520	results--reaction in comedo carcinoma	[RESULTS--Reactions in comedo carcinomas]	1.5849625007211563	4	1	0	0
27249	1520	nf-kappab n-terminal kinase activation	[NF-kappaB N-terminal kinase activation]	1.5849625007211563	4	1	0	0
27250	1520	highly conserved, ubiquitous protein	[highly conserved, ubiquitous protein]	1.5849625007211563	4	1	0	0
27251	1520	dissect the biochemical event	[dissecting the biochemical events]	1.5849625007211563	4	1	0	0
27252	1520	increase phosphorylation level	[increasing phosphorylation level]	1.5849625007211563	3	1	0	0
27253	1520	terminal differentiation of hl-60	[terminal differentiation of HL-60]	1.5849625007211563	4	1	0	0
27254	1520	limited number of cell	[limited number of cells]	1.5849625007211563	4	1	0	0
27255	1520	clonogenic cell growth	[clonogenic cell growth]	1.5849625007211563	3	1	0	0
27256	1520	NK- cell lineage	[NK- cell lineages]	1.5849625007211563	3	1	0	0
27257	1520	NF-kB T cell gene	[NF-kB T cell genes]	1.5849625007211563	4	1	0	0
27258	1520	il-4 -specific gene expression	[IL-4 -specific gene expression]	1.5849625007211563	4	1	0	0
27259	1520	one breast tissue abnormality	[one breast tissue abnormalities]	1.5849625007211563	4	1	0	0
27260	1520	inactive precursor, lyso-platelet-activating factor	[inactive precursor, lyso-platelet-activating factor]	1.5849625007211563	4	1	0	0
27261	1520	-3 DNA binding ability	[-3 DNA binding ability]	1.5849625007211563	4	1	0	0
27262	1520	steroid/thyroid hormone receptor superfamily	[steroid/thyroid hormone receptor superfamily]	1.5849625007211563	4	1	0	0
27263	1520	other mature haematopoietic population	[other mature haematopoietic populations]	1.5849625007211563	4	1	0	0
27264	1520	recombinant vp16 fusion protein	[recombinant VP16 fusion proteins]	1.5849625007211563	4	1	0	0
27265	1520	three order of magnitude	[three orders of magnitude]	1.5849625007211563	4	2	2	2
27266	1520	rapid proteolytic degradation	[rapid proteolytic degradation]	1.5849625007211563	3	1	0	0
27267	1520	absence of prior activation,	[absence of prior activation,]	1.5849625007211563	4	1	0	0
27268	1520	synthesis of ig	[synthesis of Ig]	1.5849625007211563	3	1	0	0
27269	1520	tar-deleted mutant of hiv-1	[TAR-deleted mutants of HIV-1]	1.5849625007211563	4	1	0	0
27270	1520	supernatant from lncap cell	[supernatants from LNCaP cells]	1.5849625007211563	4	1	0	0
27271	1520	protein tyrosine kinase PTK	[protein tyrosine kinases PTK]	1.5849625007211563	4	1	0	0
27272	1520	exception of a subset	[exception of a subset]	1.5849625007211563	4	1	0	0
27273	1520	TNF-alpha a cytokine	[TNF-alpha a cytokine]	1.5849625007211563	3	1	0	0
27274	1520	patient with myelomonocytic leukemia	[patient with myelomonocytic leukemia]	1.5849625007211563	4	1	0	0
27275	1520	interleukin receptor alpha subunit	[interleukin receptor alpha subunit]	1.5849625007211563	4	2	2	2
27276	1520	tumeric a ingredient	[tumeric an ingredient]	1.5849625007211563	3	1	0	0
27277	1520	t-cell clonal expansion	[T-cell clonal expansion]	1.5849625007211563	3	1	0	0
27278	1520	catalytically active ne	[catalytically active NE]	1.5849625007211563	3	1	0	0
27279	1520	antibody to FasL	[antibody to FasL]	1.5849625007211563	3	1	0	0
27280	1520	immunohistochemical procedure avidin-biotin complex	[immunohistochemical procedure avidin-biotin complex]	1.5849625007211563	4	1	0	0
27281	1520	role of family member	[roles of family members]	1.5849625007211563	4	2	2	2
27282	1520	germline transcriptional activation	[germline transcriptional activation]	1.5849625007211563	3	1	0	0
27283	1520	detectable activation in neutrophil	[detectable activation in neutrophils]	1.5849625007211563	4	1	0	0
27284	1520	intercellular adhesion molecule icam-1	[intercellular adhesion molecule ICAM-1]	1.5849625007211563	4	1	0	0
27285	1520	constitutive expression of bcl-xl	[constitutive expression of bcl-xl]	1.5849625007211563	4	1	0	0
27286	1520	functional, DNA binding form	[functional, DNA binding form]	1.5849625007211563	4	1	0	0
27287	1520	cd34(+) blast cell	[CD34(+) blast cells]	1.5849625007211563	3	1	0	0
27288	1520	translocation of cpkc-alpha	[translocation of cPKC-alpha]	1.5849625007211563	3	1	0	0
27289	1520	myeloid transcription factor pu.1	[myeloid transcription factor PU.1]	1.5849625007211563	4	1	0	0
27290	1520	substrate for shp1	[substrates for SHP1]	1.5849625007211563	3	2	2	2
27291	1520	RT-PCR -based approach	[RT-PCR -based approach]	1.5849625007211563	3	1	0	0
27292	1520	block several KV channel	[blocking several KV channels]	1.5849625007211563	4	1	0	0
27293	1520	TATA -less promoter	[TATA -less promoters]	1.5849625007211563	3	1	0	0
27294	1520	homogeneous manner in vitro.	[homogeneous manner in vitro.]	1.5849625007211563	4	1	0	0
27295	1520	human CD40-activated b lymphocyte	[human CD40-activated B lymphocytes]	1.5849625007211563	4	1	0	0
27296	1520	effect of the antibody	[effect of the antibody]	1.5849625007211563	4	1	0	0
27297	1520	igh regulatory element	[IgH regulatory elements]	1.5849625007211563	3	1	0	0
27298	1520	phosphorylation of signal transducer	[phosphorylation of signal transducer]	1.5849625007211563	4	2	1	1
27299	1520	peri-kappa b factor	[peri-kappa B factor]	1.5849625007211563	3	1	0	0
27300	1520	acidic nh2 terminus	[acidic NH2 terminus]	1.5849625007211563	3	1	0	0
27301	1520	site of granulomatous reaction	[sites of granulomatous reactions]	1.5849625007211563	4	1	0	0
27302	1520	ras-related gtpase rac-1	[Ras-related GTPase Rac-1]	1.5849625007211563	3	1	0	0
27303	1520	kappa b kappa b	[kappa B kappa B]	1.5849625007211563	4	1	0	0
27304	1520	Ca(2+) -dependent pathway	[Ca(2+) -dependent pathways]	1.5849625007211563	3	1	0	0
27305	1520	two AP-1 site	[two AP-1 sites]	1.5849625007211563	3	2	1	1
27306	1520	aberrant expression of fasL	[aberrant expression of fasL]	1.5849625007211563	4	1	0	0
27307	1520	neutralize antiserum against ifn-gamma	[Neutralizing antiserum against IFN-gamma]	1.5849625007211563	4	1	0	0
27308	1520	intrinsic abnormality in ability	[intrinsic abnormality in ability]	1.5849625007211563	4	1	0	0
27309	1520	activity in T cell	[activity in T cells]	1.5849625007211563	4	2	1	1
27310	1520	only 1 signal molecule	[only 1 signaling molecule]	1.5849625007211563	4	1	0	0
27311	1520	hypothesis the consequence	[hypothesis the consequence]	1.5849625007211563	3	1	0	0
27312	1520	dimerization domain of KBF1/p50	[dimerization domain of KBF1/p50]	1.5849625007211563	4	1	0	0
27313	1520	contain the primary translocation	[containing the primary translocation]	1.5849625007211563	4	1	0	0
27314	1520	serum amyloid A SAA	[Serum amyloid A SAA]	1.5849625007211563	4	1	0	0
27315	1520	interaction with dna.	[interaction with DNA.]	1.5849625007211563	3	1	0	0
27316	1520	four different method	[Four different methods]	1.5849625007211563	3	1	0	0
27317	1520	balance between B-cell proliferation	[balance between B-cell proliferation]	1.5849625007211563	4	1	0	0
27318	1520	complete T cell activation	[complete T cell activation]	1.5849625007211563	4	2	1	1
27319	1520	association with other	[association with other]	1.5849625007211563	3	1	0	0
27320	1520	regulation of the promoter	[regulation of the promoter]	1.5849625007211563	4	2	2	2
27321	1520	sodium butyrate nab	[sodium butyrate NaB]	1.5849625007211563	3	1	0	0
27322	1520	CD3 antigen-derived signal	[CD3 antigen-derived signals]	1.5849625007211563	3	1	0	0
27323	1520	disruption of the complexes.	[disruption of the complexes.]	1.5849625007211563	4	1	0	0
27324	1520	effect on ebna-2 transactivation	[effect on EBNA-2 transactivation]	1.5849625007211563	4	1	0	0
27325	1520	germline brca1 mutation 2418delA	[germline BRCA1 mutation 2418delA]	1.5849625007211563	4	1	0	0
27326	1520	subgroup c strain 488	[subgroup C strain 488]	1.5849625007211563	4	1	0	0
27327	1520	follow hydrocortisone injection	[following hydrocortisone injection]	1.5849625007211563	3	2	1	1
27328	1520	large number of mutant	[larger number of mutants]	1.5849625007211563	4	1	0	0
27329	1520	various immune mechanism	[various immune mechanisms]	1.5849625007211563	3	1	0	0
27330	1520	increase in calcium concentration	[increase in calcium concentration]	1.5849625007211563	4	1	0	0
27331	1520	fresh antigen-presenting cell	[fresh antigen-presenting cells]	1.5849625007211563	3	1	0	0
27332	1520	thyrotropin receptor gene	[thyrotropin receptor gene]	1.5849625007211563	3	1	0	0
27333	1520	occupation of the promoter	[occupation of the promoters]	1.5849625007211563	4	1	0	0
27334	1520	mineralocorticoid receptor in leukocyte	[mineralocorticoid receptors in leukocytes]	1.5849625007211563	4	2	2	2
27335	1520	mode of expression.	[mode of expression.]	1.5849625007211563	3	1	0	0
27336	1520	growth within Acanthamoeba castellanii	[growth within Acanthamoeba castellanii]	1.5849625007211563	4	1	0	0
27337	1520	D3 analog MC903	[D3 analogs MC903]	1.5849625007211563	3	1	0	0
27338	1520	herpes simplex virus-1 hsv-1	[herpes simplex virus-1 HSV-1]	1.5849625007211563	4	1	0	0
27339	1520	bacterial peptide rrkykqii	[bacterial peptide RRKYKQII]	1.5849625007211563	3	1	0	0
27340	1520	protein' in vivo activity.	[protein's in vivo activity.]	1.5849625007211563	4	1	0	0
27341	1520	regulation of IL-1ra	[regulation of IL-1ra]	1.5849625007211563	3	1	0	0
27342	1520	v-(d)-j recombinase activity	[V-(D)-J recombinase activity]	1.5849625007211563	3	2	1	1
27343	1520	c-Jun amino-terminal kinase JNK	[c-Jun amino-terminal kinase JNK]	1.5849625007211563	4	1	0	0
27344	1520	chi b factor	[chi B factors]	1.5849625007211563	3	1	0	0
27345	1520	second site mutation	[second site mutations]	1.5849625007211563	3	1	0	0
27346	1520	mpl receptor binding	[Mpl receptor binding]	1.5849625007211563	3	1	0	0
27347	1520	control of the response	[control of the response]	1.5849625007211563	4	1	0	0
27348	1520	multiple ets family member	[multiple Ets family members]	1.5849625007211563	4	1	0	0
27349	1520	A20 b cell	[A20 B cells]	1.5849625007211563	3	1	0	0
27350	1520	two low-mobility complex	[two low-mobility complexes]	1.5849625007211563	3	1	0	0
27351	1520	sequence divergence among species	[sequence divergence among species]	1.5849625007211563	4	1	0	0
27352	1520	SOCS/ SSI/CIS gene family	[SOCS/ SSI/CIS gene family]	1.5849625007211563	4	1	0	0
27353	1520	mass of kda.	[mass of kDa.]	1.5849625007211563	3	2	2	2
27354	1520	nf-kappa b gene	[NF-kappa B genes]	1.5849625007211563	3	2	2	2
27355	1520	mrna stability assay	[mRNA stability assay]	1.5849625007211563	3	1	0	0
27356	1520	expression of mds1/evi1	[expression of MDS1/EVI1]	1.5849625007211563	3	1	0	0
27357	1520	level of rrna	[levels of mRNAs]	1.5849625007211563	3	2	1	1
27358	1520	reduction of myeloid progenitor	[reduction of myeloid progenitors]	1.5849625007211563	4	1	0	0
27359	1520	crh promoter activity	[CRH promoter activity]	1.5849625007211563	3	1	0	0
27360	1520	short course of estrogen	[short course of estrogen]	1.5849625007211563	4	1	0	0
27361	1520	response to extracellular stimulation	[response to extracellular stimulation]	1.5849625007211563	4	1	0	0
27362	1520	hiv-2 enhancer element	[HIV-2 enhancer element]	1.5849625007211563	3	1	0	0
27363	1520	good understanding of regulation	[Better understanding of regulation]	1.5849625007211563	4	2	2	2
27364	1520	p53 tumor-suppressor gene	[p53 tumor-suppressor gene]	1.5849625007211563	3	1	0	0
27365	1520	IL-2R(alpha) chain mrna induction	[IL-2R(alpha) chain mRNA induction]	1.5849625007211563	4	1	0	0
27366	1520	major positive regulatory element	[major positive regulatory element]	1.5849625007211563	4	1	0	0
27367	1520	proil-1beta gene transcription	[proIL-1beta gene transcription]	1.5849625007211563	3	1	0	0
27368	1520	transcription through NF-kappaB	[transcription through NF-kappaB]	1.5849625007211563	3	1	0	0
27369	1520	retinaldehyde dehydrogenase 2 RALDH2	[retinaldehyde dehydrogenase 2 RALDH2]	1.5849625007211563	4	1	0	0
27370	1520	promyelocytic leukemia cell line	[promyelocytic leukemia cell line]	1.5849625007211563	4	2	2	2
27371	1520	depletion of this subunit	[depletion of this subunit]	1.5849625007211563	4	1	0	0
27372	1520	CD30 ligand cd30l	[CD30 ligand CD30L]	1.5849625007211563	3	1	0	0
27373	1520	regulation of monocyte gene	[regulation of monocyte genes]	1.5849625007211563	4	1	0	0
27374	1520	1 enhancer-dependent transcription	[1 enhancer-dependent transcription]	1.5849625007211563	3	1	0	0
27375	1520	binding site for CVZ	[binding sites for CVZ]	1.5849625007211563	4	1	0	0
27376	1520	activity of pkb/akt	[activity of PKB/Akt]	1.5849625007211563	3	1	0	0
27377	1520	phytohemagglutinin peripheral blood lymphocyte	[phytohemagglutinin peripheral blood lymphocytes]	1.5849625007211563	4	1	0	0
27378	1520	ability of interferon alpha	[ability of interferon alpha]	1.5849625007211563	4	1	0	0
27379	1520	L. donovani tyrosine phosphorylation	[L. donovani tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
27380	1520	capacity of CD40	[capacity of CD40]	1.5849625007211563	3	1	0	0
27381	1520	helix-loop-helix protein Id-3	[helix-loop-helix protein Id-3]	1.5849625007211563	3	1	0	0
27382	1520	failure of full-length bob.1/obf.1	[failure of full-length BOB.1/OBF.1]	1.5849625007211563	4	1	0	0
27383	1520	g1 cyclin D2 protein	[G1 cyclins D2 proteins]	1.5849625007211563	4	1	0	0
27384	1520	m; controls: 1.0	[M; controls: 1.0]	1.5849625007211563	3	1	0	0
27385	1520	polymerase chain reaction analysis	[polymerase chain reaction analysis]	1.5849625007211563	4	1	0	0
27386	1520	cell of monocyte lineage	[Cells of monocyte lineage]	1.5849625007211563	4	1	0	0
27387	1520	rather slow kinetics,	[rather slow kinetics,]	1.5849625007211563	3	1	0	0
27388	1520	healthy control (4419	[healthy controls (4419]	1.5849625007211563	3	1	0	0
27389	1520	expression of proinflammatory molecule	[expression of proinflammatory molecules]	1.5849625007211563	4	1	0	0
27390	1520	acute fulminant hepatitis	[acute fulminant hepatitis]	1.5849625007211563	3	1	0	0
27391	1520	major basic protein	[major basic protein]	1.5849625007211563	3	2	2	2
27392	1520	clinical symptom of PIH	[clinical symptoms of PIH]	1.5849625007211563	4	1	0	0
27393	1520	drop in activity	[drop in activity]	1.5849625007211563	3	1	0	0
27394	1520	only negligible dna-binding activity	[only negligible DNA-binding activity]	1.5849625007211563	4	1	0	0
27395	1520	specific protease inhibitor	[specific protease inhibitors]	1.5849625007211563	3	2	1	1
27396	1520	other leukocyte lineage	[other leukocyte lineages]	1.5849625007211563	3	1	0	0
27397	1520	Authentic NFAT target	[Authentic NFAT targets]	1.5849625007211563	3	1	0	0
27398	1520	IFN signal transduction pathway	[IFN signal transduction pathway]	1.5849625007211563	4	1	0	0
27399	1520	induction of il-2 production	[induction of IL-2 production]	1.5849625007211563	4	2	1	1
27400	1520	fluorescence in-situ hybridization fish	[fluorescence in-situ hybridization FISH]	1.5849625007211563	4	1	0	0
27401	1520	nf-il-2b binding activity	[NF-IL-2B binding activity]	1.5849625007211563	3	1	0	0
27402	1520	androgen receptor assay	[androgen receptor assay]	1.5849625007211563	3	2	2	2
27403	1520	distinct subset of leukemia	[distinct subsets of leukemia]	1.5849625007211563	4	2	2	2
27404	1520	ras mutation frequency	[ras mutation frequency]	1.5849625007211563	3	1	0	0
27405	1520	normal murine T cell	[normal murine T cells]	1.5849625007211563	4	1	0	0
27406	1520	up-regulation of c-jun rrna	[up-regulation of c-jun mRNAs]	1.5849625007211563	4	1	0	0
27407	1520	expression of signal transduction	[expression of signal transduction]	1.5849625007211563	4	1	0	0
27408	1520	determinant of expression	[determinant of expression]	1.5849625007211563	3	2	2	2
27409	1520	absence of nf-kappab activity	[absence of NF-kappaB activity]	1.5849625007211563	4	1	0	0
27410	1520	T cell in eosinophil	[T cells in eosinophils]	1.5849625007211563	4	1	0	0
27411	1520	accumulation of full-length gag/pol	[accumulation of full-length gag/pol]	1.5849625007211563	4	1	0	0
27412	1520	many proinflammatory cytokine gene	[many proinflammatory cytokine genes]	1.5849625007211563	4	1	0	0
27413	1520	different pathway protect	[different pathways protecting]	1.5849625007211563	3	1	0	0
27414	1520	molecular mass for tbp7	[molecular mass for TBP7]	1.5849625007211563	4	1	0	0
27415	1520	asp to asn	[Asp to Asn]	1.5849625007211563	3	1	0	0
27416	1520	Daudi cell line	[Daudi cell line]	1.5849625007211563	3	1	0	0
27417	1520	dextran-coated charcoal assay	[dextran-coated charcoal assay]	1.5849625007211563	3	1	0	0
27418	1520	okt8+ T cell	[OKT8+ T cells]	1.5849625007211563	3	2	2	2
27419	1520	human cd86 cho-cd86	[human CD86 CHO-CD86]	1.5849625007211563	3	1	0	0
27420	1520	(control versus estrogen 10(-10)-(-6)	[(control vs estrogen 10(-10)-(-6)]	1.5849625007211563	4	1	0	0
27421	1520	RXR alpha receptor	[RXR alpha receptor]	1.5849625007211563	3	1	0	0
27422	1520	chronic leukemia patient	[chronic leukemia patients]	1.5849625007211563	3	2	2	2
27423	1520	transduce a signal result	[transducing a signal resulting]	1.5849625007211563	4	1	0	0
27424	1520	IFNgamma treatment in PMA	[IFNgamma treatment in PMA]	1.5849625007211563	4	1	0	0
27425	1520	significant number of subject	[significant number of subjects]	1.5849625007211563	4	1	0	0
27426	1520	beta 1 ligands.	[beta 1 ligands.]	1.5849625007211563	3	1	0	0
27427	1520	several sequence tag dest	[several sequence tags DESTs]	1.5849625007211563	4	1	0	0
27428	1520	Northern hybridization datum	[Northern hybridization data]	1.5849625007211563	3	1	0	0
27429	1520	rate of gene expression	[rate of gene expression]	1.5849625007211563	4	1	0	0
27430	1520	p21(waf1/cip1) protein level	[p21(WAF1/CIP1) protein levels]	1.5849625007211563	3	1	0	0
27431	1520	regulatory factor-1 gene	[regulatory factor-1 gene]	1.5849625007211563	3	2	2	2
27432	1520	development of cd34+ cell	[development of CD34+ cells]	1.5849625007211563	4	1	0	0
27433	1520	other BRCA1 allele	[other BRCA1 allele]	1.5849625007211563	3	1	0	0
27434	1520	disruption of latency	[disruption of latency]	1.5849625007211563	3	2	2	2
27435	1520	lps -specific abs	[LPS -specific Abs]	1.5849625007211563	3	1	0	0
27436	1520	furthermore, point mutation	[Furthermore, point mutations]	1.5849625007211563	3	1	0	0
27437	1520	h in cell	[h in cells]	1.5849625007211563	3	2	2	2
27438	1520	promoter specific to cell	[promoter specific to cells]	1.5849625007211563	4	1	0	0
27439	1520	camp -dependent protein kinase	[cAMP -dependent protein kinase]	1.5849625007211563	4	2	1	1
27440	1520	major virus reservoir	[major virus reservoir]	1.5849625007211563	3	1	0	0
27441	1520	human androgen receptor (humara)	[human androgen receptor (HUMARA)]	1.5849625007211563	4	1	0	0
27442	1520	nf-kb binding protein	[NF-kB binding proteins]	1.5849625007211563	3	2	1	1
27443	1520	12 unrelated family	[12 unrelated families]	1.5849625007211563	3	1	0	0
27444	1520	further Northern analysis	[Further Northern analyses]	1.5849625007211563	3	1	0	0
27445	1520	downstream c(h) gene	[downstream C(H) genes]	1.5849625007211563	3	1	0	0
27446	1520	decline in the level	[decline in the level]	1.5849625007211563	4	1	0	0
27447	1520	ubiquitous, inducible nuclear component	[ubiquitous, inducible nuclear component]	1.5849625007211563	4	1	0	0
27448	1520	prolonged period of time.	[prolonged periods of time.]	1.5849625007211563	4	1	0	0
27449	1520	effect on defensin resistance	[effect on defensin resistance]	1.5849625007211563	4	1	0	0
27450	1520	glucocorticoid in patient	[glucocorticoids in patients]	1.5849625007211563	3	2	1	1
27451	1520	granular er staining	[granular ER staining]	1.5849625007211563	3	1	0	0
27452	1520	develop immune response	[developing immune response]	1.5849625007211563	3	1	0	0
27453	1520	independent mode of action,	[independent modes of action,]	1.5849625007211563	4	1	0	0
27454	1520	u-937 myeloid leukemia cell	[U-937 myeloid leukemia cells]	1.5849625007211563	4	1	0	0
27455	1520	lack the transactivate domain	[lacking the transactivating domain]	1.5849625007211563	4	1	0	0
27456	1520	only site 2	[only site 2]	1.5849625007211563	3	1	0	0
27457	1520	consensus (a/t)gata(g/ a) motif	[consensus (A/T)GATA(G/ A) motif]	1.5849625007211563	4	1	0	0
27458	1520	action of vitamin d	[actions of vitamin D]	1.5849625007211563	4	1	0	0
27459	1520	multiple myeloma cell growth	[multiple myeloma cell growth]	1.5849625007211563	4	1	0	0
27460	1520	nearby j element	[nearby J element]	1.5849625007211563	3	1	0	0
27461	1520	IL-6 gene promoter	[IL-6 gene promoter]	1.5849625007211563	3	2	1	1
27462	1520	GM-CSF promoter sequence	[GM-CSF promoter sequence]	1.5849625007211563	3	1	0	0
27463	1520	suppress nf-kappa b mobilization	[suppressing NF-kappa B mobilization]	1.5849625007211563	4	1	0	0
27464	1520	basis of linkage analysis	[basis of linkage analysis]	1.5849625007211563	4	1	0	0
27465	1520	member of the CREB/ATF	[members of the CREB/ATF]	1.5849625007211563	4	1	0	0
27466	1520	promoter of immunoglobulin gene	[promoters of immunoglobulin genes]	1.5849625007211563	4	1	0	0
27467	1520	cortivazol than the cell	[cortivazol than the cells]	1.5849625007211563	4	2	2	2
27468	1520	mammary reduction test material	[mammary reduction test material]	1.5849625007211563	4	1	0	0
27469	1520	glucocorticoid receptor binding characteristic	[glucocorticoid receptor binding characteristics]	1.5849625007211563	4	2	1	1
27470	1520	human disease syndrome	[human disease syndromes]	1.5849625007211563	3	2	1	1
27471	1520	evidence of hypertension	[evidence of hypertension]	1.5849625007211563	3	1	0	0
27472	1520	contrast, dominant-negative cdk4	[contrast, dominant-negative cdk4]	1.5849625007211563	3	1	0	0
27473	1520	hiv replication in thymocyte	[HIV replication in thymocytes]	1.5849625007211563	4	1	0	0
27474	1520	anergic T cell clone	[anergic T cell clones]	1.5849625007211563	4	1	0	0
27475	1520	human 8e51 t-cell	[human 8e51 T-cells]	1.5849625007211563	3	1	0	0
27476	1520	transferrin receptor rrna	[transferrin receptor mRNAs]	1.5849625007211563	3	1	0	0
27477	1520	absence of pressures; activation	[absence of pressures; activation]	1.5849625007211563	4	1	0	0
27478	1520	SCMV SNE site	[SCMV SNE sites]	1.5849625007211563	3	1	0	0
27479	1520	low proliferative capacity	[Low proliferative capacity]	1.5849625007211563	3	1	0	0
27480	1520	lps treatment of macrophage	[LPS treatment of macrophages]	1.5849625007211563	4	1	0	0
27481	1520	high concentration of ca2+	[high concentrations of Ca2+]	1.5849625007211563	4	1	0	0
27482	1520	different mode of action.	[different modes of action.]	1.5849625007211563	4	1	0	0
27483	1520	binding site for CBF	[binding sites for CBF]	1.5849625007211563	4	1	0	0
27484	1520	potentially through LMP1 expression	[potentially through LMP1 expression]	1.5849625007211563	4	1	0	0
27485	1520	PPARgamma ligand a member	[PPARgamma ligand a member]	1.5849625007211563	4	1	0	0
27486	1520	approximately 70% sequence	[approximately 70% sequence]	1.5849625007211563	3	1	0	0
27487	1520	non-clonal, component of immunity	[non-clonal, component of immunity]	1.5849625007211563	4	1	0	0
27488	1520	role of corticosteroid	[role of corticosteroids]	1.5849625007211563	3	1	0	0
27489	1520	dendritic cell function	[dendritic cell function]	1.5849625007211563	3	1	0	0
27490	1520	breakpoint on both chromosome	[breakpoints on both chromosomes]	1.5849625007211563	4	1	0	0
27491	1520	nf-atp -deficient mouse	[NF-ATp -deficient mice]	1.5849625007211563	3	1	0	0
27492	1520	identity of 75.3% between	[identity of 75.3% between]	1.5849625007211563	4	1	0	0
27493	1520	pathogenesis of lung inflammation	[pathogenesis of lung inflammation]	1.5849625007211563	4	1	0	0
27494	1520	regulation in cell line	[regulation in cell lines]	1.5849625007211563	4	2	2	2
27495	1520	clue to understanding	[clue to understanding]	1.5849625007211563	3	1	0	0
27496	1520	negative clinical outcome.	[negative clinical outcome.]	1.5849625007211563	3	1	0	0
27497	1520	change in intracellular ros	[changes in intracellular ROS]	1.5849625007211563	4	1	0	0
27498	1520	26s protease from erythrocyte	[26S protease from erythrocytes]	1.5849625007211563	4	1	0	0
27499	1520	heterodimeric NF-kappa b complex	[heterodimeric NF-kappa B complex]	1.5849625007211563	4	1	0	0
27500	1520	outcome after multi-agent therapy	[outcome after multi-agent therapy]	1.5849625007211563	4	1	0	0
27501	1520	addition, Northern blot analysis	[addition, Northern blot analysis]	1.5849625007211563	4	1	0	0
27502	1520	TNF-alpha transcription start site	[TNF-alpha transcription start site]	1.5849625007211563	4	1	0	0
27503	1520	production of c-Jun	[production of c-Jun]	1.5849625007211563	3	2	2	2
27504	1520	primary human lymphoid cell	[primary human lymphoid cells]	1.5849625007211563	4	1	0	0
27505	1520	intracellular glucocorticoid receptor	[intracellular glucocorticoid receptor]	1.5849625007211563	3	2	2	2
27506	1520	human c/ebpepsilon gene	[human C/EBPepsilon gene]	1.5849625007211563	3	1	0	0
27507	1520	transition of a monocyte	[transition of a monocyte]	1.5849625007211563	4	1	0	0
27508	1520	juxtapose heterologous promoter	[juxtaposing heterologous promoters]	1.5849625007211563	3	1	0	0
27509	1520	growth of cell type	[growth of cell types]	1.5849625007211563	4	2	2	2
27510	1520	such as the hippocampus	[such as the hippocampus]	1.5849625007211563	4	1	0	0
27511	1520	nf-kappa b -dependent transcription	[NF-kappa B -dependent transcription]	1.5849625007211563	4	1	0	0
27512	1520	key leukemogenetic role	[key leukemogenetic role]	1.5849625007211563	3	1	0	0
27513	1520	primarily in ability	[primarily in ability]	1.5849625007211563	3	1	0	0
27514	1520	cytolytic effector cell function	[cytolytic effector cell function]	1.5849625007211563	4	1	0	0
27515	1520	obstructive renal disease	[obstructive renal disease]	1.5849625007211563	3	2	1	1
27516	1520	cytoplasmic NF-kappa b/rel complex	[cytoplasmic NF-kappa B/Rel complexes]	1.5849625007211563	4	1	0	0
27517	1520	ebv infection in vitro	[EBV infection in vitro]	1.5849625007211563	4	1	0	0
27518	1520	follow activation by anti-CD3	[following activation by anti-CD3]	1.5849625007211563	4	1	0	0
27519	1520	fibroblast b line	[fibroblast B line]	1.5849625007211563	3	1	0	0
27520	1520	new gene therapy strategy	[new gene therapy strategies]	1.5849625007211563	4	1	0	0
27521	1520	bipartite DNA binding domain	[bipartite DNA binding domains]	1.5849625007211563	4	1	0	0
27522	1520	activity of the mycotoxin	[activity of the mycotoxins]	1.5849625007211563	4	1	0	0
27523	1520	case of leukaemia	[cases of leukaemia]	1.5849625007211563	3	2	2	2
27524	1520	b-cell line im-9	[B-cell line IM-9]	1.5849625007211563	3	2	2	2
27525	1520	Rel /NF-kappa B	[Rel /NF-kappa B]	1.5849625007211563	3	1	0	0
27526	1520	detectable level of p52	[detectable levels of p52]	1.5849625007211563	4	1	0	0
27527	1520	General transcription factor	[General transcription factors]	1.5849625007211563	3	1	0	0
27528	1520	novel family of gene	[novel family of genes]	1.5849625007211563	4	1	0	0
27529	1520	RII substrate peptide	[RII substrate peptide]	1.5849625007211563	3	1	0	0
27530	1520	glucocorticoid in the treatment	[glucocorticoids in the treatment]	1.5849625007211563	4	1	0	0
27531	1520	novel target site	[novel target site]	1.5849625007211563	3	1	0	0
27532	1520	tumor cell proliferation	[tumor cell proliferation]	1.5849625007211563	3	1	0	0
27533	1520	stability of message	[stability of message]	1.5849625007211563	3	1	0	0
27534	1520	murine g-csf receptor	[murine G-CSF receptor]	1.5849625007211563	3	1	0	0
27535	1520	negative bl 41 cell	[negative BL 41 cells]	1.5849625007211563	4	1	0	0
27536	1520	stat1 transcription factor	[STAT1 transcription factor]	1.5849625007211563	3	1	0	0
27537	1520	relative binding affinity	[relative binding affinity]	1.5849625007211563	3	2	2	2
27538	1520	addition, binding study	[addition, binding studies]	1.5849625007211563	3	1	0	0
27539	1520	induction of AP1	[induction of AP1]	1.5849625007211563	3	2	1	1
27540	1520	state of hiv-1 cell	[state of HIV-1 cells]	1.5849625007211563	4	1	0	0
27541	1520	acid receptor alpha raralpha	[acid receptor alpha RARalpha]	1.5849625007211563	4	2	2	2
27542	1520	entire extracellular domain	[entire extracellular domain]	1.5849625007211563	3	1	0	0
27543	1520	leukocyte for cell killing.	[leukocytes for cell killing.]	1.5849625007211563	4	1	0	0
27544	1520	expression of Bcl-2	[expression of Bcl-2]	1.5849625007211563	3	1	0	0
27545	1520	lack of steroid binding	[lack of steroid binding]	1.5849625007211563	4	1	0	0
27546	1520	Ii kappa B-2	[Ii kappa B-2]	1.5849625007211563	3	1	0	0
27547	1520	Ii kappa B-1	[Ii kappa B-1]	1.5849625007211563	3	2	1	1
27548	1520	presence of cytokine	[presence of cytokines]	1.5849625007211563	3	1	0	0
27549	1520	control of normal hematopoiesis	[control of normal hematopoiesis]	1.5849625007211563	4	1	0	0
27550	1520	cord lymphocyte activation	[cord lymphocyte activation]	1.5849625007211563	3	1	0	0
27551	1520	appearance of cdc2 mrna	[appearance of cdc2 mRNA]	1.5849625007211563	4	1	0	0
27552	1520	productive lai replication	[productive LAI replication]	1.5849625007211563	3	2	1	1
27553	1520	octamer contain promoter element	[octamer containing promoter element]	1.5849625007211563	4	1	0	0
27554	1520	single-stranded conformational polymorphism SSCP	[single-stranded conformational polymorphism SSCP]	1.5849625007211563	4	1	0	0
27555	1520	prime with IFN-gamma	[Priming with IFN-gamma]	1.5849625007211563	3	1	0	0
27556	1520	molecular structure of BSAP	[molecular structure of BSAP]	1.5849625007211563	4	1	0	0
27557	1520	anti-atherogenic effect of aspirin	[anti-atherogenic effect of aspirin]	1.5849625007211563	4	1	0	0
27558	1520	microgram/ml) transcription of elam-1	[microgram/ml) transcription of ELAM-1]	1.5849625007211563	4	1	0	0
27559	1520	NF-kappa b p50-p65 heterodimer	[NF-kappa B p50-p65 heterodimer]	1.5849625007211563	4	1	0	0
27560	1520	GCR in asthmatics	[GCR in asthmatics]	1.5849625007211563	3	2	1	1
27561	1520	63 cDNA clone	[63 cDNA clones]	1.5849625007211563	3	1	0	0
27562	1520	GATA-dependent hiv-1 trans-activation	[GATA-dependent HIV-1 trans-activation]	1.5849625007211563	3	1	0	0
27563	1520	unresolved, immune reaction	[unresolved, immune reactions]	1.5849625007211563	3	1	0	0
27564	1520	approximately 200 bp	[approximately 200 bp]	1.5849625007211563	3	1	0	0
27565	1520	10(-7) m 1	[10(-7) M 1]	1.5849625007211563	3	1	0	0
27566	1520	intracellular glucocorticoid receptor gr	[intracellular glucocorticoid receptor GR]	1.5849625007211563	4	1	0	0
27567	1520	significant decrease of tcrzeta	[significant decreases of TCRzeta]	1.5849625007211563	4	1	0	0
27568	1520	double-stranded rna -binding protein	[double-stranded RNA -binding protein]	1.5849625007211563	4	1	0	0
27569	1520	hour of treatment	[hours of treatment]	1.5849625007211563	3	2	2	2
27570	1520	testosterone -bsa-induced ca2+ import	[testosterone -BSA-induced Ca2+ import]	1.5849625007211563	4	1	0	0
27571	1520	study interaction of pr	[studying interactions of PR]	1.5849625007211563	4	1	0	0
27572	1520	NF-ATc a transcription factor	[NF-ATc an transcription factor]	1.5849625007211563	4	1	0	0
27573	1520	such as 12-o-tetradecanoylphorbol-13-acetate tpa	[such as 12-O-tetradecanoylphorbol-13-acetate TPA]	1.5849625007211563	4	1	0	0
27574	1520	effect on ifn-gamma activation	[effect on IFN-gamma activation]	1.5849625007211563	4	1	0	0
27575	1520	different signal transduction pathway	[different signal transduction pathways]	1.5849625007211563	4	2	1	1
27576	1520	association between the erythrocytic	[association between the erythrocytic]	1.5849625007211563	4	1	0	0
27577	1520	p65:p50 heterodimer nf-kappa b	[p65:p50 heterodimer NF-kappa B]	1.5849625007211563	4	1	0	0
27578	1520	osteolytic bone lesion	[osteolytic bone lesions]	1.5849625007211563	3	1	0	0
27579	1520	scm-1-producer T cell line	[SCM-1-producer T cell lines]	1.5849625007211563	4	2	2	2
27580	1520	three copy of TRE-1	[three copies of TRE-1]	1.5849625007211563	4	1	0	0
27581	1520	DNA lps induction	[DNA LPS induction]	1.5849625007211563	3	1	0	0
27582	1520	Ad2 early gene	[Ad2 early genes]	1.5849625007211563	3	1	0	0
27583	1520	absence of aldosterone	[absence of aldosterone]	1.5849625007211563	3	1	0	0
27584	1520	anti-cd2 receptor antibody	[Anti-CD2 receptor antibodies]	1.5849625007211563	3	1	0	0
27585	1520	chemotactic activity for pmn	[chemotactic activity for PMNs]	1.5849625007211563	4	1	0	0
27586	1520	calcium ionophore alone,	[calcium ionophores alone,]	1.5849625007211563	3	1	0	0
27587	1520	cell with pdbu	[cells with PDBu]	1.5849625007211563	3	1	0	0
27588	1520	mitogen in t-cell	[mitogens in T-cell]	1.5849625007211563	3	1	0	0
27589	1520	modulate such activity.	[modulating such activity.]	1.5849625007211563	3	1	0	0
27590	1520	X inactivation analysis	[X inactivation analysis]	1.5849625007211563	3	2	1	1
27591	1520	basic transcription machinery	[basic transcription machinery]	1.5849625007211563	3	1	0	0
27592	1520	peripheral T cell death	[peripheral T cell death]	1.5849625007211563	4	1	0	0
27593	1520	GM-CSF receptor beta subunit	[GM-CSF receptor beta subunit]	1.5849625007211563	4	1	0	0
27594	1520	tetrahydrocortisol 13.3 mg/24h; 1.4+/-0.8)	[tetrahydrocortisol 13.3 mg/24h; 1.4+/-0.8)]	1.5849625007211563	4	1	0	0
27595	1520	development of leukaemia	[development of leukaemia]	1.5849625007211563	3	1	0	0
27596	1520	chronic hiv-1 replication	[chronic HIV-1 replication]	1.5849625007211563	3	1	0	0
27597	1520	human gata3 gene	[human GATA3 gene]	1.5849625007211563	3	2	1	1
27598	1520	E3-dependent ubiquitinylation of c-Jun	[E3-dependent ubiquitinylation of c-Jun]	1.5849625007211563	4	1	0	0
27599	1520	interleukin-2 il-2 nonresponsive state	[interleukin-2 IL-2 nonresponsive state]	1.5849625007211563	4	1	0	0
27600	1520	transduction mechanism involve ros	[transduction mechanism involving ROS]	1.5849625007211563	4	1	0	0
27601	1520	particularly T cell	[particularly T cells]	1.5849625007211563	3	1	0	0
27602	1520	signal transducer stat protein	[signal transducers Stat proteins]	1.5849625007211563	4	1	0	0
27603	1520	lower, at high doses.	[lower, at higher doses.]	1.5849625007211563	4	1	0	0
27604	1520	ligand-activated IL-10 receptor	[ligand-activated IL-10 receptor]	1.5849625007211563	3	1	0	0
27605	1520	chicken anemia virus cav	[chicken anemia virus CAV]	1.5849625007211563	4	2	1	1
27606	1520	various ankyrin-rich inhibitory protein	[various ankyrin-rich inhibitory proteins]	1.5849625007211563	4	1	0	0
27607	1520	tnf-alpha beta in monocyte	[TNF-alpha beta in monocytes]	1.5849625007211563	4	1	0	0
27608	1520	similar repeat motif	[Similar repeat motifs]	1.5849625007211563	3	1	0	0
27609	1520	cytokine-mediated inflammatory disease	[cytokine-mediated inflammatory diseases]	1.5849625007211563	3	1	0	0
27610	1520	level of transcription,	[level of transcription,]	1.5849625007211563	3	2	1	1
27611	1520	defect in the binding	[defect in the binding]	1.5849625007211563	4	1	0	0
27612	1520	interaction to DNA	[Interaction to DNA]	1.5849625007211563	3	1	0	0
27613	1520	such as alpha- CD3	[such as alpha- CD3]	1.5849625007211563	4	1	0	0
27614	1520	depletion of the population	[depletion of the population]	1.5849625007211563	4	2	2	2
27615	1520	transcription factor STAT1(alpha)	[transcription factor STAT1(alpha)]	1.5849625007211563	3	1	0	0
27616	1520	normal control (p 0.05)	[normal control (P 0.05)]	1.5849625007211563	4	1	0	0
27617	1520	vcam-1 in HUVEC	[VCAM-1 in HUVEC]	1.5849625007211563	3	1	0	0
27618	1520	inhibit calcineurin activation	[inhibiting calcineurin activation]	1.5849625007211563	3	1	0	0
27619	1520	least three distinct complex	[least three distinct complexes]	1.5849625007211563	4	1	0	0
27620	1520	important role for egr-1	[important role for egr-1]	1.5849625007211563	4	1	0	0
27621	1520	pma- nf-kappa b activity	[PMA- NF-kappa B activity]	1.5849625007211563	4	1	0	0
27622	1520	positive regulatory effect	[positive regulatory effect]	1.5849625007211563	3	2	1	1
27623	1520	110 kD protein	[110 kD proteins]	1.5849625007211563	3	1	0	0
27624	1520	hiv expression by NaB	[HIV expression by NaB]	1.5849625007211563	4	1	0	0
27625	1520	modulatory effect of monocyte	[modulatory effects of monocytes]	1.5849625007211563	4	1	0	0
27626	1520	Akv MLV transcription	[Akv MLV transcription]	1.5849625007211563	3	1	0	0
27627	1520	inhibitory p50 /p50 homodimer	[inhibitory p50 /p50 homodimer]	1.5849625007211563	4	1	0	0
27628	1520	molecular cloning of slap-130	[Molecular cloning of SLAP-130]	1.5849625007211563	4	2	1	1
27629	1520	moreover, Ba/F3 cell	[Moreover, Ba/F3 cells]	1.5849625007211563	3	1	0	0
27630	1520	two mutation between -93	[two mutations between -93]	1.5849625007211563	4	1	0	0
27631	1520	different repressive effect	[different repressive effect]	1.5849625007211563	3	2	1	1
27632	1520	patient with refractory anemia	[patients with refractory anemia]	1.5849625007211563	4	1	0	0
27633	1520	activation of hiv expression	[activation of HIV expression]	1.5849625007211563	4	1	0	0
27634	1520	cloning of slap-130	[cloning of SLAP-130]	1.5849625007211563	3	2	2	2
27635	1520	apoptosis effector protein Bak	[apoptosis effector proteins Bak]	1.5849625007211563	4	1	0	0
27636	1520	-express human cell	[-expressing human cells]	1.5849625007211563	3	2	2	2
27637	1520	ifn-gamma promoter in vivo	[IFN-gamma promoter in vivo]	1.5849625007211563	4	1	0	0
27638	1520	majority of clone	[majority of clones]	1.5849625007211563	3	1	0	0
27639	1520	exogenous recombinant Tat protein	[Exogenous recombinant Tat protein]	1.5849625007211563	4	1	0	0
27640	1520	percent proliferative life span	[percent proliferative life span]	1.5849625007211563	4	1	0	0
27641	1520	use the technique	[Using the technique]	1.5849625007211563	3	1	0	0
27642	1520	subset of T lymphocyte	[subset of T lymphocytes]	1.5849625007211563	4	1	0	0
27643	1520	full proliferative response	[full proliferative response]	1.5849625007211563	3	1	0	0
27644	1520	responsiveness of LTR construct	[Responsiveness of LTR constructs]	1.5849625007211563	4	1	0	0
27645	1520	novel e2f complex	[novel E2F complexes]	1.5849625007211563	3	1	0	0
27646	1520	chronic phase CML patient	[chronic phase CML patients]	1.5849625007211563	4	1	0	0
27647	1520	isotype-specific transcription factor	[isotype-specific transcription factor]	1.5849625007211563	3	1	0	0
27648	1520	concentration of 0.1 microM.	[concentrations of 0.1 microM.]	1.5849625007211563	4	1	0	0
27649	1520	effect of tax expression	[effect of Tax expression]	1.5849625007211563	4	2	2	2
27650	1520	lps tolerant cell	[LPS tolerant cells]	1.5849625007211563	3	1	0	0
27651	1520	mutant cell line	[mutant cell line]	1.5849625007211563	3	2	1	1
27652	1520	two 5'-most ets site	[two 5'-most Ets sites]	1.5849625007211563	4	1	0	0
27653	1520	sensitive rt-pcr assay	[sensitive RT-PCR assays]	1.5849625007211563	3	1	0	0
27654	1520	synthetic peptide mapping	[synthetic peptide mapping]	1.5849625007211563	3	1	0	0
27655	1520	least 1 hour	[least 1 hr]	1.5849625007211563	3	1	0	0
27656	1520	cellular proliferation, level	[cellular proliferation, levels]	1.5849625007211563	3	1	0	0
27657	1520	fos gene family	[fos gene families]	1.5849625007211563	3	1	0	0
27658	1520	RA autoimmune inflammation	[RA autoimmune inflammation]	1.5849625007211563	3	1	0	0
27659	1520	topoisomerase ii inhibitor	[topoisomerase II inhibitors]	1.5849625007211563	3	1	0	0
27660	1520	Interleukin-2 IL-2 gene expression	[Interleukin-2 IL-2 gene expression]	1.5849625007211563	4	1	0	0
27661	1520	differentiation program foreign	[differentiation program foreign]	1.5849625007211563	3	1	0	0
27662	1520	concomitant cell proliferation	[concomitant cell proliferation]	1.5849625007211563	3	1	0	0
27663	1520	homeobox (hox) dna-binding domain	[homeobox (Hox) DNA-binding domain]	1.5849625007211563	4	1	0	0
27664	1520	effect of d-ribose	[effects of D-ribose]	1.5849625007211563	3	1	0	0
27665	1520	use gene targeting,	[Using gene targeting,]	1.5849625007211563	3	1	0	0
27666	1520	immunoregulatory gene expression	[immunoregulatory gene expression]	1.5849625007211563	3	1	0	0
27667	1520	Wp reporter construct	[Wp reporter construct]	1.5849625007211563	3	2	1	1
27668	1520	synergy between c-Maf	[synergy between c-Maf]	1.5849625007211563	3	1	0	0
27669	1520	estrogen receptor transcript similar	[estrogen receptor transcripts similar]	1.5849625007211563	4	1	0	0
27670	1520	induction of different genes,	[induction of different genes,]	1.5849625007211563	4	1	0	0
27671	1520	24r,25 (oh)2d3 dioxyvit	[24R,25 (OH)2D3 dioxyvit]	1.5849625007211563	3	1	0	0
27672	1520	calcium channel blocker	[calcium channel blocker]	1.5849625007211563	3	1	0	0
27673	1520	squirrel monkey f774l receptor	[squirrel monkey F774L receptor]	1.5849625007211563	4	1	0	0
27674	1520	nondegradable mutant kappa B	[nondegradable mutant kappa B]	1.5849625007211563	4	1	0	0
27675	1520	class IL transactivator ciita	[class IL transactivator CIITA]	1.5849625007211563	4	1	0	0
27676	1520	b cell-specific coactivator bob.1/obf.1	[B cell-specific coactivator BOB.1/OBF.1]	1.5849625007211563	4	1	0	0
27677	1520	classical T cell stimulus	[classical T cell stimuli]	1.5849625007211563	4	1	0	0
27678	1520	peptide- MHC avidity	[peptide- MHC avidity]	1.5849625007211563	3	1	0	0
27679	1520	different set of protein	[different set of proteins]	1.5849625007211563	4	1	0	0
27680	1520	basal transcription factor tfiih	[basal transcription factor TFIIH]	1.5849625007211563	4	1	0	0
27681	1520	amino acid 1-421	[amino acids 1-421]	1.5849625007211563	3	1	0	0
27682	1520	also in macrophage	[also in macrophages]	1.5849625007211563	3	1	0	0
27683	1520	induce ifn-gamma production	[inducing IFN-gamma production]	1.5849625007211563	3	2	1	1
27684	1520	large amount of ap-1	[Large amounts of AP-1]	1.5849625007211563	4	1	0	0
27685	1520	identification of nucleotide	[identification of nucleotides]	1.5849625007211563	3	2	2	2
27686	1520	activation of virus expression	[activation of virus expression]	1.5849625007211563	4	1	0	0
27687	1520	several 29-kda protein	[several 29-kDa proteins]	1.5849625007211563	3	1	0	0
27688	1520	differentiation of cell line	[differentiation of cell lines]	1.5849625007211563	4	2	2	2
27689	1520	mm-derived cell line	[MM-derived cell lines]	1.5849625007211563	3	2	1	1
27690	1520	radioactive iodine therapy	[radioactive iodine therapy]	1.5849625007211563	3	1	0	0
27691	1520	two leukemia cell line	[two leukemia cell lines]	1.5849625007211563	4	1	0	0
27692	1520	contrast, TNFRp55-deficient mouse	[contrast, TNFRp55-deficient mice]	1.5849625007211563	3	1	0	0
27693	1520	variety of t-cell line	[variety of T-cell lines]	1.5849625007211563	4	1	0	0
27694	1520	amount of vimentin mrna	[amount of vimentin mRNA]	1.5849625007211563	4	1	0	0
27695	1520	base pair region	[base pair region]	1.5849625007211563	3	2	2	2
27696	1520	subtraction potential difference SPD	[subtraction potential difference SPD]	1.5849625007211563	4	1	0	0
27697	1520	such as tnf-alpha	[such as TNF-alpha]	1.5849625007211563	3	1	0	0
27698	1520	improvement of radiologic finding	[improvement of radiologic findings]	1.5849625007211563	4	1	0	0
27699	1520	cyclic amp-responsive member	[cyclic AMP-responsive members]	1.5849625007211563	3	1	0	0
27700	1520	role in this process.	[role in this process.]	1.5849625007211563	4	1	0	0
27701	1520	regulation of the activity	[regulation of the activity]	1.5849625007211563	4	1	0	0
27702	1520	mrna expression of icam-i	[mRNA expression of ICAM-I]	1.5849625007211563	4	1	0	0
27703	1520	pmn adhesion to huvec	[PMN adhesion to HUVECs]	1.5849625007211563	4	1	0	0
27704	1520	mechanism of hiv-1 activation	[mechanism of HIV-1 activation]	1.5849625007211563	4	1	0	0
27705	1520	wild type motif	[wild type motif]	1.5849625007211563	3	2	1	1
27706	1520	ews/fli-1 fusion protein	[EWS/FLI-1 fusion protein]	1.5849625007211563	3	1	0	0
27707	1520	38 b cell	[38 B cell]	1.5849625007211563	3	1	0	0
27708	1520	tnf interleukin-1 il-1	[TNF interleukin-1 IL-1]	1.5849625007211563	3	1	0	0
27709	1520	difference in efficacy,	[difference in efficacy,]	1.5849625007211563	3	1	0	0
27710	1520	symptom due to glucocorticoid	[symptoms due to glucocorticoids]	1.5849625007211563	4	1	0	0
27711	1520	N-acetyl-L-cysteine a antioxidant	[N-acetyl-L-cysteine a antioxidant]	1.5849625007211563	3	2	2	2
27712	1520	Duffy gene promoter	[Duffy gene promoter]	1.5849625007211563	3	1	0	0
27713	1520	antigenic determinant of darc	[antigenic determinants of DARC]	1.5849625007211563	4	1	0	0
27714	1520	obligatory intracellular bacterium	[obligatory intracellular bacterium]	1.5849625007211563	3	1	0	0
27715	1520	histone h4 gene transcription	[histone H4 gene transcription]	1.5849625007211563	4	1	0	0
27716	1520	reduction of il-2 production	[Reduction of IL-2 production]	1.5849625007211563	4	1	0	0
27717	1520	addition, x-ray activation	[addition, X-ray activation]	1.5849625007211563	3	1	0	0
27718	1520	cd44 promoter-chloramphenicol acetyltransferase reporter	[CD44 promoter-chloramphenicol acetyltransferase reporter]	1.5849625007211563	4	1	0	0
27719	1520	thy-tax transgenic mouse	[Thy-tax transgenic mice]	1.5849625007211563	3	1	0	0
27720	1520	transcription polymerase chain reaction	[transcription polymerase chain reaction]	1.5849625007211563	4	2	2	2
27721	1520	human tshr extracellular domain	[human TSHR extracellular domain]	1.5849625007211563	4	1	0	0
27722	1520	Molecular, biochemical evidence	[Molecular, biochemical evidence]	1.5849625007211563	3	1	0	0
27723	1520	alpha 1 motif	[alpha 1 motif]	1.5849625007211563	3	1	0	0
27724	1520	IL-2 -independent event	[IL-2 -independent events]	1.5849625007211563	3	1	0	0
27725	1520	important role in atherosclerosis	[important role in atherosclerosis]	1.5849625007211563	4	1	0	0
27726	1520	abnormally abundant cell	[abnormally abundant cells]	1.5849625007211563	3	1	0	0
27727	1520	Hela nuclear extract	[Hela nuclear extracts]	1.5849625007211563	3	1	0	0
27728	1520	intracellular level of glutathione	[intracellular levels of glutathione]	1.5849625007211563	4	1	0	0
27729	1520	Chronic steroid therapy	[Chronic steroid therapy]	1.5849625007211563	3	1	0	0
27730	1520	response to multiple stimuli.	[response to multiple stimuli.]	1.5849625007211563	4	1	0	0
27731	1520	cyclin-like udg gene product	[cyclin-like UDG gene product]	1.5849625007211563	4	1	0	0
27732	1520	disorder ataxia telangiectasia A-T	[disorder ataxia telangiectasia A-T]	1.5849625007211563	4	1	0	0
27733	1520	same DNA element	[same DNA element]	1.5849625007211563	3	1	0	0
27734	1520	number of lps response	[number of LPS responses]	1.5849625007211563	4	1	0	0
27735	1520	method in pbmc	[method in PBMCs]	1.5849625007211563	3	1	0	0
27736	1520	autoimmune thyroid disease	[autoimmune thyroid diseases]	1.5849625007211563	3	1	0	0
27737	1520	lymphoid-specific ets transcription factor	[lymphoid-specific Ets transcription factor]	1.5849625007211563	4	1	0	0
27738	1520	cd4+ memory T	[CD4+ memory T]	1.5849625007211563	3	2	2	2
27739	1520	significant sequence homology	[Significant sequence homology]	1.5849625007211563	3	2	2	2
27740	1520	expression vector for two	[expression vectors for two]	1.5849625007211563	4	1	0	0
27741	1520	follow tcr stimulation	[following TCR stimulation]	1.5849625007211563	3	2	1	1
27742	1520	NF kappa b level	[NF kappa B levels]	1.5849625007211563	4	1	0	0
27743	1520	pituitary transcription factor pit-1b	[pituitary transcription factor Pit-1b]	1.5849625007211563	4	1	0	0
27744	1520	glucocorticoid receptor in spleen	[glucocorticoid receptors in spleen]	1.5849625007211563	4	1	0	0
27745	1520	infection of a variety	[infection of a variety]	1.5849625007211563	4	1	0	0
27746	1520	specific nuclear protein complex	[specific nuclear protein complex]	1.5849625007211563	4	1	0	0
27747	1520	phoq membrane sensor kinase	[phoQ membrane sensor kinase]	1.5849625007211563	4	1	0	0
27748	1520	Active nuclear RelB	[Active nuclear RelB]	1.5849625007211563	3	1	0	0
27749	1520	myelomonoblastic plb-985 cell	[myelomonoblastic PLB-985 cells]	1.5849625007211563	3	1	0	0
27750	1520	cd11b gene during activation	[CD11b gene during activation]	1.5849625007211563	4	1	0	0
27751	1520	diverse host cell types.	[diverse host cell types.]	1.5849625007211563	4	1	0	0
27752	1520	Janus kinase (jak)1	[Janus kinase (Jak)1]	1.5849625007211563	3	1	0	0
27753	1520	modulation of the sensitivity	[modulation of the sensitivity]	1.5849625007211563	4	1	0	0
27754	1520	function of cell	[function of cells]	1.5849625007211563	3	2	1	1
27755	1520	activation of Stat3beta	[activation of Stat3beta]	1.5849625007211563	3	1	0	0
27756	1520	tumor metastasis regulation	[tumor metastasis regulation]	1.5849625007211563	3	1	0	0
27757	1520	level of immediate-early transcript	[levels of immediate-early transcripts]	1.5849625007211563	4	1	0	0
27758	1520	endothelial production of mcp-1	[Endothelial production of MCP-1]	1.5849625007211563	4	1	0	0
27759	1520	clarification of the mechanism	[clarification of the mechanisms]	1.5849625007211563	4	1	0	0
27760	1520	medium -sized artery	[medium -sized arteries]	1.5849625007211563	3	1	0	0
27761	1520	occur in immune cell	[occurring in immune cells]	1.5849625007211563	4	1	0	0
27762	1520	putative NF-kappaB-binding site	[putative NF-kappaB-binding sites]	1.5849625007211563	3	1	0	0
27763	1520	h of TNFalpha treatment	[h of TNFalpha treatment]	1.5849625007211563	4	2	2	2
27764	1520	expression of viral gene	[expression of viral genes]	1.5849625007211563	4	2	2	2
27765	1520	contain the TATA element	[containing the TATA element]	1.5849625007211563	4	1	0	0
27766	1520	map kinases/extracellular signal kinase	[MAP kinases/extracellular signal kinases]	1.5849625007211563	4	1	0	0
27767	1520	infection with hsv	[infection with HSV]	1.5849625007211563	3	1	0	0
27768	1520	fas -mediated apoptosis	[Fas -mediated apoptosis]	1.5849625007211563	3	1	0	0
27769	1520	fc gamma riiia expression	[Fc gamma RIIIA expression]	1.5849625007211563	4	1	0	0
27770	1520	set of cDNA fragment	[set of cDNA fragments]	1.5849625007211563	4	1	0	0
27771	1520	IL-6 transcription by monocyte	[IL-6 transcription by monocytes]	1.5849625007211563	4	1	0	0
27772	1520	ehrlichiosis response to	[ehrlichiosis responses to]	1.5849625007211563	3	1	0	0
27773	1520	transactivator protein bzlf1	[transactivator protein BZLF1]	1.5849625007211563	3	1	0	0
27774	1520	other c-11 analog	[other C-11 analogs]	1.5849625007211563	3	1	0	0
27775	1520	2 h of stimulation	[2 h of stimulation]	1.5849625007211563	4	2	2	2
27776	1520	presence of cyclosporin a	[presence of cyclosporin A]	1.5849625007211563	4	1	0	0
27777	1520	PKB/Akt activity alone	[PKB/Akt activity alone]	1.5849625007211563	3	1	0	0
27778	1520	three non- b-cell line	[three non- B-cell lines]	1.5849625007211563	4	1	0	0
27779	1520	reactive oxygen intermediate formation	[reactive oxygen intermediate formation]	1.5849625007211563	4	2	2	2
27780	1520	ROS-dependent signalling pathway	[ROS-dependent signalling pathway]	1.5849625007211563	3	1	0	0
27781	1520	absence of tcr ligation	[absence of TCR ligation]	1.5849625007211563	4	1	0	0
27782	1520	adjacent activator site act-1	[adjacent activator site Act-1]	1.5849625007211563	4	1	0	0
27783	1520	pretreatment with pao	[pretreatment with PAO]	1.5849625007211563	3	1	0	0
27784	1520	sibling cell level	[sibling cell level]	1.5849625007211563	3	1	0	0
27785	1520	one family receptor level	[one family receptor levels]	1.5849625007211563	4	1	0	0
27786	1520	cat reporter gene	[cat reporter gene]	1.5849625007211563	3	1	0	0
27787	1520	effect on apoptotic signaling.	[effect on apoptotic signaling.]	1.5849625007211563	4	1	0	0
27788	1520	fibroblast cell transformation	[fibroblast cell transformation]	1.5849625007211563	3	1	0	0
27789	1520	interleukin 2 IL-2 production	[interleukin 2 IL-2 production]	1.5849625007211563	4	1	0	0
27790	1520	dose of OKT3	[dose of OKT3]	1.5849625007211563	3	1	0	0
27791	1520	c-sis/platelet-derived growth factor-B pdgf-b	[c-sis/platelet-derived growth factor-B PDGF-B]	1.5849625007211563	4	1	0	0
27792	1520	low-density lipoprotein ldl	[Low-density lipoprotein LDL]	1.5849625007211563	3	1	0	0
27793	1520	il-6 of Stat3	[IL-6 of Stat3]	1.5849625007211563	3	1	0	0
27794	1520	expression of the virus	[expression of the viruses]	1.5849625007211563	4	1	0	0
27795	1520	thymus stromal cell	[thymus stromal cells]	1.5849625007211563	3	1	0	0
27796	1520	anti- IL-10 antibody	[anti- IL-10 antibody]	1.5849625007211563	3	1	0	0
27797	1520	involvement of p21(ras)	[involvement of p21(ras)]	1.5849625007211563	3	1	0	0
27798	1520	effect of b7 costimulation	[effects of B7 costimulation]	1.5849625007211563	4	2	2	2
27799	1520	study of the mechanism	[study of the mechanisms]	1.5849625007211563	4	2	2	2
27800	1520	sublining, suggest activation	[sublining, suggesting activation]	1.5849625007211563	3	1	0	0
27801	1520	cd8(-) CD3 thymocyte	[CD8(-) CD3 thymocytes]	1.5849625007211563	3	2	2	2
27802	1520	analysis of mouse deficient	[analyses of mice deficient]	1.5849625007211563	4	1	0	0
27803	1520	sex-determining gene sry	[sex-determining gene SRY]	1.5849625007211563	3	2	1	1
27804	1520	MHC i+/ MHC iibright/cd83+/cd86+/	[MHC I+/ MHC IIbright/CD83+/CD86+/]	1.5849625007211563	4	1	0	0
27805	1520	second, recombinant lef-1	[Second, recombinant LEF-1]	1.5849625007211563	3	1	0	0
27806	1520	activation of calcineurin	[activation of calcineurin]	1.5849625007211563	3	1	0	0
27807	1520	sequence of the motif	[sequence of the motif]	1.5849625007211563	4	1	0	0
27808	1520	variety of Oct2 isoform	[variety of Oct2 isoforms]	1.5849625007211563	4	1	0	0
27809	1520	one sp1 cleavage product.	[one SP1 cleavage product.]	1.5849625007211563	4	1	0	0
27810	1520	induction of FasL	[induction of FasL]	1.5849625007211563	3	1	0	0
27811	1520	physiological concentration (10(-9)-10(-7) mol/L)	[physiological concentration (10(-9)-10(-7) mol/L)]	1.5849625007211563	4	1	0	0
27812	1520	histogenesis of B-cell lymphoma	[histogenesis of B-cell lymphomas]	1.5849625007211563	4	1	0	0
27813	1520	control of cell survival.	[control of cell survival.]	1.5849625007211563	4	1	0	0
27814	1520	lack of Jak3 expression	[lack of Jak3 expression]	1.5849625007211563	4	1	0	0
27815	1520	participation of multiple region	[participation of multiple regions]	1.5849625007211563	4	1	0	0
27816	1520	x-linked severe immunodeficiency X-SCID	[X-linked severe immunodeficiency X-SCID]	1.5849625007211563	4	1	0	0
27817	1520	However, Rta by itself	[However, Rta by itself]	1.5849625007211563	4	1	0	0
27818	1520	promoter proximal region upstream	[promoter proximal region upstream]	1.5849625007211563	4	1	0	0
27819	1520	activation of the htlv-i	[activation of the HTLV-I]	1.5849625007211563	4	1	0	0
27820	1520	initial viral promoter	[initial viral promoter]	1.5849625007211563	3	1	0	0
27821	1520	cells, support previous hypothesis	[cells, supporting previous hypothesis]	1.5849625007211563	4	1	0	0
27822	1520	terminal event of erythropoiesis	[terminal events of erythropoiesis]	1.5849625007211563	4	1	0	0
27823	1520	immediate-early gene egr-1	[immediate-early gene egr-1]	1.5849625007211563	3	1	0	0
27824	1520	involve the Jak/Stat pathway	[involving the Jak/Stat pathway]	1.5849625007211563	4	1	0	0
27825	1520	presence of a ion	[presence of an ion]	1.5849625007211563	4	1	0	0
27826	1520	cell line hl-60	[cell lines HL-60]	1.5849625007211563	3	1	0	0
27827	1520	Nuclear factor-90 of t-cell	[Nuclear factor-90 of T-cells]	1.5849625007211563	4	1	0	0
27828	1520	alpha, 25-dihydroxyvitamin D3 vd3	[alpha, 25-dihydroxyvitamin D3 VD3]	1.5849625007211563	4	2	2	2
27829	1520	otherwise susceptible target cell	[otherwise susceptible target cells]	1.5849625007211563	4	1	0	0
27830	1520	costimulatory molecule b7.1	[costimulatory molecule B7.1]	1.5849625007211563	3	2	1	1
27831	1520	rprl footprint ii	[rPRL footprint II]	1.5849625007211563	3	1	0	0
27832	1520	bZIP family of protein	[bZIP family of proteins]	1.5849625007211563	4	1	0	0
27833	1520	M. tuberculosis cell	[M. tuberculosis cells]	1.5849625007211563	3	1	0	0
27834	1520	two rdna encoding protein	[two cDNAs encoding proteins]	1.5849625007211563	4	1	0	0
27835	1520	interleukin-2 receptor alpha	[interleukin-2 receptor alpha]	1.5849625007211563	3	2	1	1
27836	1520	relatively normal mense	[relatively normal menses]	1.5849625007211563	3	1	0	0
27837	1520	expression of immunodeficiency virus	[expression of immunodeficiency virus]	1.5849625007211563	4	2	1	1
27838	1520	human il-4 receptor il-4r	[human IL-4 receptor IL-4R]	1.5849625007211563	4	1	0	0
27839	1520	expression of Ml antigen	[expression of Mls antigens]	1.5849625007211563	4	1	0	0
27840	1520	stat4 in human lymphocyte	[STAT4 in human lymphocytes]	1.5849625007211563	4	1	0	0
27841	1520	especially the isoflavone glucuronide	[especially the isoflavone glucuronides]	1.5849625007211563	4	1	0	0
27842	1520	treatment with differanisole a	[treatment with differanisole A]	1.5849625007211563	4	2	2	2
27843	1520	abdominal obese subject	[abdominal obese subjects]	1.5849625007211563	3	2	1	1
27844	1520	former two substance	[former two substances]	1.5849625007211563	3	1	0	0
27845	1520	GRE-dependent luciferase reporter gene	[GRE-dependent luciferase reporter gene]	1.5849625007211563	4	1	0	0
27846	1520	question of DC lineage	[question of DC lineage]	1.5849625007211563	4	1	0	0
27847	1520	constitutive expression of gcr	[constitutive expression of gcRs]	1.5849625007211563	4	1	0	0
27848	1520	immune response to injury	[immune response to injury]	1.5849625007211563	4	1	0	0
27849	1520	least five cis-acting region	[least five cis-acting regions]	1.5849625007211563	4	1	0	0
27850	1520	erythroid differentiation pathway	[erythroid differentiation pathways]	1.5849625007211563	3	1	0	0
27851	1520	NF-kappaB -induce kinase	[NF-kappaB -inducing kinase]	1.5849625007211563	3	1	0	0
27852	1520	phosphorylation of IkappaB-alpha	[phosphorylation of IkappaB-alpha]	1.5849625007211563	3	1	0	0
27853	1520	5' nontranscribed region	[5' nontranscribed region]	1.5849625007211563	3	1	0	0
27854	1520	effect in transfection.	[effects in transfection.]	1.5849625007211563	3	1	0	0
27855	1520	same enzymatic activity	[same enzymatic activity]	1.5849625007211563	3	1	0	0
27856	1520	shift from complex	[shift from complex]	1.5849625007211563	3	1	0	0
27857	1520	same range of concentration	[same range of concentrations]	1.5849625007211563	4	1	0	0
27858	1520	ebv-transformed lymphoblastoid cell line	[EBV-transformed lymphoblastoid cell lines]	1.5849625007211563	4	1	0	0
27859	1520	apparent Th2 differentiation defect	[apparent Th2 differentiation defect]	1.5849625007211563	4	1	0	0
27860	1520	intracellular mechanism different	[intracellular mechanisms different]	1.5849625007211563	3	1	0	0
27861	1520	PEBP2 alpha B	[PEBP2 alpha B]	1.5849625007211563	3	1	0	0
27862	1520	PEBP2 alpha A	[PEBP2 alpha A]	1.5849625007211563	3	1	0	0
27863	1520	implication for other gene	[implications for other genes]	1.5849625007211563	4	1	0	0
27864	1520	vitro binding analysis	[vitro binding analysis]	1.5849625007211563	3	1	0	0
27865	1520	limulus amoebocyte lysate	[Limulus amoebocyte lysate]	1.5849625007211563	3	1	0	0
27866	1520	cell death apoptosis	[cell death apoptosis]	1.5849625007211563	3	1	0	0
27867	1520	monitor DPD activity	[Monitoring DPD activity]	1.5849625007211563	3	1	0	0
27868	1520	T lineage cell	[T lineage cells]	1.5849625007211563	3	1	0	0
27869	1520	lipopolysaccharide-stimulated interleukin-1 beta	[lipopolysaccharide-stimulated interleukin-1 beta]	1.5849625007211563	3	1	0	0
27870	1520	rest human T cell	[resting human T cells]	1.5849625007211563	4	2	2	2
27871	1520	extracellular matrix protein	[extracellular matrix protein]	1.5849625007211563	3	1	0	0
27872	1520	nf-kappa b protein c-rel	[NF-kappa B protein c-rel]	1.5849625007211563	4	1	0	0
27873	1520	constitutive nf-kappa b activation	[Constitutive NF-kappa B activation]	1.5849625007211563	4	1	0	0
27874	1520	member of a kindred,	[members of a kindred,]	1.5849625007211563	4	1	0	0
27875	1520	100 mumol/L pdtc	[100 mumol/L PDTC]	1.5849625007211563	3	2	1	1
27876	1520	nf kappa b activation	[NF kappa B activation]	1.5849625007211563	4	2	1	1
27877	1520	APL cell line	[APL cell line]	1.5849625007211563	3	2	2	2
27878	1520	metastatic tumor in vivo	[metastatic tumors in vivo]	1.5849625007211563	4	1	0	0
27879	1520	hpa system in ad	[HPA system in AD]	1.5849625007211563	4	1	0	0
27880	1520	four specific complex	[four specific complexes]	1.5849625007211563	3	1	0	0
27881	1520	full-length cd14 coding sequence	[full-length CD14 coding sequence]	1.5849625007211563	4	1	0	0
27882	1520	various concentration of DEX	[Various concentrations of DEX]	1.5849625007211563	4	2	1	1
27883	1520	squirrel monkey lymphocyte	[squirrel monkey lymphocytes]	1.5849625007211563	3	2	1	1
27884	1520	role of Oct-2	[role of Oct-2]	1.5849625007211563	3	1	0	0
27885	1520	70% of mm patient	[70% of MM patients]	1.5849625007211563	4	1	0	0
27886	1520	h. induce CAT activity	[h, inducing CAT activity]	1.5849625007211563	4	2	2	2
27887	1520	plasma cell in ultrastructure	[plasma cells in ultrastructure]	1.5849625007211563	4	1	0	0
27888	1520	failure of TNF	[failure of TNF]	1.5849625007211563	3	1	0	0
27889	1520	uninfected parental hl-60 subclone	[uninfected parental HL-60 subclones]	1.5849625007211563	4	1	0	0
27890	1520	tcr through accessory receptor	[TCR through accessory receptors]	1.5849625007211563	4	1	0	0
27891	1520	il-2 gene induction.	[IL-2 gene induction.]	1.5849625007211563	3	1	0	0
27892	1520	FGF receptor-1 engagement	[FGF receptor-1 engagement]	1.5849625007211563	3	1	0	0
27893	1520	1 infection of cell	[1 infection of cells]	1.5849625007211563	4	2	2	2
27894	1520	regulate cellular function	[regulating cellular functions]	1.5849625007211563	3	1	0	0
27895	1520	HeLa s3 cell	[HeLa S3 cells]	1.5849625007211563	3	1	0	0
27896	1520	two distinct pathways: Lyn	[two distinct pathways: Lyn]	1.5849625007211563	4	1	0	0
27897	1520	transcription factor tfiia	[transcription factor TFIIA]	1.5849625007211563	3	1	0	0
27898	1520	absence of EKLF	[absence of EKLF]	1.5849625007211563	3	1	0	0
27899	1520	transcription factor tfiih	[transcription factor TFIIH]	1.5849625007211563	3	2	2	2
27900	1520	human myeloid cell differentiation	[human myeloid cell differentiation]	1.5849625007211563	4	2	1	1
27901	1520	same genes, against promoter	[same genes, against promoters]	1.5849625007211563	4	1	0	0
27902	1520	highly significant correlation	[Highly significant correlations]	1.5849625007211563	3	1	0	0
27903	1520	correct temporal order	[correct temporal order]	1.5849625007211563	3	1	0	0
27904	1520	granulosa cell tumor gct	[granulosa cell tumor GCT]	1.5849625007211563	4	1	0	0
27905	1520	Reverse transcriptase-polymerase chain reaction	[Reverse transcriptase-polymerase chain reaction]	1.5849625007211563	4	2	1	1
27906	1520	transient DNA transfections.	[transient DNA transfections.]	1.5849625007211563	3	1	0	0
27907	1520	hallmark of lymphocyte activation	[hallmark of lymphocyte activation]	1.5849625007211563	4	1	0	0
27908	1520	gh in granulocyte subset	[GH in granulocyte subsets]	1.5849625007211563	4	1	0	0
27909	1520	corticosteroid receptor in brain	[corticosteroid receptors in brain]	1.5849625007211563	4	1	0	0
27910	1520	effectiveness of therapy	[effectiveness of therapy]	1.5849625007211563	3	2	2	2
27911	1520	magnetic bead separation	[magnetic bead separations]	1.5849625007211563	3	1	0	0
27912	1520	c-myc regulation one	[c-myc regulation one]	1.5849625007211563	3	1	0	0
27913	1520	different experimental conditions.	[different experimental conditions.]	1.5849625007211563	3	1	0	0
27914	1520	enzyme independent of CD4	[enzyme independent of CD4]	1.5849625007211563	4	1	0	0
27915	1520	human B-lymphocyte cDNA library	[human B-lymphocyte cDNA library]	1.5849625007211563	4	1	0	0
27916	1520	dependent transcriptional activation	[dependent transcriptional activation]	1.5849625007211563	3	1	0	0
27917	1520	other polyclonal signal	[other polyclonal signals]	1.5849625007211563	3	1	0	0
27918	1520	most other cell types:	[most other cell types:]	1.5849625007211563	4	1	0	0
27919	1520	primitive hematopoietic stem cell	[primitive hematopoietic stem cells]	1.5849625007211563	4	1	0	0
27920	1520	distinct dnase-i hypersensitive site	[Distinct DNase-I hypersensitive sites]	1.5849625007211563	4	1	0	0
27921	1520	Src-family kinase Lck	[Src-family kinase Lck]	1.5849625007211563	3	1	0	0
27922	1520	effect of transmembrane signal	[effect of transmembrane signaling]	1.5849625007211563	4	1	0	0
27923	1520	Src family kinase lck	[Src family kinase Lck]	1.5849625007211563	4	1	0	0
27924	1520	majority of this TCC	[majority of these TCC]	1.5849625007211563	4	1	0	0
27925	1520	reduction of tnf-alpha transcripts.	[reduction of TNF-alpha transcripts.]	1.5849625007211563	4	1	0	0
27926	1520	promonocytic cell undergo apoptosis	[promonocytic cells undergoing apoptosis]	1.5849625007211563	4	1	0	0
27927	1520	biomarker (e.g. cd45r0+	[biomarkers (e.g. CD45R0+]	1.5849625007211563	3	1	0	0
27928	1520	such as autoimmune disease	[such as autoimmune diseases]	1.5849625007211563	4	1	0	0
27929	1520	important transcriptional element	[important transcriptional elements]	1.5849625007211563	3	1	0	0
27930	1520	healthy control individual	[healthy control individuals]	1.5849625007211563	3	1	0	0
27931	1520	conserved, mainly aromatic residue	[conserved, mainly aromatic residues]	1.5849625007211563	4	1	0	0
27932	1520	vitro experimental study	[vitro experimental studies]	1.5849625007211563	3	1	0	0
27933	1520	constitutive induction of NF-kappaB	[constitutive induction of NF-kappaB]	1.5849625007211563	4	1	0	0
27934	1520	c-Jun inhibitory response	[c-Jun inhibitory response]	1.5849625007211563	3	1	0	0
27935	1520	b cell nuclear protein	[B cell nuclear proteins]	1.5849625007211563	4	1	0	0
27936	1520	behavior of Bcl-2	[behavior of Bcl-2]	1.5849625007211563	3	1	0	0
27937	1520	central pathogenic mechanism	[central pathogenic mechanisms]	1.5849625007211563	3	1	0	0
27938	1520	parental granulocyte-macrophage colony-stimulating factor	[parental granulocyte-macrophage colony-stimulating factor]	1.5849625007211563	4	1	0	0
27939	1520	effect phorbol 13-acetate	[effect phorbol 13-acetate]	1.5849625007211563	3	1	0	0
27940	1520	isolation of a cDNA	[Isolation of a cDNA]	1.5849625007211563	4	2	1	1
27941	1520	effective immunologic barrier	[effective immunologic barrier]	1.5849625007211563	3	1	0	0
27942	1520	two characteristic domains,	[two characteristic domains,]	1.5849625007211563	3	1	0	0
27943	1520	insulin receptor substrate 1	[insulin receptor substrates 1]	1.5849625007211563	4	1	0	0
27944	1520	lead to il-2 production	[leading to IL-2 production]	1.5849625007211563	4	1	0	0
27945	1520	study use cell line	[studies using cell lines]	1.5849625007211563	4	1	0	0
27946	1520	use run-on assay	[using run-on assays]	1.5849625007211563	3	1	0	0
27947	1520	comparison with the binding	[comparison with the binding]	1.5849625007211563	4	1	0	0
27948	1520	HIV regulatory region LTR	[HIV regulatory region LTR]	1.5849625007211563	4	1	0	0
27949	1520	astrocyte-derived kappa b-binding factor	[astrocyte-derived kappa B-binding factors]	1.5849625007211563	4	1	0	0
27950	1520	CLEO -54 to -31	[CLEO -54 to -31]	1.5849625007211563	4	1	0	0
27951	1520	cytoplasm of cell	[cytoplasm of cells]	1.5849625007211563	3	2	2	2
27952	1520	biscoclaurine alkaloid contain cepharanthine	[biscoclaurine alkaloids containing cepharanthine]	1.5849625007211563	4	1	0	0
27953	1520	transient transfectin experiments,	[transient transfectin experiments,]	1.5849625007211563	3	1	0	0
27954	1520	substrate for the kinase	[substrate for the kinase]	1.5849625007211563	4	1	0	0
27955	1520	CES-2 cell-death specification protein	[CES-2 cell-death specification protein]	1.5849625007211563	4	1	0	0
27956	1520	threonine -rich domain	[threonine -rich domain]	1.5849625007211563	3	1	0	0
27957	1520	t-cell antigen receptor function	[T-cell antigen receptor function]	1.5849625007211563	4	1	0	0
27958	1520	other b lymphocyte-specific gene	[other B lymphocyte-specific genes]	1.5849625007211563	4	1	0	0
27959	1520	defect in signal event	[defects in signaling events]	1.5849625007211563	4	1	0	0
27960	1520	camp /pka activation pathway	[cAMP /PKA activation pathway]	1.5849625007211563	4	1	0	0
27961	1520	T-all cell line	[T-ALL cell line]	1.5849625007211563	3	2	1	1
27962	1520	signal transduction pathway relevant	[signal transduction pathways relevant]	1.5849625007211563	4	1	0	0
27963	1520	NF-kappa b the p50	[NF-kappa B the p50]	1.5849625007211563	4	1	0	0
27964	1520	significant level of protein	[significant levels of protein]	1.5849625007211563	4	1	0	0
27965	1520	fetal neonatal cord blood	[fetal neonatal cord bloods]	1.5849625007211563	4	1	0	0
27966	1520	important difference between antiandrogen	[important difference between antiandrogens]	1.5849625007211563	4	1	0	0
27967	1520	ability of this virus	[ability of this virus]	1.5849625007211563	4	1	0	0
27968	1520	calcineurin inhibitor cyclosporin a	[calcineurin inhibitor cyclosporin A]	1.5849625007211563	4	1	0	0
27969	1520	phorbol ester, 12-o-tetradecanoylphorbol-13-acetate	[phorbol ester, 12-O-tetradecanoylphorbol-13-acetate]	1.5849625007211563	3	1	0	0
27970	1520	segment extend base pair	[segment extending base pairs]	1.5849625007211563	4	1	0	0
27971	1520	component of nuclear factor	[component of nuclear factor]	1.5849625007211563	4	1	0	0
27972	1520	property of human ccr-4	[properties of human CCR-4]	1.5849625007211563	4	1	0	0
27973	1520	heparin-binding growth growth factor	[heparin-binding growth growth factor]	1.5849625007211563	4	2	2	2
27974	1520	maximal induction of apoptosis	[maximal induction of apoptosis]	1.5849625007211563	4	1	0	0
27975	1520	gal4-substituted hiv-1 enhancer 80-	[GAL4-substituted HIV-1 enhancer 80-]	1.5849625007211563	4	1	0	0
27976	1520	viral oncoproteins, cell transformation,	[viral oncoproteins, cell transformation,]	1.5849625007211563	4	1	0	0
27977	1520	contrast, synthesis of ifn-gamma	[contrast, synthesis of IFN-gamma]	1.5849625007211563	4	1	0	0
27978	1520	nuclear factor (s)	[nuclear factor (s)]	1.5849625007211563	3	2	1	1
27979	1520	STAT6 -responsive element	[STAT6 -responsive elements]	1.5849625007211563	3	1	0	0
27980	1520	pi 3-kinase effector	[PI 3-kinase effectors]	1.5849625007211563	3	1	0	0
27981	1520	8;21 chromosome translocation	[8;21 chromosome translocations]	1.5849625007211563	3	1	0	0
27982	1520	nuclear DNA binding	[nuclear DNA binding]	1.5849625007211563	3	1	0	0
27983	1520	design of peptide vaccine	[design of peptide vaccines]	1.5849625007211563	4	1	0	0
27984	1520	functionally responsive T cell	[functionally responsive T cells]	1.5849625007211563	4	1	0	0
27985	1520	spleen of the heterozygote	[spleens of the heterozygotes]	1.5849625007211563	4	1	0	0
27986	1520	transcription factor in monocyte	[transcription factors in monocytes]	1.5849625007211563	4	2	2	2
27987	1520	NF-kappa b dependent transcription	[NF-kappa B dependent transcription]	1.5849625007211563	4	1	0	0
27988	1520	previous mrna study	[previous mRNA studies]	1.5849625007211563	3	1	0	0
27989	1520	action of T3SO4	[action of T3SO4]	1.5849625007211563	3	1	0	0
27990	1520	functional unit ac unit	[functional unit AC unit]	1.5849625007211563	4	1	0	0
27991	1520	investigation of megakaryocytic maturation	[investigation of megakaryocytic maturation]	1.5849625007211563	4	1	0	0
27992	1520	infiltrate T cell	[infiltrating T cells]	1.5849625007211563	3	2	2	2
27993	1520	hitherto unknown mineralocorticoid may,	[hitherto unknown mineralocorticoid may,]	1.5849625007211563	4	1	0	0
27994	1520	TcR delta transcript	[TcR delta transcripts]	1.5849625007211563	3	2	2	2
27995	1520	migration protein cd44	[migration protein CD44]	1.5849625007211563	3	1	0	0
27996	1520	normal cell cycle	[normal cell cycle]	1.5849625007211563	3	1	0	0
27997	1520	il-4 receptor alpha-chain	[IL-4 receptor alpha-chain]	1.5849625007211563	3	2	1	1
27998	1520	il-3-mediated stat5b tyrosine phosphorylation.	[IL-3-mediated STAT5b tyrosine phosphorylation.]	1.5849625007211563	4	1	0	0
27999	1520	anti-HLA-DR monoclonal antibody mab	[anti-HLA-DR monoclonal antibody mAb]	1.5849625007211563	4	1	0	0
28000	1520	candidate for aids vaccine	[candidates for AIDS vaccine]	1.5849625007211563	4	1	0	0
28001	1520	viral DNA polymerase	[viral DNA polymerase]	1.5849625007211563	3	1	0	0
28002	1520	tf promoter activity	[TF promoter activity]	1.5849625007211563	3	1	0	0
28003	1520	pulmonary disease like bronchiti	[pulmonary diseases like bronchitis]	1.5849625007211563	4	1	0	0
28004	1520	suppression of gene	[suppression of genes]	1.5849625007211563	3	1	0	0
28005	1520	few gene IL-2	[Few genes IL-2]	1.5849625007211563	3	1	0	0
28006	1520	human naive cell	[human naive cells]	1.5849625007211563	3	1	0	0
28007	1520	essential role for nf-kappab	[essential role for NF-kappaB]	1.5849625007211563	4	1	0	0
28008	1520	human erythroid alas isozyme	[human erythroid ALAS isozyme]	1.5849625007211563	4	1	0	0
28009	1520	up to 30-fold high	[up to 30-fold higher]	1.5849625007211563	4	1	0	0
28010	1520	resistance against fas-mediated apoptosis	[resistance against Fas-mediated apoptosis]	1.5849625007211563	4	1	0	0
28011	1520	result in this study	[results in this study]	1.5849625007211563	4	1	0	0
28012	1520	consequence of a mechanism	[consequence of a mechanism]	1.5849625007211563	4	1	0	0
28013	1520	contrast, intracytoplasmic tnfalpha level	[contrast, intracytoplasmic TNFalpha levels]	1.5849625007211563	4	1	0	0
28014	1520	t-lymphotropic virus type	[T-lymphotropic virus type]	1.5849625007211563	3	2	1	1
28015	1520	dermal microvessel endothelial cell	[dermal microvessel endothelial cells]	1.5849625007211563	4	2	2	2
28016	1520	NF- CLE0 gamma binding	[NF- CLE0 gamma binding]	1.5849625007211563	4	1	0	0
28017	1520	70 to 73 kda)	[70 to 73 kDa)]	1.5849625007211563	4	1	0	0
28018	1520	indicate the 'default' state.	[indicating the 'default' state.]	1.5849625007211563	4	1	0	0
28019	1520	kappa b beta	[kappa B beta]	1.5849625007211563	3	1	0	0
28020	1520	different cellular factor	[different cellular factors]	1.5849625007211563	3	1	0	0
28021	1520	ltr-cat reporter construct	[LTR-CAT reporter construct]	1.5849625007211563	3	1	0	0
28022	1520	u-937 human promonocytic cell	[U-937 human promonocytic cells]	1.5849625007211563	4	1	0	0
28023	1520	monocyte/macrophage function with relevance	[monocyte/macrophage function with relevance]	1.5849625007211563	4	1	0	0
28024	1520	NK activity variance (multivariate	[NK activity variance (multivariate]	1.5849625007211563	4	1	0	0
28025	1520	Tax1 -nf-y interaction	[Tax1 -NF-Y interaction]	1.5849625007211563	3	1	0	0
28026	1520	BZLF-1 -dependent mechanism	[BZLF-1 -dependent mechanism]	1.5849625007211563	3	1	0	0
28027	1520	Vitamin d3- interaction	[Vitamin D3- interactions]	1.5849625007211563	3	1	0	0
28028	1520	induce the interaction	[inducing the interaction]	1.5849625007211563	3	1	0	0
28029	1520	weight dextran sulfate	[weight dextran sulfate]	1.5849625007211563	3	2	2	2
28030	1520	phosphorylation of Rex	[phosphorylation of Rex]	1.5849625007211563	3	1	0	0
28031	1520	cytokine mrna expression	[cytokine mRNA expression]	1.5849625007211563	3	2	2	2
28032	1520	three interact protein	[Three interacting proteins]	1.5849625007211563	3	1	0	0
28033	1520	parameter with blood pressure	[parameters with blood pressure]	1.5849625007211563	4	1	0	0
28034	1520	different tal-1 promoter	[different tal-1 promoters]	1.5849625007211563	3	1	0	0
28035	1520	concatameric linear DNA	[concatameric linear DNA]	1.5849625007211563	3	1	0	0
28036	1520	T lymphocyte from animal	[T lymphocytes from animals]	1.5849625007211563	4	1	0	0
28037	1520	anti- stat 6	[anti- STAT 6]	1.5849625007211563	3	1	0	0
28038	1520	cytolytic susceptibility during infection	[cytolytic susceptibility during infection]	1.5849625007211563	4	1	0	0
28039	1520	risk of definite coagulopathy	[risks of definite coagulopathy]	1.5849625007211563	4	1	0	0
28040	1520	albeit to level low	[albeit to levels lower]	1.5849625007211563	4	1	0	0
28041	1520	primary cellular initiator	[primary cellular initiator]	1.5849625007211563	3	1	0	0
28042	1520	CD40 /cd40 ligand interaction	[CD40 /CD40 ligand interactions]	1.5849625007211563	4	1	0	0
28043	1520	most clinically relevant form	[most clinically relevant form]	1.5849625007211563	4	1	0	0
28044	1520	normal bone marrow myeloid	[normal bone marrow myeloid]	1.5849625007211563	4	1	0	0
28045	1520	amino-terminal portion of sp140	[amino-terminal portion of Sp140]	1.5849625007211563	4	1	0	0
28046	1520	rapidak PP1 -sensitive tyrosine	[rapid, PP1 -sensitive tyrosine]	1.5849625007211563	4	1	0	0
28047	1520	Reverse transcriptase (rt) assay	[Reverse transcriptase (RT) assays]	1.5849625007211563	4	1	0	0
28048	1520	treatment of allergic disease	[treatment of allergic diseases]	1.5849625007211563	4	2	1	1
28049	1520	absence of nf-kappab signal	[absence of NF-kappaB signaling]	1.5849625007211563	4	1	0	0
28050	1520	proximal membrane signaling,	[proximal membrane signaling,]	1.5849625007211563	3	1	0	0
28051	1520	ic50 value (15.5+/-1.8	[IC50 values (15.5+/-1.8]	1.5849625007211563	3	1	0	0
28052	1520	virus host range	[virus host range,]	1.5849625007211563	3	1	0	0
28053	1520	nuclei of cd68+ cell	[nuclei of CD68+ cells]	1.5849625007211563	4	1	0	0
28054	1520	12 AIDS patient	[12 AIDS patients]	1.5849625007211563	3	1	0	0
28055	1520	abnormality of e2f function	[abnormalities of E2F function]	1.5849625007211563	4	1	0	0
28056	1520	activity of construct	[activity of constructs]	1.5849625007211563	3	1	0	0
28057	1520	porcine b-cell line	[porcine B-cell line]	1.5849625007211563	3	2	2	2
28058	1520	100 microm diacylglycerol	[100 microM diacylglycerol]	1.5849625007211563	3	1	0	0
28059	1520	G-CSF tyrosine phosphorylation	[G-CSF tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
28060	1520	replication deficient by deletion	[replication deficient by deletion]	1.5849625007211563	4	1	0	0
28061	1520	expression of spi-1	[expression of Spi-1]	1.5849625007211563	3	2	2	2
28062	1520	finding of clonal eosinophilia	[finding of clonal eosinophilia]	1.5849625007211563	4	1	0	0
28063	1520	human glucocorticoid receptor hGR	[human glucocorticoid receptor hGR]	1.5849625007211563	4	1	0	0
28064	1520	nonlymphoid (hela) cell line	[nonlymphoid (HeLa) cell lines]	1.5849625007211563	4	1	0	0
28065	1520	absence of a inhibitor	[absence of an inhibitor]	1.5849625007211563	4	1	0	0
28066	1520	CD28 costimulation use PMA	[CD28 costimulation using PMA]	1.5849625007211563	4	1	0	0
28067	1520	VDR dna-binding mutant	[VDR DNA-binding mutants]	1.5849625007211563	3	1	0	0
28068	1520	healthy woman A-CRF	[healthy women A-CRF]	1.5849625007211563	3	1	0	0
28069	1520	small cytoplasmic tail	[small cytoplasmic tail]	1.5849625007211563	3	1	0	0
28070	1520	reporter gene in transfection	[reporter gene in transfections]	1.5849625007211563	4	1	0	0
28071	1520	plasma cell formation	[plasma cell formation]	1.5849625007211563	3	1	0	0
28072	1520	leukemic U937 cell	[leukemic U937 cell]	1.5849625007211563	3	1	0	0
28073	1520	murine pro-B cell line	[murine pro-B cell line]	1.5849625007211563	4	1	0	0
28074	1520	murine ba/f3 cell	[murine BA/F3 cells]	1.5849625007211563	3	1	0	0
28075	1520	human T leukemia	[Human T leukemia]	1.5849625007211563	3	2	1	1
28076	1520	ii-constitutive b cell	[II-constitutive B cells]	1.5849625007211563	3	1	0	0
28077	1520	uninfected cell extract	[uninfected cell extract]	1.5849625007211563	3	1	0	0
28078	1520	factor-dependent pkb/akt activity	[factor-dependent PKB/Akt activity]	1.5849625007211563	3	1	0	0
28079	1520	threshold in transcription	[threshold in transcription]	1.5849625007211563	3	1	0	0
28080	1520	VDR dna-binding domain alone,	[VDR DNA-binding domain alone,]	1.5849625007211563	4	1	0	0
28081	1520	platelet-like k562 cell	[platelet-like K562 cells]	1.5849625007211563	3	1	0	0
28082	1520	course of natural cytotoxicity	[course of natural cytotoxicity]	1.5849625007211563	4	1	0	0
28083	1520	contribution of gabp factor	[contribution of GABP factors]	1.5849625007211563	4	1	0	0
28084	1520	phenotype of tumor cell	[phenotype of tumor cells]	1.5849625007211563	4	1	0	0
28085	1520	dihydrofolate reductase gene	[dihydrofolate reductase gene]	1.5849625007211563	3	1	0	0
28086	1520	two independent sequence	[two independent sequences]	1.5849625007211563	3	1	0	0
28087	1520	contrast to p70	[contrast to p70]	1.5849625007211563	3	1	0	0
28088	1520	decrease in cytotoxic function	[decrease in cytotoxic function]	1.5849625007211563	4	1	0	0
28089	1520	pkc isoform in macrophage	[PKC isoforms in macrophages]	1.5849625007211563	4	2	2	2
28090	1520	ubiquitin-activating enzyme e1	[ubiquitin-activating enzyme E1]	1.5849625007211563	3	1	0	0
28091	1520	addition of interleukin-2 il-2	[addition of interleukin-2 IL-2]	1.5849625007211563	4	1	0	0
28092	1520	ca2+ ionophore a23187	[Ca2+ ionophore A23187]	1.5849625007211563	3	1	0	0
28093	1520	chemical footprinting procedure	[chemical footprinting procedures]	1.5849625007211563	3	1	0	0
28094	1520	hiv LTR activation	[HIV LTR activation]	1.5849625007211563	3	2	1	1
28095	1520	nuclear nf-kappab activity	[nuclear NF-kappaB activity]	1.5849625007211563	3	2	1	1
28096	1520	multiple exogenous stimulus	[multiple exogenous stimuli]	1.5849625007211563	3	1	0	0
28097	1520	il-1r-associated kinase IRAK	[IL-1R-associated kinase IRAK]	1.5849625007211563	3	1	0	0
28098	1520	response to antigenic challenge	[response to antigenic challenge]	1.5849625007211563	4	1	0	0
28099	1520	inhibition of nuclear factor	[inhibition of nuclear factor]	1.5849625007211563	4	2	2	2
28100	1520	Beth Israel Hospital	[Beth Israel Hospital]	1.5849625007211563	3	1	0	0
28101	1520	transactivate rar-rxr response element	[transactivating RAR-RXR response elements]	1.5849625007211563	4	1	0	0
28102	1520	approximately 50 kda	[approximately 50 kDa]	1.5849625007211563	3	1	0	0
28103	1520	production by HUVECs	[production by HUVECs]	1.5849625007211563	3	1	0	0
28104	1520	expression in erythroid cell	[expression in erythroid cells]	1.5849625007211563	4	1	0	0
28105	1520	mononuclear phagocyte MNP	[mononuclear phagocytes MNP]	1.5849625007211563	3	1	0	0
28106	1520	breakpoint on chromosome 9	[breakpoint on chromosome 9]	1.5849625007211563	4	1	0	0
28107	1520	direct physiological effect	[direct physiological effects]	1.5849625007211563	3	1	0	0
28108	1520	b cell line b104	[B cell line B104]	1.5849625007211563	4	1	0	0
28109	1520	IL-4 another cytokine	[IL-4 another cytokine]	1.5849625007211563	3	1	0	0
28110	1520	lmp1 expression in Daudi	[LMP1 expression in Daudi]	1.5849625007211563	4	1	0	0
28111	1520	three 3' cytosin	[three 3' cytosins]	1.5849625007211563	3	1	0	0
28112	1520	peak at 6 h	[peaks at 6 h]	1.5849625007211563	4	1	0	0
28113	1520	cellular hemoglobin concentration	[cellular hemoglobin concentration]	1.5849625007211563	3	1	0	0
28114	1520	(approximately twofold increase).	[(approximately twofold increase).]	1.5849625007211563	3	1	0	0
28115	1520	shp1 protein tyrosine phosphatase	[SHP1 protein tyrosine phosphatase]	1.5849625007211563	4	1	0	0
28116	1520	thus, inhibition of gsk-3beta	[Thus, inhibition of GSK-3beta]	1.5849625007211563	4	1	0	0
28117	1520	normal binding to IFNgamma	[normal binding to IFNgamma]	1.5849625007211563	4	1	0	0
28118	1520	jun d transcript	[jun D transcripts]	1.5849625007211563	3	1	0	0
28119	1520	late phase of replication.	[late phase of replication.]	1.5849625007211563	4	1	0	0
28120	1520	dihydrochloride h7 a inhibitor	[dihydrochloride H7 an inhibitor]	1.5849625007211563	4	1	0	0
28121	1520	tyrosine phosphatase cd45	[tyrosine phosphatase CD45]	1.5849625007211563	3	1	0	0
28122	1520	difference in affinity	[differences in affinity]	1.5849625007211563	3	1	0	0
28123	1520	various concentration of insulin	[various concentrations of insulin]	1.5849625007211563	4	1	0	0
28124	1520	murine t-cell line	[murine T-cell line]	1.5849625007211563	3	1	0	0
28125	1520	nf-kb DNA binding activity	[NF-kB DNA binding activity]	1.5849625007211563	4	1	0	0
28126	1520	treatment with dexamethasone	[treatment with dexamethasone]	1.5849625007211563	3	2	1	1
28127	1520	gr binding affinity	[GR binding affinity]	1.5849625007211563	3	2	1	1
28128	1520	contain a pxqxt/ sequence	[containing a PXQXT/S sequence]	1.5849625007211563	4	1	0	0
28129	1520	number of cag	[number of CAG]	1.5849625007211563	3	1	0	0
28130	1520	Furthermore, CD28 coligation	[Furthermore, CD28 coligation]	1.5849625007211563	3	1	0	0
28131	1520	recently, human mononuclear leukocyte	[recently, human mononuclear leukocytes]	1.5849625007211563	4	1	0	0
28132	1520	Drosophila developmental control protein	[Drosophila developmental control protein]	1.5849625007211563	4	1	0	0
28133	1520	suppression of phosphorylation	[suppression of phosphorylation]	1.5849625007211563	3	1	0	0
28134	1520	dexamethasone synthetic glucocorticoid	[dexamethasone synthetic glucocorticoid]	1.5849625007211563	3	1	0	0
28135	1520	specific monoclonal antibody recognition	[specific monoclonal antibody recognition]	1.5849625007211563	4	1	0	0
28136	1520	rather, hepor transcription activity	[Rather, hEpoR transcription activity]	1.5849625007211563	4	1	0	0
28137	1520	inhibit hiv production	[inhibiting HIV production]	1.5849625007211563	3	1	0	0
28138	1520	drosophila runt protein	[Drosophila Runt protein]	1.5849625007211563	3	1	0	0
28139	1520	e2f -DNA binding activity	[E2F -DNA binding activity]	1.5849625007211563	4	1	0	0
28140	1520	molecular basis for activation	[molecular basis for activation]	1.5849625007211563	4	1	0	0
28141	1520	pathogenesis of allograft rejection	[pathogenesis of allograft rejection]	1.5849625007211563	4	1	0	0
28142	1520	modulatory effect of ifn-gamma	[modulatory effects of IFN-gamma]	1.5849625007211563	4	1	0	0
28143	1520	nitric oxide iNO	[nitric oxide iNO]	1.5849625007211563	3	1	0	0
28144	1520	effect of Epo	[effects of Epo]	1.5849625007211563	3	1	0	0
28145	1520	eccentrically place round nucleus	[eccentrically placed, round nucleus]	1.5849625007211563	4	1	0	0
28146	1520	vitd3 response element	[VitD3 response elements]	1.5849625007211563	3	1	0	0
28147	1520	rare in undifferentiated cell	[RAREs in undifferentiated cells]	1.5849625007211563	4	1	0	0
28148	1520	N-terminal region of clone	[N-terminal region of clone]	1.5849625007211563	4	1	0	0
28149	1520	cellular DNA damage	[cellular DNA damage]	1.5849625007211563	3	1	0	0
28150	1520	case of NLPHD	[cases of NLPHD]	1.5849625007211563	3	1	0	0
28151	1520	-inducible fas promoter activation	[-inducible fas promoter activation]	1.5849625007211563	4	1	0	0
28152	1520	expression of FasL	[expression of FasL]	1.5849625007211563	3	1	0	0
28153	1520	datum compare the effect	[data comparing the effects]	1.5849625007211563	4	1	0	0
28154	1520	array of protein	[array of proteins]	1.5849625007211563	3	2	2	2
28155	1520	abnormality for one probe	[Abnormalities for one probes]	1.5849625007211563	4	1	0	0
28156	1520	distinct action on erythropoiesis	[distinct action on erythropoiesis]	1.5849625007211563	4	1	0	0
28157	1520	ability of the trans-dimer	[ability of the trans-dimer]	1.5849625007211563	4	1	0	0
28158	1520	location within this cluster	[location within this cluster]	1.5849625007211563	4	1	0	0
28159	1520	zap-70 signal function	[ZAP-70 signaling function]	1.5849625007211563	3	2	2	2
28160	1520	1) rante promoter activity	[1) RANTES promoter activity]	1.5849625007211563	4	1	0	0
28161	1520	b cell ige synthesis	[B cell IgE synthesis]	1.5849625007211563	4	1	0	0
28162	1520	minimal residual disease MRD	[minimal residual disease MRD]	1.5849625007211563	4	2	1	1
28163	1520	protein kinase c substrate	[protein kinase C substrate]	1.5849625007211563	4	3	2	1
28164	1520	regulation of wnt signal	[regulation of Wnt signaling]	1.5849625007211563	4	1	0	0
28165	1520	70% level in supernatant	[70% levels in supernatants]	1.5849625007211563	4	1	0	0
28166	1520	DR alpha promoter activity	[DR alpha promoter activity]	1.5849625007211563	4	1	0	0
28167	1520	potential inhibitor of GRalpha	[potential inhibitor of GRalpha]	1.5849625007211563	4	1	0	0
28168	1520	IL-4 responsive element	[IL-4 responsive elements]	1.5849625007211563	3	1	0	0
28169	1520	potential implication for therapy	[potential implications for therapies]	1.5849625007211563	4	1	0	0
28170	1520	expression of NDP kinase	[expression of NDP kinase]	1.5849625007211563	4	1	0	0
28171	1520	differentiation of cell lineage	[differentiation of cell lineages]	1.5849625007211563	4	1	0	0
28172	1520	malignant cell cytokine production	[malignant cell cytokine production]	1.5849625007211563	4	1	0	0
28173	1520	follow JAK3 expression	[following JAK3 expression]	1.5849625007211563	3	1	0	0
28174	1520	migration in lymphocyte	[migration in lymphocytes]	1.5849625007211563	3	1	0	0
28175	1520	k562 human erythroleukemia cell	[K562 human erythroleukemia cells]	1.5849625007211563	4	2	1	1
28176	1520	patient with ad (n	[Patients with AD (n]	1.5849625007211563	4	1	0	0
28177	1520	monocytic cell by member	[monocytic cells by members]	1.5849625007211563	4	1	0	0
28178	1520	activator of camp-	[activators of cAMP-]	1.5849625007211563	3	1	0	0
28179	1520	absence of specific mrna	[absence of specific mRNA]	1.5849625007211563	4	1	0	0
28180	1520	messenger in the activation	[messengers in the activation]	1.5849625007211563	4	1	0	0
28181	1520	membrane structural order	[membrane structural order]	1.5849625007211563	3	2	2	2
28182	1520	interleukin 3 IL-3	[interleukin 3 IL-3]	1.5849625007211563	3	1	0	0
28183	1520	expression of a-myb	[Expression of A-myb]	1.5849625007211563	3	1	0	0
28184	1520	tnfrp55 -deficient mouse strain	[TNFRp55 -deficient mouse strain]	1.5849625007211563	4	1	0	0
28185	1520	two human pre-B-cell line	[two human pre-B-cell lines]	1.5849625007211563	4	1	0	0
28186	1520	IL-2 -independent cell line	[IL-2 -independent cell lines]	1.5849625007211563	4	2	1	1
28187	1520	patient with pco	[patients with PCOS]	1.5849625007211563	3	2	1	1
28188	1520	strong promoter activity	[strong promoter activity]	1.5849625007211563	3	1	0	0
28189	1520	proliferate T lymphocyte	[proliferating T lymphocytes]	1.5849625007211563	3	1	0	0
28190	1520	CD5 surface expression	[CD5 surface expression]	1.5849625007211563	3	2	1	1
28191	1520	difference in sex	[difference in sex]	1.5849625007211563	3	1	0	0
28192	1520	pituitary-specific start site	[pituitary-specific start site]	1.5849625007211563	3	1	0	0
28193	1520	different age group	[different age groups]	1.5849625007211563	3	1	0	0
28194	1520	expression of il-8	[expression of IL-8]	1.5849625007211563	3	1	0	0
28195	1520	expression of il-5	[expression of IL-5]	1.5849625007211563	3	1	0	0
28196	1520	expression of il-4	[expression of IL-4]	1.5849625007211563	3	2	2	2
28197	1520	expression of il-3	[expression of IL-3]	1.5849625007211563	3	2	2	2
28198	1520	laser scanning microscopy	[laser scanning microscopy]	1.5849625007211563	3	2	2	2
28199	1520	normal adult erythroid differentiation	[normal adult erythroid differentiation]	1.5849625007211563	4	1	0	0
28200	1520	dose of 10 mg/d.	[dose of 10 mg/d.]	1.5849625007211563	4	1	0	0
28201	1520	about 1 ng/ml.	[about 1 ng/ml.]	1.5849625007211563	3	1	0	0
28202	1520	single-cell level consist	[single-cell level consisting]	1.5849625007211563	3	1	0	0
28203	1520	context of a enhancer	[context of a enhancer]	1.5849625007211563	4	1	0	0
28204	1520	10(-11)-10(-10) m D3	[10(-11)-10(-10) M D3]	1.5849625007211563	3	1	0	0
28205	1520	tax expression vector	[Tax expression vector]	1.5849625007211563	3	1	0	0
28206	1520	interferon family of receptors,	[interferon family of receptors,]	1.5849625007211563	4	1	0	0
28207	1520	cognate ligand RANKL	[cognate ligand RANKL]	1.5849625007211563	3	1	0	0
28208	1520	totally unrelated protein	[totally unrelated proteins]	1.5849625007211563	3	1	0	0
28209	1520	cell in vitro	[cells in vitro]	1.5849625007211563	3	1	0	0
28210	1520	nf-at region transactivation	[NF-AT region transactivation]	1.5849625007211563	3	1	0	0
28211	1520	65 patient with RCC	[65 patients with RCC]	1.5849625007211563	4	1	0	0
28212	1520	p38 mapk inhibitor	[p38 MAPK inhibitor]	1.5849625007211563	3	2	2	2
28213	1520	vitro granulocytic differentiation	[vitro granulocytic differentiation]	1.5849625007211563	3	1	0	0
28214	1520	zap-70 autophosphorylation to p56(lck)	[ZAP-70 autophosphorylation to p56(lck)]	1.5849625007211563	4	1	0	0
28215	1520	first NH2-terminal 29 residue	[first NH2-terminal 29 residues]	1.5849625007211563	4	1	0	0
28216	1520	resistance to cationic protein	[resistance to cationic proteins]	1.5849625007211563	4	1	0	0
28217	1520	new recognition structure	[new recognition structure]	1.5849625007211563	3	1	0	0
28218	1520	model for hiv replication	[model for HIV replication]	1.5849625007211563	4	1	0	0
28219	1520	favour of the regulation	[favour of the regulation]	1.5849625007211563	4	1	0	0
28220	1520	metabolic labeling with [32P]orthophosphate	[metabolic labeling with [32P]orthophosphate]	1.5849625007211563	4	1	0	0
28221	1520	rectal minus oral value	[rectal minus oral values]	1.5849625007211563	4	1	0	0
28222	1520	c-fo b mrna expression	[c-fos B mRNA expression]	1.5849625007211563	4	1	0	0
28223	1520	regulation of il-4 gene	[regulation of IL-4 genes]	1.5849625007211563	4	1	0	0
28224	1520	10% xenogeneic human serum	[10% xenogeneic human serum]	1.5849625007211563	4	1	0	0
28225	1520	such as IL-4,	[such as IL-4,]	1.5849625007211563	3	1	0	0
28226	1520	nno in glia	[nNOS in glia]	1.5849625007211563	3	1	0	0
28227	1520	target ras express tumor	[targeting Ras expressing tumors]	1.5849625007211563	4	1	0	0
28228	1520	different set of signal	[different sets of signals]	1.5849625007211563	4	1	0	0
28229	1520	differentiation towards neutrophil	[differentiation towards neutrophils]	1.5849625007211563	3	1	0	0
28230	1520	pro-monocytic cell line u937	[pro-monocytic cell line U937]	1.5849625007211563	4	1	0	0
28231	1520	protein with sh3 domain	[proteins with SH3 domains]	1.5849625007211563	4	1	0	0
28232	1520	cell cycle of system	[cell cycles of systems]	1.5849625007211563	4	1	0	0
28233	1520	activation of coagulation	[activation of coagulation]	1.5849625007211563	3	1	0	0
28234	1520	cell type by interferon-gamma	[cell types by interferon-gamma]	1.5849625007211563	4	1	0	0
28235	1520	hepatic leukemia factor HLF	[hepatic leukemia factor HLF]	1.5849625007211563	4	2	1	1
28236	1520	induction of DNA breaks,	[induction of DNA breaks,]	1.5849625007211563	4	1	0	0
28237	1520	other cellular factors,	[other cellular factors,]	1.5849625007211563	3	1	0	0
28238	1520	cell stage-specific distribution.	[cell stage-specific distribution.]	1.5849625007211563	3	1	0	0
28239	1520	immunoglobulin heavy-chain (igh) enhancer	[immunoglobulin heavy-chain (IgH) enhancer]	1.5849625007211563	4	1	0	0
28240	1520	decoy oligodeoxynucleotide for NF-kappaB	[decoy oligodeoxynucleotide for NF-kappaB]	1.5849625007211563	4	1	0	0
28241	1520	response to acidic activator	[response to acidic activators]	1.5849625007211563	4	1	0	0
28242	1520	IL-1alpha promoter by nf-kappab	[IL-1alpha promoter by NF-kappaB]	1.5849625007211563	4	1	0	0
28243	1520	glucocorticoid-sensitive 6tg1.1 resistant icr27tk.3	[glucocorticoid-sensitive 6TG1.1 resistant ICR27TK.3]	1.5849625007211563	4	1	0	0
28244	1520	codon genotype tt	[codon genotype tt]	1.5849625007211563	3	1	0	0
28245	1520	mediator of transcriptional activation	[mediator of transcriptional activation]	1.5849625007211563	4	1	0	0
28246	1520	binding of p50 complex	[binding of p50 complex]	1.5849625007211563	4	1	0	0
28247	1520	regulation of stat3 phosphorylation	[regulation of STAT3 phosphorylation]	1.5849625007211563	4	1	0	0
28248	1520	demonstration of antigen	[demonstration of antigens]	1.5849625007211563	3	1	0	0
28249	1520	cell-free rna transcription assay	[cell-free RNA transcription assay]	1.5849625007211563	4	1	0	0
28250	1520	low abundance in brain	[lowest abundance in brain]	1.5849625007211563	4	1	0	0
28251	1520	three mutant -201/-184 NXS	[Three mutants -201/-184 NXS]	1.5849625007211563	4	1	0	0
28252	1520	gr mrna /microg rna	[GR mRNA /microg RNA]	1.5849625007211563	4	1	0	0
28253	1520	prototypic compound, ru24858	[prototypic compound, RU24858]	1.5849625007211563	3	1	0	0
28254	1520	responsiveness to tata	[responsiveness to tat/S]	1.5849625007211563	3	1	0	0
28255	1520	novel sequence element	[novel sequence element]	1.5849625007211563	3	1	0	0
28256	1520	suppress t-cell proliferation	[suppressing T-cell proliferation]	1.5849625007211563	3	1	0	0
28257	1520	inhibitor protein b alpha	[inhibitor protein B alpha]	1.5849625007211563	4	1	0	0
28258	1520	B-cell antigen receptor complex	[B-cell antigen receptor complex]	1.5849625007211563	4	1	0	0
28259	1520	PHA/ PMA stimulation	[PHA/ PMA stimulation]	1.5849625007211563	3	1	0	0
28260	1520	infection by EBV	[infection by EBV]	1.5849625007211563	3	2	1	1
28261	1520	efficient binding of p50p50	[efficient binding of p50p50]	1.5849625007211563	4	1	0	0
28262	1520	significant homology with p13mtcp1	[significant homology with p13MTCP1]	1.5849625007211563	4	1	0	0
28263	1520	cd28-induced il-2 promoter activity	[CD28-induced IL-2 promoter activity]	1.5849625007211563	4	1	0	0
28264	1520	one dna-binding complex	[one DNA-binding complex]	1.5849625007211563	3	1	0	0
28265	1520	Ag-activated T cell	[Ag-activated T cells]	1.5849625007211563	3	1	0	0
28266	1520	TRAF binding site	[TRAF binding sites]	1.5849625007211563	3	2	1	1
28267	1520	oligonucleotide carry base substitution	[oligonucleotides carrying base substitutions]	1.5849625007211563	4	1	0	0
28268	1520	interleukin-2 IL-2 deprivation	[interleukin-2 IL-2 deprivation]	1.5849625007211563	3	1	0	0
28269	1520	relative amount of hmg-i(y)	[relative amount of HMG-I(Y)]	1.5849625007211563	4	1	0	0
28270	1520	CRM1 from the NPC	[CRM1 from the NPC]	1.5849625007211563	4	1	0	0
28271	1520	lack the NF-kappa b	[lacking the NF-kappa B]	1.5849625007211563	4	1	0	0
28272	1520	functional ets site	[functional Ets site]	1.5849625007211563	3	1	0	0
28273	1520	vdre binding complex	[VDRE binding complexes]	1.5849625007211563	3	1	0	0
28274	1520	inheritance of certain combination	[inheritance of certain combinations]	1.5849625007211563	4	1	0	0
28275	1520	molecular process related	[molecular processes related]	1.5849625007211563	3	1	0	0
28276	1520	leucine zipper protein family	[leucine zipper protein family]	1.5849625007211563	4	1	0	0
28277	1520	A beta peptide	[A beta peptides]	1.5849625007211563	3	2	1	1
28278	1520	result in the outgrowth	[resulting in the outgrowth]	1.5849625007211563	4	1	0	0
28279	1520	media of blood cell	[media of blood cells]	1.5849625007211563	4	1	0	0
28280	1520	adhesion studies, cortisol	[adhesion studies, cortisol]	1.5849625007211563	3	1	0	0
28281	1520	2 (sh2) domain	[2 (SH2) domain]	1.5849625007211563	3	1	0	0
28282	1520	75 kilometer TNFRp75	[75 kd TNFRp75]	1.5849625007211563	3	1	0	0
28283	1520	human erythrocyte ghost membrane	[human erythrocyte ghost membrane]	1.5849625007211563	4	2	1	1
28284	1520	patient in ST remission	[patients in ST remission]	1.5849625007211563	4	2	1	1
28285	1520	legionella pneumophila rpo gene	[Legionella pneumophila rpoS gene]	1.5849625007211563	4	1	0	0
28286	1520	lps endothelial cell adhesiveness	[LPS endothelial cell adhesiveness]	1.5849625007211563	4	1	0	0
28287	1520	2 receptor beta	[2 receptor beta]	1.5849625007211563	3	1	0	0
28288	1520	use site-directed mutagenesis,	[Using site-directed mutagenesis,]	1.5849625007211563	3	1	0	0
28289	1520	inhibition of isomerase activity	[inhibition of isomerase activity]	1.5849625007211563	4	1	0	0
28290	1520	cell surface ganglioside gd3	[cell surface ganglioside GD3]	1.5849625007211563	4	1	0	0
28291	1520	surface expression of p-selectin	[surface expression of P-selectin]	1.5849625007211563	4	1	0	0
28292	1520	ig gene expression	[Ig gene expression]	1.5849625007211563	3	1	0	0
28293	1520	vd3 on cell growth	[VD3 on cell growth]	1.5849625007211563	4	1	0	0
28294	1520	background entamoeba histolytica infection	[BACKGROUND Entamoeba histolytica infection]	1.5849625007211563	4	1	0	0
28295	1520	critical regulatory element	[critical regulatory element]	1.5849625007211563	3	1	0	0
28296	1520	NF-kappaB of the ap-1	[NF-kappaB of the AP-1]	1.5849625007211563	4	1	0	0
28297	1520	expression of hla-dq	[expression of HLA-DQ]	1.5849625007211563	3	1	0	0
28298	1520	lymphocyte gene activation	[lymphocyte gene activation]	1.5849625007211563	3	2	1	1
28299	1520	il-10 c-fo expression	[IL-10 c-fos expression]	1.5849625007211563	3	1	0	0
28300	1520	trans- dominant negative inhibitor	[trans- dominant negative inhibitor]	1.5849625007211563	4	1	0	0
28301	1520	appropriate phosphorothioate oligonucleotide	[appropriate phosphorothioate oligonucleotide]	1.5849625007211563	3	1	0	0
28302	1520	sensitive polymerase chain reaction	[sensitive polymerase chain reaction]	1.5849625007211563	4	2	2	2
28303	1520	onset of inflammatory response	[onset of inflammatory responses]	1.5849625007211563	4	1	0	0
28304	1520	inducible factor nk-kappa b	[inducible factors NK-kappa B]	1.5849625007211563	4	1	0	0
28305	1520	human epsilon- globin gene	[human epsilon- globin gene]	1.5849625007211563	4	1	0	0
28306	1520	pathophysiology of ehrlichiosis response	[pathophysiology of ehrlichiosis responses]	1.5849625007211563	4	1	0	0
28307	1520	base exchange at -509	[base exchange at -509]	1.5849625007211563	4	1	0	0
28308	1520	alteration of Pebp2	[alterations of Pebp2]	1.5849625007211563	3	1	0	0
28309	1520	expression of co-stimulatory activity	[expression of co-stimulatory activity]	1.5849625007211563	4	1	0	0
28310	1520	two different protein	[two different protein]	1.5849625007211563	3	2	1	1
28311	1520	target cell hla-dr expression	[target cell HLA-DR expression]	1.5849625007211563	4	1	0	0
28312	1520	TH -dependent positive effect	[TH -dependent positive effect]	1.5849625007211563	4	1	0	0
28313	1520	activation by p59fyn	[activation by p59fyn]	1.5849625007211563	3	1	0	0
28314	1520	690 kb from sox9	[690 kb from SOX9]	1.5849625007211563	4	1	0	0
28315	1520	2-3 fold increase	[2-3 fold increase]	1.5849625007211563	3	1	0	0
28316	1520	lymphocyte of peripheral blood	[lymphocytes of peripheral blood]	1.5849625007211563	4	1	0	0
28317	1520	two cell population	[two cell populations]	1.5849625007211563	3	1	0	0
28318	1520	response to anti-CD3 stimulation	[response to anti-CD3 stimulation]	1.5849625007211563	4	1	0	0
28319	1520	epithelial specific manner	[epithelial specific manner]	1.5849625007211563	3	1	0	0
28320	1520	function of pkc isotype	[function of PKC isotypes]	1.5849625007211563	4	1	0	0
28321	1520	course of the cell	[course of the cells]	1.5849625007211563	4	1	0	0
28322	1520	oap /octamer motif	[OAP /octamer motif]	1.5849625007211563	3	1	0	0
28323	1520	influence on the effect	[influence on the effects]	1.5849625007211563	4	1	0	0
28324	1520	expression of the mrna	[expression of the mRNA]	1.5849625007211563	4	2	2	2
28325	1520	cd11b integrin expression	[CD11b integrin expression]	1.5849625007211563	3	1	0	0
28326	1520	treatment with acid	[treatment with acid]	1.5849625007211563	3	2	2	2
28327	1520	thymic population of mouse	[thymic populations of mice]	1.5849625007211563	4	1	0	0
28328	1520	occur at 0.21-0.33 nm.	[occurring at 0.21-0.33 nM.]	1.5849625007211563	4	1	0	0
28329	1520	25-hydroxyvitamin D3 trafficking	[25-hydroxyvitamin D3 trafficking]	1.5849625007211563	3	1	0	0
28330	1520	local cellular immune response	[local cellular immune response]	1.5849625007211563	4	1	0	0
28331	1520	METHODS: IBD patient	[METHODS: IBD patients]	1.5849625007211563	3	1	0	0
28332	1520	development of specific strategy	[development of specific strategies]	1.5849625007211563	4	1	0	0
28333	1520	different myeloid developmental stage	[different myeloid developmental stages]	1.5849625007211563	4	1	0	0
28334	1520	protein kinase mapk homologue	[protein kinase MAPk homologue]	1.5849625007211563	4	1	0	0
28335	1520	only transcriptional activation	[only transcriptional activation]	1.5849625007211563	3	1	0	0
28336	1520	mode of action.	[mode of action.]	1.5849625007211563	3	2	2	2
28337	1520	remove transcriptional repression	[removing transcriptional repression]	1.5849625007211563	3	1	0	0
28338	1520	mutant ach clone	[mutant ACH clones]	1.5849625007211563	3	1	0	0
28339	1520	individual cell line	[individual cell lines]	1.5849625007211563	3	1	0	0
28340	1520	epithelium of the tarsal	[epithelium of the tarsal]	1.5849625007211563	4	1	0	0
28341	1520	staphylococcal enterotoxin b	[staphylococcal enterotoxin B]	1.5849625007211563	3	1	0	0
28342	1520	just like human counterpart.	[just like human counterpart.]	1.5849625007211563	4	1	0	0
28343	1520	lymphoblast cell line msb	[lymphoblast cell line MSB]	1.5849625007211563	4	1	0	0
28344	1520	response to ifn-gamma	[response to IFN-gamma]	1.5849625007211563	3	2	1	1
28345	1520	enzyme active site	[enzyme active site]	1.5849625007211563	3	1	0	0
28346	1520	hetero dimer complex	[hetero dimer complexes]	1.5849625007211563	3	1	0	0
28347	1520	abrogate E-box-dependent bhlh homo-	[abrogating E-box-dependent bHLH homo-]	1.5849625007211563	4	1	0	0
28348	1520	increase in granulocytic differentiation	[increase in granulocytic differentiation]	1.5849625007211563	4	1	0	0
28349	1520	non- ig gene	[non- Ig genes]	1.5849625007211563	3	1	0	0
28350	1520	erythroid cell in vivo	[erythroid cells in vivo]	1.5849625007211563	4	1	0	0
28351	1520	immunoglobulin class switch	[immunoglobulin class switching]	1.5849625007211563	3	1	0	0
28352	1520	regulation of transcription factor	[regulation of transcription factors]	1.5849625007211563	4	2	1	1
28353	1520	gene' inducibility by PMA	[gene's inducibility by PMA]	1.5849625007211563	4	1	0	0
28354	1520	appearance of ebv genome	[appearance of EBV genome]	1.5849625007211563	4	1	0	0
28355	1520	ras /protein kinase c	[Ras /protein kinase C]	1.5849625007211563	4	1	0	0
28356	1520	measure postcapillary venule pcv	[measuring postcapillary venules PCVs]	1.5849625007211563	4	1	0	0
28357	1520	nf-y activity circulate monocyte	[NF-Y activity circulating monocytes]	1.5849625007211563	4	1	0	0
28358	1520	E., Pollio, G., Pellicciari,	[E., Pollio, G., Pellicciari,]	1.5849625007211563	4	1	0	0
28359	1520	separation of cell	[separation of cells]	1.5849625007211563	3	1	0	0
28360	1520	response to inflammatory stimulus	[response to inflammatory stimuli]	1.5849625007211563	4	2	2	2
28361	1520	majority of gct	[majority of GCT]	1.5849625007211563	3	1	0	0
28362	1520	central importance in tissue	[central importance in tissues]	1.5849625007211563	4	1	0	0
28363	1520	interferon-gamma-induced nuclear binding factor	[interferon-gamma-induced nuclear binding factor]	1.5849625007211563	4	1	0	0
28364	1520	macrophage-colony-stimulating factor M-CSF	[Macrophage-colony-stimulating factor M-CSF]	1.5849625007211563	3	1	0	0
28365	1520	male breast cancer patient	[male breast cancer patients]	1.5849625007211563	4	2	2	2
28366	1520	response to ligand activation	[response to ligand activation]	1.5849625007211563	4	1	0	0
28367	1520	biological function of ZEBRA	[biological functions of ZEBRA]	1.5849625007211563	4	1	0	0
28368	1520	patient with recurrent infections.	[patients with recurrent infections.]	1.5849625007211563	4	1	0	0
28369	1520	deltaspi-B spi-b rrna	[deltaspi-B spi-B mRNAs]	1.5849625007211563	3	1	0	0
28370	1520	calcineurin substrate in cells.	[calcineurin substrate in cells.]	1.5849625007211563	4	1	0	0
28371	1520	tcr beta locus	[TCR beta locus]	1.5849625007211563	3	1	0	0
28372	1520	differential expression model	[differential expression model]	1.5849625007211563	3	1	0	0
28373	1520	T cell line CEM	[T cell line CEM]	1.5849625007211563	4	2	2	2
28374	1520	Egr-1 mrna activate signal	[Egr-1 mRNA activating signals]	1.5849625007211563	4	1	0	0
28375	1520	pocket region of Rb	[pocket region of Rb]	1.5849625007211563	4	1	0	0
28376	1520	many other cell	[many other cells]	1.5849625007211563	3	1	0	0
28377	1520	possible therapeutic approach	[possible therapeutic approaches]	1.5849625007211563	3	1	0	0
28378	1520	day 7 cell	[day 7 cells]	1.5849625007211563	3	2	1	1
28379	1520	blood mononuclear cell culture	[blood mononuclear cell cultures]	1.5849625007211563	4	2	2	2
28380	1520	histologic grade, DNA aneuploidy	[histologic grade, DNA aneuploidy]	1.5849625007211563	4	2	1	1
28381	1520	time-dependent tyrosine phosphorylation	[time-dependent tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
28382	1520	characterization of CIITA mutant	[characterization of CIITA mutants]	1.5849625007211563	4	1	0	0
28383	1520	inhibit il-2 transcription	[inhibiting IL-2 transcription]	1.5849625007211563	3	1	0	0
28384	1520	complex of transcription factor	[complex of transcription factors]	1.5849625007211563	4	1	0	0
28385	1520	meaning of this finding	[meaning of this finding]	1.5849625007211563	4	1	0	0
28386	1520	basis of this assays,	[basis of these assays,]	1.5849625007211563	4	1	0	0
28387	1520	rac1 gtpase two enzyme	[Rac1 GTPases two enzymes]	1.5849625007211563	4	1	0	0
28388	1520	different subtype of lymphoma	[different subtypes of lymphomas]	1.5849625007211563	4	1	0	0
28389	1520	chemotactic migration of leukocyte	[chemotactic migration of leukocytes]	1.5849625007211563	4	2	2	2
28390	1520	PKC -dependent -independent pathway	[PKC -dependent -independent pathways]	1.5849625007211563	4	1	0	0
28391	1520	patient with lupus	[patients with lupus]	1.5849625007211563	3	1	0	0
28392	1520	cooperation between October	[cooperation between Oct]	1.5849625007211563	3	1	0	0
28393	1520	undifferentiated embryocarcinoma f9 cell	[undifferentiated embryocarcinoma F9 cells]	1.5849625007211563	4	1	0	0
28394	1520	prerequisite for the activation	[prerequisite for the activation]	1.5849625007211563	4	1	0	0
28395	1520	isotype-matched control antibody	[isotype-matched control antibody]	1.5849625007211563	3	1	0	0
28396	1520	ubiquitination of IkappaBalpha	[ubiquitination of IkappaBalpha]	1.5849625007211563	3	1	0	0
28397	1520	AIDS -c group	[AIDS -C group]	1.5849625007211563	3	2	1	1
28398	1520	Recently, transcription factor	[Recently, transcription factors]	1.5849625007211563	3	1	0	0
28399	1520	c-fo regulatory region	[c-fos regulatory region]	1.5849625007211563	3	1	0	0
28400	1520	T cell receptor-	[T cell receptor-]	1.5849625007211563	3	1	0	0
28401	1520	selective IFN responsiveness	[selective IFN responsiveness]	1.5849625007211563	3	1	0	0
28402	1520	subsequently, such cell	[Subsequently, such cells]	1.5849625007211563	3	1	0	0
28403	1520	second of ultra-violet irradiation	[seconds of UV irradiation]	1.5849625007211563	4	1	0	0
28404	1520	detection by cell	[detection by cells]	1.5849625007211563	3	1	0	0
28405	1520	field of pharmacogenetics	[field of pharmacogenetics]	1.5849625007211563	3	1	0	0
28406	1520	pituitary cell system	[pituitary cell system]	1.5849625007211563	3	1	0	0
28407	1520	(3) hhv-6 T cell	[(3) HHV-6 T cells]	1.5849625007211563	4	1	0	0
28408	1520	rprl footprint repressor site	[rPRL footprint repressor site]	1.5849625007211563	4	1	0	0
28409	1520	candidate oncoprotein Bcl-3	[candidate oncoprotein Bcl-3]	1.5849625007211563	3	1	0	0
28410	1520	hairy cell leukemia	[hairy cell leukemia]	1.5849625007211563	3	1	0	0
28411	1520	wild-type mouse EpoR	[wild-type mouse EpoR]	1.5849625007211563	3	1	0	0
28412	1520	implicate the lymphokine interferon-gamma	[implicating the lymphokine interferon-gamma]	1.5849625007211563	4	1	0	0
28413	1520	proliferation of ach-2 cell	[proliferation of ACH-2 cells]	1.5849625007211563	4	1	0	0
28414	1520	growth-affecting gene other	[growth-affecting genes other]	1.5849625007211563	3	1	0	0
28415	1520	IL-4 Stat activation cycle	[IL-4 Stat activation cycle]	1.5849625007211563	4	1	0	0
28416	1520	mitogenic signal response	[mitogenic signalling response]	1.5849625007211563	3	1	0	0
28417	1520	extensive nucleotide sequence	[extensive nucleotide sequence]	1.5849625007211563	3	1	0	0
28418	1520	cytokine-induced hiv-1 expression	[cytokine-induced HIV-1 expression]	1.5849625007211563	3	1	0	0
28419	1520	capacity of gh	[capacity of GH]	1.5849625007211563	3	1	0	0
28420	1520	action of recombinant pc4	[action of recombinant PC4]	1.5849625007211563	4	1	0	0
28421	1520	26-kDa membrane form	[26-kDa membrane form]	1.5849625007211563	3	1	0	0
28422	1520	TAL1 gene product	[TAL1 gene products]	1.5849625007211563	3	1	0	0
28423	1520	mitogen-activated kinase erk2	[mitogen-activated kinase Erk2]	1.5849625007211563	3	1	0	0
28424	1520	low level in macrophage	[lower levels in macrophages]	1.5849625007211563	4	1	0	0
28425	1520	second essential positive element	[second essential positive element]	1.5849625007211563	4	1	0	0
28426	1520	NF-kappa b inhibition	[NF-kappa B inhibition]	1.5849625007211563	3	1	0	0
28427	1520	relationship to glucocorticoid receptor	[relationship to glucocorticoid receptors]	1.5849625007211563	4	1	0	0
28428	1520	development of glucocorticoid-based drug	[development of glucocorticoid-based drugs]	1.5849625007211563	4	1	0	0
28429	1520	footprinting at the site	[footprinting at the site]	1.5849625007211563	4	1	0	0
28430	1520	functionally interact with interleukin-1	[functionally interacting with interleukin-1]	1.5849625007211563	4	1	0	0
28431	1520	other two SR patient	[other two SR patients]	1.5849625007211563	4	1	0	0
28432	1520	alveolar macrophage nuclear protein	[alveolar macrophage nuclear proteins]	1.5849625007211563	4	1	0	0
28433	1520	specific responsive element il-4re	[specific responsive element IL-4RE]	1.5849625007211563	4	1	0	0
28434	1520	158 base pair upstream	[158 base pairs upstream]	1.5849625007211563	4	1	0	0
28435	1520	elk-1 promoter activity.	[elk-1 promoter activity.]	1.5849625007211563	3	1	0	0
28436	1520	target kappa b alpha	[targeting kappa B alpha]	1.5849625007211563	4	1	0	0
28437	1520	rel protein specifically p50	[Rel proteins specifically p50]	1.5849625007211563	4	1	0	0
28438	1520	concentration of p50	[concentrations of p50]	1.5849625007211563	3	1	0	0
28439	1520	vitro immortalization of progenitor	[vitro immortalization of progenitors]	1.5849625007211563	4	1	0	0
28440	1520	resultant primer product	[resultant primer products]	1.5849625007211563	3	1	0	0
28441	1520	short DNA sequence CTG-motif	[short DNA sequence CTG-motif]	1.5849625007211563	4	1	0	0
28442	1520	mediate normal t-cell activation	[mediating normal T-cell activation]	1.5849625007211563	4	1	0	0
28443	1520	patient with plzf-rar alpha	[patients with PLZF-RAR alpha]	1.5849625007211563	4	1	0	0
28444	1520	parental k562 cell	[parental K562 cells]	1.5849625007211563	3	1	0	0
28445	1520	human chromosome 5q23-31	[human chromosome 5q23-31]	1.5849625007211563	3	1	0	0
28446	1520	5 ras peptide	[5 RAS peptides]	1.5849625007211563	3	1	0	0
28447	1520	Fli-1 expression vector	[Fli-1 expression vector]	1.5849625007211563	3	1	0	0
28448	1520	ratio of the subset	[ratio of the subsets]	1.5849625007211563	4	1	0	0
28449	1520	human il4 promoter	[Human IL4 promoter]	1.5849625007211563	3	2	1	1
28450	1520	onset of differentiation	[onset of differentiation]	1.5849625007211563	3	2	1	1
28451	1520	presence of e2f binding	[presence of E2F binding]	1.5849625007211563	4	1	0	0
28452	1520	m2 leukemic cell context	[M2 leukemic cell context]	1.5849625007211563	4	1	0	0
28453	1520	mammalian transcription factor	[mammalian transcription factor]	1.5849625007211563	3	1	0	0
28454	1520	stimulation of cck(b) receptor	[stimulation of CCK(B) receptors]	1.5849625007211563	4	1	0	0
28455	1520	signal pathway molecule analysis	[signaling pathway molecule analysis]	1.5849625007211563	4	1	0	0
28456	1520	ability of Delta	[ability of Delta]	1.5849625007211563	3	1	0	0
28457	1520	anti-mhc class ii	[anti-MHC class II]	1.5849625007211563	3	2	1	1
28458	1520	change in i-kappabalpha level	[changes in I-kappaBalpha levels]	1.5849625007211563	4	1	0	0
28459	1520	inhibit the signal-induced phosphorylation	[inhibiting the signal-induced phosphorylation]	1.5849625007211563	4	1	0	0
28460	1520	Nuclear c/ebp beta	[Nuclear C/EBP beta]	1.5849625007211563	3	1	0	0
28461	1520	hiv repeat transcription	[HIV repeat transcription]	1.5849625007211563	3	2	2	2
28462	1520	5637 non-lymphoid cell line	[5637 non-lymphoid cell line]	1.5849625007211563	4	1	0	0
28463	1520	transcription factor iid tfiid	[Transcription factor IID TFIID]	1.5849625007211563	4	1	0	0
28464	1520	72-kDa isoform of stat3	[72-kDa isoform of STAT3]	1.5849625007211563	4	1	0	0
28465	1520	specific mean fluorescence intensity	[specific mean fluorescence intensity]	1.5849625007211563	4	1	0	0
28466	1520	substantially less tyrosine stat5b	[substantially less tyrosine STAT5B]	1.5849625007211563	4	1	0	0
28467	1520	systemic hGR level	[systemic hGR levels]	1.5849625007211563	3	2	1	1
28468	1520	endogenous B29 gene	[endogenous B29 gene]	1.5849625007211563	3	1	0	0
28469	1520	leukemia inhibitory factor	[leukemia inhibitory factor]	1.5849625007211563	3	2	2	2
28470	1520	value of the young.	[values of the young.]	1.5849625007211563	4	1	0	0
28471	1520	human promonocytic u-937 cell	[human promonocytic U-937 cells]	1.5849625007211563	4	1	0	0
28472	1520	bear monosaccharide glycan	[bearing monosaccharide glycans]	1.5849625007211563	3	1	0	0
28473	1520	IL-13 like IL-4	[IL-13 like IL-4]	1.5849625007211563	3	1	0	0
28474	1520	also the human homologue	[also the human homologue]	1.5849625007211563	4	1	0	0
28475	1520	patient with deficiency-cold syndrome	[patients with deficiency-cold syndromes]	1.5849625007211563	4	1	0	0
28476	1520	immune system origin	[immune system origin]	1.5849625007211563	3	1	0	0
28477	1520	specimen from the airway	[specimens from the airways]	1.5849625007211563	4	1	0	0
28478	1520	adenovirus early region	[adenovirus early region]	1.5849625007211563	3	2	1	1
28479	1520	L-selectin promoter by tax	[L-selectin promoter by Tax]	1.5849625007211563	4	1	0	0
28480	1520	HLA-DQ isotype-specific trans-acting factor	[HLA-DQ isotype-specific trans-acting factor]	1.5849625007211563	4	1	0	0
28481	1520	corresponding to a influx.	[corresponding to an influx.]	1.5849625007211563	4	1	0	0
28482	1520	human keratinocyte pcd/dcoh	[human keratinocyte PCD/DCoH]	1.5849625007211563	3	1	0	0
28483	1520	basal transcription of htlv-i	[basal transcription of HTLV-I]	1.5849625007211563	4	1	0	0
28484	1520	increase in tyrosine phosphorylation	[increase in tyrosine phosphorylation]	1.5849625007211563	4	2	1	1
28485	1520	latent proviral transcription	[latent proviral transcription]	1.5849625007211563	3	1	0	0
28486	1520	class ii processing	[class II processing]	1.5849625007211563	3	2	1	1
28487	1520	tool for the detection	[tool for the detection]	1.5849625007211563	4	1	0	0
28488	1520	analysis of RelA(p65) mrna	[Analysis of RelA(p65) mRNA]	1.5849625007211563	4	1	0	0
28489	1520	ifn-gamma binding activity	[IFN-gamma binding activity]	1.5849625007211563	3	1	0	0
28490	1520	strong activate element	[strongest activating elements]	1.5849625007211563	3	1	0	0
28491	1520	ets protein elf-1	[Ets protein Elf-1]	1.5849625007211563	3	2	2	2
28492	1520	endogenous vitamin D3 receptor	[endogenous vitamin D3 receptor]	1.5849625007211563	4	1	0	0
28493	1520	T lymphocyte for production	[T lymphocytes for production]	1.5849625007211563	4	1	0	0
28494	1520	ERK2 protein level	[ERK2 protein levels]	1.5849625007211563	3	1	0	0
28495	1520	three individual protein factor	[three individual protein factors]	1.5849625007211563	4	1	0	0
28496	1520	polymorphonuclear (pml) leucocyte	[polymorphonuclear (PML) leucocytes]	1.5849625007211563	3	1	0	0
28497	1520	secondary hyperparathyroidism in uremia	[secondary hyperparathyroidism in uremia]	1.5849625007211563	4	1	0	0
28498	1520	similar transcription activity	[similar transcription activity]	1.5849625007211563	3	1	0	0
28499	1520	-3 gene product	[-3 gene products]	1.5849625007211563	3	1	0	0
28500	1520	follicle-center b cell centroblast	[follicle-center B cells centroblasts]	1.5849625007211563	4	1	0	0
28501	1520	TCF-1 alpha cDNA	[TCF-1 alpha cDNA]	1.5849625007211563	3	1	0	0
28502	1520	2.6-fold, 2) fibrinogen	[2.6-fold, 2) fibrinogen]	1.5849625007211563	3	1	0	0
28503	1520	lack myristoyl fatty acid	[lacking myristoyl fatty acid]	1.5849625007211563	4	1	0	0
28504	1520	three E2F dna-binding activity	[Three E2F DNA-binding activities]	1.5849625007211563	4	1	0	0
28505	1520	three different cell-specific pathway	[three different cell-specific pathways]	1.5849625007211563	4	1	0	0
28506	1520	steroid hormone receptor expression	[steroid hormone receptor expression]	1.5849625007211563	4	2	1	1
28507	1520	inhibition of tf activity	[inhibition of TF activity]	1.5849625007211563	4	1	0	0
28508	1520	cellular activation signal	[cellular activation signals]	1.5849625007211563	3	2	2	2
28509	1520	salicylate in the treatment	[salicylates in the treatment]	1.5849625007211563	4	1	0	0
28510	1520	NF-kappaB essential modulator	[NF-kappaB essential modulator]	1.5849625007211563	3	1	0	0
28511	1520	incubation of ets-1 protein	[Incubation of Ets-1 protein]	1.5849625007211563	4	1	0	0
28512	1520	IL-1 beta transcript degradation,	[IL-1 beta transcript degradation,]	1.5849625007211563	4	1	0	0
28513	1520	TCR -contact site heterogeneity	[TCR -contact site heterogeneity]	1.5849625007211563	4	1	0	0
28514	1520	stimulation il-2 gene transcription	[stimulation IL-2 gene transcription]	1.5849625007211563	4	1	0	0
28515	1520	positive cis-acting DNA element	[positive cis-acting DNA elements]	1.5849625007211563	4	1	0	0
28516	1520	particularly in the cell	[particularly in the cells]	1.5849625007211563	4	1	0	0
28517	1520	lead to gene induction	[leading to gene induction]	1.5849625007211563	4	1	0	0
28518	1520	RA receptor alpha	[RA receptors alpha]	1.5849625007211563	3	2	1	1
28519	1520	p65 protein expression	[p65 protein expression]	1.5849625007211563	3	1	0	0
28520	1520	increase in granule	[increase in granules]	1.5849625007211563	3	1	0	0
28521	1520	6 myeloma line	[6 myeloma lines]	1.5849625007211563	3	1	0	0
28522	1520	only nf-kappab activation.	[only NF-kappaB activation.]	1.5849625007211563	3	1	0	0
28523	1520	use flow cytometry	[using flow cytometry]	1.5849625007211563	3	2	1	1
28524	1520	induction of endothelial vcam-1	[induction of endothelial VCAM-1]	1.5849625007211563	4	1	0	0
28525	1520	high concentration of peptide	[high concentrations of peptide]	1.5849625007211563	4	2	2	2
28526	1520	specific ags with tcr	[specific Ags with TCR]	1.5849625007211563	4	1	0	0
28527	1520	maximal monocyte differentiation	[maximal monocyte differentiation]	1.5849625007211563	3	1	0	0
28528	1520	specific antibody in EMSA	[specific antibodies in EMSA]	1.5849625007211563	4	1	0	0
28529	1520	only vcam-1 induction	[only VCAM-1 induction]	1.5849625007211563	3	1	0	0
28530	1520	influence of tyrosine phosphorylation	[influence of tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
28531	1520	differentiation of macrophage	[differentiation of macrophages]	1.5849625007211563	3	1	0	0
28532	1520	amino-terminal region of E2A	[amino-terminal region of E2A]	1.5849625007211563	4	1	0	0
28533	1520	tumor necrosis factor gene	[tumor necrosis factor genes]	1.5849625007211563	4	1	0	0
28534	1520	cytosolic inhibitor protein ikappab-alpha	[cytosolic inhibitor protein IkappaB-alpha]	1.5849625007211563	4	1	0	0
28535	1520	induction of ifn-gamma	[induction of IFN-gamma]	1.5849625007211563	3	1	0	0
28536	1520	glucocorticoid particular dexamethasone	[glucocorticoids particular dexamethasone]	1.5849625007211563	3	1	0	0
28537	1520	transcription 1 stat1	[transcription 1 STAT1]	1.5849625007211563	3	1	0	0
28538	1520	myeloid cell line WEHI-3B/D+	[myeloid cell line WEHI-3B/D+]	1.5849625007211563	4	1	0	0
28539	1520	Ter 119 cell	[Ter 119 cells]	1.5849625007211563	3	2	2	2
28540	1520	leucocyte in woman	[leucocytes in women]	1.5849625007211563	3	2	2	2
28541	1520	blood mononuclear leucocyte	[blood mononuclear leucocyte]	1.5849625007211563	3	2	2	2
28542	1520	sla-dq antigen expression	[SLA-DQ antigen expression]	1.5849625007211563	3	1	0	0
28543	1520	level of nf-kappab activation	[levels of NF-kappaB activation]	1.5849625007211563	4	1	0	0
28544	1520	numerous genes, include cytokine	[numerous genes, including cytokines]	1.5849625007211563	4	1	0	0
28545	1520	CAAT consensus site	[CAAT consensus site]	1.5849625007211563	3	1	0	0
28546	1520	nf-m -dependent promoter construct	[NF-M -dependent promoter constructs]	1.5849625007211563	4	1	0	0
28547	1520	hematopoietic cell include macrophage	[hematopoietic cells including macrophages]	1.5849625007211563	4	1	0	0
28548	1520	cd14 mrna expression,	[CD14 mRNA expression,]	1.5849625007211563	3	1	0	0
28549	1520	underlie the inducible expression	[underlying the inducible expression]	1.5849625007211563	4	1	0	0
28550	1520	survival of naive pbl	[survival of naive PBL]	1.5849625007211563	4	1	0	0
28551	1520	hla-b8-restricted peptide rakfkqllq	[HLA-B8-restricted peptide RAKFKQLLQ]	1.5849625007211563	3	1	0	0
28552	1520	naturally occur splice variant	[naturally occurring splice variant,]	1.5849625007211563	4	1	0	0
28553	1520	illegitimate" v-(d)-j recombinase activity	[illegitimate" V-(D)-J recombinase activity]	1.5849625007211563	4	1	0	0
28554	1520	difference of VDR retention	[difference of VDR retention]	1.5849625007211563	4	1	0	0
28555	1520	denature gradient-gel electrophoresis	[denaturing gradient-gel electrophoresis]	1.5849625007211563	3	1	0	0
28556	1520	110-130-kDa nfatp protein	[110-130-kDa NFATp protein]	1.5849625007211563	3	1	0	0
28557	1520	presence of the IL-4	[presence of the IL-4]	1.5849625007211563	4	1	0	0
28558	1520	calf serum fcs	[calf serum FCS]	1.5849625007211563	3	2	2	2
28559	1520	use Wp reporter construct	[Using Wp reporter constructs]	1.5849625007211563	4	1	0	0
28560	1520	location of bind site	[location of binding site]	1.5849625007211563	4	1	0	0
28561	1520	q23-31 region of chromosome	[q23-31 region of chromosome]	1.5849625007211563	4	1	0	0
28562	1520	recruitment of stat protein	[recruitment of Stat proteins]	1.5849625007211563	4	1	0	0
28563	1520	complex upstream element	[complex upstream element]	1.5849625007211563	3	1	0	0
28564	1520	shp1 in T lymphocyte	[SHP1 in T lymphocytes]	1.5849625007211563	4	1	0	0
28565	1520	loading of peptide	[loading of peptides]	1.5849625007211563	3	1	0	0
28566	1520	patient with respiratory failure	[patients with respiratory failure]	1.5849625007211563	4	1	0	0
28567	1520	negative element in basophil	[negative element in basophils]	1.5849625007211563	4	1	0	0
28568	1520	mass action law.	[mass action law.]	1.5849625007211563	3	1	0	0
28569	1520	involvement in the potentiation	[Involvement in the potentiation]	1.5849625007211563	4	1	0	0
28570	1520	form of p85	[form of p85]	1.5849625007211563	3	1	0	0
28571	1520	dominant interfere mutant rxr	[dominant interfering mutant RXRs]	1.5849625007211563	4	1	0	0
28572	1520	regulate granulocyte functionality	[regulating granulocyte functionality]	1.5849625007211563	3	1	0	0
28573	1520	forty primary fms patient	[Forty primary FMS patients]	1.5849625007211563	4	1	0	0
28574	1520	cooperation between accessory cell	[cooperation between accessory cells]	1.5849625007211563	4	1	0	0
28575	1520	cell express p45	[cells expressing p45]	1.5849625007211563	3	1	0	0
28576	1520	cd4- cd8+ cell population	[CD4- CD8+ cell populations]	1.5849625007211563	4	1	0	0
28577	1520	loss of any one	[loss of any one]	1.5849625007211563	4	1	0	0
28578	1520	gr concentration in ad	[GR concentrations in AD]	1.5849625007211563	4	1	0	0
28579	1520	inhibitor of ca2+ mobilization	[inhibitor of Ca2+ mobilization]	1.5849625007211563	4	1	0	0
28580	1520	long terminal repeat ltr	[long terminal repeats LTRs]	1.5849625007211563	4	1	0	0
28581	1520	patient with sjogrens' syndrome	[patient with Sjogrens' syndrome]	1.5849625007211563	4	2	1	1
28582	1520	u937 human monoblastic cell	[U937 human monoblastic cells]	1.5849625007211563	4	1	0	0
28583	1520	induction of gene transcription	[induction of gene transcription]	1.5849625007211563	4	1	0	0
28584	1520	t-lineage precursor population	[T-lineage precursor populations]	1.5849625007211563	3	1	0	0
28585	1520	osteoclastogenic cytokine tnf-alpha TNF	[osteoclastogenic cytokine TNF-alpha TNF]	1.5849625007211563	4	1	0	0
28586	1520	55 C-terminal amino acid	[55 C-terminal amino acids]	1.5849625007211563	4	1	0	0
28587	1520	ras pathway activation	[Ras pathway activation]	1.5849625007211563	3	1	0	0
28588	1520	il-1ri protein kinase	[IL-1RI protein kinase]	1.5849625007211563	3	1	0	0
28589	1520	cd4+ t-cell subset	[CD4+ T-cell subset]	1.5849625007211563	3	1	0	0
28590	1520	different stimulus vitamin D3	[different stimuli vitamin D3]	1.5849625007211563	4	1	0	0
28591	1520	invariant chain-derived peptide clip	[invariant chain-derived peptides CLIP]	1.5849625007211563	4	1	0	0
28592	1520	dr3-type vitamin d-responsive element	[DR3-type vitamin D-responsive element]	1.5849625007211563	4	1	0	0
28593	1520	DNA fragmentation factor-45	[DNA fragmentation factor-45]	1.5849625007211563	3	1	0	0
28594	1520	human equivalent gos19	[human equivalent GOS19]	1.5849625007211563	3	1	0	0
28595	1520	response to inflammatory signal	[response to inflammatory signals]	1.5849625007211563	4	1	0	0
28596	1520	long terminal repeat-luciferase construct	[long terminal repeat-luciferase constructs]	1.5849625007211563	4	1	0	0
28597	1520	role of protein phosphatase	[role of protein phosphatases]	1.5849625007211563	4	1	0	0
28598	1520	regulatory p85 subunit	[regulatory p85 subunit]	1.5849625007211563	3	1	0	0
28599	1520	transcription factor, nf-kappa b	[transcription factor, NF-kappa B]	1.5849625007211563	4	1	0	0
28600	1520	important B-cell growth factor	[important B-cell growth factor]	1.5849625007211563	4	1	0	0
28601	1520	activation by CBF beta	[activation by CBF beta]	1.5849625007211563	4	1	0	0
28602	1520	stimuli, include tnf-alpha	[stimuli, including TNF-alpha]	1.5849625007211563	3	1	0	0
28603	1520	signal defect in patient	[signaling defects in patients]	1.5849625007211563	4	1	0	0
28604	1520	immunogenic primary tumor	[immunogenic primary tumors]	1.5849625007211563	3	1	0	0
28605	1520	three novel clone	[three novel clones]	1.5849625007211563	3	1	0	0
28606	1520	deletional switch recombination	[deletional switch recombination]	1.5849625007211563	3	1	0	0
28607	1520	chromosome of L. pneumophila	[chromosome of L. pneumophila]	1.5849625007211563	4	1	0	0
28608	1520	new monoclonal antibody mab	[new monoclonal antibody mAb]	1.5849625007211563	4	1	0	0
28609	1520	tyr-492 and/or tyr-493	[Tyr-492 and/or Tyr-493]	1.5849625007211563	3	1	0	0
28610	1520	presence of tetracycline	[presence of tetracycline]	1.5849625007211563	3	1	0	0
28611	1520	voltage-gated K+ channel KV	[voltage-gated K+ channels KV]	1.5849625007211563	4	1	0	0
28612	1520	seven healthy non-pregnant woman	[seven healthy non-pregnant women]	1.5849625007211563	4	1	0	0
28613	1520	M-CSF induction of M-CSF	[M-CSF induction of M-CSF]	1.5849625007211563	4	1	0	0
28614	1520	atypical pkc-zeta isoform	[atypical PKC-zeta isoforms]	1.5849625007211563	3	1	0	0
28615	1520	elution from dna-cellulose	[elution from DNA-cellulose]	1.5849625007211563	3	1	0	0
28616	1520	fc gamma RI expression.	[Fc gamma RI expression.]	1.5849625007211563	4	1	0	0
28617	1520	most potent inducer here	[most potent inducers here]	1.5849625007211563	4	1	0	0
28618	1520	effect of CIITA	[effect of CIITA]	1.5849625007211563	3	2	1	1
28619	1520	expression of these marker	[expressions of theses markers]	1.5849625007211563	4	1	0	0
28620	1520	autoregulation of SCL transcription	[autoregulation of SCL transcription]	1.5849625007211563	4	1	0	0
28621	1520	AIDS Res Hum Retroviruse	[AIDS Res Hum Retroviruses]	1.5849625007211563	4	1	0	0
28622	1520	nk-kappa b activation	[NK-kappa B activation]	1.5849625007211563	3	1	0	0
28623	1520	high grade malignant astrocytomas	[high grade malignant astrocytomas]	1.5849625007211563	4	1	0	0
28624	1520	beta globin gene region	[beta globin gene region]	1.5849625007211563	4	1	0	0
28625	1520	anti-cd28 mab clb-cd28/1	[anti-CD28 mAb CLB-CD28/1]	1.5849625007211563	3	1	0	0
28626	1520	analysis of target	[Analysis of targets]	1.5849625007211563	3	1	0	0
28627	1520	-dependent reporter gene	[-dependent reporter genes]	1.5849625007211563	3	1	0	0
28628	1520	coincident with positive selection.	[coincident with positive selection.]	1.5849625007211563	4	1	0	0
28629	1520	elevate camp level	[elevating cAMP levels]	1.5849625007211563	3	1	0	0
28630	1520	3' flank sequence	[3' flanking sequences]	1.5849625007211563	3	1	0	0
28631	1520	course of infection	[course of infections]	1.5849625007211563	3	3	2	1
28632	1520	immune inflammatory state	[immune inflammatory states]	1.5849625007211563	3	1	0	0
28633	1520	ultra-violet cross-linking experiment	[UV cross-linking experiments]	1.5849625007211563	3	1	0	0
28634	1520	15 APL patient	[15 APL patients]	1.5849625007211563	3	1	0	0
28635	1520	FOS family of gene	[FOS family of genes]	1.5849625007211563	4	1	0	0
28636	1520	downstream effector proteins,	[downstream effector proteins,]	1.5849625007211563	3	1	0	0
28637	1520	multipotent progenitor (EML)	[multipotent progenitor (EML)]	1.5849625007211563	3	1	0	0
28638	1520	patient with tsc	[patients with TSC]	1.5849625007211563	3	1	0	0
28639	1520	Tat-binding protein 7	[Tat-binding protein 7]	1.5849625007211563	3	1	0	0
28640	1520	coculture with TEC	[cocultures with TEC]	1.5849625007211563	3	1	0	0
28641	1520	first generation compound Canventol	[first generation compound Canventol]	1.5849625007211563	4	1	0	0
28642	1520	exposure to the hormone.	[exposure to the hormone.]	1.5849625007211563	4	1	0	0
28643	1520	CD3 -tcr complex,	[CD3 -TCR complex,]	1.5849625007211563	3	1	0	0
28644	1520	immunosuppressant action of CsA	[immunosuppressant action of CsA]	1.5849625007211563	4	1	0	0
28645	1520	profound T cell deficit	[profound T cell deficit]	1.5849625007211563	4	1	0	0
28646	1520	functional RAR beta	[functional RAR beta]	1.5849625007211563	3	1	0	0
28647	1520	cd40l reactive T lymphocyte	[CD40L reactive T lymphocytes]	1.5849625007211563	4	1	0	0
28648	1520	considerable genetic, biologic,	[considerable genetic, biologic,]	1.5849625007211563	3	1	0	0
28649	1520	heat shock protein 90,	[heat shock protein 90,]	1.5849625007211563	4	1	0	0
28650	1520	complex 3 binding	[complex 3 binding]	1.5849625007211563	3	1	0	0
28651	1520	defective gene type ii	[defective genes type II]	1.5849625007211563	4	1	0	0
28652	1520	switch region sequence	[switch region sequences]	1.5849625007211563	3	1	0	0
28653	1520	classical enhancer activity	[classical enhancer activity]	1.5849625007211563	3	1	0	0
28654	1520	major basic protein mbp	[major basic protein MBP]	1.5849625007211563	4	1	0	0
28655	1520	cell type specific gene	[cell type specific gene]	1.5849625007211563	4	1	0	0
28656	1520	direct evidence presented.	[Direct evidence presented.]	1.5849625007211563	3	1	0	0
28657	1520	specific binding complex	[specific binding complexes]	1.5849625007211563	3	1	0	0
28658	1520	other normal bone marrow	[other normal bone marrow]	1.5849625007211563	4	1	0	0
28659	1520	alpha chain gene	[alpha chain gene]	1.5849625007211563	3	1	0	0
28660	1520	mechanism of inhibition	[mechanism of inhibition]	1.5849625007211563	3	2	1	1
28661	1520	il-7r signal event	[IL-7R signaling events]	1.5849625007211563	3	1	0	0
28662	1520	endometriosis at different phase	[endometriosis at different phases]	1.5849625007211563	4	1	0	0
28663	1520	prevent fasl expression	[preventing FasL expression]	1.5849625007211563	3	1	0	0
28664	1520	prediction between the age	[prediction between the ages]	1.5849625007211563	4	1	0	0
28665	1520	site for transcription factor	[sites for transcription factors]	1.5849625007211563	4	2	2	2
28666	1520	however, overexpression of p95vav	[However, overexpression of p95vav]	1.5849625007211563	4	1	0	0
28667	1520	HIV-2 enhancer element	[HIV-2 enhancer element]	1.5849625007211563	3	1	0	0
28668	1520	human immunoglobulin heavy-chain enhancer	[human immunoglobulin heavy-chain enhancer]	1.5849625007211563	4	1	0	0
28669	1520	lead to the adherence	[leading to the adherence]	1.5849625007211563	4	1	0	0
28670	1520	normal splenic b cell	[normal splenic B cells]	1.5849625007211563	4	1	0	0
28671	1520	Philadelphia chromosome Ph'	[Philadelphia chromosome Ph']	1.5849625007211563	3	1	0	0
28672	1520	potential NF-kappaB binding sequence	[potential NF-kappaB binding sequence]	1.5849625007211563	4	1	0	0
28673	1520	tissue transglutaminase-dependent posttranslational modification	[Tissue transglutaminase-dependent posttranslational modification]	1.5849625007211563	4	1	0	0
28674	1520	subject (from 2849 703	[subjects (from 2849 703]	1.5849625007211563	4	1	0	0
28675	1520	fragment of the ires	[fragments of the IRES]	1.5849625007211563	4	1	0	0
28676	1520	cell lines, alone	[cell lines, alone]	1.5849625007211563	3	1	0	0
28677	1520	long-last il-2 receptivity	[Long-lasting IL-2 receptivity]	1.5849625007211563	3	1	0	0
28678	1520	E2F -mediate regulations.	[E2F -mediated regulations.]	1.5849625007211563	3	1	0	0
28679	1520	glucocorticoid target tissue	[glucocorticoid target tissues]	1.5849625007211563	3	1	0	0
28680	1520	additional screen by rt-pcr	[additional screening by RT-PCR]	1.5849625007211563	4	1	0	0
28681	1520	mother of this patient	[mother of this patient]	1.5849625007211563	4	1	0	0
28682	1520	B95-8 lymphoid cell	[B95-8 lymphoid cells]	1.5849625007211563	3	1	0	0
28683	1520	frequency of 1%	[frequency of 1%]	1.5849625007211563	3	1	0	0
28684	1520	overlapping expression pattern	[overlapping expression patterns]	1.5849625007211563	3	1	0	0
28685	1520	various thyroid state	[various thyroid states]	1.5849625007211563	3	1	0	0
28686	1520	overexpression of spi-1	[overexpression of Spi-1]	1.5849625007211563	3	1	0	0
28687	1520	b cell lymphoid malignancy	[B cell lymphoid malignancies]	1.5849625007211563	4	1	0	0
28688	1520	phase 2 neutrophil adhesion	[phase 2 neutrophil adhesion]	1.5849625007211563	4	1	0	0
28689	1520	pathogenesis of endometriosis	[pathogenesis of endometriosis]	1.5849625007211563	3	1	0	0
28690	1520	two interactive mechanism	[two interactive mechanisms]	1.5849625007211563	3	1	0	0
28691	1520	reporter gene activation	[reporter gene activation]	1.5849625007211563	3	1	0	0
28692	1520	transcription in ARH77 cell	[transcription in ARH77 cells]	1.5849625007211563	4	1	0	0
28693	1520	activation in human monocyte	[activation in human monocytes]	1.5849625007211563	4	1	0	0
28694	1520	DAPI banding pattern	[DAPI banding pattern]	1.5849625007211563	3	1	0	0
28695	1520	sucrose gradient assay	[Sucrose gradient assays]	1.5849625007211563	3	1	0	0
28696	1520	inhibition of dna-binding activity	[inhibition of DNA-binding activity]	1.5849625007211563	4	1	0	0
28697	1520	series of functional study	[series of functional studies]	1.5849625007211563	4	1	0	0
28698	1520	chemokine in HTLV-I t-cell	[chemokine in HTLV-I T-cells]	1.5849625007211563	4	1	0	0
28699	1520	NF-AT DNA binding	[NF-AT DNA binding]	1.5849625007211563	3	1	0	0
28700	1520	high nf-kappa b activity	[higher NF-kappa B activity]	1.5849625007211563	4	1	0	0
28701	1520	activation of cytokine synthesis	[activation of cytokine synthesis]	1.5849625007211563	4	1	0	0
28702	1520	two distinct complexess	[two distinct complexes,]	1.5849625007211563	3	1	0	0
28703	1520	nfat activation, fasl expression,	[NFAT activation, FasL expression,]	1.5849625007211563	4	1	0	0
28704	1520	gammadelta-type T cell	[gammadelta-type T cells]	1.5849625007211563	3	1	0	0
28705	1520	two DNA binding subunit	[two DNA binding subunits]	1.5849625007211563	4	1	0	0
28706	1520	degradation of nf-kappab /rel	[degradation of NF-kappaB /Rel]	1.5849625007211563	4	1	0	0
28707	1520	ligand-inducible transactivation function	[ligand-inducible transactivation function]	1.5849625007211563	3	1	0	0
28708	1520	several hour of treatment	[several hours of treatment]	1.5849625007211563	4	1	0	0
28709	1520	one leukemic cell	[one leukemic cell]	1.5849625007211563	3	1	0	0
28710	1520	diverse regulatory protein	[diverse regulatory proteins]	1.5849625007211563	3	1	0	0
28711	1520	TIMP-1 -positive bl line	[TIMP-1 -positive BL lines]	1.5849625007211563	4	1	0	0
28712	1520	CONCLUSION: il-5 production	[CONCLUSION: IL-5 production]	1.5849625007211563	3	1	0	0
28713	1520	constitutive activation of nf-kappab	[constitutive activation of NF-kappaB]	1.5849625007211563	4	3	2	1
28714	1520	NK cell granule	[NK cell granules]	1.5849625007211563	3	2	2	2
28715	1520	blood of normotensive volunteer	[blood of normotensive volunteers]	1.5849625007211563	4	1	0	0
28716	1520	physical linkage to XIC/XIST	[physical linkage to XIC/XIST]	1.5849625007211563	4	1	0	0
28717	1520	phospholipase c-gamma1 plc-gamma1	[phospholipase C-gamma1 PLC-gamma1]	1.5849625007211563	3	1	0	0
28718	1520	biology of this tumor	[biology of these tumors]	1.5849625007211563	4	1	0	0
28719	1520	DHEA binding site	[DHEA binding sites]	1.5849625007211563	3	1	0	0
28720	1520	analysis of mrna	[Analysis of mRNA]	1.5849625007211563	3	2	1	1
28721	1520	presence of excess 135eoh)2d3	[presence of excess 1,25(OH)2D3]	1.5849625007211563	4	1	0	0
28722	1520	several human tumor	[several human tumors]	1.5849625007211563	3	1	0	0
28723	1520	non-consensus gas motif	[non-consensus GAS motif]	1.5849625007211563	3	1	0	0
28724	1520	distinct phase of development.	[distinct phases of development.]	1.5849625007211563	4	1	0	0
28725	1520	development of APL	[development of APL]	1.5849625007211563	3	1	0	0
28726	1520	NF-AT DNA binding activity	[NF-AT DNA binding activity]	1.5849625007211563	4	1	0	0
28727	1520	be value of 0.91,	[r value of 0.91,]	1.5849625007211563	4	1	0	0
28728	1520	effect on gcr level	[effect on GCR level]	1.5849625007211563	4	1	0	0
28729	1520	AP-2 binding site	[AP-2 binding site]	1.5849625007211563	3	1	0	0
28730	1520	other non-cytokine gene	[other non-cytokine genes]	1.5849625007211563	3	1	0	0
28731	1520	human thymocyte nuclei	[human thymocyte nuclei]	1.5849625007211563	3	1	0	0
28732	1520	alpha b5a cell	[alpha B5A cells]	1.5849625007211563	3	1	0	0
28733	1520	murine leukemia cell	[murine leukemia cells]	1.5849625007211563	3	2	2	2
28734	1520	rxr in monoblast differentiation	[RXRs in monoblast differentiation]	1.5849625007211563	4	1	0	0
28735	1520	ability of Jun protein	[ability of Jun proteins]	1.5849625007211563	4	1	0	0
28736	1520	cotton-top tamarin b95-8 cell	[cotton-top tamarin B95-8 cells]	1.5849625007211563	4	1	0	0
28737	1520	other NF-kappaB family member	[other NF-kappaB family members]	1.5849625007211563	4	1	0	0
28738	1520	2.45 nm (mean	[2.45 nM (mean]	1.5849625007211563	3	1	0	0
28739	1520	human glucocorticoid receptor hgr	[human glucocorticoid receptors hGRs]	1.5849625007211563	4	1	0	0
28740	1520	normal activation of ap-1	[normal activation of AP-1]	1.5849625007211563	4	1	0	0
28741	1520	promoter element of genes,	[promoter elements of genes,]	1.5849625007211563	4	1	0	0
28742	1520	recent experimental evidence	[recent experimental evidences]	1.5849625007211563	3	1	0	0
28743	1520	content of gcr	[content of GCR]	1.5849625007211563	3	2	2	2
28744	1520	beginning of the month	[beginning of the month]	1.5849625007211563	4	1	0	0
28745	1520	T helper 1	[T helper 1]	1.5849625007211563	3	1	0	0
28746	1520	individual nfat composite element	[individual NFAT composite elements]	1.5849625007211563	4	1	0	0
28747	1520	similar ROI formation	[similar ROI formation]	1.5849625007211563	3	1	0	0
28748	1520	contrast, stat tyrosine phosphorylation	[contrast, STAT tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
28749	1520	rela /nf-kappab1 binding complex	[RelA /NF-kappaB1 binding complexes]	1.5849625007211563	4	1	0	0
28750	1520	E2F-1 transcription factor	[E2F-1 transcription factor]	1.5849625007211563	3	1	0	0
28751	1520	activate transcription factor	[activating transcription factors]	1.5849625007211563	3	2	2	2
28752	1520	cd1+relb+ dendritic cell	[CD1+RelB+ dendritic cells]	1.5849625007211563	3	2	2	2
28753	1520	heterotrimeric g protein activation	[heterotrimeric G protein activation]	1.5849625007211563	4	1	0	0
28754	1520	cloning of a gene	[cloning of a gene]	1.5849625007211563	4	2	2	2
28755	1520	protein kinase b c-akt	[Protein kinase B c-Akt]	1.5849625007211563	4	1	0	0
28756	1520	gammac chain gene promoter	[gammac chain gene promoter]	1.5849625007211563	4	1	0	0
28757	1520	GTP-GDP state of Rac	[GTP-GDP state of Rac]	1.5849625007211563	4	1	0	0
28758	1520	isoform of the er	[isoform of the ER]	1.5849625007211563	4	1	0	0
28759	1520	proximal purine box site	[proximal purine box sites]	1.5849625007211563	4	1	0	0
28760	1520	effect on base level	[effect on base levels]	1.5849625007211563	4	1	0	0
28761	1520	beta- binding activity	[beta- binding activities]	1.5849625007211563	3	1	0	0
28762	1520	10 untreated subject	[10 untreated subjects]	1.5849625007211563	3	1	0	0
28763	1520	various biochemical pathway	[various biochemical pathways]	1.5849625007211563	3	1	0	0
28764	1520	(v) a sporadic case	[(v) a sporadic case]	1.5849625007211563	4	1	0	0
28765	1520	permissive b-cell line	[permissive B-cell line]	1.5849625007211563	3	1	0	0
28766	1520	o,o'-bismyristoyl esterification of tds	[o,o'-bismyristoyl esterification of TDS]	1.5849625007211563	4	1	0	0
28767	1520	hour of treatment.	[hour of treatment.]	1.5849625007211563	3	2	2	2
28768	1520	Potential phosphorylation site	[Potential phosphorylation sites]	1.5849625007211563	3	1	0	0
28769	1520	combinatorial differentiation switch	[combinatorial differentiation switch]	1.5849625007211563	3	1	0	0
28770	1520	promoter for marker	[promoters for markers]	1.5849625007211563	3	2	2	2
28771	1520	tax -by cyclosporin a	[Tax -by cyclosporin A]	1.5849625007211563	4	1	0	0
28772	1520	unidentified cellular factor	[unidentified cellular factor]	1.5849625007211563	3	1	0	0
28773	1520	vitro transcription method	[vitro transcription methods]	1.5849625007211563	3	1	0	0
28774	1520	addition of H2O2	[addition of H2O2]	1.5849625007211563	3	1	0	0
28775	1520	only in b lymphocyte	[only in B lymphocytes]	1.5849625007211563	4	1	0	0
28776	1520	endogenous GM-CSF gene	[endogenous GM-CSF gene]	1.5849625007211563	3	1	0	0
28777	1520	subunit of nf-kappa b	[subunits of NF-kappa B]	1.5849625007211563	4	1	0	0
28778	1520	use reporter gene	[using reporter genes]	1.5849625007211563	3	1	0	0
28779	1520	HTLV-III BH10 clone	[HTLV-III BH10 clone]	1.5849625007211563	3	1	0	0
28780	1520	mn-sod rna protein level	[Mn-SOD RNA protein levels]	1.5849625007211563	4	1	0	0
28781	1520	optimal transactivation incubation	[optimal transactivation incubation]	1.5849625007211563	3	1	0	0
28782	1520	set of primer specific	[set of primers specific]	1.5849625007211563	4	1	0	0
28783	1520	vitro monocyte-derived macrophage MDMac	[vitro monocyte-derived macrophages MDMac]	1.5849625007211563	4	1	0	0
28784	1520	inhibition of Th1 development	[Inhibition of Th1 development]	1.5849625007211563	4	1	0	0
28785	1520	EBNA gene transcription	[EBNA gene transcription]	1.5849625007211563	3	1	0	0
28786	1520	J delta k cell	[J delta K cells]	1.5849625007211563	4	1	0	0
28787	1520	extracellular domain 1	[extracellular domain 1]	1.5849625007211563	3	1	0	0
28788	1520	83 control from Ireland,	[83 controls from Ireland,]	1.5849625007211563	4	1	0	0
28789	1520	variety of surface receptor	[variety of surface receptors]	1.5849625007211563	4	1	0	0
28790	1520	activator of transcription Stat3	[activator of transcription Stat3]	1.5849625007211563	4	2	1	1
28791	1520	expression of tgf-beta1	[expression of TGF-beta1]	1.5849625007211563	3	1	0	0
28792	1520	expression of l-selectin	[expression of L-selectin]	1.5849625007211563	3	2	1	1
28793	1520	two immediate-early viral gene	[two immediate-early viral genes]	1.5849625007211563	4	1	0	0
28794	1520	novel specific binding activity	[novel specific binding activity]	1.5849625007211563	4	1	0	0
28795	1520	such as hyperosmotic shock	[such as hyperosmotic shock]	1.5849625007211563	4	1	0	0
28796	1520	glycophorin a antigen	[glycophorin A antigens]	1.5849625007211563	3	1	0	0
28797	1520	uninduced, atra cd38+ cell	[uninduced, ATRA CD38+ cells]	1.5849625007211563	4	1	0	0
28798	1520	certain cell types.	[certain cell types.]	1.5849625007211563	3	1	0	0
28799	1520	eosinophil peroxidase epo	[eosinophil peroxidase EPO]	1.5849625007211563	3	1	0	0
28800	1520	double NF-kappaB site	[double NF-kappaB site]	1.5849625007211563	3	1	0	0
28801	1520	tissue-specific stage-specific regulation	[tissue-specific stage-specific regulation]	1.5849625007211563	3	1	0	0
28802	1520	transition from quiescence	[transition from quiescence]	1.5849625007211563	3	1	0	0
28803	1520	apoptosis of lymphoid cell	[apoptosis of lymphoid cells]	1.5849625007211563	4	2	2	2
28804	1520	NF-kappa b p50/p65	[NF-kappa B p50/p65]	1.5849625007211563	3	4	3	1
28805	1520	GR N-terminal transactivation domain	[GR N-terminal transactivation domain]	1.5849625007211563	4	1	0	0
28806	1520	many report of change	[many reports of changes]	1.5849625007211563	4	1	0	0
28807	1520	antisense rxr-alpha cDNA	[antisense RXR-alpha cDNA]	1.5849625007211563	3	1	0	0
28808	1520	one 63-kda isoform	[One 63-kDa isoform]	1.5849625007211563	3	1	0	0
28809	1520	type b transcript	[type B transcripts]	1.5849625007211563	3	1	0	0
28810	1520	use in vitro transcription	[using in vitro transcription]	1.5849625007211563	4	1	0	0
28811	1520	transduction/ transcription factor	[transduction/ transcription factors]	1.5849625007211563	3	1	0	0
28812	1520	ebv-encoded nuclear antigen EBNA	[EBV-encoded nuclear antigen EBNA]	1.5849625007211563	4	2	1	1
28813	1520	T cell-specific protein neg-1	[T cell-specific protein Neg-1]	1.5849625007211563	4	1	0	0
28814	1520	tnfalpha factor expression	[TNFalpha factor expression]	1.5849625007211563	3	1	0	0
28815	1520	sterol element SRE	[Sterol element SRE]	1.5849625007211563	3	2	2	2
28816	1520	follow IL-2 heterodimerization	[following IL-2 heterodimerization]	1.5849625007211563	3	1	0	0
28817	1520	strong constitutively active promoter	[strong constitutively active promoter]	1.5849625007211563	4	1	0	0
28818	1520	histogenesis of endometriosis	[histogenesis of endometriosis]	1.5849625007211563	3	1	0	0
28819	1520	upstream NF-kappaB like site	[upstream NF-kappaB like site]	1.5849625007211563	4	1	0	0
28820	1520	human cd14 cho/ cd14	[human CD14 CHO/ CD14]	1.5849625007211563	4	1	0	0
28821	1520	mSin3 family of co-repressor	[mSin3 family of co-repressors]	1.5849625007211563	4	1	0	0
28822	1520	RA vitd3 receptor	[RA VitD3 receptors]	1.5849625007211563	3	1	0	0
28823	1520	incubation of whole blood	[Incubation of whole blood]	1.5849625007211563	4	2	2	2
28824	1520	cell surface marker expression	[cell surface marker expression]	1.5849625007211563	4	1	0	0
28825	1520	b cell upon fusion	[B cells upon fusion]	1.5849625007211563	4	1	0	0
28826	1520	htlv-ii tax protein	[HTLV-II tax proteins]	1.5849625007211563	3	1	0	0
28827	1520	transcriptionally inactive p50 homodimer	[transcriptionally inactive p50 homodimer]	1.5849625007211563	4	2	1	1
28828	1520	vitro footprinting analysis	[vitro footprinting analysis]	1.5849625007211563	3	1	0	0
28829	1520	gtp -binding activity	[GTP -binding activity]	1.5849625007211563	3	1	0	0
28830	1520	addition to this elements,	[addition to these elements,]	1.5849625007211563	4	1	0	0
28831	1520	Ki-67 staining histological grade).	[Ki-67 staining histological grade).]	1.5849625007211563	4	1	0	0
28832	1520	mature cell type	[mature cell types]	1.5849625007211563	3	1	0	0
28833	1520	cell proliferation through il-4r	[cell proliferation through IL-4R]	1.5849625007211563	4	1	0	0
28834	1520	tnf-alpha mrna level	[TNF-alpha mRNA levels]	1.5849625007211563	3	1	0	0
28835	1520	weak DNA binding	[weak DNA binding]	1.5849625007211563	3	1	0	0
28836	1520	cell adhesion to fibronectin	[cell adhesion to fibronectin]	1.5849625007211563	4	2	1	1
28837	1520	activation of the kinase	[activation of the kinases]	1.5849625007211563	4	2	1	1
28838	1520	mitogen-activated mature T lymphocyte	[mitogen-activated mature T lymphocytes]	1.5849625007211563	4	1	0	0
28839	1520	transient shuttling of NFATp	[transient shuttling of NFATp]	1.5849625007211563	4	1	0	0
28840	1520	internalization of the genome	[internalization of the genome]	1.5849625007211563	4	1	0	0
28841	1520	such as graft-versus-host disease	[such as graft-versus-host disease]	1.5849625007211563	4	1	0	0
28842	1520	dna-binding of nuclear factor-kappaB	[DNA-binding of nuclear factor-kappaB]	1.5849625007211563	4	1	0	0
28843	1520	variety of biologic function	[variety of biologic functions]	1.5849625007211563	4	1	0	0
28844	1520	immunosuppressant cyclosporine a	[immunosuppressant cyclosporine A]	1.5849625007211563	3	1	0	0
28845	1520	defect in the activity	[defects in the activity]	1.5849625007211563	4	1	0	0
28846	1520	5'-untranslated leader region 5'-utr	[5'-untranslated leader region 5'-UTR]	1.5849625007211563	4	1	0	0
28847	1520	nonselfness of the remainder	[nonselfness of the remainders]	1.5849625007211563	4	1	0	0
28848	1520	hemopoietic lineage commitment	[hemopoietic lineage commitment]	1.5849625007211563	3	1	0	0
28849	1520	ERK1/2 pathway-dependent activation	[ERK1/2 pathway-dependent activation]	1.5849625007211563	3	1	0	0
28850	1520	whole b domain	[whole B domain]	1.5849625007211563	3	1	0	0
28851	1520	different trans-activate phenotype	[different trans-activating phenotypes]	1.5849625007211563	3	2	1	1
28852	1520	primary human cell	[primary human cell]	1.5849625007211563	3	2	1	1
28853	1520	Jun pfo heterodimer AP-1	[Jun /Fos heterodimer AP-1]	1.5849625007211563	4	1	0	0
28854	1520	dramatic decrease of agonist	[dramatic decrease of agonist]	1.5849625007211563	4	1	0	0
28855	1520	dominant-negative dn fashion	[dominant-negative DN fashion]	1.5849625007211563	3	1	0	0
28856	1520	constitutive hepor expression	[constitutive hEpoR expression]	1.5849625007211563	3	1	0	0
28857	1520	potential nfat-binding site	[potential NFAT-binding sites]	1.5849625007211563	3	1	0	0
28858	1520	er transcript between patient	[ER transcripts between patients]	1.5849625007211563	4	1	0	0
28859	1520	plasma cortisol concentration,	[plasma cortisol concentration,]	1.5849625007211563	3	1	0	0
28860	1520	variety of effect	[variety of effects]	1.5849625007211563	3	2	1	1
28861	1520	electron microscopic examination	[electron microscopic examinations]	1.5849625007211563	3	1	0	0
28862	1520	abnormal activation of NFkappaB	[Abnormal activation of NFkappaB]	1.5849625007211563	4	1	0	0
28863	1520	patient to glucocorticoid therapy	[patients to glucocorticoid therapy]	1.5849625007211563	4	1	0	0
28864	1520	secretion of mediator	[secretion of mediators]	1.5849625007211563	3	2	2	2
28865	1520	expression of cd23 mrna	[expression of CD23 mRNA]	1.5849625007211563	4	1	0	0
28866	1520	response to the heterodimerization	[response to the heterodimerization]	1.5849625007211563	4	1	0	0
28867	1520	reinforce the idea	[reinforcing the idea]	1.5849625007211563	3	1	0	0
28868	1520	(vmax) of the serca	[(Vmax) of the SERCA]	1.5849625007211563	4	1	0	0
28869	1520	ligation of corticosteroid receptor	[ligation of corticosteroid receptors]	1.5849625007211563	4	1	0	0
28870	1520	hiv-infected human T lymphocyte	[HIV-infected human T lymphocytes]	1.5849625007211563	4	1	0	0
28871	1520	content in T cell	[content in T cell]	1.5849625007211563	4	1	0	0
28872	1520	four DR11(+) APL patient	[four DR11(+) APL patients]	1.5849625007211563	4	1	0	0
28873	1520	IL-2/ IFN alpha treatment	[IL-2/ IFN alpha treatment]	1.5849625007211563	4	1	0	0
28874	1520	hematopoietic cell lineage commitment,	[hematopoietic cell lineage commitment,]	1.5849625007211563	4	1	0	0
28875	1520	cd19 gene expression	[CD19 gene expression]	1.5849625007211563	3	2	2	2
28876	1520	result for athlete	[results for athletes]	1.5849625007211563	3	1	0	0
28877	1520	promoter binding protein	[promoter binding protein]	1.5849625007211563	3	1	0	0
28878	1520	PKC inhibitor h7	[PKC inhibitor H7]	1.5849625007211563	3	1	0	0
28879	1520	75% respectively, of SCF	[75% respectively, of SCF]	1.5849625007211563	4	1	0	0
28880	1520	gene transfection assays,	[gene transfection assays,]	1.5849625007211563	3	1	0	0
28881	1520	post-germinal center b cell	[post-germinal center B cells]	1.5849625007211563	4	1	0	0
28882	1520	actinomycin d treatment	[actinomycin D treatment]	1.5849625007211563	3	1	0	0
28883	1520	population of T cell	[population of T cells]	1.5849625007211563	4	2	1	1
28884	1520	NFAT-1 mutant LTR	[NFAT-1 mutant LTR]	1.5849625007211563	3	1	0	0
28885	1520	nfatp complex formation	[NFATp complex formation]	1.5849625007211563	3	1	0	0
28886	1520	fetal liver culture	[fetal liver cultures]	1.5849625007211563	3	1	0	0
28887	1520	normal oestrogen target organ	[normal oestrogen target organs]	1.5849625007211563	4	2	1	1
28888	1520	lysosomal-associated membrane protein-1	[lysosomal-associated membrane protein-1]	1.5849625007211563	3	1	0	0
28889	1520	detectable DPD activity	[detectable DPD activity]	1.5849625007211563	3	1	0	0
28890	1520	Egr family protein	[Egr family proteins]	1.5849625007211563	3	1	0	0
28891	1520	inhibition of T cell	[inhibition of T cells]	1.5849625007211563	4	1	0	0
28892	1520	stat1 -dependent immune-response gene	[Stat1 -dependent immune-response genes]	1.5849625007211563	4	1	0	0
28893	1520	population in vitro	[population in vitro]	1.5849625007211563	3	1	0	0
28894	1520	SCL gene rearrangement	[SCL gene rearrangements]	1.5849625007211563	3	1	0	0
28895	1520	response to ca2+ concentration	[response to Ca2+ concentrations]	1.5849625007211563	4	1	0	0
28896	1520	-267 to +12 construct	[-267 to +12 construct]	1.5849625007211563	4	1	0	0
28897	1520	amino-terminal fragment of OCA-B	[amino-terminal fragment of OCA-B]	1.5849625007211563	4	1	0	0
28898	1520	effect on granulocytic differentiation	[effect on granulocytic differentiation]	1.5849625007211563	4	1	0	0
28899	1520	effect of anti-inflammatory agent	[effects of anti-inflammatory agents]	1.5849625007211563	4	2	2	2
28900	1520	activation of t-lymphocyte	[Activation of T-lymphocytes]	1.5849625007211563	3	2	2	2
28901	1520	plasmid with similar mutation	[plasmids with similar mutations]	1.5849625007211563	4	1	0	0
28902	1520	distant homology to Bcl-2	[distant homology to Bcl-2]	1.5849625007211563	4	1	0	0
28903	1520	high titer anti-38,000-M(r) serum	[high titer anti-38,000-M(r) serum]	1.5849625007211563	4	1	0	0
28904	1520	ifn-stimulated response element	[IFN-stimulated response element]	1.5849625007211563	3	2	2	2
28905	1520	none of the alteration	[None of the alterations]	1.5849625007211563	4	1	0	0
28906	1520	Addition of CM	[Addition of CM]	1.5849625007211563	3	1	0	0
28907	1520	only gata-binding protein	[only GATA-binding protein]	1.5849625007211563	3	1	0	0
28908	1520	40% e-selectin icam-1 induction	[40% E-selectin ICAM-1 induction]	1.5849625007211563	4	1	0	0
28909	1520	ptdin binding to mcd14	[PtdIns binding to mCD14]	1.5849625007211563	4	1	0	0
28910	1520	production of il-12 p70	[production of IL-12 p70]	1.5849625007211563	4	1	0	0
28911	1520	interpretation the primary target	[interpretation the primary target]	1.5849625007211563	4	1	0	0
28912	1520	Jurkat cd4+ T cell	[Jurkat CD4+ T cells]	1.5849625007211563	4	1	0	0
28913	1520	treatment with e2	[Treatment with E2]	1.5849625007211563	3	1	0	0
28914	1520	addition to STAT1alpha	[addition to STAT1alpha]	1.5849625007211563	3	1	0	0
28915	1520	co-cultured blood monocyte bm	[co-cultured blood monocytes BM]	1.5849625007211563	4	1	0	0
28916	1520	t-cell oncogenic protein hox11	[T-cell oncogenic protein HOX11]	1.5849625007211563	4	1	0	0
28917	1520	treatment with the regimen	[treatment with the regimen]	1.5849625007211563	4	1	0	0
28918	1520	chain (accessory factor)	[chain (accessory factor)]	1.5849625007211563	3	1	0	0
28919	1520	isolation of glutaminyl-ttg substrate	[isolation of glutaminyl-tTG substrates]	1.5849625007211563	4	1	0	0
28920	1520	cellular reduce catalyst thioredoxin	[cellular reducing catalyst thioredoxin]	1.5849625007211563	4	2	1	1
28921	1520	two different REV ltr	[two different REV LTRs]	1.5849625007211563	4	1	0	0
28922	1520	allow nuclear nf-kb expression	[allowing nuclear NF-KB expression]	1.5849625007211563	4	1	0	0
28923	1520	treatment with hm	[treatment with Hm]	1.5849625007211563	3	1	0	0
28924	1520	enhancer region of gene	[enhancer regions of genes]	1.5849625007211563	4	1	0	0
28925	1520	M3 leukemic cell	[M3 leukemic cells]	1.5849625007211563	3	1	0	0
28926	1520	high CAT activity	[highest CAT activity]	1.5849625007211563	3	2	1	1
28927	1520	human ino promoter region	[human iNOS promoter regions]	1.5849625007211563	4	1	0	0
28928	1520	origin of b cell	[origin of B cells]	1.5849625007211563	4	1	0	0
28929	1520	event in nonhuman primate	[events in nonhuman primates]	1.5849625007211563	4	1	0	0
28930	1520	Raji B cell	[Raji B cells]	1.5849625007211563	3	1	0	0
28931	1520	red cell survival	[red cell survival]	1.5849625007211563	3	1	0	0
28932	1520	fkhrl1 gene product.	[fkhrl1 gene product.]	1.5849625007211563	3	1	0	0
28933	1520	Fibroblast growth factor fgf	[Fibroblast growth factors FGFs]	1.5849625007211563	4	1	0	0
28934	1520	NF-kappaB /Rel protein	[NF-kappaB /Rel proteins]	1.5849625007211563	3	1	0	0
28935	1520	ets protein family	[ETS protein family]	1.5849625007211563	3	1	0	0
28936	1520	strand conformation polymorphism	[strand conformation polymorphism]	1.5849625007211563	3	2	2	2
28937	1520	X2 box in transcription	[X2 box in transcription]	1.5849625007211563	4	1	0	0
28938	1520	complex contain p130	[complex containing p130]	1.5849625007211563	3	1	0	0
28939	1520	(stat) protein recruitment	[(STAT) protein recruitment]	1.5849625007211563	3	1	0	0
28940	1520	ability of various dna	[abilities of various DNAs]	1.5849625007211563	4	1	0	0
28941	1520	inclusion of VDR	[inclusion of VDR]	1.5849625007211563	3	1	0	0
28942	1520	subsequent binding of member	[subsequent binding of members]	1.5849625007211563	4	1	0	0
28943	1520	glial-derived cell line	[glial-derived cell lines]	1.5849625007211563	3	1	0	0
28944	1520	active form in vitro.	[active form in vitro.]	1.5849625007211563	4	1	0	0
28945	1520	involvement of TNF	[Involvement of TNF]	1.5849625007211563	3	1	0	0
28946	1520	none of this polymorphism	[None of these polymorphisms]	1.5849625007211563	4	1	0	0
28947	1520	cooperation between E220K polyubiquitinylation	[cooperation between E220K polyubiquitinylation]	1.5849625007211563	4	1	0	0
28948	1520	common stem cell	[common stem cell]	1.5849625007211563	3	1	0	0
28949	1520	impaired humoral immunity	[impaired humoral immunity]	1.5849625007211563	3	1	0	0
28950	1520	granzyme b promoter activation	[granzyme B promoter activation]	1.5849625007211563	4	1	0	0
28951	1520	approximately a sixfold increase	[approximately a sixfold increase]	1.5849625007211563	4	1	0	0
28952	1520	induction of the factor	[induction of the factor]	1.5849625007211563	4	1	0	0
28953	1520	irrespective of the status	[irrespective of the status]	1.5849625007211563	4	1	0	0
28954	1520	novel approach attenuate hiv-1	[novel approach attenuating HIV-1]	1.5849625007211563	4	1	0	0
28955	1520	cell during differentiation.	[cells during differentiation.]	1.5849625007211563	3	1	0	0
28956	1520	ability of bhrf1	[ability of BHRF1]	1.5849625007211563	3	1	0	0
28957	1520	hiv phorbol myristate acetate-	[HIV phorbol myristate acetate-]	1.5849625007211563	4	1	0	0
28958	1520	heterologous acidic activation domain	[heterologous acidic activation domain]	1.5849625007211563	4	1	0	0
28959	1520	remarkable qualitative heterogeneity	[remarkable qualitative heterogeneity]	1.5849625007211563	3	1	0	0
28960	1520	alteration in NFkappaB activation	[alteration in NFkappaB activation]	1.5849625007211563	4	1	0	0
28961	1520	inhibitory subunit ikappabalpha	[inhibitory subunit IkappaBalpha]	1.5849625007211563	3	1	0	0
28962	1520	number of clone	[number of clones]	1.5849625007211563	3	2	1	1
28963	1520	presence of f(ab')2 fragment	[presence of F(ab')2 fragments]	1.5849625007211563	4	1	0	0
28964	1520	endothelial-leukocyte adhesion molecule 1	[endothelial-leukocyte adhesion molecule 1]	1.5849625007211563	4	1	0	0
28965	1520	cellular mcp-1 content	[cellular MCP-1 content]	1.5849625007211563	3	1	0	0
28966	1520	relationship between Ca2+-ATPase	[relationship between Ca2+-ATPase]	1.5849625007211563	3	1	0	0
28967	1520	stimulation with M. tuberculosis	[stimulation with M. tuberculosis]	1.5849625007211563	4	1	0	0
28968	1520	significantly, in each case	[Significantly, in each case]	1.5849625007211563	4	1	0	0
28969	1520	Flow cytometry analysis	[Flow cytometry analysis]	1.5849625007211563	3	2	1	1
28970	1520	positivity less than 0.05).	[positivity less than 0.05).]	1.5849625007211563	4	1	0	0
28971	1520	novel retinoic acid receptor	[novel retinoic acid receptor]	1.5849625007211563	4	1	0	0
28972	1520	design: promyelocytic cell	[DESIGN: promyelocytic cells]	1.5849625007211563	3	1	0	0
28973	1520	specificity tbp assay	[specificity TBP assay]	1.5849625007211563	3	1	0	0
28974	1520	morphology of u937 cell	[morphology of U937 cells]	1.5849625007211563	4	1	0	0
28975	1520	induction of t-cell anergy	[induction of T-cell anergy]	1.5849625007211563	4	1	0	0
28976	1520	pentazocine a competitive inhibitor	[pentazocine a competitive inhibitor]	1.5849625007211563	4	1	0	0
28977	1520	effect of BDP	[effect of BDP]	1.5849625007211563	3	1	0	0
28978	1520	nf-kappa b/rel nuclear activity	[NF-kappa B/Rel nuclear activity]	1.5849625007211563	4	2	1	1
28979	1520	"basic helix-loop-helix" protein	["basic helix-loop-helix" proteins]	1.5849625007211563	3	1	0	0
28980	1520	transcription factor by hsp90	[transcription factors by hsp90]	1.5849625007211563	4	1	0	0
28981	1520	hybrid bcr/abl mrna level	[hybrid bcr/abl mRNA levels]	1.5849625007211563	4	1	0	0
28982	1520	kappab DNA binding activity	[kappaB DNA binding activity]	1.5849625007211563	4	1	0	0
28983	1520	level of il-8	[levels of IL-8]	1.5849625007211563	3	2	2	2
28984	1520	study of cellular protein	[study of cellular proteins]	1.5849625007211563	4	1	0	0
28985	1520	level of il-4	[levels of IL-4]	1.5849625007211563	3	1	0	0
28986	1520	macrophage cell lineage	[macrophage cell lineage]	1.5849625007211563	3	2	1	1
28987	1520	monocyte chemotactic protein-1 secretion	[monocyte chemotactic protein-1 secretion]	1.5849625007211563	4	2	1	1
28988	1520	RNA polymerase promoter	[RNA polymerase promoters]	1.5849625007211563	3	2	2	2
28989	1520	environmental bacterial antigen	[environmental bacterial antigens]	1.5849625007211563	3	1	0	0
28990	1520	lps tnf-alpha production	[LPS TNF-alpha production]	1.5849625007211563	3	1	0	0
28991	1520	steroid-thyroid hormone receptor superfamily	[steroid-thyroid hormone receptor superfamily]	1.5849625007211563	4	1	0	0
28992	1520	impaired rna transcription activity	[impaired RNA transcription activity]	1.5849625007211563	4	1	0	0
28993	1520	subset of e box	[subset of E boxes]	1.5849625007211563	4	1	0	0
28994	1520	ability of pkc-epsilon	[ability of PKC-epsilon]	1.5849625007211563	3	1	0	0
28995	1520	endothelial-leukocyte adhesion molecule-1	[endothelial-leukocyte adhesion molecule-1]	1.5849625007211563	3	1	0	0
28996	1520	activation of mapk kinase-1	[activation of MAPK kinase-1]	1.5849625007211563	4	1	0	0
28997	1520	il-2 promoter stimulation	[IL-2 promoter stimulation]	1.5849625007211563	3	1	0	0
28998	1520	compounds, with the exception	[compounds, with the exception]	1.5849625007211563	4	1	0	0
28999	1520	stat protein binding	[Stat protein binding]	1.5849625007211563	3	1	0	0
29000	1520	different biological function	[different biological functions]	1.5849625007211563	3	1	0	0
29001	1520	class ii inducibility	[class II inducibility]	1.5849625007211563	3	1	0	0
29002	1520	protein nuclear localization	[protein nuclear localization]	1.5849625007211563	3	1	0	0
29003	1520	NAD(P)H:quinone reductase -dependent mechanism	[NAD(P)H:quinone reductase -dependent mechanism]	1.5849625007211563	4	1	0	0
29004	1520	relative ease of culture,	[relative ease of culture,]	1.5849625007211563	4	1	0	0
29005	1520	manifestation of human hiv-1	[manifestations of human HIV-1]	1.5849625007211563	4	1	0	0
29006	1520	Z transactivator alone	[Z transactivator alone]	1.5849625007211563	3	1	0	0
29007	1520	Molt-4 cell M4	[Molt-4 cells M4]	1.5849625007211563	3	1	0	0
29008	1520	transcription factor gabp alpha	[transcription factors GABP alpha]	1.5849625007211563	4	1	0	0
29009	1520	NFAT -1 transcriptional complex	[NFAT -1 transcriptional complex]	1.5849625007211563	4	1	0	0
29010	1520	normal menstrual cycle,	[normal menstrual cycle,]	1.5849625007211563	3	1	0	0
29011	1520	concentration of lps	[concentration of LPS]	1.5849625007211563	3	2	1	1
29012	1520	u937 histiocytic lymphoma cell	[U937 histiocytic lymphoma cells]	1.5849625007211563	4	1	0	0
29013	1520	86-amino acid fragment	[86-amino acid fragment]	1.5849625007211563	3	1	0	0
29014	1520	cell growth regulator	[cell growth regulators]	1.5849625007211563	3	1	0	0
29015	1520	part of a alu	[part of an Alu]	1.5849625007211563	4	1	0	0
29016	1520	entry of microorganism	[entry of microorganisms]	1.5849625007211563	3	1	0	0
29017	1520	absence of estrogen receptor	[absence of estrogen receptor]	1.5849625007211563	4	1	0	0
29018	1520	Elk-1 fusion protein	[Elk-1 fusion protein]	1.5849625007211563	3	2	2	2
29019	1520	Conversely, inhibition of NF-kappaB	[Conversely, inhibition of NF-kappaB]	1.5849625007211563	4	1	0	0
29020	1520	human interleukin-1 beta promoter	[human interleukin-1 beta promoter]	1.5849625007211563	4	1	0	0
29021	1520	subunit of this heterodimer	[subunits of this heterodimer]	1.5849625007211563	4	1	0	0
29022	1520	binding of 1	[Binding of 1]	1.5849625007211563	3	1	0	0
29023	1520	inter-relationship between hiv-1 infection	[inter-relationship between HIV-1 infection]	1.5849625007211563	4	1	0	0
29024	1520	nf-kappab activation by LMP1	[NF-kappaB activation by LMP1]	1.5849625007211563	4	1	0	0
29025	1520	different hs-40 motif	[different HS-40 motifs]	1.5849625007211563	3	1	0	0
29026	1520	autoreactive T cell	[autoreactive T cells]	1.5849625007211563	3	2	1	1
29027	1520	response to dhcc	[response to DHCC]	1.5849625007211563	3	1	0	0
29028	1520	peripheral human mononuclear cell	[peripheral human mononuclear cells]	1.5849625007211563	4	1	0	0
29029	1520	potent CD40 agonist	[potent CD40 agonist]	1.5849625007211563	3	1	0	0
29030	1520	single gene trans-activation	[single gene trans-activation]	1.5849625007211563	3	1	0	0
29031	1520	patients' T cell	[patients' T cells]	1.5849625007211563	3	2	1	1
29032	1520	presence of sodium n-butyrate	[presence of sodium n-butyrate]	1.5849625007211563	4	1	0	0
29033	1520	control u937 cell	[control U937 cells]	1.5849625007211563	3	1	0	0
29034	1520	result in a reduction	[resulting in a reduction]	1.5849625007211563	4	1	0	0
29035	1520	T lymphocyte-conditioned medium	[T lymphocyte-conditioned medium]	1.5849625007211563	3	1	0	0
29036	1520	lac operator sequence	[lac operator sequence]	1.5849625007211563	3	1	0	0
29037	1520	alpha2 integrin subunit	[alpha2 integrin subunit]	1.5849625007211563	3	1	0	0
29038	1520	total nf-kappa b	[total NF-kappa B]	1.5849625007211563	3	1	0	0
29039	1520	nm23/ndp kinase protein	[nm23/NDP kinase protein]	1.5849625007211563	3	1	0	0
29040	1520	intact beta interferon promoter	[intact beta interferon promoter]	1.5849625007211563	4	1	0	0
29041	1520	state of differentiation	[state of differentiation]	1.5849625007211563	3	1	0	0
29042	1520	subsequently respond to therapy	[subsequently responding to therapy]	1.5849625007211563	4	1	0	0
29043	1520	Class ii molecule	[Class II molecules]	1.5849625007211563	3	1	0	0
29044	1520	cellular oncogene c-myb	[cellular oncogene c-myb]	1.5849625007211563	3	1	0	0
29045	1520	role in transcriptional regulation	[role in transcriptional regulation]	1.5849625007211563	4	2	1	1
29046	1520	T b lymphocyte	[T B lymphocytes]	1.5849625007211563	3	1	0	0
29047	1520	one member, ICK-1A	[One member, ICK-1A]	1.5849625007211563	3	1	0	0
29048	1520	gm-csf-responsive progenitor cell	[GM-CSF-responsive progenitor cell]	1.5849625007211563	3	2	1	1
29049	1520	phenotypic characteristic of IkappaB-alphaS32/36A	[phenotypic characteristics of IkappaB-alphaS32/36A]	1.5849625007211563	4	1	0	0
29050	1520	analysis of this PBLs	[Analysis of these PBLs]	1.5849625007211563	4	1	0	0
29051	1520	b p50 /p65	[B p50 /p65]	1.5849625007211563	3	1	0	0
29052	1520	less extent interleukin-1 il-1	[lesser extent interleukin-1 IL-1]	1.5849625007211563	4	1	0	0
29053	1520	regulation of icam-1 expression	[regulation of ICAM-1 expression]	1.5849625007211563	4	1	0	0
29054	1520	blood lymphocyte from patient	[blood lymphocytes from patients]	1.5849625007211563	4	2	1	1
29055	1520	T cell activation result	[T cell activation resulting]	1.5849625007211563	4	1	0	0
29056	1520	anti- Tat sfv intrabody	[anti- Tat sFv intrabodies]	1.5849625007211563	4	1	0	0
29057	1520	concentration of 125d3	[concentrations of 1,25D3]	1.5849625007211563	3	2	2	2
29058	1520	cell dysregulation by Vpr	[cell dysregulation by Vpr]	1.5849625007211563	4	1	0	0
29059	1520	murine fra-1 gene	[murine fra-1 gene]	1.5849625007211563	3	1	0	0
29060	1520	binding of a number	[binding of a number]	1.5849625007211563	4	1	0	0
29061	1520	autoimmunity in transgenic mouse	[autoimmunity in transgenic mice]	1.5849625007211563	4	1	0	0
29062	1520	contrast, il-13 level	[contrast, IL-13 levels]	1.5849625007211563	3	1	0	0
29063	1520	cd45ra+ cells, h2o2	[CD45RA+ cells, H2O2]	1.5849625007211563	3	1	0	0
29064	1520	detectable cd14 cell surface	[detectable CD14 cell surface]	1.5849625007211563	4	1	0	0
29065	1520	bursal b cell	[bursal B cells]	1.5849625007211563	3	1	0	0
29066	1520	synthesis of a group	[synthesis of a group]	1.5849625007211563	4	1	0	0
29067	1520	intense self-perpetuated viral transcription	[intense self-perpetuated viral transcription]	1.5849625007211563	4	1	0	0
29068	1520	kappa b subunit	[kappa B subunits]	1.5849625007211563	3	1	0	0
29069	1520	mouse, in the human	[mouse, in the human]	1.5849625007211563	4	1	0	0
29070	1520	transcription of hiv	[transcription of HIV]	1.5849625007211563	3	1	0	0
29071	1520	gata-1 gene disruption	[GATA-1 gene disruption]	1.5849625007211563	3	1	0	0
29072	1520	airway of patient	[airways of patients]	1.5849625007211563	3	1	0	0
29073	1520	BL cell line	[BL cell lines]	1.5849625007211563	3	1	0	0
29074	1520	two b cell line	[Two B cell lines]	1.5849625007211563	4	2	2	2
29075	1520	etntri) expression vector	[(TNFRI) expression vector]	1.5849625007211563	3	1	0	0
29076	1520	approximately the same,	[approximately the same,]	1.5849625007211563	3	1	0	0
29077	1520	CD28 change with activation.	[CD28 changes with activation.]	1.5849625007211563	4	1	0	0
29078	1520	cd2-mediated interleukin-2 promoter activation	[CD2-mediated interleukin-2 promoter activation]	1.5849625007211563	4	1	0	0
29079	1520	trapoxin affinity matrix	[trapoxin affinity matrix]	1.5849625007211563	3	1	0	0
29080	1520	GATA-1 -erythroid cell	[GATA-1 -erythroid cells]	1.5849625007211563	3	1	0	0
29081	1520	presence of normal expression	[presence of normal expression]	1.5849625007211563	4	1	0	0
29082	1520	closely related alpha-herpesviruse	[closely related alpha-herpesviruses]	1.5849625007211563	3	1	0	0
29083	1520	basal il-1r gene expression	[basal IL-1R gene expression]	1.5849625007211563	4	1	0	0
29084	1520	c-Jun NH2-terminal kinase activation	[c-Jun NH2-terminal kinase activation]	1.5849625007211563	4	1	0	0
29085	1520	maximum transrepressive activity	[maximum transrepressive activity]	1.5849625007211563	3	1	0	0
29086	1520	context of viral replication,	[context of viral replication,]	1.5849625007211563	4	1	0	0
29087	1520	expression of PKC alpha	[expression of PKC alpha]	1.5849625007211563	4	1	0	0
29088	1520	relevant dna-binding species	[relevant DNA-binding species]	1.5849625007211563	3	1	0	0
29089	1520	vitro degradation experiment	[vitro degradation experiments]	1.5849625007211563	3	1	0	0
29090	1520	T cell by IL-12	[T cells by IL-12]	1.5849625007211563	4	1	0	0
29091	1520	relationship between ras transformation	[relationship between ras transformation]	1.5849625007211563	4	1	0	0
29092	1520	proportion of cd30+ cell	[proportion of CD30+ cells]	1.5849625007211563	4	1	0	0
29093	1520	form of additional translocations.	[form of additional translocations.]	1.5849625007211563	4	1	0	0
29094	1520	least two stages:	[least two stages:]	1.5849625007211563	3	1	0	0
29095	1520	bone marrow graft	[bone marrow grafts]	1.5849625007211563	3	1	0	0
29096	1520	lps saa gene induction	[LPS SAA gene induction]	1.5849625007211563	4	1	0	0
29097	1520	human th2 cell	[human Th2 cells]	1.5849625007211563	3	2	2	2
29098	1520	Pentoxifylline a xanthine derivative	[Pentoxifylline a xanthine derivative]	1.5849625007211563	4	1	0	0
29099	1520	nucleus of cell line	[nucleus of cell lines]	1.5849625007211563	4	1	0	0
29100	1520	activation of il-2r gamma	[activation of IL-2R gamma]	1.5849625007211563	4	1	0	0
29101	1520	patient with primary hyperparathyroidism	[patients with primary hyperparathyroidism]	1.5849625007211563	4	1	0	0
29102	1520	suggest under the control	[suggesting under the control]	1.5849625007211563	4	1	0	0
29103	1520	CBF beta -myh11	[CBF beta -MYH11]	1.5849625007211563	3	1	0	0
29104	1520	humans, alternative splicing	[humans, alternative splicing]	1.5849625007211563	3	1	0	0
29105	1520	signal via CD15	[signaling via CD15]	1.5849625007211563	3	1	0	0
29106	1520	DNA bind specificity	[DNA binding specificity]	1.5849625007211563	3	2	2	2
29107	1520	full-length PML/RARalpha cDNA	[full-length PML/RARalpha cDNA]	1.5849625007211563	3	1	0	0
29108	1520	m10 -express CEM clone	[M10 -expressing CEM clones]	1.5849625007211563	4	1	0	0
29109	1520	expression of IL-6 mrna	[expression of IL-6 mRNA]	1.5849625007211563	4	1	0	0
29110	1520	less extent than diethylstilbestrol	[lesser extent than diethylstilbestrol]	1.5849625007211563	4	1	0	0
29111	1520	virtually ubiquitous transcription factor	[virtually ubiquitous transcription factor]	1.5849625007211563	4	1	0	0
29112	1520	apoptosis suppressor protein bcl-xl	[apoptosis suppressor protein Bcl-xL]	1.5849625007211563	4	1	0	0
29113	1520	80 percent of nonresponders.	[80 percent of nonresponders.]	1.5849625007211563	4	1	0	0
29114	1520	E. coli rpo gene	[E. coli rpoS gene]	1.5849625007211563	4	1	0	0
29115	1520	exposure to stress	[exposure to stress]	1.5849625007211563	3	2	2	2
29116	1520	down-regulation of c-fo ap-1	[down-regulation of c-fos AP-1]	1.5849625007211563	4	1	0	0
29117	1520	ifn-gamma receptor chain necessary	[IFN-gamma receptor chain necessary]	1.5849625007211563	4	1	0	0
29118	1520	such permissivity factor	[such permissivity factors]	1.5849625007211563	3	1	0	0
29119	1520	substitution of Ile50	[substitution of Ile50]	1.5849625007211563	3	1	0	0
29120	1520	examination of lymphoid tissue	[Examination of lymphoid tissues]	1.5849625007211563	4	1	0	0
29121	1520	physical linkage to xic/xist	[physical linkage to XIC/XIST]	1.5849625007211563	4	1	0	0
29122	1520	tal-1 1a promoter	[tal-1 1A promoter]	1.5849625007211563	3	1	0	0
29123	1520	certain elderly subject	[certain elderly subjects]	1.5849625007211563	3	1	0	0
29124	1520	Epstein-Barr virus rta protein	[Epstein-Barr virus Rta protein]	1.5849625007211563	4	1	0	0
29125	1520	activation-deficient glucocorticoid receptor mutant	[activation-deficient glucocorticoid receptor mutant]	1.5849625007211563	4	1	0	0
29126	1520	analogue effect on VDR	[analogue effects on VDR]	1.5849625007211563	4	1	0	0
29127	1520	greatly skin tumor	[greatly skin tumor]	1.5849625007211563	3	1	0	0
29128	1520	normal heterozygous lymphocyte	[normal heterozygous lymphocytes]	1.5849625007211563	3	1	0	0
29129	1520	combination with p65	[combination with p65]	1.5849625007211563	3	1	0	0
29130	1520	contrast to the patient	[contrast to the patients]	1.5849625007211563	4	1	0	0
29131	1520	cellular proliferation, stat-5 induction	[cellular proliferation, STAT-5 induction]	1.5849625007211563	4	1	0	0
29132	1520	unique chromatin structure	[unique chromatin structure]	1.5849625007211563	3	1	0	0
29133	1520	enf)-kappa b subunit	[(NF)-kappa B subunits]	1.5849625007211563	3	1	0	0
29134	1520	murine Thy-1 gene promoter	[murine Thy-1 gene promoter]	1.5849625007211563	4	1	0	0
29135	1520	serum amyloid a gene	[serum amyloid A gene]	1.5849625007211563	4	1	0	0
29136	1520	Ets transcription factor related	[Ets transcription factor related]	1.5849625007211563	4	1	0	0
29137	1520	production of IFN-gamma	[production of IFN-gamma]	1.5849625007211563	3	1	0	0
29138	1520	functional relationship between A-myb	[functional relationship between A-myb]	1.5849625007211563	4	1	0	0
29139	1520	common inflammatory condition	[common inflammatory condition]	1.5849625007211563	3	1	0	0
29140	1520	steroid binding assay	[steroid binding assay]	1.5849625007211563	3	2	2	2
29141	1520	Bmax in quiescent pbmc	[Bmax in quiescent PBMC]	1.5849625007211563	4	1	0	0
29142	1520	1.5 nm in group	[1.5 nM in group]	1.5849625007211563	4	1	0	0
29143	1520	IL-2 mrna expression	[IL-2 mRNA expression]	1.5849625007211563	3	2	1	1
29144	1520	human leukocyte antigen status.	[human leukocyte antigen status.]	1.5849625007211563	4	1	0	0
29145	1520	potential therapeutic application	[potential therapeutic application]	1.5849625007211563	3	1	0	0
29146	1520	membrane related rapid responses.	[membrane related rapid responses.]	1.5849625007211563	4	1	0	0
29147	1520	cell with PMA ionophore	[cells with PMA ionophore]	1.5849625007211563	4	1	0	0
29148	1520	functionally different CD4 epitope	[functionally different CD4 epitopes]	1.5849625007211563	4	1	0	0
29149	1520	interaction with factor	[interaction with factors]	1.5849625007211563	3	2	2	2
29150	1520	context of the literature	[context of the literature]	1.5849625007211563	4	1	0	0
29151	1520	high abundance of jak3	[higher abundance of JAK3]	1.5849625007211563	4	1	0	0
29152	1520	formation of the complex	[Formation of the complex]	1.5849625007211563	4	2	1	1
29153	1520	(range, 5.86-6.74) nm,	[(range, 5.86-6.74) nM,]	1.5849625007211563	3	1	0	0
29154	1520	unilineage erythropoietic differentiation	[unilineage erythropoietic differentiation]	1.5849625007211563	3	2	1	1
29155	1520	ca2+ ionophore ionomycin	[Ca2+ ionophore ionomycin]	1.5849625007211563	3	1	0	0
29156	1520	rna, respectively; p	[RNA, respectively; P]	1.5849625007211563	3	1	0	0
29157	1520	constitutive gh production	[constitutive GH production]	1.5849625007211563	3	1	0	0
29158	1520	DNA binding by VDR	[DNA binding by VDR]	1.5849625007211563	4	1	0	0
29159	1520	light of the report	[light of the report]	1.5849625007211563	4	1	0	0
29160	1520	very large (12-25 repeats).	[very large (12-25 repeats).]	1.5849625007211563	4	1	0	0
29161	1520	patient young than 40.	[patients younger than 40.]	1.5849625007211563	4	1	0	0
29162	1520	erythropoietin receptor mutant defective	[erythropoietin receptor mutant defective]	1.5849625007211563	4	1	0	0
29163	1520	relation to age	[relation to age]	1.5849625007211563	3	1	0	0
29164	1520	mediate the tax response	[mediating the Tax response]	1.5849625007211563	4	1	0	0
29165	1520	binding to kappab sequence	[Binding to kappaB sequence]	1.5849625007211563	4	1	0	0
29166	1520	Drosophila gene runt	[Drosophila gene runt]	1.5849625007211563	3	1	0	0
29167	1520	digoxigenin-labeled complementary DNA probe	[digoxigenin-labeled complementary DNA probe]	1.5849625007211563	4	1	0	0
29168	1520	contrast to concentration	[contrast to concentrations]	1.5849625007211563	3	1	0	0
29169	1520	toll-like receptor tlr	[Toll-like receptors TLRs]	1.5849625007211563	3	1	0	0
29170	1520	addition, lymphocyte subset	[addition, lymphocyte subsets]	1.5849625007211563	3	1	0	0
29171	1520	e2f-dependent thymidine kinase regulation	[E2F-dependent thymidine kinase regulation]	1.5849625007211563	4	1	0	0
29172	1520	ensue cellular gene activation	[ensuing cellular gene activation]	1.5849625007211563	4	1	0	0
29173	1520	OCT-1 proximal (oct-1p)-binding site	[OCT-1 proximal (OCT-1p)-binding site]	1.5849625007211563	4	1	0	0
29174	1520	expression in tissue	[expression in tissues]	1.5849625007211563	3	2	2	2
29175	1520	GM-kappa B/ gc-box region	[GM-kappa B/ GC-box region]	1.5849625007211563	4	1	0	0
29176	1520	e2a protein concentration	[E2A protein concentrations]	1.5849625007211563	3	1	0	0
29177	1520	induction of autoimmunity	[induction of autoimmunity]	1.5849625007211563	3	1	0	0
29178	1520	comedo versus noncomedo variants.	[comedo versus noncomedo variants.]	1.5849625007211563	4	1	0	0
29179	1520	effect of DEX	[effect of DEX]	1.5849625007211563	3	2	1	1
29180	1520	ifn-gamma activation sequence	[IFN-gamma activation sequence]	1.5849625007211563	3	2	2	2
29181	1520	follicular cell FDC	[follicular cells FDC]	1.5849625007211563	3	2	2	2
29182	1520	three sp1 site	[three Sp1 sites]	1.5849625007211563	3	1	0	0
29183	1520	similar effect on cd11b	[similar effects on CD11b]	1.5849625007211563	4	1	0	0
29184	1520	activation signal pathway	[Activation signaling pathways]	1.5849625007211563	3	2	2	2
29185	1520	two purine-rich motif	[two purine-rich motifs]	1.5849625007211563	3	1	0	0
29186	1520	CD8 cell surface antigen	[CD8 cell surface antigens]	1.5849625007211563	4	1	0	0
29187	1520	level of sp140 mrna	[level of SP140 mRNA]	1.5849625007211563	4	2	1	1
29188	1520	expression of stat3 protein	[expression of Stat3 proteins]	1.5849625007211563	4	1	0	0
29189	1520	direct interaction between RFX5	[direct interaction between RFX5]	1.5849625007211563	4	1	0	0
29190	1520	target sequence TGGAAATTCC	[target sequence TGGAAATTCC]	1.5849625007211563	3	1	0	0
29191	1520	other major risk factor	[other major risk factors]	1.5849625007211563	4	1	0	0
29192	1520	dna, such as JunD	[DNA, such as JunD]	1.5849625007211563	4	1	0	0
29193	1520	EGR1 expression vector	[EGR1 expression vector]	1.5849625007211563	3	1	0	0
29194	1520	granulocyte/macrophage colony-stimulating factor gm-csf	[granulocyte/macrophage colony-stimulating factor GM-CSF]	1.5849625007211563	4	2	1	1
29195	1520	rat primary microglia	[rat primary microglia]	1.5849625007211563	3	1	0	0
29196	1520	msr ligand, ldl	[MSR ligand, LDL]	1.5849625007211563	3	1	0	0
29197	1520	specific peptide residue	[specific peptide residue]	1.5849625007211563	3	1	0	0
29198	1520	multiple functionally important ebf	[Multiple functionally important EBF]	1.5849625007211563	4	1	0	0
29199	1520	transcription factor c/ebp beta	[transcription factor C/EBP beta]	1.5849625007211563	4	2	1	1
29200	1520	alpha-subunit of the complex	[alpha-subunit of the complex]	1.5849625007211563	4	1	0	0
29201	1520	hgm-csf cell growth	[hGM-CSF cell growth]	1.5849625007211563	3	1	0	0
29202	1520	receptor from A1-VDR cell	[receptor from A1-VDR cells]	1.5849625007211563	4	1	0	0
29203	1520	basis of genetic composition	[basis of genetic composition]	1.5849625007211563	4	1	0	0
29204	1520	putative g0s gene	[putative G0S genes]	1.5849625007211563	3	1	0	0
29205	1520	role of the matrix	[role of the matrix]	1.5849625007211563	4	1	0	0
29206	1520	three gch molecule	[three GCH molecules]	1.5849625007211563	3	1	0	0
29207	1520	express low level	[expressing low levels]	1.5849625007211563	3	1	0	0
29208	1520	NF-kappa b erratum	[NF-kappa B erratum]	1.5849625007211563	3	2	1	1
29209	1520	impaired activation of nf-at	[impaired activation of NF-AT]	1.5849625007211563	4	1	0	0
29210	1520	erk2 kinase by PMA	[ERK2 kinase by PMA]	1.5849625007211563	4	1	0	0
29211	1520	sds-stable class ii	[SDS-stable class II]	1.5849625007211563	3	1	0	0
29212	1520	high level of hladq	[high levels of HLADQ]	1.5849625007211563	4	1	0	0
29213	1520	cytochrome p4501a1 gene expression	[cytochrome P4501A1 gene expression]	1.5849625007211563	4	1	0	0
29214	1520	novel large isoform, oct2ab	[novel large isoform, Oct2ab]	1.5849625007211563	4	1	0	0
29215	1520	different extracellular signal	[different extracellular signals]	1.5849625007211563	3	1	0	0
29216	1520	two REV ltr	[two REV LTRs]	1.5849625007211563	3	1	0	0
29217	1520	apparently indistinguishable sequence specificity	[apparently indistinguishable sequence specificity]	1.5849625007211563	4	1	0	0
29218	1520	pathological immune response	[pathological immune responses]	1.5849625007211563	3	1	0	0
29219	1520	actinomycin d administration	[actinomycin D administration]	1.5849625007211563	3	1	0	0
29220	1520	21.4-kb DNA clone pzvb70	[21.4-kb DNA clone pZVB70]	1.5849625007211563	4	1	0	0
29221	1520	biology of the cell	[biology of the cell]	1.5849625007211563	4	1	0	0
29222	1520	vigorous replication of hiv-1	[vigorous replication of HIV-1]	1.5849625007211563	4	1	0	0
29223	1520	human transcription factor sp1	[human transcription factor SP1]	1.5849625007211563	4	1	0	0
29224	1520	human RXR alpha	[Human RXR alpha]	1.5849625007211563	3	1	0	0
29225	1520	chloramphenicol acetyltransferase (cat) gene	[chloramphenicol acetyltransferase (CAT) gene]	1.5849625007211563	4	2	2	2
29226	1520	AP-2 binding sequence	[AP-2 binding sequences]	1.5849625007211563	3	1	0	0
29227	1520	direct activator of 5'hs3	[direct activator of 5'HS3]	1.5849625007211563	4	1	0	0
29228	1520	kinetic of Oct-2 induction	[kinetics of Oct-2 induction]	1.5849625007211563	4	1	0	0
29229	1520	S. cerevisiae pombe system	[S. cerevisiae pombe systems]	1.5849625007211563	4	1	0	0
29230	1520	differentiation of the latter	[differentiation of the latter]	1.5849625007211563	4	1	0	0
29231	1520	NF-kappa B binding site	[NF-kappa B binding sites]	1.5849625007211563	4	1	0	0
29232	1520	interferon-gamma of stat factor	[interferon-gamma of STAT factors]	1.5849625007211563	4	1	0	0
29233	1520	host inflammatory response	[host inflammatory response]	1.5849625007211563	3	1	0	0
29234	1520	specific effect of vd3	[specific effects of VD3]	1.5849625007211563	4	1	0	0
29235	1520	I alpha1 germ-line promoter	[I alpha1 germ-line promoter]	1.5849625007211563	4	1	0	0
29236	1520	predict response to glucocorticoid	[predicting response to glucocorticoids]	1.5849625007211563	4	1	0	0
29237	1520	resistance to the treatment	[resistance to the treatment]	1.5849625007211563	4	1	0	0
29238	1520	signal pathway of Ras	[signaling pathway of Ras]	1.5849625007211563	4	1	0	0
29239	1520	Marek's disease virus	[Marek's disease virus]	1.5849625007211563	3	1	0	0
29240	1520	comparison with healthy control	[comparison with healthy controls]	1.5849625007211563	4	1	0	0
29241	1520	human beta-globin expression	[human beta-globin expression]	1.5849625007211563	3	1	0	0
29242	1520	comparison to other activator	[comparison to other activators]	1.5849625007211563	4	1	0	0
29243	1520	critical rac-1 signal pathway	[critical Rac-1 signaling pathways]	1.5849625007211563	4	1	0	0
29244	1520	same extent as lps	[same extent as LPS]	1.5849625007211563	4	1	0	0
29245	1520	use ut-7/gmt cell	[Using UT-7/GMT cells]	1.5849625007211563	3	1	0	0
29246	1520	phosphorylation of TRAF2	[phosphorylation of TRAF2]	1.5849625007211563	3	1	0	0
29247	1520	transcriptional activation in response	[transcriptional activation in response]	1.5849625007211563	4	2	2	2
29248	1520	contrast to slp-76	[contrast to SLP-76]	1.5849625007211563	3	1	0	0
29249	1520	final gene rearrangement event	[final gene rearrangement events]	1.5849625007211563	4	1	0	0
29250	1520	human myelomonocytic lineage	[human myelomonocytic lineage]	1.5849625007211563	3	1	0	0
29251	1520	kd (30.3+/-2.5 nmol/L)	[Kd (30.3+/-2.5 nmol/L)]	1.5849625007211563	3	2	2	2
29252	1520	initiation of ciita expression	[initiation of CIITA expression]	1.5849625007211563	4	1	0	0
29253	1520	lymphoid-specific transcription complex NF-AT	[lymphoid-specific transcription complex NF-AT]	1.5849625007211563	4	1	0	0
29254	1520	nuclear pore complex NPC	[nuclear pore complex NPC]	1.5849625007211563	4	1	0	0
29255	1520	vitro analysis of system	[vitro analysis of systems]	1.5849625007211563	4	1	0	0
29256	1520	MHC class ii extinction	[MHC class II extinction]	1.5849625007211563	4	1	0	0
29257	1520	hodgkin' disease hd	[Hodgkin's disease HD]	1.5849625007211563	3	2	1	1
29258	1520	trapping of density lipoprotein	[trapping of density lipoprotein]	1.5849625007211563	4	1	0	0
29259	1520	mediate T lymphocyte activation	[mediating T lymphocyte activation]	1.5849625007211563	4	1	0	0
29260	1520	analysis by blotting	[analysis by blotting]	1.5849625007211563	3	2	2	2
29261	1520	ataxia telangiectasia patient	[ataxia telangiectasia patients]	1.5849625007211563	3	1	0	0
29262	1520	proteolytic clipping bandshift assay	[proteolytic clipping bandshift assays]	1.5849625007211563	4	1	0	0
29263	1520	various b cell line	[various B cell lines]	1.5849625007211563	4	1	0	0
29264	1520	mnp-1 transcription factor	[MNP-1 transcription factor]	1.5849625007211563	3	1	0	0
29265	1520	cytosolic compartment to membrane	[cytosolic compartment to membranes]	1.5849625007211563	4	1	0	0
29266	1520	hla-b8-restricted peptide rakfkqll	[HLA-B8-restricted peptide RAKFKQLL]	1.5849625007211563	3	1	0	0
29267	1520	significant level in plasmacytoma	[significant levels in plasmacytoma]	1.5849625007211563	4	1	0	0
29268	1520	mRNA for c-fe	[mRNA for c-fes]	1.5849625007211563	3	1	0	0
29269	1520	sequence-specific collinear triplex	[sequence-specific collinear triplex]	1.5849625007211563	3	1	0	0
29270	1520	RA vitd3 -signal pathway	[RA VitD3 -signaling pathways]	1.5849625007211563	4	1	0	0
29271	1520	level of this factor	[level of these factors]	1.5849625007211563	4	1	0	0
29272	1520	N-terminal 125 amino acid	[N-terminal 125 amino acids]	1.5849625007211563	4	1	0	0
29273	1520	furthermore, ikaros-null thymocyte	[Furthermore, Ikaros-null thymocytes]	1.5849625007211563	3	1	0	0
29274	1520	genomic mbob1 clone	[genomic mBob1 clone]	1.5849625007211563	3	1	0	0
29275	1520	constitutively active shp2-deltash2	[constitutively active SHP2-DeltaSH2]	1.5849625007211563	3	1	0	0
29276	1520	monoclonal antibody-mediated cross-linking	[monoclonal antibody-mediated cross-linking]	1.5849625007211563	3	1	0	0
29277	1520	tax in HTLV-I cell	[Tax in HTLV-I cells]	1.5849625007211563	4	1	0	0
29278	1520	interaction with thymic cell	[interaction with thymic cells]	1.5849625007211563	4	2	2	2
29279	1520	b cell-specific protein	[B cell-specific protein]	1.5849625007211563	3	1	0	0
29280	1520	Recent molecular evidence	[Recent molecular evidence]	1.5849625007211563	3	1	0	0
29281	1520	inhibitor of hiv replication	[inhibitor of HIV replication]	1.5849625007211563	4	2	2	2
29282	1520	PHA proliferation of pbmc	[PHA proliferation of PBMCs]	1.5849625007211563	4	1	0	0
29283	1520	protooncogene in Hyon cell	[protooncogenes in Hyon cells]	1.5849625007211563	4	1	0	0
29284	1520	transactivation by ap-1 protein	[transactivation by AP-1 proteins]	1.5849625007211563	4	1	0	0
29285	1520	et family member elf-1	[ets family member elf-1]	1.5849625007211563	4	1	0	0
29286	1520	first early-induced peak	[first early-induced peak]	1.5849625007211563	3	1	0	0
29287	1520	molecular mass of kda.	[molecular mass of kDa.]	1.5849625007211563	4	2	2	2
29288	1520	distinct replicative property	[distinct replicative properties]	1.5849625007211563	3	1	0	0
29289	1520	alpha-interferon through receptor	[alpha-interferon through receptor]	1.5849625007211563	3	1	0	0
29290	1520	germinal center formation	[germinal center formation]	1.5849625007211563	3	1	0	0
29291	1520	minimal constitutive nf-kappa b	[minimal constitutive NF-kappa B]	1.5849625007211563	4	1	0	0
29292	1520	-200 to -100 bp	[-200 to -100 bp]	1.5849625007211563	4	1	0	0
29293	1520	promoter region of gene	[promoter regions of genes]	1.5849625007211563	4	2	1	1
29294	1520	protein kinase a fashion	[protein kinase A fashion]	1.5849625007211563	4	1	0	0
29295	1520	isogenic control LTR	[isogenic control LTR]	1.5849625007211563	3	1	0	0
29296	1520	cell adhesion molecule CAM	[cell adhesion molecules CAMs]	1.5849625007211563	4	1	0	0
29297	1520	Biochim Biophys Acta	[Biochim Biophys Acta]	1.5849625007211563	3	1	0	0
29298	1520	AES peptide G75 128-135	[AES peptides G75 128-135]	1.5849625007211563	4	1	0	0
29299	1520	role in inflammation	[role in inflammation]	1.5849625007211563	3	2	2	2
29300	1520	redox status of cell	[Redox status of cells]	1.5849625007211563	4	1	0	0
29301	1520	T cell by NFATp	[T cells by NFATp]	1.5849625007211563	4	1	0	0
29302	1520	datum on the mechanism	[data on the mechanism]	1.5849625007211563	4	1	0	0
29303	1520	effect of BHA	[effect of BHA]	1.5849625007211563	3	2	2	2
29304	1520	luman of the tract	[lumen of the tract]	1.5849625007211563	4	1	0	0
29305	1520	functional activity of ligand	[functional activity of ligands]	1.5849625007211563	4	1	0	0
29306	1520	p53 level via activation	[p53 levels via activation]	1.5849625007211563	4	1	0	0
29307	1520	host cell gene	[host cell gene]	1.5849625007211563	3	2	1	1
29308	1520	signal 3 socs3	[signaling 3 SOCS3]	1.5849625007211563	3	1	0	0
29309	1520	approximately 6 kilobasis	[approximately 6 kilobases]	1.5849625007211563	3	1	0	0
29310	1520	differentiation to plasma cell	[differentiation to plasma cells]	1.5849625007211563	4	1	0	0
29311	1520	monocyte il-1ra secretion	[monocyte IL-1ra secretion]	1.5849625007211563	3	2	2	2
29312	1520	only very low affinity	[only very low affinity]	1.5849625007211563	4	1	0	0
29313	1520	th2 T cell	[Th2 T cells]	1.5849625007211563	3	1	0	0
29314	1520	monocyte in aids	[monocytes in AIDS]	1.5849625007211563	3	1	0	0
29315	1520	concentration of tpck	[concentrations of TPCK]	1.5849625007211563	3	1	0	0
29316	1520	low pkc protein expression	[low PKC protein expression]	1.5849625007211563	4	1	0	0
29317	1520	human immunodeficiency virus entry	[human immunodeficiency virus entry]	1.5849625007211563	4	2	2	2
29318	1520	characteristic of breast cancer	[characteristic of breast cancer]	1.5849625007211563	4	2	1	1
29319	1520	magnitude of catalytic activation	[magnitude of catalytic activation]	1.5849625007211563	4	1	0	0
29320	1520	activation of shp1	[activation of SHP1]	1.5849625007211563	3	1	0	0
29321	1520	381 ng/ml) groups.	[381 ng/mL) groups.]	1.5849625007211563	3	1	0	0
29322	1520	strong in DS one	[strong in DS ones]	1.5849625007211563	4	1	0	0
29323	1520	treatment with PMA p/i	[Treatment with PMA P/I]	1.5849625007211563	4	1	0	0
29324	1520	such as IL-4	[such as IL-4]	1.5849625007211563	3	1	0	0
29325	1520	effect of C3a	[effects of C3a]	1.5849625007211563	3	4	3	1
29326	1520	freshly-isolated T cell	[freshly-isolated T cells]	1.5849625007211563	3	1	0	0
29327	1520	quantitative experiment compare binding	[Quantitative experiments comparing binding]	1.5849625007211563	4	1	0	0
29328	1520	such as IL-8	[such as IL-8]	1.5849625007211563	3	1	0	0
29329	1520	key macrophage growth factor	[key macrophage growth factor]	1.5849625007211563	4	1	0	0
29330	1520	such as IL-5	[such as IL-5]	1.5849625007211563	3	1	0	0
29331	1520	NFATp 135 kda	[NFATp 135 kDa]	1.5849625007211563	3	1	0	0
29332	1520	tissue-specific promoter activity,	[tissue-specific promoter activity,]	1.5849625007211563	3	1	0	0
29333	1520	stage in this interaction	[stage in this interaction]	1.5849625007211563	4	1	0	0
29334	1520	most proximal site,	[most proximal site,]	1.5849625007211563	3	1	0	0
29335	1520	up-regulated RB expression	[up-regulated RB expression]	1.5849625007211563	3	1	0	0
29336	1520	PMA activation of ap-1	[PMA activation of AP-1]	1.5849625007211563	4	1	0	0
29337	1520	stimulation of human T	[stimulation of human T]	1.5849625007211563	4	1	0	0
29338	1520	response to phorbol 12-myristate	[response to phorbol 12-myristate]	1.5849625007211563	4	2	1	1
29339	1520	such as IL1B	[such as IL1B]	1.5849625007211563	3	1	0	0
29340	1520	rrna for all three	[mRNAs for all three]	1.5849625007211563	4	1	0	0
29341	1520	complex with the 70-	[complex with the 70-]	1.5849625007211563	4	1	0	0
29342	1520	pair of gata motif	[pair of GATA motifs]	1.5849625007211563	4	1	0	0
29343	1520	induction of m1-cat	[induction of M1-CAT]	1.5849625007211563	3	1	0	0
29344	1520	high affinity il-2 receptor	[high affinity IL-2 receptors]	1.5849625007211563	4	1	0	0
29345	1520	contain a deletion	[containing a deletion]	1.5849625007211563	3	2	2	2
29346	1520	jak2 /stat5 activation	[JAK2 /STAT5 activation]	1.5849625007211563	3	1	0	0
29347	1520	depletion of cd8+ cell	[Depletion of CD8+ cells]	1.5849625007211563	4	1	0	0
29348	1520	Ets family of regulator	[Ets family of regulators]	1.5849625007211563	4	1	0	0
29349	1520	major signal-mediating kinase	[major signal-mediating kinases]	1.5849625007211563	3	1	0	0
29350	1520	affect acute inflammation	[affecting acute inflammation]	1.5849625007211563	3	1	0	0
29351	1520	compensatory gr upregulation	[compensatory GR upregulation]	1.5849625007211563	3	1	0	0
29352	1520	same level of induction	[same level of induction]	1.5849625007211563	4	1	0	0
29353	1520	common human malignancy	[common human malignancies]	1.5849625007211563	3	1	0	0
29354	1520	time of maximal basophilia	[time of maximal basophilia]	1.5849625007211563	4	1	0	0
29355	1520	mechanism of LTR activation	[mechanism of LTR activation]	1.5849625007211563	4	1	0	0
29356	1520	antiapoptotic factor in thymocyte	[antiapoptotic factor in thymocytes]	1.5849625007211563	4	1	0	0
29357	1520	increase in thiol	[increase in thiol]	1.5849625007211563	3	1	0	0
29358	1520	transcriptional activity in cell	[transcriptional activity in cells]	1.5849625007211563	4	1	0	0
29359	1520	multidrug-resistant hl-60 cell	[multidrug-resistant HL-60 cells]	1.5849625007211563	3	2	1	1
29360	1520	potential "stress" buffer, related	[potential "stress" buffer, related]	1.5849625007211563	4	1	0	0
29361	1520	hiv-1 repeat transcription	[HIV-1 repeat transcription]	1.5849625007211563	3	2	2	2
29362	1520	inducible activation of transcription	[inducible activation of transcription]	1.5849625007211563	4	1	0	0
29363	1520	heat shock transcription factor	[heat shock transcription factor]	1.5849625007211563	4	2	2	2
29364	1520	five positive clone	[five positive clones]	1.5849625007211563	3	1	0	0
29365	1520	phosphorylation of elk-1	[phosphorylation of Elk-1]	1.5849625007211563	3	1	0	0
29366	1520	-driven chloramphenicol acetyltransferase CAT	[-driven chloramphenicol acetyltransferase CAT]	1.5849625007211563	4	1	0	0
29367	1520	knowledge of agent	[knowledge of agents]	1.5849625007211563	3	1	0	0
29368	1520	chemiluminescent (cl) response	[chemiluminescent (CL) response]	1.5849625007211563	3	1	0	0
29369	1520	additional, specific binding.	[additional, specific binding.]	1.5849625007211563	3	1	0	0
29370	1520	stimulation of killer cell	[stimulation of killer cells]	1.5849625007211563	4	1	0	0
29371	1520	different cellular systems,	[different cellular systems,]	1.5849625007211563	3	1	0	0
29372	1520	differential signal through CD3	[differential signaling through CD3]	1.5849625007211563	4	1	0	0
29373	1520	PLZF-RAR alpha fusion protein	[PLZF-RAR alpha fusion protein]	1.5849625007211563	4	1	0	0
29374	1520	human monocyte by type	[human monocytes by type]	1.5849625007211563	4	1	0	0
29375	1520	AM580 a stable derivative	[AM580 a stable derivative]	1.5849625007211563	4	2	2	2
29376	1520	up-regulation of galectin-3 expression	[up-regulation of galectin-3 expression]	1.5849625007211563	4	1	0	0
29377	1520	other anti-inflammatory drug	[other anti-inflammatory drugs]	1.5849625007211563	3	2	2	2
29378	1520	high viral load	[high viral load]	1.5849625007211563	3	1	0	0
29379	1520	subsequent occurrence of apoptosis	[subsequent occurrence of apoptosis]	1.5849625007211563	4	1	0	0
29380	1520	low receptor affinity	[low receptor affinity]	1.5849625007211563	3	2	1	1
29381	1520	use transcription analysis	[Using transcription analysis]	1.5849625007211563	3	1	0	0
29382	1520	human b-lymphocyte precursor cell	[human B-lymphocyte precursor cells]	1.5849625007211563	4	1	0	0
29383	1520	CaM kinase family KN-62	[CaM kinase family KN-62]	1.5849625007211563	4	1	0	0
29384	1520	idiopathic hypereosinophilic syndrome IHES	[idiopathic hypereosinophilic syndrome IHES]	1.5849625007211563	4	1	0	0
29385	1520	single inoculation intraperitoneally (i.p.)	[single inoculation intraperitoneally (i.p.)]	1.5849625007211563	4	1	0	0
29386	1520	human c-jun protein	[human c-Jun protein]	1.5849625007211563	3	1	0	0
29387	1520	two 3' c/ebp site	[two 3' C/EBP sites]	1.5849625007211563	4	1	0	0
29388	1520	T cell nuclear factor	[T cell nuclear factors]	1.5849625007211563	4	1	0	0
29389	1520	target of fk506	[target of FK506]	1.5849625007211563	3	1	0	0
29390	1520	long disease duration	[longer disease duration]	1.5849625007211563	3	1	0	0
29391	1520	Epstein-Barr virus nuclear protein	[Epstein-Barr virus nuclear protein]	1.5849625007211563	4	2	1	1
29392	1520	TNFalpha a proinflammatory cytokine	[TNFalpha a proinflammatory cytokine]	1.5849625007211563	4	1	0	0
29393	1520	daily phosphate supplementation	[daily phosphate supplementation]	1.5849625007211563	3	1	0	0
29394	1520	treatment with E2	[Treatment with E2]	1.5849625007211563	3	2	1	1
29395	1520	only minimal transactivation	[only minimal transactivation]	1.5849625007211563	3	1	0	0
29396	1520	human monocyte monokine synthesis	[human monocyte monokine synthesis]	1.5849625007211563	4	1	0	0
29397	1520	contain ltr with individual	[containing LTRs with individual]	1.5849625007211563	4	1	0	0
29398	1520	LTR in Jurkat cell	[LTR in Jurkat cells]	1.5849625007211563	4	1	0	0
29399	1520	glucocorticoid receptor (gr)	[glucocorticoid receptor (GR)]	1.5849625007211563	3	2	2	2
29400	1520	IRF-1 gas -binding complex	[IRF-1 GAS -binding complex]	1.5849625007211563	4	1	0	0
29401	1520	treatment with FP	[treatment with FP]	1.5849625007211563	3	1	0	0
29402	1520	t-cell receptor/CD3 complex	[T-cell receptor/CD3 complex]	1.5849625007211563	3	1	0	0
29403	1520	apoptotic mechanism in thymocyte	[apoptotic mechanisms in thymocytes]	1.5849625007211563	4	1	0	0
29404	1520	gene therapeutic agent	[gene therapeutic agents]	1.5849625007211563	3	1	0	0
29405	1520	cytokine effect on immunity	[Cytokine effects on immunity]	1.5849625007211563	4	1	0	0
29406	1520	lead to expression	[leading to expression]	1.5849625007211563	3	2	2	2
29407	1520	specific antigen recognition	[specific antigen recognition]	1.5849625007211563	3	1	0	0
29408	1520	lysp100 nuclear domain	[LYSP100 nuclear domains]	1.5849625007211563	3	1	0	0
29409	1520	ubiquitinylation of c-jun	[ubiquitinylation of c-Jun]	1.5849625007211563	3	1	0	0
29410	1520	nf-kappab inhibitor IkappaB	[NF-kappaB inhibitor IkappaB]	1.5849625007211563	3	1	0	0
29411	1520	other paraffin-embedded tissue	[other paraffin-embedded tissues]	1.5849625007211563	3	1	0	0
29412	1520	cd3/cd4+ intrafollicular T cell	[CD3/CD4+ intrafollicular T cells]	1.5849625007211563	4	1	0	0
29413	1520	arrangement of ets site	[arrangement of Ets sites]	1.5849625007211563	4	1	0	0
29414	1520	ym268 with insulin	[YM268 with insulin]	1.5849625007211563	3	1	0	0
29415	1520	biological response to ultra-violet	[biological responses to UV]	1.5849625007211563	4	1	0	0
29416	1520	PML alpha expression	[PML alpha expression]	1.5849625007211563	3	2	1	1
29417	1520	double-blind placebo-controlled crossover study	[double-blind placebo-controlled crossover study]	1.5849625007211563	4	1	0	0
29418	1520	helix-turn-helix transcription factor	[helix-turn-helix transcription factor]	1.5849625007211563	3	1	0	0
29419	1520	four BLS complementation group	[four BLS complementation groups]	1.5849625007211563	4	1	0	0
29420	1520	hypothalamus of arthritic rat	[hypothalamus of arthritic rats]	1.5849625007211563	4	1	0	0
29421	1520	enf)-kappa B/Rel nuclear activity	[(NF)-kappa B/Rel nuclear activity]	1.5849625007211563	4	1	0	0
29422	1520	translocation of NF-kappaB	[translocation of NF-kappaB]	1.5849625007211563	3	4	3	1
29423	1520	immediate-early trans-activator protein BZLF1	[immediate-early trans-activator protein BZLF1]	1.5849625007211563	4	1	0	0
29424	1520	contrast, NK activity	[contrast, NK activity]	1.5849625007211563	3	1	0	0
29425	1520	MTCP1 putative oncogene	[MTCP1 putative oncogenes]	1.5849625007211563	3	1	0	0
29426	1520	expression of this cytokine	[expression of these cytokines]	1.5849625007211563	4	1	0	0
29427	1520	two related gene	[two related genes]	1.5849625007211563	3	1	0	0
29428	1520	Mr 28000 protein	[Mr 28,000 protein]	1.5849625007211563	3	1	0	0
29429	1520	initiation of atherosclerosis	[initiation of atherosclerosis]	1.5849625007211563	3	1	0	0
29430	1520	Comparison of tumor specimen	[Comparison of tumor specimen]	1.5849625007211563	4	1	0	0
29431	1520	platelet factor 4	[platelet factor 4]	1.5849625007211563	3	1	0	0
29432	1520	kappa b cis-acting element	[kappa B cis-acting elements]	1.5849625007211563	4	1	0	0
29433	1520	x- chromosome inactivation pattern	[X- chromosome inactivation pattern]	1.5849625007211563	4	1	0	0
29434	1520	influence of a promoter	[influence of a promoter]	1.5849625007211563	4	1	0	0
29435	1520	class of t-cell oncogene	[class of T-cell oncogenes]	1.5849625007211563	4	1	0	0
29436	1520	CD40 antigen in patient	[CD40 antigen in patients]	1.5849625007211563	4	1	0	0
29437	1520	mitogen assay procedure	[mitogen assay procedure;]	1.5849625007211563	3	1	0	0
29438	1520	early inflammatory response	[early inflammatory response]	1.5849625007211563	3	2	1	1
29439	1520	non-sequence-specific C-terminal hmg box	[non-sequence-specific C-terminal HMG box]	1.5849625007211563	4	1	0	0
29440	1520	severe ner defect	[severe NER defect]	1.5849625007211563	3	1	0	0
29441	1520	kappab -binding activity	[kappaB -binding activity]	1.5849625007211563	3	2	1	1
29442	1520	treatment of monocyte	[treatment of monocytes]	1.5849625007211563	3	2	2	2
29443	1520	cellular programme drive proliferation	[cellular programme driving proliferation]	1.5849625007211563	4	1	0	0
29444	1520	cd27+ b cell	[CD27+ B cells]	1.5849625007211563	3	2	1	1
29445	1520	35 day of culture	[35 days of culture]	1.5849625007211563	4	1	0	0
29446	1520	Pit-1 gene in child	[Pit-1 gene in children]	1.5849625007211563	4	1	0	0
29447	1520	expression of wild-type shp1	[Expression of wild-type SHP1]	1.5849625007211563	4	1	0	0
29448	1520	EBV lytic cascade	[EBV lytic cascade]	1.5849625007211563	3	1	0	0
29449	1520	fk506 to fkbp	[FK506 to FKBP]	1.5849625007211563	3	1	0	0
29450	1520	support the hypothesis	[supporting the hypothesis]	1.5849625007211563	3	1	0	0
29451	1520	4% mean percent inhibition	[4% mean percent inhibition]	1.5849625007211563	4	1	0	0
29452	1520	13 c2h2 zinc finger	[13 C2H2 zinc fingers]	1.5849625007211563	4	1	0	0
29453	1520	(MHC) class ii	[(MHC) class II]	1.5849625007211563	3	2	2	2
29454	1520	defective retinoblastoma gene	[defective retinoblastoma gene]	1.5849625007211563	3	1	0	0
29455	1520	normal mande b lymphocyte	[normal mande B lymphocytes]	1.5849625007211563	4	1	0	0
29456	1520	cell receptor (tcr)/cd3	[cell receptor (TcR)/CD3]	1.5849625007211563	3	1	0	0
29457	1520	hl-60 to monocytic cell	[HL-60 to monocytic cells]	1.5849625007211563	4	1	0	0
29458	1520	hiv-protease express cell	[HIV-protease expressing cells]	1.5849625007211563	3	1	0	0
29459	1520	affect level of cu	[affecting levels of Cu]	1.5849625007211563	4	1	0	0
29460	1520	lymphocyte transcriptional activator sox-4	[lymphocyte transcriptional activator Sox-4]	1.5849625007211563	4	1	0	0
29461	1520	effect of DZA	[effect of DZA]	1.5849625007211563	3	2	2	2
29462	1520	effect of CyA	[effect of CyA]	1.5849625007211563	3	2	2	2
29463	1520	perception of quality support	[perception of quality support]	1.5849625007211563	4	1	0	0
29464	1520	regulate homotypic aggregation	[regulating homotypic aggregation]	1.5849625007211563	3	1	0	0
29465	1520	NF-kappa B/Rel nuclear activity	[NF-kappa B/Rel nuclear activity]	1.5849625007211563	4	1	0	0
29466	1520	common consensus motif WGATAR	[common consensus motif WGATAR]	1.5849625007211563	4	1	0	0
29467	1520	ubiquitous ap1 factor	[ubiquitous AP1 factors]	1.5849625007211563	3	1	0	0
29468	1520	EBV replicative gene product	[EBV replicative gene products]	1.5849625007211563	4	1	0	0
29469	1520	cytokine contain ap-1 site	[cytokines containing AP-1 sites]	1.5849625007211563	4	1	0	0
29470	1520	cell with surfactant lipid	[cells with surfactant lipids]	1.5849625007211563	4	1	0	0
29471	1520	induction of fasl expression	[induction of FasL expression]	1.5849625007211563	4	1	0	0
29472	1520	BZLF1 gene promoter zp	[BZLF1 gene promoter Zp]	1.5849625007211563	4	1	0	0
29473	1520	effect of Dex	[effect of Dex]	1.5849625007211563	3	2	1	1
29474	1520	translocation of nf-kappab	[translocation of NF-kappaB]	1.5849625007211563	3	2	1	1
29475	1520	coronary heart disease	[coronary heart disease]	1.5849625007211563	3	1	0	0
29476	1520	b cell mitogenesis	[B cell mitogenesis]	1.5849625007211563	3	1	0	0
29477	1520	regulation of cell function	[regulation of cell function]	1.5849625007211563	4	1	0	0
29478	1520	distinct growth signal pathway	[distinct growth signaling pathway]	1.5849625007211563	4	1	0	0
29479	1520	phorbol myristate acetate activation	[phorbol myristate acetate activation]	1.5849625007211563	4	1	0	0
29480	1520	level of intracellular ca2+	[level of intracellular Ca2+]	1.5849625007211563	4	1	0	0
29481	1520	sequence specific oligonucleotide type	[sequence specific oligonucleotide typing]	1.5849625007211563	4	1	0	0
29482	1520	vitro, thrombin-stimulated platelet	[vitro, thrombin-stimulated platelets]	1.5849625007211563	3	1	0	0
29483	1520	incidence of autoimmune disease	[incidence of autoimmune diseases]	1.5849625007211563	4	1	0	0
29484	1520	effect on Stat1	[effect on Stat1]	1.5849625007211563	3	1	0	0
29485	1520	additionally, ifn-gamma activity	[Additionally, IFN-gamma activity]	1.5849625007211563	3	1	0	0
29486	1520	addition, seek social support	[addition, seeking social support]	1.5849625007211563	4	1	0	0
29487	1520	downstream signalling event	[downstream signalling events]	1.5849625007211563	3	1	0	0
29488	1520	presence of c/ebp beta	[presence of C/EBP beta]	1.5849625007211563	4	1	0	0
29489	1520	surround of this cells,	[surrounding of these cells,]	1.5849625007211563	4	1	0	0
29490	1520	contrast to camp elevation	[contrast to cAMP elevation]	1.5849625007211563	4	1	0	0
29491	1520	about three time	[about three times]	1.5849625007211563	3	1	0	0
29492	1520	combine protein in vitro,	[combining proteins in vitro,]	1.5849625007211563	4	1	0	0
29493	1520	pg/ml; N supine <150)	[pg/ml; N supine <150)]	1.5849625007211563	4	1	0	0
29494	1520	complex with kinetic	[complex with kinetics]	1.5849625007211563	3	1	0	0
29495	1520	IL-4 promoter of Th1	[IL-4 promoter of Th1]	1.5849625007211563	4	1	0	0
29496	1520	N-terminal regulatory region	[N-terminal regulatory region]	1.5849625007211563	3	1	0	0
29497	1520	dimerization cofactor of hnf1	[dimerization cofactor of HNF1]	1.5849625007211563	4	1	0	0
29498	1520	pituitary- specific manner	[pituitary- specific manner]	1.5849625007211563	3	1	0	0
29499	1520	addition of TNFalpha	[addition of TNFalpha]	1.5849625007211563	3	1	0	0
29500	1520	growth factor stimulation	[growth factor stimulation]	1.5849625007211563	3	1	0	0
29501	1520	ability of GrpL	[ability of GrpL]	1.5849625007211563	3	1	0	0
29502	1520	initiation of mrna transcription	[initiation of mRNA transcription]	1.5849625007211563	4	1	0	0
29503	1520	regulation during myelopoiesis	[regulation during myelopoiesis]	1.5849625007211563	3	1	0	0
29504	1520	signal from TES1	[Signals from TES1]	1.5849625007211563	3	1	0	0
29505	1520	ebv-transformed b lymphocyte	[EBV-transformed B lymphocytes]	1.5849625007211563	3	1	0	0
29506	1520	physiological substrate for shp1	[physiological substrates for SHP1]	1.5849625007211563	4	1	0	0
29507	1520	study in hypercortisolemic patient	[study in hypercortisolemic patients]	1.5849625007211563	4	1	0	0
29508	1520	abnormal T lymphocyte development	[Abnormal T lymphocyte development]	1.5849625007211563	4	1	0	0
29509	1520	contrast, p21ras signal	[contrast, p21ras signals]	1.5849625007211563	3	1	0	0
29510	1520	group of soccer player	[group of soccer players]	1.5849625007211563	4	1	0	0
29511	1520	GM-CSF gene follow activation	[GM-CSF gene following activation]	1.5849625007211563	4	1	0	0
29512	1520	look for the expression	[looking for the expression]	1.5849625007211563	4	1	0	0
29513	1520	respect to cytochrome b558	[respect to cytochrome b558]	1.5849625007211563	4	1	0	0
29514	1520	calcineurin -dependent process	[calcineurin -dependent process]	1.5849625007211563	3	1	0	0
29515	1520	114 patient suffer	[114 patients suffering]	1.5849625007211563	3	1	0	0
29516	1520	murine pro-B line	[murine pro-B line]	1.5849625007211563	3	1	0	0
29517	1520	mrna expression of c-fo	[mRNA expression of c-fos]	1.5849625007211563	4	1	0	0
29518	1520	release of nitrogen intermediate	[release of nitrogen intermediates]	1.5849625007211563	4	1	0	0
29519	1520	3 patient with hie	[3 patients with HIE]	1.5849625007211563	4	1	0	0
29520	1520	high circulate cortisol	[high circulating cortisol]	1.5849625007211563	3	1	0	0
29521	1520	effect of CsA	[effects of CsA]	1.5849625007211563	3	2	2	2
29522	1520	even at ratio	[even at ratios]	1.5849625007211563	3	1	0	0
29523	1520	cell proliferation, differentiation,	[cell proliferation, differentiation,]	1.5849625007211563	3	1	0	0
29524	1520	nf-at core sequence tttcc	[NF-AT core sequence TTTCC]	1.5849625007211563	4	1	0	0
29525	1520	HSV-2 vp16 protein	[HSV-2 VP16 protein]	1.5849625007211563	3	1	0	0
29526	1520	adjacent activator site	[adjacent activator site]	1.5849625007211563	3	1	0	0
29527	1520	octamer in the context	[octamer in the context]	1.5849625007211563	4	1	0	0
29528	1520	IL-6 protein secretion	[IL-6 protein secretion]	1.5849625007211563	3	1	0	0
29529	1520	stimulation with mitogenic lectins	[stimulation with mitogenic lectins]	1.5849625007211563	4	1	0	0
29530	1520	NF-kappa b -dependent element.	[NF-kappa B -dependent element.]	1.5849625007211563	4	1	0	0
29531	1520	synthesis of Bcl-2	[synthesis of Bcl-2]	1.5849625007211563	3	1	0	0
29532	1520	cre-loxP recombination system	[cre-loxP recombination system]	1.5849625007211563	3	1	0	0
29533	1520	anti-apoptotic protein bcl-xL	[anti-apoptotic protein bcl-xL]	1.5849625007211563	3	1	0	0
29534	1520	nuclear factor-kappa b factor	[nuclear factor-kappa B factors]	1.5849625007211563	4	1	0	0
29535	1520	transcription initiation site)	[transcription initiation site)]	1.5849625007211563	3	1	0	0
29536	1520	effect of the cytokine	[effect of the cytokine]	1.5849625007211563	4	2	2	2
29537	1520	three linear loop peptide	[three linear loop peptides]	1.5849625007211563	4	1	0	0
29538	1520	antigen, naive cd4+ T	[antigen, naive CD4+ T]	1.5849625007211563	4	1	0	0
29539	1520	regulate cellular gene expression	[regulating cellular gene expression]	1.5849625007211563	4	1	0	0
29540	1520	hb9 transcript in pancrea	[HB9 transcripts in pancreas]	1.5849625007211563	4	1	0	0
29541	1520	response to 12-o-tetradecanoylphorbol-13-acetate	[response to 12-O-tetradecanoylphorbol-13-acetate]	1.5849625007211563	3	1	0	0
29542	1520	sex-determine gene sry	[sex-determining gene SRY]	1.5849625007211563	3	1	0	0
29543	1520	phop virulence regulon	[phoP virulence regulon]	1.5849625007211563	3	1	0	0
29544	1520	accumulation of IL-8 mrna	[accumulation of IL-8 mRNA]	1.5849625007211563	4	1	0	0
29545	1520	p210bcr-abl oncogene product	[p210bcr-abl oncogene product]	1.5849625007211563	3	1	0	0
29546	1520	regulation of haematopoiesis	[regulation of haematopoiesis]	1.5849625007211563	3	1	0	0
29547	1520	bcr signal transduction	[BCR signal transduction]	1.5849625007211563	3	1	0	0
29548	1520	distinct nfkb2 p100 rela(p65)	[distinct NFKB2 p100 RelA(p65)]	1.5849625007211563	4	1	0	0
29549	1520	promoter of the anhydrase	[promoter of the anhydrase]	1.5849625007211563	4	1	0	0
29550	1520	cortisol concentration in blood.	[cortisol concentrations in blood.]	1.5849625007211563	4	1	0	0
29551	1520	absence of a stimulus	[absence of a stimulus]	1.5849625007211563	4	1	0	0
29552	1520	antigen-presenting cell apc	[antigen-presenting cells APCs]	1.5849625007211563	3	1	0	0
29553	1520	il-6 in human pbmc	[IL-6 in human PBMCs]	1.5849625007211563	4	1	0	0
29554	1520	30 year (2/73)	[30 years (2/73)]	1.5849625007211563	3	1	0	0
29555	1520	human tonsillar mononuclear cell	[human tonsillar mononuclear cells]	1.5849625007211563	4	2	1	1
29556	1520	germline epsilon transcript,	[germline epsilon transcript,]	1.5849625007211563	3	2	1	1
29557	1520	5 ng/ml sodium selenite	[5 ng/ml sodium selenite]	1.5849625007211563	4	1	0	0
29558	1520	peak in mid-S phase	[peaks in mid-S phase]	1.5849625007211563	4	1	0	0
29559	1520	functional analog of vp16	[functional analog of VP16]	1.5849625007211563	4	1	0	0
29560	1520	7) cell hybridoma	[7) cell hybridomas]	1.5849625007211563	3	1	0	0
29561	1520	dissociation of export complex	[dissociation of export complexes]	1.5849625007211563	4	1	0	0
29562	1520	insight into role	[insight into roles]	1.5849625007211563	3	2	2	2
29563	1520	dimethyl sulfoxide pml-rar alpha	[dimethyl sulfoxide PML-RAR alpha]	1.5849625007211563	4	1	0	0
29564	1520	crosslinking of surface igm	[crosslinking of surface IgM]	1.5849625007211563	4	1	0	0
29565	1520	putative promoter area	[putative promoter area]	1.5849625007211563	3	1	0	0
29566	1520	underlying signal pathway	[underlying signaling pathways]	1.5849625007211563	3	1	0	0
29567	1520	human t-all cell line	[human T-ALL cell lines]	1.5849625007211563	4	1	0	0
29568	1520	bp to -52	[bp to -52]	1.5849625007211563	3	1	0	0
29569	1520	induction of IL-6 gene	[induction of IL-6 genes]	1.5849625007211563	4	1	0	0
29570	1520	cells, nf-kappab /rel protein	[cells, NF-kappaB /Rel proteins]	1.5849625007211563	4	1	0	0
29571	1520	alphaIIb subunit heavy chain	[alphaIIb subunit heavy chain]	1.5849625007211563	4	2	1	1
29572	1520	carry a t(3;14)(q27;q11) rearrangement	[carrying a t(3;14)(q27;q11) rearrangement]	1.5849625007211563	4	1	0	0
29573	1520	gel supershift assay	[Gel supershift assays]	1.5849625007211563	3	2	1	1
29574	1520	actin stress fiber	[actin stress fibers]	1.5849625007211563	3	1	0	0
29575	1520	reduce catalyst thioredoxin	[reducing catalyst thioredoxin]	1.5849625007211563	3	2	2	2
29576	1520	nf-kappa b p50/p65	[NF-kappa B p50/p65]	1.5849625007211563	3	2	2	2
29577	1520	increase the exposure time	[increasing the exposure time]	1.5849625007211563	4	1	0	0
29578	1520	mechanism of CTL cross-priming	[mechanism of CTL cross-priming]	1.5849625007211563	4	1	0	0
29579	1520	type ii MHC cid	[type II MHC CID]	1.5849625007211563	4	1	0	0
29580	1520	effect of gssg	[effects of GSSG]	1.5849625007211563	3	1	0	0
29581	1520	induction of ap-1	[induction of AP-1]	1.5849625007211563	3	1	0	0
29582	1520	plasma growth hormone concentration	[plasma growth hormone concentrations]	1.5849625007211563	4	1	0	0
29583	1520	euthyroid on atd	[euthyroid on ATD]	1.5849625007211563	3	1	0	0
29584	1520	binding site for nf-e2	[binding sites for NF-E2]	1.5849625007211563	4	1	0	0
29585	1520	CR of GR	[CR of GR]	1.5849625007211563	3	1	0	0
29586	1520	upregulation of certain cytokine	[upregulation of certain cytokines]	1.5849625007211563	4	1	0	0
29587	1520	complete lymphocyte suppression	[complete lymphocyte suppression]	1.5849625007211563	3	1	0	0
29588	1520	secondary tcr ligation	[secondary TCR ligation]	1.5849625007211563	3	1	0	0
29589	1520	substantial amount of p65	[substantial amounts of p65]	1.5849625007211563	4	1	0	0
29590	1520	hiv human macrophage	[HIV human macrophages]	1.5849625007211563	3	1	0	0
29591	1520	tgf-beta 1 growth inhibition	[TGF-beta 1 growth inhibition]	1.5849625007211563	4	2	2	2
29592	1520	b cell immortalization	[B cell immortalization]	1.5849625007211563	3	1	0	0
29593	1520	0.154 micromol/L; gg	[0.154 micromol/L; GG]	1.5849625007211563	3	1	0	0
29594	1520	nf-kappa b nuclear factor	[NF-kappa B nuclear factor]	1.5849625007211563	4	1	0	0
29595	1520	respectively in monocyte	[respectively in monocytes]	1.5849625007211563	3	1	0	0
29596	1520	cell growth transformation	[cell growth transformation]	1.5849625007211563	3	1	0	0
29597	1520	calcineurin a serine/threonine phosphatase	[calcineurin a serine/threonine phosphatase]	1.5849625007211563	4	2	1	1
29598	1520	il-2 production in response	[IL-2 production in response]	1.5849625007211563	4	1	0	0
29599	1520	several T cell line	[several T cell lines]	1.5849625007211563	4	1	0	0
29600	1520	patient with aml	[patients with AML]	1.5849625007211563	3	2	2	2
29601	1520	mouse tumorigenicity assay	[mouse tumorigenicity assay]	1.5849625007211563	3	1	0	0
29602	1520	result fusion gene	[resulting fusion genes]	1.5849625007211563	3	1	0	0
29603	1520	upstream promoter element	[upstream promoter element]	1.5849625007211563	3	2	1	1
29604	1520	region of calcineurin distinct	[region of calcineurin distinct]	1.5849625007211563	4	1	0	0
29605	1520	tumor necrosis factor-alpha TNF	[tumor necrosis factor-alpha TNF]	1.5849625007211563	4	2	1	1
29606	1520	kappa b binding complex	[kappa B binding complex]	1.5849625007211563	4	1	0	0
29607	1520	temporary, permissive condition	[temporary, permissive conditions]	1.5849625007211563	3	1	0	0
29608	1520	genomic sterol sequence	[genomic sterol sequence]	1.5849625007211563	3	1	0	0
29609	1520	cd3-t-cell receptor complex	[CD3-T-cell receptor complex]	1.5849625007211563	3	1	0	0
29610	1520	Daidzein glucuronide dg	[Daidzein glucuronides DG]	1.5849625007211563	3	1	0	0
29611	1520	functional role of ICSAT	[functional role of ICSAT]	1.5849625007211563	4	1	0	0
29612	1520	result of a absence	[result of an absence]	1.5849625007211563	4	1	0	0
29613	1520	neutrophil lineage by stimulation	[neutrophil lineage by stimulation]	1.5849625007211563	4	1	0	0
29614	1520	mediators: comparative study	[mediators: comparative study]	1.5849625007211563	3	1	0	0
29615	1520	study of population genetics	[studies of population genetics]	1.5849625007211563	4	1	0	0
29616	1520	two pkc inhibitor	[two PKC inhibitors]	1.5849625007211563	3	1	0	0
29617	1520	soluble protein Ag	[soluble protein Ag]	1.5849625007211563	3	1	0	0
29618	1520	result into the nucleus	[resulting into the nucleus]	1.5849625007211563	4	2	2	2
29619	1520	vector for the treatment	[vector for the treatment]	1.5849625007211563	4	1	0	0
29620	1520	human herpesvirus hhv-6	[Human herpesvirus HHV-6]	1.5849625007211563	3	4	3	1
29621	1520	transcription factor ntf	[transcription factor NTF]	1.5849625007211563	3	1	0	0
29622	1520	single e2f-dna binding complex	[single E2F-DNA binding complex]	1.5849625007211563	4	1	0	0
29623	1520	cyclosporin a-sensitive mechanism	[cyclosporin A-sensitive mechanism]	1.5849625007211563	3	1	0	0
29624	1520	expression of AhR mrna	[expression of AhR mRNA]	1.5849625007211563	4	1	0	0
29625	1520	rapid regression of fibrosarcomas	[rapid regression of fibrosarcomas]	1.5849625007211563	4	1	0	0
29626	1520	carry the tax sequence	[carrying the tax sequences]	1.5849625007211563	4	1	0	0
29627	1520	tar mutant construct	[TAR mutant constructs]	1.5849625007211563	3	1	0	0
29628	1520	GATA-1 autoregulatory enhancer	[GATA-1 autoregulatory enhancer]	1.5849625007211563	3	1	0	0
29629	1520	cell culminate in activation	[cells culminating in activation]	1.5849625007211563	4	1	0	0
29630	1520	glutathione-s-transferase (gst)-grb2 fusion protein	[Glutathione-S-transferase (GST)-Grb2 fusion proteins]	1.5849625007211563	4	1	0	0
29631	1520	new tissue-specific transcription factor	[new tissue-specific transcription factor]	1.5849625007211563	4	1	0	0
29632	1520	pituitary prl expression	[pituitary PRL expression]	1.5849625007211563	3	1	0	0
29633	1520	resistance to low-serum apoptosis	[resistance to low-serum apoptosis]	1.5849625007211563	4	1	0	0
29634	1520	inhibition of factor-kappa b	[inhibition of factor-kappa B]	1.5849625007211563	4	1	0	0
29635	1520	bacterial lipopolysaccharide macrophage	[bacterial lipopolysaccharide macrophages]	1.5849625007211563	3	1	0	0
29636	1520	myeloid- specific transcription factor	[myeloid- specific transcription factor]	1.5849625007211563	4	1	0	0
29637	1520	HTLV-1 cell line	[HTLV-1 cell line]	1.5849625007211563	3	1	0	0
29638	1520	CD95 APO-1/Fas ligand promoter	[CD95 APO-1/Fas ligand promoter]	1.5849625007211563	4	1	0	0
29639	1520	new homeobox gene HB24	[new homeobox gene HB24]	1.5849625007211563	4	1	0	0
29640	1520	core NFAT complex consist	[core NFAT complex consisting]	1.5849625007211563	4	1	0	0
29641	1520	cell to injury-induced apoptosis	[cells to injury-induced apoptosis]	1.5849625007211563	4	1	0	0
29642	1520	complex contain STAT3	[complexes containing STAT3]	1.5849625007211563	3	1	0	0
29643	1520	cell sorter analysis	[Cell sorter analysis]	1.5849625007211563	3	1	0	0
29644	1520	grow list of cytokine	[growing list of cytokines]	1.5849625007211563	4	1	0	0
29645	1520	PMA inducible function	[PMA inducible function]	1.5849625007211563	3	1	0	0
29646	1520	stimulation of viral production	[stimulation of viral production]	1.5849625007211563	4	1	0	0
29647	1520	contrast with the observation	[contrast with the observation]	1.5849625007211563	4	1	0	0
29648	1520	distal ccaat box	[distal CCAAT box]	1.5849625007211563	3	2	2	2
29649	1520	regulation of the cd19	[regulation of the CD19]	1.5849625007211563	4	1	0	0
29650	1520	additionally, by preincubation,	[additionally, by preincubation,]	1.5849625007211563	3	1	0	0
29651	1520	c-terminal amino acid	[C-terminal amino acids]	1.5849625007211563	3	2	2	2
29652	1520	other inflammatory gene	[other inflammatory genes]	1.5849625007211563	3	1	0	0
29653	1520	anti- CD30 antibody m44	[anti- CD30 antibodies M44]	1.5849625007211563	4	1	0	0
29654	1520	RESULTS: six maeca	[RESULTS: Six mAECA]	1.5849625007211563	3	1	0	0
29655	1520	progesterone receptor-specific antibody mPRI	[progesterone receptor-specific antibody mPRI]	1.5849625007211563	4	1	0	0
29656	1520	CD40-specific mAb g28-5	[CD40-specific mAb G28-5]	1.5849625007211563	3	1	0	0
29657	1520	two group of patient	[two groups of patients]	1.5849625007211563	4	2	2	2
29658	1520	heterologous cytoplasmic domain	[heterologous cytoplasmic domain]	1.5849625007211563	3	1	0	0
29659	1520	10 new epitope	[10 new epitopes]	1.5849625007211563	3	1	0	0
29660	1520	erythroid kruppel-like factor eklf	[erythroid Kruppel-like factor EKLF]	1.5849625007211563	4	1	0	0
29661	1520	completely silence a beta-promoter	[completely silencing a beta-promoter]	1.5849625007211563	4	1	0	0
29662	1520	lung of rat	[lungs of rats]	1.5849625007211563	3	1	0	0
29663	1520	pbl of healthy individual	[PBL of healthy individuals]	1.5849625007211563	4	1	0	0
29664	1520	experimental anemia in mouse	[experimental anemia in mice]	1.5849625007211563	4	1	0	0
29665	1520	degree of receptor down-regulation	[degree of receptor down-regulation]	1.5849625007211563	4	1	0	0
29666	1520	AIR-1 gene product	[AIR-1 gene product]	1.5849625007211563	3	1	0	0
29667	1520	infection with hiv-1	[infection with HIV-1]	1.5849625007211563	3	2	2	2
29668	1520	drug undecylprodigiosin UP	[drug undecylprodigiosin UP]	1.5849625007211563	3	1	0	0
29669	1520	heterodimeric nf-kappa b complex	[heterodimeric NF-kappa B complex]	1.5849625007211563	4	1	0	0
29670	1520	suggest different stat6 isoform	[suggesting different STAT6 isoforms]	1.5849625007211563	4	1	0	0
29671	1520	developmental stage specificities.	[developmental stage specificities.]	1.5849625007211563	3	1	0	0
29672	1520	FGF-1 rel/kappab binding protein	[FGF-1 Rel/kappaB binding proteins]	1.5849625007211563	4	1	0	0
29673	1520	macrophage in human atheroma	[Macrophages in human atheroma]	1.5849625007211563	4	1	0	0
29674	1520	83-kDa carboxyl-terminal stat3beta	[83-kDa carboxyl-terminal STAT3beta]	1.5849625007211563	3	1	0	0
29675	1520	jak2 tyrosine kinase	[Jak2 tyrosine kinase]	1.5849625007211563	3	1	0	0
29676	1520	furthermore, R24 treatment	[Furthermore, R24 treatment]	1.5849625007211563	3	1	0	0
29677	1520	Interestingly, co-immunoprecipitation analysis	[Interestingly, co-immunoprecipitation analysis]	1.5849625007211563	3	1	0	0
29678	1520	lymphocyte-specific protein lsp1	[lymphocyte-specific protein LSP1]	1.5849625007211563	3	2	2	2
29679	1520	antigen-responsive lymphoid cell	[antigen-responsive lymphoid cells]	1.5849625007211563	3	1	0	0
29680	1520	down-regulation of the receptor	[down-regulation of the receptor]	1.5849625007211563	4	2	2	2
29681	1520	generation of cytokine pleiotropy	[generation of cytokine pleiotropy]	1.5849625007211563	4	1	0	0
29682	1520	embryonic/fetal erythroid k562 cell	[embryonic/fetal erythroid K562 cells]	1.5849625007211563	4	1	0	0
29683	1520	rescue of b cell	[rescue of B cells]	1.5849625007211563	4	1	0	0
29684	1520	human mip-1 alpha gene	[human MIP-1 alpha gene]	1.5849625007211563	4	1	0	0
29685	1520	Ad5E1A -specific immunity	[Ad5E1A -specific immunity]	1.5849625007211563	3	1	0	0
29686	1520	remain TCRhigh population	[remaining TCRhigh population]	1.5849625007211563	3	1	0	0
29687	1520	endogenous prl gene	[endogenous PRL gene]	1.5849625007211563	3	1	0	0
29688	1520	production of protein(s)	[production of protein(s)]	1.5849625007211563	3	1	0	0
29689	1520	CD30 cytoplasmic domain	[CD30 cytoplasmic domain]	1.5849625007211563	3	1	0	0
29690	1520	role of ad5 infection	[role of Ad5 infection]	1.5849625007211563	4	1	0	0
29691	1520	severe toxicity secondary	[Severe toxicity secondary]	1.5849625007211563	3	2	2	2
29692	1520	formation of the HS	[formation of the HS]	1.5849625007211563	4	1	0	0
29693	1520	heterozygous mutation of Pax5	[heterozygous mutation of Pax5]	1.5849625007211563	4	1	0	0
29694	1520	NF-kappa B1 /rela heterodimer	[NF-kappa B1 /RelA heterodimer]	1.5849625007211563	4	1	0	0
29695	1520	binding site for ctf/cbp	[binding sites for CTF/CBP]	1.5849625007211563	4	1	0	0
29696	1520	GR precursor mrna	[GR precursor mRNA]	1.5849625007211563	3	1	0	0
29697	1520	response to this factor	[response to these factors]	1.5849625007211563	4	1	0	0
29698	1520	NF-kappaB transcriptional activity	[NF-kappaB transcriptional activity]	1.5849625007211563	3	2	2	2
29699	1520	cohort of node-positive patient	[cohort of node-positive patients]	1.5849625007211563	4	1	0	0
29700	1520	such as kidney	[such as kidney]	1.5849625007211563	3	1	0	0
29701	1520	such as c-Jun	[such as c-Jun]	1.5849625007211563	3	1	0	0
29702	1520	activation in T lymphocyte	[activation in T lymphocytes]	1.5849625007211563	4	1	0	0
29703	1520	range of 168	[range of 168]	1.5849625007211563	3	1	0	0
29704	1520	enzyme family protease inhibitor	[enzyme family protease inhibitors]	1.5849625007211563	4	2	2	2
29705	1520	platelet fibrinogen receptor	[platelet fibrinogen receptor]	1.5849625007211563	3	1	0	0
29706	1520	synchronous recognition of peptide	[Synchronous recognition of peptides]	1.5849625007211563	4	1	0	0
29707	1520	trans-activation of gene expression	[trans-activation of gene expression]	1.5849625007211563	4	1	0	0
29708	1520	phosphorylation of Rb	[phosphorylation of Rb]	1.5849625007211563	3	2	1	1
29709	1520	role of neutrophil	[role of neutrophils]	1.5849625007211563	3	1	0	0
29710	1520	use the degenerate primer	[using the degenerate primers]	1.5849625007211563	4	1	0	0
29711	1520	cytoskeleton of platelet aggregation	[cytoskeleton of platelet aggregation]	1.5849625007211563	4	1	0	0
29712	1520	tpa activation of PKC	[TPA activation of PKC]	1.5849625007211563	4	1	0	0
29713	1520	human b-cell-specific ciita	[human B-cell-specific CIITA]	1.5849625007211563	3	1	0	0
29714	1520	anti- CD28 abs	[anti- CD28 Abs]	1.5849625007211563	3	1	0	0
29715	1520	concentration of a beta	[concentrations of A beta]	1.5849625007211563	4	2	2	2
29716	1520	use standard serological technique	[using standard serological techniques]	1.5849625007211563	4	1	0	0
29717	1520	mechanism of the regulation	[mechanism of the regulation]	1.5849625007211563	4	1	0	0
29718	1520	trigger event lead	[triggering event leading]	1.5849625007211563	3	1	0	0
29719	1520	transformation of lymphocyte	[transformation of lymphocytes]	1.5849625007211563	3	2	2	2
29720	1520	loss of functional activity	[loss of functional activity]	1.5849625007211563	4	1	0	0
29721	1520	level of fosb mrna	[Levels of FOSB mRNA]	1.5849625007211563	4	1	0	0
29722	1520	subsequently cell adhesion	[subsequently cell adhesion]	1.5849625007211563	3	1	0	0
29723	1520	(40 mg bolus)	[(40 mg bolus)]	1.5849625007211563	3	1	0	0
29724	1520	very early differentiation	[very early differentiation]	1.5849625007211563	3	2	1	1
29725	1520	many lymphocyte-activating cytokine	[many lymphocyte-activating cytokines]	1.5849625007211563	3	1	0	0
29726	1520	ifn-gamma-activated sequence-binding complex	[IFN-gamma-activated sequence-binding complexes]	1.5849625007211563	3	2	1	1
29727	1520	androgen receptor (ar) gene	[androgen receptor (AR) gene]	1.5849625007211563	4	2	1	1
29728	1520	inhibition of IFN -mcp	[inhibition of IFN -MCP]	1.5849625007211563	4	2	1	1
29729	1520	3' polyA site	[3' polyA site]	1.5849625007211563	3	1	0	0
29730	1520	macrophage/monocyte type cell	[macrophage/monocyte type cells]	1.5849625007211563	3	1	0	0
29731	1520	T cell-dependent disease	[T cell-dependent diseases]	1.5849625007211563	3	1	0	0
29732	1520	rel protein c-rel	[Rel proteins c-Rel]	1.5849625007211563	3	1	0	0
29733	1520	IL-6/interferon-gamma response element	[IL-6/interferon-gamma response element]	1.5849625007211563	3	1	0	0
29734	1520	Here, Stuart Schreiber	[Here, Stuart Schreiber]	1.5849625007211563	3	1	0	0
29735	1520	m-csf signal transduction	[M-CSF signal transduction]	1.5849625007211563	3	1	0	0
29736	1520	c-jun gene product	[c-jun gene products]	1.5849625007211563	3	1	0	0
29737	1520	g1 phase expression	[G1 phase expression]	1.5849625007211563	3	1	0	0
29738	1520	level of glycophorin a	[levels of glycophorin A]	1.5849625007211563	4	1	0	0
29739	1520	such as Fos	[such as Fos]	1.5849625007211563	3	1	0	0
29740	1520	induction of ige synthesis	[induction of IgE synthesis]	1.5849625007211563	4	1	0	0
29741	1520	5'-untranslated leader region	[5'-untranslated leader region]	1.5849625007211563	3	2	2	2
29742	1520	Epstein-Barr virus (EBV) cycle	[Epstein-Barr virus (EBV) cycle]	1.5849625007211563	4	1	0	0
29743	1520	two additional cis-acting element	[two additional cis-acting elements]	1.5849625007211563	4	1	0	0
29744	1520	cd25 promoter induction	[CD25 promoter induction]	1.5849625007211563	3	1	0	0
29745	1520	additional TaqI restriction site	[additional TaqI restriction site]	1.5849625007211563	4	1	0	0
29746	1520	p21-activated protein kinase 1	[p21-activated protein kinase 1]	1.5849625007211563	4	1	0	0
29747	1520	activation of binding	[activation of binding]	1.5849625007211563	3	2	1	1
29748	1520	subset of hemopoietic cell	[subset of hemopoietic cells]	1.5849625007211563	4	1	0	0
29749	1520	Peculiarly, eccrine poroma	[Peculiarly, eccrine poromas]	1.5849625007211563	3	1	0	0
29750	1520	regulator of cell differentiation	[regulators of cell differentiation]	1.5849625007211563	4	1	0	0
29751	1520	zeta-globin promoter deletion construct	[zeta-globin promoter deletion constructs]	1.5849625007211563	4	1	0	0
29752	1520	UAS1 -140 to -87	[UAS1 -140 to -87]	1.5849625007211563	4	1	0	0
29753	1520	reciprocally mutant myc protein	[reciprocally mutant Myc protein]	1.5849625007211563	4	1	0	0
29754	1520	IL-2 binding analysis	[IL-2 binding analysis]	1.5849625007211563	3	1	0	0
29755	1520	promoter-bound multi-protein complex	[promoter-bound multi-protein complexes]	1.5849625007211563	3	1	0	0
29756	1520	proteolysis of this inhibitor.	[proteolysis of this inhibitor.]	1.5849625007211563	4	1	0	0
29757	1520	possibly via sh2 domain	[possibly via SH2 domain]	1.5849625007211563	4	1	0	0
29758	1520	U937 macrophage cell line	[U937 macrophage cell line]	1.5849625007211563	4	1	0	0
29759	1520	enhancement of NK activity	[enhancement of NK activity]	1.5849625007211563	4	1	0	0
29760	1520	216 amino acid	[216 amino acids]	1.5849625007211563	3	1	0	0
29761	1520	constitutive protein/dna interaction	[Constitutive protein/DNA interactions]	1.5849625007211563	3	3	2	1
29762	1520	development of t-all	[development of T-ALL]	1.5849625007211563	3	1	0	0
29763	1520	PU-box in B-cells.	[PU-box in B-cells.]	1.5849625007211563	3	1	0	0
29764	1520	BglII restriction site	[BglII restriction site]	1.5849625007211563	3	1	0	0
29765	1520	24 healthy woman	[24 healthy women]	1.5849625007211563	3	1	0	0
29766	1520	c-terminus of Oct-2	[C-terminus of Oct-2]	1.5849625007211563	3	1	0	0
29767	1520	NK cell population	[NK cell population]	1.5849625007211563	3	1	0	0
29768	1520	Ter 119 erythroid cell	[Ter 119 erythroid cells]	1.5849625007211563	4	2	2	2
29769	1520	dominant-negative activity RARalpha403	[dominant-negative activity RARalpha403]	1.5849625007211563	3	1	0	0
29770	1520	two novel site	[two novel sites]	1.5849625007211563	3	1	0	0
29771	1520	potent inducer of ap1	[potent inducer of AP1]	1.5849625007211563	4	1	0	0
29772	1520	recent gene target	[recent gene targeting]	1.5849625007211563	3	1	0	0
29773	1520	deletion of interdomain b	[Deletion of interdomain B]	1.5849625007211563	4	1	0	0
29774	1520	traditional Chinese medicine	[traditional Chinese medicine]	1.5849625007211563	3	1	0	0
29775	1520	factor in T lymphocyte	[factor in T lymphocytes]	1.5849625007211563	4	1	0	0
29776	1520	cloning of gene	[Cloning of genes]	1.5849625007211563	3	2	2	2
29777	1520	distinct dna-binding protein	[distinct DNA-binding proteins]	1.5849625007211563	3	2	2	2
29778	1520	distinct signal property	[Distinct signaling properties]	1.5849625007211563	3	1	0	0
29779	1520	vitamin d response element	[vitamin D response element]	1.5849625007211563	4	1	0	0
29780	1520	gene in blood cell	[gene in blood cells]	1.5849625007211563	4	1	0	0
29781	1520	unexpected expression of Spi-1	[Unexpected expression of Spi-1]	1.5849625007211563	4	1	0	0
29782	1520	plasmodium vivax erythrocyte-binding protein	[Plasmodium vivax erythrocyte-binding protein]	1.5849625007211563	4	1	0	0
29783	1520	acidic sphingomyelinase signal	[acidic sphingomyelinase signals]	1.5849625007211563	3	1	0	0
29784	1520	gr binding power	[GR binding power]	1.5849625007211563	3	1	0	0
29785	1520	plasma membrane of lymphocyte	[plasma membrane of lymphocytes]	1.5849625007211563	4	1	0	0
29786	1520	endogenous functional receptor.	[endogenous functional receptor.]	1.5849625007211563	3	1	0	0
29787	1520	certain transcription factor	[certain transcription factors]	1.5849625007211563	3	1	0	0
29788	1520	possibly one member capable	[possibly one members capable]	1.5849625007211563	4	1	0	0
29789	1520	interferon-gamma site gas	[interferon-gamma site GAS]	1.5849625007211563	3	1	0	0
29790	1520	avian defective retroviruse	[avian defective retroviruses]	1.5849625007211563	3	1	0	0
29791	1520	oxidative stress conditions,	[oxidative stress conditions,]	1.5849625007211563	3	1	0	0
29792	1520	group 1 patient	[group 1 patients]	1.5849625007211563	3	1	0	0
29793	1520	48 hours, level	[48 hours, levels]	1.5849625007211563	3	1	0	0
29794	1520	effect of estrogenic compound	[effect of estrogenic compounds]	1.5849625007211563	4	1	0	0
29795	1520	early transcriptional response	[early transcriptional response]	1.5849625007211563	3	1	0	0
29796	1520	activity of the core	[activity of the core]	1.5849625007211563	4	1	0	0
29797	1520	sample of a set	[samples of a set]	1.5849625007211563	4	1	0	0
29798	1520	EBV genome carry status.	[EBV genome carrying status.]	1.5849625007211563	4	1	0	0
29799	1520	multiple response region,	[multiple response region,]	1.5849625007211563	3	1	0	0
29800	1520	monocytic cell line mm6	[monocytic cell line MM6]	1.5849625007211563	4	1	0	0
29801	1520	unidentified Ets family protein	[unidentified Ets family protein]	1.5849625007211563	4	1	0	0
29802	1520	response to gamma interferon	[response to gamma interferon]	1.5849625007211563	4	2	1	1
29803	1520	inhibitory effect of cya	[inhibitory effects of CyA]	1.5849625007211563	4	1	0	0
29804	1520	cis-acting regulatory motif	[cis-acting regulatory motifs]	1.5849625007211563	3	1	0	0
29805	1520	hematopoietic transcription factor GATA-1	[hematopoietic transcription factors GATA-1]	1.5849625007211563	4	1	0	0
29806	1520	variety of expression level	[variety of expression levels]	1.5849625007211563	4	1	0	0
29807	1520	cell of bcl-2	[cells of bcl-2]	1.5849625007211563	3	1	0	0
29808	1520	regulatory element of hiv-1	[regulatory element of HIV-1]	1.5849625007211563	4	1	0	0
29809	1520	nf-kappab activation by ASA	[NF-kappaB activation by ASA]	1.5849625007211563	4	1	0	0
29810	1520	IL-3 promoter reporter construct	[IL-3 promoter reporter construct]	1.5849625007211563	4	1	0	0
29811	1520	protein phosphatase, calcineurin	[protein phosphatase, calcineurin]	1.5849625007211563	3	1	0	0
29812	1520	two nuclear protein	[two nuclear proteins]	1.5849625007211563	3	2	1	1
29813	1520	perpetuation of the response	[perpetuation of the response]	1.5849625007211563	4	1	0	0
29814	1520	3.7 kilobasis upstream	[3.7 kilobases upstream]	1.5849625007211563	3	1	0	0
29815	1520	prior to conservative treatment	[prior to conservative treatment]	1.5849625007211563	4	1	0	0
29816	1520	two consensus gata-binding site	[two consensus GATA-binding sites]	1.5849625007211563	4	1	0	0
29817	1520	such as Bcl-2	[such as Bcl-2]	1.5849625007211563	3	1	0	0
29818	1520	ingredient of curry spice	[ingredient of curry spice]	1.5849625007211563	4	1	0	0
29819	1520	Phase-2 neutrophil adhesion	[Phase-2 neutrophil adhesion]	1.5849625007211563	3	1	0	0
29820	1520	beta zero- thalassemia patient	[beta zero- thalassemia patients]	1.5849625007211563	4	2	1	1
29821	1520	induction of ige switch	[induction of IgE switching]	1.5849625007211563	4	1	0	0
29822	1520	action of MC903	[action of MC903]	1.5849625007211563	3	1	0	0
29823	1520	node-positive patient with outcome.	[node-positive patients with outcome.]	1.5849625007211563	4	1	0	0
29824	1520	factor, nf-kappa b	[factor, NF-kappa B]	1.5849625007211563	3	1	0	0
29825	1520	reduction in tnf-alpha release	[reduction in TNF-alpha release]	1.5849625007211563	4	1	0	0
29826	1520	rar/rxr heterodimer ie, inhibition	[RAR/RXR heterodimer ie, inhibition]	1.5849625007211563	4	1	0	0
29827	1520	two tyrosine y113	[Two tyrosines Y113]	1.5849625007211563	3	1	0	0
29828	1520	question concern the nature	[questions concerning the nature]	1.5849625007211563	4	1	0	0
29829	1520	monocytic cell lineage	[monocytic cell lineage]	1.5849625007211563	3	1	0	0
29830	1520	octamer transcription factor Oct-1	[octamer transcription factors Oct-1]	1.5849625007211563	4	1	0	0
29831	1520	difference between PMA	[difference between PMA]	1.5849625007211563	3	1	0	0
29832	1520	localization of a group	[localization of a group]	1.5849625007211563	4	1	0	0
29833	1520	secretion of ILs	[Secretion of ILs]	1.5849625007211563	3	1	0	0
29834	1520	functional interaction with lymphocyte	[functional interaction with lymphocytes]	1.5849625007211563	4	1	0	0
29835	1520	chromosome translocation t(14;14)(q11;q32.1)	[chromosome translocations t(14;14)(q11;q32.1)]	1.5849625007211563	3	1	0	0
29836	1520	hepatitis b virus genome	[hepatitis B virus genome]	1.5849625007211563	4	2	1	1
29837	1520	hemopoietic-specific zinc finger protein	[hemopoietic-specific zinc finger proteins]	1.5849625007211563	4	1	0	0
29838	1520	rise in intracellular calcium	[rise in intracellular calcium]	1.5849625007211563	4	1	0	0
29839	1520	hiv u937 cell	[HIV U937 cells]	1.5849625007211563	3	1	0	0
29840	1520	vivo, cd8+ T cell	[vivo, CD8+ T cells]	1.5849625007211563	4	1	0	0
29841	1520	thymocyte-specific gene expression	[thymocyte-specific gene expression]	1.5849625007211563	3	1	0	0
29842	1520	egta ca2+ chelator	[EGTA Ca2+ chelator]	1.5849625007211563	3	1	0	0
29843	1520	immature myelomonocytic cell	[immature myelomonocytic cells]	1.5849625007211563	3	1	0	0
29844	1520	cell line lack capability	[cell lines lacking capability]	1.5849625007211563	4	1	0	0
29845	1520	expression of cd11b/cd18	[expression of CD11b/CD18]	1.5849625007211563	3	1	0	0
29846	1520	internal repression domain	[internal repression domain]	1.5849625007211563	3	1	0	0
29847	1520	ligand-induced mpl homodimerization	[ligand-induced Mpl homodimerization]	1.5849625007211563	3	1	0	0
29848	1520	use a antibody specific	[using an antibody specific]	1.5849625007211563	4	1	0	0
29849	1520	fc gamma RI-	[Fc gamma RI-]	1.5849625007211563	3	1	0	0
29850	1520	early hematopoietic progenitor cell	[early hematopoietic progenitor cells]	1.5849625007211563	4	2	2	2
29851	1520	role in cell-cell adhesion	[roles in cell-cell adhesion]	1.5849625007211563	4	1	0	0
29852	1520	ebv-positive gastric carcinoma	[EBV-positive gastric carcinoma]	1.5849625007211563	3	1	0	0
29853	1520	major histocompatibility class ii	[major histocompatibility class II]	1.5849625007211563	4	2	2	2
29854	1520	pu.1 C.J.Hetherington, H.-M.Chen,	[PU.1 C.J.Hetherington, H.-M.Chen,]	1.5849625007211563	3	1	0	0
29855	1520	Intercellular adhesion molecule icam-1	[Intercellular adhesion molecule ICAM-1]	1.5849625007211563	4	1	0	0
29856	1520	effect of steel factor	[effects of Steel factor]	1.5849625007211563	4	1	0	0
29857	1520	fc gamma RII	[Fc gamma RII]	1.5849625007211563	3	1	0	0
29858	1520	phosphorylation of multiple protein	[phosphorylation of multiple proteins]	1.5849625007211563	4	1	0	0
29859	1520	effect of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane ym-268	[effects of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane YM-268]	1.5849625007211563	4	1	0	0
29860	1520	knowledge of monocyte differentiation	[knowledge of monocyte differentiation]	1.5849625007211563	4	1	0	0
29861	1520	development of pharmaceutical product	[development of pharmaceutical products]	1.5849625007211563	4	1	0	0
29862	1520	function as 'master regulator	[functioning as 'master regulators]	1.5849625007211563	4	1	0	0
29863	1520	mature myeloid cell	[mature myeloid cells]	1.5849625007211563	3	2	1	1
29864	1520	change in cell proliferation.	[changes in cell proliferation.]	1.5849625007211563	4	1	0	0
29865	1520	level below detection	[levels below detection]	1.5849625007211563	3	1	0	0
29866	1520	DNA-PK(CS) mrna level	[DNA-PK(CS) mRNA levels]	1.5849625007211563	3	1	0	0
29867	1520	change in receptor functionality	[change in receptor functionality]	1.5849625007211563	4	1	0	0
29868	1520	coincident with the expression	[coincident with the expression]	1.5849625007211563	4	1	0	0
29869	1520	interleukin 2 receptor alpha-chain	[interleukin 2 receptor alpha-chain]	1.5849625007211563	4	2	1	1
29870	1520	active, exogenous virus	[active, exogenous virus]	1.5849625007211563	3	1	0	0
29871	1520	peak (0:00) value (8:00)	[peak (0:00) values (8:00)]	1.5849625007211563	4	1	0	0
29872	1520	little protein tyrosine phosphorylation	[little protein tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
29873	1520	third intron of TNF-alpha	[third intron of TNF-alpha]	1.5849625007211563	4	1	0	0
29874	1520	monocyte chemotactic protein-1 mcp-1	[monocyte chemotactic protein-1 MCP-1]	1.5849625007211563	4	2	1	1
29875	1520	induction of qr activity	[induction of QR activity]	1.5849625007211563	4	1	0	0
29876	1520	phosphorylation of jak2	[phosphorylation of JAK2]	1.5849625007211563	3	1	0	0
29877	1520	role of Rho	[role of Rho]	1.5849625007211563	3	1	0	0
29878	1520	interleukin-2 IL-2 production	[interleukin-2 IL-2 production]	1.5849625007211563	3	1	0	0
29879	1520	mortality of 60	[mortality of 60]	1.5849625007211563	3	1	0	0
29880	1520	selective negative regulator	[selective negative regulator]	1.5849625007211563	3	1	0	0
29881	1520	low salt condition	[low salt conditions]	1.5849625007211563	3	1	0	0
29882	1520	progesterone receptor -bearing cell	[progesterone receptor -bearing cells]	1.5849625007211563	4	1	0	0
29883	1520	C/EBP alpha expression vector	[C/EBP alpha expression vector]	1.5849625007211563	4	1	0	0
29884	1520	definitive hematopoietic progenitor	[definitive hematopoietic progenitors]	1.5849625007211563	3	1	0	0
29885	1520	NF- kappab site	[NF- kappaB site]	1.5849625007211563	3	1	0	0
29886	1520	individual nuclear factor	[individual nuclear factor]	1.5849625007211563	3	1	0	0
29887	1520	immune response regulation	[immune response regulation]	1.5849625007211563	3	1	0	0
29888	1520	EBNA-2 -positive cell	[EBNA-2 -positive cells]	1.5849625007211563	3	1	0	0
29889	1520	organogenesis of the spleen	[organogenesis of the spleens]	1.5849625007211563	4	1	0	0
29890	1520	interaction p38 map kinase	[interaction p38 MAP kinase]	1.5849625007211563	4	1	0	0
29891	1520	prl-inducible beta-casein expression	[PRL-inducible beta-casein expression]	1.5849625007211563	3	1	0	0
29892	1520	regulation of function	[regulation of function]	1.5849625007211563	3	2	2	2
29893	1520	hormone-dependent activation of tax	[hormone-dependent activation of Tax]	1.5849625007211563	4	1	0	0
29894	1520	possibly other mononuclear cell	[possibly other mononuclear cells]	1.5849625007211563	4	1	0	0
29895	1520	protein kinase B PKB	[Protein kinase B PKB]	1.5849625007211563	4	1	0	0
29896	1520	induction of ap1	[induction of AP1]	1.5849625007211563	3	2	1	1
29897	1520	such as proliferation	[such as proliferation]	1.5849625007211563	3	1	0	0
29898	1520	absence of phosphorylation	[absence of phosphorylation]	1.5849625007211563	3	1	0	0
29899	1520	dysfunction in the regulation	[dysfunction in the regulation]	1.5849625007211563	4	1	0	0
29900	1520	Specific rrna for c-fo	[Specific mRNAs for c-fos]	1.5849625007211563	4	1	0	0
29901	1520	patient with chronic bronchiti	[patients with chronic bronchitis]	1.5849625007211563	4	1	0	0
29902	1520	basic-leucine zipper domain	[basic-leucine zipper domain]	1.5849625007211563	3	1	0	0
29903	1520	cytosol of SML cell	[cytosols of SML cells]	1.5849625007211563	4	1	0	0
29904	1520	induction of any	[induction of any]	1.5849625007211563	3	1	0	0
29905	1520	specifically due to Tat	[specifically due to Tat]	1.5849625007211563	4	1	0	0
29906	1520	effect of pervanadate	[effect of pervanadate]	1.5849625007211563	3	1	0	0
29907	1520	role regulate fas death	[role regulating Fas death]	1.5849625007211563	4	1	0	0
29908	1520	transcriptional interference from cp	[transcriptional interference from Cp]	1.5849625007211563	4	1	0	0
29909	1520	typical junb mrna	[typical junB mRNA]	1.5849625007211563	3	1	0	0
29910	1520	class II-deficient congenital immunodeficiency	[class II-deficient congenital immunodeficiency]	1.5849625007211563	4	1	0	0
29911	1520	stress responsive hsp70b promoter	[stress responsive HSP70B promoter]	1.5849625007211563	4	1	0	0
29912	1520	reverse (rt) assay	[reverse (RT) assay]	1.5849625007211563	3	1	0	0
29913	1520	additional protein-protein interaction	[additional protein-protein interactions]	1.5849625007211563	3	1	0	0
29914	1520	lipopolysaccharide lps induction	[lipopolysaccharide LPS induction]	1.5849625007211563	3	2	2	2
29915	1520	CTL cross-priming in vivo	[CTL cross-priming in vivo]	1.5849625007211563	4	1	0	0
29916	1520	activate protein-1 activation	[activating protein-1 activation]	1.5849625007211563	3	1	0	0
29917	1520	microsomal antibody level	[microsomal antibody levels]	1.5849625007211563	3	1	0	0
29918	1520	lipid-associated membrane protein LAMPf	[lipid-associated membrane proteins LAMPf]	1.5849625007211563	4	1	0	0
29919	1520	only in CLL	[only in CLL]	1.5849625007211563	3	1	0	0
29920	1520	suppress promoter activity	[suppressing promoter activity]	1.5849625007211563	3	1	0	0
29921	1520	therefore of interest	[therefore of interest]	1.5849625007211563	3	1	0	0
29922	1520	mutant form of e1a	[mutant forms of E1A]	1.5849625007211563	4	1	0	0
29923	1520	cd36 gene in cell	[CD36 gene in cells]	1.5849625007211563	4	1	0	0
29924	1520	inhibit the activation	[inhibiting the activation]	1.5849625007211563	3	2	2	2
29925	1520	role of EKLF	[role of EKLF]	1.5849625007211563	3	1	0	0
29926	1520	HVS stp-c488 p10-->r mutant	[HVS STP-C488 P10-->R mutant]	1.5849625007211563	4	1	0	0
29927	1520	pretreatment with different compound	[pretreatment with different compounds]	1.5849625007211563	4	1	0	0
29928	1520	il-1alpha promoter activity	[IL-1alpha promoter activity]	1.5849625007211563	3	1	0	0
29929	1520	LYSP100 nuclear domain land	[LYSP100 nuclear domains LANDs]	1.5849625007211563	4	1	0	0
29930	1520	Ets protein family	[Ets protein family]	1.5849625007211563	3	1	0	0
29931	1520	normal bind affinity	[normal binding affinity]	1.5849625007211563	3	1	0	0
29932	1520	binding of a component	[binding of a component]	1.5849625007211563	4	1	0	0
29933	1520	two immediate-early viral transactivator	[two immediate-early viral transactivators]	1.5849625007211563	4	1	0	0
29934	1520	NFATx1 DNA binding activity	[NFATx1 DNA binding activity]	1.5849625007211563	4	1	0	0
29935	1520	mechanism of cellular senescence	[mechanisms of cellular senescence]	1.5849625007211563	4	1	0	0
29936	1520	NF-kappa b signal	[NF-kappa B signal]	1.5849625007211563	3	1	0	0
29937	1520	few 47.10 cell (3-5%)	[few 47.10 cells (3-5%)]	1.5849625007211563	4	1	0	0
29938	1520	(gc) b cell	[(GC) B cells]	1.5849625007211563	3	1	0	0
29939	1520	IRF-1 gamma site gas	[IRF-1 gamma site GAS]	1.5849625007211563	4	1	0	0
29940	1520	activation of il-4 signal	[activation of IL-4 signaling]	1.5849625007211563	4	1	0	0
29941	1520	contact with resistant parental	[contact with resistant parental]	1.5849625007211563	4	1	0	0
29942	1520	primary erythroblast transformation	[primary erythroblast transformation]	1.5849625007211563	3	1	0	0
29943	1520	central tumor suppressor gene	[central tumor suppressor gene]	1.5849625007211563	4	1	0	0
29944	1520	ubiquitous factor Oct-1	[ubiquitous factor Oct-1]	1.5849625007211563	3	1	0	0
29945	1520	TIMP-1 suppression of pcd	[TIMP-1 suppression of PCD]	1.5849625007211563	4	1	0	0
29946	1520	varicella-zoster virus (vzv) protein	[varicella-zoster virus (VZV) proteins]	1.5849625007211563	4	1	0	0
29947	1520	human dendritic cell	[human dendritic cells]	1.5849625007211563	3	2	2	2
29948	1520	defect in viral replication	[defect in viral replication]	1.5849625007211563	4	1	0	0
29949	1520	wild-type fy*b gata	[wild-type FY*B GATA]	1.5849625007211563	3	1	0	0
29950	1520	several T cell-specific gene	[several T cell-specific genes]	1.5849625007211563	4	1	0	0
29951	1520	surface expression of e-selectin	[surface expression of E-selectin]	1.5849625007211563	4	1	0	0
29952	1520	shp2 to SIT	[SHP2 to SIT]	1.5849625007211563	3	1	0	0
29953	1520	ultraviolet absorbance maxima shift	[ultraviolet absorbance maxima shifts]	1.5849625007211563	4	1	0	0
29954	1520	component of IFNalpha-	[component of IFNalpha-]	1.5849625007211563	3	1	0	0
29955	1520	mechanism of tpa responsiveness	[mechanism of TPA responsiveness]	1.5849625007211563	4	1	0	0
29956	1520	capacity for differentiation	[capacity for differentiation]	1.5849625007211563	3	1	0	0
29957	1520	cascade of gene expression	[cascade of gene expression]	1.5849625007211563	4	1	0	0
29958	1520	pbmc of tuberculous patient	[PBMC of tuberculous patients]	1.5849625007211563	4	1	0	0
29959	1520	develop breast cancer	[developing breast cancer]	1.5849625007211563	3	1	0	0
29960	1520	induction of Ie gene	[induction of IE genes]	1.5849625007211563	4	1	0	0
29961	1520	combination of analog	[combinations of analogs]	1.5849625007211563	3	1	0	0
29962	1520	cortisol alpha-hydroxyprogesterone response	[cortisol alpha-hydroxyprogesterone response]	1.5849625007211563	3	1	0	0
29963	1520	normal number circulate neutrophil	[normal numbers circulating neutrophils]	1.5849625007211563	4	1	0	0
29964	1520	intrinsic tyrosine kinase activity,	[intrinsic tyrosine kinase activity,]	1.5849625007211563	4	1	0	0
29965	1520	ikappab kinase signalsome activation	[IkappaB kinase signalsome activation]	1.5849625007211563	4	2	2	2
29966	1520	nuclear ap-1 /oap	[nuclear AP-1 /OAP]	1.5849625007211563	3	1	0	0
29967	1520	vasculopathy in Takayasu arteritis	[vasculopathy in Takayasu arteritis]	1.5849625007211563	4	1	0	0
29968	1520	neutrophil stimulation with GM-CSF	[neutrophil stimulation with GM-CSF]	1.5849625007211563	4	1	0	0
29969	1520	platelet activate factor paf	[platelet activating factor PAF]	1.5849625007211563	4	1	0	0
29970	1520	chloramphenicol acetyl transferase reporter	[chloramphenicol acetyl transferase reporter]	1.5849625007211563	4	1	0	0
29971	1520	mechanism in cell	[mechanism in cells]	1.5849625007211563	3	2	2	2
29972	1520	granulocyte-colony-stimulating factor g-csf	[granulocyte-colony-stimulating factor G-CSF]	1.5849625007211563	3	1	0	0
29973	1520	stable complex with sos1	[stable complex with SOS1]	1.5849625007211563	4	1	0	0
29974	1520	apoptosis of hematopoietic cell	[apoptosis of hematopoietic cells]	1.5849625007211563	4	1	0	0
29975	1520	ICAM-I promoter by TaxI	[ICAM-I promoter by TaxI]	1.5849625007211563	4	1	0	0
29976	1520	t-cell regulatory cytokine	[T-cell regulatory cytokine]	1.5849625007211563	3	1	0	0
29977	1520	ifn-gamma receptor alpha-chain	[IFN-gamma receptor alpha-chain]	1.5849625007211563	3	1	0	0
29978	1520	means of hplc	[means of HPLC]	1.5849625007211563	3	1	0	0
29979	1520	induction of this genes.	[induction of these genes.]	1.5849625007211563	4	1	0	0
29980	1520	transcription factor Nuclear factor	[transcription factor Nuclear Factor]	1.5849625007211563	4	1	0	0
29981	1520	Gzero/G1 cell cycle phase	[Gzero/G1 cell cycle phase]	1.5849625007211563	4	1	0	0
29982	1520	understanding of this protein,	[understanding of this protein,]	1.5849625007211563	4	1	0	0
29983	1520	Wingless/Wnt signal transduction pathway	[Wingless/Wnt signal transduction pathway]	1.5849625007211563	4	1	0	0
29984	1520	monocytic cell line hER	[monocytic cell line hER]	1.5849625007211563	4	1	0	0
29985	1520	TCRgamma delta T cell	[TCRgamma delta T cells]	1.5849625007211563	4	1	0	0
29986	1520	annular structure characteristic	[annular structures characteristic]	1.5849625007211563	3	1	0	0
29987	1520	IM-9 cell line	[IM-9 cell line]	1.5849625007211563	3	1	0	0
29988	1520	reduction in proliferation	[reduction in proliferation]	1.5849625007211563	3	2	1	1
29989	1520	tgf beta 2	[TGF beta 2]	1.5849625007211563	3	1	0	0
29990	1520	SKW 6.4 cell	[SKW 6.4 cells]	1.5849625007211563	3	1	0	0
29991	1520	human T virus (htlv)-i	[human T virus (HTLV)-I]	1.5849625007211563	4	1	0	0
29992	1520	human interleukin 4 gene	[human interleukin 4 gene]	1.5849625007211563	4	1	0	0
29993	1520	B cell line	[B cell lines]	1.5849625007211563	3	1	0	0
29994	1520	'normal' b lymphocyte	['normal' B lymphocytes]	1.5849625007211563	3	1	0	0
29995	1520	frequency of cell	[frequency of cells]	1.5849625007211563	3	1	0	0
29996	1520	tnf-alpha mrna accumulation	[TNF-alpha mRNA accumulation]	1.5849625007211563	3	1	0	0
29997	1520	normal control (p	[normal control (P]	1.5849625007211563	3	2	1	1
29998	1520	glucocorticoid in hiv infection.	[glucocorticoids in HIV infection.]	1.5849625007211563	4	1	0	0
29999	1520	tar -independent pathway	[TAR -independent pathway]	1.5849625007211563	3	1	0	0
30000	1520	interestingly, that early events,	[Interestingly, those early events,]	1.5849625007211563	4	1	0	0
30001	1520	five different species	[five different species]	1.5849625007211563	3	1	0	0
30002	1520	unknown nuclear protein	[unknown nuclear proteins]	1.5849625007211563	3	1	0	0
30003	1520	monocyte/macrophage cell line	[monocyte/macrophage cell line]	1.5849625007211563	3	1	0	0
30004	1520	micromolar concentration of h2o2	[micromolar concentrations of H2O2]	1.5849625007211563	4	1	0	0
30005	1520	murine mast cell	[murine mast cells]	1.5849625007211563	3	1	0	0
30006	1520	ap-1 binding to DNA	[AP-1 binding to DNA]	1.5849625007211563	4	1	0	0
30007	1520	mononuclear phagocyte in vitro.	[mononuclear phagocytes in vitro.]	1.5849625007211563	4	1	0	0
30008	1520	CD34+ myelomonocytic cell line	[CD34+ myelomonocytic cell line]	1.5849625007211563	4	1	0	0
30009	1520	90-kDa heat shock protein	[90-kDa heat shock protein]	1.5849625007211563	4	1	0	0
30010	1520	solution hybridization assay	[solution hybridization assay]	1.5849625007211563	3	2	1	1
30011	1520	nfat kinase by PDTC	[NFAT kinase by PDTC]	1.5849625007211563	4	1	0	0
30012	1520	Ca(2+)-dependent transcriptional event	[Ca(2+)-dependent transcriptional events]	1.5849625007211563	3	1	0	0
30013	1520	cell cycle-dependent initiation	[Cell cycle-dependent initiation]	1.5849625007211563	3	1	0	0
30014	1520	cd8+ T cell cd8+cd18bright	[CD8+ T cells CD8+CD18bright]	1.5849625007211563	4	1	0	0
30015	1520	response to mitogenic activation	[response to mitogenic activation]	1.5849625007211563	4	1	0	0
30016	1520	tonsillar mononuclear cell	[tonsillar mononuclear cells]	1.5849625007211563	3	2	2	2
30017	1520	cell in the dermis	[cells in the dermis]	1.5849625007211563	4	1	0	0
30018	1520	Here, Stanley Korsmeyer	[Here, Stanley Korsmeyer]	1.5849625007211563	3	1	0	0
30019	1520	antigen-presenting cell type	[antigen-presenting cell type]	1.5849625007211563	3	1	0	0
30020	1520	degradation of p27kip1	[degradation of p27kip1]	1.5849625007211563	3	1	0	0
30021	1520	different stat family member	[different STAT family members]	1.5849625007211563	4	1	0	0
30022	1520	production of il-5, tnf-alpha	[production of IL-5, TNF-alpha]	1.5849625007211563	4	1	0	0
30023	1520	patient with rhinitis	[patients with rhinitis]	1.5849625007211563	3	2	1	1
30024	1520	Coproporphyrinogen oxidase cpo	[Coproporphyrinogen oxidase CPO]	1.5849625007211563	3	1	0	0
30025	1520	PC4 USA fraction	[PC4 USA fraction]	1.5849625007211563	3	1	0	0
30026	1520	leukocyte flow cytometry	[leukocytes flow cytometry]	1.5849625007211563	3	1	0	0
30027	1520	ZR-75-1 cell line	[ZR-75-1 cell line]	1.5849625007211563	3	1	0	0
30028	1520	blood mononuclear cell response	[blood mononuclear cell responses]	1.5849625007211563	4	2	2	2
30029	1520	maturation of m2-type cell	[maturation of M2-type cells]	1.5849625007211563	4	1	0	0
30030	1520	presence of histamine receptor	[presence of histamine receptor]	1.5849625007211563	4	1	0	0
30031	1520	g0s2 mrna level	[G0S2 mRNA levels]	1.5849625007211563	3	1	0	0
30032	1520	other inhibitory factor.	[other inhibitory factor.]	1.5849625007211563	3	1	0	0
30033	1520	different cell population	[different cell populations]	1.5849625007211563	3	1	0	0
30034	1520	property of a activator	[properties of a activator]	1.5849625007211563	4	1	0	0
30035	1520	number of bind site	[number of binding sites]	1.5849625007211563	4	1	0	0
30036	1520	intracellular concentration of sodium	[intracellular concentrations of sodium]	1.5849625007211563	4	1	0	0
30037	1520	optimal viral transcription	[optimal viral transcription]	1.5849625007211563	3	1	0	0
30038	1520	type of promoter used,	[type of promoter used,]	1.5849625007211563	4	1	0	0
30039	1520	p95vav in signal process	[p95vav in signaling processes]	1.5849625007211563	4	1	0	0
30040	1520	most cell line gp+e-86	[most cell lines GP+E-86]	1.5849625007211563	4	1	0	0
30041	1520	Nonimmunoglobulin gene hypermutation	[Nonimmunoglobulin gene hypermutation]	1.5849625007211563	3	1	0	0
30042	1520	early index of lmp1	[early indices of LMP1]	1.5849625007211563	4	1	0	0
30043	1520	aims of the study	[Aims of the study]	1.5849625007211563	4	1	0	0
30044	1520	monocytoid differentiation by calcitriol	[monocytoid differentiation by calcitriol]	1.5849625007211563	4	1	0	0
30045	1520	(1-231)-mediated nf-kappab activation	[(1-231)-mediated NF-kappaB activation]	1.5849625007211563	3	1	0	0
30046	1520	include the ebna2-dependent enhancer	[including the EBNA2-dependent enhancer]	1.5849625007211563	4	1	0	0
30047	1520	p4 nfat element	[P4 NFAT elements]	1.5849625007211563	3	1	0	0
30048	1520	endemic burkitt' lymphoma	[endemic Burkitt's lymphoma]	1.5849625007211563	3	1	0	0
30049	1520	serine /threonine phosphatase	[serine /threonine phosphatases]	1.5849625007211563	3	2	2	2
30050	1520	selection of cell clone	[selection of cell clones]	1.5849625007211563	4	1	0	0
30051	1520	granulosa cell tumor	[Granulosa cell tumor]	1.5849625007211563	3	2	2	2
30052	1520	adrenal cortisol suppression	[adrenal cortisol suppression]	1.5849625007211563	3	1	0	0
30053	1520	monocyte-derived nuclear protein	[monocyte-derived nuclear protein]	1.5849625007211563	3	1	0	0
30054	1520	common VDR genotype	[common VDR genotype]	1.5849625007211563	3	1	0	0
30055	1520	involve general transcription factor	[involving general transcription factors]	1.5849625007211563	4	1	0	0
30056	1520	early receptor-triggered biochemical events,	[early receptor-triggered biochemical events,]	1.5849625007211563	4	1	0	0
30057	1520	other cytokine in monocyte	[other cytokines in monocytes]	1.5849625007211563	4	1	0	0
30058	1520	normocalcemic patient with tuberculosis.	[normocalcemic patients with tuberculosis.]	1.5849625007211563	4	1	0	0
30059	1520	abundant nucleolar protein	[abundant nucleolar protein]	1.5849625007211563	3	1	0	0
30060	1520	counteract the inhibitory effect	[counteracting the inhibitory effects]	1.5849625007211563	4	1	0	0
30061	1520	downregulate the expression	[downregulating the expression]	1.5849625007211563	3	1	0	0
30062	1520	Anti- zebra activity	[Anti- ZEBRA activity]	1.5849625007211563	3	1	0	0
30063	1520	effect on the regulation	[effects on the regulation]	1.5849625007211563	4	2	1	1
30064	1520	0.5 (0.2-1.6) fmol/10(7) cell	[0.5 (0.2-1.6) fmol/10(7) cells]	1.5849625007211563	4	1	0	0
30065	1520	94 kda stat5b protein	[94 kDa STAT5B protein]	1.5849625007211563	4	1	0	0
30066	1520	overexpression of Syk	[overexpression of Syk]	1.5849625007211563	3	1	0	0
30067	1520	b lymphocyte growth transformation	[B lymphocyte growth transformation]	1.5849625007211563	4	1	0	0
30068	1520	use of protein fraction	[use of protein fractions]	1.5849625007211563	4	1	0	0
30069	1520	viable anergic T cell	[viable anergic T cells]	1.5849625007211563	4	1	0	0
30070	1520	development of inflammatory reaction	[development of inflammatory reactions]	1.5849625007211563	4	1	0	0
30071	1520	uneven x inactivation	[uneven X inactivation]	1.5849625007211563	3	1	0	0
30072	1520	lymphoblastoid cell line LCL	[lymphoblastoid cell line LCL]	1.5849625007211563	4	2	2	2
30073	1520	control of a promoter,	[control of an promoter,]	1.5849625007211563	4	1	0	0
30074	1520	IL-2R alpha mrna	[IL-2R alpha mRNA]	1.5849625007211563	3	1	0	0
30075	1520	Fc gamma RI	[Fc gamma RI]	1.5849625007211563	3	1	0	0
30076	1520	mechanism of differentiation	[mechanisms of differentiation]	1.5849625007211563	3	2	2	2
30077	1520	stimulation by various agents,	[stimulation by various agents,]	1.5849625007211563	4	1	0	0
30078	1520	alpha-globin of gamma-globin (5-fold)	[alpha-globin of gamma-globin (5-fold)]	1.5849625007211563	4	1	0	0
30079	1520	induction of Oct-2 mrna	[induction of Oct-2 mRNA]	1.5849625007211563	4	1	0	0
30080	1520	quiescent b lymphocyte	[quiescent B lymphocytes]	1.5849625007211563	3	2	2	2
30081	1520	human zeta-globin gene	[human zeta-globin gene]	1.5849625007211563	3	1	0	0
30082	1520	active transcription factor	[active transcription factor]	1.5849625007211563	3	2	2	2
30083	1520	analysis with cultured cell	[Analyses with cultured cells]	1.5849625007211563	4	1	0	0
30084	1520	Dicarba-closo-dodecaboranes as a pharmacophore	[Dicarba-closo-dodecaboranes as a pharmacophore]	1.5849625007211563	4	1	0	0
30085	1520	cd23 class ii	[CD23 class II]	1.5849625007211563	3	1	0	0
30086	1520	transmembrane domain of CD40	[transmembrane domain of CD40]	1.5849625007211563	4	1	0	0
30087	1520	activity of class promoter	[activity of class promoters]	1.5849625007211563	4	2	2	2
30088	1520	subset of activator	[subset of activators]	1.5849625007211563	3	1	0	0
30089	1520	excess of rapamycin	[excess of rapamycin]	1.5849625007211563	3	1	0	0
30090	1520	nuclear inhibitory protein NIP	[nuclear inhibitory protein NIP]	1.5849625007211563	4	1	0	0
30091	1520	C gamma gene	[C gamma gene]	1.5849625007211563	3	2	2	2
30092	1520	high proliferative potential	[high proliferative potential]	1.5849625007211563	3	2	1	1
30093	1520	tumor proliferative activity	[Tumor proliferative activity]	1.5849625007211563	3	1	0	0
30094	1520	poz-mediated protein interaction	[POZ-mediated protein interactions]	1.5849625007211563	3	1	0	0
30095	1520	extract from cell	[extracts from cells]	1.5849625007211563	3	2	2	2
30096	1520	use specific abs	[using specific Abs]	1.5849625007211563	3	2	2	2
30097	1520	human ebv LMP1	[human EBV LMP1]	1.5849625007211563	3	1	0	0
30098	1520	other construct of p85	[other constructs of p85]	1.5849625007211563	4	1	0	0
30099	1520	critical role for IL-6	[Critical role for IL-6]	1.5849625007211563	4	1	0	0
30100	1520	expression in human tissue	[expression in human tissues]	1.5849625007211563	4	1	0	0
30101	1520	inhibitory effect of PDTC	[inhibitory effect of PDTC]	1.5849625007211563	4	1	0	0
30102	1520	overexpression of v-erbA	[overexpression of v-erbA]	1.5849625007211563	3	1	0	0
30103	1520	activation of stat	[activation of STATs]	1.5849625007211563	3	2	1	1
30104	1520	leukocyte signal transduction	[leukocyte signal transduction]	1.5849625007211563	3	1	0	0
30105	1520	residue to a c	[residue to a C]	1.5849625007211563	4	1	0	0
30106	1520	transcription factor creb/atf	[transcription factors CREB/ATF]	1.5849625007211563	3	2	2	2
30107	1520	tumor necrosis factor-alpha generation	[tumor necrosis factor-alpha generation]	1.5849625007211563	4	1	0	0
30108	1520	regulate rag gene expression	[regulating RAG gene expression]	1.5849625007211563	4	1	0	0
30109	1520	production of monocyte peptide-1	[production of monocyte peptide-1]	1.5849625007211563	4	1	0	0
30110	1520	mainly as a oxidant,	[mainly as an oxidant,]	1.5849625007211563	4	1	0	0
30111	1520	tnf-treated huvec 75%	[TNF-treated HUVECs 75%]	1.5849625007211563	3	1	0	0
30112	1520	high expression of WT1	[high expression of WT1]	1.5849625007211563	4	1	0	0
30113	1520	antibody against Rb	[antibodies against Rb]	1.5849625007211563	3	1	0	0
30114	1520	g0/g1 switch g0s gene	[G0/G1 switch G0S genes]	1.5849625007211563	4	1	0	0
30115	1520	dna-binding activity of Stat1alpha	[DNA-binding activity of Stat1alpha]	1.5849625007211563	4	1	0	0
30116	1520	more mature macrophage	[more mature macrophages]	1.5849625007211563	3	1	0	0
30117	1520	mouse delta protein	[mouse delta protein]	1.5849625007211563	3	1	0	0
30118	1520	atherosclerotic plaque formation	[atherosclerotic plaque formation]	1.5849625007211563	3	1	0	0
30119	1520	normal ln T cell	[normal LN T cells]	1.5849625007211563	4	1	0	0
30120	1520	resistance to glucocorticoid therapy	[Resistance to glucocorticoid therapy]	1.5849625007211563	4	1	0	0
30121	1520	fresh primary leukemic cell	[fresh primary leukemic cells]	1.5849625007211563	4	1	0	0
30122	1520	1 -infected cell	[1 -infected cells]	1.5849625007211563	3	1	0	0
30123	1520	29 aml m4	[29 AML M4]	1.5849625007211563	3	1	0	0
30124	1520	transcription factor active	[transcription factors active]	1.5849625007211563	3	2	1	1
30125	1520	hepor promoter activity	[hEpoR promoter activity]	1.5849625007211563	3	1	0	0
30126	1520	normal hematopoietic cell	[normal hematopoietic cells]	1.5849625007211563	3	2	1	1
30127	1520	multiple cis element	[multiple cis elements]	1.5849625007211563	3	2	1	1
30128	1520	absence of member	[absence of members]	1.5849625007211563	3	1	0	0
30129	1520	corresponding to rar-rxr heterodimer	[corresponding to RAR-RXR heterodimers]	1.5849625007211563	4	1	0	0
30130	1520	interleukin 2 receptor expression	[interleukin 2 receptor expression]	1.5849625007211563	4	1	0	0
30131	1520	trace element preparation	[trace element preparation]	1.5849625007211563	3	2	1	1
30132	1520	contrast, otf-1 protein fraction	[contrast, OTF-1 protein fractions]	1.5849625007211563	4	1	0	0
30133	1520	part of physiological role	[part of physiological role]	1.5849625007211563	4	1	0	0
30134	1520	human herpesvirus 8	[human herpesvirus 8]	1.5849625007211563	3	1	0	0
30135	1520	role generate granulocyte	[role generating granulocytes]	1.5849625007211563	3	1	0	0
30136	1520	murine pro-B cell	[murine pro-B cells]	1.5849625007211563	3	1	0	0
30137	1520	il-2r alpha expression	[IL-2R alpha expression]	1.5849625007211563	3	3	2	1
30138	1520	level of mnda mrna	[level of MNDA mRNA]	1.5849625007211563	4	1	0	0
30139	1520	such as Bax	[such as Bax]	1.5849625007211563	3	1	0	0
30140	1520	anti- CD28 MoAb costimulation	[anti- CD28 MoAb costimulation]	1.5849625007211563	4	1	0	0
30141	1520	granulocyte-macrophage colony-stimumulatelany-stg factor GM-CSF	[granulocyte-macrophage colony-stimulating factor GM-CSF]	1.5849625007211563	4	1	0	0
30142	1520	86 age-matched control subject	[86 age-matched control subjects]	1.5849625007211563	4	1	0	0
30143	1520	eosinophil such as interleukin-5	[eosinophils such as interleukin-5]	1.5849625007211563	4	1	0	0
30144	1520	META(D+) binding factor	[META(D+) binding factors]	1.5849625007211563	3	1	0	0
30145	1520	gene activation in monocyte	[gene activation in monocytes]	1.5849625007211563	4	2	2	2
30146	1520	polyomavirus transcription factor t-antigen	[polyomavirus transcription factor T-antigen]	1.5849625007211563	4	1	0	0
30147	1520	mouse gene tsg101	[mouse gene tsg101]	1.5849625007211563	3	1	0	0
30148	1520	number of adaptor molecules.	[number of adaptor molecules.]	1.5849625007211563	4	1	0	0
30149	1520	kinetic of the transcription	[kinetics of the transcription]	1.5849625007211563	4	1	0	0
30150	1520	cloned, normal T lymphocyte	[Cloned, normal T lymphocytes]	1.5849625007211563	4	1	0	0
30151	1520	autocrine and/or paracrine role	[autocrine and/or paracrine role]	1.5849625007211563	4	1	0	0
30152	1520	macrophage of this cell	[macrophages of these cells]	1.5849625007211563	4	1	0	0
30153	1520	mutation of that site,	[mutation of that site,]	1.5849625007211563	4	1	0	0
30154	1520	consensus AP-1/ CRE site	[consensus AP-1/ CRE site]	1.5849625007211563	4	1	0	0
30155	1520	microenvironment-directed, two-step model	[microenvironment-directed, two-step model]	1.5849625007211563	3	1	0	0
30156	1520	pro-monocytic cell line	[pro-monocytic cell line]	1.5849625007211563	3	2	2	2
30157	1520	follow HHV-6 infection	[following HHV-6 infection]	1.5849625007211563	3	1	0	0
30158	1520	three T cell clone	[three T cell clones]	1.5849625007211563	4	1	0	0
30159	1520	NFAT -276 to -261	[NFAT -276 to -261]	1.5849625007211563	4	1	0	0
30160	1520	other protein necessary	[other proteins necessary]	1.5849625007211563	3	1	0	0
30161	1520	squirrel monkey liver	[squirrel monkey liver]	1.5849625007211563	3	1	0	0
30162	1520	T cell with subpopulations,	[T cells with subpopulations,]	1.5849625007211563	4	1	0	0
30163	1520	sh2 domain of STAT1alpha	[SH2 domain of STAT1alpha]	1.5849625007211563	4	1	0	0
30164	1520	particular, the extracellular pool	[particular, the extracellular pools]	1.5849625007211563	4	1	0	0
30165	1520	encode the HHV-6 (gs)p41	[encoding the HHV-6 (GS)P41]	1.5849625007211563	4	1	0	0
30166	1520	presence of lipopolysaccharide lps	[presence of lipopolysaccharide LPS]	1.5849625007211563	4	1	0	0
30167	1520	il-2r alpha regulation	[IL-2R alpha regulation]	1.5849625007211563	3	1	0	0
30168	1520	gene transcription for TNF-alpha	[gene transcription for TNF-alpha]	1.5849625007211563	4	1	0	0
30169	1520	SLP-76 linker protein	[SLP-76 linker protein]	1.5849625007211563	3	1	0	0
30170	1520	participation of NF-kappa b	[participation of NF-kappa B]	1.5849625007211563	4	1	0	0
30171	1520	granulocyte macrophage-colony stimulate	[granulocyte macrophage-colony stimulating]	1.5849625007211563	3	2	2	2
30172	1520	lps toler ant	[LPS toler ant]	1.5849625007211563	3	1	0	0
30173	1520	novel SP-1 site	[novel SP-1 site]	1.5849625007211563	3	1	0	0
30174	1520	t-cell-specific membrane protein	[T-cell-specific membrane proteins]	1.5849625007211563	3	1	0	0
30175	1520	product of other member	[products of other members]	1.5849625007211563	4	1	0	0
30176	1520	unusually high proline content	[unusually high proline content]	1.5849625007211563	4	1	0	0
30177	1520	different globin promoter	[different globin promoters]	1.5849625007211563	3	1	0	0
30178	1520	vivo antigen challenge	[vivo antigen challenge]	1.5849625007211563	3	1	0	0
30179	1520	murine B-cell cdna-library	[murine B-cell cDNA-library]	1.5849625007211563	3	1	0	0
30180	1520	C-type animal lectin superfamily	[C-type animal lectin superfamily]	1.5849625007211563	4	1	0	0
30181	1520	inhibitory effect of iNO	[inhibitory effects of iNO]	1.5849625007211563	4	2	1	1
30182	1520	dose- dependent manner	[dose- dependent manner]	1.5849625007211563	3	1	0	0
30183	1520	median dissociation constant kd	[median dissociation constant Kd]	1.5849625007211563	4	1	0	0
30184	1520	range between 70	[ranging between 70]	1.5849625007211563	3	1	0	0
30185	1520	kappa b complex	[kappa B complex]	1.5849625007211563	3	2	2	2
30186	1520	important role in commitment	[important role in commitment]	1.5849625007211563	4	1	0	0
30187	1520	oral glucocorticoid treatment	[oral glucocorticoid treatment]	1.5849625007211563	3	1	0	0
30188	1520	mature myelomonocytic cell	[mature myelomonocytic cells]	1.5849625007211563	3	2	2	2
30189	1520	sensitivity of lymphocyte	[sensitivity of lymphocytes]	1.5849625007211563	3	1	0	0
30190	1520	linkage with the polymorphism	[linkage with the polymorphisms]	1.5849625007211563	4	1	0	0
30191	1520	mechanism involve a silencer	[mechanism involving a silencer]	1.5849625007211563	4	1	0	0
30192	1520	activation signal to t-lymphocyte	[activation signals to T-lymphocytes]	1.5849625007211563	4	1	0	0
30193	1520	addition of GM-CSF	[addition of GM-CSF]	1.5849625007211563	3	1	0	0
30194	1520	competition with p50 /p65	[competition with p50 /p65]	1.5849625007211563	4	1	0	0
30195	1520	adult murine tissue	[adult murine tissues]	1.5849625007211563	3	1	0	0
30196	1520	latent growth-transforme infection	[latent growth-transforming infection]	1.5849625007211563	3	1	0	0
30197	1520	MiniMACS separation unit	[MiniMACS separation unit]	1.5849625007211563	3	1	0	0
30198	1520	(approximately 120 kd)	[(approximately 120 kD)]	1.5849625007211563	3	1	0	0
30199	1520	IL-9 gene expression	[IL-9 gene expression]	1.5849625007211563	3	1	0	0
30200	1520	6-week washout period	[6-week washout period]	1.5849625007211563	3	1	0	0
30201	1520	consequence of disturbance	[consequences of disturbances]	1.5849625007211563	3	1	0	0
30202	1520	p53 -independent mechanism	[p53 -independent mechanism]	1.5849625007211563	3	1	0	0
30203	1520	novel rel/stat complex	[novel Rel/STAT complexes]	1.5849625007211563	3	1	0	0
30204	1520	DNA binding subunit	[DNA binding subunits]	1.5849625007211563	3	2	2	2
30205	1520	human chronic leukemia	[human chronic leukemias]	1.5849625007211563	3	1	0	0
30206	1520	functional glucocorticoid receptor	[functional glucocorticoid receptors]	1.5849625007211563	3	2	1	1
30207	1520	only identify novel agents,	[only identifying novel agents,]	1.5849625007211563	4	1	0	0
30208	1520	modulation of intracellular calcium	[modulation of intracellular calcium]	1.5849625007211563	4	1	0	0
30209	1520	endoplasmic reticulum er	[endoplasmic reticulum ER]	1.5849625007211563	3	1	0	0
30210	1520	use [3H]thymidine incorporation	[using [3H]thymidine incorporation]	1.5849625007211563	3	1	0	0
30211	1520	transcription in u937 cell	[transcription in U937 cells]	1.5849625007211563	4	1	0	0
30212	1520	form of NFAT1	[form of NFAT1]	1.5849625007211563	3	1	0	0
30213	1520	heme-treated friend leukemia cell	[heme-treated Friend leukemia cells]	1.5849625007211563	4	2	1	1
30214	1520	number of structural motif	[number of structural motifs]	1.5849625007211563	4	1	0	0
30215	1520	human myeloid leukemia	[human myeloid leukemia]	1.5849625007211563	3	2	2	2
30216	1520	lymphocytic leukemia (b-cll) cell	[lymphocytic leukemia (B-CLL) cells]	1.5849625007211563	4	2	2	2
30217	1520	transcription factor Oct-2A	[transcription factor Oct-2A]	1.5849625007211563	3	2	2	2
30218	1520	p50 protein constituent	[p50 proteins constituents]	1.5849625007211563	3	1	0	0
30219	1520	T cell from human	[T cells from humans]	1.5849625007211563	4	1	0	0
30220	1520	affect DNA binding	[affecting DNA binding]	1.5849625007211563	3	1	0	0
30221	1520	guanine nucleotide binding protein	[guanine nucleotide binding protein]	1.5849625007211563	4	1	0	0
30222	1520	many oxidative species	[many oxidative species]	1.5849625007211563	3	1	0	0
30223	1520	follow tumor necrosis factor	[following tumor necrosis factor]	1.5849625007211563	4	1	0	0
30224	1520	principal initiator of coagulation	[principal initiator of coagulation]	1.5849625007211563	4	1	0	0
30225	1520	anti- CD30 -specific antibody,	[anti- CD30 -specific antibody,]	1.5849625007211563	4	1	0	0
30226	1520	pretreatment of endothelial cell	[pretreatment of endothelial cells]	1.5849625007211563	4	1	0	0
30227	1520	mrna for this protein	[mRNA for these proteins]	1.5849625007211563	4	1	0	0
30228	1520	plethora of strategy	[plethora of strategies]	1.5849625007211563	3	1	0	0
30229	1520	glucocorticoid receptor during hypercortisolaemia	[glucocorticoid receptors during hypercortisolaemia]	1.5849625007211563	4	1	0	0
30230	1520	gene expression of htlv-i	[gene expression of HTLV-I]	1.5849625007211563	4	1	0	0
30231	1520	abundance of bzlf1 transcript	[abundance of BZLF1 transcripts]	1.5849625007211563	4	1	0	0
30232	1520	7-bp response element	[7-bp response elements]	1.5849625007211563	3	1	0	0
30233	1520	microdeletion in this region.	[microdeletions in this region.]	1.5849625007211563	4	1	0	0
30234	1520	view of this findings,	[view of these findings,]	1.5849625007211563	4	1	0	0
30235	1520	rest blood mononuclear cell	[resting blood mononuclear cells]	1.5849625007211563	4	2	2	2
30236	1520	six case with m7	[six cases with M7]	1.5849625007211563	4	1	0	0
30237	1520	NF-AT DNA binding complex	[NF-AT DNA binding complex]	1.5849625007211563	4	1	0	0
30238	1520	supernatant from t-lymphocyte	[supernatant from T-lymphocytes]	1.5849625007211563	3	1	0	0
30239	1520	three atopic patient	[three atopic patients]	1.5849625007211563	3	1	0	0
30240	1520	high degree of similarity	[high degree of similarity]	1.5849625007211563	4	1	0	0
30241	1520	result in cell death	[resulting in cell death]	1.5849625007211563	4	1	0	0
30242	1520	sodium-proton-antiport in HML	[sodium-proton-antiport in HML]	1.5849625007211563	3	1	0	0
30243	1520	anti-I kappa b-alpha antibody	[anti-I kappa B-alpha antibody]	1.5849625007211563	4	1	0	0
30244	1520	5' purine-rich part	[5' purine-rich part]	1.5849625007211563	3	1	0	0
30245	1520	Nuclear factor from unstimulated,	[Nuclear factors from unstimulated,]	1.5849625007211563	4	1	0	0
30246	1520	early thymocyte development	[early thymocyte development]	1.5849625007211563	3	1	0	0
30247	1520	human tcf-1 protein	[human TCF-1 protein]	1.5849625007211563	3	2	1	1
30248	1520	developmental stage-specific gene expression	[developmental stage-specific gene expression]	1.5849625007211563	4	1	0	0
30249	1520	E-box motif upstream	[E-box motif upstream]	1.5849625007211563	3	1	0	0
30250	1520	common multi-point scatchard analysis	[common multi-point Scatchard analysis]	1.5849625007211563	4	1	0	0
30251	1520	result from site-directed mutation	[Results from site-directed mutations]	1.5849625007211563	4	1	0	0
30252	1520	regulation of cd14 expression	[regulation of CD14 expression]	1.5849625007211563	4	3	2	1
30253	1520	Nef expression vector	[Nef expression vector]	1.5849625007211563	3	1	0	0
30254	1520	receptor available for binding	[receptors available for binding]	1.5849625007211563	4	1	0	0
30255	1520	role of NF-M	[role of NF-M]	1.5849625007211563	3	1	0	0
30256	1520	carry point mutation	[carrying point mutations]	1.5849625007211563	3	2	1	1
30257	1520	patient T cell	[patient T cells]	1.5849625007211563	3	2	1	1
30258	1520	recombination of this region	[recombination of this region]	1.5849625007211563	4	1	0	0
30259	1520	regulation of bcl-2 expression	[regulation of bcl-2 expression]	1.5849625007211563	4	1	0	0
30260	1520	vitamin d receptor (vdr)	[vitamin D receptor (VDR)]	1.5849625007211563	4	1	0	0
30261	1520	inhibit ap-1 activation	[inhibiting AP-1 activation]	1.5849625007211563	3	1	0	0
30262	1520	nonstimulate CD28 mab	[nonstimulating CD28 mAb]	1.5849625007211563	3	1	0	0
30263	1520	transcription factor activator protein	[transcription factor activator protein]	1.5849625007211563	4	1	0	0
30264	1520	expression of GM-CSF	[expression of GM-CSF]	1.5849625007211563	3	1	0	0
30265	1520	such inhibitory step	[such inhibitory steps]	1.5849625007211563	3	1	0	0
30266	1520	immunolabeling of the subunit	[immunolabeling of the subunit]	1.5849625007211563	4	2	1	1
30267	1520	mechanism of inhibition.	[mechanism of inhibition.]	1.5849625007211563	3	1	0	0
30268	1520	human GATA3 transcription unit	[human GATA3 transcription unit]	1.5849625007211563	4	2	1	1
30269	1520	glucocorticoid receptor capacity	[glucocorticoid receptor capacity]	1.5849625007211563	3	1	0	0
30270	1520	p38 mapk inhibitor sb203580	[p38 MAPK inhibitor SB203580]	1.5849625007211563	4	1	0	0
30271	1520	lead to the suggestion	[leading to the suggestion]	1.5849625007211563	4	1	0	0
30272	1520	activation domain present	[activation domain present]	1.5849625007211563	3	2	1	1
30273	1520	BRLF1/BZLF1 coding region	[BRLF1/BZLF1 coding region]	1.5849625007211563	3	1	0	0
30274	1520	one cell per well,	[one cell per well,]	1.5849625007211563	4	1	0	0
30275	1520	antigen on antigen	[antigen on antigen]	1.5849625007211563	3	1	0	0
30276	1520	integrin -mediated cell adhesion	[integrin -mediated cell adhesion]	1.5849625007211563	4	1	0	0
30277	1520	PKC -independent pathway	[PKC -independent pathway]	1.5849625007211563	3	1	0	0
30278	1520	p-selectin-specific monoclonal antibody	[P-selectin-specific monoclonal antibodies]	1.5849625007211563	3	1	0	0
30279	1520	respect to the sequence	[respect to the sequence]	1.5849625007211563	4	1	0	0
30280	1520	signal pathway of lps	[signaling pathway of LPS]	1.5849625007211563	4	1	0	0
30281	1520	ifn-responsive reporter construct	[IFN-responsive reporter constructs]	1.5849625007211563	3	1	0	0
30282	1520	recur locally by 5	[recurring locally by 5]	1.5849625007211563	4	1	0	0
30283	1520	vitro T cell differentiation	[vitro T cell differentiation]	1.5849625007211563	4	1	0	0
30284	1520	malignant lymphoproliferative disorder	[malignant lymphoproliferative disorders]	1.5849625007211563	3	1	0	0
30285	1520	maximal response identical	[maximal response identical]	1.5849625007211563	3	1	0	0
30286	1520	infectious kinetic similar	[infectious kinetics similar]	1.5849625007211563	3	1	0	0
30287	1520	progesterone receptor status	[progesterone receptor status]	1.5849625007211563	3	1	0	0
30288	1520	NF-kappa b component c-rel	[NF-kappa B components c-Rel]	1.5849625007211563	4	1	0	0
30289	1520	expression of the il-2ralpha	[expression of the IL-2Ralpha]	1.5849625007211563	4	2	1	1
30290	1520	cref cell killing	[CREF cell killing]	1.5849625007211563	3	1	0	0
30291	1520	multiple factor include stat5	[Multiple factors including Stat5]	1.5849625007211563	4	1	0	0
30292	1520	transgenic expression of PML/RARalpha	[Transgenic expression of PML/RARalpha]	1.5849625007211563	4	1	0	0
30293	1520	use a computer program.	[using a computer program.]	1.5849625007211563	4	1	0	0
30294	1520	control translocation of p65	[controlling translocation of p65]	1.5849625007211563	4	1	0	0
30295	1520	peak at h	[peak at h]	1.5849625007211563	3	2	2	2
30296	1520	ebv cell line	[EBV cell line]	1.5849625007211563	3	1	0	0
30297	1520	r24 increase in proliferation	[R24 increases in proliferation]	1.5849625007211563	4	1	0	0
30298	1520	Glucocorticoid responsiveness of HML	[Glucocorticoid responsiveness of HML]	1.5849625007211563	4	1	0	0
30299	1520	action of RA	[action of RA]	1.5849625007211563	3	2	1	1
30300	1520	distinct b cell-specific coactivator	[distinct B cell-specific coactivators]	1.5849625007211563	4	1	0	0
30301	1520	involvement in late stage	[involvement in late stages]	1.5849625007211563	4	1	0	0
30302	1520	T cell receptor-beta tcr-beta	[T cell receptor-beta TcR-beta]	1.5849625007211563	4	1	0	0
30303	1520	kg/m2) receptor number	[kg/m2), receptor numbers]	1.5849625007211563	3	1	0	0
30304	1520	lacz reporter gene	[lacZ reporter gene]	1.5849625007211563	3	2	1	1
30305	1520	sp-a -dependent increase	[SP-A -dependent increases]	1.5849625007211563	3	1	0	0
30306	1520	DC -specific rdna	[DC -specific cDNAs]	1.5849625007211563	3	1	0	0
30307	1520	chronic virus infection	[chronic virus infection]	1.5849625007211563	3	1	0	0
30308	1520	E-selectin -nf-kappa b oligomer	[E-selectin -NF-kappa B oligomer]	1.5849625007211563	4	1	0	0
30309	1520	TCR alpha control region	[TCR alpha control region]	1.5849625007211563	4	1	0	0
30310	1520	resistance to apoptosis	[resistance to apoptosis]	1.5849625007211563	3	2	1	1
30311	1520	nfat nuclear factor	[NFAT nuclear factor]	1.5849625007211563	3	1	0	0
30312	1520	cell populations, lack	[cell populations, lack]	1.5849625007211563	3	1	0	0
30313	1520	er immunize cell	[ER immunizing cells]	1.5849625007211563	3	1	0	0
30314	1520	adequacy of resection margin	[adequacy of resection margins]	1.5849625007211563	4	1	0	0
30315	1520	3 years) remission	[3 years) remission]	1.5849625007211563	3	1	0	0
30316	1520	consensus gas motif	[consensus GAS motif]	1.5849625007211563	3	2	1	1
30317	1520	further increase in ap-1	[further increase in AP-1]	1.5849625007211563	4	1	0	0
30318	1520	identify potential therapeutic target	[identifying potential therapeutic targets]	1.5849625007211563	4	1	0	0
30319	1520	large number of individual	[large number of individuals]	1.5849625007211563	4	1	0	0
30320	1520	low-density lipoprotein oxldl	[low-density lipoproteins oxLDLs]	1.5849625007211563	3	1	0	0
30321	1520	involvement of pi3-k	[involvement of PI3-K]	1.5849625007211563	3	1	0	0
30322	1520	progesterone pregnancy lymphocyte	[progesterone pregnancy lymphocytes]	1.5849625007211563	3	1	0	0
30323	1520	nf-kappa b -binding motif	[NF-kappa B -binding motifs]	1.5849625007211563	4	1	0	0
30324	1520	specific chromosomal translocation	[specific chromosomal translocations]	1.5849625007211563	3	1	0	0
30325	1520	hypercellularity in bone marrow	[hypercellularity in bone marrow]	1.5849625007211563	4	1	0	0
30326	1520	addition to non-irradiated cell	[addition to non-irradiated cells]	1.5849625007211563	4	1	0	0
30327	1520	change in phosphorylation status	[change in phosphorylation status]	1.5849625007211563	4	1	0	0
30328	1520	overexpression of hsf2-beta	[Overexpression of HSF2-beta]	1.5849625007211563	3	1	0	0
30329	1520	cell to g-csf	[cells to G-CSF]	1.5849625007211563	3	1	0	0
30330	1520	selection against such mutation	[Selection against such mutations]	1.5849625007211563	4	1	0	0
30331	1520	43-47 kD purified.	[43-47 kD purified.]	1.5849625007211563	3	1	0	0
30332	1520	important negative role	[important negative role]	1.5849625007211563	3	1	0	0
30333	1520	stat3 DNA binding	[STAT3 DNA binding]	1.5849625007211563	3	1	0	0
30334	1520	GCR-alpha DNA binding capacity	[GCR-alpha DNA binding capacity]	1.5849625007211563	4	1	0	0
30335	1520	complex comprise a member	[complex comprising a member]	1.5849625007211563	4	1	0	0
30336	1520	effector of Rho	[effector of Rho]	1.5849625007211563	3	1	0	0
30337	1520	mechanism of corticoid resistance	[mechanism of corticoid resistance]	1.5849625007211563	4	1	0	0
30338	1520	relationship between the expression	[relationship between the expression]	1.5849625007211563	4	1	0	0
30339	1520	up-modulation of surface tr75	[up-modulation of surface TR75]	1.5849625007211563	4	1	0	0
30340	1520	primarily in West Africa.	[primarily in West Africa.]	1.5849625007211563	4	1	0	0
30341	1520	presence of CIITA	[presence of CIITA]	1.5849625007211563	3	2	1	1
30342	1520	-differentiated u-937 cell	[-differentiated U-937 cells]	1.5849625007211563	3	1	0	0
30343	1520	novel dna-binding domain	[novel DNA-binding domain]	1.5849625007211563	3	1	0	0
30344	1520	tar -independent mechanism	[TAR -independent mechanism]	1.5849625007211563	3	1	0	0
30345	1520	new insight into inflammation	[new insights into inflammation]	1.5849625007211563	4	1	0	0
30346	1520	viral antigen recognition	[viral antigen recognition]	1.5849625007211563	3	1	0	0
30347	1520	action of D3	[actions of D3]	1.5849625007211563	3	2	2	2
30348	1520	CCAAT/enhancer binding protein epsilon	[CCAAT/enhancer binding protein epsilon]	1.5849625007211563	4	1	0	0
30349	1520	impaired neutrophil maturation	[impaired neutrophil maturation]	1.5849625007211563	3	1	0	0
30350	1520	tightly latent form.	[tightly latent form.]	1.5849625007211563	3	1	0	0
30351	1520	such as gm-csf	[such as GM-CSF]	1.5849625007211563	3	1	0	0
30352	1520	surface of in t-lymphocyte	[surface of in T-lymphocytes]	1.5849625007211563	4	1	0	0
30353	1520	normal ifn-gamma induction	[normal IFN-gamma induction]	1.5849625007211563	3	1	0	0
30354	1520	cases, at least,	[cases, at least,]	1.5849625007211563	3	1	0	0
30355	1520	Differential rna display	[Differential RNA display]	1.5849625007211563	3	1	0	0
30356	1520	growth of FL hpc	[growth of FL HPCs]	1.5849625007211563	4	1	0	0
30357	1520	normal autoregulatory sequence	[normal autoregulatory sequences]	1.5849625007211563	3	1	0	0
30358	1520	vav protooncogene product	[vav protooncogene products]	1.5849625007211563	3	1	0	0
30359	1520	findings, in vitro transcription	[findings, in vitro transcription]	1.5849625007211563	4	1	0	0
30360	1520	s194 plasma cell	[S194 plasma cells]	1.5849625007211563	3	1	0	0
30361	1520	overexpression of Bcl-2	[Overexpression of Bcl-2]	1.5849625007211563	3	2	2	2
30362	1520	many cell type	[many cell types]	1.5849625007211563	3	2	1	1
30363	1520	growth factor gf stimulus	[growth factor GF stimulus]	1.5849625007211563	4	1	0	0
30364	1520	benefit from animal model	[benefit from animal models]	1.5849625007211563	4	1	0	0
30365	1520	promoter of t-cell gene	[promoters of T-cell genes]	1.5849625007211563	4	1	0	0
30366	1520	amount of g(s)alpha expression	[amount of G(S)alpha expression]	1.5849625007211563	4	1	0	0
30367	1520	hypothesis due to defect	[hypothesis due to defects]	1.5849625007211563	4	1	0	0
30368	1520	nuclear factor Sp1	[nuclear factors Sp1]	1.5849625007211563	3	1	0	0
30369	1520	exposure to cortivazol	[exposure to cortivazol]	1.5849625007211563	3	1	0	0
30370	1520	heterozygous mutant mouse	[heterozygous mutant mice]	1.5849625007211563	3	1	0	0
30371	1520	lesion disrupt regulatory domain	[lesions disrupting regulatory domain]	1.5849625007211563	4	1	0	0
30372	1520	than in unprimed cell	[than in unprimed cells]	1.5849625007211563	4	1	0	0
30373	1520	kappa b protein level	[kappa B protein levels]	1.5849625007211563	4	1	0	0
30374	1520	gata3 gene regulation	[GATA3 gene regulation]	1.5849625007211563	3	1	0	0
30375	1520	A6H mab costimulus	[A6H mAb costimulus]	1.5849625007211563	3	1	0	0
30376	1520	Calcitriol a hematolymphopoietrope [editorial]	[Calcitriol a hematolymphopoietrope [editorial]]	1.5849625007211563	4	1	0	0
30377	1520	bamhi h, r, fragment	[BamHI Z, R, fragments]	1.5849625007211563	4	1	0	0
30378	1520	MHC -restricted thymocyte	[MHC -restricted thymocytes]	1.5849625007211563	3	1	0	0
30379	1520	proapoptotic regulatory factor	[proapoptotic regulatory factor]	1.5849625007211563	3	1	0	0
30380	1520	signal downstream of notch,	[signaling downstream of Notch,]	1.5849625007211563	4	1	0	0
30381	1520	characterization of the gene	[Characterization of the genes]	1.5849625007211563	4	2	2	2
30382	1520	difference in response	[differences in responses]	1.5849625007211563	3	2	2	2
30383	1520	B-CLL patient under condition	[B-CLL patients under conditions]	1.5849625007211563	4	1	0	0
30384	1520	nf- kappab activation	[NF- kappaB activation]	1.5849625007211563	3	1	0	0
30385	1520	target certain ebv-positive malignancy	[targeting certain EBV-positive malignancies]	1.5849625007211563	4	1	0	0
30386	1520	many genes, in particular	[many genes, in particular]	1.5849625007211563	4	1	0	0
30387	1520	gel retardation experiment	[gel retardation experiment]	1.5849625007211563	3	2	1	1
30388	1520	effect of the steroid	[effect of the steroid]	1.5849625007211563	4	1	0	0
30389	1520	activity of A-MYB	[activity of A-MYB]	1.5849625007211563	3	2	2	2
30390	1520	binding of a complex	[binding of a complex]	1.5849625007211563	4	1	0	0
30391	1520	allergic bronchial asthma	[allergic bronchial asthma]	1.5849625007211563	3	1	0	0
30392	1520	5-lox activate protein flap	[5-LOX activating protein FLAP]	1.5849625007211563	4	1	0	0
30393	1520	ikappabalpha expression by cytokine	[IkappaBalpha expression by cytokines]	1.5849625007211563	4	1	0	0
30394	1520	d phosphorothioate oligonucleotide	[ds phosphorothioate oligonucleotides]	1.5849625007211563	3	1	0	0
30395	1520	nuclei of FDC	[nuclei of FDC]	1.5849625007211563	3	1	0	0
30396	1520	cellular gene regulatory molecule	[cellular gene regulatory molecules]	1.5849625007211563	4	1	0	0
30397	1520	core sequence cttgg ccaag	[core sequence CTTGG CCAAG]	1.5849625007211563	4	1	0	0
30398	1520	sequence between position -42	[sequence between position -42]	1.5849625007211563	4	1	0	0
30399	1520	importance study cytokine regulation	[importance studying cytokine regulation]	1.5849625007211563	4	1	0	0
30400	1520	myeloid cell macrophage	[myeloid cells macrophages]	1.5849625007211563	3	1	0	0
30401	1520	one cytoplasmic serine kinase	[one cytoplasmic serine kinases]	1.5849625007211563	4	1	0	0
30402	1520	predominantly by T cell	[predominantly by T cells]	1.5849625007211563	4	1	0	0
30403	1520	unknown pathway include JAK2	[unknown pathway including JAK2]	1.5849625007211563	4	1	0	0
30404	1520	-236/-145 minimal e2re	[-236/-145 minimal E2RE]	1.5849625007211563	3	1	0	0
30405	1520	IL-12 -dependent transactivation	[IL-12 -dependent transactivation]	1.5849625007211563	3	1	0	0
30406	1520	death-promoting activity of Bik	[death-promoting activity of Bik]	1.5849625007211563	4	1	0	0
30407	1520	similar mode of action.	[similar mode of action.]	1.5849625007211563	4	1	0	0
30408	1520	Stat3 monoclonal antibody	[Stat3 monoclonal antibody]	1.5849625007211563	3	1	0	0
30409	1520	recognition of BCR1/25	[recognition of BCR1/25]	1.5849625007211563	3	1	0	0
30410	1520	IL-2 T cell growth	[IL-2 T cell growth]	1.5849625007211563	4	1	0	0
30411	1520	fc gamma riia cell	[Fc gamma RIIA cells]	1.5849625007211563	4	1	0	0
30412	1520	fresh atl cell	[fresh ATL cells]	1.5849625007211563	3	1	0	0
30413	1520	adult T-cell leukemia	[Adult T-cell leukemia]	1.5849625007211563	3	1	0	0
30414	1520	childhood acute lymphoblastic leukemia	[childhood acute lymphoblastic leukemia]	1.5849625007211563	4	1	0	0
30415	1520	inhibition of the differentiation	[Inhibition of the differentiation]	1.5849625007211563	4	1	0	0
30416	1520	hiv-1 LTR promoter activity	[HIV-1 LTR promoter activity]	1.5849625007211563	4	1	0	0
30417	1520	e2f transcriptional activity	[E2F transcriptional activity]	1.5849625007211563	3	1	0	0
30418	1520	activator of transcription.	[activator of transcription.]	1.5849625007211563	3	1	0	0
30419	1520	human prl (hprl) gene	[human PRL (hPRL) gene]	1.5849625007211563	4	1	0	0
30420	1520	cd19 /vav/phosphatidylinositol-3 kinase complex	[CD19 /Vav/phosphatidylinositol-3 kinase complex]	1.5849625007211563	4	1	0	0
30421	1520	interleukin-1 il-1 signal	[interleukin-1 IL-1 signaling]	1.5849625007211563	3	1	0	0
30422	1520	single mutation site	[single mutation site]	1.5849625007211563	3	1	0	0
30423	1520	distinct b coactivator	[distinct B coactivators]	1.5849625007211563	3	1	0	0
30424	1520	expression of interleukin-1beta il-1beta	[expression of interleukin-1beta IL-1beta]	1.5849625007211563	4	1	0	0
30425	1520	relation to myeloid leukemogenesis	[relation to myeloid leukemogenesis]	1.5849625007211563	4	1	0	0
30426	1520	contrast, p65 delta	[contrast, p65 delta]	1.5849625007211563	3	1	0	0
30427	1520	other ap-1-related protein	[other AP-1-related proteins]	1.5849625007211563	3	1	0	0
30428	1520	inhibit the activity	[inhibiting the activity]	1.5849625007211563	3	2	2	2
30429	1520	HLA DQA1 locus	[HLA DQA1 locus]	1.5849625007211563	3	1	0	0
30430	1520	integrity of domain e	[integrity of domain E]	1.5849625007211563	4	1	0	0
30431	1520	expression of Aldh1 protein	[expression of Aldh1 protein]	1.5849625007211563	4	1	0	0
30432	1520	lbp (14.7 nmol/l) subject	[LBP (14.7 nmol/l) subjects]	1.5849625007211563	4	1	0	0
30433	1520	positive transcription factor bind	[positive transcription factor binding]	1.5849625007211563	4	1	0	0
30434	1520	postoperatively, however, such difference	[postoperatively, however, such differences]	1.5849625007211563	4	1	0	0
30435	1520	g1 cell cycle	[G1 cell cycle]	1.5849625007211563	3	2	2	2
30436	1520	Dithiothreitol a sulfhydryl agent	[Dithiothreitol a sulfhydryl agent]	1.5849625007211563	4	1	0	0
30437	1520	lam lipopolysaccharide lps	[LAM lipopolysaccharide LPS]	1.5849625007211563	3	1	0	0
30438	1520	least two major epitope	[least two major epitopes]	1.5849625007211563	4	1	0	0
30439	1520	study, therefore, tnf-alpha bioavailability	[study, therefore, TNF-alpha bioavailability]	1.5849625007211563	4	1	0	0
30440	1520	myelopoiesis in human cell	[myelopoiesis in human cells]	1.5849625007211563	4	1	0	0
30441	1520	addition to NF-kappa b	[addition to NF-kappa B]	1.5849625007211563	4	1	0	0
30442	1520	nf-kappab subunit p50	[NF-kappaB subunits p50]	1.5849625007211563	3	1	0	0
30443	1520	(luc) reporter gene	[(Luc) reporter gene]	1.5849625007211563	3	1	0	0
30444	1520	characterization of a variant	[characterization of an variant]	1.5849625007211563	4	1	0	0
30445	1520	receptor positive cell population	[receptor positive cell population]	1.5849625007211563	4	1	0	0
30446	1520	addition of thiol-reducing compound	[addition of thiol-reducing compounds]	1.5849625007211563	4	1	0	0
30447	1520	aids-related non-hodgkin' lymphoma arnhl	[AIDS-related non-Hodgkin's lymphoma ARNHL]	1.5849625007211563	4	1	0	0
30448	1520	tnf-alpha transcription on stimulation	[TNF-alpha transcription on stimulation]	1.5849625007211563	4	1	0	0
30449	1520	active, dimeric form	[active, dimeric form]	1.5849625007211563	3	1	0	0
30450	1520	undergo T cell development	[undergoing T cell development]	1.5849625007211563	4	1	0	0
30451	1520	role of e-protein	[role of E-proteins]	1.5849625007211563	3	1	0	0
30452	1520	cd23 mrna transcription	[CD23 mRNA transcription]	1.5849625007211563	3	1	0	0
30453	1520	pml-rar alpha blast	[PML-RAR alpha blasts]	1.5849625007211563	3	1	0	0
30454	1520	peptide match cover 10%	[peptide matches covering 10%]	1.5849625007211563	4	1	0	0
30455	1520	more viral mrna	[more viral mRNA]	1.5849625007211563	3	1	0	0
30456	1520	defect of DC	[defect of DC]	1.5849625007211563	3	1	0	0
30457	1520	such monocyte specificity,	[such monocyte specificity,]	1.5849625007211563	3	1	0	0
30458	1520	contact with CD70 transfectant	[contact with CD70 transfectants]	1.5849625007211563	4	1	0	0
30459	1520	increase the binding site	[increasing the binding sites]	1.5849625007211563	4	1	0	0
30460	1520	protein in haemopoietic cell	[proteins in haemopoietic cells]	1.5849625007211563	4	1	0	0
30461	1520	cytokine il-4 il-4	[cytokine IL-4 IL-4]	1.5849625007211563	3	1	0	0
30462	1520	gene expression of cell	[gene expression of cells]	1.5849625007211563	4	1	0	0
30463	1520	human atherosclerotic disease	[human atherosclerotic disease]	1.5849625007211563	3	1	0	0
30464	1520	epitope of thyrotropin receptor	[epitopes of thyrotropin receptor]	1.5849625007211563	4	1	0	0
30465	1520	intensity of the band	[intensity of the band]	1.5849625007211563	4	1	0	0
30466	1520	bm of MRD -negative	[BM of MRD -negative]	1.5849625007211563	4	1	0	0
30467	1520	modulation of hiv-1 replication	[modulation of HIV-1 replication]	1.5849625007211563	4	1	0	0
30468	1520	early-stage breast cancer patient	[early-stage breast cancer patients]	1.5849625007211563	4	1	0	0
30469	1520	motif in the promoter	[motif in the promoters]	1.5849625007211563	4	2	1	1
30470	1520	promonocytic U1 cell line	[promonocytic U1 cell line]	1.5849625007211563	4	1	0	0
30471	1520	unique brca1 change	[unique BRCA1 change]	1.5849625007211563	3	1	0	0
30472	1520	five complementation group	[five complementation groups]	1.5849625007211563	3	2	1	1
30473	1520	hsc/ primitive hpc proliferation	[HSC/ primitive HPC proliferation]	1.5849625007211563	4	1	0	0
30474	1520	ANG ii effect	[ANG II effect]	1.5849625007211563	3	1	0	0
30475	1520	inhibit the transcription rate	[inhibiting the transcription rate]	1.5849625007211563	4	1	0	0
30476	1520	model system of ventilation	[model system of ventilation]	1.5849625007211563	4	1	0	0
30477	1520	mouse nm23 -m1	[mouse nm23 -M1]	1.5849625007211563	3	1	0	0
30478	1520	individual nsaid family member	[individual NSAID family members]	1.5849625007211563	4	1	0	0
30479	1520	sensitivity to defensin	[sensitivities to defensin]	1.5849625007211563	3	1	0	0
30480	1520	parental hl-60 cell	[parental HL-60 cells]	1.5849625007211563	3	1	0	0
30481	1520	ms-5 stromal cell	[MS-5 stromal cells]	1.5849625007211563	3	1	0	0
30482	1520	presence of 9-cis-ra	[presence of 9-cis-RA]	1.5849625007211563	3	1	0	0
30483	1520	semiquantitative detection system	[semiquantitative detection system]	1.5849625007211563	3	1	0	0
30484	1520	p46 isoform of JNK	[p46 isoforms of JNK]	1.5849625007211563	4	1	0	0
30485	1520	disruption of latency.	[disruption of latency.]	1.5849625007211563	3	1	0	0
30486	1520	type 2a pp-2a	[type 2A PP-2A]	1.5849625007211563	3	1	0	0
30487	1520	Chronic rejection of organ	[Chronic rejection of organs]	1.5849625007211563	4	1	0	0
30488	1520	human antigen-specific T	[human antigen-specific T]	1.5849625007211563	3	1	0	0
30489	1520	chloramphenicol acetyl-transferase CAT	[chloramphenicol acetyl-transferase CAT]	1.5849625007211563	3	1	0	0
30490	1520	activation of the gene	[activation of the gene]	1.5849625007211563	4	1	0	0
30491	1520	capacity of macrophage	[capacity of macrophages]	1.5849625007211563	3	1	0	0
30492	1520	functional core of HS-40	[functional core of HS-40]	1.5849625007211563	4	1	0	0
30493	1520	endothelial vcam-1 expression	[endothelial VCAM-1 expression]	1.5849625007211563	3	1	0	0
30494	1520	mediate il-2 t-cell proliferation	[mediating IL-2 T-cell proliferation]	1.5849625007211563	4	1	0	0
30495	1520	thrombin cd69 expression	[thrombin CD69 expression]	1.5849625007211563	3	1	0	0
30496	1520	jurkat cell clone	[Jurkat cell clones]	1.5849625007211563	3	1	0	0
30497	1520	e2a-hlf t-cell apoptosis	[E2A-HLF T-cell apoptosis]	1.5849625007211563	3	2	2	2
30498	1520	3 postmenopausal patient	[3 postmenopausal patients]	1.5849625007211563	3	1	0	0
30499	1520	unique capacity of gamma-herpesvirus	[unique capacity of gamma-herpesvirus]	1.5849625007211563	4	1	0	0
30500	1520	Ectopic overexpression of irf-1	[Ectopic overexpression of IRF-1]	1.5849625007211563	4	1	0	0
30501	1520	human delta-globin-encoding gene hbd	[human delta-globin-encoding gene HBD]	1.5849625007211563	4	1	0	0
30502	1520	butyric acid BA	[Butyric acid BA]	1.5849625007211563	3	1	0	0
30503	1520	consensus kappab binding motif	[consensus kappaB binding motif]	1.5849625007211563	4	1	0	0
30504	1520	respect to transcriptional regulation	[respect to transcriptional regulation]	1.5849625007211563	4	1	0	0
30505	1520	T cell proliferation response	[T cell proliferation response]	1.5849625007211563	4	1	0	0
30506	1520	transcription factor c/ebpalpha	[transcription factor C/EBPalpha]	1.5849625007211563	3	1	0	0
30507	1520	constitutive transcription factor SP1	[constitutive transcription factor SP1]	1.5849625007211563	4	1	0	0
30508	1520	protein in eosinophil	[proteins in eosinophils]	1.5849625007211563	3	2	1	1
30509	1520	absence of staining	[absence of staining]	1.5849625007211563	3	1	0	0
30510	1520	putative NF-kappaB binding site	[putative NF-kappaB binding site]	1.5849625007211563	4	1	0	0
30511	1520	microsomal p-nitrophenyl sulfatase activity	[microsomal p-nitrophenyl sulfatase activity]	1.5849625007211563	4	1	0	0
30512	1520	(ii) protein kinase cascade	[(ii) protein kinase cascades]	1.5849625007211563	4	1	0	0
30513	1520	octamer -dependent transcription	[octamer -dependent transcription]	1.5849625007211563	3	2	1	1
30514	1520	mechanism underlie such phenomena.	[mechanisms underlying such phenomena.]	1.5849625007211563	4	1	0	0
30515	1520	regulation of t-cell mitogenesis	[regulation of T-cell mitogenesis]	1.5849625007211563	4	1	0	0
30516	1520	several other microbial agonist	[several other microbial agonists]	1.5849625007211563	4	1	0	0
30517	1520	Glycoprotein (GP) IX	[Glycoprotein (GP) IX]	1.5849625007211563	3	1	0	0
30518	1520	inhibition of nfkappab induction	[inhibition of NFkappaB induction]	1.5849625007211563	4	1	0	0
30519	1520	significantly high (p	[significantly higher (P]	1.5849625007211563	3	1	0	0
30520	1520	ebv antibody titre (p	[EBV antibody titres (P]	1.5849625007211563	4	1	0	0
30521	1520	fatty acid-binding protein	[fatty acid-binding protein]	1.5849625007211563	3	1	0	0
30522	1520	hiv- 1 LTR	[HIV- 1 LTR]	1.5849625007211563	3	1	0	0
30523	1520	carry p element	[carrying P elements]	1.5849625007211563	3	1	0	0
30524	1520	gata-3 promoter transactivation	[GATA-3 promoter transactivation]	1.5849625007211563	3	1	0	0
30525	1520	role in lymphocyte	[role in lymphocytes]	1.5849625007211563	3	2	1	1
30526	1520	monoblast-like u937 cell	[monoblast-like U937 cells]	1.5849625007211563	3	1	0	0
30527	1520	level of nf-kappab subunit	[levels of NF-kappaB subunits]	1.5849625007211563	4	2	2	2
30528	1520	significant level of virus,	[significant level of virus,]	1.5849625007211563	4	1	0	0
30529	1520	lps tolerance in monocytes/macrophages	[LPS tolerance in monocytes/macrophages]	1.5849625007211563	4	1	0	0
30530	1520	ligation of receptor, fas	[ligation of receptor, Fas]	1.5849625007211563	4	1	0	0
30531	1520	effect of pge2	[effects of PGE2]	1.5849625007211563	3	1	0	0
30532	1520	expression of endogenous gm-csf	[expression of endogenous GM-CSF]	1.5849625007211563	4	1	0	0
30533	1520	support factor value	[support factor values]	1.5849625007211563	3	1	0	0
30534	1520	tcr beta enhancer	[TCR beta enhancer]	1.5849625007211563	3	1	0	0
30535	1520	only 3 patient	[only 3 patients]	1.5849625007211563	3	1	0	0
30536	1520	role for genetic alteration	[roles for genetic alterations]	1.5849625007211563	4	1	0	0
30537	1520	potent dominant-negative suppressor	[potent dominant-negative suppressor]	1.5849625007211563	3	1	0	0
30538	1520	Stephania cepharantha Hayata	[Stephania cepharantha Hayata]	1.5849625007211563	3	1	0	0
30539	1520	withdrawal of the drug.	[withdrawal of the drug.]	1.5849625007211563	4	1	0	0
30540	1520	t(y;15)/45,x Turner mosaic pattern	[t(Y;15)/45,X Turner mosaic pattern]	1.5849625007211563	4	1	0	0
30541	1520	high risk group	[high risk groups]	1.5849625007211563	3	1	0	0
30542	1520	pathogenesis of the lesions,	[pathogenesis of the lesions,]	1.5849625007211563	4	1	0	0
30543	1520	high mitotic rate	[high mitotic rate]	1.5849625007211563	3	1	0	0
30544	1520	difference in the sequence	[differences in the sequence]	1.5849625007211563	4	2	2	2
30545	1520	leukemic cell line NS-Meg	[leukemic cell line NS-Meg]	1.5849625007211563	4	1	0	0
30546	1520	progesterone-induced lymphocyte factor	[progesterone-induced lymphocyte factors]	1.5849625007211563	3	1	0	0
30547	1520	CoCl2 hypoxia increase	[CoCl2 hypoxia increase]	1.5849625007211563	3	1	0	0
30548	1520	possible in vivo role	[possible in vivo role]	1.5849625007211563	4	1	0	0
30549	1520	thromboxane receptor gene transcription	[thromboxane receptor gene transcription]	1.5849625007211563	4	1	0	0
30550	1520	other putative site	[other putative sites]	1.5849625007211563	3	1	0	0
30551	1520	activity, DNA sequence	[activity, DNA sequence]	1.5849625007211563	3	1	0	0
30552	1520	immediate-early (ie) response gene	[immediate-early (IE) response genes]	1.5849625007211563	4	1	0	0
30553	1520	more stringent activation requirement	[more stringent activation requirements]	1.5849625007211563	4	1	0	0
30554	1520	expression of p50 subunit	[expression of p50 subunits]	1.5849625007211563	4	1	0	0
30555	1520	NF-kappaB /rel family protein	[NF-kappaB /Rel family proteins]	1.5849625007211563	4	1	0	0
30556	1520	proliferation/differentiation of leukemia cell	[proliferation/differentiation of leukemia cells]	1.5849625007211563	4	1	0	0
30557	1520	allergen-specific human t-cell clone	[allergen-specific human T-cell clones]	1.5849625007211563	4	1	0	0
30558	1520	thymocyte of c57 mice.	[thymocytes of C57 mice.]	1.5849625007211563	4	1	0	0
30559	1520	presence of serum.	[presence of serum.]	1.5849625007211563	3	1	0	0
30560	1520	study of breast carcinoma	[study of breast carcinomas]	1.5849625007211563	4	1	0	0
30561	1520	gi protein pertussis toxin	[Gi protein pertussis toxin]	1.5849625007211563	4	1	0	0
30562	1520	transient expression datum	[transient expression data]	1.5849625007211563	3	1	0	0
30563	1520	E1B 19k mutant virus	[E1B 19K mutant viruses]	1.5849625007211563	4	1	0	0
30564	1520	ecdysone-inducible drosophila transcription factor	[ecdysone-inducible Drosophila transcription factor]	1.5849625007211563	4	1	0	0
30565	1520	PEBP2 alpha b gene	[PEBP2 alpha B genes]	1.5849625007211563	4	1	0	0
30566	1520	contrast, cdc2 mrna	[contrast, cdc2 mRNA]	1.5849625007211563	3	1	0	0
30567	1520	glucocorticoid receptor GRE binding	[glucocorticoid receptor GRE binding]	1.5849625007211563	4	1	0	0
30568	1520	stabilize one of rrna	[stabilizing one of mRNAs]	1.5849625007211563	4	1	0	0
30569	1520	use d variant cell	[using D variant cells]	1.5849625007211563	4	1	0	0
30570	1520	NF-muNR binding site	[NF-muNR binding sites]	1.5849625007211563	3	1	0	0
30571	1520	glucocorticoid-resistant cem-c1 cell	[glucocorticoid-resistant CEM-C1 cells]	1.5849625007211563	3	1	0	0
30572	1520	effect of platelet	[effect of platelets]	1.5849625007211563	3	1	0	0
30573	1520	ion with a ratio	[ion with a ratio]	1.5849625007211563	4	1	0	0
30574	1520	important intracellular signal molecule	[important intracellular signaling molecules]	1.5849625007211563	4	1	0	0
30575	1520	need for vd analogue	[need for VD analogues]	1.5849625007211563	4	1	0	0
30576	1520	level of tnf-alpha beta	[levels of TNF-alpha beta]	1.5849625007211563	4	1	0	0
30577	1520	contrast to null cell	[contrast to null cells]	1.5849625007211563	4	1	0	0
30578	1520	cell sensitive to apoptosis	[cells sensitive to apoptosis]	1.5849625007211563	4	1	0	0
30579	1520	m2-type leukemic cell	[M2-type leukemic cells]	1.5849625007211563	3	1	0	0
30580	1520	presence of various isoform	[presence of various isoforms]	1.5849625007211563	4	1	0	0
30581	1520	property of a silencer	[properties of a silencer]	1.5849625007211563	4	1	0	0
30582	1520	different signal pathway upstream	[different signaling pathways upstream]	1.5849625007211563	4	1	0	0
30583	1520	plasma cell in vivo	[plasma cells in vivo]	1.5849625007211563	4	1	0	0
30584	1520	unsynchronized state of growth,	[unsynchronized state of growth,]	1.5849625007211563	4	1	0	0
30585	1520	young (mean 37 years)	[young (mean 37 years)]	1.5849625007211563	4	1	0	0
30586	1520	cell cycle upon stimulation	[cell cycle upon stimulation]	1.5849625007211563	4	1	0	0
30587	1520	proil-1 beta promoter-proximal requirement	[proIL-1 beta promoter-proximal requirement]	1.5849625007211563	4	1	0	0
30588	1520	free calcium concentration	[free calcium concentration]	1.5849625007211563	3	2	2	2
30589	1520	high-affinity cell surface receptor	[high-affinity cell surface receptors]	1.5849625007211563	4	1	0	0
30590	1520	site-specific, signal-induced phosphorylation	[site-specific, signal-induced phosphorylation]	1.5849625007211563	3	1	0	0
30591	1520	recombinant xpb protein	[recombinant XPB protein]	1.5849625007211563	3	1	0	0
30592	1520	discrete fourier transformation	[discrete Fourier transformations]	1.5849625007211563	3	1	0	0
30593	1520	constitutive transcription factor Sp1	[constitutive transcription factor Sp1]	1.5849625007211563	4	1	0	0
30594	1520	only after hiv1 infection	[only after HIV1 infection]	1.5849625007211563	4	1	0	0
30595	1520	coexpression of mad-3	[coexpression of MAD-3]	1.5849625007211563	3	1	0	0
30596	1520	percentage of lavage t-lymphocyte	[percentage of lavage T-lymphocytes]	1.5849625007211563	4	1	0	0
30597	1520	thus, positive autoregulation	[Thus, positive autoregulation]	1.5849625007211563	3	1	0	0
30598	1520	development of immunotherapy	[development of immunotherapy]	1.5849625007211563	3	1	0	0
30599	1520	protein to the region	[proteins to the region]	1.5849625007211563	4	1	0	0
30600	1520	PEBP2 alpha/AML-1 transcription factor	[PEBP2 alpha/AML-1 transcription factors]	1.5849625007211563	4	1	0	0
30601	1520	high density lipoprotein HDL	[high density lipoprotein HDL]	1.5849625007211563	4	1	0	0
30602	1520	IgH pi site	[IgH pi site]	1.5849625007211563	3	1	0	0
30603	1520	Tesmer, A.Rajadhyaksha, J.Babin,	[Tesmer, A.Rajadhyaksha, J.Babin,]	1.5849625007211563	3	1	0	0
30604	1520	RAR alpha protein	[RAR alpha proteins]	1.5849625007211563	3	1	0	0
30605	1520	varicella zoster virus	[varicella zoster virus]	1.5849625007211563	3	1	0	0
30606	1520	human tcr alpha enhancer	[human TCR alpha enhancer]	1.5849625007211563	4	1	0	0
30607	1520	such as PMA	[such as PMA]	1.5849625007211563	3	1	0	0
30608	1520	three gata element	[three GATA elements]	1.5849625007211563	3	2	2	2
30609	1520	il-6 receptor subunit	[IL-6 receptor subunit]	1.5849625007211563	3	1	0	0
30610	1520	memory b-cell pathway	[memory B-cell pathway]	1.5849625007211563	3	1	0	0
30611	1520	recognition of ZAP-70	[recognition of ZAP-70]	1.5849625007211563	3	1	0	0
30612	1520	nuclear extract of monocytes.	[nuclear extracts of monocytes.]	1.5849625007211563	4	1	0	0
30613	1520	relevant clinical implications.	[relevant clinical implications.]	1.5849625007211563	3	1	0	0
30614	1520	pattern of angiogenesis	[patterns of angiogenesis]	1.5849625007211563	3	1	0	0
30615	1520	action of endogenous protease	[action of endogenous proteases]	1.5849625007211563	4	1	0	0
30616	1520	TNF receptor family member	[TNF receptor family member]	1.5849625007211563	4	1	0	0
30617	1520	unique human protein	[unique human protein]	1.5849625007211563	3	1	0	0
30618	1520	functionally diverse subpopulation	[functionally diverse subpopulations]	1.5849625007211563	3	1	0	0
30619	1520	early gene activation	[early gene activation]	1.5849625007211563	3	2	2	2
30620	1520	vitro, soluble interleukin-2 receptor	[vitro, soluble interleukin-2 receptor]	1.5849625007211563	4	1	0	0
30621	1520	infection with a variant	[Infection with a variant]	1.5849625007211563	4	1	0	0
30622	1520	almost low value	[almost lower values]	1.5849625007211563	3	1	0	0
30623	1520	3 other autoantigen pbc.m2	[3 other autoantigens PBC.M2]	1.5849625007211563	4	1	0	0
30624	1520	mutant signal molecule	[mutant signaling molecules]	1.5849625007211563	3	1	0	0
30625	1520	hypertension in preeclamptic woman	[hypertension in preeclamptic women]	1.5849625007211563	4	1	0	0
30626	1520	prospective longitudinal study	[prospective longitudinal study]	1.5849625007211563	3	1	0	0
30627	1520	pathophysiology of coagulation activation	[pathophysiology of coagulation activation]	1.5849625007211563	4	1	0	0
30628	1520	one t-cell line	[One T-cell line]	1.5849625007211563	3	1	0	0
30629	1520	overexpression of Vav	[overexpression of Vav]	1.5849625007211563	3	2	2	2
30630	1520	eukaryotic gene expression	[eukaryotic gene expression]	1.5849625007211563	3	1	0	0
30631	1520	remain four patient	[remaining four patients]	1.5849625007211563	3	1	0	0
30632	1520	bind protein (s)	[binding protein (s)]	1.5849625007211563	3	1	0	0
30633	1520	expression of GATA-1 mrna	[Expression of GATA-1 mRNA]	1.5849625007211563	4	1	0	0
30634	1520	extrathymic t-cell population	[extrathymic T-cell populations]	1.5849625007211563	3	1	0	0
30635	1520	commitment to erythroid	[commitment to erythroid]	1.5849625007211563	3	1	0	0
30636	1520	contrast, endogenous tg receptor	[contrast, endogenous TG receptors]	1.5849625007211563	4	1	0	0
30637	1520	part of this complex	[part of this complex.]	1.5849625007211563	4	1	0	0
30638	1520	acute inflammatory reaction	[acute inflammatory reactions]	1.5849625007211563	3	1	0	0
30639	1520	slow migrating complex	[slow migrating complexes]	1.5849625007211563	3	1	0	0
30640	1520	novel b coactivator	[novel B coactivator]	1.5849625007211563	3	2	1	1
30641	1520	lineage transcription factor nf-e2	[lineage transcription factor NF-E2]	1.5849625007211563	4	1	0	0
30642	1520	uninfected Jurkat cell line	[uninfected Jurkat cell line]	1.5849625007211563	4	1	0	0
30643	1520	identification of the factor	[identification of the factors]	1.5849625007211563	4	1	0	0
30644	1520	im-9 cell growth	[IM-9 cell growth]	1.5849625007211563	3	1	0	0
30645	1520	activation of PPARgamma	[Activation of PPARgamma]	1.5849625007211563	3	1	0	0
30646	1520	prerequisite for erythroid	[prerequisite for erythroid]	1.5849625007211563	3	1	0	0
30647	1520	hiv tat expression	[HIV Tat expression]	1.5849625007211563	3	1	0	0
30648	1520	b-lymphocyte differentiation control	[B-lymphocyte differentiation control]	1.5849625007211563	3	1	0	0
30649	1520	cell surface antigen	[cell surface antigens]	1.5849625007211563	3	2	2	2
30650	1520	ar gene transcription	[AR gene transcription]	1.5849625007211563	3	1	0	0
30651	1520	inducible t-cell gene expression	[inducible T-cell gene expression]	1.5849625007211563	4	2	1	1
30652	1520	lymphocyte of the group	[lymphocytes of the group]	1.5849625007211563	4	1	0	0
30653	1520	least two distinct protein	[least two distinct proteins]	1.5849625007211563	4	1	0	0
30654	1520	functional sp1 binding element	[functional Sp1 binding elements]	1.5849625007211563	4	1	0	0
30655	1520	tyrosine phosphorylation a member	[tyrosine phosphorylation a member]	1.5849625007211563	4	1	0	0
30656	1520	affect the activity	[affecting the activity]	1.5849625007211563	3	2	2	2
30657	1520	endothelial recruitment of monocyte	[endothelial recruitment of monocytes]	1.5849625007211563	4	1	0	0
30658	1520	human c/ebp-epsilon protein	[human C/EBP-epsilon protein]	1.5849625007211563	3	1	0	0
30659	1520	thus, PKC-zeta overexpression	[Thus, PKC-zeta overexpression]	1.5849625007211563	3	1	0	0
30660	1520	c-jun expression plasmid	[c-jun expression plasmids]	1.5849625007211563	3	1	0	0
30661	1520	b- development in mouse	[B- development in mice]	1.5849625007211563	4	1	0	0
30662	1520	tsh response to TRH	[TSH response to TRH]	1.5849625007211563	4	1	0	0
30663	1520	variant a of hhv-6	[variant A of HHV-6]	1.5849625007211563	4	1	0	0
30664	1520	only with p	[only with P]	1.5849625007211563	3	1	0	0
30665	1520	metabolic consequence of hypercortisolism	[metabolic consequences of hypercortisolism]	1.5849625007211563	4	1	0	0
30666	1520	nonglucocorticoid steroid aldosterone	[nonglucocorticoid steroids aldosterone]	1.5849625007211563	3	1	0	0
30667	1520	1.2 kb fasl promoter	[1.2 kb FasL promoter]	1.5849625007211563	4	1	0	0
30668	1520	other early cytokine	[other early cytokines]	1.5849625007211563	3	1	0	0
30669	1520	Anti-Ehrlichia chaffeensis antibody	[Anti-Ehrlichia chaffeensis antibody]	1.5849625007211563	3	1	0	0
30670	1520	hormonal ovulatory situation	[hormonal ovulatory situation]	1.5849625007211563	3	1	0	0
30671	1520	stimuli-induced hiv-1 expression	[stimuli-induced HIV-1 expression]	1.5849625007211563	3	1	0	0
30672	1520	specific kappa b motif	[specific kappa B motif]	1.5849625007211563	4	1	0	0
30673	1520	novel myeloid cell line	[novel myeloid cell line]	1.5849625007211563	4	2	2	2
30674	1520	molecular weight of 39000.	[molecular weight of 39,000.]	1.5849625007211563	4	1	0	0
30675	1520	extrarenal, nonepithelial mineralocorticoid receptor	[extrarenal, nonepithelial mineralocorticoid receptors]	1.5849625007211563	4	1	0	0
30676	1520	tal-15' GC-rich region	[tal-15' GC-rich region]	1.5849625007211563	3	1	0	0
30677	1520	signal by erythropoietin	[signaling by erythropoietin]	1.5849625007211563	3	1	0	0
30678	1520	I il-1 receptor il-1r	[I IL-1 receptors IL-1R]	1.5849625007211563	4	1	0	0
30679	1520	distinct nuclear foci	[distinct nuclear foci]	1.5849625007211563	3	1	0	0
30680	1520	leucocytic er level	[leucocytic ER levels]	1.5849625007211563	3	1	0	0
30681	1520	survivor cell line	[survivor cell line]	1.5849625007211563	3	1	0	0
30682	1520	ebv-negative Burkitt' lymphoma cell	[EBV-negative Burkitt's lymphoma cells]	1.5849625007211563	4	1	0	0
30683	1520	background: Recent study	[BACKGROUND: Recent studies]	1.5849625007211563	3	1	0	0
30684	1520	part of the event	[part of the events]	1.5849625007211563	4	1	0	0
30685	1520	murine bcl6 gene	[murine BCL6 gene]	1.5849625007211563	3	1	0	0
30686	1520	lack of b activation	[lack of B activation]	1.5849625007211563	4	1	0	0
30687	1520	calcineurin docking site	[calcineurin docking site]	1.5849625007211563	3	2	2	2
30688	1520	proximal element at -65,	[proximal element at -65,]	1.5849625007211563	4	1	0	0
30689	1520	apparent m.w. of 60000	[apparent m.w. of 60,000]	1.5849625007211563	4	1	0	0
30690	1520	healthy donor of sexes.	[healthy donors of sexes.]	1.5849625007211563	4	1	0	0
30691	1520	platelet-activate factor paf	[platelet-activating factor PAF]	1.5849625007211563	3	2	2	2
30692	1520	exposure to L. donovani	[exposure to L. donovani]	1.5849625007211563	4	1	0	0
30693	1520	t(17;19) (q22;p13) chromosomal translocation	[t(17;19) (q22;p13) chromosomal translocation]	1.5849625007211563	4	1	0	0
30694	1520	NF-kappaB -dependent mechanism	[NF-kappaB -dependent mechanism]	1.5849625007211563	3	1	0	0
30695	1520	activator of transcription (stat)1	[activators of transcription (Stat)1]	1.5849625007211563	4	1	0	0
30696	1520	increase in ca2+	[increase in Ca2+]	1.5849625007211563	3	2	2	2
30697	1520	type estrogen binding site	[Type estrogen binding sites]	1.5849625007211563	4	2	2	2
30698	1520	recombination between a gene	[recombination between a gene]	1.5849625007211563	4	1	0	0
30699	1520	class ii nonexpress cell	[class II nonexpressing cells]	1.5849625007211563	4	1	0	0
30700	1520	provide biochemical evidence	[providing biochemical evidence]	1.5849625007211563	3	1	0	0
30701	1520	cd4+ human helper T	[CD4+ human helper T]	1.5849625007211563	4	1	0	0
30702	1520	pattern of TNFalpha inhibition	[pattern of TNFalpha inhibition]	1.5849625007211563	4	1	0	0
30703	1520	lymphocyte upon antigenic stimulation	[lymphocytes upon antigenic stimulation]	1.5849625007211563	4	1	0	0
30704	1520	early gene product	[early gene product]	1.5849625007211563	3	2	2	2
30705	1520	il-2 mrna in cell	[IL-2 mRNA in cells]	1.5849625007211563	4	1	0	0
30706	1520	cytokine-induced tnf gene expression	[cytokine-induced TNF gene expression]	1.5849625007211563	4	1	0	0
30707	1520	follow oxidant challenge.	[following oxidant challenge.]	1.5849625007211563	3	1	0	0
30708	1520	glycerol density gradient	[glycerol density gradient]	1.5849625007211563	3	1	0	0
30709	1520	human monocytic line	[human monocytic line]	1.5849625007211563	3	1	0	0
30710	1520	negative regulatory region	[negative regulatory region]	1.5849625007211563	3	2	1	1
30711	1520	glial cell line	[glial cell lines]	1.5849625007211563	3	1	0	0
30712	1520	CD3 pathway of activation	[CD3 pathway of activation]	1.5849625007211563	4	1	0	0
30713	1520	Non-steroidal anti-inflammatory drug	[Non-steroidal anti-inflammatory drugs]	1.5849625007211563	3	1	0	0
30714	1520	addition of actinomycin d	[addition of actinomycin D]	1.5849625007211563	4	1	0	0
30715	1520	high c-myc mrna expression	[High c-myc mRNA expression]	1.5849625007211563	4	1	0	0
30716	1520	TCF-1 alpha binding element	[TCF-1 alpha binding element]	1.5849625007211563	4	1	0	0
30717	1520	IL-2 promoter level	[IL-2 promoter level]	1.5849625007211563	3	1	0	0
30718	1520	mechanism govern positive selection	[mechanisms governing positive selection]	1.5849625007211563	4	1	0	0
30719	1520	index subject' mononuclear leukocyte	[index subject's mononuclear leukocytes]	1.5849625007211563	4	1	0	0
30720	1520	presence in the hybrid	[presence in the hybrids]	1.5849625007211563	4	1	0	0
30721	1520	tyrosine kinase receptor	[tyrosine kinase receptors]	1.5849625007211563	3	2	1	1
30722	1520	expression of several cytokine	[expression of several cytokines]	1.5849625007211563	4	2	2	2
30723	1520	transcriptional activity of gata-1	[transcriptional activity of GATA-1]	1.5849625007211563	4	1	0	0
30724	1520	cell of neuroglial origin	[cells of neuroglial origin]	1.5849625007211563	4	1	0	0
30725	1520	human IL-5 (hIL-5) promoter	[human IL-5 (hIL-5) promoter]	1.5849625007211563	4	1	0	0
30726	1520	novel primer extension method	[novel primer extension method]	1.5849625007211563	4	1	0	0
30727	1520	contrast, CD38 expression	[contrast, CD38 expression]	1.5849625007211563	3	1	0	0
30728	1520	chimeric il-6 receptor	[chimeric IL-6 receptor]	1.5849625007211563	3	1	0	0
30729	1520	possible biochemical intervention	[possible biochemical intervention]	1.5849625007211563	3	1	0	0
30730	1520	transcription of myeloid-specific gene	[transcription of myeloid-specific genes]	1.5849625007211563	4	1	0	0
30731	1520	NFATc.beta -specific probe	[NFATc.beta -specific probe]	1.5849625007211563	3	1	0	0
30732	1520	phorbol ester response element	[phorbol ester response element]	1.5849625007211563	4	1	0	0
30733	1520	3' NF-kappaB binding site	[3' NF-kappaB binding site]	1.5849625007211563	4	1	0	0
30734	1520	However, cyclosporin A	[However, cyclosporin A]	1.5849625007211563	3	1	0	0
30735	1520	surrogate light chain	[surrogate light chain]	1.5849625007211563	3	1	0	0
30736	1520	monocytic differentiation of cells.	[monocytic differentiation of cells.]	1.5849625007211563	4	1	0	0
30737	1520	correlation with tumour progression	[correlation with tumour progression]	1.5849625007211563	4	1	0	0
30738	1520	monocyte/b-cell-specific transcription factor pu.1	[monocyte/B-cell-specific transcription factor PU.1]	1.5849625007211563	4	1	0	0
30739	1520	(apparent kd, 20.4	[(apparent Kd, 20.4]	1.5849625007211563	3	1	0	0
30740	1520	alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	1.5849625007211563	4	2	2	2
30741	1520	diverse tcr profile	[diverse TCR profile]	1.5849625007211563	3	1	0	0
30742	1520	failure of hiv-1	[failure of HIV-1]	1.5849625007211563	3	1	0	0
30743	1520	only the catalytic,	[Only the catalytic,]	1.5849625007211563	3	1	0	0
30744	1520	Stat3 binding site	[Stat3 binding sites]	1.5849625007211563	3	1	0	0
30745	1520	expression of b-cell-specific gene	[expression of B-cell-specific genes]	1.5849625007211563	4	2	1	1
30746	1520	spite of a reduction	[spite of a reduction]	1.5849625007211563	4	1	0	0
30747	1520	two s-100 protein	[two S-100 proteins]	1.5849625007211563	3	1	0	0
30748	1520	many immunologically important protein	[many immunologically important proteins]	1.5849625007211563	4	1	0	0
30749	1520	human mononuclear phagocyte	[human mononuclear phagocytes]	1.5849625007211563	3	2	1	1
30750	1520	addition, expression of GATA3	[addition, expression of GATA3]	1.5849625007211563	4	1	0	0
30751	1520	antigen receptor response element	[antigen receptor response element]	1.5849625007211563	4	1	0	0
30752	1520	use the cDNA	[using the cDNA]	1.5849625007211563	3	1	0	0
30753	1520	intact tcr signal pathway	[intact TCR signaling pathway]	1.5849625007211563	4	1	0	0
30754	1520	expression of MIP-1 alpha	[expression of MIP-1 alpha]	1.5849625007211563	4	1	0	0
30755	1520	nf-kappa b and/or	[NF-kappa B and/or]	1.5849625007211563	3	1	0	0
30756	1520	multiple vzv peptide	[multiple VZV peptides]	1.5849625007211563	3	1	0	0
30757	1520	important role in hematopoiesis	[important role in hematopoiesis]	1.5849625007211563	4	1	0	0
30758	1520	Jurkat cell activation	[Jurkat cells activation]	1.5849625007211563	3	1	0	0
30759	1520	fluorescent probe react intracellularly	[fluorescent probe reacting intracellularly]	1.5849625007211563	4	1	0	0
30760	1520	use semi-purified ap1 protein	[using semi-purified AP1 proteins]	1.5849625007211563	4	1	0	0
30761	1520	binding of nf-at	[Binding of NF-AT]	1.5849625007211563	3	1	0	0
30762	1520	minimal beta-globin promoter	[minimal beta-globin promoter]	1.5849625007211563	3	1	0	0
30763	1520	tumoral T cell	[tumoral T cells]	1.5849625007211563	3	1	0	0
30764	1520	cell to cell contact	[cell to cell contact]	1.5849625007211563	4	1	0	0
30765	1520	th2-regulated response humoral immunity	[TH2-regulated responses humoral immunity]	1.5849625007211563	4	1	0	0
30766	1520	modulate erythroid differentiation	[modulating erythroid differentiation]	1.5849625007211563	3	1	0	0
30767	1520	C-terminal region of Ku	[C-terminal region of Ku]	1.5849625007211563	4	1	0	0
30768	1520	monoclonal antibody mAECA	[monoclonal antibodies mAECA]	1.5849625007211563	3	1	0	0
30769	1520	neutrophil follow G-CSF stimulation	[neutrophils following G-CSF stimulation]	1.5849625007211563	4	1	0	0
30770	1520	constitutive cell death	[constitutive cell death]	1.5849625007211563	3	1	0	0
30771	1520	site of negative regulation	[site of negative regulation]	1.5849625007211563	4	1	0	0
30772	1520	hematopoietic progenitor cell hpc	[hematopoietic progenitor cells HPCs]	1.5849625007211563	4	2	1	1
30773	1520	intestinal vitamin d receptor	[intestinal vitamin D receptor]	1.5849625007211563	4	1	0	0
30774	1520	ZEBRA a member	[ZEBRA a member]	1.5849625007211563	3	1	0	0
30775	1520	common JAK /stat pathway	[common JAK /STAT pathway]	1.5849625007211563	4	1	0	0
30776	1520	good responder cell line	[best responder cell line]	1.5849625007211563	4	1	0	0
30777	1520	apl cell alone	[APL cells alone]	1.5849625007211563	3	1	0	0
30778	1520	current classification of IDC	[current classification of IDC]	1.5849625007211563	4	1	0	0
30779	1520	also in T cell	[also in T cells]	1.5849625007211563	4	1	0	0
30780	1520	shift in the proportion	[shift in the proportion]	1.5849625007211563	4	1	0	0
30781	1520	effector of p21ras	[effector of p21ras]	1.5849625007211563	3	2	1	1
30782	1520	factor in monocyte	[factor in monocytes]	1.5849625007211563	3	2	2	2
30783	1520	effect of a mutation	[effect of a mutation]	1.5849625007211563	4	1	0	0
30784	1520	non-steroidal anti-inflammatory drug nsaid	[non-steroidal anti-inflammatory drugs NSAIDs]	1.5849625007211563	4	1	0	0
30785	1520	expression of LOX-1	[expression of LOX-1]	1.5849625007211563	3	1	0	0
30786	1520	mechanism common to all	[mechanisms common to all]	1.5849625007211563	4	1	0	0
30787	1520	humoral hbx immune response	[humoral HBx immune response]	1.5849625007211563	4	1	0	0
30788	1520	nfkappab binding activity	[NFkappaB binding activity]	1.5849625007211563	3	2	1	1
30789	1520	p38 in this response	[p38 in these responses]	1.5849625007211563	4	1	0	0
30790	1520	contain transcription factor Oct-1	[containing transcription factor Oct-1]	1.5849625007211563	4	1	0	0
30791	1520	il-6 DNA binding similar	[IL-6 DNA binding similar]	1.5849625007211563	4	1	0	0
30792	1520	loss of activation	[loss of activation]	1.5849625007211563	3	1	0	0
30793	1520	monocyte phenotype increase	[monocyte phenotype increases]	1.5849625007211563	3	1	0	0
30794	1520	pu box -dependent transactivation	[Pu box -dependent transactivation]	1.5849625007211563	4	1	0	0
30795	1520	chimeric receptor ar/tr2/ar	[chimeric receptor AR/TR2/AR]	1.5849625007211563	3	1	0	0
30796	1520	lipopolysaccharide b lymphocyte	[lipopolysaccharide B lymphocytes]	1.5849625007211563	3	1	0	0
30797	1520	potential functional motifs:	[potential functional motifs:]	1.5849625007211563	3	1	0	0
30798	1520	murine myeloid precursor	[murine myeloid precursor]	1.5849625007211563	3	1	0	0
30799	1520	1.9 kb fragment	[1.9 kb fragment]	1.5849625007211563	3	1	0	0
30800	1520	early step of infection	[early steps of infection]	1.5849625007211563	4	1	0	0
30801	1520	28-bp core region	[28-bp core region]	1.5849625007211563	3	1	0	0
30802	1520	maximal 135eoh)2d3 -vdr binding	[maximal 1,25(OH)2D3 -VDR binding]	1.5849625007211563	4	1	0	0
30803	1520	LTR to T	[LTR to T]	1.5849625007211563	3	1	0	0
30804	1520	cognate nuclear factor	[cognate nuclear factors]	1.5849625007211563	3	1	0	0
30805	1520	high-throughput assay in cell	[high-throughput assay in cells]	1.5849625007211563	4	1	0	0
30806	1520	monomeric polypeptide flexi-12	[monomeric polypeptide Flexi-12]	1.5849625007211563	3	1	0	0
30807	1520	ten healthy male volunteer	[ten healthy male volunteers]	1.5849625007211563	4	1	0	0
30808	1520	various nf-kappab /rel	[various NF-kappaB /Rel]	1.5849625007211563	3	1	0	0
30809	1520	entire NH2 regulatory domain	[entire NH2 regulatory domain]	1.5849625007211563	4	1	0	0
30810	1520	purpose: sex-related influence	[PURPOSE: Sex-related influences]	1.5849625007211563	3	1	0	0
30811	1520	exogenous tumor necrosis factor	[exogenous tumor necrosis factor]	1.5849625007211563	4	1	0	0
30812	1520	stress-activated protein kinase	[stress-activated protein kinases]	1.5849625007211563	3	2	1	1
30813	1520	synteny of genetic location	[synteny of genetic location]	1.5849625007211563	4	1	0	0
30814	1520	MHC class x box	[MHC class X box]	1.5849625007211563	4	1	0	0
30815	1520	thp-1 human monocytoid cell	[THP-1 human monocytoid cells]	1.5849625007211563	4	1	0	0
30816	1520	contain a mutation	[containing a mutation]	1.5849625007211563	3	1	0	0
30817	1520	age activity in man.	[age activity in man.]	1.5849625007211563	4	1	0	0
30818	1520	background: Recent datum	[BACKGROUND: Recent data]	1.5849625007211563	3	1	0	0
30819	1520	first few minute	[first few minutes]	1.5849625007211563	3	1	0	0
30820	1520	relatively short amino- (729-766)	[relatively short amino- (729-766)]	1.5849625007211563	4	1	0	0
30821	1520	vivo GC receptor down-regulation	[vivo GC receptor down-regulation]	1.5849625007211563	4	1	0	0
30822	1520	beta-globin locus LCR	[beta-globin locus LCR]	1.5849625007211563	3	1	0	0
30823	1520	nf-kappa b1 transcription	[NF-kappa B1 transcription]	1.5849625007211563	3	1	0	0
30824	1520	association between hSIE	[association between hSIE]	1.5849625007211563	3	1	0	0
30825	1520	human group c adenoviruse	[human group C adenoviruses]	1.5849625007211563	4	1	0	0
30826	1520	phosphatase activity of calcineurin	[phosphatase activity of calcineurin]	1.5849625007211563	4	2	1	1
30827	1520	low-dose chemotherapeutic drug	[low-dose chemotherapeutic drugs]	1.5849625007211563	3	1	0	0
30828	1520	cell line lack stat3	[cell line lacking STAT3]	1.5849625007211563	4	1	0	0
30829	1520	ebv T cell malignancy	[EBV T cell malignancies]	1.5849625007211563	4	1	0	0
30830	1520	CD28 tyrosyl phosphorylation	[CD28 tyrosyl phosphorylation]	1.5849625007211563	3	1	0	0
30831	1520	ifn-gamma -hcmv coincubation	[IFN-gamma -HCMV coincubation]	1.5849625007211563	3	1	0	0
30832	1520	regulation of receptor expression	[regulation of receptor expression]	1.5849625007211563	4	1	0	0
30833	1520	maximum 20 minute	[maximum 20 min]	1.5849625007211563	3	1	0	0
30834	1520	up-regulation of VDR	[up-regulation of VDR]	1.5849625007211563	3	1	0	0
30835	1520	delta globin gene	[delta globin gene]	1.5849625007211563	3	1	0	0
30836	1520	also the mechanism	[also the mechanism]	1.5849625007211563	3	1	0	0
30837	1520	vitro with hiv-1	[vitro with HIV-1]	1.5849625007211563	3	1	0	0
30838	1520	potential as a inducer	[potential as an inducer]	1.5849625007211563	4	1	0	0
30839	1520	induction of a trimer	[induction of a trimer]	1.5849625007211563	4	1	0	0
30840	1520	nonexpression of the locus	[nonexpression of the locus]	1.5849625007211563	4	1	0	0
30841	1520	response to ifn-alpha stimulation	[response to IFN-alpha stimulation]	1.5849625007211563	4	1	0	0
30842	1520	activate viral gene expression	[activating viral gene expression]	1.5849625007211563	4	1	0	0
30843	1520	viral plaque assay	[viral plaque assay]	1.5849625007211563	3	1	0	0
30844	1520	bacterial motility assay	[bacterial motility assays]	1.5849625007211563	3	1	0	0
30845	1520	135-(oh)2d3 receptor in lymphocyte	[1,25-(OH)2D3 receptor in lymphocytes]	1.5849625007211563	4	1	0	0
30846	1520	circulate T lymphocyte	[circulating T lymphocytes]	1.5849625007211563	3	2	2	2
30847	1520	cytoplasmic and/or nuclear receptor	[cytoplasmic and/or nuclear receptor]	1.5849625007211563	4	1	0	0
30848	1520	addition, amount of arsenic	[addition, amounts of arsenic]	1.5849625007211563	4	1	0	0
30849	1520	more critical mechanism.	[more critical mechanism.]	1.5849625007211563	3	1	0	0
30850	1520	freshly isolated T cell	[freshly isolated T cells]	1.5849625007211563	4	1	0	0
30851	1520	suggest a relationship	[suggesting a relationship]	1.5849625007211563	3	1	0	0
30852	1520	domain amino acid	[domain amino acids]	1.5849625007211563	3	2	2	2
30853	1520	endogenous MCM gene	[endogenous MCM genes]	1.5849625007211563	3	1	0	0
30854	1520	CD3 -epsilon gene expression	[CD3 -epsilon gene expression]	1.5849625007211563	4	1	0	0
30855	1520	relatively large protein ligand.	[relatively large protein ligand.]	1.5849625007211563	4	1	0	0
30856	1520	form of dex inhibition	[forms of Dex inhibition]	1.5849625007211563	4	1	0	0
30857	1520	nuclear subunit of NF-AT	[nuclear subunit of NF-AT]	1.5849625007211563	4	1	0	0
30858	1520	mutant tax protein deficient	[mutant Tax protein deficient]	1.5849625007211563	4	1	0	0
30859	1520	absence of JAK-3	[absence of JAK-3]	1.5849625007211563	3	1	0	0
30860	1520	ATLL patient (0/8	[ATLL patients (0/8]	1.5849625007211563	3	1	0	0
30861	1520	-96 octamer motif	[-96 octamer motif]	1.5849625007211563	3	1	0	0
30862	1520	mediate cytokine up-regulation	[mediating cytokine up-regulation]	1.5849625007211563	3	1	0	0
30863	1520	stimulation of human t-cell	[Stimulation of human T-cells]	1.5849625007211563	4	1	0	0
30864	1520	possibility use this cytokine	[possibility using this cytokine]	1.5849625007211563	4	1	0	0
30865	1520	repair/transcription factor tfiih	[repair/transcription factor TFIIH]	1.5849625007211563	3	1	0	0
30866	1520	cell between pld activation	[cells between PLD activation]	1.5849625007211563	4	1	0	0
30867	1520	Fc gammaR1 stat site	[Fc gammaR1 STAT site]	1.5849625007211563	4	1	0	0
30868	1520	47 kda protein	[47 kDa protein]	1.5849625007211563	3	1	0	0
30869	1520	role coordinate the activity	[role coordinating the activity]	1.5849625007211563	4	1	0	0
30870	1520	transcription factor recruitment	[transcription factor recruitment]	1.5849625007211563	3	2	1	1
30871	1520	sense cell line	[sense cell lines]	1.5849625007211563	3	1	0	0
30872	1520	Pebp2/Cbf transcription factor	[Pebp2/Cbf transcription factor]	1.5849625007211563	3	1	0	0
30873	1520	Nuclear run-off assay	[Nuclear run-off assays]	1.5849625007211563	3	1	0	0
30874	1520	erythroid pathway by Epo	[erythroid pathway by Epo]	1.5849625007211563	4	1	0	0
30875	1520	weakly NF-kappa B1 homodimer	[weakly NF-kappa B1 homodimers]	1.5849625007211563	4	1	0	0
30876	1520	differentiation of murine thymocyte	[differentiation of murine thymocytes]	1.5849625007211563	4	1	0	0
30877	1520	significant sequence similarity	[significant sequence similarity]	1.5849625007211563	3	2	1	1
30878	1520	specific biological function	[specific biological function]	1.5849625007211563	3	1	0	0
30879	1520	induction of hiv	[Induction of HIV]	1.5849625007211563	3	2	2	2
30880	1520	most ductal sample	[most ductal samples]	1.5849625007211563	3	1	0	0
30881	1520	western blot experiment	[Western blot experiments]	1.5849625007211563	3	1	0	0
30882	1520	0.0291) mrna expression,	[0.0291) mRNA expression,]	1.5849625007211563	3	1	0	0
30883	1520	approximately 2.3 kb.	[approximately 2.3 kb.]	1.5849625007211563	3	1	0	0
30884	1520	interleukin-2 (il-2)r alpha	[interleukin-2 (IL-2)R alpha]	1.5849625007211563	3	1	0	0
30885	1520	proximal tsp 1 element	[proximal TSP 1 element]	1.5849625007211563	4	1	0	0
30886	1520	healthy individual in IL-2	[healthy individuals in IL-2]	1.5849625007211563	4	1	0	0
30887	1520	il-2 transcription include c-jun	[IL-2 transcription including c-jun]	1.5849625007211563	4	1	0	0
30888	1520	CD11c promoter in	[CD11c promoters in]	1.5849625007211563	3	1	0	0
30889	1520	T lymphocyte with aging.	[T lymphocytes with aging.]	1.5849625007211563	4	1	0	0
30890	1520	flexibility in solution	[flexibility in solution]	1.5849625007211563	3	1	0	0
30891	1520	tested, er mrna	[tested, ER mRNA]	1.5849625007211563	3	1	0	0
30892	1520	human u-937 monoblast	[human U-937 monoblasts]	1.5849625007211563	3	1	0	0
30893	1520	certain cytokines, include ifn-gamma	[certain cytokines, including IFN-gamma]	1.5849625007211563	4	1	0	0
30894	1520	pathway require ROI production	[pathway requiring ROI production]	1.5849625007211563	4	1	0	0
30895	1520	mitogenesis of cd4+	[mitogenesis of CD4+]	1.5849625007211563	3	1	0	0
30896	1520	murine gm-csf gene promoter	[murine GM-CSF gene promoter]	1.5849625007211563	4	1	0	0
30897	1520	cell surface of monocyte	[cell surface of monocytes]	1.5849625007211563	4	1	0	0
30898	1520	number of proteins,	[number of proteins,]	1.5849625007211563	3	1	0	0
30899	1520	exception of t-cell	[exception of T-cells]	1.5849625007211563	3	1	0	0
30900	1520	cytotoxic T cell cd8+cd56+/cd57+	[cytotoxic T cells CD8+CD56+/CD57+]	1.5849625007211563	4	1	0	0
30901	1520	autologous lymphoblastoid cell line	[autologous lymphoblastoid cell line]	1.5849625007211563	4	2	2	2
30902	1520	expression of eosinophil-specific gene	[expression of eosinophil-specific genes]	1.5849625007211563	4	1	0	0
30903	1520	implication for the clinic.	[implications for the clinic.]	1.5849625007211563	4	1	0	0
30904	1520	BamHI ZLF-1 gene product	[BamHI ZLF-1 gene product]	1.5849625007211563	4	1	0	0
30905	1520	CD20 promoter-CAT construct	[CD20 promoter-CAT construct]	1.5849625007211563	3	1	0	0
30906	1520	direct t-cell control.	[direct T-cell control.]	1.5849625007211563	3	1	0	0
30907	1520	recombinant porcine interferon-gamma	[recombinant porcine interferon-gamma]	1.5849625007211563	3	1	0	0
30908	1520	mAb 18c7 epitope	[mAb 18C7 epitope]	1.5849625007211563	3	1	0	0
30909	1520	retinoid -dependent differentiation marker	[retinoid -dependent differentiation markers]	1.5849625007211563	4	1	0	0
30910	1520	low nm23.h1 gene expression	[low NM23.H1 gene expression]	1.5849625007211563	4	1	0	0
30911	1520	two human t-cell clone	[two human T-cell clones]	1.5849625007211563	4	1	0	0
30912	1520	most lps effects, ap-1	[most LPS effects, AP-1]	1.5849625007211563	4	1	0	0
30913	1520	change in the composition	[changes in the composition]	1.5849625007211563	4	2	1	1
30914	1520	HLA DRA promoter	[HLA DRA promoter]	1.5849625007211563	3	1	0	0
30915	1520	early signal transduction event	[early signal transduction events]	1.5849625007211563	4	1	0	0
30916	1520	importance consider receptor study	[importance considering receptor studies]	1.5849625007211563	4	1	0	0
30917	1520	2 microm 1-beta-d-arabinofuranosylcytosine	[2 microM 1-beta-D-arabinofuranosylcytosine]	1.5849625007211563	3	1	0	0
30918	1520	t(8;21) myelogenous leukemia	[t(8;21) myelogenous leukemia]	1.5849625007211563	3	2	2	2
30919	1520	substitution a residue	[substitution A residue]	1.5849625007211563	3	1	0	0
30920	1520	use staphylococcus aureus	[using Staphylococcus aureus]	1.5849625007211563	3	1	0	0
30921	1520	c-Jun N-terminal kinase cascade	[c-Jun N-terminal kinase cascade]	1.5849625007211563	4	1	0	0
30922	1520	Stat6 DNA binding activity	[Stat6 DNA binding activity]	1.5849625007211563	4	1	0	0
30923	1520	differential function of each	[differential function of each]	1.5849625007211563	4	1	0	0
30924	1520	RNA polymerase ii repeat	[RNA polymerase II repeat]	1.5849625007211563	4	1	0	0
30925	1520	lesion-derived cd4+ t-cell clone	[lesion-derived CD4+ T-cell clones]	1.5849625007211563	4	1	0	0
30926	1520	demonstrate a receptor-mediated response.	[demonstrating a receptor-mediated response.]	1.5849625007211563	4	1	0	0
30927	1520	10-60 mM nac	[10-60 mM NAC]	1.5849625007211563	3	1	0	0
30928	1520	process require direct interaction	[process requiring direct interaction]	1.5849625007211563	4	1	0	0
30929	1520	nucleotide -135 to -176	[nucleotides -135 to -176]	1.5849625007211563	4	1	0	0
30930	1520	important costimulatory role	[important costimulatory role]	1.5849625007211563	3	1	0	0
30931	1520	analysis of IkappaBalpha turnover	[analysis of IkappaBalpha turnover]	1.5849625007211563	4	1	0	0
30932	1520	y701 stat1 phosphorylation	[Y701 STAT1 phosphorylation]	1.5849625007211563	3	1	0	0
30933	1520	dominant negative Ras	[dominant negative Ras]	1.5849625007211563	3	1	0	0
30934	1520	control of lytic replication	[control of lytic replication]	1.5849625007211563	4	1	0	0
30935	1520	E3 enhancer motif CATGTGGC	[E3 enhancer motif CATGTGGC]	1.5849625007211563	4	1	0	0
30936	1520	Tcf reporter gene	[Tcf reporter genes]	1.5849625007211563	3	1	0	0
30937	1520	normal cell proliferation	[normal cell proliferation]	1.5849625007211563	3	1	0	0
30938	1520	lymphoid specific gene	[lymphoid specific gene]	1.5849625007211563	3	1	0	0
30939	1520	repressor protein bp1	[repressor proteins BP1]	1.5849625007211563	3	1	0	0
30940	1520	primary infected virus carrier	[primary infected virus carriers]	1.5849625007211563	4	1	0	0
30941	1520	addition, T cell proliferation	[addition, T cell proliferation]	1.5849625007211563	4	1	0	0
30942	1520	significant proportion of transcript	[significant proportion of transcripts]	1.5849625007211563	4	1	0	0
30943	1520	moreover, cyclosporine at concentration	[Moreover, cyclosporine at concentrations]	1.5849625007211563	4	1	0	0
30944	1520	follow corticosteroid treatment	[following corticosteroid treatment]	1.5849625007211563	3	1	0	0
30945	1520	propensity for malignant transformation	[propensity for malignant transformation]	1.5849625007211563	4	1	0	0
30946	1520	lps-stimulated tnf production 5-fold	[LPS-stimulated TNF production 5-fold]	1.5849625007211563	4	1	0	0
30947	1520	cytokine-induced vcam-1 expression	[cytokine-induced VCAM-1 expression]	1.5849625007211563	3	1	0	0
30948	1520	AP1 binding site upstream	[AP1 binding site upstream]	1.5849625007211563	4	1	0	0
30949	1520	pleiotropic effect on lymphocyte	[pleiotropic effects on lymphocytes]	1.5849625007211563	4	1	0	0
30950	1520	remain five patient	[remaining five patients]	1.5849625007211563	3	1	0	0
30951	1520	ability of mitogen	[ability of mitogens]	1.5849625007211563	3	1	0	0
30952	1520	well-defined genetic entity	[well-defined genetic entity]	1.5849625007211563	3	1	0	0
30953	1520	nucleus, correlate with ability	[nucleus, correlating with ability]	1.5849625007211563	4	1	0	0
30954	1520	rabbit beta globin gene	[rabbit beta globin gene]	1.5849625007211563	4	1	0	0
30955	1520	stability of c-Fos	[stability of c-Fos]	1.5849625007211563	3	1	0	0
30956	1520	high-titer antibody response	[high-titer antibody response]	1.5849625007211563	3	1	0	0
30957	1520	human MHC class gene	[human MHC class genes]	1.5849625007211563	4	2	2	2
30958	1520	Th1 clone 29	[Th1 clone 29]	1.5849625007211563	3	1	0	0
30959	1520	monocyte cell line U937	[monocyte cell line U937]	1.5849625007211563	4	1	0	0
30960	1520	abnormal effector mechanism	[abnormal effector mechanism]	1.5849625007211563	3	1	0	0
30961	1520	2.9 0.29 nmol/l, p	[2.9 0.29 nmol/L, p]	1.5849625007211563	4	1	0	0
30962	1520	human vaginal fluid specimen	[Human vaginal fluid specimens]	1.5849625007211563	4	1	0	0
30963	1520	single signal transduction pathway	[single signal transduction pathway]	1.5849625007211563	4	1	0	0
30964	1520	several cell-type-specific transcriptional regulator	[several cell-type-specific transcriptional regulators]	1.5849625007211563	4	1	0	0
30965	1520	pp90rsk activity by phosphorylation	[pp90rsk activity by phosphorylation]	1.5849625007211563	4	1	0	0
30966	1520	4c DNA content (100b	[4C DNA content (100B]	1.5849625007211563	4	1	0	0
30967	1520	regulation in T lymphocyte	[regulation in T lymphocytes]	1.5849625007211563	4	2	2	2
30968	1520	alter platelet aggregation	[altering platelet aggregation]	1.5849625007211563	3	1	0	0
30969	1520	hybrid protein by lymphocyte	[hybrid protein by lymphocytes]	1.5849625007211563	4	1	0	0
30970	1520	ligation of CD2	[ligation of CD2]	1.5849625007211563	3	1	0	0
30971	1520	80-kd stat5a protein	[80-kD STAT5A protein]	1.5849625007211563	3	1	0	0
30972	1520	pleiotropic cellular transcription factor	[pleiotropic cellular transcription factor]	1.5849625007211563	4	1	0	0
30973	1520	cell-mediated immune responses,	[cell-mediated immune responses,]	1.5849625007211563	3	1	0	0
30974	1520	rapid activation of nf-kappab	[rapid activation of NF-kappaB]	1.5849625007211563	4	1	0	0
30975	1520	t-cell receptor loci	[T-cell receptor loci]	1.5849625007211563	3	1	0	0
30976	1520	HLA class ii molecule	[HLA class II molecules]	1.5849625007211563	4	1	0	0
30977	1520	nuclear factor-kappa b binding	[nuclear factor-kappa B binding]	1.5849625007211563	4	1	0	0
30978	1520	transcriptional activity of NF-kappaB	[transcriptional activity of NF-kappaB]	1.5849625007211563	4	1	0	0
30979	1520	typical morphology by means	[typical morphology by means]	1.5849625007211563	4	1	0	0
30980	1520	mitogen-stimulated incorporation of [3h]thymidine	[mitogen-stimulated incorporation of [3H]thymidine]	1.5849625007211563	4	1	0	0
30981	1520	total daily dose	[total daily dose]	1.5849625007211563	3	1	0	0
30982	1520	immunoprecipitation of epitope-labeled BKO	[Immunoprecipitation of epitope-labeled BKO]	1.5849625007211563	4	1	0	0
30983	1520	other hematopoietic cell line	[other hematopoietic cell lines]	1.5849625007211563	4	1	0	0
30984	1520	Rex -viral mrna complex	[Rex -viral mRNA complexes]	1.5849625007211563	4	1	0	0
30985	1520	release of Elf-1	[release of Elf-1]	1.5849625007211563	3	1	0	0
30986	1520	low-affinity receptor for mip-1alpha	[low-affinity receptor for MIP-1alpha]	1.5849625007211563	4	1	0	0
30987	1520	NF-IL6 b site	[NF-IL6 B sites]	1.5849625007211563	3	1	0	0
30988	1520	suppression of binding	[suppression of binding]	1.5849625007211563	3	1	0	0
30989	1520	two nuclear factor	[two nuclear factor]	1.5849625007211563	3	2	1	1
30990	1520	20 preterm baby	[20 preterm babies]	1.5849625007211563	3	1	0	0
30991	1520	several different stimulus	[several different stimuli]	1.5849625007211563	3	1	0	0
30992	1520	posttransplant lymphoproliferative disorder	[posttransplant lymphoproliferative disorders]	1.5849625007211563	3	1	0	0
30993	1520	increase in pld activity	[increases in PLD activity]	1.5849625007211563	4	1	0	0
30994	1520	latent antigen-specific memory	[latent antigen-specific memory]	1.5849625007211563	3	1	0	0
30995	1520	estrogen receptor content	[estrogen receptor content]	1.5849625007211563	3	2	2	2
30996	1520	synthesis of anti-dnp antibody	[synthesis of anti-DNP antibodies]	1.5849625007211563	4	1	0	0
30997	1520	increase in intestinal permeability	[increase in intestinal permeability]	1.5849625007211563	4	1	0	0
30998	1520	basal LAL expression	[basal LAL expression]	1.5849625007211563	3	1	0	0
30999	1520	progenitor cell common	[progenitor cells common]	1.5849625007211563	3	1	0	0
31000	1520	integral membrane glycoprotein cd36	[integral membrane glycoprotein CD36]	1.5849625007211563	4	1	0	0
31001	1520	human p65 subunit	[human p65 subunit]	1.5849625007211563	3	1	0	0
31002	1520	target gene il-8	[target gene IL-8]	1.5849625007211563	3	1	0	0
31003	1520	basal phosphorylation of Jak3	[basal phosphorylation of Jak3]	1.5849625007211563	4	2	2	2
31004	1520	induction of granulocytic marker	[induction of granulocytic markers]	1.5849625007211563	4	1	0	0
31005	1520	NF.kappa b activation	[NF.kappa B activation]	1.5849625007211563	3	1	0	0
31006	1520	renewal of erythroid progenitor	[renewal of erythroid progenitors]	1.5849625007211563	4	1	0	0
31007	1520	zap-70 kinase activity	[ZAP-70 kinase activity]	1.5849625007211563	3	1	0	0
31008	1520	social support variable	[social support variable]	1.5849625007211563	3	1	0	0
31009	1520	htlv-i-negative human t-cell line	[HTLV-I-negative human T-cell lines]	1.5849625007211563	4	1	0	0
31010	1520	process of anti-igm-induced apoptosis	[process of anti-IgM-induced apoptosis]	1.5849625007211563	4	1	0	0
31011	1520	ability of IL-4	[ability of IL-4]	1.5849625007211563	3	1	0	0
31012	1520	Addisonian picture (group	[Addisonian picture (group]	1.5849625007211563	3	2	2	2
31013	1520	ikk-gamma nf-kappab essential modulator),	[IKK-gamma NF-kappaB essential modulator),]	1.5849625007211563	4	1	0	0
31014	1520	IL-2 promoter-enhancer induction	[IL-2 promoter-enhancer induction]	1.5849625007211563	3	1	0	0
31015	1520	only in NK cell	[only in NK cells]	1.5849625007211563	4	2	2	2
31016	1520	hormone-activated transcription factor	[hormone-activated transcription factor]	1.5849625007211563	3	1	0	0
31017	1520	proIL-1 beta cap site	[proIL-1 beta cap site]	1.5849625007211563	4	1	0	0
31018	1520	such as lef1	[such as LEF1]	1.5849625007211563	3	1	0	0
31019	1520	further stimulation by lipopolysaccharide	[further stimulation by lipopolysaccharide]	1.5849625007211563	4	1	0	0
31020	1520	target for dexamethasone repression	[target for dexamethasone repression]	1.5849625007211563	4	1	0	0
31021	1520	significant antimicrovascular ec activity	[significant antimicrovascular EC activity]	1.5849625007211563	4	1	0	0
31022	1520	depletion of intracellular traf2	[Depletion of intracellular TRAF2]	1.5849625007211563	4	1	0	0
31023	1520	2 microm RA	[2 microM RA]	1.5849625007211563	3	1	0	0
31024	1520	addition of any cytokine	[addition of any cytokines]	1.5849625007211563	4	1	0	0
31025	1520	recombinant glycoprotein b gb	[recombinant glycoprotein B gB]	1.5849625007211563	4	1	0	0
31026	1520	bind assay use ligand	[binding assays using ligands]	1.5849625007211563	4	1	0	0
31027	1520	essential NF-kappa b site	[essential NF-kappa B site]	1.5849625007211563	4	1	0	0
31028	1520	-319 bp upstream	[-319 bp upstream]	1.5849625007211563	3	1	0	0
31029	1520	dependent protein kinase	[dependent protein kinases]	1.5849625007211563	3	1	0	0
31030	1520	aberrant retinoic acid metabolism	[aberrant retinoic acid metabolism]	1.5849625007211563	4	1	0	0
31031	1520	such as activation	[such as activation]	1.5849625007211563	3	2	1	1
31032	1520	heat-activated unliganded receptor	[heat-activated unliganded receptors]	1.5849625007211563	3	1	0	0
31033	1520	other cell-specific factor	[other cell-specific factors]	1.5849625007211563	3	2	1	1
31034	1520	action induce icam-1 expression.	[action inducing ICAM-1 expression.]	1.5849625007211563	4	1	0	0
31035	1520	t-cell proliferation study	[T-cell proliferation studies]	1.5849625007211563	3	1	0	0
31036	1520	type t-cell leukemia virus	[type T-cell leukemia virus]	1.5849625007211563	4	1	0	0
31037	1520	gold compound AuTG	[gold compound AuTG]	1.5849625007211563	3	1	0	0
31038	1520	(human monocyte) cell	[(human monocyte) cells]	1.5849625007211563	3	1	0	0
31039	1520	m(r) of 42.6 kda	[M(r) of 42.6 kDa]	1.5849625007211563	4	1	0	0
31040	1520	tumour of patient	[tumours of patients]	1.5849625007211563	3	1	0	0
31041	1520	clinical action of glucocorticoid	[clinical action of glucocorticoids]	1.5849625007211563	4	1	0	0
31042	1520	version of 430-444 vp16	[version of 430-444 VP16]	1.5849625007211563	4	1	0	0
31043	1520	presence of stat factor	[presence of STAT factors]	1.5849625007211563	4	1	0	0
31044	1520	BZLF1 trans-activator protein	[BZLF1 trans-activator protein]	1.5849625007211563	3	1	0	0
31045	1520	treatment of hyperproliferative disorder	[treatment of hyperproliferative disorders]	1.5849625007211563	4	1	0	0
31046	1520	number of lymphocyte	[number of lymphocytes]	1.5849625007211563	3	2	1	1
31047	1520	expression of lymphokine	[expression of lymphokines]	1.5849625007211563	3	2	2	2
31048	1520	therapeutic potential of drug	[therapeutic potential of drugs]	1.5849625007211563	4	1	0	0
31049	1520	b lymphocyte stimulation	[B lymphocyte stimulation]	1.5849625007211563	3	1	0	0
31050	1520	extracellular matrix glycoprotein FN	[extracellular matrix glycoprotein FN]	1.5849625007211563	4	1	0	0
31051	1520	only to the expression	[only to the expression]	1.5849625007211563	4	1	0	0
31052	1520	process of t-cell immortalization	[process of T-cell immortalization]	1.5849625007211563	4	1	0	0
31053	1520	human gamma-globin promoter	[human gamma-globin promoter]	1.5849625007211563	3	1	0	0
31054	1520	erythroid cell growth	[erythroid cell growth]	1.5849625007211563	3	2	1	1
31055	1520	least two signals, one	[least two signals, one]	1.5849625007211563	4	1	0	0
31056	1520	il-2r alpha chain	[IL-2R alpha chain]	1.5849625007211563	3	1	0	0
31057	1520	thromboxane receptor gene promoter	[thromboxane receptor gene promoter]	1.5849625007211563	4	1	0	0
31058	1520	octamer-dependent enhancer activity	[octamer-dependent enhancer activity]	1.5849625007211563	3	1	0	0
31059	1520	human chromosome 11p15	[human chromosomes 11p15]	1.5849625007211563	3	1	0	0
31060	1520	coreceptor for hiv-1 entry	[coreceptor for HIV-1 entry]	1.5849625007211563	4	1	0	0
31061	1520	homodimer of p65	[homodimers of p65]	1.5849625007211563	3	1	0	0
31062	1520	release of granule enzyme	[release of granule enzymes]	1.5849625007211563	4	1	0	0
31063	1520	context of DRA	[context of DRA]	1.5849625007211563	3	1	0	0
31064	1520	development of monoclonal antibody	[development of monoclonal antibodies]	1.5849625007211563	4	1	0	0
31065	1520	cytoplasmic tail of il-4ralpha	[cytoplasmic tail of IL-4Ralpha]	1.5849625007211563	4	1	0	0
31066	1520	effect of hiv protease	[effects of HIV protease]	1.5849625007211563	4	1	0	0
31067	1520	retinoic acid on po-b	[retinoic acid on PO-B]	1.5849625007211563	4	1	0	0
31068	1520	role in the increase	[role in the increase]	1.5849625007211563	4	1	0	0
31069	1520	proliferation of hcd57-srei cell	[proliferation of HCD57-SREI cells]	1.5849625007211563	4	1	0	0
31070	1520	vivo footprinting agent	[vivo footprinting agent]	1.5849625007211563	3	1	0	0
31071	1520	absence of hla-dr	[absence of HLA-DR]	1.5849625007211563	3	1	0	0
31072	1520	CD40 nf-kappab activation	[CD40 NF-kappaB activation]	1.5849625007211563	3	1	0	0
31073	1520	development of thymic DC	[development of thymic DC]	1.5849625007211563	4	1	0	0
31074	1520	monocyte protein-1 mcp-1	[monocyte protein-1 MCP-1]	1.5849625007211563	3	2	2	2
31075	1520	case of ataxia-telangiectasia	[case of ataxia-telangiectasia]	1.5849625007211563	3	2	1	1
31076	1520	only in CD20	[only in CD20]	1.5849625007211563	3	1	0	0
31077	1520	GM-CSF cell line UT-7	[GM-CSF cell line UT-7]	1.5849625007211563	4	1	0	0
31078	1520	1 enhancer -binding protein	[1 enhancer -binding proteins]	1.5849625007211563	4	1	0	0
31079	1520	disease (55.3% versus 79.1%;	[disease (55.3% versus 79.1%;]	1.5849625007211563	4	1	0	0
31080	1520	BLR2 -specific mrna	[BLR2 -specific mRNA]	1.5849625007211563	3	1	0	0
31081	1520	heterogeneous clinical manifestation	[heterogeneous clinical manifestations]	1.5849625007211563	3	1	0	0
31082	1520	upregulation of NF-kappa b	[upregulation of NF-kappa B]	1.5849625007211563	4	1	0	0
31083	1520	binding to the hmr	[binding to the hMR]	1.5849625007211563	4	1	0	0
31084	1520	secretion of cellular factor	[secretion of cellular factor]	1.5849625007211563	4	1	0	0
31085	1520	PKC inhibitor staurosporin	[PKC inhibitor staurosporin]	1.5849625007211563	3	1	0	0
31086	1520	drug for the treatment	[drug for the treatment]	1.5849625007211563	4	2	2	2
31087	1520	phosphatidylinositol 3-kinase pathway	[phosphatidylinositol 3-kinase pathways]	1.5849625007211563	3	1	0	0
31088	1520	pre-B cell line pb-697	[pre-B cell line PB-697]	1.5849625007211563	4	1	0	0
31089	1520	NF-kappa b binding protein	[NF-kappa B binding proteins]	1.5849625007211563	4	2	1	1
31090	1520	hiv-1 LTR by v-src	[HIV-1 LTR by v-src]	1.5849625007211563	4	1	0	0
31091	1520	important molecule in promotion	[important molecule in promotion]	1.5849625007211563	4	1	0	0
31092	1520	HTLV-I T cell transformation	[HTLV-I T cell transformation]	1.5849625007211563	4	1	0	0
31093	1520	murine fdc-p1-derived cell line	[murine FDC-P1-derived cell line]	1.5849625007211563	4	1	0	0
31094	1520	12-day fetal liver	[12-day fetal liver]	1.5849625007211563	3	1	0	0
31095	1520	intensity of a complex	[intensity of a complex]	1.5849625007211563	4	1	0	0
31096	1520	DNA topoisomerase ii	[DNA topoisomerase II]	1.5849625007211563	3	1	0	0
31097	1520	other ethyl-methanesulfonate-derived subclone	[other ethyl-methanesulfonate-derived subclones]	1.5849625007211563	3	1	0	0
31098	1520	type i ifi	[type I IFNs]	1.5849625007211563	3	2	1	1
31099	1520	degradation of b inhibitor	[degradation of B inhibitor]	1.5849625007211563	4	2	2	2
31100	1520	ligation of CD28	[ligation of CD28]	1.5849625007211563	3	2	1	1
31101	1520	mechanism for the hypercalcemia	[mechanism for the hypercalcemia]	1.5849625007211563	4	1	0	0
31102	1520	anti- stat3 ab	[anti- STAT3 Ab]	1.5849625007211563	3	1	0	0
31103	1520	Src family kinase function	[Src family kinase function]	1.5849625007211563	4	1	0	0
31104	1520	obligate carrier of xcid	[obligate carriers of XCID]	1.5849625007211563	4	1	0	0
31105	1520	immediate preovulatory period	[immediate preovulatory period]	1.5849625007211563	3	1	0	0
31106	1520	nuclear factor NF-GM2	[nuclear factor NF-GM2]	1.5849625007211563	3	1	0	0
31107	1520	nf-kappa-b like consensus sequence	[NF-kappa-B like consensus sequence]	1.5849625007211563	4	1	0	0
31108	1520	most mammalian gene	[most mammalian genes]	1.5849625007211563	3	1	0	0
31109	1520	authentic E2F site	[authentic E2F sites]	1.5849625007211563	3	1	0	0
31110	1520	calcitriol in immune regulation	[calcitriol in immune regulation]	1.5849625007211563	4	1	0	0
31111	1520	full promoter function	[full promoter function]	1.5849625007211563	3	1	0	0
31112	1520	summary, CD40 signal	[summary, CD40 signaling]	1.5849625007211563	3	1	0	0
31113	1520	also 6-8 week	[also 6-8 weeks]	1.5849625007211563	3	1	0	0
31114	1520	region between bp upstream	[region between bp upstream]	1.5849625007211563	4	1	0	0
31115	1520	poly (i).poly (c)	[poly (I).poly (C)]	1.5849625007211563	3	1	0	0
31116	1520	immunological function of lymphocyte	[immunological functions of lymphocytes]	1.5849625007211563	4	1	0	0
31117	1520	inducible factor nf-gm2	[inducible factor NF-GM2]	1.5849625007211563	3	1	0	0
31118	1520	b surface molecule CD40	[B surface molecule CD40]	1.5849625007211563	4	1	0	0
31119	1520	il-2 secretion in response	[IL-2 secretion in response]	1.5849625007211563	4	1	0	0
31120	1520	g1 specific cellular response	[G1 specific cellular response]	1.5849625007211563	4	1	0	0
31121	1520	differentiation of myeloblast	[differentiation of myeloblasts]	1.5849625007211563	3	1	0	0
31122	1520	adenylate cyclase activator, forskolin,	[adenylate cyclase activator, forskolin,]	1.5849625007211563	4	1	0	0
31123	1520	much low affinities.	[much lower affinities.]	1.5849625007211563	3	1	0	0
31124	1520	lack of tax expression	[lack of Tax expression]	1.5849625007211563	4	1	0	0
31125	1520	tissue concentration of il-2	[tissue concentrations of IL-2]	1.5849625007211563	4	1	0	0
31126	1520	92-bp cd11b promoter	[92-bp CD11b promoter]	1.5849625007211563	3	1	0	0
31127	1520	understanding of transcriptional regulation	[understanding of transcriptional regulation]	1.5849625007211563	4	2	2	2
31128	1520	intracellular reactive oxygen species	[intracellular reactive oxygen species]	1.5849625007211563	4	1	0	0
31129	1520	secondary lymphoid organ	[secondary lymphoid organs]	1.5849625007211563	3	1	0	0
31130	1520	synergistic activation of NFAT	[synergistic activation of NFAT]	1.5849625007211563	4	1	0	0
31131	1520	hiv-1 kappab oligonucleotide	[HIV-1 kappaB oligonucleotide]	1.5849625007211563	3	1	0	0
31132	1520	c-jun inhibitory response,	[c-Jun inhibitory response,]	1.5849625007211563	3	1	0	0
31133	1520	stimulation with acid	[stimulation with acid]	1.5849625007211563	3	2	2	2
31134	1520	interact basic helix-loop-helix protein	[interacting basic helix-loop-helix proteins]	1.5849625007211563	4	1	0	0
31135	1520	ability of RFX1	[ability of RFX1]	1.5849625007211563	3	1	0	0
31136	1520	activation pathway of neutrophil	[activation pathways of neutrophils]	1.5849625007211563	4	1	0	0
31137	1520	same kappa b enhancer	[same kappa B enhancers]	1.5849625007211563	4	1	0	0
31138	1520	b-lymphocyte growth transformation	[B-lymphocyte growth transformation]	1.5849625007211563	3	2	2	2
31139	1520	beta-phorbol 12-myristate 13-acetate PMA	[beta-phorbol 12-myristate 13-acetate PMA]	1.5849625007211563	4	2	2	2
31140	1520	mononuclear cell of patient	[mononuclear cells of patients]	1.5849625007211563	4	2	2	2
31141	1520	1.4-kb human tnf-alpha promoter	[1.4-kb human TNF-alpha promoter]	1.5849625007211563	4	1	0	0
31142	1520	activation of ras	[Activation of Ras]	1.5849625007211563	3	1	0	0
31143	1520	curcumin (50 microM)	[curcumin (50 microM)]	1.5849625007211563	3	1	0	0
31144	1520	T cell lymphoma	[T cell lymphomas]	1.5849625007211563	3	2	1	1
31145	1520	presence of mM d-ribose	[presence of mM D-ribose]	1.5849625007211563	4	1	0	0
31146	1520	approximately 3 h	[approximately 3 h]	1.5849625007211563	3	1	0	0
31147	1520	level of hiv-1 rna	[level of HIV-1 RNA]	1.5849625007211563	4	1	0	0
31148	1520	early human adult hematopoiesis	[early human adult hematopoiesis]	1.5849625007211563	4	1	0	0
31149	1520	use the HIV-LTR-kappaB site	[using the HIV-LTR-kappaB site]	1.5849625007211563	4	1	0	0
31150	1520	use immunological cross-linking	[Using immunological cross-linking]	1.5849625007211563	3	1	0	0
31151	1520	macrophage maturation, integrin expression	[macrophage maturation, integrin expression]	1.5849625007211563	4	1	0	0
31152	1520	cell-extracellular matrix interaction	[cell-extracellular matrix interactions]	1.5849625007211563	3	1	0	0
31153	1520	other pre-B cell-specific gene	[other pre-B cell-specific genes]	1.5849625007211563	4	1	0	0
31154	1520	ap-2 nuclear factor bind	[AP-2 nuclear factor binding]	1.5849625007211563	4	1	0	0
31155	1520	major hcmv glycoprotein	[major HCMV glycoproteins]	1.5849625007211563	3	1	0	0
31156	1520	background: adhesion molecule expression	[BACKGROUND: Adhesion molecule expression]	1.5849625007211563	4	1	0	0
31157	1520	absence of any effect	[absence of any effect]	1.5849625007211563	4	1	0	0
31158	1520	basal transcription factor	[basal transcription factor]	1.5849625007211563	3	1	0	0
31159	1520	regulation of the event	[regulation of the events]	1.5849625007211563	4	1	0	0
31160	1520	il-5 gene segment	[IL-5 gene segment]	1.5849625007211563	3	1	0	0
31161	1520	disease-resistant sooty mangabey	[disease-resistant sooty mangabeys]	1.5849625007211563	3	1	0	0
31162	1520	viable white blood cell	[viable white blood cells]	1.5849625007211563	4	1	0	0
31163	1520	treatment of rheumatoid arthritis	[treatment of rheumatoid arthritis]	1.5849625007211563	4	1	0	0
31164	1520	patient (17 of 28)	[patients (17 of 28)]	1.5849625007211563	4	1	0	0
31165	1520	ICAM-1 promoter-dependent transcription	[ICAM-1 promoter-dependent transcription]	1.5849625007211563	3	1	0	0
31166	1520	Recombinant NFAT1 (nfatp)	[Recombinant NFAT1 (NFATp)]	1.5849625007211563	3	1	0	0
31167	1520	autosomal recessive form	[autosomal recessive form]	1.5849625007211563	3	2	1	1
31168	1520	early replicate pseudoautosomal segment	[early replicating pseudoautosomal segment]	1.5849625007211563	4	1	0	0
31169	1520	memory T cell differentiation	[memory T cell differentiation]	1.5849625007211563	4	2	2	2
31170	1520	ad vector lack most	[Ad vector lacking most]	1.5849625007211563	4	1	0	0
31171	1520	function of monocyte	[function of monocytes]	1.5849625007211563	3	1	0	0
31172	1520	colon carcinoma cell line	[colon carcinoma cell lines]	1.5849625007211563	4	2	2	2
31173	1520	functional gata-binding site	[functional GATA-binding site]	1.5849625007211563	3	1	0	0
31174	1520	form of Epstein-Barr DNA	[form of Epstein-Barr DNA]	1.5849625007211563	4	2	2	2
31175	1520	surface domain of TF	[surface domain of TF]	1.5849625007211563	4	1	0	0
31176	1520	induction of Jak	[induction of Jak]	1.5849625007211563	3	1	0	0
31177	1520	100 microg/10(6) cells.	[100 microg/10(6) cells.]	1.5849625007211563	3	1	0	0
31178	1520	T cell with calcineurin	[T cells with calcineurin]	1.5849625007211563	4	1	0	0
31179	1520	other cytokine tested,	[other cytokines tested,]	1.5849625007211563	3	1	0	0
31180	1520	tryptophan photoproduct 6-formylindolo[3,2-b]carbazole FICZ	[tryptophan photoproduct 6-formylindolo[3,2-b]carbazole FICZ]	1.5849625007211563	4	1	0	0
31181	1520	physiological shear flow condition	[physiological shear flow conditions]	1.5849625007211563	4	1	0	0
31182	1520	demonstration of estrogen	[Demonstration of estrogen]	1.5849625007211563	3	1	0	0
31183	1520	binding to the ires	[binding to the IRES]	1.5849625007211563	4	1	0	0
31184	1520	nf-kappa b nf-kappa b	[NF-kappa B NF-kappa B]	1.5849625007211563	4	1	0	0
31185	1520	and/or growth of monocyte	[and/or growth of monocytes]	1.5849625007211563	4	1	0	0
31186	1520	use the tat mutant	[using the tat mutants]	1.5849625007211563	4	1	0	0
31187	1520	case of CML	[cases of CML]	1.5849625007211563	3	1	0	0
31188	1520	percentage of cd3+ cell	[percentage of CD3+ cells]	1.5849625007211563	4	1	0	0
31189	1520	b cell antigen-receptor	[B cell antigen-receptor]	1.5849625007211563	3	1	0	0
31190	1520	beta-casein osm gene expression	[beta-casein OSM gene expression]	1.5849625007211563	4	1	0	0
31191	1520	response of k562 cell	[response of K562 cells]	1.5849625007211563	4	1	0	0
31192	1520	POU (Pit-Oct-Unc) family	[POU (Pit-Oct-Unc) family]	1.5849625007211563	3	1	0	0
31193	1520	polymorphonuclear leukocyte by cortisol	[polymorphonuclear leukocytes by cortisol]	1.5849625007211563	4	1	0	0
31194	1520	adhesion molecule icam-1	[adhesion molecule ICAM-1]	1.5849625007211563	3	2	2	2
31195	1520	ZEBRA activation domain	[ZEBRA activation domain]	1.5849625007211563	3	2	1	1
31196	1520	low frequency of response	[low frequency of response]	1.5849625007211563	4	1	0	0
31197	1520	two distinct signalling pathway	[Two distinct signalling pathways]	1.5849625007211563	4	1	0	0
31198	1520	presence of exogenous fibrinogen	[presence of exogenous fibrinogen]	1.5849625007211563	4	1	0	0
31199	1520	include infectious disease	[including infectious diseases]	1.5849625007211563	3	1	0	0
31200	1520	proliferation of lymphocyte	[proliferation of lymphocytes]	1.5849625007211563	3	2	2	2
31201	1520	synergistic activation of JNK	[synergistic activation of JNK]	1.5849625007211563	4	1	0	0
31202	1520	promote intimal plaque formation.	[promoting intimal plaque formation.]	1.5849625007211563	4	1	0	0
31203	1520	gene of TFIIH	[genes of TFIIH]	1.5849625007211563	3	1	0	0
31204	1520	expression of tf	[expression of TF]	1.5849625007211563	3	2	1	1
31205	1520	expression/repression of differentiation-associated gene	[expression/repression of differentiation-associated genes]	1.5849625007211563	4	1	0	0
31206	1520	least two distinct species,	[least two distinct species,]	1.5849625007211563	4	1	0	0
31207	1520	immunoglobulin chain expression	[immunoglobulin chain expression]	1.5849625007211563	3	1	0	0
31208	1520	Helix-loop-helix HLH transcription factor	[Helix-loop-helix HLH transcription factors]	1.5849625007211563	4	1	0	0
31209	1520	1.25 Dihydroxyvitamin D3	[1.25 Dihydroxyvitamin D3]	1.5849625007211563	3	1	0	0
31210	1520	influenza a virus	[influenza A virus]	1.5849625007211563	3	2	1	1
31211	1520	follow t-cell stimulation	[following T-cell stimulation]	1.5849625007211563	3	1	0	0
31212	1520	consequence of the interplay	[consequence of the interplay]	1.5849625007211563	4	1	0	0
31213	1520	response to transfection	[response to transfection]	1.5849625007211563	3	1	0	0
31214	1520	role modulate t-cell function	[role modulating T-cell function]	1.5849625007211563	4	1	0	0
31215	1520	evidence of transcription	[evidence of transcription]	1.5849625007211563	3	1	0	0
31216	1520	MCM modulatory action.	[MCM modulatory action.]	1.5849625007211563	3	1	0	0
31217	1520	hamartoma from the patient	[hamartoma from the patient]	1.5849625007211563	4	1	0	0
31218	1520	human adenosine deaminase	[human adenosine deaminase]	1.5849625007211563	3	1	0	0
31219	1520	Delta19 beta-catenin mutant	[Delta19 beta-catenin mutant]	1.5849625007211563	3	1	0	0
31220	1520	20-methyl derivative of vd	[20-methyl derivatives of VD]	1.5849625007211563	4	1	0	0
31221	1520	activation of Zap70	[activation of Zap70]	1.5849625007211563	3	1	0	0
31222	1520	constitutive expression of Id3	[Constitutive expression of Id3]	1.5849625007211563	4	1	0	0
31223	1520	human ifn-gamma promoter	[human IFN-gamma promoter]	1.5849625007211563	3	1	0	0
31224	1520	nuclear factor.kappa b activation	[nuclear factor.kappa B activation]	1.5849625007211563	4	1	0	0
31225	1520	interleukin 3 mrna level	[interleukin 3 mRNA levels]	1.5849625007211563	4	1	0	0
31226	1520	5-Aminolevulinate synthase ALAS	[5-Aminolevulinate synthase ALAS]	1.5849625007211563	3	1	0	0
31227	1520	such differentiation, hiv transcription	[such differentiation, HIV transcription]	1.5849625007211563	4	1	0	0
31228	1520	particular amino acid	[particular amino acid]	1.5849625007211563	3	1	0	0
31229	1520	alternate rcgcrygcgy consensus	[alternating RCGCRYGCGY consensus]	1.5849625007211563	3	1	0	0
31230	1520	down-regulatory capacity of IL-4	[down-regulatory capacity of IL-4]	1.5849625007211563	4	1	0	0
31231	1520	amount of ref-1	[amounts of REF-1]	1.5849625007211563	3	1	0	0
31232	1520	1,25-dihydroxyvitamin D3 vd	[1,25-dihydroxyvitamin D3 VD]	1.5849625007211563	3	1	0	0
31233	1520	vis-a-vis hormone metabolic status	[vis-a-vis hormone metabolic status]	1.5849625007211563	4	1	0	0
31234	1520	A/R -tolerant huvec	[A/R -tolerant HUVECs]	1.5849625007211563	3	1	0	0
31235	1520	several methods, each	[several methods, each]	1.5849625007211563	3	1	0	0
31236	1520	lytic ebv DNA replication	[lytic EBV DNA replication]	1.5849625007211563	4	1	0	0
31237	1520	il-2ralpha on mononuclear phagocyte	[IL-2Ralpha on mononuclear phagocytes]	1.5849625007211563	4	1	0	0
31238	1520	three vzv -susceptible donor	[Three VZV -susceptible donors]	1.5849625007211563	4	1	0	0
31239	1520	hiv-1 -ltr transcription	[HIV-1 -LTR transcription]	1.5849625007211563	3	1	0	0
31240	1520	various receptor mutant	[various receptor mutants]	1.5849625007211563	3	1	0	0
31241	1520	absence of dna-binding activity	[absence of DNA-binding activity]	1.5849625007211563	4	1	0	0
31242	1520	cell have eosinophilic granule	[cells having eosinophilic granules]	1.5849625007211563	4	1	0	0
31243	1520	+/- 17 binding sites/cell;	[+/- 17 binding sites/cell;]	1.5849625007211563	4	1	0	0
31244	1520	bronchoalveolar lavage (bal) fluid	[bronchoalveolar lavage (BAL) fluids]	1.5849625007211563	4	1	0	0
31245	1520	level of nf(kappa)b Oct-1	[levels of NF(kappa)B Oct-1]	1.5849625007211563	4	1	0	0
31246	1520	human allergen-specific th2 cell	[human allergen-specific Th2 cells]	1.5849625007211563	4	1	0	0
31247	1520	coactivate nf-kappab with LMP1	[coactivating NF-kappaB with LMP1]	1.5849625007211563	4	1	0	0
31248	1520	primary macrophage culture	[primary macrophage cultures]	1.5849625007211563	3	1	0	0
31249	1520	vivo rela homodimer	[vivo RelA homodimers]	1.5849625007211563	3	1	0	0
31250	1520	t-cell signal transduction	[T-cell signal transduction]	1.5849625007211563	3	1	0	0
31251	1520	magnitude of responsiveness	[magnitude of responsiveness]	1.5849625007211563	3	1	0	0
31252	1520	thr beta- ppar	[THR beta- PPAR]	1.5849625007211563	3	1	0	0
31253	1520	100 U/ml, il-10	[100 U/ml, IL-10]	1.5849625007211563	3	1	0	0
31254	1520	implication of virus	[Implication of viruses]	1.5849625007211563	3	1	0	0
31255	1520	vitro expression assay	[vitro expression assays]	1.5849625007211563	3	1	0	0
31256	1520	contain tyrosine kinase Syk	[containing tyrosine kinase Syk]	1.5849625007211563	4	1	0	0
31257	1520	case of transfusion incompatibility	[cases of transfusion incompatibility]	1.5849625007211563	4	1	0	0
31258	1520	prostate-specific antigen PSA	[prostate-specific antigen PSA]	1.5849625007211563	3	1	0	0
31259	1520	two tyrosine residue	[two tyrosine residues]	1.5849625007211563	3	2	2	2
31260	1520	LMP-1 effect on AP-1	[LMP-1 effects on AP-1]	1.5849625007211563	4	1	0	0
31261	1520	rest memory T cell	[resting memory T cells]	1.5849625007211563	4	2	1	1
31262	1520	housekeeping alas isozyme	[housekeeping ALAS isozymes]	1.5849625007211563	3	1	0	0
31263	1520	tandem gata site	[tandem GATA sites]	1.5849625007211563	3	1	0	0
31264	1520	use uninfected pbmc	[using uninfected PBMCs]	1.5849625007211563	3	1	0	0
31265	1520	nuclear kappab dna-binding activity	[nuclear kappaB DNA-binding activity]	1.5849625007211563	4	1	0	0
31266	1520	normal mouse bone marrow	[normal mouse bone marrow]	1.5849625007211563	4	1	0	0
31267	1520	Fc gamma RII	[Fc gamma RII]	1.5849625007211563	3	1	0	0
31268	1520	vivo interaction of Tax1	[vivo interaction of Tax1]	1.5849625007211563	4	1	0	0
31269	1520	Ras -Aiolos interaction	[Ras -Aiolos interaction]	1.5849625007211563	3	1	0	0
31270	1520	EBV chronic response	[EBV chronic response]	1.5849625007211563	3	1	0	0
31271	1520	human u937 promonocytic cell	[human U937 promonocytic cells]	1.5849625007211563	4	1	0	0
31272	1520	other regulatory mechanism	[other regulatory mechanisms]	1.5849625007211563	3	1	0	0
31273	1520	expression of infectious virus	[expression of infectious virus]	1.5849625007211563	4	1	0	0
31274	1520	human epor gene	[human EpoR gene]	1.5849625007211563	3	1	0	0
31275	1520	site-like DNA sequence element	[site-like DNA sequence element]	1.5849625007211563	4	1	0	0
31276	1520	patient with crohn' disease	[patients with Crohn's disease]	1.5849625007211563	4	1	0	0
31277	1520	alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	1.5849625007211563	3	2	2	2
31278	1520	IL-10 cell at G0/G1	[IL-10 cells at G0/G1]	1.5849625007211563	4	1	0	0
31279	1520	camp -induce agent	[cAMP -inducing agents]	1.5849625007211563	3	1	0	0
31280	1520	role in hiv-1 activation	[role in HIV-1 activation]	1.5849625007211563	4	2	2	2
31281	1520	several positive element	[several positive elements]	1.5849625007211563	3	2	1	1
31282	1520	dtc biological activity	[DTCs biological activities]	1.5849625007211563	3	1	0	0
31283	1520	backbone vector alone prpneo-sl3	[backbone vector alone pRPneo-SL3]	1.5849625007211563	4	1	0	0
31284	1520	trans heterodimeric HLA-DQ molecule	[trans heterodimeric HLA-DQ molecules]	1.5849625007211563	4	1	0	0
31285	1520	number (6500+/-1001 sites/cell	[number (6500+/-1001 sites/cell]	1.5849625007211563	3	1	0	0
31286	1520	engagement of the tcr	[engagement of the TCR]	1.5849625007211563	4	2	1	1
31287	1520	constitutively active cbl mutant	[constitutively active Cbl mutant]	1.5849625007211563	4	1	0	0
31288	1520	analysis of cytosolic extract	[Analysis of cytosolic extracts]	1.5849625007211563	4	1	0	0
31289	1520	bind to this sequence,	[binding to this sequence,]	1.5849625007211563	4	1	0	0
31290	1520	surface domain of tf	[surface domain of TF]	1.5849625007211563	4	2	1	1
31291	1520	T cell non-T cell	[T cells non-T cells]	1.5849625007211563	4	1	0	0
31292	1520	1.5 gram metyrapone met	[1.5 g metyrapone MET]	1.5849625007211563	4	1	0	0
31293	1520	enhancement of glut1 expression	[enhancement of GLUT1 expression]	1.5849625007211563	4	1	0	0
31294	1520	same sequence motif	[same sequence motif]	1.5849625007211563	3	1	0	0
31295	1520	However, combination of OKT3	[However, combination of OKT3]	1.5849625007211563	4	1	0	0
31296	1520	acute hiv infection	[acute HIV infection]	1.5849625007211563	3	1	0	0
31297	1520	mouse th2 d10 cell	[mouse Th2 D10 cells]	1.5849625007211563	4	1	0	0
31298	1520	three other cases.	[three other cases.]	1.5849625007211563	3	1	0	0
31299	1520	finally, by co-transfection experiment	[Finally, by co-transfection experiments]	1.5849625007211563	4	1	0	0
31300	1520	STAT5A -STAT5A homodimer	[STAT5A -STAT5A homodimers]	1.5849625007211563	3	1	0	0
31301	1520	sensitivity of this phosphatase	[sensitivity of this phosphatase]	1.5849625007211563	4	1	0	0
31302	1520	result production of c-Jun	[resulting production of c-Jun]	1.5849625007211563	4	1	0	0
31303	1520	human TAFII 105	[Human TAFII 105]	1.5849625007211563	3	1	0	0
31304	1520	T cell area p50	[T cell areas p50]	1.5849625007211563	4	1	0	0
31305	1520	IL-12R beta 2 chain	[IL-12R beta 2 chain]	1.5849625007211563	4	1	0	0
31306	1520	immunostaining of Bcl-6	[immunostaining of Bcl-6]	1.5849625007211563	3	1	0	0
31307	1520	hiv rna expression	[HIV RNA expression]	1.5849625007211563	3	2	1	1
31308	1520	surfactant protein (sp) a	[surfactant protein (SP) A]	1.5849625007211563	4	1	0	0
31309	1520	increase in intracellular ca2+	[increase in intracellular Ca2+]	1.5849625007211563	4	1	0	0
31310	1520	role regulate expression	[role regulating expression]	1.5849625007211563	3	1	0	0
31311	1520	activate nf-at complex	[activating NF-AT complex]	1.5849625007211563	3	1	0	0
31312	1520	NF-E1 ref 1-3 respectively),	[NF-E1 refs 1-3 respectively),]	1.5849625007211563	4	1	0	0
31313	1520	also camp-responsive element CRE	[also cAMP-responsive elements CRE]	1.5849625007211563	4	1	0	0
31314	1520	constitutive expression of bcl-x(l)	[constitutive expression of Bcl-x(L)]	1.5849625007211563	4	1	0	0
31315	1520	reduction of cn activity	[reduction of CN activity]	1.5849625007211563	4	1	0	0
31316	1520	ec redox environment	[EC redox environment]	1.5849625007211563	3	1	0	0
31317	1520	classical prognostic features:	[classical prognostic features:]	1.5849625007211563	3	1	0	0
31318	1520	cDNA expression library	[cDNA expression library]	1.5849625007211563	3	2	1	1
31319	1520	transcriptional repressor icer	[transcriptional repressor ICER]	1.5849625007211563	3	2	2	2
31320	1520	elucidation of the mechanism	[Elucidation of the mechanism]	1.5849625007211563	4	1	0	0
31321	1520	immunoprecipitated Jak 2	[immunoprecipitated Jak 2]	1.5849625007211563	3	1	0	0
31322	1520	metabolite of SMX	[metabolites of SMX]	1.5849625007211563	3	1	0	0
31323	1520	level of c-myc	[levels of c-Myc]	1.5849625007211563	3	1	0	0
31324	1520	HLA-DQB1 codon 57	[HLA-DQB1 codon 57]	1.5849625007211563	3	1	0	0
31325	1520	Leiomyosarcoma of the vulva	[Leiomyosarcoma of the vulva]	1.5849625007211563	4	1	0	0
31326	1520	such tolerant cell	[such tolerant cells]	1.5849625007211563	3	1	0	0
31327	1520	original al1 virus stock	[original AL1 virus stock]	1.5849625007211563	4	1	0	0
31328	1520	carboxyterminal region of HBxAg	[carboxyterminal region of HBxAg]	1.5849625007211563	4	1	0	0
31329	1520	high affinity aldosterone binding	[High affinity aldosterone binding]	1.5849625007211563	4	1	0	0
31330	1520	endogenous nf-kappab activation	[endogenous NF-kappaB activation]	1.5849625007211563	3	1	0	0
31331	1520	udg on transcriptional activity	[UDG on transcriptional activity]	1.5849625007211563	4	1	0	0
31332	1520	C-terminal cytoplasmic domain	[C-terminal cytoplasmic domain]	1.5849625007211563	3	1	0	0
31333	1520	lectin to blood cell	[lectin to blood cells]	1.5849625007211563	4	2	2	2
31334	1520	nfat -1-mediated beta-galactosidase activity	[NFAT -1-mediated beta-galactosidase activity]	1.5849625007211563	4	1	0	0
31335	1520	replication of live hiv-1	[replication of live HIV-1]	1.5849625007211563	4	1	0	0
31336	1520	use this approach	[Using this approach]	1.5849625007211563	3	1	0	0
31337	1520	Burkitt' lymphoma cell Ramos	[Burkitt's lymphoma cells Ramos]	1.5849625007211563	4	1	0	0
31338	1520	kinetic of egr-1 transcription	[Kinetics of egr-1 transcription]	1.5849625007211563	4	1	0	0
31339	1520	consist of NFAT2	[consisting of NFAT2]	1.5849625007211563	3	1	0	0
31340	1520	action of platelet-activate factor	[actions of platelet-activating factor]	1.5849625007211563	4	1	0	0
31341	1520	repression by Ikaros	[Repression by Ikaros]	1.5849625007211563	3	1	0	0
31342	1520	MHC class protein	[MHC class proteins]	1.5849625007211563	3	2	2	2
31343	1520	pma-) T cell	[PMA-) T cells]	1.5849625007211563	3	1	0	0
31344	1520	binding of hiv-tf1	[Binding of HIV-TF1]	1.5849625007211563	3	1	0	0
31345	1520	cytoplasm of fibroblast	[cytoplasm of fibroblasts]	1.5849625007211563	3	1	0	0
31346	1520	immediate time points.	[immediate time points.]	1.5849625007211563	3	1	0	0
31347	1520	set of lymphokine	[set of lymphokines]	1.5849625007211563	3	1	0	0
31348	1520	role in oncogenesis	[role in oncogenesis]	1.5849625007211563	3	2	2	2
31349	1520	autosomal dominant inheritance	[autosomal dominant inheritance]	1.5849625007211563	3	1	0	0
31350	1520	sequence into luciferase construct	[sequences into luciferase constructs]	1.5849625007211563	4	1	0	0
31351	1520	clearance of secretion	[clearance of secretions]	1.5849625007211563	3	1	0	0
31352	1520	activation rest T cell	[activation resting T cells]	1.5849625007211563	4	1	0	0
31353	1520	element in the exon	[element in the exon]	1.5849625007211563	4	1	0	0
31354	1520	murine macrophage cell line	[murine macrophage cell line]	1.5849625007211563	4	1	0	0
31355	1520	MHC class ii mrna	[MHC class II mRNA]	1.5849625007211563	4	1	0	0
31356	1520	thymic dendritic cell DC	[Thymic dendritic cells DC]	1.5849625007211563	4	1	0	0
31357	1520	active negative regulatory process	[active negative regulatory process]	1.5849625007211563	4	1	0	0
31358	1520	J Immunol Jul 15;153(2):910]	[J Immunol Jul 15;153(2):910]]	1.5849625007211563	4	1	0	0
31359	1520	prior to cytokine treatment	[prior to cytokine treatment]	1.5849625007211563	4	1	0	0
31360	1520	cushingoid feature in patient	[cushingoid features in patients]	1.5849625007211563	4	1	0	0
31361	1520	total, membrane-bound enzyme	[total, membrane-bound enzyme]	1.5849625007211563	3	1	0	0
31362	1520	tuberculosis 1 df, p=.01)	[tuberculosis 1 df, P=.01)]	1.5849625007211563	4	1	0	0
31363	1520	Th1 cell-mediated immune response	[Th1 cell-mediated immune responses]	1.5849625007211563	4	1	0	0
31364	1520	hb24 mrna levels,	[HB24 mRNA levels,]	1.5849625007211563	3	1	0	0
31365	1520	pou domain protein pit-1	[POU domain protein Pit-1]	1.5849625007211563	4	1	0	0
31366	1520	se a potent oncogene,	[se a potent oncogene,]	1.5849625007211563	4	1	0	0
31367	1520	use Ab cross-linking	[using Ab cross-linking]	1.5849625007211563	3	1	0	0
31368	1520	hematopoietic growth factor release	[hematopoietic growth factor release]	1.5849625007211563	4	1	0	0
31369	1520	action of this drugs.	[action of these drugs.]	1.5849625007211563	4	2	1	1
31370	1520	search of b4-2 DNA	[Searching of B4-2 DNA]	1.5849625007211563	4	1	0	0
31371	1520	weak binding site	[weak binding site]	1.5849625007211563	3	1	0	0
31372	1520	N-terminal portion of c/ebp-epsilon	[N-terminal portion of C/EBP-epsilon]	1.5849625007211563	4	1	0	0
31373	1520	E. coli rpo	[E. coli rpoS]	1.5849625007211563	3	2	1	1
31374	1520	Pyrrolidine dithiocarbamate PDTC	[Pyrrolidine dithiocarbamate PDTC]	1.5849625007211563	3	1	0	0
31375	1520	involvement of glial cell	[involvement of glial cells]	1.5849625007211563	4	1	0	0
31376	1520	x-inactivation center (xic)/xist	[X-inactivation center (XIC)/XIST]	1.5849625007211563	3	1	0	0
31377	1520	th1- specific gene expression	[Th1- specific gene expression]	1.5849625007211563	4	1	0	0
31378	1520	GC -insensitive asthma	[GC -insensitive asthma]	1.5849625007211563	3	1	0	0
31379	1520	tax1 -related antigen molecule	[tax1 -related antigen molecules]	1.5849625007211563	4	1	0	0
31380	1520	Wilms' tumor gene wt1	[Wilms' tumor gene WT1]	1.5849625007211563	4	2	1	1
31381	1520	serine /threonine protein phosphorylation	[serine /threonine protein phosphorylation]	1.5849625007211563	4	1	0	0
31382	1520	other enhancer-binding protein	[other enhancer-binding proteins]	1.5849625007211563	3	1	0	0
31383	1520	rac gtp-binding protein	[Rac GTP-binding proteins]	1.5849625007211563	3	1	0	0
31384	1520	peak at 5 min.	[peaking at 5 min.]	1.5849625007211563	4	1	0	0
31385	1520	friend virus (fva cells).	[Friend virus (FVA cells).]	1.5849625007211563	4	1	0	0
31386	1520	promoter deletion study	[Promoter deletion studies]	1.5849625007211563	3	1	0	0
31387	1520	vitro immunization from patient	[vitro immunization from patients]	1.5849625007211563	4	1	0	0
31388	1520	intranasal glucocorticoid at dose	[intranasal glucocorticoids at doses]	1.5849625007211563	4	1	0	0
31389	1520	survival of month	[survival of months]	1.5849625007211563	3	2	2	2
31390	1520	sheep mammary gland tissue	[sheep mammary gland tissue]	1.5849625007211563	4	1	0	0
31391	1520	other regulatory domain	[other regulatory domains]	1.5849625007211563	3	1	0	0
31392	1520	putative binding site	[putative binding sites]	1.5849625007211563	3	2	2	2
31393	1520	follow G-CSF stimulation	[following G-CSF stimulation]	1.5849625007211563	3	2	1	1
31394	1520	evidence of leukaemic change.	[evidence of leukaemic change.]	1.5849625007211563	4	1	0	0
31395	1520	two main goals: (1)	[two main goals: (1)]	1.5849625007211563	4	1	0	0
31396	1520	15 severely depressed patient	[15 severely depressed patients]	1.5849625007211563	4	1	0	0
31397	1520	transcriptional factor necessary	[transcriptional factor necessary]	1.5849625007211563	3	2	2	2
31398	1520	viral rna synthesis	[viral RNA synthesis]	1.5849625007211563	3	1	0	0
31399	1520	proliferation of human lymphocyte	[proliferation of human lymphocytes]	1.5849625007211563	4	2	1	1
31400	1520	activation of NF.kappa b	[activation of NF.kappa B]	1.5849625007211563	4	1	0	0
31401	1520	zinc finger protein sp1	[zinc finger proteins Sp1]	1.5849625007211563	4	1	0	0
31402	1520	inhibitor of proteasome activation	[inhibitors of proteasome activation]	1.5849625007211563	4	1	0	0
31403	1520	DQB reporter construct	[DQB reporter constructs]	1.5849625007211563	3	1	0	0
31404	1520	use Stat3 antibody	[using Stat3 antibodies]	1.5849625007211563	3	1	0	0
31405	1520	direct ebna-2 -pu.1 interaction.	[direct EBNA-2 -PU.1 interaction.]	1.5849625007211563	4	1	0	0
31406	1520	CD28 induction of AP-1	[CD28 induction of AP-1]	1.5849625007211563	4	1	0	0
31407	1520	evidence for the expression	[evidence for the expression]	1.5849625007211563	4	1	0	0
31408	1520	T beta 5 element	[T beta 5 element]	1.5849625007211563	4	1	0	0
31409	1520	block nfat nuclear translocation	[blocking NFAT nuclear translocation]	1.5849625007211563	4	1	0	0
31410	1520	lectin-activated T cell	[lectin-activated T cells]	1.5849625007211563	3	1	0	0
31411	1520	chronic virus replication	[chronic virus replication]	1.5849625007211563	3	1	0	0
31412	1520	transformation of human lymphocyte	[transformation of human lymphocytes]	1.5849625007211563	4	2	1	1
31413	1520	nuclear receptor superfamily,	[nuclear receptor superfamily,]	1.5849625007211563	3	1	0	0
31414	1520	IL-4 receptor il-4r	[IL-4 receptor IL-4R]	1.5849625007211563	3	1	0	0
31415	1520	CD40 a protein	[CD40 a protein]	1.5849625007211563	3	1	0	0
31416	1520	end of this incubation	[end of this incubation]	1.5849625007211563	4	1	0	0
31417	1520	target for antioxidant	[target for antioxidants]	1.5849625007211563	3	1	0	0
31418	1520	cell express the tax	[cells expressing the Tax]	1.5849625007211563	4	1	0	0
31419	1520	defective sexual differentiation	[defective sexual differentiation]	1.5849625007211563	3	1	0	0
31420	1520	role for free radical	[role for free radicals]	1.5849625007211563	4	1	0	0
31421	1520	macrophage-like hl-60 differentiation	[macrophage-like HL-60 differentiation]	1.5849625007211563	3	1	0	0
31422	1520	ip-10 mrna induction	[IP-10 mRNA induction]	1.5849625007211563	3	1	0	0
31423	1520	effect of nm23 protein	[effect of nm23 proteins]	1.5849625007211563	4	1	0	0
31424	1520	protein synthesis of junb	[protein synthesis of JunB]	1.5849625007211563	4	1	0	0
31425	1520	effect on up-regulation	[effect on up-regulation]	1.5849625007211563	3	1	0	0
31426	1520	degree of diabetic nephropathy	[degree of diabetic nephropathy]	1.5849625007211563	4	1	0	0
31427	1520	decline in insulin secretion	[decline in insulin secretion]	1.5849625007211563	4	1	0	0
31428	1520	well, on the regulation	[well, on the regulation]	1.5849625007211563	4	1	0	0
31429	1520	favor glucocorticoid action	[favoring glucocorticoid actions]	1.5849625007211563	3	1	0	0
31430	1520	proximal mouse chromosome	[proximal mouse chromosome]	1.5849625007211563	3	1	0	0
31431	1520	95 breast-cancer sample	[95 breast-cancer samples]	1.5849625007211563	3	1	0	0
31432	1520	Rap1 activation in platelet	[Rap1 activation in platelets]	1.5849625007211563	4	1	0	0
31433	1520	CD3 and/or CD2 protein	[CD3 and/or CD2 proteins]	1.5849625007211563	4	1	0	0
31434	1520	transcription of erythroid-specific gene	[transcription of erythroid-specific genes]	1.5849625007211563	4	1	0	0
31435	1520	T cell-mediated immune response	[T cell-mediated immune response]	1.5849625007211563	4	1	0	0
31436	1520	in-vitro-translated 20-kda protein	[in-vitro-translated 20-kDa protein]	1.5849625007211563	3	1	0	0
31437	1520	interest in malaria research	[interest in malaria research]	1.5849625007211563	4	1	0	0
31438	1520	infection in b cell	[infection in B cells]	1.5849625007211563	4	1	0	0
31439	1520	rest in vitro activation	[rest in vitro activation]	1.5849625007211563	4	1	0	0
31440	1520	treatment with ifn-gamma	[treatment with IFN-gamma]	1.5849625007211563	3	1	0	0
31441	1520	two type of response	[Two types of responses]	1.5849625007211563	4	1	0	0
31442	1520	memory b cell	[memory B cells]	1.5849625007211563	3	3	2	1
31443	1520	result in the induction	[resulting in the induction]	1.5849625007211563	4	2	2	2
31444	1520	activator of p38 mapk	[activator of p38 MAPk]	1.5849625007211563	4	1	0	0
31445	1520	steroid binding domain	[steroid binding domain]	1.5849625007211563	3	2	1	1
31446	1520	response to vzv peptide	[responses to VZV peptides]	1.5849625007211563	4	1	0	0
31447	1520	impairment in the activation	[impairments in the activation]	1.5849625007211563	4	2	1	1
31448	1520	monoclonal antibody (mab) 13b8-2	[monoclonal antibody (MAb) 13B8-2]	1.5849625007211563	4	1	0	0
31449	1520	homogeneous cd4+ cd8+ lymphocyte	[homogeneous CD4+ CD8+ lymphocytes]	1.5849625007211563	4	1	0	0
31450	1520	5' promoter region	[5' promoter region]	1.5849625007211563	3	1	0	0
31451	1520	result in phosphorylation	[resulting in phosphorylation]	1.5849625007211563	3	2	2	2
31452	1520	pi3-k inhibitor wortmannin	[PI3-K inhibitor wortmannin]	1.5849625007211563	3	1	0	0
31453	1520	number of nuclear factor	[number of nuclear factors]	1.5849625007211563	4	1	0	0
31454	1520	subsequent treatment with D3	[subsequent treatment with D3]	1.5849625007211563	4	1	0	0
31455	1520	mutation at different site	[Mutations at different sites]	1.5849625007211563	4	1	0	0
31456	1520	Immunol Jul 15;163(2):1091]	[Immunol Jul 15;163(2):1091]]	1.5849625007211563	3	1	0	0
31457	1520	b lymphocyte b cell	[B lymphocytes B cells]	1.5849625007211563	4	1	0	0
31458	1520	possibility of a syndrome	[possibility of a syndrome]	1.5849625007211563	4	1	0	0
31459	1520	transfection of cell line	[transfection of cell lines]	1.5849625007211563	4	1	0	0
31460	1520	change in agonist binding.	[change in agonist binding.]	1.5849625007211563	4	1	0	0
31461	1520	uncultured leukemic T cell	[uncultured leukemic T cells]	1.5849625007211563	4	1	0	0
31462	1520	induction of ICAM-1	[induction of ICAM-1]	1.5849625007211563	3	1	0	0
31463	1520	CAT enzyme activity	[CAT enzyme activity]	1.5849625007211563	3	2	2	2
31464	1520	lineage specific markers;	[lineage specific markers;]	1.5849625007211563	3	1	0	0
31465	1520	octamer binding transcription factor	[octamer binding transcription factors]	1.5849625007211563	4	1	0	0
31466	1520	Effect similar to gp160	[Effects similar to gp160]	1.5849625007211563	4	1	0	0
31467	1520	directly in cell-free system	[directly in cell-free systems]	1.5849625007211563	4	1	0	0
31468	1520	early time point	[early time points]	1.5849625007211563	3	2	1	1
31469	1520	CD2 receptor stimulation	[CD2 receptor stimulation]	1.5849625007211563	3	1	0	0
31470	1520	family of ap1 factor	[family of AP1 factors]	1.5849625007211563	4	1	0	0
31471	1520	MZF-1 binding site	[MZF-1 binding sites]	1.5849625007211563	3	1	0	0
31472	1520	isoform of histone h4	[isoforms of histone H4]	1.5849625007211563	4	1	0	0
31473	1520	numerous atypical clinical feature	[numerous atypical clinical features]	1.5849625007211563	4	1	0	0
31474	1520	lack of lineage specificity	[lack of lineage specificity]	1.5849625007211563	4	1	0	0
31475	1520	use 20- oligonucleotide probe	[using 20-mer oligonucleotide probes]	1.5849625007211563	4	1	0	0
31476	1520	combination with tnf-alpha	[combination with TNF-alpha]	1.5849625007211563	3	1	0	0
31477	1520	MIP-1 alpha expression	[MIP-1 alpha expression]	1.5849625007211563	3	1	0	0
31478	1520	ebv genome expression	[EBV genome expression]	1.5849625007211563	3	1	0	0
31479	1520	kinetic of differentiation	[kinetics of differentiation]	1.5849625007211563	3	1	0	0
31480	1520	immediate-early locus a,	[immediate-early locus A,]	1.5849625007211563	3	1	0	0
31481	1520	marker for response	[marker for response]	1.5849625007211563	3	1	0	0
31482	1520	interleukin (il)-8 production	[interleukin (IL)-8 production]	1.5849625007211563	3	1	0	0
31483	1520	germline epsilon transcript	[germline epsilon transcripts]	1.5849625007211563	3	1	0	0
31484	1520	subpopulation of small cell	[subpopulation of smaller cells]	1.5849625007211563	4	1	0	0
31485	1520	low blood lactate concentration	[lower blood lactate concentrations]	1.5849625007211563	4	1	0	0
31486	1520	strong, monocyte-specific promoter activity	[strong, monocyte-specific promoter activity]	1.5849625007211563	4	1	0	0
31487	1520	-131/+15 (position -131	[-131/+15 (positions -131]	1.5849625007211563	3	1	0	0
31488	1520	serine residue of stat1	[serine residues of STAT1]	1.5849625007211563	4	1	0	0
31489	1520	th1 cytokine ifn-gamma	[Th1 cytokine IFN-gamma]	1.5849625007211563	3	1	0	0
31490	1520	interleukin 3 factor	[interleukin 3 factor]	1.5849625007211563	3	1	0	0
31491	1520	monocyte line U937	[monocyte line U937]	1.5849625007211563	3	1	0	0
31492	1520	CD14 signal pathway	[CD14 signal pathway]	1.5849625007211563	3	1	0	0
31493	1520	PB1 sequence motif	[PB1 sequence motif]	1.5849625007211563	3	1	0	0
31494	1520	JAK /STAT signal	[JAK /STAT signaling]	1.5849625007211563	3	1	0	0
31495	1520	despite increase evidence	[Despite increasing evidence]	1.5849625007211563	3	1	0	0
31496	1520	transform cbl mutant	[transforming Cbl mutant]	1.5849625007211563	3	1	0	0
31497	1520	vitro with epstein-barr virus	[vitro with Epstein-Barr virus]	1.5849625007211563	4	1	0	0
31498	1520	HTLV-1 transcription follow CD2	[HTLV-1 transcription following CD2]	1.5849625007211563	4	1	0	0
31499	1520	phosphatidic acid dependent signalling	[phosphatidic acid dependent signalling]	1.5849625007211563	4	1	0	0
31500	1520	use 32p-labeled probe	[using 32P-labeled probe]	1.5849625007211563	3	1	0	0
31501	1520	other pro-inflammatory cytokine	[other pro-inflammatory cytokines]	1.5849625007211563	3	1	0	0
31502	1520	Epstein-Barr virus infection	[Epstein-Barr virus infection]	1.5849625007211563	3	2	2	2
31503	1520	effect of G-CSF	[effects of G-CSF]	1.5849625007211563	3	1	0	0
31504	1520	marker for metastatic potential	[marker for metastatic potential]	1.5849625007211563	4	1	0	0
31505	1520	anatomic tumor size	[anatomic tumor size]	1.5849625007211563	3	1	0	0
31506	1520	rabbit beta-globin promoter	[rabbit beta-globin promoter]	1.5849625007211563	3	1	0	0
31507	1520	pc-3 cell line	[PC-3 cell lines]	1.5849625007211563	3	1	0	0
31508	1520	atrophy of the anlage	[atrophy of the anlage]	1.5849625007211563	4	1	0	0
31509	1520	various proliferate hematopoietic cell	[various proliferating hematopoietic cells]	1.5849625007211563	4	1	0	0
31510	1520	patient with Kennedy' disease	[patient with Kennedy's disease]	1.5849625007211563	4	1	0	0
31511	1520	NF-kappa b transcriptional capacity	[NF-kappa B transcriptional capacity]	1.5849625007211563	4	1	0	0
31512	1520	CD30 nf-kappa b activation	[CD30 NF-kappa B activation]	1.5849625007211563	4	1	0	0
31513	1520	transcription activation function	[transcription activation function]	1.5849625007211563	3	1	0	0
31514	1520	set of transcriptional repressor	[set of transcriptional repressors]	1.5849625007211563	4	1	0	0
31515	1520	resultant tnf-alpha production	[resultant TNF-alpha production]	1.5849625007211563	3	1	0	0
31516	1520	human embryonic/fetal hematopoiesis	[human embryonic/fetal hematopoiesis]	1.5849625007211563	3	1	0	0
31517	1520	b cell through CBF1/RBP-Jkappa	[B cells through CBF1/RBP-Jkappa]	1.5849625007211563	4	1	0	0
31518	1520	presence of three alpha-helice	[presence of three alpha-helices]	1.5849625007211563	4	2	2	2
31519	1520	other for 32dcl3 cell	[others for 32Dcl3 cells]	1.5849625007211563	4	1	0	0
31520	1520	presence of medium	[presence of medium]	1.5849625007211563	3	1	0	0
31521	1520	unknown arthrogenic autoantigen	[unknown arthrogenic autoantigen]	1.5849625007211563	3	1	0	0
31522	1520	8 ng/ml il-8	[8 ng/ml IL-8]	1.5849625007211563	3	1	0	0
31523	1520	similar inhibitory effect	[Similar inhibitory effects]	1.5849625007211563	3	2	1	1
31524	1520	mediate interleukin-4-induced tyrosine phosphorylation	[mediating interleukin-4-induced tyrosine phosphorylation]	1.5849625007211563	4	1	0	0
31525	1520	implication for the use	[implications for the use]	1.5849625007211563	4	2	2	2
31526	1520	1,25 alpha-dihydroxycholecalciferol vitd3	[1,25 alpha-dihydroxycholecalciferol VitD3]	1.5849625007211563	3	1	0	0
31527	1520	result in a decrease	[resulting in a decrease]	1.5849625007211563	4	1	0	0
31528	1520	Octamer bind factor	[Octamer binding factors]	1.5849625007211563	3	1	0	0
31529	1520	wild-type DRA promoter	[wild-type DRA promoter]	1.5849625007211563	3	1	0	0
31530	1520	contrast, stat1 protein	[contrast, stat1 proteins]	1.5849625007211563	3	1	0	0
31531	1520	human IL-2 gene	[human IL-2 gene]	1.5849625007211563	3	1	0	0
31532	1520	intracellular signal event	[intracellular signaling events]	1.5849625007211563	3	1	0	0
31533	1520	protein of uncertain function	[protein of uncertain function]	1.5849625007211563	4	1	0	0
31534	1520	very stringent regulation	[very stringent regulation]	1.5849625007211563	3	1	0	0
31535	1520	However, induction of NF-AT	[However, induction of NF-AT]	1.5849625007211563	4	1	0	0
31536	1520	patient with t-cell leukemia	[patients with T-cell leukemia]	1.5849625007211563	4	2	2	2
31537	1520	overexpression of ALY	[Overexpression of ALY]	1.5849625007211563	3	1	0	0
31538	1520	period of time	[period of time]	1.5849625007211563	3	1	0	0
31539	1520	Rel homology family	[Rel homology family]	1.5849625007211563	3	1	0	0
31540	1520	soluble nuclear protein	[soluble nuclear protein]	1.5849625007211563	3	1	0	0
31541	1520	STAT serine kinase	[STAT serine kinase]	1.5849625007211563	3	1	0	0
31542	1520	such as Tx	[such as Tx]	1.5849625007211563	3	1	0	0
31543	1520	upregulation of fas expression	[upregulation of Fas expression]	1.5849625007211563	4	1	0	0
31544	1520	zero- thalassemia patient	[zero- thalassemia patient]	1.5849625007211563	3	2	2	2
31545	1520	postinduction repression in fibroblast	[postinduction repression in fibroblasts]	1.5849625007211563	4	1	0	0
31546	1520	analysis of primary cell	[Analysis of primary cells]	1.5849625007211563	4	1	0	0
31547	1520	tissue-specific expression of pecam-1	[tissue-specific expression of PECAM-1]	1.5849625007211563	4	1	0	0
31548	1520	number of different type	[number of different types]	1.5849625007211563	4	1	0	0
31549	1520	pituitary transcription factor	[pituitary transcription factor]	1.5849625007211563	3	2	2	2
31550	1520	less DNA binding	[less DNA binding]	1.5849625007211563	3	1	0	0
31551	1520	activation domain zebra domain	[activation domain ZEBRA domain]	1.5849625007211563	4	1	0	0
31552	1520	least in the case	[least in the case]	1.5849625007211563	4	1	0	0
31553	1520	extra TaqI restriction site	[extra TaqI restriction site]	1.5849625007211563	4	1	0	0
31554	1520	such as creb	[such as CREB]	1.5849625007211563	3	1	0	0
31555	1520	promoter of this gene,	[promoter of this gene,]	1.5849625007211563	4	1	0	0
31556	1520	contribution of gata-1	[contributions of GATA-1]	1.5849625007211563	3	1	0	0
31557	1520	(ii) a sporadic case	[(ii) a sporadic case]	1.5849625007211563	4	1	0	0
31558	1520	T hut78 cell line	[T HUT78 cell line]	1.5849625007211563	4	1	0	0
31559	1520	pdbu iono stimulation	[PDBu iono stimulation]	1.5849625007211563	3	1	0	0
31560	1520	massive monocyte cell death	[massive monocyte cell death]	1.5849625007211563	4	1	0	0
31561	1520	three RARS patient	[three RARS patients]	1.5849625007211563	3	1	0	0
31562	1520	caprine arthritis-encephalitis virus	[caprine arthritis-encephalitis virus]	1.5849625007211563	3	2	2	2
31563	1520	level of pu.1	[level of PU.1]	1.5849625007211563	3	2	1	1
31564	1520	physiologically relevant stimulation,	[physiologically relevant stimulation,]	1.5849625007211563	3	1	0	0
31565	1520	reactivation of latent hiv-1	[reactivation of latent HIV-1]	1.5849625007211563	4	1	0	0
31566	1520	activation of virus.	[activation of virus.]	1.5849625007211563	3	1	0	0
31567	1520	qualitatively different effect	[Qualitatively different effects]	1.5849625007211563	3	1	0	0
31568	1520	need for pkc stimulation	[need for PKC stimulation]	1.5849625007211563	4	1	0	0
31569	1520	nuclear translocation of protein	[nuclear translocation of proteins]	1.5849625007211563	4	1	0	0
31570	1520	normal human macrophage	[normal human macrophages]	1.5849625007211563	3	2	2	2
31571	1520	soundness of design	[soundness of design]	1.5849625007211563	3	1	0	0
31572	1520	c terminal peptide	[C terminal peptides]	1.5849625007211563	3	1	0	0
31573	1520	segregation of human chromosome	[segregation of human chromosomes]	1.5849625007211563	4	1	0	0
31574	1520	real effect of hormone	[real effect of hormones]	1.5849625007211563	4	1	0	0
31575	1520	protein-dna binding study	[Protein-DNA binding studies]	1.5849625007211563	3	1	0	0
31576	1520	functional Aiolos -binding site	[functional Aiolos -binding sites]	1.5849625007211563	4	1	0	0
31577	1520	upregulation of c-fo	[Upregulation of c-Fos]	1.5849625007211563	3	2	1	1
31578	1520	cell from healthy control	[cells from healthy controls]	1.5849625007211563	4	1	0	0
31579	1520	(27.7 3.6 nmol/l)	[(27.7 3.6 nmol/l)]	1.5849625007211563	3	1	0	0
31580	1520	introduction of site-specific mutation	[introduction of site-specific mutations]	1.5849625007211563	4	1	0	0
31581	1520	many chronic inflammatory disorder	[many chronic inflammatory disorders]	1.5849625007211563	4	1	0	0
31582	1520	calcium -dependent signal	[calcium -dependent signal]	1.5849625007211563	3	2	1	1
31583	1520	hcmv infection of monocyte	[HCMV infection of monocytes]	1.5849625007211563	4	1	0	0
31584	1520	Verdin, J. virol.	[Verdin, J. Virol.]	1.5849625007211563	3	1	0	0
31585	1520	darc gene in individual	[DARC gene in individuals]	1.5849625007211563	4	1	0	0
31586	1520	depend on costimulatory signal	[Depending on costimulatory signals]	1.5849625007211563	4	1	0	0
31587	1520	genistein at <0.5 micromol/L	[genistein at <0.5 micromol/L]	1.5849625007211563	4	1	0	0
31588	1520	jurkat-tag T cell	[Jurkat-TAg T cells]	1.5849625007211563	3	1	0	0
31589	1520	simple way accounting	[simplest way accounting]	1.5849625007211563	3	1	0	0
31590	1520	other Jun family member	[other Jun family members]	1.5849625007211563	4	1	0	0
31591	1520	I basal gene expression	[I basal gene expression]	1.5849625007211563	4	1	0	0
31592	1520	high-level enhancer activity	[high-level enhancer activity]	1.5849625007211563	3	1	0	0
31593	1520	potent immunosuppressive activity	[potent immunosuppressive activity]	1.5849625007211563	3	2	2	2
31594	1520	NF-kappaB/ IkappaB system	[NF-kappaB/ IkappaB system]	1.5849625007211563	3	1	0	0
31595	1520	cd8(+)-t-cell response to cytomegalovirus	[CD8(+)-T-cell response to cytomegalovirus]	1.5849625007211563	4	1	0	0
31596	1520	201-bp core promoter region	[201-bp core promoter region]	1.5849625007211563	4	1	0	0
31597	1520	down-regulation in patient	[down-regulation in patients]	1.5849625007211563	3	2	2	2
31598	1520	proximal il-2 promoter-enhancer	[proximal IL-2 promoter-enhancer]	1.5849625007211563	3	1	0	0
31599	1520	blot analysis of rna	[blot analysis of RNA]	1.5849625007211563	4	2	2	2
31600	1520	enhancement of the transcription	[enhancement of the transcription]	1.5849625007211563	4	1	0	0
31601	1520	CD28 co-receptor molecule	[CD28 co-receptor molecules]	1.5849625007211563	3	1	0	0
31602	1520	activation of target gene	[activation of target genes]	1.5849625007211563	4	1	0	0
31603	1520	addition of IL-10	[addition of IL-10]	1.5849625007211563	3	1	0	0
31604	1520	Rel/ NF-kappaB transcription factor	[Rel/ NF-kappaB transcription factors]	1.5849625007211563	4	1	0	0
31605	1520	putative human il-2re	[putative human IL-2rE]	1.5849625007211563	3	1	0	0
31606	1520	single viral immediate-early protein	[single viral immediate-early protein]	1.5849625007211563	4	1	0	0
31607	1520	dna-bound multi-protein complex	[DNA-bound multi-protein complexes]	1.5849625007211563	3	1	0	0
31608	1520	Pan/ e2a protein	[Pan/ E2A proteins]	1.5849625007211563	3	2	1	1
31609	1520	expression of Spi-1 gene	[expression of Spi-1 genes]	1.5849625007211563	4	1	0	0
31610	1520	level of c-jun	[levels of c-jun]	1.5849625007211563	3	2	1	1
31611	1520	phosphorylation of serine 186	[phosphorylation of serine 186]	1.5849625007211563	4	1	0	0
31612	1520	T cell to calcineurin	[T cells to calcineurin]	1.5849625007211563	4	1	0	0
31613	1520	eosinophil-committed hl-60-c15 cell	[eosinophil-committed HL-60-C15 cells]	1.5849625007211563	3	2	1	1
31614	1520	transcription factor ap-1;	[transcription factor AP-1;]	1.5849625007211563	3	1	0	0
31615	1520	two complementary dna	[Two complementary DNAs]	1.5849625007211563	3	1	0	0
31616	1520	pattern of ets protein	[pattern of Ets proteins]	1.5849625007211563	4	1	0	0
31617	1520	-150 proximal ap-1 site	[-150 proximal AP-1 site]	1.5849625007211563	4	1	0	0
31618	1520	IL-5 promoter activation	[IL-5 promoter activation]	1.5849625007211563	3	2	2	2
31619	1520	human t-cell lymphotropic virus	[Human T-cell lymphotropic virus]	1.5849625007211563	4	1	0	0
31620	1520	response to il-2 stimulation	[response to IL-2 stimulation]	1.5849625007211563	4	1	0	0
31621	1520	expression of no synthase	[expression of NO synthase]	1.5849625007211563	4	1	0	0
31622	1520	monocyte in a time-	[monocytes in a time-]	1.5849625007211563	4	1	0	0
31623	1520	map kinase pathway,	[MAP kinase pathway,]	1.5849625007211563	3	1	0	0
31624	1520	use a polyclonal antibody	[Using a polyclonal antibody]	1.5849625007211563	4	1	0	0
31625	1520	CBF alpha subunit	[CBF alpha subunit]	1.5849625007211563	3	2	1	1
31626	1520	sample from one	[sample from one]	1.5849625007211563	3	1	0	0
31627	1520	nuclear factor kappab activity	[nuclear factor kappaB activity]	1.5849625007211563	4	1	0	0
31628	1520	immunoregulatory multipotential cytokine	[immunoregulatory multipotential cytokine]	1.5849625007211563	3	1	0	0
31629	1520	cellular gene regulatory mechanism	[cellular gene regulatory mechanisms]	1.5849625007211563	4	1	0	0
31630	1520	v-Abl differentiation arrest	[v-Abl differentiation arrest]	1.5849625007211563	3	1	0	0
31631	1520	bhlh transcription factor	[bHLH transcription factor]	1.5849625007211563	3	1	0	0
31632	1520	development of disease	[development of disease.]	1.5849625007211563	3	2	1	1
31633	1520	development of monocyte	[development of monocytes]	1.5849625007211563	3	1	0	0
31634	1520	contrast to the increase	[contrast to the increase]	1.5849625007211563	4	2	1	1
31635	1520	series of B-cell mutant	[series of B-cell mutants]	1.5849625007211563	4	1	0	0
31636	1520	j(2) 15d-PGJ(2) Wyeth 14643	[J(2) 15d-PGJ(2) Wyeth 14643]	1.5849625007211563	4	1	0	0
31637	1520	overexpression of fetal hemoglobin	[overexpression of fetal hemoglobin]	1.5849625007211563	4	1	0	0
31638	1520	susceptibility to infection	[susceptibility to infections]	1.5849625007211563	3	2	2	2
31639	1520	culture of cell	[cultures of cells]	1.5849625007211563	3	2	2	2
31640	1520	include the E74 site	[including the E74 site]	1.5849625007211563	4	1	0	0
31641	1520	ikb alpha phosphorylation	[IkB alpha phosphorylation]	1.5849625007211563	3	2	1	1
31642	1520	adult chronic bronchiti	[adult chronic bronchitis]	1.5849625007211563	3	1	0	0
31643	1520	important regulatory molecule	[important regulatory molecules]	1.5849625007211563	3	1	0	0
31644	1520	leukemia-associated fusion protein aml1/mds1/evi1	[leukemia-associated fusion protein AML1/MDS1/EVI1]	1.5849625007211563	4	1	0	0
31645	1520	basal gene expression	[basal gene expression]	1.5849625007211563	3	1	0	0
31646	1520	octamer site -dependent manner	[octamer site -dependent manner]	1.5849625007211563	4	1	0	0
31647	1520	calcineurin x-ray crystal structure	[calcineurin X-ray crystal structure]	1.5849625007211563	4	1	0	0
31648	1520	(i.e. 12 month	[(i.e. 12 months]	1.5849625007211563	3	1	0	0
31649	1520	clonal eosinophilia in IHES	[clonal eosinophilia in IHES]	1.5849625007211563	4	1	0	0
31650	1520	low molecular nuclear protein	[low molecular nuclear proteins]	1.5849625007211563	4	1	0	0
31651	1520	polymerase chain reaction methodology	[polymerase chain reaction methodology]	1.5849625007211563	4	1	0	0
31652	1520	627-bp full-length promoter fragment	[627-bp full-length promoter fragment]	1.5849625007211563	4	1	0	0
31653	1520	only C/EBP family member	[only C/EBP family member]	1.5849625007211563	4	1	0	0
31654	1520	patient with t(8;21) aml	[patients with t(8;21) AML]	1.5849625007211563	4	2	1	1
31655	1520	level of signaling,	[level of signaling,]	1.5849625007211563	3	1	0	0
31656	1520	DNA binding site.	[DNA binding site.]	1.5849625007211563	3	1	0	0
31657	1520	release of superoxide anion	[release of superoxide anions]	1.5849625007211563	4	1	0	0
31658	1520	tf mrna expression	[TF mRNA expression]	1.5849625007211563	3	2	1	1
31659	1520	inflammation include interleukin-1 il-1	[inflammation including interleukin-1 IL-1]	1.5849625007211563	4	1	0	0
31660	1520	kappa b -like activity	[kappa B -like activity]	1.5849625007211563	4	1	0	0
31661	1520	several cell growth-related gene	[several cell growth-related genes]	1.5849625007211563	4	1	0	0
31662	1520	absence of sensitivity	[absence of sensitivity]	1.5849625007211563	3	1	0	0
31663	1520	transcription of different gene	[transcription of different genes]	1.5849625007211563	4	1	0	0
31664	1520	different mechanism of action.	[different mechanisms of action.]	1.5849625007211563	4	1	0	0
31665	1520	myelomonocytic lineage-specific expression	[myelomonocytic lineage-specific expression]	1.5849625007211563	3	1	0	0
31666	1520	relatively simple procedure.	[relatively simple procedure.]	1.5849625007211563	3	1	0	0
31667	1520	arterial endothelial cell ec	[arterial endothelial cells EC]	1.5849625007211563	4	1	0	0
31668	1520	role of Stat6	[role of Stat6]	1.5849625007211563	3	1	0	0
31669	1520	anti- CD28 monoclonal antibody	[anti- CD28 monoclonal antibody]	1.5849625007211563	4	1	0	0
31670	1520	fetal liver library	[fetal liver library]	1.5849625007211563	3	1	0	0
31671	1520	human glucocorticoid receptor gr	[human glucocorticoid receptor GR]	1.5849625007211563	4	1	0	0
31672	1520	existence of a pathway	[existence of a pathway]	1.5849625007211563	4	1	0	0
31673	1520	development of the cell	[development of the cells]	1.5849625007211563	4	1	0	0
31674	1520	b transcription factor Oct-2	[B transcription factor Oct-2]	1.5849625007211563	4	1	0	0
31675	1520	germline promoter Ko	[germline promoters Ko]	1.5849625007211563	3	1	0	0
31676	1520	basic helix-loop-helix-zipper protein	[basic helix-loop-helix-zipper proteins]	1.5849625007211563	3	1	0	0
31677	1520	il-2 -dependent proliferation	[IL-2 -dependent proliferation]	1.5849625007211563	3	1	0	0
31678	1520	two ebv transactivator BZLF1	[two EBV transactivators BZLF1]	1.5849625007211563	4	1	0	0
31679	1520	kinase 1/2 ERK1/2	[kinase 1/2 ERK1/2]	1.5849625007211563	3	1	0	0
31680	1520	background: Growing evidence	[BACKGROUND: Growing evidence]	1.5849625007211563	3	1	0	0
31681	1520	potential transcriptional activation element	[potential transcriptional activation elements]	1.5849625007211563	4	1	0	0
31682	1520	dmdtc T cell	[DMDTC T cells]	1.5849625007211563	3	1	0	0
31683	1520	IL-4 -dependent activation	[IL-4 -dependent activation]	1.5849625007211563	3	2	1	1
31684	1520	natural ligand CD80	[natural ligand CD80]	1.5849625007211563	3	1	0	0
31685	1520	differentiation/maturation process of monocyte	[differentiation/maturation process of monocytes]	1.5849625007211563	4	1	0	0
31686	1520	human delta-globin-encoding gene	[human delta-globin-encoding gene]	1.5849625007211563	3	2	1	1
31687	1520	activation of pka	[activation of PKA]	1.5849625007211563	3	1	0	0
31688	1520	such as multi-organ failure	[such as multi-organ failure]	1.5849625007211563	4	1	0	0
31689	1520	cell surface protein expression	[cell surface protein expression]	1.5849625007211563	4	1	0	0
31690	1520	human NKL cell line	[human NKL cell line]	1.5849625007211563	4	1	0	0
31691	1520	resting state g0	[resting state G0]	1.5849625007211563	3	1	0	0
31692	1520	tolerance to lps	[tolerance to LPS]	1.5849625007211563	3	1	0	0
31693	1520	mrna from exon	[mRNA from exon]	1.5849625007211563	3	1	0	0
31694	1520	isoleucine for valine substitution	[isoleucine for valine substitution]	1.5849625007211563	4	1	0	0
31695	1520	SNE SRF/NFkappaB-like element	[SNE SRF/NFkappaB-like element]	1.5849625007211563	3	1	0	0
31696	1520	interleukin-2 receptor-alpha gene	[interleukin-2 receptor-alpha gene]	1.5849625007211563	3	1	0	0
31697	1520	murine kappa light	[murine kappa light]	1.5849625007211563	3	1	0	0
31698	1520	minimum essential core region	[minimum essential core regions]	1.5849625007211563	4	1	0	0
31699	1520	prior to treatment	[prior to treatment]	1.5849625007211563	3	2	2	2
31700	1520	dna-binding activity of NFAT	[DNA-binding activity of NFAT]	1.5849625007211563	4	1	0	0
31701	1520	potent anti-inflammatory agent	[potent anti-inflammatory agents]	1.5849625007211563	3	2	1	1
31702	1520	six healthy man	[six healthy men]	1.5849625007211563	3	1	0	0
31703	1520	mechanical type of stress.	[mechanical types of stress.]	1.5849625007211563	4	1	0	0
31704	1520	13.3 mg/24h; 1.4+/-0.8)	[13.3 mg/24h; 1.4+/-0.8)]	1.5849625007211563	3	1	0	0
31705	1520	cross-link with immune complex	[Cross-linking with immune complexes]	1.5849625007211563	4	2	1	1
31706	1520	Epstein-Barr virus BcLF1	[Epstein-Barr virus BcLF1]	1.5849625007211563	3	1	0	0
31707	1520	mutant form of Rev	[mutant forms of Rev]	1.5849625007211563	4	1	0	0
31708	1520	cd8+ t-lymphocyte from patient	[CD8+ T-lymphocytes from patients]	1.5849625007211563	4	1	0	0
31709	1520	fas ligand (fasL) promoter	[Fas ligand (fasL) promoter]	1.5849625007211563	4	1	0	0
31710	1520	protein synthesis inhibitor anisomycin	[protein synthesis inhibitor anisomycin]	1.5849625007211563	4	1	0	0
31711	1520	TNF mrna expression	[TNF mRNA expression]	1.5849625007211563	3	1	0	0
31712	1520	absence of of JAK3	[absence of of JAK3]	1.5849625007211563	4	1	0	0
31713	1520	externalization of phosphatidylserine	[externalization of phosphatidylserine]	1.5849625007211563	3	1	0	0
31714	1520	hence create responder	[hence creating responders]	1.5849625007211563	3	1	0	0
31715	1520	double mutation ap-1(iii)/ ap3-l	[double mutation AP-1(III)/ AP3-L]	1.5849625007211563	4	1	0	0
31716	1520	stimulation of t-cell	[Stimulation of T-cells]	1.5849625007211563	3	2	2	2
31717	1520	classical negative feedback loop	[classical negative feedback loop]	1.5849625007211563	4	1	0	0
31718	1520	similar DNA control element	[similar DNA control elements]	1.5849625007211563	4	1	0	0
31719	1520	response to Ox LDL	[response to Ox LDL]	1.5849625007211563	4	1	0	0
31720	1520	follow T cell stimulation	[following T cell stimulation]	1.5849625007211563	4	1	0	0
31721	1520	inducible proximal enhancer	[inducible proximal enhancer]	1.5849625007211563	3	1	0	0
31722	1520	effective indicator of prognosis	[effective indicator of prognosis]	1.5849625007211563	4	1	0	0
31723	1520	little inhibitory effect	[little inhibitory effect]	1.5849625007211563	3	1	0	0
31724	1520	low gssg level	[low GSSG levels]	1.5849625007211563	3	1	0	0
31725	1520	murine human p40 gene	[murine human p40 genes]	1.5849625007211563	4	1	0	0
31726	1520	C delta exon	[C delta exon]	1.5849625007211563	3	2	2	2
31727	1520	intracytoplasmic signalling cascade	[intracytoplasmic signalling cascade]	1.5849625007211563	3	1	0	0
31728	1520	thyroid hormone th action	[thyroid hormone TH action]	1.5849625007211563	4	1	0	0
31729	1520	NF-kappa b consensus site	[NF-kappa B consensus sites]	1.5849625007211563	4	1	0	0
31730	1520	chronic lymphocytic leukaemia CLL	[chronic lymphocytic leukaemia CLL]	1.5849625007211563	4	1	0	0
31731	1520	vitro from hematopoietic cell	[vitro from hematopoietic cells]	1.5849625007211563	4	1	0	0
31732	1520	GH-N gene transcript	[GH-N gene transcripts]	1.5849625007211563	3	1	0	0
31733	1520	group iii ebv genome	[group III EBV genome]	1.5849625007211563	4	1	0	0
31734	1520	contain 5 copy	[containing 5 copies]	1.5849625007211563	3	1	0	0
31735	1520	include the d1/cdr3-loop	[including the D1/CDR3-loop]	1.5849625007211563	3	1	0	0
31736	1520	adrenocorticotropin in blood	[adrenocorticotropin in blood]	1.5849625007211563	3	1	0	0
31737	1520	transactivate ability through NF-kappaB	[transactivating ability through NF-kappaB]	1.5849625007211563	4	1	0	0
31738	1520	binding site per nucleus	[binding sites per nucleus]	1.5849625007211563	4	2	2	2
31739	1520	binding to this element.	[binding to this element.]	1.5849625007211563	4	1	0	0
31740	1520	natural gc of hsv-2	[natural gC of HSV-2]	1.5849625007211563	4	1	0	0
31741	1520	active nf-kappab formation	[active NF-kappaB formation]	1.5849625007211563	3	1	0	0
31742	1520	two different cell types.	[two different cell types.]	1.5849625007211563	4	1	0	0
31743	1520	one such element	[one such element]	1.5849625007211563	3	1	0	0
31744	1520	binding to NF-E2	[binding to NF-E2]	1.5849625007211563	3	1	0	0
31745	1520	human interleukin-7 receptor complex	[human interleukin-7 receptor complex]	1.5849625007211563	4	1	0	0
31746	1520	tax mutant iexc29	[Tax mutant IEXC29S]	1.5849625007211563	3	1	0	0
31747	1520	coamplification of VDR cDNA	[coamplification of VDR cDNA]	1.5849625007211563	4	1	0	0
31748	1520	tfiih from cell	[TFIIH from cells]	1.5849625007211563	3	1	0	0
31749	1520	intracellular substrate in	[intracellular substrates in]	1.5849625007211563	3	1	0	0
31750	1520	follow CD30 engagement	[following CD30 engagement]	1.5849625007211563	3	1	0	0
31751	1520	level of SRF	[levels of SRF]	1.5849625007211563	3	1	0	0
31752	1520	trans-factor to the cd28re	[trans-factors to the CD28RE]	1.5849625007211563	4	1	0	0
31753	1520	three distinct groups.	[three distinct groups.]	1.5849625007211563	3	1	0	0
31754	1520	alpha isoform of ppar	[alpha isoform of PPAR]	1.5849625007211563	4	1	0	0
31755	1520	potential for a interplay	[potential for an interplay]	1.5849625007211563	4	1	0	0
31756	1520	v-erb a oncoprotein	[v-erb A oncoprotein]	1.5849625007211563	3	1	0	0
31757	1520	c-Jun N-terminal kinase JNK	[c-Jun N-terminal kinase JNK]	1.5849625007211563	4	1	0	0
31758	1520	severe malaria [see comments]	[severe malaria [see comments]]	1.5849625007211563	4	1	0	0
31759	1520	important therapeutic benefit	[important therapeutic benefits]	1.5849625007211563	3	1	0	0
31760	1520	hypothesis a activation structure	[hypothesis an activation structure]	1.5849625007211563	4	1	0	0
31761	1520	130-kd protein (s)	[130-kD protein (s)]	1.5849625007211563	3	1	0	0
31762	1520	campomelic dysplasia cmpd1	[Campomelic dysplasia CMPD1]	1.5849625007211563	3	1	0	0
31763	1520	contain E2F binding site	[containing E2F binding site]	1.5849625007211563	4	2	1	1
31764	1520	stimulation with phytohemagglutinin	[stimulation with phytohemagglutinin]	1.5849625007211563	3	1	0	0
31765	1520	suppression of calcineurin activation	[suppression of calcineurin activation]	1.5849625007211563	4	1	0	0
31766	1520	consequence of effect	[consequence of effect]	1.5849625007211563	3	1	0	0
31767	1520	hiv-1 iiib-infected monocytoid cell	[HIV-1 IIIB-infected monocytoid cells]	1.5849625007211563	4	1	0	0
31768	1520	human thp-1 monocytic cell	[human THP-1 monocytic cells]	1.5849625007211563	4	1	0	0
31769	1520	glucocorticoid receptor mrna	[glucocorticoid receptor mRNA]	1.5849625007211563	3	2	1	1
31770	1520	Caspase-3 activation usually result	[Caspase-3 activation usually resulting]	1.5849625007211563	4	1	0	0
31771	1520	uv-irradiated Jurkat cell	[UV-irradiated Jurkat cells]	1.5849625007211563	3	1	0	0
31772	1520	critical control point	[critical control point]	1.5849625007211563	3	2	1	1
31773	1520	more mature monocyte/macrophage-like cell	[more mature monocyte/macrophage-like cells]	1.5849625007211563	4	1	0	0
31774	1520	tyrosine phosphatase inhibitor	[tyrosine phosphatase inhibitor]	1.5849625007211563	3	2	1	1
31775	1520	C. pneumoniae endothelial cell	[C. pneumoniae endothelial cells]	1.5849625007211563	4	1	0	0
31776	1520	spleen of wild-type mouse	[spleens of wild-type mice]	1.5849625007211563	4	1	0	0
31777	1520	effect on transcriptional regulation	[effect on transcriptional regulation]	1.5849625007211563	4	2	1	1
31778	1520	class ii gene transactivator	[class II gene transactivator]	1.5849625007211563	4	1	0	0
31779	1520	peripheral resistance to glucocorticoid	[peripheral resistance to glucocorticoids]	1.5849625007211563	4	2	1	1
31780	1520	patient with glucocorticoid resistance	[patient with glucocorticoid resistance]	1.5849625007211563	4	2	2	2
31781	1520	tyrosine phosphorylation status	[tyrosine phosphorylation status]	1.5849625007211563	3	2	1	1
31782	1520	asm promoter activity	[ASM promoter activity]	1.5849625007211563	3	1	0	0
31783	1520	fcr mapk activation	[FcR MAPK activation]	1.5849625007211563	3	1	0	0
31784	1520	application for diagnosis	[application for diagnosis]	1.5849625007211563	3	1	0	0
31785	1520	degradation of inhibitor	[degradation of inhibitor]	1.5849625007211563	3	2	2	2
31786	1520	expression of apoptosis protein	[expression of apoptosis proteins]	1.5849625007211563	4	1	0	0
31787	1520	action of thyroid hormone	[action of thyroid hormone]	1.5849625007211563	4	1	0	0
31788	1520	Ca2+ ]i rise	[Ca2+ ]i rise]	1.5849625007211563	3	2	1	1
31789	1520	macrophage scavenger receptor SR	[macrophage scavenger receptor SR]	1.5849625007211563	4	1	0	0
31790	1520	surround cellular background,	[surrounding cellular background,]	1.5849625007211563	3	1	0	0
31791	1520	IL-1/ il-1ra system	[IL-1/ IL-1ra system]	1.5849625007211563	3	1	0	0
31792	1520	independent signal distinct	[independent signal distinct]	1.5849625007211563	3	1	0	0
31793	1520	double-stranded RNA -dependent manner	[double-stranded RNA -dependent manner]	1.5849625007211563	4	1	0	0
31794	1520	only target cell	[Only target cells]	1.5849625007211563	3	1	0	0
31795	1520	nuclear protooncogene c-fo	[nuclear protooncogenes c-fos]	1.5849625007211563	3	1	0	0
31796	1520	presence of the protein	[presence of the proteins]	1.5849625007211563	4	1	0	0
31797	1520	intrinsic kinase domain	[intrinsic kinase domain]	1.5849625007211563	3	1	0	0
31798	1520	NF-kappaB inhibitory molecule IkappaBalpha	[NF-kappaB inhibitory molecule IkappaBalpha]	1.5849625007211563	4	1	0	0
31799	1520	inhibitory effect of NAC	[inhibitory effects of NAC]	1.5849625007211563	4	1	0	0
31800	1520	explain satisfactorily how	[explaining satisfactorily how]	1.5849625007211563	3	1	0	0
31801	1520	heat shock on HSF1	[heat shock on HSF1]	1.5849625007211563	4	1	0	0
31802	1520	lymphokine-activated killer (lak) cell	[lymphokine-activated killer (LAK) cells]	1.5849625007211563	4	1	0	0
31803	1520	12-o-tetradecanoylphorbol-13-acetate tpa a activator	[12-O-tetradecanoylphorbol-13-acetate TPA an activator]	1.5849625007211563	4	1	0	0
31804	1520	inhibition of LTR activation	[inhibition of LTR activation]	1.5849625007211563	4	2	1	1
31805	1520	TNF alpha gene promoter	[TNF alpha gene promoter]	1.5849625007211563	4	1	0	0
31806	1520	pathogenesis of this infection	[pathogenesis of this infection]	1.5849625007211563	4	1	0	0
31807	1520	target for protein	[target for proteins]	1.5849625007211563	3	2	2	2
31808	1520	split the HS2 enhancer	[Splitting the HS2 enhancer]	1.5849625007211563	4	1	0	0
31809	1520	HTLV-I leukemic t-cell line	[HTLV-I leukemic T-cell lines]	1.5849625007211563	4	1	0	0
31810	1520	proliferative activity of tumor	[proliferative activity of tumors]	1.5849625007211563	4	1	0	0
31811	1520	inhibitor of pld activation,	[inhibitor of PLD activation,]	1.5849625007211563	4	1	0	0
31812	1520	calmodulin antagonist compound r24571	[Calmodulin antagonists compound R24571]	1.5849625007211563	4	1	0	0
31813	1520	reporter plasmid code	[reporter plasmids coding]	1.5849625007211563	3	1	0	0
31814	1520	growth of bfu-e response	[growth of BFU-E response]	1.5849625007211563	4	1	0	0
31815	1520	negative regulator of transcription.	[negative regulator of transcription.]	1.5849625007211563	4	1	0	0
31816	1520	negative regulator of transcription,	[negative regulator of transcription,]	1.5849625007211563	4	1	0	0
31817	1520	granulocyte colony-stimulating factor receptor	[granulocyte colony-stimulating factor receptor]	1.5849625007211563	4	2	2	2
31818	1520	antigen-presenting cell (apc) morphology	[antigen-presenting cell (APC) morphology]	1.5849625007211563	4	1	0	0
31819	1520	drain lymph node	[draining lymph nodes]	1.5849625007211563	3	1	0	0
31820	1520	maximal induction by stimulation	[maximal induction by stimulation]	1.5849625007211563	4	1	0	0
31821	1520	human interleukin-2 receptor	[human interleukin-2 receptor]	1.5849625007211563	3	2	1	1
31822	1520	response to this antigen	[response to these antigens]	1.5849625007211563	4	1	0	0
31823	1520	effect of C. sub.	[effect of C. Sub.]	1.5849625007211563	4	2	2	2
31824	1520	number of gene necessary	[number of genes necessary]	1.5849625007211563	4	1	0	0
31825	1520	surface of blood cell	[surface of blood cells]	1.5849625007211563	4	1	0	0
31826	1520	TNF lps increase	[TNF LPS increases]	1.5849625007211563	3	1	0	0
31827	1520	clustering of e-selectin	[clustering of E-selectin]	1.5849625007211563	3	1	0	0
31828	1520	19 patient with gd	[19 patients with GD]	1.5849625007211563	4	1	0	0
31829	1520	HLA class ii	[HLA class II]	1.5849625007211563	3	2	2	2
31830	1520	stimulus-induced kappab -dependent transcription	[stimulus-induced kappaB -dependent transcription]	1.5849625007211563	4	1	0	0
31831	1520	protein kinase erk2	[protein kinase Erk2]	1.5849625007211563	3	1	0	0
31832	1520	er positive monocyte	[ER positive monocytes]	1.5849625007211563	3	1	0	0
31833	1520	ig chain synthesis	[Ig chain synthesis]	1.5849625007211563	3	1	0	0
31834	1520	amino-terminal portion of Oct2	[amino-terminal portion of Oct2]	1.5849625007211563	4	1	0	0
31835	1520	also a second factor	[also a second factor]	1.5849625007211563	4	1	0	0
31836	1520	TNF alpha production	[TNF alpha production]	1.5849625007211563	3	1	0	0
31837	1520	other developmental processes.	[other developmental processes.]	1.5849625007211563	3	1	0	0
31838	1520	binding to NF-AT	[binding to NF-AT]	1.5849625007211563	3	1	0	0
31839	1520	overexpression of slap-130	[overexpression of SLAP-130]	1.5849625007211563	3	1	0	0
31840	1520	effect on LMP1 expression	[effect on LMP1 expression]	1.5849625007211563	4	1	0	0
31841	1520	type ii Mo	[type II Mo]	1.5849625007211563	3	1	0	0
31842	1520	dna-binding activity lef1/bcf1	[DNA-binding activity LEF1/BCF1]	1.5849625007211563	3	1	0	0
31843	1520	normal lymphoid development	[normal lymphoid development]	1.5849625007211563	3	2	1	1
31844	1520	gene expression of Ramos	[gene expression of Ramos]	1.5849625007211563	4	1	0	0
31845	1520	absence of antigenic challenge	[absence of antigenic challenge]	1.5849625007211563	4	1	0	0
31846	1520	3BP2 sh2 domain	[3BP2 SH2 domain]	1.5849625007211563	3	1	0	0
31847	1520	one unusual feature	[one unusual feature]	1.5849625007211563	3	1	0	0
31848	1520	lck -negative jcam1 cell	[Lck -negative JCaM1 cells]	1.5849625007211563	4	1	0	0
31849	1520	trigger of complement receptor	[triggering of complement receptors]	1.5849625007211563	4	2	1	1
31850	1520	t-cell developmental pathway	[T-cell developmental pathway]	1.5849625007211563	3	1	0	0
31851	1520	primary ovarian carcinoma	[primary ovarian carcinoma]	1.5849625007211563	3	1	0	0
31852	1520	kB-like proto-enhancer element	[kB-like proto-enhancer element]	1.5849625007211563	3	1	0	0
31853	1520	effect on the vitality	[effects on the vitality]	1.5849625007211563	4	1	0	0
31854	1520	late phase response	[late phase response]	1.5849625007211563	3	1	0	0
31855	1520	addition of antisense oligomer	[addition of antisense oligomers]	1.5849625007211563	4	1	0	0
31856	1520	rat cerulein pancreatitis	[rat cerulein pancreatitis]	1.5849625007211563	3	2	1	1
31857	1520	embryonic-fetal liver FL	[embryonic-fetal liver FL]	1.5849625007211563	3	1	0	0
31858	1520	thus of clinical significance.	[thus of clinical significance.]	1.5849625007211563	4	1	0	0
31859	1520	ige class switch	[IgE class switching]	1.5849625007211563	3	2	1	1
31860	1520	role of bcl-6	[role of BCL-6]	1.5849625007211563	3	1	0	0
31861	1520	cell from TNFRp55-/-mutant mouse	[Cells from TNFRp55-/-mutant mice]	1.5849625007211563	4	1	0	0
31862	1520	hour to day	[hours to days,]	1.5849625007211563	3	1	0	0
31863	1520	chromosomal translocation involve 3q27	[chromosomal translocation involving 3q27]	1.5849625007211563	4	1	0	0
31864	1520	19-bp binding site	[19-bp binding site]	1.5849625007211563	3	1	0	0
31865	1520	ccaat motif present	[CCAAT motif present]	1.5849625007211563	3	1	0	0
31866	1520	tumor cell apoptosis	[tumor cell apoptosis]	1.5849625007211563	3	1	0	0
31867	1520	neutrophil anti-microbial function	[neutrophil anti-microbial functions]	1.5849625007211563	3	1	0	0
31868	1520	membrane protein gene similar	[membrane protein gene similar]	1.5849625007211563	4	1	0	0
31869	1520	subsequent cellular response	[subsequent cellular responses]	1.5849625007211563	3	1	0	0
31870	1520	also non-genomic effect	[also non-genomic effects]	1.5849625007211563	3	2	2	2
31871	1520	mutation of this element	[Mutation of these elements]	1.5849625007211563	4	1	0	0
31872	1520	establishment of a population	[establishment of a population]	1.5849625007211563	4	1	0	0
31873	1520	control cell from adults.	[control cells from adults.]	1.5849625007211563	4	1	0	0
31874	1520	activation of jak	[activation of JAKs]	1.5849625007211563	3	1	0	0
31875	1520	other thiol compound	[other thiol compounds]	1.5849625007211563	3	1	0	0
31876	1520	surprisingly complex structure	[surprisingly complex structure]	1.5849625007211563	3	1	0	0
31877	1520	gc receptor-binding abnormality	[GC receptor-binding abnormality]	1.5849625007211563	3	1	0	0
31878	1520	etiology of autoimmunity	[etiology of autoimmunity]	1.5849625007211563	3	1	0	0
31879	1520	iron storage, transcriptional regulation	[iron storage, transcriptional regulation]	1.5849625007211563	4	1	0	0
31880	1520	two T cell subclone	[two T cell subclones]	1.5849625007211563	4	1	0	0
31881	1520	three ankyrin repeat	[three ankyrin repeats]	1.5849625007211563	3	1	0	0
31882	1520	shc adaptor protein	[Shc adaptor protein]	1.5849625007211563	3	1	0	0
31883	1520	tissue-specific primary transcriptional response	[tissue-specific primary transcriptional response]	1.5849625007211563	4	1	0	0
31884	1520	tissue inhibitor of metalloproteinases-1	[tissue inhibitor of metalloproteinases-1]	1.5849625007211563	4	1	0	0
31885	1520	lectin to the CD3	[lectin to the CD3]	1.5849625007211563	4	1	0	0
31886	1520	study of various diseases,	[study of various diseases,]	1.5849625007211563	4	1	0	0
31887	1520	constitutive active version	[constitutive active version]	1.5849625007211563	3	2	2	2
31888	1520	morning plasma cortisol	[morning plasma cortisol]	1.5849625007211563	3	1	0	0
31889	1520	full-length cDNA encoding	[full-length cDNA encoding]	1.5849625007211563	3	1	0	0
31890	1520	increase in camp accumulation	[increase in cAMP accumulation]	1.5849625007211563	4	1	0	0
31891	1520	combine with [3H] dexamethasone	[combining with [3H] dexamethasone]	1.5849625007211563	4	1	0	0
31892	1520	normal cell types.	[normal cell types.]	1.5849625007211563	3	1	0	0
31893	1520	translocation of c-rel	[translocation of c-rel]	1.5849625007211563	3	1	0	0
31894	1520	many similarity to AP-1	[many similarities to AP-1]	1.5849625007211563	4	1	0	0
31895	1520	single EGR1 binding motif	[single EGR1 binding motif]	1.5849625007211563	4	1	0	0
31896	1520	kinase domain of zap-70	[kinase domain of ZAP-70]	1.5849625007211563	4	1	0	0
31897	1520	expression to specific tissue	[expression to specific tissues]	1.5849625007211563	4	1	0	0
31898	1520	c-fo gene transcription	[c-fos gene transcription]	1.5849625007211563	3	1	0	0
31899	1520	27th week of gestation	[27th week of gestation]	1.5849625007211563	4	1	0	0
31900	1520	t-lymphoid h9, CEM	[T-lymphoid H9, CEM]	1.5849625007211563	3	1	0	0
31901	1520	tal-1 chromatin structure	[tal-1 chromatin structure]	1.5849625007211563	3	1	0	0
31902	1520	nef phosphorylation on thr-15	[Nef phosphorylation on Thr-15]	1.5849625007211563	4	1	0	0
31903	1520	il-10 on ifn-gamma activity	[IL-10 on IFN-gamma activities]	1.5849625007211563	4	1	0	0
31904	1520	mechanism involve this receptor.	[mechanisms involving this receptor.]	1.5849625007211563	4	1	0	0
31905	1520	PRL biphasic expression	[PRL biphasic expression]	1.5849625007211563	3	1	0	0
31906	1520	use of specific antibody	[use of specific antibodies]	1.5849625007211563	4	1	0	0
31907	1520	(stat) family member	[(STAT) family members]	1.5849625007211563	3	1	0	0
31908	1520	express sensitive target fibroblast	[expressing sensitive target fibroblasts]	1.5849625007211563	4	1	0	0
31909	1520	(relative binding affinities: testosterone	[(relative binding affinities: testosterone]	1.5849625007211563	4	1	0	0
31910	1520	mononuclear cell mnc	[mononuclear cells MNC]	1.5849625007211563	3	1	0	0
31911	1520	action of proinflammatory stimulus	[action of proinflammatory stimuli]	1.5849625007211563	4	1	0	0
31912	1520	immediate-early activation gene expression	[immediate-early activation gene expression]	1.5849625007211563	4	1	0	0
31913	1520	potent interleukin 2	[potent interleukin 2]	1.5849625007211563	3	1	0	0
31914	1520	native peptide VP16	[native peptide VP16]	1.5849625007211563	3	1	0	0
31915	1520	expression of c-jun component	[expression of c-Jun component]	1.5849625007211563	4	1	0	0
31916	1520	activation of cell function	[activation of cell function]	1.5849625007211563	4	1	0	0
31917	1520	b-lymphocyte cell cycle activation	[B-lymphocyte cell cycle activation]	1.5849625007211563	4	1	0	0
31918	1520	CD8+ t-cell subpopulation	[CD8+ T-cell subpopulation]	1.5849625007211563	3	1	0	0
31919	1520	response to hemin	[response to hemin]	1.5849625007211563	3	1	0	0
31920	1520	CR asthmatic individual	[CR asthmatic individuals]	1.5849625007211563	3	1	0	0
31921	1520	tyrosine of slp-76	[tyrosines of SLP-76]	1.5849625007211563	3	1	0	0
31922	1520	glycoprotein iib (gpiib) gene	[glycoprotein IIb (GPIIb) gene]	1.5849625007211563	4	1	0	0
31923	1520	corresponding fast mobility form	[corresponding faster mobility forms]	1.5849625007211563	4	1	0	0
31924	1520	5 mM nac	[5 mM NAC]	1.5849625007211563	3	1	0	0
31925	1520	would novo mutation	[d novo mutation]	1.5849625007211563	3	1	0	0
31926	1520	stimulus for leukocyte chemotaxis	[stimulus for leukocyte chemotaxis]	1.5849625007211563	4	1	0	0
31927	1520	of binding to il-2ralpha	[of binding to IL-2Ralpha]	1.5849625007211563	4	1	0	0
31928	1520	superoxide anion production	[superoxide anion production]	1.5849625007211563	3	1	0	0
31929	1520	palindromic octamer sequence	[palindromic octamer sequence]	1.5849625007211563	3	2	1	1
31930	1520	potential regulatory element	[potential regulatory elements]	1.5849625007211563	3	1	0	0
31931	1520	tnf alpha treatment	[TNF alpha treatment]	1.5849625007211563	3	1	0	0
31932	1520	putative g0/g1 switch gene	[putative G0/G1 switch genes]	1.5849625007211563	4	2	2	2
31933	1520	il-2r alpha transcription	[IL-2R alpha transcription]	1.5849625007211563	3	2	2	2
31934	1520	erythroid cell-specific histone h5	[erythroid cell-specific histone H5]	1.5849625007211563	4	1	0	0
31935	1520	10, liposarcoma 5).	[10, liposarcoma 5).]	1.5849625007211563	3	1	0	0
31936	1520	finding from this analysis	[Findings from this analysis]	1.5849625007211563	4	1	0	0
31937	1520	study of transcriptional activation	[study of transcriptional activation]	1.5849625007211563	4	1	0	0
31938	1520	Patients' disease activity	[Patients' disease activity]	1.5849625007211563	3	1	0	0
31939	1520	such as the macrophage	[such as the macrophage]	1.5849625007211563	4	1	0	0
31940	1520	prevention of nuclear translocation	[prevention of nuclear translocation]	1.5849625007211563	4	1	0	0
31941	1520	normal NF-kappa B complex	[normal NF-kappa B complex]	1.5849625007211563	4	1	0	0
31942	1520	bone marrow bm	[bone marrow BM]	1.5849625007211563	3	1	0	0
31943	1520	Stat3 isoform (s)	[Stat3 isoform (s)]	1.5849625007211563	3	1	0	0
31944	1520	human breast tumour	[human breast tumours]	1.5849625007211563	3	1	0	0
31945	1520	human umbilical venous huvec	[human umbilical venous HUVECs]	1.5849625007211563	4	1	0	0
31946	1520	function of nfat protein	[functions of NFAT proteins]	1.5849625007211563	4	1	0	0
31947	1520	many erythroid-specific gene	[many erythroid-specific genes]	1.5849625007211563	3	1	0	0
31948	1520	level of regulation	[level of regulation]	1.5849625007211563	3	1	0	0
31949	1520	physiological relationship between binding	[physiological relationship between binding]	1.5849625007211563	4	1	0	0
31950	1520	only 4 mM	[only 4 mM]	1.5849625007211563	3	1	0	0
31951	1520	only a trigger role,	[only a triggering role,]	1.5849625007211563	4	1	0	0
31952	1520	use this technique	[Using this technique]	1.5849625007211563	3	1	0	0
31953	1520	inhibit cell growth	[inhibiting cell growth]	1.5849625007211563	3	1	0	0
31954	1520	necessity for stringent control	[necessity for stringent control]	1.5849625007211563	4	1	0	0
31955	1520	absence of il-3	[absence of IL-3]	1.5849625007211563	3	1	0	0
31956	1520	absence of il-2	[absence of IL-2]	1.5849625007211563	3	1	0	0
31957	1520	regulate the activity	[regulating the activities]	1.5849625007211563	3	2	1	1
31958	1520	absence of il-4	[absence of IL-4]	1.5849625007211563	3	1	0	0
31959	1520	rate corresponding to protein	[rates corresponding to proteins]	1.5849625007211563	4	1	0	0
31960	1520	stimulation of cell growth.	[stimulation of cell growth.]	1.5849625007211563	4	1	0	0
31961	1520	immediate early gene c-fo	[immediate early gene c-fos]	1.5849625007211563	4	2	1	1
31962	1520	interaction between T cell	[interaction between T cells]	1.5849625007211563	4	2	1	1
31963	1520	expression of membrane protein	[expression of membrane protein]	1.5849625007211563	4	1	0	0
31964	1520	disruption of alpha beta	[Disruption of alpha beta]	1.5849625007211563	4	1	0	0
31965	1520	several human disease	[several human diseases]	1.5849625007211563	3	1	0	0
31966	1520	gene regulatory protein	[gene regulatory proteins]	1.5849625007211563	3	1	0	0
31967	1520	cell type specific,	[cell type specific,]	1.5849625007211563	3	1	0	0
31968	1520	water in man	[water in man]	1.5849625007211563	3	1	0	0
31969	1520	il-6 transcription rate	[IL-6 transcription rate]	1.5849625007211563	3	1	0	0
31970	1520	CD28RE /ap-1 sequence	[CD28RE /AP-1 sequence]	1.5849625007211563	3	1	0	0
31971	1520	viral gene include hiv	[viral genes including HIV]	1.5849625007211563	4	1	0	0
31972	1520	ability of CIITA	[ability of CIITA]	1.5849625007211563	3	1	0	0
31973	1520	39 kilometer tax1 antigen	[39 kd tax1 antigen]	1.5849625007211563	4	1	0	0
31974	1520	regimen (20 mg bolus	[regimen (20 mg bolus]	1.5849625007211563	4	1	0	0
31975	1520	nuclear tcf-1 expression	[nuclear TCF-1 expression]	1.5849625007211563	3	1	0	0
31976	1520	cd138/syndecan-1 a proteoglycan	[CD138/syndecan-1 a proteoglycan]	1.5849625007211563	3	1	0	0
31977	1520	T cell activation gene	[T cell activation genes]	1.5849625007211563	4	1	0	0
31978	1520	cell model system	[cell model systems]	1.5849625007211563	3	1	0	0
31979	1520	Epstein-Barr virus (EBV)	[Epstein-Barr virus (EBV)]	1.5849625007211563	3	1	0	0
31980	1520	rar-rxr response pathway	[RAR-RXR response pathway]	1.5849625007211563	3	1	0	0
31981	1520	significant (p 0.001	[significant (P 0.001]	1.5849625007211563	3	1	0	0
31982	1520	untreated k562 cell	[untreated K562 cells]	1.5849625007211563	3	1	0	0
31983	1520	transcriptionally active c-fos/c-jun ap-1	[transcriptionally active c-Fos/c-Jun AP-1]	1.5849625007211563	4	1	0	0
31984	1520	influence of the affinity	[influence of the affinity]	1.5849625007211563	4	1	0	0
31985	1520	DQ3.2 -peptide complex	[DQ3.2 -peptide complex]	1.5849625007211563	3	1	0	0
31986	1520	response to the influence	[response to the influence]	1.5849625007211563	4	1	0	0
31987	1520	increase in ap-1 activity	[increase in AP-1 activity]	1.5849625007211563	4	1	0	0
31988	1520	Huh7 hepatoma cell	[Huh7 hepatoma cells]	1.5849625007211563	3	1	0	0
31989	1520	evidence of specific expression	[evidence of specific expression]	1.5849625007211563	4	1	0	0
31990	1520	transcription factor product	[transcription factor products]	1.5849625007211563	3	1	0	0
31991	1520	previous work implicate zebra	[previous work implicating ZEBRA]	1.5849625007211563	4	1	0	0
31992	1520	normal circulate human monocyte	[normal circulating human monocytes]	1.5849625007211563	4	1	0	0
31993	1520	mouse bone marrow cell	[mouse bone marrow cells]	1.5849625007211563	4	1	0	0
31994	1520	distinctive pattern of rdna	[distinctive pattern of cDNAs]	1.5849625007211563	4	1	0	0
31995	1520	sensitivity to apoptosis	[sensitivity to apoptosis]	1.5849625007211563	3	2	2	2
31996	1520	development of malignancy	[development of malignancies]	1.5849625007211563	3	2	2	2
31997	1520	impaired b cell signal	[impaired B cell signaling]	1.5849625007211563	4	1	0	0
31998	1520	5' region of SCL	[5' region of SCL]	1.5849625007211563	4	1	0	0
31999	1520	regulation of the majority	[regulation of the majority]	1.5849625007211563	4	1	0	0
32000	1520	p21(ras) in the regulation	[p21(ras) in the regulation]	1.5849625007211563	4	1	0	0
32001	1520	Balachandran, J. Virol. 2884-2894	[Balachandran, J. Virol. 2884-2894]	1.5849625007211563	4	1	0	0
32002	1520	interference with the activation	[Interference with the activation]	1.5849625007211563	4	1	0	0
32003	1520	elevation of the level	[Elevation of the levels]	1.5849625007211563	4	1	0	0
32004	1520	interleukin-2 (IL-2)-dependent t-cell line	[interleukin-2 (IL-2)-dependent T-cell line]	1.5849625007211563	4	1	0	0
32005	1520	change in level	[change in level]	1.5849625007211563	3	2	1	1
32006	1520	360-d head-down bed rest)	[360-d head-down bed rest)]	1.5849625007211563	4	1	0	0
32007	1520	cytolytic effector t-cell	[cytolytic effector T-cells]	1.5849625007211563	3	1	0	0
32008	1520	majority of the blast	[majorities of the blasts]	1.5849625007211563	4	1	0	0
32009	1520	recombinant retrovirus vector	[recombinant retrovirus vectors]	1.5849625007211563	3	1	0	0
32010	1520	type 1 receptor	[type 1 receptor]	1.5849625007211563	3	1	0	0
32011	1520	spleen of knock-out mouse	[spleens of knock-out mice]	1.5849625007211563	4	1	0	0
32012	1520	progressive inflammatory lung disease	[progressive inflammatory lung disease]	1.5849625007211563	4	1	0	0
32013	1520	hematopoietic precursor cell line	[hematopoietic precursor cell lines]	1.5849625007211563	4	2	2	2
32014	1520	induction of nfat activity	[induction of NFAT activity]	1.5849625007211563	4	1	0	0
32015	1520	signal through Jak3	[signaling through Jak3]	1.5849625007211563	3	1	0	0
32016	1520	end of the week	[end of the week]	1.5849625007211563	4	1	0	0
32017	1520	blood stem cell	[blood stem cells]	1.5849625007211563	3	2	2	2
32018	1520	only a fraction	[only a fraction]	1.5849625007211563	3	1	0	0
32019	1520	own nuclear localization	[own nuclear localization]	1.5849625007211563	3	1	0	0
32020	1520	ability of this protein	[ability of these proteins]	1.5849625007211563	4	2	1	1
32021	1520	monocyte to hiv infection	[monocytes to HIV infection]	1.5849625007211563	4	1	0	0
32022	1520	depletion of endogenous glucocorticoid	[depletion of endogenous glucocorticoids]	1.5849625007211563	4	1	0	0
32023	1520	nuclear factor like nf-il6	[nuclear factors like NF-IL6]	1.5849625007211563	4	1	0	0
32024	1520	membrane protein 1 LMP1	[membrane protein 1 LMP1]	1.5849625007211563	4	2	2	2
32025	1520	distal element at -1280	[distal element at -1280]	1.5849625007211563	4	1	0	0
32026	1520	several normal tissue	[several normal tissues]	1.5849625007211563	3	1	0	0
32027	1520	translational suppression of TNF	[translational suppression of TNF]	1.5849625007211563	4	1	0	0
32028	1520	HTLV-I tax activation	[HTLV-I tax activation]	1.5849625007211563	3	1	0	0
32029	1520	expression above basal level	[expression above basal levels]	1.5849625007211563	4	1	0	0
32030	1520	deregulation in maturation process	[deregulation in maturation process]	1.5849625007211563	4	1	0	0
32031	1520	fact, under low-ionic-strength condition	[fact, under low-ionic-strength conditions]	1.5849625007211563	4	1	0	0
32032	1520	mrp MARCKS -related protein	[MRP MARCKS -related protein]	1.5849625007211563	4	1	0	0
32033	1520	function in T cell	[function in T cells]	1.5849625007211563	4	2	1	1
32034	1520	expression by IL-4	[expression by IL-4]	1.5849625007211563	3	2	1	1
32035	1520	initiation of neutrophilic inflammation	[initiation of neutrophilic inflammation]	1.5849625007211563	4	1	0	0
32036	1520	hmrp8 promoter element	[hMRP8 promoter element]	1.5849625007211563	3	1	0	0
32037	1520	such as chronic asthma	[such as chronic asthma]	1.5849625007211563	4	1	0	0
32038	1520	monocyte macrophage cell lineage	[monocyte macrophage cell lineage]	1.5849625007211563	4	1	0	0
32039	1520	upregulation of megakaryocyte	[upregulation of megakaryocyte]	1.5849625007211563	3	1	0	0
32040	1520	patient with other MPD	[patients with other MPD]	1.5849625007211563	4	1	0	0
32041	1520	steroid-resistant asthmatic patient	[steroid-resistant asthmatic patients]	1.5849625007211563	3	1	0	0
32042	1520	lytic cycle antigen	[lytic cycle antigens]	1.5849625007211563	3	1	0	0
32043	1520	Nuclear level of nf-kappab	[Nuclear levels of NF-kappaB]	1.5849625007211563	4	1	0	0
32044	1520	use a transient assay	[using a transient assay]	1.5849625007211563	4	1	0	0
32045	1520	variant with exon 5	[Variants with exon 5]	1.5849625007211563	4	1	0	0
32046	1520	variant with exon 2	[Variants with exons 2]	1.5849625007211563	4	1	0	0
32047	1520	suppression of nf-kappab activation	[suppression of NF-kappaB activation]	1.5849625007211563	4	2	1	1
32048	1520	specific transcriptional protein	[specific transcriptional proteins]	1.5849625007211563	3	1	0	0
32049	1520	receptor tyrosine phosphorylation	[receptor tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
32050	1520	antidiabetic agent troglitazone	[antidiabetic agent troglitazone]	1.5849625007211563	3	1	0	0
32051	1520	gene coding for fkbp	[gene coding for FKBP]	1.5849625007211563	4	1	0	0
32052	1520	AP-1 transcriptional factor	[AP-1 transcriptional factor]	1.5849625007211563	3	1	0	0
32053	1520	b cell lymphoma	[B cell lymphomas]	1.5849625007211563	3	2	1	1
32054	1520	level in T lymphocyte	[levels in T lymphocytes]	1.5849625007211563	4	2	2	2
32055	1520	signal from the membrane	[signals from the membrane]	1.5849625007211563	4	1	0	0
32056	1520	interspecy somatic cell hybrid	[Interspecies somatic cell hybrids]	1.5849625007211563	4	1	0	0
32057	1520	potential nfat composite element	[potential NFAT composite elements]	1.5849625007211563	4	1	0	0
32058	1520	arterial ehuaess) endothelial cell	[arterial (HUAECs) endothelial cells]	1.5849625007211563	4	1	0	0
32059	1520	lymphocytic infiltration of tumor	[lymphocytic infiltration of tumor]	1.5849625007211563	4	1	0	0
32060	1520	unique phenotype of SIVsmmPBj14	[unique phenotype of SIVsmmPBj14]	1.5849625007211563	4	1	0	0
32061	1520	contain p37 htlv-i transcription	[containing p37 HTLV-I transcription]	1.5849625007211563	4	1	0	0
32062	1520	development of fatty streak	[development of fatty streak]	1.5849625007211563	4	1	0	0
32063	1520	YY-1 binding site	[YY-1 binding site]	1.5849625007211563	3	1	0	0
32064	1520	Rel/NF-kappa b protein	[Rel/NF-kappa B proteins]	1.5849625007211563	3	1	0	0
32065	1520	absence of tryptophan	[absence of tryptophan]	1.5849625007211563	3	1	0	0
32066	1520	clone a cDNA	[Cloning a cDNA]	1.5849625007211563	3	1	0	0
32067	1520	moreover, ach-2 cell	[Moreover, ACH-2 cells]	1.5849625007211563	3	1	0	0
32068	1520	development of a plaque	[development of an plaque]	1.5849625007211563	4	1	0	0
32069	1520	293T kidney fibroblast	[293T kidney fibroblasts]	1.5849625007211563	3	1	0	0
32070	1520	59 cDNA fragment	[59 cDNA fragments]	1.5849625007211563	3	1	0	0
32071	1520	inhibit tyrosine phosphorylation	[inhibiting tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
32072	1520	oxidative-stress sensitive transcription factor	[oxidative-stress sensitive transcription factor]	1.5849625007211563	4	1	0	0
32073	1520	c-myb 5' flank sequence	[c-myb 5' flanking sequence]	1.5849625007211563	4	1	0	0
32074	1520	zinc -specific effect	[zinc -specific effect]	1.5849625007211563	3	1	0	0
32075	1520	protein antigen ag	[protein antigen Ag]	1.5849625007211563	3	1	0	0
32076	1520	transcription of interleukin 2	[transcription of interleukin 2]	1.5849625007211563	4	1	0	0
32077	1520	determine the role	[determining the role]	1.5849625007211563	3	1	0	0
32078	1520	50 breast cancer patient	[50 breast cancer patients]	1.5849625007211563	4	1	0	0
32079	1520	change in T cell	[changes in T cells]	1.5849625007211563	4	1	0	0
32080	1520	hiv kappa b site	[HIV kappa B site]	1.5849625007211563	4	1	0	0
32081	1520	change in cellular redox	[changes in cellular redox]	1.5849625007211563	4	1	0	0
32082	1520	finger transcription factor	[finger transcription factor]	1.5849625007211563	3	1	0	0
32083	1520	EBNA2 responsive element	[EBNA2 responsive element]	1.5849625007211563	3	1	0	0
32084	1520	tax -response element	[Tax -response element]	1.5849625007211563	3	2	2	2
32085	1520	reduction in mcp-1 secretion	[reduction in MCP-1 secretion]	1.5849625007211563	4	1	0	0
32086	1520	rat air pouch model	[rat air pouch model]	1.5849625007211563	4	1	0	0
32087	1520	extent of inflammation	[extent of inflammation]	1.5849625007211563	3	1	0	0
32088	1520	tax-express cell line	[Tax-expressing cell lines]	1.5849625007211563	3	1	0	0
32089	1520	camp-response-element-binding protein CREB	[cAMP-response-element-binding protein CREB]	1.5849625007211563	3	1	0	0
32090	1520	immunophenotype of 43 idc	[immunophenotype of 43 IDCs]	1.5849625007211563	4	1	0	0
32091	1520	55 kilometer TNFRp55	[55 kd TNFRp55]	1.5849625007211563	3	1	0	0
32092	1520	proinflammatory cytokine attract chemokine	[proinflammatory cytokines attracting chemokines]	1.5849625007211563	4	1	0	0
32093	1520	variety include monocyte	[variety including monocytes]	1.5849625007211563	3	2	2	2
32094	1520	steroid/thyroid hormone response element	[steroid/thyroid hormone response elements]	1.5849625007211563	4	1	0	0
32095	1520	exist isoform Pax-5	[existing isoform Pax-5]	1.5849625007211563	3	1	0	0
32096	1520	granulocyte-macrophage colony stimulate factor	[granulocyte-macrophage colony stimulating factor]	1.5849625007211563	4	3	2	1
32097	1520	active transcriptional complex	[active transcriptional complex]	1.5849625007211563	3	1	0	0
32098	1520	extract from b cell	[extracts from B cells]	1.5849625007211563	4	2	1	1
32099	1520	only molecule capable	[only molecule capable]	1.5849625007211563	3	1	0	0
32100	1520	human b lineage cell	[human B lineage cells]	1.5849625007211563	4	2	1	1
32101	1520	suppression of transcription in	[suppression of transcription in]	1.5849625007211563	4	1	0	0
32102	1520	Rac-1 signal pathway important	[Rac-1 signaling pathways important]	1.5849625007211563	4	1	0	0
32103	1520	use a chemical probe	[Using a chemical probe]	1.5849625007211563	4	1	0	0
32104	1520	major coping strategy	[major coping strategy]	1.5849625007211563	3	1	0	0
32105	1520	k562 leukemia cell	[K562 leukemia cells]	1.5849625007211563	3	2	1	1
32106	1520	meta(d+) binding factor	[META(D+) binding factor]	1.5849625007211563	3	1	0	0
32107	1520	ERK pathway-specific inhibitor pd98059	[ERK pathway-specific inhibitor PD98059]	1.5849625007211563	4	1	0	0
32108	1520	chemical nature Arg91 one	[chemical nature Arg91 one]	1.5849625007211563	4	1	0	0
32109	1520	antiviral, antiproliferative activity	[antiviral, antiproliferative activities]	1.5849625007211563	3	1	0	0
32110	1520	presence of calcium	[presence of calcium]	1.5849625007211563	3	1	0	0
32111	1520	group of poxvirus protein	[group of poxvirus proteins]	1.5849625007211563	4	1	0	0
32112	1520	mink cell focus-forming	[mink cell focus-forming]	1.5849625007211563	3	1	0	0
32113	1520	multimerize the regulatory element	[multimerizing the regulatory elements]	1.5849625007211563	4	1	0	0
32114	1520	RA receptor network	[RA receptor network]	1.5849625007211563	3	1	0	0
32115	1520	take the IL-2 gene	[Taking the IL-2 gene]	1.5849625007211563	4	1	0	0
32116	1520	potential of lmp-1	[potential of LMP-1]	1.5849625007211563	3	2	2	2
32117	1520	level of cd11b antigen	[level of CD11b antigen]	1.5849625007211563	4	1	0	0
32118	1520	role for this alteration	[roles for these alterations]	1.5849625007211563	4	1	0	0
32119	1520	role of RA alpha	[roles of RA alpha]	1.5849625007211563	4	1	0	0
32120	1520	only four patient	[only four patients]	1.5849625007211563	3	1	0	0
32121	1520	region of slp-76	[regions of SLP-76]	1.5849625007211563	3	1	0	0
32122	1520	intact chimeric egf-gp130 receptor	[intact chimeric EGF-gp130 receptor]	1.5849625007211563	4	1	0	0
32123	1520	border of gcs	[borders of GCs]	1.5849625007211563	3	1	0	0
32124	1520	lack of il-12 signal	[Lack of IL-12 signaling]	1.5849625007211563	4	1	0	0
32125	1520	low copy repeat	[low copy repeat]	1.5849625007211563	3	1	0	0
32126	1520	response of PBMC	[responses of PBMC]	1.5849625007211563	3	1	0	0
32127	1520	phosphorylation of the protein	[phosphorylation of the proteins]	1.5849625007211563	4	1	0	0
32128	1520	DNA binding complex	[DNA binding complexes]	1.5849625007211563	3	2	1	1
32129	1520	individual' maximal oxygen uptake	[individual's maximal oxygen uptake]	1.5849625007211563	4	1	0	0
32130	1520	erythrocyte polyamine level	[Erythrocyte polyamines levels]	1.5849625007211563	3	1	0	0
32131	1520	peroxisome proliferator-activated receptor	[Peroxisome proliferator-activated receptor]	1.5849625007211563	3	4	3	1
32132	1520	2 regulatory element	[2 regulatory elements]	1.5849625007211563	3	1	0	0
32133	1520	asthma pathogenesis to one	[asthma pathogenesis to one]	1.5849625007211563	4	1	0	0
32134	1520	interferon signal transduction pathway	[interferon signal transduction pathway]	1.5849625007211563	4	1	0	0
32135	1520	transcription of immediate-early gene	[transcription of immediate-early genes]	1.5849625007211563	4	1	0	0
32136	1520	inhibition of nf-at induction	[inhibition of NF-AT induction]	1.5849625007211563	4	1	0	0
32137	1520	class transactivator-encoding air-1 locus	[class transactivator-encoding AIR-1 locus]	1.5849625007211563	4	1	0	0
32138	1520	cell of cns	[cells of CNS]	1.5849625007211563	3	1	0	0
32139	1520	stimulation of gene expression	[stimulation of gene expression]	1.5849625007211563	4	1	0	0
32140	1520	identify the nature	[identifying the nature]	1.5849625007211563	3	1	0	0
32141	1520	mouse osteopontin gene promoter	[mouse osteopontin gene promoters]	1.5849625007211563	4	1	0	0
32142	1520	three DNA-protein complex specific	[three DNA-protein complexes specific]	1.5849625007211563	4	1	0	0
32143	1520	transcription initiation sequence	[transcription initiation sequences]	1.5849625007211563	3	1	0	0
32144	1520	drosophila homeobox gene	[Drosophila homeobox gene]	1.5849625007211563	3	1	0	0
32145	1520	e lambda 2.4	[E lambda 2.4]	1.5849625007211563	3	1	0	0
32146	1520	coexpression of alpha b1	[Coexpression of alpha B1]	1.5849625007211563	4	1	0	0
32147	1520	symptom of premature aging	[symptoms of premature aging]	1.5849625007211563	4	1	0	0
32148	1520	activator protein-1 family protein	[activator protein-1 family proteins]	1.5849625007211563	4	1	0	0
32149	1520	supershift in mobility assay	[supershifts in mobility assays]	1.5849625007211563	4	1	0	0
32150	1520	nuclear) of the expression	[nuclear) of the expression]	1.5849625007211563	4	1	0	0
32151	1520	cell in vivo	[cells in vivo]	1.5849625007211563	3	2	2	2
32152	1520	hl-60 leukemia cell	[HL-60 leukemia cells]	1.5849625007211563	3	2	2	2
32153	1520	early gene bzlf1	[early genes BZLF1]	1.5849625007211563	3	1	0	0
32154	1520	indicate permanent virus transcription	[indicating permanent virus transcription]	1.5849625007211563	4	1	0	0
32155	1520	binary tf.viia complex	[binary TF.VIIa complex]	1.5849625007211563	3	1	0	0
32156	1520	drug development for treatment	[drug development for treatment]	1.5849625007211563	4	1	0	0
32157	1520	globin gene switching? gata-1	[globin gene switching? GATA-1]	1.5849625007211563	4	1	0	0
32158	1520	embryonic cardiac cell	[embryonic cardiac cells]	1.5849625007211563	3	1	0	0
32159	1520	novel octamer sequence	[novel octamer sequence]	1.5849625007211563	3	2	2	2
32160	1520	patient with MPD	[patients with MPD]	1.5849625007211563	3	2	2	2
32161	1520	bind the sre motif	[binding the SRE motif]	1.5849625007211563	4	1	0	0
32162	1520	study on eosinophil biology	[study on eosinophil biology]	1.5849625007211563	4	1	0	0
32163	1520	use monospecific antibody	[Using monospecific antibodies]	1.5849625007211563	3	1	0	0
32164	1520	relationship between the number	[relationship between the number]	1.5849625007211563	4	1	0	0
32165	1520	patient with active tuberculosis	[patients with active tuberculosis]	1.5849625007211563	4	1	0	0
32166	1520	analysis of CAT activity	[Analysis of CAT activity]	1.5849625007211563	4	1	0	0
32167	1520	codon 10 polymorphic site	[codon 10 polymorphic site]	1.5849625007211563	4	1	0	0
32168	1520	regulator of a variety	[regulator of a variety]	1.5849625007211563	4	2	2	2
32169	1520	antisense myb rna	[antisense myb RNA]	1.5849625007211563	3	2	1	1
32170	1520	synthesis of hiv rna	[synthesis of HIV RNA]	1.5849625007211563	4	1	0	0
32171	1520	macaque cell lysate	[macaque cell lysates]	1.5849625007211563	3	1	0	0
32172	1520	diesel exhaust particle dep	[diesel exhaust particles DEPs]	1.5849625007211563	4	1	0	0
32173	1520	contrast to PMA	[contrast to PMA]	1.5849625007211563	3	1	0	0
32174	1520	marker for ec activation	[markers for EC activation]	1.5849625007211563	4	1	0	0
32175	1520	ubiquitinylation of c-Jun	[ubiquitinylation of c-Jun]	1.5849625007211563	3	2	1	1
32176	1520	14 active sle (92.9%)	[14 active SLE (92.9%)]	1.5849625007211563	4	1	0	0
32177	1520	autologous lymphoblastic cell line	[autologous lymphoblastic cell lines]	1.5849625007211563	4	1	0	0
32178	1520	extensive mutagenesis of CIITA	[Extensive mutagenesis of CIITA]	1.5849625007211563	4	1	0	0
32179	1520	Disease activity Index	[Disease Activity Index]	1.5849625007211563	3	1	0	0
32180	1520	mutant erythropoietin receptor signal	[mutant erythropoietin receptor signaling]	1.5849625007211563	4	1	0	0
32181	1520	predominantly in erythroid cell	[predominantly in erythroid cells]	1.5849625007211563	4	1	0	0
32182	1520	LP mononuclear cell LPMC	[LP mononuclear cells LPMC]	1.5849625007211563	4	1	0	0
32183	1520	study in laboratory	[studies in laboratories]	1.5849625007211563	3	1	0	0
32184	1520	Ficoll density gradient	[Ficoll density gradient]	1.5849625007211563	3	1	0	0
32185	1520	monocyte into alveolar macrophage	[monocytes into alveolar macrophages]	1.5849625007211563	4	1	0	0
32186	1520	class ii-negative HeLa cell	[class II-negative HeLa cells]	1.5849625007211563	4	1	0	0
32187	1520	such as SK-N-Be(2)	[such as SK-N-Be(2)]	1.5849625007211563	3	1	0	0
32188	1520	functional 5-lox system	[functional 5-LOX system]	1.5849625007211563	3	1	0	0
32189	1520	several experimental model	[several experimental models]	1.5849625007211563	3	1	0	0
32190	1520	decrease in state level	[decrease in state levels]	1.5849625007211563	4	1	0	0
32191	1520	saturate ep level	[saturating Ep level]	1.5849625007211563	3	1	0	0
32192	1520	human NK cell activity	[human NK cell activity]	1.5849625007211563	4	1	0	0
32193	1520	ige germline promoter	[IgE germline promoter]	1.5849625007211563	3	2	1	1
32194	1520	fas cd95/apo-1 expression	[Fas CD95/APO-1 expression]	1.5849625007211563	3	1	0	0
32195	1520	natural environmental photic cycle	[natural environmental photic cycle]	1.5849625007211563	4	1	0	0
32196	1520	female with hypomelanosis	[female with hypomelanosis]	1.5849625007211563	3	1	0	0
32197	1520	additional T cell-specific protein	[additional T cell-specific protein]	1.5849625007211563	4	1	0	0
32198	1520	deregulation of TCL1	[Deregulation of TCL1]	1.5849625007211563	3	1	0	0
32199	1520	gc receptor affinity (1/kd)	[GC receptor affinity (1/Kd)]	1.5849625007211563	4	1	0	0
32200	1520	interleukin-8 il-8 secretion	[interleukin-8 IL-8 secretion]	1.5849625007211563	3	1	0	0
32201	1520	ldl -receptor gene transcription	[LDL -receptor gene transcription]	1.5849625007211563	4	2	1	1
32202	1520	use of tissue	[use of tissue]	1.5849625007211563	3	1	0	0
32203	1520	nuclear factor-kappaB nuclear translocation	[nuclear factor-kappaB nuclear translocation]	1.5849625007211563	4	1	0	0
32204	1520	hiv-1 cell fusion	[HIV-1 cell fusion]	1.5849625007211563	3	1	0	0
32205	1520	phorbol ester pkc agonist	[phorbol ester PKC agonists]	1.5849625007211563	4	1	0	0
32206	1520	premature aging syndrome	[premature aging syndromes]	1.5849625007211563	3	2	1	1
32207	1520	other nfat-family protein	[other NFAT-family proteins]	1.5849625007211563	3	1	0	0
32208	1520	IL-2 cell cycle progression	[IL-2 cell cycle progression]	1.5849625007211563	4	1	0	0
32209	1520	human IL-2Rbeta promoter	[human IL-2Rbeta promoter]	1.5849625007211563	3	1	0	0
32210	1520	enhancer element in addition	[enhancer elements in addition]	1.5849625007211563	4	1	0	0
32211	1520	other immediate-early gene	[other immediate-early genes]	1.5849625007211563	3	1	0	0
32212	1520	4.5 kilobase pair	[4.5 kilobase pairs]	1.5849625007211563	3	1	0	0
32213	1520	family of transcriptional regulator	[family of transcriptional regulators]	1.5849625007211563	4	1	0	0
32214	1520	il-4r alpha-associated kinase jak-1	[IL-4R alpha-associated kinase JAK-1]	1.5849625007211563	4	1	0	0
32215	1520	viral lytic cascade	[viral lytic cascade]	1.5849625007211563	3	1	0	0
32216	1520	stat1 protein (and mrna)	[STAT1 protein (and mRNA)]	1.5849625007211563	4	1	0	0
32217	1520	Jurkat cell clone	[Jurkat cell clones]	1.5849625007211563	3	2	2	2
32218	1520	patient with Alagille syndrome	[patient with Alagille syndrome]	1.5849625007211563	4	1	0	0
32219	1520	deficiency in nf-kappab induction	[deficiency in NF-kappaB induction]	1.5849625007211563	4	1	0	0
32220	1520	absorptive hypercalciuria stone-forming condition	[Absorptive hypercalciuria stone-forming condition]	1.5849625007211563	4	1	0	0
32221	1520	normal T cells.	[normal T cells.]	1.5849625007211563	3	1	0	0
32222	1520	erythropoietin receptor epor	[erythropoietin receptor EpoR]	1.5849625007211563	3	1	0	0
32223	1520	role regulate lymphocyte homeostasis	[role regulating lymphocyte homeostasis]	1.5849625007211563	4	1	0	0
32224	1520	eosinophil cationic protein ecp	[eosinophil cationic protein ECP]	1.5849625007211563	4	1	0	0
32225	1520	regulation of this enzyme	[regulation of this enzyme]	1.5849625007211563	4	1	0	0
32226	1520	many tyrosine include y292	[many tyrosines including Y292]	1.5849625007211563	4	1	0	0
32227	1520	Jun activation domain	[Jun activation domain]	1.5849625007211563	3	1	0	0
32228	1520	major structural role	[major structural role]	1.5849625007211563	3	1	0	0
32229	1520	use Epstein-Barr virus transformation	[using Epstein-Barr virus transformation]	1.5849625007211563	4	1	0	0
32230	1520	follow bilateral total adrenalectomy	[following bilateral total adrenalectomy]	1.5849625007211563	4	1	0	0
32231	1520	several pathologic condition	[several pathologic conditions]	1.5849625007211563	3	1	0	0
32232	1520	ulcerative colitis (56.1 51.6	[ulcerative colitis (56.1 51.6]	1.5849625007211563	4	1	0	0
32233	1520	b gene expression	[B gene expression]	1.5849625007211563	3	2	2	2
32234	1520	expression of similar construct	[expression of similar constructs]	1.5849625007211563	4	1	0	0
32235	1520	inhibition by PDTC	[inhibition by PDTC]	1.5849625007211563	3	1	0	0
32236	1520	pathogenesis of t-cell lymphoma	[pathogenesis of T-cell lymphoma]	1.5849625007211563	4	1	0	0
32237	1520	amount of actin	[amounts of actin]	1.5849625007211563	3	1	0	0
32238	1520	dominant negative transgenic mouse	[dominant negative transgenic mice]	1.5849625007211563	4	1	0	0
32239	1520	concentration of transcription factor	[concentration of transcription factors]	1.5849625007211563	4	1	0	0
32240	1520	terminal 3' c	[terminal 3' C]	1.5849625007211563	3	1	0	0
32241	1520	ectopic expression of TAL1	[ectopic expression of TAL1]	1.5849625007211563	4	1	0	0
32242	1520	mobilization of cellular calcium	[mobilization of cellular calcium]	1.5849625007211563	4	1	0	0
32243	1520	U1 monocytic cells,	[U1 monocytic cells,]	1.5849625007211563	3	1	0	0
32244	1520	75-kDa heterodimeric cytokine	[75-kDa heterodimeric cytokine]	1.5849625007211563	3	1	0	0
32245	1520	colony-forming unit granulocyte-macrophage	[colony-forming unit granulocyte-macrophage]	1.5849625007211563	3	1	0	0
32246	1520	kappa 3 site	[kappa 3 site]	1.5849625007211563	3	1	0	0
32247	1520	subsequent action of cytokine	[subsequent actions of cytokines]	1.5849625007211563	4	1	0	0
32248	1520	30% less rt-pcr product	[30% less RT-PCR product]	1.5849625007211563	4	1	0	0
32249	1520	acute ethanol exposure	[Acute ethanol exposure]	1.5849625007211563	3	1	0	0
32250	1520	tumorigenesis of colorectal cancer	[tumorigenesis of colorectal cancers]	1.5849625007211563	4	1	0	0
32251	1520	immunohistochemistry in granuloma	[immunohistochemistry in granulomas]	1.5849625007211563	3	1	0	0
32252	1520	rhythm of glucocorticoid receptor	[rhythm of glucocorticoid receptor]	1.5849625007211563	4	2	2	2
32253	1520	fusion region hybrid protein	[fusion region hybrid protein]	1.5849625007211563	4	1	0	0
32254	1520	exogenous glutathione GSH	[exogenous glutathione GSH]	1.5849625007211563	3	1	0	0
32255	1520	asp at position 442	[Asp at position 442]	1.5849625007211563	4	1	0	0
32256	1520	general mechanism for activation	[general mechanism for activation]	1.5849625007211563	4	1	0	0
32257	1520	GAL4-EBNA3C fusion protein	[GAL4-EBNA3C fusion proteins]	1.5849625007211563	3	1	0	0
32258	1520	cosmid probe of BCL6	[Cosmid probe of BCL6]	1.5849625007211563	4	1	0	0
32259	1520	sequential phosphorylation of kinase	[sequential phosphorylation of kinases]	1.5849625007211563	4	1	0	0
32260	1520	anti-e-selectin monoclonal antibody	[anti-E-selectin monoclonal antibody]	1.5849625007211563	3	1	0	0
32261	1520	variety of specificity	[variety of specificities]	1.5849625007211563	3	1	0	0
32262	1520	respect to transcriptional control	[respect to transcriptional control]	1.5849625007211563	4	1	0	0
32263	1520	same DNA sequence	[same DNA sequence]	1.5849625007211563	3	1	0	0
32264	1520	early activation of ap-1	[early activation of AP-1]	1.5849625007211563	4	2	1	1
32265	1520	initiator-like sequence present	[initiator-like sequence present]	1.5849625007211563	3	1	0	0
32266	1520	active NF-kappaB heterodimer	[active NF-kappaB heterodimer]	1.5849625007211563	3	1	0	0
32267	1520	t-lymphocyte via TGF-beta 2	[T-lymphocytes via TGF-beta 2]	1.5849625007211563	4	1	0	0
32268	1520	rev protein m10	[Rev protein M10]	1.5849625007211563	3	1	0	0
32269	1520	steroid-resistant bronchial asthma	[steroid-resistant bronchial asthma]	1.5849625007211563	3	1	0	0
32270	1520	70Z/3 induction of NFAT	[70Z/3 induction of NFAT]	1.5849625007211563	4	1	0	0
32271	1520	abnormal nf-at binding activity	[abnormal NF-AT binding activity]	1.5849625007211563	4	1	0	0
32272	1520	establishment of early branchpoint	[establishment of early branchpoints]	1.5849625007211563	4	1	0	0
32273	1520	induce tyrosine phosphorylation	[inducing tyrosine phosphorylation]	1.5849625007211563	3	1	0	0
32274	1520	Erythroid gene expression	[Erythroid gene expression]	1.5849625007211563	3	1	0	0
32275	1520	few host factor	[Few host factors]	1.5849625007211563	3	1	0	0
32276	1520	106-kDa component of LR1	[106-kDa component of LR1]	1.5849625007211563	4	1	0	0
32277	1520	RXR -raralpha403 heterodimer	[RXR -RARalpha403 heterodimer]	1.5849625007211563	3	1	0	0
32278	1520	viral peptide in vitro	[viral peptides in vitro]	1.5849625007211563	4	1	0	0
32279	1520	Kmone for 25(oh)2d3	[Km for 25(OH)2D3]	1.5849625007211563	3	1	0	0
32280	1520	T effector cell	[T effector cells]	1.5849625007211563	3	1	0	0
32281	1520	set of cell line	[set of cell lines]	1.5849625007211563	4	1	0	0
32282	1520	anti- CD28 costimulation	[anti- CD28 costimulation]	1.5849625007211563	3	1	0	0
32283	1520	target of egr1 regulation	[target of EGR1 regulation]	1.5849625007211563	4	1	0	0
32284	1520	level of this protein	[levels of this protein]	1.5849625007211563	4	2	1	1
32285	1520	distinct intracellular pathway	[distinct intracellular pathways]	1.5849625007211563	3	1	0	0
32286	1520	other mcd14 ligand in	[other mCD14 ligands in]	1.5849625007211563	4	1	0	0
32287	1520	modification of the pattern	[modification of the pattern]	1.5849625007211563	4	1	0	0
32288	1520	substitution in the domain	[substitutions in the domain]	1.5849625007211563	4	1	0	0
32289	1520	most effective signal	[most effective signals]	1.5849625007211563	3	1	0	0
32290	1520	hemodynamic compensatory phase	[hemodynamic compensatory phase]	1.5849625007211563	3	2	2	2
32291	1520	specific proteolytic activity.	[specific proteolytic activity.]	1.5849625007211563	3	1	0	0
32292	1520	inhibitory action on DC	[inhibitory action on DC]	1.5849625007211563	4	1	0	0
32293	1520	contrast to the infection	[contrast to the infection]	1.5849625007211563	4	1	0	0
32294	1520	several transgenic mouse	[several transgenic mice]	1.5849625007211563	3	1	0	0
32295	1520	5' flank sequence	[5' flanking sequence]	1.5849625007211563	3	1	0	0
32296	1520	study of the change	[study of the changes]	1.5849625007211563	4	1	0	0
32297	1520	beta thalassemia patient	[beta thalassemia patients]	1.5849625007211563	3	2	2	2
32298	1520	human Burkitt' lymphoma	[human Burkitt's lymphomas]	1.5849625007211563	3	1	0	0
32299	1520	contain the GM-CSF promoter	[containing the GM-CSF promoter]	1.5849625007211563	4	1	0	0
32300	1520	composition of each complex	[composition of each complex]	1.5849625007211563	4	1	0	0
32301	1520	transcriptional regulatory protein nf-kappab	[transcriptional regulatory protein NF-kappaB]	1.5849625007211563	4	1	0	0
32302	1520	putative chicken shc homologue	[putative chicken Shc homologue]	1.5849625007211563	4	1	0	0
32303	1520	methyl xanthine derivative pentoxifylline	[methyl xanthine derivative pentoxifylline]	1.5849625007211563	4	1	0	0
32304	1520	nuclear membrane protein related	[nuclear membrane protein related]	1.5849625007211563	4	1	0	0
32305	1520	few regulatory element	[few regulatory elements]	1.5849625007211563	3	1	0	0
32306	1520	binding activity of NF-IL6	[Binding activity of NF-IL6]	1.5849625007211563	4	1	0	0
32307	1520	binding of endogenous NFkappaB	[binding of endogenous NFkappaB]	1.5849625007211563	4	1	0	0
32308	1520	vcam-1 mrna expression	[VCAM-1 mRNA expression]	1.5849625007211563	3	2	1	1
32309	1520	multiple tumor necrosis factor	[multiple tumor necrosis factor]	1.5849625007211563	4	1	0	0
32310	1520	t-cell activation a process	[T-cell activation a process]	1.5849625007211563	4	1	0	0
32311	1520	distinct DNA binding protein	[distinct DNA binding proteins]	1.5849625007211563	4	1	0	0
32312	1520	combination with calcium mobilization	[combination with calcium mobilization]	1.5849625007211563	4	1	0	0
32313	1520	nf-kappab inhibitor ikappab-alpha	[NF-kappaB inhibitor IkappaB-alpha]	1.5849625007211563	3	1	0	0
32314	1520	kinase inhibitor h-89	[kinase inhibitor H-89]	1.5849625007211563	3	1	0	0
32315	1520	pp52 leukocyte protein	[pp52 leukocyte protein]	1.5849625007211563	3	1	0	0
32316	1520	9 binding sites/cell)	[9 binding sites/cell)]	1.5849625007211563	3	1	0	0
32317	1520	activator of transcription-4	[activator of transcription-4]	1.5849625007211563	3	1	0	0
32318	1520	various cellular gene	[various cellular genes]	1.5849625007211563	3	2	1	1
32319	1520	optimal T cell activation	[Optimal T cell activation]	1.5849625007211563	4	1	0	0
32320	1520	fibroblast medium pge2	[fibroblast medium PGE2]	1.5849625007211563	3	1	0	0
32321	1520	pleiotropic effect of RA	[pleiotropic effects of RA]	1.5849625007211563	4	1	0	0
32322	1520	inhibitor hiv-1 transcription	[inhibitor HIV-1 transcription]	1.5849625007211563	3	1	0	0
32323	1520	intrinsic biological activity,	[intrinsic biological activity,]	1.5849625007211563	3	1	0	0
32324	1520	only slight increases.	[only slight increases.]	1.5849625007211563	3	1	0	0
32325	1520	tax transactivation in vitro	[Tax transactivation in vitro]	1.5849625007211563	4	1	0	0
32326	1520	sub-optimal neutrophil differentiation	[sub-optimal neutrophil differentiation]	1.5849625007211563	3	1	0	0
32327	1520	three ap-1 site II,	[three AP-1 sites II,]	1.5849625007211563	4	1	0	0
32328	1520	increase ap-1 binding	[increasing AP-1 binding]	1.5849625007211563	3	1	0	0
32329	1520	gross rearrangement of bcl-6	[gross rearrangements of BCL-6]	1.5849625007211563	4	1	0	0
32330	1520	activate region of Oct-2a	[activating regions of Oct-2a]	1.5849625007211563	4	1	0	0
32331	1520	role regulate ige synthesis	[role regulating IgE synthesis]	1.5849625007211563	4	1	0	0
32332	1520	viability trypan blue exclusion	[viability trypan blue exclusion]	1.5849625007211563	4	1	0	0
32333	1520	helix-loop-helix protein id3	[helix-loop-helix protein Id3]	1.5849625007211563	3	1	0	0
32334	1520	classical banding techniques,	[classical banding techniques,]	1.5849625007211563	3	1	0	0
32335	1520	inducible metallothionein promoter	[inducible metallothionein promoter]	1.5849625007211563	3	2	1	1
32336	1520	incubation of blood	[Incubation of blood]	1.5849625007211563	3	2	2	2
32337	1520	constitutively active ras mutant,	[constitutively active ras mutant,]	1.5849625007211563	4	1	0	0
32338	1520	antioxidant concentration high enough	[antioxidant concentrations high enough]	1.5849625007211563	4	1	0	0
32339	1520	lymphoma of t-cell type	[lymphomas of T-cell type]	1.5849625007211563	4	1	0	0
32340	1520	c-myc mrna induction	[c-myc mRNA induction]	1.5849625007211563	3	1	0	0
32341	1520	split [E(spl)] gene	[split [E(spl)] genes]	1.5849625007211563	3	1	0	0
32342	1520	244-bp deoxycytidine kinase	[244-bp deoxycytidine kinase]	1.5849625007211563	3	1	0	0
32343	1520	thyroid hormone receptor tr	[thyroid hormone receptors TR]	1.5849625007211563	4	1	0	0
32344	1520	neonatal T lymphocyte	[neonatal T lymphocytes]	1.5849625007211563	3	2	2	2
32345	1520	methods: Peripheral blood monocyte	[METHODS: Peripheral blood monocytes]	1.5849625007211563	4	1	0	0
32346	1520	adenosine monophosphate camp	[adenosine monophosphate cAMP]	1.5849625007211563	3	2	1	1
32347	1520	induction of icam-1 molecule	[induction of ICAM-1 molecules]	1.5849625007211563	4	1	0	0
32348	1520	6 month (p	[6 months (P]	1.5849625007211563	3	1	0	0
32349	1520	normal deficient cell line	[normal deficient cell lines]	1.5849625007211563	4	1	0	0
32350	1520	membrane receptor for mineralocorticoid	[membrane receptor for mineralocorticoids]	1.5849625007211563	4	1	0	0
32351	1520	combination of ifn-gamma	[combination of IFN-gamma]	1.5849625007211563	3	1	0	0
32352	1520	androgen receptor gene lead	[androgen receptor gene leading]	1.5849625007211563	4	1	0	0
32353	1520	expression at the level	[expression at the levels]	1.5849625007211563	4	1	0	0
32354	1520	consensus motif for ap-2	[consensus motif for AP-2]	1.5849625007211563	4	1	0	0
32355	1520	neuronal cell line	[neuronal cell lines]	1.5849625007211563	3	1	0	0
32356	1520	three EBNA promoter Qp	[three EBNA promoters Qp]	1.5849625007211563	4	1	0	0
32357	1520	murine pro-B lymphocyte	[murine pro-B lymphocytes]	1.5849625007211563	3	1	0	0
32358	1520	TCR alpha beta	[TCR alpha beta]	1.5849625007211563	3	1	0	0
32359	1520	well-defined signal transduction pathway,	[well-defined signal transduction pathway,]	1.5849625007211563	4	1	0	0
32360	1520	second regulatory element	[second regulatory element]	1.5849625007211563	3	2	2	2
32361	1520	reduction of size, indicative	[reduction of size, indicative]	1.5849625007211563	4	1	0	0
32362	1520	lymphoid-enhancer binding factor 1	[lymphoid-enhancer binding factor 1]	1.5849625007211563	4	1	0	0
32363	1520	FVA cell nuclear extract	[FVA cell nuclear extracts]	1.5849625007211563	4	1	0	0
32364	1520	fork head gene subfamily	[fork head gene subfamily]	1.5849625007211563	4	1	0	0
32365	1520	bcd mrna transcript	[Bcd mRNA transcripts]	1.5849625007211563	3	1	0	0
32366	1520	Oct1 transcription factor	[Oct1 transcription factors]	1.5849625007211563	3	1	0	0
32367	1520	contain the IL-2 promoter	[containing the IL-2 promoter]	1.5849625007211563	4	2	1	1
32368	1520	hematopoietic lineage commitment	[Hematopoietic lineage commitment]	1.5849625007211563	3	2	1	1
32369	1520	CAG repeat region	[CAG repeat region]	1.5849625007211563	3	1	0	0
32370	1520	function of the stat-3	[function of the Stat-3]	1.5849625007211563	4	1	0	0
32371	1520	human gata-3 recombinant	[human GATA-3 recombinant]	1.5849625007211563	3	1	0	0
32372	1520	multiple DNA binding	[multiple DNA binding]	1.5849625007211563	3	1	0	0
32373	1520	response to LMP1 expression	[response to LMP1 expression]	1.5849625007211563	4	1	0	0
32374	1520	promyelocytic leukemia gene PML	[promyelocytic leukemia gene PML]	1.5849625007211563	4	1	0	0
32375	1520	tal-1 transgenic animal	[tal-1 transgenic animals]	1.5849625007211563	3	1	0	0
32376	1520	Finally, phorbol 12-myristate 13-acetate	[Finally, phorbol 12-myristate 13-acetate]	1.5849625007211563	4	1	0	0
32377	1520	Anti- CD28 T cell	[Anti- CD28 T cells]	1.5849625007211563	4	1	0	0
32378	1520	interleukin 1beta il-1beta	[interleukin 1beta IL-1beta]	1.5849625007211563	3	1	0	0
32379	1520	recruitment of tax	[recruitment of Tax]	1.5849625007211563	3	1	0	0
32380	1520	IL-2 -dependent proliferation,	[IL-2 -dependent proliferation,]	1.5849625007211563	3	1	0	0
32381	1520	NFAT-1 activity between t-lymphocyte	[NFAT-1 activity between T-lymphocytes]	1.5849625007211563	4	1	0	0
32382	1520	D5 tumor cell	[D5 tumor cells]	1.5849625007211563	3	1	0	0
32383	1520	transient NF-kappa b activation	[transient NF-kappa B activation]	1.5849625007211563	4	1	0	0
32384	1520	six case of aitl/gc	[Six cases of AITL/GC]	1.5849625007211563	4	1	0	0
32385	1520	-contain tyrosine phosphatase shp2	[-containing tyrosine phosphatase SHP2]	1.5849625007211563	4	1	0	0
32386	1520	peroxisome proliferator-activated receptor activator	[Peroxisome proliferator-activated receptor activators]	1.5849625007211563	4	1	0	0
32387	1520	high order transcriptional complex	[higher order transcriptional complex]	1.5849625007211563	4	1	0	0
32388	1520	kappa b nf-kappa b	[kappa B NF-kappa B]	1.5849625007211563	4	1	0	0
32389	1520	such as lung	[such as lung]	1.5849625007211563	3	1	0	0
32390	1520	bcd gene expression	[Bcd gene expression]	1.5849625007211563	3	2	1	1
32391	1520	However, CTLA-4 ligation	[However, CTLA-4 ligation]	1.5849625007211563	3	1	0	0
32392	1520	different ets family member	[different Ets family member]	1.5849625007211563	4	1	0	0
32393	1520	RpoN mutant lack pili	[RpoN mutant lacking pili]	1.5849625007211563	4	1	0	0
32394	1520	regulation of viral transcription	[regulation of viral transcription]	1.5849625007211563	4	1	0	0
32395	1520	peptide-loaded dendritic cell	[peptide-loaded dendritic cells]	1.5849625007211563	3	1	0	0
32396	1520	three enhancer-binding protein lef-1	[three enhancer-binding proteins LEF-1]	1.5849625007211563	4	1	0	0
32397	1520	overall protein structure	[overall protein structure]	1.5849625007211563	3	1	0	0
32398	1520	igh-enhancer -luciferase construct	[IgH-enhancer -luciferase construct]	1.5849625007211563	3	1	0	0
32399	1520	human peripheral mononuclear cell	[human peripheral mononuclear cells]	1.5849625007211563	4	1	0	0
32400	1520	primarily as a inability	[primarily as an inability]	1.5849625007211563	4	1	0	0
32401	1520	respectively), the extent	[respectively), the extent]	1.5849625007211563	3	1	0	0
32402	1520	accumulation of monocyte/macrophage cell	[accumulation of monocyte/macrophage cells]	1.5849625007211563	4	1	0	0
32403	1520	expression of interleukin 1beta	[Expression of interleukin 1beta]	1.5849625007211563	4	1	0	0
32404	1520	thus, exposure to il-6	[Thus, exposure to IL-6]	1.5849625007211563	4	1	0	0
32405	1520	regulation of this factors:	[regulation of these factors:]	1.5849625007211563	4	1	0	0
32406	1520	kappa b sequence ggggactttcc	[kappa B sequence GGGGACTTTCC]	1.5849625007211563	4	1	0	0
32407	1520	response to this stimuli.	[response to these stimuli.]	1.5849625007211563	4	1	0	0
32408	1520	CD4 accessory function,	[CD4 accessory function,]	1.5849625007211563	3	1	0	0
32409	1520	cell upon differentiation	[cells upon differentiation]	1.5849625007211563	3	1	0	0
32410	1520	first genetic lesion	[first genetic lesion]	1.5849625007211563	3	1	0	0
32411	1520	unique transcriptional activator,	[unique transcriptional activator,]	1.5849625007211563	3	1	0	0
32412	1520	three message-destabilizing element	[three message-destabilizing elements]	1.5849625007211563	3	1	0	0
32413	1520	phospholipase C gamma 1	[phospholipase C gamma 1]	1.5849625007211563	4	2	1	1
32414	1520	PML/ RARalpha fusion protein	[PML/ RARalpha fusion protein]	1.5849625007211563	4	1	0	0
32415	1520	class ii-positive cell	[class II-positive cells]	1.5849625007211563	3	1	0	0
32416	1520	recombination-activating gene (rag)-1	[recombination-activating gene (RAG)-1]	1.5849625007211563	3	1	0	0
32417	1520	(p 0.025, chi2 test),	[(P 0.025, chi2 test),]	1.5849625007211563	4	1	0	0
32418	1520	difference in specificity	[differences in specificity]	1.5849625007211563	3	1	0	0
32419	1520	transcriptional activation of c-jun	[transcriptional activation of c-jun]	1.5849625007211563	4	1	0	0
32420	1520	atopic asthma patient both	[atopic asthma patients both]	1.5849625007211563	4	1	0	0
32421	1520	proliferation of ar	[proliferation of AR]	1.5849625007211563	3	1	0	0
32422	1520	addition to NB4 cells,	[addition to NB4 cells,]	1.5849625007211563	4	1	0	0
32423	1520	multiple interact element	[multiple interacting elements]	1.5849625007211563	3	1	0	0
32424	1520	mcp-1 mcp-1 binding	[MCP-1 MCP-1 binding]	1.5849625007211563	3	1	0	0
32425	1520	frequency isolate false-positive dest	[frequency isolating false-positive DESTs]	1.5849625007211563	4	1	0	0
32426	1520	hxbp-1 DNA target sequence	[hXBP-1 DNA target sequence]	1.5849625007211563	4	1	0	0
32427	1520	granulocytic colony formation	[granulocytic colony formation]	1.5849625007211563	3	1	0	0
32428	1520	response to specific mitogen	[response to specific mitogens]	1.5849625007211563	4	1	0	0
32429	1520	transcriptional activation property	[transcriptional activation properties]	1.5849625007211563	3	1	0	0
32430	1520	persistent phosphorylation of erk-2	[persistent phosphorylation of ERK-2]	1.5849625007211563	4	1	0	0
32431	1520	NF-kappa b transcriptional activator	[NF-kappa B transcriptional activator]	1.5849625007211563	4	1	0	0
32432	1520	problem of antihypertensive therapy	[Problems of antihypertensive therapy]	1.5849625007211563	4	1	0	0
32433	1520	upregulation of ICAM-1	[upregulation of ICAM-1]	1.5849625007211563	3	1	0	0
32434	1520	gamma-interferon cell activation	[gamma-interferon cell activation]	1.5849625007211563	3	1	0	0
32435	1520	receptor-related 29-kda protein	[receptor-related 29-kDa protein]	1.5849625007211563	3	1	0	0
32436	1520	2.6-kilobase messenger rna present	[2.6-kilobase messenger RNA present]	1.5849625007211563	4	1	0	0
32437	1520	primary rat astrocyte	[primary rat astrocytes]	1.5849625007211563	3	1	0	0
32438	1520	inhibition of the transfer	[Inhibition of the transfer]	1.5849625007211563	4	1	0	0
32439	1520	prime with anti-CD3	[priming with anti-CD3]	1.5849625007211563	3	1	0	0
32440	1520	peripheral blood mononuclear leucocyte	[peripheral blood mononuclear leucocyte]	1.5849625007211563	4	2	1	1
32441	1520	activator of transcription 3	[activator of transcription 3]	1.5849625007211563	4	2	2	2
32442	1520	binding of nf-at complex	[binding of NF-AT complexes]	1.5849625007211563	4	1	0	0
32443	1520	serum total thyroxine tt4	[serum total thyroxine TT4]	1.5849625007211563	4	1	0	0
32444	1520	group of signal protein	[group of signaling proteins]	1.5849625007211563	4	1	0	0
32445	1520	activator of transcription 4	[activator of transcription 4]	1.5849625007211563	4	1	0	0
32446	1520	DNA fragment position -158	[DNA fragment positions -158]	1.5849625007211563	4	1	0	0
32447	1520	tcr activation of NFAT	[TCR activation of NFAT]	1.5849625007211563	4	1	0	0
32448	1520	dihydrofolate reductase gene homolog	[dihydrofolate reductase gene homolog]	1.5849625007211563	4	1	0	0
32449	1520	small intragenic mutation	[small intragenic mutations]	1.5849625007211563	3	1	0	0
32450	1520	human fosb gene G0S3	[human FOSB gene G0S3]	1.5849625007211563	4	1	0	0
32451	1520	role of different element	[role of different elements]	1.5849625007211563	4	1	0	0
32452	1520	various family member	[various family members,]	1.5849625007211563	3	1	0	0
32453	1520	IL-10 gene polymorphism	[IL-10 gene polymorphism]	1.5849625007211563	3	1	0	0
32454	1520	level of c-rel	[levels of c-Rel]	1.5849625007211563	3	2	1	1
32455	1520	immunosuppression of host immunity	[immunosuppression of host immunity]	1.5849625007211563	4	1	0	0
32456	1520	Jurkat expression library	[Jurkat expression library]	1.5849625007211563	3	1	0	0
32457	1520	two receptor isoforms,	[two receptor isoforms,]	1.5849625007211563	3	1	0	0
32458	1520	mm precursor lesion	[MM precursor lesions]	1.5849625007211563	3	1	0	0
32459	1520	respect to B-cell expansion	[respect to B-cell expansion]	1.5849625007211563	4	1	0	0
32460	1520	overexpression of Id3	[overexpression of Id3]	1.5849625007211563	3	1	0	0
32461	1520	use biochemical analysis	[Using biochemical analyses]	1.5849625007211563	3	1	0	0
32462	1520	cd8+ T lymphocyte present	[CD8+ T lymphocytes present]	1.5849625007211563	4	1	0	0
32463	1520	different risk groups.	[different risk groups.]	1.5849625007211563	3	1	0	0
32464	1520	activator of transcription)5	[activator of transcription)5]	1.5849625007211563	3	1	0	0
32465	1520	hiv-1 transcription by Taturday	[HIV-1 transcription by Tat.]	1.5849625007211563	4	1	0	0
32466	1520	alpha-globin locus enhancer	[alpha-globin locus enhancers]	1.5849625007211563	3	1	0	0
32467	1520	family of chemokine receptor	[family of chemokine receptors]	1.5849625007211563	4	1	0	0
32468	1520	Z gene product	[Z gene product]	1.5849625007211563	3	1	0	0
32469	1520	box1 motif with Ala-X-Ala	[BOX1 motif with Ala-X-Ala]	1.5849625007211563	4	1	0	0
32470	1520	mechanism of nf-kappab suppression	[mechanism of NF-kappaB suppression]	1.5849625007211563	4	1	0	0
32471	1520	cervical carcinoma HeLa cell	[cervical carcinoma HeLa cells]	1.5849625007211563	4	1	0	0
32472	1520	severe immunodeficient (scid-husint) mouse	[severe immunodeficient (SCID-HU-INT) mice]	1.5849625007211563	4	1	0	0
32473	1520	severe secondary hyperaldosteronism	[severe secondary hyperaldosteronism]	1.5849625007211563	3	1	0	0
32474	1520	increase in promoter activity	[increase in promoter activity]	1.5849625007211563	4	2	2	2
32475	1521	ets-1	[Ets-1]	1.58	1	17	6	5
32476	1522	stat5a	[STAT5A]	1.5714285714285714	1	17	9	7
32477	1523	week	[week]	1.5666666666666667	1	17	16	12
32478	1524	all-tran	[all-trans]	1.56	1	18	12	5
32479	1525	J	[J]	1.55	1	17	6	4
32480	1525	mapping	[mapping]	1.55	1	17	12	8
32481	1525	compartment	[compartment]	1.55	1	17	15	10
32482	1526	hypertension	[hypertension]	1.54	1	17	8	5
32483	1527	downregulation	[downregulation]	1.5333333333333334	1	17	15	9
32484	1528	superantigen	[superantigen]	1.5250000000000001	1	17	7	4
32485	1529	paf	[PAF]	1.52	1	17	9	5
32486	1529	cathepsin	[cathepsin]	1.52	1	17	9	5
32487	1530	DHEA	[DHEA]	1.5	1	16	9	9
32488	1530	N	[N]	1.5	1	16	3	3
32489	1530	myeloproliferative disorder in down' syndrome	[myeloproliferative disorder in Down's syndrome]	1.5	5	3	3	2
32490	1530	severe phenotype	[severe phenotype]	1.5	2	3	3	2
32491	1530	lung disease	[lung disease]	1.5	2	3	3	2
32492	1530	mapk pathway	[MAPK pathway]	1.5	2	3	3	2
32493	1530	cn	[CN]	1.5	1	16	7	7
32494	1530	envelope glycoprotein	[envelope glycoprotein]	1.5	2	3	3	2
32495	1530	mr	[MR]	1.5	1	16	4	4
32496	1530	paper	[paper]	1.5	1	17	6	3
32497	1530	disorder MDD	[disorder MDD]	1.5	2	3	3	2
32498	1530	X box	[X box]	1.5	2	3	3	2
32499	1530	hiv terminal	[HIV terminal]	1.5	2	3	3	2
32500	1530	DNase site	[DNase site]	1.5	2	3	3	2
32501	1530	Glucocorticoid resistance	[Glucocorticoid resistance]	1.5	2	3	3	2
32502	1530	receptor present	[receptor present]	1.5	2	3	3	2
32503	1530	steroid action	[steroid action]	1.5	2	3	3	2
32504	1530	male volunteer	[male volunteers]	1.5	2	3	3	2
32505	1530	nm RA	[nM RA]	1.5	2	3	3	2
32506	1530	hiv rna	[HIV RNA]	1.5	2	3	3	2
32507	1530	tnf-alpha beta	[TNF-alpha beta]	1.5	2	3	3	2
32508	1530	myosin light	[myosin light]	1.5	2	3	3	2
32509	1530	cd8(-) CD3	[CD8(-) CD3]	1.5	2	3	3	2
32510	1530	adipocyte differentiation	[adipocyte differentiation]	1.5	2	3	3	2
32511	1530	primary b-lymphocyte	[primary B-lymphocytes]	1.5	2	3	3	2
32512	1530	complete remission	[complete remission]	1.5	2	3	3	2
32513	1530	type p53	[type p53]	1.5	2	3	3	2
32514	1530	RCC explant	[RCC explants]	1.5	2	3	3	2
32515	1530	eosinophil protein	[eosinophil protein]	1.5	2	3	3	2
32516	1530	macrophage maturation	[macrophage maturation]	1.5	2	3	3	2
32517	1530	myeloid cell nuclear differentiation antigen	[myeloid cell nuclear differentiation antigen]	1.5	5	3	3	2
32518	1530	nef gene	[nef gene]	1.5	2	3	3	2
32519	1530	tat mutant	[tat mutants]	1.5	2	3	3	2
32520	1530	cyclic element	[cyclic element]	1.5	2	3	3	2
32521	1530	persistent arthritis	[persistent arthritis]	1.5	2	3	3	2
32522	1530	Nuclear transcription	[Nuclear transcription]	1.5	2	3	3	2
32523	1530	gata-1 mrna	[GATA-1 mRNA]	1.5	2	3	3	2
32524	1530	three form	[three forms]	1.5	2	3	3	2
32525	1530	SH2 domain	[SH2 domain]	1.5	2	3	3	2
32526	1530	number of receptor in lymphocyte	[number of receptors in lymphocytes]	1.5	5	3	3	2
32527	1530	cytokine network	[cytokine network]	1.5	2	3	3	2
32528	1530	T cell leukemia virus type	[T cell leukemia virus type]	1.5	5	3	3	2
32529	1530	four element	[Four elements]	1.5	2	3	3	2
32530	1530	ZEBRA	[ZEBRA]	1.5	1	16	3	3
32531	1530	flank DNA	[flanking DNA]	1.5	2	3	3	2
32532	1530	physiologic relevance	[physiologic relevance]	1.5	2	3	3	2
32533	1530	1-2 hour	[1-2 hr]	1.5	2	3	3	2
32534	1530	complementation group	[complementation groups]	1.5	2	3	3	2
32535	1530	12-lipoxygenase activity	[12-lipoxygenase activity]	1.5	2	3	3	2
32536	1530	inducible activity	[inducible activity]	1.5	2	3	3	2
32537	1530	C/EBP family	[C/EBP family]	1.5	2	3	3	2
32538	1530	cytomegalovirus hcmv	[cytomegalovirus HCMV]	1.5	2	3	3	2
32539	1530	selective regulation	[selective regulation]	1.5	2	3	3	2
32540	1530	salt concentration	[salt concentration]	1.5	2	3	3	2
32541	1530	molecular pathogenesis	[molecular pathogenesis]	1.5	2	3	3	2
32542	1530	suggest essential	[suggesting essential]	1.5	2	3	3	2
32543	1530	basophil	[basophil]	1.5	1	15	0	0
32544	1530	NH2 domain	[NH2 domain]	1.5	2	3	3	2
32545	1530	P-like element	[P-like elements]	1.5	2	3	3	2
32546	1530	integral component	[integral component]	1.5	2	3	3	2
32547	1530	IL2	[IL2]	1.5	1	16	7	7
32548	1530	susceptibility gene	[susceptibility gene]	1.5	2	3	3	2
32549	1530	growth transformation	[growth transformation]	1.5	2	3	3	2
32550	1530	12-o-tetradecanoylphorbol 13-acetate	[12-O-tetradecanoylphorbol 13-acetate]	1.5	2	3	3	2
32551	1530	transcription (stat)	[transcription (STAT)]	1.5	2	3	3	2
32552	1530	stimulatory factor	[stimulatory factor]	1.5	2	3	3	2
32553	1530	GATA	[GATA]	1.5	1	16	5	5
32554	1530	group c	[group C]	1.5	2	3	3	2
32555	1530	transdominant mutant	[transdominant mutant]	1.5	2	3	3	2
32556	1530	crucial event	[crucial event]	1.5	2	3	3	2
32557	1530	4 beta	[4 beta]	1.5	2	3	3	2
32558	1530	surface igm	[surface IgM]	1.5	2	3	3	2
32559	1530	cooperative interaction	[cooperative interaction]	1.5	2	3	3	2
32560	1530	tfiid protein	[TFIID protein]	1.5	2	3	3	2
32561	1530	NF-ATp	[NF-ATp]	1.5	1	16	3	3
32562	1530	cck(b) receptor	[CCK(B) receptor]	1.5	2	3	3	2
32563	1530	NF-ATc	[NF-ATc]	1.5	1	16	4	4
32564	1530	cytoplasmic complex	[cytoplasmic complex]	1.5	2	3	3	2
32565	1530	acute infarction	[acute infarction]	1.5	2	3	3	2
32566	1530	life cycle	[life cycle]	1.5	2	3	3	2
32567	1530	major complex (mhc) class gene	[major complex (MHC) class genes]	1.5	5	3	3	2
32568	1530	tonsillar b	[tonsillar B]	1.5	2	3	3	2
32569	1530	rnase protection	[RNase protection]	1.5	2	3	3	2
32570	1530	autoantigen la/ss-b	[autoantigen La/SS-B]	1.5	2	3	3	2
32571	1530	rs cell	[RS cells]	1.5	2	3	3	2
32572	1530	immunodeficiency virus long terminal repeat	[immunodeficiency virus long terminal repeat]	1.5	5	3	3	2
32573	1530	immune regulation	[immune regulation]	1.5	2	3	3	2
32574	1530	quiescent pbmc	[quiescent PBMC]	1.5	2	3	3	2
32575	1530	lck	[lck]	1.5	1	16	7	7
32576	1530	enhancer transcript	[enhancer transcripts]	1.5	2	3	3	2
32577	1530	nm,	[nM,]	1.5	1	16	12	12
32578	1530	adenoviral infection	[adenoviral infection]	1.5	2	3	3	2
32579	1530	include monocyte	[including monocytes]	1.5	2	3	3	2
32580	1530	polyclonal pattern	[polyclonal pattern]	1.5	2	3	3	2
32581	1530	low activation	[low activation]	1.5	2	3	3	2
32582	1530	il-8 secretion	[IL-8 secretion]	1.5	2	3	3	2
32583	1530	leukemia aml	[leukemia AML]	1.5	2	3	3	2
32584	1530	regulation of immunodeficiency virus type	[regulation of immunodeficiency virus type]	1.5	5	3	3	2
32585	1530	Rel/NF-kappa b	[Rel/NF-kappa B]	1.5	2	3	3	2
32586	1530	IkB alpha	[IkB alpha]	1.5	2	3	3	2
32587	1530	two family	[two families]	1.5	2	3	3	2
32588	1530	downstream activation	[downstream activation]	1.5	2	3	3	2
32589	1530	blood vessel	[blood vessel]	1.5	2	3	3	2
32590	1530	ctll-2 cell	[CTLL-2 cells]	1.5	2	3	3	2
32591	1530	down' syndrome	[Down's syndrome]	1.5	2	3	3	2
32592	1530	proapoptotic factor	[proapoptotic factor]	1.5	2	3	3	2
32593	1530	different domain	[different domains]	1.5	2	3	3	2
32594	1530	novel role	[novel role]	1.5	2	3	3	2
32595	1530	loss-of-function mutation	[loss-of-function mutation]	1.5	2	3	3	2
32596	1530	dex clone	[dex clones]	1.5	2	3	3	2
32597	1530	assay ELISA	[assay ELISA]	1.5	2	3	3	2
32598	1530	RESULTS:	[RESULTS:]	1.5	1	16	10	10
32599	1530	cognate interaction	[cognate interaction]	1.5	2	3	3	2
32600	1530	age-related decrease	[age-related decrease]	1.5	2	3	3	2
32601	1530	1 expression	[1 expression]	1.5	2	3	3	2
32602	1530	factor-kappa b NF-kappa b activation	[factor-kappa B NF-kappa B activation]	1.5	5	3	3	2
32603	1530	p50-p65 heterodimer	[p50-p65 heterodimer]	1.5	2	3	3	2
32604	1530	inhibitory concentration	[inhibitory concentrations]	1.5	2	3	3	2
32605	1530	modulatory effect	[modulatory effects]	1.5	2	3	3	2
32606	1530	vitro system	[vitro system]	1.5	2	3	3	2
32607	1530	hnf-1 alpha	[HNF-1 alpha]	1.5	2	3	3	2
32608	1530	cell ECs	[cells ECs]	1.5	2	3	3	2
32609	1530	great increase	[greatest increase]	1.5	2	3	3	2
32610	1530	subsequent translocation	[subsequent translocation]	1.5	2	3	3	2
32611	1530	physiologic role	[physiologic role]	1.5	2	3	3	2
32612	1530	gc insensitivity	[GC insensitivity]	1.5	2	3	3	2
32613	1530	tool	[tool]	1.5	1	16	15	15
32614	1530	receptor alpha-chain	[receptor alpha-chain]	1.5	2	3	3	2
32615	1530	beas-2b cell	[BEAS-2B cells]	1.5	2	3	3	2
32616	1530	other	[others]	1.5	1	16	3	3
32617	1530	mrna display	[mRNA display]	1.5	2	3	3	2
32618	1530	necessary component	[necessary component]	1.5	2	3	3	2
32619	1530	major (mhc) class ii gene	[major (MHC) class II genes]	1.5	5	3	3	2
32620	1530	gut inflammation	[gut inflammation]	1.5	2	3	3	2
32621	1530	B2 site	[B2 site]	1.5	2	3	3	2
32622	1530	lox-1 gene	[LOX-1 gene]	1.5	2	3	3	2
32623	1530	dimerization domain	[dimerization domain]	1.5	2	3	3	2
32624	1530	factor specific	[factor specific]	1.5	2	3	3	2
32625	1530	bacterial infection	[bacterial infections]	1.5	2	3	3	2
32626	1530	common site	[common site]	1.5	2	3	3	2
32627	1530	virus 40	[virus 40]	1.5	2	3	3	2
32628	1530	neutrophil lineage	[neutrophil lineage]	1.5	2	3	3	2
32629	1530	CD4 (+)	[CD4 (+)]	1.5	2	3	3	2
32630	1530	large lymphocyte	[large lymphocytes]	1.5	2	3	3	2
32631	1530	strike increase	[striking increase]	1.5	2	3	3	2
32632	1530	IFN factor-1	[IFN factor-1]	1.5	2	3	3	2
32633	1530	myb rna	[myb RNA]	1.5	2	3	3	2
32634	1530	ebv type	[EBV type]	1.5	2	3	3	2
32635	1530	possible correlation	[possible correlation]	1.5	2	3	3	2
32636	1530	low expression	[low expression]	1.5	2	3	3	2
32637	1530	human precursor	[human precursors]	1.5	2	3	3	2
32638	1530	ifn-gamma transcription	[IFN-gamma transcription]	1.5	2	3	3	2
32639	1530	basal	[basal]	1.5	1	16	4	4
32640	1530	sequence variation	[sequence variation]	1.5	2	3	3	2
32641	1530	repressor protein	[repressor proteins]	1.5	2	3	3	2
32642	1530	tat gene	[tat gene]	1.5	2	3	3	2
32643	1530	moderate level	[moderate levels]	1.5	2	3	3	2
32644	1530	G. vaginalis	[G. vaginalis]	1.5	2	3	3	2
32645	1530	bovine	[bovine]	1.5	1	16	8	8
32646	1530	beta globin	[beta globin]	1.5	2	3	3	2
32647	1530	single class	[single class]	1.5	2	3	3	2
32648	1530	element CRE	[element CRE]	1.5	2	3	3	2
32649	1530	cytomegalovirus CMV	[cytomegalovirus CMV]	1.5	2	3	3	2
32650	1530	granular lymphocyte	[granular lymphocytes]	1.5	2	3	3	2
32651	1530	strong expression	[strong expression]	1.5	2	3	3	2
32652	1530	non-hodgkin lymphoma	[non-Hodgkin lymphoma]	1.5	2	3	3	2
32653	1530	tissue tumor	[tissue tumors]	1.5	2	3	3	2
32654	1530	cell-specific difference	[cell-specific differences]	1.5	2	3	3	2
32655	1530	distinct family	[distinct families]	1.5	2	3	3	2
32656	1530	transient pseudohypoaldosteronism	[transient pseudohypoaldosteronism]	1.5	2	3	3	2
32657	1530	have affinity	[having affinity]	1.5	2	3	3	2
32658	1530	blood leucocyte	[blood leucocyte]	1.5	2	3	3	2
32659	1530	actin assembly	[actin assembly]	1.5	2	3	3	2
32660	1530	increase concentration	[increasing concentrations]	1.5	2	3	3	2
32661	1530	transient disorder in down' syndrome	[transient disorder in Down's syndrome]	1.5	5	3	3	2
32662	1530	number of estrogen receptor er	[number of estrogen receptors ER]	1.5	5	3	3	2
32663	1530	regulation of human immunodeficiency virus type	[regulation of human immunodeficiency virus type]	1.5	6	3	3	2
32664	1530	antioxidant pyrrolidine	[antioxidant pyrrolidine]	1.5	2	3	3	2
32665	1530	two member	[two members]	1.5	2	3	3	2
32666	1530	surface domain	[surface domain]	1.5	2	3	3	2
32667	1530	cell-specific coactivator	[cell-specific coactivators]	1.5	2	3	3	2
32668	1530	endothelial expression	[endothelial expression]	1.5	2	3	3	2
32669	1530	testosterone	[testosterone]	1.5	1	16	4	4
32670	1530	optimal activity	[optimal activity]	1.5	2	3	3	2
32671	1530	memory b	[memory B]	1.5	2	3	3	2
32672	1530	A/R challenge	[A/R challenge]	1.5	2	3	3	2
32673	1530	domain protein	[domain protein]	1.5	2	3	3	2
32674	1530	JunB	[JunB]	1.5	1	16	3	3
32675	1530	JunD	[JunD]	1.5	1	16	5	5
32676	1530	novel regulator	[novel regulator]	1.5	2	3	3	2
32677	1530	Addisonian picture	[Addisonian picture]	1.5	2	3	3	2
32678	1530	promyelocytic leukaemia	[promyelocytic leukaemia]	1.5	2	3	3	2
32679	1530	ciita expression	[CIITA expression]	1.5	2	3	3	2
32680	1530	tnf-alpha synthesis	[TNF-alpha synthesis]	1.5	2	3	3	2
32681	1530	NFkappaB translocation	[NFkappaB translocation]	1.5	2	3	3	2
32682	1530	macrophage scavenger	[macrophage scavenger]	1.5	2	3	3	2
32683	1530	beta- estradiol	[beta- estradiol]	1.5	2	3	3	2
32684	1530	replicative form	[replicative form]	1.5	2	3	3	2
32685	1530	drip coactivator	[DRIP coactivator]	1.5	2	3	3	2
32686	1530	Stat 5b	[Stat 5b]	1.5	2	3	3	2
32687	1530	coding sequence	[coding sequence]	1.5	2	3	3	2
32688	1530	unique characteristic	[unique characteristic]	1.5	2	3	3	2
32689	1530	age-related decline	[age-related decline]	1.5	2	3	3	2
32690	1530	alpha binding	[alpha binding]	1.5	2	3	3	2
32691	1530	CD28 MoAb	[CD28 MoAb]	1.5	2	3	3	2
32692	1530	50% concentration	[50% concentrations]	1.5	2	3	3	2
32693	1530	mitogen-activated protein kinase signal pathway	[mitogen-activated protein kinase signaling pathway]	1.5	5	3	3	2
32694	1530	gr isoform	[GR isoforms]	1.5	2	3	3	2
32695	1530	N-terminal half	[N-terminal half]	1.5	2	3	3	2
32696	1530	elk-1 promoter	[elk-1 promoter]	1.5	2	3	3	2
32697	1530	complement receptor	[complement receptors]	1.5	2	3	3	2
32698	1530	neutrophil apoptosis	[neutrophil apoptosis]	1.5	2	3	3	2
32699	1530	important consequence	[important consequences]	1.5	2	3	3	2
32700	1530	LTB4	[LTB4]	1.5	1	16	4	4
32701	1530	mature CD4	[mature CD4]	1.5	2	3	3	2
32702	1530	Drosophila	[Drosophila]	1.5	1	16	5	5
32703	1530	il-2 proliferation	[IL-2 proliferation]	1.5	2	3	3	2
32704	1530	kappa 3'	[kappa 3']	1.5	2	3	3	2
32705	1530	specificity of cd4+ t-cell clone	[specificity of CD4+ T-cell clones]	1.5	5	3	3	2
32706	1530	major histocompatibility (mhc) class gene	[major histocompatibility (MHC) class genes]	1.5	5	3	3	2
32707	1530	receptor gamma	[receptor gamma]	1.5	2	3	3	2
32708	1530	SL3 enhancer	[SL3 enhancer]	1.5	2	3	3	2
32709	1531	act	[acting]	1.4928571428571429	1	16	15	14
32710	1532	pair	[pair]	1.4909090909090912	1	16	12	11
32711	1533	expansion	[expansion]	1.4900000000000002	1	16	11	10
32712	1534	ikappab-alpha	[IkappaB-alpha]	1.4875	1	16	9	8
32713	1534	tax1	[Tax1]	1.4875	1	16	9	8
32714	1535	id3	[Id3]	1.4857142857142858	1	16	8	7
32715	1535	actin	[actin]	1.4857142857142858	1	16	8	7
32716	1536	B/Rel	[B/Rel]	1.4833333333333334	1	16	14	12
32717	1536	il-9	[IL-9]	1.4833333333333334	1	16	7	6
32718	1537	ifn-beta	[IFN-beta]	1.4800000000000002	1	16	6	5
32719	1537	potency	[potency]	1.4800000000000002	1	16	12	10
32720	1537	leukaemia	[leukaemia]	1.4800000000000002	1	16	12	10
32721	1538	aim	[aim]	1.475	1	19	17	4
32722	1538	hemoglobin	[hemoglobin]	1.475	1	16	10	8
32723	1538	cluster	[cluster]	1.475	1	18	13	4
32724	1539	turnover	[turnover]	1.4714285714285715	1	16	9	7
32725	1539	bzlf1	[BZLF1]	1.4714285714285715	1	16	9	7
32726	1540	volunteer	[volunteer]	1.47	1	16	13	10
32727	1541	density	[density]	1.4666666666666668	1	16	12	9
32728	1541	Interleukin	[Interleukin]	1.4666666666666668	1	16	8	6
32729	1542	status	[status]	1.4636363636363638	1	16	15	11
32730	1543	bacterium	[bacteria]	1.46	1	16	7	5
32731	1543	Bcl-6	[Bcl-6]	1.46	1	16	7	5
32732	1543	3-kinase	[3-kinase]	1.46	1	16	14	10
32733	1543	immunosuppressant	[immunosuppressant]	1.46	1	16	7	5
32734	1544	Mono	[Mono]	1.4500000000000002	1	16	6	4
32735	1544	p105	[p105]	1.4500000000000002	1	16	6	4
32736	1544	traf2	[TRAF2]	1.4500000000000002	1	16	6	4
32737	1545	pyrrolidine	[pyrrolidine]	1.4444444444444446	1	16	14	9
32738	1546	exception	[exception]	1.4400000000000002	1	17	13	5
32739	1547	tg	[TG]	1.4333333333333336	1	16	5	3
32740	1548	inducibility	[inducibility]	1.4285714285714288	1	16	12	7
32741	1548	shock	[shock]	1.4285714285714288	1	16	12	7
32742	1549	primer	[primer]	1.425	1	16	7	4
32743	1549	vein	[vein]	1.425	1	19	19	4
32744	1550	threshold	[threshold]	1.42	1	16	9	5
32745	1550	onset	[onset]	1.42	1	17	14	5
32746	1551	methylation	[methylation]	1.4166666666666667	1	16	11	6
32747	1552	balance	[balance]	1.4142857142857144	1	16	13	7
32748	1553	b-	[B-]	1.4000000000000001	1	15	5	5
32749	1553	genistein	[genistein]	1.4000000000000001	1	15	3	3
32750	1553	pdtc	[PDTC]	1.4000000000000001	1	16	10	5
32751	1553	gssg	[GSSG]	1.4000000000000001	1	15	6	6
32752	1553	proto-oncogene	[proto-oncogene]	1.4000000000000001	1	15	10	10
32753	1553	region,	[region,]	1.4000000000000001	1	15	4	4
32754	1553	B-cell	[B-cell]	1.4000000000000001	1	15	3	3
32755	1553	FDC	[FDC]	1.4000000000000001	1	15	5	5
32756	1553	ccaat	[CCAAT]	1.4000000000000001	1	15	1	1
32757	1553	igg	[IgG]	1.4000000000000001	1	15	11	11
32758	1553	trans-acting	[trans-acting]	1.4000000000000001	1	15	8	8
32759	1553	cd4(+)	[CD4(+)]	1.4000000000000001	1	15	3	3
32760	1553	rabbit	[rabbit]	1.4000000000000001	1	15	6	6
32761	1553	one	[one]	1.4000000000000001	1	15	9	9
32762	1553	pml	[PML]	1.4000000000000001	1	15	8	8
32763	1553	vzv	[VZV]	1.4000000000000001	1	15	7	7
32764	1553	lectin	[lectin]	1.4000000000000001	1	15	6	6
32765	1553	Spi-1	[Spi-1]	1.4000000000000001	1	15	10	10
32766	1553	novel	[novel]	1.4000000000000001	1	15	9	9
32767	1553	activity,	[activity,]	1.4000000000000001	1	15	9	9
32768	1553	oncoprotein	[oncoprotein]	1.4000000000000001	1	15	10	10
32769	1553	IRF-1	[IRF-1]	1.4000000000000001	1	15	4	4
32770	1553	METHODS:	[METHODS:]	1.4000000000000001	1	15	10	10
32771	1553	kilobasis	[kilobases]	1.4000000000000001	1	15	14	14
32772	1553	LMP-1	[LMP-1]	1.4000000000000001	1	15	2	2
32773	1553	symptom	[symptom]	1.4000000000000001	1	16	10	5
32774	1553	footprinting	[footprinting]	1.4000000000000001	1	15	13	13
32775	1553	nm23	[nm23]	1.4000000000000001	1	15	2	2
32776	1553	accessory	[accessory]	1.4000000000000001	1	15	4	4
32777	1553	immunophilin	[immunophilin]	1.4000000000000001	1	15	6	6
32778	1553	anti-cd28	[anti-CD28]	1.4000000000000001	1	15	5	5
32779	1554	ppargamma	[PPARgamma]	1.390909090909091	1	15	12	11
32780	1554	entry	[entry]	1.390909090909091	1	15	12	11
32781	1555	tolerance	[tolerance]	1.3900000000000001	1	15	11	10
32782	1556	dimer	[dimer]	1.388888888888889	1	15	10	9
32783	1557	mcd14	[mCD14]	1.3875000000000002	1	15	9	8
32784	1557	polypeptide	[polypeptide]	1.3875000000000002	1	15	9	8
32785	1558	estradiol	[estradiol]	1.385714285714286	1	15	8	7
32786	1559	u1	[U1]	1.3833333333333335	1	15	7	6
32787	1559	size	[size]	1.3833333333333335	1	15	7	6
32788	1559	Grb2	[Grb2]	1.3833333333333335	1	15	7	6
32789	1559	tcdd	[TCDD]	1.3833333333333335	1	15	7	6
32790	1559	mRNA	[mRNA]	1.3833333333333335	1	15	7	6
32791	1560	activation,	[activation,]	1.3800000000000001	1	15	6	5
32792	1560	strain	[strain]	1.3800000000000001	1	15	12	10
32793	1560	ltr	[LTRs]	1.3800000000000001	1	15	6	5
32794	1560	AIDS	[AIDS]	1.3800000000000001	1	15	6	5
32795	1561	insertion	[insertion]	1.375	1	16	9	4
32796	1561	apl	[APL]	1.375	1	15	5	4
32797	1561	hsp70	[hsp70]	1.375	1	15	5	4
32798	1562	tsc2	[TSC2]	1.3714285714285714	1	15	9	7
32799	1563	protein.	[protein.]	1.3666666666666667	1	15	4	3
32800	1563	beta-globin	[beta-globin]	1.3666666666666667	1	15	8	6
32801	1564	hd	[HD]	1.3625	1	15	11	8
32802	1565	stimulation.	[stimulation.]	1.36	1	15	7	5
32803	1566	E3	[E3]	1.35	1	15	6	4
32804	1566	EBNA	[EBNA]	1.35	1	15	6	4
32805	1566	5'-flanking	[5'-flanking]	1.35	1	15	9	6
32806	1566	mbp	[MBP]	1.35	1	15	9	6
32807	1566	tar	[TAR]	1.35	1	15	6	4
32808	1566	magnitude	[magnitude]	1.35	1	16	10	4
32809	1566	(nk)	[(NK)]	1.35	1	16	15	6
32810	1566	tradd	[TRADD]	1.35	1	15	6	4
32811	1567	contact	[contact]	1.3375000000000001	1	15	13	8
32812	1568	epstein-barr	[Epstein-Barr]	1.3333333333333335	1	15	5	3
32813	1568	DNase	[DNase]	1.3333333333333335	1	16	8	3
32814	1568	Oct-2a	[Oct-2a]	1.3333333333333335	1	15	5	3
32815	1569	person	[persons]	1.3285714285714287	1	15	12	7
32816	1570	epithelium	[epithelium]	1.3250000000000002	1	15	14	8
32817	1570	epor	[EpoR]	1.3250000000000002	1	15	7	4
32818	1571	p16	[p16]	1.32	1	15	9	5
32819	1572	level.	[level.]	1.3142857142857143	1	15	13	7
32820	1573	g	[G]	1.3	1	14	6	6
32821	1573	NE	[NE]	1.3	1	14	4	4
32822	1573	b2	[B2]	1.3	1	14	10	10
32823	1573	ag	[Ag]	1.3	1	14	4	4
32824	1573	dm	[DM]	1.3	1	14	3	3
32825	1573	infiltrate	[infiltrate]	1.3	1	14	9	9
32826	1573	enf)-kappa	[(NF)-kappa]	1.3	1	17	16	4
32827	1573	ganglioside	[ganglioside]	1.3	1	14	5	5
32828	1573	nf-atp	[NF-ATp]	1.3	1	14	7	7
32829	1573	results,	[results,]	1.3	1	14	3	3
32830	1573	nf-il6	[NF-IL6]	1.3	1	14	4	4
32831	1573	transcription,	[transcription,]	1.3	1	14	5	5
32832	1573	infection.	[infection.]	1.3	1	14	5	5
32833	1573	commitment	[commitment]	1.3	1	14	6	6
32834	1573	zeta	[zeta]	1.3	1	14	7	7
32835	1573	C5a	[C5a]	1.3	1	14	7	7
32836	1573	stat5b	[STAT5B]	1.3	1	14	4	4
32837	1573	MRD	[MRD]	1.3	1	14	8	8
32838	1573	histamine	[histamine]	1.3	1	14	4	4
32839	1573	Rex	[Rex]	1.3	1	14	1	1
32840	1573	cd40l	[CD40L]	1.3	1	14	7	7
32841	1573	rar	[RARS]	1.3	1	16	6	2
32842	1573	drosophila	[Drosophila]	1.3	1	14	2	2
32843	1573	proteins,	[proteins,]	1.3	1	14	9	9
32844	1573	methods:	[METHODS:]	1.3	1	14	7	7
32845	1573	tgf-beta1	[TGF-beta1]	1.3	1	14	4	4
32846	1573	Stat1alpha	[Stat1alpha]	1.3	1	14	2	2
32847	1573	sepsis	[sepsis]	1.3	1	14	3	3
32848	1573	cd16	[CD16]	1.3	1	14	7	7
32849	1573	zinc-finger	[zinc-finger]	1.3	1	14	5	5
32850	1573	abundance	[abundance]	1.3	1	15	14	7
32851	1573	CONCLUSION:	[CONCLUSION:]	1.3	1	14	3	3
32852	1573	SLP-76	[SLP-76]	1.3	1	14	6	6
32853	1573	summary,	[summary,]	1.3	1	13	0	0
32854	1573	cell-type	[cell-type]	1.3	1	14	3	3
32855	1573	LEF-1	[LEF-1]	1.3	1	14	6	6
32856	1573	CD38	[CD38]	1.3	1	14	3	3
32857	1573	investigation	[investigation]	1.3	1	16	12	4
32858	1573	hydrocortisone	[hydrocortisone]	1.3	1	14	3	3
32859	1573	ELISA	[ELISA]	1.3	1	14	2	2
32860	1574	thiol	[thiol]	1.288888888888889	1	14	10	9
32861	1575	sex	[sex]	1.2875	1	14	9	8
32862	1575	proteolysis	[proteolysis]	1.2875	1	14	9	8
32863	1576	PPARgamma	[PPARgamma]	1.2857142857142858	1	14	8	7
32864	1576	examination	[Examination]	1.2857142857142858	1	15	15	7
32865	1577	nfatc	[NFATc]	1.2833333333333334	1	14	7	6
32866	1577	transcriptase	[transcriptase]	1.2833333333333334	1	14	7	6
32867	1577	expression.	[expression.]	1.2833333333333334	1	14	7	6
32868	1577	notion	[notion]	1.2833333333333334	1	14	7	6
32869	1577	protooncogene	[protooncogene]	1.2833333333333334	1	14	7	6
32870	1578	GCR	[GCR]	1.2800000000000002	1	14	6	5
32871	1578	gcs	[GCS]	1.2800000000000002	1	14	6	5
32872	1578	content	[content]	1.2800000000000002	1	14	12	10
32873	1578	TAL1	[TAL1]	1.2800000000000002	1	14	6	5
32874	1579	h.	[h,]	1.277777777777778	1	14	11	9
32875	1580	transform	[transforming]	1.2750000000000001	1	14	5	4
32876	1580	loop	[loop]	1.2750000000000001	1	14	10	8
32877	1580	RelA	[RelA]	1.2750000000000001	1	14	5	4
32878	1580	colony-stimumulatelany-stg	[colony-stimulating]	1.2750000000000001	1	15	9	4
32879	1581	monkey	[monkey]	1.27	1	14	13	10
32880	1582	R	[R]	1.2666666666666666	1	14	8	6
32881	1582	Vav	[Vav]	1.2666666666666666	1	14	4	3
32882	1582	thromboxane	[thromboxane]	1.2666666666666666	1	15	7	3
32883	1583	nf-atc	[NF-ATc]	1.26	1	14	7	5
32884	1584	X	[X]	1.25	1	14	9	6
32885	1584	b1	[B1]	1.25	1	14	9	6
32886	1584	cleavage	[cleavage]	1.25	1	15	10	4
32887	1584	12-o-tetradecanoylphorbol-13-acetate	[12-O-tetradecanoylphorbol-13-acetate]	1.25	1	14	9	6
32888	1585	evaluation	[evaluation]	1.2444444444444445	1	14	14	9
32889	1586	HUVEC	[HUVEC]	1.2400000000000002	1	14	8	5
32890	1587	MNDA	[MNDA]	1.2333333333333334	1	14	5	3
32891	1587	actinomycin	[actinomycin]	1.2333333333333334	1	14	5	3
32892	1587	fatty	[fatty]	1.2333333333333334	1	14	5	3
32893	1588	NFATx1	[NFATx1]	1.225	1	14	7	4
32894	1589	blockade	[blockade]	1.2166666666666668	1	14	11	6
32895	1590	Y	[Y]	1.2000000000000002	1	13	3	3
32896	1590	n	[n]	1.2000000000000002	1	13	2	2
32897	1590	B2	[B2]	1.2000000000000002	1	13	2	2
32898	1590	EC	[EC]	1.2000000000000002	1	13	5	5
32899	1590	mu	[mu]	1.2000000000000002	1	13	4	4
32900	1590	Daudi	[Daudi]	1.2000000000000002	1	13	4	4
32901	1590	ratio	[ratio]	1.2000000000000002	1	14	10	5
32902	1590	ascorbate	[ascorbate]	1.2000000000000002	1	13	4	4
32903	1590	glucose	[glucose]	1.2000000000000002	1	13	5	5
32904	1590	salicylate	[salicylate]	1.2000000000000002	1	13	1	1
32905	1590	administration	[administration]	1.2000000000000002	1	14	14	7
32906	1590	heart	[heart]	1.2000000000000002	1	13	2	2
32907	1590	GRE	[GRE]	1.2000000000000002	1	13	5	5
32908	1590	phosphorothioate	[phosphorothioate]	1.2000000000000002	1	13	6	6
32909	1590	Raf-1	[Raf-1]	1.2000000000000002	1	13	3	3
32910	1590	gamma-globin	[gamma-globin]	1.2000000000000002	1	13	3	3
32911	1590	GAL4	[GAL4]	1.2000000000000002	1	13	2	2
32912	1590	rap1	[Rap1]	1.2000000000000002	1	13	1	1
32913	1590	myelopoiesis	[myelopoiesis]	1.2000000000000002	1	13	5	5
32914	1590	bat	[BAT]	1.2000000000000002	1	13	1	1
32915	1590	p52	[p52]	1.2000000000000002	1	13	3	3
32916	1590	vd3	[VD3]	1.2000000000000002	1	13	3	3
32917	1590	kidney	[kidney]	1.2000000000000002	1	13	2	2
32918	1590	stimuli.	[stimuli.]	1.2000000000000002	1	13	11	11
32919	1590	stimuli,	[stimuli,]	1.2000000000000002	1	13	7	7
32920	1590	bhlh	[bHLH]	1.2000000000000002	1	13	6	6
32921	1590	erythropoiesis	[erythropoiesis]	1.2000000000000002	1	13	6	6
32922	1590	forskolin	[forskolin]	1.2000000000000002	1	13	2	2
32923	1590	RANTES	[RANTES]	1.2000000000000002	1	13	3	3
32924	1590	tfiid	[TFIID]	1.2000000000000002	1	13	6	6
32925	1590	cle0	[CLE0]	1.2000000000000002	1	13	5	5
32926	1590	stat4	[STAT4]	1.2000000000000002	1	13	5	5
32927	1590	(mhc)	[(MHC)]	1.2000000000000002	1	14	2	1
32928	1590	surgery	[surgery]	1.2000000000000002	1	13	4	4
32929	1590	conditions,	[conditions,]	1.2000000000000002	1	13	4	4
32930	1590	gene,	[gene,]	1.2000000000000002	1	13	5	5
32931	1590	C-terminal	[C-terminal]	1.2000000000000002	1	12	0	0
32932	1590	astrocyte	[astrocytes]	1.2000000000000002	1	13	3	3
32933	1590	gp160	[gp160]	1.2000000000000002	1	13	4	4
32934	1590	Escherichia	[Escherichia]	1.2000000000000002	1	13	6	6
32935	1590	aging	[aging]	1.2000000000000002	1	13	3	3
32936	1590	CD18	[CD18]	1.2000000000000002	1	12	0	0
32937	1590	hydrogen	[hydrogen]	1.2000000000000002	1	14	10	5
32938	1590	pro-B	[pro-B]	1.2000000000000002	1	13	4	4
32939	1590	parent	[parent]	1.2000000000000002	1	13	2	2
32940	1590	IL-4R	[IL-4R]	1.2000000000000002	1	13	2	2
32941	1591	mol/L	[mol/L]	1.1916666666666667	1	13	13	12
32942	1592	pge2	[PGE2]	1.1857142857142857	1	13	8	7
32943	1593	lavage	[lavage]	1.1833333333333333	1	13	7	6
32944	1593	il-1ra	[IL-1ra]	1.1833333333333333	1	13	7	6
32945	1594	HS	[HS]	1.1800000000000002	1	13	6	5
32946	1594	SRF	[SRF]	1.1800000000000002	1	13	6	5
32947	1594	tcp	[TCP]	1.1800000000000002	1	13	6	5
32948	1594	priming	[priming]	1.1800000000000002	1	13	6	5
32949	1594	remission	[remission]	1.1800000000000002	1	13	12	10
32950	1594	half-life	[half-life]	1.1800000000000002	1	14	11	5
32951	1594	beta-catenin	[beta-catenin]	1.1800000000000002	1	13	6	5
32952	1595	MNL	[MNL]	1.175	1	13	5	4
32953	1595	ebna-2	[EBNA-2]	1.175	1	13	5	4
32954	1595	il-4r	[IL-4R]	1.175	1	13	5	4
32955	1595	tbp	[TBP]	1.175	1	13	5	4
32956	1595	breakpoint	[breakpoint]	1.175	1	13	10	8
32957	1595	laboratory	[laboratory]	1.175	1	13	5	4
32958	1595	material	[material]	1.175	1	13	5	4
32959	1596	analog	[analog]	1.1714285714285715	1	13	9	7
32960	1596	interleukin-1beta	[interleukin-1beta]	1.1714285714285715	1	13	9	7
32961	1596	pml-rar	[PML-RAR]	1.1714285714285715	1	13	9	7
32962	1597	spectrum	[spectrum]	1.17	1	13	13	10
32963	1597	protein-1	[protein-1]	1.17	1	13	13	10
32964	1598	autoregulation	[autoregulation]	1.1666666666666667	1	13	12	9
32965	1598	p95vav	[p95vav]	1.1666666666666667	1	13	4	3
32966	1599	primate	[primate]	1.1625	1	13	11	8
32967	1600	C.	[C.]	1.16	1	13	7	5
32968	1600	nf-y	[NF-Y]	1.16	1	13	7	5
32969	1601	JAK1	[JAK1]	1.1500000000000001	1	16	9	2
32970	1601	mast	[mast]	1.1500000000000001	1	17	11	2
32971	1602	immortalization	[immortalization]	1.1400000000000001	1	13	8	5
32972	1602	export	[export]	1.1400000000000001	1	13	8	5
32973	1603	dysregulation	[dysregulation]	1.1333333333333335	1	13	10	6
32974	1603	id2	[Id2]	1.1333333333333335	1	13	5	3
32975	1604	run-on	[run-on]	1.1285714285714288	1	13	12	7
32976	1605	PEBP2	[PEBP2]	1.125	1	13	7	4
32977	1606	porcine	[porcine]	1.1	1	12	3	3
32978	1606	B1	[B1]	1.1	1	12	8	8
32979	1606	Fc	[Fc]	1.1	1	14	6	2
32980	1606	morphology	[morphology]	1.1	1	12	10	10
32981	1606	anti-ig	[anti-Ig]	1.1	1	12	4	4
32982	1606	radiation	[radiation]	1.1	1	12	5	5
32983	1606	NF-Y	[NF-Y]	1.1	1	12	3	3
32984	1606	c-Fos	[c-Fos]	1.1	1	12	1	1
32985	1606	beta-	[beta-]	1.1	1	12	6	6
32986	1606	Sp3ilday	[Sp3]	1.1	1	12	3	3
32987	1606	transcription.	[transcription.]	1.1	1	13	4	2
32988	1606	inhibitory	[inhibitory]	1.1	1	12	7	7
32989	1606	(ic50	[(IC50]	1.1	1	12	4	4
32990	1606	A/R	[A/R]	1.1	1	12	4	4
32991	1606	FMLP	[FMLP]	1.1	1	12	3	3
32992	1606	B29	[B29]	1.1	1	12	3	3
32993	1606	HS-40	[HS-40]	1.1	1	12	2	2
32994	1606	screen	[screening]	1.1	1	12	7	7
32995	1606	glycoprotein	[glycoprotein]	1.1	1	12	5	5
32996	1606	spi-1	[spi-1]	1.1	1	12	6	6
32997	1606	MCM	[MCM]	1.1	1	12	4	4
32998	1606	respond	[responding]	1.1	1	12	7	7
32999	1606	v-erbA	[v-erbA]	1.1	1	12	2	2
33000	1606	il-1r	[IL-1R]	1.1	1	13	8	4
33001	1606	IFNgamma	[IFNgamma]	1.1	1	12	3	3
33002	1606	hpa	[HPA]	1.1	1	12	4	4
33003	1606	differentiate	[differentiating]	1.1	1	12	3	3
33004	1606	ptk	[PTK]	1.1	1	12	7	7
33005	1606	aml1	[AML1]	1.1	1	12	4	4
33006	1606	leucine	[leucine]	1.1	1	12	2	2
33007	1606	hla-dq	[HLA-DQ]	1.1	1	12	3	3
33008	1606	development.	[development.]	1.1	1	12	4	4
33009	1606	comparison,	[comparison,]	1.1	1	11	0	0
33010	1606	proliferation,	[proliferation,]	1.1	1	12	5	5
33011	1606	Aiolos	[Aiolos]	1.1	1	12	2	2
33012	1606	oct-1	[Oct-1]	1.1	1	12	4	4
33013	1606	MZF-1	[MZF-1]	1.1	1	12	5	5
33014	1606	U-937	[U-937]	1.1	1	12	2	2
33015	1606	vp16	[VP16]	1.1	1	12	4	4
33016	1606	atherogenesis	[atherogenesis]	1.1	1	12	2	2
33017	1606	protection	[protection]	1.1	1	12	12	12
33018	1606	present	[present]	1.1	1	12	6	6
33019	1606	antiserum	[antiserum]	1.1	1	12	8	8
33020	1606	interleukin-3	[interleukin-3]	1.1	1	12	5	5
33021	1606	NFAT1	[NFAT1]	1.1	1	12	2	2
33022	1607	mg	[mg]	1.09	1	12	11	10
33023	1608	acetate	[acetate]	1.0875000000000001	1	12	9	8
33024	1608	delivery	[delivery]	1.0875000000000001	1	12	9	8
33025	1608	lysate	[lysate]	1.0875000000000001	1	12	9	8
33026	1609	ptdin	[PtdIns]	1.0857142857142859	1	12	8	7
33027	1610	U2	[U2]	1.0833333333333335	1	12	7	6
33028	1610	cell-free	[cell-free]	1.0833333333333335	1	12	7	6
33029	1610	b-alpha	[B-alpha]	1.0833333333333335	1	12	7	6
33030	1611	cushingd'	[Cushing's]	1.08	1	12	6	5
33031	1611	panel	[panel]	1.08	1	13	11	5
33032	1611	protein-	[protein-]	1.08	1	12	6	5
33033	1611	conditions.	[conditions.]	1.08	1	12	6	5
33034	1612	tumorigenesis	[tumorigenesis]	1.075	1	12	5	4
33035	1612	ald	[ALD]	1.075	1	12	5	4
33036	1612	man	[man]	1.075	1	12	5	4
33037	1612	reticulocyte	[reticulocyte]	1.075	1	13	9	4
33038	1612	/threonine	[/threonine]	1.075	1	13	9	4
33039	1612	composition	[composition]	1.075	1	13	9	4
33040	1613	n-terminal	[N-terminal]	1.0714285714285714	1	12	9	7
33041	1614	cd34(+)	[CD34(+)]	1.0666666666666667	1	12	4	3
33042	1614	relb	[RelB]	1.0666666666666667	1	12	4	3
33043	1614	ino	[iNOS]	1.0666666666666667	1	12	8	6
33044	1614	plaque	[plaque]	1.0666666666666667	1	12	8	6
33045	1615	infiltration	[infiltration]	1.0625	1	12	11	8
33046	1616	pH	[pH]	1.06	1	13	12	5
33047	1616	defensin	[defensin]	1.06	1	12	7	5
33048	1616	ECs	[ECs]	1.06	1	12	7	5
33049	1616	complement	[complement]	1.06	1	12	7	5
33050	1617	mononuclear	[mononuclear]	1.0571428571428572	1	12	10	7
33051	1618	l-selectin	[L-selectin]	1.05	1	12	6	4
33052	1618	sea	[SEA]	1.05	1	12	3	2
33053	1618	establishment	[establishment]	1.05	1	12	6	4
33054	1618	efficacy	[efficacy]	1.05	1	13	10	4
33055	1618	fact,	[fact,]	1.05	1	12	3	2
33056	1618	anorexia	[anorexia]	1.05	1	12	3	2
33057	1619	purpose	[purpose]	1.04	1	13	13	5
33058	1619	interact	[interacting]	1.04	1	12	8	5
33059	1620	encode	[encoding]	1.0333333333333334	1	12	5	3
33060	1620	Rap1	[Rap1]	1.0333333333333334	1	12	5	3
33061	1621	separation	[separation]	1.0285714285714287	1	12	12	7
33062	1622	hodgkin'	[Hodgkin's]	1.0250000000000001	1	12	7	4
33063	1622	prostaglandin	[prostaglandin]	1.0250000000000001	1	12	7	4
33064	1623	groups.	[groups.]	1.02	1	12	9	5
33065	1623	endometrium	[endometrium]	1.02	1	12	9	5
33066	1624	T cell tyrosine kinase zap-70	[T cell tyrosine kinase ZAP-70]	1.0	5	1	0	0
33067	1624	galectin-3 level	[galectin-3 level]	1.0	2	1	0	0
33068	1624	fecal loss	[fecal losses]	1.0	2	1	0	0
33069	1624	lead to NF-kappa b nuclear localization	[leading to NF-kappa B nuclear localization]	1.0	6	1	0	0
33070	1624	cytotoxicity at concentration consistent with specificity	[cytotoxicity at concentrations consistent with specificity]	1.0	6	1	0	0
33071	1624	probably with a crh synthesis	[probably with a CRH synthesis]	1.0	5	1	0	0
33072	1624	alternative 5'-end	[alternative 5'-end]	1.0	2	1	0	0
33073	1624	MHC class protein hla-dma function	[MHC class proteins HLA-DMA function]	1.0	5	1	0	0
33074	1624	use proteolytic digestion by trypsin	[using proteolytic digestion by trypsin]	1.0	5	1	0	0
33075	1624	primary pbmc	[primary PBMC]	1.0	2	1	0	0
33076	1624	promise for the immunotherapy of cancer.	[promise for the immunotherapy of cancer.]	1.0	6	1	0	0
33077	1624	part of the cellular defense system	[part of the cellular defense system]	1.0	6	1	0	0
33078	1624	lymphocyte of the peripheral blood	[lymphocytes of the peripheral blood]	1.0	5	1	0	0
33079	1624	receptor-dependent process	[receptor-dependent process]	1.0	2	1	0	0
33080	1624	wild-type Syk	[wild-type Syk]	1.0	2	1	0	0
33081	1624	HL-60 cell express a egr-1 transgene	[HL-60 cells expressing an Egr-1 transgene]	1.0	6	1	0	0
33082	1624	immunoglobulin production	[immunoglobulin production]	1.0	2	1	0	0
33083	1624	hiv-2 infection	[HIV-2 infection]	1.0	2	2	2	2
33084	1624	role of cd27 /cd70 interaction	[role of CD27 /CD70 interaction]	1.0	5	1	0	0
33085	1624	megakaryocytic maturation	[megakaryocytic maturation]	1.0	2	1	0	0
33086	1624	nonadherent neutrophil	[Nonadherent neutrophils]	1.0	2	1	0	0
33087	1624	formation of specific transcription factor complex	[formation of specific transcription factor complexes]	1.0	6	1	0	0
33088	1624	antiparallel mode	[antiparallel mode]	1.0	2	1	0	0
33089	1624	0.13 ng	[0.13 ng]	1.0	2	1	0	0
33090	1624	4.6 kilobasis	[4.6 kilobases]	1.0	2	1	0	0
33091	1624	intact cell by hydrogen peroxide	[intact cells by hydrogen peroxide]	1.0	5	1	0	0
33092	1624	early event in the pathogenesis	[early event in the pathogenesis]	1.0	5	1	0	0
33093	1624	residue of PXQXT/S in STP-A11	[residues of PXQXT/S in STP-A11]	1.0	5	1	0	0
33094	1624	RA repression.	[RA repression.]	1.0	2	1	0	0
33095	1624	BRLF1 R	[BRLF1 R]	1.0	2	1	0	0
33096	1624	novel proto-oncogene	[novel proto-oncogene]	1.0	2	2	2	2
33097	1624	tumor necrosis factor-alpha mrna level	[tumor necrosis factor-alpha mRNA levels]	1.0	5	1	0	0
33098	1624	(10%, p	[(10%, P]	1.0	2	1	0	0
33099	1624	Callithrix jacchus	[Callithrix jacchus]	1.0	2	2	1	1
33100	1624	lymphoid specific,	[lymphoid specific,]	1.0	2	1	0	0
33101	1624	5 minutes.	[5 minutes.]	1.0	2	1	0	0
33102	1624	development of the t-cell lineage	[development of the T-cell lineage]	1.0	5	1	0	0
33103	1624	dominant fashion	[dominant fashion]	1.0	2	1	0	0
33104	1624	appearance of transcription factor nf-kappab	[appearance of transcription factor NF-kappaB]	1.0	5	1	0	0
33105	1624	autocrine fashion,	[autocrine fashion,]	1.0	2	1	0	0
33106	1624	adjacent 20-base pair upstream sequence	[adjacent 20-base pair upstream sequence]	1.0	5	1	0	0
33107	1624	second hypersensitive site (HS 2)	[second hypersensitive site (HS 2)]	1.0	5	1	0	0
33108	1624	full-length alg-4 transcription of fasl	[full-length ALG-4 transcription of FasL]	1.0	5	1	0	0
33109	1624	TH1-to-TH2 shift	[TH1-to-TH2 shift]	1.0	2	1	0	0
33110	1624	two group of hmg box protein	[Two groups of HMG box proteins]	1.0	6	1	0	0
33111	1624	IL-2 receptor alpha chain il-2r alpha	[IL-2 receptor alpha chain IL-2R alpha]	1.0	6	1	0	0
33112	1624	effect of the prb modification	[effect of the pRB modification]	1.0	5	1	0	0
33113	1624	parallel, CD2	[parallel, CD2]	1.0	2	1	0	0
33114	1624	anemic stress	[anemic stress]	1.0	2	1	0	0
33115	1624	delta-aminolaevulinic acid	[delta-aminolaevulinic acid]	1.0	2	1	0	0
33116	1624	even after 72 h in culture.	[even after 72 h in culture.]	1.0	6	1	0	0
33117	1624	divergent expression of downstream gene	[divergent expression of downstream genes]	1.0	5	1	0	0
33118	1624	(+)-skf 10047	[(+)-SKF 10,047]	1.0	2	1	0	0
33119	1624	similar manner.	[similar manner.]	1.0	2	1	0	0
33120	1624	significant sequence homology of this element	[Significant sequence homology of this element]	1.0	6	1	0	0
33121	1624	carry ig variable heavy chain sequence	[carrying Ig variable heavy chain sequences]	1.0	6	1	0	0
33122	1624	mutation present	[mutation present]	1.0	2	2	2	2
33123	1624	cytokine treatment	[cytokine treatment]	1.0	2	1	0	0
33124	1624	stat5 target	[STAT5 target]	1.0	2	2	2	2
33125	1624	melanogaster homeobox	[melanogaster homeobox]	1.0	2	1	0	0
33126	1624	motor activity.	[motor activity.]	1.0	2	1	0	0
33127	1624	alanine 113	[alanine 113]	1.0	2	1	0	0
33128	1624	c-kit ligand in fcs(-)-culture condition	[c-kit ligand in FCS(-)-culture conditions]	1.0	5	1	0	0
33129	1624	co-stimulatory activity	[co-stimulatory activity]	1.0	2	1	0	0
33130	1624	syncytia-forming capacity	[syncytia-forming capacity]	1.0	2	1	0	0
33131	1624	antigen-specific human T cell line	[antigen-specific human T cell lines]	1.0	5	1	0	0
33132	1624	immunoglobulin promoter in b cell	[immunoglobulin promoters in B cells]	1.0	5	1	0	0
33133	1624	third complex	[third complex.]	1.0	2	1	0	0
33134	1624	transform protein	[transforming protein]	1.0	2	2	2	2
33135	1624	proviral construct	[proviral constructs]	1.0	2	2	1	1
33136	1624	small population of ut-7/gm cell	[small population of UT-7/GM cells]	1.0	5	1	0	0
33137	1624	important role in b-cell differentiation	[important role in B-cell differentiation]	1.0	5	1	0	0
33138	1624	electron-transport system	[electron-transport system]	1.0	2	1	0	0
33139	1624	change in triiodothyronine leukocyte receptor kinetic	[Changes in triiodothyronine leukocyte receptor kinetics]	1.0	6	1	0	0
33140	1624	great magnitude.	[greater magnitude.]	1.0	2	1	0	0
33141	1624	tpa adherence	[TPA adherence]	1.0	2	1	0	0
33142	1624	Ig expression	[Ig expression]	1.0	2	1	0	0
33143	1624	intestinal permeability	[intestinal permeability]	1.0	2	1	0	0
33144	1624	tissue-specific deoxyribonuclease	[tissue-specific deoxyribonuclease]	1.0	2	1	0	0
33145	1624	5 library	[5 library]	1.0	2	1	0	0
33146	1624	variable region	[variable regions]	1.0	2	2	1	1
33147	1624	slide assay	[slide assay]	1.0	2	2	1	1
33148	1624	GATA-1 foci	[GATA-1 foci]	1.0	2	1	0	0
33149	1624	mutation in the relevant NF-kappa b	[Mutations in the relevant NF-kappa B]	1.0	6	1	0	0
33150	1624	potent impact on slp-76 augmentation	[potent impact on SLP-76 augmentation]	1.0	5	1	0	0
33151	1624	microtubule disruption	[microtubule disruption]	1.0	2	1	0	0
33152	1624	use antigen peptide analog with mutation	[Using antigen peptide analogs with mutations]	1.0	6	1	0	0
33153	1624	kappa b alpha protein level	[kappa B alpha protein levels]	1.0	5	1	0	0
33154	1624	cytometric sorting,	[cytometric sorting,]	1.0	2	1	0	0
33155	1624	2.3 fmol/10(7) cell in controls).	[2.3 fmol/10(7) cells in controls).]	1.0	5	1	0	0
33156	1624	effect of drug on hiv-1	[effects of drugs on HIV-1]	1.0	5	1	0	0
33157	1624	aids-related lymphoma	[AIDS-related lymphoma]	1.0	2	2	2	2
33158	1624	fivefold increase over placebo-treated subject	[fivefold increase over placebo-treated subjects]	1.0	5	1	0	0
33159	1624	IL-2 cell growth of lymphocyte	[IL-2 cell growth of lymphocytes]	1.0	5	1	0	0
33160	1624	binding activity of this factor	[binding activities of these factors]	1.0	5	1	0	0
33161	1624	overexpression of hIRAK il-1 activation	[Overexpression of hIRAK IL-1 activation]	1.0	5	1	0	0
33162	1624	appropriate control from the same individuals,	[appropriate controls from the same individuals,]	1.0	6	1	0	0
33163	1624	attachment of monocyte to MVEC	[attachment of monocytes to MVEC]	1.0	5	1	0	0
33164	1624	patient with overt hypo hyper thyroidism	[Patients with overt hypo hyper thyroidism]	1.0	6	1	0	0
33165	1624	mitogen activation of T cell	[mitogen activation of T cells]	1.0	5	1	0	0
33166	1624	encode a 5.5 kb mrna	[encoding a 5.5 kb mRNA]	1.0	5	1	0	0
33167	1624	delimitation of the transactivation domain	[delimitation of the transactivation domain]	1.0	5	1	0	0
33168	1624	I stlv-i	[I STLV-I]	1.0	2	1	0	0
33169	1624	IL-6 signal	[IL-6 signaling]	1.0	2	1	0	0
33170	1624	control culture	[control cultures]	1.0	2	1	0	0
33171	1624	mycotoxin alpha-zearalenol	[mycotoxins alpha-zearalenol]	1.0	2	1	0	0
33172	1624	occur in the BCL-6 5'-noncoding region	[occurring in the BCL-6 5'-noncoding region]	1.0	6	1	0	0
33173	1624	Steady-state level of 135(oh)2d3 receptor rna	[Steady-state levels of 1,25(OH)2D3 receptor RNA]	1.0	6	1	0	0
33174	1624	vitamin d -dependent gene regulation	[vitamin D -dependent gene regulation]	1.0	5	1	0	0
33175	1624	sensitivity of the lps response	[sensitivity of the LPS response]	1.0	5	1	0	0
33176	1624	blood leukocyte content of glucocorticoid receptor	[blood leukocyte content of glucocorticoid receptors]	1.0	6	2	1	1
33177	1624	early glucocorticoid	[earlier glucocorticoids]	1.0	2	1	0	0
33178	1624	activation-induced p65/	[activation-induced p65/]	1.0	2	1	0	0
33179	1624	consensus octamer	[consensus octamer]	1.0	2	1	0	0
33180	1624	-52 nucleotide	[-52 nucleotides]	1.0	2	1	0	0
33181	1624	dramatic effect on nfat activation	[dramatic effects on NFAT activation]	1.0	5	1	0	0
33182	1624	cd16 activation of cytokine gene	[CD16 activation of cytokine genes]	1.0	5	1	0	0
33183	1624	such as the CD4 gene	[such as the CD4 gene]	1.0	5	1	0	0
33184	1624	60 base pair of sequence	[60 base pairs of sequence]	1.0	5	1	0	0
33185	1624	multipotent /erythroid /monocytic hpc growth	[multipotent /erythroid /monocytic HPC growth]	1.0	5	1	0	0
33186	1624	NF-kappa b p50 in vitro,	[NF-kappa B p50 in vitro,]	1.0	5	1	0	0
33187	1624	interferon-responsive factor	[interferon-responsive factor]	1.0	2	1	0	0
33188	1624	cytokine on IL-2 deprivation-induced apoptosis	[cytokines on IL-2 deprivation-induced apoptosis]	1.0	5	1	0	0
33189	1624	activation of the dprl promoter construct	[Activation of the dPRL promoter construct]	1.0	6	1	0	0
33190	1624	mutant p85	[mutant p85]	1.0	2	1	0	0
33191	1624	habitual aborter	[habitual aborters]	1.0	2	1	0	0
33192	1624	b cell in lymphoid organ	[B cells in lymphoid organs]	1.0	5	1	0	0
33193	1624	sequence ggggacgtcccc	[sequence GGGGACGTCCCC]	1.0	2	1	0	0
33194	1624	expression related	[expression related]	1.0	2	1	0	0
33195	1624	cis-acting regulatory sequence (affect expression	[cis-acting regulatory sequences (affecting expression]	1.0	5	1	0	0
33196	1624	NF-ATc isoform	[NF-ATc isoforms]	1.0	2	2	2	2
33197	1624	induction of the Jakdstat gene	[induction of the JAK/STAT gene]	1.0	5	1	0	0
33198	1624	sex distribution of 135(oh)2d3 receptor	[Sex distribution of 1,25(OH)2D3 receptors]	1.0	5	1	0	0
33199	1624	several event	[several events]	1.0	2	1	0	0
33200	1624	stimulation with a synthetic ceramide analog	[stimulation with a synthetic ceramide analog]	1.0	6	1	0	0
33201	1624	ige class	[IgE class]	1.0	2	2	2	2
33202	1624	follow viral binding to human monocyte	[following viral binding to human monocytes]	1.0	6	1	0	0
33203	1624	phosphorylation defect	[phosphorylation defect]	1.0	2	1	0	0
33204	1624	mutant p53	[mutant p53]	1.0	2	2	2	2
33205	1624	other experiments,	[other experiments,]	1.0	2	1	0	0
33206	1624	dead cell	[dead cells]	1.0	2	2	1	1
33207	1624	RA sensitivity	[RA sensitivity]	1.0	2	3	2	1
33208	1624	two group of U937 promonocytic cell	[Two groups of U937 promonocytic cells]	1.0	6	1	0	0
33209	1624	transcription of the human proenkephalin gene	[transcription of the human proenkephalin gene]	1.0	6	1	0	0
33210	1624	respect to the surface receptor	[respect to the surface receptors]	1.0	5	1	0	0
33211	1624	autosomal form	[autosomal form]	1.0	2	2	2	2
33212	1624	erythroid delta-aminolevulinate synthase mrna level	[erythroid delta-aminolevulinate synthase mRNA levels]	1.0	5	1	0	0
33213	1624	role of other family member	[roles of other family members]	1.0	5	1	0	0
33214	1624	redox state	[redox state]	1.0	2	2	2	2
33215	1624	corresponding patient	[corresponding patients]	1.0	2	1	0	0
33216	1624	include some non-Ashkenazi Jewish group	[including some non-Ashkenazi Jewish groups]	1.0	5	1	0	0
33217	1624	20-bp sequence	[20-bp sequence]	1.0	2	1	0	0
33218	1624	aml sample	[AML samples]	1.0	2	2	1	1
33219	1624	triamcinolone acetonide	[triamcinolone acetonide]	1.0	2	1	0	0
33220	1624	new, ubiquitous cellular transcription factor	[new, ubiquitous cellular transcription factors]	1.0	5	1	0	0
33221	1624	antigen stimulation in eth2 cell	[antigen stimulation in eTh2 cells]	1.0	5	1	0	0
33222	1624	terminate activity in the nucleus	[terminating activity in the nucleus]	1.0	5	1	0	0
33223	1624	coexpression of constitutively active calcineurin	[coexpression of constitutively active calcineurin]	1.0	5	1	0	0
33224	1624	activation-induced apoptosis in T lymphocyte	[activation-induced apoptosis in T lymphocytes]	1.0	5	1	0	0
33225	1624	vivo in C/EBPalpha -deficient mouse	[vivo in C/EBPalpha -deficient mice]	1.0	5	1	0	0
33226	1624	hiv-2 transcription	[HIV-2 transcription]	1.0	2	2	1	1
33227	1624	activation of the two transcription factor	[activation of the two transcription factors]	1.0	6	1	0	0
33228	1624	phorbol ester-sensitive protein kinase c	[phorbol ester-sensitive protein kinase C]	1.0	5	1	0	0
33229	1624	inhibitory mechanisms,	[inhibitory mechanisms,]	1.0	2	1	0	0
33230	1624	abnormal growth	[abnormal growth]	1.0	2	1	0	0
33231	1624	Kmone value of 0.8 microm	[Km value of 0.8 microM]	1.0	5	1	0	0
33232	1624	requirement for additional protein-protein interaction	[requirement for additional protein-protein interactions]	1.0	5	1	0	0
33233	1624	beta interferon kappa b site	[beta interferon kappa B sites]	1.0	5	1	0	0
33234	1624	bzip protein	[bZIP proteins]	1.0	2	1	0	0
33235	1624	involvement of the N-terminal region	[Involvement of the N-terminal region]	1.0	5	1	0	0
33236	1624	expression of the mbcl6 gene	[Expression of the mBCL6 gene]	1.0	5	1	0	0
33237	1624	microdeletion in the short arm	[microdeletion in the short arm]	1.0	5	1	0	0
33238	1624	block cellular uptake through mcd14	[blocking cellular uptake through mCD14]	1.0	5	1	0	0
33239	1624	carboxyterminal half	[carboxyterminal half]	1.0	2	1	0	0
33240	1624	preactivation of T cell result	[Preactivation of T cells resulting]	1.0	5	1	0	0
33241	1624	retinoic acid-synthesizing enzyme aldehyde dehydrogenase	[retinoic acid-synthesizing enzyme aldehyde dehydrogenase]	1.0	5	1	0	0
33242	1624	regulatory activities,	[regulatory activities,]	1.0	2	1	0	0
33243	1624	carboxy terminal tax deletion mutant	[carboxy terminal Tax deletion mutant]	1.0	5	1	0	0
33244	1624	increase in cell v-atpase content	[increases in cell V-ATPase content]	1.0	5	1	0	0
33245	1624	degradation of the cytosolic inhibitor IkappaBalpha	[degradation of the cytosolic inhibitor IkappaBalpha]	1.0	6	1	0	0
33246	1624	respond efficiently to cellular stimulation	[responding efficiently to cellular stimulation]	1.0	5	1	0	0
33247	1624	cytokine expression in human monocyte	[cytokine expression in human monocytes]	1.0	5	1	0	0
33248	1624	mechanism responsible for this LIF effect	[mechanisms responsible for these LIF effects]	1.0	6	1	0	0
33249	1624	Ectopic alf1	[Ectopic ALF1]	1.0	2	1	0	0
33250	1624	about 25-fold less a-myb rna	[about 25-fold less A-myb RNA]	1.0	5	1	0	0
33251	1624	171.3 dpm mg-1 cytosol protein	[171.3 dpm mg-1 cytosol protein]	1.0	5	1	0	0
33252	1624	early hypotheses,	[earlier hypotheses,]	1.0	2	1	0	0
33253	1624	predictor of sertraline response in disorder	[predictor of sertraline response in disorder]	1.0	6	1	0	0
33254	1624	42 bp	[42 bp]	1.0	2	1	0	0
33255	1624	myeloid-associated growth factor receptor transcript	[myeloid-associated growth factor receptor transcripts]	1.0	5	1	0	0
33256	1624	loss of a HLF domain	[loss of an HLF domain]	1.0	5	1	0	0
33257	1624	thymocyte population	[thymocyte populations]	1.0	2	1	0	0
33258	1624	blood fat	[blood fat]	1.0	2	2	1	1
33259	1624	indigenous bacterium	[indigenous bacteria]	1.0	2	1	0	0
33260	1624	tissular pattern	[tissular patterns]	1.0	2	1	0	0
33261	1624	several antiandrogen	[Several antiandrogens]	1.0	2	1	0	0
33262	1624	hTR beta	[hTR beta]	1.0	2	2	1	1
33263	1624	inducible expression of different cytokine gene	[inducible expression of different cytokine genes]	1.0	6	1	0	0
33264	1624	BA	[BA]	1.0	1	11	4	4
33265	1624	tnf-alpha gene expression in monocyte	[TNF-alpha gene expression in monocytes]	1.0	5	1	0	0
33266	1624	viral inducer	[viral inducer]	1.0	2	1	0	0
33267	1624	least in part by 135(oh)2d3	[least in part by 1,25(OH)2D3]	1.0	5	1	0	0
33268	1624	different promoter	[different promoters]	1.0	2	2	1	1
33269	1624	fine specificity	[fine specificity]	1.0	2	1	0	0
33270	1624	easily accessible human cell model	[easily accessible human cell model]	1.0	5	1	0	0
33271	1624	E2	[E2]	1.0	1	11	7	7
33272	1624	lps response,	[LPS response,]	1.0	2	1	0	0
33273	1624	exogenous il-12.	[exogenous IL-12.]	1.0	2	1	0	0
33274	1624	more infiltrate	[more infiltrating]	1.0	2	1	0	0
33275	1624	tissue section of breast carcinoma	[tissue sections of breast carcinomas]	1.0	5	1	0	0
33276	1624	Spi-1/PU.1-family member	[Spi-1/PU.1-family members]	1.0	2	1	0	0
33277	1624	lymphoid-specific Oct-2A	[lymphoid-specific Oct-2A]	1.0	2	1	0	0
33278	1624	disordered memory T cell differentiation	[disordered memory T cell differentiation]	1.0	5	1	0	0
33279	1624	acute myelogenous leukemia 1- respectively,	[acute myelogenous leukemia 1- respectively,]	1.0	5	1	0	0
33280	1624	predominately cd11b/cd18	[predominately CD11b/CD18]	1.0	2	1	0	0
33281	1624	SCF ligation of kit/il-4r alpha	[SCF ligation of kit/IL-4R alpha]	1.0	5	1	0	0
33282	1624	construct contain the IL-4 promoter	[construct containing the IL-4 promoter]	1.0	5	1	0	0
33283	1624	chromosome analysis	[Chromosome analysis]	1.0	2	1	0	0
33284	1624	binding to a hSIE-oligonucleotide probe	[binding to an hSIE-oligonucleotide probe]	1.0	5	1	0	0
33285	1624	p65 induction of the c-rel gene	[p65 induction of the c-rel gene]	1.0	6	1	0	0
33286	1624	long exposure of Jurkat cell	[long-term exposure of Jurkat cells]	1.0	5	1	0	0
33287	1624	catalytic event	[catalytic event]	1.0	2	1	0	0
33288	1624	dominant-active inhibitor	[dominant-active inhibitor]	1.0	2	1	0	0
33289	1624	binding to a single class	[binding to a single class]	1.0	5	1	0	0
33290	1624	cdc42 protein	[Cdc42 proteins]	1.0	2	1	0	0
33291	1624	nf-atp as a e1 binding protein	[NF-ATp as an E1 binding protein]	1.0	6	1	0	0
33292	1624	gene ul49	[genes UL49]	1.0	2	1	0	0
33293	1624	IKKalpha activation, block tax induction	[IKKalpha activation, blocks Tax induction]	1.0	5	1	0	0
33294	1624	K+	[K+]	1.0	1	11	6	6
33295	1624	immunomodulatory activities.	[immunomodulatory activities.]	1.0	2	1	0	0
33296	1624	expression of the interleukin gene	[expression of the interleukin gene]	1.0	5	1	0	0
33297	1624	reactive lymph	[reactive lymph]	1.0	2	1	0	0
33298	1624	lmp promoter fragment of sizes.	[LMP promoter fragments of sizes.]	1.0	5	1	0	0
33299	1624	monocyte recruitment	[monocyte recruitment]	1.0	2	1	0	0
33300	1624	prevent activation of c-rel/ p65 heterodimer	[preventing activation of c-Rel/ p65 heterodimers]	1.0	6	1	0	0
33301	1624	IKK complex	[IKK complex]	1.0	2	2	1	1
33302	1624	about half of the cell	[about half of the cells]	1.0	5	1	0	0
33303	1624	engagement of any of this receptor	[Engagement of any of these receptors]	1.0	6	1	0	0
33304	1624	p65 translocation to the nucleus,	[p65 translocation to the nucleus,]	1.0	5	1	0	0
33305	1624	prl gene	[PRL gene]	1.0	2	2	2	2
33306	1624	hyperproliferative disorder	[hyperproliferative disorders]	1.0	2	1	0	0
33307	1624	calcineurin site	[calcineurin site]	1.0	2	2	2	2
33308	1624	GCR-alpha DNA	[GCR-alpha DNA]	1.0	2	1	0	0
33309	1624	normal exon	[normal exon]	1.0	2	1	0	0
33310	1624	two ligand	[two ligands]	1.0	2	2	2	2
33311	1624	candidate for this putative factor	[candidates for this putative factor]	1.0	5	1	0	0
33312	1624	abundance, distribution, of Pan protein	[abundance, distribution, of Pan proteins]	1.0	5	1	0	0
33313	1624	BCL-6 rearrangement	[BCL-6 rearrangements]	1.0	2	1	0	0
33314	1624	TCL1 locus on chromosome 14q32.1	[TCL1 locus on chromosome 14q32.1]	1.0	5	1	0	0
33315	1624	b2 subunit	[B2 subunit]	1.0	2	2	2	2
33316	1624	result in accumulation of m-csf mrna	[resulting in accumulation of M-CSF mRNA]	1.0	6	1	0	0
33317	1624	advantage of mutant Jurkat cell	[advantage of mutant Jurkat cells]	1.0	5	1	0	0
33318	1624	nuclear factor kappab nfkappab program	[nuclear factor kappaB NFkappaB program]	1.0	5	1	0	0
33319	1624	deletion of the Sp 1-binding site	[Deletion of the Sp 1-binding sites]	1.0	6	1	0	0
33320	1624	full activation of transduction pathway	[full activation of transduction pathways]	1.0	5	1	0	0
33321	1624	mobility of the TR:TRE complex	[mobility of the TR:TRE complex]	1.0	5	1	0	0
33322	1624	past year	[past year]	1.0	2	2	1	1
33323	1624	50 ng of total rna.	[50 ng of total RNA.]	1.0	5	1	0	0
33324	1624	mutagenesis result	[mutagenesis results]	1.0	2	1	0	0
33325	1624	co-transfection of a CAT reporter	[co-transfection of a CAT reporter]	1.0	5	1	0	0
33326	1624	firm arrest, spreading, of monocyte	[firm arrest, spreading, of monocytes]	1.0	5	1	0	0
33327	1624	nuclear stat3	[nuclear STAT3]	1.0	2	1	0	0
33328	1624	nfatc (predominant form of kda	[NFATc (predominant form of kDa]	1.0	5	1	0	0
33329	1624	tramp a novel apoptosis-mediating receptor	[TRAMP a novel apoptosis-mediating receptor]	1.0	5	1	0	0
33330	1624	interleukin-1 beta production by glucocorticoid	[interleukin-1 beta production by glucocorticoids]	1.0	5	1	0	0
33331	1624	specific manner.	[specific manner.]	1.0	2	1	0	0
33332	1624	human colonic carcinoma cell line ht29	[human colonic carcinoma cell line HT29]	1.0	6	1	0	0
33333	1624	human ah receptor tcdd receptor	[human Ah receptor TCDD receptor]	1.0	5	1	0	0
33334	1624	suggest antigen T cell-b cell interaction	[suggesting antigen T cell-B cell interactions]	1.0	6	1	0	0
33335	1624	nf-kappab transactivation of the repeat promoter	[NF-kappaB transactivation of the repeat promoter]	1.0	6	1	0	0
33336	1624	151-bp region	[151-bp region]	1.0	2	1	0	0
33337	1624	performance status	[performance status]	1.0	2	1	0	0
33338	1624	Th2 pattern	[Th2 pattern]	1.0	2	1	0	0
33339	1624	86%, vcam-1	[86%, VCAM-1]	1.0	2	1	0	0
33340	1624	high level of the neuropeptide enkephalin	[high levels of the neuropeptide enkephalin]	1.0	6	1	0	0
33341	1624	recruitment of a stat protein	[recruitment of a Stat protein]	1.0	5	1	0	0
33342	1624	50 65 kda p65 polypeptide	[50 65 kDa p65 polypeptides]	1.0	5	1	0	0
33343	1624	alteration in the redox homeostasis	[alterations in the redox homeostasis]	1.0	5	1	0	0
33344	1624	characteristic feature of immune senescence.	[characteristic feature of immune senescence.]	1.0	5	1	0	0
33345	1624	use a heterologous minimal promoter.	[using a heterologous minimal promoter.]	1.0	5	1	0	0
33346	1624	binding of the A6H mAb	[binding of the A6H mAb]	1.0	5	1	0	0
33347	1624	activation of rela/nfkappab1 -binding activity	[activation of RelA/NFkappaB1 -binding activity]	1.0	5	1	0	0
33348	1624	stress system	[stress system]	1.0	2	2	1	1
33349	1624	nf-kappab activity.	[NF-kappaB activity.]	1.0	2	1	0	0
33350	1624	net effect	[net effect]	1.0	2	2	1	1
33351	1624	case-control study	[case-control studies]	1.0	2	2	2	2
33352	1624	molecular biology study on eosinophil	[molecular biology study on eosinophils]	1.0	5	1	0	0
33353	1624	stimulation of human cd4+ T cell	[stimulation of human CD4+ T cells]	1.0	6	1	0	0
33354	1624	relation to possible therapeutic approach	[relation to possible therapeutic approaches]	1.0	5	1	0	0
33355	1624	clinical benefit.	[clinical benefit.]	1.0	2	1	0	0
33356	1624	nf-kappa b in lymphoid nuclear extract	[NF-kappa B in lymphoid nuclear extracts]	1.0	6	1	0	0
33357	1624	dyad symmetry	[dyad symmetry]	1.0	2	1	0	0
33358	1624	id family of helix-loop-helix protein	[Id family of helix-loop-helix proteins]	1.0	5	1	0	0
33359	1624	protein extract from shock lung	[protein extracts from shock lungs]	1.0	5	1	0	0
33360	1624	IL-10 effect on c-fo expression	[IL-10 effect on c-fos expression]	1.0	5	1	0	0
33361	1624	proviral latency in certain monocytic cell	[proviral latency in certain monocytic cells]	1.0	6	1	0	0
33362	1624	case-oriented evidence for a association	[case-oriented evidence for an association]	1.0	5	1	0	0
33363	1624	activity of the nadph oxidase	[activity of the NADPH oxidase]	1.0	5	1	0	0
33364	1624	use a in vitro culture system	[using an in vitro culture system]	1.0	6	1	0	0
33365	1624	egr-1 determine the differentiation pathway	[egr-1 determining the differentiation pathway]	1.0	5	1	0	0
33366	1624	monocyte infiltration critical in atherogenesis	[monocyte infiltration critical in atherogenesis]	1.0	5	1	0	0
33367	1624	cadmium treatment	[cadmium treatment]	1.0	2	1	0	0
33368	1624	c-fo expression in human b-cell	[c-fos expression in human B-cells]	1.0	5	1	0	0
33369	1624	ra/vd treatment	[RA/VD treatment]	1.0	2	1	0	0
33370	1624	exogenous provision of p65/p50 nf-kappab	[exogenous provision of p65/p50 NF-kappaB]	1.0	5	1	0	0
33371	1624	various cytokine	[various cytokines]	1.0	2	1	0	0
33372	1624	three subregion	[three subregions]	1.0	2	1	0	0
33373	1624	induction of CD8 antigen by glucocorticoid	[Induction of CD8 antigen by glucocorticoids]	1.0	6	1	0	0
33374	1624	six ebv-encoded nuclear antigen EBNA	[six EBV-encoded nuclear antigens EBNA]	1.0	5	1	0	0
33375	1624	-dependent fashion	[-dependent fashion]	1.0	2	1	0	0
33376	1624	activation of inflammatory cytokine gene	[activation of inflammatory cytokine genes]	1.0	5	1	0	0
33377	1624	human T lymphocyte jurkat cell	[human T lymphocyte Jurkat cells]	1.0	5	2	1	1
33378	1624	hsc proliferation	[HSC proliferation]	1.0	2	1	0	0
33379	1624	expression of a erythroid-specific gene	[expression of an erythroid-specific gene]	1.0	5	1	0	0
33380	1624	many b cell tumor line	[many B cell tumor lines]	1.0	5	1	0	0
33381	1624	hormone-dependent manner.	[hormone-dependent manner.]	1.0	2	1	0	0
33382	1624	es	[ES]	1.0	1	11	3	3
33383	1624	et	[ets]	1.0	1	11	4	4
33384	1624	tpa-induced c-fo	[TPA-induced c-fos]	1.0	2	1	0	0
33385	1624	il-4 treatment	[IL-4 treatment]	1.0	2	1	0	0
33386	1624	b7.1 molecule	[B7.1 molecules]	1.0	2	1	0	0
33387	1624	patient with congestive heart failure	[patients with congestive heart failure]	1.0	5	1	0	0
33388	1624	transcription activation,	[transcription activation,]	1.0	2	1	0	0
33389	1624	phenotypic analysis of lymphocyte subset	[phenotypic analysis of lymphocyte subsets]	1.0	5	1	0	0
33390	1624	active nf-kappa b for efficient transcription,	[active NF-kappa B for efficient transcription,]	1.0	6	1	0	0
33391	1624	very low failure rate (2.6%	[very low failure rate (2.6%]	1.0	5	1	0	0
33392	1624	ribonuclease protection	[ribonuclease protection]	1.0	2	2	2	2
33393	1624	CCAAT/enhancer bind protein (c/ebp) epsilon	[CCAAT/enhancer binding protein (C/EBP) epsilon]	1.0	5	1	0	0
33394	1624	inflammation response	[inflammation response]	1.0	2	1	0	0
33395	1624	ig kappa b by cytokine	[Ig kappa B by cytokine]	1.0	5	1	0	0
33396	1624	staphylococcus aureus replication initiation protein	[Staphylococcus aureus replication initiation protein]	1.0	5	1	0	0
33397	1624	gene inactivation in the mouse	[gene inactivation in the mouse]	1.0	5	1	0	0
33398	1624	allograft rejection after cardiac transplantation	[allograft rejection after cardiac transplantation]	1.0	5	1	0	0
33399	1624	Stat6 -deficient Jurkat T cell	[Stat6 -deficient Jurkat T cells]	1.0	5	1	0	0
33400	1624	glial tumor	[glial tumors]	1.0	2	1	0	0
33401	1624	signal pathway of apoptosis by cytokine	[signaling pathways of apoptosis by cytokines]	1.0	6	1	0	0
33402	1624	four different stimulus in t-cell	[four different stimuli in T-cells]	1.0	5	1	0	0
33403	1624	stimulation of the tcr receptor	[stimulation of the TCR receptors]	1.0	5	1	0	0
33404	1624	such megadosis	[such megadoses]	1.0	2	1	0	0
33405	1624	T cell receptor transgenic mouse	[T cell receptor transgenic mice]	1.0	5	1	0	0
33406	1624	anti-inflammatory corticosteroid	[anti-inflammatory corticosteroids]	1.0	2	1	0	0
33407	1624	functional interaction between the kinase	[functional interaction between the kinase]	1.0	5	1	0	0
33408	1624	ccast-binding factor	[CCAAT-binding factor]	1.0	2	1	0	0
33409	1624	binding parameter of [3H] pyrilamine binding	[Binding parameters of [3H] pyrilamine binding]	1.0	6	1	0	0
33410	1624	PGE2 release,	[PGE2 release,]	1.0	2	1	0	0
33411	1624	addition, analysis	[addition, analysis]	1.0	2	1	0	0
33412	1624	ERK-independent pathway	[ERK-independent pathways]	1.0	2	1	0	0
33413	1624	level activity	[level activity]	1.0	2	2	2	2
33414	1624	grow list	[growing list]	1.0	2	2	2	2
33415	1624	monocytic cells.	[monocytic cells.]	1.0	2	1	0	0
33416	1624	unquestionably a form of activation.	[unquestionably a form of activation.]	1.0	5	1	0	0
33417	1624	commitment event	[commitment events]	1.0	2	1	0	0
33418	1624	asthmatic proband	[asthmatic proband]	1.0	2	1	0	0
33419	1624	TNFalpha stimulation	[TNFalpha stimulation]	1.0	2	1	0	0
33420	1624	Clinical outcome	[Clinical outcome]	1.0	2	2	1	1
33421	1624	(3/5 tuberculosis patient 0/3 sarcoidosis patient	[(3/5 tuberculosis patients 0/3 sarcoidosis patients]	1.0	6	1	0	0
33422	1624	However, blockade	[However, blockade]	1.0	2	1	0	0
33423	1624	gene structure	[gene structure]	1.0	2	2	1	1
33424	1624	sex-matched healthy control in vitro.	[sex-matched healthy controls in vitro.]	1.0	5	1	0	0
33425	1624	two human t-cell line Wurzburg	[two human T-cell lines Wurzburg]	1.0	5	1	0	0
33426	1624	transcriptional activity of a template	[transcriptional activity of a template]	1.0	5	1	0	0
33427	1624	demarcation membrane	[demarcation membranes]	1.0	2	1	0	0
33428	1624	upstream of the I epsilon exon	[upstream of the I epsilon exon]	1.0	6	1	0	0
33429	1624	least some case of atll	[least some cases of ATLL]	1.0	5	1	0	0
33430	1624	ALY a context-dependent coactivator of LEF-1	[ALY a context-dependent coactivator of LEF-1]	1.0	6	1	0	0
33431	1624	activation of hiv -gene expression	[activation of HIV -gene expression]	1.0	5	1	0	0
33432	1624	cell-type-specific manner	[cell-type-specific manner]	1.0	2	1	0	0
33433	1624	er -tumor	[ER -tumors]	1.0	2	1	0	0
33434	1624	Glucocorticoid therapy	[Glucocorticoid therapy]	1.0	2	1	0	0
33435	1624	anti-inflammatory agent on adhesion molecule	[anti-inflammatory agents on adhesion molecule]	1.0	5	1	0	0
33436	1624	classical competition	[classical competition]	1.0	2	1	0	0
33437	1624	expression of the alpha2 integrin gene	[expression of the alpha2 integrin gene]	1.0	6	1	0	0
33438	1624	clinical stage	[clinical Stage]	1.0	2	1	0	0
33439	1624	presence of three alpha-helice Val10-Gln22	[presence of three alpha-helices Val10-Gln22]	1.0	5	1	0	0
33440	1624	metastasis-suppressor gene	[metastasis-suppressor gene]	1.0	2	1	0	0
33441	1624	activity of the DQB promoter	[activity of the DQB promoter]	1.0	5	1	0	0
33442	1624	mutation of Ikaros in the context	[Mutation of Ikaros in the context]	1.0	6	1	0	0
33443	1624	gene regulate the apoptotic machinery	[genes regulating the apoptotic machinery]	1.0	5	1	0	0
33444	1624	anti-igm apoptosis	[anti-IgM apoptosis]	1.0	2	1	0	0
33445	1624	mcf-7 cell	[MCF-7 cells]	1.0	2	1	0	0
33446	1624	Ca2+ transient after tcr stimulation	[Ca2+ transient after TCR stimulation]	1.0	5	1	0	0
33447	1624	effect of a ptpase inhibitor	[effects of a PTPase inhibitor]	1.0	5	1	0	0
33448	1624	conversion of 25(oh)d3 in 135(oh)2d3	[conversion of 25(OH)D3 in 1,25(OH)2D3]	1.0	5	1	0	0
33449	1624	CD69 gene	[CD69 gene]	1.0	2	1	0	0
33450	1624	human umbilical vein endothelial cell HUVEC	[human umbilical vein endothelial cells HUVEC]	1.0	6	1	0	0
33451	1624	proto-oncogene only in the context	[proto-oncogene only in the context]	1.0	5	1	0	0
33452	1624	approximately 40-fold follow okadaic acid exposure	[approximately 40-fold following okadaic acid exposure]	1.0	6	1	0	0
33453	1624	skin fibroblast with leukemic DNA	[skin fibroblasts with leukemic DNA]	1.0	5	1	0	0
33454	1624	assembly with a second family	[assembly with a second family]	1.0	5	1	0	0
33455	1624	sequence alteration in the region	[sequence alterations in the region]	1.0	5	1	0	0
33456	1624	life-long infection	[life-long infection]	1.0	2	1	0	0
33457	1624	osteoarthritis tissue	[osteoarthritis tissue]	1.0	2	1	0	0
33458	1624	same patient.	[same patient.]	1.0	2	1	0	0
33459	1624	acidic activator	[acidic activators]	1.0	2	1	0	0
33460	1624	DC pathway	[DC pathways]	1.0	2	1	0	0
33461	1624	ras transformation of b lymphocyte	[ras transformation of B lymphocytes]	1.0	5	1	0	0
33462	1624	human housekeeping	[human housekeeping]	1.0	2	1	0	0
33463	1624	4.00 nm,	[4.00 nM,]	1.0	2	1	0	0
33464	1624	disparate effect on IL-2 gene expression	[disparate effects on IL-2 gene expression]	1.0	6	1	0	0
33465	1624	functional contribution	[functional contribution]	1.0	2	1	0	0
33466	1624	ca2+ release	[Ca2+ release]	1.0	2	2	1	1
33467	1624	nordihydroguiauretic acid	[nordihydroguiauretic acid]	1.0	2	1	0	0
33468	1624	number of primary hpp-cfc colony	[number of primary HPP-CFC colonies]	1.0	5	1	0	0
33469	1624	atra necessary	[ATRA necessary]	1.0	2	1	0	0
33470	1624	defensin sensitivity	[defensin sensitivities]	1.0	2	1	0	0
33471	1624	anti-ig crosslinking	[anti-Ig crosslinking]	1.0	2	1	0	0
33472	1624	pure b	[pure B]	1.0	2	1	0	0
33473	1624	core ggaa	[core GGAAs]	1.0	2	1	0	0
33474	1624	industrial compound	[industrial compound]	1.0	2	1	0	0
33475	1624	visualization of nuclear nf-kappa b protein	[visualization of nuclear NF-kappa B proteins]	1.0	6	1	0	0
33476	1624	lt promoter activity over levels,	[LT promoter activity over levels,]	1.0	5	1	0	0
33477	1624	alloimmune neutropenia	[alloimmune neutropenia]	1.0	2	1	0	0
33478	1624	mechanism of glucocorticoid gc inhibition	[mechanism of glucocorticoid GC inhibition]	1.0	5	1	0	0
33479	1624	nf-kappab activation in monocytic cell	[NF-kappaB activation in monocytic cells]	1.0	5	1	0	0
33480	1624	logarithmic mean of er content	[logarithmic mean of ER content]	1.0	5	1	0	0
33481	1624	intentional stimulation.	[intentional stimulation.]	1.0	2	1	0	0
33482	1624	nf-kappab transcription in human monocyte	[NF-kappaB transcription in human monocytes]	1.0	5	1	0	0
33483	1624	bacterial constituent such as lps	[bacterial constituents such as LPS]	1.0	5	2	1	1
33484	1624	intranuclear icn	[intranuclear ICN]	1.0	2	1	0	0
33485	1624	whole-cell lysate by antiphosphotyrosine immunoblotting	[whole-cell lysates by antiphosphotyrosine immunoblotting]	1.0	5	1	0	0
33486	1624	several isoform	[several isoforms]	1.0	2	1	0	0
33487	1624	further, by electrophoretic mobility shift assay	[Further, by electrophoretic mobility shift assay]	1.0	6	1	0	0
33488	1624	synergistic suppression of t-cell proliferation	[Synergistic suppression of T-cell proliferation]	1.0	5	1	0	0
33489	1624	3-4 hr.	[3-4 hr.]	1.0	2	1	0	0
33490	1624	immunogenic protein ebna2-ebna6 in lymphoma	[immunogenic proteins EBNA2-EBNA6 in lymphoma]	1.0	5	1	0	0
33491	1624	use this rar-selective antagonist RXR agonist	[Using this RAR-selective antagonist RXR agonist]	1.0	6	1	0	0
33492	1624	x-inactivation pattern of the humara loci	[X-inactivation patterns of the HUMARA loci]	1.0	6	1	0	0
33493	1624	Okadaic acid a inhibitor of phosphatase	[Okadaic acid an inhibitor of phosphatases]	1.0	6	1	0	0
33494	1624	t-lymphocyte from VZV immune human donor	[T-lymphocytes from VZV immune human donors]	1.0	6	1	0	0
33495	1624	human beta-globin yeast chromosome transgene	[human beta-globin yeast chromosome transgene]	1.0	5	1	0	0
33496	1624	contrast, blood lymphocyte from patient	[contrast, blood lymphocytes from patients]	1.0	5	1	0	0
33497	1624	other factors.	[other factors.]	1.0	2	1	0	0
33498	1624	ige level	[IgE levels]	1.0	2	1	0	0
33499	1624	phosphate-supplemented patient	[phosphate-supplemented patients]	1.0	2	1	0	0
33500	1624	oct-2a binding	[Oct-2A binding]	1.0	2	1	0	0
33501	1624	T helper 2 (th2) cell	[T helper 2 (Th2) cells]	1.0	5	1	0	0
33502	1624	endothelial cell in the presence	[endothelial cells in the presence]	1.0	5	1	0	0
33503	1624	interferon-gamma promoter	[interferon-gamma promoter]	1.0	2	2	2	2
33504	1624	antiproliferative effect of the drug	[antiproliferative effects of the drug]	1.0	5	1	0	0
33505	1624	proenkephalin transcription	[proenkephalin transcription]	1.0	2	2	1	1
33506	1624	Brazilian black	[Brazilian blacks]	1.0	2	1	0	0
33507	1624	stationary phase.	[stationary phase.]	1.0	2	1	0	0
33508	1624	circadian pacemaker	[circadian pacemaker]	1.0	2	2	1	1
33509	1624	antagonist to the nongenomic activity	[antagonist to the nongenomic activities]	1.0	5	1	0	0
33510	1624	DNA homology between the breakpoint	[DNA homology between the breakpoints]	1.0	5	1	0	0
33511	1624	ikappab-alpha degradation	[IkappaB-alpha degradation]	1.0	2	2	1	1
33512	1624	c epsilon-	[C epsilon-]	1.0	2	1	0	0
33513	1624	response to interleukin (il)-4 stimulation	[response to interleukin (IL)-4 stimulation]	1.0	5	1	0	0
33514	1624	hiv-1 nre	[HIV-1 NRE]	1.0	2	1	0	0
33515	1624	pbmc response to all stimulus-	[PBMC responses to all stimulus-]	1.0	5	1	0	0
33516	1624	il-5 receptor	[IL-5 receptor]	1.0	2	2	1	1
33517	1624	confirm necessary	[confirming necessary]	1.0	2	1	0	0
33518	1624	use reverse-transcription pcr differential display	[Using reverse-transcription PCR differential display]	1.0	5	1	0	0
33519	1624	activation by phorbol 12-myristate 13-acetate	[activation by phorbol 12-myristate 13-acetate]	1.0	5	1	0	0
33520	1624	oct-1 binding	[OCT-1 binding]	1.0	2	1	0	0
33521	1624	HL-60 promyelocytic leukemia cell line	[HL-60 promyelocytic leukemia cell line]	1.0	5	1	0	0
33522	1624	treatment of hl60 cell with combination	[Treatment of HL60 cells with combinations]	1.0	6	1	0	0
33523	1624	IL-8 promoter	[IL-8 promoter]	1.0	2	2	1	1
33524	1624	erythropoietin ep	[erythropoietin Ep]	1.0	2	1	0	0
33525	1624	S element	[S elements]	1.0	2	1	0	0
33526	1624	affinity purification of recombinant protein	[affinity purification of recombinant proteins]	1.0	5	1	0	0
33527	1624	constitutively high level of p59fyn	[constitutively high levels of p59fyn]	1.0	5	1	0	0
33528	1624	second objective	[second objective]	1.0	2	1	0	0
33529	1624	macrophage-specific rdna	[macrophage-specific cDNAs]	1.0	2	1	0	0
33530	1624	cell-to-cell contact between peripheral blood lymphocyte	[Cell-to-cell contact between peripheral blood lymphocytes]	1.0	6	1	0	0
33531	1624	mature leukocyte	[mature leukocytes]	1.0	2	1	0	0
33532	1624	molecular mechanism of monocytic differentiation	[molecular mechanisms of monocytic differentiation]	1.0	5	1	0	0
33533	1624	human cell in continuous culture.	[human cells in continuous culture.]	1.0	5	1	0	0
33534	1624	markedly less viral rna production	[markedly less viral RNA production]	1.0	5	1	0	0
33535	1624	activation of the nfat element	[activation of the NFAT element]	1.0	5	1	0	0
33536	1624	(734 +/- 237 ng/10(6) cells)	[(734 +/- 237 ng/10(6) cells)]	1.0	5	1	0	0
33537	1624	dominant-negative mutant of NF-kappaB p50	[dominant-negative mutant of NF-kappaB p50]	1.0	5	1	0	0
33538	1624	second family	[second family]	1.0	2	1	0	0
33539	1624	transient response to cell activation	[transient responses to cell activation]	1.0	5	1	0	0
33540	1624	contain four base pair substitution	[containing four base pair substitutions]	1.0	5	1	0	0
33541	1624	Warren Strober	[Warren Strober]	1.0	2	1	0	0
33542	1624	loss of v-abl kinase activity	[loss of v-Abl kinase activity]	1.0	5	1	0	0
33543	1624	JAK kinase	[JAK kinases]	1.0	2	1	0	0
33544	1624	identity of cd56 in blast	[identity of CD56 in blasts]	1.0	5	1	0	0
33545	1624	inflammatory foci,	[inflammatory foci,]	1.0	2	1	0	0
33546	1624	receptor overexpression	[receptor overexpression]	1.0	2	1	0	0
33547	1624	arginine-glycine-aspartate substrata	[arginine-glycine-aspartate substrata]	1.0	2	1	0	0
33548	1624	MPRO promyelocyte	[MPRO promyelocytes]	1.0	2	1	0	0
33549	1624	CAT activity in jurkat cell	[CAT activity in Jurkat cells]	1.0	5	1	0	0
33550	1624	block factor	[blocking factor]	1.0	2	2	2	2
33551	1624	hydrolytic activity of the enzyme	[hydrolytic activity of the enzyme]	1.0	5	1	0	0
33552	1624	follow chromosomal rearrangement involve band 3q26	[following chromosomal rearrangements involving band 3q26]	1.0	6	1	0	0
33553	1624	284, control	[284, controls]	1.0	2	1	0	0
33554	1624	ikappabalpha molecule	[IkappaBalpha molecule]	1.0	2	1	0	0
33555	1624	relatively few il-12 target gene	[relatively few IL-12 target genes]	1.0	5	1	0	0
33556	1624	gc gene	[gC gene]	1.0	2	1	0	0
33557	1624	c-fo transcription	[c-Fos transcription]	1.0	2	1	0	0
33558	1624	this, decrease	[this, decrease]	1.0	2	1	0	0
33559	1624	proliferation of myeloid leukemic cell	[proliferation of myeloid leukemic cells]	1.0	5	1	0	0
33560	1624	cognate sequence,	[cognate sequence,]	1.0	2	1	0	0
33561	1624	GOS19 promoter	[GOS19 promoter]	1.0	2	1	0	0
33562	1624	artificial promoter	[artificial promoter]	1.0	2	2	1	1
33563	1624	alteration in specific isozyme activity	[alterations in specific isozyme activity]	1.0	5	1	0	0
33564	1624	base-substitution mutation	[base-substitution mutations]	1.0	2	1	0	0
33565	1624	I (htlv-i)	[I (HTLV-I)]	1.0	2	1	0	0
33566	1624	functional sequence	[functional sequences]	1.0	2	1	0	0
33567	1624	Fc receptor	[Fc receptor]	1.0	2	1	0	0
33568	1624	il-7r alpha	[IL-7R alpha]	1.0	2	2	1	1
33569	1624	13 acetate	[13 acetate]	1.0	2	1	0	0
33570	1624	various study	[various studies]	1.0	2	1	0	0
33571	1624	granulocyte-colony stimulate	[granulocyte-colony stimulating]	1.0	2	1	0	0
33572	1624	chymotryptic activity of the proteasome	[chymotryptic activity of the proteasome]	1.0	5	1	0	0
33573	1624	attainable goal	[attainable goal]	1.0	2	1	0	0
33574	1624	prevent tnf-alpha apoptosis as efficiently	[preventing TNF-alpha apoptosis as efficiently]	1.0	5	1	0	0
33575	1624	copy of the hiv-1 enhancer	[copies of the HIV-1 enhancer]	1.0	5	1	0	0
33576	1624	mutational study	[Mutational studies]	1.0	2	2	1	1
33577	1624	protein glycation in pancreatic beta cell	[protein glycation in pancreatic beta cells]	1.0	6	1	0	0
33578	1624	different cells.	[different cells.]	1.0	2	1	0	0
33579	1624	chromosome 9	[chromosome 9]	1.0	2	1	0	0
33580	1624	new member of this family	[new member of this family]	1.0	5	1	0	0
33581	1624	cell therapy,	[cell therapy,]	1.0	2	1	0	0
33582	1624	nature of the therapeutic measure	[nature of the therapeutic measures]	1.0	5	1	0	0
33583	1624	term of ligand bind affinity	[terms of ligand binding affinity]	1.0	5	1	0	0
33584	1624	pattern of alpha 4 expression	[pattern of alpha 4 expression]	1.0	5	1	0	0
33585	1624	repeat by cd8+ T cell	[repeat by CD8+ T cells]	1.0	5	1	0	0
33586	1624	interleukin-1 beta production in human monocyte	[interleukin-1 beta production in human monocytes]	1.0	6	1	0	0
33587	1624	rp1 gene	[RP1 gene]	1.0	2	1	0	0
33588	1624	endogenous "receptors"	[endogenous "receptors"]	1.0	2	1	0	0
33589	1624	monocytic line	[monocytic line]	1.0	2	2	2	2
33590	1624	signal as il-1 in mononuclear phagocyte	[signaling as IL-1 in mononuclear phagocytes]	1.0	6	1	0	0
33591	1624	sn50 apoptosis	[SN50 apoptosis]	1.0	2	1	0	0
33592	1624	eicosanoid metabolite	[eicosanoid metabolites]	1.0	2	1	0	0
33593	1624	encode LBR	[encoding LBR]	1.0	2	2	1	1
33594	1624	amino acid 1 to 115	[amino acids 1 to 115]	1.0	5	1	0	0
33595	1624	half-maximal effect at 10 nm	[half-maximal effect at 10 nM]	1.0	5	1	0	0
33596	1624	SR asthma	[SR asthma]	1.0	2	1	0	0
33597	1624	expression of the alpha-chain of il-2ralpha	[Expression of the alpha-chain of IL-2Ralpha]	1.0	6	1	0	0
33598	1624	follow multiple administration of ad vector	[following multiple administrations of Ad vectors]	1.0	6	1	0	0
33599	1624	conversion of E2 to E1	[Conversion of E2 to E1]	1.0	5	1	0	0
33600	1624	nuclear rela	[nuclear RelA]	1.0	2	1	0	0
33601	1624	nuclear relb	[nuclear RelB]	1.0	2	1	0	0
33602	1624	residual positivity	[residual positivity]	1.0	2	1	0	0
33603	1624	platelet-derived growth	[platelet-derived growth]	1.0	2	1	0	0
33604	1624	activation signal lead to virus reactivation	[activation signals leading to virus reactivation]	1.0	6	1	0	0
33605	1624	cysteine NAC	[cysteine NAC]	1.0	2	1	0	0
33606	1624	cell stage	[cell stage]	1.0	2	2	2	2
33607	1624	critical determinant	[critical determinant]	1.0	2	2	2	2
33608	1624	hiv-1 rrna	[HIV-1 mRNAs]	1.0	2	1	0	0
33609	1624	Krone body	[Kr bodies]	1.0	2	1	0	0
33610	1624	molecular analysis of the cell origin	[molecular analysis of the cell origin]	1.0	6	1	0	0
33611	1624	even in the presence of factor	[even in the presence of factor]	1.0	6	1	0	0
33612	1624	megakaryocytic gene	[megakaryocytic genes]	1.0	2	3	2	1
33613	1624	involvement in the g0/g1 switch	[involvement in the G0/G1 switch]	1.0	5	1	0	0
33614	1624	pbmc of the gc group	[PBMC of the GC group]	1.0	5	3	2	1
33615	1624	include hl-60 promyelocytic leukemia cell	[including HL-60 promyelocytic leukemia cells]	1.0	5	1	0	0
33616	1624	regulate the IL-2 IL-4 gene	[regulating the IL-2 IL-4 genes]	1.0	5	1	0	0
33617	1624	quantitative competitive reverse transcription pcr	[quantitative competitive reverse transcription PCR]	1.0	5	1	0	0
33618	1624	JAK /stat pathway per se	[JAK /STAT pathway per se]	1.0	5	1	0	0
33619	1624	AP-1 plasmid	[AP-1 plasmids]	1.0	2	1	0	0
33620	1624	reversal from stimulation to inhibition	[reversal from stimulation to inhibition]	1.0	5	1	0	0
33621	1624	potentially regulate eotaxin gene expression and/or	[potentially regulating eotaxin gene expression and/or]	1.0	6	1	0	0
33622	1624	synergistic interaction between overlapping binding site	[Synergistic interactions between overlapping binding sites]	1.0	6	1	0	0
33623	1624	analysis of the nuclear extract	[Analysis of the nuclear extracts]	1.0	5	2	1	1
33624	1624	induction of a monocytic phenotype	[induction of a monocytic phenotype]	1.0	5	1	0	0
33625	1624	p3a2 wing gene product EWG	[P3A2 wing gene product EWG]	1.0	5	1	0	0
33626	1624	Interleukin-8 IL-8	[Interleukin-8 IL-8]	1.0	2	1	0	0
33627	1624	binding of calcineurin to nfat	[binding of calcineurin to NFAT]	1.0	5	1	0	0
33628	1624	aldosterone, 17-hydroxy-progesterone	[aldosterone, 17-hydroxy-progesterone]	1.0	2	1	0	0
33629	1624	glucocorticoid receptor complex in rabbit uterine	[glucocorticoid receptor complexes in rabbit uterine]	1.0	6	1	0	0
33630	1624	inclusion of this LTR in siv	[Inclusion of this LTR in SIVs]	1.0	6	1	0	0
33631	1624	assay for the quantitative determination	[assay for the quantitative determination]	1.0	5	1	0	0
33632	1624	c-myc protooncogene	[c-myc protooncogene]	1.0	2	1	0	0
33633	1624	gene expression during lymphocyte differentiation	[gene expression during lymphocyte differentiation]	1.0	5	1	0	0
33634	1624	ifn-gamma synthesis	[IFN-gamma synthesis]	1.0	2	1	0	0
33635	1624	regulate the intensity of the response	[regulating the intensity of the response]	1.0	6	1	0	0
33636	1624	lymphoid cell resistance to glucocorticoid	[Lymphoid cell resistance to glucocorticoids]	1.0	5	1	0	0
33637	1624	several t-cell-expressed cytokine human interleukin	[several T-cell-expressed cytokines human interleukin]	1.0	5	1	0	0
33638	1624	(fc) b cell of lymph node	[(FC) B cells of lymph nodes]	1.0	6	1	0	0
33639	1624	small change in acth concentration	[smaller changes in ACTH concentrations]	1.0	5	1	0	0
33640	1624	inverse change in the expression	[inverse changes in the expression]	1.0	5	1	0	0
33641	1624	pyruvate kinase	[pyruvate kinase]	1.0	2	1	0	0
33642	1624	emit primarily in the uvb range	[emitting primarily in the UVB range]	1.0	6	1	0	0
33643	1624	P1 site	[P1 site]	1.0	2	2	1	1
33644	1624	hematopoietic growth factor HGF requirement	[hematopoietic growth factor HGF requirement]	1.0	5	1	0	0
33645	1624	negative influence on gr function	[negative influence on GR function]	1.0	5	1	0	0
33646	1624	such as the induction of activity	[such as the induction of activity]	1.0	6	1	0	0
33647	1624	transfection of c-jun promoter construct	[Transfection of c-jun promoter constructs]	1.0	5	1	0	0
33648	1624	Conversely, IL-4	[Conversely, IL-4]	1.0	2	1	0	0
33649	1624	net effect of this molecule	[net effect of this molecule]	1.0	5	1	0	0
33650	1624	phorbol 12-myristate 13-acetate (pma)-mediated differentiation	[phorbol 12-myristate 13-acetate (PMA)-mediated differentiation]	1.0	5	1	0	0
33651	1624	presence of the ebv genome	[presence of the EBV genome]	1.0	5	1	0	0
33652	1624	use a tsh receptor cDNA probe	[Using a TSH receptor cDNA probe]	1.0	6	1	0	0
33653	1624	use in vivo genomic footprinting	[Using in vivo genomic footprinting]	1.0	5	1	0	0
33654	1624	M.LaPlaca, Blood	[M.LaPlaca, Blood]	1.0	2	1	0	0
33655	1624	r-activating signal	[R-activating signal]	1.0	2	1	0	0
33656	1624	80-kDa protein	[80-kDa protein]	1.0	2	1	0	0
33657	1624	physiologic plausibility of this claims,	[physiologic plausibility of these claims,]	1.0	5	1	0	0
33658	1624	differentiation, proliferation	[differentiation, proliferation]	1.0	2	1	0	0
33659	1624	regulation effect	[Regulation effects]	1.0	2	2	2	2
33660	1624	t-helper-cell determinant in protein antigen	[T-helper-cell determinants in protein antigens]	1.0	5	1	0	0
33661	1624	palmar fibromatosis	[palmar fibromatosis]	1.0	2	2	1	1
33662	1624	lack most of the E1 region	[lacking most of the E1 region]	1.0	6	1	0	0
33663	1624	strong interaction between the x2 box	[strong interactions between the X2 box]	1.0	6	1	0	0
33664	1624	separate activity	[separate activities]	1.0	2	1	0	0
33665	1624	stimulation rest human T cell	[Stimulation resting human T cells]	1.0	5	1	0	0
33666	1624	contain domain	[containing domains]	1.0	2	2	2	2
33667	1624	nuclear transcription factor- kappab activation	[nuclear transcription factor- kappaB activation]	1.0	5	1	0	0
33668	1624	auc; p	[AUC; P]	1.0	2	1	0	0
33669	1624	residual pml/rar alpha mrna -contain cell	[residual PML/RAR alpha mRNA -containing cells]	1.0	6	1	0	0
33670	1624	(rai) therapy,	[(RAI) therapy,]	1.0	2	1	0	0
33671	1624	evolution of the great ape	[evolution of the great apes]	1.0	5	1	0	0
33672	1624	transcriptional activity of basic hlh protein	[transcriptional activities of basic HLH proteins]	1.0	6	1	0	0
33673	1624	3 binding	[3 binding]	1.0	2	2	2	2
33674	1624	E2F 1	[E2F 1]	1.0	2	1	0	0
33675	1624	express sialoadhesin	[express sialoadhesin]	1.0	2	1	0	0
33676	1624	glucocorticoid receptor characteristic on monocyte	[glucocorticoid receptor characteristics on monocytes]	1.0	5	1	0	0
33677	1624	monocyte maturation into m phi	[monocyte maturation into M phi]	1.0	5	1	0	0
33678	1624	death-promoting member	[death-promoting members]	1.0	2	1	0	0
33679	1624	many leukocyte	[many leukocytes]	1.0	2	1	0	0
33680	1624	10000-fold selectivity for aldosterone over cortisol	[10,000-fold selectivity for aldosterone over cortisol]	1.0	6	1	0	0
33681	1624	variant form	[variant form]	1.0	2	3	2	1
33682	1624	homotypic cell adhesion, il-6 production	[homotypic cell adhesion, IL-6 production]	1.0	5	1	0	0
33683	1624	ideal situation	[ideal situation]	1.0	2	1	0	0
33684	1624	peripheral blood leukocyte in runner	[peripheral blood leukocytes in runner]	1.0	5	2	2	2
33685	1624	proteolytic processing	[proteolytic processing]	1.0	2	2	1	1
33686	1624	autocrine growth of myeloma (mm) cell	[autocrine growth of myeloma (MM) cells]	1.0	6	1	0	0
33687	1624	virus progeny	[virus progeny]	1.0	2	1	0	0
33688	1624	DHEA effect on lps monocyte	[DHEA effects on LPS monocytes]	1.0	5	1	0	0
33689	1624	identify target	[identifying targets]	1.0	2	2	2	2
33690	1624	furthermore, the nuclear protein complex	[Furthermore, the nuclear protein complexes]	1.0	5	1	0	0
33691	1624	lipid metabolism	[lipid metabolism]	1.0	2	1	0	0
33692	1624	13 kda	[13 kDa]	1.0	2	1	0	0
33693	1624	les-induced nf-kappa b binding activity	[LPS-induced NF-kappa B binding activity]	1.0	5	1	0	0
33694	1624	recombinant sp1	[recombinant SP1]	1.0	2	2	1	1
33695	1624	adult t-cell leukemia cell line	[adult T-cell leukemia cell line]	1.0	5	1	0	0
33696	1624	tumor metastasis	[tumor metastasis]	1.0	2	2	1	1
33697	1624	macrophage differentiation,	[macrophage differentiation,]	1.0	2	2	1	1
33698	1624	macrophage differentiation.	[macrophage differentiation.]	1.0	2	1	0	0
33699	1624	contain six C-terminal zinc-finger motif	[containing six C-terminal zinc-finger motifs]	1.0	5	1	0	0
33700	1624	recombinant siv	[recombinant SIVs]	1.0	2	1	0	0
33701	1624	1-2 minutes.	[1-2 minutes.]	1.0	2	1	0	0
33702	1624	g0-g1 phases.	[G0-G1 phases.]	1.0	2	1	0	0
33703	1624	human immunodeficiency virus type-1 transcription role	[Human immunodeficiency virus type-1 transcription role]	1.0	6	1	0	0
33704	1624	protein-protein interaction with other molecule	[protein-protein interactions with other molecules]	1.0	5	1	0	0
33705	1624	normal human	[normal humans]	1.0	2	1	0	0
33706	1624	isoform elf-2a	[isoforms elf-2a]	1.0	2	1	0	0
33707	1624	contaminant lps	[contaminant LPS]	1.0	2	1	0	0
33708	1624	decrease in the translation rate	[decrease in the translation rate]	1.0	5	1	0	0
33709	1624	gata-1 motif	[GATA-1 motifs]	1.0	2	1	0	0
33710	1624	expression of the Epstein-Barr virus	[Expression of the Epstein-Barr virus]	1.0	5	2	2	2
33711	1624	maintain the balance of c-jun protein	[maintaining the balance of c-Jun protein]	1.0	6	1	0	0
33712	1624	ptt shift	[PTT shift]	1.0	2	2	1	1
33713	1624	placebo-treated subject	[placebo-treated subjects]	1.0	2	1	0	0
33714	1624	(aml m4	[(AML M4]	1.0	2	1	0	0
33715	1624	hepatic leukemia	[hepatic leukemia]	1.0	2	1	0	0
33716	1624	JAK3 type ii signal pathway	[JAK3 Type II signaling pathway]	1.0	5	1	0	0
33717	1624	ifn-gamma treatment of u937 cell	[IFN-gamma treatment of U937 cells]	1.0	5	1	0	0
33718	1624	result necessity of continuous monitoring	[resulting necessity of continuous monitoring]	1.0	5	1	0	0
33719	1624	DNA binding activity of RelB	[DNA binding activity of RelB]	1.0	5	1	0	0
33720	1624	amino acid sequence to the receptor	[amino acid sequence to the receptor]	1.0	6	1	0	0
33721	1624	p45 nf-e2	[p45 NF-E2]	1.0	2	2	1	1
33722	1624	supershift analysis of this region	[supershift analyses of this region]	1.0	5	1	0	0
33723	1624	induction of cytokine gene expression	[induction of cytokine gene expression]	1.0	5	1	0	0
33724	1624	c/ebpepsilon mrna level by 4-fold,	[C/EBPepsilon mRNA levels by 4-fold,]	1.0	5	1	0	0
33725	1624	nuclear nf-kappa b activity in om-10.1	[nuclear NF-kappa B activity in OM-10.1]	1.0	6	1	0	0
33726	1624	serum thyroxine	[serum thyroxine]	1.0	2	2	2	2
33727	1624	id2 mrna in human lymphocyte	[Id2 mRNA in human lymphocytes]	1.0	5	1	0	0
33728	1624	constitutive transcription in T cell	[constitutive transcription in T cells]	1.0	5	1	0	0
33729	1624	-responsive octamer	[-responsive octamer]	1.0	2	1	0	0
33730	1624	serine kinase	[serine kinase]	1.0	2	2	2	2
33731	1624	action of adenoviral e1a oncoprotein	[action of adenoviral E1A oncoprotein]	1.0	5	1	0	0
33732	1624	nuclear protein capable of binding	[nuclear proteins capable of binding]	1.0	5	1	0	0
33733	1624	also a receptor for various chemokine	[also a receptor for various chemokines]	1.0	6	1	0	0
33734	1624	dna-binding of the p50 subunit	[DNA-binding of the p50 subunit]	1.0	5	1	0	0
33735	1624	include tumor necrosis factor-alpha TNF-alpha	[including tumor necrosis factor-alpha TNF-alpha]	1.0	5	1	0	0
33736	1624	Thus, PML	[Thus, PML]	1.0	2	1	0	0
33737	1624	basic properties.	[basic properties.]	1.0	2	1	0	0
33738	1624	x gene	[X gene]	1.0	2	2	1	1
33739	1624	stimulation of blood mononuclear cell	[stimulation of blood mononuclear cells]	1.0	5	2	2	2
33740	1624	mitogen-activated protein kinase activation in monocyte	[mitogen-activated protein kinase activation in monocytes]	1.0	6	1	0	0
33741	1624	nearly complete resistance against anti-fa antibody	[nearly complete resistance against anti-Fas antibody]	1.0	6	1	0	0
33742	1624	t-antigen-expressing plasmid	[T-antigen-expressing plasmids]	1.0	2	1	0	0
33743	1624	translocation cell	[translocation cells]	1.0	2	1	0	0
33744	1624	rflp pair	[RFLP pair]	1.0	2	1	0	0
33745	1624	explore the molecular pathogenesis of APL	[exploring the molecular pathogenesis of APL]	1.0	6	1	0	0
33746	1624	pml promyelocytic leukemia protein degradation	[PML promyelocytic leukemia protein degradation]	1.0	5	1	0	0
33747	1624	fasl induction in NK cell	[FasL induction in NK cells]	1.0	5	1	0	0
33748	1624	prime with 10 nm RA	[Priming with 10 nM RA]	1.0	5	1	0	0
33749	1624	vivo, anergy	[vivo, anergy]	1.0	2	1	0	0
33750	1624	nf-kappab dna-binding	[NF-kappaB DNA-binding]	1.0	2	2	2	2
33751	1624	furthermore, multimerized region ii sequence element	[Furthermore, multimerized region II sequence elements]	1.0	6	1	0	0
33752	1624	brief introduction to lineage commitment	[brief introduction to lineage commitment]	1.0	5	1	0	0
33753	1624	inhibit the serine /threonine phosphatase calcineurin	[inhibiting the serine /threonine phosphatase calcineurin]	1.0	6	1	0	0
33754	1624	p38 mitogen-activated protein kinase mapk	[p38 mitogen-activated protein kinase MAPk]	1.0	5	1	0	0
33755	1624	rest peripheral blood mononuclear cell	[resting peripheral blood mononuclear cells]	1.0	5	2	2	2
33756	1624	bipartite system	[bipartite system]	1.0	2	1	0	0
33757	1624	stat3 of early response gene	[STAT3 of early response genes]	1.0	5	1	0	0
33758	1624	Steroid-resistant asthma	[Steroid-resistant asthma]	1.0	2	1	0	0
33759	1624	furthermore, NF-kappaB transcriptional factor of cell	[Furthermore, NF-kappaB transcriptional factor of cells]	1.0	6	1	0	0
33760	1624	Functional study in extra-renal, nonepithelial cell	[Functional studies in extra-renal, nonepithelial cells]	1.0	6	1	0	0
33761	1624	contribution of the cytoplasmic domain	[contribution of the cytoplasmic domain]	1.0	5	1	0	0
33762	1624	genetic change	[genetic changes]	1.0	2	2	1	1
33763	1624	expression of most eukaryotic gene	[expression of most eukaryotic genes]	1.0	5	1	0	0
33764	1624	90 percent of sertraline responder	[90 percent of sertraline responders]	1.0	5	1	0	0
33765	1624	T cell activation by shp1	[T cell activation by SHP1]	1.0	5	1	0	0
33766	1624	transfer into hepatocyte in cultures.	[transfer into hepatocytes in cultures.]	1.0	5	1	0	0
33767	1624	binding of 55- kda protein	[binding of 55- kDa proteins]	1.0	5	1	0	0
33768	1624	unstimulated thp-1	[unstimulated THP-1]	1.0	2	1	0	0
33769	1624	TNF (encoding tumour necrosis factor,	[TNF (encoding tumour necrosis factor,]	1.0	5	1	0	0
33770	1624	52-year-old male	[52-year-old male]	1.0	2	1	0	0
33771	1624	nuclear presence	[nuclear presence]	1.0	2	1	0	0
33772	1624	Tyrphostin AG-490	[Tyrphostin AG-490]	1.0	2	1	0	0
33773	1624	stimulation of U1 promonocytic cells.	[stimulation of U1 promonocytic cells.]	1.0	5	1	0	0
33774	1624	epo granulocyte-macrophage colony-stimumulatelany-stg factor gm-csf	[EPO granulocyte-macrophage colony-stimulating factor GM-CSF]	1.0	5	1	0	0
33775	1624	oap/octamer cis-element	[OAP/octamer cis-element]	1.0	2	1	0	0
33776	1624	effect of a progesterone antagonist	[effects of a progesterone antagonist]	1.0	5	1	0	0
33777	1624	rat splenocyte proliferation with methylprednisolone	[rat splenocyte proliferation with methylprednisolone]	1.0	5	1	0	0
33778	1624	second gcr	[second GCR]	1.0	2	2	2	2
33779	1624	inhibitor of plasma membrane ca-atpase	[inhibitor of plasma membrane Ca-ATPase]	1.0	5	1	0	0
33780	1624	mutagenesis of the consensus CKII site	[mutagenesis of the consensus CKII site]	1.0	6	1	0	0
33781	1624	135(oh)2d3 treatment	[1,25(OH)2D3 treatment]	1.0	2	1	0	0
33782	1624	ebv -positive b lymphoid cell	[EBV -positive B lymphoid cells]	1.0	5	1	0	0
33783	1624	gssg level	[GSSG levels]	1.0	2	2	2	2
33784	1624	urinary steroidogram	[urinary steroidogram]	1.0	2	1	0	0
33785	1624	corneal endothelium	[corneal endothelium]	1.0	2	2	1	1
33786	1624	high-affinity site	[high-affinity site]	1.0	2	2	1	1
33787	1624	other stress	[other stresses]	1.0	2	1	0	0
33788	1624	three mode of oxidative stress	[three modes of oxidative stress]	1.0	5	1	0	0
33789	1624	potentiation of trancriptional activity by GM-CSF	[potentiation of trancriptional activity by GM-CSF]	1.0	6	1	0	0
33790	1624	patient/histopathology datum	[patient/histopathology data]	1.0	2	1	0	0
33791	1624	TLR2 complex	[TLR2 complex.]	1.0	2	1	0	0
33792	1624	mua site	[muA sites]	1.0	2	1	0	0
33793	1624	Immunoelectron microscopy	[Immunoelectron microscopy]	1.0	2	1	0	0
33794	1624	fluticasone propionate fp for 2 weeks.	[fluticasone propionate FP for 2 weeks.]	1.0	6	1	0	0
33795	1624	two complexess	[two complexes,]	1.0	2	1	0	0
33796	1624	apoptotic leukocyte	[apoptotic leukocytes]	1.0	2	2	1	1
33797	1624	T cell from normal individual	[T cells from normal individuals]	1.0	5	1	0	0
33798	1624	igh gene	[IgH gene]	1.0	2	2	2	2
33799	1624	involve expression	[involving expression]	1.0	2	2	2	2
33800	1624	c/ebp alpha two transcription factor	[C/EBP alpha two transcription factors]	1.0	5	1	0	0
33801	1624	human il-10	[human IL-10]	1.0	2	2	2	2
33802	1624	chronic hepatitis b virus infection (6	[chronic hepatitis B virus infection (6]	1.0	6	1	0	0
33803	1624	predominant factor bind to one	[predominant factor binding to one]	1.0	5	1	0	0
33804	1624	differential expression of cell surface molecules,	[differential expression of cell surface molecules,]	1.0	6	1	0	0
33805	1624	immune hyperactivation of hiv-1 T cell	[Immune hyperactivation of HIV-1 T cells]	1.0	6	1	0	0
33806	1624	THP-1 mononuclear phagocyte cell line	[THP-1 mononuclear phagocyte cell line]	1.0	5	1	0	0
33807	1624	exposure to phorbol 12-myristate 13-acetate	[exposure to phorbol 12-myristate 13-acetate]	1.0	5	1	0	0
33808	1624	modulate the expression of proinflammatory cytokine	[modulating the expression of proinflammatory cytokines]	1.0	6	1	0	0
33809	1624	Glucocorticoid receptor in anorexia nervosa	[Glucocorticoid receptors in anorexia nervosa]	1.0	5	1	0	0
33810	1624	antiinflammatory drug	[antiinflammatory drugs]	1.0	2	1	0	0
33811	1624	karyotypic abnormality	[karyotypic abnormalities]	1.0	2	1	0	0
33812	1624	inactivation of the Rb protein	[inactivation of the Rb protein]	1.0	5	1	0	0
33813	1624	human il-2r	[human IL-2R]	1.0	2	2	1	1
33814	1624	essential component of the receptor	[essential component of the receptors]	1.0	5	2	1	1
33815	1624	GATA site in a promoter	[GATA site in a promoter]	1.0	5	1	0	0
33816	1624	site of glucocorticoid receptor gcr	[sites of glucocorticoid receptor GCR]	1.0	5	1	0	0
33817	1624	cyclosporin -resistant mutant in yeast	[cyclosporin -resistant mutants in yeast]	1.0	5	1	0	0
33818	1624	10(-5) mol/L)	[10(-5) mol/L)]	1.0	2	1	0	0
33819	1624	plasmid contain sense antisense rxr-alpha sequence	[plasmids containing sense antisense RXR-alpha sequences]	1.0	6	1	0	0
33820	1624	mitochondrial enzyme	[mitochondrial enzyme]	1.0	2	1	0	0
33821	1624	nf.kappa b	[NF.kappa B]	1.0	2	1	0	0
33822	1624	subsequent event	[subsequent events]	1.0	2	1	0	0
33823	1624	last site	[last site]	1.0	2	1	0	0
33824	1624	constitutively significant level of proto-oncogent c-jun	[constitutively significant levels of proto-oncogenes c-jun]	1.0	6	1	0	0
33825	1624	induction of factor kappa b	[induction of factor kappa B]	1.0	5	1	0	0
33826	1624	bcl-2 expression in b cell	[bcl-2 expression in B cells]	1.0	5	1	0	0
33827	1624	infection of human b cell	[Infection of human B cells]	1.0	5	1	0	0
33828	1624	-70 region	[-70 region]	1.0	2	2	2	2
33829	1624	rate-limiting step	[rate-limiting step]	1.0	2	2	1	1
33830	1624	reactivity of T cell line	[reactivity of T cell lines]	1.0	5	1	0	0
33831	1624	4e-bp1 amount	[4E-BP1 amount]	1.0	2	1	0	0
33832	1624	activation of the beta-casein promoter	[activation of the beta-casein promoter]	1.0	5	1	0	0
33833	1624	Blood, 89:	[Blood, 89:]	1.0	2	1	0	0
33834	1624	traf signal	[TRAF signaling]	1.0	2	1	0	0
33835	1624	costimulation of blood T cell activation	[Costimulation of blood T cell activation]	1.0	6	1	0	0
33836	1624	mutant tax retain transactivate ability	[mutant Tax retaining transactivating ability]	1.0	5	1	0	0
33837	1624	number of calcitriol 135eoh)2d3 receptor	[number of calcitriol 1,25(OH)2D3 receptors]	1.0	5	1	0	0
33838	1624	endotoxin-stimulated inflammatory c ytokine mrna level	[endotoxin-stimulated inflammatory c ytokine mRNA levels]	1.0	6	1	0	0
33839	1624	non-hodgkin's lymphoma of B-cell type	[non-Hodgkin's lymphoma of B-cell type]	1.0	5	1	0	0
33840	1624	cd3-cd16+ cell	[CD3-CD16+ cells]	1.0	2	1	0	0
33841	1624	phenomenon of costimulation by EC	[phenomenon of costimulation by EC]	1.0	5	1	0	0
33842	1624	mrna species IL-12 NK cell	[mRNA species IL-12 NK cells]	1.0	5	1	0	0
33843	1624	signal in primary human erythroid precursor	[signaling in primary human erythroid precursors]	1.0	6	1	0	0
33844	1624	fresh insight	[fresh insights]	1.0	2	1	0	0
33845	1624	pattern of alpha 4 integrin	[pattern of alpha 4 integrin]	1.0	5	1	0	0
33846	1624	5 years),	[5 years),]	1.0	2	1	0	0
33847	1624	+55 region nucleotide number 5'-gttaaggttcgtaggtcatgga-3'	[+55 region nucleotide numbers 5'-GTTAAGGTTCGTAGGTCATGGA-3']	1.0	5	1	0	0
33848	1624	subfragment (c26) in the region	[subfragment (C26) in the region]	1.0	5	1	0	0
33849	1624	5 years).	[5 years).]	1.0	2	1	0	0
33850	1624	dissimilar oncogenicity	[dissimilar oncogenicities]	1.0	2	1	0	0
33851	1624	c3heb/fej [H-2k]	[C3HeB/FeJ [H-2k]]	1.0	2	1	0	0
33852	1624	Furthermore, PML	[Furthermore, PML]	1.0	2	1	0	0
33853	1624	lps MDP	[LPS MDP]	1.0	2	1	0	0
33854	1624	cho cell express the CD28 ligand	[CHO cells expressing the CD28 ligands]	1.0	6	1	0	0
33855	1624	mutagenesis of the nf-kappa b motif	[mutagenesis of the NF-kappa B motif]	1.0	6	1	0	0
33856	1624	response to IL-4 receptor engagement	[response to IL-4 receptor engagement]	1.0	5	1	0	0
33857	1624	tight correlation	[tight correlation]	1.0	2	2	2	2
33858	1624	activation-dependent, T	[activation-dependent, T]	1.0	2	1	0	0
33859	1624	issue of cd8(+) T cell	[issue of CD8(+) T cells]	1.0	5	1	0	0
33860	1624	new strategy	[new strategies]	1.0	2	2	2	2
33861	1624	suppression of the immunodeficiency virus terminal	[Suppression of the immunodeficiency virus terminal]	1.0	6	1	0	0
33862	1624	protective immunity	[protective immunity]	1.0	2	2	2	2
33863	1624	Bcl-6 /cd3	[Bcl-6 /CD3]	1.0	2	1	0	0
33864	1624	treatment of cell with ptx	[Treatment of cells with PTX]	1.0	5	1	0	0
33865	1624	ebv-positive Burkitt' lymphoma cell line	[EBV-positive Burkitt's lymphoma cell lines]	1.0	5	1	0	0
33866	1624	surface expression of cd25 alpha subunit	[surface expression of CD25 alpha subunit]	1.0	6	1	0	0
33867	1624	immunolabeling of the catalytic subunit	[immunolabeling of the catalytic subunit]	1.0	5	1	0	0
33868	1624	monoclonal anti-endothelial cell antibody maeca	[monoclonal anti-endothelial cell antibodies mAECA]	1.0	5	1	0	0
33869	1624	transactivation assay	[transactivation assay]	1.0	2	2	1	1
33870	1624	135-(oh)2d3 il-1	[1,25-(OH)2D3 IL-1]	1.0	2	1	0	0
33871	1624	two nonstructural trans-acting regulatory gene	[two nonstructural trans-acting regulatory genes]	1.0	5	1	0	0
33872	1624	affect growth of diverse cell type	[affecting growth of diverse cell types]	1.0	6	1	0	0
33873	1624	part of the affinity ige receptor	[part of the affinity IgE receptor]	1.0	6	1	0	0
33874	1624	5'-flanking region of this gene	[5'-flanking region of this gene]	1.0	5	1	0	0
33875	1624	epidermal neoplasm	[epidermal neoplasms]	1.0	2	1	0	0
33876	1624	DNA consensus	[DNA consensus]	1.0	2	2	2	2
33877	1624	point mutant of zebra z(s186a)	[point mutant of ZEBRA Z(S186A)]	1.0	5	1	0	0
33878	1624	inhibit the production of cyclin D3	[inhibiting the production of cyclin D3]	1.0	6	1	0	0
33879	1624	cooperative function	[cooperative function]	1.0	2	1	0	0
33880	1624	nonsense mutation	[nonsense mutation]	1.0	2	1	0	0
33881	1624	ap3-l motif	[AP3-L motif]	1.0	2	1	0	0
33882	1624	circulate primary leukemic T cell	[circulating primary leukemic T cells]	1.0	5	1	0	0
33883	1624	CD30 cross-linking	[CD30 cross-linking]	1.0	2	1	0	0
33884	1624	northern hybridization	[northern hybridization]	1.0	2	1	0	0
33885	1624	pivotal event convert ligand-receptor interaction	[pivotal event converting ligand-receptor interactions]	1.0	5	1	0	0
33886	1624	g2, increase in cell mass,	[G2, increase in cell mass,]	1.0	5	1	0	0
33887	1624	agar cultures,	[agar cultures,]	1.0	2	1	0	0
33888	1624	negative regulation by dimethyl sulfoxide	[negative regulation by dimethyl sulfoxide]	1.0	5	1	0	0
33889	1624	epo -dependent hcd57 erythroid cell	[EPO -dependent HCD57 erythroid cells]	1.0	5	1	0	0
33890	1624	more slowly migrate b1 complex	[more slowly migrating B1 complex]	1.0	5	1	0	0
33891	1624	immunization for T cell sensitization	[immunization for T cell sensitization]	1.0	5	1	0	0
33892	1624	representative mutant	[representative mutants]	1.0	2	2	1	1
33893	1624	effect on the proliferation of hpc	[effect on the proliferation of HPCs]	1.0	6	1	0	0
33894	1624	Functional analysis of DNA fragment	[Functional analyses of DNA fragments]	1.0	5	1	0	0
33895	1624	phenol layer	[phenol layer]	1.0	2	1	0	0
33896	1624	cl-induced apoptosis	[CL-induced apoptosis]	1.0	2	1	0	0
33897	1624	potent immunosuppressive compound in vitro.	[potent immunosuppressive compound in vitro.]	1.0	5	1	0	0
33898	1624	study the link between differentiation arrest	[studying the link between differentiation arrest]	1.0	6	1	0	0
33899	1624	enhance effect of 17 beta-estradiol	[Enhancing effect of 17 beta-estradiol]	1.0	5	1	0	0
33900	1624	addition, genistein	[addition, genistein]	1.0	2	1	0	0
33901	1624	such variants,	[such variants,]	1.0	2	1	0	0
33902	1624	regulation of this cytokine gene	[regulation of these cytokine genes]	1.0	5	1	0	0
33903	1624	dual signals.	[dual signals.]	1.0	2	1	0	0
33904	1624	Karyotypic detection of chromosomal 16 abnormality	[Karyotypic detection of chromosomal 16 abnormalities]	1.0	6	1	0	0
33905	1624	gm-csf expression	[GM-CSF expression]	1.0	2	1	0	0
33906	1624	interaction with specific hormone receptor	[interaction with specific hormone receptors]	1.0	5	1	0	0
33907	1624	mouse lymphoma cell in culture.	[mouse lymphoma cells in culture.]	1.0	5	1	0	0
33908	1624	(4%) clone	[(4%) clones]	1.0	2	1	0	0
33909	1624	synergistic effect on monocyte cytotoxicity	[synergistic effect on monocyte cytotoxicity]	1.0	5	1	0	0
33910	1624	mediate il-4-induced tyrosine phosphorylation events.	[mediating IL-4-induced tyrosine phosphorylation events.]	1.0	5	1	0	0
33911	1624	SIVmac239 mutant	[SIVmac239 mutants]	1.0	2	1	0	0
33912	1624	change of calcitriol receptor in hyperparathyroidism	[Changes of calcitriol receptors in hyperparathyroidism]	1.0	6	1	0	0
33913	1624	synergistic activity	[synergistic activity]	1.0	2	2	1	1
33914	1624	rest state	[resting state]	1.0	2	1	0	0
33915	1624	nucleoside diphosphate (ndp) kinase activity	[nucleoside diphosphate (NDP) kinase activity]	1.0	5	1	0	0
33916	1624	long protection against hiv infection	[long-term protection against HIV infection]	1.0	5	1	0	0
33917	1624	noncytoxic concentration	[noncytoxic concentrations]	1.0	2	1	0	0
33918	1624	subcellular compartmentalization of this protein	[subcellular compartmentalization of these proteins]	1.0	5	1	0	0
33919	1624	heterozygous carrier	[heterozygous carriers]	1.0	2	1	0	0
33920	1624	exon 4	[exons 4]	1.0	2	1	0	0
33921	1624	exon 5	[exon 5]	1.0	2	2	1	1
33922	1624	further studies,	[further studies,]	1.0	2	1	0	0
33923	1624	evidence for inflammatory cytokine production	[evidence for inflammatory cytokine production]	1.0	5	1	0	0
33924	1624	non-express cell	[non-expressing cells]	1.0	2	1	0	0
33925	1624	nuclear factor kappab nf kappab	[nuclear factor kappaB NF kappaB]	1.0	5	1	0	0
33926	1624	phase -1	[phase -1]	1.0	2	1	0	0
33927	1624	direct bear on this transformation	[direct bearing on this transformation]	1.0	5	1	0	0
33928	1624	protein bind to GATA-1 motif	[proteins binding to GATA-1 motifs]	1.0	5	1	0	0
33929	1624	promoter upstream	[promoter upstream]	1.0	2	2	1	1
33930	1624	Drosophila esc	[Drosophila Esc]	1.0	2	1	0	0
33931	1624	vitro from bone marrow cell	[vitro from bone marrow cells]	1.0	5	1	0	0
33932	1624	nuclear relb translocation by CD40	[nuclear RelB translocation by CD40]	1.0	5	1	0	0
33933	1624	replicative/cytopathic capacity	[replicative/cytopathic capacity]	1.0	2	1	0	0
33934	1624	38-kd murine map kinase homologous	[38-kD murine MAP kinase homologous]	1.0	5	1	0	0
33935	1624	rapid expression	[rapid expression]	1.0	2	3	2	1
33936	1624	dehydroepiandrosterone modulation of lipopolysaccharide monocyte cytotoxicity	[Dehydroepiandrosterone modulation of lipopolysaccharide monocyte cytotoxicity]	1.0	6	1	0	0
33937	1624	ad of abnormal camp activity	[AD of abnormal cAMP activity]	1.0	5	1	0	0
33938	1624	kb fragment	[kb fragment]	1.0	2	2	2	2
33939	1624	notably product	[notably products]	1.0	2	1	0	0
33940	1624	nuclear fraction of nwp cell	[nuclear fractions of NWP cells]	1.0	5	1	0	0
33941	1624	inhibition of NF-kappaB transcriptional activity	[Inhibition of NF-kappaB transcriptional activity]	1.0	5	1	0	0
33942	1624	function of transcriptional activation of latency.	[functions of transcriptional activation of latency.]	1.0	6	1	0	0
33943	1624	Philadelphia chromosome	[Philadelphia chromosome]	1.0	2	2	2	2
33944	1624	estrogen receptor -negative tumor status	[estrogen receptor -negative tumor status]	1.0	5	1	0	0
33945	1624	dramatic reduction in the number	[dramatic reduction in the number]	1.0	5	1	0	0
33946	1624	two functionally distinct domains, a	[two functionally distinct domains, A]	1.0	5	1	0	0
33947	1624	distinct signal	[distinct signal]	1.0	2	2	1	1
33948	1624	nm dexamethasone	[nM dexamethasone]	1.0	2	2	1	1
33949	1624	candidate for immunodeficiency syndrome (aids) vaccine	[candidates for Immunodeficiency Syndrome (AIDS) vaccine]	1.0	6	1	0	0
33950	1624	optimal cd95 ligand reporter activity	[optimal CD95 ligand reporter activity]	1.0	5	1	0	0
33951	1624	multipotent/erythroid/monocytic to granulocytic differentiation program	[multipotent/erythroid/monocytic to granulocytic differentiation program]	1.0	5	1	0	0
33952	1624	comparison to the p50 homodimer,	[comparison to the p50 homodimer,]	1.0	5	1	0	0
33953	1624	respective region	[respective region]	1.0	2	1	0	0
33954	1624	constitutive nuclear localization of NFAT4	[constitutive nuclear localization of NFAT4]	1.0	5	1	0	0
33955	1624	succinimide residue	[succinimide residues]	1.0	2	1	0	0
33956	1624	combination with the hiv-2 tat	[combination with the HIV-2 tat]	1.0	5	1	0	0
33957	1624	differentiate monocyte	[differentiating monocytes]	1.0	2	2	2	2
33958	1624	transcription from the SL3 enhancer	[transcription from the SL3 enhancer]	1.0	5	1	0	0
33959	1624	activation of the hiv-1 promoter	[activation of the HIV-1 promoter]	1.0	5	1	0	0
33960	1624	calcitriol binding	[calcitriol binding]	1.0	2	1	0	0
33961	1624	-specific T	[-specific T]	1.0	2	1	0	0
33962	1624	pre-monocytic cells,	[pre-monocytic cells,]	1.0	2	1	0	0
33963	1624	moreover, Tax1	[Moreover, Tax1]	1.0	2	1	0	0
33964	1624	clinical remission follow atra treatment	[clinical remission following ATRA treatment]	1.0	5	1	0	0
33965	1624	certain combination	[certain combinations]	1.0	2	1	0	0
33966	1624	Il-2 gene	[Il-2 gene]	1.0	2	1	0	0
33967	1624	T cell-tropic	[T cell-tropic]	1.0	2	1	0	0
33968	1624	monomeric G protein family member	[monomeric G protein family member]	1.0	5	1	0	0
33969	1624	marker specific to the lineage	[markers specific to the lineages]	1.0	5	1	0	0
33970	1624	suggest great than previously thought.	[suggesting greater than previously thought.]	1.0	5	1	0	0
33971	1624	nonthymocyte cell	[nonthymocyte cells]	1.0	2	1	0	0
33972	1624	preeclamptic mother	[preeclamptic mother]	1.0	2	1	0	0
33973	1624	difference in cytokine secretion profile	[difference in cytokine secretion profiles]	1.0	5	1	0	0
33974	1624	human hl-60 myeloid leukemia cell	[human HL-60 myeloid leukemia cells]	1.0	5	1	0	0
33975	1624	response to certain fatty acid	[response to certain fatty acids]	1.0	5	1	0	0
33976	1624	less than 4% apoptotic cells;	[less than 4% apoptotic cells;]	1.0	5	1	0	0
33977	1624	control collagenase transcription in monocytic cell	[controlling collagenase transcription in monocytic cells]	1.0	6	1	0	0
33978	1624	none of the DNA fragment	[None of the DNA fragments]	1.0	5	1	0	0
33979	1624	metabolic labeling	[Metabolic labeling]	1.0	2	2	1	1
33980	1624	42 month (range, 31-55 months).	[42 months (range, 31-55 months).]	1.0	5	1	0	0
33981	1624	alas mrna	[ALAS mRNA]	1.0	2	2	1	1
33982	1624	profound state of viral latency	[profound state of viral latency]	1.0	5	1	0	0
33983	1624	GM5 site,	[GM5 site,]	1.0	2	1	0	0
33984	1624	numerous gene fall into that category	[numerous genes falling into those categories]	1.0	6	1	0	0
33985	1624	persistent hypophosphatemia	[persistent hypophosphatemia]	1.0	2	1	0	0
33986	1624	fk506 a block translocation affect synthesis	[FK506 A block translocation affecting synthesis]	1.0	6	1	0	0
33987	1624	repress cytokine production in the lesion	[repressing cytokine production in the lesions]	1.0	6	1	0	0
33988	1624	such as a Jurkat t-cell line	[such as a Jurkat T-cell line]	1.0	6	1	0	0
33989	1624	Furthermore, retinoic acid receptor RAR alpha	[Furthermore, retinoic acid receptor RAR alpha]	1.0	6	1	0	0
33990	1624	gene disruption	[gene disruption]	1.0	2	3	2	1
33991	1624	posttranslational activation	[posttranslational activation]	1.0	2	2	2	2
33992	1624	activation of nf-kappab DNA binding activity	[activation of NF-kappaB DNA binding activity]	1.0	6	1	0	0
33993	1624	utilize the steroid antagonist ru-486	[utilizing the steroid antagonist RU-486]	1.0	5	1	0	0
33994	1624	mechanism of action for OCA-B	[mechanism of action for OCA-B]	1.0	5	1	0	0
33995	1624	immunogenetic basis of severe infection	[immunogenetic basis of severe infections]	1.0	5	1	0	0
33996	1624	proliferation human nk-like cell line	[proliferation human NK-like cell line]	1.0	5	1	0	0
33997	1624	guamerin-derived peptide	[guamerin-derived peptide]	1.0	2	2	2	2
33998	1624	suppression of total nf-kappa b	[suppression of total NF-kappa B]	1.0	5	1	0	0
33999	1624	quiescent progenitor	[quiescent progenitors]	1.0	2	1	0	0
34000	1624	role in IL-2 transformation step	[role in IL-2 transformation steps]	1.0	5	1	0	0
34001	1624	include the t-cell antigen receptor tcr	[including the T-cell antigen receptor TCR]	1.0	6	1	0	0
34002	1624	predominant transcript in 'aged' lymphocyte	[predominant transcript in 'aged' lymphocytes]	1.0	5	1	0	0
34003	1624	Interleukin-2 IL-2 promoter -reporter gene behavior	[Interleukin-2 IL-2 promoter -reporter gene behavior]	1.0	6	1	0	0
34004	1624	include protein kinase c PKC	[including protein kinase C PKC]	1.0	5	1	0	0
34005	1624	wild-type mutant form of lps	[wild-type mutant forms of LPS]	1.0	5	1	0	0
34006	1624	early antigen	[early antigen]	1.0	2	2	1	1
34007	1624	two product	[two products]	1.0	2	1	0	0
34008	1624	Finally, CD40	[Finally, CD40]	1.0	2	1	0	0
34009	1624	nf-kappa b activation through CD28	[NF-kappa B activation through CD28]	1.0	5	1	0	0
34010	1624	1 -induced, dendritic cell-T-cell syncytia	[1 -induced, dendritic cell-T-cell syncytia]	1.0	5	1	0	0
34011	1624	inhibition of lps factor-kappaB translocation	[inhibition of LPS factor-kappaB translocation]	1.0	5	1	0	0
34012	1624	p35 mrna	[p35 mRNA]	1.0	2	1	0	0
34013	1624	activator of protein kinase c	[activator of protein kinase C]	1.0	5	1	0	0
34014	1624	human organ	[human organ]	1.0	2	1	0	0
34015	1624	follicular DC	[follicular DC]	1.0	2	2	1	1
34016	1624	65 woman with secondary neutrophilia	[65 women with secondary neutrophilia]	1.0	5	1	0	0
34017	1624	phosphatase activity of calcineurin cn	[phosphatase activity of calcineurin CN]	1.0	5	1	0	0
34018	1624	flank sequence in T cell	[flanking sequence in T cells]	1.0	5	1	0	0
34019	1624	hl-60 cell with retinoic acid	[HL-60 cells with retinoic acid]	1.0	5	1	0	0
34020	1624	requirement of thp-1 monocytic cell	[Requirement of THP-1 monocytic cells]	1.0	5	1	0	0
34021	1624	mono Mac	[Mono Mac]	1.0	2	2	2	2
34022	1624	block formation of the active dimer	[blocking formation of the active dimer]	1.0	6	1	0	0
34023	1624	combination, gamma	[combination, gamma]	1.0	2	1	0	0
34024	1624	endotoxic effect	[endotoxic effects]	1.0	2	1	0	0
34025	1624	newly emerge	[newly emerging]	1.0	2	1	0	0
34026	1624	activation in a cell line	[activation in a cell line]	1.0	5	2	2	2
34027	1624	infectious virus	[infectious virus]	1.0	2	1	0	0
34028	1624	2 enhancer	[2 enhancer]	1.0	2	1	0	0
34029	1624	study of Aldh1 gene expression	[Study of Aldh1 gene expression]	1.0	5	1	0	0
34030	1624	GAL4 domain	[GAL4 domain]	1.0	2	2	2	2
34031	1624	dual function of signal transduction	[dual function of signal transduction]	1.0	5	1	0	0
34032	1624	intense phosphorylation of the sp1 protein	[intense phosphorylation of the Sp1 protein]	1.0	6	1	0	0
34033	1624	T/NK subset in the bm	[T/NK subsets in the BM]	1.0	5	1	0	0
34034	1624	different species	[different species]	1.0	2	2	2	2
34035	1624	tcdd receptor	[TCDD receptor]	1.0	2	2	2	2
34036	1624	first T	[first T]	1.0	2	1	0	0
34037	1624	high levels.	[high levels.]	1.0	2	1	0	0
34038	1624	EL4 cell	[EL4 cells]	1.0	2	2	1	1
34039	1624	NF-YA subunit	[NF-YA subunit]	1.0	2	2	1	1
34040	1624	first h	[first h]	1.0	2	2	2	2
34041	1624	certain cell of hematopoietic origin	[certain cells of hematopoietic origin]	1.0	5	1	0	0
34042	1624	pml/raralpha expression in leukemic cell	[PML/RARalpha expression in leukemic cells]	1.0	5	1	0	0
34043	1624	high-level transcription of the il-4 gene	[high-level transcription of the IL-4 gene]	1.0	6	1	0	0
34044	1624	S. typhimurium survival within macrophage	[S. typhimurium survival within macrophages]	1.0	5	1	0	0
34045	1624	camp signal in the pathogenesis	[cAMP signaling in the pathogenesis]	1.0	5	1	0	0
34046	1624	contain a binding site for ap1	[containing a binding site for AP1]	1.0	6	1	0	0
34047	1624	however, two different x-inactivation pattern	[however, two different X-inactivation patterns]	1.0	5	1	0	0
34048	1624	increase the level of BCL-2	[Increasing the levels of BCL-2]	1.0	5	1	0	0
34049	1624	stat-1alpha signal transducer of transcription-1alpha	[STAT-1alpha signal transducer of transcription-1alpha]	1.0	5	1	0	0
34050	1624	one express a specific pattern	[one expressing a specific pattern]	1.0	5	1	0	0
34051	1624	hl60 cell express some characteristic	[HL60 cells expressing some characteristics]	1.0	5	1	0	0
34052	1624	polyclonal activator	[polyclonal activator]	1.0	2	1	0	0
34053	1624	cellular immunity result in inflammatory response	[cellular immunity resulting in inflammatory response]	1.0	6	1	0	0
34054	1624	differentiation of definitive erythroid cell	[differentiation of definitive erythroid cells]	1.0	5	1	0	0
34055	1624	inhibitor of two transcription factor	[inhibitors of two transcription factors]	1.0	5	1	0	0
34056	1624	inducible transcription factor bind site	[inducible transcription factor binding sites]	1.0	5	1	0	0
34057	1624	4 gy	[4 Gy]	1.0	2	2	2	2
34058	1624	interleukin-7 IL-7	[interleukin-7 IL-7]	1.0	2	1	0	0
34059	1624	control transcription via distinct cis-acting element	[control transcription via distinct cis-acting elements]	1.0	6	1	0	0
34060	1624	cell autonomous coregulation of activation.	[cell autonomous coregulation of activation.]	1.0	5	1	0	0
34061	1624	relative inability	[relative inability]	1.0	2	1	0	0
34062	1624	signal capable	[signals capable]	1.0	2	1	0	0
34063	1624	transcription of the cytokine tgf-beta	[transcription of the cytokine TGF-beta]	1.0	5	1	0	0
34064	1624	1-kb region of the gene	[1-kb region of the gene]	1.0	5	1	0	0
34065	1624	ataxia telangiectasia	[ataxia telangiectasia]	1.0	2	2	1	1
34066	1624	molecular mechanism of neutrophil-endothelial cell adhesion	[Molecular mechanisms of neutrophil-endothelial cell adhesion]	1.0	6	1	0	0
34067	1624	differential role for glycogen synthase kinase-3	[differential role for glycogen synthase kinase-3]	1.0	6	1	0	0
34068	1624	human prointerleukin 1 beta gene	[human prointerleukin 1 beta gene]	1.0	5	1	0	0
34069	1624	moreover, il-4 costimulation with il-2	[Moreover, IL-4 costimulation with IL-2]	1.0	5	1	0	0
34070	1624	annular structure	[annular structures]	1.0	2	1	0	0
34071	1624	transgenic IkappaBalpha	[transgenic IkappaBalpha]	1.0	2	1	0	0
34072	1624	anti-cd28 mab induction nf-kappa b	[anti-CD28 mAb induction NF-kappa B]	1.0	5	1	0	0
34073	1624	ISRE upstream	[ISRE upstream]	1.0	2	1	0	0
34074	1624	cell type-specific reporter gene expression	[cell type-specific reporter gene expression]	1.0	5	1	0	0
34075	1624	p50-p65 complex	[p50-p65 complex]	1.0	2	2	2	2
34076	1624	proline content	[proline content]	1.0	2	2	2	2
34077	1624	bind site for nuclear protein	[binding site for nuclear proteins]	1.0	5	1	0	0
34078	1624	above populations,	[above populations,]	1.0	2	1	0	0
34079	1624	transgenic animals.	[transgenic animals.]	1.0	2	1	0	0
34080	1624	hiv production by t-cell line	[HIV production by T-cell lines]	1.0	5	1	0	0
34081	1624	preclinical model	[preclinical models]	1.0	2	1	0	0
34082	1624	il-6 kappa	[IL-6 kappa]	1.0	2	1	0	0
34083	1624	role of each Tax1 pathway	[role of each Tax1 pathway]	1.0	5	1	0	0
34084	1624	interact surface	[interacting surfaces]	1.0	2	1	0	0
34085	1624	nuclear factor-kappa b subunit p65	[nuclear factor-kappa B subunit p65]	1.0	5	1	0	0
34086	1624	bcl-6 rearrangement	[BCL-6 rearrangements]	1.0	2	1	0	0
34087	1624	rare signal	[RARE signal]	1.0	2	1	0	0
34088	1624	Recently, member	[Recently, members]	1.0	2	1	0	0
34089	1624	paf binding	[PAF binding]	1.0	2	1	0	0
34090	1624	probably RanBP2	[probably RanBP2]	1.0	2	1	0	0
34091	1624	nuclear factor from the patient'	[nuclear factors from the patient's]	1.0	5	1	0	0
34092	1624	lead to a lack of responsiveness	[leading to a lack of responsiveness]	1.0	6	1	0	0
34093	1624	fc receptor lead to expression	[Fc receptors leading to expression]	1.0	5	1	0	0
34094	1624	activation scheme	[activation scheme]	1.0	2	1	0	0
34095	1624	tip of herpesvirus saimiry associate	[Tip of herpesvirus saimiri associates]	1.0	5	1	0	0
34096	1624	interleukin-3 locus	[interleukin-3 locus]	1.0	2	1	0	0
34097	1624	treatment of Jurkat T cell	[treatment of Jurkat T cells]	1.0	5	1	0	0
34098	1624	cd8+ T lymphocyte of hiv-1 individual	[CD8+ T lymphocytes of HIV-1 individuals]	1.0	6	1	0	0
34099	1624	finding consistent with the result	[finding consistent with the results]	1.0	5	1	0	0
34100	1624	recruitment phosphorylation of a variety	[recruitment phosphorylation of a variety]	1.0	5	1	0	0
34101	1624	erk1/2 cascade	[ERK1/2 cascades]	1.0	2	1	0	0
34102	1624	signal transducer of transcription transcription factor	[signal transducer of transcription transcription factors]	1.0	6	1	0	0
34103	1624	primary leukemia cell from a patient	[primary leukemia cells from a patient]	1.0	6	1	0	0
34104	1624	cytosolic protein	[cytosolic protein]	1.0	2	2	1	1
34105	1624	rare bcl-2	[rare Bcl-2]	1.0	2	1	0	0
34106	1624	individual protein	[individual proteins]	1.0	2	2	1	1
34107	1624	predominantly T	[predominantly T]	1.0	2	1	0	0
34108	1624	similarly in normal human alveolar macrophage	[similarly in normal human alveolar macrophages]	1.0	6	1	0	0
34109	1624	Specific staining	[Specific staining]	1.0	2	1	0	0
34110	1624	lysosomal degradation	[lysosomal degradation]	1.0	2	1	0	0
34111	1624	40 patient with breast cancer	[40 patients with breast cancer]	1.0	5	1	0	0
34112	1624	natural killer cell activity in response	[natural killer cell activity in response]	1.0	6	1	0	0
34113	1624	hla-a3 molecule	[HLA-A3 molecule]	1.0	2	1	0	0
34114	1624	IL-5 gene expression by GATA-3	[IL-5 gene expression by GATA-3]	1.0	5	1	0	0
34115	1624	affinity on peripheral blood mononuclear cell	[affinity on peripheral blood mononuclear cells]	1.0	6	1	0	0
34116	1624	functional response by this two mechanism	[functional responses by these two mechanisms]	1.0	6	1	0	0
34117	1624	taxreb protein	[TaxREB protein]	1.0	2	1	0	0
34118	1624	s49 cell	[S49 cells]	1.0	2	2	1	1
34119	1624	protein ebsap)	[protein (BSAP)]	1.0	2	1	0	0
34120	1624	use transactivation transrepression model in cell	[using transactivation transrepression models in cells]	1.0	6	1	0	0
34121	1624	stimulation of T cell with antigen	[Stimulation of T cells with antigen]	1.0	6	1	0	0
34122	1624	mutant mrna without exon 11	[mutant mRNA without exon 11]	1.0	5	1	0	0
34123	1624	tal-1 transcription in erythroid line	[TAL-1 transcription in erythroid lines]	1.0	5	1	0	0
34124	1624	Flow cytometry analysis on cell	[Flow cytometry analyses on cells]	1.0	5	1	0	0
34125	1624	mutation of the hGR domain	[mutation of the hGR domain]	1.0	5	1	0	0
34126	1624	putative g0/g1 switch regulatory gene	[putative G0/G1 switch regulatory genes]	1.0	5	2	1	1
34127	1624	life-threatening disease	[life-threatening disease]	1.0	2	1	0	0
34128	1624	activation of normal lymph node cell	[Activation of normal lymph node cells]	1.0	6	1	0	0
34129	1624	positive physiological role for camp	[positive physiological role for cAMP]	1.0	5	1	0	0
34130	1624	immuno-histochemical analysis	[Immuno-histochemical analysis]	1.0	2	1	0	0
34131	1624	topoisomerase inhibitor	[topoisomerase inhibitors]	1.0	2	2	1	1
34132	1624	proliferation assay	[proliferation assays]	1.0	2	1	0	0
34133	1624	several molecular aspect of IBR/F	[several molecular aspects of IBR/F]	1.0	5	1	0	0
34134	1624	human phagocyte with L. donovani	[human phagocytes with L. donovani]	1.0	5	1	0	0
34135	1624	safety reasons,	[safety reasons,]	1.0	2	1	0	0
34136	1624	lymphocyte homeostasis	[lymphocyte homeostasis]	1.0	2	2	2	2
34137	1624	transcriptional stimulation	[transcriptional stimulation]	1.0	2	2	1	1
34138	1624	bind protein/activating transcription factor (creb/atf) family	[binding protein/activating transcription factor (CREB/ATF) family]	1.0	6	1	0	0
34139	1624	proliferation rate	[Proliferation rate]	1.0	2	2	1	1
34140	1624	3-o-methyl-d-glucose uptake	[3-O-methyl-D-glucose uptake]	1.0	2	2	1	1
34141	1624	cooperative activation	[cooperative activation]	1.0	2	1	0	0
34142	1624	physiological role in the control	[physiological role in the control]	1.0	5	1	0	0
34143	1624	nf-kappab binding activity in nuclear extract	[NF-kappaB binding activity in nuclear extracts]	1.0	6	1	0	0
34144	1624	mutant rj2.2.5	[mutant RJ2.2.5]	1.0	2	1	0	0
34145	1624	E1A gene	[E1A gene]	1.0	2	2	2	2
34146	1624	respond to the factor nf-kappa b	[responding to the factor NF-kappa B]	1.0	6	1	0	0
34147	1624	Thus, Sp1	[Thus, Sp1]	1.0	2	1	0	0
34148	1624	differentiation control of primary erythroblast	[differentiation control of primary erythroblasts]	1.0	5	1	0	0
34149	1624	CD40 /cd40l	[CD40 /CD40L]	1.0	2	1	0	0
34150	1624	block transcript degradation use cycloheximide	[blocking transcript degradation using cycloheximide]	1.0	5	1	0	0
34151	1624	chronic infection	[chronic infections]	1.0	2	1	0	0
34152	1624	b cell-specific cell surface molecule	[B cell-specific cell surface molecule]	1.0	5	1	0	0
34153	1624	ERK-dependent pathway	[ERK-dependent pathways]	1.0	2	1	0	0
34154	1624	allele T	[allele T]	1.0	2	1	0	0
34155	1624	steroid responsiveness	[steroid responsiveness]	1.0	2	1	0	0
34156	1624	IL-10R together	[IL-10R together]	1.0	2	1	0	0
34157	1624	e1a-positive sample	[E1a-positive samples]	1.0	2	1	0	0
34158	1624	particular, naturally occur sequence variation	[particular, naturally occurring sequence variation]	1.0	5	1	0	0
34159	1624	protein-DNA interaction mediate ifn-beta induction	[protein-DNA interactions mediating IFN-beta induction]	1.0	5	1	0	0
34160	1624	(20 microM).	[(20 microM).]	1.0	2	1	0	0
34161	1624	proliferation of erythroid progenitor in vitro.	[proliferation of erythroid progenitors in vitro.]	1.0	6	1	0	0
34162	1624	additional protein	[additional proteins]	1.0	2	2	1	1
34163	1624	EBNA-2 trans-activate	[EBNA-2 trans-activates]	1.0	2	1	0	0
34164	1624	RelA homodimer	[RelA homodimers]	1.0	2	1	0	0
34165	1624	V3 region	[V3 region]	1.0	2	1	0	0
34166	1624	control of IL3 gene expression	[control of IL3 gene expression]	1.0	5	1	0	0
34167	1624	135eoh)2d3 receptor rna in cell	[1,25(OH)2D3 receptor RNA in cells]	1.0	5	1	0	0
34168	1624	maximal expression	[maximal expression]	1.0	2	2	2	2
34169	1624	convergence point for cell cycle signal	[convergence points for cell cycle signaling]	1.0	6	1	0	0
34170	1624	flow conditions,	[flow conditions,]	1.0	2	1	0	0
34171	1624	part, on the hmg domain	[part, on the HMG domain]	1.0	5	1	0	0
34172	1624	mediate growth inhibition during myelomonocytic differentiation	[mediating growth inhibition during myelomonocytic differentiation]	1.0	6	1	0	0
34173	1624	monocyte-derived cytokine	[monocyte-derived cytokines]	1.0	2	1	0	0
34174	1624	cd38+ cell	[CD38+ cells]	1.0	2	1	0	0
34175	1624	activation through the antigen receptor	[activation through the antigen receptor]	1.0	5	1	0	0
34176	1624	tyrosine phosphorylation of Janus kinase	[tyrosine phosphorylation of Janus kinases]	1.0	5	2	2	2
34177	1624	Glucocorticoid pharmacokinetics	[Glucocorticoid pharmacokinetics]	1.0	2	1	0	0
34178	1624	interact proteins: RXR a subunit	[interacting proteins: RXR a subunit]	1.0	5	1	0	0
34179	1624	cv-1 cell	[CV-1 cells]	1.0	2	1	0	0
34180	1624	epidermal growth factor receptor EGFR	[epidermal growth factor receptor EGFR]	1.0	5	1	0	0
34181	1624	even at dose as high	[even at doses as high]	1.0	5	1	0	0
34182	1624	HMBA alone	[HMBA alone]	1.0	2	1	0	0
34183	1624	point mutation of the PU.1 site	[Point mutations of the PU.1 site]	1.0	6	1	0	0
34184	1624	precursor p100	[precursors p100]	1.0	2	1	0	0
34185	1624	interleukin responsiveness	[interleukin responsiveness]	1.0	2	1	0	0
34186	1624	blood leukocyte in aged runner	[blood leukocytes in aged runner]	1.0	5	2	2	2
34187	1624	numerous growth factor include IL-6	[numerous growth factors including IL-6]	1.0	5	1	0	0
34188	1624	erythroid ontogeny	[erythroid ontogeny]	1.0	2	2	1	1
34189	1624	polyclonal antiserum	[polyclonal antiserum]	1.0	2	1	0	0
34190	1624	oligo sequence	[oligo sequence]	1.0	2	1	0	0
34191	1624	fluctuation of type ii EBS	[fluctuations of type II EBS]	1.0	5	1	0	0
34192	1624	expression of a rapamycin -resistant mutant	[Expression of a rapamycin -resistant mutant]	1.0	6	1	0	0
34193	1624	1.1 kb	[1.1 kb]	1.0	2	1	0	0
34194	1624	cytosolic factor	[cytosolic factor]	1.0	2	2	1	1
34195	1624	32.2-kda protein	[32.2-kDa protein]	1.0	2	1	0	0
34196	1624	induction of gas-like dna-protein binding complex	[induction of GAS-like DNA-protein binding complexes]	1.0	6	1	0	0
34197	1624	neomycin-resistance promoter	[neomycin-resistance promoter]	1.0	2	1	0	0
34198	1624	rest eosinophil	[resting eosinophils]	1.0	2	2	1	1
34199	1624	monocyte-macrophage cell	[monocyte-macrophage cells]	1.0	2	1	0	0
34200	1624	use polyclonal activator phorbol ester	[using polyclonal activator phorbol ester]	1.0	5	1	0	0
34201	1624	binding of nf-kappab to DNA	[binding of NF-kappaB to DNA]	1.0	5	1	0	0
34202	1624	sequestration process	[sequestration process]	1.0	2	1	0	0
34203	1624	catalytic activation	[catalytic activation]	1.0	2	1	0	0
34204	1624	use anti-Class ii monoclonal antibody	[using anti-Class II monoclonal antibodies]	1.0	5	1	0	0
34205	1624	camp protein kinase c pkc	[cAMP protein kinase C PKC]	1.0	5	1	0	0
34206	1624	different disorder of the water	[different disorders of the water]	1.0	5	1	0	0
34207	1624	new evidence for a possible relationship	[new evidence for a possible relationship]	1.0	6	1	0	0
34208	1624	27-kda heat	[27-kDa heat]	1.0	2	1	0	0
34209	1624	powerful assembly of cis element	[powerful assemblies of cis elements]	1.0	5	1	0	0
34210	1624	already activated, addition of rbpi21	[already activated, addition of rBPI21]	1.0	5	1	0	0
34211	1624	Intracellular calcium	[Intracellular calcium]	1.0	2	1	0	0
34212	1624	use electrophoretic mobility shift analysis	[Using electrophoretic mobility shift analysis]	1.0	5	1	0	0
34213	1624	gonadotropin-releasing hormone acth stimulation test	[Gonadotropin-releasing hormone ACTH stimulation tests]	1.0	5	1	0	0
34214	1624	remote position.	[remote position.]	1.0	2	1	0	0
34215	1624	component of the nuclear factor	[component of the nuclear factor]	1.0	5	2	2	2
34216	1624	monocyte mn superoxide dismutase sod	[monocyte Mn superoxide dismutase SOD]	1.0	5	1	0	0
34217	1624	granulocyte colony	[granulocyte colonies]	1.0	2	2	1	1
34218	1624	strong correlation	[strong correlation]	1.0	2	1	0	0
34219	1624	STAT 5	[STAT 5]	1.0	2	2	1	1
34220	1624	new site of nfat-1 activity	[new sites of NFAT-1 activity]	1.0	5	1	0	0
34221	1624	three protein of molecular mass	[three proteins of molecular mass]	1.0	5	1	0	0
34222	1624	recognition of the sessile peptide bond	[recognition of the sessile peptide bond]	1.0	6	1	0	0
34223	1624	downstream activation of map kinase	[downstream activation of MAP kinase]	1.0	5	1	0	0
34224	1624	relative importance of this protein	[relative importance of these proteins]	1.0	5	1	0	0
34225	1624	functional relationship	[functional relationship]	1.0	2	2	2	2
34226	1624	sensitive, ca2+	[sensitive, Ca2+]	1.0	2	1	0	0
34227	1624	nf-e2 complex	[NF-E2 complex]	1.0	2	2	2	2
34228	1624	signal transducing component in T cell	[signal transducing components in T cells]	1.0	6	1	0	0
34229	1624	NF-kappa b )/rel transcription factor	[NF-kappa B )/Rel transcription factors]	1.0	5	1	0	0
34230	1624	one October	[one Oct]	1.0	2	1	0	0
34231	1624	existence of a Ca2+ element	[existence of a Ca2+ element]	1.0	5	1	0	0
34232	1624	Intriguingly, surface expression of lt-alpha1beta2	[Intriguingly, surface expression of LT-alpha1beta2]	1.0	5	1	0	0
34233	1624	composite site	[composite site]	1.0	2	1	0	0
34234	1624	regulate function	[regulating functions]	1.0	2	2	2	2
34235	1624	biochemical basis.	[biochemical basis.]	1.0	2	1	0	0
34236	1624	activation signal for T lymphocyte	[activation signal for T lymphocytes]	1.0	5	1	0	0
34237	1624	up-regulation of htr beta 1	[up-regulation of hTR beta 1]	1.0	5	1	0	0
34238	1624	intrigue possibility	[intriguing possibility]	1.0	2	2	1	1
34239	1624	syncytium-forming capacity of 8e51 cell	[syncytium-forming capacity of 8e51 cells]	1.0	5	1	0	0
34240	1624	FDC cluster	[FDC clusters]	1.0	2	2	1	1
34241	1624	structural class of transcription factor	[structural classes of transcription factors]	1.0	5	1	0	0
34242	1624	tumor cell of a fraction	[tumor cells of a fraction]	1.0	5	1	0	0
34243	1624	musculin a murine transcription factor gene	[musculin a murine transcription factor gene]	1.0	6	1	0	0
34244	1624	1.5 gram	[1.5 g]	1.0	2	1	0	0
34245	1624	combination of hypoxia lymphocyte binding,	[Combinations of hypoxia lymphocyte binding,]	1.0	5	1	0	0
34246	1624	p56lck delta	[p56lck delta]	1.0	2	1	0	0
34247	1624	ap-1 DNA binding activity in lymphocyte	[AP-1 DNA binding activity in lymphocytes]	1.0	6	1	0	0
34248	1624	transcription factor activity by cytokine	[transcription factor activity by cytokines]	1.0	5	1	0	0
34249	1624	acute myeloid leukaemia (aml) blast	[acute myeloid leukaemia (AML) blasts]	1.0	5	1	0	0
34250	1624	AP-1 activity	[AP-1 activity]	1.0	2	2	1	1
34251	1624	novel transcription	[novel transcription]	1.0	2	1	0	0
34252	1624	furthermore, p65	[Furthermore, p65]	1.0	2	1	0	0
34253	1624	detectable binding	[detectable binding]	1.0	2	1	0	0
34254	1624	treponema pallidum	[Treponema pallidum]	1.0	2	2	1	1
34255	1624	recent observation	[recent observations]	1.0	2	2	1	1
34256	1624	helper 1	[helper 1]	1.0	2	1	0	0
34257	1624	baf3 cell	[BAF3 cells]	1.0	2	2	1	1
34258	1624	mineralocorticoid receptors.	[mineralocorticoid receptors.]	1.0	2	1	0	0
34259	1624	protein-binding site	[protein-binding sites]	1.0	2	2	2	2
34260	1624	effective site for specific depletion	[effective site for specific depletion]	1.0	5	1	0	0
34261	1624	coproporphyrinogen oxidase gene between cell	[coproporphyrinogen oxidase gene between cells]	1.0	5	1	0	0
34262	1624	antioxidant mechanism	[antioxidant mechanisms]	1.0	2	1	0	0
34263	1624	least one type-specific t-cell clone	[least one type-specific T-cell clone]	1.0	5	1	0	0
34264	1624	important regulator of the proliferation	[important regulators of the proliferation]	1.0	5	1	0	0
34265	1624	600 bp	[600 bp]	1.0	2	1	0	0
34266	1624	present study, use human cd34+	[present study, using human CD34+]	1.0	5	1	0	0
34267	1624	restrict expression to only that lymphocyte	[restricting expression to only those lymphocytes]	1.0	6	1	0	0
34268	1624	junb level	[JunB levels]	1.0	2	1	0	0
34269	1624	protein tyrosine kinase(s) protein kinase	[protein tyrosine kinase(s) protein kinase]	1.0	5	1	0	0
34270	1624	monoclonal model of germinal center maturation	[monoclonal model of germinal center maturation]	1.0	6	1	0	0
34271	1624	relation to glucocorticoid receptor function	[relation to glucocorticoid receptor function]	1.0	5	1	0	0
34272	1624	nfkappab induction	[NFkappaB induction]	1.0	2	2	2	2
34273	1624	effect of the CML protein	[effect of the CML proteins]	1.0	5	1	0	0
34274	1624	increase concentration of dep- pah	[increasing concentrations of DEP- PAHs]	1.0	5	1	0	0
34275	1624	majority related to a reduction	[majority related to a reduction]	1.0	5	1	0	0
34276	1624	additional enhancer,	[additional enhancer,]	1.0	2	1	0	0
34277	1624	84 kda	[84 kDa]	1.0	2	1	0	0
34278	1624	diverse protein	[diverse proteins]	1.0	2	1	0	0
34279	1624	thereby abrogate interleukin-1beta gene transcription	[thereby abrogating interleukin-1beta gene transcription]	1.0	5	1	0	0
34280	1624	control in the Irish/German population	[controls in the Irish/German population]	1.0	5	1	0	0
34281	1624	two 40mer oligonucleotide from the 1st	[Two 40mer oligonucleotides from the 1st]	1.0	6	1	0	0
34282	1624	attenuation of hla-dr expression by phagocyte	[Attenuation of HLA-DR expression by phagocytes]	1.0	6	1	0	0
34283	1624	active v-abl protein tyrosine kinase	[active v-abl protein tyrosine kinase]	1.0	5	1	0	0
34284	1624	similar downregulation of BCL-6 mrna	[Similar downregulation of BCL-6 mRNA]	1.0	5	1	0	0
34285	1624	pancreatic cancer	[pancreatic cancer]	1.0	2	1	0	0
34286	1624	high basal expression of c-fo	[high basal expression of c-fos]	1.0	5	1	0	0
34287	1624	adrenal insufficiency	[adrenal insufficiency]	1.0	2	1	0	0
34288	1624	molecular basis for the similarity	[molecular basis for the similarities]	1.0	5	1	0	0
34289	1624	myeloid commitment	[myeloid commitment]	1.0	2	1	0	0
34290	1624	major difference in t-cell immortalization mechanism	[major differences in T-cell immortalization mechanism]	1.0	6	1	0	0
34291	1624	inhibit activation of nuclear factor-kappaB	[inhibiting activation of nuclear factor-kappaB]	1.0	5	1	0	0
34292	1624	involve hiv with the end result	[involving HIV with the end result]	1.0	6	1	0	0
34293	1624	neutrophilic differentiation.	[neutrophilic differentiation.]	1.0	2	1	0	0
34294	1624	contrast, long treatment with oxldl	[contrast, long-term treatment with oxLDL]	1.0	5	1	0	0
34295	1624	ATL patient (mean 4111 ng/ml)	[ATL patients (mean 4,111 ng/mL)]	1.0	5	1	0	0
34296	1624	monocyte-binding receptor on endothelial cell	[monocyte-binding receptors on endothelial cells]	1.0	5	1	0	0
34297	1624	TF.VIIa complex	[TF.VIIa complex]	1.0	2	1	0	0
34298	1624	role of the Ikaros gene	[role of the Ikaros gene]	1.0	5	1	0	0
34299	1624	overexpression of SIT in jurkat cell	[Overexpression of SIT in Jurkat cells]	1.0	6	1	0	0
34300	1624	zinc finger transcription factor egr-1	[zinc finger transcription factor Egr-1]	1.0	5	1	0	0
34301	1624	factor with property common to	[factors with properties common to]	1.0	5	1	0	0
34302	1624	effect of glucocorticoid on the rate	[effects of glucocorticoids on the rate]	1.0	6	1	0	0
34303	1624	ocim1 cell	[OCIM1 cells]	1.0	2	2	2	2
34304	1624	control (10.9	[controls (10.9]	1.0	2	1	0	0
34305	1624	most likely interpretation of result	[most likely interpretation of results]	1.0	5	1	0	0
34306	1624	120 kD	[120 kD]	1.0	2	1	0	0
34307	1624	nuclear factor in rest PBL	[nuclear factors in resting PBL]	1.0	5	1	0	0
34308	1624	contain deletion	[containing deletions]	1.0	2	2	2	2
34309	1624	TCL1 gene sequence, to knowledge,	[TCL1 gene sequence, to knowledge,]	1.0	5	1	0	0
34310	1624	terminal differentiation of the cell line	[Terminal differentiation of the cell lines]	1.0	6	1	0	0
34311	1624	transcriptional activation of NF-AT reporter	[transcriptional activation of NF-AT reporters]	1.0	5	1	0	0
34312	1624	form of costimulation by CD28	[form of costimulation by CD28]	1.0	5	1	0	0
34313	1624	lps lipopolysaccharide	[LPS lipopolysaccharide]	1.0	2	1	0	0
34314	1624	weak affinity to NF-kappa b	[weak affinity to NF-kappa B]	1.0	5	1	0	0
34315	1624	physical linkage	[physical linkage]	1.0	2	3	2	1
34316	1624	capsid antigen	[capsid antigen]	1.0	2	2	2	2
34317	1624	70 kda heat shock protein	[70 kDa heat shock protein]	1.0	5	2	1	1
34318	1624	perhaps increase the probability of interaction	[perhaps increasing the probability of interaction]	1.0	6	1	0	0
34319	1624	ubiquitinylation of transcription factor c-Jun	[Ubiquitinylation of transcription factors c-Jun]	1.0	5	1	0	0
34320	1624	human ehrlichiosis in the State	[human ehrlichiosis in the States]	1.0	5	1	0	0
34321	1624	40 enhancer tc-ii NF-kappa b	[40 enhancer TC-II NF-kappa B]	1.0	5	1	0	0
34322	1624	b-cll survival	[B-CLL survival]	1.0	2	1	0	0
34323	1624	tr expression	[TR expression]	1.0	2	2	1	1
34324	1624	preincubation of cell with 135-(oh)2d3	[Preincubation of cells with 1,25-(OH)2D3]	1.0	5	1	0	0
34325	1624	1 transformant	[1 transformants]	1.0	2	1	0	0
34326	1624	severe nausea	[severe nausea]	1.0	2	1	0	0
34327	1624	analysis of the molecular difference	[Analysis of the molecular differences]	1.0	5	1	0	0
34328	1624	rel-related protein	[Rel-related proteins]	1.0	2	2	2	2
34329	1624	contain the intact IL-2 promoter	[containing the intact IL-2 promoter]	1.0	5	1	0	0
34330	1624	interleukin-12 IL-12 a key signal	[interleukin-12 IL-12 a key signal]	1.0	5	1	0	0
34331	1624	type ii estrogen binding site	[Type II estrogen binding sites]	1.0	5	2	2	2
34332	1624	B cell-specific nuclear factor OTF-2	[B cell-specific nuclear factor OTF-2]	1.0	5	1	0	0
34333	1624	exhibit a defect in a step	[exhibiting a defect in a step]	1.0	6	1	0	0
34334	1624	2 min,	[2 min,]	1.0	2	1	0	0
34335	1624	direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[Direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	1.0	5	1	0	0
34336	1624	contain the NF-kappa b consensus sequence	[containing the NF-kappa B consensus sequence]	1.0	6	1	0	0
34337	1624	calcium level	[calcium levels]	1.0	2	2	2	2
34338	1624	tumor ag in epithelial cancer	[tumor Ag in epithelial cancers]	1.0	5	1	0	0
34339	1624	dna-swap experiment use chloramphenicol acetyl-transferase assay	[DNA-swap experiments using chloramphenicol acetyl-transferase assay]	1.0	6	1	0	0
34340	1624	seven ebv -positive tumour tissue	[seven EBV -positive tumour tissues]	1.0	5	1	0	0
34341	1624	consolidation chemotherapy	[consolidation chemotherapy]	1.0	2	1	0	0
34342	1624	biphasic fashion,	[biphasic fashion,]	1.0	2	1	0	0
34343	1624	biphasic fashion.	[biphasic fashion.]	1.0	2	1	0	0
34344	1624	normal hemopoiesis, overexpression of gm-csf	[normal hemopoiesis, overexpression of GM-CSF]	1.0	5	1	0	0
34345	1624	role protect cell against death	[role protecting cells against death]	1.0	5	1	0	0
34346	1624	contain a single gata-binding site	[containing a single GATA-binding site]	1.0	5	1	0	0
34347	1624	STAT3 protein	[STAT3 protein]	1.0	2	1	0	0
34348	1624	abundant expression of classical pkc-alpha	[abundant expression of classical PKC-alpha]	1.0	5	1	0	0
34349	1624	limited skewing potential of il-12	[limited skewing potential of IL-12]	1.0	5	1	0	0
34350	1624	calcitonin receptor	[calcitonin receptor]	1.0	2	1	0	0
34351	1624	amount of cytoplasmic CAT mrna	[amount of cytoplasmic CAT mRNA]	1.0	5	1	0	0
34352	1624	1 mmol/L buthionine sulfoximine bso	[1 mmol/L buthionine sulfoximine BSO]	1.0	5	1	0	0
34353	1624	blood neutrophil	[blood neutrophil]	1.0	2	2	2	2
34354	1624	several peak of basal activity	[several peaks of basal activity]	1.0	5	1	0	0
34355	1624	apparent m(r)	[apparent M(r)]	1.0	2	1	0	0
34356	1624	promoter-proximal element	[promoter-proximal elements]	1.0	2	1	0	0
34357	1624	icr27tk.3 cell	[ICR27TK.3 cells]	1.0	2	2	2	2
34358	1624	bzlf1 -specific memory T cell	[BZLF1 -specific memory T cells]	1.0	5	1	0	0
34359	1624	include distinct domain for DNA	[including distinct domains for DNA]	1.0	5	1	0	0
34360	1624	fos gene	[fos gene]	1.0	2	2	2	2
34361	1624	accumulate datum from a number	[Accumulating data from a number]	1.0	5	1	0	0
34362	1624	programming of some response gene	[programming of some response genes]	1.0	5	1	0	0
34363	1624	correlation of tcrzeta level with response	[Correlations of TCRzeta levels with response]	1.0	6	1	0	0
34364	1624	Vitamin d analog involve calcium	[Vitamin D analogs involving calcium]	1.0	5	1	0	0
34365	1624	DNA recognition	[DNA recognition]	1.0	2	1	0	0
34366	1624	respect to DNA binding activity	[respect to DNA binding activity]	1.0	5	1	0	0
34367	1624	normal mouse	[normal mice]	1.0	2	1	0	0
34368	1624	other variable examined: serum calcitriol	[other variables examined: serum calcitriol]	1.0	5	1	0	0
34369	1624	affect the metabolism of methylprednisolone mp	[affecting the metabolism of methylprednisolone MP]	1.0	6	1	0	0
34370	1624	adrenal suppression	[adrenal suppression]	1.0	2	2	1	1
34371	1624	b Raji	[B Raji]	1.0	2	1	0	0
34372	1624	c-MYC promoter	[c-MYC promoter]	1.0	2	1	0	0
34373	1624	-produce Th0-like	[-producing Th0-like]	1.0	2	1	0	0
34374	1624	adp-activated platelet	[ADP-activated platelets]	1.0	2	1	0	0
34375	1624	NFkappaB activation	[NFkappaB activation]	1.0	2	2	1	1
34376	1624	dominant form of IKK alpha	[dominant forms of IKK alpha]	1.0	5	1	0	0
34377	1624	natural killer (nk) cell lineage	[natural killer (NK) cell lineage]	1.0	5	1	0	0
34378	1624	major role in transcriptional activation	[major role in transcriptional activation]	1.0	5	1	0	0
34379	1624	disruption of the tat gene	[disruption of the tat gene]	1.0	5	1	0	0
34380	1624	December 27;1264(3):409]	[Dec 27;1264(3):409]]	1.0	2	1	0	0
34381	1624	PMA in combination with ca2+ ionophore	[PMA in combination with Ca2+ ionophores]	1.0	6	1	0	0
34382	1624	implicate h2o2	[implicating H2O2]	1.0	2	1	0	0
34383	1624	arachidonic acid	[arachidonic acid]	1.0	2	2	2	2
34384	1624	several years,	[several years,]	1.0	2	1	0	0
34385	1624	level of NF kappa b	[levels of NF kappa B]	1.0	5	2	2	2
34386	1624	3' LTR	[3' LTR]	1.0	2	1	0	0
34387	1624	91 normal	[91 normals]	1.0	2	1	0	0
34388	1624	monocytic differentiation of normal cell	[monocytic differentiation of normal cells]	1.0	5	1	0	0
34389	1624	cell (sites/cell) value of 793	[cell (sites/cell) values of 793]	1.0	5	1	0	0
34390	1624	terminal differentiation.	[terminal differentiation.]	1.0	2	1	0	0
34391	1624	gene product in the follicle	[gene products in the follicles]	1.0	5	1	0	0
34392	1624	complex with activity, DNA sequence specificity,	[complexes with activity, DNA sequence specificity,]	1.0	6	1	0	0
34393	1624	mechanism responsible for this lineage-specific expression,	[mechanisms responsible for this lineage-specific expression,]	1.0	6	1	0	0
34394	1624	alveolar type	[alveolar type]	1.0	2	1	0	0
34395	1624	other ros	[other ROS]	1.0	2	1	0	0
34396	1624	expression of class ii molecule	[expression of class II molecules]	1.0	5	1	0	0
34397	1624	NF.kappa b	[NF.kappa B]	1.0	2	2	2	2
34398	1624	icr27 lymphoblast	[ICR27 lymphoblasts]	1.0	2	1	0	0
34399	1624	dioxin-mediated alteration	[dioxin-mediated alteration]	1.0	2	1	0	0
34400	1624	over-ride determinant of the strength	[over-riding determinant of the strength]	1.0	5	1	0	0
34401	1624	use plasmid contain sense rxr-alpha sequence	[Using plasmids containing sense RXR-alpha sequences]	1.0	6	1	0	0
34402	1624	thus contribute to the induction	[thus contributing to the induction]	1.0	5	1	0	0
34403	1624	synthetic oligonucleotide contain binding site	[synthetic oligonucleotides containing binding sites]	1.0	5	1	0	0
34404	1624	jun protein	[jun protein]	1.0	2	1	0	0
34405	1624	adequate approximation of the effect	[adequate approximation of the effects]	1.0	5	1	0	0
34406	1624	good correlation with the quantitative sba	[good correlation with the quantitative SBA]	1.0	6	1	0	0
34407	1624	trans-activation of the hiv promoter	[trans-activation of the HIV promoter]	1.0	5	1	0	0
34408	1624	high cytotoxicity against autologous cell	[high cytotoxicity against autologous cells]	1.0	5	1	0	0
34409	1624	activation of leukocyte by proinflammatory stimulus	[Activation of leukocytes by proinflammatory stimuli]	1.0	6	1	0	0
34410	1624	transcription of the interleukin 1beta	[transcription of the interleukin 1beta]	1.0	5	1	0	0
34411	1624	advanced tuberculosis,	[advanced tuberculosis,]	1.0	2	1	0	0
34412	1624	activation through the Ca2+ pathway	[Activation through the Ca2+ pathway]	1.0	5	1	0	0
34413	1624	human carboxylesterase	[human carboxylesterase]	1.0	2	2	1	1
34414	1624	structure/function analysis of Oct-2a effector region	[Structure/function analysis of Oct-2a effector regions]	1.0	6	1	0	0
34415	1624	biological role,	[biological role,]	1.0	2	1	0	0
34416	1624	FGF-1 alone	[FGF-1 alone]	1.0	2	1	0	0
34417	1624	signal through the human il-5 receptor	[signaling through the human IL-5 receptor]	1.0	6	1	0	0
34418	1624	comparable property	[comparable properties]	1.0	2	1	0	0
34419	1624	increase in il-2r alpha protein	[increases in IL-2R alpha protein]	1.0	5	1	0	0
34420	1624	putative hematopoietic stem cell hsc	[putative hematopoietic stem cells HSCs]	1.0	5	1	0	0
34421	1624	oxygen formation	[oxygen formation]	1.0	2	2	2	2
34422	1624	cell separation	[Cell separation]	1.0	2	2	1	1
34423	1624	IK protein	[IK protein]	1.0	2	1	0	0
34424	1624	respective immunophilin	[respective immunophilins]	1.0	2	1	0	0
34425	1624	protooncogene product	[protooncogene product]	1.0	2	2	2	2
34426	1624	however, substitution of the pro-x-pro	[However, substitution of the Pro-X-Pro]	1.0	5	1	0	0
34427	1624	transcription factor under physiological condition	[transcription factors under physiological conditions]	1.0	5	1	0	0
34428	1624	High concentration of a beta (25-35)	[Higher concentrations of A beta (25-35)]	1.0	6	1	0	0
34429	1624	splicing site of the mutant	[splicing sites of the mutants]	1.0	5	1	0	0
34430	1624	similar sequences.	[similar sequences.]	1.0	2	1	0	0
34431	1624	CD28 itself, ligation with cho-cd86	[CD28 itself, ligation with CHO-CD86]	1.0	5	1	0	0
34432	1624	beta-globin chain	[beta-globin chains]	1.0	2	1	0	0
34433	1624	late b	[late B]	1.0	2	1	0	0
34434	1624	act on the X2 box	[acting on the X2 box]	1.0	5	1	0	0
34435	1624	FGF-1 stimulation of Jurkat T cell	[FGF-1 stimulation of Jurkat T cells]	1.0	6	1	0	0
34436	1624	important mechanism underlie the initiation	[important mechanism underlying the initiation]	1.0	5	1	0	0
34437	1624	specific immunoreaction	[specific immunoreaction]	1.0	2	1	0	0
34438	1624	Malignant transformation	[Malignant transformation]	1.0	2	1	0	0
34439	1624	four isoform	[four isoforms]	1.0	2	2	1	1
34440	1624	lymphocytic aldosterone	[lymphocytic aldosterone]	1.0	2	2	1	1
34441	1624	active element of the LCR	[active elements of the LCR]	1.0	5	1	0	0
34442	1624	activity of host transcription factor	[activity of host transcription factors]	1.0	5	1	0	0
34443	1624	limited proteolysis assay ligand binding affinity	[Limited proteolysis assaying ligand binding affinities]	1.0	6	1	0	0
34444	1624	signal by this chimeric receptor	[signaling by this chimeric receptor]	1.0	5	1	0	0
34445	1624	potent activator 1 htlv-1 transcription	[potent activator 1 HTLV-1 transcription]	1.0	5	1	0	0
34446	1624	high doses.	[higher doses.]	1.0	2	1	0	0
34447	1624	cell with length e2a cDNA	[cells with length E2A cDNA]	1.0	5	1	0	0
34448	1624	key participant mediate the neurologic dysfunction	[key participants mediating the neurologic dysfunction]	1.0	6	1	0	0
34449	1624	differential expression during B-lymphocyte development	[differential expression during B-lymphocyte development]	1.0	5	1	0	0
34450	1624	only in EBNA2 positive cell extract	[only in EBNA2 positive cell extracts]	1.0	6	1	0	0
34451	1624	m phi	[M phi]	1.0	2	2	2	2
34452	1624	new t-cell-specific factor tcf-1 alpha	[new T-cell-specific factor TCF-1 alpha]	1.0	5	1	0	0
34453	1624	vitro fibroblast binding to glucocorticoid	[vitro fibroblast binding to glucocorticoid]	1.0	5	1	0	0
34454	1624	natural history	[natural history]	1.0	2	2	1	1
34455	1624	contrast, treatment of hl-60 cell	[contrast, treatment of HL-60 cells]	1.0	5	1	0	0
34456	1624	12.5-kb upstream of the IL-4 gene	[12.5-kb upstream of the IL-4 gene]	1.0	6	1	0	0
34457	1624	only high level of amplification	[only high levels of amplification]	1.0	5	1	0	0
34458	1624	IL-2R chain	[IL-2R chains]	1.0	2	1	0	0
34459	1624	phosphate absorption	[phosphate absorption]	1.0	2	1	0	0
34460	1624	hl-60 cell down the pathway	[HL-60 cells down the pathway]	1.0	5	1	0	0
34461	1624	nonerythroid cell	[nonerythroid cells]	1.0	2	2	1	1
34462	1624	hmd similar to bacterial lipopolysaccharide lps	[HMDS similar to bacterial lipopolysaccharide LPS]	1.0	6	1	0	0
34463	1624	however, nuclear target for PI3K	[However, nuclear targets for PI3K]	1.0	5	1	0	0
34464	1624	role in normal lymphoid development	[role in normal lymphoid development]	1.0	5	1	0	0
34465	1624	activate the transcription of irf-2	[activating the transcription of IRF-2]	1.0	5	1	0	0
34466	1624	(nfat) group of transcription factor	[(NFAT) group of transcription factors]	1.0	5	1	0	0
34467	1624	chromatin-integrated construct	[chromatin-integrated construct]	1.0	2	1	0	0
34468	1624	replicative gene	[replicative genes]	1.0	2	1	0	0
34469	1624	signal transduction through interferon-gamma receptor	[Signal transduction through interferon-gamma receptor]	1.0	5	1	0	0
34470	1624	intermediate mobility	[intermediate mobility]	1.0	2	1	0	0
34471	1624	ets1 transactivation in the presence	[ETS1 transactivation in the presence]	1.0	5	1	0	0
34472	1624	hence the resumption of pge2 synthesis	[hence the resumption of PGE2 synthesis]	1.0	6	1	0	0
34473	1624	1.7 kilobasis	[1.7 kilobases]	1.0	2	1	0	0
34474	1624	Kappa b	[Kappa B]	1.0	2	1	0	0
34475	1624	vitamin d-dependent ricket type ii	[vitamin D-dependent rickets type II]	1.0	5	1	0	0
34476	1624	novel treatment for allergic disease	[novel treatments for allergic diseases]	1.0	5	1	0	0
34477	1624	other possibilities, such as distribution	[other possibilities, such as distribution]	1.0	5	1	0	0
34478	1624	significant difference in nucleic acid sequence	[significant differences in nucleic acid sequence]	1.0	6	1	0	0
34479	1624	IL-10 gene	[IL-10 gene]	1.0	2	1	0	0
34480	1624	more basic, unphosphorylated 27-kda protein	[more basic, unphosphorylated 27-kDa protein]	1.0	5	1	0	0
34481	1624	use deletion mutant in expression assay	[Using deletion mutants in expression assays]	1.0	6	1	0	0
34482	1624	Isoflavones, activation of NK cell	[Isoflavones, activation of NK cells]	1.0	5	1	0	0
34483	1624	transcription activation by LEF-1 in vitro	[transcription activation by LEF-1 in vitro]	1.0	6	1	0	0
34484	1624	molecular change	[molecular changes]	1.0	2	1	0	0
34485	1624	cd4+, dqa1*0501/dqb1*0201	[CD4+, DQA1*0501/DQB1*0201]	1.0	2	1	0	0
34486	1624	-negative b-cell	[-negative B-cell]	1.0	2	1	0	0
34487	1624	tumor-specific rearrangement of the tal1 gene	[tumor-specific rearrangements of the TAL1 gene]	1.0	6	1	0	0
34488	1624	result in beta-globin gene expression	[resulting in beta-globin gene expression]	1.0	5	1	0	0
34489	1624	mechanism of MHC class signal	[mechanisms of MHC class signaling]	1.0	5	1	0	0
34490	1624	response to 5 nm D3	[response to 5 nM D3]	1.0	5	1	0	0
34491	1624	clarify the pathogenesis of pel	[clarifying the pathogenesis of PEL]	1.0	5	1	0	0
34492	1624	Endocrine status	[Endocrine status]	1.0	2	1	0	0
34493	1624	undergo apoptosis during activation of receptor	[undergoing apoptosis during activation of receptors]	1.0	6	1	0	0
34494	1624	use interferon IFN gene transfer	[using interferon IFN gene transfer]	1.0	5	1	0	0
34495	1624	virus production.	[virus production.]	1.0	2	1	0	0
34496	1624	activity of transcription factor stat1	[activity of transcription factor Stat1]	1.0	5	1	0	0
34497	1624	vsmc-myc cell	[VSMC-myc cells]	1.0	2	2	1	1
34498	1624	parallel experiments,	[parallel experiments,]	1.0	2	1	0	0
34499	1624	Cortivazol CVZ	[Cortivazol CVZ]	1.0	2	1	0	0
34500	1624	accord to a International work Formulation	[according to an International Working Formulation]	1.0	6	1	0	0
34501	1624	southwestern blotting ultra-violet cross-linking study	[Southwestern blotting UV cross-linking studies]	1.0	5	1	0	0
34502	1624	organ infiltration	[organ infiltration]	1.0	2	1	0	0
34503	1624	g3 tumor with positive margin (31%	[G3 tumors with positive margins (31%]	1.0	6	1	0	0
34504	1624	accumulation of the gag-pol mrna	[accumulation of the gag-pol mRNA]	1.0	5	2	2	2
34505	1624	finally, immunoblot analysis of nuclear extract	[Finally, immunoblot analysis of nuclear extracts]	1.0	6	1	0	0
34506	1624	coding for the beta subunit	[coding for the beta subunit]	1.0	5	1	0	0
34507	1624	recombinant plasmid	[recombinant plasmid]	1.0	2	1	0	0
34508	1624	human immunodeficiency virus (hiv)-positive patient	[human immunodeficiency virus (HIV)-positive patients]	1.0	5	1	0	0
34509	1624	her-2/neu expression of the tumor	[HER-2/neu expression of the tumor]	1.0	5	1	0	0
34510	1624	sla-dq antigens,	[SLA-DQ antigens,]	1.0	2	1	0	0
34511	1624	cyclosporin a-sensitive tumor necrosis factor	[cyclosporin A-sensitive tumor necrosis factor]	1.0	5	1	0	0
34512	1624	additional unknown factor for maximal activity	[additional unknown factors for maximal activity]	1.0	6	1	0	0
34513	1624	IL-6 kappa b binding factor ii	[IL-6 kappa B binding factor II]	1.0	6	1	0	0
34514	1624	abnormality in the p16 gene	[Abnormalities in the p16 genes]	1.0	5	1	0	0
34515	1624	phorbol myristate acetate hela cell	[phorbol myristate acetate HeLa cells]	1.0	5	1	0	0
34516	1624	pml protein	[PML protein]	1.0	2	2	2	2
34517	1624	TNFalpha signalling	[TNFalpha signalling]	1.0	2	1	0	0
34518	1624	regulator of lymphocyte-specific gene expression	[regulator of lymphocyte-specific gene expression]	1.0	5	1	0	0
34519	1624	increase of devd-cleavable caspase activity	[increase of DEVD-cleavable caspases activity]	1.0	5	1	0	0
34520	1624	moreover, zk161422	[Moreover, ZK161422]	1.0	2	1	0	0
34521	1624	tyrosine phosphorylation of Janus kinase jak	[tyrosine phosphorylation of Janus kinases JAKs]	1.0	6	1	0	0
34522	1624	effect of CsA on cell	[effects of CsA on cells]	1.0	5	1	0	0
34523	1624	hiv tat	[HIV Tat]	1.0	2	1	0	0
34524	1624	transcription at RNA polymerase promoter	[transcription at RNA polymerase promoters]	1.0	5	1	0	0
34525	1624	Furthermore, ZEBRA	[Furthermore, ZEBRA]	1.0	2	1	0	0
34526	1624	unique protein	[unique protein]	1.0	2	2	1	1
34527	1624	demonstrate reversible.	[demonstrating reversible.]	1.0	2	1	0	0
34528	1624	RU a glucocorticoid -receptor antagonist	[RU a glucocorticoid -receptor antagonist]	1.0	5	1	0	0
34529	1624	important feature of antiandrogen action	[important feature of antiandrogen action]	1.0	5	1	0	0
34530	1624	mapping experiment	[Mapping experiments]	1.0	2	1	0	0
34531	1624	use of 9-mer peptide bcr1/9	[use of 9-mer peptides BCR1/9]	1.0	5	1	0	0
34532	1624	least three erp -related transcript	[least three ERP -related transcripts]	1.0	5	1	0	0
34533	1624	generate a effective humoral immune response	[generating an effective humoral immune response]	1.0	6	1	0	0
34534	1624	RA 20%;	[RA 20%;]	1.0	2	1	0	0
34535	1624	specificity of the complex formation	[specificity of the complex formation]	1.0	5	1	0	0
34536	1624	confirm a t-cell-specific transcription factor	[confirming a T-cell-specific transcription factor]	1.0	5	1	0	0
34537	1624	B/rel transcription	[B/rel transcription]	1.0	2	1	0	0
34538	1624	functional effect	[functional effects]	1.0	2	2	2	2
34539	1624	previous study in human monocyte	[previous studies in human monocytes]	1.0	5	1	0	0
34540	1624	bind nuclear protein in b cell	[binding nuclear proteins in B cells]	1.0	6	1	0	0
34541	1624	1 tax -responsive element 1 tre-1	[1 Tax -responsive element 1 TRE-1]	1.0	6	1	0	0
34542	1624	However, X	[However, X]	1.0	2	1	0	0
34543	1624	methylation study	[Methylation studies]	1.0	2	1	0	0
34544	1624	rante	[RANTES]	1.0	1	11	4	4
34545	1624	adjoin linker	[adjoining linker]	1.0	2	1	0	0
34546	1624	induction of germline Cepsilon transcription	[induction of germline Cepsilon transcription]	1.0	5	1	0	0
34547	1624	thymic choice between T cell	[thymic choice between T cells]	1.0	5	1	0	0
34548	1624	priming of human monocyte with ifn-gamma	[Priming of human monocytes with IFN-gamma]	1.0	6	1	0	0
34549	1624	identification as lymphocyte-specific protein lsp1	[Identification as lymphocyte-specific protein LSP1]	1.0	5	1	0	0
34550	1624	potency of the corticosteroid fp	[potency of the corticosteroid FP]	1.0	5	1	0	0
34551	1624	aids patient with aids -gr	[AIDS patients with AIDS -GR]	1.0	5	1	0	0
34552	1624	APL patient express HLA dr11	[APL patients expressing HLA DR11]	1.0	5	1	0	0
34553	1624	binding site of this class.	[binding sites of this class.]	1.0	5	1	0	0
34554	1624	adenoidal tissue	[adenoidal tissues]	1.0	2	1	0	0
34555	1624	activation of the CAEV LTR	[activation of the CAEV LTR]	1.0	5	1	0	0
34556	1624	antiviral effect	[antiviral effects]	1.0	2	2	1	1
34557	1624	novel APL cell line UF-1	[novel APL cell line UF-1]	1.0	5	1	0	0
34558	1624	immature CEM T cell line	[immature CEM T cell line]	1.0	5	1	0	0
34559	1624	intravenous pretreatment of the mouse	[intravenous pretreatment of the mice]	1.0	5	1	0	0
34560	1624	one element	[one element]	1.0	2	2	2	2
34561	1624	positional specificity	[positional specificity]	1.0	2	1	0	0
34562	1624	hbd fragment	[HBD fragment]	1.0	2	1	0	0
34563	1624	l428 cell	[L428 cells]	1.0	2	1	0	0
34564	1624	negative cofactor	[negative cofactor]	1.0	2	1	0	0
34565	1624	Aclacinomycin ACLA	[Aclacinomycin ACLA]	1.0	2	1	0	0
34566	1624	UT-7 Epo	[UT-7 Epo]	1.0	2	2	1	1
34567	1624	clinical significance of this model	[clinical significance of this model]	1.0	5	1	0	0
34568	1624	GATA-3 bind	[GATA-3 binding]	1.0	2	2	1	1
34569	1624	up-regulated surface	[up-regulated surface]	1.0	2	1	0	0
34570	1624	use tumour necrosis factor TNF induction	[Using tumour necrosis factor TNF induction]	1.0	6	1	0	0
34571	1624	initial observations,	[initial observations,]	1.0	2	1	0	0
34572	1624	ebv -negative burkitt' lymphoma cell	[EBV -negative Burkitt's lymphoma cells]	1.0	5	1	0	0
34573	1624	presence of a promoter site	[presence of an promoter site]	1.0	5	1	0	0
34574	1624	interaction between class ii promoter	[interactions between class II promoters]	1.0	5	1	0	0
34575	1624	study on the circadian rhythm	[study on the circadian rhythm]	1.0	5	1	0	0
34576	1624	single major transcriptional start site	[single major transcriptional start site]	1.0	5	1	0	0
34577	1624	virus infection.	[virus infection.]	1.0	2	1	0	0
34578	1624	downstream gene	[downstream genes]	1.0	2	1	0	0
34579	1624	threonine 78	[threonine 78]	1.0	2	1	0	0
34580	1624	suggest a very specific role	[suggesting a very specific role]	1.0	5	1	0	0
34581	1624	il-6 secretion in mm cell	[IL-6 secretion in MM cells]	1.0	5	1	0	0
34582	1624	murine pu.1	[murine PU.1]	1.0	2	2	2	2
34583	1624	effect of endogenous tat protein	[effect of endogenous Tat protein]	1.0	5	1	0	0
34584	1624	identification of a leukocyte-specific component	[Identification of a leukocyte-specific component]	1.0	5	1	0	0
34585	1624	addition, two out of three	[addition, two out of three]	1.0	5	1	0	0
34586	1624	lytic cycle gene include brlf1	[lytic cycle genes including BRLF1]	1.0	5	1	0	0
34587	1624	multiple rdna	[multiple cDNAs]	1.0	2	1	0	0
34588	1624	related region.	[related region.]	1.0	2	1	0	0
34589	1624	pathological platelet	[pathological platelets]	1.0	2	1	0	0
34590	1624	PMA alone,	[PMA alone,]	1.0	2	1	0	0
34591	1624	utility use primary lymphocyte model	[utility using primary lymphocyte models]	1.0	5	1	0	0
34592	1624	contrast, APC	[contrast, APC]	1.0	2	1	0	0
34593	1624	cellular receptor	[cellular receptor]	1.0	2	2	1	1
34594	1624	viral isolate of 17 individual	[viral isolates of 17 individuals]	1.0	5	1	0	0
34595	1624	marker of vitamin D3 responsiveness	[marker of vitamin D3 responsiveness]	1.0	5	1	0	0
34596	1624	kappa b-4	[kappa B-4]	1.0	2	1	0	0
34597	1624	kappa b-1	[kappa B-1]	1.0	2	2	2	2
34598	1624	kappa b-2	[kappa B-2]	1.0	2	2	1	1
34599	1624	lipopolysaccharide expression of interleukin 1beta	[lipopolysaccharide expression of interleukin 1beta]	1.0	5	1	0	0
34600	1624	kappa b-3	[kappa B-3]	1.0	2	1	0	0
34601	1624	differentiation-promoting gene	[differentiation-promoting genes]	1.0	2	1	0	0
34602	1624	lps treatment of RAW 264.7 cell	[LPS treatment of RAW 264.7 cells]	1.0	6	1	0	0
34603	1624	intense staining	[intense staining]	1.0	2	2	1	1
34604	1624	METHODS: ten atopic asthmatic subject	[METHODS: Ten atopic asthmatic subjects]	1.0	5	1	0	0
34605	1624	minimal ppargamma	[minimal PPARgamma]	1.0	2	1	0	0
34606	1624	MDHM induction of cytokine mrna expression	[MDHM induction of cytokine mRNA expression]	1.0	6	1	0	0
34607	1624	electromobility shift assay utilize this sequence	[Electromobility shift assays utilizing this sequence]	1.0	6	1	0	0
34608	1624	dexamethasone group	[dexamethasone group]	1.0	2	1	0	0
34609	1624	significant increase in the number	[significant increase in the number]	1.0	5	1	0	0
34610	1624	signal in human b-lymphocyte precursor	[signal in human B-lymphocyte precursors]	1.0	5	1	0	0
34611	1624	ctcf mrna	[CTCF mRNA]	1.0	2	1	0	0
34612	1624	N-terminal sequence	[N-terminal sequence]	1.0	2	1	0	0
34613	1624	assay condition	[assay conditions]	1.0	2	1	0	0
34614	1624	distal delta	[distal delta]	1.0	2	1	0	0
34615	1624	negative regulatory role for gata-2	[negative regulatory role for GATA-2]	1.0	5	1	0	0
34616	1624	antigenic peptide in the er	[antigenic peptides in the ER]	1.0	5	1	0	0
34617	1624	expansion phase	[expansion phase]	1.0	2	1	0	0
34618	1624	neutralize anti- il-6 monoclonal antibody MoAb	[neutralizing anti- IL-6 monoclonal antibody MoAb]	1.0	6	1	0	0
34619	1624	transfection of a lysp100 cDNA	[transfection of a LYSP100 cDNA]	1.0	5	1	0	0
34620	1624	c-Jun expression in human plasma cell	[c-Jun expression in human plasma cells]	1.0	6	1	0	0
34621	1624	different group	[different groups]	1.0	2	2	1	1
34622	1624	occur in a number of enhancer	[occurring in a number of enhancers]	1.0	6	1	0	0
34623	1624	late erythropoiesis	[late erythropoiesis]	1.0	2	1	0	0
34624	1624	expression of wild type p53	[expression of wild type p53]	1.0	5	1	0	0
34625	1624	upstream portion	[upstream portion]	1.0	2	3	2	1
34626	1624	signal-dependent manner	[signal-dependent manner]	1.0	2	1	0	0
34627	1624	FGF receptor-1	[FGF receptor-1]	1.0	2	2	2	2
34628	1624	individual with premature aging syndrome	[individuals with premature aging syndromes]	1.0	5	1	0	0
34629	1624	various length	[various lengths]	1.0	2	2	1	1
34630	1624	possibly at the protein-protein level	[possibly at the protein-protein level]	1.0	5	1	0	0
34631	1624	induction of the IL-2 gene	[induction of the IL-2 gene]	1.0	5	1	0	0
34632	1624	ultra-violet irradiation of tryptophan solution	[UV irradiation of tryptophan solutions]	1.0	5	1	0	0
34633	1624	major signal event for proliferation	[major signaling events for proliferation]	1.0	5	1	0	0
34634	1624	cytokine alone.	[cytokine alone.]	1.0	2	1	0	0
34635	1624	latter mechanism	[latter mechanism]	1.0	2	1	0	0
34636	1624	CD40 ligand+ hyper igm syndrome	[CD40 ligand+ hyper IgM syndrome]	1.0	5	1	0	0
34637	1624	monocyte-specific response	[monocyte-specific response]	1.0	2	1	0	0
34638	1624	cell-type specific	[cell-type specific]	1.0	2	1	0	0
34639	1624	72-kDa protein	[72-kDa protein]	1.0	2	2	1	1
34640	1624	target for the immunosuppressive agent	[target for the immunosuppressive agents]	1.0	5	1	0	0
34641	1624	10, liposarcoma	[10, liposarcoma]	1.0	2	1	0	0
34642	1624	Duffy antigen	[Duffy antigens]	1.0	2	2	2	2
34643	1624	gene for AP-1 family member	[genes for AP-1 family members]	1.0	5	1	0	0
34644	1624	possible target	[possible target]	1.0	2	2	2	2
34645	1624	other factor such as c-Jun	[other factors such as c-Jun]	1.0	5	1	0	0
34646	1624	other inducers,	[other inducers,]	1.0	2	1	0	0
34647	1624	real-time study of factor/DNA interaction	[real-time study of factor/DNA interactions]	1.0	5	1	0	0
34648	1624	b95-8 cytosol	[B95-8 cytosol]	1.0	2	1	0	0
34649	1624	nuclear factor of T cell activation.	[nuclear factor of T cell activation.]	1.0	6	1	0	0
34650	1624	synergy in c-fo mrna induction	[synergy in c-fos mRNA induction]	1.0	5	1	0	0
34651	1624	T cell NFAT binding site	[T cells NFAT binding site]	1.0	5	1	0	0
34652	1624	induction of hsf3 dna-binding activity	[Induction of HSF3 DNA-binding activity]	1.0	5	1	0	0
34653	1624	cell transformation,	[cell transformation,]	1.0	2	1	0	0
34654	1624	target quantity	[target quantity]	1.0	2	1	0	0
34655	1624	express CD40	[expressing CD40]	1.0	2	2	2	2
34656	1624	also without loss of cell viability.	[also without loss of cell viability.]	1.0	6	1	0	0
34657	1624	tyrosine phosphorylation of several substrate	[tyrosine phosphorylation of several substrates]	1.0	5	2	2	2
34658	1624	critical step for endotoxic effect	[critical step for endotoxic effects]	1.0	5	1	0	0
34659	1624	pair of different jak kinase	[pairs of different JAK kinases]	1.0	5	1	0	0
34660	1624	regulatory switch	[regulatory switch]	1.0	2	1	0	0
34661	1624	T cell-specific transcription factor interact	[T cell-specific transcription factor interacting]	1.0	5	1	0	0
34662	1624	GTGGGAA j kappa recognition sequence	[GTGGGAA J kappa recognition sequence]	1.0	5	1	0	0
34663	1624	carry a t(14;14)(q11;q32) chromosome translocation	[carrying a t(14;14)(q11;q32) chromosome translocation]	1.0	5	1	0	0
34664	1624	mechanism of gm-csf gene activation	[mechanism of GM-CSF gene activation]	1.0	5	1	0	0
34665	1624	Pax5 gene	[Pax5 gene]	1.0	2	1	0	0
34666	1624	primary impairment of glucocorticoid metabolism	[primary impairment of glucocorticoid metabolism]	1.0	5	1	0	0
34667	1624	jun family	[jun family]	1.0	2	2	1	1
34668	1624	2738 nucleotide	[2,738 nucleotides]	1.0	2	1	0	0
34669	1624	adherence-dependent increase	[adherence-dependent increase]	1.0	2	1	0	0
34670	1624	mnda myeloid cell nuclear differentiation antigen	[MNDA myeloid cell nuclear differentiation antigen]	1.0	6	1	0	0
34671	1624	healthy subject 2.89 fmol/10(6) cell	[healthy subjects 2.89 fmol/10(6) cells]	1.0	5	1	0	0
34672	1624	colony stimulate	[colony stimulating]	1.0	2	2	1	1
34673	1624	raldh2 expression	[RALDH2 expression]	1.0	2	1	0	0
34674	1624	cell line represent endocrine lineage	[cell lines representing endocrine lineages]	1.0	5	1	0	0
34675	1624	modulate adhesion to extracellular matrix component	[modulating adhesion to extracellular matrix components]	1.0	6	1	0	0
34676	1624	maintain the basal level of expression	[maintaining the basal level of expression]	1.0	6	1	0	0
34677	1624	distinctive pattern of nf-kappa b activation	[distinctive patterns of NF-kappa B activation]	1.0	6	1	0	0
34678	1624	myeloid leukocyte	[myeloid leukocytes]	1.0	2	1	0	0
34679	1624	lytic expression	[lytic expression]	1.0	2	1	0	0
34680	1624	further insight into the molecular mechanism	[further insight into the molecular mechanisms]	1.0	6	1	0	0
34681	1624	alteration in the hpa axis	[alterations in the HPA axis]	1.0	5	1	0	0
34682	1624	differential rescue by specific cytokine	[differential rescue by specific cytokines]	1.0	5	1	0	0
34683	1624	free heparin	[free heparin]	1.0	2	1	0	0
34684	1624	chromosome constitution	[chromosome constitution]	1.0	2	2	2	2
34685	1624	33 patient with diabete mellitus	[33 patients with diabetes mellitus]	1.0	5	1	0	0
34686	1624	dominant negative mutant ikk1 k44m	[dominant negative mutant IKK1 K44M]	1.0	5	1	0	0
34687	1624	NFATp/AP-1 composite element within gene	[NFATp/AP-1 composite elements within genes]	1.0	5	1	0	0
34688	1624	four subunit	[four subunits]	1.0	2	1	0	0
34689	1624	availability of this variant cell	[availability of these variant cells]	1.0	5	1	0	0
34690	1624	augment effect	[augmenting effect]	1.0	2	1	0	0
34691	1624	various conditions.	[various conditions.]	1.0	2	1	0	0
34692	1624	thyroxine concentration	[thyroxine concentration]	1.0	2	1	0	0
34693	1624	even 10(-10) mol/L 9-cis RA	[even 10(-10) mol/L 9-cis RA]	1.0	5	1	0	0
34694	1624	different T leukemia cell line	[different T leukemia cell lines]	1.0	5	1	0	0
34695	1624	cd33+, cd56+, cd11a+, cd13lo, cd15lo,	[CD33+, CD56+, CD11a+, CD13lo, CD15lo,]	1.0	5	1	0	0
34696	1624	high throughput screen of microbial broth	[high throughput screening of microbial broths]	1.0	6	1	0	0
34697	1624	9 hour	[9 hr]	1.0	2	1	0	0
34698	1624	time-dependent release of il-8 antigen	[time-dependent release of IL-8 antigen]	1.0	5	1	0	0
34699	1624	other function	[other functions]	1.0	2	2	2	2
34700	1624	(3) vzv ie62 protein coding sequence	[(3) VZV IE62 protein coding sequences]	1.0	6	1	0	0
34701	1624	-binding domain	[-binding domain]	1.0	2	2	2	2
34702	1624	binding to nuclear receptor protein	[binding to nuclear receptor proteins]	1.0	5	1	0	0
34703	1624	PU.1 mrna	[PU.1 mRNA]	1.0	2	1	0	0
34704	1624	rheumatoid arthritis synovium express receptor	[rheumatoid arthritis synovium express receptors]	1.0	5	1	0	0
34705	1624	However, activation	[However, activation]	1.0	2	1	0	0
34706	1624	affinity to less than 5%	[affinity to less than 5%]	1.0	5	1	0	0
34707	1624	IL-2 release of a growth	[IL-2 release of an growth]	1.0	5	1	0	0
34708	1624	enhancement of germline cepsilon transcription switch	[enhancement of germline Cepsilon transcription switching]	1.0	6	1	0	0
34709	1624	DOR1 ligation by a dor1 agonist	[DOR1 ligation by a DOR1 agonist]	1.0	6	1	0	0
34710	1624	MMTV LTR	[MMTV LTR]	1.0	2	2	1	1
34711	1624	datum along with previous report	[data, along with previous reports]	1.0	5	1	0	0
34712	1624	mAb OKT3	[mAb OKT3]	1.0	2	1	0	0
34713	1624	human MHC hla-dra class ii	[human MHC HLA-DRA class II]	1.0	5	1	0	0
34714	1624	avidin -biotin	[avidin -biotin]	1.0	2	1	0	0
34715	1624	certain response	[certain responses]	1.0	2	1	0	0
34716	1624	multiple stimuli.	[multiple stimuli.]	1.0	2	1	0	0
34717	1624	il-6 by blood mononuclear cell	[IL-6 by blood mononuclear cells]	1.0	5	2	2	2
34718	1624	inhibitor of NF-kappa b kappa b	[inhibitor of NF-kappa B kappa B]	1.0	6	1	0	0
34719	1624	phorbol 12	[phorbol 12]	1.0	2	1	0	0
34720	1624	cyclic-AMP responsive element binding factor	[cyclic-AMP responsive element binding factor]	1.0	5	1	0	0
34721	1624	CD28 coligation of CD2 lpmc	[CD28 coligation of CD2 LPMC]	1.0	5	1	0	0
34722	1624	germline c	[germline C]	1.0	2	2	1	1
34723	1624	lack functional Ikaros transcription factor	[lacking functional Ikaros transcription factors]	1.0	5	1	0	0
34724	1624	upregulation of the cell adhesion molecule	[upregulation of the cell adhesion molecule]	1.0	6	1	0	0
34725	1624	GM-kappa b	[GM-kappa B]	1.0	2	2	2	2
34726	1624	further hypotheses.	[further hypotheses.]	1.0	2	1	0	0
34727	1624	GM-kappa B	[GM-kappa B]	1.0	2	1	0	0
34728	1624	include the activation of NF-kappa b	[including the activation of NF-kappa B]	1.0	6	1	0	0
34729	1624	signal-related kinase	[signal-related kinase]	1.0	2	1	0	0
34730	1624	alpha b2 alpha b isomer	[alpha B2 alpha B isomers]	1.0	5	1	0	0
34731	1624	tonsillar cell	[tonsillar cells]	1.0	2	2	2	2
34732	1624	indicate a effect by G. vaginalis	[indicating an effect by G. vaginalis]	1.0	6	1	0	0
34733	1624	expression of b cell-associated gene	[expression of B cell-associated genes]	1.0	5	1	0	0
34734	1624	cis-element responsible for the down regulation	[cis-elements responsible for the down regulation]	1.0	6	1	0	0
34735	1624	camp activator	[cAMP activators]	1.0	2	2	1	1
34736	1624	Thus, Egr-1	[Thus, Egr-1]	1.0	2	1	0	0
34737	1624	Thus, Egr-2	[Thus, Egr-2]	1.0	2	1	0	0
34738	1624	activation of a H7-inhibitable pathway	[activation of an H7-inhibitable pathway]	1.0	5	1	0	0
34739	1624	chloram-phenicol acetyltransferase (cat) construct contain element	[chloram-phenicol acetyltransferase (CAT) constructs containing elements]	1.0	6	1	0	0
34740	1624	Ran mutant	[Ran mutant]	1.0	2	1	0	0
34741	1624	transcriptional repression of muscle gene	[transcriptional repression of muscle genes]	1.0	5	1	0	0
34742	1624	multiple signal	[Multiple signals]	1.0	2	1	0	0
34743	1624	human T cell line C5MJ2	[human T cell line C5MJ2]	1.0	5	1	0	0
34744	1624	mutation in the gamma(c) receptor subunit	[mutations in the gamma(c) receptor subunit]	1.0	6	1	0	0
34745	1624	(bko) construct reporter gene activity	[(BKO) construct reporter gene activity]	1.0	5	1	0	0
34746	1624	typical AITL	[typical AITL]	1.0	2	1	0	0
34747	1624	antioxidant on tf expression datum	[antioxidants on TF expression data]	1.0	5	1	0	0
34748	1624	atherosclerotic process	[atherosclerotic process]	1.0	2	1	0	0
34749	1624	huvec adhesiveness.	[HUVEC adhesiveness.]	1.0	2	1	0	0
34750	1624	mitogenic stimulation of human pbl-t	[mitogenic stimulation of human PBL-T]	1.0	5	1	0	0
34751	1624	delta-opioid receptor	[delta-opioid receptor]	1.0	2	2	1	1
34752	1624	0.2 kb act in concert	[0.2 kb act in concert]	1.0	5	1	0	0
34753	1624	intact promoter	[intact promoter]	1.0	2	1	0	0
34754	1624	4 maeca	[4 mAECA]	1.0	2	1	0	0
34755	1624	PBSC collection	[PBSC collection]	1.0	2	1	0	0
34756	1624	atf/cre motif	[ATF/CRE motifs]	1.0	2	1	0	0
34757	1624	other researcher	[other researchers]	1.0	2	1	0	0
34758	1624	65-kD protein	[65-kD protein]	1.0	2	1	0	0
34759	1624	activity of class ii promoter	[activity of class II promoters]	1.0	5	2	1	1
34760	1624	subsequent proliferation	[subsequent proliferation]	1.0	2	2	1	1
34761	1624	complex capable	[complex capable]	1.0	2	2	1	1
34762	1624	upregulation evidence for the involvement	[upregulation evidence for the involvement]	1.0	5	1	0	0
34763	1624	subsequent induction	[subsequent induction]	1.0	2	1	0	0
34764	1624	expression of luciferase in this cell	[Expression of luciferase in these cells]	1.0	6	1	0	0
34765	1624	evidence of somatic hypermutation act	[evidence of somatic hypermutation acting]	1.0	5	1	0	0
34766	1624	mediate lysis in leukemic T lymphoblast	[mediating lysis in leukemic T lymphoblasts]	1.0	6	1	0	0
34767	1624	ikappabalpha phosphorylation	[IkappaBalpha phosphorylation]	1.0	2	1	0	0
34768	1624	5'-flanking sequence of the cd69 gene,	[5'-flanking sequences of the CD69 gene,]	1.0	6	1	0	0
34769	1624	inhibitor of the pld pathway,	[inhibitor of the PLD pathway,]	1.0	5	1	0	0
34770	1624	inhibition of the map kinase cascade	[Inhibition of the MAP kinase cascade]	1.0	6	1	0	0
34771	1624	EMCV mrna	[EMCV mRNA]	1.0	2	1	0	0
34772	1624	patient with atopic dermatitis ad	[patients with atopic dermatitis AD]	1.0	5	1	0	0
34773	1624	Y chromosome in great ape	[Y chromosome in great apes]	1.0	5	1	0	0
34774	1624	pha stimulation.	[PHA stimulation.]	1.0	2	1	0	0
34775	1624	1a9-m cell express human bcl2	[1A9-M cells expressing human BCL2]	1.0	5	1	0	0
34776	1624	certain individual	[certain individuals]	1.0	2	2	2	2
34777	1624	interleukin (il)-5 with the receptor	[interleukin (IL)-5 with the receptor]	1.0	5	1	0	0
34778	1624	human interleukin-6	[human interleukin-6]	1.0	2	1	0	0
34779	1624	traf1 coactivation	[TRAF1 coactivation]	1.0	2	1	0	0
34780	1624	addition to rapid time course	[addition to rapid time course]	1.0	5	1	0	0
34781	1624	human interleukin-9	[human interleukin-9]	1.0	2	1	0	0
34782	1624	bzip domain	[bZIP domain]	1.0	2	2	2	2
34783	1624	traz in transformation of human lymphocyte	[TRAFs in transformation of human lymphocytes]	1.0	6	1	0	0
34784	1624	Z together	[Z together]	1.0	2	1	0	0
34785	1624	delta-globin-encoding gene	[delta-globin-encoding gene]	1.0	2	2	2	2
34786	1624	However, B4-2	[However, B4-2]	1.0	2	1	0	0
34787	1624	Tenascin TN	[Tenascin TN]	1.0	2	1	0	0
34788	1624	major role.	[major role.]	1.0	2	1	0	0
34789	1624	n-formyl-methionyl-leucyl-phenylalanine FMLP	[N-formyl-methionyl-leucyl-phenylalanine FMLP]	1.0	2	1	0	0
34790	1624	tax alone	[Tax alone]	1.0	2	1	0	0
34791	1624	one test of this hypothesis,	[one test of this hypothesis,]	1.0	5	1	0	0
34792	1624	ar assay	[AR assay]	1.0	2	1	0	0
34793	1624	NF kappa b activation block	[NF kappa B activation block]	1.0	5	1	0	0
34794	1624	pyrimidine -rich element 5'-pyctttg-3' present	[pyrimidine -rich elements 5'-PyCTTTG-3' present]	1.0	5	1	0	0
34795	1624	expression of intercellular adhesion molecule-1 icam-1	[expression of intercellular adhesion molecule-1 ICAM-1]	1.0	6	1	0	0
34796	1624	XCI pattern with great amplification	[XCI pattern with greater amplification]	1.0	5	1	0	0
34797	1624	OBF-1 mrna	[OBF-1 mRNA]	1.0	2	1	0	0
34798	1624	early precursor to plasma cell	[early precursors to plasma cells]	1.0	5	1	0	0
34799	1624	biologic role in ig class switch	[biologic role in Ig class switching]	1.0	6	1	0	0
34800	1624	pmlrar alpha cDNA in cell	[PMLRAR alpha cDNA in cells]	1.0	5	1	0	0
34801	1624	e1b mutant	[E1B mutants]	1.0	2	2	2	2
34802	1624	fasl protein in NK cell	[FasL protein in NK cells]	1.0	5	1	0	0
34803	1624	lead to induction of NF-kappaB	[leading to induction of NF-kappaB]	1.0	5	1	0	0
34804	1624	maintain ifn-gamma receptor alpha-chain expression	[maintaining IFN-gamma receptor alpha-chain expression]	1.0	5	1	0	0
34805	1624	SP1/Egr-1 site	[SP1/Egr-1 site]	1.0	2	1	0	0
34806	1624	glucocorticoid on il-2 gene transcription	[glucocorticoids on IL-2 gene transcription]	1.0	5	1	0	0
34807	1624	transduction pathway regulate the activity	[transduction pathways regulating the activity]	1.0	5	1	0	0
34808	1624	unique, high potency synthetic glucocorticoid	[unique, high potency synthetic glucocorticoid]	1.0	5	1	0	0
34809	1624	Retroviral transfer	[Retroviral transfer]	1.0	2	1	0	0
34810	1624	iron salt	[iron salts]	1.0	2	2	2	2
34811	1624	11 gct	[11 GCT]	1.0	2	1	0	0
34812	1624	cyclic amp	[cyclic amp]	1.0	2	1	0	0
34813	1624	endogenous glucocorticoid	[endogenous glucocorticoids]	1.0	2	1	0	0
34814	1624	wild-type ebv	[wild-type EBV]	1.0	2	1	0	0
34815	1624	lack immunophilin	[lacking immunophilins]	1.0	2	1	0	0
34816	1624	two major protein of 52	[two major proteins of 52]	1.0	5	1	0	0
34817	1624	androgen insensitivity syndrome a group	[androgen insensitivity syndromes a group]	1.0	5	1	0	0
34818	1624	sequence-specific DNA	[Sequence-specific DNA]	1.0	2	1	0	0
34819	1624	inverse effect	[inverse effects]	1.0	2	1	0	0
34820	1624	hhv-6(gs) infection	[HHV-6(GS) infection]	1.0	2	2	1	1
34821	1624	virtue of the B-cell nature	[virtue of the B-cell nature]	1.0	5	1	0	0
34822	1624	number Bmax	[number Bmax]	1.0	2	1	0	0
34823	1624	secretion of matrix metalloproteinase mmp	[secretion of matrix metalloproteinases MMPs]	1.0	5	1	0	0
34824	1624	transduction event	[transduction events]	1.0	2	1	0	0
34825	1624	contrast, interleukin-1beta-converting	[contrast, interleukin-1beta-converting]	1.0	2	1	0	0
34826	1624	c/ebp consensus binding site 6	[C/EBP consensus binding site 6]	1.0	5	1	0	0
34827	1624	action of common t-cell mitogen	[action of common T-cell mitogens]	1.0	5	1	0	0
34828	1624	incubation with 2 microm mbp	[Incubation with 2 microM MBP]	1.0	5	1	0	0
34829	1624	1.9 kb	[1.9 kb]	1.0	2	1	0	0
34830	1624	ie62 peptide	[IE62 peptide]	1.0	2	1	0	0
34831	1624	cell with pyrrolidine dithiocarbamate pdtc	[cells with pyrrolidine dithiocarbamate PDTC]	1.0	5	1	0	0
34832	1624	HIV infection of fresh monocyte	[HIV infection of fresh monocytes]	1.0	5	1	0	0
34833	1624	NF-kappaB activation a pathway dependent	[NF-kappaB activation a pathway dependent]	1.0	5	1	0	0
34834	1624	activation of protein kinase c PKC	[activation of protein kinase C PKC]	1.0	6	1	0	0
34835	1624	lytic transition of Epstein-Barr virus EBV	[Lytic transition of Epstein-Barr virus EBV]	1.0	6	1	0	0
34836	1624	possible involvement in human disease	[possible involvement in human diseases]	1.0	5	1	0	0
34837	1624	transcription-enhancing activity	[transcription-enhancing activity]	1.0	2	1	0	0
34838	1624	SV40 probe	[SV40 probe]	1.0	2	1	0	0
34839	1624	two signal for optimal induction, PMA	[two signals for optimal induction, PMA]	1.0	6	1	0	0
34840	1624	differential effect of e1a expression	[differential effect of E1A expression]	1.0	5	1	0	0
34841	1624	parasitic infection	[parasitic infections]	1.0	2	1	0	0
34842	1624	mouse aml1/	[mouse AML1/]	1.0	2	1	0	0
34843	1624	tnf-alpha a PKC -independent stimulus	[TNF-alpha a PKC -independent stimulus]	1.0	5	1	0	0
34844	1624	two ubiquitous transcription factor Oct1	[two ubiquitous transcription factors Oct1]	1.0	5	1	0	0
34845	1624	fusion promoter	[fusion promoter]	1.0	2	1	0	0
34846	1624	indicator of hormone-mediated gene regulation	[indicators of hormone-mediated gene regulation]	1.0	5	1	0	0
34847	1624	Stat3EE a mutant Stat3 incapable	[Stat3EE a mutant Stat3 incapable]	1.0	5	1	0	0
34848	1624	several t-cell-restricted marker include CD2	[several T-cell-restricted markers including CD2]	1.0	5	1	0	0
34849	1624	intense positive staining for estrogen receptor	[intense positive staining for estrogen receptors]	1.0	6	1	0	0
34850	1624	differential binding	[differential binding]	1.0	2	4	3	1
34851	1624	focus on the difference in response	[focusing on the differences in response]	1.0	6	1	0	0
34852	1624	exogenous addition transform growth factor-beta	[Exogenous addition transforming growth factor-beta]	1.0	5	1	0	0
34853	1624	presence of a repressor molecule	[presence of a repressor molecule]	1.0	5	1	0	0
34854	1624	immortalization of marmoset T lymphocyte	[immortalization of marmoset T lymphocytes]	1.0	5	1	0	0
34855	1624	tnf-alpha independent in the early time	[TNF-alpha independent in the early time]	1.0	6	1	0	0
34856	1624	t-cell tumorigenesis	[T-cell tumorigenesis]	1.0	2	1	0	0
34857	1624	tcr gene rearrangement pre-T cell	[TCR gene rearrangements pre-T cells]	1.0	5	1	0	0
34858	1624	intercellular interaction	[intercellular interaction]	1.0	2	1	0	0
34859	1624	gamma globin	[gamma globin]	1.0	2	2	1	1
34860	1624	cross-link (after	[cross-linking (after]	1.0	2	1	0	0
34861	1624	intensity of the immune response	[intensity of the immune response]	1.0	5	1	0	0
34862	1624	Nuclear factor-kappaB activation in human monocyte	[Nuclear factor-kappaB activation in human monocytes]	1.0	6	1	0	0
34863	1624	however, monocyte	[however, monocytes]	1.0	2	1	0	0
34864	1624	monocyte-derived il-1beta	[monocyte-derived IL-1beta]	1.0	2	1	0	0
34865	1624	two abundant protein of 75 kD	[Two abundant proteins of 75 kD]	1.0	6	1	0	0
34866	1624	important transcriptional regulator of gene	[important transcriptional regulator of genes]	1.0	5	1	0	0
34867	1624	EVI1 I	[EVI1 I]	1.0	2	1	0	0
34868	1624	clinical picture	[clinical picture]	1.0	2	2	2	2
34869	1624	activation of the hiv-1 LTR	[activation of the HIV-1 LTR]	1.0	5	1	0	0
34870	1624	22 woman with climacteric syndrome	[22 women with climacteric syndrome]	1.0	5	1	0	0
34871	1624	large protein	[large protein]	1.0	2	1	0	0
34872	1624	uptake of low density lipoprotein	[uptake of low density lipoprotein]	1.0	5	1	0	0
34873	1624	peroxisome proliferator-activated receptor gamma ppargamma	[peroxisome proliferator-activated receptor gamma PPARgamma]	1.0	5	1	0	0
34874	1624	functional responsiveness of il-10 binding	[functional responsiveness of IL-10 binding]	1.0	5	1	0	0
34875	1624	property of natural killer NK	[properties of natural killer NK]	1.0	5	1	0	0
34876	1624	also a bind site for c-Myc	[also a binding site for c-Myc]	1.0	6	1	0	0
34877	1624	gene knock-out	[gene knock-out]	1.0	2	1	0	0
34878	1624	iNO production	[iNO production]	1.0	2	1	0	0
34879	1624	new NH2 terminus of receptor-1	[new NH2 terminus of receptor-1]	1.0	5	1	0	0
34880	1624	activator of transcription 3 Stat3	[activator of transcription 3 Stat3]	1.0	5	1	0	0
34881	1624	200 fmol/mg protein by eia).	[200 fmol/mg protein by EIA).]	1.0	5	1	0	0
34882	1624	il-1r-associated kinase	[IL-1R-associated kinase]	1.0	2	2	1	1
34883	1624	IL2 expression	[IL2 expression]	1.0	2	1	0	0
34884	1624	effects, ap-1	[effects, AP-1]	1.0	2	1	0	0
34885	1624	aids-related cancer	[AIDS-related cancers]	1.0	2	1	0	0
34886	1624	detectable deletion	[detectable deletion]	1.0	2	1	0	0
34887	1624	JNK the map kinase-related kinase	[JNK the MAP kinase-related kinase]	1.0	5	1	0	0
34888	1624	Double staining for Bcl-6 /cd20	[Double staining for Bcl-6 /CD20]	1.0	5	1	0	0
34889	1624	early human b lineage cell	[early human B lineage cells]	1.0	5	1	0	0
34890	1624	JAK3 activation	[JAK3 activation]	1.0	2	1	0	0
34891	1624	small protein	[small protein]	1.0	2	2	2	2
34892	1624	CD20(B1) gene	[CD20(B1) gene]	1.0	2	1	0	0
34893	1624	IL-4 germline c epsilon transcription	[IL-4 germline C epsilon transcription]	1.0	5	1	0	0
34894	1624	receptor-mediated anti-CD3 /anti-cd3+ anti-cd28 stimulation	[receptor-mediated anti-CD3 /anti-CD3+ anti-CD28 stimulation]	1.0	5	1	0	0
34895	1624	1 -contain	[1 -containing]	1.0	2	1	0	0
34896	1624	expression of select subordinate gene	[expression of select subordinate genes]	1.0	5	1	0	0
34897	1624	transcript of the e2a gene	[transcripts of the E2A gene]	1.0	5	1	0	0
34898	1624	"minus" clone	["minus" clones]	1.0	2	1	0	0
34899	1624	vitamin c	[vitamin C]	1.0	2	1	0	0
34900	1624	footprinting of the October -DNA interaction	[footprinting of the Oct -DNA interaction]	1.0	6	1	0	0
34901	1624	lipid moiety	[lipid moiety]	1.0	2	1	0	0
34902	1624	haematopoietic system	[haematopoietic system]	1.0	2	3	2	1
34903	1624	use a specific nfatp polyclonal antibody	[using a specific NFATp polyclonal antibody]	1.0	6	1	0	0
34904	1624	presence of a variant form	[Presence of a variant form]	1.0	5	1	0	0
34905	1624	DNase I mapping of genomic DNA	[DNase I mapping of genomic DNA]	1.0	6	1	0	0
34906	1624	adenosine triphosphate	[adenosine triphosphate]	1.0	2	1	0	0
34907	1624	inhibitor of the phosphatidylinositol 3-kinase wortmannin	[inhibitors of the phosphatidylinositol 3-kinase wortmannin]	1.0	6	1	0	0
34908	1624	9 hour in the presence	[9 hr in the presence]	1.0	5	1	0	0
34909	1624	acute attack	[acute attacks]	1.0	2	1	0	0
34910	1624	chromatin condensation	[chromatin condensation]	1.0	2	1	0	0
34911	1624	fos/g0s7 rrna	[FOS/G0S7 mRNAs]	1.0	2	1	0	0
34912	1624	solution structure	[solution structure]	1.0	2	5	4	1
34913	1624	progenitor to the eosinophil lineage	[progenitors to the eosinophil lineage]	1.0	5	1	0	0
34914	1624	phorbol ester treatment of monocyte	[Phorbol ester treatment of monocytes]	1.0	5	1	0	0
34915	1624	result in hyper-sensitivity to sunlight	[resulting in hyper-sensitivity to sunlight]	1.0	5	1	0	0
34916	1624	12-fold induction	[12-fold induction]	1.0	2	1	0	0
34917	1624	use a panel of specific antisera	[Using a panel of specific antisera]	1.0	6	1	0	0
34918	1624	T lymphocyte in the thymus	[T lymphocytes in the thymuses]	1.0	5	1	0	0
34919	1624	cell of most hematopoietic lineage	[cells of most hematopoietic lineages]	1.0	5	1	0	0
34920	1624	component of the DNA-protein complex	[components of the DNA-protein complexes]	1.0	5	1	0	0
34921	1624	amol gr mrna /microg rna, p	[amol GR mRNA /microg RNA, P]	1.0	6	1	0	0
34922	1624	mediate low shear- cytokine-induced ec-mn adhesion	[mediating low shear- cytokine-induced EC-Mn adhesion]	1.0	6	1	0	0
34923	1624	mild hypocortisolemia	[mild hypocortisolemia]	1.0	2	1	0	0
34924	1624	nuclear membrane	[nuclear membrane]	1.0	2	2	1	1
34925	1624	postmenopausal female	[postmenopausal females]	1.0	2	1	0	0
34926	1624	two discrete cell-surface isoform of cd43	[two discrete cell-surface isoforms of CD43]	1.0	6	1	0	0
34927	1624	thioredoxin trx	[thioredoxin TRX]	1.0	2	1	0	0
34928	1624	vitronectin receptor	[vitronectin receptor]	1.0	2	1	0	0
34929	1624	span portion of the promoter	[spanning portions of the promoter]	1.0	5	1	0	0
34930	1624	inhibition of NF-kappa b activation	[inhibition of NF-kappa B activation]	1.0	5	1	0	0
34931	1624	response element present in the region	[response elements present in the region]	1.0	6	1	0	0
34932	1624	important role regulate cell-cycle progression	[important role regulating cell-cycle progression]	1.0	5	1	0	0
34933	1624	Effect of ara-c on neutral sphingomyelinase	[Effects of Ara-C on neutral sphingomyelinase]	1.0	6	1	0	0
34934	1624	expression of inflammatory cytokine in monocytes/macrophages	[expression of inflammatory cytokines in monocytes/macrophages]	1.0	6	1	0	0
34935	1624	understanding of the anti-thrombotic effect	[understanding of the anti-thrombotic effects]	1.0	5	1	0	0
34936	1624	transcriptional factor of the NFAT family	[Transcriptional factors of the NFAT family]	1.0	6	1	0	0
34937	1624	two model	[two models]	1.0	2	2	2	2
34938	1624	tat transactivation	[Tat transactivation]	1.0	2	1	0	0
34939	1624	kappa locus	[kappa locus]	1.0	2	2	1	1
34940	1624	other variable include plasma hormone	[Other variables, including plasma hormone]	1.0	5	1	0	0
34941	1624	assess the risk of local failure,	[assessing the risk of local failure,]	1.0	6	1	0	0
34942	1624	estradiol, PMA	[estradiol, PMA]	1.0	2	1	0	0
34943	1624	contrast, treatment of hl-60/vinc cell	[contrast, treatment of HL-60/vinc cells]	1.0	5	1	0	0
34944	1624	phospholipid analysis	[Phospholipid analyses]	1.0	2	1	0	0
34945	1624	functional redundancy in general coactivator	[functional redundancy in general coactivators]	1.0	5	1	0	0
34946	1624	redox-sensitive way,	[redox-sensitive way,]	1.0	2	1	0	0
34947	1624	chromatin organization	[chromatin organization]	1.0	2	2	2	2
34948	1624	model of lineage switch in development	[Models of lineage switching in development]	1.0	6	1	0	0
34949	1624	characterization of a mutant cell line	[Characterization of a mutant cell line]	1.0	6	1	0	0
34950	1624	determine role	[determining role]	1.0	2	1	0	0
34951	1624	expression of the immunodeficiency virus type	[expression of the immunodeficiency virus type]	1.0	6	1	0	0
34952	1624	Addition neutralize tnf-alpha antibody antigen release	[Addition neutralizing TNF-alpha antibodies antigen release]	1.0	6	1	0	0
34953	1624	METHOD: two color flow cytometry analysis	[METHOD: Two color flow cytometry analysis]	1.0	6	1	0	0
34954	1624	95.5% overall amino acid homology	[95.5% overall amino acid homology]	1.0	5	1	0	0
34955	1624	p65-p50 heterodimer	[p65-p50 heterodimer]	1.0	2	1	0	0
34956	1624	biosynthesis of tumor necrosis factor-alpha tnf-alpha	[Biosynthesis of tumor necrosis factor-alpha TNF-alpha]	1.0	6	1	0	0
34957	1624	interleukin-8 il-8	[interleukin-8 IL-8]	1.0	2	2	1	1
34958	1624	hiv pathogenesis	[HIV pathogenesis]	1.0	2	1	0	0
34959	1624	glucocorticoid receptor/progesterone receptor pr binding	[glucocorticoid receptor/progesterone receptor PR binding]	1.0	5	1	0	0
34960	1624	treatment of T lymphocyte with ifn-alpha	[Treatment of T lymphocytes with IFN-alpha]	1.0	6	1	0	0
34961	1624	(+) thymocyte	[(+) thymocytes]	1.0	2	2	2	2
34962	1624	x-linked atrophy	[X-linked atrophy]	1.0	2	2	2	2
34963	1624	hypoxia alone	[hypoxia alone]	1.0	2	1	0	0
34964	1624	transcription of gene encode for lymphokine	[transcription of genes encoding for lymphokines]	1.0	6	1	0	0
34965	1624	CD40 up-regulation	[CD40 up-regulation]	1.0	2	2	2	2
34966	1624	lps antibody on cellular uptake	[LPS antibodies on cellular uptake]	1.0	5	1	0	0
34967	1624	Sp1 family of transcription factor	[Sp1 families of transcription factors]	1.0	5	1	0	0
34968	1624	inducible expression of a variety	[inducible expression of a variety]	1.0	5	1	0	0
34969	1624	il-2r enhancer	[IL-2R enhancer]	1.0	2	1	0	0
34970	1624	priming period,	[priming period,]	1.0	2	1	0	0
34971	1624	camp-responsive element	[cAMP-responsive element]	1.0	2	2	1	1
34972	1624	serum level	[serum level]	1.0	2	2	1	1
34973	1624	difference in plasma cortisol level	[difference in plasma cortisol level]	1.0	5	1	0	0
34974	1624	induce the expression of fas	[inducing the expression of Fas]	1.0	5	1	0	0
34975	1624	phosphorylation of protein with weight	[phosphorylation of proteins with weights]	1.0	5	1	0	0
34976	1624	slight down-regulation	[slight down-regulation]	1.0	2	1	0	0
34977	1624	surface signaling,	[surface signaling,]	1.0	2	1	0	0
34978	1624	es erythrocyte	[ES erythrocytes]	1.0	2	1	0	0
34979	1624	functional consequence at the level	[functional consequences at the level]	1.0	5	1	0	0
34980	1624	steady-state level of hiv mrna	[steady-state levels of HIV mRNA]	1.0	5	1	0	0
34981	1624	Dithiocarbamates DTCs	[Dithiocarbamates DTCs]	1.0	2	1	0	0
34982	1624	interleukin-8 expression.	[interleukin-8 expression.]	1.0	2	1	0	0
34983	1624	hormone-dependent regulator	[hormone-dependent regulator]	1.0	2	1	0	0
34984	1624	Bcl-6 expression in this tumor	[Bcl-6 expression in this tumor]	1.0	5	1	0	0
34985	1624	infection with epstein-barr virus ebv	[infection with Epstein-Barr virus EBV]	1.0	5	1	0	0
34986	1624	initiation of the life cycle	[initiation of the life cycle]	1.0	5	1	0	0
34987	1624	il-2e (which	[IL-2E (which]	1.0	2	1	0	0
34988	1624	mechanism underlie	[mechanism underlying]	1.0	2	1	0	0
34989	1624	underlie this rapid effect of aldosterone	[underlying these rapid effects of aldosterone]	1.0	6	1	0	0
34990	1624	il-2 ifn-alpha	[IL-2 IFN-alpha]	1.0	2	1	0	0
34991	1624	wild-type cbl	[wild-type Cbl]	1.0	2	1	0	0
34992	1624	negative function	[negative function]	1.0	2	2	1	1
34993	1624	wild-type cbp	[wild-type CBP]	1.0	2	1	0	0
34994	1624	increase in cd44 mrna expression	[increases in CD44 mRNA expression]	1.0	5	1	0	0
34995	1624	nf-kappa b dissociation in the cytosol	[NF-kappa B dissociation in the cytosol]	1.0	6	1	0	0
34996	1624	complete inhibition,	[complete inhibition,]	1.0	2	1	0	0
34997	1624	primary human T cell responsive	[primary human T cells responsive]	1.0	5	1	0	0
34998	1624	weak up-regulation of VDR expression	[weak up-regulation of VDR expression]	1.0	5	1	0	0
34999	1624	early-induced burst.	[early-induced burst.]	1.0	2	1	0	0
35000	1624	dnd39 cell	[DND39 cells]	1.0	2	2	2	2
35001	1624	mitogen-inducible gene	[mitogen-inducible gene]	1.0	2	2	1	1
35002	1624	intercellular communication	[intercellular communications]	1.0	2	1	0	0
35003	1624	IL-13 promoter	[IL-13 promoters]	1.0	2	1	0	0
35004	1624	cell contact	[cell contact]	1.0	2	2	2	2
35005	1624	little effect on the morphology	[little effect on the morphology]	1.0	5	1	0	0
35006	1624	E1B 19k	[E1B 19K]	1.0	2	1	0	0
35007	1624	stimulus-responsive processing	[stimulus-responsive processing]	1.0	2	1	0	0
35008	1624	CD3 -dependent phosphorylation of HS1	[CD3 -dependent phosphorylation of HS1]	1.0	5	1	0	0
35009	1624	selection of kappa b/rel dna-binding motif	[Selection of kappa B/Rel DNA-binding motifs]	1.0	6	1	0	0
35010	1624	1.0 gy	[1.0 Gy]	1.0	2	1	0	0
35011	1624	different donor	[different donors]	1.0	2	1	0	0
35012	1624	high level of cell surface molecules,	[high levels of cell surface molecules,]	1.0	6	1	0	0
35013	1624	activation of the hiv enhancer	[activation of the HIV enhancer]	1.0	5	1	0	0
35014	1624	up-regulation of x box binding	[up-regulation of X box binding]	1.0	5	1	0	0
35015	1624	69.1 pm)	[69.1 pM)]	1.0	2	1	0	0
35016	1624	homeotic gene	[homeotic genes]	1.0	2	1	0	0
35017	1624	T cell from cell carcinoma patient	[T cells from cell carcinoma patients]	1.0	6	1	0	0
35018	1624	full-length rdna	[Full-length cDNAs]	1.0	2	1	0	0
35019	1624	encode a zinc-binding potential transcription factor	[encoding a zinc-binding potential transcription factor]	1.0	6	1	0	0
35020	1624	complex c	[complex c]	1.0	2	2	1	1
35021	1624	receptor-bearing subset,	[receptor-bearing subset,]	1.0	2	1	0	0
35022	1624	wild-type id3	[wild-type Id3]	1.0	2	1	0	0
35023	1624	express the chimeric receptor kit/il-4r alpha	[expressing the chimeric receptor kit/IL-4R alpha]	1.0	6	1	0	0
35024	1624	B-cell mutant	[B-cell mutants]	1.0	2	1	0	0
35025	1624	splicing of the gc receptor	[splicing of the GC receptor]	1.0	5	2	2	2
35026	1624	apoplexy patient	[apoplexy patients]	1.0	2	1	0	0
35027	1624	nonmutational mechanism	[nonmutational mechanism]	1.0	2	1	0	0
35028	1624	mr state	[MR state]	1.0	2	1	0	0
35029	1624	egr-1 mrna expression by crosslinking	[EGR-1 mRNA expression by crosslinking]	1.0	5	1	0	0
35030	1624	mediate responsiveness to t-cell-activateivg signal	[mediating responsiveness to T-cell-activating signals]	1.0	5	1	0	0
35031	1624	intermediary factor	[intermediary factor]	1.0	2	1	0	0
35032	1624	contain the DNA bind domain	[containing the DNA binding domain]	1.0	5	1	0	0
35033	1624	dissociation of the inhibitor protein	[dissociation of the inhibitor protein]	1.0	5	1	0	0
35034	1624	common precursor	[common precursor]	1.0	2	2	1	1
35035	1624	human cell c-Myb reporter construct	[human cells c-Myb reporter constructs]	1.0	5	1	0	0
35036	1624	menopausal period	[menopausal period]	1.0	2	1	0	0
35037	1624	deficit of the mutant cell	[deficit of the mutant cells]	1.0	5	1	0	0
35038	1624	monocyte in a run-on assay	[monocytes in a run-on assay]	1.0	5	1	0	0
35039	1624	cognate cofactor	[cognate cofactor]	1.0	2	1	0	0
35040	1624	nf-kappab gene for the cytokine	[NF-kappaB genes for the cytokines]	1.0	5	1	0	0
35041	1624	neural cell	[neural cells]	1.0	2	1	0	0
35042	1624	complex x	[Complex X]	1.0	2	1	0	0
35043	1624	human pterin carbinolamine dehydratase/dimerization cofactor	[human pterin carbinolamine dehydratase/dimerization cofactor]	1.0	5	1	0	0
35044	1624	treatment of T cell with mitogen	[Treatment of T cells with mitogens]	1.0	6	1	0	0
35045	1624	estrogen predominance	[estrogen predominance]	1.0	2	1	0	0
35046	1624	result show	[results showing]	1.0	2	1	0	0
35047	1624	donor splice site of exon	[donor splice site of exon]	1.0	5	1	0	0
35048	1624	positive b	[positive B]	1.0	2	1	0	0
35049	1624	positive T	[positive T]	1.0	2	3	2	1
35050	1624	patient with chronic lymphocytic leukemia	[patients with chronic lymphocytic leukemia]	1.0	5	1	0	0
35051	1624	human immunodeficiency virus contain heterologous enhancer/promoters	[Human immunodeficiency viruses containing heterologous enhancer/promoters]	1.0	6	1	0	0
35052	1624	Calcineurin a ca2+ /calmodulin-dependent protein phosphatase	[Calcineurin a Ca2+ /calmodulin-dependent protein phosphatase]	1.0	6	1	0	0
35053	1624	plasmid contain the il-2 promoter	[plasmids containing the IL-2 promoter]	1.0	5	1	0	0
35054	1624	valuable tool in the delineation	[valuable tools in the delineation]	1.0	5	1	0	0
35055	1624	expression of aml1/mds1/evi1 block differentiation result	[expression of AML1/MDS1/EVI1 blocks differentiation resulting]	1.0	6	1	0	0
35056	1624	potent apc during primary response	[potent APC during primary responses]	1.0	5	1	0	0
35057	1624	contain six full cell cycle	[containing six full cell cycle]	1.0	5	1	0	0
35058	1624	delta Spi-B	[delta Spi-B]	1.0	2	1	0	0
35059	1624	17.5+/-1.7 nmol/l,	[17.5+/-1.7 nmol/L,]	1.0	2	1	0	0
35060	1624	modulate the expression include member	[modulating the expression including members]	1.0	5	1	0	0
35061	1624	t(17;19) acute lymphoblastic leukemia chimera	[t(17;19) acute lymphoblastic leukemia chimera]	1.0	5	1	0	0
35062	1624	use a whole-cell competitive binding assay	[Using a whole-cell competitive binding assay]	1.0	6	1	0	0
35063	1624	important regulator of this coupling.	[important regulator of this coupling.]	1.0	5	1	0	0
35064	1624	Strikingly, deletion of 346 C-terminal residue	[Strikingly, deletion of 346 C-terminal residues]	1.0	6	1	0	0
35065	1624	activation response of immature thymocyte	[activation responses of immature thymocytes]	1.0	5	1	0	0
35066	1624	cyclic undecapeptide	[cyclic undecapeptide]	1.0	2	1	0	0
35067	1624	peripheral blood mononuclear cell response	[peripheral blood mononuclear cell responses]	1.0	5	2	2	2
35068	1624	pebp2 alpha gene in T cell	[PEBP2 alpha genes in T cells]	1.0	6	1	0	0
35069	1624	such as protein kinase b	[such as protein kinase B]	1.0	5	1	0	0
35070	1624	three group	[three groups]	1.0	2	2	1	1
35071	1624	suggest mechanism	[suggesting mechanisms]	1.0	2	2	2	2
35072	1624	structural organization	[structural organization]	1.0	2	2	1	1
35073	1624	three pathway	[three pathways]	1.0	2	2	2	2
35074	1624	crucial event in the transduction	[crucial event in the transduction]	1.0	5	1	0	0
35075	1624	glucocorticosteroid receptor	[glucocorticosteroid receptors]	1.0	2	1	0	0
35076	1624	imbalance of this T lymphocyte subset	[Imbalance of these T lymphocyte subsets]	1.0	6	1	0	0
35077	1624	Tat expression	[Tat expression]	1.0	2	1	0	0
35078	1624	species specificity,	[species specificity,]	1.0	2	1	0	0
35079	1624	cd14 induction	[CD14 induction]	1.0	2	1	0	0
35080	1624	differential expression of pkc isoform	[differential expression of PKC isoforms]	1.0	5	1	0	0
35081	1624	cellular reduce catalyst thioredoxin trx	[cellular reducing catalyst thioredoxin Trx]	1.0	5	1	0	0
35082	1624	Positive autoregulation of gr expression	[Positive autoregulation of GR expression]	1.0	5	1	0	0
35083	1624	novel 35-amino acid c terminus	[novel 35-amino acid C terminus]	1.0	5	1	0	0
35084	1624	ferritin h-chain gene promoter regulation	[ferritin H-chain gene promoter regulation]	1.0	5	1	0	0
35085	1624	2-8 min.	[2-8 min.]	1.0	2	1	0	0
35086	1624	biochemical ones.	[biochemical ones.]	1.0	2	1	0	0
35087	1624	recombinant ebf	[recombinant EBF]	1.0	2	1	0	0
35088	1624	Jak3 protein	[Jak3 protein]	1.0	2	1	0	0
35089	1624	many change	[many changes]	1.0	2	2	2	2
35090	1624	interrelation between the hypothalamic-pituitary-adrenal system hpa	[Interrelations between the hypothalamic-pituitary-adrenal system HPA]	1.0	6	1	0	0
35091	1624	corresponding to the normal pml	[corresponding to the normal pml]	1.0	5	1	0	0
35092	1624	result in synthesis of a peptide	[resulting in synthesis of a peptide]	1.0	6	1	0	0
35093	1624	nfkappab activation in T lymphocyte	[NFkappaB activation in T lymphocytes]	1.0	5	1	0	0
35094	1624	theoretical pathway of transcriptional regulation	[theoretical pathway of transcriptional regulation]	1.0	5	1	0	0
35095	1624	structural complementarity for residue 57	[structural complementarity for residue 57]	1.0	5	1	0	0
35096	1624	immunomodulatory activity	[immunomodulatory activity]	1.0	2	2	1	1
35097	1624	encode a zinc finger protein	[encoding a zinc finger protein]	1.0	5	2	2	2
35098	1624	Ro-VDR cell	[Ro-VDR cells]	1.0	2	1	0	0
35099	1624	dual-specific map	[dual-specific MAP]	1.0	2	1	0	0
35100	1624	contain nuclear factor kappab NFkappaB complex	[containing nuclear factor kappaB NFkappaB complexes]	1.0	6	1	0	0
35101	1624	resistant (ic50	[resistant (IC50]	1.0	2	1	0	0
35102	1624	b cells,	[B cells,]	1.0	2	1	0	0
35103	1624	gene h-2kb	[gene H-2Kb]	1.0	2	1	0	0
35104	1624	C.botulinum toxin	[C.botulinum toxin]	1.0	2	1	0	0
35105	1624	Epstein-Barr virus nuclear antigen EBNA2	[Epstein-Barr virus nuclear antigen EBNA2]	1.0	5	2	1	1
35106	1624	C26 subfragment	[C26 subfragment]	1.0	2	1	0	0
35107	1624	cloning of the beta subunit	[Cloning of the beta subunit]	1.0	5	1	0	0
35108	1624	1 alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3	[1 alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3]	1.0	5	1	0	0
35109	1624	Comparison of the amino acid	[Comparison of the amino acids]	1.0	5	1	0	0
35110	1624	15 animal	[15 animals]	1.0	2	1	0	0
35111	1624	use this drug as probes, chemist	[Using these drugs as probes, chemists]	1.0	6	1	0	0
35112	1624	identical) protein	[identical) protein]	1.0	2	1	0	0
35113	1624	type cys2-xaa12-his2	[type Cys2-Xaa12-His2]	1.0	2	1	0	0
35114	1624	prdi domain	[PRDI domain]	1.0	2	1	0	0
35115	1624	up-regulation of GcR by ketoconazole treatment,	[up-regulation of GcR by ketoconazole treatment,]	1.0	6	1	0	0
35116	1624	co-stimulatory signal	[co-stimulatory signals]	1.0	2	1	0	0
35117	1624	type motif	[type motif]	1.0	2	2	2	2
35118	1624	blood monocyte from patient with tuberculosis	[Blood monocytes from patients with tuberculosis]	1.0	6	1	0	0
35119	1624	minimize energy study of bmt structure	[Minimizing energy studies of BMT structure]	1.0	6	1	0	0
35120	1624	site molarity	[site molarity]	1.0	2	1	0	0
35121	1624	expression of il-2 receptor component	[expression of IL-2 receptor components]	1.0	5	1	0	0
35122	1624	migration rate	[migration rate]	1.0	2	2	2	2
35123	1624	potentially toxic effect of LMP1	[potentially toxic effects of LMP1]	1.0	5	1	0	0
35124	1624	m4 cell	[M4 cells]	1.0	2	1	0	0
35125	1624	(also in human umbilical arterial cell	[(also in human umbilical arterial cells]	1.0	6	1	0	0
35126	1624	present investigation,	[present investigation,]	1.0	2	1	0	0
35127	1624	two anthracycline	[two anthracyclines]	1.0	2	1	0	0
35128	1624	anergic cell	[anergic cells]	1.0	2	1	0	0
35129	1624	cortivazol act in dex -resistant cell	[cortivazol acts in dex -resistant cells]	1.0	6	1	0	0
35130	1624	sequence corresponding to consensus binding site	[sequences corresponding to consensus binding sites]	1.0	6	1	0	0
35131	1624	early (6 wk to 12 mo)	[early (6 wk to 12 mo)]	1.0	6	1	0	0
35132	1624	least two genes, alpha a	[least two genes, alpha A]	1.0	5	1	0	0
35133	1624	use the proximal lck promoter	[using the proximal lck promoter]	1.0	5	1	0	0
35134	1624	related receptor in mononuclear leukocyte	[related receptors in mononuclear leukocytes]	1.0	5	1	0	0
35135	1624	human cd34(+) hematopoietic progenitor cell	[human CD34(+) hematopoietic progenitor cells]	1.0	5	1	0	0
35136	1624	VDR protein	[VDR protein]	1.0	2	1	0	0
35137	1624	phoq protein	[PhoQ protein]	1.0	2	2	1	1
35138	1624	bacterial constituent	[bacterial constituents]	1.0	2	2	2	2
35139	1624	transcription factor active in mammary cell	[transcription factors active in mammary cells]	1.0	6	1	0	0
35140	1624	number of low affinity il-2r	[number of low affinity IL-2Rs]	1.0	5	1	0	0
35141	1624	DRA promoter for protein-DNA interaction	[DRA promoter for protein-DNA interactions]	1.0	5	1	0	0
35142	1624	endogenous no	[endogenous NO]	1.0	2	1	0	0
35143	1624	member of the c-fos/c-jun family	[members of the c-fos/c-jun family]	1.0	5	1	0	0
35144	1624	endothelial receptor for low-density lipoprotein	[endothelial receptor for low-density lipoprotein]	1.0	5	1	0	0
35145	1624	protein kinase c gene transcription	[protein kinase C gene transcription]	1.0	5	1	0	0
35146	1624	prior to the onset of differentiation	[prior to the onset of differentiation]	1.0	6	1	0	0
35147	1624	fusion between IL-5 t-cell clone	[fusion between IL-5 T-cell clones]	1.0	5	1	0	0
35148	1624	fifth clone	[fifth clone]	1.0	2	1	0	0
35149	1624	microenvironmental homing	[microenvironmental homing]	1.0	2	1	0	0
35150	1624	legionella pneumophila	[Legionella pneumophila]	1.0	2	2	1	1
35151	1624	fetal progenitor	[fetal progenitors]	1.0	2	2	2	2
35152	1624	additional nsaid	[additional NSAIDs]	1.0	2	1	0	0
35153	1624	virus DNA	[virus DNA]	1.0	2	1	0	0
35154	1624	terminal b	[terminal B]	1.0	2	1	0	0
35155	1624	BK virus plasmid expression vector	[BK virus plasmid expression vector]	1.0	5	1	0	0
35156	1624	terminal T	[terminal T]	1.0	2	1	0	0
35157	1624	isomerase activity	[isomerase activity]	1.0	2	2	1	1
35158	1624	event result in the induction	[events resulting in the induction]	1.0	5	1	0	0
35159	1624	signal via cd27 on b cell	[signaling via CD27 on B cells]	1.0	6	1	0	0
35160	1624	exposure of human T lymphocyte	[Exposure of human T lymphocytes]	1.0	5	1	0	0
35161	1624	Rac-1 pathway	[Rac-1 pathway]	1.0	2	1	0	0
35162	1624	gr between the pco patient	[GR between the PCOS patients]	1.0	5	1	0	0
35163	1624	rest peripheral blood mononuclear cell pbmc	[resting peripheral blood mononuclear cells PBMCs]	1.0	6	1	0	0
35164	1624	intracellular glutathione	[intracellular glutathione]	1.0	2	2	1	1
35165	1624	dm function	[DM function]	1.0	2	1	0	0
35166	1624	il-2 growth	[IL-2 growth]	1.0	2	2	2	2
35167	1624	rwleu-4 cell with 24r-hydroxylase activity	[RWLeu-4 cells with 24R-hydroxylase activity]	1.0	5	1	0	0
35168	1624	major histocompatibility complex class gene	[major histocompatibility complex class genes]	1.0	5	1	0	0
35169	1624	relevant cis-element	[relevant cis-elements]	1.0	2	1	0	0
35170	1624	transactivation of the ICAM-I promoter	[Transactivation of the ICAM-I promoter]	1.0	5	1	0	0
35171	1624	enzyme level in the proband	[enzyme levels in the proband]	1.0	5	1	0	0
35172	1624	patient with nontuberculous pulmonary condition	[patients with nontuberculous pulmonary conditions]	1.0	5	1	0	0
35173	1624	PTHrP promoter	[PTHrP promoter]	1.0	2	1	0	0
35174	1624	suggest important for DC differentiation	[suggesting important for DC differentiation]	1.0	5	1	0	0
35175	1624	LUF syndrome	[LUF syndrome]	1.0	2	1	0	0
35176	1624	ligand-independent mechanism	[ligand-independent mechanisms]	1.0	2	1	0	0
35177	1624	multiple effect on the gene expression	[multiple effects on the gene expression]	1.0	6	1	0	0
35178	1624	Thus, STAT1	[Thus, STAT1]	1.0	2	1	0	0
35179	1624	ikappab phosphorylation/proteolysis	[IkappaB phosphorylation/proteolysis]	1.0	2	1	0	0
35180	1624	Thus, STAT3	[Thus, STAT3]	1.0	2	1	0	0
35181	1624	PBL generation of tumor necrosis factor-alpha	[PBL Generation of tumor necrosis factor-alpha]	1.0	6	1	0	0
35182	1624	signal follow CD40 stimulation of monocyte	[signaling following CD40 stimulation of monocytes]	1.0	6	1	0	0
35183	1624	agonist stimulation,	[agonist stimulation,]	1.0	2	1	0	0
35184	1624	argument for a lymphoid origin	[arguments for a lymphoid origin]	1.0	5	1	0	0
35185	1624	porcine MHC class ii antigen	[Porcine MHC class II antigens]	1.0	5	1	0	0
35186	1624	lipopolysaccharide lps on gene expression	[lipopolysaccharide LPS on gene expression]	1.0	5	1	0	0
35187	1624	XIST transcription	[XIST transcription]	1.0	2	1	0	0
35188	1624	involve the inactive x chromosome	[involving the inactive X chromosome]	1.0	5	1	0	0
35189	1624	defective transport	[defective transport]	1.0	2	2	2	2
35190	1624	activity of the transactivation domain	[activity of the transactivation domain]	1.0	5	1	0	0
35191	1624	bufalin apoptosis	[bufalin apoptosis]	1.0	2	1	0	0
35192	1624	normal patient	[normal patients]	1.0	2	1	0	0
35193	1624	number of potential regulatory element	[number of potential regulatory elements]	1.0	5	1	0	0
35194	1624	follow transient expression in cos-1 cell	[following transient expression in COS-1 cells]	1.0	6	1	0	0
35195	1624	cooperative interaction between c-Jun complex	[cooperative interaction between c-Jun complexes]	1.0	5	1	0	0
35196	1624	induction of receptor messenger ribonucleic acid	[induction of receptor messenger ribonucleic acid]	1.0	6	1	0	0
35197	1624	p60 phosphorylation	[p60 phosphorylation]	1.0	2	1	0	0
35198	1624	nuclear expression of c-rel/p50 heterodimer	[nuclear expression of c-Rel/p50 heterodimers]	1.0	5	1	0	0
35199	1624	such patient	[such patients]	1.0	2	1	0	0
35200	1624	increase in the expression of gene	[increases in the expression of genes]	1.0	6	1	0	0
35201	1624	dyn/cm2) for 6 h. haec	[dyn/cm2) for 6 h, HAEC]	1.0	5	1	0	0
35202	1624	disease variable	[disease variables,]	1.0	2	1	0	0
35203	1624	proximal position	[proximal position]	1.0	2	2	2	2
35204	1624	14 individual with the bb genotype	[14 individuals with the Bb genotype]	1.0	6	1	0	0
35205	1624	activity of eosinophil in patient	[activity of eosinophils in patients]	1.0	5	1	0	0
35206	1624	transcriptional activation of lytic viral promoter	[transcriptional activation of lytic viral promoters]	1.0	6	1	0	0
35207	1624	(3 0.4-fold	[(3 0.4-fold]	1.0	2	1	0	0
35208	1624	bi-directional discourse between the immune system	[bi-directional discourse between the immune system]	1.0	6	1	0	0
35209	1624	same stimuli.	[same stimuli.]	1.0	2	1	0	0
35210	1624	express beta-chain	[express beta-chain]	1.0	2	1	0	0
35211	1624	gene encode the alpha subunit	[genes encoding the alpha subunits]	1.0	5	1	0	0
35212	1624	change in the intracellular redox status	[changes in the intracellular redox status]	1.0	6	1	0	0
35213	1624	human antiviral, cd8(+) CTL response	[human antiviral, CD8(+) CTL responses]	1.0	5	1	0	0
35214	1624	difference analysis	[difference analysis]	1.0	2	2	2	2
35215	1624	endogenous RA	[Endogenous RA]	1.0	2	1	0	0
35216	1624	individual gene	[individual genes]	1.0	2	2	1	1
35217	1624	large clone	[large clone]	1.0	2	2	1	1
35218	1624	pyrrolidine dithiocarbamate a oxygen scavenger	[pyrrolidine dithiocarbamate an oxygen scavenger]	1.0	5	1	0	0
35219	1624	same experiment.	[same experiment.]	1.0	2	1	0	0
35220	1624	total disappearance	[total disappearance]	1.0	2	1	0	0
35221	1624	2 adult	[2 adult]	1.0	2	1	0	0
35222	1624	t-helper-cell epitope in protein antigen	[T-helper-cell epitopes in protein antigen]	1.0	5	1	0	0
35223	1624	lineage cell	[lineage cells]	1.0	2	2	2	2
35224	1624	PPARalpha expression in human ECs	[PPARalpha expression in human ECs]	1.0	5	1	0	0
35225	1624	upstream kinase such as Syk	[upstream kinases such as Syk]	1.0	5	1	0	0
35226	1624	differentiation of memory b cell	[differentiation of memory B cells]	1.0	5	1	0	0
35227	1624	encompass band p11.23 to p12.3	[encompassing bands p11.23 to p12.3]	1.0	5	1	0	0
35228	1624	hil-4r alphas	[hIL-4R alphas]	1.0	2	1	0	0
35229	1624	conclusions: in patient with AMI	[CONCLUSIONS: In patients with AMI]	1.0	5	1	0	0
35230	1624	bcl-2-transduced cell	[bcl-2-transduced cells]	1.0	2	1	0	0
35231	1624	15-amino acid sequence of NFATx1	[15-amino acid sequence of NFATx1]	1.0	5	2	1	1
35232	1624	PMA harc	[PMA HAECs]	1.0	2	1	0	0
35233	1624	role in b cell development	[role in B cell development]	1.0	5	2	2	2
35234	1624	pituitary adrenocorticotropic	[pituitary adrenocorticotropic]	1.0	2	1	0	0
35235	1624	2.7 kb	[2.7 kb]	1.0	2	1	0	0
35236	1624	Allelic variation	[Allelic variations]	1.0	2	1	0	0
35237	1624	cd8+ T lymphocyte (ctl) response	[CD8+ T lymphocyte (CTL) response]	1.0	5	2	2	2
35238	1624	two nf-at complex to NF-ATp	[two NF-AT complexes to NF-ATp]	1.0	5	1	0	0
35239	1624	protein bind specifically to the ap-1	[proteins binding specifically to the AP-1]	1.0	6	1	0	0
35240	1624	also a target of antibody	[also a target of antibodies]	1.0	5	1	0	0
35241	1624	T cell control over infection	[T cell controls over infection]	1.0	5	1	0	0
35242	1624	such as the lymphoid system	[such as the lymphoid system]	1.0	5	1	0	0
35243	1624	particular tyrosine	[particular tyrosine]	1.0	2	1	0	0
35244	1624	fos antibody	[Fos antibodies]	1.0	2	1	0	0
35245	1624	rrna encode receptor for D3	[mRNAs encoding receptors for D3]	1.0	5	1	0	0
35246	1624	Epstein-Barr virus binding to CD21	[Epstein-Barr virus binding to CD21]	1.0	5	1	0	0
35247	1624	anti-CD40 microgram/mL)	[anti-CD40 microgram/mL)]	1.0	2	1	0	0
35248	1624	instead, signal	[Instead, signal]	1.0	2	1	0	0
35249	1624	EBNA-2 -positive -negative nuclear extract	[EBNA-2 -positive -negative nuclear extracts]	1.0	5	1	0	0
35250	1624	lymphotropic herpesvirus	[lymphotropic herpesvirus]	1.0	2	2	1	1
35251	1624	antibody cross-linking	[Antibody cross-linking]	1.0	2	2	2	2
35252	1624	antiproliferative agent	[antiproliferative agent]	1.0	2	1	0	0
35253	1624	gastrointestinal tract	[gastrointestinal tract]	1.0	2	1	0	0
35254	1624	involvement of retinoic acid receptor	[involvement of retinoic acid receptors]	1.0	5	1	0	0
35255	1624	IFN resistance	[IFN resistance]	1.0	2	1	0	0
35256	1624	ap-1 activation in T cell	[AP-1 activation in T cells]	1.0	5	1	0	0
35257	1624	specificity to the kappab sequence	[specificity to the kappaB sequence]	1.0	5	1	0	0
35258	1624	dose range	[dose range]	1.0	2	2	1	1
35259	1624	primary immunomodulator	[primary immunomodulator]	1.0	2	1	0	0
35260	1624	transcriptional interference	[transcriptional interference]	1.0	2	1	0	0
35261	1624	t-cell-activateivg signal	[T-cell-activating signals]	1.0	2	2	1	1
35262	1624	8.5 kb	[8.5 kb]	1.0	2	1	0	0
35263	1624	Domain B	[Domain B]	1.0	2	1	0	0
35264	1624	same stimulus	[same stimuli]	1.0	2	2	1	1
35265	1624	extensive homology in dna-binding domain	[extensive homology in DNA-binding domains]	1.0	5	1	0	0
35266	1624	stat1 from the result cytosol	[STAT1 from the resulting cytosol]	1.0	5	1	0	0
35267	1624	transcriptional transactivator	[transcriptional transactivator]	1.0	2	2	2	2
35268	1624	other cytokine such as interleukin	[other cytokines such as interleukin]	1.0	5	1	0	0
35269	1624	subsequently inhibition of tcr signal	[subsequently inhibition of TCR signals]	1.0	5	1	0	0
35270	1624	thus support the transfection datum	[thus supporting the transfection data.]	1.0	5	1	0	0
35271	1624	dna-binding affinity	[DNA-binding affinity]	1.0	2	1	0	0
35272	1624	tumour differentiation	[tumour differentiation]	1.0	2	2	1	1
35273	1624	contain high titre antibody with specificity	[containing high titre antibodies with specificities]	1.0	6	1	0	0
35274	1624	molecular mimicry in autoimmune disease	[molecular mimicry in autoimmune disease]	1.0	5	1	0	0
35275	1624	Maximal increase in il-2 transcription	[Maximal increase in IL-2 transcription]	1.0	5	1	0	0
35276	1624	less frequently, cd4+ T cell	[less frequently, CD4+ T cells]	1.0	5	1	0	0
35277	1624	understanding of the transcriptional regulation	[understanding of the transcriptional regulation]	1.0	5	2	2	2
35278	1624	activation of the hiv-1 provirus	[Activation of the HIV-1 provirus]	1.0	5	1	0	0
35279	1624	association of X with phospholipid surface	[association of X with phospholipid surfaces]	1.0	6	1	0	0
35280	1624	4) clone of CVZ -resistant cell	[4) clones of CVZ -resistant cells]	1.0	6	1	0	0
35281	1624	leukocyte-platelet adhesion in patient with AMI	[leukocyte-platelet adhesion in patients with AMI]	1.0	6	1	0	0
35282	1624	stimulatory condition	[stimulatory conditions]	1.0	2	1	0	0
35283	1624	ultraviolet absorbance	[ultraviolet absorbance]	1.0	2	1	0	0
35284	1624	platelet membrane	[platelet membranes]	1.0	2	2	1	1
35285	1624	Finally, gel mobility shift assay	[Finally, gel mobility shift assays]	1.0	5	1	0	0
35286	1624	cooperative action of the two receptor	[cooperative action of the two receptors]	1.0	6	1	0	0
35287	1624	cell respond to a stimulus	[cells responding to an stimulus]	1.0	5	1	0	0
35288	1624	interferon (ifn) regulatory factor IRF-1	[interferon (IFN) regulatory factors IRF-1]	1.0	5	1	0	0
35289	1624	protein of approximately 20 kda.	[protein of approximately 20 kDa.]	1.0	5	1	0	0
35290	1624	mitogen-stimulated cell	[mitogen-stimulated cells]	1.0	2	1	0	0
35291	1624	forskolin camp	[forskolin cAMP]	1.0	2	1	0	0
35292	1624	consolidate the switch to high level	[consolidating the switch to high levels]	1.0	6	1	0	0
35293	1624	same set of word oligopeptide	[same set of words oligopeptides]	1.0	5	1	0	0
35294	1624	further results,	[Further results,]	1.0	2	1	0	0
35295	1624	dictate pattern of expression of gene	[dictating patterns of expression of genes]	1.0	6	1	0	0
35296	1624	optimal binding.	[optimal binding.]	1.0	2	1	0	0
35297	1624	Biphasic control of NF-kappa b activation	[Biphasic control of NF-kappa B activation]	1.0	6	1	0	0
35298	1624	response predictor	[response predictors]	1.0	2	1	0	0
35299	1624	cytolytic activity of NK cell	[cytolytic activity of NK cells]	1.0	5	1	0	0
35300	1624	hla-c allele	[HLA-C alleles]	1.0	2	1	0	0
35301	1624	MIP-1 alpha transcription during activation	[MIP-1 alpha transcription during activation]	1.0	5	1	0	0
35302	1624	moreover, follow	[Moreover, following]	1.0	2	1	0	0
35303	1624	namely the zymogen plasma factor VII	[namely the zymogen plasma factors VII]	1.0	6	1	0	0
35304	1624	two-fold increase in suppressor activity	[two-fold increase in suppressor activity]	1.0	5	1	0	0
35305	1624	good understanding of transcriptional regulation	[Better understanding of transcriptional regulation]	1.0	5	2	2	2
35306	1624	phorbol myristate,	[phorbol myristate,]	1.0	2	1	0	0
35307	1624	molecule b7.1	[molecule B7.1]	1.0	2	2	2	2
35308	1624	24,25-dihydroxyvitamin D3	[24,25-dihydroxyvitamin D3]	1.0	2	2	1	1
35309	1624	porcine aortic endothelial cell PAEC	[Porcine aortic endothelial cells PAEC]	1.0	5	1	0	0
35310	1624	tissue macrophage	[tissue macrophage]	1.0	2	2	1	1
35311	1624	mouse mammary tumor virus-long terminal	[mouse mammary tumor virus-long terminal]	1.0	5	1	0	0
35312	1624	suggest expression in the germ	[suggesting expression in the germ]	1.0	5	1	0	0
35313	1624	nf-kappab activation in T cell	[NF-kappaB activation in T cells]	1.0	5	1	0	0
35314	1624	mg/kg p.o.,	[mg/kg p.o.,]	1.0	2	1	0	0
35315	1624	pip binding	[Pip binding]	1.0	2	1	0	0
35316	1624	tcr expression	[TCR expression]	1.0	2	1	0	0
35317	1624	vitro T	[vitro T]	1.0	2	2	1	1
35318	1624	alzheimer's disease	[Alzheimer's disease]	1.0	2	1	0	0
35319	1624	extinction of immunoglobulin gene expression	[Extinction of immunoglobulin gene expression]	1.0	5	1	0	0
35320	1624	different function	[different functions]	1.0	2	2	1	1
35321	1624	phosphorylation of Jak2 in cell	[Phosphorylation of Jak2 in cells]	1.0	5	1	0	0
35322	1624	cellular metabolism, disposition of SMX	[cellular metabolism, disposition of SMX]	1.0	5	1	0	0
35323	1624	component of each P-like element-binding complex	[components of each P-like element-binding complexes]	1.0	6	1	0	0
35324	1624	western blotting experiment use antibody	[Western blotting experiments using antibodies]	1.0	5	1	0	0
35325	1624	impdh type ii gene expression	[IMPDH type II gene expression]	1.0	5	1	0	0
35326	1624	brid the generation of ca2+ ion	[bridging the generation of Ca2+ ions]	1.0	6	1	0	0
35327	1624	include Cbl a protooncogene product	[including Cbl a protooncogene product]	1.0	5	1	0	0
35328	1624	RESULTS: Flutamide	[RESULTS: Flutamide]	1.0	2	1	0	0
35329	1624	sigm- crosslinking	[sIgM- crosslinking]	1.0	2	2	1	1
35330	1624	low frequency,	[low frequency,]	1.0	2	1	0	0
35331	1624	T lymphocyte via factor kappab	[T lymphocytes via factor kappaB]	1.0	5	1	0	0
35332	1624	inhibit normal vdr-rxr heterodimer binding	[inhibiting normal VDR-RXR heterodimer binding]	1.0	5	1	0	0
35333	1624	increase transcription of the gene	[increasing transcription of the gene]	1.0	5	1	0	0
35334	1624	human primary b-cell by ebv	[human primary B-cells by EBV]	1.0	5	1	0	0
35335	1624	most instance	[most instances]	1.0	2	1	0	0
35336	1624	lymphokine secretion	[lymphokine secretion]	1.0	2	1	0	0
35337	1624	alloreactive response	[alloreactive responses]	1.0	2	1	0	0
35338	1624	yeast cell	[yeast cells]	1.0	2	2	2	2
35339	1624	whole-cell bind assay with [3H]dexamethasone	[whole-cell binding assay with [3H]dexamethasone]	1.0	5	1	0	0
35340	1624	sequence tag from steroid-responsive cell	[sequence tags from steroid-responsive cells]	1.0	5	1	0	0
35341	1624	coincubation of bzlf cell lysate	[coincubation of BZLF cell lysates]	1.0	5	1	0	0
35342	1624	(karyopherin)-alpha beta	[(karyopherin)-alpha beta]	1.0	2	1	0	0
35343	1624	transgenic mouse overexpress icsat in lymphocyte	[transgenic mice overexpressing ICSAT in lymphocytes]	1.0	6	1	0	0
35344	1624	frequency of cd8(+) T cell	[frequencies of CD8(+) T cells]	1.0	5	1	0	0
35345	1624	aggtcatgacct trep	[AGGTCATGACCT TREp]	1.0	2	1	0	0
35346	1624	camp forskolin	[cAMP forskolin]	1.0	2	1	0	0
35347	1624	peptide-binding groove	[peptide-binding groove]	1.0	2	1	0	0
35348	1624	pathway of nf-kappa b activation	[pathway of NF-kappa B activation]	1.0	5	1	0	0
35349	1624	b-cell-specific complex	[B-cell-specific complex]	1.0	2	1	0	0
35350	1624	hour 48 in icrf-193 cell	[hour 48 in ICRF-193 cells]	1.0	5	1	0	0
35351	1624	rat liver	[rat liver]	1.0	2	1	0	0
35352	1624	steady state,	[steady state,]	1.0	2	1	0	0
35353	1624	primary binding site for RBP-Jkappa	[primary binding site for RBP-Jkappa]	1.0	5	1	0	0
35354	1624	primitive hpc	[primitive HPCs]	1.0	2	1	0	0
35355	1624	age of the initial attack	[age of the initial attack]	1.0	5	1	0	0
35356	1624	regulation after transfer into hepatocyte	[Regulation after transfer into hepatocytes]	1.0	5	1	0	0
35357	1624	inhibit effect on the replication	[inhibiting effects on the replication]	1.0	5	1	0	0
35358	1624	contrast, Zap	[contrast, Zap]	1.0	2	1	0	0
35359	1624	vivo therapy with rifn-alpha 2c	[vivo therapy with rIFN-alpha 2c]	1.0	5	1	0	0
35360	1624	nitro blue tetrazolium reduction assay	[nitro blue tetrazolium reduction assay]	1.0	5	1	0	0
35361	1624	binding experiments, use cos-7 cell	[Binding experiments, using COS-7 cells]	1.0	5	1	0	0
35362	1624	vcam-1 gene	[VCAM-1 gene]	1.0	2	1	0	0
35363	1624	ie, the expression of gene product	[ie, the expression of gene products]	1.0	6	1	0	0
35364	1624	initiating event	[initiating event]	1.0	2	1	0	0
35365	1624	PU.1 Spi-1	[PU.1 Spi-1]	1.0	2	1	0	0
35366	1624	alter the gene of RARalpha	[altering the gene of RARalpha]	1.0	5	1	0	0
35367	1624	transcription of the c-fm proto-oncogene	[transcription of the c-fms proto-oncogene]	1.0	5	1	0	0
35368	1624	42.2% 135-(oh)2d3 induction of degradation.	[42.2% 1,25-(OH)2D3 induction of degradation.]	1.0	5	1	0	0
35369	1624	bacterial lipoprotein through toll-like receptor-2	[bacterial lipoproteins through toll-like receptor-2]	1.0	5	1	0	0
35370	1624	recognition of the SL3 core	[recognition of the SL3 cores]	1.0	5	1	0	0
35371	1624	magnitude of signal transduction pathway	[magnitude of signal transduction pathways]	1.0	5	1	0	0
35372	1624	express NF kappa b subunits.	[expressing NF kappa B subunits.]	1.0	5	1	0	0
35373	1624	Theileria annulata	[Theileria annulata]	1.0	2	2	1	1
35374	1624	activation of the axis function	[activation of the axis function]	1.0	5	1	0	0
35375	1624	effect on transcription factor binding	[effect on transcription factor binding]	1.0	5	1	0	0
35376	1624	abut a activator protein-1 ap-1 site	[abutting an activator protein-1 AP-1 site]	1.0	6	1	0	0
35377	1624	Kd allele	[Kd allele]	1.0	2	1	0	0
35378	1624	IFN signal	[IFN signal]	1.0	2	2	1	1
35379	1624	staphylococcus aureus	[Staphylococcus aureus]	1.0	2	2	2	2
35380	1624	usage in signal transduction study	[usage in signal transduction studies]	1.0	5	1	0	0
35381	1624	regulatory element the ap-1 protein	[regulatory elements the AP-1 protein]	1.0	5	1	0	0
35382	1624	two human b cell line	[two human B cell lines]	1.0	5	1	0	0
35383	1624	NK cell by interleukin-2 il-2	[NK cells by interleukin-2 IL-2]	1.0	5	1	0	0
35384	1624	two signals.	[two signals.]	1.0	2	2	1	1
35385	1624	STAT-1 p91	[STAT-1 p91]	1.0	2	1	0	0
35386	1624	48 patient with polycythemia vera	[48 patients with polycythemia vera]	1.0	5	1	0	0
35387	1624	expression of il-4 target gene	[expression of IL-4 target genes]	1.0	5	1	0	0
35388	1624	switch to ige by cytokine	[switching to IgE by cytokines]	1.0	5	1	0	0
35389	1624	normal human pulmonary alveolar macrophage PAM	[Normal human pulmonary alveolar macrophages PAM]	1.0	6	1	0	0
35390	1624	100 nm	[100 nM]	1.0	2	1	0	0
35391	1624	anergized cell	[anergized cells]	1.0	2	1	0	0
35392	1624	murine cells,	[murine cells,]	1.0	2	1	0	0
35393	1624	dose responsiveness	[dose responsiveness]	1.0	2	1	0	0
35394	1624	encounter self-antigen	[encountering self-antigens]	1.0	2	1	0	0
35395	1624	tnf-alpha release by the leukemia cell	[TNF-alpha release by the leukemia cells]	1.0	6	1	0	0
35396	1624	preliminary report.	[preliminary report.]	1.0	2	2	1	1
35397	1624	result from extensive alternative splicing	[resulting from extensive alternative splicing]	1.0	5	1	0	0
35398	1624	intrigue possibility also the mechanism	[intriguing possibility also the mechanism]	1.0	5	1	0	0
35399	1624	gene encode immunologically relevant protein	[genes encoding immunologically relevant proteins]	1.0	5	1	0	0
35400	1624	tr75 expression on om-10.1 cell	[TR75 expression on OM-10.1 cells]	1.0	5	1	0	0
35401	1624	a-t patient with t(x;14) translocation	[A-T patients with t(X;14) translocations]	1.0	5	1	0	0
35402	1624	proviral transcription	[proviral transcription]	1.0	2	2	2	2
35403	1624	p70 production	[p70 production]	1.0	2	1	0	0
35404	1624	subject group	[subject group]	1.0	2	1	0	0
35405	1624	diversity in x-chromosome methylation pattern	[diversity in X-chromosome methylation patterns]	1.0	5	1	0	0
35406	1624	nf-kappa b expression by oligodeoxynucleotides	[NF-kappa B expression by oligodeoxynucleotides]	1.0	5	1	0	0
35407	1624	contrast to wild-type b cell	[contrast to wild-type B cells]	1.0	5	1	0	0
35408	1624	different signal	[different signals]	1.0	2	2	2	2
35409	1624	fas-ligand expression	[fas-ligand expression]	1.0	2	1	0	0
35410	1624	pleural macrophage	[pleural macrophages]	1.0	2	1	0	0
35411	1624	quantitative analysis with isoform-specific C-terminal antibody	[quantitative analysis with isoform-specific C-terminal antibodies]	1.0	6	1	0	0
35412	1624	ikappabalpha degradation	[IkappaBalpha degradation]	1.0	2	3	2	1
35413	1624	agent, alone	[agent, alone]	1.0	2	1	0	0
35414	1624	sound basis for clinical therapy	[sound basis for clinical therapies]	1.0	5	1	0	0
35415	1624	apparent potency on dexamethasone stimulation	[apparent potency on dexamethasone stimulation]	1.0	5	1	0	0
35416	1624	Anaphylatoxins C5a	[Anaphylatoxins C5a]	1.0	2	1	0	0
35417	1624	protein necessary	[proteins necessary]	1.0	2	2	2	2
35418	1624	nf-kappa b (consist of subunit	[NF-kappa B (consisting of subunits]	1.0	5	1	0	0
35419	1624	two different strain of hhv-6	[Two different strains of HHV-6]	1.0	5	1	0	0
35420	1624	differentiation-inducing ability	[differentiation-inducing ability]	1.0	2	1	0	0
35421	1624	vitro coexpress	[vitro coexpress]	1.0	2	1	0	0
35422	1624	nonhepatic cell	[nonhepatic cells]	1.0	2	1	0	0
35423	1624	tsg101 transcript	[TSG101 transcripts]	1.0	2	1	0	0
35424	1624	SWI6/ankyrin repeat	[SWI6/ankyrin repeats]	1.0	2	1	0	0
35425	1624	enf)-kappa b NF-kappa b-like transcription factor	[(NF)-kappa B NF-kappa B-like transcription factors]	1.0	6	1	0	0
35426	1624	such as protein kinase c pkc	[such as protein kinase C PKC]	1.0	6	1	0	0
35427	1624	t(17;19) translocation	[t(17;19) translocation]	1.0	2	2	2	2
35428	1624	il-6 expression.	[IL-6 expression.]	1.0	2	1	0	0
35429	1624	murine DNA	[murine DNA]	1.0	2	1	0	0
35430	1624	single vector	[single vector]	1.0	2	1	0	0
35431	1624	T cell from tumor-bearing mouse	[T cells from tumor-bearing mice]	1.0	5	1	0	0
35432	1624	lead to transendothelial migration of monocyte	[leading to transendothelial migration of monocytes]	1.0	6	1	0	0
35433	1624	primitive gut	[primitive gut]	1.0	2	1	0	0
35434	1624	+/- nmol	[+/- nmol]	1.0	2	2	2	2
35435	1624	distinctly different requirement for efficient binding,	[distinctly different requirements for efficient binding,]	1.0	6	1	0	0
35436	1624	gal4 fusion	[GAL4 fusions]	1.0	2	1	0	0
35437	1624	MLL region	[MLL region]	1.0	2	1	0	0
35438	1624	key role in IL-7 proliferation	[key role in IL-7 proliferation]	1.0	5	1	0	0
35439	1624	heavy-chain gene	[heavy-chain gene]	1.0	2	2	1	1
35440	1624	t-helper cell activation by superantigen	[T-helper cell activation by superantigen]	1.0	5	1	0	0
35441	1624	electrophoretic mobility shift assay and/or	[electrophoretic mobility shift assays and/or]	1.0	5	1	0	0
35442	1624	several occasion	[several occasions]	1.0	2	1	0	0
35443	1624	patient cell	[patient cells]	1.0	2	1	0	0
35444	1624	expression status	[expression status]	1.0	2	2	1	1
35445	1624	8 aitl	[8 AITL]	1.0	2	1	0	0
35446	1624	two member of the Ets family	[two members of the Ets family]	1.0	6	1	0	0
35447	1624	gata-like site	[GATA-like sites]	1.0	2	1	0	0
35448	1624	gpix promoter	[GPIX promoter]	1.0	2	2	2	2
35449	1624	presence of cell surface receptor	[presence of cell surface receptors]	1.0	5	1	0	0
35450	1624	downregulation of two transcription factor	[downregulation of two transcription factors]	1.0	5	1	0	0
35451	1624	conditional ngf-r	[conditional NGF-R]	1.0	2	1	0	0
35452	1624	transactivation sequence	[transactivation sequence]	1.0	2	2	1	1
35453	1624	CMV cell	[CMV cells]	1.0	2	2	2	2
35454	1624	bp 5'	[bp 5']	1.0	2	1	0	0
35455	1624	identical specificity	[identical specificities]	1.0	2	1	0	0
35456	1624	susceptibility of this cell line	[Susceptibility of these cell lines]	1.0	5	1	0	0
35457	1624	interference of receptor complex binding	[interference of receptor complex binding]	1.0	5	1	0	0
35458	1624	2.6-fold, fibrinogen	[2.6-fold, fibrinogen]	1.0	2	1	0	0
35459	1624	primarily due to the induction	[primarily due to the induction]	1.0	5	1	0	0
35460	1624	up-regulation of nuclear nf-kappab level	[up-regulation of nuclear NF-kappaB levels]	1.0	5	1	0	0
35461	1624	low ratio of reduced:oxidized glutathione	[lower ratio of reduced:oxidized glutathione]	1.0	5	1	0	0
35462	1624	early serum	[early serum]	1.0	2	1	0	0
35463	1624	corticoid receptor of peripheral blood lymphocyte	[corticoid receptors of peripheral blood lymphocytes]	1.0	6	1	0	0
35464	1624	contain the factor kappa B site	[containing the factor kappa B site]	1.0	6	1	0	0
35465	1624	tmd blast	[TMD blasts]	1.0	2	1	0	0
35466	1624	include vpreb1	[including VpreB1]	1.0	2	1	0	0
35467	1624	bovine colostrum colostrum inhibitory factor	[bovine colostrum colostrum inhibitory factor]	1.0	5	1	0	0
35468	1624	nf-kappa b activation in human monocyte	[NF-kappa B activation in human monocytes]	1.0	6	1	0	0
35469	1624	chicken homolog of c/ebp beta	[chicken homolog of C/EBP beta]	1.0	5	1	0	0
35470	1624	Spi-B protein	[Spi-B protein]	1.0	2	1	0	0
35471	1624	cellular stimulation	[cellular stimulation]	1.0	2	2	1	1
35472	1624	only a subset of myocyte	[only a subset of myocytes]	1.0	5	1	0	0
35473	1624	probe specific for the 1q12 region	[probes specific for the 1q12 regions]	1.0	6	1	0	0
35474	1624	equivalent degree	[equivalent degree]	1.0	2	1	0	0
35475	1624	origin of sideroblast in patient	[origin of sideroblasts in patients]	1.0	5	1	0	0
35476	1624	signal pathway in transformation by v-Abl	[signaling pathways in transformation by v-Abl]	1.0	6	1	0	0
35477	1624	2 microm	[2 microM]	1.0	2	2	2	2
35478	1624	exogenous peptide	[exogenous peptide]	1.0	2	1	0	0
35479	1624	selenium supplementation	[selenium supplementation]	1.0	2	1	0	0
35480	1624	hiv-infected patient with receptor affinity	[HIV-infected patients with receptor affinity]	1.0	5	2	2	2
35481	1624	collagen type	[collagens type]	1.0	2	1	0	0
35482	1624	difference of the t/nk-cell phenotype	[difference of the T/NK-cell phenotype]	1.0	5	1	0	0
35483	1624	MLL rearrangement	[MLL rearrangement]	1.0	2	1	0	0
35484	1624	induction differentiation	[Induction differentiation]	1.0	2	2	2	2
35485	1624	13 die	[13 d.]	1.0	2	1	0	0
35486	1624	natural ligand to nuclear receptor	[natural ligands to nuclear receptors]	1.0	5	1	0	0
35487	1624	tnf-alpha -inducible	[TNF-alpha -inducible]	1.0	2	1	0	0
35488	1624	important sequence.	[important sequence.]	1.0	2	1	0	0
35489	1624	stimulatory effect on hiv-1 replication	[stimulatory effect on HIV-1 replication]	1.0	5	1	0	0
35490	1624	eosinophilic inflammation of atopic asthma	[eosinophilic inflammation of atopic asthma]	1.0	5	1	0	0
35491	1624	patient with ro(ssa) precipitins, 84%	[patients with Ro(SSA) precipitins, 84%]	1.0	5	1	0	0
35492	1624	augment transcription	[augmenting transcription]	1.0	2	1	0	0
35493	1624	nonproductive (latent)	[nonproductive (latent)]	1.0	2	1	0	0
35494	1624	such hypermethylation-associated silencing of gene expression	[Such hypermethylation-associated silencing of gene expression]	1.0	6	1	0	0
35495	1624	transactivation of c-myb target gene	[transactivation of c-Myb target genes]	1.0	5	1	0	0
35496	1624	little conservation with consensus site	[little conservation with consensus sites]	1.0	5	1	0	0
35497	1624	recombinant pc4	[recombinant PC4]	1.0	2	1	0	0
35498	1624	el-4 cell	[EL-4 cells]	1.0	2	2	1	1
35499	1624	SCL protein level in precursor	[SCL protein levels in precursors]	1.0	5	1	0	0
35500	1624	enzyme iNOS	[enzymes iNOS]	1.0	2	1	0	0
35501	1624	Intron-exon organization	[Intron-exon organization]	1.0	2	1	0	0
35502	1624	involve GrpL	[involving GrpL]	1.0	2	1	0	0
35503	1624	blood polymorphonuclear	[blood polymorphonuclear]	1.0	2	2	2	2
35504	1624	complex interaction occur between HHV-6	[complex interactions occurring between HHV-6]	1.0	5	1	0	0
35505	1624	e2a protein with activation property	[E2A proteins with activation properties]	1.0	5	1	0	0
35506	1624	intraductal carcinoma	[intraductal carcinoma]	1.0	2	2	2	2
35507	1624	human mononuclear leukocyte in obesity.	[human mononuclear leukocyte in obesity.]	1.0	5	1	0	0
35508	1624	induction of the TF gene	[induction of the TF gene]	1.0	5	1	0	0
35509	1624	NFAT/AP-1 complex	[NFAT/AP-1 complex]	1.0	2	1	0	0
35510	1624	three copy of imperfect repeat	[three copies of imperfect repeats]	1.0	5	1	0	0
35511	1624	formation of NF-kappa b activity	[formation of NF-kappa B activities]	1.0	5	1	0	0
35512	1624	particulate fraction	[particulate fraction]	1.0	2	2	1	1
35513	1624	Finally, protein	[Finally, protein]	1.0	2	1	0	0
35514	1624	autologous lymphoblastoid cell line stimulation	[autologous lymphoblastoid cell line stimulation]	1.0	5	1	0	0
35515	1624	contain zinc finger through 4 and,	[containing zinc fingers through 4 and,]	1.0	6	1	0	0
35516	1624	peptide exchange	[peptide exchange]	1.0	2	1	0	0
35517	1624	element in the promoter region	[element in the promoter region]	1.0	5	2	2	2
35518	1624	late complication	[late complications]	1.0	2	1	0	0
35519	1624	slight enhancement of tnf-alpha production	[slight enhancement of TNF-alpha production]	1.0	5	1	0	0
35520	1624	heat activation	[heat activation]	1.0	2	2	1	1
35521	1624	regulation of chain (igh) gene expression	[Regulation of chain (IgH) gene expression]	1.0	6	1	0	0
35522	1624	employ a novel lysis synthetic substrate	[employing a novel lysis synthetic substrate]	1.0	6	1	0	0
35523	1624	supernatant fluid from RCC explant RCC	[supernatant fluid from RCC explants RCC]	1.0	6	1	0	0
35524	1624	number of circulate T lymphocyte	[numbers of circulating T lymphocytes]	1.0	5	1	0	0
35525	1624	DSE site	[DSE sites]	1.0	2	1	0	0
35526	1624	NF-kappaB sequence	[NF-kappaB sequence]	1.0	2	1	0	0
35527	1624	j.y.h. Kim,	[J.Y.H. Kim,]	1.0	2	1	0	0
35528	1624	antagonist binding	[antagonist binding]	1.0	2	1	0	0
35529	1624	p element of the IL-4	[P elements of the IL-4]	1.0	5	1	0	0
35530	1624	cd4+ memory	[CD4+ memory]	1.0	2	2	2	2
35531	1624	shift from dephosphorylated to prb	[shift from dephosphorylated to pRB]	1.0	5	1	0	0
35532	1624	Scatchard analysis of receptor GRE binding	[Scatchard analysis of receptor GRE binding]	1.0	6	1	0	0
35533	1624	globin synthesis	[globin synthesis]	1.0	2	1	0	0
35534	1624	carry 3 kb 5'-flanking DNA	[carrying 3 kb 5'-flanking DNA]	1.0	5	1	0	0
35535	1624	regulatory effect on msr expression	[regulatory effects on MSR expression]	1.0	5	1	0	0
35536	1624	HIV repeat	[HIV repeat]	1.0	2	2	2	2
35537	1624	nuclear appearance of nf-kappa b	[nuclear appearance of NF-kappa B]	1.0	5	1	0	0
35538	1624	hitherto unrecognized property of glucocorticoid	[hitherto unrecognized property of glucocorticoids]	1.0	5	1	0	0
35539	1624	potentially disable	[potentially disabling]	1.0	2	1	0	0
35540	1624	production of the granulocyte-macrophage factor	[production of the granulocyte-macrophage factor]	1.0	5	1	0	0
35541	1624	receive adjuvant tamoxifen treatment (p	[receiving adjuvant tamoxifen treatment (P]	1.0	5	1	0	0
35542	1624	b-cell-specific coregulator	[B-cell-specific coregulator]	1.0	2	1	0	0
35543	1624	cytokine production of interleukin-1 beta	[cytokine production of interleukin-1 beta]	1.0	5	1	0	0
35544	1624	transform potential in NIH 3t3 cell	[transforming potential in NIH 3T3 cells]	1.0	6	1	0	0
35545	1624	B-cell type with bcl6 rearrangement	[B-cell type with BCL6 rearrangement]	1.0	5	1	0	0
35546	1624	b cell membrane ig expression	[B cell membrane Ig expression]	1.0	5	1	0	0
35547	1624	member of the AP-1 factor family	[members of the AP-1 factor family]	1.0	6	1	0	0
35548	1624	increase in il-1 beta message level	[increases in IL-1 beta message levels]	1.0	6	1	0	0
35549	1624	hsf1 overexpression	[HSF1 overexpression]	1.0	2	1	0	0
35550	1624	runt box polypeptide in hematopoiesis	[runt box polypeptides in hematopoiesis]	1.0	5	1	0	0
35551	1624	other apoptosis	[other apoptosis]	1.0	2	1	0	0
35552	1624	lead to export from the nucleus	[leading to export from the nucleus]	1.0	6	1	0	0
35553	1624	unactivated platelet	[unactivated platelets]	1.0	2	1	0	0
35554	1624	cd3+ T	[CD3+ T]	1.0	2	2	2	2
35555	1624	expression of all mammalian gene	[Expression of all mammalian genes]	1.0	5	1	0	0
35556	1624	tumor of the oral cavity	[tumors of the oral cavity]	1.0	5	1	0	0
35557	1624	expression of the lmp gene	[expression of the LMP gene]	1.0	5	1	0	0
35558	1624	DNA repair enzyme uracil-DNA glycosylase	[DNA repair enzyme uracil-DNA glycosylase]	1.0	5	2	2	2
35559	1624	cd14 signal	[CD14 signaling]	1.0	2	1	0	0
35560	1624	bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane ym-268 a thiazolidinedione derivative	[bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane YM-268 a thiazolidinedione derivative]	1.0	5	1	0	0
35561	1624	CsA mechanism	[CsA mechanism]	1.0	2	2	2	2
35562	1624	hiv patient	[HIV patients]	1.0	2	1	0	0
35563	1624	follow lps addition to endothelial cell	[following LPS addition to endothelial cells]	1.0	6	1	0	0
35564	1624	induction of RALDH2 by TAL1	[induction of RALDH2 by TAL1]	1.0	5	1	0	0
35565	1624	METHODS: eight malignant lymphocytic cell line	[METHODS: Eight malignant lymphocytic cell lines]	1.0	6	1	0	0
35566	1624	human csf-1r	[human CSF-1R]	1.0	2	2	1	1
35567	1624	phosphorylation of inhibitory subunit IkappaB	[phosphorylation of inhibitory subunit IkappaB]	1.0	5	1	0	0
35568	1624	foregoing datum	[foregoing data,]	1.0	2	1	0	0
35569	1624	execution of the proliferative signal	[execution of the proliferative signal]	1.0	5	1	0	0
35570	1624	contrast, nondivide	[contrast, nondividing]	1.0	2	1	0	0
35571	1624	cd14 mrna	[CD14 mRNA]	1.0	2	2	1	1
35572	1624	shear stress	[shear stress]	1.0	2	1	0	0
35573	1624	proximal NF-AT	[proximal NF-AT]	1.0	2	1	0	0
35574	1624	protein binding,	[protein binding,]	1.0	2	1	0	0
35575	1624	new site	[new site]	1.0	2	2	1	1
35576	1624	her-2/neu oncogene	[HER-2/neu oncogene]	1.0	2	2	2	2
35577	1624	promoter expression in HeLa cell	[promoter expression in HeLa cells]	1.0	5	1	0	0
35578	1624	Thus, DR3	[Thus, DR3]	1.0	2	1	0	0
35579	1624	cell line with pybf activity	[cell line with PYBF activity]	1.0	5	1	0	0
35580	1624	E1A -negative, parental cell line	[E1A -negative, parental cell lines]	1.0	5	1	0	0
35581	1624	Oct-1 member in particular nf-atp	[Oct-1 members in particular NF-ATp]	1.0	5	1	0	0
35582	1624	clinical test	[clinical test]	1.0	2	1	0	0
35583	1624	activation of a tyrosine kinase	[activation of a tyrosine kinase]	1.0	5	1	0	0
35584	1624	addition of 1 mM aminoguanidine	[addition of 1 mM aminoguanidine]	1.0	5	1	0	0
35585	1624	activation of the JAK -stat pathway	[activation of the JAK -STAT pathway]	1.0	6	1	0	0
35586	1624	(i) constitutive c-fo transcript level	[(i) constitutive c-fos transcript levels]	1.0	5	1	0	0
35587	1624	dermal microvessel	[dermal microvessel]	1.0	2	2	1	1
35588	1624	Jurkat T cell with pha abs	[Jurkat T cells with PHA Abs]	1.0	6	1	0	0
35589	1624	lymphoid architecture,	[lymphoid architecture,]	1.0	2	1	0	0
35590	1624	b cell adaptor contain sh2 domain	[B cell adaptor containing SH2 domain]	1.0	6	1	0	0
35591	1624	cell biology	[cell biology]	1.0	2	1	0	0
35592	1624	prominent defect in the ability	[prominent defects in the ability]	1.0	5	1	0	0
35593	1624	IL-10 pretreatment	[IL-10 pretreatment]	1.0	2	1	0	0
35594	1624	inflammatory activator	[inflammatory activators]	1.0	2	1	0	0
35595	1624	sites/cell respectively, p less than 0.05).	[sites/cell respectively, P less than 0.05).]	1.0	6	1	0	0
35596	1624	ill-defined border	[ill-defined border]	1.0	2	1	0	0
35597	1624	non-cytokine gene	[non-cytokine gene]	1.0	2	2	1	1
35598	1624	specific proliferation, cytotoxicity, tumor necrosis factor	[specific proliferation, cytotoxicity, tumor necrosis factor]	1.0	6	1	0	0
35599	1624	suggest also important in the increase	[suggesting also important in the increase]	1.0	6	1	0	0
35600	1624	antibody-MR complex	[antibody-MR complex]	1.0	2	1	0	0
35601	1624	presence of a autoregulatory loop	[presence of an autoregulatory loop]	1.0	5	1	0	0
35602	1624	protein kinase c activation in differentiation/retrodifferentiation	[Protein kinase C activation in differentiation/retrodifferentiation]	1.0	6	1	0	0
35603	1624	other member of this family,	[other members of this family,]	1.0	5	1	0	0
35604	1624	ap1-binding site	[AP1-binding site]	1.0	2	1	0	0
35605	1624	monocyte from the family member	[monocytes from the family members]	1.0	5	1	0	0
35606	1624	sensitivity for induction of apoptosis	[Sensitivity for induction of apoptosis]	1.0	5	1	0	0
35607	1624	However, inhibition of hiv-1 replication	[However, inhibition of HIV-1 replication]	1.0	5	1	0	0
35608	1624	hyperphosphorylated e2f-4	[hyperphosphorylated E2F-4]	1.0	2	1	0	0
35609	1624	kinase with activation of program	[kinases with activation of programs]	1.0	5	1	0	0
35610	1624	dna-binding complex in nuclear extract	[DNA-binding complexes in nuclear extracts]	1.0	5	1	0	0
35611	1624	reflect a shift of the dose-response	[reflecting a shift of the dose-response]	1.0	6	1	0	0
35612	1624	FGF receptor in the signal	[FGF receptors in the signaling]	1.0	5	1	0	0
35613	1624	differentiation dose-response	[differentiation dose-response]	1.0	2	1	0	0
35614	1624	RGD domain	[RGD domain]	1.0	2	1	0	0
35615	1624	cell of the monocyte-macrophage lineage	[Cells of the monocyte-macrophage lineage]	1.0	5	1	0	0
35616	1624	use electrophoretic mobility shift assay,	[Using electrophoretic mobility shift assay,]	1.0	5	1	0	0
35617	1624	regulate transcription	[regulating transcription]	1.0	2	2	2	2
35618	1624	glucocorticoid receptor in peripheral lymphocyte	[glucocorticoid receptors in peripheral lymphocytes]	1.0	5	2	2	2
35619	1624	transcription of the blr2 gene	[transcription of the BLR2 gene]	1.0	5	1	0	0
35620	1624	unlabeled compound	[unlabeled compound]	1.0	2	1	0	0
35621	1624	several substrate	[several substrates]	1.0	2	2	1	1
35622	1624	complex fashion	[complex fashion]	1.0	2	2	1	1
35623	1624	proper expression	[Proper expression]	1.0	2	2	2	2
35624	1624	lead to a il-2 receptor expression	[leading to a IL-2 receptor expression]	1.0	6	1	0	0
35625	1624	eosinophil stimulation by this cytokine	[eosinophil stimulation by these cytokines]	1.0	5	1	0	0
35626	1624	mycobacterial proteins.	[mycobacterial proteins.]	1.0	2	1	0	0
35627	1624	NF-kappaB regulatory effect of alpha-lipoate	[NF-kappaB regulatory effect of alpha-lipoate]	1.0	5	1	0	0
35628	1624	ebv-associated malignancy	[EBV-associated malignancies]	1.0	2	1	0	0
35629	1624	erythroid precursor by proviral insertion	[erythroid precursors by proviral insertion]	1.0	5	1	0	0
35630	1624	novel octamer-DNA binding protein distinct	[novel octamer-DNA binding proteins distinct]	1.0	5	1	0	0
35631	1624	minute 1)	[minutes 1)]	1.0	2	2	2	2
35632	1624	nbt activity of u937 cell	[NBT activity of U937 cell]	1.0	5	1	0	0
35633	1624	Drosophila embryo	[Drosophila embryos]	1.0	2	1	0	0
35634	1624	nf-kappa b translocation per se,	[NF-kappa B translocation per se,]	1.0	5	1	0	0
35635	1624	replication competence in U937 cell	[replication competence in U937 cells]	1.0	5	1	0	0
35636	1624	treatment of peripheral blood T cell	[Treatment of peripheral blood T cells]	1.0	6	1	0	0
35637	1624	tcccctcccct motif	[TCCCCTCCCCT motif]	1.0	2	1	0	0
35638	1624	endogenous NF-kappa b1 gene expression,	[endogenous NF-kappa B1 gene expression,]	1.0	5	1	0	0
35639	1624	PKC inhibitor	[PKC inhibitor]	1.0	2	2	2	2
35640	1624	normal binding activity in nuclear extract	[normal binding activities in nuclear extracts]	1.0	6	1	0	0
35641	1624	two epitope	[two epitopes]	1.0	2	2	2	2
35642	1624	polymorphic DNA marker in the gene	[polymorphic DNA markers in the genes]	1.0	6	1	0	0
35643	1624	interleukin-4-induced transcription factor IL-4 Stat	[interleukin-4-induced transcription factor IL-4 Stat]	1.0	5	1	0	0
35644	1624	role in the clinical manifestation	[role in the clinical manifestations]	1.0	5	1	0	0
35645	1624	intraperitoneal injection	[intraperitoneal injection]	1.0	2	2	2	2
35646	1624	activation of the erythropoietin receptor	[Activation of the erythropoietin receptor]	1.0	5	2	1	1
35647	1624	especially in adolescent adult patient	[especially in adolescent adult patients]	1.0	5	1	0	0
35648	1624	immunoadsorption of stat1 from the cytosol	[immunoadsorption of STAT1 from the cytosol]	1.0	6	1	0	0
35649	1624	yellow pigment in the rhizome	[yellow pigment in the rhizome]	1.0	5	1	0	0
35650	1624	mediate transcription from proximal position	[mediating transcription from proximal positions]	1.0	5	1	0	0
35651	1624	cell-specific influence	[cell-specific influences]	1.0	2	1	0	0
35652	1624	IL-2 regulation	[IL-2 regulation]	1.0	2	2	2	2
35653	1624	molecular mechanism of this inhibition.	[molecular mechanism of this inhibition.]	1.0	5	1	0	0
35654	1624	respective form	[respective forms]	1.0	2	1	0	0
35655	1624	last decade.	[last decade.]	1.0	2	1	0	0
35656	1624	delta-globin gene	[delta-globin gene]	1.0	2	1	0	0
35657	1624	use a reverse transcription-pcr-based approach	[using a reverse transcription-PCR-based approach]	1.0	5	1	0	0
35658	1624	RESULTS: in the OM-10.1 promyelocytic model	[RESULTS: In the OM-10.1 promyelocytic model]	1.0	6	1	0	0
35659	1624	ebv status	[EBV status]	1.0	2	1	0	0
35660	1624	latter role	[latter role]	1.0	2	1	0	0
35661	1624	1.5-2.6 kd	[1.5-2.6 KD]	1.0	2	1	0	0
35662	1624	new eosinophil cell line YJ	[new eosinophil cell line YJ]	1.0	5	1	0	0
35663	1624	agent indomethacin	[agents indomethacin]	1.0	2	1	0	0
35664	1624	vivo differentiation therapy with retinoid	[vivo differentiation therapy with retinoids]	1.0	5	1	0	0
35665	1624	hl-60r cell	[HL-60R cells]	1.0	2	1	0	0
35666	1624	somatic hypermutation	[somatic hypermutation]	1.0	2	2	2	2
35667	1624	statistical evaluation of the datum	[statistical evaluation of the data]	1.0	5	1	0	0
35668	1624	transgenic experiment	[transgenic experiments]	1.0	2	1	0	0
35669	1624	spastic paraparesis/	[spastic paraparesis/]	1.0	2	1	0	0
35670	1624	expression of cytokine during malignancy	[expression of cytokines during malignancy]	1.0	5	1	0	0
35671	1624	cellular localization.	[cellular localization.]	1.0	2	1	0	0
35672	1624	considerably high proportion of low responder	[Considerably higher proportions of low responders]	1.0	6	1	0	0
35673	1624	recombinant ori	[recombinant ori]	1.0	2	1	0	0
35674	1624	mol/L RA	[mol/L RA]	1.0	2	2	1	1
35675	1624	untransformed glucocorticoid receptor complex in cytosol	[untransformed glucocorticoid receptor complexes in cytosol]	1.0	6	1	0	0
35676	1624	steady-state fluorescence anisotropy of diphenylhexatriene	[steady-state fluorescence anisotropy of diphenylhexatriene]	1.0	5	1	0	0
35677	1624	multiple level	[multiple levels]	1.0	2	2	1	1
35678	1624	Erythroid differentiation	[Erythroid differentiation]	1.0	2	1	0	0
35679	1624	traf-binding site	[TRAF-binding sites]	1.0	2	1	0	0
35680	1624	rho on AP-1 transcriptional activity	[Rho on AP-1 transcriptional activity]	1.0	5	1	0	0
35681	1624	Lipopolysaccharide LPS stimulation of human neutrophil	[Lipopolysaccharide LPS stimulation of human neutrophils]	1.0	6	1	0	0
35682	1624	dual signal	[dual signal]	1.0	2	1	0	0
35683	1624	myeloid-associated growth	[myeloid-associated growth]	1.0	2	1	0	0
35684	1624	however, special culture condition and/or cytokine	[however, special cultures conditions and/or cytokine]	1.0	6	1	0	0
35685	1624	mutational analysis of uas1 sequence	[Mutational analysis of UAS1 sequences]	1.0	5	1	0	0
35686	1624	taq I	[Taq I]	1.0	2	1	0	0
35687	1624	molecular mechanism for the inhibition	[molecular mechanism for the inhibition]	1.0	5	1	0	0
35688	1624	primarily on the typical morphology	[primarily on the typical morphology]	1.0	5	1	0	0
35689	1624	clustering of lesion disrupt domain	[clustering of lesions disrupting domain]	1.0	5	1	0	0
35690	1624	follow-up period.	[follow-up period.]	1.0	2	1	0	0
35691	1624	cooperation between interferon regulatory factor-1	[cooperation between interferon regulatory factor-1]	1.0	5	1	0	0
35692	1624	identification of the ubiquitin-carrier protein	[identification of the ubiquitin-carrier protein]	1.0	5	1	0	0
35693	1624	receptor number Ro in the monocyte	[receptor numbers Ro in the monocytes]	1.0	6	1	0	0
35694	1624	analyze the normal component of NF-AT	[analyzing the normal components of NF-AT]	1.0	6	1	0	0
35695	1624	GM-CSF peripheral blood polymorphonuclear leukocyte pmn	[GM-CSF peripheral blood polymorphonuclear leukocytes PMN]	1.0	6	1	0	0
35696	1624	promoter 1a	[promoters 1a]	1.0	2	1	0	0
35697	1624	sequence-specific transcription	[sequence-specific transcription]	1.0	2	1	0	0
35698	1624	several cytoskeleton	[several cytoskeleton]	1.0	2	1	0	0
35699	1624	lineage switch	[lineage switching]	1.0	2	2	1	1
35700	1624	extensive rearrangement	[extensive rearrangements]	1.0	2	1	0	0
35701	1624	inducibility of zp by HHV-6	[inducibility of Zp by HHV-6]	1.0	5	1	0	0
35702	1624	hetero dimer	[hetero dimer]	1.0	2	2	2	2
35703	1624	activation of the immunodeficiency virus type	[activation of the immunodeficiency virus type]	1.0	6	2	1	1
35704	1624	u937 in human diploid fibroblast	[U937 in human diploid fibroblasts]	1.0	5	1	0	0
35705	1624	events; however, addition of TNF-alpha	[events; however, addition of TNF-alpha]	1.0	5	1	0	0
35706	1624	lytic transition	[lytic transition]	1.0	2	3	2	1
35707	1624	function as a proapoptotic factor	[functioning as a proapoptotic factor]	1.0	5	1	0	0
35708	1624	suggest specific	[suggesting specific]	1.0	2	1	0	0
35709	1624	alternative signal transduction pathway distinct	[alternative signal transduction pathways distinct]	1.0	5	1	0	0
35710	1624	homo- dimer	[homo- dimers]	1.0	2	1	0	0
35711	1624	tissue with high cell turnover	[tissues with high cell turnover]	1.0	5	1	0	0
35712	1624	October protein to dna, footprinting	[Oct proteins to DNA, footprinting]	1.0	5	1	0	0
35713	1624	emanate from the t-cell antigen receptor	[emanating from the T-cell antigen receptor]	1.0	6	1	0	0
35714	1624	indicate ERK2	[indicating ERK2]	1.0	2	1	0	0
35715	1624	stable adhesion	[stable adhesions]	1.0	2	1	0	0
35716	1624	transformation of primary b cell	[transformation of primary B cells]	1.0	5	2	1	1
35717	1624	support for the hypothesis a factor	[support for the hypothesis a factor]	1.0	6	1	0	0
35718	1624	mutational study of the -236 sequence	[Mutational studies of the -236 sequence]	1.0	6	1	0	0
35719	1624	probe in mobility shift assay	[probes in mobility shift assay]	1.0	5	1	0	0
35720	1624	lipopolysaccharide induction of interleukin 1beta	[lipopolysaccharide induction of interleukin 1beta]	1.0	5	1	0	0
35721	1624	transient expression of a reporter gene	[transient expression of a reporter gene]	1.0	6	1	0	0
35722	1624	germline TaqI restriction fragment length	[germline TaqI restriction fragment length]	1.0	5	1	0	0
35723	1624	result from in vivo expression study	[Results from in vivo expression studies]	1.0	6	1	0	0
35724	1624	assembly of the cognate ligand	[assembly of the cognate ligands]	1.0	5	1	0	0
35725	1624	unusual structure.	[unusual structure.]	1.0	2	1	0	0
35726	1624	detection of b p50 homodimer	[detection of B p50 homodimers]	1.0	5	1	0	0
35727	1624	expression of this gene in cell	[expression of this gene in cells]	1.0	6	1	0	0
35728	1624	ifn-stimulated response	[IFN-stimulated response]	1.0	2	1	0	0
35729	1624	htlv-i-transformed T	[HTLV-I-transformed T]	1.0	2	1	0	0
35730	1624	ectopic endometrium	[ectopic endometrium]	1.0	2	1	0	0
35731	1624	nuclear trans-acting factor in lymphocyte	[nuclear trans-acting factors in lymphocytes]	1.0	5	1	0	0
35732	1624	pnu156804 action	[PNU156804 action]	1.0	2	1	0	0
35733	1624	tissue leukostasis	[tissue leukostasis]	1.0	2	1	0	0
35734	1624	myeloid precursors.	[myeloid precursors.]	1.0	2	1	0	0
35735	1624	balance between a viral inducer	[balance between an viral inducer]	1.0	5	1	0	0
35736	1624	SAA gene	[SAA gene]	1.0	2	1	0	0
35737	1624	human monocyte binding to fibronectin	[Human monocyte binding to fibronectin]	1.0	5	1	0	0
35738	1624	qualitative difference between the effect	[qualitative differences between the effect]	1.0	5	1	0	0
35739	1624	CD20 promoter	[CD20 promoter]	1.0	2	1	0	0
35740	1624	cell type-specific permissiveness to replication	[cell type-specific permissiveness to replication]	1.0	5	1	0	0
35741	1624	thr isotype	[THR isotype]	1.0	2	1	0	0
35742	1624	hiv-1 virus	[HIV-1 virus]	1.0	2	1	0	0
35743	1624	/nf-kappa b	[/NF-kappa B]	1.0	2	2	2	2
35744	1624	constitutive nuclear localization of NF-AT	[constitutive nuclear localization of NF-AT]	1.0	5	1	0	0
35745	1624	17 patient	[17 patients]	1.0	2	1	0	0
35746	1624	differential expression in different tissue	[differential expression in different tissues]	1.0	5	1	0	0
35747	1624	dse site	[DSE sites]	1.0	2	2	2	2
35748	1624	cooperation octamer	[cooperation octamer]	1.0	2	1	0	0
35749	1624	important role in signal integration	[important role in signal integration]	1.0	5	1	0	0
35750	1624	plasma membrane from human mononuclear leukocyte	[plasma membranes from human mononuclear leukocytes]	1.0	6	1	0	0
35751	1624	high proliferation	[high proliferation]	1.0	2	1	0	0
35752	1624	treatment with soluble, bivalent mab j393	[Treatment with soluble, bivalent mAb J393]	1.0	6	1	0	0
35753	1624	such events.	[such events.]	1.0	2	1	0	0
35754	1624	cd4-cd8- murine T lymphocyte precursor	[CD4-CD8- murine T lymphocyte precursors]	1.0	5	1	0	0
35755	1624	Paradoxical priming effect of il-10	[Paradoxical priming effects of IL-10]	1.0	5	1	0	0
35756	1624	redox stabilization of mrna transcript	[redox stabilization of mRNA transcripts]	1.0	5	1	0	0
35757	1624	embryoid body	[embryoid bodies]	1.0	2	2	1	1
35758	1624	61.0 dpm mg-1 cytosol protein	[61.0 dpm mg-1 cytosol protein]	1.0	5	1	0	0
35759	1624	(-7.0 kb)	[(-7.0 kb)]	1.0	2	1	0	0
35760	1624	Octamer-dependent activation of a reporter plasmid	[Octamer-dependent activation of a reporter plasmid]	1.0	6	1	0	0
35761	1624	quantitative reverse polymerase chain method	[quantitative reverse polymerase chain method]	1.0	5	1	0	0
35762	1624	regulation of il-1beta gene expression	[regulation of IL-1beta gene expression]	1.0	5	1	0	0
35763	1624	new mechanism of drug action	[new mechanism of drug action]	1.0	5	1	0	0
35764	1624	monocyte chemoattractant protein (mcp)-1 in leukocyte	[monocyte chemoattractant protein (MCP)-1 in leukocytes]	1.0	6	1	0	0
35765	1624	PDTC dose	[PDTC dose]	1.0	2	1	0	0
35766	1624	ability of type I ifi	[ability of type I IFNs]	1.0	5	1	0	0
35767	1624	recombinant p50	[recombinant p50]	1.0	2	2	1	1
35768	1624	phospholipase c result in a increase	[phospholipase C resulting in an increase]	1.0	6	1	0	0
35769	1624	T cell with ionomycin glycerol	[T cells with ionomycin glycerol]	1.0	5	1	0	0
35770	1624	Epstein-Barr virus latency by ZEBRA	[Epstein-Barr virus latency by ZEBRA]	1.0	5	1	0	0
35771	1624	substantial amount of cytoplasmic nf-kappab	[substantial amount of cytoplasmic NF-kappaB]	1.0	5	1	0	0
35772	1624	hydrolysis of plasma membrane phospholipid	[hydrolysis of plasma membrane phospholipids]	1.0	5	1	0	0
35773	1624	activation state	[activation state]	1.0	2	1	0	0
35774	1624	90 minute of ifn-beta treatment	[90 min of IFN-beta treatment]	1.0	5	1	0	0
35775	1624	addition regulate cell fate decision	[addition regulating cell fate decisions]	1.0	5	1	0	0
35776	1624	steroid dose	[Steroid dose]	1.0	2	2	1	1
35777	1624	receptor density in RA patient	[receptor density in RA patients]	1.0	5	1	0	0
35778	1624	respiratory burst during phorbol ester-induced differentiation	[respiratory burst during phorbol ester-induced differentiation]	1.0	6	1	0	0
35779	1624	similar interaction with transcription factor	[similar interactions with transcription factors]	1.0	5	1	0	0
35780	1624	negative feedback of the hypothalamic-pituitary-adrenal axis	[negative feedback of the hypothalamic-pituitary-adrenal axis]	1.0	6	1	0	0
35781	1624	tnf-alpha promoter-driven reporter gene activity	[TNF-alpha promoter-driven reporter gene activity]	1.0	5	1	0	0
35782	1624	two exon encode a protein	[two exons encoding a protein]	1.0	5	1	0	0
35783	1624	specific feature of biological variation	[specific features of biological variation]	1.0	5	1	0	0
35784	1624	pml/rar alpha	[PML/RAR alpha]	1.0	2	2	1	1
35785	1624	IL-4 gene transcription in T cell	[IL-4 gene transcription in T cells]	1.0	6	1	0	0
35786	1624	normal cell cycle activation program	[normal cell cycle activation program]	1.0	5	1	0	0
35787	1624	basal total white blood cell	[Basal total white blood cell]	1.0	5	1	0	0
35788	1624	er associate in a ligand-dependent manner	[ER associate in a ligand-dependent manner]	1.0	6	1	0	0
35789	1624	multiple inhibitor contain ankyrin motif	[multiple inhibitors containing ankyrin motifs]	1.0	5	1	0	0
35790	1624	granulocytic differentiation.	[granulocytic differentiation.]	1.0	2	1	0	0
35791	1624	lymphotoxin-alpha gene in b cell	[lymphotoxin-alpha genes in B cells]	1.0	5	1	0	0
35792	1624	heterotrimeric nfatp	[heterotrimeric NFATp]	1.0	2	1	0	0
35793	1624	demonstrate the importance of oxidative species	[demonstrating the importance of oxidative species]	1.0	6	1	0	0
35794	1624	immunize cell	[immunizing cells]	1.0	2	2	1	1
35795	1624	syk-family kinase in mammalian cell	[Syk-family kinases in mammalian cells]	1.0	5	1	0	0
35796	1624	SK&F 96365	[SK&F 96365]	1.0	2	1	0	0
35797	1624	150 minutes).	[150 minutes).]	1.0	2	1	0	0
35798	1624	primary inducer	[primary inducer]	1.0	2	2	2	2
35799	1624	mineralocorticoid resistance	[mineralocorticoid resistance]	1.0	2	1	0	0
35800	1624	Japanese population	[Japanese population]	1.0	2	1	0	0
35801	1624	trophoblast cell at extrauterine site	[trophoblast cells at extrauterine sites]	1.0	5	1	0	0
35802	1624	use bead	[using beads]	1.0	2	2	2	2
35803	1624	redox status of fos protein	[redox status of FOS proteins]	1.0	5	1	0	0
35804	1624	adhesion property	[adhesion properties]	1.0	2	2	1	1
35805	1624	LTR mutation	[LTR mutations]	1.0	2	1	0	0
35806	1624	IRF-1 gene	[IRF-1 gene]	1.0	2	1	0	0
35807	1624	immune response of the mother	[immune response of the mother]	1.0	5	1	0	0
35808	1624	use a anti CD20 monoclonal antibody	[using an anti CD20 monoclonal antibody]	1.0	6	1	0	0
35809	1624	stimulation of precursor b cell	[stimulation of precursor B cells]	1.0	5	1	0	0
35810	1624	lack the three consensus binding site	[lacking the three consensus binding sites]	1.0	6	1	0	0
35811	1624	leukocyte infiltration	[leukocyte infiltration]	1.0	2	1	0	0
35812	1624	aberrant splicing.	[aberrant splicing.]	1.0	2	1	0	0
35813	1624	beta-galactosidase gene	[beta-galactosidase gene]	1.0	2	2	2	2
35814	1624	Nb2 T	[Nb2 T]	1.0	2	2	2	2
35815	1624	il-12 signal in th2 cell	[IL-12 signaling in Th2 cells]	1.0	5	1	0	0
35816	1624	e1a domain	[E1A domain]	1.0	2	2	2	2
35817	1624	induction of T cell proliferation	[induction of T cell proliferation]	1.0	5	1	0	0
35818	1624	posttranscriptional mechanism for the effect.	[posttranscriptional mechanism for the effect.]	1.0	5	1	0	0
35819	1624	human mcm5 promoter with mutation	[Human MCM5 promoters with mutation]	1.0	5	1	0	0
35820	1624	schizophrenic group	[schizophrenic group]	1.0	2	1	0	0
35821	1624	even more interest, ikappabalpha overexpression	[even more interest, IkappaBalpha overexpression]	1.0	5	1	0	0
35822	1624	anti-estrogen tamoxifen	[anti-estrogen tamoxifen]	1.0	2	1	0	0
35823	1624	venous blood	[venous blood]	1.0	2	2	2	2
35824	1624	lysis pathway	[lysis pathway]	1.0	2	1	0	0
35825	1624	vitamin d resistance in XLH	[vitamin D resistance in XLH]	1.0	5	1	0	0
35826	1624	pan-T-lineage marker	[pan-T-lineage marker]	1.0	2	1	0	0
35827	1624	characterization of a immediate-early gene	[Characterization of an immediate-early gene]	1.0	5	1	0	0
35828	1624	hla class ii constitutive expression	[HLA class II constitutive expression]	1.0	5	1	0	0
35829	1624	possibility extend	[possibility extending]	1.0	2	1	0	0
35830	1624	ISG expression	[ISG expression]	1.0	2	1	0	0
35831	1624	cd95l promoter	[CD95L promoter]	1.0	2	2	1	1
35832	1624	contrast to parental u937 cell	[contrast to parental U937 cells]	1.0	5	1	0	0
35833	1624	role for the NFAT family	[role for the NFAT family]	1.0	5	1	0	0
35834	1624	Phenylarsine oxide	[Phenylarsine oxide]	1.0	2	2	1	1
35835	1624	conferr the responsiveness to CMV	[conferring the responsiveness to CMV]	1.0	5	1	0	0
35836	1624	transactivation by some DNA virus	[Transactivation by some DNA viruses]	1.0	5	1	0	0
35837	1624	immune-related disease	[immune-related diseases]	1.0	2	1	0	0
35838	1624	dna-binding/immunoprecipitation assay	[DNA-binding/immunoprecipitation assay]	1.0	2	1	0	0
35839	1624	downstream event important in cd34+ hpc	[downstream events important in CD34+ HPC]	1.0	6	1	0	0
35840	1624	human T cell-specific transcription factor	[human T cell-specific transcription factor]	1.0	5	1	0	0
35841	1624	p38alpha mapk	[p38alpha MAPk]	1.0	2	2	1	1
35842	1624	murine homologue	[murine homologue]	1.0	2	2	1	1
35843	1624	such repression	[Such repression]	1.0	2	1	0	0
35844	1624	9 amino acid domain BH3	[9 amino acid domain BH3]	1.0	5	1	0	0
35845	1624	first alteration	[first alteration]	1.0	2	1	0	0
35846	1624	gene expression of proinflammatory mediator	[gene expression of proinflammatory mediators]	1.0	5	1	0	0
35847	1624	1 tax induction of nf-kappab	[1 Tax induction of NF-kappaB]	1.0	5	1	0	0
35848	1624	especially the number of integration sites,	[especially the number of integration sites,]	1.0	6	1	0	0
35849	1624	cell-type-independent lipopolysaccharide lps enhancer element	[cell-type-independent lipopolysaccharide LPS enhancer element]	1.0	5	1	0	0
35850	1624	early signal	[early signal]	1.0	2	1	0	0
35851	1624	tnf-treated human umbilical vein cell	[TNF-treated human umbilical vein cells]	1.0	5	1	0	0
35852	1624	runt expression	[runt expression]	1.0	2	1	0	0
35853	1624	indicate the result of transcriptional activation	[indicating the result of transcriptional activation]	1.0	6	1	0	0
35854	1624	heterodimeric p49/p65	[heterodimeric p49/p65]	1.0	2	1	0	0
35855	1624	use the yeast two-hybrid system	[using the yeast two-hybrid system]	1.0	5	2	1	1
35856	1624	early progenitor	[early progenitors]	1.0	2	2	1	1
35857	1624	active molecules.	[active molecules.]	1.0	2	1	0	0
35858	1624	ethanol treatment	[ethanol treatment]	1.0	2	2	2	2
35859	1624	nfaT-containing complex devoid of NFAT2	[NFAT-containing complexes devoid of NFAT2]	1.0	5	1	0	0
35860	1624	various fc gamma RIC promoter sequence	[various Fc gamma RIC promoter sequences]	1.0	6	1	0	0
35861	1624	cycle-dependent initiation	[cycle-dependent initiation]	1.0	2	1	0	0
35862	1624	-131/+15 (position	[-131/+15 (positions]	1.0	2	1	0	0
35863	1624	rna gene	[RNA genes]	1.0	2	2	2	2
35864	1624	CD28 stimulation by b7-transfected CHO cell	[CD28 stimulation by B7-transfected CHO cells]	1.0	6	1	0	0
35865	1624	use Burkitt' lymphoma rael cell	[using Burkitt's lymphoma Rael cells]	1.0	5	1	0	0
35866	1624	nuclear translocation of c-Rel /p65 heterodimer	[nuclear translocation of c-Rel /p65 heterodimers]	1.0	6	2	1	1
35867	1624	January 9;93(1):524]	[Jan 9;93(1):524]]	1.0	2	1	0	0
35868	1624	normal T cell repertoire development	[normal T cell repertoire development]	1.0	5	1	0	0
35869	1624	cell with the cytokine il-6	[cells with the cytokine IL-6]	1.0	5	1	0	0
35870	1624	multistep disorder	[multistep disorder]	1.0	2	1	0	0
35871	1624	lineage-specific transcription	[lineage-specific transcription]	1.0	2	1	0	0
35872	1624	Leu F774L	[Leu F774L]	1.0	2	1	0	0
35873	1624	ipr cd4-8- T cell consistent	[Ipr CD4-8- T cells consistent]	1.0	5	1	0	0
35874	1624	also cd8+	[also CD8+]	1.0	2	1	0	0
35875	1624	SLP-76 two hematopoietic cell specific molecule	[SLP-76 two hematopoietic cell specific molecules]	1.0	6	1	0	0
35876	1624	Maggi, A.	[Maggi, A.]	1.0	2	1	0	0
35877	1624	intracytoplasmic delivery	[intracytoplasmic delivery]	1.0	2	1	0	0
35878	1624	consensus kappa b binding sequence	[consensus kappa B binding sequence]	1.0	5	1	0	0
35879	1624	Nuclear receptor	[Nuclear receptors]	1.0	2	1	0	0
35880	1624	lack the transcriptional activator function af-1	[lacking the transcriptional activator functions AF-1]	1.0	6	1	0	0
35881	1624	various processes,	[various processes,]	1.0	2	2	2	2
35882	1624	Mol.Cell. biol.14:373-381,	[Mol.Cell. Biol.14:373-381,]	1.0	2	1	0	0
35883	1624	EBV SM	[EBV SM]	1.0	2	1	0	0
35884	1624	developmental-specific expression of ets member	[developmental-specific expression of Ets members]	1.0	5	1	0	0
35885	1624	Rhom-2 mrna	[Rhom-2 mRNA]	1.0	2	1	0	0
35886	1624	encode the interleukin-2 receptor alpha chain	[encoding the interleukin-2 receptor alpha chain]	1.0	6	1	0	0
35887	1624	glucocorticoid dexamethasone	[glucocorticoid dexamethasone]	1.0	2	2	1	1
35888	1624	selective inhibition of p24 production	[selective inhibition of p24 production]	1.0	5	1	0	0
35889	1624	several tissue	[several tissues]	1.0	2	2	2	2
35890	1624	3 beta	[3 beta]	1.0	2	1	0	0
35891	1624	11-base-pair DNA sequence motif unique	[11-base-pair DNA sequence motif unique]	1.0	5	1	0	0
35892	1624	stable lmp1	[stable LMP1]	1.0	2	1	0	0
35893	1624	lymphocyte-specific promoter	[lymphocyte-specific promoter]	1.0	2	1	0	0
35894	1624	such as intercellular adhesion molecule-1 icam-1	[such as intercellular adhesion molecule-1 ICAM-1]	1.0	6	1	0	0
35895	1624	32 bp deletion in exon	[32 bp deletion in exon]	1.0	5	1	0	0
35896	1624	young adults.	[young adults.]	1.0	2	1	0	0
35897	1624	binding of the immune complex	[binding of the immune complex]	1.0	5	1	0	0
35898	1624	regulate differentiation	[regulating differentiation]	1.0	2	2	2	2
35899	1624	activation of the IL-5 promoter	[activation of the IL-5 promoter]	1.0	5	2	1	1
35900	1624	1,25-dihydroxy-vitamin D3	[1,25-dihydroxy-vitamin D3]	1.0	2	1	0	0
35901	1624	cross-link cd19 on b lineage cell	[Cross-linking CD19 on B lineage cells]	1.0	6	1	0	0
35902	1624	negative activity	[negative activity]	1.0	2	2	2	2
35903	1624	activation of the Ras pathway	[activation of the Ras pathway]	1.0	5	1	0	0
35904	1624	same mobility	[same mobility]	1.0	2	2	1	1
35905	1624	such allele	[Such alleles]	1.0	2	1	0	0
35906	1624	formation of a tripartite complex	[formation of a tripartite complex]	1.0	5	1	0	0
35907	1624	loss-of-function mutation in one allele	[loss-of-function mutation in one allele]	1.0	5	1	0	0
35908	1624	four patient with idiopathic myelofibrosis	[four patients with idiopathic myelofibrosis]	1.0	5	1	0	0
35909	1624	regard to	[regarding to]	1.0	2	1	0	0
35910	1624	c-rel activity	[c-Rel activities]	1.0	2	1	0	0
35911	1624	starting with a replication-incompetent molecular clone	[Starting with a replication-incompetent molecular clone]	1.0	6	1	0	0
35912	1624	DNA binding by cell-free hGR	[DNA binding by cell-free hGR]	1.0	5	1	0	0
35913	1624	early marker of monocytic differentiation	[early markers of monocytic differentiation]	1.0	5	1	0	0
35914	1624	progressive narrowing of this repertoire	[progressive narrowing of this repertoire]	1.0	5	1	0	0
35915	1624	leukemia CML	[leukemia CML]	1.0	2	2	2	2
35916	1624	contain fc gamma RIC promoter sequence	[containing Fc gamma RIC promoter sequences]	1.0	6	1	0	0
35917	1624	hence translocation to the nucleus.	[hence translocation to the nucleus.]	1.0	5	1	0	0
35918	1624	other signal	[other signals]	1.0	2	2	2	2
35919	1624	intracellular signaling.	[intracellular signaling.]	1.0	2	1	0	0
35920	1624	specific interaction	[specific interaction]	1.0	2	2	1	1
35921	1624	low temperature	[low temperature]	1.0	2	1	0	0
35922	1624	Ig level	[Ig levels]	1.0	2	1	0	0
35923	1624	target the CD28 costimulatory pathway	[targeting the CD28 costimulatory pathway]	1.0	5	1	0	0
35924	1624	cloning of a human homologue	[cloning of a human homologue]	1.0	5	1	0	0
35925	1624	false-positive dest	[false-positive DESTs]	1.0	2	1	0	0
35926	1624	blood leukocyte from obligate carrier	[blood leukocytes from obligate carriers]	1.0	5	1	0	0
35927	1624	Ras/Raf/ERK pathway	[Ras/Raf/ERK pathway]	1.0	2	1	0	0
35928	1624	T cell membrane expression of il-2r	[T cell membrane expression of IL-2R]	1.0	6	1	0	0
35929	1624	contrast, two other nonsteroidal drug	[contrast, two other nonsteroidal drugs]	1.0	5	1	0	0
35930	1624	result in heterodimer dna-binding complex	[resulting in heterodimer DNA-binding complexes]	1.0	5	1	0	0
35931	1624	antigen tumor necrosis factor alpha	[antigens tumor necrosis factor alpha]	1.0	5	1	0	0
35932	1624	herpetic lesion	[herpetic lesions]	1.0	2	1	0	0
35933	1624	inducible promoter,	[inducible promoter,]	1.0	2	1	0	0
35934	1624	transcriptional function	[transcriptional function]	1.0	2	2	1	1
35935	1624	lps with	[LPS with]	1.0	2	1	0	0
35936	1624	Mono a	[Mono A]	1.0	2	1	0	0
35937	1624	Mono b	[Mono B]	1.0	2	2	1	1
35938	1624	persistent bronchiolitis	[persistent bronchiolitis]	1.0	2	1	0	0
35939	1624	EBV transformation	[EBV transformation]	1.0	2	1	0	0
35940	1624	cd3+/cd4+ T	[CD3+/CD4+ T]	1.0	2	1	0	0
35941	1624	normal variant.	[normal variant.]	1.0	2	1	0	0
35942	1624	fmol/mg of lymphocyte cytosolic protein	[fmol/mg of lymphocyte cytosolic protein]	1.0	5	1	0	0
35943	1624	acid liberation	[acid liberation]	1.0	2	2	2	2
35944	1624	maximum inhibition	[maximum inhibition]	1.0	2	1	0	0
35945	1624	autoinduction of glucocorticoid receptor expression	[autoinduction of glucocorticoid receptor expression]	1.0	5	1	0	0
35946	1624	Recent experiment	[Recent experiments]	1.0	2	1	0	0
35947	1624	nucleotide 245	[nucleotides 245]	1.0	2	1	0	0
35948	1624	apoptotic death of T cell hybridoma	[apoptotic death of T cell hybridomas]	1.0	6	1	0	0
35949	1624	centimorgan cm	[centimorgan cM]	1.0	2	1	0	0
35950	1624	such as the gene for interleukin	[such as the genes for interleukin]	1.0	6	1	0	0
35951	1624	T cell from the elderly.	[T cells from the elderly.]	1.0	5	1	0	0
35952	1624	binding characteristic of the glucocorticoid receptor	[Binding characteristics of the glucocorticoid receptor]	1.0	6	1	0	0
35953	1624	kappa b alpha -deficient mouse	[kappa B alpha -deficient mice]	1.0	5	1	0	0
35954	1624	Mono A	[Mono A]	1.0	2	2	1	1
35955	1624	Mono B	[Mono B]	1.0	2	1	0	0
35956	1624	Ar-5 cell	[Ar-5 cells]	1.0	2	1	0	0
35957	1624	enhancer repressor overlap matrix attachment region	[enhancer repressor overlap matrix attachment regions]	1.0	6	1	0	0
35958	1624	functional motif in the cd3-epsilon	[functional motifs in the CD3-epsilon]	1.0	5	1	0	0
35959	1624	head-down bed	[head-down bed]	1.0	2	1	0	0
35960	1624	differential lineage requirement for expression	[differential lineage requirements for expression]	1.0	5	1	0	0
35961	1624	such as the early activation	[such as the early activation]	1.0	5	1	0	0
35962	1624	defect in the T lymphocyte	[defect in the T lymphocytes]	1.0	5	1	0	0
35963	1624	IL-11 mrna	[IL-11 mRNA]	1.0	2	1	0	0
35964	1624	monocytic differentiation upon vd treatment	[monocytic differentiation upon VD treatment]	1.0	5	1	0	0
35965	1624	virus with four sp1 site	[virus with four Sp1 sites]	1.0	5	1	0	0
35966	1624	transcription factor by the pathway	[transcription factors by the pathway]	1.0	5	1	0	0
35967	1624	shift in the molecular weight	[shift in the molecular weight]	1.0	5	1	0	0
35968	1624	also in normal mammary gland	[also in normal mammary glands]	1.0	5	1	0	0
35969	1624	HL cytosol	[HL cytosol]	1.0	2	3	2	1
35970	1624	ubiquitous oct-1	[ubiquitous Oct-1]	1.0	2	1	0	0
35971	1624	AP-1 reporter	[AP-1 reporters]	1.0	2	1	0	0
35972	1624	HLA-DRA the prototype class gene	[HLA-DRA the prototype class gene]	1.0	5	1	0	0
35973	1624	especially low density lipoprotein ldl	[especially low density lipoprotein LDL]	1.0	5	1	0	0
35974	1624	caml -interactor	[CAML -interactor]	1.0	2	1	0	0
35975	1624	As2O3 treatment	[As2O3 treatment]	1.0	2	1	0	0
35976	1624	ets1 specific	[ETS1 specific]	1.0	2	1	0	0
35977	1624	fly embryogenesis	[fly embryogenesis]	1.0	2	1	0	0
35978	1624	p65 subunit of nf-kappa b	[p65 subunit of NF-kappa B]	1.0	5	1	0	0
35979	1624	GM-CSF promoter CBF site TGTGGTCA	[GM-CSF promoter CBF site TGTGGTCA]	1.0	5	1	0	0
35980	1624	mmp9 activity, unique to cell	[MMP9 activity, unique to cells]	1.0	5	1	0	0
35981	1624	devd-cleavable caspase	[DEVD-cleavable caspases]	1.0	2	1	0	0
35982	1624	ERK MAPKS	[ERK MAPKS]	1.0	2	1	0	0
35983	1624	tax response	[Tax response]	1.0	2	2	2	2
35984	1624	90 patient	[90 patients]	1.0	2	1	0	0
35985	1624	autophosphorylation of the immunoprecipitated kinase	[autophosphorylation of the immunoprecipitated kinase]	1.0	5	1	0	0
35986	1624	LTR synergy	[LTR synergy]	1.0	2	1	0	0
35987	1624	however, proliferation	[however, proliferation]	1.0	2	1	0	0
35988	1624	stimulation with the same stimulus	[stimulation with the same stimuli]	1.0	5	1	0	0
35989	1624	15 minute of lps stimulation	[15 min of LPS stimulation]	1.0	5	1	0	0
35990	1624	functional component of the il-4r	[functional component of the IL-4R]	1.0	5	1	0	0
35991	1624	tcdd increase	[TCDD increase]	1.0	2	1	0	0
35992	1624	4922 (range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564 3413 (range,	[4922 (range, 4484-5643), 3413 (range,]	1.0	5	1	0	0
35993	1624	transfection of 2 different line	[transfection of 2 different lines]	1.0	5	1	0	0
35994	1624	vary at the DQA1 locus	[varying at the DQA1 locus]	1.0	5	1	0	0
35995	1624	regulation of il-13 gene expression	[regulation of IL-13 gene expression]	1.0	5	1	0	0
35996	1624	oncoprotein c-Myc	[oncoproteins c-Myc]	1.0	2	1	0	0
35997	1624	useful tool to the understanding	[useful tool to the understanding]	1.0	5	1	0	0
35998	1624	high HbF	[high HbF]	1.0	2	1	0	0
35999	1624	reporter construct contain the region	[reporter construct containing the region]	1.0	5	1	0	0
36000	1624	two potential nf-kappa b binding sites)	[two potential NF-kappa B binding sites)]	1.0	6	1	0	0
36001	1624	(3H) dexamethasone	[(3H) dexamethasone]	1.0	2	1	0	0
36002	1624	40s ribosomal protein s6 kinase	[40S ribosomal protein S6 kinase]	1.0	5	1	0	0
36003	1624	ap-1 binding activity in human monocyte	[AP-1 binding activity in human monocytes]	1.0	6	1	0	0
36004	1624	rip in lymphoblastoid cell line	[RIP in lymphoblastoid cell lines]	1.0	5	1	0	0
36005	1624	high level of type ii EBS	[higher levels of type II EBS]	1.0	6	1	0	0
36006	1624	h of culture in murine splenocyte	[h of culture in murine splenocytes]	1.0	6	1	0	0
36007	1624	x-linked ricket	[X-linked rickets]	1.0	2	2	2	2
36008	1624	studies, tpa	[studies, TPA]	1.0	2	1	0	0
36009	1624	selective inhibition signal through Janus kinase	[selective inhibition signaling through Janus kinases]	1.0	6	1	0	0
36010	1624	inhibition of dexamethasone binding to receptor	[Inhibition of dexamethasone binding to receptor]	1.0	6	1	0	0
36011	1624	Ro 25-7386	[Ro 25-7386]	1.0	2	1	0	0
36012	1624	low molecular weight stat5 isoform	[lower molecular weight STAT5 isoforms]	1.0	5	1	0	0
36013	1624	zp activity	[Zp activity]	1.0	2	1	0	0
36014	1624	analysis of DNA binding site	[analysis of DNA binding sites]	1.0	5	1	0	0
36015	1624	high level of expression in mouse	[high levels of expression in mice]	1.0	6	1	0	0
36016	1624	hRAR alpha-lbd	[hRAR alpha-LBD]	1.0	2	1	0	0
36017	1624	number of lymphocyte glucocorticoid receptor	[number of lymphocyte glucocorticoid receptors]	1.0	5	2	2	2
36018	1624	10 min,	[10 min,]	1.0	2	1	0	0
36019	1624	synchronization to temporary, permissive condition	[synchronization to temporary, permissive conditions]	1.0	5	1	0	0
36020	1624	late induction of activation-related genes.	[later induction of activation-related genes.]	1.0	5	1	0	0
36021	1624	silencer activity	[silencer activity]	1.0	2	2	1	1
36022	1624	lt promoter	[LT promoter]	1.0	2	1	0	0
36023	1624	Antisense oligonucleotide to the p65 subunit	[Antisense oligonucleotides to the p65 subunit]	1.0	6	1	0	0
36024	1624	sequence-binding complex	[sequence-binding complexes]	1.0	2	2	2	2
36025	1624	initiation binding repressor [corrected] ibr	[Initiation binding repressor [corrected] IBR]	1.0	5	1	0	0
36026	1624	requirement for synergy in induction	[requirements for synergy in induction]	1.0	5	1	0	0
36027	1624	gel retardation assay with stat-binding oligonucleotide	[Gel retardation assays with STAT-binding oligonucleotides]	1.0	6	1	0	0
36028	1624	role in inflammation, for rheumatoid synovitis,	[role in inflammation, for rheumatoid synovitis,]	1.0	6	1	0	0
36029	1624	blockade of t-cell activation by dithiocarbamate	[Blockade of T-cell activation by dithiocarbamates]	1.0	6	1	0	0
36030	1624	treatment of the b-cell line	[Treatment of the B-cell line]	1.0	5	2	2	2
36031	1624	phosphotyrosine residue	[phosphotyrosine residue]	1.0	2	2	1	1
36032	1624	modification of reproductive target tissue	[modifications of reproductive target tissues]	1.0	5	1	0	0
36033	1624	identical half-life	[identical half-life]	1.0	2	1	0	0
36034	1624	binding of ifn-gamma to human eosinophil	[binding of IFN-gamma to human eosinophils]	1.0	6	1	0	0
36035	1624	10, leiomyosarcoma 10, liposarcoma 5).	[10, leiomyosarcoma 10, liposarcoma 5).]	1.0	5	1	0	0
36036	1624	dlcl pathogenesis	[DLCL pathogenesis]	1.0	2	2	2	2
36037	1624	preclinical study of therapeutic regimen	[preclinical studies of therapeutic regimens]	1.0	5	1	0	0
36038	1624	dimeric complex	[dimeric complexes]	1.0	2	1	0	0
36039	1624	immunosuppression observed.	[immunosuppression observed.]	1.0	2	1	0	0
36040	1624	inflammatory tissue	[inflammatory tissues]	1.0	2	1	0	0
36041	1624	c-fos/c-jun at the mrna level	[c-fos/c-jun at the mRNA level]	1.0	5	1	0	0
36042	1624	Northern blot analysis of rna	[Northern blot analysis of RNA]	1.0	5	2	1	1
36043	1624	use centromere specific probe for chromosome	[using centromere specific probes for chromosomes]	1.0	6	1	0	0
36044	1624	alpha- luciferase	[alpha- luciferase]	1.0	2	1	0	0
36045	1624	cyto-differentiaterentiating treatment	[cyto-differentiating treatment]	1.0	2	2	2	2
36046	1624	important role in the process	[important role in the process]	1.0	5	2	2	2
36047	1624	hemopoietic cells.	[hemopoietic cells.]	1.0	2	1	0	0
36048	1624	vitro inhibition	[vitro inhibition]	1.0	2	1	0	0
36049	1624	adherence to the vascular endothelium,	[adherence to the vascular endothelium,]	1.0	5	1	0	0
36050	1624	binding, transcription	[binding, transcription]	1.0	2	1	0	0
36051	1624	Sialoadhesin expression	[Sialoadhesin expression]	1.0	2	1	0	0
36052	1624	anti-cd2 pathway	[anti-CD2 pathway]	1.0	2	1	0	0
36053	1624	industrial chemical	[industrial chemicals]	1.0	2	1	0	0
36054	1624	42.6 kda	[42.6 kDa]	1.0	2	1	0	0
36055	1624	(10(-7) m)	[(10(-7) M)]	1.0	2	1	0	0
36056	1624	pretreatment a	[pretreatment A]	1.0	2	1	0	0
36057	1624	third month	[third month]	1.0	2	1	0	0
36058	1624	cognate Ag	[cognate Ag]	1.0	2	1	0	0
36059	1624	nuclear protein binding site for Sp1	[nuclear protein binding sites for Sp1]	1.0	6	1	0	0
36060	1624	thus support a role for transactivation	[thus supporting a role for transactivation]	1.0	6	1	0	0
36061	1624	stromal cell rescue of T cell	[stromal cell rescue of T cells]	1.0	6	1	0	0
36062	1624	nuclear calcium/calmodulin-dependent protein kinase ii	[nuclear calcium/calmodulin-dependent protein kinase II]	1.0	5	1	0	0
36063	1624	respective transcript	[respective transcripts]	1.0	2	1	0	0
36064	1624	sre motif	[SRE motif]	1.0	2	2	1	1
36065	1624	(contain a single base pair mutation	[(containing a single base pair mutation]	1.0	6	1	0	0
36066	1624	contain the human ciita gene	[containing the human CIITA gene]	1.0	5	1	0	0
36067	1624	revert to a rest state,	[reverting to a resting state,]	1.0	5	1	0	0
36068	1624	four copy of the nf-at site	[four copies of the NF-AT site]	1.0	6	1	0	0
36069	1624	nf-kappab induction	[NF-kappaB induction]	1.0	2	2	1	1
36070	1624	haemoglobin production in ut-7 cell	[haemoglobin production in UT-7 cells]	1.0	5	1	0	0
36071	1624	important regulator of erythroid cell development	[important regulators of erythroid cell development]	1.0	6	1	0	0
36072	1624	cell along and/or megakaryocytic lineage	[cells along and/or megakaryocytic lineages]	1.0	5	1	0	0
36073	1624	enhancement of specific DNA binding capacity	[enhancement of specific DNA binding capacity]	1.0	6	1	0	0
36074	1624	use hpr cDNA region-specific probe	[Using hPR cDNA region-specific probes]	1.0	5	1	0	0
36075	1624	steroid-treated patient	[steroid-treated patients]	1.0	2	1	0	0
36076	1624	Spi-B activity	[Spi-B activity]	1.0	2	1	0	0
36077	1624	gi protein	[Gi protein]	1.0	2	2	1	1
36078	1624	gain insight into the function	[gaining insight into the function]	1.0	5	1	0	0
36079	1624	production of tumor necrosis factor-alpha	[production of tumor necrosis factor-alpha]	1.0	5	2	1	1
36080	1624	200 mu/l physiological upper limit	[200 mU/L physiological upper limit]	1.0	5	1	0	0
36081	1624	antioxidant treatment	[antioxidant treatment]	1.0	2	2	2	2
36082	1624	intracellular molecule	[intracellular molecules]	1.0	2	1	0	0
36083	1624	gc-r number	[GC-R numbers]	1.0	2	1	0	0
36084	1624	tyrosine phosphorylation of most proteins,	[tyrosine phosphorylation of most proteins,]	1.0	5	1	0	0
36085	1624	125d3 variant	[1,25D3 variants]	1.0	2	1	0	0
36086	1624	PMA induction of nuclear factor	[PMA induction of nuclear factor]	1.0	5	1	0	0
36087	1624	one transformation effector site TES1	[One transformation effector site TES1]	1.0	5	1	0	0
36088	1624	er- cell	[ER- cells]	1.0	2	2	1	1
36089	1624	discordant expression of a novel mutation	[discordant expression of a novel mutation]	1.0	6	1	0	0
36090	1624	inhibition of phosphotyrosine phosphatase activity	[inhibition of phosphotyrosine phosphatase activity]	1.0	5	1	0	0
36091	1624	monocytic precursor	[monocytic precursors]	1.0	2	1	0	0
36092	1624	repression of the enhancer element	[repression of the enhancer element]	1.0	5	1	0	0
36093	1624	T transcription factor tcf-1 alpha	[T transcription factor TCF-1 alpha]	1.0	5	1	0	0
36094	1624	2250 nucleotide	[2,250 nucleotides]	1.0	2	1	0	0
36095	1624	monocyte in response to CoCl2	[monocytes in response to CoCl2]	1.0	5	1	0	0
36096	1624	two site around position -585	[two sites around positions -585]	1.0	5	1	0	0
36097	1624	include two stop codon mutant	[including two stop codon mutants]	1.0	5	1	0	0
36098	1624	tonically suppress central nervous system	[tonically suppressing central nervous system]	1.0	5	1	0	0
36099	1624	pb precursor	[PB precursors]	1.0	2	1	0	0
36100	1624	contain motif	[containing motifs]	1.0	2	1	0	0
36101	1624	contain HLF consensus binding site	[containing HLF consensus binding sites]	1.0	5	1	0	0
36102	1624	dexamethasone to temporal artery-SCID chimera	[dexamethasone to temporal artery-SCID chimeras]	1.0	5	1	0	0
36103	1624	mediate signal	[mediating signals]	1.0	2	2	1	1
36104	1624	neutrophil elastase	[neutrophil elastase]	1.0	2	2	2	2
36105	1624	anti-inflammatory glucocorticoid	[anti-inflammatory glucocorticoids]	1.0	2	1	0	0
36106	1624	factor traf6	[factor TRAF6]	1.0	2	2	2	2
36107	1624	requirement for antigen, t-cell signal	[requirement for antigen, T-cell signals]	1.0	5	1	0	0
36108	1624	several molecules,	[Several molecules,]	1.0	2	2	1	1
36109	1624	evidence flexible in differentiation potential	[evidence flexible in differentiation potential]	1.0	5	1	0	0
36110	1624	activation of this nuclear factor	[activation of this nuclear factor]	1.0	5	1	0	0
36111	1624	ig mutation,	[Ig mutation,]	1.0	2	1	0	0
36112	1624	April 11;92(8):3632]	[Apr 11;92(8):3632]]	1.0	2	1	0	0
36113	1624	related lymphoma	[related lymphomas]	1.0	2	1	0	0
36114	1624	role of this p element	[role of these P elements]	1.0	5	1	0	0
36115	1624	innate system	[innate system]	1.0	2	1	0	0
36116	1624	constitutive form	[constitutive form]	1.0	2	1	0	0
36117	1624	organ failure	[organ failure]	1.0	2	1	0	0
36118	1624	imbalanced expression of the gr isoform	[imbalanced expression of the GR isoforms]	1.0	6	1	0	0
36119	1624	available iron result in activation	[available iron resulting in activation]	1.0	5	1	0	0
36120	1624	human dermal microvessel endothelial cell MVEC	[human dermal microvessel endothelial cells MVEC]	1.0	6	1	0	0
36121	1624	activatable pld	[activatable PLD]	1.0	2	1	0	0
36122	1624	direct-repeat palindrome	[direct-repeat palindrome]	1.0	2	1	0	0
36123	1624	ikk protein	[IKK protein]	1.0	2	2	1	1
36124	1624	cause complete T cell activation	[causing complete T cell activation]	1.0	5	1	0	0
36125	1624	role of signal transduction element	[role of signal transduction elements]	1.0	5	1	0	0
36126	1624	27 combination of different promoter	[27 combinations of different promoters]	1.0	5	1	0	0
36127	1624	PHA-activated T	[PHA-activated T]	1.0	2	1	0	0
36128	1624	primary adult t-cell leukemia cell	[primary adult T-cell leukemia cells]	1.0	5	1	0	0
36129	1624	corresponding site	[corresponding sites]	1.0	2	1	0	0
36130	1624	nearly wild-type level of gene expression	[nearly wild-type levels of gene expression]	1.0	6	1	0	0
36131	1624	kappa B/rel in the IL-4	[kappa B/rel in the IL-4]	1.0	5	1	0	0
36132	1624	c-rel inhibition	[c-Rel inhibition]	1.0	2	1	0	0
36133	1624	approximately 1 ng/ml endogenous tbp-1	[approximately 1 ng/ml endogenous TBP-1]	1.0	5	1	0	0
36134	1624	native-Western analysis of pituitary beta-cell	[native-Western analyses of pituitary beta-cells]	1.0	5	1	0	0
36135	1624	quiescent hpc	[quiescent HPCs]	1.0	2	1	0	0
36136	1624	material in the present study,	[MATERIAL In the present study,]	1.0	5	1	0	0
36137	1624	c-type lectin leukocyte receptor aim/cd69	[C-type lectin leukocyte receptor AIM/CD69]	1.0	5	1	0	0
36138	1624	superoxide anion	[superoxide anions]	1.0	2	2	1	1
36139	1624	cytokine expression at the level	[cytokine expression at the levels]	1.0	5	1	0	0
36140	1624	PMA phosphorylation of a 47-kda protein	[PMA phosphorylation of a 47-kDa protein]	1.0	6	1	0	0
36141	1624	Thus, hTLR2	[Thus, hTLR2]	1.0	2	1	0	0
36142	1624	CHO-DR/ b7	[CHO-DR/ B7]	1.0	2	1	0	0
36143	1624	2 bp deletion in exon	[2 bp deletion in exon]	1.0	5	1	0	0
36144	1624	Interleukin-6 production in hemorrhagic shock	[Interleukin-6 production in hemorrhagic shock]	1.0	5	1	0	0
36145	1624	chromatin degradation	[chromatin degradation]	1.0	2	1	0	0
36146	1624	homodimer formation	[homodimer formation]	1.0	2	1	0	0
36147	1624	expression of the c-fo gene	[expression of the c-fos gene]	1.0	5	1	0	0
36148	1624	critical role in the pathogenesis	[critical role in the pathogenesis]	1.0	5	1	0	0
36149	1624	other DNA	[other DNA]	1.0	2	1	0	0
36150	1624	ebv gene	[EBV genes]	1.0	2	2	2	2
36151	1624	extinguishing mechanism	[extinguishing mechanism]	1.0	2	1	0	0
36152	1624	amount of available iron result	[amount of available iron resulting]	1.0	5	1	0	0
36153	1624	few virus-exposed cell from elderly donor	[Fewer virus-exposed cells from elderly donors]	1.0	6	1	0	0
36154	1624	use a combination of monoclonal reagent	[using a combination of monoclonal reagents]	1.0	6	1	0	0
36155	1624	interfollicular zone	[interfollicular zones]	1.0	2	2	2	2
36156	1624	such as 12-o-tetradecanoyl-phorbol-13 acetate tpa	[such as 12-O-tetradecanoyl-phorbol-13 acetate TPA]	1.0	5	1	0	0
36157	1624	octamer- binding protein in control	[octamer- binding proteins in control]	1.0	5	1	0	0
36158	1624	normal rat	[normal rats]	1.0	2	1	0	0
36159	1624	stat5b in primary human erythroid precursor	[STAT5B in primary human erythroid precursors]	1.0	6	1	0	0
36160	1624	ifn-gamma responsiveness;	[IFN-gamma responsiveness;]	1.0	2	1	0	0
36161	1624	present observation	[present observations]	1.0	2	1	0	0
36162	1624	viral stock	[viral stock]	1.0	2	2	1	1
36163	1624	multipotent progenitor	[multipotent progenitor]	1.0	2	2	1	1
36164	1624	differentiation/retrodifferentiation of u-937 leukemia cell	[differentiation/retrodifferentiation of U-937 leukemia cells]	1.0	5	1	0	0
36165	1624	steady-state mrna level in human lipopolysaccharide	[steady-state mRNA levels in human lipopolysaccharide]	1.0	6	1	0	0
36166	1624	new antibody	[new antibody]	1.0	2	2	2	2
36167	1624	lytic cell	[lytic cells]	1.0	2	1	0	0
36168	1624	hsv-specific T	[HSV-specific T]	1.0	2	1	0	0
36169	1624	inhibitor Canventol	[inhibitor Canventol]	1.0	2	1	0	0
36170	1624	plant flavonoid	[plant flavonoid]	1.0	2	1	0	0
36171	1624	pattern of pro-/antiinflammatory cytokine secretion	[pattern of pro-/antiinflammatory cytokine secretion]	1.0	5	1	0	0
36172	1624	1) lipid a myristoyl fatty acid	[1) lipid A myristoyl fatty acid]	1.0	6	1	0	0
36173	1624	il-2r expression lead to proliferation	[IL-2R expression leading to proliferation]	1.0	5	1	0	0
36174	1624	use T cell from VZV donor	[using T cells from VZV donors]	1.0	6	1	0	0
36175	1624	suggest the absence of disulfide bridge	[suggesting the absence of disulfide bridges]	1.0	6	1	0	0
36176	1624	trough value between 2300 hr.	[trough values between 2300 hr.]	1.0	5	1	0	0
36177	1624	minor importance after influenza infection	[minor importance after influenza infection]	1.0	5	1	0	0
36178	1624	surrogate gamma'-chain	[surrogate gamma'-chain]	1.0	2	1	0	0
36179	1624	4 weeks.	[4 weeks.]	1.0	2	2	1	1
36180	1624	several subsets,	[several subsets,]	1.0	2	1	0	0
36181	1624	nonspecific esterase	[nonspecific esterase]	1.0	2	1	0	0
36182	1624	removal of the N-terminal amino acid	[removal of the N-terminal amino acids]	1.0	6	2	2	2
36183	1624	diverse (non-recurrent) tcr beta clonotype	[diverse (non-recurrent) TCR beta clonotypes]	1.0	5	1	0	0
36184	1624	dermal fibroblast	[dermal fibroblasts]	1.0	2	2	1	1
36185	1624	member of the CREB/ATF family	[members of the CREB/ATF family]	1.0	5	1	0	0
36186	1624	human b cell line skw6.4	[human B cell line SKW6.4]	1.0	5	1	0	0
36187	1624	s194 cell	[S194 cells]	1.0	2	2	1	1
36188	1624	fy*b promoter	[FY*B promoter]	1.0	2	1	0	0
36189	1624	two stages:	[two stages:]	1.0	2	2	2	2
36190	1624	occur in patient suffer from telangiectasia	[occurring in patients suffering from telangiectasia]	1.0	6	1	0	0
36191	1624	accurate evaluation of the prognostic importance	[accurate evaluation of the prognostic importance]	1.0	6	1	0	0
36192	1624	mouse b cell with igm	[mouse B cells with IgM]	1.0	5	1	0	0
36193	1624	growth, differentiation,	[growth, differentiation,]	1.0	2	2	1	1
36194	1624	ap1 formation	[AP1 formation]	1.0	2	1	0	0
36195	1624	GATA-1 a zinc-finger transcription factor	[GATA-1 a zinc-finger transcription factor]	1.0	5	1	0	0
36196	1624	flc to a reporter gene	[FLCs to a reporter gene]	1.0	5	1	0	0
36197	1624	B-1 cell	[B-1 cells]	1.0	2	1	0	0
36198	1624	follow activation of U937 promonocytic cell	[following activation of U937 promonocytic cells]	1.0	6	1	0	0
36199	1624	novel hiv-1 isolate contain alteration	[novel HIV-1 isolate containing alterations]	1.0	5	1	0	0
36200	1624	hallmark of terminal b differentiation	[hallmarks of terminal B differentiation]	1.0	5	1	0	0
36201	1624	GC box contain a site	[GC box containing a site]	1.0	5	1	0	0
36202	1624	activation of this transcription factor	[activation of this transcription factor]	1.0	5	2	1	1
36203	1624	mutation in this transcription factor	[Mutations in these transcription factors]	1.0	5	1	0	0
36204	1624	addition to nf-kappa b translocation	[addition to NF-kappa B translocation]	1.0	5	1	0	0
36205	1624	activity, DNA	[activity, DNA]	1.0	2	1	0	0
36206	1624	increase intracellular glutathione disulfide level	[increasing intracellular glutathione disulfide levels]	1.0	5	1	0	0
36207	1624	fetal development.	[fetal development.]	1.0	2	1	0	0
36208	1624	dense body	[dense bodies]	1.0	2	1	0	0
36209	1624	molecule such as bacterial endotoxin	[molecules such as bacterial endotoxin]	1.0	5	1	0	0
36210	1624	anti-proliferative activity	[anti-proliferative activity]	1.0	2	1	0	0
36211	1624	human tuberculosis	[human tuberculosis]	1.0	2	1	0	0
36212	1624	important insight into parasite survival strategy	[important insights into parasite survival strategies]	1.0	6	1	0	0
36213	1624	use a synthetic peptide substrate	[using a synthetic peptide substrate]	1.0	5	1	0	0
36214	1624	normal monocyte activation in patient	[normal monocyte activation in patients]	1.0	5	1	0	0
36215	1624	plasma il-1	[plasma IL-1]	1.0	2	1	0	0
36216	1624	second wave,	[second wave,]	1.0	2	1	0	0
36217	1624	brl 49653	[BRL 49653]	1.0	2	1	0	0
36218	1624	zebrafish pax-b	[zebrafish Pax-b]	1.0	2	1	0	0
36219	1624	10 fold	[10 fold]	1.0	2	1	0	0
36220	1624	human group	[human group]	1.0	2	1	0	0
36221	1624	vincristine resistance	[vincristine resistance]	1.0	2	1	0	0
36222	1624	prominent substrate	[prominent substrates]	1.0	2	1	0	0
36223	1624	zinc-finger primer	[zinc-finger primers]	1.0	2	1	0	0
36224	1624	complex structure	[complex structure]	1.0	2	2	2	2
36225	1624	48000 receptors,	[48,000 receptors,]	1.0	2	1	0	0
36226	1624	phorbol ester responsiveness of primate cytomegalovirus	[phorbol ester responsiveness of primate cytomegalovirus]	1.0	6	1	0	0
36227	1624	development factor	[development factor]	1.0	2	1	0	0
36228	1624	heterologous promoter.	[heterologous promoter.]	1.0	2	2	1	1
36229	1624	lytic cascade	[lytic cascade]	1.0	2	2	1	1
36230	1624	minimal effect on slp-76 function	[minimal effect on SLP-76 function]	1.0	5	1	0	0
36231	1624	human t-cell clone reactive with gc	[Human T-cell clones reactive with gC]	1.0	6	1	0	0
36232	1624	nonradioactive oligonucleotide	[nonradioactive oligonucleotides]	1.0	2	1	0	0
36233	1624	Fc gamma RI transcript level	[Fc gamma RI transcript levels]	1.0	5	1	0	0
36234	1624	Ciprofibrate a hypolipidaemic peroxisome proliferator	[Ciprofibrate an hypolipidaemic peroxisome proliferator]	1.0	5	1	0	0
36235	1624	stimulus-induced degradation	[stimulus-induced degradation]	1.0	2	1	0	0
36236	1624	apparently "nonresponsive"	[apparently "nonresponsive"]	1.0	2	1	0	0
36237	1624	human pro-interleukin-1beta	[human pro-interleukin-1beta]	1.0	2	1	0	0
36238	1624	association in reduction of symptom	[association in reduction of symptoms]	1.0	5	1	0	0
36239	1624	Heinz body	[Heinz bodies]	1.0	2	2	1	1
36240	1624	cellular composition	[cellular composition]	1.0	2	2	1	1
36241	1624	gamma-globin transcript	[gamma-globin transcripts]	1.0	2	1	0	0
36242	1624	activation of T cell LAT	[activation of T cells LAT]	1.0	5	1	0	0
36243	1624	functional architecture for antigen processing	[functional architecture for antigen processing]	1.0	5	1	0	0
36244	1624	induction of numerous cytokine promoter	[induction of numerous cytokine promoters]	1.0	5	1	0	0
36245	1624	exposure of rwleu-4 cell to vd3	[Exposure of RWLeu-4 cells to VD3]	1.0	6	1	0	0
36246	1624	survival factor	[survival factors]	1.0	2	2	2	2
36247	1624	Jun family member in T cell	[Jun family members in T cells]	1.0	6	1	0	0
36248	1624	542 bp	[542 bp]	1.0	2	1	0	0
36249	1624	defect in this cell line	[defect in this cell line]	1.0	5	1	0	0
36250	1624	similar response	[similar response]	1.0	2	2	2	2
36251	1624	tax expression in JPX9 cell	[Tax expression in JPX9 cells]	1.0	5	1	0	0
36252	1624	N-terminal portion	[N-terminal portion]	1.0	2	2	2	2
36253	1624	lps dose	[LPS dose]	1.0	2	1	0	0
36254	1624	Richter' syndrome	[Richter's syndrome]	1.0	2	1	0	0
36255	1624	amount of glucocorticoid receptor in lymphocyte	[amount of glucocorticoid receptors in lymphocytes]	1.0	6	1	0	0
36256	1624	mutation in a gene class transactivator	[mutations in a gene class transactivator]	1.0	6	1	0	0
36257	1624	progenitor proliferation in the spleen	[progenitor proliferation in the spleen]	1.0	5	1	0	0
36258	1624	t(15;17) translocation	[t(15;17) translocation]	1.0	2	2	2	2
36259	1624	induction of apoptosis of endothelial cell	[induction of apoptosis of endothelial cells]	1.0	6	1	0	0
36260	1624	hit cell	[HIT cells]	1.0	2	1	0	0
36261	1624	moreover, monocyte	[Moreover, monocytes]	1.0	2	1	0	0
36262	1624	intact x	[intact X]	1.0	2	1	0	0
36263	1624	intrapulmonary instillation of phosphonate-containing liposome	[intrapulmonary instillation of phosphonate-containing liposomes]	1.0	5	1	0	0
36264	1624	fra-1 rrna	[fra-1 mRNAs]	1.0	2	1	0	0
36265	1624	motor neuron	[motor neuron]	1.0	2	2	2	2
36266	1624	promoter/5'-flank contain the sre- binding site	[promoter/5'-flank containing the SRE- binding sites]	1.0	6	1	0	0
36267	1624	impaired response	[impaired responses]	1.0	2	2	2	2
36268	1624	appearance of the STAT1 factor	[Appearance of the STAT1 factor]	1.0	5	1	0	0
36269	1624	ebv immortalization of b cell	[EBV immortalization of B cells]	1.0	5	1	0	0
36270	1624	t-cell-specific enhancer	[T-cell-specific enhancer]	1.0	2	2	1	1
36271	1624	leukocyte integrin	[Leukocyte integrins]	1.0	2	2	1	1
36272	1624	repeat region	[repeat region]	1.0	2	2	2	2
36273	1624	30% reduction	[30% reduction]	1.0	2	1	0	0
36274	1624	receptor subunit	[receptor subunit]	1.0	2	2	2	2
36275	1624	methods: Eleven patient with ulcerative colitis	[METHODS: Eleven patients with ulcerative colitis]	1.0	6	1	0	0
36276	1624	skw cell	[SKW cells]	1.0	2	2	2	2
36277	1624	important limitations.	[important limitations.]	1.0	2	1	0	0
36278	1624	ifn-gamma-induced class ii gene expression	[IFN-gamma-induced class II gene expression]	1.0	5	1	0	0
36279	1624	17-bp sequence between position -51	[17-bp sequence between positions -51]	1.0	5	1	0	0
36280	1624	human monocytic thp 1 cell	[human monocytic THP 1 cells]	1.0	5	1	0	0
36281	1624	signal transduction in T lymphocyte	[signal transduction in T lymphocytes]	1.0	5	1	0	0
36282	1624	Exploration at the level of induction	[Exploration at the level of induction]	1.0	6	1	0	0
36283	1624	170-kd protein	[170-kD protein]	1.0	2	1	0	0
36284	1624	immunohistochemical evidence of low proliferative activity	[Immunohistochemical evidence of low proliferative activity]	1.0	6	1	0	0
36285	1624	Conversely, genistein another tyrosine kinase inhibitor	[Conversely, genistein another tyrosine kinase inhibitor]	1.0	6	1	0	0
36286	1624	2 expression	[2 expression]	1.0	2	2	2	2
36287	1624	two distinct promoter in monocytes/macrophages	[two distinct promoters in monocytes/macrophages]	1.0	5	1	0	0
36288	1624	polyamine in human breast cancer	[Polyamines in human breast cancer]	1.0	5	1	0	0
36289	1624	proliferative control	[proliferative control]	1.0	2	1	0	0
36290	1624	contrast, BA	[contrast, BA]	1.0	2	1	0	0
36291	1624	hemopoietic differentiation	[hemopoietic differentiation]	1.0	2	1	0	0
36292	1624	evasion of the impending immune response	[evasion of the impending immune response]	1.0	6	1	0	0
36293	1624	inhibitor of protein kinase C	[inhibitors of protein kinase C]	1.0	5	1	0	0
36294	1624	activate transcription with the W-X-Y	[activating transcription with the W-X-Y]	1.0	5	1	0	0
36295	1624	human I	[human I]	1.0	2	2	1	1
36296	1624	cd34+cd71+ cell	[CD34+CD71+ cells]	1.0	2	1	0	0
36297	1624	liver specimen	[Liver specimens]	1.0	2	1	0	0
36298	1624	NK cell in a ftoc	[NK cells in an FTOC]	1.0	5	1	0	0
36299	1624	human a	[human A]	1.0	2	1	0	0
36300	1624	production of matrix metalloproteinase 1	[production of matrix metalloproteinases 1]	1.0	5	1	0	0
36301	1624	nf-y protein	[NF-Y proteins]	1.0	2	1	0	0
36302	1624	pathological event of tuberculosis infection	[pathological events of tuberculosis infection]	1.0	5	1	0	0
36303	1624	contrast, out of 59 patient	[contrast, out of 59 patients]	1.0	5	1	0	0
36304	1624	binding site of transcription factor	[binding sites of transcription factors]	1.0	5	1	0	0
36305	1624	nonopsonic phagocytosis of pseudomonas aeruginosa	[Nonopsonic phagocytosis of Pseudomonas aeruginosa]	1.0	5	2	1	1
36306	1624	nucleotide -46	[nucleotide -46]	1.0	2	1	0	0
36307	1624	level relevant to human disease	[levels relevant to human disease]	1.0	5	1	0	0
36308	1624	single human tonsillar gc b cell	[single human tonsillar GC B cells]	1.0	6	1	0	0
36309	1624	normotensive volunteer with essential hypertension.	[normotensive volunteers with essential hypertension.]	1.0	5	1	0	0
36310	1624	use as a probe cysteamine	[Using as a probe cysteamine]	1.0	5	1	0	0
36311	1624	b lymphocyte responsive to 1 alpha,25(OH)2D3	[B lymphocytes responsive to 1 alpha,25(OH)2D3]	1.0	6	1	0	0
36312	1624	T lymphocyte activation by camp	[T lymphocyte activation by cAMP]	1.0	5	1	0	0
36313	1624	Staurosporine a nonspecific inhibitor of PKC	[Staurosporine a nonspecific inhibitor of PKC]	1.0	6	1	0	0
36314	1624	other cells,	[other cells,]	1.0	2	2	1	1
36315	1624	new era in biomedical research	[new era in biomedical research]	1.0	5	1	0	0
36316	1624	transactivate property of NF-kappa b	[transactivating properties of NF-kappa B]	1.0	5	1	0	0
36317	1624	reactivity of the target cell	[reactivity of the target cells]	1.0	5	1	0	0
36318	1624	incubation of jurkat cell with antisense,	[incubation of Jurkat cells with antisense,]	1.0	6	1	0	0
36319	1624	other abnormality of Y chromosome sequence	[other abnormalities of Y chromosome sequences]	1.0	6	1	0	0
36320	1624	E6 motif	[E6 motif]	1.0	2	2	2	2
36321	1624	non-hodgkin lymphoma exhibit plasmacytoid differentiation	[non-Hodgkin lymphomas exhibiting plasmacytoid differentiation]	1.0	5	1	0	0
36322	1624	interaction with the site-specific activator	[interaction with the site-specific activators]	1.0	5	1	0	0
36323	1624	DNA binding of ap-1 October	[DNA binding of AP-1 Oct]	1.0	5	1	0	0
36324	1624	suggest a multicomponent receptor model	[suggesting a multicomponent receptor model]	1.0	5	1	0	0
36325	1624	functional promoter in b lymphocyte	[functional promoters in B lymphocytes]	1.0	5	1	0	0
36326	1624	proteolytic activation of this zymogen	[proteolytic activation of this zymogen]	1.0	5	1	0	0
36327	1624	addition, transcriptional activity of il-2	[addition, transcriptional activity of IL-2]	1.0	5	1	0	0
36328	1624	IL-2 promoter -chloramphenicol acetyltransferase construct	[IL-2 promoter -chloramphenicol acetyltransferase constructs]	1.0	5	1	0	0
36329	1624	induce the viral lytic cycle	[inducing the viral lytic cycle]	1.0	5	1	0	0
36330	1624	activation of a protein phosphatase	[activation of a protein phosphatase]	1.0	5	1	0	0
36331	1624	include adhesion-dependent pathway of monocyte activation	[including adhesion-dependent pathways of monocyte activation]	1.0	6	1	0	0
36332	1624	indicate different aetiology for this disorders.	[indicating different aetiologies for these disorders.]	1.0	6	1	0	0
36333	1624	transcription of the il-6 gene	[transcription of the IL-6 gene]	1.0	5	1	0	0
36334	1624	activation of il-5 t-cell clone	[activation of IL-5 T-cell clones]	1.0	5	1	0	0
36335	1624	viral material	[viral material]	1.0	2	1	0	0
36336	1624	consensus binding site for p52	[consensus binding sites for p52]	1.0	5	1	0	0
36337	1624	AP-1 cytokine mrna expression, result	[AP-1 cytokine mRNA expression, results]	1.0	5	1	0	0
36338	1624	three sequence	[three sequences]	1.0	2	2	1	1
36339	1624	different subpopulation of t- lymphocyte	[different subpopulations of T- lymphocytes]	1.0	5	1	0	0
36340	1624	transient transfection.	[transient transfection.]	1.0	2	1	0	0
36341	1624	usually result from delta psi(m) collapse	[usually resulting from delta psi(m) collapse]	1.0	6	1	0	0
36342	1624	time- increase	[time- increases]	1.0	2	1	0	0
36343	1624	"spontaneous stimulation"	["spontaneous stimulation"]	1.0	2	1	0	0
36344	1624	erythroblastic progeny	[erythroblastic progeny]	1.0	2	2	2	2
36345	1624	follow cellular activation than control line	[following cellular activation than control lines]	1.0	6	1	0	0
36346	1624	t- all	[T- ALL]	1.0	2	1	0	0
36347	1624	down-regulation of ALY by anti-sense oligonucleotide	[down-regulation of ALY by anti-sense oligonucleotides]	1.0	6	1	0	0
36348	1624	renal disease	[renal disease]	1.0	2	2	2	2
36349	1624	transcription of a U2 rna(snrna)-encoding gene	[Transcription of a U2 RNA(snRNA)-encoding gene]	1.0	6	1	0	0
36350	1624	cytoplasmic pools.	[cytoplasmic pools.]	1.0	2	1	0	0
36351	1624	cell line in to group ii	[cell lines in to group II]	1.0	6	1	0	0
36352	1624	devd-p-nitroanilide (devd-pna)	[DEVD-p-nitroanilide (DEVD-pNA)]	1.0	2	1	0	0
36353	1624	essential component of the element	[essential component of the element]	1.0	5	1	0	0
36354	1624	12-o-tetradecanoyl 12-phorbol 13-acetate T cell	[12-O-tetradecanoyl 12-phorbol 13-acetate T cells]	1.0	5	1	0	0
36355	1624	contain chemically amino acid side chain	[containing chemically amino acid side chains]	1.0	6	1	0	0
36356	1624	0 degree	[0 degrees]	1.0	2	1	0	0
36357	1624	epitope-encoded sequence	[epitope-encoded sequences]	1.0	2	1	0	0
36358	1624	normoxic controls.	[normoxic controls.]	1.0	2	1	0	0
36359	1624	40% e-selectin	[40% E-selectin]	1.0	2	1	0	0
36360	1624	such cells, DNA binding activity	[such cells, DNA binding activity]	1.0	5	1	0	0
36361	1624	18 patient	[18 patients]	1.0	2	2	1	1
36362	1624	two most active nfat-like element	[two most active NFAT-like elements]	1.0	5	1	0	0
36363	1624	G1/S boundary	[G1/S boundary]	1.0	2	1	0	0
36364	1624	transactivation of the hiv LTR	[transactivation of the HIV LTR]	1.0	5	1	0	0
36365	1624	infiltrate a herpes simplex virus lesion	[infiltrating a herpes simplex virus lesion]	1.0	6	1	0	0
36366	1624	osteoclastic maturity	[osteoclastic maturity]	1.0	2	1	0	0
36367	1624	cDNA microarray	[cDNA microarrays]	1.0	2	1	0	0
36368	1624	urine catecholamine	[urine catecholamines]	1.0	2	1	0	0
36369	1624	2 week	[2 weeks]	1.0	2	1	0	0
36370	1624	high level in monocytoid u937	[high levels in monocytoid U937]	1.0	5	1	0	0
36371	1624	corticosteroid suppression of blood eosinophilia	[corticosteroid suppression of blood eosinophilia]	1.0	5	1	0	0
36372	1624	expression of t-cell growth factor	[expression of T-cell growth factor]	1.0	5	1	0	0
36373	1624	mapk 1)	[MAPK 1)]	1.0	2	1	0	0
36374	1624	tissue-specific expression of immunoglobulin gene	[tissue-specific expression of immunoglobulin genes]	1.0	5	1	0	0
36375	1624	avidity window	[avidity window]	1.0	2	1	0	0
36376	1624	promoter analysis of a iron-responsive element	[promoter analysis of an iron-responsive element]	1.0	6	1	0	0
36377	1624	interferon receptor	[interferon receptor]	1.0	2	2	1	1
36378	1624	MTHC system	[MTHC system]	1.0	2	1	0	0
36379	1624	3.8 kb) in all tissue	[3.8 kb) in all tissues]	1.0	5	1	0	0
36380	1624	activity complex	[activity complex]	1.0	2	2	2	2
36381	1624	difference in glucocorticoid receptor number	[difference in glucocorticoid receptor number]	1.0	5	1	0	0
36382	1624	MRP14 promoter	[MRP14 promoter]	1.0	2	2	2	2
36383	1624	design of the clinical trial	[design of the clinical trials]	1.0	5	1	0	0
36384	1624	co-activation of ca(2+) -dependent pathway	[co-activation of Ca(2+) -dependent pathways]	1.0	5	1	0	0
36385	1624	stimulation, b lymphocyte contain nf-kappa b	[stimulation, B lymphocytes containing NF-kappa B]	1.0	6	1	0	0
36386	1624	transcription factor in lineage commitment	[transcription factors in lineage commitment]	1.0	5	1	0	0
36387	1624	indicate due to the ability	[indicating due to the ability]	1.0	5	1	0	0
36388	1624	transcriptionally-active conformation in erythroid cell	[transcriptionally-active conformation in erythroid cells]	1.0	5	1	0	0
36389	1624	inversion inv14(q11;q32.1) with tcr alpha/beta loci	[inversions inv14(q11;q32.1) with TCR alpha/beta loci]	1.0	6	1	0	0
36390	1624	genetic program underlie monocytic differentiation	[genetic program underlying monocytic differentiation]	1.0	5	1	0	0
36391	1624	wild-type pp56(lck)	[wild-type pp56(lck)]	1.0	2	1	0	0
36392	1624	variety of kappa b site	[variety of kappa B sites]	1.0	5	1	0	0
36393	1624	use lysate from blin-1 cell	[using lysates from BLIN-1 cells]	1.0	5	1	0	0
36394	1624	finger region	[finger region]	1.0	2	1	0	0
36395	1624	biochemical change	[biochemical changes]	1.0	2	2	2	2
36396	1624	vivo regulation of the receptor	[vivo regulation of the receptor]	1.0	5	1	0	0
36397	1624	electrophoretic mobility of 80 kda	[electrophoretic mobility of 80 kDa]	1.0	5	1	0	0
36398	1624	epitope of the (ie62) protein	[epitopes of the (IE62) protein]	1.0	5	1	0	0
36399	1624	7-base-pair mutation	[7-base-pair mutation]	1.0	2	1	0	0
36400	1624	high level expression of mmtv	[high level expression of MMTV]	1.0	5	1	0	0
36401	1624	viral fragment	[viral fragment]	1.0	2	1	0	0
36402	1624	various protein	[various proteins]	1.0	2	2	2	2
36403	1624	transcription factor binding to the promoter	[transcription factor binding to the promoter]	1.0	6	1	0	0
36404	1624	certain cell type hela cell	[certain cell types HeLa cells]	1.0	5	1	0	0
36405	1624	47-bp sequence position -306 relative	[47-bp sequence positions -306 relative]	1.0	5	1	0	0
36406	1624	anti-CD40 up-regulation	[anti-CD40 up-regulation]	1.0	2	1	0	0
36407	1624	gata-2	[GATA-2]	1.0	1	11	2	2
36408	1624	il-6 mrna	[IL-6 mRNA]	1.0	2	2	1	1
36409	1624	icsat interferon consensus sequence binding protein	[ICSAT Interferon Consensus Sequence binding protein]	1.0	6	1	0	0
36410	1624	gr density	[GR density]	1.0	2	1	0	0
36411	1624	CYC1 promoter	[CYC1 promoter]	1.0	2	1	0	0
36412	1624	cd2-mediated interleukin-2	[CD2-mediated interleukin-2]	1.0	2	1	0	0
36413	1624	beta-catenin localize in the nucleus	[beta-catenin localizes in the nucleus]	1.0	5	1	0	0
36414	1624	target for this immunoregulatory hormone	[targets for this immunoregulatory hormone]	1.0	5	1	0	0
36415	1624	expression c-fo	[expression c-fos]	1.0	2	2	2	2
36416	1624	heterodimerizerizerizerizerizerizerizerizerizerize with thr in solution.	[heterodimerizing with THR in solution.]	1.0	5	1	0	0
36417	1624	subsequent dissociation of the NF-kappa B	[subsequent dissociation of the NF-kappa B]	1.0	6	1	0	0
36418	1624	hiv-infected pbmc with anti-cd2 mab	[HIV-infected PBMC with anti-CD2 mAb]	1.0	5	1	0	0
36419	1624	Site B	[Site B]	1.0	2	1	0	0
36420	1624	megakaryocytic-specific promoter	[megakaryocytic-specific promoter]	1.0	2	1	0	0
36421	1624	previous finding	[previous findings]	1.0	2	2	2	2
36422	1624	Site I	[Site I]	1.0	2	2	1	1
36423	1624	other species.	[other species.]	1.0	2	1	0	0
36424	1624	Cytokine IL-2	[Cytokine IL-2]	1.0	2	1	0	0
36425	1624	ligation of histocompatibility complex class	[ligation of histocompatibility complex class]	1.0	5	2	2	2
36426	1624	cellular level	[cellular levels]	1.0	2	3	2	1
36427	1624	(1) vzv gE protein coding sequence	[(1) VZV gE protein coding sequences]	1.0	6	1	0	0
36428	1624	metastatic ability	[metastatic ability]	1.0	2	1	0	0
36429	1624	(inactivated) prb	[(inactivated) pRB]	1.0	2	1	0	0
36430	1624	inhibition of Ie gene induction	[inhibition of IE gene induction]	1.0	5	1	0	0
36431	1624	secretory vesicle	[secretory vesicles]	1.0	2	1	0	0
36432	1624	lead to NF-kappaB activation by tax	[leading to NF-kappaB activation by Tax]	1.0	6	1	0	0
36433	1624	act on the IL-2 promoter element	[acting on the IL-2 promoter elements]	1.0	6	1	0	0
36434	1624	membrane protein of Epstein-Barr virus	[membrane protein of Epstein-Barr virus]	1.0	5	2	2	2
36435	1624	naive human helper T cell	[naive human helper T cells]	1.0	5	1	0	0
36436	1624	conserved, residue	[conserved, residues]	1.0	2	1	0	0
36437	1624	six line	[six lines]	1.0	2	2	2	2
36438	1624	anionic phosphatidylserine	[anionic phosphatidylserine]	1.0	2	1	0	0
36439	1624	expression of responsiveness to lps	[expression of responsiveness to LPS]	1.0	5	1	0	0
36440	1624	129 patient	[129 patients]	1.0	2	1	0	0
36441	1624	60 minute exposure to RA	[60 minutes exposure to RA]	1.0	5	1	0	0
36442	1624	lipopolysaccharide expression of inflammatory mediator	[lipopolysaccharide expression of inflammatory mediators]	1.0	5	1	0	0
36443	1624	optimal response to G(Anh)MTetra induction	[optimal response to G(Anh)MTetra induction]	1.0	5	1	0	0
36444	1624	certain cell upon heat shock	[certain cells upon heat shock]	1.0	5	1	0	0
36445	1624	mcp-1 gene	[MCP-1 gene]	1.0	2	1	0	0
36446	1624	calcium-dependent manner	[calcium-dependent manner]	1.0	2	1	0	0
36447	1624	cyclosporin a a cyclic undecapeptide	[cyclosporin A a cyclic undecapeptide]	1.0	5	1	0	0
36448	1624	clinical correlation.	[clinical correlation.]	1.0	2	1	0	0
36449	1624	critical component in the development	[critical component in the development]	1.0	5	1	0	0
36450	1624	apoptosis of nuclear factor kappab	[apoptosis of nuclear factor kappaB]	1.0	5	1	0	0
36451	1624	signal system	[signaling systems]	1.0	2	2	2	2
36452	1624	(1) karyotype	[(1) karyotype]	1.0	2	1	0	0
36453	1624	lymphocyte gcii	[lymphocyte GCII]	1.0	2	1	0	0
36454	1624	high level of ap-1 activity	[high levels of AP-1 activities]	1.0	5	1	0	0
36455	1624	good correlation between this inhibition	[good correlation between this inhibition]	1.0	5	1	0	0
36456	1624	infectious disease	[infectious diseases]	1.0	2	2	2	2
36457	1624	EBNA transcription	[EBNA transcription]	1.0	2	1	0	0
36458	1624	JNK transcriptional activation of AP-1	[JNK transcriptional activation of AP-1]	1.0	5	1	0	0
36459	1624	cytokine of apoptotic cell death	[cytokines of apoptotic cell death]	1.0	5	1	0	0
36460	1624	germline change	[germline changes]	1.0	2	1	0	0
36461	1624	human interleukin-13	[Human interleukin-13]	1.0	2	1	0	0
36462	1624	mpc11 plasmacytoma	[MPC11 plasmacytoma]	1.0	2	1	0	0
36463	1624	addition, monocyte	[addition, monocytes]	1.0	2	1	0	0
36464	1624	protein mad3/	[protein MAD3/]	1.0	2	1	0	0
36465	1624	leukemic cell of ATL patient	[leukemic cells of ATL patients]	1.0	5	1	0	0
36466	1624	400 microM.	[400 microM.]	1.0	2	1	0	0
36467	1624	dnase 1	[DNase 1]	1.0	2	2	1	1
36468	1624	essential hypertensive	[essential hypertensives]	1.0	2	1	0	0
36469	1624	regulation of expression of this gene	[regulation of expression of these genes]	1.0	6	1	0	0
36470	1624	binding of transcription factor AP-1	[binding of transcription factors AP-1]	1.0	5	1	0	0
36471	1624	same ec epitope bind specificity	[same EC epitope binding specificity]	1.0	5	1	0	0
36472	1624	dnase i	[DNase I]	1.0	2	1	0	0
36473	1624	dnase I	[DNase I]	1.0	2	2	1	1
36474	1624	downregulation of Wilms' tumor gene wt1	[Downregulation of Wilms' tumor gene WT1]	1.0	6	1	0	0
36475	1624	human mzf-2	[human MZF-2]	1.0	2	2	1	1
36476	1624	tumor necrosis factor-alpha tnf-alpha degradation	[tumor necrosis factor-alpha TNF-alpha degradation]	1.0	5	1	0	0
36477	1624	proportion of mature, TCRhigh thymocyte	[proportion of mature, TCRhigh thymocytes]	1.0	5	1	0	0
36478	1624	ligand fkbp12	[ligand FKBP12]	1.0	2	1	0	0
36479	1624	mechanism(s) of action of GCH	[mechanism(s) of action of GCH]	1.0	5	1	0	0
36480	1624	Spi-1/PU.1 proto-oncogene	[Spi-1/PU.1 proto-oncogene]	1.0	2	1	0	0
36481	1624	staT-dependent early response gene expression	[STAT-dependent early response gene expression]	1.0	5	1	0	0
36482	1624	early hematopoiesis	[early hematopoiesis]	1.0	2	2	1	1
36483	1624	th0-type human T cell clone	[Th0-type human T cell clones]	1.0	5	1	0	0
36484	1624	lamin c	[lamin C]	1.0	2	1	0	0
36485	1624	different molecular origin than contraction	[different molecular origin than contractions]	1.0	5	1	0	0
36486	1624	cell proliferation,	[cell proliferation,]	1.0	2	2	2	2
36487	1624	crucial signal	[crucial signals]	1.0	2	1	0	0
36488	1624	proviral genome	[proviral genome]	1.0	2	2	2	2
36489	1624	transcription of the endogenous the gene	[transcription of the endogenous the gene]	1.0	6	1	0	0
36490	1624	indicate dependent	[indicating dependent]	1.0	2	2	2	2
36491	1624	conservative surgery	[conservative surgery]	1.0	2	2	1	1
36492	1624	human irf-1	[human IRF-1]	1.0	2	1	0	0
36493	1624	human irf-2	[human IRF-2]	1.0	2	1	0	0
36494	1624	powerful activator of factor responsible	[powerful activators of factors responsible]	1.0	5	1	0	0
36495	1624	binding atf/creb	[binding ATF/CREB]	1.0	2	1	0	0
36496	1624	PEBP2 site	[PEBP2 site]	1.0	2	1	0	0
36497	1624	capacity of the cytosolic component	[capacity of the cytosolic component]	1.0	5	1	0	0
36498	1624	adhesion molecule-1 on endothelial cell	[adhesion molecule-1 on endothelial cells]	1.0	5	2	2	2
36499	1624	membrane-related response	[membrane-related responses]	1.0	2	1	0	0
36500	1624	4.5 kb	[4.5 kb]	1.0	2	1	0	0
36501	1624	beta 1 integrin with antibody	[beta 1 integrins with antibodies]	1.0	5	1	0	0
36502	1624	monocyte il-1ra secretion in vitro,	[monocyte IL-1ra secretion in vitro,]	1.0	5	1	0	0
36503	1624	diminish germline C epsilon transcription	[diminishing germline C epsilon transcription]	1.0	5	1	0	0
36504	1624	activation of Epstein-Barr virus ebv replication	[activation of Epstein-Barr virus EBV replication]	1.0	6	1	0	0
36505	1624	LTR variant	[LTR variants]	1.0	2	1	0	0
36506	1624	butylated hydroxytoluene	[butylated hydroxytoluene]	1.0	2	1	0	0
36507	1624	disrupt nf-kappa b signal in monocyte	[disrupting NF-kappa B signaling in monocytes]	1.0	6	1	0	0
36508	1624	up-regulation of rar(alpha) gene expression	[Up-regulation of RAR(alpha) gene expression]	1.0	5	1	0	0
36509	1624	cDNA cloning of a transcription factor	[cDNA cloning of a transcription factor]	1.0	6	1	0	0
36510	1624	prl response	[PRL response]	1.0	2	1	0	0
36511	1624	affect the glucocorticoid effector mechanism	[affecting the glucocorticoid effector mechanism]	1.0	5	1	0	0
36512	1624	cell-cycle analysis	[Cell-cycle analysis]	1.0	2	1	0	0
36513	1624	region/leucine zipper	[region/leucine zipper]	1.0	2	2	2	2
36514	1624	different set	[different set]	1.0	2	5	4	1
36515	1624	perturbation of the proliferation response	[perturbation of the proliferation response]	1.0	5	1	0	0
36516	1624	recent advance in transcriptional regulation	[recent advances in transcriptional regulation]	1.0	5	1	0	0
36517	1624	[3H]aldosterone -MBP-HBD	[[3H]aldosterone -MBP-HBD]	1.0	2	1	0	0
36518	1624	p45 nf-e2 expression in erythroid differentiation	[p45 NF-E2 expression in erythroid differentiation]	1.0	6	1	0	0
36519	1624	stat3 complex	[STAT3 complexes]	1.0	2	1	0	0
36520	1624	involve the addition of fos	[involving the addition of Fos]	1.0	5	1	0	0
36521	1624	interferon beta in T lymphocyte	[interferon beta in T lymphocytes]	1.0	5	1	0	0
36522	1624	antigenic challenge.	[antigenic challenge.]	1.0	2	1	0	0
36523	1624	many stimuli,	[many stimuli,]	1.0	2	1	0	0
36524	1624	cofactor for amino acid hydroxylase	[cofactor for amino acid hydroxylases]	1.0	5	1	0	0
36525	1624	role of cell surface molecule	[role of cell surface molecules]	1.0	5	1	0	0
36526	1624	beta-binding profile	[beta-binding profiles]	1.0	2	1	0	0
36527	1624	zap-70 responsiveness to expression of CD3	[ZAP-70 responsiveness to expression of CD3]	1.0	6	1	0	0
36528	1624	mitogenic response	[mitogenic response]	1.0	2	2	1	1
36529	1624	Jun family of transcription factor	[Jun families of transcription factors]	1.0	5	1	0	0
36530	1624	clinical use.	[clinical use.]	1.0	2	1	0	0
36531	1624	Recently, p57	[Recently, p57]	1.0	2	1	0	0
36532	1624	normal activation	[normal activation]	1.0	2	2	1	1
36533	1624	b Ad3	[B Ad3]	1.0	2	1	0	0
36534	1624	long a subject of controversy.	[long a subject of controversy.]	1.0	5	1	0	0
36535	1624	human abf-1	[human ABF-1]	1.0	2	1	0	0
36536	1624	intracellular signal molecule include tradd	[intracellular signaling molecules including TRADD]	1.0	5	1	0	0
36537	1624	promoter region (-508 to -501).	[promoter region (-508 to -501).]	1.0	5	1	0	0
36538	1624	antigen-specific tolerance in T lymphocyte	[antigen-specific tolerance in T lymphocytes]	1.0	5	1	0	0
36539	1624	NF-kappa b p65 -dependent transcriptional activation	[NF-kappa B p65 -dependent transcriptional activation]	1.0	6	1	0	0
36540	1624	gel shift assay study with oligonucleotide	[Gel shift assay studies with oligonucleotides]	1.0	6	1	0	0
36541	1624	maintenance of the T cell phenotype	[maintenance of the T cell phenotype]	1.0	6	1	0	0
36542	1624	erythroid mrna	[erythroid mRNA]	1.0	2	1	0	0
36543	1624	transactivation of kappa b reporter construct	[transactivation of kappa B reporter constructs]	1.0	6	1	0	0
36544	1624	kappa b gamma isoform with property	[kappa B gamma isoforms with properties]	1.0	6	1	0	0
36545	1624	ROS pathway	[ROS pathway]	1.0	2	1	0	0
36546	1624	moreover, supernatant from dep-pah-activated cell	[Moreover, supernatants from DEP-PAH-activated cells]	1.0	5	1	0	0
36547	1624	induce g1 cell cycle arrest	[inducing G1 cell cycle arrest]	1.0	5	1	0	0
36548	1624	distinct gene	[distinct genes]	1.0	2	2	2	2
36549	1624	small-bowel resection in ileostomized patient	[Small-bowel resection in ileostomized patients]	1.0	5	1	0	0
36550	1624	unidentified estrogen	[unidentified estrogen]	1.0	2	1	0	0
36551	1624	15 patient with ss control	[15 patients with SS controls]	1.0	5	1	0	0
36552	1624	suggest a role for ras upstream	[suggesting a role for ras upstream]	1.0	6	1	0	0
36553	1624	amount of constitutive nf-kappa b	[amount of constitutive NF-kappa B]	1.0	5	1	0	0
36554	1624	two different negative regulatory pathway	[two different negative regulatory pathways]	1.0	5	1	0	0
36555	1624	same experiments,	[same experiments,]	1.0	2	1	0	0
36556	1624	binding of the 65-kDa heterodimer	[Binding of the 65-kDa heterodimer]	1.0	5	1	0	0
36557	1624	multiple criterion	[multiple criteria]	1.0	2	1	0	0
36558	1624	bind specificity of the protein	[binding specificity of the protein]	1.0	5	1	0	0
36559	1624	distal signal	[distal signals]	1.0	2	1	0	0
36560	1624	butyrate esterase	[butyrate esterase]	1.0	2	1	0	0
36561	1624	significant sequence homology to SWI3	[significant sequence homology to SWI3]	1.0	5	1	0	0
36562	1624	il-18 receptor	[IL-18 receptor]	1.0	2	1	0	0
36563	1624	IFN synthesis to hiv-1 -infected cell	[IFN synthesis to HIV-1 -infected cells]	1.0	6	1	0	0
36564	1624	DNA sequence contain a core 5'-ggaa-3'	[DNA sequences containing a core 5'-GGAA-3']	1.0	6	1	0	0
36565	1624	genetic counseling	[genetic counseling]	1.0	2	1	0	0
36566	1624	mAb g28-5	[mAb G28-5]	1.0	2	2	1	1
36567	1624	wild-type tax	[wild-type Tax]	1.0	2	1	0	0
36568	1624	irregular menstruation	[irregular menstruations]	1.0	2	1	0	0
36569	1624	135-(oh)2d3 regulation	[1,25-(OH)2D3 regulation]	1.0	2	1	0	0
36570	1624	alpha globin	[alpha globin]	1.0	2	2	2	2
36571	1624	PMA (with	[PMA (with]	1.0	2	1	0	0
36572	1624	binding to the gas-motif sequence	[binding to the GAS-motif sequences]	1.0	5	1	0	0
36573	1624	Deletional analysis	[Deletional analysis]	1.0	2	2	1	1
36574	1624	contain various length in a region	[containing various lengths in a region]	1.0	6	1	0	0
36575	1624	characterization of the CD48 gene	[Characterization of the CD48 gene]	1.0	5	1	0	0
36576	1624	lymphoid-specific factor	[lymphoid-specific factor]	1.0	2	2	2	2
36577	1624	serine 32	[serines 32]	1.0	2	1	0	0
36578	1624	alpha TNF-alpha	[alpha TNF-alpha]	1.0	2	1	0	0
36579	1624	inhibition of T cell activation	[Inhibition of T cell activation]	1.0	5	2	1	1
36580	1624	two kind	[two kinds]	1.0	2	2	1	1
36581	1624	T cell recognition of specific peptide	[T cell recognition of specific peptides]	1.0	6	1	0	0
36582	1624	expression of the acid receptor	[expression of the acid receptors]	1.0	5	2	1	1
36583	1624	human monocyte cell line thp-1	[human monocyte cell line THP-1]	1.0	5	1	0	0
36584	1624	human erythroleukemia cell line k562	[human erythroleukemia cell line K562]	1.0	5	1	0	0
36585	1624	developmental expression	[developmental expression]	1.0	2	1	0	0
36586	1624	sequence variation in the 3' utr	[sequence variations in the 3' UTR]	1.0	6	1	0	0
36587	1624	KOX 1-32	[KOX 1-32]	1.0	2	1	0	0
36588	1624	alteration in NF kappab family protein	[alterations in NF kappaB family proteins]	1.0	6	1	0	0
36589	1624	hormone receptor protein in cell	[hormone receptor proteins in cells]	1.0	5	1	0	0
36590	1624	restoration of content of t- lymphocyte	[restoration of content of T- lymphocytes]	1.0	6	1	0	0
36591	1624	early bud	[Early buds]	1.0	2	1	0	0
36592	1624	U1B formation	[U1B formation]	1.0	2	1	0	0
36593	1624	post-translational regulation	[post-translational regulation]	1.0	2	1	0	0
36594	1624	19-bp element	[19-bp element]	1.0	2	1	0	0
36595	1624	similar upregulation of 12-lipoxygenase activity	[similar upregulation of 12-lipoxygenase activity]	1.0	5	1	0	0
36596	1624	icam-1 upregulation	[ICAM-1 upregulation]	1.0	2	1	0	0
36597	1624	varicella vaccination	[varicella vaccination]	1.0	2	1	0	0
36598	1624	average by 6.8%) during MPE	[average by 6.8%) during MPE]	1.0	5	1	0	0
36599	1624	transcriptional activity of the igh enhancer	[transcriptional activity of the IgH enhancer]	1.0	6	1	0	0
36600	1624	gene enhancer	[gene enhancer]	1.0	2	2	2	2
36601	1624	cell of the nervous system	[cells of the nervous system]	1.0	5	2	1	1
36602	1624	overlapping activity on human T cell	[overlapping activities on human T cells]	1.0	6	1	0	0
36603	1624	post-gc b-cells,	[post-GC B-cells,]	1.0	2	1	0	0
36604	1624	difference in expression of tnf receptor	[differences in expression of TNF receptors]	1.0	6	1	0	0
36605	1624	stimulation of monocytic cell with lps	[stimulation of monocytic cells with LPS]	1.0	6	1	0	0
36606	1624	number of immunoregulatory gene IL-1beta	[number of immunoregulatory genes IL-1beta]	1.0	5	1	0	0
36607	1624	-533 basis from translation start site	[-533 bases from translation start site]	1.0	6	1	0	0
36608	1624	endocrine compartment	[endocrine compartment]	1.0	2	1	0	0
36609	1624	include cytokine	[including cytokines]	1.0	2	2	2	2
36610	1624	considerable increase in c-fo protein expression	[considerable increases in c-Fos protein expression]	1.0	6	1	0	0
36611	1624	insertion of this chimeric promoter upstream	[Insertion of this chimeric promoter upstream]	1.0	6	1	0	0
36612	1624	cd8+ t-lymphocyte	[CD8+ T-lymphocytes]	1.0	2	2	2	2
36613	1624	serine 61	[serine 61]	1.0	2	1	0	0
36614	1624	five group	[five groups]	1.0	2	1	0	0
36615	1624	h1-antagonist pyrilamine	[H1-antagonists pyrilamine]	1.0	2	1	0	0
36616	1624	belong to the signal transducer	[belonging to the signal transducer]	1.0	5	1	0	0
36617	1624	expression of the antibody-encoding gene	[expression of the antibody-encoding genes]	1.0	5	1	0	0
36618	1624	suppress tyrosine phosphorylation of stat1	[suppressing tyrosine phosphorylation of STAT1]	1.0	5	1	0	0
36619	1624	Retrospective study	[Retrospective study]	1.0	2	1	0	0
36620	1624	engagement of the T cell receptor	[Engagement of the T cell receptor]	1.0	6	1	0	0
36621	1624	homologous serum,	[homologous serum,]	1.0	2	1	0	0
36622	1624	evidence for various genetic defect	[evidence for various genetic defects]	1.0	5	1	0	0
36623	1624	regulatory region of b cell-specific gene	[regulatory regions of B cell-specific genes]	1.0	6	1	0	0
36624	1624	sodium in HML without incubation	[sodium in HML without incubation]	1.0	5	1	0	0
36625	1624	erythroid-specific activation	[erythroid-specific activation]	1.0	2	1	0	0
36626	1624	IL-4 expression	[IL-4 expression]	1.0	2	2	1	1
36627	1624	regulation of transcription factor belong	[regulation of transcription factors belonging]	1.0	5	1	0	0
36628	1624	gr level with age activity	[GR levels with age activity]	1.0	5	1	0	0
36629	1624	contrast to the enhancer-dependent effect	[contrast to the enhancer-dependent effect]	1.0	5	1	0	0
36630	1624	amino acid sequence of all protein	[Amino acid sequences of all proteins]	1.0	6	1	0	0
36631	1624	recent characterization	[recent characterization]	1.0	2	1	0	0
36632	1624	selective blockade of granulocytic differentiation	[selective blockade of granulocytic differentiation]	1.0	5	1	0	0
36633	1624	ru-486 p	[RU-486 P]	1.0	2	1	0	0
36634	1624	normal virus-immortalized human b cell	[normal virus-immortalized human B cells]	1.0	5	1	0	0
36635	1624	early region 1a reiteration mutant	[early region 1A reiteration mutants]	1.0	5	1	0	0
36636	1624	sequence, glu-asp-gly-lys-lys-phe-asp	[sequence, Glu-Asp-Gly-Lys-Lys-Phe-Asp]	1.0	2	1	0	0
36637	1624	potent stimulator of the MLR	[potent stimulators of the MLR]	1.0	5	1	0	0
36638	1624	xp-b cell	[XP-B cells]	1.0	2	1	0	0
36639	1624	heavy-chain locus	[heavy-chain locus]	1.0	2	1	0	0
36640	1624	contain GAL4 DNA binding site	[containing GAL4 DNA binding sites]	1.0	5	1	0	0
36641	1624	control the development of the disease	[controlling the development of the disease.]	1.0	6	1	0	0
36642	1624	NF-kappa b activation by antioxidant	[NF-kappa B activation by antioxidants]	1.0	5	1	0	0
36643	1624	adult-type profile	[adult-type profile]	1.0	2	1	0	0
36644	1624	ras transformation	[Ras transformation]	1.0	2	2	2	2
36645	1624	monocyte arrest	[Monocyte arrest]	1.0	2	2	2	2
36646	1624	granulocyte- macrophage colony-stimumulatelany-stg factor gm-csf	[granulocyte- macrophage colony-stimulating factor GM-CSF]	1.0	5	1	0	0
36647	1624	succinimide derivative of this peptide	[succinimide derivative of this peptide]	1.0	5	1	0	0
36648	1624	recruitment of EKLF to 5'HS3	[recruitment of EKLF to 5'HS3]	1.0	5	2	1	1
36649	1624	Nuclear factor of T cell nfat	[Nuclear factor of T cells NFAT]	1.0	6	1	0	0
36650	1624	increase the amount of CAT mrna	[increasing the amount of CAT mRNA]	1.0	6	1	0	0
36651	1624	immune activity	[immune activity]	1.0	2	1	0	0
36652	1624	half-maximal activation	[half-maximal activation]	1.0	2	1	0	0
36653	1624	transcription of hiv-1 in T cell	[transcription of HIV-1 in T cells]	1.0	6	1	0	0
36654	1624	subcellular localization of pkc isoenzyme	[subcellular localization of PKC isoenzymes]	1.0	5	1	0	0
36655	1624	protein secretion of il-6 in pbmc	[protein secretion of IL-6 in PBMCs]	1.0	6	1	0	0
36656	1624	tal-1 transcription	[TAL-1 transcription]	1.0	2	2	1	1
36657	1624	ig gene class switch recombination.	[Ig gene class switch recombination.]	1.0	5	1	0	0
36658	1624	great than 10-fold low activity.	[greater than 10-fold lower activity.]	1.0	5	1	0	0
36659	1624	calcium -dependent dephosphorylation of nfat	[calcium -dependent dephosphorylation of NFAT]	1.0	5	1	0	0
36660	1624	specific decrease in the dna-binding activity	[specific decrease in the DNA-binding activity]	1.0	6	1	0	0
36661	1624	abnormal clone	[abnormal clone]	1.0	2	1	0	0
36662	1624	nuclear factor kappa b NFkappaB	[nuclear factor kappa B NFkappaB]	1.0	5	1	0	0
36663	1624	convey protection against a apoptotic signal	[conveying protection against an apoptotic signal]	1.0	6	1	0	0
36664	1624	mitochondrial respiration	[mitochondrial respiration]	1.0	2	1	0	0
36665	1624	treatment of the cell with ionomycin	[Treatment of the cells with ionomycin]	1.0	6	1	0	0
36666	1624	serine/threonine kinase	[serine/threonine kinases]	1.0	2	1	0	0
36667	1624	gr -dependent transcription in HeLa cell	[GR -dependent transcription in HeLa cells]	1.0	6	1	0	0
36668	1624	gh (except in one obese patient	[GH (except in one obese patient]	1.0	6	1	0	0
36669	1624	form of transcription factor creb	[forms of transcription factor CREB]	1.0	5	2	2	2
36670	1624	mechanism regulate immunodeficiency virus persistence	[mechanisms regulating immunodeficiency virus persistence]	1.0	5	2	1	1
36671	1624	orphan receptor	[orphan receptor]	1.0	2	1	0	0
36672	1624	ebv-immortalised b-cell	[EBV-immortalised B-cells]	1.0	2	1	0	0
36673	1624	contrast, priming under that condition	[contrast, priming under those conditions]	1.0	5	1	0	0
36674	1624	condition of chronic kidney insufficiency	[conditions of chronic kidney insufficiency]	1.0	5	1	0	0
36675	1624	critical serine residue of IkappaB	[critical serine residues of IkappaB]	1.0	5	1	0	0
36676	1624	mechanism of down-regulation of icam-1	[mechanism of down-regulation of ICAM-1]	1.0	5	1	0	0
36677	1624	activity of p70(s6k) a response	[activity of p70(s6k) a response]	1.0	5	1	0	0
36678	1624	However, result of intracellular staining	[However, results of intracellular staining]	1.0	5	1	0	0
36679	1624	monocytic cell by cryptococcus neoforman	[monocytic cells by Cryptococcus neoformans]	1.0	5	1	0	0
36680	1624	gene expression at early stage	[gene expression at early stages]	1.0	5	1	0	0
36681	1624	replication cycle	[replication cycle]	1.0	2	2	2	2
36682	1624	AITL /GC	[AITL /GC]	1.0	2	1	0	0
36683	1624	effect on nuclear factor activation	[effect on nuclear factor activation]	1.0	5	1	0	0
36684	1624	ribosomal complex	[ribosomal complex]	1.0	2	1	0	0
36685	1624	h2o2 nf-kappab activation in Wurzburg cell	[H2O2 NF-kappaB activation in Wurzburg cells]	1.0	6	1	0	0
36686	1624	three systems.	[three systems.]	1.0	2	1	0	0
36687	1624	use a double immunostaining technique	[using a double immunostaining technique]	1.0	5	1	0	0
36688	1624	lipopolysaccharide cell	[lipopolysaccharide cells]	1.0	2	1	0	0
36689	1624	splice variant	[splice variant]	1.0	2	2	2	2
36690	1624	circulate hormone concentration in blood	[circulating hormone concentrations in blood]	1.0	5	1	0	0
36691	1624	nonreceptor tyrosine	[nonreceptor tyrosine]	1.0	2	1	0	0
36692	1624	c-jun transcription by okadaic acid	[c-jun transcription by okadaic acid]	1.0	5	1	0	0
36693	1624	oral cavity	[oral cavity]	1.0	2	1	0	0
36694	1624	isoform Pax-5d	[Isoforms Pax-5d]	1.0	2	1	0	0
36695	1624	heterozygous female	[heterozygous females]	1.0	2	1	0	0
36696	1624	isoform Pax-5b	[Isoforms Pax-5b]	1.0	2	1	0	0
36697	1624	u1 u1a/u1b	[U1 U1A/U1B]	1.0	2	1	0	0
36698	1624	antithyroid drug	[antithyroid drugs]	1.0	2	1	0	0
36699	1624	member of the nfat group	[member of the NFAT group]	1.0	5	1	0	0
36700	1624	expression of endothelial adhesion molecule	[expression of endothelial adhesion molecules]	1.0	5	1	0	0
36701	1624	a protein	[A protein]	1.0	2	2	2	2
36702	1624	activation of specific functional program	[activation of specific functional programs]	1.0	5	1	0	0
36703	1624	electrophoretic mobility shift eems) analysis	[electrophoretic mobility shift (EMS) analyses]	1.0	5	1	0	0
36704	1624	v3 loop	[V3 loop]	1.0	2	2	2	2
36705	1624	gene transcription in the context	[gene transcription in the context]	1.0	5	1	0	0
36706	1624	alkylaryl polyether alcohol polymer detergent	[alkylaryl polyether alcohol polymer detergent]	1.0	5	1	0	0
36707	1624	New strategy	[New strategies]	1.0	2	1	0	0
36708	1624	SL3-3 murine leukemia retroviruse mlv	[SL3-3 murine leukemia retroviruses MLVs]	1.0	5	1	0	0
36709	1624	response to GM-CSF in pmn	[response to GM-CSF in PMN]	1.0	5	1	0	0
36710	1624	lps lps	[LPS LPS]	1.0	2	1	0	0
36711	1624	member of the RFX family	[member of the RFX family]	1.0	5	1	0	0
36712	1624	exposure to a stimulus lipopolysaccharide	[exposure to a stimulus lipopolysaccharide]	1.0	5	1	0	0
36713	1624	functionally distinct isoform of stat5	[functionally distinct isoforms of STAT5]	1.0	5	1	0	0
36714	1624	role of this cell population	[role of this cell population]	1.0	5	1	0	0
36715	1624	overexpression of the catalytic subunit	[overexpression of the catalytic subunit]	1.0	5	2	1	1
36716	1624	25 uncomplicated pregnancy by measurement	[25 uncomplicated pregnancies by measurement]	1.0	5	1	0	0
36717	1624	tolerance induction in T cell	[tolerance induction in T cells]	1.0	5	1	0	0
36718	1624	human retinoblastoma	[human retinoblastoma]	1.0	2	1	0	0
36719	1624	78-nucleotide segment	[78-nucleotide segment]	1.0	2	1	0	0
36720	1624	induction of intercellular adhesion molecule-1 ICAM-1	[induction of intercellular adhesion molecule-1 ICAM-1]	1.0	6	1	0	0
36721	1624	different condition	[different conditions]	1.0	2	2	2	2
36722	1624	10000 time	[10,000 times]	1.0	2	1	0	0
36723	1624	inhibition of protein kinase activation	[inhibition of protein kinase activation]	1.0	5	1	0	0
36724	1624	affect elongation more than the initiation	[affecting elongation more than the initiation]	1.0	6	1	0	0
36725	1624	induction of a factor bind	[induction of an factor binding]	1.0	5	1	0	0
36726	1624	increase in lt biologic activity	[increase in LT biologic activity]	1.0	5	1	0	0
36727	1624	regulatory task	[regulatory tasks]	1.0	2	1	0	0
36728	1624	ap1 -dependent reporter construct (ic50	[AP1 -dependent reporter constructs (IC50]	1.0	5	1	0	0
36729	1624	dephosphorylation by in vitro treatment	[Dephosphorylation by in vitro treatment]	1.0	5	1	0	0
36730	1624	absence of tumor necrosis factor-alpha	[absence of tumor necrosis factor-alpha]	1.0	5	1	0	0
36731	1624	laser scanning	[laser scanning]	1.0	2	2	1	1
36732	1624	human mammary	[human mammary]	1.0	2	1	0	0
36733	1624	mammalian tissue	[mammalian tissues]	1.0	2	1	0	0
36734	1624	human csf-1	[human CSF-1]	1.0	2	1	0	0
36735	1624	form virus (sffv) envelope glycoprotein	[forming virus (SFFV) envelope glycoprotein]	1.0	5	1	0	0
36736	1624	p less	[p less]	1.0	2	2	2	2
36737	1624	interleukin 2 receptor alpha-chain il-2r alpha	[interleukin 2 receptor alpha-chain IL-2R alpha]	1.0	6	1	0	0
36738	1624	murine embryonic stem (es) cell	[murine embryonic stem (ES) cells]	1.0	5	1	0	0
36739	1624	single agent	[single agents]	1.0	2	1	0	0
36740	1624	rante expression in T lymphocyte	[RANTES expression in T lymphocytes]	1.0	5	1	0	0
36741	1624	as in Jurkat T lymphoma cell	[as in Jurkat T lymphoma cells]	1.0	6	1	0	0
36742	1624	susceptibility to a productive infection	[susceptibility to a productive infection]	1.0	5	1	0	0
36743	1624	pu.1 promoter	[PU.1 promoter]	1.0	2	2	1	1
36744	1624	same subjects.	[same subjects.]	1.0	2	1	0	0
36745	1624	major depressive disorder MDD in adolescent	[Major depressive disorder MDD in adolescents]	1.0	6	1	0	0
36746	1624	selective kappa b binding site	[selective kappa B binding sites]	1.0	5	1	0	0
36747	1624	Specific antibody	[Specific antibodies]	1.0	2	1	0	0
36748	1624	selective inhibition of pkc enzymatic activity	[selective inhibition of PKC enzymatic activity]	1.0	6	1	0	0
36749	1624	only hiv1	[only HIV1]	1.0	2	1	0	0
36750	1624	exogenous il-4	[Exogenous IL-4]	1.0	2	1	0	0
36751	1624	exogenous il-6	[exogenous IL-6]	1.0	2	1	0	0
36752	1624	monoclonal antibody bz1 to BZLF1	[monoclonal antibody BZ1 to BZLF1]	1.0	5	1	0	0
36753	1624	mononuclear cell from healthy subject	[mononuclear cells from healthy subjects]	1.0	5	1	0	0
36754	1624	strong tyrosine phosphorylation of stat4	[strong tyrosine phosphorylation of STAT4]	1.0	5	1	0	0
36755	1624	further analysis of this cells,	[further analysis of these cells,]	1.0	5	1	0	0
36756	1624	physiological concentrations,	[physiological concentrations,]	1.0	2	1	0	0
36757	1624	phosphorylation of il-4 stat stat6	[phosphorylation of IL-4 STAT STAT6]	1.0	5	1	0	0
36758	1624	promoter/enhancer region	[promoter/enhancer region]	1.0	2	1	0	0
36759	1624	new type	[new type]	1.0	2	1	0	0
36760	1624	stimulus-dependent cd44 transcription in b	[stimulus-dependent CD44 transcription in B]	1.0	5	1	0	0
36761	1624	prl stimulation	[PRL stimulation]	1.0	2	2	1	1
36762	1624	mitogenic lectins	[mitogenic lectins]	1.0	2	2	1	1
36763	1624	binding activity in nuclear extract	[binding activity in nuclear extracts]	1.0	5	2	1	1
36764	1624	herpes simplex virus icp27 protein	[herpes simplex virus ICP27 protein]	1.0	5	1	0	0
36765	1624	pathologic, result in tissue fibrosis	[pathologic, resulting in tissue fibrosis]	1.0	5	1	0	0
36766	1624	drosophila homeodomain	[Drosophila homeodomain]	1.0	2	1	0	0
36767	1624	Antioxidant-mediated inhibition of cytokine production	[Antioxidant-mediated inhibition of cytokine production]	1.0	5	1	0	0
36768	1624	anti-mhc class ii antibody Ab	[anti-MHC class II antibodies Ab]	1.0	5	1	0	0
36769	1624	infection, tnf	[infection, TNF]	1.0	2	1	0	0
36770	1624	same extent	[same extent]	1.0	2	3	2	1
36771	1624	response to corticotropin-releasing hormone crh	[response to corticotropin-releasing hormone CRH]	1.0	5	1	0	0
36772	1624	skin sample	[skin samples]	1.0	2	2	1	1
36773	1624	variant peptide	[variant peptide]	1.0	2	1	0	0
36774	1624	constitutive expression of c-myb mrna	[constitutive expression of c-myb mRNA]	1.0	5	1	0	0
36775	1624	human keratinocyte HaCaT cell line	[human keratinocytes HaCaT cell line]	1.0	5	1	0	0
36776	1624	subfamily of zinc finger protein	[subfamily of zinc finger proteins]	1.0	5	1	0	0
36777	1624	transcription through the p sequence	[transcription through the P sequence]	1.0	5	1	0	0
36778	1624	3' portion	[3' portion]	1.0	2	2	1	1
36779	1624	creb binding	[CREB binding]	1.0	2	2	2	2
36780	1624	human monocytic m-csf receptor promoter	[human monocytic M-CSF receptor promoter]	1.0	5	1	0	0
36781	1624	polymerase ii	[polymerase II]	1.0	2	2	1	1
36782	1624	physiological concentrations;	[physiological concentrations;]	1.0	2	1	0	0
36783	1624	expression of a single tal1 allele	[expression of a single TAL1 allele]	1.0	6	1	0	0
36784	1624	more than one molecular mechanism	[more than one molecular mechanism]	1.0	5	1	0	0
36785	1624	endogenous gc production express sialoadhesin	[endogenous GC production express sialoadhesin]	1.0	5	1	0	0
36786	1624	study gene regulation of the h(+)-atpase	[studying gene regulation of the H(+)-ATPase]	1.0	6	1	0	0
36787	1624	loss of DNA binding activity	[loss of DNA binding activity]	1.0	5	1	0	0
36788	1624	hormone constitutively	[hormone constitutively]	1.0	2	1	0	0
36789	1624	indirect interaction	[indirect interaction]	1.0	2	1	0	0
36790	1624	phorbol ester mononuclear cell differentiation	[Phorbol ester mononuclear cell differentiation]	1.0	5	1	0	0
36791	1624	tnf-alpha icam-1 transcription in cell	[TNF-alpha ICAM-1 transcription in cells]	1.0	5	1	0	0
36792	1624	Serum ACTH	[Serum ACTH]	1.0	2	1	0	0
36793	1624	Cp/Wp promoter	[Cp/Wp promoter]	1.0	2	1	0	0
36794	1624	means of rhodamine 123 staining	[means of rhodamine 123 staining]	1.0	5	1	0	0
36795	1624	well-known il-2 -dependent cell transformation	[well-known IL-2 -dependent cell transformation]	1.0	5	1	0	0
36796	1624	central role initiate t-cell activation	[central role initiating T-cell activation]	1.0	5	1	0	0
36797	1624	tetanus toxoid antigen-specific T cell proliferation	[tetanus toxoid antigen-specific T cell proliferation]	1.0	6	1	0	0
36798	1624	infectious molecular clone of HTLV-II	[infectious molecular clone of HTLV-II]	1.0	5	1	0	0
36799	1624	pma/bt2camp-treated cell	[PMA/Bt2cAMP-treated cells]	1.0	2	1	0	0
36800	1624	undergo apoptosis after serum withdrawal	[undergoing apoptosis after serum withdrawal]	1.0	5	1	0	0
36801	1624	young individual	[young individuals]	1.0	2	1	0	0
36802	1624	92 kda	[92 kDa]	1.0	2	1	0	0
36803	1624	ebv-positive effusion lymphoma cell line	[EBV-positive effusion lymphoma cell lines]	1.0	5	1	0	0
36804	1624	composite motif	[composite motif]	1.0	2	1	0	0
36805	1624	human atherosclerosis	[human atherosclerosis]	1.0	2	1	0	0
36806	1624	ems analysis utilize a series	[EMS analyses utilizing a series]	1.0	5	1	0	0
36807	1624	developmental regulation of hemoglobin switch	[developmental regulation of hemoglobin switching]	1.0	5	1	0	0
36808	1624	type-ii estrogen -binding site type-II EBS	[Type-II estrogen -binding sites type-II EBS]	1.0	6	1	0	0
36809	1624	(p 0.001).	[(P 0.001).]	1.0	2	1	0	0
36810	1624	important site	[important site]	1.0	2	2	2	2
36811	1624	Nuclear factor kappa B NFkappaB	[Nuclear Factor kappa B NFkappaB]	1.0	5	1	0	0
36812	1624	potentiate il-3 commitment of eml cell	[potentiating IL-3 commitment of EML cells]	1.0	6	1	0	0
36813	1624	macromolecular synthesis	[macromolecular synthesis]	1.0	2	2	1	1
36814	1624	protein production,	[protein production,]	1.0	2	1	0	0
36815	1624	multi-agent therapy	[multi-agent therapy]	1.0	2	1	0	0
36816	1624	important feature	[important feature]	1.0	2	2	2	2
36817	1624	antiviral protein	[antiviral proteins]	1.0	2	1	0	0
36818	1624	RIC GIRE	[RIC GIRE]	1.0	2	1	0	0
36819	1624	beta-galactoside-binding lectin	[beta-galactoside-binding lectin]	1.0	2	2	1	1
36820	1624	ventilatory response	[ventilatory response]	1.0	2	1	0	0
36821	1624	mouse thymus cDNA expression library	[mouse thymus cDNA expression library]	1.0	5	1	0	0
36822	1624	addition to the cd11b gene	[addition to the CD11b gene]	1.0	5	1	0	0
36823	1624	various signal	[Various signals]	1.0	2	2	2	2
36824	1624	requirement of the individual e-box	[requirements of the individual E-boxes]	1.0	5	1	0	0
36825	1624	inhibitory effect,	[inhibitory effect,]	1.0	2	1	0	0
36826	1624	[125i]-aldosterone derivative	[[125I]-aldosterone derivative]	1.0	2	1	0	0
36827	1624	arachidonic acid,	[arachidonic acid,]	1.0	2	1	0	0
36828	1624	protease pathway	[protease pathways]	1.0	2	1	0	0
36829	1624	limit amount of the coactivator cbp	[limiting amounts of the coactivator CBP]	1.0	6	1	0	0
36830	1624	typical seminoma	[typical seminoma]	1.0	2	1	0	0
36831	1624	more than 900 normal x-chromosomes	[more than 900 normal X-chromosomes]	1.0	5	1	0	0
36832	1624	factor oap	[factors OAP]	1.0	2	1	0	0
36833	1624	gtp-bound ras in anti- ras immunoprecipitate	[GTP-bound Ras in anti- Ras immunoprecipitates]	1.0	6	1	0	0
36834	1624	large family	[large family]	1.0	2	2	1	1
36835	1624	Initial signal through the CD4 receptor	[Initial signaling through the CD4 receptor]	1.0	6	1	0	0
36836	1624	induction by glucocorticoid by ifn-beta	[Induction by glucocorticoids by IFN-beta]	1.0	5	1	0	0
36837	1624	gene in anti-CD3-activated human T lymphocyte	[genes in anti-CD3-activated human T lymphocytes]	1.0	6	1	0	0
36838	1624	NFAT sequence	[NFAT sequence]	1.0	2	1	0	0
36839	1624	single BCS	[single BCS]	1.0	2	1	0	0
36840	1624	nuclear factor of T lymphocyte nfat	[nuclear factor of T lymphocytes NFAT]	1.0	6	1	0	0
36841	1624	hsf inhibition	[HSF inhibition]	1.0	2	1	0	0
36842	1624	closely related DNA bind specificity	[closely related DNA binding specificity]	1.0	5	1	0	0
36843	1624	T cell receptor beta gene	[T cell receptor beta genes]	1.0	5	1	0	0
36844	1624	further examination	[Further examination]	1.0	2	2	1	1
36845	1624	CHO-DR/ B7 LFA-3 triple transfectant	[CHO-DR/ B7 LFA-3 triple transfectant]	1.0	5	1	0	0
36846	1624	clear-cut defect in the synthesis	[clear-cut defects in the synthesis]	1.0	5	1	0	0
36847	1624	heterogeneity of the intrafollicular t-cell population	[heterogeneity of the intrafollicular T-cell population]	1.0	6	1	0	0
36848	1624	c-fm proto-oncogent	[c-fms proto-oncogenes]	1.0	2	1	0	0
36849	1624	Wilms' tumor suppressor gene WT1	[Wilms' tumor suppressor gene WT1]	1.0	5	1	0	0
36850	1624	rodent plasmacytoma	[rodent plasmacytomas]	1.0	2	1	0	0
36851	1624	2 T helper cell cytokine production	[2 T helper cell cytokine production]	1.0	6	1	0	0
36852	1624	effect on glucocorticoid receptor (gr)	[effects on glucocorticoid receptor (GR)]	1.0	5	1	0	0
36853	1624	influence expression	[influencing expression]	1.0	2	2	2	2
36854	1624	virtually all hiv- hd express	[virtually all HIV- HD express]	1.0	5	1	0	0
36855	1624	rapidak gradually accumulating, long-lasting tyrosine	[rapid, gradually accumulating, long-lasting tyrosine]	1.0	5	1	0	0
36856	1624	cd34+ hpc	[CD34+ HPC]	1.0	2	2	2	2
36857	1624	remodeling of promoter chromatin structure result	[remodeling of promoter chromatin structure resulting]	1.0	6	1	0	0
36858	1624	transcription-enhancer region	[transcription-enhancer region]	1.0	2	1	0	0
36859	1624	p65 subunit of NF-kappa b	[p65 subunit of NF-kappa B]	1.0	5	1	0	0
36860	1624	-130 site	[-130 site]	1.0	2	1	0	0
36861	1624	4.3 pts; fluticasone: 2.4 1.55 pts)	[4.3 pts; fluticasone: 2.4 1.55 pts)]	1.0	6	1	0	0
36862	1624	helper activity for IgE synthesis	[helper activity for IgE synthesis]	1.0	5	1	0	0
36863	1624	function of the HTLV-I enhancer	[function of the HTLV-I enhancer]	1.0	5	1	0	0
36864	1624	normal pbl	[normal PBL]	1.0	2	2	2	2
36865	1624	normal pbm	[normal PBM]	1.0	2	1	0	0
36866	1624	characterization of the nuclear component	[Characterization of the nuclear components]	1.0	5	1	0	0
36867	1624	contrast, v-myb	[contrast, v-myb]	1.0	2	1	0	0
36868	1624	p100 inhibition of rela function	[p100 inhibition of RelA function]	1.0	5	1	0	0
36869	1624	Addition of GM-CSF to this cocktail	[Addition of GM-CSF to this cocktail]	1.0	6	1	0	0
36870	1624	regulation of glucocorticoid receptor (gr) expression	[Regulation of glucocorticoid receptor (GR) expression]	1.0	6	1	0	0
36871	1624	contrast, lps	[contrast, LPS]	1.0	2	1	0	0
36872	1624	Threonine 78	[Threonine 78]	1.0	2	1	0	0
36873	1624	previous example.	[previous example.]	1.0	2	1	0	0
36874	1624	granulocyte-macrophage colony stimulate factor gm-csf	[Granulocyte-macrophage colony stimulating factor GM-CSF]	1.0	5	1	0	0
36875	1624	novel step in the activation	[novel step in the activation]	1.0	5	1	0	0
36876	1624	binding of ubiquitous ap-1 factor	[binding of ubiquitous AP-1 factors]	1.0	5	1	0	0
36877	1624	DNA of cord blood lymphocyte	[DNA of cord blood lymphocytes]	1.0	5	1	0	0
36878	1624	thrombin platelet	[thrombin platelets]	1.0	2	1	0	0
36879	1624	(gc) b-cell of cd3/cd4+ T cell	[(GC) B-cells of CD3/CD4+ T cells]	1.0	6	1	0	0
36880	1624	only MCR	[Only MCR]	1.0	2	1	0	0
36881	1624	Skeletal myogenesis	[Skeletal myogenesis]	1.0	2	1	0	0
36882	1624	second enhancer	[second enhancer]	1.0	2	2	1	1
36883	1624	incubation transform growth factor beta	[incubation transforming growth factor beta]	1.0	5	1	0	0
36884	1624	transcription factor in T cell	[transcription factors in T cells]	1.0	5	1	0	0
36885	1624	primary (partial) cortisol receptor resistance	[Primary (partial) cortisol receptor resistance]	1.0	5	1	0	0
36886	1624	125i-labeled aldosterone	[125I-labeled aldosterone]	1.0	2	1	0	0
36887	1624	megakaryocytic pathway	[megakaryocytic pathway]	1.0	2	2	1	1
36888	1624	differential staining,	[differential staining,]	1.0	2	1	0	0
36889	1624	initial interaction	[initial interaction]	1.0	2	1	0	0
36890	1624	hematopoietic-specific gene	[hematopoietic-specific gene]	1.0	2	1	0	0
36891	1624	single ap-2- like consensus sequence	[single AP-2- like consensus sequences]	1.0	5	1	0	0
36892	1624	basis for the discordant expression	[basis for the discordant expression]	1.0	5	1	0	0
36893	1624	glucocorticoid autoregulation of gr expression	[glucocorticoid autoregulation of GR expression]	1.0	5	1	0	0
36894	1624	tacrolimus fk-506	[tacrolimus FK-506]	1.0	2	1	0	0
36895	1624	NK cell with mutant tnfri	[NK cells with mutant TNFRI]	1.0	5	1	0	0
36896	1624	mcp-1 expression in human monocyte	[MCP-1 expression in human monocytes]	1.0	5	1	0	0
36897	1624	emergence of nuclear binding protein	[emergence of nuclear binding proteins]	1.0	5	1	0	0
36898	1624	tcr )/cd3	[TCR )/CD3]	1.0	2	1	0	0
36899	1624	nuclear factor-kappaB a transcriptional activator	[nuclear factor-kappaB a transcriptional activator]	1.0	5	1	0	0
36900	1624	example intracellular glucocorticoid receptor hGR	[example intracellular glucocorticoid receptors hGR]	1.0	5	1	0	0
36901	1624	one approach	[one approach]	1.0	2	1	0	0
36902	1624	body burden of 2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[body burdens of 2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	1.0	5	1	0	0
36903	1624	other, E(gre)	[other, E(gre)]	1.0	2	1	0	0
36904	1624	cells, member	[cells, members]	1.0	2	1	0	0
36905	1624	transcription factor as target for signalling	[Transcription factors as targets for signalling]	1.0	6	1	0	0
36906	1624	contrast, camp in the presence	[contrast, cAMP in the presence]	1.0	5	1	0	0
36907	1624	DNA binding activity of nf-kappab	[DNA binding activity of NF-kappaB]	1.0	5	1	0	0
36908	1624	molecular mechanism of rante expression	[molecular mechanisms of RANTES expression]	1.0	5	1	0	0
36909	1624	blood pb	[blood PB]	1.0	2	2	2	2
36910	1624	T cell produce the regulating protein	[T cells producing the regulating proteins]	1.0	6	1	0	0
36911	1624	hemin-mediated differentiation	[hemin-mediated differentiation]	1.0	2	2	2	2
36912	1624	IL2R alpha	[IL2R alpha]	1.0	2	1	0	0
36913	1624	Glucocorticoid resistance in chronic asthma	[Glucocorticoid resistance in chronic asthma]	1.0	5	1	0	0
36914	1624	single stimulus,	[single stimulus,]	1.0	2	1	0	0
36915	1624	gene coding for a transcript	[gene coding for a transcript]	1.0	5	1	0	0
36916	1624	structural alteration in T cell	[structural alterations in T cells]	1.0	5	1	0	0
36917	1624	blood cell in normal individual	[blood cells in normal individuals]	1.0	5	1	0	0
36918	1624	biological relevance of the observation	[biological relevance of the observation]	1.0	5	1	0	0
36919	1624	indicate cell-specific difference in transactivation	[indicating cell-specific differences in transactivation]	1.0	5	1	0	0
36920	1624	transcription of a number of genes,	[transcription of a number of genes,]	1.0	6	1	0	0
36921	1624	simultaneously, DHEA	[simultaneously, DHEA]	1.0	2	1	0	0
36922	1624	growth retardation	[growth retardation]	1.0	2	1	0	0
36923	1624	tnf-related apoptosis	[TNF-related apoptosis]	1.0	2	1	0	0
36924	1624	life-table analysis	[Life-table analysis]	1.0	2	1	0	0
36925	1624	intracellular thiol	[intracellular thiols]	1.0	2	1	0	0
36926	1624	5 mM	[5 mM]	1.0	2	1	0	0
36927	1624	induction of VCAM-1 mrna by TNF	[induction of VCAM-1 mRNA by TNF]	1.0	6	1	0	0
36928	1624	important role influence differential expression	[important role influencing differential expression]	1.0	5	1	0	0
36929	1624	specific signal	[specific signaling]	1.0	2	2	2	2
36930	1624	interleukin-1beta-converting enzyme family protease inhibitor	[interleukin-1beta-converting enzyme family protease inhibitors]	1.0	5	2	1	1
36931	1624	non-irradiated cell of x-ray cell	[non-irradiated cells of X-ray cells]	1.0	5	1	0	0
36932	1624	Study of the ring chromosome	[Studies of the ring chromosome]	1.0	5	1	0	0
36933	1624	5 mg	[5 mg]	1.0	2	1	0	0
36934	1624	many year	[many years]	1.0	2	2	1	1
36935	1624	pre- values.	[pre- values.]	1.0	2	1	0	0
36936	1624	Spi-1 oncogene	[Spi-1 oncogene]	1.0	2	2	2	2
36937	1624	T lymphocyte through antigen receptor	[T lymphocytes through antigen receptor]	1.0	5	1	0	0
36938	1624	critical hormone.	[critical hormone.]	1.0	2	1	0	0
36939	1624	early peak	[early peak]	1.0	2	1	0	0
36940	1624	microg/ml)/mn2+ (50 microM) for 2 h	[microg/ml)/Mn2+ (50 microM) for 2 h]	1.0	6	1	0	0
36941	1624	own ability	[own ability]	1.0	2	1	0	0
36942	1624	murine retroviruse	[murine retroviruses]	1.0	2	1	0	0
36943	1624	activation of mature b cell	[Activation of mature B cells]	1.0	5	1	0	0
36944	1624	lymphocytic cell	[lymphocytic cells]	1.0	2	2	2	2
36945	1624	promoter selectivity	[promoter selectivity]	1.0	2	1	0	0
36946	1624	epo factor	[EPO factor]	1.0	2	2	2	2
36947	1624	morphological stage	[morphological stages]	1.0	2	1	0	0
36948	1624	modulation of endogenous il-1 beta	[Modulation of endogenous IL-1 beta]	1.0	5	1	0	0
36949	1624	c-fo proto-oncogent	[c-fos proto-oncogenes]	1.0	2	1	0	0
36950	1624	activation of the ikappab kinase alpha	[activation of the IkappaB kinase alpha]	1.0	6	1	0	0
36951	1624	low expression of interleukin-2 il-2	[low expression of interleukin-2 IL-2]	1.0	5	1	0	0
36952	1624	red cell gene like globin	[red cell genes like globin]	1.0	5	1	0	0
36953	1624	change depend on the particular combination	[changing depending on the particular combination]	1.0	6	1	0	0
36954	1624	undetectable follow consolidation with chemotherapy	[undetectable following consolidation with chemotherapy]	1.0	5	1	0	0
36955	1624	value from L- MPL rat	[values from L- MPL rats]	1.0	5	1	0	0
36956	1624	various degree of androgen insensitivity	[various degrees of androgen insensitivity]	1.0	5	1	0	0
36957	1624	occur at a dose of microM.	[occurring at a dose of microM.]	1.0	6	1	0	0
36958	1624	TF complex	[TF complex]	1.0	2	2	1	1
36959	1624	critical role cause cellular transformation	[critical role causing cellular transformation]	1.0	5	1	0	0
36960	1624	binding to the nfat motif	[binding to the NFAT motif]	1.0	5	1	0	0
36961	1624	high frequency of germ-line brca2 mutation	[High frequency of germ-line BRCA2 mutations]	1.0	6	1	0	0
36962	1624	low mobility ap-1 binding activity	[low mobility AP-1 binding activity]	1.0	5	1	0	0
36963	1624	activation of the IKK complex	[activation of the IKK complex]	1.0	5	1	0	0
36964	1624	inhibition of the pkc activity	[inhibition of the PKC activity]	1.0	5	1	0	0
36965	1624	er mrna by reverse transcription	[ER mRNA by reverse transcription]	1.0	5	1	0	0
36966	1624	human g-csfr	[human G-CSFR]	1.0	2	1	0	0
36967	1624	(23.1%, p	[(23.1%, P]	1.0	2	1	0	0
36968	1624	Thus, EBNA-2 transactivation of LMP1	[Thus, EBNA-2 transactivation of LMP1]	1.0	5	1	0	0
36969	1624	NF-E1 expression	[NF-E1 expression]	1.0	2	1	0	0
36970	1624	non-genomic event	[non-genomic events]	1.0	2	1	0	0
36971	1624	il-1 nf-kappa b -dependent gene transcription	[IL-1 NF-kappa B -dependent gene transcription]	1.0	6	1	0	0
36972	1624	two subdomain	[two subdomains]	1.0	2	1	0	0
36973	1624	wehi 7.2	[WEHI 7.2]	1.0	2	1	0	0
36974	1624	activator of transcription of transformation,	[activator of transcription of transformation,]	1.0	5	1	0	0
36975	1624	disruption of the PEBP2/CBF site	[Disruption of the PEBP2/CBF site]	1.0	5	1	0	0
36976	1624	engagement of cd15 on monocyte	[engagement of CD15 on monocytes]	1.0	5	1	0	0
36977	1624	express a defective hiv virus	[expressing a defective HIV virus]	1.0	5	1	0	0
36978	1624	same cultures.	[same cultures.]	1.0	2	1	0	0
36979	1624	virtue of affinity for CAML	[virtue of affinity for CAML]	1.0	5	1	0	0
36980	1624	stimulation of CD40 signal pathway	[stimulation of CD40 signaling pathways]	1.0	5	1	0	0
36981	1624	lai replication	[LAI replication]	1.0	2	3	2	1
36982	1624	jun/fo early response gene expression	[jun/fos early response gene expression]	1.0	5	1	0	0
36983	1624	hla-dm function	[HLA-DM function]	1.0	2	1	0	0
36984	1624	case of ige hyperimmunoglobulin e	[cases of IgE hyperimmunoglobulin E]	1.0	5	1	0	0
36985	1624	Anti-immunoglobulin m	[Anti-immunoglobulin M]	1.0	2	1	0	0
36986	1624	participation of the upstream regulatory element	[participation of the upstream regulatory element]	1.0	6	1	0	0
36987	1624	abnormal karyotype	[abnormal karyotypes]	1.0	2	1	0	0
36988	1624	lung interstitium	[lung interstitium]	1.0	2	1	0	0
36989	1624	m22 130tl-as	[M22 130TL-AS]	1.0	2	1	0	0
36990	1624	ribonucleoproteins Ro(SSA)	[ribonucleoproteins Ro(SSA)]	1.0	2	1	0	0
36991	1624	complete understanding	[complete understanding]	1.0	2	1	0	0
36992	1624	mediate responsiveness	[mediating responsiveness]	1.0	2	2	2	2
36993	1624	regulatory mechanism of vcam-1 induction	[regulatory mechanisms of VCAM-1 induction]	1.0	5	1	0	0
36994	1624	functional cooperation	[functional cooperation]	1.0	2	2	2	2
36995	1624	numerous cellular abnormality in immune regulation	[Numerous cellular abnormalities in immune regulation]	1.0	6	1	0	0
36996	1624	apoptotic vascular smooth muscle cell	[apoptotic vascular smooth muscle cells]	1.0	5	1	0	0
36997	1624	target molecule	[target molecules]	1.0	2	1	0	0
36998	1624	size discrepancy	[size discrepancy]	1.0	2	1	0	0
36999	1624	awareness of avascular necrosis of bone	[awareness of avascular necrosis of bone]	1.0	6	1	0	0
37000	1624	physiological state	[physiological state]	1.0	2	1	0	0
37001	1624	stimulation of monocyte by IFN	[stimulation of monocytes by IFN]	1.0	5	1	0	0
37002	1624	preexisting, T	[preexisting, T]	1.0	2	1	0	0
37003	1624	nf-kappabp65 than patient without complication	[NF-kappaBp65 than patients without complications]	1.0	5	1	0	0
37004	1624	primary cultures.	[primary cultures.]	1.0	2	1	0	0
37005	1624	1 promoter	[1 promoter]	1.0	2	1	0	0
37006	1624	monocyte cell	[monocyte cell]	1.0	2	2	1	1
37007	1624	dm genes,	[DM genes,]	1.0	2	1	0	0
37008	1624	IL-2 responsiveness on the other hand,	[IL-2 responsiveness on the other hand,]	1.0	6	1	0	0
37009	1624	fetal bovine	[fetal bovine]	1.0	2	1	0	0
37010	1624	result from the deficient activity	[resulting from the deficient activity]	1.0	5	1	0	0
37011	1624	terminal granulocytic differentiation of mpro promyelocyte	[terminal granulocytic differentiation of MPRO promyelocytes]	1.0	6	1	0	0
37012	1624	immunodominant peptide	[immunodominant peptide]	1.0	2	2	2	2
37013	1624	lytic transition of Epstein-Barr virus	[lytic transition of Epstein-Barr virus]	1.0	5	2	1	1
37014	1624	acid phosphatase	[acid phosphatase]	1.0	2	2	1	1
37015	1624	mechanism accounting for the response	[mechanisms accounting for the responses]	1.0	5	1	0	0
37016	1624	Effect of glucocorticoid in rheumatoid arthritis	[Effects of glucocorticoids in rheumatoid arthritis]	1.0	6	1	0	0
37017	1624	TPA-GR synergism	[TPA-GR synergism]	1.0	2	1	0	0
37018	1624	monocyte adhesion to ecv304 cell	[monocyte adhesion to ECV304 cells]	1.0	5	1	0	0
37019	1624	identical karyotype	[identical karyotype]	1.0	2	1	0	0
37020	1624	potent inducer of CD38 expression	[potent inducer of CD38 expression]	1.0	5	1	0	0
37021	1624	region( of the steroid receptor	[region(s) of the steroid receptor]	1.0	5	1	0	0
37022	1624	32-34 kda protein in lymphocyte	[32-34 kDa protein in lymphocytes]	1.0	5	1	0	0
37023	1624	progressive infection.	[progressive infection.]	1.0	2	1	0	0
37024	1624	use the K562 cell line	[using the K562 cell line]	1.0	5	1	0	0
37025	1624	pulse-chase experiment	[pulse-chase experiments]	1.0	2	1	0	0
37026	1624	mrna assay	[mRNA assay]	1.0	2	1	0	0
37027	1624	abnormal nfkappab activation after stimulation	[Abnormal NFkappaB activation after stimulation]	1.0	5	1	0	0
37028	1624	monocyte count	[monocyte counts]	1.0	2	1	0	0
37029	1624	activation express t-cell leukemia virus type	[activation expressing T-cell leukemia virus type]	1.0	6	1	0	0
37030	1624	least creb-	[least CREB-]	1.0	2	1	0	0
37031	1624	solution structure of a homeodomain	[Solution structure of a homeodomain]	1.0	5	2	1	1
37032	1624	Rel protein	[Rel proteins]	1.0	2	1	0	0
37033	1624	defective hiv-1	[defective HIV-1]	1.0	2	1	0	0
37034	1624	state of maturation of monocyte	[state of maturation of monocytes]	1.0	5	1	0	0
37035	1624	il-10 receptor	[IL-10 receptor]	1.0	2	2	2	2
37036	1624	new nomenclature for IFN gene	[new nomenclature for IFN genes]	1.0	5	1	0	0
37037	1624	flow cytometry,	[flow cytometry,]	1.0	2	2	1	1
37038	1624	strictly erythroid-specific property in vitro	[strictly erythroid-specific properties in vitro]	1.0	5	1	0	0
37039	1624	natural killer cell T lymphocyte function	[natural killer cell T lymphocyte functions]	1.0	6	1	0	0
37040	1624	CD4 accessory	[CD4 accessory]	1.0	2	2	2	2
37041	1624	nodular lymphocyte predominance hodgkin' disease	[nodular lymphocyte predominance Hodgkin's disease]	1.0	5	1	0	0
37042	1624	contrast to the wild type,	[contrast to the wild type,]	1.0	5	1	0	0
37043	1624	30 min,	[30 min,]	1.0	2	1	0	0
37044	1624	three mouse strain C57BL/10SnJ [h-2b]	[Three mouse strains C57BL/10SnJ [H-2b]]	1.0	5	1	0	0
37045	1624	305 +/-	[305 +/-]	1.0	2	1	0	0
37046	1624	different domain of the pp56(lck) molecule	[different domains of the pp56(lck) molecule]	1.0	6	1	0	0
37047	1624	c-Rel subunit	[c-Rel subunits]	1.0	2	1	0	0
37048	1624	id-3l protein	[Id-3L protein]	1.0	2	1	0	0
37049	1624	further definition of this pathway	[Further definition of this pathway]	1.0	5	1	0	0
37050	1624	retinoic acid during neutrophil maturation	[retinoic acid during neutrophil maturation]	1.0	5	1	0	0
37051	1624	significant correlation between the degree	[significant correlation between the degree]	1.0	5	1	0	0
37052	1624	property of very early stage cell	[properties of very early stage cells]	1.0	6	1	0	0
37053	1624	functional domain of the protein	[functional domains of the protein]	1.0	5	2	1	1
37054	1624	6 gene	[6 genes]	1.0	2	1	0	0
37055	1624	intracellular homology	[intracellular homology]	1.0	2	1	0	0
37056	1624	immunohistochemical study of c-fos-positive lymphocyte	[Immunohistochemical study of c-fos-positive lymphocytes]	1.0	5	1	0	0
37057	1624	Tax1 activation	[Tax1 activation]	1.0	2	1	0	0
37058	1624	cDNA clone for the alas isozyme	[cDNA clones for the ALAS isozyme]	1.0	6	1	0	0
37059	1624	high quality	[high quality]	1.0	2	1	0	0
37060	1624	responsive promoter	[responsive promoters]	1.0	2	1	0	0
37061	1624	new insight into the pathogenesis	[new insights into the pathogenesis]	1.0	5	1	0	0
37062	1624	"adult" pattern	["adult" pattern]	1.0	2	1	0	0
37063	1624	transcription of the nf-il6 gene	[transcription of the NF-IL6 gene]	1.0	5	1	0	0
37064	1624	basic leucine zipper (bzip) dna-binding	[basic leucine zipper (bZIP) DNA-binding]	1.0	5	1	0	0
37065	1624	different signal transducing pathway lead	[different signal transducing pathways leading]	1.0	5	1	0	0
37066	1624	previously unrecognized form of leukemia	[previously unrecognized form of leukemia]	1.0	5	2	1	1
37067	1624	ACT-1 site	[ACT-1 site]	1.0	2	1	0	0
37068	1624	protein kinase c activator PMA	[protein kinase C activator PMA]	1.0	5	1	0	0
37069	1624	squamous epithelium	[squamous epithelium]	1.0	2	1	0	0
37070	1624	anti-Jun abs	[anti-Jun Abs]	1.0	2	1	0	0
37071	1624	serum level of endogenous cortisol	[serum levels of endogenous cortisol]	1.0	5	1	0	0
37072	1624	two-color immunohistochemistry	[Two-color immunohistochemistry]	1.0	2	1	0	0
37073	1624	unique terminus	[unique terminus]	1.0	2	1	0	0
37074	1624	htlv-1-transformed cell	[HTLV-1-transformed cells]	1.0	2	1	0	0
37075	1624	B-cell nature	[B-cell nature]	1.0	2	1	0	0
37076	1624	interleukin-13 IL-13	[interleukin-13 IL-13]	1.0	2	2	1	1
37077	1624	bovine fkbp	[bovine FKBP]	1.0	2	2	1	1
37078	1624	use the streptoavidin -biotin peroxidase method	[using the streptoavidin -biotin peroxidase method]	1.0	6	1	0	0
37079	1624	Bcl-6 protein	[Bcl-6 protein]	1.0	2	1	0	0
37080	1624	hepatocyte factor	[hepatocyte factor]	1.0	2	2	2	2
37081	1624	pyrrolidine dithiocarbamate a potent inhibitor	[Pyrrolidine dithiocarbamate a potent inhibitor]	1.0	5	1	0	0
37082	1624	r-responsive element in HeLa cell	[R-responsive element in HeLa cells]	1.0	5	1	0	0
37083	1624	follow differentiation	[following differentiation]	1.0	2	2	1	1
37084	1624	difference in glucocorticoid receptor expression	[differences in glucocorticoid receptor expression]	1.0	5	1	0	0
37085	1624	injection of sea to adult mouse	[Injection of SEA to adult mice]	1.0	6	1	0	0
37086	1624	tnf stimulation	[TNF stimulation]	1.0	2	1	0	0
37087	1624	cases, induction of gene transcription	[cases, induction of gene transcription]	1.0	5	1	0	0
37088	1624	response to different extracellular signal	[response to different extracellular signals]	1.0	5	1	0	0
37089	1624	functional mutant	[functional mutants]	1.0	2	1	0	0
37090	1624	variable degree	[variable degree]	1.0	2	2	1	1
37091	1624	high radiosensitivity.	[high radiosensitivity.]	1.0	2	1	0	0
37092	1624	simultaneous treatment of the cell	[simultaneous treatment of the cells]	1.0	5	1	0	0
37093	1624	early induction of stat protein	[early induction of STAT proteins]	1.0	5	1	0	0
37094	1624	tumor necrosis factor-alpha -responsive element	[tumor necrosis factor-alpha -responsive elements]	1.0	5	1	0	0
37095	1624	UT-7 epo	[UT-7 Epo]	1.0	2	1	0	0
37096	1624	number of AML1 /eto transcript	[number of AML1 /ETO transcripts]	1.0	5	1	0	0
37097	1624	wild-type p53	[wild-type p53]	1.0	2	1	0	0
37098	1624	hiv-1 promoter-enhancer	[HIV-1 promoter-enhancer]	1.0	2	1	0	0
37099	1624	2 day	[2 days]	1.0	2	1	0	0
37100	1624	position 1	[position 1]	1.0	2	1	0	0
37101	1624	ikappab-alpha protein	[IkappaB-alpha protein]	1.0	2	1	0	0
37102	1624	upregulation of human epsilon germline transcription	[upregulation of human epsilon germline transcription]	1.0	6	1	0	0
37103	1624	presence of multiple creb isoform	[presence of multiple CREB isoforms]	1.0	5	1	0	0
37104	1624	tar -independent transactivation of hiv-1 transcription	[TAR -independent transactivation of HIV-1 transcription]	1.0	6	2	1	1
37105	1624	NF-kappaB p65	[NF-kappaB p65]	1.0	2	1	0	0
37106	1624	NF-AT4 mrna	[NF-AT4 mRNA]	1.0	2	1	0	0
37107	1624	similar time course in induction	[similar time course in induction]	1.0	5	1	0	0
37108	1624	tissue-specific structure	[tissue-specific structure]	1.0	2	2	1	1
37109	1624	il-13 expression of cd23 class	[IL-13 expression of CD23 class]	1.0	5	1	0	0
37110	1624	-express human fibroblastic human cell	[-expressing human fibroblastic human cells]	1.0	5	1	0	0
37111	1624	mrna stabilization in dox cell	[mRNA stabilization in DOX cells]	1.0	5	1	0	0
37112	1624	other reactive oxygen species ROS	[other reactive oxygen species ROS]	1.0	5	1	0	0
37113	1624	transfection into Nb2 T cell	[transfection into Nb2 T cells]	1.0	5	1	0	0
37114	1624	thereby link Grb2 sh3-binding protein sos1	[thereby linking Grb2 SH3-binding proteins SOS1]	1.0	6	1	0	0
37115	1624	treatment of hl-60 cell with tpa	[Treatment of HL-60 cells with TPA]	1.0	6	1	0	0
37116	1624	N-Oct-3 factor	[N-Oct-3 factor]	1.0	2	1	0	0
37117	1624	express the delta-opioid receptor dor1	[expressing the delta-opioid receptor DOR1]	1.0	5	1	0	0
37118	1624	Maximal inhibition of p24 antigen production	[Maximal inhibition of p24 antigen production]	1.0	6	1	0	0
37119	1624	pharmacological effect include antitumor activity	[pharmacological effects including antitumor activities]	1.0	5	1	0	0
37120	1624	adenoviral group	[adenoviral groups]	1.0	2	2	2	2
37121	1624	anti- Jun	[anti- Jun]	1.0	2	1	0	0
37122	1624	anti-CD3-activated peripheral human T lymphocyte	[anti-CD3-activated peripheral human T lymphocytes]	1.0	5	1	0	0
37123	1624	DMSO differentiation of hl-60 cell	[DMSO differentiation of HL-60 cells]	1.0	5	1	0	0
37124	1624	majority of the positive case	[majority of the positive cases]	1.0	5	1	0	0
37125	1624	overrepresentation of clinically aggressive histologic type	[overrepresentation of clinically aggressive histologic types]	1.0	6	1	0	0
37126	1624	growth transformation of primary normal b-cell	[Growth transformation of primary normal B-cells]	1.0	6	1	0	0
37127	1624	Pan transcripts,	[Pan transcripts,]	1.0	2	1	0	0
37128	1624	have a proline -rich region	[having a proline -rich region]	1.0	5	1	0	0
37129	1624	cleavage of the carboxyl terminus	[cleavage of the carboxyl terminus]	1.0	5	1	0	0
37130	1624	apoptotic signaling.	[apoptotic signaling.]	1.0	2	1	0	0
37131	1624	specific protein interaction with CREB	[specific protein interactions with CREB]	1.0	5	1	0	0
37132	1624	subclone jct6	[subclone JCT6]	1.0	2	1	0	0
37133	1624	J element	[J element]	1.0	2	1	0	0
37134	1624	bind factor	[binding factors]	1.0	2	1	0	0
37135	1624	gamma-activate sequence	[gamma-activating sequence]	1.0	2	1	0	0
37136	1624	125i-labeled c-c chemokine in mammalian cell	[125I-labeled C-C chemokines in mammalian cells]	1.0	6	1	0	0
37137	1624	functional copy	[functional copy]	1.0	2	1	0	0
37138	1624	multiple copy of the vpr protein	[multiple copies of the vpr protein]	1.0	6	1	0	0
37139	1624	fetal lifer	[fetal livers]	1.0	2	1	0	0
37140	1624	activation of this lipid kinase	[Activation of this lipid kinase]	1.0	5	1	0	0
37141	1624	other MPD	[other MPD]	1.0	2	1	0	0
37142	1624	increase in the transcription rate	[increase in the transcription rates]	1.0	5	1	0	0
37143	1624	role of the gr receptor	[role of the GR receptor]	1.0	5	1	0	0
37144	1624	gel-retardation experiment	[Gel-retardation experiments]	1.0	2	1	0	0
37145	1624	sequence include 3 kb of DNA	[sequence including 3 kb of DNA]	1.0	6	1	0	0
37146	1624	represent different activation and/or differentiation stage	[representing different activation and/or differentiation stages]	1.0	6	1	0	0
37147	1624	mechanism of action of therapy	[mechanisms of action of therapy]	1.0	5	1	0	0
37148	1624	t-cell activation such as ctla-4	[T-cell activation such as CTLA-4]	1.0	5	1	0	0
37149	1624	test myricetin	[tested, myricetin]	1.0	2	1	0	0
37150	1624	telomeric position	[telomeric position]	1.0	2	1	0	0
37151	1624	recipient joint	[recipient joints]	1.0	2	1	0	0
37152	1624	structural motif include Src homology	[structural motifs including Src homology]	1.0	5	1	0	0
37153	1624	age-related impairment	[age-related impairments]	1.0	2	2	2	2
37154	1624	promoter-proximal e(gre)	[promoter-proximal E(gre)]	1.0	2	1	0	0
37155	1624	therefore transiently convert the transactivation	[therefore transiently converting the transactivation]	1.0	5	1	0	0
37156	1624	rightward transcript in the absence	[rightward transcripts in the absence]	1.0	5	1	0	0
37157	1624	glucocorticoid receptor mrna expression (p	[glucocorticoid receptor mRNA expression (P]	1.0	5	1	0	0
37158	1624	gene responsible for the cause	[gene responsible for the cause]	1.0	5	1	0	0
37159	1624	camp response element (cre) binding site	[cAMP response element (CRE) binding sites]	1.0	6	1	0	0
37160	1624	ck-1 element	[CK-1 element]	1.0	2	1	0	0
37161	1624	camp production	[cAMP production]	1.0	2	2	1	1
37162	1624	thrombin receptor activation peptide a peptide	[Thrombin receptor activation peptide a peptide]	1.0	6	1	0	0
37163	1624	signal transduction cascade in lymphocyte	[signal transduction cascades in lymphocytes]	1.0	5	1	0	0
37164	1624	BZLF1 mRNA a immediate-early gene	[BZLF1 mRNA an immediate-early gene]	1.0	5	1	0	0
37165	1624	15 patient in short-term (st;	[15 patients in short-term (ST;]	1.0	5	1	0	0
37166	1624	primary regulator of platelet production	[primary regulator of platelet production]	1.0	5	1	0	0
37167	1624	sodium dodecyl sulfate-polyacrylamide gel electrophoresis	[Sodium dodecyl sulfate-polyacrylamide gel electrophoresis]	1.0	5	1	0	0
37168	1624	RA resistance	[RA resistance]	1.0	2	2	1	1
37169	1624	activation of U2 snrna transcription	[activation of U2 snRNA transcription]	1.0	5	1	0	0
37170	1624	make use of the residual gr	[making use of the residual GR]	1.0	6	1	0	0
37171	1624	activate stat3 signal transducer of transcription-3	[activating STAT3 signal transducer of transcription-3]	1.0	6	1	0	0
37172	1624	lead to NF-kappa b induction	[leading to NF-kappa B induction]	1.0	5	1	0	0
37173	1624	viral inhibition	[viral inhibition]	1.0	2	1	0	0
37174	1624	twelve amino acid peptide encompass	[Twelve amino acid peptides encompassing]	1.0	5	1	0	0
37175	1624	contrast, mutation	[contrast, mutation]	1.0	2	2	1	1
37176	1624	increase the rate of synthesis	[increasing the rate of synthesis]	1.0	5	1	0	0
37177	1624	DNA binding site for proteins,	[DNA binding sites for proteins,]	1.0	5	1	0	0
37178	1624	less than p less than 0.01	[less than P less than 0.01]	1.0	6	1	0	0
37179	1624	gene important for the defense	[genes important for the defense]	1.0	5	1	0	0
37180	1624	transcriptional signal	[transcriptional signal]	1.0	2	1	0	0
37181	1624	molecular mechanism of the effect	[molecular mechanism of the effect]	1.0	5	2	1	1
37182	1624	produce cell	[producing cells]	1.0	2	1	0	0
37183	1624	e29.1 T	[E29.1 T]	1.0	2	1	0	0
37184	1624	involve two distinct transcription factor family	[involving two distinct transcription factor families]	1.0	6	1	0	0
37185	1624	cam-k ii	[CaM-K II]	1.0	2	1	0	0
37186	1624	camp signal	[cAMP signal]	1.0	2	2	2	2
37187	1624	interleukin(IL)-2 expression	[interleukin(IL)-2 expression]	1.0	2	1	0	0
37188	1624	CD3-stimulated T	[CD3-stimulated T]	1.0	2	1	0	0
37189	1624	stimulation of T lymphocyte population	[stimulation of T lymphocyte populations]	1.0	5	1	0	0
37190	1624	[mechanism of action of steroid hormone	[[Mechanism of action of steroid hormones]	1.0	6	1	0	0
37191	1624	exogenous proliferation	[exogenous proliferation]	1.0	2	1	0	0
37192	1624	addition to a glucocorticoid effect	[addition to a glucocorticoid effect]	1.0	5	1	0	0
37193	1624	activation of tgf-beta 2 transcription	[Activation of TGF-beta 2 transcription]	1.0	5	1	0	0
37194	1624	three copy of the gc-box	[three copies of the GC-box]	1.0	5	1	0	0
37195	1624	imprint a more permanent th2 phenotype	[imprinting a more permanent Th2 phenotype]	1.0	6	1	0	0
37196	1624	murine th1	[murine Th1]	1.0	2	1	0	0
37197	1624	t-cell maturation	[T-cell maturation]	1.0	2	2	2	2
37198	1624	gamma delta T cell development	[gamma delta T cell development]	1.0	5	1	0	0
37199	1624	multiple gene in human monocyte	[multiple genes in human monocytes]	1.0	5	1	0	0
37200	1624	tumor necrosis factor alpha gene expression	[tumor necrosis factor alpha gene expression]	1.0	6	1	0	0
37201	1624	13-kilobase-pair (kb) human c-fe transgene	[13-kilobase-pair (kb) human c-fes transgene]	1.0	5	1	0	0
37202	1624	result from the t (15;17) translocation	[resulting from the t (15;17) translocation]	1.0	6	1	0	0
37203	1624	second, tyrphostin a tyrosine kinase inhibitor	[Second, tyrphostin a tyrosine kinase inhibitor]	1.0	6	1	0	0
37204	1624	differentiation of monocyte by csf	[differentiation of monocytes by CSFs]	1.0	5	1	0	0
37205	1624	index of a analogous pattern	[index of an analogous pattern]	1.0	5	1	0	0
37206	1624	include surface ag receptor signal event	[including surface Ag receptor signaling events]	1.0	6	1	0	0
37207	1624	well-standardized criteria,	[well-standardized criteria,]	1.0	2	1	0	0
37208	1624	expression study on tcf-1 protein	[Expression studies on TCF-1 protein]	1.0	5	1	0	0
37209	1624	potent anti-proliferative effect on T cell	[potent anti-proliferative effects on T cells]	1.0	6	1	0	0
37210	1624	defense mechanism	[defense mechanisms]	1.0	2	2	2	2
37211	1624	characterization of expression of the gene	[Characterization of expression of the gene]	1.0	6	1	0	0
37212	1624	associate signal molecule include Syk	[associates signaling molecules including Syk]	1.0	5	1	0	0
37213	1624	37745 dalton	[37,745 daltons]	1.0	2	1	0	0
37214	1624	human t-cell-leukemia virus type 1	[human T-cell-leukemia virus type 1]	1.0	5	1	0	0
37215	1624	evaluate study individual for the presence	[evaluating study individuals for the presence]	1.0	6	1	0	0
37216	1624	oligonucleotide competition experiments, nf-kappa b	[oligonucleotide competition experiments, NF-kappa B]	1.0	5	1	0	0
37217	1624	cell cycle-dependent	[cell cycle-dependent]	1.0	2	2	2	2
37218	1624	Fenton reaction	[Fenton reactions]	1.0	2	1	0	0
37219	1624	cross-link of the CD3 molecule	[Cross-linking of the CD3 molecules]	1.0	5	1	0	0
37220	1624	endothelial-RAW264.7 coculture	[endothelial-RAW264.7 cocultures]	1.0	2	1	0	0
37221	1624	L&H cell	[L&H cells]	1.0	2	2	2	2
37222	1624	intact element	[intact element]	1.0	2	1	0	0
37223	1624	efficacy of serotonin reuptake inhibitor	[efficacy of serotonin reuptake inhibitors]	1.0	5	1	0	0
37224	1624	response to stimulation with lipopolysaccharide	[response to stimulation with lipopolysaccharide]	1.0	5	1	0	0
37225	1624	necessity for appropriate spatial alignment	[necessity for appropriate spatial alignment]	1.0	5	1	0	0
37226	1624	important medication	[important medications]	1.0	2	1	0	0
37227	1624	culture plate	[culture plate]	1.0	2	1	0	0
37228	1624	cell cytoplasm	[cell cytoplasm]	1.0	2	1	0	0
37229	1624	fibroblasts, macrophages,	[fibroblasts, macrophages,]	1.0	2	1	0	0
37230	1624	several other b cell-encoded gene	[several other B cell-encoded genes]	1.0	5	1	0	0
37231	1624	sooty mangabey	[sooty mangabeys]	1.0	2	2	1	1
37232	1624	stage of b cell development	[stages of B cell development]	1.0	5	1	0	0
37233	1624	anti-CD3 il-2	[anti-CD3 IL-2]	1.0	2	1	0	0
37234	1624	calcineurin such as okadaic acid	[calcineurin such as okadaic acid]	1.0	5	1	0	0
37235	1624	ap2 mrna	[aP2 mRNA]	1.0	2	1	0	0
37236	1624	direct sequencing of the product	[direct sequencing of the product]	1.0	5	1	0	0
37237	1624	CD2 activation	[CD2 activation]	1.0	2	2	1	1
37238	1624	63 kD	[63 kD]	1.0	2	1	0	0
37239	1624	tolerization of ad5e1a -specific CTL activity	[tolerization of Ad5E1A -specific CTL activity]	1.0	6	1	0	0
37240	1624	partial independence from exogenous growth stimulus	[partial independence from exogenous growth stimuli]	1.0	6	1	0	0
37241	1624	(Ca2+)i requirement for nf-kb activation	[(Ca2+)i requirement for NF-kB activation]	1.0	5	1	0	0
37242	1624	block the accumulation of IL2 mrna	[blocking the accumulation of IL2 mRNA]	1.0	6	1	0	0
37243	1624	il-2 secretion by neonatal cell	[IL-2 secretion by neonatal cells]	1.0	5	1	0	0
37244	1624	less time	[less time]	1.0	2	1	0	0
37245	1624	induction of apoptosis in lymphocyte	[Induction of apoptosis in lymphocytes]	1.0	5	1	0	0
37246	1624	cytokine pattern on antigen recognition	[cytokine pattern on antigen recognition]	1.0	5	1	0	0
37247	1624	incubation medium	[incubation medium]	1.0	2	1	0	0
37248	1624	same intensity,	[same intensity,]	1.0	2	1	0	0
37249	1624	various diseases, include hematological malignancy	[various diseases, including hematological malignancies]	1.0	5	1	0	0
37250	1624	nonstimulated platelet for 6 hours,	[nonstimulated platelets for 6 hours,]	1.0	5	1	0	0
37251	1624	introduction of a cDNA expression library	[Introduction of a cDNA expression library]	1.0	6	1	0	0
37252	1624	region between-3134	[region between-3134]	1.0	2	1	0	0
37253	1624	camp level in T cell	[cAMP levels in T cells]	1.0	5	1	0	0
37254	1624	PAS region	[PAS region]	1.0	2	1	0	0
37255	1624	human differentiation	[human differentiation]	1.0	2	2	1	1
37256	1624	acetyl salicylic	[acetyl salicylic]	1.0	2	2	1	1
37257	1624	bacterial peptide	[bacterial peptide]	1.0	2	1	0	0
37258	1624	DHL-9 cell	[DHL-9 cells]	1.0	2	1	0	0
37259	1624	regular interval during the treatment,	[regular intervals during the treatment,]	1.0	5	1	0	0
37260	1624	search protein ag for cluster	[searching protein Ag for clusters]	1.0	5	1	0	0
37261	1624	protein kinase c pkc activity	[protein kinase C PKC activity]	1.0	5	1	0	0
37262	1624	mmp-9 activity	[MMP-9 activity]	1.0	2	2	2	2
37263	1624	C/EBP beta in rheumatoid arthritis	[C/EBP beta in rheumatoid arthritis]	1.0	5	1	0	0
37264	1624	STAT1 activity	[STAT1 activity]	1.0	2	1	0	0
37265	1624	ifna gene	[IFNA gene]	1.0	2	1	0	0
37266	1624	regard ebv latency in carcinoma cell	[regarding EBV latency in carcinoma cells]	1.0	6	1	0	0
37267	1624	HLA dq2-restricted,	[HLA DQ2-restricted,]	1.0	2	1	0	0
37268	1624	protein tyrosine phosphatase inhibitor role	[protein tyrosine phosphatase inhibitors role]	1.0	5	1	0	0
37269	1624	multiple rdna encode mouse oct2	[multiple cDNAs encoding mouse Oct2]	1.0	5	1	0	0
37270	1624	side effect,	[side effect,]	1.0	2	1	0	0
37271	1624	sensitive structure of the receptors.	[sensitive structures of the receptors.]	1.0	5	1	0	0
37272	1624	cytosolic level	[cytosolic levels]	1.0	2	1	0	0
37273	1624	fact, cellular nf-kappa b activity	[fact, cellular NF-kappa B activity]	1.0	5	1	0	0
37274	1624	However, dc	[However, DCs]	1.0	2	1	0	0
37275	1624	promoterless construct	[promoterless constructs]	1.0	2	1	0	0
37276	1624	chromatographic step	[chromatographic steps]	1.0	2	2	2	2
37277	1624	essential feature for c-fo induction	[essential feature for c-fos induction]	1.0	5	1	0	0
37278	1624	accessibility of MHC class promoter	[accessibility of MHC class promoters]	1.0	5	1	0	0
37279	1624	use anti-ERK extracellular signal-regulated kinase antibody	[using anti-ERK extracellular signal-regulated kinase antibodies]	1.0	6	1	0	0
37280	1624	molecular cloning of ptf gamma	[molecular cloning of PTF gamma]	1.0	5	1	0	0
37281	1624	binding of a hsv-2 vp-16-derived peptide	[binding of an HSV-2 VP-16-derived peptide]	1.0	6	1	0	0
37282	1624	cell-permeable diacylglycerol	[cell-permeable diacylglycerol]	1.0	2	1	0	0
37283	1624	activation of protein tyrosine kinase ptk	[activation of protein tyrosine kinases PTK]	1.0	6	2	2	2
37284	1624	expression of PPARgamma a heterodimer partner	[Expression of PPARgamma a heterodimer partner]	1.0	6	1	0	0
37285	1624	activation of a protein kinase	[activation of a protein kinase]	1.0	5	1	0	0
37286	1624	Sp1 protein in uninduced expression	[Sp1 proteins in uninduced expression]	1.0	5	1	0	0
37287	1624	cognate receptor	[cognate receptor]	1.0	2	1	0	0
37288	1624	phagocytic stimulus	[phagocytic stimuli]	1.0	2	2	1	1
37289	1624	hyponatremia (118	[hyponatremia (118]	1.0	2	1	0	0
37290	1624	replication of macrophage-tropic strain of hiv	[replication of macrophage-tropic strains of HIV]	1.0	6	1	0	0
37291	1624	I ligation	[I ligation]	1.0	2	1	0	0
37292	1624	affinity in mnc from septic patient	[affinity in MNC from septic patients]	1.0	6	1	0	0
37293	1624	virulence defect	[virulence defect]	1.0	2	1	0	0
37294	1624	active sle	[active SLE]	1.0	2	2	2	2
37295	1624	two repeat of 15 amino acid	[two repeats of 15 amino acids]	1.0	6	1	0	0
37296	1624	change in cell-cycle gene activation	[changes in cell-cycle gene activation]	1.0	5	1	0	0
37297	1624	regulate germline C epsilon transcription	[regulating germline C epsilon transcription]	1.0	5	1	0	0
37298	1624	role of the cytokine interleukin-7	[role of the cytokine interleukin-7]	1.0	5	1	0	0
37299	1624	stimulus-induced expression	[stimulus-induced expression]	1.0	2	1	0	0
37300	1624	mononuclear leukocyte of young subject	[mononuclear leukocytes of young subjects]	1.0	5	1	0	0
37301	1624	nuclear binding	[nuclear binding]	1.0	2	2	1	1
37302	1624	use a highly sensitive screen assay	[Using a highly sensitive screening assay]	1.0	6	1	0	0
37303	1624	p-selectin through ligand on monocyte	[P-selectin through ligands on monocytes]	1.0	5	1	0	0
37304	1624	mouse lymph node T cell	[mouse lymph node T cells]	1.0	5	1	0	0
37305	1624	coassociated protein	[coassociated proteins]	1.0	2	1	0	0
37306	1624	component of the transcription factor ap-1	[component of the transcription factor AP-1]	1.0	6	2	1	1
37307	1624	endosomal/lysosomal system	[endosomal/lysosomal system]	1.0	2	1	0	0
37308	1624	fibroblast growth	[fibroblast growth]	1.0	2	1	0	0
37309	1624	concentration dependent between 10 ng/ml	[concentration dependent between 10 ng/ml]	1.0	5	1	0	0
37310	1624	monocyte-macrophage differentiation	[Monocyte-macrophage differentiation]	1.0	2	2	1	1
37311	1624	epo stimulation	[EPO stimulation]	1.0	2	2	1	1
37312	1624	tcdd treatment	[TCDD treatment]	1.0	2	1	0	0
37313	1624	correspondent protein	[correspondent proteins]	1.0	2	1	0	0
37314	1624	CD3 receptor	[CD3 receptors]	1.0	2	2	1	1
37315	1624	encode the form of Ig chain	[encoding the form of Ig chain]	1.0	6	1	0	0
37316	1624	suppressive effect on the induction	[suppressive effect on the induction]	1.0	5	1	0	0
37317	1624	system cell	[system cells]	1.0	2	2	2	2
37318	1624	inhibition signal	[Inhibition signalling]	1.0	2	2	2	2
37319	1624	rapidly expand	[rapidly expanding]	1.0	2	1	0	0
37320	1624	protein component	[protein component]	1.0	2	2	1	1
37321	1624	use a yeast two-hybrid screen	[Using a yeast two-hybrid screen]	1.0	5	1	0	0
37322	1624	follow adherence of human monocyte	[following adherence of human monocytes]	1.0	5	1	0	0
37323	1624	excellent correlation with IL-2 production,	[excellent correlation with IL-2 production,]	1.0	5	1	0	0
37324	1624	differentiation antigen	[differentiation antigen]	1.0	2	2	2	2
37325	1624	lipopolysaccharide signal in monocytic cell	[lipopolysaccharide signaling in monocytic cells]	1.0	5	1	0	0
37326	1624	contrast, three lymphoblastoid cell line	[contrast, three lymphoblastoid cell lines]	1.0	5	1	0	0
37327	1624	1 alpha-hydroxylase	[1 alpha-hydroxylase]	1.0	2	1	0	0
37328	1624	support of this interpretation, mutation	[support of this interpretation, mutation]	1.0	5	1	0	0
37329	1624	aberrant splicing of the tsg101 gene	[Aberrant splicing of the TSG101 genes]	1.0	6	1	0	0
37330	1624	nfat protein	[NFAT proteins]	1.0	2	3	2	1
37331	1624	drive the progression of immune responsiveness	[driving the progression of immune responsiveness]	1.0	6	1	0	0
37332	1624	novel duplication	[novel duplications]	1.0	2	1	0	0
37333	1624	remain c-terminal residue amino acid	[remaining C-terminal residues amino acids]	1.0	5	1	0	0
37334	1624	ebv serology (include zebra activity	[EBV serology (including ZEBRA activity]	1.0	5	1	0	0
37335	1624	decrease the vmax of monocyte mitochondrial	[decreasing the Vmax of monocyte mitochondrial]	1.0	6	1	0	0
37336	1624	nuclear vitamin	[nuclear vitamin]	1.0	2	1	0	0
37337	1624	mutation in the 742 bp region	[mutations in the 742 bp region]	1.0	6	1	0	0
37338	1624	nuclei of lymphocyte from FDC cluster	[Nuclei of lymphocytes from FDC clusters]	1.0	6	1	0	0
37339	1624	transcription of cellular gene include gm-csf	[transcription of cellular genes including GM-CSF]	1.0	6	1	0	0
37340	1624	clonality of bone marrow progenitor	[clonality of bone marrow progenitors]	1.0	5	1	0	0
37341	1624	mosaicism of 46,x,-y,t(y;15)(q12;p13)/45,x cell line	[Mosaicism of 46,X,-Y,t(Y;15)(q12;p13)/45,X cell lines]	1.0	5	1	0	0
37342	1624	sibling cd34	[sibling CD34]	1.0	2	1	0	0
37343	1624	cytokine imbalance	[cytokine imbalance]	1.0	2	1	0	0
37344	1624	multimeric form	[multimeric forms]	1.0	2	1	0	0
37345	1624	hiv replication in cd8+ t-cell	[HIV replication in CD8+ T-cells]	1.0	5	1	0	0
37346	1624	3bp2 a Abl sh3-interacting protein	[3BP2 an Abl SH3-interacting protein]	1.0	5	1	0	0
37347	1624	adhesion molecule expression on huvec	[adhesion molecule expression on HUVECs]	1.0	5	1	0	0
37348	1624	gp160 on nf-kappa b activation	[gp160 on NF-kappa B activation]	1.0	5	1	0	0
37349	1624	inhibitor of ptk genistein Gen	[inhibitor of PTK genistein Gen]	1.0	5	1	0	0
37350	1624	zipper mutation	[zipper mutation]	1.0	2	1	0	0
37351	1624	colony growth	[colony growth]	1.0	2	2	2	2
37352	1624	>25 F.M in ach2 cell	[>25 F.M in Ach2 cells]	1.0	5	1	0	0
37353	1624	NF-kappaB promoter	[NF-kappaB promoter]	1.0	2	2	1	1
37354	1624	present with severe immunodeficiency SCID	[presenting with severe immunodeficiency SCID]	1.0	5	1	0	0
37355	1624	PECAM-1 gene	[PECAM-1 gene]	1.0	2	1	0	0
37356	1624	antigen signal	[antigen signal]	1.0	2	1	0	0
37357	1624	two chronically hiv-1 cell line	[Two chronically HIV-1 cell lines]	1.0	5	1	0	0
37358	1624	slight hypertension	[slight hypertension]	1.0	2	1	0	0
37359	1624	class iii	[class III]	1.0	2	2	2	2
37360	1624	dissection of the biochemical event	[dissection of the biochemical events]	1.0	5	1	0	0
37361	1624	mAb-stimulated T	[mAb-stimulated T]	1.0	2	1	0	0
37362	1624	DHEA modulation of monocyte cytotoxicity	[DHEA modulation of monocyte cytotoxicity]	1.0	5	1	0	0
37363	1624	GM-CSF promoter in T cell	[GM-CSF promoter in T cells]	1.0	5	1	0	0
37364	1624	10:00 P;	[10:00 h;]	1.0	2	1	0	0
37365	1624	active pkb	[active PKB]	1.0	2	1	0	0
37366	1624	peptide elisa	[peptide ELISAs]	1.0	2	1	0	0
37367	1624	2 nmol	[2 nmol]	1.0	2	1	0	0
37368	1624	udg promoter	[UDG promoter]	1.0	2	1	0	0
37369	1624	evidence different in Jurkat cell	[evidence different in Jurkat cells]	1.0	5	1	0	0
37370	1624	aids-related primary effusion lymphoma pel	[AIDS-related primary effusion lymphoma PEL]	1.0	5	1	0	0
37371	1624	expression of PML gene in hematopoiesis	[Expression of PML gene in hematopoiesis]	1.0	6	1	0	0
37372	1624	rna sample	[RNA samples]	1.0	2	2	2	2
37373	1624	double-negative thymocyte	[double-negative thymocytes]	1.0	2	1	0	0
37374	1624	suppress nuclear factor-kappa b mobilization	[suppressing nuclear factor-kappa B mobilization]	1.0	5	1	0	0
37375	1624	hd6 cell	[HD6 cells]	1.0	2	2	1	1
37376	1624	part of a set of repressor	[part of a set of repressors]	1.0	6	1	0	0
37377	1624	interleukin 10, granulocyte-macrophage colony-stimulating factor	[interleukin 10, granulocyte-macrophage colony-stimulating factor]	1.0	5	1	0	0
37378	1624	cox-2 enzyme	[COX-2 enzyme]	1.0	2	1	0	0
37379	1624	recent advance in understanding of mechanism	[recent advances in understanding of mechanisms]	1.0	6	1	0	0
37380	1624	gt ii	[GT II]	1.0	2	1	0	0
37381	1624	erythroid marker expression in blast	[erythroid markers expression in blasts]	1.0	5	1	0	0
37382	1624	involvement of the lymphokine element 0	[involvement of the lymphokine element 0]	1.0	6	1	0	0
37383	1624	addition of ebv nuclear protein	[addition of EBV nuclear proteins]	1.0	5	1	0	0
37384	1624	mutation in the GATA-3 site	[mutations in the GATA-3 site]	1.0	5	1	0	0
37385	1624	moderate increase	[moderate increase]	1.0	2	2	2	2
37386	1624	monocytes/macrophages in human atherosclerotic lesion	[monocytes/macrophages in human atherosclerotic lesions]	1.0	5	1	0	0
37387	1624	other type of inflammatory process	[other types of inflammatory processes]	1.0	5	1	0	0
37388	1624	transformation of primary rodent cell	[transformation of primary rodent cells]	1.0	5	1	0	0
37389	1624	cd95l expression in T cell	[CD95L expression in T cells]	1.0	5	1	0	0
37390	1624	activation-specific expression in T cell	[activation-specific expression in T cells]	1.0	5	1	0	0
37391	1624	precursor b cell with il-7	[precursor B cells with IL-7]	1.0	5	1	0	0
37392	1624	proximal c-jun tre-like promoter element	[proximal c-jun TRE-like promoter element]	1.0	5	1	0	0
37393	1624	tissue origin,	[tissue origin,]	1.0	2	1	0	0
37394	1624	suggest direct control of Bcl-2 expression	[suggesting direct control of Bcl-2 expression]	1.0	6	1	0	0
37395	1624	complex formation by nuclear extract	[complex formation by nuclear extracts]	1.0	5	1	0	0
37396	1624	transcriptional activation in Jurkat T cell	[transcriptional activation in Jurkat T cells]	1.0	6	1	0	0
37397	1624	latter issue	[latter issue]	1.0	2	1	0	0
37398	1624	protein present in nuclear extract	[proteins present in nuclear extracts]	1.0	5	1	0	0
37399	1624	ige cd23	[IgE CD23]	1.0	2	1	0	0
37400	1624	irf-1 promoter	[IRF-1 promoter]	1.0	2	1	0	0
37401	1624	similar level	[similar level]	1.0	2	6	5	1
37402	1624	interleukin-2 IL-2 receptor beta-chain il-2rbeta	[interleukin-2 IL-2 receptor beta-chain IL-2Rbeta]	1.0	5	1	0	0
37403	1624	inflammatory protein-1alpha	[inflammatory protein-1alpha]	1.0	2	2	2	2
37404	1624	egr-1 mrna	[Egr-1 mRNA]	1.0	2	2	2	2
37405	1624	cross-competition assay among the P-like element	[Cross-competition assays among the P-like elements]	1.0	6	1	0	0
37406	1624	direct control	[direct control]	1.0	2	2	2	2
37407	1624	mad-3 protein	[MAD-3 protein]	1.0	2	1	0	0
37408	1624	Egr-1 site	[Egr-1 site]	1.0	2	2	1	1
37409	1624	identification of the molecular target	[Identification of the molecular target]	1.0	5	1	0	0
37410	1624	pentoxifylline pf	[pentoxifylline PF]	1.0	2	1	0	0
37411	1624	acute episode	[acute episode]	1.0	2	1	0	0
37412	1624	nuclear component of human nf-at	[nuclear component of human NF-AT]	1.0	5	1	0	0
37413	1624	META(D+) transcription of a luciferase gene	[META(D+) transcription of a luciferase gene]	1.0	6	1	0	0
37414	1624	cytokine effect on target cell	[cytokine effects on target cells]	1.0	5	1	0	0
37415	1624	1 alpha, 25-dihydroxyvitamin D3 vd3	[1 alpha, 25-dihydroxyvitamin D3 VD3]	1.0	5	2	2	2
37416	1624	core of the promoter position	[core of the promoter positions]	1.0	5	1	0	0
37417	1624	human fetal	[human fetal]	1.0	2	1	0	0
37418	1624	enzyme catalyze the rate-limiting step	[enzyme catalyzing the rate-limiting step]	1.0	5	1	0	0
37419	1624	tcr-mediated apoptosis in t-cell hybridoma	[TCR-mediated apoptosis in T-cell hybridomas]	1.0	5	1	0	0
37420	1624	antibody against CRE -binding (creb) protein	[Antibodies against CRE -binding (CREB) protein]	1.0	6	1	0	0
37421	1624	synthetic steroid	[synthetic steroids]	1.0	2	1	0	0
37422	1624	activity of a immunoglobulin promoter	[activity of a immunoglobulin promoter]	1.0	5	1	0	0
37423	1624	specificity-conferring mechanism	[specificity-conferring mechanism]	1.0	2	2	2	2
37424	1624	E2F binding	[E2F binding]	1.0	2	1	0	0
37425	1624	rp1 protein	[RP1 protein]	1.0	2	1	0	0
37426	1624	proenkephalin promoter	[proenkephalin promoter]	1.0	2	3	2	1
37427	1624	previous level	[previous levels]	1.0	2	1	0	0
37428	1624	normal human lymphocyte from peripheral blood	[normal human lymphocytes from peripheral blood]	1.0	6	1	0	0
37429	1624	costimulation with anti- CD28 MoAb	[Costimulation with anti- CD28 MoAb]	1.0	5	1	0	0
37430	1624	stem cell factor-dependent erythroid progenitor	[stem cell factor-dependent erythroid progenitors]	1.0	5	1	0	0
37431	1624	whole spectrum of B-cell differentiation	[whole spectrum of B-cell differentiation]	1.0	5	1	0	0
37432	1624	factor for optimal cell differentiation	[factor for optimal cell differentiation]	1.0	5	1	0	0
37433	1624	inflammatory activity	[inflammatory activity]	1.0	2	2	1	1
37434	1624	bfu-e response to erythropoietin epo	[BFU-E response to erythropoietin Epo]	1.0	5	1	0	0
37435	1624	essential role in the control	[essential role in the control]	1.0	5	2	1	1
37436	1624	charybdotoxin-sensitive, ca(2+) -dependent membrane potential change	[Charybdotoxin-sensitive, Ca(2+) -dependent membrane potential changes]	1.0	6	1	0	0
37437	1624	architectural protein	[architectural proteins]	1.0	2	1	0	0
37438	1624	hypertensive patient of various age]	[hypertensive patients of various age]]	1.0	5	1	0	0
37439	1624	T lymphocyte from all patient	[T lymphocytes from all patients]	1.0	5	1	0	0
37440	1624	contain the -257 to +74 region	[containing the -257 to +74 region]	1.0	6	1	0	0
37441	1624	examine ciita construct for effect	[examining CIITA constructs for effect]	1.0	5	1	0	0
37442	1624	cells: p105	[cells: p105]	1.0	2	1	0	0
37443	1624	binding affinity for that ICSs	[binding affinities for those ICSs]	1.0	5	1	0	0
37444	1624	Northern analysis use a probe	[Northern analysis using a probe]	1.0	5	1	0	0
37445	1624	level of estradiol in plasma	[level of estradiol in plasma]	1.0	5	1	0	0
37446	1624	fos kinetic	[FOS kinetics]	1.0	2	1	0	0
37447	1624	cortisol binding	[cortisol binding]	1.0	2	2	2	2
37448	1624	DNA binding of signal transducer	[DNA binding of signal transducer]	1.0	5	1	0	0
37449	1624	nuclear extract of Jurkat cell	[nuclear extracts of Jurkat cells]	1.0	5	1	0	0
37450	1624	active complex	[active complex]	1.0	2	2	2	2
37451	1624	serum-supplemented medium	[serum-supplemented medium]	1.0	2	1	0	0
37452	1624	LMP-1 e2re	[LMP-1 E2RE]	1.0	2	1	0	0
37453	1624	code for the enzyme luciferase	[coding for the enzyme luciferase]	1.0	5	1	0	0
37454	1624	close link between the induction	[close link between the induction]	1.0	5	1	0	0
37455	1624	block reaction	[blocking reactions]	1.0	2	1	0	0
37456	1624	PMA differentiation;	[PMA differentiation;]	1.0	2	1	0	0
37457	1624	ca. bp	[ca. bp]	1.0	2	1	0	0
37458	1624	tnf factor 2 traf2 traf3	[TNF factor 2 TRAF2 TRAF3]	1.0	5	1	0	0
37459	1624	cd16 stimulation	[CD16 stimulation]	1.0	2	1	0	0
37460	1624	cell-specific mechanism	[cell-specific mechanism]	1.0	2	1	0	0
37461	1624	different mechanism in each cell type.	[different mechanisms in each cell type.]	1.0	6	1	0	0
37462	1624	hematopoietic control	[hematopoietic control]	1.0	2	1	0	0
37463	1624	close association with T cell	[close association with T cells]	1.0	5	1	0	0
37464	1624	role for change in immunophilin	[role for changes in immunophilins]	1.0	5	1	0	0
37465	1624	45 microM.	[45 microM.]	1.0	2	1	0	0
37466	1624	LTR promoter	[LTR promoter]	1.0	2	1	0	0
37467	1624	alpha-globin expression	[alpha-globin expression]	1.0	2	1	0	0
37468	1624	act together in insertional actin polymerization	[acting together in insertional actin polymerization]	1.0	6	1	0	0
37469	1624	small cell	[smaller cells]	1.0	2	1	0	0
37470	1624	block TNF	[blocking TNF]	1.0	2	1	0	0
37471	1624	phorbol ester stimulation of KG1	[phorbol ester stimulation of KG1]	1.0	5	1	0	0
37472	1624	many study	[Many studies]	1.0	2	2	1	1
37473	1624	small difference in virus production	[small differences in virus production]	1.0	5	1	0	0
37474	1624	potential tool for clinical evaluation	[potential tool for clinical evaluation]	1.0	5	1	0	0
37475	1624	potentially important regulator of atherogenesis	[potentially important regulator of atherogenesis]	1.0	5	1	0	0
37476	1624	factor NF-AT	[factor NF-AT]	1.0	2	2	2	2
37477	1624	cytoplasmic sequestration of the tax protein	[cytoplasmic sequestration of the Tax protein]	1.0	6	1	0	0
37478	1624	Spi-1 transcript at permissive temperature	[Spi-1 transcripts at permissive temperature]	1.0	5	1	0	0
37479	1624	oncogenic potential	[oncogenic potential]	1.0	2	2	2	2
37480	1624	human astroglioma cell line CRT	[human astroglioma cell line CRT]	1.0	5	1	0	0
37481	1624	phytohemagglutinin PMA	[phytohemagglutinin PMA]	1.0	2	1	0	0
37482	1624	activation of endogenous cholesterol synthesis	[activation of endogenous cholesterol synthesis]	1.0	5	1	0	0
37483	1624	binding to cell-surface heparan sulphate	[binding to cell-surface heparan sulphate]	1.0	5	1	0	0
37484	1624	T cell response to TSHR peptide	[T cell responses to TSHR peptides]	1.0	6	1	0	0
37485	1624	recall infection	[recall infections]	1.0	2	1	0	0
37486	1624	novel target of drug development	[novel target of drug development]	1.0	5	1	0	0
37487	1624	DNA ploidy	[DNA ploidy]	1.0	2	1	0	0
37488	1624	tpa transcription of the c-jun gene	[TPA transcription of the c-jun gene]	1.0	6	1	0	0
37489	1624	thymocyte from thy-tax transgenic mouse	[thymocytes from Thy-tax transgenic mice]	1.0	5	1	0	0
37490	1624	gm-csf receptor alpha promoter activity	[GM-CSF receptor alpha promoter activity]	1.0	5	1	0	0
37491	1624	(40 P;	[(40 h;]	1.0	2	1	0	0
37492	1624	herpesvirus saimiry a oncogenic virus	[Herpesvirus saimiri an oncogenic virus]	1.0	5	1	0	0
37493	1624	good correlation between tyrosine phosphorylation	[good correlation between tyrosine phosphorylation]	1.0	5	1	0	0
37494	1624	cd34 mrna	[CD34 mRNA]	1.0	2	2	1	1
37495	1624	TCR, IL-4	[TCR, IL-4]	1.0	2	1	0	0
37496	1624	transcription of a minimal promoter	[Transcription of a minimal promoter]	1.0	5	1	0	0
37497	1624	upper range	[upper range]	1.0	2	1	0	0
37498	1624	NH2 regulatory, domain of pp56(lck)	[NH2 regulatory, domain of pp56(lck)]	1.0	5	1	0	0
37499	1624	nuclear translocation of nf-kappa b p50/p65	[nuclear translocation of NF-kappa B p50/p65]	1.0	6	1	0	0
37500	1624	important positive regulatory element NF-AT-1	[important positive regulatory element NF-AT-1]	1.0	5	1	0	0
37501	1624	sequestration of the b subunit	[sequestration of the B subunit]	1.0	5	1	0	0
37502	1624	Recent work from several laboratory	[Recent work from several laboratories]	1.0	5	1	0	0
37503	1624	kappa b alpha embryonic fibroblast	[kappa B alpha embryonic fibroblasts]	1.0	5	1	0	0
37504	1624	encode the t-cell receptor tcr beta	[encoding the T-cell receptor TCR beta]	1.0	6	1	0	0
37505	1624	t3 suppressibility	[T3 suppressibility]	1.0	2	1	0	0
37506	1624	ikappab -alpha ikappab -epsilon disappearance	[IkappaB -alpha IkappaB -epsilon disappearance]	1.0	5	1	0	0
37507	1624	degradation of inhibitor kappa b	[degradation of inhibitor kappa B]	1.0	5	1	0	0
37508	1624	addition to well-recognized adhesive role,	[addition to well-recognized adhesive role,]	1.0	5	1	0	0
37509	1624	fnf-e2 promoter	[fNF-E2 promoter]	1.0	2	1	0	0
37510	1624	effect on insulin gene transcription	[effects on insulin gene transcription]	1.0	5	1	0	0
37511	1624	cytolytic machinery of NK cell	[cytolytic machinery of NK cells]	1.0	5	1	0	0
37512	1624	use a kappaB-regulated luciferase encoding vector	[using a kappaB-regulated luciferase encoding vector]	1.0	6	1	0	0
37513	1624	other flavonoid	[other flavonoids]	1.0	2	1	0	0
37514	1624	gr level	[GR levels]	1.0	2	2	2	2
37515	1624	active compound	[active compounds]	1.0	2	1	0	0
37516	1624	class switch recombination of b lymphocyte	[class switch recombination of B lymphocytes]	1.0	6	1	0	0
37517	1624	suppression of t-cell il-5 synthesis	[suppression of T-cell IL-5 synthesis]	1.0	5	1	0	0
37518	1624	thus, tal1 activation in this patient	[Thus, TAL1 activation in these patients]	1.0	6	1	0	0
37519	1624	gene encode the t-cell receptor	[genes encoding the T-cell receptor]	1.0	5	1	0	0
37520	1624	event related	[events related]	1.0	2	2	2	2
37521	1624	IL-10 STAT1	[IL-10 STAT1]	1.0	2	1	0	0
37522	1624	critical role during hematopoiesis translocation	[critical role during hematopoiesis translocations]	1.0	5	1	0	0
37523	1624	evaluation of large cohort of patient	[Evaluation of large cohorts of patients]	1.0	6	1	0	0
37524	1624	range from plant to mammal	[ranging from plants to mammals]	1.0	5	1	0	0
37525	1624	rescue b cell from apoptosis	[rescuing B cells from apoptosis]	1.0	5	1	0	0
37526	1624	new aspect	[new aspect]	1.0	2	2	2	2
37527	1624	gata-1 protein	[GATA-1 protein]	1.0	2	2	1	1
37528	1624	il-2 mrna expression in neonate	[IL-2 mRNA expression in neonates]	1.0	5	1	0	0
37529	1624	(20 mm)	[(20 mM)]	1.0	2	1	0	0
37530	1624	blood plasma	[blood plasma]	1.0	2	2	2	2
37531	1624	octamer family of transcription factor	[octamer families of transcription factors]	1.0	5	1	0	0
37532	1624	CTL memory	[CTL memory]	1.0	2	2	2	2
37533	1624	drop-mediated transfer	[drop-mediated transfer]	1.0	2	1	0	0
37534	1624	pkc- dependent activation of ERK	[PKC- dependent activation of ERK]	1.0	5	1	0	0
37535	1624	bhlh antagonist	[bHLH antagonists]	1.0	2	1	0	0
37536	1624	elicit oxidative stress such as cytokine	[eliciting oxidative stress such as cytokines]	1.0	6	1	0	0
37537	1624	further evidence of the coexpression	[further evidence of the coexpression]	1.0	5	1	0	0
37538	1624	gene characteristic for immature cell	[genes characteristic for immature cells]	1.0	5	1	0	0
37539	1624	two subgroup	[two subgroups]	1.0	2	1	0	0
37540	1624	rest T cell from patient	[resting T cells from patients]	1.0	5	1	0	0
37541	1624	western blotting of NK cell	[Western blotting of NK cell]	1.0	5	1	0	0
37542	1624	insulin-gene activity	[insulin-gene activity]	1.0	2	1	0	0
37543	1624	t-cell-specific expression of the il-2	[T-cell-specific expression of the IL-2]	1.0	5	1	0	0
37544	1624	clinical variable	[clinical variables]	1.0	2	2	1	1
37545	1624	follow ligand engagement (e.g. cell-to-cell contact).	[following ligand engagement (e.g. cell-to-cell contact).]	1.0	6	1	0	0
37546	1624	IkappaBalpha phosphorylation	[IkappaBalpha phosphorylation]	1.0	2	2	1	1
37547	1624	0 C	[0 C]	1.0	2	1	0	0
37548	1624	other evidence	[other evidence]	1.0	2	1	0	0
37549	1624	activation of NF-kappa b in	[activation of NF-kappa B in]	1.0	5	1	0	0
37550	1624	distinct pattern of viral growth	[distinct patterns of viral growth]	1.0	5	1	0	0
37551	1624	immune modulate effect of RA	[immune modulating effects of RA]	1.0	5	1	0	0
37552	1624	characterization of the basic mechanism	[Characterization of the basic mechanisms]	1.0	5	1	0	0
37553	1624	ctg-dimer virus	[CTG-dimer virus]	1.0	2	1	0	0
37554	1624	beta-globin cluster	[beta-globin cluster]	1.0	2	1	0	0
37555	1624	u.v. cross-linking	[u.v. cross-linking]	1.0	2	1	0	0
37556	1624	valid technique for the measurement	[valid technique for the measurement]	1.0	5	1	0	0
37557	1624	exogenous stimuli.	[exogenous stimuli.]	1.0	2	1	0	0
37558	1624	competition with endogenous transcription factor	[competition with endogenous transcription factors]	1.0	5	1	0	0
37559	1624	complementation assay	[complementation assay]	1.0	2	1	0	0
37560	1624	human antigen-specific cd4+ t-cell line	[human antigen-specific CD4+ T-cell lines]	1.0	5	1	0	0
37561	1624	evidence for reactivity of pregnancy lymphocyte	[evidence for reactivity of pregnancy lymphocytes]	1.0	6	1	0	0
37562	1624	b series	[B series]	1.0	2	2	2	2
37563	1624	NF-kappaB/Rel family of transcription factors,	[NF-kappaB/Rel family of transcription factors,]	1.0	5	1	0	0
37564	1624	tax m32	[Tax M32]	1.0	2	1	0	0
37565	1624	antioxidant condition	[antioxidant conditions]	1.0	2	1	0	0
37566	1624	-m2 protein	[-M2 proteins]	1.0	2	1	0	0
37567	1624	reproduce the function of intact USA	[reproducing the function of intact USA]	1.0	6	1	0	0
37568	1624	mutant LTR	[mutant LTR]	1.0	2	1	0	0
37569	1624	primitive hematopoiesis	[primitive hematopoiesis]	1.0	2	1	0	0
37570	1624	GRR element	[GRR element]	1.0	2	1	0	0
37571	1624	adrenal androgen	[adrenal androgens]	1.0	2	1	0	0
37572	1624	gas exchange in patient with failure	[gas exchange in patients with failure]	1.0	6	1	0	0
37573	1624	leukemic cd4+	[leukemic CD4+]	1.0	2	1	0	0
37574	1624	three aspect of the involvement	[Three aspects of the involvement]	1.0	5	1	0	0
37575	1624	1.2 kb	[1.2 kb]	1.0	2	1	0	0
37576	1624	such as the central nervous system	[such as the central nervous system]	1.0	6	1	0	0
37577	1624	low affinity.	[lower affinity.]	1.0	2	1	0	0
37578	1624	selective binding	[selective binding]	1.0	2	1	0	0
37579	1624	increase in the plasma activity	[increase in the plasma activity]	1.0	5	1	0	0
37580	1624	manipulate T cell response in	[manipulating T cell responses in]	1.0	5	1	0	0
37581	1624	dense tubules:	[dense tubules:]	1.0	2	1	0	0
37582	1624	constitutive pag activation (phenotype phopc	[constitutive pag activation (phenotype PhoPc]	1.0	5	1	0	0
37583	1624	pretreatment of the effector cell	[pretreatment of the effector cells]	1.0	5	1	0	0
37584	1624	cellular treatment	[cellular treatment]	1.0	2	1	0	0
37585	1624	ad5e1a-expressing tumor	[Ad5E1A-expressing tumors]	1.0	2	1	0	0
37586	1624	anti-inflammatory function	[anti-inflammatory functions]	1.0	2	1	0	0
37587	1624	eosinophil-depleted leukocyte from this patient	[Eosinophil-depleted leukocytes from this patient]	1.0	5	1	0	0
37588	1624	consist of residue 122 to 293	[consisting of residues 122 to 293]	1.0	6	1	0	0
37589	1624	six nonresponder	[six nonresponders]	1.0	2	1	0	0
37590	1624	specific binding site of glucocorticoid receptor	[specific binding sites of glucocorticoid receptors]	1.0	6	1	0	0
37591	1624	several cellular gene include IL-2	[several cellular genes including IL-2]	1.0	5	1	0	0
37592	1624	neurite process	[neurite processes]	1.0	2	1	0	0
37593	1624	unlabeled ligand	[unlabeled ligand]	1.0	2	1	0	0
37594	1624	fibroblast cell	[fibroblast cells]	1.0	2	1	0	0
37595	1624	costimulation of camp kinase c pathway	[Costimulation of cAMP kinase C pathways]	1.0	6	1	0	0
37596	1624	class ii promoter occupancy alteration	[class II promoter occupancy alterations]	1.0	5	1	0	0
37597	1624	characterization of peripheral blood t-lymphocyte	[Characterization of peripheral blood T-lymphocytes]	1.0	5	1	0	0
37598	1624	n-acetyl-cysteine treatment	[N-acetyl-cysteine treatment]	1.0	2	1	0	0
37599	1624	Intracellular il	[Intracellular ILs]	1.0	2	1	0	0
37600	1624	component of this regulatory system	[components of this regulatory system]	1.0	5	1	0	0
37601	1624	coreceptor for T hiv-1 entry	[coreceptor for T HIV-1 entry]	1.0	5	1	0	0
37602	1624	mouse chromosome	[mouse chromosome]	1.0	2	2	2	2
37603	1624	node-positive patient	[node-positive patients]	1.0	2	1	0	0
37604	1624	human immunodeficiency virus long repeat	[human immunodeficiency virus long repeat]	1.0	5	2	2	2
37605	1624	solubilization of the receptor protein	[Solubilization of the receptor protein]	1.0	5	1	0	0
37606	1624	regulatory activity	[regulatory activity]	1.0	2	2	2	2
37607	1624	5' end of the gene	[5' ends of the genes]	1.0	5	1	0	0
37608	1624	human immunodeficiency virus hiv transcription	[human immunodeficiency virus HIV transcription]	1.0	5	1	0	0
37609	1624	HeLa cell in the presence	[HeLa cells in the presence]	1.0	5	1	0	0
37610	1624	specific program	[specific program]	1.0	2	2	2	2
37611	1624	up-regulation of the gamma-globin promoter	[up-regulation of the gamma-globin promoter]	1.0	5	1	0	0
37612	1624	such trans-dimer	[such trans-dimers]	1.0	2	1	0	0
37613	1624	expression of the beta-globin gene	[expression of the beta-globin gene]	1.0	5	1	0	0
37614	1624	osteoblast-specific element	[osteoblast-specific element]	1.0	2	1	0	0
37615	1624	SLP-76-associated substrate	[SLP-76-associated substrate]	1.0	2	1	0	0
37616	1624	5 m D3 induce monocyte differentiation	[5 M D3 inducing monocyte differentiation]	1.0	6	1	0	0
37617	1624	cell apoptosis	[cell apoptosis]	1.0	2	2	2	2
37618	1624	camp concentration such as dibutyryl camp	[cAMP concentrations such as dibutyryl cAMP]	1.0	6	1	0	0
37619	1624	alpha-globin gene	[alpha-globin gene]	1.0	2	2	1	1
37620	1624	sequence from -417 to -207 5'	[sequences from -417 to -207 5']	1.0	6	1	0	0
37621	1624	liganded mr	[liganded MR]	1.0	2	1	0	0
37622	1624	comprise the dna-binding lac repressor	[comprising the DNA-binding lac repressor]	1.0	5	1	0	0
37623	1624	kappa b free from NF-kappa b	[kappa B free from NF-kappa B]	1.0	6	1	0	0
37624	1624	cd11b/cd18 on monocytic hl60 cell	[CD11b/CD18 on monocytic HL60 cells]	1.0	5	1	0	0
37625	1624	similar cd11b+ population in transgenic mouse	[similar CD11b+ populations in transgenic mice]	1.0	6	1	0	0
37626	1624	IL-4R alpha	[IL-4R alpha]	1.0	2	1	0	0
37627	1624	support the expression of the alpha-subunit	[supporting the expression of the alpha-subunit]	1.0	6	1	0	0
37628	1624	TNF translation	[TNF translation]	1.0	2	1	0	0
37629	1624	lps induction of tf gene expression	[LPS induction of TF gene expression]	1.0	6	1	0	0
37630	1624	reactivity of murine monoclonal antibody	[reactivity of murine monoclonal antibodies]	1.0	5	1	0	0
37631	1624	nf-kappa b mobilization by aspirin	[NF-kappa B mobilization by aspirin]	1.0	5	1	0	0
37632	1624	above region,	[above region,]	1.0	2	1	0	0
37633	1624	cis-acting element with NF kappa b	[Cis-acting elements with NF kappa B]	1.0	6	1	0	0
37634	1624	tcr-induced fasl	[TCR-induced FasL]	1.0	2	1	0	0
37635	1624	single strand conformation polymorphism analysis application	[Single strand conformation polymorphism analysis application]	1.0	6	1	0	0
37636	1624	SR patient	[SR patients]	1.0	2	2	1	1
37637	1624	relationship between receptor level in leukocyte	[relationship between receptor levels in leukocytes]	1.0	6	1	0	0
37638	1624	result from genital herpes simplex virus	[resulting from genital herpes simplex virus]	1.0	6	1	0	0
37639	1624	nf kappab -dependent enzyme ino	[NF kappaB -dependent enzyme iNOS]	1.0	5	1	0	0
37640	1624	soluble form in the regulation	[soluble forms in the regulation]	1.0	5	1	0	0
37641	1624	elucidated, glucocorticoid	[elucidated, glucocorticoids]	1.0	2	1	0	0
37642	1624	15-30 minute	[15-30 min]	1.0	2	1	0	0
37643	1624	second component	[second component]	1.0	2	1	0	0
37644	1624	B-cell chronic lymphocytic leukemia B-CLL	[B-cell chronic lymphocytic leukemia B-CLL]	1.0	5	1	0	0
37645	1624	(6 wk	[(6 wk]	1.0	2	1	0	0
37646	1624	evidence at the molecular level	[evidence at the molecular level]	1.0	5	1	0	0
37647	1624	il-8 induction	[IL-8 induction]	1.0	2	1	0	0
37648	1624	activation of T helper cell	[Activation of T helper cells]	1.0	5	1	0	0
37649	1624	transient decrease	[transient decrease]	1.0	2	1	0	0
37650	1624	series (b) of such variants,	[series (B) of such variants,]	1.0	5	1	0	0
37651	1624	medical relevance.	[medical relevance.]	1.0	2	1	0	0
37652	1624	cytokine in macrophage through CD14	[cytokines in macrophages through CD14]	1.0	5	1	0	0
37653	1624	c-myc RNA	[c-myc RNA]	1.0	2	1	0	0
37654	1624	deflazacort DFC	[deflazacort DFC]	1.0	2	1	0	0
37655	1624	specific role in gene expression	[specific role in gene expression]	1.0	5	1	0	0
37656	1624	apoptotic response	[apoptotic response]	1.0	2	1	0	0
37657	1624	rna transcript	[RNA transcripts]	1.0	2	2	2	2
37658	1624	protein in the second group	[Proteins in the second group]	1.0	5	1	0	0
37659	1624	1e8 immature b cell line	[1E8 immature B cell line]	1.0	5	1	0	0
37660	1624	th2 response	[Th2 responses]	1.0	2	2	1	1
37661	1624	suggest a role for PKC	[suggesting a role for PKC]	1.0	5	1	0	0
37662	1624	upstream of the PU.1 site	[upstream of the PU.1 site]	1.0	5	1	0	0
37663	1624	regulatory sites.	[regulatory sites.]	1.0	2	2	2	2
37664	1624	autoimmune/inflammatory disease	[autoimmune/inflammatory diseases]	1.0	2	1	0	0
37665	1624	prominent tyrosine phosphorylation of a protein	[prominent tyrosine phosphorylation of a protein]	1.0	6	1	0	0
37666	1624	triiodothyronine receptor mrna in human tissue	[triiodothyronine receptor mRNA in human tissues]	1.0	6	1	0	0
37667	1624	surprisingly high replicative capacity NF-kappaB	[surprisingly high replicative capacity NF-kappaB]	1.0	5	1	0	0
37668	1624	c-Myb	[c-Myb]	1.0	1	11	3	3
37669	1624	distinct set of transcription factor	[distinct sets of transcription factors]	1.0	5	1	0	0
37670	1624	other inducer of the factor.	[other inducers of the factor.]	1.0	5	1	0	0
37671	1624	different effect in T cell representative	[different effects in T cells representative]	1.0	6	1	0	0
37672	1624	hiv-1 Tat	[HIV-1 Tat]	1.0	2	3	2	1
37673	1624	anti-cd2 mab	[anti-CD2 mAb]	1.0	2	1	0	0
37674	1624	tumor necrosis factor TNF alpha	[tumor necrosis factor TNF alpha]	1.0	5	1	0	0
37675	1624	distinct LT-betaR TNF receptor system	[distinct LT-betaR TNF receptor systems]	1.0	5	1	0	0
37676	1624	direct coupling of receptor factor	[direct coupling of receptor factor]	1.0	5	1	0	0
37677	1624	M-CSF addition	[M-CSF addition]	1.0	2	2	1	1
37678	1624	ppt tcdd	[ppt TCDD]	1.0	2	2	2	2
37679	1624	only Sp1	[only Sp1]	1.0	2	1	0	0
37680	1624	one copy of the octamer site	[one copy of the octamer site]	1.0	6	1	0	0
37681	1624	hla allele	[HLA alleles]	1.0	2	1	0	0
37682	1624	repress transcription	[repressing transcription]	1.0	2	1	0	0
37683	1624	repressive function over the gene activation	[repressive function over the gene activation]	1.0	6	1	0	0
37684	1624	CRE pathway	[CRE pathway]	1.0	2	1	0	0
37685	1624	additional mutation	[additional mutations]	1.0	2	1	0	0
37686	1624	T cell in nuclear complex	[T cells in nuclear complexes]	1.0	5	1	0	0
37687	1624	early growth response-1 gene egr-1	[early growth response-1 gene EGR-1]	1.0	5	1	0	0
37688	1624	abnormality in corticosteroid receptor characteristic	[abnormalities in corticosteroid receptor characteristics]	1.0	5	1	0	0
37689	1624	migration alone, suggest local proliferation.	[migration alone, suggesting local proliferation.]	1.0	5	1	0	0
37690	1624	accumulate mrna	[accumulating mRNA]	1.0	2	1	0	0
37691	1624	distinct genes,	[distinct genes,]	1.0	2	1	0	0
37692	1624	high-level expression	[High-level expression]	1.0	2	2	2	2
37693	1624	smad2 phosphorylation in hs-72 cell	[Smad2 phosphorylation in HS-72 cells]	1.0	5	1	0	0
37694	1624	activation of the hiv repeat	[activation of the HIV repeat]	1.0	5	2	1	1
37695	1624	B-cell chronic lymphocytic leukemia (b-cll) cell	[B-cell chronic lymphocytic leukemia (B-CLL) cells]	1.0	6	1	0	0
37696	1624	dynamic change in the expression	[dynamic changes in the expression]	1.0	5	1	0	0
37697	1624	PML mrna	[PML mRNA]	1.0	2	2	1	1
37698	1624	three 21-bp repeat tax-responsive element-1	[three 21-bp repeats Tax-responsive element-1]	1.0	5	1	0	0
37699	1624	activation of the hiv-2 enhancer	[activation of the HIV-2 enhancer]	1.0	5	1	0	0
37700	1624	signal via CD28 of T lymphocyte	[Signalling via CD28 of T lymphocytes]	1.0	6	1	0	0
37701	1624	CD3 stimulation	[CD3 stimulation]	1.0	2	2	2	2
37702	1624	persist genome	[persisting genome]	1.0	2	1	0	0
37703	1624	costimulation through CD28 and/or CD2	[Costimulation through CD28 and/or CD2]	1.0	5	1	0	0
37704	1624	Thus, Smad6	[Thus, Smad6]	1.0	2	1	0	0
37705	1624	bind to upstream promoter element	[binding to upstream promoter elements]	1.0	5	1	0	0
37706	1624	frameshift of a stop codon	[frameshift of a stop codon]	1.0	5	1	0	0
37707	1624	activate stat3	[activating STAT3]	1.0	2	2	1	1
37708	1624	expression of a kb id-3l transcript	[expression of a kb Id-3L transcript]	1.0	6	1	0	0
37709	1624	median (interquartile	[median (interquartile]	1.0	2	1	0	0
37710	1624	human umbilical vein cell HUVECs	[human umbilical vein cells HUVECs]	1.0	5	2	2	2
37711	1624	aberrant intracellular signal include hyperresponsiveness	[aberrant intracellular signaling including hyperresponsiveness]	1.0	5	1	0	0
37712	1624	micrococcal nuclease	[micrococcal nuclease]	1.0	2	1	0	0
37713	1624	ability of ifn-activated NK cell	[ability of IFN-activated NK cells]	1.0	5	1	0	0
37714	1624	inverse change	[inverse changes]	1.0	2	2	2	2
37715	1624	namely activator protein-1 nuclear factor il-6	[namely activator protein-1 nuclear factor IL-6]	1.0	6	1	0	0
37716	1624	generate b cell in thymus environment	[generating B cells in thymus environment]	1.0	6	1	0	0
37717	1624	cooperation among nf-kappa b- binding sequence	[cooperation among NF-kappa B- binding sequences]	1.0	6	1	0	0
37718	1624	creb isoform	[CREB isoforms]	1.0	2	2	1	1
37719	1624	microtubule dynamic	[microtubule dynamics]	1.0	2	1	0	0
37720	1624	however, suppression of il-1r gene expression	[However, suppression of IL-1R gene expression]	1.0	6	1	0	0
37721	1624	retargeting of NF-kappa b p50	[retargeting of NF-kappa B p50]	1.0	5	1	0	0
37722	1624	specific program of monocyte differentiation	[specific program of monocyte differentiation]	1.0	5	1	0	0
37723	1624	activation of T lymphocyte by ags	[Activation of T lymphocytes by Ags]	1.0	6	1	0	0
37724	1624	myogenic factor	[myogenic factors]	1.0	2	1	0	0
37725	1624	pi-3,4,5-p3 production	[PI-3,4,5-P3 production]	1.0	2	1	0	0
37726	1624	regulation of the pyruvate kinase promoter	[regulation of the pyruvate kinase promoter]	1.0	6	1	0	0
37727	1624	lining cell	[lining cell]	1.0	2	1	0	0
37728	1624	pathophysiological condition	[pathophysiological conditions]	1.0	2	2	2	2
37729	1624	calm rearrangement	[CALM rearrangements]	1.0	2	1	0	0
37730	1624	insight on the origin of cytokine	[insight on the origin of cytokine]	1.0	6	1	0	0
37731	1624	mechanism responsible for the (minute	[mechanisms responsible for the (minutes)]	1.0	5	1	0	0
37732	1624	haemopoietic differentiation	[Haemopoietic differentiation]	1.0	2	1	0	0
37733	1624	suggest a mixture of latency	[suggesting a mixture of latency]	1.0	5	1	0	0
37734	1624	two monkey	[two monkeys]	1.0	2	1	0	0
37735	1624	predominant expression of p50-p65 heterodimer	[predominant expression of p50-p65 heterodimers]	1.0	5	1	0	0
37736	1624	active role on GM-CSF transcription	[active role on GM-CSF transcription]	1.0	5	1	0	0
37737	1624	anti-inflammatory mediator	[anti-inflammatory mediators]	1.0	2	2	1	1
37738	1624	individual gene of the cluster	[individual genes of the cluster]	1.0	5	1	0	0
37739	1624	viral replication by phorbol ester	[viral replication by phorbol ester]	1.0	5	1	0	0
37740	1624	analysis of intracellular ca2+ mobilization	[Analysis of intracellular Ca2+ mobilization]	1.0	5	1	0	0
37741	1624	phosphorylation of the C-terminal region	[phosphorylation of the C-terminal region]	1.0	5	1	0	0
37742	1624	easy means assess cell proliferation.	[easy means assessing cell proliferation.]	1.0	5	1	0	0
37743	1624	ifn-gamma stimulation	[IFN-gamma stimulation]	1.0	2	1	0	0
37744	1624	Tat- hiv-1 with wild-type ltr	[Tat- HIV-1 with wild-type LTRs]	1.0	5	1	0	0
37745	1624	ppargamma mrna	[PPARgamma mRNA]	1.0	2	1	0	0
37746	1624	actin nucleation	[actin nucleation]	1.0	2	1	0	0
37747	1624	constitutive transcription	[constitutive transcription]	1.0	2	2	1	1
37748	1624	monocyte/macrophage receptor for the complex	[monocyte/macrophage receptor for the complex]	1.0	5	1	0	0
37749	1624	supershif the DNA-protein complex with Abs	[supershifting the DNA-protein complexes with Abs]	1.0	6	1	0	0
37750	1624	seven unstable untreated asthmatic patient	[seven unstable untreated asthmatic patients]	1.0	5	1	0	0
37751	1624	human b lymphocyte immunoglobulin production	[human B lymphocyte immunoglobulin production]	1.0	5	1	0	0
37752	1624	cell such as muscle cell	[cells such as muscle cells]	1.0	5	2	2	2
37753	1624	p21ras small gtp binding protein	[p21ras small GTP binding proteins]	1.0	5	1	0	0
37754	1624	nos inhibitor	[NOS inhibitors]	1.0	2	1	0	0
37755	1624	RAR -specific	[RAR -specific]	1.0	2	1	0	0
37756	1624	successful response	[successful response]	1.0	2	1	0	0
37757	1624	cell sorting of normal bone marrow	[Cell sorting of normal bone marrow]	1.0	6	1	0	0
37758	1624	binding site.	[binding site.]	1.0	2	1	0	0
37759	1624	Thus, Tax1	[Thus, Tax1]	1.0	2	1	0	0
37760	1624	anergic condition	[anergic conditions]	1.0	2	1	0	0
37761	1624	PMA ionomycin synthesis of nfatc	[PMA ionomycin synthesis of NFATc]	1.0	5	1	0	0
37762	1624	model for tissue-specific gene expression	[model for tissue-specific gene expression]	1.0	5	1	0	0
37763	1624	contain a pxqxt/ core sequence	[containing a PXQXT/S core sequence]	1.0	5	1	0	0
37764	1624	subsequent expression	[subsequent expression]	1.0	2	1	0	0
37765	1624	important role in cell signal	[important role in cell signaling]	1.0	5	1	0	0
37766	1624	transcript deletion	[transcript deletions]	1.0	2	2	2	2
37767	1624	swi6/ankyrin repeat	[SWI6/ankyrin repeats]	1.0	2	1	0	0
37768	1624	il-6 stimulation	[IL-6 stimulation]	1.0	2	1	0	0
37769	1624	i.e. beta-casein	[i.e. beta-casein]	1.0	2	1	0	0
37770	1624	low shear stress flow pattern	[low shear stress flow patterns]	1.0	5	1	0	0
37771	1624	two t-cell-specific transcription factor TCF-1	[two T-cell-specific transcription factors TCF-1]	1.0	5	1	0	0
37772	1624	mue3 -binding protein tfe3 alone	[muE3 -binding protein TFE3 alone]	1.0	5	1	0	0
37773	1624	genomic diversity	[genomic diversity]	1.0	2	1	0	0
37774	1624	twenty-four hour	[Twenty-four hour]	1.0	2	1	0	0
37775	1624	solution structure of the hmg box	[Solution structure of the HMG box]	1.0	6	1	0	0
37776	1624	rodent thermosensitive mutant cell chotsh1-1	[rodent thermosensitive mutant cells CHOtsH1-1]	1.0	5	1	0	0
37777	1624	t-cell homeostasis	[T-cell homeostasis]	1.0	2	2	1	1
37778	1624	include antagonic.	[including antagonic.]	1.0	2	1	0	0
37779	1624	encode a B7 costimulatory molecule	[encoding a B7 costimulatory molecule]	1.0	5	1	0	0
37780	1624	ManLAM activation	[ManLAM activation]	1.0	2	1	0	0
37781	1624	presence of a cytosine binding	[presence of a cytosine binding]	1.0	5	1	0	0
37782	1624	Furthermore, PU.1	[Furthermore, PU.1]	1.0	2	1	0	0
37783	1624	synergistic enhancement of il-2 secretion	[synergistic enhancement of IL-2 secretion]	1.0	5	1	0	0
37784	1624	complex on the proximal site	[complex on the proximal site]	1.0	5	1	0	0
37785	1624	postmenopausal patient	[postmenopausal patients]	1.0	2	2	1	1
37786	1624	non-malignant cell	[non-malignant cells]	1.0	2	1	0	0
37787	1624	cell important for the maintenance	[cells important for the maintenance]	1.0	5	1	0	0
37788	1624	unique phenotype	[unique phenotype]	1.0	2	2	1	1
37789	1624	accord to lymph node involvement	[according to lymph node involvement]	1.0	5	1	0	0
37790	1624	25-hydroxyvitamin D3	[25-hydroxyvitamin D3]	1.0	2	1	0	0
37791	1624	differentiation,	[differentiation,]	1.0	1	11	3	3
37792	1624	same phenotype of nf-kappab suppression	[same phenotype of NF-kappaB suppression]	1.0	5	1	0	0
37793	1624	NF-GM2 complex	[NF-GM2 complex]	1.0	2	2	1	1
37794	1624	e2f-dependent thymidine	[E2F-dependent thymidine]	1.0	2	1	0	0
37795	1624	lytic cycle of ebv infection	[lytic cycle of EBV infection]	1.0	5	1	0	0
37796	1624	rna analysis in this cell	[RNA analysis in these cells]	1.0	5	1	0	0
37797	1624	immunoglobulin heavy-chain igh gene rearrangement	[immunoglobulin heavy-chain IgH gene rearrangement]	1.0	5	1	0	0
37798	1624	Cepsilon germline	[Cepsilon germline]	1.0	2	2	2	2
37799	1624	cytokine regulation	[cytokine regulation]	1.0	2	2	2	2
37800	1624	use a radioligand bind assay analysis	[using a radioligand binding assay analysis]	1.0	6	1	0	0
37801	1624	specific nf-kappa b /rel subunit	[specific NF-kappa B /Rel subunits]	1.0	5	1	0	0
37802	1624	D not 4816 to 4851	[D nt 4816 to 4851]	1.0	5	1	0	0
37803	1624	hiv infection.	[HIV infection.]	1.0	2	2	1	1
37804	1624	lps stimulation of il-6 promoter activity	[LPS stimulation of IL-6 promoter activity]	1.0	6	1	0	0
37805	1624	drug-induced toxicity in a patient	[drug-induced toxicity in a patient]	1.0	5	1	0	0
37806	1624	simian CMV scmv by treatment	[simian CMV SCMV by treatment]	1.0	5	1	0	0
37807	1624	gr variant	[GR variants]	1.0	2	1	0	0
37808	1624	priming effect	[priming effect]	1.0	2	2	1	1
37809	1624	three gene	[three genes]	1.0	2	2	1	1
37810	1624	cytokine activation of hiv transcription	[cytokine activation of HIV transcription]	1.0	5	1	0	0
37811	1624	nf-kappab motif	[NF-kappaB motifs]	1.0	2	1	0	0
37812	1624	t-cell receptor (tcr) beta-chain promoter	[T-cell receptor (TCR) beta-chain promoters]	1.0	5	1	0	0
37813	1624	peculiar difference	[peculiar differences]	1.0	2	1	0	0
37814	1624	lymphocyte-specific factor bind to the tced	[lymphocyte-specific factors binding to the TCEd]	1.0	6	1	0	0
37815	1624	nf-kb level	[NF-kB levels]	1.0	2	1	0	0
37816	1624	erythroid-lineage cell with epo treatment	[erythroid-lineage cells with EPO treatment]	1.0	5	1	0	0
37817	1624	peripheral blood;	[peripheral blood;]	1.0	2	1	0	0
37818	1624	increase in c-jun mrna level	[increases in c-jun mRNA levels]	1.0	5	2	2	2
37819	1624	heat shock transcription factor hsf1	[heat shock transcription factor HSF1]	1.0	5	1	0	0
37820	1624	probably functionally antagonize the IL-1 synthesis	[probably functionally antagonizing the IL-1 synthesis]	1.0	6	1	0	0
37821	1624	nf-at sequence	[NF-AT sequence]	1.0	2	1	0	0
37822	1624	mouse l929 cells, gr binding affinity	[mouse L929 cells, GR binding affinity]	1.0	6	1	0	0
37823	1624	lipopolysaccharide lps stimulation in monocyte	[lipopolysaccharide LPS stimulation in monocytes]	1.0	5	1	0	0
37824	1624	follow glucocorticoid treatment of 6tg1.1 cell	[Following glucocorticoid treatment of 6TG1.1 cells]	1.0	6	1	0	0
37825	1624	human t-lymphotrophic virus type HTLV-I	[human T-lymphotrophic virus type HTLV-I]	1.0	5	1	0	0
37826	1624	helix 1	[helix 1]	1.0	2	1	0	0
37827	1624	human c-mpl	[human c-Mpl]	1.0	2	1	0	0
37828	1624	analysis of a series of 5'-truncation	[Analysis of a series of 5'-truncations]	1.0	6	1	0	0
37829	1624	nucleotide 2,317	[nucleotide 2,317]	1.0	2	1	0	0
37830	1624	cd34+ cell into T cell	[CD34+ cells into T cells]	1.0	5	1	0	0
37831	1624	il-6-induced cell	[IL-6-induced cells]	1.0	2	1	0	0
37832	1624	constitutively active mutant of shp1	[constitutively active mutants of SHP1]	1.0	5	1	0	0
37833	1624	side reaction	[side reaction]	1.0	2	1	0	0
37834	1624	SCL hemopoietic helix-loop-helix transcription factor	[SCL hemopoietic helix-loop-helix transcription factors]	1.0	5	1	0	0
37835	1624	sufficient number of functional glucocorticoid receptor	[sufficient numbers of functional glucocorticoid receptors]	1.0	6	1	0	0
37836	1624	replicative senescence.	[replicative senescence.]	1.0	2	1	0	0
37837	1624	il-2r alpha-	[IL-2R alpha-]	1.0	2	1	0	0
37838	1624	further, complete activation of T cell	[Further, complete activation of T cells]	1.0	6	1	0	0
37839	1624	Interleukin-3 expression by T cell	[Interleukin-3 expression by T cells]	1.0	5	1	0	0
37840	1624	only in myeloid u937 cell	[only in myeloid U937 cells]	1.0	5	1	0	0
37841	1624	Spi-1 and/or Fli-1 transcription factor	[Spi-1 and/or Fli-1 transcription factors]	1.0	5	1	0	0
37842	1624	aids pathogenesis	[AIDS pathogenesis]	1.0	2	2	2	2
37843	1624	40 micron/ml	[40 micron/ml]	1.0	2	1	0	0
37844	1624	full potential.	[full potential.]	1.0	2	1	0	0
37845	1624	delivery of the normal gene	[delivery of the normal gene]	1.0	5	1	0	0
37846	1624	135eoh)2d3 repression in jurkat cell	[1,25(OH)2D3 repression in Jurkat cells]	1.0	5	1	0	0
37847	1624	degradative enzyme	[degradative enzymes]	1.0	2	1	0	0
37848	1624	indicate likely a mouse ccr-4	[indicating likely a mouse CCR-4]	1.0	5	1	0	0
37849	1624	stimulation of platelet-activate factor paf	[stimulation of platelet-activating factor PAF]	1.0	5	1	0	0
37850	1624	il-6 mrna stability in cell line	[IL-6 mRNA stability in cell lines]	1.0	6	1	0	0
37851	1624	40 nm.	[40 nM.]	1.0	2	1	0	0
37852	1624	stat3 protein in T cell	[STAT3 proteins in T cells]	1.0	5	1	0	0
37853	1624	fatty streak	[fatty streak]	1.0	2	2	1	1
37854	1624	tyrosine phosphorylation of this protein	[Tyrosine phosphorylation of this protein]	1.0	5	1	0	0
37855	1624	activation of the Jak -Stat pathway	[Activation of the Jak -Stat pathway]	1.0	6	1	0	0
37856	1624	135(oh)2d3 modulation of gene transcription	[1,25(OH)2D3 modulation of gene transcription]	1.0	5	1	0	0
37857	1624	transcription rate of er gene	[transcription rate of ER gene]	1.0	5	1	0	0
37858	1624	5637 cell	[5637 cells]	1.0	2	1	0	0
37859	1624	CD28 binding	[CD28 binding]	1.0	2	1	0	0
37860	1624	primary structure	[primary structure]	1.0	2	1	0	0
37861	1624	restriction fragment length polymorphism rflp	[restriction fragment length polymorphisms RFLPs]	1.0	5	1	0	0
37862	1624	binding site for this factor	[binding sites for these factors]	1.0	5	1	0	0
37863	1624	induced, Il-2	[induced, Il-2]	1.0	2	1	0	0
37864	1624	detectable nf-kappab DNA binding activity	[detectable NF-kappaB DNA binding activity]	1.0	5	1	0	0
37865	1624	PPARgamma activation in mononuclear phagocyte	[PPARgamma activation in mononuclear phagocytes]	1.0	5	1	0	0
37866	1624	several region	[several regions]	1.0	2	2	2	2
37867	1624	lead to the binding of calmodulin	[leading to the binding of calmodulin]	1.0	6	1	0	0
37868	1624	erythroid-specific hypersensitive site HS2 enhancer	[erythroid-specific hypersensitive site HS2 enhancer]	1.0	5	1	0	0
37869	1624	contain ltr	[containing LTRs]	1.0	2	2	2	2
37870	1624	pim-1 gene	[pim-1 genes]	1.0	2	1	0	0
37871	1624	platelet glycoprotein	[platelet glycoprotein]	1.0	2	2	1	1
37872	1624	poz domain	[POZ domain]	1.0	2	1	0	0
37873	1624	CD45RA+ (naive)	[CD45RA+ (naive)]	1.0	2	1	0	0
37874	1624	six viral nuclear antigen EBNAs	[six viral nuclear antigen EBNAs]	1.0	5	2	1	1
37875	1624	synergistic transactivation of the BMRF1 promoter	[Synergistic transactivation of the BMRF1 promoter]	1.0	6	1	0	0
37876	1624	human cd34(+)	[human CD34(+)]	1.0	2	2	1	1
37877	1624	respect to the cellular factor	[respect to the cellular factors]	1.0	5	1	0	0
37878	1624	overexpression of the immunophilin fkbp51	[overexpression of the immunophilin FKBP51]	1.0	5	1	0	0
37879	1624	addition of 1.4 nm aldosterone	[addition of 1.4 nM aldosterone]	1.0	5	1	0	0
37880	1624	event lead from the receptor	[events leading from the receptor]	1.0	5	1	0	0
37881	1624	CD28 coligation	[CD28 coligation]	1.0	2	2	2	2
37882	1624	suppression of the nf-at activation	[suppression of the NF-AT activation]	1.0	5	1	0	0
37883	1624	BMRF1 promoter in jurkat cell	[BMRF1 promoter in Jurkat cells]	1.0	5	1	0	0
37884	1624	old) in pbl from individual	[old) in PBL from individuals]	1.0	5	1	0	0
37885	1624	human thromboxane	[human thromboxane]	1.0	2	1	0	0
37886	1624	autologous tec	[autologous TEC]	1.0	2	1	0	0
37887	1624	350 case	[350 cases]	1.0	2	1	0	0
37888	1624	DNA electrophoresis mobility gel shift assay	[DNA electrophoresis mobility gel shift assays]	1.0	6	1	0	0
37889	1624	sex-determining gene	[sex-determining gene]	1.0	2	1	0	0
37890	1624	apoptosis in eosinophil by cytokine	[apoptosis in eosinophils by cytokines]	1.0	5	1	0	0
37891	1624	steroid-treated cells.	[steroid-treated cells.]	1.0	2	1	0	0
37892	1624	nuclear induction	[nuclear induction]	1.0	2	1	0	0
37893	1624	SLA-DR induction	[SLA-DR induction]	1.0	2	1	0	0
37894	1624	contrast to the result present	[contrast to the result present]	1.0	5	1	0	0
37895	1624	novel mechanism.	[novel mechanism.]	1.0	2	1	0	0
37896	1624	involvement of this family members.	[involvement of these family members.]	1.0	5	1	0	0
37897	1624	Jun Liu,	[Jun Liu,]	1.0	2	1	0	0
37898	1624	low base	[low base]	1.0	2	1	0	0
37899	1624	adoptive transfer of such preparation	[adoptive transfer of such preparations]	1.0	5	1	0	0
37900	1624	interaction with the glucocorticoid receptor	[interactions with the glucocorticoid receptor]	1.0	5	1	0	0
37901	1624	especially in the case of FOSB	[especially in the case of FOSB]	1.0	6	1	0	0
37902	1624	direct participation	[direct participation]	1.0	2	2	2	2
37903	1624	human osteocalcin	[human osteocalcin]	1.0	2	1	0	0
37904	1624	cDNA encode a novel component	[cDNA encoding a novel component]	1.0	5	1	0	0
37905	1624	multiple immunization with adenovirus vector	[multiple immunizations with adenovirus vectors]	1.0	5	1	0	0
37906	1624	exogenous 135eoh)2d3	[exogenous 1,25(OH)2D3]	1.0	2	2	1	1
37907	1624	matrice such as hyaluronic acid	[matrices such as hyaluronic acid]	1.0	5	1	0	0
37908	1624	response to multiple activating agents.	[response to multiple activating agents.]	1.0	5	1	0	0
37909	1624	smooth muscle myosin heavy chain	[smooth muscle myosin heavy chain]	1.0	5	1	0	0
37910	1624	ap-1 response	[AP-1 response]	1.0	2	1	0	0
37911	1624	hyaluronic acid	[hyaluronic acid]	1.0	2	1	0	0
37912	1624	transcription from the interleukin-2 receptor alpha-chain	[transcription from the interleukin-2 receptor alpha-chain]	1.0	6	1	0	0
37913	1624	TNFalpha nfkappab activity by myricetin	[TNFalpha NFkappaB activity by myricetin]	1.0	5	1	0	0
37914	1624	mediate cell death by MTBE	[mediating cell death by MTBE]	1.0	5	1	0	0
37915	1624	parp degradation	[PARP degradation]	1.0	2	1	0	0
37916	1624	Thus, OBF-1	[Thus, OBF-1]	1.0	2	1	0	0
37917	1624	sp1 cleavage	[SP1 cleavage]	1.0	2	2	2	2
37918	1624	association with cytoplasmic signal molecule	[association with cytoplasmic signaling molecules]	1.0	5	1	0	0
37919	1624	substantial sequence similarity to SLP-76	[substantial sequence similarity to SLP-76]	1.0	5	1	0	0
37920	1624	with the murine cDNA clone	[With the murine cDNA clones]	1.0	5	1	0	0
37921	1624	STAT5	[STAT5]	1.0	1	11	4	4
37922	1624	5'-regulatory sequence	[5'-regulatory sequences]	1.0	2	1	0	0
37923	1624	ca(2+)-dependent pathway	[Ca(2+)-dependent pathway]	1.0	2	1	0	0
37924	1624	specific strategy	[specific strategies]	1.0	2	1	0	0
37925	1624	ribosomal entry	[ribosomal entry]	1.0	2	1	0	0
37926	1624	activation by the t-cell antigen receptor	[Activation by the T-cell antigen receptor]	1.0	6	1	0	0
37927	1624	underlying lymphocyte	[underlying lymphocytes]	1.0	2	1	0	0
37928	1624	phospholipase A2	[phospholipase A2]	1.0	2	1	0	0
37929	1624	different cocktail of the ligand	[Different cocktails of the ligands]	1.0	5	1	0	0
37930	1624	several cell line of hematopoietic origin	[Several cell lines of hematopoietic origin]	1.0	6	1	0	0
37931	1624	5' region of the gene	[5' region of the gene]	1.0	5	2	2	2
37932	1624	nonasthmatic individual	[nonasthmatic individuals]	1.0	2	1	0	0
37933	1624	p95vav overexpression	[p95vav overexpression]	1.0	2	1	0	0
37934	1624	receptor transcript	[Receptor transcripts]	1.0	2	1	0	0
37935	1624	overexpression of cbl-b in T cell	[overexpression of Cbl-b in T cells]	1.0	6	1	0	0
37936	1624	endogenous protease	[endogenous proteases]	1.0	2	2	1	1
37937	1624	relationship between ikappabalpha constitutive expression	[Relationship between IkappaBalpha constitutive expression]	1.0	5	1	0	0
37938	1624	macrolide fk506	[macrolide FK506]	1.0	2	1	0	0
37939	1624	BZLF1 gene	[BZLF1 gene]	1.0	2	1	0	0
37940	1624	first exon,	[first exon,]	1.0	2	1	0	0
37941	1624	bzlf 1 -contain cell lysate	[BZLF 1 -containing cell lysates]	1.0	5	1	0	0
37942	1624	also by IL-2 receptor stimulation	[also by IL-2 receptor stimulation]	1.0	5	1	0	0
37943	1624	autoregulatory loop,	[autoregulatory loop,]	1.0	2	1	0	0
37944	1624	nuclei from GATA-1 -mutant stem cell	[Nuclei from GATA-1 -mutant stem cells]	1.0	6	1	0	0
37945	1624	responsive region	[responsive region]	1.0	2	1	0	0
37946	1624	il-4 stimulation in transfection experiments,	[IL-4 stimulation in transfection experiments,]	1.0	5	1	0	0
37947	1624	low back	[low back]	1.0	2	2	1	1
37948	1624	SF suppression	[SF suppression]	1.0	2	1	0	0
37949	1624	more than half of the expansion	[More than half of the expansions]	1.0	6	1	0	0
37950	1624	1 aml-m5	[1 AML-M5]	1.0	2	1	0	0
37951	1624	mycobacterial infection	[mycobacterial infection]	1.0	2	1	0	0
37952	1624	level of L. pneumophila rpose	[level of L. pneumophila RpoS]	1.0	5	1	0	0
37953	1624	bacterial lysate use immunomagnetic separation	[bacterial lysates using immunomagnetic separation]	1.0	5	1	0	0
37954	1624	whole sequence in GenBank database	[whole sequences in GenBank database]	1.0	5	1	0	0
37955	1624	low threshold	[low threshold]	1.0	2	1	0	0
37956	1624	reduce mrna stability, suggest gamma-ifn inhibition	[reducing mRNA stability, suggesting gamma-IFN inhibition]	1.0	6	1	0	0
37957	1624	sensitivity to inhibitor of activation	[sensitivity to inhibitors of activation]	1.0	5	1	0	0
37958	1624	beta- versus alpha- globin chain	[beta- versus alpha- globin chains]	1.0	5	1	0	0
37959	1624	cytoplasmic anchor	[cytoplasmic anchor]	1.0	2	1	0	0
37960	1624	activation of a tyrosine phosphatase	[activation of a tyrosine phosphatase]	1.0	5	1	0	0
37961	1624	belong to the monocyte/macrophage lineage	[belonging to the monocyte/macrophage lineage]	1.0	5	1	0	0
37962	1624	However, transactivation of the CD4 promoter	[However, transactivation of the CD4 promoter]	1.0	6	1	0	0
37963	1624	cytogenetic analysis	[cytogenetic analysis]	1.0	2	1	0	0
37964	1624	mobility shift assay with extract	[mobility shift assay with extract]	1.0	5	2	2	2
37965	1624	selection against the long expression	[selection against the long-term expression]	1.0	5	1	0	0
37966	1624	rs cell of all histologic category	[RS cells of all histologic categories]	1.0	6	1	0	0
37967	1624	chronic infection,	[chronic infection,]	1.0	2	1	0	0
37968	1624	LNCaP human prostate cancer cell	[LNCaP human prostate cancer cells]	1.0	5	1	0	0
37969	1624	polymorphonuclear leukocyte bind to glucocorticoid	[polymorphonuclear leukocytes binding to glucocorticoid]	1.0	5	1	0	0
37970	1624	class processing	[class processing]	1.0	2	2	2	2
37971	1624	develop mature human T lymphocyte erratum	[developing mature human T lymphocytes erratum]	1.0	6	1	0	0
37972	1624	precursor frequency of anti-SSB T cell	[Precursor frequency of anti-SSB T cells]	1.0	6	1	0	0
37973	1624	body fat	[body fat]	1.0	2	1	0	0
37974	1624	1,25-dihydroxyvitamin D3 determination in lymphocyte	[1,25-dihydroxyvitamin D3 determination in lymphocytes]	1.0	5	1	0	0
37975	1624	environmental lighting	[environmental lighting]	1.0	2	1	0	0
37976	1624	mutant-activated ras	[mutant-activated Ras]	1.0	2	1	0	0
37977	1624	ebv transactivator	[EBV transactivators]	1.0	2	2	1	1
37978	1624	bear a tal1 gene rearrangement	[bearing a TAL1 gene rearrangement]	1.0	5	1	0	0
37979	1624	transcriptional activate	[transcriptional activating]	1.0	2	1	0	0
37980	1624	human neoplasm	[human neoplasms]	1.0	2	1	0	0
37981	1624	abnormality of the hpa system	[abnormalities of the HPA system]	1.0	5	1	0	0
37982	1624	express only the mutant allele	[expressing only the mutant allele]	1.0	5	1	0	0
37983	1624	level of id3 mrna increase,	[levels of Id3 mRNA increase,]	1.0	5	1	0	0
37984	1624	chromosomal damage in t-cell tumor	[chromosomal damage in T-cell tumors]	1.0	5	1	0	0
37985	1624	cd23 of germ-line epsilon transcript	[CD23 of germ-line epsilon transcripts]	1.0	5	1	0	0
37986	1624	MZF-1 mrna	[MZF-1 mRNA]	1.0	2	1	0	0
37987	1624	forty-one hd sample (19 nlphd	[Forty-one HD samples (19 NLPHD]	1.0	5	1	0	0
37988	1624	fludarabine immunosuppression	[Fludarabine immunosuppression]	1.0	2	1	0	0
37989	1624	ifn-gamma responses.	[IFN-gamma responses.]	1.0	2	1	0	0
37990	1624	cell of the monocyte lineage	[cells of the monocyte lineage]	1.0	5	1	0	0
37991	1624	alveolar lymphocyte	[alveolar lymphocytes]	1.0	2	1	0	0
37992	1624	treatment with anti-human cd14 antibody	[treatment with anti-human CD14 antibody]	1.0	5	1	0	0
37993	1624	GS strain	[GS strain]	1.0	2	1	0	0
37994	1624	immune cell infiltrate the tumor	[immune cells infiltrating the tumor]	1.0	5	1	0	0
37995	1624	rar cases,	[RARS cases,]	1.0	2	1	0	0
37996	1624	inhibitor of the DNA polymerase	[inhibitors of the DNA polymerase]	1.0	5	1	0	0
37997	1624	reversible reduction	[reversible reduction]	1.0	2	1	0	0
37998	1624	t-cell anergy	[T-cell anergy]	1.0	2	1	0	0
37999	1624	specific hla-dq allele with autoimmunity	[specific HLA-DQ alleles with autoimmunity]	1.0	5	1	0	0
38000	1624	5-fold increase	[5-fold increase]	1.0	2	1	0	0
38001	1624	cooh-terminal portion	[COOH-terminal portion]	1.0	2	1	0	0
38002	1624	erythroid cells.	[erythroid cells.]	1.0	2	1	0	0
38003	1624	dexamethasone suppressibility of [3H]thymidine incorporation	[dexamethasone suppressibility of [3H]thymidine incorporation]	1.0	5	1	0	0
38004	1624	binding of transcription factor factor	[binding of transcription factor factor]	1.0	5	1	0	0
38005	1624	consequently, apoptosis	[consequently, apoptosis]	1.0	2	1	0	0
38006	1624	dr beta	[DR beta]	1.0	2	1	0	0
38007	1624	chemical induction, superinfection with ebv	[chemical induction, superinfection with EBV]	1.0	5	1	0	0
38008	1624	amount of b-cll cell death	[amount of B-CLL cell death]	1.0	5	1	0	0
38009	1624	cross-specy effectiveness of human ciita	[cross-species effectiveness of human CIITA]	1.0	5	1	0	0
38010	1624	commitment period	[commitment period]	1.0	2	1	0	0
38011	1624	carry mutation in the e-protein gene	[carrying mutations in the E-protein genes]	1.0	6	1	0	0
38012	1624	adrenocortical function	[adrenocortical function]	1.0	2	1	0	0
38013	1624	sequence of the EBNA2 element	[sequences of the EBNA2 element]	1.0	5	1	0	0
38014	1624	immunosuppressive compound	[immunosuppressive compound]	1.0	2	2	1	1
38015	1624	phenylpyrazolo glucocorticoid of high potency	[phenylpyrazolo glucocorticoid of high potency]	1.0	5	1	0	0
38016	1624	sequence analysis of the 5'-flanking region	[Sequence analysis of the 5'-flanking region]	1.0	6	1	0	0
38017	1624	-cd3 CD3	[-CD3 CD3]	1.0	2	1	0	0
38018	1624	genetic counseling.	[genetic counseling.]	1.0	2	1	0	0
38019	1624	p65/p50 heterodimer	[P65/P50 heterodimer]	1.0	2	1	0	0
38020	1624	target cell with cytopathic virus	[target cells with cytopathic viruses]	1.0	5	1	0	0
38021	1624	suggest a carboxy-terminal negative regulatory domain	[suggesting a carboxy-terminal negative regulatory domain]	1.0	6	1	0	0
38022	1624	positive- element	[positive- elements]	1.0	2	1	0	0
38023	1624	lead to stat3 tyrosine phosphorylation	[leading to STAT3 tyrosine phosphorylation]	1.0	5	1	0	0
38024	1624	tissue-specific regulators/adapter	[tissue-specific regulators/adapters]	1.0	2	1	0	0
38025	1624	receptor response	[receptor response]	1.0	2	2	2	2
38026	1624	interference in the transactivation function	[interference in the transactivation function]	1.0	5	1	0	0
38027	1624	mechanism of generation of p50	[mechanism of generation of p50]	1.0	5	1	0	0
38028	1624	140-kDa surface antigen for mab	[140-kDa surface antigen for mAb]	1.0	5	1	0	0
38029	1624	differentiation step.	[differentiation step.]	1.0	2	1	0	0
38030	1624	1,25-(oh)2 D3 in human monocyte	[1,25-(OH)2 D3 in human monocytes]	1.0	5	1	0	0
38031	1624	mutant nm23-h2hi protein nm23-h2 protein	[mutant nm23-H2His protein nm23-H2 protein]	1.0	5	1	0	0
38032	1624	mechanism of the antiapoptotic effect	[mechanism of the antiapoptotic effects]	1.0	5	1	0	0
38033	1624	participate in the apoptosis pathway	[participating in the apoptosis pathway]	1.0	5	1	0	0
38034	1624	erythroid colony by iron staining	[erythroid colonies by iron staining]	1.0	5	1	0	0
38035	1624	rescue cytokine	[rescue cytokine]	1.0	2	1	0	0
38036	1624	anti-capsular antibody	[anti-capsular antibody]	1.0	2	1	0	0
38037	1624	OKT3 antibody	[OKT3 antibody]	1.0	2	1	0	0
38038	1624	involve macrophage	[involving macrophages]	1.0	2	1	0	0
38039	1624	therapeutic regimen	[therapeutic regimens]	1.0	2	1	0	0
38040	1624	overexpression of Bcl-2 in tumor cell	[Overexpression of Bcl-2 in tumor cells]	1.0	6	1	0	0
38041	1624	one-site kinetic	[one-site kinetics]	1.0	2	1	0	0
38042	1624	proto-oncogent c-jun	[proto-oncogenes c-jun]	1.0	2	2	1	1
38043	1624	overlap the consensus gas motif	[overlapping the consensus GAS motif]	1.0	5	1	0	0
38044	1624	recombinant polypeptide	[recombinant polypeptide]	1.0	2	1	0	0
38045	1624	immediate translocation,	[immediate translocation,]	1.0	2	1	0	0
38046	1624	antiinflammatory therapy	[antiinflammatory therapy]	1.0	2	2	1	1
38047	1624	polymorphonuclear leucocyte	[polymorphonuclear leucocytes]	1.0	2	2	1	1
38048	1624	chymotryptic activity	[chymotryptic activity]	1.0	2	2	1	1
38049	1624	human k562 cell erythroid differentiation	[human K562 cells erythroid differentiation]	1.0	5	1	0	0
38050	1624	(ie) response	[(IE) response]	1.0	2	1	0	0
38051	1624	use water soluble phorbol ester	[using water soluble phorbol esters]	1.0	5	1	0	0
38052	1624	suppression of cytokine gene expression	[suppression of cytokine gene expression]	1.0	5	1	0	0
38053	1624	cipro (20	[cipro (20]	1.0	2	1	0	0
38054	1624	murine il-2	[murine IL-2]	1.0	2	1	0	0
38055	1624	member of the IL-8 family interferon-gamma	[members of the IL-8 family interferon-gamma]	1.0	6	1	0	0
38056	1624	elucidate how	[elucidating how]	1.0	2	1	0	0
38057	1624	expression of CREB/ATF-1/CREM family member	[expression of CREB/ATF-1/CREM family members]	1.0	5	1	0	0
38058	1624	Interferon-gamma ifn-gamma	[Interferon-gamma IFN-gamma]	1.0	2	1	0	0
38059	1624	several b cell-specific transcription factor	[several B cell-specific transcription factors]	1.0	5	1	0	0
38060	1624	induce apoptosis in some CD40 MMs	[inducing apoptosis in some CD40 MMs]	1.0	6	1	0	0
38061	1624	basic helix-loop-helix protein in the regulation	[basic helix-loop-helix proteins in the regulation]	1.0	6	1	0	0
38062	1624	evidence a major target for immunosuppression	[evidence a major target for immunosuppression]	1.0	6	1	0	0
38063	1624	Rather, helenalin	[Rather, helenalin]	1.0	2	1	0	0
38064	1624	little effect on G-CSF colony formation	[little effect on G-CSF colony formation]	1.0	6	1	0	0
38065	1624	BZLF1 promoter	[BZLF1 promoter]	1.0	2	2	1	1
38066	1624	only under certain growth condition	[only under certain growth conditions]	1.0	5	1	0	0
38067	1624	constitutive manner	[constitutive manner]	1.0	2	1	0	0
38068	1624	footprinting analysis	[footprinting analysis]	1.0	2	2	1	1
38069	1624	hela	[HeLa]	1.0	1	11	6	6
38070	1624	il-3 commitment of eml cell	[IL-3 commitment of EML cells]	1.0	5	2	2	2
38071	1624	regulation of mnda expression in monocyte	[Regulation of MNDA expression in monocytes]	1.0	6	1	0	0
38072	1624	lymphoid extract	[lymphoid extracts]	1.0	2	2	1	1
38073	1624	cellular immune response to hiv-1	[cellular immune response to HIV-1]	1.0	5	1	0	0
38074	1624	promoter element for constitutive transcription	[promoter elements for constitutive transcription]	1.0	5	1	0	0
38075	1624	0.5-gy exposure	[0.5-Gy exposure]	1.0	2	2	1	1
38076	1624	biochemical finding	[biochemical findings]	1.0	2	1	0	0
38077	1624	fundamental difference in the phosphorylation	[fundamental differences in the phosphorylation]	1.0	5	1	0	0
38078	1624	e(2) receptor-positive murine monocytic line,	[E(2) receptor-positive murine monocytic line,]	1.0	5	1	0	0
38079	1624	rat macrophage cell line R2	[rat macrophage cell line R2]	1.0	5	1	0	0
38080	1624	vincristine-selected, multidrug resistance on 12-o-tetradecanoylphorbol-13-acetate	[vincristine-selected, multidrug resistance on 12-O-tetradecanoylphorbol-13-acetate]	1.0	5	1	0	0
38081	1624	CD28RE sequence	[CD28RE sequence]	1.0	2	1	0	0
38082	1624	Kinase activity	[Kinase activity]	1.0	2	1	0	0
38083	1624	IL-1 kinase on nfkappab activation	[IL-1 kinase on NFkappaB activation]	1.0	5	1	0	0
38084	1624	lmp-1 molecule	[LMP-1 molecule]	1.0	2	1	0	0
38085	1624	epo -responsiveness	[EPO -responsiveness]	1.0	2	1	0	0
38086	1624	electrophoretic DNA	[electrophoretic DNA]	1.0	2	1	0	0
38087	1624	fasl regulation	[FasL regulation]	1.0	2	1	0	0
38088	1624	well-established risk factor for atherosclerosis	[well-established risk factor for atherosclerosis]	1.0	5	1	0	0
38089	1624	elevate nf-il6	[elevated NF-IL6]	1.0	2	1	0	0
38090	1624	certain process	[certain processes]	1.0	2	1	0	0
38091	1624	subsequent internalization	[subsequent internalization]	1.0	2	1	0	0
38092	1624	pre-treatment of pbmc with IL-10	[pre-treatment of PBMC with IL-10]	1.0	5	1	0	0
38093	1624	celiac disease due to molecular mimicry	[celiac disease due to molecular mimicry]	1.0	6	1	0	0
38094	1624	posttranscriptional effect	[posttranscriptional effect]	1.0	2	2	1	1
38095	1624	PMA induction of CAT activity	[PMA induction of CAT activity]	1.0	5	1	0	0
38096	1624	macrophage protein-1alpha	[macrophage protein-1alpha]	1.0	2	2	2	2
38097	1624	CD4 negative T cell line	[CD4 negative T cell lines]	1.0	5	1	0	0
38098	1624	26 degree	[26 degrees]	1.0	2	1	0	0
38099	1624	serum-supplemented culture	[serum-supplemented cultures]	1.0	2	1	0	0
38100	1624	PECAM-1 promoter	[PECAM-1 promoter]	1.0	2	1	0	0
38101	1624	acute exposure to ionize radiation	[acute exposure to ionizing radiation]	1.0	5	1	0	0
38102	1624	optimal kappa b/rel dna-binding motif	[optimal kappa B/Rel DNA-binding motifs]	1.0	5	1	0	0
38103	1624	thus implicate this region in DNA	[thus implicating this region in DNA]	1.0	6	1	0	0
38104	1624	multiple X1 box-specific dna-binding activity	[multiple X1 box-specific DNA-binding activities]	1.0	5	1	0	0
38105	1624	endothelial leukocyte adhesion molecule (elam)-1	[endothelial leukocyte adhesion molecule (ELAM)-1]	1.0	5	1	0	0
38106	1624	lymphotoxin promoter	[lymphotoxin promoter]	1.0	2	1	0	0
38107	1624	IRF-1 gas element after cytokine stimulation	[IRF-1 GAS elements after cytokine stimulation]	1.0	6	1	0	0
38108	1624	GCII sites/cell	[GCII sites/cell]	1.0	2	1	0	0
38109	1624	adhesion molecule for neutrophil leukocyte	[adhesion molecules for neutrophils leukocytes]	1.0	5	1	0	0
38110	1624	coordinate suppression of MHC class	[coordinate suppression of MHC class]	1.0	5	1	0	0
38111	1624	mutation in the 5' noncode region	[mutations in the 5' noncoding region]	1.0	6	1	0	0
38112	1624	activation of the TAL1 scl) gene	[Activation of the TAL1 SCL) gene]	1.0	6	1	0	0
38113	1624	leukocyte protein of 76 kD slp-76	[leukocyte protein of 76 kD SLP-76]	1.0	6	1	0	0
38114	1624	nuclear periphery,	[nuclear periphery,]	1.0	2	1	0	0
38115	1624	parallel with differentiation, hiv transcription	[parallel with differentiation, HIV transcription]	1.0	5	1	0	0
38116	1624	immunoprecipitation experiment	[Immunoprecipitation experiments]	1.0	2	1	0	0
38117	1624	mediate transcription	[mediating transcription]	1.0	2	2	2	2
38118	1624	synergistic induction of il-8 expression	[synergistic induction of IL-8 expression]	1.0	5	1	0	0
38119	1624	laboratory datum	[laboratory data]	1.0	2	1	0	0
38120	1624	diploid state of the genome	[diploid state of the genome]	1.0	5	1	0	0
38121	1624	immunoglobulin rearrangement	[immunoglobulin rearrangement]	1.0	2	1	0	0
38122	1624	3' portion of this sequence	[3' portion of this sequence]	1.0	5	1	0	0
38123	1624	2 h of cryptococcal stimulation	[2 h of cryptococcal stimulation]	1.0	5	1	0	0
38124	1624	burst-forming unit-erythroid (bfu-e) colony formation	[burst-forming unit-erythroid (BFU-E) colony formation]	1.0	5	1	0	0
38125	1624	activation of a reporter gene	[activation of a reporter gene]	1.0	5	2	1	1
38126	1624	high ratios,	[higher ratios,]	1.0	2	1	0	0
38127	1624	dominant regulator	[dominant regulator]	1.0	2	2	2	2
38128	1624	insect cell as a protein	[insect cells as a protein]	1.0	5	1	0	0
38129	1624	1 month	[1 month]	1.0	2	1	0	0
38130	1624	arterial endothelium	[arterial endothelium]	1.0	2	1	0	0
38131	1624	effect via phosphorylation of creb	[effects via phosphorylation of CREB]	1.0	5	1	0	0
38132	1624	fos/jun protein	[Fos/Jun proteins]	1.0	2	1	0	0
38133	1624	construct contain 5' deletion mutant	[constructs containing 5' deletion mutants]	1.0	5	1	0	0
38134	1624	ifn-alpha stat1	[IFN-alpha STAT1]	1.0	2	2	1	1
38135	1624	lavage cell (12/12 tuberculosis patient	[lavage cells (12/12 tuberculosis patients]	1.0	5	1	0	0
38136	1624	cell epithelioma	[cell epitheliomas]	1.0	2	2	2	2
38137	1624	transfect human T lymphocyte jurkat cell	[transfecting human T lymphocyte Jurkat cells]	1.0	6	1	0	0
38138	1624	Ro in the CS group	[Ro in the CS group]	1.0	5	1	0	0
38139	1624	non-lymphoid cell	[non-lymphoid cells]	1.0	2	1	0	0
38140	1624	regulate the expression of this proteinase	[regulating the expression of this proteinase]	1.0	6	1	0	0
38141	1624	differential expression of pax-5 isoform	[differential expression of Pax-5 isoforms]	1.0	5	1	0	0
38142	1624	contain a BP1 binding site	[containing a BP1 binding site]	1.0	5	1	0	0
38143	1624	human monocyte il-1 receptor antagonist	[Human monocyte IL-1 receptor antagonist]	1.0	5	1	0	0
38144	1624	action on human dendritic cell (dc)	[action on human dendritic cells (DC)]	1.0	6	1	0	0
38145	1624	transactivation domain of NF-kappa b p65	[transactivation domain of NF-kappa B p65]	1.0	6	1	0	0
38146	1624	direct sequencing of pcr product	[direct sequencing of PCR products]	1.0	5	1	0	0
38147	1624	activation of germline region promoter	[activation of germline region promoters]	1.0	5	1	0	0
38148	1624	proliferative status	[proliferative status]	1.0	2	1	0	0
38149	1624	upstream segment	[upstream segment]	1.0	2	1	0	0
38150	1624	tre -DNA	[TRE -DNA]	1.0	2	1	0	0
38151	1624	tumor necrosis factor receptor-1 tnfr-1	[Tumor necrosis factor receptor-1 TNFR-1]	1.0	5	1	0	0
38152	1624	pha pbl from elderly adult	[PHA PBL from elderly adults]	1.0	5	1	0	0
38153	1624	twou ms-2beta	[two, MS-2beta]	1.0	2	1	0	0
38154	1624	start at the early stage	[starting at the earliest stages]	1.0	5	1	0	0
38155	1624	embryonic gene	[embryonic gene]	1.0	2	1	0	0
38156	1624	ttcaaag motif	[TTCAAAG motif]	1.0	2	1	0	0
38157	1624	ns-meg cell	[NS-Meg cells]	1.0	2	1	0	0
38158	1624	indicate sequence-specific	[indicating sequence-specific]	1.0	2	1	0	0
38159	1624	colony-forming unit	[colony-forming unit]	1.0	2	2	2	2
38160	1624	transactivate rela	[transactivating RelA]	1.0	2	1	0	0
38161	1624	serum response factor (srf) peptide	[serum response factor (SRF) peptides]	1.0	5	1	0	0
38162	1624	latent complex with nf-kappa b	[latent complexes with NF-kappa B]	1.0	5	1	0	0
38163	1624	sensitivity (id50) of the lymphocyte	[Sensitivity (ID50) of the lymphocytes]	1.0	5	1	0	0
38164	1624	ige switch in b cell	[IgE switching in B cells]	1.0	5	1	0	0
38165	1624	maturation of lineage (day 21	[maturation of lineages (days 21]	1.0	5	1	0	0
38166	1624	continuously grow	[continuously growing]	1.0	2	1	0	0
38167	1624	mediate neutrophil adhesion during inflammation	[mediating neutrophil adhesion during inflammation]	1.0	5	1	0	0
38168	1624	expression in hematopoietic cell line	[expression in hematopoietic cell lines]	1.0	5	1	0	0
38169	1624	be value	[r value]	1.0	2	1	0	0
38170	1624	il-10 cytokine	[IL-10 cytokines]	1.0	2	1	0	0
38171	1624	possible involvement of the activity	[possible involvement of the activity]	1.0	5	1	0	0
38172	1624	TATA motif	[TATA motif]	1.0	2	1	0	0
38173	1624	catalyst thioredoxin	[catalyst thioredoxin]	1.0	2	2	2	2
38174	1624	camp-response element CRE TGACGTCA present	[cAMP-response element CRE TGACGTCA present]	1.0	5	1	0	0
38175	1624	10-15 min.	[10-15 min.]	1.0	2	1	0	0
38176	1624	interaction with the rar/rxr heterodimer	[interaction with the RAR/RXR heterodimer]	1.0	5	1	0	0
38177	1624	switch region bind protein LR1	[switch region binding protein LR1]	1.0	5	1	0	0
38178	1624	nih3t3 cell	[NIH3T3 cells]	1.0	2	2	1	1
38179	1624	allele specificity of tal1 transcription	[allele specificity of TAL1 transcription]	1.0	5	1	0	0
38180	1624	bone-resorbing activity	[bone-resorbing activity]	1.0	2	1	0	0
38181	1624	human myelomonocytic cell line enhancement	[human myelomonocytic cell line enhancement]	1.0	5	1	0	0
38182	1624	m.tremblay, j.exp.med.183:39-48,	[M.Tremblay, J.Exp.Med.183:39-48,]	1.0	2	1	0	0
38183	1624	kappa B-fos-CAT	[kappa B-fos-CAT]	1.0	2	1	0	0
38184	1624	systematic approach	[systematic approach]	1.0	2	1	0	0
38185	1624	specific antisera	[specific antisera]	1.0	2	2	2	2
38186	1624	cytoskeletal structure	[cytoskeletal structure]	1.0	2	1	0	0
38187	1624	Interleukin-12 IL-12 a heterodimeric cytokine	[Interleukin-12 IL-12 a heterodimeric cytokine]	1.0	5	1	0	0
38188	1624	5-fold stimulation	[5-fold stimulation]	1.0	2	1	0	0
38189	1624	clinical/histological parameter	[clinical/histological parameters]	1.0	2	1	0	0
38190	1624	react intracellularly with hydrogen peroxide	[reacting intracellularly with hydrogen peroxide]	1.0	5	1	0	0
38191	1624	heterodimeric NFKB2	[heterodimeric NFKB2]	1.0	2	1	0	0
38192	1624	proteolytic cleavage by cathepsin b	[proteolytic cleavage by cathepsin B]	1.0	5	1	0	0
38193	1624	silencing of human fetal globin expression	[Silencing of human fetal globin expression]	1.0	6	1	0	0
38194	1624	developmental- regulation by trans-acting factor	[developmental- regulation by trans-acting factors]	1.0	5	1	0	0
38195	1624	series of c-jun promoter fragment	[series of c-jun promoter fragments]	1.0	5	1	0	0
38196	1624	E1A expression	[E1A expression]	1.0	2	1	0	0
38197	1624	critical b cell-specific gene blk	[critical B cell-specific gene blk]	1.0	5	1	0	0
38198	1624	PD 098059	[PD 098,059]	1.0	2	1	0	0
38199	1624	overall therefore, exposure to nsaid	[Overall therefore, exposure to NSAIDs]	1.0	5	1	0	0
38200	1624	MIP-1 alpha	[MIP-1 alpha]	1.0	2	2	1	1
38201	1624	anti-CD3 proliferation of T cell	[anti-CD3 proliferation of T cells]	1.0	5	1	0	0
38202	1624	serum-inducible element	[serum-inducible element]	1.0	2	2	2	2
38203	1624	captopril treatment	[captopril treatment]	1.0	2	2	2	2
38204	1624	Furthermore, epithelial level of stat1	[Furthermore, epithelial levels of Stat1]	1.0	5	1	0	0
38205	1624	single cytokine	[single cytokine]	1.0	2	1	0	0
38206	1624	beta-gal activity	[beta-gal activity]	1.0	2	1	0	0
38207	1624	(htlv-1)-associated disease	[(HTLV-1)-associated diseases]	1.0	2	1	0	0
38208	1624	mouse granulocyte/macrophage	[mouse granulocyte/macrophage]	1.0	2	1	0	0
38209	1624	danazol on site in vitro.	[danazol on sites in vitro.]	1.0	5	1	0	0
38210	1624	dose-dependent stimulation of c-jun synthesis.	[dose-dependent stimulation of c-jun synthesis.]	1.0	5	1	0	0
38211	1624	human DC	[human DC]	1.0	2	2	1	1
38212	1624	advanced infection	[advanced infection]	1.0	2	1	0	0
38213	1624	anti- il-8	[anti- IL-8]	1.0	2	1	0	0
38214	1624	set of ms2-hbx fusion protein	[set of MS2-HBx fusion proteins]	1.0	5	1	0	0
38215	1624	recognize a 17-amino acid epitope	[recognizing a 17-amino acid epitope]	1.0	5	1	0	0
38216	1624	form of Epstein-Barr viral DNA	[form of Epstein-Barr viral DNA]	1.0	5	2	2	2
38217	1624	binding of a nuclear factor	[binding of a nuclear factor]	1.0	5	1	0	0
38218	1624	abnormal thymopoiesis	[abnormal thymopoiesis]	1.0	2	1	0	0
38219	1624	IL2 region	[IL2 region]	1.0	2	2	2	2
38220	1624	(consist of subunit a dp65	[(consisting of subunits an dp65]	1.0	5	1	0	0
38221	1624	nature of stat protein capable	[nature of STAT proteins capable]	1.0	5	1	0	0
38222	1624	T lymphocyte the predominant producer	[T lymphocytes the predominant producers]	1.0	5	1	0	0
38223	1624	member of the TNFR superfamily	[member of the TNFR superfamily]	1.0	5	2	1	1
38224	1624	g1- phase	[G1- phase]	1.0	2	1	0	0
38225	1624	soluble peptide	[soluble peptide]	1.0	2	1	0	0
38226	1624	high mobility	[high mobility]	1.0	2	1	0	0
38227	1624	combination of all-tran retinoic acid RA	[Combinations of all-trans retinoic acid RA]	1.0	6	1	0	0
38228	1624	induction of the pilot gene	[Induction of the PILOT gene]	1.0	5	1	0	0
38229	1624	Ab l227	[Ab L227]	1.0	2	1	0	0
38230	1624	differentiation in response to all analog	[Differentiation in response to all analogs]	1.0	6	1	0	0
38231	1624	various immediate early serum gene	[various immediate early serum genes]	1.0	5	1	0	0
38232	1624	alter position within the protein.	[altering position within the protein.]	1.0	5	1	0	0
38233	1624	IL-4 receptor alpha-chain cytoplasmic domain	[IL-4 receptor alpha-chain cytoplasmic domain]	1.0	5	1	0	0
38234	1624	requirement of tyrosine kinase activation	[Requirement of tyrosine kinase activation]	1.0	5	1	0	0
38235	1624	neonatal than adult T cell	[neonatal than adult T cells]	1.0	5	1	0	0
38236	1624	express the chimeric ebna2 protein	[expressing the chimeric EBNA2 protein]	1.0	5	1	0	0
38237	1624	transrepressive activity	[transrepressive activity]	1.0	2	2	2	2
38238	1624	malignancy-associated defect in this cell	[malignancy-associated defect in these cells]	1.0	5	1	0	0
38239	1624	dominant control	[dominant control]	1.0	2	1	0	0
38240	1624	three subunit	[three subunits]	1.0	2	1	0	0
38241	1624	8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride	[8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride]	1.0	2	1	0	0
38242	1624	cytolytic assays.	[cytolytic assays.]	1.0	2	1	0	0
38243	1624	activation signal to the apc	[activation signals to the APC]	1.0	5	1	0	0
38244	1624	point mutation of a CCACC site	[Point mutation of a CCACC site]	1.0	6	1	0	0
38245	1624	human NK	[Human NK]	1.0	2	2	1	1
38246	1624	glial cell in the pathogenesis	[glial cells in the pathogenesis]	1.0	5	1	0	0
38247	1624	IL-5 a potent growth factor	[IL-5 a potent growth factor]	1.0	5	1	0	0
38248	1624	oncogenic process	[oncogenic processes]	1.0	2	1	0	0
38249	1624	mammalian NF-kappaB	[mammalian NF-kappaB]	1.0	2	1	0	0
38250	1624	Fas cd95/apo-1	[Fas CD95/APO-1]	1.0	2	1	0	0
38251	1624	11+/cd4+ T lymphocyte from this mouse	[11+/CD4+ T lymphocytes from these mice]	1.0	6	1	0	0
38252	1624	slightly c-fo	[slightly c-fos]	1.0	2	1	0	0
38253	1624	secretion of TNF the product	[Secretion of TNF the product]	1.0	5	1	0	0
38254	1624	pwm stimulation	[PWM stimulation]	1.0	2	1	0	0
38255	1624	include expression of the proviral genome	[including expression of the proviral genome]	1.0	6	1	0	0
38256	1624	enzyme expression	[enzyme expression]	1.0	2	1	0	0
38257	1624	IL-2 phosphorylation of il-2r beta	[IL-2 phosphorylation of IL-2R beta]	1.0	5	1	0	0
38258	1624	significant systemic effect of glucocorticoid	[significant systemic effects of glucocorticoids]	1.0	5	1	0	0
38259	1624	DNA sequence homology of E1A gene	[DNA sequence homology of E1A genes]	1.0	6	1	0	0
38260	1624	24,25-dihydroxy-vitamin D3 2422(oh)2d3 a response	[24,25-dihydroxy-vitamin D3 24,25(OH)2D3 a response]	1.0	5	1	0	0
38261	1624	two T. pallidum lipoprotein Tpp47	[two T. pallidum lipoproteins Tpp47]	1.0	5	1	0	0
38262	1624	selective activation of intracellular signal cascade	[selective activation of intracellular signaling cascades]	1.0	6	1	0	0
38263	1624	human U2	[human U2]	1.0	2	1	0	0
38264	1624	estrogen receptor in vernal keratoconjunctivitis	[Estrogen receptors in vernal keratoconjunctivitis]	1.0	5	1	0	0
38265	1624	make interruption of a locus	[making interruption of a locus]	1.0	5	1	0	0
38266	1624	PMA differentiation in u937 monoblastic cell	[PMA differentiation in U937 monoblastic cells]	1.0	6	1	0	0
38267	1624	involvement of nfatp in activation	[involvement of NFATp in activation]	1.0	5	1	0	0
38268	1624	up-regulation of the growth factor-B proto-oncogene	[up-regulation of the growth factor-B proto-oncogene]	1.0	6	1	0	0
38269	1624	regulation of il-2 gene expression	[regulation of IL-2 gene expression]	1.0	5	2	1	1
38270	1624	METHODS: EC	[METHODS: EC]	1.0	2	1	0	0
38271	1624	bipartite human interleukin-4 IL-4 receptor	[bipartite human interleukin-4 IL-4 receptor]	1.0	5	1	0	0
38272	1624	activation of stat in T	[activation of STATs in T]	1.0	5	1	0	0
38273	1624	indicate heterogeneity of the t-cell population	[indicating heterogeneity of the T-cell population]	1.0	6	1	0	0
38274	1624	ERK1 activity	[ERK1 activity]	1.0	2	1	0	0
38275	1624	hit-t15 cell use a sugar	[HIT-T15 cells using a sugar]	1.0	5	1	0	0
38276	1624	A element,	[A element,]	1.0	2	1	0	0
38277	1624	mammalian small nuclear rna (snrna) gene	[mammalian small nuclear RNA (snRNA) genes]	1.0	6	1	0	0
38278	1624	10 bp	[10 bp]	1.0	2	2	1	1
38279	1624	synovial compartment	[synovial compartment]	1.0	2	1	0	0
38280	1624	myeloid-specific gene	[myeloid-specific genes]	1.0	2	2	2	2
38281	1624	[3h] dexamethasone binding in cytosolic preparation	[[3H] dexamethasone binding in cytosolic preparations]	1.0	6	1	0	0
38282	1624	typical inducer of monocytic differentiation	[typical inducer of monocytic differentiation]	1.0	5	1	0	0
38283	1624	leukaemic change.	[leukaemic change.]	1.0	2	1	0	0
38284	1624	Kinase C	[Kinase C]	1.0	2	1	0	0
38285	1624	pivotal event	[pivotal event]	1.0	2	2	2	2
38286	1624	apoptosis of erythroid progenitor cell	[apoptosis of erythroid progenitor cells]	1.0	5	1	0	0
38287	1624	differentiation to alveolar macrophage AMs	[differentiation to alveolar macrophages AMs]	1.0	5	1	0	0
38288	1624	include change	[including changes]	1.0	2	2	2	2
38289	1624	synthesis of the 85-kDa phospholipase a2	[synthesis of the 85-kDa phospholipase A2]	1.0	6	1	0	0
38290	1624	modulation of expression of gene	[modulation of expression of genes]	1.0	5	1	0	0
38291	1624	consensus sequence in the region	[consensus sequence in the region]	1.0	5	1	0	0
38292	1624	LAI LTR	[LAI LTR]	1.0	2	1	0	0
38293	1624	HS ii	[HS II]	1.0	2	1	0	0
38294	1624	human ec	[human EC]	1.0	2	1	0	0
38295	1624	role in human b-cell activation	[role in human B-cell activation]	1.0	5	1	0	0
38296	1624	Y-box element	[Y-box element]	1.0	2	2	1	1
38297	1624	human gr	[human GR]	1.0	2	2	1	1
38298	1624	cytoplasmic retention	[cytoplasmic retention]	1.0	2	2	2	2
38299	1624	DNA binding by deletion mutant	[DNA binding by deletion mutants]	1.0	5	1	0	0
38300	1624	Stat5 expression	[Stat5 expression]	1.0	2	1	0	0
38301	1624	IkappaB alpha phosphorylation on Ser-32	[IkappaB alpha phosphorylation on Ser-32]	1.0	5	1	0	0
38302	1624	polyamine concentration	[polyamine concentrations]	1.0	2	1	0	0
38303	1624	human er	[human ER]	1.0	2	1	0	0
38304	1624	result in NF-kappa b translocation cell	[resulting in NF-kappa B translocation cells]	1.0	6	1	0	0
38305	1624	CD40 activation of b lymphocyte	[CD40 activation of B lymphocytes]	1.0	5	1	0	0
38306	1624	efficient inhibitor of ifn-gamma induction	[efficient inhibitor of IFN-gamma induction]	1.0	5	1	0	0
38307	1624	factor promoter	[factor promoter]	1.0	2	2	2	2
38308	1624	biologically distinct subset of DLCL	[biologically distinct subsets of DLCL]	1.0	5	1	0	0
38309	1624	especially in chronic inflammatory-type condition	[especially in chronic inflammatory-type conditions]	1.0	5	1	0	0
38310	1624	Also, VitD3	[Also, VitD3]	1.0	2	1	0	0
38311	1624	high level in this cells.	[high levels in these cells.]	1.0	5	1	0	0
38312	1624	ligand binding datum include polysaccharide specificity	[ligand binding data, including polysaccharide specificity]	1.0	6	1	0	0
38313	1624	such as 12-o-tetradecanoyl phorbol 13-acetate tpa	[such as 12-O-tetradecanoyl phorbol 13-acetate TPA]	1.0	6	1	0	0
38314	1624	lt activity	[LT activity]	1.0	2	2	2	2
38315	1624	initial decrease	[initial decrease]	1.0	2	1	0	0
38316	1624	human mm	[human MM]	1.0	2	1	0	0
38317	1624	co-stimulatory molecule by antigen-presenting cell	[co-stimulatory molecules by antigen-presenting cells]	1.0	5	1	0	0
38318	1624	hepatic cirrhosis	[hepatic cirrhosis]	1.0	2	1	0	0
38319	1624	express some characteristic of promyelocyte	[expressing some characteristics of promyelocytes]	1.0	5	1	0	0
38320	1624	more than 24 month (24-58	[more than 24 months (24-58]	1.0	5	1	0	0
38321	1624	fra-1 follow engagement of CD40	[fra-1 following engagement of CD40]	1.0	5	1	0	0
38322	1624	CD4 signal	[CD4 signaling]	1.0	2	1	0	0
38323	1624	serine-rich region	[serine-rich region]	1.0	2	1	0	0
38324	1624	thyrotropin receptor in thyroid disease	[thyrotropin receptor in thyroid diseases]	1.0	5	1	0	0
38325	1624	vivo differentiation:	[vivo differentiation:]	1.0	2	1	0	0
38326	1624	genetic composition	[genetic composition]	1.0	2	1	0	0
38327	1624	b cell -specific transcription factor	[B cell -specific transcription factor]	1.0	5	1	0	0
38328	1624	tata-less promoter	[TATA-less promoter]	1.0	2	2	1	1
38329	1624	emergence of this dna-binding protein	[emergence of these DNA-binding proteins]	1.0	5	1	0	0
38330	1624	eg, tumor necrosis factor alpha	[eg, tumor necrosis factor alpha]	1.0	5	1	0	0
38331	1624	late G1	[late G1]	1.0	2	1	0	0
38332	1624	result in a frame shift	[resulting in a frame shift]	1.0	5	1	0	0
38333	1624	approximately 300 bp of the 3'-region	[approximately 300 bp of the 3'-region]	1.0	6	1	0	0
38334	1624	normal concentration of plasma cortisol	[normal concentration of plasma cortisol]	1.0	5	1	0	0
38335	1624	specify high affinity for GRE site	[specifying high affinity for GRE sites]	1.0	6	1	0	0
38336	1624	time course of sp1 cleavage	[time course of SP1 cleavage]	1.0	5	1	0	0
38337	1624	33-kDa protein	[33-kDa protein]	1.0	2	1	0	0
38338	1624	e1a-binding protein	[E1A-binding protein]	1.0	2	1	0	0
38339	1624	purine-rich region	[purine-rich region]	1.0	2	1	0	0
38340	1624	important consequence in the clinical use	[important consequences in the clinical use]	1.0	6	1	0	0
38341	1624	TBP-associated factor	[TBP-associated factor]	1.0	2	1	0	0
38342	1624	human sr	[human SR]	1.0	2	1	0	0
38343	1624	female development	[female development]	1.0	2	1	0	0
38344	1624	5 steroid hormone anti-sera estradiol	[5 steroid hormone anti-sera estradiol]	1.0	5	1	0	0
38345	1624	human GM-CSF receptor alpha promoter	[human GM-CSF receptor alpha promoter]	1.0	5	1	0	0
38346	1624	human t-	[human T-]	1.0	2	1	0	0
38347	1624	resistance to tricyclic antidepressant of hypercortisolemia	[resistance to tricyclic antidepressants of hypercortisolemia]	1.0	6	1	0	0
38348	1624	ultra-violet irradiation of human keratinocyte	[UV irradiation of human keratinocytes]	1.0	5	1	0	0
38349	1624	il-10 of proinflammatory cytokine release	[IL-10 of proinflammatory cytokine release]	1.0	5	1	0	0
38350	1624	only the x1- box of HLA-DRA	[only the X1- boxes of HLA-DRA]	1.0	6	1	0	0
38351	1624	nf-kappab activity by mobility shift assay	[NF-kappaB activity by mobility shift assay]	1.0	6	1	0	0
38352	1624	eosinophil infiltrate into different pathologic process	[eosinophils infiltrating into different pathologic processes]	1.0	6	1	0	0
38353	1624	adaptor function	[adaptor function]	1.0	2	2	2	2
38354	1624	basal phosphorylation	[basal phosphorylation]	1.0	2	2	2	2
38355	1624	cruciform DNA	[cruciform DNA]	1.0	2	1	0	0
38356	1624	13-acetate tpa	[13-acetate TPA]	1.0	2	1	0	0
38357	1624	analysis of erythroblast co-express Spi-1	[Analysis of erythroblasts co-expressing Spi-1]	1.0	5	1	0	0
38358	1624	icam-1 in adult-t-cell-leukemia cell line	[ICAM-1 in adult-T-cell-leukemia cell lines]	1.0	5	1	0	0
38359	1624	18-hydroxycorticosterone level	[18-hydroxycorticosterone levels]	1.0	2	1	0	0
38360	1624	only through evaluation of clinical evidence	[Only through evaluation of clinical evidence]	1.0	6	1	0	0
38361	1624	role of NF-kappa b complex	[role of NF-kappa B complexes]	1.0	5	1	0	0
38362	1624	use the THP-1 phagocyte cell line	[using the THP-1 phagocyte cell line]	1.0	6	1	0	0
38363	1624	mononuclear cell particularly b cell	[mononuclear cells particularly B cells]	1.0	5	1	0	0
38364	1624	intact cells,	[intact cells,]	1.0	2	1	0	0
38365	1624	2% concentration in the presence	[2% concentration in the presence]	1.0	5	1	0	0
38366	1624	biochemical sign	[biochemical signs]	1.0	2	2	2	2
38367	1624	critical cytokine	[critical cytokine]	1.0	2	2	2	2
38368	1624	promoter of the gene coding	[promoter of the gene coding]	1.0	5	1	0	0
38369	1624	free radical gene transcription in t-cell	[free radical gene transcription in T-cells]	1.0	6	1	0	0
38370	1624	patient with primary glucocorticoid resistance	[patients with primary glucocorticoid resistance]	1.0	5	1	0	0
38371	1624	pnu156804 inhibition of NF-kappa b activation	[PNU156804 inhibition of NF-kappa B activation]	1.0	6	1	0	0
38372	1624	il-10 pretreatment	[IL-10 pretreatment]	1.0	2	1	0	0
38373	1624	human monocyte to macrophage maturation	[human monocyte to macrophage maturation]	1.0	5	1	0	0
38374	1624	eosinophilic characteristic	[eosinophilic characteristics]	1.0	2	2	1	1
38375	1624	deregulation of the c-myc allele	[deregulation of the c-myc allele]	1.0	5	1	0	0
38376	1624	strong signal	[strong signals]	1.0	2	1	0	0
38377	1624	rela -i kappa b alpha	[RelA -I kappa B alpha]	1.0	5	1	0	0
38378	1624	factor, miss	[factor, missing]	1.0	2	1	0	0
38379	1624	progenitor/precursor cell grow in culture.	[progenitor/precursor cells growing in culture.]	1.0	5	1	0	0
38380	1624	expression of closely related gene	[expression of closely related genes]	1.0	5	1	0	0
38381	1624	subsequent monocyte adhesion in endothelial cell	[subsequent monocyte adhesion in endothelial cells]	1.0	6	1	0	0
38382	1624	expression of gh in subset	[expression of GH in subsets]	1.0	5	1	0	0
38383	1624	cellular system	[cellular system]	1.0	2	2	1	1
38384	1624	functional significance	[functional significance]	1.0	2	4	3	1
38385	1624	response to the same stimuli.	[response to the same stimuli.]	1.0	5	1	0	0
38386	1624	propidium iodide	[propidium iodide]	1.0	2	2	2	2
38387	1624	examined, breast	[examined, breast]	1.0	2	1	0	0
38388	1624	(atf) family CREB two isoform	[(ATF) family CREB two isoforms]	1.0	5	1	0	0
38389	1624	constitutive pkb/akt	[constitutive PKB/Akt]	1.0	2	1	0	0
38390	1624	kb 5'	[kb 5']	1.0	2	2	2	2
38391	1624	dramatic dose-dependent shift from erythroid	[dramatic dose-dependent shift from erythroid]	1.0	5	1	0	0
38392	1624	binding of human nf-kappa b	[binding of human NF-kappa B]	1.0	5	1	0	0
38393	1624	pharmacological dose	[pharmacological doses]	1.0	2	1	0	0
38394	1624	conventional means	[conventional means]	1.0	2	1	0	0
38395	1624	simultaneous induction	[simultaneous induction]	1.0	2	1	0	0
38396	1624	homeostatic control	[homeostatic control]	1.0	2	1	0	0
38397	1624	human nf-at	[human NF-AT]	1.0	2	1	0	0
38398	1624	Glucocorticoid effect	[Glucocorticoid effects]	1.0	2	1	0	0
38399	1624	daily excretion	[daily excretion]	1.0	2	1	0	0
38400	1624	most study on the expression	[Most studies on the expression]	1.0	5	1	0	0
38401	1624	similar kd.	[similar Kd.]	1.0	2	1	0	0
38402	1624	c-fo promoter activity in serum-activated Jurkat	[c-fos promoter activity in serum-activated Jurkat]	1.0	6	1	0	0
38403	1624	myb family of transcription factor	[myb family of transcription factors]	1.0	5	1	0	0
38404	1624	bp -92	[bp -92]	1.0	2	1	0	0
38405	1624	pretranslational level	[pretranslational level]	1.0	2	1	0	0
38406	1624	antioxidant molecule	[antioxidant molecule]	1.0	2	2	1	1
38407	1624	bsap in a large panel	[BSAP in a large panel]	1.0	5	1	0	0
38408	1624	intracellular granule	[intracellular granules]	1.0	2	1	0	0
38409	1624	incubation of lymphocyte with pha	[incubation of lymphocytes with PHA]	1.0	5	1	0	0
38410	1624	mediate the effect of anti-inflammatory drug	[mediating the effects of anti-inflammatory drugs]	1.0	6	1	0	0
38411	1624	contain the human GATA3 transcription unit	[containing the human GATA3 transcription unit]	1.0	6	1	0	0
38412	1624	two subtypes.	[two subtypes.]	1.0	2	1	0	0
38413	1624	interleukin-2 a typical T cell cytokine	[interleukin-2 a typical T cell cytokine]	1.0	6	1	0	0
38414	1624	6 epstein-barr	[6 Epstein-Barr]	1.0	2	1	0	0
38415	1624	stable expression in human jurkat-t cell	[stable expression in human Jurkat-T cells]	1.0	6	1	0	0
38416	1624	gh3 ne	[GH3 NE]	1.0	2	1	0	0
38417	1624	only a low degree of transcription,	[only a low degree of transcription,]	1.0	6	1	0	0
38418	1624	human gingival	[human gingival]	1.0	2	2	1	1
38419	1624	precise role of this protein	[precise role of these proteins]	1.0	5	1	0	0
38420	1624	general effect	[general effects]	1.0	2	1	0	0
38421	1624	network aspect,	[network aspect,]	1.0	2	1	0	0
38422	1624	examination of IkappaB alpha regulation	[Examination of IkappaB alpha regulation]	1.0	5	1	0	0
38423	1624	level of cAMP-dependent protein kinase	[levels of cAMP-dependent protein kinase]	1.0	5	1	0	0
38424	1624	expression of a active pkb	[expression of an active PKB]	1.0	5	1	0	0
38425	1624	anti-tumour activity in haematopoietic tumour	[anti-tumour activity in haematopoietic tumours]	1.0	5	1	0	0
38426	1624	thus, localization of both factor	[Thus, localization of both factors]	1.0	5	1	0	0
38427	1624	transcript from the BamHI-A region	[Transcripts from the BamHI-A region]	1.0	5	1	0	0
38428	1624	minor salivary gland of patient	[minor salivary glands of patients]	1.0	5	1	0	0
38429	1624	pml transcript	[PML transcript]	1.0	2	1	0	0
38430	1624	1 to 7.5 mm) in vitro,	[1 to 7.5 mM) in vitro,]	1.0	6	1	0	0
38431	1624	concentration range from 1 mmol/L.	[concentrations ranging from 1 mmol/L.]	1.0	5	1	0	0
38432	1624	include NFAT-1	[including NFAT-1]	1.0	2	1	0	0
38433	1624	Ras signal in T cell	[Ras signaling in T cells]	1.0	5	1	0	0
38434	1624	support replication of E1a- ad vector	[supporting replication of E1a- Ad vectors]	1.0	6	1	0	0
38435	1624	use specimens,	[using specimens,]	1.0	2	1	0	0
38436	1624	feature characteristic	[features characteristic]	1.0	2	2	2	2
38437	1624	inhibitory action of six flavonoid	[inhibitory action of six flavonoids]	1.0	5	1	0	0
38438	1624	analysis of alkaline phosphatase activity	[Analysis of alkaline phosphatase activity]	1.0	5	1	0	0
38439	1624	human monocyte/macrophage	[human monocyte/macrophage]	1.0	2	1	0	0
38440	1624	retrovirus vector	[retrovirus vector]	1.0	2	2	1	1
38441	1624	bp -72	[bp -72]	1.0	2	1	0	0
38442	1624	infection, ebv	[infection, EBV]	1.0	2	1	0	0
38443	1624	hepatocyte damage in hepatitis b	[hepatocyte damage in hepatitis B]	1.0	5	1	0	0
38444	1624	melanoma cell	[melanoma cells]	1.0	2	1	0	0
38445	1624	transmembrane mechanism in human T lymphocyte	[transmembrane mechanism in human T lymphocytes]	1.0	6	1	0	0
38446	1624	dna-binding activity of Jun-Fos heterodimer	[DNA-binding activities of Jun-Fos heterodimers]	1.0	5	1	0	0
38447	1624	bp -60	[bp -60]	1.0	2	1	0	0
38448	1624	heterozygous status of the twin	[heterozygous status of the twins]	1.0	5	1	0	0
38449	1624	IL-8 gene	[IL-8 gene]	1.0	2	2	1	1
38450	1624	homozygous type	[homozygous type]	1.0	2	1	0	0
38451	1624	peripheral eosinophil	[peripheral eosinophils]	1.0	2	1	0	0
38452	1624	ligand-induced phosphorylation	[ligand-induced phosphorylation]	1.0	2	1	0	0
38453	1624	il-6 gene expression in human monocyte	[IL-6 gene expression in human monocytes]	1.0	6	1	0	0
38454	1624	immunoradiometric assay	[immunoradiometric assay]	1.0	2	1	0	0
38455	1624	cell-to-cell contact activation of NF-kappaB	[Cell-to-cell contact activation of NF-kappaB]	1.0	5	1	0	0
38456	1624	benzoquinone cytotoxicity	[benzoquinone cytotoxicity]	1.0	2	1	0	0
38457	1624	LMP1 ct	[LMP1 CT]	1.0	2	1	0	0
38458	1624	transcription from a igh promoter	[transcription from an IgH promoter]	1.0	5	1	0	0
38459	1624	unwanted specificity	[unwanted specificities]	1.0	2	1	0	0
38460	1624	platelet-activating factor (paf)- receptor antagonist cv3988	[platelet-activating factor (PAF)- receptor antagonist CV3988]	1.0	6	1	0	0
38461	1624	progesterone on peripheral blood lymphocyte	[progesterone on peripheral blood lymphocytes]	1.0	5	1	0	0
38462	1624	enhance region	[enhancing regions]	1.0	2	1	0	0
38463	1624	12 menopausal woman without diabete	[12 menopausal women without diabetes]	1.0	5	1	0	0
38464	1624	cortisol on IFN alpha production	[cortisol on IFN alpha production]	1.0	5	1	0	0
38465	1624	promonocytic leukemias.	[promonocytic leukemias.]	1.0	2	1	0	0
38466	1624	steroid-regulated apoptosis	[steroid-regulated apoptosis]	1.0	2	2	1	1
38467	1624	artery wall	[artery wall]	1.0	2	1	0	0
38468	1624	beta fragment	[beta fragment]	1.0	2	1	0	0
38469	1624	little response,	[little response,]	1.0	2	1	0	0
38470	1624	competition with each GATA site	[competitions with each GATA site]	1.0	5	1	0	0
38471	1624	average of E1a copy number	[average of E1a copy number]	1.0	5	1	0	0
38472	1624	70 kda)	[70 kDa)]	1.0	2	2	1	1
38473	1624	/a23187 stimulation	[/A23187 stimulation]	1.0	2	1	0	0
38474	1624	cellular signal in vivo modulation	[cellular signal in vivo modulation]	1.0	5	1	0	0
38475	1624	terminal differentiation of megakaryocytic lineage	[terminal differentiation of megakaryocytic lineages]	1.0	5	1	0	0
38476	1624	2 kilobasis	[2 kilobases]	1.0	2	1	0	0
38477	1624	small gtp -binding protein rho	[small GTP -binding protein Rho]	1.0	5	1	0	0
38478	1624	ifn-beta promoter	[IFN-beta promoter]	1.0	2	1	0	0
38479	1624	pkc activation of nf-kappa b	[PKC activation of NF-kappa B]	1.0	5	1	0	0
38480	1624	rearrangement of the tcr beta-chain	[rearrangement of the TCR beta-chain]	1.0	5	1	0	0
38481	1624	actin mrna	[actin mRNA]	1.0	2	1	0	0
38482	1624	block p50	[blocking p50]	1.0	2	1	0	0
38483	1624	expression vectors,	[expression vectors,]	1.0	2	1	0	0
38484	1624	Peripheral T lymphocyte from woman	[Peripheral T lymphocytes from women]	1.0	5	1	0	0
38485	1624	liver cytosol	[liver cytosols]	1.0	2	1	0	0
38486	1624	human immunodeficiency virus 1 hiv-1	[human immunodeficiency virus 1 HIV-1]	1.0	5	1	0	0
38487	1624	chromosome mapping	[chromosome mapping]	1.0	2	1	0	0
38488	1624	beta-amyloid peptide in murine microglia	[beta-amyloid peptides in murine microglia]	1.0	5	1	0	0
38489	1624	0.3 nm	[0.3 nM]	1.0	2	1	0	0
38490	1624	such compound	[Such compounds]	1.0	2	1	0	0
38491	1624	human T lymphocyte cell line	[human T lymphocyte cell line]	1.0	5	1	0	0
38492	1624	place	[place]	1.0	1	11	1	1
38493	1624	other nonsteroidal anti-inflammatory drug nsaid	[other nonsteroidal anti-inflammatory drugs NSAIDs]	1.0	5	1	0	0
38494	1624	type IFN	[type IFN]	1.0	2	1	0	0
38495	1624	Megakaryocyte/Platelet-specific enhancer	[Megakaryocyte/Platelet-specific enhancer]	1.0	2	1	0	0
38496	1624	active wild-type	[active wild-type]	1.0	2	1	0	0
38497	1624	c-fos/c-jun ap-1	[c-Fos/c-Jun AP-1]	1.0	2	2	2	2
38498	1624	stressful condition	[stressful conditions]	1.0	2	1	0	0
38499	1624	t- lymphocyte	[T- lymphocytes]	1.0	2	3	2	1
38500	1624	quantitative analysis of GR mrna	[quantitative analysis of GR mRNA]	1.0	5	1	0	0
38501	1624	use a specific proteasome inhibitor z-lll-h	[using a specific proteasome inhibitor Z-LLL-H]	1.0	6	1	0	0
38502	1624	high-resolution, two-dimensional gel electrophoresis system	[high-resolution, two-dimensional gel electrophoresis system]	1.0	5	1	0	0
38503	1624	segregation of human autosome 11	[segregation of human autosome 11]	1.0	5	1	0	0
38504	1624	gene-targeted mouse	[gene-targeted mice]	1.0	2	2	1	1
38505	1624	C termini	[C termini]	1.0	2	1	0	0
38506	1624	stimulate cytokine production from T cell	[stimulating cytokine production from T cells]	1.0	6	1	0	0
38507	1624	cbp/p300 coactivator protein with stat1	[CBP/p300 coactivator proteins with Stat1]	1.0	5	1	0	0
38508	1624	caspase inhibitor	[caspase inhibitor]	1.0	2	2	2	2
38509	1624	related 16-bp see srf/ ets element	[related 16-bp SEE SRF/ ETS element]	1.0	6	1	0	0
38510	1624	immunization with a fusion protein	[immunization with a fusion protein]	1.0	5	1	0	0
38511	1624	factor Sp1	[factor Sp1]	1.0	2	2	2	2
38512	1624	beta2 integrin	[beta2 integrin]	1.0	2	2	1	1
38513	1624	control transcription	[control transcription]	1.0	2	2	2	2
38514	1624	suggest detectable in the nucleus	[suggesting detectable in the nucleus]	1.0	5	1	0	0
38515	1624	lectin to blood mononuclear cell	[lectin to blood mononuclear cells]	1.0	5	2	1	1
38516	1624	expression of DNA in reticulocyte lysate	[Expression of DNA in reticulocyte lysates]	1.0	6	1	0	0
38517	1624	macrophage receptor	[macrophage receptors]	1.0	2	1	0	0
38518	1624	IL3 colony	[IL3 colony]	1.0	2	1	0	0
38519	1624	Anti- TNF-alpha	[Anti- TNF-alpha]	1.0	2	1	0	0
38520	1624	cross-react with a monoclonal antibody	[cross-reacting with a monoclonal antibody]	1.0	5	1	0	0
38521	1624	Double staining	[Double staining]	1.0	2	2	1	1
38522	1624	immunoblot experiment	[immunoblot experiments]	1.0	2	1	0	0
38523	1624	86 kda	[86 kDa]	1.0	2	1	0	0
38524	1624	ppar-alpha rrna	[PPAR-alpha mRNAs]	1.0	2	1	0	0
38525	1624	principally tnf-alpha	[principally TNF-alpha]	1.0	2	1	0	0
38526	1624	use site-directed mutagenesis of human HSs	[Using site-directed mutagenesis of human HSs]	1.0	6	1	0	0
38527	1624	human glioblastoma	[human glioblastoma]	1.0	2	1	0	0
38528	1624	NF kappa B2 nucleoprotein complex	[NF kappa B2 nucleoprotein complex]	1.0	5	1	0	0
38529	1624	footprint	[footprint]	1.0	1	11	8	8
38530	1624	hrar alpha	[hRAR alpha]	1.0	2	2	2	2
38531	1624	harbour the luciferase reporter gene	[harbouring the luciferase reporter gene]	1.0	5	1	0	0
38532	1624	HSV cell	[HSV cells]	1.0	2	1	0	0
38533	1624	differentiation induction	[differentiation induction]	1.0	2	2	2	2
38534	1624	thus, constitutive activation of Egr-1 gene	[Thus, constitutive activation of Egr-1 gene]	1.0	6	1	0	0
38535	1624	growth-related metabolism	[growth-related metabolism]	1.0	2	1	0	0
38536	1624	explanation for a previous observation	[explanation for a previous observation]	1.0	5	1	0	0
38537	1624	c/ebp activator	[C/EBP activator]	1.0	2	2	1	1
38538	1624	bhlf1/noti oligoprobe on tumour sample	[BHLF1/NotI oligoprobes on tumour samples]	1.0	5	1	0	0
38539	1624	term baby	[term babies]	1.0	2	1	0	0
38540	1624	important role modulate immune function	[important role modulating immune function]	1.0	5	1	0	0
38541	1624	inhibition of expression by dexamethasone	[inhibition of expression by dexamethasone]	1.0	5	1	0	0
38542	1624	protein of the ap-1 family	[protein of the AP-1 family]	1.0	5	1	0	0
38543	1624	understanding of the molecular process	[understanding of the molecular process]	1.0	5	1	0	0
38544	1624	general role for tax induction	[general role for Tax induction]	1.0	5	1	0	0
38545	1624	hematologic malignancy	[hematologic malignancies]	1.0	2	2	1	1
38546	1624	reactive T	[reactive T]	1.0	2	2	2	2
38547	1624	cell line bear dqa1*0501/dqb1*0201 heterodimer	[cell lines bearing DQA1*0501/DQB1*0201 heterodimers]	1.0	5	1	0	0
38548	1624	moreover, electrophoretic mobility shift assay	[Moreover, electrophoretic mobility shift assays]	1.0	5	1	0	0
38549	1624	one mechanism restrict hiv-1 gene expression	[one mechanism restricting HIV-1 gene expression]	1.0	6	1	0	0
38550	1624	oral leukoplakia	[oral leukoplakia]	1.0	2	1	0	0
38551	1624	antiapoptotic factor	[antiapoptotic factor]	1.0	2	2	1	1
38552	1624	B10 mouse	[B10 mice]	1.0	2	1	0	0
38553	1624	relative proportion of fatty acid	[relative proportions of fatty acids]	1.0	5	1	0	0
38554	1624	promote the differentiation into plasma cell	[promoting the differentiation into plasma cells]	1.0	6	1	0	0
38555	1624	one member of this family, aml-1b	[one member of this family, AML-1B]	1.0	6	1	0	0
38556	1624	two cysteine -rich region LIM domain	[two cysteine -rich regions LIM domains]	1.0	6	1	0	0
38557	1624	6 patient	[6 patients]	1.0	2	1	0	0
38558	1624	molecular switch	[molecular switch]	1.0	2	2	2	2
38559	1624	nfkb2 synthesis	[NFKB2 synthesis]	1.0	2	1	0	0
38560	1624	antiandrogen drug	[antiandrogen drug]	1.0	2	1	0	0
38561	1624	sodium butyrate	[sodium butyrate]	1.0	2	2	1	1
38562	1624	(affect expression	[(affecting expression]	1.0	2	1	0	0
38563	1624	placental trophoblast	[placental trophoblasts]	1.0	2	1	0	0
38564	1624	major determinant	[major determinant]	1.0	2	2	2	2
38565	1624	cystine concentration	[cystine concentrations]	1.0	2	1	0	0
38566	1624	kinase-deficient mutant	[kinase-deficient mutant]	1.0	2	2	2	2
38567	1624	diurnal fluctuation	[diurnal fluctuations]	1.0	2	1	0	0
38568	1624	utilize a OTF-2 expression vector	[utilizing an OTF-2 expression vector]	1.0	5	1	0	0
38569	1624	involve the acid receptor alpha locus	[involving the acid receptor alpha locus]	1.0	6	1	0	0
38570	1624	human T cell thymic progenitor	[human T cell thymic progenitors]	1.0	5	1	0	0
38571	1624	valine substitution	[valine substitution]	1.0	2	2	2	2
38572	1624	binding to the core promoter	[binding to the core promoter]	1.0	5	1	0	0
38573	1624	search of a molecular mechanism	[search of a molecular mechanism]	1.0	5	1	0	0
38574	1624	however, like NF kappa B	[However, like NF kappa B]	1.0	5	1	0	0
38575	1624	approximately 350 kb of DNA	[approximately 350 kb of DNA]	1.0	5	1	0	0
38576	1624	to trigger	[to triggering]	1.0	2	1	0	0
38577	1624	high level of IFN synthesis	[high levels of IFN synthesis]	1.0	5	1	0	0
38578	1624	two polypeptide of 106 kda	[two polypeptides of 106 kDa]	1.0	5	1	0	0
38579	1624	nf-at binding	[NF-AT binding]	1.0	2	1	0	0
38580	1624	leukemic clone	[leukemic clone]	1.0	2	2	1	1
38581	1624	down-regulated sequence	[down-regulated sequences]	1.0	2	1	0	0
38582	1624	maximal stimulation of the ea-d promoter	[maximal stimulation of the EA-D promoter]	1.0	6	1	0	0
38583	1624	dysregulation of the hypothalamic-pituitary-adrenal system	[dysregulation of the hypothalamic-pituitary-adrenal system]	1.0	5	1	0	0
38584	1624	bind to the 5' promoter	[binding to the 5' promoter]	1.0	5	1	0	0
38585	1624	-independent transactivation by Tat in cell	[-independent transactivation by Tat in cells]	1.0	6	1	0	0
38586	1624	DNA sequence-	[DNA sequence-]	1.0	2	1	0	0
38587	1624	vimentin level in promonocytic cell	[vimentin levels in promonocytic cells]	1.0	5	1	0	0
38588	1624	b-cell-specific transcription of this gene	[B-cell-specific transcription of this gene]	1.0	5	1	0	0
38589	1624	cell system	[cell system]	1.0	2	2	1	1
38590	1624	cell cycle-dependent transcription factor e2f-1	[cell cycle-dependent transcription factor E2F-1]	1.0	5	1	0	0
38591	1624	cytokine activation	[cytokine activation]	1.0	2	2	2	2
38592	1624	such as high bcl-xl expression	[such as high Bcl-XL expression]	1.0	5	1	0	0
38593	1624	NF-ATc /C	[NF-ATc /C]	1.0	2	1	0	0
38594	1624	aberrancy in the regulation of c-fos/c-jun	[aberrancies in the regulation of c-fos/c-jun]	1.0	6	1	0	0
38595	1624	identification of a cDNA clone	[identification of a cDNA clone]	1.0	5	1	0	0
38596	1624	synthesis of nfatc (predominant form	[synthesis of NFATc (predominant form]	1.0	5	1	0	0
38597	1624	use polyclonal anti- tf antibody	[using polyclonal anti- TF antibody]	1.0	5	1	0	0
38598	1624	mutual contact	[mutual contact]	1.0	2	1	0	0
38599	1624	response of the IL-5 promoter	[response of the IL-5 promoter]	1.0	5	1	0	0
38600	1624	Probucol microM)	[Probucol microM)]	1.0	2	1	0	0
38601	1624	sigma ligand,	[sigma ligand,]	1.0	2	1	0	0
38602	1624	e47 product	[E47 product]	1.0	2	1	0	0
38603	1624	normal platelet	[normal platelets]	1.0	2	1	0	0
38604	1624	gp160 activation of nf-kappa b	[gp160 activation of NF-kappa B]	1.0	5	1	0	0
38605	1624	nf(p) interaction	[NF(P) interaction]	1.0	2	1	0	0
38606	1624	autocrine role for this chemokine	[autocrine role for this chemokine]	1.0	5	1	0	0
38607	1624	Differential regulation of proto-oncogent c-jun	[Differential regulation of proto-oncogenes c-jun]	1.0	5	1	0	0
38608	1624	capacity of neonatal T cell	[capacity of neonatal T cells]	1.0	5	1	0	0
38609	1624	OKA stimulation	[OKA stimulation]	1.0	2	1	0	0
38610	1624	contrast to the negative autoregulation	[contrast to the negative autoregulation]	1.0	5	1	0	0
38611	1624	ie2 transactivation of various promoter	[IE2 transactivation of various promoters]	1.0	5	1	0	0
38612	1624	0.03)) overexpression	[0.003), overexpression]	1.0	2	1	0	0
38613	1624	cytomegalovirus (CMV)	[Cytomegalovirus (CMV)]	1.0	2	1	0	0
38614	1624	use 32pi-labeled stat5 binding site	[using 32Pi-labeled STAT5 binding site]	1.0	5	1	0	0
38615	1624	total number of 135(oh)2d3 receptor	[total number of 1,25(OH)2D3 receptors]	1.0	5	1	0	0
38616	1624	such as the tumor-suppressor protein prb	[such as the tumor-suppressor protein pRb]	1.0	6	1	0	0
38617	1624	express the shigella icsa protein	[expressing the Shigella IcsA protein]	1.0	5	1	0	0
38618	1624	cgmp analogue	[cGMP analogues]	1.0	2	1	0	0
38619	1624	basis of activation of monocyte	[basis of activation of monocytes]	1.0	5	1	0	0
38620	1624	pbmc cell	[PBMC cells]	1.0	2	2	2	2
38621	1624	ms patient	[MS patients]	1.0	2	2	2	2
38622	1624	molecular weight of 59.5 kilometer	[molecular weights of 59.5 kd]	1.0	5	1	0	0
38623	1624	0.25 millileter	[0.25 ml]	1.0	2	1	0	0
38624	1624	macroscopic multiplicity	[macroscopic multiplicity]	1.0	2	1	0	0
38625	1624	CD4 trigger	[CD4 triggering]	1.0	2	2	1	1
38626	1624	different nf-kappa b /rel subunit	[different NF-kappa B /Rel subunits]	1.0	5	1	0	0
38627	1624	normal peripheral blood mononuclear cell	[normal peripheral blood mononuclear cells]	1.0	5	2	1	1
38628	1624	lysp100 structure	[LYSP100 structures]	1.0	2	1	0	0
38629	1624	proteolytic activity of the enzyme	[Proteolytic activity of the enzyme]	1.0	5	1	0	0
38630	1624	bcd gene	[Bcd gene]	1.0	2	1	0	0
38631	1624	internal deletion of the BOX1 motif	[internal deletion of the BOX1 motif]	1.0	6	1	0	0
38632	1624	potential relevance of this mechanism	[potential relevance of this mechanism]	1.0	5	1	0	0
38633	1624	IL-2 message	[IL-2 message]	1.0	2	1	0	0
38634	1624	EB1 a EBV early product	[EB1 an EBV early product]	1.0	5	1	0	0
38635	1624	factor-kappa beta	[factor-kappa beta]	1.0	2	2	2	2
38636	1624	T substitution	[T substitution]	1.0	2	2	1	1
38637	1624	vimentin transcript	[vimentin transcripts]	1.0	2	1	0	0
38638	1624	level of nuclear nf-kb activity	[levels of nuclear NF-kB activity]	1.0	5	1	0	0
38639	1624	human herpesvirus 6 hhv-6 strain	[human herpesvirus 6 HHV-6 strains]	1.0	5	1	0	0
38640	1624	transcription factor of the NFAT family	[Transcription factors of the NFAT family]	1.0	6	1	0	0
38641	1624	p56(lck) signal	[p56(lck) signaling]	1.0	2	1	0	0
38642	1624	mechanism control this developmental choice	[mechanisms controlling this developmental choice]	1.0	5	1	0	0
38643	1624	docking site for stat protein	[docking sites for Stat proteins]	1.0	5	1	0	0
38644	1624	different set of Janus kinase	[different set of Janus kinases]	1.0	5	1	0	0
38645	1624	proline region	[proline region]	1.0	2	2	2	2
38646	1624	primarily from the degradation of ikappab-alpha	[primarily from the degradation of IkappaB-alpha]	1.0	6	1	0	0
38647	1624	recombinant IL-2	[recombinant IL-2]	1.0	2	1	0	0
38648	1624	contain a pml/rar alpha fusion gene	[containing a pml/RAR alpha fusion gene]	1.0	6	1	0	0
38649	1624	sex-matched controls.	[sex-matched controls.]	1.0	2	1	0	0
38650	1624	stimulation of blood T lymphocyte	[stimulation of blood T lymphocytes]	1.0	5	1	0	0
38651	1624	background	[background]	1.0	1	11	7	7
38652	1624	regulate inducible t-cell gene expression	[regulating inducible T-cell gene expression]	1.0	5	1	0	0
38653	1624	activation of STAT5 by IL-4	[Activation of STAT5 by IL-4]	1.0	5	1	0	0
38654	1624	(irf) family of transcription factors,	[(IRF) family of transcription factors,]	1.0	5	1	0	0
38655	1624	cluster of gene with expression pattern	[Clusters of genes with expression patterns]	1.0	6	1	0	0
38656	1624	potential clinical relevance for gastroenterology	[potential clinical relevance for gastroenterology]	1.0	5	1	0	0
38657	1624	thus positioning NFAT for immediate dephosphorylation	[thus positioning NFAT for immediate dephosphorylation]	1.0	6	1	0	0
38658	1624	immunosuppressant fk506	[immunosuppressant FK506]	1.0	2	1	0	0
38659	1624	least in part through activation	[least in part through activation]	1.0	5	1	0	0
38660	1624	Loss- mutation	[Loss- mutations]	1.0	2	1	0	0
38661	1624	HeLa cells,	[HeLa cells,]	1.0	2	1	0	0
38662	1624	approximately substSpl234	[approximately substSpl234]	1.0	2	1	0	0
38663	1624	provide evidence for in vivo interaction	[providing evidence for in vivo interaction]	1.0	6	1	0	0
38664	1624	thymocyte differentiation	[thymocyte differentiation]	1.0	2	1	0	0
38665	1624	herpesviral protein	[herpesviral proteins]	1.0	2	1	0	0
38666	1624	progressive 5'-deletion construct of a segment	[progressive 5'-deletion constructs of a segment]	1.0	6	1	0	0
38667	1624	transcription factor nuclear factor-kappa b	[transcription factors nuclear factor-kappa B]	1.0	5	1	0	0
38668	1624	functional change	[functional changes]	1.0	2	1	0	0
38669	1624	mbp gene	[MBP gene]	1.0	2	1	0	0
38670	1624	multiple t-cell receptor signal pathway	[multiple T-cell receptor signaling pathways]	1.0	5	1	0	0
38671	1624	carry point mutation in the element	[carrying point mutations in the elements]	1.0	6	1	0	0
38672	1624	expression of a distinct set	[expression of a distinct set]	1.0	5	1	0	0
38673	1624	immunologic activation.	[immunologic activation.]	1.0	2	1	0	0
38674	1624	factor-beta promoter polymorphism in allergy	[factor-beta promoter polymorphisms in allergies]	1.0	5	1	0	0
38675	1624	overexpression of the il-4 gene	[overexpression of the IL-4 gene]	1.0	5	1	0	0
38676	1624	intact human mononuclear leukocyte HML	[intact human mononuclear leukocytes HML]	1.0	5	1	0	0
38677	1624	ie, inhibition of hsc/ hpc proliferation	[ie, inhibition of HSC/ HPC proliferation]	1.0	6	1	0	0
38678	1624	Zta interference	[Zta interference]	1.0	2	1	0	0
38679	1624	human colony-stimumulatelany-stg factor-1 receptor csf-1r	[human colony-stimulating factor-1 receptor CSF-1R]	1.0	5	1	0	0
38680	1624	IE2 gene product of cytomegalovirus	[IE2 gene product of cytomegalovirus]	1.0	5	1	0	0
38681	1624	use the puc 1.77 probe specific	[using the pUC 1.77 probes specific]	1.0	6	1	0	0
38682	1624	molecular mass of 41 kilodalton	[molecular mass of 41 kilodaltons]	1.0	5	1	0	0
38683	1624	implication of protein tyrosine kinase(s)	[implication of protein tyrosine kinase(s)]	1.0	5	1	0	0
38684	1624	RAKFKQLLQ -specific CTL precursor frequency	[RAKFKQLLQ -specific CTL precursor frequencies]	1.0	5	1	0	0
38685	1624	beta-Catenin complex	[beta-Catenin complexes]	1.0	2	1	0	0
38686	1624	selection of the T cell repertoire	[Selection of the T cell repertoire]	1.0	6	1	0	0
38687	1624	different clonotype	[different clonotypes]	1.0	2	1	0	0
38688	1624	15-lo expression	[15-LO expression]	1.0	2	1	0	0
38689	1624	GM-CSF gene transcription by factor	[GM-CSF gene transcription by factor]	1.0	5	1	0	0
38690	1624	long isoform	[long isoforms]	1.0	2	2	2	2
38691	1624	pattern similar	[pattern similar]	1.0	2	2	2	2
38692	1624	MYH11 gene	[MYH11 gene]	1.0	2	1	0	0
38693	1624	tcr alpha join gene segment	[TCR alpha joining gene segments]	1.0	5	1	0	0
38694	1624	3 cmml	[3 CMML]	1.0	2	1	0	0
38695	1624	examine the effect of deletion mutation	[examining the effects of deletion mutations]	1.0	6	1	0	0
38696	1624	stability of this binding result	[stability of this binding results]	1.0	5	1	0	0
38697	1624	LPS group	[LPS group]	1.0	2	1	0	0
38698	1624	cell within the lymphoid lineage	[cells within the lymphoid lineage]	1.0	5	1	0	0
38699	1624	means of a common immunophilin	[means of a common immunophilin]	1.0	5	1	0	0
38700	1624	phorbol ester phorbol 12-myristate 13-acetate	[phorbol ester phorbol 12-myristate 13-acetate]	1.0	5	1	0	0
38701	1624	hiv evolution	[HIV evolution]	1.0	2	1	0	0
38702	1624	binding to the CBF alpha subunit	[binding to the CBF alpha subunit]	1.0	6	1	0	0
38703	1624	56-59-kilodalton protein	[56-59-kilodalton protein]	1.0	2	1	0	0
38704	1624	key cytokine of T lymphocyte	[key cytokine of T lymphocytes]	1.0	5	1	0	0
38705	1624	bioactive macrophage colony-stimumulatelany-stg factor protein	[bioactive macrophage colony-stimulating factor protein]	1.0	5	1	0	0
38706	1624	p100 mrna	[p100 mRNA]	1.0	2	1	0	0
38707	1624	135-(oh)2d3 il-1 beta mrna level	[1,25-(OH)2D3 IL-1 beta mRNA levels]	1.0	5	1	0	0
38708	1624	signal from the cell membrane	[signals from the cell membrane]	1.0	5	1	0	0
38709	1624	transcription of BZLF-1 a early gene	[transcription of BZLF-1 an early gene]	1.0	6	1	0	0
38710	1624	comparable decrease in il-2r alpha	[comparable decrease in IL-2R alpha]	1.0	5	1	0	0
38711	1624	human ehrlichiosis	[human ehrlichiosis]	1.0	2	1	0	0
38712	1624	epithelial stat1 other control transcription factor	[epithelial Stat1 other control transcription factors]	1.0	6	1	0	0
38713	1624	primary syndrome	[primary syndromes]	1.0	2	2	2	2
38714	1624	follow stimulation of monocytic line	[following stimulation of monocytic lines]	1.0	5	1	0	0
38715	1624	same range	[same range,]	1.0	2	2	1	1
38716	1624	two deletion within the EBNA-2 gene	[Two deletions within the EBNA-2 gene]	1.0	6	1	0	0
38717	1624	killing activity,	[killing activity,]	1.0	2	1	0	0
38718	1624	viral peptide residue contact tcr	[viral peptide residues contacting TCR]	1.0	5	1	0	0
38719	1624	nuclear factor kappa b nf-kappab	[nuclear factor kappa B NF-kappaB]	1.0	5	1	0	0
38720	1624	polyamine level	[polyamine levels]	1.0	2	2	1	1
38721	1624	different receptor binding specificity cd336	[different receptor binding specificity CD336]	1.0	5	1	0	0
38722	1624	thrombin stimulation	[Thrombin stimulation]	1.0	2	1	0	0
38723	1624	immunomodulatory properties.	[immunomodulatory properties.]	1.0	2	1	0	0
38724	1624	two repeat	[two repeats]	1.0	2	2	1	1
38725	1624	particular interest:	[particular interest:]	1.0	2	1	0	0
38726	1624	sodium diclofenac at 15 microm	[sodium diclofenac at 15 microM]	1.0	5	1	0	0
38727	1624	alpha globin regulatory element HS-40	[alpha globin regulatory element HS-40]	1.0	5	1	0	0
38728	1624	typical pattern.	[typical pattern.]	1.0	2	1	0	0
38729	1624	oncogenic property	[oncogenic properties]	1.0	2	1	0	0
38730	1624	atra treatment of Kasumi-1 cell	[ATRA treatment of Kasumi-1 cells]	1.0	5	1	0	0
38731	1624	multiple functional element include binding site	[multiple functional elements including binding sites]	1.0	6	1	0	0
38732	1624	vivo modification	[vivo modification]	1.0	2	1	0	0
38733	1624	60 year	[60 years]	1.0	2	1	0	0
38734	1624	similar complex	[Similar complexes]	1.0	2	1	0	0
38735	1624	acute phase protein in response	[acute phase proteins in response]	1.0	5	1	0	0
38736	1624	isoform to the particulate fraction	[isoforms to the particulate fraction]	1.0	5	1	0	0
38737	1624	leukocyte chemotaxis	[leukocyte chemotaxis]	1.0	2	2	2	2
38738	1624	estrogen receptor gene in monocyte	[estrogen receptor gene in monocytes]	1.0	5	1	0	0
38739	1624	contrast, am580	[contrast, AM580]	1.0	2	1	0	0
38740	1624	induction of Cepsilon germline transcript	[Induction of Cepsilon germline transcripts]	1.0	5	1	0	0
38741	1624	20-methyl derivative	[20-methyl derivatives]	1.0	2	1	0	0
38742	1624	cell types, include T cell	[cell types, including T cells]	1.0	5	1	0	0
38743	1624	Mediterranean diet	[Mediterranean diet]	1.0	2	1	0	0
38744	1624	protein-dna complex of constitutive nf-kappa b	[Protein-DNA complexes of constitutive NF-kappa B]	1.0	6	1	0	0
38745	1624	critical role in the development	[critical role in the development]	1.0	5	1	0	0
38746	1624	full-length cDNA clone in bacterium	[full-length cDNA clones in bacteria]	1.0	5	1	0	0
38747	1624	expression of fusion reporter gene	[expression of fusion reporter genes]	1.0	5	1	0	0
38748	1624	Finally, chromosomal localization use fluorescence	[Finally, chromosomal localization using fluorescence]	1.0	5	1	0	0
38749	1624	viral trans-activator	[Viral trans-activators]	1.0	2	2	1	1
38750	1624	lymphocyte syndrome-associated	[lymphocyte syndrome-associated]	1.0	2	2	2	2
38751	1624	cytoplasmic inhibitory molecule kappa bs	[cytoplasmic inhibitory molecules kappa Bs]	1.0	5	1	0	0
38752	1624	Environmental estrogen	[Environmental estrogens]	1.0	2	1	0	0
38753	1624	androgen-regulated gene	[androgen-regulated gene]	1.0	2	1	0	0
38754	1624	filarial disease	[filarial disease]	1.0	2	1	0	0
38755	1624	TNF lps	[TNF LPS]	1.0	2	2	1	1
38756	1624	information on pancrea development in general.	[information on pancreas development in general.]	1.0	6	1	0	0
38757	1624	octamer enhancer	[octamer enhancer]	1.0	2	2	1	1
38758	1624	aes peptide	[AES peptides]	1.0	2	1	0	0
38759	1624	evidence for a strong genetic component	[evidence for a strong genetic component]	1.0	6	1	0	0
38760	1624	process related	[processes related]	1.0	2	2	2	2
38761	1624	AP-1 transcription of a reporter gene	[AP-1 transcription of a reporter gene]	1.0	6	1	0	0
38762	1624	leucine-rich domain	[leucine-rich domain]	1.0	2	1	0	0
38763	1624	fibrin deposition	[fibrin deposition]	1.0	2	2	2	2
38764	1624	probably lead to a protection	[probably leading to a protection]	1.0	5	1	0	0
38765	1624	V region	[V region]	1.0	2	2	2	2
38766	1624	similar enhancement of ig-secreting cell	[similar enhancement of Ig-secreting cells]	1.0	5	1	0	0
38767	1624	other component	[other component]	1.0	2	3	2	1
38768	1624	efficient induction,	[efficient induction,]	1.0	2	1	0	0
38769	1624	specific ligands.	[specific ligands.]	1.0	2	1	0	0
38770	1624	particular major histocompatibility (mhc) haplotype	[particular major histocompatibility (MHC) haplotypes]	1.0	5	1	0	0
38771	1624	organ inflammation independent of tnf	[organ inflammation independent of TNF]	1.0	5	1	0	0
38772	1624	airway tissue	[airway tissue]	1.0	2	1	0	0
38773	1624	electrolyte	[electrolyte]	1.0	1	11	5	5
38774	1624	growth of IL-3 pro-B cell	[growth of IL-3 pro-B cells]	1.0	5	1	0	0
38775	1624	vitamin D3 responsiveness in tissues.	[vitamin D3 responsiveness in tissues.]	1.0	5	1	0	0
38776	1624	proto-oncogent in acute myeloid leukemia	[proto-oncogenes in acute myeloid leukemia]	1.0	5	1	0	0
38777	1624	decrease of er level in cell	[decrease of ER levels in cell]	1.0	6	1	0	0
38778	1624	cross-reactive specificities, suggest a key role	[cross-reactive specificities, suggesting a key role]	1.0	6	1	0	0
38779	1624	cooperation between different signal pathway	[cooperation between different signaling pathways]	1.0	5	1	0	0
38780	1624	however, restimulation of human th2 line	[However, restimulation of human Th2 lines]	1.0	6	1	0	0
38781	1624	moreover, replacement of the DQB x2-box	[Moreover, replacement of the DQB X2-box]	1.0	6	1	0	0
38782	1624	30 kb telomeric to GR6	[30 kb telomeric to GR6]	1.0	5	1	0	0
38783	1624	T cell receptor involvement UV-	[T cell receptor involvement UV-]	1.0	5	1	0	0
38784	1624	modulation subsequent to in vivo therapy	[modulations subsequent to in vivo therapy]	1.0	6	1	0	0
38785	1624	diseases, such as hiv infection	[diseases, such as HIV infection]	1.0	5	1	0	0
38786	1624	potent pkc inhibitor ro 31-8425	[potent PKC inhibitor Ro 31-8425]	1.0	5	1	0	0
38787	1624	point mutation in the ar gene	[Point mutations in the AR gene]	1.0	6	1	0	0
38788	1624	19 kd	[19 kDs]	1.0	2	1	0	0
38789	1624	Fine mapping by in vivo footprinting	[Fine mapping by in vivo footprinting]	1.0	6	1	0	0
38790	1624	NF-kappaB up-regulation	[NF-kappaB up-regulation]	1.0	2	2	2	2
38791	1624	blocking factor	[blocking factor]	1.0	2	2	1	1
38792	1624	gastric carcinoma	[gastric carcinoma]	1.0	2	2	2	2
38793	1624	dual activity.	[dual activity.]	1.0	2	1	0	0
38794	1624	presence of specific intracellular receptor	[presence of specific intracellular receptors]	1.0	5	1	0	0
38795	1624	NF-kappaB activation in response to signal	[NF-kappaB activation in response to signals]	1.0	6	1	0	0
38796	1624	furthermore, NFkappaB translocation follow lps activation	[Furthermore, NFkappaB translocation following LPS activation]	1.0	6	1	0	0
38797	1624	il-1beta expression	[IL-1beta expression]	1.0	2	2	1	1
38798	1624	various inhibitors.	[various inhibitors.]	1.0	2	1	0	0
38799	1624	cortisol ratio in the depressed group	[cortisol ratio in the depressed group]	1.0	6	1	0	0
38800	1624	affect change in cytosolic ca2+	[affecting changes in cytosolic Ca2+]	1.0	5	1	0	0
38801	1624	gabp alpha	[GABP alpha]	1.0	2	2	2	2
38802	1624	immunoglobulin heavy-chain mu e1 site	[immunoglobulin heavy-chain mu E1 site]	1.0	5	1	0	0
38803	1624	general role	[general role]	1.0	2	2	2	2
38804	1624	kinetic similar to IL-6 mrna	[kinetics similar to IL-6 mRNA]	1.0	5	1	0	0
38805	1624	human bob.1/obf.1	[human BOB.1/OBF.1]	1.0	2	1	0	0
38806	1624	such as phorbol myristate acetate PMA	[such as phorbol myristate acetate PMA]	1.0	6	1	0	0
38807	1624	delta 1	[delta 1]	1.0	2	1	0	0
38808	1624	human population	[human population]	1.0	2	1	0	0
38809	1624	insight in the molecular event	[insights in the molecular events]	1.0	5	1	0	0
38810	1624	activation mechanism	[activation mechanism]	1.0	2	1	0	0
38811	1624	viral response	[viral response]	1.0	2	1	0	0
38812	1624	co-treatment of RBC with tcdd	[Co-treatment of RBCs with TCDD]	1.0	5	1	0	0
38813	1624	vivo footprint analysis cell-specific interaction	[vivo footprint analysis cell-specific interaction]	1.0	5	1	0	0
38814	1624	use antibody against the p50 subunit	[Using antibodies against the p50 subunits]	1.0	6	1	0	0
38815	1624	c-fo control via surface immunoglobulin	[c-fos control via surface immunoglobulin]	1.0	5	1	0	0
38816	1624	ltr with individual of NF-kappa b	[LTRs with individual of NF-kappa B]	1.0	6	1	0	0
38817	1624	member of the NF-kappaB /Rel family	[members of the NF-kappaB /Rel family]	1.0	6	1	0	0
38818	1624	inhibitor ikb	[inhibitor IKB]	1.0	2	1	0	0
38819	1624	2-phase neutrophil	[2-phase neutrophil]	1.0	2	1	0	0
38820	1624	interleukin-6 expression involve NK-chi b	[interleukin-6 expression involving NK-chi B]	1.0	5	1	0	0
38821	1624	human T cell by R24	[human T cells by R24]	1.0	5	1	0	0
38822	1624	HTLV-1 transformation	[HTLV-1 transformation]	1.0	2	2	2	2
38823	1624	major regulator of gene expression	[major regulator of gene expression]	1.0	5	1	0	0
38824	1624	400-base pair	[400-base pair]	1.0	2	1	0	0
38825	1624	candidate gene,	[candidate gene,]	1.0	2	1	0	0
38826	1624	identification of the same sequence	[identification of the same sequence]	1.0	5	1	0	0
38827	1624	amebic infection of human intestine	[amebic infection of human intestine]	1.0	5	1	0	0
38828	1624	cysteine thiol on hiv-1 replication	[cysteine thiols on HIV-1 replication]	1.0	5	1	0	0
38829	1624	nfat binding	[NFAT binding]	1.0	2	2	2	2
38830	1624	Ras Ca2+	[Ras Ca2+]	1.0	2	1	0	0
38831	1624	mnda mrna in primary monocyte	[MNDA mRNA in primary monocytes]	1.0	5	1	0	0
38832	1624	further differentiation	[further differentiation]	1.0	2	1	0	0
38833	1624	affect the activity of NFkappaB	[affecting the activities of NFkappaB]	1.0	5	1	0	0
38834	1624	tumor promoter	[tumor promoter]	1.0	2	2	2	2
38835	1624	ras expression	[ras expression]	1.0	2	1	0	0
38836	1624	one Ets binding site EBS	[one Ets binding site EBS]	1.0	5	1	0	0
38837	1624	syncytia formation of p24 antigen	[syncytia formation of p24 antigen]	1.0	5	1	0	0
38838	1624	near-basal level	[near-basal levels]	1.0	2	1	0	0
38839	1624	44 bp	[44 bp]	1.0	2	1	0	0
38840	1624	chromosomal aberration	[chromosomal aberrations]	1.0	2	1	0	0
38841	1624	gr binding affinity by 11-fold.	[GR binding affinity by 11-fold.]	1.0	5	1	0	0
38842	1624	cell-death pathway	[cell-death pathway]	1.0	2	1	0	0
38843	1624	total number	[total number]	1.0	2	3	2	1
38844	1624	RNase protection	[RNase protection]	1.0	2	2	2	2
38845	1624	survivalepromot protein	[survival-promoting proteins]	1.0	2	2	2	2
38846	1624	sole cause of growth arrest.	[sole cause of growth arrest.]	1.0	5	1	0	0
38847	1624	additional experiment	[Additional experiments]	1.0	2	1	0	0
38848	1624	However, BRL49653 a ppargamma ligand	[However, BRL49653 a PPARgamma ligand]	1.0	5	1	0	0
38849	1624	promoter strength	[promoter strength]	1.0	2	2	1	1
38850	1624	susceptible segment	[susceptible segments]	1.0	2	1	0	0
38851	1624	rest cell	[resting cells]	1.0	2	2	1	1
38852	1624	well-defined signal	[well-defined signal]	1.0	2	1	0	0
38853	1624	differential dependency of fetal b-lymphopoiesis	[differential dependency of fetal B-lymphopoiesis]	1.0	5	1	0	0
38854	1624	thiol modify agent like diamide	[Thiol modifying agents like diamide]	1.0	5	1	0	0
38855	1624	use the proteasome inhibitor n-acetyl-l-leucinyl-l-leucinyl-l-norleucinal	[using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal]	1.0	5	1	0	0
38856	1624	several observations,	[several observations,]	1.0	2	1	0	0
38857	1624	pathway regulate alpha2 integrin gene expression	[pathway regulating alpha2 integrin gene expression]	1.0	6	1	0	0
38858	1624	92-kDa protein	[92-kDa protein]	1.0	2	1	0	0
38859	1624	Epstein-Barr virus a human gammaherpesvirus	[Epstein-Barr virus a human gammaherpesvirus]	1.0	5	1	0	0
38860	1624	recombinant Jun	[recombinant Jun]	1.0	2	1	0	0
38861	1624	m-csf gene in primary myelodysplastic syndrome	[M-CSF genes in primary myelodysplastic syndromes]	1.0	6	1	0	0
38862	1624	unlikely candidate	[unlikely candidate]	1.0	2	1	0	0
38863	1624	radiation-induced signal	[radiation-induced signals]	1.0	2	1	0	0
38864	1624	murine pre-B	[murine pre-B]	1.0	2	2	2	2
38865	1624	LEF-1 site	[LEF-1 sites]	1.0	2	1	0	0
38866	1624	protein kinase C PKC activation	[Protein kinase C PKC activation]	1.0	5	1	0	0
38867	1624	slow kinetics.	[slower kinetics.]	1.0	2	1	0	0
38868	1624	RXR-RAR reporter	[RXR-RAR reporter]	1.0	2	1	0	0
38869	1624	intracellular parasite	[intracellular parasite]	1.0	2	2	1	1
38870	1624	T cell in the periphery.	[T cells in the periphery.]	1.0	5	1	0	0
38871	1624	hormone binding	[hormone binding]	1.0	2	2	2	2
38872	1624	similar signal mechanism induce transcription	[similar signaling mechanisms inducing transcription]	1.0	5	1	0	0
38873	1624	endogenous wt1	[endogenous WT1]	1.0	2	1	0	0
38874	1624	activator protein-1 in Jurkat t-cells.	[activator protein-1 in Jurkat T-cells.]	1.0	5	1	0	0
38875	1624	nuclear localization signal of rela	[nuclear localization signal of RelA]	1.0	5	1	0	0
38876	1624	respiratory failure	[respiratory failure]	1.0	2	1	0	0
38877	1624	inducible expression of t-cell gene	[inducible expression of T-cell genes]	1.0	5	1	0	0
38878	1624	opportunistic infection	[opportunistic infections]	1.0	2	1	0	0
38879	1624	underphosphorylated traf2	[underphosphorylated TRAF2]	1.0	2	1	0	0
38880	1624	response to cytokine factor stimulation	[response to cytokine factor stimulation]	1.0	5	1	0	0
38881	1624	prerequisite step in the activation	[prerequisite step in the activation]	1.0	5	1	0	0
38882	1624	Bal 31 deletion mapping datum	[Bal 31 deletion mapping data]	1.0	5	1	0	0
38883	1624	findings,	[findings,]	1.0	1	10	0	0
38884	1624	anti-cancer drug such as 1-beta-d-arabino-furanosylcytosine	[anti-cancer drug such as 1-beta-D-arabino-furanosylcytosine]	1.0	5	1	0	0
38885	1624	thalassemia patient	[thalassemia patient]	1.0	2	2	2	2
38886	1624	LOX-1 gene	[LOX-1 gene]	1.0	2	1	0	0
38887	1624	transactivation of pthrp by tax	[Transactivation of PTHrP by Tax]	1.0	5	1	0	0
38888	1624	six dhs	[six DHS]	1.0	2	1	0	0
38889	1624	span the calcineurin docking site	[spanning the calcineurin docking site]	1.0	5	1	0	0
38890	1624	induce antiviral protection in this cells.	[inducing antiviral protection in these cells.]	1.0	6	1	0	0
38891	1624	human T helper 1 cell	[human T helper 1 cells]	1.0	5	1	0	0
38892	1624	infiltrate T cell in rheumatoid arthritis	[infiltrating T cells in rheumatoid arthritis]	1.0	6	1	0	0
38893	1624	age, 10%	[age, 10%]	1.0	2	1	0	0
38894	1624	strong similarity to a initiator	[strong similarity to an initiator]	1.0	5	1	0	0
38895	1624	JCam/ Lck JCam cell with lck	[JCam/ Lck JCam cells with Lck]	1.0	6	1	0	0
38896	1624	site-specific activator	[site-specific activators]	1.0	2	1	0	0
38897	1624	determine the ultimate outcome of exposure	[determining the ultimate outcome of exposure]	1.0	6	1	0	0
38898	1624	g0s24 product	[G0S24 product]	1.0	2	1	0	0
38899	1624	growth retarding	[growth retarding]	1.0	2	1	0	0
38900	1624	synergy with T cell mitogen	[synergy with T cell mitogens]	1.0	5	1	0	0
38901	1624	nine patient with diabetic nephropathy	[nine patients with diabetic nephropathy]	1.0	5	1	0	0
38902	1624	dna-binding specificity mutant of EKLF	[DNA-binding specificity mutants of EKLF]	1.0	5	1	0	0
38903	1624	Jurkat induction with phorbol ester	[Jurkat induction with phorbol esters]	1.0	5	1	0	0
38904	1624	distinct role in gene expression	[distinct roles in gene expression]	1.0	5	1	0	0
38905	1624	erythropoietin -dependent induction of hemoglobin synthesis	[Erythropoietin -dependent induction of hemoglobin synthesis]	1.0	6	1	0	0
38906	1624	NF-kappa b consist of p50/p65 heterodimer	[NF-kappa B consisting of p50/p65 heterodimer]	1.0	6	1	0	0
38907	1624	non-toxic concentration	[non-toxic concentration]	1.0	2	1	0	0
38908	1624	effect on activation of T lymphocyte	[effect on activation of T lymphocytes]	1.0	6	1	0	0
38909	1624	phospholipid turnover	[phospholipid turnover]	1.0	2	1	0	0
38910	1624	-responsive T	[-responsive T]	1.0	2	1	0	0
38911	1624	ifn-gamma expression	[IFN-gamma expression]	1.0	2	2	2	2
38912	1624	month (6-15	[months (6-15]	1.0	2	1	0	0
38913	1624	downmodulation of lineage-restricted transcription factor	[downmodulation of lineage-restricted transcription factors]	1.0	5	1	0	0
38914	1624	transcriptionally active form of aml1	[transcriptionally active form of AML1]	1.0	5	1	0	0
38915	1624	affect the E2F -binding site	[affecting the E2F -binding sites]	1.0	5	1	0	0
38916	1624	lps the p38 mapk isoform	[LPS the p38 MAPk isoforms]	1.0	5	1	0	0
38917	1624	promoter 1	[promoter 1]	1.0	2	1	0	0
38918	1624	promoter 2	[promoter 2]	1.0	2	1	0	0
38919	1624	induction mechanism	[induction mechanism]	1.0	2	2	1	1
38920	1624	beta I	[beta I]	1.0	2	1	0	0
38921	1624	transcription factor at a element	[transcription factors at a element]	1.0	5	1	0	0
38922	1624	repressor icer	[repressor ICER]	1.0	2	2	2	2
38923	1624	A-myb genome	[A-myb genome]	1.0	2	1	0	0
38924	1624	two female monozygotic (mz) twin	[two female monozygotic (MZ) twins]	1.0	5	1	0	0
38925	1624	rapid tyrosine phosphorylation of JAK2	[rapid tyrosine phosphorylation of JAK2]	1.0	5	1	0	0
38926	1624	hematopoietic tumor	[hematopoietic tumors]	1.0	2	1	0	0
38927	1624	T cell through the tcr	[T cells through the TCR]	1.0	5	1	0	0
38928	1624	immune surveillance	[immune surveillance]	1.0	2	2	1	1
38929	1624	activation of nf-at in eosinophil	[activation of NF-AT in eosinophils]	1.0	5	1	0	0
38930	1624	several cytokine in T lymphocyte	[several cytokines in T lymphocytes]	1.0	5	1	0	0
38931	1624	part of the NF-kappa B complex	[part of the NF-kappa B complex]	1.0	6	1	0	0
38932	1624	common site of chromosomal damage	[common site of chromosomal damage]	1.0	5	1	0	0
38933	1624	much the most abundant protein.	[much the most abundant protein.]	1.0	5	1	0	0
38934	1624	adult alpha -globin promoter activity	[adult alpha -globin promoter activity]	1.0	5	1	0	0
38935	1624	redundant role in lymphoid development	[redundant roles in lymphoid development]	1.0	5	1	0	0
38936	1624	allogeneic stimulation,	[allogeneic stimulation,]	1.0	2	1	0	0
38937	1624	association with different atopic disorder	[association with different atopic disorders]	1.0	5	1	0	0
38938	1624	strong homology	[strong homology]	1.0	2	2	2	2
38939	1624	Fos expression	[Fos expression]	1.0	2	1	0	0
38940	1624	TNF family	[TNF family]	1.0	2	1	0	0
38941	1624	bal cell	[BAL cells]	1.0	2	1	0	0
38942	1624	stimulate agent	[stimulating agents]	1.0	2	1	0	0
38943	1624	three peptide	[three peptides]	1.0	2	2	1	1
38944	1624	terminal phase	[terminal phase]	1.0	2	1	0	0
38945	1624	essential role of this site	[essential role of this site]	1.0	5	1	0	0
38946	1624	nature of the factor responsible	[nature of the factors responsible]	1.0	5	1	0	0
38947	1624	unaffected sister	[unaffected sister]	1.0	2	1	0	0
38948	1624	role for protein tyrosine kinase	[role for protein tyrosine kinases]	1.0	5	1	0	0
38949	1624	undetectable nf-kappa b activity, p65 complex	[undetectable NF-kappa B activity, p65 complexes]	1.0	6	1	0	0
38950	1624	tnf-alpha level in culture supernatant	[TNF-alpha level in culture supernatants]	1.0	5	1	0	0
38951	1624	complementary role	[complementary role]	1.0	2	1	0	0
38952	1624	novel component of the NB	[novel component of the NB]	1.0	5	1	0	0
38953	1624	use construct	[Using constructs]	1.0	2	2	1	1
38954	1624	increase in il-2 gene expression	[increase in IL-2 gene expression]	1.0	5	1	0	0
38955	1624	primary human cd34+ progenitor cell	[primary human CD34+ progenitor cells]	1.0	5	1	0	0
38956	1624	tissue-specific down-regulation	[tissue-specific down-regulation]	1.0	2	1	0	0
38957	1624	bZIP activator	[bZIP activator]	1.0	2	1	0	0
38958	1624	family of cell surface glycoprotein	[family of cell surface glycoproteins]	1.0	5	1	0	0
38959	1624	estrone e1	[estrone E1]	1.0	2	1	0	0
38960	1624	90 minute	[90 min]	1.0	2	2	1	1
38961	1624	motifs, site	[motifs, site]	1.0	2	1	0	0
38962	1624	coordinate downregulation of alpha globin	[coordinate downregulation of alpha globin]	1.0	5	1	0	0
38963	1624	Specific depletion of the B-cell population	[Specific depletion of the B-cell population]	1.0	6	1	0	0
38964	1624	investigate the nature of cold syndrome	[investigating the nature of cold syndromes]	1.0	6	1	0	0
38965	1624	female (2.32	[females (2.32]	1.0	2	1	0	0
38966	1624	mouse transgenic for human csf-1r	[mice transgenic for human CSF-1R]	1.0	5	1	0	0
38967	1624	isg15 mrna accumulation in u937 cell	[ISG15 mRNA accumulation in U937 cells]	1.0	6	1	0	0
38968	1624	expression level of monocyte-binding receptor	[expression levels of monocyte-binding receptors]	1.0	5	1	0	0
38969	1624	b-cell lineage	[B-cell lineage]	1.0	2	2	2	2
38970	1624	inappropriate activation of kappa b-driven gene	[inappropriate activation of kappa B-driven genes]	1.0	6	1	0	0
38971	1624	Genetic evidence	[Genetic evidence]	1.0	2	2	1	1
38972	1624	confocal microscopy	[confocal microscopy]	1.0	2	1	0	0
38973	1624	phosphotyrosine phosphatase	[phosphotyrosine phosphatase]	1.0	2	1	0	0
38974	1624	b-cell-specific transcription of immunoglobulin gene	[B-cell-specific transcription of immunoglobulin genes]	1.0	5	1	0	0
38975	1624	activation of the immunodeficiency virus	[activation of the immunodeficiency virus]	1.0	5	1	0	0
38976	1624	stimulation of cell with ifn-alpha	[Stimulation of cells with IFN-alpha]	1.0	5	1	0	0
38977	1624	decrease of er level in leukocyte	[decrease of ER level in leukocytes]	1.0	6	1	0	0
38978	1624	use RNAzol	[using RNAzol]	1.0	2	1	0	0
38979	1624	purification of the sr 31747a-binding protein	[Purification of the SR 31747A-binding protein]	1.0	6	1	0	0
38980	1624	leukemic ecem)	[leukemic (CEM)]	1.0	2	1	0	0
38981	1624	junb protein in th2 cell	[JunB protein in Th2 cells]	1.0	5	1	0	0
38982	1624	lysophosphatidylcholine lysoPC	[lysophosphatidylcholine lysoPC]	1.0	2	1	0	0
38983	1624	expression of glucocorticoid receptor beta	[expression of glucocorticoid receptor beta]	1.0	5	1	0	0
38984	1624	enhancement of the dna-binding activity	[enhancement of the DNA-binding activity]	1.0	5	1	0	0
38985	1624	five transcription factor binding site	[five transcription factor binding sites]	1.0	5	1	0	0
38986	1624	inflammatory model.	[inflammatory model.]	1.0	2	1	0	0
38987	1624	increase physical exercise to maximal	[increasing physical exercise to maximal]	1.0	5	1	0	0
38988	1624	early studies,	[earlier studies,]	1.0	2	1	0	0
38989	1624	differentiation of multipotential progenitor cell	[differentiation of multipotential progenitor cells]	1.0	5	1	0	0
38990	1624	cd11a /cd18	[CD11a /CD18]	1.0	2	1	0	0
38991	1624	immune activation	[immune activation]	1.0	2	1	0	0
38992	1624	binding of specific transcription factor	[binding of specific transcription factors]	1.0	5	1	0	0
38993	1624	toxicity secondary	[toxicity secondary]	1.0	2	2	2	2
38994	1624	use a NF-kappa b binding sequence	[using an NF-kappa B binding sequence]	1.0	6	1	0	0
38995	1624	thyromimetic effect on the activity	[thyromimetic effect on the activity]	1.0	5	1	0	0
38996	1624	vertebrate development,	[vertebrate development,]	1.0	2	1	0	0
38997	1624	differentiation of some cell line	[differentiation of some cell lines]	1.0	5	1	0	0
38998	1624	threshold of cathepsin g alone	[threshold of cathepsin G alone]	1.0	5	1	0	0
38999	1624	control peptide corresponding to the pml	[Control peptides corresponding to the pml]	1.0	6	1	0	0
39000	1624	tested: dephosphorylation of nuclear factor	[tested: dephosphorylation of nuclear factor]	1.0	5	1	0	0
39001	1624	mrna of three gata-binding protein	[mRNA of three GATA-binding proteins]	1.0	5	1	0	0
39002	1624	initiator-like sequence	[initiator-like sequence]	1.0	2	1	0	0
39003	1624	ig/tcr gene rearrangement in this cells.	[Ig/TcR gene rearrangements in these cells.]	1.0	6	1	0	0
39004	1624	base order	[base order]	1.0	2	1	0	0
39005	1624	moreover, anti- TNF-alpha hiv-1 long repeat	[Moreover, anti- TNF-alpha HIV-1 long repeat]	1.0	6	1	0	0
39006	1624	negative regulator in erythroid differentiation	[negative regulators in erythroid differentiation]	1.0	5	1	0	0
39007	1624	active phorbolester	[active phorbolester]	1.0	2	1	0	0
39008	1624	result in the transcription repressor evi1	[resulting in the transcription repressor EVI1]	1.0	6	1	0	0
39009	1624	conventional procedure	[conventional procedures]	1.0	2	1	0	0
39010	1624	adult testis	[adult testis]	1.0	2	1	0	0
39011	1624	region.	[region.]	1.0	1	11	4	4
39012	1624	direct involvement of this receptor	[direct involvement of this receptor]	1.0	5	1	0	0
39013	1624	important trigger for a sequence	[important trigger for a sequence]	1.0	5	1	0	0
39014	1624	previous characterization of the GPIX promoter	[Previous characterization of the GPIX promoter]	1.0	6	1	0	0
39015	1624	cd4- cd8-	[CD4- CD8-]	1.0	2	1	0	0
39016	1624	interleukin-3 (il-3)- GM colony formation	[interleukin-3 (IL-3)- GM colony formation]	1.0	5	1	0	0
39017	1624	specific nucleosome	[specific nucleosome]	1.0	2	1	0	0
39018	1624	comprise the GM-CSF promoter element responsible	[comprising the GM-CSF promoter element responsible]	1.0	6	1	0	0
39019	1624	LMP-1 promoter	[LMP-1 promoter]	1.0	2	1	0	0
39020	1624	critical regulator	[critical regulator]	1.0	2	3	2	1
39021	1624	potential target for antiviral therapy	[potential target for antiviral therapy]	1.0	5	1	0	0
39022	1624	tumour burden	[tumour burden]	1.0	2	1	0	0
39023	1624	reveal a selective role for traf6	[revealing a selective role for TRAF6]	1.0	6	1	0	0
39024	1624	return to baseline after 24 P.	[returning to baseline after 24 h.]	1.0	6	1	0	0
39025	1624	hiv-1 individual	[HIV-1 individuals]	1.0	2	2	1	1
39026	1624	pld action	[PLD action]	1.0	2	1	0	0
39027	1624	human neutrophils.	[human neutrophils.]	1.0	2	2	1	1
39028	1624	transcriptional activation in pma-treated fibroblast	[transcriptional activation in PMA-treated fibroblasts]	1.0	5	1	0	0
39029	1624	combination of the rar-selective antagonist	[combination of the RAR-selective antagonist]	1.0	5	1	0	0
39030	1624	comparison, nuclei of human lymphocyte	[comparison, nuclei of human lymphocytes]	1.0	5	1	0	0
39031	1624	1 minute of receptor stimulation	[1 min of receptor stimulation]	1.0	5	1	0	0
39032	1624	use antibody against subunit of protein	[using antibodies against subunits of proteins]	1.0	6	1	0	0
39033	1624	mrp14 expression	[MRP14 expression]	1.0	2	1	0	0
39034	1624	ratio of bcl-2 to CD3	[ratio of BCL-2 to CD3]	1.0	5	1	0	0
39035	1624	clinical importance	[clinical importance]	1.0	2	2	2	2
39036	1624	beta-gal expression	[beta-gal expression]	1.0	2	1	0	0
39037	1624	vitamin d receptor VDR gene	[vitamin D receptor VDR gene]	1.0	5	1	0	0
39038	1624	complement-opsonized particle	[complement-opsonized particles]	1.0	2	1	0	0
39039	1624	incubation of the tumor cell	[incubation of the tumor cells]	1.0	5	1	0	0
39040	1624	extreme c-terminus	[extreme C-terminus]	1.0	2	1	0	0
39041	1624	presence of the CD4 tail	[presence of the CD4 tail]	1.0	5	1	0	0
39042	1624	steel factor on SCL expression	[Steel factor on SCL expression]	1.0	5	1	0	0
39043	1624	inhibitor-kappaB alpha	[inhibitor-kappaB alpha]	1.0	2	1	0	0
39044	1624	Erythroid-specific gene	[Erythroid-specific genes]	1.0	2	1	0	0
39045	1624	immunohistochemistry use the BZ1 antibody	[immunohistochemistry using the BZ1 antibody]	1.0	5	1	0	0
39046	1624	signal event mediate this effect	[signaling events mediating this effect]	1.0	5	1	0	0
39047	1624	immune function in hiv infection	[immune function in HIV infection]	1.0	5	1	0	0
39048	1624	T cell from cancer patient	[T cells from cancer patients]	1.0	5	1	0	0
39049	1624	identity between the p60 protein	[identity between the p60 protein]	1.0	5	1	0	0
39050	1624	important region	[important region]	1.0	2	2	1	1
39051	1624	proportion of dp1 to dp2	[proportion of DP1 to DP2]	1.0	5	1	0	0
39052	1624	leukocyte adhesion to endothelial cell	[leukocyte adhesion to endothelial cells]	1.0	5	2	2	2
39053	1624	expression of b target gene	[expression of B target genes]	1.0	5	1	0	0
39054	1624	thus result in the lack	[thus resulting in the lack]	1.0	5	1	0	0
39055	1624	GATA-1 a erythroid transcription factor	[GATA-1 an erythroid transcription factor]	1.0	5	1	0	0
39056	1624	contain the human cytomegalovirus immediate-early enhancer	[containing the human cytomegalovirus immediate-early enhancer]	1.0	6	1	0	0
39057	1624	ultra-violet activation of NF-kappa b	[UV activation of NF-kappa B]	1.0	5	1	0	0
39058	1624	cell-specific binding of protein, presumably Sp1	[cell-specific binding of protein, presumably Sp1]	1.0	6	1	0	0
39059	1624	glucocorticoid-resistant primate.	[glucocorticoid-resistant primate.]	1.0	2	1	0	0
39060	1624	induction of T cell anergy	[Induction of T cell anergy]	1.0	5	1	0	0
39061	1624	il-10 effect	[IL-10 effect]	1.0	2	2	1	1
39062	1624	potential site for transcription factor	[potential sites for transcription factors]	1.0	5	1	0	0
39063	1624	ec costimulation	[EC costimulation]	1.0	2	1	0	0
39064	1624	activation of the g-csf-r /il-7r alpha	[Activation of the G-CSF-R /IL-7R alpha]	1.0	6	1	0	0
39065	1624	significant protection to T cell line	[significant protection to T cell lines]	1.0	6	1	0	0
39066	1624	G0S2 mrna	[G0S2 mRNA]	1.0	2	1	0	0
39067	1624	cd14+ monocyte	[CD14+ monocytes]	1.0	2	2	2	2
39068	1624	IL-1 synthesis of a protein(s)	[IL-1 synthesis of a protein(s)]	1.0	5	1	0	0
39069	1624	However, IL-10	[However, IL-10]	1.0	2	1	0	0
39070	1624	high stringency	[high stringency]	1.0	2	1	0	0
39071	1624	transcription of il-2r beta gene	[transcription of IL-2R beta gene]	1.0	5	1	0	0
39072	1624	interaction with thymic epithelial cell TEC	[interaction with thymic epithelial cells TEC]	1.0	6	1	0	0
39073	1624	binding site for stat protein	[binding site for STAT proteins]	1.0	5	2	2	2
39074	1624	analyse the ag amino acid sequence	[analysing the Ag amino acid sequence]	1.0	6	1	0	0
39075	1624	effect on the IL-10 modulation	[effect on the IL-10 modulation]	1.0	5	1	0	0
39076	1624	upregulate NF-kappa b1 gene expression	[upregulating NF-kappa B1 gene expression]	1.0	5	1	0	0
39077	1624	pbmc proliferation	[PBMC proliferation]	1.0	2	1	0	0
39078	1624	inert monomer	[inert monomer]	1.0	2	1	0	0
39079	1624	GAS element	[GAS elements]	1.0	2	1	0	0
39080	1624	4 patient	[4 patients]	1.0	2	1	0	0
39081	1624	CEM c1	[CEM C1]	1.0	2	2	1	1
39082	1624	high capacity	[high capacity]	1.0	2	2	2	2
39083	1624	hormone-receptor interaction	[hormone-receptor interactions]	1.0	2	2	1	1
39084	1624	short isoform	[short isoform]	1.0	2	1	0	0
39085	1624	endotoxic shock	[endotoxic shock]	1.0	2	1	0	0
39086	1624	constituent of several cytokine receptor	[constituent of several cytokine receptors]	1.0	5	1	0	0
39087	1624	NF-AT plasmid	[NF-AT plasmids]	1.0	2	1	0	0
39088	1624	assay for a viral transactivator activity	[assaying for a viral transactivator activity]	1.0	6	1	0	0
39089	1624	RESULTS: lps	[RESULTS: LPS]	1.0	2	1	0	0
39090	1624	na(+)-h+ antiport	[Na(+)-H+ antiport]	1.0	2	1	0	0
39091	1624	human lysosomal acid lipase LAL	[Human lysosomal acid lipase LAL]	1.0	5	1	0	0
39092	1624	16-27 years,	[16-27 years,]	1.0	2	1	0	0
39093	1624	ifn-gamma pretreatment	[IFN-gamma pretreatment]	1.0	2	1	0	0
39094	1624	tgf-beta1-transcribing macrophage	[TGF-beta1-transcribing macrophages]	1.0	2	1	0	0
39095	1624	Interleukin-7 IL-7	[Interleukin-7 IL-7]	1.0	2	1	0	0
39096	1624	functional defect,	[functional defect,]	1.0	2	1	0	0
39097	1624	expression of wt1 in fibroblast	[expression of WT1 in fibroblasts]	1.0	5	2	2	2
39098	1624	human donor	[human donors]	1.0	2	1	0	0
39099	1624	g-csf stimulation	[G-CSF stimulation]	1.0	2	1	0	0
39100	1624	corresponding haplotype	[corresponding haplotypes]	1.0	2	1	0	0
39101	1624	substrate recognition by structural loci	[substrate recognition by structural loci]	1.0	5	1	0	0
39102	1624	activation events.	[activation events.]	1.0	2	1	0	0
39103	1624	standard methods.	[standard methods.]	1.0	2	1	0	0
39104	1624	activate gst-pi promoter in plasma cell	[activating GST-pi promoter in plasma cells]	1.0	6	1	0	0
39105	1624	t-cell factor	[T-cell factor]	1.0	2	1	0	0
39106	1624	p 0.01	[P 0.01]	1.0	2	2	2	2
39107	1624	signal lead to gene transcription	[signals leading to gene transcription]	1.0	5	1	0	0
39108	1624	rat cerulein pancreatitis by peptide	[rat cerulein pancreatitis by peptide]	1.0	5	1	0	0
39109	1624	nf-kappab transcription of the IkappaBalpha gene	[NF-kappaB transcription of the IkappaBalpha gene]	1.0	6	1	0	0
39110	1624	drug-induced apoptosis	[drug-induced apoptosis]	1.0	2	1	0	0
39111	1624	Study of the function of SCL	[Studies of the function of SCL]	1.0	6	1	0	0
39112	1624	other peroxisome proliferator receptor ppar	[Other peroxisome proliferator receptor PPAR]	1.0	5	1	0	0
39113	1624	protection of the hinge region	[protection of the hinge region]	1.0	5	1	0	0
39114	1624	1.3E2 cell	[1.3E2 cells]	1.0	2	1	0	0
39115	1624	upstream enhancer	[upstream enhancer]	1.0	2	2	1	1
39116	1624	Surprisingly, traf	[Surprisingly, TRAF]	1.0	2	1	0	0
39117	1624	encompass all of the acidic domain	[encompassing all of the acidic domain]	1.0	6	1	0	0
39118	1624	insertion mutation	[insertion mutation]	1.0	2	2	1	1
39119	1624	I tax	[I Tax]	1.0	2	2	1	1
39120	1624	human promyeloid leukemia cell line	[human promyeloid leukemia cell line]	1.0	5	1	0	0
39121	1624	different variant	[different variants]	1.0	2	2	1	1
39122	1624	variation in cell proliferation rate	[variation in cell proliferation rates]	1.0	5	1	0	0
39123	1624	systemic symptoms.	[systemic symptoms.]	1.0	2	1	0	0
39124	1624	exogenous il-12	[exogenous IL-12]	1.0	2	1	0	0
39125	1624	three other ATL cell line TL-OmI	[Three other ATL cell lines TL-OmI]	1.0	6	1	0	0
39126	1624	17 kda	[17 kDa]	1.0	2	1	0	0
39127	1624	TRE -DNA	[TRE -DNA]	1.0	2	1	0	0
39128	1624	high-frequency rearrangement of kappa light-chain gene	[high-frequency rearrangement of kappa light-chain genes]	1.0	6	1	0	0
39129	1624	undetectable level in rest platelet	[undetectable levels in resting platelets]	1.0	5	1	0	0
39130	1624	development of some lymphoid lineage	[development of some lymphoid lineages]	1.0	5	1	0	0
39131	1624	tenfold increase in glucocorticoid apoptosis	[tenfold increase in glucocorticoid apoptosis]	1.0	5	1	0	0
39132	1624	human osteoclast	[human osteoclasts]	1.0	2	1	0	0
39133	1624	one substrate	[One substrate]	1.0	2	1	0	0
39134	1624	spirochetal lipoprotein	[spirochetal lipoproteins]	1.0	2	1	0	0
39135	1624	persistent activation of NF-kappa b	[persistent activation of NF-kappa B]	1.0	5	1	0	0
39136	1624	1-long terminal repeat hiv-1-ltr CAT construct	[1-long terminal repeat HIV-1-LTR CAT constructs]	1.0	6	1	0	0
39137	1624	general cofactor	[general cofactors]	1.0	2	1	0	0
39138	1624	antiinflammatory activity	[antiinflammatory activity]	1.0	2	2	1	1
39139	1624	certain processes,	[certain processes,]	1.0	2	1	0	0
39140	1624	EKLF-/- colony	[EKLF-/- colonies]	1.0	2	1	0	0
39141	1624	impaired silencing of gamma-globin expression	[Impaired silencing of gamma-globin expression]	1.0	5	1	0	0
39142	1624	high grade	[high grade]	1.0	2	2	1	1
39143	1624	study role in the process	[studying role in the process]	1.0	5	1	0	0
39144	1624	many characteristic	[many characteristics]	1.0	2	1	0	0
39145	1624	plasminogen activator inhibitor type pai-1	[plasminogen activator inhibitor type PAI-1]	1.0	5	1	0	0
39146	1624	suggest genotypic marker for a region	[suggesting genotypic markers for an region]	1.0	6	1	0	0
39147	1624	biomedical research on cell therapy,	[biomedical research on cell therapy,]	1.0	5	1	0	0
39148	1624	activity of the CaM kinase	[Activity of the CaM kinases]	1.0	5	1	0	0
39149	1624	b cell the target cell	[B cells the target cells]	1.0	5	1	0	0
39150	1624	probe encompass a common region	[probe encompassing a common region]	1.0	5	1	0	0
39151	1624	purine-box/nuclear factor	[purine-box/nuclear factor]	1.0	2	1	0	0
39152	1624	two related protein- tyrosine kinase	[two related protein- tyrosine kinases]	1.0	5	1	0	0
39153	1624	differentiation of human erythroleukemic cell	[differentiation of human erythroleukemic cells]	1.0	5	1	0	0
39154	1624	RCC supernatant	[RCC supernatants]	1.0	2	1	0	0
39155	1624	enhancer DEN	[enhancer DEN]	1.0	2	1	0	0
39156	1624	63% nucleotide identity with a core	[63% nucleotide identity with a core]	1.0	6	1	0	0
39157	1624	contact with the pou domain	[contact with the POU domain]	1.0	5	1	0	0
39158	1624	Ig heavy chain switch region sequence	[Ig heavy chain switch region sequences]	1.0	6	1	0	0
39159	1624	human breast cancer mcf-7 cell	[human breast cancer MCF-7 cells]	1.0	5	1	0	0
39160	1624	initial induction of this signal	[initial induction of these signals]	1.0	5	1	0	0
39161	1624	mycoplasma product	[mycoplasma products]	1.0	2	1	0	0
39162	1624	similarity with respect to b cell	[similarities with respect to B cells]	1.0	6	1	0	0
39163	1624	Rat splenocyte	[Rat splenocytes]	1.0	2	1	0	0
39164	1624	5 patient	[5 patients]	1.0	2	2	1	1
39165	1624	precise spacing	[precise spacing]	1.0	2	1	0	0
39166	1624	dna-binding conformation	[DNA-binding conformation]	1.0	2	1	0	0
39167	1624	saturate level	[saturating levels]	1.0	2	1	0	0
39168	1624	result of the present study	[results of the present study]	1.0	5	1	0	0
39169	1624	variation during the menstrual cycle	[variations during the menstrual cycle]	1.0	5	1	0	0
39170	1624	chromosome 9q33-34.1	[chromosome 9Q33-34.1]	1.0	2	1	0	0
39171	1624	EBV mrna transcript encode transactivator	[EBV mRNA transcripts encoding transactivators]	1.0	5	1	0	0
39172	1624	precursor present	[precursors present]	1.0	2	1	0	0
39173	1624	spread on human endothelial cell	[spreading on human endothelial cells]	1.0	5	1	0	0
39174	1624	trap-positive mgc	[TRAP-positive MGC]	1.0	2	1	0	0
39175	1624	Addition of a TNF alpha antibody	[Addition of an TNF alpha antibody]	1.0	6	1	0	0
39176	1624	DQ2 binding	[DQ2 binding]	1.0	2	1	0	0
39177	1624	OCTA site	[OCTA site]	1.0	2	1	0	0
39178	1624	electrophoresis mobility	[Electrophoresis mobility]	1.0	2	2	2	2
39179	1624	tnf-alpha activation of hiv-1 replication	[TNF-alpha activation of HIV-1 replication]	1.0	5	1	0	0
39180	1624	AP1	[AP1]	1.0	1	11	1	1
39181	1624	several patient	[several patients]	1.0	2	2	1	1
39182	1624	viral factor	[viral factors]	1.0	2	1	0	0
39183	1624	Myb-Et oncoprotein	[Myb-Ets oncoprotein]	1.0	2	1	0	0
39184	1624	two class of LTR size variant	[Two classes of LTR size variants]	1.0	6	1	0	0
39185	1624	approximately 1000 VDR by 24 P.	[approximately 1000 VDR by 24 h.]	1.0	6	1	0	0
39186	1624	encode a kruppel-type zinc finger protein	[encoding a Kruppel-type zinc finger protein]	1.0	6	1	0	0
39187	1624	lineage-positive cell	[lineage-positive cells]	1.0	2	1	0	0
39188	1624	apparent discrepancy,	[apparent discrepancy,]	1.0	2	1	0	0
39189	1624	primary human cd4+ T cell	[primary human CD4+ T cells]	1.0	5	1	0	0
39190	1624	plasmacytoma cell	[plasmacytoma cells]	1.0	2	2	1	1
39191	1624	tnfrii associate with TNFR factor	[TNFRII associating with TNFR factors]	1.0	5	1	0	0
39192	1624	UT-7 cell	[UT-7 cells]	1.0	2	1	0	0
39193	1624	renal dysplasia	[renal dysplasia]	1.0	2	1	0	0
39194	1624	sulfonyl)-2-methylpiperazine a inhibitor of PKC	[sulfonyl)-2-methylpiperazine an inhibitor of PKC]	1.0	5	1	0	0
39195	1624	MNDA mrna level in adherent monocyte	[MNDA mRNA level in adherent monocytes]	1.0	6	1	0	0
39196	1624	4 nm,	[4 nM,]	1.0	2	1	0	0
39197	1624	various endogenous host transcription factor	[various endogenous host transcription factors]	1.0	5	1	0	0
39198	1624	24 hour time culture for IL-8	[24 hours time culture for IL-8]	1.0	6	1	0	0
39199	1624	atl16t(-) cell	[ATL16T(-) cells]	1.0	2	1	0	0
39200	1624	nuclear factor-kappaB nf-kappab transcription factor	[nuclear factor-kappaB NF-kappaB transcription factors]	1.0	5	1	0	0
39201	1624	enhancer property	[enhancer properties]	1.0	2	1	0	0
39202	1624	expression of id2 mrna in lymphocyte	[Expression of Id2 mRNA in lymphocytes]	1.0	6	1	0	0
39203	1624	phospholipase c gamma 1 overexpression	[Phospholipase C gamma 1 overexpression]	1.0	5	1	0	0
39204	1624	murine cDNA encoding transcription factor	[murine cDNA encoding transcription factor]	1.0	5	1	0	0
39205	1624	tumor necrosis factor-alpha -dependent mechanism	[tumor necrosis factor-alpha -dependent mechanisms]	1.0	5	1	0	0
39206	1624	6 woman	[6 women]	1.0	2	2	1	1
39207	1624	novel il-10	[novel IL-10]	1.0	2	1	0	0
39208	1624	transcription, suggest important in lymphomagenesis	[transcription, suggesting important in lymphomagenesis]	1.0	5	1	0	0
39209	1624	inhibitor of Ca(2+)-dependent K+ channel	[inhibitor of Ca(2+)-dependent K+ channels]	1.0	5	1	0	0
39210	1624	100 U/ml, il-10 tnf-alpha release	[100 U/ml, IL-10 TNF-alpha release]	1.0	5	1	0	0
39211	1624	IL-7R alpha	[IL-7R alpha]	1.0	2	1	0	0
39212	1624	only of the intracellular domain icn	[only of the intracellular domain ICN]	1.0	6	1	0	0
39213	1624	sequence specific	[sequence specific]	1.0	2	1	0	0
39214	1624	globin mrna	[globin mRNA]	1.0	2	2	1	1
39215	1624	distinct signals,	[distinct signals,]	1.0	2	1	0	0
39216	1624	JAK /stat activation of qp	[JAK /STAT activation of Qp]	1.0	5	1	0	0
39217	1624	Epstein-Barr virus in b lymphocyte	[Epstein-Barr virus in B lymphocytes]	1.0	5	1	0	0
39218	1624	interaction between transcription factor in lymphocyte	[interactions between transcription factors in lymphocytes]	1.0	6	1	0	0
39219	1624	thus, stable expression of HB24	[Thus, stable expression of HB24]	1.0	5	1	0	0
39220	1624	combination of the cis-acting element	[combination of the cis-acting elements]	1.0	5	1	0	0
39221	1624	positively stain	[positively staining]	1.0	2	1	0	0
39222	1624	PKC delta	[PKC delta]	1.0	2	1	0	0
39223	1624	(type I	[(type I]	1.0	2	2	1	1
39224	1624	functional studies, interferon-gamma piec clone	[functional studies, interferon-gamma PIEC clones]	1.0	5	1	0	0
39225	1624	structural analysis	[structural analysis]	1.0	2	2	1	1
39226	1624	b2 factor	[B2 factor]	1.0	2	1	0	0
39227	1624	activation of proenkephalin transcription by JunD	[Activation of proenkephalin transcription by JunD]	1.0	6	1	0	0
39228	1624	c-Jun protein	[c-Jun protein]	1.0	2	1	0	0
39229	1624	tyrosine phosphorylation of stat4 in lymphocyte	[tyrosine phosphorylation of STAT4 in lymphocytes]	1.0	6	1	0	0
39230	1624	likely consequence	[likely consequence]	1.0	2	1	0	0
39231	1624	gp41 il-10 production in monocyte	[gp41 IL-10 production in monocytes]	1.0	5	1	0	0
39232	1624	difference in the positional specificity	[differences in the positional specificity]	1.0	5	1	0	0
39233	1624	stably cell	[stably cells]	1.0	2	1	0	0
39234	1624	substantial increase in ap-1 binding activity	[substantial increases in AP-1 binding activity]	1.0	6	1	0	0
39235	1624	cortisol resistance in immunodeficiency syndrome	[Cortisol resistance in immunodeficiency syndrome]	1.0	5	1	0	0
39236	1624	mobilization of the nuclear factor	[mobilization of the nuclear factor]	1.0	5	1	0	0
39237	1624	ester derivative	[ester derivatives]	1.0	2	1	0	0
39238	1624	expression of Jagged1 a ligand	[expression of Jagged1 a ligand]	1.0	5	1	0	0
39239	1624	ability of the TATA box	[ability of the TATA box]	1.0	5	1	0	0
39240	1624	expression of the il-5 gene	[expression of the IL-5 gene]	1.0	5	1	0	0
39241	1624	transform activity in multiple cell culture	[transforming activity in multiple cell culture]	1.0	6	1	0	0
39242	1624	sex difference in pbmc receptor	[sex difference in PBMC receptors]	1.0	5	1	0	0
39243	1624	Rather, IFN-gamma	[Rather, IFN-gamma]	1.0	2	1	0	0
39244	1624	consider group of patient together	[considering groups of patients together]	1.0	5	1	0	0
39245	1624	receptor interaction	[receptor interactions]	1.0	2	1	0	0
39246	1624	key cytokine	[key cytokine]	1.0	2	2	1	1
39247	1624	seek support as a coping strategy	[seeking support as a coping strategy]	1.0	6	2	2	2
39248	1624	immunohistochemical finding	[immunohistochemical findings]	1.0	2	1	0	0
39249	1624	high resolution	[high resolution]	1.0	2	1	0	0
39250	1624	follow binding	[following binding]	1.0	2	2	2	2
39251	1624	Cdk2-dependent phosphorylation	[Cdk2-dependent phosphorylation]	1.0	2	1	0	0
39252	1624	two human myeloid cell line	[two human myeloid cell lines]	1.0	5	1	0	0
39253	1624	complex change in immune-endocrine function	[complex change in immune-endocrine function]	1.0	5	1	0	0
39254	1624	phorbol 12-myristate 13-acetate stimulation T	[phorbol 12-myristate 13-acetate stimulation T]	1.0	5	1	0	0
39255	1624	intercellular adhesion molecule-1 on cell	[intercellular adhesion molecule-1 on cells]	1.0	5	2	2	2
39256	1624	co-stimulatory molecule	[co-stimulatory molecules]	1.0	2	1	0	0
39257	1624	severe phenotype of x-scid patient	[severe phenotype of X-SCID patients]	1.0	5	1	0	0
39258	1624	acute promyelocytic myeloblastic leukemia cell	[acute promyelocytic myeloblastic leukemia cells]	1.0	5	1	0	0
39259	1624	two subset	[two subsets]	1.0	2	1	0	0
39260	1624	1) PMA for 24 h.	[1) PMA for 24 h,]	1.0	5	1	0	0
39261	1624	c-Jun alone	[c-Jun alone]	1.0	2	1	0	0
39262	1624	13 sex-and age-matched healthy subject	[13 sex-and age-matched healthy subjects]	1.0	5	1	0	0
39263	1624	expression of the runt domain	[Expression of the Runt domain]	1.0	5	1	0	0
39264	1624	signal of the CALM yac	[signals of the CALM YACS]	1.0	5	1	0	0
39265	1624	IL-4 complex	[IL-4 complex]	1.0	2	1	0	0
39266	1624	use the human bcl6 (hbcl6) cDNA	[using the human BCL6 (hBCL6) cDNA]	1.0	6	1	0	0
39267	1624	sigma receptor	[sigma receptor]	1.0	2	2	2	2
39268	1624	tata-box binding protein tbp tfiib	[TATA-box binding protein TBP TFIIB]	1.0	5	1	0	0
39269	1624	nuclear transcription factor kappa b	[nuclear transcription factor kappa B]	1.0	5	1	0	0
39270	1624	truncate mutation	[truncating mutations]	1.0	2	2	2	2
39271	1624	stage selector	[stage selector]	1.0	2	2	2	2
39272	1624	Ox LDL	[Ox LDL]	1.0	2	2	1	1
39273	1624	parent promoter	[parent promoter]	1.0	2	1	0	0
39274	1624	represent tumor defense in patient	[representing tumor defense in patients]	1.0	5	1	0	0
39275	1624	master switch for the expression	[master switch for the expression]	1.0	5	1	0	0
39276	1624	hormone level	[hormone levels]	1.0	2	1	0	0
39277	1624	Porphyromonas gingivalis lps P- lps	[Porphyromonas gingivalis LPS P- LPS]	1.0	5	1	0	0
39278	1624	Nmi a protein of function	[Nmi a protein of function]	1.0	5	1	0	0
39279	1624	minute (phase	[minutes (phase]	1.0	2	2	2	2
39280	1624	erk2 kinase	[ERK2 kinase]	1.0	2	2	1	1
39281	1624	productive infection of T cell	[Productive infection of T cells]	1.0	5	1	0	0
39282	1624	direct interaction of steroid -receptor complex	[direct interaction of steroid -receptor complexes]	1.0	6	1	0	0
39283	1624	authors' objective	[authors' objective]	1.0	2	1	0	0
39284	1624	use a variety of b site	[using a variety of B sites]	1.0	6	1	0	0
39285	1624	t-cell transformation	[T-cell transformation]	1.0	2	2	1	1
39286	1624	high affinity binding of the radioligand	[High affinity binding of the radioligand]	1.0	6	1	0	0
39287	1624	NFAT motif	[NFAT motif]	1.0	2	1	0	0
39288	1624	specificity of (although documented significance	[specificities of (although documented) significance]	1.0	5	1	0	0
39289	1624	steady-state level of vcam-1 mrna	[steady-state levels of VCAM-1 mRNA]	1.0	5	1	0	0
39290	1624	parallel variation	[parallel variations]	1.0	2	1	0	0
39291	1624	response to this ebv antigen	[Responses to these EBV antigens]	1.0	5	1	0	0
39292	1624	furthermore, activation-dependent tyrosine phosphorylation of HS1	[Furthermore, activation-dependent tyrosine phosphorylation of HS1]	1.0	6	1	0	0
39293	1624	expression of the specificity phosphatase	[expression of the specificity phosphatase]	1.0	5	1	0	0
39294	1624	Jun/Fos protein	[Jun/Fos proteins]	1.0	2	1	0	0
39295	1624	cortisol concentration across the subjects.	[cortisol concentrations across the subjects.]	1.0	5	1	0	0
39296	1624	RelA(p65) subunit	[RelA(p65) subunit]	1.0	2	1	0	0
39297	1624	FcgammaRI promoter	[FcgammaRI promoter]	1.0	2	1	0	0
39298	1624	ig expression	[Ig expression]	1.0	2	1	0	0
39299	1624	term of the differentiation-inducing ability	[terms of the differentiation-inducing ability]	1.0	5	1	0	0
39300	1624	Cupric ion	[Cupric ion]	1.0	2	1	0	0
39301	1624	mutation in this dna-binding site	[Mutations in this DNA-binding site]	1.0	5	1	0	0
39302	1624	include c-fo	[including c-fos]	1.0	2	2	2	2
39303	1624	delivery (96	[delivery (96]	1.0	2	1	0	0
39304	1624	treatment of u-937 cell with tpa	[Treatment of U-937 cells with TPA]	1.0	6	1	0	0
39305	1624	other protein in human platelet	[other proteins in human platelets]	1.0	5	1	0	0
39306	1624	proinflammatory agonist as lipopolysaccharide lps	[proinflammatory agonists as lipopolysaccharide LPS]	1.0	5	1	0	0
39307	1624	use of the dnase i	[use of the DNase I]	1.0	5	1	0	0
39308	1624	rapamycin-regulated signal for e2f regulation	[rapamycin-regulated signals for E2F regulation]	1.0	5	1	0	0
39309	1624	PtdIns 3-kinase	[PtdIns 3-kinase]	1.0	2	2	2	2
39310	1624	RAR ligand	[RAR ligands]	1.0	2	2	2	2
39311	1624	drug-free control	[drug-free controls]	1.0	2	1	0	0
39312	1624	important determinant for MLV transcriptional activity	[important determinants for MLV transcriptional activity]	1.0	6	1	0	0
39313	1624	La(SSB) antigen,	[La(SSB) antigen,]	1.0	2	1	0	0
39314	1624	transcription from the co-transfected IL-2 promoter	[transcription from the co-transfected IL-2 promoter]	1.0	6	1	0	0
39315	1624	3t3-l1 cell	[3T3-L1 cells]	1.0	2	1	0	0
39316	1624	mechanism of the immunosuppressive effect	[mechanism of the immunosuppressive effect]	1.0	5	1	0	0
39317	1624	t-cell immune	[T-cell immune]	1.0	2	1	0	0
39318	1624	PLB-985 cell	[PLB-985 cells]	1.0	2	1	0	0
39319	1624	h1-agonist histamine	[H1-agonists histamine]	1.0	2	1	0	0
39320	1624	inhibition of U1 cellular proliferation	[inhibition of U1 cellular proliferation]	1.0	5	1	0	0
39321	1624	radioactive iodine	[radioactive iodine]	1.0	2	1	0	0
39322	1624	authentic enhancer	[authentic enhancer]	1.0	2	1	0	0
39323	1624	latent provirus	[latent provirus]	1.0	2	1	0	0
39324	1624	SF2 strain	[SF2 strain]	1.0	2	1	0	0
39325	1624	inflammatory synovitis	[inflammatory synovitis]	1.0	2	1	0	0
39326	1624	recombination event	[recombination events]	1.0	2	2	2	2
39327	1624	several criteria, include cell distribution	[several criteria, including cell distribution]	1.0	5	1	0	0
39328	1624	mutation of the sp1/ap-2 site	[mutation of the Sp1/AP-2 site]	1.0	5	1	0	0
39329	1624	intranuclear localization	[intranuclear localization]	1.0	2	1	0	0
39330	1624	untreated samples.	[untreated samples.]	1.0	2	1	0	0
39331	1624	kappa3 element	[kappa3 element]	1.0	2	1	0	0
39332	1624	polyamine in breast cancer development.	[polyamines in breast cancer development.]	1.0	5	1	0	0
39333	1624	signal-induced activation	[signal-induced activation]	1.0	2	1	0	0
39334	1624	C3a(desArg) lps mrna level for il-6	[C3a(desArg) LPS mRNA levels for IL-6]	1.0	6	1	0	0
39335	1624	self-renewal event	[self-renewal events]	1.0	2	1	0	0
39336	1624	m47 319ll-r	[M47 319LL-RS]	1.0	2	1	0	0
39337	1624	signal transducer of transcription (stat)	[signal transducers of transcription (STAT)]	1.0	5	1	0	0
39338	1624	apoptotic machinery	[apoptotic machinery]	1.0	2	1	0	0
39339	1624	presence of NF-kappaB family member	[presence of NF-kappaB family members,]	1.0	5	1	0	0
39340	1624	assembly of a protein complex	[assembly of a protein complex]	1.0	5	1	0	0
39341	1624	Glucocorticoid inhibition of rante expression	[Glucocorticoid inhibition of RANTES expression]	1.0	5	1	0	0
39342	1624	benefit protein	[b proteins]	1.0	2	1	0	0
39343	1624	include estrogen	[including estrogen]	1.0	2	1	0	0
39344	1624	stable clone of two B-cell line	[stable clones of two B-cell lines]	1.0	6	1	0	0
39345	1624	expression of other adhesion molecule	[Expression of other adhesion molecules]	1.0	5	1	0	0
39346	1624	E1A protein	[E1A protein]	1.0	2	1	0	0
39347	1624	ebv-positive npc cell line in culture	[EBV-positive NPC cell lines in culture]	1.0	6	1	0	0
39348	1624	only in the presence of p65	[only in the presence of p65]	1.0	6	1	0	0
39349	1624	cellular promoter	[cellular promoters]	1.0	2	2	2	2
39350	1624	host's defense	[host's defense]	1.0	2	1	0	0
39351	1624	gamma ray	[gamma rays]	1.0	2	1	0	0
39352	1624	decrease the amount of e2f	[decreasing the amount of E2F]	1.0	5	1	0	0
39353	1624	key signal	[key signal]	1.0	2	1	0	0
39354	1624	protein production	[protein production]	1.0	2	1	0	0
39355	1624	act as cofactor for gata3	[acting as cofactors for GATA3]	1.0	5	1	0	0
39356	1624	c-myb protein	[c-Myb protein]	1.0	2	2	1	1
39357	1624	role in recognition of antigen	[role in recognition of antigens]	1.0	5	1	0	0
39358	1624	Balb/c3T3 cell use a supernatant	[Balb/c3T3 cells using a supernatant]	1.0	5	1	0	0
39359	1624	further requirement for tcr coengagement	[further requirement for TCR coengagement]	1.0	5	1	0	0
39360	1624	mm patient	[MM patients]	1.0	2	2	2	2
39361	1624	dominant effect	[dominant effect]	1.0	2	2	2	2
39362	1624	effector response	[effector response]	1.0	2	1	0	0
39363	1624	activity in Jurkat T cell	[activity in Jurkat T cells]	1.0	5	1	0	0
39364	1624	il-2r alpha cell surface expression	[IL-2R alpha cell surface expression]	1.0	5	1	0	0
39365	1624	human corticotropin-releasing hormone gene promoter	[human corticotropin-releasing hormone gene promoter]	1.0	5	1	0	0
39366	1624	Yin-Yang 1	[Yin-Yang 1]	1.0	2	2	1	1
39367	1624	erythroid-specific gene in megakaryoblastic disorder	[erythroid-specific genes in megakaryoblastic disorders]	1.0	5	1	0	0
39368	1624	mrna expression of glucose transporter	[mRNA expression of glucose transporter]	1.0	5	1	0	0
39369	1624	biphasic expression	[biphasic expression]	1.0	2	2	2	2
39370	1624	viral infectivity.	[viral infectivity.]	1.0	2	1	0	0
39371	1624	however, activation from a remote position	[However, activation from a remote position]	1.0	6	1	0	0
39372	1624	Ig-silenced (common)	[Ig-silenced (common)]	1.0	2	1	0	0
39373	1624	tumour cell of non-hodgkin' lymphoma	[tumour cells of non-Hodgkin's lymphoma]	1.0	5	1	0	0
39374	1624	however, cell	[However, cells]	1.0	2	2	2	2
39375	1624	cd15 engagement,	[CD15 engagement,]	1.0	2	1	0	0
39376	1624	follow stable expression in vitro	[following stable expression in vitro]	1.0	5	1	0	0
39377	1624	bufalin in wild-type u937 cell	[bufalin in wild-type U937 cells]	1.0	5	1	0	0
39378	1624	T cell of elderly individual	[T cells of elderly individuals]	1.0	5	1	0	0
39379	1624	regulatory region of target gene	[regulatory regions of target genes]	1.0	5	1	0	0
39380	1624	similar level of gata-1 mrna	[similar levels of GATA-1 mRNA]	1.0	5	1	0	0
39381	1624	pld activity	[PLD activity]	1.0	2	2	1	1
39382	1624	humoral immune	[humoral immune]	1.0	2	1	0	0
39383	1624	renin suppression	[renin suppression]	1.0	2	1	0	0
39384	1624	ebv protein expression by IH	[EBV protein expression by IH]	1.0	5	1	0	0
39385	1624	cleavage product	[cleavage products]	1.0	2	2	2	2
39386	1624	various other intracellular signal protein	[various other intracellular signaling proteins]	1.0	5	1	0	0
39387	1624	regulation of this pivotal gene,	[regulation of this pivotal gene,]	1.0	5	1	0	0
39388	1624	relation also to plasma testosterone	[relation also to plasma testosterone]	1.0	5	1	0	0
39389	1624	JNK activation.	[JNK activation.]	1.0	2	2	1	1
39390	1624	negative regulation in U937 cell	[negative regulation in U937 cells]	1.0	5	1	0	0
39391	1624	sites/cell; kd	[sites/cell; Kd]	1.0	2	1	0	0
39392	1624	d.baltimore, nature	[D.Baltimore, Nature]	1.0	2	1	0	0
39393	1624	indicate a regulatory function of PPARalpha	[indicating a regulatory function of PPARalpha]	1.0	6	1	0	0
39394	1624	9.0 micromol/L,	[9.0 micromol/L,]	1.0	2	1	0	0
39395	1624	U1 u1a/u1b	[U1 U1A/U1B]	1.0	2	2	2	2
39396	1624	express tumor	[expressing tumors]	1.0	2	2	1	1
39397	1624	include a PU.1 consensus site	[including a PU.1 consensus site]	1.0	5	1	0	0
39398	1624	Cbl	[Cbl]	1.0	1	11	2	2
39399	1624	spectrum of tumor-derived cell line	[spectrum of tumor-derived cell lines]	1.0	5	1	0	0
39400	1624	72 bp of 5' -flanking sequence	[72 bp of 5' -flanking sequence]	1.0	6	1	0	0
39401	1624	single exon	[single exon]	1.0	2	2	1	1
39402	1624	stress-induced apoptosis	[stress-induced apoptosis]	1.0	2	1	0	0
39403	1624	identification of ets binding site	[identification of Ets binding sites]	1.0	5	1	0	0
39404	1624	bound kinase	[bound kinase]	1.0	2	1	0	0
39405	1624	long treatment	[long-term treatment]	1.0	2	2	1	1
39406	1624	consecutive IL-1beta-	[Consecutive IL-1beta-]	1.0	2	1	0	0
39407	1624	more nfat1	[more NFAT1]	1.0	2	1	0	0
39408	1624	tal-1 mouse	[tal-1 mice]	1.0	2	2	1	1
39409	1624	(include the complete VDR coding region	[(including the complete VDR coding region]	1.0	6	1	0	0
39410	1624	il-4 inducibility	[IL-4 inducibility]	1.0	2	1	0	0
39411	1624	biological marker for personality characteristic	[biological marker for personality characteristics]	1.0	5	1	0	0
39412	1624	ZIP site	[ZIP site]	1.0	2	1	0	0
39413	1624	normal protein	[normal proteins]	1.0	2	1	0	0
39414	1624	thereby promote the nuclear translocation	[thereby promoting the nuclear translocation]	1.0	5	1	0	0
39415	1624	homotypic aggregation	[homotypic aggregation]	1.0	2	2	2	2
39416	1624	major coat protein of ebv	[major coat protein of EBV]	1.0	5	1	0	0
39417	1624	C/EBPbeta expression	[C/EBPbeta expression]	1.0	2	1	0	0
39418	1624	il-1 receptor antagonist (il1-ra) gene expression	[IL-1 receptor antagonist (IL1-RA) gene expression]	1.0	6	1	0	0
39419	1624	paralysis of T cell function	[paralysis of T cell function]	1.0	5	1	0	0
39420	1624	same parameter	[same parameters]	1.0	2	1	0	0
39421	1624	C/EBPepsilon mRNA	[C/EBPepsilon mRNA]	1.0	2	1	0	0
39422	1624	3.20 nm,	[3.20 nM,]	1.0	2	1	0	0
39423	1624	region (lining	[region (lining]	1.0	2	1	0	0
39424	1624	impaired recycling	[impaired recycling]	1.0	2	1	0	0
39425	1624	nf-kappa b nuclear factor-kappa b	[NF-kappa B nuclear factor-kappa B]	1.0	5	1	0	0
39426	1624	effect related	[effects related]	1.0	2	2	2	2
39427	1624	induction of the binding complex	[induction of the binding complexes]	1.0	5	1	0	0
39428	1624	cell wall derivative of bacterium	[cell wall derivatives of bacteria]	1.0	5	1	0	0
39429	1624	transcriptional transactivation	[transcriptional transactivation]	1.0	2	1	0	0
39430	1624	encode the lectin-type ldl receptor olr1	[encoding the lectin-type LDL receptor OLR1]	1.0	6	1	0	0
39431	1624	nuclear dot	[nuclear dots]	1.0	2	1	0	0
39432	1624	CTL repertoire	[CTL repertoire]	1.0	2	1	0	0
39433	1624	vitro sensitization	[vitro sensitization]	1.0	2	1	0	0
39434	1624	gene transcriptional inhibition during activation	[gene transcriptional inhibition during activation]	1.0	5	1	0	0
39435	1624	soluble tnf-alpha receptor type ii	[soluble TNF-alpha receptor type II]	1.0	5	1	0	0
39436	1624	distinct mechanism for immune suppression	[distinct mechanism for immune suppression]	1.0	5	1	0	0
39437	1624	receptor stimulation	[receptor stimulation]	1.0	2	1	0	0
39438	1624	isolation of a alternative transcript encode	[isolation of an alternative transcript encoding]	1.0	6	1	0	0
39439	1624	transcription of the nuclear proto-oncogent c-fo	[transcription of the nuclear proto-oncogenes c-fos]	1.0	6	1	0	0
39440	1624	nfatp a cyclosporin-sensitive dna-binding protein	[NFATp a cyclosporin-sensitive DNA-binding protein]	1.0	5	1	0	0
39441	1624	accord to stage of maturation,	[according to stage of maturation,]	1.0	5	1	0	0
39442	1624	variable weak phosphorylation of stat3	[variable weak phosphorylation of STAT3]	1.0	5	1	0	0
39443	1624	dna-associated protein	[DNA-associated proteins]	1.0	2	1	0	0
39444	1624	simply a function of ability	[simply a function of ability]	1.0	5	1	0	0
39445	1624	DNA staining	[DNA staining]	1.0	2	2	1	1
39446	1624	cyclooxygenase-2 expression by 4-trifluoromethyl derivative	[cyclooxygenase-2 expression by 4-trifluoromethyl derivatives]	1.0	5	1	0	0
39447	1624	phagocyte stimulation	[phagocyte stimulation]	1.0	2	1	0	0
39448	1624	reactive oxygen intermediate -release of monocyte	[Reactive oxygen intermediate -release of monocytes]	1.0	6	1	0	0
39449	1624	gr affinity	[GR affinity]	1.0	2	3	2	1
39450	1624	rise to a long last proliferation	[rise to a long lasting proliferation]	1.0	6	1	0	0
39451	1624	il-7 receptor (il-7r) alpha subunit	[IL-7 receptor (IL-7R) alpha subunit]	1.0	5	1	0	0
39452	1624	mutagenesis of a nf-kappab-like site	[mutagenesis of an NF-kappaB-like site]	1.0	5	1	0	0
39453	1624	signalling process	[signalling processes]	1.0	2	2	2	2
39454	1624	morphological change consistent with apoptosis	[morphological changes consistent with apoptosis]	1.0	5	1	0	0
39455	1624	construct express CAT under control	[constructs expressing CAT under control]	1.0	5	1	0	0
39456	1624	functional analysis of 5'-flanking region	[functional analysis of 5'-flanking region]	1.0	5	1	0	0
39457	1624	nucleoprotein dna-binding activity regulate gene expression	[nucleoprotein DNA-binding activities regulating gene expression]	1.0	6	1	0	0
39458	1624	receptor abnormality	[receptor abnormality]	1.0	2	2	1	1
39459	1624	T lymphocyte with anti-cd2 antibody	[T lymphocytes with anti-CD2 antibodies]	1.0	5	1	0	0
39460	1624	/mad-3	[/MAD-3]	1.0	1	12	4	2
39461	1624	prolonged time.	[prolonged time.]	1.0	2	1	0	0
39462	1624	cell with a growth fraction	[cells with a growth fraction]	1.0	5	1	0	0
39463	1624	great number	[great number]	1.0	2	2	2	2
39464	1624	slp-76 protein	[SLP-76 proteins]	1.0	2	1	0	0
39465	1624	level of the promoter activity	[levels of the promoter activity]	1.0	5	1	0	0
39466	1624	nuclear dual-specific map kinase phosphatase	[nuclear dual-specific MAP kinase phosphatases]	1.0	5	1	0	0
39467	1624	great diversity among that clone	[great diversity among those clones]	1.0	5	1	0	0
39468	1624	anti CD28	[anti CD28]	1.0	2	2	1	1
39469	1624	lymphoid-specific protein	[lymphoid-specific protein]	1.0	2	2	1	1
39470	1624	little activation.	[little activation.]	1.0	2	1	0	0
39471	1624	vasoactive peptide	[vasoactive peptide]	1.0	2	1	0	0
39472	1624	CD28 -dependent effect on NF-kappaB	[CD28 -dependent effects on NF-kappaB]	1.0	5	1	0	0
39473	1624	addition, treatment of this extract	[addition, treatment of these extracts]	1.0	5	1	0	0
39474	1624	extracellular stimulation	[extracellular stimulation]	1.0	2	1	0	0
39475	1624	adult drosophila	[adult Drosophila]	1.0	2	1	0	0
39476	1624	NF-kappaB effect	[NF-kappaB effect]	1.0	2	2	2	2
39477	1624	controls, peripheral white blood cell	[controls, peripheral white blood cell]	1.0	5	1	0	0
39478	1624	-300bp of the artificial promoter	[-300bp of the artificial promoter]	1.0	5	1	0	0
39479	1624	Rh:33 cell	[Rh:33 cells]	1.0	2	1	0	0
39480	1624	gp Ib alpha promoter activity	[GP Ib alpha promoter activity]	1.0	5	1	0	0
39481	1624	aml (10	[AML (10]	1.0	2	1	0	0
39482	1624	strategy for therapy of disease	[strategy for therapy of diseases]	1.0	5	1	0	0
39483	1624	acute myeloid leukemia gene AML1	[acute myeloid leukemia gene AML1]	1.0	5	1	0	0
39484	1624	antiatherogenic property	[antiatherogenic properties]	1.0	2	1	0	0
39485	1624	il-13 response	[IL-13 responses]	1.0	2	1	0	0
39486	1624	immunization of tcf-1 knock-out mouse	[immunization of TCF-1 knock-out mice]	1.0	5	1	0	0
39487	1624	murine myeloma	[murine myeloma]	1.0	2	1	0	0
39488	1624	bovine homologue of this enzyme.	[bovine homologue of this enzyme.]	1.0	5	1	0	0
39489	1624	least one sp 1-binding site	[least one Sp 1-binding site]	1.0	5	1	0	0
39490	1624	kinase 1/2	[kinase 1/2]	1.0	2	2	2	2
39491	1624	FI of the migration rate	[FI of the migration rate]	1.0	5	1	0	0
39492	1624	(lymphocyte) DNA	[(lymphocyte) DNA]	1.0	2	1	0	0
39493	1624	spontaneous lymphocyte proliferation by glucocorticoid	[spontaneous lymphocyte proliferation by glucocorticoids]	1.0	5	1	0	0
39494	1624	common regulatory mechanism for gene transcription	[common regulatory mechanisms for gene transcription]	1.0	6	1	0	0
39495	1624	nfat-dependent transactivation	[NFAT-dependent transactivation]	1.0	2	1	0	0
39496	1624	glut1 expression through ppargamma activation	[GLUT1 expression through PPARgamma activation]	1.0	5	1	0	0
39497	1624	sterol element	[Sterol element]	1.0	2	2	2	2
39498	1624	receptor in cord blood lymphocyte	[receptors in cord blood lymphocytes]	1.0	5	2	2	2
39499	1624	Importantly, culture of mm cell	[Importantly, culture of MM cells]	1.0	5	1	0	0
39500	1624	simple strategy	[simple strategy]	1.0	2	1	0	0
39501	1624	great (p	[greater (P]	1.0	2	1	0	0
39502	1624	bare lymphocyte syndrome ebls) patients.	[Bare Lymphocyte Syndrome (BLS) patients.]	1.0	5	1	0	0
39503	1624	direct stimulation with different cytokine	[direct stimulation with different cytokines]	1.0	5	1	0	0
39504	1624	prolonged treatment	[prolonged treatment]	1.0	2	1	0	0
39505	1624	many hour	[many hours]	1.0	2	1	0	0
39506	1624	level of kinase inhibitor p27kip1	[levels of kinase inhibitor p27Kip1]	1.0	5	1	0	0
39507	1624	deletion of the PAS domain	[Deletion of the PAS domain]	1.0	5	1	0	0
39508	1624	combination) in Jurkat T cell	[combination) in Jurkat T cells]	1.0	5	1	0	0
39509	1624	strike contrast	[striking contrast]	1.0	2	1	0	0
39510	1624	hygromycin resistant	[hygromycin resistant]	1.0	2	1	0	0
39511	1624	IFN production	[IFN production]	1.0	2	2	1	1
39512	1624	deletion of a NF-kappaB binding site	[Deletion of a NF-kappaB binding site]	1.0	6	1	0	0
39513	1624	protein trans-factor	[protein trans-factors]	1.0	2	1	0	0
39514	1624	pAT 591/egr2	[pAT 591/EGR2]	1.0	2	1	0	0
39515	1624	gcs withdrawal	[GCS withdrawal]	1.0	2	1	0	0
39516	1624	regulator of b cell function	[regulator of B cell functions]	1.0	5	1	0	0
39517	1624	coordinate modulation	[coordinate modulation]	1.0	2	1	0	0
39518	1624	principal initiator	[principal initiator]	1.0	2	1	0	0
39519	1624	phosphorylation of the transcription factor atf-1	[phosphorylation of the transcription factors ATF-1]	1.0	6	1	0	0
39520	1624	p4) in the IL-4 promoter	[P4) in the IL-4 promoter]	1.0	5	1	0	0
39521	1624	N-terminal portion of the protein	[N-terminal portion of the protein]	1.0	5	1	0	0
39522	1624	synthetic lipopeptide	[synthetic lipopeptides]	1.0	2	1	0	0
39523	1624	avoid apoptosis	[avoiding apoptosis]	1.0	2	1	0	0
39524	1624	membrane extract	[membrane extracts]	1.0	2	2	1	1
39525	1624	soluble preparation	[soluble preparations]	1.0	2	1	0	0
39526	1624	start at 30 minute after stimulation.	[starting at 30 min after stimulation.]	1.0	6	1	0	0
39527	1624	several novel kRAB-containing zinc finger gene	[several novel KRAB-containing zinc finger genes]	1.0	6	1	0	0
39528	1624	recent studies.	[recent studies.]	1.0	2	1	0	0
39529	1624	expression of 135(oh)2d3 receptor rna	[expression of 1,25(OH)2D3 receptor RNA]	1.0	5	1	0	0
39530	1624	CD2 antigen	[CD2 antigen]	1.0	2	1	0	0
39531	1624	myeloid differentiation of cd34+ cell	[myeloid differentiation of CD34+ cells]	1.0	5	2	1	1
39532	1624	n-formyl-methionyl-leucyl-phenylalanine cytokine granulocyte/macrophage colony-stimulating factor gm-csf	[N-formyl-methionyl-leucyl-phenylalanine cytokines granulocyte/macrophage colony-stimulating factor GM-CSF]	1.0	6	1	0	0
39533	1624	disrupt the donor splice site	[disrupting the donor splice site]	1.0	5	1	0	0
39534	1624	use of interferon-gamma-treated u937 cell	[use of interferon-gamma-treated U937 cells]	1.0	5	1	0	0
39535	1624	prevent the degradation of inhibitor	[preventing the degradation of inhibitor]	1.0	5	1	0	0
39536	1624	use reverse transcription-polymerase chain reaction	[using reverse transcription-polymerase chain reaction]	1.0	5	1	0	0
39537	1624	fetal b-lymphopoiesis	[fetal B-lymphopoiesis]	1.0	2	1	0	0
39538	1624	pth level	[PTH levels]	1.0	2	1	0	0
39539	1624	silastic membrane	[Silastic membrane]	1.0	2	1	0	0
39540	1624	phd/ttc domain	[PHD/TTC domain]	1.0	2	1	0	0
39541	1624	major element	[major element]	1.0	2	2	2	2
39542	1624	erythroid characteristic	[erythroid characteristics]	1.0	2	1	0	0
39543	1624	expression of retinoid x receptor alpha	[Expression of Retinoid X Receptor alpha]	1.0	6	1	0	0
39544	1624	potential phosphorylated.	[potential phosphorylated.]	1.0	2	1	0	0
39545	1624	response acquisition.	[response acquisition.]	1.0	2	1	0	0
39546	1624	inhibition of sequence-specific dna-binding protein	[Inhibition of sequence-specific DNA-binding proteins]	1.0	5	1	0	0
39547	1624	front of a luciferase reporter	[front of a luciferase reporter]	1.0	5	1	0	0
39548	1624	mapping of the transcriptional repression domain	[Mapping of the transcriptional repression domain]	1.0	6	1	0	0
39549	1624	beta-interferon gene	[beta-interferon gene]	1.0	2	1	0	0
39550	1624	alternative possibility	[alternative possibility]	1.0	2	1	0	0
39551	1624	inducer-mediated stimulation	[inducer-mediated stimulation]	1.0	2	1	0	0
39552	1624	high percentage infiltrate T cell	[high percentage infiltrating T cells]	1.0	5	1	0	0
39553	1624	kinase 3	[kinase 3]	1.0	2	2	2	2
39554	1624	il-16 gene	[IL-16 gene]	1.0	2	2	2	2
39555	1624	map kinase kinase-3 MKK3 a activator	[MAP kinase kinase-3 MKK3 a activator]	1.0	6	1	0	0
39556	1624	pu.1 Elf-1	[PU.1 Elf-1]	1.0	2	1	0	0
39557	1624	12-lipoxygenase activity of murine macrophage	[12-lipoxygenase activity of murine macrophages]	1.0	5	1	0	0
39558	1624	sequence-specific binding	[sequence-specific binding]	1.0	2	2	1	1
39559	1624	recurrent abnormality	[recurrent abnormality]	1.0	2	2	2	2
39560	1624	initial change	[initial changes]	1.0	2	1	0	0
39561	1624	factor-alpha TNF-alpha	[factor-alpha TNF-alpha]	1.0	2	1	0	0
39562	1624	unfractionated leukocyte	[unfractionated leukocytes]	1.0	2	1	0	0
39563	1624	short- effect of tax expression	[short- effects of Tax expression]	1.0	5	1	0	0
39564	1624	B-cell stimulation by microbial superantigen	[B-cell stimulation by microbial superantigens]	1.0	5	1	0	0
39565	1624	STAT5b protein	[STAT5b proteins]	1.0	2	1	0	0
39566	1624	depend on the cell-specific microenvironment.	[depending on the cell-specific microenvironment.]	1.0	5	1	0	0
39567	1624	monocyte tf induction by CsA	[monocyte TF induction by CsA]	1.0	5	1	0	0
39568	1624	complete 491-amino-acid sequence of ie-1	[complete 491-amino-acid sequence of IE-1]	1.0	5	1	0	0
39569	1624	vitro-translated pu.1 from nuclear extract	[vitro-translated PU.1 from nuclear extracts]	1.0	5	1	0	0
39570	1624	response to alpha CD3 ab	[response to alpha CD3 Ab]	1.0	5	1	0	0
39571	1624	analogous cell-cycle-regulated phosphorylation of Id3	[analogous cell-cycle-regulated phosphorylation of Id3]	1.0	5	1	0	0
39572	1624	expression of the CD5 antigen	[expression of the CD5 antigen]	1.0	5	1	0	0
39573	1624	autoreactive t-cell	[autoreactive T-cells]	1.0	2	2	2	2
39574	1624	cd19+ b-cell	[CD19+ B-cells]	1.0	2	1	0	0
39575	1624	modulation by anti- lps mab	[modulation by anti- LPS mAbs]	1.0	5	1	0	0
39576	1624	depend on the cellular environment	[depending on the cellular environment]	1.0	5	1	0	0
39577	1624	membrane form of human csf-1	[membrane form of human CSF-1]	1.0	5	1	0	0
39578	1624	bind to this promoter element	[binding to these promoter elements]	1.0	5	1	0	0
39579	1624	induction of lt promoter activity	[induction of LT promoter activity]	1.0	5	1	0	0
39580	1624	1 long terminal repeat LTR	[1 long terminal repeat LTR]	1.0	5	1	0	0
39581	1624	hiv-1 activation with heat shock	[HIV-1 activation with heat shock]	1.0	5	1	0	0
39582	1624	rapid tyrosine phosphorylation of Jak2	[rapid tyrosine phosphorylation of Jak2]	1.0	5	1	0	0
39583	1624	2015 subject	[2015 subjects]	1.0	2	1	0	0
39584	1624	20 mu/l (physiological testing concentration),	[20 mU/L (physiological testing concentration),]	1.0	5	1	0	0
39585	1624	statistical analysis	[Statistical analysis]	1.0	2	1	0	0
39586	1624	FOS rrna	[FOS mRNAs]	1.0	2	1	0	0
39587	1624	cadmium stimulation	[cadmium stimulation]	1.0	2	1	0	0
39588	1624	dual role	[dual role]	1.0	2	1	0	0
39589	1624	significant modification in the expression	[significant modification in the expression]	1.0	5	1	0	0
39590	1624	interleukin-6 expression in human monocyte	[interleukin-6 expression in human monocytes]	1.0	5	1	0	0
39591	1624	control gene expression in hematopoietic cell	[controlling gene expression in hematopoietic cells]	1.0	6	1	0	0
39592	1624	adt pretreatment	[ADT pretreatment]	1.0	2	2	1	1
39593	1624	IL-2/ IFN alpha -based therapy	[IL-2/ IFN alpha -based therapy]	1.0	5	1	0	0
39594	1624	section from hiv lymph node	[sections from HIV lymph nodes]	1.0	5	1	0	0
39595	1624	initial peak	[initial peak]	1.0	2	1	0	0
39596	1624	clinical glucocorticoid resistance in chronic asthma	[clinical glucocorticoid resistance in chronic asthma]	1.0	6	1	0	0
39597	1624	dayus- level	[day, levels]	1.0	2	1	0	0
39598	1624	polyclonal level	[polyclonal level]	1.0	2	1	0	0
39599	1624	superoxide dismutase	[superoxide dismutase]	1.0	2	2	1	1
39600	1624	clonal relationship	[clonal relationship]	1.0	2	1	0	0
39601	1624	inhibitory domain	[inhibitory domain]	1.0	2	2	1	1
39602	1624	NF-E1 YY1	[NF-E1 YY1]	1.0	2	2	1	1
39603	1624	fas ligand regulatory element FLRE	[Fas ligand regulatory element FLRE]	1.0	5	1	0	0
39604	1624	gamma interferon activation site gas	[gamma interferon activation site GAS]	1.0	5	1	0	0
39605	1624	current understanding of the role	[current understanding of the role]	1.0	5	1	0	0
39606	1624	assembly of the surface domain	[assembly of the surface domain]	1.0	5	1	0	0
39607	1624	Seminoma in a postmenopausal woman	[Seminoma in a postmenopausal woman]	1.0	5	1	0	0
39608	1624	structure of the human gata3 gene	[Structure of the human GATA3 gene]	1.0	6	1	0	0
39609	1624	Retinoidal antagonist	[Retinoidal antagonists]	1.0	2	1	0	0
39610	1624	b cell in the lifer	[B cells in the livers]	1.0	5	1	0	0
39611	1624	new enzyme,	[new enzyme,]	1.0	2	1	0	0
39612	1624	nordihydroquairetic acid	[nordihydroquairetic acid]	1.0	2	1	0	0
39613	1624	change in the enhancer element	[changes in the enhancer element]	1.0	5	1	0	0
39614	1624	several T cell surface receptor	[several T cell surface receptors]	1.0	5	1	0	0
39615	1624	raf-1 activity	[Raf-1 activity]	1.0	2	1	0	0
39616	1624	administration of the cytokine interleukin-2 IL-2	[Administration of the cytokine interleukin-2 IL-2]	1.0	6	1	0	0
39617	1624	divergent site	[divergent site]	1.0	2	1	0	0
39618	1624	6 h)	[6 h)]	1.0	2	1	0	0
39619	1624	expression of atf-2 in S. cerevisiae	[Expression of ATF-2 in S. cerevisiae]	1.0	6	1	0	0
39620	1624	tpa cell	[TPA cells]	1.0	2	1	0	0
39621	1624	5'-flanking DNA	[5'-flanking DNA]	1.0	2	2	2	2
39622	1624	use of stabilizer like beta 2-m	[use of stabilizers like beta 2-m]	1.0	6	1	0	0
39623	1624	IL-12 expression in b cell	[IL-12 expression in B cells]	1.0	5	1	0	0
39624	1624	several system	[several systems]	1.0	2	2	2	2
39625	1624	Fli-1	[Fli-1]	1.0	1	11	3	3
39626	1624	p21ras oncoprotein	[p21ras oncoprotein]	1.0	2	1	0	0
39627	1624	mediator(s) of this maturation process	[mediator(s) of this maturation process]	1.0	5	1	0	0
39628	1624	expression of c/ebp epsilon protein	[expression of C/EBP epsilon protein]	1.0	5	1	0	0
39629	1624	59 woman	[59 women]	1.0	2	1	0	0
39630	1624	personality characteristic such as sensation	[personality characteristics such as sensation]	1.0	5	1	0	0
39631	1624	hemopoietic-derived tissue	[hemopoietic-derived tissue]	1.0	2	1	0	0
39632	1624	enhancer site in the intron	[enhancer site in the intron]	1.0	5	1	0	0
39633	1624	consequent modulation of gene expression	[consequent modulation of gene expression]	1.0	5	1	0	0
39634	1624	involvement of this signal molecule	[involvement of this signaling molecule]	1.0	5	1	0	0
39635	1624	lymphocyte of patient with breast cancer	[lymphocytes of patients with breast cancer]	1.0	6	1	0	0
39636	1624	cellular background	[cellular background]	1.0	2	1	0	0
39637	1624	DNA binding activity of stat protein	[DNA binding activity of STAT proteins]	1.0	6	1	0	0
39638	1624	essential upstream IL-2 response element	[essential upstream IL-2 response element]	1.0	5	1	0	0
39639	1624	reactive oxygen intermediate as messenger	[Reactive oxygen intermediates as messengers]	1.0	5	1	0	0
39640	1624	onset of nf-kappa b activation	[onset of NF-kappa B activation]	1.0	5	1	0	0
39641	1624	cycloheximide alone	[cycloheximide alone]	1.0	2	1	0	0
39642	1624	inhibitor of serine/threonine protein phosphatase	[inhibitor of serine/threonine protein phosphatases]	1.0	5	1	0	0
39643	1624	ss patient	[SS patients]	1.0	2	2	1	1
39644	1624	analysis of the inactive specific methylation	[Analysis of the inactive specific methylation]	1.0	6	1	0	0
39645	1624	ifn-gamma signal	[IFN-gamma signaling]	1.0	2	1	0	0
39646	1624	two other DNA fragment pzvb10	[two other DNA fragments pZVB10]	1.0	5	1	0	0
39647	1624	expression of constitutively active raf-1	[Expression of constitutively active Raf-1]	1.0	5	1	0	0
39648	1624	selectin family	[selectin family]	1.0	2	1	0	0
39649	1624	haematopoietic cell	[haematopoietic cells]	1.0	2	2	1	1
39650	1624	interleukin expression	[interleukin expression]	1.0	2	2	2	2
39651	1624	certain subset of T cell	[certain subsets of T cells]	1.0	5	1	0	0
39652	1624	incubation with ifn-gamma for h.	[incubation with IFN-gamma for h,]	1.0	5	1	0	0
39653	1624	cytoplasmic periphery	[cytoplasmic periphery]	1.0	2	1	0	0
39654	1624	specific dna-binding	[specific DNA-binding]	1.0	2	2	1	1
39655	1624	major objective	[major objectives]	1.0	2	1	0	0
39656	1624	enhance activity	[enhancing activity]	1.0	2	2	1	1
39657	1624	cd14 surface	[CD14 surface]	1.0	2	1	0	0
39658	1624	expression of dominant negative mapkk-1	[Expression of dominant negative MAPKK-1]	1.0	5	1	0	0
39659	1624	mapk pathway by tcc assembly	[MAPK pathway by TCC assembly]	1.0	5	1	0	0
39660	1624	68.5-kb segment	[68.5-kb segment]	1.0	2	1	0	0
39661	1624	Tat effect	[Tat effect]	1.0	2	2	2	2
39662	1624	unwanted cell	[unwanted cells]	1.0	2	1	0	0
39663	1624	LTR activation	[LTR activation]	1.0	2	4	3	1
39664	1624	two methods.	[two methods.]	1.0	2	1	0	0
39665	1624	free radical	[free radicals]	1.0	2	1	0	0
39666	1624	potential agonist	[potential agonists]	1.0	2	1	0	0
39667	1624	two structurally unique pml/ raralpha	[two structurally unique PML/ RARalpha]	1.0	5	1	0	0
39668	1624	two other synthetic nonselective RAR ligand	[two other synthetic nonselective RAR ligands]	1.0	6	1	0	0
39669	1624	CD11c promoter	[CD11c promoter]	1.0	2	3	2	1
39670	1624	ciita transcript	[CIITA transcripts]	1.0	2	2	1	1
39671	1624	response to challenge by lps	[response to challenge by LPS]	1.0	5	1	0	0
39672	1624	primarily because of the increase	[primarily because of the increase]	1.0	5	1	0	0
39673	1624	use a specific nf-kappab oligoprobe	[using a specific NF-kappaB oligoprobe]	1.0	5	1	0	0
39674	1624	Fas	[Fas]	1.0	1	11	5	5
39675	1624	corticosteroid resistance	[corticosteroid resistance]	1.0	2	2	2	2
39676	1624	major function	[major functions]	1.0	2	1	0	0
39677	1624	little effect on the antiapoptotic property	[little effect on the antiapoptotic property]	1.0	6	1	0	0
39678	1624	reporter gene with binding site	[reporter genes with binding sites]	1.0	5	1	0	0
39679	1624	active proliferation,	[active proliferation,]	1.0	2	1	0	0
39680	1624	also a potential TFIID binding site	[also a potential TFIID binding site]	1.0	6	1	0	0
39681	1624	significant role in the activation	[significant roles in the activation]	1.0	5	1	0	0
39682	1624	depletion of the B-cell population	[depletion of the B-cell population]	1.0	5	2	2	2
39683	1624	Furthermore, IL-2	[Furthermore, IL-2]	1.0	2	1	0	0
39684	1624	processing of NF-kappa b1/ p105	[processing of NF-kappa B1/ p105]	1.0	5	1	0	0
39685	1624	patient with rheumatoid arthritis RA	[patients with rheumatoid arthritis RA]	1.0	5	1	0	0
39686	1624	promoter activity from HIV repeat	[promoter activity from HIV repeat]	1.0	5	1	0	0
39687	1624	Stable expression of tax in CTLL-2	[Stable expression of Tax in CTLL-2]	1.0	6	1	0	0
39688	1624	intracellular adhesion	[intracellular adhesion]	1.0	2	1	0	0
39689	1624	novel gene,	[novel gene,]	1.0	2	1	0	0
39690	1624	initial pathway	[initial pathways]	1.0	2	1	0	0
39691	1624	survival, growth	[survival, growth]	1.0	2	1	0	0
39692	1624	vascular cell adhesion molecule-1 expression	[vascular cell adhesion molecule-1 expression]	1.0	5	2	2	2
39693	1624	use the ROI -reactive fluorochrome dcfh	[using the ROI -reactive fluorochrome DCFH-DA]	1.0	6	1	0	0
39694	1624	stat1 stat2	[STAT1 STAT2]	1.0	2	1	0	0
39695	1624	expression level on cell epithelioma	[expression level on cell epitheliomas]	1.0	5	1	0	0
39696	1624	3'untranslated region	[3'untranslated region]	1.0	2	1	0	0
39697	1624	inflammatory vasculopathy	[inflammatory vasculopathy]	1.0	2	1	0	0
39698	1624	11 index	[11 index]	1.0	2	1	0	0
39699	1624	strong element	[strong element]	1.0	2	2	1	1
39700	1624	important regulator of monocyte/macrophage function	[important regulator of monocyte/macrophage function]	1.0	5	1	0	0
39701	1624	b3 factor	[B3 factor]	1.0	2	1	0	0
39702	1624	continental Europe,	[continental Europe,]	1.0	2	1	0	0
39703	1624	use the BZ1 monoclonal antibody	[using the BZ1 monoclonal antibody]	1.0	5	1	0	0
39704	1624	pleiotropic regulator of numerous gene	[pleiotropic regulator of numerous genes]	1.0	5	1	0	0
39705	1624	free t4	[free T4]	1.0	2	2	1	1
39706	1624	mutational analysis of the HIV-1 LTR	[Mutational analyses of the HIV-1 LTR]	1.0	6	1	0	0
39707	1624	primary b cell with ebv	[primary B cells with EBV]	1.0	5	1	0	0
39708	1624	measure cellular incorporation of 3h-thymidine	[measuring cellular incorporation of 3H-thymidine]	1.0	5	1	0	0
39709	1624	eventual progression toward immunodeficiency syndrome	[eventual progression toward immunodeficiency syndrome]	1.0	5	1	0	0
39710	1624	response to many lymphocyte-activating cytokine	[response to many lymphocyte-activating cytokines]	1.0	5	1	0	0
39711	1624	hh514-16 cell	[HH514-16 cells]	1.0	2	1	0	0
39712	1624	NF-kappaB suppression by RCC -S	[NF-kappaB suppression by RCC -S]	1.0	5	1	0	0
39713	1624	notch-1 expression	[Notch-1 expression]	1.0	2	1	0	0
39714	1624	mammalian stress	[mammalian stress]	1.0	2	1	0	0
39715	1624	fasl induction	[FasL induction]	1.0	2	2	1	1
39716	1624	gr function	[GR function]	1.0	2	2	2	2
39717	1624	GTPase Rho	[GTPase Rho]	1.0	2	1	0	0
39718	1624	activation of c-Jun n-terminal kinase	[Activation of c-Jun N-terminal kinase]	1.0	5	1	0	0
39719	1624	less concurrent enhancement of lps uptake	[less concurrent enhancement of LPS uptake]	1.0	6	1	0	0
39720	1624	expression of marker in patient	[expression of markers in patients]	1.0	5	1	0	0
39721	1624	flow of information from receptor	[flow of information from receptors]	1.0	5	1	0	0
39722	1624	expression of the lysosomal enzyme	[expression of the lysosomal enzyme]	1.0	5	1	0	0
39723	1624	transform potential	[transforming potential]	1.0	2	2	2	2
39724	1624	Egr-1 NGFI-A	[Egr-1 NGFI-A]	1.0	2	1	0	0
39725	1624	Oct-2 expression	[Oct-2 expression]	1.0	2	1	0	0
39726	1624	28 patient	[28 patients]	1.0	2	1	0	0
39727	1624	exogenous cytokine	[exogenous cytokines]	1.0	2	1	0	0
39728	1624	eosinophil via the release of il-4	[eosinophils via the release of IL-4]	1.0	6	1	0	0
39729	1624	addition to general initiation factor	[addition to general initiation factors]	1.0	5	1	0	0
39730	1624	differentiation of naive cd4+ cell	[differentiation of naive CD4+ cells]	1.0	5	1	0	0
39731	1624	microtubule function	[microtubule function]	1.0	2	1	0	0
39732	1624	polyadenylation site	[polyadenylation site]	1.0	2	2	2	2
39733	1624	15% fetal calf serum fcs	[15% fetal calf serum FCS]	1.0	5	1	0	0
39734	1624	interact with the pou(s) domain	[interacting with the POU(S) domains]	1.0	5	1	0	0
39735	1624	molecular weight,	[molecular weight,]	1.0	2	1	0	0
39736	1624	molecular weight.	[molecular weight.]	1.0	2	1	0	0
39737	1624	bone marrow cell from transgenic mouse	[bone marrow cells from transgenic mice]	1.0	6	1	0	0
39738	1624	glutathione-s-transferase pi gst-pi use immunocytochemical method	[glutathione-S-transferase pi GST-pi using immunocytochemical methods]	1.0	6	1	0	0
39739	1624	novel agent with hepatoprotective activity	[novel agent with hepatoprotective activity]	1.0	5	1	0	0
39740	1624	tumour necrosis factor alpha tnf alpha	[tumour necrosis factor alpha TNF alpha]	1.0	6	1	0	0
39741	1624	Deletional mutagenesis	[Deletional mutagenesis]	1.0	2	1	0	0
39742	1624	IL-12 nonresponsiveness	[IL-12 nonresponsiveness]	1.0	2	1	0	0
39743	1624	contain 35s- tr alpha 1	[containing 35S- TR alpha 1]	1.0	5	1	0	0
39744	1624	expression of the PML gene	[expression of the PML gene]	1.0	5	1	0	0
39745	1624	fourfold decrease in apparent potency	[fourfold decrease in apparent potency]	1.0	5	1	0	0
39746	1624	75% increase	[75% increase]	1.0	2	1	0	0
39747	1624	stable complex	[stable complex]	1.0	2	2	1	1
39748	1624	6 hr.	[6 hr.]	1.0	2	2	1	1
39749	1624	trigger of cytotoxic effector function	[triggering of cytotoxic effector function]	1.0	5	1	0	0
39750	1624	NFAT induction	[NFAT induction]	1.0	2	1	0	0
39751	1624	Indeed, transient transfection of HLA-DRA	[Indeed, transient transfection of HLA-DRA]	1.0	5	1	0	0
39752	1624	use a sperm type protocol	[Using a sperm typing protocol]	1.0	5	1	0	0
39753	1624	extracellular signal-regulated protein kinase (erk)-dependent	[Extracellular signal-regulated protein kinase (ERK)-dependent]	1.0	5	1	0	0
39754	1624	antigen-presenting cell with specific receptor	[antigen-presenting cells with specific receptors]	1.0	5	1	0	0
39755	1624	represent differentiated, plasma cell-like b cell	[representing differentiated, plasma cell-like B cells]	1.0	6	1	0	0
39756	1624	result from the Ig hypermutation process	[resulting from the Ig hypermutation process]	1.0	6	1	0	0
39757	1624	enhancer activity of this motif,	[enhancer activity of this motif,]	1.0	5	1	0	0
39758	1624	wild-type counterpart,	[wild-type counterpart,]	1.0	2	1	0	0
39759	1624	phorbol 12-myristate 13-acetate for a hours.	[phorbol 12-myristate 13-acetate for a hours.]	1.0	6	1	0	0
39760	1624	moderate form of x-linked immunodeficiency	[moderate form of X-linked immunodeficiency]	1.0	5	1	0	0
39761	1624	77 +/- 16 versus 35 +/-	[77 +/- 16 versus 35 +/-]	1.0	6	1	0	0
39762	1624	also Jak1	[also Jak1]	1.0	2	1	0	0
39763	1624	mechanistic explanation	[mechanistic explanation]	1.0	2	1	0	0
39764	1624	Complementary DNA	[Complementary DNA]	1.0	2	2	1	1
39765	1624	factor other than the insert	[factors other than the insert]	1.0	5	1	0	0
39766	1624	growth of this culture-adapted tax-transformed fibroblast	[growth of these culture-adapted Tax-transformed fibroblasts]	1.0	6	1	0	0
39767	1624	total mrna	[total mRNA]	1.0	2	2	1	1
39768	1624	intercellular adhesion molecule-1 icam-1 cd11b/cd18	[intercellular adhesion molecule-1 ICAM-1 CD11b/CD18]	1.0	5	1	0	0
39769	1624	brca1 splicing	[BRCA1 splicing]	1.0	2	1	0	0
39770	1624	cd95 receptor	[CD95 receptor]	1.0	2	1	0	0
39771	1624	Effect of overexpression of IL-1 kinase	[Effects of overexpression of IL-1 kinase]	1.0	6	1	0	0
39772	1624	Raf kinase	[Raf kinase]	1.0	2	2	1	1
39773	1624	nine different 2.3-kb cDNA clone	[nine different 2.3-kb cDNA clones]	1.0	5	1	0	0
39774	1624	identification of upstream regulatory element	[Identification of upstream regulatory elements]	1.0	5	1	0	0
39775	1624	expression of a IkappaB mutant	[expression of a IkappaB mutant]	1.0	5	1	0	0
39776	1624	thus, failure of virus-exposed T cell	[Thus, failure of virus-exposed T cells]	1.0	6	1	0	0
39777	1624	TG alone	[TG alone]	1.0	2	1	0	0
39778	1624	cysteine cys gsh blood cell	[cysteine CYS GSH blood cells]	1.0	5	1	0	0
39779	1624	glutathione s-transferase-	[glutathione S-transferase-]	1.0	2	1	0	0
39780	1624	role of the PEBP2/CBF factor	[role of the PEBP2/CBF factors]	1.0	5	1	0	0
39781	1624	HTLV-1 transformation of normal cell	[HTLV-1 transformation of normal cells]	1.0	5	1	0	0
39782	1624	member of the Pax-gene family	[member of the Pax-gene family]	1.0	5	1	0	0
39783	1624	raralpha exhibit dominant-negative activity RARalpha403	[RARalpha exhibiting dominant-negative activity RARalpha403]	1.0	5	1	0	0
39784	1624	resemble a basic dbd adjacent	[resembling a basic DBD adjacent]	1.0	5	1	0	0
39785	1624	stat phosphorylation	[Stat phosphorylation]	1.0	2	1	0	0
39786	1624	human beta-globin promoter chromatin structure	[human beta-globin promoter chromatin structure]	1.0	5	1	0	0
39787	1624	monocyte differentiation analogous to role	[monocyte differentiation analogous to role]	1.0	5	1	0	0
39788	1624	action of cell-type-specific trans-acting factor	[actions of cell-type-specific trans-acting factors]	1.0	5	1	0	0
39789	1624	decrease in c-myc mrna level	[decrease in c-myc mRNA levels]	1.0	5	1	0	0
39790	1624	inflammatory mediator include hemodynamic instability	[inflammatory mediators including hemodynamic instability]	1.0	5	1	0	0
39791	1624	Inactive calcineurin	[Inactive calcineurin]	1.0	2	1	0	0
39792	1624	Differential utilization in the stimulation	[Differential utilization in the stimulation]	1.0	5	1	0	0
39793	1624	regulate this early inflammatory response	[regulating this early inflammatory response]	1.0	5	1	0	0
39794	1624	subsequent transformation of T cell	[subsequent transformation of T cells]	1.0	5	1	0	0
39795	1624	glutathione deficiency	[glutathione deficiency]	1.0	2	1	0	0
39796	1624	irf-1 cotransfection	[IRF-1 cotransfection]	1.0	2	1	0	0
39797	1624	cell type-specific subunit of tfiid	[cell type-specific subunit of TFIID]	1.0	5	1	0	0
39798	1624	estrogen receptor concentration as predictor	[Estrogen receptor concentration as predictors]	1.0	5	1	0	0
39799	1624	However, CD80	[However, CD80]	1.0	2	1	0	0
39800	1624	binding site for NF-kappa b	[binding site for NF-kappa B]	1.0	5	2	1	1
39801	1624	contrast, analysis of pp90rsk activity	[contrast, analysis of pp90rsk activity]	1.0	5	1	0	0
39802	1624	cell activation signal in T	[cell activation signals in T]	1.0	5	1	0	0
39803	1624	act as a Locus Control Region	[acting as a Locus Control Region]	1.0	6	1	0	0
39804	1624	cle0 element	[CLE0 element]	1.0	2	1	0	0
39805	1624	PML/RARalpha role	[PML/RARalpha role]	1.0	2	1	0	0
39806	1624	untreated euthymic	[untreated euthymic]	1.0	2	1	0	0
39807	1624	hgata-3-specific mrna	[hGATA-3-specific mRNA]	1.0	2	1	0	0
39808	1624	induce acute respiratory distress syndrome ARDS	[inducing acute respiratory distress syndrome ARDS]	1.0	6	1	0	0
39809	1624	transcription of the tal1/scl gene	[transcription of the TAL1/SCL gene]	1.0	5	1	0	0
39810	1624	vivo function	[vivo function]	1.0	2	1	0	0
39811	1624	peripheral blood lymphocyte from normal individual	[peripheral blood lymphocytes from normal individuals]	1.0	6	1	0	0
39812	1624	detailed characterization of the murine homolog	[detailed characterization of the murine homolog]	1.0	6	1	0	0
39813	1624	interfere with the erk-2 pathway	[interfering with the ERK-2 pathway]	1.0	5	1	0	0
39814	1624	HT-2 cell express the epor	[HT-2 cells expressing the EPOR]	1.0	5	1	0	0
39815	1624	arise in case of ataxia-telangiectasia at	[arising in cases of ataxia-telangiectasia AT]	1.0	6	1	0	0
39816	1624	important role of bsap pax-5	[important role of BSAP Pax-5]	1.0	5	1	0	0
39817	1624	component of the affinity receptor	[component of the affinity receptor]	1.0	5	1	0	0
39818	1624	tr55 expression	[TR55 expression]	1.0	2	1	0	0
39819	1624	yeast cell resistant to the effect	[yeast cells resistant to the effects]	1.0	6	1	0	0
39820	1624	characteristic similar to the mr	[characteristics similar to the MR]	1.0	5	1	0	0
39821	1624	individual responsiveness	[individual responsiveness]	1.0	2	1	0	0
39822	1624	necessity of chemotherapy follow atra therapy	[necessity of chemotherapy following ATRA therapy]	1.0	6	1	0	0
39823	1624	homologous member	[homologous members]	1.0	2	2	1	1
39824	1624	monoamine oxidase b in blood cell	[monoamine oxidase B in blood cells]	1.0	6	1	0	0
39825	1624	xp-d patient	[XP-D patients]	1.0	2	1	0	0
39826	1624	mbp over the concentration range	[MBP over the concentration range]	1.0	5	1	0	0
39827	1624	20) meeting	[20) meeting]	1.0	2	1	0	0
39828	1624	cycloheximide anytime during the h	[cycloheximide anytime during the h]	1.0	5	1	0	0
39829	1624	additional hemoglobinopathybthybinobinybinybinybinybinie	[additional hemoglobinopathies]	1.0	2	1	0	0
39830	1624	psa secretion	[PSA secretion]	1.0	2	1	0	0
39831	1624	two tandem ap1 binding site	[Two tandem AP1 binding sites]	1.0	5	2	1	1
39832	1624	adjuvant chemotherapy for breast carcinoma	[adjuvant chemotherapy for breast carcinoma]	1.0	5	1	0	0
39833	1624	trans- gene expression for day	[trans- gene expression for days]	1.0	5	1	0	0
39834	1624	neutrophil property	[neutrophil properties]	1.0	2	1	0	0
39835	1624	binding of two low-mobility complex	[binding of two low-mobility complexes]	1.0	5	1	0	0
39836	1624	contain level	[containing levels]	1.0	2	2	2	2
39837	1624	dna-binding protein human x box	[DNA-binding protein human X box]	1.0	5	1	0	0
39838	1624	several Ets	[several Ets]	1.0	2	1	0	0
39839	1624	Ca2+ requirement	[Ca2+ requirement]	1.0	2	1	0	0
39840	1624	neuroendocrine cell	[neuroendocrine cells]	1.0	2	1	0	0
39841	1624	virus-uninfected human T cell line	[virus-uninfected human T cell lines]	1.0	5	1	0	0
39842	1624	ifn-gamma -dependent up-regulation of mcp-1 production	[IFN-gamma -dependent up-regulation of MCP-1 production]	1.0	6	1	0	0
39843	1624	granulocytic differentiation of 32dcl3 cell	[granulocytic differentiation of 32Dcl3 cells]	1.0	5	1	0	0
39844	1624	abnormality of the cd3/t-cell antigen receptor	[abnormalities of the CD3/T-cell antigen receptor]	1.0	6	1	0	0
39845	1624	hormone-inducible trans-activate protein in transient transfection	[hormone-inducible trans-activating proteins in transient transfection]	1.0	6	1	0	0
39846	1624	addition, JNK activation by PMA	[addition, JNK activation by PMA]	1.0	5	1	0	0
39847	1624	actinomycin D	[actinomycin D]	1.0	2	2	1	1
39848	1624	50% inhibition of lymphocyte proliferation ic50	[50% inhibition of lymphocyte proliferation IC50s]	1.0	6	1	0	0
39849	1624	viral oncogene	[viral oncogene]	1.0	2	1	0	0
39850	1624	evidence for a role for PKCalpha	[Evidence for a role for PKCalpha]	1.0	6	1	0	0
39851	1624	Conversely, c-jun	[Conversely, c-jun]	1.0	2	1	0	0
39852	1624	region encode the Runt domain	[region encoding the Runt domain]	1.0	5	1	0	0
39853	1624	map unit	[map units]	1.0	2	2	2	2
39854	1624	reflect the binding of p75	[reflecting the binding of p75]	1.0	5	1	0	0
39855	1624	secretion of the IL-12 heterodimer	[secretion of the IL-12 heterodimer]	1.0	5	1	0	0
39856	1624	642 fmol/mg	[642 fmol/mg]	1.0	2	1	0	0
39857	1624	1/oct coactivator from b cell bob1/obf-1/oca-b	[1/Oct coactivator from B cells Bob1/OBF-1/OCA-B]	1.0	6	1	0	0
39858	1624	Fas /Fas ligand FasL interaction	[Fas /Fas ligand FasL interaction]	1.0	5	1	0	0
39859	1624	control (p	[control (P]	1.0	2	2	2	2
39860	1624	Biochemical analysis	[Biochemical analysis]	1.0	2	2	2	2
39861	1624	mouse b cell transfectant express CD40	[mouse B cell transfectants expressing CD40]	1.0	6	1	0	0
39862	1624	activation of lyn gene expression	[activation of lyn gene expression]	1.0	5	1	0	0
39863	1624	translational machinery	[translational machinery]	1.0	2	1	0	0
39864	1624	representative factor	[representative factor]	1.0	2	1	0	0
39865	1624	Epstein-Barr virus latency bamhi-q promoter	[Epstein-Barr virus latency BamHI-Q promoter]	1.0	5	1	0	0
39866	1624	agonist activity in reproductive tissue	[agonist activity in reproductive tissue]	1.0	5	1	0	0
39867	1624	th2 clone from atopic clone	[Th2 clones from atopics clones]	1.0	5	1	0	0
39868	1624	Staphylococcus aureus	[Staphylococcus aureus]	1.0	2	1	0	0
39869	1624	absence of a additional costimulatory signal	[absence of an additional costimulatory signal]	1.0	6	1	0	0
39870	1624	presence in a physiologic setting	[presence in a physiologic setting]	1.0	5	1	0	0
39871	1624	E2F-1 rrna	[E2F-1 mRNAs]	1.0	2	1	0	0
39872	1624	tandem copy of this enhancer	[Tandem copies of this enhancer]	1.0	5	1	0	0
39873	1624	p38 phosphorylation	[p38 phosphorylation]	1.0	2	1	0	0
39874	1624	experimental agent	[experimental agents]	1.0	2	1	0	0
39875	1624	species specific, with no effect	[species specific, with no effect]	1.0	5	1	0	0
39876	1624	periodontal disease	[periodontal diseases]	1.0	2	1	0	0
39877	1624	promoter transactivation	[promoter transactivation]	1.0	2	1	0	0
39878	1624	(2 male	[(2 males]	1.0	2	1	0	0
39879	1624	transcriptional activation of tnf-alpha gene	[transcriptional activation of TNF-alpha gene]	1.0	5	1	0	0
39880	1624	expression of the protein bcl-xL	[expression of the protein bcl-xL]	1.0	5	1	0	0
39881	1624	difference in transcription efficiency from template	[differences in transcription efficiencies from templates]	1.0	6	1	0	0
39882	1624	treatment.	[treatment.]	1.0	1	11	2	2
39883	1624	low-level expression	[low-level expression]	1.0	2	2	2	2
39884	1624	dose-dependent shift	[dose-dependent shift]	1.0	2	2	1	1
39885	1624	two b cell-specific transcription factor	[two B cell-specific transcription factors]	1.0	5	1	0	0
39886	1624	recurrent theme in the regulation	[recurrent theme in the regulation]	1.0	5	1	0	0
39887	1624	receptor in this cell line	[receptor in these cell lines]	1.0	5	1	0	0
39888	1624	large number of cellular response	[large number of cellular responses]	1.0	5	1	0	0
39889	1624	100 nmol/L.	[100 nmol/L.]	1.0	2	1	0	0
39890	1624	human monoblastic leukemia u937 cell	[human monoblastic leukemia U937 cells]	1.0	5	2	1	1
39891	1624	contrast, otf-1	[contrast, OTF-1]	1.0	2	1	0	0
39892	1624	however, expression of the reporter gene	[However, expression of the reporter gene]	1.0	6	1	0	0
39893	1624	full-sized notch1	[full-sized NOTCH1]	1.0	2	1	0	0
39894	1624	false (positive)	[false (positive)]	1.0	2	1	0	0
39895	1624	gralpha expression	[GRalpha expression]	1.0	2	1	0	0
39896	1624	AML1 /eto transcript in leukemia	[AML1 /ETO transcripts in leukemia]	1.0	5	1	0	0
39897	1624	continue for at least 24 P.	[continuing for at least 24 h.]	1.0	6	1	0	0
39898	1624	maximal basophilia	[maximal basophilia]	1.0	2	1	0	0
39899	1624	E-selectin gene	[E-selectin gene]	1.0	2	1	0	0
39900	1624	class I	[class I]	1.0	2	2	1	1
39901	1624	distinct member	[distinct members]	1.0	2	1	0	0
39902	1624	contrast, ap-1 from PHA-activated cell	[contrast, AP-1 from PHA-activated cells]	1.0	5	1	0	0
39903	1624	different mutation	[different mutation]	1.0	2	2	2	2
39904	1624	actual transcription of chromatin structure	[actual transcription of chromatin structure]	1.0	5	1	0	0
39905	1624	precursor protein	[precursor protein]	1.0	2	2	1	1
39906	1624	DNA rearrangement	[DNA rearrangements]	1.0	2	1	0	0
39907	1624	Unexpectedly, stimulation of jurkat T cell	[Unexpectedly, stimulation of Jurkat T cells]	1.0	6	1	0	0
39908	1624	relevance for the immune response	[relevance for the immune response]	1.0	5	1	0	0
39909	1624	causative agent	[causative agent]	1.0	2	2	2	2
39910	1624	vitro expansion	[vitro expansion]	1.0	2	1	0	0
39911	1624	hybridization signal	[hybridization signals]	1.0	2	2	2	2
39912	1624	functional activation of hemopoietic cell	[functional activation of hemopoietic cells]	1.0	5	1	0	0
39913	1624	stimulation with mitogen in vitro.	[stimulation with mitogens in vitro.]	1.0	5	1	0	0
39914	1624	peptide microsequencing of this protein	[peptide microsequencing of this protein]	1.0	5	1	0	0
39915	1624	there, wild-type dex -resistant clone	[there, wild-type dex -resistant clones]	1.0	5	1	0	0
39916	1624	nature of CD40 -dependent signal	[nature of CD40 -dependent signals]	1.0	5	1	0	0
39917	1624	j kappa	[J kappa]	1.0	2	1	0	0
39918	1624	abnormal apoptosis progression in human	[Abnormal apoptosis progression in humans]	1.0	5	1	0	0
39919	1624	accordance with improvement of finding	[accordance with improvement of findings]	1.0	5	1	0	0
39920	1624	crude extract	[crude extracts]	1.0	2	3	2	1
39921	1624	protease treatment of nuclear extract	[Protease treatment of nuclear extracts]	1.0	5	1	0	0
39922	1624	t(8;21) acute myelogenous leukemia aml	[t(8;21) acute myelogenous leukemia AML]	1.0	5	1	0	0
39923	1624	ifn-gamma transcription of the icam-1 gene	[IFN-gamma transcription of the ICAM-1 gene]	1.0	6	1	0	0
39924	1624	control group consist of male	[control group consisting of males]	1.0	5	1	0	0
39925	1624	immunological function	[immunological functions]	1.0	2	2	2	2
39926	1624	f.r., m.m., P. g.) with bcr1/25	[F.R., M.M., P. G.) with BCR1/25]	1.0	6	1	0	0
39927	1624	transcriptional control of cd95l expression	[transcriptional control of CD95L expression]	1.0	5	1	0	0
39928	1624	REV ltr	[REV LTRs]	1.0	2	2	1	1
39929	1624	corresponding to the sequence 125-135	[corresponding to the sequence 125-135]	1.0	5	1	0	0
39930	1624	addition, pretreatment of the cell	[addition, pretreatment of the cells]	1.0	5	1	0	0
39931	1624	31 manic)	[31 manic)]	1.0	2	1	0	0
39932	1624	EBNA-2 transcript	[EBNA-2 transcripts]	1.0	2	1	0	0
39933	1624	enhance inactivation	[enhancing inactivation]	1.0	2	2	1	1
39934	1624	child with pituitary hormone deficiency	[children with pituitary hormone deficiency]	1.0	5	2	1	1
39935	1624	position 61	[position 61]	1.0	2	2	1	1
39936	1624	fibrosis score	[fibrosis score]	1.0	2	1	0	0
39937	1624	8 patient with extrinsic asthma	[8 patients with extrinsic asthma]	1.0	5	1	0	0
39938	1624	aldosterone (p	[aldosterone (P]	1.0	2	1	0	0
39939	1624	double-stranded DNA	[double-stranded DNA]	1.0	2	2	2	2
39940	1624	receptor-dependent mechanism	[receptor-dependent mechanism]	1.0	2	1	0	0
39941	1624	Interleukin (IL)-4	[Interleukin (IL)-4]	1.0	2	1	0	0
39942	1624	48 hr.	[48 hr.]	1.0	2	1	0	0
39943	1624	igkappa expression	[Igkappa expression]	1.0	2	1	0	0
39944	1624	activation-induced expression	[activation-induced expression]	1.0	2	1	0	0
39945	1624	caprine arthritis-encephalitis virus terminal repeat	[caprine arthritis-encephalitis virus terminal repeat]	1.0	5	2	2	2
39946	1624	lysis mechanism	[lysis mechanism]	1.0	2	1	0	0
39947	1624	nuclear factor-DNA	[nuclear factor-DNA]	1.0	2	1	0	0
39948	1624	intracellular signal transduction of il-5	[intracellular signal transduction of IL-5]	1.0	5	1	0	0
39949	1624	other nf-kappab subunit include RelA	[other NF-kappaB subunits including RelA]	1.0	5	1	0	0
39950	1624	inhibition of ino synthase ino activity	[Inhibition of iNO synthase iNOS activity]	1.0	6	1	0	0
39951	1624	significant role in ligand binding	[significant role in ligand binding]	1.0	5	1	0	0
39952	1624	positive cooperativity in the estrogenic response	[positive cooperativity in the estrogenic response]	1.0	6	1	0	0
39953	1624	multiple cytokine receptor interleukin (il)-2	[multiple cytokine receptors interleukin (IL)-2]	1.0	5	1	0	0
39954	1624	self-perpetuation of human immunodeficiency virus transcription	[self-perpetuation of human immunodeficiency virus transcription]	1.0	6	1	0	0
39955	1624	constitutive version	[constitutive version]	1.0	2	2	2	2
39956	1624	position 12	[position 12]	1.0	2	1	0	0
39957	1624	gr in peripheral blood leukocyte	[GR in peripheral blood leukocytes]	1.0	5	2	1	1
39958	1624	instead of NF kappa b	[Instead of NF kappa B]	1.0	5	1	0	0
39959	1624	particularly in relationship to nephrotoxicity	[particularly in relationship to nephrotoxicity]	1.0	5	1	0	0
39960	1624	-zeta in T cell activation	[-zeta in T cell activation]	1.0	5	1	0	0
39961	1624	0.5 nm.	[0.5 nM.]	1.0	2	1	0	0
39962	1624	role mediate diverse immune response	[roles mediating diverse immune responses]	1.0	5	1	0	0
39963	1624	midbrain patterning	[midbrain patterning]	1.0	2	1	0	0
39964	1624	12-day period	[12-day period]	1.0	2	1	0	0
39965	1624	NK cell with cd16 ligand	[NK cells with CD16 ligands]	1.0	5	1	0	0
39966	1624	less rigid,	[less rigid,]	1.0	2	1	0	0
39967	1624	exposure to the drug in	[exposure to the drug in]	1.0	5	1	0	0
39968	1624	transmembrane signal	[transmembrane signaling]	1.0	2	1	0	0
39969	1624	relatively low affinity for gata-1	[relatively low affinity for GATA-1]	1.0	5	1	0	0
39970	1624	expression of downstream target gene	[expression of downstream target genes]	1.0	5	1	0	0
39971	1624	conventional cytogenetics	[conventional cytogenetics]	1.0	2	1	0	0
39972	1624	Flutamide in the treatment of hirsutism	[Flutamide in the treatment of hirsutism]	1.0	6	1	0	0
39973	1624	primary human T cell response	[primary human T cell responses]	1.0	5	1	0	0
39974	1624	adrenal function	[adrenal function]	1.0	2	1	0	0
39975	1624	presence of DNA binding site	[presence of DNA binding sites]	1.0	5	1	0	0
39976	1624	normal population	[normal population]	1.0	2	1	0	0
39977	1624	general role in myeloid differentiation	[general role in myeloid differentiation]	1.0	5	1	0	0
39978	1624	proteolytic assay	[proteolytic assay]	1.0	2	1	0	0
39979	1624	LIF effect	[LIF effects]	1.0	2	2	2	2
39980	1624	ii) of cAMP-dependent protein kinase	[II) of cAMP-dependent protein kinase]	1.0	5	1	0	0
39981	1624	addition, deletion of the region	[addition, deletion of the region]	1.0	5	1	0	0
39982	1624	inhibit the transcription of gene	[inhibiting the transcription of genes]	1.0	5	1	0	0
39983	1624	clinical malaria	[clinical malaria]	1.0	2	1	0	0
39984	1624	adenomatous polyposis	[adenomatous polyposis]	1.0	2	1	0	0
39985	1624	Ikaros gene	[Ikaros gene]	1.0	2	2	1	1
39986	1624	two- increase	[two- increase]	1.0	2	2	2	2
39987	1624	activity of the protein kinase family	[Activity of the protein kinase family]	1.0	6	1	0	0
39988	1624	gabp beta	[GABP beta]	1.0	2	1	0	0
39989	1624	generation of Smu/Sepsilon switch fragment	[generation of Smu/Sepsilon switch fragments]	1.0	5	1	0	0
39990	1624	female steroid hormone estrogen e2	[female steroid hormones estrogen E2]	1.0	5	1	0	0
39991	1624	HTLV-I long terminal repeat LTR	[HTLV-I long terminal repeat LTR]	1.0	5	1	0	0
39992	1624	loss of cytolytic susceptibility to apoptosis	[Loss of cytolytic susceptibility to apoptosis]	1.0	6	1	0	0
39993	1624	glucocorticoid membrane perturbation the possibility	[glucocorticoid membrane perturbation the possibility]	1.0	5	1	0	0
39994	1624	Germline C gamma gene transcription	[Germline C gamma gene transcription]	1.0	5	1	0	0
39995	1624	latter cells.	[latter cells.]	1.0	2	1	0	0
39996	1624	gene corresponding to a novel factor	[genes corresponding to a novel factor]	1.0	6	1	0	0
39997	1624	(creb/atf) family of transcription factor	[(CREB/ATF) family of transcription factors]	1.0	5	1	0	0
39998	1624	target structure	[target structure]	1.0	2	2	2	2
39999	1624	many aspect of leukocyte function	[Many aspects of leukocyte function]	1.0	5	1	0	0
40000	1624	2-5 fold increase in number	[2-5 fold increase in number]	1.0	5	1	0	0
40001	1624	cox-2 protein expression in cell	[COX-2 protein expression in cells]	1.0	5	1	0	0
40002	1624	suggest dependent	[suggesting dependent]	1.0	2	2	2	2
40003	1624	endotoxic challenge	[endotoxic challenge]	1.0	2	2	1	1
40004	1624	difference from early passage cell	[difference from early passage cells]	1.0	5	1	0	0
40005	1624	normal myeloblast	[normal myeloblasts]	1.0	2	1	0	0
40006	1624	factor( binding	[factor(s) binding]	1.0	2	2	2	2
40007	1624	cell to phorbol myristate acetate	[cells to phorbol myristate acetate]	1.0	5	1	0	0
40008	1624	adjuvant chemotherapy consist of cyclophosphamide CMF	[adjuvant chemotherapy consisting of cyclophosphamide CMF]	1.0	6	1	0	0
40009	1624	patient with active cushingd' disease	[patients with active Cushing's disease]	1.0	5	2	1	1
40010	1624	vary degree	[varying degrees]	1.0	2	1	0	0
40011	1624	include human immunodeficiency virus hiv gene	[including human immunodeficiency virus HIV genes]	1.0	6	1	0	0
40012	1624	redox regulation of NF-kappa b	[Redox regulation of NF-kappa B]	1.0	5	1	0	0
40013	1624	tcf-1 T cell factor 1	[TCF-1 T cell factor 1]	1.0	5	1	0	0
40014	1624	maturation of monocyte into macrophage	[maturation of monocytes into macrophages]	1.0	5	1	0	0
40015	1624	activation of tlr by microbial lipoprotein	[Activation of TLRs by microbial lipoproteins]	1.0	6	1	0	0
40016	1624	overexpression of camp inhibition of transcription	[overexpression of cAMP inhibition of transcription]	1.0	6	1	0	0
40017	1624	percentage of cell express CD40	[percentage of cells expressing CD40]	1.0	5	1	0	0
40018	1624	threshold of cathepsin g platelet aggregation	[threshold of cathepsin G platelet aggregation]	1.0	6	1	0	0
40019	1624	molecular mechanism of action of glucocorticoid	[molecular mechanisms of action of glucocorticoids]	1.0	6	1	0	0
40020	1624	contain deletion in this region,	[containing deletions in this region,]	1.0	5	1	0	0
40021	1624	receptor-negative s49 murine thymoma cell	[receptor-negative S49 murine thymoma cells]	1.0	5	1	0	0
40022	1624	IL-5 -inducible gene in eosinophil	[IL-5 -inducible genes in eosinophils]	1.0	5	1	0	0
40023	1624	Rex protein	[Rex protein]	1.0	2	1	0	0
40024	1624	three alpha-helice	[three alpha-helices]	1.0	2	2	2	2
40025	1624	export complex	[export complexes]	1.0	2	2	2	2
40026	1624	hydrogen peroxide at 20 microM,	[hydrogen peroxide at 20 microM,]	1.0	5	1	0	0
40027	1624	other pathway lead to tnf-alpha production	[other pathways leading to TNF-alpha production]	1.0	6	1	0	0
40028	1624	murine peritoneal macrophage by interleukin	[murine peritoneal macrophages by interleukins]	1.0	5	1	0	0
40029	1624	affinity purification of fusion protein	[affinity purification of fusion proteins]	1.0	5	1	0	0
40030	1624	h2 receptor	[H2 receptors]	1.0	2	2	1	1
40031	1624	vcam-1 e-selectin	[VCAM-1 E-selectin]	1.0	2	1	0	0
40032	1624	express adhesive molecule for leukocyte	[expressing adhesive molecules for leukocytes]	1.0	5	1	0	0
40033	1624	DeltaSpi-B product	[DeltaSpi-B product]	1.0	2	1	0	0
40034	1624	distinct pattern of gene expression	[distinct patterns of gene expression]	1.0	5	1	0	0
40035	1624	specific promoter	[specific promoters]	1.0	2	1	0	0
40036	1624	rna transcriptional activity of promoter-enhancer.	[RNA transcriptional activity of promoter-enhancer.]	1.0	5	1	0	0
40037	1624	50 kda/65 kda (p50/p65) heterodimer	[50 kDa/65 kDa (p50/p65) heterodimer]	1.0	5	1	0	0
40038	1624	response to the pcd41 trans-activation	[response to the pCD41 trans-activation]	1.0	5	1	0	0
40039	1624	65 kilodalton	[65 kilodaltons]	1.0	2	1	0	0
40040	1624	addition, 135(oh)2d3	[addition, 1,25(OH)2D3]	1.0	2	1	0	0
40041	1624	c-fo synthesis	[c-fos synthesis]	1.0	2	1	0	0
40042	1624	human atheroma	[human atheroma]	1.0	2	2	1	1
40043	1624	cell growth-regulated expression of mammalian mcm5	[Cell growth-regulated expression of mammalian MCM5]	1.0	6	1	0	0
40044	1624	transcription at the basal level	[transcription at the basal level]	1.0	5	1	0	0
40045	1624	myeloid zinc finger gene MZF-1	[myeloid zinc finger gene MZF-1]	1.0	5	1	0	0
40046	1624	gene inactivation study on the pu.1	[Gene inactivation studies on the PU.1]	1.0	6	1	0	0
40047	1624	CRE element in T lymphocyte	[CRE elements in T lymphocytes]	1.0	5	1	0	0
40048	1624	lymphocyte subpopulation with receptor concentration	[lymphocyte subpopulations with receptor concentrations]	1.0	5	1	0	0
40049	1624	S1 subsite	[S1 subsites]	1.0	2	1	0	0
40050	1624	Stat1 alpha	[Stat1 alpha]	1.0	2	1	0	0
40051	1624	fusion region	[fusion region]	1.0	2	4	3	1
40052	1624	human T cell during aging	[human T cells during aging]	1.0	5	1	0	0
40053	1624	cytokine function of virus-infected t-cell	[cytokine functions of virus-infected T-cells]	1.0	5	1	0	0
40054	1624	display expression	[displaying expression]	1.0	2	2	2	2
40055	1624	pkc isoform in alveolar macrophage	[PKC isoforms in alveolar macrophages]	1.0	5	2	1	1
40056	1624	start at day 0/1 of cultivation	[starting at day 0/1 of cultivation]	1.0	6	1	0	0
40057	1624	tax activation of the cd28re	[Tax activation of the CD28RE]	1.0	5	1	0	0
40058	1624	expression of laz3/bcl6 in follicular center	[Expression of LAZ3/BCL6 in follicular center]	1.0	6	1	0	0
40059	1624	transcription in T cell of SL3	[transcription in T cells of SL3]	1.0	6	1	0	0
40060	1624	CREB isoform	[CREB isoforms]	1.0	2	2	2	2
40061	1624	different study,	[different study,]	1.0	2	1	0	0
40062	1624	characterization of Pax-5 pro-B cell	[characterization of Pax-5 pro-B cells]	1.0	5	1	0	0
40063	1624	chromosome breakpoint	[chromosome breakpoint]	1.0	2	2	2	2
40064	1624	strong inducibility	[strong inducibility]	1.0	2	1	0	0
40065	1624	co-immunoprecipitation experiment	[Co-immunoprecipitation experiments]	1.0	2	1	0	0
40066	1624	Jun kinase in cell line	[Jun kinase in cell lines]	1.0	5	1	0	0
40067	1624	viral pathogens,	[viral pathogens,]	1.0	2	1	0	0
40068	1624	use Jurkat	[using Jurkat]	1.0	2	1	0	0
40069	1624	form of Ig heavy chain	[form of Ig heavy chain]	1.0	5	1	0	0
40070	1624	several peculiarity	[several peculiarities]	1.0	2	1	0	0
40071	1624	STAT factor	[STAT factor]	1.0	2	2	2	2
40072	1624	intracrine mechanism	[intracrine mechanisms]	1.0	2	1	0	0
40073	1624	lack of response to mineralocorticoid	[lack of response to mineralocorticoids]	1.0	5	1	0	0
40074	1624	respective promoter	[respective promoter]	1.0	2	1	0	0
40075	1624	c-myb gene product by itself	[c-myb gene product by itself]	1.0	5	1	0	0
40076	1624	phorbol-12-myristate-13-acetate response	[phorbol-12-myristate-13-acetate response]	1.0	2	1	0	0
40077	1624	EBNA2 mrna	[EBNA2 mRNA]	1.0	2	1	0	0
40078	1624	6.18 (range,	[6.18 (range,]	1.0	2	1	0	0
40079	1624	high activity in erythroid ocim1	[high activity in erythroid OCIM1]	1.0	5	1	0	0
40080	1624	Pan molecule	[Pan molecules]	1.0	2	1	0	0
40081	1624	subtractive cloning of the region.	[subtractive cloning of the region.]	1.0	5	1	0	0
40082	1624	1.3-kb transcript	[1.3-kb transcript]	1.0	2	1	0	0
40083	1624	nf-kappab regulation	[NF-kappaB regulation]	1.0	2	2	2	2
40084	1624	region distinct	[region distinct]	1.0	2	2	1	1
40085	1624	IL-2 -secret cell consist mainly	[IL-2 -secreting cells consisting mainly]	1.0	5	1	0	0
40086	1624	recombinant thioredoxin	[recombinant thioredoxin]	1.0	2	1	0	0
40087	1624	coimmunoprecipitation experiment use cos cell	[coimmunoprecipitation experiments using COS cells]	1.0	5	1	0	0
40088	1624	neonatal T cell il-2 production	[neonatal T cell IL-2 production]	1.0	5	1	0	0
40089	1624	normal hematopoiesis of mature leukocyte	[normal hematopoiesis of mature leukocytes]	1.0	5	1	0	0
40090	1624	27 patient	[27 patients]	1.0	2	1	0	0
40091	1624	interaction with the transcription factor e2f	[interaction with the transcription factor E2F]	1.0	6	1	0	0
40092	1624	consistent site of chromosome translocation	[consistent sites of chromosome translocation]	1.0	5	1	0	0
40093	1624	certain immediate early response gene	[certain immediate early response genes]	1.0	5	1	0	0
40094	1624	expression of the chemokine receptor blr2/ebi1	[Expression of the chemokine receptor BLR2/EBI1]	1.0	6	1	0	0
40095	1624	role in b- cell development	[roles in B- cell development]	1.0	5	1	0	0
40096	1624	adult T cell leukemia ATL	[adult T cell leukemia ATL]	1.0	5	1	0	0
40097	1624	variant present in breast cancer	[variants present in breast cancer]	1.0	5	1	0	0
40098	1624	cd11a+, cd13lo, cd15lo, cd34+/-, hla-dr cd16	[CD11a+, CD13lo, CD15lo, CD34+/-, HLA-DR CD16]	1.0	6	1	0	0
40099	1624	aml1/eto mrna	[AML1/ETO mRNA]	1.0	2	1	0	0
40100	1624	low effect	[lower effect]	1.0	2	2	2	2
40101	1624	vimentin mrna	[vimentin mRNA]	1.0	2	3	2	1
40102	1624	cord lymphocyte	[cord lymphocyte]	1.0	2	2	2	2
40103	1624	endothelial cell surface adhesion molecule	[endothelial cell surface adhesion molecules]	1.0	5	1	0	0
40104	1624	potential role in the regulation	[potential role in the regulation]	1.0	5	1	0	0
40105	1624	augment viral replication in monocyte	[augmenting viral replication in monocytes]	1.0	5	1	0	0
40106	1624	src homology (sh)2 domain -contain molecule	[src homology (SH)2 domain -containing molecules]	1.0	6	1	0	0
40107	1624	lymphoid reservoir	[lymphoid reservoir]	1.0	2	1	0	0
40108	1624	activity of dihydropyrimidine dehydrogenase DPD	[activity of dihydropyrimidine dehydrogenase DPD]	1.0	5	1	0	0
40109	1624	10(7.0) pfu of Ad5 /animal,	[10(7.0) pfu of Ad5 /animal,]	1.0	5	1	0	0
40110	1624	protein kinase C PKC depletion	[Protein kinase C PKC depletion]	1.0	5	1	0	0
40111	1624	2 response	[2 response]	1.0	2	1	0	0
40112	1624	nur77 beta	[nur77 beta]	1.0	2	1	0	0
40113	1624	ikb alpha phosphorylation /degradation irrespective	[IkB alpha phosphorylation /degradation irrespective]	1.0	5	1	0	0
40114	1624	addition to Bcl-x a molecule	[addition to Bcl-x a molecule]	1.0	5	1	0	0
40115	1624	ap-1-binding site	[AP-1-binding sites]	1.0	2	1	0	0
40116	1624	SAA promoter sequence between -280	[SAA promoter sequence between -280]	1.0	5	1	0	0
40117	1624	expression of the hla-dq haplotype	[expression of the HLA-DQ haplotype]	1.0	5	1	0	0
40118	1624	CD3-stimulated human peripheral T lymphocyte	[CD3-stimulated human peripheral T lymphocytes]	1.0	5	1	0	0
40119	1624	inactivate the tumor suppressor gene brca1	[inactivating the tumor suppressor gene BRCA1]	1.0	6	1	0	0
40120	1624	-retinoic acid receptor alpha403 heterodimer	[-retinoic acid receptor alpha403 heterodimers]	1.0	5	1	0	0
40121	1624	GRalpha transactivation in Jurkat cell	[GRalpha transactivation in Jurkat cells]	1.0	5	1	0	0
40122	1624	il-2 production by T cell	[IL-2 production by T cells]	1.0	5	2	1	1
40123	1624	PKC activator, the Zp induction	[PKC activator, the Zp induction]	1.0	5	1	0	0
40124	1624	number of glucocorticoid receptor gr	[number of glucocorticoid receptors GR]	1.0	5	1	0	0
40125	1624	alteration of the receptor-ligand affinity,	[alteration of the receptor-ligand affinity,]	1.0	5	1	0	0
40126	1624	fluid phase macromolecule uptake fitc-dextran	[fluid phase macromolecule uptake FITC-dextran]	1.0	5	1	0	0
40127	1624	frequent cause of maternal morbidity	[frequent cause of maternal morbidity]	1.0	5	1	0	0
40128	1624	vivo, despite a efficient entry	[vivo, despite an efficient entry]	1.0	5	1	0	0
40129	1624	cross-link antibody	[cross-linking antibodies]	1.0	2	1	0	0
40130	1624	il-2r signal	[IL-2R signaling]	1.0	2	1	0	0
40131	1624	sources. here	[sources. Here]	1.0	2	1	0	0
40132	1624	Musculin protein	[Musculin protein]	1.0	2	1	0	0
40133	1624	antibody d07	[antibody D07]	1.0	2	1	0	0
40134	1624	gal4 dbd	[GAL4 DBD]	1.0	2	1	0	0
40135	1624	tat-expressing cell	[Tat-expressing cells]	1.0	2	1	0	0
40136	1624	role for 17 beta-hydroxysteroid dehydrogenase	[role for 17 beta-hydroxysteroid dehydrogenase]	1.0	5	1	0	0
40137	1624	lack c-terminal 13 a fail	[lacking C-terminal 13 aa fail]	1.0	5	1	0	0
40138	1624	expression of the first peak.	[expression of the first peak.]	1.0	5	1	0	0
40139	1624	vivo footprint of this factor,	[vivo footprint of this factor,]	1.0	5	1	0	0
40140	1624	therapeutic option	[therapeutic options]	1.0	2	2	2	2
40141	1624	certain malignancy	[certain malignancies]	1.0	2	2	1	1
40142	1624	direct evidence for the first time	[direct evidence for the first time]	1.0	6	1	0	0
40143	1624	advanced malignancy	[advanced malignancy]	1.0	2	1	0	0
40144	1624	100% of patient with CLL	[100% of patients with CLL]	1.0	5	1	0	0
40145	1624	other region of the protein.	[other regions of the protein.]	1.0	5	1	0	0
40146	1624	impaired transcriptional response in leishmania-infected cell	[impaired transcriptional responses in leishmania-infected cells]	1.0	6	1	0	0
40147	1624	differential priming of the cell	[differential priming of the cells]	1.0	5	1	0	0
40148	1624	-deficient b	[-deficient B]	1.0	2	2	1	1
40149	1624	span nucleotide -158 to -90	[spanning nucleotides -158 to -90]	1.0	5	1	0	0
40150	1624	morphological study	[Morphological studies]	1.0	2	1	0	0
40151	1624	avidin -biotin peroxidase detection system	[avidin -biotin peroxidase detection system]	1.0	5	1	0	0
40152	1624	sp-a inflammation	[SP-A inflammation]	1.0	2	1	0	0
40153	1624	BLR2 mrna	[BLR2 mRNA]	1.0	2	2	1	1
40154	1624	naive T cell from the elderly	[naive T cells from the elderly]	1.0	6	1	0	0
40155	1624	cytopathic virus	[cytopathic virus]	1.0	2	2	1	1
40156	1624	25 microm	[25 microM]	1.0	2	2	1	1
40157	1624	immunosuppressive and/or	[immunosuppressive and/or]	1.0	2	1	0	0
40158	1624	phorbol ester ionomycin activation of ap1	[phorbol ester ionomycin activation of AP1]	1.0	6	1	0	0
40159	1624	cs group	[CS group]	1.0	2	1	0	0
40160	1624	cd44 induction	[CD44 induction]	1.0	2	1	0	0
40161	1624	stat1 binding activity in control	[STAT1 binding activity in control]	1.0	5	1	0	0
40162	1624	receptor engagement by natural ligands,	[receptor engagement by natural ligands,]	1.0	5	1	0	0
40163	1624	quiescent monocyte	[quiescent monocytes]	1.0	2	1	0	0
40164	1624	lim-only protein	[LIM-only proteins]	1.0	2	1	0	0
40165	1624	thus, phosphorylation	[Thus, phosphorylation]	1.0	2	1	0	0
40166	1624	plasma membrane of T cell	[plasma membranes of T cells]	1.0	5	1	0	0
40167	1624	two ls mutation -201/-184 NXS	[two LS mutations -201/-184 NXS]	1.0	5	1	0	0
40168	1624	important gene for cytokine regulation	[important genes for cytokine regulation]	1.0	5	1	0	0
40169	1624	indicate due to a increase	[indicating due to an increase]	1.0	5	1	0	0
40170	1624	calmodulin-regulated kinase	[calmodulin-regulated kinase]	1.0	2	1	0	0
40171	1624	ROI -nf-kappa b signalling pathway	[ROI -NF-kappa B signalling pathway]	1.0	5	1	0	0
40172	1624	Aldh1 mrna	[Aldh1 mRNA]	1.0	2	2	1	1
40173	1624	receptor kinetics.	[receptor kinetics.]	1.0	2	1	0	0
40174	1624	Hence, Ca2+	[Hence, Ca2+]	1.0	2	1	0	0
40175	1624	Btk promoter	[Btk promoter]	1.0	2	1	0	0
40176	1624	suicidal inversion of antigen responsiveness	[suicidal inversion of antigen responsiveness]	1.0	5	1	0	0
40177	1624	little ability	[little ability]	1.0	2	1	0	0
40178	1624	NF-kappa b transcription factor in phagocyte	[NF-kappa B transcription factors in phagocytes]	1.0	6	1	0	0
40179	1624	CMV Ie	[CMV IE]	1.0	2	2	2	2
40180	1624	blockade of a signal lead	[blockade of a signal leading]	1.0	5	1	0	0
40181	1624	atopic disease	[atopic diseases]	1.0	2	1	0	0
40182	1624	virus-encoded protein	[virus-encoded proteins]	1.0	2	1	0	0
40183	1624	cellular fraction of resting cell	[cellular fractions of resting cells]	1.0	5	1	0	0
40184	1624	biologic effect	[biologic effects]	1.0	2	2	2	2
40185	1624	tissue expression	[Tissue expression]	1.0	2	2	2	2
40186	1624	progress understand the death signal	[progress understanding the death signals]	1.0	5	1	0	0
40187	1624	however, latent, transformation-associated viral gene	[However, latent, transformation-associated viral genes]	1.0	5	1	0	0
40188	1624	rhombotin gene	[rhombotin gene]	1.0	2	3	2	1
40189	1624	3.5-10 nm	[3.5-10 nM]	1.0	2	1	0	0
40190	1624	cytolytic potential.	[cytolytic potential.]	1.0	2	1	0	0
40191	1624	research	[research]	1.0	1	11	7	7
40192	1624	different route on nuclear signalling	[different routes on nuclear signalling]	1.0	5	1	0	0
40193	1624	differential role	[differential role]	1.0	2	2	2	2
40194	1624	acid 1-180) in 12 of 17	[acids 1-180) in 12 of 17]	1.0	6	1	0	0
40195	1624	overall survival	[overall survival]	1.0	2	1	0	0
40196	1624	cortisol metabolism	[cortisol metabolism]	1.0	2	1	0	0
40197	1624	indicate a function for phospholipase a2	[indicating a function for phospholipase A2]	1.0	6	1	0	0
40198	1624	fibroblastic tumor	[fibroblastic tumors]	1.0	2	1	0	0
40199	1624	exon 11	[exon 11]	1.0	2	2	1	1
40200	1624	IL-5- eosinophil	[IL-5- eosinophils]	1.0	2	1	0	0
40201	1624	gamma-globin gene	[gamma-globin gene]	1.0	2	2	1	1
40202	1624	receptor clustering	[receptor clustering]	1.0	2	2	1	1
40203	1624	survival of this labile inhibitor.	[survival of this labile inhibitor.]	1.0	5	1	0	0
40204	1624	however, stimulation	[However, stimulation]	1.0	2	2	2	2
40205	1624	one explanation for the perpetuation	[One explanation for the perpetuation]	1.0	5	1	0	0
40206	1624	exposure of CML cell to ifn-alpha	[Exposure of CML cells to IFN-alpha]	1.0	6	1	0	0
40207	1624	production of Jurkat cell line	[production of Jurkat cell lines]	1.0	5	1	0	0
40208	1624	plastic dish	[plastic dishes]	1.0	2	1	0	0
40209	1624	mediator of light via binding	[mediators of light via binding]	1.0	5	1	0	0
40210	1624	clonogenic assay	[clonogenic assay]	1.0	2	1	0	0
40211	1624	six group	[six groups]	1.0	2	2	2	2
40212	1624	inducible complex	[inducible complex]	1.0	2	2	1	1
40213	1624	AGS patient	[AGS patient]	1.0	2	2	2	2
40214	1624	native envelope glycoprotein of hiv	[native envelope glycoproteins of HIV]	1.0	5	1	0	0
40215	1624	generation of low molecular isoform	[generation of lower molecular isoforms]	1.0	5	1	0	0
40216	1624	lipopolysaccharide neutrophil	[lipopolysaccharide neutrophils]	1.0	2	1	0	0
40217	1624	similar activity.	[similar activity.]	1.0	2	1	0	0
40218	1624	maturation of the immune system	[maturation of the immune system]	1.0	5	1	0	0
40219	1624	conjunction with phorbol 12-myristate 13-acetate	[conjunction with phorbol 12-myristate 13-acetate]	1.0	5	1	0	0
40220	1624	T cell development in thymus	[T cell development in thymus]	1.0	5	1	0	0
40221	1624	low levels,	[low levels,]	1.0	2	1	0	0
40222	1624	even after 12 hour of treatment.	[even after 12 hr of treatment.]	1.0	6	1	0	0
40223	1624	NK-kappa b transcription factor complex	[NK-kappa B transcription factor complex]	1.0	5	1	0	0
40224	1624	STAT6 activation	[STAT6 activation]	1.0	2	1	0	0
40225	1624	binding of NFATp from lysate	[binding of NFATp from lysates]	1.0	5	1	0	0
40226	1624	protein (lbp)	[protein (LBP)]	1.0	2	1	0	0
40227	1624	c-fo of c-myc mrna level	[c-fos of c-myc mRNA levels]	1.0	5	1	0	0
40228	1624	6 microM.	[6 microM.]	1.0	2	1	0	0
40229	1624	endocrine change	[endocrine changes]	1.0	2	1	0	0
40230	1624	qualitative difference in the response	[qualitative differences in the response]	1.0	5	1	0	0
40231	1624	related hmg box transcription factor	[related HMG box transcription factors]	1.0	5	1	0	0
40232	1624	wild-type LMP1	[wild-type LMP1]	1.0	2	1	0	0
40233	1624	analysis of NF-Y subunit expression	[Analysis of NF-Y subunit expression]	1.0	5	1	0	0
40234	1624	use a combination of transfection	[Using a combination of transfection]	1.0	5	1	0	0
40235	1624	primary human blood mononuclear cell	[primary human blood mononuclear cells]	1.0	5	2	1	1
40236	1624	pkb/pi3-kinase activity	[PKB/PI3-kinase activity]	1.0	2	1	0	0
40237	1624	deleterious effects.	[deleterious effects.]	1.0	2	1	0	0
40238	1624	inducibility of IL-6 promoter activity	[inducibility of IL-6 promoter activity]	1.0	5	1	0	0
40239	1624	wild-type protein	[wild-type protein]	1.0	2	2	1	1
40240	1624	PstI repeat	[PstI repeats]	1.0	2	1	0	0
40241	1624	whole mouse il-2 enhancer construct	[whole mouse IL-2 enhancer construct]	1.0	5	1	0	0
40242	1624	significant defect	[significant defect]	1.0	2	2	2	2
40243	1624	evidence of transcriptional regulation by IFNs	[evidence of transcriptional regulation by IFNs]	1.0	6	1	0	0
40244	1624	TF gene	[TF gene]	1.0	2	2	2	2
40245	1624	classical action,	[classical action,]	1.0	2	1	0	0
40246	1624	translation of the complementary DNA	[translation of the complementary DNA]	1.0	5	1	0	0
40247	1624	sequencing of the gr cDNA	[Sequencing of the GR cDNA]	1.0	5	1	0	0
40248	1624	involve another heat-labile serum factor (s)	[involving another heat-labile serum factor (s)]	1.0	6	1	0	0
40249	1624	high mobility group protein i/y	[high mobility group protein I/Y]	1.0	5	1	0	0
40250	1624	only with kappa b alpha	[only with kappa B alpha]	1.0	5	1	0	0
40251	1624	use specific antibody against transcription factor	[using specific antibodies against transcription factors]	1.0	6	1	0	0
40252	1624	activation protein	[Activation protein]	1.0	2	2	1	1
40253	1624	motif capable	[motifs capable]	1.0	2	1	0	0
40254	1624	surface immunoglobulin on b cell	[surface immunoglobulin on B cells]	1.0	5	1	0	0
40255	1624	PG490 triptolide	[PG490 triptolide]	1.0	2	1	0	0
40256	1624	>10(-14) mol/L for b cell	[>10(-14) mol/L for B cells]	1.0	5	1	0	0
40257	1624	contrast, treatment with okadaic acid	[contrast, treatment with okadaic acid]	1.0	5	1	0	0
40258	1624	proximal nf-kappa b motif L1	[proximal NF-kappa B motif L1]	1.0	5	1	0	0
40259	1624	particular gene	[particular gene]	1.0	2	1	0	0
40260	1624	nuclear protein-DNA	[nuclear protein-DNA]	1.0	2	1	0	0
40261	1624	particular, staurosporine	[particular, staurosporine]	1.0	2	1	0	0
40262	1624	part of the panoply of change	[part of the panoply of changes]	1.0	6	1	0	0
40263	1624	epithelial cancer	[epithelial cancers]	1.0	2	1	0	0
40264	1624	several B-cell marker include vpreb1	[several B-cell markers including VpreB1]	1.0	5	1	0	0
40265	1624	promyelocyte	[promyelocyte]	1.0	1	11	4	4
40266	1624	differentiation-inducing capacity	[differentiation-inducing capacity]	1.0	2	2	1	1
40267	1624	human RBC	[human RBCs]	1.0	2	1	0	0
40268	1624	adult erythroblast	[adult erythroblasts]	1.0	2	1	0	0
40269	1624	capacity, mobility on 5-20% sucrose gradients,	[capacity, mobility on 5-20% sucrose gradients,]	1.0	6	1	0	0
40270	1624	transcription of the il-2 gene	[transcription of the IL-2 gene]	1.0	5	2	1	1
40271	1624	core enhancer of hypersensitivity site	[core enhancer of hypersensitivity site]	1.0	5	1	0	0
40272	1624	sequence proximal	[sequences proximal]	1.0	2	1	0	0
40273	1624	human RAR	[human RAR]	1.0	2	1	0	0
40274	1624	inhibitory effect on the proliferation	[inhibitory effect on the proliferation]	1.0	5	1	0	0
40275	1624	normal immature human myeloid cell	[normal immature human myeloid cells]	1.0	5	1	0	0
40276	1624	first month	[first month]	1.0	2	2	2	2
40277	1624	other lysophospholipid	[other lysophospholipids]	1.0	2	1	0	0
40278	1624	competitive reverse transcriptase polymerase chain reaction	[competitive reverse transcriptase polymerase chain reaction]	1.0	6	1	0	0
40279	1624	tcr response	[TCR response]	1.0	2	2	1	1
40280	1624	such as von willebrand factor vwf	[such as von Willebrand factor vWf]	1.0	6	1	0	0
40281	1624	extreme susceptibility	[extreme susceptibility]	1.0	2	1	0	0
40282	1624	cell origin	[cell origin]	1.0	2	2	2	2
40283	1624	interleukin-10 increases,	[interleukin-10 increases,]	1.0	2	1	0	0
40284	1624	pulse treatment	[pulse treatment]	1.0	2	1	0	0
40285	1624	monocyte fraction	[monocyte fraction]	1.0	2	1	0	0
40286	1624	major role in immune response	[major role in immune responses]	1.0	5	1	0	0
40287	1624	mutation frequency datum on allele	[mutation frequency data on alleles]	1.0	5	1	0	0
40288	1624	repressor raz	[repressor RAZ]	1.0	2	1	0	0
40289	1624	high mobility group protein hmg	[high mobility group protein HMG]	1.0	5	1	0	0
40290	1624	important mechanism for il-10 suppression	[important mechanism for IL-10 suppression]	1.0	5	1	0	0
40291	1624	immunosuppressant ciclosporin	[immunosuppressants ciclosporin]	1.0	2	1	0	0
40292	1624	CV-1 cell	[CV-1 cells]	1.0	2	1	0	0
40293	1624	involve expression of stat4 inducible protein	[involving expression of Stat4 inducible proteins]	1.0	6	1	0	0
40294	1624	endocrine aspect	[endocrine aspect]	1.0	2	1	0	0
40295	1624	clinical recovery,	[clinical recovery,]	1.0	2	1	0	0
40296	1624	extract from RAW 264.7 cell	[extracts from RAW 264.7 cells]	1.0	5	1	0	0
40297	1624	proteasome degradation	[proteasome degradation]	1.0	2	2	2	2
40298	1624	glycosphingolipid lactosylceramide	[glycosphingolipid lactosylceramide]	1.0	2	1	0	0
40299	1624	developmental control of globin gene	[developmental control of globin genes]	1.0	5	1	0	0
40300	1624	initial reduction	[initial reduction]	1.0	2	1	0	0
40301	1624	activator protein-1 transcription factor expression	[activator protein-1 transcription factor expression]	1.0	5	1	0	0
40302	1624	dominant-negative version of C/EBP beta	[dominant-negative version of C/EBP beta]	1.0	5	1	0	0
40303	1624	further optimization of culture conditions, type	[Further optimization of culture conditions, type]	1.0	6	1	0	0
40304	1624	potent inducer of IL-6 gene expression	[potent inducers of IL-6 gene expression]	1.0	6	1	0	0
40305	1624	cloning of the Epstein-Barr virus dutpase	[Cloning of the Epstein-Barr virus dUTPase]	1.0	6	1	0	0
40306	1624	50 mcr	[50, MCR]	1.0	2	1	0	0
40307	1624	regulation upon cd16 ligand binding	[regulation upon CD16 ligand binding]	1.0	5	1	0	0
40308	1624	clear evidence of tumor progression	[clear evidence of tumor progression]	1.0	5	1	0	0
40309	1624	corticosteroid produce 50% inhibition ic50	[corticosteroid producing 50% inhibition IC50]	1.0	5	1	0	0
40310	1624	cooperative interaction between this proteins.	[cooperative interactions between these proteins.]	1.0	5	1	0	0
40311	1624	nfil2 b	[NFIL2 B]	1.0	2	1	0	0
40312	1624	nfil2 a	[NFIL2 A]	1.0	2	1	0	0
40313	1624	monocyte-endothelial interactions.	[monocyte-endothelial interactions.]	1.0	2	1	0	0
40314	1624	various antioxidant such as pyrrolidine dithiocarbamate	[Various antioxidants such as pyrrolidine dithiocarbamate]	1.0	6	1	0	0
40315	1624	transcription in response to stimulation	[transcription in response to stimulation]	1.0	5	1	0	0
40316	1624	(0.1 nmol/L to 100 mumol/L)	[(0.1 nmol/L to 100 mumol/L)]	1.0	5	1	0	0
40317	1624	fast kinetic of tumor development	[fast kinetics of tumor development]	1.0	5	1	0	0
40318	1624	quantitative difference between Oct-1 factor	[quantitative differences between Oct-1 factors]	1.0	5	1	0	0
40319	1624	Phorbol ester	[Phorbol ester]	1.0	2	1	0	0
40320	1624	block this two crucial element	[blocking these two crucial elements]	1.0	5	1	0	0
40321	1624	h2o2 lipid peroxidation in Wurzburg cell	[H2O2 lipid peroxidation in Wurzburg cells]	1.0	6	1	0	0
40322	1624	normal female	[normal females]	1.0	2	1	0	0
40323	1624	nf-kappa b activation in this setting.	[NF-kappa B activation in this setting.]	1.0	6	1	0	0
40324	1624	only tepoxalin,	[only tepoxalin,]	1.0	2	1	0	0
40325	1624	clinically sensitive chronic leukemia patient	[clinically sensitive chronic leukemia patients]	1.0	5	1	0	0
40326	1624	involve successive stage of commitment	[involving successive stages of commitment]	1.0	5	1	0	0
40327	1624	two tyrosine phosphoprotein of 38	[Two tyrosine phosphoproteins of 38]	1.0	5	1	0	0
40328	1624	operational characteristic	[operational characteristics]	1.0	2	1	0	0
40329	1624	down-regulation of protein kinase pathway	[down-regulation of protein kinase pathways]	1.0	5	1	0	0
40330	1624	most lineage	[most lineages]	1.0	2	2	2	2
40331	1624	E2F family of transcription factor	[E2F family of transcription factors]	1.0	5	1	0	0
40332	1624	anti- igm	[anti- IgM]	1.0	2	1	0	0
40333	1624	polyamine metabolism	[polyamine metabolism]	1.0	2	1	0	0
40334	1624	crucial role in the survival	[crucial role in the survival]	1.0	5	1	0	0
40335	1624	differentiation-blocked erythroblast	[differentiation-blocked erythroblasts]	1.0	2	1	0	0
40336	1624	il-2 proliferation of all il-2 cell	[IL-2 proliferation of all IL-2 cells]	1.0	6	1	0	0
40337	1624	patient suffer from cushingd' syndrome	[patients suffering from Cushing's syndrome]	1.0	5	1	0	0
40338	1624	natural compound	[natural compound]	1.0	2	1	0	0
40339	1624	few gene	[few genes]	1.0	2	2	2	2
40340	1624	initial attack	[initial attack]	1.0	2	1	0	0
40341	1624	endothelial cell by cyclosporin A	[endothelial cells by cyclosporin A]	1.0	5	1	0	0
40342	1624	PEBP2betaMYH11 fusion	[PEBP2betaMYH11 fusion]	1.0	2	1	0	0
40343	1624	psychiatric disorder	[psychiatric disorders]	1.0	2	2	2	2
40344	1624	hacat cell after 3 h	[HaCaT cells after 3 h]	1.0	5	1	0	0
40345	1624	(approximately 1-5 nm) of calyculin a	[(approximately 1-5 nM) of calyculin A]	1.0	6	1	0	0
40346	1624	subsequent recurrence	[subsequent recurrences]	1.0	2	1	0	0
40347	1624	nf-kappab transcription in human monocytic cell	[NF-kappaB transcription in human monocytic cells]	1.0	6	1	0	0
40348	1624	only the immunodominant kd-restricted epitope	[only the immunodominant Kd-restricted epitope]	1.0	5	1	0	0
40349	1624	5 human red blood cell	[5 human red blood cells]	1.0	5	1	0	0
40350	1624	therapeutic value in the treatment	[therapeutic value in the treatment]	1.0	5	1	0	0
40351	1624	Electrophoretic mobility shift assay use	[Electrophoretic mobility shift assay using]	1.0	5	1	0	0
40352	1624	posttranscriptional level	[posttranscriptional level]	1.0	2	1	0	0
40353	1624	suggest a regulatory role of e220k	[suggesting a regulatory role of E220K]	1.0	6	1	0	0
40354	1624	consequent activation	[consequent activation]	1.0	2	2	2	2
40355	1624	leukocyte pmn	[leukocyte PMN]	1.0	2	2	2	2
40356	1624	hemoglobin Hb	[hemoglobin Hb]	1.0	2	1	0	0
40357	1624	critical threshold	[critical threshold]	1.0	2	1	0	0
40358	1624	prior analysis	[Prior analyses]	1.0	2	1	0	0
40359	1624	activation signal pathway of apoptosis	[Activation signaling pathways of apoptosis]	1.0	5	1	0	0
40360	1624	single strand conformation polymorphism analysis	[Single strand conformation polymorphism analysis]	1.0	5	2	1	1
40361	1624	mononuclear leucocyte with this chemokine	[mononuclear leucocytes with this chemokine]	1.0	5	1	0	0
40362	1624	impaired cortisol	[Impaired cortisol]	1.0	2	1	0	0
40363	1624	endocrine cell type-specific complex formation	[endocrine cell type-specific complex formation]	1.0	5	1	0	0
40364	1624	extracellular receptor	[extracellular receptors]	1.0	2	1	0	0
40365	1624	site mutation	[site mutation]	1.0	2	2	2	2
40366	1624	RA formation	[RA formation]	1.0	2	1	0	0
40367	1624	fy*b allele	[FY*B allele]	1.0	2	2	1	1
40368	1624	Zp activation	[Zp activation]	1.0	2	1	0	0
40369	1624	inhibit expression	[inhibiting expression]	1.0	2	2	2	2
40370	1624	early growth response gene egr-1	[early growth response gene egr-1]	1.0	5	1	0	0
40371	1624	transcriptional level,	[transcriptional level,]	1.0	2	1	0	0
40372	1624	u-937 cell adhesion to tnf-alpha	[U-937 cell adhesion to TNF-alpha]	1.0	5	1	0	0
40373	1624	complete degradation.	[complete degradation.]	1.0	2	1	0	0
40374	1624	calcium -signal	[calcium -signal]	1.0	2	2	2	2
40375	1624	establishment of effusion lymphoma cell line	[Establishment of effusion lymphoma cell lines]	1.0	6	1	0	0
40376	1624	low-level activation of endogenous lt	[low-level activation of endogenous LT]	1.0	5	1	0	0
40377	1624	optimal neutrophil	[optimal neutrophil]	1.0	2	1	0	0
40378	1624	growth of NB4 apl cell	[growth of NB4 APL cells]	1.0	5	1	0	0
40379	1624	0.1 u/ml	[0.1 U/ml]	1.0	2	1	0	0
40380	1624	nuclear uptake of NF-kappa b complex	[nuclear uptake of NF-kappa B complexes]	1.0	6	1	0	0
40381	1624	clinical significance of this finding	[clinical significance of these findings]	1.0	5	1	0	0
40382	1624	renal sodium	[renal sodium]	1.0	2	1	0	0
40383	1624	t-cell (tcr)	[T-cell (TCR)]	1.0	2	1	0	0
40384	1624	b-cell-specific regulation	[B-cell-specific regulation]	1.0	2	1	0	0
40385	1624	other gene transcription in sle patient	[other gene transcription in SLE patients]	1.0	6	1	0	0
40386	1624	normal subject (bind capacity 3.3	[normal subjects (binding capacity 3.3]	1.0	5	1	0	0
40387	1624	cellular kinase	[cellular kinases]	1.0	2	1	0	0
40388	1624	reduce kv1.3 component of KV current	[reducing Kv1.3 components of KV current]	1.0	6	1	0	0
40389	1624	good correlation in the cell	[good correlation in the cells]	1.0	5	1	0	0
40390	1624	erbA-binding site	[erbA-binding site]	1.0	2	1	0	0
40391	1624	rare cell in the biopsy	[rare cells in the biopsies]	1.0	5	1	0	0
40392	1624	rhombotin-2 binding et transcription factor	[rhombotin-2 binding ets transcription factor]	1.0	5	1	0	0
40393	1624	human breast cancer cell line	[human breast cancer cell lines]	1.0	5	2	1	1
40394	1624	51659 daltons.	[51,659 daltons.]	1.0	2	1	0	0
40395	1624	two variants,	[two variants,]	1.0	2	1	0	0
40396	1624	bind the consensus ap-1 tre motif	[binding the consensus AP-1 TRE motifs]	1.0	6	1	0	0
40397	1624	protein expression in endothelial cell	[protein expression in endothelial cells]	1.0	5	1	0	0
40398	1624	phenotypic characteristic	[phenotypic characteristics]	1.0	2	2	2	2
40399	1624	20 case	[20 cases]	1.0	2	2	1	1
40400	1624	multiple time	[multiple times]	1.0	2	1	0	0
40401	1624	adhesion assay under shear flow condition	[Adhesion assays under shear flow conditions]	1.0	6	1	0	0
40402	1624	PMA /iono	[PMA /Iono]	1.0	2	1	0	0
40403	1624	frequency, distribution, of this mutation	[frequency, distribution, of these mutations]	1.0	5	1	0	0
40404	1624	17 case	[17 cases]	1.0	2	2	1	1
40405	1624	macrophage precursors,	[macrophage precursors,]	1.0	2	1	0	0
40406	1624	TR beta	[TR beta]	1.0	2	2	1	1
40407	1624	polymerase chain reaction in five	[polymerase chain reaction in five]	1.0	5	1	0	0
40408	1624	level of nuclear protein capable	[level of nuclear proteins capable]	1.0	5	1	0	0
40409	1624	novel motif in the promoter	[novel motif in the promoters]	1.0	5	1	0	0
40410	1624	macrophage factor	[macrophage factor]	1.0	2	2	2	2
40411	1624	interfollicular area	[interfollicular areas]	1.0	2	1	0	0
40412	1624	kinase-related kinase	[kinase-related kinase]	1.0	2	1	0	0
40413	1624	contain the NF-kappa b binding site	[containing the NF-kappa B binding site]	1.0	6	1	0	0
40414	1624	context-dependent manner.	[context-dependent manner.]	1.0	2	1	0	0
40415	1624	important mediator of septic shock	[important mediator of septic shock]	1.0	5	1	0	0
40416	1624	corresponding locus	[corresponding locus]	1.0	2	1	0	0
40417	1624	240 bp	[240 bp]	1.0	2	1	0	0
40418	1624	promonocytic cells,	[promonocytic cells,]	1.0	2	1	0	0
40419	1624	depend on the reconstitution condition	[depending on the reconstitution conditions]	1.0	5	1	0	0
40420	1624	GRbeta expression	[GRbeta expression]	1.0	2	1	0	0
40421	1624	nb4 cell to 9-cis RA	[NB4 cells to 9-cis RA]	1.0	5	1	0	0
40422	1624	ec expression of adhesion molecule	[EC expression of adhesion molecules]	1.0	5	1	0	0
40423	1624	ability of A beta peptide	[ability of A beta peptides]	1.0	5	1	0	0
40424	1624	apoptosis in ebv-infected lymphoblastoid cell	[apoptosis in EBV-infected lymphoblastoid cells]	1.0	5	1	0	0
40425	1624	group difference in cortisol level	[group differences in cortisol levels]	1.0	5	1	0	0
40426	1624	peptide epitope	[peptide epitope]	1.0	2	1	0	0
40427	1624	eosinophil granule major basic protein mbp	[Eosinophil granule major basic protein MBP]	1.0	6	1	0	0
40428	1624	nuclear factor from T lymphocyte	[nuclear factors from T lymphocytes]	1.0	5	1	0	0
40429	1624	expression of the mutant form	[expression of the mutant forms]	1.0	5	1	0	0
40430	1624	cytotoxic cytokine	[cytotoxic cytokines]	1.0	2	1	0	0
40431	1624	patient with severe heart failure	[patient with severe heart failure]	1.0	5	1	0	0
40432	1624	cellular cytoplasm	[cellular cytoplasm]	1.0	2	1	0	0
40433	1624	one hour	[One hour]	1.0	2	1	0	0
40434	1624	Interferon-gamma IFN-gamma	[Interferon-gamma IFN-gamma]	1.0	2	1	0	0
40435	1624	mm cell with RB antisense	[MM cells with RB antisense]	1.0	5	1	0	0
40436	1624	single ubiquitous cyclic amp-responsive element	[single ubiquitous cyclic AMP-responsive element]	1.0	5	1	0	0
40437	1624	vivo: role of 26s proteasome	[vivo: role of 26S proteasome]	1.0	5	1	0	0
40438	1624	regulation of lymphoid-specific immunoglobulin mu	[Regulation of lymphoid-specific immunoglobulin mu]	1.0	5	1	0	0
40439	1624	gr receptor	[GR receptor]	1.0	2	2	2	2
40440	1624	leukemia-specific retinoic acid receptor pml-rar	[leukemia-specific retinoic acid receptor PML-RAR]	1.0	5	1	0	0
40441	1624	CTLA-4 ligation	[CTLA-4 ligation]	1.0	2	1	0	0
40442	1624	membrane-bound tnf-alpha	[membrane-bound TNF-alpha]	1.0	2	1	0	0
40443	1624	replicative cycle.	[replicative cycle.]	1.0	2	1	0	0
40444	1624	multiple member	[multiple members]	1.0	2	3	2	1
40445	1624	sequence variation in the repeat region	[Sequence variation in the repeat region]	1.0	6	1	0	0
40446	1624	wild-type phenotype	[wild-type phenotype]	1.0	2	2	2	2
40447	1624	ar level	[AR levels]	1.0	2	2	1	1
40448	1624	further support	[further support]	1.0	2	1	0	0
40449	1624	central core	[central core]	1.0	2	1	0	0
40450	1624	Oct2 expression	[Oct2 expression]	1.0	2	1	0	0
40451	1624	chicken cytokine	[chicken cytokine]	1.0	2	2	2	2
40452	1624	HIV-1 Tat	[HIV-1 Tat]	1.0	2	2	1	1
40453	1624	match point mutation in 5'hs3	[matching point mutations in 5'HS3]	1.0	5	1	0	0
40454	1624	same assay.	[same assay.]	1.0	2	1	0	0
40455	1624	specific function in this process	[specific function in these processes]	1.0	5	1	0	0
40456	1624	and/or differentiation	[and/or differentiation]	1.0	2	2	1	1
40457	1624	inhibit the binding of nuclear factor	[inhibiting the binding of nuclear factors]	1.0	6	1	0	0
40458	1624	immune property	[immune properties]	1.0	2	1	0	0
40459	1624	allelic nucleotide	[allelic nucleotides]	1.0	2	1	0	0
40460	1624	phagocyte recognition	[Phagocyte recognition]	1.0	2	1	0	0
40461	1624	Positive induction of GR mrna	[Positive induction of GR mRNA]	1.0	5	1	0	0
40462	1624	cysteine region	[cysteine regions]	1.0	2	2	2	2
40463	1624	steroid nucleus	[steroid nucleus]	1.0	2	1	0	0
40464	1624	s-adenosylhomocysteine hydrolase	[S-adenosylhomocysteine hydrolase]	1.0	2	1	0	0
40465	1624	Rel-related, mitogen-inducible, kappa b-binding protein	[Rel-related, mitogen-inducible, kappa B-binding protein]	1.0	5	1	0	0
40466	1624	CD14 the pattern recognition receptor	[CD14 the pattern recognition receptor]	1.0	5	1	0	0
40467	1624	human class ii MHC Ag	[Human class II MHC Ag]	1.0	5	1	0	0
40468	1624	expression level of RA receptor	[expression levels of RA receptors]	1.0	5	1	0	0
40469	1624	Th1 subset in immune response	[Th1 subsets in immune responses]	1.0	5	1	0	0
40470	1624	variability of the natural history	[variability of the natural history]	1.0	5	1	0	0
40471	1624	inhibition of cyclooxygenase-2 expression 2-hydroxy-4-trifluoromethylbenzoic acid	[Inhibition of cyclooxygenase-2 expression 2-hydroxy-4-trifluoromethylbenzoic acid]	1.0	6	1	0	0
40472	1624	leukemic blast	[leukemic blasts]	1.0	2	2	2	2
40473	1624	lps -mcd14 binding response in monocyte	[LPS -mCD14 binding responses in monocytes]	1.0	6	1	0	0
40474	1624	transcription factor responsible for the response	[transcription factors responsible for the response]	1.0	6	1	0	0
40475	1624	mouse embryo	[mouse embryo]	1.0	2	1	0	0
40476	1624	il-2 expression in this cells.	[IL-2 expression in these cells.]	1.0	5	1	0	0
40477	1624	full activation of the map kinase	[Full activation of the MAP kinases]	1.0	6	1	0	0
40478	1624	presence of a nuclear factor	[presence of a nuclear factor]	1.0	5	1	0	0
40479	1624	25 kD	[25 kD]	1.0	2	1	0	0
40480	1624	1753-bp fragment	[1753-bp fragment]	1.0	2	1	0	0
40481	1624	methylation interference analysis of the region	[Methylation interference analysis of the region]	1.0	6	1	0	0
40482	1624	costimulatory signals.	[costimulatory signals.]	1.0	2	1	0	0
40483	1624	double oligomer	[double oligomers]	1.0	2	1	0	0
40484	1624	monocytic (U937)	[monocytic (U937)]	1.0	2	1	0	0
40485	1624	broad range	[broad range]	1.0	2	2	2	2
40486	1624	activity of DNA relax enzyme	[activity of DNA relaxing enzymes]	1.0	5	1	0	0
40487	1624	dna-binding of each transcription factor	[DNA-binding of each transcription factor]	1.0	5	1	0	0
40488	1624	positive lymph node at surgery	[positive lymph nodes at surgery]	1.0	5	1	0	0
40489	1624	include member of the NF-kappa B/Rel	[including members of the NF-kappa B/Rel]	1.0	6	1	0	0
40490	1624	hiv-long terminal	[HIV-long terminal]	1.0	2	1	0	0
40491	1624	cytokine production in human monocyte	[cytokine production in human monocytes]	1.0	5	1	0	0
40492	1624	contain promoter element in fibroblast	[containing promoter element in fibroblasts]	1.0	5	1	0	0
40493	1624	results: incubation of human whole blood	[RESULTS: Incubation of human whole blood]	1.0	6	1	0	0
40494	1624	human SP1	[human SP1]	1.0	2	1	0	0
40495	1624	C- terminal	[C- terminal]	1.0	2	1	0	0
40496	1624	localization outside of the deletion.	[localization outside of the deletion.]	1.0	5	1	0	0
40497	1624	immunodepletion study	[Immunodepletion studies]	1.0	2	1	0	0
40498	1624	use DC	[using DC]	1.0	2	2	1	1
40499	1624	camp accumulation in T cell	[cAMP accumulation in T cells]	1.0	5	1	0	0
40500	1624	pml/rar-alpha protein	[pml/RAR-alpha protein]	1.0	2	1	0	0
40501	1624	phenotype suggestive of T cell	[phenotype suggestive of T cells]	1.0	5	1	0	0
40502	1624	bed rest	[bed rest]	1.0	2	3	2	1
40503	1624	follow activation of cd36 cho cell	[following activation of CD36 CHO cells]	1.0	6	1	0	0
40504	1624	IFN-alpha protection	[IFN-alpha protection]	1.0	2	1	0	0
40505	1624	positive role in cell proliferation,	[positive role in cell proliferation,]	1.0	5	1	0	0
40506	1624	promoter by nuclear trans-acting factor	[promoters by nuclear trans-acting factors]	1.0	5	1	0	0
40507	1624	subsequent addition of H2 agonist	[subsequent addition of H2 agonists]	1.0	5	1	0	0
40508	1624	non-genomic aldosterone	[non-genomic aldosterone]	1.0	2	1	0	0
40509	1624	use fac	[Using FACS]	1.0	2	1	0	0
40510	1624	50 kb	[50 kb]	1.0	2	1	0	0
40511	1624	thyroid disease	[thyroid disease]	1.0	2	2	1	1
40512	1624	negative-acting sequence	[negative-acting sequences]	1.0	2	1	0	0
40513	1624	c-jun induction	[c-jun induction]	1.0	2	2	1	1
40514	1624	soot particle	[soot particle]	1.0	2	1	0	0
40515	1624	atra washed,	[ATRA washed,]	1.0	2	1	0	0
40516	1624	phytohemagglutin pha	[phytohemagglutin PHA]	1.0	2	1	0	0
40517	1624	gata-3 protein	[GATA-3 protein]	1.0	2	2	1	1
40518	1624	delta sequence	[delta sequence]	1.0	2	1	0	0
40519	1624	affinity column fraction, approximately 12-fold	[affinity column fraction, approximately 12-fold]	1.0	5	1	0	0
40520	1624	cellular membrane	[cellular membrane]	1.0	2	1	0	0
40521	1624	calcineurin mutant	[Calcineurin mutants]	1.0	2	1	0	0
40522	1624	interleukin-1 gene	[interleukin-1 genes]	1.0	2	1	0	0
40523	1624	activation, coincident with rante expression	[activation, coincident with RANTES expression]	1.0	5	1	0	0
40524	1624	model, cell	[model, cells]	1.0	2	1	0	0
40525	1624	repression of class transactivator mrna expression	[Repression of class transactivator mRNA expression]	1.0	6	1	0	0
40526	1624	tri-molecular complex	[tri-molecular complex]	1.0	2	1	0	0
40527	1624	t-lymphocyte differentiation	[T-lymphocyte differentiation]	1.0	2	1	0	0
40528	1624	human immunodeficiency virus hodgkin' disease	[Human immunodeficiency virus Hodgkin's disease]	1.0	5	2	1	1
40529	1624	non-syntenic locus	[non-syntenic locus]	1.0	2	1	0	0
40530	1624	that: (1) induction of c-jun	[that: (1) induction of c-jun]	1.0	5	1	0	0
40531	1624	peptide contain amino acid side chain	[peptides containing amino acid side chains]	1.0	6	1	0	0
40532	1624	weakly c-jun	[weakly c-jun]	1.0	2	1	0	0
40533	1624	cytosolic preparation from rat tissue	[cytosolic preparations from rat tissues]	1.0	5	1	0	0
40534	1624	c-myc protein	[c-myc protein]	1.0	2	1	0	0
40535	1624	LY294002 study	[LY294002 study]	1.0	2	1	0	0
40536	1624	lef-1 among T cell-specific transcription factor	[LEF-1 among T cell-specific transcription factors]	1.0	6	1	0	0
40537	1624	multiple copy of the p sequence	[multiple copies of the P sequence]	1.0	6	1	0	0
40538	1624	insulin secretion from beta cell	[insulin secretion from beta cells]	1.0	5	1	0	0
40539	1624	induction of the GM-CSF gene	[induction of the GM-CSF gene]	1.0	5	2	1	1
40540	1624	CD4 expression	[CD4 expression]	1.0	2	1	0	0
40541	1624	progress define the tyrosine kinase	[progress defining the tyrosine kinases]	1.0	5	1	0	0
40542	1624	nuclei of cd3+/cd4+ T cell	[nuclei of CD3+/CD4+ T cells]	1.0	5	1	0	0
40543	1624	colony-stimumulatelany-stg factor 1 macrophage colony-stimulating factor	[colony-stimulating factor 1 macrophage colony-stimulating factor]	1.0	6	1	0	0
40544	1624	development of secondary lymphoid tissue	[Development of secondary lymphoid tissues]	1.0	5	1	0	0
40545	1624	human b cell nuclear extract	[human B cell nuclear extract]	1.0	5	1	0	0
40546	1624	T cell from lupus patient	[T cells from lupus patients]	1.0	5	1	0	0
40547	1624	abnormal glucocorticoid receptor on lymphocyte	[abnormal glucocorticoid receptors on lymphocytes]	1.0	5	1	0	0
40548	1624	multifocal cancer of the colon,	[multifocal cancer of the colon,]	1.0	5	1	0	0
40549	1624	peptide antigen	[peptide antigen]	1.0	2	1	0	0
40550	1624	activate agents.	[activating agents.]	1.0	2	1	0	0
40551	1624	human immunodeficiency virus hiv entry	[human immunodeficiency virus HIV entry]	1.0	5	1	0	0
40552	1624	rpo gene	[rpoS gene]	1.0	2	1	0	0
40553	1624	use e1a- adenovirus (ad) type vector	[using E1a- adenovirus (Ad) type vectors]	1.0	6	1	0	0
40554	1624	upstream of a CAT reporter	[upstream of a CAT reporter]	1.0	5	1	0	0
40555	1624	putative novel cancer related loci relevant	[putative novel cancer related loci relevant]	1.0	6	1	0	0
40556	1624	30 year	[30 years]	1.0	2	1	0	0
40557	1624	physical interaction between Ets NF-kappaB/NFAT protein	[Physical interactions between Ets NF-kappaB/NFAT proteins]	1.0	6	1	0	0
40558	1624	nuclear translocation of NF-kappa b	[nuclear translocation of NF-kappa B]	1.0	5	1	0	0
40559	1624	increase of il-2r alpha gene transcription	[Increase of IL-2R alpha gene transcription]	1.0	6	1	0	0
40560	1624	3'- end of the silencer,	[3'- ends of the silencer,]	1.0	5	1	0	0
40561	1624	IFN-beta synthesis	[IFN-beta synthesis]	1.0	2	1	0	0
40562	1624	DNA affinity	[DNA affinity]	1.0	2	2	2	2
40563	1624	b cell octamer-binding protein 1/octamer-binding factor	[B cell octamer-binding protein 1/octamer-binding factor]	1.0	6	1	0	0
40564	1624	maximal induction between 1 h.	[maximal induction between 1 h,]	1.0	5	1	0	0
40565	1624	less thrombin	[less thrombin]	1.0	2	1	0	0
40566	1624	hemopoietic cell line by immunoblotting	[hemopoietic cell lines by immunoblotting]	1.0	5	1	0	0
40567	1624	use DNA template contain two copy	[using DNA templates containing two copies]	1.0	6	1	0	0
40568	1624	use a solution hybridization assay	[using a solution hybridization assay]	1.0	5	1	0	0
40569	1624	treatment of the hl60 cell	[Treatment of the HL60 cells]	1.0	5	1	0	0
40570	1624	pretreatment of monocyte with pertussis toxin	[Pretreatment of monocytes with pertussis toxin]	1.0	6	1	0	0
40571	1624	two overlap antisense rna probe	[two overlapping antisense RNA probes]	1.0	5	1	0	0
40572	1624	SLP-76 a adaptor protein functioning	[SLP-76 an adaptor protein functioning]	1.0	5	1	0	0
40573	1624	phytohemagglutinin pha	[phytohemagglutinin PHA]	1.0	2	1	0	0
40574	1624	importance of the cis-acting element	[importance of the cis-acting elements]	1.0	5	1	0	0
40575	1624	transcription of certain erythrocyte gene	[transcription of certain erythrocyte genes]	1.0	5	1	0	0
40576	1624	crystal structure	[crystal structures]	1.0	2	1	0	0
40577	1624	two novel lymphoma cell line	[two novel lymphoma cell lines]	1.0	5	1	0	0
40578	1624	expression of the gm-csf gene	[expression of the GM-CSF gene]	1.0	5	1	0	0
40579	1624	24-hydroxylated metabolite	[24-hydroxylated metabolites]	1.0	2	1	0	0
40580	1624	transfection of a expression vector	[Transfection of an expression vector]	1.0	5	1	0	0
40581	1624	HIV-1 Vpr	[HIV-1 Vpr]	1.0	2	1	0	0
40582	1624	hiv expression by ascorbic acid	[HIV expression by ascorbic acid]	1.0	5	1	0	0
40583	1624	30-40 min,	[30-40 min,]	1.0	2	1	0	0
40584	1624	hiv-1 multiplication	[HIV-1 multiplication]	1.0	2	1	0	0
40585	1624	biochemical marker	[biochemical marker]	1.0	2	2	2	2
40586	1624	coexpression of the N-terminal domain	[coexpression of the N-terminal domain]	1.0	5	1	0	0
40587	1624	same family	[same family]	1.0	2	1	0	0
40588	1624	avian cell	[avian cells]	1.0	2	1	0	0
40589	1624	tropical paraparesis	[tropical paraparesis]	1.0	2	2	2	2
40590	1624	mobility in gel shift assay	[mobilities in gel shift assays]	1.0	5	1	0	0
40591	1624	wild-type version	[wild-type version]	1.0	2	1	0	0
40592	1624	preference for the Oct2ab isoform	[preference for the Oct2ab isoforms]	1.0	5	1	0	0
40593	1624	tyrosine phosphorylation of stat 3	[tyrosine phosphorylation of STATs 3]	1.0	5	1	0	0
40594	1624	follow PMA	[following PMA]	1.0	2	2	1	1
40595	1624	vivo occupancy of this site	[vivo occupancy of this site]	1.0	5	1	0	0
40596	1624	immunogenic ebna	[immunogenic EBNAs]	1.0	2	1	0	0
40597	1624	interrupt the on-going lps signal	[interrupting the on-going LPS signal]	1.0	5	1	0	0
40598	1624	stimulation, neutrophil	[stimulation, neutrophils]	1.0	2	1	0	0
40599	1624	messenger mediate directly the release	[messengers mediating directly the release]	1.0	5	1	0	0
40600	1624	hematopoiesis of the bone marrow	[hematopoiesis of the bone marrow]	1.0	5	1	0	0
40601	1624	exocrine gland	[exocrine glands]	1.0	2	1	0	0
40602	1624	elongation block	[elongation block]	1.0	2	2	1	1
40603	1624	inactivation of the x chromosome	[inactivation of the X chromosome]	1.0	5	1	0	0
40604	1624	E2F-1 promoter	[E2F-1 promoter]	1.0	2	1	0	0
40605	1624	aldosterone -selectivity	[aldosterone -selectivity]	1.0	2	1	0	0
40606	1624	mouse human T cell blast	[mouse human T cell blasts]	1.0	5	1	0	0
40607	1624	eosinophil infiltrate hamster cutaneous wound	[Eosinophils infiltrating hamster cutaneous wounds]	1.0	5	1	0	0
40608	1624	follow integration	[Following integration]	1.0	2	1	0	0
40609	1624	specific role	[specific role]	1.0	2	2	2	2
40610	1624	inhibit the activation of nf-kappa b	[inhibiting the activation of NF-kappa B]	1.0	6	1	0	0
40611	1624	glycogen synthase kinase-3 in fibroblast	[glycogen synthase kinase-3 in fibroblasts]	1.0	5	1	0	0
40612	1624	other, ciita	[other, CIITA]	1.0	2	1	0	0
40613	1624	B-lymphoid-specific gene	[B-lymphoid-specific genes]	1.0	2	1	0	0
40614	1624	function- manner	[function- manner]	1.0	2	1	0	0
40615	1624	c-fo expression in human b cell	[c-fos expression in human B cells]	1.0	6	1	0	0
40616	1624	CONCLUSIONS: (1) gcs of AITL/GC	[CONCLUSIONS: (1) GCs of AITL/GC]	1.0	5	1	0	0
40617	1624	NIH 3t3 cell lack alf1	[NIH 3T3 cells lacking ALF1]	1.0	5	1	0	0
40618	1624	very low level of c-myb protein	[very low levels of c-Myb protein]	1.0	6	1	0	0
40619	1624	positive selection,	[positive selection,]	1.0	2	1	0	0
40620	1624	relationship to PML nuclear body	[relationship to PML nuclear bodies]	1.0	5	1	0	0
40621	1624	small alteration	[small alterations]	1.0	2	1	0	0
40622	1624	isoform of this transcription factor	[isoforms of this transcription factor]	1.0	5	1	0	0
40623	1624	B-cell immortalization	[B-cell immortalization]	1.0	2	2	2	2
40624	1624	haptenation of the toxic metabolite	[haptenation of the toxic metabolites]	1.0	5	1	0	0
40625	1624	substantial amount of stat5a /stat5b heterodimerization	[substantial amounts of STAT5A /STAT5B heterodimerization]	1.0	6	1	0	0
40626	1624	zinc-binding protein	[zinc-binding proteins]	1.0	2	1	0	0
40627	1624	-200 to -100 bp relative	[-200 to -100 bp relative]	1.0	5	1	0	0
40628	1624	three repeat of the nfat element	[three repeats of the NFAT element]	1.0	6	1	0	0
40629	1624	stimulation of macrophage procoagulant activity	[stimulation of macrophage procoagulant activity]	1.0	5	1	0	0
40630	1624	tax responsiveness	[Tax responsiveness]	1.0	2	1	0	0
40631	1624	hemoglobin hb	[hemoglobin Hb]	1.0	2	1	0	0
40632	1624	G1 vs. S phase prl response	[G1 vs. S phase PRL responses]	1.0	6	1	0	0
40633	1624	phase response	[phase response]	1.0	2	2	2	2
40634	1624	ets-1 function as a transcriptional activator	[ets-1 functions as a transcriptional activator]	1.0	6	1	0	0
40635	1624	nuclear oncogene	[nuclear oncogene]	1.0	2	1	0	0
40636	1624	addition down-regulate the immune response	[addition down-regulating the immune response]	1.0	5	1	0	0
40637	1624	stat6 activation in b cell	[STAT6 activation in B cells]	1.0	5	1	0	0
40638	1624	Addition of a preparation of otf-1	[Addition of a preparation of OTF-1]	1.0	6	1	0	0
40639	1624	5-fluorouracil toxicity	[5-fluorouracil toxicity]	1.0	2	1	0	0
40640	1624	B-cell commitment to plasma cell	[B-cell commitment to plasma cells]	1.0	5	1	0	0
40641	1624	egr1 regulation in b cell	[EGR1 regulation in B cells]	1.0	5	1	0	0
40642	1624	different pattern of functional response	[different patterns of functional responses]	1.0	5	1	0	0
40643	1624	recurrent abnormality in myeloproliferative disorder	[recurrent abnormality in myeloproliferative disorders]	1.0	5	1	0	0
40644	1624	new epitope	[new epitopes]	1.0	2	2	2	2
40645	1624	implication for a translational component	[implications for a translational component]	1.0	5	1	0	0
40646	1624	addition, transfection of T lymphocyte	[addition, transfection of T lymphocytes]	1.0	5	1	0	0
40647	1624	hiv-2 enhancer	[HIV-2 enhancer]	1.0	2	2	1	1
40648	1624	transition from a proliferate g1	[transition from a proliferating G1]	1.0	5	1	0	0
40649	1624	2-bp mutation	[2-bp mutation]	1.0	2	1	0	0
40650	1624	weak agonist	[weak agonist]	1.0	2	1	0	0
40651	1624	Elf-1 transcription	[Elf-1 transcription]	1.0	2	2	2	2
40652	1624	complex common	[complexes common]	1.0	2	2	2	2
40653	1624	differential accumulation of the mrna	[differential accumulation of the mRNA]	1.0	5	1	0	0
40654	1624	regulation of interferon-gamma gene expression	[Regulation of interferon-gamma gene expression]	1.0	5	1	0	0
40655	1624	adult hematopoiesis	[adult hematopoiesis]	1.0	2	2	2	2
40656	1624	significant decrease in the percentage	[significant decrease in the percentage]	1.0	5	1	0	0
40657	1624	suggest operational in T lymphocyte as	[suggesting operational in T lymphocytes as]	1.0	6	1	0	0
40658	1624	transcription of the c-rel gene	[transcription of the c-rel gene]	1.0	5	1	0	0
40659	1624	individual e-box	[individual E-boxes]	1.0	2	1	0	0
40660	1624	blot assay	[blot assay]	1.0	2	2	2	2
40661	1624	human pancreatitis	[human pancreatitis]	1.0	2	1	0	0
40662	1624	produce the transcriptional regulating protein fos	[producing the transcriptional regulating proteins Fos]	1.0	6	1	0	0
40663	1624	addition, mutation	[addition, mutation]	1.0	2	1	0	0
40664	1624	glucocorticoid metabolism in the asthmatics	[glucocorticoid metabolism in the asthmatics]	1.0	5	1	0	0
40665	1624	human ciita in the pig	[human CIITA in the pig]	1.0	5	1	0	0
40666	1624	26 primary ovarian carcinoma patient	[26 primary ovarian carcinoma patients]	1.0	5	1	0	0
40667	1624	cell in the granulocyte-macrophage lineage	[cells in the granulocyte-macrophage lineage]	1.0	5	1	0	0
40668	1624	responsiveness to il-4 of transfectant	[responsiveness to IL-4 of transfectants]	1.0	5	1	0	0
40669	1624	acute exposure	[acute exposure]	1.0	2	2	2	2
40670	1624	immune response to foreign antigens.	[immune responses to foreign antigens.]	1.0	5	1	0	0
40671	1624	plastic multidish	[plastic multidishes]	1.0	2	1	0	0
40672	1624	primary precursor	[primary precursors]	1.0	2	2	1	1
40673	1624	cognate interaction between T cell	[cognate interaction between T cells]	1.0	5	1	0	0
40674	1624	729-6 b	[729-6 B]	1.0	2	1	0	0
40675	1624	digital image	[digital image]	1.0	2	1	0	0
40676	1624	6 microm	[6 microM]	1.0	2	1	0	0
40677	1624	develop prostate cancer in man	[developing prostate cancer in men]	1.0	5	1	0	0
40678	1624	methylation-free island	[methylation-free island]	1.0	2	1	0	0
40679	1624	rflp genotype	[RFLP genotypes]	1.0	2	1	0	0
40680	1624	u937 monocytic cell to ec	[U937 monocytic cells to EC]	1.0	5	1	0	0
40681	1624	hmg box contain transcription factor	[HMG box containing transcription factors]	1.0	5	1	0	0
40682	1624	expression of IkappaBalpha in the nucleus	[Expression of IkappaBalpha in the nucleus]	1.0	6	1	0	0
40683	1624	uf-1 cell	[UF-1 cells]	1.0	2	3	2	1
40684	1624	basal human t-cell lymphotropic virus type	[basal human T-cell lymphotropic virus type]	1.0	6	1	0	0
40685	1624	concept of heterotrans-activation of JAK1	[concept of heterotrans-activation of JAK1]	1.0	5	1	0	0
40686	1624	cytokine such as interleukin (il)-2	[cytokines such as interleukin (IL)-2]	1.0	5	1	0	0
40687	1624	recombinant oct-1	[recombinant Oct-1]	1.0	2	1	0	0
40688	1624	inhibition of adenylyl cyclase by pretreatment	[Inhibition of adenylyl cyclase by pretreatment]	1.0	6	1	0	0
40689	1624	extract of nuclei from monocyte	[extracts of nuclei from monocytes]	1.0	5	1	0	0
40690	1624	Raf	[Raf]	1.0	1	11	4	4
40691	1624	reactivity to the lipophilic ligand	[reactivity to the lipophilic ligand]	1.0	5	1	0	0
40692	1624	TPA treatment of hl-60 cell	[TPA treatment of HL-60 cells]	1.0	5	1	0	0
40693	1624	gel retardation experiment with oligonucleotide	[gel retardation experiment with oligonucleotides]	1.0	5	1	0	0
40694	1624	monocyte-specific transcription of the csf-1 receptor	[monocyte-specific transcription of the CSF-1 receptor]	1.0	6	1	0	0
40695	1624	dithiothreitol dtt	[dithiothreitol DTT]	1.0	2	1	0	0
40696	1624	contain a novel enhancer-like element	[containing a novel enhancer-like element]	1.0	5	1	0	0
40697	1624	decrease in rap1 protein expression	[decrease in Rap1 protein expression]	1.0	5	1	0	0
40698	1624	cell response	[cell response]	1.0	2	2	2	2
40699	1624	27.8 kda	[27.8 kDa]	1.0	2	1	0	0
40700	1624	treatment of u937 with ifn-gamma	[Treatment of U937 with IFN-gamma]	1.0	5	1	0	0
40701	1624	Ba/F3 cell	[Ba/F3 cells]	1.0	2	2	1	1
40702	1624	steady state level of mrna	[steady state levels of mRNA]	1.0	5	2	2	2
40703	1624	synthesis of the p105 precursor	[synthesis of the p105 precursor]	1.0	5	1	0	0
40704	1624	ltb4 adhesion	[LTB4 adhesion]	1.0	2	1	0	0
40705	1624	regional localization	[regional localizations]	1.0	2	1	0	0
40706	1624	events, thrombin	[events, thrombin]	1.0	2	1	0	0
40707	1624	magnitude of this functional response	[magnitude of these functional responses]	1.0	5	1	0	0
40708	1624	individual between 20-50% of cell	[individuals between 20-50% of cells]	1.0	5	1	0	0
40709	1624	endogenous I kappa b alpha	[endogenous I kappa B alpha]	1.0	5	1	0	0
40710	1624	uncommitted T helper (th) cell	[uncommitted T helper (TH) cells]	1.0	5	1	0	0
40711	1624	filament expression	[filament expression]	1.0	2	1	0	0
40712	1624	reactivation of inactive x-chromosome material	[reactivation of inactive X-chromosome material]	1.0	5	1	0	0
40713	1624	however, long period of incubation	[However, longer periods of incubation]	1.0	5	1	0	0
40714	1624	mitogenic T cell activation signal	[mitogenic T cell activation signals]	1.0	5	1	0	0
40715	1624	cotransfection of CMV Ie gene	[Cotransfection of CMV IE genes]	1.0	5	1	0	0
40716	1624	two positive regulatory region PRRI	[two positive regulatory regions PRRI]	1.0	5	1	0	0
40717	1624	adhere cell	[adhering cells]	1.0	2	1	0	0
40718	1624	same position	[same position]	1.0	2	1	0	0
40719	1624	composition of the nf-kappab (level	[composition of the NF-kappaB (levels]	1.0	5	1	0	0
40720	1624	isoleucine lmp1 in mammalian cells,	[isoleucine LMP1 in mammalian cells,]	1.0	5	1	0	0
40721	1624	2.5 to 2.7 microg/g tissue	[2.5 to 2.7 microg/g tissue]	1.0	5	1	0	0
40722	1624	however, activation	[However, activation]	1.0	2	2	2	2
40723	1624	nucleoside diphosphate	[nucleoside diphosphate]	1.0	2	2	2	2
40724	1624	rat embryonal fibroblast ref52 cell	[rat embryonal fibroblast REF52 cells]	1.0	5	1	0	0
40725	1624	gc asthma	[GC asthma]	1.0	2	2	1	1
40726	1624	tf protein	[TF protein]	1.0	2	2	2	2
40727	1624	Time-course experiment	[Time-course experiments]	1.0	2	1	0	0
40728	1624	transcriptional ap-1	[transcriptional AP-1]	1.0	2	1	0	0
40729	1624	distinct immunostaining against at least 1	[distinct immunostaining against at least 1]	1.0	6	1	0	0
40730	1624	protein-DNA binding,	[protein-DNA binding,]	1.0	2	1	0	0
40731	1624	However, apoptosis	[However, apoptosis]	1.0	2	1	0	0
40732	1624	lipoxygenase metabolite	[lipoxygenase metabolites]	1.0	2	1	0	0
40733	1624	time-dependent increase in icam-1 mrna	[time-dependent increases in ICAM-1 mRNA]	1.0	5	1	0	0
40734	1624	lymphocyte infiltration in breast tumor	[lymphocyte infiltration in breast tumor]	1.0	5	1	0	0
40735	1624	Glucocorticoid hormone	[Glucocorticoid hormone]	1.0	2	1	0	0
40736	1624	trypsin digestion of antiandrogen receptor	[trypsin digestion of antiandrogen receptor]	1.0	5	1	0	0
40737	1624	activate the latent ebv genome	[activating the latent EBV genome]	1.0	5	1	0	0
40738	1624	subfamily of the ets family	[subfamily of the Ets family]	1.0	5	1	0	0
40739	1624	contain the Epstein-Barr virus cp promoter	[containing the Epstein-Barr virus Cp promoter]	1.0	6	1	0	0
40740	1624	cytoplasmic rela	[cytoplasmic RelA]	1.0	2	1	0	0
40741	1624	Candida albican on hiv expression	[Candida albicans on HIV expression]	1.0	5	1	0	0
40742	1624	single-stranded region.	[single-stranded region.]	1.0	2	1	0	0
40743	1624	differentiation of hiv1 u937 cell	[differentiation of HIV1 U937 cells]	1.0	5	1	0	0
40744	1624	such observations,	[such observations,]	1.0	2	1	0	0
40745	1624	measurement of gr mrna turnover	[Measurement of GR mRNA turnover]	1.0	5	1	0	0
40746	1624	[change in level of estrogen receptor	[[Changes in levels of estrogen receptor]	1.0	6	1	0	0
40747	1624	Furthermore, analysis with cd8+ T cell	[Furthermore, analysis with CD8+ T cells]	1.0	6	1	0	0
40748	1624	T cell with calcium ionophore	[T cells with calcium ionophore]	1.0	5	1	0	0
40749	1624	(auc of 211 +/- 8 nmol	[(AUC of 211 +/- 8 nmol]	1.0	6	1	0	0
40750	1624	first, tax	[First, Tax]	1.0	2	1	0	0
40751	1624	control levels,	[control levels,]	1.0	2	1	0	0
40752	1624	activator of transcription 3 STAT3	[activator of transcription 3 STAT3]	1.0	5	1	0	0
40753	1624	member of a protein family, homologous	[Members of a protein family, homologous]	1.0	6	1	0	0
40754	1624	40 60 mM d-ribose respectively.	[40 60 mM D-ribose respectively.]	1.0	5	1	0	0
40755	1624	epo stimulation of the epor	[EPO stimulation of the EPOR]	1.0	5	1	0	0
40756	1624	clinical trial	[clinical trials]	1.0	2	2	1	1
40757	1624	sem) (p	[SEM) (P]	1.0	2	1	0	0
40758	1624	potential cis-element	[potential cis-elements]	1.0	2	1	0	0
40759	1624	P- lps in the cell	[P- LPS in the cells]	1.0	5	1	0	0
40760	1624	use 100 ng/ml of il-10	[using 100 ng/ml of IL-10]	1.0	5	1	0	0
40761	1624	l-selectin of cf11/cd18 adhesion receptor	[L-selectin of CD11/CD18 adhesion receptors]	1.0	5	1	0	0
40762	1624	novel approach to the study	[novel approach to the study]	1.0	5	1	0	0
40763	1624	unique set of latent gene	[unique set of latent genes]	1.0	5	1	0	0
40764	1624	first time,	[first time,]	1.0	2	1	0	0
40765	1624	first time.	[first time.]	1.0	2	1	0	0
40766	1624	trigger of the nuclear expression	[triggering of the nuclear expression]	1.0	5	1	0	0
40767	1624	only upon exposure of hd6 cell	[only upon exposure of HD6 cells]	1.0	6	1	0	0
40768	1624	ACH-2 T cell by NAC	[ACH-2 T cells by NAC]	1.0	5	1	0	0
40769	1624	factor necessary	[factor necessary]	1.0	2	2	2	2
40770	1624	however, in contrast to GATA-1	[However, in contrast to GATA-1]	1.0	5	1	0	0
40771	1624	mrp14 macrophage migration inhibitory related protein	[MRP14 Macrophage migration inhibitory related protein]	1.0	6	1	0	0
40772	1624	TAR region	[TAR regions]	1.0	2	1	0	0
40773	1624	binding affinity of this receptor	[binding affinities of these receptors]	1.0	5	1	0	0
40774	1624	Glucocorticosteroid receptor on leukocyte of patient	[Glucocorticosteroid receptors on leukocytes of patients]	1.0	6	1	0	0
40775	1624	neuroendocrine-immune interaction	[neuroendocrine-immune interactions]	1.0	2	2	2	2
40776	1624	different surface	[different surface]	1.0	2	1	0	0
40777	1624	12 month of age, 10%	[12 months of age, 10%]	1.0	5	1	0	0
40778	1624	equivalent increase in mrna expression	[equivalent increase in mRNA expression]	1.0	5	1	0	0
40779	1624	/kbf1 p50	[/KBF1 p50]	1.0	2	1	0	0
40780	1624	important role in host defense	[important role in host defense]	1.0	5	1	0	0
40781	1624	6-8 week	[6-8 weeks]	1.0	2	2	1	1
40782	1624	combination of p49(100) nf-kappa b	[combination of p49(100) NF-kappa B]	1.0	5	1	0	0
40783	1624	mineralocorticoid of the zona glomerulosa	[mineralocorticoids of the zona glomerulosa]	1.0	5	1	0	0
40784	1624	composite cis-element	[composite cis-element]	1.0	2	1	0	0
40785	1624	such test	[Such tests]	1.0	2	1	0	0
40786	1624	gr count	[GR count]	1.0	2	2	1	1
40787	1624	viral structural protein expression gag	[viral structural protein expression Gag]	1.0	5	1	0	0
40788	1624	second phase	[second phase]	1.0	2	1	0	0
40789	1624	phenotype similar	[phenotype similar]	1.0	2	1	0	0
40790	1624	intracellular localization	[intracellular localization]	1.0	2	3	2	1
40791	1624	soluble CD4	[soluble CD4]	1.0	2	2	2	2
40792	1624	40-kda polypeptide	[40-kDa polypeptide]	1.0	2	1	0	0
40793	1624	prime nb4 cell for monocytic differentiation	[prime NB4 cells for monocytic differentiation]	1.0	6	1	0	0
40794	1624	binding to b cell enhancer site	[binding to B cell enhancer sites]	1.0	6	1	0	0
40795	1624	protein footprint	[protein footprint]	1.0	2	1	0	0
40796	1624	addition activate stat3 signal transducer	[addition activating STAT3 signal transducer]	1.0	5	1	0	0
40797	1624	brca1 allele	[BRCA1 allele]	1.0	2	2	2	2
40798	1624	mouse homologue	[mouse homologue]	1.0	2	3	2	1
40799	1624	complementary dna	[complementary DNAs]	1.0	2	2	1	1
40800	1624	two independent assays), a value	[two independent assays), a value]	1.0	5	1	0	0
40801	1624	specific dna-binding of Stat 5b	[specific DNA-binding of Stat 5b]	1.0	5	1	0	0
40802	1624	endotoxin lethality	[endotoxin lethality]	1.0	2	1	0	0
40803	1624	EB1 element	[EB1 element]	1.0	2	2	2	2
40804	1624	young sister of one patient	[young sister of one patient]	1.0	5	1	0	0
40805	1624	traf protein	[TRAF proteins]	1.0	2	2	2	2
40806	1624	antiandrogen binding	[antiandrogen binding]	1.0	2	1	0	0
40807	1624	consanguinous parent	[consanguinous parents]	1.0	2	1	0	0
40808	1624	new zinc finger transcription factor	[new zinc finger transcription factor]	1.0	5	1	0	0
40809	1624	contrast, c-fo	[contrast, c-fos]	1.0	2	1	0	0
40810	1624	myeloid cell of transgenic mouse	[myeloid cells of transgenic mice]	1.0	5	1	0	0
40811	1624	reporter construct contain different region	[reporter constructs containing different regions]	1.0	5	1	0	0
40812	1624	active nf-kappab	[active NF-kappaB]	1.0	2	1	0	0
40813	1624	dihydroxyvitamin D3	[dihydroxyvitamin D3]	1.0	2	2	1	1
40814	1624	direct sequencing of the viral genome	[Direct sequencing of the viral genomes]	1.0	6	1	0	0
40815	1624	element in the first 0.2 kb	[elements in the first 0.2 kb]	1.0	6	1	0	0
40816	1624	glucocorticoid receptor characteristic on mononuclear leukocyte	[glucocorticoid receptor characteristics on mononuclear leukocytes]	1.0	6	1	0	0
40817	1624	ebv virus	[EBV virus]	1.0	2	1	0	0
40818	1624	include c-jun	[including c-jun]	1.0	2	2	2	2
40819	1624	obligate carrier	[obligate carriers]	1.0	2	2	2	2
40820	1624	beta-galactosidase beta-gal	[beta-galactosidase beta-gal]	1.0	2	1	0	0
40821	1624	departure of the ventilatory response	[departure of the ventilatory response]	1.0	5	1	0	0
40822	1624	tnf-treated T	[TNF-treated T]	1.0	2	1	0	0
40823	1624	effect of 100 nm dexamethasone	[effects of 100 nM dexamethasone]	1.0	5	1	0	0
40824	1624	human cd34+ erythroid progenitor cell	[human CD34+ erythroid progenitor cells]	1.0	5	1	0	0
40825	1624	calyculin a,	[calyculin A,]	1.0	2	1	0	0
40826	1624	37 degree anti-CD3 interleukin-2 secretion	[37 degrees anti-CD3 interleukin-2 secretion]	1.0	5	1	0	0
40827	1624	important cytokine for the proliferation	[important cytokines for the proliferation]	1.0	5	1	0	0
40828	1624	expression of the cytokine il-2	[expression of the cytokines IL-2]	1.0	5	1	0	0
40829	1624	novel antigen	[novel antigen]	1.0	2	1	0	0
40830	1624	synteny with mouse chromosome 3	[synteny with mouse chromosome 3]	1.0	5	1	0	0
40831	1624	implicate this kinase in the response	[implicating these kinases in the response]	1.0	6	1	0	0
40832	1624	limited proliferation	[limited proliferation]	1.0	2	1	0	0
40833	1624	change affect the viral LTR	[changes affecting the viral LTR]	1.0	5	1	0	0
40834	1624	one patient with incomplete androgen insensitivity	[One patient with incomplete androgen insensitivity]	1.0	6	1	0	0
40835	1624	metastatic suppressor	[metastatic suppressor]	1.0	2	1	0	0
40836	1624	two b cell membrane protein	[two B cell membrane proteins]	1.0	5	1	0	0
40837	1624	breakdown of IkappaBbeta in T lymphocyte	[breakdown of IkappaBbeta in T lymphocytes]	1.0	6	1	0	0
40838	1624	significant difference in the amount	[significant difference in the amounts]	1.0	5	1	0	0
40839	1624	parental line	[parental line]	1.0	2	2	1	1
40840	1624	Src	[Src]	1.0	1	11	4	4
40841	1624	high level of vitamin d receptor	[high levels of vitamin D receptor]	1.0	6	1	0	0
40842	1624	beta-sheet conformation	[beta-sheet conformation]	1.0	2	1	0	0
40843	1624	antitumor immune response in patient	[antitumor immune responses in patients]	1.0	5	1	0	0
40844	1624	rest of the Y chromosome	[rest of the Y chromosome]	1.0	5	1	0	0
40845	1624	lai expression	[LAI expression]	1.0	2	1	0	0
40846	1624	use immunostaining of cytospin preparation	[using immunostaining of cytospin preparations]	1.0	5	1	0	0
40847	1624	pcl gamma 1 tyrosine phosphorylation	[PCL gamma 1 tyrosine phosphorylation]	1.0	5	1	0	0
40848	1624	primary culture of lymphocytic leukemia	[primary cultures of lymphocytic leukemia]	1.0	5	1	0	0
40849	1624	benefit	[benefit]	1.0	1	11	9	9
40850	1624	hematopoietic tissue from this mouse	[Hematopoietic tissues from these mice]	1.0	5	1	0	0
40851	1624	inhibition of immunodeficiency virus type replication	[Inhibition of immunodeficiency virus type replication]	1.0	6	2	2	2
40852	1624	contain the PYBF -binding site	[containing the PYBF -binding site]	1.0	5	1	0	0
40853	1624	high ligand	[high ligand]	1.0	2	1	0	0
40854	1624	lymphocyte aggregation	[lymphocyte aggregation]	1.0	2	1	0	0
40855	1624	molecular basis for cytokine redundancy	[molecular bases for cytokine redundancy]	1.0	5	1	0	0
40856	1624	exchangeable ca2+	[exchangeable Ca2+]	1.0	2	2	2	2
40857	1624	reticulocyte-type 15-lipoxygenase	[reticulocyte-type 15-lipoxygenase]	1.0	2	2	2	2
40858	1624	different conditions.	[different conditions.]	1.0	2	1	0	0
40859	1624	Mpl receptor	[Mpl receptor]	1.0	2	1	0	0
40860	1624	C-terminal activating	[C-terminal activating]	1.0	2	1	0	0
40861	1624	eight family	[eight families]	1.0	2	1	0	0
40862	1624	further evidence important in malignant transformation	[further evidence important in malignant transformation]	1.0	6	1	0	0
40863	1624	p38 jun-B	[p38 jun-B]	1.0	2	1	0	0
40864	1624	indicate a subtle down-regulatory effect.	[indicating a subtle down-regulatory effect.]	1.0	5	1	0	0
40865	1624	existence of a DHEA receptor	[existence of a DHEA receptor]	1.0	5	1	0	0
40866	1624	requirement in normal erythroid development	[requirement in normal erythroid development]	1.0	5	1	0	0
40867	1624	enhancerless plasmid	[enhancerless plasmids]	1.0	2	1	0	0
40868	1624	endogenous ligand	[endogenous ligands]	1.0	2	1	0	0
40869	1624	fetal/adult gene	[fetal/adult genes]	1.0	2	1	0	0
40870	1624	show a direct effect of hgata-3	[showing a direct effect of hGATA-3]	1.0	6	1	0	0
40871	1624	growth-modulating effect	[growth-modulating effect]	1.0	2	1	0	0
40872	1624	synthetic retinoid	[synthetic retinoid]	1.0	2	2	1	1
40873	1624	dimethyl sulfate	[dimethyl sulfate]	1.0	2	1	0	0
40874	1624	mutual association of signal transducing protein	[Mutual association of signal transducing proteins]	1.0	6	1	0	0
40875	1624	regulation of cd95 efas) ligand expression	[Regulation of CD95 (Fas) ligand expression]	1.0	6	1	0	0
40876	1624	T cytokine	[T cytokines]	1.0	2	1	0	0
40877	1624	age young than 40 years,	[age younger than 40 years,]	1.0	5	1	0	0
40878	1624	eicosanoid generation	[eicosanoid generation]	1.0	2	1	0	0
40879	1624	intermediate calcineurin	[intermediate calcineurin]	1.0	2	1	0	0
40880	1624	moreover, il-10	[Moreover, IL-10]	1.0	2	1	0	0
40881	1624	chemokine important for leucocyte recruitment	[chemokine important for leucocyte recruitment]	1.0	5	1	0	0
40882	1624	human erythropoietin	[human erythropoietin]	1.0	2	1	0	0
40883	1624	vascular remodeling	[vascular remodeling]	1.0	2	1	0	0
40884	1624	diverse group	[diverse group]	1.0	2	2	2	2
40885	1624	pathophysiologic events, include granuloma formation	[pathophysiologic events, including granuloma formation]	1.0	5	1	0	0
40886	1624	mad3 mrna	[MAD3 mRNA]	1.0	2	1	0	0
40887	1624	offersugg a new aspect of down-regulation	[offersuggesting a new aspect of down-regulation]	1.0	6	1	0	0
40888	1624	318 pmol/L).	[318 pmol/L).]	1.0	2	1	0	0
40889	1624	311% increase in the mbc	[311% increase in the MBC]	1.0	5	1	0	0
40890	1624	response to NK cell activation	[response to NK cell activation]	1.0	5	1	0	0
40891	1624	patient suffer from ataxia telangiectasia	[patients suffering from ataxia telangiectasia]	1.0	5	1	0	0
40892	1624	oligonucleotide of this binding site	[oligonucleotide of this binding site]	1.0	5	1	0	0
40893	1624	same conditions,	[same conditions,]	1.0	2	1	0	0
40894	1624	alpha4 integrin	[alpha4 integrin]	1.0	2	1	0	0
40895	1624	Fibroblast growth	[Fibroblast growth]	1.0	2	2	2	2
40896	1624	noncanonical egr	[noncanonical Egr]	1.0	2	1	0	0
40897	1624	HTLV-I tax with the proteasome	[HTLV-I Tax with the proteasome]	1.0	5	1	0	0
40898	1624	role in foam cell formation	[role in foam cell formation]	1.0	5	1	0	0
40899	1624	727 phosphorylation	[727 phosphorylation]	1.0	2	1	0	0
40900	1624	Dihydroxyvitamin D3	[Dihydroxyvitamin D3]	1.0	2	2	2	2
40901	1624	cortisol receptor	[cortisol receptor]	1.0	2	2	2	2
40902	1624	mumol/L pdtc	[mumol/L PDTC]	1.0	2	2	2	2
40903	1624	nf-kappab protein	[NF-kappaB proteins]	1.0	2	2	2	2
40904	1624	IL-2 patient	[IL-2 patients]	1.0	2	1	0	0
40905	1624	human retinoic acid receptor alpha	[human retinoic acid receptor alpha]	1.0	5	2	2	2
40906	1624	healthy T cell in vitro	[healthy T cells in vitro]	1.0	5	1	0	0
40907	1624	physiologic repressor	[physiologic repressor]	1.0	2	1	0	0
40908	1624	RXR-alpha mrna	[RXR-alpha mRNA]	1.0	2	1	0	0
40909	1624	bear dqa1*0201 in comparison to DQA1*0501	[bearing DQA1*0201 in comparison to DQA1*0501]	1.0	6	1	0	0
40910	1624	other sequence	[other sequences]	1.0	2	2	1	1
40911	1624	critical interaction	[critical interaction]	1.0	2	1	0	0
40912	1624	study of G0S2 a member	[studies of G0S2 a member]	1.0	5	1	0	0
40913	1624	NF-kappa b -dependent granulocyte-macrophage colony	[NF-kappa B -dependent granulocyte-macrophage colony]	1.0	5	1	0	0
40914	1624	p24 production by hiv macrophage	[p24 production by HIV macrophages]	1.0	5	1	0	0
40915	1624	vivo genomic DMS footprinting upstream	[vivo genomic DMS footprinting upstream]	1.0	5	1	0	0
40916	1624	JNK pathway	[JNK pathway]	1.0	2	1	0	0
40917	1624	similar masses;	[similar masses;]	1.0	2	1	0	0
40918	1624	decisive role.	[decisive role.]	1.0	2	1	0	0
40919	1624	hiv-1 patient	[HIV-1 patients]	1.0	2	2	2	2
40920	1624	induce mnp-1 expression in t-cell	[inducing MNP-1 expression in T-cells]	1.0	5	1	0	0
40921	1624	induce 135(oh)2d3 degradation through enhancement	[inducing 1,25(OH)2D3 degradation through enhancement]	1.0	5	1	0	0
40922	1624	Trident mrna	[Trident mRNA]	1.0	2	1	0	0
40923	1624	zn sod	[Zn SOD]	1.0	2	1	0	0
40924	1624	basis define the operational characteristic	[basis defining the operational characteristics]	1.0	5	1	0	0
40925	1624	nuclear p62c-fo	[nuclear p62c-fos]	1.0	2	2	1	1
40926	1624	Angiotensin ii	[Angiotensin II]	1.0	2	1	0	0
40927	1624	downstream target	[downstream targets]	1.0	2	1	0	0
40928	1624	express progenitor	[expressing progenitors]	1.0	2	1	0	0
40929	1624	nucleocytoplasmic translocation	[nucleocytoplasmic translocation]	1.0	2	1	0	0
40930	1624	patient with t-cell acute leukemia	[patients with T-cell acute leukemia]	1.0	5	2	2	2
40931	1624	mutation of the variant octamer motif	[mutation of the variant octamer motif]	1.0	6	1	0	0
40932	1624	role of mammalian runt product	[role of mammalian runt products]	1.0	5	1	0	0
40933	1624	sexual difference in the incidence	[sexual difference in the incidence]	1.0	5	1	0	0
40934	1624	proline- region at COOH terminus	[proline- region at COOH terminus]	1.0	5	1	0	0
40935	1624	ptk substrate	[PTK substrate]	1.0	2	2	1	1
40936	1624	instructive fashion	[instructive fashion]	1.0	2	1	0	0
40937	1624	deletion of two ccaat box	[deletion of two CCAAT boxes]	1.0	5	1	0	0
40938	1624	lack the gene encode EBNA 2	[lacking the gene encoding EBNA 2]	1.0	6	1	0	0
40939	1624	Paget's disease	[Paget's disease]	1.0	2	1	0	0
40940	1624	i of type ii receptor	[I of Type II receptors]	1.0	5	1	0	0
40941	1624	positive response	[positive response]	1.0	2	1	0	0
40942	1624	simultaneous early expression of BZLF-1	[simultaneous early expression of BZLF-1]	1.0	5	1	0	0
40943	1624	classical prognostic features: clinical implications.	[classical prognostic features: clinical implications.]	1.0	5	1	0	0
40944	1624	interaction between the canonical gata site	[Interactions between the canonical GATA site]	1.0	6	1	0	0
40945	1624	155 kD.	[155 kD.]	1.0	2	1	0	0
40946	1624	physiological regulator of the activity	[physiological regulator of the activity]	1.0	5	1	0	0
40947	1624	control of simian virus 40	[control of simian virus 40]	1.0	5	1	0	0
40948	1624	Burkitt lymphoma	[Burkitt lymphoma]	1.0	2	2	1	1
40949	1624	previous assumptions,	[previous assumptions,]	1.0	2	1	0	0
40950	1624	chromatin from uninfected T lymphocyte	[chromatin from uninfected T lymphocytes]	1.0	5	1	0	0
40951	1624	molecular biology	[molecular biology]	1.0	2	1	0	0
40952	1624	496 clinical stage I-II patient	[496 clinical Stage I-II patients]	1.0	5	1	0	0
40953	1624	cell death of hematopoietic precurser	[cell death of hematopoietic precursers]	1.0	5	1	0	0
40954	1624	il-2-deprived cell	[IL-2-deprived cells]	1.0	2	1	0	0
40955	1624	deletion of NF kappa b	[deletion of NF kappa B]	1.0	5	1	0	0
40956	1624	include c-myc	[including c-myc]	1.0	2	1	0	0
40957	1624	different gc at therapeutic concentration	[different GC at therapeutic concentrations]	1.0	5	1	0	0
40958	1624	expression of the fos protein	[expression of the FOS proteins]	1.0	5	1	0	0
40959	1624	include 11 zinc finger motif	[including 11 zinc finger motifs]	1.0	5	1	0	0
40960	1624	modulation of function of nuclear protein	[modulation of functions of nuclear proteins]	1.0	6	1	0	0
40961	1624	lead to the conversion from latent	[leading to the conversion from latent]	1.0	6	1	0	0
40962	1624	exon 5007+2insA	[exon 5007+2insA]	1.0	2	1	0	0
40963	1624	ap-1-related protein	[AP-1-related protein]	1.0	2	2	1	1
40964	1624	electrolyte abnormality	[electrolyte abnormalities]	1.0	2	1	0	0
40965	1624	relative quantification of specific mrna	[relative quantification of specific mRNA]	1.0	5	1	0	0
40966	1624	stimulation, mrna from T lymphocyte	[stimulation, mRNA from T lymphocytes]	1.0	5	1	0	0
40967	1624	sp1 binding	[Sp1 binding]	1.0	2	2	2	2
40968	1624	ebna2-dependent enhancer	[EBNA2-dependent enhancer]	1.0	2	2	1	1
40969	1624	critical role in platelet activation	[critical role in platelet activation]	1.0	5	1	0	0
40970	1624	recombinant adenovirus	[recombinant adenovirus]	1.0	2	1	0	0
40971	1624	putative binding site for sp1	[putative binding sites for Sp1]	1.0	5	1	0	0
40972	1624	powerful skewer induce ifn-gamma production	[powerful skewer inducing IFN-gamma production]	1.0	5	1	0	0
40973	1624	fos heterodimer	[Fos heterodimers]	1.0	2	1	0	0
40974	1624	fibrillar collagen	[fibrillar collagen]	1.0	2	1	0	0
40975	1624	sensitive patient	[sensitive patients]	1.0	2	1	0	0
40976	1624	gcrbeta immunoreactivity	[GCRbeta immunoreactivity]	1.0	2	1	0	0
40977	1624	EMSA displacement study with sp1	[EMSA displacement studies with Sp1]	1.0	5	1	0	0
40978	1624	further evidence to previous observation	[further evidence to previous observations]	1.0	5	1	0	0
40979	1624	human fosb	[human FOSB]	1.0	2	1	0	0
40980	1624	phagocytic ability	[phagocytic ability]	1.0	2	1	0	0
40981	1624	L cell	[L cells]	1.0	2	1	0	0
40982	1624	t-cell-specific expression	[T-cell-specific expression]	1.0	2	2	1	1
40983	1624	rna polymerase ii transcription system	[RNA polymerase II transcription systems]	1.0	5	2	2	2
40984	1624	only occasionally in mantle cell lymphoma	[only occasionally in mantle cell lymphoma]	1.0	6	1	0	0
40985	1624	stat-6-binding site	[STAT-6-binding site]	1.0	2	1	0	0
40986	1624	Ad-infected cell	[Ad-infected cells]	1.0	2	1	0	0
40987	1624	inhibit inducible protein kinase c activity	[inhibiting inducible protein kinase C activity]	1.0	6	1	0	0
40988	1624	similar conditions.	[similar conditions.]	1.0	2	2	1	1
40989	1624	chromosome 20q in polycythemia vera	[chromosome 20q in polycythemia vera]	1.0	5	1	0	0
40990	1624	reticuloendotheliosis virus long terminal repeat element	[Reticuloendotheliosis virus long terminal repeat elements]	1.0	6	1	0	0
40991	1624	Recent isolation of the CD11b promoter	[Recent isolation of the CD11b promoter]	1.0	6	1	0	0
40992	1624	specifically in thymic T cell	[specifically in thymic T cells]	1.0	5	1	0	0
40993	1624	early stage of b-cell differentiation	[early stages of B-cell differentiation]	1.0	5	1	0	0
40994	1624	tnfalpha production	[TNFalpha production]	1.0	2	1	0	0
40995	1624	potent antioxidant for hydroxyl radical	[potent antioxidant for hydroxyl radicals]	1.0	5	1	0	0
40996	1624	alteration of gene transcription by inhibition	[Alteration of gene transcription by inhibition]	1.0	6	1	0	0
40997	1624	9.5+/-0.3 nmol/L)	[9.5+/-0.3 nmol/L)]	1.0	2	1	0	0
40998	1624	breast conservation	[breast conservation]	1.0	2	1	0	0
40999	1624	contrast, protein kinase c stimulation	[contrast, protein kinase C stimulation]	1.0	5	1	0	0
41000	1624	important mediator of th1-type response	[important mediators of Th1-type responses]	1.0	5	1	0	0
41001	1624	role regulate hiv-1 gene expression	[role regulating HIV-1 gene expression]	1.0	5	1	0	0
41002	1624	leucine-zipper motif	[leucine-zipper motif]	1.0	2	1	0	0
41003	1624	microvessel cell	[microvessel cells]	1.0	2	2	2	2
41004	1624	tissue hypoxia	[tissue hypoxia]	1.0	2	1	0	0
41005	1624	gene activity,	[gene activity,]	1.0	2	1	0	0
41006	1624	pax-5 gene	[PAX-5 gene]	1.0	2	1	0	0
41007	1624	suppressive action	[suppressive action]	1.0	2	2	1	1
41008	1624	plasma IFN alpha on monocyte	[plasma IFN alpha on monocytes]	1.0	5	1	0	0
41009	1624	polyclonal b	[polyclonal B]	1.0	2	2	1	1
41010	1624	chromosome 15	[chromosome 15]	1.0	2	1	0	0
41011	1624	presumably by inhibition of calcineurin activity	[presumably by inhibition of calcineurin activity]	1.0	6	1	0	0
41012	1624	phenotypic expression	[phenotypic expression]	1.0	2	1	0	0
41013	1624	chromosome 20	[chromosome 20]	1.0	2	1	0	0
41014	1624	response to cell cycle control	[response to cell cycle controls]	1.0	5	1	0	0
41015	1624	activation of the il-2 receptor (il-2r)	[activation of the IL-2 receptor (IL-2R)]	1.0	6	1	0	0
41016	1624	cell-specific interaction at the octamer site	[cell-specific interaction at the octamer site]	1.0	6	1	0	0
41017	1624	biological oxidation	[biological oxidation]	1.0	2	1	0	0
41018	1624	neuronal differentiation	[neuronal differentiation]	1.0	2	1	0	0
41019	1624	receptor clustering.	[receptor clustering.]	1.0	2	1	0	0
41020	1624	stimulate the release of chemotactic cytokine	[stimulating the release of chemotactic cytokines]	1.0	6	1	0	0
41021	1624	(mnl) of 10 patient with pco	[(MNL) of 10 patients with PCOS]	1.0	6	1	0	0
41022	1624	IgE germline promoter reporter gene construct	[IgE germline promoter reporter gene constructs]	1.0	6	1	0	0
41023	1624	structural gene	[structural gene]	1.0	2	1	0	0
41024	1624	gm-csf 12%;	[GM-CSF 12%;]	1.0	2	1	0	0
41025	1624	interaction between product of this loci	[interactions between products of these loci]	1.0	6	1	0	0
41026	1624	Anetholdithiolthione ADT	[Anetholdithiolthione ADT]	1.0	2	1	0	0
41027	1624	ability of eosinophil granule protein	[ability of eosinophil granule protein]	1.0	5	1	0	0
41028	1624	low doses.	[lower doses.]	1.0	2	1	0	0
41029	1624	combination of a novel inhibitor	[combination of a novel inhibitor]	1.0	5	1	0	0
41030	1624	cyclosporin treatment	[cyclosporin treatment]	1.0	2	1	0	0
41031	1624	24 all of the null	[24 ALL of the null]	1.0	5	1	0	0
41032	1624	suggest independent of p23 a molecule	[suggesting independent of p23 a molecule]	1.0	6	1	0	0
41033	1624	mouse AML1/ PEBP2 alpha b	[mouse AML1/ PEBP2 alpha B]	1.0	5	1	0	0
41034	1624	two dose of budesonide bud	[two doses of budesonide BUD]	1.0	5	1	0	0
41035	1624	promoter of cell type-specific gene	[promoters of cell type-specific genes]	1.0	5	1	0	0
41036	1624	other gene,	[other gene,]	1.0	2	1	0	0
41037	1624	stage -specific expression of CD20	[stage -specific expression of CD20]	1.0	5	1	0	0
41038	1624	secondary neutrophilia	[secondary neutrophilia]	1.0	2	2	1	1
41039	1624	selection of differential therapeutic strategy	[selection of differential therapeutic strategies]	1.0	5	1	0	0
41040	1624	cotransfection of a hGATA-3 expression plasmid	[Cotransfection of an hGATA-3 expression plasmid]	1.0	6	1	0	0
41041	1624	MHC-I ligation	[MHC-I ligation]	1.0	2	1	0	0
41042	1624	pharmacological concentration	[pharmacological concentration]	1.0	2	2	1	1
41043	1624	proteasome activation	[proteasome activation]	1.0	2	2	1	1
41044	1624	activator act	[activator acting]	1.0	2	1	0	0
41045	1624	function of the transactivation domain	[function of the transactivation domain]	1.0	5	1	0	0
41046	1624	addition of anti- icam-1 antibody	[addition of anti- ICAM-1 antibodies]	1.0	5	1	0	0
41047	1624	high level in b cell	[high levels in B cells]	1.0	5	1	0	0
41048	1624	reactive hyperplasia	[reactive hyperplasia]	1.0	2	2	2	2
41049	1624	Recent analysis of gene-targeted mouse	[Recent analysis of gene-targeted mice]	1.0	5	1	0	0
41050	1624	cysteine thiol	[cysteine thiols]	1.0	2	2	1	1
41051	1624	memory phenotype	[memory phenotype]	1.0	2	1	0	0
41052	1624	same regions.	[same regions.]	1.0	2	1	0	0
41053	1624	effect on IL-2 gene expression	[effect on IL-2 gene expression]	1.0	5	2	2	2
41054	1624	important role augment antitumor immunity	[important role augmenting antitumor immunity]	1.0	5	1	0	0
41055	1624	transactivation of the reporter gene luciferase	[transactivation of the reporter gene luciferase]	1.0	6	1	0	0
41056	1624	functional assay	[functional assays]	1.0	2	1	0	0
41057	1624	celiac sprue	[celiac sprue]	1.0	2	1	0	0
41058	1624	severe thrombocytopenia	[severe thrombocytopenia]	1.0	2	1	0	0
41059	1624	a (of ebv type 1	[A (of EBV type 1]	1.0	5	1	0	0
41060	1624	inflammation, for example, rheumatoid synovitis,	[inflammation, for example, rheumatoid synovitis,]	1.0	5	1	0	0
41061	1624	egr2 (maximal	[EGR2 (maximal]	1.0	2	1	0	0
41062	1624	il-13-induced regulatory factor in monocyte	[IL-13-induced regulatory factors in monocytes]	1.0	5	1	0	0
41063	1624	kappa b motif -specific activity	[kappa B motif -specific activity]	1.0	5	1	0	0
41064	1624	other application	[Other applications]	1.0	2	1	0	0
41065	1624	Specific inhibitor of p70(S6)-kinase rapamycin	[Specific inhibitors of p70(S6)-kinase rapamycin]	1.0	5	1	0	0
41066	1624	base level of c/ebp epsilon	[base levels of C/EBP epsilon]	1.0	5	1	0	0
41067	1624	LBR gene	[LBR gene]	1.0	2	1	0	0
41068	1624	formation of a transcription complex	[formation of a transcription complex]	1.0	5	1	0	0
41069	1624	vitro-translated protein	[vitro-translated proteins]	1.0	2	1	0	0
41070	1624	9-cis retinoic acid 9-cis RA	[9-cis retinoic acid 9-cis RA]	1.0	5	1	0	0
41071	1624	Oct-2 responsivity to tpa /ca2+	[Oct-2 responsivity to TPA /Ca2+]	1.0	5	1	0	0
41072	1624	clonal assay	[Clonal assay]	1.0	2	1	0	0
41073	1624	differentiation of t-helper (th) cell	[differentiation of T-helper (Th) cells]	1.0	5	1	0	0
41074	1624	rather low surface icam-1 expression	[rather low surface ICAM-1 expression]	1.0	5	1	0	0
41075	1624	Surprisingly, multimer of kappa 1-kappa 3	[Surprisingly, multimers of kappa 1-kappa 3]	1.0	6	1	0	0
41076	1624	optimum binding	[optimum binding]	1.0	2	1	0	0
41077	1624	virus such as Epstein-Barr virus	[viruses such as Epstein-Barr virus]	1.0	5	1	0	0
41078	1624	eosinophilia such as chronic asthma	[eosinophilia such as chronic asthma]	1.0	5	1	0	0
41079	1624	94 kda	[94 kDa]	1.0	2	1	0	0
41080	1624	ige concentratio	[IgE concentratios]	1.0	2	1	0	0
41081	1624	time, by a unknown mechanism,	[time, by an unknown mechanism,]	1.0	5	1	0	0
41082	1624	abundant protein	[abundant protein]	1.0	2	2	2	2
41083	1624	technique of transcription-polymerase chain reaction	[technique of transcription-polymerase chain reaction]	1.0	5	1	0	0
41084	1624	T cell during ebv infection	[T cells during EBV infection]	1.0	5	1	0	0
41085	1624	(range, (range,	[(range, (range,]	1.0	2	2	2	2
41086	1624	nf-kb expression	[NF-KB expression]	1.0	2	2	2	2
41087	1624	product of the proto-oncogene c-rel	[product of the proto-oncogene c-rel]	1.0	5	1	0	0
41088	1624	transcriptional elongation	[transcriptional elongation]	1.0	2	1	0	0
41089	1624	alpha chain	[alpha chain]	1.0	2	2	2	2
41090	1624	transcription regulatory function of MZF-1	[transcription regulatory function of MZF-1]	1.0	5	1	0	0
41091	1624	clonality analysis use x-chromosome inactivation	[Clonality analysis using X-chromosome inactivation]	1.0	5	1	0	0
41092	1624	fmol/mg protein	[fmol/mg protein]	1.0	2	2	2	2
41093	1624	little tetrahydrobiopterin	[little tetrahydrobiopterin]	1.0	2	1	0	0
41094	1624	further examination.	[further examination.]	1.0	2	1	0	0
41095	1624	CD28 -signal	[CD28 -signaling]	1.0	2	1	0	0
41096	1624	one clone C3/5, CD3(+), CD4(+), CD8(-)	[One clone C3/5, CD3(+), CD4(+), CD8(-)]	1.0	6	1	0	0
41097	1624	critical mediator	[critical mediators]	1.0	2	1	0	0
41098	1624	CTLA-4 engagement by mab inhibits,	[CTLA-4 engagement by mAbs inhibits,]	1.0	5	1	0	0
41099	1624	discordant expression	[discordant expression]	1.0	2	2	1	1
41100	1624	pmn-mediated lung injury include ARDS	[PMN-mediated lung injury including ARDS]	1.0	5	1	0	0
41101	1624	hypochlorous acid	[hypochlorous acid]	1.0	2	2	1	1
41102	1624	receptor concentration in myocardial infarction	[receptor concentration in myocardial infarction]	1.0	5	1	0	0
41103	1624	human neoplasia	[human neoplasia]	1.0	2	1	0	0
41104	1624	AP-1 factor	[AP-1 factor]	1.0	2	2	1	1
41105	1624	inducible cyclosporin	[inducible cyclosporin]	1.0	2	1	0	0
41106	1624	thus, ligation of CD28 with CD80	[Thus, ligation of CD28 with CD80]	1.0	6	1	0	0
41107	1624	transcription factor with a function	[transcription factor with a function]	1.0	5	1	0	0
41108	1624	inducible activator	[inducible activator]	1.0	2	2	2	2
41109	1624	bind interaction with type-ii EBS	[binding interaction with type-II EBS]	1.0	5	1	0	0
41110	1624	E2A-HLF	[E2A-HLF]	1.0	1	11	1	1
41111	1624	new hypothesis for the etiology	[new hypothesis for the etiology]	1.0	5	1	0	0
41112	1624	eosinophilic differentiation of the progenitor cell	[eosinophilic differentiation of the progenitor cells]	1.0	6	1	0	0
41113	1624	vivo from the viral protease	[vivo from the viral protease]	1.0	5	1	0	0
41114	1624	p38 pathway	[p38 pathway]	1.0	2	2	1	1
41115	1624	[ca2+]i of fura-2-loaded T cell	[[Ca2+]i of Fura-2-loaded T cells]	1.0	5	1	0	0
41116	1624	ssb T cell in control	[SSB T cells in controls]	1.0	5	1	0	0
41117	1624	endogenous shp1	[endogenous SHP1]	1.0	2	1	0	0
41118	1624	steady state level of cd19 mrna	[steady state levels of CD19 mRNA]	1.0	6	1	0	0
41119	1624	RelB expression	[RelB expression]	1.0	2	1	0	0
41120	1624	TNT system	[TNT System]	1.0	2	1	0	0
41121	1624	chloramphenicol acetyltransferase reporter gene system	[chloramphenicol acetyltransferase reporter gene system]	1.0	5	1	0	0
41122	1624	CL response of ifn-u937 cell	[CL responses of IFN-U937 cells]	1.0	5	1	0	0
41123	1624	stimulation with a peptide with affinity	[stimulation with a peptide with affinity]	1.0	6	1	0	0
41124	1624	cytoplasmic domain of the receptor	[cytoplasmic domain of the receptor]	1.0	5	1	0	0
41125	1624	determine the pattern of expression	[determining the patterns of expression]	1.0	5	1	0	0
41126	1624	initial concentration	[initial concentration]	1.0	2	1	0	0
41127	1624	hiv protein	[HIV proteins]	1.0	2	1	0	0
41128	1624	stimulation of T cell with BW	[Stimulation of T cells with BW]	1.0	6	1	0	0
41129	1624	maximal inhibition	[maximal inhibition]	1.0	2	2	1	1
41130	1624	change in the binding activity	[change in the binding activity]	1.0	5	1	0	0
41131	1624	(+) tumor cell of CHD	[(+) tumor cells of CHD]	1.0	5	1	0	0
41132	1624	only a subset of signalling pathway	[only a subset of signalling pathways]	1.0	6	1	0	0
41133	1624	nuclear protein from IARC 301	[nuclear proteins from IARC 301]	1.0	5	1	0	0
41134	1624	thrombin-stimulated platelet	[thrombin-stimulated platelets]	1.0	2	2	2	2
41135	1624	subnuclear fractionation	[Subnuclear fractionation]	1.0	2	1	0	0
41136	1624	five animal	[five animals]	1.0	2	1	0	0
41137	1624	Specific receptor for 1,25 Dihydroxyvitamin D3	[Specific receptors for 1,25 Dihydroxyvitamin D3]	1.0	6	1	0	0
41138	1624	secondary hyperaldosteronism	[secondary hyperaldosteronism]	1.0	2	2	2	2
41139	1624	p100 inhibitor	[p100 inhibitors]	1.0	2	1	0	0
41140	1624	ag exposure	[Ag exposure]	1.0	2	1	0	0
41141	1624	independent T cell receptor tcr	[independent T cell receptor TcR]	1.0	5	1	0	0
41142	1624	addition, antagonist	[addition, antagonists]	1.0	2	1	0	0
41143	1624	up-regulation of domain i-binding factor-1	[up-regulation of domain I-binding factor-1]	1.0	5	1	0	0
41144	1624	promote the resolution of inflammatory disease	[promoting the resolution of inflammatory diseases]	1.0	6	1	0	0
41145	1624	undetectable level in whole brain	[undetectable levels in whole brain]	1.0	5	1	0	0
41146	1624	contribution to T cell-specific expression	[contribution to T cell-specific expression]	1.0	5	1	0	0
41147	1624	high spi-1 -DNA binding activity	[high Spi-1 -DNA binding activity]	1.0	5	1	0	0
41148	1624	10 bp for optimal binding.	[10 bp for optimal binding.]	1.0	5	1	0	0
41149	1624	high percentage	[high percentage]	1.0	2	2	2	2
41150	1624	unilineage erythroid	[unilineage erythroid]	1.0	2	1	0	0
41151	1624	pharmacokinetic study	[Pharmacokinetic studies]	1.0	2	1	0	0
41152	1624	influence of estradiol on susceptibility	[Influence of estradiol on susceptibility]	1.0	5	1	0	0
41153	1624	microbicidal activity	[microbicidal activity]	1.0	2	2	1	1
41154	1624	erythropoietic potential	[erythropoietic potential]	1.0	2	1	0	0
41155	1624	HB24 transfectant	[HB24 transfectants]	1.0	2	1	0	0
41156	1624	gene egr-1	[gene egr-1]	1.0	2	2	2	2
41157	1624	modification of the suppressor function	[modification of the suppressor function]	1.0	5	1	0	0
41158	1624	interaction between this beta-glucan neutrophil	[interaction between this beta-glucan neutrophils]	1.0	5	1	0	0
41159	1624	disorder result from the activity	[disorder resulting from the activity]	1.0	5	1	0	0
41160	1624	express the membrane form of csf-1	[expressing the membrane form of CSF-1]	1.0	6	1	0	0
41161	1624	hiv-1 genome	[HIV-1 genome]	1.0	2	2	1	1
41162	1624	vitro by NF-kappa b protein	[vitro by NF-kappa B proteins]	1.0	5	1	0	0
41163	1624	b cell versus T cell	[B cells vs T cells]	1.0	5	1	0	0
41164	1624	however, in contrast with tnf-alpha	[However, in contrast with TNF-alpha]	1.0	5	1	0	0
41165	1624	one mechanism lead to the conversion	[one mechanism leading to the conversion]	1.0	6	1	0	0
41166	1624	transient transfection experiment with expression vector	[Transient transfection experiments with expression vectors]	1.0	6	1	0	0
41167	1624	K-RAS peptide	[K-RAS peptide]	1.0	2	1	0	0
41168	1624	Interferon IFNs	[Interferons IFNs]	1.0	2	1	0	0
41169	1624	lt-alpha1beta2 expression	[LT-alpha1beta2 expression]	1.0	2	1	0	0
41170	1624	suggest crucial for the induction	[suggesting crucial for the induction]	1.0	5	1	0	0
41171	1624	alphoid array	[alphoid arrays]	1.0	2	1	0	0
41172	1624	IL-12 activation of NK T cell	[IL-12 activation of NK T cells]	1.0	6	1	0	0
41173	1624	activate the nf-at transcription factor	[activating the NF-AT transcription factor]	1.0	5	1	0	0
41174	1624	fibric acid	[fibric acid]	1.0	2	2	1	1
41175	1624	expression of MHC class ii	[expression of MHC class II]	1.0	5	1	0	0
41176	1624	HZF 11-42	[HZF 11-42]	1.0	2	1	0	0
41177	1624	immune induction	[Immune induction]	1.0	2	1	0	0
41178	1624	restore tat responsiveness in the context	[restoring Tat responsiveness in the context]	1.0	6	1	0	0
41179	1624	corresponding to a 12% increase	[corresponding to a 12% increase]	1.0	5	1	0	0
41180	1624	case report	[case report]	1.0	2	1	0	0
41181	1624	1 alpha,	[1 alpha,]	1.0	2	2	2	2
41182	1624	rate of ikb alpha phosphorylation	[rate of IkB alpha phosphorylation]	1.0	5	1	0	0
41183	1624	antigen b27	[Antigen B27]	1.0	2	1	0	0
41184	1624	clonal human b cell line	[clonal human B cell lines]	1.0	5	1	0	0
41185	1624	human gata-1	[human GATA-1]	1.0	2	2	1	1
41186	1624	complex interaction	[complex interaction]	1.0	2	2	2	2
41187	1624	cell in the immune system	[cells in the immune system]	1.0	5	1	0	0
41188	1624	close donor	[closest donor]	1.0	2	1	0	0
41189	1624	activation of the hypothalamic-hypophyseal-adrenocortical system	[activation of the hypothalamic-hypophyseal-adrenocortical system]	1.0	5	1	0	0
41190	1624	susceptibility killing by NK cell	[susceptibility killing by NK cells]	1.0	5	1	0	0
41191	1624	monocyte- macrophage	[monocyte- macrophages]	1.0	2	1	0	0
41192	1624	microbial product	[microbial products]	1.0	2	2	1	1
41193	1624	tumor necrosis factor factor traf6	[Tumor necrosis factor factor TRAF6]	1.0	5	1	0	0
41194	1624	Northern blot analysis of poly(A) rna	[Northern blot analysis of poly(A) RNA]	1.0	6	1	0	0
41195	1624	b cell neoplasm express mnda	[B cell neoplasms expressing MNDA]	1.0	5	1	0	0
41196	1624	gene encode general initiation factor	[Genes encoding general initiation factors]	1.0	5	1	0	0
41197	1624	lymphocyte of two male sibling	[lymphocytes of two male siblings]	1.0	5	1	0	0
41198	1624	such important mediator of inflammation	[such important mediators of inflammation]	1.0	5	1	0	0
41199	1624	transient up-regulation	[transient up-regulation]	1.0	2	2	2	2
41200	1624	stimulation of interleukin-1 gene transcription	[Stimulation of interleukin-1 gene transcription]	1.0	5	1	0	0
41201	1624	low shear-	[low shear-]	1.0	2	1	0	0
41202	1624	Prostaglandin E2 up-regulate hiv-1 long terminal	[Prostaglandin E2 Up-regulates HIV-1 long terminal]	1.0	6	1	0	0
41203	1624	only low level of ifn-gamma	[only low levels of IFN-gamma]	1.0	5	1	0	0
41204	1624	differential pattern	[differential patterns]	1.0	2	1	0	0
41205	1624	defective transcription of the il-2 gene	[Defective transcription of the IL-2 gene]	1.0	6	1	0	0
41206	1624	developmental choice	[developmental choice]	1.0	2	1	0	0
41207	1624	gene expression of inflammatory mediator	[gene expression of inflammatory mediators]	1.0	5	1	0	0
41208	1624	nucleotide upstream	[nucleotides upstream]	1.0	2	2	2	2
41209	1624	permissiveness to replication of immunodeficiency virus	[Permissiveness to replication of immunodeficiency virus]	1.0	6	1	0	0
41210	1624	serine phosphatase	[serine phosphatase]	1.0	2	1	0	0
41211	1624	production of a fusion gene	[production of a fusion gene]	1.0	5	1	0	0
41212	1624	creb ap1	[CREB AP1]	1.0	2	1	0	0
41213	1624	low level of serum 135eoh)2d3	[low levels of serum 1,25(OH)2D3]	1.0	5	1	0	0
41214	1624	prominent enzyme in the endocytic pathway	[prominent enzymes in the endocytic pathway]	1.0	6	1	0	0
41215	1624	overall effect of heat shock	[overall effect of heat shock]	1.0	5	1	0	0
41216	1624	two Duffy polymorphic antigen Fya	[two Duffy polymorphic antigens Fya]	1.0	5	1	0	0
41217	1624	NH2 -terminal amino acid sequence analysis	[NH2 -terminal amino acid sequence analysis]	1.0	6	1	0	0
41218	1624	also terminal of FK506 -sensitive pathway	[also terminals of FK506 -sensitive pathway]	1.0	6	1	0	0
41219	1624	activity of the protein kinase	[activity of the protein kinase]	1.0	5	1	0	0
41220	1624	IL-4 transcription factor signal transducer	[IL-4 transcription factor signal transducer]	1.0	5	1	0	0
41221	1624	long proliferation	[long-term proliferation]	1.0	2	2	1	1
41222	1624	Novel therapy for inflammatory bowel disease	[Novel therapies for inflammatory bowel disease]	1.0	6	1	0	0
41223	1624	dna-binding trimer	[DNA-binding trimer]	1.0	2	2	1	1
41224	1624	human gata-3	[human GATA-3]	1.0	2	2	2	2
41225	1624	renal salt	[renal salt]	1.0	2	1	0	0
41226	1624	addition to activation gamma 1	[addition to activation gamma 1]	1.0	5	1	0	0
41227	1624	histone deacetylation	[histone deacetylation]	1.0	2	1	0	0
41228	1624	subsequent coactivator	[subsequent coactivator]	1.0	2	1	0	0
41229	1624	cotransfection assay,	[cotransfection assay,]	1.0	2	1	0	0
41230	1624	mobilization of nuclear factor kappa b	[mobilization of nuclear factor kappa B]	1.0	6	1	0	0
41231	1624	persistent loss of tnf-alpha synthesis	[persistent loss of TNF-alpha synthesis]	1.0	5	1	0	0
41232	1624	high potency	[high potency]	1.0	2	2	2	2
41233	1624	transcriptional complex	[transcriptional complex]	1.0	2	2	1	1
41234	1624	c-jun as oligonucleotide cell adhesion	[C-JUN AS oligonucleotides cell adhesion]	1.0	5	1	0	0
41235	1624	NIH 3t3	[NIH 3T3]	1.0	2	1	0	0
41236	1624	t-cell translocation	[T-cell translocations]	1.0	2	2	2	2
41237	1624	hiv-1 expression.	[HIV-1 expression.]	1.0	2	2	1	1
41238	1624	unique terminus of pp52 mrna	[unique terminus of pp52 mRNA]	1.0	5	1	0	0
41239	1624	200 kD	[200 kD]	1.0	2	1	0	0
41240	1624	IL-4 NAF	[IL-4 NAF]	1.0	2	2	1	1
41241	1624	hypotonic cytosol	[hypotonic cytosol]	1.0	2	1	0	0
41242	1624	autologous pbsct	[autologous PBSCT]	1.0	2	1	0	0
41243	1624	ca(2+)-transport by platelet membrane vesicle	[Ca(2+)-transport by platelet membrane vesicles]	1.0	5	1	0	0
41244	1624	expression of the immediate early gene	[expression of the immediate early genes]	1.0	6	1	0	0
41245	1624	J kappa	[J kappa]	1.0	2	2	1	1
41246	1624	specific complexes.	[specific complexes.]	1.0	2	1	0	0
41247	1624	diacylglycerol formation	[diacylglycerol formation]	1.0	2	1	0	0
41248	1624	such as correction of hemoglobinopathybthybinobinybinybinybinybinie	[such as correction of hemoglobinopathies]	1.0	5	1	0	0
41249	1624	act concurrently on AP-1- binding site	[acting concurrently on AP-1- binding sites]	1.0	6	1	0	0
41250	1624	b cell by all-tran RA	[B cells by all-trans RA]	1.0	5	1	0	0
41251	1624	same differentiation response to retinoid	[same differentiation response to retinoids]	1.0	5	1	0	0
41252	1624	granule protein	[granule proteins]	1.0	2	2	2	2
41253	1624	subject endometria	[subject endometria]	1.0	2	1	0	0
41254	1624	protein kinase in t-lymphocyte cell line	[protein kinases in T-lymphocyte cell lines]	1.0	6	1	0	0
41255	1624	characteristic immunophenotype	[characteristic immunophenotype]	1.0	2	1	0	0
41256	1624	inhibition for the entire period,	[inhibition for the entire period,]	1.0	5	1	0	0
41257	1624	p105 processing by NF-kappaB protein	[p105 processing by NF-kappaB proteins]	1.0	5	1	0	0
41258	1624	enhancer activity of the PRE	[enhancer activity of the PRE]	1.0	5	1	0	0
41259	1624	1 long repeat in T cell	[1 long repeat in T cells]	1.0	6	1	0	0
41260	1624	two set of independent evidence	[Two sets of independent evidences]	1.0	5	1	0	0
41261	1624	CD3-epsilon enhancer	[CD3-epsilon enhancer]	1.0	2	1	0	0
41262	1624	human fra-1	[human fra-1]	1.0	2	1	0	0
41263	1624	fibronectin -vla-5 fibronectin receptor interaction	[fibronectin -VLA-5 fibronectin receptor interaction]	1.0	5	1	0	0
41264	1624	IRF family transcription factor gene expression	[IRF family transcription factor gene expression]	1.0	6	1	0	0
41265	1624	tnf-mediated apoptosis	[TNF-mediated apoptosis]	1.0	2	1	0	0
41266	1624	transient transfection in u937 cell	[transient transfection in U937 cells]	1.0	5	1	0	0
41267	1624	variety of endocrine cell lineage	[variety of endocrine cell lineages]	1.0	5	1	0	0
41268	1624	x chromosome lack xist DNA	[X chromosome lacking XIST DNA]	1.0	5	1	0	0
41269	1624	1 infection of myeloid cell	[1 infection of myeloid cells]	1.0	5	1	0	0
41270	1624	two representative form of proteins, aml1a	[two representative forms of proteins, AML1a]	1.0	6	1	0	0
41271	1624	complementary dna'	[complementary DNA's]	1.0	2	1	0	0
41272	1624	expression level of RAR alpha	[expression levels of RAR alpha]	1.0	5	1	0	0
41273	1624	first example of b cell	[first examples of B cells]	1.0	5	1	0	0
41274	1624	dephosphorylation event	[dephosphorylation events]	1.0	2	1	0	0
41275	1624	involvement of nuclear factor-kappa b activation	[Involvement of nuclear factor-kappa B activation]	1.0	6	1	0	0
41276	1624	nuclear protein from u937 cell	[nuclear proteins from U937 cells]	1.0	5	1	0	0
41277	1624	nasal lymphoma	[nasal lymphoma]	1.0	2	2	2	2
41278	1624	control pbmc	[control PBMC]	1.0	2	1	0	0
41279	1624	estrogenic effect	[estrogenic effects]	1.0	2	1	0	0
41280	1624	mutation in the DNA bind domain	[mutations in the DNA binding domains]	1.0	6	1	0	0
41281	1624	inhibition of monocyte tf induction	[Inhibition of monocyte TF induction]	1.0	5	1	0	0
41282	1624	generation of a cellular response	[generation of a cellular response]	1.0	5	1	0	0
41283	1624	optimal activation of cd95 ligand	[optimal activation of CD95 ligand]	1.0	5	1	0	0
41284	1624	increase gamma-globin promoter /luciferase gene expression	[increasing gamma-globin promoter /luciferase gene expression]	1.0	6	1	0	0
41285	1624	binding to appropriate cellular receptors.	[binding to appropriate cellular receptors.]	1.0	5	1	0	0
41286	1624	i.e., defect in t-cell signal molecule	[i.e., defects in T-cell signaling molecules]	1.0	6	1	0	0
41287	1624	NF-kappa b activation follow tnf-alpha-	[NF-kappa B activation following TNF-alpha-]	1.0	5	1	0	0
41288	1624	two 5'-most distal carg sequence	[two 5'-most distal CArG sequences]	1.0	5	1	0	0
41289	1624	proviral insertion	[proviral insertion]	1.0	2	1	0	0
41290	1624	interleukin-12 IL-12	[interleukin-12 IL-12]	1.0	2	2	1	1
41291	1624	P. aeruginosa pak lack pili	[P. aeruginosa PAK lacking pili]	1.0	5	1	0	0
41292	1624	peptide corresponding to the domain	[peptide corresponding to the domain]	1.0	5	1	0	0
41293	1624	challenging problem	[challenging problem]	1.0	2	2	2	2
41294	1624	50% reduction in cell proliferation	[50% reduction in cell proliferation]	1.0	5	1	0	0
41295	1624	polymyxin b	[polymyxin B]	1.0	2	1	0	0
41296	1624	Inflammatory infiltrate	[Inflammatory infiltrates]	1.0	2	1	0	0
41297	1624	different transcription factor at stage	[different transcription factors at stages]	1.0	5	1	0	0
41298	1624	glucocorticoid effect.	[glucocorticoid effect.]	1.0	2	1	0	0
41299	1624	regulation of the beta-casein gene	[regulation of the beta-casein gene]	1.0	5	2	2	2
41300	1624	0.37%; 17-isoaldosterone	[0.37%; 17-isoaldosterone]	1.0	2	1	0	0
41301	1624	activate function.	[activating function.]	1.0	2	1	0	0
41302	1624	normal pattern	[normal pattern]	1.0	2	2	2	2
41303	1624	pos site	[POS sites]	1.0	2	1	0	0
41304	1624	il-3 deprivation	[IL-3 deprivation]	1.0	2	1	0	0
41305	1624	destabilization of the interleukin-1 beta mrna	[destabilization of the interleukin-1 beta mRNA]	1.0	6	1	0	0
41306	1624	human blood mononuclear cell PBMC	[human blood mononuclear cells PBMC]	1.0	5	2	2	2
41307	1624	erg2 gene	[ERG2 gene]	1.0	2	1	0	0
41308	1624	zinc cation	[zinc cations]	1.0	2	1	0	0
41309	1624	xenopus embryo	[Xenopus embryos]	1.0	2	2	1	1
41310	1624	use abs	[using Abs]	1.0	2	2	2	2
41311	1624	part of the large subunit	[part of the large subunit]	1.0	5	1	0	0
41312	1624	signal pathway.	[signaling pathway.]	1.0	2	1	0	0
41313	1624	four patient in a region	[four patients in a region]	1.0	5	1	0	0
41314	1624	mapping of the interaction site	[Mapping of the interaction site]	1.0	5	1	0	0
41315	1624	peripheral blood mononuclear cell by 38%.	[peripheral blood mononuclear cells by 38%.]	1.0	6	1	0	0
41316	1624	calcineurin docking site on NFAT	[calcineurin docking site on NFAT]	1.0	5	1	0	0
41317	1624	adolescent major depressive disorder MDD	[adolescent major depressive disorder MDD]	1.0	5	1	0	0
41318	1624	high eukaryote	[higher eukaryotes]	1.0	2	1	0	0
41319	1624	antiinflammatory effect	[antiinflammatory effects]	1.0	2	1	0	0
41320	1624	Furthermore, transfection with LMP1 expression vector	[Furthermore, transfection with LMP1 expression vector]	1.0	6	1	0	0
41321	1624	promoter-proximal site	[promoter-proximal site]	1.0	2	1	0	0
41322	1624	Phytohemagglutinin lymphocyte	[Phytohemagglutinin lymphocytes]	1.0	2	1	0	0
41323	1624	EBV immediate-early gene transcript bzlf1	[EBV immediate-early gene transcripts BZLF1]	1.0	5	1	0	0
41324	1624	such protein	[such proteins]	1.0	2	1	0	0
41325	1624	nfat transactivation	[NFAT transactivation]	1.0	2	1	0	0
41326	1624	DNA bind specificity of 3	[DNA binding specificity of 3]	1.0	5	1	0	0
41327	1624	tnf-alpha stimulation	[TNF-alpha stimulation]	1.0	2	1	0	0
41328	1624	biochemically distinct form of free e2f	[biochemically distinct forms of free E2F]	1.0	6	1	0	0
41329	1624	c-fo serum response element sre	[c-fos serum response element SRE]	1.0	5	1	0	0
41330	1624	competent transcription	[Competent transcription]	1.0	2	1	0	0
41331	1624	striking contrast to the increase	[striking contrast to the increase]	1.0	5	1	0	0
41332	1624	nuclear localization in accessory cell	[nuclear localization in accessory cells]	1.0	5	1	0	0
41333	1624	dictate specificities.	[dictating specificities.]	1.0	2	1	0	0
41334	1624	non-monocytic cell	[non-monocytic cells]	1.0	2	1	0	0
41335	1624	follow infection.	[following infection.]	1.0	2	1	0	0
41336	1624	steady-state level of hiv rna	[steady-state levels of HIV RNA]	1.0	5	1	0	0
41337	1624	severe infection	[severe infections]	1.0	2	1	0	0
41338	1624	hpv cell	[HPV cells]	1.0	2	1	0	0
41339	1624	subnuclear structure	[subnuclear structures]	1.0	2	1	0	0
41340	1624	cell leukemia	[cell leukemia]	1.0	2	2	2	2
41341	1624	immediate-early major tegument protein ie62	[immediate-early major tegument protein IE62]	1.0	5	1	0	0
41342	1624	human DR alpha x box	[human DR alpha X box]	1.0	5	1	0	0
41343	1624	mutation of the ap1 motif	[Mutation of the AP1 motif]	1.0	5	1	0	0
41344	1624	effect of danazol on site	[effects of danazol on sites]	1.0	5	1	0	0
41345	1624	affinity receptor	[affinity receptor]	1.0	2	2	2	2
41346	1624	approximately substSpl2	[approximately substSpl2]	1.0	2	2	1	1
41347	1624	human gene encode cyclophilin b-binding-proteins	[human genes encoding cyclophilin B-binding-proteins]	1.0	5	1	0	0
41348	1624	biologic response	[biologic response]	1.0	2	1	0	0
41349	1624	graft infiltration with killer (nk) cell	[graft infiltration with killer (NK) cells]	1.0	6	1	0	0
41350	1624	phosphorylation of STAT3alpha on serine 727	[phosphorylation of STAT3alpha on serine 727]	1.0	6	1	0	0
41351	1624	135(oh)2d3 action	[1,25(OH)2D3 action]	1.0	2	1	0	0
41352	1624	apparent change	[apparent change]	1.0	2	1	0	0
41353	1624	activation of the NF-kappaB transcription factor	[activation of the NF-kappaB transcription factor]	1.0	6	2	1	1
41354	1624	hiv-1 tat gene hela-tat cell	[HIV-1 tat gene HeLa-tat cells]	1.0	5	1	0	0
41355	1624	aldosterone from human mononuclear leukocyte	[aldosterone from human mononuclear leukocytes]	1.0	5	1	0	0
41356	1624	steroid hormone with immunomodulating properties	[steroid hormone with immunomodulating properties,]	1.0	5	1	0	0
41357	1624	pag expression	[pag expression]	1.0	2	1	0	0
41358	1624	Rho family	[Rho family]	1.0	2	1	0	0
41359	1624	cck-8 effect on interleukin-2 expression	[CCK-8 effect on interleukin-2 expression]	1.0	5	1	0	0
41360	1624	result of reporter gene analysis	[results of reporter gene analyses]	1.0	5	1	0	0
41361	1624	addition inhibit the cox-2 activity	[addition inhibiting the COX-2 activity]	1.0	5	1	0	0
41362	1624	cDNA encode nuclear factor (nf)-il6	[cDNA encoding nuclear factor (NF)-IL6]	1.0	5	1	0	0
41363	1624	MTCP1 gene	[MTCP1 gene]	1.0	2	1	0	0
41364	1624	include the cytokine interleukin (il)-1 beta	[including the cytokine interleukin (IL)-1 beta]	1.0	6	1	0	0
41365	1624	endocytic pathway	[endocytic pathway]	1.0	2	2	1	1
41366	1624	hepatitis b virus infection (6	[hepatitis B virus infection (6]	1.0	5	2	2	2
41367	1624	immune cells.	[immune cells.]	1.0	2	1	0	0
41368	1624	english-language literature	[English-language literature]	1.0	2	1	0	0
41369	1624	pbmc capacity	[PBMC capacity]	1.0	2	1	0	0
41370	1624	initiation codon	[initiation codon]	1.0	2	1	0	0
41371	1624	downstream interactor	[downstream interactor]	1.0	2	1	0	0
41372	1624	enhancer replacement	[Enhancer replacement]	1.0	2	1	0	0
41373	1624	intracellular mediator of tgf-beta1 signal	[intracellular mediator of TGF-beta1 signaling]	1.0	5	1	0	0
41374	1624	two messenger	[two messengers]	1.0	2	2	2	2
41375	1624	key transcriptional regulator of response	[key transcriptional regulator of responses]	1.0	5	1	0	0
41376	1624	CpG-rich island	[CpG-rich island]	1.0	2	2	2	2
41377	1624	RA apoptosis	[RA apoptosis]	1.0	2	1	0	0
41378	1624	confocal laser scanning microscopy clsm	[confocal laser scanning microscopy CLSM]	1.0	5	1	0	0
41379	1624	b lymphoma cell line, b104	[B lymphoma cell line, B104]	1.0	5	1	0	0
41380	1624	activation of select nf-kappa b gene	[activation of select NF-kappa B genes]	1.0	6	1	0	0
41381	1624	cell population.	[cell population.]	1.0	2	1	0	0
41382	1624	lung nf-kappab in the model.	[lung NF-kappaB in the model.]	1.0	5	1	0	0
41383	1624	plaque rupture	[plaque rupture]	1.0	2	1	0	0
41384	1624	pi3-kinase activity	[PI3-kinase activity]	1.0	2	1	0	0
41385	1624	consist of a repeat lrr domain	[consisting of a repeat LRR domain]	1.0	6	1	0	0
41386	1624	binding of a transcription factor	[binding of a transcription factor]	1.0	5	1	0	0
41387	1624	HIV-1 Nef	[HIV-1 Nef]	1.0	2	1	0	0
41388	1624	il-1 stimulation	[IL-1 stimulation]	1.0	2	1	0	0
41389	1624	large extent,	[large extent,]	1.0	2	1	0	0
41390	1624	conventional b-2 cell with anti-ig	[conventional B-2 cells with anti-Ig]	1.0	5	1	0	0
41391	1624	il-1 lps nf-kappab -luciferase activity	[IL-1 LPS NF-kappaB -luciferase activity]	1.0	5	1	0	0
41392	1624	restriction analysis	[Restriction analysis]	1.0	2	1	0	0
41393	1624	actively fuse	[actively fusing]	1.0	2	1	0	0
41394	1624	reconstitution of a cell-free processing system	[reconstitution of a cell-free processing system]	1.0	6	1	0	0
41395	1624	least one other nfat-sensitive gene	[least one other NFAT-sensitive gene]	1.0	5	1	0	0
41396	1624	IP-10 mrna inducibility by IFNgamma	[IP-10 mRNA inducibility by IFNgamma]	1.0	5	1	0	0
41397	1624	primary human T cell modulation	[primary human T cells modulation]	1.0	5	1	0	0
41398	1624	mouse embryogenesis	[mouse embryogenesis]	1.0	2	1	0	0
41399	1624	chronic condition	[chronic conditions]	1.0	2	1	0	0
41400	1624	C5a a potent peptide chemoattractant	[C5a a potent peptide chemoattractant]	1.0	5	1	0	0
41401	1624	calcium mobilization by a ionophore	[calcium mobilization by an ionophore]	1.0	5	1	0	0
41402	1624	role of protein kinase pathway	[role of protein kinase pathway]	1.0	5	1	0	0
41403	1624	pkr expression	[PKR expression]	1.0	2	1	0	0
41404	1624	activation of the m-csf gene	[activation of the M-CSF gene]	1.0	5	1	0	0
41405	1624	common mechanisms, such as the one	[common mechanisms, such as the one]	1.0	6	1	0	0
41406	1624	Jurkat T cell stably express tax	[Jurkat T cells stably expressing tax]	1.0	6	1	0	0
41407	1624	risk independent of resection margins: tumor	[risk independent of resection margins: tumors]	1.0	6	1	0	0
41408	1624	nuclear translocation of c-Rel/p65 heterodimer	[nuclear translocation of c-Rel/p65 heterodimers]	1.0	5	2	1	1
41409	1624	basis of the therapeutic effect	[basis of the therapeutic effect]	1.0	5	1	0	0
41410	1624	congenital defect in different aspect	[congenital defects in different aspects]	1.0	5	1	0	0
41411	1624	hiv replication in mononuclear phagocyte	[HIV replication in mononuclear phagocytes]	1.0	5	1	0	0
41412	1624	c-fo increase	[c-fos increase]	1.0	2	1	0	0
41413	1624	prl stimulation,	[PRL stimulation,]	1.0	2	1	0	0
41414	1624	diverse group of industrial chemical	[diverse group of industrial chemicals]	1.0	5	1	0	0
41415	1624	therapy the number of patient respond	[therapy the number of patients responding]	1.0	6	1	0	0
41416	1624	proliferation in response to TG	[Proliferation in response to TG]	1.0	5	1	0	0
41417	1624	addition to the trans-activation domain	[addition to the trans-activation domain]	1.0	5	1	0	0
41418	1624	thymidine incorporation	[thymidine incorporation]	1.0	2	2	1	1
41419	1624	18 aml sample by EMSA	[18 AML samples by EMSA]	1.0	5	1	0	0
41420	1624	suggest extensive cross-talk between the partner	[suggesting extensive cross-talk between the partners]	1.0	6	1	0	0
41421	1624	NF-IL6 mRNA	[NF-IL6 mRNA]	1.0	2	1	0	0
41422	1624	adjacent ets binding motif TTCC	[adjacent ETS binding motifs TTCC]	1.0	5	1	0	0
41423	1624	drug reaction	[drug reaction]	1.0	2	1	0	0
41424	1624	protein, rfx5	[protein, RFX5]	1.0	2	1	0	0
41425	1624	plate-bound anti-CD3 monoclonal antibody mab	[plate-bound anti-CD3 monoclonal antibody mAb]	1.0	5	1	0	0
41426	1624	group c, adenovirus serotype 5 ad5	[Group C, adenovirus serotype 5 Ad5]	1.0	6	1	0	0
41427	1624	human vein endothelial cell HUVECs	[human vein endothelial cells HUVECs]	1.0	5	2	2	2
41428	1624	platelet parameter	[platelet parameters]	1.0	2	1	0	0
41429	1624	numerous feature	[numerous features]	1.0	2	2	1	1
41430	1624	caspase in T cell development	[caspases in T cell development]	1.0	5	1	0	0
41431	1624	er peptides,	[ER peptides,]	1.0	2	1	0	0
41432	1624	androgen-binding domain of the androgen receptor	[androgen-binding domains of the androgen receptor]	1.0	6	1	0	0
41433	1624	3,4-diacetoxy derivative	[3,4-diacetoxy derivative]	1.0	2	1	0	0
41434	1624	concomitant engagement of the cd3.tcr complex	[concomitant engagement of the CD3.TcR complex]	1.0	6	1	0	0
41435	1624	transcription efficiency	[transcription efficiency]	1.0	2	2	1	1
41436	1624	largely through inhibition of cytokine expression	[largely through inhibition of cytokine expression]	1.0	6	1	0	0
41437	1624	decrease in il-1ra mrna expression	[decrease in IL-1ra mRNA expression]	1.0	5	1	0	0
41438	1624	different point	[different points]	1.0	2	1	0	0
41439	1624	phorbol ester cell at any time	[phorbol ester cells at any time]	1.0	6	1	0	0
41440	1624	mainly sesquiterpene lactone such as helenalin	[mainly sesquiterpene lactones such as helenalin]	1.0	6	1	0	0
41441	1624	expression of il-6 in lps	[expression of IL-6 in LPS]	1.0	5	1	0	0
41442	1624	mp value for adrenal suppression	[MP values for adrenal suppression]	1.0	5	1	0	0
41443	1624	t- activation	[T- activation]	1.0	2	1	0	0
41444	1624	expression from a alpha-globin promoter	[expression from an alpha-globin promoter]	1.0	5	1	0	0
41445	1624	use mrna display reverse transcriptase pcr	[using mRNA display reverse transcriptase PCR]	1.0	6	1	0	0
41446	1624	portion of the er region	[portion of the ER region]	1.0	5	1	0	0
41447	1624	insight to the molecular mechanism	[insight to the molecular mechanisms]	1.0	5	1	0	0
41448	1624	follow the addition of interferon alpha	[following the addition of interferon alpha]	1.0	6	1	0	0
41449	1624	mouse notch-1	[mouse Notch-1]	1.0	2	1	0	0
41450	1624	6 Philips	[6 Philips]	1.0	2	1	0	0
41451	1624	mitogen activation of T lymphocyte	[mitogen activation of T lymphocytes]	1.0	5	3	2	1
41452	1624	rhesus monkey	[rhesus monkey]	1.0	2	2	2	2
41453	1624	common stat protein in the generation	[common Stat proteins in the generation]	1.0	6	1	0	0
41454	1624	suggest a link between the magnitude	[suggesting a link between the magnitude]	1.0	6	1	0	0
41455	1624	display difference in transcriptional activity	[displaying differences in transcriptional activity]	1.0	5	1	0	0
41456	1624	expression of a active ras mutant,	[expression of a active ras mutant,]	1.0	6	1	0	0
41457	1624	sequester bhlh target in inactive heterodimer	[sequestering bHLH targets in inactive heterodimers]	1.0	6	1	0	0
41458	1624	human MCM	[human MCM]	1.0	2	1	0	0
41459	1624	Bcl-6 gene product a phosphoprotein	[Bcl-6 gene product a phosphoprotein]	1.0	5	1	0	0
41460	1624	e2f binding	[E2F binding]	1.0	2	2	2	2
41461	1624	-182 to -37 base pair (bp))	[-182 to -37 base pairs (bp))]	1.0	6	1	0	0
41462	1624	As2O3 apoptosis	[As2O3 apoptosis]	1.0	2	1	0	0
41463	1624	misfunction in the regulatory system	[misfunction in the regulatory systems]	1.0	5	1	0	0
41464	1624	activity of intracellular tyrosine phosphatase	[activity of intracellular tyrosine phosphatase]	1.0	5	1	0	0
41465	1624	pretreatment of ACH-2 T cell	[Pretreatment of ACH-2 T cells]	1.0	5	1	0	0
41466	1624	LCR HSs	[LCR HSs]	1.0	2	2	1	1
41467	1624	Deoxycorticosterone acetate	[Deoxycorticosterone acetate]	1.0	2	1	0	0
41468	1624	component of the gr heterocomplex	[components of the GR heterocomplex]	1.0	5	1	0	0
41469	1624	V beta	[V beta]	1.0	2	2	2	2
41470	1624	contain kappab site by p65	[containing kappaB sites by p65]	1.0	5	1	0	0
41471	1624	genetic end target of fk506-sensitive pathway	[genetic end targets of FK506-sensitive pathway]	1.0	6	1	0	0
41472	1624	human MHC	[human MHC]	1.0	2	1	0	0
41473	1624	thus, qualitative difference in the capacity	[Thus, qualitative differences in the capacity]	1.0	6	1	0	0
41474	1624	activation of protein kinase C	[activation of protein kinase C]	1.0	5	2	1	1
41475	1624	mapping of b-cell epitope x protein	[Mapping of B-cell epitopes X protein]	1.0	6	1	0	0
41476	1624	Rhom-2 gene	[Rhom-2 gene]	1.0	2	1	0	0
41477	1624	critical issue	[critical issue]	1.0	2	1	0	0
41478	1624	isolation procedure	[isolation procedure,]	1.0	2	1	0	0
41479	1624	remodeling of beta-globin promoter chromatin structure	[remodeling of beta-globin promoter chromatin structure]	1.0	6	1	0	0
41480	1624	catalytic core	[catalytic core]	1.0	2	1	0	0
41481	1624	inducible import of nf-kappa b	[inducible import of NF-kappa B]	1.0	5	2	2	2
41482	1624	gamma-globin expression	[gamma-globin expression]	1.0	2	2	2	2
41483	1624	basal level.	[basal level.]	1.0	2	1	0	0
41484	1624	cho-cd80 stimulation	[CHO-CD80 stimulation]	1.0	2	1	0	0
41485	1624	response except for tcrzeta level	[response except for TCRzeta levels]	1.0	5	1	0	0
41486	1624	whole spectrum	[whole spectrum]	1.0	2	2	2	2
41487	1624	acidic ph,	[acidic pH,]	1.0	2	1	0	0
41488	1624	monocyte/macrophage receptor	[monocyte/macrophage receptor]	1.0	2	2	1	1
41489	1624	assembly of a prothrombinase complex	[assembly of a prothrombinase complex]	1.0	5	1	0	0
41490	1624	T cell from young donor	[T cells from young donors]	1.0	5	2	1	1
41491	1624	intracellular electrolyte	[intracellular electrolytes]	1.0	2	2	1	1
41492	1624	beta-globin yeast	[beta-globin yeast]	1.0	2	1	0	0
41493	1624	super-shift analysis	[Super-shift analysis]	1.0	2	1	0	0
41494	1624	very high amount of v-erbA	[very high amounts of v-erbA]	1.0	5	1	0	0
41495	1624	cytokine modulation of hiv expression	[Cytokine modulation of HIV expression]	1.0	5	1	0	0
41496	1624	r-pk promoter	[R-PK promoter]	1.0	2	2	1	1
41497	1624	dna-mobility-shift assay	[DNA-mobility-shift assays]	1.0	2	1	0	0
41498	1624	p105 gene	[p105 gene]	1.0	2	1	0	0
41499	1624	contain the CAII -specific erba-binding site	[containing the CAII -specific erbA-binding site]	1.0	6	1	0	0
41500	1624	carry mutation in the Sp1 site	[carrying mutations in the Sp1 sites]	1.0	6	1	0	0
41501	1624	overall change in protein tyrosine phosphorylation	[overall changes in protein tyrosine phosphorylation]	1.0	6	1	0	0
41502	1624	Glucocorticoid resistance in the squirrel monkey	[Glucocorticoid resistance in the squirrel monkey]	1.0	6	1	0	0
41503	1624	signal pathway from fc receptor	[signaling pathway from Fc receptors]	1.0	5	1	0	0
41504	1624	azeptin pbl	[Azeptin PBL]	1.0	2	1	0	0
41505	1624	il-3 expression to approximately normal	[IL-3 expression to approximately normal]	1.0	5	1	0	0
41506	1624	constitutive activation of nuclear factor	[constitutive activation of nuclear factor]	1.0	5	1	0	0
41507	1624	inhibitory effect of plzf-rar alpha	[inhibitory effect of PLZF-RAR alpha]	1.0	5	1	0	0
41508	1624	interaction with two specific region	[interaction with two specific regions]	1.0	5	1	0	0
41509	1624	uv cross-linking	[uv cross-linking]	1.0	2	1	0	0
41510	1624	isgf3 gamma	[ISGF3 gamma]	1.0	2	2	2	2
41511	1624	edema formation	[edema formation]	1.0	2	1	0	0
41512	1624	arnt heterodimerization, of a conformation	[Arnt heterodimerization, of a conformation]	1.0	5	1	0	0
41513	1624	88% sequence identity between mouse	[88% sequence identity between mouse]	1.0	5	1	0	0
41514	1624	efficient long lymphoblastoid cell outgrowth	[efficient long-term lymphoblastoid cell outgrowth]	1.0	5	1	0	0
41515	1624	yield of viral structural protein	[yields of viral structural proteins]	1.0	5	1	0	0
41516	1624	important contributor to il-12 signal	[important contributor to IL-12 signaling]	1.0	5	1	0	0
41517	1624	(il-2r) receptor on the parental line	[(IL-2R) receptors on the parental line]	1.0	6	1	0	0
41518	1624	thymus section use specific abs	[thymus sections using specific Abs]	1.0	5	1	0	0
41519	1624	induction of the adaptive immune response	[Induction of the adaptive immune response]	1.0	6	1	0	0
41520	1624	tumor originate from epidermal cell	[tumors originating from epidermal cells]	1.0	5	1	0	0
41521	1624	Differential expression	[Differential expression]	1.0	2	3	2	1
41522	1624	involve factor of T cell	[involving factor of T cell]	1.0	5	2	2	2
41523	1624	requirement of gata-1 transcription factor	[requirement of GATA-1 transcription factors]	1.0	5	1	0	0
41524	1624	use a gamma activation site probe	[using a gamma activation site probe]	1.0	6	1	0	0
41525	1624	removal of a major part	[removal of a major part]	1.0	5	1	0	0
41526	1624	isoelectric focus	[Isoelectric focusing]	1.0	2	1	0	0
41527	1624	T cell with immunodeficiency virus	[T cells with immunodeficiency virus]	1.0	5	1	0	0
41528	1624	b-chronic lymphocytic leukemia (b-cll) cell	[B-chronic lymphocytic leukemia (B-CLL) cells]	1.0	5	1	0	0
41529	1624	t(15;17) case	[t(15;17) cases]	1.0	2	1	0	0
41530	1624	EBV promoter	[EBV promoter]	1.0	2	2	1	1
41531	1624	re/ap reporter	[RE/AP reporter]	1.0	2	1	0	0
41532	1624	protease-treated extract	[protease-treated extracts]	1.0	2	1	0	0
41533	1624	NF-kappaB dna-binding complex with activity	[NF-kappaB DNA-binding complexes with activity]	1.0	5	1	0	0
41534	1624	human T lymphocyte with pge2	[human T lymphocytes with PGE2]	1.0	5	1	0	0
41535	1624	nuclear factor of T cell nf-at-1	[nuclear factor of T cells NF-AT-1]	1.0	6	1	0	0
41536	1624	specimen of perihepatic lymph node	[specimens of perihepatic lymph nodes]	1.0	5	1	0	0
41537	1624	effect of novel ventilatory strategy	[effects of novel ventilatory strategies]	1.0	5	1	0	0
41538	1624	nuclear factor Kappa-B NF-kappa b	[nuclear factor Kappa-B NF-kappa B]	1.0	5	1	0	0
41539	1624	other product	[other products]	1.0	2	2	2	2
41540	1624	relationship between the glucocorticoid receptor	[relationship between the glucocorticoid receptor]	1.0	5	1	0	0
41541	1624	significant effect on the transcription	[significant effect on the transcription]	1.0	5	1	0	0
41542	1624	plasmacytoid differentiation	[plasmacytoid differentiation]	1.0	2	1	0	0
41543	1624	sequencing of the genomic region	[Sequencing of the genomic region]	1.0	5	1	0	0
41544	1624	However, sequence specificity of NF-AT	[However, sequence specificity of NF-AT]	1.0	5	1	0	0
41545	1624	activation of cytoplasmic tyrosine kinase	[Activation of cytoplasmic tyrosine kinases]	1.0	5	1	0	0
41546	1624	high level of two protein	[high levels of two proteins]	1.0	5	1	0	0
41547	1624	consequent function during early-phase infection	[consequent function during early-phase infection]	1.0	5	1	0	0
41548	1624	vivo model	[vivo model]	1.0	2	2	1	1
41549	1624	mechanism responsible for tissue-specific expression	[mechanisms responsible for tissue-specific expression]	1.0	5	1	0	0
41550	1624	such alteration	[Such alterations]	1.0	2	1	0	0
41551	1624	strong production of interleukin 2 il-2	[strong production of interleukin 2 IL-2]	1.0	6	1	0	0
41552	1624	45 bp downstream of the nre	[45 bp downstream of the NRE]	1.0	6	1	0	0
41553	1624	intracellular stat-1 by flow cytometry	[intracellular STAT-1 by flow cytometry]	1.0	5	1	0	0
41554	1624	mosaic with regard to the allele	[mosaic with regard to the allele]	1.0	6	1	0	0
41555	1624	il-2 -secret Jurkat T cell	[IL-2 -secreting Jurkat T cells]	1.0	5	1	0	0
41556	1624	one-hybrid assay in yeast nf-atp	[One-hybrid assays in yeast NF-ATp]	1.0	5	1	0	0
41557	1624	study of the molecular mechanism	[study of the molecular mechanisms]	1.0	5	1	0	0
41558	1624	same ifn-gamma activation site-like sequence	[same IFN-gamma activation site-like sequence]	1.0	5	1	0	0
41559	1624	mitogen binding	[mitogen binding]	1.0	2	1	0	0
41560	1624	gene expression in lymphoid cell	[gene expression in lymphoid cells]	1.0	5	1	0	0
41561	1624	TCF-1 gene	[TCF-1 gene]	1.0	2	1	0	0
41562	1624	form of the transcription factor	[form of the transcription factor]	1.0	5	1	0	0
41563	1624	vaginal physiology	[vaginal physiology]	1.0	2	1	0	0
41564	1624	evidence for a glycosphingolipid beta-(1,3)-glucan receptor	[evidence for a glycosphingolipid beta-(1,3)-glucan receptor]	1.0	6	1	0	0
41565	1624	60 residue	[60 residues]	1.0	2	2	1	1
41566	1624	activation role	[activation role]	1.0	2	2	2	2
41567	1624	significant level of il-8 production	[significant levels of IL-8 production]	1.0	5	1	0	0
41568	1624	expression of the IL-13 gene	[expression of the IL-13 genes]	1.0	5	1	0	0
41569	1624	55-kDa isoform kappa b gamma-2	[55-kDa isoform kappa B gamma-2]	1.0	5	1	0	0
41570	1624	soft agar) of CTLL-2/ tax	[soft agar) of CTLL-2/ Tax]	1.0	5	1	0	0
41571	1624	transcription factor activation protein ap-1	[transcription factor activation protein AP-1]	1.0	5	1	0	0
41572	1624	encode a protein of 14 kda	[encoding a protein of 14 kDa]	1.0	6	1	0	0
41573	1624	phasing analysis	[phasing analyses]	1.0	2	1	0	0
41574	1624	tissue itself,	[tissue itself,]	1.0	2	1	0	0
41575	1624	decrease in concentration of parath hormone	[decrease in concentration of parath hormone]	1.0	6	1	0	0
41576	1624	human il-9ralpha	[human IL-9Ralpha]	1.0	2	1	0	0
41577	1624	express the tax transform protein	[expressing the Tax transforming protein]	1.0	5	1	0	0
41578	1624	information on association dissociation rate	[information on association dissociation rates]	1.0	5	1	0	0
41579	1624	level of hepor gene expression	[level of hEpoR gene expression]	1.0	5	1	0	0
41580	1624	hypoxic endothelia	[Hypoxic endothelia]	1.0	2	1	0	0
41581	1624	Rb inactivation, lead to e2f activation	[Rb inactivation, leading to E2F activation]	1.0	6	1	0	0
41582	1624	high amount of monocytic precursor	[highest amounts of monocytic precursors]	1.0	5	1	0	0
41583	1624	accessory cell of the response	[accessory cells of the response]	1.0	5	2	1	1
41584	1624	9,11-dihydro derivative of the latter.	[9,11-dihydro derivative of the latter.]	1.0	5	1	0	0
41585	1624	peritoneal macrophage of transgenic mouse	[Peritoneal macrophages of transgenic mice]	1.0	5	1	0	0
41586	1624	normal floram	[normal flora,]	1.0	2	1	0	0
41587	1624	20-epi analogue of 1,25-dihydroxyvitamin D3	[20-Epi analogues of 1,25-dihydroxyvitamin D3]	1.0	5	1	0	0
41588	1624	minimal level of hiv expression	[minimal levels of HIV expression]	1.0	5	1	0	0
41589	1624	significant increase in the fragment	[significant increase in the fragment]	1.0	5	1	0	0
41590	1624	PMA (iono, ic50 of ng/ml).	[PMA (Iono, IC50 of ng/ml).]	1.0	5	1	0	0
41591	1624	analysis of CD40 cytoplasmic domain truncation	[Analysis of CD40 cytoplasmic domain truncation]	1.0	6	1	0	0
41592	1624	pseudomonas aeruginosa	[Pseudomonas aeruginosa]	1.0	2	2	2	2
41593	1624	sle patient	[SLE patients]	1.0	2	3	2	1
41594	1624	oriP the origin for episomal maintenance	[oriP the origin for episomal maintenance]	1.0	6	1	0	0
41595	1624	compare the FISH result with parameter	[comparing the FISH results with parameters]	1.0	6	1	0	0
41596	1624	maintenance of optimal NK function	[maintenance of optimal NK functions]	1.0	5	1	0	0
41597	1624	kinetic in cemxl74 cell nfkappab	[kinetics in CEMxl74 cells NFKappaB]	1.0	5	1	0	0
41598	1624	gender difference in the number	[Gender difference in the number]	1.0	5	1	0	0
41599	1624	new probe specific for the deletion	[new probes specific for the deletion]	1.0	6	1	0	0
41600	1624	lipoprotein blp	[lipoproteins BLPs]	1.0	2	1	0	0
41601	1624	gc-r bmax in quiescent pbmc	[GC-R Bmax in quiescent PBMC]	1.0	5	1	0	0
41602	1624	spi-1 overexpression	[spi-1 overexpression]	1.0	2	2	1	1
41603	1624	clone C3/5	[Clone C3/5]	1.0	2	1	0	0
41604	1624	direct the expression of a receptor	[directing the expression of a receptor]	1.0	6	1	0	0
41605	1624	molecular size	[molecular size]	1.0	2	2	2	2
41606	1624	represent cytotoxic T lymphocyte (ctl) epitope	[representing cytotoxic T lymphocyte (CTL) epitopes]	1.0	6	1	0	0
41607	1624	NAD(P)H:quinone reductase	[NAD(P)H:quinone reductase]	1.0	2	2	1	1
41608	1624	IL-10 up-regulation of cytokine production	[IL-10 up-regulation of cytokine production]	1.0	5	1	0	0
41609	1624	important role protect vascular injury	[important role protecting vascular injury]	1.0	5	1	0	0
41610	1624	paf kappa b binding activity	[PAF kappa B binding activity]	1.0	5	1	0	0
41611	1624	such as nf-kappa b activation	[such as NF-kappa B activation]	1.0	5	1	0	0
41612	1624	induction of T cell lymphoma	[induction of T cell lymphomas]	1.0	5	1	0	0
41613	1624	NF kappab	[NF kappaB]	1.0	2	2	2	2
41614	1624	Differanisole A	[Differanisole A]	1.0	2	2	1	1
41615	1624	12 case	[12 cases]	1.0	2	1	0	0
41616	1624	72 hours.	[72 hours.]	1.0	2	1	0	0
41617	1624	hirsute woman	[hirsute women]	1.0	2	1	0	0
41618	1624	two enzyme	[two enzymes]	1.0	2	2	2	2
41619	1624	proteolytic reaction	[proteolytic reactions]	1.0	2	1	0	0
41620	1624	exogenous tnf-alpha	[exogenous TNF-alpha]	1.0	2	1	0	0
41621	1624	utilize CD4 positive T cell line	[Utilizing CD4 positive T cell lines]	1.0	6	1	0	0
41622	1624	Spi-C a novel ets protein	[Spi-C a novel Ets protein]	1.0	5	1	0	0
41623	1624	hiv-1 transactivator	[HIV-1 transactivator]	1.0	2	2	2	2
41624	1624	AP-1(I,II,III), ap3-l	[AP-1(I,II,III), AP3-L]	1.0	2	1	0	0
41625	1624	precursor of the antioxidant glutathione	[precursor of the antioxidant glutathione]	1.0	5	1	0	0
41626	1624	IL-4 binding site per cell.	[IL-4 binding sites per cell.]	1.0	5	1	0	0
41627	1624	majority related	[majority related]	1.0	2	1	0	0
41628	1624	cytokine on the monocyte maturation/differentiation	[cytokines on the monocyte maturation/differentiation]	1.0	5	1	0	0
41629	1624	mean survival	[mean survival]	1.0	2	1	0	0
41630	1624	oxidative event	[oxidative events]	1.0	2	1	0	0
41631	1624	NF kappa b by trx	[NF kappa B by Trx]	1.0	5	1	0	0
41632	1624	th2-type lymphokine such as IL-4	[Th2-type lymphokines such as IL-4]	1.0	5	1	0	0
41633	1624	unde3r this circumstances, Calphostin C	[unde3r these circumstances, Calphostin C]	1.0	5	1	0	0
41634	1624	nh2- terminal domain of bob.1/obf.1	[NH2- terminal domains of BOB.1/OBF.1]	1.0	5	1	0	0
41635	1624	such as NF kappa b	[such as NF kappa B]	1.0	5	1	0	0
41636	1624	Glucocorticoid receptor gr hormone-binding activity	[Glucocorticoid receptor GR hormone-binding activity]	1.0	5	1	0	0
41637	1624	plasma t4	[plasma T4]	1.0	2	1	0	0
41638	1624	convenient tool	[convenient tool]	1.0	2	1	0	0
41639	1624	alpha2beta1 integrin a collagen receptor	[alpha2beta1 integrin a collagen receptor]	1.0	5	1	0	0
41640	1624	suppression of c-jun by antisense oligonucleotide	[Suppression of c-jun by antisense oligonucleotides]	1.0	6	1	0	0
41641	1624	topoisomerase associated,	[topoisomerase associated,]	1.0	2	1	0	0
41642	1624	serum-response element	[serum-response element]	1.0	2	1	0	0
41643	1624	lymphocyte reaction	[lymphocyte reaction]	1.0	2	2	1	1
41644	1624	deltadna-binding domain RXR contain a deletion	[deltaDNA-binding domain RXR containing a deletion]	1.0	6	1	0	0
41645	1624	such activation	[such activation]	1.0	2	2	2	2
41646	1624	contain protein	[containing proteins]	1.0	2	2	2	2
41647	1624	allow rapid testing of the effect	[allowing rapid testing of the effects]	1.0	6	1	0	0
41648	1624	ring sideroblast	[ring sideroblasts]	1.0	2	2	2	2
41649	1624	les-induced expression of ap-1 protein.	[LPS-induced expression of AP-1 protein.]	1.0	5	1	0	0
41650	1624	monofactorial analysis	[Monofactorial analysis]	1.0	2	1	0	0
41651	1624	phosphorylation of creb camp element	[phosphorylation of CREB cAMP element]	1.0	5	1	0	0
41652	1624	two major product of monocyte	[two major products of monocytes]	1.0	5	1	0	0
41653	1624	cell phenotype	[cell phenotype]	1.0	2	2	1	1
41654	1624	cd95, tnfalpha	[CD95, TNFalpha]	1.0	2	1	0	0
41655	1624	expression in peripheral blood lymphocyte	[Expression in peripheral blood lymphocytes]	1.0	5	2	2	2
41656	1624	il-1 alpha	[IL-1 alpha]	1.0	2	2	1	1
41657	1624	sodium oleate	[sodium oleate]	1.0	2	1	0	0
41658	1624	high incidence	[higher incidence]	1.0	2	2	2	2
41659	1624	lipid oxidation	[lipid oxidation]	1.0	2	1	0	0
41660	1624	substitution of the peptide sequence	[Substitution of the peptide sequence]	1.0	5	1	0	0
41661	1624	14 nonatopic control subject ige 112+/-28	[14 nonatopic control subjects IgE 112+/-28]	1.0	6	1	0	0
41662	1624	thyroid hormone responsiveness to a promoter	[thyroid hormone responsiveness to a promoter]	1.0	6	1	0	0
41663	1624	weight variant	[weight variant]	1.0	2	2	2	2
41664	1624	t-cell enhancer	[T-cell enhancers]	1.0	2	1	0	0
41665	1624	sequence similar	[sequences similar]	1.0	2	2	2	2
41666	1624	defective htlv-i	[defective HTLV-I]	1.0	2	1	0	0
41667	1624	glucocorticoid asthma	[glucocorticoid asthma]	1.0	2	1	0	0
41668	1624	transcription of lymphokine receptor gene	[transcription of lymphokine receptor genes]	1.0	5	1	0	0
41669	1624	vitro acetylation	[vitro acetylation]	1.0	2	1	0	0
41670	1624	result study 1,25-dihydroxyvitamin D3 calcitriol	[results studying 1,25-dihydroxyvitamin D3 calcitriol]	1.0	5	1	0	0
41671	1624	response to the different stimuli,	[response to the different stimuli,]	1.0	5	1	0	0
41672	1624	human cytomegalovirus hcmv a betaherpesvirus	[Human cytomegalovirus HCMV a betaherpesvirus]	1.0	5	1	0	0
41673	1624	various stages.	[various stages.]	1.0	2	1	0	0
41674	1624	cloning of the murine b-cell coactivator	[Cloning of the murine B-cell coactivator]	1.0	6	1	0	0
41675	1624	Pan protein	[Pan proteins]	1.0	2	4	3	1
41676	1624	MDD group;	[MDD group;]	1.0	2	1	0	0
41677	1624	130 kda	[130 kDa]	1.0	2	1	0	0
41678	1624	c-myb mRNA	[c-myb mRNA]	1.0	2	1	0	0
41679	1624	transient increase in the mrna level	[transient increase in the mRNA levels]	1.0	6	1	0	0
41680	1624	part, the ATF binding site	[part, the ATF binding site]	1.0	5	1	0	0
41681	1624	interferon-regulated gene	[interferon-regulated gene]	1.0	2	2	1	1
41682	1624	culture protein	[culture protein]	1.0	2	1	0	0
41683	1624	direct the expression of class gene	[directing the expression of class genes]	1.0	6	1	0	0
41684	1624	activity of the msr promoter	[activity of the MSR promoter]	1.0	5	1	0	0
41685	1624	eiconsanoid thromboxane a2 b4 ltb4	[eiconsanoids thromboxane A2 B4 LTB4]	1.0	5	1	0	0
41686	1624	total, enzyme	[total, enzyme]	1.0	2	1	0	0
41687	1624	CD4 cell number to ebv	[CD4 cell number to EBV]	1.0	5	1	0	0
41688	1624	multiple cytokine	[multiple cytokines]	1.0	2	1	0	0
41689	1624	positive thymocyte	[positive thymocytes]	1.0	2	1	0	0
41690	1624	many mechanism	[many mechanisms]	1.0	2	1	0	0
41691	1624	member of the Ets family	[member of the Ets family]	1.0	5	2	2	2
41692	1624	peptide cover the sequence individual	[peptides covering the sequence individuals]	1.0	5	1	0	0
41693	1624	selective antagonist	[selective antagonist]	1.0	2	1	0	0
41694	1624	immediate ones,	[immediate ones,]	1.0	2	1	0	0
41695	1624	gc inhibition	[GC inhibition]	1.0	2	2	2	2
41696	1624	interaction with another enhancer element	[interaction with another enhancer element]	1.0	5	1	0	0
41697	1624	primary role	[primary role]	1.0	2	2	2	2
41698	1624	expression of the corresponding mrna	[expression of the corresponding mRNA]	1.0	5	1	0	0
41699	1624	expression of the H+-ATPase b2 subunit	[expression of the H+-ATPase B2 subunit]	1.0	6	1	0	0
41700	1624	respective virus	[respective viruses]	1.0	2	1	0	0
41701	1624	Circadian rhythm	[Circadian rhythm]	1.0	2	2	2	2
41702	1624	addition to well-known cell transformation	[addition to well-known cell transformation]	1.0	5	1	0	0
41703	1624	Epstein-Barr virus EBV a human gamma-herpesvirus	[Epstein-Barr virus EBV a human gamma-herpesvirus]	1.0	6	1	0	0
41704	1624	post-translational acetylation	[post-translational acetylation]	1.0	2	1	0	0
41705	1624	fasl gene	[FasL gene]	1.0	2	1	0	0
41706	1624	control of transcription in T cell	[control of transcription in T cells]	1.0	6	1	0	0
41707	1624	inhibition of protein phosphatase 2a	[Inhibition of protein phosphatase 2A]	1.0	5	1	0	0
41708	1624	activation of Rel/kappaB a family	[activation of Rel/kappaB a family]	1.0	5	1	0	0
41709	1624	normal erythropoiesis.	[normal erythropoiesis.]	1.0	2	1	0	0
41710	1624	tumor cell in most case	[tumor cells in most cases]	1.0	5	1	0	0
41711	1624	15d-pgj(2) PPARgamma	[15d-PGJ(2) PPARgamma]	1.0	2	1	0	0
41712	1624	New datum on the pharmacokinetics	[New data on the pharmacokinetics]	1.0	5	1	0	0
41713	1624	activation of DNA response element	[activation of DNA response elements]	1.0	5	1	0	0
41714	1624	cellular collaboration	[cellular collaboration]	1.0	2	1	0	0
41715	1624	amount of the transcription factor	[amounts of the transcription factors]	1.0	5	1	0	0
41716	1624	suggest a regulator of a set	[suggesting a regulator of a set]	1.0	6	1	0	0
41717	1624	differential gene expression in Th1/Th2	[differential gene expression in Th1/Th2]	1.0	5	1	0	0
41718	1624	responsiveness to t-cell activation signal	[responsiveness to T-cell activation signals]	1.0	5	1	0	0
41719	1624	activate hiv-1 through a tar pathway	[activating HIV-1 through a TAR pathway]	1.0	6	1	0	0
41720	1624	substantial decrease in mineralocorticoid (mr)	[substantial decreases in mineralocorticoid (MR)]	1.0	5	1	0	0
41721	1624	multiple TcR delta transcript derive	[Multiple TcR delta transcripts deriving]	1.0	5	1	0	0
41722	1624	Alagille syndrome	[Alagille syndrome]	1.0	2	2	2	2
41723	1624	inducible expression of coactivator bob.1/obf.1 comments]	[Inducible expression of coactivator BOB.1/OBF.1 comments]]	1.0	6	1	0	0
41724	1624	Furthermore, PD98059	[Furthermore, PD98059]	1.0	2	1	0	0
41725	1624	such regulation.	[such regulation.]	1.0	2	1	0	0
41726	1624	neutrophil il-8	[neutrophil IL-8]	1.0	2	2	2	2
41727	1624	igg level in the culture supernatant	[IgG levels in the culture supernatant]	1.0	6	1	0	0
41728	1624	nuclear extract from Jurkat cell	[nuclear extracts from Jurkat cells]	1.0	5	1	0	0
41729	1624	protein levels,	[protein levels,]	1.0	2	2	1	1
41730	1624	control entry into the cell cycle	[controlling entry into the cell cycle]	1.0	6	1	0	0
41731	1624	biomarker cd45r0+	[biomarkers CD45R0+]	1.0	2	1	0	0
41732	1624	bind to the AP-1 element	[binding to the AP-1 element]	1.0	5	2	2	2
41733	1624	GM2 sequence	[GM2 sequence]	1.0	2	2	2	2
41734	1624	inhibition of fas -mediated killing	[inhibition of Fas -mediated killing]	1.0	5	1	0	0
41735	1624	one undifferentiated SCC cell line	[one undifferentiated SCC cell line]	1.0	5	1	0	0
41736	1624	stimulation of peripheral blood mononuclear cell	[stimulation of peripheral blood mononuclear cells]	1.0	6	2	2	2
41737	1624	stimulation of this kinase in u-937	[stimulation of this kinase in U-937]	1.0	6	1	0	0
41738	1624	A-myb gene	[A-myb gene]	1.0	2	1	0	0
41739	1624	metalloproteinase inhibition	[metalloproteinase inhibition]	1.0	2	1	0	0
41740	1624	matrix-associated region	[matrix-associated region]	1.0	2	1	0	0
41741	1624	transcription of the long terminal repeat	[transcription of the long terminal repeat]	1.0	6	2	2	2
41742	1624	expression of runt polypeptide differentiate cell	[expression of runt polypeptides differentiating cells]	1.0	6	1	0	0
41743	1624	background: patient with anorexia nervosa	[BACKGROUND: Patients with anorexia nervosa]	1.0	5	1	0	0
41744	1624	Functional analysis of monocytic thp-1 cell	[Functional analysis of monocytic THP-1 cells]	1.0	6	1	0	0
41745	1624	10 follow differentiation of a monocyte	[10 following differentiation of a monocyte]	1.0	6	1	0	0
41746	1624	follow expression of the viral protein	[following expression of the viral protein]	1.0	6	1	0	0
41747	1624	process of differentiation of monocyte	[process of differentiation of monocytes]	1.0	5	1	0	0
41748	1624	Interfollicular bcl-6 +/cd3+ cell in AITL/GC	[Interfollicular Bcl-6 +/CD3+ cells in AITL/GC]	1.0	6	1	0	0
41749	1624	multimer of the microb motif	[multimer of the microB motif]	1.0	5	1	0	0
41750	1624	NLS peptide	[NLS peptide]	1.0	2	1	0	0
41751	1624	antiapoptotic activity	[antiapoptotic activity]	1.0	2	1	0	0
41752	1624	pld factor	[PLD factor]	1.0	2	1	0	0
41753	1624	powerful tool for the mapping	[powerful tool for the mapping]	1.0	5	1	0	0
41754	1624	epstein-barr virus latency as carcinoma	[Epstein-Barr virus latency as carcinoma]	1.0	5	1	0	0
41755	1624	only in patient with glomerulonephritis	[only in patients with glomerulonephritis]	1.0	5	1	0	0
41756	1624	transcription factor such as ap-1	[transcription factors such as AP-1]	1.0	5	2	2	2
41757	1624	HTLV-1 T	[HTLV-1 T]	1.0	2	2	2	2
41758	1624	signal by the g-csfr in neutrophil	[signaling by the G-CSFR in neutrophils]	1.0	6	1	0	0
41759	1624	lt-293 activity	[LT-293 activity]	1.0	2	1	0	0
41760	1624	killing by NK cell follow immortalization	[killing by NK cells following immortalization]	1.0	6	1	0	0
41761	1624	express different level of hsf2-alpha	[expressing different levels of HSF2-alpha]	1.0	5	1	0	0
41762	1624	express ebv during different stage	[expressing EBV during different stages]	1.0	5	1	0	0
41763	1624	translocation involve the BCL-6 gene	[Translocations involving the BCL-6 gene]	1.0	5	1	0	0
41764	1624	mineralocorticoid aldosterone	[mineralocorticoid aldosterone]	1.0	2	1	0	0
41765	1624	transcription stat6	[transcription STAT6]	1.0	2	2	2	2
41766	1624	Separate Cox analysis for premenopausal patient	[Separate Cox analysis for premenopausal patients]	1.0	6	1	0	0
41767	1624	opioid receptor by thymic T lymphocyte	[opioid receptors by thymic T lymphocytes]	1.0	6	1	0	0
41768	1624	cd8(+)-t-cell response	[CD8(+)-T-cell response]	1.0	2	2	2	2
41769	1624	cos-1 cell	[COS-1 cells]	1.0	2	2	1	1
41770	1624	negative element from bp -267	[negative element from bp -267]	1.0	5	1	0	0
41771	1624	transport of class ii molecule	[transport of class II molecules]	1.0	5	2	1	1
41772	1624	downstream 3'	[downstream 3']	1.0	2	1	0	0
41773	1624	positive signal in T cell	[positive signal in T cells]	1.0	5	1	0	0
41774	1624	expression of the il-2r alpha-chain	[expression of the IL-2R alpha-chain]	1.0	5	1	0	0
41775	1624	addition, BMT	[addition, BMT]	1.0	2	1	0	0
41776	1624	leukocyte activity	[leukocyte activity]	1.0	2	2	2	2
41777	1624	effect of prostaglandin e2 PGE2	[effects of prostaglandin E2 PGE2]	1.0	5	1	0	0
41778	1624	total level of creb protein	[total level of CREB protein]	1.0	5	1	0	0
41779	1624	IL-2-inducible enhancer	[IL-2-inducible enhancer]	1.0	2	1	0	0
41780	1624	tnf-alpha transcription	[TNF-alpha transcription]	1.0	2	2	2	2
41781	1624	distal T	[distal T]	1.0	2	1	0	0
41782	1624	deletion of C-terminal 70z/3 sequence	[deletions of C-terminal 70Z/3 sequences]	1.0	5	1	0	0
41783	1624	intrinsic ability	[intrinsic ability]	1.0	2	1	0	0
41784	1624	microscopic examination	[microscopic examination]	1.0	2	1	0	0
41785	1624	bear a NF- chi b site	[bearing a NF- chi B site]	1.0	6	1	0	0
41786	1624	mutant allele	[mutant allele]	1.0	2	2	1	1
41787	1624	very early activation of ap-1	[very early activation of AP-1]	1.0	5	1	0	0
41788	1624	monocyte counter-receptor for endothelial selectin	[monocyte counter-receptor for endothelial selectins]	1.0	5	1	0	0
41789	1624	molecular immunology	[molecular immunology]	1.0	2	1	0	0
41790	1624	response of the hiv-1 LTR	[response of the HIV-1 LTR]	1.0	5	1	0	0
41791	1624	(86 man	[(86 men]	1.0	2	1	0	0
41792	1624	novel membrane receptor for aldosterone	[novel membrane receptor for aldosterone]	1.0	5	1	0	0
41793	1624	tumor necrosis factor production in monocyte	[tumor necrosis factor production in monocytes]	1.0	6	1	0	0
41794	1624	hiv-1 accessory gene product vpr	[HIV-1 accessory gene product Vpr]	1.0	5	1	0	0
41795	1624	addition, fluorescent	[addition, fluorescent]	1.0	2	1	0	0
41796	1624	induce transcription through IL-6 response element	[inducing transcription through IL-6 response elements]	1.0	6	1	0	0
41797	1624	Indeed, monocyte	[Indeed, monocytes]	1.0	2	1	0	0
41798	1624	gt box	[GT box]	1.0	2	1	0	0
41799	1624	include IkappaBalpha	[including IkappaBalpha]	1.0	2	1	0	0
41800	1624	overexpression of dr-nm23 a protein	[Overexpression of DR-nm23 a protein]	1.0	5	1	0	0
41801	1624	ubiquitous Oct-1	[ubiquitous Oct-1]	1.0	2	1	0	0
41802	1624	transcriptional competence of a subfamily	[transcriptional competence of a subfamily]	1.0	5	1	0	0
41803	1624	role in pathophysiology of leukaemia	[role in pathophysiology of leukaemia]	1.0	5	1	0	0
41804	1624	important source of 135(oh)2d3 production	[important source of 1,25(OH)2D3 production]	1.0	5	1	0	0
41805	1624	i.e. fatigue	[i.e. fatigue]	1.0	2	1	0	0
41806	1624	neutrophilic lineage	[neutrophilic lineage]	1.0	2	1	0	0
41807	1624	gsh gssg	[GSH GSSG]	1.0	2	2	2	2
41808	1624	GAL4 activator capable of stimulation	[GAL4 activators capable of stimulation]	1.0	5	1	0	0
41809	1624	region of the BZLF-1 locus	[regions of the BZLF-1 locus]	1.0	5	1	0	0
41810	1624	mitogen-activated protein kinase signal cascade	[mitogen-activated protein kinase signaling cascade]	1.0	5	1	0	0
41811	1624	rapamycin process	[rapamycin processes]	1.0	2	1	0	0
41812	1624	rs cell of hiv-hd express CD40	[RS cells of HIV-HD express CD40]	1.0	6	1	0	0
41813	1624	450 kb	[450 kb]	1.0	2	1	0	0
41814	1624	IKK -alpha	[IKK -alpha]	1.0	2	1	0	0
41815	1624	strain of tal-1 transgenic mouse	[strain of tal-1 transgenic mice]	1.0	5	1	0	0
41816	1624	Escherichia coli lps 30 micrograms/kg).	[Escherichia coli LPS 30 micrograms/kg).]	1.0	5	1	0	0
41817	1624	378 bp)	[378 bp)]	1.0	2	1	0	0
41818	1624	effect on N-terminal c-jun kinase	[effects on N-terminal c-Jun kinase]	1.0	5	1	0	0
41819	1624	mutation frequency	[mutation frequency]	1.0	2	2	1	1
41820	1624	competence phase	[competence phase]	1.0	2	1	0	0
41821	1624	ifn-gamma receptor	[IFN-gamma receptor]	1.0	2	1	0	0
41822	1624	activate interleukin-2 (il-2) gene expression	[activating interleukin-2 (IL-2) gene expression]	1.0	5	1	0	0
41823	1624	specific activity	[specific activity]	1.0	2	1	0	0
41824	1624	vitro transcription of 15B-7 cDNA	[vitro transcription of 15B-7 cDNA]	1.0	5	1	0	0
41825	1624	differentiation of bone marrow cell	[differentiation of bone marrow cells]	1.0	5	1	0	0
41826	1624	analysis of different creb mutant	[Analysis of different CREB mutants]	1.0	5	1	0	0
41827	1624	Ig-expressing hybrid	[Ig-expressing hybrids]	1.0	2	1	0	0
41828	1624	potential binding site for stat protein	[potential binding sites for STAT proteins]	1.0	6	1	0	0
41829	1624	signal transduction event in cell	[signal transduction events in cells]	1.0	5	1	0	0
41830	1624	apparent mass	[apparent mass]	1.0	2	3	2	1
41831	1624	IL-4 element	[IL-4 elements]	1.0	2	2	2	2
41832	1624	reconstitution of a cell-free system	[Reconstitution of a cell-free system]	1.0	5	1	0	0
41833	1624	c-rel induction	[c-Rel induction]	1.0	2	2	1	1
41834	1624	lps nf kappa b activation	[LPS NF kappa B activation]	1.0	5	1	0	0
41835	1624	correlation between glucocorticosteroid receptor number	[correlation between glucocorticosteroid receptor number]	1.0	5	1	0	0
41836	1624	20 patient with breast cancer	[20 patients with breast cancer]	1.0	5	1	0	0
41837	1624	monocytic cell adhesion to cell	[monocytic cell adhesion to cells]	1.0	5	2	2	2
41838	1624	two-phase neutrophil-endothelial cell adhesion response	[two-phase neutrophil-endothelial cell adhesion response]	1.0	5	1	0	0
41839	1624	sensitization of cell to apoptosis	[sensitization of cells to apoptosis]	1.0	5	1	0	0
41840	1624	10 ng/ml of phorbol ester	[10 ng/ml of phorbol ester]	1.0	5	1	0	0
41841	1624	mutation occur	[mutations occurring]	1.0	2	1	0	0
41842	1624	nf-kappa b activity in T lymphocyte	[NF-kappa B activity in T lymphocytes]	1.0	6	2	2	2
41843	1624	protein product of this gene	[protein products of this gene]	1.0	5	1	0	0
41844	1624	molecular mechanism of EBNA2 transactivation	[molecular mechanism of EBNA2 transactivation]	1.0	5	1	0	0
41845	1624	cytoplasmic extract from this subclone	[cytoplasmic extracts from these subclones]	1.0	5	1	0	0
41846	1624	count the percentage of macrophage	[counting the percentage of macrophages]	1.0	5	1	0	0
41847	1624	removal of the tnf-alpha contain medium	[removal of the TNF-alpha containing medium]	1.0	6	1	0	0
41848	1624	special precaution	[special precautions]	1.0	2	1	0	0
41849	1624	direct, effect	[direct, effects]	1.0	2	1	0	0
41850	1624	involvement of reactive oxygen species	[involvement of reactive oxygen species]	1.0	5	2	1	1
41851	1624	almost no effect on c-jun	[almost no effect on c-jun]	1.0	5	1	0	0
41852	1624	use this cDNA as the probe,	[Using this cDNA as the probe,]	1.0	6	1	0	0
41853	1624	tissue-specific induction.	[tissue-specific induction.]	1.0	2	1	0	0
41854	1624	adult T cell leukemia(atl) cell	[adult T cell leukemia(ATL) cells]	1.0	5	1	0	0
41855	1624	suppression sla-dr	[suppression SLA-DR]	1.0	2	2	2	2
41856	1624	Crkl a SH2/SH3 adapter protein	[Crkl an SH2/SH3 adapter protein]	1.0	5	1	0	0
41857	1624	contrast, Oct-2A	[contrast, Oct-2A]	1.0	2	1	0	0
41858	1624	a g	[A G]	1.0	2	1	0	0
41859	1624	number of IL-4 binding site	[number of IL-4 binding sites]	1.0	5	1	0	0
41860	1624	lps activation of the nuclear factor	[LPS activation of the nuclear factor]	1.0	6	1	0	0
41861	1624	Glucocorticoid apoptosis	[Glucocorticoid apoptosis]	1.0	2	3	2	1
41862	1624	regard the role of alveolar macrophage	[regarding the role of alveolar macrophages]	1.0	6	1	0	0
41863	1624	two protein of 75 kD	[two proteins of 75 kD]	1.0	5	2	1	1
41864	1624	clonal growth of this cells.	[clonal growth of these cells.]	1.0	5	1	0	0
41865	1624	segment polarity;	[segment polarity;]	1.0	2	1	0	0
41866	1624	stat factor	[STAT factors]	1.0	2	3	2	1
41867	1624	therapeutic benefit	[therapeutic benefits]	1.0	2	2	2	2
41868	1624	mrna stability between the allele	[mRNA stability between the alleles]	1.0	5	1	0	0
41869	1624	single form	[single form]	1.0	2	1	0	0
41870	1624	exon V in patient individual	[exon V in patient individuals]	1.0	5	1	0	0
41871	1624	carrier of the mutation present	[carriers of the mutation present]	1.0	5	1	0	0
41872	1624	human DNA	[human DNA]	1.0	2	2	2	2
41873	1624	activity of the ac cascade	[activity of the AC cascade]	1.0	5	1	0	0
41874	1624	T lymphoblast	[T lymphoblasts]	1.0	2	2	2	2
41875	1624	total dose	[total dose]	1.0	2	1	0	0
41876	1624	partial sequence	[partial sequences]	1.0	2	1	0	0
41877	1624	phenotypic effect	[phenotypic effects]	1.0	2	1	0	0
41878	1624	such as the nfatc transcription factor	[such as the NFATc transcription factor]	1.0	6	1	0	0
41879	1624	Functional characterization of the murine homolog	[Functional characterization of the murine homolog]	1.0	6	1	0	0
41880	1624	lytic gene	[lytic gene]	1.0	2	1	0	0
41881	1624	cd1+relb+ cell	[CD1+RelB+ cells]	1.0	2	2	2	2
41882	1624	sp1 protein	[Sp1 protein]	1.0	2	2	1	1
41883	1624	inability of the cortisol level	[inability of the cortisol levels]	1.0	5	1	0	0
41884	1624	AU motif	[AU motifs]	1.0	2	1	0	0
41885	1624	p53 level	[p53 levels]	1.0	2	2	1	1
41886	1624	pkc-zeta	[PKC-zeta]	1.0	1	11	5	5
41887	1624	differentiation capacity	[differentiation capacity]	1.0	2	1	0	0
41888	1624	active material	[active material]	1.0	2	1	0	0
41889	1624	T cell by the mab BW	[T cells by the mAb BW]	1.0	6	1	0	0
41890	1624	relationship of the N-Oct protein	[relationship of the N-Oct proteins]	1.0	5	1	0	0
41891	1624	leukocyte adhesion to corneal endothelial cell	[leukocyte adhesion to corneal endothelial cells]	1.0	6	1	0	0
41892	1624	group sequence	[group sequences]	1.0	2	1	0	0
41893	1624	synthesis of additional protein factor	[synthesis of additional protein factors]	1.0	5	1	0	0
41894	1624	prostatic spermine	[prostatic spermine]	1.0	2	1	0	0
41895	1624	significant level of Spi-B mrna	[significant levels of Spi-B mRNA]	1.0	5	1	0	0
41896	1624	four time	[four times]	1.0	2	1	0	0
41897	1624	mutation of the CBF1/RBP-Jkappa binding site	[Mutation of the CBF1/RBP-Jkappa binding site]	1.0	6	1	0	0
41898	1624	c-fo induction,	[c-fos induction,]	1.0	2	1	0	0
41899	1624	nf-at-1 element	[NF-AT-1 element]	1.0	2	1	0	0
41900	1624	a/r	[A/R]	1.0	1	11	2	2
41901	1624	induction during t-cell activation by antigen	[Induction during T-cell activation by antigen]	1.0	6	1	0	0
41902	1624	[rh]-dex-bind assay	[[3H]-DEX-binding assays]	1.0	2	1	0	0
41903	1624	multiple sclerosis	[multiple sclerosis]	1.0	2	2	1	1
41904	1624	1 alpha,25-dihydroxyvitamin D3 gene regulation	[1 alpha,25-dihydroxyvitamin D3 gene regulation]	1.0	5	1	0	0
41905	1624	other cytokines,	[other cytokines,]	1.0	2	1	0	0
41906	1624	calcineurin mutation	[calcineurin mutations]	1.0	2	1	0	0
41907	1624	cytoplasmic region	[cytoplasmic region]	1.0	2	1	0	0
41908	1624	0.05) thyroglobulin	[0.05), thyroglobulin]	1.0	2	1	0	0
41909	1624	core binding factor- alpha (aml1)	[core binding factor- alpha (AML1)]	1.0	5	1	0	0
41910	1624	relatively young (18- to 35-year-old)	[relatively young (18- to 35-year-old)]	1.0	5	1	0	0
41911	1624	Finally, addition of ref-1 from monocyte	[Finally, addition of REF-1 from monocytes]	1.0	6	1	0	0
41912	1624	hormone/receptor complex	[hormone/receptor complexes]	1.0	2	2	1	1
41913	1624	human mineralocorticoid	[human mineralocorticoid]	1.0	2	1	0	0
41914	1624	part of the NF-kappaB complex	[part of the NF-kappaB complex]	1.0	5	1	0	0
41915	1624	various activators, include 15-deoxy-delta12,14-prostaglandin J2	[various activators, including 15-deoxy-delta12,14-prostaglandin J2]	1.0	5	1	0	0
41916	1624	more intense staining in comedo	[more intense staining in comedo]	1.0	5	1	0	0
41917	1624	expression of this related gene	[expression of these related genes]	1.0	5	1	0	0
41918	1624	tyrosine phosphatase specific inhibitor pervanadate	[tyrosine phosphatase specific inhibitor pervanadate]	1.0	5	1	0	0
41919	1624	slight increase	[slight increase]	1.0	2	2	2	2
41920	1624	transcription of human immunodeficiency virus-1	[transcription of human immunodeficiency virus-1]	1.0	5	1	0	0
41921	1624	abnormality of cellular glucocorticoid receptor	[abnormalities of cellular glucocorticoid receptors]	1.0	5	1	0	0
41922	1624	wild-type strain	[wild-type strain]	1.0	2	1	0	0
41923	1624	cord blood cd4+ T cell	[cord blood CD4+ T cells]	1.0	5	1	0	0
41924	1624	induction of a monocyte phenotype	[induction of a monocyte phenotype]	1.0	5	1	0	0
41925	1624	human immunodeficiency virus hiv individual	[human immunodeficiency virus HIV individuals]	1.0	5	1	0	0
41926	1624	common haplotype	[common haplotypes]	1.0	2	2	2	2
41927	1624	kinetic of the LIF effect	[kinetics of the LIF effects]	1.0	5	1	0	0
41928	1624	high activity of the transcriptional activator	[high activities of the transcriptional activators]	1.0	6	1	0	0
41929	1624	activation status of the chromosome	[activation status of the chromosomes]	1.0	5	1	0	0
41930	1624	extracellular domain stem cell factor	[extracellular domain stem cell factor]	1.0	5	1	0	0
41931	1624	induction of NF kappa b	[induction of NF kappa B]	1.0	5	1	0	0
41932	1624	neoplastic follicle	[neoplastic follicles]	1.0	2	1	0	0
41933	1624	il-1 convert enzyme caspase-3 -like cpp32/yama/apopain	[IL-1 converting enzyme caspase-3 -like CPP32/Yama/apopain]	1.0	6	1	0	0
41934	1624	multiple transcript in pre-B line	[multiple transcripts in pre-B lines]	1.0	5	1	0	0
41935	1624	contain c-rel	[containing c-rel]	1.0	2	1	0	0
41936	1624	mlv transcription in lymphoid cell line	[MLV transcription in lymphoid cell lines]	1.0	6	1	0	0
41937	1624	nuclear extract from Daudi cell	[nuclear extract from Daudi cells]	1.0	5	1	0	0
41938	1624	10 microM.	[10 microM.]	1.0	2	1	0	0
41939	1624	proteolysis-resistant inhibitor	[proteolysis-resistant inhibitor]	1.0	2	1	0	0
41940	1624	10 microM,	[10 microM,]	1.0	2	1	0	0
41941	1624	fibroblast context	[fibroblast context]	1.0	2	1	0	0
41942	1624	pd-c hydrogenation of 3,21-diacetoxy-5 beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[Pd-C hydrogenation of 3,21-diacetoxy-5 beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	1.0	5	1	0	0
41943	1624	important tissue-specific regulatory DNA element	[important tissue-specific regulatory DNA element]	1.0	5	1	0	0
41944	1624	(MHC) class	[(MHC) class]	1.0	2	2	2	2
41945	1624	p105 protein	[p105 protein]	1.0	2	1	0	0
41946	1624	cell-specific activity of the enhancer	[cell-specific activity of the enhancer]	1.0	5	1	0	0
41947	1624	e1a expression on the phenotype	[E1A expression on the phenotypes]	1.0	5	1	0	0
41948	1624	hyperlipidemic patient	[hyperlipidemic patients]	1.0	2	1	0	0
41949	1624	two site in the promoter	[two sites in the promoter]	1.0	5	1	0	0
41950	1624	Mn sod in human monocyte	[Mn SOD in human monocytes]	1.0	5	1	0	0
41951	1624	site-specific transcriptional property for E2A- HLF	[site-specific transcriptional properties for E2A- HLF]	1.0	6	1	0	0
41952	1624	hsf2 isoform	[HSF2 isoforms]	1.0	2	1	0	0
41953	1624	gas sequence	[GAS sequence]	1.0	2	1	0	0
41954	1624	N-terminal activation domain of GATA-1	[N-terminal activation domain of GATA-1]	1.0	5	1	0	0
41955	1624	1-60 min.	[1-60 min.]	1.0	2	1	0	0
41956	1624	low mobility	[low mobility]	1.0	2	1	0	0
41957	1624	globin program	[globin program]	1.0	2	2	2	2
41958	1624	phosphorylation of numerous intracellular substrate	[phosphorylation of numerous intracellular substrates]	1.0	5	1	0	0
41959	1624	monocyte adherent	[monocytes adherent]	1.0	2	2	2	2
41960	1624	number of cell contain gamma-globin	[numbers of cells containing gamma-globin]	1.0	5	1	0	0
41961	1624	neoplastic counterpart	[neoplastic counterparts]	1.0	2	1	0	0
41962	1624	several mechanisms,	[several mechanisms,]	1.0	2	1	0	0
41963	1624	initial step of leukocyte adhesion	[initial step of leukocyte adhesion]	1.0	5	1	0	0
41964	1624	small percentage	[small percentage]	1.0	2	2	2	2
41965	1624	originate approximately 204 bp upstream	[originating approximately 204 bp upstream]	1.0	5	1	0	0
41966	1624	self peptide	[self peptides]	1.0	2	2	1	1
41967	1624	evidence for a NAD(P)H:quinone reductase mechanism	[evidence for a NAD(P)H:quinone reductase mechanism]	1.0	6	1	0	0
41968	1624	stat1 activity	[Stat1 activity]	1.0	2	2	1	1
41969	1624	induction of Mn sod mrna	[induction of Mn SOD mRNA]	1.0	5	1	0	0
41970	1624	gene expression in mammary cell	[gene expression in mammary cells]	1.0	5	1	0	0
41971	1624	3 hour with the antibody,	[3 hr with the antibody,]	1.0	5	1	0	0
41972	1624	suggest essential for interaction with protein	[suggesting essential for interaction with proteins]	1.0	6	1	0	0
41973	1624	[3H]Thymidine incorporation	[[3H]Thymidine incorporation]	1.0	2	1	0	0
41974	1624	difference in the regulatory domain	[differences in the regulatory domain]	1.0	5	1	0	0
41975	1624	rna coding for the receptor	[RNA coding for the receptor]	1.0	5	1	0	0
41976	1624	activation of the IkappaBalpha gene	[activation of the IkappaBalpha gene]	1.0	5	1	0	0
41977	1624	iron	[iron]	1.0	1	11	4	4
41978	1624	radical scavenger	[radical scavenger]	1.0	2	2	1	1
41979	1624	human choriocarcinoma	[human choriocarcinoma]	1.0	2	1	0	0
41980	1624	shock syndrome	[shock syndrome]	1.0	2	2	2	2
41981	1624	potential therapy	[potential therapy]	1.0	2	1	0	0
41982	1624	two pathway essential for this stage	[two pathways essential for this stage]	1.0	6	1	0	0
41983	1624	inhibitor of the T immune response	[inhibitors of the T immune response]	1.0	6	1	0	0
41984	1624	adenoviral technique	[adenoviral technique]	1.0	2	2	1	1
41985	1624	alpha subunit of the il-2 receptor	[alpha subunit of the IL-2 receptor]	1.0	6	1	0	0
41986	1624	follow exposure	[following exposure]	1.0	2	2	2	2
41987	1624	cortisol (12.2+/-1.6	[cortisol (12.2+/-1.6]	1.0	2	1	0	0
41988	1624	hiv-infected patient	[HIV-infected patients]	1.0	2	2	2	2
41989	1624	vivo, after bone marrow transplantation	[vivo, after bone marrow transplantation]	1.0	5	1	0	0
41990	1624	expression of the myeloid-specific surface marker	[expression of the myeloid-specific surface markers]	1.0	6	1	0	0
41991	1624	nuclear I(kappa)B(alpha)	[nuclear I(kappa)B(alpha)]	1.0	2	1	0	0
41992	1624	encode interferon (ifn) consensus sequence-bind protein	[encoding interferon (IFN) consensus sequence-binding protein]	1.0	6	1	0	0
41993	1624	tax gene	[tax gene]	1.0	2	5	4	1
41994	1624	postreceptor level	[postreceptor level]	1.0	2	1	0	0
41995	1624	distinct stimulus	[distinct stimuli]	1.0	2	1	0	0
41996	1624	such as the squirrel monkey	[such as the squirrel monkey]	1.0	5	1	0	0
41997	1624	fl5.12 line	[FL5.12 line]	1.0	2	1	0	0
41998	1624	two dna-binding complex in human eosinophil	[two DNA-binding complexes in human eosinophils]	1.0	6	1	0	0
41999	1624	strong increase	[strong increase]	1.0	2	2	2	2
42000	1624	other pathogens.	[other pathogens.]	1.0	2	1	0	0
42001	1624	human CD4	[human CD4]	1.0	2	1	0	0
42002	1624	follow immunization of syngeneic mouse	[following immunization of syngeneic mice]	1.0	5	1	0	0
42003	1624	characterization of the dna-binding protein	[Characterization of the DNA-binding protein]	1.0	5	1	0	0
42004	1624	double-stranded oligonucleotide contain nf-kappab binding sequence	[double-stranded oligonucleotides containing NF-kappaB binding sequence]	1.0	6	1	0	0
42005	1624	RAR alpha in CD38 expression	[RAR alpha in CD38 expression]	1.0	5	1	0	0
42006	1624	ontogeny use a box antiserum	[ontogeny using an box antiserum]	1.0	5	1	0	0
42007	1624	recombinant ifn-gamma	[recombinant IFN-gamma]	1.0	2	1	0	0
42008	1624	most hybrid	[Most hybrids]	1.0	2	1	0	0
42009	1624	collagenase promoter	[collagenase promoter]	1.0	2	2	1	1
42010	1624	functional analysis of deletion mutant	[functional analysis of deletion mutants]	1.0	5	1	0	0
42011	1624	even in the presence of epo	[even in the presence of EPO]	1.0	6	1	0	0
42012	1624	hypersensitivity site	[hypersensitivity site]	1.0	2	2	2	2
42013	1624	such as generation of inositol phosphate	[such as generation of inositol phosphates]	1.0	6	1	0	0
42014	1624	However, replication of ebv in vivo	[However, replication of EBV in vivo]	1.0	6	1	0	0
42015	1624	gh synthesis	[GH synthesis]	1.0	2	1	0	0
42016	1624	hla-restricting determinant	[HLA-restricting determinant]	1.0	2	1	0	0
42017	1624	cell in the lining positive	[cells in the lining positive]	1.0	5	1	0	0
42018	1624	dimerization domain of hnf-1 alpha	[dimerization domain of HNF-1 alpha]	1.0	5	1	0	0
42019	1624	stimulation of interleukin-2 il-2 promoter	[stimulation of interleukin-2 IL-2 promoter]	1.0	5	1	0	0
42020	1624	similarity to the il-2 cd28re	[similarity to the IL-2 CD28RE]	1.0	5	1	0	0
42021	1624	retinoid differentiation	[retinoid differentiation]	1.0	2	2	2	2
42022	1624	band 11p13	[band 11p13]	1.0	2	1	0	0
42023	1624	band 11p15	[band 11p15]	1.0	2	1	0	0
42024	1624	J2 in human monocyte-derived macrophage	[J2 in human monocyte-derived macrophages]	1.0	5	1	0	0
42025	1624	tissue destruction	[tissue destruction]	1.0	2	1	0	0
42026	1624	function of ssb T cell	[function of SSB T cells]	1.0	5	1	0	0
42027	1624	multimer of individual enhancer sequence	[multimers of individual enhancer sequences]	1.0	5	1	0	0
42028	1624	supershift assay use NFATp- antibody	[supershift assays using NFATp- antibodies]	1.0	5	1	0	0
42029	1624	cell proliferation such as c-myc	[cell proliferation such as c-myc]	1.0	5	1	0	0
42030	1624	m Azeptin	[M Azeptin]	1.0	2	2	2	2
42031	1624	mechanism independent	[mechanism independent]	1.0	2	2	1	1
42032	1624	synthesis of cytokine -specific mrna	[synthesis of cytokine -specific mRNA]	1.0	5	1	0	0
42033	1624	novel component	[novel component]	1.0	2	1	0	0
42034	1624	use technique	[using techniques]	1.0	2	2	2	2
42035	1624	diverse tissue	[diverse tissues]	1.0	2	1	0	0
42036	1624	IL-6 mRNAs	[IL-6 mRNAs]	1.0	2	1	0	0
42037	1624	IFN stimulation	[IFN stimulation]	1.0	2	1	0	0
42038	1624	10(-5) m	[10(-5) M]	1.0	2	2	1	1
42039	1624	prevalent complex	[prevalent complex]	1.0	2	1	0	0
42040	1624	-specific memory	[-specific memory]	1.0	2	2	2	2
42041	1624	Intracellular signal	[Intracellular signals]	1.0	2	1	0	0
42042	1624	cortisol in the binding media.	[cortisol in the binding media.]	1.0	5	1	0	0
42043	1624	50% of total cell gelatinase	[50% of total cell gelatinase]	1.0	5	1	0	0
42044	1624	hypothalamic-pituitary-adrenal function	[hypothalamic-pituitary-adrenal function]	1.0	2	1	0	0
42045	1624	multiple blood sample in parallel,	[multiple blood samples in parallel,]	1.0	5	1	0	0
42046	1624	same side	[same side]	1.0	2	1	0	0
42047	1624	Immunol Jul	[Immunol Jul]	1.0	2	2	2	2
42048	1624	Differential phosphorylation	[Differential phosphorylation]	1.0	2	1	0	0
42049	1624	CD28 ligation	[CD28 ligation]	1.0	2	1	0	0
42050	1624	10-d-pregnant rat	[10-d-pregnant rats]	1.0	2	1	0	0
42051	1624	Edman sequence	[Edman sequencing]	1.0	2	1	0	0
42052	1624	different stage of myeloid commitment	[different stages of myeloid commitment]	1.0	5	1	0	0
42053	1624	pharmacologic strategy	[pharmacologic strategy]	1.0	2	2	2	2
42054	1624	antagonist of p50/nf-kappa b inhibition	[antagonist of p50/NF-kappa B inhibition]	1.0	5	1	0	0
42055	1624	effect of pyrrolidine dithiocarbamate pdtc	[effect of pyrrolidine dithiocarbamate PDTC]	1.0	5	1	0	0
42056	1624	constitutive expression in vivo of Fos	[Constitutive expression in vivo of Fos]	1.0	6	1	0	0
42057	1624	human b lymphocyte ig production	[human B lymphocyte Ig production]	1.0	5	1	0	0
42058	1624	expression of the progesterone receptor	[expression of the progesterone receptor]	1.0	5	2	1	1
42059	1624	activation of a reporter gene construct	[activation of a reporter gene construct]	1.0	6	1	0	0
42060	1624	treat hl-60 cell with tpa	[treating HL-60 cells with TPA]	1.0	5	1	0	0
42061	1624	additional pathway regulate gene expression	[additional pathways regulating gene expression]	1.0	5	1	0	0
42062	1624	transcription of the interleukin-2 gene	[transcription of the interleukin-2 gene]	1.0	5	1	0	0
42063	1624	DS subject	[DS subjects]	1.0	2	1	0	0
42064	1624	serine 186	[serine 186]	1.0	2	2	2	2
42065	1624	contain a additional bind site	[containing an additional binding site]	1.0	5	1	0	0
42066	1624	isolation of the first exon	[Isolation of the first exon]	1.0	5	1	0	0
42067	1624	different member of NFAT gene family	[different members of NFAT gene family]	1.0	6	1	0	0
42068	1624	severe vkc	[severe VKC]	1.0	2	1	0	0
42069	1624	natural killer cell (nk) activation	[natural killer cell (NK) activation]	1.0	5	1	0	0
42070	1624	cdc2 mrna expression in cell	[cdc2 mRNA expression in cells]	1.0	5	1	0	0
42071	1624	anti-vcam antibody	[anti-VCAM antibodies]	1.0	2	1	0	0
42072	1624	primer extension analysis of c/ebp-epsilon mrna	[Primer extension analysis of C/EBP-epsilon mRNA]	1.0	6	1	0	0
42073	1624	include the Janus kinase Jak1	[including the Janus kinases Jak1]	1.0	5	1	0	0
42074	1624	downregulation of erythroid transcription factor	[downregulation of erythroid transcription factors]	1.0	5	1	0	0
42075	1624	strong reduction	[strong reduction]	1.0	2	2	1	1
42076	1624	il-6 inducibility	[IL-6 inducibility]	1.0	2	1	0	0
42077	1624	co-stimulatory gene	[co-stimulatory gene]	1.0	2	1	0	0
42078	1624	latter method	[latter method]	1.0	2	1	0	0
42079	1624	human jurkat lymphoblastic T cell	[human Jurkat lymphoblastic T cells]	1.0	5	1	0	0
42080	1624	coordinate induction	[coordinate induction]	1.0	2	2	2	2
42081	1624	heat shock (hs)/stress protein hsp	[heat shock (HS)/stress proteins HSP]	1.0	5	1	0	0
42082	1624	(nk)- kappa b dna-binding activity	[(NK)- kappa B DNA-binding activity]	1.0	5	1	0	0
42083	1624	compelling link between the efficiency	[compelling links between the efficiency]	1.0	5	1	0	0
42084	1624	third approach	[third approach]	1.0	2	1	0	0
42085	1624	however, two potent immunosuppressive agent	[However, two potent immunosuppressive agents]	1.0	5	1	0	0
42086	1624	LMP1 signal	[LMP1 signaling]	1.0	2	2	2	2
42087	1624	PMA activation of a transcription factor	[PMA activation of a transcription factor]	1.0	6	1	0	0
42088	1624	various combination	[various combinations]	1.0	2	2	1	1
42089	1624	chimeric surface	[chimeric surface]	1.0	2	1	0	0
42090	1624	primary t-lymphocyte	[primary T-lymphocytes]	1.0	2	2	2	2
42091	1624	fetal development	[fetal development]	1.0	2	2	1	1
42092	1624	D3 receptor	[D3 receptor]	1.0	2	2	2	2
42093	1624	ebv serology include anti- zebra activity	[EBV serology including anti- ZEBRA activity]	1.0	6	1	0	0
42094	1624	extracellular signal-regulated protein kinase erk	[extracellular signal-regulated protein kinase ERK]	1.0	5	1	0	0
42095	1624	nsaid NFkappaB	[NSAIDs NFkappaB]	1.0	2	1	0	0
42096	1624	granulocyte-macrophage colony-stimulating factor gene expression	[granulocyte-macrophage colony-stimulating factor gene expression]	1.0	5	1	0	0
42097	1624	cellular level,	[cellular level,]	1.0	2	1	0	0
42098	1624	nuclear processing	[nuclear processing]	1.0	2	1	0	0
42099	1624	turn, assembly of this complex	[turn, assembly of this complex]	1.0	5	1	0	0
42100	1624	level of this tcrzeta molecule	[levels of these TCRzeta molecules]	1.0	5	1	0	0
42101	1624	reliable tool predict the occurrence	[reliable tool predicting the occurrence]	1.0	5	1	0	0
42102	1624	important T cell transcription factor	[important T cell transcription factors]	1.0	5	1	0	0
42103	1624	cellular substrate by the G-CSFR	[cellular substrates by the G-CSFR]	1.0	5	1	0	0
42104	1624	receptor on normal T cell	[receptor on normal T cells]	1.0	5	1	0	0
42105	1624	active site	[active site]	1.0	2	2	1	1
42106	1624	circadian rhythm of plasma cortisol	[circadian rhythm of plasma cortisol]	1.0	5	1	0	0
42107	1624	cytokine expression by T helper	[cytokine expression by T helper]	1.0	5	1	0	0
42108	1624	EA-D BMRF1 promoter regulation by Z	[EA-D BMRF1 promoter regulation by Z]	1.0	6	1	0	0
42109	1624	unlabelled testosterone	[unlabelled testosterone]	1.0	2	1	0	0
42110	1624	potent immunogens,	[potent immunogens,]	1.0	2	1	0	0
42111	1624	different member	[different members]	1.0	2	2	1	1
42112	1624	recognition of the pou domain	[recognition of the POU domain]	1.0	5	1	0	0
42113	1624	K+ channel blockade by progesterone	[K+ channel blockade by progesterone]	1.0	5	1	0	0
42114	1624	electro mobility shift assay EMSA	[electro mobility shift assay EMSA]	1.0	5	1	0	0
42115	1624	proliferation of human T cell	[proliferation of human T cells]	1.0	5	2	1	1
42116	1624	binding to the interferon-gamma activation sequence	[binding to the interferon-gamma activation sequence]	1.0	6	1	0	0
42117	1624	8 nmol/l,	[8 nmol/L,]	1.0	2	1	0	0
42118	1624	non-erythroid gene contain gata-responsive element	[non-erythroid genes containing GATA-responsive elements]	1.0	5	1	0	0
42119	1624	tumor necrosis factor signal transducer molecule	[tumor necrosis factor signal transducer molecules]	1.0	6	1	0	0
42120	1624	activation of expression in precursor	[activation of expression in precursors]	1.0	5	1	0	0
42121	1624	IL-4 substitute	[IL-4 substitutes]	1.0	2	1	0	0
42122	1624	include 20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2 5-dihydroxyvitamin D3 kh1060	[including 20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2 5-dihydroxyvitamin D3 KH1060]	1.0	5	1	0	0
42123	1624	LTR superactivation	[LTR superactivation]	1.0	2	1	0	0
42124	1624	bcl-2 expression in cell types,	[bcl-2 expression in cell types,]	1.0	5	1	0	0
42125	1624	globin locus	[globin locus]	1.0	2	2	2	2
42126	1624	suggest primarily dependent on structural constraint	[suggesting primarily dependent on structural constraints]	1.0	6	1	0	0
42127	1624	ribosomal protein	[ribosomal protein]	1.0	2	1	0	0
42128	1624	endocrine gland	[endocrine glands]	1.0	2	1	0	0
42129	1624	2) cross-linking	[2) cross-linking]	1.0	2	1	0	0
42130	1624	utilization of distinct stat protein	[utilization of distinct STAT proteins]	1.0	5	1	0	0
42131	1624	IL4 receptor	[IL4 receptors]	1.0	2	1	0	0
42132	1624	current scheme for asthma pathogenesis	[current scheme for asthma pathogenesis]	1.0	5	1	0	0
42133	1624	trans activate the VCAM-1 promoter	[trans activating the VCAM-1 promoter]	1.0	5	1	0	0
42134	1624	blood platelet	[blood platelets]	1.0	2	2	2	2
42135	1624	biological system	[biological systems]	1.0	2	1	0	0
42136	1624	autosomal xy sex reversal sra1	[autosomal XY sex reversal SRA1]	1.0	5	1	0	0
42137	1624	fasl gene activation follow cd16 cross-linking	[FasL gene activation following CD16 cross-linking]	1.0	6	1	0	0
42138	1624	approach 90%.	[approaching 90%.]	1.0	2	1	0	0
42139	1624	relative role in cytokine gene transcription	[relative role in cytokine gene transcription]	1.0	6	1	0	0
42140	1624	gc box binding protein bteb2	[GC box binding proteins BTEB2]	1.0	5	1	0	0
42141	1624	calcium influx signal in T lymphocytes.	[calcium influx signaling in T lymphocytes.]	1.0	6	1	0	0
42142	1624	human cytomegalovirus binding to human monocyte	[Human cytomegalovirus binding to human monocytes]	1.0	6	1	0	0
42143	1624	membrane cd14	[membrane CD14]	1.0	2	2	2	2
42144	1624	addition to a ubiquitous band	[addition to a ubiquitous band]	1.0	5	1	0	0
42145	1624	m41 h287a	[M41 H287A]	1.0	2	1	0	0
42146	1624	[corrected] cd45ra	[[corrected] CD45RA]	1.0	2	1	0	0
42147	1624	overlap ifngr1 frameshift small deletion	[overlapping IFNGR1 frameshift small deletions]	1.0	5	1	0	0
42148	1624	cytokine in parallel with regulation	[cytokines in parallel with regulation]	1.0	5	1	0	0
42149	1624	mrna level for M-CSF by MM-LDL	[mRNA levels for M-CSF by MM-LDL]	1.0	6	1	0	0
42150	1624	Itk a T cell-specific tyrosine kinase	[Itk a T cell-specific tyrosine kinase]	1.0	6	1	0	0
42151	1624	cryptic epitope for mAb j393	[cryptic epitopes for mAb J393]	1.0	5	1	0	0
42152	1624	cellular homeostasis	[cellular homeostasis]	1.0	2	2	1	1
42153	1624	one 5'hs	[one 5'HS]	1.0	2	1	0	0
42154	1624	vascular endothelial smooth muscle cell	[vascular endothelial smooth muscle cells]	1.0	5	1	0	0
42155	1624	granulocytic colony	[granulocytic colonies]	1.0	2	1	0	0
42156	1624	T cell antigen receptor function	[T cell antigen receptor function]	1.0	5	1	0	0
42157	1624	receptor-receptor dimerization	[receptor-receptor dimerizations]	1.0	2	1	0	0
42158	1624	IL-1beta stimulation of epithelial cell	[IL-1beta stimulation of epithelial cells]	1.0	5	1	0	0
42159	1624	inducible transcription factor nf-kappa b	[inducible transcription factor NF-kappa B]	1.0	5	1	0	0
42160	1624	CD40 induction	[CD40 induction]	1.0	2	2	2	2
42161	1624	potential interaction with other cytokine	[potential interactions with other cytokines]	1.0	5	1	0	0
42162	1624	bodily protein include the surface	[bodily proteins including the surface]	1.0	5	1	0	0
42163	1624	interleukin-10 IL-10	[interleukin-10 IL-10]	1.0	2	1	0	0
42164	1624	lymphocyte from hematopoietic stem cell	[lymphocytes from hematopoietic stem cells]	1.0	5	1	0	0
42165	1624	adult T cell leukemia-derived factor	[adult T cell leukemia-derived factor]	1.0	5	1	0	0
42166	1624	GST- hbd	[GST- HBD]	1.0	2	1	0	0
42167	1624	transduction of biochemical signal lead	[transduction of biochemical signals leading]	1.0	5	1	0	0
42168	1624	nuclear translocation of the transcription factor	[nuclear translocation of the transcription factor]	1.0	6	2	1	1
42169	1624	receptor (gr)	[receptor (GR)]	1.0	2	2	2	2
42170	1624	leucine-rich repeat	[leucine-rich repeat]	1.0	2	1	0	0
42171	1624	nf-(kappa)b activity	[NF-(kappa)B activity]	1.0	2	1	0	0
42172	1624	identification transactivate hhv-6 (gs) gene fragment	[identification transactivating HHV-6 (GS) gene fragments]	1.0	6	1	0	0
42173	1624	apl blast	[APL blasts]	1.0	2	2	1	1
42174	1624	lymphocyte of the fosb gene	[lymphocytes of the FOSB gene]	1.0	5	1	0	0
42175	1624	stat-3 isoform	[Stat-3 isoform]	1.0	2	1	0	0
42176	1624	activation involvement of the lymphokine element	[activation involvement of the lymphokine element]	1.0	6	1	0	0
42177	1624	species-mediated suppression	[species-mediated suppression]	1.0	2	1	0	0
42178	1624	HeLaS3 cells, transfection of Egr-1	[HeLaS3 cells, transfection of Egr-1]	1.0	5	1	0	0
42179	1624	IL-10 secretion	[IL-10 secretion]	1.0	2	2	1	1
42180	1624	atopic individual	[atopic individuals]	1.0	2	1	0	0
42181	1624	T cell through the barrier	[T cells through the barrier]	1.0	5	1	0	0
42182	1624	prolongation of cell cycle time	[prolongation of cell cycle time]	1.0	5	1	0	0
42183	1624	steroid-sensitive group	[steroid-sensitive group]	1.0	2	1	0	0
42184	1624	interaction circulate T cell with cell	[interactions circulating T cells with cells]	1.0	6	1	0	0
42185	1624	rearrangement of amide-containing amino acid	[rearrangements of amide-containing amino acids]	1.0	5	1	0	0
42186	1624	use amino acid sequence information	[Using amino acid sequence information]	1.0	5	1	0	0
42187	1624	mutagenesis of the activator protein-1 site	[Mutagenesis of the activator protein-1 site]	1.0	6	1	0	0
42188	1624	human retinoic x receptor alpha	[human retinoic X receptor alpha]	1.0	5	1	0	0
42189	1624	depolarization of the membrane potential	[depolarization of the membrane potential]	1.0	5	1	0	0
42190	1624	p50/p50 heterodimer	[p50/p50 heterodimers]	1.0	2	1	0	0
42191	1624	[effect of antihypertensive therapy with captopril	[[Effect of antihypertensive therapy with captopril]	1.0	6	1	0	0
42192	1624	G0-->S transition,	[G0-->S transition,]	1.0	2	1	0	0
42193	1624	approximately 50-kda	[approximately 50-kDa]	1.0	2	1	0	0
42194	1624	such as hyaluronic acid through cd44	[such as hyaluronic acid through CD44]	1.0	6	1	0	0
42195	1624	function similar to il-6r in cell	[functions similar to IL-6R in cells]	1.0	6	1	0	0
42196	1624	polyclonal pattern of x inactivation	[polyclonal pattern of X inactivation]	1.0	5	1	0	0
42197	1624	one possibility toward this goal	[One possibility toward this goal]	1.0	5	1	0	0
42198	1624	contain constitutive nuclear nf-kappa b	[containing constitutive nuclear NF-kappa B]	1.0	5	1	0	0
42199	1624	induction of heat shock protein	[induction of heat shock proteins]	1.0	5	1	0	0
42200	1624	include pre-B acute lymphoblastic leukemia	[including pre-B acute lymphoblastic leukemia]	1.0	5	1	0	0
42201	1624	opposite effects:	[opposite effects:]	1.0	2	1	0	0
42202	1624	NK cell-induced hla-dr alpha mrna expression	[NK cell-induced HLA-DR alpha mRNA expression]	1.0	6	1	0	0
42203	1624	nuclear factor-kappaB NF-kappaB binding site	[nuclear factor-kappaB NF-kappaB binding site]	1.0	5	1	0	0
42204	1624	NF-kappa b site at position	[NF-kappa B site at positions]	1.0	5	1	0	0
42205	1624	nuclear factor nf-at (ref. 1)	[nuclear factor NF-AT (ref. 1)]	1.0	5	1	0	0
42206	1624	phorbol ester,	[phorbol ester,]	1.0	2	1	0	0
42207	1624	presence of the codon-10-variant type	[presence of the codon-10-variant type]	1.0	5	1	0	0
42208	1624	binding of the NF-muNR repressor	[binding of the NF-muNR repressor]	1.0	5	1	0	0
42209	1624	several cytokine by human monocyte	[several cytokines by human monocytes]	1.0	5	1	0	0
42210	1624	less infiltrate	[less infiltrating]	1.0	2	1	0	0
42211	1624	cell resistant to the side effect	[cells resistant to the side effects]	1.0	6	1	0	0
42212	1624	binding of c-Rel/ p65 heterodimer	[binding of c-Rel/ p65 heterodimers]	1.0	5	1	0	0
42213	1624	monocytic differentiation of M1 cell	[monocytic differentiation of M1 cells]	1.0	5	1	0	0
42214	1624	effect on the electrolyte transport	[effects on the electrolyte transport]	1.0	5	1	0	0
42215	1624	biomedical importance.	[biomedical importance.]	1.0	2	1	0	0
42216	1624	gata-1 level	[GATA-1 levels]	1.0	2	2	2	2
42217	1624	increase in adherence to plastic	[increase in adherence to plastic]	1.0	5	1	0	0
42218	1624	nf-kappab nuclear translocation in pbmc	[NF-kappaB nuclear translocation in PBMCs]	1.0	5	1	0	0
42219	1624	nfkappab activity in T cell	[NFkappaB activity in T cells]	1.0	5	1	0	0
42220	1624	response to cell activation signal	[response to cell activation signals]	1.0	5	1	0	0
42221	1624	promote ige synthesis by b cell	[promoting IgE synthesis by B cells]	1.0	6	1	0	0
42222	1624	dn construct of myeloid differentiation protein	[DN constructs of myeloid differentiation protein]	1.0	6	1	0	0
42223	1624	underlie the diversification of ig gene	[underlying the diversification of Ig genes]	1.0	6	1	0	0
42224	1624	fragment of Oct-2 contain pouhd	[fragment of Oct-2 containing POUHD]	1.0	5	1	0	0
42225	1624	one individual	[one individual]	1.0	2	1	0	0
42226	1624	extreme phenotype in a spectrum	[extreme phenotypes in a spectrum]	1.0	5	1	0	0
42227	1624	level of mnda mrna variation	[level of MNDA mRNA variation]	1.0	5	1	0	0
42228	1624	signal agonist	[signaling agonists]	1.0	2	1	0	0
42229	1624	binding study with BSAP recognition sequence	[Binding studies with BSAP recognition sequences]	1.0	6	1	0	0
42230	1624	b-cell-specific response	[B-cell-specific response]	1.0	2	1	0	0
42231	1624	macrophage-CSF M-CSF in human monocyte	[macrophage-CSF M-CSF in human monocytes]	1.0	5	1	0	0
42232	1624	xist-specific fish	[XIST-specific FISH]	1.0	2	1	0	0
42233	1624	zinc-finger region	[zinc-finger region]	1.0	2	1	0	0
42234	1624	bcl-2 gene	[BCL-2 gene]	1.0	2	2	2	2
42235	1624	influence the IL-2 octamer motif	[influencing the IL-2 octamer motif]	1.0	5	1	0	0
42236	1624	significative change in ebv latency	[significative changes in EBV latency]	1.0	5	1	0	0
42237	1624	Ca2+ influx	[Ca2+ influx]	1.0	2	1	0	0
42238	1624	high values.	[higher values.]	1.0	2	1	0	0
42239	1624	2 woman with dupuytren' disease	[2 women with Dupuytren's disease]	1.0	5	1	0	0
42240	1624	result of this other study	[results of these other studies]	1.0	5	1	0	0
42241	1624	dm promoter	[DM promoters]	1.0	2	2	1	1
42242	1624	regulate transcription from the hiv- LTR	[regulating transcription from the HIV- LTR]	1.0	6	1	0	0
42243	1624	porcine ec	[porcine EC]	1.0	2	1	0	0
42244	1624	kappab-responsive element	[kappaB-responsive elements]	1.0	2	2	1	1
42245	1624	CEM c7 cell t-cell line	[CEM C7 cells T-cell line]	1.0	5	1	0	0
42246	1624	induce apoptosis of malignant lymphoid cell	[inducing apoptosis of malignant lymphoid cells]	1.0	6	1	0	0
42247	1624	compensatory response of cell culminate	[compensatory response of cells culminating]	1.0	5	1	0	0
42248	1624	Bcl-x b cell from apoptosis	[Bcl-x B cells from apoptosis]	1.0	5	1	0	0
42249	1624	computational approach	[computational approach]	1.0	2	1	0	0
42250	1624	alpha B5A	[alpha B5A]	1.0	2	1	0	0
42251	1624	thus, deregulation of gene encode	[Thus, deregulation of genes encoding]	1.0	5	1	0	0
42252	1624	T leukemia	[T leukemia]	1.0	2	2	2	2
42253	1624	mechanism of leukemic cell infiltration	[mechanism of leukemic cell infiltration]	1.0	5	1	0	0
42254	1624	secondary increase in the production	[secondary increase in the production]	1.0	5	1	0	0
42255	1624	various set of somatic cell hybrid	[various sets of somatic cell hybrids]	1.0	6	1	0	0
42256	1624	l-selectin mrna	[L-selectin mRNA]	1.0	2	2	1	1
42257	1624	AMP camp	[AMP cAMP]	1.0	2	2	2	2
42258	1624	cell-mediated tcell	[cell-mediated Tcell]	1.0	2	1	0	0
42259	1624	ori1yt enhancer	[ORI1yt enhancer]	1.0	2	1	0	0
42260	1624	dimerization of a mammalian homeodomain protein	[dimerization of a mammalian homeodomain protein]	1.0	6	1	0	0
42261	1624	ap-2 DNA binding during hl-60 differentiation	[AP-2 DNA binding during HL-60 differentiation]	1.0	6	1	0	0
42262	1624	monocyte-mediated killing	[monocyte-mediated killing]	1.0	2	1	0	0
42263	1624	general population	[general population]	1.0	2	1	0	0
42264	1624	CRE site in region ii	[CRE sites in region II]	1.0	5	1	0	0
42265	1624	contrast, camp	[contrast, cAMP]	1.0	2	2	1	1
42266	1624	myeloid-specific expression of a reporter gene	[myeloid-specific expression of a reporter gene]	1.0	6	1	0	0
42267	1624	pu.1 function as transcriptional activator	[PU.1 function as transcriptional activators]	1.0	5	1	0	0
42268	1624	ab secretion	[Ab secretion]	1.0	2	1	0	0
42269	1624	immunoglobulin molecule	[immunoglobulin molecules]	1.0	2	2	2	2
42270	1624	mutation of the microb DNA motif	[mutation of the microB DNA motif]	1.0	6	1	0	0
42271	1624	six exon	[six exons]	1.0	2	1	0	0
42272	1624	regulation of the promoter BMRF1	[regulation of the promoter BMRF1]	1.0	5	1	0	0
42273	1624	transcription factor by the process	[transcription factors by the process]	1.0	5	1	0	0
42274	1624	Jurkat cells,	[Jurkat cells,]	1.0	2	2	1	1
42275	1624	submandibular gland	[submandibular gland]	1.0	2	1	0	0
42276	1624	t-cell treatment	[T-cells treatment]	1.0	2	1	0	0
42277	1624	adherence of monocyte to endothelium	[adherence of monocytes to endothelium]	1.0	5	1	0	0
42278	1624	level of icam-1 mrna expression	[levels of ICAM-1 mRNA expression]	1.0	5	1	0	0
42279	1624	resistance to NK cell lysis	[resistance to NK cell lysis]	1.0	5	1	0	0
42280	1624	intracellular trafficking	[intracellular trafficking]	1.0	2	1	0	0
42281	1624	level of pge2 bind to receptor	[levels of PGE2 bind to receptors]	1.0	6	1	0	0
42282	1624	100 ng/ml	[100 ng/ml]	1.0	2	1	0	0
42283	1624	Thus, p65	[Thus, p65]	1.0	2	1	0	0
42284	1624	interleukin 1-beta	[interleukin 1-beta]	1.0	2	1	0	0
42285	1624	putative lymphocyte g0/g1 switch gene	[putative lymphocyte G0/G1 switch gene]	1.0	5	2	2	2
42286	1624	biological variation	[biological variation]	1.0	2	1	0	0
42287	1624	-contain regimen	[-containing regimens]	1.0	2	1	0	0
42288	1624	pertain to macrophage response to LPS	[pertaining to macrophage response to LPS]	1.0	6	1	0	0
42289	1624	LTR modification	[LTR modification]	1.0	2	1	0	0
42290	1624	ige production for b cell	[IgE production for B cells]	1.0	5	1	0	0
42291	1624	little effect on c-fo induction	[little effect on c-fos induction]	1.0	5	1	0	0
42292	1624	er gene	[ER gene]	1.0	2	2	2	2
42293	1624	aminothiol compound with antioxidant activity	[aminothiol compound with antioxidant activity]	1.0	5	1	0	0
42294	1624	hnf1 pcd/dcoh	[HNF1 PCD/DCoH]	1.0	2	1	0	0
42295	1624	agonist combination	[agonist combinations]	1.0	2	1	0	0
42296	1624	anti-CD3 mab/il-2-	[anti-CD3 mAb/IL-2-]	1.0	2	1	0	0
42297	1624	interaction of EBNA-2 with the DNA	[interaction of EBNA-2 with the DNA]	1.0	6	1	0	0
42298	1624	hematopoietic tissue	[hematopoietic tissues]	1.0	2	2	1	1
42299	1624	inducible phosphorylation to two serine	[inducible phosphorylation to two serines]	1.0	5	1	0	0
42300	1624	typical morphology,	[typical morphology,]	1.0	2	1	0	0
42301	1624	intracellular accumulation of the rrna	[intracellular accumulation of the mRNAs]	1.0	5	1	0	0
42302	1624	55 kD tnf receptor tr55	[55 kD TNF receptor TR55]	1.0	5	1	0	0
42303	1624	oxidative stress on nfat activation	[oxidative stresses on NFAT activation]	1.0	5	1	0	0
42304	1624	lipoprotein ldl	[lipoprotein LDL]	1.0	2	2	2	2
42305	1624	variant er	[variant ER]	1.0	2	1	0	0
42306	1624	other nf-kappa b -binding element	[other NF-kappa B -binding elements]	1.0	5	1	0	0
42307	1624	clinical responsiveness	[clinical responsiveness]	1.0	2	2	2	2
42308	1624	immune parameter	[Immune parameters]	1.0	2	1	0	0
42309	1624	accord to the amlcg86/92 protocol	[according to the AMLCG86/92 protocols]	1.0	5	1	0	0
42310	1624	emanate from specific cytokine factor receptor	[emanating from specific cytokine factor receptors]	1.0	6	1	0	0
42311	1624	cya	[CyA]	1.0	1	11	3	3
42312	1624	tyrosine phosphorylation of the tpo receptor	[tyrosine phosphorylation of the TPO receptor]	1.0	6	1	0	0
42313	1624	surface expression of the chimeric receptor	[surface expression of the chimeric receptor]	1.0	6	1	0	0
42314	1624	hla-dq expression	[HLA-DQ expression]	1.0	2	1	0	0
42315	1624	expression of the bcl6 gene	[expression of the BCL6 gene]	1.0	5	1	0	0
42316	1624	two different promoters, anf-e2 promoter	[two different promoters, aNF-E2 promoter]	1.0	5	1	0	0
42317	1624	expression of mip-1 alpha /gos19	[expression of MIP-1 alpha /GOS19]	1.0	5	1	0	0
42318	1624	Rap1 activation	[Rap1 activation]	1.0	2	2	2	2
42319	1624	luciferase reporter construct contain element	[luciferase reporter construct containing elements]	1.0	5	1	0	0
42320	1624	small animal model of xenotransplantation	[small animal models of xenotransplantation]	1.0	5	1	0	0
42321	1624	primary granulocyte	[primary granulocytes]	1.0	2	1	0	0
42322	1624	interactive protein	[interactive proteins]	1.0	2	1	0	0
42323	1624	highly efficient class ii processing	[highly efficient class II processing]	1.0	5	1	0	0
42324	1624	activation of the ikappab alpha kinase	[activation of the IkappaB alpha kinases]	1.0	6	1	0	0
42325	1624	mechanism of transactivation by NFAT1	[mechanisms of transactivation by NFAT1]	1.0	5	1	0	0
42326	1624	use the HL-60 leukemia cell line	[using the HL-60 leukemia cell line]	1.0	6	1	0	0
42327	1624	potential target for the development	[potential target for the development]	1.0	5	1	0	0
42328	1624	phosphorylation of the cytoplasmic inhibitor	[Phosphorylation of the cytoplasmic inhibitor]	1.0	5	1	0	0
42329	1624	bad prognosis,	[worse prognosis,]	1.0	2	1	0	0
42330	1624	mutation in the androgen receptor gene	[mutations in the androgen receptor gene]	1.0	6	1	0	0
42331	1624	transactivation of the bcl-x promoter	[transactivation of the bcl-x promoter]	1.0	5	1	0	0
42332	1624	nfat function	[NFAT function]	1.0	2	1	0	0
42333	1624	luteinize hormone	[luteinizing hormone]	1.0	2	1	0	0
42334	1624	granulocyte clonality.	[granulocyte clonality.]	1.0	2	1	0	0
42335	1624	interferon-y ifn-gamma	[interferon-y IFN-gamma]	1.0	2	1	0	0
42336	1624	cell from highly malignant lymphoma	[cells from highly malignant lymphomas]	1.0	5	1	0	0
42337	1624	lectin pha	[lectin PHA]	1.0	2	1	0	0
42338	1624	peripheral blood stem cell PBSC	[peripheral blood stem cells PBSC]	1.0	5	1	0	0
42339	1624	chronic hyperglycemia	[chronic hyperglycemia]	1.0	2	1	0	0
42340	1624	narrow range	[narrow range]	1.0	2	2	1	1
42341	1624	dexamethasone on both cell type	[dexamethasone on both cell types]	1.0	5	1	0	0
42342	1624	normal decline in cortisol level	[normal decline in cortisol levels]	1.0	5	1	0	0
42343	1624	wild type,	[wild type,]	1.0	2	1	0	0
42344	1624	microgram/ml), expression of the tnf gene	[microgram/ml), expression of the TNF gene]	1.0	6	1	0	0
42345	1624	wild type.	[wild type.]	1.0	2	1	0	0
42346	1624	mrna of clone pAT 133	[mRNA of clone pAT 133]	1.0	5	1	0	0
42347	1624	distinct role for the two form	[distinct roles for the two forms]	1.0	6	1	0	0
42348	1624	level of estrogen receptor er	[levels of estrogen receptor ER]	1.0	5	1	0	0
42349	1624	association of Nmi a protein	[association of Nmi a protein]	1.0	5	1	0	0
42350	1624	aminoterminal region	[aminoterminal region]	1.0	2	1	0	0
42351	1624	antioxidant druilkience	[antioxidant drug,]	1.0	2	1	0	0
42352	1624	HLH protein	[HLH proteins]	1.0	2	1	0	0
42353	1624	early hematopoietic progenitor cell hpc	[early hematopoietic progenitor cells HPCs]	1.0	5	1	0	0
42354	1624	IL-4 stimulation	[IL-4 stimulation]	1.0	2	2	1	1
42355	1624	downstream interactor (s) limit transcription	[downstream interactor (s) limits transcription]	1.0	5	1	0	0
42356	1624	late endosome	[late endosomes]	1.0	2	1	0	0
42357	1624	four familiess	[four families,]	1.0	2	1	0	0
42358	1624	xenotransplanted tissue	[xenotransplanted tissue]	1.0	2	1	0	0
42359	1624	low amount	[low amounts]	1.0	2	2	2	2
42360	1624	series of gel retardation assay	[series of gel retardation assays]	1.0	5	1	0	0
42361	1624	exclusive role	[exclusive role]	1.0	2	1	0	0
42362	1624	tnf-alpha receptor	[TNF-alpha receptors]	1.0	2	2	1	1
42363	1624	erythroid-specific expression	[erythroid-specific expression]	1.0	2	2	1	1
42364	1624	two drug	[two drugs]	1.0	2	2	1	1
42365	1624	binding of gata-1 to consensus site	[binding of GATA-1 to consensus sites]	1.0	6	1	0	0
42366	1624	synergistic activation of ap-1 transcription	[synergistic activation of AP-1 transcription]	1.0	5	1	0	0
42367	1624	different level	[different levels]	1.0	2	2	2	2
42368	1624	series of promoter deletion construct	[series of promoter deletion constructs]	1.0	5	1	0	0
42369	1624	LMP1 mrna	[LMP1 mRNA]	1.0	2	1	0	0
42370	1624	human interferon regulatory factor 1	[human interferon regulatory factor 1]	1.0	5	1	0	0
42371	1624	receptor CD28	[receptor CD28]	1.0	2	2	2	2
42372	1624	distinct transcription factor in neutrophil	[distinct transcription factors in neutrophils]	1.0	5	1	0	0
42373	1624	neutrophil recruitment	[neutrophil recruitment]	1.0	2	1	0	0
42374	1624	similar role.	[similar role.]	1.0	2	1	0	0
42375	1624	different effect on the cell.	[different effects on the cell.]	1.0	5	1	0	0
42376	1624	increase gata-1 level in ocim1 cell	[increasing GATA-1 levels in OCIM1 cells]	1.0	6	1	0	0
42377	1624	removal of the carboxy terminus	[Removal of the carboxy terminus]	1.0	5	1	0	0
42378	1624	p.k. manuscript	[P.K. manuscript]	1.0	2	1	0	0
42379	1624	bp upstream from the transcription site	[bp upstream from the transcription site]	1.0	6	1	0	0
42380	1624	gm-csf stimulation	[GM-CSF stimulation]	1.0	2	1	0	0
42381	1624	exposure to weak oxidative stress	[exposure to weak oxidative stress]	1.0	5	1	0	0
42382	1624	Ca2+ influx,	[Ca2+ influx,]	1.0	2	1	0	0
42383	1624	gliadin peptide -hla class ii	[gliadin peptide -HLA class II]	1.0	5	1	0	0
42384	1624	Nuclear appearance of a factor	[Nuclear appearance of a factor]	1.0	5	1	0	0
42385	1624	-dependent pathway	[-dependent pathways]	1.0	2	1	0	0
42386	1624	non-pregnant woman	[non-pregnant women]	1.0	2	2	2	2
42387	1624	el4 6.1 overexpress human (h) irak	[EL4 6.1 overexpressing human (h) IRAK]	1.0	6	1	0	0
42388	1624	estradiol-dependent activation	[estradiol-dependent activation]	1.0	2	1	0	0
42389	1624	surround the IL-13 gene locus	[surrounding the IL-13 gene locus]	1.0	5	1	0	0
42390	1624	CTLA-4 signal	[CTLA-4 signaling]	1.0	2	1	0	0
42391	1624	suggest the presence of a inhibitor	[suggesting the presence of an inhibitor]	1.0	6	1	0	0
42392	1624	inflammatory state	[inflammatory states]	1.0	2	2	1	1
42393	1624	own receptor	[own receptor]	1.0	2	1	0	0
42394	1624	gggatttcacc motif	[GGGATTTCACC motif]	1.0	2	1	0	0
42395	1624	basal adhesion	[basal adhesion]	1.0	2	1	0	0
42396	1624	PKC activation	[PKC activation]	1.0	2	1	0	0
42397	1624	basic dbd	[basic DBD]	1.0	2	1	0	0
42398	1624	role of nuclear factor-kappa b	[role of nuclear factor-kappa B]	1.0	5	1	0	0
42399	1624	CD4+ T cell proliferative response	[CD4+ T cell proliferative responses]	1.0	5	1	0	0
42400	1624	inductive stimulation	[inductive stimulations]	1.0	2	1	0	0
42401	1624	strong ap-1 activity by gel-shift analysis	[strong AP-1 activity by gel-shift analysis]	1.0	6	1	0	0
42402	1624	fresh blood	[fresh blood]	1.0	2	1	0	0
42403	1624	hypopigmented skin	[hypopigmented skin]	1.0	2	1	0	0
42404	1624	multipotential progenitor	[multipotential progenitors]	1.0	2	1	0	0
42405	1624	jak kinase signal transducer protein	[JAK kinases Signal transducers proteins]	1.0	5	1	0	0
42406	1624	Richter' cell	[Richter's cells]	1.0	2	1	0	0
42407	1624	1beta,25-dihydroxyvitamin D3 HL the antagonist	[1beta,25-dihydroxyvitamin D3 HL the antagonist]	1.0	5	1	0	0
42408	1624	function of a variant form	[function of a variant form]	1.0	5	1	0	0
42409	1624	extracellular matrix	[extracellular matrix]	1.0	2	2	1	1
42410	1624	none of this proximal region	[none of these proximal regions]	1.0	5	1	0	0
42411	1624	membrane phospholipid	[membrane phospholipids]	1.0	2	1	0	0
42412	1624	ifn-gamma icam-1 expression in monocyte	[IFN-gamma ICAM-1 expression in monocytes]	1.0	5	1	0	0
42413	1624	artifact of the selection procedure	[artifact of the selection procedure]	1.0	5	1	0	0
42414	1624	trans-activation of the H4 promoter	[trans-activation of the H4 promoter]	1.0	5	1	0	0
42415	1624	36 amino	[36 amino]	1.0	2	1	0	0
42416	1624	loosely adherent cell with neurite process	[loosely adherent cells with neurite processes]	1.0	6	1	0	0
42417	1624	mitogenic stimulation with phytohaemagglutinin pha	[mitogenic stimulation with phytohaemagglutinin PHA]	1.0	5	1	0	0
42418	1624	IL-4 gene regulation in general	[IL-4 gene regulation in general]	1.0	5	1	0	0
42419	1624	vivo differentiation of APL cell	[vivo differentiation of APL cells]	1.0	5	1	0	0
42420	1624	normally express this receptors, leukocyte	[normally expressing these receptors, leukocytes]	1.0	5	1	0	0
42421	1624	2-fold increase in the infectivity	[2-fold increase in the infectivity]	1.0	5	1	0	0
42422	1624	use a probe encompass a region	[using a probe encompassing a region]	1.0	6	1	0	0
42423	1624	expression of MEK1 -interfer mutant	[Expression of MEK1 -interfering mutants]	1.0	5	1	0	0
42424	1624	mediate tnf-alpha induction of hiv transcription	[mediating TNF-alpha induction of HIV transcription]	1.0	6	1	0	0
42425	1624	stimulation of pml expression by interferon	[stimulation of PML expression by interferons]	1.0	6	1	0	0
42426	1624	upstream of a heterologous promoter	[upstream of a heterologous promoter]	1.0	5	1	0	0
42427	1624	laboratory work	[laboratory work]	1.0	2	1	0	0
42428	1624	potential therapeutic index of antioxidant	[potential therapeutic index of antioxidants]	1.0	5	1	0	0
42429	1624	bovine leucocyte	[bovine leucocytes]	1.0	2	2	1	1
42430	1624	cortisol ratio	[cortisol ratio]	1.0	2	2	1	1
42431	1624	kilobasis upstream	[kilobases upstream]	1.0	2	2	2	2
42432	1624	pharmacological kinetic (high turnover) property identical	[pharmacological kinetic (high turnover) properties identical]	1.0	6	1	0	0
42433	1624	renin value	[renin values]	1.0	2	2	2	2
42434	1624	homology to the ELK-1 genes,	[homology to the ELK-1 genes,]	1.0	5	1	0	0
42435	1624	gamma-interferon expression	[gamma-Interferon expression]	1.0	2	1	0	0
42436	1624	interleukin 2 IL-2 gene promoter	[interleukin 2 IL-2 gene promoter]	1.0	5	1	0	0
42437	1624	early b-cell factor a regulator	[early B-cell factor a regulator]	1.0	5	1	0	0
42438	1624	Somatic hypermutation	[Somatic hypermutation]	1.0	2	1	0	0
42439	1624	comparison with the sedentary group	[comparison with the sedentary group]	1.0	5	1	0	0
42440	1624	additional patient.	[additional patient.]	1.0	2	1	0	0
42441	1624	glucocorticoid GC	[Glucocorticoids GC]	1.0	2	1	0	0
42442	1624	quantitative control	[quantitative control]	1.0	2	1	0	0
42443	1624	monocyte adhesion on signal pathway	[monocyte adhesion on signaling pathways]	1.0	5	1	0	0
42444	1624	alteration in the e2f-4 profile	[alteration in the E2F-4 profile]	1.0	5	1	0	0
42445	1624	other construct	[other constructs]	1.0	2	2	1	1
42446	1624	especially S	[especially S]	1.0	2	1	0	0
42447	1624	c-myc allele in Burkitt' lymphoma	[c-myc allele in Burkitt's lymphoma]	1.0	5	1	0	0
42448	1624	parafollicular (monocytoid) b cell lymphoma	[parafollicular (monocytoid) B cell lymphoma]	1.0	5	1	0	0
42449	1624	induction of stat by cytokine	[induction of STATs by cytokines]	1.0	5	1	0	0
42450	1624	peak in gata-1 DNA binding	[peak in GATA-1 DNA binding]	1.0	5	1	0	0
42451	1624	functional significance,	[functional significance,]	1.0	2	1	0	0
42452	1624	functional significance.	[functional significance.]	1.0	2	1	0	0
42453	1624	immunohistochemical study of steroid hormone	[Immunohistochemical study of steroid hormones]	1.0	5	1	0	0
42454	1624	tf activity in human monocyte	[TF activity in human monocytes]	1.0	5	1	0	0
42455	1624	human erythroid 5-aminolevulinate synthase promoter analysis	[Human erythroid 5-aminolevulinate synthase promoter analysis]	1.0	6	1	0	0
42456	1624	colony-stimumulatelany-stg factor protein by monocyte	[colony-stimulating factor protein by monocytes]	1.0	5	1	0	0
42457	1624	endogenous nfat activity by FK506	[endogenous NFAT activity by FK506]	1.0	5	1	0	0
42458	1624	expression of functional differentiation marker	[expression of functional differentiation markers]	1.0	5	1	0	0
42459	1624	specific translocation	[specific translocation]	1.0	2	2	2	2
42460	1624	neutrophil development	[neutrophil development]	1.0	2	2	1	1
42461	1624	suggest the existence of fundamental difference	[suggesting the existence of fundamental differences]	1.0	6	1	0	0
42462	1624	activity of cellular transcription factor	[activity of cellular transcription factors]	1.0	5	2	1	1
42463	1624	macrophage cell surface ags include cd14	[macrophage cell surface Ags including CD14]	1.0	6	1	0	0
42464	1624	distal nf-kappab transcription factor binding site	[distal NF-kappaB transcription factor binding sites]	1.0	6	1	0	0
42465	1624	inhibit the synthesis of ig mrna	[inhibiting the synthesis of Ig mRNA]	1.0	6	1	0	0
42466	1624	comprise the tumour burden, the stage	[comprising the tumour burden, the stage]	1.0	6	1	0	0
42467	1624	relative proportion of (palmitic acid	[relative proportions of (palmitic acids]	1.0	5	1	0	0
42468	1624	isolation of a candidate repressor/activator NF-E1	[Isolation of a candidate repressor/activator NF-E1]	1.0	6	1	0	0
42469	1624	inducible expression of the promoter	[inducible expression of the promoter]	1.0	5	1	0	0
42470	1624	inducible transcription factor NF-kappa b	[inducible transcription factors NF-kappa B]	1.0	5	1	0	0
42471	1624	anti-Jun antibody	[anti-Jun antibodies]	1.0	2	1	0	0
42472	1624	growth inhibition of U937 cell	[growth inhibition of U937 cells]	1.0	5	1	0	0
42473	1624	stimulation of il-2r alpha expression	[stimulation of IL-2R alpha expression]	1.0	5	1	0	0
42474	1624	autoregulatory control	[autoregulatory control]	1.0	2	2	2	2
42475	1624	pathological situation	[pathological situations]	1.0	2	1	0	0
42476	1624	stat3 tyrosine	[STAT3 tyrosine]	1.0	2	2	2	2
42477	1624	3 exon	[3 exons]	1.0	2	1	0	0
42478	1624	close correlation to the expression	[close correlation to the expression]	1.0	5	1	0	0
42479	1624	individual with renal cell carcinoma	[individuals with renal cell carcinoma]	1.0	5	1	0	0
42480	1624	second, TRE -DNA binding protein	[Second, TRE -DNA binding proteins]	1.0	5	1	0	0
42481	1624	favor expansion of the Th2 lineage	[favoring expansion of the Th2 lineage]	1.0	6	1	0	0
42482	1624	treatment of a T-lymphocytic cell line	[Treatment of a T-lymphocytic cell line]	1.0	6	1	0	0
42483	1624	carboxyl-terminal tail	[carboxyl-terminal tail]	1.0	2	1	0	0
42484	1624	il-3 commitment of eml cell lineage.	[IL-3 commitment of EML cells lineage.]	1.0	6	1	0	0
42485	1624	lead to the secretion of il-2	[leading to the secretion of IL-2]	1.0	6	1	0	0
42486	1624	differentiation-dependent peroxisomal proliferator-activated receptor gamma ppargamma	[differentiation-dependent peroxisomal proliferator-activated receptor gamma PPARgamma]	1.0	6	1	0	0
42487	1624	role in growth of cell	[role in growth of cells]	1.0	5	1	0	0
42488	1624	cf airway	[CF airway]	1.0	2	1	0	0
42489	1624	vitro model of blood monocyte	[vitro model of blood monocytes]	1.0	5	1	0	0
42490	1624	suggest a important bioinactivation mechanism	[suggesting an important bioinactivation mechanism]	1.0	5	1	0	0
42491	1624	phosphorylation of one signal transducer	[phosphorylation of one signal transducer]	1.0	5	1	0	0
42492	1624	suppression of productive lai replication	[suppression of productive LAI replication]	1.0	5	1	0	0
42493	1624	map kinase signal transduction pathway	[MAP kinase signal transduction pathway]	1.0	5	1	0	0
42494	1624	examination of the basal factor interact	[Examination of the basal factors interacting]	1.0	6	1	0	0
42495	1624	hemoglobin concentration	[Hemoglobin concentration]	1.0	2	2	1	1
42496	1624	virus -bhrf1	[virus -BHRF1]	1.0	2	1	0	0
42497	1624	autologous bone marrow transplantation BMT	[autologous bone marrow transplantation BMT]	1.0	5	1	0	0
42498	1624	Oct2 transactivation from a enhancer position	[Oct2 transactivation from a enhancer position]	1.0	6	1	0	0
42499	1624	comparison with clinical prognostic factor	[comparison with clinical prognostic factors]	1.0	5	1	0	0
42500	1624	induction of NF-kappaB family member	[induction of NF-kappaB family members]	1.0	5	1	0	0
42501	1624	agonistic property for a androgen receptor	[agonistic properties for a androgen receptor]	1.0	6	1	0	0
42502	1624	inactivity of the related progesterone	[inactivity of the related progesterone]	1.0	5	1	0	0
42503	1624	gamma-ifn inhibition of 135eoh)2d3 transactivate function.	[gamma-IFN inhibition of 1,25(OH)2D3 transactivating function.]	1.0	6	1	0	0
42504	1624	SMX itself, to the surface	[SMX itself, to the surface]	1.0	5	1	0	0
42505	1624	also the mechanism cause the haploinsufficiency	[also the mechanism causing the haploinsufficiency]	1.0	6	1	0	0
42506	1624	mutation of the dse site	[mutation of the DSE sites]	1.0	5	1	0	0
42507	1624	cox-2-mediated prostaglandin	[COX-2-mediated prostaglandin]	1.0	2	1	0	0
42508	1624	transfection of a GRbeta expression vector	[Transfection of a GRbeta expression vector]	1.0	6	1	0	0
42509	1624	vitro from gm-csf-responsive progenitor cell	[vitro from GM-CSF-responsive progenitor cells]	1.0	5	1	0	0
42510	1624	necessary component of this process.	[necessary component of this process.]	1.0	5	1	0	0
42511	1624	estrogenic compound	[estrogenic compounds]	1.0	2	2	1	1
42512	1624	inhibition of spontaneous lymphocyte proliferation	[inhibition of spontaneous lymphocyte proliferation]	1.0	5	1	0	0
42513	1624	cortisol in hml of patient	[cortisol in HML of patients]	1.0	5	1	0	0
42514	1624	latent, restricted,	[latent, restricted,]	1.0	2	1	0	0
42515	1624	Interleukin-13 IL-13	[Interleukin-13 IL-13]	1.0	2	1	0	0
42516	1624	further document	[further document]	1.0	2	1	0	0
42517	1624	thus indicate sensitive to action.	[thus indicating sensitive to action.]	1.0	5	1	0	0
42518	1624	suggest up-regulation of Bcl-6 expression	[suggesting up-regulation of Bcl-6 expression]	1.0	5	1	0	0
42519	1624	two putative ets binding site EBS	[two putative Ets binding sites EBS]	1.0	6	1	0	0
42520	1624	weak chi b complex formation	[weaker chi B complex formation]	1.0	5	1	0	0
42521	1624	tgf beta	[TGF beta]	1.0	2	2	2	2
42522	1624	lipid anabolism	[lipid anabolism]	1.0	2	1	0	0
42523	1624	average of 33 nucleotide change	[average of 33 nucleotide changes]	1.0	5	1	0	0
42524	1624	Putative cis-acting control element present	[Putative cis-acting control elements present]	1.0	5	1	0	0
42525	1624	Mn sod 2) endotoxin induction	[Mn SOD 2) endotoxin induction]	1.0	5	1	0	0
42526	1624	mean type ii EBS level	[mean type II EBS levels]	1.0	5	1	0	0
42527	1624	transfection assays,	[transfection assays,]	1.0	2	3	2	1
42528	1624	NF-kB site.	[NF-kB site.]	1.0	2	1	0	0
42529	1624	high level of sp140 mrna	[High levels of Sp140 mRNA]	1.0	5	1	0	0
42530	1624	efficient transport	[efficient transport]	1.0	2	1	0	0
42531	1624	down-regulation of human granzyme b expression	[Down-regulation of human granzyme B expression]	1.0	6	1	0	0
42532	1624	glucocorticoid receptor of protein synthesis,	[glucocorticoid receptors of protein synthesis,]	1.0	5	1	0	0
42533	1624	collagenase transcription	[collagenase transcription]	1.0	2	2	2	2
42534	1624	novel approach to therapeutic intervention.	[novel approach to therapeutic intervention.]	1.0	5	1	0	0
42535	1624	activation of individual cd4+ T cell	[Activation of individual CD4+ T cells]	1.0	6	1	0	0
42536	1624	affect ap-1	[affecting AP-1]	1.0	2	1	0	0
42537	1624	non-ig sequence	[non-Ig sequences]	1.0	2	1	0	0
42538	1624	NFATd element	[NFATd element]	1.0	2	1	0	0
42539	1624	bind ga-binding protein alpha gabp alpha	[binding GA-binding protein alpha GABP alpha]	1.0	6	1	0	0
42540	1624	protein/dna interaction at the IFN-gamma locus	[protein/DNA interactions at the IFN-gamma locus]	1.0	6	1	0	0
42541	1624	menopausal type	[menopausal type]	1.0	2	2	1	1
42542	1624	human il-5 promoter/enhancer-luciferase gene construct	[Human IL-5 promoter/enhancer-luciferase gene construct]	1.0	5	1	0	0
42543	1624	resistance to host defense mechanism	[resistance to host defense mechanisms]	1.0	5	1	0	0
42544	1624	lead to NK cell development	[leading to NK cell development]	1.0	5	1	0	0
42545	1624	human blood lymphocyte with hiv-1	[human blood lymphocytes with HIV-1]	1.0	5	1	0	0
42546	1624	e2f complexes.	[E2F complexes.]	1.0	2	1	0	0
42547	1624	other function during hiv replication	[other functions during HIV replication]	1.0	5	1	0	0
42548	1624	cell-specific regulation	[cell-specific regulation]	1.0	2	2	2	2
42549	1624	PIN*POINT assay	[PIN*POINT assay]	1.0	2	1	0	0
42550	1624	only in a position-dependent manner	[only in a position-dependent manner]	1.0	5	1	0	0
42551	1624	SOCS-3 protein	[SOCS-3 protein]	1.0	2	1	0	0
42552	1624	further factor protein to dna,	[further factor proteins to DNA,]	1.0	5	1	0	0
42553	1624	135(oh)2d3 resistance	[1,25(OH)2D3 resistance]	1.0	2	1	0	0
42554	1624	further evidence for a dysregulation	[further evidence for a dysregulation]	1.0	5	1	0	0
42555	1624	secretion of human macrophage inflammatory protein-1alpha	[secretion of human macrophage inflammatory protein-1alpha]	1.0	6	1	0	0
42556	1624	soluble TN	[soluble TN]	1.0	2	1	0	0
42557	1624	plasma cortisol concentration in 15	[plasma cortisol concentrations in 15]	1.0	5	1	0	0
42558	1624	African population	[African populations]	1.0	2	2	1	1
42559	1624	hiv expression in U1 cell	[HIV expression in U1 cells]	1.0	5	1	0	0
42560	1624	protein-free, medium	[protein-free, medium]	1.0	2	1	0	0
42561	1624	interaction of sickle erythrocyte with cell	[Interaction of sickle erythrocytes with cells]	1.0	6	1	0	0
42562	1624	optimum time of pretreatment with 135-(oh)2d3	[optimum time of pretreatment with 1,25-(OH)2D3]	1.0	6	1	0	0
42563	1624	pre- value of cancer patient	[pre- values of cancer patients]	1.0	5	1	0	0
42564	1624	autocrine fashion	[autocrine fashion]	1.0	2	1	0	0
42565	1624	previous study in mononuclear leukocyte	[previous studies in mononuclear leukocytes]	1.0	5	1	0	0
42566	1624	5669 binding site per cell)	[5669 binding sites per cell)]	1.0	5	1	0	0
42567	1624	crucial role in the immortalization	[crucial role in the immortalization]	1.0	5	1	0	0
42568	1624	igg response against VZV gE	[IgG response against VZV gE]	1.0	5	1	0	0
42569	1624	Lac+to Lac-.	[Lac+to Lac-.]	1.0	2	1	0	0
42570	1624	NFAT peptide	[NFAT peptide]	1.0	2	1	0	0
42571	1624	GD patient	[GD patients]	1.0	2	1	0	0
42572	1624	endothelial vcam-1	[endothelial VCAM-1]	1.0	2	2	2	2
42573	1624	kd value for cortisol in hml	[Kd values for cortisol in HML]	1.0	6	1	0	0
42574	1624	homeodomain-containing protein	[homeodomain-containing protein]	1.0	2	1	0	0
42575	1624	contain part of the LTR region	[containing parts of the LTR region]	1.0	6	1	0	0
42576	1624	simultaneous treatment with differanisole a	[simultaneous treatment with differanisole A]	1.0	5	1	0	0
42577	1624	cotransfection of ebna-2 expression vector	[cotransfection of EBNA-2 expression vectors]	1.0	5	1	0	0
42578	1624	specific nuclear RA receptor rar	[specific nuclear RA receptors RARs]	1.0	5	1	0	0
42579	1624	result neutrophil-mediated tissue damage in response	[resulting neutrophil-mediated tissue damage in response]	1.0	6	1	0	0
42580	1624	addition, tyrosine	[addition, tyrosine]	1.0	2	1	0	0
42581	1624	hematopoietic gene	[hematopoietic genes]	1.0	2	2	2	2
42582	1624	factors, related	[factors, related]	1.0	2	1	0	0
42583	1624	associate with the TNFRI death domain	[associating with the TNFRI death domain]	1.0	6	1	0	0
42584	1624	abnormality of other gene related	[abnormalities of other genes related]	1.0	5	1	0	0
42585	1624	autoimmune feature	[autoimmune features]	1.0	2	1	0	0
42586	1624	major obstacle	[major obstacle]	1.0	2	2	2	2
42587	1624	exon 5-13	[exons 5-13]	1.0	2	1	0	0
42588	1624	significant amount of e2 from E1	[significant amounts of E2 from E1]	1.0	6	1	0	0
42589	1624	use separation	[using separation]	1.0	2	2	2	2
42590	1624	pleckstrin phosphorylation	[pleckstrin phosphorylation]	1.0	2	1	0	0
42591	1624	patient xp11be	[patient XP11BE]	1.0	2	1	0	0
42592	1624	assess responsiveness to glucocorticoid therapy	[assessing responsiveness to glucocorticoid therapy]	1.0	5	1	0	0
42593	1624	N termini	[N termini]	1.0	2	1	0	0
42594	1624	encode for the nuclear autoantigen la/ss-b	[encoding for the nuclear autoantigen La/SS-B]	1.0	6	1	0	0
42595	1624	49 case	[49 cases]	1.0	2	2	2	2
42596	1624	haematopoietic cytokine	[haematopoietic cytokines]	1.0	2	1	0	0
42597	1624	tateas tat	[tat/AS tat]	1.0	2	1	0	0
42598	1624	Similarly, CTL	[Similarly, CTL]	1.0	2	1	0	0
42599	1624	embryo fibroblast	[embryo fibroblasts]	1.0	2	1	0	0
42600	1624	squamous differentiation.	[squamous differentiation.]	1.0	2	1	0	0
42601	1624	5.5, p	[5.5, p]	1.0	2	1	0	0
42602	1624	kb transcript	[kb transcript]	1.0	2	2	2	2
42603	1624	S2' subsite of cathepsin b	[S2' subsites of cathepsin B]	1.0	5	1	0	0
42604	1624	presence of igh gene rearrangement	[presence of IgH gene rearrangement]	1.0	5	1	0	0
42605	1624	gene expression with phosphorothioate oligonucleotide	[gene expression with phosphorothioate oligonucleotides]	1.0	5	1	0	0
42606	1624	tyrosine phosphorylation of the g-csfr	[tyrosine phosphorylation of the G-CSFR]	1.0	5	1	0	0
42607	1624	one hundred milligram of hydrocortisone	[One hundred milligram of hydrocortisone]	1.0	5	1	0	0
42608	1624	patient with acute promyelocytic leukaemia	[patient with acute promyelocytic leukaemia]	1.0	5	1	0	0
42609	1624	heptamer element	[heptamer element]	1.0	2	1	0	0
42610	1624	distinct expression of cytokine profile	[distinct expression of cytokine profiles]	1.0	5	1	0	0
42611	1624	naive huvec	[naive HUVECs]	1.0	2	1	0	0
42612	1624	strong similarity with the one	[strong similarities with the one]	1.0	5	1	0	0
42613	1624	use the PL/IM 430 monoclonal antibody	[using the PL/IM 430 monoclonal antibody]	1.0	6	1	0	0
42614	1624	first indication	[first indication]	1.0	2	1	0	0
42615	1624	c-jun tre	[c-jun TRE]	1.0	2	2	1	1
42616	1624	one interpretation of this datum	[One interpretation of these data]	1.0	5	1	0	0
42617	1624	significant amount of nf-kappa b	[significant amounts of NF-kappa B]	1.0	5	1	0	0
42618	1624	several model	[several models]	1.0	2	2	1	1
42619	1624	germinal center b cell differentiation	[germinal center B cell differentiation]	1.0	5	1	0	0
42620	1624	h2o2 activation of the transcription factor	[H2O2 activation of the transcription factor]	1.0	6	1	0	0
42621	1624	first event in the initiation	[first event in the initiation]	1.0	5	1	0	0
42622	1624	increase in SCL protein level	[increase in SCL protein levels]	1.0	5	1	0	0
42623	1624	immunohistochemistry IH	[immunohistochemistry IH]	1.0	2	1	0	0
42624	1624	iv isoform of 17 beta-hydroxysteroid dehydrogenase	[IV isoforms of 17 beta-hydroxysteroid dehydrogenase]	1.0	6	1	0	0
42625	1624	progression beyond a cell stage	[progression beyond an cell stage]	1.0	5	1	0	0
42626	1624	responder patient	[responder patients]	1.0	2	1	0	0
42627	1624	stable level	[stable levels]	1.0	2	1	0	0
42628	1624	probe beta-casein	[probes beta-casein]	1.0	2	1	0	0
42629	1624	gene encode the beta subunit	[gene encoding the beta subunit]	1.0	5	1	0	0
42630	1624	additional size heterogeneity of nfatc	[Additional size heterogeneity of NFATc]	1.0	5	1	0	0
42631	1624	direct participation in cytoplasmic/nuclear signal	[direct participation in cytoplasmic/nuclear signaling]	1.0	5	1	0	0
42632	1624	several copy of the viral genome	[several copies of the viral genome]	1.0	6	1	0	0
42633	1624	human t-cell leukemia virus type ii	[human T-cell leukemia virus type II]	1.0	6	1	0	0
42634	1624	exon of the androgen receptor gene	[Exons of the androgen receptor gene]	1.0	6	1	0	0
42635	1624	interferon regulatory factor-1 irf-1 gene	[interferon regulatory factor-1 IRF-1 gene]	1.0	5	1	0	0
42636	1624	mr construct	[MR constructs]	1.0	2	1	0	0
42637	1624	little transactivation	[little transactivation]	1.0	2	1	0	0
42638	1624	I footprint	[I footprints]	1.0	2	1	0	0
42639	1624	see motif	[SEE motif]	1.0	2	1	0	0
42640	1624	major goal of this study	[major goal of this study]	1.0	5	1	0	0
42641	1624	ataxia-telangiectasia at a immunodeficiency syndrome	[ataxia-telangiectasia AT an immunodeficiency syndrome]	1.0	5	1	0	0
42642	1624	ikappab expression	[IkappaB expression]	1.0	2	1	0	0
42643	1624	transcription of several cytokine gene	[transcription of several cytokine genes]	1.0	5	1	0	0
42644	1624	IL-6 apoptosis	[IL-6 apoptosis]	1.0	2	1	0	0
42645	1624	biomedical research	[biomedical research]	1.0	2	2	1	1
42646	1624	lymphoid-restricted, octamer	[lymphoid-restricted, octamer]	1.0	2	1	0	0
42647	1624	arthritis patient	[arthritis patients]	1.0	2	1	0	0
42648	1624	Soluble factor	[Soluble factors]	1.0	2	1	0	0
42649	1624	follow hiv infection of human lymphocyte	[following HIV infection of human lymphocytes]	1.0	6	1	0	0
42650	1624	novel form	[novel form]	1.0	2	2	1	1
42651	1624	endothelial hypoxia	[endothelial hypoxia]	1.0	2	1	0	0
42652	1624	value as a reporter gene	[value as a reporter gene]	1.0	5	1	0	0
42653	1624	natural position	[natural position]	1.0	2	1	0	0
42654	1624	T cell by antigen, lectin	[T cells by antigen, lectin]	1.0	5	1	0	0
42655	1624	luciferase expression	[luciferase expression]	1.0	2	2	1	1
42656	1624	member of the -C-C family	[members of the -C-C family]	1.0	5	1	0	0
42657	1624	cross communication	[cross communication]	1.0	2	1	0	0
42658	1624	granulocyte antibody of potential clinical significance.	[granulocyte antibodies of potential clinical significance.]	1.0	6	1	0	0
42659	1624	calcineurin a serine/threonine phosphatase necessary	[calcineurin a serine/threonine phosphatase necessary]	1.0	5	1	0	0
42660	1624	oral calcitriol	[oral calcitriol]	1.0	2	1	0	0
42661	1624	tax on VCAM-1 gene transcription	[Tax on VCAM-1 gene transcription]	1.0	5	1	0	0
42662	1624	plasmid bear the promoter region	[plasmids bearing the promoter regions]	1.0	5	1	0	0
42663	1624	c1-c3 formation	[C1-C3 formation]	1.0	2	1	0	0
42664	1624	mutant thymocyte	[mutant thymocytes]	1.0	2	1	0	0
42665	1624	dramatic effect	[dramatic effects]	1.0	2	2	2	2
42666	1624	disease progression.	[disease progression.]	1.0	2	1	0	0
42667	1624	primary hypothyroidism	[primary hypothyroidism]	1.0	2	1	0	0
42668	1624	tethering by p-selectin nuclear translocation	[tethering by P-selectin nuclear translocation]	1.0	5	1	0	0
42669	1624	pou-specific domain	[POU-specific domain]	1.0	2	2	1	1
42670	1624	repression of the myeloperoxidase gene	[repression of the myeloperoxidase genes]	1.0	5	1	0	0
42671	1624	use stable transfection with a series	[Using stable transfection with a series]	1.0	6	1	0	0
42672	1624	65 kD	[65 kD]	1.0	2	1	0	0
42673	1624	29.9% cd3+ cell (2.2% of cd3+	[29.9% CD3+ cells (2.2% of CD3+]	1.0	6	1	0	0
42674	1624	adult alpha	[adult alpha]	1.0	2	1	0	0
42675	1624	cytolytic action of NK cell	[cytolytic action of NK cells]	1.0	5	1	0	0
42676	1624	stimulation of mature peripheral T cell	[Stimulation of mature peripheral T cells]	1.0	6	1	0	0
42677	1624	(e.g. cd45r0+	[(e.g. CD45R0+]	1.0	2	1	0	0
42678	1624	However, DCoH	[However, DCoH]	1.0	2	1	0	0
42679	1624	STAT5 all	[STAT5 all]	1.0	2	1	0	0
42680	1624	collectively, transcriptional factor necessary for expression	[Collectively, transcriptional factor necessary for expression]	1.0	6	1	0	0
42681	1624	normal expression	[normal expression]	1.0	2	2	1	1
42682	1624	gt motif of the locus LCR	[GT motifs of the locus LCR]	1.0	6	1	0	0
42683	1624	environmental mycobacteria	[environmental mycobacteria]	1.0	2	1	0	0
42684	1624	novel inhibitor	[novel inhibitor]	1.0	2	2	1	1
42685	1624	cell-specific control	[cell-specific controls]	1.0	2	1	0	0
42686	1624	Agonist dexamethasone	[Agonist dexamethasone]	1.0	2	1	0	0
42687	1624	transcriptional activator of viral gene	[transcriptional activator of viral genes]	1.0	5	1	0	0
42688	1624	NF-kB DNA.	[NF-kB DNA.]	1.0	2	1	0	0
42689	1624	one contraction	[One contraction]	1.0	2	1	0	0
42690	1624	cytokine gene of cell-surface receptor	[cytokine genes of cell-surface receptors]	1.0	5	1	0	0
42691	1624	central nervous system pyramidal cell	[central nervous system pyramidal cells]	1.0	5	1	0	0
42692	1624	euthymic patient	[euthymic patients]	1.0	2	2	2	2
42693	1624	lung macrophage	[lung macrophage]	1.0	2	1	0	0
42694	1624	supernatant from cd8+ T cell	[supernatants from CD8+ T cells]	1.0	5	1	0	0
42695	1624	Intracellular adhesion molecule-1 induction by PMA	[Intracellular adhesion molecule-1 induction by PMA]	1.0	6	1	0	0
42696	1624	peripheral blood mononuclear cell culture	[peripheral blood mononuclear cell cultures]	1.0	5	2	1	1
42697	1624	mitogenic effect on various organ	[mitogenic effects on various organs]	1.0	5	1	0	0
42698	1624	isoleucine att	[isoleucine ATT]	1.0	2	1	0	0
42699	1624	platelet production	[platelet production]	1.0	2	2	1	1
42700	1624	stimulation of the cos cell	[stimulation of the COS cells]	1.0	5	1	0	0
42701	1624	replacement of the NF-kappa b element	[Replacement of the NF-kappa B elements]	1.0	6	1	0	0
42702	1624	mitogenic agent upon glucocorticoid action	[mitogenic agents upon glucocorticoid action]	1.0	5	1	0	0
42703	1624	electrolyte value	[electrolyte values]	1.0	2	1	0	0
42704	1624	critical region of THR beta	[critical region of THR beta]	1.0	5	1	0	0
42705	1624	enhancement of hiv rna expression	[enhancement of HIV RNA expression]	1.0	5	1	0	0
42706	1624	enhancer of il-2 gene transcription	[enhancers of IL-2 gene transcription]	1.0	5	1	0	0
42707	1624	lps adhesion	[LPS adhesion]	1.0	2	1	0	0
42708	1624	U937 differentiation	[U937 differentiation]	1.0	2	1	0	0
42709	1624	prolactin gene	[prolactin genes]	1.0	2	1	0	0
42710	1624	transcription factor such as nf-kappab	[transcription factors such as NF-kappaB]	1.0	5	1	0	0
42711	1624	bhlh protein	[bHLH proteins]	1.0	2	2	1	1
42712	1624	Nuclear factor-IL6	[Nuclear factor-IL6]	1.0	2	1	0	0
42713	1624	Mental retardation	[Mental retardation]	1.0	2	1	0	0
42714	1624	inhibition of T lymphocyte activation	[Inhibition of T lymphocyte activation]	1.0	5	1	0	0
42715	1624	inhibition of transcription factor belong	[Inhibition of transcription factors belonging]	1.0	5	1	0	0
42716	1624	IL-10 alone	[IL-10 alone]	1.0	2	1	0	0
42717	1624	chronic exposure to hydrogen peroxide	[chronic exposure to hydrogen peroxide]	1.0	5	1	0	0
42718	1624	Lin- murine bone marrow progenitor cell	[Lin- murine bone marrow progenitor cells]	1.0	6	1	0	0
42719	1624	single transcript of 2 kilobasis	[single transcript of 2 kilobases]	1.0	5	1	0	0
42720	1624	treatment with 125 mg flutamide	[treatment with 125 mg flutamide]	1.0	5	1	0	0
42721	1624	cDNA clone corresponding to mrna species	[cDNA clones corresponding to mRNA species]	1.0	6	1	0	0
42722	1624	body burden of pcdd in adult	[body burdens of PCDDs/PCDFs in adults]	1.0	6	1	0	0
42723	1624	molecular basis for this synergism,	[molecular basis for this synergism,]	1.0	5	1	0	0
42724	1624	southwestern blot	[Southwestern blot]	1.0	2	1	0	0
42725	1624	lps core-	[LPS core-]	1.0	2	1	0	0
42726	1624	inducible band	[inducible bands]	1.0	2	1	0	0
42727	1624	less than 24 month (6-15	[less than 24 months (6-15]	1.0	5	1	0	0
42728	1624	nonstimulated platelet	[nonstimulated platelets]	1.0	2	2	1	1
42729	1624	T cell receptor gamma enhancer	[T cell receptor gamma enhancer]	1.0	5	1	0	0
42730	1624	vitro, hyperthermia	[vitro, hyperthermia]	1.0	2	1	0	0
42731	1624	other T cell-specific control region	[other T cell-specific control regions]	1.0	5	1	0	0
42732	1624	two enhancer by t-cell activator	[two enhancers by T-cell activators]	1.0	5	1	0	0
42733	1624	two different transcription initiation site	[two different transcription initiation sites]	1.0	5	1	0	0
42734	1624	tam il-2	[TAM IL-2]	1.0	2	1	0	0
42735	1624	specificity for the AACAAAG motif	[specificity for the AACAAAG motif]	1.0	5	1	0	0
42736	1624	response to E. histolytica infection	[response to E. histolytica infection]	1.0	5	1	0	0
42737	1624	adjacent site	[adjacent sites]	1.0	2	2	2	2
42738	1624	result in production of interleukin-2 il-2	[resulting in production of interleukin-2 IL-2]	1.0	6	1	0	0
42739	1624	soluble activator	[soluble activators]	1.0	2	1	0	0
42740	1624	chronic treatment	[chronic treatment]	1.0	2	1	0	0
42741	1624	gamma interferon ifn-gamma hla-dr expression	[gamma interferon IFN-gamma HLA-DR expression]	1.0	5	1	0	0
42742	1624	immunoregulatory hormone	[immunoregulatory hormone]	1.0	2	2	2	2
42743	1624	clinical benefit in this patient	[clinical benefit in these patients]	1.0	5	1	0	0
42744	1624	YY-1 protein	[YY-1 protein]	1.0	2	1	0	0
42745	1624	efficient induction of transcriptional activation	[efficient induction of transcriptional activation]	1.0	5	1	0	0
42746	1624	BJA-B cell	[BJA-B cells]	1.0	2	1	0	0
42747	1624	selective pathway,	[selective pathway,]	1.0	2	1	0	0
42748	1624	distinct activation	[distinct activation]	1.0	2	1	0	0
42749	1624	corticosteroid type	[Corticosteroid Type]	1.0	2	1	0	0
42750	1624	monocyte surface	[monocyte surface]	1.0	2	1	0	0
42751	1624	neutrophil biology	[neutrophil biology]	1.0	2	1	0	0
42752	1624	14 age-	[14 age-]	1.0	2	1	0	0
42753	1624	phagocytic stimulus in human neutrophils.	[phagocytic stimuli in human neutrophils.]	1.0	5	1	0	0
42754	1624	span base pair -1 to -275	[spanning base pairs -1 to -275]	1.0	6	1	0	0
42755	1624	approximately 2 mol/L for budesonide	[approximately 2 mol/L for budesonide]	1.0	5	1	0	0
42756	1624	extent,	[extent,]	1.0	1	11	5	5
42757	1624	presentation of the protein ie1	[presentation of the protein IE1]	1.0	5	1	0	0
42758	1624	frequent polyomavirus	[frequent polyomavirus]	1.0	2	1	0	0
42759	1624	54 kda	[54 kDa]	1.0	2	1	0	0
42760	1624	specific antibody induction of supershift	[specific antibody induction of supershifts]	1.0	5	1	0	0
42761	1624	result in il-8 gene expression	[resulting in IL-8 gene expression]	1.0	5	1	0	0
42762	1624	colony of bone marrow cell	[colonies of bone marrow cells]	1.0	5	1	0	0
42763	1624	activity of a osteocalcin promoter	[activity of a osteocalcin promoter]	1.0	5	1	0	0
42764	1624	specific binding activity to CRE	[specific binding activity to CRE]	1.0	5	1	0	0
42765	1624	rare transcription	[RARE transcription]	1.0	2	2	1	1
42766	1624	Thus, IkappaB-alphaS32/36A	[Thus, IkappaB-alphaS32/36A]	1.0	2	1	0	0
42767	1624	endothelial monolayer in nonstatic assay	[endothelial monolayers in nonstatic assays]	1.0	5	1	0	0
42768	1624	eosinophilic disease	[eosinophilic disease.]	1.0	2	2	2	2
42769	1624	phosphorylation of Rb of cyclin D3	[phosphorylation of Rb of cyclin D3]	1.0	6	1	0	0
42770	1624	MTBE apoptosis	[MTBE apoptosis]	1.0	2	1	0	0
42771	1624	phorbol myristate acetate (pma) treatment	[phorbol myristate acetate (PMA) treatment]	1.0	5	1	0	0
42772	1624	transfection of the piec line	[transfection of the PIEC line]	1.0	5	1	0	0
42773	1624	interleukin 2 receptor alpha subunit	[interleukin 2 receptor alpha subunit]	1.0	5	1	0	0
42774	1624	chromosome 12p12-p13	[chromosome 12p12-p13]	1.0	2	1	0	0
42775	1624	anti-igm stimulation of primary b lymphocyte	[anti-IgM stimulation of primary B lymphocytes]	1.0	6	1	0	0
42776	1624	high level of ap-2 activation	[high levels of AP-2 activation]	1.0	5	1	0	0
42777	1624	use the reporter gene strategy	[using the reporter gene strategy]	1.0	5	1	0	0
42778	1624	Latent membrane protein 1 LMP1	[Latent membrane protein 1 LMP1]	1.0	5	1	0	0
42779	1624	case map	[case maps]	1.0	2	1	0	0
42780	1624	p-creb level between pbmc cell	[P-CREB levels between PBMC cells]	1.0	5	1	0	0
42781	1624	single chromosome	[single chromosome]	1.0	2	1	0	0
42782	1624	extend from -870 to +54	[extending from -870 to +54]	1.0	5	1	0	0
42783	1624	deletion in NFATx1 of the residue	[deletion in NFATx1 of the residues]	1.0	6	1	0	0
42784	1624	follow intracranial inoculation in mice,	[Following intracranial inoculation in mice,]	1.0	5	1	0	0
42785	1624	high correlation of ebv infection	[high correlation of EBV infection]	1.0	5	1	0	0
42786	1624	pai-1 overproduction	[PAI-1 overproduction]	1.0	2	1	0	0
42787	1624	relatively high specificity for pkc,	[relatively high specificity for PKC,]	1.0	5	1	0	0
42788	1624	study with helper T cell	[study with helper T cells]	1.0	5	1	0	0
42789	1624	steroid-responsive cell	[steroid-responsive cells]	1.0	2	1	0	0
42790	1624	initiation binding repressor a factor	[Initiation binding repressor a factor]	1.0	5	1	0	0
42791	1624	epitope enhancement	[Epitope enhancement]	1.0	2	1	0	0
42792	1624	hiv-2 transcription follow t-cell activation	[HIV-2 transcription following T-cell activation]	1.0	5	1	0	0
42793	1624	-dp transcription	[-DP transcription]	1.0	2	1	0	0
42794	1624	low abundance	[lowest abundance]	1.0	2	2	2	2
42795	1624	hormone bind domain variant in	[hormone binding domain variants in]	1.0	5	1	0	0
42796	1624	u937 calcineurin	[U937 calcineurin]	1.0	2	1	0	0
42797	1624	differentiation assay use water phorbol ester	[Differentiation assays using water phorbol esters]	1.0	6	1	0	0
42798	1624	induction of pif DNA binding activity	[induction of PIF DNA binding activity]	1.0	6	1	0	0
42799	1624	50k subunit	[50K subunit]	1.0	2	1	0	0
42800	1624	unknown etiology	[unknown etiology]	1.0	2	1	0	0
42801	1624	delineation of the CD28 signal cascade	[Delineation of the CD28 signaling cascade]	1.0	6	1	0	0
42802	1624	other form	[other forms]	1.0	2	2	1	1
42803	1624	abrogation of the isre binding	[abrogation of the ISRE binding]	1.0	5	1	0	0
42804	1624	stimulation of the AP-1 content	[stimulation of the AP-1 contents]	1.0	5	1	0	0
42805	1624	suggest some misfunction in the system	[suggesting some misfunction in the systems]	1.0	6	1	0	0
42806	1624	activation of the CD28 surface molecule	[activation of the CD28 surface molecule]	1.0	6	1	0	0
42807	1624	few patient	[few patients]	1.0	2	1	0	0
42808	1624	TCF-1 expression	[TCF-1 expression]	1.0	2	1	0	0
42809	1624	two distinct ligand-induced, docking site	[two distinct ligand-induced, docking sites]	1.0	5	1	0	0
42810	1624	target the viral protein to cp	[targeting the viral protein to Cp]	1.0	6	1	0	0
42811	1624	triiodothyronine t3	[triiodothyronine T3]	1.0	2	2	2	2
42812	1624	only in cell of hematopoietic origin	[only in cells of hematopoietic origin]	1.0	6	1	0	0
42813	1624	t3 administration	[T3 administration]	1.0	2	1	0	0
42814	1624	molecular mechanism underlie monocytic differentiation	[molecular mechanisms underlying monocytic differentiation]	1.0	5	1	0	0
42815	1624	counteract 5' negative regulatory DNA sequence	[counteracting 5' negative regulatory DNA sequences]	1.0	6	1	0	0
42816	1624	chromosome translocation in t-cell leukemia	[chromosome translocation in T-cell leukemia]	1.0	5	1	0	0
42817	1624	use nuclear extract from human brain	[using nuclear extracts from human brain]	1.0	6	1	0	0
42818	1624	normal receptor affinity to glucocorticoid	[normal receptor affinity to glucocorticoids]	1.0	5	1	0	0
42819	1624	possibility establish new cell line	[possibility establishing new cell lines]	1.0	5	1	0	0
42820	1624	IL-2Ralpha promoter	[IL-2Ralpha promoter]	1.0	2	1	0	0
42821	1624	dnasei footprinting	[DNaseI footprinting]	1.0	2	1	0	0
42822	1624	human sle of polyomavirus t-antigen	[human SLE of polyomavirus T-antigen]	1.0	5	1	0	0
42823	1624	hiv-1 long terminal repeat LTR transcription	[HIV-1 long terminal repeat LTR transcription]	1.0	6	1	0	0
42824	1624	normal system	[normal system]	1.0	2	2	1	1
42825	1624	binding to downstream NF-kappa b site	[binding to downstream NF-kappa B site]	1.0	6	2	1	1
42826	1624	primary effect of the receptor	[primary effect of the receptor]	1.0	5	1	0	0
42827	1624	(52 euthymic,	[(52 euthymic,]	1.0	2	1	0	0
42828	1624	susceptibility to this immune-mediated lysis	[susceptibility to this immune-mediated lysis]	1.0	5	1	0	0
42829	1624	full transcriptional activation by CIITA	[full transcriptional activation by CIITA]	1.0	5	1	0	0
42830	1624	stimulation of U1 cell by lps	[Stimulation of U1 cells by LPS]	1.0	6	1	0	0
42831	1624	CD15 engagement by monoclonal antibody	[CD15 engagement by monoclonal antibody]	1.0	5	1	0	0
42832	1624	tissue transplantation	[tissue transplantations]	1.0	2	1	0	0
42833	1624	activator of transcription (stat) activation pathway	[activator of transcription (STAT) activation pathways]	1.0	6	1	0	0
42834	1624	hmg-i isoform	[HMG-I isoforms]	1.0	2	1	0	0
42835	1624	spectrum bind site-specific transcriptional property	[spectrum binding site-specific transcriptional properties]	1.0	5	1	0	0
42836	1624	signal receptor	[signaling receptor]	1.0	2	1	0	0
42837	1624	similar alteration	[Similar alterations]	1.0	2	1	0	0
42838	1624	DEX apoptosis	[DEX apoptosis]	1.0	2	1	0	0
42839	1624	attractive target for a response	[attractive target for a response]	1.0	5	1	0	0
42840	1624	circulate t-cell	[circulating T-cells]	1.0	2	2	2	2
42841	1624	protease mapping	[protease mapping]	1.0	2	1	0	0
42842	1624	breast/ovarian cancer	[breast/ovarian cancer]	1.0	2	2	2	2
42843	1624	B-cell leukaemias	[B-cell leukaemias]	1.0	2	1	0	0
42844	1624	sequence of the ion 793	[sequence of the ion 793]	1.0	5	1	0	0
42845	1624	result in level of beta-catenin	[resulting in levels of beta-catenin]	1.0	5	1	0	0
42846	1624	follow antigen stimulation of T lymphocyte	[following antigen stimulation of T lymphocytes]	1.0	6	1	0	0
42847	1624	subsequent recurrences,	[subsequent recurrences,]	1.0	2	1	0	0
42848	1624	control the phosphorylation state of substrates.	[controlling the phosphorylation state of substrates.]	1.0	6	1	0	0
42849	1624	skin lesion	[skin lesions]	1.0	2	1	0	0
42850	1624	form heterodimer	[forming heterodimers]	1.0	2	2	2	2
42851	1624	virion production	[virion production]	1.0	2	1	0	0
42852	1624	marmoset t-lymphocyte transformation in vitro	[marmoset T-lymphocyte transformation in vitro]	1.0	5	1	0	0
42853	1624	tal1 mutant bind to DNA	[TAL1 mutant binding to DNA]	1.0	5	1	0	0
42854	1624	mutant of KBF1/p50 delta sp	[mutant of KBF1/p50 delta SP]	1.0	5	1	0	0
42855	1624	least one mechanism for activation	[least one mechanism for activation]	1.0	5	1	0	0
42856	1624	X1 box	[X1 box]	1.0	2	2	2	2
42857	1624	IFN beta	[IFN beta]	1.0	2	1	0	0
42858	1624	specific binding of nuclear protein	[specific binding of nuclear protein]	1.0	5	1	0	0
42859	1624	ga-binding protein (gabp) transcription factor	[GA-binding protein (GABP) transcription factors]	1.0	5	1	0	0
42860	1624	respective gene	[respective genes]	1.0	2	2	1	1
42861	1624	18 male breast cancer patient	[18 male breast cancer patients]	1.0	5	1	0	0
42862	1624	difference between il-10 in activity	[difference between IL-10 in activity]	1.0	5	1	0	0
42863	1624	hiv infection of blood lymphocyte	[HIV infection of blood lymphocytes]	1.0	5	1	0	0
42864	1624	specific target	[specific target]	1.0	2	2	2	2
42865	1624	C. elegan	[C. elegans]	1.0	2	1	0	0
42866	1624	nf.kappa b protein from cytoplasmic store	[NF.kappa B proteins from cytoplasmic stores]	1.0	6	1	0	0
42867	1624	encode for the autoantigen la/ss-b	[encoding for the autoantigen La/SS-B]	1.0	5	2	2	2
42868	1624	normal cem-c7	[normal CEM-C7]	1.0	2	1	0	0
42869	1624	transcriptional assay	[transcriptional assays]	1.0	2	1	0	0
42870	1624	cycle ergometer	[cycle ergometer]	1.0	2	1	0	0
42871	1624	direct binding on the DNA	[direct binding on the DNA]	1.0	5	1	0	0
42872	1624	pattern of tyrosine phosphorylation result	[pattern of tyrosine phosphorylation resulting]	1.0	5	1	0	0
42873	1624	efficiency of the msv LTR promoter	[efficiency of the MSV LTR promoter]	1.0	6	1	0	0
42874	1624	ifn-gamma monocyte	[IFN-gamma monocytes]	1.0	2	1	0	0
42875	1624	main aim of this work	[main aims of this work]	1.0	5	1	0	0
42876	1624	primary transcript	[primary transcript]	1.0	2	2	1	1
42877	1624	morphologic change in the pancrea	[morphologic changes in the pancreas]	1.0	5	1	0	0
42878	1624	alternative approach,	[alternative approach,]	1.0	2	1	0	0
42879	1624	adaptive system	[adaptive system]	1.0	2	1	0	0
42880	1624	member of the receptor family	[member of the receptor family]	1.0	5	1	0	0
42881	1624	reduction of surface MHC class expression	[reduction of surface MHC class expression]	1.0	6	1	0	0
42882	1624	patient with this multifactorial disease	[patients with this multifactorial disease]	1.0	5	1	0	0
42883	1624	il-12 responsiveness	[IL-12 responsiveness]	1.0	2	1	0	0
42884	1624	ap-1 (Fos/Jun)	[AP-1 (Fos/Jun)]	1.0	2	1	0	0
42885	1624	overexpression of the protein id3	[overexpression of the protein Id3]	1.0	5	1	0	0
42886	1624	posttranscriptional regulation	[Posttranscriptional regulation]	1.0	2	2	1	1
42887	1624	JNK phosphorylation	[JNK phosphorylation]	1.0	2	1	0	0
42888	1624	induction of gene by NFATx1	[induction of genes by NFATx1]	1.0	5	1	0	0
42889	1624	killing by the death ligand TNF	[killing by the death ligands TNF]	1.0	6	1	0	0
42890	1624	surgical treatment	[surgical treatment]	1.0	2	1	0	0
42891	1624	recombinant ebna-2	[recombinant EBNA-2]	1.0	2	1	0	0
42892	1624	bp -267	[bp -267]	1.0	2	1	0	0
42893	1624	PGE2 modulation of reporter gene activity	[PGE2 modulation of reporter gene activity]	1.0	6	1	0	0
42894	1624	cytosol protein	[cytosol protein]	1.0	2	1	0	0
42895	1624	tnf-alpha release in culture supernatant	[TNF-alpha release in culture supernatants]	1.0	5	1	0	0
42896	1624	yj cell	[YJ cells]	1.0	2	2	1	1
42897	1624	sequence alteration	[sequence alterations]	1.0	2	2	2	2
42898	1624	immunoglobulin Ig	[immunoglobulin Ig]	1.0	2	1	0	0
42899	1624	deletion analysis of the carboxyl-terminal region	[Deletion analysis of the carboxyl-terminal region]	1.0	6	1	0	0
42900	1624	estrogen receptor,	[estrogen receptor,]	1.0	2	1	0	0
42901	1624	mammalian development	[mammalian development]	1.0	2	1	0	0
42902	1624	elk-1 gene expression in monocyte	[elk-1 gene expression in monocytes]	1.0	5	1	0	0
42903	1624	abrogate kappab -driven gene expression	[abrogates kappaB -driven gene expression]	1.0	5	1	0	0
42904	1624	c-Rel p100	[c-Rel p100]	1.0	2	1	0	0
42905	1624	novel subline,	[novel subline,]	1.0	2	1	0	0
42906	1624	important cofactor in the development	[important cofactor in the development]	1.0	5	1	0	0
42907	1624	JAK2 kinase	[JAK2 kinase]	1.0	2	1	0	0
42908	1624	TCF/LEF protein	[TCF/LEF proteins]	1.0	2	1	0	0
42909	1624	Vitamin d receptor expression in lymphocyte	[Vitamin D receptor expression in lymphocytes]	1.0	6	1	0	0
42910	1624	jurkat-t cell	[Jurkat-T cells]	1.0	2	2	2	2
42911	1624	1 replication in monocyte by 1,25-dihydroxycholecalciferol	[1 replication in monocytes by 1,25-dihydroxycholecalciferol]	1.0	6	1	0	0
42912	1624	physiological relevance of this phenomenon	[physiological relevance of this phenomenon]	1.0	5	1	0	0
42913	1624	transcription factor in human monocyte	[transcription factors in human monocytes]	1.0	5	2	1	1
42914	1624	such as multi-organ failure during sepsis	[such as multi-organ failure during sepsis]	1.0	6	1	0	0
42915	1624	95-kDa protein contain zinc-finger motif	[95-kDa protein containing zinc-finger motifs]	1.0	5	1	0	0
42916	1624	cell pigmentation	[cell pigmentation]	1.0	2	1	0	0
42917	1624	VDR -retinoid x receptor heterodimer	[VDR -retinoid X receptor heterodimer]	1.0	5	1	0	0
42918	1624	member of the STAT family	[members of the STAT family]	1.0	5	1	0	0
42919	1624	increase understanding of the molecular pathway	[increasing understanding of the molecular pathways]	1.0	6	1	0	0
42920	1624	release of the inhibitory subunit	[release of the inhibitory subunit]	1.0	5	1	0	0
42921	1624	Oct2 isoform	[Oct2 isoforms]	1.0	2	2	2	2
42922	1624	T cell receptor tcr responsiveness	[T cell receptor TCR responsiveness]	1.0	5	1	0	0
42923	1624	5-fold levels,	[5-fold levels,]	1.0	2	1	0	0
42924	1624	expression of hl60 cell binding	[expression of HL60 cell binding]	1.0	5	1	0	0
42925	1624	genetic variation in this gene	[genetic variation in these genes]	1.0	5	1	0	0
42926	1624	Northern hybridization	[Northern hybridization]	1.0	2	1	0	0
42927	1624	circulate t4	[circulating T4]	1.0	2	1	0	0
42928	1624	tumor/growth suppressor	[tumor/growth suppressor]	1.0	2	1	0	0
42929	1624	early hyperpolarization	[early hyperpolarization]	1.0	2	1	0	0
42930	1624	hereditary hypercholesteremia of homozygous type	[hereditary hypercholesteremia of homozygous type]	1.0	5	1	0	0
42931	1624	infection of primary b lymphocyte	[infection of primary B lymphocytes]	1.0	5	1	0	0
42932	1624	major gc-box binding activity A1	[major GC-box binding activity A1]	1.0	5	1	0	0
42933	1624	CAML -interact	[CAML -interacting]	1.0	2	1	0	0
42934	1624	protein/protein interaction with transcription factor	[protein/protein interactions with transcription factors]	1.0	5	1	0	0
42935	1624	number of immunoglobulin eig)-secreting cell	[number of immunoglobulin (Ig)-secreting cells]	1.0	5	1	0	0
42936	1624	different species of heterodimer involve rxr-alpha	[different species of heterodimers involving RXR-alpha]	1.0	6	1	0	0
42937	1624	binding capacity of the receptor	[binding capacity of the receptor]	1.0	5	1	0	0
42938	1624	mutant b lymphoblastoid cell line	[mutant B lymphoblastoid cell line]	1.0	5	1	0	0
42939	1624	primarily at the transcriptional level	[primarily at the transcriptional level]	1.0	5	1	0	0
42940	1624	wide range of tcr affinity	[wide range of TCR affinities]	1.0	5	1	0	0
42941	1624	apoptotic death of T lymphocyte	[apoptotic death of T lymphocyte]	1.0	5	1	0	0
42942	1624	lymphocyte transformation by herpesvirus Saimiri STP	[lymphocyte transformation by herpesvirus Saimiri STP]	1.0	6	1	0	0
42943	1624	tissue inhibitor of metalloproteinase (timp)-1	[tissue inhibitor of metalloproteinases (TIMP)-1]	1.0	5	1	0	0
42944	1624	contribution of the two isoform	[contribution of the two isoforms]	1.0	5	1	0	0
42945	1624	heat shock protein 90 complex	[heat shock protein 90 complexes]	1.0	5	1	0	0
42946	1624	alteration of the immune response	[alteration of the immune response]	1.0	5	1	0	0
42947	1624	Latent infection of b lymphocyte	[Latent infection of B lymphocytes]	1.0	5	1	0	0
42948	1624	results: co-culture of NK cell	[RESULTS: Co-culture of NK cells]	1.0	5	1	0	0
42949	1624	1 aneusomy with 1p36 under-representation	[1 aneusomy with 1p36 under-representation]	1.0	5	1	0	0
42950	1624	result in activation of DNA present	[resulting in activation of DNA present]	1.0	6	1	0	0
42951	1624	hyperthyroid patient	[hyperthyroid patients]	1.0	2	1	0	0
42952	1624	augment inflammation	[augment inflammation]	1.0	2	1	0	0
42953	1624	transactivation of the tcr-regulated nuclear factor	[transactivation of the TCR-regulated nuclear factor]	1.0	6	1	0	0
42954	1624	resistance of the cell line	[resistance of the cell lines]	1.0	5	1	0	0
42955	1624	block nf-kappab	[blocking NF-kappaB]	1.0	2	2	1	1
42956	1624	lymphomagenic Akv	[lymphomagenic Akv]	1.0	2	1	0	0
42957	1624	heterodimer with other nuclear hormone receptor	[heterodimers with other nuclear hormone receptors]	1.0	6	1	0	0
42958	1624	use PMA	[using PMA]	1.0	2	2	1	1
42959	1624	5' upstream of the coding region	[5' upstream of the coding region]	1.0	6	1	0	0
42960	1624	Thus, PPARgamma	[Thus, PPARgamma]	1.0	2	1	0	0
42961	1624	6 hours' exposure to 135(oh)2d3	[6 hours' exposure to 1,25(OH)2D3]	1.0	5	1	0	0
42962	1624	GM-CSF to this basic cocktail	[GM-CSF to this basic cocktail]	1.0	5	1	0	0
42963	1624	high specificity.	[high specificity.]	1.0	2	1	0	0
42964	1624	relative molecular mass 50000 (50k)	[relative molecular mass 50,000 (50K)]	1.0	5	1	0	0
42965	1624	similar density	[similar densities]	1.0	2	1	0	0
42966	1624	only marginally in undifferentiated cell	[only marginally in undifferentiated cells]	1.0	5	1	0	0
42967	1624	Finally, proliferation	[Finally, proliferation]	1.0	2	1	0	0
42968	1624	subcellular fractionation	[subcellular fractionation]	1.0	2	1	0	0
42969	1624	moreover, tyrosine	[Moreover, tyrosine]	1.0	2	1	0	0
42970	1624	11p15 target	[11p15 target]	1.0	2	1	0	0
42971	1624	transcription of the globin gene	[transcription of the globin genes]	1.0	5	1	0	0
42972	1624	switch from the eosinophil to lineage	[switching from the eosinophil to lineages]	1.0	6	1	0	0
42973	1624	granulocytic clone	[granulocytic clones]	1.0	2	1	0	0
42974	1624	follow iv dosing in rat	[following IV dosing in rats]	1.0	5	1	0	0
42975	1624	Differential responsiveness of the il-5 gene	[Differential responsiveness of the IL-5 genes]	1.0	6	1	0	0
42976	1624	pma+ ionomycin	[PMA+ ionomycin]	1.0	2	1	0	0
42977	1624	Nuclear extract of anti- cd15 cell	[Nuclear extracts of anti- CD15 cells]	1.0	6	1	0	0
42978	1624	inhibitory effect on cytokine expression	[inhibitory effects on cytokine expression]	1.0	5	1	0	0
42979	1624	analysis of phosphotyrosine -contain protein	[Analysis of phosphotyrosine -containing proteins]	1.0	5	1	0	0
42980	1624	current drugs.	[current drugs.]	1.0	2	1	0	0
42981	1624	immediate early lytic cycle protein	[Immediate early lytic cycle proteins]	1.0	5	1	0	0
42982	1624	as the probe, a 3.8-kb fragment	[as the probe, a 3.8-kb fragment]	1.0	6	1	0	0
42983	1624	dominant characteristic.	[dominant characteristic.]	1.0	2	1	0	0
42984	1624	DNA fragment contain 128 bp	[DNA fragment containing 128 bp]	1.0	5	1	0	0
42985	1624	fusion gene	[fusion gene]	1.0	2	2	2	2
42986	1624	important element	[important element]	1.0	2	2	2	2
42987	1624	recent analysis	[recent analysis]	1.0	2	2	2	2
42988	1624	Oct-1 oct1.2	[Oct-1 Oct1.2]	1.0	2	1	0	0
42989	1624	cell communication	[cell communication]	1.0	2	1	0	0
42990	1624	COOH terminus	[COOH terminus]	1.0	2	2	2	2
42991	1624	30 minutes.	[30 minutes.]	1.0	2	1	0	0
42992	1624	presence of aberrant er form	[presence of aberrant ER forms]	1.0	5	1	0	0
42993	1624	eukaryotic gene	[eukaryotic gene]	1.0	2	2	2	2
42994	1624	interaction with other specific factor	[interaction with other specific factors]	1.0	5	1	0	0
42995	1624	stimulation with tumor necrosis factor-alpha	[stimulation with tumor necrosis factor-alpha]	1.0	5	1	0	0
42996	1624	GrpL a Grb2 -related adaptor protein	[GrpL a Grb2 -related adaptor protein]	1.0	6	1	0	0
42997	1624	human T lymphocyte during aging.	[human T lymphocytes during aging.]	1.0	5	1	0	0
42998	1624	zebra activation	[ZEBRA activation]	1.0	2	1	0	0
42999	1624	recent evidence	[recent evidence]	1.0	2	2	2	2
43000	1624	cd21 the CR2 complement receptor	[CD21 the CR2 complement receptor]	1.0	5	1	0	0
43001	1624	hla-dr haplotype	[HLA-DR haplotypes]	1.0	2	1	0	0
43002	1624	include the leukemic T cell line	[including the leukemic T cell line]	1.0	6	1	0	0
43003	1624	egr-1 gene	[EGR-1 genes]	1.0	2	1	0	0
43004	1624	more importantly, C-JUN as oligonucleotide	[More importantly, C-JUN AS oligonucleotides]	1.0	5	1	0	0
43005	1624	terminal differentiation of b cell	[Terminal differentiation of B cells]	1.0	5	1	0	0
43006	1624	basic cocktail	[basic cocktail]	1.0	2	1	0	0
43007	1624	immunogold electron microscopy on intact cell	[immunogold electron microscopy on intact cells]	1.0	6	1	0	0
43008	1624	possible influence on vaginal physiology	[possible influence on vaginal physiology]	1.0	5	1	0	0
43009	1624	mrna level of various v-atpase subunit	[mRNA levels of various V-ATPase subunits]	1.0	6	1	0	0
43010	1624	differential activity within this cell	[differential activities within these cells]	1.0	5	1	0	0
43011	1624	role as a negative regulator	[role as a negative regulator]	1.0	5	1	0	0
43012	1624	protozoan host	[protozoan host]	1.0	2	1	0	0
43013	1624	Effect of cd45 on NF-kappa b	[Effects of CD45 on NF-kappa B]	1.0	6	1	0	0
43014	1624	1 microgram/ml]	[1 microgram/ml]]	1.0	2	1	0	0
43015	1624	specific site	[specific site]	1.0	2	1	0	0
43016	1624	promoter each	[promoter each]	1.0	2	1	0	0
43017	1624	rapid rise	[rapid rise]	1.0	2	1	0	0
43018	1624	change in the intracellular level	[changes in the intracellular levels]	1.0	5	1	0	0
43019	1624	immunoglobulin mu	[immunoglobulin mu]	1.0	2	2	2	2
43020	1624	normal regulation	[normal regulation]	1.0	2	2	1	1
43021	1624	direct coupling between cytokine receptor	[direct coupling between cytokine receptor]	1.0	5	1	0	0
43022	1624	NF kappa b binding complex	[NF kappa B binding complexes]	1.0	5	1	0	0
43023	1624	alpha- complex	[alpha- complexes]	1.0	2	1	0	0
43024	1624	inhibition of gtp-cyclohydrolase (an enzyme	[inhibition of GTP-cyclohydrolase (an enzyme]	1.0	5	1	0	0
43025	1624	cause secretion of inflammatory mediator	[causing secretion of inflammatory mediators]	1.0	5	1	0	0
43026	1624	essential step	[essential step]	1.0	2	2	2	2
43027	1624	include the sequence thr729-lys984 of hmr	[including the sequence Thr729-Lys984 of hMR]	1.0	6	1	0	0
43028	1624	other activator of NF-kappa b	[other activators of NF-kappa B]	1.0	5	1	0	0
43029	1624	core sequence aggc for binding	[core sequence AGGC for binding]	1.0	5	1	0	0
43030	1624	random sequence	[random sequences]	1.0	2	1	0	0
43031	1624	least sevenfold) of site 3.	[least sevenfold) of site 3.]	1.0	5	1	0	0
43032	1624	135eoh)2d3 receptor rna however; analysis	[1,25(OH)2D3 receptor RNA however; analysis]	1.0	5	1	0	0
43033	1624	many gene in human monocyte	[many genes in human monocytes]	1.0	5	1	0	0
43034	1624	role for c-Myc in apoptosis	[role for c-Myc in apoptosis]	1.0	5	1	0	0
43035	1624	human anti-porcine t-cell immune response	[human anti-porcine T-cell immune responses]	1.0	5	1	0	0
43036	1624	occupancy of the gasd element	[occupancy of the GASd element]	1.0	5	1	0	0
43037	1624	antisense tat	[antisense tat]	1.0	2	1	0	0
43038	1624	nuclear matrix attachment (Scheuermann, R. h.,	[nuclear matrix attachment (Scheuermann, R. H.,]	1.0	6	1	0	0
43039	1624	competitive inhibitor of NF-kappa b	[competitive inhibitor of NF-kappa B]	1.0	5	1	0	0
43040	1624	pretreatment of monocyte with ifn-beta	[Pretreatment of monocytes with IFN-beta]	1.0	5	1	0	0
43041	1624	y341 F	[Y341 F]	1.0	2	1	0	0
43042	1624	up-regulation of cell surface molecule	[up-regulation of cell surface molecules]	1.0	5	1	0	0
43043	1624	initial events,	[initial events,]	1.0	2	1	0	0
43044	1624	Nuclear translocation of NF-kappaB subunit	[Nuclear translocation of NF-kappaB subunits]	1.0	5	1	0	0
43045	1624	basal levels,	[basal levels,]	1.0	2	1	0	0
43046	1624	ebna-2 response	[EBNA-2 responses]	1.0	2	1	0	0
43047	1624	D variant cell use technique	[D variant cells using techniques]	1.0	5	1	0	0
43048	1624	adaptor function for the protein 3bp2	[Adaptor function for the protein 3BP2]	1.0	6	1	0	0
43049	1624	immune remission	[immune remission]	1.0	2	1	0	0
43050	1624	focus of attention in biology	[focus of attention in biology]	1.0	5	1	0	0
43051	1624	clinical practice	[clinical practice]	1.0	2	1	0	0
43052	1624	endolysosomial membrane	[endolysosomial membrane]	1.0	2	1	0	0
43053	1624	regulation of the nuclear level	[regulation of the nuclear levels]	1.0	5	1	0	0
43054	1624	induction of IL-4 gene expression	[induction of IL-4 gene expression]	1.0	5	1	0	0
43055	1624	b cell in healthy donor	[B cells in healthy donors]	1.0	5	1	0	0
43056	1624	Study on the biological activity	[Studies on the biological activity]	1.0	5	1	0	0
43057	1624	liposomal transfection	[Liposomal transfection]	1.0	2	1	0	0
43058	1624	subcellular distribution	[subcellular distribution]	1.0	2	2	1	1
43059	1624	molt-4 cell	[Molt-4 cells]	1.0	2	1	0	0
43060	1624	fk506 (ic50	[FK506 (IC50]	1.0	2	1	0	0
43061	1624	require the activation of gene product	[requiring the activation of gene products]	1.0	6	1	0	0
43062	1624	nuclear expression of the c-jun	[nuclear expression of the c-Jun]	1.0	5	1	0	0
43063	1624	evidence for the functional relationship	[evidence for the functional relationship]	1.0	5	1	0	0
43064	1624	nf-kappa b serum response factor	[NF-kappa B serum response factor]	1.0	5	1	0	0
43065	1624	patient with malignant melanoma RCC	[patients with malignant melanoma RCC]	1.0	5	1	0	0
43066	1624	inducible oct-2 DNA binding activity	[inducible Oct-2 DNA binding activity]	1.0	5	1	0	0
43067	1624	oestrogen target	[oestrogen target]	1.0	2	2	1	1
43068	1624	enzyme-generated restriction fragment length polymorphism	[enzyme-generated restriction fragment length polymorphisms]	1.0	5	1	0	0
43069	1624	mutation in the purine -rich region	[mutations in the purine -rich region]	1.0	6	1	0	0
43070	1624	adhesion of this adhesion molecule	[adhesion of these adhesion molecules]	1.0	5	1	0	0
43071	1624	CD40 activation of b cell	[CD40 activation of B cells]	1.0	5	1	0	0
43072	1624	burst response	[burst response]	1.0	2	2	2	2
43073	1624	id3 level	[Id3 levels]	1.0	2	1	0	0
43074	1624	stimulation of neutrophil with factor g-csf	[Stimulation of neutrophils with factor G-CSF]	1.0	6	1	0	0
43075	1624	significant inhibition of hiv-1 replication	[significant inhibition of HIV-1 replication]	1.0	5	1	0	0
43076	1624	DNA binding by all four	[DNA binding by all four]	1.0	5	1	0	0
43077	1624	1,25-dihydroxycholecalciferol 135-(oh)2d3	[1,25-dihydroxycholecalciferol 1,25-(OH)2D3]	1.0	2	1	0	0
43078	1624	erythrocyte receptor	[erythrocyte receptor]	1.0	2	1	0	0
43079	1624	bind to the GM-CSF element	[binding to the GM-CSF element]	1.0	5	1	0	0
43080	1624	expression of the c-jun protooncogene	[expression of the c-jun protooncogene]	1.0	5	1	0	0
43081	1624	alternative type of La mrna	[alternative type of La mRNA]	1.0	5	1	0	0
43082	1624	monocytoid leukemia cell line u937	[monocytoid leukemia cell lines U937]	1.0	5	1	0	0
43083	1624	transactivation ability	[transactivation ability]	1.0	2	2	1	1
43084	1624	significantly into phosphatidylethanolamine at concentration range	[significantly into phosphatidylethanolamine at concentrations ranging]	1.0	6	1	0	0
43085	1624	carboxylesterase gene transcription in thp-1 cell	[carboxylesterase gene transcription in THP-1 cells]	1.0	6	1	0	0
43086	1624	ets family protein principally ga-binding protein	[Ets family proteins principally GA-binding protein]	1.0	6	1	0	0
43087	1624	T cell proliferation without tcr engagement	[T cell proliferation without TCR engagement]	1.0	6	1	0	0
43088	1624	dmso solvent/media control for 0, 6-8,	[DMSO solvent/media control for 0, 6-8,]	1.0	6	1	0	0
43089	1624	start at concentration of >10(-14) mol/L	[starting at concentrations of >10(-14) mol/L]	1.0	6	1	0	0
43090	1624	remarkable change in androgen binding site	[remarkable changes in androgen binding sites]	1.0	6	1	0	0
43091	1624	remodeling of promoter chromatin structure	[remodeling of promoter chromatin structure]	1.0	5	2	1	1
43092	1624	fetal lymphocyte	[Fetal lymphocytes]	1.0	2	1	0	0
43093	1624	1-10 microM.	[1-10 microM.]	1.0	2	1	0	0
43094	1624	nuclear expression of a activity	[nuclear expression of a activity]	1.0	5	1	0	0
43095	1624	human thp-1 monocytic leukemia cell	[human THP-1 monocytic leukemia cells]	1.0	5	1	0	0
43096	1624	oppose effect	[opposing effects]	1.0	2	2	2	2
43097	1624	pivotal gene,	[pivotal gene,]	1.0	2	1	0	0
43098	1624	(0.2 mm)	[(0.2 mM)]	1.0	2	1	0	0
43099	1624	patients' T	[patients' T]	1.0	2	2	2	2
43100	1624	T cell in T lymphocyte	[T cells in T lymphocytes]	1.0	5	1	0	0
43101	1624	FIGURE 3	[FIGURE 3]	1.0	2	1	0	0
43102	1624	nf-kappab p65 rela in vitro	[NF-kappaB p65 RelA in vitro]	1.0	5	1	0	0
43103	1624	myeloid/natural killer cell acute leukemia	[myeloid/natural killer cell acute leukemia]	1.0	5	1	0	0
43104	1624	dideoxy atp	[dideoxy ATP]	1.0	2	1	0	0
43105	1624	gene expression of interferon protein	[gene expression of interferon protein]	1.0	5	1	0	0
43106	1624	ig synthesis by blood mononuclear cell	[Ig synthesis by blood mononuclear cells]	1.0	6	1	0	0
43107	1624	stat-specific antisera	[Stat-specific antisera]	1.0	2	1	0	0
43108	1624	stimulation-dependent manner.	[stimulation-dependent manner.]	1.0	2	1	0	0
43109	1624	none of the three gene	[none of the three genes]	1.0	5	1	0	0
43110	1624	lps addition.	[LPS addition.]	1.0	2	1	0	0
43111	1624	intervention at the phosphoinositide turnover	[intervention at the phosphoinositide turnover]	1.0	5	1	0	0
43112	1624	ICK-1 site	[ICK-1 site]	1.0	2	1	0	0
43113	1624	monocyte adherent on plastic surface	[monocytes adherent on plastic surfaces]	1.0	5	1	0	0
43114	1624	self renewal in erythroid progenitor	[self renewal in erythroid progenitors]	1.0	5	1	0	0
43115	1624	engagement of NK cell inhibitory receptor	[engagement of NK cell inhibitory receptors]	1.0	6	1	0	0
43116	1624	cutaneous T cell lymphoma line	[cutaneous T cell lymphoma lines]	1.0	5	1	0	0
43117	1624	MHC antigen	[MHC antigen]	1.0	2	2	1	1
43118	1624	co-ordinate fashion,	[co-ordinate fashion,]	1.0	2	1	0	0
43119	1624	proliferative response of the anti-cd3-	[proliferative response of the anti-CD3-]	1.0	5	1	0	0
43120	1624	nucleoplasmic domain	[nucleoplasmic domain]	1.0	2	1	0	0
43121	1624	inflammatory effector gene product similar	[inflammatory effector gene products similar]	1.0	5	1	0	0
43122	1624	T cell from a patient	[T cells from a patient]	1.0	5	1	0	0
43123	1624	tradd residue	[TRADD residues]	1.0	2	2	2	2
43124	1624	Peripheral blood mononuclear cell glucocorticoid receptor	[Peripheral blood mononuclear cell glucocorticoid receptors]	1.0	6	1	0	0
43125	1624	IEF-1 a pancreatic beta-cell type-specific complex	[IEF-1 a pancreatic beta-cell type-specific complex]	1.0	6	1	0	0
43126	1624	TF activity	[TF activity]	1.0	2	1	0	0
43127	1624	alpha gene regulation in phorbol ester	[alpha gene regulation in phorbol ester]	1.0	6	1	0	0
43128	1624	HL-60 promyelocyte	[HL-60 promyelocytes]	1.0	2	1	0	0
43129	1624	good insight	[better insight]	1.0	2	1	0	0
43130	1624	actin gene	[actin genes]	1.0	2	1	0	0
43131	1624	Bcl-6 expression	[Bcl-6 expression]	1.0	2	2	2	2
43132	1624	hallmark of nonstimulated b cell	[hallmark of nonstimulated B cells]	1.0	5	1	0	0
43133	1624	nk-kappa b	[NK-kappa B]	1.0	2	2	2	2
43134	1624	respond to oral salt supplementation	[responding to oral salt supplementation]	1.0	5	1	0	0
43135	1624	circumstances, activation	[circumstances, activation]	1.0	2	1	0	0
43136	1624	human T cell leukemia virus-1 htlv-1	[human T cell leukemia virus-1 HTLV-1]	1.0	6	1	0	0
43137	1624	clinical evaluation	[clinical evaluation]	1.0	2	1	0	0
43138	1624	IFN-U937 cell	[IFN-U937 cells]	1.0	2	2	1	1
43139	1624	recalcitrant asthma	[recalcitrant asthma]	1.0	2	1	0	0
43140	1624	differentiation rest cd4+ memory T cell	[differentiation resting CD4+ memory T cells]	1.0	6	1	0	0
43141	1624	polyclonal stimulus in primary b-cell	[polyclonal stimuli in primary B-cells]	1.0	5	1	0	0
43142	1624	ICI 182780	[ICI 182,780]	1.0	2	1	0	0
43143	1624	beta (p75) gene in T cell	[beta (p75) genes in T cells]	1.0	6	1	0	0
43144	1624	il4 promoter	[IL4 promoter]	1.0	2	2	2	2
43145	1624	two haplotype	[two haplotypes]	1.0	2	2	2	2
43146	1624	10-fold, zk161422	[10-fold, ZK161422]	1.0	2	1	0	0
43147	1624	interference with other transcription factor	[interference with other transcription factors]	1.0	5	1	0	0
43148	1624	HIV protease	[HIV protease]	1.0	2	1	0	0
43149	1624	tumor necrosis factor protein tradd	[tumor necrosis factor proteins TRADD]	1.0	5	1	0	0
43150	1624	inappropriate activation of T cell	[inappropriate activation of T cells]	1.0	5	1	0	0
43151	1624	transcriptional enhancement	[transcriptional enhancement]	1.0	2	2	1	1
43152	1624	mimic alteration	[mimics alterations]	1.0	2	1	0	0
43153	1624	introduction of protein family member	[introduction of protein family members]	1.0	5	1	0	0
43154	1624	patient with gc -insensitive asthma	[Patients with GC -insensitive asthma]	1.0	5	1	0	0
43155	1624	CD40 response during stimulation with ligand	[CD40 responses during stimulation with ligand]	1.0	6	1	0	0
43156	1624	post-receptor defect	[post-receptor defect]	1.0	2	1	0	0
43157	1624	histidine residue in the nh2-	[histidine residue in the NH2-]	1.0	5	1	0	0
43158	1624	mutation of the PU.1 /elf-1 site	[Mutation of the PU.1 /Elf-1 site]	1.0	6	1	0	0
43159	1624	up-regulation of the ige germline promoter	[up-regulation of the IgE germline promoter]	1.0	6	1	0	0
43160	1624	RESULTS: the number of glucocorticoid receptor	[RESULTS: The number of glucocorticoid receptors]	1.0	6	1	0	0
43161	1624	firm structural basis for mimicry	[firm structural basis for mimicry]	1.0	5	1	0	0
43162	1624	transactivate function	[transactivating function]	1.0	2	2	2	2
43163	1624	anionic glycerophospholipid,	[anionic glycerophospholipid,]	1.0	2	1	0	0
43164	1624	human bactericidal/permeability-increasing	[human bactericidal/permeability-increasing]	1.0	2	1	0	0
43165	1624	hiv production by PMA t-cell line	[HIV production by PMA T-cell lines]	1.0	6	1	0	0
43166	1624	general principle	[general principle]	1.0	2	1	0	0
43167	1624	(10 microM)	[(10 microM)]	1.0	2	1	0	0
43168	1624	serum deprivation	[serum deprivation]	1.0	2	1	0	0
43169	1624	rapid disappearance	[rapid disappearance]	1.0	2	1	0	0
43170	1624	multiple t-cell gene during thymocyte ontogeny	[multiple T-cell genes during thymocyte ontogeny]	1.0	6	1	0	0
43171	1624	Previously, transcription of the c-fo gene	[Previously, transcription of the c-fos gene]	1.0	6	1	0	0
43172	1624	respect to inhibition by CIF	[respect to inhibition by CIF]	1.0	5	1	0	0
43173	1624	expression of the il-2 mrna	[expression of the IL-2 mRNA]	1.0	5	1	0	0
43174	1624	transformation system	[transformation system]	1.0	2	1	0	0
43175	1624	130 kda.	[130 kDa.]	1.0	2	1	0	0
43176	1624	level of NF-kappaB dna-binding complex	[level of NF-kappaB DNA-binding complexes]	1.0	5	1	0	0
43177	1624	large variety	[large variety]	1.0	2	1	0	0
43178	1624	action of the transcription factor	[action of the transcription factors]	1.0	5	1	0	0
43179	1624	pi3k pkb	[PI3K PKB]	1.0	2	1	0	0
43180	1624	progression of the hiv-1 infection	[progression of the HIV-1 infection]	1.0	5	1	0	0
43181	1624	distinct regulatory pathway during activation	[distinct regulatory pathways during activation]	1.0	5	1	0	0
43182	1624	b-lymphocyte growth	[B-lymphocyte growth]	1.0	2	2	2	2
43183	1624	multimer of von willebrand factor	[multimers of von Willebrand factor]	1.0	5	1	0	0
43184	1624	mechanism of action of CsA	[mechanism of action of CsA]	1.0	5	1	0	0
43185	1624	effect in a unprecedented fashion.	[effects in an unprecedented fashion.]	1.0	5	1	0	0
43186	1624	role for BCL-6 in development.	[role for BCL-6 in development.]	1.0	5	1	0	0
43187	1624	corresponding up-regulation	[corresponding up-regulation]	1.0	2	1	0	0
43188	1624	indicate the presence of a loop	[indicating the presence of an loop]	1.0	6	1	0	0
43189	1624	cytokine-stimulated human saphenous vein endothelial cell	[cytokine-stimulated human saphenous vein endothelial cells]	1.0	6	1	0	0
43190	1624	breast recurrence in premenopausal patient	[breast recurrence in premenopausal patients]	1.0	5	1	0	0
43191	1624	40-kDa activator	[40-kDa activator]	1.0	2	1	0	0
43192	1624	difference in glucocorticoid sensitivity between tissues.	[differences in glucocorticoid sensitivity between tissues.]	1.0	6	1	0	0
43193	1624	activation of protein kinase c isoform	[activation of protein kinase C isoforms]	1.0	6	1	0	0
43194	1624	putative transcriptional regulator of differentiation	[putative transcriptional regulator of differentiation]	1.0	5	1	0	0
43195	1624	suggest a rapid mode of action	[suggesting a rapid mode of action]	1.0	6	1	0	0
43196	1624	erp protein	[ERP protein]	1.0	2	1	0	0
43197	1624	TNF stimulation	[TNF stimulation]	1.0	2	1	0	0
43198	1624	two adjacent kappa b site	[two adjacent kappa B sites]	1.0	5	1	0	0
43199	1624	plzf-rar alpha on ra-induced differentiation	[PLZF-RAR alpha on RA-induced differentiation]	1.0	5	1	0	0
43200	1624	bl-2 cell	[BL-2 cells]	1.0	2	2	1	1
43201	1624	t(X;14)(q28;q11) translocation	[t(X;14)(q28;q11) translocation]	1.0	2	1	0	0
43202	1624	SP1 phosphorylation	[SP1 phosphorylation]	1.0	2	1	0	0
43203	1624	-288ctttttgctt-tgc-300 NRE-II	[-288CTTTTTGCTT-TGC-300 NRE-II]	1.0	2	1	0	0
43204	1624	objective of the present study	[objective of the present study]	1.0	5	2	1	1
43205	1624	phosphorylating proteins,	[phosphorylating proteins,]	1.0	2	1	0	0
43206	1624	overexpression of SRF in b cell	[Overexpression of SRF in B cells]	1.0	6	1	0	0
43207	1624	host cell activation by t-cell mitogen	[host cell activation by T-cell mitogens]	1.0	6	1	0	0
43208	1624	primary blood mononuclear cell PBMC	[primary blood mononuclear cells PBMC]	1.0	5	3	2	1
43209	1624	powerful inhibitor of nf-kappab activation	[powerful inhibitors of NF-kappaB activation]	1.0	5	1	0	0
43210	1624	c-Raf phosphorylation of gabp factor	[c-Raf phosphorylation of GABP factors]	1.0	5	1	0	0
43211	1624	tat cDNA in antisense orientation	[tat cDNA in antisense orientation]	1.0	5	1	0	0
43212	1624	nf-kappab level	[NF-kappaB levels]	1.0	2	2	1	1
43213	1624	two transcripts,	[two transcripts,]	1.0	2	1	0	0
43214	1624	autologous thymic epithelial cell TEC	[autologous thymic epithelial cells TEC]	1.0	5	1	0	0
43215	1624	allele-specific mrna stability in cell	[allele-specific mRNA stability in cells]	1.0	5	1	0	0
43216	1624	heart failure,	[heart failure,]	1.0	2	1	0	0
43217	1624	factor of T cell (nfat) protein	[factor of T cells (NFAT) proteins]	1.0	6	1	0	0
43218	1624	few viruses, like the Herpesviruses	[few viruses, like the Herpesviruses]	1.0	5	1	0	0
43219	1624	nm vd3	[nM VD3]	1.0	2	2	2	2
43220	1624	host cell,	[host cell,]	1.0	2	1	0	0
43221	1624	express tax	[expressing tax]	1.0	2	2	2	2
43222	1624	such as mitogen-activated protein kinase-1	[such as mitogen-activated protein kinase-1]	1.0	5	1	0	0
43223	1624	pml-containing body	[PML-containing bodies]	1.0	2	1	0	0
43224	1624	primary human peripheral blood lymphocyte	[primary human peripheral blood lymphocytes]	1.0	5	1	0	0
43225	1624	analysis of cytokine signal in patient	[Analysis of cytokine signaling in patients]	1.0	6	1	0	0
43226	1624	particular emphasis on the result	[particular emphasis on the results]	1.0	5	1	0	0
43227	1624	such segment	[Such segments]	1.0	2	1	0	0
43228	1624	expression of (mhc) class antigen	[expression of (MHC) class antigens]	1.0	5	1	0	0
43229	1624	antibody titre against the enzyme.	[antibody titres against the enzyme.]	1.0	5	1	0	0
43230	1624	socs-3 expression in response to IL-2	[SOCS-3 expression in response to IL-2]	1.0	6	1	0	0
43231	1624	maximal activity in lymphoid cell	[maximal activity in lymphoid cells]	1.0	5	1	0	0
43232	1624	prevent nuclear translocation of c-Rel/p65 heterodimer	[preventing nuclear translocation of c-Rel/p65 heterodimers]	1.0	6	1	0	0
43233	1624	promyelocytic cell in bone marrow	[promyelocytic cells in bone marrow]	1.0	5	1	0	0
43234	1624	lps induction of kappaB-dependent gene expression	[LPS induction of kappaB-dependent gene expression]	1.0	6	1	0	0
43235	1624	rapid progress in the understanding	[rapid progress in the understanding]	1.0	5	1	0	0
43236	1624	ras-transformed lymphocyte	[ras-transformed lymphocytes]	1.0	2	1	0	0
43237	1624	nearly all control mouse (94.4%)	[nearly all control mice (94.4%)]	1.0	5	1	0	0
43238	1624	retrovirus-mediated gene	[retrovirus-mediated gene]	1.0	2	1	0	0
43239	1624	suppression by cd8+ T cell	[suppression by CD8+ T cells]	1.0	5	1	0	0
43240	1624	transgenic evil	[transgenic Evil]	1.0	2	1	0	0
43241	1624	contrast to the MF individual	[contrast to the MF individuals]	1.0	5	1	0	0
43242	1624	c81-66-45 cells,	[C81-66-45 cells,]	1.0	2	1	0	0
43243	1624	second series	[second series]	1.0	2	1	0	0
43244	1624	hypoxia po2 approximately 14-18 Torr,	[hypoxia PO2 approximately 14-18 Torr,]	1.0	5	1	0	0
43245	1624	pebp2	[PEBP2]	1.0	1	11	6	6
43246	1624	several oncogene	[several oncogenes]	1.0	2	1	0	0
43247	1624	four derivate	[four derivates,]	1.0	2	1	0	0
43248	1624	gene encode for growth factor	[genes encoding for growth factors]	1.0	5	1	0	0
43249	1624	contrast, aspirin	[contrast, aspirin]	1.0	2	1	0	0
43250	1624	YY-1 site	[YY-1 site]	1.0	2	1	0	0
43251	1624	concomitant transendothelial migration of monocyte	[concomitant transendothelial migration of monocytes]	1.0	5	1	0	0
43252	1624	function of individual ptk substrate	[function of individual PTK substrates]	1.0	5	1	0	0
43253	1624	regulation of stimulus-dependent cd44 transcription	[regulation of stimulus-dependent CD44 transcription]	1.0	5	1	0	0
43254	1624	follow stimulation,	[Following stimulation,]	1.0	2	2	1	1
43255	1624	expression of a kda stat5 isoform	[expression of a kDa STAT5 isoform]	1.0	6	1	0	0
43256	1624	abnormality of Oct-1 DNA binding	[Abnormality of Oct-1 DNA binding]	1.0	5	1	0	0
43257	1624	two stable b cell line	[Two stable B cell lines]	1.0	5	1	0	0
43258	1624	TPA-dependent activation of the htlv-i enhancer	[TPA-dependent activation of the HTLV-I enhancer]	1.0	6	1	0	0
43259	1624	patient T	[patient T]	1.0	2	2	2	2
43260	1624	more sensitive polymerase chain reaction	[more sensitive polymerase chain reaction]	1.0	5	2	1	1
43261	1624	D.M.Powell, M.M.Lightfoote, S.Benn, m.a. Martin,	[D.M.Powell, M.M.Lightfoote, S.Benn, M.A. Martin,]	1.0	5	1	0	0
43262	1624	(nk) minus T cell subtractive library	[(NK) minus T cell subtractive library]	1.0	6	1	0	0
43263	1624	endothelial protein	[endothelial proteins]	1.0	2	2	2	2
43264	1624	include human immunodeficiency virus tat	[including human immunodeficiency virus Tat]	1.0	5	1	0	0
43265	1624	culture of pbmc on Teflon	[cultures of PBMC on Teflon]	1.0	5	1	0	0
43266	1624	NF-kappaB inhibitory effect of FCM	[NF-kappaB inhibitory effect of FCM]	1.0	5	1	0	0
43267	1624	EBNA-2 expression in Daudi cell	[EBNA-2 expression in Daudi cells]	1.0	5	1	0	0
43268	1624	ptdin 3-kinase in Ras signal	[PtdIns 3-kinase in Ras signaling]	1.0	5	1	0	0
43269	1624	unfused fibroblast	[unfused fibroblasts]	1.0	2	1	0	0
43270	1624	dense lymphocyte infiltration of the tumor	[dense lymphocyte infiltration of the tumor]	1.0	6	1	0	0
43271	1624	identify MNDA as a interferon-regulated gene	[identifying MNDA as a interferon-regulated gene]	1.0	6	1	0	0
43272	1624	10 consecutive cardiac transplant recipient	[10 consecutive cardiac transplant recipients]	1.0	5	1	0	0
43273	1624	nine woman with recurrent spontaneous abortion	[nine women with recurrent spontaneous abortion]	1.0	6	1	0	0
43274	1624	interferon-treated cell	[interferon-treated cells]	1.0	2	1	0	0
43275	1624	nre	[NRE]	1.0	1	11	5	5
43276	1624	rate limit in remodeling of tissue	[rate limiting in remodeling of tissues]	1.0	6	1	0	0
43277	1624	expression of the il-2 receptor	[expression of the IL-2 receptor]	1.0	5	1	0	0
43278	1624	ubiquitous protein	[ubiquitous protein]	1.0	2	2	1	1
43279	1624	transcription from the NFAT site	[transcription from the NFAT site]	1.0	5	1	0	0
43280	1624	51 bp	[51 bp]	1.0	2	1	0	0
43281	1624	0.5 microM)	[0.5 microM)]	1.0	2	1	0	0
43282	1624	viral titre	[Viral titres]	1.0	2	1	0	0
43283	1624	include tumor necrosis factor alpha TNF	[including tumor necrosis factor alpha TNF]	1.0	6	1	0	0
43284	1624	31 woman with reactive thrombocytosis	[31 women with reactive thrombocytosis]	1.0	5	1	0	0
43285	1624	NDP kinase	[NDP kinase]	1.0	2	2	2	2
43286	1624	phorbol 12-myristate 13-acetate PMA stimulation,	[phorbol 12-myristate 13-acetate PMA stimulation,]	1.0	5	1	0	0
43287	1624	p21ras signal	[p21ras signals]	1.0	2	2	2	2
43288	1624	use reporter chloramphenicol acetyltransferase plasmid	[using reporter chloramphenicol acetyltransferase plasmids]	1.0	5	1	0	0
43289	1624	CD4 on the cell surface	[CD4 on the cell surface]	1.0	5	1	0	0
43290	1624	own chromatin	[own chromatin]	1.0	2	1	0	0
43291	1624	rest normal human T cell	[resting normal human T cells]	1.0	5	1	0	0
43292	1624	mineralocorticoid receptor in mononuclear leukocyte	[mineralocorticoid receptors in mononuclear leukocytes]	1.0	5	2	1	1
43293	1624	mediate tnf-alpha release by b cell	[mediating TNF-alpha release by B cells]	1.0	6	1	0	0
43294	1624	use a sox9 coding sequence polymorphism	[using a SOX9 coding sequence polymorphism]	1.0	6	1	0	0
43295	1624	vzv product of orf 62	[VZV product of ORF 62]	1.0	5	1	0	0
43296	1624	proto-oncogene c-erbA	[proto-oncogene c-erbA]	1.0	2	1	0	0
43297	1624	late phase of allergic reaction	[late phase of allergic reaction]	1.0	5	1	0	0
43298	1624	interaction between the vitamin D3 receptor	[interactions between the vitamin D3 receptor]	1.0	6	1	0	0
43299	1624	switch gear during t-cell maturation rante	[Switching gears during T-cell maturation RANTES]	1.0	6	1	0	0
43300	1624	'late' (three	['late' (three]	1.0	2	1	0	0
43301	1624	insufficient suppression of serum cortisol concentration	[insufficient suppression of serum cortisol concentrations]	1.0	6	1	0	0
43302	1624	nuclear factor kappa b site	[nuclear factor kappa B site]	1.0	5	1	0	0
43303	1624	CREB phosphorylation	[CREB phosphorylation]	1.0	2	1	0	0
43304	1624	Cbl-b a homologue of Cbl	[Cbl-b a homologue of Cbl]	1.0	5	1	0	0
43305	1624	maturation, result in severe thrombocytopenia	[maturation, resulting in severe thrombocytopenia]	1.0	5	1	0	0
43306	1624	activator and/or	[activator and/or]	1.0	2	1	0	0
43307	1624	encode the transcription factor egr-1	[encoding the transcription factor egr-1]	1.0	5	1	0	0
43308	1624	T cell mitogen murine splenocyte	[T cell mitogens murine splenocytes]	1.0	5	1	0	0
43309	1624	radioligand method	[radioligand method]	1.0	2	1	0	0
43310	1624	significant increase in CD4 thymocyte	[significant increase in CD4 thymocytes]	1.0	5	1	0	0
43311	1624	human T cell receptor gamma tcrg	[human T cell receptor gamma TCRG]	1.0	6	1	0	0
43312	1624	camp pathway	[cAMP pathway]	1.0	2	2	2	2
43313	1624	growth stimulation	[growth stimulation]	1.0	2	1	0	0
43314	1624	-negative lymphoid	[-negative lymphoid]	1.0	2	1	0	0
43315	1624	thus implicate the N-terminal hydrophilic domain	[thus implicating the N-terminal hydrophilic domain]	1.0	6	1	0	0
43316	1624	cfp extract devoid of manlam	[CFP extracts devoid of ManLAM]	1.0	5	1	0	0
43317	1624	undifferentiated DC in normal skin	[undifferentiated DC in normal skin]	1.0	5	1	0	0
43318	1624	Glucocorticoid receptor in peripheral blood lymphocyte	[Glucocorticoid receptors in peripheral blood lymphocytes]	1.0	6	1	0	0
43319	1624	use coping	[using coping]	1.0	2	1	0	0
43320	1624	Zap-70 /Syk	[Zap-70 /Syk]	1.0	2	1	0	0
43321	1624	glucocorticoid in the immunodeficiency syndrome	[Glucocorticoids in the immunodeficiency syndrome]	1.0	5	1	0	0
43322	1624	chemotactic migration	[chemotactic migration]	1.0	2	2	2	2
43323	1624	JunB -control of IL-4 expression	[JunB -control of IL-4 expression]	1.0	5	1	0	0
43324	1624	macrophage maturation such as FcgammaRI	[macrophage maturation such as FcgammaRI]	1.0	5	1	0	0
43325	1624	nf-kappa b by a loop	[NF-kappa B by an loop]	1.0	5	1	0	0
43326	1624	pathway alone	[pathways alone]	1.0	2	1	0	0
43327	1624	depend on the cellular context	[depending on the cellular context]	1.0	5	1	0	0
43328	1624	Thus, tap	[Thus, Tap]	1.0	2	1	0	0
43329	1624	concentration mol/L)	[concentration mol/L)]	1.0	2	2	2	2
43330	1624	point mutation suppress gabp binding	[point mutations suppressing GABP binding]	1.0	5	1	0	0
43331	1624	characterization of the immunodeficiency virus type	[Characterization of the immunodeficiency virus type]	1.0	6	1	0	0
43332	1624	7 human mm cell line	[7 human MM cell lines]	1.0	5	1	0	0
43333	1624	various signals.	[various signals.]	1.0	2	1	0	0
43334	1624	pattern of expression in mouse tissue	[pattern of expression in mouse tissues]	1.0	6	1	0	0
43335	1624	aging change of glucocorticoid receptor	[aging changes of glucocorticoid receptor]	1.0	5	1	0	0
43336	1624	small proportion	[small proportion]	1.0	2	2	1	1
43337	1624	erythrocyte phenotype	[erythrocyte phenotype]	1.0	2	1	0	0
43338	1624	potential relevance in septic shock	[potential relevance in septic shock]	1.0	5	1	0	0
43339	1624	human pebp2 alpha a aml1	[human PEBP2 alpha A AML1]	1.0	5	1	0	0
43340	1624	homodimeric form	[homodimeric forms]	1.0	2	1	0	0
43341	1624	induction of Jurkat leukemic T cell	[Induction of Jurkat leukemic T cells]	1.0	6	1	0	0
43342	1624	enable T cell a nongenomic response	[enabling T cells a nongenomic response]	1.0	6	1	0	0
43343	1624	antisense oligodeoxynucleotides	[antisense oligodeoxynucleotides]	1.0	2	2	2	2
43344	1624	dominant negative form of Stat1alpha	[Dominant negative forms of Stat1alpha]	1.0	5	1	0	0
43345	1624	Physiol. 275,	[Physiol. 275,]	1.0	2	1	0	0
43346	1624	December 27;271(52):33705]	[Dec 27;271(52):33705]]	1.0	2	1	0	0
43347	1624	specificity-conferring mechanism at the level	[specificity-conferring mechanism at the level]	1.0	5	1	0	0
43348	1624	proliferative effect of this cytokine	[proliferative effect of this cytokine]	1.0	5	1	0	0
43349	1624	accord to pbmc sensitivity to prednisolone	[according to PBMC sensitivity to prednisolone]	1.0	6	1	0	0
43350	1624	g-protein coupling	[G-protein coupling]	1.0	2	1	0	0
43351	1624	arsenic content	[arsenic content]	1.0	2	2	2	2
43352	1624	reporter vector	[reporter vector]	1.0	2	1	0	0
43353	1624	branching morphogenesis	[branching morphogenesis]	1.0	2	1	0	0
43354	1624	IFN synthesis	[IFN synthesis]	1.0	2	2	2	2
43355	1624	fact disturbed.	[fact disturbed.]	1.0	2	1	0	0
43356	1624	Tat increase	[Tat increase]	1.0	2	1	0	0
43357	1624	mutant endotoxin	[mutant endotoxin]	1.0	2	2	1	1
43358	1624	5 person	[5 persons]	1.0	2	1	0	0
43359	1624	therapeutic response	[therapeutic response]	1.0	2	1	0	0
43360	1624	possible need	[possible need]	1.0	2	1	0	0
43361	1624	analysis of the sequence immediately upstream	[Analysis of the sequence immediately upstream]	1.0	6	1	0	0
43362	1624	inhibition of IFNgamma- gene expression	[inhibition of IFNgamma- gene expression]	1.0	5	1	0	0
43363	1624	state of nonproductive hiv-1 infection	[state of nonproductive HIV-1 infection]	1.0	5	1	0	0
43364	1624	activity of the PPARgamma ligand	[activity of the PPARgamma ligand]	1.0	5	1	0	0
43365	1624	binding to NF-kappa b site	[binding to NF-kappa B site]	1.0	5	2	2	2
43366	1624	forty-eight hour	[Forty-eight hours]	1.0	2	1	0	0
43367	1624	heterozygote carrier	[heterozygote carriers]	1.0	2	1	0	0
43368	1624	significant specificity	[significant specificity]	1.0	2	1	0	0
43369	1624	induction of stat1 by tax	[induction of STAT1 by Tax]	1.0	5	1	0	0
43370	1624	two mutants.	[two mutants.]	1.0	2	1	0	0
43371	1624	gross abnormality	[gross abnormalities]	1.0	2	1	0	0
43372	1624	B-2 cell	[B-2 cells]	1.0	2	1	0	0
43373	1624	simultaneous presence of two kind	[simultaneous presence of two kinds]	1.0	5	1	0	0
43374	1624	conflicting observation	[conflicting observations]	1.0	2	1	0	0
43375	1624	-1280 element	[-1280 element]	1.0	2	1	0	0
43376	1624	expression of bhrf1 in mcfffas cell	[Expression of BHRF1 in MCF-Fas cells]	1.0	6	1	0	0
43377	1624	Furthermore, addition of the recombinant nf-y	[Furthermore, addition of the recombinant NF-Y]	1.0	6	1	0	0
43378	1624	tnf-alpha cell	[TNF-alpha cells]	1.0	2	2	1	1
43379	1624	molecular subclassification	[molecular subclassification]	1.0	2	1	0	0
43380	1624	sedentary subject	[sedentary subjects]	1.0	2	1	0	0
43381	1624	thus, replication of the transcriptional template	[Thus, replication of the transcriptional template]	1.0	6	1	0	0
43382	1624	Platelet/endothelial cell adhesion molecule-1 pecam-1	[Platelet/endothelial cell adhesion molecule-1 PECAM-1]	1.0	5	1	0	0
43383	1624	one feature of this chromatin reorganization	[One feature of this chromatin reorganization]	1.0	6	1	0	0
43384	1624	HTLV-1 infection	[HTLV-1 infection]	1.0	2	1	0	0
43385	1624	ZAP-70	[ZAP-70]	1.0	1	11	3	3
43386	1624	CD40-activated b	[CD40-activated B]	1.0	2	1	0	0
43387	1624	ligand-dependent manner	[ligand-dependent manner]	1.0	2	2	1	1
43388	1624	damage to extrathymic t-cell precursor	[damage to extrathymic T-cell precursors]	1.0	5	1	0	0
43389	1624	47 kda factor have affinity	[47 kDa factor having affinity]	1.0	5	1	0	0
43390	1624	tissue-specific component	[tissue-specific components]	1.0	2	1	0	0
43391	1624	NF-chi B	[NF-chi B]	1.0	2	2	1	1
43392	1624	glucocorticoid-responsive element	[glucocorticoid-responsive element]	1.0	2	1	0	0
43393	1624	various antioxidant	[Various antioxidants]	1.0	2	2	1	1
43394	1624	glutathione -depleting agent diethyl maleate	[glutathione -depleting agent diethyl maleate]	1.0	5	1	0	0
43395	1624	c-rel-specific antiserum	[c-rel-specific antiserum]	1.0	2	1	0	0
43396	1624	lysosomal enzyme	[lysosomal enzyme]	1.0	2	1	0	0
43397	1624	genetic mechanism	[genetic mechanisms]	1.0	2	1	0	0
43398	1624	erythroid-specific genes,	[erythroid-specific genes,]	1.0	2	1	0	0
43399	1624	human pathology,	[human pathology,]	1.0	2	1	0	0
43400	1624	mechanistic consequence	[mechanistic consequences]	1.0	2	1	0	0
43401	1624	nonsteroidal anti-inflammatory drug such as salicylate	[Nonsteroidal anti-inflammatory drugs such as salicylates]	1.0	6	1	0	0
43402	1624	case of deficiency-cold syndrome dcs	[cases of deficiency-cold syndrome DCS]	1.0	5	1	0	0
43403	1624	RelA p65	[RelA p65]	1.0	2	1	0	0
43404	1624	nac treatment	[NAC treatment]	1.0	2	1	0	0
43405	1624	chronic lymphocytic leukemia (cll) sample	[chronic lymphocytic leukemia (CLL) samples]	1.0	5	1	0	0
43406	1624	cd3+ cell among all cell	[CD3+ cells among all cells]	1.0	5	1	0	0
43407	1624	vitro assay	[vitro assay]	1.0	2	1	0	0
43408	1624	negative region	[negative region]	1.0	2	2	1	1
43409	1624	histone deacetylase (hdac) inhibitor trichostatin	[histone deacetylase (HDAC) inhibitor trichostatin]	1.0	5	1	0	0
43410	1624	consensus binding site for GATA-1	[consensus binding sites for GATA-1]	1.0	5	1	0	0
43411	1624	embryonic zeta	[embryonic zeta]	1.0	2	1	0	0
43412	1624	b cell line lack JAK3	[B cell lines lacking JAK3]	1.0	5	1	0	0
43413	1624	support the notion a transcription factor	[supporting the notion a transcription factor]	1.0	6	1	0	0
43414	1624	hla-dq -restricted T cell recognition	[HLA-DQ -restricted T cell recognition]	1.0	5	1	0	0
43415	1624	5' enhancer	[5' enhancer]	1.0	2	1	0	0
43416	1624	exogenous gata-1	[exogenous GATA-1]	1.0	2	1	0	0
43417	1624	icsat overexpression	[ICSAT overexpression]	1.0	2	2	1	1
43418	1624	immunologic tolerance,	[immunologic tolerance,]	1.0	2	1	0	0
43419	1624	ML-1 human myeloblastic leukemia cell	[ML-1 human myeloblastic leukemia cells]	1.0	5	1	0	0
43420	1624	generate high level of lucigenin-enhanced cl	[generating high levels of lucigenin-enhanced CL]	1.0	6	1	0	0
43421	1624	tumour necrosis factor alpha expression	[tumour necrosis factor alpha expression]	1.0	5	1	0	0
43422	1624	specifically bind to the gata site	[specifically binding to the GATA site]	1.0	6	1	0	0
43423	1624	cell cycle-related protein include c-myc	[cell cycle-related proteins including c-myc]	1.0	5	1	0	0
43424	1624	active process	[active process]	1.0	2	2	2	2
43425	1624	pld	[PLD]	1.0	1	11	5	5
43426	1624	intron g	[intron G]	1.0	2	1	0	0
43427	1624	cytotoxic chemotherapy	[cytotoxic chemotherapy]	1.0	2	2	2	2
43428	1624	use the c-fo promoter element probe	[using the c-fos promoter element probe]	1.0	6	1	0	0
43429	1624	aldosterone (>2000	[aldosterone (>2000]	1.0	2	1	0	0
43430	1624	bcr1 type-pml/RAR alpha fusion protein	[bcr1 type-pml/RAR alpha fusion protein]	1.0	5	1	0	0
43431	1624	KOX 18	[KOX 18]	1.0	2	1	0	0
43432	1624	rapid dominance of one pathway	[rapid dominance of one pathway]	1.0	5	1	0	0
43433	1624	epstein-barr virus DNA polymerase activity	[Epstein-Barr virus DNA polymerase activity]	1.0	5	1	0	0
43434	1624	partially substitute	[partially substitute]	1.0	2	2	2	2
43435	1624	Nuclear factor kappa b a mediator	[Nuclear factor kappa B a mediator]	1.0	6	1	0	0
43436	1624	treatment of a HTLV-I t-cell line	[Treatment of an HTLV-I T-cell line]	1.0	6	1	0	0
43437	1624	require specific signal for initiation.	[requiring specific signals for initiation.]	1.0	5	1	0	0
43438	1624	rest t-lymphocyte	[resting T-lymphocytes]	1.0	2	1	0	0
43439	1624	positively sequence	[positively sequences]	1.0	2	1	0	0
43440	1624	thp-1-hgh cell	[THP-1-hGH cells]	1.0	2	1	0	0
43441	1624	dimerization cofactor of HNF-1 alpha	[dimerization cofactor of HNF-1 alpha]	1.0	5	1	0	0
43442	1624	ankyrin motif	[ankyrin motifs]	1.0	2	1	0	0
43443	1624	cotransfection of the C/EBP-epsilon sense	[Cotransfection of the C/EBP-epsilon sense]	1.0	5	1	0	0
43444	1624	nuclear factor kappa b activation	[nuclear factor kappa B activation]	1.0	5	2	1	1
43445	1624	antisera contain high titre antibody	[antisera containing high titre antibodies]	1.0	5	1	0	0
43446	1624	4.04 nm,	[4.04 nM,]	1.0	2	1	0	0
43447	1624	generation of cd1+relb+ dendritic cell	[Generation of CD1+RelB+ dendritic cells]	1.0	5	1	0	0
43448	1624	early event of T cell activation	[early events of T cell activation]	1.0	6	1	0	0
43449	1624	distal element upstream of -224	[distal element upstream of -224,]	1.0	5	1	0	0
43450	1624	LMP1 ct a 333 to 386	[LMP1 CT aa 333 to 386]	1.0	6	1	0	0
43451	1624	DNase I hypersensitive site DHS mapping	[DNase I hypersensitive site DHS mapping]	1.0	6	1	0	0
43452	1624	human pathology	[human pathologies]	1.0	2	2	1	1
43453	1624	two general cellular transcription factor	[two general cellular transcription factors]	1.0	5	1	0	0
43454	1624	include tumor necrosis factor (TNF)alpha	[including tumor necrosis factor (TNF)alpha]	1.0	5	1	0	0
43455	1624	vitro analysis	[vitro analysis]	1.0	2	2	1	1
43456	1624	molecular difference of the a6h molecule	[Molecular differences of the A6H molecule]	1.0	6	1	0	0
43457	1624	functional correlate of dqa1 polymorphism	[functional correlate of DQA1 polymorphism]	1.0	5	1	0	0
43458	1624	late time point (40 P;	[later time points (40 h;]	1.0	5	1	0	0
43459	1624	similar role for RAR alpha	[similar role for RAR alpha]	1.0	5	1	0	0
43460	1624	normal human blood T cell	[normal human blood T cells]	1.0	5	1	0	0
43461	1624	new factor	[new factor]	1.0	2	2	1	1
43462	1624	zebra staining in any case	[ZEBRA staining in any case]	1.0	5	1	0	0
43463	1624	PHA-activated cell	[PHA-activated cells]	1.0	2	3	2	1
43464	1624	replication of the hiv type	[replication of the HIV type]	1.0	5	1	0	0
43465	1624	(il-6) a immunoregulatory multipotential cytokine	[(IL-6) an immunoregulatory multipotential cytokine]	1.0	5	1	0	0
43466	1624	similar activity	[similar activity]	1.0	2	2	1	1
43467	1624	cd40-cd40 ligand	[CD40-CD40 ligand]	1.0	2	1	0	0
43468	1624	TNF transcript	[TNF transcripts]	1.0	2	1	0	0
43469	1624	alpha G2S	[alpha G2S]	1.0	2	1	0	0
43470	1624	p53 molecule	[p53 molecule]	1.0	2	1	0	0
43471	1624	180 day	[180 days]	1.0	2	1	0	0
43472	1624	membrane order	[membrane order]	1.0	2	2	2	2
43473	1624	first hour	[first hours]	1.0	2	1	0	0
43474	1624	Erythroid lineage	[Erythroid lineage]	1.0	2	1	0	0
43475	1624	monokine induction	[monokine induction]	1.0	2	1	0	0
43476	1624	t(x;14) translocation	[t(X;14) translocations]	1.0	2	3	2	1
43477	1624	risk factor for local failure	[Risk factors for local failure]	1.0	5	1	0	0
43478	1624	functional region	[functional regions]	1.0	2	2	2	2
43479	1624	nuclear expression of human c-rel	[nuclear expression of human c-Rel]	1.0	5	1	0	0
43480	1624	CD2 signal	[CD2 signaling]	1.0	2	2	2	2
43481	1624	activate the t-cell-specific transcription factor nf-at	[activating the T-cell-specific transcription factors NF-AT]	1.0	6	1	0	0
43482	1624	dna-binding phosphoprotein effect of cyclosporin a	[DNA-binding phosphoproteins effects of cyclosporin A]	1.0	6	1	0	0
43483	1624	prerequisite for a high level	[prerequisite for a high level]	1.0	5	1	0	0
43484	1624	cyclin a	[Cyclin A]	1.0	2	2	1	1
43485	1624	il-4 activation of stat6 gene expression	[IL-4 activation of STAT6 gene expression]	1.0	6	1	0	0
43486	1624	ga-binding protein factor in concert	[GA-binding protein factors in concert]	1.0	5	1	0	0
43487	1624	suppression continue for 24 hours.	[suppression continuing for 24 hours.]	1.0	5	1	0	0
43488	1624	34-fold high than b cell	[34-fold higher than B cells]	1.0	5	1	0	0
43489	1624	constitutive serine phosphorylation of stat1	[constitutive serine phosphorylation of STAT1]	1.0	5	1	0	0
43490	1624	il-1 beta protein in response	[IL-1 beta protein in response]	1.0	5	1	0	0
43491	1624	responsive cell	[responsive cells]	1.0	2	1	0	0
43492	1624	translational mechanism	[translational mechanisms]	1.0	2	1	0	0
43493	1624	nuclear extract of htlv-1-transformed cell	[nuclear extracts of HTLV-1-transformed cells]	1.0	5	1	0	0
43494	1624	Comparison of the dose response	[Comparison of the dose response]	1.0	5	1	0	0
43495	1624	postnatally, typically die by 8 days.	[postnatally, typically dying by 8 days.]	1.0	6	1	0	0
43496	1624	cholesteryl ester	[cholesteryl esters]	1.0	2	1	0	0
43497	1624	group of 60 male subject	[group of 60 male subjects]	1.0	5	1	0	0
43498	1624	anti-immunoglobulin-treated b	[anti-immunoglobulin-treated B]	1.0	2	1	0	0
43499	1624	question of the DNA sequence	[question of the DNA sequences]	1.0	5	1	0	0
43500	1624	ige germline	[IgE germline]	1.0	2	2	1	1
43501	1624	induction of the transcription factor oct-1	[induction of the transcription factors OCT-1]	1.0	6	1	0	0
43502	1624	association with p50 in vitro,	[association with p50 in vitro,]	1.0	5	1	0	0
43503	1624	small deletion within beta-catenin Delta19	[small deletion within beta-catenin Delta19]	1.0	5	1	0	0
43504	1624	ongoing transcription of hiv provirus	[ongoing transcription of HIV provirus]	1.0	5	1	0	0
43505	1624	significant correlation between ngal expression	[significant correlation between NGAL expression]	1.0	5	1	0	0
43506	1624	enhance effect of the cytokine	[enhancing effect of the cytokine]	1.0	5	1	0	0
43507	1624	b-cell-restricted activity	[B-cell-restricted activity]	1.0	2	1	0	0
43508	1624	role maintain the basal level	[role maintaining the basal level]	1.0	5	1	0	0
43509	1624	sequence of humoral, non-specific action	[sequence of humoral, non-specific actions]	1.0	5	1	0	0
43510	1624	1, 25(oh)2d3	[1, 25(OH)2D3]	1.0	2	2	1	1
43511	1624	activation by the transcription factor vp16	[activation by the transcription factor VP16]	1.0	6	1	0	0
43512	1624	strain express PhoQ without PhoP	[strains expressing PhoQ without PhoP]	1.0	5	1	0	0
43513	1624	active calcineurin	[active calcineurin]	1.0	2	2	2	2
43514	1624	IL-6 promoter activity by LAM	[IL-6 promoter activity by LAM]	1.0	5	1	0	0
43515	1624	anti-cd28 stimulation	[anti-CD28 stimulation]	1.0	2	1	0	0
43516	1624	hydrophobic domain of cyclophilin ligand	[hydrophobic domain of cyclophilin ligand]	1.0	5	1	0	0
43517	1624	70% of maximal oxygen uptake)	[70% of maximal oxygen uptake)]	1.0	5	1	0	0
43518	1624	inhibition of nf-kappa b activity	[Inhibition of NF-kappa B activity]	1.0	5	2	1	1
43519	1624	gene, srg3	[gene, SRG3]	1.0	2	1	0	0
43520	1624	gabp factor	[GABP factors]	1.0	2	4	3	1
43521	1624	rapidak measurement	[rapid, measurement]	1.0	2	1	0	0
43522	1624	BFRF3 promoter	[BFRF3 promoters]	1.0	2	1	0	0
43523	1624	adjunctive substance	[adjunctive substances]	1.0	2	1	0	0
43524	1624	mutation in this binding site	[Mutations in these binding sites]	1.0	5	1	0	0
43525	1624	GM-CSF -dependent proliferation of mo7e cell	[GM-CSF -dependent proliferation of MO7e cells]	1.0	6	1	0	0
43526	1624	ef1 activity	[EF1 activity]	1.0	2	1	0	0
43527	1624	minimum of protein binding sequence	[minimum of protein binding sequences]	1.0	5	1	0	0
43528	1624	opposite situation	[opposite situation]	1.0	2	1	0	0
43529	1624	cytosol of blood mononuclear cell	[cytosol of blood mononuclear cells]	1.0	5	1	0	0
43530	1624	Th1 phenotype	[Th1 phenotype]	1.0	2	1	0	0
43531	1624	Nuclear localization of this protein	[Nuclear localization of these proteins]	1.0	5	1	0	0
43532	1624	repression of adult globin genes.	[repression of adult globin genes.]	1.0	5	1	0	0
43533	1624	cerebral malaria	[cerebral malaria]	1.0	2	1	0	0
43534	1624	active heterodimer	[active heterodimer]	1.0	2	2	2	2
43535	1624	tissue-specific manner	[tissue-specific manner]	1.0	2	2	1	1
43536	1624	several member of the NF-kappaB family	[several members of the NF-kappaB family]	1.0	6	1	0	0
43537	1624	refractory anemia	[refractory anemia]	1.0	2	2	1	1
43538	1624	lipopolysaccharide-activated toll-like	[lipopolysaccharide-activated toll-like]	1.0	2	1	0	0
43539	1624	change in the transcription rate	[changes in the transcription rate]	1.0	5	1	0	0
43540	1624	antibody study	[Antibody studies]	1.0	2	1	0	0
43541	1624	evaluation of stat to GRR	[evaluation of STATs to GRR]	1.0	5	1	0	0
43542	1624	low level of lipopolysaccharide lps	[low levels of lipopolysaccharide LPS]	1.0	5	1	0	0
43543	1624	delta CaM-AI	[delta CaM-AI]	1.0	2	1	0	0
43544	1624	pre-terminal differentiation	[pre-terminal differentiation]	1.0	2	1	0	0
43545	1624	deleterious effect	[deleterious effect]	1.0	2	1	0	0
43546	1624	degenerative tropical spastic paraparesis tsp	[degenerative tropical spastic paraparesis TSP]	1.0	5	1	0	0
43547	1624	rapid increase in mad3 mrna	[rapid increase in MAD3 mRNA]	1.0	5	1	0	0
43548	1624	specific band	[specific band]	1.0	2	2	2	2
43549	1624	signal isoform of FGF receptor-1	[signaling isoform of FGF receptor-1]	1.0	5	1	0	0
43550	1624	tissue-specific promoter precede the exon	[tissue-specific promoter preceding the exon]	1.0	5	1	0	0
43551	1624	7.9 nm)	[7.9 nM)]	1.0	2	1	0	0
43552	1624	novel, proline -rich carboxy terminus	[novel, proline -rich carboxy terminus]	1.0	5	1	0	0
43553	1624	HVS cd8+ T cell clone	[HVS CD8+ T cell clone]	1.0	5	1	0	0
43554	1624	fusion of the trans-activation domain	[fusion of the trans-activation domain]	1.0	5	1	0	0
43555	1624	CBF beta -myh11 positive, 1	[CBF beta -MYH11 positive, 1]	1.0	5	1	0	0
43556	1624	E2A- HLF	[E2A- HLF]	1.0	2	2	1	1
43557	1624	il-5 -nonproduce T cell clone	[IL-5 -nonproducing T cell clones]	1.0	5	1	0	0
43558	1624	experimental anemia	[experimental anemia]	1.0	2	2	2	2
43559	1624	nonspecific increase	[nonspecific increase]	1.0	2	1	0	0
43560	1624	calcium-stimulated, cyclosporin a -sensitive induction	[calcium-stimulated, cyclosporin A -sensitive induction]	1.0	5	1	0	0
43561	1624	ap-1-like domain	[AP-1-like domain]	1.0	2	1	0	0
43562	1624	proline sequence	[proline sequence]	1.0	2	1	0	0
43563	1624	subset of normal b lymphocytes.	[subset of normal B lymphocytes.]	1.0	5	1	0	0
43564	1624	NH2-terminal kinase	[NH2-terminal kinases]	1.0	2	1	0	0
43565	1624	inhibition of rna polymerase ii transcription	[Inhibition of RNA polymerase II transcription]	1.0	6	1	0	0
43566	1624	platelet thromboxane receptor after infarction	[platelet thromboxane receptors after infarction]	1.0	5	1	0	0
43567	1624	soc protein	[SOCS proteins]	1.0	2	1	0	0
43568	1624	low level in normal b	[low levels in normal B]	1.0	5	1	0	0
43569	1624	viral function	[viral functions]	1.0	2	1	0	0
43570	1624	important trigger	[important trigger]	1.0	2	2	2	2
43571	1624	significant level of basal transcription	[significant levels of basal transcription]	1.0	5	1	0	0
43572	1624	minimal enhancer contain the mua	[minimal enhancer containing the muA]	1.0	5	1	0	0
43573	1624	entire surface	[entire surface]	1.0	2	1	0	0
43574	1624	U1 line overexpress c/ebp activator nf-il-6	[U1 lines overexpressing C/EBP activator NF-IL-6]	1.0	6	1	0	0
43575	1624	bind to the hCLEO region	[binding to the hCLEO region]	1.0	5	1	0	0
43576	1624	il-6 receptor	[IL-6 receptor]	1.0	2	2	2	2
43577	1624	viral replication.	[viral replication.]	1.0	2	1	0	0
43578	1624	ROI-dependent NF-kappaB	[ROI-dependent NF-kappaB]	1.0	2	1	0	0
43579	1624	TNF-alpha nuclear translocation primarily of p50-p65	[TNF-alpha nuclear translocation primarily of p50-p65]	1.0	6	1	0	0
43580	1624	viral replication,	[viral replication,]	1.0	2	1	0	0
43581	1624	quiescent human blood T lymphocyte	[quiescent human blood T lymphocytes]	1.0	5	1	0	0
43582	1624	cd34+thy-1-cd45ra- subset	[CD34+Thy-1-CD45RA- subsets]	1.0	2	1	0	0
43583	1624	subsequent analysis	[Subsequent analysis]	1.0	2	2	2	2
43584	1624	evaluation of the role of ligand	[Evaluation of the role of ligand]	1.0	6	1	0	0
43585	1624	mitogen induction	[Mitogen induction]	1.0	2	1	0	0
43586	1624	Janus protein tyrosine kinase Jak	[Janus protein tyrosine kinases Jak]	1.0	5	1	0	0
43587	1624	thus, defective il-2 gene transcription	[Thus, defective IL-2 gene transcription]	1.0	5	1	0	0
43588	1624	pivotal role transduce membrane-associated signal	[pivotal role transducing membrane-associated signals]	1.0	5	1	0	0
43589	1624	use a nucleosome -assembly system	[using a nucleosome -assembly system]	1.0	5	1	0	0
43590	1624	however, inhibition of Tat -mediated activation	[however, inhibition of Tat -mediated activation]	1.0	6	1	0	0
43591	1624	g protein in the activation	[G protein in the activation]	1.0	5	1	0	0
43592	1624	tumour suppressor	[tumour suppressor]	1.0	2	2	2	2
43593	1624	negative autoregulation in im-9 cell	[negative autoregulation in IM-9 cells]	1.0	5	1	0	0
43594	1624	SF, DC	[SF, DC]	1.0	2	1	0	0
43595	1624	Moreover, DEM	[Moreover, DEM]	1.0	2	1	0	0
43596	1624	protective effect of notch-1 on apoptosis	[Protective effects of notch-1 on apoptosis]	1.0	6	1	0	0
43597	1624	IL-1beta promoter	[IL-1beta promoter]	1.0	2	2	2	2
43598	1624	molecular mechanism of positive regulation	[molecular mechanism of positive regulation]	1.0	5	1	0	0
43599	1624	indicate apparently independent of NFATc	[indicating apparently independent of NFATc]	1.0	5	1	0	0
43600	1624	zinc-finger transcription	[zinc-finger transcription]	1.0	2	2	2	2
43601	1624	3 member of the signal transducer	[3 members of the signal transducer]	1.0	6	1	0	0
43602	1624	lymphoid-restricted gene	[lymphoid-restricted gene]	1.0	2	2	2	2
43603	1624	use a mutant viral stock	[using a mutant viral stock]	1.0	5	1	0	0
43604	1624	(tgf)-beta1 responsiveness of this locus.	[(TGF)-beta1 responsiveness of this locus.]	1.0	5	1	0	0
43605	1624	day cell	[day cells]	1.0	2	2	2	2
43606	1624	ELISA screen	[ELISA screening]	1.0	2	1	0	0
43607	1624	receptor-mediated mechanism of cell survival.	[receptor-mediated mechanism of cell survival.]	1.0	5	1	0	0
43608	1624	macrophage by bacterial lipopolysaccharide lps	[macrophages by bacterial lipopolysaccharide LPS]	1.0	5	1	0	0
43609	1624	late stage.	[later stage.]	1.0	2	1	0	0
43610	1624	regulate the activation of NF-kappa b	[regulating the activation of NF-kappa B]	1.0	6	1	0	0
43611	1624	particularly cd40l reactive T cell	[particularly CD40L reactive T cells]	1.0	5	1	0	0
43612	1624	p65 component of NF-kappa b	[p65 components of NF-kappa B]	1.0	5	1	0	0
43613	1624	dermal activation of the hiv-ltr	[dermal activation of the HIV-LTR]	1.0	5	1	0	0
43614	1624	ige concentration	[IgE concentrations]	1.0	2	1	0	0
43615	1624	[3h]-dexamethasone binding	[[3H]-Dexamethasone binding]	1.0	2	1	0	0
43616	1624	ctcf protein	[CTCF protein]	1.0	2	1	0	0
43617	1624	GH mrna	[GH mRNA]	1.0	2	1	0	0
43618	1624	two small nuclear rna gene	[two small nuclear RNA genes]	1.0	5	1	0	0
43619	1624	phosphonate-containing liposome	[phosphonate-containing liposomes]	1.0	2	1	0	0
43620	1624	entry into the cell cycle	[entry into the cell cycle]	1.0	5	1	0	0
43621	1624	formation of a dna-binding complex	[formation of a DNA-binding complex]	1.0	5	1	0	0
43622	1624	reverse transcriptase-polymerase chain reaction RT-PCR	[reverse transcriptase-polymerase chain reaction RT-PCR]	1.0	5	1	0	0
43623	1624	CREB/ATF factor	[CREB/ATF factors]	1.0	2	1	0	0
43624	1624	human gm-csf	[human GM-CSF]	1.0	2	2	2	2
43625	1624	T-lymphocyte lineage	[T-lymphocyte lineage]	1.0	2	1	0	0
43626	1624	affect the expression of other cytokine	[affecting the expression of other cytokines]	1.0	6	1	0	0
43627	1624	various physiologic concentration of DEX	[Various physiologic concentrations of DEX]	1.0	5	1	0	0
43628	1624	department of lymphocyte from stem cell	[Department of lymphocytes from stem cells]	1.0	6	1	0	0
43629	1624	first regulatory protein of hiv-1	[first regulatory protein of HIV-1]	1.0	5	1	0	0
43630	1624	adult upon	[adults upon]	1.0	2	1	0	0
43631	1624	L-selectin gene	[L-selectin gene]	1.0	2	2	1	1
43632	1624	level of transcription factor ap-1	[levels of transcription factor AP-1]	1.0	5	1	0	0
43633	1624	effect EC	[effects EC]	1.0	2	1	0	0
43634	1624	pyrolidine dithiocarbamate	[pyrolidine dithiocarbamate]	1.0	2	1	0	0
43635	1624	high concentration in this cell	[high concentrations in these cells]	1.0	5	1	0	0
43636	1624	integrin alpha	[integrin alpha]	1.0	2	1	0	0
43637	1624	La mrna	[La mRNA]	1.0	2	2	1	1
43638	1624	12 control	[12 controls]	1.0	2	2	2	2
43639	1624	brain development	[brain development]	1.0	2	2	2	2
43640	1624	evaluation CD4	[evaluation CD4]	1.0	2	1	0	0
43641	1624	human progenitor	[human progenitors]	1.0	2	2	1	1
43642	1624	previous study use antisense oligonucleotide	[Previous studies using antisense oligonucleotides]	1.0	5	1	0	0
43643	1624	human cell by treponema pallidum	[human cells by Treponema pallidum]	1.0	5	1	0	0
43644	1624	promoter upregulation	[promoter upregulation]	1.0	2	1	0	0
43645	1624	effect of vincristine-selected, multidrug resistance	[effects of vincristine-selected, multidrug resistance]	1.0	5	1	0	0
43646	1624	il-1beta treatment	[IL-1beta treatment]	1.0	2	1	0	0
43647	1624	phosphorylation of the transcription factor	[phosphorylation of the transcription factors]	1.0	5	2	2	2
43648	1624	potentially novel protein (around 35 kda	[potentially novel proteins (around 35 kDa]	1.0	6	1	0	0
43649	1624	various species	[various species]	1.0	2	1	0	0
43650	1624	-inducible interferon	[-inducible interferon]	1.0	2	1	0	0
43651	1624	type ii estrogen binding site variation	[Type II estrogen binding sites variations]	1.0	6	1	0	0
43652	1624	62 (ie62)	[62 (IE62)]	1.0	2	1	0	0
43653	1624	clinical latency	[clinical latency]	1.0	2	1	0	0
43654	1624	five tonsil	[five tonsils]	1.0	2	1	0	0
43655	1624	potent antiproliferative effect in T cell	[potent antiproliferative effects in T cells]	1.0	6	1	0	0
43656	1624	chemically-exposed group	[chemically-exposed group]	1.0	2	1	0	0
43657	1624	32p-labeled oligonucleotide	[32P-labeled oligonucleotide]	1.0	2	2	1	1
43658	1624	low the/thf	[low THE/THF]	1.0	2	2	1	1
43659	1624	vitro glucocorticoid receptor binding study	[vitro glucocorticoid receptor binding studies]	1.0	5	1	0	0
43660	1624	polyclonal b lymphocyte in vitro.	[polyclonal B lymphocytes in vitro.]	1.0	5	1	0	0
43661	1624	further analysis of general coactivator requirement	[Further analysis of general coactivator requirements]	1.0	6	1	0	0
43662	1624	pcr study	[PCR studies]	1.0	2	1	0	0
43663	1624	mechanism of transactivation by nuclear factor	[Mechanisms of transactivation by nuclear factor]	1.0	6	1	0	0
43664	1624	transcription factor bind to PRE-I	[transcription factors binding to PRE-I]	1.0	5	1	0	0
43665	1624	however, mutation of the AP-1 site	[However, mutation of the AP-1 site]	1.0	6	1	0	0
43666	1624	retinoblastoma phosphorylation	[retinoblastoma phosphorylation]	1.0	2	1	0	0
43667	1624	novel finding	[novel finding]	1.0	2	1	0	0
43668	1624	pertinent model	[pertinent model]	1.0	2	1	0	0
43669	1624	express lmp-1	[expressing LMP-1]	1.0	2	1	0	0
43670	1624	difference in the time course	[difference in the time course]	1.0	5	1	0	0
43671	1624	-phosphorylated lat in detergent lysate	[-phosphorylated LAT in detergent lysates]	1.0	5	1	0	0
43672	1624	latent component	[latent component]	1.0	2	1	0	0
43673	1624	nuclear extract of U937 cell	[nuclear extracts of U937 cells]	1.0	5	1	0	0
43674	1624	DNA probe	[DNA probe]	1.0	2	2	1	1
43675	1624	However, 135(oh)2d3	[However, 1,25(OH)2D3]	1.0	2	1	0	0
43676	1624	high level induction of il-2r	[high level induction of IL-2R]	1.0	5	1	0	0
43677	1624	cells/ml) with a natural thiol antioxidant	[cells/ml) with a natural thiol antioxidant]	1.0	6	1	0	0
43678	1624	mediterranean diet	[mediterranean diet]	1.0	2	1	0	0
43679	1624	significant effect.	[significant effect.]	1.0	2	1	0	0
43680	1624	CD3 depletion, indicate the importance	[CD3 depletion, indicating the importance]	1.0	5	1	0	0
43681	1624	trans-activation activity on various promoter element	[trans-activation activities on various promoter elements]	1.0	6	1	0	0
43682	1624	phosphorylation of the ets-1 protein.	[phosphorylation of the Ets-1 protein.]	1.0	5	1	0	0
43683	1624	proinflammatory function	[proinflammatory functions]	1.0	2	1	0	0
43684	1624	ISGF3 alpha the latent component	[ISGF3 alpha the latent component]	1.0	5	1	0	0
43685	1624	five major DNase-I hypersensitive site HS	[Five major DNase-I hypersensitive sites HS]	1.0	6	1	0	0
43686	1624	important role in the establishment	[important role in the establishment]	1.0	5	2	1	1
43687	1624	first encounter	[first encounter]	1.0	2	2	2	2
43688	1624	human pterin	[human pterin]	1.0	2	1	0	0
43689	1624	n-formyl-methionine-leucine-phenyl-alanine fmlp	[N-formyl-methionine-leucine-phenyl-alanine fMLP]	1.0	2	1	0	0
43690	1624	CLEO element	[CLEO element]	1.0	2	2	1	1
43691	1624	cell-derived supernatant	[cell-derived supernatants]	1.0	2	1	0	0
43692	1624	possible role in the release	[possible role in the release]	1.0	5	1	0	0
43693	1624	fc gamma RI gamma RII	[Fc gamma RI gamma RII]	1.0	5	1	0	0
43694	1624	follicular border	[follicular borders]	1.0	2	1	0	0
43695	1624	immune status	[immune status]	1.0	2	1	0	0
43696	1624	Potent attenuation of live-hiv-1 by gain	[Potent attenuation of live-HIV-1 by gain]	1.0	6	1	0	0
43697	1624	normal signal-dependent nf-kappa b activation	[normal signal-dependent NF-kappa B activation]	1.0	5	1	0	0
43698	1624	molecular target of antiinflammatory drug	[molecular target of antiinflammatory drugs]	1.0	5	1	0	0
43699	1624	human partner	[human partners]	1.0	2	1	0	0
43700	1624	880 comparison	[880 comparisons]	1.0	2	1	0	0
43701	1624	pha blast	[PHA blasts]	1.0	2	1	0	0
43702	1624	react with nuclei of the layer	[reacting with nuclei of the layer]	1.0	6	1	0	0
43703	1624	production of human interleukin 1beta	[production of human interleukin 1beta]	1.0	5	1	0	0
43704	1624	infiltrate joint from a patient	[infiltrating joints from a patient]	1.0	5	1	0	0
43705	1624	stable divergence in cytokine profile	[stable divergence in cytokine profiles]	1.0	5	1	0	0
43706	1624	concomitant elevation in the peripheral level	[concomitant elevations in the peripheral levels]	1.0	6	1	0	0
43707	1624	glycation reaction	[glycation reaction]	1.0	2	1	0	0
43708	1624	profile of transcription factor activation	[profile of transcription factor activation]	1.0	5	1	0	0
43709	1624	potent property	[potent properties]	1.0	2	2	2	2
43710	1624	co-transfection with dominant-negative mutant TNFRI	[Co-transfection with dominant-negative mutant TNFRI]	1.0	5	1	0	0
43711	1624	antiglucocorticoid ru486	[antiglucocorticoid RU486]	1.0	2	1	0	0
43712	1624	therapeutic measure	[therapeutic measures]	1.0	2	2	1	1
43713	1624	receptor change	[receptor changes]	1.0	2	2	1	1
43714	1624	potent immunosuppressive activity of tgf-beta	[potent immunosuppressive activity of TGF-beta]	1.0	5	1	0	0
43715	1624	cellular context [il-2]-dependent ht-2 line	[cellular context [IL-2]-dependent HT-2 line]	1.0	5	1	0	0
43716	1624	neu oncogene-initiated rat mammary carcinoma	[neu oncogene-initiated rat mammary carcinomas]	1.0	5	1	0	0
43717	1624	10 polymorphism to physiological condition	[10 polymorphism to physiological conditions]	1.0	5	1	0	0
43718	1624	caspase-dependent apoptosis	[caspase-dependent apoptosis]	1.0	2	1	0	0
43719	1624	urinary thf with low the/thf	[urinary THF with low THE/THF]	1.0	5	1	0	0
43720	1624	poor prognosis,	[poor prognosis,]	1.0	2	2	2	2
43721	1624	poor prognosis.	[poor prognosis.]	1.0	2	1	0	0
43722	1624	transactivation function of nfatp induction	[transactivation functions of NFATp induction]	1.0	5	1	0	0
43723	1624	circulate T cell with endothelial cell	[circulating T cells with endothelial cells]	1.0	6	1	0	0
43724	1624	Alone, PMA	[Alone, PMA]	1.0	2	1	0	0
43725	1624	more cortivazol	[more cortivazol]	1.0	2	2	2	2
43726	1624	Rapid induction of promoter activity	[Rapid induction of promoter activity]	1.0	5	1	0	0
43727	1624	specific event	[specific event]	1.0	2	2	1	1
43728	1624	nf-kappab activation as a adjunct	[NF-kappaB activation as an adjunct]	1.0	5	1	0	0
43729	1624	bacterial flagellum	[bacterial flagellum]	1.0	2	1	0	0
43730	1624	immunologic machinery	[immunologic machinery]	1.0	2	1	0	0
43731	1624	qr activity	[QR activity]	1.0	2	2	1	1
43732	1624	use a semiquantitative competitive hybridization assay	[using a semiquantitative competitive hybridization assay]	1.0	6	1	0	0
43733	1624	b mobilization	[B mobilization]	1.0	2	2	2	2
43734	1624	antibody specific for the domain	[antibodies specific for the domain]	1.0	5	1	0	0
43735	1624	expression of the tax protein	[expression of the Tax protein]	1.0	5	2	1	1
43736	1624	NF-activated T cell binding site	[NF-activated T cell binding sites]	1.0	5	1	0	0
43737	1624	contain binding site for ets protein	[containing binding sites for Ets proteins]	1.0	6	1	0	0
43738	1624	POUHD moiety	[POUHD moiety]	1.0	2	1	0	0
43739	1624	Functionally, galectin-3	[Functionally, galectin-3]	1.0	2	1	0	0
43740	1624	secretion of prostate-specific antigen psa	[secretion of prostate-specific antigen PSA]	1.0	5	1	0	0
43741	1624	defective translocation	[defective translocation]	1.0	2	2	2	2
43742	1624	hiv-1 transcription on chromatin-assembled DNA	[HIV-1 transcription on chromatin-assembled DNA]	1.0	5	1	0	0
43743	1624	sk-n-be(2) cell protein kinase c pkc	[SK-N-Be(2) cells protein kinase C PKC]	1.0	6	1	0	0
43744	1624	erythropoietin epo protein kinase b pkb/akt	[erythropoietin EPO protein kinase B PKB/Akt]	1.0	6	1	0	0
43745	1624	gene induction	[gene induction]	1.0	2	2	2	2
43746	1624	anti-cd mab	[anti-CD4 mAb]	1.0	2	2	1	1
43747	1624	kd value of 7.1 nm	[Kd values of 7.1 nM]	1.0	5	1	0	0
43748	1624	delta sp	[delta SP]	1.0	2	2	1	1
43749	1624	appropriate stimulation	[appropriate stimulation]	1.0	2	1	0	0
43750	1624	transcriptional regulation of this gene	[transcriptional regulation of these genes]	1.0	5	1	0	0
43751	1624	T cell receptor alpha tcr alpha	[T cell receptor alpha TCR alpha]	1.0	6	1	0	0
43752	1624	alpha-rb oligomer	[alpha-Rb oligomers]	1.0	2	1	0	0
43753	1624	loss of interleukin 6 (il-6) receptor	[loss of interleukin 6 (IL-6) receptor]	1.0	6	1	0	0
43754	1624	murine cyclin-dependent	[murine cyclin-dependent]	1.0	2	1	0	0
43755	1624	nuclear t3r mbc of lymphocyte	[nuclear T3R MBC of lymphocytes]	1.0	5	1	0	0
43756	1624	iron-responsive element	[iron-responsive element]	1.0	2	2	1	1
43757	1624	wild-type kinetic	[wild-type kinetics]	1.0	2	1	0	0
43758	1624	2-3 fold	[2-3 fold]	1.0	2	1	0	0
43759	1624	currently the subject of intense study.	[currently the subject of intense study.]	1.0	6	1	0	0
43760	1624	methods: tnf receptor surface expression	[METHODS: TNF receptor surface expression]	1.0	5	1	0	0
43761	1624	-dependent activate	[-dependent activating]	1.0	2	1	0	0
43762	1624	regulate the growth of hematopoietic cell	[regulating the growth of hematopoietic cells]	1.0	6	1	0	0
43763	1624	proliferation activity	[proliferation activity]	1.0	2	2	1	1
43764	1624	neonatal respiratory distress syndrome NRDS	[neonatal respiratory distress syndrome NRDS]	1.0	5	1	0	0
43765	1624	prognostic importance	[prognostic importance]	1.0	2	2	2	2
43766	1624	vivo dnase	[vivo DNase]	1.0	2	2	1	1
43767	1624	CONCLUSIONS: MZF-1	[CONCLUSIONS: MZF-1]	1.0	2	1	0	0
43768	1624	macrophage-CSF M-CSF	[macrophage-CSF M-CSF]	1.0	2	2	1	1
43769	1624	granulocyte-macrophage factor proliferation of cd34+ cell	[granulocyte-macrophage factor proliferation of CD34+ cells]	1.0	6	1	0	0
43770	1624	existence of a complex family	[existence of a complex family]	1.0	5	1	0	0
43771	1624	pi 3-kinase in T cell	[PI 3-kinase in T cells]	1.0	5	1	0	0
43772	1624	suggest a link between estrogenic pathway	[suggesting a link between estrogenic pathways]	1.0	6	1	0	0
43773	1624	age-related decrease in the number	[age-related decrease in the number]	1.0	5	1	0	0
43774	1624	fibroblast-like synoviocyte	[fibroblast-like synoviocytes]	1.0	2	1	0	0
43775	1624	serum-starved mm	[serum-starved MM]	1.0	2	1	0	0
43776	1624	SR 31747a -binding protein SR-BP	[SR 31747A -binding protein SR-BP]	1.0	5	1	0	0
43777	1624	significant difference in the architecture	[significant differences in the architecture]	1.0	5	1	0	0
43778	1624	ubiquitous oligopeptide in all proteins.	[ubiquitous oligopeptides in all proteins.]	1.0	5	1	0	0
43779	1624	CD4 t-cell	[CD4 T-cell]	1.0	2	2	1	1
43780	1624	gold compound contain gold ion	[gold compound containing gold ion]	1.0	5	2	2	2
43781	1624	calcineurin cell	[calcineurin cells]	1.0	2	1	0	0
43782	1624	expression of the molecule b7.1	[expression of the molecule B7.1]	1.0	5	1	0	0
43783	1624	modify the retinoid differentiation pathway	[modifying the retinoid differentiation pathway]	1.0	5	1	0	0
43784	1624	identification of a tissue-specific deoxyribonuclease	[identification of a tissue-specific deoxyribonuclease]	1.0	5	1	0	0
43785	1624	relation to the cell cycle	[relation to the cell cycle]	1.0	5	1	0	0
43786	1624	also IL-4 activation of stat5	[also IL-4 activation of STAT5]	1.0	5	1	0	0
43787	1624	chemical agent	[chemical agents]	1.0	2	1	0	0
43788	1624	mutation along with DNA binding study	[mutations along with DNA binding studies]	1.0	6	1	0	0
43789	1624	malignant lymphoma, diffuse, large cell" type	[malignant lymphoma, diffuse, large cell" type]	1.0	6	1	0	0
43790	1624	Nuclear expression of this protein	[Nuclear expression of these proteins]	1.0	5	1	0	0
43791	1624	cellular activities,	[cellular activities,]	1.0	2	1	0	0
43792	1624	acidic residue	[acidic residues]	1.0	2	1	0	0
43793	1624	il-2 survival	[IL-2 survival]	1.0	2	1	0	0
43794	1624	T cell during thymic development	[T cells during thymic development]	1.0	5	1	0	0
43795	1624	find hlh-2 expression in all case	[finding hLH-2 expression in all cases]	1.0	6	1	0	0
43796	1624	human RAR alpha hrar alpha	[human RAR alpha hRAR alpha]	1.0	5	1	0	0
43797	1624	ion 793	[ion 793]	1.0	2	1	0	0
43798	1624	pre-B cell by bacterial lipopolysaccharide	[pre-B cells by bacterial lipopolysaccharide]	1.0	5	1	0	0
43799	1624	extensive apoptosis of T cell	[extensive apoptosis of T cells]	1.0	5	1	0	0
43800	1624	64000-M(r) protein	[64,000-M(r) protein]	1.0	2	1	0	0
43801	1624	estrogen receptor (estrogen binding activity)	[estrogen receptor (estrogen binding activity)]	1.0	5	1	0	0
43802	1624	cd23 transcript in b cell	[CD23 transcripts in B cells]	1.0	5	1	0	0
43803	1624	NFAT minimal promoter by Tpl-2	[NFAT minimal promoter by Tpl-2]	1.0	5	1	0	0
43804	1624	dpm mg-1	[dpm mg-1]	1.0	2	2	2	2
43805	1624	CD4 at the d1/ cdr2-loop	[CD4 at the D1/ CDR2-loop]	1.0	5	1	0	0
43806	1624	pivotal event in the progression	[pivotal event in the progression]	1.0	5	1	0	0
43807	1624	extensive splicing	[extensive splicing]	1.0	2	1	0	0
43808	1624	use clsm	[using CLSM]	1.0	2	1	0	0
43809	1624	effector function in T cell	[effector functions in T cells]	1.0	5	1	0	0
43810	1624	subset of b cell neoplasm	[subset of B cell neoplasms]	1.0	5	1	0	0
43811	1624	consequence of p38 mapk activation	[consequences of p38 MAPk activation]	1.0	5	1	0	0
43812	1624	human t-cell fk506 -binding protein	[human T-cell FK506 -binding protein]	1.0	5	1	0	0
43813	1624	GRE-dependent luciferase	[GRE-dependent luciferase]	1.0	2	1	0	0
43814	1624	various age]	[various age]]	1.0	2	1	0	0
43815	1624	C. pneumoniae-mediated activation of endothelial cell	[C. pneumoniae-mediated activation of endothelial cells]	1.0	6	1	0	0
43816	1624	Thus, c-erbA/TR	[Thus, c-erbA/TR]	1.0	2	1	0	0
43817	1624	galectin-3 promoter	[galectin-3 promoter]	1.0	2	1	0	0
43818	1624	protein, respectively)	[protein, respectively)]	1.0	2	1	0	0
43819	1624	high thymidine kinase mrna expression	[higher thymidine kinase mRNA expression]	1.0	5	1	0	0
43820	1624	early g1	[early G1]	1.0	2	1	0	0
43821	1624	good prognosis in breast cancer	[good prognosis in breast cancer]	1.0	5	1	0	0
43822	1624	cell selectivity of the effect.	[cell selectivity of the effect.]	1.0	5	1	0	0
43823	1624	(8 subject	[(8 subjects]	1.0	2	1	0	0
43824	1624	signal across the membrane result	[signal across the membrane resulting]	1.0	5	1	0	0
43825	1624	concentration of binding site similar	[concentration of binding sites similar]	1.0	5	1	0	0
43826	1624	one J kappa -binding site	[one J kappa -binding site]	1.0	5	1	0	0
43827	1624	Paramyxovirus infection	[Paramyxovirus infection]	1.0	2	1	0	0
43828	1624	in-vitro transcription/translation of this cDNA	[In-vitro transcription/translation of this cDNA]	1.0	5	1	0	0
43829	1624	positive signal for erk activation	[positive signal for ERK activation]	1.0	5	1	0	0
43830	1624	expression of the TINUR gene	[expression of the TINUR gene]	1.0	5	1	0	0
43831	1624	intracellular pool	[intracellular pool]	1.0	2	2	1	1
43832	1624	alternatively mediate in a variety	[alternatively mediating in a variety]	1.0	5	1	0	0
43833	1624	accumulation of the respective transcript	[accumulation of the respective transcripts]	1.0	5	1	0	0
43834	1624	glutamine-rich region	[glutamine-rich regions]	1.0	2	1	0	0
43835	1624	lead to NF-kappaB nuclear translocation	[leading to NF-kappaB nuclear translocation]	1.0	5	1	0	0
43836	1624	19.2+/-2.4 nmol/L)	[19.2+/-2.4 nmol/L)]	1.0	2	1	0	0
43837	1624	interleukin-1 signal mediator in cell	[interleukin-1 signaling mediators in cells]	1.0	5	1	0	0
43838	1624	three order	[three orders]	1.0	2	2	2	2
43839	1624	unequivocal evidence of ig gene hypermutation	[unequivocal evidence of Ig gene hypermutation]	1.0	6	1	0	0
43840	1624	early growth response protein egr-1	[early growth response protein EGR-1]	1.0	5	1	0	0
43841	1624	western blot of t-cell lysate	[Western blots of T-cell lysates]	1.0	5	1	0	0
43842	1624	estrogen receptor expression by tumor cell	[estrogen receptor expression by tumor cells]	1.0	6	1	0	0
43843	1624	map unit 0.67 to 0.73	[map units 0.67 to 0.73]	1.0	5	1	0	0
43844	1624	substantial decrease in antiproliferative response	[substantial decrease in antiproliferative response]	1.0	5	1	0	0
43845	1624	cytokine proliferation	[cytokine proliferation]	1.0	2	1	0	0
43846	1624	monocyte infiltration	[monocyte infiltration]	1.0	2	2	2	2
43847	1624	excess of c/ebp binding site	[excess of C/EBP binding sites]	1.0	5	1	0	0
43848	1624	cytosolic phospholipase	[cytosolic phospholipase]	1.0	2	2	2	2
43849	1624	13-cis RA	[13-cis RA]	1.0	2	2	2	2
43850	1624	dual-function protein	[dual-function protein]	1.0	2	1	0	0
43851	1624	August, 1992	[August, 1992,]	1.0	2	1	0	0
43852	1624	pro-inflammatory stimuli,	[pro-inflammatory stimuli,]	1.0	2	1	0	0
43853	1624	12 ss	[12 SS]	1.0	2	1	0	0
43854	1624	cd14 antigen	[CD14 antigen]	1.0	2	1	0	0
43855	1624	function of the viral protein	[functions of the viral protein]	1.0	5	1	0	0
43856	1624	tre-like camp	[TRE-like cAMP]	1.0	2	1	0	0
43857	1624	cells, however,	[cells, however,]	1.0	2	1	0	0
43858	1624	pxqxt/s-containing sequence	[PXQXT/S-containing sequence]	1.0	2	1	0	0
43859	1624	DNA binding of a panel	[DNA binding of a panel]	1.0	5	1	0	0
43860	1624	weak aggregation	[weak aggregation]	1.0	2	1	0	0
43861	1624	often converge in common intracellular pathway	[often converging in common intracellular pathways]	1.0	6	1	0	0
43862	1624	thp-1 macrophage	[THP-1 macrophages]	1.0	2	1	0	0
43863	1624	activity of the CBF site	[Activity of the CBF site]	1.0	5	1	0	0
43864	1624	tax induction of nuclear c-rel expression	[Tax induction of nuclear c-Rel expression]	1.0	6	1	0	0
43865	1624	C-terminal end	[C-terminal end]	1.0	2	1	0	0
43866	1624	P/I induction of FasL mrna	[P/I induction of FasL mRNA]	1.0	5	1	0	0
43867	1624	3 month	[3 months]	1.0	2	2	1	1
43868	1624	type a b ebv carrier	[type A B EBV carriers]	1.0	5	1	0	0
43869	1624	non tumour	[non tumour]	1.0	2	1	0	0
43870	1624	pd195599 PPARbeta	[PD195599 PPARbeta]	1.0	2	1	0	0
43871	1624	one abnormality, the majority related	[one abnormality, the majority related]	1.0	5	1	0	0
43872	1624	acute myeloid leukemia m2-type cell line	[acute myeloid leukemia M2-type cell line]	1.0	6	1	0	0
43873	1624	blood lactate	[blood lactate]	1.0	2	2	2	2
43874	1624	TAP1-/- cell	[TAP1-/- cells]	1.0	2	1	0	0
43875	1624	inducible nos	[inducible NOS]	1.0	2	1	0	0
43876	1624	series of clone with promoter	[series of clones with promoter]	1.0	5	1	0	0
43877	1624	differentiation inducer	[differentiation inducers]	1.0	2	2	1	1
43878	1624	pseudo-tumor necrosis factor receptor tnfr	[pseudo-tumor necrosis factor receptor TNFR]	1.0	5	1	0	0
43879	1624	ap1 activation	[AP1 activation]	1.0	2	2	2	2
43880	1624	role of IKK1 in lipopolysaccharide signal	[Role of IKK1 in lipopolysaccharide signaling]	1.0	6	1	0	0
43881	1624	novel sequence.	[novel sequence.]	1.0	2	1	0	0
43882	1624	glucocorticoid therapy in ulcerative colitis	[glucocorticoid therapy in ulcerative colitis]	1.0	5	1	0	0
43883	1624	genetic variation	[genetic variation]	1.0	2	1	0	0
43884	1624	related target	[related targeting]	1.0	2	1	0	0
43885	1624	induction of the lytic cycle	[induction of the lytic cycle]	1.0	5	1	0	0
43886	1624	potential effect	[potential effects]	1.0	2	2	2	2
43887	1624	key element	[key element]	1.0	2	2	2	2
43888	1624	(10 U/ml,	[(10 U/ml,]	1.0	2	1	0	0
43889	1624	adult hematopoietic cell polypryrimidine-binding factor	[adult hematopoietic cells polypryrimidine-binding factor]	1.0	5	1	0	0
43890	1624	induction of transcription by IL-10	[induction of transcription by IL-10]	1.0	5	1	0	0
43891	1624	encephalomyocarditis virus	[Encephalomyocarditis virus]	1.0	2	2	2	2
43892	1624	disproportionate occurrence in a subset	[disproportionate occurrence in a subset]	1.0	5	1	0	0
43893	1624	6 hours,	[6 hours,]	1.0	2	1	0	0
43894	1624	early infancy	[early infancy]	1.0	2	1	0	0
43895	1624	erythroblast from adult human bone marrow	[erythroblasts from adult human bone marrow]	1.0	6	1	0	0
43896	1624	property different	[properties different]	1.0	2	1	0	0
43897	1624	gs in primary human T lymphocyte	[GS in primary human T lymphocytes]	1.0	6	1	0	0
43898	1624	order complex	[order complex]	1.0	2	2	2	2
43899	1624	concomitant activation of the v-j recombination	[concomitant activation of the V-J recombination]	1.0	6	1	0	0
43900	1624	molecular pathogenesis of B-cell lymphoma	[molecular pathogenesis of B-cell lymphoma]	1.0	5	1	0	0
43901	1624	three compartment	[three compartments]	1.0	2	1	0	0
43902	1624	delete regions.	[deleting regions.]	1.0	2	1	0	0
43903	1624	demonstration of hormone receptor protein	[demonstration of hormone receptor proteins]	1.0	5	1	0	0
43904	1624	further decrease	[further decrease]	1.0	2	1	0	0
43905	1624	promonocytic u1 cell with r-h-tbp-1	[promonocytic U1 cells with r-h-TBP-1]	1.0	5	1	0	0
43906	1624	expression of MHC hla-dra class gene	[Expression of MHC HLA-DRA class gene]	1.0	6	1	0	0
43907	1624	recessive form	[recessive form]	1.0	2	2	2	2
43908	1624	involve nuclear factor of T cell	[involving nuclear factor of T cell]	1.0	6	2	1	1
43909	1624	T cell antigen receptor signal	[T cell antigen receptor signaling]	1.0	5	1	0	0
43910	1624	host immunity	[host immunity]	1.0	2	2	1	1
43911	1624	repeats, bind kappa b site	[repeats, bind kappa B sites]	1.0	5	1	0	0
43912	1624	rachitic chick	[rachitic chick]	1.0	2	1	0	0
43913	1624	susceptibility of the transgenic mouse	[susceptibility of the transgenic mice]	1.0	5	1	0	0
43914	1624	CsA -sensitive regulation of nfatp	[CsA -sensitive regulation of NFATp]	1.0	5	1	0	0
43915	1624	Dexamethasone	[Dexamethasone]	1.0	1	11	1	1
43916	1624	two major responses, nf-kappab activation	[two major responses, NF-kappaB activation]	1.0	5	1	0	0
43917	1624	ap1 factor	[AP1 factors]	1.0	2	2	2	2
43918	1624	loss of splenic precursor cell	[loss of splenic precursor cells]	1.0	5	1	0	0
43919	1624	coding intron	[coding intron]	1.0	2	1	0	0
43920	1624	haploinsufficiency of other pax gene	[haploinsufficiency of other Pax genes]	1.0	5	1	0	0
43921	1624	inability thymocyte	[inability thymocytes]	1.0	2	1	0	0
43922	1624	concentration of receptor of hormonal form	[Concentration of receptors of hormonal form]	1.0	6	1	0	0
43923	1624	Interestingly, Oct1	[Interestingly, Oct1]	1.0	2	1	0	0
43924	1624	bind affinity kd for dexamethasone	[binding affinity Kd for dexamethasone]	1.0	5	1	0	0
43925	1624	physiologic significance of this modification	[physiologic significance of this modification]	1.0	5	1	0	0
43926	1624	hybrid bcr/abl	[hybrid bcr/abl]	1.0	2	1	0	0
43927	1624	biological significance for different mechanism	[biological significance for different mechanisms]	1.0	5	1	0	0
43928	1624	analysis of the expression human I	[Analysis of the expression human I]	1.0	6	1	0	0
43929	1624	activity of NF-kappa b gene	[activity of NF-kappa B genes]	1.0	5	1	0	0
43930	1624	activity of several regulatory element	[activity of several regulatory elements]	1.0	5	1	0	0
43931	1624	locus activation	[locus activation]	1.0	2	1	0	0
43932	1624	stability of the c-fo transcript	[stability of the c-fos transcripts]	1.0	5	1	0	0
43933	1624	mip-1alpha-r mrna in this cell	[MIP-1alpha-R mRNA in these cells]	1.0	5	1	0	0
43934	1624	Sp1/NF-AT binding site in the region	[Sp1/NF-AT binding sites in the region]	1.0	6	1	0	0
43935	1624	strategy involve inhibition of nf-kappab activation	[strategies involving inhibition of NF-kappaB activation]	1.0	6	1	0	0
43936	1624	production of more mature double-positive population	[production of more mature double-positive populations]	1.0	6	1	0	0
43937	1624	viral oncogenesis	[viral oncogenesis]	1.0	2	1	0	0
43938	1624	concentration low	[concentration low]	1.0	2	2	2	2
43939	1624	stat1 in Jurkat T lymphocyte	[STAT1 in Jurkat T lymphocytes]	1.0	5	1	0	0
43940	1624	range in number from 3	[ranging in number from 3]	1.0	5	1	0	0
43941	1624	induction of a immediate-early gene	[induction of an immediate-early gene]	1.0	5	1	0	0
43942	1624	cd56+, cd11a+, cd13lo, cd15lo, cd34+/-, hla-dr	[CD56+, CD11a+, CD13lo, CD15lo, CD34+/-, HLA-DR]	1.0	6	1	0	0
43943	1624	binding factor in the native promoter	[binding factors in the native promoter]	1.0	6	1	0	0
43944	1624	ut-7/gm cell	[UT-7/GM cells]	1.0	2	3	2	1
43945	1624	ldl -receptor gene transcription in lymphocyte	[LDL -receptor gene transcription in lymphocytes]	1.0	6	1	0	0
43946	1624	protein release	[protein release]	1.0	2	1	0	0
43947	1624	addition of the -236 sequence	[addition of the -236 sequence]	1.0	5	1	0	0
43948	1624	substantial constitutive nf-kappa b -binding activity	[substantial constitutive NF-kappa B -binding activity]	1.0	6	1	0	0
43949	1624	undergo differentiation	[undergoing differentiation]	1.0	2	2	2	2
43950	1624	physical interaction of AML1 with BSAP	[Physical interaction of AML1 with BSAP]	1.0	6	1	0	0
43951	1624	I il-1ri	[I IL-1RI]	1.0	2	1	0	0
43952	1624	degradation of IkappaBalpha in T cell	[degradation of IkappaBalpha in T cells]	1.0	6	1	0	0
43953	1624	presence of the bacterial flagellum	[presence of the bacterial flagellum]	1.0	5	1	0	0
43954	1624	constitutive degradation	[constitutive degradation]	1.0	2	2	1	1
43955	1624	complex isgf3	[complex ISGF3]	1.0	2	1	0	0
43956	1624	CD40 engagement	[CD40 engagement]	1.0	2	1	0	0
43957	1624	increase in NF-kappa b level	[increase in NF-kappa B levels]	1.0	5	1	0	0
43958	1624	ebv binding	[EBV binding]	1.0	2	2	2	2
43959	1624	AML1 CBFalpha2	[AML1 CBFalpha2]	1.0	2	1	0	0
43960	1624	STAT family	[STAT family]	1.0	2	3	2	1
43961	1624	transcription of the Ad2 gene	[transcription of the Ad2 genes]	1.0	5	1	0	0
43962	1624	Recombinant murine	[Recombinant murine]	1.0	2	1	0	0
43963	1624	synthesis of long enhancer transcript	[synthesis of long enhancer transcripts]	1.0	5	1	0	0
43964	1624	two cases,	[two cases,]	1.0	2	1	0	0
43965	1624	follow CD4 oligomerization by antibody	[following CD4 oligomerization by antibodies]	1.0	5	1	0	0
43966	1624	glucocorticoid apoptosis in T cell	[glucocorticoid apoptosis in T cells]	1.0	5	1	0	0
43967	1624	express ebna2 as chimeric fusion protein	[expressing EBNA2 as chimeric fusion protein]	1.0	6	1	0	0
43968	1624	bactericidal/permeability-increasing protein	[bactericidal/permeability-increasing protein]	1.0	2	2	1	1
43969	1624	addition to diffuse nucleoplasmic localization	[addition to diffuse nucleoplasmic localization]	1.0	5	1	0	0
43970	1624	binding datum	[Binding data]	1.0	2	1	0	0
43971	1624	contain STAT3 alone with complex	[containing STAT3 alone with complexes]	1.0	5	1	0	0
43972	1624	il-12 signal in Th2 development	[IL-12 signaling in Th2 development]	1.0	5	1	0	0
43973	1624	e1a transfection	[E1A transfection]	1.0	2	1	0	0
43974	1624	conventional stains,	[conventional stains,]	1.0	2	1	0	0
43975	1624	Ficoll gradient	[Ficoll gradient]	1.0	2	1	0	0
43976	1624	thus, ebv binding to cellular receptor	[Thus, EBV binding to cellular receptor]	1.0	6	1	0	0
43977	1624	promoter activity in b cell	[promoter activity in B cells]	1.0	5	1	0	0
43978	1624	efficient down-regulation	[efficient down-regulation]	1.0	2	1	0	0
43979	1624	high affinity.	[high affinity.]	1.0	2	1	0	0
43980	1624	cell rescue	[cell rescue]	1.0	2	2	2	2
43981	1624	ED50 cortisol concentration give inhibition	[ED50 cortisol concentration giving inhibition]	1.0	5	1	0	0
43982	1624	g1-s-associated DNA	[G1-S-associated DNA]	1.0	2	1	0	0
43983	1624	couple ligand	[couple ligand]	1.0	2	1	0	0
43984	1624	activation of STAT (signal transducer	[activation of STAT (signal transducer]	1.0	5	1	0	0
43985	1624	immunoglobulin kappa 3' enhancer activity	[immunoglobulin kappa 3' enhancer activity]	1.0	5	1	0	0
43986	1624	point mutagenesis	[point mutagenesis]	1.0	2	1	0	0
43987	1624	5 defects.	[5 defects.]	1.0	2	1	0	0
43988	1624	wild-type tdag51	[wild-type TDAG51]	1.0	2	1	0	0
43989	1624	transactivate reporter	[transactivating reporters]	1.0	2	1	0	0
43990	1624	Kinase assay	[Kinase assays]	1.0	2	1	0	0
43991	1624	epor promoter	[EpoR promoter]	1.0	2	1	0	0
43992	1624	direct modification	[direct modification]	1.0	2	1	0	0
43993	1624	several lymphoid leukemia cell line	[several lymphoid leukemia cell lines]	1.0	5	1	0	0
43994	1624	apply the electrophoretic mobility shift assay	[applying the electrophoretic mobility shift assay]	1.0	6	1	0	0
43995	1624	antioxidant agent	[antioxidant agents]	1.0	2	2	1	1
43996	1624	however, a inhibition of transcription	[however, a inhibition of transcription]	1.0	5	1	0	0
43997	1624	protein phosphatase inhibitor Calyculin a	[protein phosphatase inhibitor Calyculin A]	1.0	5	1	0	0
43998	1624	il-4 gene expression in atopy	[IL-4 gene expression in atopy]	1.0	5	1	0	0
43999	1624	interphase cells,	[interphase cells,]	1.0	2	1	0	0
44000	1624	day 10.	[day 10.]	1.0	2	1	0	0
44001	1624	erk kinase	[ERK kinase]	1.0	2	2	2	2
44002	1624	proliferation of the k562 cell	[Proliferation of the K562 cells]	1.0	5	1	0	0
44003	1624	produce stimulation at lower, at doses.	[producing stimulation at lower, at doses.]	1.0	6	1	0	0
44004	1624	induction of apoptosis by dil	[induction of apoptosis by DILs]	1.0	5	1	0	0
44005	1624	bulbar conjunctiva of patient with vkc	[bulbar conjunctiva of patients with VKC]	1.0	6	1	0	0
44006	1624	(30 micrograms/d)	[(30 micrograms/d)]	1.0	2	1	0	0
44007	1624	mechanism for the pleiotropic effect	[mechanism for the pleiotropic effects]	1.0	5	1	0	0
44008	1624	level of leucocytic estrogen receptor	[levels of leucocytic estrogen receptor]	1.0	5	1	0	0
44009	1624	first year,	[first year,]	1.0	2	1	0	0
44010	1624	hla DQ2	[HLA DQ2]	1.0	2	1	0	0
44011	1624	Stat5 /mek pathway from e2f regulation	[Stat5 /MEK pathways from E2F regulation]	1.0	6	1	0	0
44012	1624	hypotonic extract of unstimulated T cell	[hypotonic extracts of unstimulated T cells]	1.0	6	1	0	0
44013	1624	interleukin -10	[interleukin -10]	1.0	2	1	0	0
44014	1624	brca2 mutation	[BRCA2 mutation]	1.0	2	2	1	1
44015	1624	cyclic nucleotide-dependent protein kinase inhibitor ha-1004	[cyclic nucleotide-dependent protein kinase inhibitor HA-1004]	1.0	6	1	0	0
44016	1624	p50/rela dimer	[p50/RelA dimers]	1.0	2	1	0	0
44017	1624	t-cell growth factor interleukin (il)-2	[T-cell growth factor interleukin (IL)-2]	1.0	5	1	0	0
44018	1624	stress treatment	[stress treatments]	1.0	2	1	0	0
44019	1624	cytokine message	[cytokine message]	1.0	2	2	2	2
44020	1624	icam-1 gene expression in rat astrocyte	[ICAM-1 gene expression in rat astrocytes]	1.0	6	1	0	0
44021	1624	inability of E1A gene product	[inability of E1A gene products]	1.0	5	1	0	0
44022	1624	interaction with cytoplasmic effector protein	[interaction with cytoplasmic effector proteins]	1.0	5	1	0	0
44023	1624	absolute time	[absolute time]	1.0	2	1	0	0
44024	1624	4e-bp2 amount	[4E-BP2 amount]	1.0	2	1	0	0
44025	1624	common requirement for the formation	[common requirements for the formation]	1.0	5	1	0	0
44026	1624	good model	[good model]	1.0	2	2	1	1
44027	1624	Sp-deficient drosophila Schneider 2 cell	[Sp-deficient Drosophila Schneider 2 cells]	1.0	5	1	0	0
44028	1624	ptf beta	[PTF beta]	1.0	2	2	1	1
44029	1624	such repeat	[such repeats]	1.0	2	1	0	0
44030	1624	bare lymphocyte syndrome-associated transactivator ciita	[bare lymphocyte syndrome-associated transactivators CIITA]	1.0	5	1	0	0
44031	1624	ap-1 dna-binding activity in t-cell	[AP-1 DNA-binding activity in T-cells]	1.0	5	2	1	1
44032	1624	IFN-alpha rna	[IFN-alpha RNA]	1.0	2	1	0	0
44033	1624	50% decrease in VDR level	[50% decrease in VDR levels]	1.0	5	1	0	0
44034	1624	regulate the physiological cell death pathway	[regulating the physiological cell death pathway]	1.0	6	1	0	0
44035	1624	cell stably	[cells stably]	1.0	2	1	0	0
44036	1624	disturbance of the immune surveillance	[Disturbance of the immune surveillance]	1.0	5	1	0	0
44037	1624	29 depressed,	[29 depressed,]	1.0	2	1	0	0
44038	1624	"differential repression"	["differential repression"]	1.0	2	1	0	0
44039	1624	transcriptional rate	[transcriptional rate]	1.0	2	1	0	0
44040	1624	translocation involve the x chromosome	[translocations involving the X chromosome]	1.0	5	1	0	0
44041	1624	orientation-independent manner.	[orientation-independent manner.]	1.0	2	1	0	0
44042	1624	mammalian mcm5	[mammalian MCM5]	1.0	2	2	1	1
44043	1624	t-cell transcription	[T-cell transcription]	1.0	2	3	2	1
44044	1624	extend from -643 to +33	[extending from -643 to +33]	1.0	5	1	0	0
44045	1624	Electrophoretic mobility shift assay EMSAs	[Electrophoretic mobility shift assays EMSAs]	1.0	5	1	0	0
44046	1624	inducible phosphorylation of the protein.	[inducible phosphorylation of the protein.]	1.0	5	1	0	0
44047	1624	gm-csf receptor beta common subunit	[GM-CSF receptor beta common subunit]	1.0	5	1	0	0
44048	1624	recent report	[recent report]	1.0	2	1	0	0
44049	1624	CD40 molecule at the basal state	[CD40 molecules at the basal state]	1.0	6	1	0	0
44050	1624	basolateral surface.	[basolateral surface.]	1.0	2	1	0	0
44051	1624	valuable model clarify the pathogenesis	[valuable model clarifying the pathogenesis]	1.0	5	1	0	0
44052	1624	tcr alpha/delta	[TCR alpha/delta]	1.0	2	2	1	1
44053	1624	new mutation	[new mutations]	1.0	2	1	0	0
44054	1624	maintain the phenotype of the cell	[maintaining the phenotype of the cells]	1.0	6	1	0	0
44055	1624	IL-10-activated STAT1	[IL-10-activated STAT1]	1.0	2	1	0	0
44056	1624	Furthermore, LMP1 cell size increase	[Furthermore, LMP1 cell size increase]	1.0	5	1	0	0
44057	1624	erythroid r-pk	[erythroid R-PK]	1.0	2	1	0	0
44058	1624	tg epsilon26 fetal liver cell	[tg epsilon26 fetal liver cells]	1.0	5	1	0	0
44059	1624	glucocorticoid of the CD8 antigen	[glucocorticoids of the CD8 antigens]	1.0	5	1	0	0
44060	1624	link abnormal behavior of stat pathway	[linking abnormal behavior of STAT pathways]	1.0	6	1	0	0
44061	1624	human NF-kappa b p65 mutant	[human NF-kappa B p65 mutants]	1.0	5	1	0	0
44062	1624	phytohemagglutinin pha-p	[phytohemagglutinin PHA-p]	1.0	2	1	0	0
44063	1624	transcriptional activity of tcf-1 alpha	[transcriptional activity of TCF-1 alpha]	1.0	5	1	0	0
44064	1624	mcd14 ligand	[mCD14 ligands]	1.0	2	2	2	2
44065	1624	other ion of similar masses;	[other ions of similar masses;]	1.0	5	1	0	0
44066	1624	notion multifactorial, involve genetic alteration	[notion multifactorial, involving genetic alterations]	1.0	5	1	0	0
44067	1624	activation of protein kinase c pkc	[activation of protein kinase C PKC]	1.0	6	1	0	0
44068	1624	T cell antigen receptor activation	[T cell antigen receptor activation]	1.0	5	1	0	0
44069	1624	roset around L&H cell in NLPHD	[rosetting around L&H cells in NLPHD]	1.0	6	1	0	0
44070	1624	molecular mimicry between one gliadin peptide	[molecular mimicry between one gliadin peptides]	1.0	6	1	0	0
44071	1624	thyroid peroxidase	[thyroid peroxidase]	1.0	2	2	1	1
44072	1624	correlation between receptor level in vitro.	[correlation between receptor level in vitro.]	1.0	6	1	0	0
44073	1624	develop vessel	[developing vessels]	1.0	2	1	0	0
44074	1624	accumulation of cell at g2, increase	[accumulation of cells at G2, increase]	1.0	6	1	0	0
44075	1624	specific member of the jun	[specific members of the jun]	1.0	5	1	0	0
44076	1624	expression of the orf transactivator	[expression of the ORF transactivator]	1.0	5	1	0	0
44077	1624	role of the protooncogene c-fo	[role of the protooncogene c-fos]	1.0	5	1	0	0
44078	1624	stimulation of huvec with thrombin	[Stimulation of HUVEC with thrombin]	1.0	5	1	0	0
44079	1624	inhibitory effect on tnf-alpha secretion	[inhibitory effect on TNF-alpha secretion]	1.0	5	1	0	0
44080	1624	social variable	[social variable]	1.0	2	1	0	0
44081	1624	basal transcription activity in vitro.	[basal transcription activity in vitro.]	1.0	5	1	0	0
44082	1624	tax-express cell	[Tax-expressing cells]	1.0	2	1	0	0
44083	1624	absence of anti- CD28 MoAb	[absence of anti- CD28 MoAb]	1.0	5	1	0	0
44084	1624	tumor cell reflect the gc	[tumor cells reflecting the GC]	1.0	5	1	0	0
44085	1624	divergence of nuclear factor kappab	[divergence of nuclear factor kappaB]	1.0	5	1	0	0
44086	1624	induction of new creb complex	[Induction of new CREB complexes]	1.0	5	1	0	0
44087	1624	major factor	[major factor]	1.0	2	2	2	2
44088	1624	intron/exon junctions, the 5'-regulatory region	[intron/exon junctions, the 5'-regulatory region]	1.0	5	1	0	0
44089	1624	Here, cytokine activation of Stat3	[Here, cytokine activation of Stat3]	1.0	5	1	0	0
44090	1624	cellular level of ikappabalpha mrna	[cellular levels of IkappaBalpha mRNA]	1.0	5	1	0	0
44091	1624	transcription of heat shock gene	[transcription of heat shock genes]	1.0	5	1	0	0
44092	1624	critical role in signal transduction	[critical role in signal transduction]	1.0	5	1	0	0
44093	1624	b-cell-specific gene	[B-cell-specific genes]	1.0	2	2	1	1
44094	1624	Rb mutant	[Rb mutants]	1.0	2	1	0	0
44095	1624	oocyte development	[oocyte development]	1.0	2	1	0	0
44096	1624	v-abl protein	[v-abl protein]	1.0	2	3	2	1
44097	1624	activation of the sp1 factor	[activation of the Sp1 factor]	1.0	5	1	0	0
44098	1624	inadequate response to glucocorticoid therapy	[inadequate response to glucocorticoid therapy]	1.0	5	1	0	0
44099	1624	cytokine-induced modulation of PML expression	[Cytokine-induced modulation of PML expression]	1.0	5	1	0	0
44100	1624	deficiency-cold syndrome	[deficiency-cold syndrome]	1.0	2	2	1	1
44101	1624	ap-1 /oap	[AP-1 /OAP]	1.0	2	2	2	2
44102	1624	differential activity between the two promoter	[differential activity between the two promoters]	1.0	6	1	0	0
44103	1624	point mutation of the c-Myb site	[Point mutation of the c-Myb site]	1.0	6	1	0	0
44104	1624	have a ec50 of 1.5 microM.	[having an EC50 of 1.5 microM.]	1.0	6	1	0	0
44105	1624	regulate differentiation of center b cell	[regulating differentiation of center B cells]	1.0	6	1	0	0
44106	1624	myeloid-promyelocytic lineage	[myeloid-promyelocytic lineage]	1.0	2	1	0	0
44107	1624	estradiol receptor level in tumor	[estradiol receptor levels in tumor]	1.0	5	1	0	0
44108	1624	many tissues.	[many tissues.]	1.0	2	1	0	0
44109	1624	endogenous hsf2-alpha	[endogenous HSF2-alpha]	1.0	2	1	0	0
44110	1624	contain the promoter-binding protein Sp1	[containing the promoter-binding protein Sp1]	1.0	5	1	0	0
44111	1624	estrogenic response	[estrogenic response]	1.0	2	1	0	0
44112	1624	hemodynamic phase	[hemodynamic phase]	1.0	2	2	1	1
44113	1624	one hybrid	[one hybrid]	1.0	2	1	0	0
44114	1624	appearance of DNA binding activity	[appearance of DNA binding activity]	1.0	5	1	0	0
44115	1624	abnormal binding of transcription factor	[abnormal binding of transcription factors]	1.0	5	1	0	0
44116	1624	antibody specific for CaM kinase	[antibody specific for CaM kinase]	1.0	5	1	0	0
44117	1624	cell in	[cells in]	1.0	2	1	0	0
44118	1624	atl-16t cell	[ATL-16T cells]	1.0	2	2	1	1
44119	1624	thus, type 2 effector function	[Thus, type 2 effector function]	1.0	5	1	0	0
44120	1624	Maximal induction of TNF alpha mrna	[Maximal induction of TNF alpha mRNA]	1.0	6	1	0	0
44121	1624	seven patient with severe vkc	[seven patients with severe VKC]	1.0	5	1	0	0
44122	1624	relevant role	[relevant role]	1.0	2	2	2	2
44123	1624	significant change in haemoglobin production	[significant changes in haemoglobin production]	1.0	5	1	0	0
44124	1624	rat macrophage	[rat macrophages]	1.0	2	3	2	1
44125	1624	interleukin-3-dependent apoptosis	[interleukin-3-dependent apoptosis]	1.0	2	1	0	0
44126	1624	cell ec	[cell EC]	1.0	2	2	2	2
44127	1624	activation of hiv gene expression	[activation of HIV gene expression]	1.0	5	1	0	0
44128	1624	bcl-6 in normal B-cell development	[BCL-6 in normal B-cell development]	1.0	5	1	0	0
44129	1624	previous study on the function	[previous studies on the function]	1.0	5	1	0	0
44130	1624	target cell during acute inflammation	[target cells during acute inflammation]	1.0	5	1	0	0
44131	1624	growth of human myeloid leukemia cell	[growth of human myeloid leukemia cells]	1.0	6	1	0	0
44132	1624	undergo observation.	[undergoing observation.]	1.0	2	1	0	0
44133	1624	subcellular localization,	[subcellular localization,]	1.0	2	1	0	0
44134	1624	potential element	[potential elements]	1.0	2	2	2	2
44135	1624	id3 overexpression	[Id3 overexpression]	1.0	2	1	0	0
44136	1624	exclusively cytoplasmic 105k precursor p105	[exclusively cytoplasmic 105K precursor p105]	1.0	5	1	0	0
44137	1624	nonmatrix compartment	[nonmatrix compartments]	1.0	2	1	0	0
44138	1624	cax repeat	[CAX repeat]	1.0	2	1	0	0
44139	1624	human ebv include virus-induced tumorigenesis.	[human EBV including virus-induced tumorigenesis.]	1.0	5	1	0	0
44140	1624	positive function	[positive function]	1.0	2	1	0	0
44141	1624	tax apoptosis in T cell	[Tax apoptosis in T cells]	1.0	5	1	0	0
44142	1624	AP-2 cDNA in DNA binding	[AP-2 cDNA in DNA binding]	1.0	5	1	0	0
44143	1624	potency as cell growth inhibitor	[potency as cell growth inhibitors]	1.0	5	1	0	0
44144	1624	allow translocation into the nucleus	[allowing translocation into the nucleus]	1.0	5	2	2	2
44145	1624	human t-cell-leukemia	[human T-cell-leukemia]	1.0	2	1	0	0
44146	1624	T cell express cd40l consistent	[T cells expressing CD40L consistent]	1.0	5	1	0	0
44147	1624	endoplasmic reticulum	[endoplasmic reticulum]	1.0	2	2	2	2
44148	1624	thus form a complex system	[thus forming a complex system]	1.0	5	1	0	0
44149	1624	consecutive sample of fresh blood	[consecutive samples of fresh blood]	1.0	5	1	0	0
44150	1624	control kappa b-alpha proteolysis by phosphorylation	[Control kappa B-alpha proteolysis by phosphorylation]	1.0	6	1	0	0
44151	1624	transform latent membrane protein-1 lmp-1	[transforming latent membrane protein-1 LMP-1]	1.0	5	1	0	0
44152	1624	antiserum specific	[Antiserum specific]	1.0	2	1	0	0
44153	1624	trimer of the octamer sequence	[trimer of the octamer sequence]	1.0	5	1	0	0
44154	1624	effective activation	[effective activation]	1.0	2	1	0	0
44155	1624	clonal anergy	[clonal anergy]	1.0	2	1	0	0
44156	1624	novel species	[novel species]	1.0	2	1	0	0
44157	1624	kappa b alpha /mad-3 mrna level	[kappa B alpha /MAD-3 mRNA levels]	1.0	6	1	0	0
44158	1624	HTLV-1 transformation of T cell	[HTLV-1 transformation of T cells]	1.0	5	1	0	0
44159	1624	trans-activate phenotype	[trans-activating phenotypes]	1.0	2	2	2	2
44160	1624	concentration of a beta (25-35)	[concentrations of A beta (25-35)]	1.0	5	2	2	2
44161	1624	Mechanical ventilation	[Mechanical ventilation]	1.0	2	1	0	0
44162	1624	modification of Sp1 such as phosphorylation,	[modification of Sp1 such as phosphorylation,]	1.0	6	1	0	0
44163	1624	Southern blotting	[Southern blotting]	1.0	2	2	1	1
44164	1624	normal macrophage	[normal macrophages]	1.0	2	2	2	2
44165	1624	similarly, a kinase-deficient mutant of NIK	[Similarly, a kinase-deficient mutant of NIK]	1.0	6	1	0	0
44166	1624	such as multiplex messenger assay	[such as multiplex messenger assays]	1.0	5	1	0	0
44167	1624	six animal	[six animals]	1.0	2	1	0	0
44168	1624	only kbf1	[only KBF1]	1.0	2	1	0	0
44169	1624	tcr activation of nuclear factor	[TCR activation of nuclear factor]	1.0	5	1	0	0
44170	1624	protein capable to three regulatory sequence	[proteins capable to three regulatory sequences]	1.0	6	1	0	0
44171	1624	sperm type	[sperm typing]	1.0	2	2	2	2
44172	1624	17q breakpoint	[17q breakpoint]	1.0	2	2	1	1
44173	1624	heterodimeric receptor.	[heterodimeric receptor.]	1.0	2	1	0	0
44174	1624	mammalian homeodomain	[mammalian homeodomains]	1.0	2	1	0	0
44175	1624	long survival	[long-term survival]	1.0	2	2	2	2
44176	1624	only in subset of cell	[only in subsets of cells]	1.0	5	1	0	0
44177	1624	suggest overlapping mechanism of action,	[suggesting overlapping mechanisms of action,]	1.0	5	1	0	0
44178	1624	inhibitory factor	[inhibitory factor]	1.0	2	2	1	1
44179	1624	bind tpa responsive element TRE	[binding TPA responsive elements TRE]	1.0	5	1	0	0
44180	1624	CD40 trigger of human monocyte	[CD40 triggering of human monocytes]	1.0	5	1	0	0
44181	1624	cd23 cross-linking	[CD23 cross-linking]	1.0	2	1	0	0
44182	1624	Jak1 expression in E1C3 cell	[Jak1 expression in E1C3 cells]	1.0	5	1	0	0
44183	1624	Functional study in extrarenal, non-epithelial cell	[Functional studies in extrarenal, non-epithelial cells]	1.0	6	1	0	0
44184	1624	induction of the RAR(alpha) PML-RAR rrna	[induction of the RAR(alpha) PML-RAR mRNAs]	1.0	6	1	0	0
44185	1624	addition to generation of isoform	[addition to generation of isoforms]	1.0	5	1	0	0
44186	1624	Palombella (Palombella, Rando, O.J., Goldberg, a.l.,	[Palombella (Palombella, Rando, O.J., Goldberg, A.L.,]	1.0	6	1	0	0
44187	1624	RBP-Jkappa response element within DNA.	[RBP-Jkappa response elements within DNA.]	1.0	5	1	0	0
44188	1624	growth arrest in b cell	[growth arrest in B cells]	1.0	5	1	0	0
44189	1624	MOLT-4 cell	[MOLT-4 cells]	1.0	2	1	0	0
44190	1624	Yae antibody	[Yae antibody]	1.0	2	1	0	0
44191	1624	element of the IL-2 promoter	[elements of the IL-2 promoter]	1.0	5	2	1	1
44192	1624	certain growth-	[certain growth-]	1.0	2	1	0	0
44193	1624	high rakfkqllq	[high RAKFKQLLQ]	1.0	2	1	0	0
44194	1624	variable proportion of tumor cell	[variable proportions of tumor cells]	1.0	5	1	0	0
44195	1624	peptidyl prolyl cis-tran isomerase activity	[peptidyl prolyl cis-trans isomerase activities]	1.0	5	1	0	0
44196	1624	variation of the cysteine supply	[variations of the cysteine supply]	1.0	5	1	0	0
44197	1624	i.e. the activation of NF-kappa b	[i.e. the activation of NF-kappa B]	1.0	6	1	0	0
44198	1624	nuclear p52	[nuclear p52]	1.0	2	1	0	0
44199	1624	first series	[first series]	1.0	2	1	0	0
44200	1624	cortivazol than the normal cell	[cortivazol than the normal cells]	1.0	5	2	2	2
44201	1624	maturation suppression of nb4 cell	[maturation suppression of NB4 cells]	1.0	5	1	0	0
44202	1624	level of plc gamma 1	[level of PLC gamma 1]	1.0	5	1	0	0
44203	1624	20%; 18-deoxyaldosterone	[20%; 18-deoxyaldosterone]	1.0	2	1	0	0
44204	1624	cess cell	[CESS cells]	1.0	2	1	0	0
44205	1624	selective effect of DNA damage agent	[Selective effects of DNA damaging agents]	1.0	6	1	0	0
44206	1624	hormone-responsive block	[hormone-responsive block]	1.0	2	1	0	0
44207	1624	AP-1 element	[AP-1 element]	1.0	2	2	2	2
44208	1624	hiv infection in human monocyte	[HIV infection in human monocytes]	1.0	5	1	0	0
44209	1624	stimulation of t-cell in conjunction	[Stimulation of T-cells in conjunction]	1.0	5	1	0	0
44210	1624	5' to the mrna cap site	[5' to the mRNA cap site]	1.0	6	1	0	0
44211	1624	other work	[other work]	1.0	2	1	0	0
44212	1624	mutant motif	[mutant motif]	1.0	2	1	0	0
44213	1624	costimulatory signal from T cell	[costimulatory signals from T cells]	1.0	5	1	0	0
44214	1624	ifn-gamma tyrosine phosphorylation of stat-1alpha	[IFN-gamma tyrosine phosphorylation of STAT-1alpha]	1.0	5	1	0	0
44215	1624	pathway with differential sensitivity to Bcl-2	[pathways with differential sensitivity to Bcl-2]	1.0	6	1	0	0
44216	1624	exercise twice,	[exercise twice,]	1.0	2	1	0	0
44217	1624	Oct-1 a POU domain transcription factor	[Oct-1 a POU domain transcription factor]	1.0	6	1	0	0
44218	1624	differentiation of human myeloid cells.	[differentiation of human myeloid cells.]	1.0	5	1	0	0
44219	1624	abnormal b	[abnormal B]	1.0	2	1	0	0
44220	1624	amplify th2 cell differentiation switch	[amplifying Th2 cell differentiation switching]	1.0	5	1	0	0
44221	1624	hallmark of unstimulated b cell	[hallmark of unstimulated B cells]	1.0	5	1	0	0
44222	1624	human monocyte/neutrophil	[human monocyte/neutrophil]	1.0	2	1	0	0
44223	1624	accounting for the common requirement	[accounting for the common requirements]	1.0	5	1	0	0
44224	1624	expression construct of c/ebp alpha	[expression constructs of C/EBP alpha]	1.0	5	1	0	0
44225	1624	biochemical consequence of the mutation.	[biochemical consequences of the mutation.]	1.0	5	1	0	0
44226	1624	regulate cd95 ligand gene expression	[regulating CD95 ligand gene expression]	1.0	5	1	0	0
44227	1624	membrane-bound enzyme	[membrane-bound enzyme]	1.0	2	2	2	2
44228	1624	anti-class i monoclonal antibody mab	[anti-class I monoclonal antibody mAb]	1.0	5	1	0	0
44229	1624	mineralocorticoid receptor mrna in monocyte	[mineralocorticoid receptor mRNA in monocytes]	1.0	5	1	0	0
44230	1624	Jurkat T cell by 65%	[Jurkat T cells by 65%]	1.0	5	1	0	0
44231	1624	important role in anti-inflammatory effect	[important role in anti-inflammatory effects]	1.0	5	1	0	0
44232	1624	detectable level of c-jun gene transcription	[detectable levels of c-jun gene transcription]	1.0	6	1	0	0
44233	1624	generation in mouse peritoneal macrophage	[generation in mouse peritoneal macrophages]	1.0	5	1	0	0
44234	1624	foreign cell	[foreign cells]	1.0	2	2	1	1
44235	1624	inflammatory lesion	[inflammatory lesions]	1.0	2	1	0	0
44236	1624	downstream of p21ras in the induction	[downstream of p21ras in the induction]	1.0	6	1	0	0
44237	1624	process dependent on nf-kappa b	[processes dependent on NF-kappa B]	1.0	5	1	0	0
44238	1624	heterologous thymidine	[heterologous thymidine]	1.0	2	1	0	0
44239	1624	granulocyte antibody	[granulocyte antibodies]	1.0	2	2	1	1
44240	1624	cell surface receptor for testosterone	[cell surface receptors for testosterone]	1.0	5	2	1	1
44241	1624	prolonged period in myeloid cell	[prolonged periods in myeloid cells]	1.0	5	1	0	0
44242	1624	EpoR (R129C)	[EpoR (R129C)]	1.0	2	1	0	0
44243	1624	indicate critical for thrombin inducibility	[indicating critical for thrombin inducibility]	1.0	5	1	0	0
44244	1624	expression of the cd19 gene	[expression of the CD19 gene]	1.0	5	1	0	0
44245	1624	tax1 mutant	[Tax1 mutants]	1.0	2	1	0	0
44246	1624	-516 motif	[-516 motif]	1.0	2	1	0	0
44247	1624	pleiotropic cytokine	[pleiotropic cytokine]	1.0	2	2	1	1
44248	1624	bHLH family	[bHLH family]	1.0	2	1	0	0
44249	1624	446 bp of c-fe 5'-flanking sequence	[446 bp of c-fes 5'-flanking sequences]	1.0	6	1	0	0
44250	1624	rare phenotype	[rare phenotype]	1.0	2	1	0	0
44251	1624	b cell by ig cross-linking	[B cells by Ig cross-linking]	1.0	5	1	0	0
44252	1624	adult male	[adult male]	1.0	2	2	2	2
44253	1624	molecular mechanism responsible for downmodulation	[molecular mechanisms responsible for downmodulation]	1.0	5	1	0	0
44254	1624	insect cell	[insect cells]	1.0	2	2	1	1
44255	1624	incubation with a combination of IL-2	[incubation with a combination of IL-2]	1.0	6	1	0	0
44256	1624	estradiol inactivation by U937 cell	[estradiol inactivation by U937 cells]	1.0	5	1	0	0
44257	1624	prostatic spermine binding protein mrna	[prostatic spermine binding protein mRNA]	1.0	5	1	0	0
44258	1624	indicate functional importance in the expression	[indicating functional importance in the expression]	1.0	6	1	0	0
44259	1624	biochemical defect	[biochemical defect]	1.0	2	1	0	0
44260	1624	calcium-stimulated, cyclosporin	[calcium-stimulated, cyclosporin]	1.0	2	1	0	0
44261	1624	novel RAR -selective antagonist er27191	[novel RAR -selective antagonist ER27191]	1.0	5	1	0	0
44262	1624	property in common with hsf1	[properties in common with HSF1]	1.0	5	1	0	0
44263	1624	only the two sh2 domain	[only the two SH2 domains]	1.0	5	1	0	0
44264	1624	v-src expression	[v-src expression]	1.0	2	1	0	0
44265	1624	other arm of the molecule.	[other arm of the molecule.]	1.0	5	1	0	0
44266	1624	helenalin to a less degree, 11alpha,13-dihydrohelenalin	[helenalin to a lesser degree, 11alpha,13-dihydrohelenalin]	1.0	6	1	0	0
44267	1624	expression of kappa b-responsive gene	[expression of kappa B-responsive genes]	1.0	5	1	0	0
44268	1624	novel, specific,	[novel, specific,]	1.0	2	1	0	0
44269	1624	e7 oncoprotein	[E7 oncoprotein]	1.0	2	1	0	0
44270	1624	self-reactive cell	[self-reactive cells]	1.0	2	1	0	0
44271	1624	fibronectin receptor	[fibronectin receptor]	1.0	2	2	1	1
44272	1624	optimal expression	[optimal expression]	1.0	2	1	0	0
44273	1624	critical role for this gene	[critical role for this gene]	1.0	5	1	0	0
44274	1624	mononuclear (mnl)	[mononuclear (MNL)]	1.0	2	1	0	0
44275	1624	low responder	[low responders]	1.0	2	2	2	2
44276	1624	interleukin-8 AP-1	[interleukin-8 AP-1]	1.0	2	1	0	0
44277	1624	use a nuclear run-on assay	[Using a nuclear run-on assay]	1.0	5	1	0	0
44278	1624	ifn-gamma tumor necrosis factor-alpha tnf-alpha	[IFN-gamma tumor necrosis factor-alpha TNF-alpha]	1.0	5	1	0	0
44279	1624	extremely low reporter mrna level	[extremely low reporter mRNA levels]	1.0	5	1	0	0
44280	1624	Dexamethasone Dex a synthetic glucocorticoid hormone	[Dexamethasone Dex a synthetic glucocorticoid hormone]	1.0	6	1	0	0
44281	1624	molecular marker	[molecular markers]	1.0	2	1	0	0
44282	1624	T cell receptor signal pathway	[T cell receptor signaling pathways]	1.0	5	1	0	0
44283	1624	tumor necrosis factor gene expression	[tumor necrosis factor gene expression]	1.0	5	1	0	0
44284	1624	only in cooperation with CIITA	[only in cooperation with CIITA]	1.0	5	1	0	0
44285	1624	human T cell lymphotropic virus	[Human T cell lymphotropic virus]	1.0	5	1	0	0
44286	1624	magnitude of the thrombin response	[magnitude of the thrombin response]	1.0	5	1	0	0
44287	1624	presence of a binding site	[presence of a binding site]	1.0	5	1	0	0
44288	1624	various concentration of the compound.	[various concentrations of the compound.]	1.0	5	1	0	0
44289	1624	Nuclear factor of T cell NF-AT	[Nuclear factor of T cells NF-AT]	1.0	6	1	0	0
44290	1624	interaction between the x2 box	[interactions between the X2 box]	1.0	5	2	1	1
44291	1624	moderate correlation between bind affinity	[moderate correlation between binding affinity]	1.0	5	1	0	0
44292	1624	subsequent accumulation of nuclear c-rel	[subsequent accumulation of nuclear c-Rel]	1.0	5	1	0	0
44293	1624	feasible strategy	[feasible strategy]	1.0	2	1	0	0
44294	1624	nip activity	[NIP activity]	1.0	2	1	0	0
44295	1624	interleukin-4, tumor necrosis factor alpha	[interleukin-4, tumor necrosis factor alpha]	1.0	5	1	0	0
44296	1624	contrast to e1a activities, sensitization	[contrast to E1A activities, sensitization]	1.0	5	1	0	0
44297	1624	648 bp capable of coding	[648 bp capable of coding]	1.0	5	1	0	0
44298	1624	wild-type grf40 in jurkat cell	[wild-type Grf40 in Jurkat cells]	1.0	5	1	0	0
44299	1624	NFATC family	[NFATC family]	1.0	2	1	0	0
44300	1624	exogenous tnf	[exogenous TNF]	1.0	2	1	0	0
44301	1624	production of several cytokine in vitro	[production of several cytokines in vitro]	1.0	6	1	0	0
44302	1624	fact, ifi	[fact, IFNs]	1.0	2	1	0	0
44303	1624	chromosome constitution of hybrid arise	[chromosome constitution of hybrids arising]	1.0	5	1	0	0
44304	1624	matrix metalloproteinase mmp include mmp-9	[matrix metalloproteinases MMPs including MMP-9]	1.0	5	1	0	0
44305	1624	regulation of protein kinase activation	[regulation of protein kinase activation]	1.0	5	1	0	0
44306	1624	IL2 enhancer	[IL2 enhancer]	1.0	2	1	0	0
44307	1624	change of any cysteine residue	[Changes of any cysteine residue]	1.0	5	1	0	0
44308	1624	theileria-infected cell	[Theileria-infected cells]	1.0	2	1	0	0
44309	1624	number from 3 to 20	[number from 3 to 20]	1.0	5	1	0	0
44310	1624	expression of the protooncogene c-fo	[Expression of the protooncogene c-fos]	1.0	5	1	0	0
44311	1624	active, form	[active, form]	1.0	2	2	2	2
44312	1624	part to a DNA bend	[part to a DNA bend]	1.0	5	1	0	0
44313	1624	basic mechanism	[basic mechanisms]	1.0	2	2	1	1
44314	1624	cd23 receptor	[CD23 receptor]	1.0	2	1	0	0
44315	1624	Recently, activation of NF-kappa b	[Recently, activation of NF-kappa B]	1.0	5	1	0	0
44316	1624	heterotetramer p65	[heterotetramer p65s]	1.0	2	1	0	0
44317	1624	mobilize Ca2+ from intracellular stores.	[mobilizing Ca2+ from intracellular stores.]	1.0	5	1	0	0
44318	1624	ice-like protease	[ICE-like proteases]	1.0	2	1	0	0
44319	1624	30 minute at 37 degree	[30 min at 37 degrees]	1.0	5	1	0	0
44320	1624	conjunction with overexpression of c-Rel	[conjunction with overexpression of c-Rel]	1.0	5	1	0	0
44321	1624	hlh-2 expression	[hLH-2 expression]	1.0	2	2	2	2
44322	1624	overexpression of RAR alpha alone	[overexpression of RAR alpha alone]	1.0	5	1	0	0
44323	1624	carboxy terminus of the ar	[carboxy terminus of the AR]	1.0	5	1	0	0
44324	1624	binding activity of this protein.	[binding activity of this protein.]	1.0	5	1	0	0
44325	1624	bioactive macrophage	[bioactive macrophage]	1.0	2	1	0	0
44326	1624	I kappa b-alpha protein level	[I kappa B-alpha protein levels]	1.0	5	1	0	0
44327	1624	NF-kappa b block cd11b expression	[NF-kappa B block CD11b expression]	1.0	5	1	0	0
44328	1624	lipoxygenase isoform	[lipoxygenase isoforms]	1.0	2	1	0	0
44329	1624	2a pp2a	[2A PP2A]	1.0	2	1	0	0
44330	1624	human adult	[human adult]	1.0	2	1	0	0
44331	1624	phase protein	[phase proteins]	1.0	2	2	2	2
44332	1624	peripheral blood mononuclear cell of patient	[peripheral blood mononuclear cells of patients]	1.0	6	1	0	0
44333	1624	2 hours,	[2 hours,]	1.0	2	1	0	0
44334	1624	significant inhibition	[significant inhibition]	1.0	2	5	4	1
44335	1624	lack in late G1 phase	[lack in late G1 phases]	1.0	5	1	0	0
44336	1624	physiological relevance of this findings,	[physiological relevance of these findings,]	1.0	5	1	0	0
44337	1624	mature granulocytes.	[mature granulocytes.]	1.0	2	1	0	0
44338	1624	link between the p38 pathway	[link between the p38 pathway]	1.0	5	1	0	0
44339	1624	hl-60 promyelocyte	[HL-60 promyelocytes]	1.0	2	2	1	1
44340	1624	p53-/- mouse	[p53-/- mice]	1.0	2	1	0	0
44341	1624	analysis of the binding protein	[Analysis of the binding proteins]	1.0	5	1	0	0
44342	1624	hCLEO region	[hCLEO region]	1.0	2	2	1	1
44343	1624	inhibitory effect on inflammatory response	[inhibitory effect on inflammatory responses]	1.0	5	1	0	0
44344	1624	study of the physiologic mechanism	[studies of the physiologic mechanisms]	1.0	5	1	0	0
44345	1624	direct CTL control in vivo	[direct CTL control in vivo]	1.0	5	1	0	0
44346	1624	phosphorylation process	[phosphorylation processes]	1.0	2	1	0	0
44347	1624	dexamethasone binding	[dexamethasone binding]	1.0	2	2	2	2
44348	1624	demonstrate feasible.	[demonstrating feasible.]	1.0	2	1	0	0
44349	1624	uncontrolled replication of a virus	[Uncontrolled replication of a virus]	1.0	5	1	0	0
44350	1624	synthesis of the trans-activate protein	[synthesis of the trans-activating protein]	1.0	5	1	0	0
44351	1624	nuclear factor of cell nf-at	[nuclear factor of cells NF-AT]	1.0	5	1	0	0
44352	1624	contain the immunodeficiency virus terminal repeat	[containing the immunodeficiency virus terminal repeat]	1.0	6	1	0	0
44353	1624	appropriate switch region for recombination	[appropriate switch region for recombination]	1.0	5	1	0	0
44354	1624	understand the variability of the history	[understanding the variability of the history]	1.0	6	1	0	0
44355	1624	ebv-positive case of hodgkin' disease	[EBV-positive cases of Hodgkin's disease]	1.0	5	1	0	0
44356	1624	specific phase	[specific phase]	1.0	2	1	0	0
44357	1624	1 alpha,25-OH)2D3	[1 alpha,25-OH)2D3]	1.0	2	1	0	0
44358	1624	nf-kappab activation in leukemic cell	[NF-kappaB activation in leukemic cells]	1.0	5	1	0	0
44359	1624	total enzyme.	[total enzyme.]	1.0	2	1	0	0
44360	1624	accelerate pace.	[accelerating pace.]	1.0	2	1	0	0
44361	1624	molecule capable	[molecule capable]	1.0	2	2	2	2
44362	1624	c12 cell	[c12 cells]	1.0	2	1	0	0
44363	1624	(signal transducer	[(signal transducer]	1.0	2	1	0	0
44364	1624	cell surface mu heavy chain	[cell surface mu heavy chain]	1.0	5	1	0	0
44365	1624	B-cell factor	[B-cell factor]	1.0	2	2	2	2
44366	1624	direct information about the presence	[direct information about the presence]	1.0	5	1	0	0
44367	1624	Southern and/or	[Southern and/or]	1.0	2	1	0	0
44368	1624	promoter of the CD19 gene	[promoter of the CD19 gene]	1.0	5	1	0	0
44369	1624	N-terminal Leu	[N-terminal Leu]	1.0	2	1	0	0
44370	1624	important role in hiv-1 activation	[important role in HIV-1 activation]	1.0	5	1	0	0
44371	1624	key regulator of viral gene	[key regulator of viral genes]	1.0	5	1	0	0
44372	1624	tcr triggering,	[TCR triggering,]	1.0	2	1	0	0
44373	1624	T cells-family protein NFAT1/ nfatp	[T cells-family proteins NFAT1/ NFATp]	1.0	5	1	0	0
44374	1624	mmp-9 secretion	[MMP-9 secretion]	1.0	2	1	0	0
44375	1624	expression of recombination activate gene	[expression of recombination activating genes]	1.0	5	1	0	0
44376	1624	same cell lineage as GATA-1	[same cell lineages as GATA-1]	1.0	5	1	0	0
44377	1624	45 days.	[45 days.]	1.0	2	1	0	0
44378	1624	design: urine	[DESIGN: Urine]	1.0	2	1	0	0
44379	1624	unexpectedly, in one plasma cell line,	[unexpectedly, in one plasma cell line,]	1.0	6	1	0	0
44380	1624	cd14 one	[CD14 one]	1.0	2	1	0	0
44381	1624	ALY a novel lef-1 -interact protein	[ALY a novel LEF-1 -interacting protein]	1.0	6	1	0	0
44382	1624	protein expression in RA -resistant cells.	[protein expression in RA -resistant cells.]	1.0	6	1	0	0
44383	1624	two NF-kappa B /rel binding site	[two NF-kappa B /Rel binding sites]	1.0	6	1	0	0
44384	1624	secretion (85	[secretion (85]	1.0	2	1	0	0
44385	1624	show physical interaction between October factor	[showing physical interactions between Oct factors]	1.0	6	1	0	0
44386	1624	add exogenous ttg to extract	[adding exogenous tTG to extracts]	1.0	5	1	0	0
44387	1624	balance between repression by ZEB	[balance between repression by ZEB]	1.0	5	1	0	0
44388	1624	gtp -cyclohydrolase	[GTP -cyclohydrolase]	1.0	2	1	0	0
44389	1624	need for further activation requirement	[need for further activation requirements]	1.0	5	1	0	0
44390	1624	inducible activation.	[inducible activation.]	1.0	2	1	0	0
44391	1624	loop structure	[loop structure]	1.0	2	1	0	0
44392	1624	shp1	[SHP1]	1.0	1	11	4	4
44393	1624	physiologic concentration	[physiologic concentrations]	1.0	2	2	2	2
44394	1624	expression of the receptor protein	[expression of the receptor protein]	1.0	5	1	0	0
44395	1624	conclusion, production	[conclusion, production]	1.0	2	1	0	0
44396	1624	essential components.	[essential components.]	1.0	2	1	0	0
44397	1624	subunit of multiple cytokine receptor	[subunit of multiple cytokine receptors]	1.0	5	1	0	0
44398	1624	hemo-lymphoid progenitor	[hemo-lymphoid progenitors]	1.0	2	1	0	0
44399	1624	ox ldl	[Ox LDL]	1.0	2	2	1	1
44400	1624	bimodal increase of junb mrna	[bimodal increase of junB mRNA]	1.0	5	1	0	0
44401	1624	tcf-mediated transcription in T cell	[Tcf-mediated transcription in T cells]	1.0	5	1	0	0
44402	1624	role of this 3' element	[role of these 3' elements]	1.0	5	1	0	0
44403	1624	even p65	[even p65]	1.0	2	1	0	0
44404	1624	neutrophil adhesivity	[neutrophil adhesivity]	1.0	2	1	0	0
44405	1624	distinct subset of acute leukemia	[distinct subsets of acute leukemia]	1.0	5	2	2	2
44406	1624	5- increase of AhR mrna	[5- increase of AhR mRNA]	1.0	5	1	0	0
44407	1624	transcriptional control of 15-lo expression	[transcriptional control of 15-LO expression]	1.0	5	1	0	0
44408	1624	physiologic mechanism,	[physiologic mechanism,]	1.0	2	1	0	0
44409	1624	suggest constitutively present in b cell	[suggesting constitutively present in B cells]	1.0	6	1	0	0
44410	1624	sv40 t-antigen in transgenic mouse	[SV40 T-antigen in transgenic mice]	1.0	5	1	0	0
44411	1624	gene encode the hepatocyte factor	[genes encoding the hepatocyte factors]	1.0	5	1	0	0
44412	1624	express a number of marker	[expressing a number of markers]	1.0	5	1	0	0
44413	1624	NF-kappaB/Rel factor	[NF-kappaB/Rel factors]	1.0	2	1	0	0
44414	1624	role of the X2 box	[Role of the X2 box]	1.0	5	1	0	0
44415	1624	trans-dominant expression vector of ras	[trans-dominant expression vectors of ras]	1.0	5	1	0	0
44416	1624	interferon gamma function on a promoter	[interferon gamma functions on a promoter]	1.0	6	1	0	0
44417	1624	use electrophoretic mobility shift assay EMSA	[Using electrophoretic mobility shift assays EMSA]	1.0	6	1	0	0
44418	1624	Eighteen hirsute patient with regular mense	[Eighteen hirsute patients with regular menses]	1.0	6	1	0	0
44419	1624	normal kinetic	[normal kinetics]	1.0	2	1	0	0
44420	1624	study alteration in monokine gene expression	[studying alterations in monokine gene expression]	1.0	6	1	0	0
44421	1624	regulate cp activity in LCL	[regulating Cp activity in LCL]	1.0	5	1	0	0
44422	1624	human lcr/gamma-globin	[human LCR/gamma-globin]	1.0	2	1	0	0
44423	1624	kinase ERK	[kinase ERK]	1.0	2	2	2	2
44424	1624	mnda mrna in phorbol ester	[MNDA mRNA in phorbol ester]	1.0	5	1	0	0
44425	1624	kappab motif	[kappaB motif]	1.0	2	1	0	0
44426	1624	multi-protein hematopoietic-specific transcription factor complex	[multi-protein hematopoietic-specific transcription factor complex]	1.0	5	1	0	0
44427	1624	(sh2) domain of the stat protein	[(SH2) domain of the Stat protein]	1.0	6	1	0	0
44428	1624	involve factor	[involving factor]	1.0	2	2	2	2
44429	1624	nuclear t3r	[nuclear T3R]	1.0	2	2	1	1
44430	1624	clear correlation to clinical response.	[clear correlation to clinical response.]	1.0	5	1	0	0
44431	1624	CD28 cosignaling of il-2 secretion	[CD28 cosignaling of IL-2 secretion]	1.0	5	1	0	0
44432	1624	manner opposite	[manner opposite]	1.0	2	1	0	0
44433	1624	mouse swi2	[mouse SWI2]	1.0	2	1	0	0
44434	1624	further insight into the suppression phenomenon	[further insight into the suppression phenomenon]	1.0	6	1	0	0
44435	1624	autoimmune disorder	[autoimmune disorders]	1.0	2	1	0	0
44436	1624	p49(100) DNA binding subunit together	[p49(100) DNA binding subunit together]	1.0	5	1	0	0
44437	1624	nuclear rna	[nuclear RNA]	1.0	2	2	1	1
44438	1624	binding to the interleukin-4 -responsive element	[binding to the interleukin-4 -responsive element]	1.0	6	1	0	0
44439	1624	rrna encode the ap-1 protein	[mRNAs encoding the AP-1 proteins]	1.0	5	1	0	0
44440	1624	acute phase	[acute phase]	1.0	2	2	1	1
44441	1624	tpa -resistant	[TPA -resistant]	1.0	2	1	0	0
44442	1624	commitment along the eosinophil lineage	[commitment along the eosinophil lineage]	1.0	5	1	0	0
44443	1624	ELISA procedure	[ELISA procedures]	1.0	2	1	0	0
44444	1624	assay system	[assay system]	1.0	2	2	2	2
44445	1624	Similarly, cycloheximide	[Similarly, cycloheximide]	1.0	2	1	0	0
44446	1624	gene-suppressive activity of NRE gamma	[gene-suppressive activity of NRE gamma]	1.0	5	1	0	0
44447	1624	three regions.	[three regions.]	1.0	2	1	0	0
44448	1624	other's actions, raise the possibility	[other's actions, raising the possibility]	1.0	5	1	0	0
44449	1624	indicate reversible.	[indicating reversible.]	1.0	2	1	0	0
44450	1624	receptor study	[receptor studies]	1.0	2	1	0	0
44451	1624	extensive footprint	[extensive footprints]	1.0	2	2	2	2
44452	1624	contain a deletion of the domain	[containing a deletion of the domain]	1.0	6	1	0	0
44453	1624	alpha-globin enhancer	[alpha-globin enhancer]	1.0	2	2	1	1
44454	1624	role of cellular redox status	[role of cellular redox status]	1.0	5	1	0	0
44455	1624	N-terminal residue	[N-terminal residues]	1.0	2	1	0	0
44456	1624	individual site	[individual sites]	1.0	2	1	0	0
44457	1624	0.95 kb	[0.95 kb]	1.0	2	1	0	0
44458	1624	analyze the clonality of blood cell	[analyzing the clonality of blood cells]	1.0	6	1	0	0
44459	1624	(3.5 kb	[(3.5 kb]	1.0	2	1	0	0
44460	1624	different genes,	[different genes,]	1.0	2	1	0	0
44461	1624	beta activation of stat6 by il-4	[beta activation of STAT6 by IL-4]	1.0	6	1	0	0
44462	1624	diurnal variation	[diurnal variation]	1.0	2	2	2	2
44463	1624	also as a repressor molecule	[also as a repressor molecule]	1.0	5	1	0	0
44464	1624	major role in the stimulation	[major role in the stimulation]	1.0	5	1	0	0
44465	1624	low activity.	[lower activity.]	1.0	2	2	1	1
44466	1624	activation of the hypothalamic-pituitary-adrenal axis	[Activation of the hypothalamic-pituitary-adrenal axis]	1.0	5	2	1	1
44467	1624	regulation of the gene coding	[regulation of the gene coding]	1.0	5	1	0	0
44468	1624	combination of zip binding site	[combination of ZIP binding sites]	1.0	5	1	0	0
44469	1624	critical mechanism	[critical mechanism]	1.0	2	2	2	2
44470	1624	tissue differentiation in drosophila elegan	[tissue differentiation in Drosophila elegans]	1.0	5	1	0	0
44471	1624	uterine cavity	[uterine cavity]	1.0	2	1	0	0
44472	1624	transcription of the DRA gene	[transcription of the DRA gene]	1.0	5	1	0	0
44473	1624	efficient rescue of the defect	[Efficient rescue of the defect]	1.0	5	1	0	0
44474	1624	altruistic suicide	[altruistic suicide]	1.0	2	1	0	0
44475	1624	standard techniques.	[standard techniques.]	1.0	2	1	0	0
44476	1624	b-cell-specific expression of immunoglobulin gene	[B-cell-specific expression of immunoglobulin genes]	1.0	5	1	0	0
44477	1624	First, STAT4	[First, STAT4]	1.0	2	1	0	0
44478	1624	effect on inducible Rel A	[effect on inducible Rel A]	1.0	5	1	0	0
44479	1624	all-tran RA at 10(-7) m,	[all-trans RA at 10(-7) M,]	1.0	5	1	0	0
44480	1624	motor activity	[motor activity]	1.0	2	2	2	2
44481	1624	'stressful' disease	['stressful' disease.]	1.0	2	1	0	0
44482	1624	transcriptional activity of ap-1/tpa responsive element	[transcriptional activity of AP-1/TPA responsive elements]	1.0	6	1	0	0
44483	1624	scid phenotype	[SCID phenotype]	1.0	2	1	0	0
44484	1624	Listeria monocytogent	[Listeria monocytogenes]	1.0	2	1	0	0
44485	1624	contrast, inhibition	[contrast, inhibition]	1.0	2	2	2	2
44486	1624	rest human peripheral blood monocyte	[resting human peripheral blood monocytes]	1.0	5	1	0	0
44487	1624	anti-apoptotic effect	[anti-apoptotic effect]	1.0	2	2	1	1
44488	1624	main activity of the silencer	[main activity of the silencer]	1.0	5	1	0	0
44489	1624	interindividual difference in platelet monoamine oxidase	[interindividual differences in platelet monoamine oxidase]	1.0	6	1	0	0
44490	1624	c-terminal half of human mzf-2	[C-terminal half of human MZF-2]	1.0	5	1	0	0
44491	1624	il2rbeta promoter	[IL2Rbeta promoter]	1.0	2	1	0	0
44492	1624	interleukin (il)-1beta	[interleukin (IL)-1beta]	1.0	2	1	0	0
44493	1624	expression of specific adhesion molecule	[expression of specific adhesion molecules]	1.0	5	1	0	0
44494	1624	multiple member of repressor protein	[multiple members of repressor proteins]	1.0	5	1	0	0
44495	1624	progressively enlarge	[progressively enlarging]	1.0	2	1	0	0
44496	1624	vitro stimulation with epitope cell	[vitro stimulation with epitope cells]	1.0	5	1	0	0
44497	1624	partially substitute for the ca2+ co-stimulus	[partially substitutes for the Ca2+ co-stimulus]	1.0	6	1	0	0
44498	1624	outward migration	[outward migration]	1.0	2	2	1	1
44499	1624	many puzzle of the drug	[many puzzles of the drugs]	1.0	5	1	0	0
44500	1624	constitutive phosphorylation of Jak kinase	[Constitutive phosphorylation of Jak kinases]	1.0	5	1	0	0
44501	1624	cytokine rescue from glucocorticoid apoptosis	[Cytokine rescue from glucocorticoid apoptosis]	1.0	5	1	0	0
44502	1624	implication for regulation of chain expression	[Implications for regulation of chain expression]	1.0	6	1	0	0
44503	1624	nuclear translocation in neonatal T cell	[nuclear translocation in neonatal T cells]	1.0	6	1	0	0
44504	1624	early b cell factor EBF	[Early B cell factor EBF]	1.0	5	1	0	0
44505	1624	Addition of the -176 sequence	[Addition of the -176 sequence]	1.0	5	1	0	0
44506	1624	NF-kappaB complex in viral function	[NF-kappaB complexes in viral functions]	1.0	5	1	0	0
44507	1624	ige switch	[IgE switching]	1.0	2	2	2	2
44508	1624	3 motif	[3 motifs]	1.0	2	1	0	0
44509	1624	Immunofluorescent staining	[Immunofluorescent staining]	1.0	2	1	0	0
44510	1624	hormone-activated transcription	[hormone-activated transcription]	1.0	2	1	0	0
44511	1624	several human tumor cell line	[several human tumor cell lines]	1.0	5	1	0	0
44512	1624	model system examine overall change	[model system examining overall changes]	1.0	5	1	0	0
44513	1624	co-treatment with phenylarsine oxide pao	[co-treatment with phenylarsine oxide PAO]	1.0	5	1	0	0
44514	1624	infection of target cell with virus	[Infection of target cells with viruses]	1.0	6	1	0	0
44515	1624	heterozygous woman	[heterozygous women]	1.0	2	1	0	0
44516	1624	cytolytic susceptibility,	[cytolytic susceptibility,]	1.0	2	1	0	0
44517	1624	increase in ap-1 binding activity	[increase in AP-1 binding activity]	1.0	5	2	1	1
44518	1624	cause glucocorticoid resistance in neotropical primate	[causing glucocorticoid resistance in neotropical primates]	1.0	6	1	0	0
44519	1624	intracellular ROI	[intracellular ROI]	1.0	2	2	1	1
44520	1624	luciferase assay	[luciferase assays]	1.0	2	1	0	0
44521	1624	RU 43044	[RU 43044]	1.0	2	1	0	0
44522	1624	disruption of Epstein-Barr virus latency	[disruption of Epstein-Barr virus latency]	1.0	5	1	0	0
44523	1624	Chemical cross-linking with 125i-labeled tgf-beta 1	[Chemical cross-linking with 125I-labeled TGF-beta 1]	1.0	6	1	0	0
44524	1624	two domains,	[two domains,]	1.0	2	2	2	2
44525	1624	intact e(gre) motif mediate transcriptional activation	[intact E(gre) motifs mediating transcriptional activation]	1.0	6	1	0	0
44526	1624	human cd3-cd16+ natural killer cell	[Human CD3-CD16+ natural killer cells]	1.0	5	1	0	0
44527	1624	hormonal regulation of nuclear t3r	[hormonal regulation of nuclear T3R]	1.0	5	1	0	0
44528	1624	breast-cancer pathology	[breast-cancer pathology]	1.0	2	1	0	0
44529	1624	antibody supershift experiment in extract	[antibody supershift experiments in extracts]	1.0	5	1	0	0
44530	1624	nrd baby	[NRDS babies]	1.0	2	1	0	0
44531	1624	crosslinking of cell surface immunoglobulin	[crosslinking of cell surface immunoglobulin]	1.0	5	1	0	0
44532	1624	erythroid differentiation of this cells.	[erythroid differentiation of these cells.]	1.0	5	1	0	0
44533	1624	alpha A1 alpha a -gene product	[alpha A1 alpha A -gene product]	1.0	6	1	0	0
44534	1624	surface expression of vcam-1 activation	[surface expression of VCAM-1 activation]	1.0	5	1	0	0
44535	1624	human granulocyte/macrophage-colony stimulate factor gm-csf	[human granulocyte/macrophage-colony stimulating factor GM-CSF]	1.0	5	1	0	0
44536	1624	primary culture.	[primary culture.]	1.0	2	1	0	0
44537	1624	HSV-2 buttock	[HSV-2 buttock]	1.0	2	1	0	0
44538	1624	exogenous hgf	[exogenous HGFs]	1.0	2	1	0	0
44539	1624	human T cell in vitro	[human T cells in vitro]	1.0	5	1	0	0
44540	1624	myeloid/monocytic differentiation	[myeloid/monocytic differentiation]	1.0	2	1	0	0
44541	1624	replicative form of ebv DNA	[replicative form of EBV DNA]	1.0	5	1	0	0
44542	1624	additional support	[additional support]	1.0	2	1	0	0
44543	1624	major NFAT family member responsible	[major NFAT family member responsible]	1.0	5	1	0	0
44544	1624	coordinate activation of reporter construct	[coordinate activation of reporter constructs]	1.0	5	1	0	0
44545	1624	recloning capacity	[recloning capacity]	1.0	2	1	0	0
44546	1624	Jurkat cell human T lymphocyte	[Jurkat cells human T lymphocytes]	1.0	5	1	0	0
44547	1624	possible factor	[possible factors]	1.0	2	1	0	0
44548	1624	addition, blp	[addition, BLPs]	1.0	2	1	0	0
44549	1624	preleukemic condition	[preleukemic condition]	1.0	2	1	0	0
44550	1624	ap-1 consensus	[AP-1 consensus]	1.0	2	1	0	0
44551	1624	pmn chemotaxis	[PMNs chemotaxis]	1.0	2	2	2	2
44552	1624	latent Epstein-Barr virus EBV infection	[latent Epstein-Barr virus EBV infection]	1.0	5	1	0	0
44553	1624	unusual cd56+ cd16- egl present	[unusual CD56+ CD16- eGLs present]	1.0	5	1	0	0
44554	1624	pld stimulation	[PLD stimulation]	1.0	2	1	0	0
44555	1624	T cell anergy by concentration	[T cell anergy by concentrations]	1.0	5	1	0	0
44556	1624	indicate responsible for class ii expression	[indicating responsible for class II expression]	1.0	6	1	0	0
44557	1624	induction of the CIITA gene	[induction of the CIITA gene]	1.0	5	1	0	0
44558	1624	gp130 receptor	[gp130 receptors]	1.0	2	1	0	0
44559	1624	analysis of the ligand-binding domain	[Analysis of the ligand-binding domain]	1.0	5	1	0	0
44560	1624	focus on the lymphocyte predominance subtype	[focusing on the lymphocyte predominance subtype]	1.0	6	1	0	0
44561	1624	medium treatment	[medium treatment]	1.0	2	1	0	0
44562	1624	glucocorticoid on human interleukin -12	[glucocorticoids on human interleukin -12]	1.0	5	1	0	0
44563	1624	E2F transcription	[E2F transcription]	1.0	2	1	0	0
44564	1624	characterization of the murine homolog	[characterization of the murine homolog]	1.0	5	2	2	2
44565	1624	anergic T helper 1 cell	[anergic T helper 1 cells]	1.0	5	1	0	0
44566	1624	protein heterodimer	[protein heterodimers]	1.0	2	2	1	1
44567	1624	proteasome activity	[proteasome activity]	1.0	2	2	2	2
44568	1624	dna-mobility shift of a site	[DNA-mobility shift of a site]	1.0	5	1	0	0
44569	1624	activity of the reticulum ca2+-atpase	[activity of the reticulum Ca2+-ATPase]	1.0	5	1	0	0
44570	1624	regulation of immunodeficiency virus type 1	[regulation of immunodeficiency virus type 1]	1.0	6	2	2	2
44571	1624	contrast, expression within normal limits.	[contrast, expression within normal limits.]	1.0	5	1	0	0
44572	1624	various promoter	[various promoters]	1.0	2	2	1	1
44573	1624	produce a putative new human retrovirus	[producing a putative new human retrovirus]	1.0	6	1	0	0
44574	1624	collagenase induction in monocytic cell	[collagenase induction in monocytic cells]	1.0	5	1	0	0
44575	1624	high affinity binding of GATA-3	[high affinity binding of GATA-3]	1.0	5	1	0	0
44576	1624	mAECA ec	[mAECA EC]	1.0	2	2	1	1
44577	1624	total serum	[total serum]	1.0	2	1	0	0
44578	1624	insertion of a EKLF binding site	[insertion of an EKLF binding site]	1.0	6	1	0	0
44579	1624	temporal change in ig synthesis	[temporal changes in Ig synthesis]	1.0	5	1	0	0
44580	1624	IL-10 release of il-1beta from pbmc	[IL-10 release of IL-1beta from PBMC]	1.0	6	1	0	0
44581	1624	contain region	[containing regions]	1.0	2	2	2	2
44582	1624	robust proliferation	[robust proliferation]	1.0	2	1	0	0
44583	1624	use a consensus nf-kappa b oligonucleotide	[using a consensus NF-kappa B oligonucleotide]	1.0	6	1	0	0
44584	1624	delta-domain motif	[delta-domain motif]	1.0	2	1	0	0
44585	1624	Grb2-binding protein in platelet activation	[Grb2-binding proteins in platelet activation]	1.0	5	1	0	0
44586	1624	therapeutic approach to hiv-2 infection	[therapeutic approaches to HIV-2 infection]	1.0	5	1	0	0
44587	1624	fos-B gene	[fos-B gene]	1.0	2	1	0	0
44588	1624	relation to CD4 cell number	[relation to CD4 cell number]	1.0	5	1	0	0
44589	1624	thus, stimulation of monocyte cell line	[Thus, stimulation of monocyte cell lines]	1.0	6	1	0	0
44590	1624	similar (inhibitory) effect on RA-independent differentiation	[similar (inhibitory) effects on RA-independent differentiation]	1.0	6	1	0	0
44591	1624	fetal allograft	[fetal allograft]	1.0	2	1	0	0
44592	1624	western blot analysis of nuclear extract	[Western blot analysis of nuclear extracts]	1.0	6	1	0	0
44593	1624	sensitivity of human monocyte /macrophage	[sensitivity of human monocytes /macrophages]	1.0	5	1	0	0
44594	1624	immunofluorescence microscopy	[immunofluorescence microscopy]	1.0	2	1	0	0
44595	1624	lineage specification of NK/T cell progenitor	[lineage specification of NK/T cell progenitors]	1.0	6	1	0	0
44596	1624	restoration of the CCAAT box	[Restoration of the CCAAT box]	1.0	5	1	0	0
44597	1624	emanate from the t-cell receptor	[emanating from the T-cell receptor]	1.0	5	1	0	0
44598	1624	other cells, include erythroid precursor	[other cells, including erythroid precursors]	1.0	5	1	0	0
44599	1624	rel-related factor	[Rel-related factors]	1.0	2	1	0	0
44600	1624	diethyl dithiocarbamate	[diethyl dithiocarbamate]	1.0	2	1	0	0
44601	1624	Similarly, IL-2	[Similarly, IL-2]	1.0	2	1	0	0
44602	1624	activation of the VCAM promoter	[activation of the VCAM promoter]	1.0	5	1	0	0
44603	1624	different sizes.	[different sizes.]	1.0	2	1	0	0
44604	1624	transcription factor regulate cytokine production	[transcription factors regulating cytokine production]	1.0	5	1	0	0
44605	1624	rapid tyrosine	[rapid tyrosine]	1.0	2	1	0	0
44606	1624	use various VCAM-1 promoter construct	[using various VCAM-1 promoter constructs]	1.0	5	1	0	0
44607	1624	X-Y element	[X-Y elements]	1.0	2	1	0	0
44608	1624	growth modulator	[growth modulator]	1.0	2	1	0	0
44609	1624	CD30 coengagement	[CD30 coengagement]	1.0	2	1	0	0
44610	1624	costimulation of mouse T cell	[costimulation of mouse T cells]	1.0	5	1	0	0
44611	1624	prominent level of id2 mrna	[prominent levels of Id2 mRNA]	1.0	5	1	0	0
44612	1624	activation of the map kinase kinase	[activation of the MAP kinase kinase]	1.0	6	1	0	0
44613	1624	immunoregulatory cell	[immunoregulatory cells]	1.0	2	1	0	0
44614	1624	camp-activated th2 cell th1 cell	[cAMP-activated Th2 cells Th1 cells]	1.0	5	1	0	0
44615	1624	complex regulation	[complex regulation]	1.0	2	2	2	2
44616	1624	p100 rela(p65)	[p100 RelA(p65)]	1.0	2	1	0	0
44617	1624	bcl-6 protein on normal epidermis	[bcl-6 protein on normal epidermis]	1.0	5	1	0	0
44618	1624	hybridize close to the pseudoautosomal segment	[hybridizes close to the pseudoautosomal segment]	1.0	6	1	0	0
44619	1624	il-2 in Jurkat T cell	[IL-2 in Jurkat T cells]	1.0	5	1	0	0
44620	1624	fresh pbmc from healthy individual	[fresh PBMC from healthy individuals]	1.0	5	1	0	0
44621	1624	cell release from the g1 phase	[cell release from the G1 phase]	1.0	6	1	0	0
44622	1624	nonpermissive cell	[nonpermissive cells]	1.0	2	1	0	0
44623	1624	MZF-2 mrna	[MZF-2 mRNA]	1.0	2	1	0	0
44624	1624	basal activity suggest the presence	[basal activity suggesting the presence]	1.0	5	1	0	0
44625	1624	fos gene family member in 12-O-tetradecanoylphorbol-13-acetate	[fos gene family members in 12-O-tetradecanoylphorbol-13-acetate]	1.0	6	1	0	0
44626	1624	hiv-1 production in t-lymphoid CEM	[HIV-1 production in T-lymphoid CEM]	1.0	5	1	0	0
44627	1624	signal by il-2 cytokine jak	[Signaling by IL-2 cytokines JAKs]	1.0	5	1	0	0
44628	1624	c2h2 type	[C2H2 type]	1.0	2	1	0	0
44629	1624	t-helper cell	[T-helper cells]	1.0	2	2	1	1
44630	1624	-beta activity	[-beta activity]	1.0	2	1	0	0
44631	1624	e74-like factor	[E74-like factor]	1.0	2	1	0	0
44632	1624	c group;	[C group;]	1.0	2	1	0	0
44633	1624	positive reaction	[positive reaction]	1.0	2	2	2	2
44634	1624	synthetic hormone	[synthetic hormone]	1.0	2	2	1	1
44635	1624	gata-responsive element	[GATA-responsive elements]	1.0	2	1	0	0
44636	1624	I receptor type ii receptor	[I receptors Type II receptors]	1.0	5	1	0	0
44637	1624	transcription of c-jun promoter (position	[transcription of c-jun promoter (positions]	1.0	5	1	0	0
44638	1624	AML1a expression	[AML1a expression]	1.0	2	1	0	0
44639	1624	divide lymphocyte	[dividing lymphocytes]	1.0	2	2	2	2
44640	1624	secretion of cytokine in macrophage	[secretion of cytokines in macrophages]	1.0	5	1	0	0
44641	1624	murine lymphocyte	[murine lymphocytes]	1.0	2	2	2	2
44642	1624	factor of the NF-kappaB family	[factors of the NF-kappaB family]	1.0	5	1	0	0
44643	1624	diagnosis of the primary tumour	[diagnosis of the primary tumours]	1.0	5	1	0	0
44644	1624	common malignancy	[common malignancies]	1.0	2	1	0	0
44645	1624	formation of the NFAT transcriptional complex	[Formation of the NFAT transcriptional complex]	1.0	6	1	0	0
44646	1624	increase in lt-293 CAT activity	[increase in LT-293 CAT activity]	1.0	5	1	0	0
44647	1624	cytoplasmic level of il-1 beta mrna	[cytoplasmic levels of IL-1 beta mRNA]	1.0	6	1	0	0
44648	1624	induce apoptosis in human t-cell lineage	[inducing apoptosis in human T-cell lineages]	1.0	6	1	0	0
44649	1624	nf-kappab complex in the nucleus.	[NF-kappaB complexes in the nucleus.]	1.0	5	1	0	0
44650	1624	blot analysis,	[blot analysis,]	1.0	2	2	2	2
44651	1624	importance of deamidation in vitro	[importance of deamidation in vitro]	1.0	5	1	0	0
44652	1624	chemical structure,	[chemical structure,]	1.0	2	1	0	0
44653	1624	nf-kappa b in the cytoplasm	[NF-kappa B in the cytoplasm]	1.0	5	1	0	0
44654	1624	cellular process	[cellular processes]	1.0	2	2	1	1
44655	1624	16 abnormality by classical metaphase analysis	[16 abnormalities by classical metaphase analysis]	1.0	6	1	0	0
44656	1624	T cell with cyclosporin a	[T cells with cyclosporin A]	1.0	5	1	0	0
44657	1624	production of all blood cell	[production of all blood cells]	1.0	5	1	0	0
44658	1624	interleukin-2 receptor alpha chain il-2r alpha	[interleukin-2 receptor alpha chain IL-2R alpha]	1.0	6	1	0	0
44659	1624	mitogen-activated kinase	[mitogen-activated kinase]	1.0	2	2	2	2
44660	1624	anti-Fos mab	[anti-Fos mAb]	1.0	2	1	0	0
44661	1624	IkappaB expression	[IkappaB expression]	1.0	2	1	0	0
44662	1624	number of ut-7 cell (2400	[number of UT-7 cells (2400]	1.0	5	1	0	0
44663	1624	IFN change	[IFN change]	1.0	2	1	0	0
44664	1624	G1 arrest	[G1 arrest]	1.0	2	1	0	0
44665	1624	encode the murine b-cell coactivator mbob1	[encoding the murine B-cell coactivator mBob1]	1.0	6	1	0	0
44666	1624	corresponding region	[corresponding region]	1.0	2	2	2	2
44667	1624	MAPK pathway	[MAPK pathway]	1.0	2	1	0	0
44668	1624	urinary free cortisol excretion in FMS	[Urinary free cortisol excretion in FMS]	1.0	6	1	0	0
44669	1624	alpha integrin	[alpha integrin]	1.0	2	2	2	2
44670	1624	sensitivity of cell to apoptosis	[sensitivity of cells to apoptosis]	1.0	5	1	0	0
44671	1624	superoxide formation	[superoxide formation]	1.0	2	2	1	1
44672	1624	integrin-mediated tyrosine phosphorylation in monocytic cell	[Integrin-mediated tyrosine phosphorylation in monocytic cells]	1.0	6	1	0	0
44673	1624	nf-kappab activation in lung, level	[NF-kappaB activation in lung, levels]	1.0	5	1	0	0
44674	1624	next week,	[next week,]	1.0	2	1	0	0
44675	1624	antiatherogenic effect	[antiatherogenic effects]	1.0	2	1	0	0
44676	1624	c-Fos/c-Jun ap-1	[c-Fos/c-Jun AP-1]	1.0	2	1	0	0
44677	1624	switch the cell to the temperature	[Switching the cells to the temperature]	1.0	6	1	0	0
44678	1624	suggest particularly deleterious in preinjured lung	[suggesting particularly deleterious in preinjured lungs]	1.0	6	1	0	0
44679	1624	latter one	[latter one]	1.0	2	1	0	0
44680	1624	analysis of il-2r alpha expression	[Analysis of IL-2R alpha expression]	1.0	5	1	0	0
44681	1624	individual member	[individual members]	1.0	2	1	0	0
44682	1624	acute promyelocytic leukemia (apl): ii	[acute promyelocytic leukemia (APL): II]	1.0	5	1	0	0
44683	1624	U1 cell by lps alone	[U1 cells by LPS alone]	1.0	5	1	0	0
44684	1624	B7-independent T	[B7-independent T]	1.0	2	1	0	0
44685	1624	abnormal characteristics.	[abnormal characteristics.]	1.0	2	1	0	0
44686	1624	intranasal glucocorticoid	[intranasal glucocorticoids]	1.0	2	2	2	2
44687	1624	allogeneic cell	[allogeneic cells]	1.0	2	1	0	0
44688	1624	glucocorticoid sensitivity	[glucocorticoid sensitivity]	1.0	2	2	1	1
44689	1624	Richter' transformation	[Richter's transformation]	1.0	2	1	0	0
44690	1624	two human gata3 zinc finger	[two human GATA3 zinc fingers]	1.0	5	1	0	0
44691	1624	three major infectious disease tuberculosis	[three major infectious diseases tuberculosis]	1.0	5	1	0	0
44692	1624	lack of (a) transcriptional factor necessary	[lack of (a) transcriptional factor necessary]	1.0	6	1	0	0
44693	1624	activation of S6 kinase pp90rsk	[activation of S6 kinase pp90rsk]	1.0	5	1	0	0
44694	1624	contain one nf-kappa b element	[containing one NF-kappa B elements]	1.0	5	1	0	0
44695	1624	igg-positive cell	[IgG-positive cells]	1.0	2	1	0	0
44696	1624	include enhancement of T cell activation	[including enhancement of T cell activation]	1.0	6	1	0	0
44697	1624	monocyte in suspension on surface	[monocytes in suspension on surfaces]	1.0	5	1	0	0
44698	1624	low nuclear expression of NF-kappa b	[low nuclear expression of NF-kappa B]	1.0	6	1	0	0
44699	1624	1 infection	[1 infection]	1.0	2	2	2	2
44700	1624	effect of retinoic acid RA	[effect of retinoic acids RA]	1.0	5	2	1	1
44701	1624	human t-cell lymphoma cell line	[human T-cell lymphoma cell line]	1.0	5	1	0	0
44702	1624	50 kda protein on sds-page	[50 kDa protein on SDS-PAGE]	1.0	5	1	0	0
44703	1624	SP1 protein	[SP1 proteins]	1.0	2	1	0	0
44704	1624	TCF-1 protein	[TCF-1 protein]	1.0	2	1	0	0
44705	1624	effect drug	[effects drug]	1.0	2	1	0	0
44706	1624	develop thymocyte a mutant form	[developing thymocytes a mutant form]	1.0	5	1	0	0
44707	1624	Class ii antigen express t-cell line	[Class II antigen expressing T-cell lines]	1.0	6	1	0	0
44708	1624	overexpression of ikappab-alpha in endothelial cell	[overexpression of IkappaB-alpha in endothelial cells]	1.0	6	1	0	0
44709	1624	site adjacent	[site adjacent]	1.0	2	1	0	0
44710	1624	1,25(OH)2D3 receptor	[1,25(OH)2D3 receptor]	1.0	2	2	2	2
44711	1624	Preliminary experiment	[Preliminary experiments]	1.0	2	1	0	0
44712	1624	use increase amount of recombinant nfatp	[using increasing amounts of recombinant NFATp]	1.0	6	1	0	0
44713	1624	moreover, STAT5	[Moreover, STAT5]	1.0	2	1	0	0
44714	1624	tyrosine-based inhibition	[tyrosine-based inhibition]	1.0	2	1	0	0
44715	1624	cytokine receptor gamma chain gamma c	[cytokine receptor gamma chain gamma c]	1.0	6	1	0	0
44716	1624	frequency of abnormal nfkappab activation	[frequency of abnormal NFkappaB activation]	1.0	5	1	0	0
44717	1624	lymphocytic mineralocorticoid	[lymphocytic mineralocorticoid]	1.0	2	1	0	0
44718	1624	contain a sequence-specific hmg box	[containing a sequence-specific HMG box]	1.0	5	1	0	0
44719	1624	only the 50 kD protein	[only the 50 kD protein]	1.0	5	1	0	0
44720	1624	bind to one of this sites.	[binding to one of these sites.]	1.0	6	1	0	0
44721	1624	steroid-binding property	[steroid-binding properties]	1.0	2	1	0	0
44722	1624	important role in tissue-specific expression	[important role in tissue-specific expression]	1.0	5	1	0	0
44723	1624	trna gene transcription than chromatin	[tRNA gene transcription than chromatin]	1.0	5	1	0	0
44724	1624	two components:	[two components:]	1.0	2	1	0	0
44725	1624	Bcl-6 /CD57	[Bcl-6 /CD57]	1.0	2	1	0	0
44726	1624	NF-kappaB a LPS -responsive member	[NF-kappaB an LPS -responsive member]	1.0	5	1	0	0
44727	1624	second transcript	[second transcript]	1.0	2	1	0	0
44728	1624	4 nm epidermal growth factor	[4 nM epidermal growth factor]	1.0	5	1	0	0
44729	1624	hla-dr molecule	[HLA-DR molecules]	1.0	2	1	0	0
44730	1624	il-1 activation	[IL-1 activation]	1.0	2	2	2	2
44731	1624	pro-B cell from ebf mouse	[pro-B cells from EBF mice]	1.0	5	1	0	0
44732	1624	fasL mrna	[fasL mRNA]	1.0	2	2	2	2
44733	1624	I receptor in mononuclear leukocyte	[I receptors in mononuclear leukocytes]	1.0	5	1	0	0
44734	1624	potent stimulator of direct t-cell recognition	[potent stimulators of direct T-cell recognition]	1.0	6	1	0	0
44735	1624	tal-1 protein expression in lymphoid tissue	[tal-1 protein expression in lymphoid tissues]	1.0	6	1	0	0
44736	1624	Functional study use human endothelial cell	[Functional studies using human endothelial cells]	1.0	6	1	0	0
44737	1624	Egr-1 induction	[Egr-1 induction]	1.0	2	2	1	1
44738	1624	specifically accumulation of the gag-pol mrna	[specifically accumulation of the gag-pol mRNA]	1.0	6	1	0	0
44739	1624	binding of CsA T cell factor	[binding of CsA T cell factors]	1.0	6	1	0	0
44740	1624	transcriptional activator property in lymphoid cell	[transcriptional activator properties in lymphoid cells]	1.0	6	1	0	0
44741	1624	number of epo -binding site	[number of Epo -binding sites]	1.0	5	1	0	0
44742	1624	conventional responsiveness	[conventional responsiveness]	1.0	2	1	0	0
44743	1624	nuclear run-on	[nuclear run-on]	1.0	2	2	1	1
44744	1624	pou homeodomain	[POU homeodomain]	1.0	2	1	0	0
44745	1624	cell of the myeloid lineage	[cells of the myeloid lineage]	1.0	5	1	0	0
44746	1624	variation in the cellular composition	[variations in the cellular composition]	1.0	5	1	0	0
44747	1624	tumor necrosis factor receptor expression	[Tumor necrosis factor receptor expression]	1.0	5	1	0	0
44748	1624	covalent homodimer of e47 individually	[covalent homodimer of E47 individually]	1.0	5	1	0	0
44749	1624	consider receptor study in the context	[considering receptor studies in the context]	1.0	6	1	0	0
44750	1624	complex with nf-kappab family protein	[complex with NF-kappaB family proteins]	1.0	5	1	0	0
44751	1624	ifn-gammar conjugation	[IFN-gammaR conjugation]	1.0	2	1	0	0
44752	1624	common feature of all stage	[common feature of all stages]	1.0	5	1	0	0
44753	1624	mutational inactivation	[mutational inactivation]	1.0	2	1	0	0
44754	1624	alpha,25-dihydroxyvitamin	[alpha,25-dihydroxyvitamin]	1.0	1	12	6	3
44755	1624	AML1 gene	[AML1 gene]	1.0	2	2	1	1
44756	1624	transplantation through effect on il-6	[transplantation through effects on IL-6]	1.0	5	1	0	0
44757	1624	dendritic process extend from cytoplasm	[dendritic processes extending from cytoplasm]	1.0	5	1	0	0
44758	1624	herpesvirus type-8	[herpesvirus type-8]	1.0	2	2	2	2
44759	1624	S6 protein	[S6 protein]	1.0	2	1	0	0
44760	1624	Ab- VDR	[Ab- VDR]	1.0	2	1	0	0
44761	1624	antigenic property	[antigenic properties]	1.0	2	1	0	0
44762	1624	akt/pkb activation	[Akt/PKB activation]	1.0	2	1	0	0
44763	1624	lymphokine production	[lymphokine production]	1.0	2	2	1	1
44764	1624	leukocyte population in eutopic endometrium	[leukocyte populations in eutopic endometrium]	1.0	5	1	0	0
44765	1624	mol/L PMA	[mol/L PMA]	1.0	2	1	0	0
44766	1624	patient with acute fulminant hepatitis	[patients with acute fulminant hepatitis]	1.0	5	1	0	0
44767	1624	level of expression of 135eoh)2d3 receptor	[levels of expression of 1,25(OH)2D3 receptor]	1.0	6	1	0	0
44768	1624	LAM -inducible il-6 promoter activity	[LAM -inducible IL-6 promoter activity]	1.0	5	1	0	0
44769	1624	low bcl-2	[low Bcl-2]	1.0	2	1	0	0
44770	1624	approximately 500-bp	[approximately 500-bp]	1.0	2	1	0	0
44771	1624	nef region	[nef region]	1.0	2	1	0	0
44772	1624	complement-dependent lysis.	[complement-dependent lysis.]	1.0	2	1	0	0
44773	1624	unstimulated b	[unstimulated B]	1.0	2	1	0	0
44774	1624	patient respond to any peptide	[patients responding to any peptide]	1.0	5	1	0	0
44775	1624	activation of pp90rsk response-1 gene expression	[Activation of pp90rsk response-1 gene expression]	1.0	6	1	0	0
44776	1624	change in the cellular level	[changes in the cellular levels]	1.0	5	1	0	0
44777	1624	reactive oxygen species in inflammatory disease	[Reactive oxygen species in inflammatory diseases]	1.0	6	1	0	0
44778	1624	mtbe induction of cell death	[MTBE induction of cell death]	1.0	5	1	0	0
44779	1624	sodium/proton exchanger	[sodium/proton exchanger]	1.0	2	2	1	1
44780	1624	tissue culture	[tissue culture]	1.0	2	2	1	1
44781	1624	early adulthood,	[early adulthood,]	1.0	2	1	0	0
44782	1624	IL-6 macrophage-differentiation	[IL-6 macrophage-differentiation]	1.0	2	2	2	2
44783	1624	20 minute	[20 min]	1.0	2	2	1	1
44784	1624	effect of gdsp on weight	[effects of GDSP on weight]	1.0	5	1	0	0
44785	1624	study of three candidate genes.	[study of three candidate genes.]	1.0	5	1	0	0
44786	1624	physiological involution	[physiological involution]	1.0	2	1	0	0
44787	1624	prl (hprl)	[PRL (hPRL)]	1.0	2	1	0	0
44788	1624	difference in binding of glucocorticoid receptor	[Differences in binding of glucocorticoid receptor]	1.0	6	1	0	0
44789	1624	v-erbA overexpression	[v-erbA overexpression]	1.0	2	1	0	0
44790	1624	dominant negative mutant of NIK	[Dominant negative mutants of NIK]	1.0	5	1	0	0
44791	1624	Inorganic lead	[Inorganic lead]	1.0	2	2	1	1
44792	1624	Egr-3 PILOT	[Egr-3 PILOT]	1.0	2	1	0	0
44793	1624	basal 12-myristate 13-acetate -inducible transcription	[basal 12-myristate 13-acetate -inducible transcription]	1.0	5	1	0	0
44794	1624	strong similarity	[strong similarity]	1.0	2	2	1	1
44795	1624	sport activity.	[sport activity.]	1.0	2	1	0	0
44796	1624	tested, (ii) constitutive mrna level	[tested, (ii) constitutive mRNA levels]	1.0	5	1	0	0
44797	1624	human whole blood with PGG-Glucan	[human whole blood with PGG-Glucan]	1.0	5	1	0	0
44798	1624	IL-1 responsiveness,	[IL-1 responsiveness,]	1.0	2	1	0	0
44799	1624	artificial construct	[artificial construct]	1.0	2	1	0	0
44800	1624	T cell expression of il-3	[T cell expression of IL-3]	1.0	5	1	0	0
44801	1624	contain repeat	[containing repeats]	1.0	2	2	2	2
44802	1624	immunologic function of T lymphocyte	[immunologic function of T lymphocytes]	1.0	5	1	0	0
44803	1624	CD28 CD3	[CD28 CD3]	1.0	2	1	0	0
44804	1624	molecular mechanism underlie this role	[molecular mechanism underlying this role]	1.0	5	1	0	0
44805	1624	binding of hmg-i(y) to this oligonucleotide	[binding of HMG-I(Y) to this oligonucleotide]	1.0	6	1	0	0
44806	1624	(apparent kd,	[(apparent Kd,]	1.0	2	2	1	1
44807	1624	T cell (nfat) family protein	[T cells (NFAT) family proteins]	1.0	5	1	0	0
44808	1624	transcriptional activity of the heterodimer	[transcriptional activity of the heterodimer]	1.0	5	1	0	0
44809	1624	opposite effect,	[opposite effect,]	1.0	2	1	0	0
44810	1624	polyclonal antibody to Fos protein	[polyclonal antibodies to Fos proteins]	1.0	5	1	0	0
44811	1624	kappab -mutated, hiv-1 LTR region	[kappaB -mutated, HIV-1 LTR region]	1.0	5	1	0	0
44812	1624	belong by a transdominant negative mutant	[belonging by a transdominant negative mutant]	1.0	6	1	0	0
44813	1624	use of Tat sfv intrabody	[use of Tat sFv intrabodies]	1.0	5	1	0	0
44814	1624	msr level	[MSR levels]	1.0	2	1	0	0
44815	1624	vary time of hypoxic exposure	[varying times of hypoxic exposure]	1.0	5	1	0	0
44816	1624	interferon alpha include interferon gamma	[interferon alpha including interferon gamma]	1.0	5	1	0	0
44817	1624	role of egr-1 in regulation	[role of egr-1 in regulation]	1.0	5	1	0	0
44818	1624	potential et transcription factor binding site	[potential ets transcription factor binding sites]	1.0	6	1	0	0
44819	1624	appearance of nf-kappab dna-binding activity	[appearance of NF-kappaB DNA-binding activity]	1.0	5	1	0	0
44820	1624	four C	[four C]	1.0	2	1	0	0
44821	1624	effect of dm on expression	[effect of DM on expression]	1.0	5	1	0	0
44822	1624	id inhibitor of DNA binding	[Id inhibitor of DNA binding]	1.0	5	1	0	0
44823	1624	contain STAT3	[containing STAT3]	1.0	2	2	2	2
44824	1624	enhancement of 24-hydroxylase mrna level	[enhancement of 24-hydroxylase mRNA levels]	1.0	5	1	0	0
44825	1624	member of the CCACC/Sp1 family	[members of the CCACC/Sp1 family]	1.0	5	1	0	0
44826	1624	similar extent in control cell	[similar extents in control cells]	1.0	5	1	0	0
44827	1624	treatment of gp160 with soluble cd4-igg	[treatment of gp160 with soluble CD4-IgG]	1.0	6	1	0	0
44828	1624	hiv protease between phenylalanine 112	[HIV protease between phenylalanine 112]	1.0	5	1	0	0
44829	1624	SCMV SNEs	[SCMV SNEs]	1.0	2	1	0	0
44830	1624	coactivator OCA-B	[Coactivator OCA-B]	1.0	2	1	0	0
44831	1624	expression in mouse spleen development	[expression in mouse spleen development]	1.0	5	1	0	0
44832	1624	generation of germline epsilon transcript,	[generation of germline epsilon transcript,]	1.0	5	1	0	0
44833	1624	t-cell lymphoma/leukemia	[T-cell lymphoma/leukemia]	1.0	2	2	2	2
44834	1624	result in the gag protein synthesis	[resulting in the Gag protein synthesis]	1.0	6	1	0	0
44835	1624	variant species	[variant species]	1.0	2	1	0	0
44836	1624	trace element	[trace element]	1.0	2	2	2	2
44837	1624	c-myb mrna	[c-myb mRNA]	1.0	2	5	4	1
44838	1624	chronic asthma	[chronic asthma]	1.0	2	3	2	1
44839	1624	multiple regulatory region include the enhancer	[multiple regulatory regions including the enhancer]	1.0	6	1	0	0
44840	1624	insulin receptor	[insulin receptor]	1.0	2	2	2	2
44841	1624	normal volunteer	[normal volunteers]	1.0	2	2	1	1
44842	1624	role of tumor necrosis factor alpha	[role of tumor necrosis factor alpha]	1.0	6	2	1	1
44843	1624	specific genes.	[specific genes.]	1.0	2	2	2	2
44844	1624	virus peptide	[virus peptides]	1.0	2	2	2	2
44845	1624	overlying endothelium	[overlying endothelium]	1.0	2	1	0	0
44846	1624	several proteins.	[several proteins.]	1.0	2	1	0	0
44847	1624	2 enhancer activation in monocyte	[2 enhancer activation in monocytes]	1.0	5	1	0	0
44848	1624	several lipoprotein	[Several lipoproteins]	1.0	2	1	0	0
44849	1624	hd of the general population.	[HD of the general population.]	1.0	5	1	0	0
44850	1624	hd of the general population,	[HD of the general population,]	1.0	5	1	0	0
44851	1624	arterial cell	[arterial cells]	1.0	2	2	2	2
44852	1624	insulin secretion	[insulin secretion]	1.0	2	2	2	2
44853	1624	aspirin-like drug	[Aspirin-like drugs]	1.0	2	3	2	1
44854	1624	peptide substrate	[peptide substrate]	1.0	2	2	2	2
44855	1624	inducibility of the hybrid promoter	[inducibility of the hybrid promoters]	1.0	5	1	0	0
44856	1624	physiologically relevant concentration of ethanol	[physiologically relevant concentrations of ethanol]	1.0	5	1	0	0
44857	1624	CD40 response	[CD40 responses]	1.0	2	2	1	1
44858	1624	IL-8 gene expression by U937	[IL-8 gene expression by U937]	1.0	5	1	0	0
44859	1624	hxbp-1 protein	[hXBP-1 protein]	1.0	2	1	0	0
44860	1624	LPS response	[LPS response]	1.0	2	1	0	0
44861	1624	allow translocation	[allowing translocation]	1.0	2	2	2	2
44862	1624	hsv-specific clone	[HSV-specific clones]	1.0	2	1	0	0
44863	1624	disparate fate of hl-60 cell	[disparate fates of HL-60 cells]	1.0	5	1	0	0
44864	1624	follow factor	[following factors]	1.0	2	1	0	0
44865	1624	down-regulation of a costimulatory molecule,	[down-regulation of a costimulatory molecule,]	1.0	5	1	0	0
44866	1624	ras-related protein	[Ras-related protein]	1.0	2	2	1	1
44867	1624	calcineurin expression of the interleukin promoter	[calcineurin expression of the interleukin promoter]	1.0	6	1	0	0
44868	1624	natural killer (nk) activity variance	[natural killer (NK) activity variance]	1.0	5	1	0	0
44869	1624	e2f regulation in T lymphocyte	[E2F regulation in T lymphocytes]	1.0	5	1	0	0
44870	1624	professional antigen present cell apc	[professional antigen presenting cells APCs]	1.0	5	1	0	0
44871	1624	use homologous recombination, eklf allele	[Using homologous recombination, EKLF alleles]	1.0	5	1	0	0
44872	1624	other pb mononuclear cell population	[other PB mononuclear cell populations]	1.0	5	1	0	0
44873	1624	dominant interfere	[dominant interfering]	1.0	2	1	0	0
44874	1624	hRAR alpha	[hRAR alpha]	1.0	2	1	0	0
44875	1624	intestinal xenograft	[intestinal xenografts]	1.0	2	2	1	1
44876	1624	parental haplotype	[parental haplotypes]	1.0	2	1	0	0
44877	1624	constitutive factor	[constitutive factor]	1.0	2	2	2	2
44878	1624	positive staining	[positive staining]	1.0	2	2	2	2
44879	1624	phosphorylation of the rap1 protein	[phosphorylation of the Rap1 protein]	1.0	5	1	0	0
44880	1624	transcription from the B2 promoter	[transcription from the B2 promoter]	1.0	5	1	0	0
44881	1624	inhibition of il-2 tyrosine phosphorylation	[inhibition of IL-2 tyrosine phosphorylation]	1.0	5	1	0	0
44882	1624	CMV transactivator	[CMV transactivator]	1.0	2	2	1	1
44883	1624	camp level include cholera toxin	[cAMP levels including cholera toxin]	1.0	5	1	0	0
44884	1624	any, effect on c-jun transcription	[any, effect on c-jun transcription]	1.0	5	1	0	0
44885	1624	implication for the design of approach	[implications for the design of approaches]	1.0	6	1	0	0
44886	1624	(mab) 13b8-2	[(MAb) 13B8-2]	1.0	2	1	0	0
44887	1624	such tumor	[such tumors]	1.0	2	1	0	0
44888	1624	visual demonstration	[visual demonstration]	1.0	2	1	0	0
44889	1624	mutagenesis of the critical guanine nucleotide	[mutagenesis of the critical guanine nucleotides]	1.0	6	1	0	0
44890	1624	water concentration	[water concentrations]	1.0	2	1	0	0
44891	1624	cp include the ebna2-dependent enhancer	[Cp including the EBNA2-dependent enhancer]	1.0	5	1	0	0
44892	1624	approximately substnfkappab approximately substSpl2 approximately substSp23	[approximately substNFkappaB approximately substSpl2 approximately substSp23]	1.0	6	1	0	0
44893	1624	prominent role	[prominent role]	1.0	2	1	0	0
44894	1624	causal linkage	[causal linkage]	1.0	2	1	0	0
44895	1624	leukemic ml-1	[leukemic ML-1]	1.0	2	1	0	0
44896	1624	two patient with transient pseudohypoaldosteronism	[two patients with transient pseudohypoaldosteronism]	1.0	5	1	0	0
44897	1624	trypan blue exclusion cell counting	[trypan blue exclusion cell counting]	1.0	5	1	0	0
44898	1624	complementation analysis to this group.	[complementation analysis to this group.]	1.0	5	1	0	0
44899	1624	tissue microenvironment	[tissue microenvironment]	1.0	2	1	0	0
44900	1624	functional property	[functional properties]	1.0	2	1	0	0
44901	1624	detailed study	[Detailed studies]	1.0	2	1	0	0
44902	1624	stat induction	[STAT induction]	1.0	2	2	2	2
44903	1624	span 45 kb of genomic DNA	[spanning 45 kb of genomic DNA]	1.0	6	1	0	0
44904	1624	Clinical outcome in ovarian carcinoma	[Clinical outcome in ovarian carcinoma]	1.0	5	1	0	0
44905	1624	tcr zeta	[TCR zeta]	1.0	2	2	2	2
44906	1624	variant receptor transcript lack exon 5	[Variant receptor transcripts lacking exon 5]	1.0	6	1	0	0
44907	1624	promoter regulation	[promoter regulation]	1.0	2	1	0	0
44908	1624	furthermore, txa2	[furthermore, TXA2]	1.0	2	1	0	0
44909	1624	characterization of hb24 expression in lymphoid	[Characterization of HB24 expression in lymphoid]	1.0	6	1	0	0
44910	1624	number of immature neutrophilic cell	[numbers of immature neutrophilic cells]	1.0	5	1	0	0
44911	1624	recombinant bcl-6	[recombinant BCL-6]	1.0	2	1	0	0
44912	1624	wild-type phenotype for marmoset t-lymphocyte transformation	[wild-type phenotype for marmoset T-lymphocyte transformation]	1.0	6	1	0	0
44913	1624	cytoskeletal rearrangement	[cytoskeletal rearrangement]	1.0	2	1	0	0
44914	1624	mrna transcript of the jun family	[mRNA transcripts of the jun family]	1.0	6	1	0	0
44915	1624	involve the NF-kappa b motif	[involving the NF-kappa B motif]	1.0	5	1	0	0
44916	1624	anti-apoptotic transcription	[anti-apoptotic transcription]	1.0	2	1	0	0
44917	1624	non-tumor material	[non-tumor material]	1.0	2	1	0	0
44918	1624	n-Acetyl-L-cysteine NAC a potent antioxidant,	[n-Acetyl-L-cysteine NAC a potent antioxidant,]	1.0	5	1	0	0
44919	1624	B-cell apoptosis	[B-cell apoptosis]	1.0	2	2	2	2
44920	1624	m-tat cell	[M-TAT cells]	1.0	2	2	1	1
44921	1624	analysis of x-chromosome inactivation pattern	[Analysis of X-chromosome inactivation patterns]	1.0	5	1	0	0
44922	1624	activation of the il-4r kinase jak-1	[activation of the IL-4R kinase JAK-1]	1.0	6	1	0	0
44923	1624	induction of tf mrna expression	[Induction of TF mRNA expression]	1.0	5	1	0	0
44924	1624	important genetic determinant of the ability	[important genetic determinants of the ability]	1.0	6	1	0	0
44925	1624	genotypic variation	[genotypic variation]	1.0	2	1	0	0
44926	1624	However, V3-BH10	[However, V3-BH10]	1.0	2	1	0	0
44927	1624	serum-contain medium	[serum-containing medium]	1.0	2	1	0	0
44928	1624	mmp-9 activity through PPARgamma activation	[MMP-9 activity through PPARgamma activation]	1.0	5	1	0	0
44929	1624	several family	[several families]	1.0	2	2	2	2
44930	1624	enhancer activity with transcription factor	[enhancer activity with transcription factors]	1.0	5	1	0	0
44931	1624	glucocorticoid in healthy aged subject	[glucocorticoids in healthy aged subjects]	1.0	5	1	0	0
44932	1624	RFX complex	[RFX complex]	1.0	2	1	0	0
44933	1624	patient with perennial allergic rhinitis	[patients with perennial allergic rhinitis]	1.0	5	1	0	0
44934	1624	mediate transcription by a subset	[mediating transcription by a subset]	1.0	5	1	0	0
44935	1624	IL-4 stimulation of X-SCID b cell	[IL-4 stimulation of X-SCID B cells]	1.0	6	1	0	0
44936	1624	sensitivity against various enzyme inhibitor	[Sensitivity against various enzyme inhibitors]	1.0	5	1	0	0
44937	1624	parameter of cerulein-induced acute pancreatitis	[parameters of cerulein-induced acute pancreatitis]	1.0	5	1	0	0
44938	1624	leukaemic cell	[leukaemic cells]	1.0	2	1	0	0
44939	1624	P. aeruginosa	[P. aeruginosa]	1.0	2	2	2	2
44940	1624	patient respond	[patients responding]	1.0	2	2	2	2
44941	1624	certain aspect of tcr response	[Certain aspects of TCR responses]	1.0	5	1	0	0
44942	1624	therefore, inhibition of nf-kappa b activation	[Therefore, inhibition of NF-kappa B activation]	1.0	6	1	0	0
44943	1624	reticulocyte lysate	[reticulocyte lysate]	1.0	2	3	2	1
44944	1624	hs1 phosphorylation	[HS1 phosphorylation]	1.0	2	2	2	2
44945	1624	more potent inducer of monocyte differentiation	[more potent inducers of monocyte differentiation]	1.0	6	1	0	0
44946	1624	Nonpituitary human prolactin gene transcription	[Nonpituitary human prolactin gene transcription]	1.0	5	1	0	0
44947	1624	basal enhancement	[basal enhancement]	1.0	2	1	0	0
44948	1624	early change	[early changes]	1.0	2	1	0	0
44949	1624	notion of the functional conservation	[notion of the functional conservation]	1.0	5	1	0	0
44950	1624	cytokine signalling,	[cytokine signalling,]	1.0	2	1	0	0
44951	1624	TCR delta	[TCR delta]	1.0	2	2	1	1
44952	1624	clonal development	[clonal development]	1.0	2	2	1	1
44953	1624	monocytic differentiation of k562 cell	[monocytic differentiation of K562 cells]	1.0	5	1	0	0
44954	1624	lymphoid cell with interleukin-1beta il-1beta	[lymphoid cells with interleukin-1beta IL-1beta]	1.0	5	1	0	0
44955	1624	T lineage	[T lineage]	1.0	2	2	2	2
44956	1624	glutathione depletion	[glutathione depletion]	1.0	2	1	0	0
44957	1624	intensity of c/ebp beta staining	[intensity of C/EBP beta staining]	1.0	5	1	0	0
44958	1624	retinoic acid-	[retinoic acid-]	1.0	2	1	0	0
44959	1624	retinoic acid.	[retinoic acid.]	1.0	2	1	0	0
44960	1624	b-cell apoptosis	[B-cell apoptosis]	1.0	2	1	0	0
44961	1624	vitro dnase	[vitro DNase]	1.0	2	1	0	0
44962	1624	ad5-induced inhibition of IFN -mcp	[Ad5-induced inhibition of IFN -MCP]	1.0	5	1	0	0
44963	1624	abnormality of the lymphoid organ	[abnormalities of the lymphoid organs]	1.0	5	1	0	0
44964	1624	soluble tnf-alpha	[soluble TNF-alpha]	1.0	2	1	0	0
44965	1624	complement-dependent lps uptake by monocyte	[complement-dependent LPS uptake by monocytes]	1.0	5	1	0	0
44966	1624	phorbol ester treatment of blood monocyte	[phorbol ester treatment of blood monocytes]	1.0	6	1	0	0
44967	1624	significant production of tumor necrosis factor-alpha	[significant production of tumor necrosis factor-alpha]	1.0	6	1	0	0
44968	1624	induction of vitamin gene regulation	[induction of vitamin gene regulation]	1.0	5	1	0	0
44969	1624	three stimulus	[three stimuli]	1.0	2	1	0	0
44970	1624	tumor-draining lymph node T cell	[tumor-draining lymph node T cells]	1.0	5	1	0	0
44971	1624	release of the chemokine il-8	[release of the chemokines IL-8]	1.0	5	1	0	0
44972	1624	Furthermore, compound	[Furthermore, compounds]	1.0	2	1	0	0
44973	1624	Further, Tax1	[Further, Tax1]	1.0	2	1	0	0
44974	1624	surface CD4	[surface CD4]	1.0	2	1	0	0
44975	1624	human T cell lymphotropic virus type	[Human T cell lymphotropic virus type]	1.0	6	1	0	0
44976	1624	isolation of sequence tag from cell	[Isolation of sequence tags from cells]	1.0	6	1	0	0
44977	1624	IL-2 induction	[IL-2 induction]	1.0	2	1	0	0
44978	1624	Cardiac disease	[Cardiac diseases]	1.0	2	1	0	0
44979	1624	decidual transformation of the endometrial stroma	[decidual transformation of the endometrial stroma]	1.0	6	1	0	0
44980	1624	Addition of platelet to adherent monocyte	[Addition of platelets to adherent monocytes]	1.0	6	1	0	0
44981	1624	Hypothetically, on/off switch of lineage-restricted transactivator	[Hypothetically, on/off switches of lineage-restricted transactivators]	1.0	6	1	0	0
44982	1624	il-2r stimulation	[IL-2R stimulation]	1.0	2	1	0	0
44983	1624	nuclear factor-kappa b dna-binding activity	[nuclear factor-kappa B DNA-binding activity]	1.0	5	1	0	0
44984	1624	upregulation of the bcl-2 oncogene	[upregulation of the bcl-2 oncogene]	1.0	5	1	0	0
44985	1624	inadequate response	[inadequate response]	1.0	2	2	2	2
44986	1624	other change	[other changes]	1.0	2	1	0	0
44987	1624	five distinct DNA binding subunit	[five distinct DNA binding subunits]	1.0	5	1	0	0
44988	1624	recombinant gp41 aa565-647 the extracellular domain	[recombinant gp41 aa565-647 the extracellular domain]	1.0	6	1	0	0
44989	1624	x receptor -vitamin d response element	[X receptor -vitamin D response element]	1.0	6	1	0	0
44990	1624	lps responsiveness	[LPS responsiveness]	1.0	2	2	1	1
44991	1624	anti-igm antibody	[anti-IgM antibodies]	1.0	2	1	0	0
44992	1624	gene of the kda precursor	[gene of the kDa precursor]	1.0	5	1	0	0
44993	1624	functional il-13r	[functional IL-13R]	1.0	2	1	0	0
44994	1624	initiate t-cell activation through the induction	[initiating T-cell activation through the induction]	1.0	6	1	0	0
44995	1624	proto-oncoprotein c-Rel	[proto-oncoprotein c-Rel]	1.0	2	1	0	0
44996	1624	apoptosis in ebv-negative Burkitt lymphoma	[apoptosis in EBV-negative Burkitt lymphoma]	1.0	5	1	0	0
44997	1624	cognate peptide	[cognate peptide]	1.0	2	2	1	1
44998	1624	embryonal carcinoma	[embryonal carcinoma]	1.0	2	1	0	0
44999	1624	cell migration.	[cell migration.]	1.0	2	1	0	0
45000	1624	blood-derived monocyte	[blood-derived monocytes]	1.0	2	2	1	1
45001	1624	high concentration of ambient 125d3	[higher concentrations of ambient 1,25D3]	1.0	5	1	0	0
45002	1624	anti-cd28 abs	[anti-CD28 Abs]	1.0	2	1	0	0
45003	1624	long-standing notion	[long-standing notion]	1.0	2	1	0	0
45004	1624	nf of T cell protein	[NF of T cells proteins]	1.0	5	1	0	0
45005	1624	rela subunit	[RelA subunit]	1.0	2	3	2	1
45006	1624	western blot with a N-terminal antibody	[Western blot with an N-terminal antibody]	1.0	6	1	0	0
45007	1624	chromosome loss,	[chromosome loss,]	1.0	2	1	0	0
45008	1624	lack the entire catalytic domain	[lacking the entire catalytic domain]	1.0	5	1	0	0
45009	1624	SP6 kappa promoter kappay element	[SP6 kappa promoter kappaY element]	1.0	5	1	0	0
45010	1624	many virus	[many viruses]	1.0	2	1	0	0
45011	1624	p21ras signal act in synergy	[p21ras signals acting in synergy]	1.0	5	1	0	0
45012	1624	protein substrate	[protein substrate]	1.0	2	2	2	2
45013	1624	T cell development use mouse	[T cell development using mice]	1.0	5	1	0	0
45014	1624	use a genetic screen in yeast,	[Using a genetic screen in yeast,]	1.0	6	1	0	0
45015	1624	precursor level of NF kappa b	[precursor levels of NF kappa B]	1.0	6	1	0	0
45016	1624	fetal antigen	[fetal antigens]	1.0	2	1	0	0
45017	1624	several month	[several months]	1.0	2	1	0	0
45018	1624	relative formation of homo- dimer	[relative formation of homo- dimers]	1.0	5	1	0	0
45019	1624	mutation of the Sp1 binding site	[Mutation of the Sp1 binding site]	1.0	6	1	0	0
45020	1624	Ras Raf	[Ras Raf]	1.0	2	1	0	0
45021	1624	serum-free medium	[serum-free medium]	1.0	2	3	2	1
45022	1624	-dependent T	[-dependent T]	1.0	2	2	2	2
45023	1624	domain 1	[domain 1]	1.0	2	2	2	2
45024	1624	isomer 9-cis RA in FL hematopoiesis	[isomer 9-cis RA in FL hematopoiesis]	1.0	6	1	0	0
45025	1624	4 different T cell line	[4 different T cell lines]	1.0	5	1	0	0
45026	1624	upstream of the J delta segment	[upstream of the J delta segment]	1.0	6	1	0	0
45027	1624	three stimuli.	[three stimuli.]	1.0	2	1	0	0
45028	1624	several different levels, include suppression	[several different levels, including suppression]	1.0	5	1	0	0
45029	1624	maturation of class alphabeta dimer	[maturation of class alphabeta dimers]	1.0	5	1	0	0
45030	1624	monocyte/macrophage lineage,	[monocyte/macrophage lineage,]	1.0	2	1	0	0
45031	1624	increase hiv expression in the tract	[increasing HIV expression in the tract]	1.0	6	1	0	0
45032	1624	MOPC 141	[MOPC 141]	1.0	2	1	0	0
45033	1624	8 patient	[8 patients]	1.0	2	2	1	1
45034	1624	activation of the human tf gene	[activation of the human TF gene]	1.0	6	1	0	0
45035	1624	splenic lymphocyte	[splenic lymphocytes]	1.0	2	1	0	0
45036	1624	extension of the reverse primer	[extension of the reverse primer]	1.0	5	1	0	0
45037	1624	48 h in culture media.	[48 h in culture media.]	1.0	5	1	0	0
45038	1624	contrast, expression of b gene	[contrast, expression of B genes]	1.0	5	1	0	0
45039	1624	day 22.	[day 22.]	1.0	2	1	0	0
45040	1624	loci on the proximal short arm	[loci on the proximal short arm]	1.0	6	1	0	0
45041	1624	low growth	[low growth]	1.0	2	1	0	0
45042	1624	cotransfection with C/EBPbeta expression vector	[Cotransfection with C/EBPbeta expression vectors]	1.0	5	1	0	0
45043	1624	anti-CD3 treatment	[anti-CD3 treatment]	1.0	2	1	0	0
45044	1624	cytokine IL-2	[cytokines IL-2]	1.0	2	2	1	1
45045	1624	AIDS IBLP	[AIDS IBLP]	1.0	2	1	0	0
45046	1624	unrelated pathway of T cell activation	[unrelated pathways of T cell activation]	1.0	6	1	0	0
45047	1624	change in this regulatory network	[Changes in this regulatory network]	1.0	5	1	0	0
45048	1624	(mean years)	[(mean years)]	1.0	2	2	2	2
45049	1624	T cell in the thymus	[T cells in the thymus]	1.0	5	2	1	1
45050	1624	W696-bp coding region encompass exon	[3696-bp coding region encompassing exons]	1.0	5	1	0	0
45051	1624	binding of c-Rel /p65 heterodimer	[binding of c-Rel /p65 heterodimers]	1.0	5	1	0	0
45052	1624	region other	[region other]	1.0	2	1	0	0
45053	1624	activation of stat6 by il-4	[activation of STAT6 by IL-4]	1.0	5	1	0	0
45054	1624	murine spleen	[murine spleen]	1.0	2	1	0	0
45055	1624	cellular/molecular event of renal inflammation	[cellular/molecular events of renal inflammation]	1.0	5	1	0	0
45056	1624	new human leukemia cell line	[new human leukemia cell line]	1.0	5	1	0	0
45057	1624	bind to the CD28 response element	[binding to the CD28 response element]	1.0	6	1	0	0
45058	1624	c-sis/platelet-derived growth	[c-sis/platelet-derived growth]	1.0	2	1	0	0
45059	1624	template lack the x element	[templates lacking the X element]	1.0	5	1	0	0
45060	1624	change in endothelial cell glutathione gsh	[changes in endothelial cell glutathione GSH]	1.0	6	1	0	0
45061	1624	subsequent activation of erk kinase	[subsequent activation of ERK kinase]	1.0	5	1	0	0
45062	1624	CEM-C7 a cd4+ t-lymphocyte cell line	[CEM-C7 a CD4+ T-lymphocyte cell line]	1.0	6	1	0	0
45063	1624	vitro lymphocyte	[vitro lymphocytes]	1.0	2	1	0	0
45064	1624	il4 expression	[IL4 expression]	1.0	2	1	0	0
45065	1624	cold shock	[cold shock]	1.0	2	1	0	0
45066	1624	furthermore, JAK2	[Furthermore, JAK2]	1.0	2	1	0	0
45067	1624	significant repression.	[significant repression.]	1.0	2	1	0	0
45068	1624	role in il-4 -dependent induction	[role in IL-4 -dependent induction]	1.0	5	1	0	0
45069	1624	element restrict expression to that lymphocyte	[elements restricting expression to those lymphocytes]	1.0	6	1	0	0
45070	1624	stimulatory effect on this promoter	[stimulatory effect on this promoter]	1.0	5	1	0	0
45071	1624	differentiation potential	[differentiation potential]	1.0	2	2	2	2
45072	1624	signal emanate	[signals emanating]	1.0	2	2	1	1
45073	1624	codon 10 of exon 1	[codon 10 of exon 1]	1.0	5	1	0	0
45074	1624	HS 2	[HS 2]	1.0	2	1	0	0
45075	1624	extensive xanthomatosis	[extensive xanthomatosis]	1.0	2	1	0	0
45076	1624	two distinct il-4 signal pathway	[two distinct IL-4 signaling pathways]	1.0	5	1	0	0
45077	1624	Jak2 kinase	[Jak2 kinase]	1.0	2	1	0	0
45078	1624	processing of the p105 precursor,	[processing of the p105 precursor,]	1.0	5	1	0	0
45079	1624	Moreover, Sp1	[Moreover, Sp1]	1.0	2	1	0	0
45080	1624	considerable extent.	[considerable extent.]	1.0	2	1	0	0
45081	1624	other, twin	[other, twin]	1.0	2	1	0	0
45082	1624	same b-cell	[same B-cell]	1.0	2	1	0	0
45083	1624	cd4+ lymphocyte at polyclonal level,	[CD4+ lymphocytes at polyclonal level,]	1.0	5	1	0	0
45084	1624	important cofactor	[important cofactor]	1.0	2	2	2	2
45085	1624	tyrosine phosphorylation of specific protein substrate	[tyrosine phosphorylation of specific protein substrates]	1.0	6	1	0	0
45086	1624	selective role	[selective role]	1.0	2	2	2	2
45087	1624	alpha degradation	[alpha degradation]	1.0	2	1	0	0
45088	1624	region ii -119 to -88	[region II -119 to -88]	1.0	5	1	0	0
45089	1624	emcv ires	[EMCV IRES]	1.0	2	1	0	0
45090	1624	erythrocytic marker	[erythrocytic markers]	1.0	2	1	0	0
45091	1624	J-C intron	[J-C intron]	1.0	2	1	0	0
45092	1624	two coactivator	[two coactivators]	1.0	2	2	2	2
45093	1624	genomic configuration	[genomic configuration]	1.0	2	2	2	2
45094	1624	monoamine oxidase b enzyme activity	[monoamine oxidase B enzyme activity]	1.0	5	1	0	0
45095	1624	elucidation of the biochemical nature	[Elucidation of the biochemical nature]	1.0	5	1	0	0
45096	1624	result from il-2 mrna stability.	[resulting from IL-2 mRNA stability.]	1.0	5	1	0	0
45097	1624	require a a at the position	[requiring an A at the position]	1.0	6	1	0	0
45098	1624	IkB alpha in Jurkat T	[IkB alpha in Jurkat T]	1.0	5	1	0	0
45099	1624	DRE 1 -binding protein, p37	[DRE 1 -binding protein, p37]	1.0	5	1	0	0
45100	1624	involve the retinoic acid receptor alpha	[involving the retinoic acid receptor alpha]	1.0	6	1	0	0
45101	1624	CD45-deficient variant of Jurkat cell	[CD45-deficient variants of Jurkat cells]	1.0	5	1	0	0
45102	1624	AIR-1 locus	[AIR-1 locus]	1.0	2	2	2	2
45103	1624	treatment of human rest T cell	[Treatment of human resting T cells]	1.0	6	1	0	0
45104	1624	high level of serum ast/alt	[high levels of serum AST/ALT]	1.0	5	1	0	0
45105	1624	additional work, employ sequential deletion	[Additional work, employing sequential deletions]	1.0	5	1	0	0
45106	1624	activation status of the il-2r pathway	[activation status of the IL-2R pathway]	1.0	6	1	0	0
45107	1624	overt leukemia	[overt leukemia]	1.0	2	1	0	0
45108	1624	pas domain	[PAS domain]	1.0	2	1	0	0
45109	1624	December 1988	[December 1988,]	1.0	2	1	0	0
45110	1624	rapid production	[rapid production]	1.0	2	1	0	0
45111	1624	hla antigen	[HLA antigens]	1.0	2	2	1	1
45112	1624	even in normal thymus environment	[even in normal thymus environment]	1.0	5	1	0	0
45113	1624	unique subclone of a bone	[unique subclone of a bone]	1.0	5	1	0	0
45114	1624	bcd proto-oncogene	[Bcd proto-oncogene]	1.0	2	1	0	0
45115	1624	inducible phosphorylation in a cell-free system	[inducible phosphorylation in a cell-free system]	1.0	6	1	0	0
45116	1624	furthermore, persistent hiv infection of monocyte	[Furthermore, persistent HIV infection of monocytes]	1.0	6	1	0	0
45117	1624	cellular activation of cd4+ t-cell	[cellular activation of CD4+ T-cells]	1.0	5	1	0	0
45118	1624	microsequence analysis	[microsequence analysis]	1.0	2	1	0	0
45119	1624	class trans-activator	[class trans-activator]	1.0	2	2	2	2
45120	1624	same arrangement of positively sequence	[same arrangement of positively sequences]	1.0	5	1	0	0
45121	1624	relevance for human atherosclerotic disease	[relevance for human atherosclerotic disease]	1.0	5	1	0	0
45122	1624	spontaneous expression	[spontaneous expression]	1.0	2	2	2	2
45123	1624	fmol/million cells)	[fmol/million cells)]	1.0	2	1	0	0
45124	1624	PMA /alphacd28	[PMA /alphaCD28]	1.0	2	1	0	0
45125	1624	Interferon regulatory factor 2 irf-2	[Interferon regulatory factor 2 IRF-2]	1.0	5	1	0	0
45126	1624	induction of the il-2 promoter-enhancer	[induction of the IL-2 promoter-enhancer]	1.0	5	1	0	0
45127	1624	nuclear factor (NF)-kappaB consensus sequence	[nuclear factor (NF)-kappaB consensus sequence]	1.0	5	1	0	0
45128	1624	activity of the Iepsilon promoter	[activity of the Iepsilon promoter]	1.0	5	1	0	0
45129	1624	fmol/million cells;	[fmol/million cells;]	1.0	2	2	2	2
45130	1624	Stat3 protein	[Stat3 proteins]	1.0	2	1	0	0
45131	1624	presumably reflect the unique c-terminal domain	[presumably reflecting the unique C-terminal domain]	1.0	6	1	0	0
45132	1624	suppression of a cellular differentiation program	[Suppression of a cellular differentiation program]	1.0	6	1	0	0
45133	1624	potential treatment,	[potential treatment,]	1.0	2	1	0	0
45134	1624	b-cell proliferation follow cortisol depletion	[B-cell proliferation following cortisol depletion]	1.0	5	1	0	0
45135	1624	-STAT 1	[-STAT 1]	1.0	2	1	0	0
45136	1624	I2 PGI2	[I2 PGI2]	1.0	2	1	0	0
45137	1624	androgen receptor on this cell	[androgen receptor on these cells]	1.0	5	1	0	0
45138	1624	mutation in the tat gene	[Mutations in the tat gene]	1.0	5	1	0	0
45139	1624	further glucocorticoid	[further glucocorticoids]	1.0	2	1	0	0
45140	1624	nf-kappab component	[NF-kappaB components]	1.0	2	2	2	2
45141	1624	contain the intact il-2 promoter	[containing the intact IL-2 promoter]	1.0	5	1	0	0
45142	1624	co-infection of T cell by hiv-1	[Co-infection of T cells by HIV-1]	1.0	6	1	0	0
45143	1624	three major transcription initiation site	[three major transcription initiation sites]	1.0	5	1	0	0
45144	1624	NK cell with ec e-selectin	[NK cells with EC E-selectin]	1.0	5	1	0	0
45145	1624	conditional form of the protein	[conditional form of the protein]	1.0	5	1	0	0
45146	1624	first natural DNA response element	[first natural DNA response element]	1.0	5	1	0	0
45147	1624	core-specific mAb	[Core-specific mAb]	1.0	2	1	0	0
45148	1624	myeloid gene	[myeloid genes]	1.0	2	1	0	0
45149	1624	separation of beneficial from effects.	[separation of beneficial from effects.]	1.0	5	1	0	0
45150	1624	ap-1 binding activity from p62c-fo	[AP-1 binding activity from p62c-fos]	1.0	5	1	0	0
45151	1624	lef/tcf binding	[LEF/TCF binding]	1.0	2	1	0	0
45152	1624	future prognosis of the patient	[future prognosis of the patient]	1.0	5	1	0	0
45153	1624	human immunodeficiency virus vpr product	[Human immunodeficiency virus vpr product]	1.0	5	1	0	0
45154	1624	differentiate in unilineage erythroid culture	[differentiating in unilineage erythroid cultures]	1.0	5	1	0	0
45155	1624	nf-kappa b binding activity in monocyte	[NF-kappa B binding activity in monocytes]	1.0	6	1	0	0
45156	1624	NF-ATc expression	[NF-ATc expression]	1.0	2	1	0	0
45157	1624	molecular basis of il-12 action,	[molecular basis of IL-12 action,]	1.0	5	1	0	0
45158	1624	regulate hiv-1 gene expression in t-cell	[regulating HIV-1 gene expression in T-cells]	1.0	6	1	0	0
45159	1624	cell-cycle motif	[cell-cycle motifs]	1.0	2	1	0	0
45160	1624	expression of the L-selectin mrna	[expression of the L-selectin mRNA]	1.0	5	1	0	0
45161	1624	biologic level.	[biologic level.]	1.0	2	1	0	0
45162	1624	signal-transducing pathway of P- lps	[signal-transducing pathway of P- LPS]	1.0	5	1	0	0
45163	1624	positive functional role for otf-2	[positive functional role for OTF-2]	1.0	5	1	0	0
45164	1624	41 kilodalton	[41 kilodaltons]	1.0	2	1	0	0
45165	1624	IRES element	[IRES elements]	1.0	2	1	0	0
45166	1624	such observation	[Such observations]	1.0	2	1	0	0
45167	1624	non-Ashkenazi Jew	[non-Ashkenazi Jews]	1.0	2	1	0	0
45168	1624	successful generation of surrogate receptor	[successful generation of surrogate receptors]	1.0	5	1	0	0
45169	1624	information available in the literature	[information available in the literature]	1.0	5	1	0	0
45170	1624	g1 cyclin	[G1 cyclins]	1.0	2	2	1	1
45171	1624	hypersensitive element	[hypersensitive element]	1.0	2	1	0	0
45172	1624	GC border	[GC borders]	1.0	2	1	0	0
45173	1624	promoter position	[promoter positions]	1.0	2	2	2	2
45174	1624	single tumor cell from blood	[single tumor cells from blood]	1.0	5	1	0	0
45175	1624	exposure to 32 nm tpa	[exposure to 32 nM TPA]	1.0	5	1	0	0
45176	1624	X1 activity	[X1 activities]	1.0	2	2	2	2
45177	1624	cox-2 gene	[COX-2 gene]	1.0	2	1	0	0
45178	1624	mutation at the B2 site	[Mutations at the B2 site]	1.0	5	1	0	0
45179	1624	DC response	[DC responses]	1.0	2	1	0	0
45180	1624	implicate this gene as a factor	[implicating this gene as an factor]	1.0	6	1	0	0
45181	1624	expression from the dm promoter	[expression from the DM promoters]	1.0	5	1	0	0
45182	1624	moreover, impaired activation of NFkappaB	[Moreover, impaired activation of NFkappaB]	1.0	5	1	0	0
45183	1624	structure important in oocyte development	[structure important in oocyte development]	1.0	5	1	0	0
45184	1624	hb9 protein	[HB9 protein]	1.0	2	1	0	0
45185	1624	disruption of the NF-kappaB signal pathway	[disruption of the NF-kappaB signaling pathway]	1.0	6	1	0	0
45186	1624	CpG dinucleotide in this element	[CpG dinucleotide in this element]	1.0	5	1	0	0
45187	1624	increase in number of cell	[increase in numbers of cells]	1.0	5	1	0	0
45188	1624	'master regulator of t-cell differentiation	['master regulators of T-cell differentiation]	1.0	5	1	0	0
45189	1624	availability of interactor (s) limit transcription	[availability of interactor (s) limits transcription]	1.0	6	1	0	0
45190	1624	germline Cepsilon transcription by IL-4	[germline Cepsilon transcription by IL-4]	1.0	5	1	0	0
45191	1624	stimulation, two new kappa B-specific complex	[stimulation, two new kappa B-specific complexes]	1.0	6	1	0	0
45192	1624	gamma regions.	[gamma regions.]	1.0	2	1	0	0
45193	1624	TNF-alpha RNA	[TNF-alpha RNA]	1.0	2	1	0	0
45194	1624	expression of nucleoside diphosphate(ndp) kinase	[Expression of nucleoside diphosphate(NDP) kinase]	1.0	5	1	0	0
45195	1624	contain a additional open reading frame	[containing an additional open reading frame]	1.0	6	1	0	0
45196	1624	expression of gene control apoptosis	[expression of genes controlling apoptosis]	1.0	5	1	0	0
45197	1624	more severe leukopenia in transgenic	[more severe leukopenia in transgenic]	1.0	5	1	0	0
45198	1624	novel way	[novel ways]	1.0	2	1	0	0
45199	1624	protein family	[protein family]	1.0	2	2	1	1
45200	1624	human triiodothyronine t3 plasma clearance rate	[human triiodothyronine T3 plasma clearance rates]	1.0	6	1	0	0
45201	1624	cell interaction	[cell interaction]	1.0	2	2	2	2
45202	1624	event such as muscle contraction	[events such as muscle contraction]	1.0	5	1	0	0
45203	1624	regulator of a different set	[regulator of a different set]	1.0	5	1	0	0
45204	1624	various TP1 promoter-reporter gene construct	[various TP1 promoter-reporter gene constructs]	1.0	5	1	0	0
45205	1624	ec50 value	[EC50 values]	1.0	2	2	2	2
45206	1624	receptor mutant subclone of cem-c7	[Receptor mutant subclones of CEM-C7]	1.0	5	1	0	0
45207	1624	real time	[real time]	1.0	2	1	0	0
45208	1624	use cell	[using cells]	1.0	2	2	2	2
45209	1624	disruption of HIV-TF1 -binding site	[disruption of HIV-TF1 -binding site]	1.0	5	1	0	0
45210	1624	ATF/CREB factor	[ATF/CREB factors]	1.0	2	1	0	0
45211	1624	binding to the retinoblastoma protein	[binding to the retinoblastoma protein]	1.0	5	1	0	0
45212	1624	replacement domain	[replacement domain]	1.0	2	1	0	0
45213	1624	only, site of pkc responsiveness	[only, site of PKC responsiveness]	1.0	5	1	0	0
45214	1624	only CsA component limit signal	[only CsA component limiting signaling]	1.0	5	1	0	0
45215	1624	interferon-gamma activation of human monocyte	[interferon-gamma activation of human monocytes]	1.0	5	1	0	0
45216	1624	induce monocyte differentiation in the absence	[inducing monocyte differentiation in the absence]	1.0	6	1	0	0
45217	1624	only in SCM-1-producer T cell line	[only in SCM-1-producer T cell lines]	1.0	6	1	0	0
45218	1624	pseudo-hypoaldosteronism pha	[Pseudo-hypoaldosteronism PHA]	1.0	2	1	0	0
45219	1624	distant enhancer	[distant enhancer]	1.0	2	1	0	0
45220	1624	unique immunophenotype:	[unique immunophenotype:]	1.0	2	1	0	0
45221	1624	traf6 in ligand-induced activation event	[TRAF6 in ligand-induced activation events]	1.0	5	1	0	0
45222	1624	anti-diabetic action	[anti-diabetic actions]	1.0	2	1	0	0
45223	1624	ifn-alpha/beta-induced transcription	[IFN-alpha/beta-induced transcription]	1.0	2	1	0	0
45224	1624	Functional il-12	[Functional IL-12]	1.0	2	1	0	0
45225	1624	CD40 stimulation.	[CD40 stimulation.]	1.0	2	1	0	0
45226	1624	include the Janus kinase JAK1	[including the Janus kinases JAK1]	1.0	5	1	0	0
45227	1624	cytoplasmic subunit	[cytoplasmic subunit]	1.0	2	2	2	2
45228	1624	subsequent study	[Subsequent studies]	1.0	2	1	0	0
45229	1624	compelling evidence	[compelling evidence]	1.0	2	2	1	1
45230	1624	tumour size	[tumour size]	1.0	2	1	0	0
45231	1624	use vary conditions, three distinct complex	[Using varying conditions, three distinct complexes]	1.0	6	1	0	0
45232	1624	dominant negative mutant of Ras	[dominant negative mutants of Ras]	1.0	5	1	0	0
45233	1624	rel b	[Rel B]	1.0	2	1	0	0
45234	1624	poly(A) rna	[poly(A) RNA]	1.0	2	2	2	2
45235	1624	other models.	[other models.]	1.0	2	1	0	0
45236	1624	underlie ebv b cell transformation	[underlying EBV B cell transformation]	1.0	5	1	0	0
45237	1624	intracellular pool of NF-kappaB /IkappaBalpha	[intracellular pool of NF-kappaB /IkappaBalpha]	1.0	5	1	0	0
45238	1624	collagenase-1 transcription	[collagenase-1 transcription]	1.0	2	2	2	2
45239	1624	double-blind fashion.	[double-blind fashion.]	1.0	2	1	0	0
45240	1624	human brain	[human brain]	1.0	2	2	2	2
45241	1624	cd8(+)-t-cell epitope	[CD8(+)-T-cell epitopes]	1.0	2	2	1	1
45242	1624	means of the hypothalamic-pituitary-adrenal axis	[means of the hypothalamic-pituitary-adrenal axis]	1.0	5	1	0	0
45243	1624	CstF-64 to the proximal polyA site	[CstF-64 to the proximal polyA site]	1.0	6	1	0	0
45244	1624	cd23 mrna	[CD23 mRNA]	1.0	2	2	2	2
45245	1624	transient transfection of HEK 293 cell	[transient transfection of HEK 293 cells]	1.0	6	1	0	0
45246	1624	C-terminal part of the region	[C-terminal part of the region]	1.0	5	1	0	0
45247	1624	regulate ige synthesis by b cell	[regulating IgE synthesis by B cells]	1.0	6	1	0	0
45248	1624	monocyte migration	[Monocyte migration]	1.0	2	1	0	0
45249	1624	growth inhibition of bone marrow myeloid	[growth inhibition of bone marrow myeloid]	1.0	6	1	0	0
45250	1624	TRAF2	[TRAF2]	1.0	1	11	1	1
45251	1624	relative resistance of b-cell line	[relative resistance of B-cell lines]	1.0	5	1	0	0
45252	1624	growth signal	[growth signals]	1.0	2	2	1	1
45253	1624	concept dependent on the expression	[concept dependent on the expression]	1.0	5	1	0	0
45254	1624	tumor necrosis factor alpha activation	[tumor necrosis factor alpha activation]	1.0	5	1	0	0
45255	1624	effect on specific gene expression	[effect on specific gene expression]	1.0	5	1	0	0
45256	1624	67 kilodalton	[67 kilodaltons]	1.0	2	1	0	0
45257	1624	binding to the ah receptor	[binding to the Ah receptor]	1.0	5	1	0	0
45258	1624	anemia-inducing strain	[anemia-inducing strain]	1.0	2	1	0	0
45259	1624	expression of gene encode other protein	[expression of genes encoding other proteins]	1.0	6	1	0	0
45260	1624	remote position	[remote position]	1.0	2	2	1	1
45261	1624	tf gene transcription in human monocyte	[TF gene transcription in human monocytes]	1.0	6	1	0	0
45262	1624	inhibit expression of the adhesion molecule	[inhibiting expression of the adhesion molecules]	1.0	6	1	0	0
45263	1624	functional differentiation of hl-60 cell	[functional differentiation of HL-60 cells]	1.0	5	1	0	0
45264	1624	alteration in the cytokine level	[alterations in the cytokine levels]	1.0	5	1	0	0
45265	1624	erythropoietic development	[erythropoietic development]	1.0	2	1	0	0
45266	1624	slight increase in the percentage	[slight increase in the percentage]	1.0	5	1	0	0
45267	1624	seven patient with steroid-resistant asthma	[seven patients with steroid-resistant asthma]	1.0	5	1	0	0
45268	1624	tumor outgrowth	[tumor outgrowth]	1.0	2	1	0	0
45269	1624	thyroid hormone- response element with affinity.	[thyroid hormone- response elements with affinity.]	1.0	6	1	0	0
45270	1624	level of the mature protein	[levels of the mature protein]	1.0	5	1	0	0
45271	1624	functional ebna2	[functional EBNA2]	1.0	2	1	0	0
45272	1624	I site near the trinucleotide repeat	[I sites near the trinucleotide repeat]	1.0	6	1	0	0
45273	1624	head domain	[head domain]	1.0	2	1	0	0
45274	1624	binding peptide	[binding peptide]	1.0	2	2	2	2
45275	1624	long period of latent infection	[long periods of latent infection]	1.0	5	1	0	0
45276	1624	calcium influx	[calcium influx]	1.0	2	2	2	2
45277	1624	HLA-DM gene	[HLA-DM genes]	1.0	2	1	0	0
45278	1624	AP1/c-jun proto-oncogene	[AP1/c-jun proto-oncogene]	1.0	2	1	0	0
45279	1624	compare the expression of gene	[comparing the expression of genes]	1.0	5	1	0	0
45280	1624	impaired b	[impaired B]	1.0	2	1	0	0
45281	1624	interferon-inducible gene	[interferon-inducible genes]	1.0	2	1	0	0
45282	1624	late kinetic a finding inconsistent	[late kinetics a finding inconsistent]	1.0	5	1	0	0
45283	1624	activation from a response element	[activation from a response element]	1.0	5	1	0	0
45284	1624	activation-induced transcription	[activation-induced transcription]	1.0	2	1	0	0
45285	1624	suggest the presence of activation motif	[suggesting the presence of activation motifs]	1.0	6	1	0	0
45286	1624	Zta expression	[Zta expression]	1.0	2	1	0	0
45287	1624	NF-kappa b /Rel binding site	[NF-kappa B /Rel binding sites]	1.0	5	1	0	0
45288	1624	use the 1G5 cell line	[Using the 1G5 cell line]	1.0	5	1	0	0
45289	1624	synergistic induction of the IL-6 gene	[Synergistic induction of the IL-6 gene]	1.0	6	1	0	0
45290	1624	hhv-6 infection	[HHV-6 infection]	1.0	2	1	0	0
45291	1624	IL-2 deprivation	[IL-2 deprivation]	1.0	2	1	0	0
45292	1624	4-24 h	[4-24 h]	1.0	2	1	0	0
45293	1624	functional element	[functional element]	1.0	2	2	1	1
45294	1624	celiac disease	[celiac disease]	1.0	2	2	2	2
45295	1624	v-abl oncogene	[v-abl oncogene]	1.0	2	1	0	0
45296	1624	cortisol binding to glucocorticoid receptor	[cortisol binding to glucocorticoid receptors]	1.0	5	2	1	1
45297	1624	relevant mechanism.	[relevant mechanism.]	1.0	2	1	0	0
45298	1624	insight into the different role	[insight into the different role]	1.0	5	1	0	0
45299	1624	jak1 in human T lymphocyte	[JAK1 in human T lymphocytes]	1.0	5	1	0	0
45300	1624	nf-kappa factor	[NF-kappa factor]	1.0	2	1	0	0
45301	1624	cellular phenotype,	[cellular phenotype,]	1.0	2	1	0	0
45302	1624	additional region	[additional region]	1.0	2	2	2	2
45303	1624	Glucocorticoid receptor in normal leukocyte	[Glucocorticoid receptors in normal leukocytes]	1.0	5	1	0	0
45304	1624	important target	[important targets]	1.0	2	2	1	1
45305	1624	rabbit antisera	[rabbit antisera]	1.0	2	1	0	0
45306	1624	addition, cotransfection of a molecule	[addition, cotransfection of a molecule]	1.0	5	1	0	0
45307	1624	NB4 promyelocyte	[NB4 promyelocytes]	1.0	2	1	0	0
45308	1624	sedimentation on sucrose density gradient	[sedimentation on sucrose density gradients]	1.0	5	1	0	0
45309	1624	central issue in herpesvirus biology	[central issue in herpesvirus biology]	1.0	5	1	0	0
45310	1624	p95vav involvement in tcr signal	[p95vav involvement in TCR signaling]	1.0	5	1	0	0
45311	1624	efficient phosphorylation of the epor	[efficient phosphorylation of the EPOR]	1.0	5	1	0	0
45312	1624	rd cell with cemx174 cell	[RD cells with CEMx174 cells]	1.0	5	1	0	0
45313	1624	dna-binding motif	[DNA-binding motifs]	1.0	2	2	2	2
45314	1624	different dose of dexamethasone DEX	[different doses of dexamethasone DEX]	1.0	5	1	0	0
45315	1624	first generation	[first generation]	1.0	2	1	0	0
45316	1624	obligatory step for the inactivation	[obligatory steps for the inactivation]	1.0	5	1	0	0
45317	1624	bear Val50	[bearing Val50]	1.0	2	1	0	0
45318	1624	pharmacodynamic model	[pharmacodynamic model]	1.0	2	2	2	2
45319	1624	tf promoter	[TF promoter]	1.0	2	1	0	0
45320	1624	interaction between various cellular protein	[interactions between various cellular proteins]	1.0	5	1	0	0
45321	1624	screening of a library of compound	[Screening of a library of compounds]	1.0	6	1	0	0
45322	1624	rapid change	[rapid changes]	1.0	2	2	2	2
45323	1624	activation by the N-terminal domain	[activation by the N-terminal domain]	1.0	5	1	0	0
45324	1624	accordingly, western blot with antibody specific	[Accordingly, Western blots with antibodies specific]	1.0	6	1	0	0
45325	1624	rapamycin inhibition of il-2 proliferation	[rapamycin inhibition of IL-2 proliferation]	1.0	5	1	0	0
45326	1624	sh (0.8	[SH (0.8]	1.0	2	1	0	0
45327	1624	CD30 -dependent degradation of traf2	[CD30 -dependent degradation of TRAF2]	1.0	5	1	0	0
45328	1624	GM-CSF template	[GM-CSF templates]	1.0	2	1	0	0
45329	1624	signal component	[signaling component]	1.0	2	2	2	2
45330	1624	htlv-ii p37tax	[HTLV-II p37tax]	1.0	2	1	0	0
45331	1624	respectively, the lack of zebra staining	[respectively, the lack of ZEBRA staining]	1.0	6	1	0	0
45332	1624	same signal	[same signal]	1.0	2	1	0	0
45333	1624	one nuclear factor in macrophage	[one nuclear factors in macrophages]	1.0	5	1	0	0
45334	1624	fos to the pre-exist complex	[Fos to the pre-existing complex]	1.0	5	1	0	0
45335	1624	mainly of T cell origin	[mainly of T cell origin]	1.0	5	1	0	0
45336	1624	mitotic rate	[mitotic rate]	1.0	2	2	2	2
45337	1624	glucocorticoid-induced apoptosis of lymphoid cell	[Glucocorticoid-induced apoptosis of lymphoid cells]	1.0	5	1	0	0
45338	1624	potential tool	[potential tool]	1.0	2	2	1	1
45339	1624	therapeutic concentration	[therapeutic concentrations]	1.0	2	1	0	0
45340	1624	evidence indicate a regulatory function	[evidence indicating a regulatory function]	1.0	5	1	0	0
45341	1624	ultra-violet -irradiation	[UV -irradiation]	1.0	2	1	0	0
45342	1624	attenuation of gamma interferon tyrosine phosphorylation	[Attenuation of gamma interferon tyrosine phosphorylation]	1.0	6	1	0	0
45343	1624	effector phenotypes.	[effector phenotypes.]	1.0	2	1	0	0
45344	1624	DRA expression	[DRA expression]	1.0	2	2	1	1
45345	1624	gene by a tracking mechanism	[gene by a tracking mechanism]	1.0	5	1	0	0
45346	1624	poor expression	[poor expression]	1.0	2	1	0	0
45347	1624	ino production	[iNO production]	1.0	2	1	0	0
45348	1624	parent peptide	[parent peptide]	1.0	2	2	1	1
45349	1624	(1-1.5 mg/day)	[(1-1.5 mg/day)]	1.0	2	1	0	0
45350	1624	physiological context	[physiological context]	1.0	2	1	0	0
45351	1624	other lymphycryptoviruss	[other lymphycryptoviruses]	1.0	2	1	0	0
45352	1624	considerable protection from tcr-mediated apoptosis	[considerable protection from TCR-mediated apoptosis]	1.0	5	1	0	0
45353	1624	ig secretion	[Ig secretion]	1.0	2	1	0	0
45354	1624	complement atttgcat	[complement ATTTGCAT]	1.0	2	1	0	0
45355	1624	local metabolism of steroid by normal	[local metabolism of steroids by normal]	1.0	6	1	0	0
45356	1624	qualitative aspect of the induction	[qualitative aspects of the induction]	1.0	5	1	0	0
45357	1624	key role in FL hematopoiesis	[key role in FL hematopoiesis]	1.0	5	1	0	0
45358	1624	difference in expression of the enzyme	[differences in expression of the enzyme]	1.0	6	1	0	0
45359	1624	decrease use weak binding peptide	[decrease using weaker binding peptides]	1.0	5	1	0	0
45360	1624	W box	[W box]	1.0	2	2	2	2
45361	1624	therapeutic effect of radiation therapy	[therapeutic effects of radiation therapy]	1.0	5	1	0	0
45362	1624	differentiate thymocyte	[differentiating thymocyte]	1.0	2	2	1	1
45363	1624	vivo phosphorylation	[vivo phosphorylation]	1.0	2	2	1	1
45364	1624	several chemoattract	[several chemoattractants]	1.0	2	1	0	0
45365	1624	subsequent deletion of the macrophage	[subsequent deletion of the macrophage]	1.0	5	1	0	0
45366	1624	megakaryoblastic disorder	[megakaryoblastic disorders]	1.0	2	1	0	0
45367	1624	potent inhibitor of tyrosine kinase	[potent inhibitor of tyrosine kinase]	1.0	5	1	0	0
45368	1624	balance of stat1 transcriptional activity	[balance of Stat1 transcriptional activity]	1.0	5	1	0	0
45369	1624	single binding	[single binding]	1.0	2	1	0	0
45370	1624	neoplastic transformation	[neoplastic transformation]	1.0	2	1	0	0
45371	1624	NFAT binding to the calcineurin domain	[NFAT binding to the calcineurin domain]	1.0	6	1	0	0
45372	1624	degradative loss	[degradative loss]	1.0	2	1	0	0
45373	1624	stat3 binding	[Stat3 binding]	1.0	2	1	0	0
45374	1624	alveolar exudate	[alveolar exudate]	1.0	2	1	0	0
45375	1624	dna-binding of the transcription factor	[DNA-binding of the transcription factor]	1.0	5	1	0	0
45376	1624	presence of protein binding site	[presence of protein binding sites]	1.0	5	1	0	0
45377	1624	synovial fibroblast	[synovial fibroblasts]	1.0	2	1	0	0
45378	1624	family transcription	[family transcription]	1.0	2	2	2	2
45379	1624	Th1/Th0 response	[Th1/Th0 responses]	1.0	2	1	0	0
45380	1624	part of the interaction with calcineurin	[part of the interaction with calcineurin]	1.0	6	1	0	0
45381	1624	place of the NF-kappa b	[place of the NF-kappa B]	1.0	5	1	0	0
45382	1624	transcriptional response to cellular activation	[transcriptional response to cellular activation]	1.0	5	1	0	0
45383	1624	viral insertion	[viral insertion]	1.0	2	2	1	1
45384	1624	regulate enhancement of germline cepsilon transcription	[regulating enhancement of germline Cepsilon transcription]	1.0	6	1	0	0
45385	1624	cell from inactive cytoplasmic form	[cells from inactive cytoplasmic form]	1.0	5	1	0	0
45386	1624	oct2-positive clone	[Oct2-positive clones]	1.0	2	1	0	0
45387	1624	role of serine /threonine phosphatase	[role of serine /threonine phosphatases]	1.0	5	1	0	0
45388	1624	signal in myeloid leukemic cell	[signals in myeloid leukemic cells]	1.0	5	1	0	0
45389	1624	progesterone Prog	[progesterone Prog]	1.0	2	1	0	0
45390	1624	hypotonic extract	[hypotonic extracts]	1.0	2	2	2	2
45391	1624	two major pkc substrate marck	[two major PKC substrates MARCKS]	1.0	5	1	0	0
45392	1624	AIR-1 trans-activator	[AIR-1 trans-activator]	1.0	2	1	0	0
45393	1624	important part	[important part]	1.0	2	2	2	2
45394	1624	pre-leukemic phase of friend erythroleukemia	[pre-leukemic phase of Friend erythroleukemia]	1.0	5	1	0	0
45395	1624	381 ng/ml)	[381 ng/mL)]	1.0	2	2	2	2
45396	1624	direct substrate for shp1 in cells.	[direct substrates for SHP1 in cells.]	1.0	6	1	0	0
45397	1624	low receptor affinity to glucocorticoid	[low receptor affinity to glucocorticoids]	1.0	5	1	0	0
45398	1624	contrast, cotransfection with a combination	[contrast, cotransfection with a combination]	1.0	5	1	0	0
45399	1624	cp activity in the LCLs	[Cp activity in the LCLs]	1.0	5	1	0	0
45400	1624	increase in p24 antigen production	[increase in p24 antigen production]	1.0	5	2	2	2
45401	1624	interaction with pkc -dependent signal system	[interactions with PKC -dependent signaling systems]	1.0	6	1	0	0
45402	1624	human promyeloid	[human promyeloid]	1.0	2	2	1	1
45403	1624	intracellular signal for two chemoattract	[intracellular signaling for two chemoattractants]	1.0	5	1	0	0
45404	1624	evolutionary benefit for high eukaryote	[evolutionary benefit for higher eukaryotes]	1.0	5	1	0	0
45405	1624	involvement of cyclic amp-dependent protein kinase	[Involvement of cyclic AMP-dependent protein kinases]	1.0	6	1	0	0
45406	1624	main mediator	[main mediators]	1.0	2	1	0	0
45407	1624	atherosclerotic event	[atherosclerotic events]	1.0	2	1	0	0
45408	1624	paf change in l-selectin expression	[PAF changes in L-selectin expression]	1.0	5	1	0	0
45409	1624	such enhancement	[such enhancement]	1.0	2	1	0	0
45410	1624	asm activity	[ASM activity]	1.0	2	1	0	0
45411	1624	dna-binding activity of chicken gata-1	[DNA-binding activities of chicken GATA-1]	1.0	5	1	0	0
45412	1624	analyze the 2.5-kilobase sequence upstream	[analyzing the 2.5-kilobase sequence upstream]	1.0	5	1	0	0
45413	1624	endogenous ig heavy chain enhancer	[endogenous Ig heavy chain enhancer]	1.0	5	1	0	0
45414	1624	lymphocyte ability	[lymphocyte ability]	1.0	2	1	0	0
45415	1624	10(-7) mol/L	[10(-7) mol/L]	1.0	2	2	2	2
45416	1624	human leucocyte	[human leucocytes]	1.0	2	3	2	1
45417	1624	leucocytic estrogen receptor in patient	[leucocytic estrogen receptor in patients]	1.0	5	1	0	0
45418	1624	biologic mediator	[biologic mediators]	1.0	2	1	0	0
45419	1624	(0-125 microM) of zinc sulfate	[(0-125 microM) of zinc sulfate]	1.0	5	1	0	0
45420	1624	calcium ionophore a23187 in T cell	[calcium ionophore A23187 in T cells]	1.0	6	1	0	0
45421	1624	lymphocyte treatment	[lymphocyte treatment]	1.0	2	1	0	0
45422	1624	hydrocortisone-induced apoptosis	[hydrocortisone-induced apoptosis]	1.0	2	1	0	0
45423	1624	yeast activator	[yeast activator]	1.0	2	1	0	0
45424	1624	main circadian pacemaker of GR	[main circadian pacemaker of GR]	1.0	5	1	0	0
45425	1624	possible role of 5-hydroxyeicosatetraenoic acid	[possible role of 5-hydroxyeicosatetraenoic acid]	1.0	5	1	0	0
45426	1624	Dehydroepiandrosterone DHEA the predominant androgen	[Dehydroepiandrosterone DHEA the predominant androgen]	1.0	5	1	0	0
45427	1624	clinical feature	[clinical features]	1.0	2	2	2	2
45428	1624	use anti- c/ebp beta abs	[using anti- C/EBP beta Abs]	1.0	5	1	0	0
45429	1624	prostatic carcinoma	[prostatic carcinoma]	1.0	2	1	0	0
45430	1624	stimulation of human lymphocyte proliferation	[Stimulation of human lymphocyte proliferation]	1.0	5	1	0	0
45431	1624	development of sideroblast in colony	[development of sideroblasts in colonies]	1.0	5	1	0	0
45432	1624	level of nf-kappa b activity	[level of NF-kappa B activity]	1.0	5	1	0	0
45433	1624	fas ligand FasL on cytotoxic lymphocyte	[Fas ligand FasL on cytotoxic lymphocytes]	1.0	6	1	0	0
45434	1624	androgen receptor in mononuclear leukocyte	[androgen receptors in mononuclear leukocytes]	1.0	5	3	2	1
45435	1624	th2 differentiation in T cell	[Th2 differentiation in T cells]	1.0	5	1	0	0
45436	1624	Hunninghake, G. W. (1998) Am. J.	[Hunninghake, G. W. (1998) Am. J.]	1.0	6	1	0	0
45437	1624	immature class	[immature class]	1.0	2	1	0	0
45438	1624	computer analysis	[computer analysis]	1.0	2	1	0	0
45439	1624	surface expression of several adhesion molecule	[surface expression of several adhesion molecules]	1.0	6	1	0	0
45440	1624	CD5 gene	[CD5 gene]	1.0	2	3	2	1
45441	1624	[molecular mechanism of cytokine gene expression	[[Molecular mechanism of cytokine gene expression]	1.0	6	1	0	0
45442	1624	DNA binding of NF-kappa b	[DNA binding of NF-kappa B]	1.0	5	1	0	0
45443	1624	activation property	[activation properties]	1.0	2	2	2	2
45444	1624	PMA induction of c-fo mrna	[PMA induction of c-fos mRNA]	1.0	5	1	0	0
45445	1624	reinfusion of CD4 T cell	[reinfusion of CD4 T cells]	1.0	5	1	0	0
45446	1624	molecular mechanism govern lineage switch	[molecular mechanisms governing lineage switching]	1.0	5	1	0	0
45447	1624	complex family	[complex family]	1.0	2	1	0	0
45448	1624	neutrophilic inflammation in animal model	[neutrophilic inflammation in animal models]	1.0	5	1	0	0
45449	1624	CsA -resistant	[CsA -resistant]	1.0	2	2	2	2
45450	1624	latent membrane protein 1 lmp1	[latent membrane protein 1 LMP1]	1.0	5	1	0	0
45451	1624	lymphocyte population	[lymphocyte populations]	1.0	2	2	1	1
45452	1624	use a in vitro model,	[using an in vitro model,]	1.0	5	1	0	0
45453	1624	level of AP-1 fos/cun-contain nf-at complex	[levels of AP-1 Fos/Jun-containing NF-AT complexes]	1.0	6	1	0	0
45454	1624	erythroid protein	[erythroid protein]	1.0	2	2	1	1
45455	1624	high level of il-6 protein	[high levels of IL-6 protein]	1.0	5	1	0	0
45456	1624	Fas mrna	[Fas mRNA]	1.0	2	1	0	0
45457	1624	biopsy specimen	[biopsy specimen]	1.0	2	2	2	2
45458	1624	direct exposure to 10 nm 2,3,377-tc	[Direct exposure to 10 nM 2,3,7,8-TCDD]	1.0	6	1	0	0
45459	1624	pebp2 alpha	[PEBP2 alpha]	1.0	2	2	2	2
45460	1624	c-sis/pdgb proto-oncogene	[c-sis/PDGF-B proto-oncogene]	1.0	2	1	0	0
45461	1624	TCL1 oncogene	[TCL1 oncogene]	1.0	2	2	1	1
45462	1624	thiol insufficiency	[thiol insufficiency]	1.0	2	1	0	0
45463	1624	nur77 gamma	[nur77 gamma]	1.0	2	1	0	0
45464	1624	Murine fra-1	[Murine fra-1]	1.0	2	1	0	0
45465	1624	datum point	[data point]	1.0	2	1	0	0
45466	1624	permanently produce functional hiv tat protein	[permanently producing functional HIV Tat protein]	1.0	6	1	0	0
45467	1624	human polymorphonuclear	[human polymorphonuclear]	1.0	2	1	0	0
45468	1624	nucleotide substitution	[nucleotide substitution]	1.0	2	2	1	1
45469	1624	importance of the carbon-20 position	[importance of the carbon-20 position]	1.0	5	1	0	0
45470	1624	accessory protein	[accessory proteins]	1.0	2	1	0	0
45471	1624	specific antisera in immunoprecipitation assay	[specific antisera in immunoprecipitation assays]	1.0	5	1	0	0
45472	1624	high content	[higher content]	1.0	2	2	2	2
45473	1624	expression of gene in ctll-2 beta-casein	[expression of genes in CTLL-2 beta-casein]	1.0	6	1	0	0
45474	1624	13 patient with essential hypertension	[13 patients with essential hypertension]	1.0	5	1	0	0
45475	1624	MDD patient	[MDD patients]	1.0	2	2	2	2
45476	1624	contain the common sh3-sh2-sh3 motif	[containing the common SH3-SH2-SH3 motif]	1.0	5	1	0	0
45477	1624	physiologic condition	[physiologic conditions]	1.0	2	1	0	0
45478	1624	little change in the mrna level	[little change in the mRNA level]	1.0	6	1	0	0
45479	1624	knowledge of the intracellular signal pathway	[knowledge of the intracellular signaling pathways]	1.0	6	1	0	0
45480	1624	D5 tumor	[D5 tumors]	1.0	2	1	0	0
45481	1624	maximum of 2100 binding sites/nucleus	[maximum of 2100 binding sites/nucleus]	1.0	5	1	0	0
45482	1624	docking	[docking]	1.0	1	11	4	4
45483	1624	only in response to IL-13 treatment	[only in response to IL-13 treatment]	1.0	6	1	0	0
45484	1624	c-erbB2 amplification	[c-erbB2 amplification]	1.0	2	2	2	2
45485	1624	indicate specificity.	[indicating specificity.]	1.0	2	1	0	0
45486	1624	cell from disease-susceptible rhesus macaque	[cells from disease-susceptible rhesus macaques]	1.0	5	1	0	0
45487	1624	plb-985 cell	[PLB-985 cells]	1.0	2	2	1	1
45488	1624	affinity kd	[affinity Kd]	1.0	2	2	1	1
45489	1624	stabilization assay	[stabilization assay]	1.0	2	1	0	0
45490	1624	anaphylatoxin C3a	[anaphylatoxin C3a]	1.0	2	1	0	0
45491	1624	transient response	[transient responses]	1.0	2	1	0	0
45492	1624	stat1 in airway epithelial cell	[Stat1 in airway epithelial cells]	1.0	5	1	0	0
45493	1624	cytokine dysregulation	[Cytokine dysregulation]	1.0	2	2	2	2
45494	1624	test steroid	[test steroids]	1.0	2	1	0	0
45495	1624	allergen-specific T cell in atopic patient	[Allergen-specific T cells in atopic patients]	1.0	6	1	0	0
45496	1624	reactive hyperplasias	[reactive hyperplasias]	1.0	2	2	1	1
45497	1624	redistribution of suppressor-inducer T cell	[redistribution of suppressor-inducer T cells]	1.0	5	1	0	0
45498	1624	R24 mab	[R24 mAb]	1.0	2	1	0	0
45499	1624	functional receptor	[functional receptors]	1.0	2	2	2	2
45500	1624	adenoviral gene expression in lymphocyte	[adenoviral gene expression in lymphocytes]	1.0	5	1	0	0
45501	1624	Philadelphia leukemia	[Philadelphia leukemia]	1.0	2	2	2	2
45502	1624	anaphylatoxin C5a	[anaphylatoxins C5a]	1.0	2	2	1	1
45503	1624	effect on the time course	[effect on the time course]	1.0	5	1	0	0
45504	1624	mrna for interleukin (il),1 beta	[mRNA for interleukin (IL),1 beta]	1.0	5	1	0	0
45505	1624	acquisition of sensitivity to apoptosis	[acquisition of sensitivity to apoptosis]	1.0	5	1	0	0
45506	1624	supernatant from the b line	[supernatant from the B line]	1.0	5	1	0	0
45507	1624	deletion analysis of reporter construct	[deletion analysis of reporter constructs]	1.0	5	1	0	0
45508	1624	ca2+-binding protein	[Ca2+-binding proteins]	1.0	2	1	0	0
45509	1624	intermediate affinity	[intermediate affinity]	1.0	2	1	0	0
45510	1624	prognostic significance	[prognostic significance]	1.0	2	1	0	0
45511	1624	series of construct contain deletion	[series of constructs containing deletions]	1.0	5	1	0	0
45512	1624	jurkat cell with anti-CD3 mab	[Jurkat cells with anti-CD3 mAb]	1.0	5	1	0	0
45513	1624	hyperadhesion response	[hyperadhesion response]	1.0	2	1	0	0
45514	1624	histological grade).	[histological grade).]	1.0	2	1	0	0
45515	1624	calphostin c	[calphostin C]	1.0	2	1	0	0
45516	1624	latter pathway	[latter pathway]	1.0	2	1	0	0
45517	1624	consequence for mononuclear cell activation	[consequences for mononuclear cell activation]	1.0	5	1	0	0
45518	1624	amino acid 154 to 462	[amino acids 154 to 462]	1.0	5	1	0	0
45519	1624	nonspecific toxicity	[nonspecific toxicity]	1.0	2	1	0	0
45520	1624	anti-choleretic agent	[anti-choleretic agent]	1.0	2	1	0	0
45521	1624	shift assay	[shift assay]	1.0	2	2	2	2
45522	1624	Jurkat J6	[Jurkat J6]	1.0	2	1	0	0
45523	1624	activation of unknown host intracellular event	[Activation of unknown host intracellular events]	1.0	6	1	0	0
45524	1624	erythropoietin (Epo)	[Erythropoietin (Epo)]	1.0	2	1	0	0
45525	1624	Glucocorticoid receptor binding in cell type	[Glucocorticoid receptor binding in cell types]	1.0	6	1	0	0
45526	1624	most cases,	[most cases,]	1.0	2	1	0	0
45527	1624	activate a tyrosine-phosphorylated DNA binding protein	[activating a tyrosine-phosphorylated DNA binding protein]	1.0	6	1	0	0
45528	1624	proviral induction	[proviral induction]	1.0	2	1	0	0
45529	1624	PRDII element	[PRDII element]	1.0	2	2	2	2
45530	1624	role in lps nf-kappab activation	[role in LPS NF-kappaB activation]	1.0	5	1	0	0
45531	1624	only in cell contain lck	[only in cells containing Lck]	1.0	5	1	0	0
45532	1624	other sequences.	[other sequences.]	1.0	2	1	0	0
45533	1624	ngfi-b/nur77-related transcription	[NGFI-B/nur77-related transcription]	1.0	2	1	0	0
45534	1624	essential protein	[essential protein]	1.0	2	2	1	1
45535	1624	adult lineage	[adult lineage]	1.0	2	1	0	0
45536	1624	remain	[remaining]	1.0	1	10	0	0
45537	1624	use of the antibody ki-67	[use of the antibody Ki-67]	1.0	5	1	0	0
45538	1624	DNA binding of the receptor	[DNA binding of the receptor]	1.0	5	1	0	0
45539	1624	pathophysiology of chronic myeloid leukaemia	[pathophysiology of chronic myeloid leukaemia]	1.0	5	1	0	0
45540	1624	cells, with osteoclast phenotypic property	[cells, with osteoclast phenotypic properties]	1.0	5	1	0	0
45541	1624	express c-myc vsmc-myc with a area	[expressing c-myc VSMC-myc with an area]	1.0	6	1	0	0
45542	1624	in PBL	[in PBL]	1.0	2	1	0	0
45543	1624	cytospin preparation	[cytospin preparations]	1.0	2	2	1	1
45544	1624	for (TWHf)	[f (TWHf)]	1.0	2	1	0	0
45545	1624	15 control	[15 controls]	1.0	2	2	1	1
45546	1624	anionic phospholipid	[anionic phospholipids]	1.0	2	1	0	0
45547	1624	196 base pair long region	[196 base pair long region]	1.0	5	1	0	0
45548	1624	il-4 signaling.	[IL-4 signaling.]	1.0	2	1	0	0
45549	1624	include a response to retinoic acid	[including a response to retinoic acid]	1.0	6	1	0	0
45550	1624	ap-1 translocation	[AP-1 translocation]	1.0	2	1	0	0
45551	1624	menopausal status	[menopausal status]	1.0	2	2	1	1
45552	1624	selectable marker,	[selectable marker,]	1.0	2	1	0	0
45553	1624	cloning of the complementary DNA	[cloning of the complementary DNA]	1.0	5	1	0	0
45554	1624	Communication between resident tissue fibroblast	[Communication between resident tissue fibroblasts]	1.0	5	1	0	0
45555	1624	apparent alteration	[apparent alteration]	1.0	2	1	0	0
45556	1624	other molecule such as glucocorticoid	[other molecules such as glucocorticoid]	1.0	5	1	0	0
45557	1624	g0s2 mrna	[G0S2 mRNA]	1.0	2	2	2	2
45558	1624	increase in blood monocyte number	[increase in blood monocyte number]	1.0	5	1	0	0
45559	1624	I kappa b alpha gene	[I kappa B alpha gene]	1.0	5	1	0	0
45560	1624	effect on the GM-CSF promoter	[effects on the GM-CSF promoter]	1.0	5	1	0	0
45561	1624	Pathological evaluation	[Pathological evaluation]	1.0	2	1	0	0
45562	1624	diisopropyl fluorophosphate-thrombin	[diisopropyl fluorophosphate-thrombin]	1.0	2	1	0	0
45563	1624	protein mds1/evi1	[protein MDS1/EVI1]	1.0	2	2	2	2
45564	1624	Specific inhibitor of p38alpha mapk	[Specific inhibitors of p38alpha MAPk]	1.0	5	1	0	0
45565	1624	50 tissue	[50 tissues]	1.0	2	1	0	0
45566	1624	1 alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[1 alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	1.0	5	2	1	1
45567	1624	survival valume	[survival value,]	1.0	2	1	0	0
45568	1624	T helper (th) cell subset	[T helper (Th) cell subsets]	1.0	5	1	0	0
45569	1624	member of the fos family	[members of the fos family]	1.0	5	1	0	0
45570	1624	92-kd stat5b	[92-kD STAT5B]	1.0	2	1	0	0
45571	1624	malignant cell	[malignant cells]	1.0	2	2	2	2
45572	1624	high incidence of leukemic relapse	[high incidence of leukemic relapse]	1.0	5	1	0	0
45573	1624	lining layer,	[lining layer,]	1.0	2	1	0	0
45574	1624	novel proto-oncogene in the vicinity	[novel proto-oncogene in the vicinity]	1.0	5	1	0	0
45575	1624	oncogenic transformation	[oncogenic transformation]	1.0	2	1	0	0
45576	1624	WY 14643	[WY 14,643]	1.0	2	1	0	0
45577	1624	such as the renal tubule	[such as the renal tubules]	1.0	5	1	0	0
45578	1624	cd68- apc	[CD68- APC]	1.0	2	1	0	0
45579	1624	mtcp1 rearrangement	[MTCP1 rearrangements]	1.0	2	1	0	0
45580	1624	il-1 responsiveness	[IL-1 responsiveness]	1.0	2	1	0	0
45581	1624	gp130 activity	[gp130 activity]	1.0	2	1	0	0
45582	1624	stem cell factor (scf) receptor	[stem cell factor (SCF) receptor]	1.0	5	1	0	0
45583	1624	class II-specific transcription factor RFX	[class II-specific transcription factors RFX]	1.0	5	1	0	0
45584	1624	c-Myc oncoprotein	[c-Myc oncoprotein]	1.0	2	1	0	0
45585	1624	receptor for unidentified c-c chemokine	[receptor for unidentified C-C chemokine]	1.0	5	1	0	0
45586	1624	c3/5 cell	[C3/5 cells]	1.0	2	1	0	0
45587	1624	response to influenza virus antigen	[response to influenza virus antigen]	1.0	5	1	0	0
45588	1624	specific binding of [3H]dexamethasone (p 0.01)	[specific binding of [3H]dexamethasone (P 0.01)]	1.0	6	1	0	0
45589	1624	contain the ifn-stimulated response element	[containing the IFN-stimulated response element]	1.0	5	1	0	0
45590	1624	NF-kappa b induction in vivo	[NF-kappa B induction in vivo]	1.0	5	1	0	0
45591	1624	ala asp	[Ala Asp]	1.0	2	1	0	0
45592	1624	multiple copy of the consensus sequence	[multiple copies of the consensus sequence]	1.0	6	1	0	0
45593	1624	maximal suppression	[maximal suppression]	1.0	2	2	1	1
45594	1624	high level of c-erbB2 amplification	[high levels of c-erbB2 amplification]	1.0	5	1	0	0
45595	1624	4.2 kilobasis of 5'-upstream sequence	[4.2 kilobases of 5'-upstream sequence]	1.0	5	1	0	0
45596	1624	feature of the human disease	[features of the human disease]	1.0	5	1	0	0
45597	1624	multiple alteration	[multiple alterations]	1.0	2	1	0	0
45598	1624	induction of so-called lysis gene	[induction of so-called lysis genes]	1.0	5	1	0	0
45599	1624	lack the x consensus element	[lacking the X consensus element]	1.0	5	1	0	0
45600	1624	normal individual.	[normal individual.]	1.0	2	1	0	0
45601	1624	deletion of all three element	[Deletion of all three elements]	1.0	5	1	0	0
45602	1624	epo il-3	[Epo IL-3]	1.0	2	2	1	1
45603	1624	gamma interferon class transactivator expression	[gamma interferon class transactivator expression]	1.0	5	1	0	0
45604	1624	express dq0302 at acidic pH	[expressing DQ0302 at acidic pH]	1.0	5	1	0	0
45605	1624	docking site for transcription factor	[docking sites for transcription factors]	1.0	5	1	0	0
45606	1624	h-7-sensitive kinase	[H-7-sensitive kinases]	1.0	2	1	0	0
45607	1624	possible marker of brain involution	[possible marker of brain involution]	1.0	5	1	0	0
45608	1624	er overexpression between risk group	[ER overexpression between risk groups]	1.0	5	1	0	0
45609	1624	cell-sorted monocyte	[cell-sorted monocytes]	1.0	2	1	0	0
45610	1624	mucosal inflammation	[mucosal inflammation]	1.0	2	1	0	0
45611	1624	staurosporine a	[staurosporine A]	1.0	2	1	0	0
45612	1624	encode the beta2 integrin cd11b	[encoding the beta2 integrin CD11b]	1.0	5	1	0	0
45613	1624	m D3	[M D3]	1.0	2	2	2	2
45614	1624	activation of factor of T cell	[Activation of factor of T cells]	1.0	6	2	2	2
45615	1624	(both with cognate DNA element	[(both with cognate DNA elements]	1.0	5	1	0	0
45616	1624	However, reintroduction of a 5-lox system	[However, reintroduction of a 5-LOX system]	1.0	6	1	0	0
45617	1624	MKK6 all	[MKK6 all]	1.0	2	1	0	0
45618	1624	RFLAT-1 a zinc finger transcription factor	[RFLAT-1 a zinc finger transcription factor]	1.0	6	1	0	0
45619	1624	crohn' disease	[Crohn's disease]	1.0	2	2	1	1
45620	1624	Reverse transcriptase polymerase chain reaction	[Reverse transcriptase polymerase chain reaction]	1.0	5	1	0	0
45621	1624	contrast to rel T cell	[contrast to Rel T cells]	1.0	5	1	0	0
45622	1624	systemic disease	[systemic diseases]	1.0	2	1	0	0
45623	1624	use electrophoresis mobility shift assay	[using electrophoresis mobility shift assays]	1.0	5	1	0	0
45624	1624	transformation through carboxyl-terminal cytoplasmic tail	[transformation through carboxyl-terminal cytoplasmic tail]	1.0	5	1	0	0
45625	1624	hmg-i binding to most of	[HMG-I binding to most of]	1.0	5	1	0	0
45626	1624	basal [3H]thymidine incorporation in MNL	[Basal [3H]thymidine incorporation in MNL]	1.0	5	1	0	0
45627	1624	c-Myb site	[c-Myb site]	1.0	2	2	2	2
45628	1624	status of x chromosome inactivation	[status of X chromosome inactivation]	1.0	5	1	0	0
45629	1624	scid mouse	[SCID mice]	1.0	2	1	0	0
45630	1624	thromboxane receptor gene promoter/ chloramphenicol acetyltransferase	[thromboxane receptor gene promoter/ chloramphenicol acetyltransferase]	1.0	6	1	0	0
45631	1624	Oct-1 factor	[Oct-1 factors]	1.0	2	2	1	1
45632	1624	cell of the b-cell lineage	[cells of the B-cell lineage]	1.0	5	1	0	0
45633	1624	tfiih of xeroderma pigmentosum group b	[TFIIH of xeroderma pigmentosum group B]	1.0	6	1	0	0
45634	1624	steroid receptor by DNA transfection	[steroid receptors by DNA transfections]	1.0	5	1	0	0
45635	1624	vernal keratoconjunctivitis	[vernal keratoconjunctivitis]	1.0	2	2	2	2
45636	1624	product of the c-fps/fe protooncogene	[product of the c-fps/fes protooncogene]	1.0	5	1	0	0
45637	1624	sequence analysis of cDNA clone	[Sequence analysis of cDNA clones]	1.0	5	2	1	1
45638	1624	addition to the inducible phosphorylation	[addition to the inducible phosphorylation]	1.0	5	1	0	0
45639	1624	transcription of sv40 t-antigen in mouse	[transcription of SV40 T-antigen in mice]	1.0	6	1	0	0
45640	1624	thymus-derived lymphocyte	[thymus-derived lymphocytes]	1.0	2	1	0	0
45641	1624	b cell type oct-2 protein	[B cell type Oct-2 proteins]	1.0	5	1	0	0
45642	1624	active regulatory event in the thyrocyte	[active regulatory events in the thyrocyte]	1.0	6	1	0	0
45643	1624	further fraction	[further fraction]	1.0	2	1	0	0
45644	1624	close proximity to mammalian homologue	[close proximity to mammalian homologues]	1.0	5	1	0	0
45645	1624	chromosomal damage	[chromosomal damage]	1.0	2	1	0	0
45646	1624	Functional analysis of 5' deletion construct	[Functional analysis of 5' deletion constructs]	1.0	6	1	0	0
45647	1624	vital importance during critical illness.	[vital importance during critical illness.]	1.0	5	1	0	0
45648	1624	indicate the presence of nf-e2 complex	[indicating the presence of NF-E2 complex]	1.0	6	1	0	0
45649	1624	novel model	[novel model]	1.0	2	2	2	2
45650	1624	use the pou family primer	[using the POU family primers]	1.0	5	1	0	0
45651	1624	neutrophil of the Jak3 kinase	[neutrophils of the Jak3 kinase]	1.0	5	1	0	0
45652	1624	association between hla class ii antigen	[Associations between HLA class II antigens]	1.0	6	1	0	0
45653	1624	mrna cap	[mRNA cap]	1.0	2	2	1	1
45654	1624	comparative analysis	[Comparative analysis]	1.0	2	2	1	1
45655	1624	inhibition of tnf-alpha secretion by lps	[Inhibition of TNF-alpha secretion by LPS]	1.0	6	1	0	0
45656	1624	contain a mouse p sequence	[containing a mouse P sequence]	1.0	5	1	0	0
45657	1624	bipartite motif	[bipartite motif]	1.0	2	1	0	0
45658	1624	tyrosine phosphorylation of this proteins,	[tyrosine phosphorylation of these proteins,]	1.0	5	1	0	0
45659	1624	same response	[same response]	1.0	2	1	0	0
45660	1624	1,24(oh)2-22-ene-24-cyclopropyl-vitamin D3	[1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3]	1.0	2	1	0	0
45661	1624	stimulation of mouse b cell	[Stimulation of mouse B cells]	1.0	5	1	0	0
45662	1624	sugar with deoxidizing activity, d-ribose	[sugar with deoxidizing activity, D-ribose]	1.0	5	1	0	0
45663	1624	(0.2 microM),	[(0.2 microM),]	1.0	2	1	0	0
45664	1624	glucocorticoid resistance in major disorder	[glucocorticoid resistance in major disorder]	1.0	5	2	2	2
45665	1624	indicate derivation from gc b cell	[indicating derivation from GC B cells]	1.0	6	1	0	0
45666	1624	co-transfection of the wild-type promoter construct	[co-transfections of the wild-type promoter construct]	1.0	6	1	0	0
45667	1624	granulocyte-macrophage colony-stimumulatelany-stg factor mrna level	[granulocyte-macrophage colony-stimulating factor mRNA levels]	1.0	5	1	0	0
45668	1624	dimeric complex activator protein-1 ap-1	[dimeric complex activator protein-1 AP-1]	1.0	5	1	0	0
45669	1624	contrast, ligand activation of c-Kit	[contrast, ligand activation of c-Kit]	1.0	5	1	0	0
45670	1624	negative-act segment	[negative-acting segment]	1.0	2	1	0	0
45671	1624	use human cd4+ T cell	[using human CD4+ T cells]	1.0	5	1	0	0
45672	1624	even in a B-cell line	[even in a B-cell line]	1.0	5	1	0	0
45673	1624	fas death	[Fas death]	1.0	2	2	1	1
45674	1624	proximal step in cd8+ t-cell activation	[proximal steps in CD8+ T-cell activation]	1.0	6	1	0	0
45675	1624	class cell	[class cells]	1.0	2	2	2	2
45676	1624	identification in the transcriptional initiation site	[Identification in the transcriptional initiation site]	1.0	6	1	0	0
45677	1624	Nuclear factor of t-cell NFAT-1	[Nuclear factor of T-cells NFAT-1]	1.0	5	1	0	0
45678	1624	induction of nuclear nf-kb binding protein	[induction of nuclear NF-kB binding proteins]	1.0	6	1	0	0
45679	1624	increase in concentration of blood substrate	[increases in concentrations of blood substrates]	1.0	6	1	0	0
45680	1624	b-cell lymphoma	[B-cell lymphomas]	1.0	2	2	2	2
45681	1624	progesterone suppression of pregnancy lymphocyte	[Progesterone suppression of pregnancy lymphocytes]	1.0	5	1	0	0
45682	1624	pou family	[POU families]	1.0	2	1	0	0
45683	1624	five responder	[five responders]	1.0	2	1	0	0
45684	1624	addition to sp100 homology region	[addition to SP100 homology regions]	1.0	5	1	0	0
45685	1624	a and/or protein kinase C	[A and/or protein kinase C]	1.0	5	1	0	0
45686	1624	viral binding	[viral binding]	1.0	2	1	0	0
45687	1624	relative bind affinity of Oct-1	[relative binding affinity of Oct-1]	1.0	5	1	0	0
45688	1624	c-myb in myelomonocytic lineage-specific expression	[c-Myb in myelomonocytic lineage-specific expression]	1.0	5	1	0	0
45689	1624	two general transcriptional activator RelA	[two general transcriptional activators RelA]	1.0	5	1	0	0
45690	1624	nf-kappa b activity by cysteine derivative	[NF-kappa B activity by cysteine derivatives]	1.0	6	1	0	0
45691	1624	CD2 lpmc	[CD2 LPMC]	1.0	2	2	1	1
45692	1624	transcription of the hiv-1 genome	[transcription of the HIV-1 genome]	1.0	5	1	0	0
45693	1624	postanoxic huvec to human neutrophil	[postanoxic HUVECs to human neutrophils]	1.0	5	1	0	0
45694	1624	OAP40 complex	[OAP40 complex]	1.0	2	1	0	0
45695	1624	B2 factor	[B2 factor]	1.0	2	1	0	0
45696	1624	abundance of a dna-protein complex	[abundance of a DNA-protein complex]	1.0	5	1	0	0
45697	1624	simultaneously induce stat3 tyrosine phosphorylation	[simultaneously inducing STAT3 tyrosine phosphorylation]	1.0	5	1	0	0
45698	1624	cross-competition electrophoretic mobility shift assay	[cross-competition electrophoretic mobility shift assays]	1.0	5	1	0	0
45699	1624	vitamin D-dependent ricket type ii	[vitamin D-dependent rickets type II]	1.0	5	1	0	0
45700	1624	only in the cytoplasm of lymphocyte	[only in the cytoplasm of lymphocytes]	1.0	6	1	0	0
45701	1624	serum-contain mediuhd small adherent colony	[serum-containing medium, small adherent colonies]	1.0	5	1	0	0
45702	1624	three type	[three types]	1.0	2	2	2	2
45703	1624	analysis of Gal4-Elf-1 fusion protein	[Analysis of Gal4-Elf-1 fusion proteins]	1.0	5	1	0	0
45704	1624	mutation of a 20-base pair sequence	[Mutation of a 20-base pair sequence]	1.0	6	1	0	0
45705	1624	Pan protein in gh/prl- produce	[Pan proteins in GH/PRL- producing]	1.0	5	1	0	0
45706	1624	t-cell receptor gene in s194 cell	[T-cell receptor genes in S194 cells]	1.0	6	1	0	0
45707	1624	suggest responsible for the inhibition.	[suggesting responsible for the inhibition.]	1.0	5	1	0	0
45708	1624	cell toxicity	[cell toxicity]	1.0	2	1	0	0
45709	1624	control the expression of class molecule	[controlling the expression of class molecules]	1.0	6	1	0	0
45710	1624	Ca2+/calmodulin-dependent protein kinase iv camkiv	[Ca2+/calmodulin-dependent protein kinase IV CaMKIV]	1.0	5	1	0	0
45711	1624	aldosterone specificity)	[aldosterone specificity)]	1.0	2	1	0	0
45712	1624	two pathways.	[two pathways.]	1.0	2	1	0	0
45713	1624	human genomic DNA sequence upstream	[human genomic DNA sequence upstream]	1.0	5	1	0	0
45714	1624	mitogenic T	[mitogenic T]	1.0	2	1	0	0
45715	1624	regard the class of transcription factor	[regarding the class of transcription factors]	1.0	6	1	0	0
45716	1624	regulation of the alpha2 integrin gene	[regulation of the alpha2 integrin gene]	1.0	6	1	0	0
45717	1624	disease susceptibility,	[disease susceptibility,]	1.0	2	1	0	0
45718	1624	cell line of b origin	[cell lines of B origin]	1.0	5	1	0	0
45719	1624	mouse perforin	[mouse perforin]	1.0	2	2	2	2
45720	1624	activator protein 1 ap-1 dna-binding activity	[activator protein 1 AP-1 DNA-binding activity]	1.0	6	1	0	0
45721	1624	t-cell dysfunction	[T-cell dysfunction]	1.0	2	2	1	1
45722	1624	BAT box	[BAT box]	1.0	2	1	0	0
45723	1624	common target for cellular protein	[common target for cellular proteins]	1.0	5	1	0	0
45724	1624	level of ongoing hiv-1 replication	[level of ongoing HIV-1 replication]	1.0	5	1	0	0
45725	1624	viral coreceptor	[viral coreceptors]	1.0	2	1	0	0
45726	1624	biologic action of this drugs.	[biologic actions of these drugs.]	1.0	5	1	0	0
45727	1624	linkage analysis of cDNA library	[linkage analysis of cDNA libraries]	1.0	5	1	0	0
45728	1624	integrin-mediated adhesion	[integrin-mediated adhesion]	1.0	2	1	0	0
45729	1624	neutrophil gelatinase-associated lipocalin from human	[neutrophil gelatinase-associated lipocalin from humans]	1.0	5	1	0	0
45730	1624	other virus	[other viruses]	1.0	2	2	1	1
45731	1624	synthase ino	[synthase iNOS]	1.0	2	1	0	0
45732	1624	possible marker	[possible marker]	1.0	2	2	2	2
45733	1624	genetic disorder	[genetic disorder]	1.0	2	2	1	1
45734	1624	x protein	[X protein]	1.0	2	2	1	1
45735	1624	nfat site	[NFAT sites]	1.0	2	2	1	1
45736	1624	two enhancer	[two enhancers]	1.0	2	2	1	1
45737	1624	neoplastic progression of e1a-immortalized cell	[neoplastic progression of E1A-immortalized cells]	1.0	5	1	0	0
45738	1624	identical experiment	[identical experiments]	1.0	2	1	0	0
45739	1624	hiv/siv genome	[HIV/SIV genome]	1.0	2	1	0	0
45740	1624	46,xx karyotype	[46,XX karyotypes]	1.0	2	1	0	0
45741	1624	cell res.	[Cell Res.]	1.0	2	1	0	0
45742	1624	stimulation with mycoplasma-derived material mdhm	[stimulation with mycoplasma-derived material MDHM]	1.0	5	1	0	0
45743	1624	milliliter concentration	[milliliter concentrations]	1.0	2	1	0	0
45744	1624	signal integration of tcr /cd28 costimulation	[signal integration of TCR /CD28 costimulation]	1.0	6	1	0	0
45745	1624	prl IL-2	[PRL IL-2]	1.0	2	1	0	0
45746	1624	CIITA occupation of MHC class promoter	[CIITA occupation of MHC class promoters]	1.0	6	1	0	0
45747	1624	element necessary	[element necessary]	1.0	2	2	2	2
45748	1624	vitamin d treatment in XLH	[vitamin D treatment in XLH]	1.0	5	1	0	0
45749	1624	ethidium bromide	[ethidium bromide]	1.0	2	1	0	0
45750	1624	42 different zinc finger protein	[42 different zinc finger proteins]	1.0	5	1	0	0
45751	1624	htlv-1 pathogenesis	[HTLV-1 pathogenesis]	1.0	2	1	0	0
45752	1624	T cell from elderly subject	[T cells from elderly subjects]	1.0	5	2	2	2
45753	1624	such as tyrosine phosphorylation of shc	[such as tyrosine phosphorylation of Shc]	1.0	6	1	0	0
45754	1624	liquid nitrogen	[liquid nitrogen]	1.0	2	1	0	0
45755	1624	wild-type littermate	[Wild-type littermates]	1.0	2	1	0	0
45756	1624	ttg act on the prb protein	[tTG acting on the pRB protein]	1.0	6	1	0	0
45757	1624	note, enhancement	[note, enhancement]	1.0	2	1	0	0
45758	1624	sequence contiguous to the region	[sequences contiguous to the regions]	1.0	5	1	0	0
45759	1624	human peripheral blood mononuclear precursor	[human peripheral blood mononuclear precursors]	1.0	5	1	0	0
45760	1624	normal receptor	[normal receptor]	1.0	2	1	0	0
45761	1624	differentiation-inducing therapy of hematopoietic tumor	[differentiation-inducing therapy of hematopoietic tumors]	1.0	5	1	0	0
45762	1624	kb upstream	[kb upstream]	1.0	2	2	2	2
45763	1624	new isotype.	[new isotype.]	1.0	2	1	0	0
45764	1624	183-bp region	[183-bp region]	1.0	2	1	0	0
45765	1624	range from 85 to 45 kda	[ranging from 85 to 45 kDa]	1.0	6	1	0	0
45766	1624	macrophage protein-2	[macrophage protein-2]	1.0	2	2	2	2
45767	1624	adhesion molecule include integrin alpha	[adhesion molecules including integrin alpha]	1.0	5	1	0	0
45768	1624	superoxide release	[Superoxide release]	1.0	2	1	0	0
45769	1624	apc protein	[APC protein]	1.0	2	1	0	0
45770	1624	large part	[large part]	1.0	2	3	2	1
45771	1624	interaction with a e box	[interaction with an E box]	1.0	5	1	0	0
45772	1624	nasal epithelium	[nasal epithelium]	1.0	2	1	0	0
45773	1624	activation of CD4 positive T cell	[Activation of CD4 positive T cells]	1.0	6	1	0	0
45774	1624	tcf-1 activity	[TCF-1 activity]	1.0	2	1	0	0
45775	1624	limited proliferation,	[limited proliferation,]	1.0	2	1	0	0
45776	1624	deletion construct of the pcd41 clone	[Deletion constructs of the pCD41 clone]	1.0	6	1	0	0
45777	1624	GCR binding affinity for budesonide	[GCR binding affinity for budesonide]	1.0	5	1	0	0
45778	1624	observation, together with the fact	[observation, together with the fact]	1.0	5	1	0	0
45779	1624	-110 bp	[-110 bp]	1.0	2	1	0	0
45780	1624	gene transcription in this lineage	[gene transcription in these lineages]	1.0	5	1	0	0
45781	1624	murine retroviruse in T lymphocyte	[murine retroviruses in T lymphocytes]	1.0	5	1	0	0
45782	1624	p95vav activity	[p95vav activity]	1.0	2	1	0	0
45783	1624	site related	[site related]	1.0	2	1	0	0
45784	1624	undesirable overexpression	[undesirable overexpression]	1.0	2	1	0	0
45785	1624	generation of a kD molecule	[generation of a kD molecule]	1.0	5	1	0	0
45786	1624	Genomic organization	[Genomic organization]	1.0	2	1	0	0
45787	1624	sea stimulation	[SEA stimulation]	1.0	2	1	0	0
45788	1624	6.41 p	[6.41, P]	1.0	2	1	0	0
45789	1624	first step in the study	[first step in the study]	1.0	5	1	0	0
45790	1624	48-hr t-cell	[48-hr T-cells]	1.0	2	1	0	0
45791	1624	transcription by binding of NF-E1	[transcription by binding of NF-E1]	1.0	5	1	0	0
45792	1624	cotransfection experiments,	[cotransfection experiments,]	1.0	2	1	0	0
45793	1624	phorbol ester/IL-2,	[phorbol ester/IL-2,]	1.0	2	1	0	0
45794	1624	Epstein-Barr virus EBV bmrf1 promoter	[Epstein-Barr virus EBV BMRF1 promoter]	1.0	5	1	0	0
45795	1624	exclusively, nfatp	[exclusively, NFATp]	1.0	2	1	0	0
45796	1624	relative abundance	[relative abundance]	1.0	2	1	0	0
45797	1624	DC characteristic	[DC characteristics]	1.0	2	2	2	2
45798	1624	significant number	[significant number]	1.0	2	2	1	1
45799	1624	analysis of cell line Daudi	[Analysis of cell lines Daudi]	1.0	5	1	0	0
45800	1624	similar finding	[Similar findings]	1.0	2	1	0	0
45801	1624	one major minor transcription start site	[One major minor transcription start site]	1.0	6	1	0	0
45802	1624	induce apoptosis in human t-lymphoblastoid cell	[inducing apoptosis in human T-lymphoblastoid cells]	1.0	6	1	0	0
45803	1624	certain oxidant	[certain oxidants]	1.0	2	1	0	0
45804	1624	IkappaB kinase	[IkappaB kinase]	1.0	2	2	2	2
45805	1624	elf-1 expression	[Elf-1 expression]	1.0	2	1	0	0
45806	1624	promoter domain of the LTR	[promoter domain of the LTR]	1.0	5	1	0	0
45807	1624	five dnase I hypersensitive site 5'hs1-5	[five DNase I hypersensitive sites 5'HS1-5]	1.0	6	1	0	0
45808	1624	hyporesponsiveness of the ino promoter	[hyporesponsiveness of the iNOS promoter]	1.0	5	1	0	0
45809	1624	dysregulation of rara by gene fusion	[dysregulation of RARA by gene fusion]	1.0	6	1	0	0
45810	1624	almost complete elimination of suppression	[almost complete elimination of suppression]	1.0	5	1	0	0
45811	1624	cytosolic extract of mammalian cell	[cytosolic extracts of mammalian cells]	1.0	5	1	0	0
45812	1624	rat prolactin	[rat prolactin]	1.0	2	1	0	0
45813	1624	HIV1 infection of human monocyte	[HIV1 infection of human monocytes]	1.0	5	1	0	0
45814	1624	structure-function analysis	[structure-function analysis]	1.0	2	1	0	0
45815	1624	3-methylcholanthrene a ligand of ahr	[3-methylcholanthrene a ligand of AhR]	1.0	5	1	0	0
45816	1624	killing by cd8(+) cytotoxic T lymphocyte	[killing by CD8(+) cytotoxic T lymphocytes]	1.0	6	1	0	0
45817	1624	one possible explanation for mechanism-based toxicity	[one possible explanation for mechanism-based toxicities]	1.0	6	1	0	0
45818	1624	analysis of gr chimeric receptor	[Analysis of GR chimeric receptors]	1.0	5	1	0	0
45819	1624	Lipopolysaccharide induction	[Lipopolysaccharide induction]	1.0	2	1	0	0
45820	1624	ppargamma activator	[PPARgamma activators]	1.0	2	1	0	0
45821	1624	squamous cell carcinoma in sample	[squamous cell carcinomas in samples]	1.0	5	1	0	0
45822	1624	hl60 cell with various combination	[HL60 cells with various combinations]	1.0	5	1	0	0
45823	1624	Active metabolite of vitamin D3	[Active metabolite of vitamin D3]	1.0	5	1	0	0
45824	1624	hiv-1 gp41 il-10 up-regulation in monocyte	[HIV-1 gp41 IL-10 up-regulation in monocytes]	1.0	6	1	0	0
45825	1624	replication of some mutant virus	[replication of some mutant viruses]	1.0	5	1	0	0
45826	1624	other t-helper cell cytokine IL-2	[other T-helper cell cytokines IL-2]	1.0	5	1	0	0
45827	1624	heme-responsive factor	[heme-responsive factor]	1.0	2	1	0	0
45828	1624	differentiation, survival, of unit-granulocyte-macrophage progenitor cell	[differentiation, survival, of unit-granulocyte-macrophage progenitor cells]	1.0	6	1	0	0
45829	1624	antihuman tnf-alpha	[antihuman TNF-alpha]	1.0	2	1	0	0
45830	1624	culture conditions,	[culture conditions,]	1.0	2	2	2	2
45831	1624	40 kilometer tax1 antigen molecule	[40 kd tax1 antigen molecules]	1.0	5	1	0	0
45832	1624	RXR -specific	[RXR -specific]	1.0	2	1	0	0
45833	1624	contain the hiv-1 nf-kb probe	[containing the HIV-1 NF-kB probe]	1.0	5	1	0	0
45834	1624	major obstacle design a vector	[major obstacle designing a vector]	1.0	5	1	0	0
45835	1624	alteration of the TATA box	[alteration of the TATA box]	1.0	5	1	0	0
45836	1624	binding of RBP to this site	[Binding of RBP to this site]	1.0	6	1	0	0
45837	1624	GPIX promoter	[GPIX promoter]	1.0	2	2	1	1
45838	1624	expression of c/ebp epsilon mrna	[expression of C/EBP epsilon mRNA]	1.0	5	1	0	0
45839	1624	different stimuli.	[different stimuli.]	1.0	2	1	0	0
45840	1624	5-lipoxygenase 5-lox	[5-lipoxygenase 5-LOX]	1.0	2	1	0	0
45841	1624	different stimuli,	[different stimuli,]	1.0	2	2	1	1
45842	1624	tandem CRE	[tandem CRE]	1.0	2	1	0	0
45843	1624	resting pbl-t	[resting PBL-T]	1.0	2	1	0	0
45844	1624	cell-type-specific suppression	[cell-type-specific suppression]	1.0	2	1	0	0
45845	1624	human peripheral monocyte nuclear extract	[human peripheral monocyte nuclear extracts]	1.0	5	1	0	0
45846	1624	absence of dna-protein binding formation	[absence of DNA-protein binding formation]	1.0	5	1	0	0
45847	1624	adult tonsil	[adult tonsil]	1.0	2	1	0	0
45848	1624	chromatin structure lead to accessibility	[chromatin structure leading to accessibility]	1.0	5	1	0	0
45849	1624	bandshift experiment	[Bandshift experiments]	1.0	2	1	0	0
45850	1624	pml/raralpha expression	[PML/RARalpha expression]	1.0	2	2	2	2
45851	1624	T lymphocyte in the adult.	[T lymphocytes in the adult.]	1.0	5	1	0	0
45852	1624	activate caspase	[activating caspases]	1.0	2	1	0	0
45853	1624	early increase of junb protein	[early increase of JunB protein]	1.0	5	1	0	0
45854	1624	tumor-derived soluble product from RCC explant	[Tumor-derived soluble products from RCC explants]	1.0	6	1	0	0
45855	1624	sequence 5'-ggaacctccccc-3'	[sequence 5'-GGAACCTCCCCC-3']	1.0	2	1	0	0
45856	1624	endotoxin lps signal transduction in monocyte	[Endotoxin LPS signal transduction in monocytes]	1.0	6	1	0	0
45857	1624	chimeric type	[chimeric type]	1.0	2	1	0	0
45858	1624	2 lesion	[2 lesions]	1.0	2	1	0	0
45859	1624	low temperature (26 degree c)	[low temperature (26 degrees C)]	1.0	5	1	0	0
45860	1624	second motif	[second motif]	1.0	2	1	0	0
45861	1624	ability of the glucocorticoid receptor	[ability of the glucocorticoid receptor]	1.0	5	1	0	0
45862	1624	proliferation of human T lymphocyte	[proliferation of human T lymphocytes]	1.0	5	1	0	0
45863	1624	minimal promoter (-62 to +54)	[minimal promoter (-62 to +54)]	1.0	5	1	0	0
45864	1624	isolation of gelatinase granule from neutrophil	[Isolation of gelatinase granules from neutrophils]	1.0	6	1	0	0
45865	1624	mature human monocyte-derived m phi	[maturing human monocyte-derived M phi]	1.0	5	1	0	0
45866	1624	surface charge	[surface charge]	1.0	2	1	0	0
45867	1624	fibrinogen (10-100	[fibrinogen (10-100]	1.0	2	1	0	0
45868	1624	tar loop	[TAR loop]	1.0	2	2	1	1
45869	1624	follow trigger of hla-dr antigen	[following triggering of HLA-DR antigens]	1.0	5	1	0	0
45870	1624	M22 mutant	[M22 mutant]	1.0	2	1	0	0
45871	1624	cd69 antigen	[CD69 antigen]	1.0	2	1	0	0
45872	1624	induction of nf-kappab -dependent gene expression	[Induction of NF-kappaB -dependent gene expression]	1.0	6	1	0	0
45873	1624	transcriptional repressor activity of Eed	[transcriptional repressor activity of Eed]	1.0	5	1	0	0
45874	1624	control of the MRP14 promoter	[control of the MRP14 promoter]	1.0	5	1	0	0
45875	1624	IL-4 cell	[IL-4 cells]	1.0	2	1	0	0
45876	1624	parallel, upregulation	[parallel, upregulation]	1.0	2	1	0	0
45877	1624	HS2 sequence	[HS2 sequence]	1.0	2	1	0	0
45878	1624	production of hiv-1 from cell	[Production of HIV-1 from cells]	1.0	5	1	0	0
45879	1624	Stat3 antibody	[Stat3 antibody]	1.0	2	2	2	2
45880	1624	5 case	[5 cases]	1.0	2	1	0	0
45881	1624	expression of s phase gene	[expression of S phase genes]	1.0	5	1	0	0
45882	1624	adolescent MDD	[adolescent MDD]	1.0	2	1	0	0
45883	1624	clinical benefit	[clinical benefit]	1.0	2	2	2	2
45884	1624	display s phase DNA binding activity	[displaying S phase DNA binding activity]	1.0	6	1	0	0
45885	1624	nature of the nuclear factor	[nature of the nuclear factors]	1.0	5	1	0	0
45886	1624	mutation of the genuine octamer-binding site	[Mutations of the genuine octamer-binding site]	1.0	6	1	0	0
45887	1624	promoter region span base pair	[promoter region spanning base pairs]	1.0	5	1	0	0
45888	1624	lymphoblastoid t-cell-line-expressing wild-type CD4 receptor	[lymphoblastoid T-cell-line-expressing wild-type CD4 receptors]	1.0	5	1	0	0
45889	1624	allo drug	[allo drug]	1.0	2	1	0	0
45890	1624	transcription 6 stat6 tyrosine phosphorylation	[transcription 6 STAT6 tyrosine phosphorylation]	1.0	5	1	0	0
45891	1624	Furthermore, deletion	[Furthermore, deletion]	1.0	2	1	0	0
45892	1624	activation signal in b cell	[activation signals in B cells]	1.0	5	1	0	0
45893	1624	assembly of order nucleoprotein complex	[assembly of order nucleoprotein complexes]	1.0	5	1	0	0
45894	1624	wild-type reversion	[wild-type reversion]	1.0	2	1	0	0
45895	1624	transcription factor control the expression	[transcription factor controlling the expression]	1.0	5	1	0	0
45896	1624	pro-oxidative condition	[pro-oxidative conditions]	1.0	2	1	0	0
45897	1624	MCR /EIC	[MCR /EIC]	1.0	2	1	0	0
45898	1624	T cell transcription factor nf-at	[T cells transcription factor NF-AT]	1.0	5	1	0	0
45899	1624	thp-1 cell with hiv expression	[THP-1 cells with HIV expression]	1.0	5	1	0	0
45900	1624	zidovudine AZT	[zidovudine AZT]	1.0	2	1	0	0
45901	1624	translocation involve the human CBFA2 locus	[Translocations involving the human CBFA2 locus]	1.0	6	1	0	0
45902	1624	Bacterial peptidoglycan	[Bacterial peptidoglycan]	1.0	2	1	0	0
45903	1624	RB status of a series	[RB status of a series]	1.0	5	1	0	0
45904	1624	105k precursor	[105K precursor]	1.0	2	2	2	2
45905	1624	polypryrimidine-binding factor	[polypryrimidine-binding factor]	1.0	2	1	0	0
45906	1624	such event	[such events]	1.0	2	1	0	0
45907	1624	use of glucocorticoid in leukemia	[use of glucocorticoids in leukemia]	1.0	5	1	0	0
45908	1624	ionize radiation in the dose range	[ionizing radiation in the dose range]	1.0	6	1	0	0
45909	1624	binding activity of the transcription factor	[binding activity of the transcription factor]	1.0	6	1	0	0
45910	1624	50 mcr in woman young	[50, MCR in women younger]	1.0	5	1	0	0
45911	1624	myeloid leukemogenesis	[myeloid leukemogenesis]	1.0	2	1	0	0
45912	1624	regulatory sequence important for promoter activity,	[regulatory sequences important for promoter activity,]	1.0	6	1	0	0
45913	1624	IkappaB-alpha transfer	[IkappaB-alpha transfer]	1.0	2	1	0	0
45914	1624	CD28 change	[CD28 changes]	1.0	2	1	0	0
45915	1624	T cell line in group	[T cell lines in groups]	1.0	5	1	0	0
45916	1624	number of receptor per cell	[number of receptors per cell]	1.0	5	2	2	2
45917	1624	immunosuppressive effect of SR 31747a	[immunosuppressive effect of SR 31747A]	1.0	5	1	0	0
45918	1624	encode the 105-kDa protein p105 precursor	[encoding the 105-kDa protein p105 precursor]	1.0	6	1	0	0
45919	1624	ng/ml)-mediated proliferation	[ng/mL)-mediated proliferation]	1.0	2	1	0	0
45920	1624	protein lsp1	[protein LSP1]	1.0	2	2	2	2
45921	1624	crh regulation	[CRH regulation]	1.0	2	1	0	0
45922	1624	major form	[major form]	1.0	2	1	0	0
45923	1624	well-standardized criteria, extremely unbalanced inactivation	[well-standardized criteria, extremely unbalanced inactivation]	1.0	5	1	0	0
45924	1624	serum transaminase	[serum transaminase]	1.0	2	1	0	0
45925	1624	nonphlogistic phagocytosis of apoptotic leukocyte	[nonphlogistic phagocytosis of apoptotic leukocytes]	1.0	5	1	0	0
45926	1624	periductal angiogenesis	[Periductal angiogenesis]	1.0	2	1	0	0
45927	1624	km-h2 cell	[KM-H2 cells]	1.0	2	1	0	0
45928	1624	androgen receptor in peripheral mononuclear leukocyte	[androgen receptors in peripheral mononuclear leukocytes]	1.0	6	1	0	0
45929	1624	tumor necrosis factor receptor tnfr	[tumor necrosis factor receptor TNFR]	1.0	5	1	0	0
45930	1624	dominant c-fo	[dominant c-Fos]	1.0	2	2	1	1
45931	1624	transcriptional activity of this factor	[transcriptional activities of these factors]	1.0	5	1	0	0
45932	1624	however, inhibition of protein synthesis	[However, inhibition of protein synthesis]	1.0	5	1	0	0
45933	1624	ab blocking	[Ab blocking]	1.0	2	1	0	0
45934	1624	molecular pathway	[molecular pathways]	1.0	2	2	2	2
45935	1624	suggest activation in the lining,	[suggesting activation in the lining,]	1.0	5	1	0	0
45936	1624	nongenomic effects.	[nongenomic effects.]	1.0	2	1	0	0
45937	1624	molecular study	[molecular studies]	1.0	2	1	0	0
45938	1624	valine substitution at amino acid	[valine substitution at amino acid]	1.0	5	2	1	1
45939	1624	leukocyte recruitment	[leukocyte recruitment]	1.0	2	2	1	1
45940	1624	chromosome breakpoint in human leukemia	[chromosome breakpoints in human leukemias]	1.0	5	1	0	0
45941	1624	leukemic cell line CEM c7	[leukemic cell lines CEM C7]	1.0	5	1	0	0
45942	1624	acceleration of the cytopathic effects.	[acceleration of the cytopathic effects.]	1.0	5	1	0	0
45943	1624	lymphoid system	[lymphoid system]	1.0	2	2	1	1
45944	1624	Bcl-2 phosphorylation	[Bcl-2 phosphorylation]	1.0	2	1	0	0
45945	1624	specific antibodies	[specific antibodies,]	1.0	2	1	0	0
45946	1624	signal lead to the activation	[Signals leading to the activation]	1.0	5	1	0	0
45947	1624	murine nfatp	[murine NFATp]	1.0	2	1	0	0
45948	1624	accelerate the rate and/or extent	[accelerating the rate and/or extent]	1.0	5	1	0	0
45949	1624	functional immunity	[functional immunity]	1.0	2	1	0	0
45950	1624	lobular sample	[Lobular samples]	1.0	2	1	0	0
45951	1624	distinct cytokine	[distinct cytokines]	1.0	2	1	0	0
45952	1624	activation of two enzyme participate	[activation of two enzymes participating]	1.0	5	1	0	0
45953	1624	Stepwise deletion into the proximal promoter	[Stepwise deletions into the proximal promoter]	1.0	6	1	0	0
45954	1624	synthesize this cytokine in the light	[synthesizing this cytokine in the light]	1.0	6	1	0	0
45955	1624	expression of gene encode cytokine	[expression of genes encoding cytokines]	1.0	5	2	1	1
45956	1624	human T helper cell mrna	[human T helper cell mRNA]	1.0	5	1	0	0
45957	1624	proto-oncogene c-rel	[proto-oncogene c-rel]	1.0	2	2	1	1
45958	1624	different subtype	[different subtypes]	1.0	2	2	2	2
45959	1624	molecular cloning	[molecular cloning]	1.0	2	7	6	1
45960	1624	alpha 1	[alpha 1]	1.0	2	1	0	0
45961	1624	NF-kappaB in MNC nuclear extract	[NF-kappaB in MNC nuclear extracts]	1.0	5	1	0	0
45962	1624	level of membrane-associated pkc activity	[levels of membrane-associated PKC activity]	1.0	5	1	0	0
45963	1624	alpha A	[alpha A]	1.0	2	1	0	0
45964	1624	gene KOX	[genes KOX]	1.0	2	1	0	0
45965	1624	human immunodeficiency virus infection (5/24)	[human immunodeficiency virus infection (5/24)]	1.0	5	1	0	0
45966	1624	stimulus PMA	[stimuli PMA]	1.0	2	1	0	0
45967	1624	several signal	[several signals]	1.0	2	1	0	0
45968	1624	animal 20	[animals 20]	1.0	2	2	1	1
45969	1624	NFAT-1 activity	[NFAT-1 activity]	1.0	2	2	1	1
45970	1624	Culture supernatant from uninduced U937 cell	[Culture supernatants from uninduced U937 cells]	1.0	6	1	0	0
45971	1624	ifn-gamma activity	[IFN-gamma activity]	1.0	2	2	2	2
45972	1624	inhibit mature c epsilon transcription	[inhibiting mature C epsilon transcription]	1.0	5	1	0	0
45973	1624	accessory molecule	[Accessory molecules]	1.0	2	1	0	0
45974	1624	Antioxidant molecule	[Antioxidant molecules]	1.0	2	1	0	0
45975	1624	latent cytoplasmic precursor isgf3 alpha	[latent cytoplasmic precursors ISGF3 alpha]	1.0	5	1	0	0
45976	1624	blood leukocyte to soluble activator	[blood leukocytes to soluble activators]	1.0	5	1	0	0
45977	1624	three agent	[Three agents]	1.0	2	2	1	1
45978	1624	positive activity	[positive activity]	1.0	2	2	1	1
45979	1624	H9 cell	[H9 cells]	1.0	2	1	0	0
45980	1624	Likewise, activation of this reporter	[Likewise, activation of this reporter]	1.0	5	1	0	0
45981	1624	g1 arrest,	[G1 arrest,]	1.0	2	1	0	0
45982	1624	effect of tcdd on expression	[effect of TCDD on expression]	1.0	5	1	0	0
45983	1624	two family of transcription factor	[Two families of transcription factors]	1.0	5	2	1	1
45984	1624	uninduced hepatocyte	[uninduced hepatocytes]	1.0	2	1	0	0
45985	1624	important constituent	[important constituent]	1.0	2	1	0	0
45986	1624	specific pattern of viral latency	[specific pattern of viral latency]	1.0	5	1	0	0
45987	1624	ca(2+)-mobilize agents,	[Ca(2+)-mobilizing agents,]	1.0	2	1	0	0
45988	1624	occur upon activation of PKC subfamily	[occurring upon activation of PKC subfamilies]	1.0	6	1	0	0
45989	1624	various kind of human cell	[various kinds of human cells]	1.0	5	1	0	0
45990	1624	nuclear translocalization	[nuclear translocalization]	1.0	2	1	0	0
45991	1624	specifically the failure of p65 translocation	[specifically the failure of p65 translocation]	1.0	6	1	0	0
45992	1624	finding in alpha- herpesvirus system	[findings in alpha- herpesvirus systems]	1.0	5	1	0	0
45993	1624	glutathione precursor	[glutathione precursor]	1.0	2	1	0	0
45994	1624	cell-cycle regulation	[cell-cycle regulation]	1.0	2	1	0	0
45995	1624	low-stringency condition	[low-stringency conditions]	1.0	2	1	0	0
45996	1624	putative protein	[putative protein]	1.0	2	1	0	0
45997	1624	84-kda protein	[84-kDa protein]	1.0	2	1	0	0
45998	1624	21 channels,	[21 channels,]	1.0	2	1	0	0
45999	1624	Interphase fluorescence	[Interphase fluorescence]	1.0	2	1	0	0
46000	1624	natural DNA	[natural DNA]	1.0	2	1	0	0
46001	1624	down-regulation of the glucocorticoid receptor	[down-regulation of the glucocorticoid receptor]	1.0	5	2	1	1
46002	1624	membrane alteration	[membrane alterations]	1.0	2	1	0	0
46003	1624	various cells, in cell culture	[various cells, in cell culture]	1.0	5	1	0	0
46004	1624	social support,	[social support,]	1.0	2	1	0	0
46005	1624	lineage switch in hematopoietic development	[lineage switching in hematopoietic development]	1.0	5	1	0	0
46006	1624	use vcam-1 promoter reporter gene construct	[using VCAM-1 promoter reporter gene constructs]	1.0	6	1	0	0
46007	1624	use mouse	[using mice]	1.0	2	2	2	2
46008	1624	Rac-1 function	[Rac-1 function]	1.0	2	1	0	0
46009	1624	induction mechanism of saa gene	[induction mechanism of SAA gene]	1.0	5	1	0	0
46010	1624	viral dutpase	[viral dUTPase]	1.0	2	1	0	0
46011	1624	il-1 activation of sap kinase	[IL-1 activation of SAP kinases]	1.0	5	1	0	0
46012	1624	nuclear factor of T cell NF-MATp35	[nuclear factor of T cells NF-MATp35]	1.0	6	1	0	0
46013	1624	macrophage chemotactic protein-1 another member	[macrophage chemotactic protein-1 another member]	1.0	5	1	0	0
46014	1624	human adult globin (hbb) promoter	[human adult globin (HBB) promoter]	1.0	5	1	0	0
46015	1624	key protein of b cell	[key protein of B cells]	1.0	5	1	0	0
46016	1624	Nuclear factor of T cells-family protein	[Nuclear factor of T cells-family proteins]	1.0	6	1	0	0
46017	1624	mammalian species	[mammalian species]	1.0	2	1	0	0
46018	1624	hiv-1 latency	[HIV-1 latency]	1.0	2	2	2	2
46019	1624	primary melanoma	[primary melanomas]	1.0	2	2	2	2
46020	1624	Exclusive paternal expression of WT1	[Exclusive paternal expression of WT1]	1.0	5	1	0	0
46021	1624	member of the SOCS/CIS/SSI family	[Members of the SOCS/CIS/SSI family]	1.0	5	1	0	0
46022	1624	different feature	[different features]	1.0	2	1	0	0
46023	1624	target effector	[target effectors]	1.0	2	1	0	0
46024	1624	8, p	[8, P]	1.0	2	1	0	0
46025	1624	proapoptotic function	[proapoptotic functions]	1.0	2	1	0	0
46026	1624	enhance activity by the corticosteroid	[enhancing activity by the corticosteroids]	1.0	5	1	0	0
46027	1624	prevent nuclear translocation of NF-kappaB complex	[preventing nuclear translocation of NF-kappaB complexes]	1.0	6	1	0	0
46028	1624	murine cell	[murine cells]	1.0	2	2	1	1
46029	1624	52 kD	[52 kD]	1.0	2	1	0	0
46030	1624	multiple complex	[multiple complexes]	1.0	2	2	1	1
46031	1624	lung cell	[lung cell]	1.0	2	2	2	2
46032	1624	mouse T lymphocyte in culture,	[mouse T lymphocytes in culture,]	1.0	5	1	0	0
46033	1624	homozygote for a polymorphism at codon	[Homozygotes for a polymorphism at codon]	1.0	6	1	0	0
46034	1624	anti-igm crosslinking	[anti-IgM crosslinking]	1.0	2	1	0	0
46035	1624	KOX 9	[KOX 9]	1.0	2	1	0	0
46036	1624	lymphokine gene in T cell	[lymphokine genes in T cells]	1.0	5	1	0	0
46037	1624	il-1 beta convertase mrna accumulation	[IL-1 beta convertase mRNA accumulation]	1.0	5	1	0	0
46038	1624	lack of effect on mrna stability	[lack of effect on mRNA stability]	1.0	6	1	0	0
46039	1624	equal concentration	[equal concentration]	1.0	2	1	0	0
46040	1624	receptor in patient with sepsis	[receptors in patients with sepsis]	1.0	5	2	2	2
46041	1624	nfat export	[NFAT export]	1.0	2	1	0	0
46042	1624	methods: protein production in supernatant	[METHODS: Protein production in supernatants]	1.0	5	1	0	0
46043	1624	functional kappa b enhancer element	[functional kappa B enhancer elements]	1.0	5	1	0	0
46044	1624	critical region for the induction	[critical region for the induction]	1.0	5	1	0	0
46045	1624	porcine endothelium	[porcine endothelium]	1.0	2	1	0	0
46046	1624	heparin gag	[heparin GAGs]	1.0	2	2	2	2
46047	1624	possibility of a feedback sensitivity	[possibility of a feedback sensitivity]	1.0	5	1	0	0
46048	1624	addition, aberrancy in NF-kappaB activity	[addition, aberrancies in NF-kappaB activity]	1.0	5	1	0	0
46049	1624	Epstein-Barr virus EBV nuclear antigen	[Epstein-Barr virus EBV nuclear antigen]	1.0	5	2	2	2
46050	1624	small dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[small doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	1.0	5	1	0	0
46051	1624	peptide antagonist	[peptide antagonists]	1.0	2	1	0	0
46052	1624	ciprofibrate alone	[ciprofibrate alone]	1.0	2	1	0	0
46053	1624	study with other prolyl isomerase inhibitor	[studies with other prolyl isomerase inhibitors]	1.0	6	1	0	0
46054	1624	activation of ca(2+) -dependent pathway	[Activation of Ca(2+) -dependent pathways]	1.0	5	2	1	1
46055	1624	large part,	[large part,]	1.0	2	1	0	0
46056	1624	DNA protein	[DNA protein]	1.0	2	2	2	2
46057	1624	stress-activated protein kinase (sapk)/jun n-terminal kinase	[stress-activated protein kinase (SAPK)/Jun N-terminal kinase]	1.0	6	1	0	0
46058	1624	expression of surface MHC class	[expression of surface MHC class]	1.0	5	1	0	0
46059	1624	normal cells.	[normal cells.]	1.0	2	1	0	0
46060	1624	uncommonly Bcl-2	[uncommonly Bcl-2]	1.0	2	1	0	0
46061	1624	ig beta	[Ig beta]	1.0	2	1	0	0
46062	1624	immunize mouse with group c adenoviruse	[immunizing mice with group C adenoviruses]	1.0	6	1	0	0
46063	1624	5' UTR	[5' UTR]	1.0	2	1	0	0
46064	1624	sex-matched control	[sex-matched controls]	1.0	2	2	2	2
46065	1624	human platelet-activating factor receptor pafr	[human platelet-activating factor receptor PAFR]	1.0	5	1	0	0
46066	1624	two transcription factor a inhibitor	[two transcription factors an inhibitor]	1.0	5	1	0	0
46067	1624	contain a pou-specific (pou[s]) domain	[containing a POU-specific (POU[S]) domain]	1.0	5	1	0	0
46068	1624	cell of the monocyte lineage.	[cells of the monocyte lineage.]	1.0	5	1	0	0
46069	1624	graves' disease	[Graves' disease]	1.0	2	2	2	2
46070	1624	RJ 2.2.5	[RJ 2.2.5]	1.0	2	1	0	0
46071	1624	u937 transfectant express antisense VDR mrna	[U937 transfectants expressing antisense VDR mRNA]	1.0	6	1	0	0
46072	1624	rabbit antiserum	[Rabbit antiserum]	1.0	2	1	0	0
46073	1624	serotype belong to subgroup A	[serotypes belonging to subgroups A]	1.0	5	1	0	0
46074	1624	shift in the distribution of cell	[shifts in the distribution of cells]	1.0	6	1	0	0
46075	1624	binding to a tcf-1 site	[binding to a TCF-1 site]	1.0	5	1	0	0
46076	1624	alpha B	[alpha B]	1.0	2	1	0	0
46077	1624	tcr cross-linking for cd69 expression	[TCR cross-linking for CD69 expression]	1.0	5	1	0	0
46078	1624	weak stimulatory effect on hiv production	[weak stimulatory effects on HIV production]	1.0	6	1	0	0
46079	1624	implication for differential gene expression	[implications for differential gene expression]	1.0	5	1	0	0
46080	1624	non-consensus gas	[non-consensus GAS]	1.0	2	1	0	0
46081	1624	induction of AP-1 by p21ras	[induction of AP-1 by p21ras]	1.0	5	1	0	0
46082	1624	express human t-cell leukemia virus type	[expressing human T-cell leukemia virus type]	1.0	6	1	0	0
46083	1624	neuroectodermal origin	[neuroectodermal origin]	1.0	2	1	0	0
46084	1624	heat-shock chloride	[Heat-shock chloride]	1.0	2	1	0	0
46085	1624	downstream component	[downstream component]	1.0	2	1	0	0
46086	1624	10(-7) mol/L 9-cis RA (12 hours)	[10(-7) mol/L 9-cis RA (12 hours)]	1.0	6	1	0	0
46087	1624	hypophosphorylated form	[hypophosphorylated form]	1.0	2	1	0	0
46088	1624	information available	[information available]	1.0	2	2	2	2
46089	1624	novel cellular tip-associated protein tap	[novel cellular Tip-associated protein Tap]	1.0	5	1	0	0
46090	1624	Challenge develop new therapeutic strategy	[Challenges developing new therapeutic strategies]	1.0	5	1	0	0
46091	1624	renal complication	[renal complications]	1.0	2	1	0	0
46092	1624	Messenger rna production coding for IL-8	[Messenger RNA production coding for IL-8]	1.0	6	1	0	0
46093	1624	immunosuppressive reagent	[immunosuppressive reagents]	1.0	2	1	0	0
46094	1624	southwestern renaturation experiment with the use	[Southwestern renaturation experiments with the use]	1.0	6	1	0	0
46095	1624	redox regulation of NF kappa b	[redox regulation of NF kappa B]	1.0	6	1	0	0
46096	1624	indicate dependent on ongoing protein synthesis.	[indicating dependent on ongoing protein synthesis.]	1.0	6	1	0	0
46097	1624	exposure to IL-4 gamma 3	[exposure to IL-4 gamma 3]	1.0	5	1	0	0
46098	1624	difference of NDP kinase expression	[difference of NDP kinase expression]	1.0	5	1	0	0
46099	1624	additional factor(s)	[additional factor(s).]	1.0	2	1	0	0
46100	1624	sharp contrast, in b cell	[sharp contrast, in B cells]	1.0	5	1	0	0
46101	1624	redox-regulated enzyme	[redox-regulated enzymes]	1.0	2	1	0	0
46102	1624	use a combination of panning	[Using a combination of panning]	1.0	5	1	0	0
46103	1624	contain divalent gold ion HAuCl3	[containing divalent gold ion HAuCl3]	1.0	5	1	0	0
46104	1624	C terminus	[C terminus]	1.0	2	2	1	1
46105	1624	phase-1 adhesion	[phase-1 adhesion]	1.0	2	1	0	0
46106	1624	msr promoter	[MSR promoter]	1.0	2	2	2	2
46107	1624	lymphocyte gr receptor binding parameter	[lymphocyte GR receptor binding parameters]	1.0	5	1	0	0
46108	1624	site of chronic immune-mediated inflammation	[sites of chronic immune-mediated inflammation]	1.0	5	1	0	0
46109	1624	nucleus ISGF3	[nucleus ISGF3]	1.0	2	1	0	0
46110	1624	regulation of the leukocyte-type 12-lipoxygenase	[regulation of the leukocyte-type 12-lipoxygenase]	1.0	5	1	0	0
46111	1624	kappa b-dependent il-6 promoter activity	[kappa B-dependent IL-6 promoter activity]	1.0	5	1	0	0
46112	1624	rotamase activity	[rotamase activity]	1.0	2	2	2	2
46113	1624	monocytic differentiation of hl-60 cell	[monocytic differentiation of HL-60 cells]	1.0	5	1	0	0
46114	1624	follow fc gamma riia stimulation	[following Fc gamma RIIA stimulation]	1.0	5	1	0	0
46115	1624	1 polysomy	[1 polysomy]	1.0	2	1	0	0
46116	1624	rest fibroblast	[resting fibroblasts]	1.0	2	1	0	0
46117	1624	apparent abnormality	[apparent abnormalities]	1.0	2	1	0	0
46118	1624	include the Sp1 binding site	[including the Sp1 binding sites]	1.0	5	1	0	0
46119	1624	additional complex	[additional complex]	1.0	2	2	1	1
46120	1624	Also, smoking	[Also, smoking]	1.0	2	1	0	0
46121	1624	12 nonspecific reactive follicular hyperplasia fh	[12 nonspecific reactive follicular hyperplasia FH]	1.0	6	1	0	0
46122	1624	Glucocorticoid receptor -ligand binding study	[Glucocorticoid receptor -ligand binding studies]	1.0	5	1	0	0
46123	1624	antiserum titer	[antiserum titers]	1.0	2	1	0	0
46124	1624	novel mutant	[novel mutants]	1.0	2	1	0	0
46125	1624	nf-at oligonucleotide	[NF-AT oligonucleotide]	1.0	2	1	0	0
46126	1624	chloramphenicol acetyl transferase (cat) reporter gene	[chloramphenicol acetyl transferase (CAT) reporter gene]	1.0	6	1	0	0
46127	1624	closely related protein c/ebp alpha	[closely related protein C/EBP alpha]	1.0	5	1	0	0
46128	1624	three enzyme	[three enzymes]	1.0	2	1	0	0
46129	1624	ikappabalpha expression	[IkappaBalpha expression]	1.0	2	2	2	2
46130	1624	tyloxapol a polyether alcohol polymer detergent	[tyloxapol an polyether alcohol polymer detergent]	1.0	6	1	0	0
46131	1624	130-kD member	[130-kD member]	1.0	2	1	0	0
46132	1624	such as the map kinase pathway	[such as the MAP kinase pathways]	1.0	6	1	0	0
46133	1624	Ets motif	[Ets motifs]	1.0	2	1	0	0
46134	1624	-dependent transcription	[-dependent transcription]	1.0	2	2	2	2
46135	1624	factor-1 ef1	[factor-1 EF1]	1.0	2	1	0	0
46136	1624	GR binding capacity in MNL	[GR binding capacity in MNL]	1.0	5	1	0	0
46137	1624	property of the blast cell M7	[properties of the blast cells M7]	1.0	6	1	0	0
46138	1624	gammac gene	[gammac gene]	1.0	2	1	0	0
46139	1624	dose-dependent inhibition of gene expression	[dose-dependent inhibition of gene expression]	1.0	5	1	0	0
46140	1624	then after every 20 exposures.	[then after every 20 exposures.]	1.0	5	1	0	0
46141	1624	activity of prl response element	[activity of PRL response elements]	1.0	5	1	0	0
46142	1624	related inhibitor	[related inhibitors]	1.0	2	1	0	0
46143	1624	epithelial (h292)	[epithelial (H292)]	1.0	2	1	0	0
46144	1624	p40 monomer	[p40 monomer]	1.0	2	1	0	0
46145	1624	vivo footprint on nf-e2 ap-1	[vivo footprints on NF-E2 AP-1]	1.0	5	1	0	0
46146	1624	loss of NF-kappaB binding activity	[loss of NF-kappaB binding activity]	1.0	5	1	0	0
46147	1624	such as raloxifene in pma-differentiated cell	[such as Raloxifene in PMA-differentiated cells]	1.0	6	1	0	0
46148	1624	mutation of the YY1 binding site	[mutation of the YY1 binding site]	1.0	6	1	0	0
46149	1624	ETS-domain protein	[ETS-domain proteins]	1.0	2	1	0	0
46150	1624	function for Trident divide lymphocyte	[function for Trident dividing lymphocytes]	1.0	5	1	0	0
46151	1624	253 nucleotide	[253 nucleotides]	1.0	2	1	0	0
46152	1624	continuous culture.	[continuous culture.]	1.0	2	1	0	0
46153	1624	primarily NFATx2	[primarily NFATx2]	1.0	2	1	0	0
46154	1624	lipopolysaccharide-stimulated mouse splenic b cell	[lipopolysaccharide-stimulated mouse splenic B cells]	1.0	5	1	0	0
46155	1624	effector domain,	[effector domain,]	1.0	2	1	0	0
46156	1624	neutrophil pmn	[neutrophils PMN]	1.0	2	2	2	2
46157	1624	pgf2 alpha	[PGF2 alpha]	1.0	2	1	0	0
46158	1624	large amount of detailed information	[large amount of detailed information]	1.0	5	1	0	0
46159	1624	cut edge: expression of the nf	[Cutting edge: expression of the NF]	1.0	6	1	0	0
46160	1624	mutagenesis of the gata-1 gene	[mutagenesis of the GATA-1 gene]	1.0	5	1	0	0
46161	1624	CEM c1 cell by dexamethasone	[CEM C1 cells by dexamethasone]	1.0	5	1	0	0
46162	1624	three case	[Three cases]	1.0	2	1	0	0
46163	1624	bind property	[binding properties]	1.0	2	2	1	1
46164	1624	partial homology	[partial homology]	1.0	2	1	0	0
46165	1624	phosphotyrosine phosphatase activity by bis(maltolato)oxovanadium-iv	[phosphotyrosine phosphatase activity by bis(maltolato)oxovanadium-IV]	1.0	5	1	0	0
46166	1624	antisera specific for stat3alpha protein	[antisera specific for STAT3alpha proteins]	1.0	5	1	0	0
46167	1624	lysis by cytolytic lymphocyte CL	[lysis by cytolytic lymphocytes CLs]	1.0	5	1	0	0
46168	1624	NFAT family	[NFAT family]	1.0	2	8	7	1
46169	1624	functional role of erk and/or p38	[functional roles of ERK and/or p38]	1.0	6	1	0	0
46170	1624	bind activity in the cytosol	[binding activity in the cytosol]	1.0	5	1	0	0
46171	1624	survival signal	[survival signals]	1.0	2	1	0	0
46172	1624	L-selectin promoter	[L-selectin promoter]	1.0	2	2	2	2
46173	1624	more rapidly migrate b2 complex	[more rapidly migrating B2 complex]	1.0	5	1	0	0
46174	1624	mechanism alone	[mechanism alone]	1.0	2	1	0	0
46175	1624	cytotoxicity marker	[Cytotoxicity markers]	1.0	2	1	0	0
46176	1624	transient pulse	[transient pulses]	1.0	2	1	0	0
46177	1624	transcription of the class gene	[transcription of the class genes]	1.0	5	1	0	0
46178	1624	innate defense mechanism against infectious pathogen	[innate defense mechanisms against infectious pathogens]	1.0	6	1	0	0
46179	1624	apparent effect on cell growth.	[apparent effect on cell growth.]	1.0	5	1	0	0
46180	1624	transcribe il-2	[transcribing IL-2]	1.0	2	1	0	0
46181	1624	variant size	[variant sizes]	1.0	2	1	0	0
46182	1624	neutrophil apoptosis of neutrophil function	[Neutrophil apoptosis of neutrophil function]	1.0	5	1	0	0
46183	1624	zebra protein from Epstein-Barr virus	[ZEBRA protein from Epstein-Barr virus]	1.0	5	1	0	0
46184	1624	coexpression of the p65 subunit	[coexpression of the p65 subunit]	1.0	5	1	0	0
46185	1624	mab R24	[mAb R24]	1.0	2	1	0	0
46186	1624	coherent expression pattern in cell	[coherent expression patterns in cells]	1.0	5	1	0	0
46187	1624	c-erbA/T3 receptor	[c-erbA/T3 receptor]	1.0	2	1	0	0
46188	1624	stable transformant	[stable transformant]	1.0	2	1	0	0
46189	1624	thymus-specific member	[thymus-specific member]	1.0	2	1	0	0
46190	1624	normal level of il-2 production	[normal levels of IL-2 production]	1.0	5	1	0	0
46191	1624	specific aldosterone binding indicate the absence	[specific aldosterone binding indicating the absence]	1.0	6	1	0	0
46192	1624	T cell (NFAT) family member	[T cell (NFAT) family members]	1.0	5	1	0	0
46193	1624	family history for breast/ovarian cancer	[family history for breast/ovarian cancer]	1.0	5	1	0	0
46194	1624	use a progesterone receptor cDNA probe	[using a progesterone receptor cDNA probe]	1.0	6	1	0	0
46195	1624	nf-kappa b binding activity in cell	[NF-kappa B binding activity in cells]	1.0	6	1	0	0
46196	1624	use neuroblastoma cell line as models,	[Using neuroblastoma cell lines as models,]	1.0	6	1	0	0
46197	1624	hmg-i(y) protein	[HMG-I(Y) proteins]	1.0	2	1	0	0
46198	1624	caml gene	[CAML gene]	1.0	2	1	0	0
46199	1624	preexisting, T cell-specific component nf-atp	[preexisting, T cell-specific component NF-ATp]	1.0	5	1	0	0
46200	1624	consist of two subunits, p50	[consisting of two subunits, p50]	1.0	5	1	0	0
46201	1624	deficient proliferative ability in response	[deficient proliferative ability in response]	1.0	5	1	0	0
46202	1624	differentiate progenitor	[differentiating progenitors]	1.0	2	2	2	2
46203	1624	zap-70 associate with the receptor	[ZAP-70 associates with the receptor]	1.0	5	1	0	0
46204	1624	secondary factor	[secondary factor]	1.0	2	1	0	0
46205	1624	ZAP-70 mutant	[ZAP-70 mutant]	1.0	2	1	0	0
46206	1624	infection with human immunodeficiency virus	[infection with human immunodeficiency virus]	1.0	5	1	0	0
46207	1624	lps stimulation of human monocyte	[LPS stimulation of human monocytes]	1.0	5	1	0	0
46208	1624	positive sample	[positive samples]	1.0	2	1	0	0
46209	1624	FGF receptor	[FGF receptor]	1.0	2	2	1	1
46210	1624	majority of class ii molecule	[majority of class II molecules]	1.0	5	1	0	0
46211	1624	hl-60 cell in the presence	[HL-60 cells in the presence]	1.0	5	1	0	0
46212	1624	same nuclear protein suggest Oct-1	[same nuclear proteins suggesting Oct-1]	1.0	5	1	0	0
46213	1624	physiologic product of pld action	[physiologic product of PLD action]	1.0	5	1	0	0
46214	1624	intensive hybridization signal in interphase	[intensive hybridization signals in interphase]	1.0	5	1	0	0
46215	1624	costimulatory action	[costimulatory actions]	1.0	2	1	0	0
46216	1624	calcineurin domain	[calcineurin domain]	1.0	2	2	2	2
46217	1624	New knowledge on the mechanism	[New knowledge on the mechanism]	1.0	5	1	0	0
46218	1624	promote the differentiation of th2 cells.	[promoting the differentiation of Th2 cells.]	1.0	6	1	0	0
46219	1624	however, analysis of sucrose gradient fraction	[However, analysis of sucrose gradient fractions]	1.0	6	1	0	0
46220	1624	DNA binding activity of Sp1	[DNA binding activity of Sp1]	1.0	5	1	0	0
46221	1624	five lymph node with follicular hyperplasia	[five lymph nodes with follicular hyperplasia]	1.0	6	1	0	0
46222	1624	undifferentiated non-PRL-secreting endometrial stromal cell	[undifferentiated non-PRL-secreting endometrial stromal cells]	1.0	5	1	0	0
46223	1624	importance of signal transducing pathway	[importance of signal transducing pathways]	1.0	5	1	0	0
46224	1624	role for the transcription factor	[role for the transcription factor]	1.0	5	2	2	2
46225	1624	genital tract	[genital tract]	1.0	2	2	1	1
46226	1624	anti-CD3 shift	[anti-CD3 shift]	1.0	2	1	0	0
46227	1624	phosphatidic acid	[phosphatidic acid]	1.0	2	2	1	1
46228	1624	nfat-1 deletion	[NFAT-1 deletion]	1.0	2	1	0	0
46229	1624	use PD98059	[using PD98059]	1.0	2	1	0	0
46230	1624	monocyte tf expression in transplant recipient	[monocyte TF expression in transplant recipients]	1.0	6	1	0	0
46231	1624	particularly in the stage of development.	[particularly in the stages of development.]	1.0	6	1	0	0
46232	1624	radiation injury	[radiation injury]	1.0	2	1	0	0
46233	1624	intracellular store of latent nf-kappa b	[intracellular stores of latent NF-kappa B]	1.0	6	1	0	0
46234	1624	promoter dependent on this element	[promoters dependent on these elements]	1.0	5	1	0	0
46235	1624	patient with a chronic MPD	[patients with a chronic MPD]	1.0	5	2	1	1
46236	1624	murine multipotential fdcp-mix a4 cell	[murine multipotential FDCP-mix A4 cells]	1.0	5	1	0	0
46237	1624	predominantly as a result of transcription	[predominantly as a result of transcription]	1.0	6	1	0	0
46238	1624	normal immunoregulation	[normal immunoregulation]	1.0	2	1	0	0
46239	1624	T lymphocyte of a child	[T lymphocytes of a child]	1.0	5	1	0	0
46240	1624	leukocyte activation	[leukocyte activation]	1.0	2	1	0	0
46241	1624	important role modulate the balance	[important role modulating the balance]	1.0	5	1	0	0
46242	1624	CD4 gene transcription in cd4(-) cell	[CD4 gene transcription in CD4(-) cells]	1.0	6	1	0	0
46243	1624	T cell p55/p75 early late	[T cells p55/p75 early late]	1.0	5	1	0	0
46244	1624	Thus, bob.1/obf.1	[Thus, BOB.1/OBF.1]	1.0	2	1	0	0
46245	1624	demonstrate necessary	[demonstrating necessary]	1.0	2	1	0	0
46246	1624	cell in the synovial lining	[cells in the synovial lining]	1.0	5	1	0	0
46247	1624	b cell ig secretion (greater	[B cell Ig secretion (greater]	1.0	5	1	0	0
46248	1624	17beta-estradiol E2 il-1beta promoter CAT activity	[17beta-estradiol E2 IL-1beta promoter CAT activity]	1.0	6	1	0	0
46249	1624	express cell in contrast to cell	[expressing cells in contrast to cells]	1.0	6	1	0	0
46250	1624	interleukin iil)-1alpha	[interleukin (IL)-1alpha]	1.0	2	1	0	0
46251	1624	adult control	[adult controls]	1.0	2	2	1	1
46252	1624	polyacrylamide gel	[polyacrylamide gel]	1.0	2	3	2	1
46253	1624	potential amphipatic alpha-helical protein segment	[potential amphipatic alpha-helical protein segments]	1.0	5	1	0	0
46254	1624	17 individual	[17 individuals]	1.0	2	1	0	0
46255	1624	Grb2-binding protein	[Grb2-binding proteins]	1.0	2	2	1	1
46256	1624	2 mol/L	[2 mol/L]	1.0	2	2	2	2
46257	1624	upstream of activation of phospholipase c	[upstream of activation of phospholipase C]	1.0	6	1	0	0
46258	1624	dominant inhibitor	[dominant inhibitor]	1.0	2	2	2	2
46259	1624	probe, nuclear extract from unstimulated T	[probe, nuclear extracts from unstimulated T]	1.0	6	1	0	0
46260	1624	then target the GATA-1 gene	[then targeting the GATA-1 gene]	1.0	5	1	0	0
46261	1624	cellular reduce status for fasl induction	[cellular reducing status for FasL induction]	1.0	6	1	0	0
46262	1624	advanced age	[advanced age]	1.0	2	1	0	0
46263	1624	component of the transcription factor	[component of the transcription factor]	1.0	5	2	2	2
46264	1624	vcam-1 protein	[VCAM-1 protein]	1.0	2	1	0	0
46265	1624	lps binding to plasma membrane receptor	[LPS binding to plasma membrane receptors]	1.0	6	1	0	0
46266	1624	element contain nf-e2 gata binding site	[elements containing NF-E2 GATA binding sites]	1.0	6	1	0	0
46267	1624	reactivity against a mhc/peptide complex	[reactivity against a MHC/peptide complex]	1.0	5	1	0	0
46268	1624	size similar	[size similar]	1.0	2	1	0	0
46269	1624	glucose phosphate isomerase-1 (gpi-1) isozyme	[glucose phosphate isomerase-1 (GPI-1) isozymes]	1.0	5	1	0	0
46270	1624	tradd residue 296 to 302.	[TRADD residues 296 to 302.]	1.0	5	1	0	0
46271	1624	permanent clone	[permanent clones]	1.0	2	1	0	0
46272	1624	childrens' T	[childrens' T]	1.0	2	2	1	1
46273	1624	New World primate cell extract	[New World primate cell extracts]	1.0	5	1	0	0
46274	1624	osteoclast marker	[Osteoclast markers]	1.0	2	2	1	1
46275	1624	dexamethasone (10(-7)	[dexamethasone (10(-7)]	1.0	2	1	0	0
46276	1624	m-crf: 1.1	[M-CRF: 1.1]	1.0	2	1	0	0
46277	1624	peripheral blood of healthy donor	[peripheral blood of healthy donors]	1.0	5	1	0	0
46278	1624	demonstration of replicative gene expression	[Demonstration of replicative gene expression]	1.0	5	1	0	0
46279	1624	restriction fragment length polymorphism analysis	[restriction fragment length polymorphism analysis]	1.0	5	1	0	0
46280	1624	fungal stimuli.	[fungal stimuli.]	1.0	2	1	0	0
46281	1624	adult-progenitor culture	[adult-progenitor culture]	1.0	2	1	0	0
46282	1624	x-linked marker	[X-linked markers]	1.0	2	1	0	0
46283	1624	possible pseudogene	[possible pseudogenes]	1.0	2	1	0	0
46284	1624	tnf-alpha endothelium	[TNF-alpha endothelium]	1.0	2	1	0	0
46285	1624	il-2 production by neonatal T cell	[IL-2 production by neonatal T cells]	1.0	6	1	0	0
46286	1624	immune response,	[immune response,]	1.0	2	1	0	0
46287	1624	control of other protein necessary	[control of other proteins necessary]	1.0	5	1	0	0
46288	1624	myeloma (mm)	[myeloma (MM)]	1.0	2	1	0	0
46289	1624	confirm the importance of endogenous nfat	[confirming the importance of endogenous NFAT]	1.0	6	1	0	0
46290	1624	high level of g(s)alpha expression	[higher levels of G(S)alpha expression]	1.0	5	1	0	0
46291	1624	disruption of the transcription isgf3	[disruption of the transcription ISGF3]	1.0	5	1	0	0
46292	1624	result similar	[Results similar]	1.0	2	1	0	0
46293	1624	human nm23-h2	[human nm23-H2]	1.0	2	1	0	0
46294	1624	different phase	[different phases]	1.0	2	1	0	0
46295	1624	complete failure	[complete failure]	1.0	2	1	0	0
46296	1624	Precise deletion of the exon	[Precise deletion of the exons]	1.0	5	1	0	0
46297	1624	antiatherosclerotic potential	[antiatherosclerotic potential]	1.0	2	2	1	1
46298	1624	pattern of protein binding site	[pattern of protein binding sites]	1.0	5	1	0	0
46299	1624	eicosanoid profile	[eicosanoid profile]	1.0	2	2	1	1
46300	1624	T cell response against factor	[T cell responses against factors]	1.0	5	1	0	0
46301	1624	mastocytic/basophilic lineage	[mastocytic/basophilic lineages]	1.0	2	1	0	0
46302	1624	insulin-like growth	[insulin-like growth]	1.0	2	1	0	0
46303	1624	total mrna in rest lymphocyte	[total mRNA in resting lymphocytes]	1.0	5	1	0	0
46304	1624	recurrent translocation	[recurrent translocation]	1.0	2	1	0	0
46305	1624	IL-1 signal	[IL-1 signaling]	1.0	2	2	1	1
46306	1624	50000 (50k)	[50,000 (50K)]	1.0	2	1	0	0
46307	1624	upregulation of this molecule inflammation	[upregulation of these molecules inflammation]	1.0	5	1	0	0
46308	1624	infection interleukin-8 IL-8 gene transcription lead	[infection interleukin-8 IL-8 gene transcription leading]	1.0	6	1	0	0
46309	1624	region homologous to the oncogene rel	[regions homologous to the oncogene rel]	1.0	6	1	0	0
46310	1624	differential signal	[differential signaling]	1.0	2	2	1	1
46311	1624	different affinity for this subunit.	[different affinities for this subunit.]	1.0	5	1	0	0
46312	1624	suggest control	[suggesting control]	1.0	2	2	2	2
46313	1624	phosphotyrosine-containing peptide	[phosphotyrosine-containing peptides]	1.0	2	1	0	0
46314	1624	c-fo upregulation	[c-fos upregulation]	1.0	2	1	0	0
46315	1624	16p13.3 marker	[16p13.3 markers]	1.0	2	1	0	0
46316	1624	target structure for human t-lymphocyte	[target structure for human T-lymphocytes]	1.0	5	1	0	0
46317	1624	induction of the three adhesion protein	[induction of the three adhesion proteins]	1.0	6	1	0	0
46318	1624	endothelial selectin	[endothelial selectins]	1.0	2	1	0	0
46319	1624	month (24-58	[months (24-58]	1.0	2	1	0	0
46320	1624	key regulator of b-cell development	[key regulator of B-cell development]	1.0	5	1	0	0
46321	1624	human disorder	[human disorder]	1.0	2	2	1	1
46322	1624	recent demonstration of JAK phosphorylation	[recent demonstration of JAK phosphorylation]	1.0	5	1	0	0
46323	1624	heterogeneous population	[heterogeneous population]	1.0	2	2	2	2
46324	1624	latter colony	[latter colonies]	1.0	2	1	0	0
46325	1624	effect on nip -mediated repression	[effects on NIP -mediated repression]	1.0	5	1	0	0
46326	1624	viral trans-activator such as tax	[Viral trans-activators such as Tax]	1.0	5	1	0	0
46327	1624	direct coupling	[direct coupling]	1.0	2	2	2	2
46328	1624	prevent apoptosis of monoblastoid cell	[preventing apoptosis of monoblastoid cells]	1.0	5	1	0	0
46329	1624	-dependent activation	[-dependent activation]	1.0	2	2	2	2
46330	1624	transcription factor effect on chromosome constitution	[Transcription factor effects on chromosome constitution]	1.0	6	1	0	0
46331	1624	girl with immunological feature indistinguishable	[girl with immunological features indistinguishable]	1.0	5	1	0	0
46332	1624	kappa B-specific binding factor present	[kappa B-specific binding factors present]	1.0	5	1	0	0
46333	1624	fourteen percent of isolated fragment	[Fourteen percent of isolated fragments]	1.0	5	1	0	0
46334	1624	mitogenic stimulus of T cell	[mitogenic stimuli of T cells]	1.0	5	1	0	0
46335	1624	eml cell to the lineage	[EML cells to the lineage]	1.0	5	1	0	0
46336	1624	phenotype of mouse transgenic line	[phenotype of mouse transgenic lines]	1.0	5	1	0	0
46337	1624	element of the CD95 ligand promoter.	[elements of the CD95 ligand promoter.]	1.0	6	1	0	0
46338	1624	tnf factor	[TNF factor]	1.0	2	2	2	2
46339	1624	fusion cDNA	[fusion cDNA]	1.0	2	1	0	0
46340	1624	high level of reporter gene activity	[high levels of reporter gene activity]	1.0	6	1	0	0
46341	1624	antibody response	[antibody response]	1.0	2	2	1	1
46342	1624	competition experiment analyze the component	[competition experiments analyzing the components]	1.0	5	1	0	0
46343	1624	tpa b cell harbour type 1	[TPA B cells harbouring type 1]	1.0	6	1	0	0
46344	1624	activation antigen	[activation antigen]	1.0	2	2	2	2
46345	1624	pleiotropic activity	[pleiotropic activities]	1.0	2	1	0	0
46346	1624	second pathway	[second pathway]	1.0	2	2	1	1
46347	1624	key mediator	[key mediators]	1.0	2	2	2	2
46348	1624	effect of the inactive camkiv	[effects of the inactive CaMKIV]	1.0	5	1	0	0
46349	1624	stimulation of interleukin-1 alpha production	[stimulation of interleukin-1 alpha production]	1.0	5	1	0	0
46350	1624	metastatic disease	[metastatic disease]	1.0	2	1	0	0
46351	1624	dominant-negative RXR	[dominant-negative RXR]	1.0	2	1	0	0
46352	1624	cut edge: tcr stimulation by antibody	[Cutting edge: TCR stimulation by antibody]	1.0	6	1	0	0
46353	1624	sh2 domain-contain	[SH2 domain-containing]	1.0	2	1	0	0
46354	1624	addition, tax	[addition, Tax]	1.0	2	1	0	0
46355	1624	cytokine gene expression in th1	[cytokine gene expression in Th1]	1.0	5	1	0	0
46356	1624	recruitment of leukocyte to inflammatory	[recruitment of leukocytes to inflammatory]	1.0	5	1	0	0
46357	1624	component of the signal transduction pathway	[components of the signal transduction pathway]	1.0	6	1	0	0
46358	1624	Nuclear NF-ATp	[Nuclear NF-ATp]	1.0	2	1	0	0
46359	1624	g-csf myeloid	[G-CSF myeloid]	1.0	2	1	0	0
46360	1624	entire mds1/evi1	[entire MDS1/EVI1]	1.0	2	1	0	0
46361	1624	application of this form of testing	[Application of this form of testing]	1.0	6	1	0	0
46362	1624	approximately 31 kda in 12-o-tetradecanoyl-phorbol-13-acetate	[approximately 31 kDa in 12-O-tetradecanoyl-phorbol-13-acetate]	1.0	5	1	0	0
46363	1624	high activity against macrovascular ec	[high activity against macrovascular EC]	1.0	5	1	0	0
46364	1624	degree c) twice/d, 30 min/exposure,	[degrees C) twice/d, 30 min/exposure,]	1.0	5	1	0	0
46365	1624	aids iblp	[AIDS IBLP]	1.0	2	2	2	2
46366	1624	constitutive activation of stat protein	[constitutive activation of STAT proteins]	1.0	5	1	0	0
46367	1624	mitogen-activated protein kinase mapk activity	[mitogen-activated protein kinase MAPK activities]	1.0	5	1	0	0
46368	1624	NF-kappa b sp1 binding motif	[NF-kappa B Sp1 binding motifs]	1.0	5	1	0	0
46369	1624	overexpress icsat	[overexpressing ICSAT]	1.0	2	2	2	2
46370	1624	inhibition of nf kappa b activation	[inhibition of NF kappa B activation]	1.0	6	1	0	0
46371	1624	study the mechanism of monocytic differentiation	[studying the mechanisms of monocytic differentiation]	1.0	6	1	0	0
46372	1624	posttranslational modification of nuclear protein	[posttranslational modification of nuclear proteins]	1.0	5	1	0	0
46373	1624	suggest a role in activation	[suggesting a role in activation]	1.0	5	1	0	0
46374	1624	HLA dqa1*0201	[HLA DQA1*0201]	1.0	2	1	0	0
46375	1624	two hexameric receptor binding site	[two hexameric receptor binding sites]	1.0	5	1	0	0
46376	1624	human T cell transcription factor gata-3	[Human T cell transcription factor GATA-3]	1.0	6	1	0	0
46377	1624	135(oh)2d3 action in immune cell	[1,25(OH)2D3 action in immune cells]	1.0	5	1	0	0
46378	1624	activation of the JAK /stat pathway	[Activation of the JAK /STAT pathway]	1.0	6	1	0	0
46379	1624	105 kD	[105 kD]	1.0	2	1	0	0
46380	1624	adenovirus infection of human cell	[adenovirus infection of human cells]	1.0	5	1	0	0
46381	1624	structural change in a silencer	[structural changes in a silencer]	1.0	5	1	0	0
46382	1624	correlation of differentiation-inducing activity of retinoid	[Correlation of differentiation-inducing activity of retinoids]	1.0	6	1	0	0
46383	1624	Erythropoietin EPO	[Erythropoietin EPO]	1.0	2	1	0	0
46384	1624	level of nuclear regulatory protein	[levels of nuclear regulatory proteins]	1.0	5	1	0	0
46385	1624	fraction of bq dead cell	[fraction of BQ dead cells]	1.0	5	1	0	0
46386	1624	adult red blood cell HPFH	[adult red blood cells HPFH]	1.0	5	1	0	0
46387	1624	similar maximal increase in c-fo (99+/-15	[similar maximal increases in c-fos (99+/-15]	1.0	6	1	0	0
46388	1624	IkappaBalpha degradation	[IkappaBalpha degradation]	1.0	2	1	0	0
46389	1624	function in addition to activation	[function in addition to activation]	1.0	5	1	0	0
46390	1624	nucleotide sequence of the cd11a	[nucleotide sequences of the CD11a]	1.0	5	1	0	0
46391	1624	effect of temperature, beta 2-microglobulin	[effect of temperature, beta 2-microglobulin]	1.0	5	1	0	0
46392	1624	saf-like transcription	[SAF-like transcription]	1.0	2	1	0	0
46393	1624	loss of bamhi-q promoter activity	[loss of BamHI-Q promoter activity]	1.0	5	1	0	0
46394	1624	protein recognize this enhancer element	[protein recognizing this enhancer element]	1.0	5	1	0	0
46395	1624	activity of the Jun kinase	[activity of the Jun kinase]	1.0	5	1	0	0
46396	1624	33-47% identity with swi3 protein	[33-47% identity with SWI3 protein]	1.0	5	1	0	0
46397	1624	level of a nuclear factor(	[levels of a nuclear factor(s)]	1.0	5	1	0	0
46398	1624	female population	[female population]	1.0	2	1	0	0
46399	1624	activity of the kappa b enhancer	[Activity of the kappa B enhancer]	1.0	6	1	0	0
46400	1624	plasma b	[plasma B]	1.0	2	1	0	0
46401	1624	Daidzein glucuronide	[Daidzein glucuronides]	1.0	2	2	2	2
46402	1624	11 alpha-chloromethyl	[11 alpha-chloromethyl]	1.0	2	1	0	0
46403	1624	th1- cytokine	[Th1- cytokines]	1.0	2	1	0	0
46404	1624	encode a kappa b dna-binding protein	[encoding a kappa B DNA-binding protein]	1.0	6	1	0	0
46405	1624	potent regulator of hematopoletic differentiation	[potent regulators of hematopoletic differentiation]	1.0	5	1	0	0
46406	1624	U1 (monocytic)	[U1 (monocytic)]	1.0	2	1	0	0
46407	1624	beta- gene in the cell population	[beta- genes in the cell populations]	1.0	6	1	0	0
46408	1624	HL60R cell	[HL60R cells]	1.0	2	1	0	0
46409	1624	promoter with DNA regulatory motif	[promoters with DNA regulatory motifs]	1.0	5	1	0	0
46410	1624	expression in adenovirus 12 cell	[expression in adenovirus 12 cells]	1.0	5	1	0	0
46411	1624	addition, recombinant	[addition, recombinant]	1.0	2	1	0	0
46412	1624	expression of the Itk mutant	[expression of the Itk mutant]	1.0	5	1	0	0
46413	1624	peptide-binding cleft	[peptide-binding cleft]	1.0	2	1	0	0
46414	1624	cooperative inhibition	[cooperative inhibition]	1.0	2	2	1	1
46415	1624	analysis of the induction of factor-kappaB	[analyses of the induction of factor-kappaB]	1.0	6	1	0	0
46416	1624	mutation affect the 5' guanine residue	[Mutations affecting the 5' guanine residues]	1.0	6	1	0	0
46417	1624	CONCLUSIONS: HCS	[CONCLUSIONS: HCS]	1.0	2	1	0	0
46418	1624	malignant phenotype	[malignant phenotype]	1.0	2	1	0	0
46419	1624	progenitor of the monocyte/macrophage lineage	[progenitors of the monocyte/macrophage lineage]	1.0	5	1	0	0
46420	1624	e-selectin elam-1	[E-selectin ELAM-1]	1.0	2	1	0	0
46421	1624	loss-of-function alone	[loss-of-function alone]	1.0	2	1	0	0
46422	1624	il-6 chloramphenicol acetyl transferase (cat)	[IL-6 chloramphenicol acetyl transferase (CAT)]	1.0	5	1	0	0
46423	1624	PPARalpha activation	[PPARalpha activation]	1.0	2	1	0	0
46424	1624	Initial dexamethasone in vitro fibroblast binding	[Initial dexamethasone in vitro fibroblast binding]	1.0	6	1	0	0
46425	1624	contrast, anti-CD3	[contrast, anti-CD3]	1.0	2	1	0	0
46426	1624	mutation in the LEF-1 -binding site	[mutations in the LEF-1 -binding site]	1.0	6	1	0	0
46427	1624	h2o2 treatment	[H2O2 treatment]	1.0	2	3	2	1
46428	1624	soluble CD40 ligand fibroblast activation	[soluble CD40 ligand fibroblast activation]	1.0	5	1	0	0
46429	1624	7 hour	[7 hr]	1.0	2	2	1	1
46430	1624	oct1 protein	[Oct1 protein]	1.0	2	1	0	0
46431	1624	high level cd19 promoter expression	[high level CD19 promoter expression]	1.0	5	1	0	0
46432	1624	lysis of hla b8+ LCL target	[lysis of HLA B8+ LCL targets]	1.0	6	1	0	0
46433	1624	calcium mobilization a essential component	[calcium mobilization an essential component]	1.0	5	1	0	0
46434	1624	bja-b cell	[BJA-B cells]	1.0	2	2	1	1
46435	1624	response to sickle blood cell	[response to sickle blood cells]	1.0	5	1	0	0
46436	1624	retinoid analog	[retinoid analogs]	1.0	2	1	0	0
46437	1624	also specific binding interaction between CIITA	[also specific binding interactions between CIITA]	1.0	6	1	0	0
46438	1624	14 kda	[14 kDa]	1.0	2	2	1	1
46439	1624	suppressor gene	[suppressor gene]	1.0	2	2	2	2
46440	1624	silencer of the CD4 gene	[silencer of the CD4 gene]	1.0	5	1	0	0
46441	1624	Thapsigargin TG a inhibitor of ca(2+)-atpase	[Thapsigargin TG an inhibitor of Ca(2+)-ATPase]	1.0	6	1	0	0
46442	1624	PMA in scm-1-producer T cell line	[PMA in SCM-1-producer T cell lines]	1.0	6	1	0	0
46443	1624	concentration compatible with plasma level	[concentrations compatible with plasma levels]	1.0	5	1	0	0
46444	1624	simian virus 40 (sv40) promoter	[simian virus 40 (SV40) promoters]	1.0	5	1	0	0
46445	1624	etiologic agent of human ehrlichiosis	[etiologic agent of human ehrlichiosis]	1.0	5	1	0	0
46446	1624	circadian variation in environmental lighting	[circadian variations in environmental lighting]	1.0	5	1	0	0
46447	1624	principal epo -responsive cell type	[principal EPO -responsive cell type]	1.0	5	1	0	0
46448	1624	affinity to vitamin d-binding protein	[affinity to vitamin D-binding protein]	1.0	5	1	0	0
46449	1624	il-1beta production	[IL-1beta production]	1.0	2	2	1	1
46450	1624	reduction in lambda L chain	[reduction in lambda L chain]	1.0	5	1	0	0
46451	1624	cr group	[CR group]	1.0	2	2	1	1
46452	1624	vitro exposure to therapeutical level	[vitro exposure to therapeutical levels]	1.0	5	1	0	0
46453	1624	subtle modification in flanking sequence	[subtle modifications in flanking sequences]	1.0	5	1	0	0
46454	1624	Hemin induction of k562 cell	[Hemin induction of K562 cells]	1.0	5	1	0	0
46455	1624	functional implication of a novel mutation	[functional implications of a novel mutation]	1.0	6	1	0	0
46456	1624	transcription factor of the helix-loop-helix family	[transcription factors of the helix-loop-helix family]	1.0	6	1	0	0
46457	1624	protein rna complex with extract	[protein RNA complex with extracts]	1.0	5	1	0	0
46458	1624	30 minute follow il-2 stimulation	[30 min following IL-2 stimulation]	1.0	5	1	0	0
46459	1624	thereby modulate the expression of gene	[thereby modulating the expression of genes]	1.0	6	1	0	0
46460	1624	adhesion molecule on rest neutrophil	[adhesion molecules on resting neutrophils]	1.0	5	1	0	0
46461	1624	other intp	[other dNTPs]	1.0	2	1	0	0
46462	1624	Lysophosphatidylethanolamine lysoPE	[Lysophosphatidylethanolamine lysoPE]	1.0	2	1	0	0
46463	1624	endonuclease analysis	[Endonuclease analyses]	1.0	2	1	0	0
46464	1624	quantitative thin-layer chromatography tlc analysis	[Quantitative thin-layer chromatography TLC analyses]	1.0	5	1	0	0
46465	1624	t-cell-derived chromosome	[T-cell-derived chromosome]	1.0	2	1	0	0
46466	1624	lbp patient	[LBP patients]	1.0	2	2	1	1
46467	1624	parasite-mediated transformation	[parasite-mediated transformation]	1.0	2	1	0	0
46468	1624	30 minute of sp-a treatment	[30 min of SP-A treatment]	1.0	5	1	0	0
46469	1624	subtractive hybridization	[subtractive hybridization]	1.0	2	1	0	0
46470	1624	footprint analysis	[footprint analysis]	1.0	2	1	0	0
46471	1624	calcineurin a type 2B protein phosphatase	[calcineurin a type 2B protein phosphatase]	1.0	6	1	0	0
46472	1624	abnormal eosinophil	[abnormal eosinophils]	1.0	2	2	1	1
46473	1624	other neuron	[other neurons]	1.0	2	1	0	0
46474	1624	activation-related genes.	[activation-related genes.]	1.0	2	1	0	0
46475	1624	Duffy antigen/chemokine receptor gene darc	[Duffy antigen/chemokine receptor gene DARC]	1.0	5	1	0	0
46476	1624	expression of the second peak	[expression of the second peak]	1.0	5	1	0	0
46477	1624	die cell	[dying cells]	1.0	2	1	0	0
46478	1624	selective activity	[selective activity]	1.0	2	2	2	2
46479	1624	vascular invasion	[vascular invasion]	1.0	2	1	0	0
46480	1624	SIE gas motif contain oligonucleotide probe	[SIE GAS motif containing oligonucleotide probes]	1.0	6	1	0	0
46481	1624	analyze the relationship between DC	[analyzing the relationships between DC]	1.0	5	1	0	0
46482	1624	c-fo /c-Jun heterodimer in unstimulated cell	[c-Fos /c-Jun heterodimers in unstimulated cells]	1.0	6	1	0	0
46483	1624	fas ligand induction in NK cell	[Fas ligand induction in NK cells]	1.0	6	1	0	0
46484	1624	tissue sample	[tissue samples]	1.0	2	2	1	1
46485	1624	stat3 -activation	[Stat3 -activation]	1.0	2	1	0	0
46486	1624	marmoset T	[marmoset T]	1.0	2	1	0	0
46487	1624	ultimately regulate adhesion, nf-kappab activation	[ultimately regulating adhesion, NF-kappaB activation]	1.0	5	1	0	0
46488	1624	tnf-alpha antibody	[TNF-alpha antibody]	1.0	2	2	2	2
46489	1624	affinity for the 1,25(OH)2D3 receptor	[affinity for the 1,25(OH)2D3 receptor]	1.0	5	1	0	0
46490	1624	criterion for steroid binding site	[criteria for steroid binding sites]	1.0	5	1	0	0
46491	1624	granulocyte macrophage-colony stimulate factor gm-csf	[granulocyte macrophage-colony stimulating factor GM-CSF]	1.0	5	1	0	0
46492	1624	glucose transporter in 3t3-l1 adipocyte	[glucose transporter in 3T3-L1 adipocytes]	1.0	5	1	0	0
46493	1624	full-length receptor	[full-length receptor]	1.0	2	1	0	0
46494	1624	cytokine pattern with ast/alt level	[cytokine patterns with AST/ALT levels]	1.0	5	1	0	0
46495	1624	human immunodeficiency virus (HIV) promoter	[human immunodeficiency virus (HIV) promoter]	1.0	5	1	0	0
46496	1624	wp activity by transcriptional interference	[Wp activity by transcriptional interference]	1.0	5	1	0	0
46497	1624	several member of the BCL-2 family	[several members of the BCL-2 family]	1.0	6	1	0	0
46498	1624	possible correlation between c-fo expression	[possible correlation between c-fos expression]	1.0	5	1	0	0
46499	1624	follow stimulation with a tumor promoter	[following stimulation with a tumor promoter]	1.0	6	1	0	0
46500	1624	tumor necrosis factor-alpha in b lymphocyte	[tumor necrosis factor-alpha in B lymphocytes]	1.0	6	1	0	0
46501	1624	TPA treatment	[TPA treatment]	1.0	2	2	1	1
46502	1624	different type	[different types]	1.0	2	4	3	1
46503	1624	signal-induced degradation	[signal-induced degradation]	1.0	2	1	0	0
46504	1624	tcrzeta level	[TCRzeta levels]	1.0	2	2	2	2
46505	1624	promoter fragment	[promoter fragment]	1.0	2	2	2	2
46506	1624	cytoplasmic location: rest memory T cell	[cytoplasmic location: resting memory T cells]	1.0	6	1	0	0
46507	1624	nuclear extract from hypoxic ECs	[nuclear extracts from hypoxic ECs]	1.0	5	1	0	0
46508	1624	phospholipase Cgamma1	[phospholipase Cgamma1]	1.0	2	1	0	0
46509	1624	pcr approach with degenerate oligonucleotide	[PCR approach with degenerate oligonucleotides]	1.0	5	1	0	0
46510	1624	treatment with a large variety	[treatment with a large variety]	1.0	5	1	0	0
46511	1624	regulation of nf-kappa b activity	[Regulation of NF-kappa B activity]	1.0	5	1	0	0
46512	1624	same cis-	[same cis-]	1.0	2	1	0	0
46513	1624	a at the fifth position	[A at the fifth position]	1.0	5	1	0	0
46514	1624	modulation of DNA binding activity	[modulation of DNA binding activity]	1.0	5	1	0	0
46515	1624	11 alpha-	[11 alpha-]	1.0	2	1	0	0
46516	1624	erythroid kruppel-like	[erythroid Kruppel-like]	1.0	2	2	1	1
46517	1624	n-acetyl cysteine	[N-acetyl cysteine]	1.0	2	1	0	0
46518	1624	endotoxin tolerance	[endotoxin tolerance]	1.0	2	1	0	0
46519	1624	il-4- factor such as STAT	[IL-4- factors such as STAT]	1.0	5	1	0	0
46520	1624	relb protein	[RelB protein]	1.0	2	2	1	1
46521	1624	distinct histogenetic subtype of hodgkin' disease	[distinct histogenetic subtypes of Hodgkin's disease]	1.0	6	1	0	0
46522	1624	gardnerella vaginalis	[Gardnerella vaginalis]	1.0	2	1	0	0
46523	1624	differentiation pathway of cell precursor	[differentiation pathway of cell precursors]	1.0	5	1	0	0
46524	1624	novel subgroup	[novel subgroup]	1.0	2	1	0	0
46525	1624	30 nucleotide	[30 nucleotides]	1.0	2	1	0	0
46526	1624	two group of patient suffer	[two groups of patients suffering]	1.0	5	1	0	0
46527	1624	respect to polymorphonuclear leukocyte adhesion	[respect to polymorphonuclear leukocyte adhesion]	1.0	5	1	0	0
46528	1624	expression of rrna encode receptor	[expression of mRNAs encoding receptors]	1.0	5	1	0	0
46529	1624	two form of transcription factor creb	[Two forms of transcription factor CREB]	1.0	6	2	2	2
46530	1624	malignant transformation.	[malignant transformation.]	1.0	2	1	0	0
46531	1624	E2A gene	[E2A gene]	1.0	2	1	0	0
46532	1624	nuclear factor-kappa B/Rel nuclear activity	[nuclear factor-kappa B/Rel nuclear activity]	1.0	5	1	0	0
46533	1624	include the 2.3-kb coding region,	[including the 2.3-kb coding region,]	1.0	5	1	0	0
46534	1624	mrna splicing	[mRNA splicing]	1.0	2	1	0	0
46535	1624	constitutive induction	[constitutive induction]	1.0	2	2	2	2
46536	1624	up-regulation of endogenous il-1ra production	[up-regulation of endogenous IL-1ra production]	1.0	5	1	0	0
46537	1624	Thus, RFX5	[Thus, RFX5]	1.0	2	1	0	0
46538	1624	effect of anti-estrogen toremifene therapy	[effect of anti-estrogen toremifene therapy]	1.0	5	1	0	0
46539	1624	full differentiation response with combination	[full differentiation response with combinations]	1.0	5	1	0	0
46540	1624	clone with promoter of irf-2	[clones with promoter of IRF-2]	1.0	5	1	0	0
46541	1624	key role in the development	[key role in the development]	1.0	5	1	0	0
46542	1624	latent state	[latent state]	1.0	2	1	0	0
46543	1624	include cell	[including cells]	1.0	2	2	2	2
46544	1624	-dependent transactivation of a reporter gene	[-dependent transactivation of a reporter gene]	1.0	6	1	0	0
46545	1624	recognize DNA	[recognizing DNA]	1.0	2	2	2	2
46546	1624	class antibody	[class antibodies]	1.0	2	2	2	2
46547	1624	alf1 activity	[ALF1 activity]	1.0	2	1	0	0
46548	1624	PML expression	[PML expression]	1.0	2	2	1	1
46549	1624	fact that:	[fact that:]	1.0	2	1	0	0
46550	1624	response to tumor necrosis factor-alpha	[response to tumor necrosis factor-alpha]	1.0	5	1	0	0
46551	1624	ctl-specific expression	[CTL-specific expression]	1.0	2	2	1	1
46552	1624	nfat dna-binding activity in T cell	[NFAT DNA-binding activity in T cells]	1.0	6	1	0	0
46553	1624	circadian variation in cortisol concentration	[circadian variation in cortisol concentration]	1.0	5	1	0	0
46554	1624	use a novel flow-cytometric assay	[Using a novel flow-cytometric assay]	1.0	5	1	0	0
46555	1624	T cell proliferation in Hashimoto' thyroiditis	[T cell proliferation in Hashimoto's thyroiditis]	1.0	6	1	0	0
46556	1624	NF-E2/AP1 motif	[NF-E2/AP1 motifs]	1.0	2	2	2	2
46557	1624	epo of 5-aminolevulinate synthetase transcript	[EPO of 5-aminolevulinate synthetase transcripts]	1.0	5	1	0	0
46558	1624	stable benzoic derivative of acid	[stable benzoic derivative of acid]	1.0	5	1	0	0
46559	1624	involvement of signal transduction pathway	[involvement of signal transduction pathways]	1.0	5	1	0	0
46560	1624	86 woman with chronic mpd	[86 women with chronic MPDs]	1.0	5	1	0	0
46561	1624	two main piece of datum	[Two main pieces of data]	1.0	5	1	0	0
46562	1624	similarity between the effect of dexamethasone	[Similarities between the effects of dexamethasone]	1.0	6	1	0	0
46563	1624	reverse orientation	[reverse orientation]	1.0	2	1	0	0
46564	1624	three latent membrane protein lmp1	[three latent membrane proteins LMP1]	1.0	5	1	0	0
46565	1624	specific receptor on the surface	[specific receptors on the surface]	1.0	5	1	0	0
46566	1624	different role in gene regulation.	[different roles in gene regulation.]	1.0	5	1	0	0
46567	1624	constitutively express the murine g-csfr	[constitutively expressing the murine G-CSFR]	1.0	5	1	0	0
46568	1624	4 mutated).	[4 mutated).]	1.0	2	1	0	0
46569	1624	ca2+ -modulate cyclophilin ligand CAML	[Ca2+ -modulating cyclophilin ligand CAML]	1.0	5	1	0	0
46570	1624	cref cell	[CREF cells]	1.0	2	2	1	1
46571	1624	functional Jun	[functional Jun]	1.0	2	1	0	0
46572	1624	adult T cell mean values:	[adult T cells mean values:]	1.0	5	1	0	0
46573	1624	social support from the patient' physician	[social support from the patient's physician]	1.0	6	1	0	0
46574	1624	high level of all nf-kappa b	[high levels of all NF-kappa B]	1.0	6	1	0	0
46575	1624	cause the haploinsufficiency of pax gene	[causing the haploinsufficiency of Pax genes]	1.0	6	1	0	0
46576	1624	haemolytic disease of the newborn	[haemolytic disease of the newborn]	1.0	5	1	0	0
46577	1624	expression of dominant negative n17rac	[Expression of dominant negative N17Rac]	1.0	5	1	0	0
46578	1624	mouse bone	[mouse bone]	1.0	2	2	2	2
46579	1624	edge: dominant effect of Ile50Val variant	[edge: dominant effect of Ile50Val variant]	1.0	6	1	0	0
46580	1624	response to a epstein-barr virus	[response to an Epstein-Barr virus]	1.0	5	1	0	0
46581	1624	primitive erythropoiesis	[primitive erythropoiesis]	1.0	2	1	0	0
46582	1624	level of CRE binding protein	[level of CRE binding protein]	1.0	5	1	0	0
46583	1624	vivo anti-inflammatory effect of IL-11	[vivo anti-inflammatory effects of IL-11]	1.0	5	1	0	0
46584	1624	PML nuclear body PML NBs	[PML nuclear bodies PML NBs]	1.0	5	1	0	0
46585	1624	induce the expression of Jagged1	[inducing the expression of Jagged1]	1.0	5	1	0	0
46586	1624	accumulation of mature b cell	[accumulation of mature B cells]	1.0	5	1	0	0
46587	1624	mammalian pax-2	[mammalian Pax-2]	1.0	2	1	0	0
46588	1624	40 major late promoter erratum	[40 major late promoter erratum]	1.0	5	1	0	0
46589	1624	monocyte chemotactic protein-1 mcp-1 secretion	[monocyte chemotactic protein-1 MCP-1 secretion]	1.0	5	1	0	0
46590	1624	stat5 homologue	[STAT5 homologues]	1.0	2	2	2	2
46591	1624	diffuse large b cell lymphoma	[diffuse large B cell lymphomas]	1.0	5	1	0	0
46592	1624	transcription factor nf kappa b	[transcription factor NF kappa B]	1.0	5	2	1	1
46593	1624	ovulation induction	[ovulation induction]	1.0	2	1	0	0
46594	1624	polyether alcohol	[polyether alcohol]	1.0	2	1	0	0
46595	1624	hinge region	[hinge region]	1.0	2	3	2	1
46596	1624	anti- CD28 together with PMA	[anti- CD28 together with PMA]	1.0	5	1	0	0
46597	1624	murine b-cell	[murine B-cell]	1.0	2	2	1	1
46598	1624	DQB y-box	[DQB Y-box]	1.0	2	1	0	0
46599	1624	current datum	[current data]	1.0	2	1	0	0
46600	1624	different theory of the histogenesis	[different theories of the histogenesis]	1.0	5	1	0	0
46601	1624	LTR size	[LTR size]	1.0	2	2	2	2
46602	1624	survival, proliferation	[survival, proliferation]	1.0	2	1	0	0
46603	1624	human antigen-specific T cell clone	[human antigen-specific T cell clones]	1.0	5	1	0	0
46604	1624	expression of tax protein in 19d	[Expression of Tax protein in 19D]	1.0	6	1	0	0
46605	1624	Northern blot analysis of polyadenylated rna	[Northern blot analysis of polyadenylated RNA]	1.0	6	1	0	0
46606	1624	acute myeloid leukemic (aml) blast	[acute myeloid leukemic (AML) blasts]	1.0	5	1	0	0
46607	1624	Polyclonal CTL	[Polyclonal CTL]	1.0	2	1	0	0
46608	1624	inducible nitric oxide synthase -mRNA level	[inducible nitric oxide synthase -mRNA level]	1.0	6	1	0	0
46609	1624	control of cell cycle entry	[Control of cell cycle entry]	1.0	5	1	0	0
46610	1624	corresponding to the distal nf-at site	[corresponding to the distal NF-AT site]	1.0	6	1	0	0
46611	1624	contain a glucocorticosteroid response element ngre	[containing a glucocorticosteroid response element nGRE]	1.0	6	1	0	0
46612	1624	other MHC class ii ligand	[other MHC class II ligands]	1.0	5	1	0	0
46613	1624	kd-value of approximately 0.1 nm	[Kd-values of approximately 0.1 nM]	1.0	5	1	0	0
46614	1624	inhibitor of factor kappa b	[inhibitor of factor kappa B]	1.0	5	2	2	2
46615	1624	early-late-class phosphoprotein	[early-late-class phosphoprotein]	1.0	2	1	0	0
46616	1624	large sequence	[larger sequences]	1.0	2	1	0	0
46617	1624	naive T	[naive T]	1.0	2	3	2	1
46618	1624	little effect on C5a calcium mobilization	[little effect on C5a calcium mobilization]	1.0	6	1	0	0
46619	1624	affinity for the minor groove	[affinity for the minor groove]	1.0	5	1	0	0
46620	1624	GATA-1 site	[GATA-1 site]	1.0	2	2	2	2
46621	1624	IL-2 tyrosine phosphorylation of stat1 alpha	[IL-2 tyrosine phosphorylation of STAT1 alpha]	1.0	6	1	0	0
46622	1624	circularization of the ebv genome	[Circularization of the EBV genome]	1.0	5	1	0	0
46623	1624	bind specifically	[binding specifically]	1.0	2	2	2	2
46624	1624	triple loop	[triple loop]	1.0	2	1	0	0
46625	1624	nm (mean	[nM (mean]	1.0	2	2	2	2
46626	1624	indicate important for affinity and/or specificity	[indicating important for affinity and/or specificity]	1.0	6	1	0	0
46627	1624	granulocyte-colony-stimulating factor	[granulocyte-colony-stimulating factor]	1.0	2	2	2	2
46628	1624	mean value for plasma aldosterone	[Mean values for plasma aldosterone]	1.0	5	1	0	0
46629	1624	cd28-responsive element	[CD28-responsive element]	1.0	2	1	0	0
46630	1624	rela protein	[RelA proteins]	1.0	2	1	0	0
46631	1624	only partially.	[only partially.]	1.0	2	1	0	0
46632	1624	nucleoside analog	[nucleoside analog]	1.0	2	1	0	0
46633	1624	impairment in the translocation of Rel-B	[Impairments in the translocation of Rel-B]	1.0	6	1	0	0
46634	1624	NFAT-DNA complex	[NFAT-DNA complexes]	1.0	2	1	0	0
46635	1624	tumor er concentration with NK activity	[tumor ER concentration with NK activity]	1.0	6	1	0	0
46636	1624	interleukin-4 IL-4 on cellular function	[interleukin-4 IL-4 on cellular functions]	1.0	5	1	0	0
46637	1624	contain a ap-1 enhancer element	[containing an AP-1 enhancer element]	1.0	5	1	0	0
46638	1624	inhibitor of serine /threonine kinase	[inhibitor of serine /threonine kinases]	1.0	5	2	1	1
46639	1624	bind calcineurin, a calcium-dependent phosphatase	[binding calcineurin, a calcium-dependent phosphatase]	1.0	5	1	0	0
46640	1624	proliferation of various cell lineage	[proliferation of various cell lineages]	1.0	5	1	0	0
46641	1624	indicate the presence of a element	[indicating the presence of a element]	1.0	6	1	0	0
46642	1624	only in epithelial cell line	[only in epithelial cell lines]	1.0	5	1	0	0
46643	1624	variant profile	[variant profile]	1.0	2	1	0	0
46644	1624	interaction at the antigen receptor	[interactions at the antigen receptor]	1.0	5	1	0	0
46645	1624	differential expression of the gene	[differential expression of the genes]	1.0	5	1	0	0
46646	1624	same site.	[same site.]	1.0	2	1	0	0
46647	1624	small complex	[smaller complex]	1.0	2	1	0	0
46648	1624	such as nf-kappab for inducible expression.	[such as NF-kappaB for inducible expression.]	1.0	6	1	0	0
46649	1624	receptor-effector mechanism	[receptor-effector mechanisms]	1.0	2	1	0	0
46650	1624	various tissue	[various tissues]	1.0	2	1	0	0
46651	1624	hl-60 eosinophilic subline with interleukin-5	[HL-60 eosinophilic sublines with interleukin-5]	1.0	5	1	0	0
46652	1624	cell adhesion to endothelial cell	[cell adhesion to endothelial cells]	1.0	5	3	2	1
46653	1624	particular, tax	[particular, Tax]	1.0	2	1	0	0
46654	1624	human dermal microvessel endothelial cell	[human dermal microvessel endothelial cells]	1.0	5	2	2	2
46655	1624	(a) of 125d3 -resistant variant	[(A) of 1,25D3 -resistant variants]	1.0	5	1	0	0
46656	1624	statistical significance	[statistical significance]	1.0	2	2	1	1
46657	1624	cytoplasmic precursor	[cytoplasmic precursor]	1.0	2	2	2	2
46658	1624	yet, for many pathogens, the molecule	[Yet, for many pathogens, the molecules]	1.0	6	1	0	0
46659	1624	gata box	[GATA box]	1.0	2	1	0	0
46660	1624	use ad 2/5 E1a-specific primer	[Using Ad 2/5 E1a-specific primers]	1.0	5	1	0	0
46661	1624	adult-onset form	[adult-onset form]	1.0	2	1	0	0
46662	1624	3' 5' xpb helicase defect	[3' 5' XPB helicase defect]	1.0	5	1	0	0
46663	1624	carry the zinc finger domain	[carrying the zinc finger domains]	1.0	5	1	0	0
46664	1624	JNK MAPKs	[JNK MAPKs]	1.0	2	1	0	0
46665	1624	certain class of AIDS NHL	[Certain classes of AIDS NHL]	1.0	5	1	0	0
46666	1624	virus reservoir	[virus reservoir]	1.0	2	2	2	2
46667	1624	example interleukin-1 MHC class gene	[example interleukin-1 MHC class genes]	1.0	5	1	0	0
46668	1624	breakpoint of most transcript deletion	[breakpoints of most transcript deletions]	1.0	5	1	0	0
46669	1624	anti-ro(ssa) autoantibody	[Anti-Ro(SSA) autoantibodies]	1.0	2	1	0	0
46670	1624	several aspect of cytokine network	[several aspects of cytokine networks]	1.0	5	1	0	0
46671	1624	immune reaction	[immune reactions]	1.0	2	2	1	1
46672	1624	above signals,	[above signals,]	1.0	2	1	0	0
46673	1624	Abl sh3-interacting protein of function.	[Abl SH3-interacting protein of function.]	1.0	5	1	0	0
46674	1624	functionally indistinguishable kappa b complex	[functionally indistinguishable kappa B complexes]	1.0	5	1	0	0
46675	1624	proximal octamer -75 to -66	[proximal octamer -75 to -66]	1.0	5	1	0	0
46676	1624	furthermore, 68 triple-labelling with mab	[Furthermore, 68 triple-labellings with mAbs]	1.0	5	1	0	0
46677	1624	dqa1 allele	[DQA1 allele]	1.0	2	1	0	0
46678	1624	RA effect	[RA effect]	1.0	2	2	1	1
46679	1624	gtp-bound ras in anti- c5b-9 immunoprecipitate	[GTP-bound Ras in anti- C5b-9 immunoprecipitates]	1.0	6	1	0	0
46680	1624	sh-group in the bind domain	[SH-groups in the binding domain]	1.0	5	1	0	0
46681	1624	SRI responder	[SRI responders]	1.0	2	2	2	2
46682	1624	rxr-rxr pathway	[RXR-RXR pathway]	1.0	2	1	0	0
46683	1624	nf-kappab activation in this cells.	[NF-kappaB activation in these cells.]	1.0	5	1	0	0
46684	1624	contain the IL-13 p element site	[containing the IL-13 P element sites]	1.0	6	1	0	0
46685	1624	partial inhibition of LTR activation	[partial inhibition of LTR activation]	1.0	5	1	0	0
46686	1624	10(2) normal cell in vitro.	[10(2) normal cells in vitro.]	1.0	5	1	0	0
46687	1624	effect of the active pkc	[effects of the active PKCs]	1.0	5	1	0	0
46688	1624	two related c-c chemokine receptor-like gene	[two related C-C chemokine receptor-like genes]	1.0	6	1	0	0
46689	1624	tf activity of human monocyte	[TF activity of human monocytes]	1.0	5	1	0	0
46690	1624	primary rhesus monkey alveolar macrophage	[primary rhesus monkey alveolar macrophages]	1.0	5	1	0	0
46691	1624	tonsil b	[tonsil B]	1.0	2	2	2	2
46692	1624	female twin	[female twins]	1.0	2	1	0	0
46693	1624	peripheral blood lymphocyte of patient	[peripheral blood lymphocytes of patients]	1.0	5	2	1	1
46694	1624	native promoter construct in Jurkat cell	[native promoter constructs in Jurkat cells]	1.0	6	1	0	0
46695	1624	unique 60 amino acid carboxy-terminus	[unique 60 amino acid carboxy-terminus]	1.0	5	1	0	0
46696	1624	ORF 68	[ORF 68]	1.0	2	1	0	0
46697	1624	NF-kappa b activation in response	[NF-kappa B activation in response]	1.0	5	1	0	0
46698	1624	modulation of glucocorticoid receptor content	[modulation of glucocorticoid receptor content]	1.0	5	1	0	0
46699	1624	ORF 50	[ORF 50]	1.0	2	1	0	0
46700	1624	novel target for genetic manipulation	[novel targets for genetic manipulation]	1.0	5	1	0	0
46701	1624	analysis of the redox status	[Analysis of the redox status]	1.0	5	1	0	0
46702	1624	conditions, engagement	[conditions, engagement]	1.0	2	1	0	0
46703	1624	internal deletion of the Y box	[internal deletion of the Y box]	1.0	6	1	0	0
46704	1624	specific regulation of two repressor	[specific regulation of two repressors]	1.0	5	1	0	0
46705	1624	contain multiple consensus binding site	[containing multiple consensus binding sites]	1.0	5	1	0	0
46706	1624	pmn (10(-10)	[PMNs (10(-10)]	1.0	2	1	0	0
46707	1624	effect of constitutive tax expression	[effect of constitutive Tax expression]	1.0	5	1	0	0
46708	1624	k46 transfectant	[K46 transfectants]	1.0	2	1	0	0
46709	1624	chronic myelogenous leukemia CML cell	[chronic myelogenous leukemia CML cells]	1.0	5	1	0	0
46710	1624	immunoregulatory protein	[immunoregulatory protein]	1.0	2	2	1	1
46711	1624	also at the translational level	[also at the translational level]	1.0	5	1	0	0
46712	1624	family history	[family history]	1.0	2	2	2	2
46713	1624	TR alpha	[TR alpha]	1.0	2	1	0	0
46714	1624	luciferase construct	[luciferase constructs]	1.0	2	2	2	2
46715	1624	expression (maximal at 4 hours)	[expression (maximal at 4 hours)]	1.0	5	1	0	0
46716	1624	specific consequence of lmp1 expression	[specific consequence of LMP1 expression]	1.0	5	1	0	0
46717	1624	gc box.	[GC box.]	1.0	2	1	0	0
46718	1624	alpha- herpesvirus system herpes simplex	[alpha- herpesvirus systems herpes simplex]	1.0	5	1	0	0
46719	1624	different mutation on each allele:	[different mutation on each allele:]	1.0	5	1	0	0
46720	1624	salicylic acid	[salicylic acid]	1.0	2	2	2	2
46721	1624	pathogen invasion	[pathogen invasion]	1.0	2	1	0	0
46722	1624	binding sites/cell,	[binding sites/cell,]	1.0	2	1	0	0
46723	1624	synthesis of new protein factor	[synthesis of new protein factors]	1.0	5	1	0	0
46724	1624	activation of proviral DNA present	[activation of proviral DNA present]	1.0	5	1	0	0
46725	1624	mutation of the gc box	[mutation of the GC box]	1.0	5	1	0	0
46726	1624	Spi-1/ pu.1	[Spi-1/ PU.1]	1.0	2	2	1	1
46727	1624	lead to disruption of ebv latency	[leading to disruption of EBV latency]	1.0	6	1	0	0
46728	1624	lysis of the normal -resistant cell	[lysis of the normal -resistant cells]	1.0	6	1	0	0
46729	1624	T cell interleukin-2 receptor expression	[T cell interleukin-2 receptor expression]	1.0	5	1	0	0
46730	1624	particular allele	[particular allele]	1.0	2	1	0	0
46731	1624	apparent kd	[apparent Kd]	1.0	2	2	1	1
46732	1624	early branchpoint	[early branchpoints]	1.0	2	1	0	0
46733	1624	premature aging	[premature aging]	1.0	2	1	0	0
46734	1624	two overlapping cosmid encode human ciita	[two overlapping cosmids encoding human CIITA]	1.0	6	1	0	0
46735	1624	none of the non-B lymphoma	[none of the non-B lymphomas]	1.0	5	1	0	0
46736	1624	octamer-binding factor	[octamer-binding factor]	1.0	2	2	1	1
46737	1624	former pathway	[former pathway]	1.0	2	1	0	0
46738	1624	-65 region	[-65 region]	1.0	2	1	0	0
46739	1624	defective NF- chi b site	[defective NF- chi B site]	1.0	5	1	0	0
46740	1624	positive element active in basophil	[positive element active in basophils]	1.0	5	1	0	0
46741	1624	high level of fasL mrna	[high levels of fasL mRNA]	1.0	5	1	0	0
46742	1624	leukemia line	[leukemia line]	1.0	2	2	1	1
46743	1624	classical t(15;17)	[classical t(15;17)]	1.0	2	1	0	0
46744	1624	mitogenically incompetent human g-csfr mutant	[mitogenically incompetent human G-CSFR mutant]	1.0	5	1	0	0
46745	1624	c-terminal 92 amino acid residue	[C-terminal 92 amino acid residues]	1.0	5	1	0	0
46746	1624	amino terminus	[amino terminus]	1.0	2	1	0	0
46747	1624	concentration of the transcription factor	[concentration of the transcription factors]	1.0	5	1	0	0
46748	1624	unique feature	[unique features]	1.0	2	2	1	1
46749	1624	uterine pregnancy	[uterine pregnancy]	1.0	2	2	2	2
46750	1624	different cell	[different cells]	1.0	2	2	2	2
46751	1624	early viral rna splicing pattern	[Early viral RNA splicing patterns]	1.0	5	1	0	0
46752	1624	human b cell line bjab	[human B cell line BJAB]	1.0	5	1	0	0
46753	1624	result in tissue factor expression	[resulting in tissue factor expression]	1.0	5	1	0	0
46754	1624	PMA dose	[PMA dose]	1.0	2	1	0	0
46755	1624	functional complex encompass the cd28re	[functional complexes encompassing the CD28RE]	1.0	5	1	0	0
46756	1624	undergo the phagocytosis of yeast	[undergoing the phagocytosis of yeasts]	1.0	5	1	0	0
46757	1624	marker for B-cell activation, differentiation,	[markers for B-cell activation, differentiation,]	1.0	5	1	0	0
46758	1624	kappa b-site	[kappa B-site]	1.0	2	1	0	0
46759	1624	family of eukaryotic transcription factor	[family of eukaryotic transcription factors]	1.0	5	1	0	0
46760	1624	ikappab inhibitor	[IkappaB inhibitor]	1.0	2	2	2	2
46761	1624	p13mtcp1 protein	[p13MTCP1 protein]	1.0	2	2	1	1
46762	1624	minimal element inducible by lps	[minimal element inducible by LPS]	1.0	5	1	0	0
46763	1624	intragenic promoter	[intragenic promoter]	1.0	2	1	0	0
46764	1624	transcription of a number of cytokine	[transcription of a number of cytokine]	1.0	6	1	0	0
46765	1624	IL-4 treatment	[IL-4 treatment]	1.0	2	1	0	0
46766	1624	internal homology	[internal homology]	1.0	2	1	0	0
46767	1624	rela overexpression	[RelA overexpression]	1.0	2	1	0	0
46768	1624	factor-kappaB induction	[factor-kappaB induction]	1.0	2	2	2	2
46769	1624	transcription stat pathway in asthma	[transcription STAT pathway in asthma]	1.0	5	1	0	0
46770	1624	il-4re of the IL-4 gene	[IL-4RE of the IL-4 gene]	1.0	5	1	0	0
46771	1624	normal response	[normal response]	1.0	2	2	2	2
46772	1624	however, analysis of deletion mutant	[However, analysis of deletion mutants]	1.0	5	1	0	0
46773	1624	rt (2.3	[RT (2.3]	1.0	2	1	0	0
46774	1624	tcf-mediated transcription	[Tcf-mediated transcription]	1.0	2	1	0	0
46775	1624	differentiation-inducing effect	[differentiation-inducing effect]	1.0	2	2	1	1
46776	1624	minority of the total number	[minority of the total number]	1.0	5	1	0	0
46777	1624	tyrosine phosphorylation of signal transducer	[tyrosine phosphorylation of signal transducer]	1.0	5	1	0	0
46778	1624	expression of the gene, suppressor	[expression of the gene, suppressor]	1.0	5	1	0	0
46779	1624	only NF-AT1	[Only NF-AT1]	1.0	2	1	0	0
46780	1624	pharmacological target	[pharmacological target]	1.0	2	1	0	0
46781	1624	induction of expression of differentiation-associated phenotype	[induction of expression of differentiation-associated phenotypes]	1.0	6	1	0	0
46782	1624	promoter induction	[promoter induction]	1.0	2	1	0	0
46783	1624	dose-dependent inhibition of ige synthesis	[dose-dependent inhibition of IgE synthesis]	1.0	5	1	0	0
46784	1624	transcription activator protein-2 binding site	[transcription activator protein-2 binding site]	1.0	5	1	0	0
46785	1624	Pax-5b protein	[Pax-5b proteins]	1.0	2	1	0	0
46786	1624	interleukin-1 induction of gene expression	[interleukin-1 induction of gene expression]	1.0	5	1	0	0
46787	1624	rare disorder	[rare disorder]	1.0	2	2	1	1
46788	1624	5869-bp region include 1695 bp	[5869-bp region including 1695 bp]	1.0	5	1	0	0
46789	1624	major constitutive dnase i-hypersensitive site	[major constitutive DNase I-hypersensitive site]	1.0	5	1	0	0
46790	1624	expression of appropriate reporter gene	[expression of appropriate reporter genes]	1.0	5	1	0	0
46791	1624	mcf13 murine leukemia virus long terminal	[MCF13 murine leukemia virus long terminal]	1.0	6	1	0	0
46792	1624	tpa/ca(2+)-induced signal	[TPA/Ca(2+)-induced signals]	1.0	2	1	0	0
46793	1624	expression of elam-1 p 0.005	[expression of ELAM-1 P 0.005,]	1.0	5	1	0	0
46794	1624	fasl -dependent reporter construct in mrl-lpr/lpr	[FasL -dependent reporter constructs in MRL-lpr/lpr]	1.0	6	1	0	0
46795	1624	RXR-RARalpha403 heterodimer	[RXR-RARalpha403 heterodimers]	1.0	2	1	0	0
46796	1624	assessment of synovial lymphocyte reactivity	[assessment of synovial lymphocyte reactivity]	1.0	5	1	0	0
46797	1624	antioxidant-based therapy	[antioxidant-based therapies]	1.0	2	1	0	0
46798	1624	of induce lap much as am580	[of inducing LAP much as AM580]	1.0	6	1	0	0
46799	1624	135(oh)2d3 binding to a receptor	[1,25(OH)2D3 binding to a receptor]	1.0	5	1	0	0
46800	1624	oncogenic virus	[oncogenic virus]	1.0	2	2	1	1
46801	1624	S-allyl cysteine	[S-allyl cysteine]	1.0	2	1	0	0
46802	1624	strong activation	[strong activation]	1.0	2	2	2	2
46803	1624	dephosphorylated (activated) prb block transition	[dephosphorylated (activated) pRB blocks transition]	1.0	5	1	0	0
46804	1624	mmtv induction	[MMTV induction]	1.0	2	1	0	0
46805	1624	interaction between protein kinase c pkc	[Interaction between protein kinase C PKC]	1.0	6	1	0	0
46806	1624	ability of the G region	[ability of the G region]	1.0	5	1	0	0
46807	1624	virus-replicative lesion in several aspect	[virus-replicative lesions in several aspects]	1.0	5	1	0	0
46808	1624	patient sample	[patient samples]	1.0	2	1	0	0
46809	1624	express e2a-hlf	[expressing E2A-HLF]	1.0	2	2	1	1
46810	1624	follicular lymphoma (25 of 59	[follicular lymphoma (25 of 59]	1.0	5	1	0	0
46811	1624	human matrix	[human matrix]	1.0	2	1	0	0
46812	1624	Recent work	[Recent work]	1.0	2	2	1	1
46813	1624	abnormal regulation of the IL-2 promoter	[Abnormal regulation of the IL-2 promoter]	1.0	6	1	0	0
46814	1624	binding of c-Jun -contain complex	[binding of c-Jun -containing complexes]	1.0	5	1	0	0
46815	1624	ifn-gamma on the transcription factor	[IFN-gamma on the transcription factors]	1.0	5	1	0	0
46816	1624	number of affinity of glucocorticoid-receptors	[number of affinity of glucocorticoid-receptors]	1.0	5	1	0	0
46817	1624	deletion of the CD5 gene	[deletion of the CD5 gene]	1.0	5	1	0	0
46818	1624	Surprisingly, LMP1	[Surprisingly, LMP1]	1.0	2	1	0	0
46819	1624	such mutation	[such mutations]	1.0	2	2	1	1
46820	1624	native hGR	[native hGR]	1.0	2	1	0	0
46821	1624	second site	[second site]	1.0	2	2	1	1
46822	1624	3'NF-E2/AP1 motif	[3'NF-E2/AP1 motif]	1.0	2	1	0	0
46823	1624	ability of nuclear glucocorticoid receptor	[ability of nuclear glucocorticoid receptors]	1.0	5	1	0	0
46824	1624	tyrosine -protein kinase -specific inhibitor	[tyrosine -protein kinase -specific inhibitor]	1.0	5	1	0	0
46825	1624	ebv-immortalized b	[EBV-immortalized B]	1.0	2	1	0	0
46826	1624	specific 'pre-activation'	[specific 'pre-activation']	1.0	2	1	0	0
46827	1624	contain a histone promoter-driven beta-galactosidase gene	[containing a histone promoter-driven beta-galactosidase gene]	1.0	6	1	0	0
46828	1624	fp promoter	[Fp promoter]	1.0	2	1	0	0
46829	1624	intronic enhancer	[intronic enhancer]	1.0	2	1	0	0
46830	1624	NFAT-1 alone	[NFAT-1 alone]	1.0	2	1	0	0
46831	1624	cut/cdp protein a transcriptional repressor	[cut/CDP protein a transcriptional repressor]	1.0	5	1	0	0
46832	1624	alpha activation;	[alpha activation;]	1.0	2	1	0	0
46833	1624	calcineurin kappab -dependent reporter activity	[calcineurin kappaB -dependent reporter activity]	1.0	5	1	0	0
46834	1624	downstream event of the activation cascade	[downstream events of the activation cascade]	1.0	6	1	0	0
46835	1624	glucocorticoid in peripheral blood leukocyte	[glucocorticoids in peripheral blood leukocytes]	1.0	5	1	0	0
46836	1624	-dependent cell	[-dependent cell]	1.0	2	1	0	0
46837	1624	member of the nuclear receptor superfamily	[members of the nuclear receptor superfamily]	1.0	6	1	0	0
46838	1624	jurkat-derived T	[Jurkat-derived T]	1.0	2	1	0	0
46839	1624	identification of transcriptional suppressor protein	[Identification of transcriptional suppressor proteins]	1.0	5	1	0	0
46840	1624	anti-e-selectin mab	[anti-E-selectin mAb]	1.0	2	1	0	0
46841	1624	p50 alone	[p50 alone]	1.0	2	1	0	0
46842	1624	ICAM-I mRNA	[ICAM-I mRNA]	1.0	2	1	0	0
46843	1624	glycophorin a	[glycophorin A]	1.0	2	2	1	1
46844	1624	cell cycle progression use flow cytometry	[cell cycle progression using flow cytometry]	1.0	6	1	0	0
46845	1624	Native PTF beta in protein fraction	[Native PTF beta in protein fractions]	1.0	6	1	0	0
46846	1624	refractory anemia with ring sideroblast	[refractory anemia with ring sideroblasts]	1.0	5	1	0	0
46847	1624	convenient generation	[convenient generation]	1.0	2	1	0	0
46848	1624	CD30 ligation	[CD30 ligation]	1.0	2	1	0	0
46849	1624	repression event	[repression events]	1.0	2	1	0	0
46850	1624	hb synthesis	[Hb synthesis]	1.0	2	2	2	2
46851	1624	include CD2	[including CD2]	1.0	2	1	0	0
46852	1624	novel growth-factor-dependent myeloid cell line	[novel growth-factor-dependent myeloid cell line]	1.0	5	1	0	0
46853	1624	monocytoid cell	[monocytoid cells]	1.0	2	1	0	0
46854	1624	peroxisome proliferator-activated receptor ppar member	[Peroxisome proliferator-activated receptors PPARs members]	1.0	5	1	0	0
46855	1624	subclone to dexamethasone in serum-free medium	[subclones to dexamethasone in serum-free medium]	1.0	6	1	0	0
46856	1624	expression of factor kappa b	[expression of factor kappa B]	1.0	5	1	0	0
46857	1624	many kind	[many kinds]	1.0	2	1	0	0
46858	1624	b-cell-specific cofactor	[B-cell-specific cofactor]	1.0	2	2	1	1
46859	1624	abnormal hematopoiesis	[abnormal hematopoiesis]	1.0	2	1	0	0
46860	1624	Fusion of subdomain of bob.1/obf.1	[Fusion of subdomains of BOB.1/OBF.1]	1.0	5	1	0	0
46861	1624	prb 105	[pRb 105]	1.0	2	1	0	0
46862	1624	interindividual variation	[interindividual variation]	1.0	2	2	2	2
46863	1624	negatively acting	[negatively acting]	1.0	2	1	0	0
46864	1624	product of the ets-1 proto-oncogene	[product of the ets-1 proto-oncogene]	1.0	5	1	0	0
46865	1624	inducible promoter contain cis element	[inducible promoter containing cis elements]	1.0	5	1	0	0
46866	1624	human lymphocyte g0/g1 switch gene	[human lymphocyte G0/G1 switch gene]	1.0	5	2	2	2
46867	1624	normal role	[normal role]	1.0	2	1	0	0
46868	1624	follow autologous pbsct in study.	[following autologous PBSCT in study.]	1.0	5	1	0	0
46869	1624	human hsf1	[human HSF1]	1.0	2	1	0	0
46870	1624	interfer with nf-kappab activation proteasome inhibitor	[Interfering with NF-kappaB activation proteasome inhibitor]	1.0	6	1	0	0
46871	1624	express the hla-dr11 restrict molecule	[expressing the HLA-DR11 restricting molecule]	1.0	5	1	0	0
46872	1624	provocative mechanism for the disruption	[provocative mechanism for the disruption]	1.0	5	1	0	0
46873	1624	prime with anti-cd28 in the absence	[priming with anti-CD28 in the absence]	1.0	6	1	0	0
46874	1624	KOX 25 on chromosome band 7q21q22	[KOX 25 on chromosome bands 7q21q22]	1.0	6	1	0	0
46875	1624	c-Myb protein	[c-Myb protein]	1.0	2	1	0	0
46876	1624	oestrogen on oestrogen -receptive organ	[oestrogens on oestrogen -receptive organs]	1.0	5	1	0	0
46877	1624	MHC class ii antigen processing	[MHC class II antigen processing]	1.0	5	1	0	0
46878	1624	p50.c-rel heterodimer	[p50.c-rel heterodimers]	1.0	2	1	0	0
46879	1624	phase 1	[phase 1]	1.0	2	2	1	1
46880	1624	phase 2	[phase 2]	1.0	2	1	0	0
46881	1624	Btk expression	[Btk expression]	1.0	2	1	0	0
46882	1624	soluble beta-(1,3)-glucan	[soluble beta-(1,3)-glucan]	1.0	2	1	0	0
46883	1624	p40-kappaB site	[p40-kappaB site]	1.0	2	1	0	0
46884	1624	putative transcription factor with affinity	[putative transcription factor with affinity]	1.0	5	1	0	0
46885	1624	Staurosporine alone	[Staurosporine alone]	1.0	2	1	0	0
46886	1624	5-10% difference in virus production	[5-10% difference in virus production]	1.0	5	1	0	0
46887	1624	different hiv-1 LTR -based vector	[different HIV-1 LTR -based vectors]	1.0	5	1	0	0
46888	1624	expression of this key regulator	[expression of these key regulators]	1.0	5	1	0	0
46889	1624	native protein	[native proteins]	1.0	2	1	0	0
46890	1624	Jak -STAT pathway in T cell	[Jak -STAT pathway in T cells]	1.0	6	1	0	0
46891	1624	granulocyte lineage	[granulocyte lineage]	1.0	2	1	0	0
46892	1624	expression of a reporter construct	[expression of a reporter construct]	1.0	5	1	0	0
46893	1624	include phorbol 12-myristate 13-acetate PMA	[including phorbol 12-myristate 13-acetate PMA]	1.0	5	1	0	0
46894	1624	activin a	[activin A]	1.0	2	2	1	1
46895	1624	protect naive b cell from apoptosis	[protecting naive B cells from apoptosis]	1.0	6	1	0	0
46896	1624	other monocytic/myeloid leukemia-derived cell line	[other monocytic/myeloid leukemia-derived cell lines]	1.0	5	1	0	0
46897	1624	activin A	[activin A]	1.0	2	1	0	0
46898	1624	lung transplantation	[lung transplantation]	1.0	2	2	1	1
46899	1624	chromatin fragmentation	[chromatin fragmentation]	1.0	2	2	1	1
46900	1624	patients' cell	[patients' cells]	1.0	2	1	0	0
46901	1624	Kit225 cell	[Kit225 cells]	1.0	2	1	0	0
46902	1624	kappa b gamma isoform with activity	[kappa B gamma isoforms with activities]	1.0	6	1	0	0
46903	1624	regulate the stringency of viral latency	[regulating the stringency of viral latency]	1.0	6	1	0	0
46904	1624	migration of 48-hr media-stimulated t-cell	[migration of 48-hr media-stimulated T-cells]	1.0	5	1	0	0
46905	1624	7.27 micromol/L.	[7.27 micromol/L.]	1.0	2	1	0	0
46906	1624	latter phenomenon	[latter phenomenon]	1.0	2	1	0	0
46907	1624	untransfected cell	[untransfected cells]	1.0	2	1	0	0
46908	1624	IL-2 production by CsA cell	[IL-2 production by CsA cells]	1.0	5	1	0	0
46909	1624	Glucocorticoid receptor in blood mononuclear cell	[Glucocorticoid receptors in blood mononuclear cells]	1.0	6	1	0	0
46910	1624	include possibly other sp1 binding protein	[including possibly other Sp1 binding proteins]	1.0	6	1	0	0
46911	1624	addition to the hmg domain	[addition to the HMG domain]	1.0	5	1	0	0
46912	1624	post-transcriptional level	[post-transcriptional level]	1.0	2	1	0	0
46913	1624	novel site	[novel site]	1.0	2	2	1	1
46914	1624	contain deletion in the same samples.	[containing deletions in the same samples.]	1.0	6	1	0	0
46915	1624	excess beta-catenin	[Excess beta-catenin]	1.0	2	1	0	0
46916	1624	nuclear extract from PMA cell	[nuclear extracts from PMA cells]	1.0	5	1	0	0
46917	1624	basic fibroblast growth factor bFGF	[basic fibroblast growth factor bFGF]	1.0	5	1	0	0
46918	1624	two tiny ring x chromosome	[two tiny ring X chromosomes]	1.0	5	1	0	0
46919	1624	one site	[one site]	1.0	2	2	1	1
46920	1624	interruption in response gene inducibility	[interruption in response gene inducibility]	1.0	5	1	0	0
46921	1624	event other than Jak3 /Stat activation	[events other than Jak3 /Stat activation]	1.0	6	1	0	0
46922	1624	loss of heterozygosity in pb granulocyte	[Loss of heterozygosity in PB granulocytes]	1.0	6	1	0	0
46923	1624	use immunohistochemistry	[using immunohistochemistry]	1.0	2	2	2	2
46924	1624	high intracellular level of camp	[high intracellular levels of cAMP]	1.0	5	1	0	0
46925	1624	internal standard consist of concentration	[internal standard consisting of concentrations]	1.0	5	1	0	0
46926	1624	ligation of a distinct inhibitory receptor	[ligation of a distinct inhibitory receptor]	1.0	6	1	0	0
46927	1624	gene encode eosinophil granule protein	[genes encoding eosinophil granule proteins]	1.0	5	1	0	0
46928	1624	E-selectin upregulation	[E-selectin upregulation]	1.0	2	1	0	0
46929	1624	relevance of this molecular event	[relevance of these molecular events]	1.0	5	1	0	0
46930	1624	differentiation of naive th cell	[differentiation of naive Th cells]	1.0	5	1	0	0
46931	1624	implicate the involvement of a protein	[implicating the involvement of an protein]	1.0	6	1	0	0
46932	1624	cytokine gene indicate a function	[cytokine genes indicating a function]	1.0	5	1	0	0
46933	1624	own production, indicate the presence	[own production, indicating the presence]	1.0	5	1	0	0
46934	1624	cytolytic lymphocyte	[cytolytic lymphocytes]	1.0	2	2	1	1
46935	1624	investigate cytokine	[Investigating cytokines]	1.0	2	1	0	0
46936	1624	association with the p62 complex	[association with the p62 complex]	1.0	5	1	0	0
46937	1624	novel amino-	[novel amino-]	1.0	2	1	0	0
46938	1624	cell sorter	[Cell sorter]	1.0	2	2	2	2
46939	1624	Ca(2+)-stimulated K+	[Ca(2+)-stimulated K+]	1.0	2	1	0	0
46940	1624	unphosphorylated protein	[unphosphorylated proteins]	1.0	2	1	0	0
46941	1624	binding site for a protein	[binding site for a protein]	1.0	5	1	0	0
46942	1624	use inhibitor	[using inhibitors]	1.0	2	2	2	2
46943	1624	thymic cortex	[thymic cortex]	1.0	2	1	0	0
46944	1624	calcium-mobilize receptor to nuclear factor	[calcium-mobilizing receptors to nuclear factor]	1.0	5	1	0	0
46945	1624	continuous process,	[continuous process,]	1.0	2	1	0	0
46946	1624	include Cbl	[including Cbl]	1.0	2	1	0	0
46947	1624	alter the th1/th2 balance in condition	[altering the Th1/Th2 balance in conditions]	1.0	6	1	0	0
46948	1624	initial proliferation of rest b lymphocyte	[initial proliferation of resting B lymphocytes]	1.0	6	1	0	0
46949	1624	critical step	[critical step]	1.0	2	2	2	2
46950	1624	T cell surface molecule CD28	[T cell surface molecule CD28]	1.0	5	1	0	0
46951	1624	PMA nf-at	[PMA NF-AT]	1.0	2	1	0	0
46952	1624	5-day culture	[5-day culture]	1.0	2	1	0	0
46953	1624	pzvh14 (8.7	[pZVH14 (8.7]	1.0	2	1	0	0
46954	1624	ifn-beta treatment	[IFN-beta treatment]	1.0	2	1	0	0
46955	1624	antihypertensive therapy	[antihypertensive therapy]	1.0	2	2	2	2
46956	1624	possible use	[possible use]	1.0	2	2	2	2
46957	1624	bind distinct c-fos/c-jun promoter element	[binding distinct c-fos/c-jun promoter elements]	1.0	5	1	0	0
46958	1624	number of signal transduction pathway	[number of signal transduction pathways]	1.0	5	1	0	0
46959	1624	6-keto-PGF1 alpha	[6-keto-PGF1 alpha]	1.0	2	1	0	0
46960	1624	native monocyte	[native monocytes]	1.0	2	1	0	0
46961	1624	anti-inflammatory remedy	[anti-inflammatory remedies]	1.0	2	1	0	0
46962	1624	receptor, cd21	[receptor, CD21]	1.0	2	2	1	1
46963	1624	intact nuclei	[intact nuclei]	1.0	2	1	0	0
46964	1624	IL-4 inducibility	[IL-4 inducibility]	1.0	2	1	0	0
46965	1624	Jak1 activity	[Jak1 activity]	1.0	2	1	0	0
46966	1624	m) activation of NF-kappa b	[M) activation of NF-kappa B]	1.0	5	1	0	0
46967	1624	use of a reporter construct	[use of a reporter construct]	1.0	5	1	0	0
46968	1624	human zeta	[human zeta]	1.0	2	1	0	0
46969	1624	only mechanism,	[only mechanism,]	1.0	2	1	0	0
46970	1624	TNF activation of nf-kappa b	[TNF activation of NF-kappa B]	1.0	5	1	0	0
46971	1624	cell of the granulocyte-macrophage lineage	[cells of the granulocyte-macrophage lineage]	1.0	5	1	0	0
46972	1624	constitutive expression of 135eoh)2d3 receptor rna	[Constitutive expression of 1,25(OH)2D3 receptor RNA]	1.0	6	1	0	0
46973	1624	appreciable level of CAT activity	[appreciable level of CAT activity]	1.0	5	1	0	0
46974	1624	corresponding to residue of the protein	[corresponding to residues of the protein]	1.0	6	1	0	0
46975	1624	nuclear nfat	[nuclear NFAT]	1.0	2	1	0	0
46976	1624	maximal response	[maximal response]	1.0	2	2	2	2
46977	1624	differentiation-promoting substance	[differentiation-promoting substances]	1.0	2	1	0	0
46978	1624	chromosome loss	[chromosome loss]	1.0	2	1	0	0
46979	1624	PLZF-RAR alpha	[PLZF-RAR alpha]	1.0	2	1	0	0
46980	1624	protein kinase inhibitor h-7 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine	[protein kinase inhibitor H-7 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine]	1.0	5	1	0	0
46981	1624	tat 22/	[tat 22/S]	1.0	2	1	0	0
46982	1624	t-cell line with tal-1 rearrangement	[T-cell lines with tal-1 rearrangements]	1.0	5	1	0	0
46983	1624	major determinant of b-cell-specific expression	[major determinant of B-cell-specific expression]	1.0	5	1	0	0
46984	1624	upregulation of c-fo in T lymphoid	[Upregulation of c-Fos in T lymphoid]	1.0	6	1	0	0
46985	1624	key regulator of lymphocyte proliferation	[key regulator of lymphocyte proliferation]	1.0	5	1	0	0
46986	1624	(100 micrograms/ml)	[(100 micrograms/ml)]	1.0	2	1	0	0
46987	1624	detergent-insoluble cytoskeleton	[detergent-insoluble cytoskeleton]	1.0	2	1	0	0
46988	1624	various vcam-1 promoter reporter gene construct	[various VCAM-1 promoter reporter gene constructs]	1.0	6	1	0	0
46989	1624	brain ischemia	[brain ischemia]	1.0	2	1	0	0
46990	1624	DNA binding activity nuclear factor	[DNA binding activity nuclear factor]	1.0	5	1	0	0
46991	1624	regulation of the cell cycle	[regulation of the cell cycle]	1.0	5	1	0	0
46992	1624	contrast, development into NK cell	[contrast, development into NK cells]	1.0	5	1	0	0
46993	1624	unknown step in the transmission	[unknown step in the transmission]	1.0	5	1	0	0
46994	1624	second phase,	[second phase,]	1.0	2	1	0	0
46995	1624	follow human CMV hcmv infection	[following human CMV HCMV infection]	1.0	5	1	0	0
46996	1624	about the very early event	[about the very early events]	1.0	5	1	0	0
46997	1624	action of the Nef protein,	[action of the Nef protein,]	1.0	5	1	0	0
46998	1624	more profoundly for protein substrate	[more profoundly for protein substrate]	1.0	5	1	0	0
46999	1624	normal mature human b lymphocyte	[normal mature human B lymphocytes]	1.0	5	1	0	0
47000	1624	prominent constitutive binding between JAK1	[prominent constitutive binding between JAK1]	1.0	5	1	0	0
47001	1624	several form of egr-1 protein	[Several forms of EGR-1 protein]	1.0	5	1	0	0
47002	1624	oxidative process	[oxidative processes]	1.0	2	1	0	0
47003	1624	oxidative signalling during lymphocyte activation	[oxidative signalling during lymphocyte activation]	1.0	5	1	0	0
47004	1624	relative efficiency of the enhancer	[relative efficiency of the enhancers]	1.0	5	1	0	0
47005	1624	tumor necrosis factor 3 traf3	[tumor necrosis factor 3 TRAF3]	1.0	5	1	0	0
47006	1624	efficient down-regulation of caii transcription	[efficient down-regulation of CAII transcription]	1.0	5	1	0	0
47007	1624	inhibitor of cytosolic phospholipase a2	[inhibitors of cytosolic phospholipase A2]	1.0	5	1	0	0
47008	1624	R.C. Gallo, Science 231:850-853, 1986).	[R.C. Gallo, Science 231:850-853, 1986).]	1.0	5	1	0	0
47009	1624	IL-4Ralpha chain	[IL-4Ralpha chain]	1.0	2	2	1	1
47010	1624	cell protein	[cell protein]	1.0	2	2	2	2
47011	1624	RA synovitis	[RA synovitis]	1.0	2	1	0	0
47012	1624	ligand-dependent opening	[ligand-dependent opening]	1.0	2	1	0	0
47013	1624	activator site	[activator site]	1.0	2	2	2	2
47014	1624	NF-microB-binding site	[NF-microB-binding site]	1.0	2	1	0	0
47015	1624	activity of multiple effector pathway	[activity of multiple effector pathways]	1.0	5	1	0	0
47016	1624	NRL in rat mammary carcinoma	[NRL in rat mammary carcinomas]	1.0	5	1	0	0
47017	1624	abortive stimulation lead to anergy	[abortive stimulation leading to anergy]	1.0	5	1	0	0
47018	1624	mitogenic signal	[mitogenic signaling]	1.0	2	1	0	0
47019	1624	lipid mediator	[lipid mediator]	1.0	2	2	1	1
47020	1624	cellular surface	[cellular surface]	1.0	2	1	0	0
47021	1624	murine leukemia virus enhancer core	[murine leukemia virus enhancer cores]	1.0	5	1	0	0
47022	1624	high rate	[higher rate]	1.0	2	2	1	1
47023	1624	membrane level	[membrane level]	1.0	2	1	0	0
47024	1624	probe Fr35-II	[probe Fr35-II]	1.0	2	1	0	0
47025	1624	intraperitoneally (i.p.)	[intraperitoneally (i.p.)]	1.0	2	1	0	0
47026	1624	Recently, investigator	[Recently, investigators]	1.0	2	1	0	0
47027	1624	substantial evidence	[substantial evidence]	1.0	2	2	2	2
47028	1624	CD2 cross-linking phosphorylation of CREB	[CD2 cross-linking phosphorylation of CREB]	1.0	5	1	0	0
47029	1624	expression of human immunodeficiency virus hiv	[expression of human immunodeficiency virus HIV]	1.0	6	1	0	0
47030	1624	new probe	[new probes]	1.0	2	2	1	1
47031	1624	encephalomyocarditis virus entry site rna-protein interaction	[Encephalomyocarditis virus entry site RNA-protein interactions]	1.0	6	1	0	0
47032	1624	sp1 motif	[SP1 motifs]	1.0	2	1	0	0
47033	1624	only in the NFAT family	[only in the NFAT family]	1.0	5	1	0	0
47034	1624	necessary feature	[necessary feature]	1.0	2	1	0	0
47035	1624	eosinophil peroxidase	[eosinophil peroxidase]	1.0	2	2	1	1
47036	1624	gene encode a chicken cytokine	[gene encoding a chicken cytokine]	1.0	5	1	0	0
47037	1624	effect of n-acetyl-l-cysteine nac antioxidant	[effects of N-acetyl-L-cysteine NAC antioxidant]	1.0	5	1	0	0
47038	1624	biochemical signal	[biochemical signals]	1.0	2	2	2	2
47039	1624	N element with the sequence	[N element with the sequence]	1.0	5	1	0	0
47040	1624	6 mAECA	[6 mAECA]	1.0	2	1	0	0
47041	1624	view of the increase use	[view of the increasing use]	1.0	5	1	0	0
47042	1624	inappropriate cell	[inappropriate cells]	1.0	2	1	0	0
47043	1624	defective translocation of protein kinase c	[Defective translocation of protein kinase C]	1.0	6	1	0	0
47044	1624	regulation of gr binding by FKBP51	[Regulation of GR binding by FKBP51]	1.0	6	1	0	0
47045	1624	native hugata-3	[native huGATA-3]	1.0	2	1	0	0
47046	1624	co-cultured bm	[co-cultured BM]	1.0	2	1	0	0
47047	1624	ems analysis	[EMS analyses]	1.0	2	2	1	1
47048	1624	cellular promoter of certain growth-	[cellular promoters of certain growth-]	1.0	5	1	0	0
47049	1624	b7 costimulation on IL-2 expression	[B7 costimulation on IL-2 expression]	1.0	5	1	0	0
47050	1624	Schizosaccharomyces pombe Mc mating type	[Schizosaccharomyces pombe Mc mating type]	1.0	5	1	0	0
47051	1624	(termed UAS1	[(termed UAS1]	1.0	2	1	0	0
47052	1624	only cell	[only cells]	1.0	2	2	1	1
47053	1624	analogous pattern	[analogous pattern]	1.0	2	1	0	0
47054	1624	T cell from this patient	[T cells from these patients]	1.0	5	1	0	0
47055	1624	mature macrophages.	[mature macrophages.]	1.0	2	1	0	0
47056	1624	total workload	[total workload]	1.0	2	1	0	0
47057	1624	anti-cd28 mab to anti-CD3-stimulated cell	[anti-CD28 mAb to anti-CD3-stimulated cells]	1.0	5	1	0	0
47058	1624	NF-kappa b binding to consensus sequence	[NF-kappa B binding to consensus sequences]	1.0	6	1	0	0
47059	1624	use a panel of B-cell line	[using a panel of B-cell lines]	1.0	6	1	0	0
47060	1624	ebv -receptor interaction on T cell	[EBV -receptor interactions on T cells]	1.0	6	1	0	0
47061	1624	novel mitogen-inducible gene product related	[novel mitogen-inducible gene product related]	1.0	5	1	0	0
47062	1624	activator sequence within the repeat	[activator sequence within the repeat]	1.0	5	1	0	0
47063	1624	Reverse transcription-PCR	[Reverse transcription-PCR]	1.0	2	1	0	0
47064	1624	inducibility of the IL-2 promoter	[inducibility of the IL-2 promoter]	1.0	5	1	0	0
47065	1624	activation of this protein, hstat5	[activation of this protein, hStat5]	1.0	5	1	0	0
47066	1624	characterization of defensin resistance phenotype	[Characterization of defensin resistance phenotypes]	1.0	5	1	0	0
47067	1624	such methods,	[such methods,]	1.0	2	1	0	0
47068	1624	dexamethasone DEX	[dexamethasone DEX]	1.0	2	2	2	2
47069	1624	b lymphocyte from the peripheral blood	[B lymphocytes from the peripheral blood]	1.0	6	1	0	0
47070	1624	indicate enhancement of adipocyte differentiation	[indicating enhancement of adipocyte differentiation]	1.0	5	1	0	0
47071	1624	nf(p) binding	[NF(P) binding]	1.0	2	1	0	0
47072	1624	hot acetic	[hot acetic]	1.0	2	1	0	0
47073	1624	oap40 element	[OAP40 element]	1.0	2	1	0	0
47074	1624	(3h)-e2 binding	[(3H)-E2 binding]	1.0	2	1	0	0
47075	1624	expression of this t-cell gene	[expression of these T-cell genes]	1.0	5	1	0	0
47076	1624	most mutation	[Most mutations]	1.0	2	1	0	0
47077	1624	single oligonucleotide	[single oligonucleotides]	1.0	2	1	0	0
47078	1624	proliferative samples,	[proliferative samples,]	1.0	2	1	0	0
47079	1624	normal myelopoiesis	[normal myelopoiesis]	1.0	2	1	0	0
47080	1624	adhesion property of hl-60 granulocyte	[adhesion properties of HL-60 granulocytes]	1.0	5	1	0	0
47081	1624	respective LTR	[respective LTR]	1.0	2	1	0	0
47082	1624	contrast, factor	[contrast, factors]	1.0	2	2	2	2
47083	1624	protein-affinity chromatography	[protein-affinity chromatography]	1.0	2	1	0	0
47084	1624	prostaglandin pge2 in human monocyte	[prostaglandin PGE2 in human monocytes]	1.0	5	1	0	0
47085	1624	cd3+ T cell in tissue	[CD3+ T cells in tissues]	1.0	5	1	0	0
47086	1624	interleukin-6 expression	[interleukin-6 expression]	1.0	2	2	2	2
47087	1624	certainly cytokine	[certainly cytokines]	1.0	2	1	0	0
47088	1624	early b-cell	[early B-cell]	1.0	2	1	0	0
47089	1624	two genes.	[two genes.]	1.0	2	1	0	0
47090	1624	CD19 expression	[CD19 expression]	1.0	2	1	0	0
47091	1624	same language.	[same language.]	1.0	2	1	0	0
47092	1624	cell activation by bacterial lipoprotein	[Cell activation by bacterial lipoproteins]	1.0	5	1	0	0
47093	1624	two distinct mitogen-inducible dna-binding complex	[two distinct mitogen-inducible DNA-binding complexes]	1.0	5	1	0	0
47094	1624	active enzyme	[active enzyme]	1.0	2	1	0	0
47095	1624	competition study with steroid ligands.	[competition studies with steroid ligands.]	1.0	5	1	0	0
47096	1624	Maximal induction of the c-fo gene	[Maximal induction of the c-fos gene]	1.0	6	1	0	0
47097	1624	such marker	[Such markers]	1.0	2	1	0	0
47098	1624	cd19 protein	[CD19 protein]	1.0	2	1	0	0
47099	1624	erythroid cell growth in vitro,	[erythroid cell growth in vitro,]	1.0	5	1	0	0
47100	1624	activity of the dprl promoter	[activity of the dPRL promoter]	1.0	5	1	0	0
47101	1624	th1/th2 balance	[TH1/TH2 balance]	1.0	2	2	1	1
47102	1624	IL-2 regulation of stat3 protein	[IL-2 regulation of STAT3 proteins]	1.0	5	1	0	0
47103	1624	material in the present work,	[MATERIALS In the present work,]	1.0	5	1	0	0
47104	1624	low range	[lower range]	1.0	2	2	2	2
47105	1624	unresuscitated hs	[unresuscitated HS]	1.0	2	1	0	0
47106	1624	noticeable side-effect	[noticeable side-effects]	1.0	2	1	0	0
47107	1624	conalbumin promoter	[conalbumin promoter]	1.0	2	2	1	1
47108	1624	tartrate-resistant acid	[tartrate-resistant acid]	1.0	2	1	0	0
47109	1624	radiologic finding	[radiologic findings]	1.0	2	1	0	0
47110	1624	rapid proliferation	[rapid proliferation]	1.0	2	1	0	0
47111	1624	SIT interact transmembrane adaptor protein	[SIT interacting transmembrane adaptor protein]	1.0	5	1	0	0
47112	1624	Band A	[Band A]	1.0	2	1	0	0
47113	1624	Cyclosporine CsA	[Cyclosporine CsA]	1.0	2	1	0	0
47114	1624	down-modulation of okadaic acid phosphatase	[down-modulation of okadaic acid phosphatases]	1.0	5	1	0	0
47115	1624	n-acetyl-L-cysteine NAC a potent thiol antioxidant	[n-acetyl-L-cysteine NAC a potent thiol antioxidant]	1.0	6	1	0	0
47116	1624	mouse AML1/	[mouse AML1/]	1.0	2	2	2	2
47117	1624	stimulate the expression of several genes.	[stimulating the expression of several genes.]	1.0	6	1	0	0
47118	1624	dendritic cells,	[dendritic cells,]	1.0	2	1	0	0
47119	1624	broad spectrum of K+ channel	[broad spectrum of K+ channels]	1.0	5	1	0	0
47120	1624	expression of v-src in T cell	[Expression of v-src in T cells]	1.0	6	1	0	0
47121	1624	wild-type gene	[wild-type gene]	1.0	2	1	0	0
47122	1624	Fas CD95	[Fas CD95]	1.0	2	1	0	0
47123	1624	affinity close	[affinity close]	1.0	2	1	0	0
47124	1624	b lymphopoiesis	[B lymphopoiesis]	1.0	2	2	2	2
47125	1624	higher-molecular-weight species of NFATc (of 110	[Higher-molecular-weight species of NFATc (of 110]	1.0	6	1	0	0
47126	1624	allogeneic DC	[allogeneic DC]	1.0	2	1	0	0
47127	1624	indicate defective in this cells.	[indicating defective in these cells.]	1.0	5	1	0	0
47128	1624	gelatinase granule from human neutrophil	[gelatinase granules from human neutrophils]	1.0	5	1	0	0
47129	1624	identification of human stat protein	[Identification of human Stat proteins]	1.0	5	1	0	0
47130	1624	competent activator	[competent activator]	1.0	2	1	0	0
47131	1624	series of breast cancer patient	[series of breast cancer patients]	1.0	5	1	0	0
47132	1624	p21(waf1/cip1) transcript	[p21(WAF1/CIP1) transcript]	1.0	2	2	1	1
47133	1624	Biochemical analysis of the region	[Biochemical analysis of the region]	1.0	5	1	0	0
47134	1624	replicative infection.	[replicative infection.]	1.0	2	1	0	0
47135	1624	occur in FDC clusters, p50	[occurring in FDC clusters, p50]	1.0	5	1	0	0
47136	1624	G(Anh)MTetra a cell wall breakdown product	[G(Anh)MTetra a cell wall breakdown product]	1.0	6	1	0	0
47137	1624	so-called octamer transcription factor October	[so-called octamer transcription factors Oct]	1.0	5	1	0	0
47138	1624	virus activation	[virus activation]	1.0	2	2	1	1
47139	1624	select a patient with heart failure	[selecting a patient with heart failure]	1.0	6	1	0	0
47140	1624	E6-AP the p53 -conjugating ligase	[E6-AP the p53 -conjugating ligase]	1.0	5	1	0	0
47141	1624	absent MHC class ii expression	[absent MHC class II expression]	1.0	5	1	0	0
47142	1624	staining pattern	[staining pattern]	1.0	2	1	0	0
47143	1624	two other EBV-associated, hla-b8-restricted epitope	[two other EBV-associated, HLA-B8-restricted epitopes]	1.0	5	1	0	0
47144	1624	rest (G0) T cell with mobility	[resting (G0) T cells with mobilities]	1.0	6	1	0	0
47145	1624	reverse transcriptase -polymerase chain reaction analysis	[reverse transcriptase -polymerase chain reaction analysis]	1.0	6	1	0	0
47146	1624	several other hallmark of t-lymphocyte activation	[several other hallmarks of T-lymphocyte activation]	1.0	6	1	0	0
47147	1624	adaptive mechanism	[adaptive mechanisms]	1.0	2	1	0	0
47148	1624	signal-mediated induction of p105 processing	[signal-mediated induction of p105 processing]	1.0	5	1	0	0
47149	1624	phosphorylation by protein kinase c	[phosphorylation by protein kinase C]	1.0	5	1	0	0
47150	1624	inducible activation	[inducible activation]	1.0	2	2	2	2
47151	1624	lead to activation of several genes.	[leading to activation of several genes.]	1.0	6	1	0	0
47152	1624	use differential RNA display DD	[using differential RNA display DD]	1.0	5	1	0	0
47153	1624	sepsis-associated disease	[sepsis-associated disease]	1.0	2	1	0	0
47154	1624	normal peripheral blood pb DC	[normal peripheral blood PB DC]	1.0	5	1	0	0
47155	1624	significant difference in the turnover	[significant difference in the turnover]	1.0	5	1	0	0
47156	1624	il-2 mrna in ald cell	[IL-2 mRNA in ALD cells]	1.0	5	1	0	0
47157	1624	Stat3 activation.	[Stat3 activation.]	1.0	2	1	0	0
47158	1624	leukocyte-derived oxidant	[leukocyte-derived oxidants]	1.0	2	1	0	0
47159	1624	specific limitations.	[specific limitations.]	1.0	2	1	0	0
47160	1624	transcription rate of this gene	[transcription rate of these genes]	1.0	5	1	0	0
47161	1624	accord to the tumor cell type	[according to the tumor cell types]	1.0	6	1	0	0
47162	1624	wild-type plasmid	[wild-type plasmid]	1.0	2	1	0	0
47163	1624	lipopolysaccharide production	[lipopolysaccharide production]	1.0	2	2	2	2
47164	1624	two adjacent site at position -50	[two adjacent sites at positions -50]	1.0	6	1	0	0
47165	1624	activity of a reporter construct	[activity of a reporter construct]	1.0	5	1	0	0
47166	1624	vcam -inducer	[VCAM -inducer]	1.0	2	1	0	0
47167	1624	significant sequence similarity to the family	[significant sequence similarities to the family]	1.0	6	1	0	0
47168	1624	early event in acute inflammation	[early event in acute inflammation]	1.0	5	1	0	0
47169	1624	mammalian genome	[mammalian genome]	1.0	2	1	0	0
47170	1624	include the sry (sex determine region	[including the SRY (sex determining region]	1.0	6	1	0	0
47171	1624	dexamethasone Dex	[dexamethasone Dex]	1.0	2	1	0	0
47172	1624	80 kda.	[80 kDa.]	1.0	2	1	0	0
47173	1624	syndrome DS	[syndrome DS]	1.0	2	1	0	0
47174	1624	differentiate agent retinoic acid RA	[differentiating agent retinoic acid RA]	1.0	5	1	0	0
47175	1624	cytokine tumor	[cytokine tumor]	1.0	2	2	2	2
47176	1624	several diseases.	[several diseases.]	1.0	2	1	0	0
47177	1624	activation of Jurkat T cell	[activation of Jurkat T cells]	1.0	5	2	1	1
47178	1624	several diseases,	[several diseases,]	1.0	2	1	0	0
47179	1624	lymphocyte proliferation in spleen cell	[lymphocyte proliferation in spleen cells]	1.0	5	1	0	0
47180	1624	Jurkat cell (in the presence	[Jurkat cells (in the presence]	1.0	5	1	0	0
47181	1624	transactivation of the hiv-1 LTR	[transactivation of the HIV-1 LTR]	1.0	5	1	0	0
47182	1624	recent datum implicate gata-1 function	[recent data implicating GATA-1 function]	1.0	5	1	0	0
47183	1624	decrease in il-2 receptor expression	[decrease in IL-2 receptor expression]	1.0	5	1	0	0
47184	1624	alpha isoform	[alpha isoform]	1.0	2	2	1	1
47185	1624	pleiotropic regulator of a variety	[pleiotropic regulator of a variety]	1.0	5	1	0	0
47186	1624	relevant concentrations.	[relevant concentrations.]	1.0	2	2	2	2
47187	1624	stimulation of monocyte with ltb4	[stimulation of monocytes with LTB4]	1.0	5	1	0	0
47188	1624	DNA binding site for sp-1	[DNA binding sites for SP-1]	1.0	5	1	0	0
47189	1624	disease MRD	[disease MRD]	1.0	2	2	2	2
47190	1624	endothelial cells,	[endothelial cells,]	1.0	2	1	0	0
47191	1624	two immediate early gene c-fo	[two immediate early genes c-fos]	1.0	5	1	0	0
47192	1624	prior activation,	[prior activation,]	1.0	2	2	1	1
47193	1624	subsequent adherence of polymorphonuclear leukocyte	[subsequent adherence of polymorphonuclear leukocytes]	1.0	5	1	0	0
47194	1624	b cell-specific transcriptional promoter activity	[B cell-specific transcriptional promoter activity]	1.0	5	1	0	0
47195	1624	Furthermore, study	[Furthermore, studies]	1.0	2	1	0	0
47196	1624	p65 RelA	[p65 RelA]	1.0	2	1	0	0
47197	1624	atypical pkc-zeta	[atypical PKC-zeta]	1.0	2	1	0	0
47198	1624	response to IL-13 by human monocyte	[responses to IL-13 by human monocytes]	1.0	6	1	0	0
47199	1624	and/or PMA	[and/or PMA]	1.0	2	1	0	0
47200	1624	related zinc-finger	[related zinc-finger]	1.0	2	1	0	0
47201	1624	analog activity	[analog activity]	1.0	2	1	0	0
47202	1624	different role in different cell type	[different roles in different cell types]	1.0	6	1	0	0
47203	1624	of binding to double-stranded rna	[of binding to double-stranded RNA]	1.0	5	1	0	0
47204	1624	polymorphonucleate cell	[polymorphonucleate cells]	1.0	2	1	0	0
47205	1624	actual binding of this peptide	[actual binding of these peptides]	1.0	5	1	0	0
47206	1624	[corrected] erratum	[[corrected] erratum]	1.0	2	1	0	0
47207	1624	prolactin a pituitary peptide hormone	[prolactin a pituitary peptide hormone]	1.0	5	1	0	0
47208	1624	activity of lymphocyte-specific transcription factor	[activity of lymphocyte-specific transcription factors]	1.0	5	1	0	0
47209	1624	high il-2	[high IL-2]	1.0	2	1	0	0
47210	1624	low ki-67	[low Ki-67]	1.0	2	1	0	0
47211	1624	cell in the b series	[Cells in the B series]	1.0	5	1	0	0
47212	1624	high il-4	[high IL-4]	1.0	2	1	0	0
47213	1624	recombinant fragment	[recombinant fragment]	1.0	2	2	2	2
47214	1624	lpr/lpr mouse	[lpr/lpr mice]	1.0	2	1	0	0
47215	1624	i.e., granulocyte-colony-stimulating factor receptor mrna	[i.e., granulocyte-colony-stimulating factor receptor mRNA]	1.0	5	1	0	0
47216	1624	dexamethasone Kd	[dexamethasone Kd]	1.0	2	1	0	0
47217	1624	DNA-relaxing activity in nuclear extract	[DNA-relaxing activity in nuclear extracts]	1.0	5	1	0	0
47218	1624	72 h.	[72 h,]	1.0	2	1	0	0
47219	1624	b-lineage-specific gene	[B-lineage-specific gene]	1.0	2	1	0	0
47220	1624	effect of the Tat protein	[effect of the Tat protein]	1.0	5	1	0	0
47221	1624	covalent modification	[covalent modification]	1.0	2	2	2	2
47222	1624	modulation of the immune competence	[modulation of the immune competence]	1.0	5	1	0	0
47223	1624	NM23 gene	[NM23 gene]	1.0	2	1	0	0
47224	1624	small subunit	[smallest subunit]	1.0	2	1	0	0
47225	1624	use magnetic bead with DNA	[Using magnetic beads with DNA]	1.0	5	1	0	0
47226	1624	kinetics, ganglioside	[kinetics, gangliosides]	1.0	2	1	0	0
47227	1624	Oct-2 transcription	[Oct-2 transcription]	1.0	2	2	1	1
47228	1624	acute asthma	[acute asthma]	1.0	2	1	0	0
47229	1624	cord blood-derived cd34(+) stem/progenitor cell	[cord blood-derived CD34(+) stem/progenitor cells]	1.0	5	1	0	0
47230	1624	product of the c-rel proto-oncogene	[product of the c-rel proto-oncogene]	1.0	5	1	0	0
47231	1624	External stimuli,	[External stimuli,]	1.0	2	1	0	0
47232	1624	accumulation of AP-1 transcription factor complex	[accumulation of AP-1 transcription factor complexes]	1.0	6	1	0	0
47233	1624	oncoprotein e2a-pbx1	[oncoprotein E2a-Pbx1]	1.0	2	2	2	2
47234	1624	role of retinoic acid (ra)	[role of retinoic acid (RA)]	1.0	5	1	0	0
47235	1624	two parallel protein kinase pathway	[two parallel protein kinase pathways]	1.0	5	1	0	0
47236	1624	even in the absence of glucocorticoid	[even in the absence of glucocorticoid]	1.0	6	1	0	0
47237	1624	transgenic thymocyte	[transgenic thymocytes]	1.0	2	1	0	0
47238	1624	therapeutic option alter the th1/th2 balance	[therapeutic options altering the Th1/Th2 balance]	1.0	6	1	0	0
47239	1624	effect on protein kinase C	[effect on protein kinase C]	1.0	5	2	1	1
47240	1624	pharmacokinetic behavior	[pharmacokinetic behaviors]	1.0	2	1	0	0
47241	1624	contrast, tyrosine-phosphorylated peptide contain Tyr374	[contrast, tyrosine-phosphorylated peptides containing Tyr374]	1.0	5	1	0	0
47242	1624	PML NBs	[PML NBs]	1.0	2	2	2	2
47243	1624	Interestingly, evidence for the presence	[Interestingly, evidence for the presence]	1.0	5	1	0	0
47244	1624	percentage of gamma/delta tcr+ cell	[percentage of gamma/delta TCR+ cells]	1.0	5	1	0	0
47245	1624	IL 6	[IL 6]	1.0	2	1	0	0
47246	1624	early, stage of B-cell differentiation	[early, stages of B-cell differentiation]	1.0	5	1	0	0
47247	1624	use primary cd4+ T cell	[using primary CD4+ T cells]	1.0	5	1	0	0
47248	1624	overexpression of the bcl-2 protein	[overexpression of the Bcl-2 protein]	1.0	5	1	0	0
47249	1624	mechanism(s) responsible	[mechanism(s) responsible]	1.0	2	1	0	0
47250	1624	parallel induction	[parallel induction]	1.0	2	1	0	0
47251	1624	biological modification on target tissue	[biological modifications on target tissues]	1.0	5	1	0	0
47252	1624	135(oh)2d3 production by lavage cell	[1,25(OH)2D3 production by lavage cells]	1.0	5	1	0	0
47253	1624	Dr. Dezube	[Dr. Dezube]	1.0	2	1	0	0
47254	1624	cell proliferation by cell counting	[cell proliferation by cell counting]	1.0	5	1	0	0
47255	1624	sigm- crosslinking with antibody elevation	[sIgM- crosslinking with antibodies elevation]	1.0	5	1	0	0
47256	1624	use of a selective antagonist	[use of a selective antagonist]	1.0	5	1	0	0
47257	1624	site, meta(d-) adjacent to META(D+)	[site, META(D-) adjacent to META(D+)]	1.0	5	1	0	0
47258	1624	glutathione -s-transferase gst affinity-binding assay	[glutathione -S-transferase GST affinity-binding assay]	1.0	5	1	0	0
47259	1624	vitro from cd34+ stem cell	[vitro from CD34+ stem cells]	1.0	5	1	0	0
47260	1624	such as stage in instances.	[such as stage in instances.]	1.0	5	1	0	0
47261	1624	G.Furlini, M. Vignoli, E.Ramazzotti, M.C.Re, G.Visani,	[G.Furlini, M. Vignoli, E.Ramazzotti, M.C.Re, G.Visani,]	1.0	6	1	0	0
47262	1624	human x-scid	[human X-SCID]	1.0	2	1	0	0
47263	1624	subdiploid population	[subdiploid population]	1.0	2	1	0	0
47264	1624	cd4+ t-lymphocyte	[CD4+ T-lymphocytes]	1.0	2	2	1	1
47265	1624	significant apoptosis	[significant apoptosis]	1.0	2	1	0	0
47266	1624	hematopoietic-specific ets family transcription factor	[hematopoietic-specific Ets family transcription factor]	1.0	5	1	0	0
47267	1624	rapid tyrosine phosphorylation of Jak	[rapid tyrosine phosphorylation of Jak]	1.0	5	1	0	0
47268	1624	metabolic step	[metabolic steps]	1.0	2	1	0	0
47269	1624	transcription of gene encode cytokine	[transcription of genes encoding cytokines]	1.0	5	1	0	0
47270	1624	functional collaboration of multiple protein	[functional collaboration of multiple proteins]	1.0	5	1	0	0
47271	1624	further characterization of this cell	[Further characterization of these cells]	1.0	5	1	0	0
47272	1624	mononuclear leukocyte from healthy male	[mononuclear leukocytes from healthy males]	1.0	5	1	0	0
47273	1624	y;15 translocation	[Y;15 translocation]	1.0	2	1	0	0
47274	1624	heterozygous loss-of-function mutation in this gene	[heterozygous loss-of-function mutation in these genes]	1.0	6	1	0	0
47275	1624	myeloid-specific expression	[myeloid-specific expression]	1.0	2	2	2	2
47276	1624	sensitize tumor	[sensitizing tumor]	1.0	2	1	0	0
47277	1624	cause retarded mobility on gel	[causing retarded mobility on gels]	1.0	5	1	0	0
47278	1624	vaccine for this related alpha-herpesviruse	[vaccine for these related alpha-herpesviruses]	1.0	5	1	0	0
47279	1624	clonal eosinophilia	[clonal eosinophilia]	1.0	2	2	1	1
47280	1624	proteasomal degradation	[proteasomal degradation]	1.0	2	1	0	0
47281	1624	regulatory cytokine in the lung	[regulatory cytokine in the lung]	1.0	5	1	0	0
47282	1624	human monocytic leukemia cell line	[human monocytic leukemia cell line]	1.0	5	2	1	1
47283	1624	redox mechanism	[redox mechanism]	1.0	2	1	0	0
47284	1624	universal finding only in CLL	[universal finding only in CLL]	1.0	5	1	0	0
47285	1624	zp activation	[Zp activation]	1.0	2	1	0	0
47286	1624	transcription by both cell type	[transcription by both cell types]	1.0	5	1	0	0
47287	1624	follow results:	[following results:]	1.0	2	1	0	0
47288	1624	induction of MNP-1 in Jurkat t-cell	[induction of MNP-1 in Jurkat T-cells]	1.0	6	1	0	0
47289	1624	differentiation therapy	[differentiation therapy]	1.0	2	2	2	2
47290	1624	selective regulation of il-5 gene transcription	[Selective regulation of IL-5 gene transcription]	1.0	6	1	0	0
47291	1624	ciita mrna	[CIITA mRNA]	1.0	2	1	0	0
47292	1624	nuclear factor kappa b NF-kappa b	[nuclear factor kappa B NF-kappa B]	1.0	6	1	0	0
47293	1624	importance in the DRA promoter	[importance in the DRA promoter]	1.0	5	1	0	0
47294	1624	calcitriol receptor in primary hyperparathyroidism	[calcitriol receptors in primary hyperparathyroidism]	1.0	5	1	0	0
47295	1624	present hla molecule of the first	[presenting HLA molecule of the first]	1.0	6	1	0	0
47296	1624	cyclosporin a -binding protein cyclophilin	[cyclosporin A -binding protein cyclophilin]	1.0	5	1	0	0
47297	1624	megakaryocytic feature	[megakaryocytic features]	1.0	2	1	0	0
47298	1624	differentiation of human monocytic cell	[differentiation of human monocytic cells]	1.0	5	1	0	0
47299	1624	immunoregulatory effect	[immunoregulatory effects]	1.0	2	2	2	2
47300	1624	stat1 phosphorylation	[STAT1 phosphorylation]	1.0	2	1	0	0
47301	1624	result in low transactivation activity	[resulting in lower transactivation activity]	1.0	5	1	0	0
47302	1624	weak, interaction at the x box	[weak, interactions at the X boxes]	1.0	6	1	0	0
47303	1624	mutation in the gene encode fas	[mutations in the genes encoding Fas]	1.0	6	1	0	0
47304	1624	analyze the mechanism of action	[analyzing the mechanism of action]	1.0	5	1	0	0
47305	1624	70- kda heat shock protein	[70- kDa heat shock proteins]	1.0	5	1	0	0
47306	1624	wild-type e	[wild-type E]	1.0	2	1	0	0
47307	1624	high level of hlh-2 expression	[High levels of hLH-2 expression]	1.0	5	1	0	0
47308	1624	potential role in gene transcription	[potential role in gene transcription]	1.0	5	1	0	0
47309	1624	hiv-seronegative donor	[HIV-seronegative donors]	1.0	2	1	0	0
47310	1624	stimulation of tpa (0.5 microM)	[stimulation of TPA (0.5 microM)]	1.0	5	1	0	0
47311	1624	CD2 receptor	[CD2 receptor]	1.0	2	2	1	1
47312	1624	patient with risk breast cancer	[patients with risk breast cancer]	1.0	5	1	0	0
47313	1624	drive proliferation in this cell line	[driving proliferation in these cell lines]	1.0	6	1	0	0
47314	1624	high-density lipoprotein	[high-density lipoprotein]	1.0	2	1	0	0
47315	1624	reporter activity	[reporter activity]	1.0	2	1	0	0
47316	1624	borrelia burgdorferi	[Borrelia burgdorferi]	1.0	2	2	1	1
47317	1624	old woman	[old woman]	1.0	2	1	0	0
47318	1624	different T	[different T]	1.0	2	1	0	0
47319	1624	can metabolism during kidney failure	[Ca metabolism during kidney failure]	1.0	5	1	0	0
47320	1624	transcription factor of cytokine gene	[transcription factors of cytokine genes]	1.0	5	1	0	0
47321	1624	interaction with thymic epithelial cell	[interaction with thymic epithelial cells]	1.0	5	2	1	1
47322	1624	Differential expression of gr isoform	[Differential expression of GR isoforms]	1.0	5	1	0	0
47323	1624	clinical relevance of this alteration	[clinical relevance of these alterations]	1.0	5	1	0	0
47324	1624	latter effect	[latter effects]	1.0	2	1	0	0
47325	1624	Ran GTP	[Ran GTP]	1.0	2	1	0	0
47326	1624	HUVEC nuclei	[HUVEC nuclei]	1.0	2	1	0	0
47327	1624	HLA binding	[HLA binding]	1.0	2	1	0	0
47328	1624	histamine receptor subtype on concentration	[histamine receptor subtypes on concentration]	1.0	5	1	0	0
47329	1624	NF-kappa b activation minimal in cell	[NF-kappa B activation minimal in cells]	1.0	6	1	0	0
47330	1624	use two lymphoblastoid cell line	[using two lymphoblastoid cell lines]	1.0	5	1	0	0
47331	1624	pharmacological modification of cytokine dysregulation	[Pharmacological modification of cytokine dysregulation]	1.0	5	1	0	0
47332	1624	pro-B-cell development	[pro-B-cell development]	1.0	2	1	0	0
47333	1624	non-monocytic cells,	[non-monocytic cells,]	1.0	2	1	0	0
47334	1624	physiologic status	[physiologic status]	1.0	2	1	0	0
47335	1624	activation of p38 protein kinase	[activation of p38 protein kinase]	1.0	5	1	0	0
47336	1624	underlie the isotype switch to IgE	[underlying the isotype switch to IgE]	1.0	6	1	0	0
47337	1624	late (hours)	[late (hours)]	1.0	2	1	0	0
47338	1624	expression of IL-2 transcriptional regulator c-fo	[expression of IL-2 transcriptional regulators c-fos]	1.0	6	1	0	0
47339	1624	cotransfection with a transdominant negative mutant	[Cotransfection with a transdominant negative mutant]	1.0	6	1	0	0
47340	1624	cellular, humoral,	[cellular, humoral,]	1.0	2	1	0	0
47341	1624	native long terminal repeat LTR	[native long terminal repeat LTR]	1.0	5	1	0	0
47342	1624	approach statistical significance for patient	[approaching statistical significance for patients]	1.0	5	1	0	0
47343	1624	ductal cancer	[ductal cancers]	1.0	2	1	0	0
47344	1624	brca1	[BRCA1]	1.0	1	11	7	7
47345	1624	between-subject variability.	[between-subject variability.]	1.0	2	1	0	0
47346	1624	encode a thyroid hormone receptor	[encoding a thyroid hormone receptor]	1.0	5	1	0	0
47347	1624	apparently healthy volunteer (86 man	[apparently healthy volunteers (86 men]	1.0	5	1	0	0
47348	1624	NFKB2 precursor	[NFKB2 precursor]	1.0	2	1	0	0
47349	1624	contrast, anti-AIM	[contrast, anti-AIM]	1.0	2	1	0	0
47350	1624	E74 the drosophila transcription factor	[E74 the Drosophila transcription factor]	1.0	5	1	0	0
47351	1624	good prognosis	[good prognosis]	1.0	2	1	0	0
47352	1624	conjunction with the octamer element	[conjunction with the octamer element]	1.0	5	1	0	0
47353	1624	primary stimulation of spleen cell	[primary stimulations of spleen cells]	1.0	5	1	0	0
47354	1624	more oligoclonal,	[more oligoclonal,]	1.0	2	1	0	0
47355	1624	il-6 gene expression by IL-4	[IL-6 gene expression by IL-4]	1.0	5	1	0	0
47356	1624	stimulate antigen	[stimulating antigens]	1.0	2	1	0	0
47357	1624	akt/pkb activity	[Akt/PKB activity]	1.0	2	1	0	0
47358	1624	adult rat	[adult rats]	1.0	2	1	0	0
47359	1624	other epitope	[other epitopes]	1.0	2	2	2	2
47360	1624	infection by the variant b	[infection by the variant B]	1.0	5	1	0	0
47361	1624	c-fo activity	[c-Fos activity]	1.0	2	1	0	0
47362	1624	exogenous fibrinogen	[exogenous fibrinogen]	1.0	2	1	0	0
47363	1624	v-myb oncogene	[v-myb oncogene]	1.0	2	2	1	1
47364	1624	hemoglobin-producing cell	[hemoglobin-producing cells]	1.0	2	1	0	0
47365	1624	Thus, IL-2 il-2r alpha promoter activity	[Thus, IL-2 IL-2R alpha promoter activity]	1.0	6	1	0	0
47366	1624	normal thyroid tissue of euthyroid patient	[normal thyroid tissue of euthyroid patients]	1.0	6	1	0	0
47367	1624	define a small deletion hotspot	[defining a small deletion hotspot]	1.0	5	1	0	0
47368	1624	cytosol of the T lymphocyte	[cytosol of the T lymphocytes]	1.0	5	1	0	0
47369	1624	multiple level in the pathogenesis	[multiple levels in the pathogenesis]	1.0	5	1	0	0
47370	1624	rare hybrid	[rare hybrids]	1.0	2	1	0	0
47371	1624	understand the pathogenesis of the immunodeficiency	[understanding the pathogenesis of the immunodeficiency]	1.0	6	1	0	0
47372	1624	simultaneous presence	[simultaneous presence]	1.0	2	2	2	2
47373	1624	ceramide release	[ceramide release]	1.0	2	2	1	1
47374	1624	surprisingly, different combination of disable mutation	[Surprisingly, different combinations of disabling mutations]	1.0	6	1	0	0
47375	1624	code for a 14-kd protein	[codes for a 14-kD protein]	1.0	5	1	0	0
47376	1624	ec activation.	[EC activation.]	1.0	2	1	0	0
47377	1624	developmental pathway	[developmental pathway]	1.0	2	2	2	2
47378	1624	HTLV-I replication	[HTLV-I replication]	1.0	2	1	0	0
47379	1624	4855 sites/cell	[4855 sites/cell]	1.0	2	1	0	0
47380	1624	Helix iii	[Helix III]	1.0	2	1	0	0
47381	1624	lps uptake	[LPS uptake]	1.0	2	2	1	1
47382	1624	genetic lesion	[genetic lesion]	1.0	2	2	2	2
47383	1624	adsorption to property from dna-cellulose	[adsorption to properties from DNA-cellulose]	1.0	5	1	0	0
47384	1624	cycloheximide-sensitive manner	[cycloheximide-sensitive manner]	1.0	2	1	0	0
47385	1624	active mapk	[active MAPK]	1.0	2	1	0	0
47386	1624	activity of the B29 promoter	[activity of the B29 promoter]	1.0	5	1	0	0
47387	1624	part of a order complex	[part of a order complex]	1.0	5	1	0	0
47388	1624	several genes.	[several genes.]	1.0	2	4	3	1
47389	1624	gene under nuclear factor-kappaB control	[genes under nuclear factor-kappaB control]	1.0	5	1	0	0
47390	1624	intestinal calcium	[intestinal calcium]	1.0	2	1	0	0
47391	1624	class ii MHC antigen expression	[class II MHC antigen expression]	1.0	5	1	0	0
47392	1624	unrearranged 2.3-kb tcr delta transcript	[unrearranged 2.3-kb TcR delta transcript]	1.0	5	1	0	0
47393	1624	transcription of the gamma chain	[transcription of the gamma chain]	1.0	5	1	0	0
47394	1624	exogenous nf-kappab in Jurkat cell	[exogenous NF-kappaB in Jurkat cells]	1.0	5	1	0	0
47395	1624	requirement of another regulatory element	[requirement of another regulatory element]	1.0	5	1	0	0
47396	1624	distance geometry	[distance geometry]	1.0	2	1	0	0
47397	1624	Furthermore, inhibition of nf-kappab activation	[Furthermore, inhibition of NF-kappaB activation]	1.0	5	1	0	0
47398	1624	autoregulation of the inflammatory cascade	[autoregulation of the inflammatory cascade]	1.0	5	1	0	0
47399	1624	[3h] testosterone	[[3H] testosterone]	1.0	2	1	0	0
47400	1624	normal progenitor	[normal progenitors]	1.0	2	3	2	1
47401	1624	cell huvec	[cell HUVEC]	1.0	2	2	2	2
47402	1624	adenovirus region	[adenovirus region]	1.0	2	2	2	2
47403	1624	mitogen-activated protein (map) kinase pathway	[mitogen-activated protein (MAP) kinase pathways]	1.0	5	1	0	0
47404	1624	human hematopoietic	[human hematopoietic]	1.0	2	1	0	0
47405	1624	contribution to the replicative capacity	[Contribution to the replicative capacity]	1.0	5	1	0	0
47406	1624	distinct nuclear protein- dependent complex	[distinct nuclear protein- dependent complexes]	1.0	5	1	0	0
47407	1624	il-6 by human blood mononuclear cell	[IL-6 by human blood mononuclear cells]	1.0	6	2	2	2
47408	1624	such as the interleukin-2 il-2 gene	[such as the interleukin-2 IL-2 gene]	1.0	6	1	0	0
47409	1624	key reactivities.	[key reactivities.]	1.0	2	1	0	0
47410	1624	lipid-lowering agent	[lipid-lowering agents]	1.0	2	1	0	0
47411	1624	gamma delta T cell line	[gamma delta T cell line]	1.0	5	1	0	0
47412	1624	transcription from the IL-2 promoter	[transcription from the IL-2 promoter]	1.0	5	2	1	1
47413	1624	protein of 968 amino acid	[protein of 968 amino acids]	1.0	5	1	0	0
47414	1624	N-acetylcysteine NAC	[N-acetylcysteine NAC]	1.0	2	1	0	0
47415	1624	control virus	[control virus]	1.0	2	1	0	0
47416	1624	lysosomal protein	[lysosomal proteins]	1.0	2	1	0	0
47417	1624	NF-ATp mouse	[NF-ATp mice]	1.0	2	2	2	2
47418	1624	mechanism of HS2 enhancer function	[mechanism of HS2 enhancer function]	1.0	5	1	0	0
47419	1624	BALB/c 3t3	[BALB/c 3T3]	1.0	2	1	0	0
47420	1624	basal acetate PMA promoter activity	[basal acetate PMA promoter activity]	1.0	5	1	0	0
47421	1624	ctg-monomer virus	[CTG-monomer virus]	1.0	2	1	0	0
47422	1624	metabolic stimulus	[metabolic stimuli]	1.0	2	1	0	0
47423	1624	apoptotic cell within atherosclerotic plaque	[Apoptotic cells within atherosclerotic plaques]	1.0	5	1	0	0
47424	1624	(3 day with dimethylsulfoxide dmso	[(3 days) with dimethylsulfoxide DMSO]	1.0	5	1	0	0
47425	1624	copyright Elsevier Science Ireland Ltd.	[Copyright Elsevier Science Ireland Ltd.]	1.0	5	1	0	0
47426	1624	p19 cell	[P19 cells]	1.0	2	2	1	1
47427	1624	increase in plasma renin activity	[increase in plasma renin activity]	1.0	5	1	0	0
47428	1624	level of 135eoh)2d3 receptor protein	[Levels of 1,25(OH)2D3 receptor protein]	1.0	5	1	0	0
47429	1624	Intestinal cell	[Intestinal cells]	1.0	2	2	2	2
47430	1624	stat3 protein	[STAT3 proteins]	1.0	2	3	2	1
47431	1624	identification of the TCL1 gene	[Identification of the TCL1 gene]	1.0	5	1	0	0
47432	1624	patient with pulmonary heart disease	[patients with pulmonary heart disease]	1.0	5	3	2	1
47433	1624	manifestation of the physiological state	[manifestation of the physiological state]	1.0	5	1	0	0
47434	1624	cysteine-rich domain	[cysteine-rich domain]	1.0	2	2	2	2
47435	1624	class switch	[class switch]	1.0	2	2	1	1
47436	1624	chromatin of the tcr alpha	[chromatin of the TCR alpha]	1.0	5	1	0	0
47437	1624	primary type	[primary type]	1.0	2	1	0	0
47438	1624	several condition	[several conditions]	1.0	2	2	2	2
47439	1624	tumour necrosis factor-alpha in t-cell	[tumour necrosis factor-alpha in T-cells]	1.0	5	1	0	0
47440	1624	four sea urchin binding site	[four sea urchin binding sites]	1.0	5	1	0	0
47441	1624	amplification of the cag repeat	[amplification of the CAG repeats]	1.0	5	1	0	0
47442	1624	abnormal cytokine	[abnormal cytokine]	1.0	2	1	0	0
47443	1624	fmol/10(7)	[fmol/10(7)]	1.0	1	11	6	6
47444	1624	use well,	[using well,]	1.0	2	1	0	0
47445	1624	immunoreactivity of the regulatory subunit	[immunoreactivity of the regulatory subunits]	1.0	5	1	0	0
47446	1624	continuous treatment of monocyte with il-1beta	[Continuous treatment of monocytes with IL-1beta]	1.0	6	1	0	0
47447	1624	strategic site	[strategic sites]	1.0	2	1	0	0
47448	1624	relationship of nf-kappa b activation	[relationship of NF-kappa B activation]	1.0	5	1	0	0
47449	1624	gene encode the Epstein-Barr virus	[gene encoding the Epstein-Barr virus]	1.0	5	1	0	0
47450	1624	differentiation of human leukemia cell	[differentiation of human leukemia cells]	1.0	5	2	2	2
47451	1624	positive regulation of ifn-gamma production	[positive regulation of IFN-gamma production]	1.0	5	1	0	0
47452	1624	genetic system	[genetic system]	1.0	2	2	1	1
47453	1624	toll-like receptor-2	[toll-like receptor-2]	1.0	2	2	2	2
47454	1624	formation of transcriptionally active tetrameric complex	[formation of transcriptionally active tetrameric complexes]	1.0	6	1	0	0
47455	1624	ige class switch by interferon-y	[IgE class switching by interferon-y]	1.0	5	1	0	0
47456	1624	hiv-1 replication in cell line	[HIV-1 replication in cell lines]	1.0	5	1	0	0
47457	1624	human peripheral blood mononuclear cell pbmc	[human peripheral blood mononuclear cells PBMC]	1.0	6	1	0	0
47458	1624	monocytic differentiation of the c-jun	[monocytic differentiation of the c-jun]	1.0	5	1	0	0
47459	1624	functionally distinct receptor on T lymphocyte	[functionally distinct receptors on T lymphocytes]	1.0	6	1	0	0
47460	1624	distinguish this atra -nonresponsive case	[distinguishing these ATRA -nonresponsive cases]	1.0	5	1	0	0
47461	1624	common type	[common type]	1.0	2	1	0	0
47462	1624	12 normal woman of childbearing age.	[12 normal women of childbearing age.]	1.0	6	1	0	0
47463	1624	gm2/gc-box sequence	[GM2/GC-box sequence]	1.0	2	1	0	0
47464	1624	crh promoter	[CRH promoter]	1.0	2	2	1	1
47465	1624	interference with transcription factor ap-1	[interference with transcription factors AP-1]	1.0	5	2	1	1
47466	1624	process related to b cell activation	[processes related to B cell activation]	1.0	6	1	0	0
47467	1624	rapid manner	[rapid manner]	1.0	2	1	0	0
47468	1624	low level of glucocorticoid receptor	[lower levels of glucocorticoid receptors]	1.0	5	1	0	0
47469	1624	high level of progeny virion	[high level of progeny virions]	1.0	5	1	0	0
47470	1624	patient with chronic hepatitis b	[patients with chronic hepatitis B]	1.0	5	1	0	0
47471	1624	blood-brain barrier	[blood-brain barrier]	1.0	2	1	0	0
47472	1624	target spleen with liposomal mpl	[targeting spleen with liposomal MPL]	1.0	5	1	0	0
47473	1624	ap-1 expression	[AP-1 expression]	1.0	2	2	1	1
47474	1624	certain cellular processes, for example,	[certain cellular processes, for example,]	1.0	5	1	0	0
47475	1624	suggest a role for xanthine oxidase	[suggesting a role for xanthine oxidase]	1.0	6	1	0	0
47476	1624	turn phosphorylate	[turn phosphorylates]	1.0	2	1	0	0
47477	1624	follow activation.	[following activation.]	1.0	2	2	1	1
47478	1624	follow activation,	[following activation,]	1.0	2	1	0	0
47479	1624	Glucocorticoid receptor of 3-o-methyl-d-glucose uptake	[Glucocorticoid receptor of 3-O-methyl-D-glucose uptake]	1.0	5	1	0	0
47480	1624	erythroid-specific aminolaevulinic acid synthase alas-e	[erythroid-specific aminolaevulinic acid synthase ALAS-E]	1.0	5	1	0	0
47481	1624	affinity for a sequence motif	[affinity for a sequence motif]	1.0	5	1	0	0
47482	1624	certain deviation	[certain deviations]	1.0	2	1	0	0
47483	1624	mediator in human dermal endothelial cell	[mediators in human dermal endothelial cells]	1.0	6	1	0	0
47484	1624	inhibition of blood T cell proliferation	[inhibition of blood T cell proliferation]	1.0	6	1	0	0
47485	1624	inherent feature	[inherent feature]	1.0	2	1	0	0
47486	1624	phosphorylation of the transcription factor nfatp	[Phosphorylation of the transcription factor NFATp]	1.0	6	1	0	0
47487	1624	perhaps by regulation of gtp -cyclohydrolase	[perhaps by regulation of GTP -cyclohydrolase]	1.0	6	1	0	0
47488	1624	Little effect	[Little effect]	1.0	2	1	0	0
47489	1624	Secondarily, heat shock of Hyon cell	[Secondarily, heat shock of Hyon cells]	1.0	6	1	0	0
47490	1624	one repeats;	[one repeats;]	1.0	2	1	0	0
47491	1624	four protoenhancer	[four protoenhancers]	1.0	2	1	0	0
47492	1624	recent discovery	[recent discovery]	1.0	2	2	1	1
47493	1624	immaturity as a cell line	[immaturity as a cell line]	1.0	5	1	0	0
47494	1624	physical interaction between human gata-1	[physical interaction between human GATA-1]	1.0	5	1	0	0
47495	1624	affect the r-dependent enhancer activity	[affecting the R-dependent enhancer activity]	1.0	5	1	0	0
47496	1624	marrow-derived macrophage	[marrow-derived macrophages]	1.0	2	1	0	0
47497	1624	defective recruitment of NF-kappa b	[defective recruitment of NF-kappa B]	1.0	5	1	0	0
47498	1624	phosphorylation of JAK2 Janus kinase	[phosphorylation of JAK2 Janus kinase]	1.0	5	1	0	0
47499	1624	ciita (for class ii transactivator	[CIITA (for class II transactivator]	1.0	5	1	0	0
47500	1624	cytokine pathway	[cytokine pathway]	1.0	2	2	2	2
47501	1624	cytotoxic chemotherapy follow atra therapy	[cytotoxic chemotherapy following ATRA therapy]	1.0	5	1	0	0
47502	1624	host factor	[host factors]	1.0	2	2	2	2
47503	1624	hla b8+	[HLA B8+]	1.0	2	2	1	1
47504	1624	amp-responsive element	[AMP-responsive element]	1.0	2	2	1	1
47505	1624	subdominant epitope outside this region	[subdominant epitopes outside this region]	1.0	5	1	0	0
47506	1624	subcellular localization	[subcellular localization]	1.0	2	3	2	1
47507	1624	microvascular ec human bone marrow ec	[microvascular EC human bone marrow EC]	1.0	6	1	0	0
47508	1624	class ii restriction element differ	[class II restriction element differing]	1.0	5	1	0	0
47509	1624	lymphocyte glucocorticoid receptor binding during depression	[Lymphocyte glucocorticoid receptor binding during depression]	1.0	6	1	0	0
47510	1624	microbicidal effect	[microbicidal effects]	1.0	2	1	0	0
47511	1624	N-Acetylcysteine treatment	[N-Acetylcysteine treatment]	1.0	2	1	0	0
47512	1624	insulin concentration change under condition	[insulin concentration change under conditions]	1.0	5	1	0	0
47513	1624	sequence present	[sequence present]	1.0	2	2	2	2
47514	1624	intracellular ros	[intracellular ROS]	1.0	2	1	0	0
47515	1624	reveal a unexpected functional redundancy	[revealing an unexpected functional redundancy.]	1.0	5	1	0	0
47516	1624	nuclease-hypersensitive site	[nuclease-hypersensitive site]	1.0	2	1	0	0
47517	1624	progesterone immunomodulation	[progesterone immunomodulation]	1.0	2	2	2	2
47518	1624	association between expression of adhesion molecule-1	[Association between expression of adhesion molecule-1]	1.0	6	1	0	0
47519	1624	human myeloblastic leukemia hl-60 cell	[human myeloblastic leukemia HL-60 cells]	1.0	5	1	0	0
47520	1624	distal part	[distal part]	1.0	2	2	1	1
47521	1624	include the surface of viable cell	[including the surface of viable cells]	1.0	6	1	0	0
47522	1624	hrxr alpha receptor for 9-cis RA	[hRXR alpha receptor for 9-cis RA]	1.0	6	1	0	0
47523	1624	neutrophil induce	[neutrophils inducing]	1.0	2	1	0	0
47524	1624	hormone receptor on the tumour.	[hormone receptors on the tumour.]	1.0	5	1	0	0
47525	1624	infection of the host cell	[infection of the host cell]	1.0	5	1	0	0
47526	1624	mature erythrocytes.	[mature erythrocytes.]	1.0	2	1	0	0
47527	1624	apparently distinct DNA binding specificity	[apparently distinct DNA binding specificities]	1.0	5	1	0	0
47528	1624	construction characterization of a fusion protein	[Construction characterization of an fusion protein]	1.0	6	1	0	0
47529	1624	CD8 lineage	[CD8 lineage]	1.0	2	1	0	0
47530	1624	inhibit the activity of nuclear factor	[inhibiting the activity of nuclear factor]	1.0	6	1	0	0
47531	1624	Ca2+ channel blocker, SK&F 96365,	[Ca2+ channel blocker, SK&F 96365,]	1.0	5	1	0	0
47532	1624	intense exercise	[intense exercise]	1.0	2	2	2	2
47533	1624	other mediators.	[other mediators.]	1.0	2	1	0	0
47534	1624	permanent growth with herpesvirus saimiry	[permanent growth with Herpesvirus saimiri]	1.0	5	1	0	0
47535	1624	regulate protein	[regulating proteins]	1.0	2	2	1	1
47536	1624	least in part, via activation	[least in part, via activation]	1.0	5	1	0	0
47537	1624	CD30 a member (tnf) receptor family,	[CD30 a member (TNF) receptor family,]	1.0	6	1	0	0
47538	1624	promoter's activity	[promoter's activity]	1.0	2	1	0	0
47539	1624	nfat-1 nuclear factor of t-cell	[NFAT-1 nuclear factor of T-cells]	1.0	5	1	0	0
47540	1624	essential role of NF-kappa b	[essential role of NF-kappa B]	1.0	5	1	0	0
47541	1624	mpro promyelocyte	[MPRO promyelocytes]	1.0	2	2	2	2
47542	1624	transcription Stat3	[transcription Stat3]	1.0	2	2	2	2
47543	1624	control oligonucleotide	[control oligonucleotides]	1.0	2	1	0	0
47544	1624	PI3-K activation	[PI3-K activation]	1.0	2	1	0	0
47545	1624	single major transcription start site	[single major transcription start site]	1.0	5	1	0	0
47546	1624	malignant clone	[malignant clone]	1.0	2	2	1	1
47547	1624	nf-kappab /c-ebp	[NF-kappaB /C-EBP]	1.0	2	1	0	0
47548	1624	AIDS-C patient	[AIDS-C patients]	1.0	2	1	0	0
47549	1624	effect of the two cytokine	[effects of the two cytokines]	1.0	5	1	0	0
47550	1624	octamer consensus	[octamer consensus]	1.0	2	1	0	0
47551	1624	binding of the basic helix-loop-helix protein	[binding of the basic helix-loop-helix protein]	1.0	6	1	0	0
47552	1624	primary peripheral blood mononuclear cell	[primary peripheral blood mononuclear cells]	1.0	5	2	2	2
47553	1624	eosinophilic characteristic of yj cell	[eosinophilic characteristics of YJ cells]	1.0	5	1	0	0
47554	1624	pyrimidine-rich region upstream from HBD	[pyrimidine-rich region upstream from HBD]	1.0	5	1	0	0
47555	1624	enhancer, respond	[enhancer, responding]	1.0	2	1	0	0
47556	1624	aids-related non-hodgkin' lymphoma AIDS NHL	[AIDS-related non-Hodgkin's lymphoma AIDS NHL]	1.0	5	1	0	0
47557	1624	introduction of the hiv-1 plasmid	[Introduction of the HIV-1 plasmids]	1.0	5	1	0	0
47558	1624	hiv-1 genome carry the cDNA	[HIV-1 genome carrying the cDNA]	1.0	5	1	0	0
47559	1624	Ph' the hallmark of CML	[Ph' the hallmark of CML]	1.0	5	1	0	0
47560	1624	non-phlogistic manner	[non-phlogistic manner]	1.0	2	1	0	0
47561	1624	nfat recognition	[NFAT recognition]	1.0	2	1	0	0
47562	1624	Epstein-Barr early region (EBER) RNA-positive	[Epstein-Barr early region (EBER) RNA-positive]	1.0	5	1	0	0
47563	1624	interaction of tax1 with NF-YB	[interaction of Tax1 with NF-YB]	1.0	5	1	0	0
47564	1624	generation of second-messenger ca2+ ion	[generation of second-messenger Ca2+ ions]	1.0	5	1	0	0
47565	1624	herbimycin A a potent inhibitor	[herbimycin A a potent inhibitor]	1.0	5	1	0	0
47566	1624	disturbance of the hypothalamic-pituitary-adrenal hpa system	[disturbances of the hypothalamic-pituitary-adrenal HPA system]	1.0	6	1	0	0
47567	1624	control of the g0 phase	[control of the G0 phases]	1.0	5	1	0	0
47568	1624	gsk-3beta activity	[GSK-3beta activity]	1.0	2	1	0	0
47569	1624	cluster of three binding site	[cluster of three binding sites]	1.0	5	1	0	0
47570	1624	viral interference with the antigen-processing pathway	[viral interference with the antigen-processing pathway]	1.0	6	1	0	0
47571	1624	transcriptional activation of the interleukin-2	[transcriptional activation of the interleukin-2]	1.0	5	1	0	0
47572	1624	human ifna2	[human IFNA2]	1.0	2	1	0	0
47573	1624	bcl-2 proto-oncogene	[bcl-2 proto-oncogene]	1.0	2	1	0	0
47574	1624	anoxia/reoxygenation-induced neutrophil adherence to cell	[anoxia/reoxygenation-induced neutrophil adherence to cells]	1.0	5	1	0	0
47575	1624	staphylococcal enterotoxin	[staphylococcal enterotoxin]	1.0	2	2	2	2
47576	1624	lead to gene transcription activation	[leading to gene transcription activation]	1.0	5	1	0	0
47577	1624	create a pml-rar alpha fusion oncoprotein	[creating a PML-RAR alpha fusion oncoprotein]	1.0	6	1	0	0
47578	1624	DRA "octamer"	[DRA "octamer"]	1.0	2	1	0	0
47579	1624	magnitude of kappa b activity	[magnitude of kappa B activity]	1.0	5	1	0	0
47580	1624	efficient recovery	[efficient recovery]	1.0	2	1	0	0
47581	1624	infection of ebv b-cell line	[infection of EBV B-cell lines]	1.0	5	1	0	0
47582	1624	autoimmune response	[autoimmune response]	1.0	2	1	0	0
47583	1624	antiinflammatory potential of classic glucocorticoid	[antiinflammatory potential of classic glucocorticoids]	1.0	5	1	0	0
47584	1624	significant inhibition of GRalpha transactivation	[significant inhibition of GRalpha transactivation]	1.0	5	1	0	0
47585	1624	diverse set	[diverse set]	1.0	2	2	1	1
47586	1624	chimeric fusion	[chimeric fusion]	1.0	2	1	0	0
47587	1624	c-jun mrna by okadaic acid	[c-jun mRNA by okadaic acid]	1.0	5	1	0	0
47588	1624	presurgical group.	[presurgical group.]	1.0	2	1	0	0
47589	1624	hla-b8-restricted peptide	[HLA-B8-restricted peptide]	1.0	2	2	2	2
47590	1624	antiproliferative response	[antiproliferative response]	1.0	2	1	0	0
47591	1624	ribosomal scanning	[ribosomal scanning]	1.0	2	1	0	0
47592	1624	erythroid-specific activity	[erythroid-specific activity]	1.0	2	1	0	0
47593	1624	54-year-old woman	[54-year-old woman]	1.0	2	1	0	0
47594	1624	various stimulus of T cell	[Various stimuli of T cells]	1.0	5	1	0	0
47595	1624	class ii trans- activator CIITA	[class II trans- activator CIITA]	1.0	5	1	0	0
47596	1624	proteolytic activity	[Proteolytic activity]	1.0	2	2	1	1
47597	1624	recombinant virus	[recombinant virus]	1.0	2	2	2	2
47598	1624	deletion analysis of the pcd41 orf-a	[Deletion analyses of the pCD41 ORF-A]	1.0	6	1	0	0
47599	1624	molecular mass between 94 kda	[molecular mass between 94 kDa]	1.0	5	1	0	0
47600	1624	respectively, in monocyte from CS individual	[respectively, in monocytes from CS individuals]	1.0	6	1	0	0
47601	1624	overwhelming evidence	[overwhelming evidence]	1.0	2	1	0	0
47602	1624	addition, component of the pathway	[addition, components of the pathway]	1.0	5	1	0	0
47603	1624	contain different il-6-responsive gene element	[containing different IL-6-responsive gene elements]	1.0	5	1	0	0
47604	1624	level of gene activity plasmid	[levels of gene activity plasmids]	1.0	5	1	0	0
47605	1624	background: glucocorticoid	[BACKGROUND: Glucocorticoids]	1.0	2	1	0	0
47606	1624	immunoglobulin alpha-locus	[immunoglobulin alpha-locus]	1.0	2	1	0	0
47607	1624	primary activation, with phytohemagglutinin to CD3	[primary activation, with phytohemagglutinin to CD3]	1.0	6	1	0	0
47608	1624	induction by hemin increases, induction	[Induction by hemin increases, induction]	1.0	5	1	0	0
47609	1624	JAK3 kinase	[JAK3 kinase]	1.0	2	1	0	0
47610	1624	level of pafr transcript leukocyte-type	[levels of PAFR transcript leukocyte-type]	1.0	5	1	0	0
47611	1624	Epstein-Barr DNA	[Epstein-Barr DNA]	1.0	2	2	2	2
47612	1624	cd95 ligand on T cell	[CD95 ligand on T cells]	1.0	5	1	0	0
47613	1624	anti-CD3 alone	[anti-CD3 alone]	1.0	2	1	0	0
47614	1624	patient with low renin value	[patients with lower renin values]	1.0	5	1	0	0
47615	1624	sequence 5'-ggccaatggg-3'	[sequence 5'-GGCCAATGGG-3']	1.0	2	1	0	0
47616	1624	stable homodimer	[stable homodimers]	1.0	2	1	0	0
47617	1624	alpha expression	[alpha expression]	1.0	2	2	1	1
47618	1624	il-2r beta-chain	[IL-2R beta-chain]	1.0	2	1	0	0
47619	1624	i.e. polymorphonuclear neutrophilic granulocyte pmn	[i.e. polymorphonuclear neutrophilic granulocytes PMN]	1.0	5	1	0	0
47620	1624	nf-kappab activation in T. cell	[NF-kappaB activation in T. cells]	1.0	5	1	0	0
47621	1624	steroid addition	[steroid addition]	1.0	2	1	0	0
47622	1624	24 h follow lps stimulation	[24 h following LPS stimulation]	1.0	5	1	0	0
47623	1624	SEK/ JNK c-jun ap-1 pathway	[SEK/ JNK c-Jun AP-1 pathway]	1.0	5	1	0	0
47624	1624	form the mature p50 subunit	[forming the mature p50 subunit]	1.0	5	1	0	0
47625	1624	therefore a EB1 -responsive b-cell-specific element	[therefore an EB1 -responsive B-cell-specific element]	1.0	6	1	0	0
47626	1624	calcium ionophores;	[calcium ionophores;]	1.0	2	1	0	0
47627	1624	form N-IRAK	[form N-IRAK]	1.0	2	1	0	0
47628	1624	pp52 mrna	[pp52 mRNA]	1.0	2	1	0	0
47629	1624	two kinase	[two kinases]	1.0	2	1	0	0
47630	1624	probe specific	[probes specific]	1.0	2	2	2	2
47631	1624	inducible binding of p50-p65 nf-kappab heterodimer	[inducible binding of p50-p65 NF-kappaB heterodimers]	1.0	6	1	0	0
47632	1624	affect phosphorylation	[affecting phosphorylation]	1.0	2	1	0	0
47633	1624	transcriptional activity of class ii promoter	[transcriptional activity of class II promoters]	1.0	6	1	0	0
47634	1624	several domains,	[several domains,]	1.0	2	1	0	0
47635	1624	specific antigen	[specific antigens]	1.0	2	1	0	0
47636	1624	important effect	[important effects]	1.0	2	2	2	2
47637	1624	cell lymphotropic	[cell lymphotropic]	1.0	2	1	0	0
47638	1624	encode jun-B the nuclear transcription protein	[encoding jun-B the nuclear transcription protein]	1.0	6	1	0	0
47639	1624	mutant IkappaBalpha	[mutant IkappaBalpha]	1.0	2	2	1	1
47640	1624	sr 31747a	[SR 31747A]	1.0	2	2	2	2
47641	1624	nucleotide -404/-220	[nucleotides -404/-220]	1.0	2	1	0	0
47642	1624	chimeric gp130	[chimeric gp130]	1.0	2	1	0	0
47643	1624	morphologically distinct subset of leukemia	[morphologically distinct subsets of leukemia]	1.0	5	2	2	2
47644	1624	proliferation-associated il-2ralpha	[proliferation-associated IL-2Ralpha]	1.0	2	1	0	0
47645	1624	enf)-kappa b DNA binding activity	[(NF)-kappa B DNA binding activities]	1.0	5	1	0	0
47646	1624	product of the c-rel protooncogene	[product of the c-rel protooncogene]	1.0	5	1	0	0
47647	1624	co-cultured bronchial epithelial cell BEAS-2B	[co-cultured bronchial epithelial cells BEAS-2B]	1.0	5	1	0	0
47648	1624	transfection experiment with c-myc promoter construct	[Transfection experiments with c-myc promoter constructs]	1.0	6	1	0	0
47649	1624	health state	[health state]	1.0	2	1	0	0
47650	1624	cytokine in normal human monocyte	[cytokines in normal human monocytes]	1.0	5	1	0	0
47651	1624	differentiation-inducing concentrations,	[differentiation-inducing concentrations,]	1.0	2	1	0	0
47652	1624	proximal sequence	[proximal sequence]	1.0	2	1	0	0
47653	1624	cytokine signalling	[cytokine signalling]	1.0	2	1	0	0
47654	1624	involve the synthesis of ROI	[involving the synthesis of ROI]	1.0	5	1	0	0
47655	1624	demonstration of EBV mrna transcript	[Demonstration of EBV mRNA transcripts]	1.0	5	1	0	0
47656	1624	peripheral-blood granulocyte	[peripheral-blood granulocytes]	1.0	2	2	2	2
47657	1624	normally menstruate	[normally menstruating]	1.0	2	1	0	0
47658	1624	expression of the bcl-6 protein	[expression of the BCL-6 protein]	1.0	5	1	0	0
47659	1624	increase nuclear factor of T cell	[increasing nuclear factor of T cells]	1.0	6	1	0	0
47660	1624	achieve immunosuppression.	[achieving immunosuppression.]	1.0	2	1	0	0
47661	1624	lymphocyte from the site of disease	[Lymphocytes from the site of disease]	1.0	6	1	0	0
47662	1624	DNA binding in normal T cell	[DNA binding in normal T cells]	1.0	6	1	0	0
47663	1624	differential activation of multiple member	[differential activation of multiple members]	1.0	5	1	0	0
47664	1624	phorbol acetate	[phorbol acetate]	1.0	2	2	2	2
47665	1624	inducible component	[inducible component]	1.0	2	2	2	2
47666	1624	result in activator protein-1 -dependent transcription	[resulting in activator protein-1 -dependent transcription]	1.0	6	1	0	0
47667	1624	ZII domain	[ZII domain]	1.0	2	2	2	2
47668	1624	in-frame splicing out of exon	[in-frame splicing out of exon]	1.0	5	1	0	0
47669	1624	rest tissue	[resting tissues]	1.0	2	1	0	0
47670	1624	profound influence	[profound influence]	1.0	2	1	0	0
47671	1624	ganglioside in supernatant from RCC explant	[gangliosides in supernatants from RCC explants]	1.0	6	1	0	0
47672	1624	prion protein	[Prion protein]	1.0	2	1	0	0
47673	1624	divergent x2-box	[divergent X2-box]	1.0	2	2	1	1
47674	1624	CD40 cross-linking	[CD40 cross-linking]	1.0	2	2	1	1
47675	1624	receptor number on the control day	[Receptor number on the control day]	1.0	6	1	0	0
47676	1624	Arg91 one	[Arg91 one]	1.0	2	1	0	0
47677	1624	response to T cell activation	[response to T cell activation]	1.0	5	1	0	0
47678	1624	lysosomal serine	[lysosomal serine]	1.0	2	1	0	0
47679	1624	thus, microtubule	[Thus, microtubules]	1.0	2	1	0	0
47680	1624	allele-specific expression	[allele-specific expression]	1.0	2	2	1	1
47681	1624	dose of methylprednisolone in man.	[doses of methylprednisolone in man.]	1.0	5	1	0	0
47682	1624	prooxidant condition	[prooxidant conditions]	1.0	2	1	0	0
47683	1624	vWF secretion	[vWF secretion]	1.0	2	1	0	0
47684	1624	expression of exogenous c-erba/tr-alpha in erythroblast	[expression of exogenous c-erbA/TR-alpha in erythroblasts]	1.0	6	1	0	0
47685	1624	2.3-kb cDNA	[2.3-kb cDNA]	1.0	2	1	0	0
47686	1624	two well-characterized Ets family member Ets-1	[Two well-characterized Ets family members Ets-1]	1.0	6	1	0	0
47687	1624	bone marrow such as kidney	[bone marrow such as kidney]	1.0	5	1	0	0
47688	1624	erythroid specificity to a reporter gene	[erythroid specificity to a reporter gene]	1.0	6	1	0	0
47689	1624	gtp binding	[GTP binding]	1.0	2	1	0	0
47690	1624	expression of the tal1 gene	[expression of the TAL1 gene]	1.0	5	1	0	0
47691	1624	expression level of p27kip1 mrna	[expression level of p27Kip1 mRNA]	1.0	5	1	0	0
47692	1624	finding inconsistent	[finding inconsistent]	1.0	2	1	0	0
47693	1624	CAT reporter gene suggest activity	[CAT reporter gene suggesting activity]	1.0	5	1	0	0
47694	1624	such as ap-1 -binding proto-oncogene product	[such as AP-1 -binding proto-oncogene products]	1.0	6	1	0	0
47695	1624	regulation in human cell line	[regulation in human cell lines]	1.0	5	2	2	2
47696	1624	ubiquitinylation pathway	[ubiquitinylation pathways]	1.0	2	1	0	0
47697	1624	hematopoietic system.	[hematopoietic system.]	1.0	2	1	0	0
47698	1624	Animal lectins	[Animal lectins]	1.0	2	1	0	0
47699	1624	expression of four cell gene	[expression of four cell genes]	1.0	5	1	0	0
47700	1624	ligand-inducible degradation	[ligand-inducible degradation]	1.0	2	1	0	0
47701	1624	DNA binding in the patient	[DNA binding in the patients]	1.0	5	1	0	0
47702	1624	member of the AP-1/ATF/CREB family	[members of the AP-1/ATF/CREB families]	1.0	5	1	0	0
47703	1624	presence of estrogen type I	[presence of estrogen type I]	1.0	5	1	0	0
47704	1624	native envelope glycoprotein of hiv-1 gp160	[native envelope glycoproteins of HIV-1 gp160]	1.0	6	1	0	0
47705	1624	activation of the CD28 surface receptor	[Activation of the CD28 surface receptor]	1.0	6	1	0	0
47706	1624	incubation increase extracellular concentration of cysteine	[incubation increasing extracellular concentrations of cysteine]	1.0	6	1	0	0
47707	1624	nuclear nf-atp	[nuclear NF-ATp]	1.0	2	1	0	0
47708	1624	reporter gene under the control	[reporter gene under the control]	1.0	5	1	0	0
47709	1624	human colony form unit-erythroid cell	[human colony forming unit-erythroid cells]	1.0	5	1	0	0
47710	1624	c-Myc up-regulates,	[c-Myc up-regulates,]	1.0	2	1	0	0
47711	1624	cell-dependent b cell immunopoiesis occur	[cell-dependent B cell immunopoiesis occurring]	1.0	5	1	0	0
47712	1624	es reticulocyte	[ES reticulocytes]	1.0	2	2	1	1
47713	1624	protein kinase mapk pathway PD	[protein kinase MAPK pathway PD]	1.0	5	1	0	0
47714	1624	NFKB2 lyt-10	[NFKB2 lyt-10]	1.0	2	2	1	1
47715	1624	potent regulator of cell growth	[potent regulators of cell growth]	1.0	5	1	0	0
47716	1624	T lineage differentiation of precursor	[T lineage differentiation of precursors]	1.0	5	1	0	0
47717	1624	five kappa b-related sequence element	[five kappa B-related sequence elements]	1.0	5	1	0	0
47718	1624	IgH locus	[IgH locus]	1.0	2	1	0	0
47719	1624	reduction of CIITA mrna transcription	[reduction of CIITA mRNA transcription]	1.0	5	1	0	0
47720	1624	nuclear protein (s) from lam-	[nuclear protein (s) from LAM-]	1.0	5	1	0	0
47721	1624	unprimed cell	[unprimed cells]	1.0	2	1	0	0
47722	1624	analysis of recombinant mouse strain	[analysis of recombinant mouse strains]	1.0	5	1	0	0
47723	1624	3-hydroxy-3-methylglutaryl coenzyme	[3-hydroxy-3-methylglutaryl coenzyme]	1.0	2	1	0	0
47724	1624	J Biol Chem Jun 17;269(24):16983]	[J Biol Chem Jun 17;269(24):16983]]	1.0	5	1	0	0
47725	1624	novel b-cell-specific transcription factor BSAP	[novel B-cell-specific transcription factor BSAP]	1.0	5	1	0	0
47726	1624	cycloheximide response	[cycloheximide response]	1.0	2	1	0	0
47727	1624	native HS	[native HS]	1.0	2	1	0	0
47728	1624	role in monocyte differentiation analogous	[role in monocyte differentiation analogous]	1.0	5	1	0	0
47729	1624	truncation mutant of LEF-1 HMG-88	[truncation mutant of LEF-1 HMG-88]	1.0	5	1	0	0
47730	1624	id family	[Id family]	1.0	2	2	2	2
47731	1624	cell IL3	[cell IL3]	1.0	2	1	0	0
47732	1624	il-6 activity	[IL-6 activity]	1.0	2	1	0	0
47733	1624	cortisol secretion	[cortisol secretion]	1.0	2	1	0	0
47734	1624	molecular background of the defect	[molecular background of the defects]	1.0	5	1	0	0
47735	1624	human intestine	[human intestine]	1.0	2	1	0	0
47736	1624	vitro activation	[vitro activation]	1.0	2	2	1	1
47737	1624	human leukemic cell line model	[human leukemic cell line model]	1.0	5	1	0	0
47738	1624	monocyte lineage	[monocyte lineage]	1.0	2	2	2	2
47739	1624	biphasic kinetics.	[biphasic kinetics.]	1.0	2	1	0	0
47740	1624	protein of about 150 kD	[protein of about 150 kD]	1.0	5	1	0	0
47741	1624	polyomavirus enhancer	[polyomavirus enhancer]	1.0	2	1	0	0
47742	1624	develop cns	[developing CNS]	1.0	2	1	0	0
47743	1624	c-maf cDNA	[c-Maf cDNA]	1.0	2	1	0	0
47744	1624	kappa b-dependent gene in microglia	[kappa B-dependent genes in microglia]	1.0	5	1	0	0
47745	1624	different stimulus mediate different aspect	[different stimuli mediating different aspects]	1.0	5	1	0	0
47746	1624	activation of lymphocyte by phytohaemagglutinin	[activation of lymphocytes by phytohaemagglutinin]	1.0	5	1	0	0
47747	1624	Hungarian male breast cancer patient	[Hungarian male breast cancer patients]	1.0	5	1	0	0
47748	1624	T cell sensitization in vivo	[T cell sensitization in vivo]	1.0	5	1	0	0
47749	1624	inflammatory pathogenesis	[inflammatory pathogenesis]	1.0	2	2	1	1
47750	1624	include the identification of novel family	[including the identification of novel families]	1.0	6	1	0	0
47751	1624	novel B-cell lineage-specific transcription factor	[novel B-cell lineage-specific transcription factor]	1.0	5	1	0	0
47752	1624	site together	[sites together]	1.0	2	1	0	0
47753	1624	and/or c-rel	[and/or c-Rel]	1.0	2	1	0	0
47754	1624	induce transform growth factor-beta expression	[inducing transforming growth factor-beta expression]	1.0	5	1	0	0
47755	1624	reach peak CsA drug level	[reaching peak CsA drug levels]	1.0	5	1	0	0
47756	1624	series cell	[series cells]	1.0	2	1	0	0
47757	1624	Nonhuman primate	[Nonhuman primates]	1.0	2	1	0	0
47758	1624	crucial role ensure the differentiation	[crucial role ensuring the differentiation]	1.0	5	1	0	0
47759	1624	rapid effect	[rapid effects]	1.0	2	2	1	1
47760	1624	-20 GATA binding site AGATAA	[-20 GATA binding site AGATAA]	1.0	5	1	0	0
47761	1624	"housekeeping" promoter	["housekeeping" promoter]	1.0	2	1	0	0
47762	1624	eight family form of inheritance	[eight families: forms of inheritance]	1.0	5	1	0	0
47763	1624	Finally, TFIIA	[Finally, TFIIA]	1.0	2	1	0	0
47764	1624	814 bp	[814 bp]	1.0	2	1	0	0
47765	1624	abnormally low plasma cysteine level	[abnormally low plasma cysteine levels]	1.0	5	1	0	0
47766	1624	Jak1 phosphorylation	[Jak1 phosphorylation]	1.0	2	1	0	0
47767	1624	Furthermore, expression of shp-1 phosphatase	[Furthermore, expression of SHP-1 phosphatase]	1.0	5	1	0	0
47768	1624	CsA patient	[CsA patients]	1.0	2	1	0	0
47769	1624	chemical induction,	[chemical induction,]	1.0	2	1	0	0
47770	1624	several methods,	[several methods,]	1.0	2	2	2	2
47771	1624	L2 domain	[L2 domains]	1.0	2	1	0	0
47772	1624	nmol/l, p	[nmol/L, p]	1.0	2	2	2	2
47773	1624	upregulation of the lipoxygenase activity	[upregulation of the lipoxygenase activity]	1.0	5	1	0	0
47774	1624	C/EBPalpha mouse	[C/EBPalpha mice]	1.0	2	2	2	2
47775	1624	Lipopolysaccharide lps	[Lipopolysaccharide LPS]	1.0	2	1	0	0
47776	1624	mutation in the glucocorticoid receptor	[mutations in the glucocorticoid receptor]	1.0	5	1	0	0
47777	1624	immediate-early manner	[immediate-early manner]	1.0	2	1	0	0
47778	1624	potential role of the expression	[potential role of the expression]	1.0	5	1	0	0
47779	1624	multifocal cancer	[multifocal cancer]	1.0	2	1	0	0
47780	1624	normal tissues,	[normal tissues,]	1.0	2	1	0	0
47781	1624	negative signal	[negative signals]	1.0	2	1	0	0
47782	1624	12 hour of 135(oh)2d3 treatment	[12 hours of 1,25(OH)2D3 treatment]	1.0	5	1	0	0
47783	1624	neuron-specific enolase	[neuron-specific enolase]	1.0	2	1	0	0
47784	1624	results: after nonspecific stimulation, il-5 production	[RESULTS: After nonspecific stimulation, IL-5 production]	1.0	6	1	0	0
47785	1624	response to a apoptotic stimulus	[response to a apoptotic stimuli]	1.0	5	1	0	0
47786	1624	endonuclease activity	[endonuclease activity]	1.0	2	1	0	0
47787	1624	fragment of a 3.6 kb sequence	[Fragments of a 3.6 kb sequence]	1.0	6	1	0	0
47788	1624	predictive protein-coding region of RP1	[predictive protein-coding region of RP1]	1.0	5	1	0	0
47789	1624	LT-kappa b	[LT-kappa B]	1.0	2	2	2	2
47790	1624	respective target	[respective target]	1.0	2	1	0	0
47791	1624	NF-IL6 motif	[NF-IL6 motifs]	1.0	2	1	0	0
47792	1624	SHP1 -DeltaSH2	[SHP1 -DeltaSH2]	1.0	2	2	1	1
47793	1624	rest immature (ccrf-cem) t-cell line	[resting immature (CCRF-CEM) T-cell lines]	1.0	5	1	0	0
47794	1624	I -182 to -162 bp	[I -182 to -162 bp]	1.0	5	1	0	0
47795	1624	plasma membrane receptor for aldosterone	[plasma membrane receptors for aldosterone]	1.0	5	1	0	0
47796	1624	t) cell from 11 11	[T) cells from 11 11]	1.0	5	1	0	0
47797	1624	IL-2 control il-2 receptor alpha	[IL-2 control IL-2 receptor alpha]	1.0	5	1	0	0
47798	1624	binding activity of nf-kappa b	[binding activity of NF-kappa B]	1.0	5	1	0	0
47799	1624	other methods.	[other methods.]	1.0	2	1	0	0
47800	1624	contain the negative respond element NREs	[containing the negative responding elements NREs]	1.0	6	1	0	0
47801	1624	biological variation among the samples.	[biological variation among the samples.]	1.0	5	1	0	0
47802	1624	pulmonary infiltrate	[pulmonary infiltrates]	1.0	2	1	0	0
47803	1624	intrathymic maturation	[intrathymic maturation]	1.0	2	1	0	0
47804	1624	flap inhibitors,	[FLAP inhibitors,]	1.0	2	1	0	0
47805	1624	ach2 cell	[Ach2 cells]	1.0	2	2	1	1
47806	1624	intracellular na+	[intracellular Na+]	1.0	2	1	0	0
47807	1624	cellular organelle	[cellular organelle]	1.0	2	2	1	1
47808	1624	definition of the body axis	[definition of the body axis]	1.0	5	1	0	0
47809	1624	respective receptors.	[respective receptors.]	1.0	2	1	0	0
47810	1624	one other distinct "octamer" complex	[one other distinct "octamer" complex]	1.0	5	1	0	0
47811	1624	placental cell	[placental cells]	1.0	2	1	0	0
47812	1624	effect of acidic activator protein	[effects of acidic activator proteins]	1.0	5	1	0	0
47813	1624	ap-1 concentration in primary lymphocyte	[AP-1 concentrations in primary lymphocytes]	1.0	5	1	0	0
47814	1624	Hardy-Weinberg distribution	[Hardy-Weinberg distribution]	1.0	2	1	0	0
47815	1624	transcription of the cytokine il-4	[transcription of the cytokine IL-4]	1.0	5	1	0	0
47816	1624	human monocytes.	[human monocytes.]	1.0	2	1	0	0
47817	1624	patient with persistent inflammatory arthritis	[patients with persistent inflammatory arthritis]	1.0	5	1	0	0
47818	1624	allergy-driven overproduction	[allergy-driven overproduction]	1.0	2	1	0	0
47819	1624	nerve cell	[nerve cells]	1.0	2	1	0	0
47820	1624	two catalytically similar proteins, cyclophilin	[two catalytically similar proteins, cyclophilin]	1.0	5	1	0	0
47821	1624	different ad2/ad12 hybrid e1a gene product	[different Ad2/Ad12 hybrid E1A gene products]	1.0	6	1	0	0
47822	1624	specific block	[specific block]	1.0	2	1	0	0
47823	1624	nf kappab in most cells;	[NF kappaB in most cells;]	1.0	5	1	0	0
47824	1624	alphabeta lineage	[alphabeta lineage]	1.0	2	1	0	0
47825	1624	peripheral blood T cell proliferation	[peripheral blood T cell proliferation]	1.0	5	1	0	0
47826	1624	Transcription-independent turnover	[Transcription-independent turnover]	1.0	2	1	0	0
47827	1624	th suppression	[TH suppression]	1.0	2	1	0	0
47828	1624	allergic rhinitis	[allergic rhinitis]	1.0	2	3	2	1
47829	1624	regulation of nuclear factor-kappa b	[Regulation of nuclear factor-kappa B]	1.0	5	1	0	0
47830	1624	GATA-1 -mutant embryonic stem cell	[GATA-1 -mutant embryonic stem cells]	1.0	5	1	0	0
47831	1624	inhibition of nuclear factor kappab activation	[Inhibition of nuclear factor kappaB activation]	1.0	6	1	0	0
47832	1624	ehrlichial binding	[ehrlichial binding]	1.0	2	1	0	0
47833	1624	adenovirus early region 3 ES	[adenovirus early region 3 ES]	1.0	5	1	0	0
47834	1624	circulate t-cell from individual with pathology	[Circulating T-cells from individuals with pathology]	1.0	6	1	0	0
47835	1624	critical event in t-cell transformation	[critical event in T-cell transformation]	1.0	5	1	0	0
47836	1624	such as proliferation, cell death,	[such as proliferation, cell death,]	1.0	5	1	0	0
47837	1624	mycobacterial component	[mycobacterial components]	1.0	2	1	0	0
47838	1624	anti- STAT	[anti- STAT]	1.0	2	1	0	0
47839	1624	hypermethylation within the promoter of gene	[Hypermethylation within the promoters of genes]	1.0	6	1	0	0
47840	1624	ROI in various cell type	[ROIs in various cell types]	1.0	5	1	0	0
47841	1624	effect of overexpression of bcl-2	[effect of overexpression of bcl-2]	1.0	5	1	0	0
47842	1624	molecular target for SR 31747a	[molecular target for SR 31747A]	1.0	5	1	0	0
47843	1624	perennial rhinitis.	[perennial rhinitis.]	1.0	2	1	0	0
47844	1624	two peptide	[Two peptides]	1.0	2	1	0	0
47845	1624	TNF-alpha nuclear localization of NFkappaB	[TNF-alpha nuclear localization of NFkappaB]	1.0	5	1	0	0
47846	1624	allow rapid activation of NF-kappa b	[allowing rapid activation of NF-kappa B]	1.0	6	1	0	0
47847	1624	hiv-1 gene expression in vitro.	[HIV-1 gene expression in vitro.]	1.0	5	1	0	0
47848	1624	egr-1 induction	[EGR-1 induction]	1.0	2	1	0	0
47849	1624	viral clearance	[viral clearance]	1.0	2	1	0	0
47850	1624	alpha-Tocopheryl succinate	[alpha-Tocopheryl succinate]	1.0	2	1	0	0
47851	1624	distal octamer	[distal octamer]	1.0	2	1	0	0
47852	1624	c-fo control	[c-fos control]	1.0	2	2	2	2
47853	1624	Ras activation	[Ras activation]	1.0	2	1	0	0
47854	1624	holo- TFIIA with GST- tax	[holo- TFIIA with GST- Tax]	1.0	5	1	0	0
47855	1624	ability of the envelope glycoprotein	[ability of the envelope glycoprotein]	1.0	5	1	0	0
47856	1624	rodent cell	[rodent cells]	1.0	2	2	1	1
47857	1624	class ii MHC x1 box	[class II MHC X1 box]	1.0	5	1	0	0
47858	1624	membrane-associated lymphotoxin on natural killer cell	[Membrane-associated lymphotoxin on natural killer cells]	1.0	6	1	0	0
47859	1624	include the case with t(11;17)	[including the case with t(11;17)]	1.0	5	1	0	0
47860	1624	hiv-1 infection of myelomonoblastic cell	[HIV-1 infection of myelomonoblastic cells]	1.0	5	1	0	0
47861	1624	contrast, activation in thp-1 cell	[contrast, activation in THP-1 cells]	1.0	5	1	0	0
47862	1624	nucleus compartment	[nucleus compartment]	1.0	2	1	0	0
47863	1624	DNA binding, mutant retain either	[DNA binding, mutants retaining either]	1.0	5	1	0	0
47864	1624	tow of the XISTE- ring chromosome	[tow of the XISTE- ring chromosomes]	1.0	6	1	0	0
47865	1624	functionally related hepatocyte nuclear factor	[functionally related hepatocyte nuclear factors]	1.0	5	1	0	0
47866	1624	tumor-suppressor gene	[tumor-suppressor genes]	1.0	2	1	0	0
47867	1624	stimulation with tumor necrosis factor	[stimulation with tumor necrosis factor]	1.0	5	1	0	0
47868	1624	regulation of the ferritin heavy-chain gene	[regulation of the ferritin heavy-chain gene]	1.0	6	1	0	0
47869	1624	activation-dependent, T cell-specific transacting factor	[activation-dependent, T cell-specific transacting factors]	1.0	5	1	0	0
47870	1624	optimal transcription in monocytic cell	[optimal transcription in monocytic cells]	1.0	5	1	0	0
47871	1624	considerable evidence	[considerable evidence]	1.0	2	1	0	0
47872	1624	time-dependent manner.	[time-dependent manner.]	1.0	2	1	0	0
47873	1624	il-8 expression u937 lymphoma cell	[IL-8 expression U937 lymphoma cells]	1.0	5	1	0	0
47874	1624	tax gene product htlv-i p40tax	[tax gene product HTLV-I p40tax]	1.0	5	1	0	0
47875	1624	GATA-1 -mutant	[GATA-1 -mutant]	1.0	2	1	0	0
47876	1624	important role in B-cell growth	[important role in B-cell growth]	1.0	5	1	0	0
47877	1624	sequence-specific binding of tcf-1 alpha	[sequence-specific binding of TCF-1 alpha]	1.0	5	1	0	0
47878	1624	production of the blocking factor	[production of the blocking factor]	1.0	5	1	0	0
47879	1624	minimal effect on promoter expression	[minimal effects on promoter expression]	1.0	5	1	0	0
47880	1624	pha lymphocyte	[PHA lymphocytes]	1.0	2	2	1	1
47881	1624	non- mcd14	[non- mCD14]	1.0	2	1	0	0
47882	1624	beta-adrenergic receptor	[beta-adrenergic receptor]	1.0	2	1	0	0
47883	1624	lymphocytic infiltrate of exocrine gland	[lymphocytic infiltrates of exocrine glands]	1.0	5	1	0	0
47884	1624	leukocyte biology,	[leukocyte biology,]	1.0	2	1	0	0
47885	1624	transcriptional activation of the IL-2 promoter	[transcriptional activation of the IL-2 promoter]	1.0	6	1	0	0
47886	1624	two clone	[Two clones]	1.0	2	1	0	0
47887	1624	transcription of the gm-csf gene	[transcription of the GM-CSF gene]	1.0	5	1	0	0
47888	1624	utilize sp1 binding site oligonucleotide	[utilizing Sp1 binding site oligonucleotides]	1.0	5	1	0	0
47889	1624	Similarly, Jurkat T cell line deficient	[Similarly, Jurkat T cell lines deficient]	1.0	6	1	0	0
47890	1624	culturing procedure	[culturing procedure]	1.0	2	1	0	0
47891	1624	isotype specificity,	[isotype specificity,]	1.0	2	1	0	0
47892	1624	expression of the beta 2-integrin gene	[Expression of the beta 2-integrin genes]	1.0	6	1	0	0
47893	1624	thus overcome the differentiation arrest	[thus overcoming the differentiation arrest]	1.0	5	1	0	0
47894	1624	lps inducibility	[LPS inducibility]	1.0	2	1	0	0
47895	1624	epitope peptide-loaded dendritic cell dc	[epitope peptide-loaded dendritic cells DCs]	1.0	5	1	0	0
47896	1624	regulation of gene expression at stage	[Regulation of gene expression at stages]	1.0	6	1	0	0
47897	1624	gssg deficiency	[GSSG deficiency]	1.0	2	2	2	2
47898	1624	mediate tyrosine phosphorylation of crucial molecule	[mediating tyrosine phosphorylation of crucial molecules]	1.0	6	1	0	0
47899	1624	lead to cytokine gene transcription	[leading to cytokine gene transcription]	1.0	5	1	0	0
47900	1624	GM-CSF gene activation in T cell	[GM-CSF gene activation in T cells]	1.0	6	1	0	0
47901	1624	involve proviral clone with ltr	[involving proviral clones with LTRs]	1.0	5	1	0	0
47902	1624	2 receptor alpha-chain il-2r alpha	[2 receptor alpha-chain IL-2R alpha]	1.0	5	1	0	0
47903	1624	association of SCL with proliferation	[association of SCL with proliferation]	1.0	5	1	0	0
47904	1624	functional NF-AT1 transcription factor complex	[functional NF-AT1 transcription factor complexes]	1.0	5	1	0	0
47905	1624	pretreatment (or up minute posttreatment) relative	[Pretreatment (or up minutes posttreatment) relative]	1.0	6	1	0	0
47906	1624	case of deficiency-heat syndrome dhs	[cases of deficiency-heat syndrome DHS]	1.0	5	1	0	0
47907	1624	new participant	[new participant]	1.0	2	1	0	0
47908	1624	natural killer cell with il-12	[natural killer cells with IL-12]	1.0	5	1	0	0
47909	1624	anti- ebv antibody titre (13	[anti- EBV antibody titres (13]	1.0	5	1	0	0
47910	1624	vitro transcription of a gene	[vitro transcription of an gene]	1.0	5	1	0	0
47911	1624	inhibition of the transcription of gene	[inhibition of the transcription of genes]	1.0	6	1	0	0
47912	1624	RESULTS: administration of the antisense oligonucleotide	[RESULTS: Administration of the antisense oligonucleotide]	1.0	6	1	0	0
47913	1624	specific transcription factor binding site	[specific transcription factor binding sites]	1.0	5	1	0	0
47914	1624	bind affinity of NF-kappa b	[binding affinity of NF-kappa B]	1.0	5	1	0	0
47915	1624	pathological condition include breast cancer	[pathological conditions including breast cancer]	1.0	5	1	0	0
47916	1624	YAC contig	[YAC contig]	1.0	2	1	0	0
47917	1624	potent transactivator	[potent transactivator]	1.0	2	2	1	1
47918	1624	limit signal	[limiting signaling]	1.0	2	1	0	0
47919	1624	mammalian il2	[mammalian IL2s]	1.0	2	1	0	0
47920	1624	complex phenomenon await further elucidation.	[complex phenomenon awaiting further elucidation.]	1.0	5	1	0	0
47921	1624	transcriptional activation of ig gene	[transcriptional activation of Ig genes]	1.0	5	1	0	0
47922	1624	respectively, in three independent fusions.	[respectively, in three independent fusions.]	1.0	5	1	0	0
47923	1624	high degree of substrate specificity	[high degree of substrate specificity]	1.0	5	1	0	0
47924	1624	ligation of ag receptor in T	[Ligation of Ag receptors in T]	1.0	6	1	0	0
47925	1624	include IL-2	[including IL-2]	1.0	2	1	0	0
47926	1624	human carcinoma cell line ht29	[human carcinoma cell line HT29]	1.0	5	2	2	2
47927	1624	master controller	[master controller]	1.0	2	1	0	0
47928	1624	untreated controls.	[untreated controls.]	1.0	2	1	0	0
47929	1624	direct action	[direct action]	1.0	2	2	1	1
47930	1624	characterize NF-kappa b -independent transcriptional activation	[characterizing NF-kappa B -independent transcriptional activation]	1.0	6	1	0	0
47931	1624	comedo carcinoma	[comedo carcinomas]	1.0	2	2	1	1
47932	1624	region contain E2F binding site	[region containing E2F binding site]	1.0	5	1	0	0
47933	1624	tumor necrosis factor (tnf)-alpha gene	[tumor necrosis factor (TNF)-alpha gene]	1.0	5	1	0	0
47934	1624	aged group	[aged group]	1.0	2	2	1	1
47935	1624	Interferon-alpha IFN-alpha	[Interferon-alpha IFN-alpha]	1.0	2	1	0	0
47936	1624	structural role	[structural role]	1.0	2	2	2	2
47937	1624	tax expression in Jurkat T cell	[Tax expression in Jurkat T cells]	1.0	6	1	0	0
47938	1624	low serum	[low serum]	1.0	2	1	0	0
47939	1624	maintain survival in hematopoietic stem	[maintaining survival in hematopoietic stem]	1.0	5	1	0	0
47940	1624	double transfectant	[double transfectants]	1.0	2	1	0	0
47941	1624	specific test	[specific test]	1.0	2	1	0	0
47942	1624	use the DNA affinity precipitation assay	[Using the DNA affinity precipitation assay]	1.0	6	1	0	0
47943	1624	derive from a TcR delta gene	[deriving from an TcR delta gene]	1.0	6	1	0	0
47944	1624	vcam-1 transcription	[VCAM-1 transcription]	1.0	2	1	0	0
47945	1624	erythroid maturation,	[erythroid maturation,]	1.0	2	1	0	0
47946	1624	compare binding of this transcription factor	[comparing binding of these transcription factors]	1.0	6	1	0	0
47947	1624	inhibition of apoptosis by curcumin	[inhibition of apoptosis by curcumin]	1.0	5	1	0	0
47948	1624	discrete gene	[discrete genes]	1.0	2	1	0	0
47949	1624	fiberoptic bronchoscopy with endobronchial biopsy	[fiberoptic bronchoscopy with endobronchial biopsy]	1.0	5	1	0	0
47950	1624	express the epor with ba/f3 cell	[expressing the EPOR with Ba/F3 cells]	1.0	6	1	0	0
47951	1624	analysis of a yeast chromosome contig	[analyses of a yeast chromosome contig]	1.0	6	1	0	0
47952	1624	extracellular signal-regulated kinase erk pathway	[extracellular signal-regulated kinase Erk pathway]	1.0	5	1	0	0
47953	1624	measure blood plasma cortisol concentration	[measuring blood plasma cortisol concentration]	1.0	5	1	0	0
47954	1624	transcript abnormality	[transcript abnormalities]	1.0	2	1	0	0
47955	1624	partner, the retinoid x receptor	[partner, the retinoid X receptor]	1.0	5	1	0	0
47956	1624	double-stranded oligonucleotide	[double-stranded oligonucleotides]	1.0	2	2	2	2
47957	1624	patient with adult t-cell leukemia/lymphoma	[patients with adult T-cell leukemia/lymphoma]	1.0	5	1	0	0
47958	1624	cytokine production by T lymphocyte	[cytokine production by T lymphocytes]	1.0	5	1	0	0
47959	1624	difference in ROI -form mechanism	[differences in ROI -forming mechanisms]	1.0	5	1	0	0
47960	1624	dd-restricted CTL	[Dd-restricted CTLs]	1.0	2	1	0	0
47961	1624	receptor -negative status s-phase fraction	[receptor -negative status S-phase fraction]	1.0	5	1	0	0
47962	1624	HL 60 cell (granulocytic differentiated)	[HL 60 cells (granulocytic differentiated)]	1.0	5	1	0	0
47963	1624	accounting for approximately 1% to 8%	[accounting for approximately 1% to 8%]	1.0	6	1	0	0
47964	1624	eklf allele in stem (es) cell	[EKLF alleles in stem (ES) cells]	1.0	6	1	0	0
47965	1624	bind characteristic	[binding characteristics]	1.0	2	2	1	1
47966	1624	normal tonsils.	[normal tonsils.]	1.0	2	1	0	0
47967	1624	DNA sequence bind affinity profile	[DNA sequence binding affinity profile]	1.0	5	1	0	0
47968	1624	gr deficiency	[GR deficiency]	1.0	2	2	2	2
47969	1624	redox sensitive cytosolic transcription factor	[redox sensitive cytosolic transcription factor]	1.0	5	1	0	0
47970	1624	two species.	[two species.]	1.0	2	1	0	0
47971	1624	failure in effectiveness from delivery	[failures in effectiveness from delivery]	1.0	5	1	0	0
47972	1624	primary human bone marrow culture	[primary human bone marrow cultures]	1.0	5	1	0	0
47973	1624	kappa b alpha mut-i kappa b	[kappa B alpha mut-I kappa B]	1.0	6	1	0	0
47974	1624	protein kinase c -dependent signal	[protein kinase C -dependent signals]	1.0	5	1	0	0
47975	1624	3) failure of the mutant endotoxin	[3) failure of the mutant endotoxin]	1.0	6	1	0	0
47976	1624	bifunctional role	[bifunctional role]	1.0	2	2	2	2
47977	1624	mean gc-r bmax in pbmc	[mean GC-R Bmax in PBMC]	1.0	5	1	0	0
47978	1624	menopausal woman	[menopausal women]	1.0	2	2	1	1
47979	1624	postgerminal center	[postgerminal center]	1.0	2	1	0	0
47980	1624	importance of cell surface molecule	[importance of cell surface molecules]	1.0	5	1	0	0
47981	1624	high level of bcl-6 mrna	[high levels of BCL-6 mRNA]	1.0	5	1	0	0
47982	1624	nf-kappa b activation in monocytes-macrophages	[NF-kappa B activation in monocytes-macrophages]	1.0	5	1	0	0
47983	1624	binding to multiple E2F site	[binding to multiple E2F sites]	1.0	5	1	0	0
47984	1624	OCA-B interaction	[OCA-B interactions]	1.0	2	1	0	0
47985	1624	fundamental role in inflammatory reaction	[fundamental role in inflammatory reactions]	1.0	5	1	0	0
47986	1624	ligand-induced tyrosine phosphorylation of the STATs	[Ligand-induced tyrosine phosphorylation of the STATs]	1.0	6	1	0	0
47987	1624	threshold of cathepsin g platelet	[threshold of cathepsin G platelets]	1.0	5	1	0	0
47988	1624	activation of multiple tyrosine kinase	[activation of multiple tyrosine kinases]	1.0	5	1	0	0
47989	1624	certain hla b8+ LCL target	[certain HLA B8+ LCL targets]	1.0	5	1	0	0
47990	1624	Ad-infected target	[Ad-infected targets]	1.0	2	1	0	0
47991	1624	HIV adult	[HIV adults]	1.0	2	1	0	0
47992	1624	well-known immunosuppressive and/or anti-inflammatory cytokine	[well-known immunosuppressive and/or anti-inflammatory cytokine]	1.0	5	1	0	0
47993	1624	ra-induced differentiation	[RA-induced differentiation]	1.0	2	1	0	0
47994	1624	160 pm),	[160 pM),]	1.0	2	1	0	0
47995	1624	Interferon gamma	[Interferon gamma]	1.0	2	1	0	0
47996	1624	10000 bu/ml)	[10000 BU/mL)]	1.0	2	1	0	0
47997	1624	non- T cell from 1	[non- T cells from 1]	1.0	5	1	0	0
47998	1624	DR unit	[DR units]	1.0	2	1	0	0
47999	1624	reduction of intracellular peroxide level	[reduction of intracellular peroxide level]	1.0	5	1	0	0
48000	1624	prostate	[prostate]	1.0	1	11	4	4
48001	1624	response to anti-CD3 mab stimulation	[response to anti-CD3 mAb stimulation]	1.0	5	1	0	0
48002	1624	previous datum from human fibroblast	[previous data from human fibroblasts]	1.0	5	1	0	0
48003	1624	human 15-lipoxygenase gene promoter analysis	[Human 15-lipoxygenase gene promoter analysis]	1.0	5	1	0	0
48004	1624	type a family of cytokine	[Type a family of cytokines]	1.0	5	1	0	0
48005	1624	use a protein kinase inhibitor h-7	[using a protein kinase inhibitor H-7]	1.0	6	1	0	0
48006	1624	sickle erythrocyte with endothelial cell	[sickle erythrocytes with endothelial cells]	1.0	5	1	0	0
48007	1624	MHC /peptide density requirement ed50	[MHC /peptide density requirements ED50]	1.0	5	1	0	0
48008	1624	SERCA activity	[SERCA activity]	1.0	2	1	0	0
48009	1624	suppress the tyrosine phosphorylation of stat1	[suppressing the tyrosine phosphorylation of STAT1]	1.0	6	1	0	0
48010	1624	Th2 type	[Th2 type]	1.0	2	2	2	2
48011	1624	inflammatory process in the lung	[inflammatory processes in the lung]	1.0	5	1	0	0
48012	1624	moreover, deletion of 5' nf-kappab site	[Moreover, deletion of 5' NF-kappaB sites]	1.0	6	1	0	0
48013	1624	indicate the presence of IFN activity	[indicating the presence of IFN activity]	1.0	6	1	0	0
48014	1624	insertion of 47 amino acid	[insertion of 47 amino acids]	1.0	5	1	0	0
48015	1624	drug resistance inhibition of apoptosis	[drug resistance inhibition of apoptosis]	1.0	5	1	0	0
48016	1624	hiv-1 reactivation rest blood mononuclear cell	[HIV-1 reactivation resting blood mononuclear cells]	1.0	6	1	0	0
48017	1624	reversible transformation	[reversible transformation]	1.0	2	1	0	0
48018	1624	heterodimeric cytokine	[heterodimeric cytokine]	1.0	2	2	2	2
48019	1624	HRBC group	[HRBC group,]	1.0	2	1	0	0
48020	1624	23% overall blood histamine response	[23% overall blood histamine response]	1.0	5	1	0	0
48021	1624	"Plus" clone	["Plus" clones]	1.0	2	1	0	0
48022	1624	increase in il-2 promoter activity	[increase in IL-2 promoter activity]	1.0	5	2	2	2
48023	1624	interleukin (il)-8	[interleukin (IL)-8]	1.0	2	1	0	0
48024	1624	interleukin (il)-4	[interleukin (IL)-4]	1.0	2	1	0	0
48025	1624	involvement of Stat3 in igm production	[Involvement of Stat3 in IgM production]	1.0	6	1	0	0
48026	1624	origin replication	[origin replication]	1.0	2	1	0	0
48027	1624	parental Jak1 -express counterpart 1d4	[parental Jak1 -expressing counterpart 1D4]	1.0	5	1	0	0
48028	1624	fine tuning	[fine tuning]	1.0	2	1	0	0
48029	1624	15- to 20-fold reduction in expression	[15- to 20-fold reduction in expression]	1.0	6	1	0	0
48030	1624	acute myeloid leukemia blast cell	[acute myeloid leukemia blast cells]	1.0	5	1	0	0
48031	1624	coimmunoprecipitation assay	[coimmunoprecipitation assay]	1.0	2	1	0	0
48032	1624	caii transcription	[CAII transcription]	1.0	2	2	1	1
48033	1624	slp-76 -dependent interleukin (il)-2 promoter	[SLP-76 -dependent interleukin (IL)-2 promoter]	1.0	5	1	0	0
48034	1624	various diseases.	[various diseases.]	1.0	2	1	0	0
48035	1624	lymphoid cell on reporter gene	[lymphoid cells on reporter genes]	1.0	5	1	0	0
48036	1624	IL-2 heterodimerization of receptor partner	[IL-2 heterodimerization of receptor partners]	1.0	5	1	0	0
48037	1624	use T cell from naive donor	[using T cells from naive donors]	1.0	6	1	0	0
48038	1624	induction of a labile inhibitory factor	[induction of a labile inhibitory factor]	1.0	6	1	0	0
48039	1624	independent T	[independent T]	1.0	2	1	0	0
48040	1624	g protein-coupled transcription factor activation	[G protein-coupled transcription factor activation]	1.0	5	1	0	0
48041	1624	follow the trigger of hla-dr antigen	[following the triggering of HLA-DR antigens]	1.0	6	1	0	0
48042	1624	activation of activator protein-1 ap-1	[activation of activator protein-1 AP-1]	1.0	5	1	0	0
48043	1624	gc treatment	[GC treatment]	1.0	2	1	0	0
48044	1624	region of the HIV promoter	[regions of the HIV promoter]	1.0	5	1	0	0
48045	1624	lymphocyte maturation	[lymphocyte maturation]	1.0	2	1	0	0
48046	1624	estrogen receptor in human monocyte	[estrogen receptor in human monocytes]	1.0	5	2	2	2
48047	1624	R24 mAb	[R24 mAb]	1.0	2	1	0	0
48048	1624	microtubule damage)	[microtubule damage)]	1.0	2	1	0	0
48049	1624	loss of recognition of one	[loss of recognition of one]	1.0	5	1	0	0
48050	1624	cell replication	[cell replication]	1.0	2	1	0	0
48051	1624	same preparation.	[same preparation.]	1.0	2	1	0	0
48052	1624	syphilitic chancre	[syphilitic chancre]	1.0	2	1	0	0
48053	1624	mutation in this sequence element	[mutations in these sequence elements]	1.0	5	1	0	0
48054	1624	patient with t-cell lymphoblastic leukemia	[patients with T-cell lymphoblastic leukemia]	1.0	5	2	2	2
48055	1624	NFAT3 protein	[NFAT3 protein]	1.0	2	1	0	0
48056	1624	Study of the action of factor	[Studies of the actions of factor]	1.0	6	1	0	0
48057	1624	neutralize abs to the hcmv glycoprotein	[neutralizing Abs to the HCMV glycoproteins]	1.0	6	1	0	0
48058	1624	decrease in the burst activity	[decrease in the burst activity]	1.0	5	1	0	0
48059	1624	high concentration of soluble peptide	[high concentrations of soluble peptide]	1.0	5	1	0	0
48060	1624	142 residue	[142 residues]	1.0	2	1	0	0
48061	1624	hbxag protein	[HBxAg protein]	1.0	2	2	1	1
48062	1624	20-base pair	[20-base pair]	1.0	2	2	2	2
48063	1624	role for et transcription factor	[role for ets transcription factors]	1.0	5	1	0	0
48064	1624	35 kda	[35 kDa]	1.0	2	2	2	2
48065	1624	acute lymphoblastic leukemia of childhood.	[acute lymphoblastic leukemia of childhood.]	1.0	5	1	0	0
48066	1624	suppression of T lymphocyte activation	[suppression of T lymphocyte activation]	1.0	5	1	0	0
48067	1624	black woman in good health	[black women in good health]	1.0	5	1	0	0
48068	1624	mutation of the AP-1/ CRE site	[Mutation of the AP-1/ CRE site]	1.0	6	1	0	0
48069	1624	hiv gp120	[HIV gp120]	1.0	2	1	0	0
48070	1624	steady state mrna level equivalent	[steady state mRNA levels equivalent]	1.0	5	1	0	0
48071	1624	thus, activation	[Thus, activation]	1.0	2	2	2	2
48072	1624	multiple myeloma	[multiple myeloma]	1.0	2	2	1	1
48073	1624	vitro CD4 cross-linking by ligand	[vitro CD4 cross-linking by ligands]	1.0	5	1	0	0
48074	1624	one region of the protein	[one region of the protein]	1.0	5	1	0	0
48075	1624	such as lipopolysaccharide lps the endotoxin	[such as lipopolysaccharide LPS the endotoxin]	1.0	6	1	0	0
48076	1624	concentration of about 10(-6) m	[concentrations of about 10(-6) M]	1.0	5	1	0	0
48077	1624	enhancer function in pre-B cell	[enhancer function in pre-B cells]	1.0	5	1	0	0
48078	1624	SMX hypersensitivity	[SMX hypersensitivity]	1.0	2	1	0	0
48079	1624	hematopoietic precursor cell line u937	[hematopoietic precursor cell lines U937]	1.0	5	1	0	0
48080	1624	subsequent step of nf-kappab activation	[subsequent steps of NF-kappaB activation]	1.0	5	1	0	0
48081	1624	transcription in	[transcription in]	1.0	2	1	0	0
48082	1624	approximately deltanfkappabdeltasp1	[approximately deltaNFkappaBdeltaSp1]	1.0	2	1	0	0
48083	1624	immunization with adenovirus, express ad5e1a	[immunization with adenovirus, expressing Ad5E1A]	1.0	5	1	0	0
48084	1624	consist of the extracellular domain	[consisting of the extracellular domain]	1.0	5	2	1	1
48085	1624	Drosophila Schneider cell by coexpression	[Drosophila Schneider cells by coexpression]	1.0	5	1	0	0
48086	1624	human immunodeficiency virus type-1 hiv	[human immunodeficiency virus type-1 HIV]	1.0	5	1	0	0
48087	1624	lipid antioxidant	[lipid antioxidants]	1.0	2	1	0	0
48088	1624	five severe atopic dermatitis patient	[five severe atopic dermatitis patients]	1.0	5	1	0	0
48089	1624	human t-cell leukemia virus type I	[Human T-cell leukemia virus type I]	1.0	6	3	2	1
48090	1624	activation of NK cell by interleukin-2	[activation of NK cells by interleukin-2]	1.0	6	1	0	0
48091	1624	IL-3 -dependent murine pro-B cell	[IL-3 -dependent murine pro-B cells]	1.0	5	1	0	0
48092	1624	chimeric gene,	[chimeric gene,]	1.0	2	1	0	0
48093	1624	SN50 apoptosis	[SN50 apoptosis]	1.0	2	1	0	0
48094	1624	p50- sequence	[p50- sequences]	1.0	2	1	0	0
48095	1624	point mutation within the eed gene	[Point mutations within the eed gene]	1.0	6	1	0	0
48096	1624	moreover, alteration of any one cis-element	[Moreover, alteration of any one cis-element]	1.0	6	1	0	0
48097	1624	interleukin-2 dependence	[interleukin-2 dependence]	1.0	2	1	0	0
48098	1624	erythroid differentiation in this cells,	[erythroid differentiation in these cells,]	1.0	5	1	0	0
48099	1624	glucocorticoid receptor in human lymphocyte	[glucocorticoid receptors in human lymphocytes]	1.0	5	2	2	2
48100	1624	transcriptional activity of activator protein-1	[transcriptional activity of activator protein-1]	1.0	5	1	0	0
48101	1624	fc epsilon RI- gamma chain	[Fc epsilon RI- gamma chain]	1.0	5	1	0	0
48102	1624	specific down-regulation of transcription factor	[specific down-regulation of transcription factors]	1.0	5	1	0	0
48103	1624	tissue factor expression of human monocyte	[Tissue factor expression of human monocytes]	1.0	6	1	0	0
48104	1624	inactive x	[inactive X]	1.0	2	1	0	0
48105	1624	otf-1	[OTF-1]	1.0	1	11	4	4
48106	1624	beta,19-cyclopregn-5-ene-4,20-dione (11)	[beta,19-cyclopregn-5-ene-4,20-dione (11)]	1.0	2	1	0	0
48107	1624	gradual downmodulation of cd34 mrna	[gradual downmodulation of CD34 mRNA]	1.0	5	1	0	0
48108	1624	several stimulus	[several stimuli]	1.0	2	2	2	2
48109	1624	protection against hiv-1 latency reactivation	[protection against HIV-1 latency reactivation]	1.0	5	1	0	0
48110	1624	percentage of hb -synthesizing cell	[percentage of Hb -synthesizing cells]	1.0	5	1	0	0
48111	1624	consider a common regulatory element	[Considering a common regulatory element]	1.0	5	1	0	0
48112	1624	several stimuli.	[several stimuli.]	1.0	2	1	0	0
48113	1624	death domain -contain receptor related	[death domain -containing receptor related]	1.0	5	1	0	0
48114	1624	switch during late G1-to- phase	[switch during late G1-to-S phase]	1.0	5	1	0	0
48115	1624	regulate human T cell activation	[regulating human T cell activation]	1.0	5	1	0	0
48116	1624	assembly mechanism	[assembly mechanism]	1.0	2	1	0	0
48117	1624	constitutively express the htlv-i tax protein	[constitutively expressing the HTLV-I Tax protein]	1.0	6	1	0	0
48118	1624	maximal induction.	[maximal induction.]	1.0	2	1	0	0
48119	1624	also in nonimmune hela cell	[also in nonimmune HeLa cells]	1.0	5	1	0	0
48120	1624	caspase-3 inhibitor	[caspase-3 inhibitor]	1.0	2	2	1	1
48121	1624	granulocytic, clonogenesis	[granulocytic, clonogenesis]	1.0	2	1	0	0
48122	1624	nf-kappa b activation within 1 hour	[NF-kappa B activation within 1 hr]	1.0	6	1	0	0
48123	1624	mouse t-lymphoma cell line bw5147	[mouse T-lymphoma cell line BW5147]	1.0	5	1	0	0
48124	1624	repertoire of the memory response	[repertoire of the memory response]	1.0	5	1	0	0
48125	1624	Recombinant NFAT1	[Recombinant NFAT1]	1.0	2	1	0	0
48126	1624	immune competence	[immune competence]	1.0	2	1	0	0
48127	1624	mature population	[mature populations]	1.0	2	2	2	2
48128	1624	CLL case	[CLL cases]	1.0	2	1	0	0
48129	1624	respond to granulocyte/ macrophage colony-stimumulatelany-stg factor	[responding to granulocyte/ macrophage colony-stimulating factor]	1.0	6	1	0	0
48130	1624	person with no history of varicella	[persons with no history of varicella]	1.0	6	1	0	0
48131	1624	inflammatory stimulus in human neutrophil	[inflammatory stimuli in human neutrophils]	1.0	5	1	0	0
48132	1624	c-rel translocation	[c-rel translocation]	1.0	2	1	0	0
48133	1624	tgf-beta1 signal	[TGF-beta1 signaling]	1.0	2	2	1	1
48134	1624	include the vitamin a derivative, acid	[including the vitamin A derivative, acid]	1.0	6	1	0	0
48135	1624	transcription of the E2F-1 gene	[transcription of the E2F-1 gene]	1.0	5	1	0	0
48136	1624	increase recognition of the peptide bond	[increasing recognition of the peptide bond]	1.0	6	1	0	0
48137	1624	cytoplasmic portion	[cytoplasmic portion]	1.0	2	1	0	0
48138	1624	purified, peripheral blood T cell	[purified, peripheral blood T cells]	1.0	5	1	0	0
48139	1624	effector function of T cell	[effector functions of T cells]	1.0	5	1	0	0
48140	1624	il-2 immunotherapy	[IL-2 immunotherapy]	1.0	2	2	1	1
48141	1624	feature characteristic of transcriptional activator	[features characteristic of transcriptional activators]	1.0	5	1	0	0
48142	1624	high affinity aldosterone binding site	[High affinity aldosterone binding sites]	1.0	5	1	0	0
48143	1624	C terminal section of sm	[C terminal section of SM]	1.0	5	1	0	0
48144	1624	mitomycin c	[mitomycin C]	1.0	2	1	0	0
48145	1624	function in the immune system	[Function in the immune system]	1.0	5	2	2	2
48146	1624	synergistic proinflammatory effect of mechanical stress	[Synergistic proinflammatory effects of mechanical stress]	1.0	6	1	0	0
48147	1624	CXC subfamily	[CXC subfamily]	1.0	2	1	0	0
48148	1624	inhibition of nf-kappa b activity.	[inhibition of NF-kappa B activity.]	1.0	5	1	0	0
48149	1624	d mrna	[D mRNA]	1.0	2	1	0	0
48150	1624	distinct activity, DNA sequence specificity,	[distinct activity, DNA sequence specificity,]	1.0	5	1	0	0
48151	1624	AP-1 the polypeptide product of c-jun	[AP-1 the polypeptide product of c-jun]	1.0	6	1	0	0
48152	1624	mp treatment with suppression continue	[MP treatments with suppression continuing]	1.0	5	1	0	0
48153	1624	requirement for hiv LTR activation	[requirements for HIV LTR activation]	1.0	5	1	0	0
48154	1624	value 68.28	[value 68.28]	1.0	2	1	0	0
48155	1624	immunosuppressive capacity	[immunosuppressive capacities]	1.0	2	1	0	0
48156	1624	retroviral infection	[retroviral infection]	1.0	2	1	0	0
48157	1624	several method	[several methods]	1.0	2	2	1	1
48158	1624	virus latency	[virus latency]	1.0	2	2	1	1
48159	1624	adult hpc	[adult HPC]	1.0	2	2	1	1
48160	1624	RelA complex	[RelA complexes]	1.0	2	1	0	0
48161	1624	physiological marker of growth rate	[physiological marker of growth rate]	1.0	5	1	0	0
48162	1624	STAT1 complex	[STAT1 complexes]	1.0	2	1	0	0
48163	1624	NF-kappa b binding by a protein	[NF-kappa B binding by an protein]	1.0	6	1	0	0
48164	1624	cell line co-express gata -1	[cell lines co-expressing GATA -1]	1.0	5	1	0	0
48165	1624	adhesion molecule expression in venous	[adhesion molecule expression in venous]	1.0	5	2	1	1
48166	1624	encode hsv-2 type-specific cd4+ antigen	[encoding HSV-2 type-specific CD4+ antigens]	1.0	5	1	0	0
48167	1624	one region,	[One region,]	1.0	2	1	0	0
48168	1624	receptors, leukocyte of the b-	[receptors, leukocytes of the B-]	1.0	5	1	0	0
48169	1624	adult type,	[adult type,]	1.0	2	1	0	0
48170	1624	encode sequence in all member	[encoding sequences in all members]	1.0	5	1	0	0
48171	1624	membrane lipoprotein	[membrane lipoproteins]	1.0	2	1	0	0
48172	1624	novel astrocyte-derived kappa b-binding activity	[novel astrocyte-derived kappa B-binding activity]	1.0	5	1	0	0
48173	1624	4/12 t-cell	[4/12 T-cell]	1.0	2	1	0	0
48174	1624	comparative sequence	[Comparative sequence]	1.0	2	1	0	0
48175	1624	early T cell activation event	[early T cell activation events]	1.0	5	1	0	0
48176	1624	TGF-beta promoter	[TGF-beta promoter]	1.0	2	1	0	0
48177	1624	(D. e.) CD4 T cell	[(D. E.) CD4 T cells]	1.0	5	1	0	0
48178	1624	transcriptional function of AP-1 complex	[transcriptional function of AP-1 complexes]	1.0	5	1	0	0
48179	1624	MLA 144 T cell line	[MLA 144 T cell line]	1.0	5	1	0	0
48180	1624	E1A cell	[E1A cells]	1.0	2	2	2	2
48181	1624	explore physical stress-induced signal pathway	[exploring physical stress-induced signaling pathways]	1.0	5	1	0	0
48182	1624	survival rate in this animal	[survival rate in these animals]	1.0	5	1	0	0
48183	1624	similar degree to heat shock	[similar degree to heat shock]	1.0	5	1	0	0
48184	1624	first contrast IL-12 IFN -alpha-inducible gene	[first contrasting IL-12 IFN -alpha-inducible genes]	1.0	6	1	0	0
48185	1624	c-sis/pdgb promoter	[c-sis/PDGF-B promoter]	1.0	2	3	2	1
48186	1624	b-lymphocyte development	[B-lymphocyte development]	1.0	2	2	2	2
48187	1624	human Raji b lymphoblastoid cell	[human Raji B lymphoblastoid cells]	1.0	5	1	0	0
48188	1624	only protein	[only protein]	1.0	2	2	1	1
48189	1624	mAb 18c7	[mAb 18C7]	1.0	2	1	0	0
48190	1624	resting monocyte	[Resting monocytes]	1.0	2	1	0	0
48191	1624	methallothionein (mtiia) mrna expression level	[methallothionein (MTIIa) mRNA expression levels]	1.0	5	1	0	0
48192	1624	cell adhesion assay with RBC	[cell adhesion assays with RBCs]	1.0	5	1	0	0
48193	1624	antioxidant defence	[antioxidant defence]	1.0	2	2	1	1
48194	1624	effect of HU on regulation	[effects of HU on regulation]	1.0	5	1	0	0
48195	1624	recruiting factor	[recruiting factors]	1.0	2	1	0	0
48196	1624	22-kDa c-terminal sp1 protein fragment	[22-kDa C-terminal SP1 protein fragment]	1.0	5	1	0	0
48197	1624	latent phase	[latent phases]	1.0	2	1	0	0
48198	1624	Antisense experiment	[Antisense experiments]	1.0	2	1	0	0
48199	1624	proline-rich sequence	[proline-rich sequence]	1.0	2	2	1	1
48200	1624	activation of human il4 transcription	[activation of human IL4 transcription]	1.0	5	1	0	0
48201	1624	Similarly, interferon	[Similarly, interferons]	1.0	2	1	0	0
48202	1624	complex group of transient response	[complex group of transient responses]	1.0	5	1	0	0
48203	1624	Safety parameter	[Safety parameters]	1.0	2	1	0	0
48204	1624	part of the NFAT complex	[part of the NFAT complex]	1.0	5	1	0	0
48205	1624	drug hypersensitivity	[drug hypersensitivity]	1.0	2	1	0	0
48206	1624	avidity, CD8 variable contribution compensate	[avidity, CD8 variable contribution compensating]	1.0	5	1	0	0
48207	1624	therapeutic efficiency	[therapeutic efficiency]	1.0	2	1	0	0
48208	1624	clinical use	[clinical use]	1.0	2	2	2	2
48209	1624	tcr -ligand	[TCR -ligand]	1.0	2	1	0	0
48210	1624	pbsc harvest	[PBSC harvests]	1.0	2	2	1	1
48211	1624	alanine substitution	[Alanine substitutions]	1.0	2	1	0	0
48212	1624	binding in response to PMA together	[binding in response to PMA together]	1.0	6	1	0	0
48213	1624	embryonic expression	[embryonic expression]	1.0	2	2	1	1
48214	1624	human aortic endothelial cell harc	[human aortic endothelial cells HAECs]	1.0	5	1	0	0
48215	1624	b domain	[B domain]	1.0	2	2	2	2
48216	1624	ebv LMP1 include the ability	[EBV LMP1 including the ability]	1.0	5	1	0	0
48217	1624	terminal differentiation of the DC	[terminal differentiation of the DC]	1.0	5	1	0	0
48218	1624	level of the factor activator protein-1	[levels of the factor activator protein-1]	1.0	6	1	0	0
48219	1624	PMLRAR alpha	[PMLRAR alpha]	1.0	2	1	0	0
48220	1624	negative regulator of DNA binding,	[negative regulators of DNA binding,]	1.0	5	1	0	0
48221	1624	up-regulated beta-	[up-regulated beta-]	1.0	2	1	0	0
48222	1624	major aspect of nongenomic effects.	[major aspects of nongenomic effects.]	1.0	5	1	0	0
48223	1624	functional redundancy among NGFI-B/nur77 family	[functional redundancy among NGFI-B/nur77 family]	1.0	5	1	0	0
48224	1624	correlate to cell shape change	[correlating to cell shape changes]	1.0	5	1	0	0
48225	1624	il-9 tyrosine phosphorylation of jak kinase	[IL-9 tyrosine phosphorylation of JAK kinases]	1.0	6	1	0	0
48226	1624	m32 y196a	[M32 Y196A]	1.0	2	1	0	0
48227	1624	show variable degree of staining.	[showing variable degrees of staining.]	1.0	5	1	0	0
48228	1624	typical morphology	[typical morphology]	1.0	2	2	2	2
48229	1624	(NF) activation by protein kinase C	[(NF) activation by protein kinase C]	1.0	6	1	0	0
48230	1624	"dose-sparing" effect	["dose-sparing" effects]	1.0	2	1	0	0
48231	1624	mononuclear cell of CLL patient	[mononuclear cells of CLL patients]	1.0	5	1	0	0
48232	1624	use peripheral blood mononuclear cell pbmc	[Using peripheral blood mononuclear cells PBMC]	1.0	6	1	0	0
48233	1624	p3hr-1-infected cell	[P3HR-1-infected cells]	1.0	2	1	0	0
48234	1624	use a thymic lymphoma-derived hybridoma pc60	[using a thymic lymphoma-derived hybridoma PC60]	1.0	6	1	0	0
48235	1624	cytoplasmic acidification	[cytoplasmic acidification]	1.0	2	1	0	0
48236	1624	role in T helper cell differentiation	[role in T helper cell differentiation]	1.0	6	1	0	0
48237	1624	p105 processing in T cell	[p105 processing in T cells]	1.0	5	1	0	0
48238	1624	aml-1 protein in dna-binding assay	[AML-1 proteins in DNA-binding assays]	1.0	5	1	0	0
48239	1624	T factor	[T factor]	1.0	2	2	2	2
48240	1624	Wnt signal	[Wnt signals]	1.0	2	1	0	0
48241	1624	great transcription	[greater transcription]	1.0	2	1	0	0
48242	1624	pkc-epsilon pkc-alpha	[PKC-epsilon PKC-alpha]	1.0	2	1	0	0
48243	1624	differentiation of a leukemia cell line	[differentiation of a leukemia cell line]	1.0	6	1	0	0
48244	1624	mononuclear leukocyte glucocorticoid receptor binding characteristic	[Mononuclear leukocyte glucocorticoid receptor binding characteristics]	1.0	6	1	0	0
48245	1624	cytochalasin d	[cytochalasin D]	1.0	2	1	0	0
48246	1624	inefficient termination of antigen response	[Inefficient termination of antigen responses]	1.0	5	1	0	0
48247	1624	such elusive oct2 target gene	[such elusive Oct2 target genes]	1.0	5	1	0	0
48248	1624	human interleukin-9 receptor alpha chain	[human interleukin-9 receptor alpha chain]	1.0	5	1	0	0
48249	1624	hiv-1 LTR -dependent gene expression	[HIV-1 LTR -dependent gene expression]	1.0	5	1	0	0
48250	1624	step of the heme pathway	[step of the heme pathway]	1.0	5	2	2	2
48251	1624	complex in	[complex in]	1.0	2	1	0	0
48252	1624	1 ap-1	[1 AP-1]	1.0	2	2	1	1
48253	1624	marker for t-derived lymphoid cell	[marker for T-derived lymphoid cells]	1.0	5	1	0	0
48254	1624	correction for other TNF polymorphism	[correction for other TNF polymorphisms]	1.0	5	1	0	0
48255	1624	non-genomic effect on transmembrane electrolyte movement	[non-genomic effects on transmembrane electrolyte movements]	1.0	6	2	2	2
48256	1624	30-bp sequence	[30-bp sequence]	1.0	2	1	0	0
48257	1624	extremely low level of otf-2	[extremely low levels of OTF-2]	1.0	5	1	0	0
48258	1624	pair sequence	[pair sequence]	1.0	2	2	2	2
48259	1624	analysis of the immediate promoter	[analysis of the immediate promoter]	1.0	5	1	0	0
48260	1624	inducible, T	[inducible, T]	1.0	2	1	0	0
48261	1624	pcr fragment	[PCR fragments]	1.0	2	1	0	0
48262	1624	follow amplification of IFN mrna	[following amplification of IFN mRNA]	1.0	5	1	0	0
48263	1624	vitro cultivation,	[vitro cultivation,]	1.0	2	1	0	0
48264	1624	5' LTR	[5' LTR]	1.0	2	1	0	0
48265	1624	cytoplasmic inhibitory ikbalpha protein degradation	[cytoplasmic inhibitory IkBalpha protein degradation]	1.0	5	1	0	0
48266	1624	aml m4 without eosinophilic abnormality	[AML M4 without eosinophilic abnormalities]	1.0	5	1	0	0
48267	1624	respective chromosome	[respective chromosomes]	1.0	2	1	0	0
48268	1624	lead to oxidative stress-dependent activation	[leading to oxidative stress-dependent activation]	1.0	5	1	0	0
48269	1624	use chloramphenicol acetyltransferase (cat) gene	[using chloramphenicol acetyltransferase (CAT) gene]	1.0	5	1	0	0
48270	1624	antitumor immunity	[antitumor immunity]	1.0	2	2	1	1
48271	1624	indicate critical for NFAT complex formation	[indicating critical for NFAT complex formation]	1.0	6	1	0	0
48272	1624	allele ratio	[allele ratio]	1.0	2	2	2	2
48273	1624	pbl from individual between 20-50%	[PBL from individuals between 20-50%]	1.0	5	1	0	0
48274	1624	Oct2-isoform expression in splenic b cell	[Oct2-isoform expression in splenic B cells]	1.0	6	1	0	0
48275	1624	sites/cell, p	[sites/cell, P]	1.0	2	1	0	0
48276	1624	adaptor molecule	[adaptor molecule]	1.0	2	2	1	1
48277	1624	familial sclerosis	[familial sclerosis]	1.0	2	1	0	0
48278	1624	differentiative activity of this agent	[differentiative activities of these agents]	1.0	5	1	0	0
48279	1624	germinal center of lymph node	[germinal centers of lymph nodes]	1.0	5	1	0	0
48280	1624	clinical gene	[clinical gene]	1.0	2	1	0	0
48281	1624	role of this two factor	[roles of these two factors]	1.0	5	1	0	0
48282	1624	elucidation of il-5 -specific regulatory mechanism	[Elucidation of IL-5 -specific regulatory mechanisms]	1.0	6	1	0	0
48283	1624	cd34	[CD34]	1.0	1	11	2	2
48284	1624	calpain inhibitor	[calpain inhibitor]	1.0	2	1	0	0
48285	1624	hla class ii antigen expression	[HLA class II antigens expression]	1.0	5	1	0	0
48286	1624	outgrowth of immortal cell line	[outgrowth of immortal cell lines]	1.0	5	1	0	0
48287	1624	none of the hybrid reporter construct	[None of the hybrid reporter constructs]	1.0	6	1	0	0
48288	1624	tumor necrosis factor TNF interleukin-1	[tumor necrosis factor TNF interleukin-1]	1.0	5	1	0	0
48289	1624	mutation in the Pit-1 gene	[Mutations in the Pit-1 gene]	1.0	5	1	0	0
48290	1624	biological relevance for this model.	[biological relevance for this model.]	1.0	5	1	0	0
48291	1624	intraarterial measurement	[intraarterial measurements]	1.0	2	1	0	0
48292	1624	cell-cycle position	[cell-cycle position]	1.0	2	1	0	0
48293	1624	antiestrogen h1285	[antiestrogens H1285]	1.0	2	1	0	0
48294	1624	use [3h]dihydrotestosterone	[using [3H]dihydrotestosterone]	1.0	2	1	0	0
48295	1624	characterization of the human elk-1 promoter	[Characterization of the human elk-1 promoter]	1.0	6	1	0	0
48296	1624	135-(oh)2d3 induction	[1,25-(OH)2D3 induction]	1.0	2	2	2	2
48297	1624	compound use transactivation transrepression model	[compounds using transactivation transrepression models]	1.0	5	1	0	0
48298	1624	il-6 kappa b binding factor ii	[IL-6 kappa B binding factor II]	1.0	6	1	0	0
48299	1624	hsp90 modulate dioxin receptor function	[hsp90 modulating dioxin receptor function]	1.0	5	1	0	0
48300	1624	Fine mutagenesis	[Fine mutagenesis]	1.0	2	1	0	0
48301	1624	buthionine sulfoximine	[buthionine sulfoximine]	1.0	2	2	1	1
48302	1624	identity of the cell type	[identity of the cell type]	1.0	5	1	0	0
48303	1624	vitro-differentiated bcl-xL	[vitro-differentiated bcl-xL]	1.0	2	1	0	0
48304	1624	hnf -3alpha	[HNF -3alpha]	1.0	2	1	0	0
48305	1624	inhibit nf-kappab	[inhibiting NF-kappaB]	1.0	2	1	0	0
48306	1624	use early hematopoietic progenitor cell HPC	[using early hematopoietic progenitor cells HPC]	1.0	6	1	0	0
48307	1624	phosphatidylinositol turnover	[phosphatidylinositol turnover]	1.0	2	3	2	1
48308	1624	protein level.	[protein level.]	1.0	2	1	0	0
48309	1624	protein level,	[protein level,]	1.0	2	2	1	1
48310	1624	signal event related to DNA damage	[signaling events related to DNA damage]	1.0	6	1	0	0
48311	1624	expression of triptolide degradation of parp	[expression of triptolide degradation of PARP]	1.0	6	1	0	0
48312	1624	glucocorticoid receptor messenger ribonucleic acid	[glucocorticoid receptor messenger ribonucleic acid]	1.0	5	1	0	0
48313	1624	3.1+/-0.2 nmol/L) versus 9.5+/-0.3 nmol/L)	[3.1+/-0.2 nmol/L) versus 9.5+/-0.3 nmol/L)]	1.0	5	1	0	0
48314	1624	2-50 gy	[2-50 Gy]	1.0	2	1	0	0
48315	1624	Epstein-Barr virus transactivator in arthritis	[Epstein-Barr virus transactivators in arthritis]	1.0	5	1	0	0
48316	1624	p75 binding	[p75 binding]	1.0	2	1	0	0
48317	1624	related DNA sequence through homo-	[related DNA sequences through homo-]	1.0	5	1	0	0
48318	1624	biphasic, produce stimulation at lower,	[biphasic, producing stimulation at lower,]	1.0	5	1	0	0
48319	1624	prevent apoptosis	[preventing apoptosis]	1.0	2	2	1	1
48320	1624	only the 22 kda form	[only the 22 kDa form]	1.0	5	1	0	0
48321	1624	tal-1 promoter	[tal-1 promoter]	1.0	2	2	1	1
48322	1624	C-terminal domain of the precursor	[C-terminal domain of the precursor]	1.0	5	1	0	0
48323	1624	tgf-alpha expression in human eosinophil	[TGF-alpha expression in human eosinophils]	1.0	5	1	0	0
48324	1624	ebna2 activation,	[EBNA2 activation,]	1.0	2	1	0	0
48325	1624	plasma cell-specific repressor function suppressor	[plasma cell-specific repressor function suppressor]	1.0	5	1	0	0
48326	1624	various agents.	[various agents.]	1.0	2	2	1	1
48327	1624	various agents,	[various agents,]	1.0	2	1	0	0
48328	1624	undergo elective termination of uterine pregnancy	[undergoing elective termination of uterine pregnancy]	1.0	6	1	0	0
48329	1624	overexpression of a dominant-active inhibitor	[overexpression of a dominant-active inhibitor]	1.0	5	1	0	0
48330	1624	ic50 value of 31 nmol/l,	[IC50 values of 31 nmol/L,]	1.0	5	1	0	0
48331	1624	action of D3 on myelopoiesis	[actions of D3 on myelopoiesis]	1.0	5	1	0	0
48332	1624	hardly in the Th2 clone	[hardly in the Th2 clones]	1.0	5	1	0	0
48333	1624	datum on specific regulation of promoter	[data on specific regulation of promoters]	1.0	6	1	0	0
48334	1624	Importantly, nucleoprotein extract show dna-binding activity	[Importantly, nucleoprotein extracts showing DNA-binding activity]	1.0	6	1	0	0
48335	1624	bcr1/25 a 25-mer pml/ rar-alpha	[BCR1/25 a 25-mer pml/ RAR-alpha]	1.0	5	1	0	0
48336	1624	little activation in response to p40tax	[little activation in response to p40tax]	1.0	6	1	0	0
48337	1624	PMA stimulation.	[PMA stimulation.]	1.0	2	2	1	1
48338	1624	patient with pulmonary granulomatous disease	[patients with pulmonary granulomatous diseases]	1.0	5	2	1	1
48339	1624	proteasome-mediated processing	[proteasome-mediated processing]	1.0	2	1	0	0
48340	1624	MCM family	[MCM family]	1.0	2	1	0	0
48341	1624	form of the NOTCH1 transmembrane receptor	[forms of the NOTCH1 transmembrane receptor]	1.0	6	1	0	0
48342	1624	jurkat cell human T lymphocyte	[Jurkat cells human T lymphocytes]	1.0	5	1	0	0
48343	1624	bypass T cell receptor tcr signal	[bypassing T cell receptor TCR signaling]	1.0	6	1	0	0
48344	1624	eklf-/- erythrocyte in adult animal	[EKLF-/- erythrocytes in adult animals]	1.0	5	1	0	0
48345	1624	expression of active nf-kappa b	[expression of active NF-kappa B]	1.0	5	1	0	0
48346	1624	proliferative parameter	[proliferative parameter]	1.0	2	1	0	0
48347	1624	Asp584 (d584aqpqagr),	[Asp584 (D584AQPQAGR),]	1.0	2	1	0	0
48348	1624	trigger of the t-cell receptor-CD3 complex	[Triggering of the T-cell receptor-CD3 complex]	1.0	6	1	0	0
48349	1624	correlation between kappab binding activity	[correlation between kappaB binding activity]	1.0	5	1	0	0
48350	1624	include Sp1	[including Sp1]	1.0	2	2	2	2
48351	1624	89% reduction	[89% reduction]	1.0	2	1	0	0
48352	1624	synergism with Oct-2 by RAR	[synergism with Oct-2 by RAR]	1.0	5	1	0	0
48353	1624	incubation of endothelial cell with MM-LDL	[Incubation of endothelial cells with MM-LDL]	1.0	6	1	0	0
48354	1624	raise the activity of glucocorticoid receptor	[raising the activity of glucocorticoid receptors]	1.0	6	1	0	0
48355	1624	transactivation of the IL-1alpha promoter	[transactivation of the IL-1alpha promoter]	1.0	5	1	0	0
48356	1624	nuclear protein from monocytic cell	[nuclear proteins from monocytic cells]	1.0	5	1	0	0
48357	1624	mutagenesis of this cis element	[mutagenesis of these cis elements]	1.0	5	1	0	0
48358	1624	transcription factor usf1 up-regulate gene expression	[Transcription factors USF1 up-regulate gene expression]	1.0	6	1	0	0
48359	1624	eventual loss	[eventual loss]	1.0	2	1	0	0
48360	1624	partial suppression of ap-1 activity	[partial suppression of AP-1 activity]	1.0	5	1	0	0
48361	1624	constitutive nf-kappab DNA binding activity	[constitutive NF-kappaB DNA binding activity]	1.0	5	1	0	0
48362	1624	Study over the past few year	[Studies over the past few years]	1.0	6	1	0	0
48363	1624	number of splenic T cell	[numbers of splenic T cells]	1.0	5	1	0	0
48364	1624	hmba-induced cell	[HMBA-induced cells]	1.0	2	1	0	0
48365	1624	880 comparison of granulocyte DNA	[880 comparisons of granulocyte DNA]	1.0	5	1	0	0
48366	1624	interference in dna-binding activity of gata-1	[interference in DNA-binding activities of GATA-1]	1.0	6	1	0	0
48367	1624	myeloid cells,	[myeloid cells,]	1.0	2	1	0	0
48368	1624	humara gene	[HUMARA gene]	1.0	2	1	0	0
48369	1624	potential factor	[potential factor]	1.0	2	2	2	2
48370	1624	growth arrest of the cell	[growth arrest of the cells]	1.0	5	1	0	0
48371	1624	different form of joint disease	[different forms of joint disease.]	1.0	5	1	0	0
48372	1624	antigen response in nf-atp mouse	[antigen responses in NF-ATp mice]	1.0	5	1	0	0
48373	1624	lipophilic ligand	[lipophilic ligand]	1.0	2	1	0	0
48374	1624	tpa responsiveness	[TPA responsiveness]	1.0	2	2	2	2
48375	1624	rare variant translocation in APL	[rare variant translocations in APL]	1.0	5	1	0	0
48376	1624	same cell cycle regulate protein	[same cell cycle regulating proteins]	1.0	5	1	0	0
48377	1624	glucocorticoid-based drug	[glucocorticoid-based drugs]	1.0	2	1	0	0
48378	1624	concomitant 40-50% decrease in ap-1	[concomitant 40-50% decrease in AP-1]	1.0	5	1	0	0
48379	1624	differentiation of hl-60 leukemia cell	[differentiation of HL-60 leukemia cells]	1.0	5	1	0	0
48380	1624	proof of clonality in individual,	[proof of clonality in individual,]	1.0	5	1	0	0
48381	1624	aa2 cell	[AA2 cells]	1.0	2	1	0	0
48382	1624	PMA cell	[PMA cells]	1.0	2	2	1	1
48383	1624	2-kb downstream of a CpG island	[2-kb downstream of a CpG island]	1.0	6	1	0	0
48384	1624	tissue specificity of gene expression	[tissue specificity of gene expression]	1.0	5	1	0	0
48385	1624	mutation screen	[mutation screening]	1.0	2	1	0	0
48386	1624	extravascular inflammation	[extravascular inflammation]	1.0	2	1	0	0
48387	1624	transgenic mouse with a lymphocyte-specific defect	[Transgenic mice with a lymphocyte-specific defect]	1.0	6	1	0	0
48388	1624	ABC method	[ABC method]	1.0	2	1	0	0
48389	1624	induction of cell adhesion molecule-1	[induction of cell adhesion molecule-1]	1.0	5	2	1	1
48390	1624	physiologic mechanism	[physiologic mechanisms]	1.0	2	1	0	0
48391	1624	monoblastic differentiation	[monoblastic differentiation]	1.0	2	1	0	0
48392	1624	intermediate complex	[intermediate complex]	1.0	2	1	0	0
48393	1624	serine phosphorylation of this stat	[serine phosphorylation of these STATs]	1.0	5	1	0	0
48394	1624	il-2 expression in t-cell line	[IL-2 expression in T-cell lines]	1.0	5	1	0	0
48395	1624	selective suppression of th1 function	[selective suppression of TH1 functions]	1.0	5	1	0	0
48396	1624	activation of protein- tyrosine kinase	[activation of protein- tyrosine kinases]	1.0	5	1	0	0
48397	1624	only otf-1	[only OTF-1]	1.0	2	1	0	0
48398	1624	c/ebp-epsilon transcription	[C/EBP-epsilon transcription]	1.0	2	2	1	1
48399	1624	gata motif from globin cis-element	[GATA motifs from globin cis-elements]	1.0	5	1	0	0
48400	1624	formylated indolocarbazole	[formylated indolocarbazoles]	1.0	2	1	0	0
48401	1624	interpretation, mutation	[interpretation, mutation]	1.0	2	1	0	0
48402	1624	process critical	[process critical]	1.0	2	1	0	0
48403	1624	hydrophobic region	[hydrophobic region]	1.0	2	1	0	0
48404	1624	pancrea organogenesis	[Pancreas organogenesis]	1.0	2	1	0	0
48405	1624	addition of pu.1 to extract	[addition of PU.1 to extracts]	1.0	5	1	0	0
48406	1624	subset of chronic lymphocytic leukemia	[subset of chronic lymphocytic leukemias]	1.0	5	1	0	0
48407	1624	use two different experimental approach	[using two different experimental approaches]	1.0	5	1	0	0
48408	1624	Partial sequence from exon 1-8	[Partial sequences from exons 1-8]	1.0	5	1	0	0
48409	1624	factor present in nuclear extract	[factor present in nuclear extracts]	1.0	5	2	2	2
48410	1624	tnf-alpha in alveolar macrophage-depleted rat	[TNF-alpha in alveolar macrophage-depleted rats]	1.0	5	1	0	0
48411	1624	Cox analysis	[Cox analysis]	1.0	2	2	2	2
48412	1624	never any effect upon Bcl-2	[never any effect upon Bcl-2]	1.0	5	1	0	0
48413	1624	tcr/cd3 stimulation	[TCR/CD3 stimulation]	1.0	2	1	0	0
48414	1624	identification of the gene sry	[identification of the gene Sry]	1.0	5	1	0	0
48415	1624	+/- 0.92	[+/- 0.92]	1.0	2	1	0	0
48416	1624	octamer probe	[octamer probe]	1.0	2	1	0	0
48417	1624	translocation involve the 14q32.1 region	[translocations involving the 14q32.1 regions]	1.0	5	1	0	0
48418	1624	minus clone	[minus clones]	1.0	2	1	0	0
48419	1624	binding sites/nucleus	[binding sites/nucleus]	1.0	2	2	2	2
48420	1624	release of NF kappa b	[release of NF kappa B]	1.0	5	1	0	0
48421	1624	JunD protein	[JunD proteins]	1.0	2	1	0	0
48422	1624	nfatp migration on SDS-polyacrylamide gel electrophoresis	[NFATp migration on SDS-polyacrylamide gel electrophoresis]	1.0	6	1	0	0
48423	1624	c-myc mrna expression constitutively high	[c-myc mRNA expression constitutively high]	1.0	5	1	0	0
48424	1624	Polymyxin B	[Polymyxin B]	1.0	2	1	0	0
48425	1624	x inactivation result in inactivity	[X inactivation resulting in inactivity]	1.0	5	1	0	0
48426	1624	prior to in vivo IL-2 administration,	[Prior to in vivo IL-2 administration,]	1.0	6	1	0	0
48427	1624	functional versatility	[functional versatility]	1.0	2	1	0	0
48428	1624	proliferation of prostate tumour cell	[proliferation of prostate tumour cells]	1.0	5	1	0	0
48429	1624	different theory	[different theories]	1.0	2	1	0	0
48430	1624	nm23h2 protein	[Nm23H2 protein]	1.0	2	1	0	0
48431	1624	rar-beta expression	[RAR-beta expression]	1.0	2	1	0	0
48432	1624	optimal agents, doses, and/or schedule	[optimal agents, doses, and/or schedules]	1.0	5	1	0	0
48433	1624	ubiquitous protein,	[ubiquitous protein,]	1.0	2	1	0	0
48434	1624	signal transmission in T cell	[signal transmission in T cells]	1.0	5	1	0	0
48435	1624	subsequent inhibition of cytokine production	[subsequent inhibition of cytokine production]	1.0	5	1	0	0
48436	1624	transcription factor upstream stimulatory factor	[transcription factor upstream stimulatory factor]	1.0	5	1	0	0
48437	1624	result from activation of a receptor	[resulting from activation of a receptor]	1.0	6	1	0	0
48438	1624	tbp tata box binding protein	[TBP TATA box binding protein]	1.0	5	1	0	0
48439	1624	human rhom-2	[Human Rhom-2]	1.0	2	1	0	0
48440	1624	isotype-matched antibody	[isotype-matched antibody]	1.0	2	1	0	0
48441	1624	significant differences,	[significant differences,]	1.0	2	1	0	0
48442	1624	antibody ki-67	[antibody Ki-67]	1.0	2	2	2	2
48443	1624	infected cell	[infected cells]	1.0	2	1	0	0
48444	1624	formation of the IFN-gamma complex	[formation of the IFN-gamma complex]	1.0	5	1	0	0
48445	1624	sodium -proton-antiport	[sodium -proton-antiport]	1.0	2	1	0	0
48446	1624	allergic inflammation	[allergic inflammation]	1.0	2	1	0	0
48447	1624	dimer consist of p50 nfkappab1	[dimers consisting of p50 NFkappaB1]	1.0	5	1	0	0
48448	1624	regulate the expression of erythroid-specific gene	[regulating the expression of erythroid-specific genes]	1.0	6	1	0	0
48449	1624	length	[length]	1.0	1	11	7	7
48450	1624	DR-nm23 mrna	[DR-nm23 mRNA]	1.0	2	1	0	0
48451	1624	consensus motif a/t a/t c	[consensus motif A/T A/T C]	1.0	5	1	0	0
48452	1624	human peripheral jurkat T cell	[human peripheral Jurkat T cells]	1.0	5	1	0	0
48453	1624	activation of the tyrosine kinase	[activation of the tyrosine kinases]	1.0	5	2	2	2
48454	1624	differentiation of cancer lncap cell	[differentiation of cancer LNCaP cells]	1.0	5	1	0	0
48455	1624	efficacy of the ln cell	[efficacy of the LN cells]	1.0	5	1	0	0
48456	1624	complex formation between T ag	[complex formation between T ag]	1.0	5	1	0	0
48457	1624	normal expansion of T cell	[normal expansion of T cells]	1.0	5	1	0	0
48458	1624	AML1 protein	[AML1 proteins]	1.0	2	1	0	0
48459	1624	important role in cooperative activation	[important role in cooperative activation]	1.0	5	1	0	0
48460	1624	Rel/ NF-kappa B family of transcription	[Rel/ NF-kappa B family of transcription]	1.0	6	1	0	0
48461	1624	co-transfect bko	[co-transfecting BKO]	1.0	2	1	0	0
48462	1624	lymphoid jurkat	[lymphoid Jurkat]	1.0	2	1	0	0
48463	1624	front of the start site	[front of the start site]	1.0	5	1	0	0
48464	1624	reverse sequence	[reverse sequence]	1.0	2	1	0	0
48465	1624	role regulate the self-renewal capacity	[role regulating the self-renewal capacity]	1.0	5	1	0	0
48466	1624	resting B	[Resting B]	1.0	2	1	0	0
48467	1624	EGR1 -express	[EGR1 -expressing]	1.0	2	1	0	0
48468	1624	nuclei from normal human monocyte	[nuclei from normal human monocytes]	1.0	5	1	0	0
48469	1624	infectious clone	[infectious clone]	1.0	2	2	2	2
48470	1624	Southern and/or slot blot technique	[Southern and/or slot blot techniques]	1.0	5	1	0	0
48471	1624	Anti- La(SSB) specific T cell	[Anti- La(SSB) specific T cells]	1.0	5	1	0	0
48472	1624	kinase zap-70	[kinase zap-70]	1.0	2	2	1	1
48473	1624	cleavage of the transcription factor	[cleavage of the transcription factor]	1.0	5	1	0	0
48474	1624	cis-tran isomerase	[cis-trans isomerase]	1.0	2	2	2	2
48475	1624	NF of T cell nf-at	[NF of T cells NF-AT]	1.0	5	1	0	0
48476	1624	major T lymphocyte growth factor	[major T lymphocyte growth factor]	1.0	5	1	0	0
48477	1624	hepatic nuclear factor 3 beta	[hepatic nuclear factor 3 beta]	1.0	5	1	0	0
48478	1624	Ox ldl	[Ox LDL]	1.0	2	1	0	0
48479	1624	transcription factor through this receptor	[transcription factors through these receptors]	1.0	5	1	0	0
48480	1624	pancreatic endocrine-lineage	[pancreatic endocrine-lineage]	1.0	2	1	0	0
48481	1624	otf-2 in DRA gene transcription	[OTF-2 in DRA gene transcription]	1.0	5	1	0	0
48482	1624	present a hierarchical structure similar	[presenting a hierarchical structure similar]	1.0	5	1	0	0
48483	1624	induce differentiation	[inducing differentiation]	1.0	2	2	2	2
48484	1624	HeLa cell extract than in Raji	[HeLa cell extracts than in Raji]	1.0	6	1	0	0
48485	1624	S9a at 10 to 100 nm	[S9a at 10 to 100 nM]	1.0	6	1	0	0
48486	1624	rate of endogenous cholesterol synthesis	[rate of endogenous cholesterol synthesis]	1.0	5	1	0	0
48487	1624	molecular consequence of pf treatment	[molecular consequences of PF treatment]	1.0	5	1	0	0
48488	1624	physical exercise on bicycle ergometer) level	[physical exercise on bicycle ergometer) levels]	1.0	6	1	0	0
48489	1624	47 hsv-specific cd4+ t-cell clone	[47 HSV-specific CD4+ T-cell clones]	1.0	5	1	0	0
48490	1624	potent transactivator of viral gene expression.	[potent transactivators of viral gene expression.]	1.0	6	1	0	0
48491	1624	gene regulation,	[gene regulation,]	1.0	2	2	1	1
48492	1624	primary immunization	[primary immunization]	1.0	2	1	0	0
48493	1624	patient TFIIHwt	[patient TFIIHwt]	1.0	2	1	0	0
48494	1624	heat shock protein 60 hsp60	[heat shock protein 60 Hsp60]	1.0	5	1	0	0
48495	1624	polymorphic site	[polymorphic site]	1.0	2	1	0	0
48496	1624	rrna for eosinophil-associated granule protein	[mRNAs for eosinophil-associated granule proteins]	1.0	5	1	0	0
48497	1624	regulatory signal	[regulatory signals]	1.0	2	2	2	2
48498	1624	concentration dependent,	[concentration dependent,]	1.0	2	1	0	0
48499	1624	Cooperation of binding site for STAT6	[Cooperation of binding sites for STAT6]	1.0	6	1	0	0
48500	1624	mouse interleukin-2 receptor alpha gene expression	[Mouse interleukin-2 receptor alpha gene expression]	1.0	6	1	0	0
48501	1624	key determinant	[key determinant]	1.0	2	2	2	2
48502	1624	most IL-2 independent cell line	[most IL-2 independent cell lines]	1.0	5	1	0	0
48503	1624	apparently due to the rapid desensitization	[apparently due to the rapid desensitization]	1.0	6	1	0	0
48504	1624	erythroid development.	[erythroid development.]	1.0	2	1	0	0
48505	1624	second messenger in T cell	[second messengers in T cells]	1.0	5	1	0	0
48506	1624	gene isg	[genes ISGs]	1.0	2	2	2	2
48507	1624	primary function	[primary function]	1.0	2	1	0	0
48508	1624	transcription from the lmp-2a loci	[transcription from the LMP-2A loci]	1.0	5	1	0	0
48509	1624	moreover, in contrast to healthy subject	[Moreover, in contrast to healthy subjects]	1.0	6	1	0	0
48510	1624	mrna encoding c-fo a component	[mRNA encoding c-Fos a component]	1.0	5	1	0	0
48511	1624	only specific nf-kappa b heteromer	[only specific NF-kappa B heteromers]	1.0	5	1	0	0
48512	1624	analysis of promoter with DNA motif	[analysis of promoters with DNA motifs]	1.0	6	1	0	0
48513	1624	CTLA-4 inhibition	[CTLA-4 inhibition]	1.0	2	2	1	1
48514	1624	interleukin-4 expression	[interleukin-4 expression]	1.0	2	1	0	0
48515	1624	activation of MAPK by bufalin	[activation of MAPK by bufalin]	1.0	5	1	0	0
48516	1624	3.49 nm,	[3.49 nM,]	1.0	2	1	0	0
48517	1624	trans-acting factor of the lineage	[trans-acting factor of the lineage]	1.0	5	1	0	0
48518	1624	GCRbeta expression in gc-insensitive asthma	[GCRbeta expression in GC-insensitive asthma]	1.0	5	1	0	0
48519	1624	negative, positive,	[Negative, positive,]	1.0	2	1	0	0
48520	1624	glucocorticoid metabolism	[glucocorticoid metabolism]	1.0	2	1	0	0
48521	1624	il-10 up-regulation	[IL-10 up-regulation]	1.0	2	2	1	1
48522	1624	allelic variations.	[allelic variations.]	1.0	2	1	0	0
48523	1624	factor nf-il6	[factor NF-IL6]	1.0	2	2	2	2
48524	1624	high responsiveness to the stimulation.	[higher responsiveness to the stimulation.]	1.0	5	1	0	0
48525	1624	treatment of b lymphocyte with h-89	[treatment of B lymphocytes with H-89]	1.0	6	1	0	0
48526	1624	gene, analysis	[gene, analysis]	1.0	2	1	0	0
48527	1624	activity of nf-kappa b /rel	[activity of NF-kappa B /rel]	1.0	5	1	0	0
48528	1624	least 3-fold less CAT activity	[least 3-fold less CAT activity]	1.0	5	1	0	0
48529	1624	1 all	[1 ALL]	1.0	2	1	0	0
48530	1624	unique morphologic feature nuclear membrane	[unique morphologic features nuclear membranes]	1.0	5	1	0	0
48531	1624	report on nur77 knock-out mouse	[reports on nur77 knock-out mice]	1.0	5	1	0	0
48532	1624	lymphokine production in T cell	[lymphokine production in T cells]	1.0	5	1	0	0
48533	1624	non-globin promoters,	[non-globin promoters,]	1.0	2	1	0	0
48534	1624	positive action on th2-specific cytokine	[positive actions on Th2-specific cytokines]	1.0	5	1	0	0
48535	1624	employ the b cell line skw6.4	[Employing the B cell line SKW6.4]	1.0	6	1	0	0
48536	1624	previous study in non-human primate	[previous studies in non-human primates]	1.0	5	1	0	0
48537	1624	and/or elf-1	[and/or Elf-1]	1.0	2	1	0	0
48538	1624	kinase kinase	[kinase kinase]	1.0	2	1	0	0
48539	1624	kd nmol/L)	[Kd nmol/L)]	1.0	2	2	2	2
48540	1624	bsap pax-5	[BSAP Pax-5]	1.0	2	2	2	2
48541	1624	non-proliferative state	[non-proliferative state]	1.0	2	2	1	1
48542	1624	p85 mutant	[p85 mutants]	1.0	2	1	0	0
48543	1624	T3 -group	[T3 -group]	1.0	2	1	0	0
48544	1624	define efficacy	[defining efficacy]	1.0	2	1	0	0
48545	1624	transactivation transrepression	[transactivation transrepression]	1.0	2	1	0	0
48546	1624	thus dose-	[Thus dose-]	1.0	2	1	0	0
48547	1624	follow activation of u937 cell	[following activation of U937 cells]	1.0	5	1	0	0
48548	1624	7- colony	[7- colonies]	1.0	2	1	0	0
48549	1624	hiv production by G. vaginalis	[HIV production by G. vaginalis]	1.0	5	1	0	0
48550	1624	Clathrin Assembly Lymphoid Myeloid leukemia gene	[Clathrin Assembly Lymphoid Myeloid leukemia gene]	1.0	6	1	0	0
48551	1624	cd45ra+ T cell subset during aging.	[CD45RA+ T cell subsets during aging.]	1.0	6	1	0	0
48552	1624	optimal site	[optimal site]	1.0	2	1	0	0
48553	1624	same dose	[same dose]	1.0	2	2	2	2
48554	1624	nasal NK-	[Nasal NK-]	1.0	2	1	0	0
48555	1624	protein of the Ras superfamily	[Proteins of the Ras superfamily]	1.0	5	1	0	0
48556	1624	disruption of the myd88 gene	[disruption of the MyD88 gene]	1.0	5	1	0	0
48557	1624	function of the zeta-globin promoter	[function of the zeta-globin promoter]	1.0	5	1	0	0
48558	1624	expression of E1A gene product	[expression of E1A gene products]	1.0	5	1	0	0
48559	1624	profound conformational change in p21ras	[profound conformational change in p21ras]	1.0	5	1	0	0
48560	1624	nonradioactive assay	[nonradioactive assay]	1.0	2	1	0	0
48561	1624	related il-6	[related IL-6]	1.0	2	1	0	0
48562	1624	human tonsil	[human tonsils]	1.0	2	2	1	1
48563	1624	mosaicism of the 45,x cell line	[mosaicism of the 45,X cell line]	1.0	6	1	0	0
48564	1624	weak activity	[weak activity]	1.0	2	1	0	0
48565	1624	activator of the adenylate cyclase	[activators of the adenylate cyclase]	1.0	5	1	0	0
48566	1624	exogenous promoter	[exogenous promoter]	1.0	2	1	0	0
48567	1624	gene regulation in T lymphocyte	[gene regulation in T lymphocytes]	1.0	5	1	0	0
48568	1624	stringent control of NF-kappa b	[stringent control of NF-kappa B]	1.0	5	1	0	0
48569	1624	inflammatory synovial	[inflammatory synovial]	1.0	2	1	0	0
48570	1624	Comparison of constitutive transcriptional enhancement	[Comparison of constitutive transcriptional enhancement]	1.0	5	1	0	0
48571	1624	40 SV40	[40 SV40]	1.0	2	1	0	0
48572	1624	fas killing	[Fas killing]	1.0	2	2	2	2
48573	1624	include brlf1	[including BRLF1]	1.0	2	1	0	0
48574	1624	important molecular mediator of immunotoxicity	[important molecular mediator of immunotoxicity]	1.0	5	1	0	0
48575	1624	existence of alternative pax-5 transcript	[existence of alternative Pax-5 transcripts]	1.0	5	1	0	0
48576	1624	activation of the interleukin-2 promoter	[activation of the interleukin-2 promoter]	1.0	5	1	0	0
48577	1624	steroid/thyroid hormone receptor response element	[steroid/thyroid hormone receptor response elements]	1.0	5	1	0	0
48578	1624	antibody supershift assay in EMSA complex	[antibody supershift assays in EMSA complexes]	1.0	6	1	0	0
48579	1624	discrete dna-binding	[discrete DNA-binding]	1.0	2	1	0	0
48580	1624	43 idc	[43 IDCs]	1.0	2	1	0	0
48581	1624	(86% identity).	[(86% identity).]	1.0	2	1	0	0
48582	1624	cd26 expression	[CD26 expression]	1.0	2	1	0	0
48583	1624	non-specific manner	[non-specific manner]	1.0	2	1	0	0
48584	1624	stable derivative	[stable derivative]	1.0	2	2	2	2
48585	1624	multiple, biochemically distinct dna-binding protein	[multiple, biochemically distinct DNA-binding proteins]	1.0	5	1	0	0
48586	1624	vivo close	[vivo close]	1.0	2	1	0	0
48587	1624	molecular basis for the pathogenesis	[molecular basis for the pathogenesis]	1.0	5	1	0	0
48588	1624	shortly after engagement of this receptor.	[shortly after engagement of this receptor.]	1.0	6	1	0	0
48589	1624	anti- hcmv immunoglobulin g-seropositive donor	[anti- HCMV immunoglobulin G-seropositive donors]	1.0	5	1	0	0
48590	1624	antiglucocorticoid RU	[antiglucocorticoid RU]	1.0	2	1	0	0
48591	1624	structural characteristic of zinc finger protein	[structural characteristics of zinc finger proteins]	1.0	6	1	0	0
48592	1624	mouse mammary tumor virus MMTV	[mouse mammary tumor virus MMTV]	1.0	5	1	0	0
48593	1624	coronary artery	[coronary arteries]	1.0	2	1	0	0
48594	1624	38 pmol/l	[38 pmol/l]	1.0	2	1	0	0
48595	1624	core region of the enhancer	[core regions of the enhancer]	1.0	5	1	0	0
48596	1624	stimulate il-6 release from adherent cell	[stimulating IL-6 release from adherent cells]	1.0	6	1	0	0
48597	1624	type-specific October	[type-specific Oct]	1.0	2	1	0	0
48598	1624	additional interaction	[additional interactions]	1.0	2	1	0	0
48599	1624	infectious mononucleosis	[infectious mononucleosis]	1.0	2	1	0	0
48600	1624	three human cell line u-937	[three human cell lines U-937]	1.0	5	1	0	0
48601	1624	very little detectable activation of ap-1	[very little detectable activation of AP-1]	1.0	6	1	0	0
48602	1624	many promoter	[many promoters]	1.0	2	2	2	2
48603	1624	myeloid-related lineage	[myeloid-related lineage]	1.0	2	1	0	0
48604	1624	16 sequence	[16 sequences]	1.0	2	1	0	0
48605	1624	peripheral blood polymorphonuclear cell pmnc	[peripheral blood polymorphonuclear cells PMNCs]	1.0	5	1	0	0
48606	1624	b cell of the bursa	[B cells of the bursa]	1.0	5	1	0	0
48607	1624	epitope mapping	[epitope mapping]	1.0	2	2	1	1
48608	1624	homologous region	[homologous regions]	1.0	2	1	0	0
48609	1624	interleukin-1beta gene	[interleukin-1beta gene]	1.0	2	2	2	2
48610	1624	expression of the il-2 gene	[Expression of the IL-2 gene]	1.0	5	1	0	0
48611	1624	conjunction with the factor otf2	[conjunction with the factor OTF2]	1.0	5	1	0	0
48612	1624	ngal mrna	[NGAL mRNA]	1.0	2	1	0	0
48613	1624	express protein	[expressed, protein]	1.0	2	2	2	2
48614	1624	diurnal change	[diurnal changes]	1.0	2	1	0	0
48615	1624	comparable event related to tolerance induction	[comparable events related to tolerance induction]	1.0	6	1	0	0
48616	1624	polyoma enhancer	[polyoma enhancer]	1.0	2	1	0	0
48617	1624	affinity of sr-bp 50-fold high	[affinity of SR-BP 50-fold higher]	1.0	5	1	0	0
48618	1624	tandem copy of the E6 motif	[tandem copies of the E6 motif]	1.0	6	1	0	0
48619	1624	genetic marker of icenko- cushingd' syndrome	[genetic markers of Icenko- Cushing's syndrome]	1.0	6	1	0	0
48620	1624	Furthermore, OFT-1	[Furthermore, OFT-1]	1.0	2	1	0	0
48621	1624	apoptosis of cd34+ progenitor cell	[apoptosis of CD34+ progenitor cells]	1.0	5	2	1	1
48622	1624	normal brother.	[normal brother.]	1.0	2	1	0	0
48623	1624	contain a gata-factor presumably gata-1	[containing a GATA-factor presumably GATA-1]	1.0	5	1	0	0
48624	1624	test: corticosteroid receptor regulation in leukocyte	[test: corticosteroid receptors regulation in leukocytes]	1.0	6	1	0	0
48625	1624	ad vector lack immunodominant antigen	[Ad vectors lacking immunodominant antigens]	1.0	5	1	0	0
48626	1624	usage of the BamHI-Q promoter	[usage of the BamHI-Q promoter]	1.0	5	1	0	0
48627	1624	show LR1 -DNA binding activity	[showing LR1 -DNA binding activity]	1.0	5	1	0	0
48628	1624	Cross titration analysis of the effect	[Cross titration analyses of the effects]	1.0	6	1	0	0
48629	1624	granulocytic/neutrophillic differentiation	[granulocytic/neutrophillic differentiation]	1.0	2	1	0	0
48630	1624	prior to t-cell receptor gene rearrangement	[prior to T-cell receptor gene rearrangement]	1.0	6	1	0	0
48631	1624	mixture of all dihydro derivative	[mixture of all dihydro derivatives]	1.0	5	1	0	0
48632	1624	zebra activity	[ZEBRA activity]	1.0	2	2	2	2
48633	1624	tnf- and/or	[TNF- and/or]	1.0	2	1	0	0
48634	1624	lack of requirement of element	[lack of requirement of elements]	1.0	5	1	0	0
48635	1624	tcf/lef function in this organism	[TCF/LEF function in these organisms]	1.0	5	1	0	0
48636	1624	degradation of nf-kappa b inhibitor	[degradation of NF-kappa B inhibitor]	1.0	5	2	2	2
48637	1624	major phorbol ester -responsive motif	[major phorbol ester -responsive motifs]	1.0	5	1	0	0
48638	1624	several gpix promoter /reporter construct	[several GPIX promoter /reporter constructs]	1.0	5	1	0	0
48639	1624	Shigella movement	[Shigella movement]	1.0	2	1	0	0
48640	1624	NF-kappaB motif	[NF-kappaB motif]	1.0	2	2	1	1
48641	1624	transactivation of a heterologous promoter construct	[transactivation of a heterologous promoter construct]	1.0	6	1	0	0
48642	1624	DNA methylation change in hematologic malignancy	[DNA methylation changes in hematologic malignancies]	1.0	6	1	0	0
48643	1624	tcr/cd3 ligation	[TCR/CD3 ligation]	1.0	2	1	0	0
48644	1624	G1 stage	[G1 stages]	1.0	2	1	0	0
48645	1624	NCL lymphocyte	[NCL lymphocytes]	1.0	2	1	0	0
48646	1624	component of the NF-kappaB complex	[components of the NF-kappaB complexes]	1.0	5	1	0	0
48647	1624	model of adenovirus ad5 infection	[model of adenovirus Ad5 infection]	1.0	5	1	0	0
48648	1624	negligible effect on huvec adhesion molecule	[negligible effects on HUVEC adhesion molecules]	1.0	6	1	0	0
48649	1624	sudden increase	[sudden increase]	1.0	2	1	0	0
48650	1624	action of ifn-alpha in CML	[action of IFN-alpha in CML]	1.0	5	1	0	0
48651	1624	use a adult erythroid cell system	[using a adult erythroid cell system]	1.0	6	1	0	0
48652	1624	diethylstilbestrol DES tamoxifen tam quercetin	[diethylstilbestrol DES tamoxifen TAM quercetin]	1.0	5	1	0	0
48653	1624	STAT1 pathway	[STAT1 pathway]	1.0	2	1	0	0
48654	1624	only mature normal myelomonocytic cell	[only maturing normal myelomonocytic cells]	1.0	5	1	0	0
48655	1624	recent functional analysis by Miyatake	[recent functional analysis by Miyatake]	1.0	5	1	0	0
48656	1624	steroid sparing	[steroid sparing]	1.0	2	1	0	0
48657	1624	ELAM-1 by TNF in MVEC	[ELAM-1 by TNF in MVEC]	1.0	5	1	0	0
48658	1624	apoptosis induction	[apoptosis induction]	1.0	2	1	0	0
48659	1624	clinical consequence include the possibility	[clinical consequences including the possibility]	1.0	5	1	0	0
48660	1624	interleukin-4 Stat	[interleukin-4 Stat]	1.0	2	1	0	0
48661	1624	mobility-shift analysis of nuclear extract	[mobility-shift analysis of nuclear extracts]	1.0	5	1	0	0
48662	1624	mcfffas cell	[MCF-Fas cells]	1.0	2	2	1	1
48663	1624	ngal expression in breast cancer	[NGAL expression in breast cancer]	1.0	5	1	0	0
48664	1624	costimulatory signal to PHA-stimulated pbl	[costimulatory signals to PHA-stimulated PBL]	1.0	5	1	0	0
48665	1624	all-tran retinoic acid at dose	[all-trans retinoic acid at doses]	1.0	5	1	0	0
48666	1624	especially the heat-shock protein hsp90	[especially the heat-shock protein hsp90]	1.0	5	1	0	0
48667	1624	result in inactivity of the x	[resulting in inactivity of the X]	1.0	6	1	0	0
48668	1624	p46 isoform	[p46 isoforms]	1.0	2	1	0	0
48669	1624	il-8 tumor necrosis factor-alpha secretion	[IL-8 tumor necrosis factor-alpha secretion]	1.0	5	1	0	0
48670	1624	phenotypic differentiation	[phenotypic differentiation]	1.0	2	2	1	1
48671	1624	sequence specificity of the proteins.	[sequence specificity of the proteins.]	1.0	5	1	0	0
48672	1624	homodimer RXR-RXR	[homodimers RXR-RXR]	1.0	2	1	0	0
48673	1624	stimulation of cell with anti-igm	[Stimulation of cells with anti-IgM]	1.0	5	1	0	0
48674	1624	results, together with transactivation experiment	[results, together with transactivation experiments]	1.0	5	1	0	0
48675	1624	use a rare semen sample	[using a rare semen sample]	1.0	5	1	0	0
48676	1624	typical (ie, aitl without gc	[typical (ie, AITL without GC]	1.0	5	1	0	0
48677	1624	four sibling	[four siblings]	1.0	2	1	0	0
48678	1624	Electrophoretic mobility gel shift assay	[Electrophoretic mobility gel shift assay]	1.0	5	1	0	0
48679	1624	gr mrna in 6tg1.1 cell	[GR mRNA in 6TG1.1 cells]	1.0	5	1	0	0
48680	1624	TUNEL staining	[TUNEL staining]	1.0	2	1	0	0
48681	1624	hiv-1 LTR activity in b lymphocyte	[HIV-1 LTR activity in B lymphocytes]	1.0	6	1	0	0
48682	1624	gm-csf mrna	[GM-CSF mRNA]	1.0	2	2	2	2
48683	1624	SD 41.0	[SD 41.0]	1.0	2	1	0	0
48684	1624	region include the pseudoautosomal region	[region including the pseudoautosomal region]	1.0	5	1	0	0
48685	1624	toxic shock syndrome toxin-1 tsst-1	[toxic shock syndrome toxin-1 TSST-1]	1.0	5	1	0	0
48686	1624	KBF1 factor	[KBF1 factor]	1.0	2	1	0	0
48687	1624	CsA fk506 -sensitive nuclear factor	[CsA FK506 -sensitive nuclear factor]	1.0	5	1	0	0
48688	1624	transcription of over-lapping set of gene	[transcription of over-lapping sets of genes]	1.0	6	1	0	0
48689	1624	analysis of the IL-8 promoter	[analysis of the IL-8 promoters]	1.0	5	1	0	0
48690	1624	component of the third complex	[component of the third complex.]	1.0	5	1	0	0
48691	1624	vimentin expression	[vimentin expression]	1.0	2	1	0	0
48692	1624	corresponding mutation in murine calcineurin	[corresponding mutations in murine calcineurin]	1.0	5	1	0	0
48693	1624	c-Fos mutant protein include wbJun	[c-Fos mutant proteins including wbJun]	1.0	5	1	0	0
48694	1624	difference in expression of FOS	[differences in expression of FOS]	1.0	5	1	0	0
48695	1624	amino acid sequence of NFATc.beta	[amino acid sequence of NFATc.beta]	1.0	5	1	0	0
48696	1624	irf-1 gene expression in hl-60	[IRF-1 gene expression in HL-60]	1.0	5	1	0	0
48697	1624	gb ul55	[gB UL55]	1.0	2	1	0	0
48698	1624	evidence for allele-specific mrna stability	[evidence for allele-specific mRNA stability]	1.0	5	1	0	0
48699	1624	clonal population	[clonal population]	1.0	2	2	2	2
48700	1624	DNA damage-induced apoptosis a response	[DNA damage-induced apoptosis a response]	1.0	5	1	0	0
48701	1624	hhv-8 +/ebv+ pel in the case	[HHV-8 +/EBV+ PEL in the case]	1.0	6	1	0	0
48702	1624	study on the ebv oncogenicity	[studies on the EBV oncogenicity]	1.0	5	1	0	0
48703	1624	shift in prb molecular weight	[shift in pRB molecular weight]	1.0	5	1	0	0
48704	1624	band q34	[band q34]	1.0	2	2	1	1
48705	1624	high activity.	[highest activity.]	1.0	2	1	0	0
48706	1624	mp of about 5 ng/ml	[MP of about 5 ng/ml]	1.0	5	1	0	0
48707	1624	activation of expression of gene	[Activation of expression of genes]	1.0	5	1	0	0
48708	1624	sucrose gradient	[sucrose gradient]	1.0	2	2	1	1
48709	1624	Clinical remission	[Clinical remissions]	1.0	2	1	0	0
48710	1624	135(oh)2d3 production by this cell	[1,25(OH)2D3 production by these cells]	1.0	5	1	0	0
48711	1624	follow infection	[following infection]	1.0	2	2	1	1
48712	1624	antigenic response	[antigenic response]	1.0	2	1	0	0
48713	1624	Soluble tumor necrosis factor receptor	[Soluble tumor necrosis factor receptors]	1.0	5	1	0	0
48714	1624	N-terminal myristylation	[N-terminal myristylation]	1.0	2	1	0	0
48715	1624	new approach study protein-protein interaction	[new approach studying protein-protein interactions]	1.0	5	1	0	0
48716	1624	detailed information	[detailed information]	1.0	2	1	0	0
48717	1624	non-lineage-specific silencer	[non-lineage-specific silencer]	1.0	2	1	0	0
48718	1624	multiple region	[multiple regions]	1.0	2	2	2	2
48719	1624	increase in intracellular calcium level,	[increase in intracellular calcium level,]	1.0	5	1	0	0
48720	1624	lymphoid cell molt4 T cell	[lymphoid cells MOLT4 T cell]	1.0	5	1	0	0
48721	1624	blockade of this intracellular signalling event	[Blockade of this intracellular signalling event]	1.0	6	1	0	0
48722	1624	erythrocytic progenitor	[erythrocytic progenitors]	1.0	2	1	0	0
48723	1624	follow T cell antigen receptor stimulation	[Following T cell antigen receptor stimulation]	1.0	6	1	0	0
48724	1624	phorbol ester in leukemia cell	[phorbol esters in leukemia cells]	1.0	5	1	0	0
48725	1624	other inducers, such as hemin	[other inducers, such as hemin]	1.0	5	1	0	0
48726	1624	NK cell lysis in oncogene-expressing	[NK cell lysis in oncogene-expressing]	1.0	5	1	0	0
48727	1624	htlv-1 tax in jurkat t-cell	[HTLV-1 tax in Jurkat T-cells]	1.0	5	1	0	0
48728	1624	different haplotype	[different haplotypes]	1.0	2	1	0	0
48729	1624	activation of class ii gene	[activation of class II genes]	1.0	5	1	0	0
48730	1624	induction of c-fo by CD40	[induction of c-fos by CD40]	1.0	5	1	0	0
48731	1624	20 patient with deficiency syndrome	[20 patients with deficiency syndromes]	1.0	5	1	0	0
48732	1624	metallothionein promoter	[metallothionein promoter]	1.0	2	3	2	1
48733	1624	decoy oligodeoxynucleotides	[decoy oligodeoxynucleotides]	1.0	2	2	2	2
48734	1624	direct inhibition of NFATp/AP-1 complex formation	[direct inhibition of NFATp/AP-1 complex formation]	1.0	6	1	0	0
48735	1624	also a inhibitor of hiv replication	[also an inhibitor of HIV replication]	1.0	6	1	0	0
48736	1624	binding site for the factor-mu regulator	[binding sites for the factor-mu regulator]	1.0	6	1	0	0
48737	1624	similar activity in b cell	[similar activity in B cells]	1.0	5	1	0	0
48738	1624	binding of this different protein	[binding of these different proteins]	1.0	5	1	0	0
48739	1624	stat in qp function, qp	[STATs in Qp function, Qp]	1.0	5	1	0	0
48740	1624	precursor frequency	[Precursor frequency]	1.0	2	3	2	1
48741	1624	key regulator of adipocyte differentiation	[key regulator of adipocyte differentiation]	1.0	5	1	0	0
48742	1624	general octamer site -dependent transcription	[general octamer site -dependent transcription]	1.0	5	1	0	0
48743	1624	indicate the absence of sh-group	[indicating the absence of SH-groups]	1.0	5	1	0	0
48744	1624	IFN-alpha /beta	[IFN-alpha /beta]	1.0	2	1	0	0
48745	1624	intact region	[intact region]	1.0	2	1	0	0
48746	1624	10% homologous porcine serum (control)	[10% homologous porcine serum (control)]	1.0	5	1	0	0
48747	1624	patient with gammac chain deficiency	[patients with gammac chain deficiency]	1.0	5	1	0	0
48748	1624	mitogenic combination of anti CD2	[mitogenic combination of anti CD2]	1.0	5	1	0	0
48749	1624	specific signal from the epor	[specific signaling from the EpoR]	1.0	5	1	0	0
48750	1624	neutrophil granulocyte	[neutrophil granulocytes]	1.0	2	2	1	1
48751	1624	35.2 kda.	[35.2 kDa.]	1.0	2	1	0	0
48752	1624	differential use	[differential use]	1.0	2	1	0	0
48753	1624	soluble mediators, include various growth factor	[soluble mediators, including various growth factors]	1.0	6	1	0	0
48754	1624	use interleukin-2 sequence specific oligonucleotide probe	[using interleukin-2 sequence specific oligonucleotide probes]	1.0	6	1	0	0
48755	1624	belong to subgroup A Ad12	[belonging to subgroups A Ad12]	1.0	5	1	0	0
48756	1624	glucocorticoid C	[glucocorticoids C]	1.0	2	1	0	0
48757	1624	(64 8 mv), normalize after delivery	[(64 8 mV), normalizing after delivery]	1.0	6	1	0	0
48758	1624	697 pmol/L (p less than 0.025).	[697 pmol/L (P less than 0.025).]	1.0	6	1	0	0
48759	1624	tissue inflammation	[tissue inflammation]	1.0	2	1	0	0
48760	1624	confirm the source of ROI	[confirming the source of ROIs]	1.0	5	1	0	0
48761	1624	CD2 activation of the factor	[CD2 activation of the factor]	1.0	5	1	0	0
48762	1624	(24 hour	[(24 hours]	1.0	2	1	0	0
48763	1624	Raf enhancement	[Raf enhancement]	1.0	2	1	0	0
48764	1624	immunocompetent cell	[immunocompetent cells]	1.0	2	2	1	1
48765	1624	human T cell leukemia/lymphoma t-all	[human T cell leukemia/lymphoma T-ALL]	1.0	5	1	0	0
48766	1624	average value from healthy volunteer	[average values from healthy volunteers]	1.0	5	1	0	0
48767	1624	oncogene c-myc	[oncogene c-Myc]	1.0	2	1	0	0
48768	1624	somatic fusion	[somatic fusions]	1.0	2	1	0	0
48769	1624	common target	[common target]	1.0	2	2	2	2
48770	1624	neu-related lipocalin NRL a member	[neu-related lipocalin NRL a member]	1.0	5	1	0	0
48771	1624	synthesis of 4,19-disubstituted derivative of doc	[Synthesis of 4,19-disubstituted derivatives of DOC]	1.0	6	1	0	0
48772	1624	Trident expression	[Trident expression]	1.0	2	1	0	0
48773	1624	Genetic evidence for a additional factor	[Genetic evidence for an additional factor]	1.0	6	1	0	0
48774	1624	significant progress	[Significant progress]	1.0	2	1	0	0
48775	1624	disruption of the human SCL locus	[Disruption of the human SCL locus]	1.0	6	1	0	0
48776	1624	Pharmacodynamic modeling	[Pharmacodynamic modeling]	1.0	2	1	0	0
48777	1624	five healthy human leukocyte antigen-B8	[Five healthy human leukocyte antigen-B8]	1.0	5	1	0	0
48778	1624	newborn mouse	[newborn mice]	1.0	2	1	0	0
48779	1624	induce qr	[inducing QR]	1.0	2	1	0	0
48780	1624	formal proof	[formal proof]	1.0	2	1	0	0
48781	1624	tumour load	[tumour load]	1.0	2	1	0	0
48782	1624	main factor	[main factor]	1.0	2	1	0	0
48783	1624	activation potential	[activation potential]	1.0	2	1	0	0
48784	1624	53 bp	[53 bp]	1.0	2	1	0	0
48785	1624	binding of creb/atf-1 to TRE-1	[binding of CREB/ATF-1 to TRE-1]	1.0	5	1	0	0
48786	1624	slp-76 phosphoprotein of 130 kda.	[SLP-76 phosphoprotein of 130 kDa.]	1.0	5	1	0	0
48787	1624	Cepharanthine dose	[Cepharanthine dose]	1.0	2	1	0	0
48788	1624	expression of the mouse ino gene	[expression of the mouse iNOS gene]	1.0	6	1	0	0
48789	1624	catecholamine norepinephrine	[catecholamines norepinephrine]	1.0	2	1	0	0
48790	1624	in vitro colony formation assay	[in vitro colony formation assays]	1.0	5	1	0	0
48791	1624	demonstrate novel coupling between sIg protein	[demonstrating novel coupling between sIg proteins]	1.0	6	1	0	0
48792	1624	circular DNA	[circular DNA]	1.0	2	1	0	0
48793	1624	expression of different gene important	[expression of different genes important]	1.0	5	1	0	0
48794	1624	signal pathway involve pkc activation	[signaling pathways involving PKC activation]	1.0	5	1	0	0
48795	1624	strong homology with binding site	[strong homology with binding sites]	1.0	5	1	0	0
48796	1624	include PKC	[including PKC]	1.0	2	1	0	0
48797	1624	differanisole a in combination with 9cisra	[Differanisole A in combination with 9cisRA]	1.0	6	1	0	0
48798	1624	microtitre assay system for receptor	[microtitre assay system for receptors]	1.0	5	2	1	1
48799	1624	TNF receptor	[TNF receptor]	1.0	2	2	2	2
48800	1624	th1 phenotype	[TH1 phenotype]	1.0	2	1	0	0
48801	1624	novel transcription factor binding site	[novel transcription factor binding sites]	1.0	5	1	0	0
48802	1624	transactivator together	[transactivators together]	1.0	2	1	0	0
48803	1624	RALDH2 gene	[RALDH2 gene]	1.0	2	1	0	0
48804	1624	deviation of methylation in granulocyte	[deviation of methylation in granulocytes]	1.0	5	1	0	0
48805	1624	nonhomologous end-end	[nonhomologous end-end]	1.0	2	1	0	0
48806	1624	potent suppressor	[potent suppressor]	1.0	2	2	2	2
48807	1624	basis -186	[bases -186]	1.0	2	1	0	0
48808	1624	target promoters,	[target promoters,]	1.0	2	1	0	0
48809	1624	plasma aldosterone in woman with PIH	[Plasma aldosterone in women with PIH]	1.0	6	1	0	0
48810	1624	rheumatoid arthritis five with spondyloarthropathyathypathyartypathyartypathyarty	[rheumatoid arthritis five with spondyloarthropathies]	1.0	5	1	0	0
48811	1624	1.7 nm at 24 degree	[1.7 nM at 24 degrees]	1.0	5	1	0	0
48812	1624	calcitriol number	[calcitriol number]	1.0	2	1	0	0
48813	1624	interfere with this acute process	[interfering with these acute processes]	1.0	5	1	0	0
48814	1624	ng/10(6) cells)	[ng/10(6) cells)]	1.0	2	1	0	0
48815	1624	abnormal renal tubular phosphate transport	[Abnormal renal tubular phosphate transport]	1.0	5	1	0	0
48816	1624	cytosolic I(kappa)B(alpha)	[cytosolic I(kappa)B(alpha)]	1.0	2	1	0	0
48817	1624	binding of NF-kappa b heterodimer	[binding of NF-kappa B heterodimer]	1.0	5	1	0	0
48818	1624	several gene specific for the erythroid	[several genes specific for the erythroid]	1.0	6	1	0	0
48819	1624	sis-inducible element	[sis-inducible element]	1.0	2	1	0	0
48820	1624	nuclear factor from THP-1 cell	[nuclear factor from THP-1 cells]	1.0	5	1	0	0
48821	1624	cd95l transcription	[CD95L transcription]	1.0	2	1	0	0
48822	1624	vitro adherence,	[vitro adherence,]	1.0	2	1	0	0
48823	1624	hematopoietin receptor	[hematopoietin receptors]	1.0	2	2	1	1
48824	1624	endogenous tnf-alpha	[endogenous TNF-alpha]	1.0	2	2	1	1
48825	1624	intron-exon structure	[intron-exon structure]	1.0	2	2	1	1
48826	1624	calcium/calmodulin-dependent protein kinase CaM kinase	[calcium/calmodulin-dependent protein kinase CaM kinase]	1.0	5	1	0	0
48827	1624	Nm23H2 in b cell nuclear extract	[Nm23H2 in B cell nuclear extracts]	1.0	6	1	0	0
48828	1624	beta isoform	[beta isoform]	1.0	2	1	0	0
48829	1624	however, in contrast to human lymphocyte	[However, in contrast to human lymphocytes]	1.0	6	1	0	0
48830	1624	lps stimulation in human monocyte	[LPS stimulation in human monocytes]	1.0	5	1	0	0
48831	1624	murine T cell hybridoma model	[murine T cell hybridoma model]	1.0	5	1	0	0
48832	1624	few vdr	[fewer VDRs]	1.0	2	1	0	0
48833	1624	lung damage	[lung damage]	1.0	2	1	0	0
48834	1624	expression of the hiv LTR	[expression of the HIV LTR]	1.0	5	1	0	0
48835	1624	possible importance such as creb	[possible importance such as CREB]	1.0	5	1	0	0
48836	1624	20-bp region	[20-bp region]	1.0	2	1	0	0
48837	1624	MHC class I class ii molecule	[MHC class I class II molecules]	1.0	6	1	0	0
48838	1624	intracellular response	[intracellular responses]	1.0	2	1	0	0
48839	1624	il-2 secretion,	[IL-2 secretion,]	1.0	2	1	0	0
48840	1624	spite of the fact disturbed.	[spite of the fact disturbed.]	1.0	5	1	0	0
48841	1624	exogenous bcl-2	[exogenous Bcl-2]	1.0	2	2	1	1
48842	1624	induction of M-CSF by M-CSF	[induction of M-CSF by M-CSF]	1.0	5	1	0	0
48843	1624	nf-kappa B/Rel	[NF-kappa B/Rel]	1.0	2	1	0	0
48844	1624	only ifn-alpha	[only IFN-alpha]	1.0	2	1	0	0
48845	1624	twenty subject	[Twenty subjects]	1.0	2	1	0	0
48846	1624	Epo alone	[Epo alone]	1.0	2	1	0	0
48847	1624	cpo gene between erythroid cell	[CPO gene between erythroid cells]	1.0	5	1	0	0
48848	1624	down regulation	[down regulation]	1.0	2	2	2	2
48849	1624	substitution of Ile for Val	[substitution of Ile for Val]	1.0	5	1	0	0
48850	1624	gene inactivation	[Gene inactivation]	1.0	2	2	2	2
48851	1624	predict the occurrence of such proliferations.	[predicting the occurrence of such proliferations.]	1.0	6	1	0	0
48852	1624	basal brain	[basal brain]	1.0	2	2	1	1
48853	1624	construct with a ap-1 element	[constructs with a AP-1 element]	1.0	5	1	0	0
48854	1624	minimal maturation effect on nb4 cell	[minimal maturation effect on NB4 cells]	1.0	6	1	0	0
48855	1624	premenopausal patient with ductal cancer	[premenopausal patients with ductal cancers]	1.0	5	1	0	0
48856	1624	disruption of the Jak1 Box1 region	[Disruption of the Jak1 Box1 region]	1.0	6	1	0	0
48857	1624	e2f activity	[E2F activity]	1.0	2	3	2	1
48858	1624	pp65 phosphoprotein	[pp65 phosphoprotein]	1.0	2	1	0	0
48859	1624	truncation analysis of peptide binding	[Truncation analyses of peptide binding]	1.0	5	1	0	0
48860	1624	major components.	[major components.]	1.0	2	1	0	0
48861	1624	addition, high level of expression	[addition, high level of expression]	1.0	5	1	0	0
48862	1624	ifn-gamma -inducible expression of ciita	[IFN-gamma -inducible expression of CIITA]	1.0	5	1	0	0
48863	1624	cytokine production,	[cytokine production,]	1.0	2	1	0	0
48864	1624	cold-air exposure	[cold-air exposures]	1.0	2	2	1	1
48865	1624	increase in blood hormone concentration	[increases in blood hormone concentrations]	1.0	5	1	0	0
48866	1624	U5 region	[U5 region]	1.0	2	1	0	0
48867	1624	employed, incorporate multiple microbiological antigen	[employed, incorporating multiple microbiological antigens]	1.0	5	1	0	0
48868	1624	differentiation of primary erythroid cell	[differentiation of primary erythroid cells]	1.0	5	1	0	0
48869	1624	enhance gene expression in cd4+ lymphocyte	[enhancing gene expression in CD4+ lymphocytes]	1.0	6	1	0	0
48870	1624	aged rat	[aged rats]	1.0	2	1	0	0
48871	1624	potent inhibitory effect of 9-cis-ra	[potent inhibitory effect of 9-cis-RA]	1.0	5	1	0	0
48872	1624	tsc2 mother	[TSC2 mother]	1.0	2	1	0	0
48873	1624	anti-ig treatment	[anti-Ig treatment]	1.0	2	1	0	0
48874	1624	Functional role	[Functional roles]	1.0	2	2	1	1
48875	1624	apoptotic injury	[apoptotic injury]	1.0	2	1	0	0
48876	1624	cya upon	[CyA upon]	1.0	2	1	0	0
48877	1624	site-specific antibody,	[site-specific antibody,]	1.0	2	1	0	0
48878	1624	expression of the transcription unit	[expression of the transcription unit]	1.0	5	1	0	0
48879	1624	early pregnancy	[early pregnancy]	1.0	2	1	0	0
48880	1624	incubation of human whole blood	[Incubation of human whole blood]	1.0	5	2	2	2
48881	1624	quantitative immunohistochemical analysis of mononuclear	[Quantitative immunohistochemical analysis of mononuclear]	1.0	5	1	0	0
48882	1624	large number of individual gene	[large number of individual genes]	1.0	5	1	0	0
48883	1624	involvement of this amino acid	[involvement of this amino acid]	1.0	5	1	0	0
48884	1624	predominantly c-Rel	[predominantly c-Rel]	1.0	2	1	0	0
48885	1624	low dose of peptide (10 micrograms),	[low doses of peptide (10 micrograms),]	1.0	6	1	0	0
48886	1624	reactivity of patients' T cell	[reactivity of patients' T cells]	1.0	5	1	0	0
48887	1624	period, cd41 immunofluorescence of leukocyte	[period, CD41 immunofluorescence of leukocytes]	1.0	5	1	0	0
48888	1624	solid tumor	[solid tumors]	1.0	2	1	0	0
48889	1624	half-maximal binding	[half-maximal binding]	1.0	2	1	0	0
48890	1624	5' triplet	[5' triplet]	1.0	2	1	0	0
48891	1624	protein of the atf/ creb class	[Proteins of the ATF/ CREB class]	1.0	6	1	0	0
48892	1624	use probe	[using probes]	1.0	2	2	2	2
48893	1624	even in response to retinoic acid	[even in response to retinoic acid]	1.0	6	1	0	0
48894	1624	kappa b/mad-3	[kappa B/MAD-3]	1.0	2	2	1	1
48895	1624	amylase increase	[amylase increases]	1.0	2	1	0	0
48896	1624	functional alpha-helice	[functional alpha-helices]	1.0	2	1	0	0
48897	1624	c-erb b-2	[c-erb B-2]	1.0	2	2	2	2
48898	1624	cellular haptenation by SMX -NO	[Cellular haptenation by SMX -NO]	1.0	5	1	0	0
48899	1624	also non-genomic effect on electrolyte movement	[also non-genomic effects on electrolyte movements]	1.0	6	2	2	2
48900	1624	encode receptor for D3 VDR	[encoding receptors for D3 VDR]	1.0	5	1	0	0
48901	1624	other infections.	[other infections.]	1.0	2	1	0	0
48902	1624	CD40 signal cascade like tnf-alpha	[CD40 signaling cascade like TNF-alpha]	1.0	5	1	0	0
48903	1624	c-Jun complex	[c-Jun complexes]	1.0	2	1	0	0
48904	1624	bind dopamine	[bind dopamine]	1.0	2	1	0	0
48905	1624	means of transmission electron microscopy	[means of transmission electron microscopy]	1.0	5	1	0	0
48906	1624	band 14q11	[band 14q11]	1.0	2	1	0	0
48907	1624	fura toxicity	[FUra toxicity]	1.0	2	1	0	0
48908	1624	two paf receptor antagonist WEB 2086	[two PAF receptor antagonists WEB 2086]	1.0	6	1	0	0
48909	1624	bind to the 12-bp insert	[binding to the 12-bp insert]	1.0	5	1	0	0
48910	1624	cell viability	[cell viability]	1.0	2	2	2	2
48911	1624	2 domain	[2 domains]	1.0	2	1	0	0
48912	1624	vast majority of T cell	[vast majority of T cells]	1.0	5	1	0	0
48913	1624	expression of the prl (hprl) gene	[Expression of the PRL (hPRL) gene]	1.0	6	1	0	0
48914	1624	camp levels,	[cAMP levels,]	1.0	2	1	0	0
48915	1624	proteolytic event	[proteolytic event]	1.0	2	1	0	0
48916	1624	cell of most hemopoietic lineage	[cells of most hemopoietic lineages]	1.0	5	1	0	0
48917	1624	death-inducing receptor such as tnfr1	[death-inducing receptors such as TNFR1]	1.0	5	1	0	0
48918	1624	stress-activated protein kinase/c-Jun NH2-terminal kinase	[stress-activated protein kinase/c-Jun NH2-terminal kinases]	1.0	5	1	0	0
48919	1624	necessary, optimal induction of bcl-2 expression	[necessary, optimal induction of bcl-2 expression]	1.0	6	1	0	0
48920	1624	ectopic decidua	[ectopic decidua]	1.0	2	1	0	0
48921	1624	removal of the upstream sequence	[Removal of the upstream sequences]	1.0	5	1	0	0
48922	1624	mrna transcription by RNA polymerase	[mRNA transcription by RNA polymerase]	1.0	5	1	0	0
48923	1624	10 band	[10 bands]	1.0	2	1	0	0
48924	1624	three step	[three steps]	1.0	2	2	1	1
48925	1624	activity of tumor necrosis factor	[activity of tumor necrosis factor]	1.0	5	2	1	1
48926	1624	mutant sequence	[mutant sequence]	1.0	2	1	0	0
48927	1624	cellular transactivation	[cellular transactivation]	1.0	2	1	0	0
48928	1624	day 12 fetal hematopoietic liver	[day 12 fetal hematopoietic liver]	1.0	5	1	0	0
48929	1624	large amount of viral rna	[Large amounts of viral RNA]	1.0	5	1	0	0
48930	1624	human immunodeficiency virus (hiv)-1 replication	[human immunodeficiency virus (HIV)-1 replication]	1.0	5	1	0	0
48931	1624	high affinity for interleukin-6 IL-6	[high affinity for interleukin-6 IL-6]	1.0	5	1	0	0
48932	1624	human ifngr1 small deletion hotspot	[human IFNGR1 small deletion hotspot]	1.0	5	1	0	0
48933	1624	therapeutic potency	[therapeutic potency]	1.0	2	1	0	0
48934	1624	xenobiotic response	[xenobiotic response]	1.0	2	1	0	0
48935	1624	monocyte chemotactic activity of mcp-1 production	[monocyte chemotactic activity of MCP-1 production]	1.0	6	1	0	0
48936	1624	specific cytokine namely, by il-2	[specific cytokines namely, by IL-2]	1.0	5	1	0	0
48937	1624	major evidence	[major evidence]	1.0	2	1	0	0
48938	1624	regulation of the interleukin-2 gene	[regulation of the interleukin-2 gene]	1.0	5	2	2	2
48939	1624	TNF 5'-region	[TNF 5'-region]	1.0	2	1	0	0
48940	1624	k562 cell with sodium phenylacetate	[K562 cells with sodium phenylacetate]	1.0	5	1	0	0
48941	1624	growth of b cell lymphoma line	[growth of B cell lymphoma lines]	1.0	6	1	0	0
48942	1624	il-2 message by CD4 cell	[IL-2 message by CD4 cells]	1.0	5	1	0	0
48943	1624	63 clone	[63 clones]	1.0	2	1	0	0
48944	1624	substitution mutations,	[Substitution mutations,]	1.0	2	1	0	0
48945	1624	mutation of the CRE site	[Mutations of the CRE site]	1.0	5	1	0	0
48946	1624	1) CVZ	[1) CVZ]	1.0	2	1	0	0
48947	1624	cd56+ cell	[CD56+ cells]	1.0	2	1	0	0
48948	1624	gp160 treatment	[gp160 treatment]	1.0	2	1	0	0
48949	1624	express a catalytically inactive form	[expressing a catalytically inactive form]	1.0	5	1	0	0
48950	1624	primarily consist	[primarily consisting]	1.0	2	1	0	0
48951	1624	retinaldehyde dehydrogenase	[retinaldehyde dehydrogenase]	1.0	2	2	1	1
48952	1624	deletion of the 5'-most Ets site	[Deletion of the 5'-most Ets site]	1.0	6	1	0	0
48953	1624	mycoplasma fermentans-derived high-molecular-weight material MDHM	[Mycoplasma fermentans-derived high-molecular-weight material MDHM]	1.0	5	1	0	0
48954	1624	expression of tcl1 (at 14q32	[expression of TCL1 (at 14q32]	1.0	5	1	0	0
48955	1624	il-10 up-regulation in human monocyte	[IL-10 up-regulation in human monocytes]	1.0	5	1	0	0
48956	1624	il-2-induced NK cytolytic proliferative activity	[IL-2-induced NK cytolytic proliferative activities]	1.0	5	1	0	0
48957	1624	endothelial nos	[endothelial NOS]	1.0	2	1	0	0
48958	1624	unstimulated human peripheral b cell	[unstimulated human peripheral B cells]	1.0	5	1	0	0
48959	1624	encode the transcription factor Egr-1	[encoding the transcription factor Egr-1]	1.0	5	1	0	0
48960	1624	difference between the peak value	[difference between the peak values]	1.0	5	1	0	0
48961	1624	conditions, dexamethasone	[conditions, dexamethasone]	1.0	2	1	0	0
48962	1624	identical steroid hormone receptor expression	[identical steroid hormone receptor expression]	1.0	5	1	0	0
48963	1624	naive donor for the assays.	[naive donors for the assays.]	1.0	5	1	0	0
48964	1624	hiv-1 latency reactivation by dehydroepiandrosterone	[HIV-1 latency reactivation by dehydroepiandrosterone]	1.0	5	1	0	0
48965	1624	osteoblast extract	[osteoblast extracts]	1.0	2	1	0	0
48966	1624	functional significance of p38alpha protein kinase	[functional significance of p38alpha protein kinase]	1.0	6	1	0	0
48967	1624	Southern analysis	[Southern analysis]	1.0	2	1	0	0
48968	1624	annexin V	[annexin V]	1.0	2	2	2	2
48969	1624	assay ligand binding affinity of receptor	[assaying ligand binding affinities of receptors]	1.0	6	1	0	0
48970	1624	medullary thymocyte	[medullary thymocytes]	1.0	2	2	1	1
48971	1624	low concentration of smx -nhoh	[lower concentrations of SMX -NHOH]	1.0	5	1	0	0
48972	1624	substrate specificity	[substrate specificity]	1.0	2	2	2	2
48973	1624	ebv latent	[EBV latent]	1.0	2	1	0	0
48974	1624	cysteamine treatment,	[cysteamine treatment,]	1.0	2	1	0	0
48975	1624	HLA-DR chain	[HLA-DR chain]	1.0	2	1	0	0
48976	1624	cercopithicine herpesvirus	[cercopithicine herpesvirus]	1.0	2	2	2	2
48977	1624	apoptosis sensitivity in anticancer treatment	[apoptosis sensitivity in anticancer treatment]	1.0	5	1	0	0
48978	1624	detection of intracellular signal transduction molecule	[Detection of intracellular signal transduction molecules]	1.0	6	1	0	0
48979	1624	study the effect of drug	[studying the effects of drugs]	1.0	5	1	0	0
48980	1624	normal development.	[normal development.]	1.0	2	1	0	0
48981	1624	endothelial icam-1	[endothelial ICAM-1]	1.0	2	2	1	1
48982	1624	growth-regulated expression of mammalian mcm5	[growth-regulated expression of mammalian MCM5]	1.0	5	1	0	0
48983	1624	transcription factor nfat nuclear factor	[transcription factor NFAT nuclear factor]	1.0	5	1	0	0
48984	1624	member of the Janus kinase family	[members of the Janus kinase family]	1.0	6	1	0	0
48985	1624	suppressor function	[suppressor function]	1.0	2	2	1	1
48986	1624	prip restriction fragment length polymorphism rflp	[PRIP Restriction Fragment Length Polymorphism RFLP]	1.0	6	1	0	0
48987	1624	demonstration of the complete dependence	[Demonstration of the complete dependence]	1.0	5	1	0	0
48988	1624	about 0.8 microm for dutp	[about 0.8 microM for dUTP]	1.0	5	1	0	0
48989	1624	retroviral vectors.	[retroviral vectors.]	1.0	2	1	0	0
48990	1624	transform growth factor beta tgf-beta	[transforming growth factor beta TGF-beta]	1.0	5	1	0	0
48991	1624	il-4 response	[IL-4 responses]	1.0	2	1	0	0
48992	1624	anti-tag antibody	[anti-tag antibody]	1.0	2	1	0	0
48993	1624	CIITA mRNA	[CIITA mRNA]	1.0	2	1	0	0
48994	1624	activation of the IL-6 promoter	[Activation of the IL-6 promoter]	1.0	5	1	0	0
48995	1624	granulocyte subset	[granulocyte subsets]	1.0	2	1	0	0
48996	1624	understand the involvement of camp signal	[understanding the involvement of cAMP signaling]	1.0	6	1	0	0
48997	1624	affinity (Kd)	[affinity (Kd)]	1.0	2	2	2	2
48998	1624	proliferative capacity	[proliferative capacity]	1.0	2	2	1	1
48999	1624	48 hour time culture for mcp-1	[48 hours time culture for MCP-1]	1.0	6	1	0	0
49000	1624	potent chemotactic factor for granulocyte	[potent chemotactic factor for granulocytes]	1.0	5	1	0	0
49001	1624	constant (Kd) of the fms nmol/l)	[constant (Kd) of the FMS nmol/l)]	1.0	6	1	0	0
49002	1624	cloning of human gata-4 hgata-4	[cloning of human GATA-4 hGATA-4]	1.0	5	1	0	0
49003	1624	leader region	[leader region]	1.0	2	2	2	2
49004	1624	wild-type receptor	[wild-type receptor]	1.0	2	2	1	1
49005	1624	low potencies, with ec50 value	[lower potencies, with EC50 values]	1.0	5	1	0	0
49006	1624	viral rna production in U937 cell	[viral RNA production in U937 cells]	1.0	6	1	0	0
49007	1624	effective dose	[effective dose]	1.0	2	2	2	2
49008	1624	paclitaxel-induced apoptosis	[paclitaxel-induced apoptosis]	1.0	2	1	0	0
49009	1624	comparable functional effect on b-cll cell	[comparable functional effects on B-CLL cells]	1.0	6	1	0	0
49010	1624	tbp mutant defective in interaction	[TBP mutant defective in interaction]	1.0	5	1	0	0
49011	1624	kappa b-like site binding complex	[kappa B-like site binding complexes]	1.0	5	1	0	0
49012	1624	basis for gene therapy strategy	[basis for gene therapy strategies]	1.0	5	1	0	0
49013	1624	include bone marrow cell at rest	[including bone marrow cells at rest]	1.0	6	1	0	0
49014	1624	Comparison of the protein sequence	[Comparison of the protein sequence]	1.0	5	1	0	0
49015	1624	ikappab level in MNC homogenate	[IkappaB levels in MNC homogenates]	1.0	5	1	0	0
49016	1624	rnase treatment prior to hybridization	[RNase treatment prior to hybridization]	1.0	5	1	0	0
49017	1624	nuclear activity of NF-kappa B	[nuclear activity of NF-kappa B]	1.0	5	1	0	0
49018	1624	many signal	[many signals]	1.0	2	1	0	0
49019	1624	human cytokine	[human cytokine]	1.0	2	1	0	0
49020	1624	consist of lmp1+ tumour cell	[consisting of LMP1+ tumour cells]	1.0	5	1	0	0
49021	1624	member of the transcription factor family	[members of the transcription factor family]	1.0	6	1	0	0
49022	1624	carboxyl-terminal cytoplasmic domain of cd36	[carboxyl-terminal cytoplasmic domain of CD36]	1.0	5	1	0	0
49023	1624	high level of 5s rrna	[higher levels of 5S rRNA]	1.0	5	1	0	0
49024	1624	putative silencer of homeotic gene	[putative silencer of homeotic genes]	1.0	5	1	0	0
49025	1624	vanadate peroxide	[vanadate peroxide]	1.0	2	2	1	1
49026	1624	footprint erythroid cell express the fetal	[footprinting erythroid cells expressing the fetal]	1.0	6	1	0	0
49027	1624	central role in HTLV-1 transformation	[central role in HTLV-1 transformation]	1.0	5	1	0	0
49028	1624	memory T cell differentiation in patient	[memory T cell differentiation in patients]	1.0	6	1	0	0
49029	1624	originate from tissue structural cell	[originating from tissue structural cells]	1.0	5	1	0	0
49030	1624	proinflammatory molecule	[proinflammatory molecules]	1.0	2	1	0	0
49031	1624	therapeutical level	[therapeutical levels]	1.0	2	1	0	0
49032	1624	bhlh factor	[bHLH factors]	1.0	2	2	1	1
49033	1624	prostate-specific antigen	[prostate-specific antigen]	1.0	2	2	2	2
49034	1624	pathway responsible for this role	[pathway responsible for this role]	1.0	5	1	0	0
49035	1624	phospholipase d	[phospholipase D]	1.0	2	2	2	2
49036	1624	transfection study of LTR reporter construct	[Transfection studies of LTR reporter constructs]	1.0	6	1	0	0
49037	1624	Differential effect of lipopolysaccharide factor	[Differential effects of lipopolysaccharide factor]	1.0	5	1	0	0
49038	1624	mrna species of approximately 1.8 kilobasis	[mRNA species of approximately 1.8 kilobases]	1.0	6	1	0	0
49039	1624	mbp release of il-8 by neutrophil	[MBP release of IL-8 by neutrophils]	1.0	6	1	0	0
49040	1624	basis -280	[bases -280]	1.0	2	1	0	0
49041	1624	135(oh)2d3 receptor in myeloid cell	[1,25(OH)2D3 receptors in myeloid cells]	1.0	5	1	0	0
49042	1624	outcome of the immune reaction	[outcome of the immune reactions]	1.0	5	1	0	0
49043	1624	apoptotic cascade	[apoptotic cascade]	1.0	2	2	2	2
49044	1624	estrogen-dependent regulation	[estrogen-dependent regulation]	1.0	2	1	0	0
49045	1624	phospholipase C	[phospholipase C]	1.0	2	2	2	2
49046	1624	transcription of the cd36 gene	[transcription of the CD36 gene]	1.0	5	1	0	0
49047	1624	transactivation of this transcription factor	[transactivation of this transcription factor]	1.0	5	1	0	0
49048	1624	rxr-rxr homodimer	[RXR-RXR homodimers]	1.0	2	1	0	0
49049	1624	ligand-binding activity	[ligand-binding activity]	1.0	2	1	0	0
49050	1624	regulation of the transcription factor nf-kappab	[Regulation of the transcription factor NF-kappaB]	1.0	6	1	0	0
49051	1624	population of large, immature cell	[population of large, immature cells]	1.0	5	1	0	0
49052	1624	IL-2Ralpha expression	[IL-2Ralpha expression]	1.0	2	1	0	0
49053	1624	basis -214	[bases -214]	1.0	2	1	0	0
49054	1624	T cell of atopic patient	[T cells of atopic patients]	1.0	5	1	0	0
49055	1624	growth transformation of this b-cell	[growth transformation of these B-cells]	1.0	5	1	0	0
49056	1624	4-hour advancement	[4-hour advancement]	1.0	2	1	0	0
49057	1624	response to a diverse set	[response to a diverse set]	1.0	5	1	0	0
49058	1624	IL-12 signal	[IL-12 signal]	1.0	2	2	1	1
49059	1624	cellular factor in this region.	[cellular factors in this region.]	1.0	5	1	0	0
49060	1624	HL-60/vinc/R cell	[HL-60/vinc/R cells]	1.0	2	1	0	0
49061	1624	E1A sensitization to injury-induced apoptosis	[E1A sensitization to injury-induced apoptosis]	1.0	5	1	0	0
49062	1624	transactivate ability	[transactivating ability]	1.0	2	2	2	2
49063	1624	transcription factor nf-kappab heterodimer p50/p65	[transcription factor NF-kappaB heterodimer p50/p65]	1.0	5	1	0	0
49064	1624	tcr apoptosis	[TCR apoptosis]	1.0	2	2	1	1
49065	1624	critical role regulate il-4 transcription	[critical role regulating IL-4 transcription]	1.0	5	1	0	0
49066	1624	cytoplasmic transcription	[cytoplasmic transcription]	1.0	2	1	0	0
49067	1624	lineage-specific expression	[lineage-specific expression]	1.0	2	2	1	1
49068	1624	maximum level of this marker	[maximum levels of these markers]	1.0	5	1	0	0
49069	1624	patient group	[patient groups]	1.0	2	1	0	0
49070	1624	expression of this differentiation marker	[expression of these differentiation markers]	1.0	5	1	0	0
49071	1624	pro-B-cell line	[pro-B-cell lines]	1.0	2	1	0	0
49072	1624	anti-sense rna	[anti-sense RNA]	1.0	2	1	0	0
49073	1624	Stat1, Stat3	[Stat1, Stat3]	1.0	2	1	0	0
49074	1624	arthritis RA	[arthritis RA]	1.0	2	2	2	2
49075	1624	result in all cell line	[Results in all cell lines]	1.0	5	1	0	0
49076	1624	NF90 protein	[NF90 protein]	1.0	2	1	0	0
49077	1624	suppression of trans- gene expression	[suppression of trans- gene expression]	1.0	5	1	0	0
49078	1624	correlation with impairment of function	[correlation with impairment of functions]	1.0	5	1	0	0
49079	1624	oct-1-binding genotype	[OCT-1-binding genotype]	1.0	2	1	0	0
49080	1624	immunocompetent animal	[immunocompetent animals]	1.0	2	1	0	0
49081	1624	beta-globin loci	[beta-globin loci]	1.0	2	1	0	0
49082	1624	Myc-associated zinc finger protein maz	[Myc-associated zinc finger protein MAZ]	1.0	5	1	0	0
49083	1624	local control	[local control]	1.0	2	1	0	0
49084	1624	lyn expression	[lyn expression]	1.0	2	1	0	0
49085	1624	include the phenomenon of steroid-induced rebound,	[including the phenomenon of steroid-induced rebound,]	1.0	6	1	0	0
49086	1624	er -status	[ER -status]	1.0	2	1	0	0
49087	1624	oxidative stress.	[oxidative stress.]	1.0	2	1	0	0
49088	1624	nh2cl (30-50	[NH2Cl (30-50]	1.0	2	1	0	0
49089	1624	erythroid differentiation of ut-7/gm cell	[erythroid differentiation of UT-7/GM cells]	1.0	5	1	0	0
49090	1624	periovulatory period	[periovulatory period]	1.0	2	1	0	0
49091	1624	kilobasis 5'	[kilobases 5']	1.0	2	2	2	2
49092	1624	blot experiment	[blot experiments]	1.0	2	2	2	2
49093	1624	high level of plasma aldosterone	[high levels of plasma aldosterone]	1.0	5	1	0	0
49094	1624	dna-binding/dimerization domain	[DNA-binding/dimerization domain]	1.0	2	1	0	0
49095	1624	pkc -dependent linkage between CD40	[PKC -dependent linkage between CD40]	1.0	5	1	0	0
49096	1624	tnf-treated T cell during aging.	[TNF-treated T cells during aging.]	1.0	5	1	0	0
49097	1624	immunoglobulin chain	[immunoglobulin chain]	1.0	2	2	2	2
49098	1624	nuclear factor-kappa B NF-kappaB family	[nuclear factor-kappa B NF-kappaB family]	1.0	5	1	0	0
49099	1624	DRA transcription	[DRA transcription]	1.0	2	1	0	0
49100	1624	cd3/cd28 coligation	[CD3/CD28 coligation]	1.0	2	1	0	0
49101	1624	precursor of the p50 component	[precursor of the p50 component]	1.0	5	1	0	0
49102	1624	act as bacterial response element	[acting as bacterial response elements]	1.0	5	1	0	0
49103	1624	erythrocyte ghost	[erythrocyte ghosts]	1.0	2	1	0	0
49104	1624	mafK mrna	[mafK mRNA]	1.0	2	1	0	0
49105	1624	fusion between this amino acid	[fusion between these amino acids]	1.0	5	1	0	0
49106	1624	male with x-linked severe immunodeficiency xscid	[Males with X-linked severe immunodeficiency XSCID]	1.0	6	1	0	0
49107	1624	CD28 costimulation of il-2 production	[CD28 costimulation of IL-2 production]	1.0	5	1	0	0
49108	1624	transcription factor during sodium phenylacetate	[transcription factors during sodium phenylacetate]	1.0	5	1	0	0
49109	1624	event upstream of the map	[events upstream of the MAP]	1.0	5	1	0	0
49110	1624	multiple effect on the development, maturation,	[multiple effects on the development, maturation,]	1.0	6	1	0	0
49111	1624	specific cytokine in th cell	[specific cytokines in Th cells]	1.0	5	1	0	0
49112	1624	h incubation	[h incubation]	1.0	2	2	2	2
49113	1624	major histocompatibility complex surface protein	[major histocompatibility complex surface proteins]	1.0	5	1	0	0
49114	1624	cellular binding protein for fk506	[cellular binding protein for FK506]	1.0	5	1	0	0
49115	1624	XY female	[XY female]	1.0	2	2	1	1
49116	1624	VDR calcitriol	[VDR calcitriol]	1.0	2	1	0	0
49117	1624	sex-binding globulin	[sex-binding globulin]	1.0	2	1	0	0
49118	1624	tyrosine phosphoprotein	[tyrosine phosphoprotein]	1.0	2	2	1	1
49119	1624	common variant	[common variants]	1.0	2	1	0	0
49120	1624	three repeat	[three repeats]	1.0	2	2	2	2
49121	1624	small dose of radiation therapy	[small doses of radiation therapy]	1.0	5	1	0	0
49122	1624	change in surface antigen expression,	[changes in surface antigen expression,]	1.0	5	1	0	0
49123	1624	hd of the general population	[HD of the general population]	1.0	5	1	0	0
49124	1624	different pattern of some enzyme activities,	[different patterns of some enzyme activities,]	1.0	6	1	0	0
49125	1624	coding for the c-myc oncogene	[coding for the c-myc oncogene]	1.0	5	1	0	0
49126	1624	full-length bob.1/obf.1	[full-length BOB.1/OBF.1]	1.0	2	1	0	0
49127	1624	antibody titre	[antibody titres]	1.0	2	2	1	1
49128	1624	TNFR1 death	[TNFR1 death]	1.0	2	1	0	0
49129	1624	important role control cell release	[important role controlling cell release]	1.0	5	1	0	0
49130	1624	cytotoxic t-lymphocyte	[cytotoxic T-lymphocyte]	1.0	2	1	0	0
49131	1624	U2 snrna transcription in b-cell	[U2 snRNA transcription in B-cells]	1.0	5	1	0	0
49132	1624	modulation of the transcription factor	[modulation of the transcription factor]	1.0	5	1	0	0
49133	1624	xenoreactive antibody	[xenoreactive antibodies]	1.0	2	1	0	0
49134	1624	5' part	[5' part]	1.0	2	1	0	0
49135	1624	gr number	[GR number]	1.0	2	2	2	2
49136	1624	activation of N-WASP by IcsA	[Activation of N-WASP by IcsA]	1.0	5	1	0	0
49137	1624	transcriptional activation involve transcript initiation	[transcriptional activation involving transcript initiation]	1.0	5	1	0	0
49138	1624	(10(-10) to 10(-7) mol/L) in combination	[(10(-10) to 10(-7) mol/L) in combination]	1.0	6	1	0	0
49139	1624	potential role of Grb2-binding protein	[potential role of Grb2-binding proteins]	1.0	5	1	0	0
49140	1624	lps response by interferon gamma	[LPS responses by interferon gamma]	1.0	5	1	0	0
49141	1624	overexpression of protein kinase c -zeta	[Overexpression of protein kinase C -zeta]	1.0	6	1	0	0
49142	1624	hormone responsiveness of u937 cell	[hormone responsiveness of U937 cells]	1.0	5	1	0	0
49143	1624	vivo differentiation	[vivo differentiation]	1.0	2	2	2	2
49144	1624	relative mass	[relative mass]	1.0	2	2	2	2
49145	1624	same pathway as wild-type zap-70	[same pathways as wild-type ZAP-70]	1.0	5	1	0	0
49146	1624	only in the H9 t-cell line	[only in the H9 T-cell line]	1.0	6	1	0	0
49147	1624	hb24 mrna	[HB24 mRNA]	1.0	2	2	1	1
49148	1624	high abundance	[highest abundance]	1.0	2	2	2	2
49149	1624	K protein	[K protein]	1.0	2	1	0	0
49150	1624	binding by anti-P selectin antibody	[binding by anti-P selectin antibodies]	1.0	5	1	0	0
49151	1624	0.5 microgram/day for 1 month	[0.5 microgram/day for 1 month]	1.0	5	1	0	0
49152	1624	RI gas	[RI GAS]	1.0	2	2	1	1
49153	1624	expression of the BCL2 gene	[expression of the BCL2 gene]	1.0	5	1	0	0
49154	1624	inhibitor specific	[inhibitor specific]	1.0	2	2	1	1
49155	1624	mouse model	[mouse model]	1.0	2	2	2	2
49156	1624	mouse myeloid leukemia M1 cell	[mouse myeloid leukemia M1 cells]	1.0	5	1	0	0
49157	1624	functional state	[functional state]	1.0	2	2	2	2
49158	1624	rrna processing	[rRNA processing]	1.0	2	1	0	0
49159	1624	10 cellularity)	[10 cellularity)]	1.0	2	1	0	0
49160	1624	calcium metabolism of the chick	[calcium metabolism of the chick]	1.0	5	1	0	0
49161	1624	lps induction of the gene	[LPS induction of the gene]	1.0	5	1	0	0
49162	1624	1 year: 4.1 versus 14.1	[1 year: 4.1 versus 14.1]	1.0	5	1	0	0
49163	1624	immunoglobulin g	[immunoglobulin G]	1.0	2	2	2	2
49164	1624	immunoglobulin m	[immunoglobulin M]	1.0	2	1	0	0
49165	1624	cytosolic calcium	[cytosolic calcium]	1.0	2	2	2	2
49166	1624	dominant-negative suppressor	[dominant-negative suppressor]	1.0	2	2	1	1
49167	1624	short-lived signal	[short-lived signal]	1.0	2	1	0	0
49168	1624	change in the phosphorylation pattern	[changes in the phosphorylation pattern]	1.0	5	1	0	0
49169	1624	several criteria,	[several criteria,]	1.0	2	2	2	2
49170	1624	maximum minute	[maximum min]	1.0	2	2	2	2
49171	1624	IL-1 gene expression in tissue	[IL-1 gene expression in tissue]	1.0	5	1	0	0
49172	1624	central role in ebv-induced growth transformation	[central role in EBV-induced growth transformation]	1.0	6	1	0	0
49173	1624	control of hil-5 promoter activity	[control of hIL-5 promoter activity]	1.0	5	1	0	0
49174	1624	only a few cd8(+)-t-cell epitope	[only a few CD8(+)-T-cell epitopes]	1.0	5	1	0	0
49175	1624	21 element	[21 elements]	1.0	2	1	0	0
49176	1624	10 patient with active cushingd' disease	[10 patients with active Cushing's disease]	1.0	6	1	0	0
49177	1624	mitogen-activated protein kinase kinase MEK	[mitogen-activated protein kinase kinase MEK]	1.0	5	1	0	0
49178	1624	encoding gene	[encoding gene]	1.0	2	1	0	0
49179	1624	facilitate progression through the g1 phase	[facilitating progression through the G1 phase]	1.0	6	1	0	0
49180	1624	myb-transformed cell	[Myb-transformed cells]	1.0	2	2	2	2
49181	1624	c-rel complex	[c-Rel complexes]	1.0	2	1	0	0
49182	1624	plasmodium vivax	[Plasmodium vivax]	1.0	2	2	2	2
49183	1624	environmental carcinogen	[environmental carcinogens]	1.0	2	1	0	0
49184	1624	25(oh)d3-24-hydroxylase activity	[25(OH)D3-24-hydroxylase activity]	1.0	2	1	0	0
49185	1624	feature of myeloid (nk) cell	[features of myeloid (NK) cells]	1.0	5	1	0	0
49186	1624	cytotoxic lymphocyte	[cytotoxic lymphocytes]	1.0	2	2	2	2
49187	1624	early sign of immune remission	[early sign of immune remission]	1.0	5	1	0	0
49188	1624	gender reactivity	[Gender reactivity]	1.0	2	1	0	0
49189	1624	monoclonal CR1	[monoclonal CR1]	1.0	2	1	0	0
49190	1624	mucolytic agent	[mucolytic agent]	1.0	2	1	0	0
49191	1624	formation of Stat1alpha -DNA complex	[formation of Stat1alpha -DNA complexes]	1.0	5	1	0	0
49192	1624	same event	[same event]	1.0	2	1	0	0
49193	1624	cytoplasmic nf-kappab	[cytoplasmic NF-kappaB]	1.0	2	1	0	0
49194	1624	target of the IRF-1 gas	[Targeting of the IRF-1 GAS]	1.0	5	1	0	0
49195	1624	comparison with the stat protein	[comparison with the Stat proteins]	1.0	5	1	0	0
49196	1624	early signal event such as generation	[early signaling events such as generation]	1.0	6	1	0	0
49197	1624	age receptor	[age receptors]	1.0	2	1	0	0
49198	1624	igd antibody	[IgD antibodies]	1.0	2	1	0	0
49199	1624	IL-6 downregulation of the BCL2 gene	[IL-6 downregulation of the BCL2 gene]	1.0	6	1	0	0
49200	1624	granulocyte-macrophage CSF	[granulocyte-macrophage CSF]	1.0	2	2	1	1
49201	1624	co-cultivated T	[co-cultivated T]	1.0	2	1	0	0
49202	1624	il-12 stimulation.	[IL-12 stimulation.]	1.0	2	1	0	0
49203	1624	Hydroxyurea HU	[Hydroxyurea HU]	1.0	2	1	0	0
49204	1624	human b-lcl	[human B-LCL]	1.0	2	1	0	0
49205	1624	three subunits.	[three subunits.]	1.0	2	1	0	0
49206	1624	p45 expression	[p45 expression]	1.0	2	1	0	0
49207	1624	new insight into t-cell development	[new insights into T-cell development]	1.0	5	1	0	0
49208	1624	Jurkat cell lymphocyte cell line	[Jurkat cells lymphocyte cell line]	1.0	5	1	0	0
49209	1624	Degenerate primer corresponding amino acid sequence	[Degenerate primers corresponding amino acid sequences]	1.0	6	1	0	0
49210	1624	way, diversity	[way, diversity]	1.0	2	1	0	0
49211	1624	elevation of adhesion molecule expression	[elevation of adhesion molecule expression]	1.0	5	1	0	0
49212	1624	ligation of major histocompatibility class	[ligation of major histocompatibility class]	1.0	5	2	2	2
49213	1624	alteration in glucocorticoid receptor gr binding	[alterations in glucocorticoid receptor GR binding]	1.0	6	1	0	0
49214	1624	Study of the kinetic of induction	[Studies of the kinetics of induction]	1.0	6	1	0	0
49215	1624	increase in the ca2+ concentration	[increase in the Ca2+ concentration]	1.0	5	1	0	0
49216	1624	3'-CAGGTG e-box	[3'-CAGGTG E-box]	1.0	2	1	0	0
49217	1624	transform baby rat kidney (brk) cell	[transforming baby rat kidney (BRK) cells]	1.0	6	1	0	0
49218	1624	strong regulator	[strong regulator]	1.0	2	2	2	2
49219	1624	predominant expression	[predominant expression]	1.0	2	2	2	2
49220	1624	similar selective effect on nf-kappab transcription	[Similar selective effects on NF-kappaB transcription]	1.0	6	1	0	0
49221	1624	ligand-binding experiment	[ligand-binding experiments]	1.0	2	1	0	0
49222	1624	tissue-specific response	[tissue-specific response]	1.0	2	1	0	0
49223	1624	heme-treated friend leukemia cell flc	[heme-treated Friend leukemia cells FLCs]	1.0	5	1	0	0
49224	1624	transcription of the second wave,	[transcription of the second wave,]	1.0	5	1	0	0
49225	1624	induction of hiv-1- gene expression	[induction of HIV-1- gene expression]	1.0	5	1	0	0
49226	1624	age-related hyporesponsiveness	[age-related hyporesponsiveness]	1.0	2	1	0	0
49227	1624	ino expression in endothelial cell	[iNOS expression in endothelial cells]	1.0	5	1	0	0
49228	1624	addition of rabbit reticulocyte lysate	[addition of rabbit reticulocyte lysate]	1.0	5	1	0	0
49229	1624	human embryonic zeta globin gene	[human embryonic zeta globin gene]	1.0	5	1	0	0
49230	1624	two transcript	[two transcripts]	1.0	2	2	1	1
49231	1624	transient myeloproliferative disorder in down' syndrome	[transient myeloproliferative disorder in Down's syndrome]	1.0	6	3	2	1
49232	1624	past decade	[past decade]	1.0	2	1	0	0
49233	1624	tsh level	[TSH levels]	1.0	2	1	0	0
49234	1624	own preferential gas DNA binding pattern	[own preferential GAS DNA binding patterns]	1.0	6	1	0	0
49235	1624	actual target of the silencing.	[actual target of the silencing.]	1.0	5	1	0	0
49236	1624	class ii-positive b cell line	[class II-positive B cell lines]	1.0	5	1	0	0
49237	1624	activation of this cytokine signal pathway	[activation of these cytokine signaling pathways]	1.0	6	1	0	0
49238	1624	C5a pbmc	[C5a PBMC]	1.0	2	1	0	0
49239	1624	T lymphocyte a cellular target	[T lymphocytes a cellular target]	1.0	5	1	0	0
49240	1624	T cell specific inducible expression:	[T cell specific inducible expression:]	1.0	5	1	0	0
49241	1624	DNase i footprinting of the region	[DNase I footprinting of the region]	1.0	6	1	0	0
49242	1624	PML/RAR alpha fusion gene result	[PML/RAR alpha fusion gene resulting]	1.0	5	1	0	0
49243	1624	immunity impairment	[immunity impairments]	1.0	2	1	0	0
49244	1624	mite allergen,	[mite allergen,]	1.0	2	1	0	0
49245	1624	mzf-1 protein	[MZF-1 protein]	1.0	2	2	1	1
49246	1624	conclusion a necessary signal component	[conclusion a necessary signaling component]	1.0	5	1	0	0
49247	1624	molecular weight of 64.6 k.0	[molecular weight of 64.6 kd,]	1.0	5	1	0	0
49248	1624	receptor level in mononuclear leukocyte	[receptor levels in mononuclear leukocytes]	1.0	5	2	1	1
49249	1624	about 90 degree with helice	[about 90 degrees with helices]	1.0	5	1	0	0
49250	1624	bone marrow-derived mip-1 alpha /gos19	[bone marrow-derived MIP-1 alpha /GOS19]	1.0	5	1	0	0
49251	1624	signal branch	[signaling branch]	1.0	2	1	0	0
49252	1624	CACCC boxes,	[CACCC boxes,]	1.0	2	1	0	0
49253	1624	cell to adverse environmental condition	[cells to adverse environmental conditions]	1.0	5	1	0	0
49254	1624	factor responsible for this activity	[factor responsible for this activity]	1.0	5	1	0	0
49255	1624	RAR beta-	[RAR beta-]	1.0	2	1	0	0
49256	1624	matrix-associated Site	[matrix-associated Site]	1.0	2	1	0	0
49257	1624	wild-type fragment	[wild-type fragment]	1.0	2	1	0	0
49258	1624	androgen-modulated rat ventral prostate tissue	[androgen-modulated rat ventral prostate tissue]	1.0	5	1	0	0
49259	1624	indicate entry into the lytic cycle	[indicating entry into the lytic cycle]	1.0	6	1	0	0
49260	1624	increase moderately during exposure to tpa	[increasing moderately during exposure to TPA]	1.0	6	1	0	0
49261	1624	accumulation of nf-kappab /rel protein	[accumulation of NF-kappaB /Rel proteins]	1.0	5	1	0	0
49262	1624	further analysis:	[further analysis:]	1.0	2	1	0	0
49263	1624	further analysis.	[further analysis.]	1.0	2	1	0	0
49264	1624	infection respectively.	[infection respectively.]	1.0	2	1	0	0
49265	1624	incubation of Jurkat T cell cells/ml)	[Incubation of Jurkat T cells cells/ml)]	1.0	6	1	0	0
49266	1624	hla-dr antigen by mAb L243	[HLA-DR antigens by mAb L243]	1.0	5	1	0	0
49267	1624	fresh peripheral blood mononuclear cell	[fresh peripheral blood mononuclear cells]	1.0	5	2	1	1
49268	1624	putative ar-cre	[putative AR-CRE]	1.0	2	1	0	0
49269	1624	urogenital mesoderm	[urogenital mesoderm]	1.0	2	1	0	0
49270	1624	only in that particular cell line	[only in that particular cell line]	1.0	6	1	0	0
49271	1624	first peak.	[first peak.]	1.0	2	1	0	0
49272	1624	migration of S6 on SDS-PAGE	[migration of S6 on SDS-PAGE]	1.0	5	1	0	0
49273	1624	two factors:	[two factors:]	1.0	2	1	0	0
49274	1624	single gene	[single gene]	1.0	2	2	1	1
49275	1624	binding of 3 h- pgg-glucan	[binding of 3 H- PGG-Glucan]	1.0	5	1	0	0
49276	1624	yac span the AF10 breakpoint.	[YAC spanning the AF10 breakpoint.]	1.0	5	1	0	0
49277	1624	binding of the nuclear protein hmg-i	[binding of the nuclear protein HMG-I]	1.0	6	1	0	0
49278	1624	Autoreactive b-cell	[Autoreactive B-cells]	1.0	2	1	0	0
49279	1624	Rat spleen	[Rat spleen]	1.0	2	1	0	0
49280	1624	take age-related change into account.	[taking age-related changes into account.]	1.0	5	1	0	0
49281	1624	subunit 6 of the 26s protease	[subunit 6 of the 26S protease]	1.0	6	1	0	0
49282	1624	classical model	[classical model]	1.0	2	1	0	0
49283	1624	RESULTS: Electrophoretic mobility shift assay	[RESULTS: Electrophoretic mobility shift assays]	1.0	5	1	0	0
49284	1624	8% dead cell at day g-csf	[8% dead cells at day G-CSF]	1.0	6	1	0	0
49285	1624	ikk complex	[IKK complex]	1.0	2	1	0	0
49286	1624	cell of the granulocytic lineage	[cells of the granulocytic lineage]	1.0	5	1	0	0
49287	1624	signal requirement by western blot	[Signal requirements by western blots]	1.0	5	1	0	0
49288	1624	overall nf-kappa b signal transduction	[overall NF-kappa B signal transduction]	1.0	5	1	0	0
49289	1624	equilibrium fashion	[equilibrium fashion]	1.0	2	1	0	0
49290	1624	novel ubiquitin-protein	[novel ubiquitin-protein]	1.0	2	1	0	0
49291	1624	structural order.	[structural order.]	1.0	2	1	0	0
49292	1624	induce 5.7-fold the CAT activity	[inducing 5.7-fold the CAT activity]	1.0	5	1	0	0
49293	1624	extract-DNA complex	[extract-DNA complexes]	1.0	2	2	2	2
49294	1624	2 subunit CBF alpha 2-451	[2 subunit CBF alpha 2-451]	1.0	5	1	0	0
49295	1624	IL-4 tyrosine phosphorylation of Stat6	[IL-4 tyrosine phosphorylation of Stat6]	1.0	5	1	0	0
49296	1624	reliability of this regression model	[reliability of this regression model]	1.0	5	1	0	0
49297	1624	use culture of T cell	[using cultures of T cells]	1.0	5	1	0	0
49298	1624	pH variation	[pH variation]	1.0	2	1	0	0
49299	1624	ap-1 part	[AP-1 part]	1.0	2	1	0	0
49300	1624	allograft rejection	[allograft rejection]	1.0	2	2	2	2
49301	1624	relationship between the immunohistochemical finding	[relationship between the immunohistochemical findings]	1.0	5	1	0	0
49302	1624	role alter the physiologic status	[role altering the physiologic status]	1.0	5	1	0	0
49303	1624	plasma lipase	[plasma lipase]	1.0	2	1	0	0
49304	1624	human pmn	[human PMN]	1.0	2	1	0	0
49305	1624	hence, phosphorylation of linker protein	[Hence, phosphorylation of linker proteins]	1.0	5	1	0	0
49306	1624	strike degree	[striking degree]	1.0	2	1	0	0
49307	1624	peak at the promyelocyte stage	[peaking at the promyelocyte stage]	1.0	5	1	0	0
49308	1624	tnf-alpha synthesis at the mrna	[TNF-alpha synthesis at the mRNA]	1.0	5	1	0	0
49309	1624	rheumatoid synovium	[rheumatoid synovium]	1.0	2	2	1	1
49310	1624	bp fragment	[bp fragment]	1.0	2	2	2	2
49311	1624	cell express the e1a oncoprotein	[Cells expressing the E1A oncoprotein]	1.0	5	1	0	0
49312	1624	cd8+ T cell of subject	[CD8+ T cells of subjects]	1.0	5	1	0	0
49313	1624	haec model	[hAEC model]	1.0	2	1	0	0
49314	1624	nuclear extract from b cell	[nuclear extracts from B cells]	1.0	5	1	0	0
49315	1624	black people	[black people]	1.0	2	1	0	0
49316	1624	gene mutation	[gene mutations]	1.0	2	1	0	0
49317	1624	Thus, C/EBPepsilon	[Thus, C/EBPepsilon]	1.0	2	1	0	0
49318	1624	particularly u1rnp	[particularly U1RNP]	1.0	2	1	0	0
49319	1624	proinflammatory mediator leukotriene b4 LTB4	[proinflammatory mediator leukotriene B4 LTB4]	1.0	5	1	0	0
49320	1624	dicoumarol a qr -specific inhibitor	[dicoumarol a QR -specific inhibitor]	1.0	5	1	0	0
49321	1624	tumor necrosis factor tnf activation	[tumor necrosis factor TNF activation]	1.0	5	1	0	0
49322	1624	prolonged activation	[prolonged activation]	1.0	2	1	0	0
49323	1624	RNA analyses,	[RNA analyses,]	1.0	2	1	0	0
49324	1624	most erythroblastic permanent cell line	[most erythroblastic permanent cell lines]	1.0	5	1	0	0
49325	1624	interleukin production	[interleukin production]	1.0	2	2	2	2
49326	1624	contain the minimal beta-casein stat5 element	[containing the minimal beta-casein STAT5 element]	1.0	6	1	0	0
49327	1624	extracellular pH	[extracellular pH]	1.0	2	1	0	0
49328	1624	HTLV-I myelopathy	[HTLV-I myelopathy]	1.0	2	1	0	0
49329	1624	fibronectin alone	[fibronectin alone]	1.0	2	1	0	0
49330	1624	introduce a cryptic splice site	[introducing a cryptic splice site]	1.0	5	1	0	0
49331	1624	one cell	[one cell]	1.0	2	2	2	2
49332	1624	important insight into plaque formation	[important insight into plaque formation]	1.0	5	1	0	0
49333	1624	human tcr	[human TCR]	1.0	2	1	0	0
49334	1624	cbl mutant	[Cbl mutant]	1.0	2	2	2	2
49335	1624	probably at a site different	[probably at a site different]	1.0	5	1	0	0
49336	1624	lack the 1.8 kb promoter	[lacking the 1.8 kb promoter]	1.0	5	1	0	0
49337	1624	IL-2 production by T cell	[IL-2 production by T cells]	1.0	5	1	0	0
49338	1624	expression pattern,	[expression pattern,]	1.0	2	1	0	0
49339	1624	nutritional component	[nutritional component]	1.0	2	1	0	0
49340	1624	nonconsensus site	[nonconsensus sites]	1.0	2	1	0	0
49341	1624	87 nm	[87 nM]	1.0	2	1	0	0
49342	1624	protein kinase C PKC isoform	[protein kinase C PKC isoforms]	1.0	5	1	0	0
49343	1624	elusive, curcumin	[elusive, curcumin]	1.0	2	1	0	0
49344	1624	down-regulation of 17beta-HSD iv mrna expression	[Down-regulation of 17beta-HSD IV mRNA expression]	1.0	6	1	0	0
49345	1624	protect adenovirus gene therapy vector	[protecting adenovirus gene therapy vectors]	1.0	5	1	0	0
49346	1624	presence of a ap-1 protein	[presence of an AP-1 protein]	1.0	5	1	0	0
49347	1624	inhibition involvement of the mineralocorticoid receptor	[Inhibition involvement of the mineralocorticoid receptor]	1.0	6	1	0	0
49348	1624	bind activity of preexisting nf-il6	[binding activity of preexisting NF-IL6]	1.0	5	1	0	0
49349	1624	hmg motif	[HMG motif]	1.0	2	2	1	1
49350	1624	Germinal center	[Germinal center]	1.0	2	1	0	0
49351	1624	gata-2 in mbp gene transcription	[GATA-2 in MBP gene transcription]	1.0	5	1	0	0
49352	1624	th2 cell differentiation switch to ige	[Th2 cell differentiation switching to IgE]	1.0	6	1	0	0
49353	1624	present paper,	[present paper,]	1.0	2	1	0	0
49354	1624	lymphocyte ca2+	[lymphocyte Ca2+]	1.0	2	1	0	0
49355	1624	binding mutant	[binding mutants]	1.0	2	1	0	0
49356	1624	five mother	[five mothers]	1.0	2	1	0	0
49357	1624	sediment gradient	[sedimenting gradient]	1.0	2	1	0	0
49358	1624	EBV cell	[EBV cells]	1.0	2	1	0	0
49359	1624	nm, bmax	[nM, Bmax]	1.0	2	2	2	2
49360	1624	similar half-life	[similar half-life]	1.0	2	1	0	0
49361	1624	ar allele	[AR allele]	1.0	2	1	0	0
49362	1624	aortic ec	[aortic EC]	1.0	2	2	2	2
49363	1624	prognostic character in spontaneous abortion	[prognostic character in spontaneous abortion]	1.0	5	1	0	0
49364	1624	36 normal race- control subject	[36 normal race- control subjects]	1.0	5	1	0	0
49365	1624	PMA inducibility on a heterologous promoter	[PMA inducibility on a heterologous promoter]	1.0	6	1	0	0
49366	1624	respond to a immunogenic stimulus	[responding to an immunogenic stimulus]	1.0	5	1	0	0
49367	1624	cytokine cooperativity	[cytokine cooperativity]	1.0	2	1	0	0
49368	1624	translocation a new variant translocation	[Translocation a new variant translocation]	1.0	5	1	0	0
49369	1624	jak3 in il-2 receptor complex	[JAK3 in IL-2 receptor complexes]	1.0	5	1	0	0
49370	1624	non-parametric test	[non-parametric test]	1.0	2	1	0	0
49371	1624	crucial event in the process	[crucial event in the process]	1.0	5	1	0	0
49372	1624	adherent leukocyte	[adherent leukocytes]	1.0	2	1	0	0
49373	1624	certain area of tissue insult	[certain areas of tissue insult]	1.0	5	1	0	0
49374	1624	nonpilus adhesin	[nonpilus adhesins]	1.0	2	1	0	0
49375	1624	granulosa cell tumor of the ovary	[Granulosa cell tumor of the ovary]	1.0	6	1	0	0
49376	1624	determine factor in DNA damage	[determining factor in DNA damage]	1.0	5	1	0	0
49377	1624	only affect naive th cell	[only affecting naive Th cells]	1.0	5	1	0	0
49378	1624	24-hydroxylase mrna expression in u937 cell	[24-hydroxylase mRNA expression in U937 cells]	1.0	6	1	0	0
49379	1624	nature of the factor (s)	[nature of the factor (s)]	1.0	5	1	0	0
49380	1624	N-WASP contain a verprolin-homology region	[N-WASP containing a verprolin-homology region]	1.0	5	1	0	0
49381	1624	member of the id family	[members of the Id family]	1.0	5	1	0	0
49382	1624	-independent hiv promoter domain activity	[-independent HIV promoter domain activity]	1.0	5	1	0	0
49383	1624	plasma cortisol receptor in leukocyte	[plasma cortisol receptors in leukocytes]	1.0	5	1	0	0
49384	1624	site GM5	[site GM5]	1.0	2	1	0	0
49385	1624	full activity.	[full activity.]	1.0	2	1	0	0
49386	1624	increase interest.	[increasing interest.]	1.0	2	1	0	0
49387	1624	CD14 translocation of nuclear factor-kappa b	[CD14 translocation of nuclear factor-kappa B]	1.0	6	1	0	0
49388	1624	constituent protein	[constituent proteins]	1.0	2	1	0	0
49389	1624	responsive genes.	[responsive genes.]	1.0	2	1	0	0
49390	1624	il-2 repression	[IL-2 repression]	1.0	2	1	0	0
49391	1624	individual with defect in CD40	[individuals with defects in CD40]	1.0	5	1	0	0
49392	1624	macrophage form of the receptor	[macrophage form of the receptor]	1.0	5	1	0	0
49393	1624	previous hypothesis	[previous hypothesis]	1.0	2	1	0	0
49394	1624	interaction between the glucocorticoid receptor	[interaction between the glucocorticoid receptor]	1.0	5	2	1	1
49395	1624	Jurkat cell with mAb j393	[Jurkat cells with mAb J393]	1.0	5	1	0	0
49396	1624	supplement the datum on the processing	[Supplementing the data on the processing]	1.0	6	1	0	0
49397	1624	most recipient of the drug.	[most recipients of the drug.]	1.0	5	1	0	0
49398	1624	different populations,	[different populations,]	1.0	2	1	0	0
49399	1624	transcription factor in addition to Oct2	[transcription factors in addition to Oct2]	1.0	6	1	0	0
49400	1624	octamer-bound Oct-1	[octamer-bound Oct-1]	1.0	2	1	0	0
49401	1624	mediate different aspect of the process.	[mediating different aspects of the process.]	1.0	6	1	0	0
49402	1624	value of the clinical test	[value of the clinical test]	1.0	5	1	0	0
49403	1624	autoimmune diseases)	[autoimmune diseases).]	1.0	2	1	0	0
49404	1624	surface expression of a subset	[surface expression of a subset]	1.0	5	1	0	0
49405	1624	gene transcription in T lymphocyte	[gene transcription in T lymphocytes]	1.0	5	1	0	0
49406	1624	male breast cancer in Hungary.	[male breast cancer in Hungary.]	1.0	5	1	0	0
49407	1624	male breast cancer in Hungary,	[male breast cancer in Hungary,]	1.0	5	1	0	0
49408	1624	patient without detectable tal1 rearrangement	[patients without detectable TAL1 rearrangements]	1.0	5	1	0	0
49409	1624	favor of the p50/p65 heterodimer	[favor of the p50/p65 heterodimers]	1.0	5	1	0	0
49410	1624	lambda gene	[lambda genes]	1.0	2	1	0	0
49411	1624	Indeed, binding of the igh enhancer	[Indeed, binding of the IgH enhancer]	1.0	6	1	0	0
49412	1624	difference in pattern of expression	[differences in patterns of expression]	1.0	5	1	0	0
49413	1624	on-off switch,	[on-off switch,]	1.0	2	1	0	0
49414	1624	closely resemble a RBP-Jkappa binding site	[closely resembling a RBP-Jkappa binding site]	1.0	6	1	0	0
49415	1624	IL-12 -dependent up-regulation of irf-1	[IL-12 -dependent up-regulation of IRF-1]	1.0	5	1	0	0
49416	1624	treatment of 10 with warm hcl	[Treatment of 10 with warm HCl]	1.0	6	1	0	0
49417	1624	c-Rel/p65 heterodimer	[c-Rel/p65 heterodimers]	1.0	2	5	4	1
49418	1624	expression of multiple cellular promoter	[expression of multiple cellular promoters]	1.0	5	1	0	0
49419	1624	activity of several transcription factor	[activity of several transcription factors]	1.0	5	1	0	0
49420	1624	wild-type phenotype in viral replication	[wild-type phenotype in viral replication]	1.0	5	1	0	0
49421	1624	series of gm-csf-responsive cell line	[series of GM-CSF-responsive cell lines]	1.0	5	1	0	0
49422	1624	function of the tf protein	[function of the TF protein]	1.0	5	1	0	0
49423	1624	disease parameters,	[disease parameters,]	1.0	2	1	0	0
49424	1624	Ca2+ ionophore	[Ca2+ ionophore]	1.0	2	1	0	0
49425	1624	c-Fos /c-Jun	[c-Fos /c-Jun]	1.0	2	1	0	0
49426	1624	a-myb expression	[A-myb expression]	1.0	2	2	1	1
49427	1624	next hr.	[next hr.]	1.0	2	2	2	2
49428	1624	cd36 epor	[CD36 EpoR]	1.0	2	1	0	0
49429	1624	follow lps	[following LPS]	1.0	2	2	1	1
49430	1624	same tendency	[same tendency]	1.0	2	1	0	0
49431	1624	perhaps act at the level	[perhaps acting at the level]	1.0	5	1	0	0
49432	1624	nuclear factor of t-cell (nfat) site	[nuclear factors of T-cell (NFAT) sites]	1.0	6	1	0	0
49433	1624	wild-type ebna2	[wild-type EBNA2]	1.0	2	1	0	0
49434	1624	murine protein	[Murine proteins]	1.0	2	1	0	0
49435	1624	thyroid cell	[thyroid cells]	1.0	2	1	0	0
49436	1624	only IKKbeta	[only IKKbeta]	1.0	2	1	0	0
49437	1624	human granulocyte-macrophage CSF gm-csf gene	[human granulocyte-macrophage CSF GM-CSF gene]	1.0	5	1	0	0
49438	1624	intracellular ROI in this cell	[intracellular ROI in these cells]	1.0	5	1	0	0
49439	1624	immune-specific manner	[immune-specific manner]	1.0	2	1	0	0
49440	1624	g0/g1 switch gene 2 g0s2	[G0/G1 switch gene 2 G0S2]	1.0	5	1	0	0
49441	1624	intravascular thrombosis	[intravascular thrombosis]	1.0	2	1	0	0
49442	1624	biscoclaurine alkaloid	[biscoclaurine alkaloid]	1.0	2	2	1	1
49443	1624	cell-type specificity	[cell-type specificity]	1.0	2	1	0	0
49444	1624	(2.2 nm)	[(2.2 nM)]	1.0	2	1	0	0
49445	1624	progesterone receptor pr by immunohistochemistry	[progesterone receptors PR by immunohistochemistry]	1.0	5	1	0	0
49446	1624	sequence in the upstream promoter region	[sequences in the upstream promoter region]	1.0	6	1	0	0
49447	1624	receptor EPOR	[receptor EPOR]	1.0	2	1	0	0
49448	1624	Genetic variation in cytokine promoter region	[Genetic variation in cytokine promoter regions]	1.0	6	1	0	0
49449	1624	pattern, peak	[pattern, peaking]	1.0	2	1	0	0
49450	1624	functional consequence	[functional consequences]	1.0	2	2	1	1
49451	1624	i.e., curcumin	[i.e., curcumin]	1.0	2	1	0	0
49452	1624	S-X-Y region	[S-X-Y region]	1.0	2	2	1	1
49453	1624	50 micromol/L.	[50 micromol/L.]	1.0	2	1	0	0
49454	1624	operative kinase	[operative kinase]	1.0	2	1	0	0
49455	1624	mapk/erk-specific inhibitor	[MAPK/ERK-specific inhibitor]	1.0	2	1	0	0
49456	1624	unactivated T	[unactivated T]	1.0	2	1	0	0
49457	1624	family members.	[family members.]	1.0	2	2	2	2
49458	1624	culture lack fresh antigen-presenting cell	[cultures lacking fresh antigen-presenting cells]	1.0	5	1	0	0
49459	1624	Ets site	[Ets sites]	1.0	2	1	0	0
49460	1624	receptor molecule	[receptor molecule]	1.0	2	1	0	0
49461	1624	MODY mody3	[MODY MODY3]	1.0	2	1	0	0
49462	1624	response to the CD28 signal	[response to the CD28 signal]	1.0	5	1	0	0
49463	1624	scant cytoplasm with fine azurophilic granularity	[scant cytoplasm with fine azurophilic granularity]	1.0	6	1	0	0
49464	1624	great amount	[greater amounts]	1.0	2	2	2	2
49465	1624	molecular weight 13000 to 24000	[molecular weight 13,000 to 24,000]	1.0	5	1	0	0
49466	1624	common property of inducible gene	[common property of inducible genes]	1.0	5	1	0	0
49467	1624	membrane fraction	[membrane fraction]	1.0	2	1	0	0
49468	1624	il-3 commitment	[IL-3 commitment]	1.0	2	2	2	2
49469	1624	ifn-gamma stat1 receptor activation in CLL	[IFN-gamma STAT1 receptor activation in CLL]	1.0	6	1	0	0
49470	1624	oncogenic virus of nonhuman primate	[oncogenic virus of nonhuman primates]	1.0	5	1	0	0
49471	1624	accompany the rapid turnover the I	[Accompanying the rapid turnover the I]	1.0	6	1	0	0
49472	1624	in define	[in defining]	1.0	2	1	0	0
49473	1624	effect on LTR activity in	[effect on LTR activity in]	1.0	5	1	0	0
49474	1624	regulation of the transcription factor	[Regulation of the transcription factor]	1.0	5	2	2	2
49475	1624	promoter contain a octamer motif	[promoter containing an octamer motif]	1.0	5	1	0	0
49476	1624	(bear two nf-kappa b site	[(bearing two NF-kappa B sites]	1.0	5	1	0	0
49477	1624	tshr antibody	[TSHR antibody]	1.0	2	1	0	0
49478	1624	only the exon of E1A	[only the exon of E1A]	1.0	5	1	0	0
49479	1624	unique band	[unique band]	1.0	2	1	0	0
49480	1624	several kinase	[several kinases]	1.0	2	2	1	1
49481	1624	cloning of a mitogen-inducible gene	[Cloning of a mitogen-inducible gene]	1.0	5	1	0	0
49482	1624	transient transfection analysis with target plasmid	[Transient transfection analysis with target plasmids]	1.0	6	1	0	0
49483	1624	processing p65	[processing p65]	1.0	2	1	0	0
49484	1624	-proximal region	[-proximal region]	1.0	2	1	0	0
49485	1624	fibroblast from patient with hypercholesteremia	[fibroblasts from patients with hypercholesteremia]	1.0	5	1	0	0
49486	1624	il-1ra production	[IL-1ra production]	1.0	2	2	2	2
49487	1624	inhibition of interleukin-2 receptor alpha	[inhibition of interleukin-2 receptor alpha]	1.0	5	1	0	0
49488	1624	IL-5 synthesis	[IL-5 synthesis]	1.0	2	1	0	0
49489	1624	tumor suppression	[tumor suppression]	1.0	2	1	0	0
49490	1624	addition of anti-cd28 mab induction	[addition of anti-CD28 mAb induction]	1.0	5	1	0	0
49491	1624	Subcellular localization analysis in various cells,	[Subcellular localization analysis in various cells,]	1.0	6	1	0	0
49492	1624	human autosome	[human autosome]	1.0	2	1	0	0
49493	1624	A-CRF with mild-moderate renal insufficiency M-CRF	[A-CRF with mild-moderate renal insufficiency M-CRF]	1.0	6	1	0	0
49494	1624	Specific DNA protein complex formation	[Specific DNA protein complex formation]	1.0	5	1	0	0
49495	1624	cell growth in the system	[cell growth in the system]	1.0	5	1	0	0
49496	1624	th1/th2-like cytokine	[Th1/Th2-like cytokines]	1.0	2	1	0	0
49497	1624	7td1 cell	[7TD1 cells]	1.0	2	1	0	0
49498	1624	transactivation activity in this complex	[transactivation activity in this complex]	1.0	5	1	0	0
49499	1624	alternative promoter	[alternative promoter]	1.0	2	2	1	1
49500	1624	range from 10(-9) to 10(-6) M.	[ranging from 10(-9) to 10(-6) M.]	1.0	6	1	0	0
49501	1624	further examination of this system	[Further examination of this system]	1.0	5	1	0	0
49502	1624	blue exclusion	[blue exclusion]	1.0	2	2	1	1
49503	1624	two dhs in intron 2	[two DHS in intron 2]	1.0	5	1	0	0
49504	1624	human androgen	[human androgen]	1.0	2	2	1	1
49505	1624	vitro exposure of mononuclear cell	[vitro exposure of mononuclear cells]	1.0	5	1	0	0
49506	1624	1 carboxyl-terminal peptide in jy25 cell	[1 carboxyl-terminal peptide in JY25 cells]	1.0	6	1	0	0
49507	1624	none of the signal-mediating kinase	[none of the signal-mediating kinases]	1.0	5	1	0	0
49508	1624	ptf-oct-1-dna complex	[PTF-Oct-1-DNA complex]	1.0	2	1	0	0
49509	1624	non-fusion protein	[non-fusion protein]	1.0	2	1	0	0
49510	1624	include 1 case without detectable calm	[including 1 case without detectable CALM]	1.0	6	1	0	0
49511	1624	other immunosuppressant	[other immunosuppressants]	1.0	2	1	0	0
49512	1624	specific modification of a cofactor	[specific modification of a cofactor]	1.0	5	1	0	0
49513	1624	alveoli, elevation of bronchoalveolar lavage cellularity	[alveoli, elevation of bronchoalveolar lavage cellularity]	1.0	6	1	0	0
49514	1624	human hiv-1	[human HIV-1]	1.0	2	1	0	0
49515	1624	minor groove	[minor groove]	1.0	2	1	0	0
49516	1624	full activity	[Full activity]	1.0	2	1	0	0
49517	1624	induction of vascular cell adhesion molecule-1	[Induction of vascular cell adhesion molecule-1]	1.0	6	1	0	0
49518	1624	current opinion	[current opinion]	1.0	2	1	0	0
49519	1624	3h-tdr incorporation	[3H-TdR incorporation]	1.0	2	1	0	0
49520	1624	tissue-specific expression of interleukin-3 il-3	[Tissue-specific expression of interleukin-3 IL-3]	1.0	5	1	0	0
49521	1624	beta gene in Jurkat cell	[beta genes in Jurkat cells]	1.0	5	1	0	0
49522	1624	Deoxycholate treatment of the cytoplasmic extract	[Deoxycholate treatment of the cytoplasmic extract]	1.0	6	1	0	0
49523	1624	patient with bare lymphocyte syndrome	[patients with bare lymphocyte syndrome]	1.0	5	1	0	0
49524	1624	kd change	[Kd change]	1.0	2	1	0	0
49525	1624	binding of IL-2 to receptor	[binding of IL-2 to receptor]	1.0	5	1	0	0
49526	1624	nonreceptor tyrosine kinase from plc-gamma1	[nonreceptor tyrosine kinases from PLC-gamma1]	1.0	5	1	0	0
49527	1624	role of 135eoh)2d3 -vdr interaction	[role of 1,25(OH)2D3 -VDR interaction]	1.0	5	1	0	0
49528	1624	human k562	[human K562]	1.0	2	1	0	0
49529	1624	essentially normal tgf-beta receptor profile	[essentially normal TGF-beta receptor profile]	1.0	5	1	0	0
49530	1624	CD40 by CD40 ligand cd40l	[CD40 by CD40 ligand CD40L]	1.0	5	1	0	0
49531	1624	three distinct element within the enhancer	[three distinct elements within the enhancer]	1.0	6	1	0	0
49532	1624	various stimuli.	[various stimuli.]	1.0	2	1	0	0
49533	1624	various stimuli,	[Various stimuli,]	1.0	2	1	0	0
49534	1624	synergy between signal transduction pathway	[Synergy between signal transduction pathways]	1.0	5	1	0	0
49535	1624	cd4+ T lymphocyte in patient	[CD4+ T lymphocytes in patients]	1.0	5	1	0	0
49536	1624	FDCP-2 cell	[FDCP-2 cells]	1.0	2	1	0	0
49537	1624	transduce signal from this receptor	[transduce signals from these receptors]	1.0	5	1	0	0
49538	1624	physiological molecule	[physiological molecules]	1.0	2	1	0	0
49539	1624	ZEBRA activation domain swap construct	[ZEBRA activation domain swap constructs]	1.0	5	1	0	0
49540	1624	cd45 in human T cell	[CD45 in human T cells]	1.0	5	1	0	0
49541	1624	natural ligand gp39-cd8 fusion protein	[natural ligand gp39-CD8 fusion protein]	1.0	5	1	0	0
49542	1624	5 min,	[5 min,]	1.0	2	1	0	0
49543	1624	direct immunoprecipitation	[direct immunoprecipitation]	1.0	2	1	0	0
49544	1624	change in this signal molecule	[Changes in these signaling molecules]	1.0	5	1	0	0
49545	1624	100 ng/ml)	[100 ng/mL)]	1.0	2	1	0	0
49546	1624	oligonucleotide primer	[Oligonucleotide primers]	1.0	2	2	1	1
49547	1624	il-4r p140	[IL-4R p140]	1.0	2	1	0	0
49548	1624	characterization of cis -regulatory element	[characterization of cis -regulatory elements]	1.0	5	1	0	0
49549	1624	functional effect of this interaction	[functional effects of these interactions]	1.0	5	1	0	0
49550	1624	ro 25-7386	[Ro 25-7386]	1.0	2	1	0	0
49551	1624	reticulocyte TRs	[reticulocyte TRs]	1.0	2	1	0	0
49552	1624	pkc mutant	[PKC mutants]	1.0	2	1	0	0
49553	1624	BASH a novel signal molecule	[BASH a novel signaling molecule]	1.0	5	1	0	0
49554	1624	promyelocytic (apl)	[promyelocytic (APL)]	1.0	2	1	0	0
49555	1624	type 2 T lymphocyte th2	[type 2 T lymphocytes Th2]	1.0	5	1	0	0
49556	1624	role in the immune response	[role in the immune response]	1.0	5	1	0	0
49557	1624	pulse exposure of hl60 to hormone	[Pulse exposure of HL60 to hormone]	1.0	6	1	0	0
49558	1624	chloramphenicol acetyltransferase expression construct contain region	[Chloramphenicol acetyltransferase expression constructs containing regions]	1.0	6	1	0	0
49559	1624	th2-specific expression of the interleukin-5 gene	[Th2-specific expression of the interleukin-5 gene]	1.0	6	1	0	0
49560	1624	results: phorbol-myristate-acetate	[RESULTS: Phorbol-myristate-acetate]	1.0	2	1	0	0
49561	1624	signal transduction through IFN-gammaR on eosinophil	[signal transduction through IFN-gammaR on eosinophils]	1.0	6	1	0	0
49562	1624	concentration-dependent manner,	[concentration-dependent manner,]	1.0	2	2	1	1
49563	1624	rapid action	[rapid action]	1.0	2	2	2	2
49564	1624	response to initial signal event	[response to initial signaling events]	1.0	5	1	0	0
49565	1624	asymptomatic twin	[asymptomatic twin]	1.0	2	1	0	0
49566	1624	receptor/stat interaction	[Receptor/Stat interaction]	1.0	2	1	0	0
49567	1624	hie than control subject pg/ml	[HIE than control subjects pg/mL]	1.0	5	1	0	0
49568	1624	characterization of a CD43/leukosialin pathway	[Characterization of a CD43/leukosialin pathway]	1.0	5	1	0	0
49569	1624	clinical considerations.	[clinical considerations.]	1.0	2	1	0	0
49570	1624	feature suggestive of a migration	[features suggestive of an migration]	1.0	5	1	0	0
49571	1624	biochemical mechanism underlie this response	[biochemical mechanism underlying this response]	1.0	5	1	0	0
49572	1624	contain mutation in the ap-1(iii)	[containing mutations in the AP-1(III)]	1.0	5	1	0	0
49573	1624	human rar-alpha	[human RAR-alpha]	1.0	2	1	0	0
49574	1624	replication defect for most mutants.	[replication defects for most mutants.]	1.0	5	1	0	0
49575	1624	Fabry disease a disorder result	[Fabry disease an disorder resulting]	1.0	5	1	0	0
49576	1624	similar capacity	[similar capacity]	1.0	2	2	1	1
49577	1624	g-csf growth	[G-CSF growth]	1.0	2	1	0	0
49578	1624	detectable level of c-jun transcription	[detectable levels of c-jun transcription]	1.0	5	1	0	0
49579	1624	hla-dr fashion	[HLA-DR fashion]	1.0	2	1	0	0
49580	1624	NF-kappa b-	[NF-kappa B-]	1.0	2	1	0	0
49581	1624	er enzyme immunoassay er -eia	[ER enzyme immunoassay ER -EIA]	1.0	5	1	0	0
49582	1624	Ter cell	[Ter cells]	1.0	2	2	2	2
49583	1624	distribution of nf-at transcriptional activity	[distribution of NF-AT transcriptional activity]	1.0	5	1	0	0
49584	1624	a-induced growth	[A-induced growth]	1.0	2	1	0	0
49585	1624	human cancer	[human cancers]	1.0	2	1	0	0
49586	1624	binding property	[binding properties]	1.0	2	2	1	1
49587	1624	human immunodeficiency virus-1 tat protein	[human immunodeficiency virus-1 Tat protein]	1.0	5	1	0	0
49588	1624	activate region	[activating region]	1.0	2	2	2	2
49589	1624	cytoplasmic inhibitor of nf-kappa b	[cytoplasmic inhibitor of NF-kappa B]	1.0	5	1	0	0
49590	1624	high-proliferative potential colony-forming cell hppecfcs	[high-proliferative potential colony-forming cells HPP-CFCs]	1.0	5	1	0	0
49591	1624	malignant expansion	[malignant expansion]	1.0	2	1	0	0
49592	1624	expression of fas ligand fasl	[expression of Fas ligand FasL]	1.0	5	1	0	0
49593	1624	insight into the mechanism of senescence	[insight into the mechanisms of senescence]	1.0	6	1	0	0
49594	1624	gm-csfr alpha	[GM-CSFR alpha]	1.0	2	1	0	0
49595	1624	human immunodeficiency virus-type 1 hiv-1	[Human immunodeficiency virus-type 1 HIV-1]	1.0	5	1	0	0
49596	1624	series of drand_ reporter construct	[series of DRA/DQB reporter constructs]	1.0	5	1	0	0
49597	1624	erythroid protein to the silencer	[erythroid proteins to the silencer]	1.0	5	1	0	0
49598	1624	inert quality	[inert quality]	1.0	2	1	0	0
49599	1624	outside-in signal for cellular activation	[outside-in signals for cellular activation]	1.0	5	1	0	0
49600	1624	bandshift analysis	[bandshift analysis]	1.0	2	1	0	0
49601	1624	LMP1 effect	[LMP1 effects]	1.0	2	1	0	0
49602	1624	bcl-6 mrna expression, b cell	[BCL-6 MRNA expression, B cells]	1.0	5	1	0	0
49603	1624	monocytic ikappab kinase signalsome activation	[monocytic IkappaB kinase signalsome activation]	1.0	5	1	0	0
49604	1624	vitro by incubation with dose	[vitro by incubation with doses]	1.0	5	1	0	0
49605	1624	induce nf-kb expression in the nuclei	[inducing NF-KB expression in the nuclei]	1.0	6	1	0	0
49606	1624	high concentration of plasma cortisol	[higher concentration of plasma cortisol]	1.0	5	1	0	0
49607	1624	cd69 promoter-based reporter gene construct	[CD69 promoter-based reporter gene constructs]	1.0	5	1	0	0
49608	1624	introduce mutation into the kappab site	[introducing mutations into the kappaB sites]	1.0	6	1	0	0
49609	1624	novel strategy	[novel strategies]	1.0	2	1	0	0
49610	1624	antiandrogen action	[antiandrogen action]	1.0	2	2	2	2
49611	1624	use a pkc -specific inhibitor	[Using a PKC -specific inhibitor]	1.0	5	1	0	0
49612	1624	only the 5' 62 base pair	[only the 5' 62 base pairs]	1.0	6	1	0	0
49613	1624	BMLF1 of the six early protein	[BMLF1 of the six early proteins]	1.0	6	1	0	0
49614	1624	soluble beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer	[soluble beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer]	1.0	5	1	0	0
49615	1624	other neoplasm	[other neoplasms]	1.0	2	1	0	0
49616	1624	little capacity	[little capacity]	1.0	2	1	0	0
49617	1624	g0 phase	[G0 phase]	1.0	2	2	1	1
49618	1624	activation of the tal1 gene	[activation of the TAL1 gene]	1.0	5	1	0	0
49619	1624	regulation of the nuclear factor	[Regulation of the nuclear factor]	1.0	5	1	0	0
49620	1624	molecular mechanism of Rb rescue	[molecular mechanism of Rb rescue]	1.0	5	1	0	0
49621	1624	Th0 clone	[Th0 clones]	1.0	2	1	0	0
49622	1624	profound pathogenesis	[profound pathogenesis]	1.0	2	1	0	0
49623	1624	dexamethasone dex	[dexamethasone Dex]	1.0	2	1	0	0
49624	1624	function of MCM gene product	[function of MCM gene products]	1.0	5	1	0	0
49625	1624	selective manner.	[selective manner.]	1.0	2	1	0	0
49626	1624	cell-type-specific transcription in b lymphocyte	[cell-type-specific transcription in B lymphocytes]	1.0	5	1	0	0
49627	1624	cytokine -secret effector th cell	[cytokine -secreting effector Th cells]	1.0	5	1	0	0
49628	1624	dlcl development.	[DLCL development.]	1.0	2	1	0	0
49629	1624	receive 5-fluorouracil FUra as adjuvant chemotherapy	[receiving 5-fluorouracil FUra as adjuvant chemotherapy]	1.0	6	1	0	0
49630	1624	acetylsalicylic acid	[Acetylsalicylic acid]	1.0	2	2	1	1
49631	1624	complete coding sequence of mrna	[complete coding sequence of mRNA]	1.0	5	1	0	0
49632	1624	hgata-1 transactivation	[hGATA-1 transactivation]	1.0	2	1	0	0
49633	1624	matrix metalloproteinase-9 in this model system	[matrix metalloproteinase-9 in this model system]	1.0	6	1	0	0
49634	1624	LMP-1 a Epstein-Barr virus membrane protein	[LMP-1 an Epstein-Barr virus membrane protein]	1.0	6	1	0	0
49635	1624	series of pp repeat element	[series of pp repeat elements]	1.0	5	1	0	0
49636	1624	use of a arrest assay	[use of a arrest assay]	1.0	5	1	0	0
49637	1624	p50/rela(p65) heterodimer	[p50/RelA(p65) heterodimers]	1.0	2	2	1	1
49638	1624	inhibition of cytokine production by PBMC	[Inhibition of cytokine production by PBMC]	1.0	6	1	0	0
49639	1624	obscure, several line of investigation	[obscure, several lines of investigation]	1.0	5	1	0	0
49640	1624	sds-gel electrophoresis	[SDS-gel electrophoresis]	1.0	2	1	0	0
49641	1624	dexamethasone treatment of a cell clone	[Dexamethasone treatment of a cell clone]	1.0	6	1	0	0
49642	1624	more cortivazol than the normal cell	[more cortivazol than the normal cells]	1.0	6	2	1	1
49643	1624	cellular substrate	[cellular substrates]	1.0	2	2	2	2
49644	1624	inhibition of apoptosis in eosinophil	[Inhibition of apoptosis in eosinophils]	1.0	5	1	0	0
49645	1624	homing receptor	[homing receptor]	1.0	2	2	1	1
49646	1624	mrna expression in cd4+ T cell	[mRNA expression in CD4+ T cells]	1.0	6	1	0	0
49647	1624	effective therapy	[effective therapy]	1.0	2	2	1	1
49648	1624	respond cell	[responding cells]	1.0	2	1	0	0
49649	1624	hbx-antigen of hepatitis b virus	[HBx-antigen of hepatitis B virus]	1.0	5	1	0	0
49650	1624	other transcription factor of possible importance	[other transcription factors of possible importance]	1.0	6	1	0	0
49651	1624	primarily by lps a constituent	[primarily by LPS a constituent]	1.0	5	1	0	0
49652	1624	minimum region	[minimum region]	1.0	2	1	0	0
49653	1624	crucial role in the development	[crucial role in the development]	1.0	5	1	0	0
49654	1624	alternative pathway of Tat activation	[alternative pathway of Tat activation]	1.0	5	1	0	0
49655	1624	Vpr suppression	[Vpr suppression]	1.0	2	1	0	0
49656	1624	evidence for a inducible autoregulatory pathway	[evidence for an inducible autoregulatory pathway]	1.0	6	1	0	0
49657	1624	interaction at the octamer site	[interaction at the octamer site]	1.0	5	2	1	1
49658	1624	il-4 b cell in vitro.	[IL-4 B cells in vitro.]	1.0	5	1	0	0
49659	1624	transcriptional trans-activator	[transcriptional trans-activator]	1.0	2	2	1	1
49660	1624	tissue rich in fibrillar collagen	[tissues rich in fibrillar collagen]	1.0	5	1	0	0
49661	1624	pulse-field gel electrophoresis (pfge) analysis	[Pulse-field gel electrophoresis (PFGE) analysis]	1.0	5	1	0	0
49662	1624	oligosaccharide residue	[oligosaccharide residues]	1.0	2	1	0	0
49663	1624	raji cell ebv -positive b-cell	[Raji cells EBV -positive B-cell]	1.0	5	1	0	0
49664	1624	vla-5 receptor on CD4 cell	[VLA-5 receptor on CD4 cells]	1.0	5	1	0	0
49665	1624	(il-1ra) messenger ribonucleic acid (mrna) expression	[(IL-1ra) messenger ribonucleic acid (mRNA) expression]	1.0	6	1	0	0
49666	1624	intracellular action	[intracellular actions]	1.0	2	1	0	0
49667	1624	select the most specific oligonucleotide sequence	[selecting the most specific oligonucleotide sequence]	1.0	6	1	0	0
49668	1624	however, expression	[However, expression]	1.0	2	2	2	2
49669	1624	binding of the prominent factor,	[binding of the prominent factor,]	1.0	5	1	0	0
49670	1624	240 minute	[240 minutes]	1.0	2	2	2	2
49671	1624	IL-4 -dependent regulation of tgf-alpha expression	[IL-4 -dependent regulation of TGF-alpha expression]	1.0	6	1	0	0
49672	1624	expression of oncoproteins, cell transformation,	[expression of oncoproteins, cell transformation,]	1.0	5	1	0	0
49673	1624	depend on NF-kappa b activation	[depending on NF-kappa B activation]	1.0	5	1	0	0
49674	1624	alteration in signal transduction pathway	[alterations in signal transduction pathways]	1.0	5	1	0	0
49675	1624	initial enzyme	[initial enzyme]	1.0	2	1	0	0
49676	1624	tnfr1 signal	[TNFR1 signaling]	1.0	2	1	0	0
49677	1624	weak constitutive activation of NFkappaB	[weak constitutive activation of NFkappaB]	1.0	5	1	0	0
49678	1624	macrolide rapamycin	[macrolide rapamycin]	1.0	2	1	0	0
49679	1624	vaccination with a CTL epitope	[vaccination with a CTL epitope]	1.0	5	1	0	0
49680	1624	5-day anti-CD3	[5-day anti-CD3]	1.0	2	1	0	0
49681	1624	interferon-gamma receptor on human eosinophil	[interferon-gamma receptor on human eosinophils]	1.0	5	1	0	0
49682	1624	interconversion of the cis- rotamer	[interconversion of the cis- rotamers]	1.0	5	1	0	0
49683	1624	ms-2 erratum	[MS-2 erratum]	1.0	2	1	0	0
49684	1624	single strand conformation polymorphism (sscp) analysis	[Single strand conformation polymorphism (SSCP) analysis]	1.0	6	1	0	0
49685	1624	HB24 mrna	[HB24 mRNA]	1.0	2	1	0	0
49686	1624	endotoxin lipopolysaccharide	[endotoxin lipopolysaccharide]	1.0	2	2	2	2
49687	1624	u-937 monocyte-like cell to huvec	[U-937 monocyte-like cells to HUVECs]	1.0	5	1	0	0
49688	1624	identification of intergenic fusion transcript	[identification of intergenic fusion transcripts]	1.0	5	1	0	0
49689	1624	0.23 p less than 0.001)	[0.23, P less than 0.001)]	1.0	5	1	0	0
49690	1624	ambiguity intrinsic to molecular study	[ambiguities intrinsic to molecular studies]	1.0	5	1	0	0
49691	1624	competitive inhibitor of Jun phosphorylation	[competitive inhibitor of Jun phosphorylation]	1.0	5	1	0	0
49692	1624	similar level of NF kappa b	[similar levels of NF kappa B]	1.0	6	1	0	0
49693	1624	contain mutant glucocorticoid receptor l753f	[containing mutant glucocorticoid receptors L753F]	1.0	5	1	0	0
49694	1624	myeloblast-derived lambda	[myeloblast-derived lambda]	1.0	2	1	0	0
49695	1624	methylation pattern	[methylation patterns]	1.0	2	1	0	0
49696	1624	additional enhancement of ifn-gamma production	[additional enhancement of IFN-gamma production]	1.0	5	1	0	0
49697	1624	expression of tip in jurkat-t cell	[Expression of Tip in Jurkat-T cells]	1.0	6	1	0	0
49698	1624	5 minute of monocyte adhesion	[5 min of monocyte adhesion]	1.0	5	1	0	0
49699	1624	equal, unequal paternal expression in three,	[equal, unequal paternal expression in three,]	1.0	6	1	0	0
49700	1624	express the CD28 ligand CD80	[expressing the CD28 ligands CD80]	1.0	5	1	0	0
49701	1624	protein differ only at amino termini	[proteins differing only at amino termini]	1.0	6	1	0	0
49702	1624	BCL-6 expression	[BCL-6 expression]	1.0	2	2	1	1
49703	1624	subsequent release of bioactive m-csf protein	[subsequent release of bioactive M-CSF protein]	1.0	6	1	0	0
49704	1624	response to phorbol myristate acetate	[response to phorbol myristate acetate]	1.0	5	1	0	0
49705	1624	cotransfection of a yb-1 expression plasmid	[Cotransfection of a YB-1 expression plasmid]	1.0	6	1	0	0
49706	1624	sequence requirement for il-4 expression	[sequence requirements for IL-4 expression]	1.0	5	1	0	0
49707	1624	objective: activation of the hypothalamic-pituitary-adrenal axis	[OBJECTIVE: Activation of the hypothalamic-pituitary-adrenal axis]	1.0	6	1	0	0
49708	1624	ln T	[LN T]	1.0	2	2	2	2
49709	1624	Circadian rhythm in glucocorticoid receptor gr	[Circadian rhythm in glucocorticoid receptor GR]	1.0	6	1	0	0
49710	1624	cd4+ cd8+ T cell subpopulation	[CD4+ CD8+ T cell subpopulations]	1.0	5	1	0	0
49711	1624	stress-activated kinase pathway SAPK /jnk	[stress-activated kinase pathway SAPK /JNK]	1.0	5	1	0	0
49712	1624	asthma bronchiale	[asthma bronchiale]	1.0	2	1	0	0
49713	1624	only the inhibition of reporter activation	[only the inhibition of reporter activation]	1.0	6	1	0	0
49714	1624	MHC class ii homologous protein	[MHC class II homologous proteins]	1.0	5	1	0	0
49715	1624	various type	[various type]	1.0	2	3	2	1
49716	1624	induction of a distinct set	[induction of a distinct set]	1.0	5	1	0	0
49717	1624	hla-a2 molecule	[HLA-A2 molecule]	1.0	2	1	0	0
49718	1624	oct2 protein in enhancer activation	[Oct2 protein in enhancer activation]	1.0	5	1	0	0
49719	1624	icam-1 induction	[ICAM-1 induction]	1.0	2	1	0	0
49720	1624	thus initiate dna-unwinding a prerequisite	[thus initiating DNA-unwinding a prerequisite]	1.0	5	1	0	0
49721	1624	two serine	[two serines]	1.0	2	1	0	0
49722	1624	splice alternative	[splice alternatives]	1.0	2	2	2	2
49723	1624	deletion of the long arm	[deletion of the long arm]	1.0	5	1	0	0
49724	1624	NF-kappa b /rel family protein	[NF-kappa B /Rel family proteins]	1.0	5	1	0	0
49725	1624	pathophysiological relevance	[pathophysiological relevance]	1.0	2	1	0	0
49726	1624	distinct intrinsic DNA binding affinity	[distinct intrinsic DNA binding affinities]	1.0	5	1	0	0
49727	1624	less extent.	[lesser extent.]	1.0	2	1	0	0
49728	1624	progesterone antagonist	[progesterone antagonist]	1.0	2	2	2	2
49729	1624	uterine decidua	[uterine decidua]	1.0	2	1	0	0
49730	1624	CCAAT element present in orientation	[CCAAT element present in orientation]	1.0	5	1	0	0
49731	1624	protein turnover-degradation	[protein turnover-degradation]	1.0	2	1	0	0
49732	1624	induction of po-b DNA binding	[induction of PO-B DNA binding]	1.0	5	1	0	0
49733	1624	gc insensitivity in this condition	[GC insensitivity in this condition]	1.0	5	1	0	0
49734	1624	integrin on human neutrophil granulocyte	[integrins on human neutrophil granulocytes]	1.0	5	1	0	0
49735	1624	antigenic challenge, cytokine gene expression	[antigenic challenge, cytokine gene expression]	1.0	5	1	0	0
49736	1624	recent advance	[recent advances]	1.0	2	3	2	1
49737	1624	ic50 in the low micromolar range).	[IC50s in the low micromolar range).]	1.0	6	1	0	0
49738	1624	control of the il-5 gene	[control of the IL-5 gene]	1.0	5	1	0	0
49739	1624	A-to-G transition	[A-to-G transition]	1.0	2	1	0	0
49740	1624	first presentation.	[first presentation.]	1.0	2	1	0	0
49741	1624	However, BAL content of C5a	[However, BAL content of C5a]	1.0	5	1	0	0
49742	1624	cyclic AMP -responsive element -dependent activation	[Cyclic AMP -responsive element -dependent activation]	1.0	6	1	0	0
49743	1624	calcium -independent CD28 -specific pathway	[calcium -independent CD28 -specific pathway]	1.0	5	1	0	0
49744	1624	carboxy terminal	[carboxy terminal]	1.0	2	2	1	1
49745	1624	suppress transcription of erythrocyte-specific gene	[suppressing transcription of erythrocyte-specific genes]	1.0	5	1	0	0
49746	1624	distinct regulation	[distinct regulation]	1.0	2	2	2	2
49747	1624	1 cell	[1 cells]	1.0	2	1	0	0
49748	1624	hmg-coa synthase	[HMG-CoA synthase]	1.0	2	1	0	0
49749	1624	viral pathogenicity	[viral pathogenicity]	1.0	2	1	0	0
49750	1624	small region	[small region]	1.0	2	2	2	2
49751	1624	same family,	[same family,]	1.0	2	1	0	0
49752	1624	BCL-6 gene	[BCL-6 gene]	1.0	2	2	1	1
49753	1624	co-ligation of the a6h antigen	[Co-ligation of the A6H antigen]	1.0	5	1	0	0
49754	1624	Stat4 action on Th1 development	[Stat4 actions on Th1 development]	1.0	5	1	0	0
49755	1624	adherence dependent,	[adherence dependent,]	1.0	2	1	0	0
49756	1624	important role in the development	[important role in the development]	1.0	5	1	0	0
49757	1624	plasma adrenocorticotropin	[plasma adrenocorticotropin]	1.0	2	1	0	0
49758	1624	ap-2 antibody	[AP-2 antibodies]	1.0	2	1	0	0
49759	1624	cd4+ cd8-	[CD4+ CD8-]	1.0	2	1	0	0
49760	1624	cd4+ cd8+	[CD4+ CD8+]	1.0	2	1	0	0
49761	1624	granulocyte/macrophage-colony-stimulating factor	[granulocyte/macrophage-colony-stimulating factor]	1.0	2	1	0	0
49762	1624	early phase	[early phase]	1.0	2	4	3	1
49763	1624	similar increase in il-2r alpha	[similar increase in IL-2R alpha]	1.0	5	1	0	0
49764	1624	gene encode gamma-globin deaminase pbgd	[genes encoding gamma-globin deaminase PBGD]	1.0	5	1	0	0
49765	1624	phosphatase treatment	[phosphatase treatment]	1.0	2	1	0	0
49766	1624	individual cd4+	[individual CD4+]	1.0	2	1	0	0
49767	1624	product of the murine homolog	[product of the murine homolog]	1.0	5	1	0	0
49768	1624	virtual abrogation of the activation	[virtual abrogation of the activation]	1.0	5	1	0	0
49769	1624	identification of a novel factor	[Identification of a novel factor]	1.0	5	1	0	0
49770	1624	env mrna	[env mRNA]	1.0	2	1	0	0
49771	1624	U-937 as a model study alteration	[U-937 as a model studying alterations]	1.0	6	1	0	0
49772	1624	erythrocyte membrane	[erythrocyte membranes]	1.0	2	2	1	1
49773	1624	trans-activation of a IL-4 -inducible reporter	[trans-activation of an IL-4 -inducible reporter]	1.0	6	1	0	0
49774	1624	primary culture of leukemia cell	[primary culture of leukemia cells]	1.0	5	1	0	0
49775	1624	concern the nature of ebv latency	[concerning the nature of EBV latency]	1.0	6	1	0	0
49776	1624	cell-to-cell activation of hiv-1 LTR	[cell-to-cell activation of HIV-1 LTR]	1.0	5	1	0	0
49777	1624	repertoire heterogeneity,	[repertoire heterogeneity,]	1.0	2	1	0	0
49778	1624	CD4 trigger on T cell	[CD4 triggering on T cell]	1.0	5	1	0	0
49779	1624	TCR engagement	[TCR engagement]	1.0	2	1	0	0
49780	1624	subsequent apoptosis in T lymphocyte	[subsequent apoptosis in T lymphocytes]	1.0	5	1	0	0
49781	1624	important target of hiv infection	[important targets of HIV infection]	1.0	5	1	0	0
49782	1624	long outgrowth	[long-term outgrowth]	1.0	2	1	0	0
49783	1624	include adherence of the cell	[including adherence of the cells]	1.0	5	1	0	0
49784	1624	Functional study with IL-6 promoter	[Functional studies with IL-6 promoter]	1.0	5	1	0	0
49785	1624	factor nf-gm2	[factor NF-GM2]	1.0	2	2	2	2
49786	1624	novel domain	[novel domain]	1.0	2	2	2	2
49787	1624	suggest autoregulatory control of gata-1 transcription	[suggesting autoregulatory control of GATA-1 transcription]	1.0	6	1	0	0
49788	1624	group I Burkitt tumor cell	[group I Burkitt tumor cells]	1.0	5	1	0	0
49789	1624	Consequently, inhibition of nf-kappab nuclear translocation	[Consequently, inhibition of NF-kappaB nuclear translocation]	1.0	6	1	0	0
49790	1624	monochloramine derivative	[Monochloramine derivatives]	1.0	2	1	0	0
49791	1624	exogenous e1	[exogenous E1]	1.0	2	1	0	0
49792	1624	T lymphocytic cell line Jurkat	[T lymphocytic cell line Jurkat]	1.0	5	1	0	0
49793	1624	significant effect on the ability	[significant effects on the ability]	1.0	5	1	0	0
49794	1624	EGF treatment	[EGF treatment]	1.0	2	2	1	1
49795	1624	reduction of IkappaBalpha by DZA	[reduction of IkappaBalpha by DZA]	1.0	5	1	0	0
49796	1624	(tnf) receptor	[(TNF) receptors]	1.0	2	1	0	0
49797	1624	tnf-alpha signalling	[TNF-alpha signalling]	1.0	2	1	0	0
49798	1624	CTL response to virus infection	[CTL response to virus infection]	1.0	5	1	0	0
49799	1624	regulate signal by virtue of ability	[regulating signaling by virtue of ability]	1.0	6	1	0	0
49800	1624	expression of this two protein	[expression of these two proteins]	1.0	5	2	1	1
49801	1624	use vector contain wild-type kappab site	[using vectors containing wild-type kappaB sites]	1.0	6	1	0	0
49802	1624	hypo eu hyper thyroid patient	[hypo eu hyper thyroid patients]	1.0	5	1	0	0
49803	1624	synergy between the kinase c activation	[synergy between the kinase C activation]	1.0	6	1	0	0
49804	1624	transient activity.	[transient activity.]	1.0	2	1	0	0
49805	1624	several assay	[several assays]	1.0	2	1	0	0
49806	1624	restoration of murine il-2 mrna	[restoration of murine IL-2 mRNA]	1.0	5	1	0	0
49807	1624	repressor of non-heat shock gene	[repressor of non-heat shock genes]	1.0	5	1	0	0
49808	1624	chemical mismatch	[chemical mismatch]	1.0	2	1	0	0
49809	1624	examination of the amino acid sequence	[Examination of the amino acid sequence]	1.0	6	1	0	0
49810	1624	soluble interleukin-2 receptor -alpha IL-2Ralpha	[Soluble interleukin-2 receptor -alpha IL-2Ralpha]	1.0	5	1	0	0
49811	1624	clone in the presence of IFN-alpha	[clones in the presence of IFN-alpha]	1.0	6	1	0	0
49812	1624	suggest a possible role of Ras	[suggesting a possible role of Ras]	1.0	6	1	0	0
49813	1624	tumor necrosis factor alpha tnfalpha	[tumor necrosis factor alpha TNFalpha]	1.0	5	1	0	0
49814	1624	three family	[three families]	1.0	2	1	0	0
49815	1624	26 squamous cell carcinoma SCC	[26 squamous cell carcinomas SCCs]	1.0	5	1	0	0
49816	1624	thus, cosignaling via the lt-beta	[Thus, cosignaling via the LT-beta]	1.0	5	1	0	0
49817	1624	dox-treated cell	[DOX-treated cells]	1.0	2	1	0	0
49818	1624	binding capacity (4978+/-391 versus 4131+/-321	[Binding capacity (4978+/-391 versus 4131+/-321]	1.0	5	1	0	0
49819	1624	activation of ap-1 by PMA	[activation of AP-1 by PMA]	1.0	5	2	1	1
49820	1624	completely substitute for the ca2+ co-stimulus	[completely substitutes for the Ca2+ co-stimulus]	1.0	6	1	0	0
49821	1624	cellular differentiation.	[cellular differentiation.]	1.0	2	1	0	0
49822	1624	adenovirus-transformed cell	[adenovirus-transformed cells]	1.0	2	1	0	0
49823	1624	consequence of p80c-rel tyrosine phosphorylation	[consequences of p80c-rel tyrosine phosphorylation]	1.0	5	1	0	0
49824	1624	second transformation effector site TES2	[second transformation effector site TES2]	1.0	5	1	0	0
49825	1624	glycogen synthase	[glycogen synthase]	1.0	2	2	1	1
49826	1624	expression of the BSAP gene	[expression of the BSAP gene]	1.0	5	1	0	0
49827	1624	tnf-alpha degradation	[TNF-alpha degradation]	1.0	2	2	2	2
49828	1624	gel shift analysis on nuclear extract	[gel shift analysis on nuclear extracts]	1.0	6	1	0	0
49829	1624	transcription of certain pro-inflammatory mediator	[transcription of certain pro-inflammatory mediators]	1.0	5	1	0	0
49830	1624	DNA binding activity of nuclear extract	[DNA binding activity of nuclear extracts]	1.0	6	1	0	0
49831	1624	75 kilometer	[75 kd]	1.0	2	2	1	1
49832	1624	IFN response	[IFN response]	1.0	2	1	0	0
49833	1624	hormonal response	[hormonal responses]	1.0	2	1	0	0
49834	1624	rt- pcr	[RT- PCR]	1.0	2	3	2	1
49835	1624	protooncogene p21ras	[protooncogene p21ras]	1.0	2	1	0	0
49836	1624	25(OH)D3 transport	[25(OH)D3 transport]	1.0	2	1	0	0
49837	1624	individual experiments).	[individual experiments).]	1.0	2	1	0	0
49838	1624	CD40 induction of b cell	[CD40 induction of B cells]	1.0	5	1	0	0
49839	1624	CD40 -ig	[CD40 -Ig]	1.0	2	1	0	0
49840	1624	alpha thf/thf	[alpha THF/THF]	1.0	2	2	2	2
49841	1624	anti-sense rna to SRG3 mrna	[anti-sense RNA to SRG3 mRNA]	1.0	5	1	0	0
49842	1624	transcription factor binding to dna.	[transcription factor binding to DNA.]	1.0	5	1	0	0
49843	1624	leukocyte adherence	[leukocyte adherence]	1.0	2	1	0	0
49844	1624	expression of the b2 subunit	[expression of the B2 subunit]	1.0	5	1	0	0
49845	1624	zap-70 activation	[zap-70 activation]	1.0	2	1	0	0
49846	1624	developmental stage-	[developmental stage-]	1.0	2	1	0	0
49847	1624	uncommitted T	[uncommitted T]	1.0	2	1	0	0
49848	1624	response to T cell activation signal	[Response to T cell activation signals]	1.0	6	1	0	0
49849	1624	nine sequence	[nine sequences]	1.0	2	1	0	0
49850	1624	fundamental role	[fundamental role]	1.0	2	2	1	1
49851	1624	first description	[first description]	1.0	2	3	2	1
49852	1624	human immunodeficiency virus hiv promoter	[human immunodeficiency virus HIV promoter]	1.0	5	1	0	0
49853	1624	inducible T	[inducible T]	1.0	2	1	0	0
49854	1624	phorbol ester such as 12-o-tetradecanoyl-phorbol-13 acetate	[phorbol esters such as 12-O-tetradecanoyl-phorbol-13 acetate]	1.0	6	1	0	0
49855	1624	effect of ts on NFkappaB	[effects of TS on NFkappaB]	1.0	5	1	0	0
49856	1624	one case	[one case]	1.0	2	2	2	2
49857	1624	inhibin a	[inhibin A]	1.0	2	1	0	0
49858	1624	compensation mechanism	[compensation mechanism]	1.0	2	1	0	0
49859	1624	oxidant stimulus	[oxidant stimuli]	1.0	2	1	0	0
49860	1624	chronic activation	[chronic activation]	1.0	2	1	0	0
49861	1624	interaction with the pou domain	[interaction with the POU domains]	1.0	5	1	0	0
49862	1624	CMV transactivation	[CMV transactivation]	1.0	2	1	0	0
49863	1624	dual effect on nf-kappab regulation	[dual effects on NF-kappaB regulation]	1.0	5	1	0	0
49864	1624	stage-specific expression of the cd20/b1 antigen	[stage-specific expression of the CD20/B1 antigen]	1.0	6	1	0	0
49865	1624	ap-1 sequence	[AP-1 sequence]	1.0	2	1	0	0
49866	1624	T cell response to some antigens,	[T cell responses to some antigens,]	1.0	6	1	0	0
49867	1624	chromosomal translocation involve the gene	[Chromosomal translocations involving the genes]	1.0	5	1	0	0
49868	1624	use of early receptor binding study	[use of earlier receptor binding studies]	1.0	6	1	0	0
49869	1624	anti-ig antibody in b cell	[anti-Ig antibody in B cells]	1.0	5	1	0	0
49870	1624	immunoblastic lymphoma plasmacytoid AIDS iblp	[immunoblastic lymphoma plasmacytoid AIDS IBLP]	1.0	5	1	0	0
49871	1624	absent type	[Absent type]	1.0	2	1	0	0
49872	1624	low level of ifn-gamma secretion	[low levels of IFN-gamma secretion]	1.0	5	1	0	0
49873	1624	nkl cell on target cell	[NKL cells on target cells]	1.0	5	1	0	0
49874	1624	CMV pneumonitis	[CMV pneumonitis]	1.0	2	1	0	0
49875	1624	binding of various transcription factor	[binding of various transcription factors]	1.0	5	1	0	0
49876	1624	lymphocyte cell	[lymphocyte cell]	1.0	2	2	1	1
49877	1624	potent inductive signal for AP-1	[potent inductive signal for AP-1]	1.0	5	1	0	0
49878	1624	low nm23.h1	[low NM23.H1]	1.0	2	1	0	0
49879	1624	immediate-early gene for ebv replication,	[immediate-early gene for EBV replication,]	1.0	5	1	0	0
49880	1624	selective phosphorylation	[selective phosphorylation]	1.0	2	1	0	0
49881	1624	regulation of hiv by acid	[regulation of HIV by acid]	1.0	5	1	0	0
49882	1624	DNA binding site for factor	[DNA binding sites for factors]	1.0	5	1	0	0
49883	1624	non-depressed control	[non-depressed control]	1.0	2	2	2	2
49884	1624	withdrawal of the antithyroid drug.	[withdrawal of the antithyroid drug.]	1.0	5	1	0	0
49885	1624	Tal-1 rearrangement	[Tal-1 rearrangements]	1.0	2	1	0	0
49886	1624	relevant chromosome,	[relevant chromosome,]	1.0	2	1	0	0
49887	1624	(1) ige production in asthma	[(1) IgE production in asthma]	1.0	5	1	0	0
49888	1624	tata-binding protein	[TATA-binding protein]	1.0	2	2	2	2
49889	1624	tumor necrosis factor-alpha mrna accumulation	[Tumor necrosis factor-alpha mRNA accumulation]	1.0	5	1	0	0
49890	1624	induce the action include member	[inducing the action including members]	1.0	5	1	0	0
49891	1624	haplotype analysis of the patient	[Haplotype analysis of the patient]	1.0	5	1	0	0
49892	1624	induction of the hiv-1 provirus	[induction of the HIV-1 provirus]	1.0	5	1	0	0
49893	1624	calcineurin synergize	[calcineurin synergize]	1.0	2	1	0	0
49894	1624	class major histocompatibility complex promoter	[class major histocompatibility complex promoters]	1.0	5	1	0	0
49895	1624	NMR model	[NMR model]	1.0	2	1	0	0
49896	1624	induction of a nuclear factor	[induction of a nuclear factor]	1.0	5	1	0	0
49897	1624	+/- nmol/l,	[+/- nmol/L,]	1.0	2	1	0	0
49898	1624	low malignancy	[low malignancy]	1.0	2	1	0	0
49899	1624	mammary tissue	[mammary tissue]	1.0	2	2	1	1
49900	1624	add-back experiment with cytokine IL-2	[Add-back experiments with cytokines IL-2]	1.0	5	1	0	0
49901	1624	biochemical fractionation	[biochemical fractionation]	1.0	2	1	0	0
49902	1624	nf kappa b DNA binding	[NF kappa B DNA binding]	1.0	5	1	0	0
49903	1624	signal-induced event	[signal-induced event]	1.0	2	1	0	0
49904	1624	attract chemokine	[attracting chemokines]	1.0	2	1	0	0
49905	1624	tpa responsiveness in transient assay	[TPA responsiveness in transient assays]	1.0	5	1	0	0
49906	1624	relb protein in human accessory cell	[RelB proteins in human accessory cells]	1.0	6	1	0	0
49907	1624	human naive neonatal T lymphocyte	[human naive neonatal T lymphocytes]	1.0	5	1	0	0
49908	1624	alkaline phosphatase activity in assay	[alkaline phosphatase activity in assays]	1.0	5	1	0	0
49909	1624	two site in the cytosol	[two sites in the cytosol]	1.0	5	1	0	0
49910	1624	binding of a ubiquitous polypeptide	[binding of a ubiquitous polypeptide]	1.0	5	1	0	0
49911	1624	cytokine gene in NK cell	[cytokine genes in NK cells]	1.0	5	1	0	0
49912	1624	simultaneous study	[simultaneous study]	1.0	2	2	2	2
49913	1624	latent to active viral infection	[latent to active viral infection]	1.0	5	1	0	0
49914	1624	understanding of the immortalize potential	[understanding of the immortalizing potential]	1.0	5	1	0	0
49915	1624	radioiodine uptake	[radioiodine uptake]	1.0	2	1	0	0
49916	1624	presence of a n-terminal half	[presence of an N-terminal half]	1.0	5	1	0	0
49917	1624	Fusion of the upstream portion	[Fusion of the upstream portion]	1.0	5	1	0	0
49918	1624	retinoid-like receptor	[Retinoid-like receptors]	1.0	2	1	0	0
49919	1624	Oligoclonal expansion of b cell	[Oligoclonal expansion of B cells]	1.0	5	1	0	0
49920	1624	negative regulator,	[negative regulator,]	1.0	2	2	1	1
49921	1624	include f6t	[including F6T]	1.0	2	1	0	0
49922	1624	SCL expression proliferate erythroid cell	[SCL expression proliferating erythroid cells]	1.0	5	1	0	0
49923	1624	partially due to a lower	[partially due to a lowering]	1.0	5	1	0	0
49924	1624	small intestine	[small intestine]	1.0	2	1	0	0
49925	1624	other variable	[Other variables,]	1.0	2	2	2	2
49926	1624	extracellular-regulated kinase-kinase	[extracellular-regulated kinase-kinase]	1.0	2	1	0	0
49927	1624	full er	[full ER]	1.0	2	1	0	0
49928	1624	lethal endotoxemia	[lethal endotoxemia]	1.0	2	1	0	0
49929	1624	2 il-2	[2 IL-2]	1.0	2	1	0	0
49930	1624	nuclear trans-acting	[nuclear trans-acting]	1.0	2	1	0	0
49931	1624	prb of p130 form 3	[pRb of p130 Form 3]	1.0	5	1	0	0
49932	1624	microh chain	[microH chain]	1.0	2	1	0	0
49933	1624	CholecystokininB receptor from jurkat T cell	[CholecystokininB receptor from Jurkat T cells]	1.0	6	1	0	0
49934	1624	rapamycin inhibition of t-cell cycle entry,	[rapamycin inhibition of T-cell cycle entry,]	1.0	6	1	0	0
49935	1624	major difference	[major differences]	1.0	2	2	2	2
49936	1624	kappa b from NF-kappa b	[kappa B from NF-kappa B]	1.0	5	1	0	0
49937	1624	20 mu/l	[20 mU/L]	1.0	2	1	0	0
49938	1624	transient expression of this construct	[transient expression of these constructs]	1.0	5	1	0	0
49939	1624	il-6 induction	[IL-6 induction]	1.0	2	1	0	0
49940	1624	ra-induced differentiation.	[RA-induced differentiation.]	1.0	2	1	0	0
49941	1624	bind dna.	[binding DNA.]	1.0	2	1	0	0
49942	1624	potent androgen	[potent androgens]	1.0	2	1	0	0
49943	1624	65-kD subunit	[65-kD subunit]	1.0	2	1	0	0
49944	1624	lymphoid follicle	[lymphoid follicle]	1.0	2	2	2	2
49945	1624	extrinsic asthmatics	[extrinsic asthmatics]	1.0	2	1	0	0
49946	1624	unstimulated pbl	[unstimulated PBL]	1.0	2	2	1	1
49947	1624	more than 130 kb from sox9	[more than 130 kb from SOX9]	1.0	6	1	0	0
49948	1624	(bhlh) transcription	[(bHLH) transcription]	1.0	2	2	1	1
49949	1624	parallel with the cytokine generation	[parallel with the cytokine generation]	1.0	5	1	0	0
49950	1624	determination of glucocorticoid receptor site	[determination of glucocorticoid receptor sites]	1.0	5	1	0	0
49951	1624	immunoglobulin kappa 3' enhancer kappa e3'	[immunoglobulin kappa 3' enhancer kappa E3']	1.0	6	1	0	0
49952	1624	close match	[closest match]	1.0	2	1	0	0
49953	1624	However, Spi-C	[However, Spi-C]	1.0	2	1	0	0
49954	1624	gene transcription of inflammatory mediator	[gene transcription of inflammatory mediators]	1.0	5	1	0	0
49955	1624	important determinant of cell proliferation	[important determinant of cell proliferation]	1.0	5	1	0	0
49956	1624	200 microgram	[200 micrograms]	1.0	2	1	0	0
49957	1624	two cytokine	[two cytokines]	1.0	2	1	0	0
49958	1624	involvement of a b-cell-specific cofactor	[involvement of a B-cell-specific cofactor]	1.0	5	1	0	0
49959	1624	hiv-2 gene expression by transcriptional activation	[HIV-2 gene expression by transcriptional activation]	1.0	6	1	0	0
49960	1624	lps receptor	[LPS receptor]	1.0	2	2	2	2
49961	1624	proximal domain of the cytoplasmic tail	[proximal domains of the cytoplasmic tail]	1.0	6	1	0	0
49962	1624	nfat-1 activity	[NFAT-1 activity]	1.0	2	2	2	2
49963	1624	bone metabolism	[bone metabolism]	1.0	2	1	0	0
49964	1624	human cell lines, tcf-1 expression	[human cell lines, TCF-1 expression]	1.0	5	1	0	0
49965	1624	195-kd protein	[195-kD protein]	1.0	2	1	0	0
49966	1624	u937 adhesion	[U937 adhesion]	1.0	2	1	0	0
49967	1624	extent outside	[extent outside]	1.0	2	1	0	0
49968	1624	biological effect of a beta	[biological effects of A beta]	1.0	5	1	0	0
49969	1624	CD2 receptor modulation of transcription	[CD2 receptor modulation of transcription]	1.0	5	1	0	0
49970	1624	10(3) units/ml human recombinant m-csf	[10(3) units/ml human recombinant M-CSF]	1.0	5	1	0	0
49971	1624	exogenous ets1	[Exogenous ETS1]	1.0	2	1	0	0
49972	1624	transcription 6	[transcription 6]	1.0	2	2	2	2
49973	1624	(stat) 1	[(STAT) 1]	1.0	2	1	0	0
49974	1624	stress kinase	[stress kinases]	1.0	2	1	0	0
49975	1624	NF kappa b p50 subunit	[NF kappa B p50 subunit]	1.0	5	1	0	0
49976	1624	il-6 CAT	[IL-6 CAT]	1.0	2	1	0	0
49977	1624	transcription 3	[transcription 3]	1.0	2	2	2	2
49978	1624	gradient gel electrophoresis of the receptor-cDNA	[gradient gel electrophoresis of the receptor-cDNA]	1.0	6	1	0	0
49979	1624	phytohemagglutinin lymphocyte	[phytohemagglutinin lymphocytes]	1.0	2	1	0	0
49980	1624	nuclear form	[nuclear form]	1.0	2	2	2	2
49981	1624	NF-kappa B a transcription factor	[NF-kappa B a transcription factor]	1.0	5	1	0	0
49982	1624	LCR hs	[LCR HS]	1.0	2	1	0	0
49983	1624	suggest the need for activation requirement	[suggesting the need for activation requirements]	1.0	6	1	0	0
49984	1624	elective ptca	[elective PTCA]	1.0	2	1	0	0
49985	1624	cloning of a human homeobox gene	[Cloning of a human homeobox gene]	1.0	6	1	0	0
49986	1624	NF-kappaB element	[NF-kappaB element]	1.0	2	2	2	2
49987	1624	messenger molecule	[messenger molecules]	1.0	2	1	0	0
49988	1624	rapamycin-resistant component	[rapamycin-resistant components]	1.0	2	1	0	0
49989	1624	effect of partial cn inhibition	[effect of partial CN inhibition]	1.0	5	1	0	0
49990	1624	icam-1 mrna	[ICAM-1 mRNA]	1.0	2	2	2	2
49991	1624	hormone binding.	[hormone binding.]	1.0	2	1	0	0
49992	1624	turnover of the vitamin d receptor	[turnover of the vitamin D receptor]	1.0	6	1	0	0
49993	1624	distinct stat5 protein by il-5	[distinct STAT5 proteins by IL-5]	1.0	5	1	0	0
49994	1624	construct Delta	[construct Delta]	1.0	2	1	0	0
49995	1624	threonine residues,	[threonine residues,]	1.0	2	1	0	0
49996	1624	4 h at 37 degree	[4 h at 37 degrees]	1.0	5	1	0	0
49997	1624	susceptibility to infection with hiv-1	[susceptibility to infection with HIV-1]	1.0	5	1	0	0
49998	1624	p45 mrna in the neutrophil	[p45 mRNA in the neutrophils]	1.0	5	1	0	0
49999	1624	eight healthy untrained male volunteer	[Eight healthy untrained male volunteers]	1.0	5	1	0	0
50000	1624	unifying hypothesis	[unifying hypothesis]	1.0	2	1	0	0
50001	1624	modulate agent	[modulating agent]	1.0	2	1	0	0
50002	1624	neonatal T lymphocyte to anti-cd2	[neonatal T lymphocytes to anti-CD2]	1.0	5	1	0	0
50003	1624	control of steroid-regulated gene network	[control of steroid-regulated gene networks]	1.0	5	1	0	0
50004	1624	first description of a agent	[first description of an agent]	1.0	5	1	0	0
50005	1624	GCR of the aged person	[GCR of the aged persons]	1.0	5	1	0	0
50006	1624	notion a t-cell-specific transcription factor	[notion a T-cell-specific transcription factor]	1.0	5	1	0	0
50007	1624	peripheral blood cell from patient	[peripheral blood cells from patients]	1.0	5	1	0	0
50008	1624	LCD motif	[LCD motifs]	1.0	2	2	2	2
50009	1624	regulation by inducible metallothionein promoter	[regulation by inducible metallothionein promoters]	1.0	5	1	0	0
50010	1624	gr concentration	[GR concentration]	1.0	2	3	2	1
50011	1624	level of V beta t-cell receptor	[levels of V beta T-cell receptors]	1.0	6	1	0	0
50012	1624	hsv-1-mediated induction of hiv-1 provirus	[HSV-1-mediated induction of HIV-1 provirus]	1.0	5	1	0	0
50013	1624	p85 construct	[p85 constructs]	1.0	2	1	0	0
50014	1624	one exception,	[one exception,]	1.0	2	1	0	0
50015	1624	modulation of differentiation by T3	[modulation of differentiation by T3]	1.0	5	1	0	0
50016	1624	ionophore	[ionophore]	1.0	1	11	6	6
50017	1624	transcriptional activation of the MMTV LTR	[transcriptional activation of the MMTV LTR]	1.0	6	1	0	0
50018	1624	base-pay substitution in the TF site	[Base-pair substitutions in the TF site]	1.0	6	1	0	0
50019	1624	dual pattern of genetic transmission	[dual pattern of genetic transmission]	1.0	5	1	0	0
50020	1624	55 year	[55 year]	1.0	2	1	0	0
50021	1624	further course	[further course]	1.0	2	1	0	0
50022	1624	reactivity with the tegument protein	[Reactivity with the tegument protein]	1.0	5	1	0	0
50023	1624	mutant subclone	[mutant subclone]	1.0	2	1	0	0
50024	1624	early replication	[early replication]	1.0	2	2	1	1
50025	1624	more cortivazol than the cell	[more cortivazol than the cells]	1.0	5	2	2	2
50026	1624	graft-vs-host reaction	[graft-vs-host reactions]	1.0	2	1	0	0
50027	1624	phenyl ring	[phenyl ring]	1.0	2	1	0	0
50028	1624	4.27 (range, 4-.11), (range, 5.86-6.74) nm,	[4.27 (range, 4-5.13), (range, 5.86-6.74) nM,]	1.0	6	1	0	0
50029	1624	functionally express receptor mutant Ba/F3	[functionally expressing receptor mutants Ba/F3]	1.0	5	1	0	0
50030	1624	interleukin-10 il-10	[interleukin-10 IL-10]	1.0	2	2	2	2
50031	1624	transactivation study	[Transactivation studies]	1.0	2	1	0	0
50032	1624	(aa) of the fkhrl1 gene	[(aa) of the fkhrl1 gene]	1.0	5	1	0	0
50033	1624	major histocompatibility complex (mhc) class gene	[major histocompatibility complex (MHC) class genes]	1.0	6	1	0	0
50034	1624	identification of a gata-2 binding element	[identification of a GATA-2 binding element]	1.0	6	1	0	0
50035	1624	9.2 kb.	[9.2 kB.]	1.0	2	1	0	0
50036	1624	tissue expression of the gene	[tissue expression of the gene]	1.0	5	1	0	0
50037	1624	latter possibility,	[latter possibility,]	1.0	2	1	0	0
50038	1624	density-gradient centrifugation	[density-gradient centrifugations]	1.0	2	1	0	0
50039	1624	Northern blot analysis of L132 cell	[Northern blot analysis of L132 cells]	1.0	6	1	0	0
50040	1624	8 h of TNFalpha treatment	[8 h of TNFalpha treatment]	1.0	5	1	0	0
50041	1624	(0.3 microM)	[(0.3 microM)]	1.0	2	1	0	0
50042	1624	mutation of the PU.1 site	[Mutation of the PU.1 site]	1.0	5	1	0	0
50043	1624	interferon IFNs	[interferons IFNs]	1.0	2	2	1	1
50044	1624	coexpression of dominant negative ras	[Coexpression of dominant negative Ras]	1.0	5	1	0	0
50045	1624	multiple activity	[multiple activities]	1.0	2	2	2	2
50046	1624	functional antagonism	[functional antagonism]	1.0	2	2	2	2
50047	1624	natural context,	[natural context,]	1.0	2	1	0	0
50048	1624	exon:intron structure of chicken IL2	[exon:intron structure of chicken IL2]	1.0	5	1	0	0
50049	1624	clinical endpoint	[clinical endpoints]	1.0	2	1	0	0
50050	1624	3 weeks.	[3 weeks.]	1.0	2	2	2	2
50051	1624	moreover, use a promoter construct	[Moreover, using a promoter construct]	1.0	5	1	0	0
50052	1624	vivo selection	[vivo selection]	1.0	2	1	0	0
50053	1624	DNA bind by in gr	[DNA binding by in GR]	1.0	5	1	0	0
50054	1624	primary cirrhosis	[primary cirrhosis]	1.0	2	2	1	1
50055	1624	cp activity in b lymphocyte	[Cp activity in B lymphocytes]	1.0	5	1	0	0
50056	1624	SH2 domain-contain protein 76 slp-76	[SH2 domain-containing protein 76 SLP-76]	1.0	5	1	0	0
50057	1624	fkhrl1 gene	[fkhrl1 gene]	1.0	2	2	2	2
50058	1624	th2-selective expression	[Th2-selective expression]	1.0	2	1	0	0
50059	1624	crucial step	[crucial step]	1.0	2	2	2	2
50060	1624	cho/ cd14	[CHO/ CD14]	1.0	2	2	2	2
50061	1624	effect on NF kappa b	[effect on NF kappa B]	1.0	5	1	0	0
50062	1624	kinase activity in monocytic cell	[kinase activity in monocytic cells]	1.0	5	1	0	0
50063	1624	activation of nf-kappab by pha	[activation of NF-kappaB by PHA]	1.0	5	1	0	0
50064	1624	t-cell growth	[T-cell growth]	1.0	2	2	1	1
50065	1624	transactivation activity in T cell	[transactivation activity in T cells]	1.0	5	1	0	0
50066	1624	gene encode the lymphocyte homing	[gene encoding the lymphocyte homing]	1.0	5	1	0	0
50067	1624	ro 25-6603	[Ro 25-6603]	1.0	2	1	0	0
50068	1624	hypoxic exposure	[hypoxic exposure]	1.0	2	2	1	1
50069	1624	glioblastoma cell	[glioblastoma cell]	1.0	2	2	1	1
50070	1624	tyrosine-based signal	[tyrosine-based signaling]	1.0	2	1	0	0
50071	1624	macrophage-tropic strain	[macrophage-tropic strains]	1.0	2	2	2	2
50072	1624	ebv-positive b	[EBV-positive B]	1.0	2	1	0	0
50073	1624	cortisol determination	[cortisol determination]	1.0	2	1	0	0
50074	1624	c-jun activation of ap-1 activity	[c-Jun activation of AP-1 activity]	1.0	5	1	0	0
50075	1624	cross-linking of the CD40 receptor	[cross-linking of the CD40 receptor]	1.0	5	1	0	0
50076	1624	ldl particle.	[LDL particle.]	1.0	2	1	0	0
50077	1624	different corticosteroid	[different corticosteroids]	1.0	2	1	0	0
50078	1624	cognate motif.	[cognate motif.]	1.0	2	1	0	0
50079	1624	connection with impaired glucocorticoid induction	[connection with impaired glucocorticoid induction]	1.0	5	1	0	0
50080	1624	MHC I	[MHC I]	1.0	2	1	0	0
50081	1624	upregulate il-6 secretion by mm cell	[upregulating IL-6 secretion by MM cells]	1.0	6	1	0	0
50082	1624	hormone concentration	[hormone concentration]	1.0	2	2	2	2
50083	1624	frequent maternal expression in placentae	[frequent maternal expression in placentae]	1.0	5	1	0	0
50084	1624	one in the phop locus	[ones in the phoP locus]	1.0	5	1	0	0
50085	1624	p, p2	[P, P2]	1.0	2	1	0	0
50086	1624	suggest the involvement of calcineurin	[suggesting the involvement of calcineurin]	1.0	5	1	0	0
50087	1624	implication for disorder of the water	[implications for disorders of the water]	1.0	6	1	0	0
50088	1624	sh2 domain-contain leukocyte protein of kilodaltons),	[SH2 domain-containing leukocyte protein of kilodaltons),]	1.0	6	1	0	0
50089	1624	almost complete inhibition of histamine	[almost complete inhibition of histamine]	1.0	5	1	0	0
50090	1624	clinical stigmata of Turner syndrome	[clinical stigmata of Turner syndrome]	1.0	5	1	0	0
50091	1624	cellular response to extracellular cues,	[cellular responses to extracellular cues,]	1.0	5	1	0	0
50092	1624	pbmc preparation	[pbmc preparations]	1.0	2	1	0	0
50093	1624	physiologic relevance of this increase	[physiologic relevance of this increase]	1.0	5	1	0	0
50094	1624	tuberous sclerosis	[tuberous sclerosis]	1.0	2	2	2	2
50095	1624	nuclear subunit	[nuclear subunit]	1.0	2	2	2	2
50096	1624	molecular basis for cytokine expression	[molecular basis for cytokine expression]	1.0	5	1	0	0
50097	1624	expression of the b1 transcript	[expression of the B1 transcript]	1.0	5	1	0	0
50098	1624	il-2 ligation	[IL-2 ligation]	1.0	2	1	0	0
50099	1624	NB4 a APL cell line	[NB4 an APL cell line]	1.0	5	1	0	0
50100	1624	high level of cytokine gene expression	[High levels of cytokine gene expression]	1.0	6	1	0	0
50101	1624	activate domain	[activating domains]	1.0	2	1	0	0
50102	1624	VZV ie62	[VZV IE62]	1.0	2	1	0	0
50103	1624	-45 site	[-45 site]	1.0	2	1	0	0
50104	1624	1 alpha,25(OH)2D3	[1 alpha,25(OH)2D3]	1.0	2	3	2	1
50105	1624	underlie the biological activity of Tat	[underlying the biological activity of Tat]	1.0	6	1	0	0
50106	1624	short-term systemic effect of glucocorticoid	[short-term systemic effects of glucocorticoids]	1.0	5	1	0	0
50107	1624	one binding	[one binding]	1.0	2	1	0	0
50108	1624	aml protein	[AML proteins]	1.0	2	1	0	0
50109	1624	breakpoint of the t(14;14) translocation	[breakpoint of the t(14;14) translocation]	1.0	5	1	0	0
50110	1624	PKC-zeta (mut)	[PKC-zeta (mut)]	1.0	2	1	0	0
50111	1624	high intracellular level of stat1	[higher intracellular levels of STAT1]	1.0	5	1	0	0
50112	1624	potential role in T cell leukemia	[potential role in T cell leukemia]	1.0	6	1	0	0
50113	1624	p105 transcript	[p105 transcripts]	1.0	2	1	0	0
50114	1624	fc receptor	[Fc receptors]	1.0	2	2	1	1
50115	1624	attractive candidate	[attractive candidates]	1.0	2	1	0	0
50116	1624	enhance the DNA binding activity	[enhancing the DNA binding activities]	1.0	5	1	0	0
50117	1624	functional modulation of cell phenotype	[functional modulation of cell phenotype]	1.0	5	1	0	0
50118	1624	neonatal cell	[neonatal cells]	1.0	2	2	1	1
50119	1624	patient with androgen insensitivity syndrome	[patients with androgen insensitivity syndromes]	1.0	5	1	0	0
50120	1624	Jun protein	[Jun proteins]	1.0	2	2	1	1
50121	1624	4 h in HU cell	[4 h in HU cells]	1.0	5	1	0	0
50122	1624	jun d proto-oncogent in peripheral-blood granulocyte	[jun D proto-oncogenes in peripheral-blood granulocytes]	1.0	6	1	0	0
50123	1624	bipolar patient	[bipolar patients]	1.0	2	1	0	0
50124	1624	same clinical picture of pseudohypoaldosteronism	[same clinical picture of pseudohypoaldosteronism]	1.0	5	1	0	0
50125	1624	contrast, sodium	[contrast, sodium]	1.0	2	1	0	0
50126	1624	binding of the transcription factor	[binding of the transcription factor]	1.0	5	2	2	2
50127	1624	stat factor in blood cell	[STAT factors in blood cells]	1.0	5	1	0	0
50128	1624	Study with deletion CD20 promoter-CAT construct	[Studies with deletion CD20 promoter-CAT constructs]	1.0	6	1	0	0
50129	1624	interleukin 2 T cell growth erratum	[interleukin 2 T cell growth erratum]	1.0	6	1	0	0
50130	1624	important feature with this functional datum	[important features with these functional data.]	1.0	6	1	0	0
50131	1624	successful immunotherapy	[successful immunotherapy]	1.0	2	1	0	0
50132	1624	lead to expression of c-fo	[leading to expression of c-fos]	1.0	5	1	0	0
50133	1624	removal of 20 additional residue	[removal of 20 additional residues]	1.0	5	1	0	0
50134	1624	matrix-adherent cell	[matrix-adherent cells]	1.0	2	1	0	0
50135	1624	multiple pathway	[multiple pathways]	1.0	2	2	2	2
50136	1624	change in the transcription of gene	[changes in the transcription of genes]	1.0	6	1	0	0
50137	1624	molecular difference	[molecular differences]	1.0	2	2	2	2
50138	1624	c-terminal half	[C-terminal half]	1.0	2	2	2	2
50139	1624	59 patient	[59 patients]	1.0	2	1	0	0
50140	1624	activator of transcription stat-1 alpha	[activator of transcription STAT-1 alpha]	1.0	5	1	0	0
50141	1624	transfection of nf-atp into T	[transfection of NF-ATp into T]	1.0	5	1	0	0
50142	1624	B-cell type	[B-cell type]	1.0	2	1	0	0
50143	1624	nuclear translocation of hiv-1 tat	[nuclear translocation of HIV-1 Tat]	1.0	5	1	0	0
50144	1624	enhancer/promoter region	[enhancer/promoter region]	1.0	2	2	1	1
50145	1624	IL-2 immunotherapy	[IL-2 immunotherapy]	1.0	2	1	0	0
50146	1624	expression of the beta-galactoside-binding lectin galectin-3	[expression of the beta-galactoside-binding lectin galectin-3]	1.0	6	1	0	0
50147	1624	pse of rna polymerase ii	[PSE of RNA polymerase II]	1.0	5	1	0	0
50148	1624	gm-csf receptor	[GM-CSF receptor]	1.0	2	2	2	2
50149	1624	antigen responsiveness in T lymphocyte	[antigen responsiveness in T lymphocytes]	1.0	5	1	0	0
50150	1624	cancer development	[cancer development]	1.0	2	1	0	0
50151	1624	balance between th1 immune response	[balance between Th1 immune responses]	1.0	5	1	0	0
50152	1624	first express the epo receptor	[first expressing the Epo receptor]	1.0	5	1	0	0
50153	1624	antipaternal antibody	[antipaternal antibodies]	1.0	2	1	0	0
50154	1624	AML1 gene on chromosome 21	[AML1 gene on chromosome 21]	1.0	5	1	0	0
50155	1624	result occupancy	[resulting occupancy]	1.0	2	1	0	0
50156	1624	eosinophil response	[eosinophil responses]	1.0	2	1	0	0
50157	1624	April 15;90(8):3775]	[Apr 15;90(8):3775]]	1.0	2	1	0	0
50158	1624	48 hours.	[48 hours.]	1.0	2	1	0	0
50159	1624	effective strategy	[effective strategy]	1.0	2	2	2	2
50160	1624	effect on humoral immune response	[effects on humoral immune responses]	1.0	5	1	0	0
50161	1624	1 kb	[1 kb]	1.0	2	1	0	0
50162	1624	il-5 synthesis of t-cell clone	[IL-5 synthesis of T-cell clones]	1.0	5	1	0	0
50163	1624	octamer factor	[octamer factor]	1.0	2	1	0	0
50164	1624	human c-type lectin leukocyte receptor	[human C-type lectin leukocyte receptor]	1.0	5	1	0	0
50165	1624	Deletional analysis of the EA-D promoter	[Deletional analysis of the EA-D promoter]	1.0	6	1	0	0
50166	1624	1 mM	[1 mM]	1.0	2	1	0	0
50167	1624	iga production	[IgA production]	1.0	2	1	0	0
50168	1624	additional translocations.	[additional translocations.]	1.0	2	1	0	0
50169	1624	expression of the hiv-1 transactivator	[Expression of the HIV-1 transactivator]	1.0	5	1	0	0
50170	1624	pattern of intracellular signal transduction	[patterns of intracellular signal transduction]	1.0	5	1	0	0
50171	1624	TNF-alpha release	[TNF-alpha release]	1.0	2	1	0	0
50172	1624	cloned, sequenced,	[cloned, sequenced,]	1.0	2	1	0	0
50173	1624	pkc alpha to the nuclear fraction	[PKC alpha to the nuclear fraction]	1.0	6	1	0	0
50174	1624	cell line with epo il-3	[cell line with Epo IL-3]	1.0	5	1	0	0
50175	1624	NK cell-mediated cytolysis IFN cytoprotection	[NK cell-mediated cytolysis IFN cytoprotection]	1.0	5	1	0	0
50176	1624	(catalytic) cn b (regulatory) subunit	[(catalytic) CN B (regulatory) subunits]	1.0	5	1	0	0
50177	1624	combination of phorbol-12-myristate acetate PMA	[combination of phorbol-12-myristate acetate PMA]	1.0	5	1	0	0
50178	1624	parallel the cell type specificity	[paralleling the cell type specificity]	1.0	5	1	0	0
50179	1624	caspase -1	[caspase -1]	1.0	2	1	0	0
50180	1624	demonstrate active	[demonstrating active]	1.0	2	1	0	0
50181	1624	enhancer HS-40	[enhancer HS-40]	1.0	2	1	0	0
50182	1624	5.25, p	[5.25, p]	1.0	2	1	0	0
50183	1624	SL3 virus	[SL3 virus]	1.0	2	1	0	0
50184	1624	surrogate receptor	[surrogate receptors]	1.0	2	2	1	1
50185	1624	significant number of normal granulocyte	[significant numbers of normal granulocytes]	1.0	5	1	0	0
50186	1624	Smu-->S gamma	[Smu-->S gamma]	1.0	2	1	0	0
50187	1624	identical conditions,	[identical conditions,]	1.0	2	1	0	0
50188	1624	negligible activity	[negligible activity]	1.0	2	2	1	1
50189	1624	three time	[three times]	1.0	2	2	2	2
50190	1624	annealing dg/sa	[annealing DG/SA]	1.0	2	1	0	0
50191	1624	stat3 mrna	[Stat3 mRNA]	1.0	2	1	0	0
50192	1624	vitamin d -resistant cell nuclear extract	[vitamin D -resistant cell nuclear extract]	1.0	6	1	0	0
50193	1624	random oligonucleotide	[random oligonucleotides]	1.0	2	1	0	0
50194	1624	fresh PBL	[fresh PBL]	1.0	2	1	0	0
50195	1624	multiple transcription start site region	[multiple transcription start site region]	1.0	5	1	0	0
50196	1624	new agent	[new agents]	1.0	2	1	0	0
50197	1624	sign of acute adrenal failure	[signs of acute adrenal failure]	1.0	5	1	0	0
50198	1624	identification of a proximal pebp2/cbf site	[identification of a proximal PEBP2/CBF site]	1.0	6	1	0	0
50199	1624	identification of a C-terminal splice variant	[identification of a C-terminal splice variant]	1.0	6	1	0	0
50200	1624	beta interferon	[beta interferon]	1.0	2	2	2	2
50201	1624	blood b	[blood B]	1.0	2	1	0	0
50202	1624	expression of the 135-(oh)2d3 receptor	[expression of the 1,25-(OH)2D3 receptor]	1.0	5	1	0	0
50203	1624	represent stage	[representing stages]	1.0	2	2	2	2
50204	1624	Addition of ubiquitin protein ligase e3	[Addition of ubiquitin protein ligase E3]	1.0	6	1	0	0
50205	1624	nfkb2 p52	[NFKB2 p52]	1.0	2	1	0	0
50206	1624	thymic atrophy	[thymic atrophy]	1.0	2	1	0	0
50207	1624	U/mL in the AIDS -c group	[U/mL in the AIDS -C group]	1.0	6	1	0	0
50208	1624	internal ribosomal entry site IRES	[internal ribosomal entry site IRES]	1.0	5	1	0	0
50209	1624	TA-rich sequence	[TA-rich sequence]	1.0	2	1	0	0
50210	1624	1 wk	[1 wk]	1.0	2	1	0	0
50211	1624	terminal region of the hbd fragment	[terminal region of the HBD fragment]	1.0	6	1	0	0
50212	1624	nfkb2 p49	[NFKB2 p49]	1.0	2	2	1	1
50213	1624	sequence comparison	[Sequence comparisons]	1.0	2	1	0	0
50214	1624	tsc2 mutation on the basis	[TSC2 mutations on the basis]	1.0	5	1	0	0
50215	1624	overall structure	[overall structure]	1.0	2	1	0	0
50216	1624	role of individual gata factor	[roles of individual GATA factors]	1.0	5	1	0	0
50217	1624	heterodimeric activator protein-1 transcription complex	[heterodimeric activator protein-1 transcription complex]	1.0	5	1	0	0
50218	1624	monocytoid u937	[monocytoid U937]	1.0	2	1	0	0
50219	1624	appropriate stimulants.	[appropriate stimulants.]	1.0	2	1	0	0
50220	1624	result in protein with a domain	[resulting in proteins with a domain]	1.0	6	1	0	0
50221	1624	indicate the functionally active factor	[indicating the functionally active factor]	1.0	5	1	0	0
50222	1624	functional studies,	[functional studies,]	1.0	2	1	0	0
50223	1624	signal abnormality in inflammatory airway disease	[signaling abnormalities in inflammatory airway disease]	1.0	6	1	0	0
50224	1624	Potential site for transcription factor ap1	[Potential sites for transcription factors AP1]	1.0	6	1	0	0
50225	1624	SDS-PAGE analysis of the receptor protein	[SDS-PAGE analysis of the receptor protein]	1.0	6	1	0	0
50226	1624	presumably due to the expression	[presumably due to the expression]	1.0	5	1	0	0
50227	1624	B-cell immortalization by Epstein-Barr virus EBV	[B-cell immortalization by Epstein-Barr virus EBV]	1.0	6	1	0	0
50228	1624	most attention	[most attention]	1.0	2	1	0	0
50229	1624	intracellular concentration of Ca2+ ca2+	[intracellular concentration of Ca2+ Ca2+]	1.0	5	1	0	0
50230	1624	reinfection kinetic	[reinfection kinetics]	1.0	2	1	0	0
50231	1624	ap-1 NF-kappa b transcription factor	[AP-1 NF-kappa B transcription factors]	1.0	5	1	0	0
50232	1624	biochemical pathway	[biochemical pathways]	1.0	2	2	2	2
50233	1624	a b epstein-barr virus infection	[A B Epstein-Barr virus infection]	1.0	5	1	0	0
50234	1624	p50 nf-kappab heterodimer binding to DNA,	[p50 NF-kappaB heterodimer binding to DNA,]	1.0	6	1	0	0
50235	1624	xist DNA	[XIST DNA]	1.0	2	2	1	1
50236	1624	gag-pol mrna	[gag-pol mRNA]	1.0	2	2	2	2
50237	1624	cell-type-specific manner.	[cell-type-specific manner.]	1.0	2	1	0	0
50238	1624	single theory	[single theory]	1.0	2	1	0	0
50239	1624	study population	[study population]	1.0	2	1	0	0
50240	1624	three cytokines,	[three cytokines,]	1.0	2	1	0	0
50241	1624	nf kappa b factor kappa b	[NF kappa B factor kappa B]	1.0	6	1	0	0
50242	1624	leukocyte recruitment to atherosclerotic lesion	[leukocyte recruitment to atherosclerotic lesions]	1.0	5	1	0	0
50243	1624	pat 225/egr1	[pAT 225/EGR1]	1.0	2	1	0	0
50244	1624	lymphocyte metaphass	[lymphocyte metaphases]	1.0	2	1	0	0
50245	1624	increase in c-fo mrna level	[increase in c-fos mRNA levels]	1.0	5	1	0	0
50246	1624	suppression of tnf translation efficiency	[suppression of TNF translation efficiency]	1.0	5	1	0	0
50247	1624	activation of ifn-gamma -responsive gene	[Activation of IFN-gamma -responsive genes]	1.0	5	1	0	0
50248	1624	induction of jun/fo response gene expression	[induction of jun/fos response gene expression]	1.0	6	1	0	0
50249	1624	transactivation of the TNF gene	[transactivation of the TNF gene]	1.0	5	1	0	0
50250	1624	alpha-tocopherol a free radical scavenger	[alpha-tocopherol a free radical scavenger]	1.0	5	1	0	0
50251	1624	episomal DNA	[episomal DNA]	1.0	2	1	0	0
50252	1624	energy substrate hormone response during exercise	[Energy substrates, hormone responses during exercise]	1.0	6	1	0	0
50253	1624	signal-transming receptor	[signal-transmitting receptor]	1.0	2	1	0	0
50254	1624	normal affinity	[normal affinity]	1.0	2	2	2	2
50255	1624	variant octamer)	[variant octamer)]	1.0	2	1	0	0
50256	1624	possibility important in signal activity	[possibility important in signaling activities]	1.0	5	1	0	0
50257	1624	erythroleukaemia cell	[erythroleukaemia cells]	1.0	2	1	0	0
50258	1624	surface expression of the cell adhesion	[surface expression of the cell adhesion]	1.0	6	1	0	0
50259	1624	large 14-day colony (>1 mm)	[large 14-day colonies (>1 mm)]	1.0	5	1	0	0
50260	1624	oxidant stress lead to adhesion	[oxidant stress leading to adhesion]	1.0	5	1	0	0
50261	1624	3 would	[3 d]	1.0	2	1	0	0
50262	1624	synthesis of full-length hiv transcript	[synthesis of full-length HIV transcripts]	1.0	5	1	0	0
50263	1624	use 3-methylcholanthrene rat liver microsome	[using 3-methylcholanthrene rat liver microsomes]	1.0	5	1	0	0
50264	1624	activator of transcription 6 stat6	[activator of transcription 6 Stat6]	1.0	5	1	0	0
50265	1624	monocyte il-1ra secretion by cortisol	[monocyte IL-1ra secretion by cortisol]	1.0	5	1	0	0
50266	1624	same transcription	[same transcription]	1.0	2	1	0	0
50267	1624	one case,	[one case,]	1.0	2	1	0	0
50268	1624	tnf-alpha-induced vcam-1	[TNF-alpha-induced VCAM-1]	1.0	2	1	0	0
50269	1624	expression of set of gene	[expression of sets of genes]	1.0	5	2	2	2
50270	1624	transcriptional activity of the gene	[transcriptional activity of the gene]	1.0	5	1	0	0
50271	1624	40000 form	[40,000 form]	1.0	2	1	0	0
50272	1624	other region	[other regions]	1.0	2	2	1	1
50273	1624	binding to the intracellular glucocorticoid receptor	[binding to the intracellular glucocorticoid receptor]	1.0	6	1	0	0
50274	1624	49 female patient with MPD	[49 female patients with MPD]	1.0	5	1	0	0
50275	1624	promoter occupation	[promoter occupation]	1.0	2	2	1	1
50276	1624	glucocorticoid receptor in blood lymphocyte	[glucocorticoid receptors in blood lymphocytes]	1.0	5	1	0	0
50277	1624	octamer sequence in the promoter	[octamer sequence in the promoter]	1.0	5	1	0	0
50278	1624	DNA strand competition between sequence	[DNA strand competition between sequences]	1.0	5	1	0	0
50279	1624	gssg ratio	[GSSG ratio]	1.0	2	1	0	0
50280	1624	support a new, two-step model	[supporting a new, two-step model]	1.0	5	1	0	0
50281	1624	signal event result in activation	[signaling events resulting in activation]	1.0	5	1	0	0
50282	1624	suppression of sla-dra mrna induction	[suppression of SLA-DRA mRNA induction]	1.0	5	1	0	0
50283	1624	hydrophobic c-terminal tail of CAML	[hydrophobic C-terminal tail of CAML]	1.0	5	1	0	0
50284	1624	contrast, anergic cd4+ T cell	[contrast, anergic CD4+ T cells]	1.0	5	1	0	0
50285	1624	alpha-tcp on a IL-1 response	[alpha-tcp on an IL-1 response]	1.0	5	1	0	0
50286	1624	fivefold transactivation	[fivefold transactivation]	1.0	2	1	0	0
50287	1624	hiv-1 mrna	[HIV-1 mRNA]	1.0	2	1	0	0
50288	1624	cyclosporine a	[cyclosporine A]	1.0	2	2	1	1
50289	1624	Th2 cells,	[Th2 cells,]	1.0	2	1	0	0
50290	1624	erythropoietin EPO	[erythropoietin EPO]	1.0	2	1	0	0
50291	1624	vitro exhibit	[vitro exhibits]	1.0	2	1	0	0
50292	1624	alpha mouse	[alpha mice]	1.0	2	1	0	0
50293	1624	major mechanism of MDS progression	[major mechanism of MDS progression]	1.0	5	1	0	0
50294	1624	belong to the HHV-6 variant b	[belonging to the HHV-6 variant B]	1.0	6	1	0	0
50295	1624	29 patient	[29 patients]	1.0	2	2	1	1
50296	1624	interleukin-10 stat molecule in monocyte	[interleukin-10 STAT molecules in monocytes]	1.0	5	1	0	0
50297	1624	anti-ifn-alpha/beta antibody	[anti-IFN-alpha/beta antibody]	1.0	2	1	0	0
50298	1624	x-chromosome-specific element	[X-chromosome-specific elements]	1.0	2	1	0	0
50299	1624	long regulation	[long-term regulation]	1.0	2	1	0	0
50300	1624	IL-16 promoter in T cell	[IL-16 promoter in T cells]	1.0	5	1	0	0
50301	1624	artificial light	[artificial light]	1.0	2	1	0	0
50302	1624	phosphotyrosine	[phosphotyrosine]	1.0	1	11	6	6
50303	1624	receptor activator of NF-kappaB rank	[Receptor activator of NF-kappaB RANK]	1.0	5	1	0	0
50304	1624	transcription activator	[transcription activator]	1.0	2	2	2	2
50305	1624	single major tr TREp complex	[single major TR TREp complex]	1.0	5	1	0	0
50306	1624	hypereosinophilic syndrome	[hypereosinophilic syndrome]	1.0	2	2	1	1
50307	1624	virus dutpase	[virus dUTPase]	1.0	2	1	0	0
50308	1624	specific pattern	[specific pattern]	1.0	2	3	2	1
50309	1624	chemical synthesis	[chemical synthesis]	1.0	2	1	0	0
50310	1624	expression of human monkey glucocorticoid receptor	[Expressions of human monkey glucocorticoid receptors]	1.0	6	1	0	0
50311	1624	human peripheral blood monocyte pbmo	[human peripheral blood monocytes PBMo]	1.0	5	1	0	0
50312	1624	complement in small animal model	[complement in small animal models]	1.0	5	1	0	0
50313	1624	p50/p65 contain nf-kappa b dimer	[p50/p65 containing NF-kappa B dimers]	1.0	5	1	0	0
50314	1624	fura-2-loaded T	[Fura-2-loaded T]	1.0	2	1	0	0
50315	1624	haematopoietic differentiation	[haematopoietic differentiation]	1.0	2	1	0	0
50316	1624	functional difference in this cells.	[functional differences in these cells.]	1.0	5	1	0	0
50317	1624	lps signal in microvessel cell	[LPS signaling in microvessel cells]	1.0	5	1	0	0
50318	1624	somatic cell hybrid between IARC 301.5	[somatic cell hybrids between IARC 301.5]	1.0	6	1	0	0
50319	1624	lps -binding protein a transfer protein	[LPS -binding protein a transfer protein]	1.0	6	1	0	0
50320	1624	-177 bp	[-177 bp]	1.0	2	1	0	0
50321	1624	th1-type response such as hypersensitivity	[Th1-type responses such as hypersensitivity]	1.0	5	1	0	0
50322	1624	disease remission	[disease remission]	1.0	2	1	0	0
50323	1624	therapy of disease with pathogenesis	[therapy of diseases with pathogenesis]	1.0	5	1	0	0
50324	1624	passage of the NPC cell line	[Passaging of the NPC cell line]	1.0	6	1	0	0
50325	1624	inactivation of the phosphatase calcineurin	[inactivation of the phosphatase calcineurin]	1.0	5	1	0	0
50326	1624	lymphoid-restricted gene in lymphoid differentiation	[lymphoid-restricted gene in lymphoid differentiation]	1.0	5	1	0	0
50327	1624	HUMARA assay	[HUMARA assay]	1.0	2	1	0	0
50328	1624	bone marrow transplantation in mouse	[bone marrow transplantation in mice]	1.0	5	1	0	0
50329	1624	gene expression of a osteoblast-specific gene	[gene expression of an osteoblast-specific gene]	1.0	6	1	0	0
50330	1624	ATRA	[ATRA]	1.0	1	11	1	1
50331	1624	HS iii	[HS III]	1.0	2	1	0	0
50332	1624	circulate T cell from a subset	[circulating T cells from a subset]	1.0	6	1	0	0
50333	1624	activation of a second protein related	[Activation of a second protein related]	1.0	6	1	0	0
50334	1624	use the protein synthesis inhibitor cycloheximide	[using the protein synthesis inhibitor cycloheximide]	1.0	6	1	0	0
50335	1624	two interferon-stimulated response element ISRE	[Two interferon-stimulated response elements ISRE]	1.0	5	1	0	0
50336	1624	PKC pathway	[PKC pathway]	1.0	2	2	2	2
50337	1624	cell antibody	[cell antibodies]	1.0	2	2	2	2
50338	1624	only for the 2 patient	[only for the 2 patients]	1.0	5	1	0	0
50339	1624	multiprotein complex	[multiprotein complexes]	1.0	2	1	0	0
50340	1624	hemoglobin-positive cell	[hemoglobin-positive cells]	1.0	2	1	0	0
50341	1624	high molecular weight dextran sulfate	[High molecular weight dextran sulfate]	1.0	5	2	1	1
50342	1624	Nuclear rel-a	[Nuclear Rel-A]	1.0	2	1	0	0
50343	1624	Bcl6 mutation	[Bcl6 mutation]	1.0	2	1	0	0
50344	1624	different concentration of alpha 4	[different concentrations of alpha 4]	1.0	5	1	0	0
50345	1624	mutation in the mouse genome	[mutations in the mouse genome]	1.0	5	1	0	0
50346	1624	spontaneous production	[spontaneous production]	1.0	2	2	1	1
50347	1624	accelerate the degradation of IkB alpha	[accelerating the degradation of IkB alpha]	1.0	6	1	0	0
50348	1624	specific tyrosine phosphorylation follow ptk activation	[specific tyrosine phosphorylation following PTK activation]	1.0	6	1	0	0
50349	1624	stat protein in nuclear extract	[STAT proteins in nuclear extracts]	1.0	5	1	0	0
50350	1624	BSAP gene	[BSAP gene]	1.0	2	2	1	1
50351	1624	single-point mutation	[single-point mutation]	1.0	2	1	0	0
50352	1624	three lineages.	[three lineages.]	1.0	2	1	0	0
50353	1624	hemin hm	[hemin Hm]	1.0	2	1	0	0
50354	1624	tax mutant segregate this pathway	[Tax mutants segregating these pathways]	1.0	5	1	0	0
50355	1624	possibly stat3	[possibly STAT3]	1.0	2	1	0	0
50356	1624	IL-4 naf	[IL-4 NAF]	1.0	2	1	0	0
50357	1624	day 15 of cycle one	[day 15 of cycle one]	1.0	5	1	0	0
50358	1624	allergic airway	[allergic airway]	1.0	2	1	0	0
50359	1624	enhancer element activity under similar conditions.	[enhancer element activities under similar conditions.]	1.0	6	1	0	0
50360	1624	-specific ligand	[-specific ligands]	1.0	2	1	0	0
50361	1624	binding of a fetal -specific protein	[binding of a fetal -specific protein]	1.0	6	1	0	0
50362	1624	human T lymphoid jurkat cell	[human T lymphoid Jurkat cells]	1.0	5	1	0	0
50363	1624	Further, cotransfection analysis in Drosophila cell	[Further, cotransfection analysis in Drosophila cells]	1.0	6	1	0	0
50364	1624	impdh type	[IMPDH type]	1.0	2	2	2	2
50365	1624	novel region	[novel region]	1.0	2	2	2	2
50366	1624	1d4 cell	[1D4 cells]	1.0	2	1	0	0
50367	1624	transactivate capacity	[transactivating capacity]	1.0	2	1	0	0
50368	1624	tumor ag	[tumor Ag]	1.0	2	2	2	2
50369	1624	Glucocorticoid apoptosis of human leukemic cell	[Glucocorticoid apoptosis of human leukemic cells]	1.0	6	1	0	0
50370	1624	correlate with the enhancer activity	[correlating with the enhancer activity]	1.0	5	1	0	0
50371	1624	chimaeric oncoprotein	[chimaeric oncoprotein]	1.0	2	1	0	0
50372	1624	kox zinc	[KOX zinc]	1.0	2	1	0	0
50373	1624	inhibitory complex	[inhibitory complex]	1.0	2	2	1	1
50374	1624	dominant-negative MEK	[dominant-negative MEK]	1.0	2	1	0	0
50375	1624	'latency ii'	['latency II']	1.0	2	1	0	0
50376	1624	monocytic characteristic of YJ cell	[monocytic characteristics of YJ cells]	1.0	5	1	0	0
50377	1624	contrast, several mutant p85 allele	[contrast, several mutant p85 alleles]	1.0	5	1	0	0
50378	1624	DNA helix	[DNA helix]	1.0	2	1	0	0
50379	1624	2 pre-B	[2 pre-B]	1.0	2	1	0	0
50380	1624	K+ channel in T cell	[K+ channels in T cells]	1.0	5	1	0	0
50381	1624	non-irradiated cell	[non-irradiated cells]	1.0	2	1	0	0
50382	1624	evidence for a additional bind site	[evidence for an additional binding site]	1.0	6	1	0	0
50383	1624	MNDA mrna level in granulocyte	[MNDA mRNA level in granulocytes]	1.0	5	1	0	0
50384	1624	epo -inducible	[Epo -inducible]	1.0	2	1	0	0
50385	1624	surface ligand	[surface ligand]	1.0	2	1	0	0
50386	1624	813-bp open reading frame ORF	[813-bp open reading frame ORF]	1.0	5	1	0	0
50387	1624	52 centipoise).	[52 centipoise).]	1.0	2	1	0	0
50388	1624	staT3-containing complex	[STAT3-containing complexes]	1.0	2	1	0	0
50389	1624	HTLV-I promoter	[HTLV-I promoter]	1.0	2	1	0	0
50390	1624	specific subdomain	[specific subdomains]	1.0	2	1	0	0
50391	1624	influence of the latent protein	[influence of the latent proteins]	1.0	5	1	0	0
50392	1624	IkappaB production	[IkappaB production]	1.0	2	1	0	0
50393	1624	effector function in immune response	[effector functions in immune responses]	1.0	5	1	0	0
50394	1624	suggest traffic between the cytoplasm	[suggesting traffic between the cytoplasm]	1.0	5	1	0	0
50395	1624	immature b cell from apoptosis.	[immature B cells from apoptosis.]	1.0	5	1	0	0
50396	1624	specific stimulus	[specific stimulus]	1.0	2	2	1	1
50397	1624	Rho activity with C3 transferase	[Rho activity with C3 transferase]	1.0	5	1	0	0
50398	1624	10(3) units/ml	[10(3) units/ml]	1.0	2	1	0	0
50399	1624	adult t-cell leukemia ATL patient	[adult T-cell leukemia ATL patients]	1.0	5	1	0	0
50400	1624	ets domain	[Ets domain]	1.0	2	2	1	1
50401	1624	seven cases;	[seven cases;]	1.0	2	1	0	0
50402	1624	difficult-to-control asthma	[difficult-to-control asthma]	1.0	2	1	0	0
50403	1624	(Chr) 20	[(Chr) 20]	1.0	2	1	0	0
50404	1624	monocyte from the proband ii-2	[monocytes from the proband II-2]	1.0	5	1	0	0
50405	1624	important aspect of signal transduction	[important aspect of signal transduction]	1.0	5	1	0	0
50406	1624	donor age, memory T cell	[donor age, memory T cells]	1.0	5	1	0	0
50407	1624	POU-homeodomain domain	[POU-homeodomain domain]	1.0	2	1	0	0
50408	1624	receptor available	[receptors available]	1.0	2	2	2	2
50409	1624	cytoplasmic tail,	[cytoplasmic tail,]	1.0	2	1	0	0
50410	1624	one family of host transcription factor	[One family of host transcription factors]	1.0	6	1	0	0
50411	1624	either on the minimal promoter	[either on the minimal promoter]	1.0	5	1	0	0
50412	1624	(affect expression of a tal1 allele	[(affecting expression of a TAL1 allele]	1.0	6	1	0	0
50413	1624	immunoglobulin-like transcript-2/leukocyte	[immunoglobulin-like transcript-2/leukocyte]	1.0	2	1	0	0
50414	1624	concentration of a VDR CDNA	[concentrations of a VDR CDNA]	1.0	5	1	0	0
50415	1624	activation of rna polymerase iii-dependent gene	[activation of RNA polymerase III-dependent genes]	1.0	6	1	0	0
50416	1624	rar, VDR	[RAR, VDR]	1.0	2	1	0	0
50417	1624	three 3rd base substitution polymorphism	[Three 3rd base substitution polymorphisms]	1.0	5	1	0	0
50418	1624	protein-protein interaction with other component	[protein-protein interaction with other components]	1.0	5	1	0	0
50419	1624	expression of bcl2 a oncogene	[expression of bcl2 an oncogene]	1.0	5	1	0	0
50420	1624	organ infitration	[organ infitration]	1.0	2	1	0	0
50421	1624	cell damage	[cell damage]	1.0	2	2	2	2
50422	1624	response to many pathogenic signal	[response to many pathogenic signals]	1.0	5	1	0	0
50423	1624	specific autoantibody	[specific autoantibodies]	1.0	2	1	0	0
50424	1624	special program of gene expression	[special program of gene expression]	1.0	5	1	0	0
50425	1624	Dibutyryl cAMP	[Dibutyryl cAMP]	1.0	2	1	0	0
50426	1624	appearance of a fusion transcript	[appearance of a fusion transcript]	1.0	5	1	0	0
50427	1624	include aml	[including AML]	1.0	2	2	2	2
50428	1624	cell nucleolus	[cell nucleolus]	1.0	2	1	0	0
50429	1624	reactive tonsil	[reactive tonsil]	1.0	2	1	0	0
50430	1624	atypical presentation	[atypical presentation]	1.0	2	1	0	0
50431	1624	palindromic sequence within site b	[palindromic sequence within site B]	1.0	5	1	0	0
50432	1624	deletion upstream of the PRDII element	[Deletions upstream of the PRDII element]	1.0	6	1	0	0
50433	1624	CD3 cross-linking	[CD3 cross-linking]	1.0	2	1	0	0
50434	1624	er status	[ER status]	1.0	2	1	0	0
50435	1624	rapid induction of ikk activity	[rapid induction of IKK activity]	1.0	5	1	0	0
50436	1624	use form of the IL-6 promoter	[using forms of the IL-6 promoter]	1.0	6	1	0	0
50437	1624	untreated ht-2 cell with calcineurin	[untreated HT-2 cells with calcineurin]	1.0	5	1	0	0
50438	1624	stimulate T cell blast with CD80	[stimulating T cell blasts with CD80]	1.0	6	1	0	0
50439	1624	induction of cell surface marker	[induction of cell surface markers]	1.0	5	1	0	0
50440	1624	suggest necessary	[suggesting necessary]	1.0	2	2	1	1
50441	1624	also in non-classic target tissue	[also in non-classic target tissues]	1.0	5	1	0	0
50442	1624	positive effect of the ctg-motif	[positive effect of the CTG-motif]	1.0	5	1	0	0
50443	1624	direct output of lmp signal	[direct output of LMP signaling]	1.0	5	1	0	0
50444	1624	Glucocorticoid -resistance in peripheral-blood lymphocyte	[Glucocorticoid -resistance in peripheral-blood lymphocytes]	1.0	5	1	0	0
50445	1624	patient with x-linked severe immunodeficiency	[patients with X-linked severe immunodeficiency]	1.0	5	2	1	1
50446	1624	signal transducing	[signal transducing]	1.0	2	2	2	2
50447	1624	PU.1/Spi-1 proto-oncogene	[PU.1/Spi-1 proto-oncogene]	1.0	2	1	0	0
50448	1624	1 allele allele ratio 3:1)	[1 allele allele ratio 3:1)]	1.0	5	1	0	0
50449	1624	promoter activity of fusion plasmid	[promoter activity of fusion plasmids]	1.0	5	1	0	0
50450	1624	hair follicle of the twin	[hair follicles of the twins]	1.0	5	1	0	0
50451	1624	examination of Stat6 dna-binding activity	[Examination of Stat6 DNA-binding activity]	1.0	5	1	0	0
50452	1624	direct correlation between the rate	[direct correlation between the rate]	1.0	5	1	0	0
50453	1624	novel agent	[novel agent]	1.0	2	2	2	2
50454	1624	Raif Geha	[Raif Geha]	1.0	2	1	0	0
50455	1624	response of pbmc from patient	[Responses of PBMC from patients]	1.0	5	1	0	0
50456	1624	protein phosphatase by okadaic acid	[protein phosphatases by okadaic acid]	1.0	5	1	0	0
50457	1624	murine counterpart	[murine counterpart]	1.0	2	2	2	2
50458	1624	simultaneous correction	[simultaneous correction]	1.0	2	1	0	0
50459	1624	phosphatidyl inositol	[phosphatidyl inositol]	1.0	2	1	0	0
50460	1624	ca2+ influx.	[Ca2+ influx.]	1.0	2	1	0	0
50461	1624	several other rheumatoid arthritis patient	[several other rheumatoid arthritis patients]	1.0	5	1	0	0
50462	1624	THP-1 cells,	[THP-1 cells,]	1.0	2	1	0	0
50463	1624	level of nuclear nf-kappa b	[levels of nuclear NF-kappa B]	1.0	5	2	2	2
50464	1624	peripheral end-effector	[peripheral end-effectors]	1.0	2	1	0	0
50465	1624	endogenous protein	[endogenous protein]	1.0	2	1	0	0
50466	1624	nuclear factor of T cell nfat-1	[nuclear factor of T cells NFAT-1]	1.0	6	1	0	0
50467	1624	hybridization histochemistry	[hybridization histochemistry]	1.0	2	1	0	0
50468	1624	number of glucocorticoid receptor constant	[number of glucocorticoid receptors constant]	1.0	5	1	0	0
50469	1624	RU 486.	[RU 486.]	1.0	2	1	0	0
50470	1624	c-c chemokine	[C-C chemokine]	1.0	2	2	2	2
50471	1624	T cell reactivity to thyroid antigen	[T cell reactivity to thyroid antigens]	1.0	6	1	0	0
50472	1624	three cytokine	[three cytokines]	1.0	2	1	0	0
50473	1624	activity against macrovascular ec HUVEC	[Activity against macrovascular EC HUVEC]	1.0	5	1	0	0
50474	1624	nf-kappab expression	[NF-kappaB expression]	1.0	2	1	0	0
50475	1624	nf-kappab activity in T cell	[NF-kappaB activity in T cells]	1.0	5	1	0	0
50476	1624	inhibitory receptor	[inhibitory receptor]	1.0	2	2	1	1
50477	1624	canonical homeodomain	[canonical homeodomains]	1.0	2	1	0	0
50478	1624	expression of the IL-12R beta chain	[expression of the IL-12R beta chain]	1.0	6	1	0	0
50479	1624	contain il-1 beta promoter/enhancer sequence	[containing IL-1 beta promoter/enhancer sequences]	1.0	5	1	0	0
50480	1624	RA addition.	[RA addition.]	1.0	2	1	0	0
50481	1624	defective transport of class ii molecule	[defective transport of class II molecules]	1.0	6	1	0	0
50482	1624	tsh receptor	[TSH receptor]	1.0	2	2	2	2
50483	1624	human ldl	[Human LDL]	1.0	2	1	0	0
50484	1624	link the expression of the complex	[linking the expression of the complex]	1.0	6	1	0	0
50485	1624	consequently death.	[consequently death.]	1.0	2	1	0	0
50486	1624	region coding	[region coding]	1.0	2	2	2	2
50487	1624	partial cDNA	[partial cDNA]	1.0	2	1	0	0
50488	1624	mechanism responsible for this differences,	[mechanisms responsible for these differences,]	1.0	5	1	0	0
50489	1624	pharmacological approaches; however, monocyte interaction	[pharmacological approaches; however, monocyte interactions]	1.0	5	1	0	0
50490	1624	TCR beta	[TCR beta]	1.0	2	2	1	1
50491	1624	human monocytic cell line u1	[human monocytic cell line U1]	1.0	5	1	0	0
50492	1624	positive role in t-cell signal	[positive role in T-cell signaling]	1.0	5	1	0	0
50493	1624	33 nucleotide change (with respect	[33 nucleotide changes (with respect]	1.0	5	1	0	0
50494	1624	Pb at physiologically relevant concentration	[Pb at physiologically relevant concentrations]	1.0	5	1	0	0
50495	1624	persistent cytokine	[persistent cytokine]	1.0	2	1	0	0
50496	1624	Aldh1 expression	[Aldh1 expression]	1.0	2	1	0	0
50497	1624	il-2r alpha-chain	[IL-2R alpha-chain]	1.0	2	2	2	2
50498	1624	structure-activity relationship	[structure-activity relationship]	1.0	2	1	0	0
50499	1624	endogenous IL-1	[endogenous IL-1]	1.0	2	1	0	0
50500	1624	signal via the map kinase pathway	[signaling via the MAP kinase pathway]	1.0	6	1	0	0
50501	1624	ccaat motif	[CCAAT motif]	1.0	2	2	1	1
50502	1624	current literature	[current literature]	1.0	2	1	0	0
50503	1624	transcription of the growth growth factor	[transcription of the growth growth factor]	1.0	6	1	0	0
50504	1624	17beta-(3H) estradiol	[17beta-(3H) estradiol]	1.0	2	2	2	2
50505	1624	leukocyte accumulation	[leukocyte accumulation]	1.0	2	1	0	0
50506	1624	extend 1053 base pair upstream	[extending 1053 base pairs upstream]	1.0	5	1	0	0
50507	1624	experiment with a block antibody	[Experiments with a blocking antibody]	1.0	5	1	0	0
50508	1624	e2a- HLF	[E2A- HLF]	1.0	2	1	0	0
50509	1624	ald stimulus	[ALD stimulus]	1.0	2	1	0	0
50510	1624	principal inhibitor	[principal inhibitor]	1.0	2	1	0	0
50511	1624	cooh-terminal region	[COOH-terminal region]	1.0	2	2	2	2
50512	1624	thirteen preterm of the latter group	[Thirteen preterms of the latter group]	1.0	6	1	0	0
50513	1624	pp52 promoter	[pp52 promoter]	1.0	2	3	2	1
50514	1624	sequence-specific hmg-box	[sequence-specific HMG-box]	1.0	2	1	0	0
50515	1624	neutrophilic inflammation	[neutrophilic inflammation]	1.0	2	1	0	0
50516	1624	Moreover, RA	[Moreover, RA]	1.0	2	1	0	0
50517	1624	cyclic AMP response element CRE	[cyclic AMP response element CRE]	1.0	5	1	0	0
50518	1624	patient with chronic myeloproliferative disease	[patients with chronic myeloproliferative diseases]	1.0	5	1	0	0
50519	1624	many c-11-substituted 1 alpha,25-(OH)2D3 analog	[many C-11-substituted 1 alpha,25-(OH)2D3 analogs]	1.0	5	1	0	0
50520	1624	constitutional loss of one allele	[constitutional losses of one allele]	1.0	5	1	0	0
50521	1624	development of acute lymphoblastic leukemia	[development of acute lymphoblastic leukemia]	1.0	5	1	0	0
50522	1624	gc in the MDD patient	[GC in the MDD patients]	1.0	5	1	0	0
50523	1624	hiv expression in GM-CSF cell	[HIV expression in GM-CSF cells]	1.0	5	1	0	0
50524	1624	down-modulate inflammation.	[down-modulate inflammation.]	1.0	2	1	0	0
50525	1624	t-cell lymphotropic virus type htlv-1	[T-cell lymphotropic virus type HTLV-1]	1.0	5	2	2	2
50526	1624	37 control	[37 control]	1.0	2	1	0	0
50527	1624	il-1 il-6	[IL-1 IL-6]	1.0	2	1	0	0
50528	1624	specific antiserum against aml-1 protein	[specific antiserum against AML-1 proteins]	1.0	5	1	0	0
50529	1624	human chromosomes,	[human chromosomes,]	1.0	2	1	0	0
50530	1624	normal adult	[normal adults]	1.0	2	1	0	0
50531	1624	IL-2 promoter-reporter	[IL-2 promoter-reporter]	1.0	2	1	0	0
50532	1624	t-cell lymphotrophic	[T-cell lymphotrophic]	1.0	2	2	1	1
50533	1624	fatty acid inhibit endothelial activation	[fatty acids inhibiting endothelial activation]	1.0	5	1	0	0
50534	1624	renal transplantation	[renal transplantation]	1.0	2	1	0	0
50535	1624	induction of cell death pcd	[induction of cell death PCD]	1.0	5	1	0	0
50536	1624	change in the thyroid status	[changes in the thyroid status]	1.0	5	1	0	0
50537	1624	three cases,	[three cases,]	1.0	2	1	0	0
50538	1624	normal myeloid progenitor cell growth	[normal myeloid progenitor cell growth]	1.0	5	1	0	0
50539	1624	secretion level of interleukin-6 il-6	[secretion levels of interleukin-6 IL-6]	1.0	5	1	0	0
50540	1624	control total serum ige level	[controlling total serum IgE levels]	1.0	5	1	0	0
50541	1624	interleukin-6 level	[Interleukin-6 levels]	1.0	2	1	0	0
50542	1624	p24rex production	[p24rex production]	1.0	2	1	0	0
50543	1624	dominant Ras	[dominant Ras]	1.0	2	1	0	0
50544	1624	tumour necrosis factor (tnf) transcript	[tumour necrosis factor (TNF) transcript]	1.0	5	1	0	0
50545	1624	CD38 antigen	[CD38 antigen]	1.0	2	2	2	2
50546	1624	genetic blockade of hl-60 differentiation	[genetic blockade of HL-60 differentiation]	1.0	5	1	0	0
50547	1624	signal mechanism distinct from kinase	[signaling mechanisms distinct from kinase]	1.0	5	1	0	0
50548	1624	dose-response manner	[dose-response manner]	1.0	2	1	0	0
50549	1624	experiments, socs-3	[experiments, SOCS-3]	1.0	2	1	0	0
50550	1624	proliferation of blood T cell	[proliferation of blood T cells]	1.0	5	1	0	0
50551	1624	contrast, eosinophil	[contrast, eosinophils]	1.0	2	1	0	0
50552	1624	Specific formation	[Specific formation]	1.0	2	2	2	2
50553	1624	life-threatening hypokalemia	[life-threatening hypokalemia]	1.0	2	1	0	0
50554	1624	tonsil	[tonsil]	1.0	1	11	3	3
50555	1624	overexpression of the subunit ikappabalpha	[overexpression of the subunit IkappaBalpha]	1.0	5	1	0	0
50556	1624	contain 151 bp of 5'-flanking sequence	[containing 151 bp of 5'-flanking sequences]	1.0	6	1	0	0
50557	1624	polymorphism for the vitamin d receptor	[polymorphism for the vitamin D receptor]	1.0	6	1	0	0
50558	1624	primary effect of heat shock	[primary effect of heat shock]	1.0	5	1	0	0
50559	1624	multiple tissue	[multiple tissues]	1.0	2	2	1	1
50560	1624	kappab3 site	[kappaB3 sites]	1.0	2	1	0	0
50561	1624	microb element	[microB element]	1.0	2	1	0	0
50562	1624	2-4 fold	[2-4 fold]	1.0	2	1	0	0
50563	1624	similar potentiation of tnf effect	[similar potentiation of TNF effects]	1.0	5	1	0	0
50564	1624	such as cystic fibrosis (cf)	[such as cystic fibrosis (CF)]	1.0	5	1	0	0
50565	1624	gamma activation site gas probe	[gamma activation site GAS probe]	1.0	5	1	0	0
50566	1624	Janus kinase 3 phosphorylation induction	[Janus kinase 3 phosphorylation induction]	1.0	5	1	0	0
50567	1624	cellular target	[cellular target]	1.0	2	2	1	1
50568	1624	specific positive regulation in T cell	[specific positive regulation in T cells]	1.0	6	1	0	0
50569	1624	suppression of hla-dra mrna synthesis	[suppression of HLA-DRA mRNA synthesis]	1.0	5	1	0	0
50570	1624	"octamer" motif	["octamer" motif]	1.0	2	2	1	1
50571	1624	eosinophil in patient with vkc	[eosinophils in patients with VKC]	1.0	5	1	0	0
50572	1624	biological activity.	[biological activity.]	1.0	2	1	0	0
50573	1624	b cell antigen-specific signal response	[B cell antigen-specific signaling responses]	1.0	5	1	0	0
50574	1624	solution structure of the hmg-box	[solution structure of the HMG-box]	1.0	5	1	0	0
50575	1624	lavage t-lymphocyte	[Lavage T-lymphocytes]	1.0	2	2	2	2
50576	1624	ebv serology	[EBV serology]	1.0	2	2	2	2
50577	1624	part of a dyad symmetry element	[part of a dyad symmetry element]	1.0	6	1	0	0
50578	1624	phosphorylation of the retinoblastoma protein	[Phosphorylation of the retinoblastoma protein]	1.0	5	1	0	0
50579	1624	transcription of the rag-1 gene	[transcription of the RAG-1 gene]	1.0	5	1	0	0
50580	1624	long effect	[long-term effects]	1.0	2	2	2	2
50581	1624	activation of unsuppressed T cell	[activation of unsuppressed T cells]	1.0	5	1	0	0
50582	1624	subcellular mechanism	[subcellular mechanisms]	1.0	2	1	0	0
50583	1624	prolonged, i.e. 28 dayus- glucocorticoid therapy	[prolonged, i.e. 28 day, glucocorticoid therapy]	1.0	6	1	0	0
50584	1624	gel-shift analysis in the presence	[Gel-shift analysis in the presence]	1.0	5	1	0	0
50585	1624	partial inhibition	[partial inhibition]	1.0	2	2	2	2
50586	1624	Tat mutant	[Tat mutants]	1.0	2	2	2	2
50587	1624	transcription factor NF kappa b	[transcription factor NF kappa B]	1.0	5	1	0	0
50588	1624	histone deacetylase catalytic subunit hd1	[histone deacetylase catalytic subunit HD1]	1.0	5	1	0	0
50589	1624	sickle blood cell ss RBC	[sickle blood cells SS RBC]	1.0	5	2	2	2
50590	1624	number of retrievable alveolar macrophage	[number of retrievable alveolar macrophages]	1.0	5	1	0	0
50591	1624	gata-1 by the estrogen receptor	[GATA-1 by the estrogen receptor]	1.0	5	1	0	0
50592	1624	other functions,	[other functions,]	1.0	2	1	0	0
50593	1624	two nf-kappa b DNA binding site	[two NF-kappa B DNA binding sites]	1.0	6	1	0	0
50594	1624	screen a T cell cDNA library	[screening a T cell cDNA library]	1.0	6	1	0	0
50595	1624	mammary epithelial cell in vitro	[mammary epithelial cells in vitro]	1.0	5	1	0	0
50596	1624	particular bl	[particular BL]	1.0	2	1	0	0
50597	1624	exogeneous il-2	[exogeneous IL-2]	1.0	2	1	0	0
50598	1624	monocyte/macrophage system	[monocyte/macrophage system]	1.0	2	1	0	0
50599	1624	tissue-specific regulation of the ecto-5'-nucleotidase promoter	[Tissue-specific regulation of the ecto-5'-nucleotidase promoter]	1.0	6	1	0	0
50600	1624	gata1 expression	[GATA1 expression]	1.0	2	1	0	0
50601	1624	sequence psptspt	[sequence PSPTSPT]	1.0	2	1	0	0
50602	1624	1-2 peak at 4-6 h.	[1-2 peaks at 4-6 h,]	1.0	5	1	0	0
50603	1624	regulation of id3 cell cycle function	[Regulation of Id3 cell cycle function]	1.0	6	1	0	0
50604	1624	Rhombotin-2 RBTN-2	[Rhombotin-2 RBTN-2]	1.0	2	1	0	0
50605	1624	suggest pha related to the importance	[suggesting PHA related to the importance]	1.0	6	1	0	0
50606	1624	growth-inhibitory effect	[growth-inhibitory effect]	1.0	2	6	5	1
50607	1624	12-o-tetradecanoylphorbol-13-acetate tpa hl-60 cell differentiation	[12-O-tetradecanoylphorbol-13-acetate TPA HL-60 cell differentiation]	1.0	5	1	0	0
50608	1624	dna-binding capacity	[DNA-binding capacity]	1.0	2	1	0	0
50609	1624	average expansion	[average expansion]	1.0	2	1	0	0
50610	1624	t(15; 17)	[t(15; 17)]	1.0	2	1	0	0
50611	1624	variant d5g6	[variant D5G6]	1.0	2	1	0	0
50612	1624	human acute lymphoblastic t-cell line	[human acute lymphoblastic T-cell line]	1.0	5	1	0	0
50613	1624	human cells,	[human cells,]	1.0	2	2	1	1
50614	1624	rna-packaging defect	[RNA-packaging defect]	1.0	2	1	0	0
50615	1624	small increase	[small increase]	1.0	2	2	2	2
50616	1624	level in breast cancer patient	[levels in breast cancer patients]	1.0	5	1	0	0
50617	1624	additional region of 142 residue	[additional region of 142 residues]	1.0	5	1	0	0
50618	1624	activation of ifn-alpha/b-stimulated early response gene	[activation of IFN-alpha/B-stimulated early response genes]	1.0	6	1	0	0
50619	1624	serum-equilibrated ptdin	[Serum-equilibrated PtdIns]	1.0	2	1	0	0
50620	1624	include the T cell line HPB.ALL	[including the T cell line HPB.ALL]	1.0	6	1	0	0
50621	1624	ganglioside as important cell membrane constituent	[gangliosides as important cell membrane constituents]	1.0	6	1	0	0
50622	1624	RA alone	[RA alone]	1.0	2	1	0	0
50623	1624	vivo effect on calcium metabolism	[vivo effect on calcium metabolism]	1.0	5	1	0	0
50624	1624	Hemin induction	[Hemin induction]	1.0	2	2	1	1
50625	1624	block NF-kappaB in the rheumatoid joint	[Blocking NF-kappaB in the rheumatoid joint]	1.0	6	1	0	0
50626	1624	platelet of patient with heart failure	[platelets of patients with heart failure]	1.0	6	1	0	0
50627	1624	several form	[Several forms]	1.0	2	2	1	1
50628	1624	nf-at transcription responsive to calcium ionophore	[NF-AT transcription responsive to calcium ionophore]	1.0	6	1	0	0
50629	1624	AIR-1 gene	[AIR-1 gene]	1.0	2	1	0	0
50630	1624	spleen-cell culture	[spleen-cell culture]	1.0	2	1	0	0
50631	1624	control the pattern of alpha expression	[controlling the pattern of alpha expression]	1.0	6	1	0	0
50632	1624	interleukin-5 IL-5	[interleukin-5 IL-5]	1.0	2	1	0	0
50633	1624	NMR analysis	[NMR analysis]	1.0	2	1	0	0
50634	1624	Scatchard analysis of [3H]dexamethasone binding	[Scatchard analysis of [3H]dexamethasone binding]	1.0	5	1	0	0
50635	1624	combination of bacterial motility assay	[combination of bacterial motility assays]	1.0	5	1	0	0
50636	1624	then differentiation	[then differentiation]	1.0	2	1	0	0
50637	1624	human p40	[human p40]	1.0	2	2	2	2
50638	1624	abrupt downregulation	[abrupt downregulation]	1.0	2	1	0	0
50639	1624	use hsv-1 intertypic recombinant virus	[using HSV-1 intertypic recombinant virus]	1.0	5	1	0	0
50640	1624	ews/fli-1 peptide	[EWS/FLI-1 peptide]	1.0	2	1	0	0
50641	1624	differential response	[differential response]	1.0	2	2	2	2
50642	1624	carry genetic defect in the choice	[carrying genetic defect in the choice]	1.0	6	1	0	0
50643	1624	activator of transcription protein stat3	[activator of transcription proteins Stat3]	1.0	5	1	0	0
50644	1624	cell cycle regulation a activity	[cell cycle regulation a activity]	1.0	5	1	0	0
50645	1624	observation in the murine system	[observations in the murine system]	1.0	5	1	0	0
50646	1624	tnf-alpha release in NF-kappaB induction	[TNF-alpha release in NF-kappaB induction]	1.0	5	1	0	0
50647	1624	ar-5 cell	[Ar-5 cells]	1.0	2	1	0	0
50648	1624	basis for further study signal	[basis for further studies signaling]	1.0	5	1	0	0
50649	1624	d-type cyclin	[D-type cyclins]	1.0	2	1	0	0
50650	1624	synthesis of tissue factor tf	[synthesis of tissue factor TF]	1.0	5	1	0	0
50651	1624	tsh-r transcript level in thyroid fragment	[TSH-R transcript levels in thyroid fragments]	1.0	6	1	0	0
50652	1624	November 3;270(44):26721]	[Nov 3;270(44):26721]]	1.0	2	1	0	0
50653	1624	human p65	[human p65]	1.0	2	1	0	0
50654	1624	patient experience severe toxicity secondary	[patients experiencing severe toxicity secondary]	1.0	5	1	0	0
50655	1624	augmentation of b cell proliferation	[augmentation of B cell proliferation]	1.0	5	1	0	0
50656	1624	b-cll proliferation	[B-CLL proliferation]	1.0	2	1	0	0
50657	1624	hybrid receptor	[hybrid receptor]	1.0	2	1	0	0
50658	1624	normal epidermis	[normal epidermis]	1.0	2	1	0	0
50659	1624	U937 monocyte to TNF huvec	[U937 monocytes to TNF HUVECs]	1.0	5	1	0	0
50660	1624	relative bind affinity of quercetin	[relative binding affinity of quercetin]	1.0	5	1	0	0
50661	1624	production of cytokine by DC	[production of cytokines by DC]	1.0	5	1	0	0
50662	1624	RAR beta /rxr DNA binding	[RAR beta /RXR DNA binding]	1.0	5	1	0	0
50663	1624	mouse interleukin	[mouse interleukin]	1.0	2	1	0	0
50664	1624	ip-10 gene	[IP-10 gene]	1.0	2	1	0	0
50665	1624	steroid lysis	[steroid lysis]	1.0	2	1	0	0
50666	1624	central role in the control	[central role in the control]	1.0	5	1	0	0
50667	1624	mouse thymoma line el-4 cell	[Mouse thymoma line EL-4 cells]	1.0	5	1	0	0
50668	1624	exon encode the N terminus	[exon encoding the N terminus]	1.0	5	1	0	0
50669	1624	namely the activation-induced lymphocyte proliferation	[namely the activation-induced lymphocyte proliferation]	1.0	5	1	0	0
50670	1624	cooperative model for ebv entry	[cooperative model for EBV entry]	1.0	5	1	0	0
50671	1624	transgenic-mouse model	[transgenic-mouse models]	1.0	2	1	0	0
50672	1624	1 long terminal repeat quasispecy	[1 long terminal repeat quasispecies]	1.0	5	1	0	0
50673	1624	binding of a specific antibody	[Binding of a specific antibody]	1.0	5	1	0	0
50674	1624	demonstrable effect on the differentiation	[demonstrable effect on the differentiation]	1.0	5	1	0	0
50675	1624	primarily by host immune mechanism select	[primarily by host immune mechanisms selecting]	1.0	6	1	0	0
50676	1624	chronic arthritis	[chronic arthritis]	1.0	2	2	1	1
50677	1624	E1A gene between ad group	[E1A genes between Ad groups]	1.0	5	1	0	0
50678	1624	mutation in the NF-kappa b site	[mutations in the NF-kappa B site]	1.0	6	1	0	0
50679	1624	many cytokine such as IL-4,	[many cytokines such as IL-4,]	1.0	5	1	0	0
50680	1624	NF-kappaB complex with nuclear extract	[NF-kappaB complex with nuclear extract]	1.0	5	1	0	0
50681	1624	negative influence on cytokine gene transcription	[negative influences on cytokine gene transcription]	1.0	6	1	0	0
50682	1624	immediate early gene in cell	[immediate early genes in cells]	1.0	5	1	0	0
50683	1624	therapeutic activity	[therapeutic activity]	1.0	2	1	0	0
50684	1624	possible existence of er variant	[possible existence of ER variants]	1.0	5	1	0	0
50685	1624	activator protein 1 transcription factor	[activator protein 1 transcription factors]	1.0	5	1	0	0
50686	1624	caspase substrate poly eadp-ribose) polymerase	[caspase substrate poly (ADP-ribose) polymerase]	1.0	5	1	0	0
50687	1624	cd4+ T lymphocyte n.engl.j. med.324:308-317,	[CD4+ T lymphocytes N.Engl.J. Med.324:308-317,]	1.0	5	1	0	0
50688	1624	serum responsive element SRE present	[serum responsive element SRE present]	1.0	5	1	0	0
50689	1624	classic glucocorticoid	[classic glucocorticoids]	1.0	2	1	0	0
50690	1624	baseline interview	[baseline interview]	1.0	2	1	0	0
50691	1624	enzymatic process	[enzymatic processes]	1.0	2	1	0	0
50692	1624	endothelial leukocyte adhesion molecule ELAM	[endothelial leukocyte adhesion molecule ELAM]	1.0	5	1	0	0
50693	1624	BMLF1 transcript	[BMLF1 transcript]	1.0	2	1	0	0
50694	1624	human ada	[human ADA]	1.0	2	1	0	0
50695	1624	mixture of heparin gag with mcp-1	[mixture of heparin GAGs with MCP-1]	1.0	6	1	0	0
50696	1624	oxygen therapy	[oxygen therapy]	1.0	2	1	0	0
50697	1624	tec ifn-gamma	[TEC IFN-gamma]	1.0	2	1	0	0
50698	1624	molecular mechanism of t-lymphocyte anergy in	[molecular mechanisms of T-lymphocyte anergy in]	1.0	6	1	0	0
50699	1624	Bcl6 gene	[Bcl6 gene]	1.0	2	1	0	0
50700	1624	novel pathway for mineralocorticoid action	[novel pathway for mineralocorticoid action]	1.0	5	1	0	0
50701	1624	great than stimulation of activity,	[greater than stimulation of activity,]	1.0	5	1	0	0
50702	1624	immune recognition	[immune recognition]	1.0	2	1	0	0
50703	1624	role of a upstream site	[role of an upstream site]	1.0	5	1	0	0
50704	1624	b-cell-specific activity	[B-cell-specific activity]	1.0	2	1	0	0
50705	1624	development of feature in response	[development of features in response]	1.0	5	1	0	0
50706	1624	inflammatory pathology	[inflammatory pathologies]	1.0	2	2	2	2
50707	1624	corticoid resistance	[corticoid resistance]	1.0	2	1	0	0
50708	1624	additional b cell-specific enhancer element	[additional B cell-specific enhancer elements]	1.0	5	1	0	0
50709	1624	genomic region	[genomic region]	1.0	2	2	2	2
50710	1624	CD40 cross-linking in b lymphocyte	[CD40 cross-linking in B lymphocytes]	1.0	5	1	0	0
50711	1624	ability of this mutant strain	[ability of this mutant strain]	1.0	5	1	0	0
50712	1624	glucocorticoid at clinically relevant concentration	[glucocorticoids at clinically relevant concentrations]	1.0	5	1	0	0
50713	1624	fkbp binding of rotamase activity	[FKBP binding of rotamase activity]	1.0	5	1	0	0
50714	1624	stat6 protein present in pbmc	[Stat6 protein present in PBMCs]	1.0	5	1	0	0
50715	1624	pha proliferation of blood T lymphocyte	[PHA proliferation of blood T lymphocytes]	1.0	6	1	0	0
50716	1624	sh- VDR	[Sh- VDR]	1.0	2	1	0	0
50717	1624	fludarabine in	[fludarabine in]	1.0	2	1	0	0
50718	1624	results: monolayer	[RESULTS: Monolayers]	1.0	2	1	0	0
50719	1624	close association	[close association]	1.0	2	2	1	1
50720	1624	present evidence	[Present evidence]	1.0	2	1	0	0
50721	1624	CCAAT site	[CCAAT site]	1.0	2	1	0	0
50722	1624	reverse transcriptase polymerase chain reaction analysis	[reverse transcriptase polymerase chain reaction analysis]	1.0	6	1	0	0
50723	1624	-76 site	[-76 site]	1.0	2	1	0	0
50724	1624	CTLA-4 -mediated inhibition of early event	[CTLA-4 -Mediated inhibition of early events]	1.0	6	1	0	0
50725	1624	MDHM pbmo	[MDHM PBMo]	1.0	2	1	0	0
50726	1624	differentiation of u-937 cell with 12-o-tetradecanoylphorbol-13-acetate	[Differentiation of U-937 cells with 12-O-tetradecanoylphorbol-13-acetate]	1.0	6	1	0	0
50727	1624	herbimycin a -protein kinase inhibitor	[herbimycin a -protein kinase inhibitor]	1.0	5	1	0	0
50728	1624	b-1 cell	[B-1 cells]	1.0	2	2	2	2
50729	1624	morphologic analysis	[Morphologic analysis]	1.0	2	1	0	0
50730	1624	such preparation	[such preparations]	1.0	2	1	0	0
50731	1624	role direct the cytolytic action	[role directing the cytolytic action]	1.0	5	1	0	0
50732	1624	major cause	[major cause]	1.0	2	2	2	2
50733	1624	LEF-1 /gal4	[LEF-1 /GAL4]	1.0	2	1	0	0
50734	1624	positive regulator of pi 3-kinase	[positive regulator of PI 3-kinase]	1.0	5	1	0	0
50735	1624	hypothesis concern the possible role	[hypothesis concerning the possible role]	1.0	5	1	0	0
50736	1624	cd4+ T helper (pth) cell	[CD4+ T helper (pTh) cells]	1.0	5	1	0	0
50737	1624	1-2 min.	[1-2 min.]	1.0	2	1	0	0
50738	1624	chromosome 8q24	[chromosome 8q24]	1.0	2	1	0	0
50739	1624	biodisposal of all-tran retinoic acid	[biodisposal of all-trans retinoic acid]	1.0	5	1	0	0
50740	1624	cellular lysate	[cellular lysates]	1.0	2	1	0	0
50741	1624	chickens, estrogen	[chickens, estrogens]	1.0	2	1	0	0
50742	1624	difference in systemic hGR level	[difference in systemic hGR levels]	1.0	5	1	0	0
50743	1624	nuclear nf-at	[nuclear NF-AT]	1.0	2	1	0	0
50744	1624	Epstein-Barr nuclear antigen EBNA expression	[Epstein-Barr nuclear antigen EBNA expression]	1.0	5	1	0	0
50745	1624	vitro binding of ets-1, pu.1	[vitro binding of Ets-1, PU.1]	1.0	5	1	0	0
50746	1624	receptor family	[receptor family]	1.0	2	2	1	1
50747	1624	12-o-tetradecanoyl phorbol-13-acetate	[12-O-tetradecanoyl phorbol-13-acetate]	1.0	2	1	0	0
50748	1624	tal1 transcription in t-all cell	[TAL1 transcription in T-ALL cells]	1.0	5	1	0	0
50749	1624	involvement in transcription of rna gene	[involvement in transcription of RNA genes]	1.0	6	1	0	0
50750	1624	engineering a vaccine for this alpha-herpesviruse	[engineering a vaccine for these alpha-herpesviruses]	1.0	6	1	0	0
50751	1624	entire period,	[entire period,]	1.0	2	1	0	0
50752	1624	hla class ii molecule distal	[HLA class II molecules distal]	1.0	5	1	0	0
50753	1624	downmodulation of the alpha isozyme	[downmodulation of the alpha isozymes]	1.0	5	1	0	0
50754	1624	camp inducibility of transcriptional repressor icer	[cAMP inducibility of transcriptional repressor ICER]	1.0	6	1	0	0
50755	1624	hiv-enhancer domain	[HIV-enhancer domain]	1.0	2	1	0	0
50756	1624	b cell in normal thymus	[B cells in normal thymus]	1.0	5	1	0	0
50757	1624	modulation of nf-kappa b activation	[modulation of NF-kappa B activation]	1.0	5	1	0	0
50758	1624	proliferative response in T cell	[proliferative response in T cells]	1.0	5	1	0	0
50759	1624	cDNA of the myf3 gene	[cDNA of the myf3 gene]	1.0	5	1	0	0
50760	1624	approximately 42 different gene HZF	[approximately 42 different genes HZF]	1.0	5	1	0	0
50761	1624	woman with endometriosis at phase	[women with endometriosis at phases]	1.0	5	1	0	0
50762	1624	promoter element control collagenase transcription	[promoter elements controlling collagenase transcription]	1.0	5	1	0	0
50763	1624	(dys)regulation of NF-kappa b /rel	[(dys)regulation of NF-kappa B /Rel]	1.0	5	1	0	0
50764	1624	Nuclear translocation of cytosolic nf-kappa b	[Nuclear translocation of cytosolic NF-kappa B]	1.0	6	1	0	0
50765	1624	characterization of this cDNA clone	[Characterization of this cDNA clone]	1.0	5	1	0	0
50766	1624	proto-oncogene activation	[proto-oncogene activation]	1.0	2	1	0	0
50767	1624	cellular repressor	[cellular repressor]	1.0	2	1	0	0
50768	1624	datum along with previous observation	[data along with previous observations]	1.0	5	1	0	0
50769	1624	such as distribution of lymphocyte subpopulation	[such as distribution of lymphocyte subpopulations]	1.0	6	1	0	0
50770	1624	cell extract with the antiserum	[cell extract with the antiserum]	1.0	5	1	0	0
50771	1624	protein- tre	[protein- TRE]	1.0	2	2	1	1
50772	1624	3 mo.	[3 mo.]	1.0	2	1	0	0
50773	1624	tax gene product I htlv-i	[tax gene product I HTLV-I]	1.0	5	1	0	0
50774	1624	several thymocyte from the medulla	[several thymocytes from the medulla]	1.0	5	1	0	0
50775	1624	transcription of the NF-IL6 gene	[transcription of the NF-IL6 gene]	1.0	5	1	0	0
50776	1624	Epstein-Barr virus EBV cell line	[Epstein-Barr virus EBV cell line]	1.0	5	1	0	0
50777	1624	tcr transcript	[TcR transcript]	1.0	2	1	0	0
50778	1624	anti-CD3-stimulated cord blood mononuclear cell	[anti-CD3-stimulated cord blood mononuclear cells]	1.0	5	1	0	0
50779	1624	human stomach	[human stomach]	1.0	2	1	0	0
50780	1624	human myeloid zinc finger protein mzf-1	[Human myeloid zinc finger protein MZF-1]	1.0	6	1	0	0
50781	1624	tpa ca(2+) signal for the regulation	[TPA Ca(2+) signals for the regulation]	1.0	6	1	0	0
50782	1624	early erythroid progenitor burst-form units-erythroid	[early erythroid progenitors burst-forming units-erythroid]	1.0	5	1	0	0
50783	1624	additional factor(	[additional factor(s)]	1.0	2	1	0	0
50784	1624	ratio-dependent increase in hiv production	[ratio-dependent increase in HIV production]	1.0	5	1	0	0
50785	1624	family history of breast/ovarian cancer	[family history of breast/ovarian cancer]	1.0	5	1	0	0
50786	1624	bypass the need for il-12 signaling,	[bypassing the need for IL-12 signaling,]	1.0	6	1	0	0
50787	1624	up-regulation of c-fo with anti-CD3 stimulation	[up-regulation of c-fos with anti-CD3 stimulation]	1.0	6	1	0	0
50788	1624	implication for replication of hiv-1	[Implications for replication of HIV-1]	1.0	5	1	0	0
50789	1624	second messenger for the effect	[second messenger for the effects]	1.0	5	1	0	0
50790	1624	NF-kappa b activity in T cell	[NF-kappa B activity in T cells]	1.0	6	1	0	0
50791	1624	cell cytotoxicity	[cell cytotoxicity]	1.0	2	1	0	0
50792	1624	repression of the beta-globin gene	[repression of the beta-globin gene]	1.0	5	2	1	1
50793	1624	expression of pebp2 alpha a	[expression of PEBP2 alpha A]	1.0	5	1	0	0
50794	1624	include nuclear factor kappa b	[including nuclear factor kappa B]	1.0	5	1	0	0
50795	1624	gc-r parameter	[GC-R parameters]	1.0	2	1	0	0
50796	1624	clinical implications.	[clinical implications.]	1.0	2	2	1	1
50797	1624	homologous gene	[homologous genes]	1.0	2	2	2	2
50798	1624	T cell recognize T antigen	[T cells recognizing T antigen]	1.0	5	1	0	0
50799	1624	effect on the intracellular sodium	[effects on the intracellular sodium]	1.0	5	1	0	0
50800	1624	cDNA of a factor-kappaB inhibitor	[cDNA of a factor-kappaB inhibitor]	1.0	5	1	0	0
50801	1624	hormone effect	[hormone effect]	1.0	2	1	0	0
50802	1624	hypothalamic-pituitary-adrenocortical axis in adult rat	[hypothalamic-pituitary-adrenocortical axis in adult rats]	1.0	5	1	0	0
50803	1624	two class of signal molecule	[two classes of signaling molecules]	1.0	5	1	0	0
50804	1624	pro-apoptotic effect,	[pro-apoptotic effect,]	1.0	2	1	0	0
50805	1624	bhlh domain	[bHLH domain]	1.0	2	1	0	0
50806	1624	transcription of the terminal repeat	[transcription of the terminal repeat]	1.0	5	2	2	2
50807	1624	protection employ nuclear extract from B	[protection employing nuclear extracts from B]	1.0	6	1	0	0
50808	1624	various reverse effect on macrophage	[various reverse effects on macrophages]	1.0	5	1	0	0
50809	1624	different model accounting for the haploinsufficiency	[different models accounting for the haploinsufficiency]	1.0	6	1	0	0
50810	1624	hil-5 signal	[hIL-5 signal]	1.0	2	1	0	0
50811	1624	protein with cysteine -rich region	[protein with cysteine -rich regions]	1.0	5	1	0	0
50812	1624	several protein of molecular mass	[several proteins of molecular mass]	1.0	5	1	0	0
50813	1624	integer number of helical turn	[integer numbers of helical turns]	1.0	5	1	0	0
50814	1624	lack exon	[lacking exon]	1.0	2	2	2	2
50815	1624	Ig heavy chain class switch	[Ig heavy chain class switching]	1.0	5	1	0	0
50816	1624	specific glucocorticoid receptor blocker RU43044	[specific glucocorticoid receptor blocker RU43044]	1.0	5	1	0	0
50817	1624	patient with x-linked hypophosphatemic ricket	[patients with X-linked hypophosphatemic rickets]	1.0	5	1	0	0
50818	1624	human lymphoblastic Jurkat T cell	[human lymphoblastic Jurkat T cells]	1.0	5	1	0	0
50819	1624	allele ratio great than 3:1,	[allele ratio greater than 3:1,]	1.0	5	1	0	0
50820	1624	endothelial expression of adhesion molecule	[endothelial expression of adhesion molecules]	1.0	5	2	1	1
50821	1624	component of the immune system	[components of the immune system]	1.0	5	1	0	0
50822	1624	human renal cell carcinoma RCC	[human renal cell carcinoma RCC]	1.0	5	1	0	0
50823	1624	gene expression in k562 cell	[gene expression in K562 cells]	1.0	5	1	0	0
50824	1624	(HS 2)	[(HS 2)]	1.0	2	1	0	0
50825	1624	glucocorticoid receptor binding in mononuclear leukocyte	[glucocorticoid receptor binding in mononuclear leukocytes]	1.0	6	1	0	0
50826	1624	bsm i	[Bsm I]	1.0	2	1	0	0
50827	1624	DC in the T cell zone	[DC in the T cell zone]	1.0	6	1	0	0
50828	1624	(88.6+/-11.5 pg/ml versus 11.5+/-7.1 pg/mL,	[(88.6+/-11.5 pg/mL vs 11.5+/-7.1 pg/mL,]	1.0	5	1	0	0
50829	1624	discrete stage of erythropoietic development	[discrete stages of erythropoietic development]	1.0	5	1	0	0
50830	1624	il-1 necrosis factor alpha change	[IL-1 necrosis factor alpha changes]	1.0	5	1	0	0
50831	1624	detection of oestrogen receptor variant	[Detection of oestrogen receptor variants]	1.0	5	1	0	0
50832	1624	cord lymphocyte maximum c-fo expression (82+/-6	[cord lymphocyte maximum c-fos expression (82+/-6]	1.0	6	1	0	0
50833	1624	suggest important for this activity	[suggesting important for this activity]	1.0	5	1	0	0
50834	1624	six patient with reactive eosinophilias	[six patients with reactive eosinophilias]	1.0	5	1	0	0
50835	1624	sulfhydryl agent	[sulfhydryl agent]	1.0	2	2	2	2
50836	1624	treatment of cell with pd98059	[Treatment of cells with PD98059]	1.0	5	1	0	0
50837	1624	erythropoietic wave	[erythropoietic wave]	1.0	2	1	0	0
50838	1624	anti-CD3 nf-at	[anti-CD3 NF-AT]	1.0	2	1	0	0
50839	1624	arise in this cell fusion	[arising in these cell fusions]	1.0	5	1	0	0
50840	1624	intact c3a	[intact C3a]	1.0	2	1	0	0
50841	1624	traf3 binding site in LMP1	[TRAF3 binding sites in LMP1]	1.0	5	1	0	0
50842	1624	100 nm.	[100 nM.]	1.0	2	1	0	0
50843	1624	three individual with primary infection	[three individuals with primary infection]	1.0	5	1	0	0
50844	1624	two homologue of the rhombotin gene	[Two homologues of the rhombotin gene]	1.0	6	1	0	0
50845	1624	dna-streptavidin matrix	[DNA-streptavidin matrix]	1.0	2	1	0	0
50846	1624	aging change	[aging change]	1.0	2	2	1	1
50847	1624	micromolar concentration of h2o2 exhibit	[micromolar concentrations of H2O2 exhibit]	1.0	5	1	0	0
50848	1624	heteromeric interaction	[heteromeric interactions]	1.0	2	1	0	0
50849	1624	-182 bp	[-182 bp]	1.0	2	1	0	0
50850	1624	immunoperoxidase staining of cell monolayer	[immunoperoxidase staining of cell monolayers]	1.0	5	1	0	0
50851	1624	inflammatory signal	[inflammatory signals]	1.0	2	1	0	0
50852	1624	anomaly in hpa axis function	[anomalies in HPA axis function]	1.0	5	1	0	0
50853	1624	CD5 expression	[CD5 expression]	1.0	2	2	1	1
50854	1624	cytokine tgf-beta	[cytokine TGF-beta]	1.0	2	2	2	2
50855	1624	delta subunit	[delta subunits]	1.0	2	1	0	0
50856	1624	several human b cell line	[several human B cell lines]	1.0	5	1	0	0
50857	1624	Pan gene	[Pan gene]	1.0	2	1	0	0
50858	1624	striking heterogeneity of clonal development	[striking heterogeneity of clonal development]	1.0	5	1	0	0
50859	1624	expression of several th2 cytokine	[expression of several Th2 cytokines]	1.0	5	1	0	0
50860	1624	human aging	[human aging]	1.0	2	1	0	0
50861	1624	c-rel subunit	[c-Rel subunits]	1.0	2	1	0	0
50862	1624	include p53	[including p53]	1.0	2	1	0	0
50863	1624	severe immunodeficiency due to defective binding	[Severe immunodeficiency due to defective binding]	1.0	6	1	0	0
50864	1624	encode a integral membrane protein	[encoding an integral membrane protein]	1.0	5	1	0	0
50865	1624	R24 treatment	[R24 treatment]	1.0	2	2	1	1
50866	1624	kasumi-1 cell	[Kasumi-1 cells]	1.0	2	2	1	1
50867	1624	same properties	[same properties,]	1.0	2	1	0	0
50868	1624	include p65	[including p65]	1.0	2	1	0	0
50869	1624	analysis of the expression of gene	[Analysis of the expression of genes]	1.0	6	1	0	0
50870	1624	receptor contain the gamma chain	[receptors containing the gamma chain]	1.0	5	1	0	0
50871	1624	1 patient	[1 patient]	1.0	2	1	0	0
50872	1624	effect of 24,25-dihydroxyvitamin D3 dioxyvit	[effect of 24,25-dihydroxyvitamin D3 dioxyvit]	1.0	5	1	0	0
50873	1624	mutagenesis experiment	[Mutagenesis experiments]	1.0	2	1	0	0
50874	1624	structural order	[structural order]	1.0	2	2	2	2
50875	1624	RXR alpha in monocytic differentiation	[RXR alpha in monocytic differentiation]	1.0	5	1	0	0
50876	1624	induction phase	[induction phase]	1.0	2	2	2	2
50877	1624	Recognition of this new leukemic entity	[Recognition of this new leukemic entity]	1.0	6	1	0	0
50878	1624	link bcr signal to the induction	[linking BCR signals to the induction]	1.0	6	1	0	0
50879	1624	two repressor	[two repressors]	1.0	2	2	1	1
50880	1624	serine phosphorylation of stat3 stat5	[serine phosphorylation of Stat3 Stat5]	1.0	5	1	0	0
50881	1624	expression level of icam-1 rrna	[expression level of ICAM-1 mRNAs]	1.0	5	1	0	0
50882	1624	different promoter in monocytic cell	[different promoters in monocytic cells]	1.0	5	1	0	0
50883	1624	base pair of the ifn-gamma promoter	[base pairs of the IFN-gamma promoter]	1.0	6	1	0	0
50884	1624	analysis of human gata-3 factor	[Analysis of human GATA-3 factors]	1.0	5	1	0	0
50885	1624	NF-kappa b activation pyrrolidine dithiocarbamate	[NF-kappa B activation pyrrolidine dithiocarbamate]	1.0	5	1	0	0
50886	1624	regulation of the human interleukin-2 gene	[Regulation of the human interleukin-2 gene]	1.0	6	1	0	0
50887	1624	new mrna synthesis for c-rel	[new mRNA synthesis for c-rel]	1.0	5	1	0	0
50888	1624	anti- CD40	[anti- CD40]	1.0	2	1	0	0
50889	1624	ss rbc	[SS RBC]	1.0	2	2	2	2
50890	1624	function of	[function of]	1.0	2	1	0	0
50891	1624	actual binding	[actual binding]	1.0	2	2	1	1
50892	1624	b protein in nuclear extract	[B proteins in nuclear extracts]	1.0	5	1	0	0
50893	1624	IL-6 level in all IBD group	[IL-6 levels in all IBD groups]	1.0	6	1	0	0
50894	1624	contribution ca(2+)-	[contribution Ca(2+)-]	1.0	2	1	0	0
50895	1624	join gene segment within this locus.	[joining gene segments within this locus.]	1.0	6	1	0	0
50896	1624	CHEMR1 gene	[CHEMR1 gene]	1.0	2	1	0	0
50897	1624	10 days.	[10 days.]	1.0	2	1	0	0
50898	1624	gamma/delta tcr	[gamma/delta TCR]	1.0	2	1	0	0
50899	1624	temperature, beta 2-microglobulin beta 2-m	[temperature, beta 2-microglobulin beta 2-m]	1.0	5	1	0	0
50900	1624	prior to infection with hcmv	[prior to infection with HCMV]	1.0	5	1	0	0
50901	1624	kinetic in cemxl74 cell sivmac239	[kinetics in CEMxl74 cells SIVmac239]	1.0	5	1	0	0
50902	1624	alveolar macrophages.	[alveolar macrophages.]	1.0	2	1	0	0
50903	1624	viral replication in hela cell	[viral replication in HeLa cells]	1.0	5	1	0	0
50904	1624	cd3+ cell in ectopic pregnancy	[CD3+ cells in ectopic pregnancy]	1.0	5	1	0	0
50905	1624	hiv-1 (-139)long terminal repeat-cat construct	[HIV-1 (-139)long terminal repeat-CAT construct]	1.0	5	1	0	0
50906	1624	relatively little nfat transcriptional activity	[relatively little NFAT transcriptional activity]	1.0	5	1	0	0
50907	1624	select group of transcription factor	[select group of transcription factors]	1.0	5	1	0	0
50908	1624	reach a maximum by 10-15 min,	[reaching a maximum by 10-15 min,]	1.0	6	1	0	0
50909	1624	analysis of the modulation of activity	[Analysis of the modulation of activity]	1.0	6	1	0	0
50910	1624	glioblastoma line	[glioblastoma line]	1.0	2	1	0	0
50911	1624	activation of a latent infection	[activation of a latent infection]	1.0	5	1	0	0
50912	1624	spite of cortisol plasma level	[spite of cortisol plasma levels]	1.0	5	1	0	0
50913	1624	binding activity of the nfil3 protein	[binding activity of the Nfil3 protein]	1.0	6	1	0	0
50914	1624	90% inhibition	[90% inhibition]	1.0	2	2	2	2
50915	1624	(b) dxm	[(b) DXM]	1.0	2	1	0	0
50916	1624	pre-exist component	[pre-existing component]	1.0	2	1	0	0
50917	1624	initiation region	[initiation region]	1.0	2	1	0	0
50918	1624	33 stretch	[33 stretch]	1.0	2	1	0	0
50919	1624	critical factor in the generation	[critical factor in the generation]	1.0	5	1	0	0
50920	1624	hardly any binding of p50p50	[hardly any binding of p50p50]	1.0	5	1	0	0
50921	1624	plasma sample	[plasma samples]	1.0	2	2	1	1
50922	1624	environmental estrogenic	[environmental estrogenic]	1.0	2	1	0	0
50923	1624	increase of human motor activity	[increase of human motor activity]	1.0	5	1	0	0
50924	1624	tf induction	[TF induction]	1.0	2	2	1	1
50925	1624	t-cell antigen receptor signal transduction	[T-cell antigen receptor signal transduction]	1.0	5	1	0	0
50926	1624	trans-activation of the TP1 promoter	[Trans-activation of the TP1 promoter]	1.0	5	1	0	0
50927	1624	block factor at the site	[blocking factors at the site]	1.0	5	1	0	0
50928	1624	sequence related	[Sequences related]	1.0	2	1	0	0
50929	1624	advanced RCC	[advanced RCC]	1.0	2	1	0	0
50930	1624	immunosuppression by cyclosporin A CsA	[immunosuppression by cyclosporin A CsA]	1.0	5	1	0	0
50931	1624	switch recombination.	[switch recombination.]	1.0	2	1	0	0
50932	1624	Interleukin-5 signal in human eosinophil	[Interleukin-5 signaling in human eosinophils]	1.0	5	1	0	0
50933	1624	deletion of the NF-kappa b element	[Deletion of the NF-kappa B elements]	1.0	6	1	0	0
50934	1624	use a surface plasmon resonance approach	[using a surface plasmon resonance approach]	1.0	6	1	0	0
50935	1624	primary murine bone marrow cell	[primary murine bone marrow cells]	1.0	5	1	0	0
50936	1624	0.2 nm)	[0.2 nM)]	1.0	2	1	0	0
50937	1624	activation of the proenkephalin promoter	[activation of the proenkephalin promoter]	1.0	5	2	1	1
50938	1624	thiazolidinedione derivative on glucose uptake	[thiazolidinedione derivative on glucose uptake]	1.0	5	1	0	0
50939	1624	late onset	[late onset]	1.0	2	1	0	0
50940	1624	Initial experiment	[Initial experiments]	1.0	2	1	0	0
50941	1624	site-mediated immunoglobulin gene promoter activity	[site-mediated immunoglobulin gene promoter activity]	1.0	5	1	0	0
50942	1624	asthmatic subject	[asthmatic subjects]	1.0	2	2	1	1
50943	1624	activation of several downstream kinase	[activation of several downstream kinases]	1.0	5	1	0	0
50944	1624	lytic replication of Epstein-Barr virus	[lytic replication of Epstein-Barr virus]	1.0	5	1	0	0
50945	1624	patient with receptor affinity to glucocorticoid	[patients with receptor affinity to glucocorticoids]	1.0	6	2	2	2
50946	1624	genetic transmission	[genetic transmission]	1.0	2	1	0	0
50947	1624	several transcription factor include sp1	[several transcription factors including Sp1]	1.0	5	1	0	0
50948	1624	immediate-early transcript in cd4+ T lymphocyte	[immediate-early transcripts in CD4+ T lymphocytes]	1.0	6	1	0	0
50949	1624	serum ige	[serum IgE]	1.0	2	2	2	2
50950	1624	four exon	[four exons]	1.0	2	1	0	0
50951	1624	y341 F mutant of Syk	[Y341 F mutant of Syk]	1.0	5	1	0	0
50952	1624	target for multiple kinase pathway	[targets for multiple kinase pathways]	1.0	5	1	0	0
50953	1624	change in the mrna level	[change in the mRNA level]	1.0	5	2	1	1
50954	1624	Jak family of tyrosine kinase	[Jak family of tyrosine kinases]	1.0	5	1	0	0
50955	1624	key event underlie lymphocyte action	[key event underlying lymphocyte action]	1.0	5	1	0	0
50956	1624	direct circulate leukocyte into extravascular tissue	[directing circulating leukocytes into extravascular tissues]	1.0	6	1	0	0
50957	1624	lymphocyte glucocorticoid receptor binding parameter	[Lymphocyte glucocorticoid receptor binding parameters]	1.0	5	1	0	0
50958	1624	DNA specifically,	[DNA specifically,]	1.0	2	1	0	0
50959	1624	subtotal colectomy	[subtotal colectomy]	1.0	2	1	0	0
50960	1624	hcmv binding	[HCMV binding]	1.0	2	2	1	1
50961	1624	common requirement	[common requirements]	1.0	2	2	2	2
50962	1624	control subjects.	[control subjects.]	1.0	2	1	0	0
50963	1624	il-5 expression in T cell	[IL-5 expression in T cells]	1.0	5	1	0	0
50964	1624	gene organization within the nucleus	[gene organization within the nucleus]	1.0	5	1	0	0
50965	1624	chromosomal assignment	[chromosomal assignment]	1.0	2	1	0	0
50966	1624	nf-chi b	[NF-chi B]	1.0	2	2	2	2
50967	1624	body weight	[Body weight]	1.0	2	1	0	0
50968	1624	expression of CD30 by this cell	[Expression of CD30 by these cells]	1.0	6	1	0	0
50969	1624	two SH2 domain of SHP1	[two SH2 domains of SHP1]	1.0	5	1	0	0
50970	1624	ras function	[Ras function]	1.0	2	1	0	0
50971	1624	mutation of Aiolos -binding site	[Mutation of Aiolos -binding sites]	1.0	5	1	0	0
50972	1624	IL-10 cell	[IL-10 cells]	1.0	2	2	1	1
50973	1624	tumor suppressor protein as regulator	[Tumor suppressor proteins as regulators]	1.0	5	1	0	0
50974	1624	A-myb expression in b cell	[A-myb expression in B cells]	1.0	5	1	0	0
50975	1624	3.16 mg/24h; n: 2.7+/-2.0) excretion,	[3.16 mg/24h; N: 2.7+/-2.0) excretion,]	1.0	5	1	0	0
50976	1624	activator protein-1 -responsive gene activation	[activator protein-1 -responsive gene activation]	1.0	5	1	0	0
50977	1624	diverse pathway of monocyte differentiation	[diverse pathway of monocyte differentiation]	1.0	5	1	0	0
50978	1624	allelic form	[allelic form]	1.0	2	2	2	2
50979	1624	receptor affinity,	[receptor affinity,]	1.0	2	1	0	0
50980	1624	change in constitutive nf-kappa b	[change in constitutive NF-kappa B]	1.0	5	1	0	0
50981	1624	BCR-ABL chimera	[BCR-ABL chimera]	1.0	2	1	0	0
50982	1624	acetyltransferase reporter	[acetyltransferase reporter]	1.0	2	1	0	0
50983	1624	IL-8 concentration of the cell-free supernatant	[IL-8 concentration of the cell-free supernatant]	1.0	6	1	0	0
50984	1624	Glucocorticoid apoptosis of nf-kappab activity	[Glucocorticoid apoptosis of NF-kappaB activity]	1.0	5	1	0	0
50985	1624	several day	[several days,]	1.0	2	2	1	1
50986	1624	other subclone	[other subclones).]	1.0	2	2	1	1
50987	1624	20 min.	[20 min.]	1.0	2	1	0	0
50988	1624	20 min,	[20 min,]	1.0	2	1	0	0
50989	1624	20 mM	[20 mM]	1.0	2	1	0	0
50990	1624	simian immunodeficiency virus variant sivsmmpbj14	[simian immunodeficiency virus variant SIVsmmPBj14]	1.0	5	1	0	0
50991	1624	multiple cis element especially S	[multiple cis elements especially S]	1.0	5	1	0	0
50992	1624	mutation in the gene sox9	[mutations in the gene SOX9]	1.0	5	1	0	0
50993	1624	tcr/cd3 signal	[TcR/CD3 signals]	1.0	2	1	0	0
50994	1624	three distinct DNA binding complex	[three distinct DNA binding complexes]	1.0	5	1	0	0
50995	1624	major promoter	[major promoter]	1.0	2	2	2	2
50996	1624	intrigue issue	[intriguing issue]	1.0	2	1	0	0
50997	1624	Thus, CIITA	[Thus, CIITA]	1.0	2	1	0	0
50998	1624	signal through the t-cell receptor	[signalling through the T-cell receptor]	1.0	5	1	0	0
50999	1624	c-Raf increase in il-2 induction	[c-Raf increase in IL-2 induction]	1.0	5	1	0	0
51000	1624	Id3 mrna	[Id3 mRNA]	1.0	2	1	0	0
51001	1624	test a series of clone	[testing a series of clones]	1.0	5	1	0	0
51002	1624	Computer analysis	[Computer analysis]	1.0	2	1	0	0
51003	1624	endogenous function	[endogenous function]	1.0	2	1	0	0
51004	1624	case of a 54-year-old woman	[case of a 54-year-old woman]	1.0	5	1	0	0
51005	1624	p65 delta	[p65 delta]	1.0	2	2	1	1
51006	1624	growth hormone on tnf-alpha secretion	[growth hormone on TNF-alpha secretion]	1.0	5	1	0	0
51007	1624	protein kinase pathway by complement complex	[protein kinase pathway by complement complexes]	1.0	6	1	0	0
51008	1624	underlie the development of neoplasia	[underlying the development of neoplasia]	1.0	5	1	0	0
51009	1624	serum-starved cell	[serum-starved cells]	1.0	2	1	0	0
51010	1624	glucocorticoid receptor gr binding characteristic	[glucocorticoid receptor GR binding characteristics]	1.0	5	1	0	0
51011	1624	two bind motif for Pit-1	[two binding motifs for Pit-1]	1.0	5	1	0	0
51012	1624	inhibitor il-1ra	[inhibitor IL-1ra]	1.0	2	1	0	0
51013	1624	C3 transferase	[C3 transferase]	1.0	2	2	1	1
51014	1624	Nb2 T cell kilobasis (kb)	[Nb2 T cells kilobases (kb)]	1.0	5	1	0	0
51015	1624	amount of trypsin -resistant fragment	[amount of trypsin -resistant fragments]	1.0	5	1	0	0
51016	1624	u937 cell to human ECs	[U937 cells to human ECs]	1.0	5	1	0	0
51017	1624	putative human homolog of nrl	[putative human homolog of NRL]	1.0	5	1	0	0
51018	1624	important role in wound healing	[important roles in wound healing]	1.0	5	1	0	0
51019	1624	stable transfection	[stable transfection]	1.0	2	2	2	2
51020	1624	proteins, the heat-shock protein hsp90	[proteins, the heat-shock protein hsp90]	1.0	5	1	0	0
51021	1624	coexpress B7	[coexpressing B7]	1.0	2	1	0	0
51022	1624	target cell sensitization to injury	[target cell sensitization to injury]	1.0	5	1	0	0
51023	1624	Epstein-Barr virus cp latency-associated promoter	[Epstein-Barr virus Cp latency-associated promoter]	1.0	5	1	0	0
51024	1624	distinct pattern of chromosome 1 abnormality	[Distinct patterns of chromosome 1 abnormalities]	1.0	6	1	0	0
51025	1624	soon relapsed.	[soon relapsed.]	1.0	2	1	0	0
51026	1624	glutathione gssg	[glutathione GSSG]	1.0	2	2	1	1
51027	1624	frequent infection of Reed-Sternberg (rs) cell	[frequent infection of Reed-Sternberg (RS) cells]	1.0	6	1	0	0
51028	1624	synthesis of functional il-6 protein	[synthesis of functional IL-6 protein]	1.0	5	1	0	0
51029	1624	Comparison of cDNA genomic sequence	[Comparison of cDNA genomic sequences]	1.0	5	1	0	0
51030	1624	contain region of the collagenase-1 promoter	[containing regions of the collagenase-1 promoter]	1.0	6	1	0	0
51031	1624	nuclear T	[nuclear T]	1.0	2	1	0	0
51032	1624	radioimmune assay	[radioimmune assays]	1.0	2	1	0	0
51033	1624	Molecular, cellular,	[Molecular, cellular,]	1.0	2	1	0	0
51034	1624	peptide from the amino enhancer	[peptides from the amino enhancer]	1.0	5	1	0	0
51035	1624	suppressive effects.	[suppressive effects.]	1.0	2	1	0	0
51036	1624	low level rag gene expression	[low level RAG gene expression]	1.0	5	1	0	0
51037	1624	endocrine event	[endocrine events]	1.0	2	1	0	0
51038	1624	anti-CD3-stimulated cell	[anti-CD3-stimulated cells]	1.0	2	1	0	0
51039	1624	follicular b	[follicular B]	1.0	2	1	0	0
51040	1624	follow incubation	[following incubation]	1.0	2	2	2	2
51041	1624	proto-oncogene belong to a family	[proto-oncogene belonging to a family]	1.0	5	1	0	0
51042	1624	9 patient	[9 patients]	1.0	2	1	0	0
51043	1624	survival of T cell blast	[survival of T cell blasts]	1.0	5	1	0	0
51044	1624	tf mrna expression by LPS	[TF mRNA expression by LPS]	1.0	5	1	0	0
51045	1624	nine patient	[nine patients]	1.0	2	2	1	1
51046	1624	pre-B (hyon)	[pre-B (Hyon)]	1.0	2	1	0	0
51047	1624	IL-2 receptor	[IL-2 receptor]	1.0	2	2	1	1
51048	1624	fk506 action	[FK506 action]	1.0	2	1	0	0
51049	1624	nf-at element	[NF-AT element]	1.0	2	1	0	0
51050	1624	YY1 a human transcription factor	[YY1 a human transcription factor]	1.0	5	1	0	0
51051	1624	induce transcription from unrearranged ch gene	[inducing transcription from unrearranged CH genes]	1.0	6	1	0	0
51052	1624	J. Bernard, R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,	[J. Bernard, R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,]	1.0	6	1	0	0
51053	1624	fusion point	[fusion point]	1.0	2	2	1	1
51054	1624	dexamethasone DEX a synthetic glucocorticoid	[dexamethasone DEX a synthetic glucocorticoid]	1.0	5	1	0	0
51055	1624	transmission of cellular activation signal	[transmission of cellular activation signals]	1.0	5	1	0	0
51056	1624	defect in T cell proliferation	[defects in T cell proliferation]	1.0	5	1	0	0
51057	1624	malignant tissue	[malignant tissues]	1.0	2	1	0	0
51058	1624	study, serum	[study, serum]	1.0	2	1	0	0
51059	1624	gene expression in eukaryotic cell	[gene expression in eukaryotic cells]	1.0	5	1	0	0
51060	1624	sh3 domain	[SH3 domain]	1.0	2	2	2	2
51061	1624	SDS-polyacrylamide gel	[SDS-polyacrylamide gel]	1.0	2	1	0	0
51062	1624	Lymphocytic level of glucocorticoid receptor	[Lymphocytic levels of glucocorticoid receptors]	1.0	5	1	0	0
51063	1624	specific protein kinase c pkc	[specific protein kinase C PKC]	1.0	5	1	0	0
51064	1624	3' end of cag repeat	[3' end of CAG repeats]	1.0	5	1	0	0
51065	1624	lymphocyte line	[lymphocyte line]	1.0	2	2	2	2
51066	1624	response to numerous growth factor	[response to numerous growth factors]	1.0	5	1	0	0
51067	1624	general, deletion	[general, deletions]	1.0	2	1	0	0
51068	1624	induce fasL promoter-dependent reporter construct	[inducing fasL promoter-dependent reporter constructs]	1.0	5	1	0	0
51069	1624	immune suppression	[immune suppression]	1.0	2	2	1	1
51070	1624	expression of the transcription factor stat6	[expression of the transcription factor STAT6]	1.0	6	1	0	0
51071	1624	neuronal (type	[Neuronal (type]	1.0	2	1	0	0
51072	1624	CD4 silencer	[CD4 silencer]	1.0	2	2	1	1
51073	1624	part of the bcl6 molecule	[part of the BCL6 molecule]	1.0	5	1	0	0
51074	1624	viral transcription,	[Viral transcription,]	1.0	2	1	0	0
51075	1624	cytolytic effector molecule granzyme b	[cytolytic effector molecules granzyme B]	1.0	5	1	0	0
51076	1624	non-erythroid cell of a factor	[non-erythroid cells of a factor]	1.0	5	1	0	0
51077	1624	stringent systems, such as cell-free extract	[stringent systems, such as cell-free extracts]	1.0	6	1	0	0
51078	1624	lymphocytic infiltration of tumor tissue	[lymphocytic infiltration of tumor tissue]	1.0	5	1	0	0
51079	1624	miss the -417 to -207 region	[missing the -417 to -207 region]	1.0	6	1	0	0
51080	1624	implicate IL-4R as a component	[implicating IL-4R as a component]	1.0	5	1	0	0
51081	1624	sequence of the 5'-flanking region	[sequences of the 5'-flanking region]	1.0	5	1	0	0
51082	1624	enter lytic	[entering lytic]	1.0	2	1	0	0
51083	1624	T cell with a variety	[T cells with a variety]	1.0	5	1	0	0
51084	1624	define the pattern of alpha integrin	[defining the pattern of alpha integrin]	1.0	6	1	0	0
51085	1624	primary cd45ra	[primary CD45RA]	1.0	2	1	0	0
51086	1624	tf gene expression in cell	[TF gene expression in cells]	1.0	5	1	0	0
51087	1624	20 bp	[20 bp]	1.0	2	1	0	0
51088	1624	57 protein	[57 protein]	1.0	2	1	0	0
51089	1624	neoplastic clone	[neoplastic clone]	1.0	2	2	1	1
51090	1624	increase gata-1 level via co-transfection	[increasing GATA-1 levels via co-transfection]	1.0	5	1	0	0
51091	1624	apoptosis pathway	[apoptosis pathway]	1.0	2	2	1	1
51092	1624	treat event such as leukocyte migration	[treating events such as leukocyte migration]	1.0	6	1	0	0
51093	1624	expression of adhesion molecule on neutrophil	[expression of adhesion molecules on neutrophils]	1.0	6	1	0	0
51094	1624	modulating hemopoiesis.	[modulating hemopoiesis.]	1.0	2	1	0	0
51095	1624	distribution of the remain cell	[distribution of the remaining cells]	1.0	5	1	0	0
51096	1624	even in the presence of cycloheximide	[even in the presence of cycloheximide]	1.0	6	1	0	0
51097	1624	transcriptional activation of cAMP-dependent reporter gene	[transcriptional activation of cAMP-dependent reporter genes]	1.0	6	1	0	0
51098	1624	subcellular redistribution	[subcellular redistribution]	1.0	2	1	0	0
51099	1624	cardiac transplant	[cardiac transplant]	1.0	2	1	0	0
51100	1624	contain element of the tnf gene	[containing elements of the TNF gene]	1.0	6	1	0	0
51101	1624	less than 4 fmol/mg protein).	[less than 4 fmol/mg protein).]	1.0	5	1	0	0
51102	1624	maximal expression of the gene.	[maximal expression of the gene.]	1.0	5	1	0	0
51103	1624	stat-3 protein	[Stat-3 protein]	1.0	2	1	0	0
51104	1624	isolation of a rel-related human cDNA	[Isolation of a rel-related human cDNA]	1.0	6	1	0	0
51105	1624	other proteins.	[other proteins.]	1.0	2	1	0	0
51106	1624	persistence	[persistence]	1.0	1	12	10	5
51107	1624	DNA transfer	[DNA transfer]	1.0	2	2	2	2
51108	1624	expression of gata-1 mrna concomitant	[expression of GATA-1 mRNA concomitant]	1.0	5	1	0	0
51109	1624	moderate decrease in LTR transcriptional activity	[moderate decreases in LTR transcriptional activity]	1.0	6	1	0	0
51110	1624	granulocyte colony-stimulating factor receptor promoter	[granulocyte colony-stimulating factor receptor promoter]	1.0	5	1	0	0
51111	1624	morbidity in sickle cell disease	[morbidity in sickle cell disease]	1.0	5	1	0	0
51112	1624	40 minute	[40 min]	1.0	2	2	1	1
51113	1624	pecam-1 phosphorylation,	[PECAM-1 phosphorylation,]	1.0	2	1	0	0
51114	1624	human umbilical cord T lymphocyte	[human umbilical cord T lymphocytes]	1.0	5	1	0	0
51115	1624	high-level replication of immunodeficiency virus	[high-level replication of immunodeficiency virus]	1.0	5	2	2	2
51116	1624	most probably in the suprachiasmatic nuclei	[most probably in the suprachiasmatic nuclei]	1.0	6	1	0	0
51117	1624	expression of the human nfil3/e4bp4 cDNA	[expression of the human NFIL3/E4BP4 cDNA]	1.0	6	1	0	0
51118	1624	concentration range between 200-500 nm.	[concentrations ranging between 200-500 nM.]	1.0	5	1	0	0
51119	1624	4-6 fold	[4-6 fold]	1.0	2	1	0	0
51120	1624	3070 crh	[3070 CRH]	1.0	2	1	0	0
51121	1624	very little activity on the promoter	[very little activity on the promoter]	1.0	6	1	0	0
51122	1624	cotransfection study with this cDNA	[Cotransfection studies with this cDNA]	1.0	5	1	0	0
51123	1624	co-immunoprecipitation analysis	[co-immunoprecipitation analysis]	1.0	2	2	2	2
51124	1624	human ebv	[human EBV]	1.0	2	2	1	1
51125	1624	Interferon -alpha	[Interferon -alpha]	1.0	2	1	0	0
51126	1624	differentiate agent	[differentiating agent]	1.0	2	2	1	1
51127	1624	express the hpv type 16 hpv-16	[expressing the HPV type 16 HPV-16]	1.0	6	1	0	0
51128	1624	impaired induction	[Impaired induction]	1.0	2	2	2	2
51129	1624	mitotic signal	[mitotic signaling]	1.0	2	1	0	0
51130	1624	phosphorylation level	[phosphorylation level]	1.0	2	2	1	1
51131	1624	DNA-protein complex formation with member	[DNA-protein complex formation with members]	1.0	5	1	0	0
51132	1624	nf kappa b a factor	[NF kappa B a factor]	1.0	5	1	0	0
51133	1624	15 micrograms/ml of the C. sub.	[15 micrograms/ml of the C. Sub.]	1.0	6	1	0	0
51134	1624	thus, stress	[Thus, stress]	1.0	2	1	0	0
51135	1624	functional gene	[functional genes]	1.0	2	1	0	0
51136	1624	molecular analysis of regulatory gene expression	[molecular analysis of regulatory gene expression]	1.0	6	1	0	0
51137	1624	modulate gata-1 activity through protein-protein interaction	[modulating GATA-1 activity through protein-protein interaction]	1.0	6	1	0	0
51138	1624	hypothalamic-pituitary-adrenal axis activation during critical illness	[hypothalamic-pituitary-adrenal axis activation during critical illness]	1.0	6	1	0	0
51139	1624	id2 expression	[Id2 expression]	1.0	2	1	0	0
51140	1624	mouse SRG3	[mouse SRG3]	1.0	2	1	0	0
51141	1624	deletion mutation	[deletion mutation]	1.0	2	2	1	1
51142	1624	lavage t-lymphocyte express 135eoh)2d3 receptor	[lavage T-lymphocytes expressing 1,25(OH)2D3 receptors]	1.0	5	1	0	0
51143	1624	monocyte gene	[monocyte gene]	1.0	2	2	2	2
51144	1624	small subset	[small subset]	1.0	2	2	1	1
51145	1624	expression of the Btk gene	[expression of the Btk gene]	1.0	5	1	0	0
51146	1624	ISRE probe	[ISRE probe]	1.0	2	1	0	0
51147	1624	role of reactive oxygen species	[role of reactive oxygen species]	1.0	5	1	0	0
51148	1624	(p50/p65)- expression vector into Jurkat cell	[(p50/p65)- expression vectors into Jurkat cells]	1.0	6	1	0	0
51149	1624	genomic clone of human herpesvirus-6	[genomic clones of human herpesvirus-6]	1.0	5	1	0	0
51150	1624	difference in T cell response	[differences in T cell responses]	1.0	5	1	0	0
51151	1624	understand the mechanism of bind affinity	[understanding the mechanism of binding affinity]	1.0	6	1	0	0
51152	1624	oligonucleotide contain the consensus GRE	[Oligonucleotides containing the consensus GRE]	1.0	5	1	0	0
51153	1624	chemokine RANTES	[chemokine RANTES]	1.0	2	1	0	0
51154	1624	CTLA-4 engagement	[CTLA-4 engagement]	1.0	2	2	1	1
51155	1624	indicate the presence of a factor	[indicating the presence of a factor]	1.0	6	1	0	0
51156	1624	binding of cognate nuclear factor	[binding of cognate nuclear factors]	1.0	5	1	0	0
51157	1624	stimulate expression of lytic cycle gene	[stimulating expression of lytic cycle genes]	1.0	6	1	0	0
51158	1624	expression in IL-3 murine pro-B cell	[expression in IL-3 murine pro-B cells]	1.0	6	1	0	0
51159	1624	phosphonoformic acid	[phosphonoformic acid]	1.0	2	1	0	0
51160	1624	inhibitory function	[inhibitory function]	1.0	2	2	1	1
51161	1624	myeloid cd15)	[myeloid CD15)]	1.0	2	1	0	0
51162	1624	activity of the IL-2 promoter	[activity of the IL-2 promoter]	1.0	5	2	1	1
51163	1624	moreover, induction of tyrosine phosphorylation	[Moreover, induction of tyrosine phosphorylation]	1.0	5	1	0	0
51164	1624	0.0001 n	[0.0001, n]	1.0	2	1	0	0
51165	1624	protein/activation transcription	[protein/activation transcription]	1.0	2	1	0	0
51166	1624	activation phenotype	[activation phenotype]	1.0	2	1	0	0
51167	1624	overexpression of a SCL gene	[overexpression of a SCL gene]	1.0	5	1	0	0
51168	1624	novel, as unknown, effector molecule	[novel, as unknown, effector molecule]	1.0	5	1	0	0
51169	1624	naive donor	[naive donors]	1.0	2	2	2	2
51170	1624	lead to proteolysis of specific substrate	[leading to proteolysis of specific substrates]	1.0	6	1	0	0
51171	1624	add with RA (10(-6) m).	[adding with RA (10(-6) M).]	1.0	5	1	0	0
51172	1624	nf-il6 protein	[NF-IL6 proteins]	1.0	2	1	0	0
51173	1624	CBF alpha CBF beta subunit	[CBF alpha CBF beta subunits]	1.0	5	1	0	0
51174	1624	non- HTLV-I T cell line	[non- HTLV-I T cell lines]	1.0	5	1	0	0
51175	1624	inductive effects.	[inductive effects.]	1.0	2	1	0	0
51176	1624	DNA breakage	[DNA breakage]	1.0	2	2	2	2
51177	1624	receptor available for DNA binding	[receptors available for DNA binding]	1.0	5	1	0	0
51178	1624	C3 transferase a RhoA mutant	[C3 transferase a RhoA mutant]	1.0	5	1	0	0
51179	1624	coimmunoadsorption of the other stat protein	[coimmunoadsorption of the other STAT protein]	1.0	6	1	0	0
51180	1624	contain the human gamma 3 ECS	[containing the human gamma 3 ECS]	1.0	6	1	0	0
51181	1624	rat cerulein	[rat cerulein]	1.0	2	2	2	2
51182	1624	regulate b alpha /mad-3 mrna level	[regulating B alpha /MAD-3 mRNA levels]	1.0	6	1	0	0
51183	1624	such finding	[Such findings]	1.0	2	1	0	0
51184	1624	one function	[one function]	1.0	2	2	2	2
51185	1624	n-terminal sequencing 20 amino acid	[N-Terminal sequencing 20 amino acids]	1.0	5	1	0	0
51186	1624	prior to activation with ltb4	[prior to activation with LTB4]	1.0	5	1	0	0
51187	1624	contain 128 bp of upstream sequence	[containing 128 bp of upstream sequence]	1.0	6	1	0	0
51188	1624	monocyte adhesion.	[monocyte adhesion.]	1.0	2	1	0	0
51189	1624	transient expression experiment of 5'-deletion fragment	[Transient expression experiments of 5'-deletion fragments]	1.0	6	1	0	0
51190	1624	Theileria infection	[Theileria infection]	1.0	2	1	0	0
51191	1624	sp1-binding site	[SP1-binding sites]	1.0	2	1	0	0
51192	1624	C3a alone	[C3a alone]	1.0	2	1	0	0
51193	1624	integration of t-cell-leukemia virus type	[integration of T-cell-leukemia virus type]	1.0	5	2	1	1
51194	1624	two gel shift complex Mono A	[Two gel shift complexes Mono A]	1.0	6	1	0	0
51195	1624	very low level of hiv-1	[very low levels of HIV-1]	1.0	5	1	0	0
51196	1624	first demonstration of a role	[first demonstration of a role]	1.0	5	1	0	0
51197	1624	eosinophil differentiation	[eosinophil differentiation]	1.0	2	2	1	1
51198	1624	autosomal sex	[autosomal sex]	1.0	2	1	0	0
51199	1624	IL-7 a crucial factor for thymopoiesis	[IL-7 a crucial factor for thymopoiesis]	1.0	6	1	0	0
51200	1624	cell surface expression of Jagged1	[Cell surface expression of Jagged1]	1.0	5	1	0	0
51201	1624	tissue culture cell express ebv	[tissue culture cells expressing EBV]	1.0	5	1	0	0
51202	1624	unknown mechanism,	[unknown mechanism,]	1.0	2	1	0	0
51203	1624	80-kda protein	[80-kDa protein]	1.0	2	1	0	0
51204	1624	mononuclear leukocyte from young person	[Mononuclear leukocytes from young persons]	1.0	5	1	0	0
51205	1624	human mono Mac 6 cell	[human Mono Mac 6 cells]	1.0	5	1	0	0
51206	1624	use the yeast two-hybrid system,	[using the yeast two-hybrid system,]	1.0	5	1	0	0
51207	1624	parental myeloblast	[parental myeloblasts]	1.0	2	1	0	0
51208	1624	inhibitor of myosin light chain kinase	[inhibitors of myosin light chain kinase]	1.0	6	1	0	0
51209	1624	e1a protein in Ad-infected target	[E1A proteins in Ad-infected targets]	1.0	5	1	0	0
51210	1624	induce the expansion per se,	[inducing the expansion per se,]	1.0	5	1	0	0
51211	1624	il-8 transcription	[IL-8 transcription]	1.0	2	1	0	0
51212	1624	functional outcome	[functional outcome]	1.0	2	2	1	1
51213	1624	bacterial surface	[bacterial surface]	1.0	2	1	0	0
51214	1624	cd14 receptor	[CD14 receptor]	1.0	2	1	0	0
51215	1624	B, October	[B, Oct]	1.0	2	1	0	0
51216	1624	HIV1 monocyte	[HIV1 monocytes]	1.0	2	1	0	0
51217	1624	mapk response	[MAPK response]	1.0	2	1	0	0
51218	1624	flexible linker	[flexible linker]	1.0	2	2	1	1
51219	1624	ileal resection	[ileal resection]	1.0	2	1	0	0
51220	1624	platelet-induced activation of the nf-kappab system	[Platelet-induced activation of the NF-kappaB system]	1.0	6	1	0	0
51221	1624	BCL-6 expression during B-cell activation.	[BCL-6 expression during B-cell activation.]	1.0	5	1	0	0
51222	1624	mnda expression in normal maturing granulocyte	[MNDA expression in normal maturing granulocytes]	1.0	6	1	0	0
51223	1624	2.7 repeats.	[2.7 repeats.]	1.0	2	1	0	0
51224	1624	normal retinoic-acid receptor type alpha potentiation	[normal retinoic-acid receptors type alpha potentiation]	1.0	6	1	0	0
51225	1624	26s proteasome	[26S proteasome]	1.0	2	2	1	1
51226	1624	principal cytoplasmic inhibitor of nf-kappab	[principal cytoplasmic inhibitor of NF-kappaB]	1.0	5	1	0	0
51227	1624	glucocorticoid receptor antagonist RU 38486	[glucocorticoid receptor antagonist RU 38486]	1.0	5	1	0	0
51228	1624	family with a asthmatic proband	[families with an asthmatic proband]	1.0	5	1	0	0
51229	1624	contact of killer (nk) cell	[contact of killer (NK) cells]	1.0	5	1	0	0
51230	1624	resistance to vitamin d treatment	[resistance to vitamin D treatment]	1.0	5	1	0	0
51231	1624	b lymphocyte in the peripheral circulation	[B lymphocytes in the peripheral circulation]	1.0	6	1	0	0
51232	1624	t(10;11) (p13;q14)	[t(10;11) (p13;q14)]	1.0	2	1	0	0
51233	1624	cellular phenotype	[cellular phenotype]	1.0	2	1	0	0
51234	1624	IFN-beta mrna at low level	[IFN-beta mRNA at low levels]	1.0	5	1	0	0
51235	1624	human peripheral leucocyte in woman	[human peripheral leucocytes in women]	1.0	5	2	2	2
51236	1624	lysopc to 10 micromol/L) dose-dependently	[lysoPC to 10 micromol/L) dose-dependently]	1.0	5	1	0	0
51237	1624	mrna expression of transcription factor	[mRNA expression of transcription factors]	1.0	5	1	0	0
51238	1624	expression of gene in cell	[expression of genes in cells]	1.0	5	2	2	2
51239	1624	group i BL cell line	[group I BL cell lines]	1.0	5	1	0	0
51240	1624	contrast, integrin ligation with antibody	[contrast, integrin ligation with antibodies]	1.0	5	1	0	0
51241	1624	Chr 20	[Chr 20]	1.0	2	2	1	1
51242	1624	Id1 protein	[Id1 protein]	1.0	2	1	0	0
51243	1624	most early lytic cycle gene	[most early lytic cycle genes]	1.0	5	1	0	0
51244	1624	thus prevent cell surface expression	[thus preventing cell surface expression]	1.0	5	1	0	0
51245	1624	C5b6 level.	[C5b6 level.]	1.0	2	1	0	0
51246	1624	differentiation of monocyte into macrophage	[differentiation of monocytes into macrophages]	1.0	5	1	0	0
51247	1624	productive infection,	[productive infection,]	1.0	2	1	0	0
51248	1624	regulatory point	[regulatory point]	1.0	2	2	2	2
51249	1624	DNA-protein complex common to each	[DNA-protein complexes common to each]	1.0	5	1	0	0
51250	1624	Daudi b-cell	[Daudi B-cells]	1.0	2	1	0	0
51251	1624	change in expression of nf-kappab	[changes in expression of NF-kappaB]	1.0	5	1	0	0
51252	1624	Cross talk between cell death	[Cross talk between cell death]	1.0	5	1	0	0
51253	1624	pbmc respond to any peptide	[PBMC responding to any peptide]	1.0	5	1	0	0
51254	1624	c-type chemokine	[C-type chemokine]	1.0	2	1	0	0
51255	1624	significant role	[significant role]	1.0	2	7	6	1
51256	1624	alpha/beta interferon (ifn-alpha/beta)-induced gene expression.	[alpha/beta interferon (IFN-alpha/beta)-induced gene expression.]	1.0	5	1	0	0
51257	1624	response to infection with bacterium	[response to infection with bacteria]	1.0	5	1	0	0
51258	1624	latter elements,	[latter elements,]	1.0	2	1	0	0
51259	1624	nondivide macrophage from normal individual	[Nondividing macrophages from normal individuals]	1.0	5	1	0	0
51260	1624	lineage specification	[lineage specification]	1.0	2	2	2	2
51261	1624	symptom score	[symptom score]	1.0	2	2	1	1
51262	1624	5 h),	[5 h),]	1.0	2	1	0	0
51263	1624	protein tradd	[protein TRADD]	1.0	2	2	2	2
51264	1624	competition between tpo for binding	[competition between TPO for binding]	1.0	5	1	0	0
51265	1624	phorbol ester on mnda mrna	[phorbol ester on MNDA mRNA]	1.0	5	1	0	0
51266	1624	diversity of the b-cell repertoire	[diversity of the B-cell repertoire]	1.0	5	1	0	0
51267	1624	ductal epithelium	[ductal epithelium]	1.0	2	2	1	1
51268	1624	stimulation through the Fas/APO-1 receptor	[Stimulation through the Fas/APO-1 receptor]	1.0	5	1	0	0
51269	1624	number of the ets family	[number of the ETS family]	1.0	5	1	0	0
51270	1624	b-cell proliferation of early G1-regulating protein	[B-cell proliferation of early G1-regulating proteins]	1.0	6	1	0	0
51271	1624	background: cytokine	[BACKGROUND: Cytokines]	1.0	2	1	0	0
51272	1624	approximately -250 to +50 bp	[approximately -250 to +50 bp]	1.0	5	1	0	0
51273	1624	fos expression.	[FOS expression.]	1.0	2	1	0	0
51274	1624	autoimmune reaction	[autoimmune reaction]	1.0	2	1	0	0
51275	1624	formation of a new, complex	[formation of a new, complex]	1.0	5	1	0	0
51276	1624	resorption lacunae	[Resorption lacunae]	1.0	2	1	0	0
51277	1624	several anti-ig response element within Zp	[several anti-Ig response elements within Zp]	1.0	6	1	0	0
51278	1624	eosinophilic abnormality	[eosinophilic abnormalities]	1.0	2	1	0	0
51279	1624	cell express CD40 in T	[cells expressing CD40 in T]	1.0	5	1	0	0
51280	1624	time reduced.	[time reduced.]	1.0	2	1	0	0
51281	1624	rat thymus	[rat thymus]	1.0	2	1	0	0
51282	1624	role in T fasl expression	[role in T FasL expression]	1.0	5	1	0	0
51283	1624	Interestingly, treatment of hiv-tf1 by phosphatase	[Interestingly, treatment of HIV-TF1 by phosphatase]	1.0	6	1	0	0
51284	1624	partial characterization of HZF 11-42	[partial characterization of HZF 11-42]	1.0	5	1	0	0
51285	1624	dual cyclooxygenase/5-lipoxygenase	[dual cyclooxygenase/5-lipoxygenase]	1.0	2	1	0	0
51286	1624	eventual recovery of surface expression	[eventual recovery of surface expression]	1.0	5	1	0	0
51287	1624	viral mechanism	[viral mechanisms]	1.0	2	1	0	0
51288	1624	clinical practice,	[clinical practice,]	1.0	2	1	0	0
51289	1624	addition, il-13 insulin response substrate-1	[addition, IL-13 insulin response substrate-1]	1.0	5	1	0	0
51290	1624	trans-activate protein	[trans-activating protein]	1.0	2	2	2	2
51291	1624	oxidative stress on transcriptional activity	[oxidative stress on transcriptional activities]	1.0	5	1	0	0
51292	1624	contrast, inhibition of IL-1 beta	[contrast, inhibition of IL-1 beta]	1.0	5	1	0	0
51293	1624	dominant-negative activity	[dominant-negative activity]	1.0	2	2	2	2
51294	1624	glucocorticoid such as budesonide by virtue	[glucocorticoids such as budesonide by virtue]	1.0	6	1	0	0
51295	1624	il-2 by peripheral T lymphocyte	[IL-2 by peripheral T lymphocytes]	1.0	5	1	0	0
51296	1624	antigenic site,	[antigenic site,]	1.0	2	1	0	0
51297	1624	various dna	[various DNAs]	1.0	2	1	0	0
51298	1624	56-kDa protein of moderate abundance	[56-kDa protein of moderate abundance]	1.0	5	1	0	0
51299	1624	stimulation, via a CsA mechanism	[stimulation, via a CsA mechanism]	1.0	5	1	0	0
51300	1624	nf-e2, gata-1	[NF-E2, GATA-1]	1.0	2	1	0	0
51301	1624	ebv-transformed b-cell	[EBV-transformed B-cells]	1.0	2	1	0	0
51302	1624	d cyclin in t-cell activation	[D cyclins in T-cell activation]	1.0	5	1	0	0
51303	1624	response to t-cell activation: purification	[responses to T-cell activation: purification]	1.0	5	1	0	0
51304	1624	loss of this tumor suppressor gene	[loss of this tumor suppressor gene]	1.0	6	1	0	0
51305	1624	leukotriene biosynthesis	[leukotriene biosynthesis]	1.0	2	1	0	0
51306	1624	nf-kappa b p65 DNA binding	[NF-kappa B p65 DNA binding]	1.0	5	1	0	0
51307	1624	tyrosine phosphorylation of the signal transducer	[tyrosine phosphorylation of the signal transducers]	1.0	6	1	0	0
51308	1624	biological stimulation	[biological stimulation]	1.0	2	1	0	0
51309	1624	loss of heterozygosity on chromosome	[loss of heterozygosity on chromosome]	1.0	5	1	0	0
51310	1624	transcriptional regulatory protein in eukaryote	[transcriptional regulatory proteins in eukaryotes]	1.0	5	1	0	0
51311	1624	high level of udg expression	[High levels of UDG expression]	1.0	5	1	0	0
51312	1624	rar-selective antagonist	[RAR-selective antagonist]	1.0	2	2	1	1
51313	1624	differanisole A	[Differanisole A]	1.0	2	1	0	0
51314	1624	and/or cytokine	[and/or cytokine]	1.0	2	2	2	2
51315	1624	appearance of the monocytic phenotype	[appearance of the monocytic phenotype]	1.0	5	1	0	0
51316	1624	CD2 signalling	[CD2 signalling]	1.0	2	1	0	0
51317	1624	mononuclear cell of lupus patient	[mononuclear cells of lupus patients]	1.0	5	1	0	0
51318	1624	addition, protein	[addition, protein]	1.0	2	1	0	0
51319	1624	Furthermore, loss of CD5 surface expression	[Furthermore, loss of CD5 surface expression]	1.0	6	1	0	0
51320	1624	treatment by NE of atp-depleted platelet	[Treatment by NE of ATP-depleted platelets]	1.0	6	1	0	0
51321	1624	(HIV) repeat	[(HIV) repeat]	1.0	2	2	2	2
51322	1624	nf-il4 share a DNA bind motif	[NF-IL4 sharing a DNA binding motif]	1.0	6	1	0	0
51323	1624	GCR-beta cell	[GCR-beta cells]	1.0	2	1	0	0
51324	1624	palindromic nf-kappa b probe homologous	[palindromic NF-kappa B probe homologous]	1.0	5	1	0	0
51325	1624	3' 5' xpb helicase activity.	[3' 5' XPB helicase activity.]	1.0	5	1	0	0
51326	1624	biochemical mechanism	[biochemical mechanism]	1.0	2	2	2	2
51327	1624	il-5 synthesis in atopic disease	[IL-5 synthesis in atopic diseases]	1.0	5	1	0	0
51328	1624	chromosomal localization	[Chromosomal localization]	1.0	2	2	2	2
51329	1624	SLP-76 a Grb2-associated tyrosine -phosphorylated protein	[SLP-76 a Grb2-associated tyrosine -phosphorylated protein]	1.0	6	1	0	0
51330	1624	specific target of cyclosporin a	[specific target of cyclosporin A]	1.0	5	1	0	0
51331	1624	'latency I'	['latency I']	1.0	2	1	0	0
51332	1624	activation of g-protein-coupled chemoattractant receptor	[activation of G-protein-coupled chemoattractant receptors]	1.0	5	1	0	0
51333	1624	reverse profile	[reverse profile]	1.0	2	1	0	0
51334	1624	antisense orientation	[antisense orientation]	1.0	2	2	1	1
51335	1624	DNA binding through the bzip domain	[DNA binding through the bZIP domain]	1.0	6	1	0	0
51336	1624	apparent inconsistency	[apparent inconsistencies]	1.0	2	1	0	0
51337	1624	different mobilities,	[different mobilities,]	1.0	2	1	0	0
51338	1624	activate the b domain zre-b	[activating the B domain ZRE-B]	1.0	5	1	0	0
51339	1624	dramatic response in single cases.	[dramatic response in single cases.]	1.0	5	1	0	0
51340	1624	inhibitor kappa b alpha evidence	[inhibitor kappa B alpha evidence]	1.0	5	1	0	0
51341	1624	ligation of the CD3 receptor	[ligation of the CD3 receptors]	1.0	5	1	0	0
51342	1624	trans activation	[trans activation]	1.0	2	2	2	2
51343	1624	non-human primate	[non-human primates]	1.0	2	1	0	0
51344	1624	one patient use DNA transfer	[one patient using DNA transfer]	1.0	5	1	0	0
51345	1624	HePTP in the signal cascade	[HePTP in the signaling cascade]	1.0	5	1	0	0
51346	1624	addition, inhibition of mrna synthesis	[addition, inhibition of mRNA synthesis]	1.0	5	1	0	0
51347	1624	include lymphocyte	[including lymphocytes]	1.0	2	2	2	2
51348	1624	intracellular staining	[intracellular staining]	1.0	2	2	1	1
51349	1624	encode the two splice product	[encoding the two splice products]	1.0	5	1	0	0
51350	1624	T cell with mAb 9.3	[T cells with mAb 9.3]	1.0	5	1	0	0
51351	1624	hemoglobin synthesis in m-tat/gm-csf cell	[hemoglobin synthesis in M-TAT/GM-CSF cells]	1.0	5	1	0	0
51352	1624	result from down-regulation of a molecule,	[resulting from down-regulation of a molecule,]	1.0	6	1	0	0
51353	1624	peripheral blood cell of individual	[peripheral blood cells of individuals]	1.0	5	1	0	0
51354	1624	gene c-fo	[gene c-fos]	1.0	2	2	2	2
51355	1624	distinct pathways.	[distinct pathways.]	1.0	2	1	0	0
51356	1624	transcription factor from several family	[transcription factors from several families]	1.0	5	1	0	0
51357	1624	estrogen -dependent lymphoblastoid cell line	[estrogen -dependent lymphoblastoid cell lines]	1.0	5	1	0	0
51358	1624	variety of actions, include effect	[variety of actions, including effects]	1.0	5	1	0	0
51359	1624	aged population	[aged population]	1.0	2	1	0	0
51360	1624	active, gtp-bound form of Rap1	[active, GTP-bound form of Rap1]	1.0	5	1	0	0
51361	1624	crisis transition	[crisis transition]	1.0	2	1	0	0
51362	1624	DNA-protein interaction	[DNA-protein interactions]	1.0	2	2	2	2
51363	1624	common region of both isoform	[common region of both isoforms]	1.0	5	1	0	0
51364	1624	lps induction of hiv expression	[LPS induction of HIV expression]	1.0	5	1	0	0
51365	1624	ed50 value	[ED50 values]	1.0	2	1	0	0
51366	1624	affinity il-2r	[affinity IL-2R]	1.0	2	2	2	2
51367	1624	early signal event in proliferate cell	[early signaling events in proliferating cells]	1.0	6	1	0	0
51368	1624	consequently lead to variable anemic severity	[consequently leading to variable anemic severity]	1.0	6	1	0	0
51369	1624	High-risk patient	[High-risk patients]	1.0	2	1	0	0
51370	1624	ligand binding affinity of nuclear receptor	[ligand binding affinities of nuclear receptors]	1.0	6	1	0	0
51371	1624	M1 cell	[M1 cells]	1.0	2	2	1	1
51372	1624	use non-transformed murine Th1 th2 clone	[using non-transformed murine Th1 Th2 clones]	1.0	6	1	0	0
51373	1624	activation of cytokine gene expression	[activation of cytokine gene expression]	1.0	5	1	0	0
51374	1624	accessory gene such as nef	[accessory genes such as nef]	1.0	5	1	0	0
51375	1624	neonatal lethality	[neonatal lethality]	1.0	2	1	0	0
51376	1624	icam-1 molecules, Northern blot analysis	[ICAM-1 molecules, Northern blot analysis]	1.0	5	1	0	0
51377	1624	B1 p50	[B1 p50]	1.0	2	2	1	1
51378	1624	interaction with this histone acetyltransferase	[interactions with these histone acetyltransferases]	1.0	5	1	0	0
51379	1624	campomelic dysplasia	[campomelic dysplasia]	1.0	2	2	1	1
51380	1624	immediate promoter	[immediate promoter]	1.0	2	1	0	0
51381	1624	endogenous long terminal repeat transcriptional activity	[endogenous long terminal repeat transcriptional activity]	1.0	6	1	0	0
51382	1624	early events,	[early events,]	1.0	2	2	2	2
51383	1624	interaction of Hsp60 T cell	[interactions of Hsp60 T cells]	1.0	5	1	0	0
51384	1624	human 15-LO	[human 15-LO]	1.0	2	1	0	0
51385	1624	formation consistent	[formation consistent]	1.0	2	2	2	2
51386	1624	different genes, include adhesive molecule	[different genes, including adhesive molecules]	1.0	5	1	0	0
51387	1624	b cell with pu.1 expression	[B cells with PU.1 expression]	1.0	5	1	0	0
51388	1624	mainly on the role of mineralocorticoid	[mainly on the role of mineralocorticoids]	1.0	6	1	0	0
51389	1624	clinical recovery	[clinical recovery]	1.0	2	1	0	0
51390	1624	mutation of the mnp site	[mutation of the MNP site]	1.0	5	1	0	0
51391	1624	two different anti-onco-genic transcription factor	[two different anti-onco-genic transcription factors]	1.0	5	1	0	0
51392	1624	prostaglandin of the e series	[Prostaglandins of the E series]	1.0	5	1	0	0
51393	1624	glucocorticosteroid action	[glucocorticosteroid action]	1.0	2	1	0	0
51394	1624	phorbol 12-myristate 13-acetate PMA hiv-1 replication	[phorbol 12-myristate 13-acetate PMA HIV-1 replication]	1.0	6	1	0	0
51395	1624	microarchitecture as	[microarchitecture as]	1.0	2	1	0	0
51396	1624	PGE2 production	[PGE2 production]	1.0	2	1	0	0
51397	1624	constitutive dimerization	[constitutive dimerization]	1.0	2	1	0	0
51398	1624	useful marker	[useful marker]	1.0	2	2	2	2
51399	1624	namely, by il-2 in th1 cell	[namely, by IL-2 in Th1 cells]	1.0	6	1	0	0
51400	1624	presence of a RFX species	[presence of an RFX species]	1.0	5	1	0	0
51401	1624	hGR -Ile	[hGR -Ile]	1.0	2	3	2	1
51402	1624	ability of prototype stress hormone	[ability of prototype stress hormones]	1.0	5	1	0	0
51403	1624	develop spleen	[developing spleen]	1.0	2	1	0	0
51404	1624	erythroid heterokaryon	[erythroid heterokaryons]	1.0	2	1	0	0
51405	1624	24 hour after the injection.	[24 hr after the injection.]	1.0	5	1	0	0
51406	1624	broad role	[broad role]	1.0	2	1	0	0
51407	1624	growth phase-dependent resistance to stress	[growth phase-dependent resistance to stress]	1.0	5	1	0	0
51408	1624	such as lps in monocytes/macrophages	[such as LPS in monocytes/macrophages]	1.0	5	1	0	0
51409	1624	autocrine production	[autocrine production]	1.0	2	1	0	0
51410	1624	certain combination of hla-dq haplotype	[certain combinations of HLA-DQ haplotypes]	1.0	5	1	0	0
51411	1624	Chronic human immunodeficiency virus type	[Chronic human immunodeficiency virus type]	1.0	5	1	0	0
51412	1624	healthy neonate	[healthy neonates]	1.0	2	1	0	0
51413	1624	patient free	[patients free]	1.0	2	1	0	0
51414	1624	sequence identity	[sequence identity]	1.0	2	2	2	2
51415	1624	rpmi 8226	[RPMI 8226]	1.0	2	1	0	0
51416	1624	maternal expression	[maternal expression]	1.0	2	2	1	1
51417	1624	two distinguishable gr bind abnormalities: 15	[two distinguishable GR binding abnormalities: 15]	1.0	6	1	0	0
51418	1624	sequence analysis,	[sequence analysis,]	1.0	2	1	0	0
51419	1624	cortisol receptor resistance the variability	[Cortisol receptor resistance the variability]	1.0	5	1	0	0
51420	1624	oxygen production	[oxygen production]	1.0	2	2	2	2
51421	1624	non hiv hyperplastic lymph node	[non HIV hyperplastic lymph nodes]	1.0	5	1	0	0
51422	1624	reporter construct contain four copy	[reporter construct containing four copies]	1.0	5	1	0	0
51423	1624	unfractionated extract	[unfractionated extract]	1.0	2	1	0	0
51424	1624	inhibition of vitamin d receptor -retinoid	[Inhibition of vitamin D receptor -retinoid]	1.0	6	1	0	0
51425	1624	rnase treatment	[RNase treatment]	1.0	2	2	2	2
51426	1624	hsp90 by a monoclonal anti-hsp antibody	[hsp90 by a monoclonal anti-hsp antibody]	1.0	6	1	0	0
51427	1624	mitotic recombination	[mitotic recombination]	1.0	2	1	0	0
51428	1624	southwestern blotting	[Southwestern blotting]	1.0	2	2	2	2
51429	1624	TCF-2 alpha	[TCF-2 alpha]	1.0	2	1	0	0
51430	1624	receptor binding study with dexamethasone	[Receptor binding studies with dexamethasone]	1.0	5	1	0	0
51431	1624	constitutive expression of the enzyme	[constitutive expression of the enzyme]	1.0	5	1	0	0
51432	1624	emergence of second-site LTR revertant	[emergence of second-site LTR revertants]	1.0	5	1	0	0
51433	1624	IL-6 macrophage-differentiation of 1a9-m cell	[IL-6 macrophage-differentiation of 1A9-M cells]	1.0	5	1	0	0
51434	1624	allergen-specific cd4+ T cell clone tcc	[allergen-specific CD4+ T cell clones TCC]	1.0	6	1	0	0
51435	1624	IL-1 kinase	[IL-1 kinase]	1.0	2	2	2	2
51436	1624	gr expression in 6tg1.1 cell	[GR expression in 6TG1.1 cells]	1.0	5	1	0	0
51437	1624	use inhibitor of protein kinase c	[using inhibitors of protein kinase C]	1.0	6	1	0	0
51438	1624	supernatant fluid	[supernatant fluid]	1.0	2	2	2	2
51439	1624	unique property	[unique properties]	1.0	2	1	0	0
51440	1624	b cell precursor acute leukemia	[B cell precursor acute leukemias]	1.0	5	1	0	0
51441	1624	prevention of degradation of alpha	[prevention of degradation of alpha]	1.0	5	1	0	0
51442	1624	over 17 kb of DNA	[over 17 kb of DNA]	1.0	5	1	0	0
51443	1624	20 year	[20 years]	1.0	2	1	0	0
51444	1624	patient groups, with the group	[patient groups, with the group]	1.0	5	1	0	0
51445	1624	contain the Escherichia coli lac operator	[containing the Escherichia coli lac operator]	1.0	6	1	0	0
51446	1624	x-thr-pro repeat	[X-Thr-Pro repeat]	1.0	2	1	0	0
51447	1624	activation of ISGF3 alpha the component	[Activation of ISGF3 alpha the component]	1.0	6	1	0	0
51448	1624	t-cell immortalization	[T-cell immortalization]	1.0	2	2	2	2
51449	1624	high concentration of native peptide ligand	[high concentrations of native peptide ligand]	1.0	6	1	0	0
51450	1624	radioligand-binding assay in extrinsic asthmatics	[radioligand-binding assay in extrinsic asthmatics]	1.0	5	1	0	0
51451	1624	characteristic feature of erythroid differentiation	[characteristic features of erythroid differentiation]	1.0	5	1	0	0
51452	1624	(lp) T	[(LP) T]	1.0	2	1	0	0
51453	1624	nb4 cell promyelocytic leukemia line	[NB4 cells promyelocytic leukemia line]	1.0	5	1	0	0
51454	1624	amelioration of rat cerulein pancreatitis	[Amelioration of rat cerulein pancreatitis]	1.0	5	1	0	0
51455	1624	effect of 10(-12) to 10(-6)	[effect of 10(-12) to 10(-6)]	1.0	5	1	0	0
51456	1624	large colony	[large colonies]	1.0	2	2	1	1
51457	1624	helper T cell (th) clone	[helper T cell (Th) clones]	1.0	5	1	0	0
51458	1624	nucleotide -299	[nucleotides -299]	1.0	2	1	0	0
51459	1624	kappaB- Sp1 concatamer -295 to -286	[kappaB- Sp1 concatamers -295 to -286]	1.0	6	1	0	0
51460	1624	modulate activity.	[modulating activity.]	1.0	2	2	2	2
51461	1624	specific anti-Fc gamma R mab	[specific anti-Fc gamma R mAb]	1.0	5	1	0	0
51462	1624	nucleotide -276	[nucleotides -276]	1.0	2	1	0	0
51463	1624	nucleotide -271	[nucleotides -271]	1.0	2	1	0	0
51464	1624	preterm (with	[preterm (with]	1.0	2	1	0	0
51465	1624	af-2 only,	[AF-2 only,]	1.0	2	1	0	0
51466	1624	effect of alpha, 25-dihydroxyvitamin D3	[effects of alpha, 25-dihydroxyvitamin D3]	1.0	5	1	0	0
51467	1624	molecular mass of 105 kda	[molecular mass of 105 kDa]	1.0	5	1	0	0
51468	1624	biological relevance	[biological relevance]	1.0	2	2	2	2
51469	1624	subsequent degradation.	[subsequent degradation.]	1.0	2	1	0	0
51470	1624	costimulatory molecule(s)	[costimulatory molecule(s)]	1.0	2	1	0	0
51471	1624	Duffy protein	[Duffy protein]	1.0	2	2	1	1
51472	1624	histone acetylation	[histone acetylation]	1.0	2	2	1	1
51473	1624	large tsg101 intragenic transcript deletion	[Large TSG101 intragenic transcript deletions]	1.0	5	1	0	0
51474	1624	PKC-dependent pathway	[PKC-dependent pathways]	1.0	2	1	0	0
51475	1624	nfaT-containing complex	[NFAT-containing complexes]	1.0	2	2	1	1
51476	1624	activation of a number most	[activation of a number most]	1.0	5	1	0	0
51477	1624	chronic hepatitis b virus infection	[chronic hepatitis B virus infection]	1.0	5	2	2	2
51478	1624	(p 0.001) in the t3	[(p 0.001) in the T3]	1.0	5	1	0	0
51479	1624	TCR/ CD3	[TCR/ CD3]	1.0	2	1	0	0
51480	1624	over 6 kilobasis of dna.	[over 6 kilobases of DNA.]	1.0	5	1	0	0
51481	1624	transcription of the germ-line igh gene	[Transcription of the germ-line IgH genes]	1.0	6	1	0	0
51482	1624	two day	[two days]	1.0	2	2	1	1
51483	1624	fivefold decrease in clonal growth	[fivefold decrease in clonal growth]	1.0	5	1	0	0
51484	1624	2 beta	[2 beta]	1.0	2	1	0	0
51485	1624	human T lymphocyte by IFN-beta	[human T lymphocytes by IFN-beta]	1.0	5	1	0	0
51486	1624	cognate motif	[cognate motif]	1.0	2	1	0	0
51487	1624	priming of CD4 T cell	[priming of CD4 T cells]	1.0	5	1	0	0
51488	1624	IARC 301.5	[IARC 301.5]	1.0	2	2	2	2
51489	1624	transfection study with reporter construct	[Transfection studies with reporter constructs]	1.0	5	1	0	0
51490	1624	significant reduction in the induction	[significant reduction in the induction]	1.0	5	1	0	0
51491	1624	gene regulation by "differential repression"	[gene regulation by "differential repression"]	1.0	5	1	0	0
51492	1624	role for endogenous ceramide release	[role for endogenous ceramide release]	1.0	5	1	0	0
51493	1624	potential target for anti- hiv-1 therapy	[potential targets for anti- HIV-1 therapy]	1.0	6	1	0	0
51494	1624	pharmacological control of antigen responsiveness	[Pharmacological control of antigen responsiveness]	1.0	5	1	0	0
51495	1624	binding of pac-1 approximately 5.5-fold	[binding of PAC-1 approximately 5.5-fold]	1.0	5	1	0	0
51496	1624	pancreatic weight	[pancreatic weight]	1.0	2	1	0	0
51497	1624	monocyte-macrophage lineage-associated surface antigen cd14	[monocyte-macrophage lineage-associated surface antigen CD14]	1.0	5	1	0	0
51498	1624	anti-atherosclerotic molecule	[anti-atherosclerotic molecule]	1.0	2	1	0	0
51499	1624	likely target for gssg action	[likely targets for GSSG action]	1.0	5	1	0	0
51500	1624	weak expression.	[weaker expression.]	1.0	2	1	0	0
51501	1624	NK cell-mediated k562 cancer cell killing	[NK cell-mediated K562 cancer cell killing]	1.0	6	1	0	0
51502	1624	induction of this distal il-2 enhancer	[Induction of this distal IL-2 enhancer]	1.0	6	1	0	0
51503	1624	blood histamine	[blood histamine]	1.0	2	2	2	2
51504	1624	contain the 94 kda stat5 protein	[containing the 94 kDa STAT5 proteins]	1.0	6	1	0	0
51505	1624	rise in intracellular ca2+ concentration	[rise in intracellular Ca2+ concentration]	1.0	5	1	0	0
51506	1624	role of the 3' region	[roles of the 3' regions]	1.0	5	1	0	0
51507	1624	number of novel metalloproteinase activity	[number of novel metalloproteinase activities]	1.0	5	1	0	0
51508	1624	relevant epitope	[relevant epitope]	1.0	2	1	0	0
51509	1624	immunologic parameter	[immunologic parameters]	1.0	2	1	0	0
51510	1624	role in the developmental regulation	[role in the developmental regulation]	1.0	5	1	0	0
51511	1624	activate signal in a lymphoma model	[activating signals in a lymphoma model]	1.0	6	1	0	0
51512	1624	drug regimen	[drug regimen]	1.0	2	1	0	0
51513	1624	anti-lambda antibody	[anti-lambda antibodies]	1.0	2	1	0	0
51514	1624	normal Rh(D)	[normal Rh(D)]	1.0	2	1	0	0
51515	1624	b cell surface molecule cd19	[B cell surface molecule CD19]	1.0	5	1	0	0
51516	1624	IL-8 mrna in the cytosol	[IL-8 mRNA in the cytosol]	1.0	5	1	0	0
51517	1624	target antigen	[Target antigens]	1.0	2	1	0	0
51518	1624	human interleukin-2 receptor beta-chain promoter	[human interleukin-2 receptor beta-chain promoter]	1.0	5	1	0	0
51519	1624	necessary prerequisite of enhancer activity	[necessary prerequisite of enhancer activity]	1.0	5	1	0	0
51520	1624	brdu incorporation with propidium iodide	[BrdU incorporation with propidium iodide]	1.0	5	1	0	0
51521	1624	different behavior	[different behavior]	1.0	2	1	0	0
51522	1624	lps ifn-gamma	[LPS IFN-gamma]	1.0	2	1	0	0
51523	1624	initiation of the cytokine repertoire	[initiation of the cytokine repertoire]	1.0	5	1	0	0
51524	1624	contrast, monocyte	[contrast, monocytes]	1.0	2	1	0	0
51525	1624	level consistent	[level consistent]	1.0	2	1	0	0
51526	1624	activate phosphorylation	[activating phosphorylation]	1.0	2	1	0	0
51527	1624	l132 fibroblast	[L132 fibroblasts]	1.0	2	1	0	0
51528	1624	encode the interleukin receptor alpha subunit	[encoding the interleukin receptor alpha subunit]	1.0	6	1	0	0
51529	1624	effect of Rho on AP-1	[effect of Rho on AP-1]	1.0	5	1	0	0
51530	1624	ap-1 activity in Jurkat T cell	[AP-1 activity in Jurkat T cells]	1.0	6	1	0	0
51531	1624	bind to the CRE site	[binding to the CRE site]	1.0	5	1	0	0
51532	1624	hypothalamic-pituitary-gonadal axis	[hypothalamic-pituitary-gonadal axis]	1.0	2	1	0	0
51533	1624	frame shift	[frame shift]	1.0	2	2	1	1
51534	1624	bacterial toxin	[bacterial toxins]	1.0	2	2	1	1
51535	1624	binding of traf2 to CD40	[binding of TRAF2 to CD40]	1.0	5	1	0	0
51536	1624	Instead, ATF-2	[Instead, ATF-2]	1.0	2	1	0	0
51537	1624	ifngamma treatment	[IFNgamma treatment]	1.0	2	1	0	0
51538	1624	NF-kappaB nuclear translocation of virus production	[NF-kappaB nuclear translocation of virus production]	1.0	6	1	0	0
51539	1624	pbmc from patient with tuberculosis.	[PBMC from patients with tuberculosis.]	1.0	5	1	0	0
51540	1624	predominantly cd56+	[predominantly CD56+]	1.0	2	1	0	0
51541	1624	part of a global mechanism	[part of a global mechanism]	1.0	5	1	0	0
51542	1624	two transcription factor pat 225/egr1	[two transcription factors pAT 225/EGR1]	1.0	5	1	0	0
51543	1624	receptors/cell; controls, 306 +/- 168)	[receptors/cell; controls, 306 +/- 168)]	1.0	5	1	0	0
51544	1624	contain a adult globin (hbb) promoter	[containing a adult globin (HBB) promoter]	1.0	6	1	0	0
51545	1624	encode for certain hemopoietic growth factor	[encoding for certain hemopoietic growth factors]	1.0	6	1	0	0
51546	1624	functional outcome of antigen processing	[functional outcome of antigen processing]	1.0	5	1	0	0
51547	1624	contain a highly basic region (4c)	[containing a highly basic region (4c)]	1.0	6	1	0	0
51548	1624	myeloid-related DC	[myeloid-related DC]	1.0	2	1	0	0
51549	1624	nucleotide -180	[nucleotide -180]	1.0	2	1	0	0
51550	1624	position in the E3 promoter	[position in the E3 promoter]	1.0	5	1	0	0
51551	1624	human aml1	[human AML1]	1.0	2	1	0	0
51552	1624	human recombinant tumor necrosis factor	[human recombinant tumor necrosis factor]	1.0	5	1	0	0
51553	1624	use a specific monoclonal antibody	[using a specific monoclonal antibody]	1.0	5	1	0	0
51554	1624	cyclic adenosine monophosphate camp accumulation	[cyclic adenosine monophosphate cAMP accumulation]	1.0	5	1	0	0
51555	1624	alpha-globin g 5' flank region	[alpha-globin G 5' flanking region]	1.0	5	1	0	0
51556	1624	stimulation of the neutrophil with FMLP	[stimulation of the neutrophil with FMLP]	1.0	6	1	0	0
51557	1624	alternative procedure	[alternative procedure]	1.0	2	1	0	0
51558	1624	thyroid antigen	[thyroid antigens]	1.0	2	2	1	1
51559	1624	functional importance for the activity	[functional importance for the activity]	1.0	5	1	0	0
51560	1624	inhibition of lymphocyte proliferation ic50	[inhibition of lymphocyte proliferation IC50s]	1.0	5	2	1	1
51561	1624	structural alteration in the p16	[structural alterations in the p16]	1.0	5	1	0	0
51562	1624	therapeutic intervention.	[therapeutic intervention.]	1.0	2	1	0	0
51563	1624	nucleotide -120	[nucleotide -120]	1.0	2	1	0	0
51564	1624	introduce a protease expression vector	[introducing a protease expression vector]	1.0	5	1	0	0
51565	1624	anti-atherosclerotic agent	[anti-atherosclerotic agents]	1.0	2	1	0	0
51566	1624	stat1 p91	[STAT1 p91]	1.0	2	2	1	1
51567	1624	interferon gamma stimulation a condition	[interferon gamma stimulation a condition]	1.0	5	1	0	0
51568	1624	activation of PKC with PMA	[activation of PKC with PMA]	1.0	5	2	1	1
51569	1624	Interleukin 1beta	[Interleukin 1beta]	1.0	2	1	0	0
51570	1624	intragenic suppressor	[intragenic suppressor]	1.0	2	1	0	0
51571	1624	accord to serum urinary cortisol level	[according to serum urinary cortisol levels]	1.0	6	1	0	0
51572	1624	monoallelic expression	[monoallelic expression]	1.0	2	1	0	0
51573	1624	host defence	[host defence]	1.0	2	2	1	1
51574	1624	peptide microsequencing	[peptide microsequencing]	1.0	2	2	1	1
51575	1624	feasibility use interferon gene transfer	[feasibility using interferon gene transfer]	1.0	5	1	0	0
51576	1624	result in the induction of gene	[resulting in the induction of genes]	1.0	6	1	0	0
51577	1624	infection with herpes simplex virus type	[infection with herpes simplex virus type]	1.0	6	1	0	0
51578	1624	metabolite htb	[metabolite HTB]	1.0	2	1	0	0
51579	1624	somatic DNA	[somatic DNA]	1.0	2	1	0	0
51580	1624	saturate amount of the inhibitory	[saturating amounts of the inhibitory]	1.0	5	1	0	0
51581	1624	Maximal inhibition of ige production	[Maximal inhibition of IgE production]	1.0	5	1	0	0
51582	1624	transendothelial migration of monocyte-like hl-60 cell	[transendothelial migration of monocyte-like HL-60 cells]	1.0	6	1	0	0
51583	1624	contrast, antisense inhibition of tax	[contrast, antisense inhibition of Tax]	1.0	5	1	0	0
51584	1624	subsequent step in the signal pathway	[subsequent steps in the signaling pathway]	1.0	6	1	0	0
51585	1624	suggest reliable surrogate for the study	[suggesting reliable surrogates for the study]	1.0	6	1	0	0
51586	1624	factor protein	[factor protein]	1.0	2	2	2	2
51587	1624	parallel decline in site alpha-	[parallel decline in site alpha-]	1.0	5	1	0	0
51588	1624	particularly of the p50-p65 complex	[particularly of the p50-p65 complex]	1.0	5	1	0	0
51589	1624	B29 promoter	[B29 promoter]	1.0	2	2	2	2
51590	1624	tissue-specific metabolism	[tissue-specific metabolism]	1.0	2	1	0	0
51591	1624	CD28 response complex transcription factor	[CD28 response complex transcription factor]	1.0	5	1	0	0
51592	1624	RNA extraction	[RNA extraction]	1.0	2	1	0	0
51593	1624	5-day anti-CD3 /il-2 activation, level	[5-day anti-CD3 /IL-2 activation, levels]	1.0	5	1	0	0
51594	1624	analysis of the biochemical property	[Analysis of the biochemical properties]	1.0	5	1	0	0
51595	1624	thus, activation of nf-kappa b	[Thus, activation of NF-kappa B]	1.0	5	1	0	0
51596	1624	pml/raralpha transgenic	[PML/RARalpha transgenic]	1.0	2	1	0	0
51597	1624	b cell proliferation in the presence	[B cell proliferation in the presence]	1.0	6	1	0	0
51598	1624	various isoform	[various isoforms]	1.0	2	2	1	1
51599	1624	lps-treated cell	[LPS-treated cells]	1.0	2	1	0	0
51600	1624	M7 blast	[M7 blasts]	1.0	2	1	0	0
51601	1624	24 h with thp-1 cell	[24 h with THP-1 cells]	1.0	5	1	0	0
51602	1624	several fold.	[several fold.]	1.0	2	1	0	0
51603	1624	biochemical events.	[biochemical events.]	1.0	2	1	0	0
51604	1624	repeat activity	[repeat activity]	1.0	2	2	2	2
51605	1624	four region in this DNA fragment	[Four regions in this DNA fragment]	1.0	6	1	0	0
51606	1624	CD40 stimulation	[CD40 stimulation]	1.0	2	2	2	2
51607	1624	bcl-6 syn-1	[BCL-6 syn-1]	1.0	2	2	1	1
51608	1624	granulocyte-macrophage colony-stimumulatelany-stg factor promoter activity	[granulocyte-macrophage colony-stimulating factor promoter activity]	1.0	5	1	0	0
51609	1624	primary rodent cell in cooperation	[primary rodent cells in cooperation]	1.0	5	1	0	0
51610	1624	DNA region	[DNA region]	1.0	2	2	2	2
51611	1624	use gel mobility shift assay	[using gel mobility shift assays]	1.0	5	1	0	0
51612	1624	cytokine-mediated jak3 /stat5a/b signal transduction	[cytokine-mediated JAK3 /STAT5a/b signal transduction]	1.0	5	1	0	0
51613	1624	CD34+ progenitor	[CD34+ progenitors]	1.0	2	1	0	0
51614	1624	appreciable effect	[appreciable effect]	1.0	2	1	0	0
51615	1624	nf-kappa b activation in vitro	[NF-kappa B activation in vitro]	1.0	5	1	0	0
51616	1624	RAW 264.7	[RAW 264.7]	1.0	2	1	0	0
51617	1624	[3h]pyrilamine binding	[[3H]pyrilamine binding]	1.0	2	1	0	0
51618	1624	calcium mobilization of protein kinase c	[calcium mobilization of protein kinase C]	1.0	6	1	0	0
51619	1624	interaction with a heterodimeric receptor.	[interaction with a heterodimeric receptor.]	1.0	5	1	0	0
51620	1624	costimulatory molecule such as CD28	[costimulatory molecules such as CD28]	1.0	5	1	0	0
51621	1624	acid activation	[acid activation]	1.0	2	1	0	0
51622	1624	expression of a active form	[expression of a active form]	1.0	5	2	2	2
51623	1624	Raf-1 activity	[Raf-1 activity]	1.0	2	1	0	0
51624	1624	T cell prolymphocytic leukaemia t-pll	[T cell prolymphocytic leukaemia T-PLL]	1.0	5	1	0	0
51625	1624	use a in vitro system	[using an in vitro system]	1.0	5	1	0	0
51626	1624	human immunodeficiency virus type 1 hiv	[human immunodeficiency virus type 1 HIV]	1.0	6	1	0	0
51627	1624	nfat activation with ic50 of nm	[NFAT activation with IC50s of nM]	1.0	6	1	0	0
51628	1624	two ald	[two ALD]	1.0	2	1	0	0
51629	1624	often comprise a minor b-cell component	[often comprising a minor B-cell component]	1.0	6	1	0	0
51630	1624	potency of the transactivation domain	[potencies of the transactivation domains]	1.0	5	1	0	0
51631	1624	androgen-sensitive prostate cancer lncap cell	[androgen-sensitive prostate cancer LNCaP cells]	1.0	5	1	0	0
51632	1624	protein synthesis with cycloheximide anytime	[protein synthesis with cycloheximide anytime]	1.0	5	1	0	0
51633	1624	Deoxycholate treatment of cytoplasmic extract	[Deoxycholate treatment of cytoplasmic extracts]	1.0	5	1	0	0
51634	1624	localize to genital hsv -2 lesion	[localizing to genital HSV -2 lesions]	1.0	6	1	0	0
51635	1624	serial sectioning of 6 micrometer	[Serial sectioning of 6 micrometer]	1.0	5	1	0	0
51636	1624	epsilon degradation	[epsilon degradation]	1.0	2	1	0	0
51637	1624	cytosolic inhibitor	[cytosolic inhibitor]	1.0	2	2	1	1
51638	1624	low level of nuclear i(kappa)b(alpha)	[Low levels of nuclear I(kappa)B(alpha)]	1.0	5	1	0	0
51639	1624	PPARgamma mrna expression in U937 cell	[PPARgamma mRNA expression in U937 cells]	1.0	6	1	0	0
51640	1624	common member of the apoptotic cascade	[common members of the apoptotic cascade]	1.0	6	1	0	0
51641	1624	implicate zebra	[implicating ZEBRA]	1.0	2	1	0	0
51642	1624	further hours.	[further hours.]	1.0	2	1	0	0
51643	1624	hla stabilization experiment use transfectant	[HLA stabilization experiments using transfectants]	1.0	5	1	0	0
51644	1624	lps at a low concentration	[LPS at a lower concentration]	1.0	5	1	0	0
51645	1624	activation of the pro-interleukin-1beta gene	[activation of the pro-interleukin-1beta gene]	1.0	5	1	0	0
51646	1624	monocyte chemotaxis	[monocyte chemotaxis]	1.0	2	1	0	0
51647	1624	proliferation index as a prognostic marker	[Proliferation index as a prognostic marker]	1.0	6	1	0	0
51648	1624	5-hydroxyeicosatetraenoic acid	[5-hydroxyeicosatetraenoic acid]	1.0	2	2	2	2
51649	1624	cell-cell adhesion of the Wnt	[cell-cell adhesion of the Wnt]	1.0	5	1	0	0
51650	1624	c3 fragment	[C3 fragments]	1.0	2	1	0	0
51651	1624	inflammatory condition	[inflammatory condition]	1.0	2	2	2	2
51652	1624	antiphosphotyrosine immunoblot of whole cell lysate	[Antiphosphotyrosine immunoblots of whole cell lysates]	1.0	6	1	0	0
51653	1624	(10 subject	[(10 subjects]	1.0	2	1	0	0
51654	1624	patient with the disorder ataxia telangiectasia	[Patients with the disorder ataxia telangiectasia]	1.0	6	1	0	0
51655	1624	h9, CEM	[H9, CEM]	1.0	2	1	0	0
51656	1624	c/ebp beta in chronic inflammation	[C/EBP beta in chronic inflammation]	1.0	5	1	0	0
51657	1624	molecular model	[molecular model]	1.0	2	1	0	0
51658	1624	other inhibitors.	[other inhibitors.]	1.0	2	1	0	0
51659	1624	stat3 phosphorylation in T cell	[STAT3 phosphorylation in T cells]	1.0	5	1	0	0
51660	1624	ligand-dependent recruitment	[ligand-dependent recruitment]	1.0	2	1	0	0
51661	1624	interleukin (il)	[interleukin (IL)]	1.0	2	2	1	1
51662	1624	early cycle	[early cycle]	1.0	2	2	2	2
51663	1624	potent factor	[potent factor]	1.0	2	2	2	2
51664	1624	repression of il-2 gene activation	[repression of IL-2 gene activation]	1.0	5	1	0	0
51665	1624	effect of the agonist combination	[effect of the agonist combinations]	1.0	5	1	0	0
51666	1624	early arrest of T cell development	[early arrest of T cell development]	1.0	6	1	0	0
51667	1624	heat shock protein glycoprotein peptide	[heat shock protein glycoprotein peptides]	1.0	5	1	0	0
51668	1624	pathway for cytokine gene transcription	[pathways for cytokine gene transcription]	1.0	5	1	0	0
51669	1624	murine T cell line EL4	[murine T cell line EL4]	1.0	5	1	0	0
51670	1624	B7 stimulation	[B7 stimulation]	1.0	2	1	0	0
51671	1624	experimental basis for a hypothesis	[experimental basis for an hypothesis]	1.0	5	1	0	0
51672	1624	Systemic hGR level in patient	[Systemic hGR levels in patients]	1.0	5	1	0	0
51673	1624	analysis of the complete coding sequence	[analysis of the complete coding sequence]	1.0	6	1	0	0
51674	1624	U1 u1a/u1b U2 dna-protein complex	[U1 U1A/U1B U2 DNA-protein complexes]	1.0	5	1	0	0
51675	1624	immunostainable ppargamma	[immunostainable PPARgamma]	1.0	2	1	0	0
51676	1624	vitro transformation	[vitro transformation]	1.0	2	2	2	2
51677	1624	subsequent therapy,	[subsequent therapy,]	1.0	2	1	0	0
51678	1624	expression of this vzv protein	[expression of these VZV proteins]	1.0	5	1	0	0
51679	1624	promoter analysis	[Promoter analysis]	1.0	2	2	1	1
51680	1624	accumulation of unspliced mrna I HTLV-I	[accumulation of unspliced mRNA I HTLV-I]	1.0	6	1	0	0
51681	1624	leukocyte-endothelium interaction	[leukocyte-endothelium interaction]	1.0	2	1	0	0
51682	1624	link between epo signal mechanism	[link between Epo signaling mechanisms]	1.0	5	1	0	0
51683	1624	means modulate sensitivity of cells.	[means modulating sensitivity of cells.]	1.0	5	1	0	0
51684	1624	represent endocrine lineage use polyclonal antisera	[representing endocrine lineages using polyclonal antisera]	1.0	6	1	0	0
51685	1624	region of the IL-2 promoter	[region of the IL-2 promoter]	1.0	5	1	0	0
51686	1624	apoptosis-resistant t-cell transfectant with tax	[apoptosis-resistant T-cell transfectants with Tax]	1.0	5	1	0	0
51687	1624	level of mrna encoding c-fo	[level of mRNA encoding c-Fos]	1.0	5	1	0	0
51688	1624	tyrosine phosphorylation of jak2 of stat5	[tyrosine phosphorylation of JAK2 of STAT5]	1.0	6	1	0	0
51689	1624	addition of the third intron	[addition of the third intron]	1.0	5	1	0	0
51690	1624	positive control.	[positive control.]	1.0	2	1	0	0
51691	1624	CAV isolate from across the world	[CAV isolates from across the world]	1.0	6	1	0	0
51692	1624	interleukin-1 beta convert enzyme ice	[interleukin-1 beta converting enzyme ICE]	1.0	5	1	0	0
51693	1624	response to costimulation with CD3	[response to costimulation with CD3]	1.0	5	1	0	0
51694	1624	etiological agent	[etiological agent]	1.0	2	3	2	1
51695	1624	assembly of integrin-containing focal adhesion	[assembly of integrin-containing focal adhesions]	1.0	5	1	0	0
51696	1624	human hepatitis b virus hbv	[human hepatitis B virus HBV]	1.0	5	1	0	0
51697	1624	membrane by high salt concentration	[membranes by high salt concentrations]	1.0	5	1	0	0
51698	1624	Fusion of anergic murine T cell	[Fusion of anergic murine T cells]	1.0	6	1	0	0
51699	1624	such phenomena.	[such phenomena.]	1.0	2	1	0	0
51700	1624	trans-activating factor	[trans-activating factors]	1.0	2	2	1	1
51701	1624	such cells.	[such cells.]	1.0	2	1	0	0
51702	1624	c3 receptor	[C3 receptor]	1.0	2	1	0	0
51703	1624	separable gene regulatory inhibitory response	[separable gene regulatory inhibitory responses]	1.0	5	1	0	0
51704	1624	surface expression of class molecule	[surface expression of class molecules]	1.0	5	1	0	0
51705	1624	other genotype	[other genotypes]	1.0	2	1	0	0
51706	1624	costimulatory receptor	[costimulatory receptors]	1.0	2	1	0	0
51707	1624	existence of NF-kappa b mechanism	[existence of NF-kappa B mechanisms]	1.0	5	1	0	0
51708	1624	significant influence on the binding	[significant influence on the binding]	1.0	5	1	0	0
51709	1624	particle exposure of co-cultured bm	[particle exposure of co-cultured BM]	1.0	5	1	0	0
51710	1624	fos-related protein	[Fos-related proteins]	1.0	2	1	0	0
51711	1624	group of rdna represent rrna	[group of cDNAs representing mRNAs]	1.0	5	1	0	0
51712	1624	3) hyaluronan	[3) hyaluronan]	1.0	2	1	0	0
51713	1624	express the surface antigen CD8	[expressing the surface antigen CD8]	1.0	5	1	0	0
51714	1624	erythropoeitin receptor	[erythropoeitin receptor]	1.0	2	1	0	0
51715	1624	many basic helix-loop-helix (bhlh) transcription factor	[many basic helix-loop-helix (bHLH) transcription factors]	1.0	6	1	0	0
51716	1624	systemic glucose	[systemic glucose]	1.0	2	1	0	0
51717	1624	possible indicator	[possible indicator]	1.0	2	1	0	0
51718	1624	CD4 promoter activation by forskolin,	[CD4 promoter activation by forskolin,]	1.0	5	1	0	0
51719	1624	vascular adhesion	[vascular adhesion]	1.0	2	1	0	0
51720	1624	20-30 year	[20-30 yr]	1.0	2	1	0	0
51721	1624	only a partial dna-binding domain	[only a partial DNA-binding domain]	1.0	5	1	0	0
51722	1624	early inflammatory event in atherogenesis	[early inflammatory events in atherogenesis]	1.0	5	1	0	0
51723	1624	show specific for hiv-1 tat	[showing specific for HIV-1 tat]	1.0	5	1	0	0
51724	1624	deletion of the E1a region	[deletion of the E1a region]	1.0	5	1	0	0
51725	1624	repertoire selection	[Repertoire selection]	1.0	2	1	0	0
51726	1624	full-length ERP	[Full-length ERP]	1.0	2	1	0	0
51727	1624	various mode of basic helix-loop-helix regulation	[Various modes of basic helix-loop-helix regulation]	1.0	6	1	0	0
51728	1624	normal RBC	[Normal RBC]	1.0	2	1	0	0
51729	1624	unstimulated state,	[unstimulated state,]	1.0	2	1	0	0
51730	1624	monocytic differentiation with the differentiation	[monocytic differentiation with the differentiation]	1.0	5	1	0	0
51731	1624	additional information regard the class	[additional information regarding the class]	1.0	5	1	0	0
51732	1624	translocation of isoform to the fraction	[translocation of isoforms to the fraction]	1.0	6	1	0	0
51733	1624	B-cell proliferation	[B-cell proliferation]	1.0	2	1	0	0
51734	1624	high homology with the IL-2 gene	[high homology with the IL-2 gene]	1.0	6	1	0	0
51735	1624	two box	[two box]	1.0	2	1	0	0
51736	1624	rapid inducibility	[rapid inducibility]	1.0	2	1	0	0
51737	1624	stable maintenance	[stable maintenance]	1.0	2	1	0	0
51738	1624	ubiquitous otf-1 "octamer" binding protein	[ubiquitous OTF-1 "octamer" binding proteins]	1.0	5	1	0	0
51739	1624	metastatic properties	[metastatic properties,]	1.0	2	1	0	0
51740	1624	Finally, micromolar amount of pyrrolidine dithiocarbamate	[Finally, micromolar amounts of pyrrolidine dithiocarbamate]	1.0	6	1	0	0
51741	1624	EGR-1 gene	[EGR-1 genes]	1.0	2	1	0	0
51742	1624	vector expression of vzv protein	[vector expression of VZV proteins]	1.0	5	1	0	0
51743	1624	such as a effect on structure	[such as an effect on structure]	1.0	6	1	0	0
51744	1624	clonality assay	[clonality assays]	1.0	2	1	0	0
51745	1624	B-cell maturation	[B-cell maturation]	1.0	2	1	0	0
51746	1624	protein BZLF1	[protein BZLF1]	1.0	2	2	2	2
51747	1624	contain the human ciita coding sequence	[containing the human CIITA coding sequence]	1.0	6	1	0	0
51748	1624	apoptotic signal	[apoptotic signal]	1.0	2	2	2	2
51749	1624	retinoic acid-alpha receptor RAR alpha	[retinoic acid-alpha receptor RAR alpha]	1.0	5	1	0	0
51750	1624	expression of human ikappab alpha	[expression of human IkappaB alpha]	1.0	5	1	0	0
51751	1624	tumor-associated phenomenon	[tumor-associated phenomenon]	1.0	2	1	0	0
51752	1624	level comparable to the level	[levels comparable to the levels]	1.0	5	1	0	0
51753	1624	tf activation occur in mononuclear cell	[TF activation occurring in mononuclear cells]	1.0	6	1	0	0
51754	1624	subsequently, increase	[Subsequently, increasing]	1.0	2	1	0	0
51755	1624	level of rrna for gene	[levels of mRNAs for genes]	1.0	5	1	0	0
51756	1624	enhancement of expression of tf	[Enhancement of expression of TF]	1.0	5	1	0	0
51757	1624	mg at 11 p.m.) type	[mg at 11 p.m.) Type]	1.0	5	1	0	0
51758	1624	anti-cd2 alone,	[anti-CD2 alone,]	1.0	2	1	0	0
51759	1624	binding to a cell surface receptor	[binding to a cell surface receptor]	1.0	6	1	0	0
51760	1624	intricate arrangement of binding site	[intricate arrangement of binding sites]	1.0	5	1	0	0
51761	1624	OBF-1 a novel b cell-specific coactivator	[OBF-1 a novel B cell-specific coactivator]	1.0	6	1	0	0
51762	1624	ORFs U86	[ORFs U86]	1.0	2	1	0	0
51763	1624	fos mrna	[FOS mRNA]	1.0	2	1	0	0
51764	1624	nonmobilized peripheral blood mononuclear cell	[nonmobilized peripheral blood mononuclear cells]	1.0	5	1	0	0
51765	1624	I kappa b gamma isoform	[I kappa B gamma isoforms]	1.0	5	1	0	0
51766	1624	molecular analysis use Southern blot hybridisation	[Molecular analysis using Southern blot hybridisation]	1.0	6	1	0	0
51767	1624	ikappab proteolysis	[IkappaB proteolysis]	1.0	2	1	0	0
51768	1624	lck promoter	[lck promoter]	1.0	2	2	2	2
51769	1624	Pyrrolidinedithiocarbamate mg-132	[Pyrrolidinedithiocarbamate MG-132]	1.0	2	1	0	0
51770	1624	peripheral blood of 7 patient	[peripheral blood of 7 patients]	1.0	5	1	0	0
51771	1624	subsequent step	[subsequent steps]	1.0	2	2	2	2
51772	1624	mammalian homolog	[mammalian homolog]	1.0	2	1	0	0
51773	1624	0.05, n	[0.05, n]	1.0	2	1	0	0
51774	1624	expression of the human tcf-1 protein	[expression of the human TCF-1 protein]	1.0	6	1	0	0
51775	1624	0.05, p	[0.05, P]	1.0	2	2	2	2
51776	1624	limit in remodeling of tissue rich	[limiting in remodeling of tissues rich]	1.0	6	1	0	0
51777	1624	least in part, by damage	[least in part, by damage]	1.0	5	1	0	0
51778	1624	Rel a	[Rel A]	1.0	2	1	0	0
51779	1624	transcription factor ap-1 by CD28	[transcription factor AP-1 by CD28]	1.0	5	1	0	0
51780	1624	resistant mechanism	[resistant mechanism]	1.0	2	1	0	0
51781	1624	Recombinant c-Jun	[Recombinant c-Jun]	1.0	2	1	0	0
51782	1624	low-ionic-strength condition	[low-ionic-strength conditions]	1.0	2	1	0	0
51783	1624	retinoic-acid receptor type alpha rar(alpha)	[retinoic-acid receptor type alpha RAR(alpha)]	1.0	5	1	0	0
51784	1624	5 u/ml interleukin-2 over 48-h	[5 U/ml interleukin-2 over 48-h]	1.0	5	1	0	0
51785	1624	ets-like factor with the exception	[ETS-like factors with the exception]	1.0	5	1	0	0
51786	1624	cause a influx of calcium	[causing an influx of calcium]	1.0	5	1	0	0
51787	1624	new enhancer	[new enhancer]	1.0	2	1	0	0
51788	1624	functional gene such as ICAM-1	[functional genes such as ICAM-1]	1.0	5	1	0	0
51789	1624	G2/M interphase	[G2/M interphase]	1.0	2	1	0	0
51790	1624	VZV donor	[VZV donors]	1.0	2	2	2	2
51791	1624	stress this mouse with sublethal irradiation	[stressing these mice with sublethal irradiation]	1.0	6	1	0	0
51792	1624	sequence analysis of nineteen ltr	[Sequence analysis of nineteen LTRs]	1.0	5	1	0	0
51793	1624	several regulatory region include CBF	[several regulatory regions including CBF]	1.0	5	1	0	0
51794	1624	unique latency in the tumour cell	[unique latency in the tumour cells]	1.0	6	1	0	0
51795	1624	il-9 activation of stat3 of c-myc	[IL-9 activation of STAT3 of c-myc]	1.0	6	1	0	0
51796	1624	DC at many effector site	[DC at many effector sites]	1.0	5	1	0	0
51797	1624	macrophage-like morphology	[macrophage-like morphology]	1.0	2	1	0	0
51798	1624	specific enzyme	[specific enzymes]	1.0	2	1	0	0
51799	1624	Thus, TNF alpha nf-kappa b activation	[Thus, TNF alpha NF-kappa B activation]	1.0	6	1	0	0
51800	1624	cell sensitive	[cells sensitive]	1.0	2	2	2	2
51801	1624	wild-type receptor in the induction	[wild-type receptors in the induction]	1.0	5	1	0	0
51802	1624	view of the therapeutic efficiency	[view of the therapeutic efficiency]	1.0	5	1	0	0
51803	1624	tat cDNA	[tat cDNA]	1.0	2	2	2	2
51804	1624	Pb activation of NF-kappa b	[Pb activation of NF-kappa B]	1.0	5	1	0	0
51805	1624	unstimulated monocyte	[unstimulated monocytes]	1.0	2	1	0	0
51806	1624	mononuclear differentiation	[mononuclear differentiation]	1.0	2	1	0	0
51807	1624	initial interleukin-1beta mrna transcription rate	[initial interleukin-1beta mRNA transcription rate]	1.0	5	1	0	0
51808	1624	unbound ligand.	[unbound ligand.]	1.0	2	1	0	0
51809	1624	suppression of T cell function	[suppression of T cell function]	1.0	5	2	1	1
51810	1624	induction of mcp-1 by RA	[induction of MCP-1 by RA]	1.0	5	1	0	0
51811	1624	surround the HIV protease cleavage site	[surrounding the HIV protease cleavage site]	1.0	6	1	0	0
51812	1624	present experiment,	[present experiment,]	1.0	2	1	0	0
51813	1624	constitutive apoptosis in human neutrophil	[constitutive apoptosis in human neutrophils]	1.0	5	1	0	0
51814	1624	several gene in human neutrophil	[several genes in human neutrophils]	1.0	5	1	0	0
51815	1624	detectable il-2	[detectable IL-2]	1.0	2	1	0	0
51816	1624	underlie differentiation	[underlying differentiation]	1.0	2	2	2	2
51817	1624	responsiveness to nuclear factor kappa b	[responsiveness to nuclear factor kappa B]	1.0	6	1	0	0
51818	1624	useful tool study the regulation	[useful tool studying the regulation]	1.0	5	1	0	0
51819	1624	half-life study	[half-life studies]	1.0	2	1	0	0
51820	1624	specific proliferation	[specific proliferation]	1.0	2	1	0	0
51821	1624	four-subunit ptf	[four-subunit PTF]	1.0	2	1	0	0
51822	1624	advanced infection with this virus.	[advanced infection with this virus.]	1.0	5	1	0	0
51823	1624	core-binding factor	[core-binding factor]	1.0	2	2	1	1
51824	1624	complex regulation of gene expression	[complex regulation of gene expression]	1.0	5	1	0	0
51825	1624	normal differentiation from stem cell	[normal differentiation from stem cells]	1.0	5	1	0	0
51826	1624	Nicoletti technique	[Nicoletti technique]	1.0	2	1	0	0
51827	1624	regulate gene transcription in lymphoid tissue	[regulating gene transcription in lymphoid tissues]	1.0	6	1	0	0
51828	1624	constitutive dephosphorylation of a member	[Constitutive dephosphorylation of a member]	1.0	5	1	0	0
51829	1624	blood leukocyte content of receptor	[blood leukocyte content of receptors]	1.0	5	2	2	2
51830	1624	CD38 expression in leukemia cell	[CD38 expression in leukemia cells]	1.0	5	1	0	0
51831	1624	+/- 1.07	[+/- 1.07]	1.0	2	1	0	0
51832	1624	unidentified superantigen	[unidentified superantigen]	1.0	2	1	0	0
51833	1624	Grb2-binding protein in human platelet	[Grb2-binding proteins in human platelets]	1.0	5	1	0	0
51834	1624	induction of endothelial adhesion molecule	[Induction of endothelial adhesion molecules]	1.0	5	1	0	0
51835	1624	unknown gene	[unknown gene]	1.0	2	2	1	1
51836	1624	precursor of the p50 subunit	[precursor of the p50 subunit]	1.0	5	1	0	0
51837	1624	vice versa,	[vice versa,]	1.0	2	1	0	0
51838	1624	rt-pcr result in the isolation	[RT-PCR resulting in the isolation]	1.0	5	1	0	0
51839	1624	regulatory motif	[regulatory motif]	1.0	2	2	2	2
51840	1624	deletion of the PLZF POZ domain	[Deletion of the PLZF POZ domain]	1.0	6	1	0	0
51841	1624	protein interact	[proteins interacting]	1.0	2	1	0	0
51842	1624	5' promoter	[5' promoter]	1.0	2	2	2	2
51843	1624	microb site	[microB site]	1.0	2	2	1	1
51844	1624	gel-retardation assay	[gel-retardation assay]	1.0	2	1	0	0
51845	1624	TCEd distal T cell element	[TCEd distal T cell element]	1.0	5	1	0	0
51846	1624	December 1;270(48):29038]	[Dec 1;270(48):29038]]	1.0	2	1	0	0
51847	1624	hybridization analysis	[hybridization analysis]	1.0	2	2	2	2
51848	1624	differential regulation of octamer site	[differential regulation of octamer sites]	1.0	5	1	0	0
51849	1624	IL-1beta transcription	[IL-1beta transcription]	1.0	2	1	0	0
51850	1624	significant inhibition of cell growth	[significant inhibition of cell growth]	1.0	5	1	0	0
51851	1624	use immunohistochemistry with antibody against protein	[using immunohistochemistry with antibodies against proteins]	1.0	6	1	0	0
51852	1624	secondary organ	[secondary organs]	1.0	2	1	0	0
51853	1624	Vitamin d receptor no evidence	[Vitamin D receptor no evidence]	1.0	5	1	0	0
51854	1624	guardian of thymus-derived t-cell homeostasis	[guardian of thymus-derived T-cell homeostasis]	1.0	5	1	0	0
51855	1624	glucocorticoid receptor in hypertensive patient	[glucocorticoid receptors in hypertensive patients]	1.0	5	1	0	0
51856	1624	mechanism underlie this rapid effect	[mechanisms underlying these rapid effects]	1.0	5	1	0	0
51857	1624	p130 form	[p130 Form]	1.0	2	2	1	1
51858	1624	interleukin-10 il-10 production in human monocyte	[interleukin-10 IL-10 production in human monocytes]	1.0	6	1	0	0
51859	1624	transcript level	[transcript levels]	1.0	2	2	1	1
51860	1624	alternative splicing,	[alternative splicing,]	1.0	2	1	0	0
51861	1624	synergize with signal from TCR- CD3	[synergizing with signals from TCR- CD3]	1.0	6	1	0	0
51862	1624	renal deterioration	[renal deteriorations]	1.0	2	1	0	0
51863	1624	stable, complex	[stable, complexes]	1.0	2	1	0	0
51864	1624	tf molecule	[TF molecule]	1.0	2	1	0	0
51865	1624	PO-B dna-binding	[PO-B DNA-binding]	1.0	2	1	0	0
51866	1624	activation of Janus tyrosine kinase	[activation of Janus tyrosine kinase]	1.0	5	2	2	2
51867	1624	rapid degradation,	[rapid degradation,]	1.0	2	1	0	0
51868	1624	3-5 min.	[3-5 min.]	1.0	2	1	0	0
51869	1624	use the human t-cell line JPX-9	[using the human T-cell line JPX-9]	1.0	6	1	0	0
51870	1624	two copy of the PRDII domain	[two copies of the PRDII domain]	1.0	6	1	0	0
51871	1624	essential step maintain the phenotype	[essential step maintaining the phenotype]	1.0	5	1	0	0
51872	1624	antibody against the NF-kappa B protein	[Antibodies against the NF-kappa B proteins]	1.0	6	1	0	0
51873	1624	osteoclast differentiation	[osteoclast differentiation]	1.0	2	2	1	1
51874	1624	Interfollicular cell	[Interfollicular cells]	1.0	2	1	0	0
51875	1624	expression of the gata-1 gene	[expression of the GATA-1 gene]	1.0	5	1	0	0
51876	1624	Thus, CD45	[Thus, CD45]	1.0	2	1	0	0
51877	1624	alternate mechanism	[alternate mechanism]	1.0	2	1	0	0
51878	1624	two proteins.	[two proteins.]	1.0	2	1	0	0
51879	1624	two proteins,	[two proteins,]	1.0	2	1	0	0
51880	1624	physiopathologic role in a number	[physiopathologic role in a number]	1.0	5	1	0	0
51881	1624	natural retinoid	[natural retinoid]	1.0	2	1	0	0
51882	1624	problem of the neuro-immuno interaction	[problem of the neuro-immuno interactions]	1.0	5	1	0	0
51883	1624	t-cell lymphotropic virus type tax	[T-cell lymphotropic virus type Tax]	1.0	5	2	2	2
51884	1624	monocyte through complement receptor-1 CR1	[monocytes through complement receptor-1 CR1]	1.0	5	1	0	0
51885	1624	sharp contrast to endometrial cell	[sharp contrast to endometrial cells]	1.0	5	1	0	0
51886	1624	intrauterine contraception	[intrauterine contraception]	1.0	2	1	0	0
51887	1624	ligand-induced degradation	[ligand-induced degradation]	1.0	2	1	0	0
51888	1624	activation of the cdc42 effector n-wasp	[Activation of the CDC42 effector N-WASP]	1.0	6	1	0	0
51889	1624	reject allograft	[rejecting allografts]	1.0	2	1	0	0
51890	1624	molecular characterization of tissue expression	[Molecular characterization of tissue expression]	1.0	5	1	0	0
51891	1624	allergic disorder	[allergic disorders]	1.0	2	1	0	0
51892	1624	patient with acute promyelocytic leukemia	[patients with acute promyelocytic leukemia]	1.0	5	2	1	1
51893	1624	signal into the t-cell nucleus	[Signalling into the T-cell nucleus]	1.0	5	1	0	0
51894	1624	V3 loop of immunodeficiency virus type	[V3 loop of immunodeficiency virus type]	1.0	6	1	0	0
51895	1624	abnormality of retinoblastoma protein prb	[Abnormalities of retinoblastoma protein pRB]	1.0	5	1	0	0
51896	1624	Hans Clevers	[Hans Clevers]	1.0	2	1	0	0
51897	1624	host response to mycobacterium tuberculosis	[host response to Mycobacterium tuberculosis]	1.0	5	1	0	0
51898	1624	fmlp activation	[FMLP activation]	1.0	2	1	0	0
51899	1624	Cyclin A	[Cyclin A]	1.0	2	2	1	1
51900	1624	key role in the pathogenesis	[key role in the pathogenesis]	1.0	5	1	0	0
51901	1624	runt polypeptide differentiate myeloid cell	[runt polypeptides differentiating myeloid cells]	1.0	5	1	0	0
51902	1624	endogenous catalase	[endogenous catalase]	1.0	2	1	0	0
51903	1624	intracellular reactive oxygen species generation	[intracellular reactive oxygen species generation]	1.0	5	1	0	0
51904	1624	activation of protein tyrosine kinase	[activation of protein tyrosine kinases]	1.0	5	2	2	2
51905	1624	contain the 5' flank region	[containing the 5' flanking region]	1.0	5	1	0	0
51906	1624	ec50 value for camp production	[EC50 values for cAMP production]	1.0	5	1	0	0
51907	1624	selectively in extract of lymphoid cell	[selectively in extracts of lymphoid cells]	1.0	6	1	0	0
51908	1624	immunogenotypic study	[immunogenotypic studies]	1.0	2	1	0	0
51909	1624	il-1 activation of the transcription factor	[IL-1 activation of the transcription factor]	1.0	6	1	0	0
51910	1624	cho/cd14 cell	[CHO/CD14 cells]	1.0	2	1	0	0
51911	1624	agonist of histamine receptor subtype	[agonists of histamine receptor subtypes]	1.0	5	1	0	0
51912	1624	frameshift mutation in the 3'-end	[frameshift mutation in the 3'-end]	1.0	5	1	0	0
51913	1624	mitogenic coactivator	[mitogenic coactivator]	1.0	2	1	0	0
51914	1624	diabete maturity-onset diabete of the young	[diabetes maturity-onset diabetes of the young]	1.0	6	1	0	0
51915	1624	40-kda protein	[40-kDa protein]	1.0	2	2	2	2
51916	1624	effect of catecholamine on IL-12	[effects of catecholamine on IL-12]	1.0	5	1	0	0
51917	1624	Differanisole A a novel antitumor antibiotic	[Differanisole A a novel antitumor antibiotic]	1.0	6	1	0	0
51918	1624	monocyte differentiation of hl60 cell	[monocyte differentiation of HL60 cells]	1.0	5	1	0	0
51919	1624	peptide hormone	[peptide hormone]	1.0	2	2	2	2
51920	1624	approximately 10-fold 4 to 5 day	[approximately 10-fold 4 to 5 days]	1.0	6	1	0	0
51921	1624	mrna level for il-13r alpha1	[mRNA levels for IL-13R alpha1]	1.0	5	1	0	0
51922	1624	preparation of bone marrow cell	[Preparation of bone marrow cells]	1.0	5	1	0	0
51923	1624	lat from T cell lysate	[LAT from T cell lysates]	1.0	5	1	0	0
51924	1624	NF-kappa b as inducible transcriptional activator	[NF-kappa B as inducible transcriptional activator]	1.0	6	1	0	0
51925	1624	expression plasmid encode region of RFX5	[Expression plasmids encoding regions of RFX5]	1.0	6	1	0	0
51926	1624	suggest a association of SCL	[suggesting an association of SCL]	1.0	5	1	0	0
51927	1624	characterization of interleukin-10 receptor expression	[Characterization of interleukin-10 receptor expression]	1.0	5	1	0	0
51928	1624	separate gene on different chromosomes.	[separate genes on different chromosomes.]	1.0	5	1	0	0
51929	1624	mostly from increase in transcription.	[mostly from increases in transcription.]	1.0	5	1	0	0
51930	1624	mouse homolog	[mouse homolog]	1.0	2	1	0	0
51931	1624	hiv-1 ihiv-1	[HIV-1 iHIV-1]	1.0	2	1	0	0
51932	1624	hiv-infected patient with affinity to glucocorticoid	[HIV-infected patients with affinity to glucocorticoids]	1.0	6	2	2	2
51933	1624	PBSC harvest	[PBSC harvests]	1.0	2	2	1	1
51934	1624	alteration of the 5' triplet	[alteration of the 5' triplet]	1.0	5	1	0	0
51935	1624	gig18 induction	[GIG18 induction]	1.0	2	1	0	0
51936	1624	Here, Markus Neurath, Eckhard Stuber	[Here, Markus Neurath, Eckhard Stuber]	1.0	5	1	0	0
51937	1624	up- of nuclear nf kappab	[up- of nuclear NF kappaB]	1.0	5	1	0	0
51938	1624	AP-1 polypeptide	[AP-1 polypeptides]	1.0	2	1	0	0
51939	1624	different mechanism of il-2 activation	[different mechanisms of IL-2 activation]	1.0	5	1	0	0
51940	1624	activation of the cell cycle	[activation of the cell cycle]	1.0	5	1	0	0
51941	1624	16 h	[16 h]	1.0	2	1	0	0
51942	1624	steroidal effect	[steroidal effects]	1.0	2	1	0	0
51943	1624	codon 231	[codon 231]	1.0	2	1	0	0
51944	1624	NCL individual	[NCL individuals]	1.0	2	1	0	0
51945	1624	allele-specific regulatory system of WT1	[allele-specific regulatory system of WT1]	1.0	5	1	0	0
51946	1624	use the human t-cell line Jurkat	[using the human T-cell lines Jurkat]	1.0	6	1	0	0
51947	1624	matrix metalloproteinase 9 factor ap-1	[matrix metalloproteinase 9 factor AP-1]	1.0	5	1	0	0
51948	1624	biological evaluation	[biological evaluation]	1.0	2	1	0	0
51949	1624	b site	[B sites]	1.0	2	2	1	1
51950	1624	strong transactivation of the cd25 promoter	[strong transactivation of the CD25 promoter]	1.0	6	1	0	0
51951	1624	ikappab-alpha phosphorylation	[IkappaB-alpha phosphorylation]	1.0	2	1	0	0
51952	1624	comparison with protein in Genbank	[comparison with proteins in Genbank]	1.0	5	1	0	0
51953	1624	xenopus hepatocyte	[Xenopus hepatocytes]	1.0	2	1	0	0
51954	1624	total rna in cell-sorted monocyte	[total RNA in cell-sorted monocytes]	1.0	5	1	0	0
51955	1624	ADT a pro- glutathione antioxidant	[ADT a pro- glutathione antioxidant]	1.0	5	1	0	0
51956	1624	monokine secretion	[monokine secretion]	1.0	2	1	0	0
51957	1624	cell clonogenic	[cell clonogenic]	1.0	2	1	0	0
51958	1624	patient with vddr-ii rh- VDR	[patients with VDDR-II Rh- VDR]	1.0	5	1	0	0
51959	1624	biology of this tumor study	[biology of this tumor studies]	1.0	5	1	0	0
51960	1624	S phase,	[S phase,]	1.0	2	1	0	0
51961	1624	mutation machinery	[mutation machinery]	1.0	2	1	0	0
51962	1624	fetal liver of pu.1-/- mouse	[fetal liver of PU.1-/- mice]	1.0	5	1	0	0
51963	1624	involvement of erythroid transcription factor	[involvement of erythroid transcription factors]	1.0	5	1	0	0
51964	1624	CD28 stimulation	[CD28 stimulation]	1.0	2	3	2	1
51965	1624	position -44	[positions -44]	1.0	2	1	0	0
51966	1624	position -42	[position -42]	1.0	2	1	0	0
51967	1624	hemin heat shock gene expression	[hemin heat shock gene expression]	1.0	5	1	0	0
51968	1624	systemic resistance	[systemic resistance]	1.0	2	1	0	0
51969	1624	numerous substrate	[numerous substrates]	1.0	2	1	0	0
51970	1624	two atf/ creb recognition motif	[two ATF/ CREB recognition motifs]	1.0	5	1	0	0
51971	1624	269.0 ng/ml	[269.0 ng/mL]	1.0	2	1	0	0
51972	1624	constitutive nuclear nf-kappa b in cell	[Constitutive nuclear NF-kappa B in cells]	1.0	6	1	0	0
51973	1624	cell-intrinsic mechanism	[cell-intrinsic mechanism]	1.0	2	1	0	0
51974	1624	secondary infection	[secondary infections]	1.0	2	1	0	0
51975	1624	malignant disorder	[malignant disorders]	1.0	2	1	0	0
51976	1624	hl-60 leukemia cell to macrophage	[HL-60 leukemia cells to macrophages]	1.0	5	1	0	0
51977	1624	arginine residue in this domain	[arginine residues in this domain]	1.0	5	1	0	0
51978	1624	human toll signal pathway divergence	[human toll signaling pathway divergence]	1.0	5	1	0	0
51979	1624	transient activation	[transient activation]	1.0	2	2	2	2
51980	1624	sensitive cell	[sensitive cells]	1.0	2	1	0	0
51981	1624	nf-kappa b in cho/ cd14	[NF-kappa B in CHO/ CD14]	1.0	5	1	0	0
51982	1624	10 microm of C-JUN as oligonucleotide	[10 microM of C-JUN AS oligonucleotides]	1.0	6	1	0	0
51983	1624	tyrosine phosphorylation,	[tyrosine phosphorylation,]	1.0	2	1	0	0
51984	1624	I retroviruse	[I retroviruses]	1.0	2	1	0	0
51985	1624	modest nuclear translocation of kappab-binding protein	[modest nuclear translocation of kappaB-binding proteins]	1.0	6	1	0	0
51986	1624	protoenhancer alone	[protoenhancers alone]	1.0	2	1	0	0
51987	1624	R/U5 region	[R/U5 region]	1.0	2	1	0	0
51988	1624	putative intracellular receptor for fk506	[putative intracellular receptors for FK506]	1.0	5	1	0	0
51989	1624	gro-alpha immobilization	[GRO-alpha immobilization]	1.0	2	1	0	0
51990	1624	other differential cDNA cloning strategy	[other differential cDNA cloning strategies]	1.0	5	1	0	0
51991	1624	contain a BP1 binding site.	[containing a BP1 binding site.]	1.0	5	1	0	0
51992	1624	IFN alpha level in aids -gr	[IFN alpha levels in AIDS -GR]	1.0	6	1	0	0
51993	1624	c-jun expression good parallel differentiation.	[c-jun expression best paralleling differentiation.]	1.0	5	1	0	0
51994	1624	shift from multipotent/erythroid/monocytic to differentiation program	[shift from multipotent/erythroid/monocytic to differentiation program]	1.0	6	1	0	0
51995	1624	sequential recruitment	[sequential recruitment]	1.0	2	1	0	0
51996	1624	implication for therapy of leukemia patient	[implications for therapy of leukemia patients]	1.0	6	1	0	0
51997	1624	removal of the octamer-binding site	[removal of the octamer-binding site]	1.0	5	1	0	0
51998	1624	p50 homodimer in human monocyte	[p50 homodimer in human monocytes]	1.0	5	1	0	0
51999	1624	Ran alone	[Ran alone]	1.0	2	1	0	0
52000	1624	vitro macrophage	[vitro macrophages]	1.0	2	2	2	2
52001	1624	IL-2 signal	[IL-2 signaling]	1.0	2	1	0	0
52002	1624	long nuclear expression of NF-kappa b	[long-term nuclear expression of NF-kappa B]	1.0	6	1	0	0
52003	1624	infiltrate human genital herpes lesion	[infiltrating human genital herpes lesions]	1.0	5	1	0	0
52004	1624	social factor	[social factors]	1.0	2	2	1	1
52005	1624	vitro response of T cell	[vitro responses of T cells]	1.0	5	1	0	0
52006	1624	functional interplay	[functional interplay]	1.0	2	1	0	0
52007	1624	injury-induced necrosis	[injury-induced necrosis]	1.0	2	1	0	0
52008	1624	methods: peptide	[METHODS: Peptides]	1.0	2	1	0	0
52009	1624	protein of about 65-75 kda	[proteins of about 65-75 kDa]	1.0	5	1	0	0
52010	1624	stat protein on serine residue	[STAT proteins on serine residues]	1.0	5	1	0	0
52011	1624	extracellular region	[extracellular regions]	1.0	2	1	0	0
52012	1624	conclusion rate-limiting for the activation	[conclusion rate-limiting for the activation]	1.0	5	1	0	0
52013	1624	translation analysis	[translation analysis]	1.0	2	1	0	0
52014	1624	systemic effect of cortisol level	[systemic effects of cortisol level]	1.0	5	1	0	0
52015	1624	react intracellularly	[reacting intracellularly]	1.0	2	1	0	0
52016	1624	regulation within the NF-AT family	[regulation within the NF-AT family]	1.0	5	1	0	0
52017	1624	heterogeneous nuclear ribonucleoprotein k protein	[heterogeneous nuclear ribonucleoprotein K protein]	1.0	5	1	0	0
52018	1624	low il-4	[low IL-4]	1.0	2	1	0	0
52019	1624	low il-2	[low IL-2]	1.0	2	1	0	0
52020	1624	cushingd' syndrome type ii corticosteroid receptor	[Cushing's syndrome Type II corticosteroid receptors]	1.0	6	1	0	0
52021	1624	increase of nuclear protein complex	[increases of nuclear protein complexes]	1.0	5	1	0	0
52022	1624	damage to the gene encode protein	[Damage to the genes encoding proteins]	1.0	6	1	0	0
52023	1624	spontaneous mutation	[spontaneous mutations]	1.0	2	1	0	0
52024	1624	human pbl-t	[human PBL-T]	1.0	2	1	0	0
52025	1624	activation of nf-kappa b transcription factor	[activation of NF-kappa B transcription factors]	1.0	6	1	0	0
52026	1624	recombinant chloramphenicol	[recombinant chloramphenicol]	1.0	2	1	0	0
52027	1624	Shigella movement,	[Shigella movement,]	1.0	2	1	0	0
52028	1624	availability of selective proteasome inhibitor	[availability of selective proteasome inhibitors]	1.0	5	1	0	0
52029	1624	SAF activity.	[SAF activity.]	1.0	2	1	0	0
52030	1624	40 P.	[40 h.]	1.0	2	1	0	0
52031	1624	Specific lymphocyte	[Specific lymphocytes]	1.0	2	1	0	0
52032	1624	extensive immunocytochemical evaluation of tissue	[extensive immunocytochemical evaluation of tissues]	1.0	5	1	0	0
52033	1624	ibr cDNA	[IBR cDNA]	1.0	2	1	0	0
52034	1624	terminal b differentiation in vivo;	[terminal B differentiation in vivo;]	1.0	5	1	0	0
52035	1624	CsA leukocyte	[CsA leukocytes]	1.0	2	1	0	0
52036	1624	transcript of the other gene	[transcripts of the other genes]	1.0	5	1	0	0
52037	1624	long form,	[longest form,]	1.0	2	2	2	2
52038	1624	IL-8 expression	[IL-8 expression]	1.0	2	1	0	0
52039	1624	hl60 to hormone for h	[HL60 to hormone for h]	1.0	5	1	0	0
52040	1624	Bcl-2 protein	[Bcl-2 protein]	1.0	2	1	0	0
52041	1624	procedure suitable for cloning rrna	[procedure suitable for cloning mRNAs]	1.0	5	1	0	0
52042	1624	position -70	[positions -70]	1.0	2	1	0	0
52043	1624	include sp1	[including Sp1]	1.0	2	2	2	2
52044	1624	position -79	[positions -79]	1.0	2	1	0	0
52045	1624	position -78	[positions -78]	1.0	2	2	1	1
52046	1624	marker of differentiation, respiratory burst	[marker of differentiation, respiratory burst]	1.0	5	1	0	0
52047	1624	L gene	[L gene]	1.0	2	1	0	0
52048	1624	differentiation in the cell line	[differentiation in the cell lines]	1.0	5	1	0	0
52049	1624	identification of Bcd a novel proto-oncogene	[Identification of Bcd a novel proto-oncogene]	1.0	6	1	0	0
52050	1624	Interleukin (IL)-10	[Interleukin (IL)-10]	1.0	2	1	0	0
52051	1624	okadaic acid-sensitive ser /thr phosphatase	[okadaic acid-sensitive Ser /Thr phosphatases]	1.0	5	1	0	0
52052	1624	total rap1	[total Rap1]	1.0	2	1	0	0
52053	1624	position -53	[positions -53]	1.0	2	1	0	0
52054	1624	adverse effect of peptide vaccination	[adverse effect of peptide vaccination]	1.0	5	1	0	0
52055	1624	hematopoietic growth factor-dependent cell line	[hematopoietic growth factor-dependent cell lines]	1.0	5	1	0	0
52056	1624	acute ethanol treatment in vitro	[acute ethanol treatment in vitro]	1.0	5	1	0	0
52057	1624	include granulocyte-macrophage colony-stimulating factor gm-csf	[including granulocyte-macrophage colony-stimulating factor GM-CSF]	1.0	5	1	0	0
52058	1624	glucocorticoid receptor beta in airway cell	[glucocorticoid receptor beta in airway cells]	1.0	6	1	0	0
52059	1624	enhancer-mediated activation of the promoter	[enhancer-mediated activation of the promoter]	1.0	5	1	0	0
52060	1624	gamma-ifn inducible DNA binding activity	[gamma-IFN inducible DNA binding activity]	1.0	5	1	0	0
52061	1624	unknown protein(s).	[unknown protein(s).]	1.0	2	1	0	0
52062	1624	develop tissue	[developing tissues]	1.0	2	2	1	1
52063	1624	b-lineage commitment in the liver	[B-lineage commitment in the liver]	1.0	5	1	0	0
52064	1624	coagulation factor on a surface	[coagulation factors on an surface]	1.0	5	1	0	0
52065	1624	gel retardation assay use a 32p-probe	[Gel retardation assays using a 32P-probe]	1.0	6	1	0	0
52066	1624	t-cell oncogene	[T-cell oncogenes]	1.0	2	1	0	0
52067	1624	383-bp (delta383)	[383-bp (delta383)]	1.0	2	1	0	0
52068	1624	bind pattern of transcription factor	[binding pattern of transcription factors]	1.0	5	2	2	2
52069	1624	il-3, il-5,	[IL-3, IL-5,]	1.0	2	1	0	0
52070	1624	recognizable association of cytokine pattern	[recognizable association of cytokine patterns]	1.0	5	1	0	0
52071	1624	control (156.7+/-27.3	[control (156.7+/-27.3]	1.0	2	1	0	0
52072	1624	expression of surface immunoglobulin m	[expression of surface immunoglobulin M]	1.0	5	1	0	0
52073	1624	gamma-positive cell	[gamma-positive cells]	1.0	2	1	0	0
52074	1624	time-dependent decrease	[time-dependent decrease]	1.0	2	1	0	0
52075	1624	biochemical evidence	[biochemical evidence]	1.0	2	2	2	2
52076	1624	developmental process	[developmental process]	1.0	2	2	1	1
52077	1624	translocation process	[translocation process]	1.0	2	1	0	0
52078	1624	CAT activity in this cells,	[CAT activity in these cells,]	1.0	5	1	0	0
52079	1624	recruitment phenomenon,	[recruitment phenomenon,]	1.0	2	1	0	0
52080	1624	tumor with low ki-67 values.	[tumors with low Ki-67 values.]	1.0	5	1	0	0
52081	1624	spi-1 transfectant	[spi-1 transfectants]	1.0	2	1	0	0
52082	1624	radiation-induced apoptosis	[radiation-induced apoptosis]	1.0	2	1	0	0
52083	1624	initial viral latent gene promoter	[initial viral latent gene promoter]	1.0	5	1	0	0
52084	1624	cellular synthesis	[cellular synthesis]	1.0	2	1	0	0
52085	1624	1 (hiv-1) therapy in this study.	[1 (HIV-1) therapy in this study.]	1.0	6	1	0	0
52086	1624	soluble gp120	[soluble gp120]	1.0	2	1	0	0
52087	1624	differentiation of RA uf-1 cell	[differentiation of RA UF-1 cells]	1.0	5	1	0	0
52088	1624	NF-kappaB promoter in monocyte-derived macrophage	[NF-kappaB promoter in monocyte-derived macrophages]	1.0	5	1	0	0
52089	1624	ifn-regulated gene	[IFN-regulated genes]	1.0	2	1	0	0
52090	1624	b-cell line of late differentiation	[B-cell lines of later differentiation]	1.0	5	1	0	0
52091	1624	mitogenic stimulation rest T lymphocyte	[mitogenic stimulation resting T lymphocytes]	1.0	5	1	0	0
52092	1624	member of the rel family	[members of the rel family]	1.0	5	1	0	0
52093	1624	humara analysis	[HUMARA analysis]	1.0	2	3	2	1
52094	1624	expression of the m-csf receptor	[expression of the M-CSF receptor]	1.0	5	1	0	0
52095	1624	Ras-Raf-1-MAP kinase	[Ras-Raf-1-MAP kinase]	1.0	2	1	0	0
52096	1624	dominant-negative activity of the raralpha	[dominant-negative activity of the RARalpha]	1.0	5	1	0	0
52097	1624	il-6 luciferase activity in lps	[IL-6 luciferase activity in LPS]	1.0	5	1	0	0
52098	1624	Eed homeotic gene expression during embryogenesis	[Eed homeotic gene expression during embryogenesis]	1.0	6	1	0	0
52099	1624	p50 epitope	[p50 epitopes]	1.0	2	1	0	0
52100	1624	loss of both of this receptor	[loss of both of these receptors]	1.0	6	1	0	0
52101	1624	R272A mutation	[R272A mutation]	1.0	2	1	0	0
52102	1624	coexpression of the class transactivator ciita	[Coexpression of the class transactivator CIITA]	1.0	6	1	0	0
52103	1624	252, lbp	[252, LBP]	1.0	2	1	0	0
52104	1624	antisense c/ebp-epsilon	[antisense C/EBP-epsilon]	1.0	2	1	0	0
52105	1624	growth inhibition of cd34+ progenitor cell	[growth inhibition of CD34+ progenitor cells]	1.0	6	1	0	0
52106	1624	ces-2 cell death specification protein	[CES-2 cell death specification protein]	1.0	5	1	0	0
52107	1624	subunit of the bipartite il-4r	[subunit of the bipartite IL-4R]	1.0	5	1	0	0
52108	1624	inhibition of il-1 beta release	[inhibition of IL-1 beta release]	1.0	5	1	0	0
52109	1624	eosinophilic granule	[eosinophilic granules]	1.0	2	1	0	0
52110	1624	expression experiment	[expression experiments]	1.0	2	2	2	2
52111	1624	asymptomatic subject	[asymptomatic subjects]	1.0	2	1	0	0
52112	1624	effect on the dna-binding activity	[effect on the DNA-binding activity]	1.0	5	2	2	2
52113	1624	fifth position	[fifth position]	1.0	2	1	0	0
52114	1624	first non-mammalian cytokine gene mapped.	[first non-mammalian cytokine gene mapped.]	1.0	5	1	0	0
52115	1624	cross-linking of fc gamma receptor	[Cross-linking of Fc gamma receptors]	1.0	5	1	0	0
52116	1624	cold-shock-induced apoptosis	[cold-shock-induced apoptosis]	1.0	2	1	0	0
52117	1624	Epstein-Barr virus-immortalized lymphoblastoid cell line	[Epstein-Barr virus-immortalized lymphoblastoid cell lines]	1.0	5	1	0	0
52118	1624	transcription factor (the ICK-1 family	[transcription factors (the ICK-1 family]	1.0	5	1	0	0
52119	1624	p50/p65 complex	[p50/p65 complexes]	1.0	2	2	1	1
52120	1624	more sensitive polymerase chain reaction pcr	[more sensitive polymerase chain reaction PCR]	1.0	6	1	0	0
52121	1624	include the rel homology domain,	[including the rel homology domain,]	1.0	5	1	0	0
52122	1624	human adenovirus	[human adenovirus]	1.0	2	1	0	0
52123	1624	pulmonary surfactant	[pulmonary surfactant]	1.0	2	1	0	0
52124	1624	nucleotide 5'	[nucleotides 5']	1.0	2	2	2	2
52125	1624	196, p less than 0.005).	[196, p less than 0.005).]	1.0	5	1	0	0
52126	1624	32Dcl3 cell express exogenous bcl-2	[32Dcl3 cells expressing exogenous Bcl-2]	1.0	5	1	0	0
52127	1624	Turner syndrome	[Turner syndrome]	1.0	2	2	1	1
52128	1624	pha -stimulation	[PHA -stimulation]	1.0	2	1	0	0
52129	1624	stimulation of the t-cell antigen receptor	[Stimulation of the T-cell antigen receptor]	1.0	6	1	0	0
52130	1624	beneficial inflammation	[beneficial inflammation]	1.0	2	1	0	0
52131	1624	such carrier	[such carriers]	1.0	2	1	0	0
52132	1624	human cd34(+) bone marrow cell	[human CD34(+) bone marrow cells]	1.0	5	2	1	1
52133	1624	couple to the c5a receptor	[couple to the C5a receptor]	1.0	5	1	0	0
52134	1624	approximately eightfold	[approximately eightfold]	1.0	2	1	0	0
52135	1624	far, transcriptional analysis of p40	[far, transcriptional analyses of p40]	1.0	5	1	0	0
52136	1624	18 h	[18 h]	1.0	2	2	2	2
52137	1624	discrete block	[discrete block]	1.0	2	1	0	0
52138	1624	induce certain characteristic of b cell	[inducing certain characteristics of B cells]	1.0	6	1	0	0
52139	1624	congenital malformation	[congenital malformations]	1.0	2	1	0	0
52140	1624	mechanism for transduction of il-6 signal	[Mechanisms for transduction of IL-6 signals]	1.0	6	1	0	0
52141	1624	b-cell-specific footprint in the region	[B-cell-specific footprint in the region]	1.0	5	1	0	0
52142	1624	novel concept for drug discovery	[novel concept for drug discovery]	1.0	5	1	0	0
52143	1624	neoplastic groups,	[neoplastic groups,]	1.0	2	1	0	0
52144	1624	autoantigen ssb	[autoantigen SSB]	1.0	2	1	0	0
52145	1624	gr mrna turnover in cell	[GR mRNA turnover in cells]	1.0	5	1	0	0
52146	1624	cover the entire surface by 15	[covering the entire surface by 15]	1.0	6	1	0	0
52147	1624	enhancer mutation	[enhancer mutations]	1.0	2	1	0	0
52148	1624	residue 402	[residue 402]	1.0	2	1	0	0
52149	1624	two additional NF-IL6 binding site	[two additional NF-IL6 binding sites]	1.0	5	1	0	0
52150	1624	ca(2+) kinase	[Ca(2+) kinases]	1.0	2	1	0	0
52151	1624	contrast, T	[contrast, T]	1.0	2	1	0	0
52152	1624	residue 418	[residue 418]	1.0	2	1	0	0
52153	1624	residue 431	[residues 431]	1.0	2	1	0	0
52154	1624	immunological variable	[immunological variable]	1.0	2	2	2	2
52155	1624	phase of tcr gene rearrangement	[phase of TCR gene rearrangement]	1.0	5	1	0	0
52156	1624	mAb enhancement of mcd14 lps uptake	[mAb enhancement of mCD14 LPS uptake]	1.0	6	1	0	0
52157	1624	mutation in the at box	[Mutations in the AT box]	1.0	5	1	0	0
52158	1624	encode the Epstein-Barr virus EBV dutpase	[encoding the Epstein-Barr virus EBV dUTPase]	1.0	6	1	0	0
52159	1624	supraoptimal concentration of immunodominant peptide	[supraoptimal concentrations of immunodominant peptide]	1.0	5	1	0	0
52160	1624	contain high level of nf-kappab	[containing high levels of NF-kappaB]	1.0	5	1	0	0
52161	1624	dp 1	[DP 1]	1.0	2	1	0	0
52162	1624	multiparameter flow	[multiparameter flow]	1.0	2	1	0	0
52163	1624	nucleoprotein complex	[nucleoprotein complex]	1.0	2	2	1	1
52164	1624	also other polymorphic dinucleotide trinucleotide repeat	[also other polymorphic dinucleotide trinucleotide repeats]	1.0	6	1	0	0
52165	1624	large fraction of T cell	[large fraction of T cells]	1.0	5	1	0	0
52166	1624	similarity with the dimerization domain	[similarity with the dimerization domains]	1.0	5	1	0	0
52167	1624	reticuloendotheliosis virus	[Reticuloendotheliosis virus]	1.0	2	2	2	2
52168	1624	ability of type i ifi	[ability of type I IFNs]	1.0	5	1	0	0
52169	1624	ras activation	[ras activation]	1.0	2	2	1	1
52170	1624	contain 10% fetal bovine serum	[containing 10% fetal bovine serum]	1.0	5	1	0	0
52171	1624	hiv gene	[HIV gene]	1.0	2	2	2	2
52172	1624	reduce tnf production in PBMC	[reducing TNF production in PBMC]	1.0	5	1	0	0
52173	1624	c-myb 5'	[c-myb 5']	1.0	2	2	1	1
52174	1624	th1 function	[TH1 functions]	1.0	2	2	1	1
52175	1624	cells/tube in the assay volume millileter	[cells/tube in the assay volume ml]	1.0	6	1	0	0
52176	1624	repeat gene activity in T cell	[repeat gene activity in T cells]	1.0	6	1	0	0
52177	1624	gene factor	[gene factor]	1.0	2	2	2	2
52178	1624	two protein products, p27rex /p21rex	[two protein products, p27rex /p21rex]	1.0	5	1	0	0
52179	1624	effect on the promoter function	[effect on the promoter function]	1.0	5	1	0	0
52180	1624	control the expression of gene	[controlling the expression of genes]	1.0	5	1	0	0
52181	1624	inappropriate apoptosis	[inappropriate apoptosis]	1.0	2	1	0	0
52182	1624	requirement of catalytically active ne	[requirement of catalytically active NE]	1.0	5	1	0	0
52183	1624	subtractive cloning	[subtractive cloning]	1.0	2	1	0	0
52184	1624	modulation of cd23 a common b	[modulation of CD23 a common B]	1.0	6	1	0	0
52185	1624	12 cases)	[12 cases)]	1.0	2	1	0	0
52186	1624	sp1 transcription	[Sp1 transcription]	1.0	2	2	2	2
52187	1624	critical region for CD4 dimerization	[critical region for CD4 dimerization]	1.0	5	1	0	0
52188	1624	pax-5 code	[Pax-5 codes]	1.0	2	1	0	0
52189	1624	change in patient with yang-deficiency	[changes in patients with yang-deficiency]	1.0	5	1	0	0
52190	1624	wild-type Chinese hamster ovary (cho)-k1 cell	[Wild-type Chinese hamster ovary (CHO)-K1 cells]	1.0	6	1	0	0
52191	1624	various globin	[various globin]	1.0	2	1	0	0
52192	1624	Finally, time	[Finally, time]	1.0	2	1	0	0
52193	1624	sry protein DNA binding ability	[SRY protein DNA binding ability]	1.0	5	1	0	0
52194	1624	mutation of the e-box motif	[mutation of the E-box motif]	1.0	5	1	0	0
52195	1624	physiological oxidant	[physiological oxidants]	1.0	2	1	0	0
52196	1624	blood cell of elderly woman	[blood cells of elderly women]	1.0	5	1	0	0
52197	1624	use a series of construct	[Using a series of constructs]	1.0	5	1	0	0
52198	1624	susceptibility to natural killer cell	[Susceptibility to natural killer cells]	1.0	5	1	0	0
52199	1624	stress-induced down-regulation of immune response	[stress-induced down-regulation of immune responses]	1.0	5	1	0	0
52200	1624	Rather, TNF	[Rather, TNF]	1.0	2	1	0	0
52201	1624	transcriptional activity in HeLa cell	[transcriptional activity in HeLa cells]	1.0	5	1	0	0
52202	1624	cellular iron availability during erythropoiesis	[cellular iron availability during erythropoiesis]	1.0	5	1	0	0
52203	1624	40 mM	[40 mM]	1.0	2	1	0	0
52204	1624	also in term of modulation	[also in terms of modulation]	1.0	5	1	0	0
52205	1624	antibody-encoding gene	[antibody-encoding genes]	1.0	2	1	0	0
52206	1624	protein-DNA interaction in the cell	[protein-DNA interactions in the cell]	1.0	5	1	0	0
52207	1624	hiv long terminal repeat transcription	[HIV long terminal repeat transcription]	1.0	5	1	0	0
52208	1624	sequence from the translocation partner	[sequences from the translocation partner]	1.0	5	1	0	0
52209	1624	692 binding site per nucleus	[692 binding sites per nucleus]	1.0	5	1	0	0
52210	1624	stimulation of phospholipase d pld	[stimulation of phospholipase D PLD]	1.0	5	1	0	0
52211	1624	host defence response to infection,	[host defence response to infection,]	1.0	5	1	0	0
52212	1624	thyroid function measure blood plasma triidothyronine	[thyroid function measuring blood plasma triidothyronine]	1.0	6	1	0	0
52213	1624	own study	[own studies]	1.0	2	1	0	0
52214	1624	sequence analysis of DD product	[Sequence analysis of DD products]	1.0	5	1	0	0
52215	1624	pattern of expression between Spi-B	[patterns of expression between Spi-B]	1.0	5	1	0	0
52216	1624	use a monoclonal antibody Lt-4	[Using a monoclonal antibody Lt-4]	1.0	5	1	0	0
52217	1624	stat5 protein	[STAT5 proteins]	1.0	2	2	1	1
52218	1624	Finally, IL-2	[Finally, IL-2]	1.0	2	1	0	0
52219	1624	translational suppression	[translational suppression]	1.0	2	2	2	2
52220	1624	rna splice of 3863 basis	[RNA splice of 3863 bases]	1.0	5	1	0	0
52221	1624	polyomavirus t-antigen	[polyomavirus T-antigen]	1.0	2	1	0	0
52222	1624	erythroid cell by a silencer	[erythroid cells by a silencer]	1.0	5	1	0	0
52223	1624	branchial myoblast	[branchial myoblasts]	1.0	2	1	0	0
52224	1624	thp-1 monoblast	[THP-1 monoblasts]	1.0	2	1	0	0
52225	1624	costimulation of human cd4+ T cell	[Costimulation of human CD4+ T cells]	1.0	6	1	0	0
52226	1624	tcr-alpha enhancer	[TCR-alpha enhancers]	1.0	2	1	0	0
52227	1624	3,605 984 binding site per nucleus	[3,605 984 binding sites per nucleus]	1.0	6	1	0	0
52228	1624	modulation of gene expression via binding	[modulation of gene expression via binding]	1.0	6	1	0	0
52229	1624	irf-1 interferon regulatory factor 1	[IRF-1 interferon regulatory factor 1]	1.0	5	1	0	0
52230	1624	critical factor modulate the differentiation-dependent transcription	[critical factors modulating the differentiation-dependent transcription]	1.0	6	1	0	0
52231	1624	indicate a direct genetic target	[indicating a direct genetic target]	1.0	5	1	0	0
52232	1624	nonactive dna-binding fragment in yeast	[nonactive DNA-binding fragments in yeast]	1.0	5	1	0	0
52233	1624	increase in steady-state tnf-alpha mrna	[increase in steady-state TNF-alpha mRNA]	1.0	5	1	0	0
52234	1624	selective block	[selective block]	1.0	2	1	0	0
52235	1624	IFN assembly of signal transducer	[IFN assembly of signal transducer]	1.0	5	1	0	0
52236	1624	development of the immune system	[development of the immune system]	1.0	5	1	0	0
52237	1624	picture emerge	[picture emerging]	1.0	2	1	0	0
52238	1624	fkbp alone	[FKBP alone]	1.0	2	1	0	0
52239	1624	il-6 release	[IL-6 release]	1.0	2	2	1	1
52240	1624	30 minute of monocyte adherence	[30 min of monocyte adherence]	1.0	5	1	0	0
52241	1624	bacterial fraction	[bacterial fractions]	1.0	2	1	0	0
52242	1624	trophic effect result from activation	[trophic effect resulting from activation]	1.0	5	1	0	0
52243	1624	nfat activation in T cell	[NFAT activation in T cells]	1.0	5	1	0	0
52244	1624	hiv-1 infection a immunoregulatory cytokine	[HIV-1 infection an immunoregulatory cytokine]	1.0	5	1	0	0
52245	1624	response of the t3 receptor	[response of the T3 receptor]	1.0	5	1	0	0
52246	1624	initiate proinflammatory event in monocyte	[initiating proinflammatory events in monocytes]	1.0	5	1	0	0
52247	1624	current knowledge	[current knowledge]	1.0	2	2	2	2
52248	1624	dominant-negative effect	[dominant-negative effect]	1.0	2	2	1	1
52249	1624	disease for up to 80%	[disease for up to 80%]	1.0	5	1	0	0
52250	1624	mrna of the RA receptor alpha	[mRNA of the RA receptor alpha]	1.0	6	1	0	0
52251	1624	prevention of the activation of NFkappaB	[prevention of the activation of NFkappaB]	1.0	6	1	0	0
52252	1624	predict NK activity at follow-up	[predicting NK activity at follow-up]	1.0	5	1	0	0
52253	1624	activity of a il4 promoter	[activity of a IL4 promoter]	1.0	5	1	0	0
52254	1624	significant effect on the production	[significant effect on the production]	1.0	5	1	0	0
52255	1624	early change in gene expression	[early changes in gene expression]	1.0	5	1	0	0
52256	1624	tax apoptosis	[Tax apoptosis]	1.0	2	2	2	2
52257	1624	sixty-six paper	[Sixty-six papers]	1.0	2	1	0	0
52258	1624	two activity	[two activities]	1.0	2	2	2	2
52259	1624	latent gene	[latent genes]	1.0	2	2	1	1
52260	1624	inflammatory mechanism in rheumatoid synovium	[inflammatory mechanisms in rheumatoid synovium]	1.0	5	1	0	0
52261	1624	role of the 5'-untranslated leader region	[role of the 5'-untranslated leader region]	1.0	6	1	0	0
52262	1624	MZF-2 rrna	[MZF-2 mRNAs]	1.0	2	1	0	0
52263	1624	interleukin-1 IL-1	[interleukin-1 IL-1]	1.0	2	1	0	0
52264	1624	incomplete suppression	[incomplete suppression]	1.0	2	1	0	0
52265	1624	recognize the AP-1 consensus tre motif	[recognizing the AP-1 consensus TRE motif]	1.0	6	1	0	0
52266	1624	mAb g10-2	[mAb G10-2]	1.0	2	1	0	0
52267	1624	surface expression of icam-1 on endothelium	[surface expression of ICAM-1 on endothelium]	1.0	6	1	0	0
52268	1624	ap-1 in T lymphoid jurkat cell	[AP-1 in T lymphoid Jurkat cells]	1.0	6	1	0	0
52269	1624	very effective treatment for asthma	[very effective treatment for asthma]	1.0	5	1	0	0
52270	1624	Cl- channel	[Cl- channels]	1.0	2	1	0	0
52271	1624	potential NFAT composite element in promoter	[potential NFAT composite elements in promoters]	1.0	6	1	0	0
52272	1624	Fas stimulation	[Fas stimulation]	1.0	2	1	0	0
52273	1624	effect of two ls mutation	[effects of two LS mutations]	1.0	5	1	0	0
52274	1624	four region	[four regions]	1.0	2	2	2	2
52275	1624	inhibition of T cell signal	[Inhibition of T cell signaling]	1.0	5	1	0	0
52276	1624	rotamase activity of fkbp alone	[rotamase activity of FKBP alone]	1.0	5	1	0	0
52277	1624	(13 pg/ml,	[(13 pg/ml,]	1.0	2	1	0	0
52278	1624	interferon-responsive factor (irf) binding site	[interferon-responsive factor (IRF) binding site]	1.0	5	1	0	0
52279	1624	interleukin (IL)-2 homology NFAT-1 region	[interleukin (IL)-2 homology NFAT-1 region]	1.0	5	1	0	0
52280	1624	anti- VCAM-1 monoclonal antibody 1g11	[anti- VCAM-1 monoclonal antibody 1G11]	1.0	5	1	0	0
52281	1624	fact consistent with the mass	[fact consistent with the mass]	1.0	5	1	0	0
52282	1624	addition, transcript	[addition, transcripts]	1.0	2	2	1	1
52283	1624	cooperative transcription	[cooperative transcription]	1.0	2	1	0	0
52284	1624	latent antigen	[latent antigens]	1.0	2	1	0	0
52285	1624	kappa b-binding	[kappa B-binding]	1.0	2	2	2	2
52286	1624	functional icam-1	[functional ICAM-1]	1.0	2	1	0	0
52287	1624	current model	[current models]	1.0	2	1	0	0
52288	1624	modulate the viral fusion/entry process	[modulating the viral fusion/entry process]	1.0	5	1	0	0
52289	1624	transcription of estrogen receptor gene	[transcription of estrogen receptor gene]	1.0	5	1	0	0
52290	1624	bcl-6 mrna	[BCL-6 mRNA]	1.0	2	2	1	1
52291	1624	complete suppression of ap-1 activity	[Complete suppression of AP-1 activity]	1.0	5	1	0	0
52292	1624	include hydroxyanisole bha tetrahydropapaveroline thp	[including hydroxyanisole BHA tetrahydropapaveroline THP]	1.0	5	1	0	0
52293	1624	independent sample	[independent sample]	1.0	2	1	0	0
52294	1624	high-grade b	[high-grade B]	1.0	2	1	0	0
52295	1624	brief review of immune property	[brief review of immune properties]	1.0	5	1	0	0
52296	1624	CONCLUSIONS: leukocyte adhesion to the endothelium	[CONCLUSIONS: Leukocyte adhesion to the endothelium]	1.0	6	1	0	0
52297	1624	degradation in lipopolysaccharide human monocytic cell	[degradation in lipopolysaccharide human monocytic cells]	1.0	6	1	0	0
52298	1624	consensus binding sequence for Sp1	[consensus binding sequences for Sp1]	1.0	5	1	0	0
52299	1624	high-affinity receptor	[high-affinity receptor]	1.0	2	2	1	1
52300	1624	Functional testosterone receptor in plasma membrane	[Functional testosterone receptors in plasma membranes]	1.0	6	1	0	0
52301	1624	hypothesis responsible for expression result	[hypothesis responsible for expression resulting]	1.0	5	1	0	0
52302	1624	recruitment of erythroid kruppel-like factor	[recruitment of erythroid Kruppel-like factor]	1.0	5	1	0	0
52303	1624	leukocyte traffic	[leukocyte traffic]	1.0	2	1	0	0
52304	1624	Oct-1 function	[Oct-1 function]	1.0	2	1	0	0
52305	1624	member of the bZIP family	[member of the bZIP family]	1.0	5	1	0	0
52306	1624	lack of full activation of nf-at	[Lack of full activation of NF-AT]	1.0	6	1	0	0
52307	1624	c-Myc protein	[c-Myc protein]	1.0	2	1	0	0
52308	1624	primary regulator of the production	[primary regulator of the production]	1.0	5	1	0	0
52309	1624	hydrochlorothiazide therapy	[Hydrochlorothiazide therapy]	1.0	2	1	0	0
52310	1624	contain the -148 to +60 region	[containing the -148 to +60 region]	1.0	6	1	0	0
52311	1624	However, PDTC	[However, PDTC]	1.0	2	1	0	0
52312	1624	variable kinetic	[variable kinetics]	1.0	2	1	0	0
52313	1624	activation of the CD4 promoter	[Activation of the CD4 promoter]	1.0	5	1	0	0
52314	1624	activate subunit in that nucleus	[activating subunit in th nucleus]	1.0	5	1	0	0
52315	1624	include immuno-modulatory effect in vivo	[including immuno-modulatory effects in vivo]	1.0	5	1	0	0
52316	1624	IL-4 NAF IL-4 nuclear-activating factor	[IL-4 NAF IL-4 nuclear-activating factors]	1.0	5	1	0	0
52317	1624	two mab	[two mAbs]	1.0	2	1	0	0
52318	1624	particular the Burkitt' cell line	[particular the Burkitt's cell line]	1.0	5	1	0	0
52319	1624	two adjacent cis-acting regulatory elements,	[two adjacent cis-acting regulatory elements,]	1.0	5	1	0	0
52320	1624	viral latency in b cell	[viral latency in B cells]	1.0	5	1	0	0
52321	1624	leukemic t-cell	[leukemic T-cell]	1.0	2	1	0	0
52322	1624	CALM region	[CALM region]	1.0	2	2	1	1
52323	1624	DNA binding activity of ap-1	[DNA binding activities of AP-1]	1.0	5	1	0	0
52324	1624	encode 108 amino acid residue	[encoding 108 amino acid residues]	1.0	5	1	0	0
52325	1624	nf-kappab signal	[NF-kappaB signaling]	1.0	2	2	1	1
52326	1624	vitro result	[vitro results]	1.0	2	1	0	0
52327	1624	reduction in lymphocyte gene activation	[reduction in lymphocyte gene activation]	1.0	5	1	0	0
52328	1624	indicate sensitive to this drugs.	[indicating sensitive to these drugs.]	1.0	5	1	0	0
52329	1624	transcription from the interleukin-2 enhancer	[transcription from the interleukin-2 enhancer]	1.0	5	1	0	0
52330	1624	antigen presenting cell apc peptide	[Antigen Presenting Cells APC peptides]	1.0	5	1	0	0
52331	1624	inflammatory responses,	[inflammatory responses,]	1.0	2	1	0	0
52332	1624	Spi-B mrna in the medulla	[Spi-B mRNA in the medulla]	1.0	5	1	0	0
52333	1624	strike tissue-	[striking tissue-]	1.0	2	1	0	0
52334	1624	CD95L promoter	[CD95L promoter]	1.0	2	2	1	1
52335	1624	progenitor growth	[progenitor growth]	1.0	2	1	0	0
52336	1624	pathology such as graft-versus-host disease	[pathologies such as graft-versus-host disease]	1.0	5	1	0	0
52337	1624	computer-assisted imaging	[computer-assisted imaging]	1.0	2	1	0	0
52338	1624	resemble the typical G receptor	[resembling the typical G receptor]	1.0	5	1	0	0
52339	1624	vitro-translated nf-yb	[vitro-translated NF-YB]	1.0	2	1	0	0
52340	1624	tumor aggressivity (axillary node involvement	[tumor aggressivity (axillary node involvement]	1.0	5	1	0	0
52341	1624	disease phenotype	[disease phenotype]	1.0	2	1	0	0
52342	1624	nuclear p50p50	[nuclear p50p50]	1.0	2	1	0	0
52343	1624	protein kinase c-depleted endothelial cell	[protein kinase C-depleted endothelial cells]	1.0	5	1	0	0
52344	1624	again, treatment with high-dose RA	[again, treatment with high-dose RA]	1.0	5	1	0	0
52345	1624	stat induction by cytokine receptor	[STAT induction by cytokine receptors]	1.0	5	1	0	0
52346	1624	sequence requirement for PMA induction	[sequence requirements for PMA induction]	1.0	5	1	0	0
52347	1624	mouse strain with congenital defect	[mouse strains with congenital defects]	1.0	5	1	0	0
52348	1624	memory rest T helper lymphocyte	[memory resting T helper lymphocytes]	1.0	5	1	0	0
52349	1624	Chronic hiv-1 infection of myeloid cell	[Chronic HIV-1 infection of myeloid cells]	1.0	6	1	0	0
52350	1624	level of class ii determinant	[levels of class II determinants]	1.0	5	1	0	0
52351	1624	latter region	[latter region]	1.0	2	1	0	0
52352	1624	polymorphic allele	[polymorphic alleles]	1.0	2	1	0	0
52353	1624	p50/p65 kappa b dna-binding complex	[p50/p65 kappa B DNA-binding complexes]	1.0	5	1	0	0
52354	1624	active p50/	[active p50/]	1.0	2	1	0	0
52355	1624	mutagenesis of one of this motif	[mutagenesis of one of these motifs]	1.0	6	1	0	0
52356	1624	rejection response	[rejection responses]	1.0	2	1	0	0
52357	1624	several aspect of T cell immunity	[several aspects of T cell immunity]	1.0	6	1	0	0
52358	1624	corticosteroid-sensitive (cs)	[corticosteroid-sensitive (CS)]	1.0	2	1	0	0
52359	1624	high-affinity il-2r	[high-affinity IL-2Rs]	1.0	2	1	0	0
52360	1624	Nuclear expression of NF-kappa b	[Nuclear expression of NF-kappa B]	1.0	5	1	0	0
52361	1624	nuclear t3r alteration circulate lymphocyte	[nuclear T3R alterations circulating lymphocytes]	1.0	5	1	0	0
52362	1624	Spi-1/ PU.1	[Spi-1/ PU.1]	1.0	2	1	0	0
52363	1624	rescue by cytokine of cell death	[Rescue by cytokines of cell death]	1.0	6	1	0	0
52364	1624	Tat effect on the redox state	[Tat effects on the redox state]	1.0	6	1	0	0
52365	1624	5' upstream	[5' upstream]	1.0	2	2	2	2
52366	1624	physiologic status of the cell	[physiologic status of the cells]	1.0	5	1	0	0
52367	1624	characteristic result of htlv-i infection	[characteristic result of HTLV-I infection]	1.0	5	1	0	0
52368	1624	regulation kappa b alpha in monocyte	[Regulation kappa B alpha in monocytes]	1.0	6	1	0	0
52369	1624	Native human erythrocyte ndp kinase protein	[Native human erythrocyte NDP kinase protein]	1.0	6	1	0	0
52370	1624	encode the nf-kappab component c-rel	[encoding the NF-kappaB components c-Rel]	1.0	5	1	0	0
52371	1624	depend on the type of lymphocyte	[Depending on the type of lymphocytes]	1.0	6	1	0	0
52372	1624	se, n	[SE, n]	1.0	2	1	0	0
52373	1624	promyelocytic morphology	[promyelocytic morphology]	1.0	2	1	0	0
52374	1624	co-transfection with expression plasmid for Sp1	[Co-transfections with expression plasmids for Sp1]	1.0	6	1	0	0
52375	1624	myeloid cell differentiation a role	[myeloid cell differentiation a role]	1.0	5	1	0	0
52376	1624	hepatic microsome in short term culture	[Hepatic microsomes in short term culture]	1.0	6	1	0	0
52377	1624	arthritic rat	[arthritic rats]	1.0	2	1	0	0
52378	1624	TPA dexamethasone	[TPA dexamethasone]	1.0	2	1	0	0
52379	1624	jun-B transfection	[jun-B transfection]	1.0	2	1	0	0
52380	1624	nucleus (9.2	[nucleus (9.2]	1.0	2	1	0	0
52381	1624	long period.	[long period.]	1.0	2	1	0	0
52382	1624	interact with the IL-1 receptor complex	[interacting with the IL-1 receptor complex]	1.0	6	1	0	0
52383	1624	unique activation signal to b cell	[unique activation signals to B cells]	1.0	6	1	0	0
52384	1624	further characterization of gelatinase granule	[Further characterization of gelatinase granules]	1.0	5	1	0	0
52385	1624	(10 nm),	[(10 nM),]	1.0	2	1	0	0
52386	1624	culture condition	[cultures conditions]	1.0	2	2	2	2
52387	1624	specific negative regulation in fibroblast	[specific negative regulation in fibroblasts]	1.0	5	1	0	0
52388	1624	glucocorticoid receptor per cell ro	[glucocorticoid receptors per cell Ro]	1.0	5	1	0	0
52389	1624	cellular content	[cellular content]	1.0	2	3	2	1
52390	1624	number of gr in MNL	[number of GR in MNL]	1.0	5	1	0	0
52391	1624	apoptosis in lymphocyte by glucocorticoid	[apoptosis in lymphocytes by glucocorticoids]	1.0	5	1	0	0
52392	1624	stimulatory activity	[stimulatory activity]	1.0	2	2	2	2
52393	1624	gene encode a major component	[genes encoding a major component]	1.0	5	1	0	0
52394	1624	cd19 cross-linking	[CD19 cross-linking]	1.0	2	2	2	2
52395	1624	lps alone	[LPS alone]	1.0	2	1	0	0
52396	1624	promote transcription	[promoting transcription]	1.0	2	1	0	0
52397	1624	similar domains.	[similar domains.]	1.0	2	1	0	0
52398	1624	live-attenuated human immunodeficiency virus hiv	[Live-attenuated human immunodeficiency viruses HIVs]	1.0	5	1	0	0
52399	1624	similar vitamin d receptor content	[similar vitamin D receptor content]	1.0	5	1	0	0
52400	1624	3 cases,	[3 cases,]	1.0	2	1	0	0
52401	1624	initiator element	[initiator element]	1.0	2	1	0	0
52402	1624	105-kd protein	[105-kD protein]	1.0	2	1	0	0
52403	1624	con a	[Con A]	1.0	2	2	1	1
52404	1624	tr75 expression	[TR75 expression]	1.0	2	2	2	2
52405	1624	tyrosine phosphorylation on mutual contact	[tyrosine phosphorylation on mutual contact]	1.0	5	1	0	0
52406	1624	total rna.	[total RNA.]	1.0	2	1	0	0
52407	1624	transfection of human erythroleukemia cell	[transfection of human erythroleukemia cells]	1.0	5	1	0	0
52408	1624	third pathway.	[third pathway.]	1.0	2	1	0	0
52409	1624	selective function for different pkc isotype	[selective functions for different PKC isotypes]	1.0	6	1	0	0
52410	1624	pattern of stat protein phosphorylation	[pattern of STAT protein phosphorylation]	1.0	5	1	0	0
52411	1624	deregulation of the c-myc oncogene	[deregulation of the c-myc oncogene]	1.0	5	1	0	0
52412	1624	secretion of a b chemokine	[secretion of a B chemokine]	1.0	5	1	0	0
52413	1624	hiv infection of the CNS	[HIV infection of the CNS]	1.0	5	1	0	0
52414	1624	rapid assessment of stat-1 phosphorylation	[rapid assessment of STAT-1 phosphorylation]	1.0	5	1	0	0
52415	1624	IL-2 tyrosine phosphorylation of stat5b	[IL-2 tyrosine phosphorylation of STAT5b]	1.0	5	1	0	0
52416	1624	current work	[current work]	1.0	2	1	0	0
52417	1624	b-lymphocyte cell use magnetic separation	[B-lymphocyte cells using magnetic separation]	1.0	5	1	0	0
52418	1624	abundance of the VDR mrna	[abundance of the VDR mRNA]	1.0	5	2	1	1
52419	1624	100 microgram	[100 micrograms]	1.0	2	1	0	0
52420	1624	disappearance of NF kappa b	[disappearance of NF kappa B]	1.0	5	2	1	1
52421	1624	clonality analysis utilize x-chromosome inactivation	[Clonality analysis utilizing X-chromosome inactivation]	1.0	5	1	0	0
52422	1624	costimulation of the T cell receptor	[costimulation of the T cell receptor]	1.0	6	1	0	0
52423	1624	5 m 9-cis RA together	[5 M 9-cis RA together]	1.0	5	1	0	0
52424	1624	intermediate-dependent nf-kappab activation by interleukin-1beta	[intermediate-dependent NF-kappaB activation by interleukin-1beta]	1.0	5	1	0	0
52425	1624	several parameter	[several parameters]	1.0	2	1	0	0
52426	1624	NF-kappa b in nuclear extract	[NF-kappa B in nuclear extracts]	1.0	5	1	0	0
52427	1624	clinical medicine	[clinical medicine]	1.0	2	1	0	0
52428	1624	5-day m phi ingestion of erythrocyte	[5-day M phi ingestion of erythrocytes]	1.0	6	1	0	0
52429	1624	weakly in normal lymph node	[weakly in normal lymph nodes]	1.0	5	1	0	0
52430	1624	expression of the class a msr	[expression of the class A MSR]	1.0	6	1	0	0
52431	1624	fifty-three case	[Fifty-three cases]	1.0	2	1	0	0
52432	1624	creb factor	[CREB factor]	1.0	2	1	0	0
52433	1624	multiple positive transcriptional regulatory element	[multiple positive transcriptional regulatory elements]	1.0	5	1	0	0
52434	1624	mitogenic effect	[mitogenic effect]	1.0	2	3	2	1
52435	1624	dose-response study	[Dose-response studies]	1.0	2	1	0	0
52436	1624	oncogene of avian erythroblastosis virus	[oncogene of avian erythroblastosis virus]	1.0	5	1	0	0
52437	1624	cellular event lead to monocyte activation	[cellular events leading to monocyte activation]	1.0	6	1	0	0
52438	1624	increase the spacing between the CRE	[increasing the spacing between the CRE]	1.0	6	1	0	0
52439	1624	VP16, CIITA	[VP16, CIITA]	1.0	2	1	0	0
52440	1624	expression of the qr gene	[expression of the QR gene]	1.0	5	1	0	0
52441	1624	CD48 gene	[CD48 gene]	1.0	2	2	1	1
52442	1624	to: acute exposure to hydrogen peroxide	[to: acute exposure to hydrogen peroxide]	1.0	6	1	0	0
52443	1624	glucocorticoid gene	[glucocorticoid genes]	1.0	2	1	0	0
52444	1624	normal Ter 119 erythroid cell	[normal Ter 119 erythroid cells]	1.0	5	1	0	0
52445	1624	uncoupling of ap-1 binding activity	[uncoupling of AP-1 binding activity]	1.0	5	1	0	0
52446	1624	110 kD.	[110 kD.]	1.0	2	1	0	0
52447	1624	testing datum	[testing data]	1.0	2	1	0	0
52448	1624	TATA binding	[TATA binding]	1.0	2	1	0	0
52449	1624	cytokine receptor activation on eosinophil	[cytokine receptor activation on eosinophils]	1.0	5	1	0	0
52450	1624	transcription by 80-90% in HeLa,	[transcription by 80-90% in HeLa,]	1.0	5	1	0	0
52451	1624	rights reserved.	[Rights Reserved.]	1.0	2	1	0	0
52452	1624	molecular mechanism control the pattern	[molecular mechanisms controlling the pattern]	1.0	5	1	0	0
52453	1624	a cell	[A cells]	1.0	2	1	0	0
52454	1624	AP-1 Fos	[AP-1 Fos]	1.0	2	1	0	0
52455	1624	provirus induction	[provirus induction]	1.0	2	1	0	0
52456	1624	v-src complex	[v-src complex]	1.0	2	1	0	0
52457	1624	JunB phosphorylation	[JunB phosphorylation]	1.0	2	1	0	0
52458	1624	-1053/+34 construct	[-1053/+34 construct]	1.0	2	1	0	0
52459	1624	identify high malignancy human melanoma	[identifying high malignancy human melanomas]	1.0	5	1	0	0
52460	1624	subject young than 20 year	[subjects younger than 20 years]	1.0	5	1	0	0
52461	1624	null cell	[null cells]	1.0	2	1	0	0
52462	1624	platelet-progenitor cell	[platelet-progenitor cells]	1.0	2	1	0	0
52463	1624	determine receptor function in this cells.	[determining receptor function in these cells.]	1.0	6	1	0	0
52464	1624	associate with TNFR factor TRAF1	[associating with TNFR factors TRAF1]	1.0	5	1	0	0
52465	1624	DNA fragment,	[DNA fragment,]	1.0	2	1	0	0
52466	1624	ikk-beta activity	[IKK-beta activity]	1.0	2	1	0	0
52467	1624	receptor /cell	[receptors /cell]	1.0	2	2	2	2
52468	1624	potent inhibitor for s-adenosylhomocysteine hydrolase	[potent inhibitor for S-adenosylhomocysteine hydrolase]	1.0	5	1	0	0
52469	1624	trigger the proliferation of T cell	[triggering the proliferation of T cells]	1.0	6	1	0	0
52470	1624	nf-kappab -dependent reporter gene expression	[NF-kappaB -dependent reporter gene expression]	1.0	5	1	0	0
52471	1624	detail of the regulatory mechanism	[details of the regulatory mechanism]	1.0	5	1	0	0
52472	1624	mineralocorticoid effector mechanism in preeclampsia	[Mineralocorticoid effector mechanism in preeclampsia]	1.0	5	1	0	0
52473	1624	diversity selection	[diversity selection]	1.0	2	1	0	0
52474	1624	protein kinase c inhibitor staurosporine	[Protein kinase C inhibitor staurosporine]	1.0	5	1	0	0
52475	1624	atherosclerosis of the blood vessel	[atherosclerosis of the blood vessels]	1.0	5	1	0	0
52476	1624	Paradoxically, removal of interdomain b	[Paradoxically, removal of interdomain B]	1.0	5	1	0	0
52477	1624	strong induction of the enzyme	[strong induction of the enzyme]	1.0	5	1	0	0
52478	1624	four family	[four families]	1.0	2	2	2	2
52479	1624	apoptosis protein	[apoptosis protein]	1.0	2	2	2	2
52480	1624	influence of the receptor antagonist	[influence of the receptor antagonist]	1.0	5	1	0	0
52481	1624	microbial superantigen	[microbial superantigens]	1.0	2	1	0	0
52482	1624	primary culture of human megakaryocyte	[primary cultures of human megakaryocytes]	1.0	5	1	0	0
52483	1624	transduce membrane-associated signal to the nucleus	[transducing membrane-associated signals to the nucleus]	1.0	6	1	0	0
52484	1624	immunoglobulin g-seropositive	[immunoglobulin G-seropositive]	1.0	2	1	0	0
52485	1624	half of the sporadic case	[half of the sporadic cases]	1.0	5	1	0	0
52486	1624	N-terminal peptide	[N-terminal peptides]	1.0	2	1	0	0
52487	1624	govern process of normal differentiation	[governing processes of normal differentiation]	1.0	5	1	0	0
52488	1624	PU.1 site	[PU.1 site]	1.0	2	4	3	1
52489	1624	signal emanate from cytokine factor receptor	[signals emanating from cytokine factor receptors]	1.0	6	1	0	0
52490	1624	characteristic of child with different variant	[characteristic of children with different variants]	1.0	6	1	0	0
52491	1624	lak cell-mediated lysis of control	[LAK cell-mediated lysis of control]	1.0	5	1	0	0
52492	1624	expression level of adhesion molecule-1	[expression levels of adhesion molecule-1]	1.0	5	1	0	0
52493	1624	mouse homologue of human baf170	[mouse homologue of human BAF170]	1.0	5	1	0	0
52494	1624	parathyroid gland	[parathyroid glands]	1.0	2	3	2	1
52495	1624	important role in ige synthesis	[important role in IgE synthesis]	1.0	5	1	0	0
52496	1624	modulate the differentiation of th cell	[modulating the differentiation of Th cells]	1.0	6	1	0	0
52497	1624	respective proteins.	[respective proteins.]	1.0	2	1	0	0
52498	1624	lps induction of tf protein	[LPS induction of TF protein]	1.0	5	1	0	0
52499	1624	pattern of nf-kappa b-related moiety	[pattern of NF-kappa B-related moieties]	1.0	5	1	0	0
52500	1624	hepatic microsome	[Hepatic microsomes]	1.0	2	2	1	1
52501	1624	thapsigargin stimulation	[thapsigargin stimulation]	1.0	2	1	0	0
52502	1624	proximal beta	[proximal beta]	1.0	2	1	0	0
52503	1624	25-kDa lipocalin	[25-kDa lipocalin]	1.0	2	1	0	0
52504	1624	response of normal T cell	[response of normal T cells]	1.0	5	1	0	0
52505	1624	p24 antigen	[p24 antigen]	1.0	2	2	1	1
52506	1624	nfat (60%)	[NFAT (60%)]	1.0	2	1	0	0
52507	1624	putative site	[putative site]	1.0	2	2	2	2
52508	1624	understanding of the mechanistic consequence	[understanding of the mechanistic consequences]	1.0	5	1	0	0
52509	1624	base difference within the gc-box	[base difference within the GC-box]	1.0	5	1	0	0
52510	1624	virtual complete amino acid sequence identity	[virtual complete amino acid sequence identity]	1.0	6	1	0	0
52511	1624	TAP-independent fashion	[TAP-independent fashion]	1.0	2	1	0	0
52512	1624	phosphorylation profile	[phosphorylation profiles]	1.0	2	1	0	0
52513	1624	induce the emergence of transcription factor	[inducing the emergence of transcription factors]	1.0	6	1	0	0
52514	1624	ad 2/5 e1a sequence present	[Ad 2/5 E1a sequences present]	1.0	5	1	0	0
52515	1624	lymphocyte (ctl)	[lymphocyte (CTL)]	1.0	2	2	2	2
52516	1624	human plasma	[human plasma]	1.0	2	1	0	0
52517	1624	il-13 regulation of tnf-alpha production	[IL-13 regulation of TNF-alpha production]	1.0	5	1	0	0
52518	1624	retinoblastoma susceptibility gene product Rb	[retinoblastoma susceptibility gene product Rb]	1.0	5	1	0	0
52519	1624	correlation between chromosome 1 alteration	[correlation between chromosome 1 alterations]	1.0	5	1	0	0
52520	1624	75-kD protein	[75-kD protein]	1.0	2	1	0	0
52521	1624	molecular mechanism of this difference	[molecular mechanism of this difference]	1.0	5	1	0	0
52522	1624	gene encode endothelial adhesion molecule	[genes encoding endothelial adhesion molecules]	1.0	5	1	0	0
52523	1624	encode tissue-specific component of signal transduction	[encoding tissue-specific components of signal transduction]	1.0	6	1	0	0
52524	1624	hormonal regulator of a variety	[hormonal regulators of a variety]	1.0	5	1	0	0
52525	1624	(9.36 3.44 nm in group	[(9.36 3.44 nM in group]	1.0	5	1	0	0
52526	1624	Egr-1 gene	[Egr-1 gene]	1.0	2	2	1	1
52527	1624	Chlamydia pneumoniae	[Chlamydia pneumoniae]	1.0	2	2	1	1
52528	1624	association of cbp/p300 coactivator protein	[association of CBP/p300 coactivator proteins]	1.0	5	1	0	0
52529	1624	low effect of C. sub.	[lower effect of C. Sub.]	1.0	5	1	0	0
52530	1624	hypersensitive site 4481 to 4982	[hypersensitive site 4481 to 4982]	1.0	5	1	0	0
52531	1624	precursor, p105	[precursor, p105]	1.0	2	1	0	0
52532	1624	METHODS: allergen-specific T cell clone	[METHODS: Allergen-specific T cell clones]	1.0	5	1	0	0
52533	1624	Effect of aldosterone on intralymphocytic sodium	[Effects of aldosterone on intralymphocytic sodium]	1.0	6	1	0	0
52534	1624	regulatory factor-1	[regulatory factor-1]	1.0	2	2	1	1
52535	1624	replacement of the isopropylidine group	[replacement of the isopropylidine group]	1.0	5	1	0	0
52536	1624	several transcription factor include NF-AT	[several transcription factors including NF-AT]	1.0	5	1	0	0
52537	1624	induction of IL-5 gene expression	[induction of IL-5 gene expression]	1.0	5	1	0	0
52538	1624	TNF induction	[TNF induction]	1.0	2	1	0	0
52539	1624	nuclear-located kruppel-type zinc finger protein	[nuclear-located Kruppel-type zinc finger protein]	1.0	5	1	0	0
52540	1624	T cell activation-induced fasl expression	[T cell activation-induced FasL expression]	1.0	5	1	0	0
52541	1624	KBF1/p50 homodimer	[KBF1/p50 homodimer]	1.0	2	1	0	0
52542	1624	specific inhibitor of nf-kappab activation	[specific inhibitors of NF-kappaB activation]	1.0	5	1	0	0
52543	1624	two year	[two years]	1.0	2	1	0	0
52544	1624	low affinity class of site	[lower affinity class of sites]	1.0	5	1	0	0
52545	1624	sufficient number	[sufficient numbers]	1.0	2	2	1	1
52546	1624	particular interest	[particular interest]	1.0	2	1	0	0
52547	1624	encode the homolog Escherichia coli stress	[encoding the homolog Escherichia coli stress]	1.0	6	1	0	0
52548	1624	role for growth factor release	[role for growth factor release]	1.0	5	1	0	0
52549	1624	expression of all family member	[expression of all family members]	1.0	5	1	0	0
52550	1624	normal volunteers, MRD +/lt patient	[normal volunteers, MRD +/LT patients]	1.0	5	1	0	0
52551	1624	lck expression in ifn-alpha cell	[Lck expression in IFN-alpha cells]	1.0	5	1	0	0
52552	1624	Janus kinase -signal transducer activator	[Janus kinase -signal transducer activator]	1.0	5	1	0	0
52553	1624	tobacco smoking	[tobacco smoking]	1.0	2	1	0	0
52554	1624	homodimer junb	[homodimer JunB]	1.0	2	1	0	0
52555	1624	17 beta-estradiol on NK activity	[17 beta-estradiol on NK activity]	1.0	5	1	0	0
52556	1624	e2 pge2	[E2 PGE2]	1.0	2	1	0	0
52557	1624	important ramification in T cell development	[important ramifications in T cell development]	1.0	6	1	0	0
52558	1624	pRb 105	[pRb 105]	1.0	2	1	0	0
52559	1624	contrast, dexamethasone	[contrast, dexamethasone]	1.0	2	1	0	0
52560	1624	U937 monocyte	[U937 monocytes]	1.0	2	2	2	2
52561	1624	physiological process regulate the intensity	[physiological process regulating the intensity]	1.0	5	1	0	0
52562	1624	sequence-specific breakage join recombination event	[sequence-specific breakage joining recombination events]	1.0	5	1	0	0
52563	1624	efficient transcription initiation from cp	[efficient transcription initiation from Cp]	1.0	5	1	0	0
52564	1624	il-2 -produce	[IL-2 -producing]	1.0	2	1	0	0
52565	1624	extensive similarity	[extensive similarity]	1.0	2	1	0	0
52566	1624	tumor necrosis factor -alphaproduction by monocyte	[tumor necrosis factor -alphaproduction by monocytes]	1.0	6	1	0	0
52567	1624	suggest a direct action of RA	[suggesting a direct action of RA]	1.0	6	1	0	0
52568	1624	il-2 production in T lymphocyte	[IL-2 production in T lymphocytes]	1.0	5	1	0	0
52569	1624	oligonucleotide contain a binding site	[oligonucleotide containing a binding site]	1.0	5	1	0	0
52570	1624	Polyubiquitinylated c-Jun	[Polyubiquitinylated c-Jun]	1.0	2	1	0	0
52571	1624	present review	[present review]	1.0	2	1	0	0
52572	1624	presence in several t-cell-expressed cytokine gene	[presence in several T-cell-expressed cytokine genes]	1.0	6	1	0	0
52573	1624	mip-1alpha expression in PMA/PHA cell	[MIP-1alpha expression in PMA/PHA cells]	1.0	5	1	0	0
52574	1624	Jul 15;153(2):910]	[Jul 15;153(2):910]]	1.0	2	1	0	0
52575	1624	express a specific pattern of cytokine	[expressing a specific pattern of cytokines]	1.0	6	1	0	0
52576	1624	camp accumulation	[cAMP accumulation]	1.0	2	3	2	1
52577	1624	molecular probe study intracellular signal transduction	[molecular probes studying intracellular signal transduction]	1.0	6	1	0	0
52578	1624	IARC 301	[IARC 301]	1.0	2	2	1	1
52579	1624	production of il-8 by hypoxic ECs	[Production of IL-8 by hypoxic ECs]	1.0	6	1	0	0
52580	1624	susceptibility to killer cell-induced lysis	[susceptibility to killer cell-induced lysis]	1.0	5	1	0	0
52581	1624	NF-AT-binding site	[NF-AT-binding site]	1.0	2	2	1	1
52582	1624	il-6 by peripheral blood mononuclear cell	[IL-6 by peripheral blood mononuclear cells]	1.0	6	2	2	2
52583	1624	role in class ii gene regulation	[role in class II gene regulation]	1.0	6	1	0	0
52584	1624	nuclear extract of T cell	[nuclear extracts of T cells]	1.0	5	1	0	0
52585	1624	TNFalpha gene	[TNFalpha gene]	1.0	2	1	0	0
52586	1624	early lesion in the development	[earliest lesion in the development]	1.0	5	1	0	0
52587	1624	38000 m(r).	[38,000 M(r).]	1.0	2	1	0	0
52588	1624	disease tuberculosis	[diseases tuberculosis]	1.0	2	2	2	2
52589	1624	prerequisite for expression with kinetic	[prerequisite for expression with kinetics]	1.0	5	1	0	0
52590	1624	impaired function,	[impaired function,]	1.0	2	1	0	0
52591	1624	safe peptide vaccine against tumor	[safe peptide vaccines against tumors]	1.0	5	1	0	0
52592	1624	proliferative disorder	[proliferative disorders]	1.0	2	1	0	0
52593	1624	classical protein kinase C PKC isoenzyme	[classical protein kinase C PKC isoenzymes]	1.0	6	1	0	0
52594	1624	hypothesis of glucocorticoid receptor number	[hypothesis of glucocorticoid receptor numbers]	1.0	5	1	0	0
52595	1624	heat stable placental alkaline phosphatase	[heat stable placental alkaline phosphatase]	1.0	5	1	0	0
52596	1624	cis-activation by the t(9;22)(q34;q11) translocation	[cis-activation by the t(9;22)(q34;q11) translocation]	1.0	5	1	0	0
52597	1624	insulin gene	[insulin gene]	1.0	2	2	2	2
52598	1624	Thus, T3SO4	[Thus, T3SO4]	1.0	2	1	0	0
52599	1624	multiple phosphorylations.	[multiple phosphorylations.]	1.0	2	1	0	0
52600	1624	cellular uptake	[cellular uptake]	1.0	2	2	1	1
52601	1624	western-blot analysis of the sedimentation peak	[Western-blot analysis of the sedimentation peak]	1.0	6	1	0	0
52602	1624	activate the NF-kappaB/Rel transcription factor family	[activating the NF-kappaB/Rel transcription factor family]	1.0	6	1	0	0
52603	1624	atra expression of CD38 antigen	[ATRA expression of CD38 antigen]	1.0	5	1	0	0
52604	1624	immunomodulatory effect on a number	[immunomodulatory effects on a number]	1.0	5	1	0	0
52605	1624	pbmc from patient with gd	[PBMC from patients with GD]	1.0	5	1	0	0
52606	1624	epo granulocyte/macrophage colony stimulate factor gm-csf	[Epo granulocyte/macrophage colony stimulating factor GM-CSF]	1.0	6	1	0	0
52607	1624	multiple signals, include exogenous cytokine	[multiple signals, including exogenous cytokines]	1.0	5	1	0	0
52608	1624	virus stock	[virus stocks]	1.0	2	2	1	1
52609	1624	rat brain	[rat brain]	1.0	2	1	0	0
52610	1624	cd44 promoter-chloramphenicol	[CD44 promoter-chloramphenicol]	1.0	2	2	1	1
52611	1624	c-myc probe	[c-myc probe]	1.0	2	1	0	0
52612	1624	experimental support	[experimental support]	1.0	2	1	0	0
52613	1624	H-89 lps	[H-89 LPS]	1.0	2	1	0	0
52614	1624	subcellular redistribution,	[subcellular redistribution,]	1.0	2	1	0	0
52615	1624	activation of the protein factor (nf)-kb	[activation of the protein factor (NF)-kB]	1.0	6	1	0	0
52616	1624	transcription of the class transplantation gene	[transcription of the class transplantation gene]	1.0	6	1	0	0
52617	1624	pyrimidine-rich region	[pyrimidine-rich region]	1.0	2	2	1	1
52618	1624	physiologic relevance of this observations.	[physiologic relevance of these observations.]	1.0	5	1	0	0
52619	1624	alpha-tcp effect	[alpha-tcp effect]	1.0	2	1	0	0
52620	1624	expression of glucocorticoid receptor GRs	[expression of glucocorticoid receptors GRs]	1.0	5	1	0	0
52621	1624	electrophoretic mobility shift assay in pbmc	[electrophoretic mobility shift assays in PBMC]	1.0	6	1	0	0
52622	1624	hormone-activated binding	[hormone-activated binding]	1.0	2	1	0	0
52623	1624	Jurkat T cell complementary DNA	[Jurkat T cell complementary DNA]	1.0	5	1	0	0
52624	1624	defective pathway	[defective pathway]	1.0	2	1	0	0
52625	1624	number of GR in MNL	[number of GR in MNL]	1.0	5	1	0	0
52626	1624	other population	[other populations]	1.0	2	1	0	0
52627	1624	transgenic bone	[transgenic bone]	1.0	2	1	0	0
52628	1624	7-day mdm	[7-day MDMs]	1.0	2	1	0	0
52629	1624	similar spectrum of transcript deletion	[similar spectrum of transcript deletions]	1.0	5	1	0	0
52630	1624	transcription of the ifn-gamma gene	[transcription of the IFN-gamma gene]	1.0	5	1	0	0
52631	1624	pha related to the major importance	[PHA related to the major importance]	1.0	6	1	0	0
52632	1624	10 minute in Jurkat cell	[10 minutes in Jurkat cells]	1.0	5	1	0	0
52633	1624	high level of hiv replication	[high levels of HIV replication]	1.0	5	1	0	0
52634	1624	vitamin D3 repression of il-2 expression	[vitamin D3 repression of IL-2 expression]	1.0	6	1	0	0
52635	1624	non- T	[non- T]	1.0	2	1	0	0
52636	1624	component tyrosine	[components tyrosine]	1.0	2	1	0	0
52637	1624	il-6 during 24 h of stimulation	[IL-6 during 24 h of stimulation]	1.0	6	1	0	0
52638	1624	persistent viral replication in monocyte	[persistent viral replication in monocytes]	1.0	5	1	0	0
52639	1624	GR number in the patient' lymphocyte	[GR number in the patient's lymphocytes]	1.0	6	1	0	0
52640	1624	female with ring x chromosome	[females with ring X chromosomes]	1.0	5	1	0	0
52641	1624	3q21 gene	[3q21 genes]	1.0	2	1	0	0
52642	1624	protein CREB	[protein CREB]	1.0	2	2	2	2
52643	1624	Fusion protein	[Fusion proteins]	1.0	2	2	1	1
52644	1624	follow 3-day exposure to 12-o-tetradecanoylphorbol-13-acetate tpa	[following 3-day exposures to 12-O-tetradecanoylphorbol-13-acetate TPA]	1.0	6	1	0	0
52645	1624	thaz, in the case of cd16	[that, in the case of CD16]	1.0	6	1	0	0
52646	1624	chromosome constitution of cell hybrid	[chromosome constitution of cell hybrids]	1.0	5	1	0	0
52647	1624	level of transcription in cell extract	[levels of transcription in cell extracts]	1.0	6	1	0	0
52648	1624	deletion of the ebna2-dependent enhancer upstream	[Deletion of the EBNA2-dependent enhancer upstream]	1.0	6	1	0	0
52649	1624	thymic cellularity of this mouse	[thymic cellularity of these mice]	1.0	5	1	0	0
52650	1624	proliferative block	[proliferative block]	1.0	2	1	0	0
52651	1624	phi) for 24 h with methylprednisolone	[phi) for 24 h with methylprednisolone]	1.0	6	1	0	0
52652	1624	om10.1 a promyelocyte cell line	[OM10.1 a promyelocyte cell line]	1.0	5	1	0	0
52653	1624	previous experiments,	[previous experiments,]	1.0	2	1	0	0
52654	1624	nuclear c/ebp	[nuclear C/EBP]	1.0	2	1	0	0
52655	1624	probably through cell signal pathway	[probably through cell signaling pathways]	1.0	5	1	0	0
52656	1624	bsap expression	[BSAP expression]	1.0	2	1	0	0
52657	1624	pgn activation of CREB /atf	[PGN activation of CREB /ATF]	1.0	5	1	0	0
52658	1624	microa motif	[microA motif]	1.0	2	1	0	0
52659	1624	probably compete with MNP-2 for binding	[probably competing with MNP-2 for binding]	1.0	6	1	0	0
52660	1624	DNA bind nf-kappa b dimer	[DNA binding NF-kappa B dimers]	1.0	5	1	0	0
52661	1624	activate a interleukin-2 reporter gene	[activating an interleukin-2 reporter gene]	1.0	5	1	0	0
52662	1624	signal cascade transduce this effect	[signal cascade transducing this effect]	1.0	5	1	0	0
52663	1624	smooth muscle	[smooth muscle]	1.0	2	1	0	0
52664	1624	interferon-stimulated gene	[interferon-stimulated genes]	1.0	2	1	0	0
52665	1624	outgrowth of ad5e1a -express tumor	[outgrowth of Ad5E1A -expressing tumors]	1.0	5	1	0	0
52666	1624	lymphocyte express the Notch1/TAN-1 receptor	[lymphocytes expressing the Notch1/TAN-1 receptor]	1.0	5	1	0	0
52667	1624	region of 16 to 21	[region of 16 to 21]	1.0	5	1	0	0
52668	1624	GCRbeta expression	[GCRbeta expression]	1.0	2	2	2	2
52669	1624	5 ng/ml	[5 ng/ml]	1.0	2	2	2	2
52670	1624	interferon regulatory factor-1 gene expression	[interferon regulatory factor-1 gene expression]	1.0	5	1	0	0
52671	1624	specific sequence.	[specific sequence.]	1.0	2	1	0	0
52672	1624	lack lactoferrin	[lacking lactoferrin]	1.0	2	1	0	0
52673	1624	aging subject	[aging subjects]	1.0	2	1	0	0
52674	1624	thrombotic event	[thrombotic events]	1.0	2	1	0	0
52675	1624	human embryonic kidney 293 cell	[human embryonic kidney 293 cells]	1.0	5	1	0	0
52676	1624	high level of viral replication	[higher levels of viral replication]	1.0	5	1	0	0
52677	1624	Clinical cr	[Clinical CR]	1.0	2	1	0	0
52678	1624	camp -dependent protein kinase a pka	[cAMP -dependent protein kinase A PKA]	1.0	6	1	0	0
52679	1624	nf-kappab activation by proinflammatory cytokine	[NF-kappaB activation by proinflammatory cytokines]	1.0	5	1	0	0
52680	1624	recurrent infections.	[recurrent infections.]	1.0	2	1	0	0
52681	1624	even by a partial depletion	[even by a partial depletion]	1.0	5	1	0	0
52682	1624	alpha 4 beta 1 ligand	[alpha 4 beta 1 ligands]	1.0	5	1	0	0
52683	1624	t/nk-cell subset	[T/NK-cell subsets]	1.0	2	1	0	0
52684	1624	transduce a signal across the membrane	[transducing a signal across the membrane]	1.0	6	1	0	0
52685	1624	myeloid differentiation of k562 cell	[myeloid differentiation of K562 cells]	1.0	5	2	2	2
52686	1624	expression in Oct2 b cell	[expression in Oct2 B cells]	1.0	5	1	0	0
52687	1624	membrane-proximal box 1 pxp motif	[membrane-proximal box 1 PXP motif]	1.0	5	1	0	0
52688	1624	significant increase in the Kcat	[significant increase in the Kcat]	1.0	5	1	0	0
52689	1624	phosphorylation of Elk-1 fusion protein	[phosphorylation of Elk-1 fusion protein]	1.0	5	1	0	0
52690	1624	response to the tshr molecule.	[response to the TSHR molecule.]	1.0	5	1	0	0
52691	1624	immunoglobulin beta-chain	[immunoglobulin beta-chain]	1.0	2	1	0	0
52692	1624	cell-specific expression of helix-loop-helix transcription factor	[Cell-specific expression of helix-loop-helix transcription factors]	1.0	6	1	0	0
52693	1624	several member	[several members]	1.0	2	2	2	2
52694	1624	function of the inflammatory infiltrate	[function of the inflammatory infiltrate]	1.0	5	1	0	0
52695	1624	crucial role determine the efficiency	[crucial roles determining the efficiency]	1.0	5	1	0	0
52696	1624	change in endothelial cell gssg /gsh	[changes in endothelial cell GSSG /GSH]	1.0	6	1	0	0
52697	1624	progression of the hiv-1 disease	[progression of the HIV-1 disease]	1.0	5	1	0	0
52698	1624	il-2 il-3	[IL-2 IL-3]	1.0	2	1	0	0
52699	1624	HeLa cell with b cell	[HeLa cells with B cells]	1.0	5	1	0	0
52700	1624	-protein kinase	[-protein kinase]	1.0	2	1	0	0
52701	1624	transfection of a reporter construct	[Transfection of a reporter construct]	1.0	5	1	0	0
52702	1624	NF-kappa b activation by PMA	[NF-kappa B activation by PMA]	1.0	5	1	0	0
52703	1624	MR preeclampsia	[MR preeclampsia]	1.0	2	1	0	0
52704	1624	two chemoattract	[two chemoattractants]	1.0	2	1	0	0
52705	1624	progressive decline	[progressive decline]	1.0	2	2	1	1
52706	1624	supershift analysis use specific antibody	[supershift analysis using specific antibodies]	1.0	5	1	0	0
52707	1624	activation region	[activation region]	1.0	2	2	1	1
52708	1624	include in antigen T cell	[including in antigen T cells]	1.0	5	1	0	0
52709	1624	HsN3 subunit of the proteasome	[HsN3 subunit of the proteasome]	1.0	5	1	0	0
52710	1624	MRD patient	[MRD patients]	1.0	2	2	1	1
52711	1624	thp-1 cell with the antibody	[THP-1 cells with the antibody]	1.0	5	1	0	0
52712	1624	alphaiibbeta3 activation	[alphaIIbbeta3 activation]	1.0	2	1	0	0
52713	1624	30 minute of heat shock	[30 min of heat shock]	1.0	5	1	0	0
52714	1624	five family with various degree	[five families with various degrees]	1.0	5	1	0	0
52715	1624	b29 transcription	[B29 transcription]	1.0	2	1	0	0
52716	1624	three tnf produce cell line	[three TNF producing cell lines]	1.0	5	1	0	0
52717	1624	distal region	[distal region]	1.0	2	2	1	1
52718	1624	six 5'	[six 5']	1.0	2	1	0	0
52719	1624	affect the NF-kappa b translocation step	[affecting the NF-kappa B translocation step]	1.0	6	1	0	0
52720	1624	of switch	[of switching]	1.0	2	1	0	0
52721	1624	Oct-2 mrna induction during t-cell activation	[Oct-2 mRNA induction during T-cell activation]	1.0	6	1	0	0
52722	1624	DPD activity	[DPD activity]	1.0	2	2	2	2
52723	1624	81% increment in promoter activity	[81% increment in promoter activity]	1.0	5	1	0	0
52724	1624	binding site at the core region	[Binding sites at the core region]	1.0	6	1	0	0
52725	1624	intervene (i) region upstream of switch	[intervening (I) regions upstream of switch]	1.0	6	1	0	0
52726	1624	tyrosine phosphorylation of the protein	[tyrosine phosphorylation of the proteins]	1.0	5	1	0	0
52727	1624	cooperative stabilization	[cooperative stabilization]	1.0	2	2	1	1
52728	1624	reactive intermediate	[reactive intermediates]	1.0	2	1	0	0
52729	1624	twenty two healthy man aged	[Twenty two healthy men aged]	1.0	5	1	0	0
52730	1624	nature of the transcription factor	[nature of the transcription factor]	1.0	5	1	0	0
52731	1624	modification of the original ddpcr protocol	[Modifications of the original DDPCR protocol]	1.0	6	1	0	0
52732	1624	structure of the 5' end	[structure of the 5' end]	1.0	5	1	0	0
52733	1624	prl- secreting	[PRL- secreting]	1.0	2	1	0	0
52734	1624	22 patient	[22 patients]	1.0	2	1	0	0
52735	1624	granulocyte-macrophage colony-stimulating factor gene promoter	[granulocyte-macrophage colony-stimulating factor gene promoter]	1.0	5	1	0	0
52736	1624	tnf-alpha secretion by gh production	[TNF-alpha secretion by GH production]	1.0	5	1	0	0
52737	1624	2-3 times.	[2-3 times.]	1.0	2	1	0	0
52738	1624	nuclear nf-kappab	[nuclear NF-kappaB]	1.0	2	2	1	1
52739	1624	SM protein	[SM protein]	1.0	2	1	0	0
52740	1624	IL-1RII mrna level by IFN-gamma	[IL-1RII mRNA levels by IFN-gamma]	1.0	5	1	0	0
52741	1624	t-lymphocyte by t-cell receptor tcr	[T-lymphocytes by T-cell receptor TcR]	1.0	5	1	0	0
52742	1624	coincide with the release of platelet	[coinciding with the release of platelets]	1.0	6	1	0	0
52743	1624	superoxide formation in the human neutrophil	[superoxide formation in the human neutrophils]	1.0	6	1	0	0
52744	1624	Turner mosaicism	[Turner mosaicism]	1.0	2	1	0	0
52745	1624	lineage- manner.	[lineage- manner.]	1.0	2	1	0	0
52746	1624	synergistic complex formation between protein	[synergistic complex formation between proteins]	1.0	5	1	0	0
52747	1624	11 woman	[11 women]	1.0	2	1	0	0
52748	1624	differentiation of leukemic cell line	[differentiation of leukemic cell lines]	1.0	5	1	0	0
52749	1624	non-pregnant individual	[non-pregnant individuals]	1.0	2	1	0	0
52750	1624	0.1 microM.	[0.1 microM.]	1.0	2	1	0	0
52751	1624	two pkc NF-kappa b inhibitors, pentoxifylline	[two PKC NF-kappa B inhibitors, pentoxifylline]	1.0	6	1	0	0
52752	1624	elevation of intracellular cyclic AMP	[elevation of intracellular cyclic AMP]	1.0	5	1	0	0
52753	1624	t-cell surface	[T-cell surface]	1.0	2	1	0	0
52754	1624	pulmonary leukostasis,	[pulmonary leukostasis,]	1.0	2	1	0	0
52755	1624	same gene.	[same gene.]	1.0	2	1	0	0
52756	1624	intracellular cholesterol synthesis in hypercholesterolemia	[intracellular cholesterol synthesis in hypercholesterolemia]	1.0	5	1	0	0
52757	1624	aim of this present study	[aim of this present study]	1.0	5	1	0	0
52758	1624	NDP kinase expression between KA	[NDP kinase expression between KA]	1.0	5	1	0	0
52759	1624	moreover, gp120	[Moreover, gp120]	1.0	2	1	0	0
52760	1624	drug-immunophilin complex	[drug-immunophilin complex]	1.0	2	1	0	0
52761	1624	alpha-tocopherol acetate	[alpha-tocopherol acetate]	1.0	2	1	0	0
52762	1624	bcl-2 protein	[Bcl-2 protein]	1.0	2	2	2	2
52763	1624	regulation of a reporter gene	[regulation of an reporter gene]	1.0	5	1	0	0
52764	1624	murine b-cell specific coactivator mbob1	[murine B-cell specific coactivator mBob1]	1.0	5	1	0	0
52765	1624	critical region with general cofactor	[critical regions with general cofactors]	1.0	5	1	0	0
52766	1624	more than 5.6 kb of DNA	[more than 5.6 kb of DNA]	1.0	6	1	0	0
52767	1624	macrophage-like phenotype	[macrophage-like phenotype]	1.0	2	1	0	0
52768	1624	understand the cis- acting factor	[Understanding the cis- acting factors]	1.0	5	1	0	0
52769	1624	chronic glomerulonephritis	[chronic glomerulonephritis]	1.0	2	1	0	0
52770	1624	6-cis-locked conformer	[6-cis-locked conformer]	1.0	2	1	0	0
52771	1624	defective gene	[defective gene]	1.0	2	2	1	1
52772	1624	similar sensitivity to a proteasome inhibitor	[similar sensitivities to a proteasome inhibitor]	1.0	6	1	0	0
52773	1624	regulatory interaction	[regulatory interaction]	1.0	2	2	2	2
52774	1624	death effector	[death effector]	1.0	2	2	1	1
52775	1624	CD4 tail	[CD4 tail]	1.0	2	2	2	2
52776	1624	antagonism by dexamethasone of endotoxin inflammation	[antagonism by dexamethasone of endotoxin inflammation]	1.0	6	1	0	0
52777	1624	transcription assay	[transcription assays]	1.0	2	2	1	1
52778	1624	deactivate effect on pbmc response	[deactivating effects on PBMC responses]	1.0	5	1	0	0
52779	1624	low to undetectable level of c-jun	[low to undetectable levels of c-jun]	1.0	6	1	0	0
52780	1624	activity of the rela homodimer	[activity of the RelA homodimer]	1.0	5	1	0	0
52781	1624	immune homeostasis	[immune homeostasis]	1.0	2	1	0	0
52782	1624	other phosphatidylinositide	[other phosphatidylinositides]	1.0	2	1	0	0
52783	1624	second peak at 24 h	[second peak at 24 h]	1.0	5	1	0	0
52784	1624	caspase Mch	[caspase Mch]	1.0	2	2	2	2
52785	1624	first objective of this study	[first objective of this study]	1.0	5	1	0	0
52786	1624	one feature	[One feature]	1.0	2	2	2	2
52787	1624	nordihydroguaiaretic acid	[nordihydroguaiaretic acid]	1.0	2	1	0	0
52788	1624	lung vascular leak of albumin	[lung vascular leak of albumin]	1.0	5	1	0	0
52789	1624	risk factor for breast recurrence	[Risk factors for breast recurrence]	1.0	5	1	0	0
52790	1624	nucleotide sequence responsible for this effect	[nucleotide sequences responsible for this effect]	1.0	6	1	0	0
52791	1624	RNA from control resting cell	[RNA from control resting cells]	1.0	5	1	0	0
52792	1624	October coactivator	[Oct coactivator]	1.0	2	1	0	0
52793	1624	basal machinery.	[basal machinery.]	1.0	2	1	0	0
52794	1624	hiv-1 LTR activity in monocytes/macrophages	[HIV-1 LTR activity in monocytes/macrophages]	1.0	5	1	0	0
52795	1624	transcriptional up-regulation	[transcriptional up-regulation]	1.0	2	2	1	1
52796	1624	number of T cell line	[number of T cell lines]	1.0	5	1	0	0
52797	1624	only the time between infection	[only the time between infection]	1.0	5	1	0	0
52798	1624	nf- il-6	[NF- IL-6]	1.0	2	1	0	0
52799	1624	leukocyte adhesion to vascular endothelium	[leukocyte adhesion to vascular endothelium]	1.0	5	1	0	0
52800	1624	activation of thp-1 cell with gamma-interferon	[Activation of THP-1 cells with gamma-interferon]	1.0	6	1	0	0
52801	1624	gata sequence at position -24	[GATA sequence at position -24]	1.0	5	1	0	0
52802	1624	-70 bp	[-70 bp]	1.0	2	1	0	0
52803	1624	two highly homologous gene encode scm-1alpha	[two highly homologous genes encoding SCM-1alpha]	1.0	6	1	0	0
52804	1624	transcriptional activity through element specific	[transcriptional activity through elements specific]	1.0	5	1	0	0
52805	1624	pafr gene expression by paf	[PAFR gene expression by PAF]	1.0	5	1	0	0
52806	1624	mutation in the GATA-1(d) motif	[Mutation in the GATA-1(d) motif]	1.0	5	1	0	0
52807	1624	coli endotoxin	[coli endotoxin]	1.0	2	1	0	0
52808	1624	notion a critical control point	[notion a critical control point]	1.0	5	1	0	0
52809	1624	presence of a DHEA receptor	[presence of a DHEA receptor]	1.0	5	1	0	0
52810	1624	However, NF-YB	[However, NF-YB]	1.0	2	1	0	0
52811	1624	0.2 ng/ml	[0.2 ng/ml]	1.0	2	1	0	0
52812	1624	testis-derermine region.	[testis-determining region.]	1.0	2	1	0	0
52813	1624	wild-type endotoxin,	[wild-type endotoxin,]	1.0	2	1	0	0
52814	1624	formation of the protein-DNA complex	[Formation of the protein-DNA complex]	1.0	5	1	0	0
52815	1624	constitutive repressor	[constitutive repressors]	1.0	2	1	0	0
52816	1624	BZLF1 protein of Epstein-Barr virus	[BZLF1 protein of Epstein-Barr virus]	1.0	5	1	0	0
52817	1624	0.4 nm)	[0.4 nM)]	1.0	2	1	0	0
52818	1624	antagonistic effect	[antagonistic effect]	1.0	2	2	1	1
52819	1624	tyrosyl phosphorylation of several cellular protein	[tyrosyl phosphorylation of several cellular proteins]	1.0	6	1	0	0
52820	1624	such as nuclear factor enf)-kappa b	[such as nuclear factor (NF)-kappa B]	1.0	6	1	0	0
52821	1624	constitutive expression of E2a- Pbx1	[Constitutive expression of E2a- Pbx1]	1.0	5	1	0	0
52822	1624	initial depletion	[initial depletion]	1.0	2	1	0	0
52823	1624	same way.	[same way.]	1.0	2	1	0	0
52824	1624	three functional protein binding sequence	[three functional protein binding sequences]	1.0	5	1	0	0
52825	1624	vitro, CsA	[vitro, CsA]	1.0	2	1	0	0
52826	1624	indicate essential for thrombin response	[indicating essential for thrombin response]	1.0	5	1	0	0
52827	1624	cyclin d1	[cyclin D1]	1.0	2	1	0	0
52828	1624	fluorescence intensity	[fluorescence intensity]	1.0	2	1	0	0
52829	1624	leukocyte subpopulation	[leukocyte subpopulations]	1.0	2	1	0	0
52830	1624	L2 mutation	[L2 mutation]	1.0	2	1	0	0
52831	1624	minimal inhibition of il-8 expression	[minimal inhibition of IL-8 expression]	1.0	5	1	0	0
52832	1624	precancerous mastopathy	[precancerous mastopathy]	1.0	2	1	0	0
52833	1624	bind the ubiquitous "octamer" binding protein	[binding the ubiquitous "octamer" binding proteins]	1.0	6	1	0	0
52834	1624	Long term culture u-937 cell	[Long term culture U-937 cells]	1.0	5	1	0	0
52835	1624	vascular tone	[vascular tone]	1.0	2	1	0	0
52836	1624	functional promoter	[functional promoter]	1.0	2	2	2	2
52837	1624	Finally, tpa addition to monocyte	[Finally, TPA addition to monocytes]	1.0	5	1	0	0
52838	1624	human kg-1 myeloid leukemia cell	[human KG-1 myeloid leukemia cells]	1.0	5	1	0	0
52839	1624	adenovirus-mediated gene transfer of IkappaB-alpha	[adenovirus-mediated gene transfer of IkappaB-alpha]	1.0	5	1	0	0
52840	1624	competition assay	[Competition assays]	1.0	2	1	0	0
52841	1624	phosphotyrosine-containing protein	[phosphotyrosine-containing protein]	1.0	2	1	0	0
52842	1624	two p50	[two p50s]	1.0	2	1	0	0
52843	1624	24 h of TNFalpha treatment	[24 h of TNFalpha treatment]	1.0	5	1	0	0
52844	1624	DC stimulation	[DC stimulation]	1.0	2	1	0	0
52845	1624	electrolyte response	[electrolyte response]	1.0	2	2	1	1
52846	1624	suggest the presence of a repressor.	[suggesting the presence of a repressor.]	1.0	6	1	0	0
52847	1624	generation of cytotoxic lymphocyte against peptide	[generation of cytotoxic lymphocytes against peptides]	1.0	6	1	0	0
52848	1624	cell leukemia virus type htlv-1	[cell leukemia virus type HTLV-1]	1.0	5	1	0	0
52849	1624	several hours.	[several hours.]	1.0	2	1	0	0
52850	1624	median 10 year Gail risk probability)	[median 10 year Gail risk probability)]	1.0	6	1	0	0
52851	1624	activation of extracellular signal-regulated kinase	[activation of extracellular signal-regulated kinases]	1.0	5	1	0	0
52852	1624	thirty percent of gc b cell	[Thirty percent of GC B cells]	1.0	6	1	0	0
52853	1624	indicate intact.	[indicating intact.]	1.0	2	1	0	0
52854	1624	identify a human genetic disorder	[identifying a human genetic disorder]	1.0	5	1	0	0
52855	1624	transactivation of a reporter plasmid	[transactivation of a reporter plasmid]	1.0	5	1	0	0
52856	1624	result in suppression of nf-kappa b	[resulting in suppression of NF-kappa B]	1.0	6	1	0	0
52857	1624	agonist-dependent phosphorylation	[agonist-dependent phosphorylation]	1.0	2	1	0	0
52858	1624	NFATx1 of the 60 residue	[NFATx1 of the 60 residues]	1.0	5	1	0	0
52859	1624	nonexpress subclone	[nonexpressing subclones]	1.0	2	1	0	0
52860	1624	number of erythroid progenitor cell	[number of erythroid progenitor cells]	1.0	5	1	0	0
52861	1624	75 kilometer tnf receptor tr75	[75 kd TNF receptor TR75]	1.0	5	1	0	0
52862	1624	g(s)alpha expression	[G(S)alpha expression]	1.0	2	4	3	1
52863	1624	newborn daughter,	[newborn daughter,]	1.0	2	1	0	0
52864	1624	immune hyperactivation	[Immune hyperactivation]	1.0	2	2	1	1
52865	1624	bcl-2 expression in breast carcinoma	[bcl-2 expression in breast carcinoma]	1.0	5	1	0	0
52866	1624	expression of e2a-hlf t-cell apoptosis	[Expression of E2A-HLF T-cell apoptosis]	1.0	5	2	1	1
52867	1624	dissociation of the inhibitory molecule	[dissociation of the inhibitory molecule]	1.0	5	1	0	0
52868	1624	lps stimulation of hdmec thp-1 cell	[LPS stimulation of HDMEC THP-1 cells]	1.0	6	1	0	0
52869	1624	infectious progeny	[infectious progeny]	1.0	2	1	0	0
52870	1624	independent mechanisms,	[independent mechanisms,]	1.0	2	1	0	0
52871	1624	own synthesis	[own synthesis]	1.0	2	1	0	0
52872	1624	expression of the two gene	[expression of the two genes]	1.0	5	1	0	0
52873	1624	indicate a role for nuclear protooncogene	[indicating a role for nuclear protooncogenes]	1.0	6	1	0	0
52874	1624	human epsilon-	[human epsilon-]	1.0	2	1	0	0
52875	1624	study in platelet from woman	[study in platelets from women]	1.0	5	1	0	0
52876	1624	EKLF-/- cell	[EKLF-/- cells]	1.0	2	1	0	0
52877	1624	human T lymphocyte by curcumin	[human T lymphocytes by curcumin]	1.0	5	1	0	0
52878	1624	protein LMP1	[protein LMP1]	1.0	2	2	2	2
52879	1624	T cell representative of stage	[T cells representative of stages]	1.0	5	1	0	0
52880	1624	hiv-1 gp120	[HIV-1 gp120]	1.0	2	1	0	0
52881	1624	bob.1/obf.1 expression	[BOB.1/OBF.1 expression]	1.0	2	1	0	0
52882	1624	functional t-cell receptor signal pathway	[functional T-cell receptor signaling pathway]	1.0	5	1	0	0
52883	1624	prolonged stimulation	[prolonged stimulation]	1.0	2	1	0	0
52884	1624	Raji pattern	[Raji pattern]	1.0	2	1	0	0
52885	1624	kinase responsible for the process	[kinases responsible for the processes]	1.0	5	1	0	0
52886	1624	2 woman	[2 women]	1.0	2	1	0	0
52887	1624	differentiation status of this cell.	[differentiation status of this cell.]	1.0	5	1	0	0
52888	1624	Concanavalin a cycling T cell blast	[Concanavalin A cycling T cell blasts]	1.0	6	1	0	0
52889	1624	demonstrate a active inhibitory process	[demonstrating an active inhibitory process]	1.0	5	1	0	0
52890	1624	T cell into diverse subpopulation	[T cells into diverse subpopulations]	1.0	5	1	0	0
52891	1624	nuclear factor enf)-kappa b activation	[nuclear factor (NF)-kappa B activation]	1.0	5	1	0	0
52892	1624	monocytic leukemia	[monocytic leukemia]	1.0	2	2	1	1
52893	1624	expression upon hl-60 cell differentiation	[expression upon HL-60 cell differentiation]	1.0	5	1	0	0
52894	1624	additionally, virus reactivation in rest pbmc	[Additionally, virus reactivation in resting PBMCs]	1.0	6	1	0	0
52895	1624	apparent difference between Th1 clone	[apparent differences between Th1 clones]	1.0	5	1	0	0
52896	1624	stat in primary human T	[STATs in primary human T]	1.0	5	1	0	0
52897	1624	position 727	[position 727]	1.0	2	1	0	0
52898	1624	potent agonist	[potent agonist]	1.0	2	2	2	2
52899	1624	platelet activating	[platelet activating]	1.0	2	2	2	2
52900	1624	incubation of nuclear extract NE	[incubation of nuclear extracts NE]	1.0	5	1	0	0
52901	1624	gradual differentiation	[gradual differentiation]	1.0	2	1	0	0
52902	1624	various function of nm23 protein	[various functions of nm23 proteins]	1.0	5	1	0	0
52903	1624	platelet activation	[platelet activation]	1.0	2	3	2	1
52904	1624	additional event	[additional event]	1.0	2	1	0	0
52905	1624	positive margin	[positive margins]	1.0	2	1	0	0
52906	1624	nuclear factor enf)-kappa b binding activity	[nuclear factor (NF)-kappa B binding activities]	1.0	6	1	0	0
52907	1624	induction of il-10 production by gp41	[induction of IL-10 production by gp41]	1.0	6	1	0	0
52908	1624	human prointerleukin	[human prointerleukin]	1.0	2	2	1	1
52909	1624	inhibit activation of factor kappa b	[inhibiting activation of factor kappa B]	1.0	6	1	0	0
52910	1624	cellular permissivity to virus replication	[cellular permissivity to virus replication]	1.0	5	1	0	0
52911	1624	baseline condition	[baseline conditions]	1.0	2	1	0	0
52912	1624	2 micrograms/day for 7 day	[2 micrograms/day for 7 days)]	1.0	5	1	0	0
52913	1624	potent modulator of gene expression	[potent modulator of gene expression]	1.0	5	1	0	0
52914	1624	thymic cellularity	[thymic cellularity]	1.0	2	2	1	1
52915	1624	Nfil3/ E4bp4	[Nfil3/ E4bp4]	1.0	2	1	0	0
52916	1624	continual proliferation	[continual proliferation]	1.0	2	1	0	0
52917	1624	synergistic signal	[synergistic signals]	1.0	2	1	0	0
52918	1624	-1.7 kb	[-1.7 kb]	1.0	2	1	0	0
52919	1624	beta-like globin	[beta-like globin]	1.0	2	1	0	0
52920	1624	fhit transcript	[FHIT transcripts]	1.0	2	1	0	0
52921	1624	tfiid from all three organism	[TFIIDs from all three organisms]	1.0	5	1	0	0
52922	1624	myeloid surface	[myeloid surface]	1.0	2	1	0	0
52923	1624	CD40 b	[CD40 B]	1.0	2	2	2	2
52924	1624	intact human platelet to thrombin	[intact human platelets to thrombin]	1.0	5	1	0	0
52925	1624	1-bp difference	[1-bp difference]	1.0	2	2	1	1
52926	1624	anti- CD28 ab stimulation study	[anti- CD28 Ab stimulation studies]	1.0	5	1	0	0
52927	1624	cytokine TNF	[cytokine TNF]	1.0	2	1	0	0
52928	1624	downstream tre-like camp response element	[downstream TRE-like cAMP response elements]	1.0	5	1	0	0
52929	1624	pathogenic factor	[pathogenic factors]	1.0	2	1	0	0
52930	1624	further knowledge of the IL-12R complex	[further knowledge of the IL-12R complex]	1.0	6	1	0	0
52931	1624	influence on NF-kappa b activation	[influence on NF-kappa B activation]	1.0	5	1	0	0
52932	1624	long terminal repeat (ltr) region	[long terminal repeat (LTR) region]	1.0	5	1	0	0
52933	1624	Jurkat line	[Jurkat line]	1.0	2	1	0	0
52934	1624	cross-link CD3	[cross-linking CD3]	1.0	2	1	0	0
52935	1624	DNA domain	[DNA domain]	1.0	2	2	2	2
52936	1624	expression of stat1 stat5 rrna	[expression of STAT1 STAT5 mRNAs]	1.0	5	1	0	0
52937	1624	t-cell tumour	[T-cell tumours]	1.0	2	1	0	0
52938	1624	plasma sialyltransferase	[plasma sialyltransferase]	1.0	2	2	2	2
52939	1624	reciprocal translocation	[reciprocal translocation]	1.0	2	3	2	1
52940	1624	patient with acute hbv infection	[patients with acute HBV infection]	1.0	5	1	0	0
52941	1624	major role in proliferative signal	[major role in proliferative signaling]	1.0	5	1	0	0
52942	1624	protein with similar molecular weight	[proteins with similar molecular weights]	1.0	5	1	0	0
52943	1624	GATA-1 activity	[GATA-1 activities]	1.0	2	1	0	0
52944	1624	expression of mmp-9 a enzyme	[expression of MMP-9 an enzyme]	1.0	5	1	0	0
52945	1624	kappa b-specific DNA binding protein	[Kappa B-specific DNA binding proteins]	1.0	5	1	0	0
52946	1624	sry protein	[SRY protein]	1.0	2	1	0	0
52947	1624	transcription of kappa L chain	[transcription of kappa L chain]	1.0	5	1	0	0
52948	1624	VDR genotype	[VDR genotype]	1.0	2	2	2	2
52949	1624	eutopic first trimester human pregnancy	[eutopic first trimester human pregnancies]	1.0	5	1	0	0
52950	1624	dna-bound stat6	[DNA-bound STAT6]	1.0	2	1	0	0
52951	1624	induction of bcd gene expression	[induction of Bcd gene expression]	1.0	5	1	0	0
52952	1624	role of the host response	[role of the host response]	1.0	5	1	0	0
52953	1624	METHODS: platelet	[METHODS: Platelets]	1.0	2	1	0	0
52954	1624	antigen in the form of peptide	[antigens in the form of peptides]	1.0	6	1	0	0
52955	1624	expression of Spi-1 in this cell	[Expression of Spi-1 in these cells]	1.0	6	1	0	0
52956	1624	repeat element	[repeat element]	1.0	2	2	2	2
52957	1624	Pterin carbinolamine dehydratase/dimerization cofactor of hnf1	[Pterin carbinolamine dehydratase/dimerization cofactor of HNF1]	1.0	6	1	0	0
52958	1624	upstream site	[upstream site]	1.0	2	2	1	1
52959	1624	zinc finger protein binding region	[zinc finger protein binding region]	1.0	5	1	0	0
52960	1624	human T cell il-5 synthesis	[human T cell IL-5 synthesis]	1.0	5	1	0	0
52961	1624	2 h.	[2 h,]	1.0	2	2	1	1
52962	1624	ICAM-1 induction	[ICAM-1 induction]	1.0	2	1	0	0
52963	1624	carboxy terminal of a leucine-zipper structure	[carboxy terminal of a leucine-zipper structure]	1.0	6	1	0	0
52964	1624	unexpected redundancy	[unexpected redundancy.]	1.0	2	1	0	0
52965	1624	oxidative stimulus	[oxidative stimuli]	1.0	2	1	0	0
52966	1624	murine p105	[murine p105]	1.0	2	1	0	0
52967	1624	study indicate a role for calcitriol	[studies indicating a role for calcitriol]	1.0	6	1	0	0
52968	1624	general coactivator	[general coactivators]	1.0	2	1	0	0
52969	1624	permanently a major challenge for immunology	[Permanently a major challenge for immunology]	1.0	6	1	0	0
52970	1624	effect of Nef in hiv infection	[effects of Nef in HIV infection]	1.0	6	1	0	0
52971	1624	regulatory site	[regulatory sites]	1.0	2	2	2	2
52972	1624	control human b29 gene expression	[controlling human B29 gene expression]	1.0	5	1	0	0
52973	1624	xscid, x-chromosome inactivation in carrier	[XSCID, X-chromosome inactivation in carriers]	1.0	5	1	0	0
52974	1624	phosphoinositide hydrolysis	[phosphoinositide hydrolysis]	1.0	2	2	1	1
52975	1624	four bzip transcription factor as candidate	[four bZIP transcription factors as candidates]	1.0	6	1	0	0
52976	1624	mean sem).	[mean SEM).]	1.0	2	1	0	0
52977	1624	effect on GATA-1 a transcription factor	[effects on GATA-1 an transcription factor]	1.0	6	1	0	0
52978	1624	Z/R combination,	[Z/R combination,]	1.0	2	1	0	0
52979	1624	OTF interaction	[OTF interactions]	1.0	2	1	0	0
52980	1624	546-nucleotide open reading frame ORF	[546-nucleotide open reading frame ORF]	1.0	5	1	0	0
52981	1624	il-2 receptor on T cell	[IL-2 receptors on T cells]	1.0	5	1	0	0
52982	1624	intrapulmonary activation	[intrapulmonary activation]	1.0	2	1	0	0
52983	1624	2 mM	[2 mM]	1.0	2	1	0	0
52984	1624	temporal control of igh gene expression	[Temporal control of IgH gene expression]	1.0	6	1	0	0
52985	1624	low molecular weight variant of stat5	[lower molecular weight variants of STAT5]	1.0	6	1	0	0
52986	1624	such as the interleukin beta gene	[such as the interleukin beta gene]	1.0	6	1	0	0
52987	1624	fast assay	[faster assay]	1.0	2	1	0	0
52988	1624	dnase footprinting	[DNase footprinting]	1.0	2	2	1	1
52989	1624	transient pattern of nuclear induction	[transient pattern of nuclear induction]	1.0	5	1	0	0
52990	1624	acyclovir cell	[acyclovir cells]	1.0	2	1	0	0
52991	1624	attachment of the actin tail	[attachment of the actin tail]	1.0	5	1	0	0
52992	1624	MEDLINE search of the literature	[MEDLINE search of the literature]	1.0	5	1	0	0
52993	1624	such element	[such element]	1.0	2	2	2	2
52994	1624	complete correlation between the expression pattern	[complete correlation between the expression pattern]	1.0	6	1	0	0
52995	1624	comparison, a very inefficient inducer	[comparison, a very inefficient inducer]	1.0	5	1	0	0
52996	1624	cross-priming of CTL response in vivo	[Cross-priming of CTL responses in vivo]	1.0	6	1	0	0
52997	1624	Negative selection	[Negative selection]	1.0	2	2	1	1
52998	1624	However, synthesis	[However, synthesis]	1.0	2	1	0	0
52999	1624	other gata-binding protein family member	[other GATA-binding protein family members]	1.0	5	1	0	0
53000	1624	such defect in fetal/neonatal t-cell activation	[such defects in fetal/neonatal T-cell activation]	1.0	6	1	0	0
53001	1624	homologous disruption	[homologous disruption]	1.0	2	1	0	0
53002	1624	chimeric mouse	[chimeric mice]	1.0	2	1	0	0
53003	1624	adult human	[Adult humans]	1.0	2	1	0	0
53004	1624	gamma/delta T cell receptor (tcr)	[gamma/delta T cell receptor (TCR)]	1.0	5	1	0	0
53005	1624	total igg-aeca	[total IgG-AECA]	1.0	2	1	0	0
53006	1624	leukocyte-type 12-lipoxygenase	[leukocyte-type 12-lipoxygenase]	1.0	2	2	1	1
53007	1624	block chromatin fragmentation as inhibition	[blocking chromatin fragmentation as inhibition]	1.0	5	1	0	0
53008	1624	transfection with the nf-kappab binding sequence	[transfection with the NF-kappaB binding sequence]	1.0	6	2	1	1
53009	1624	respective roles.	[respective roles.]	1.0	2	1	0	0
53010	1624	transcription factor belong to the factor	[Transcription factors belonging to the factor]	1.0	6	1	0	0
53011	1624	cognate site	[cognate site]	1.0	2	1	0	0
53012	1624	immediate precursor	[immediate precursors]	1.0	2	1	0	0
53013	1624	promyelocyte stage	[promyelocyte stage]	1.0	2	2	1	1
53014	1624	chromium-release assay	[chromium-release assay]	1.0	2	1	0	0
53015	1624	protein/drug complex	[protein/drug complexes]	1.0	2	1	0	0
53016	1624	one purpose of this study	[One purpose of this study]	1.0	5	1	0	0
53017	1624	significant effect on virus expression	[significant effect on virus expression]	1.0	5	1	0	0
53018	1624	il-2 expression.	[IL-2 expression.]	1.0	2	1	0	0
53019	1624	tced DNA	[TCEd DNA]	1.0	2	1	0	0
53020	1624	cd45-negative variant	[CD45-negative variant]	1.0	2	1	0	0
53021	1624	Th2 clone	[Th2 clones]	1.0	2	2	1	1
53022	1624	gc apoptosis	[GC apoptosis]	1.0	2	1	0	0
53023	1624	protein ag	[protein Ag]	1.0	2	2	2	2
53024	1624	human aortic endothelial cell HAEC	[human aortic endothelial cells HAEC]	1.0	5	1	0	0
53025	1624	include member	[including members]	1.0	2	2	2	2
53026	1624	DM+, DO- human T cell line	[DM+, DO- human T cell line]	1.0	6	1	0	0
53027	1624	membrane from yeast express SR-BP	[membranes from yeast expressing SR-BP]	1.0	5	1	0	0
53028	1624	apparently the product of alternative splicing	[apparently the products of alternative splicing]	1.0	6	1	0	0
53029	1624	high-level expression of reporter gata-1/lacz gene	[high-level expression of reporter GATA-1/lacZ genes]	1.0	6	1	0	0
53030	1624	endothelial and/or leukocyte adhesion molecule	[endothelial and/or leukocyte adhesion molecules]	1.0	5	1	0	0
53031	1624	1 alpha,25-dihydroxyvitamin	[1 alpha,25-dihydroxyvitamin]	1.0	2	1	0	0
53032	1624	single-copy gene with (amino acid)	[single-copy gene with (amino acid)]	1.0	5	1	0	0
53033	1624	constitutive expression in b cell	[constitutive expression in B cells]	1.0	5	1	0	0
53034	1624	mutation at the CRE site	[mutations at the CRE site]	1.0	5	1	0	0
53035	1624	high level of proenkephalin mrna	[high levels of proenkephalin mRNA]	1.0	5	1	0	0
53036	1624	approximately 120-kDa	[approximately 120-kDa]	1.0	2	1	0	0
53037	1624	pha/ PMA	[PHA/ PMA]	1.0	2	1	0	0
53038	1624	oct2 protein	[Oct2 protein]	1.0	2	2	1	1
53039	1624	Study with human umbilical vein segment	[Studies with human umbilical vein segments]	1.0	6	1	0	0
53040	1624	tpa-treated u-937	[TPA-treated U-937]	1.0	2	1	0	0
53041	1624	several malignant human b-cell line	[several malignant human B-cell lines]	1.0	5	1	0	0
53042	1624	human primary t-lymphocyte via CD2	[human primary T-lymphocytes via CD2]	1.0	5	1	0	0
53043	1624	putative guanine nucleotide exchange domain	[putative guanine nucleotide exchange domain]	1.0	5	1	0	0
53044	1624	IL-3 enhancer	[IL-3 enhancer]	1.0	2	1	0	0
53045	1624	pharmacologic inhibition of DNA methyltransferase	[pharmacologic inhibition of DNA methyltransferase]	1.0	5	1	0	0
53046	1624	multiple aspect of v-Abl signal	[multiple aspects of v-Abl signaling]	1.0	5	1	0	0
53047	1624	prime importance	[prime importance]	1.0	2	1	0	0
53048	1624	operate downstream of the tcr	[operating downstream of the TCR]	1.0	5	1	0	0
53049	1624	B-cell activation, differentiation, in ilf	[B-cell activation, differentiation, in ILFs]	1.0	5	1	0	0
53050	1624	improvement in urinary protein excretion	[Improvement in urinary protein excretion]	1.0	5	1	0	0
53051	1624	signal pathway in normal T cell	[signaling pathways in normal T cells]	1.0	6	1	0	0
53052	1624	phenotype of RelB knockout mouse	[phenotype of RelB knockout mice]	1.0	5	1	0	0
53053	1624	(2) intrafollicular cd3+ T cell	[(2) Intrafollicular CD3+ T cells]	1.0	5	1	0	0
53054	1624	DNA variation	[DNA variation]	1.0	2	2	2	2
53055	1624	rest human tonsillar b cell	[resting human tonsillar B cells]	1.0	5	1	0	0
53056	1624	renal fibrosis	[renal fibrosis]	1.0	2	1	0	0
53057	1624	BLS group	[BLS group]	1.0	2	1	0	0
53058	1624	incubation ultra-violet	[incubation UV]	1.0	2	1	0	0
53059	1624	CD5 surface	[CD5 surface]	1.0	2	2	2	2
53060	1624	healthy controls.	[healthy controls.]	1.0	2	1	0	0
53061	1624	several subregion	[several subregions]	1.0	2	1	0	0
53062	1624	megakaryoblastic leukaemia	[megakaryoblastic leukaemia]	1.0	2	2	2	2
53063	1624	monoblast lineage	[monoblast lineage]	1.0	2	1	0	0
53064	1624	ec activity	[EC activity]	1.0	2	2	2	2
53065	1624	compounds, 20-epi	[compounds, 20-epi]	1.0	2	1	0	0
53066	1624	minimal EBNA-2 -responsive lmp-1 promoter	[minimal EBNA-2 -responsive LMP-1 promoter]	1.0	5	1	0	0
53067	1624	tumor cell in 9 gct	[Tumor cells in 9 GCT]	1.0	5	1	0	0
53068	1624	<10 nm.	[<10 nM.]	1.0	2	1	0	0
53069	1624	short term	[short term]	1.0	2	2	1	1
53070	1624	presence of genuine nf-e2 complex	[presence of genuine NF-E2 complex]	1.0	5	1	0	0
53071	1624	T lymphocyte from old individual	[T lymphocytes from older individuals]	1.0	5	1	0	0
53072	1624	hiv-infected T	[HIV-infected T]	1.0	2	1	0	0
53073	1624	c/ebp subfamily	[C/EBP subfamilies]	1.0	2	1	0	0
53074	1624	synergism modulate perforin gene expression	[synergism modulating perforin gene expression]	1.0	5	1	0	0
53075	1624	mouse ada	[mouse ADA]	1.0	2	1	0	0
53076	1624	affinity similar	[affinity similar]	1.0	2	1	0	0
53077	1624	closely related simian immunodeficiency virus	[closely related simian immunodeficiency virus]	1.0	5	1	0	0
53078	1624	transactivate domain,	[transactivating domain,]	1.0	2	1	0	0
53079	1624	100 microg/10(6)	[100 microg/10(6)]	1.0	2	1	0	0
53080	1624	Ab-associated change in the uptake	[Ab-associated changes in the uptake]	1.0	5	1	0	0
53081	1624	5' from the GATA-3 initiation site	[5' from the GATA-3 initiation site]	1.0	6	1	0	0
53082	1624	switch during initial stage of infection	[switching during initial stages of infection]	1.0	6	1	0	0
53083	1624	critical illness.	[critical illness.]	1.0	2	1	0	0
53084	1624	transactivation of gene (nf)-kappab pathway	[transactivation of genes (NF)-kappaB pathway]	1.0	5	1	0	0
53085	1624	alcoholic extract form Arnicae flo	[Alcoholic extracts form Arnicae flos]	1.0	5	1	0	0
53086	1624	lung condition	[lung conditions]	1.0	2	1	0	0
53087	1624	Michael Owen	[Michael Owen]	1.0	2	1	0	0
53088	1624	insight into molecular event coincide	[insights into molecular events coinciding]	1.0	5	1	0	0
53089	1624	promoter deletion	[promoter deletion]	1.0	2	2	1	1
53090	1624	ag-induced T	[Ag-induced T]	1.0	2	1	0	0
53091	1624	oncogenic ras	[oncogenic Ras]	1.0	2	1	0	0
53092	1624	oncogenic rat	[oncogenic rats]	1.0	2	1	0	0
53093	1624	(54%) clone from the germinal centre	[(54%) clones from the germinal centre]	1.0	6	1	0	0
53094	1624	putative tissue-	[putative tissue-]	1.0	2	1	0	0
53095	1624	regulation of interleukin-1 beta production	[Regulation of interleukin-1 beta production]	1.0	5	1	0	0
53096	1624	activation of the interleukin IL-2 gene	[Activation of the interleukin IL-2 gene]	1.0	6	1	0	0
53097	1624	Twenty-two difference from the human sequence	[Twenty-two differences from the human sequence]	1.0	6	1	0	0
53098	1624	toxic side	[toxic side]	1.0	2	1	0	0
53099	1624	physiological target cell of ebv	[physiological target cells of EBV]	1.0	5	1	0	0
53100	1624	determination of dissociation constant kDa	[determination of dissociation constants kDa]	1.0	5	1	0	0
53101	1624	mediate signal from the TCR/CD3 complex	[mediating signals from the TCR/CD3 complex]	1.0	6	1	0	0
53102	1624	Th2 pathway	[Th2 pathway]	1.0	2	1	0	0
53103	1624	use a steroid binding assay SBA	[using a steroid binding assay SBA]	1.0	6	1	0	0
53104	1624	70.6 kd.	[70.6 kd.]	1.0	2	1	0	0
53105	1624	Z29 strain	[Z29 strain]	1.0	2	1	0	0
53106	1624	evidence for functional disomy of Xp.	[evidence for functional disomy of Xp.]	1.0	6	1	0	0
53107	1624	cell preparations.	[cell preparations.]	1.0	2	1	0	0
53108	1624	important role in defense mechanism	[important role in defense mechanisms]	1.0	5	1	0	0
53109	1624	key role define the pattern	[key role defining the pattern]	1.0	5	1	0	0
53110	1624	correspondence with common allelic variant	[correspondence with common allelic variants]	1.0	5	1	0	0
53111	1624	maximum activity	[maximum activity]	1.0	2	2	2	2
53112	1624	Itk mutant	[Itk mutant]	1.0	2	2	2	2
53113	1624	respect to hla-dr-constitutive b cell	[respect to HLA-DR-constitutive B cells]	1.0	5	1	0	0
53114	1624	immunocytochemistry for ad5 e1a protein	[immunocytochemistry for Ad5 E1A protein]	1.0	5	1	0	0
53115	1624	afternoon acth	[Afternoon ACTH]	1.0	2	1	0	0
53116	1624	mol wilometer	[mol wt]	1.0	2	1	0	0
53117	1624	cell in the human host	[cells in the human host]	1.0	5	1	0	0
53118	1624	therapeutic effect of liuwei dihuang pill	[therapeutic effect of liuwei dihuang pills]	1.0	6	1	0	0
53119	1624	lesion result	[Lesions resulting]	1.0	2	1	0	0
53120	1624	syncytia-forming activity of 8e51 cell	[syncytia-forming activity of 8e51 cells]	1.0	5	1	0	0
53121	1624	express macrophage cell surface ags	[expressing macrophage cell surface Ags]	1.0	5	1	0	0
53122	1624	component of a b complex	[component of a B complex]	1.0	5	1	0	0
53123	1624	(within 30 min) nf-kappa b	[(within 30 min) NF-kappa B]	1.0	5	1	0	0
53124	1624	promoter segment	[promoter segment]	1.0	2	1	0	0
53125	1624	different disorder	[different disorders]	1.0	2	2	2	2
53126	1624	several new, clinically relevant compound	[Several new, clinically relevant compounds]	1.0	5	1	0	0
53127	1624	basophil cell return to blood	[basophil cell return to blood]	1.0	5	1	0	0
53128	1624	megakaryoblastic transformation	[megakaryoblastic transformation]	1.0	2	1	0	0
53129	1624	major molecule	[major molecules]	1.0	2	1	0	0
53130	1624	stat5 with other signal pathway	[STAT5 with other signaling pathways]	1.0	5	1	0	0
53131	1624	contrast, glucocorticoid	[contrast, glucocorticoids]	1.0	2	1	0	0
53132	1624	development of chronic eosinophilic inflammation	[development of chronic eosinophilic inflammation]	1.0	5	1	0	0
53133	1624	comparison to PHA-stimulated T lymphocyte	[comparison to PHA-stimulated T lymphocytes]	1.0	5	1	0	0
53134	1624	allele distribution	[allele distributions]	1.0	2	1	0	0
53135	1624	antibody from patient with hepatitis	[antibodies from patients with hepatitis]	1.0	5	1	0	0
53136	1624	trend of molecular biology study	[trend of molecular biology study]	1.0	5	1	0	0
53137	1624	viral gene in b cell	[viral genes in B cells]	1.0	5	1	0	0
53138	1624	concentration of endogenous gm-csf mrna	[concentration of endogenous GM-CSF mRNA]	1.0	5	1	0	0
53139	1624	Reverse transcriptase-polymerase chain reaction rt-pcr	[Reverse transcriptase-polymerase chain reaction RT-PCR]	1.0	5	1	0	0
53140	1624	interfere with the activity of protein	[interfering with the activity of proteins]	1.0	6	1	0	0
53141	1624	Jak 2 -STAT 1 pathway	[Jak 2 -STAT 1 pathway]	1.0	5	1	0	0
53142	1624	distribution of m (igm)-, igd-,	[distribution of M (IgM)-, IgD-,]	1.0	5	1	0	0
53143	1624	short-term effect	[short-term effects]	1.0	2	2	2	2
53144	1624	20 nmol/l, incubation time 2 h	[20 nmol/l, incubation time 2 h]	1.0	6	1	0	0
53145	1624	primary regulator	[primary regulator]	1.0	2	2	2	2
53146	1624	induce transcription through il-6-responsive element	[inducing transcription through IL-6-responsive elements]	1.0	5	1	0	0
53147	1624	CONCLUSIONS: Flutamide	[CONCLUSIONS: Flutamide]	1.0	2	1	0	0
53148	1624	ikk complex protein stimulus-mediated transcription,	[IKK complex protein stimulus-mediated transcription,]	1.0	5	1	0	0
53149	1624	degree similar	[degree similar]	1.0	2	1	0	0
53150	1624	only low level of this protein	[only low levels of this protein]	1.0	6	1	0	0
53151	1624	this, wild-type	[this, wild-type]	1.0	2	1	0	0
53152	1624	interleukin-1beta il-1beta in non-monocytic cells,	[interleukin-1beta IL-1beta in non-monocytic cells,]	1.0	5	1	0	0
53153	1624	basal gonadotropin	[basal gonadotropins]	1.0	2	1	0	0
53154	1624	acid-synthesizing enzyme	[acid-synthesizing enzyme]	1.0	2	1	0	0
53155	1624	expression of several inflammatory cytokine	[expression of several inflammatory cytokines]	1.0	5	1	0	0
53156	1624	aqueous phenol	[aqueous phenol]	1.0	2	1	0	0
53157	1624	hes-1 transcript in T cell	[HES-1 transcripts in T cells]	1.0	5	1	0	0
53158	1624	purpose of the present study	[purpose of the present study]	1.0	5	1	0	0
53159	1624	LTR activity	[LTR activity]	1.0	2	2	2	2
53160	1624	extensive sequence	[extensive sequence]	1.0	2	2	2	2
53161	1624	ifn-responsive gene	[IFN-responsive genes]	1.0	2	1	0	0
53162	1624	leukemic transformation.	[leukemic transformation.]	1.0	2	1	0	0
53163	1624	ppt i-te	[ppt I-TE]	1.0	2	2	2	2
53164	1624	epo signal for erythroid differentiation	[EPO signal for erythroid differentiation]	1.0	5	1	0	0
53165	1624	weight loss	[weight loss]	1.0	2	1	0	0
53166	1624	potential antagonism	[potential antagonism]	1.0	2	1	0	0
53167	1624	unstimulated pbl from different donor	[unstimulated PBL from different donors]	1.0	5	1	0	0
53168	1624	suggest a positive feedback loop	[suggesting a positive feedback loop]	1.0	5	1	0	0
53169	1624	somewhat divergent region of STP-C488	[somewhat divergent region of STP-C488]	1.0	5	1	0	0
53170	1624	charybdotoxin a inhibitor of K+ channel	[charybdotoxin a inhibitor of K+ channels]	1.0	6	1	0	0
53171	1624	70 nm,	[70 nM,]	1.0	2	1	0	0
53172	1624	part of a locus control region	[part of a locus control region]	1.0	6	1	0	0
53173	1624	human cDNA	[human cDNA]	1.0	2	2	2	2
53174	1624	coding for 216 amino acid	[coding for 216 amino acids]	1.0	5	1	0	0
53175	1624	Ad2/Ad12 hybrid e1a gene product	[Ad2/Ad12 hybrid E1A gene product]	1.0	5	1	0	0
53176	1624	regulate stat serine phosphorylation in response	[regulating STAT serine phosphorylation in response]	1.0	6	1	0	0
53177	1624	critical role in monocytic differentiation	[critical roles in monocytic differentiation]	1.0	5	1	0	0
53178	1624	tyrosine phosphatase inhibitor phenylarsine oxide	[tyrosine phosphatase inhibitor phenylarsine oxide]	1.0	5	1	0	0
53179	1624	modulate the yield and/or the function	[modulating the yield and/or the function]	1.0	6	1	0	0
53180	1624	subclone Wurzburg cell oxidant challenge [ca2+]i	[subclone Wurzburg cells oxidant challenge [Ca2+]i]	1.0	6	1	0	0
53181	1624	functional release	[functional release]	1.0	2	1	0	0
53182	1624	9 woman	[9 women]	1.0	2	1	0	0
53183	1624	EC alone	[EC alone]	1.0	2	1	0	0
53184	1624	Mutagenesis of the CKII site	[Mutagenesis of the CKII site]	1.0	5	1	0	0
53185	1624	activation cascade.	[activation cascade.]	1.0	2	1	0	0
53186	1624	mouse pro-B cell line Baf-3	[mouse pro-B cell lines Baf-3]	1.0	5	1	0	0
53187	1624	upregulation of protein expression by IFN-alpha	[upregulation of protein expression by IFN-alpha]	1.0	6	1	0	0
53188	1624	mutant of this kinase gamma B*CaM-K	[mutants of these kinases gamma B*CaM-K]	1.0	6	1	0	0
53189	1624	effect in the line Jurkat	[effect in the line Jurkat]	1.0	5	1	0	0
53190	1624	bind competition by bhlh protein	[binding competition by bHLH proteins]	1.0	5	1	0	0
53191	1624	growth, differentiation, death, of cell	[growth, differentiation, death, of cells]	1.0	5	1	0	0
53192	1624	57.1 dpm mg-1 cytosol protein	[57.1 dpm mg-1 cytosol protein]	1.0	5	1	0	0
53193	1624	elderly donors.	[elderly donors.]	1.0	2	1	0	0
53194	1624	follow irradiation PML/RARalpha transgenic mouse	[Following irradiation PML/RARalpha transgenic mice]	1.0	5	1	0	0
53195	1624	Differential regulation of coproporphyrinogen oxidase gene	[Differential regulation of coproporphyrinogen oxidase gene]	1.0	6	1	0	0
53196	1624	gh-n gene	[GH-N gene]	1.0	2	1	0	0
53197	1624	level of the nf-at complex	[levels of the NF-AT complex]	1.0	5	1	0	0
53198	1624	epo -dependent differentiation in primary erythroblast	[Epo -dependent differentiation in primary erythroblasts]	1.0	6	1	0	0
53199	1624	pcd41 clone	[pCD41 clone]	1.0	2	2	1	1
53200	1624	reduce the intracellular oxidant stress	[reducing the intracellular oxidant stress]	1.0	5	1	0	0
53201	1624	interleukin-8 gene	[interleukin-8 gene]	1.0	2	1	0	0
53202	1624	monocytic expression	[monocytic expression]	1.0	2	1	0	0
53203	1624	investigation of the cellular event	[investigation of the cellular events]	1.0	5	1	0	0
53204	1624	PGE2 activation effect on hiv-1 transcription	[PGE2 activation effect on HIV-1 transcription]	1.0	6	1	0	0
53205	1624	protein tbp	[protein TBP]	1.0	2	1	0	0
53206	1624	anti-DNA antibody	[anti-DNA antibodies]	1.0	2	1	0	0
53207	1624	19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione (13).	[19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione (13).]	1.0	2	1	0	0
53208	1624	Cooperation between core binding factor	[Cooperation between core binding factor]	1.0	5	1	0	0
53209	1624	avidin-biotin complex	[avidin-biotin complex]	1.0	2	1	0	0
53210	1624	35 kD	[35 kD]	1.0	2	1	0	0
53211	1624	erk activation in t-cell line	[ERK activation in T-cell lines]	1.0	5	1	0	0
53212	1624	pediatric age	[pediatric age]	1.0	2	1	0	0
53213	1624	MDHM elevation of cytokine mrna level	[MDHM elevation of cytokine mRNA levels]	1.0	6	1	0	0
53214	1624	various mechanisms.	[various mechanisms.]	1.0	2	1	0	0
53215	1624	response to il-4 receptor stimulation	[response to IL-4 receptor stimulation]	1.0	5	1	0	0
53216	1624	determine the TCR beta chain sequence	[determining the TCR beta chain sequences]	1.0	6	1	0	0
53217	1624	bhrf1 in ebv epithelial cell	[BHRF1 in EBV epithelial cells]	1.0	5	1	0	0
53218	1624	m dexamethasone	[M dexamethasone]	1.0	2	2	2	2
53219	1624	expression of the monocyte-macrophage ag	[expression of the monocyte-macrophage Ag]	1.0	5	1	0	0
53220	1624	GATA family	[GATA family]	1.0	2	2	1	1
53221	1624	10 minutes.	[10 minutes.]	1.0	2	1	0	0
53222	1624	variant thereof	[variants thereof]	1.0	2	1	0	0
53223	1624	transcription-activating domain	[transcription-activating domain]	1.0	2	1	0	0
53224	1624	ifn-gamma-treated cell	[IFN-gamma-treated cells]	1.0	2	2	1	1
53225	1624	mAb okt3	[mAb OKT3]	1.0	2	1	0	0
53226	1624	positive regulation in b-cell line	[positive regulation in B-cell lines]	1.0	5	1	0	0
53227	1624	vaccine design	[vaccine design]	1.0	2	1	0	0
53228	1624	very high level of exogenous bcl-2	[very high levels of exogenous Bcl-2]	1.0	6	1	0	0
53229	1624	human u937	[human U937]	1.0	2	1	0	0
53230	1624	B-cell chronic lymphocytic leukemia CLL	[B-cell chronic lymphocytic leukemia CLL]	1.0	5	1	0	0
53231	1624	daily dose	[daily dose]	1.0	2	2	2	2
53232	1624	inhibition replication	[Inhibition replication]	1.0	2	2	2	2
53233	1624	mutant form of the human protein	[mutant forms of the human protein]	1.0	6	1	0	0
53234	1624	LAZ3/BCL6 transcript	[LAZ3/BCL6 transcript]	1.0	2	1	0	0
53235	1624	mediate immune responsiveness in the cns	[mediating immune responsiveness in the CNS]	1.0	6	1	0	0
53236	1624	thrombin (auc of 260 +/-	[thrombin (AUC of 260 +/-]	1.0	5	1	0	0
53237	1624	non-significant trend towards a down-regulation	[non-significant trend towards a down-regulation]	1.0	5	1	0	0
53238	1624	tax express T cell line	[Tax expressing T cell lines]	1.0	5	1	0	0
53239	1624	pathological condition	[pathological conditions]	1.0	2	2	2	2
53240	1624	cell type-specificity of gene expression	[cell type-specificity of gene expression]	1.0	5	1	0	0
53241	1624	thp-1 cell with gamma-interferon gamma-ifn	[THP-1 cells with gamma-interferon gamma-IFN]	1.0	5	1	0	0
53242	1624	strong transactivation of this promoter	[strong transactivation of these promoters]	1.0	5	1	0	0
53243	1624	Spi-B function	[Spi-B function]	1.0	2	1	0	0
53244	1624	patient with early rheumatoid arthritis	[patients with early rheumatoid arthritis]	1.0	5	1	0	0
53245	1624	CD2 pathway	[CD2 pathway]	1.0	2	1	0	0
53246	1624	dual enzyme inhibitor of cyclooxygenase	[dual enzyme inhibitor of cyclooxygenase]	1.0	5	1	0	0
53247	1624	lbp group	[LBP group]	1.0	2	1	0	0
53248	1624	(8;21)(q22;q22) translocation	[(8;21)(q22;q22) translocations]	1.0	2	1	0	0
53249	1624	hiv-1 viral burden in monocyte	[HIV-1 viral burden in monocytes]	1.0	5	1	0	0
53250	1624	chronological sequence of biochemical event	[chronological sequence of biochemical events]	1.0	5	1	0	0
53251	1624	inflammatory effect of gamma-ifn signal	[inflammatory effects of gamma-IFN signaling]	1.0	5	1	0	0
53252	1624	whole genome.	[whole genome.]	1.0	2	1	0	0
53253	1624	nuclear factor of T lymphocyte	[nuclear factor of T lymphocytes]	1.0	5	2	1	1
53254	1624	autosomal recessive pattern of inheritance	[autosomal recessive pattern of inheritance]	1.0	5	1	0	0
53255	1624	analysis of mouse strain with defect	[Analyses of mouse strains with defects]	1.0	6	1	0	0
53256	1624	(pebp2/cbf) family	[(PEBP2/CBF) family]	1.0	2	1	0	0
53257	1624	induction of apoptosis of mononucleated cell	[Induction of apoptosis of mononucleated cells]	1.0	6	1	0	0
53258	1624	Rex function	[Rex function]	1.0	2	2	2	2
53259	1624	competition with a ap-1 motif	[Competition with an AP-1 motif]	1.0	5	1	0	0
53260	1624	protein tp1	[protein TP1]	1.0	2	1	0	0
53261	1624	TCL1 oncogene expression in aids-related lymphoma	[TCL1 oncogene expression in AIDS-related lymphomas]	1.0	6	1	0	0
53262	1624	transcription of the -137 element	[transcription of the -137 element]	1.0	5	1	0	0
53263	1624	expression of tumor necrosis factor-responsive gene	[expression of tumor necrosis factor-responsive genes]	1.0	6	1	0	0
53264	1624	family with x-linked spinal atrophy	[families with X-linked spinal atrophy]	1.0	5	1	0	0
53265	1624	transcription factor bind to this sequence	[transcription factors binding to this sequence]	1.0	6	1	0	0
53266	1624	Ki-67 antigen in single tumor cell	[Ki-67 antigens in single tumor cells]	1.0	6	1	0	0
53267	1624	contain low level of nf-kappab	[containing low levels of NF-kappaB]	1.0	5	1	0	0
53268	1624	32 hours.	[32 hours.]	1.0	2	1	0	0
53269	1624	binding activity of transcription factor	[binding activities of transcription factors]	1.0	5	1	0	0
53270	1624	other myelomonocytic cell specific gene	[other myelomonocytic cell specific genes]	1.0	5	1	0	0
53271	1624	Time-course study	[Time-course studies]	1.0	2	1	0	0
53272	1624	HLA-DRA promoter	[HLA-DRA promoter]	1.0	2	1	0	0
53273	1624	autocrine secretion	[autocrine secretion]	1.0	2	1	0	0
53274	1624	e2f-1 activity	[E2F-1 activity]	1.0	2	1	0	0
53275	1624	CD18 antigen	[CD18 antigen]	1.0	2	1	0	0
53276	1624	manage further setting of vascular pathology	[managing further settings of vascular pathology]	1.0	6	1	0	0
53277	1624	namely c-rel	[namely c-rel]	1.0	2	1	0	0
53278	1624	major focus of this research	[major focus of this research]	1.0	5	1	0	0
53279	1624	other cases.	[other cases.]	1.0	2	2	1	1
53280	1624	Sjogren' syndrome related antigen la(ssb)	[Sjogren's syndrome related antigen La(SSB)]	1.0	5	1	0	0
53281	1624	encode hepatocyte nuclear factor -3alpha	[encoding hepatocyte nuclear factor -3alpha]	1.0	5	1	0	0
53282	1624	intermediate stage of erythroid differentiation	[intermediate stages of erythroid differentiation]	1.0	5	1	0	0
53283	1624	aberrancy in transcriptional regulatory protein	[aberrancies in transcriptional regulatory proteins]	1.0	5	1	0	0
53284	1624	control level.	[control level.]	1.0	2	1	0	0
53285	1624	long persistence of reactive CTL clone	[long-term persistence of reactive CTL clones]	1.0	6	1	0	0
53286	1624	promoter activity in cell type	[promoter activity in cell types]	1.0	5	1	0	0
53287	1624	vaccinia vector	[vaccinia vector]	1.0	2	1	0	0
53288	1624	normal cd56+, cd16- NK precursor cell	[normal CD56+, CD16- NK precursor cells]	1.0	6	1	0	0
53289	1624	cell line express the dominant ikappab	[cell lines expressing the dominant IkappaB]	1.0	6	1	0	0
53290	1624	nf-atc tad-a	[NF-ATc TAD-A]	1.0	2	1	0	0
53291	1624	granulocyte macrophage-CSF	[granulocyte macrophage-CSF]	1.0	2	1	0	0
53292	1624	subsequently respond to ifn-alpha therapy	[subsequently responding to IFN-alpha therapy]	1.0	5	1	0	0
53293	1624	lymphocyte lysis	[lymphocyte lysis]	1.0	2	1	0	0
53294	1624	primary human T lymphocyte with	[primary human T lymphocytes with]	1.0	5	1	0	0
53295	1624	study of affinity for glucocorticosteroids	[study of affinity for glucocorticosteroids]	1.0	5	1	0	0
53296	1624	endogenous no production by L-N-monomethyl-arginine	[endogenous NO production by L-N-monomethyl-arginine]	1.0	5	1	0	0
53297	1624	preincubated cells,	[preincubated cells,]	1.0	2	1	0	0
53298	1624	interleukin-2 receptor expression in phagocyte	[interleukin-2 receptor expression in phagocytes]	1.0	5	1	0	0
53299	1624	CD40 antigen expression of lymphocyte	[CD40 antigen expression of lymphocytes]	1.0	5	1	0	0
53300	1624	Glucocorticoid receptor in cord blood lymphocyte	[Glucocorticoid receptors in cord blood lymphocytes]	1.0	6	1	0	0
53301	1624	second transformation	[second transformation]	1.0	2	1	0	0
53302	1624	leukocyte of patient with sle	[leukocytes of patients with SLE]	1.0	5	1	0	0
53303	1624	effective therapy of hiv-1 infection	[effective therapy of HIV-1 infection]	1.0	5	1	0	0
53304	1624	cos cell express gata-binding protein	[COS cells expressing GATA-binding proteins]	1.0	5	1	0	0
53305	1624	cdk6 construct	[cdk6 constructs]	1.0	2	1	0	0
53306	1624	GM-CSF locus	[GM-CSF locus]	1.0	2	1	0	0
53307	1624	absence of absorbance maxima shift	[absence of absorbance maxima shifts]	1.0	5	1	0	0
53308	1624	stimulatory g	[stimulatory G]	1.0	2	1	0	0
53309	1624	t-cell activation by cognate antigen	[T-cell activation by cognate antigen]	1.0	5	1	0	0
53310	1624	BMRF1 promoter	[BMRF1 promoter]	1.0	2	3	2	1
53311	1624	addition of oxygen scavenger enzyme	[addition of oxygen scavenger enzymes]	1.0	5	1	0	0
53312	1624	60 min.	[60 min.]	1.0	2	1	0	0
53313	1624	one signal	[one signal]	1.0	2	2	1	1
53314	1624	role of the gr isoform	[roles of the GR isoforms]	1.0	5	1	0	0
53315	1624	CD34 promoter	[CD34 promoter]	1.0	2	2	1	1
53316	1624	former works,	[former works,]	1.0	2	1	0	0
53317	1624	localize cis-element responsible for the regulation	[localizing cis-elements responsible for the regulation]	1.0	6	1	0	0
53318	1624	glucocorticoid gcs	[Glucocorticoids GCS]	1.0	2	1	0	0
53319	1624	excessive lyonization of normal cell	[excessive lyonization of normal cells]	1.0	5	1	0	0
53320	1624	human activation	[human activation]	1.0	2	1	0	0
53321	1624	cell localization of GCRbeta expression	[Cell localization of GCRbeta expression]	1.0	5	1	0	0
53322	1624	hdac-containing repressor	[HDAC-containing repressor]	1.0	2	1	0	0
53323	1624	tcf-controlled transcription	[Tcf-controlled transcription]	1.0	2	1	0	0
53324	1624	myeloid precursor cell line hl60	[myeloid precursor cell lines HL60]	1.0	5	1	0	0
53325	1624	sequence similarity to the site GAS	[sequence similarity to the site GAS]	1.0	6	1	0	0
53326	1624	Furthermore, recruitment of EKLF to 5'HS3	[Furthermore, recruitment of EKLF to 5'HS3]	1.0	6	1	0	0
53327	1624	dominant negative version of TRAF6	[dominant negative version of TRAF6]	1.0	5	1	0	0
53328	1624	susceptibility to NK cell killing	[susceptibility to NK cell killing]	1.0	5	1	0	0
53329	1624	PML/ RARalpha	[PML/ RARalpha]	1.0	2	1	0	0
53330	1624	molecular link between microbial product	[molecular link between microbial products]	1.0	5	1	0	0
53331	1624	important component of the mechanism	[important component of the mechanism]	1.0	5	1	0	0
53332	1624	RA change in the expression	[RA changes in the expression]	1.0	5	1	0	0
53333	1624	strong ca2+ response to h2o2	[strong Ca2+ responses to H2O2]	1.0	5	1	0	0
53334	1624	cell with drug resistant marker Neo(r)	[cells with drug resistant marker Neo(r)]	1.0	6	1	0	0
53335	1624	upstream nuclear factor-kappa b NF-kappa b	[upstream nuclear factor-kappa B NF-kappa B]	1.0	6	1	0	0
53336	1624	intragenic tsg101 deletion in rna transcript	[Intragenic TSG101 deletions in RNA transcripts]	1.0	6	1	0	0
53337	1624	ifn-gamma-inducible gene	[IFN-gamma-inducible genes]	1.0	2	1	0	0
53338	1624	all-tran retinoic acid atra washed,	[all-trans retinoic acid ATRA washed,]	1.0	5	1	0	0
53339	1624	cd4+ lymphocyte supt in culture	[CD4+ lymphocytes SupT in culture]	1.0	5	1	0	0
53340	1624	ligand-induced degradation,	[ligand-induced degradation,]	1.0	2	1	0	0
53341	1624	ig loci	[Ig loci]	1.0	2	1	0	0
53342	1624	genetic level	[genetic level]	1.0	2	1	0	0
53343	1624	proper expression of the gene	[Proper expression of the genes]	1.0	5	1	0	0
53344	1624	subtoxic concentration	[subtoxic concentrations]	1.0	2	1	0	0
53345	1624	large subunit	[large subunit]	1.0	2	1	0	0
53346	1624	5' deletion CD20 promoter-CAT construct	[5' deletion CD20 promoter-CAT constructs]	1.0	5	1	0	0
53347	1624	immediate-early transcript	[immediate-early transcripts]	1.0	2	2	1	1
53348	1624	hbb transcription	[HBB transcription]	1.0	2	1	0	0
53349	1624	active suppression	[active suppression]	1.0	2	2	1	1
53350	1624	ro 09-2210	[Ro 09-2210]	1.0	2	1	0	0
53351	1624	Preclinical study	[Preclinical studies]	1.0	2	1	0	0
53352	1624	interact with the DNA sequence	[interacting with the DNA sequence]	1.0	5	1	0	0
53353	1624	recent definition	[recent definition]	1.0	2	1	0	0
53354	1624	human placentae	[human placentae]	1.0	2	1	0	0
53355	1624	encode a seven transmembrane receptor	[encoding a seven transmembrane receptor]	1.0	5	1	0	0
53356	1624	treatment period	[treatment period]	1.0	2	2	1	1
53357	1624	percentage of the t/nk-cell subset	[percentages of the T/NK-cell subsets]	1.0	5	1	0	0
53358	1624	down-regulation of progenitor-specific surface marker	[down-regulation of progenitor-specific surface markers]	1.0	5	1	0	0
53359	1624	60 mM	[60 mM]	1.0	2	1	0	0
53360	1624	addition to the TATA box	[addition to the TATA box]	1.0	5	1	0	0
53361	1624	pbmc receptor for Dihydroxyvitamin D3	[PBMC receptors for Dihydroxyvitamin D3]	1.0	5	1	0	0
53362	1624	sequence of the small subunit	[sequence of the smallest subunit]	1.0	5	1	0	0
53363	1624	cd11b gene	[CD11b gene]	1.0	2	4	3	1
53364	1624	promoter activity in erythroid cell	[promoter activity in erythroid cells]	1.0	5	1	0	0
53365	1624	h5 promoter	[H5 promoter]	1.0	2	1	0	0
53366	1624	involvement of mitogen-activated protein kinase pathway	[Involvement of mitogen-activated protein kinase pathways]	1.0	6	1	0	0
53367	1624	acetyltransferase (cat)	[acetyltransferase (CAT)]	1.0	2	2	1	1
53368	1624	moreover, TCR phosphorylation of pp36-38	[Moreover, TCR phosphorylation of pp36-38]	1.0	5	1	0	0
53369	1624	further study of the molecular defect(s)	[further study of the molecular defect(s)]	1.0	6	1	0	0
53370	1624	promoter of stat5 target gene	[promoters of STAT5 target genes]	1.0	5	1	0	0
53371	1624	H5sub304 infection of cref cell	[H5sub304 infection of CREF cells]	1.0	5	1	0	0
53372	1624	age activity	[age activity]	1.0	2	2	2	2
53373	1624	pkr activity,	[PKR activity,]	1.0	2	1	0	0
53374	1624	p40 promoter	[p40 promoter]	1.0	2	1	0	0
53375	1624	additional difference in stat induction pattern	[additional differences in STAT induction patterns]	1.0	6	1	0	0
53376	1624	transcription of the c-fo gene	[transcription of the c-fos gene]	1.0	5	2	1	1
53377	1624	SL3 core	[SL3 core]	1.0	2	2	1	1
53378	1624	megakaryocytic enhancer in the 5' flank	[megakaryocytic enhancers in the 5' flank]	1.0	6	1	0	0
53379	1624	six patient with steroid-sensitive asthma	[six patients with steroid-sensitive asthma]	1.0	5	1	0	0
53380	1624	change in the composition ap-1	[changes in the composition AP-1]	1.0	5	1	0	0
53381	1624	il-2 receptor expression on T cell	[IL-2 receptor expression on T cells]	1.0	6	1	0	0
53382	1624	western immunoblot	[Western immunoblots]	1.0	2	1	0	0
53383	1624	oral tolerance	[oral tolerance]	1.0	2	1	0	0
53384	1624	tumor cell from malignant effusion	[tumor cells from malignant effusions]	1.0	5	1	0	0
53385	1624	control subclone	[control subclone.]	1.0	2	1	0	0
53386	1624	c-jun mrna expression by hydroxyurea	[c-jun mRNA expression by hydroxyurea]	1.0	5	1	0	0
53387	1624	latter compound	[latter compounds]	1.0	2	1	0	0
53388	1624	point assay	[point assay]	1.0	2	2	2	2
53389	1624	molecular mechanism of fasl regulation	[molecular mechanisms of FasL regulation]	1.0	5	1	0	0
53390	1624	p65 p50 NF-kappa b component	[p65 p50 NF-kappa B components]	1.0	5	1	0	0
53391	1624	basis for a fast assay	[basis for a faster assay]	1.0	5	1	0	0
53392	1624	novel regulatory role for nno	[novel regulatory role for nNOS]	1.0	5	1	0	0
53393	1624	binding consistent with two site	[binding consistent with two sites]	1.0	5	1	0	0
53394	1624	control donor	[control donors]	1.0	2	2	2	2
53395	1624	TRAF2 a signal transduction molecule	[TRAF2 a signal transduction molecule]	1.0	5	1	0	0
53396	1624	however, mutation of the pu box	[However, mutation of the PU box]	1.0	6	1	0	0
53397	1624	suppressor activity	[suppressor activity]	1.0	2	2	1	1
53398	1624	mouse AML1/ pebp2 alpha b	[mouse AML1/ PEBP2 alpha B]	1.0	5	1	0	0
53399	1624	thus, erythroid development of m-tat cell	[Thus, erythroid development of M-TAT cells]	1.0	6	1	0	0
53400	1624	characteristic of a transcriptional 'silencer'	[characteristics of a transcriptional 'silencer']	1.0	5	1	0	0
53401	1624	splenic b	[splenic B]	1.0	2	2	2	2
53402	1624	aldosterone action,	[aldosterone action,]	1.0	2	1	0	0
53403	1624	age dependence of risk factor	[age dependence of risk factors]	1.0	5	1	0	0
53404	1624	cell death in lymphoid cell	[cell death in lymphoid cells]	1.0	5	1	0	0
53405	1624	deplete neutrophil from SCID-HU-INT mouse	[depleting neutrophils from SCID-HU-INT mice]	1.0	5	1	0	0
53406	1624	inhibition by il-10 of cytokine release	[Inhibition by IL-10 of cytokine release]	1.0	6	1	0	0
53407	1624	2M-1 cell	[2M-1 cells]	1.0	2	2	2	2
53408	1624	N-Myc interactor	[N-Myc interactor]	1.0	2	1	0	0
53409	1624	mrna encoding	[mRNA encoding]	1.0	2	2	2	2
53410	1624	nf-kappab element	[NF-kappaB element]	1.0	2	2	1	1
53411	1624	(kappa B) enhancer binding protein	[(kappa B) enhancer binding proteins]	1.0	5	1	0	0
53412	1624	fact, transgenic bone marrow cell	[fact, transgenic bone marrow cells]	1.0	5	1	0	0
53413	1624	HB9 gene	[HB9 gene]	1.0	2	1	0	0
53414	1624	cellular permissivity	[cellular permissivity]	1.0	2	1	0	0
53415	1624	third site	[third site]	1.0	2	1	0	0
53416	1624	apparent expression	[apparent expression]	1.0	2	2	2	2
53417	1624	model for a feedback mechanism	[model for a feedback mechanism]	1.0	5	1	0	0
53418	1624	upper layer	[upper layer]	1.0	2	1	0	0
53419	1624	hlh protein	[HLH proteins]	1.0	2	2	1	1
53420	1624	signal originate from tissue cell	[signals originating from tissue cells]	1.0	5	1	0	0
53421	1624	molecular mechanism of transcriptional control	[molecular mechanisms of transcriptional control]	1.0	5	1	0	0
53422	1624	efficient delivery vehicle for cytokine	[efficient delivery vehicle for cytokines]	1.0	5	1	0	0
53423	1624	restriction endonuclease	[restriction endonucleases]	1.0	2	1	0	0
53424	1624	use kappaB- Sp1 concatamer -295	[using kappaB- Sp1 concatamers -295]	1.0	5	1	0	0
53425	1624	egr-1 promoter	[egr-1 promoter]	1.0	2	1	0	0
53426	1624	release of up ng/ml il-8	[release of up ng/ml IL-8]	1.0	5	1	0	0
53427	1624	il-1 receptor nf-kappab signal cascade	[IL-1 receptor NF-kappaB signaling cascade]	1.0	5	1	0	0
53428	1624	mrna degradation	[mRNA degradation]	1.0	2	1	0	0
53429	1624	same interval.	[same interval.]	1.0	2	1	0	0
53430	1624	native ability	[native abilities]	1.0	2	1	0	0
53431	1624	cellular mechanism of ifn-gamma production	[Cellular mechanisms of IFN-gamma production]	1.0	5	1	0	0
53432	1624	positive autoregulation in 6tg1.1 cell	[positive autoregulation in 6TG1.1 cells]	1.0	5	1	0	0
53433	1624	product p50	[product p50]	1.0	2	1	0	0
53434	1624	expression of the impdh type gene	[expression of the IMPDH type gene]	1.0	6	1	0	0
53435	1624	lps expression	[LPS expression]	1.0	2	2	1	1
53436	1624	monocytic leukemia cell line thp-1	[monocytic leukemia cell line THP-1]	1.0	5	2	2	2
53437	1624	N-WASP Arp2/3	[N-WASP Arp2/3]	1.0	2	1	0	0
53438	1624	Fusion protein present in leukemic cell	[Fusion proteins present in leukemic cells]	1.0	6	1	0	0
53439	1624	heat shock element-cont reporter construct	[heat shock element-containing reporter construct]	1.0	5	1	0	0
53440	1624	different tissues.	[different tissues.]	1.0	2	1	0	0
53441	1624	three child	[three children]	1.0	2	2	2	2
53442	1624	translocation near the rhombotin gene	[translocations near the rhombotin gene]	1.0	5	1	0	0
53443	1624	inhibitor of protein (map) kinase	[inhibitor of protein (MAP) kinase]	1.0	5	1	0	0
53444	1624	simian immunodeficiency virus SIVmac251 in vitro.	[simian immunodeficiency virus SIVmac251 in vitro.]	1.0	6	1	0	0
53445	1624	transcriptionally active creb protein p-creb	[transcriptionally active CREB protein P-CREB]	1.0	5	1	0	0
53446	1624	IL-2 mrna expression of c-fo	[IL-2 mRNA expression of c-fos]	1.0	5	1	0	0
53447	1624	nuclear extract of mouse astrocyte	[nuclear extracts of mouse astrocytes]	1.0	5	1	0	0
53448	1624	GP Ib alpha promoter activity	[GP Ib alpha promoter activity]	1.0	5	1	0	0
53449	1624	vitro of the IL-2mRNA synthesis	[vitro of the IL-2mRNA synthesis]	1.0	5	1	0	0
53450	1624	aids -related Epstein-Barr virus EBV	[AIDS -related Epstein-Barr virus EBV]	1.0	5	1	0	0
53451	1624	Raf-1 protein	[Raf-1 protein]	1.0	2	1	0	0
53452	1624	ligand-induced activation of signal-transduce smad protein	[ligand-induced activation of signal-transducing Smad proteins]	1.0	6	1	0	0
53453	1624	alpha thf/thf (0.35; n: 0.92+/-0.42) ratios.	[alpha THF/THF (0.35; N: 0.92+/-0.42) ratios.]	1.0	6	1	0	0
53454	1624	direct inhibition of K+ channel	[direct inhibition of K+ channels]	1.0	5	1	0	0
53455	1624	activation of the IL-1RI kinase	[activation of the IL-1RI kinase]	1.0	5	1	0	0
53456	1624	synthesis of type I interferon	[synthesis of type I interferon]	1.0	5	1	0	0
53457	1624	other organism	[other organisms,]	1.0	2	1	0	0
53458	1624	activation of the tcrg enhancer	[activation of the TCRG enhancer]	1.0	5	1	0	0
53459	1624	interaction between hugata-3 transcription factor	[interactions between huGATA-3 transcription factor]	1.0	5	1	0	0
53460	1624	Germline transcript	[Germline transcripts]	1.0	2	1	0	0
53461	1624	novel cDNA clone (1.8 kb)	[novel cDNA clone (1.8 kb)]	1.0	5	1	0	0
53462	1624	multiple nuclear factor binding motif	[multiple nuclear factor binding motifs]	1.0	5	1	0	0
53463	1624	corresponding to the C-terminal acidic domain	[corresponding to the C-terminal acidic domain]	1.0	6	1	0	0
53464	1624	60% decrease in the level	[60% decrease in the level]	1.0	5	1	0	0
53465	1624	Biochemical purification	[Biochemical purification]	1.0	2	1	0	0
53466	1624	7-o- glucuronide	[7-O- glucuronides]	1.0	2	1	0	0
53467	1624	important cytokine for b function	[important cytokine for B function]	1.0	5	1	0	0
53468	1624	sepsis syndrome	[sepsis syndrome]	1.0	2	2	1	1
53469	1624	Nuclear factor-kappaB induction in cd45ro+	[Nuclear factor-kappaB induction in CD45RO+]	1.0	5	1	0	0
53470	1624	dominant epitope	[dominant epitope]	1.0	2	1	0	0
53471	1624	contain transcription factor in lymphocyte differentiation	[containing transcription factors in lymphocyte differentiation]	1.0	6	1	0	0
53472	1624	front of a reporter gene	[front of a reporter gene]	1.0	5	1	0	0
53473	1624	induction with 12-o-tetradecanoylphorbol-13-acetate represses, gene expression	[induction with 12-O-tetradecanoylphorbol-13-acetate represses, gene expression]	1.0	6	1	0	0
53474	1624	otf-1 activation	[OTF-1 activation]	1.0	2	1	0	0
53475	1624	cell cytosol	[cell cytosol]	1.0	2	1	0	0
53476	1624	FL, follicle	[FL, follicles]	1.0	2	1	0	0
53477	1624	cell proliferation of CEM-C7 cell	[Cell proliferation of CEM-C7 cells]	1.0	5	1	0	0
53478	1624	congenital absence of the receptor	[congenital absence of the receptor]	1.0	5	1	0	0
53479	1624	mechanism of action of BHRF1	[mechanism of action of BHRF1]	1.0	5	1	0	0
53480	1624	t (1;14)	[t (1;14)]	1.0	2	1	0	0
53481	1624	active cn	[active CN]	1.0	2	1	0	0
53482	1624	3 factor	[3 factor]	1.0	2	2	2	2
53483	1624	DNA recombination	[DNA recombination]	1.0	2	2	1	1
53484	1624	3' site	[3' site]	1.0	2	2	2	2
53485	1624	human adult erythroid cell haec	[human adult erythroid cell hAEC]	1.0	5	1	0	0
53486	1624	even in the absence of cyclosporin	[even in the absence of cyclosporin]	1.0	6	1	0	0
53487	1624	NIP site	[NIP site]	1.0	2	1	0	0
53488	1624	also for maintenance of transformation.	[also for maintenance of transformation.]	1.0	5	1	0	0
53489	1624	probability of disease-free survival idfs)	[probability of disease-free survival (DFS)]	1.0	5	1	0	0
53490	1624	peptide a class restriction element	[peptide a class restriction element]	1.0	5	1	0	0
53491	1624	cognate antigen	[cognate antigen]	1.0	2	1	0	0
53492	1624	abundant receptor	[abundant receptors]	1.0	2	1	0	0
53493	1624	mutation of the individual binding site	[mutation of the individual binding sites]	1.0	6	1	0	0
53494	1624	virtually all erythroid cell-specific gene	[virtually all erythroid cell-specific genes]	1.0	5	1	0	0
53495	1624	normal primitive myeloid progenitor cell	[normal primitive myeloid progenitor cells]	1.0	5	1	0	0
53496	1624	core histone at promoter site	[core histones at promoter sites]	1.0	5	1	0	0
53497	1624	indicate common in monocytic maturation	[indicating common in monocytic maturation]	1.0	5	1	0	0
53498	1624	T cell expression of interleukin il-3	[T cell expression of interleukin IL-3]	1.0	6	1	0	0
53499	1624	same mutation	[same mutations]	1.0	2	2	1	1
53500	1624	IL-13 treatment of blood monocyte	[IL-13 treatment of blood monocytes]	1.0	5	1	0	0
53501	1624	chromosome 17p	[chromosome 17p]	1.0	2	1	0	0
53502	1624	high level of hb24 mrna	[high levels of HB24 mRNA]	1.0	5	1	0	0
53503	1624	role of this G region	[role of this G region]	1.0	5	1	0	0
53504	1624	major promoter for ebna expression	[major promoter for EBNA expression]	1.0	5	1	0	0
53505	1624	inhibitory kappaB-alpha	[inhibitory kappaB-alpha]	1.0	2	2	1	1
53506	1624	transcriptional defect	[transcriptional defect]	1.0	2	1	0	0
53507	1624	immunohistochemistry on a panel of tissue	[Immunohistochemistry on a panel of tissues]	1.0	6	1	0	0
53508	1624	analysis of il-2 alpha expression	[Analysis of IL-2 alpha expression]	1.0	5	1	0	0
53509	1624	regulation of human pml expression	[regulation of human PML expression]	1.0	5	1	0	0
53510	1624	C-terminal region of hiv-1 Tat	[C-terminal region of HIV-1 Tat]	1.0	5	1	0	0
53511	1624	common intermediate structure during deamidation	[common intermediate structure during deamidation]	1.0	5	1	0	0
53512	1624	ifn-gamma priming	[IFN-gamma priming]	1.0	2	2	2	2
53513	1624	molar ratio of hsf2-alpha isoform	[molar ratio of HSF2-alpha isoforms]	1.0	5	1	0	0
53514	1624	result of this activation process	[result of this activation process]	1.0	5	1	0	0
53515	1624	aids-related non-hodgkin'	[AIDS-related non-Hodgkin's]	1.0	2	1	0	0
53516	1624	enfeebled, hiv-1/siv	[enfeebled, HIV-1/SIV]	1.0	2	1	0	0
53517	1624	Functional analysis	[Functional analysis]	1.0	2	7	6	1
53518	1624	dramatic inhibition	[dramatic inhibition]	1.0	2	1	0	0
53519	1624	contain this ets-1 binding site	[containing this ets-1 binding site]	1.0	5	1	0	0
53520	1624	cellular adhesion	[cellular adhesion]	1.0	2	1	0	0
53521	1624	tumor necrosis factor granulocyte-macrophage colony-stimulating factor	[tumor necrosis factor granulocyte-macrophage colony-stimulating factor]	1.0	6	1	0	0
53522	1624	strong binding to double-stranded DNA	[strong binding to double-stranded DNA]	1.0	5	1	0	0
53523	1624	hominid evolution	[hominid evolution]	1.0	2	1	0	0
53524	1624	critical component of long outgrowth	[critical component of long-term outgrowth]	1.0	5	1	0	0
53525	1624	22-60 year	[22-60 yr]	1.0	2	1	0	0
53526	1624	Cdk2 function	[Cdk2 functions]	1.0	2	1	0	0
53527	1624	kappa enhancer	[kappa enhancers]	1.0	2	1	0	0
53528	1624	potential mechanism for this difference	[potential mechanism for these differences]	1.0	5	1	0	0
53529	1624	Chinese medicine	[Chinese medicine]	1.0	2	2	2	2
53530	1624	fluorescence chromosomal	[fluorescence chromosomal]	1.0	2	1	0	0
53531	1624	cp usage	[Cp usage]	1.0	2	1	0	0
53532	1624	c-fos-positive lymphocyte into tumor tissue	[c-fos-positive lymphocytes into tumor tissues]	1.0	5	1	0	0
53533	1624	anti-CD3/anti-CD28 mab	[anti-CD3/anti-CD28 mAb]	1.0	2	1	0	0
53534	1624	1,9-dideoxy forskolin	[1,9-dideoxy forskolin]	1.0	2	1	0	0
53535	1624	equivalent level of e1a protein	[equivalent levels of E1A proteins]	1.0	5	1	0	0
53536	1624	phenotype cd38+,	[phenotype CD38+,]	1.0	2	1	0	0
53537	1624	use reverse transcriptase polymerase chain reaction	[using reverse transcriptase polymerase chain reaction]	1.0	6	1	0	0
53538	1624	expression of tax1 a protein	[expression of tax1 a protein]	1.0	5	1	0	0
53539	1624	dimerization of NF-KB2 with RelA(p65)	[Dimerization of NF-KB2 with RelA(p65)]	1.0	5	1	0	0
53540	1624	series of 5' deletion derivative	[series of 5' deletion derivatives]	1.0	5	1	0	0
53541	1624	transient-transfection experiment	[Transient-transfection experiments]	1.0	2	2	1	1
53542	1624	CD4 coreceptor	[CD4 coreceptor]	1.0	2	2	1	1
53543	1624	protein kinase c lead to expression	[protein kinase C leading to expression]	1.0	6	1	0	0
53544	1624	interfere with mar-bp1 /enhancer interaction	[interfering with MAR-BP1 /enhancer interaction]	1.0	5	1	0	0
53545	1624	many genes,	[many genes,]	1.0	2	1	0	0
53546	1624	regulatory hierarchy	[regulatory hierarchy]	1.0	2	1	0	0
53547	1624	importance of the relative ratio	[importance of the relative ratio]	1.0	5	1	0	0
53548	1624	sequence similarity with the NF-kappa b	[sequence similarity with the NF-kappa B]	1.0	6	1	0	0
53549	1624	normally function	[normally functioning]	1.0	2	1	0	0
53550	1624	DQB X-box the DQB-W region	[DQB X-box the DQB-W region]	1.0	5	1	0	0
53551	1624	multiple proteins.	[multiple proteins.]	1.0	2	1	0	0
53552	1624	prognostic indicator	[prognostic indicator]	1.0	2	2	2	2
53553	1624	suppression of MHC class ii expression	[Suppression of MHC class II expression]	1.0	6	1	0	0
53554	1624	mapk p38	[MAPK p38]	1.0	2	1	0	0
53555	1624	direct analysis of this cell act	[Direct analysis of these cells acting]	1.0	6	1	0	0
53556	1624	gene in ctll-2 i.e. beta-casein	[genes in CTLL-2 i.e. beta-casein]	1.0	5	1	0	0
53557	1624	peptide sequence	[peptide sequence]	1.0	2	2	2	2
53558	1624	retinoid on leukemia cell line	[retinoids on leukemia cell lines]	1.0	5	1	0	0
53559	1624	intestinal epithelium	[intestinal epithelium]	1.0	2	2	1	1
53560	1624	histidine-rich putative zinc finger domain	[histidine-rich putative zinc finger domains]	1.0	5	1	0	0
53561	1624	early-response gene	[early-response genes]	1.0	2	1	0	0
53562	1624	primary isolate	[primary isolate]	1.0	2	2	2	2
53563	1624	chromosome 20q	[chromosome 20q]	1.0	2	1	0	0
53564	1624	melana/mart1+ mm	[MelanA/MART1+ MM]	1.0	2	1	0	0
53565	1624	genetic control	[genetic control]	1.0	2	1	0	0
53566	1624	BSAP site	[BSAP sites]	1.0	2	1	0	0
53567	1624	kinetic for virus contain mutation	[kinetics for viruses containing mutations]	1.0	5	1	0	0
53568	1624	PLB-IIIB cell	[PLB-IIIB cells]	1.0	2	1	0	0
53569	1624	many cell types, oct-2 expression	[many cell types, Oct-2 expression]	1.0	5	1	0	0
53570	1624	other IL-4 substrate include JAK1	[other IL-4 substrates including JAK1]	1.0	5	1	0	0
53571	1624	control reactvation of KSHV from latency.	[controlling reactvation of KSHV from latency.]	1.0	6	1	0	0
53572	1624	porcine serum	[porcine serum]	1.0	2	2	1	1
53573	1624	phenotype reversal of human th2 cell	[phenotype reversal of human Th2 cells]	1.0	6	1	0	0
53574	1624	major depression	[major depression]	1.0	2	1	0	0
53575	1624	coexpression of a myc protein	[coexpression of a Myc protein]	1.0	5	1	0	0
53576	1624	agreement with gel shift datum	[agreement with gel shift data.]	1.0	5	1	0	0
53577	1624	non-genomic effect on electrolyte movement	[non-genomic effects on electrolyte movements]	1.0	5	2	2	2
53578	1624	inhibitory drug interaction affect the metabolism	[Inhibitory drug interactions affecting the metabolism]	1.0	6	1	0	0
53579	1624	cytokine gene specificity of nfat protein	[cytokine gene specificity of NFAT proteins]	1.0	6	1	0	0
53580	1624	mononitrosyl iron complex with pdtc	[mononitrosyl iron complexes with PDTC]	1.0	5	1	0	0
53581	1624	Furthermore, overexpression	[Furthermore, overexpression]	1.0	2	1	0	0
53582	1624	obvious sequence similarity to transcription factor	[obvious sequence similarity to transcription factors]	1.0	6	1	0	0
53583	1624	osteoclast vitronectin receptor with nuclearity,	[osteoclasts vitronectin receptor with nuclearity,]	1.0	5	1	0	0
53584	1624	vp16 transcription	[VP16 transcription]	1.0	2	1	0	0
53585	1624	ifnalpha-stimulated tyrosine phosphorylation of Jak1	[IFNalpha-stimulated tyrosine phosphorylation of Jak1]	1.0	5	1	0	0
53586	1624	significant defect in t-cell signal	[significant defects in T-cell signaling]	1.0	5	1	0	0
53587	1624	transcription of gene encode adhesion molecule	[transcription of genes encoding adhesion molecules]	1.0	6	1	0	0
53588	1624	safety phenotype of viral genome	[safety phenotype of viral genome]	1.0	5	1	0	0
53589	1624	half-life (t1/2) of 135eoh)2d3 receptor rna	[Half-life (t1/2) of 1,25(OH)2D3 receptor RNA]	1.0	6	1	0	0
53590	1624	thr729-leu765 sequence	[Thr729-Leu765 sequence]	1.0	2	1	0	0
53591	1624	IL-13 a cytokine similar to IL-4	[IL-13 a cytokine similar to IL-4]	1.0	6	1	0	0
53592	1624	ligand binding.	[ligand binding.]	1.0	2	1	0	0
53593	1624	tip function	[Tip function]	1.0	2	1	0	0
53594	1624	protein-protein interaction with the er	[protein-protein interaction with the ER]	1.0	5	1	0	0
53595	1624	p50 subunit of NF-kappa b	[p50 subunit of NF-kappa B]	1.0	5	1	0	0
53596	1624	(>10 microm in om10.1 cell	[(>10 microM in OM10.1 cells]	1.0	5	1	0	0
53597	1624	concentration of binding site (nmax)	[concentration of binding sites (Nmax)]	1.0	5	1	0	0
53598	1624	immunoglobulin molecule on the surface	[Immunoglobulin molecules on the surface]	1.0	5	1	0	0
53599	1624	PMLRARalpha transgene	[PMLRARalpha transgene]	1.0	2	1	0	0
53600	1624	cyclic AMP -responsive element CRE	[cyclic AMP -responsive element CRE]	1.0	5	1	0	0
53601	1624	macrophage-like lineage	[macrophage-like lineage]	1.0	2	1	0	0
53602	1624	jurkat protein,	[Jurkat protein,]	1.0	2	1	0	0
53603	1624	pu.1 promoter in HeLa cell	[PU.1 promoter in HeLa cells]	1.0	5	1	0	0
53604	1624	diverse etiologies.	[diverse etiologies.]	1.0	2	1	0	0
53605	1624	pharmacokinetic mechanism	[pharmacokinetic mechanisms]	1.0	2	1	0	0
53606	1624	calcium pathway	[calcium pathways]	1.0	2	1	0	0
53607	1624	dicysteine motif	[dicysteine motif]	1.0	2	1	0	0
53608	1624	second group	[second group]	1.0	2	2	1	1
53609	1624	transcription of class in vitro.	[transcription of classes in vitro.]	1.0	5	1	0	0
53610	1624	tur cell	[TUR cells]	1.0	2	2	1	1
53611	1624	include GRE -specific DNA binding	[including GRE -specific DNA binding]	1.0	5	1	0	0
53612	1624	basic-helix-loop-helix protein	[basic-helix-loop-helix proteins]	1.0	2	1	0	0
53613	1624	2061 bp	[2061 bp]	1.0	2	1	0	0
53614	1624	hemo-lymphoid system	[hemo-lymphoid system]	1.0	2	1	0	0
53615	1624	thyroid hormone receptor alpha c-erba/tr-alpha	[thyroid hormone receptor alpha c-erbA/TR-alpha]	1.0	5	1	0	0
53616	1624	CIITA overexpression in normal cell	[CIITA overexpression in normal cells]	1.0	5	1	0	0
53617	1624	herpes simplex virus t-cell antigen	[herpes simplex virus T-cell antigen]	1.0	5	1	0	0
53618	1624	oppose macrophage differentiation of monocyte /macrophage	[opposing macrophage differentiation of monocytes /macrophages]	1.0	6	1	0	0
53619	1624	differentiate human,	[differentiating human,]	1.0	2	1	0	0
53620	1624	human immunodeficiency virus in thymocyte	[human immunodeficiency virus in thymocytes]	1.0	5	1	0	0
53621	1624	sequential deletion of N-terminal activation domain	[sequential deletions of N-terminal activation domain]	1.0	6	1	0	0
53622	1624	E. histolytica	[E. histolytica]	1.0	2	1	0	0
53623	1624	RESULTS: immunohistochemistry	[RESULTS: Immunohistochemistry]	1.0	2	1	0	0
53624	1624	gr concentration in the hypothalamus	[GR concentrations in the hypothalamus]	1.0	5	1	0	0
53625	1624	cd34 expression in cell line	[CD34 expression in cell lines]	1.0	5	1	0	0
53626	1624	condition of active DNA replication	[conditions of active DNA replication]	1.0	5	1	0	0
53627	1624	potential regulator of monocyte differentiation	[potential regulators of monocyte differentiation]	1.0	5	1	0	0
53628	1624	interassay variation	[interassay variation]	1.0	2	1	0	0
53629	1624	tnf-alpha bioavailability from mononuclear cell	[TNF-alpha bioavailability from mononuclear cells]	1.0	5	1	0	0
53630	1624	isotype switch of b lymphocyte	[isotype switching of B lymphocytes]	1.0	5	1	0	0
53631	1624	lps tf expression of human monocyte	[LPS TF expression of human monocytes]	1.0	6	1	0	0
53632	1624	fetal population	[fetal populations]	1.0	2	1	0	0
53633	1624	transcription of the site HS2 enhancer	[Transcription of the site HS2 enhancer]	1.0	6	1	0	0
53634	1624	insulin expression	[insulin expression]	1.0	2	1	0	0
53635	1624	expression of the reticulocyte-type 15-lipoxygenase	[expression of the reticulocyte-type 15-lipoxygenase]	1.0	5	1	0	0
53636	1624	24 healthy volunteer without psychiatric disorder	[24 healthy volunteers without psychiatric disorders]	1.0	6	1	0	0
53637	1624	induction of the lytic replication cycle	[induction of the lytic replication cycle]	1.0	6	1	0	0
53638	1624	cn action	[CN action]	1.0	2	1	0	0
53639	1624	transcriptional activation of the jun	[transcriptional activation of the jun]	1.0	5	1	0	0
53640	1624	fetal haematopoiesis	[fetal haematopoiesis]	1.0	2	1	0	0
53641	1624	verprolin-homology region a cofilin-homology sequence	[verprolin-homology region a cofilin-homology sequence]	1.0	5	1	0	0
53642	1624	bone marrow cell of 26 patient	[bone marrow cells of 26 patients]	1.0	6	1	0	0
53643	1624	phosphotyrosine labeling of several proteins.	[phosphotyrosine labeling of several proteins.]	1.0	5	1	0	0
53644	1624	proportion of CD40 cell (26%)	[proportion of CD40 cells (26%)]	1.0	5	1	0	0
53645	1624	stimulation in the EGR1 subclone	[stimulation in the EGR1 subclone]	1.0	5	1	0	0
53646	1624	identification of the promoter region	[Identification of the promoter region]	1.0	5	1	0	0
53647	1624	decrease in the structural order.	[decrease in the structural order.]	1.0	5	1	0	0
53648	1624	bear the promoter region ebv	[bearing the promoter regions EBV]	1.0	5	1	0	0
53649	1624	member of the Rel/NF-kB family	[members of the Rel/NF-kB family]	1.0	5	1	0	0
53650	1624	induction of the il-2 gene	[induction of the IL-2 gene]	1.0	5	2	1	1
53651	1624	20 oligonucleotide	[20 oligonucleotides]	1.0	2	1	0	0
53652	1624	inhibitory peptide	[inhibitory peptide]	1.0	2	2	1	1
53653	1624	cell of the hematopoietic lineage	[cells of the hematopoietic lineage]	1.0	5	1	0	0
53654	1624	lymphocyte subpopulation	[lymphocyte subpopulations]	1.0	2	2	2	2
53655	1624	Rb-defective cell	[Rb-defective cells]	1.0	2	1	0	0
53656	1624	only p50 nf-kappa b protein	[Only p50 NF-kappa B protein]	1.0	5	1	0	0
53657	1624	salmonella typhimurium strain with mutation	[Salmonella typhimurium strains with mutations]	1.0	5	1	0	0
53658	1624	little activation	[little activation]	1.0	2	2	2	2
53659	1624	free scavenger	[free scavenger]	1.0	2	1	0	0
53660	1624	manipulation of mammary epithelial cell	[manipulations of mammary epithelial cells]	1.0	5	1	0	0
53661	1624	stably express a transdominant rev protein	[stably expressing a transdominant Rev protein]	1.0	6	1	0	0
53662	1624	hormone-binding domain	[hormone-binding domain]	1.0	2	2	2	2
53663	1624	Namalwa cell	[Namalwa cells]	1.0	2	1	0	0
53664	1624	two other member of the family	[Two other members of the family]	1.0	6	1	0	0
53665	1624	graft rejection	[graft rejection]	1.0	2	1	0	0
53666	1624	T lymphocyte resistant to cyclosporin a	[T lymphocytes resistant to cyclosporin A]	1.0	6	1	0	0
53667	1624	apc of heat shock protein glycoprotein	[APCs of heat shock protein glycoprotein]	1.0	6	1	0	0
53668	1624	oxidant such as hydrogen peroxide	[Oxidants such as hydrogen peroxide]	1.0	5	1	0	0
53669	1624	transfection analysis with the E3 promoter	[transfection analysis with the E3 promoter]	1.0	6	1	0	0
53670	1624	cellular processes,	[cellular processes,]	1.0	2	2	2	2
53671	1624	docking platform	[docking platforms]	1.0	2	1	0	0
53672	1624	assembly of this tri-molecular complex	[assembly of this tri-molecular complex]	1.0	5	1	0	0
53673	1624	cross-linking of MHC class ii molecule	[cross-linking of MHC class II molecules]	1.0	6	1	0	0
53674	1624	daughter pair	[daughter pair]	1.0	2	1	0	0
53675	1624	level of other nuclear factor	[Levels of other nuclear factors]	1.0	5	1	0	0
53676	1624	stat5 activation	[STAT5 activation]	1.0	2	2	2	2
53677	1624	m; sh	[M; SH]	1.0	2	1	0	0
53678	1624	monocytic differentiation by okadaic acid	[monocytic differentiation by okadaic acid]	1.0	5	1	0	0
53679	1624	binding of b /rel subunit	[binding of B /Rel subunits]	1.0	5	2	2	2
53680	1624	ligand-dependent activation of the receptor	[ligand-dependent activation of the receptor]	1.0	5	1	0	0
53681	1624	brdu incorporation	[BrdU incorporation]	1.0	2	2	2	2
53682	1624	different phenotype	[different phenotypes]	1.0	2	2	2	2
53683	1624	concern the regulation of gene transcription	[concerning the regulation of gene transcription]	1.0	6	1	0	0
53684	1624	2-deoxyglucose uptake	[2-deoxyglucose uptake]	1.0	2	1	0	0
53685	1624	Hence, PPAR	[Hence, PPAR]	1.0	2	1	0	0
53686	1624	position -82 to -91 gggaactacc	[positions -82 to -91 GGGAACTACC]	1.0	5	1	0	0
53687	1624	strong inhibitory activity in HeLa cell	[stronger inhibitory activity in HeLa cells]	1.0	6	1	0	0
53688	1624	contrast to blood b lymphocyte	[contrast to blood B lymphocytes]	1.0	5	1	0	0
53689	1624	RA sensitivity of RA-resistant hematopoietic cell	[RA sensitivity of RA-resistant hematopoietic cells]	1.0	6	1	0	0
53690	1624	transgenic megakaryocyte	[transgenic megakaryocytes]	1.0	2	2	1	1
53691	1624	cell maturation	[cell maturation]	1.0	2	2	1	1
53692	1624	seven IDCs	[seven IDCs]	1.0	2	1	0	0
53693	1624	replicative gene expression in tumour cell	[replicative gene expression in tumour cells]	1.0	6	1	0	0
53694	1624	actively bind	[actively binding]	1.0	2	1	0	0
53695	1624	interstitial collagenase mmp-1 a metalloproteinase	[Interstitial collagenase MMP-1 a metalloproteinase]	1.0	5	1	0	0
53696	1624	ability pkc	[ability PKC]	1.0	2	1	0	0
53697	1624	unknown event	[unknown event]	1.0	2	1	0	0
53698	1624	common cis-element	[common cis-element]	1.0	2	1	0	0
53699	1624	synergize with pkc -dependent pathway	[synergize with PKC -dependent pathways]	1.0	5	1	0	0
53700	1624	clearly tyrosine	[clearly tyrosine]	1.0	2	1	0	0
53701	1624	hypothetical model	[hypothetical model]	1.0	2	1	0	0
53702	1624	10 mg/d.	[10 mg/d.]	1.0	2	1	0	0
53703	1624	gr binding capacity in subject	[GR binding capacity in subjects]	1.0	5	1	0	0
53704	1624	feasibility of this systematic approach	[feasibility of this systematic approach]	1.0	5	1	0	0
53705	1624	nm, bmax 183 +/- 29.8	[nM, Bmax 183 +/- 29.8]	1.0	5	1	0	0
53706	1624	synergistic increase in virus expression	[synergistic increase in virus expression]	1.0	5	1	0	0
53707	1624	trans-dominant form	[trans-dominant form]	1.0	2	1	0	0
53708	1624	Cepsilon germline transcript in b cell	[Cepsilon germline transcripts in B cells]	1.0	6	1	0	0
53709	1624	total cellular pkc enzymatic activity	[Total cellular PKC enzymatic activity]	1.0	5	1	0	0
53710	1624	ebv-transformed lcl	[EBV-transformed LCLs]	1.0	2	1	0	0
53711	1624	molecular structure	[molecular structure]	1.0	2	2	1	1
53712	1624	vitro to monocyte-derived macrophage mdm	[vitro to monocyte-derived macrophages MDMs]	1.0	5	1	0	0
53713	1624	segregate the human Chr 20	[segregating the human Chr 20]	1.0	5	1	0	0
53714	1624	endothelial cell in large vessel	[endothelial cells in large vessel]	1.0	5	1	0	0
53715	1624	nonstatic assay	[nonstatic assays]	1.0	2	1	0	0
53716	1624	continuous treatment	[Continuous treatment]	1.0	2	2	2	2
53717	1624	role of gata-1 in proliferation	[Role of GATA-1 in proliferation]	1.0	5	1	0	0
53718	1624	role of ppargamma in atherosclerosis	[role of PPARgamma in atherosclerosis]	1.0	5	1	0	0
53719	1624	carboxyl termini	[carboxyl termini]	1.0	2	1	0	0
53720	1624	cytokine-mediated disease	[cytokine-mediated diseases]	1.0	2	1	0	0
53721	1624	result in endothelial cell-monocyte (ec-mn) adhesion	[resulting in endothelial cell-monocyte (EC-Mn) adhesion]	1.0	6	1	0	0
53722	1624	second approach,	[second approach,]	1.0	2	1	0	0
53723	1624	STAT4 expression	[STAT4 expression]	1.0	2	1	0	0
53724	1624	individual component of this element	[individual components of this element]	1.0	5	1	0	0
53725	1624	protein coding	[protein coding]	1.0	2	2	2	2
53726	1624	generation of memory b cell	[generation of memory B cells]	1.0	5	1	0	0
53727	1624	thr residue	[Thr residues]	1.0	2	1	0	0
53728	1624	ciita trans-activator	[CIITA trans-activator]	1.0	2	2	1	1
53729	1624	Stable expression of transdominant rev protein	[Stable expression of transdominant Rev protein]	1.0	6	1	0	0
53730	1624	lysis by killer (lak) cell	[lysis by killer (LAK) cells]	1.0	5	1	0	0
53731	1624	nf-at sequence,	[NF-AT sequence,]	1.0	2	1	0	0
53732	1624	also for several region between -201	[also for several regions between -201]	1.0	6	1	0	0
53733	1624	human Kruppel-related zinc finger protein	[human Kruppel-related zinc finger proteins]	1.0	5	1	0	0
53734	1624	colony size (10-fold expansion) occur	[colony size (10-fold expansion) occurring]	1.0	5	1	0	0
53735	1624	anti-hapten single-chain ab variable fragment	[anti-hapten single-chain Ab variable fragment]	1.0	5	1	0	0
53736	1624	amino acid 346 to 543	[amino acids 346 to 543]	1.0	5	1	0	0
53737	1624	anti- tnf-alpha inhibition of cell proliferation	[anti- TNF-alpha inhibition of cell proliferation]	1.0	6	1	0	0
53738	1624	mitogen stimulation of EL-4 cell	[mitogen stimulation of EL-4 cells]	1.0	5	1	0	0
53739	1624	overexpress the tyrosine kinase p59fyn	[overexpressing the tyrosine kinase p59fyn]	1.0	5	1	0	0
53740	1624	dna-binding form	[DNA-binding form]	1.0	2	1	0	0
53741	1624	adhesion process	[adhesion process]	1.0	2	1	0	0
53742	1624	significant role in the control	[significant role in the control]	1.0	5	1	0	0
53743	1624	ML-9 differentiation	[ML-9 differentiation]	1.0	2	1	0	0
53744	1624	(e.g. fibroblast	[(e.g. fibroblasts]	1.0	2	1	0	0
53745	1624	virus-encoded transactivator	[virus-encoded transactivator]	1.0	2	1	0	0
53746	1624	human interferon regulatory factor 2 gene	[Human interferon regulatory factor 2 gene]	1.0	6	1	0	0
53747	1624	human dendritic cell from blood	[human dendritic cells from blood]	1.0	5	1	0	0
53748	1624	factor-mediated suppression	[factor-mediated suppression]	1.0	2	1	0	0
53749	1624	response to steel factor stimulation,	[response to Steel factor stimulation,]	1.0	5	1	0	0
53750	1624	(i) stimulation of phosphatidylinositol turnover	[(i) stimulation of phosphatidylinositol turnover]	1.0	5	1	0	0
53751	1624	quantitation of glucocorticoid receptor GCR	[Quantitation of glucocorticoid receptors GCR]	1.0	5	1	0	0
53752	1624	also a potent inhibitor of cell	[also a potent inhibitor of cells]	1.0	6	1	0	0
53753	1624	wide range	[wide range]	1.0	2	11	10	1
53754	1624	specific protease	[specific proteases]	1.0	2	1	0	0
53755	1624	lef-1 CBF alpha2 pebp2 alpha	[LEF-1 CBF alpha2 PEBP2 alpha]	1.0	5	1	0	0
53756	1624	thyroid system	[thyroid system]	1.0	2	1	0	0
53757	1624	Functional analysis of cis-linked regulatory sequence	[Functional analysis of cis-linked regulatory sequences]	1.0	6	1	0	0
53758	1624	type 5	[type 5]	1.0	2	2	2	2
53759	1624	marker of the monocyte/macrophage phenotype	[markers of the monocyte/macrophage phenotype]	1.0	5	1	0	0
53760	1624	actively divide	[actively dividing]	1.0	2	1	0	0
53761	1624	regulatory (b) subunit binding domain.	[regulatory (B) subunit binding domain.]	1.0	5	1	0	0
53762	1624	independent sites.	[independent sites.]	1.0	2	1	0	0
53763	1624	les-induced il-6	[LPS-induced IL-6]	1.0	2	1	0	0
53764	1624	camp response to prostaglandin E2	[cAMP response to prostaglandin E2]	1.0	5	1	0	0
53765	1624	neutrophil lipocalin	[neutrophil lipocalin]	1.0	2	3	2	1
53766	1624	synthetic analog	[synthetic analogs]	1.0	2	2	1	1
53767	1624	rante gene expression in fibroblasts,	[RANTES gene expression in fibroblasts,]	1.0	5	1	0	0
53768	1624	ankyrin protein	[ankyrin protein]	1.0	2	2	1	1
53769	1624	small number	[small number]	1.0	2	4	3	1
53770	1624	early marker	[early markers]	1.0	2	1	0	0
53771	1624	adhesion of u937 cell to ECs	[adhesion of U937 cells to ECs]	1.0	6	1	0	0
53772	1624	potent inhibition	[potent inhibition]	1.0	2	1	0	0
53773	1624	genomic sex	[genomic sex]	1.0	2	1	0	0
53774	1624	constant surveillance of liver function	[constant surveillance of liver function]	1.0	5	1	0	0
53775	1624	down-regulation of mcp-1 expression by aspirin	[down-regulation of MCP-1 expression by aspirin]	1.0	6	1	0	0
53776	1624	eosinophil-derived neurotoxin	[eosinophil-derived neurotoxin]	1.0	2	2	1	1
53777	1624	stimulation of interferon beta gene transcription	[Stimulation of interferon beta gene transcription]	1.0	6	1	0	0
53778	1624	surround the transcription start site (-7	[surrounding the transcription start site (-7]	1.0	6	1	0	0
53779	1624	mouse homologue of aml1 gene	[mouse homologue of AML1 gene]	1.0	5	1	0	0
53780	1624	detectable deviation in this immunological variable	[detectable deviations in these immunological variables]	1.0	6	1	0	0
53781	1624	DNA binding of multiple transcription factor	[DNA binding of multiple transcription factors]	1.0	6	1	0	0
53782	1624	ikappabalpha level	[IkappaBalpha levels]	1.0	2	2	2	2
53783	1624	immediate/early gene	[immediate/early gene]	1.0	2	1	0	0
53784	1624	leucocyte-activating property of pre-exist mcp-1	[leucocyte-activating properties of pre-existing MCP-1]	1.0	5	1	0	0
53785	1624	primer specific for the domain	[primers specific for the domains]	1.0	5	1	0	0
53786	1624	il-1beta response	[IL-1beta response]	1.0	2	1	0	0
53787	1624	different combination of stat protein	[different combinations of Stat proteins]	1.0	5	1	0	0
53788	1624	mapk activity	[MAPK activity]	1.0	2	2	1	1
53789	1624	indicate sensitive	[indicating sensitive]	1.0	2	2	2	2
53790	1624	viral ligand	[viral ligands]	1.0	2	1	0	0
53791	1624	same genes,	[same genes,]	1.0	2	2	2	2
53792	1624	il-12 p70	[IL-12 p70]	1.0	2	1	0	0
53793	1624	excisional biopsy as surgical treatment	[excisional biopsy as surgical treatment]	1.0	5	1	0	0
53794	1624	small deletion	[small deletion]	1.0	2	2	1	1
53795	1624	adverse condition	[adverse conditions]	1.0	2	1	0	0
53796	1624	host mechanism	[host mechanisms]	1.0	2	1	0	0
53797	1624	role of cholecystokinin (cck(b)) receptor	[role of cholecystokinin (CCK(B)) receptor]	1.0	5	1	0	0
53798	1624	lytic effect in leukemic cell	[lytic effect in leukemic cells]	1.0	5	1	0	0
53799	1624	(ifn)-gamma production	[(IFN)-gamma production]	1.0	2	1	0	0
53800	1624	Positive regulation of immunoglobulin gene expression	[Positive regulation of immunoglobulin gene expression]	1.0	6	1	0	0
53801	1624	CD40-stimulated b	[CD40-stimulated B]	1.0	2	1	0	0
53802	1624	crosslinkage of the CD3/TCR complex	[crosslinkage of the CD3/TCR complex]	1.0	5	1	0	0
53803	1624	chemotactic protein-1	[chemotactic protein-1]	1.0	2	2	2	2
53804	1624	significantly low concentration (21.7 5.1	[significantly lower concentration (21.7 5.1]	1.0	5	1	0	0
53805	1624	latter defect	[latter defect]	1.0	2	1	0	0
53806	1624	deficient response	[deficient response]	1.0	2	1	0	0
53807	1624	69 bp	[69 bp]	1.0	2	1	0	0
53808	1624	upstream signal molecule of ERK	[upstream signaling molecules of ERK]	1.0	5	1	0	0
53809	1624	block in MHC class inducibility	[block in MHC class inducibility]	1.0	5	1	0	0
53810	1624	antibody to other stat protein	[antibodies to other Stat proteins]	1.0	5	1	0	0
53811	1624	arachidonate release	[arachidonate release]	1.0	2	1	0	0
53812	1624	renal function	[renal function]	1.0	2	1	0	0
53813	1624	central part	[central part]	1.0	2	1	0	0
53814	1624	b element	[B elements]	1.0	2	2	2	2
53815	1624	proteolytic stability	[proteolytic stability]	1.0	2	1	0	0
53816	1624	receptor density; thus, patient with RA	[receptor density; thus, patients with RA]	1.0	6	1	0	0
53817	1624	natural killer cell in bone marrow	[natural killer cells in bone marrow]	1.0	6	1	0	0
53818	1624	e-selectin by tumor necrosis factor-alpha TNF	[E-selectin by tumor necrosis factor-alpha TNF]	1.0	6	1	0	0
53819	1624	contain receptor	[containing receptors]	1.0	2	2	1	1
53820	1624	recombinant retroviruse	[recombinant retroviruses]	1.0	2	1	0	0
53821	1624	Functional characterization of this element	[Functional characterization of this element]	1.0	5	1	0	0
53822	1624	characterization of cytokine differential induction	[Characterization of cytokine differential induction]	1.0	5	1	0	0
53823	1624	flavonoid quercetin	[flavonoids quercetin]	1.0	2	1	0	0
53824	1624	expression among breast tumor sample	[expression among breast tumor samples]	1.0	5	1	0	0
53825	1624	background: tumor necrosis factor alpha TNF-alpha	[BACKGROUND: Tumor necrosis factor alpha TNF-alpha]	1.0	6	1	0	0
53826	1624	product of the b29 gene	[product of the B29 gene]	1.0	5	1	0	0
53827	1624	statistically-significant difference between each mean group	[statistically-significant differences between each mean group]	1.0	6	1	0	0
53828	1624	tumor necrosis factor alpha mrna production	[Tumor necrosis factor alpha mRNA production]	1.0	6	1	0	0
53829	1624	mediate il-4- gene expression in monocyte	[mediating IL-4- gene expression in monocytes]	1.0	6	1	0	0
53830	1624	sense oligomer	[sense oligomer]	1.0	2	1	0	0
53831	1624	uncommitted precursor	[uncommitted precursors]	1.0	2	1	0	0
53832	1624	src family	[Src family]	1.0	2	1	0	0
53833	1624	hiv cells,	[HIV cells,]	1.0	2	1	0	0
53834	1624	(45-50 min) in untreated acid cell	[(45-50 min) in untreated acid cells]	1.0	6	1	0	0
53835	1624	same concentration,	[same concentration,]	1.0	2	1	0	0
53836	1624	interleukin-2 receptor alpha chain promoter	[interleukin-2 receptor alpha chain promoter]	1.0	5	1	0	0
53837	1624	accompanying paper	[accompanying paper]	1.0	2	1	0	0
53838	1624	hemorrhagic shock	[hemorrhagic shock]	1.0	2	2	2	2
53839	1624	fusion protein comprise the lac repressor	[fusion proteins comprising the lac repressor]	1.0	6	1	0	0
53840	1624	nf-kappa b activation and/or translocation	[NF-kappa B activation and/or translocation]	1.0	5	1	0	0
53841	1624	purpose other than stem-loop stability	[purposes other than stem-loop stability]	1.0	5	1	0	0
53842	1624	essential role in z responsiveness,	[essential role in Z responsiveness,]	1.0	5	1	0	0
53843	1624	active metabolite of vitamin d	[active metabolite of vitamin D]	1.0	5	1	0	0
53844	1624	encode a putative zinc finger protein	[encoding a putative zinc finger protein]	1.0	6	1	0	0
53845	1624	pattern of contact with factor	[pattern of contacts with factors]	1.0	5	1	0	0
53846	1624	histologic type	[histologic types]	1.0	2	2	2	2
53847	1624	immunofluorescence study of human monocyte	[Immunofluorescence studies of human monocytes]	1.0	5	1	0	0
53848	1624	SEB induction of interleukin-2 IL-2	[SEB induction of interleukin-2 IL-2]	1.0	5	1	0	0
53849	1624	c-myb mrna in k562 cell	[c-myb mRNA in K562 cells]	1.0	5	1	0	0
53850	1624	80 exposures.	[80 exposures.]	1.0	2	1	0	0
53851	1624	activation of the tyrosine kinase JAK1	[activation of the tyrosine kinases JAK1]	1.0	6	1	0	0
53852	1624	three gch	[three GCH]	1.0	2	1	0	0
53853	1624	signal process	[signaling processes]	1.0	2	2	2	2
53854	1624	RXR-beta mrna	[RXR-beta mRNA]	1.0	2	1	0	0
53855	1624	dna-binding level	[DNA-binding level]	1.0	2	1	0	0
53856	1624	role as a hormone-dependent trans-activator	[role as a hormone-dependent trans-activator]	1.0	5	1	0	0
53857	1624	tyrosine phosphorylation of 42- kda protein	[tyrosine phosphorylation of 42- kDa proteins]	1.0	6	1	0	0
53858	1624	gene expression pattern in cancer	[gene expression patterns in cancers]	1.0	5	1	0	0
53859	1624	hemin response	[hemin response]	1.0	2	1	0	0
53860	1624	hepor promoter	[hEpoR promoter]	1.0	2	1	0	0
53861	1624	HEL/S cell	[HEL/S cells]	1.0	2	1	0	0
53862	1624	third series	[third series]	1.0	2	1	0	0
53863	1624	strong induction of hiv expression	[strong induction of HIV expression]	1.0	5	1	0	0
53864	1624	AC unit	[AC unit]	1.0	2	1	0	0
53865	1624	38000-M(r) protein	[38,000-M(r) protein]	1.0	2	1	0	0
53866	1624	lps treatment	[LPS treatment]	1.0	2	3	2	1
53867	1624	transcription factor in immune-mediated disease	[Transcription factors in immune-mediated disease]	1.0	5	1	0	0
53868	1624	TCR-dependent signal	[TCR-dependent signal]	1.0	2	1	0	0
53869	1624	sre DNA	[SRE DNA]	1.0	2	1	0	0
53870	1624	single-strand conformation polymorphism (sscp) technique	[single-strand conformation polymorphism (SSCP) technique]	1.0	5	1	0	0
53871	1624	high dose of specific peptide	[high doses of specific peptide]	1.0	5	1	0	0
53872	1624	autoregulatory enhancer	[autoregulatory enhancer]	1.0	2	1	0	0
53873	1624	HLA-DR type	[HLA-DR typing]	1.0	2	1	0	0
53874	1624	monocyte adhesion to endothelial monolayer	[monocyte adhesion to endothelial monolayers]	1.0	5	1	0	0
53875	1624	4 beta-phorbol	[4 beta-phorbol]	1.0	2	2	1	1
53876	1624	activation by the RFX5 fusion protein	[activation by the RFX5 fusion protein]	1.0	6	1	0	0
53877	1624	electrolyte concentration	[electrolyte concentrations]	1.0	2	1	0	0
53878	1624	tyrosine phosphorylation of linker protein	[Tyrosine phosphorylation of linker proteins]	1.0	5	1	0	0
53879	1624	concert with PMA/ionomycin inducible factor	[concert with PMA/ionomycin inducible factors]	1.0	5	1	0	0
53880	1624	prospective study	[prospective study]	1.0	2	1	0	0
53881	1624	cytoplasmic ikappab-alpha	[cytoplasmic IkappaB-alpha]	1.0	2	1	0	0
53882	1624	adhesion of monocyte to cell	[adhesion of monocytes to cells]	1.0	5	1	0	0
53883	1624	Ie gene	[IE genes]	1.0	2	2	2	2
53884	1624	granulocyte pmn	[granulocytes PMN]	1.0	2	2	1	1
53885	1624	Internal labeling with [35s]methionine with anti-igm	[Internal labeling with [35S]methionine with anti-IgM]	1.0	6	1	0	0
53886	1624	role of hiv-1 nef expression	[Role of HIV-1 Nef expression]	1.0	5	1	0	0
53887	1624	human neonate	[human neonates]	1.0	2	1	0	0
53888	1624	promoter of the TP1 gene	[promoter of the TP1 gene]	1.0	5	1	0	0
53889	1624	post-receptor mechanism	[post-receptor mechanisms]	1.0	2	1	0	0
53890	1624	content of gcr in leukocyte	[content of GCR in leukocytes]	1.0	5	2	1	1
53891	1624	phosphorylation of nuclear tal1 protein	[phosphorylation of nuclear TAL1 protein]	1.0	5	1	0	0
53892	1624	polymerase chain reaction (pcr)-assisted method	[polymerase chain reaction (PCR)-assisted method]	1.0	5	1	0	0
53893	1624	platelet-activate factor on b lymphocyte	[platelet-activating factor on B lymphocytes]	1.0	5	1	0	0
53894	1624	ebv -positive b cell line	[EBV -positive B cell lines]	1.0	5	1	0	0
53895	1624	inhibit cell death by 40%.	[inhibiting cell death by 40%.]	1.0	5	1	0	0
53896	1624	proper regulation of the activation	[proper regulation of the activation]	1.0	5	1	0	0
53897	1624	mechanism of the immunosuppressive capacity	[mechanisms of the immunosuppressive capacities]	1.0	5	1	0	0
53898	1624	migration of double oligomer representative	[migration of double oligomers representative]	1.0	5	1	0	0
53899	1624	activation of the sodium/proton exchanger	[activation of the sodium/proton exchanger]	1.0	5	1	0	0
53900	1624	syncytium formation with dendritic cell	[syncytium formation with dendritic cells]	1.0	5	1	0	0
53901	1624	tf.viia complex	[TF.VIIa complex]	1.0	2	2	2	2
53902	1624	inhibition of nf-at -dependent transcription	[Inhibition of NF-AT -dependent transcription]	1.0	5	1	0	0
53903	1624	biophysical properties	[biophysical properties,]	1.0	2	1	0	0
53904	1624	induction of chloramphenicol acetyltransferase activity	[induction of chloramphenicol acetyltransferase activity]	1.0	5	1	0	0
53905	1624	evidence for the role of Sp1	[evidence for the role of Sp1]	1.0	6	1	0	0
53906	1624	perhaps cd21	[perhaps CD21]	1.0	2	1	0	0
53907	1624	human interferon	[Human interferon]	1.0	2	2	1	1
53908	1624	cell hemoglobinization	[Cell hemoglobinization]	1.0	2	1	0	0
53909	1624	S. Kenney, Proc. Natl. Acad. Sci.	[S. Kenney, Proc. Natl. Acad. Sci.]	1.0	6	1	0	0
53910	1624	least in certain cell types,	[least in certain cell types,]	1.0	5	1	0	0
53911	1624	receptor GRE	[receptor GRE]	1.0	2	1	0	0
53912	1624	e2f complex	[E2F complex]	1.0	2	2	2	2
53913	1624	great potency	[greatest potency]	1.0	2	1	0	0
53914	1624	rest pbl	[resting PBL]	1.0	2	2	2	2
53915	1624	group iii	[group III]	1.0	2	2	1	1
53916	1624	adenovirus e1b	[adenovirus E1B]	1.0	2	2	2	2
53917	1624	induction of icam-1 by tax1	[Induction of ICAM-1 by Tax1]	1.0	5	1	0	0
53918	1624	u-937 cell with 12-o-tetradecanoylphorbol-13-acetate tpa	[U-937 cells with 12-O-tetradecanoylphorbol-13-acetate TPA]	1.0	5	1	0	0
53919	1624	insertion site	[insertion site]	1.0	2	2	2	2
53920	1624	phosphatase inhibition	[phosphatase inhibition]	1.0	2	1	0	0
53921	1624	lps -inducible factor nf-kappa b	[LPS -inducible factor NF-kappa B]	1.0	5	1	0	0
53922	1624	bipotential capacity,	[bipotential capacity,]	1.0	2	1	0	0
53923	1624	nonproductive fashion	[nonproductive fashion]	1.0	2	1	0	0
53924	1624	indicate dependent upon a protein(s)	[indicating dependent upon a protein(s)]	1.0	5	1	0	0
53925	1624	exposure duration.	[exposure duration.]	1.0	2	1	0	0
53926	1624	association of glucocorticoid insensitivity with expression	[Association of glucocorticoid insensitivity with expression]	1.0	6	1	0	0
53927	1624	Histological diagnosis	[Histological diagnosis]	1.0	2	1	0	0
53928	1624	reactive thrombocytosis	[reactive thrombocytosis]	1.0	2	2	1	1
53929	1624	R-PK DNA fragment extend relative	[R-PK DNA fragment extending relative]	1.0	5	1	0	0
53930	1624	contain amino terminal insert exon 7a	[containing amino terminal insert exon 7a]	1.0	6	1	0	0
53931	1624	expression in some breast tumor	[expression in some breast tumors]	1.0	5	1	0	0
53932	1624	CD8 interaction with a anti-cd8 mab	[CD8 interaction with an anti-CD8 mAb]	1.0	6	1	0	0
53933	1624	preferential induction	[preferential induction]	1.0	2	2	1	1
53934	1624	seven xpa	[seven XPA]	1.0	2	1	0	0
53935	1624	comparable level of Pan protein	[comparable levels of Pan proteins]	1.0	5	1	0	0
53936	1624	DNA binding of various transcription factor	[DNA binding of various transcription factors]	1.0	6	1	0	0
53937	1624	murine counterpart of human AML1	[murine counterpart of human AML1]	1.0	5	1	0	0
53938	1624	radioligand-binding assay	[radioligand-binding assay]	1.0	2	2	1	1
53939	1624	intestinal inflammation	[intestinal inflammation]	1.0	2	1	0	0
53940	1624	activation of a nfat kinase	[activation of an NFAT kinase]	1.0	5	1	0	0
53941	1624	experimental group	[experimental groups]	1.0	2	1	0	0
53942	1624	rbp binding	[RBP binding]	1.0	2	2	2	2
53943	1624	activation of human CD4 T lymphocyte	[Activation of human CD4 T lymphocytes]	1.0	6	1	0	0
53944	1624	early report	[earlier reports.]	1.0	2	1	0	0
53945	1624	single critical c-myb binding site	[single critical c-Myb binding site]	1.0	5	1	0	0
53946	1624	transcriptional activity of a number	[transcriptional activity of a number]	1.0	5	1	0	0
53947	1624	specific signal event through association	[specific signaling events through association]	1.0	5	1	0	0
53948	1624	high ca2+ follow thapsigargin treatment	[high Ca2+ following thapsigargin treatment]	1.0	5	1	0	0
53949	1624	human B-cell specific transcription factor	[human B-cell specific transcription factor]	1.0	5	1	0	0
53950	1624	decrease nf-at accumulation in the nuclei	[decreasing NF-AT accumulation in the nuclei]	1.0	6	1	0	0
53951	1624	quiescent mantle zone b cell	[quiescent mantle zone B cells]	1.0	5	1	0	0
53952	1624	degenerate probe	[degenerate probes]	1.0	2	1	0	0
53953	1624	hepatocyte nuclear factor-1 alpha hnf-1 alpha	[Hepatocyte nuclear factor-1 alpha HNF-1 alpha]	1.0	6	1	0	0
53954	1624	new method	[new method]	1.0	2	1	0	0
53955	1624	cd69 molecule	[CD69 molecule]	1.0	2	1	0	0
53956	1624	finding consistent with a linkage	[finding consistent with a linkage]	1.0	5	1	0	0
53957	1624	NF kappa b like heterodimeric complex	[NF kappa B like heterodimeric complexes]	1.0	6	1	0	0
53958	1624	erythroid cell in hematopoietic lineage	[erythroid cells in hematopoietic lineage]	1.0	5	1	0	0
53959	1624	interaction between the phosphatase calcineurin	[interaction between the phosphatase calcineurin]	1.0	5	1	0	0
53960	1624	costimulation of cell with lps	[Costimulation of cells with LPS]	1.0	5	1	0	0
53961	1624	include the enhancer in immunodeficiency virus	[including the enhancer in immunodeficiency virus]	1.0	6	1	0	0
53962	1624	Interestingly, coincubation of 35s- tr alpha	[Interestingly, coincubation of 35S- TR alpha]	1.0	6	1	0	0
53963	1624	pharmacologic strategy like the one	[pharmacologic strategy like the one]	1.0	5	1	0	0
53964	1624	steroidal effect on the sodium-proton-antiport	[steroidal effects on the sodium-proton-antiport]	1.0	5	1	0	0
53965	1624	heterogeneous expression of the lipocalin ngal	[Heterogeneous expression of the lipocalin NGAL]	1.0	6	1	0	0
53966	1624	-160 site	[-160 site]	1.0	2	1	0	0
53967	1624	cytokine like tumor necrosis factor	[cytokines like tumor necrosis factor]	1.0	5	1	0	0
53968	1624	mutation in the E2F site	[mutation in the E2F sites]	1.0	5	1	0	0
53969	1624	Tat activation	[Tat activation]	1.0	2	2	2	2
53970	1624	such as estrogen receptor binding	[such as estrogen receptor binding]	1.0	5	1	0	0
53971	1624	Finally, GM3	[Finally, GM3]	1.0	2	1	0	0
53972	1624	expression of all adhesion molecule	[expression of all adhesion molecules]	1.0	5	1	0	0
53973	1624	p40 production	[p40 production]	1.0	2	1	0	0
53974	1624	T lymphocyte from NF-ATp mouse	[T lymphocytes from NF-ATp mice]	1.0	5	1	0	0
53975	1624	human promyeloid leukemia cell hl-60	[human promyeloid leukemia cells HL-60]	1.0	5	1	0	0
53976	1624	expression of the l-selectin gene	[expression of the L-selectin gene]	1.0	5	1	0	0
53977	1624	two mechanisms;	[two mechanisms;]	1.0	2	1	0	0
53978	1624	6 cases,	[6 cases,]	1.0	2	1	0	0
53979	1624	endometriotic lesion	[endometriotic lesion]	1.0	2	2	1	1
53980	1624	CIITA gene	[CIITA gene]	1.0	2	2	1	1
53981	1624	get some insight into the mechanism	[getting some insights into the mechanisms]	1.0	6	1	0	0
53982	1624	32.2 kda	[32.2 kDa]	1.0	2	1	0	0
53983	1624	proinflammatory cytokine gene expression in monocyte	[proinflammatory cytokine gene expression in monocytes]	1.0	6	1	0	0
53984	1624	human immunodeficiency virus hodgkin' disease hiv-hd	[Human immunodeficiency virus Hodgkin's disease HIV-HD]	1.0	6	1	0	0
53985	1624	response to notch receptor signalling,	[response to Notch receptors signalling,]	1.0	5	1	0	0
53986	1624	tumor transformation	[tumor transformation]	1.0	2	1	0	0
53987	1624	use ligand	[Using ligands]	1.0	2	2	2	2
53988	1624	amino terminus,	[amino terminus,]	1.0	2	1	0	0
53989	1624	Thus, IL-12	[Thus, IL-12]	1.0	2	1	0	0
53990	1624	sequence homology,	[Sequence homology,]	1.0	2	2	1	1
53991	1624	severe immunosuppression	[severe immunosuppression]	1.0	2	1	0	0
53992	1624	CTL recognition of a peptide	[CTL recognition of an peptide]	1.0	5	1	0	0
53993	1624	tight correlation between c-jun expression	[tight correlation between c-jun expression]	1.0	5	1	0	0
53994	1624	lymphocyte gr	[lymphocyte GR]	1.0	2	2	2	2
53995	1624	progesterone status	[progesterone status]	1.0	2	1	0	0
53996	1624	inhibitor (ik)	[Inhibitor (IK)]	1.0	2	1	0	0
53997	1624	hexasaccharide chain	[hexasaccharide chains]	1.0	2	1	0	0
53998	1624	DRE sequence	[DRE sequence]	1.0	2	2	2	2
53999	1624	three additional isoform of NFATx	[three additional isoforms of NFATx]	1.0	5	1	0	0
54000	1624	transcriptionally active extract from Jurkat	[transcriptionally active extracts from Jurkat]	1.0	5	1	0	0
54001	1624	parallel, up-regulate	[parallel, up-regulates]	1.0	2	1	0	0
54002	1624	staphylococcal exotoxin	[staphylococcal exotoxin]	1.0	2	1	0	0
54003	1624	VCAM-1 surface expression in huvec	[VCAM-1 surface expression in HUVECs]	1.0	5	1	0	0
54004	1624	malignant disease	[malignant diseases]	1.0	2	1	0	0
54005	1624	4-6 h.	[4-6 h,]	1.0	2	1	0	0
54006	1624	cortisol incubation	[cortisol incubation]	1.0	2	1	0	0
54007	1624	high estrogen	[high estrogen]	1.0	2	1	0	0
54008	1624	two unrearranged TcR delta transcript	[Two unrearranged TcR delta transcripts]	1.0	5	1	0	0
54009	1624	explanation for the erythroid-specific repression	[explanation for the erythroid-specific repression]	1.0	5	1	0	0
54010	1624	ifn-gamma responsiveness on a heterologous promoter	[IFN-gamma responsiveness on a heterologous promoter]	1.0	6	1	0	0
54011	1624	human spleen	[human spleen]	1.0	2	1	0	0
54012	1624	certain circumstances,	[certain circumstances,]	1.0	2	1	0	0
54013	1624	certain circumstances.	[certain circumstances.]	1.0	2	1	0	0
54014	1624	nm aldosterone	[nM aldosterone]	1.0	2	2	1	1
54015	1624	detectable activation of caspase -1	[detectable activation of caspase -1]	1.0	5	1	0	0
54016	1624	attendant symptom of this disorder	[attendant symptoms of this disorder]	1.0	5	1	0	0
54017	1624	cell in the subline region,	[cells in the sublining region,]	1.0	5	1	0	0
54018	1624	rheumatoid synovial fluid monocyte /macrophage	[rheumatoid synovial fluid monocytes /macrophages]	1.0	5	1	0	0
54019	1624	CD3 -dependent T cell activation	[CD3 -dependent T cell activation]	1.0	5	1	0	0
54020	1624	increase in ap-1 -binding activity	[increase in AP-1 -binding activity]	1.0	5	1	0	0
54021	1624	125(oh)2d2 production by T lymphocyte	[1,25(OH)2D2 production by T lymphocytes]	1.0	5	1	0	0
54022	1624	hormone-dependent trans-activator	[hormone-dependent trans-activator]	1.0	2	1	0	0
54023	1624	constitutive complex	[constitutive complex]	1.0	2	2	1	1
54024	1624	cd11c promoter	[CD11c promoter]	1.0	2	2	1	1
54025	1624	hsf of NFkappaB in monocyte	[HSF of NFkappaB in monocytes]	1.0	5	1	0	0
54026	1624	gr transrepression	[GR transrepression]	1.0	2	1	0	0
54027	1624	unstimulated cells,	[unstimulated cells,]	1.0	2	1	0	0
54028	1624	addition, aspirin	[addition, aspirin]	1.0	2	1	0	0
54029	1624	physical association of the kinase	[physical association of the kinase]	1.0	5	1	0	0
54030	1624	lps (10	[LPS (10]	1.0	2	1	0	0
54031	1624	activation of ca(2+) -dependent pathway alone	[Activation of Ca(2+) -dependent pathways alone]	1.0	6	1	0	0
54032	1624	Subunit S6 a integral component	[Subunit S6 an integral component]	1.0	5	1	0	0
54033	1624	most HTLV-I -bear cell line	[most HTLV-I -bearing cell lines]	1.0	5	1	0	0
54034	1624	estradiol e2	[estradiol E2]	1.0	2	1	0	0
54035	1624	characterization of the two gene	[Characterization of the two genes]	1.0	5	1	0	0
54036	1624	dna-bound complex	[DNA-bound complexes]	1.0	2	2	2	2
54037	1624	hematopoietic differentiation	[hematopoietic differentiation]	1.0	2	2	2	2
54038	1624	PMA PMA	[PMA PMA]	1.0	2	1	0	0
54039	1624	two NF-kappa b dna-binding activity	[two NF-kappa B DNA-binding activities]	1.0	5	1	0	0
54040	1624	foam cell formation by uptake	[foam cell formation by uptake]	1.0	5	1	0	0
54041	1624	axillary lymph node involvement (p	[axillary lymph node involvement (P]	1.0	5	1	0	0
54042	1624	transcription factor in b cell	[transcription factors in B cells]	1.0	5	1	0	0
54043	1624	ligand binding of the il-10 receptor	[Ligand binding of the IL-10 receptor]	1.0	6	1	0	0
54044	1624	site suitable for peptide recognition	[sites suitable for peptide recognition]	1.0	5	1	0	0
54045	1624	such approaches.	[such approaches.]	1.0	2	1	0	0
54046	1624	rapid responses.	[rapid responses.]	1.0	2	1	0	0
54047	1624	very little information about the regulation	[very little information about the regulation]	1.0	6	1	0	0
54048	1624	MHC-peptide complex	[MHC-peptide complexes]	1.0	2	1	0	0
54049	1624	corticosterone level	[corticosterone levels]	1.0	2	1	0	0
54050	1624	tetracycline-regulatable system	[tetracycline-regulatable system]	1.0	2	1	0	0
54051	1624	NF-kappa b activation by inducer	[NF-kappa B activation by inducers]	1.0	5	1	0	0
54052	1624	opposite directions.	[opposite directions.]	1.0	2	1	0	0
54053	1624	bivalent cation such as mg2+	[Bivalent cations such as Mg2+]	1.0	5	1	0	0
54054	1624	exposure time to the steroid	[exposure time to the steroid]	1.0	5	1	0	0
54055	1624	tumor site	[tumor site]	1.0	2	1	0	0
54056	1624	IL-12 stat4	[IL-12 STAT4]	1.0	2	1	0	0
54057	1624	CRE element	[CRE element]	1.0	2	2	2	2
54058	1624	three immunophilin	[three immunophilins]	1.0	2	2	1	1
54059	1624	breast recurrence	[breast recurrence]	1.0	2	2	2	2
54060	1624	seborrheic keratose	[seborrheic keratoses,]	1.0	2	1	0	0
54061	1624	24 h of prl stimulation	[24 h of PRL stimulation]	1.0	5	1	0	0
54062	1624	GM-CSF rrna	[GM-CSF mRNAs]	1.0	2	1	0	0
54063	1624	intrinsic high potential for mutation expansion	[intrinsic high potential for mutation expansion]	1.0	6	1	0	0
54064	1624	overexpression of the p50 protein	[Overexpression of the p50 proteins]	1.0	5	1	0	0
54065	1624	human prostatic cancer lncap cell	[human prostatic cancer LNCaP cells]	1.0	5	1	0	0
54066	1624	hiv-1-infected cell	[HIV-1-infected cells]	1.0	2	1	0	0
54067	1624	functional datum	[functional data.]	1.0	2	2	1	1
54068	1624	pkc isotype	[PKC isotypes]	1.0	2	2	2	2
54069	1624	fertile woman	[fertile women]	1.0	2	1	0	0
54070	1624	spleen development	[spleen development]	1.0	2	1	0	0
54071	1624	adhesion of monocytic u937 cell	[adhesion of monocytic U937 cells]	1.0	5	1	0	0
54072	1624	senescent cell	[senescent cells]	1.0	2	1	0	0
54073	1624	globin chain	[globin chains]	1.0	2	2	2	2
54074	1624	two disorders: xeroderma pigmentosum XP	[two disorders: xeroderma pigmentosum XP]	1.0	5	1	0	0
54075	1624	PEBP2/CBF family	[PEBP2/CBF family]	1.0	2	2	2	2
54076	1624	deletion of the glucocorticoid response element	[Deletion of the glucocorticoid response elements]	1.0	6	1	0	0
54077	1624	serum induction	[serum induction]	1.0	2	1	0	0
54078	1624	1.3 kb)	[1.3 kb)]	1.0	2	1	0	0
54079	1624	T lymphocyte proliferation utilize CD40	[T lymphocyte proliferation utilizing CD40]	1.0	5	1	0	0
54080	1624	one order	[one order]	1.0	2	1	0	0
54081	1624	inhibitor of nitric oxide synthase	[inhibitor of nitric oxide synthase]	1.0	5	1	0	0
54082	1624	contain a bind site for Sp1	[containing a binding site for Sp1]	1.0	6	1	0	0
54083	1624	embryonic-fetal phenotype	[embryonic-fetal phenotype]	1.0	2	1	0	0
54084	1624	inhibitor of viral reverse transcriptase	[inhibitor of viral reverse transcriptase]	1.0	5	1	0	0
54085	1624	amino acid 199 to 214,	[amino acids 199 to 214,]	1.0	5	1	0	0
54086	1624	IkB alpha phosphorylation by PKC-	[IkB alpha phosphorylation by PKC-]	1.0	5	1	0	0
54087	1624	antiproliferative effect of vd analogue	[antiproliferative effect of VD analogues]	1.0	5	1	0	0
54088	1624	functional characterization of this promoter	[functional characterization of this promoter]	1.0	5	1	0	0
54089	1624	USF/c-Myc up-regulation of cxcr4 promoter activity	[USF/c-Myc up-regulation of CXCR4 promoter activity]	1.0	6	1	0	0
54090	1624	antitumor effect	[antitumor effect]	1.0	2	1	0	0
54091	1624	biologic implications.	[biologic implications.]	1.0	2	1	0	0
54092	1624	human endometrium	[human endometrium]	1.0	2	1	0	0
54093	1624	murine interleukin (il)-2 receptor alpha chain	[murine interleukin (IL)-2 receptor alpha chain]	1.0	6	1	0	0
54094	1624	presentation of self-antigen by DC	[presentation of self-antigen by DC]	1.0	5	1	0	0
54095	1624	KBF1/p50 factor	[KBF1/p50 factor]	1.0	2	1	0	0
54096	1624	substantial amount	[substantial amount]	1.0	2	4	3	1
54097	1624	distinct deletion	[distinct deletion]	1.0	2	1	0	0
54098	1624	proper microarchitecture	[proper microarchitecture]	1.0	2	1	0	0
54099	1624	control p	[controls P]	1.0	2	2	2	2
54100	1624	isolation of the cDNA clone	[isolation of the cDNA clone]	1.0	5	1	0	0
54101	1624	polyomavirus enhancer-binding protein 2/core-binding factor pebp2/cbf	[polyomavirus enhancer-binding protein 2/core-binding factor PEBP2/CBF]	1.0	6	1	0	0
54102	1624	adeno-associated virus	[adeno-associated virus]	1.0	2	2	1	1
54103	1624	tissue specific regulation of gene expression	[Tissue specific regulation of gene expression]	1.0	6	1	0	0
54104	1624	tpa increase in c-jun mrna level	[TPA increases in c-jun mRNA levels]	1.0	6	1	0	0
54105	1624	methods: thp-1 cell a cell line	[METHODS: THP-1 cells a cell line]	1.0	6	1	0	0
54106	1624	pore complex	[pore complex]	1.0	2	2	2	2
54107	1624	conventional id-3	[conventional Id-3]	1.0	2	1	0	0
54108	1624	L. monocytogent	[L. monocytogenes]	1.0	2	1	0	0
54109	1624	additional pathway	[additional pathways]	1.0	2	2	1	1
54110	1624	none of the other leukemia	[None of the other leukemias]	1.0	5	1	0	0
54111	1624	Rac response of ap-1 activation	[Rac responses of AP-1 activation]	1.0	5	1	0	0
54112	1624	t-cell epitope	[T-cell epitope]	1.0	2	2	2	2
54113	1624	tfiie beta	[TFIIE beta]	1.0	2	1	0	0
54114	1624	-specific antisense (as) phosphorothioate oligonucleotide	[-specific antisense (AS) phosphorothioate oligonucleotides]	1.0	5	1	0	0
54115	1624	maximum of 310 binding sites/nucleus	[maximum of 310 binding sites/nucleus]	1.0	5	1	0	0
54116	1624	molecular cue	[Molecular cues]	1.0	2	1	0	0
54117	1624	evidence for gene topography independent	[evidence for gene topography independent]	1.0	5	1	0	0
54118	1624	[3h]glycosaminoglycan synthesis	[[3H]glycosaminoglycan synthesis]	1.0	2	1	0	0
54119	1624	stat-1alpha binding	[STAT-1alpha binding]	1.0	2	1	0	0
54120	1624	ige secretion	[IgE secretion]	1.0	2	1	0	0
54121	1624	activate many of this pathways.	[activating many of these pathways.]	1.0	5	1	0	0
54122	1624	lipopolysaccharide (lps)-stimulated production of inflammatory cytokine	[lipopolysaccharide (LPS)-stimulated production of inflammatory cytokines]	1.0	6	1	0	0
54123	1624	E3 alpha	[E3 alpha]	1.0	2	1	0	0
54124	1624	inducible regulator	[inducible regulator]	1.0	2	2	2	2
54125	1624	receptor 1	[receptor 1]	1.0	2	2	1	1
54126	1624	alter the cellular redox state.	[altering the cellular redox state.]	1.0	5	1	0	0
54127	1624	tobacco smoke	[Tobacco smoke]	1.0	2	2	1	1
54128	1624	stat1 alpha with stat1 alpha	[STAT1 alpha with STAT1 alpha]	1.0	5	1	0	0
54129	1624	ability of various transcription factor	[ability of various transcription factors]	1.0	5	1	0	0
54130	1624	contain cepharanthine as a major component,	[containing cepharanthine as a major component,]	1.0	6	1	0	0
54131	1624	addition contribute to the understanding	[addition contributing to the understanding]	1.0	5	1	0	0
54132	1624	signalling event	[signalling event]	1.0	2	2	2	2
54133	1624	precise factor	[precise factors]	1.0	2	1	0	0
54134	1624	2.5-fold increase in promoter activity	[2.5-fold increase in promoter activity]	1.0	5	1	0	0
54135	1624	helix-loop-helix transcription	[helix-loop-helix transcription]	1.0	2	2	1	1
54136	1624	11.8 pm)	[11.8 pM)]	1.0	2	1	0	0
54137	1624	Recently, CD40	[Recently, CD40]	1.0	2	1	0	0
54138	1624	gammac mutation	[gammac mutations]	1.0	2	1	0	0
54139	1624	b lymphocyte by Epstein-Barr virus	[B lymphocytes by Epstein-Barr virus]	1.0	5	2	1	1
54140	1624	cytoskeletal protein	[cytoskeletal proteins]	1.0	2	1	0	0
54141	1624	b7.1 rdna	[B7.1 cDNAs]	1.0	2	1	0	0
54142	1624	Addition of untreated thp-1 cell	[Addition of untreated THP-1 cells]	1.0	5	1	0	0
54143	1624	gh ul75	[gH UL75]	1.0	2	1	0	0
54144	1624	locus region	[locus-activating region]	1.0	2	1	0	0
54145	1624	antioxidant on tumor necrosis factor	[antioxidants on tumor necrosis factor]	1.0	5	1	0	0
54146	1624	synaptic transmission	[synaptic transmission]	1.0	2	1	0	0
54147	1624	cellular sensitivity to NK cell	[cellular sensitivity to NK cells]	1.0	5	1	0	0
54148	1624	aids case	[AIDS cases]	1.0	2	1	0	0
54149	1624	level of several inflammatory cytokine	[levels of several inflammatory cytokines]	1.0	5	1	0	0
54150	1624	Fc gamma	[Fc gamma]	1.0	2	2	1	1
54151	1624	novel human homeobox gene HB9	[novel human homeobox gene HB9]	1.0	5	1	0	0
54152	1624	many function of human alveolar macrophage	[many functions of human alveolar macrophages]	1.0	6	1	0	0
54153	1624	cytosol of tnf T cell	[cytosols of TNF T cells]	1.0	5	1	0	0
54154	1624	novel therapy	[novel therapies]	1.0	2	1	0	0
54155	1624	replicate as a result of recombination	[replicating as a result of recombination]	1.0	6	1	0	0
54156	1624	EBV latency	[EBV latency]	1.0	2	1	0	0
54157	1624	further investigation	[further investigations]	1.0	2	1	0	0
54158	1624	negative reaction	[negative reaction]	1.0	2	1	0	0
54159	1624	direct expression of vcam-1 in huvec	[directing expression of VCAM-1 in HUVEC]	1.0	6	1	0	0
54160	1624	ar loci on the long arm,	[AR loci on the long arm,]	1.0	6	1	0	0
54161	1624	ovary syndrome	[ovary syndrome]	1.0	2	2	2	2
54162	1624	sp1 cleavage during anti-igm-induced apoptosis	[SP1 cleavage during anti-IgM-induced apoptosis]	1.0	5	1	0	0
54163	1624	moreover, induction of G(S)alpha expression	[Moreover, induction of G(S)alpha expression]	1.0	5	1	0	0
54164	1624	few alterations,	[few alterations,]	1.0	2	1	0	0
54165	1624	brainstem nuclei	[brainstem nuclei]	1.0	2	1	0	0
54166	1624	antigen-driven hypermutation	[antigen-driven hypermutation]	1.0	2	1	0	0
54167	1624	STAT3alpha serine	[STAT3alpha serine]	1.0	2	1	0	0
54168	1624	level of c-fo and/or c-jun mrna	[levels of c-fos and/or c-jun mRNA]	1.0	6	1	0	0
54169	1624	chromosome 9p21	[chromosome 9p21]	1.0	2	1	0	0
54170	1624	Study use	[Studies using]	1.0	2	1	0	0
54171	1624	PKC down-regulation	[PKC down-regulation]	1.0	2	1	0	0
54172	1624	nf-y binding	[NF-Y binding]	1.0	2	2	1	1
54173	1624	binding assay use 125i-labeled c-c chemokine	[Binding assays using 125I-labeled C-C chemokines]	1.0	6	1	0	0
54174	1624	interferon-gamma receptor	[interferon-gamma receptor]	1.0	2	2	2	2
54175	1624	BA differentiation	[BA differentiation]	1.0	2	1	0	0
54176	1624	contain functional ebf -binding site	[containing functional EBF -binding sites]	1.0	5	1	0	0
54177	1624	abnormality of cyclic adenosine monophosphate signal	[Abnormalities of cyclic adenosine monophosphate signaling]	1.0	6	1	0	0
54178	1624	construct capable	[construct capable]	1.0	2	1	0	0
54179	1624	erythrocytic (globins)	[erythrocytic (globins)]	1.0	2	1	0	0
54180	1624	transient-transfection experiment in embryonal carcinoma cell	[Transient-transfection experiments in embryonal carcinoma cells]	1.0	6	1	0	0
54181	1624	CD28 ligation,	[CD28 ligation,]	1.0	2	1	0	0
54182	1624	c-rel (proto)oncogenes	[c-rel (proto)oncogenes]	1.0	2	1	0	0
54183	1624	March 12;259(5101):1523]	[Mar 12;259(5101):1523]]	1.0	2	1	0	0
54184	1624	135-(oh)2d3 induction of 24-hydroxylase mrna level	[1,25-(OH)2D3 induction of 24-hydroxylase mRNA levels]	1.0	6	1	0	0
54185	1624	bl cell	[BL cells]	1.0	2	2	2	2
54186	1624	different compound	[different compounds]	1.0	2	1	0	0
54187	1624	novel assay	[novel assay]	1.0	2	2	1	1
54188	1624	encode the t-cell fk506 -binding protein	[encoding the T-cell FK506 -binding protein]	1.0	6	1	0	0
54189	1624	pharmacologic inhibition	[pharmacologic inhibition]	1.0	2	1	0	0
54190	1624	IL-5 cell	[IL-5 cells]	1.0	2	1	0	0
54191	1624	gene activation culminate in cell	[gene activation culminating in cells]	1.0	5	1	0	0
54192	1624	immunofluorescence colocalization	[Immunofluorescence colocalization]	1.0	2	1	0	0
54193	1624	knowledge of the polyamine pattern	[knowledge of the polyamine pattern]	1.0	5	1	0	0
54194	1624	interaction of fibronectin with vla-5 receptor	[Interaction of fibronectin with VLA-5 receptor]	1.0	6	1	0	0
54195	1624	direct binding by the z protein	[direct binding by the Z protein]	1.0	6	1	0	0
54196	1624	effector domain	[effector domains]	1.0	2	2	1	1
54197	1624	bcd transcript	[Bcd transcripts]	1.0	2	1	0	0
54198	1624	important role in immune response	[important roles in immune responses]	1.0	5	1	0	0
54199	1624	expression of adult beta-like globin gene	[expression of adult beta-like globin genes]	1.0	6	1	0	0
54200	1624	NF-kappaB component with monocyte differentiation	[NF-kappaB components with monocyte differentiation]	1.0	5	1	0	0
54201	1624	several gene regulate the growth	[several genes regulating the growth]	1.0	5	1	0	0
54202	1624	example, in experiment involve clone	[example, in experiments involving clones]	1.0	5	1	0	0
54203	1624	abnormal myelopoiesis due to pml/raralpha expression	[abnormal myelopoiesis due to PML/RARalpha expression]	1.0	6	1	0	0
54204	1624	similar signalling,	[similar signalling,]	1.0	2	1	0	0
54205	1624	new complex	[new complex]	1.0	2	2	2	2
54206	1624	lps nf-kappa b/c-rel nuclear translocation	[LPS NF-kappa B/c-Rel nuclear translocation]	1.0	5	1	0	0
54207	1624	molecular size of 37745 dalton	[molecular size of 37,745 daltons]	1.0	5	1	0	0
54208	1624	three molecular clone of hiv-1	[Three molecular clones of HIV-1]	1.0	5	1	0	0
54209	1624	stimulation of the tcr/cd3 complex	[stimulation of the TCR/CD3 complex]	1.0	5	1	0	0
54210	1624	effect on mcp-1 expression in monocyte	[effect on MCP-1 expression in monocytes]	1.0	6	1	0	0
54211	1624	assay reproducibility	[assay reproducibility]	1.0	2	1	0	0
54212	1624	cellular calcium	[cellular calcium]	1.0	2	1	0	0
54213	1624	similar potentiation	[similar potentiation]	1.0	2	2	2	2
54214	1624	oligomer corresponding	[oligomer corresponding]	1.0	2	1	0	0
54215	1624	apoptosis of myeloid progenitor cells,	[apoptosis of myeloid progenitor cells,]	1.0	5	1	0	0
54216	1624	production of cytokine of neutrophil	[production of cytokines of neutrophils]	1.0	5	1	0	0
54217	1624	also proliferation.	[also proliferation.]	1.0	2	1	0	0
54218	1624	pp repeat	[pp repeat]	1.0	2	1	0	0
54219	1624	48 hour	[48 hours]	1.0	2	3	2	1
54220	1624	resident gene	[resident genes]	1.0	2	1	0	0
54221	1624	attribute the lack of cortisol inhibition	[attributing the lack of cortisol inhibition]	1.0	6	1	0	0
54222	1624	rho v14rho	[Rho V14Rho]	1.0	2	1	0	0
54223	1624	cellular activation,	[cellular activation,]	1.0	2	1	0	0
54224	1624	neutrophil maturation.	[neutrophil maturation.]	1.0	2	1	0	0
54225	1624	strike increase in the level	[striking increase in the levels]	1.0	5	1	0	0
54226	1624	ubiquitous polypeptide	[ubiquitous polypeptide]	1.0	2	1	0	0
54227	1624	allergic asthma	[allergic asthma]	1.0	2	2	1	1
54228	1624	suffer from icenko- cushingd' syndrome	[suffering from Icenko- Cushing's syndrome]	1.0	5	1	0	0
54229	1624	functional cooperativity in transfection study	[functional cooperativity in transfection studies]	1.0	5	1	0	0
54230	1624	Recent studies,	[Recent studies,]	1.0	2	1	0	0
54231	1624	protein of the NF-kappaB family	[proteins of the NF-kappaB family]	1.0	5	1	0	0
54232	1624	level of Oct-1 binding protein	[level of Oct-1 binding proteins]	1.0	5	1	0	0
54233	1624	extravascular compartment	[extravascular compartment]	1.0	2	1	0	0
54234	1624	presence of the box motif	[presence of the box motifs]	1.0	5	1	0	0
54235	1624	severe vkc for the presence	[severe VKC for the presence]	1.0	5	1	0	0
54236	1624	(gamma c)	[(gamma c)]	1.0	2	1	0	0
54237	1624	cytolytic activity	[cytolytic activity]	1.0	2	2	1	1
54238	1624	TNF -dependent nf-kappa b activation	[TNF -dependent NF-kappa B activation]	1.0	5	1	0	0
54239	1624	apparent dissociation rate of [3H]dexamethasone	[apparent dissociation rate of [3H]dexamethasone]	1.0	5	1	0	0
54240	1624	annexinv labeling	[AnnexinV labeling]	1.0	2	1	0	0
54241	1624	Janus kinase 3 tyrosine kinase	[Janus kinase 3 tyrosine kinase]	1.0	5	1	0	0
54242	1624	dna-binding component	[DNA-binding component]	1.0	2	1	0	0
54243	1624	mammary reduction	[mammary reduction]	1.0	2	2	2	2
54244	1624	Succinate alone	[Succinate alone]	1.0	2	1	0	0
54245	1624	ca2+ influx	[Ca2+ influx]	1.0	2	2	1	1
54246	1624	accumulation of interleukin-1 beta mrna	[accumulation of interleukin-1 beta mRNA]	1.0	5	1	0	0
54247	1624	bronchial hyperresponsiveness	[bronchial hyperresponsiveness]	1.0	2	1	0	0
54248	1624	anti-CD3 stimulation of T cell	[anti-CD3 stimulation of T cells]	1.0	5	1	0	0
54249	1624	trilineage potential	[trilineage potential]	1.0	2	1	0	0
54250	1624	mechanism of action of Ro	[mechanism of action of Ro]	1.0	5	1	0	0
54251	1624	tumor necrosis factor TNF other cytokine	[tumor necrosis factor TNF other cytokines]	1.0	6	1	0	0
54252	1624	thigh lesion of five patient	[thigh lesions of five patients]	1.0	5	1	0	0
54253	1624	steroid effect on this cell	[steroid effects on these cells]	1.0	5	1	0	0
54254	1624	2.5 h.	[2.5 h,]	1.0	2	1	0	0
54255	1624	induction of IkappaBalpha by DEX	[induction of IkappaBalpha by DEX]	1.0	5	1	0	0
54256	1624	B-cell specificity	[B-cell specificity]	1.0	2	2	1	1
54257	1624	expression of the CD5 gene	[expression of the CD5 gene]	1.0	5	1	0	0
54258	1624	band neutrophil	[band neutrophils]	1.0	2	1	0	0
54259	1624	cortical thymocyte undergo negative selection	[cortical thymocytes undergoing negative selection]	1.0	5	1	0	0
54260	1624	tumor size	[tumor size]	1.0	2	2	1	1
54261	1624	consistent pattern of variation in expression	[consistent patterns of variation in expression]	1.0	6	1	0	0
54262	1624	many tissue include hematopoietic cell	[many tissues including hematopoietic cells]	1.0	5	1	0	0
54263	1624	rhythmic differentiation	[rhythmic differentiation]	1.0	2	1	0	0
54264	1624	predominantly activate	[predominantly activating]	1.0	2	1	0	0
54265	1624	10 subject	[10 subjects]	1.0	2	2	2	2
54266	1624	x;17 translocation	[X;17 translocation]	1.0	2	1	0	0
54267	1624	mac-1 cell surface antigen expression	[Mac-1 cell surface antigen expression]	1.0	5	1	0	0
54268	1624	evidence for a trans-acting activator function	[Evidence for a trans-acting activator function]	1.0	6	1	0	0
54269	1624	contrast, p107	[contrast, p107]	1.0	2	1	0	0
54270	1624	cell cycle behavior in T cell	[cell cycle behavior in T cells]	1.0	6	1	0	0
54271	1624	t-cell apoptosis	[T-cell apoptosis]	1.0	2	1	0	0
54272	1624	ability of wild type domain	[ability of wild type domain]	1.0	5	1	0	0
54273	1624	PKC depletion	[PKC depletion]	1.0	2	1	0	0
54274	1624	potentially more common pharmacogenetic syndrome	[potentially more common pharmacogenetic syndrome]	1.0	5	1	0	0
54275	1624	4 and, in the carboxy-terminus	[4 and, in the carboxy-terminus]	1.0	5	1	0	0
54276	1624	Acquisition of hsf3 dna-binding activity	[Acquisition of HSF3 DNA-binding activity]	1.0	5	1	0	0
54277	1624	resting eosinophil	[resting eosinophils]	1.0	2	1	0	0
54278	1624	nuclear proto-oncogent	[nuclear proto-oncogenes]	1.0	2	1	0	0
54279	1624	noncleavable alteration	[noncleavable alterations]	1.0	2	1	0	0
54280	1624	multiple cellular dna-binding transcription factor	[Multiple cellular DNA-binding transcription factors]	1.0	5	1	0	0
54281	1624	antibody in sera of patient	[Antibodies in sera of patients]	1.0	5	1	0	0
54282	1624	rodent homolog	[rodent homologs]	1.0	2	1	0	0
54283	1624	negative control	[negative control]	1.0	2	1	0	0
54284	1624	AP-1 transcription	[AP-1 transcription]	1.0	2	2	2	2
54285	1624	antiviral therapy	[antiviral therapy]	1.0	2	1	0	0
54286	1624	different chromosomes.	[different chromosomes.]	1.0	2	1	0	0
54287	1624	internalization of lps into monocyte	[internalization of LPS into monocytes]	1.0	5	1	0	0
54288	1624	2 receptor alpha il-2r alpha	[2 receptor alpha IL-2R alpha]	1.0	5	1	0	0
54289	1624	previous investigation on the formation	[previous investigations on the formation]	1.0	5	1	0	0
54290	1624	Positive hybridization	[Positive hybridization]	1.0	2	1	0	0
54291	1624	nh2cl (20-70	[NH2Cl (20-70]	1.0	2	1	0	0
54292	1624	cytolytic action	[cytolytic action]	1.0	2	2	1	1
54293	1624	suggest persistence despite defective onset	[suggesting persistence despite defective onset]	1.0	5	1	0	0
54294	1624	synergism between the CD3 antigen-	[Synergism between the CD3 antigen-]	1.0	5	1	0	0
54295	1624	different part of the sequence	[different parts of the sequence]	1.0	5	1	0	0
54296	1624	mutagenesis studies,	[Mutagenesis studies,]	1.0	2	1	0	0
54297	1624	control of globin gene expression	[control of globin gene expression]	1.0	5	1	0	0
54298	1624	nuclear t3 maximal binding capacity MBC	[nuclear T3 maximal binding capacity MBC]	1.0	6	1	0	0
54299	1624	Active suppression	[Active suppression]	1.0	2	1	0	0
54300	1624	protein bind the interferon-inducible regulatory element	[proteins binding the interferon-inducible regulatory element]	1.0	6	1	0	0
54301	1624	transcription from the IL-2R alpha promoter	[Transcription from the IL-2R alpha promoter]	1.0	6	1	0	0
54302	1624	rather important marker for tcr gene	[rather important markers for TCR genes]	1.0	6	1	0	0
54303	1624	mouse embryonic stem (es) cell	[mouse embryonic stem (ES) cells]	1.0	5	1	0	0
54304	1624	t-cell receptor alpha- delta- chain	[T-cell receptor alpha- delta- chains]	1.0	5	1	0	0
54305	1624	histochemical marker	[histochemical markers]	1.0	2	1	0	0
54306	1624	strong association of the disease	[strong association of the disease]	1.0	5	1	0	0
54307	1624	tfiie alpha	[TFIIE alpha]	1.0	2	1	0	0
54308	1624	301 nuclei	[301 nuclei]	1.0	2	1	0	0
54309	1624	il-2 regulation	[IL-2 regulation]	1.0	2	1	0	0
54310	1624	significantly more glucocorticoid receptor gr	[significantly more glucocorticoid receptors GR]	1.0	5	1	0	0
54311	1624	utilize oligonucleotide homologous to each	[utilizing oligonucleotides homologous to each]	1.0	5	1	0	0
54312	1624	all-tran differentiation of the cells.	[all-trans differentiation of the cells.]	1.0	5	1	0	0
54313	1624	normal function	[normal function]	1.0	2	2	2	2
54314	1624	activation response	[activation response]	1.0	2	2	2	2
54315	1624	such as nerve growth factor NGF	[such as nerve growth factor NGF]	1.0	6	1	0	0
54316	1624	functional site	[functional site]	1.0	2	2	2	2
54317	1624	expression of the c-fm gene	[expression of the c-fms gene]	1.0	5	1	0	0
54318	1624	critical component of U1 u1a/u1b	[critical components of U1 U1A/U1B]	1.0	5	1	0	0
54319	1624	nf of T cell NFAT	[NF of T cells NFAT]	1.0	5	1	0	0
54320	1624	combinatorial effect of monocyte adhesion	[combinatorial effects of monocyte adhesion]	1.0	5	1	0	0
54321	1624	result in the generation of mediator	[resulting in the generation of mediators]	1.0	6	1	0	0
54322	1624	palmitate conjugate of a antibody	[palmitate conjugate of a antibody]	1.0	5	1	0	0
54323	1624	two plasmacytoma	[two plasmacytomas]	1.0	2	1	0	0
54324	1624	macrophage-lymphocyte interaction	[macrophage-lymphocyte interactions]	1.0	2	1	0	0
54325	1624	understand the mechanism of developmental regulation	[Understanding the mechanism of developmental regulation]	1.0	6	1	0	0
54326	1624	positive correlation between the transcriptional	[positive correlation between the transcriptional]	1.0	5	1	0	0
54327	1624	reason for the dissimilar oncogenicity	[reasons for the dissimilar oncogenicities]	1.0	5	1	0	0
54328	1624	T cell activation involve shp2	[T cell activation involving SHP2]	1.0	5	1	0	0
54329	1624	suppression of T immune response	[suppression of T immune responses]	1.0	5	1	0	0
54330	1624	plasma 18-hydroxycorticosterone	[Plasma 18-hydroxycorticosterone]	1.0	2	1	0	0
54331	1624	ability of the peptide ANG	[ability of the peptide ANG]	1.0	5	1	0	0
54332	1624	use a sensitive western blot assay	[using a sensitive Western blot assay]	1.0	6	1	0	0
54333	1624	Spi-C RNA	[Spi-C RNA]	1.0	2	1	0	0
54334	1624	factor with indistinguishable sequence specificity	[factor with indistinguishable sequence specificity]	1.0	5	1	0	0
54335	1624	B-cell expansion	[B-cell expansion]	1.0	2	1	0	0
54336	1624	auto-inhibitory domain	[auto-inhibitory domains]	1.0	2	1	0	0
54337	1624	more interior	[more interior]	1.0	2	1	0	0
54338	1624	c-terminal peptide	[C-terminal peptide]	1.0	2	2	2	2
54339	1624	wp activity in non-B cell	[Wp activity in non-B cells]	1.0	5	1	0	0
54340	1624	transient cotransfection	[Transient cotransfection]	1.0	2	2	2	2
54341	1624	calcium ionophore,	[calcium ionophore,]	1.0	2	1	0	0
54342	1624	CD20 e box binding protein	[CD20 E box binding proteins]	1.0	5	1	0	0
54343	1624	induction of cell surface adhesion molecule	[Induction of cell surface adhesion molecules]	1.0	6	1	0	0
54344	1624	occur in multiple distinct allelic family	[occurring in multiple distinct allelic families]	1.0	6	1	0	0
54345	1624	vascular disease	[vascular disease]	1.0	2	1	0	0
54346	1624	nuclear signalling	[nuclear signalling]	1.0	2	1	0	0
54347	1624	propagation of the Tat mutant	[propagation of the Tat mutants]	1.0	5	1	0	0
54348	1624	tcp (200 microM, 72 h),	[TCP (200 microM, 72 h),]	1.0	5	1	0	0
54349	1624	bind to a intracellular receptor belong	[binding to an intracellular receptor belonging]	1.0	6	1	0	0
54350	1624	ifn-induced tyrosine phosphorylation of STAT1	[IFN-induced tyrosine phosphorylation of STAT1]	1.0	5	1	0	0
54351	1624	expression of the M-CSF gene	[expression of the M-CSF gene]	1.0	5	1	0	0
54352	1624	allergic inflammatory disease include asthma	[allergic inflammatory diseases including asthma]	1.0	5	1	0	0
54353	1624	microm inhibitor	[microM inhibitors]	1.0	2	1	0	0
54354	1624	16 abnormality	[16 abnormalities]	1.0	2	2	2	2
54355	1624	generally permissive enhancer/ promoter interaction	[generally permissive enhancer/ promoter interaction]	1.0	5	1	0	0
54356	1624	(i) constitutive level of oncogene transcript	[(i) constitutive levels of oncogene transcripts]	1.0	6	1	0	0
54357	1624	single cDNA	[single cDNA]	1.0	2	1	0	0
54358	1624	term of inhibition in monocyte	[terms of inhibition in monocytes]	1.0	5	1	0	0
54359	1624	gene domain	[gene domain]	1.0	2	1	0	0
54360	1624	IL-2 receptor beta chain IL-2Rbeta	[IL-2 receptor beta chain IL-2Rbeta]	1.0	5	1	0	0
54361	1624	differentiation in vitro to macrophage	[differentiation in vitro to macrophages]	1.0	5	1	0	0
54362	1624	encoding cytokine	[encoding cytokines]	1.0	2	1	0	0
54363	1624	mesenchymal cell include human fibroblast	[mesenchymal cells including human fibroblasts]	1.0	5	1	0	0
54364	1624	direct interaction between the glucocorticoid receptor	[direct interaction between the glucocorticoid receptor]	1.0	6	1	0	0
54365	1624	time-frame of action of cysteamine	[time-frame of action of cysteamine]	1.0	5	1	0	0
54366	1624	target of autoreactive t-cell in iddm	[target of autoreactive T-cells in IDDM]	1.0	6	1	0	0
54367	1624	human granurocyte	[human granurocytes]	1.0	2	1	0	0
54368	1624	central mediator in cytokine activation	[central mediator in cytokine activation]	1.0	5	1	0	0
54369	1624	RAR activation	[RAR activation]	1.0	2	1	0	0
54370	1624	stat3 activation with kinetic similar	[Stat3 activation with kinetics similar]	1.0	5	1	0	0
54371	1624	recurrent aborter	[recurrent aborters]	1.0	2	1	0	0
54372	1624	translation lysate	[translation lysates]	1.0	2	1	0	0
54373	1624	receptor DNA	[receptor DNA]	1.0	2	1	0	0
54374	1624	B-cell activation	[B-cell activation]	1.0	2	1	0	0
54375	1624	N.Israel, j.virol.72:5852-5861,	[N.Israel, J.Virol.72:5852-5861,]	1.0	2	1	0	0
54376	1624	activation of the interleukin 6 gene	[Activation of the interleukin 6 gene]	1.0	6	1	0	0
54377	1624	impaired induction of c-fos/c-jun gene	[Impaired induction of c-fos/c-jun genes]	1.0	5	1	0	0
54378	1624	standard culture	[standard culture]	1.0	2	1	0	0
54379	1624	vitro kinase	[vitro kinase]	1.0	2	2	2	2
54380	1624	NF-kappaB family of transcription factor	[NF-kappaB family of transcription factors]	1.0	5	1	0	0
54381	1624	two tandem cysteine -rich LIM domain	[two tandem cysteine -rich LIM domains]	1.0	6	1	0	0
54382	1624	B-lymphoblastoid cell line clone 13	[B-lymphoblastoid cell line clone 13]	1.0	5	1	0	0
54383	1624	(three individual from the first group),	[(three individuals from the first group),]	1.0	6	1	0	0
54384	1624	cytogenetic abnormality	[cytogenetic abnormalities]	1.0	2	2	2	2
54385	1624	sp1 element	[Sp1 elements]	1.0	2	1	0	0
54386	1624	intra-cytoplasmic domain	[intra-cytoplasmic domain]	1.0	2	1	0	0
54387	1624	complex enhancer	[complex enhancer]	1.0	2	1	0	0
54388	1624	11 subject	[11 subjects]	1.0	2	2	1	1
54389	1624	tnf-alpha T lymphocyte from donor	[TNF-alpha T lymphocytes from donors]	1.0	5	1	0	0
54390	1624	stat5 binding	[STAT5 binding]	1.0	2	2	1	1
54391	1624	retention of the normal brca1 allele	[Retention of the normal BRCA1 allele]	1.0	6	1	0	0
54392	1624	peripheral leukocyte in asthmatic subject	[peripheral leukocytes in asthmatic subjects]	1.0	5	1	0	0
54393	1624	il-4 synthesis	[IL-4 synthesis]	1.0	2	1	0	0
54394	1624	nf-at motif	[NF-AT motifs]	1.0	2	1	0	0
54395	1624	modulatory switch	[modulatory switch]	1.0	2	1	0	0
54396	1624	c-fo messenger	[c-fos messenger]	1.0	2	1	0	0
54397	1624	supershift experiment use specific abs	[supershift experiments using specific Abs]	1.0	5	1	0	0
54398	1624	replication of hiv-1 in macrophage	[replication of HIV-1 in macrophages]	1.0	5	1	0	0
54399	1624	human bone	[human bone]	1.0	2	2	1	1
54400	1624	strict lineage-	[strict lineage-]	1.0	2	1	0	0
54401	1624	2- vector	[2- vectors]	1.0	2	1	0	0
54402	1624	constitutive signal	[constitutive signaling]	1.0	2	1	0	0
54403	1624	Further, Vpr	[Further, Vpr]	1.0	2	1	0	0
54404	1624	eklf heterozygote	[EKLF heterozygotes]	1.0	2	1	0	0
54405	1624	growth similar to serum-supplemented cultures.	[growth similar to serum-supplemented cultures.]	1.0	5	1	0	0
54406	1624	other enhancer	[other enhancers]	1.0	2	1	0	0
54407	1624	simultaneously; (3) non-dividing, normal pbl	[simultaneously; (3) non-dividing, normal PBL]	1.0	5	1	0	0
54408	1624	radiation dose of 4, 10,	[radiation doses of 4, 10,]	1.0	5	1	0	0
54409	1624	104-522 ppt i-te in blood fat	[104-522 ppt I-TE in blood fat]	1.0	6	1	0	0
54410	1624	macrophage-like characteristic	[macrophage-like characteristics]	1.0	2	1	0	0
54411	1624	c-ring modification	[C-ring modifications]	1.0	2	1	0	0
54412	1624	creb )/activating transcription factor-1 (atf-1) family	[CREB )/activating transcription factor-1 (ATF-1) family]	1.0	6	1	0	0
54413	1624	molecular target for oxidative signalling	[molecular targets for oxidative signalling]	1.0	5	1	0	0
54414	1624	enhancer upstream	[enhancer upstream]	1.0	2	2	2	2
54415	1624	activation of effector gene product	[activation of effector gene products]	1.0	5	1	0	0
54416	1624	il-2 message	[IL-2 message]	1.0	2	2	1	1
54417	1624	conclusion, activation	[conclusion, activation]	1.0	2	1	0	0
54418	1624	CD14	[CD14]	1.0	1	11	5	5
54419	1624	cell with a Ran mutant	[cells with a Ran mutant]	1.0	5	1	0	0
54420	1624	manlam activation	[ManLAM activation]	1.0	2	1	0	0
54421	1624	4.7%; 18,21-anhydroaldosterone	[4.7%; 18,21-anhydroaldosterone]	1.0	2	1	0	0
54422	1624	association of specific hla-dq allele	[association of specific HLA-DQ alleles]	1.0	5	1	0	0
54423	1624	even with a therapy as specific	[Even with a therapy as specific]	1.0	6	1	0	0
54424	1624	activity of a exogenous promoter	[activity of an exogenous promoter]	1.0	5	1	0	0
54425	1624	inhibitor of protein tyrosine phosphatase	[inhibitor of protein tyrosine phosphatases]	1.0	5	1	0	0
54426	1624	expression in early hematopoietic stage	[expression in early hematopoietic stages]	1.0	5	1	0	0
54427	1624	n.engl.j. med.324:308-317,	[N.Engl.J. Med.324:308-317,]	1.0	2	1	0	0
54428	1624	strain with mutation in gene	[Strains with mutations in gene]	1.0	5	1	0	0
54429	1624	ecd45ra+) T	[(CD45RA+) T]	1.0	2	2	2	2
54430	1624	expression of several b-cell-specific gene	[expression of several B-cell-specific genes]	1.0	5	1	0	0
54431	1624	secretion of tumor necrosis factor alpha	[secretion of tumor necrosis factor alpha]	1.0	6	1	0	0
54432	1624	interleukin-6 apoptosis of 1a9-m cell	[interleukin-6 apoptosis of 1A9-M cells]	1.0	5	1	0	0
54433	1624	level in the culture supernatant	[level in the culture supernatants]	1.0	5	2	2	2
54434	1624	adverse effect	[adverse effect]	1.0	2	2	1	1
54435	1624	determine how	[determining how]	1.0	2	1	0	0
54436	1624	transcriptional activation in T cell	[transcriptional activation in T cells]	1.0	5	2	1	1
54437	1624	Stat5 in human platelet lysate	[Stat5 in human platelet lysates]	1.0	5	1	0	0
54438	1624	total level	[total level]	1.0	2	1	0	0
54439	1624	first degree	[first degree]	1.0	2	1	0	0
54440	1624	thymic lymphocyte	[thymic lymphocytes]	1.0	2	1	0	0
54441	1624	-120 region	[-120 region]	1.0	2	1	0	0
54442	1624	gc resistance,	[GC resistance,]	1.0	2	1	0	0
54443	1624	c-fo mrna level in human monocyte	[c-fos mRNA levels in human monocytes]	1.0	6	1	0	0
54444	1624	cell-type-specific il-2r alpha gene expression	[cell-type-specific IL-2R alpha gene expression]	1.0	5	1	0	0
54445	1624	consequent up-regulation	[consequent up-regulation]	1.0	2	1	0	0
54446	1624	two other T cell line CEM	[Two other T cell lines CEM]	1.0	6	1	0	0
54447	1624	limit the duration of this response	[limiting the duration of this response]	1.0	6	1	0	0
54448	1624	2'-deoxy-3'-adenosine monophosphate	[2'-deoxy-3'-adenosine monophosphate]	1.0	2	1	0	0
54449	1624	cell surface receptor for prl	[cell surface receptors for PRL]	1.0	5	1	0	0
54450	1624	resting granulocyte	[resting granulocytes]	1.0	2	1	0	0
54451	1624	unsuppressed T	[unsuppressed T]	1.0	2	1	0	0
54452	1624	factor activity	[factor activity]	1.0	2	2	1	1
54453	1624	selective interaction	[selective interaction]	1.0	2	1	0	0
54454	1624	association dissociation rate for hugata-3	[association dissociation rates for huGATA-3]	1.0	5	1	0	0
54455	1624	distribution of this membrane protein	[distribution of this membrane protein]	1.0	5	1	0	0
54456	1624	inflammatory model	[inflammatory model]	1.0	2	1	0	0
54457	1624	il2r gamma	[IL2R gamma]	1.0	2	1	0	0
54458	1624	signal pathway in T cell	[signaling pathways in T cells]	1.0	5	2	2	2
54459	1624	DNA binding specificity of complex 3	[DNA binding specificity of complex 3]	1.0	6	1	0	0
54460	1624	costimulation of u1 cell with lps	[Costimulation of U1 cells with LPS]	1.0	6	1	0	0
54461	1624	functional criteria,	[functional criteria,]	1.0	2	1	0	0
54462	1624	region from -429 to -245	[region from -429 to -245]	1.0	5	1	0	0
54463	1624	plasma cortisol in the same group	[plasma cortisol in the same group]	1.0	6	1	0	0
54464	1624	delta gene	[delta gene]	1.0	2	1	0	0
54465	1624	specificity of ANG ii nf-kappab activation	[Specificity of ANG II NF-kappaB activation]	1.0	6	1	0	0
54466	1624	herpes simplex virus hsv lesion	[herpes simplex virus HSV lesion]	1.0	5	1	0	0
54467	1624	gel-shift assay use a probe	[gel-shift assays using an probe]	1.0	5	1	0	0
54468	1624	GM-CSF reporter	[GM-CSF reporter]	1.0	2	1	0	0
54469	1624	recombinant chloramphenicol acetyltransferase CAT plasmid	[recombinant chloramphenicol acetyltransferase CAT plasmids]	1.0	5	1	0	0
54470	1624	expression of the cd14 ag	[expression of the CD14 Ag]	1.0	5	1	0	0
54471	1624	salicylate treatment	[salicylate treatment]	1.0	2	1	0	0
54472	1624	stimuli, indicate the active factor	[stimuli, indicating the active factor]	1.0	5	1	0	0
54473	1624	AD1 transactivation domain of E2A	[AD1 transactivation domains of E2A]	1.0	5	1	0	0
54474	1624	colonic mucosa	[colonic mucosa]	1.0	2	1	0	0
54475	1624	48 hrs.	[48 hrs.]	1.0	2	1	0	0
54476	1624	hiv long terminal repeat -cat construct	[HIV long terminal repeat -CAT constructs]	1.0	6	1	0	0
54477	1624	pmn neutrophil granulocyte in vitro.	[PMN neutrophil granulocytes in vitro.]	1.0	5	1	0	0
54478	1624	common immunophilin	[common immunophilin]	1.0	2	1	0	0
54479	1624	ligation of immunoglobulin (ig) m	[ligation of immunoglobulin (Ig) M]	1.0	5	1	0	0
54480	1624	such cross-talking among distinct adhesion molecule	[such cross-talking among distinct adhesion molecules]	1.0	6	1	0	0
54481	1624	different response of myeloid cell	[different response of myeloid cells]	1.0	5	1	0	0
54482	1624	use recombinant zebra protein as antigen	[using recombinant ZEBRA protein as antigens]	1.0	6	1	0	0
54483	1624	promoter central 21 bp repeat	[promoter central 21 bp repeat]	1.0	5	1	0	0
54484	1624	rapid increase in the activity	[rapid increase in the activities]	1.0	5	1	0	0
54485	1624	important adaptor	[important adaptor]	1.0	2	1	0	0
54486	1624	sla-dq antigen	[SLA-DQ antigen]	1.0	2	2	2	2
54487	1624	creb camp response element binding protein	[CREB cAMP response element binding protein]	1.0	6	1	0	0
54488	1624	cluster of t-cell leukemia-specific translocation	[cluster of T-cell leukemia-specific translocations]	1.0	5	1	0	0
54489	1624	T lymphocyte in healthy female	[T lymphocytes in healthy females]	1.0	5	1	0	0
54490	1624	use chloram-phenicol acetyltransferase (cat) construct	[using chloram-phenicol acetyltransferase (CAT) constructs]	1.0	5	1	0	0
54491	1624	functional analysis by mammalian cell transfection	[functional analysis by mammalian cell transfection]	1.0	6	1	0	0
54492	1624	tnf-alpha signal	[TNF-alpha signaling]	1.0	2	1	0	0
54493	1624	cell hybridoma	[cell hybridoma]	1.0	2	2	1	1
54494	1624	androgen insensitivity in prostate cancer	[androgen insensitivity in prostate cancer]	1.0	5	1	0	0
54495	1624	Specific bright foci of gata-1 fluorescence	[Specific bright foci of GATA-1 fluorescence]	1.0	6	1	0	0
54496	1624	mechanism of action of dm	[mechanism of action of DM]	1.0	5	1	0	0
54497	1624	hence, induction of cell surface expression	[Hence, induction of cell surface expression]	1.0	6	1	0	0
54498	1624	T cell nf-at1 in tax-expressing	[T cells NF-AT1 in Tax-expressing]	1.0	5	1	0	0
54499	1624	expressed; however, cell express receptor	[expressed; however, cells expressing receptors]	1.0	5	1	0	0
54500	1624	lps induction of collagenase transcription	[LPS induction of collagenase transcription]	1.0	5	1	0	0
54501	1624	c-rel protooncogene	[c-rel protooncogene]	1.0	2	2	1	1
54502	1624	p50-p56 heterodimer of nf-kappa b	[p50-p56 heterodimer of NF-kappa B]	1.0	5	1	0	0
54503	1624	lysate from CD19 1e8 cell	[Lysates from CD19 1E8 cells]	1.0	5	1	0	0
54504	1624	A-T patient contain the translocation	[A-T patients containing the translocation]	1.0	5	1	0	0
54505	1624	MODY and/or late-onset type diabete	[MODY and/or late-onset type diabetes]	1.0	5	1	0	0
54506	1624	lineage commitment,	[lineage commitment,]	1.0	2	1	0	0
54507	1624	20-methyl- eneanalogue	[20-methyl- eneanalogues]	1.0	2	1	0	0
54508	1624	pathway distinct	[pathway distinct]	1.0	2	2	1	1
54509	1624	low CBG	[lower CBG]	1.0	2	1	0	0
54510	1624	two toxin	[two toxins]	1.0	2	1	0	0
54511	1624	human endothelial cell in hypoxia	[human endothelial cells in hypoxia]	1.0	5	1	0	0
54512	1624	1 bp deletion in exon	[1 bp deletion in exon]	1.0	5	1	0	0
54513	1624	bcl-2 expression by creb protein	[bcl-2 expression by CREB proteins]	1.0	5	1	0	0
54514	1624	only CD3	[only CD3]	1.0	2	1	0	0
54515	1624	nonerythroid nuclei	[nonerythroid nuclei]	1.0	2	1	0	0
54516	1624	platelet mass	[platelet mass]	1.0	2	1	0	0
54517	1624	range from 1 to 10 mmol/L.	[ranging from 1 to 10 mmol/L.]	1.0	6	1	0	0
54518	1624	camp response element bind protein	[cAMP response element binding protein]	1.0	5	1	0	0
54519	1624	three different isoform of CBF beta	[Three different isoforms of CBF beta]	1.0	6	1	0	0
54520	1624	other antioxidant --including ascorbic acid	[other antioxidants --including ascorbic acid]	1.0	5	1	0	0
54521	1624	ebv-transformed 244b human lymphoblastoid cell	[EBV-transformed 244B human lymphoblastoid cells]	1.0	5	1	0	0
54522	1624	basal promoter	[basal promoter]	1.0	2	2	2	2
54523	1624	gtpase rac	[GTPase Rac]	1.0	2	1	0	0
54524	1624	c-myb expression during t-cell activation	[c-myb expression during T-cell activation]	1.0	5	1	0	0
54525	1624	most gene	[most genes]	1.0	2	2	2	2
54526	1624	also in airway epithelial cell	[also in airway epithelial cells]	1.0	5	1	0	0
54527	1624	homology to the rel oncogene	[homology to the rel oncogene]	1.0	5	1	0	0
54528	1624	apl with the pml-rar alpha	[APLs with the PML-RAR alpha]	1.0	5	1	0	0
54529	1624	belong to the NF-kappa B family	[belonging to the NF-kappa B family]	1.0	6	1	0	0
54530	1624	modulate apoptosis	[modulating apoptosis]	1.0	2	1	0	0
54531	1624	activation of nf-kappa b activity	[activation of NF-kappa B activity]	1.0	5	1	0	0
54532	1624	ligand-induced tyrosine phosphorylation of Jak3	[ligand-induced tyrosine phosphorylation of Jak3]	1.0	5	1	0	0
54533	1624	host defense,	[host defense,]	1.0	2	2	1	1
54534	1624	I gamma	[I gamma]	1.0	2	2	2	2
54535	1624	kappab binding	[kappaB binding]	1.0	2	1	0	0
54536	1624	family of zinc finger protein	[family of zinc finger proteins]	1.0	5	1	0	0
54537	1624	il-1beta signal	[IL-1beta signal]	1.0	2	1	0	0
54538	1624	several distinct role for hsp90	[Several distinct roles for hsp90]	1.0	5	1	0	0
54539	1624	conclusion, strong c-myc mrna expression	[conclusion, strong c-myc mRNA expression]	1.0	5	1	0	0
54540	1624	addition to the transcription factor	[addition to the transcription factors]	1.0	5	1	0	0
54541	1624	two infant	[two infants]	1.0	2	2	2	2
54542	1624	caml (calcium-modulator	[CAML (calcium-modulator]	1.0	2	1	0	0
54543	1624	response to T cell receptor	[response to T cell receptor]	1.0	5	1	0	0
54544	1624	retain either of the transactivation domain	[retaining either of the transactivation domains]	1.0	6	1	0	0
54545	1624	uninfected thymocyte	[uninfected thymocytes]	1.0	2	1	0	0
54546	1624	nuclear extract from jurkat cell	[nuclear extracts from Jurkat cells]	1.0	5	1	0	0
54547	1624	fk506 (ref	[FK506 (refs]	1.0	2	1	0	0
54548	1624	region (-97	[region (-97]	1.0	2	1	0	0
54549	1624	clinical response.	[clinical response.]	1.0	2	1	0	0
54550	1624	Effect of 1 alpha, 25-dihydroxyvitamin D3	[Effects of 1 alpha, 25-dihydroxyvitamin D3]	1.0	6	1	0	0
54551	1624	monocyte activity	[monocyte activity]	1.0	2	2	2	2
54552	1624	inflammatory process such as atherosclerosis	[inflammatory processes such as atherosclerosis]	1.0	5	1	0	0
54553	1624	cellular rrna	[cellular mRNAs]	1.0	2	1	0	0
54554	1624	novel palindromic octamer sequence pos	[novel palindromic octamer sequence POS]	1.0	5	1	0	0
54555	1624	t-cell cycle	[T-cell cycle]	1.0	2	3	2	1
54556	1624	regulate fas death a major pathway	[regulating Fas death a major pathway]	1.0	6	1	0	0
54557	1624	only CSF	[only CSF]	1.0	2	1	0	0
54558	1624	mobilization of nuclear factor-kappaB nf-kappab	[Mobilization of nuclear factor-kappaB NF-kappaB]	1.0	5	1	0	0
54559	1624	CD patient	[CD patients]	1.0	2	1	0	0
54560	1624	Bcl-2 overexpression	[Bcl-2 overexpression]	1.0	2	1	0	0
54561	1624	allergic patient	[allergic patients]	1.0	2	1	0	0
54562	1624	genetic response	[genetic response]	1.0	2	1	0	0
54563	1624	proil-1 beta	[proIL-1 beta]	1.0	2	2	1	1
54564	1624	novel pathway	[novel pathway]	1.0	2	2	2	2
54565	1624	nuclear protein -408 to -386	[nuclear proteins -408 to -386]	1.0	5	1	0	0
54566	1624	sIgM -crosslinking	[sIgM -crosslinking]	1.0	2	1	0	0
54567	1624	antioxidative capacity	[antioxidative capacities]	1.0	2	1	0	0
54568	1624	use FUra as the substrate.	[using FUra as the substrate.]	1.0	5	1	0	0
54569	1624	response signal	[response signalling]	1.0	2	1	0	0
54570	1624	TCRalpha beta	[TCRalpha beta]	1.0	2	1	0	0
54571	1624	genomic event	[genomic events]	1.0	2	1	0	0
54572	1624	primary sequence of this motif	[primary sequence of these motifs]	1.0	5	1	0	0
54573	1624	17beta-HSD iv	[17beta-HSD IV]	1.0	2	2	1	1
54574	1624	implicate zebra in the activation	[implicating ZEBRA in the activation]	1.0	5	1	0	0
54575	1624	function of the adrenal cortex	[function of the adrenal cortex]	1.0	5	1	0	0
54576	1624	differentiative signal	[differentiative signals]	1.0	2	1	0	0
54577	1624	one class	[one class]	1.0	2	2	2	2
54578	1624	binding of this factor to ZII	[Binding of these factors to ZII]	1.0	6	1	0	0
54579	1624	granulocyte macrophage-colony	[granulocyte macrophage-colony]	1.0	2	2	1	1
54580	1624	activation of divergent protein kinase	[activation of divergent protein kinases]	1.0	5	1	0	0
54581	1624	three subtypes,	[three subtypes,]	1.0	2	1	0	0
54582	1624	peptide onto class ii molecule	[peptides onto class II molecules]	1.0	5	1	0	0
54583	1624	nucleosome remodeling	[nucleosome remodeling]	1.0	2	1	0	0
54584	1624	accompany aging	[accompanying aging]	1.0	2	1	0	0
54585	1624	persistence of the e1b mutant genome	[persistence of the E1B mutant genome]	1.0	6	1	0	0
54586	1624	excellent model	[excellent model]	1.0	2	1	0	0
54587	1624	mrna synthesis with actinomycin D	[mRNA synthesis with actinomycin D]	1.0	5	1	0	0
54588	1624	comedo than in noncomedo carcinoma	[comedo than in noncomedo carcinomas]	1.0	5	1	0	0
54589	1624	lead to sporadic androgen insensitivity syndrome	[leading to sporadic androgen insensitivity syndrome]	1.0	6	1	0	0
54590	1624	phosphatidylinositol -4-phosphate	[phosphatidylinositol -4-phosphate]	1.0	2	1	0	0
54591	1624	binding on the cell surface	[binding on the cell surface]	1.0	5	1	0	0
54592	1624	LTR gene expression in cell	[LTR gene expression in cells]	1.0	5	1	0	0
54593	1624	lymphoblastoid cell of a AGS patient	[lymphoblastoid cells of an AGS patient]	1.0	6	1	0	0
54594	1624	extensive analysis for the bind specificity	[extensive analyses for the binding specificity]	1.0	6	1	0	0
54595	1624	tumor specimen	[tumor specimen]	1.0	2	2	1	1
54596	1624	active metabolite of vitamin D3	[active metabolite of vitamin D3]	1.0	5	1	0	0
54597	1624	complete 1h	[Complete 1H]	1.0	2	1	0	0
54598	1624	RA sensitivity of hematopoietic precursor cell	[RA sensitivity of hematopoietic precursor cells]	1.0	6	1	0	0
54599	1624	primary b cell transformation assay	[primary B cell transformation assays]	1.0	5	1	0	0
54600	1624	(62-97 yr)	[(62-97 yr)]	1.0	2	1	0	0
54601	1624	cell immunoglobulin	[cell immunoglobulin]	1.0	2	2	1	1
54602	1624	induction of apoptosis of cell	[Induction of apoptosis of cells]	1.0	5	2	2	2
54603	1624	peripheral blood monocyte during sepsis	[peripheral blood monocytes during sepsis]	1.0	5	1	0	0
54604	1624	antibody against subunit of gtp-binding protein	[antibodies against subunits of GTP-binding proteins]	1.0	6	1	0	0
54605	1624	tyrosine phosphorylation of specific protein substrates.	[tyrosine phosphorylation of specific protein substrates.]	1.0	6	1	0	0
54606	1624	possibly syk protein tyrosine kinase SIT	[possibly syk protein tyrosine kinases SIT]	1.0	6	1	0	0
54607	1624	sequence upstream from the TATA box	[Sequences upstream from the TATA box]	1.0	6	1	0	0
54608	1624	morning fev1	[morning FEV1]	1.0	2	1	0	0
54609	1624	use DQ2 homo hetero zygous bulcl	[using DQ2 homo hetero zygous B-LCLs]	1.0	6	1	0	0
54610	1624	29-kda fragment	[29-kDa fragment]	1.0	2	1	0	0
54611	1624	Nuclear extract from lps zymosan cell	[Nuclear extracts from LPS zymosan cells]	1.0	6	1	0	0
54612	1624	contain the IL-6 gene promoter	[containing the IL-6 gene promoter]	1.0	5	1	0	0
54613	1624	four mrna isoform of 2.6 kb	[four mRNA isoforms of 2.6 kb]	1.0	6	1	0	0
54614	1624	minimal extent	[minimal extent]	1.0	2	1	0	0
54615	1624	cell-type-specific transactivation I htlv-i tax	[Cell-type-specific transactivation I HTLV-I tax]	1.0	5	1	0	0
54616	1624	3H-triamcinolone acetonide	[3H-triamcinolone acetonide]	1.0	2	1	0	0
54617	1624	involve 3q27	[involving 3q27]	1.0	2	1	0	0
54618	1624	include the Oct-2A binding site	[including the Oct-2A binding site]	1.0	5	1	0	0
54619	1624	prooxidant state	[prooxidant state]	1.0	2	2	1	1
54620	1624	cobalt chloride signal in endothelium lead	[Cobalt chloride signaling in endothelium leading]	1.0	6	1	0	0
54621	1624	NF-kappaB-binding site	[NF-kappaB-binding sites]	1.0	2	2	1	1
54622	1624	follow transfection-cocultivation	[following transfection-cocultivation]	1.0	2	1	0	0
54623	1624	self-renewal capacity	[self-renewal capacity]	1.0	2	1	0	0
54624	1624	carg motif	[CArG motifs]	1.0	2	1	0	0
54625	1624	transfection of the rdna for cn	[transfection of the cDNAs for CN]	1.0	6	1	0	0
54626	1624	molecular basis for the notion	[molecular basis for the notion]	1.0	5	1	0	0
54627	1624	element upstream from the gene	[element upstream from the gene]	1.0	5	1	0	0
54628	1624	differential response in gene expression	[differential responses in gene expression]	1.0	5	1	0	0
54629	1624	cyclin-dependent kinase cdk inhibitor p21(waf1/cip1)	[cyclin-dependent kinase cdk inhibitor p21(WAF1/CIP1)]	1.0	5	1	0	0
54630	1624	factor (s)	[factor (s)]	1.0	2	2	2	2
54631	1624	representational difference	[representational difference]	1.0	2	1	0	0
54632	1624	NH2Cl neutrophil	[NH2Cl neutrophils]	1.0	2	1	0	0
54633	1624	thp-1 differentiation	[THP-1 differentiation]	1.0	2	1	0	0
54634	1624	thereby contribute to disease progression	[thereby contributing to disease progression]	1.0	5	1	0	0
54635	1624	gene responsive to growth factor	[genes responsive to growth factors]	1.0	5	1	0	0
54636	1624	eventually lead to t-cell activation	[eventually leading to T-cell activation]	1.0	5	1	0	0
54637	1624	direct the expression of this regulator	[directing the expression of these regulators]	1.0	6	1	0	0
54638	1624	10 u/ml.	[10 U/ml.]	1.0	2	1	0	0
54639	1624	chimeric tcr	[chimeric TCR]	1.0	2	1	0	0
54640	1624	tyrosine phosphorylation of several intracellular substrate	[tyrosine phosphorylation of several intracellular substrates]	1.0	6	1	0	0
54641	1624	inhibition of class gene expression	[inhibition of class gene expression]	1.0	5	1	0	0
54642	1624	protein kinase a expression vector	[protein kinase A expression vectors]	1.0	5	1	0	0
54643	1624	1 receptor	[1 receptor]	1.0	2	2	2	2
54644	1624	t-cell expression of the gata-3 gene	[T-cell expression of the GATA-3 gene]	1.0	6	1	0	0
54645	1624	interferon (ifn)-gamma	[interferon (IFN)-gamma]	1.0	2	2	1	1
54646	1624	two marker of PMA differentiation;	[two markers of PMA differentiation;]	1.0	5	1	0	0
54647	1624	murine homolog	[murine homolog]	1.0	2	4	3	1
54648	1624	negative role for phosphoinositide 3-kinase	[negative role for phosphoinositide 3-kinase]	1.0	5	1	0	0
54649	1624	IL-2 cyclosporin a il-2r alpha inhibition,	[IL-2 cyclosporin A IL-2R alpha inhibition,]	1.0	6	1	0	0
54650	1624	epo treatment	[Epo treatment]	1.0	2	2	1	1
54651	1624	suppression of nfkappab binding activity	[suppression of NFkappaB binding activity]	1.0	5	1	0	0
54652	1624	various degree	[various degrees]	1.0	2	1	0	0
54653	1624	multiple biological response to the hormone,	[multiple biological responses to the hormone,]	1.0	6	1	0	0
54654	1624	dependence on octamer for activation	[dependence on octamer for activation]	1.0	5	1	0	0
54655	1624	region responsible	[region responsible]	1.0	2	2	2	2
54656	1624	hpfh phenotype	[HPFH phenotype]	1.0	2	1	0	0
54657	1624	cell death in this model.	[cell death in this model.]	1.0	5	1	0	0
54658	1624	c-myc expression by protein synthesis	[c-myc expression by protein synthesis]	1.0	5	1	0	0
54659	1624	immunoprecipitated kinase	[immunoprecipitated kinase]	1.0	2	1	0	0
54660	1624	messenger system	[messenger system]	1.0	2	2	1	1
54661	1624	patient with adult t-cell lymphoma/leukemia	[patients with adult T-cell lymphoma/leukemia]	1.0	5	1	0	0
54662	1624	well-characterized chick	[well-characterized chick]	1.0	2	1	0	0
54663	1624	anti-estrogen therapy	[anti-estrogen therapy]	1.0	2	2	1	1
54664	1624	present antigen	[present antigen]	1.0	2	1	0	0
54665	1624	deliver the second activation signal	[delivering the second activation signal]	1.0	5	1	0	0
54666	1624	reagent such as nerve growth factor	[reagents such as nerve growth factor]	1.0	6	1	0	0
54667	1624	clearly illustrate a major target.	[clearly illustrating a major target.]	1.0	5	1	0	0
54668	1624	e2 alone	[E2 alone]	1.0	2	1	0	0
54669	1624	nuclear translocation of hiv-1 transactivator tat	[nuclear translocation of HIV-1 transactivator TAT]	1.0	6	1	0	0
54670	1624	control the early step signal cascade	[controlling the early steps signaling cascade]	1.0	6	1	0	0
54671	1624	use the [3H]thymidine proliferation assay	[Using the [3H]thymidine proliferation assay]	1.0	5	1	0	0
54672	1624	promoter factor	[promoter factors]	1.0	2	1	0	0
54673	1624	phytohemagglutinin-stimulated peripheral blood lymphocyte culture	[phytohemagglutinin-stimulated peripheral blood lymphocyte cultures]	1.0	5	1	0	0
54674	1624	carry transgene in various combination	[carrying transgenes in various combinations]	1.0	5	1	0	0
54675	1624	ZEB a vertebrate homolog of Zfh-1	[ZEB a vertebrate homolog of Zfh-1]	1.0	6	1	0	0
54676	1624	abrogate bhlh homo hetero dimer formation	[abrogating bHLH homo hetero dimer formation]	1.0	6	1	0	0
54677	1624	efficient entry	[efficient entry]	1.0	2	1	0	0
54678	1624	(lps)-induced human monocyte tnf-alpha production	[(LPS)-induced human monocyte TNF-alpha production]	1.0	5	1	0	0
54679	1624	relative proportion	[relative proportions]	1.0	2	2	2	2
54680	1624	several IL-2 -inducible DNA binding activity	[several IL-2 -inducible DNA binding activities]	1.0	6	1	0	0
54681	1624	support of the allele regulation	[support of the allele regulation]	1.0	5	1	0	0
54682	1624	(7/8 patient positive for c-jun	[(7/8 patients positive for c-Jun]	1.0	5	1	0	0
54683	1624	role in chronic hepatitis b	[role in chronic hepatitis B]	1.0	5	1	0	0
54684	1624	glucocorticoid resistance in depressive disorder	[glucocorticoid resistance in depressive disorder]	1.0	5	2	2	2
54685	1624	novel Ets family member Elf-1	[novel Ets family member Elf-1]	1.0	5	1	0	0
54686	1624	leukemic sample	[leukemic sample]	1.0	2	1	0	0
54687	1624	only GATA-4	[only GATA-4]	1.0	2	1	0	0
54688	1624	human peripheral blood monocyte Mo	[Human peripheral blood monocytes Mo]	1.0	5	1	0	0
54689	1624	H4 promoter	[H4 promoter]	1.0	2	2	1	1
54690	1624	macrophagelike cell	[macrophagelike cells]	1.0	2	1	0	0
54691	1624	inducible system	[inducible system]	1.0	2	1	0	0
54692	1624	expression of the c-jun gene	[expression of the c-Jun genes]	1.0	5	1	0	0
54693	1624	encode a zinc finger protein nf-e1	[encoding a zinc finger protein NF-E1]	1.0	6	1	0	0
54694	1624	i.e. adult cd34+ bone marrow cell	[i.e. adult CD34+ bone marrow cells]	1.0	6	1	0	0
54695	1624	robust Janus kinase 3 jak3 activity	[robust Janus kinase 3 JAK3 activity]	1.0	6	1	0	0
54696	1624	regulatory region of several gene	[regulatory regions of several genes]	1.0	5	1	0	0
54697	1624	70-bp motif	[70-bp motif]	1.0	2	1	0	0
54698	1624	Zfh family	[Zfh family]	1.0	2	1	0	0
54699	1624	mouse mutation	[mouse mutation]	1.0	2	1	0	0
54700	1624	key role in the transcription	[key role in the transcription]	1.0	5	2	1	1
54701	1624	ebv infection of b cell	[EBV infection of B cells]	1.0	5	1	0	0
54702	1624	nongenomic activity	[nongenomic activities]	1.0	2	1	0	0
54703	1624	maximal expression of many cytokine	[maximal expression of many cytokines]	1.0	5	1	0	0
54704	1624	active nuclear nf-kappa b complex	[active nuclear NF-kappa B complex]	1.0	5	1	0	0
54705	1624	phytohemaglutinin pha	[phytohemaglutinin PHA]	1.0	2	1	0	0
54706	1624	nur77 alpha	[nur77 alpha]	1.0	2	1	0	0
54707	1624	cdk inhibitor	[cdk inhibitor]	1.0	2	2	2	2
54708	1624	phorbol ester treatment cd19 expression	[Phorbol ester treatment CD19 expression]	1.0	5	1	0	0
54709	1624	xpb mutation	[XPB mutation]	1.0	2	1	0	0
54710	1624	potentially in cell cycle regulation.	[potentially in cell cycle regulation.]	1.0	5	1	0	0
54711	1624	direct result of distinct activation	[direct result of distinct activation]	1.0	5	1	0	0
54712	1624	DNA organization	[DNA organization]	1.0	2	1	0	0
54713	1624	characteristic of a signal transducer	[characteristics of a signal transducer]	1.0	5	1	0	0
54714	1624	1 mumol/L,	[1 mumol/L,]	1.0	2	1	0	0
54715	1624	RAR band	[RAR band]	1.0	2	1	0	0
54716	1624	integrity of the chromatin structure	[integrity of the chromatin structure]	1.0	5	1	0	0
54717	1624	hbsag stimulation, expression of ifn-gamma	[HBsAg stimulation, expression of IFN-gamma]	1.0	5	1	0	0
54718	1624	salmonella typhimurium	[Salmonella typhimurium]	1.0	2	2	1	1
54719	1624	variant of the transcription factor	[variant of the transcription factor]	1.0	5	1	0	0
54720	1624	histone h1	[histone H1]	1.0	2	1	0	0
54721	1624	histone h5	[histone H5]	1.0	2	2	2	2
54722	1624	suggest responsible for stimulation of phagocytosis	[suggesting responsible for stimulation of phagocytosis]	1.0	6	1	0	0
54723	1624	interleukin-2 receptor in T lymphocyte	[interleukin-2 receptors in T lymphocytes]	1.0	5	1	0	0
54724	1624	allergic response	[allergic response]	1.0	2	2	1	1
54725	1624	oligonucleotide span the DQB X-box	[oligonucleotides spanning the DQB X-box]	1.0	5	1	0	0
54726	1624	5.53 nm	[5.53 nM]	1.0	2	1	0	0
54727	1624	downstream, gene	[downstream, genes]	1.0	2	1	0	0
54728	1624	oxidative stress include thiol deprivation	[oxidative stress including thiol deprivation]	1.0	5	1	0	0
54729	1624	anti-inflammatory sesquiterpene lactone from Arnica	[anti-inflammatory sesquiterpene lactone from Arnica]	1.0	5	1	0	0
54730	1624	transcriptional co-activator	[transcriptional co-activator]	1.0	2	2	1	1
54731	1624	up-regulate the activity of transcription factor	[up-regulating the activity of transcription factors]	1.0	6	1	0	0
54732	1624	direct activation of PKC with PMA	[Direct activation of PKC with PMA]	1.0	6	1	0	0
54733	1624	other interaction	[other interactions]	1.0	2	2	1	1
54734	1624	human androgen receptor assay humara	[human androgen receptor assay HUMARA]	1.0	5	1	0	0
54735	1624	activation-inducer molecule/cd69	[activation-inducer molecule/CD69]	1.0	2	1	0	0
54736	1624	oxidant scavenger	[oxidant scavenger]	1.0	2	1	0	0
54737	1624	E1a reiteration	[E1a reiteration]	1.0	2	2	1	1
54738	1624	sequencing of the gamma c gene	[sequencing of the gamma c gene]	1.0	6	1	0	0
54739	1624	peptide rakfkqllq	[peptide RAKFKQLLQ]	1.0	2	2	1	1
54740	1624	active state	[active state]	1.0	2	2	2	2
54741	1624	lipopolysaccharide-induced interleukin-1	[lipopolysaccharide-induced interleukin-1]	1.0	2	1	0	0
54742	1624	two anlage	[two anlage]	1.0	2	1	0	0
54743	1624	analysis of monocyte from (fh) subject	[Analysis of monocytes from (FH) subjects]	1.0	6	1	0	0
54744	1624	distinct promoter	[distinct promoters]	1.0	2	2	2	2
54745	1624	further insight into the pathogenesis	[further insight into the pathogenesis]	1.0	5	1	0	0
54746	1624	retinoblastoma susceptibility	[retinoblastoma susceptibility]	1.0	2	2	2	2
54747	1624	immunocytochemical experiment	[immunocytochemical experiments]	1.0	2	1	0	0
54748	1624	receptor ligation	[receptor ligation]	1.0	2	1	0	0
54749	1624	VCAM-1 transcription	[VCAM-1 transcription]	1.0	2	1	0	0
54750	1624	isolation of a cDNA clone	[isolation of a cDNA clone]	1.0	5	1	0	0
54751	1624	nef expression in Jurkat cell	[Nef expression in Jurkat cells]	1.0	5	1	0	0
54752	1624	important nf-kappab/ntat ets binding site	[important NF-kappaB/NFAT Ets binding sites]	1.0	5	1	0	0
54753	1624	different type of granulomatous disease	[different types of granulomatous disease]	1.0	5	1	0	0
54754	1624	IFN-gammaRalpha chain	[IFN-gammaRalpha chain]	1.0	2	1	0	0
54755	1624	temporal artery	[temporal arteries]	1.0	2	1	0	0
54756	1624	noncatalytic N terminus with Erk	[noncatalytic N terminus with Erk]	1.0	5	1	0	0
54757	1624	elk-1 transcription	[elk-1 transcription]	1.0	2	2	1	1
54758	1624	related alpha-herpesviruse	[related alpha-herpesviruses]	1.0	2	1	0	0
54759	1624	early, transient stimulation of c-jun	[early, transient stimulation of c-jun]	1.0	5	1	0	0
54760	1624	mutation of the e box	[Mutation of the E box]	1.0	5	1	0	0
54761	1624	individual repeat	[individual repeats]	1.0	2	1	0	0
54762	1624	969-base pair	[969-base pair]	1.0	2	1	0	0
54763	1624	virus-transformed cell	[virus-transformed cells]	1.0	2	1	0	0
54764	1624	resistant segment in Ag may,	[resistant segments in Ag may,]	1.0	5	1	0	0
54765	1624	DNA conformation	[DNA conformation]	1.0	2	1	0	0
54766	1624	sne motif	[SNE motifs]	1.0	2	1	0	0
54767	1624	However, Rta	[However, Rta]	1.0	2	2	1	1
54768	1624	interaction of within the nuclear compartment	[interaction of within the nuclear compartment]	1.0	6	1	0	0
54769	1624	intracellular mechanism for this effect	[intracellular mechanisms for these effects]	1.0	5	1	0	0
54770	1624	large-cell component	[large-cell component]	1.0	2	1	0	0
54771	1624	T cell activation factor nf-atc	[T cell activation factor NF-ATc]	1.0	5	1	0	0
54772	1624	promoter lack the binding site	[promoter lacking the binding sites]	1.0	5	1	0	0
54773	1624	binding of a aldosterone derivative	[binding of a aldosterone derivative]	1.0	5	1	0	0
54774	1624	general population.	[general population.]	1.0	2	1	0	0
54775	1624	general population,	[general population,]	1.0	2	1	0	0
54776	1624	circulate level	[circulating levels]	1.0	2	2	2	2
54777	1624	po-b dna-binding in hl-60 cell	[PO-B DNA-binding in HL-60 cells]	1.0	5	1	0	0
54778	1624	Jak -STAT pathway in eosinophil	[Jak -STAT pathways in eosinophils]	1.0	5	1	0	0
54779	1624	androgen on mature immunocompetent cell	[androgens on mature immunocompetent cells]	1.0	5	1	0	0
54780	1624	central regulator for the induction	[central regulator for the induction]	1.0	5	1	0	0
54781	1624	cooperation of different transcription factor	[cooperation of different transcription factors]	1.0	5	1	0	0
54782	1624	con a pha t-cell mitogenesis	[Con A PHA T-cell mitogenesis]	1.0	5	1	0	0
54783	1624	T cells,	[T cells,]	1.0	2	2	1	1
54784	1624	murine homologue to the coactivator	[murine homologue to the coactivator]	1.0	5	1	0	0
54785	1624	alloreactive T	[alloreactive T]	1.0	2	1	0	0
54786	1624	free thiol in the IL-1RI complex	[free thiols in the IL-1RI complex]	1.0	6	1	0	0
54787	1624	receptor-1 activation	[receptor-1 activation]	1.0	2	1	0	0
54788	1624	impaired plasticity	[impaired plasticity]	1.0	2	1	0	0
54789	1624	human g0/g1 switch gene G0S2	[human G0/G1 switch gene G0S2]	1.0	5	1	0	0
54790	1624	lps activation of NF-kappaB reporter gene	[LPS activation of NF-kappaB reporter gene]	1.0	6	1	0	0
54791	1624	specific mab	[specific mAb]	1.0	2	1	0	0
54792	1624	iL1-induced activity of the MHC class	[IL1-induced activity of the MHC class]	1.0	6	1	0	0
54793	1624	MAPKK-1 /erk-2	[MAPKK-1 /ERK-2]	1.0	2	1	0	0
54794	1624	ability of constitutively active ras	[ability of constitutively active Ras]	1.0	5	1	0	0
54795	1624	maximal response to adenovirus antigen	[maximal responses to adenovirus antigen]	1.0	5	1	0	0
54796	1624	evaluation of monoclonal anti-D reagent	[Evaluation of monoclonal anti-D reagents]	1.0	5	1	0	0
54797	1624	mutant hcamkiv	[mutant hCaMKIV]	1.0	2	1	0	0
54798	1624	modulate differentiation	[modulating differentiation]	1.0	2	2	1	1
54799	1624	transcriptional inducibility	[transcriptional inducibility]	1.0	2	1	0	0
54800	1624	(2.5 points), low body mass	[(2.5 points), low body mass]	1.0	5	1	0	0
54801	1624	defect in b cell activation	[defect in B cell activation]	1.0	5	1	0	0
54802	1624	vitro-activated t-lymphocyte	[vitro-activated T-lymphocytes]	1.0	2	1	0	0
54803	1624	functional T	[functional T]	1.0	2	1	0	0
54804	1624	scmv mie	[SCMV MIE]	1.0	2	1	0	0
54805	1624	blood DNA	[blood DNA]	1.0	2	1	0	0
54806	1624	molecular basis for the interplay	[molecular basis for the interplay]	1.0	5	1	0	0
54807	1624	chromosomal translocation result in abnormal expression	[Chromosomal translocation resulting in abnormal expression]	1.0	6	1	0	0
54808	1624	nuclear RA	[nuclear RA]	1.0	2	1	0	0
54809	1624	more precisely similarity among lipopolysaccharide (lps)-	[more precisely similarities among lipopolysaccharide (LPS)-]	1.0	6	1	0	0
54810	1624	expression of a nuclear factor	[expression of a nuclear factor]	1.0	5	2	1	1
54811	1624	alter normal immunoregulatory signal transduction	[altering normal immunoregulatory signal transduction]	1.0	5	1	0	0
54812	1624	rare event in this disorder.	[rare event in this disorder.]	1.0	5	1	0	0
54813	1624	neutrophil differentiation of hl60 cell	[neutrophil differentiation of HL60 cells]	1.0	5	2	1	1
54814	1624	fmol/million cells; p less than 0.01)	[fmol/million cells; P less than 0.01)]	1.0	6	1	0	0
54815	1624	tcell survival	[Tcell survival]	1.0	2	1	0	0
54816	1624	normal bone	[normal bone]	1.0	2	1	0	0
54817	1624	La( rSSB	[La( rSSB]	1.0	2	1	0	0
54818	1624	main activity	[main activity]	1.0	2	2	2	2
54819	1624	stress response of senescent T lymphocyte	[Stress response of senescent T lymphocytes]	1.0	6	1	0	0
54820	1624	promote syncytia	[promoting syncytia]	1.0	2	1	0	0
54821	1624	tumor necrosis factor factor traf	[tumor necrosis factor factor TRAF]	1.0	5	1	0	0
54822	1624	nuclear affinity Ka for T3	[nuclear affinity Ka for T3]	1.0	5	1	0	0
54823	1624	feature control the pp52 promoter	[features controlling the pp52 promoter]	1.0	5	1	0	0
54824	1624	LAK cell	[LAK cells]	1.0	2	1	0	0
54825	1624	rate of replication of hiv-1	[rate of replication of HIV-1]	1.0	5	1	0	0
54826	1624	subtle difference	[subtle differences]	1.0	2	2	2	2
54827	1624	receptor er	[receptor ER]	1.0	2	2	2	2
54828	1624	[regulatory effect of insulin on receptor	[[Regulatory effect of insulin on receptor]	1.0	6	1	0	0
54829	1624	gamma- chain	[gamma- chains]	1.0	2	1	0	0
54830	1624	stability of the HLA/peptide complex	[stability of the HLA/peptide complex]	1.0	5	1	0	0
54831	1624	circulate human lymphocyte in hyper- thyroidism	[circulating human lymphocytes in hyper- thyroidism]	1.0	6	1	0	0
54832	1624	immature testis	[immature testis]	1.0	2	1	0	0
54833	1624	prevail hypothesis	[prevailing hypothesis]	1.0	2	1	0	0
54834	1624	pma-induced mrna	[PMA-induced mRNA]	1.0	2	1	0	0
54835	1624	interleukin (IL)-12	[interleukin (IL)-12]	1.0	2	1	0	0
54836	1624	11 index absorptive hypercalciuric patient	[11 index absorptive hypercalciuric patients]	1.0	5	1	0	0
54837	1624	peptide bcr1/25	[peptide BCR1/25]	1.0	2	2	1	1
54838	1624	putative role	[putative role]	1.0	2	2	2	2
54839	1624	serine/threonine phosphatase -1 okadaic acid	[serine/threonine phosphatases -1 okadaic acid]	1.0	5	1	0	0
54840	1624	receptor kd	[receptor Kd]	1.0	2	2	1	1
54841	1624	kappa b nf kappa b	[kappa B NF kappa B]	1.0	5	1	0	0
54842	1624	one arm of the hmg box	[one arm of the HMG box]	1.0	6	1	0	0
54843	1624	cell of the myelomonocytic lineage	[cells of the myelomonocytic lineage]	1.0	5	2	2	2
54844	1624	t-cell activation by vanadate peroxide	[T-cell activation by vanadate peroxide]	1.0	5	1	0	0
54845	1624	major interest of this project	[major interest of this project]	1.0	5	1	0	0
54846	1624	proteolysis product	[Proteolysis products]	1.0	2	1	0	0
54847	1624	eutopic pregnancy	[eutopic pregnancies]	1.0	2	1	0	0
54848	1624	(2) Jak2	[(2) Jak2]	1.0	2	1	0	0
54849	1624	cDNA clone of myeloid differentiation	[cDNA clones of myeloid differentiation]	1.0	5	1	0	0
54850	1624	underlying difference between h-rs cell	[underlying difference between H-RS cells]	1.0	5	1	0	0
54851	1624	protein than virus-negative T cell	[proteins than virus-negative T cells]	1.0	5	1	0	0
54852	1624	only NF-kappa b p50 /p50	[only NF-kappa B p50 /p50]	1.0	5	1	0	0
54853	1624	effect on the cell growth	[effect on the cell growth]	1.0	5	1	0	0
54854	1624	1-bp difference in transcription assay	[1-bp difference in transcription assays]	1.0	5	1	0	0
54855	1624	other adaptor addition to p300/cbp	[other adaptors addition to p300/CBP]	1.0	5	1	0	0
54856	1624	hcleo element	[hCLEO element]	1.0	2	1	0	0
54857	1624	lps concentration of 1.0 micrograms/ml	[LPS concentrations of 1.0 micrograms/ml]	1.0	5	1	0	0
54858	1624	future prognosis	[future prognosis]	1.0	2	1	0	0
54859	1624	Extract of Tripterygium wilfordii Hook	[Extract of Tripterygium wilfordii Hook]	1.0	5	1	0	0
54860	1624	mutation of the enhancer motif	[mutations of the enhancer motif]	1.0	5	1	0	0
54861	1624	inhibition of ige class switch	[inhibition of IgE class switching]	1.0	5	1	0	0
54862	1624	important role in t-cell activation	[important role in T-cell activation]	1.0	5	1	0	0
54863	1624	muscle myosin	[muscle myosin]	1.0	2	1	0	0
54864	1624	prevent the release of IkappaB	[preventing the release of IkappaB]	1.0	5	1	0	0
54865	1624	ongoing study of transgenic mouse	[ongoing study of transgenic mice]	1.0	5	1	0	0
54866	1624	aids deletion of accessory gene	[AIDS deletion of accessory genes]	1.0	5	1	0	0
54867	1624	monocyte chemotactic protein-1 CC chemokine	[monocyte chemotactic protein-1 CC chemokine]	1.0	5	1	0	0
54868	1624	nf-kappa b binding activity T	[NF-kappa B binding activity T]	1.0	5	1	0	0
54869	1624	vitro surrogate	[vitro surrogate]	1.0	2	1	0	0
54870	1624	Tal-1 gene	[Tal-1 gene]	1.0	2	1	0	0
54871	1624	subtle effect.	[subtle effect.]	1.0	2	1	0	0
54872	1624	pituitary (gh3)	[pituitary (GH3)]	1.0	2	1	0	0
54873	1624	deletion mutant of the c-fo promoter	[deletion mutants of the c-fos promoter]	1.0	6	1	0	0
54874	1624	il-2r alpha expression by transfection	[IL-2R alpha expression by transfection]	1.0	5	1	0	0
54875	1624	sexual transmission	[sexual transmission]	1.0	2	1	0	0
54876	1624	precise number of the CAG	[precise number of the CAGs]	1.0	5	1	0	0
54877	1624	constitutive degradation of cytoplasmic inhibitor	[constitutive degradation of cytoplasmic inhibitors]	1.0	5	1	0	0
54878	1624	human peripheral blood lymphocyte generation	[human peripheral blood lymphocytes Generation]	1.0	5	1	0	0
54879	1624	phorbol activation	[Phorbol activation]	1.0	2	1	0	0
54880	1624	bronchiolitis obliteran	[bronchiolitis obliterans]	1.0	2	2	2	2
54881	1624	detection of estrogen receptor er	[detection of estrogen receptors ER]	1.0	5	1	0	0
54882	1624	rhombotin family of cysteine oncogene	[rhombotin family of cysteine oncogenes]	1.0	5	1	0	0
54883	1624	FasL promoter	[FasL promoter]	1.0	2	2	1	1
54884	1624	elevation of free cytosolic calcium	[elevation of free cytosolic calcium]	1.0	5	1	0	0
54885	1624	further, mutation in this region	[further, mutations in these regions]	1.0	5	1	0	0
54886	1624	senescent organism	[senescent organisms]	1.0	2	1	0	0
54887	1624	C/EBP motif	[C/EBP motif]	1.0	2	1	0	0
54888	1624	other stimulus	[other stimuli]	1.0	2	1	0	0
54889	1624	alternative splicing of the gc receptor	[Alternative splicing of the GC receptor]	1.0	6	2	2	2
54890	1624	primary haemopoietic	[primary haemopoietic]	1.0	2	1	0	0
54891	1624	extracellular cues,	[extracellular cues,]	1.0	2	1	0	0
54892	1624	OCIM1 cell	[OCIM1 cells]	1.0	2	1	0	0
54893	1624	bind to the promoter site	[binding to the promoter site]	1.0	5	1	0	0
54894	1624	rat lymphocyte	[rat lymphocytes]	1.0	2	1	0	0
54895	1624	antisense expression	[antisense expression]	1.0	2	1	0	0
54896	1624	major goal	[major goal]	1.0	2	2	1	1
54897	1624	additional role	[additional role]	1.0	2	2	2	2
54898	1624	768-bp upstream negative regulatory region	[768-bp upstream negative regulatory region]	1.0	5	1	0	0
54899	1624	exon of the EVI1 gene,	[exon of the EVI1 gene,]	1.0	5	1	0	0
54900	1624	factor-1 gene	[factor-1 gene]	1.0	2	2	2	2
54901	1624	surround sequence of the IL-4 gene	[surrounding sequences of the IL-4 gene]	1.0	6	1	0	0
54902	1624	marginal level of c-rel protein	[marginal levels of c-Rel proteins]	1.0	5	1	0	0
54903	1624	immunosuppressant target the CD28 pathway	[immunosuppressants targeting the CD28 pathway]	1.0	5	1	0	0
54904	1624	intrahepatic lymphoid follicle ILF formation	[Intrahepatic lymphoid follicle ILF formation]	1.0	5	1	0	0
54905	1624	TAL-1 gene	[TAL-1 gene]	1.0	2	1	0	0
54906	1624	heavy-chain (igh)	[heavy-chain (IgH)]	1.0	2	1	0	0
54907	1624	belong to a family of regulator	[belonging to a family of regulators]	1.0	6	1	0	0
54908	1624	SCC with metastasis without metastasis	[SCC with metastasis without metastasis]	1.0	5	1	0	0
54909	1624	Ii chain	[Ii chain]	1.0	2	2	2	2
54910	1624	bleed disorder	[bleeding disorder]	1.0	2	1	0	0
54911	1624	rel-related transcription	[Rel-related transcription]	1.0	2	1	0	0
54912	1624	il-2 response	[IL-2 response]	1.0	2	2	1	1
54913	1624	Avian cell	[Avian cells]	1.0	2	1	0	0
54914	1624	multiple stage of B cell development	[multiple stages of B cell development]	1.0	6	1	0	0
54915	1624	mab j393	[mAb J393]	1.0	2	2	1	1
54916	1624	gata-1 synthesis	[GATA-1 synthesis]	1.0	2	1	0	0
54917	1624	importantly, constitutive expression of Rev M10	[Importantly, constitutive expression of Rev M10]	1.0	6	1	0	0
54918	1624	multifactorial disease	[multifactorial disease]	1.0	2	1	0	0
54919	1624	oppose effect on hiv expression	[opposing effects on HIV expression]	1.0	5	1	0	0
54920	1624	nuclear t3	[nuclear T3]	1.0	2	2	2	2
54921	1624	irrespective of the position of xic/xist	[irrespective of the position of XIC/XIST]	1.0	6	1	0	0
54922	1624	bcr signal	[BCR signal]	1.0	2	2	2	2
54923	1624	leukocyte endothelial-leukocyte adhesion molecule elam-1	[leukocytes endothelial-leukocyte adhesion molecule ELAM-1]	1.0	5	1	0	0
54924	1624	patient with advanced renal carcinoma	[patients with advanced renal carcinoma]	1.0	5	1	0	0
54925	1624	suggest largely responsible for the decrease	[suggesting largely responsible for the decrease]	1.0	6	1	0	0
54926	1624	anti-peptide antibody	[anti-peptide antibodies]	1.0	2	1	0	0
54927	1624	bodily protein	[bodily proteins]	1.0	2	1	0	0
54928	1624	possible mechanism for dioxin-mediated alteration	[possible mechanism for dioxin-mediated alteration]	1.0	5	1	0	0
54929	1624	induction of hiv by C. neoforman	[Induction of HIV by C. neoformans]	1.0	6	1	0	0
54930	1624	carry a vd response element	[carrying a VD response element]	1.0	5	1	0	0
54931	1624	polymerase chain reaction (lm-pcr) technique	[polymerase chain reaction (LM-PCR) techniques]	1.0	5	1	0	0
54932	1624	activate transcription from a reporter gene	[activating transcription from a reporter gene]	1.0	6	1	0	0
54933	1624	langerhan cell	[Langerhans cells]	1.0	2	1	0	0
54934	1624	other stimuli,	[other stimuli,]	1.0	2	1	0	0
54935	1624	caspase activity	[caspase activity]	1.0	2	2	2	2
54936	1624	promoter-binding protein	[promoter-binding protein]	1.0	2	2	1	1
54937	1624	use anti-c/ebpbeta NF-IL6 anti-c/ebpdelta nf-il6beta	[Using anti-C/EBPbeta NF-IL6 anti-C/EBPdelta NF-IL6beta]	1.0	5	1	0	0
54938	1624	paracrine action of endogenous tnf-alpha	[paracrine action of endogenous TNF-alpha]	1.0	5	1	0	0
54939	1624	protein in the first group	[Proteins in the first group]	1.0	5	1	0	0
54940	1624	rna activator protein-1 binding activity	[RNA activator protein-1 binding activity]	1.0	5	1	0	0
54941	1624	response to the stimulus lam	[response to the stimuli LAM]	1.0	5	1	0	0
54942	1624	u-937 cell in the absence	[U-937 cells in the absence]	1.0	5	1	0	0
54943	1624	cytosolic compartment	[cytosolic compartment]	1.0	2	2	1	1
54944	1624	release of a inhibitory subunit	[release of an inhibitory subunit]	1.0	5	1	0	0
54945	1624	homeostasis of the immune system	[homeostasis of the immune system]	1.0	5	1	0	0
54946	1624	activation of the colony-stimulating factor receptor	[Activation of the colony-stimulating factor receptor]	1.0	6	1	0	0
54947	1624	distinct transcripts,	[distinct transcripts,]	1.0	2	1	0	0
54948	1624	monocytes: role of the 65-kda	[monocytes: role of the 65-kDa]	1.0	5	1	0	0
54949	1624	basic helix-loop-helix bhlh motif contiguous	[basic helix-loop-helix bHLH motif contiguous]	1.0	5	1	0	0
54950	1624	gene expression in T lymphocyte	[gene expression in T lymphocytes]	1.0	5	2	1	1
54951	1624	dopamine treatment	[dopamine treatment]	1.0	2	1	0	0
54952	1624	cell type specificity for nfat-1 factor	[Cell type specificity for NFAT-1 factor]	1.0	6	1	0	0
54953	1624	e.g. interleukin-3 macrophage colony-stimumulatelany-stg factor	[e.g. interleukin-3 macrophage colony-stimulating factor]	1.0	5	1	0	0
54954	1624	granulocyte-macrophage (gm)-csf receptor alpha subunit	[granulocyte-macrophage (GM)-CSF receptor alpha subunit]	1.0	5	1	0	0
54955	1624	role in light-regulated biological rhythm	[role in light-regulated biological rhythms]	1.0	5	1	0	0
54956	1624	map erk kinase kinase-1 MEKK1	[MAP ERK kinase kinase-1 MEKK1]	1.0	5	1	0	0
54957	1624	TcR delta	[TcR delta]	1.0	2	2	2	2
54958	1624	induction of transcription factor nf-at	[induction of transcription factors NF-AT]	1.0	5	1	0	0
54959	1624	hypothesis, 4-h NK cytolysis assay	[hypothesis, 4-h NK cytolysis assays]	1.0	5	1	0	0
54960	1624	contain both	[containing both]	1.0	2	1	0	0
54961	1624	thrombogenic surface	[thrombogenic surfaces]	1.0	2	1	0	0
54962	1624	expression of protein kinase C isoform	[expression of protein kinase C isoforms]	1.0	6	1	0	0
54963	1624	linkage analysis	[linkage analysis]	1.0	2	2	2	2
54964	1624	presence of tandem array range	[presence of tandem arrays ranging]	1.0	5	1	0	0
54965	1624	1-(5-chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride ml-9 a inhibitor	[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride ML-9 an inhibitor]	1.0	5	1	0	0
54966	1624	other stat	[other STATs]	1.0	2	1	0	0
54967	1624	cell of lymphocytic hemopoietic system	[cells of lymphocytic hemopoietic systems]	1.0	5	1	0	0
54968	1624	contrast to the differential signal	[contrast to the differential signaling]	1.0	5	1	0	0
54969	1624	R alone	[R alone]	1.0	2	1	0	0
54970	1624	expression of the tnf gene	[expression of the TNF gene]	1.0	5	2	2	2
54971	1624	T cell with tpa ionophore	[T cells with TPA ionophore]	1.0	5	1	0	0
54972	1624	related steroid	[related steroids]	1.0	2	1	0	0
54973	1624	only the response to lps	[only the response to LPS]	1.0	5	1	0	0
54974	1624	phorbol dibutyrate/calcium ionophore a23187 PDBu/iono combination	[phorbol dibutyrate/calcium ionophore A23187 PDBu/iono combination]	1.0	6	1	0	0
54975	1624	expression in several erythroid cell line	[expression in several erythroid cell lines]	1.0	6	1	0	0
54976	1624	constitutive ets1	[constitutive ETS1]	1.0	2	1	0	0
54977	1624	virus-induced erythroleukemia	[virus-induced erythroleukemia]	1.0	2	1	0	0
54978	1624	dominant function	[dominant functions]	1.0	2	1	0	0
54979	1624	hiv-1 upregulation	[HIV-1 upregulation]	1.0	2	1	0	0
54980	1624	3 isoform	[3 isoforms]	1.0	2	1	0	0
54981	1624	concert with the 0.2-kb region	[concert with the 0.2-kb region]	1.0	5	1	0	0
54982	1624	rapid shuttling	[rapid shuttling]	1.0	2	1	0	0
54983	1624	inhibit endothelial expression of adhesion molecule	[inhibiting endothelial expression of adhesion molecules]	1.0	6	1	0	0
54984	1624	cellular element	[cellular elements]	1.0	2	1	0	0
54985	1624	expression of tissue inhibitor metalloproteinase	[expression of tissue inhibitor metalloproteinases]	1.0	5	1	0	0
54986	1624	suggest the involvement of transcription factor	[suggesting the involvement of transcription factors]	1.0	6	1	0	0
54987	1624	use version of pi 3-kinase	[using versions of PI 3-kinase]	1.0	5	1	0	0
54988	1624	beta 5'	[beta 5']	1.0	2	1	0	0
54989	1624	human IL-4	[human IL-4]	1.0	2	1	0	0
54990	1624	ick-1 binding	[ICK-1 binding]	1.0	2	1	0	0
54991	1624	CD36 Chinese hampster ovary (cho) cell	[CD36 Chinese hampster ovary (CHO) cells]	1.0	6	1	0	0
54992	1624	mature erythrocyte in the blood	[mature erythrocytes in the blood]	1.0	5	1	0	0
54993	1624	zinc addition	[zinc addition]	1.0	2	1	0	0
54994	1624	1 alpha, 25-Dihydroxyvitamin D3 vd	[1 alpha, 25-Dihydroxyvitamin D3 VD]	1.0	5	1	0	0
54995	1624	most importantly a NF-kappa b site	[most importantly an NF-kappa B site]	1.0	6	1	0	0
54996	1624	phorbol inducibility	[phorbol inducibility]	1.0	2	1	0	0
54997	1624	ionize radiation	[ionizing radiation]	1.0	2	2	2	2
54998	1624	enzymatic means use deoxyribonuclease dnase	[enzymatic means using deoxyribonuclease DNase]	1.0	5	1	0	0
54999	1624	addition to this E2F complex	[addition to these E2F complexes]	1.0	5	1	0	0
55000	1624	mitogen-activated T	[mitogen-activated T]	1.0	2	1	0	0
55001	1624	interleukin factor	[interleukin factor]	1.0	2	1	0	0
55002	1624	genetic approach with saccharomy cerevisiae	[genetic approach with Saccharomyces cerevisiae]	1.0	5	1	0	0
55003	1624	estrogen binding site in blood monocyte	[Estrogen binding sites in blood monocytes]	1.0	6	1	0	0
55004	1624	molecular mechanism lead to hiv-1 replication	[Molecular mechanisms leading to HIV-1 replication]	1.0	6	1	0	0
55005	1624	-contain receptor related to tnfr-1	[-containing receptor related to TNFR-1]	1.0	5	1	0	0
55006	1624	transcriptional activation.	[transcriptional activation.]	1.0	2	1	0	0
55007	1624	c-jun transcription in u-937 cell	[c-jun transcription in U-937 cells]	1.0	5	1	0	0
55008	1624	granulocytic marker	[granulocytic markers]	1.0	2	2	1	1
55009	1624	specific protein binding site between -3110	[specific protein binding sites between -3110]	1.0	6	1	0	0
55010	1624	tandem enhancer	[tandem enhancer]	1.0	2	1	0	0
55011	1624	bacteriophage lambda cDNA expression library	[bacteriophage lambda cDNA expression libraries]	1.0	5	1	0	0
55012	1624	dose dependence	[dose dependence]	1.0	2	1	0	0
55013	1624	analysis of various tax mutant	[Analysis of various Tax mutants]	1.0	5	1	0	0
55014	1624	phorbol ester treatment of cell	[phorbol ester treatment of cells]	1.0	5	1	0	0
55015	1624	long double	[longer doubling]	1.0	2	1	0	0
55016	1624	mutation of potential stat-binding site	[mutation of potential STAT-binding sites]	1.0	5	1	0	0
55017	1624	jr-st cell	[JR-St cells]	1.0	2	1	0	0
55018	1624	STAT1 alpha activation by IL-12	[STAT1 alpha activation by IL-12]	1.0	5	1	0	0
55019	1624	mapping study	[mapping studies]	1.0	2	2	2	2
55020	1624	infectious pathogen	[infectious pathogens]	1.0	2	2	2	2
55021	1624	effector pathway	[effector pathways]	1.0	2	2	1	1
55022	1624	binding of the respective factor	[binding of the respective factors]	1.0	5	1	0	0
55023	1624	role in the inflammatory process	[role in the inflammatory process]	1.0	5	1	0	0
55024	1624	jurkat t-cell	[Jurkat T-cells]	1.0	2	3	2	1
55025	1624	oxidative stress than lipid peroxidation	[oxidative stress than lipid peroxidation]	1.0	5	1	0	0
55026	1624	first approach,	[first approach,]	1.0	2	1	0	0
55027	1624	pre-activation level	[pre-activation levels]	1.0	2	1	0	0
55028	1624	second messenger in the induction	[second messengers in the induction]	1.0	5	1	0	0
55029	1624	cortisol in the bind media	[cortisol in the binding media]	1.0	5	1	0	0
55030	1624	transcription of a chemotactic cytokine	[transcription of a chemotactic cytokine]	1.0	5	1	0	0
55031	1624	leukemic transformation of T cell	[leukemic transformation of T cells]	1.0	5	1	0	0
55032	1624	design of combination hormonal protocol	[design of combination hormonal protocols]	1.0	5	1	0	0
55033	1624	neutralize anti- csf-1r monoclonal antibody	[neutralizing anti- CSF-1R monoclonal antibodies]	1.0	5	1	0	0
55034	1624	nuclear grade (p less than 0.0001)	[nuclear grade (P less than 0.0001),]	1.0	6	1	0	0
55035	1624	conclusion: monocyte	[CONCLUSION: Monocytes]	1.0	2	1	0	0
55036	1624	processing of the precursor p100	[processing of the precursors p100]	1.0	5	1	0	0
55037	1624	absence of slow migrating form	[absence of slow migrating forms]	1.0	5	1	0	0
55038	1624	Differential nuclear localization of p50	[Differential nuclear localization of p50]	1.0	5	1	0	0
55039	1624	Nuclear transcription study in vitro	[Nuclear transcription studies in vitro]	1.0	5	1	0	0
55040	1624	unaffected, inhibitor of nadph oxidase	[unaffected, inhibitors of NADPH oxidase]	1.0	5	1	0	0
55041	1624	anti-cd3/ CD28	[anti-CD3/ CD28]	1.0	2	1	0	0
55042	1624	diverse agent	[diverse agents]	1.0	2	1	0	0
55043	1624	ets-1 protein with CaM kinase	[Ets-1 protein with CaM kinase]	1.0	5	1	0	0
55044	1624	mean concentration	[mean concentrations]	1.0	2	1	0	0
55045	1624	interferon alone	[interferons alone]	1.0	2	1	0	0
55046	1624	CD40 antigen expression by phosphorothioate oligonucleotide	[CD40 antigen expression by phosphorothioate oligonucleotides]	1.0	6	1	0	0
55047	1624	cytokine mrna in NK cell	[cytokine mRNA in NK cells]	1.0	5	1	0	0
55048	1624	THP-1 mature monocytic cell line	[THP-1 mature monocytic cell line]	1.0	5	1	0	0
55049	1624	Southern hybridization	[Southern hybridization]	1.0	2	1	0	0
55050	1624	agreement with this finding, experiment	[agreement with this finding, experiments]	1.0	5	1	0	0
55051	1624	positive factor	[positive factors]	1.0	2	2	2	2
55052	1624	new, model	[new, model]	1.0	2	1	0	0
55053	1624	mitogen-stimulated t-cell	[mitogen-stimulated T-cells]	1.0	2	1	0	0
55054	1624	heterodimer rxr-rar	[heterodimers RXR-RAR]	1.0	2	1	0	0
55055	1624	antigen specific T cell-b cell interaction	[antigen specific T cell-B cell interactions]	1.0	6	1	0	0
55056	1624	PMA hiv-1 p24 antigen production	[PMA HIV-1 p24 antigen production]	1.0	5	1	0	0
55057	1624	self renewal	[Self renewal]	1.0	2	2	2	2
55058	1624	mechanism of the therapeutic response	[mechanisms of the therapeutic response]	1.0	5	1	0	0
55059	1624	calcineurin a Ca2+/calmodulin-regulated, serine/threonine-specific protein phosphatase	[calcineurin a Ca2+/calmodulin-regulated, serine/threonine-specific protein phosphatase]	1.0	6	1	0	0
55060	1624	loss of p130 form 3	[loss of p130 Form 3]	1.0	5	1	0	0
55061	1624	ifngamma-driven, stat1 -dependent gene activation	[IFNgamma-driven, Stat1 -dependent gene activation]	1.0	5	1	0	0
55062	1624	calcineurin inhibitor	[calcineurin inhibitor]	1.0	2	2	2	2
55063	1624	expression of antisense myb rna	[Expression of antisense myb RNA]	1.0	5	1	0	0
55064	1624	osteoblast-specific gene	[osteoblast-specific gene]	1.0	2	2	1	1
55065	1624	placental clone	[placental clones]	1.0	2	1	0	0
55066	1624	such as tnf-alpha in vitro.	[such as TNF-alpha in vitro.]	1.0	5	1	0	0
55067	1624	HS-40 region.	[HS-40 region.]	1.0	2	1	0	0
55068	1624	apparent seasonal variation in gr	[apparent seasonal variation in GR]	1.0	5	1	0	0
55069	1624	role of transcription factor e2f	[role of transcription factor E2F]	1.0	5	1	0	0
55070	1624	transcriptional activation of the CAT gene	[transcriptional activation of the CAT gene]	1.0	6	1	0	0
55071	1624	50 kda nf-kappa b protein	[50 kDa NF-kappa B protein]	1.0	5	1	0	0
55072	1624	vascular cell adhesion molecule-1 gene	[vascular cell adhesion molecule-1 genes]	1.0	5	1	0	0
55073	1624	permit rapid translocation into the nucleus	[permitting rapid translocation into the nucleus]	1.0	6	1	0	0
55074	1624	megakaryocyte-specific promoter	[megakaryocyte-specific promoters]	1.0	2	1	0	0
55075	1624	co-operative interaction between all-tran RA	[co-operative interactions between all-trans RA]	1.0	5	1	0	0
55076	1624	ut-7/gmt cell	[UT-7/GMT cells]	1.0	2	2	2	2
55077	1624	gos19.1 promoter	[GOS19.1 promoter]	1.0	2	1	0	0
55078	1624	VDR target	[VDR target]	1.0	2	1	0	0
55079	1624	characterization of a T lymphocyte protein	[Characterization of a T lymphocyte protein]	1.0	6	1	0	0
55080	1624	even weak T cell response	[even weaker T cell response]	1.0	5	1	0	0
55081	1624	CD28 induction	[CD28 induction]	1.0	2	2	2	2
55082	1624	MAPK kinase-1	[MAPK kinase-1]	1.0	2	1	0	0
55083	1624	important role in the quiescence	[important role in the quiescence]	1.0	5	1	0	0
55084	1624	position 10182 of exon 5	[position 10182 of exon 5]	1.0	5	1	0	0
55085	1624	limited expression of lymphoid marker	[limited expression of lymphoid markers]	1.0	5	1	0	0
55086	1624	codon 10	[codon 10]	1.0	2	2	1	1
55087	1624	overlapping pathway	[overlapping pathways]	1.0	2	1	0	0
55088	1624	transcriptional mechanisms.	[transcriptional mechanisms.]	1.0	2	1	0	0
55089	1624	mood alteration	[mood alterations]	1.0	2	1	0	0
55090	1624	regulate important aspect of hematopoiesis	[regulating important aspects of hematopoiesis]	1.0	5	1	0	0
55091	1624	specifically in myeloid cell in vivo	[specifically in myeloid cells in vivo]	1.0	6	1	0	0
55092	1624	hsv-1 strain	[HSV-1 strain]	1.0	2	3	2	1
55093	1624	NF-YA mrna	[NF-YA mRNA]	1.0	2	1	0	0
55094	1624	white pulp of the spleen	[white pulp of the spleen]	1.0	5	1	0	0
55095	1624	PGE2 alpha	[PGE2 alpha]	1.0	2	1	0	0
55096	1624	mb-1 promoter	[mb-1 promoter]	1.0	2	1	0	0
55097	1624	expression of rrna for Fra-1	[expression of mRNAs for Fra-1]	1.0	5	1	0	0
55098	1624	hiv1 infection in the expression	[HIV1 infection in the expression]	1.0	5	1	0	0
55099	1624	CD28 -dependent induction of c-jun expression	[CD28 -dependent induction of c-jun expression]	1.0	6	1	0	0
55100	1624	respiratory epithelium of normal with cf	[respiratory epithelium of normals with CF]	1.0	6	1	0	0
55101	1624	pu.1 binding site in promoter	[PU.1 binding sites in promoters]	1.0	5	1	0	0
55102	1624	loss of heterozygosity in DNA	[loss of heterozygosity in DNA]	1.0	5	1	0	0
55103	1624	nuclear regulatory factor-kappa beta enf-kappa	[nuclear regulatory factor-kappa beta (NF-kappa]	1.0	5	1	0	0
55104	1624	MHC antigen expression on target cell	[MHC antigen expression on target cells]	1.0	6	1	0	0
55105	1624	good medium	[best medium]	1.0	2	1	0	0
55106	1624	endosomal compartment	[endosomal compartment]	1.0	2	1	0	0
55107	1624	activation program	[activation program]	1.0	2	1	0	0
55108	1624	basolateral surface	[basolateral surface]	1.0	2	1	0	0
55109	1624	ner defect	[NER defect]	1.0	2	2	1	1
55110	1624	many circumstance	[many circumstances]	1.0	2	1	0	0
55111	1624	expression of only this gene	[expression of only these genes]	1.0	5	1	0	0
55112	1624	10-50 kilobasis	[10-50 kilobases]	1.0	2	1	0	0
55113	1624	Tcf-dependent transcription in T lymphocyte	[Tcf-dependent transcription in T lymphocytes]	1.0	5	1	0	0
55114	1624	clinical presentation	[clinical presentation]	1.0	2	1	0	0
55115	1624	gain of a proteolysis-resistant inhibitor	[gain of a proteolysis-resistant inhibitor]	1.0	5	1	0	0
55116	1624	other inhibitor of ptpase include pervanadate	[other inhibitors of PTPase including pervanadate]	1.0	6	1	0	0
55117	1624	neutrophil influx	[neutrophil influx]	1.0	2	1	0	0
55118	1624	stimulation of Jurkat T cell cho-cd80	[stimulation of Jurkat T cells CHO-CD80]	1.0	6	1	0	0
55119	1624	expression of erythrocyte Duffy protein	[expression of erythrocyte Duffy protein]	1.0	5	1	0	0
55120	1624	expression of CAT reporter gene	[expression of CAT reporter gene]	1.0	5	1	0	0
55121	1624	14.3 kda	[14.3 kDa]	1.0	2	1	0	0
55122	1624	RelB rna	[RelB RNA]	1.0	2	1	0	0
55123	1624	main difference	[main difference]	1.0	2	2	1	1
55124	1624	early atherogenesis	[early atherogenesis]	1.0	2	1	0	0
55125	1624	lysis by lymphokine-activated killer cell	[lysis by lymphokine-activated killer cells]	1.0	5	1	0	0
55126	1624	activation of the HTLV-I enhancer	[activation of the HTLV-I enhancer]	1.0	5	1	0	0
55127	1624	cis-acting region	[cis-acting region]	1.0	2	2	2	2
55128	1624	follow observation	[Following observations]	1.0	2	1	0	0
55129	1624	thus activate transcription factor responsible	[thus activating transcription factors responsible]	1.0	5	1	0	0
55130	1624	footprinting experiment	[footprinting experiments]	1.0	2	1	0	0
55131	1624	little information available on the response	[little information available on the response]	1.0	6	1	0	0
55132	1624	fasl expression in T cell	[FasL expression in T cells]	1.0	5	1	0	0
55133	1624	high level of endogenous protease	[high levels of endogenous proteases]	1.0	5	1	0	0
55134	1624	cord blood lymphocyte of neonate	[cord blood lymphocytes of neonates]	1.0	5	1	0	0
55135	1624	promoter-proximal position	[promoter-proximal position]	1.0	2	1	0	0
55136	1624	role upstream of this pathways,	[role upstream of these pathways,]	1.0	5	1	0	0
55137	1624	activation of a serine /threonine kinase	[Activation of a serine /threonine kinase]	1.0	6	1	0	0
55138	1624	IL-10 treatment	[IL-10 treatment]	1.0	2	2	1	1
55139	1624	AM580 a stable retinobenzoic derivative	[AM580 a stable retinobenzoic derivative]	1.0	5	1	0	0
55140	1624	negative regulation of traf signal	[negative regulation of TRAF signaling]	1.0	5	1	0	0
55141	1624	visualization of heavy chain gene	[visualization of heavy chain genes]	1.0	5	1	0	0
55142	1624	one line, re-expression of RB	[one line, re-expression of RB]	1.0	5	1	0	0
55143	1624	adenovirus infection	[adenovirus infection]	1.0	2	2	2	2
55144	1624	multiple complexes.	[multiple complexes.]	1.0	2	1	0	0
55145	1624	enhance binding activity to consensus sequence	[enhancing binding activity to consensus sequence]	1.0	6	1	0	0
55146	1624	October 4;254(5028):11]	[Oct 4;254(5028):11]]	1.0	2	1	0	0
55147	1624	selective lysis of hpv cell	[selective lysis of HPV cells]	1.0	5	1	0	0
55148	1624	radioreceptor assay of some corticosteroid derivative	[Radioreceptor assay of some corticosteroid derivatives]	1.0	6	1	0	0
55149	1624	calcium-dependent apoptosis	[calcium-dependent apoptosis]	1.0	2	1	0	0
55150	1624	alpha B2	[alpha B2]	1.0	2	1	0	0
55151	1624	alpha B1	[alpha B1]	1.0	2	1	0	0
55152	1624	effect of long term therapy	[effect of long term therapy]	1.0	5	1	0	0
55153	1624	signalsome component	[signalsome components]	1.0	2	1	0	0
55154	1624	putative Sp1 Ap2 binding site/	[putative Sp1 Ap2 binding site/s]	1.0	5	1	0	0
55155	1624	(1) htlv-i infection per se	[(1) HTLV-I infection per se]	1.0	5	1	0	0
55156	1624	t-cell response against a antigen	[T-cell responses against a antigen]	1.0	5	1	0	0
55157	1624	biological significance in cutaneous carcinogenesis	[biological significance in cutaneous carcinogenesis]	1.0	5	1	0	0
55158	1624	equivalent level	[equivalent levels]	1.0	2	2	1	1
55159	1624	level of stat6 protein present	[Levels of Stat6 protein present]	1.0	5	1	0	0
55160	1624	2 retinoid -dependent granulocytic marker	[2 retinoid -dependent granulocytic markers]	1.0	5	1	0	0
55161	1624	Fli-1 binding	[Fli-1 binding]	1.0	2	1	0	0
55162	1624	thus, substitution within the ligand-binding domain	[Thus, substitutions within the ligand-binding domain]	1.0	6	1	0	0
55163	1624	b-cell-specific coactivator	[B-cell-specific coactivator]	1.0	2	1	0	0
55164	1624	include t-cell mitogens, proinflammatory cytokine	[including T-cell mitogens, proinflammatory cytokines]	1.0	5	1	0	0
55165	1624	nuclear import of nf-kappa b	[nuclear import of NF-kappa B]	1.0	5	2	2	2
55166	1624	hematopoietic cell particularly T cell	[hematopoietic cells particularly T cells]	1.0	5	1	0	0
55167	1624	monocyte to a macrophage-like cell	[monocytes to a macrophage-like cell]	1.0	5	1	0	0
55168	1624	bisdioxopiperazine icrf-193	[bisdioxopiperazine ICRF-193]	1.0	2	1	0	0
55169	1624	some, gene	[some, genes]	1.0	2	1	0	0
55170	1624	precursor b cell by stimulation	[precursor B cells by stimulation]	1.0	5	1	0	0
55171	1624	similar findings:	[similar findings:]	1.0	2	1	0	0
55172	1624	anti-estrogenic action to the monocyte	[anti-estrogenic action to the monocytes]	1.0	5	1	0	0
55173	1624	sequence-related gene	[sequence-related genes]	1.0	2	1	0	0
55174	1624	regulation of c-jun mrna expression	[Regulation of c-jun mRNA expression]	1.0	5	1	0	0
55175	1624	growth experiment	[Growth experiments]	1.0	2	1	0	0
55176	1624	human myeloid leukemia cell line	[human myeloid leukemia cell lines]	1.0	5	2	1	1
55177	1624	transient overexpression of mutant IkappaBalpha	[transient overexpression of mutant IkappaBalpha]	1.0	5	1	0	0
55178	1624	high chromosome	[high chromosome]	1.0	2	1	0	0
55179	1624	form functional heterodimer with the mutant	[forming functional heterodimers with the mutant]	1.0	6	1	0	0
55180	1624	testosterone responsiveness of T cell	[testosterone responsiveness of T cells]	1.0	5	1	0	0
55181	1624	interaction with the upstream regulatory element	[interaction with the upstream regulatory element]	1.0	6	1	0	0
55182	1624	(from hour	[(from hours]	1.0	2	2	2	2
55183	1624	overlap October	[overlapping Oct-]	1.0	2	1	0	0
55184	1624	eosinophil-specific gene	[eosinophil-specific genes]	1.0	2	2	1	1
55185	1624	inverse regulation	[inverse regulation]	1.0	2	1	0	0
55186	1624	EA/S motif	[EA/S motif]	1.0	2	1	0	0
55187	1624	activity of late promoter-reporter fusion	[activities of late promoter-reporter fusions]	1.0	5	1	0	0
55188	1624	product of the T-helper subset	[product of the T-helper subset]	1.0	5	1	0	0
55189	1624	other glucocorticoid	[other glucocorticoids]	1.0	2	2	1	1
55190	1624	mostly at the translational level	[mostly at the translational level]	1.0	5	1	0	0
55191	1624	42 degree for 2 h	[42 degrees for 2 h]	1.0	5	1	0	0
55192	1624	result hybridoma	[resulting hybridomas]	1.0	2	1	0	0
55193	1624	consist mainly of heterodimeric p50/p65 complex	[consisting mainly of heterodimeric p50/p65 complexes]	1.0	6	1	0	0
55194	1624	potent activator of the proliferation	[potent activator of the proliferation]	1.0	5	1	0	0
55195	1624	monoclonal pmnc	[monoclonal PMNCs]	1.0	2	1	0	0
55196	1624	transcriptional difference between this ltr	[Transcriptional differences between these LTRs]	1.0	5	1	0	0
55197	1624	interaction of the LCR holocomplex	[interaction of the LCR holocomplex]	1.0	5	1	0	0
55198	1624	52 binding site per cell; mean	[52 binding sites per cell; mean]	1.0	6	1	0	0
55199	1624	follow PHA stimulation of PBL	[Following PHA stimulation of PBL]	1.0	5	1	0	0
55200	1624	beta ii	[beta II]	1.0	2	1	0	0
55201	1624	DC formation	[DC formation]	1.0	2	1	0	0
55202	1624	mouse fibroblast	[mouse fibroblasts]	1.0	2	1	0	0
55203	1624	gr in peripheral mononuclear leukocyte	[GR in peripheral mononuclear leukocytes]	1.0	5	1	0	0
55204	1624	differentiation of myeloid progenitor cell	[differentiation of myeloid progenitor cells]	1.0	5	1	0	0
55205	1624	NF-kappaB -dependent intracellular signal pathway	[NF-kappaB -dependent intracellular signaling pathway]	1.0	5	1	0	0
55206	1624	antisense inhibition	[antisense inhibition]	1.0	2	2	1	1
55207	1624	Functional activation of a HIV reporter	[Functional activation of an HIV reporter]	1.0	6	1	0	0
55208	1624	southwestern screen	[Southwestern screening]	1.0	2	1	0	0
55209	1624	ap-1 binding ap-1 enhancer activity	[AP-1 binding AP-1 enhancer activity]	1.0	5	1	0	0
55210	1624	indicate fk506 -sensitive in spite	[indicating FK506 -sensitive in spite]	1.0	5	1	0	0
55211	1624	(6.2 kb)	[(6.2 kb)]	1.0	2	1	0	0
55212	1624	structural alteration	[structural alterations]	1.0	2	2	2	2
55213	1624	transgenic mouse with human cd3epsilon gene	[Transgenic mice with human CD3epsilon gene]	1.0	6	1	0	0
55214	1624	other protein,	[other protein,]	1.0	2	1	0	0
55215	1624	upstream delta	[upstream delta]	1.0	2	1	0	0
55216	1624	creb/atf homodimer	[CREB/ATF homodimers]	1.0	2	1	0	0
55217	1624	several animal model of autoimmunity,	[several animal models of autoimmunity,]	1.0	5	1	0	0
55218	1624	thymic T	[thymic T]	1.0	2	2	1	1
55219	1624	reproductive tissue	[reproductive tissue]	1.0	2	2	1	1
55220	1624	activation of the CD11c promoter	[activation of the CD11c promoters]	1.0	5	1	0	0
55221	1624	other potential transcription factor binding site	[other potential transcription factor binding sites]	1.0	6	1	0	0
55222	1624	however, use ATL-16T nuclear extract	[However, using ATL-16T nuclear extract]	1.0	5	1	0	0
55223	1624	joint disease	[joint disease.]	1.0	2	1	0	0
55224	1624	lps induction of the tf gene	[LPS induction of the TF gene]	1.0	6	1	0	0
55225	1624	beta e2	[beta E2]	1.0	2	1	0	0
55226	1624	presence of common structural element	[presence of common structural elements]	1.0	5	1	0	0
55227	1624	hemoglobin switch	[Hemoglobin switching]	1.0	2	2	2	2
55228	1624	-85 bp	[-85 bp]	1.0	2	1	0	0
55229	1624	Antisense cDNA	[Antisense cDNA]	1.0	2	1	0	0
55230	1624	calcium-calmodulin-dependent phosphatase	[calcium-calmodulin-dependent phosphatase]	1.0	2	1	0	0
55231	1624	transcriptional factor such as ap-1	[transcriptional factors such as AP-1]	1.0	5	1	0	0
55232	1624	AP-2 mrna	[AP-2 mRNA]	1.0	2	1	0	0
55233	1624	contrast to anti-cd3/ ln cell	[contrast to anti-CD3/ LN cells]	1.0	5	1	0	0
55234	1624	cell growth.	[cell growth.]	1.0	2	2	2	2
55235	1624	her-2/neu activation	[HER-2/neu activation]	1.0	2	1	0	0
55236	1624	immunoreaction against steroid hormone anti-sera	[immunoreaction against steroid hormone anti-sera]	1.0	5	1	0	0
55237	1624	gene expression by transcription factor	[gene expression by transcription factors]	1.0	5	1	0	0
55238	1624	rapid non-genomic action of mineralocorticoid	[rapid non-genomic actions of mineralocorticoids]	1.0	5	1	0	0
55239	1624	Study of pluripotent islet culture	[Studies of pluripotent islet cultures]	1.0	5	1	0	0
55240	1624	kappa b protein in carcinoma cell	[kappa B protein in carcinoma cells]	1.0	6	1	0	0
55241	1624	peripheral blood mononuclear cell hla b8+	[peripheral blood mononuclear cells HLA B8+]	1.0	6	1	0	0
55242	1624	human T cell leukemia virus-i htlv-i	[Human T cell leukemia virus-I HTLV-I]	1.0	6	1	0	0
55243	1624	rel homology domain of protein	[Rel homology domain of proteins]	1.0	5	1	0	0
55244	1624	yeast system	[yeast system]	1.0	2	2	2	2
55245	1624	primary immune response in human	[primary immune responses in humans]	1.0	5	1	0	0
55246	1624	common polymorphism within the VDR 3'-utr	[common polymorphisms within the VDR 3'-UTR]	1.0	6	1	0	0
55247	1624	monocyte number	[monocyte numbers]	1.0	2	1	0	0
55248	1624	transformation-related activity	[transformation-related activity]	1.0	2	1	0	0
55249	1624	Nuclear transcription factor kB NF-kappa b	[Nuclear transcription factor kB NF-kappa B]	1.0	6	1	0	0
55250	1624	alpha b2	[alpha B2]	1.0	2	2	1	1
55251	1624	macrophage in the adrenal gland,y	[macrophages in the adrenal gland,]	1.0	5	1	0	0
55252	1624	T cell of RCC patient.	[T cells of RCC patient.]	1.0	5	1	0	0
55253	1624	mouse hybridoma	[mouse hybridoma]	1.0	2	1	0	0
55254	1624	further increase in the expression	[further increase in the expression]	1.0	5	1	0	0
55255	1624	(35 min)	[(35 min)]	1.0	2	1	0	0
55256	1624	different corticosteroid inhibit the generation	[different corticosteroids inhibiting the generation]	1.0	5	1	0	0
55257	1624	bind activity of nf-kb less	[binding activity of NF-kB less]	1.0	5	1	0	0
55258	1624	tumor necrosis factor-alpha a cytokine	[tumor necrosis factor-alpha a cytokine]	1.0	5	1	0	0
55259	1624	biphasic fashion	[biphasic fashion]	1.0	2	1	0	0
55260	1624	methov with platelet-activate factor paf	[METHODS with platelet-activating factor PAF]	1.0	5	1	0	0
55261	1624	p38 MAPk	[p38 MAPk]	1.0	2	1	0	0
55262	1624	costimulatory signal essential for lymphokine production	[costimulatory signals essential for lymphokine production]	1.0	6	1	0	0
55263	1624	HB9 homeodomain	[HB9 homeodomain]	1.0	2	1	0	0
55264	1624	off-rate experiment	[off-rate experiments]	1.0	2	1	0	0
55265	1624	unfractionated peripheral blood mononuclear cell	[unfractionated peripheral blood mononuclear cells]	1.0	5	1	0	0
55266	1624	A-myb transcription	[A-myb transcription]	1.0	2	2	1	1
55267	1624	point mutant	[point mutant]	1.0	2	2	1	1
55268	1624	798+/-67 pg/ml	[798+/-67 pg/mL]	1.0	2	1	0	0
55269	1624	2343 bp	[2343 bp]	1.0	2	1	0	0
55270	1624	functional role of c/ebp protein	[functional role of C/EBP proteins]	1.0	5	1	0	0
55271	1624	acid 1-180)	[acids 1-180)]	1.0	2	1	0	0
55272	1624	multiple protein exhibit Arre-2 binding activity	[Multiple proteins exhibiting ARRE-2 binding activity]	1.0	6	1	0	0
55273	1624	b rdna	[B cDNAs]	1.0	2	1	0	0
55274	1624	phenotypic difference	[phenotypic differences]	1.0	2	1	0	0
55275	1624	activation of STAT nuclear factor	[activation of STAT nuclear factors]	1.0	5	1	0	0
55276	1624	gata-3 in IL-5 promoter activation	[GATA-3 in IL-5 promoter activation]	1.0	5	1	0	0
55277	1624	contraction of the plasma volume	[contraction of the plasma volume]	1.0	5	1	0	0
55278	1624	Pentoxifylline for the treatment of infection	[Pentoxifylline for the treatment of infection]	1.0	6	1	0	0
55279	1624	concomitant decrease in expression of spi-1	[concomitant decrease in expression of Spi-1]	1.0	6	1	0	0
55280	1624	hiv-1 ap-1 DNA recognition sequence	[HIV-1 AP-1 DNA recognition sequences]	1.0	5	1	0	0
55281	1624	nuclear extract from this cell	[nuclear extracts from these cells]	1.0	5	1	0	0
55282	1624	target promoter	[target promoter]	1.0	2	1	0	0
55283	1624	respiratory burst in U937 cell	[respiratory burst in U937 cells]	1.0	5	1	0	0
55284	1624	laz3/bcl6 expression	[LAZ3/BCL6 expression]	1.0	2	1	0	0
55285	1624	transfect tumor cell with il-12	[transfecting tumor cells with IL-12]	1.0	5	1	0	0
55286	1624	contrast, gp41	[contrast, gp41]	1.0	2	1	0	0
55287	1624	several indication	[several indications]	1.0	2	1	0	0
55288	1624	costimulatory signal in T cell	[costimulatory signals in T cells]	1.0	5	1	0	0
55289	1624	tyrosine phosphorylation of cellular substrate	[tyrosine phosphorylation of cellular substrates]	1.0	5	2	1	1
55290	1624	Grf40 a novel Grb2 family member	[Grf40 A novel Grb2 family member]	1.0	6	1	0	0
55291	1624	calcium signal in Jurkat cell	[calcium signals in Jurkat cells]	1.0	5	1	0	0
55292	1624	icam-1 cd54 expression in endothelial cell	[ICAM-1 CD54 expression in endothelial cells]	1.0	6	1	0	0
55293	1624	NK- kappa b dna-binding activity	[NK- kappa B DNA-binding activity]	1.0	5	1	0	0
55294	1624	myb:maf status	[Myb:Maf status]	1.0	2	1	0	0
55295	1624	specific receptor.	[specific receptor.]	1.0	2	1	0	0
55296	1624	functional significance of c-rel involvement	[functional significance of c-Rel involvement]	1.0	5	1	0	0
55297	1624	evidence the result of double infection	[evidence the result of double infection]	1.0	6	1	0	0
55298	1624	ligand, il-10	[ligand, IL-10]	1.0	2	1	0	0
55299	1624	mouse macrophage RAW 264.7 cell	[mouse macrophage RAW 264.7 cells]	1.0	5	1	0	0
55300	1624	relative difference in binding affinity	[relative differences in binding affinities]	1.0	5	1	0	0
55301	1624	use cytosol	[using cytosol]	1.0	2	2	2	2
55302	1624	cell-specific heterogeneity	[cell-specific heterogeneity]	1.0	2	1	0	0
55303	1624	enzyme family protease inhibitor on glucocorticoid-	[enzyme family protease inhibitors on glucocorticoid-]	1.0	6	1	0	0
55304	1624	tumor-derived ganglioside	[tumor-derived gangliosides]	1.0	2	1	0	0
55305	1624	(maximal at 20 min), c-jun,	[(maximal at 20 min), c-jun,]	1.0	5	1	0	0
55306	1624	two type of reactivity: il-13	[two types of reactivity: IL-13]	1.0	5	1	0	0
55307	1624	crucial element	[crucial element]	1.0	2	2	2	2
55308	1624	involve GrpL in T cell	[involving GrpL in T cells]	1.0	5	1	0	0
55309	1624	regulatory sequence from glucocorticoid -repressible gene	[regulatory sequences from glucocorticoid -repressible genes]	1.0	6	1	0	0
55310	1624	age-matched control	[age-matched controls]	1.0	2	1	0	0
55311	1624	antidepressant medication	[antidepressant medication]	1.0	2	1	0	0
55312	1624	recent finding of association between Ikaros	[recent findings of associations between Ikaros]	1.0	6	1	0	0
55313	1624	modification in signal transduction capacity	[modifications in signal transduction capacity]	1.0	5	1	0	0
55314	1624	binding of bob.1/obf.1 to Oct1	[binding of BOB.1/OBF.1 to Oct1]	1.0	5	1	0	0
55315	1624	supershift assay only in DC	[supershift assay only in DC]	1.0	5	1	0	0
55316	1624	ectopic expression of ciita rdna	[ectopic expression of CIITA cDNAs]	1.0	5	1	0	0
55317	1624	two phosphatase	[two phosphatases]	1.0	2	1	0	0
55318	1624	tissue factor tf expression by cell	[Tissue factor TF expression by cells]	1.0	6	1	0	0
55319	1624	infant cord	[infant cord]	1.0	2	1	0	0
55320	1624	inhibitor for nf-kappa b activation	[inhibitor for NF-kappa B activation]	1.0	5	1	0	0
55321	1624	use a oligonucleotide probe corresponding	[using an oligonucleotide probe corresponding]	1.0	5	1	0	0
55322	1624	synthesis of almost all cytokine	[synthesis of almost all cytokines]	1.0	5	1	0	0
55323	1624	unknown factor	[unknown factor]	1.0	2	2	2	2
55324	1624	tradd residue 294 to 312	[TRADD residues 294 to 312]	1.0	5	1	0	0
55325	1624	Sp1 interaction	[Sp1 interaction]	1.0	2	1	0	0
55326	1624	ability of this nuclear protein	[ability of these nuclear proteins]	1.0	5	1	0	0
55327	1624	binding capacity +/- 0.4 fmol	[binding capacity +/- 0.4 fmol]	1.0	5	1	0	0
55328	1624	three male	[three males]	1.0	2	1	0	0
55329	1624	distinct biological role in the control	[distinct biological roles in the control]	1.0	6	1	0	0
55330	1624	clone-13 to the divergent x2-box	[clone-13 to the divergent X2-box]	1.0	5	1	0	0
55331	1624	granulocyte DNA from four patient	[Granulocyte DNA from four patients]	1.0	5	1	0	0
55332	1624	effect of MCM on proliferation	[effects of MCM on proliferation]	1.0	5	1	0	0
55333	1624	unique characteristic among nuclear factor	[unique characteristic among nuclear factors]	1.0	5	1	0	0
55334	1624	CMAT complex	[CMAT complex]	1.0	2	1	0	0
55335	1624	site-specific mutation	[site-specific mutations]	1.0	2	1	0	0
55336	1624	result in a heterozygosity rate	[resulting in a heterozygosity rate]	1.0	5	1	0	0
55337	1624	endogenous ptdin	[endogenous PtdIns]	1.0	2	1	0	0
55338	1624	interaction of NFAT with calcineurin	[interaction of NFAT with calcineurin]	1.0	5	1	0	0
55339	1624	cDNA coding	[cDNA coding]	1.0	2	1	0	0
55340	1624	Nuclear p65	[Nuclear p65]	1.0	2	1	0	0
55341	1624	T cell response RAI therapy	[T cell response RAI therapy]	1.0	5	1	0	0
55342	1624	protein gene	[protein gene]	1.0	2	2	2	2
55343	1624	regulation of (il)-2 gene expression	[regulation of (IL)-2 gene expression]	1.0	5	1	0	0
55344	1624	Stat1-dependent phase	[Stat1-dependent phases]	1.0	2	1	0	0
55345	1624	regulation of granulocyte-macrophage colony-stimulating factor	[Regulation of granulocyte-macrophage colony-stimulating factor]	1.0	5	1	0	0
55346	1624	IKK alpha	[IKK alpha]	1.0	2	1	0	0
55347	1624	use a anti-runt box antiserum	[using an anti-runt box antiserum]	1.0	5	1	0	0
55348	1624	limited processing	[limited processing]	1.0	2	1	0	0
55349	1624	high prevalence of promoter methylation	[high prevalence of promoter methylation]	1.0	5	1	0	0
55350	1624	internal ribosomal entry site rna-protein interaction	[internal ribosomal entry site RNA-protein interactions]	1.0	6	1	0	0
55351	1624	specific anti- hrbc antibody production	[specific anti- HRBC antibody production]	1.0	5	1	0	0
55352	1624	1,25-dihydroxyvitamin	[1,25-dihydroxyvitamin]	1.0	1	11	4	4
55353	1624	engagement of the Lewis X antigen	[Engagement of the Lewis X antigen]	1.0	6	1	0	0
55354	1624	mineralocorticoid receptor mr in leucocyte	[mineralocorticoid receptor MR in leucocytes]	1.0	5	1	0	0
55355	1624	-3 tyrosine phosphorylation of 92-kda protein	[-3 tyrosine phosphorylation of 92-kDa protein]	1.0	6	1	0	0
55356	1624	two multicopy basal enhancer motif	[Two multicopy basal enhancer motifs]	1.0	5	1	0	0
55357	1624	granulocytic differentiation of hl-60 cell	[granulocytic differentiation of HL-60 cells]	1.0	5	1	0	0
55358	1624	Alpha-tocopherol treatment of the mouse	[Alpha-tocopherol treatment of the mice]	1.0	5	1	0	0
55359	1624	T cell dependent on activation,	[T cells dependent on activation,]	1.0	5	1	0	0
55360	1624	IL-13 gene 5' flank region	[IL-13 gene 5' flank region]	1.0	5	1	0	0
55361	1624	thiol-reduce compounds, such as l-cystine	[thiol-reducing compounds, such as L-cystine]	1.0	5	1	0	0
55362	1624	lead to T cell differentiation	[leading to T cell differentiation]	1.0	5	1	0	0
55363	1624	outcome of a antigenic response	[outcome of an antigenic response]	1.0	5	1	0	0
55364	1624	a moiety	[A moiety]	1.0	2	1	0	0
55365	1624	cloning of the c/ebp-epsilon transcription factor	[Cloning of the C/EBP-epsilon transcription factor]	1.0	6	1	0	0
55366	1624	proximal gamma-promoter	[proximal gamma-promoter]	1.0	2	1	0	0
55367	1624	pretreatment of pbmc with pertussis toxin	[Pretreatment of PBMCs with pertussis toxin]	1.0	6	1	0	0
55368	1624	B-cell antigen receptor bcr signal	[B-cell antigen receptor BCR signals]	1.0	5	1	0	0
55369	1624	vascular response	[vascular responses]	1.0	2	1	0	0
55370	1624	important consequence for cell effector function	[important consequences for cell effector function]	1.0	6	1	0	0
55371	1624	functional block	[functional block]	1.0	2	1	0	0
55372	1624	molecular mechanism of hiv inhibition	[molecular mechanism of HIV inhibition]	1.0	5	1	0	0
55373	1624	five variables.	[five variables.]	1.0	2	1	0	0
55374	1624	involvement of Janus kinase /signal transducer	[Involvement of Janus kinase /signal transducer]	1.0	6	1	0	0
55375	1624	medium alone.	[medium alone.]	1.0	2	1	0	0
55376	1624	inhibitory effect of growth hormone	[Inhibitory effect of growth hormone]	1.0	5	1	0	0
55377	1624	atypical pkc isoenzyme include pkc-zeta	[atypical PKC isoenzymes including PKC-zeta]	1.0	5	1	0	0
55378	1624	antiandrogen of steroid hormone receptor	[antiandrogens of steroid hormone receptors]	1.0	5	1	0	0
55379	1624	hiv-1 infection of CEM subclone	[HIV-1 infection of CEM subclones]	1.0	5	1	0	0
55380	1624	expression of il-2r alpha tac	[expression of IL-2R alpha Tac]	1.0	5	1	0	0
55381	1624	control mice.	[control mice.]	1.0	2	1	0	0
55382	1624	major part	[major part]	1.0	2	1	0	0
55383	1624	subtle difference in the sequence	[subtle differences in the sequence]	1.0	5	1	0	0
55384	1624	Rel/ NF-kappa b transcription factor	[Rel/ NF-kappa B transcription factors]	1.0	5	1	0	0
55385	1624	p53 interference	[p53 interference]	1.0	2	1	0	0
55386	1624	second exon, result in protein	[second exon, resulting in proteins]	1.0	5	1	0	0
55387	1624	disease association	[disease associations]	1.0	2	1	0	0
55388	1624	tumor with high ki-67 proliferation index	[Tumors with high Ki-67 proliferation indices]	1.0	6	1	0	0
55389	1624	(irf) family	[(IRF) family]	1.0	2	2	2	2
55390	1624	granulocyte-monocyte colony	[granulocyte-monocyte colony]	1.0	2	1	0	0
55391	1624	two unknown cDNA sequence Nov1	[two unknown cDNA sequences Nov1]	1.0	5	1	0	0
55392	1624	reactivity of the immune system	[reactivity of the immune system]	1.0	5	1	0	0
55393	1624	second, strong RBP-Jkappa -binding site	[second, stronger RBP-Jkappa -binding site]	1.0	5	1	0	0
55394	1624	dexamethasone stimulation of CAT activity	[dexamethasone stimulation of CAT activity]	1.0	5	1	0	0
55395	1624	analogous effect	[analogous effect]	1.0	2	1	0	0
55396	1624	use synthetic peptide in subunit vaccine	[using synthetic peptides in subunit vaccines]	1.0	6	1	0	0
55397	1624	expression of mineralocorticoid receptor mrna	[expression of mineralocorticoid receptor mRNA]	1.0	5	1	0	0
55398	1624	two isozyme	[two isozymes]	1.0	2	1	0	0
55399	1624	functional ras	[functional Ras]	1.0	2	1	0	0
55400	1624	reflect the presence of progenitor	[reflecting the presence of progenitors]	1.0	5	1	0	0
55401	1624	enhance the safety phenotype of genome	[enhancing the safety phenotype of genome]	1.0	6	1	0	0
55402	1624	administration of dexamethasone to artery-SCID chimera	[Administration of dexamethasone to artery-SCID chimeras]	1.0	6	1	0	0
55403	1624	hematopoietic protein- tyrosine phosphatase heptp	[hematopoietic protein- tyrosine phosphatase HePTP]	1.0	5	1	0	0
55404	1624	recombinant thyroid hormone receptor TRs	[recombinant thyroid hormone receptors TRs]	1.0	5	1	0	0
55405	1624	moreover, cd3+ intrafollicular T cell	[Moreover, CD3+ intrafollicular T cells]	1.0	5	1	0	0
55406	1624	p50. c-Rel	[p50. c-Rel]	1.0	2	1	0	0
55407	1624	particular, western promoter deletion analysis	[particular, Western promoter deletion analyses]	1.0	5	1	0	0
55408	1624	promoter domain	[promoter domain]	1.0	2	2	2	2
55409	1624	differentiation, such as camp production	[differentiation, such as cAMP production]	1.0	5	1	0	0
55410	1624	latent protein	[latent proteins]	1.0	2	2	2	2
55411	1624	use a synthetic E6 motif	[using a synthetic E6 motif]	1.0	5	1	0	0
55412	1624	homologous groups,	[homologous groups,]	1.0	2	1	0	0
55413	1624	alternative use	[alternative use]	1.0	2	4	3	1
55414	1624	individual-specific modifier	[individual-specific modifier]	1.0	2	1	0	0
55415	1624	seven preterm	[Seven preterms]	1.0	2	1	0	0
55416	1624	endogenous IFN	[endogenous IFN]	1.0	2	1	0	0
55417	1624	molecular basis for the commitment	[molecular basis for the commitment]	1.0	5	1	0	0
55418	1624	downstream binding factor (dbf) site	[downstream binding factor (DBF) site]	1.0	5	1	0	0
55419	1624	IL-4 -dependent activation of Stat6	[IL-4 -dependent activation of Stat6]	1.0	5	1	0	0
55420	1624	certain NF-kappaB/Rel member predominantly c-rel	[certain NF-kappaB/Rel members predominantly c-Rel]	1.0	5	1	0	0
55421	1624	extracellular signal-related kinase n-terminal kinase	[extracellular signal-related kinase N-terminal kinase]	1.0	5	1	0	0
55422	1624	cytokine interleukin-1 beta il-1 beta	[cytokines interleukin-1 beta IL-1 beta]	1.0	5	1	0	0
55423	1624	cortisol production	[cortisol production]	1.0	2	1	0	0
55424	1624	different domain of il-9ralpha other	[different domains of IL-9Ralpha other]	1.0	5	1	0	0
55425	1624	quantification of hiv genomic rna	[quantification of HIV genomic RNA]	1.0	5	1	0	0
55426	1624	leukocyte arrest	[leukocyte arrest]	1.0	2	1	0	0
55427	1624	effect on nf-kappa b activation	[effects on NF-kappa B activation]	1.0	5	2	1	1
55428	1624	January 1956	[January 1956]	1.0	2	1	0	0
55429	1624	cell-dependent b	[cell-dependent B]	1.0	2	2	1	1
55430	1624	involvement of the cck(b) receptor	[involvement of the CCK(B) receptor]	1.0	5	1	0	0
55431	1624	adult mammal	[adult mammals]	1.0	2	1	0	0
55432	1624	1 enhancer	[1 enhancer]	1.0	2	2	2	2
55433	1624	cells, hsp70	[cells, Hsp70]	1.0	2	1	0	0
55434	1624	NFAT-1 complex	[NFAT-1 complex]	1.0	2	1	0	0
55435	1624	PHA pbl	[PHA PBL]	1.0	2	1	0	0
55436	1624	Hsp70 overexpression	[Hsp70 overexpression]	1.0	2	1	0	0
55437	1624	OTF-2 alone	[OTF-2 alone]	1.0	2	1	0	0
55438	1624	blr1 expression	[BLR1 expression]	1.0	2	1	0	0
55439	1624	more slowly migrate complex pu-sf	[more slowly migrating complex PU-SF]	1.0	5	1	0	0
55440	1624	adherent pbmc	[adherent PBMC]	1.0	2	1	0	0
55441	1624	January 1987	[January 1987]	1.0	2	1	0	0
55442	1624	intercellular adhesion molecule-1 in huvec	[intercellular adhesion molecule-1 in HUVECs]	1.0	5	1	0	0
55443	1624	macrovascular ec	[macrovascular EC]	1.0	2	2	2	2
55444	1624	factor 5 to 10, as	[factor 5 to 10, as]	1.0	5	1	0	0
55445	1624	gene repression	[gene repression]	1.0	2	1	0	0
55446	1624	reciprocal mechanism	[reciprocal mechanism]	1.0	2	1	0	0
55447	1624	wild-type hla-dr/-dq	[wild-type HLA-DR/-DQ]	1.0	2	1	0	0
55448	1624	methylation of HpaII I site	[Methylation of HpaII I sites]	1.0	5	1	0	0
55449	1624	antioxidant-dependent manner	[antioxidant-dependent manner]	1.0	2	1	0	0
55450	1624	60 amino	[60 amino]	1.0	2	1	0	0
55451	1624	further elucidation.	[further elucidation.]	1.0	2	1	0	0
55452	1624	pathologic picture	[pathologic picture]	1.0	2	1	0	0
55453	1624	progress into the S phase	[progressing into the S phase]	1.0	5	1	0	0
55454	1624	glucocorticoid reduction of IL-12 production	[glucocorticoid reduction of IL-12 production]	1.0	5	1	0	0
55455	1624	only in late b cell development	[only in late B cell development]	1.0	6	1	0	0
55456	1624	self renewal of normal erythroid progenitor	[Self renewal of normal erythroid progenitors]	1.0	6	1	0	0
55457	1624	CMV hcmv	[CMV HCMV]	1.0	2	2	2	2
55458	1624	Furthermore, SLP-76	[Furthermore, SLP-76]	1.0	2	1	0	0
55459	1624	ratio of adult beta-globin/alpha-globin mrna	[ratio of adult beta-globin/alpha-globin mRNA]	1.0	5	1	0	0
55460	1624	primarily by a transcriptional mechanism	[primarily by a transcriptional mechanism]	1.0	5	1	0	0
55461	1624	tyrosine phosphorylation of stat1, stat3	[tyrosine phosphorylation of STAT1, STAT3]	1.0	5	1	0	0
55462	1624	significant decrease in b-cell mitogenesis	[significant decrease in B-cell mitogenesis]	1.0	5	1	0	0
55463	1624	disorder such as fibrosis (cf)	[disorders such as fibrosis (CF)]	1.0	5	1	0	0
55464	1624	megakaryocytic lineages.	[megakaryocytic lineages.]	1.0	2	1	0	0
55465	1624	cell-specific pattern	[cell-specific pattern]	1.0	2	2	2	2
55466	1624	30 patient	[30 patients]	1.0	2	2	1	1
55467	1624	minimal extent,	[minimal extent,]	1.0	2	1	0	0
55468	1624	together with difference in the spacing	[together with differences in the spacing]	1.0	6	1	0	0
55469	1624	induction of IgE by IL-4	[induction of IgE by IL-4]	1.0	5	1	0	0
55470	1624	therefore, chromosome band 11p15 rhombotin	[Therefore, chromosome bands 11p15 rhombotin]	1.0	5	1	0	0
55471	1624	relative contribution of CD28 signal	[relative contribution of CD28 signals]	1.0	5	1	0	0
55472	1624	proliferate, expression	[proliferate, expression]	1.0	2	1	0	0
55473	1624	3.5 kb	[3.5 kb]	1.0	2	1	0	0
55474	1624	1 aml m2 with eosinophilia	[1 AML M2 with eosinophilia]	1.0	5	1	0	0
55475	1624	tropical spastic paraparesis/ htlv-i myelopathy	[tropical spastic paraparesis/ HTLV-I myelopathy]	1.0	5	1	0	0
55476	1624	bacterial ligand	[bacterial ligands]	1.0	2	2	1	1
55477	1624	transcription initiation from the IL-3 gene	[transcription initiation from the IL-3 gene]	1.0	6	1	0	0
55478	1624	partial proteolysis profile of this protein	[partial proteolysis profile of this protein]	1.0	6	1	0	0
55479	1624	T cell activation at neutral pH	[T cell activation at neutral pH]	1.0	6	1	0	0
55480	1624	element 1	[element 1]	1.0	2	2	2	2
55481	1624	YY1 binding site around -300	[YY1 binding site around -300]	1.0	5	1	0	0
55482	1624	second class	[second class]	1.0	2	1	0	0
55483	1624	strong inducer of hiv-ltr activation	[strong inducer of HIV-LTR activation]	1.0	5	1	0	0
55484	1624	stimulation of blood platelet with alpha-thrombin	[Stimulation of blood platelets with alpha-thrombin]	1.0	6	1	0	0
55485	1624	good understanding of the impact	[better understanding of the impact]	1.0	5	1	0	0
55486	1624	precise mechanism lead to B-cell apoptosis	[precise mechanisms leading to B-cell apoptosis]	1.0	6	1	0	0
55487	1624	il-5 mrna	[IL-5 mRNA]	1.0	2	2	1	1
55488	1624	signal-dependent phosphorylation	[signal-dependent phosphorylation]	1.0	2	1	0	0
55489	1624	human t-lymphotropic virus type 1 htlv-1	[human T-lymphotropic virus type 1 HTLV-1]	1.0	6	1	0	0
55490	1624	METHODS: CD23	[METHODS: CD23]	1.0	2	1	0	0
55491	1624	smx -no	[SMX -NO]	1.0	2	1	0	0
55492	1624	glutamic acid	[glutamic acid]	1.0	2	1	0	0
55493	1624	Study on unicellular daughter cell culture	[Studies on unicellular daughter cell culture]	1.0	6	1	0	0
55494	1624	-180 site	[-180 site]	1.0	2	1	0	0
55495	1624	comparison, platelet activating factor paf	[comparison, platelet activating factor PAF]	1.0	5	1	0	0
55496	1624	ah receptor deficient c12 cell line	[Ah receptor deficient c12 cell lines]	1.0	6	1	0	0
55497	1624	leukocyte phenotype	[leukocyte phenotype]	1.0	2	1	0	0
55498	1624	proliferation of this cells, accumulation	[proliferation of these cells, accumulation]	1.0	5	1	0	0
55499	1624	malfunction of the normal glucocorticoid response	[malfunction of the normal glucocorticoid response]	1.0	6	1	0	0
55500	1624	relb gene	[relB genes]	1.0	2	1	0	0
55501	1624	receive glucocorticoid therapy for systemic disease	[receiving glucocorticoid therapy for systemic diseases]	1.0	6	1	0	0
55502	1624	result in differentiation of this cell	[resulting in differentiation of these cells]	1.0	6	1	0	0
55503	1624	spontaneous tumorigenesis	[spontaneous tumorigenesis]	1.0	2	1	0	0
55504	1624	VDR halflife	[VDR halflife]	1.0	2	1	0	0
55505	1624	agonist-induced phosphorylation	[agonist-induced phosphorylation]	1.0	2	1	0	0
55506	1624	study 1,25-dihydroxyvitamin D3 calcitriol in lymphocyte	[studying 1,25-dihydroxyvitamin D3 calcitriol in lymphocytes]	1.0	6	1	0	0
55507	1624	Sp1 transcription	[Sp1 transcription]	1.0	2	3	2	1
55508	1624	n-myc gene	[N-myc genes]	1.0	2	1	0	0
55509	1624	cd19 cross-linking in 1e8 cell	[CD19 cross-linking in 1E8 cells]	1.0	5	1	0	0
55510	1624	il-7r signal	[IL-7R signaling]	1.0	2	1	0	0
55511	1624	[10-23 tcdd	[[10-23 TCDD]	1.0	2	1	0	0
55512	1624	non-lna-bind dimer	[non-DNA-binding dimer]	1.0	2	1	0	0
55513	1624	follow infection with Chlamydia pneumoniae	[following infection with Chlamydia pneumoniae]	1.0	5	1	0	0
55514	1624	T cell receptor (tcr) alpha	[T cell receptor (TCR) alpha]	1.0	5	1	0	0
55515	1624	(p great than 0.05, p	[(P greater than 0.05, P]	1.0	5	1	0	0
55516	1624	peripheral organ	[peripheral organs]	1.0	2	1	0	0
55517	1624	vzv protein	[VZV proteins]	1.0	2	2	2	2
55518	1624	inhibitory agent	[inhibitory agent]	1.0	2	1	0	0
55519	1624	expression of il-1alpha by HTLV-I cell	[Expression of IL-1alpha by HTLV-I cells]	1.0	6	1	0	0
55520	1624	tissue such as the system	[tissues such as the system]	1.0	5	1	0	0
55521	1624	signal transducer a transcription factor	[signal transducer a transcription factor]	1.0	5	1	0	0
55522	1624	hiv-2 transactivator	[HIV-2 transactivators]	1.0	2	1	0	0
55523	1624	Chignard, M. (1993) Blood 82,	[Chignard, M. (1993) Blood 82,]	1.0	5	1	0	0
55524	1624	terminate nf-kappa b -DNA interaction	[terminating NF-kappa B -DNA interaction]	1.0	5	1	0	0
55525	1624	monocyte production of inflammatory cytokine	[monocyte production of inflammatory cytokines]	1.0	5	1	0	0
55526	1624	affinity chromatography in UT-7 Epo	[affinity chromatography in UT-7 Epo]	1.0	5	1	0	0
55527	1624	(200 mg/dl)	[(200 mg/dl)]	1.0	2	1	0	0
55528	1624	member of the protein kinase family	[members of the protein kinase family]	1.0	6	1	0	0
55529	1624	all-tran RA at 10(-8) m,	[all-trans RA at 10(-8) M,]	1.0	5	1	0	0
55530	1624	Inactive shp1	[Inactive SHP1]	1.0	2	1	0	0
55531	1624	c-rel expression	[c-Rel expression]	1.0	2	2	2	2
55532	1624	prior to complete arrest in G1,	[prior to complete arrest in G1,]	1.0	6	1	0	0
55533	1624	tax cDNA	[Tax cDNA]	1.0	2	1	0	0
55534	1624	anti-inflammatory therapy	[anti-inflammatory therapy]	1.0	2	1	0	0
55535	1624	upper limit	[upper limit]	1.0	2	2	2	2
55536	1624	number of octamer factor variant	[number of octamer factor variants]	1.0	5	1	0	0
55537	1624	induction of reactive oxygen intermediate ROI	[induction of reactive oxygen intermediates ROI]	1.0	6	1	0	0
55538	1624	NF-kappa b nuclear translocation cell	[NF-kappa B nuclear translocation cells]	1.0	5	1	0	0
55539	1624	endogenous Itk	[endogenous Itk]	1.0	2	1	0	0
55540	1624	multipotential cell	[multipotential cells]	1.0	2	1	0	0
55541	1624	deletion study	[Deletion studies]	1.0	2	1	0	0
55542	1624	il-2r-alpha expression	[IL-2R-alpha expression]	1.0	2	1	0	0
55543	1624	level of constitutive nf-kappa b	[level of constitutive NF-kappa B]	1.0	5	1	0	0
55544	1624	replication of human immunodeficiency virus-1	[Replication of human immunodeficiency virus-1]	1.0	5	1	0	0
55545	1624	approximately -500 to -250 bp	[approximately -500 to -250 bp]	1.0	5	1	0	0
55546	1624	two allele	[two alleles]	1.0	2	2	2	2
55547	1624	CD40 up-regulation of the Bfl-1 gene	[CD40 up-regulation of the Bfl-1 genes]	1.0	6	1	0	0
55548	1624	hemoglobin-encoding gene	[hemoglobin-encoding genes]	1.0	2	1	0	0
55549	1624	er expression	[ER expressions]	1.0	2	1	0	0
55550	1624	recognize the T cell nfatc	[recognizing the T cell NFATc]	1.0	5	1	0	0
55551	1624	antitumor agent	[antitumor agent]	1.0	2	1	0	0
55552	1624	mechanism for the antiinflammatory effect	[mechanism for the antiinflammatory effects]	1.0	5	1	0	0
55553	1624	primary hemopoietic cell in G0	[primary hemopoietic cells in G0]	1.0	5	1	0	0
55554	1624	SRI responder differ from nonresponder	[SRI responders differing from nonresponders]	1.0	5	1	0	0
55555	1624	recruitment cooperate nuclear transcription factor	[recruitment cooperating nuclear transcription factors]	1.0	5	1	0	0
55556	1624	gene activation from a promoter	[gene activation from a promoter]	1.0	5	1	0	0
55557	1624	transient outgrowth of erythroid cell	[transient outgrowth of erythroid cells]	1.0	5	1	0	0
55558	1624	t(15;17) acute promyelocytic leukemia APL	[t(15;17) acute promyelocytic leukemia APL]	1.0	5	1	0	0
55559	1624	tyrosine phosphorylation of multiple signal protein	[tyrosine phosphorylation of multiple signaling proteins]	1.0	6	1	0	0
55560	1624	RB a novel e2f-1 binding protein	[RB a novel E2F-1 binding protein]	1.0	6	1	0	0
55561	1624	only the phoq gene product	[only the phoQ gene product]	1.0	5	1	0	0
55562	1624	primary tumor in Group B.	[primary tumors in Group B.]	1.0	5	1	0	0
55563	1624	cooperation augment il-2 promoter activity	[cooperation augmenting IL-2 promoter activity]	1.0	5	1	0	0
55564	1624	such gene	[Such genes]	1.0	2	1	0	0
55565	1624	alveolar collapse in the area	[alveolar collapse in the areas]	1.0	5	1	0	0
55566	1624	nuclear factor of kappab nf-kappab	[nuclear factor of kappaB NF-kappaB]	1.0	5	1	0	0
55567	1624	member of the GATA family	[member of the GATA family]	1.0	5	1	0	0
55568	1624	possible role negatively regulate e2f	[possible role negatively regulating E2F]	1.0	5	1	0	0
55569	1624	nf-kappa b activation after anti-CD3 stimulation	[NF-kappa B activation after anti-CD3 stimulation]	1.0	6	1	0	0
55570	1624	airway instillation of dichloromethylene diphosphonate	[airway instillation of dichloromethylene diphosphonate]	1.0	5	1	0	0
55571	1624	precise point	[precise point]	1.0	2	1	0	0
55572	1624	human T leukemia virus type htlv-1	[Human T leukemia virus type HTLV-1]	1.0	6	1	0	0
55573	1624	regulatory function at the hypothalamic level,	[regulatory function at the hypothalamic level,]	1.0	6	1	0	0
55574	1624	gene with coherent expression pattern	[genes with coherent expression patterns]	1.0	5	1	0	0
55575	1624	inhibit the expression of a set	[inhibiting the expression of a set]	1.0	6	1	0	0
55576	1624	perennial rhinitis	[perennial rhinitis]	1.0	2	2	2	2
55577	1624	RAR ro	[RAR Ro]	1.0	2	1	0	0
55578	1624	eosinophil in the hypereosinophilic syndrome	[eosinophils in the hypereosinophilic syndrome]	1.0	5	1	0	0
55579	1624	coding gene	[coding gene]	1.0	2	1	0	0
55580	1624	most important trans-acting factor nf-kb	[most important trans-acting factors NF-kB]	1.0	5	1	0	0
55581	1624	vd analogue	[VD analogues]	1.0	2	2	2	2
55582	1624	1 phosphatase	[1 phosphatases]	1.0	2	1	0	0
55583	1624	two structurally distinct immunophilin-drug complex	[two structurally distinct immunophilin-drug complexes]	1.0	5	1	0	0
55584	1624	cys gsh human peripheral blood cell	[CYS GSH human peripheral blood cells]	1.0	6	1	0	0
55585	1624	co-receptor molecule such as CD28	[co-receptor molecule such as CD28]	1.0	5	1	0	0
55586	1624	oxidative signalling.	[oxidative signalling.]	1.0	2	1	0	0
55587	1624	SCL/tal-1, e2a	[SCL/tal-1, E2A]	1.0	2	1	0	0
55588	1624	immature mature T cell in	[immature mature T cells in]	1.0	5	1	0	0
55589	1624	only the 4.5-kilobase pair mrna	[only the 4.5-kilobase pair mRNA]	1.0	5	1	0	0
55590	1624	p3hr1 cell	[P3HR1 cells]	1.0	2	1	0	0
55591	1624	cross-link of fcr with immune complex	[Cross-linking of FcR with immune complexes]	1.0	6	1	0	0
55592	1624	MHC class Ii invariant chain	[MHC class Ii invariant chain]	1.0	5	1	0	0
55593	1624	different affinity	[different affinities]	1.0	2	2	2	2
55594	1624	binding of nuclear transcription factor	[binding of nuclear transcription factors]	1.0	5	1	0	0
55595	1624	pattern of SCL protein synthesis	[pattern of SCL protein synthesis]	1.0	5	1	0	0
55596	1624	possibly evasion of immune response	[possibly evasion of immune responses]	1.0	5	1	0	0
55597	1624	primary leukocyte	[primary leukocytes]	1.0	2	1	0	0
55598	1624	activation of stat1 gene transcription	[activation of STAT1 gene transcription]	1.0	5	1	0	0
55599	1624	GT box	[GT box]	1.0	2	2	2	2
55600	1624	alphaiibbeta3 integrin	[alphaIIbbeta3 integrin]	1.0	2	1	0	0
55601	1624	human cell follow hydrocortisone injection	[human cells following hydrocortisone injection]	1.0	5	1	0	0
55602	1624	functional density	[functional density]	1.0	2	1	0	0
55603	1624	ebv-encoded antigen	[EBV-encoded antigen]	1.0	2	2	2	2
55604	1624	hypoxic tissue	[hypoxic tissue]	1.0	2	1	0	0
55605	1624	extensive footprint over the canonical elements,	[extensive footprints over the canonical elements,]	1.0	6	1	0	0
55606	1624	effect mutate the binding site	[effect mutating the binding site]	1.0	5	1	0	0
55607	1624	also in the presence of genistein	[also in the presence of genistein]	1.0	6	1	0	0
55608	1624	frequency of this genetic defect	[frequency of this genetic defect]	1.0	5	1	0	0
55609	1624	transactivation at a Sp1 site	[transactivation at an Sp1 site]	1.0	5	1	0	0
55610	1624	hl-60/vinc cell with okadaic acid	[HL-60/vinc cells with okadaic acid]	1.0	5	1	0	0
55611	1624	apoptosis of the T cell clone	[apoptosis of the T cell clones]	1.0	6	1	0	0
55612	1624	sequence similarity with the factor	[sequence similarity with the factor]	1.0	5	1	0	0
55613	1624	DNA binding by this receptor	[DNA binding by these receptors]	1.0	5	1	0	0
55614	1624	7 case	[7 cases]	1.0	2	1	0	0
55615	1624	nf-y CBF	[NF-Y CBF]	1.0	2	1	0	0
55616	1624	close homology	[close homology]	1.0	2	1	0	0
55617	1624	MHC class ii antigen expression	[MHC class II antigens expression]	1.0	5	1	0	0
55618	1624	minimal effect on cell growth,	[minimal effect on cell growth,]	1.0	5	1	0	0
55619	1624	c-fo induction via h2 receptor	[c-fos induction via H2 receptors]	1.0	5	1	0	0
55620	1624	four domain	[four domains]	1.0	2	2	1	1
55621	1624	normal amount of Oct-1 protein	[normal amounts of Oct-1 proteins]	1.0	5	1	0	0
55622	1624	immature normal myeloid cell StatG	[immature normal myeloid cells StatG]	1.0	5	1	0	0
55623	1624	concomitant loss	[concomitant loss]	1.0	2	2	1	1
55624	1624	stimulation with hematopoietic growth factor	[stimulation with hematopoietic growth factors]	1.0	5	1	0	0
55625	1624	prior to the stimulation of cell	[prior to the stimulation of cells]	1.0	6	1	0	0
55626	1624	interleukin 6 colony-stimulating factor receptor	[interleukin 6 colony-stimulating factor receptors]	1.0	5	1	0	0
55627	1624	frequency of fgf-1 T cell	[frequency of FGF-1 T cells]	1.0	5	1	0	0
55628	1624	long arm	[long arm]	1.0	2	2	1	1
55629	1624	none of the PKC isotype	[none of the PKC isotypes]	1.0	5	1	0	0
55630	1624	role in the proliferative control	[role in the proliferative control]	1.0	5	1	0	0
55631	1624	new antiapoptotic role for Notch-1	[new antiapoptotic role for Notch-1]	1.0	5	1	0	0
55632	1624	genetic level.	[genetic level.]	1.0	2	1	0	0
55633	1624	infectable cell	[infectable cells]	1.0	2	1	0	0
55634	1624	significant role in hiv regulation	[significant role in HIV regulation]	1.0	5	1	0	0
55635	1624	ketoconazole therapy	[ketoconazole therapy]	1.0	2	1	0	0
55636	1624	th2- type	[Th2- type]	1.0	2	1	0	0
55637	1624	granuloma formation at site of infection	[granuloma formation at sites of infection]	1.0	6	1	0	0
55638	1624	direct effect on IL-2 expression	[direct effect on IL-2 expression]	1.0	5	1	0	0
55639	1624	relate ros activity to inflammatory disease	[relating ROS activity to inflammatory diseases]	1.0	6	1	0	0
55640	1624	high m(r)	[higher M(r)]	1.0	2	1	0	0
55641	1624	oxygen scavenger	[oxygen scavenger]	1.0	2	2	2	2
55642	1624	nonproliferating, neutrophil	[nonproliferating, neutrophils]	1.0	2	1	0	0
55643	1624	define crucial signal for the biogenesis	[defining crucial signals for the biogenesis]	1.0	6	1	0	0
55644	1624	p40 chain	[p40 chains]	1.0	2	1	0	0
55645	1624	overexpression of a form of Rho	[overexpression of an form of Rho]	1.0	6	1	0	0
55646	1624	indirect response	[indirect response]	1.0	2	1	0	0
55647	1624	cell develop from blood precursor	[cells developing from blood precursors]	1.0	5	1	0	0
55648	1624	clinical relevance of cytokine therapy	[clinical relevance of cytokine therapy]	1.0	5	1	0	0
55649	1624	trans-activator protein	[trans-activator protein]	1.0	2	2	2	2
55650	1624	neurologic syndrome	[neurologic syndrome]	1.0	2	1	0	0
55651	1624	relative insensitivity	[relative insensitivity]	1.0	2	1	0	0
55652	1624	il-4 activity	[IL-4 activity]	1.0	2	1	0	0
55653	1624	mAb j393	[mAb J393]	1.0	2	2	2	2
55654	1624	gel electrophoresis mobility shift assay	[Gel electrophoresis mobility shift assays]	1.0	5	1	0	0
55655	1624	physiological relevance of this finding	[physiological relevance of this finding]	1.0	5	1	0	0
55656	1624	mapping of the structural requirement	[Mapping of the structural requirements]	1.0	5	1	0	0
55657	1624	lack pili	[lacking pili]	1.0	2	2	2	2
55658	1624	study the mechanism of viral latency	[studying the mechanism of viral latency]	1.0	6	1	0	0
55659	1624	opening of the chromatin structure	[opening of the chromatin structure]	1.0	5	1	0	0
55660	1624	CsA sensitivity to the nfat element	[CsA sensitivity to the NFAT element]	1.0	6	1	0	0
55661	1624	distinction between this response element	[distinction between these response elements]	1.0	5	1	0	0
55662	1624	amino acids,	[amino acids,]	1.0	2	1	0	0
55663	1624	first attempt	[first attempt]	1.0	2	1	0	0
55664	1624	glutamine synthetase in the cell	[glutamine synthetase in the cells]	1.0	5	1	0	0
55665	1624	173% increase in intracellular camp	[173% increase in intracellular cAMP]	1.0	5	1	0	0
55666	1624	discovery of this signal pathway	[discovery of these signaling pathways]	1.0	5	1	0	0
55667	1624	distal position.	[distal position.]	1.0	2	1	0	0
55668	1624	characteristic of HTLV-I T cell	[characteristic of HTLV-I T cells]	1.0	5	1	0	0
55669	1624	activation of MAPK by Tpl-2	[activation of MAPK by Tpl-2]	1.0	5	1	0	0
55670	1624	unexpected expression of megakaryocytic gene	[unexpected expression of megakaryocytic genes]	1.0	5	1	0	0
55671	1624	use the human t-cell line	[using the human T-cell line]	1.0	5	2	2	2
55672	1624	mitogen phytohemagglutinin	[mitogen phytohemagglutinin]	1.0	2	2	1	1
55673	1624	human androgen receptor gene humara	[human androgen receptor gene HUMARA]	1.0	5	1	0	0
55674	1624	Dramatic stimulation of actin assembly	[Dramatic stimulation of actin assembly]	1.0	5	1	0	0
55675	1624	50% HCS	[50% HCS]	1.0	2	1	0	0
55676	1624	expression of the other immediate-early factor	[expression of the other immediate-early factor]	1.0	6	1	0	0
55677	1624	three minor protein of 82	[three minor proteins of 82]	1.0	5	1	0	0
55678	1624	number of morning glucocorticoid receptor	[number of morning glucocorticoid receptors]	1.0	5	1	0	0
55679	1624	calcium-mediated, cyclosporin	[calcium-mediated, cyclosporin]	1.0	2	1	0	0
55680	1624	experiment with T cell hybridoma	[Experiments with T cell hybridomas]	1.0	5	1	0	0
55681	1624	th2 phenotype	[Th2 phenotype]	1.0	2	2	1	1
55682	1624	antiestrogenic activity	[antiestrogenic activity]	1.0	2	1	0	0
55683	1624	encode for a 41-kDa nuclear protein	[encoding for a 41-kDa nuclear protein]	1.0	6	1	0	0
55684	1624	Thus, Oct-2A	[Thus, Oct-2A]	1.0	2	1	0	0
55685	1624	cd45r0 cd4+ T cell subset	[CD45R0 CD4+ T cell subsets]	1.0	5	1	0	0
55686	1624	transcriptional regulatory element for factor	[transcriptional regulatory elements for factor]	1.0	5	1	0	0
55687	1624	bind pattern	[binding pattern]	1.0	2	2	2	2
55688	1624	critical regulator of several gene	[critical regulator of several genes]	1.0	5	1	0	0
55689	1624	CMPD1 translocation	[CMPD1 translocation]	1.0	2	1	0	0
55690	1624	dose-response experiment	[Dose-response experiments]	1.0	2	1	0	0
55691	1624	compare the effect of ras	[comparing the effects of Ras]	1.0	5	1	0	0
55692	1624	neutrophil commitment	[neutrophil commitment]	1.0	2	1	0	0
55693	1624	activation of NF kappa b	[activation of NF kappa B]	1.0	5	1	0	0
55694	1624	induction of neutrophil binding by lps	[induction of neutrophil binding by LPS]	1.0	6	1	0	0
55695	1624	monocytic differentiation.	[monocytic differentiation.]	1.0	2	1	0	0
55696	1624	pre-existing, T	[pre-existing, T]	1.0	2	1	0	0
55697	1624	transcriptional activation of the glucocorticoid receptor	[transcriptional activation of the glucocorticoid receptor]	1.0	6	1	0	0
55698	1624	similar reactivity	[similar reactivities]	1.0	2	1	0	0
55699	1624	Proinflammatory cytokine such as IL-1beta	[Proinflammatory cytokines such as IL-1beta]	1.0	5	1	0	0
55700	1624	40 ng/ml).	[40 ng/ml).]	1.0	2	1	0	0
55701	1624	conformation of the hinge region	[conformation of the hinge region]	1.0	5	1	0	0
55702	1624	carry the kappa b enhancer alone.	[carrying the kappa B enhancer alone.]	1.0	6	1	0	0
55703	1624	positive regulator of signal transduction	[positive regulators of signal transduction]	1.0	5	1	0	0
55704	1624	15 individual	[15 individuals]	1.0	2	1	0	0
55705	1624	internal site of oxidant production	[internal sites of oxidant production]	1.0	5	1	0	0
55706	1624	primary transformation	[primary transformation]	1.0	2	1	0	0
55707	1624	monocytic differentiation of u-937 cell	[monocytic differentiation of U-937 cells]	1.0	5	1	0	0
55708	1624	bone marrow sample from 33 patient	[Bone marrow samples from 33 patients]	1.0	6	1	0	0
55709	1624	Chinese hamster ovary (cho) cell	[Chinese hamster ovary (CHO) cells]	1.0	5	1	0	0
55710	1624	young adult	[young adults]	1.0	2	2	2	2
55711	1624	(palmitic acid	[(palmitic acids]	1.0	2	1	0	0
55712	1624	transactivation of a reporter gene construct	[transactivation of a reporter gene construct]	1.0	6	1	0	0
55713	1624	genital region	[genital regions]	1.0	2	1	0	0
55714	1624	lymphotropic virus	[lymphotropic virus]	1.0	2	2	1	1
55715	1624	three intron	[three introns]	1.0	2	1	0	0
55716	1624	pathophysiologic amounts,	[pathophysiologic amounts,]	1.0	2	1	0	0
55717	1624	ttca sequence in monocytic cell	[TTCA sequence in monocytic cells]	1.0	5	1	0	0
55718	1624	growth arrest;	[growth arrest;]	1.0	2	2	1	1
55719	1624	synergistic suppression	[Synergistic suppression]	1.0	2	2	1	1
55720	1624	3-deazaadenosine a S-adenosylhomocysteine hydrolase inhibitor	[3-deazaadenosine a S-adenosylhomocysteine hydrolase inhibitor]	1.0	5	1	0	0
55721	1624	growth arrest.	[growth arrest.]	1.0	2	1	0	0
55722	1624	regulate ige synthesis in b cell	[regulating IgE synthesis in B cells]	1.0	6	1	0	0
55723	1624	activity of A-MYB in B	[activity of A-MYB in B]	1.0	5	1	0	0
55724	1624	NFkappaB activity	[NFkappaB activity]	1.0	2	2	1	1
55725	1624	CD28 engagement,	[CD28 engagement,]	1.0	2	1	0	0
55726	1624	IL-1 nf-kappa b DNA localization	[IL-1 NF-kappa B DNA localization]	1.0	5	1	0	0
55727	1624	same patient	[same patients]	1.0	2	1	0	0
55728	1624	inactive camkiv	[inactive CaMKIV]	1.0	2	1	0	0
55729	1624	major property of steroidal effect	[major properties of steroidal effects]	1.0	5	1	0	0
55730	1624	14.3-kda protein	[14.3-kDa protein]	1.0	2	1	0	0
55731	1624	nuclear translocation of nuclear factor-kappaB	[nuclear translocation of nuclear factor-kappaB]	1.0	5	1	0	0
55732	1624	cis-acting region GM-kappa B/GC-box position	[cis-acting region GM-kappa B/GC-box positions]	1.0	5	1	0	0
55733	1624	binding to the kappa b element	[binding to the kappa B elements]	1.0	6	1	0	0
55734	1624	human homolog of the pip/lsirf	[human homolog of the Pip/LSIRF]	1.0	5	1	0	0
55735	1624	recombinant il-10	[recombinant IL-10]	1.0	2	1	0	0
55736	1624	various report	[Various reports]	1.0	2	1	0	0
55737	1624	sds-stable class ii alphabeta dimer	[SDS-stable class II alphabeta dimers]	1.0	5	1	0	0
55738	1624	p53 paradox in the pathogenesis	[p53 paradox in the pathogenesis]	1.0	5	1	0	0
55739	1624	other normal oestrogen target organ	[other normal oestrogen target organs]	1.0	5	1	0	0
55740	1624	tal-1 protein during human hematopoiesis	[tal-1 proteins during human hematopoiesis]	1.0	5	1	0	0
55741	1624	predominantly negative regulation of the promoter	[predominantly negative regulation of the promoter]	1.0	6	1	0	0
55742	1624	(tf) receptor	[(TF) receptor]	1.0	2	1	0	0
55743	1624	IL-6 treatment	[IL-6 treatment]	1.0	2	1	0	0
55744	1624	gene expression in human monocyte	[gene expression in human monocytes]	1.0	5	2	1	1
55745	1624	CIITA promoter	[CIITA promoter]	1.0	2	1	0	0
55746	1624	potent drug for the treatment	[potent drug for the treatment]	1.0	5	1	0	0
55747	1624	restimulated, however, anergic T cell	[restimulated, however, anergic T cells]	1.0	5	1	0	0
55748	1624	mainly block induction of il-2	[mainly blocking induction of IL-2]	1.0	5	1	0	0
55749	1624	transcriptional regulation of T lymphocyte development	[Transcriptional regulation of T lymphocyte development]	1.0	6	1	0	0
55750	1624	cytoskeletal integrity	[cytoskeletal integrity]	1.0	2	1	0	0
55751	1624	kinetic of the phosphorylation event	[kinetics of the phosphorylation events]	1.0	5	1	0	0
55752	1624	-571 bp	[-571 bp]	1.0	2	1	0	0
55753	1624	nonmacrophage cell	[nonmacrophage cells]	1.0	2	1	0	0
55754	1624	anti-cd3/ PMA	[anti-CD3/ PMA]	1.0	2	1	0	0
55755	1624	23 patient	[23 patients]	1.0	2	1	0	0
55756	1624	follow activation with a variety	[following activation with a variety]	1.0	5	1	0	0
55757	1624	3 P.	[3 h.]	1.0	2	1	0	0
55758	1624	IL-10 lps	[IL-10 LPS]	1.0	2	1	0	0
55759	1624	mutation of the glucocorticoid receptor	[mutation of the glucocorticoid receptor]	1.0	5	1	0	0
55760	1624	squamous cell carcinoma (scc) cell line	[squamous cell carcinoma (SCC) cell lines]	1.0	6	1	0	0
55761	1624	immunophilin fkbp	[immunophilin FKBP]	1.0	2	1	0	0
55762	1624	induction of ap-1 binding protein	[induction of AP-1 binding proteins]	1.0	5	1	0	0
55763	1624	allosteric drug	[allosteric drug]	1.0	2	1	0	0
55764	1624	significant loss	[significant loss]	1.0	2	2	2	2
55765	1624	repressor activity of the 5'-UTR	[repressor activity of the 5'-UTR]	1.0	5	1	0	0
55766	1624	activity of the b-cell-specific promoter	[activity of the B-cell-specific promoter]	1.0	5	1	0	0
55767	1624	ectopic tissue	[ectopic tissue]	1.0	2	1	0	0
55768	1624	certain transcription	[certain transcription]	1.0	2	1	0	0
55769	1624	90 min) of c-jun transcript	[90 min) of c-jun transcripts]	1.0	5	1	0	0
55770	1624	patient with connective tissue diseases,	[patients with connective tissue diseases,]	1.0	5	1	0	0
55771	1624	4 beta-phorbol 12-myristate 13-acetate PMA	[4 beta-phorbol 12-myristate 13-acetate PMA]	1.0	5	2	1	1
55772	1624	expression cloning with this region	[Expression cloning with this region]	1.0	5	1	0	0
55773	1624	gene' inducibility	[gene's inducibility]	1.0	2	1	0	0
55774	1624	renal insufficiency	[renal insufficiency]	1.0	2	2	1	1
55775	1624	stimulation of eosinophil with il-5	[stimulation of eosinophils with IL-5]	1.0	5	1	0	0
55776	1624	expression of the cyclic AMP response	[Expression of the cyclic AMP response]	1.0	6	1	0	0
55777	1624	wild-type tes2	[wild-type TES2]	1.0	2	1	0	0
55778	1624	36 month	[36 months]	1.0	2	1	0	0
55779	1624	45 kilodalton	[45 kilodaltons]	1.0	2	1	0	0
55780	1624	formation of DNA-protein complex common	[formation of DNA-protein complexes common]	1.0	5	1	0	0
55781	1624	whole lung	[whole lung]	1.0	2	1	0	0
55782	1624	major problem	[major problem]	1.0	2	1	0	0
55783	1624	neuroglial origin	[neuroglial origin]	1.0	2	1	0	0
55784	1624	proliferate cell follow g-csf stimulation	[proliferating cells following G-CSF stimulation]	1.0	5	1	0	0
55785	1624	GC receptor	[GC receptor]	1.0	2	1	0	0
55786	1624	tumor necrosis factor alpha decreases,	[Tumor necrosis factor alpha decreases,]	1.0	5	1	0	0
55787	1624	cytokine modulating activity of tepoxalin	[cytokine modulating activity of tepoxalin]	1.0	5	1	0	0
55788	1624	site-specific, phosphorylation	[site-specific, phosphorylation]	1.0	2	1	0	0
55789	1624	IL-10 preincubation	[IL-10 preincubation]	1.0	2	1	0	0
55790	1624	invariant chain	[invariant chain]	1.0	2	1	0	0
55791	1624	constitutively express a egr-1 transgene hl-60egr-1	[constitutively expressing an Egr-1 transgene HL-60Egr-1]	1.0	6	1	0	0
55792	1624	glycation-induced cell	[glycation-induced cells]	1.0	2	1	0	0
55793	1624	htlv-infected cell	[HTLV-infected cells]	1.0	2	1	0	0
55794	1624	MR count	[MR count]	1.0	2	1	0	0
55795	1624	transcription from immediate early gene	[transcription from immediate early genes]	1.0	5	1	0	0
55796	1624	CEM-ICR 27 leukemic lymphoblast a clone	[CEM-ICR 27 leukemic lymphoblasts a clone]	1.0	6	1	0	0
55797	1624	physiologic concentration of all three	[physiologic concentrations of all three]	1.0	5	1	0	0
55798	1624	wild-type er	[wild-type ER]	1.0	2	1	0	0
55799	1624	significant weight	[significant weight]	1.0	2	1	0	0
55800	1624	non-B NHL	[non-B NHL]	1.0	2	1	0	0
55801	1624	possibly by a phosphorylation reaction	[possibly by a phosphorylation reaction]	1.0	5	1	0	0
55802	1624	hemizygotic nephew	[hemizygotic nephew]	1.0	2	1	0	0
55803	1624	ATF/CRE site	[ATF/CRE site]	1.0	2	1	0	0
55804	1624	encode the b cell transcription factor	[encoding the B cell transcription factor]	1.0	6	1	0	0
55805	1624	nf-at-like factor	[NF-AT-like factor]	1.0	2	2	1	1
55806	1624	4- bp insertion between muE3	[4- bp insertion between muE3]	1.0	5	1	0	0
55807	1624	differential diagnostic purpose in view.	[differential diagnostic purposes in view.]	1.0	5	1	0	0
55808	1624	basal lesion	[basal lesions]	1.0	2	1	0	0
55809	1624	10,11-dihydroxyaporphine dha	[10,11-dihydroxyaporphine DHA]	1.0	2	1	0	0
55810	1624	inhibitor of nfat beta-galactosidase activity	[inhibitors of NFAT beta-galactosidase activity]	1.0	5	1	0	0
55811	1624	have affinity for a sterol sequence	[having affinity for a sterol sequence]	1.0	6	1	0	0
55812	1624	substantial nuclear hormone receptor coactivator activity	[substantial nuclear hormone receptor coactivator activity]	1.0	6	1	0	0
55813	1624	functional inhibition	[functional inhibition]	1.0	2	2	2	2
55814	1624	appropriate regulation of immune response	[appropriate regulation of immune responses]	1.0	5	1	0	0
55815	1624	spleen primordia	[spleen primordia]	1.0	2	1	0	0
55816	1624	GABP expression	[GABP expression]	1.0	2	1	0	0
55817	1624	antibody supershift	[antibody supershift]	1.0	2	2	2	2
55818	1624	lymphoid lineage.	[lymphoid lineage.]	1.0	2	1	0	0
55819	1624	il-6 luciferase	[IL-6 luciferase]	1.0	2	2	2	2
55820	1624	autosomal dominant mode of transmission	[autosomal dominant mode of transmission]	1.0	5	1	0	0
55821	1624	20 h in the presence	[20 h in the presence]	1.0	5	1	0	0
55822	1624	kappab transcription	[kappaB transcription]	1.0	2	2	2	2
55823	1624	contain the common gamma chain	[containing the common gamma chain]	1.0	5	1	0	0
55824	1624	U2 snrna -encode gene activation	[U2 snRNA -encoding gene activation]	1.0	5	1	0	0
55825	1624	vasculitic syndrome	[vasculitic syndrome]	1.0	2	1	0	0
55826	1624	substitution promoter	[Substitution promoters]	1.0	2	1	0	0
55827	1624	difference between tcr signal pathway	[differences between TCR signaling pathways]	1.0	5	1	0	0
55828	1624	full capacity	[full capacity]	1.0	2	1	0	0
55829	1624	2-50 gy result in expression	[2-50 Gy results in expression]	1.0	5	1	0	0
55830	1624	X chromosome inactivation in PMNs	[X chromosome inactivation in PMNs]	1.0	5	1	0	0
55831	1624	asymptomatic phase of hiv-2 infection	[asymptomatic phase of HIV-2 infection]	1.0	5	1	0	0
55832	1624	bone resorption,	[bone resorption,]	1.0	2	1	0	0
55833	1624	different variant of nephrotic syndrome	[different variants of nephrotic syndrome]	1.0	5	1	0	0
55834	1624	potential site for ccaat-box binding factor	[potential sites for CCAAT-box binding factors]	1.0	6	1	0	0
55835	1624	eukaryotic nucleus	[eukaryotic nucleus]	1.0	2	1	0	0
55836	1624	cellular stimulus.	[cellular stimulus.]	1.0	2	1	0	0
55837	1624	CONCLUSIONS: NF-kappaB	[CONCLUSIONS: NF-kappaB]	1.0	2	1	0	0
55838	1624	role in terminal neutrophil maturation	[role in terminal neutrophil maturation]	1.0	5	1	0	0
55839	1624	induction of 2422-erh)2d3 synthesis by 135(oh)2d3	[Induction of 24,25-(OH)2D3 synthesis by 1,25(OH)2D3]	1.0	6	1	0	0
55840	1624	trophic effect	[trophic effect]	1.0	2	2	2	2
55841	1624	conjunction with gel retardation assay	[conjunction with gel retardation assays]	1.0	5	1	0	0
55842	1624	inhibition of the gut inflammatory response	[Inhibition of the gut inflammatory response]	1.0	6	1	0	0
55843	1624	native weight	[native weights]	1.0	2	1	0	0
55844	1624	intracellular signal protein include Vav	[intracellular signaling proteins including Vav]	1.0	5	1	0	0
55845	1624	cortisol feedback resistance in combination	[cortisol feedback resistance in combination]	1.0	5	1	0	0
55846	1624	follow cortisol depletion by met	[following cortisol depletion by MET]	1.0	5	1	0	0
55847	1624	different amount of the various isoform	[Different amounts of the various isoforms]	1.0	6	1	0	0
55848	1624	pilot protein	[PILOT protein]	1.0	2	1	0	0
55849	1624	switch in human b cell	[switching in human B cells]	1.0	5	1	0	0
55850	1624	Gene target experiment in the mouse	[Gene targeting experiments in the mouse]	1.0	6	1	0	0
55851	1624	induce loss of membrane viability,	[inducing loss of membrane viability,]	1.0	5	1	0	0
55852	1624	gene topography	[gene topography]	1.0	2	2	2	2
55853	1624	member of the PEBP2/CBF family	[members of the PEBP2/CBF family]	1.0	5	2	1	1
55854	1624	kda factor	[kDa factor]	1.0	2	2	2	2
55855	1624	include the estrogen receptor (er) gene	[including the estrogen receptor (ER) gene]	1.0	6	1	0	0
55856	1624	AITL /gc,	[AITL /GC,]	1.0	2	1	0	0
55857	1624	NFAT promoter	[NFAT promoter]	1.0	2	2	2	2
55858	1624	chromosome inactivation	[chromosome inactivation]	1.0	2	2	2	2
55859	1624	decrease in the nuclear localization	[decreases in the nuclear localization]	1.0	5	1	0	0
55860	1624	thiol modulation	[Thiol modulation]	1.0	2	1	0	0
55861	1624	obvious regulation of the number	[obvious regulation of the number]	1.0	5	1	0	0
55862	1624	Postoperatively, blood	[Postoperatively, blood]	1.0	2	1	0	0
55863	1624	leukemic k562	[leukemic K562]	1.0	2	1	0	0
55864	1624	expansion of the Th2 lineage relative	[expansion of the Th2 lineage relative]	1.0	6	1	0	0
55865	1624	DNA binding activity between matrix	[DNA binding activity between matrix]	1.0	5	1	0	0
55866	1624	heteromeric kappa b-binding complex with RelB	[heteromeric kappa B-binding complexes with RelB]	1.0	6	1	0	0
55867	1624	predict the location of t-helper-cell epitope	[predicting the location of T-helper-cell epitopes]	1.0	6	1	0	0
55868	1624	HS I-III	[HS I-III]	1.0	2	1	0	0
55869	1624	gcs with well-defined gc border	[GCs with well-defined GC borders]	1.0	5	1	0	0
55870	1624	day 10	[day 10]	1.0	2	1	0	0
55871	1624	CD30 in b cell differentiation	[CD30 in B cell differentiation]	1.0	5	1	0	0
55872	1624	day 14	[day 14]	1.0	2	2	1	1
55873	1624	day 12	[day 12]	1.0	2	1	0	0
55874	1624	cell populations).	[cell populations).]	1.0	2	1	0	0
55875	1624	normal limits.	[normal limits.]	1.0	2	2	1	1
55876	1624	b-cell extract	[B-cell extracts]	1.0	2	1	0	0
55877	1624	TNF-alpha mrna	[TNF-alpha mRNA]	1.0	2	1	0	0
55878	1624	constitutively active form of nf-kb	[constitutively active form of NF-kB]	1.0	5	1	0	0
55879	1624	phorbol ester-induced differentiation by dexamethasone	[phorbol ester-induced differentiation by dexamethasone]	1.0	5	1	0	0
55880	1624	less active nf-kappab dna-binding complex	[less active NF-kappaB DNA-binding complex]	1.0	5	1	0	0
55881	1624	second factor	[second factor]	1.0	2	2	1	1
55882	1624	response of patient to therapy	[response of patients to therapy]	1.0	5	1	0	0
55883	1624	pfp9a20 contain only -73 bp	[PFP9a20 containing only -73 bp]	1.0	5	1	0	0
55884	1624	day 5.	[day 5.]	1.0	2	1	0	0
55885	1624	vascular cell adhesion molecule (vcam)-1	[vascular cell adhesion molecule (VCAM)-1]	1.0	5	1	0	0
55886	1624	transcription factor/	[transcription factor/]	1.0	2	1	0	0
55887	1624	effect stimulate T cell blast	[effects stimulating T cell blasts]	1.0	5	1	0	0
55888	1624	limiting-dilution analysis of blood mononuclear cell	[limiting-dilution analysis of blood mononuclear cells]	1.0	6	1	0	0
55889	1624	day 7)	[day 7)]	1.0	2	1	0	0
55890	1624	directly to the respiratory epithelium	[directly to the respiratory epithelium]	1.0	5	1	0	0
55891	1624	granulocyte-macrophage lineage	[granulocyte-macrophage lineage]	1.0	2	3	2	1
55892	1624	intrinsic DNA affinity of pouhd	[intrinsic DNA affinity of POUHD]	1.0	5	1	0	0
55893	1624	day 6;	[day 6;]	1.0	2	1	0	0
55894	1624	nuclear kinase	[nuclear kinase]	1.0	2	1	0	0
55895	1624	such adaptive change in tr expression	[such adaptive changes in TR expression]	1.0	6	1	0	0
55896	1624	active role in the physiology	[active role in the physiology]	1.0	5	1	0	0
55897	1624	heparin-binding protein crucial to embryogenesis	[heparin-binding proteins crucial to embryogenesis]	1.0	5	1	0	0
55898	1624	nf-kappa b -dependent luciferase construct	[NF-kappa B -dependent luciferase constructs]	1.0	5	1	0	0
55899	1624	stimulation of the camp signal pathway	[Stimulation of the cAMP signaling pathway]	1.0	6	1	0	0
55900	1624	h2o2 release from blood mononuclear cell	[H2O2 release from blood mononuclear cells]	1.0	6	1	0	0
55901	1624	wy14,643 pparalpha	[Wy14,643 PPARalpha]	1.0	2	1	0	0
55902	1624	induce ifn-gamma production in th cell	[inducing IFN-gamma production in Th cells]	1.0	6	1	0	0
55903	1624	alternative rna	[alternative RNA]	1.0	2	1	0	0
55904	1624	study of early B-cell development	[study of early B-cell development]	1.0	5	1	0	0
55905	1624	Comparison of the transactivation domain	[Comparison of the transactivation domains]	1.0	5	1	0	0
55906	1624	contain a serine alanine substitution	[containing a serine alanine substitution]	1.0	5	1	0	0
55907	1624	transcription deficiency	[transcription deficiency]	1.0	2	1	0	0
55908	1624	Comparison of htlv-i basal transcription	[Comparison of HTLV-I basal transcription]	1.0	5	1	0	0
55909	1624	potent transactivation of this enhancer.	[potent transactivation of this enhancer.]	1.0	5	1	0	0
55910	1624	acute inflammatory injury in rat lung	[Acute inflammatory injury in rat lung]	1.0	6	1	0	0
55911	1624	lysozyme LZ	[lysozyme LZ]	1.0	2	1	0	0
55912	1624	rar(alpha) gene expression by IFN(alpha)	[RAR(alpha) gene expression by IFN(alpha)]	1.0	5	1	0	0
55913	1624	alpha production	[alpha production]	1.0	2	2	1	1
55914	1624	constituent of the cell wall	[constituent of the cell wall]	1.0	5	1	0	0
55915	1624	separate surface	[separate surface]	1.0	2	1	0	0
55916	1624	OCTA enhancer activity in cell	[OCTA enhancer activity in cells]	1.0	5	1	0	0
55917	1624	encode gamma-globin deaminase pbgd a enzyme	[encoding gamma-globin deaminase PBGD an enzyme]	1.0	6	1	0	0
55918	1624	ubiquitous band	[ubiquitous band]	1.0	2	1	0	0
55919	1624	HIV1 cell	[HIV1 cells]	1.0	2	1	0	0
55920	1624	expression of paf receptor transcript	[expression of PAF receptor transcript]	1.0	5	1	0	0
55921	1624	interfere with intracellular calcium increase	[interfering with intracellular calcium increase]	1.0	5	1	0	0
55922	1624	novel enzyme	[novel enzyme]	1.0	2	1	0	0
55923	1624	high-affinity binding	[high-affinity binding]	1.0	2	1	0	0
55924	1624	il-5 signal	[IL-5 signaling]	1.0	2	1	0	0
55925	1624	blood viscosity	[blood viscosity]	1.0	2	1	0	0
55926	1624	nfat regulation	[NFAT regulation]	1.0	2	2	1	1
55927	1624	mrna expression of a gene c-fo	[mRNA expression of an gene c-fos]	1.0	6	1	0	0
55928	1624	uninfected monocyte	[uninfected monocytes]	1.0	2	1	0	0
55929	1624	specific marker	[specific marker]	1.0	2	2	2	2
55930	1624	many decade	[many decades]	1.0	2	1	0	0
55931	1624	region of the human collagenase-1 promoter	[regions of the human collagenase-1 promoter]	1.0	6	1	0	0
55932	1624	30-36 day	[30-36 days,]	1.0	2	1	0	0
55933	1624	function of a NFAT-1 site	[function of a NFAT-1 site]	1.0	5	1	0	0
55934	1624	chromatin structure surround the gene	[chromatin structure surrounding the genes]	1.0	5	1	0	0
55935	1624	key mediator of neuroendocrine-immune regulatory interaction	[key mediators of neuroendocrine-immune regulatory interactions]	1.0	6	1	0	0
55936	1624	percentage to,	[percentage to,]	1.0	2	1	0	0
55937	1624	expression of the homing receptor blr1	[expression of the homing receptor BLR1]	1.0	6	1	0	0
55938	1624	il-6-type cytokine	[IL-6-type cytokines]	1.0	2	1	0	0
55939	1624	deletion of p16 alone of p16	[deletion of p16 alone of p16]	1.0	6	1	0	0
55940	1624	element-specific complex	[element-specific complexes]	1.0	2	1	0	0
55941	1624	detailed characterization	[Detailed characterization]	1.0	2	2	2	2
55942	1624	aberrant results.	[aberrant results.]	1.0	2	1	0	0
55943	1624	live hiv-1	[live HIV-1]	1.0	2	1	0	0
55944	1624	Chinese hamster ovary (cho)-dr transfectant	[Chinese hamster ovary (CHO)-DR transfectants]	1.0	5	1	0	0
55945	1624	important role transduce distal signal	[important role transducing distal signals]	1.0	5	1	0	0
55946	1624	alteration in resistance to protein	[alterations in resistance to proteins]	1.0	5	1	0	0
55947	1624	accordance with the action law.	[accordance with the action law.]	1.0	5	1	0	0
55948	1624	synthase ino gene in response	[synthase iNOS genes in response]	1.0	5	1	0	0
55949	1624	stationary-phase-dependent resistance	[stationary-phase-dependent resistance]	1.0	2	1	0	0
55950	1624	activation of expression of bzlf1	[activation of expression of BZLF1]	1.0	5	1	0	0
55951	1624	primary tumour	[primary tumours]	1.0	2	1	0	0
55952	1624	transcriptional activation of a plasmid	[transcriptional activation of a plasmid]	1.0	5	1	0	0
55953	1624	member of the JAK kinase family	[members of the JAK kinase family]	1.0	6	1	0	0
55954	1624	inhibition of il-1r gene expression	[Inhibition of IL-1R gene expression]	1.0	5	1	0	0
55955	1624	p16 in normal human lymphocyte	[p16 in normal human lymphocytes]	1.0	5	1	0	0
55956	1624	Positive selection	[Positive selection]	1.0	2	1	0	0
55957	1624	transcriptional control in B-cell development	[transcriptional control in B-cell development]	1.0	5	1	0	0
55958	1624	phorbol myristate acetate PMA stimulation p40	[phorbol myristate acetate PMA stimulation p40]	1.0	6	1	0	0
55959	1624	median 10 year gail risk	[median 10 year Gail risk]	1.0	5	1	0	0
55960	1624	examine in vitro-differentiated embryonic stem cell	[examining in vitro-differentiated embryonic stem cells]	1.0	6	1	0	0
55961	1624	BA overexpression of erythroid gene	[BA overexpression of erythroid genes]	1.0	5	1	0	0
55962	1624	extra c-terminal peptide of 128	[extra C-terminal peptides of 128]	1.0	5	1	0	0
55963	1624	conservation therapy	[conservation therapy]	1.0	2	1	0	0
55964	1624	differentiation of human naive cell	[differentiation of human naive cells]	1.0	5	1	0	0
55965	1624	tataaa box	[TATAAA box]	1.0	2	1	0	0
55966	1624	ifn-gamma pre-treatment	[IFN-gamma pre-treatment]	1.0	2	1	0	0
55967	1624	expression of hsp60 6 hour	[expression of Hsp60 6 hr]	1.0	5	1	0	0
55968	1624	(memory) clone	[(memory) clones]	1.0	2	1	0	0
55969	1624	transactivate the CD48 NF-kappa b site	[transactivating the CD48 NF-kappa B site]	1.0	6	1	0	0
55970	1624	dt-40 b	[DT-40 B]	1.0	2	1	0	0
55971	1624	however, alteration of NF kappa b	[however, alterations of NF kappa B]	1.0	6	1	0	0
55972	1624	phosphorylation of serum response factor	[phosphorylation of serum response factor]	1.0	5	1	0	0
55973	1624	circular permutation	[Circular permutation]	1.0	2	1	0	0
55974	1624	thrombopoietin tpo	[Thrombopoietin TPO]	1.0	2	1	0	0
55975	1624	similar comparison with protease-treated extract	[similar comparison with protease-treated extracts]	1.0	5	1	0	0
55976	1624	97-kDa protein	[97-kDa protein]	1.0	2	2	1	1
55977	1624	ras activity	[ras activity]	1.0	2	1	0	0
55978	1624	silencer sequences.	[silencer sequences.]	1.0	2	1	0	0
55979	1624	patient' elbow	[patient's elbow]	1.0	2	1	0	0
55980	1624	bind the alpha receptor with specificity.	[binding the alpha receptor with specificity.]	1.0	6	1	0	0
55981	1624	VDR -retinoid	[VDR -retinoid]	1.0	2	1	0	0
55982	1624	activity of the lytic origin	[activity of the lytic origin]	1.0	5	1	0	0
55983	1624	entry site	[entry site]	1.0	2	2	2	2
55984	1624	regulation of the beta-globin locus	[Regulation of the beta-globin locus]	1.0	5	1	0	0
55985	1624	b-cell malignancy	[B-cell malignancies]	1.0	2	1	0	0
55986	1624	use adenovirus	[using adenovirus]	1.0	2	1	0	0
55987	1624	patient with early untreated RA	[patients with early untreated RA]	1.0	5	1	0	0
55988	1624	almost twofold,	[almost twofold,]	1.0	2	1	0	0
55989	1624	aldosterone binding	[aldosterone binding]	1.0	2	2	2	2
55990	1624	placebo of a nacl solution	[placebo of an NaCl solution]	1.0	5	1	0	0
55991	1624	addition, cell-free	[addition, cell-free]	1.0	2	1	0	0
55992	1624	mild hypertension	[mild hypertension]	1.0	2	1	0	0
55993	1624	role of the nuclear transcription factor	[role of the nuclear transcription factor]	1.0	6	1	0	0
55994	1624	IL -2	[IL -2]	1.0	2	1	0	0
55995	1624	5/12 t-cell	[5/12 T-cell]	1.0	2	1	0	0
55996	1624	signal transduction through tyrosine kinase activation	[Signal transduction through tyrosine kinase activation]	1.0	6	1	0	0
55997	1624	kappa b-1 in human tnf-alpha promoter	[kappa B-1 in human TNF-alpha promoter]	1.0	6	1	0	0
55998	1624	inhibit the function of this element	[inhibiting the function of this element]	1.0	6	1	0	0
55999	1624	70-bp element	[70-bp element]	1.0	2	1	0	0
56000	1624	CBF site,	[CBF site,]	1.0	2	1	0	0
56001	1624	promotor strength	[promotor strength]	1.0	2	1	0	0
56002	1624	80% identical.	[80% identical.]	1.0	2	1	0	0
56003	1624	maximal stimulation of the lymphocyte	[maximal stimulation of the lymphocytes]	1.0	5	1	0	0
56004	1624	characterization of the NF-kappa B1 promoter	[Characterization of the NF-kappa B1 promoter]	1.0	6	1	0	0
56005	1624	dibutyryl cAMP	[dibutyryl cAMP]	1.0	2	1	0	0
56006	1624	possibly other cells; a component	[possibly other cells; a component]	1.0	5	1	0	0
56007	1624	ap-1 (120%),	[AP-1 (120%),]	1.0	2	1	0	0
56008	1624	ikappab-alpha level	[IkappaB-alpha levels]	1.0	2	1	0	0
56009	1624	existence of a intragenic promoter	[existence of an intragenic promoter]	1.0	5	1	0	0
56010	1624	inhibitory function in human T lymphocyte	[inhibitory functions in human T lymphocytes]	1.0	6	1	0	0
56011	1624	1-3 min.	[1-3 min.]	1.0	2	1	0	0
56012	1624	MTHC in the presence of TNF-alpha	[MTHC in the presence of TNF-alpha]	1.0	6	1	0	0
56013	1624	Instead, IL-10	[Instead, IL-10]	1.0	2	1	0	0
56014	1624	Act-1 site	[Act-1 sites]	1.0	2	1	0	0
56015	1624	significant fraction	[significant fraction]	1.0	2	2	1	1
56016	1624	ELISA test	[ELISA tests]	1.0	2	1	0	0
56017	1624	include sequence from the sex	[including sequences from the sex]	1.0	5	1	0	0
56018	1624	1 microgram/ml	[1 microgram/ml]	1.0	2	1	0	0
56019	1624	rj 2.2.5	[RJ 2.2.5]	1.0	2	1	0	0
56020	1624	surface expression of tnf receptor	[surface expression of TNF receptors]	1.0	5	1	0	0
56021	1624	expression of GCRbeta in specimen	[expression of GCRbeta in specimens]	1.0	5	1	0	0
56022	1624	patient with the nephrotic syndrome	[patients with the nephrotic syndrome]	1.0	5	1	0	0
56023	1624	nuclear factor enf)-kappa b activity	[nuclear factor (NF)-kappa B activity]	1.0	5	1	0	0
56024	1624	fibroblast phosphatidylinositol 3-kinase ptdin 3-kinase	[fibroblasts Phosphatidylinositol 3-kinase PtdIns 3-kinase]	1.0	5	1	0	0
56025	1624	nuclear structure	[nuclear structures]	1.0	2	2	1	1
56026	1624	1p36 under-representation	[1p36 under-representation]	1.0	2	2	2	2
56027	1624	deletion mapping	[Deletion mapping]	1.0	2	1	0	0
56028	1624	macrophage from the T cell area	[macrophages from the T cell area]	1.0	6	1	0	0
56029	1624	high conservation	[high conservation]	1.0	2	1	0	0
56030	1624	fluorescence hplc	[Fluorescence HPLC]	1.0	2	1	0	0
56031	1624	IL-10 lymphocyte	[IL-10 lymphocytes]	1.0	2	1	0	0
56032	1624	crucial regulatory event in the activation	[crucial regulatory events in the activation]	1.0	6	1	0	0
56033	1624	Cepsilon germline transcript by IL-4	[Cepsilon germline transcripts by IL-4]	1.0	5	1	0	0
56034	1624	activate signal in helper T cell	[activating signals in helper T cells]	1.0	6	1	0	0
56035	1624	cytoplasmic inhibitor kappa b alpha	[cytoplasmic inhibitor kappa B alpha]	1.0	5	1	0	0
56036	1624	cle0 sequence	[CLE0 sequence]	1.0	2	1	0	0
56037	1624	closely related retinoic acid receptor	[closely related retinoic acid receptor]	1.0	5	1	0	0
56038	1624	mouse csf-1	[mouse CSF-1]	1.0	2	1	0	0
56039	1624	spatial separation	[spatial separation]	1.0	2	1	0	0
56040	1624	protein component of this complex	[protein components of this complex]	1.0	5	1	0	0
56041	1624	functional disomy	[functional disomy]	1.0	2	2	2	2
56042	1624	tcr zeta-chain	[TCR zeta-chain]	1.0	2	2	1	1
56043	1624	one biomarker	[one biomarkers]	1.0	2	1	0	0
56044	1624	oxidative stress in plasma sample	[oxidative stress in plasma samples]	1.0	5	1	0	0
56045	1624	point mutation of the GATA site	[Point mutations of the GATA site]	1.0	6	1	0	0
56046	1624	b-alpha mrna	[B-alpha mRNA]	1.0	2	1	0	0
56047	1624	addition, lymphocyte	[addition, lymphocyte]	1.0	2	1	0	0
56048	1624	characterization of a nuclear complex	[characterization of a nuclear complex]	1.0	5	1	0	0
56049	1624	primary hemopoietic cell in g0	[primary hemopoietic cells in G0]	1.0	5	1	0	0
56050	1624	2) biochemical sign of secondary hypothyroidism	[2) biochemical signs of secondary hypothyroidism]	1.0	6	1	0	0
56051	1624	unstimulated sp-b21	[unstimulated SP-B21]	1.0	2	1	0	0
56052	1624	chicken t-cell	[chicken T-cells]	1.0	2	2	1	1
56053	1624	recognize other epithelial tumor ag	[recognizing other epithelial tumor Ag]	1.0	5	1	0	0
56054	1624	rest peripheral blood T lymphocyte	[resting peripheral blood T lymphocytes]	1.0	5	1	0	0
56055	1624	member of the grow family	[member of the growing family]	1.0	5	1	0	0
56056	1624	reactivity to recombinant ssb rssb	[reactivity to recombinant SSB rSSB]	1.0	5	1	0	0
56057	1624	cho cell	[CHO cells]	1.0	2	2	1	1
56058	1624	such as cyclosporin a CsA	[such as cyclosporin A CsA]	1.0	5	1	0	0
56059	1624	b-cll differentiation	[B-CLL differentiation]	1.0	2	1	0	0
56060	1624	lack p56	[lacking p56]	1.0	2	1	0	0
56061	1624	activation of Jun kinase JNK	[activation of Jun kinase JNK]	1.0	5	1	0	0
56062	1624	colony size	[colony size]	1.0	2	2	1	1
56063	1624	originate from case of Burkitt' lymphoma	[originating from cases of Burkitt's lymphoma]	1.0	6	1	0	0
56064	1624	cytokine -inducible neutrophil chemoattractant cinc	[cytokine -inducible neutrophil chemoattractant CINC]	1.0	5	1	0	0
56065	1624	protein-binding region	[protein-binding region]	1.0	2	2	1	1
56066	1624	specific abs	[specific Abs]	1.0	2	2	1	1
56067	1624	erythrocyte nuclei	[erythrocyte nuclei]	1.0	2	1	0	0
56068	1624	expression of a retroviral transgene	[expression of a retroviral transgene]	1.0	5	1	0	0
56069	1624	latency into the lytic cycle	[latency into the lytic cycle]	1.0	5	1	0	0
56070	1624	(10 mumol/L),	[(10 mumol/L),]	1.0	2	1	0	0
56071	1624	patient with inflammatory bowel disease	[patients with inflammatory bowel disease]	1.0	5	1	0	0
56072	1624	spontaneous cytotoxicity	[spontaneous cytotoxicity]	1.0	2	1	0	0
56073	1624	interleukin-1 alpha	[interleukin-1 alpha]	1.0	2	2	1	1
56074	1624	growth inhibition,	[growth inhibition,]	1.0	2	1	0	0
56075	1624	IL-7 enhancement	[IL-7 enhancement]	1.0	2	1	0	0
56076	1624	oxidative stress dependent nf-kappab activation	[oxidative stress dependent NF-kappaB activation]	1.0	5	1	0	0
56077	1624	LNCaP cell	[LNCaP cells]	1.0	2	1	0	0
56078	1624	pml expression in normal hematopoiesis	[PML expression in normal hematopoiesis]	1.0	5	1	0	0
56079	1624	three bind site for c/ebp protein	[Three binding sites for C/EBP proteins]	1.0	6	1	0	0
56080	1624	radiation damage	[radiation damage]	1.0	2	1	0	0
56081	1624	operate downstream	[operating downstream]	1.0	2	1	0	0
56082	1624	synthetase (oas) gene expression with kinetics.	[synthetase (OAS) gene expression with kinetics.]	1.0	6	1	0	0
56083	1624	specific complex with this element,	[specific complex with this element,]	1.0	5	1	0	0
56084	1624	cell line deficient in this factor	[cell lines deficient in these factors]	1.0	6	1	0	0
56085	1624	nuclear factor of chicken t-cell	[nuclear factors of chicken T-cells]	1.0	5	1	0	0
56086	1624	peptide mapping	[peptide mapping]	1.0	2	2	1	1
56087	1624	response to secondary pathogenic infection	[response to secondary pathogenic infections]	1.0	5	1	0	0
56088	1624	concentration of corticosteroid produce inhibition	[concentration of corticosteroid producing inhibition]	1.0	5	1	0	0
56089	1624	il-2 deprivation in ctll-2 cell	[IL-2 deprivation in CTLL-2 cells]	1.0	5	1	0	0
56090	1624	beta-globin-expressing murine erythroid leukemia cell	[beta-globin-expressing murine erythroid leukemia cells]	1.0	5	1	0	0
56091	1624	inactive state,	[inactive state,]	1.0	2	1	0	0
56092	1624	receptor quantitation	[receptor quantitation]	1.0	2	1	0	0
56093	1624	IFN stimulus response element ISRE	[IFN stimulus response element ISRE]	1.0	5	1	0	0
56094	1624	b-lymphocyte precursor	[B-lymphocyte precursors]	1.0	2	4	3	1
56095	1624	zap-70 signal function in lymphocyte	[ZAP-70 signaling function in lymphocytes]	1.0	5	1	0	0
56096	1624	tyrosine motif	[tyrosine motif]	1.0	2	2	2	2
56097	1624	LTB4 adhesive interaction between cell	[LTB4 adhesive interactions between cells]	1.0	5	1	0	0
56098	1624	disease-resistant background	[disease-resistant background]	1.0	2	1	0	0
56099	1624	gata-1 expression differentiate hematopoietic progenitor	[GATA-1 expression differentiating hematopoietic progenitors]	1.0	5	1	0	0
56100	1624	promoter dependent	[promoter dependent]	1.0	2	2	2	2
56101	1624	chromosome 16p12-16p13.3	[chromosome 16p12-16p13.3]	1.0	2	1	0	0
56102	1624	repeat structure	[repeat structures]	1.0	2	1	0	0
56103	1624	airway disease	[airway disease]	1.0	2	2	2	2
56104	1624	il-10 receptor activation on cell	[IL-10 receptor activation on cells]	1.0	5	1	0	0
56105	1624	different region of the 5'-utr	[different regions of the 5'-UTR]	1.0	5	1	0	0
56106	1624	physical activity	[physical activity]	1.0	2	1	0	0
56107	1624	human apoptosis	[human apoptosis]	1.0	2	2	1	1
56108	1624	individual gata factor in erythropoiesis	[individual GATA factors in erythropoiesis]	1.0	5	1	0	0
56109	1624	biological significance of nf-kappab activation	[biological significance of NF-kappaB activation]	1.0	5	1	0	0
56110	1624	feedback loop	[feedback loop]	1.0	2	2	2	2
56111	1624	only the nfat complex present	[only the NFAT complexes present]	1.0	5	1	0	0
56112	1624	serum amylase	[serum amylase]	1.0	2	1	0	0
56113	1624	phosphoprotein	[phosphoprotein]	1.0	1	11	7	7
56114	1624	additional genes,	[additional genes,]	1.0	2	1	0	0
56115	1624	x-ray irradiation	[X-ray irradiation]	1.0	2	1	0	0
56116	1624	anti-estrogen concentration	[anti-estrogen concentrations]	1.0	2	1	0	0
56117	1624	Cdk-2-dependent phosphorylation	[Cdk-2-dependent phosphorylation]	1.0	2	1	0	0
56118	1624	interleukin-4 il-4 on endothelial cell	[interleukin-4 IL-4 on endothelial cells]	1.0	5	1	0	0
56119	1624	monocyte differentiation into dendritic cell	[monocyte differentiation into dendritic cells]	1.0	5	1	0	0
56120	1624	cell with number of VDR	[cells with numbers of VDR]	1.0	5	1	0	0
56121	1624	cathepsin d	[cathepsin D]	1.0	2	1	0	0
56122	1624	homo hetero	[homo hetero]	1.0	2	2	2	2
56123	1624	heme-treated friend	[heme-treated Friend]	1.0	2	1	0	0
56124	1624	include binding site for creb- factor	[including binding sites for CREB- factors]	1.0	6	1	0	0
56125	1624	protein Bcl-3	[protein Bcl-3]	1.0	2	1	0	0
56126	1624	lack the amino terminal amino acid	[lacking the amino terminal amino acids]	1.0	6	1	0	0
56127	1624	cis inactivation of autosomal material	[cis inactivation of autosomal material]	1.0	5	1	0	0
56128	1624	soluble il-1rii	[soluble IL-1RII]	1.0	2	1	0	0
56129	1624	Duffy Antigen Receptor for Chemokines	[Duffy Antigen Receptor for Chemokines]	1.0	5	1	0	0
56130	1624	70-kda protein corresponding in size	[70-kDa protein corresponding in size]	1.0	5	1	0	0
56131	1624	expression of tissue factor tf	[expression of tissue factor TF]	1.0	5	1	0	0
56132	1624	NF-kB motif	[NF-kB motifs]	1.0	2	1	0	0
56133	1624	formation of DNA binding complex	[formation of DNA binding complexes]	1.0	5	1	0	0
56134	1624	impairment of the effector mechanism	[impairment of the effector mechanism]	1.0	5	1	0	0
56135	1624	high level in leukemic cell	[high levels in leukemic cells]	1.0	5	1	0	0
56136	1624	male combat Vietnam veteran with ptsd	[male combat Vietnam veterans with PTSD]	1.0	6	1	0	0
56137	1624	transient expression of hiv-1 Tat	[Transient expression of HIV-1 Tat]	1.0	5	1	0	0
56138	1624	develop brain.	[developing brain.]	1.0	2	1	0	0
56139	1624	constitutively active form of Raf-1	[constitutively active forms of Raf-1]	1.0	5	1	0	0
56140	1624	u937 with ifn-gamma for hour	[U937 with IFN-gamma for hr]	1.0	5	1	0	0
56141	1624	heavy-chain promoter	[heavy-chain promoter]	1.0	2	2	1	1
56142	1624	undesirable overexpression of this protein.	[undesirable overexpression of this protein.]	1.0	5	1	0	0
56143	1624	GATA-1 expression	[GATA-1 expression]	1.0	2	2	1	1
56144	1624	A site	[A site]	1.0	2	1	0	0
56145	1624	activation of the IL-1alpha gene	[activation of the IL-1alpha gene]	1.0	5	1	0	0
56146	1624	two sibling	[two siblings]	1.0	2	1	0	0
56147	1624	immunological implication of this result	[immunological implications of these results]	1.0	5	1	0	0
56148	1624	action mechanism	[action mechanism]	1.0	2	1	0	0
56149	1624	modulate the activity of transcription factor	[modulating the activity of transcription factors]	1.0	6	1	0	0
56150	1624	bacille calmette-guerin vaccine in human	[bacille Calmette-Guerin vaccine in humans]	1.0	5	1	0	0
56151	1624	only in a appropriate redox status	[only in an appropriate redox status]	1.0	6	1	0	0
56152	1624	co-renaturation experiments.	[co-renaturation experiments.]	1.0	2	1	0	0
56153	1624	uncertain function	[uncertain function]	1.0	2	1	0	0
56154	1624	erythroid-specific repression	[erythroid-specific repression]	1.0	2	1	0	0
56155	1624	carry the nuclear localization sequence	[carrying the nuclear localization sequence]	1.0	5	1	0	0
56156	1624	intermediate stage of B-cell differentiation	[intermediate stage of B-cell differentiation]	1.0	5	1	0	0
56157	1624	oxidative effect	[oxidative effects]	1.0	2	1	0	0
56158	1624	distinct function	[distinct functions]	1.0	2	2	1	1
56159	1624	cyclic AMP inhibition of transcription	[cyclic AMP inhibition of transcription]	1.0	5	1	0	0
56160	1624	expression of a transcription factor	[expression of a transcription factor]	1.0	5	2	1	1
56161	1624	thrombotic complication	[thrombotic complications]	1.0	2	1	0	0
56162	1624	mediator of stress activation pathways.	[mediator of stress activation pathways.]	1.0	5	1	0	0
56163	1624	(10-fold expansion) occur between day 7	[(10-fold expansion) occurring between day 7]	1.0	6	1	0	0
56164	1624	tpa differentiation of ml-1 cell	[TPA differentiation of ML-1 cells]	1.0	5	1	0	0
56165	1624	inhibition experiment with specific antagonist	[inhibition experiments with specific antagonists]	1.0	5	1	0	0
56166	1624	moderate increase in nf-kappab2 p52	[moderate increase in NF-kappaB2 p52]	1.0	5	1	0	0
56167	1624	finding related to social support	[finding related to social support]	1.0	5	1	0	0
56168	1624	20 patient undergo elective ptca	[20 patients undergoing elective PTCA]	1.0	5	1	0	0
56169	1624	TAL1 expression	[TAL1 expression]	1.0	2	2	1	1
56170	1624	camp -dependent intracellular signal pathway	[cAMP -dependent intracellular signaling pathways]	1.0	5	1	0	0
56171	1624	b-lymphotropic herpesvirus	[B-lymphotropic herpesvirus]	1.0	2	1	0	0
56172	1624	apoptotic cell death of lymphocyte	[apoptotic cell death of lymphocytes]	1.0	5	1	0	0
56173	1624	expression of the mouse e2a gene	[expression of the mouse E2A gene]	1.0	6	1	0	0
56174	1624	I interferon ifn-alpha/beta to specific receptor	[I interferon IFN-alpha/beta to specific receptors]	1.0	6	1	0	0
56175	1624	ra-mediated type ii tgase up-regulation	[RA-mediated type II TGase up-regulation]	1.0	5	1	0	0
56176	1624	effect on alpha-globin promoter activity	[effect on alpha-globin promoter activity]	1.0	5	1	0	0
56177	1624	latency ii	[latency II]	1.0	2	1	0	0
56178	1624	binding site for several transcription factor	[binding sites for several transcription factors]	1.0	6	1	0	0
56179	1624	span position -78 to +16	[spanning positions -78 to +16]	1.0	5	1	0	0
56180	1624	hiv-1 long terminal repeat transcription	[HIV-1 long terminal repeat transcription]	1.0	5	2	2	2
56181	1624	finely granular Sudan black b	[finely granular Sudan black B]	1.0	5	1	0	0
56182	1624	nf-kappab activation/translocation	[NF-kappaB activation/translocation]	1.0	2	1	0	0
56183	1624	requirement for CD28 up-regulation of re/ap	[requirement for CD28 up-regulation of RE/AP]	1.0	6	1	0	0
56184	1624	However, CsA	[However, CsA]	1.0	2	1	0	0
56185	1624	exposure to sf during priming	[Exposure to SFs during priming]	1.0	5	1	0	0
56186	1624	Site IV	[Site IV]	1.0	2	2	1	1
56187	1624	presence of three alpha-helice each	[presence of three alpha-helices each]	1.0	5	1	0	0
56188	1624	carry the chimeric ebna2 gene	[carrying the chimeric EBNA2 gene]	1.0	5	1	0	0
56189	1624	novel family of transcription factor	[novel families of transcription factors]	1.0	5	1	0	0
56190	1624	garlic compound, s-allyl cysteine sac	[garlic compound, S-allyl cysteine SAC]	1.0	5	1	0	0
56191	1624	use a erythroid cell line	[Using an erythroid cell line]	1.0	5	1	0	0
56192	1624	different factor	[different factors]	1.0	2	2	2	2
56193	1624	appearance of a monocytic phenotype	[appearance of a monocytic phenotype]	1.0	5	1	0	0
56194	1624	concomitant of the aging process	[concomitant of the aging process]	1.0	5	1	0	0
56195	1624	only slightly on epidermal cell	[only slightly on epidermal cells]	1.0	5	1	0	0
56196	1624	novel regulator of blood cell development	[novel regulators of blood cell development]	1.0	6	1	0	0
56197	1624	placebo (in the placebo treatment period	[placebo (in the placebo treatment period]	1.0	6	1	0	0
56198	1624	possibility of rapid mutational analysis	[possibility of rapid mutational analysis]	1.0	5	1	0	0
56199	1624	endocrine cell	[endocrine cell]	1.0	2	2	1	1
56200	1624	3-fold respectively)	[3-fold respectively)]	1.0	2	1	0	0
56201	1624	86-nucleotide fragment	[86-nucleotide fragment]	1.0	2	1	0	0
56202	1624	GH3 extract	[GH3 extract]	1.0	2	1	0	0
56203	1624	perforin locus	[perforin locus]	1.0	2	1	0	0
56204	1624	substantial evidence for a allosteric effect	[substantial evidence for an allosteric effect]	1.0	6	1	0	0
56205	1624	Oestrogen-dependent tumour	[Oestrogen-dependent tumours]	1.0	2	1	0	0
56206	1624	IL-5 signal	[IL-5 signals]	1.0	2	1	0	0
56207	1624	active element	[active elements]	1.0	2	2	2	2
56208	1624	c-myb targets, such as Bcl-2	[c-Myb targets, such as Bcl-2]	1.0	5	1	0	0
56209	1624	member of the Janus family	[members of the Janus family]	1.0	5	1	0	0
56210	1624	mouse genomic DNA clone for CPO	[mouse genomic DNA clones for CPO]	1.0	6	1	0	0
56211	1624	stress-induced down-regulation	[stress-induced down-regulation]	1.0	2	1	0	0
56212	1624	nutritionally relevant concentration in vitro,	[nutritionally relevant concentrations in vitro,]	1.0	5	1	0	0
56213	1624	protein latent infection membrane protein 1	[protein latent infection membrane protein 1]	1.0	6	1	0	0
56214	1624	il-2 binding to il-2 receptor	[IL-2 binding to IL-2 receptors]	1.0	5	1	0	0
56215	1624	(10 microM),	[(10 microM),]	1.0	2	2	1	1
56216	1624	viral mrna	[viral mRNA]	1.0	2	2	2	2
56217	1624	heterologous gene	[heterologous gene]	1.0	2	1	0	0
56218	1624	number of mineralocorticoid receptor /cell	[number of mineralocorticoid receptors /cell]	1.0	5	1	0	0
56219	1624	little tnf	[little TNF]	1.0	2	1	0	0
56220	1624	functional gr	[functional GR]	1.0	2	1	0	0
56221	1624	pebp2/cbf aml1	[PEBP2/CBF AML1]	1.0	2	1	0	0
56222	1624	phosphorylation of stat3 on serine	[phosphorylation of STAT3 on serine]	1.0	5	1	0	0
56223	1624	5' deletion	[5' deletion]	1.0	2	1	0	0
56224	1624	5 alpha-dihydrotestosterone	[5 alpha-dihydrotestosterone]	1.0	2	1	0	0
56225	1624	AP-1(I,II,III) site	[AP-1(I,II,III) sites]	1.0	2	1	0	0
56226	1624	oct2 target	[Oct2 target]	1.0	2	2	2	2
56227	1624	-responsive rat	[-responsive rat]	1.0	2	1	0	0
56228	1624	relative ratio	[relative ratio]	1.0	2	1	0	0
56229	1624	specific protein kinase c inhibitor	[specific protein kinase C inhibitor]	1.0	5	1	0	0
56230	1624	cytokine expression by immune system cell	[Cytokine expression by immune system cells]	1.0	6	1	0	0
56231	1624	hiv-1 ltr lack c/ebp site	[HIV-1 LTRs lacking C/EBP sites]	1.0	5	1	0	0
56232	1624	direct involvement	[direct involvement]	1.0	2	2	2	2
56233	1624	drug in	[drug in]	1.0	2	1	0	0
56234	1624	TCR signal	[TCR signaling]	1.0	2	1	0	0
56235	1624	different receptor and/or transduction pathway	[different receptors and/or transduction pathways]	1.0	5	1	0	0
56236	1624	tnf-alpha release from peripheral blood monocyte	[TNF-alpha release from peripheral blood monocytes]	1.0	6	1	0	0
56237	1624	glycoprotein iib	[glycoprotein IIb]	1.0	2	2	2	2
56238	1624	c-mpl a receptor for thrombopoietin	[c-Mpl a receptor for thrombopoietin]	1.0	5	1	0	0
56239	1624	govern proliferation in this cells.	[governing proliferation in these cells.]	1.0	5	1	0	0
56240	1624	nonadherent culture	[nonadherent culture]	1.0	2	1	0	0
56241	1624	stringent control	[stringent control]	1.0	2	2	1	1
56242	1624	nf-gm2 polypeptide	[NF-GM2 polypeptide]	1.0	2	1	0	0
56243	1624	constitutive nf-kappa b dna-binding activity	[constitutive NF-kappa B DNA-binding activity]	1.0	5	1	0	0
56244	1624	cellular mutant,	[cellular mutant,]	1.0	2	1	0	0
56245	1624	lack all four signal transducer	[lacking all four signal transducers]	1.0	5	1	0	0
56246	1624	retinoidal activity	[retinoidal activity]	1.0	2	2	1	1
56247	1624	gata repeat	[GATA repeat]	1.0	2	1	0	0
56248	1624	most cells;	[most cells;]	1.0	2	1	0	0
56249	1624	COS-1 cell	[COS-1 cells]	1.0	2	2	2	2
56250	1624	congenital defect	[congenital defects]	1.0	2	1	0	0
56251	1624	most cells,	[most cells,]	1.0	2	1	0	0
56252	1624	expression of the nfat-1 activity	[expression of the NFAT-1 activity]	1.0	5	1	0	0
56253	1624	nonlinear relationship	[nonlinear relationship]	1.0	2	1	0	0
56254	1624	i ifi	[I IFNs]	1.0	2	2	1	1
56255	1624	expression of androgen receptor ar	[expression of androgen receptor AR]	1.0	5	1	0	0
56256	1624	human matrix metalloproteinase 9 mmp9	[human matrix metalloproteinase 9 MMP9]	1.0	5	1	0	0
56257	1624	analysis of msr promoter activity	[Analysis of MSR promoter activity]	1.0	5	1	0	0
56258	1624	B95-8 cytosol	[B95-8 cytosol]	1.0	2	1	0	0
56259	1624	rna polymerase iii-dependent gene expression	[RNA polymerase III-dependent gene expression]	1.0	5	1	0	0
56260	1624	multiple malignancy	[multiple malignancies]	1.0	2	1	0	0
56261	1624	include the retinoblastoma susceptibility gene product	[including the retinoblastoma susceptibility gene product]	1.0	6	1	0	0
56262	1624	expression profile	[expression profiles]	1.0	2	1	0	0
56263	1624	Octamer independent activation of transcription	[Octamer independent activation of transcription]	1.0	5	1	0	0
56264	1624	different mutation of dq2-anchor residue	[different mutations of DQ2-anchor residues]	1.0	5	1	0	0
56265	1624	breast cancer of early stage	[breast cancer of early stages]	1.0	5	1	0	0
56266	1624	fra-1 expression	[fra-1 expression]	1.0	2	1	0	0
56267	1624	recombinant b-cell	[recombinant B-cells]	1.0	2	1	0	0
56268	1624	analysis of the chromatin organization	[Analysis of the chromatin organization]	1.0	5	1	0	0
56269	1624	culture of beta thalassemia patient	[cultures of beta thalassemia patients]	1.0	5	1	0	0
56270	1624	functional analysis of the promoter	[functional analysis of the promoter]	1.0	5	1	0	0
56271	1624	prognostic character	[prognostic character]	1.0	2	2	1	1
56272	1624	histologic examination	[Histologic examination]	1.0	2	1	0	0
56273	1624	difference in transcriptional enhancer of hiv-1	[Differences in transcriptional enhancers of HIV-1]	1.0	6	1	0	0
56274	1624	woman old than 60 year	[women older than 60 years]	1.0	5	1	0	0
56275	1624	molecular switch for lineage specification	[molecular switch for lineage specification]	1.0	5	1	0	0
56276	1624	phosphatidylinositol ptdin	[phosphatidylinositol PtdIns]	1.0	2	1	0	0
56277	1624	transplantation of hematopoietic stem cell	[transplantation of hematopoietic stem cells]	1.0	5	1	0	0
56278	1624	lavage t-lymphocyte from patient with tuberculosis	[Lavage T-lymphocytes from patients with tuberculosis]	1.0	6	1	0	0
56279	1624	existence of ap2 binding site	[existence of AP2 binding sites]	1.0	5	1	0	0
56280	1624	adhere pmn of the response.	[adhering PMN of the response.]	1.0	5	1	0	0
56281	1624	ebv infection of T cell	[EBV infection of T cells]	1.0	5	1	0	0
56282	1624	three patient with campomelic dysplasia	[three patients with campomelic dysplasia]	1.0	5	1	0	0
56283	1624	drosophila transcription	[Drosophila transcription]	1.0	2	1	0	0
56284	1624	metastatic capacity	[metastatic capacity]	1.0	2	2	2	2
56285	1624	expression of the colony-stimulating factor	[expression of the colony-stimulating factor]	1.0	5	1	0	0
56286	1624	forty animal	[Forty animals]	1.0	2	1	0	0
56287	1624	retention of inactive nuclear factor-kappaB	[retention of inactive nuclear factor-kappaB]	1.0	5	1	0	0
56288	1624	early event in oncogenic transformation	[early event in oncogenic transformation]	1.0	5	1	0	0
56289	1624	neutrophil binding	[neutrophil binding]	1.0	2	2	1	1
56290	1624	il-5 -produce T cell clone	[IL-5 -producing T cell clones]	1.0	5	1	0	0
56291	1624	naive Mono Mac 6 cell	[naive Mono Mac 6 cells]	1.0	5	1	0	0
56292	1624	whole animal	[whole animals]	1.0	2	1	0	0
56293	1624	malarial parasite	[malarial parasite]	1.0	2	1	0	0
56294	1624	lineage-specific gene	[lineage-specific genes]	1.0	2	1	0	0
56295	1624	proliferation adjustment	[proliferation adjustments]	1.0	2	1	0	0
56296	1624	Recent progress understand the regulation	[Recent progress understanding the regulation]	1.0	5	1	0	0
56297	1624	4 femaless with the syndromee	[4 females) with the syndrome.]	1.0	5	1	0	0
56298	1624	preterm suffer from distress syndrome	[preterms suffering from distress syndrome]	1.0	5	1	0	0
56299	1624	VZV IE62	[VZV IE62]	1.0	2	1	0	0
56300	1624	disruption of a gata motif	[Disruption of a GATA motif]	1.0	5	1	0	0
56301	1624	important implication for the design	[important implications for the design]	1.0	5	2	1	1
56302	1624	positively regulate	[positively regulating]	1.0	2	1	0	0
56303	1624	other phenotypic characteristic of monocytic differentiation	[other phenotypic characteristics of monocytic differentiation]	1.0	6	1	0	0
56304	1624	reason(s) for this functional change	[reason(s) for these functional changes]	1.0	5	1	0	0
56305	1624	instead of a TATA sequence	[instead of a TATA sequence]	1.0	5	1	0	0
56306	1624	understand the evolutionary event of some,	[understanding the evolutionary events of some,]	1.0	6	1	0	0
56307	1624	50 nm 1 alpha,25-dihydroxyvitamin D3 D3	[50 nM 1 alpha,25-dihydroxyvitamin D3 D3]	1.0	6	1	0	0
56308	1624	b-cell-specific factor	[B-cell-specific factor]	1.0	2	1	0	0
56309	1624	monoclonal gammopathy	[monoclonal gammopathy]	1.0	2	1	0	0
56310	1624	tumor-infiltrating lymphocyte	[tumor-infiltrating lymphocytes]	1.0	2	1	0	0
56311	1624	3' g	[3' G]	1.0	2	2	1	1
56312	1624	tnfalpha synthesis	[TNFalpha synthesis]	1.0	2	1	0	0
56313	1624	(1) the nuclear appearance of NF-kappaB	[(1) the nuclear appearance of NF-kappaB]	1.0	6	1	0	0
56314	1624	lymphocyte from the same preparation.	[lymphocytes from the same preparation.]	1.0	5	1	0	0
56315	1624	most New World primate nwp	[Most New World primate NWP]	1.0	5	1	0	0
56316	1624	fetal globin	[fetal globin]	1.0	2	2	2	2
56317	1624	suggest regulated.	[suggesting regulated.]	1.0	2	1	0	0
56318	1624	surface expression of the cd45 ptpase	[surface expression of the CD45 PTPase]	1.0	6	1	0	0
56319	1624	synthesis of a protein(s) responsible	[synthesis of a protein(s) responsible]	1.0	5	1	0	0
56320	1624	latent adenovirus	[latent adenovirus]	1.0	2	1	0	0
56321	1624	alternative splicing of rna transcript	[Alternative splicing of RNA transcripts]	1.0	5	1	0	0
56322	1624	seventeen case	[Seventeen cases]	1.0	2	1	0	0
56323	1624	human (U937)	[human (U937)]	1.0	2	1	0	0
56324	1624	neighbor element	[neighboring elements]	1.0	2	1	0	0
56325	1624	transient increase in the activity	[transient increases in the activities]	1.0	5	1	0	0
56326	1624	sequence motif within the core	[sequence motifs within the core]	1.0	5	1	0	0
56327	1624	functional conservation	[functional conservation]	1.0	2	1	0	0
56328	1624	potential application	[potential application]	1.0	2	2	2	2
56329	1624	substitute for the ca2+ co-stimulus	[substitutes for the Ca2+ co-stimulus]	1.0	5	2	2	2
56330	1624	expression of the gene encode	[expression of the gene encoding]	1.0	5	1	0	0
56331	1624	counteract effect of th2 cytokine	[counteracting effect of Th2 cytokines]	1.0	5	1	0	0
56332	1624	in vitro substrate for calcineurin	[in vitro substrate for calcineurin]	1.0	5	1	0	0
56333	1624	aml M4Eo	[AML M4Eo]	1.0	2	1	0	0
56334	1624	herpesvirus with a host range	[herpesvirus with an host range,]	1.0	5	1	0	0
56335	1624	notably sscp	[notably SSCP]	1.0	2	1	0	0
56336	1624	Rb protein	[Rb protein]	1.0	2	2	2	2
56337	1624	include thiol deprivation with hydrogen peroxide	[including thiol deprivation with hydrogen peroxide]	1.0	6	1	0	0
56338	1624	signal capacity of CD28 change	[signaling capacity of CD28 changes]	1.0	5	1	0	0
56339	1624	three distinct form of virus latency	[three distinct forms of virus latency]	1.0	6	1	0	0
56340	1624	formation of the PU-SF complex	[formation of the PU-SF complex]	1.0	5	1	0	0
56341	1624	redox-regulatory mechanism	[redox-regulatory mechanism]	1.0	2	1	0	0
56342	1624	myeloid cell transcription factor pu.1	[myeloid cell transcription factor PU.1]	1.0	5	1	0	0
56343	1624	clonality of eosinophil in the syndrome	[Clonality of eosinophils in the syndrome]	1.0	6	1	0	0
56344	1624	th action	[TH action]	1.0	2	1	0	0
56345	1624	Mammalian cell	[Mammalian cells]	1.0	2	1	0	0
56346	1624	T cell type i pathway	[T cell Type I pathway]	1.0	5	1	0	0
56347	1624	cloning of a TATA binding factor	[Cloning of a TATA binding factor]	1.0	6	1	0	0
56348	1624	signal transduction in T cell	[signal transduction in T cells]	1.0	5	1	0	0
56349	1624	activity of transcription factor ap-1	[activity of transcription factor AP-1]	1.0	5	2	1	1
56350	1624	general feature of signal transduction	[general features of signal transduction]	1.0	5	1	0	0
56351	1624	cell apc	[cells APCs]	1.0	2	2	1	1
56352	1624	explain this collection of datum	[explaining this collection of data.]	1.0	5	1	0	0
56353	1624	beclomethasone dipropionate	[beclomethasone dipropionate]	1.0	2	1	0	0
56354	1624	interleukin 1	[interleukin 1]	1.0	2	1	0	0
56355	1624	myeloproliferative disease	[myeloproliferative diseases]	1.0	2	2	2	2
56356	1624	early growth response gene-1 egr-1	[early growth response gene-1 EGR-1]	1.0	5	1	0	0
56357	1624	IL-8 secretion	[IL-8 secretion]	1.0	2	1	0	0
56358	1624	differential manner	[differential manner]	1.0	2	1	0	0
56359	1624	expression from the DRA promoter	[expression from the DRA promoter]	1.0	5	1	0	0
56360	1624	tubal epithelium	[tubal epithelium]	1.0	2	1	0	0
56361	1624	Ca(2+)-independent stimuli.	[Ca(2+)-independent stimuli.]	1.0	2	1	0	0
56362	1624	Rb expression	[Rb expression]	1.0	2	2	1	1
56363	1624	follow hiv infection of human macrophage	[following HIV infection of human macrophages]	1.0	6	1	0	0
56364	1624	bladder carcinoma	[bladder carcinoma]	1.0	2	1	0	0
56365	1624	gene expression of tcf-responsive gene	[gene expression of Tcf-responsive genes]	1.0	5	1	0	0
56366	1624	pcr product show ptt shift	[PCR products showing PTT shifts]	1.0	5	1	0	0
56367	1624	6) donor	[6) donors]	1.0	2	1	0	0
56368	1624	similar level of two elf-2 transcript	[similar levels of two elf-2 transcripts]	1.0	6	1	0	0
56369	1624	growth of various normal cell type	[growth of various normal cell types]	1.0	6	1	0	0
56370	1624	differentiation-dependent change of the protein	[differentiation-dependent changes of the proteins]	1.0	5	1	0	0
56371	1624	retinoid -dependent granulocytic marker expression	[retinoid -dependent granulocytic markers expression]	1.0	5	1	0	0
56372	1624	leukotriene b4 adhesion of neutrophil	[leukotriene B4 adhesion of neutrophils]	1.0	5	1	0	0
56373	1624	make extract from myelo- monocytic cell	[making extracts from myelo- monocytic cells]	1.0	6	1	0	0
56374	1624	Lung disease	[Lung disease]	1.0	2	1	0	0
56375	1624	IkappaB-alpha overexpression.	[IkappaB-alpha overexpression.]	1.0	2	1	0	0
56376	1624	strong effect of this element	[strong effect of this element]	1.0	5	1	0	0
56377	1624	NF-kappa b transcription factor activation	[NF-kappa B transcription factor activation]	1.0	5	1	0	0
56378	1624	nonhematopoietic lineage	[nonhematopoietic lineage]	1.0	2	1	0	0
56379	1624	Ectopic expression of Oct2 cDNA	[Ectopic expression of Oct2 cDNA]	1.0	5	1	0	0
56380	1624	plasmodium falciparum	[Plasmodium falciparum]	1.0	2	1	0	0
56381	1624	ECS-dependent luciferase reporter gene activation	[ECS-dependent luciferase reporter gene activation]	1.0	5	1	0	0
56382	1624	effect of dexamethasone of glucocorticoid	[effect of dexamethasone of glucocorticoids]	1.0	5	1	0	0
56383	1624	hbxag stimulation	[HBxAg stimulation]	1.0	2	1	0	0
56384	1624	e7 protein	[E7 proteins]	1.0	2	1	0	0
56385	1624	cytokine responsiveness	[cytokine responsiveness]	1.0	2	1	0	0
56386	1624	massive amplification	[massive amplification]	1.0	2	1	0	0
56387	1624	large part of the gene	[Large part of the genes]	1.0	5	1	0	0
56388	1624	adenomyotic lesion	[adenomyotic lesions]	1.0	2	1	0	0
56389	1624	occurrence of T cell response	[occurrence of T cell responses]	1.0	5	1	0	0
56390	1624	granulocyte fraction	[granulocyte fraction]	1.0	2	3	2	1
56391	1624	receptor determination	[receptor determination]	1.0	2	2	2	2
56392	1624	coexpression of a IkappaBalpha construct	[coexpression of a IkappaBalpha construct]	1.0	5	1	0	0
56393	1624	translation rate	[translation rate]	1.0	2	2	1	1
56394	1624	use the indexing term immunology	[using the indexing terms immunology]	1.0	5	1	0	0
56395	1624	piec clone	[PIEC clones]	1.0	2	1	0	0
56396	1624	degradation rate of er mrna	[degradation rate of ER mRNA]	1.0	5	1	0	0
56397	1624	surface marker expression of il-2r alpha-chain	[surface marker expression of IL-2R alpha-chain]	1.0	6	1	0	0
56398	1624	reporter gene in transfection assay	[reporter genes in transfection assays]	1.0	5	1	0	0
56399	1624	pharmaceutical agent	[pharmaceutical agents]	1.0	2	1	0	0
56400	1624	gcr of spleen lymphocytic cell	[GCR of spleen lymphocytic cell]	1.0	5	1	0	0
56401	1624	'conditional phenotype'	['conditional phenotype']	1.0	2	1	0	0
56402	1624	CEM t-cell	[CEM T-cells]	1.0	2	1	0	0
56403	1624	CD2:lymphocyte ag-3	[CD2:lymphocyte Ag-3]	1.0	2	1	0	0
56404	1624	apoptosis by cytokine in eosinophil	[apoptosis by cytokines in eosinophils]	1.0	5	1	0	0
56405	1624	JNK protein	[JNK proteins]	1.0	2	1	0	0
56406	1624	CD28 complex	[CD28 complex]	1.0	2	2	2	2
56407	1624	potent apc	[potent APC]	1.0	2	2	1	1
56408	1624	lps induction of kappab transcription	[LPS induction of kappaB transcription]	1.0	5	1	0	0
56409	1624	responsiveness to antigen stimulation signal	[responsiveness to antigen stimulation signals]	1.0	5	1	0	0
56410	1624	lipid homeostasis	[lipid homeostasis]	1.0	2	1	0	0
56411	1624	conformation polymorphism	[conformation polymorphism]	1.0	2	2	2	2
56412	1624	T cell the antigen-presenting cell	[T cells the antigen-presenting cells]	1.0	5	1	0	0
56413	1624	example, osteoarthritis	[example, osteoarthritis]	1.0	2	1	0	0
56414	1624	normal lifer	[normal livers]	1.0	2	1	0	0
56415	1624	receptor in growth of hemopoietic cell	[receptors in growth of hemopoietic cells]	1.0	6	1	0	0
56416	1624	(0.1 mm)	[(0.1 mM)]	1.0	2	1	0	0
56417	1624	homodimerization of the IL-4Ralpha chain	[homodimerization of the IL-4Ralpha chain]	1.0	5	1	0	0
56418	1624	implication for a hpfh syndrome	[implications for an HPFH syndrome]	1.0	5	1	0	0
56419	1624	concomitant activation of nf-kappa b	[concomitant activation of NF-kappa B]	1.0	5	1	0	0
56420	1624	65,000 point	[65,000 point]	1.0	2	1	0	0
56421	1624	t-cell stimulation	[T-cell stimulation]	1.0	2	2	1	1
56422	1624	binding to proline -rich region	[binding to proline -rich regions]	1.0	5	1	0	0
56423	1624	protein binding property of wild-type element	[protein binding properties of wild-type elements]	1.0	6	1	0	0
56424	1624	SCL protein level in BFU-E cell	[SCL protein levels in BFU-E cells]	1.0	6	1	0	0
56425	1624	p50 homodimer in lps cell	[p50 homodimers in LPS cells]	1.0	5	1	0	0
56426	1624	intravenous glucocorticoid	[intravenous glucocorticoids]	1.0	2	1	0	0
56427	1624	mechanism regulate t-cell gene expression	[mechanism regulating T-cell gene expression]	1.0	5	1	0	0
56428	1624	differentiation-dependent peroxisomal proliferator-activated receptor gamma	[differentiation-dependent peroxisomal proliferator-activated receptor gamma]	1.0	5	1	0	0
56429	1624	replicative capacity of the mutant	[replicative capacities of the mutants]	1.0	5	1	0	0
56430	1624	CD2 cross-linking	[CD2 cross-linking]	1.0	2	2	1	1
56431	1624	respectively atf-1	[respectively ATF-1]	1.0	2	1	0	0
56432	1624	Finally, oxidant	[Finally, oxidants]	1.0	2	1	0	0
56433	1624	nuclear expression of c-rel /p50	[nuclear expression of c-Rel /p50]	1.0	5	1	0	0
56434	1624	human immunodeficiency virus hiv expression	[Human immunodeficiency virus HIV expression]	1.0	5	1	0	0
56435	1624	mature protein	[mature protein]	1.0	2	1	0	0
56436	1624	lead to adhesion of monocyte	[leading to adhesion of monocytes]	1.0	5	1	0	0
56437	1624	clinical variable such as stage	[clinical variables such as stage]	1.0	5	1	0	0
56438	1624	intracellular activity	[intracellular activity]	1.0	2	2	1	1
56439	1624	promoter of class histocompatibility gene	[promoters of class histocompatibility genes]	1.0	5	1	0	0
56440	1624	T cell with BW 828	[T cells with BW 828]	1.0	5	1	0	0
56441	1624	histone h4 mark chromatin domain	[histone H4 marking chromatin domains]	1.0	5	1	0	0
56442	1624	rapid activation of gene expression	[rapid activation of gene expression]	1.0	5	1	0	0
56443	1624	TRAF aggregation in LMP1 signal	[TRAF aggregation in LMP1 signaling]	1.0	5	1	0	0
56444	1624	variant fusion partner of RARA	[variant fusion partners of RARA]	1.0	5	1	0	0
56445	1624	wild-type shp2	[wild-type SHP2]	1.0	2	1	0	0
56446	1624	b lymphocyte from patient with leukemia	[B lymphocytes from patients with leukemia]	1.0	6	1	0	0
56447	1624	Anti- HLA-DR	[Anti- HLA-DR]	1.0	2	1	0	0
56448	1624	nuclear translocation of individual member	[nuclear translocation of individual members]	1.0	5	1	0	0
56449	1624	irreversible reduction	[irreversible reduction]	1.0	2	1	0	0
56450	1624	action of this two molecule	[actions of these two molecules]	1.0	5	1	0	0
56451	1624	signal molecule of blood T lymphocyte	[signaling molecules of blood T lymphocytes]	1.0	6	1	0	0
56452	1624	alpha 4 beta 1 ligation alone	[alpha 4 beta 1 ligation alone]	1.0	6	1	0	0
56453	1624	cysteine residue	[cysteine residue]	1.0	2	2	2	2
56454	1624	gene expression in gm-csf pmn	[gene expression in GM-CSF PMN]	1.0	5	1	0	0
56455	1624	VDR secondary to persistent hypophosphatemia	[VDR secondary to persistent hypophosphatemia]	1.0	5	1	0	0
56456	1624	Stat binding to the intracellular domain	[Stat binding to the intracellular domain]	1.0	6	1	0	0
56457	1624	molecular mass of this factor	[molecular mass of these factors]	1.0	5	1	0	0
56458	1624	involve protein kinase C by PAF	[involving protein kinase C by PAF]	1.0	6	1	0	0
56459	1624	cell-specific background	[cell-specific background]	1.0	2	1	0	0
56460	1624	future research in this area	[future research in this area]	1.0	5	1	0	0
56461	1624	NF-kappaB generation	[NF-kappaB generation]	1.0	2	1	0	0
56462	1624	B3 factor	[B3 factor]	1.0	2	1	0	0
56463	1624	high-level expression nonproliferateraterateratiferatiferatiferatiferati b cell	[High-level expression nonproliferating B cells]	1.0	5	1	0	0
56464	1624	new protein,	[new protein,]	1.0	2	1	0	0
56465	1624	b-alpha level in pbmc from subject	[B-alpha levels in PBMC from subjects]	1.0	6	1	0	0
56466	1624	encode the tetracycline trans-activator protein	[encoding the tetracycline trans-activator protein]	1.0	5	1	0	0
56467	1624	cell line nb4 myeloid leukemia	[cell lines NB4 myeloid leukemia]	1.0	5	1	0	0
56468	1624	number of small intragenic mutation	[number of small intragenic mutations]	1.0	5	1	0	0
56469	1624	transcription of the two gene	[transcription of the two genes]	1.0	5	1	0	0
56470	1624	il-2 level	[IL-2 levels]	1.0	2	2	2	2
56471	1624	alteration in the functional activity	[alterations in the functional activity]	1.0	5	1	0	0
56472	1624	specific cooperation between Spi-1 (r129c)	[specific cooperation between Spi-1 (R129C)]	1.0	5	1	0	0
56473	1624	only in tg epsilon26 mice,	[only in tg epsilon26 mice,]	1.0	5	1	0	0
56474	1624	thymocyte cell under hormone condition	[thymocyte cells under hormone conditions]	1.0	5	1	0	0
56475	1624	induction of (ie) response gene	[induction of (IE) response genes]	1.0	5	1	0	0
56476	1624	definitive cell	[definitive cells]	1.0	2	2	2	2
56477	1624	transgenic pig	[transgenic pig]	1.0	2	1	0	0
56478	1624	myristate acetate	[myristate acetate]	1.0	2	2	1	1
56479	1624	Paul Scholl	[Paul Scholl]	1.0	2	1	0	0
56480	1624	lipopolysaccharide-induced transcription	[lipopolysaccharide-induced transcription]	1.0	2	2	1	1
56481	1624	important role in the balance	[important role in the balance]	1.0	5	1	0	0
56482	1624	large germline deletion of tsc2	[Large germline deletions of TSC2]	1.0	5	1	0	0
56483	1624	constitutive nuclear nf kappa b	[constitutive nuclear NF kappa B]	1.0	5	1	0	0
56484	1624	novel complex	[novel complex]	1.0	2	1	0	0
56485	1624	transcriptional activation by c-Myb /et	[transcriptional activation by c-Myb /Ets]	1.0	5	1	0	0
56486	1624	specific mitogen	[specific mitogens]	1.0	2	1	0	0
56487	1624	wild-type human acid receptor alpha	[wild-type human acid receptor alpha]	1.0	5	1	0	0
56488	1624	class non-inducible, RB -defective line	[class non-inducible, RB -defective lines]	1.0	5	1	0	0
56489	1624	USF protein	[USF proteins]	1.0	2	1	0	0
56490	1624	completely inhibit vdrnrar- vdre complex formation	[completely inhibiting VDR-RXR- VDRE complex formation]	1.0	6	1	0	0
56491	1624	NF-kappa b -dependent il-6 expression	[NF-kappa B -dependent IL-6 expression]	1.0	5	1	0	0
56492	1624	sequence alteration in this region	[sequence alterations in this region]	1.0	5	1	0	0
56493	1624	Th1 development distinct from positive action	[Th1 development distinct from positive actions]	1.0	6	1	0	0
56494	1624	low base order-dependent stem-loop potential	[low base order-dependent stem-loop potential]	1.0	5	1	0	0
56495	1624	dioxyvit action,	[dioxyvit action,]	1.0	2	1	0	0
56496	1624	such differentiation block by AML1a	[Such differentiation block by AML1a]	1.0	5	1	0	0
56497	1624	interact with the bp repeat element	[interacting with the bp repeat elements]	1.0	6	1	0	0
56498	1624	relatively early event in erythroid maturation	[relatively early events in erythroid maturation]	1.0	6	1	0	0
56499	1624	also against a excess of cysteine	[also against an excess of cysteine]	1.0	6	1	0	0
56500	1624	nf-kappab sn-50	[NF-kappaB SN-50]	1.0	2	1	0	0
56501	1624	(outer limits, 127 to 283), one	[(outer limits, 127 to 283), one]	1.0	6	1	0	0
56502	1624	lambda L chain mrna level	[lambda L chain mRNA levels]	1.0	5	1	0	0
56503	1624	such polymorphism	[such polymorphisms]	1.0	2	1	0	0
56504	1624	use a partial nucleotide sequence	[using a partial nucleotide sequence]	1.0	5	1	0	0
56505	1624	interferon-alpha ifn-alpha	[interferon-alpha IFN-alpha]	1.0	2	2	2	2
56506	1624	leukocyte population	[Leukocyte populations]	1.0	2	2	2	2
56507	1624	activation of NF-kappa b in vivo	[Activation of NF-kappa B in vivo]	1.0	6	1	0	0
56508	1624	post-dose until 120 h. spleen	[post-dosing until 120 h, spleen]	1.0	5	1	0	0
56509	1624	use a gel shift assay	[using a gel shift assay]	1.0	5	1	0	0
56510	1624	engagement of natural cytotoxicity program	[Engagement of natural cytotoxicity programs]	1.0	5	1	0	0
56511	1624	result in a transient induction	[resulting in a transient induction]	1.0	5	1	0	0
56512	1624	interleukin 2 transcription in murine lymphocyte	[interleukin 2 transcription in murine lymphocytes]	1.0	6	1	0	0
56513	1624	flow cytometry on T cell	[flow cytometry on T cells]	1.0	5	1	0	0
56514	1624	retroviral transduction of g-csf receptor	[retroviral transduction of G-CSF receptors]	1.0	5	1	0	0
56515	1624	nucleotide sequence requirement for u1	[nucleotide sequence requirements for U1]	1.0	5	1	0	0
56516	1624	important aspect	[important aspect]	1.0	2	2	2	2
56517	1624	modulate release of endothelium-derived vasoactive factor	[modulating release of endothelium-derived vasoactive factors]	1.0	6	1	0	0
56518	1624	asymmetric molecule	[asymmetric molecules]	1.0	2	1	0	0
56519	1624	4 hours.	[4 hours.]	1.0	2	1	0	0
56520	1624	4 hours,	[4 hours,]	1.0	2	1	0	0
56521	1624	human lineage	[human lineage]	1.0	2	1	0	0
56522	1624	follow incubation of l540 cell	[following incubation of L540 cells]	1.0	5	1	0	0
56523	1624	encode the tata-box binding protein tfiib	[encoding the TATA-box binding protein TFIIB]	1.0	6	1	0	0
56524	1624	receptor kd of 10.5 nmol/L	[receptor Kd of 10.5 nmol/L]	1.0	5	1	0	0
56525	1624	gf 109203x	[GF 109203X]	1.0	2	1	0	0
56526	1624	(tf) expression by peripheral blood monocyte	[(TF) expression by peripheral blood monocytes]	1.0	6	1	0	0
56527	1624	oestrogen receptor variant in endometrium	[oestrogen receptor variants in endometrium]	1.0	5	1	0	0
56528	1624	2.6 kb	[2.6 kb]	1.0	2	2	1	1
56529	1624	relationship between ebv latent gene	[relationships between EBV latent genes]	1.0	5	1	0	0
56530	1624	key inflammatory mediator during syphilis disease	[key inflammatory mediators during syphilis disease]	1.0	6	1	0	0
56531	1624	early lymphoid precursor of human	[early lymphoid precursors of humans]	1.0	5	1	0	0
56532	1624	protein degradation.	[protein degradation.]	1.0	2	1	0	0
56533	1624	potent effector of b-lymphocyte activation	[potent effector of B-lymphocyte activation]	1.0	5	1	0	0
56534	1624	two member of the nsaid	[two members of the NSAIDs]	1.0	5	1	0	0
56535	1624	free drug	[free drug]	1.0	2	1	0	0
56536	1624	lps induction of tf expression	[LPS induction of TF expression]	1.0	5	1	0	0
56537	1624	estrogen disrupter	[estrogen disrupters]	1.0	2	1	0	0
56538	1624	ebv latency in squamous epithelium	[EBV latency in squamous epithelium]	1.0	5	1	0	0
56539	1624	LT promoter LT-293 CAT construct	[LT promoter LT-293 CAT construct]	1.0	5	1	0	0
56540	1624	functional study of the enhancer element	[functional studies of the enhancer elements]	1.0	6	1	0	0
56541	1624	decrease in the cellular component	[decreases in the cellular components]	1.0	5	1	0	0
56542	1624	normal control from RCC patient	[normal controls from RCC patients]	1.0	5	1	0	0
56543	1624	il-2r alpha transcription by IL-2	[IL-2R alpha transcription by IL-2]	1.0	5	1	0	0
56544	1624	compensatory phase	[compensatory phase]	1.0	2	2	2	2
56545	1624	cross-over DNA	[cross-over DNA]	1.0	2	1	0	0
56546	1624	very limited stimulation of il-2	[very limited stimulation of IL-2]	1.0	5	1	0	0
56547	1624	stat5 activity	[STAT5 activity]	1.0	2	2	2	2
56548	1624	nodular lymphocyte predominance hd nlphd	[nodular lymphocyte predominance HD NLPHD]	1.0	5	1	0	0
56549	1624	stoichiometry directly interact transcription factor	[stoichiometry directly interacting transcription factors]	1.0	5	1	0	0
56550	1624	signal capability of the il-10r	[signaling capabilities of the IL-10R]	1.0	5	1	0	0
56551	1624	30 minute post- pha stimulation,	[30 min post- PHA stimulation,]	1.0	5	1	0	0
56552	1624	idea of a close association	[idea of a close association]	1.0	5	1	0	0
56553	1624	treatment on thyroid antibody production	[treatment on thyroid antibody production]	1.0	5	1	0	0
56554	1624	naive pbl	[naive PBL]	1.0	2	1	0	0
56555	1624	inflammatory pathway in human monocyte	[inflammatory pathways in human monocytes]	1.0	5	1	0	0
56556	1624	suppress activation of STAT6 by IL-4	[suppressing activation of STAT6 by IL-4]	1.0	6	1	0	0
56557	1624	intracellular signal mediate tnf-alpha release	[intracellular signals mediating TNF-alpha release]	1.0	5	1	0	0
56558	1624	cellular regulation of BZLF1 transcription	[Cellular regulation of BZLF1 transcription]	1.0	5	1	0	0
56559	1624	different caspase	[different caspases]	1.0	2	1	0	0
56560	1624	b cell ag receptor bcr	[B cell Ag receptor BCR]	1.0	5	1	0	0
56561	1624	follow the differentiation of U937 cell	[following the differentiation of U937 cells]	1.0	6	1	0	0
56562	1624	ibd patient	[IBD patients]	1.0	2	2	2	2
56563	1624	moderate (p	[moderate (P]	1.0	2	1	0	0
56564	1624	Bcl-2 family	[Bcl-2 family]	1.0	2	4	3	1
56565	1624	adenosine deaminase	[adenosine deaminase]	1.0	2	2	2	2
56566	1624	leave intact the proline threonine domain	[leaving intact the proline threonine domain]	1.0	6	1	0	0
56567	1624	SRF motif	[SRF motifs]	1.0	2	1	0	0
56568	1624	protein kinase c activation ?)	[protein kinase C activation ?)]	1.0	5	1	0	0
56569	1624	three organisms.	[three organisms.]	1.0	2	1	0	0
56570	1624	Ad5 E1A epithelial cell line	[Ad5 E1A epithelial cell lines]	1.0	5	1	0	0
56571	1624	important lymphokine	[important lymphokine]	1.0	2	1	0	0
56572	1624	Furthermore, S9a in combination, at concentration	[Furthermore, S9a in combination, at concentrations]	1.0	6	1	0	0
56573	1624	inhibit activation of the ap-1 site	[inhibiting activation of the AP-1 site]	1.0	6	1	0	0
56574	1624	notably phospholipase c gamma 1	[notably phospholipase C gamma 1]	1.0	5	1	0	0
56575	1624	variant sequence	[variant sequence]	1.0	2	1	0	0
56576	1624	expression of monocyte-macrophage surface antigen	[expression of monocyte-macrophage surface antigen]	1.0	5	1	0	0
56577	1624	potent activity	[potent activity]	1.0	2	2	2	2
56578	1624	aberrant consequence of immunological memory	[aberrant consequence of immunological memory]	1.0	5	1	0	0
56579	1624	functional correlate	[functional correlate]	1.0	2	2	1	1
56580	1624	enhancer a	[enhancer A]	1.0	2	1	0	0
56581	1624	105-kDa precursor,	[105-kDa precursor,]	1.0	2	1	0	0
56582	1624	protein of 317 amino acid	[protein of 317 amino acids]	1.0	5	1	0	0
56583	1624	two population	[two populations]	1.0	2	2	2	2
56584	1624	position -585	[positions -585]	1.0	2	1	0	0
56585	1624	RXR Ro	[RXR Ro]	1.0	2	1	0	0
56586	1624	culminate in the inducible phosphorylation	[culminating in the inducible phosphorylation]	1.0	5	1	0	0
56587	1624	narrow window	[narrow window]	1.0	2	1	0	0
56588	1624	virulent mutant	[virulent mutants]	1.0	2	1	0	0
56589	1624	core enhancer	[core enhancer]	1.0	2	2	1	1
56590	1624	PKC-zeta cell	[PKC-zeta cells]	1.0	2	1	0	0
56591	1624	transmembrane signal of T cell	[transmembrane signaling of T cells]	1.0	5	1	0	0
56592	1624	Bcl-3 protein	[Bcl-3 protein]	1.0	2	1	0	0
56593	1624	cell cycle.	[cell cycle.]	1.0	2	2	1	1
56594	1624	coexpression of the interleukin-13 gene	[Coexpression of the interleukin-13 genes]	1.0	5	1	0	0
56595	1624	HTLV-I peripheral blood T cell	[HTLV-I peripheral blood T cells]	1.0	5	1	0	0
56596	1624	cloning of the 5' region UTR	[Cloning of the 5' region UTR]	1.0	6	1	0	0
56597	1624	tumor development in this thymocyte	[tumor development in these thymocytes]	1.0	5	1	0	0
56598	1624	aduct however,	[adult, however,]	1.0	2	1	0	0
56599	1624	encompass the promoter /enhancer region	[encompassing the promoter /enhancer region]	1.0	5	1	0	0
56600	1624	TPA responsiveness of CMV element	[TPA responsiveness of CMV elements]	1.0	5	1	0	0
56601	1624	include macrophage	[including macrophages]	1.0	2	1	0	0
56602	1624	nf-kappab activation in human monocyte	[NF-kappaB activation in human monocytes]	1.0	5	1	0	0
56603	1624	T cell (nfat) transcriptional complex	[T cells (NFAT) transcriptional complex]	1.0	5	1	0	0
56604	1624	high level of g0s2 mrna	[high levels of G0S2 mRNA]	1.0	5	1	0	0
56605	1624	activate protein	[activating protein]	1.0	2	2	2	2
56606	1624	nf(kappa)b expression by serine protease inhibitor	[NF(kappa)B expression by serine protease inhibitors]	1.0	6	1	0	0
56607	1624	natural gene	[natural gene]	1.0	2	1	0	0
56608	1624	sequential accumulation	[sequential accumulation]	1.0	2	1	0	0
56609	1624	double-positive cell	[double-positive cells]	1.0	2	1	0	0
56610	1624	steady state level of tnf mrna	[steady state levels of TNF mRNA]	1.0	6	1	0	0
56611	1624	internal store	[internal stores]	1.0	2	1	0	0
56612	1624	activation of the enhancer upon overexpression	[Activation of the enhancer upon overexpression]	1.0	6	1	0	0
56613	1624	differentiation-associated pattern of BZLF1 expression	[differentiation-associated pattern of BZLF1 expression]	1.0	5	1	0	0
56614	1624	1;14 translocation	[1;14 translocations]	1.0	2	1	0	0
56615	1624	high level of pu.1 Spi-1	[high levels of PU.1 Spi-1]	1.0	5	1	0	0
56616	1624	regulation of the interleukin-1 beta gene	[Regulation of the interleukin-1 beta gene]	1.0	6	1	0	0
56617	1624	immunological activation	[immunological activations]	1.0	2	1	0	0
56618	1624	association between the mitogenic response	[association between the mitogenic response]	1.0	5	1	0	0
56619	1624	distinct N-terminal half of MZF-2	[distinct N-terminal half of MZF-2]	1.0	5	1	0	0
56620	1624	different jak kinase interferon receptor	[different JAK kinases interferon receptors]	1.0	5	1	0	0
56621	1624	phenolic, lipid-soluble, chain-breaking antioxidant hydroxyanisole bha	[phenolic, lipid-soluble, chain-breaking antioxidants hydroxyanisole BHA]	1.0	6	1	0	0
56622	1624	functional VDR	[functional VDR]	1.0	2	1	0	0
56623	1624	only MKK3	[only MKK3]	1.0	2	1	0	0
56624	1624	pretreatment of cell with vanadate	[Pretreatment of cells with vanadate]	1.0	5	1	0	0
56625	1624	phosphorylating creb	[phosphorylating CREB]	1.0	2	1	0	0
56626	1624	treatment with m alphav5 dihydroxyvitamin D3	[treatment with M alpha,25 dihydroxyvitamin D3]	1.0	6	1	0	0
56627	1624	nonreceptor protein tyrosine kinase ptk	[nonreceptor protein tyrosine kinases PTKs]	1.0	5	1	0	0
56628	1624	lps activation.	[LPS activation.]	1.0	2	1	0	0
56629	1624	qp responsiveness to Janus kinase (JAK)-1	[Qp responsiveness to Janus kinase (JAK)-1]	1.0	6	1	0	0
56630	1624	(in comparison to anti-CD3 antibody	[(in comparison to anti-CD3 antibodies]	1.0	5	1	0	0
56631	1624	use HIV LTR deletion mutant	[using HIV LTR deletion mutants]	1.0	5	1	0	0
56632	1624	little research	[little research]	1.0	2	1	0	0
56633	1624	contrast, overexpression	[contrast, overexpression]	1.0	2	3	2	1
56634	1624	such as with a lactose analogue	[such as with a lactose analogue]	1.0	6	1	0	0
56635	1624	relatively few cell-specific steroid-regulated gene	[relatively few cell-specific steroid-regulated genes]	1.0	5	1	0	0
56636	1624	early stage of myeloid differentiation	[early stages of myeloid differentiation]	1.0	5	1	0	0
56637	1624	bacterial content	[bacterial content]	1.0	2	1	0	0
56638	1624	phosphotyrosine immunoprecipitation	[Phosphotyrosine immunoprecipitation]	1.0	2	1	0	0
56639	1624	grave' disease	[Grave's disease]	1.0	2	1	0	0
56640	1624	include suppression of DNA binding	[including suppression of DNA binding]	1.0	5	1	0	0
56641	1624	important part in this process.	[important part in this process.]	1.0	5	1	0	0
56642	1624	methods: method	[METHODS: Methods]	1.0	2	1	0	0
56643	1624	activation of the alpha isoform	[activation of the alpha isoform]	1.0	5	1	0	0
56644	1624	inhibition of litaf mrna expression	[Inhibition of LITAF mRNA expression]	1.0	5	1	0	0
56645	1624	Curcumin diferuoylmethane	[Curcumin diferuoylmethane]	1.0	2	1	0	0
56646	1624	number of er in leucocyte	[number of ER in leucocytes]	1.0	5	1	0	0
56647	1624	[molecular mechanism of age-related lymphocyte dysfunction	[[Molecular mechanisms of age-related lymphocyte dysfunction]	1.0	6	1	0	0
56648	1624	conclusion: Mutated human ciita construct	[CONCLUSION: Mutated human CIITA constructs]	1.0	5	1	0	0
56649	1624	antioxidant probucol	[antioxidant probucol]	1.0	2	1	0	0
56650	1624	MHC class 1 gene expression	[MHC class 1 gene expression]	1.0	5	1	0	0
56651	1624	redox regulation in nf-kappab activation	[redox regulation in NF-kappaB activation]	1.0	5	1	0	0
56652	1624	important protein	[important protein]	1.0	2	2	2	2
56653	1624	non-proliferating cell	[non-proliferating cells]	1.0	2	1	0	0
56654	1624	receptor consist	[receptor consisting]	1.0	2	2	2	2
56655	1624	soluble cytokine	[soluble cytokines]	1.0	2	1	0	0
56656	1624	surface expression of icam-1 on huvec	[Surface expression of ICAM-1 on HUVECs]	1.0	6	1	0	0
56657	1624	GH-V gene	[GH-V gene]	1.0	2	1	0	0
56658	1624	bind affinity for the receptor	[binding affinity for the receptor]	1.0	5	1	0	0
56659	1624	gcs up-regulate cytokine receptor expression	[GCS up-regulate cytokine receptor expression]	1.0	5	1	0	0
56660	1624	exposure of monocyte to m-csf	[exposure of monocytes to M-CSF]	1.0	5	1	0	0
56661	1624	apparent potency	[apparent potency]	1.0	2	1	0	0
56662	1624	development of responsive T cell	[development of responsive T cells]	1.0	5	1	0	0
56663	1624	40 promoter	[40 promoter]	1.0	2	2	2	2
56664	1624	patient with affinity to glucocorticoid	[patients with affinity to glucocorticoids]	1.0	5	2	2	2
56665	1624	transcriptional repressor of the c-myc	[transcriptional repressor of the c-myc]	1.0	5	1	0	0
56666	1624	role for transactivation in apoptosis	[role for transactivation in apoptosis]	1.0	5	1	0	0
56667	1624	G0S2 expression	[G0S2 expression]	1.0	2	1	0	0
56668	1624	immunophilin FKBP51	[immunophilin FKBP51]	1.0	2	1	0	0
56669	1624	human blood mononuclear cell response	[human blood mononuclear cell responses]	1.0	5	2	1	1
56670	1624	possibly through NF-kappa b activation	[possibly through NF-kappa B activation]	1.0	5	1	0	0
56671	1624	linear configuration	[linear configuration]	1.0	2	1	0	0
56672	1624	tumor suppressor as a repressor	[tumor suppressor as a repressor]	1.0	5	1	0	0
56673	1624	vitamin derivative	[vitamin derivatives]	1.0	2	1	0	0
56674	1624	specific pkc inhibition with Bis	[specific PKC inhibition with Bis]	1.0	5	1	0	0
56675	1624	other molecule in T cell	[other molecules in T cells]	1.0	5	1	0	0
56676	1624	X chromosome inactivation pattern in female	[X chromosome inactivation patterns in females]	1.0	6	1	0	0
56677	1624	Recent datum on the signal	[Recent data on the signals]	1.0	5	1	0	0
56678	1624	express the Ad12 13S mrna product	[expressing the Ad12 13S mRNA product]	1.0	6	1	0	0
56679	1624	chemokine pathway	[chemokine pathways]	1.0	2	1	0	0
56680	1624	include leukemia	[including leukemia]	1.0	2	2	1	1
56681	1624	eukaryotic transcription factor nf-kappa b	[eukaryotic transcription factor NF-kappa B]	1.0	5	1	0	0
56682	1624	treatment with v3 loop antibody	[treatment with V3 loop antibody]	1.0	5	1	0	0
56683	1624	Stat3 activity	[Stat3 activity]	1.0	2	1	0	0
56684	1624	other, agent	[other, agents]	1.0	2	1	0	0
56685	1624	peptide g75	[peptide G75]	1.0	2	1	0	0
56686	1624	resistant variant	[resistant variants]	1.0	2	1	0	0
56687	1624	platelet attachment	[platelet attachment]	1.0	2	1	0	0
56688	1624	promoter switch	[promoter switching]	1.0	2	2	2	2
56689	1624	bind affinity of the gr	[binding affinity of the GR]	1.0	5	1	0	0
56690	1624	cytoplasmic p39c-jun	[cytoplasmic p39c-jun]	1.0	2	1	0	0
56691	1624	expression of th1 th2 type cytokine	[Expression of Th1 Th2 type cytokines]	1.0	6	1	0	0
56692	1624	use a chimeric receptor system	[using a chimeric receptor system]	1.0	5	1	0	0
56693	1624	Interleukin-6 protein	[Interleukin-6 protein]	1.0	2	1	0	0
56694	1624	uninfected T	[uninfected T]	1.0	2	1	0	0
56695	1624	functional binding site for Oct2	[functional binding sites for Oct2]	1.0	5	1	0	0
56696	1624	cloning of the glucocorticoid receptor	[Cloning of the glucocorticoid receptor]	1.0	5	1	0	0
56697	1624	putative NF-kappa b -binding site	[putative NF-kappa B -binding site]	1.0	5	1	0	0
56698	1624	evidence of receptor binding defect	[evidence of receptor binding defect]	1.0	5	1	0	0
56699	1624	adenylate cyclase inhibitor sq 22536	[adenylate cyclase inhibitor SQ 22536]	1.0	5	1	0	0
56700	1624	3 different factor with affinity	[3 different factors with affinity]	1.0	5	1	0	0
56701	1624	recognition by the C3/5 clone	[recognition by the C3/5 clone]	1.0	5	1	0	0
56702	1624	ets-binding site	[ets-binding sites]	1.0	2	1	0	0
56703	1624	effector plasmid express human trx	[effector plasmid expressing human Trx]	1.0	5	1	0	0
56704	1624	several mutant	[Several mutants]	1.0	2	1	0	0
56705	1624	sp1 response	[SP1 response]	1.0	2	1	0	0
56706	1624	h2o2 treatment of T lymphocyte	[H2O2 treatment of T lymphocytes]	1.0	5	1	0	0
56707	1624	inhibition studies.	[inhibition studies.]	1.0	2	1	0	0
56708	1624	dl312 virus defective after infection	[dl312 virus defective after infection]	1.0	5	1	0	0
56709	1624	camp regulatory element binding protein	[cAMP regulatory element binding protein]	1.0	5	1	0	0
56710	1624	binding of a myeloid-specific factor pu.1	[binding of a myeloid-specific factor PU.1]	1.0	6	1	0	0
56711	1624	study of gr in human	[studies of GR in humans]	1.0	5	1	0	0
56712	1624	Hyon cell	[Hyon cells]	1.0	2	2	2	2
56713	1624	inducible protein complex Band a	[inducible protein complex Band A]	1.0	5	1	0	0
56714	1624	minimal enhancer	[minimal enhancer]	1.0	2	2	2	2
56715	1624	er variants,	[ER variants,]	1.0	2	1	0	0
56716	1624	family of transcriptional activate proteins,	[family of transcriptional activating proteins,]	1.0	5	1	0	0
56717	1624	suggest activated.	[suggesting activated.]	1.0	2	1	0	0
56718	1624	creatininemia (2.5	[creatininemia (2.5]	1.0	2	1	0	0
56719	1624	human type	[human type]	1.0	2	2	1	1
56720	1624	macrophage in human atherosclerotic lesion	[macrophages in human atherosclerotic lesions]	1.0	5	1	0	0
56721	1624	gene element	[gene elements]	1.0	2	2	2	2
56722	1624	NH2-terminal truncation mutant of TRAF6	[NH2-terminal truncation mutant of TRAF6]	1.0	5	1	0	0
56723	1624	myeloperoxidase activity in tissue homogenate	[myeloperoxidase activity in tissue homogenates]	1.0	5	1	0	0
56724	1624	component of the AP1 regulator	[component of the AP1 regulator]	1.0	5	1	0	0
56725	1624	hil-5 promoter	[hIL-5 promoter]	1.0	2	2	2	2
56726	1624	inducer-mediated degradation	[inducer-mediated degradation]	1.0	2	1	0	0
56727	1624	T cell deficient in cd45	[T cells deficient in CD45]	1.0	5	1	0	0
56728	1624	tcr activation of the ras pathway	[TCR activation of the Ras pathway]	1.0	6	1	0	0
56729	1624	uncultured cell	[uncultured cells]	1.0	2	2	1	1
56730	1624	rel/nf-kappab protein in the cytosol	[Rel/NF-kappaB proteins in the cytosol]	1.0	5	1	0	0
56731	1624	ets-like motif	[ETS-like motifs]	1.0	2	1	0	0
56732	1624	induce nfat-	[inducing NFAT-]	1.0	2	1	0	0
56733	1624	other disease	[other diseases]	1.0	2	2	2	2
56734	1624	However, IL2	[However, IL2]	1.0	2	1	0	0
56735	1624	MHC class ii immunodeficiency erratum	[MHC class II immunodeficiency erratum]	1.0	5	1	0	0
56736	1624	-66 region	[-66 region]	1.0	2	2	2	2
56737	1624	activate sequence	[activating sequences]	1.0	2	1	0	0
56738	1624	Bufalin treatment	[Bufalin treatment]	1.0	2	1	0	0
56739	1624	human astroglioma	[human astroglioma]	1.0	2	1	0	0
56740	1624	signal in human monocytic cell	[signaling in human monocytic cells]	1.0	5	1	0	0
56741	1624	B-cell origin	[B-cell origin]	1.0	2	1	0	0
56742	1624	lead to activation of NF-kappa b	[leading to activation of NF-kappa B]	1.0	6	1	0	0
56743	1624	suffer from respiratory distress syndrome	[suffering from respiratory distress syndrome]	1.0	5	1	0	0
56744	1624	future clinical gene therapy trials,	[future clinical gene therapy trials,]	1.0	5	1	0	0
56745	1624	promyelocytic cell	[promyelocytic cells]	1.0	2	2	2	2
56746	1624	cd21 promoter	[CD21 promoter]	1.0	2	1	0	0
56747	1624	human oncogene	[human oncogene]	1.0	2	1	0	0
56748	1624	immortalize T cell in vitro	[immortalizing T cells in vitro]	1.0	5	1	0	0
56749	1624	mutation of the xpb XPD gene	[mutation of the XPB XPD gene]	1.0	6	1	0	0
56750	1624	protective response	[protective response]	1.0	2	1	0	0
56751	1624	accord to results, however, distinct entities.	[According to results, however, distinct entities.]	1.0	6	1	0	0
56752	1624	many flavonoid	[many flavonoids]	1.0	2	1	0	0
56753	1624	role for c/ebp-epsilon transcription factor	[role for C/EBP-epsilon transcription factor]	1.0	5	1	0	0
56754	1624	great ability	[greater ability]	1.0	2	1	0	0
56755	1624	wild-type HLF	[wild-type HLF]	1.0	2	1	0	0
56756	1624	c-fo sre DNA sequence motif	[c-fos SRE DNA sequence motifs]	1.0	5	1	0	0
56757	1624	ox-ox40 ligand	[OX-OX40 ligand]	1.0	2	1	0	0
56758	1624	distinct form of transcription factor creb	[distinct forms of transcription factor CREB]	1.0	6	2	2	2
56759	1624	80% identity with the tfiid protein	[80% identity with the TFIID protein]	1.0	6	1	0	0
56760	1624	G1/S phase control and/or enhancement	[G1/S phase control and/or enhancement]	1.0	5	1	0	0
56761	1624	bacterium surface	[bacterium surface]	1.0	2	1	0	0
56762	1624	-beta protein	[-beta proteins]	1.0	2	1	0	0
56763	1624	involvement of different transduction pathway	[Involvement of different transduction pathways]	1.0	5	1	0	0
56764	1624	formation of reactive oxygen intermediate	[formation of reactive oxygen intermediates]	1.0	5	2	2	2
56765	1624	element TCEd	[element TCEd]	1.0	2	1	0	0
56766	1624	Ca2+ /calmodulin kinase type iv/gr	[Ca2+ /calmodulin kinase type IV/Gr]	1.0	5	1	0	0
56767	1624	30-fold, block	[30-fold, blocks]	1.0	2	1	0	0
56768	1624	carboxyl-terminal 15-amino acid sequence of NFATx1	[Carboxyl-terminal 15-amino acid sequence of NFATx1]	1.0	6	1	0	0
56769	1624	none of the Spi-1 family member	[none of the Spi-1 family members]	1.0	6	1	0	0
56770	1624	indicator of cellular oxidant stress	[indicators of cellular oxidant stress]	1.0	5	1	0	0
56771	1624	CpG island with gc box	[CpG island with GC boxes]	1.0	5	1	0	0
56772	1624	activation domain requirement for disruption	[Activation domain requirements for disruption]	1.0	5	1	0	0
56773	1624	kinetic similar	[kinetics similar]	1.0	2	2	2	2
56774	1624	different approaches,	[different approaches,]	1.0	2	1	0	0
56775	1624	gammac response include stat6 phosphorylation	[gammac responses including STAT6 phosphorylation]	1.0	5	1	0	0
56776	1624	minority of LYSP100 nuclear dot	[minority of LYSP100 nuclear dots]	1.0	5	1	0	0
56777	1624	position -345	[positions -345]	1.0	2	1	0	0
56778	1624	mRNA expression	[mRNA expression]	1.0	2	2	1	1
56779	1624	activation of MHC class ii promoter	[Activation of MHC class II promoters]	1.0	6	1	0	0
56780	1624	induction of gene expression in cell	[Induction of gene expression in cells]	1.0	6	2	2	2
56781	1624	expression of downstream, function-related gene	[expression of downstream, function-related genes]	1.0	5	1	0	0
56782	1624	unspliced mrna	[unspliced mRNA]	1.0	2	2	1	1
56783	1624	pre-Talpha mrna	[pre-Talpha mRNA]	1.0	2	1	0	0
56784	1624	epithelial cell malignancy nasopharyngeal carcinoma	[epithelial cell malignancies nasopharyngeal carcinoma]	1.0	5	1	0	0
56785	1624	il-1 beta mrna expression in splenocyte	[IL-1 beta mRNA expression in splenocytes]	1.0	6	1	0	0
56786	1624	size of the common region	[size of the common region]	1.0	5	1	0	0
56787	1624	characteristic with the transcription factor	[characteristics with the transcription factor]	1.0	5	1	0	0
56788	1624	competitive enzyme-linked immunosorbent assay ELISA	[competitive enzyme-linked immunosorbent assay ELISA]	1.0	5	1	0	0
56789	1624	one consequence of mef2c activation	[One consequence of MEF2C activation]	1.0	5	1	0	0
56790	1624	confirm the involvement of FDC	[confirming the involvement of FDC]	1.0	5	1	0	0
56791	1624	young subject type ii receptor	[young subjects Type II receptors]	1.0	5	1	0	0
56792	1624	hiv lai	[HIV LAI]	1.0	2	1	0	0
56793	1624	specific p38 mapk inhibitor SK&F	[specific p38 MAPk inhibitor SK&F]	1.0	5	1	0	0
56794	1624	macrophage scavenger receptor in macrophage	[macrophage scavenger receptor in macrophages]	1.0	5	1	0	0
56795	1624	Rel/ NF-kappa B family factor	[Rel/ NF-kappa B family factors]	1.0	5	1	0	0
56796	1624	individual domain	[individual domains]	1.0	2	1	0	0
56797	1624	distinct components.	[distinct components.]	1.0	2	1	0	0
56798	1624	post-triggering stage	[post-triggering stage]	1.0	2	1	0	0
56799	1624	Oct-2 a B-cell transcription factor	[Oct-2 a B-cell transcription factor]	1.0	5	1	0	0
56800	1624	well-studied example	[well-studied example]	1.0	2	1	0	0
56801	1624	vitamin e derivative tcp succinate	[vitamin E derivative TCP succinate]	1.0	5	1	0	0
56802	1624	two type of antioxidant molecule	[two types of antioxidant molecules]	1.0	5	1	0	0
56803	1624	immunoglobulin heavy-chain	[immunoglobulin heavy-chain]	1.0	2	2	2	2
56804	1624	phosphorylation of the ikappab cytoplasmic inhibitor	[Phosphorylation of the IkappaB cytoplasmic inhibitors]	1.0	6	1	0	0
56805	1624	inhibitory activity RAR gamma tgase	[inhibitory activity RAR gamma TGase]	1.0	5	1	0	0
56806	1624	role in the transcriptional regulation	[role in the transcriptional regulation]	1.0	5	2	1	1
56807	1624	further insight	[further insight]	1.0	2	4	3	1
56808	1624	tissue-specific mechanism govern the control	[tissue-specific mechanisms governing the control]	1.0	5	1	0	0
56809	1624	dissection of a full range	[dissection of a full range]	1.0	5	1	0	0
56810	1624	thrombin -generate	[thrombin -generating]	1.0	2	2	2	2
56811	1624	single-chain Fv	[single-chain Fv]	1.0	2	2	2	2
56812	1624	majority of the female population	[majority of the female population]	1.0	5	1	0	0
56813	1624	tyrosine phosphorylation of phospholipase Cgamma	[tyrosine phosphorylation of phospholipase Cgamma]	1.0	5	1	0	0
56814	1624	precise sequence	[precise sequence]	1.0	2	1	0	0
56815	1624	inhibitory mechanism	[inhibitory mechanism]	1.0	2	1	0	0
56816	1624	whole cell assay with 3h-dex	[whole cell assay with 3H-Dex]	1.0	5	1	0	0
56817	1624	contact identical to b-cell line	[contacts identical to B-cell lines]	1.0	5	1	0	0
56818	1624	one nuclear factor nf-kappa b (position	[one nuclear factor NF-kappa B (positions]	1.0	6	1	0	0
56819	1624	Lung instillation of tnf-alpha in rat	[Lung instillation of TNF-alpha in rats]	1.0	6	1	0	0
56820	1624	nonimmunocompromised patient	[nonimmunocompromised patients]	1.0	2	1	0	0
56821	1624	Active Stat3	[Active Stat3]	1.0	2	1	0	0
56822	1624	provide evidence of a immune-endocrine interplay	[providing evidence of an immune-endocrine interplay]	1.0	6	1	0	0
56823	1624	phenotypical differentiation	[phenotypical differentiation]	1.0	2	1	0	0
56824	1624	costimulatory molecule,	[costimulatory molecule,]	1.0	2	1	0	0
56825	1624	activity of a nuclear kinase	[activity of a nuclear kinase]	1.0	5	1	0	0
56826	1624	TNF gene expression in monocyte	[TNF gene expression in monocytes]	1.0	5	1	0	0
56827	1624	Tat activity	[Tat activity]	1.0	2	1	0	0
56828	1624	receptor concentration in mononuclear leukocyte	[receptor concentration in mononuclear leukocytes]	1.0	5	2	2	2
56829	1624	innate response	[innate response]	1.0	2	2	2	2
56830	1624	glucocorticoid receptor number during depression	[glucocorticoid receptor numbers during depression]	1.0	5	1	0	0
56831	1624	opioid level	[opioid levels]	1.0	2	1	0	0
56832	1624	(il) -8	[(IL) -8]	1.0	2	1	0	0
56833	1624	PAF up-regulation of HB-EGF mrna	[PAF up-regulation of HB-EGF mRNA]	1.0	5	1	0	0
56834	1624	inclusion of 1 microm RU 38486	[inclusion of 1 microM RU 38486]	1.0	6	1	0	0
56835	1624	vivo effect of liposomal formulation	[vivo effect of liposomal formulation]	1.0	5	1	0	0
56836	1624	finding inconsistent with the model	[finding inconsistent with the models]	1.0	5	1	0	0
56837	1624	intracellular killing	[intracellular killing]	1.0	2	1	0	0
56838	1624	effect on IL-1 gene expression	[effect on IL-1 gene expression]	1.0	5	1	0	0
56839	1624	myelomonoblastic cell	[myelomonoblastic cells]	1.0	2	3	2	1
56840	1624	pre-B lymphocyte	[pre-B lymphocytes]	1.0	2	1	0	0
56841	1624	lack of hla -dq alpha	[lack of HLA -DQ alpha]	1.0	5	1	0	0
56842	1624	250 kb	[250 kb]	1.0	2	1	0	0
56843	1624	system study the link arrest	[system studying the link arrest]	1.0	5	1	0	0
56844	1624	NF-IL6 enhancer	[NF-IL6 enhancer]	1.0	2	1	0	0
56845	1624	receptor for leukocyte chemoattract include chemokine	[Receptors for leukocyte chemoattractants including chemokines]	1.0	6	1	0	0
56846	1624	Negative selection in the cortex	[Negative selection in the cortex]	1.0	5	1	0	0
56847	1624	human antigen-specific T helper clone	[human antigen-specific T helper clones]	1.0	5	1	0	0
56848	1624	aberrant fasL up-regulation in lpr/lpr	[aberrant fasL up-regulation in lpr/lpr]	1.0	5	1	0	0
56849	1624	60-min time	[60-min time]	1.0	2	1	0	0
56850	1624	G28-5 igg	[G28-5 IgG]	1.0	2	1	0	0
56851	1624	K. Arai, Mole Cell. Biol. 8:5581-5587,	[K. Arai, Mol. Cell. Biol. 8:5581-5587,]	1.0	6	1	0	0
56852	1624	position -460	[positions -460]	1.0	2	1	0	0
56853	1624	low level in mature erythrocyte	[lower levels in mature erythrocytes]	1.0	5	1	0	0
56854	1624	Stat4 action	[Stat4 actions]	1.0	2	1	0	0
56855	1624	exhibit rapid change in phosphorylation	[exhibiting rapid changes in phosphorylation]	1.0	5	1	0	0
56856	1624	plasma hormone	[plasma hormones]	1.0	2	1	0	0
56857	1624	deletion construct contain 72 bp	[Deletion constructs containing 72 bp]	1.0	5	1	0	0
56858	1624	lps enhancement of hiv expression	[LPS enhancement of HIV expression]	1.0	5	1	0	0
56859	1624	motif present a strong similarity	[motif presenting a strong similarity]	1.0	5	1	0	0
56860	1624	bp insertion	[bp insertion]	1.0	2	2	2	2
56861	1624	indicate heterogeneity	[indicating heterogeneity]	1.0	2	2	2	2
56862	1624	adherence parameter	[adherence parameter]	1.0	2	1	0	0
56863	1624	structure-function study of the gata-1 protein	[Structure-function studies of the GATA-1 protein]	1.0	6	1	0	0
56864	1624	NK cell for 7 hour	[NK cells for 7 hr]	1.0	5	1	0	0
56865	1624	similar construct	[similar constructs]	1.0	2	2	1	1
56866	1624	alteration of a single serine	[Alteration of a single serine]	1.0	5	1	0	0
56867	1624	induction as a model, experiment	[induction as a model, experiments]	1.0	5	1	0	0
56868	1624	hematopoietic/lymphoid tissue	[hematopoietic/lymphoid tissues]	1.0	2	1	0	0
56869	1624	signal through the lymphotoxin-beta receptor	[Signaling through the lymphotoxin-beta receptor]	1.0	5	1	0	0
56870	1624	human T cell leukemia virus type	[human T cell leukemia virus type]	1.0	6	1	0	0
56871	1624	programme of viral gene expression	[programme of viral gene expression]	1.0	5	1	0	0
56872	1624	jak (i.e. growth hormone receptor	[JAK (i.e. growth hormone receptors]	1.0	5	1	0	0
56873	1624	Biochemical study	[Biochemical studies]	1.0	2	1	0	0
56874	1624	time dependent	[time dependent]	1.0	2	1	0	0
56875	1624	u1a formation	[U1A formation]	1.0	2	1	0	0
56876	1624	subsequent mutagenesis of the L1	[subsequent mutagenesis of the L1]	1.0	5	1	0	0
56877	1624	specificity of a immune response	[specificity of an immune response]	1.0	5	1	0	0
56878	1624	syndrome, tumorigenesis	[syndrome, tumorigenesis]	1.0	2	1	0	0
56879	1624	number most	[number most]	1.0	2	1	0	0
56880	1624	IL-10 release	[IL-10 release]	1.0	2	2	1	1
56881	1624	potential role for c/ebp beta	[potential role for C/EBP beta]	1.0	5	1	0	0
56882	1624	several element in the promoter-proximal region	[several elements in the promoter-proximal region]	1.0	6	1	0	0
56883	1624	cluster algorithm	[clustering algorithm]	1.0	2	1	0	0
56884	1624	cf11/cd18 adhesion receptor on neutrophil	[CD11/CD18 adhesion receptors on neutrophils]	1.0	5	1	0	0
56885	1624	differentiation cell	[differentiation cells]	1.0	2	2	2	2
56886	1624	15-LO promoter	[15-LO promoter]	1.0	2	1	0	0
56887	1624	previous reports,	[previous reports,]	1.0	2	1	0	0
56888	1624	Ehrlichia chaffeensis	[Ehrlichia chaffeensis]	1.0	2	1	0	0
56889	1624	Effect	[Effects]	1.0	1	20	20	2
56890	1624	phenotypic analysis of possible T	[phenotypic analysis of possible T]	1.0	5	1	0	0
56891	1624	substantial affect upon cytokine production	[substantial affect upon cytokine production]	1.0	5	1	0	0
56892	1624	extracellular egta	[extracellular EGTA]	1.0	2	1	0	0
56893	1624	cyclosporin A CsA fk506 factor	[cyclosporin A CsA FK506 factor]	1.0	5	1	0	0
56894	1624	various stage	[various stages]	1.0	2	2	1	1
56895	1624	activation of other PKC subfamily	[activation of other PKC subfamilies]	1.0	5	1	0	0
56896	1624	ras oncogene	[Ras oncogene]	1.0	2	2	1	1
56897	1624	human colon carcinoma cell line	[human colon carcinoma cell lines]	1.0	5	2	1	1
56898	1624	existence of a and/or receptor	[existence of a and/or receptor]	1.0	5	1	0	0
56899	1624	identified: region	[identified: region]	1.0	2	1	0	0
56900	1624	Ca(2+) activator	[Ca(2+) activator]	1.0	2	1	0	0
56901	1624	entire x-box	[entire X-box]	1.0	2	1	0	0
56902	1624	only mnp-2	[only MNP-2]	1.0	2	1	0	0
56903	1624	2.4 nm).	[2.4 nM).]	1.0	2	1	0	0
56904	1624	tr2 orphan	[TR2 orphan]	1.0	2	2	2	2
56905	1624	incubation of APL cell with ifn-gamma	[Incubation of APL cells with IFN-gamma]	1.0	6	1	0	0
56906	1624	only in scm-1-producer T cell line	[only in SCM-1-producer T cell lines]	1.0	6	1	0	0
56907	1624	characterization of a new isoform	[Characterization of a new isoform]	1.0	5	1	0	0
56908	1624	th1 th2 type cytokine respond	[Th1 Th2 type cytokines responding]	1.0	5	1	0	0
56909	1624	simultaneous activation of ig synthesis	[Simultaneous activation of Ig synthesis]	1.0	5	1	0	0
56910	1624	bp a silencer between bp	[bp a silencer between bp]	1.0	5	1	0	0
56911	1624	b lymphoblast	[B lymphoblasts]	1.0	2	2	2	2
56912	1624	basal expression in uninduced cell	[basal expression in uninduced cells]	1.0	5	1	0	0
56913	1624	second patient	[second patient]	1.0	2	3	2	1
56914	1624	v-Fos protein the retroviral counterpart	[v-Fos protein the retroviral counterpart]	1.0	5	1	0	0
56915	1624	t3 -subject	[T3 -subjects]	1.0	2	1	0	0
56916	1624	molecule of peripheral blood T lymphocyte	[molecules of peripheral blood T lymphocytes]	1.0	6	1	0	0
56917	1624	camp -dependent protein kinase inhibitor	[cAMP -dependent protein kinase inhibitor]	1.0	5	1	0	0
56918	1624	bind activity in T cell	[binding activity in T cells]	1.0	5	1	0	0
56919	1624	synthesis of tumor necrosis factor-alpha tnf-alpha	[synthesis of tumor necrosis factor-alpha TNF-alpha]	1.0	6	1	0	0
56920	1624	vitro suppression of cell death	[vitro suppression of cell death]	1.0	5	1	0	0
56921	1624	same kinetics.	[same kinetics.]	1.0	2	1	0	0
56922	1624	(ap-1) binding	[(AP-1) binding]	1.0	2	1	0	0
56923	1624	novel mechanism of gene regulation	[novel mechanism of gene regulation]	1.0	5	2	1	1
56924	1624	strong promoter	[strong promoter]	1.0	2	2	2	2
56925	1624	gas-motif sequence	[GAS-motif sequence]	1.0	2	3	2	1
56926	1624	potential cellular homologue of cyclosporin a	[potential cellular homologues of cyclosporin A]	1.0	6	1	0	0
56927	1624	mechanism a promonocytic cell line	[mechanisms a promonocytic cell line]	1.0	5	1	0	0
56928	1624	expression of pu.1 in nonmyeloid cell	[Expression of PU.1 in nonmyeloid cells]	1.0	6	1	0	0
56929	1624	(kb) upstream of the start site	[(kb) upstream of the start site]	1.0	6	1	0	0
56930	1624	polymorphic nucleotide within the IL-10	[polymorphic nucleotides within the IL-10]	1.0	5	1	0	0
56931	1624	transcript of the ALAS IRE	[transcript of the ALAS IRE]	1.0	5	1	0	0
56932	1624	binding of glucocorticoid to hGR	[Binding of glucocorticoids to hGR]	1.0	5	1	0	0
56933	1624	activation of a NFAT reporter	[activation of a NFAT reporter]	1.0	5	1	0	0
56934	1624	stimulation experiment in the presence	[Stimulation experiments in the presence]	1.0	5	1	0	0
56935	1624	stimulation of ppargamma with troglitazone	[Stimulation of PPARgamma with troglitazone]	1.0	5	1	0	0
56936	1624	position -153	[positions -153]	1.0	2	1	0	0
56937	1624	anti-MHC class	[anti-MHC class]	1.0	2	2	1	1
56938	1624	virtue of gcr binding affinity	[virtue of GCR binding affinities]	1.0	5	1	0	0
56939	1624	gamma- globin	[gamma- globin]	1.0	2	1	0	0
56940	1624	unactivated monocyte	[unactivated monocytes]	1.0	2	1	0	0
56941	1624	recombinant b4-2	[recombinant B4-2]	1.0	2	1	0	0
56942	1624	T cell-specific negative regulation of transcription	[T cell-specific negative regulation of transcription]	1.0	6	1	0	0
56943	1624	contain a asparagine (succinimide) residue	[containing a asparagine (succinimide) residue]	1.0	5	1	0	0
56944	1624	same subunit	[same subunits]	1.0	2	1	0	0
56945	1624	e-selectin expression	[E-selectin expression]	1.0	2	1	0	0
56946	1624	Tat transactivation in t-cell line	[Tat transactivation in T-cell lines]	1.0	5	1	0	0
56947	1624	corresponding gene	[corresponding genes]	1.0	2	1	0	0
56948	1624	long expression	[long-term expression]	1.0	2	2	2	2
56949	1624	CD4 promoter transactivation by human herpesvirus	[CD4 promoter transactivation by human herpesvirus]	1.0	6	1	0	0
56950	1624	TNF gene	[TNF gene]	1.0	2	2	1	1
56951	1624	position -103	[position -103]	1.0	2	1	0	0
56952	1624	appearance of nuclear egr1 protein	[appearance of nuclear EGR1 protein]	1.0	5	1	0	0
56953	1624	pet site	[pets site]	1.0	2	1	0	0
56954	1624	other leukocyte adhesion molecule e-selectin	[other leukocyte adhesion molecules E-selectin]	1.0	5	1	0	0
56955	1624	Acquisition of heat shock factor 2	[Acquisition of heat shock factor 2]	1.0	6	1	0	0
56956	1624	lytic transcript	[lytic transcripts]	1.0	2	2	1	1
56957	1624	homo- stat1 alpha consistent with synergism	[homo- STAT1 alpha consistent with synergism]	1.0	6	1	0	0
56958	1624	PHA-stimulated T	[PHA-stimulated T]	1.0	2	1	0	0
56959	1624	treatment of hpc with alpha-pml	[treatment of HPCs with alpha-PML]	1.0	5	1	0	0
56960	1624	two sites.	[two sites.]	1.0	2	1	0	0
56961	1624	inducible nuclear form of NF-AT	[inducible nuclear form of NF-AT]	1.0	5	1	0	0
56962	1624	intracellular formation	[intracellular formation]	1.0	2	2	2	2
56963	1624	100 degree	[100 degrees]	1.0	2	1	0	0
56964	1624	cyclin e kinase activity within h	[cyclin E kinase activity within h]	1.0	6	1	0	0
56965	1624	suppression of hla-dra mrna expression	[suppression of HLA-DRA mRNA expression]	1.0	5	1	0	0
56966	1624	present study.	[present study.]	1.0	2	1	0	0
56967	1624	3'-flanking sequence	[3'-flanking sequences]	1.0	2	1	0	0
56968	1624	maxillary sinus	[maxillary sinus]	1.0	2	1	0	0
56969	1624	proinflammatory stimulus	[proinflammatory stimuli]	1.0	2	2	1	1
56970	1624	important area.	[important area.]	1.0	2	1	0	0
56971	1624	T cell line from apoptosis	[T cell lines from apoptosis]	1.0	5	1	0	0
56972	1624	ranq69l cytosol	[RanQ69L cytosol]	1.0	2	1	0	0
56973	1624	immortalization of human b lymphocyte	[immortalization of human B lymphocytes]	1.0	5	1	0	0
56974	1624	p50/p65 dimer	[p50/p65 dimers]	1.0	2	1	0	0
56975	1624	negative growth	[negative growth]	1.0	2	1	0	0
56976	1624	activate the transcription of gene	[activating the transcription of genes]	1.0	5	1	0	0
56977	1624	glucocorticoid treatment for 4 weeks.	[glucocorticoid treatment for 4 weeks.]	1.0	5	1	0	0
56978	1624	trypsin digestion	[trypsin digestion]	1.0	2	2	1	1
56979	1624	bzlf1 expression	[BZLF1 expression]	1.0	2	1	0	0
56980	1624	lead to the commitment to death.	[leading to the commitment to death.]	1.0	6	1	0	0
56981	1624	molecular chaperone	[molecular chaperone]	1.0	2	1	0	0
56982	1624	kB site	[kB sites]	1.0	2	1	0	0
56983	1624	expression in mouse hematopoietic tissue	[expression in mouse hematopoietic tissues]	1.0	5	1	0	0
56984	1624	fourth, extensive purification by several cycle	[Fourth, extensive purification by several cycles]	1.0	6	1	0	0
56985	1624	eosinophil life-prolonging effect of hemopoietin	[eosinophil life-prolonging effects of hemopoietins]	1.0	5	1	0	0
56986	1624	main model	[main model]	1.0	2	1	0	0
56987	1624	twelve in-vitro-stimulated normal cord blood	[twelve in-vitro-stimulated normal cord blood]	1.0	5	1	0	0
56988	1624	karyotypic male	[karyotypic males]	1.0	2	1	0	0
56989	1624	hmg i/y	[HMG I/Y]	1.0	2	1	0	0
56990	1624	kappa 3)	[kappa 3)]	1.0	2	1	0	0
56991	1624	cytotoxicity of NK cell granule	[cytotoxicity of NK cell granules]	1.0	5	1	0	0
56992	1624	radixin protein	[radixin proteins]	1.0	2	1	0	0
56993	1624	83% increase in promoter activity	[83% increase in promoter activity]	1.0	5	1	0	0
56994	1624	antigen processing by the epithelium	[antigen processing by the epithelium]	1.0	5	1	0	0
56995	1624	inactivity of the intact x	[inactivity of the intact X]	1.0	5	1	0	0
56996	1624	sr-bp 50-fold	[SR-BP 50-fold]	1.0	2	1	0	0
56997	1624	cDNA probe	[cDNA probe]	1.0	2	1	0	0
56998	1624	increase in Ca2+ pkc isoform	[increase in Ca2+ PKC isoforms]	1.0	5	1	0	0
56999	1624	1 receptor in human mononuclear leukocyte	[1 receptors in human mononuclear leukocytes]	1.0	6	1	0	0
57000	1624	VDR allele	[VDR alleles]	1.0	2	1	0	0
57001	1624	CsA inhibition,	[CsA inhibition,]	1.0	2	1	0	0
57002	1624	4 channel	[4 channels]	1.0	2	1	0	0
57003	1624	specific protein- tre -DNA interaction	[specific protein- TRE -DNA interactions]	1.0	5	1	0	0
57004	1624	transcriptional basis	[transcriptional basis]	1.0	2	1	0	0
57005	1624	reduced:oxidized glutathione	[reduced:oxidized glutathione]	1.0	2	1	0	0
57006	1624	protein sequence against various database	[protein sequences against various databases]	1.0	5	1	0	0
57007	1624	site of one genes, loss	[site of one genes, loss]	1.0	5	1	0	0
57008	1624	binding to a cis-acting element	[binding to an cis-acting element]	1.0	5	2	1	1
57009	1624	regulation of GM-CSF gene transcription	[Regulation of GM-CSF gene transcription]	1.0	5	1	0	0
57010	1624	factor-1 irf-1	[factor-1 IRF-1]	1.0	2	2	2	2
57011	1624	different I kappa b molecule	[different I kappa B molecules]	1.0	5	1	0	0
57012	1624	spirochetal lipopeptide	[spirochetal lipopeptides]	1.0	2	1	0	0
57013	1624	nuclear factor-kappa b NK-kappa b	[nuclear factor-kappa B NK-kappa B]	1.0	5	1	0	0
57014	1624	Costimulatory signals, such as activation	[Costimulatory signals, such as activation]	1.0	5	1	0	0
57015	1624	c-erbA function	[c-erbA function]	1.0	2	1	0	0
57016	1624	alteration affect the NF-kappa b element	[alterations affecting the NF-kappa B element]	1.0	6	1	0	0
57017	1624	human lh-2	[human LH-2]	1.0	2	1	0	0
57018	1624	ii-constitutive b	[II-constitutive B]	1.0	2	1	0	0
57019	1624	tata-like motif	[TATA-like motif]	1.0	2	1	0	0
57020	1624	transcriptional stimulatory activity of CREB	[transcriptional stimulatory activity of CREB]	1.0	5	1	0	0
57021	1624	43-me oligonucleotide	[43-mer oligonucleotide]	1.0	2	1	0	0
57022	1624	four phases.	[four phases.]	1.0	2	1	0	0
57023	1624	response to a cocktail factor	[response to a cocktail factor]	1.0	5	1	0	0
57024	1624	three time per day for 12	[three times per day for 12]	1.0	6	1	0	0
57025	1624	aml1 gene	[AML1 gene]	1.0	2	2	2	2
57026	1624	variety of reporter gene construct	[variety of reporter gene constructs]	1.0	5	1	0	0
57027	1624	hhv-6 from the locus a,	[HHV-6 from the locus A,]	1.0	5	1	0	0
57028	1624	downregulation of p27(kip1 a protein	[downregulation of p27(Kip1 an protein]	1.0	5	1	0	0
57029	1624	blockade of the dna-binding complex	[Blockade of the DNA-binding complexes]	1.0	5	1	0	0
57030	1624	cDNA clone encode tcf-1 alpha	[cDNA clones encoding TCF-1 alpha]	1.0	5	1	0	0
57031	1624	ebv LMP1	[EBV LMP1]	1.0	2	2	2	2
57032	1624	represent different stage of B-cell differentiation	[representing different stages of B-cell differentiation]	1.0	6	1	0	0
57033	1624	present finding	[present findings]	1.0	2	1	0	0
57034	1624	use EMSA	[using EMSA]	1.0	2	1	0	0
57035	1624	stability of the protein complex	[stability of the protein complex]	1.0	5	1	0	0
57036	1624	hiv-infected individual	[HIV-infected individual]	1.0	2	1	0	0
57037	1624	protein membrane	[protein membrane]	1.0	2	1	0	0
57038	1624	fcs+ culture	[FCS+ culture]	1.0	2	1	0	0
57039	1624	CIF block at the level	[CIF blocks at the level]	1.0	5	1	0	0
57040	1624	single cases.	[single cases.]	1.0	2	1	0	0
57041	1624	mitogenic stimuli.	[mitogenic stimuli.]	1.0	2	1	0	0
57042	1624	monocyte of aids -gr patient	[Monocytes of AIDS -GR patients]	1.0	5	1	0	0
57043	1624	two leucine domain LCD motif	[two leucine domains LCD motifs]	1.0	5	1	0	0
57044	1624	antiapoptotic molecule	[antiapoptotic molecule]	1.0	2	2	1	1
57045	1624	genetic diversity	[genetic diversity]	1.0	2	1	0	0
57046	1624	medical treatment	[medical treatments]	1.0	2	1	0	0
57047	1624	nuclear level.	[nuclear level.]	1.0	2	1	0	0
57048	1624	high-level transcription	[high-level transcription]	1.0	2	2	1	1
57049	1624	two kox zinc finger gene	[two KOX zinc finger genes]	1.0	5	1	0	0
57050	1624	position -206	[positions -206]	1.0	2	1	0	0
57051	1624	granulocytic hpc	[granulocytic HPCs]	1.0	2	1	0	0
57052	1624	binding of transcription factor with tre-1	[binding of transcription factors with TRE-1]	1.0	6	1	0	0
57053	1624	heptamer site	[heptamer sites]	1.0	2	1	0	0
57054	1624	simple model	[simplest model]	1.0	2	1	0	0
57055	1624	differentiation/activation stimulus allow nf-kb expression	[differentiation/activation stimuli allowing NF-KB expression]	1.0	5	1	0	0
57056	1624	human GATA-3	[human GATA-3]	1.0	2	1	0	0
57057	1624	result of lack of oxygen	[result of lacking of oxygen]	1.0	5	1	0	0
57058	1624	il-2 -dependent T cell proliferation	[IL-2 -dependent T cell proliferation]	1.0	5	1	0	0
57059	1624	autocrine action of cytokine tnf	[autocrine action of cytokines TNF]	1.0	5	1	0	0
57060	1624	TNF-alpha- mrna	[TNF-alpha- mRNA]	1.0	2	1	0	0
57061	1624	hormonal parameter	[hormonal parameters]	1.0	2	1	0	0
57062	1624	Tpl-2 kinase	[Tpl-2 kinase]	1.0	2	1	0	0
57063	1624	However, NAC	[However, NAC]	1.0	2	1	0	0
57064	1624	inflammation of the vessel wall	[inflammation of the vessel wall]	1.0	5	1	0	0
57065	1624	IL-2 gene transcription in T cell	[IL-2 gene transcription in T cells]	1.0	6	1	0	0
57066	1624	suggest independent of PGE2 formation	[suggesting independent of PGE2 formation]	1.0	5	1	0	0
57067	1624	multiple member of the gata-binding protein	[multiple members of the GATA-binding proteins]	1.0	6	1	0	0
57068	1624	regulatory cytokine	[regulatory cytokine]	1.0	2	2	2	2
57069	1624	multiple stat protein include stat5a	[multiple STAT proteins including STAT5a]	1.0	5	1	0	0
57070	1624	growth-stimulatet property	[growth-stimulating properties]	1.0	2	1	0	0
57071	1624	maximal effect	[maximal effect]	1.0	2	1	0	0
57072	1624	cytotoxic granule	[cytotoxic granules]	1.0	2	1	0	0
57073	1624	stat1 beta	[Stat1 beta]	1.0	2	1	0	0
57074	1624	several inducer	[several inducers]	1.0	2	1	0	0
57075	1624	cytokine utilize this transcription factor	[cytokines utilizing these transcription factors]	1.0	5	1	0	0
57076	1624	local adjacent augmentative cis element	[local adjacent augmentative cis elements]	1.0	5	1	0	0
57077	1624	ductal cell	[Ductal cells]	1.0	2	1	0	0
57078	1624	Epstein-Barr virus oncogene product latent	[Epstein-Barr virus oncogene product latent]	1.0	5	1	0	0
57079	1624	ubiquitous otf-1	[ubiquitous OTF-1]	1.0	2	1	0	0
57080	1624	inhibitor, I kappa b alpha	[inhibitor, I kappa B alpha]	1.0	5	1	0	0
57081	1624	moment, however,	[moment, however,]	1.0	2	1	0	0
57082	1624	lead to T lymphocyte activation	[leading to T lymphocyte activation]	1.0	5	1	0	0
57083	1624	early times.	[early times.]	1.0	2	1	0	0
57084	1624	hypothesis dependent	[hypothesis dependent]	1.0	2	1	0	0
57085	1624	somatic mutation	[somatic mutations]	1.0	2	2	2	2
57086	1624	synergistic effect on growth inhibition	[synergistic effect on growth inhibition]	1.0	5	1	0	0
57087	1624	fc3 plasmid	[FC3 plasmid]	1.0	2	1	0	0
57088	1624	IL-5 production	[IL-5 production]	1.0	2	1	0	0
57089	1624	52-year-old female	[52-year-old female]	1.0	2	1	0	0
57090	1624	exon:intron structure	[exon:intron structure]	1.0	2	2	1	1
57091	1624	significance of the present study	[significance of the present study]	1.0	5	1	0	0
57092	1624	inactive state	[inactive state]	1.0	2	2	1	1
57093	1624	synergistic interaction	[Synergistic interactions]	1.0	2	2	1	1
57094	1624	24 h stimulation with concanavalin	[24 h stimulation with concanavalin]	1.0	5	1	0	0
57095	1624	second signal,	[second signal,]	1.0	2	1	0	0
57096	1624	encode a protein with a mass	[encoding a protein with an mass]	1.0	6	1	0	0
57097	1624	similar phenomenon	[similar phenomenon]	1.0	2	1	0	0
57098	1624	transgenic mouse display erythroid-specific expression	[transgenic mice displaying erythroid-specific expression]	1.0	5	1	0	0
57099	1624	a transcript	[A transcripts]	1.0	2	2	1	1
57100	1624	inhibition of stat3 tyrosine phosphorylation	[inhibition of STAT3 tyrosine phosphorylation]	1.0	5	1	0	0
57101	1624	1) inhibition through adenosine triphosphate depletion	[1) inhibition through adenosine triphosphate depletion]	1.0	6	1	0	0
57102	1624	control vascular-specific expression of PECAM-1	[controlling vascular-specific expression of PECAM-1]	1.0	5	1	0	0
57103	1624	experimental expression	[Experimental expression]	1.0	2	2	1	1
57104	1624	HS IV-VII	[HS IV-VII]	1.0	2	1	0	0
57105	1624	steroid-responsive gene	[steroid-responsive genes]	1.0	2	1	0	0
57106	1624	src-related proto-oncogent	[SRC-related proto-oncogenes]	1.0	2	1	0	0
57107	1624	activation of a protein tyrosine kinase	[activation of a protein tyrosine kinase]	1.0	6	1	0	0
57108	1624	IL4R alpha	[IL4R alpha]	1.0	2	1	0	0
57109	1624	10 cold	[10 cold]	1.0	2	1	0	0
57110	1624	mature erythrocyte	[mature erythrocytes]	1.0	2	2	1	1
57111	1624	important component in the progression	[important component in the progression]	1.0	5	1	0	0
57112	1624	500-bp fragment encompass this site	[500-bp fragment encompassing this site]	1.0	5	1	0	0
57113	1624	resection margins: tumor with mcr	[resection margins: tumors with MCR]	1.0	5	1	0	0
57114	1624	TCL1 oncogene on human chromosome	[TCL1 oncogene on human chromosome]	1.0	5	1	0	0
57115	1624	protein vital to cell growth	[protein vital to cell growth]	1.0	5	1	0	0
57116	1624	DNase footprinting	[DNase footprinting]	1.0	2	1	0	0
57117	1624	overexpression of a v14rho construct incapable	[Overexpression of a V14Rho construct incapable]	1.0	6	1	0	0
57118	1624	bcr -cross-linking	[BCR -cross-linking]	1.0	2	1	0	0
57119	1624	ets-related gene	[ets-related genes]	1.0	2	1	0	0
57120	1624	three kinase	[three kinases]	1.0	2	1	0	0
57121	1624	p100 function	[p100 functions]	1.0	2	1	0	0
57122	1624	il-12 receptor	[IL-12 receptor]	1.0	2	1	0	0
57123	1624	J393/ CD43	[J393/ CD43]	1.0	2	1	0	0
57124	1624	DNA binding activity in cyclosporin b	[DNA binding activity in cyclosporin B]	1.0	6	1	0	0
57125	1624	multiple copy of the binding site	[multiple copies of the binding sites]	1.0	6	1	0	0
57126	1624	cellular distribution of fitc- lps	[cellular distribution of FITC- LPS]	1.0	5	1	0	0
57127	1624	inducible nfkappab	[inducible NFkappaB]	1.0	2	1	0	0
57128	1624	dansylcadaverine a potent enzyme inhibitor	[dansylcadaverine a potent enzyme inhibitor]	1.0	5	1	0	0
57129	1624	IL-10 inhibition of icam-1 expression	[IL-10 inhibition of ICAM-1 expression]	1.0	5	1	0	0
57130	1624	Pan protein in cell formation	[Pan proteins in cell formation]	1.0	5	1	0	0
57131	1624	stably express the tax protein	[stably expressing the Tax protein]	1.0	5	1	0	0
57132	1624	cytokine gene transcription in monocyte	[cytokine gene transcription in monocytes]	1.0	5	1	0	0
57133	1624	nwp cell	[NWP cells]	1.0	2	1	0	0
57134	1624	inhibition of b104 cell growth	[inhibition of B104 cell growth]	1.0	5	1	0	0
57135	1624	other cells; ubiquitously active factor	[other cells; ubiquitously active factors]	1.0	5	1	0	0
57136	1624	blood of type of skin	[blood of types of skin]	1.0	5	1	0	0
57137	1624	CCK(B) receptor	[CCK(B) receptors]	1.0	2	1	0	0
57138	1624	U2 formation	[U2 formation]	1.0	2	1	0	0
57139	1624	protein dimerization	[protein dimerization]	1.0	2	2	1	1
57140	1624	Adherence-isolated monocyte	[Adherence-isolated monocytes]	1.0	2	1	0	0
57141	1624	animal experiment	[animal experiment]	1.0	2	1	0	0
57142	1624	d1/cdr2-loop ligand	[D1/CDR2-loop ligands]	1.0	2	1	0	0
57143	1624	expression construct in lymphoblastoid cell	[expression constructs in lymphoblastoid cells]	1.0	5	1	0	0
57144	1624	exhibit property of early stage cell	[exhibiting properties of early stage cells]	1.0	6	1	0	0
57145	1624	indicate molecular heterogeneity within fetal muscle	[indicating molecular heterogeneity within fetal muscle]	1.0	6	1	0	0
57146	1624	translocation case	[translocation cases]	1.0	2	2	2	2
57147	1624	indirect manner.	[indirect manner.]	1.0	2	1	0	0
57148	1624	ductal compartment	[ductal compartments]	1.0	2	1	0	0
57149	1624	use fluorescence	[Using fluorescence]	1.0	2	2	1	1
57150	1624	HeLa cell from b cell	[HeLa cells from B cells]	1.0	5	1	0	0
57151	1624	negative cross-talk with the calcineurin-	[negative cross-talk with the calcineurin-]	1.0	5	1	0	0
57152	1624	human b-cell transcription factor Oct-2	[human B-cell transcription factor Oct-2]	1.0	5	1	0	0
57153	1624	affect synthesis of the nuclear subunit	[affecting synthesis of the nuclear subunit]	1.0	6	1	0	0
57154	1624	result in the generation of cytokine	[resulting in the generation of cytokines]	1.0	6	1	0	0
57155	1624	prevent degradation	[preventing degradation]	1.0	2	1	0	0
57156	1624	cell volume,	[cell volume,]	1.0	2	1	0	0
57157	1624	HSF activation	[HSF activation]	1.0	2	1	0	0
57158	1624	induction of tyrosine phosphorylation a inhibitor	[Induction of tyrosine phosphorylation an inhibitor]	1.0	6	1	0	0
57159	1624	normal level of lymphocytic aldosterone receptor	[normal level of lymphocytic aldosterone receptors]	1.0	6	1	0	0
57160	1624	implication for the stringent control	[implications for the stringent control]	1.0	5	1	0	0
57161	1624	COS-1 cell co-express the human il-10r	[COS-1 cells co-expressing the human IL-10R]	1.0	6	1	0	0
57162	1624	lead to factor kappa b activation	[leading to factor kappa B activation]	1.0	6	1	0	0
57163	1624	interaction between the class ii transactivator	[Interactions between the class II transactivator]	1.0	6	1	0	0
57164	1624	peroxisome receptor-alpha PPARalpha a member	[Peroxisome receptor-alpha PPARalpha a member]	1.0	5	1	0	0
57165	1624	employ a derivative e box	[employing a derivative E box]	1.0	5	1	0	0
57166	1624	Epstein-Barr virus replicative gene transcription	[Epstein-Barr virus replicative gene transcription]	1.0	5	1	0	0
57167	1624	clinical features.	[clinical features.]	1.0	2	1	0	0
57168	1624	ability of promonocytic thp-1 cell	[ability of promonocytic THP-1 cells]	1.0	5	1	0	0
57169	1624	alpha-helix 3	[alpha-helix 3]	1.0	2	1	0	0
57170	1624	pcr analysis	[PCR analysis]	1.0	2	2	1	1
57171	1624	investigation of the tcr beta gene	[investigation of the TCR beta gene]	1.0	6	1	0	0
57172	1624	underlying mechanism for disease expression	[underlying mechanism for disease expression]	1.0	5	1	0	0
57173	1624	photoaffinity labeling of plasma membrane receptor	[Photoaffinity labeling of plasma membrane receptors]	1.0	6	1	0	0
57174	1624	+/- 44	[+/- 44]	1.0	2	1	0	0
57175	1624	mechanism similar to cell gene	[mechanisms similar to cell genes]	1.0	5	1	0	0
57176	1624	sites, include a NF-kappa b element	[sites, including a NF-kappa B element]	1.0	6	1	0	0
57177	1624	target study	[targeting studies]	1.0	2	1	0	0
57178	1624	cytosol fraction	[cytosol fractions]	1.0	2	1	0	0
57179	1624	Finally, transfection of creb protein	[Finally, transfection of CREB protein]	1.0	5	1	0	0
57180	1624	beta-chemokine family	[beta-chemokine family]	1.0	2	1	0	0
57181	1624	expression with lipopolysaccharide viral production	[expression with lipopolysaccharide viral production]	1.0	5	1	0	0
57182	1624	finding consistent	[finding consistent]	1.0	2	2	2	2
57183	1624	healthy man	[healthy men]	1.0	2	2	2	2
57184	1624	quantitative determination	[quantitative determination]	1.0	2	1	0	0
57185	1624	Functional analysis of the promoter	[Functional analysis of the promoter]	1.0	5	2	1	1
57186	1624	pth cell	[pTh cells]	1.0	2	2	2	2
57187	1624	IL-15	[IL-15]	1.0	1	10	0	0
57188	1624	increase in the expression rna	[increases in the expression RNAs]	1.0	5	1	0	0
57189	1624	early transcriptional regulation of TNF	[early transcriptional regulation of TNF]	1.0	5	1	0	0
57190	1624	Jiang, L.Szekely, V.Wendel-Hansen, N.Ringertz, G.Klein,	[Jiang, L.Szekely, V.Wendel-Hansen, N.Ringertz, G.Klein,]	1.0	5	1	0	0
57191	1624	direct assay of pkc activity	[Direct assays of PKC activity]	1.0	5	1	0	0
57192	1624	th2-specific complex	[Th2-specific complexes]	1.0	2	1	0	0
57193	1624	activity of nf-kappa b/rel activity	[activity of NF-kappa B/Rel activity]	1.0	5	1	0	0
57194	1624	immunofluorescence study use a ab	[Immunofluorescence studies using an Ab]	1.0	5	1	0	0
57195	1624	difference in redox sensitivity, allow	[differences in redox sensitivity, allowing]	1.0	5	1	0	0
57196	1624	restriction mapping	[Restriction mapping]	1.0	2	1	0	0
57197	1624	nuclear nfkappab	[nuclear NFkappaB]	1.0	2	1	0	0
57198	1624	Ca(2+) -independent	[Ca(2+) -independent]	1.0	2	1	0	0
57199	1624	hybrid promoter	[hybrid promoter]	1.0	2	2	2	2
57200	1624	form of hsp27 by immunoprecipitation study	[forms of HSP27 by immunoprecipitation studies]	1.0	6	1	0	0
57201	1624	translocation of a nfat component	[translocation of an NFAT component]	1.0	5	1	0	0
57202	1624	aging: evidence for ikappab-alpha phosphorylation	[aging: evidence for IkappaB-alpha phosphorylation]	1.0	5	1	0	0
57203	1624	truncation of the beta globin promoter	[Truncation of the beta globin promoter]	1.0	6	1	0	0
57204	1624	transcriptional regulation of adhesion molecule	[transcriptional regulation of adhesion molecules]	1.0	5	1	0	0
57205	1624	14q32.1 region	[14q32.1 regions]	1.0	2	1	0	0
57206	1624	functional stimulation of human monocyte	[functional stimulation of human monocytes]	1.0	5	1	0	0
57207	1624	murine sequence	[murine sequence]	1.0	2	1	0	0
57208	1624	premenopausal patient with neither risk factor	[Premenopausal patients with neither risk factor]	1.0	6	1	0	0
57209	1624	ELAM mRNA	[ELAM mRNA]	1.0	2	1	0	0
57210	1624	product of the c-fm protooncogene	[product of the c-fms protooncogene]	1.0	5	1	0	0
57211	1624	substitution mutation in this consensus sequence	[Substitution mutations in this consensus sequence]	1.0	6	1	0	0
57212	1624	Gerald Crabtree	[Gerald Crabtree]	1.0	2	1	0	0
57213	1624	culminate in activation of cholesterol synthesis	[culminating in activation of cholesterol synthesis]	1.0	6	1	0	0
57214	1624	zinc finger transcription factor GATA-1	[zinc finger transcription factor GATA-1]	1.0	5	1	0	0
57215	1624	least 130 kb from sox9	[least 130 kb from SOX9]	1.0	5	1	0	0
57216	1624	intermediate stage	[intermediate stage]	1.0	2	2	2	2
57217	1624	change in pkc isoform in macrophage	[Changes in PKC isoforms in macrophages]	1.0	6	1	0	0
57218	1624	logarithmic growth	[logarithmic growth]	1.0	2	1	0	0
57219	1624	clinical stage.	[clinical stage.]	1.0	2	1	0	0
57220	1624	basophilic granulocyte	[basophilic granulocytes]	1.0	2	1	0	0
57221	1624	16HBE human bronchial epithelial cell	[16HBE human bronchial epithelial cells]	1.0	5	1	0	0
57222	1624	DNA repair enzyme uracil-DNA glycosylase udg	[DNA repair enzyme uracil-DNA glycosylase UDG]	1.0	6	1	0	0
57223	1624	recognition site	[recognition site]	1.0	2	2	1	1
57224	1624	compensate for difference in tcr affinity	[compensating for differences in TCR affinities]	1.0	6	1	0	0
57225	1624	drug available	[drugs available]	1.0	2	1	0	0
57226	1624	important mediator of tip function	[important mediator of Tip function]	1.0	5	1	0	0
57227	1624	erythroid-expressed gene	[erythroid-expressed genes]	1.0	2	1	0	0
57228	1624	thus exclude skewedness of random x-inactivation	[thus excluding skewedness of random X-inactivation]	1.0	6	1	0	0
57229	1624	second translocation adjacent to rhombotin	[second translocation adjacent to rhombotin]	1.0	5	1	0	0
57230	1624	second, in contrast to recent result	[Second, in contrast to recent results]	1.0	6	1	0	0
57231	1624	2 case	[2 cases]	1.0	2	1	0	0
57232	1624	rhu tnfr:fc	[rhu TNFR:Fc]	1.0	2	2	2	2
57233	1624	hypotonic buffer	[hypotonic buffer]	1.0	2	1	0	0
57234	1624	single-chain protein	[single-chain protein]	1.0	2	1	0	0
57235	1624	56 bp	[56 bp]	1.0	2	1	0	0
57236	1624	gene expression in jurkat cell	[gene expression in Jurkat cells]	1.0	5	1	0	0
57237	1624	24 healthy pregnant woman (11	[24 healthy pregnant women (11]	1.0	5	1	0	0
57238	1624	differentiation potential of normal myeloid cell	[differentiation potential of normal myeloid cells]	1.0	6	1	0	0
57239	1624	HIV-2 enhancer	[HIV-2 enhancer]	1.0	2	2	1	1
57240	1624	two-hybrid system	[two-hybrid system]	1.0	2	1	0	0
57241	1624	cd36 gene	[CD36 gene]	1.0	2	2	1	1
57242	1624	specifically on the NF-kappa B/Rel activation	[specifically on the NF-kappa B/Rel activation]	1.0	6	1	0	0
57243	1624	apoptosis sensitivity	[apoptosis sensitivity]	1.0	2	2	1	1
57244	1624	suppress gabp binding to the DSE	[suppressing GABP binding to the DSE]	1.0	6	1	0	0
57245	1624	experiment utilize the steroid antagonist	[experiments utilizing the steroid antagonist]	1.0	5	1	0	0
57246	1624	IFN induction of cytolytic resistance	[IFN induction of cytolytic resistance]	1.0	5	1	0	0
57247	1624	transform growth factor (tgf)-beta1 responsiveness	[transforming growth factor (TGF)-beta1 responsiveness]	1.0	5	1	0	0
57248	1624	21 different emcv ires fragment	[21 different EMCV IRES fragments]	1.0	5	1	0	0
57249	1624	costimulation for cytokine secretion in response	[costimulation for cytokine secretion in response]	1.0	6	1	0	0
57250	1624	mitogenesis production	[mitogenesis production]	1.0	2	1	0	0
57251	1624	Glucocorticoid receptor in systemic lupus erythematosus	[Glucocorticoid receptors in systemic lupus erythematosus]	1.0	6	1	0	0
57252	1624	protein, p37,	[protein, p37,]	1.0	2	1	0	0
57253	1624	reverse transcription polymerase chain reaction	[reverse transcription polymerase chain reaction]	1.0	5	2	1	1
57254	1624	81 bp	[81 bp]	1.0	2	1	0	0
57255	1624	different concentration of two ald	[different concentrations of two ALD]	1.0	5	1	0	0
57256	1624	transform growth factor-beta promoter polymorphism	[transforming growth factor-beta promoter polymorphisms]	1.0	5	1	0	0
57257	1624	anti-thrombotic effect	[anti-thrombotic effects]	1.0	2	1	0	0
57258	1624	two groups.	[two groups.]	1.0	2	1	0	0
57259	1624	stimulation of hiv replication in phagocyte	[Stimulation of HIV replication in phagocytes]	1.0	6	1	0	0
57260	1624	use Burkitt' lymphoma b cell line	[using Burkitt's lymphoma B cell lines]	1.0	6	1	0	0
57261	1624	mutagenized promoter	[mutagenized promoters]	1.0	2	1	0	0
57262	1624	nuclear factor of T cell NFATp	[nuclear factor of T cells NFATp]	1.0	6	1	0	0
57263	1624	expression of latent membrane protein-1	[expression of latent membrane protein-1]	1.0	5	1	0	0
57264	1624	pathogenic role	[pathogenic role]	1.0	2	2	1	1
57265	1624	just upstream of a NF-AT site	[just upstream of an NF-AT site]	1.0	6	1	0	0
57266	1624	distinct exon	[distinct exons]	1.0	2	1	0	0
57267	1624	resistance to certain infectious disease	[resistance to certain infectious diseases]	1.0	5	1	0	0
57268	1624	second oligonucleotide	[second oligonucleotide]	1.0	2	1	0	0
57269	1624	new probe of this region,	[new probes of this region,]	1.0	5	1	0	0
57270	1624	bipotential precursor	[bipotential precursors]	1.0	2	1	0	0
57271	1624	breast tissue	[Breast tissue]	1.0	2	2	1	1
57272	1624	spontaneous lymphoblastoid cell line LCL	[spontaneous lymphoblastoid cell lines LCL]	1.0	5	1	0	0
57273	1624	xscid phenotype	[XSCID phenotype]	1.0	2	1	0	0
57274	1624	retinoid differentiation therapy in promyelocytic leukemia	[Retinoid differentiation therapy in promyelocytic leukemia]	1.0	6	1	0	0
57275	1624	stat3 proteins.	[STAT3 proteins.]	1.0	2	1	0	0
57276	1624	induction with the response gene	[induction with the response genes]	1.0	5	1	0	0
57277	1624	useful target in the development	[useful target in the development]	1.0	5	1	0	0
57278	1624	novel sequence	[novel sequence]	1.0	2	1	0	0
57279	1624	normal peripheral blood b lymphocyte	[normal peripheral blood B lymphocytes]	1.0	5	1	0	0
57280	1624	ar mrna	[AR mRNA]	1.0	2	1	0	0
57281	1624	IL-1beta /CAT	[IL-1beta /CAT]	1.0	2	1	0	0
57282	1624	Rap1 protein	[Rap1 protein]	1.0	2	1	0	0
57283	1624	only to the single site	[only to the single site]	1.0	5	1	0	0
57284	1624	non- t-cell	[non- T-cells]	1.0	2	1	0	0
57285	1624	NDP kinase expression between SCC	[NDP kinase expression between SCC]	1.0	5	1	0	0
57286	1624	allow for differential gene expression	[allowing for differential gene expression]	1.0	5	1	0	0
57287	1624	gasd element	[GASd element]	1.0	2	2	2	2
57288	1624	overlapping palindrome	[overlapping palindromes]	1.0	2	1	0	0
57289	1624	immunosuppressive property	[immunosuppressive property]	1.0	2	2	1	1
57290	1624	DQB X2-box	[DQB X2-box]	1.0	2	1	0	0
57291	1624	type IL-1R	[type IL-1R]	1.0	2	2	2	2
57292	1624	genital tract infection with G. vaginalis	[genital tract infection with G. vaginalis]	1.0	6	1	0	0
57293	1624	distribution of the receptor e-selectin	[distribution of the receptors E-selectin]	1.0	5	1	0	0
57294	1624	nodal involvement	[nodal involvement]	1.0	2	1	0	0
57295	1624	stability of the T allele	[stability of the T allele]	1.0	5	1	0	0
57296	1624	addition Spi-B	[addition Spi-B]	1.0	2	1	0	0
57297	1624	low-molecular-weight chemokine	[low-molecular-weight chemokines]	1.0	2	1	0	0
57298	1624	renal inflammation	[renal inflammation]	1.0	2	1	0	0
57299	1624	hormone receptor of the tumor	[hormone receptors of the tumor]	1.0	5	1	0	0
57300	1624	antigen to T cell receptor tcr	[antigen to T cell receptors TCRs]	1.0	6	1	0	0
57301	1624	FACS analysis	[FACS analysis]	1.0	2	1	0	0
57302	1624	3-kinase pi3-k	[3-kinase PI3-K]	1.0	2	1	0	0
57303	1624	promoter activity.	[promoter activity.]	1.0	2	1	0	0
57304	1624	promoter activity,	[promoter activity,]	1.0	2	2	2	2
57305	1624	positional effect	[positional effects]	1.0	2	2	2	2
57306	1624	direct inhibition of the gene transcription	[direct inhibition of the gene transcription]	1.0	6	1	0	0
57307	1624	MAD-3 cDNA	[MAD-3 cDNA]	1.0	2	1	0	0
57308	1624	large palindromic sequence in each	[larger palindromic sequences in each]	1.0	5	1	0	0
57309	1624	early initiation	[early initiation]	1.0	2	1	0	0
57310	1624	indicate a important determinant of expression	[indicating an important determinant of expression]	1.0	6	1	0	0
57311	1624	subunit of the 26s protease	[subunit of the 26S protease]	1.0	5	1	0	0
57312	1624	endothelial and/or	[endothelial and/or]	1.0	2	1	0	0
57313	1624	h-7-sensitive pathway	[H-7-sensitive pathways]	1.0	2	1	0	0
57314	1624	patient with various inflammatory disease	[patients with various inflammatory diseases]	1.0	5	1	0	0
57315	1624	relative decrease in the expression	[relative decrease in the expression]	1.0	5	1	0	0
57316	1624	1-kb fragment	[1-kb fragment]	1.0	2	2	1	1
57317	1624	use a -biotin peroxidase detection system	[Using an -biotin peroxidase detection system]	1.0	6	1	0	0
57318	1624	myeloid differentiation.	[myeloid differentiation.]	1.0	2	1	0	0
57319	1624	senescent human T lymphocyte culture	[Senescent human T lymphocyte cultures]	1.0	5	1	0	0
57320	1624	preleukemic state	[preleukemic state]	1.0	2	2	1	1
57321	1624	circadian variation	[circadian variation]	1.0	2	3	2	1
57322	1624	lack the transcription factor look.	[lacking the transcription factor look.]	1.0	5	1	0	0
57323	1624	only expression	[only expression]	1.0	2	2	2	2
57324	1624	normal program	[normal program]	1.0	2	1	0	0
57325	1624	function.	[function.]	1.0	1	11	5	5
57326	1624	regulation of the tissue factor gene	[Regulation of the tissue factor gene]	1.0	6	1	0	0
57327	1624	(25%) other autoimmune disease subject	[(25%) other autoimmune disease subjects]	1.0	5	1	0	0
57328	1624	AES protein	[AES proteins]	1.0	2	1	0	0
57329	1624	functional unresponsiveness	[functional unresponsiveness]	1.0	2	1	0	0
57330	1624	IL-10 treatment of T cell	[IL-10 treatment of T cells]	1.0	5	1	0	0
57331	1624	HTLV-I -bear	[HTLV-I -bearing]	1.0	2	2	2	2
57332	1624	mutation analysis of the VCAM-1 promoter	[mutation analyses of the VCAM-1 promoter]	1.0	6	1	0	0
57333	1624	nuclei of CD40-stimulated b cell	[nuclei of CD40-stimulated B cells]	1.0	5	1	0	0
57334	1624	T antigen	[T antigen]	1.0	2	2	2	2
57335	1624	binding site for the Ets family	[binding sites for the Ets family]	1.0	6	2	2	2
57336	1624	factor with gene silencing activity	[factor with gene silencing activity]	1.0	5	1	0	0
57337	1624	standard treatment of acute attack	[standard treatment of acute attacks]	1.0	5	1	0	0
57338	1624	cysteine protease	[cysteine proteases]	1.0	2	1	0	0
57339	1624	exogenous pge2	[exogenous PGE2]	1.0	2	1	0	0
57340	1624	diffuse one	[diffuse one]	1.0	2	1	0	0
57341	1624	egr2 mrna	[EGR2 mRNA]	1.0	2	1	0	0
57342	1624	herbimycin A a tyrosine kinase inhibitor	[herbimycin A a tyrosine kinase inhibitor]	1.0	6	1	0	0
57343	1624	myeloid leukaemia	[myeloid leukaemia]	1.0	2	2	2	2
57344	1624	immunological defect	[immunological defects]	1.0	2	1	0	0
57345	1624	low level of il-8 secretion	[low levels of IL-8 secretion]	1.0	5	1	0	0
57346	1624	Latent membrane protein (lmp) 2a mrna	[Latent membrane protein (LMP) 2A mRNA]	1.0	6	1	0	0
57347	1624	2-5 fold	[2-5 fold]	1.0	2	1	0	0
57348	1624	different assays.	[different assays.]	1.0	2	1	0	0
57349	1624	inhibition of hiv-1 latency reactivation	[Inhibition of HIV-1 latency reactivation]	1.0	5	1	0	0
57350	1624	1e8 cell	[1E8 cells]	1.0	2	2	1	1
57351	1624	B4-2 clone	[B4-2 clone]	1.0	2	1	0	0
57352	1624	truncate mutation in the brca2	[truncating mutations in the BRCA2]	1.0	5	1	0	0
57353	1624	nuclear translocation of mitogen-activated protein kinase	[nuclear translocation of mitogen-activated protein kinase]	1.0	6	1	0	0
57354	1624	same agent	[same agents]	1.0	2	1	0	0
57355	1624	function for cytosolic phospholipase a2	[function for cytosolic phospholipase A2]	1.0	5	1	0	0
57356	1624	calmodulin binding	[calmodulin binding]	1.0	2	1	0	0
57357	1624	mechanism for C5a il-8 production	[mechanisms for C5a IL-8 production]	1.0	5	1	0	0
57358	1624	apparent chromosome	[apparent chromosome]	1.0	2	1	0	0
57359	1624	monoblastic leukemia	[monoblastic leukemia]	1.0	2	1	0	0
57360	1624	full-length c-rel	[full-length c-rel]	1.0	2	1	0	0
57361	1624	Thus, GATA-3	[Thus, GATA-3]	1.0	2	1	0	0
57362	1624	Thus, GATA-1	[Thus, GATA-1]	1.0	2	1	0	0
57363	1624	complex model of the regulation	[complex model of the regulation]	1.0	5	1	0	0
57364	1624	two receptor	[two receptors]	1.0	2	1	0	0
57365	1624	focus attention on the determinant	[focusing attention on the determinants]	1.0	5	1	0	0
57366	1624	72 P; in addition, protein	[72 h; in addition, protein]	1.0	5	1	0	0
57367	1624	Potent gene	[Potent gene]	1.0	2	1	0	0
57368	1624	egr-1 protein	[EGR-1 protein]	1.0	2	2	2	2
57369	1624	other class	[other class]	1.0	2	1	0	0
57370	1624	inactivation of the protein tyrosine kinase	[inactivation of the protein tyrosine kinase]	1.0	6	1	0	0
57371	1624	transcription of the lacz gene	[transcription of the lacZ gene]	1.0	5	1	0	0
57372	1624	NF-kappa b activation by TNF alpha	[NF-kappa B activation by TNF alpha]	1.0	6	1	0	0
57373	1624	use hiv-1(bal)	[using HIV-1(BaL)]	1.0	2	1	0	0
57374	1624	treatment with 1 microm dexamethasone	[treatment with 1 microM dexamethasone]	1.0	5	1	0	0
57375	1624	Pan expression of Pan protein	[Pan expression of Pan proteins]	1.0	5	1	0	0
57376	1624	conferr il-2 responsiveness to a promoter	[conferring IL-2 responsiveness to a promoter]	1.0	6	1	0	0
57377	1624	5 protein binding region br	[5 protein binding regions BRs]	1.0	5	1	0	0
57378	1624	mouse lack a transcription factor	[mice lacking a transcription factor]	1.0	5	1	0	0
57379	1624	senescent T cell the ability	[senescent T cells the ability]	1.0	5	1	0	0
57380	1624	nfkappab translocation	[NFkappaB translocation]	1.0	2	1	0	0
57381	1624	physiological regulator	[physiological regulator]	1.0	2	2	2	2
57382	1624	result in a three- enhancement	[resulting in a three- enhancement]	1.0	5	1	0	0
57383	1624	icam-1 gene	[ICAM-1 gene]	1.0	2	2	1	1
57384	1624	single October	[single Oct]	1.0	2	1	0	0
57385	1624	allele in a size range	[allele in an size range]	1.0	5	1	0	0
57386	1624	action of the phosphatase inhibitor	[action of the phosphatase inhibitors]	1.0	5	1	0	0
57387	1624	vdre -binding protein (s), distinct	[VDRE -binding protein (s), distinct]	1.0	5	1	0	0
57388	1624	expression of the her-2/neu oncogene	[expression of the HER-2/neu oncogene]	1.0	5	2	1	1
57389	1624	IFN regulation of cell growth	[IFN regulation of cell growth]	1.0	5	1	0	0
57390	1624	control of prl gene expression	[control of PRL gene expression]	1.0	5	1	0	0
57391	1624	point mutation of a GATA-1 site	[Point mutation of a GATA-1 site]	1.0	6	1	0	0
57392	1624	B cell-associated surface molecule CD40	[B cell-associated surface molecule CD40]	1.0	5	1	0	0
57393	1624	endogenous kinase	[endogenous kinases]	1.0	2	1	0	0
57394	1624	causative agent of infectious mononucleosis	[causative agent of infectious mononucleosis]	1.0	5	1	0	0
57395	1624	nih-3t3 cell	[NIH-3T3 cells]	1.0	2	1	0	0
57396	1624	ifn-gamma gene transcription in T cell	[IFN-gamma gene transcription in T cells]	1.0	6	1	0	0
57397	1624	activity of the terminal repeat	[activity of the terminal repeat]	1.0	5	2	2	2
57398	1624	primary tumor in Group C	[primary tumors in Group C]	1.0	5	1	0	0
57399	1624	primary tumor in Group A	[primary tumors in Group A]	1.0	5	1	0	0
57400	1624	change in the tyrosine phosphorylation status	[changes in the tyrosine phosphorylation status]	1.0	6	1	0	0
57401	1624	her-2/neu	[HER-2/neu]	1.0	1	11	4	4
57402	1624	camp expression	[cAMP expression]	1.0	2	1	0	0
57403	1624	transition	[transition]	1.0	1	12	8	4
57404	1624	two biological model of a situation	[two biological models of an situation]	1.0	6	1	0	0
57405	1624	belong to the steroid receptor superfamily	[belonging to the steroid receptor superfamily]	1.0	6	1	0	0
57406	1624	rhinitis to house dust mite	[rhinitis to house dust mite]	1.0	5	1	0	0
57407	1624	bcl-xL mediate erythroid cell survival	[bcl-xL mediating erythroid cell survival]	1.0	5	1	0	0
57408	1624	il-12 production by human macrophage	[IL-12 production by human macrophages]	1.0	5	1	0	0
57409	1624	mrna-type promoter	[mRNA-type promoter]	1.0	2	1	0	0
57410	1624	various monocyte cell model system	[various monocyte cell model systems]	1.0	5	1	0	0
57411	1624	activity of topoisomerase in nuclear extract	[activity of topoisomerases in nuclear extracts]	1.0	6	1	0	0
57412	1624	oral prednisone	[oral prednisone]	1.0	2	1	0	0
57413	1624	il-4 promoter	[IL-4 promoter]	1.0	2	2	2	2
57414	1624	expression of protein (map) kinase pathway	[expression of protein (MAP) kinase pathways]	1.0	6	1	0	0
57415	1624	GenBank database	[GenBank database]	1.0	2	2	1	1
57416	1624	Furthermore, transcript of PEBP2 alpha a	[Furthermore, transcripts of PEBP2 alpha A]	1.0	6	1	0	0
57417	1624	ilt-mat cell	[ILT-mat cells]	1.0	2	1	0	0
57418	1624	her-2/neu overexpression	[HER-2/neu overexpression]	1.0	2	2	2	2
57419	1624	transendothelial migration of monocyte in response	[transendothelial migration of monocytes in response]	1.0	6	1	0	0
57420	1624	basis for the synergistic action	[basis for the synergistic actions]	1.0	5	1	0	0
57421	1624	distinct activity	[distinct activities]	1.0	2	2	2	2
57422	1624	inhibition of this activation pathway	[inhibition of this activation pathway]	1.0	5	1	0	0
57423	1624	Tal-1 transcription	[Tal-1 transcription]	1.0	2	1	0	0
57424	1624	u937 cell stably overexpress pkc-zeta	[U937 cells stably overexpressing PKC-zeta]	1.0	5	1	0	0
57425	1624	--basic research	[--basic research]	1.0	2	1	0	0
57426	1624	important role in gene transcription	[important role in gene transcription]	1.0	5	1	0	0
57427	1624	upregulation of platelet thromboxane receptor	[upregulation of platelet thromboxane receptors]	1.0	5	1	0	0
57428	1624	hpr gene	[hPR gene]	1.0	2	1	0	0
57429	1624	membrane-associated signal	[membrane-associated signals]	1.0	2	1	0	0
57430	1624	appearance of a novel M(r)	[appearance of a novel M(r)]	1.0	5	1	0	0
57431	1624	two major transcription initiation site	[two major transcription initiation sites]	1.0	5	1	0	0
57432	1624	normal t-cell	[normal T-cells]	1.0	2	1	0	0
57433	1624	tumorigenic transformation of cell line	[tumorigenic transformation of cell lines]	1.0	5	1	0	0
57434	1624	selective displacement of fatty acid	[selective displacement of fatty acids]	1.0	5	1	0	0
57435	1624	high circulate level of steroid hormone	[high circulating levels of steroid hormones]	1.0	6	1	0	0
57436	1624	treatment of endothelial cell with lps	[Treatment of endothelial cells with LPS]	1.0	6	1	0	0
57437	1624	two type of effector cell	[Two types of effector cells]	1.0	5	1	0	0
57438	1624	IFNalpha production	[IFNalpha production]	1.0	2	1	0	0
57439	1624	site of active pulmonary tuberculosis	[sites of active pulmonary tuberculosis]	1.0	5	1	0	0
57440	1624	Ca(2+)-regulated kinase	[Ca(2+)-regulated kinases]	1.0	2	1	0	0
57441	1624	single strand nick in DNA,	[single strand nicks in DNA,]	1.0	5	1	0	0
57442	1624	redox imbalance	[redox imbalance]	1.0	2	1	0	0
57443	1624	inhibitory action of alpha-lipoic acid	[inhibitory action of alpha-lipoic acid]	1.0	5	1	0	0
57444	1624	hepatoprotective activity	[hepatoprotective activity]	1.0	2	1	0	0
57445	1624	positioning of the ZII domain upstream	[positioning of the ZII domain upstream]	1.0	6	1	0	0
57446	1624	mrna level.	[mRNA level.]	1.0	2	1	0	0
57447	1624	neutrophil accumulation of lung injury	[Neutrophil accumulation of lung injury]	1.0	5	1	0	0
57448	1624	age-related defect	[age-related defects]	1.0	2	1	0	0
57449	1624	tester strain	[tester strain]	1.0	2	1	0	0
57450	1624	vascular-rich organ	[vascular-rich organs]	1.0	2	1	0	0
57451	1624	five member of this family MYC	[Five members of this family MYC]	1.0	6	1	0	0
57452	1624	heterogeneous expression	[Heterogeneous expression]	1.0	2	3	2	1
57453	1624	maternal morbidity	[maternal morbidity]	1.0	2	1	0	0
57454	1624	pre-incubation of nuclear extract with dmdtc	[pre-incubation of nuclear extracts with DMDTC]	1.0	6	1	0	0
57455	1624	human estrogen	[human estrogen]	1.0	2	1	0	0
57456	1624	hla-dr expression by mononuclear phagocyte	[HLA-DR expression by mononuclear phagocytes]	1.0	5	1	0	0
57457	1624	down-regulation of glucocorticoid receptor mrna expression	[down-regulation of glucocorticoid receptor mRNA expression]	1.0	6	1	0	0
57458	1624	1 long terminal repeat hiv-1-ltr	[1 long terminal repeat HIV-1-LTR]	1.0	5	1	0	0
57459	1624	benefit beta.	[b beta,]	1.0	2	1	0	0
57460	1624	sodium phenylacetate treatment of k562 cell	[sodium phenylacetate treatment of K562 cells]	1.0	6	1	0	0
57461	1624	distinct role for this region	[distinct role for this region]	1.0	5	1	0	0
57462	1624	different response of pml-rar alpha	[different responses of PML-RAR alpha]	1.0	5	1	0	0
57463	1624	nontransformed human mouse T cell	[nontransformed human mouse T cells]	1.0	5	1	0	0
57464	1624	highly dexamethasone	[highly dexamethasone]	1.0	2	1	0	0
57465	1624	IL-10 inhibition of ICAM-1 steady-state mrna	[IL-10 inhibition of ICAM-1 steady-state mRNA]	1.0	6	1	0	0
57466	1624	organizational pattern of regulatory element	[organizational pattern of regulatory elements]	1.0	5	1	0	0
57467	1624	tf mrna	[TF mRNA]	1.0	2	2	1	1
57468	1624	composite element of a NFATp/c	[composite elements of a NFATp/c]	1.0	5	1	0	0
57469	1624	mutant with a 3' g	[mutant with a 3' G]	1.0	5	1	0	0
57470	1624	CD80 alone	[CD80 alone]	1.0	2	1	0	0
57471	1624	macrophage activation of stress gene	[macrophage activation of stress genes]	1.0	5	1	0	0
57472	1624	deleted, rank	[deleted, RANK]	1.0	2	1	0	0
57473	1624	protein tyrosine kinase activity 0.5-fold)	[protein tyrosine kinase activity 0.5-fold)]	1.0	5	1	0	0
57474	1624	CD-40 pathway	[CD-40 pathway]	1.0	2	1	0	0
57475	1624	cd4+ memory T cell from patient	[CD4+ memory T cells from patients]	1.0	6	1	0	0
57476	1624	transcription of the IL-1 beta gene	[transcription of the IL-1 beta gene]	1.0	6	1	0	0
57477	1624	dexamethasone (apparent	[dexamethasone (apparent]	1.0	2	1	0	0
57478	1624	antibody elevation of camp level	[antibodies elevation of cAMP levels]	1.0	5	1	0	0
57479	1624	mouse MHC class ii gene	[mouse MHC class II genes]	1.0	5	1	0	0
57480	1624	EBNAI of the QUK splice pattern	[EBNAI of the QUK splice pattern]	1.0	6	1	0	0
57481	1624	sex steroid regulation of the production	[Sex steroid regulation of the production]	1.0	6	1	0	0
57482	1624	collagen-coated plastic	[collagen-coated plastic]	1.0	2	1	0	0
57483	1624	probably through cell cycle -stimulatory activity	[probably through cell cycle -stimulatory activity]	1.0	6	1	0	0
57484	1624	pr complex	[PR complex]	1.0	2	3	2	1
57485	1624	CD40 activation	[CD40 activation]	1.0	2	2	2	2
57486	1624	aids-associated disorder	[AIDS-associated disorders]	1.0	2	1	0	0
57487	1624	molecule on human Jurkat T cell	[molecules on human Jurkat T cells]	1.0	6	1	0	0
57488	1624	viral stimulus	[viral stimuli]	1.0	2	1	0	0
57489	1624	binding to the response element	[binding to the response elements]	1.0	5	2	2	2
57490	1624	comparable level of epo-r mrna	[comparable levels of Epo-R mRNA]	1.0	5	1	0	0
57491	1624	antisense oligomer	[antisense oligomers]	1.0	2	2	1	1
57492	1624	stimulus such as h2o2 PMA	[stimuli such as H2O2 PMA]	1.0	5	1	0	0
57493	1624	other element regulate il-4 gene expression	[other elements regulating IL-4 gene expression]	1.0	6	1	0	0
57494	1624	rela(p65) protein	[RelA(p65) protein]	1.0	2	1	0	0
57495	1624	murine B-cell	[murine B-cell]	1.0	2	1	0	0
57496	1624	lead to gene transcription in leukocyte	[leading to gene transcription in leukocytes]	1.0	6	1	0	0
57497	1624	apoptotic vsmc express c-myc vsmc-myc	[apoptotic VSMCs expressing c-myc VSMC-myc]	1.0	5	1	0	0
57498	1624	substantial decrease of il-2 production	[Substantial decreases of IL-2 production]	1.0	5	1	0	0
57499	1624	frequent emergence	[frequent emergence]	1.0	2	1	0	0
57500	1624	suppressor of immune response gene	[suppressor of immune response genes]	1.0	5	1	0	0
57501	1624	rather, analysis of this system	[Rather, analysis of this system]	1.0	5	1	0	0
57502	1624	dominant negative form of CBP	[dominant negative form of CBP]	1.0	5	1	0	0
57503	1624	However, Nef	[However, Nef]	1.0	2	1	0	0
57504	1624	cell express the nef gene	[cells expressing the nef gene]	1.0	5	1	0	0
57505	1624	central regulator	[central regulator]	1.0	2	2	2	2
57506	1624	differential binding of cellular factor	[differential binding of cellular factors]	1.0	5	1	0	0
57507	1624	1 mrna	[1 mRNA]	1.0	2	1	0	0
57508	1624	drug concentration	[drug concentrations]	1.0	2	2	1	1
57509	1624	transfection of a ap-2 expression	[Transfection of an AP-2 expression]	1.0	5	1	0	0
57510	1624	negative regulator of t-cell activation	[negative regulators of T-cell activation]	1.0	5	1	0	0
57511	1624	doxorubicin DOX	[doxorubicin DOX]	1.0	2	1	0	0
57512	1624	particular, the histone h5 gene	[particular, the histone H5 gene]	1.0	5	1	0	0
57513	1624	weight gain (14 +/- 2	[weight gain (14 +/- 2]	1.0	5	1	0	0
57514	1624	two form of stat3 stat3alpha	[two forms of STAT3 STAT3alpha]	1.0	5	1	0	0
57515	1624	hsf2-alpha isoform	[HSF2-alpha isoform]	1.0	2	2	1	1
57516	1624	32), stat1	[32), STAT1]	1.0	2	1	0	0
57517	1624	datum demonstrate a general consequence	[data demonstrating a general consequence]	1.0	5	1	0	0
57518	1624	p16 the inhibitor of cyclin-dependent-kinase-	[p16 the inhibitor of cyclin-dependent-kinase-]	1.0	5	1	0	0
57519	1624	peripheral blood-derived human monocyte pbm	[peripheral blood-derived human monocytes PBM]	1.0	5	1	0	0
57520	1624	11 beta-phenyl	[11 beta-phenyl]	1.0	2	1	0	0
57521	1624	chemokine superfamily	[chemokine superfamily]	1.0	2	2	1	1
57522	1624	DZA on NF-kappaB transcriptional activity	[DZA on NF-kappaB transcriptional activity]	1.0	5	1	0	0
57523	1624	neuro-immuno interaction	[neuro-immuno interactions]	1.0	2	1	0	0
57524	1624	c-jun phosphorylation on the other.	[c-Jun phosphorylation on the other.]	1.0	5	1	0	0
57525	1624	clonal growth	[clonal growth]	1.0	2	1	0	0
57526	1624	produce hsp70	[producing hsp70]	1.0	2	1	0	0
57527	1624	other activator	[other activators]	1.0	2	1	0	0
57528	1624	potential antagonism of the production	[potential antagonism of the production]	1.0	5	1	0	0
57529	1624	tar transactivation of hiv-1 transcription	[TAR transactivation of HIV-1 transcription]	1.0	5	2	2	2
57530	1624	level of this critical hormone.	[levels of this critical hormone.]	1.0	5	1	0	0
57531	1624	cell type of prostate epithelia	[cell types of prostate epithelia]	1.0	5	1	0	0
57532	1624	regulation of erythroid-specific gene expression	[regulation of erythroid-specific gene expression]	1.0	5	1	0	0
57533	1624	erythroid-specific gata-1	[erythroid-specific GATA-1]	1.0	2	1	0	0
57534	1624	CD40 signal to b cell	[CD40 signaling to B cells]	1.0	5	1	0	0
57535	1624	coactivator oca-b	[coactivator OCA-B]	1.0	2	2	2	2
57536	1624	kappa 1-kappa	[kappa 1-kappa]	1.0	2	2	2	2
57537	1624	radiation therapy in tumor tissue	[radiation therapy in tumor tissues]	1.0	5	1	0	0
57538	1624	er codon	[ER codon]	1.0	2	2	1	1
57539	1624	Thus, ceramide	[Thus, ceramide]	1.0	2	1	0	0
57540	1624	linker substitution	[linker substitution]	1.0	2	2	2	2
57541	1624	quantitative, qualitative,	[quantitative, qualitative,]	1.0	2	1	0	0
57542	1624	allergen-specific human helper T cell	[allergen-specific human helper T cells]	1.0	5	1	0	0
57543	1624	immunoglobulin major histocompatibility (mhc) gene	[immunoglobulin major histocompatibility (MHC) genes]	1.0	5	1	0	0
57544	1624	control cell with a reduction	[control cells with a reduction]	1.0	5	1	0	0
57545	1624	human Burkitt	[human Burkitt]	1.0	2	1	0	0
57546	1624	vivo, icer	[vivo, ICER]	1.0	2	1	0	0
57547	1624	tumor necrosis factor-alpha (25 ng/ml)	[tumor necrosis factor-alpha (25 ng/ml)]	1.0	5	1	0	0
57548	1624	severe skewing of x inactivation result	[Severe skewing of X inactivation resulting]	1.0	6	1	0	0
57549	1624	il-2a (which	[IL-2A (which]	1.0	2	1	0	0
57550	1624	overexpression in tumor cell type	[overexpression in tumor cell types]	1.0	5	1	0	0
57551	1624	translocation of protein kinase c	[translocation of protein kinase C]	1.0	5	2	1	1
57552	1624	sp ii	[SP II]	1.0	2	1	0	0
57553	1624	15 minute of il-5 stimulation	[15 min of IL-5 stimulation]	1.0	5	1	0	0
57554	1624	potent mediator	[potent mediator]	1.0	2	4	3	1
57555	1624	major orf2	[major ORF2]	1.0	2	1	0	0
57556	1624	(nfat) protein	[(NFAT) proteins]	1.0	2	1	0	0
57557	1624	two technique	[two techniques]	1.0	2	1	0	0
57558	1624	viscosity of cystic fibrosis sputum	[viscosity of cystic fibrosis sputum]	1.0	5	1	0	0
57559	1624	allele -specific regulation of Pax5	[allele -specific regulation of Pax5]	1.0	5	1	0	0
57560	1624	NF-kappa b by interleukin 2	[NF-kappa B by interleukin 2]	1.0	5	1	0	0
57561	1624	Bcl-2 a repressor of lymphocyte death	[Bcl-2 a repressor of lymphocyte death]	1.0	6	1	0	0
57562	1624	individual with filarial inflammatory disease	[individuals with filarial inflammatory disease]	1.0	5	1	0	0
57563	1624	12 hour	[12 hr]	1.0	2	3	2	1
57564	1624	interleukin-1beta transcription by Epstein-Barr virus	[interleukin-1beta transcription by Epstein-Barr virus]	1.0	5	1	0	0
57565	1624	endocytic compartment	[endocytic compartment]	1.0	2	1	0	0
57566	1624	fkbp	[FKBP]	1.0	1	11	4	4
57567	1624	trep binding	[TREp binding]	1.0	2	1	0	0
57568	1624	effect on the tyrosine kinase gene	[effects on the tyrosine kinase genes]	1.0	6	1	0	0
57569	1624	stimulation of cd4+ T cell	[stimulation of CD4+ T cells]	1.0	5	2	2	2
57570	1624	clinical sign	[clinical signs]	1.0	2	1	0	0
57571	1624	specific receptor intracellular domain sequence	[specific receptor intracellular domain sequences]	1.0	5	1	0	0
57572	1624	Interferon alpha	[Interferon alpha]	1.0	2	1	0	0
57573	1624	phorbol myristate acetate Egr-1 mrna expression	[Phorbol myristate acetate Egr-1 mRNA expression]	1.0	6	1	0	0
57574	1624	study interaction	[studying interactions]	1.0	2	2	2	2
57575	1624	Ca2+ -dependent induction of gene	[Ca2+ -dependent induction of genes]	1.0	5	1	0	0
57576	1624	molt 4	[MOLT 4]	1.0	2	1	0	0
57577	1624	combination with the lymphokine interleukin-1	[combination with the lymphokine interleukin-1]	1.0	5	1	0	0
57578	1624	mrna stability.	[mRNA stability.]	1.0	2	1	0	0
57579	1624	U937 cell of a provirus	[U937 cells of an provirus]	1.0	5	1	0	0
57580	1624	variant b	[variant B]	1.0	2	2	1	1
57581	1624	variant a	[variant A]	1.0	2	2	1	1
57582	1624	Glucocorticoid repression of cytokine gene transcription	[Glucocorticoid repression of cytokine gene transcription]	1.0	6	1	0	0
57583	1624	effector phase	[effector phase]	1.0	2	2	1	1
57584	1624	B-cell chronic lymphocytic leukemia cell	[B-cell chronic lymphocytic leukemia cells]	1.0	5	1	0	0
57585	1624	clinical side	[clinical side]	1.0	2	1	0	0
57586	1624	occupancy element.	[occupancy element.]	1.0	2	1	0	0
57587	1624	decline of the arsenic content	[decline of the arsenic content]	1.0	5	1	0	0
57588	1624	fas promoter	[Fas promoter]	1.0	2	2	2	2
57589	1624	early (minute	[early (minutes)]	1.0	2	1	0	0
57590	1624	moreover, simian virus 40 enhancer activity	[Moreover, simian virus 40 enhancer activity]	1.0	6	1	0	0
57591	1624	wild-type level of U2 snrna	[wild-type levels of U2 snRNA]	1.0	5	1	0	0
57592	1624	either on the minimal b29 promoter	[either on the minimal B29 promoter]	1.0	6	1	0	0
57593	1624	sequence responsible for the phosphorylation	[sequences responsible for the phosphorylation]	1.0	5	1	0	0
57594	1624	steroid binding of hbd mutant	[steroid binding of HBD mutants]	1.0	5	1	0	0
57595	1624	promoter assay	[Promoter assays]	1.0	2	1	0	0
57596	1624	confirm the role of NF-kappa b	[confirming the role of NF-kappa B]	1.0	6	1	0	0
57597	1624	B-cell population	[B-cell population]	1.0	2	2	1	1
57598	1624	p55/ c-rel	[p55/ c-Rel]	1.0	2	1	0	0
57599	1624	atherosclerosis lesion	[atherosclerosis lesions]	1.0	2	1	0	0
57600	1624	peptide represent the fusion region	[peptide representing the fusion region]	1.0	5	1	0	0
57601	1624	lck-negative jcam1 cell by Syk	[Lck-negative JCaM1 cells by Syk]	1.0	5	1	0	0
57602	1624	operational definition of ebv latency	[operational definition of EBV latencies]	1.0	5	1	0	0
57603	1624	two subunits,	[two subunits,]	1.0	2	1	0	0
57604	1624	inhibition of proliferation of T lymphocyte	[Inhibition of proliferation of T lymphocytes]	1.0	6	1	0	0
57605	1624	chronic activation in HIV individual	[chronic activation in HIV individuals]	1.0	5	1	0	0
57606	1624	interestingly, the combination of 1, 25(oh)2d3	[Interestingly, the combination of 1, 25(OH)2D3]	1.0	6	1	0	0
57607	1624	molecular alteration	[molecular alteration]	1.0	2	2	2	2
57608	1624	treatment of hcd57 cell with SCF	[Treatment of HCD57 cells with SCF]	1.0	6	1	0	0
57609	1624	protein extract of th2 clone	[protein extracts of Th2 clones]	1.0	5	1	0	0
57610	1624	late treatment	[late treatment]	1.0	2	1	0	0
57611	1624	coordinate manner.	[coordinate manner.]	1.0	2	1	0	0
57612	1624	calcium signalling in T cell	[Calcium signalling in T cells]	1.0	5	1	0	0
57613	1624	other protein of the regulatory cascade	[other proteins of the regulatory cascade]	1.0	6	1	0	0
57614	1624	Ad2 infection	[Ad2 infection]	1.0	2	1	0	0
57615	1624	competition between ZEB /heb protein	[competition between ZEB /HEB proteins]	1.0	5	1	0	0
57616	1624	receptor gcr	[receptor GCR]	1.0	2	2	2	2
57617	1624	a/r challenge	[A/R challenge]	1.0	2	2	2	2
57618	1624	test activity in transgenic mouse	[Testing activity in transgenic mice]	1.0	5	1	0	0
57619	1624	jak3 activation	[JAK3 activation]	1.0	2	1	0	0
57620	1624	single class of site similar	[single class of sites similar]	1.0	5	1	0	0
57621	1624	Jurkat T cell with phytohemaglutinin	[Jurkat T cells with phytohemaglutinin]	1.0	5	1	0	0
57622	1624	vivo survival	[vivo survival]	1.0	2	1	0	0
57623	1624	beas-2b cell in a transwell system	[BEAS-2B cells in a transwell system]	1.0	6	1	0	0
57624	1624	affinity between the receptor binding site	[affinity between the receptor binding sites]	1.0	6	1	0	0
57625	1624	MAPK	[MAPK]	1.0	1	11	2	2
57626	1624	basal activity of promoter in fibroblast	[basal activity of promoters in fibroblasts]	1.0	6	1	0	0
57627	1624	RNA splicing,	[RNA splicing,]	1.0	2	1	0	0
57628	1624	transcription of the tf gene	[transcription of the TF gene]	1.0	5	1	0	0
57629	1624	tnf-alpha mrna induction by PMA	[TNF-alpha mRNA induction by PMA]	1.0	5	2	1	1
57630	1624	cd34(+) bone	[CD34(+) bone]	1.0	2	2	2	2
57631	1624	(low affinity, high capacity) binding site	[(low affinity, high capacity) binding sites]	1.0	6	1	0	0
57632	1624	transcription factor in T lymphocyte	[transcription factors in T lymphocytes]	1.0	5	1	0	0
57633	1624	proliferation of phytohemagglutinin pha blast	[proliferation of phytohemagglutinin PHA blasts]	1.0	5	1	0	0
57634	1624	response.	[response.]	1.0	1	11	4	4
57635	1624	physiological level	[physiological levels]	1.0	2	2	2	2
57636	1624	significant p42/44 (erk) mapk activation	[significant p42/44 (ERK) MAPk activation]	1.0	5	1	0	0
57637	1624	platelet (auc of 332 15 nmol	[platelets (AUC of 332 15 nmol]	1.0	6	1	0	0
57638	1624	+/- 2	[+/- 2]	1.0	2	1	0	0
57639	1624	6 kilobasis	[6 kilobases]	1.0	2	2	2	2
57640	1624	Spi-B expression	[Spi-B expression]	1.0	2	1	0	0
57641	1624	patient with immunodeficiency syndrome AIDS	[patients with immunodeficiency syndrome AIDS]	1.0	5	1	0	0
57642	1624	activation of the factor almost completely,	[activation of the factor almost completely,]	1.0	6	1	0	0
57643	1624	silent mutation	[silent mutation]	1.0	2	2	1	1
57644	1624	protein-1 in cd4+ T cell	[protein-1 in CD4+ T cells]	1.0	5	1	0	0
57645	1624	eukaryotic transcription factor NF-kappa b	[eukaryotic transcription factor NF-kappa B]	1.0	5	1	0	0
57646	1624	three heat shock transcription factor hsf	[three heat shock transcription factor HSF]	1.0	6	1	0	0
57647	1624	development in the human thymus	[development in the human thymus]	1.0	5	1	0	0
57648	1624	structural versatility	[structural versatility]	1.0	2	1	0	0
57649	1624	death-inducing receptor	[death-inducing receptors]	1.0	2	1	0	0
57650	1624	granulocyte apoptosis	[granulocyte apoptosis]	1.0	2	2	2	2
57651	1624	major PB1 nuclear protein-binding complex	[major PB1 nuclear protein-binding complex]	1.0	5	1	0	0
57652	1624	expression pattern of ki-67, cd23,	[expression patterns of Ki-67, CD23,]	1.0	5	1	0	0
57653	1624	such that Th2 lymphocyte-mediated effect	[such that Th2 lymphocyte-mediated effects]	1.0	5	1	0	0
57654	1624	first event	[first event]	1.0	2	2	2	2
57655	1624	3-fold range	[3-fold range]	1.0	2	2	2	2
57656	1624	stat1 mab	[stat1 mAb]	1.0	2	1	0	0
57657	1624	oxygen radical scavenger enzyme catalase	[oxygen radical scavenger enzymes catalase]	1.0	5	1	0	0
57658	1624	group of naturally-occurg phenolic compound	[group of naturally-occurring phenolic compounds]	1.0	5	1	0	0
57659	1624	granulocyte/macrophage colony-stimulating	[granulocyte/macrophage colony-stimulating]	1.0	2	2	2	2
57660	1624	receptor of the receptor superfamily	[receptor of the receptor superfamily]	1.0	5	1	0	0
57661	1624	mutation of the pu.1 -binding site	[mutation of the PU.1 -binding site]	1.0	6	1	0	0
57662	1624	functional activation in that inducibility	[functional activation in that inducibility]	1.0	5	1	0	0
57663	1624	span the transcription initiation site	[spanning the transcription initiation site]	1.0	5	1	0	0
57664	1625	fluid	[fluid]	0.9875	1	11	9	8
57665	1625	hours.	[hours.]	0.9875	1	11	9	8
57666	1626	RU	[RU]	0.9857142857142858	1	11	8	7
57667	1626	variable	[variable]	0.9857142857142858	1	11	8	7
57668	1626	heterogeneity	[heterogeneity]	0.9857142857142858	1	11	8	7
57669	1626	effects.	[effects.]	0.9857142857142858	1	11	8	7
57670	1627	proto-oncogent	[proto-oncogenes]	0.9833333333333334	1	11	7	6
57671	1627	presentation	[presentation]	0.9833333333333334	1	11	7	6
57672	1627	transmission	[transmission]	0.9833333333333334	1	11	7	6
57673	1627	melanoma	[melanoma]	0.9833333333333334	1	11	7	6
57674	1627	circulate	[circulating]	0.9833333333333334	1	11	7	6
57675	1628	signals.	[signals.]	0.9800000000000001	1	11	6	5
57676	1628	ppar	[PPAR]	0.9800000000000001	1	11	6	5
57677	1628	elk-1	[elk-1]	0.9800000000000001	1	11	6	5
57678	1628	interleukin-8	[interleukin-8]	0.9800000000000001	1	11	6	5
57679	1628	Oct-2A	[Oct-2A]	0.9800000000000001	1	11	6	5
57680	1629	homologue	[homologue]	0.9777777777777779	1	11	11	9
57681	1630	sp	[Sp]	0.9750000000000001	1	11	5	4
57682	1630	feedback	[feedback]	0.9750000000000001	1	11	5	4
57683	1630	otf-2	[OTF-2]	0.9750000000000001	1	11	5	4
57684	1631	transfer	[transfer]	0.9714285714285714	1	11	9	7
57685	1631	explanation	[explanation]	0.9714285714285714	1	11	9	7
57686	1631	homolog	[homolog]	0.9714285714285714	1	11	9	7
57687	1632	SR	[SR]	0.9666666666666667	1	11	8	6
57688	1632	knowledge	[knowledge]	0.9666666666666667	1	11	8	6
57689	1632	TPA	[TPA]	0.9666666666666667	1	11	4	3
57690	1632	superoxide	[superoxide]	0.9666666666666667	1	11	8	6
57691	1632	ut-7	[UT-7]	0.9666666666666667	1	11	4	3
57692	1632	flavonoid	[flavonoid]	0.9666666666666667	1	11	4	3
57693	1632	burst	[burst]	0.9666666666666667	1	11	8	6
57694	1633	occupancy	[occupancy]	0.9625	1	11	11	8
57695	1634	diagnosis	[diagnosis]	0.96	1	11	7	5
57696	1634	sre	[SRE]	0.96	1	11	7	5
57697	1634	linker	[linker]	0.96	1	11	7	5
57698	1635	amplification	[amplification]	0.9571428571428572	1	11	10	7
57699	1636	integration	[integration]	0.9500000000000001	1	11	9	6
57700	1636	clonality	[clonality]	0.9500000000000001	1	11	9	6
57701	1636	cause	[cause]	0.9500000000000001	1	11	9	6
57702	1636	ERK	[ERK]	0.9500000000000001	1	11	3	2
57703	1636	objective	[objective]	0.9500000000000001	1	11	9	6
57704	1636	aging.	[aging.]	0.9500000000000001	1	11	3	2
57705	1636	Addition	[Addition]	0.9500000000000001	1	19	19	2
57706	1636	replacement	[replacement]	0.9500000000000001	1	11	9	6
57707	1637	injury	[injury]	0.9400000000000001	1	11	8	5
57708	1637	co-transfection	[co-transfection]	0.9400000000000001	1	11	8	5
57709	1637	phagocytosis	[phagocytosis]	0.9400000000000001	1	11	8	5
57710	1637	immunoblot	[immunoblot]	0.9400000000000001	1	11	8	5
57711	1637	Stat	[Stat]	0.9400000000000001	1	11	8	5
57712	1638	supernatant	[supernatant]	0.9333333333333335	1	11	10	6
57713	1638	septic	[septic]	0.9333333333333335	1	12	8	3
57714	1638	isotype	[isotype]	0.9333333333333335	1	11	10	6
57715	1638	a23187	[A23187]	0.9333333333333335	1	12	8	3
57716	1638	IkappaB-alpha	[IkappaB-alpha]	0.9333333333333335	1	11	5	3
57717	1639	interfere	[interfering]	0.925	1	12	11	4
57718	1639	cross-link	[cross-link]	0.925	1	11	7	4
57719	1639	preincubation	[preincubation]	0.925	1	12	11	4
57720	1640	G	[G]	0.9	1	10	1	1
57721	1640	L	[L]	0.9	1	12	6	2
57722	1640	s	[S]	0.9	1	10	4	4
57723	1640	indomethacin	[indomethacin]	0.9	1	9	0	0
57724	1640	Cepsilon	[Cepsilon]	0.9	1	12	9	3
57725	1640	E.	[E.]	0.9	1	10	3	3
57726	1640	TG	[TG]	0.9	1	10	5	5
57727	1640	ah	[Ah]	0.9	1	12	3	1
57728	1640	mM	[mM]	0.9	1	10	9	9
57729	1640	lt	[LT]	0.9	1	10	8	8
57730	1640	E2F-1	[E2F-1]	0.9	1	10	3	3
57731	1640	Cushing'	[Cushing's]	0.9	1	10	2	2
57732	1640	gabp	[GABP]	0.9	1	10	5	5
57733	1640	oxldl	[oxLDL]	0.9	1	10	2	2
57734	1640	vimentin	[vimentin]	0.9	1	10	3	3
57735	1640	gelatinase	[gelatinase]	0.9	1	11	6	3
57736	1640	NGAL	[NGAL]	0.9	1	11	4	2
57737	1640	t-all	[T-ALL]	0.9	1	10	2	2
57738	1640	TGF-beta	[TGF-beta]	0.9	1	11	4	2
57739	1640	c-Myc	[c-Myc]	0.9	1	10	3	3
57740	1640	provirus	[provirus]	0.9	1	10	4	4
57741	1640	Duffy	[Duffy]	0.9	1	10	1	1
57742	1640	As2O3	[As2O3]	0.9	1	10	3	3
57743	1640	CD5	[CD5]	0.9	1	10	4	4
57744	1640	Dex	[Dex]	0.9	1	10	2	2
57745	1640	EPO	[EPO]	0.9	1	10	4	4
57746	1640	fibrinogen	[fibrinogen]	0.9	1	10	3	3
57747	1640	solution	[solution]	0.9	1	10	3	3
57748	1640	HIV-1	[HIV-1]	0.9	1	10	4	4
57749	1640	hemin	[hemin]	0.9	1	10	4	4
57750	1640	IL3	[IL3]	0.9	1	10	1	1
57751	1640	Id3	[Id3]	0.9	1	10	2	2
57752	1640	LMO	[LMO]	0.9	1	9	0	0
57753	1640	MEK	[MEK]	0.9	1	10	2	2
57754	1640	RFX	[RFX]	0.9	1	10	1	1
57755	1640	FasL	[FasL]	0.9	1	10	5	5
57756	1640	interleukin-10	[interleukin-10]	0.9	1	10	5	5
57757	1640	lef-1	[LEF-1]	0.9	1	10	7	7
57758	1640	e1b	[E1B]	0.9	1	10	4	4
57759	1640	dex	[dex]	0.9	1	10	5	5
57760	1640	erk	[ERK]	0.9	1	10	5	5
57761	1640	tepoxalin	[tepoxalin]	0.9	1	10	2	2
57762	1640	author	[authors]	0.9	1	9	0	0
57763	1640	ifi	[IFNs]	0.9	1	10	3	3
57764	1640	acth	[ACTH]	0.9	1	10	5	5
57765	1640	PRE-I	[PRE-I]	0.9	1	10	2	2
57766	1640	msr	[MSR]	0.9	1	10	5	5
57767	1640	c-fe	[c-fes]	0.9	1	10	3	3
57768	1640	lfa-3	[LFA-3]	0.9	1	9	0	0
57769	1640	GRbeta	[GRbeta]	0.9	1	9	0	0
57770	1640	p59fyn	[p59fyn]	0.9	1	10	1	1
57771	1640	side	[side]	0.9	1	10	7	7
57772	1640	methylprednisolone	[methylprednisolone]	0.9	1	10	5	5
57773	1640	elf-1	[Elf-1]	0.9	1	10	1	1
57774	1640	collagenase	[collagenase]	0.9	1	10	7	7
57775	1640	gammac	[gammac]	0.9	1	10	1	1
57776	1640	homeodomain	[homeodomain]	0.9	1	10	8	8
57777	1640	tata	[TATA]	0.9	1	10	4	4
57778	1640	cyclophilin	[cyclophilin]	0.9	1	10	4	4
57779	1640	IFNs	[IFNs]	0.9	1	10	3	3
57780	1640	dopamine	[dopamine]	0.9	1	10	1	1
57781	1640	polyomavirus	[polyomavirus]	0.9	1	10	5	5
57782	1640	traf	[TRAF]	0.9	1	10	5	5
57783	1640	cd25	[CD25]	0.9	1	10	3	3
57784	1640	twin	[twin]	0.9	1	10	5	5
57785	1640	Burkitt	[Burkitt]	0.9	1	10	3	3
57786	1640	splice	[splice]	0.9	1	10	8	8
57787	1640	fra-1	[fra-1]	0.9	1	10	5	5
57788	1640	p-selectin	[P-selectin]	0.9	1	10	5	5
57789	1640	transport	[transport]	0.9	1	10	6	6
57790	1640	Rel/	[Rel/]	0.9	1	9	0	0
57791	1640	ankyrin	[ankyrin]	0.9	1	10	5	5
57792	1640	paper,	[paper,]	0.9	1	10	1	1
57793	1640	gp120	[gp120]	0.9	1	10	2	2
57794	1640	dmso	[DMSO]	0.9	1	10	3	3
57795	1640	C/EBPbeta	[C/EBPbeta]	0.9	1	10	3	3
57796	1640	GATA-2	[GATA-2]	0.9	1	10	1	1
57797	1640	ovary	[ovary]	0.9	1	10	8	8
57798	1640	il-13r	[IL-13R]	0.9	1	10	4	4
57799	1640	immunosuppression	[immunosuppression]	0.9	1	10	6	6
57800	1640	diversity	[diversity]	0.9	1	10	5	5
57801	1640	CD19	[CD19]	0.9	1	10	4	4
57802	1640	NGFI-B/nur77	[NGFI-B/nur77]	0.9	1	10	1	1
57803	1640	cholesterol	[cholesterol]	0.9	1	10	2	2
57804	1640	factor,	[factor,]	0.9	1	10	4	4
57805	1640	antisense	[antisense]	0.9	1	10	7	7
57806	1640	benzene	[benzene]	0.9	1	10	2	2
57807	1640	transfectant	[transfectants]	0.9	1	10	7	7
57808	1640	IkappaBbeta	[IkappaBbeta]	0.9	1	10	1	1
57809	1640	myeloma	[myeloma]	0.9	1	10	4	4
57810	1641	box	[box]	0.8875000000000001	1	10	9	8
57811	1641	program	[program]	0.8875000000000001	1	10	9	8
57812	1642	hpc	[HPC]	0.8857142857142858	1	10	8	7
57813	1642	area	[area]	0.8857142857142858	1	10	8	7
57814	1642	phosphate	[phosphate]	0.8857142857142858	1	10	8	7
57815	1642	cis-element	[cis-element]	0.8857142857142858	1	10	8	7
57816	1642	recombination	[recombination]	0.8857142857142858	1	10	8	7
57817	1643	silencing	[silencing]	0.8833333333333334	1	10	7	6
57818	1643	homeostasis	[homeostasis]	0.8833333333333334	1	10	7	6
57819	1643	microM)	[microM)]	0.8833333333333334	1	10	7	6
57820	1643	nac	[NAC]	0.8833333333333334	1	10	7	6
57821	1643	eosinophilia	[eosinophilia]	0.8833333333333334	1	10	7	6
57822	1643	tcl1	[TCL1]	0.8833333333333334	1	10	7	6
57823	1644	e1	[E1]	0.8800000000000001	1	10	6	5
57824	1644	exercise	[exercise]	0.8800000000000001	1	10	6	5
57825	1644	linkage	[linkage]	0.8800000000000001	1	10	6	5
57826	1644	b-cll	[B-CLL]	0.8800000000000001	1	10	6	5
57827	1644	CD80	[CD80]	0.8800000000000001	1	10	6	5
57828	1644	humara	[HUMARA]	0.8800000000000001	1	10	6	5
57829	1644	pathogen	[pathogen]	0.8800000000000001	1	10	6	5
57830	1644	nsaid	[NSAID]	0.8800000000000001	1	10	6	5
57831	1645	adenosine	[adenosine]	0.875	1	10	5	4
57832	1645	identity	[identity]	0.875	1	10	10	8
57833	1645	source	[source]	0.875	1	10	10	8
57834	1645	version	[version]	0.875	1	10	10	8
57835	1645	profile	[profile]	0.875	1	10	10	8
57836	1645	galectin-3	[galectin-3]	0.875	1	10	5	4
57837	1646	problem	[problem]	0.8714285714285714	1	10	9	7
57838	1646	alpha1	[alpha1]	0.8714285714285714	1	10	9	7
57839	1646	challenge	[challenge]	0.8714285714285714	1	10	9	7
57840	1646	potentiation	[potentiation]	0.8714285714285714	1	10	9	7
57841	1647	PPARalpha	[PPARalpha]	0.8666666666666667	1	10	8	6
57842	1647	augmentation	[augmentation]	0.8666666666666667	1	11	7	3
57843	1647	ca(2+)	[Ca(2+)]	0.8666666666666667	1	10	4	3
57844	1647	arm	[arm]	0.8666666666666667	1	10	8	6
57845	1647	deficiency	[deficiency]	0.8666666666666667	1	10	4	3
57846	1647	rxr	[RXRs]	0.8666666666666667	1	11	7	3
57847	1647	p27(kip1)	[p27(KIP1)]	0.8666666666666667	1	10	4	3
57848	1647	g0/g1	[G0/G1]	0.8666666666666667	1	10	4	3
57849	1647	mycobacterium	[Mycobacterium]	0.8666666666666667	1	11	7	3
57850	1647	hsv-2	[HSV-2]	0.8666666666666667	1	10	4	3
57851	1648	ring	[ring]	0.86	1	10	7	5
57852	1648	example	[example]	0.86	1	10	7	5
57853	1648	tsp	[TSP]	0.86	1	10	7	5
57854	1648	effects,	[effects,]	0.86	1	10	7	5
57855	1648	fibrosis	[fibrosis]	0.86	1	10	7	5
57856	1649	outcome	[outcome]	0.8571428571428572	1	10	10	7
57857	1649	impairment	[impairment]	0.8571428571428572	1	10	10	7
57858	1650	belong	[belonging]	0.8500000000000001	1	10	9	6
57859	1650	RAW	[RAW]	0.8500000000000001	1	10	6	4
57860	1650	SMX	[SMX]	0.8500000000000001	1	10	3	2
57861	1650	GRalpha	[GRalpha]	0.8500000000000001	1	10	3	2
57862	1650	monocytes/macrophages	[monocytes/macrophages]	0.8500000000000001	1	11	5	2
57863	1650	interplay	[interplay]	0.8500000000000001	1	10	6	4
57864	1650	bsap	[BSAP]	0.8500000000000001	1	10	6	4
57865	1650	subpopulation	[subpopulation]	0.8500000000000001	1	10	9	6
57866	1650	NFATc	[NFATc]	0.8500000000000001	1	10	3	2
57867	1651	impact	[impact]	0.8400000000000001	1	10	8	5
57868	1651	axis	[axis]	0.8400000000000001	1	10	8	5
57869	1652	sequencing	[sequencing]	0.8333333333333335	1	11	8	3
57870	1652	hr.	[hr.]	0.8333333333333335	1	10	10	6
57871	1652	jak	[JAK]	0.8333333333333335	1	10	5	3
57872	1653	SCF	[SCF]	0.8250000000000001	1	10	7	4
57873	1653	herbimycin	[herbimycin]	0.8250000000000001	1	10	7	4
57874	1654	cortex	[cortex]	0.82	1	10	9	5
57875	1655	antitumor	[antitumor]	0.8	1	9	3	3
57876	1655	fmlp	[FMLP]	0.8	1	9	2	2
57877	1655	HU	[HU]	0.8	1	9	1	1
57878	1655	SE	[SE]	0.8	1	9	3	3
57879	1655	at	[AT]	0.8	1	9	5	5
57880	1655	g0	[G0]	0.8	1	9	1	1
57881	1655	mp	[MP]	0.8	1	9	5	5
57882	1655	p2	[P2]	0.8	1	8	0	0
57883	1655	tr	[TR]	0.8	1	9	5	5
57884	1655	stimulate	[stimulating]	0.8	1	9	4	4
57885	1655	AML1a	[AML1a]	0.8	1	9	2	2
57886	1655	CREB/ATF	[CREB/ATF]	0.8	1	9	2	2
57887	1655	G(Anh)MTetra	[G(Anh)MTetra]	0.8	1	9	4	4
57888	1655	pax-5	[Pax-5]	0.8	1	9	3	3
57889	1655	latent	[latent]	0.8	1	9	5	5
57890	1655	serine/threonine	[serine/threonine]	0.8	1	9	2	2
57891	1655	element.	[element.]	0.8	1	9	2	2
57892	1655	IL-1alpha	[IL-1alpha]	0.8	1	9	2	2
57893	1655	monocytic	[monocytic]	0.8	1	10	2	1
57894	1655	tal-1	[tal-1]	0.8	1	9	2	2
57895	1655	polyamine	[polyamine]	0.8	1	9	5	5
57896	1655	nfat-1	[NFAT-1]	0.8	1	9	5	5
57897	1655	cyclosporine	[cyclosporine]	0.8	1	9	4	4
57898	1655	threonine	[threonine]	0.8	1	9	1	1
57899	1655	jun-B	[jun-B]	0.8	1	9	3	3
57900	1655	grow	[growing]	0.8	1	9	3	3
57901	1655	c/ebp-epsilon	[C/EBP-epsilon]	0.8	1	9	3	3
57902	1655	ETS1	[ETS1]	0.8	1	9	1	1
57903	1655	subgroup	[subgroup]	0.8	1	9	6	6
57904	1655	il-2ralpha	[IL-2Ralpha]	0.8	1	9	6	6
57905	1655	kilometer	[kd]	0.8	1	9	8	8
57906	1655	inositol	[inositol]	0.8	1	9	5	5
57907	1655	granzyme	[granzyme]	0.8	1	9	2	2
57908	1655	pathophysiology	[pathophysiology]	0.8	1	11	6	2
57909	1655	b-binding	[B-binding]	0.8	1	11	9	3
57910	1655	infection,	[infection,]	0.8	1	9	3	3
57911	1655	mzf-1	[MZF-1]	0.8	1	9	5	5
57912	1655	APC	[APC]	0.8	1	9	4	4
57913	1655	hsf1	[HSF1]	0.8	1	9	4	4
57914	1655	E2A	[E2A]	0.8	1	10	2	1
57915	1655	plasmacytoma	[plasmacytoma]	0.8	1	9	5	5
57916	1655	HS2	[HS2]	0.8	1	9	2	2
57917	1655	particular,	[particular,]	0.8	1	9	2	2
57918	1655	nf(p)	[NF(P)]	0.8	1	9	1	1
57919	1655	Itk	[Itk]	0.8	1	9	3	3
57920	1655	LIF	[LIF]	0.8	1	9	3	3
57921	1655	MDD	[MDD]	0.8	1	9	4	4
57922	1655	Lck	[Lck]	0.8	1	9	1	1
57923	1655	PAF	[PAF]	0.8	1	10	2	1
57924	1655	SLE	[SLE]	0.8	1	9	1	1
57925	1655	SP1	[SP1]	0.8	1	9	4	4
57926	1655	gata3	[GATA3]	0.8	1	9	4	4
57927	1655	Vpr	[Vpr]	0.8	1	8	0	0
57928	1655	WT1	[WT1]	0.8	1	9	2	2
57929	1655	im-9	[IM-9]	0.8	1	9	2	2
57930	1655	ZEB	[ZEB]	0.8	1	9	1	1
57931	1655	cultures.	[cultures.]	0.8	1	9	2	2
57932	1655	il-7r	[IL-7R]	0.8	1	9	2	2
57933	1655	crh	[CRH]	0.8	1	9	5	5
57934	1655	advantage	[advantage]	0.8	1	10	6	3
57935	1655	gtp	[GTP]	0.8	1	9	3	3
57936	1655	lmp	[LMP]	0.8	1	8	0	0
57937	1655	mdm	[MDMs]	0.8	1	9	1	1
57938	1655	p24	[p24]	0.8	1	9	3	3
57939	1655	ptf	[PTF]	0.8	1	9	4	4
57940	1655	salt	[salt]	0.8	1	9	2	2
57941	1655	endometriosis	[endometriosis]	0.8	1	9	1	1
57942	1655	wild-type	[wild-type]	0.8	1	9	5	5
57943	1655	however,	[however,]	0.8	1	9	5	5
57944	1655	derivative	[derivative]	0.8	1	9	8	8
57945	1655	progeny	[progeny]	0.8	1	9	8	8
57946	1655	complementation	[complementation]	0.8	1	9	3	3
57947	1655	microb	[microB]	0.8	1	9	1	1
57948	1655	non-B	[non-B]	0.8	1	9	4	4
57949	1655	test	[test]	0.8	1	9	7	7
57950	1655	measurement	[measurement]	0.8	1	11	9	3
57951	1655	tlr2	[TLR2]	0.8	1	9	4	4
57952	1655	study.	[study.]	0.8	1	9	4	4
57953	1655	influenza	[influenza]	0.8	1	9	2	2
57954	1655	ethanol	[ethanol]	0.8	1	9	5	5
57955	1655	baseline	[baseline]	0.8	1	9	2	2
57956	1655	hypothesis,	[hypothesis,]	0.8	1	8	0	0
57957	1655	AITL	[AITL]	0.8	1	9	3	3
57958	1655	beta-galactosidase	[beta-galactosidase]	0.8	1	9	5	5
57959	1655	proliferation.	[proliferation.]	0.8	1	9	3	3
57960	1655	transplant	[transplant]	0.8	1	9	4	4
57961	1655	pp56(lck)	[pp56(lck)]	0.8	1	9	3	3
57962	1655	steel	[Steel]	0.8	1	10	4	2
57963	1655	chemotherapy	[chemotherapy]	0.8	1	9	5	5
57964	1655	cell-surface	[cell-surface]	0.8	1	9	7	7
57965	1655	HTLV-II	[HTLV-II]	0.8	1	9	4	4
57966	1655	proenkephalin	[proenkephalin]	0.8	1	9	5	5
57967	1655	hepatocyte	[hepatocyte]	0.8	1	9	4	4
57968	1655	osteoclast	[osteoclast]	0.8	1	9	7	7
57969	1655	colon	[colon]	0.8	1	9	1	1
57970	1655	triptolide	[triptolide]	0.8	1	9	4	4
57971	1655	antagonism	[antagonism]	0.8	1	9	6	6
57972	1655	haplotype	[haplotype]	0.8	1	9	7	7
57973	1655	TPCK	[TPCK]	0.8	1	8	0	0
57974	1655	rodent	[rodent]	0.8	1	10	4	2
57975	1655	e2f-4	[E2F-4]	0.8	1	9	3	3
57976	1655	prolactin	[prolactin]	0.8	1	9	2	2
57977	1655	sarcoidosis	[sarcoidosis]	0.8	1	9	4	4
57978	1655	hsv-1	[HSV-1]	0.8	1	9	4	4
57979	1655	nm).	[nM).]	0.8	1	9	1	1
57980	1655	erk2	[ERK2]	0.8	1	9	3	3
57981	1655	NF-E2	[NF-E2]	0.8	1	9	2	2
57982	1655	NF-E1	[NF-E1]	0.8	1	9	6	6
57983	1655	Bob1	[Bob1]	0.8	1	8	0	0
57984	1655	purpose,	[purpose,]	0.8	1	8	0	0
57985	1655	Stat4	[Stat4]	0.8	1	9	3	3
57986	1655	PML/RARalpha	[PML/RARalpha]	0.8	1	9	3	3
57987	1655	antisera	[antisera]	0.8	1	10	8	4
57988	1656	min,	[min,]	0.7875000000000001	1	9	9	8
57989	1656	ng/ml)	[ng/mL)]	0.7875000000000001	1	9	9	8
57990	1657	carrier	[carriers]	0.7857142857142858	1	9	8	7
57991	1657	male	[male]	0.7857142857142858	1	9	8	7
57992	1657	indicator	[indicator]	0.7857142857142858	1	9	8	7
57993	1658	signals,	[signals,]	0.7833333333333333	1	9	7	6
57994	1659	STAT6	[STAT6]	0.78	1	9	6	5
57995	1659	nucleoprotein	[nucleoprotein]	0.78	1	9	6	5
57996	1659	cd3+	[CD3+]	0.78	1	9	6	5
57997	1659	cd15	[CD15]	0.78	1	9	6	5
57998	1659	UT-7	[UT-7]	0.78	1	9	6	5
57999	1660	introduction	[introduction]	0.775	1	10	9	4
58000	1660	qp	[Qp]	0.775	1	9	5	4
58001	1660	cd11b/cd18	[CD11b/CD18]	0.775	1	9	5	4
58002	1660	surfactant	[surfactant]	0.775	1	9	5	4
58003	1660	LR1	[LR1]	0.775	1	9	5	4
58004	1660	igm	[IgM]	0.775	1	9	5	4
58005	1660	sialoadhesin	[sialoadhesin]	0.775	1	9	5	4
58006	1660	lmp1	[LMP1]	0.775	1	9	5	4
58007	1660	dna.	[DNA.]	0.775	1	9	5	4
58008	1660	responder	[responder]	0.775	1	9	5	4
58009	1661	isolate	[isolate]	0.7714285714285715	1	9	9	7
58010	1662	fetal	[fetal]	0.7666666666666667	1	9	4	3
58011	1662	EBS	[EBS]	0.7666666666666667	1	9	4	3
58012	1662	factor-alpha	[factor-alpha]	0.7666666666666667	1	9	8	6
58013	1662	lambda	[lambda]	0.7666666666666667	1	9	4	3
58014	1662	culture.	[culture.]	0.7666666666666667	1	9	4	3
58015	1662	leukemogenesis	[leukemogenesis]	0.7666666666666667	1	9	4	3
58016	1662	conclusion	[conclusion]	0.7666666666666667	1	9	4	3
58017	1663	work,	[work,]	0.7666666666666666	1	10	7	3
58018	1663	conjunction	[conjunction]	0.7666666666666666	1	11	10	3
58019	1663	(il)-2	[(IL)-2]	0.7666666666666666	1	10	7	3
58020	1664	bob.1/obf.1	[BOB.1/OBF.1]	0.76	1	9	7	5
58021	1664	occurrence	[occurrence]	0.76	1	9	7	5
58022	1665	Ro	[Ro]	0.75	1	9	6	4
58023	1665	reactivation	[reactivation]	0.75	1	9	9	6
58024	1665	cd28re	[CD28RE]	0.75	1	9	3	2
58025	1665	hla-dra	[HLA-DRA]	0.75	1	9	6	4
58026	1665	replication.	[replication.]	0.75	1	9	3	2
58027	1665	mobility-shift	[mobility-shift]	0.75	1	9	3	2
58028	1665	anti-CD40	[anti-CD40]	0.75	1	9	6	4
58029	1665	AML	[AML]	0.75	1	9	3	2
58030	1665	finger	[finger]	0.75	1	10	5	2
58031	1665	self	[self]	0.75	1	9	3	2
58032	1665	rhythm	[rhythm]	0.75	1	9	9	6
58033	1665	reverse	[reverse]	0.75	1	9	3	2
58034	1665	B-CLL	[B-CLL]	0.75	1	9	3	2
58035	1666	immunization	[immunization]	0.7400000000000001	1	9	8	5
58036	1667	Ie	[IE]	0.7333333333333334	1	9	5	3
58037	1667	prevalence	[prevalence]	0.7333333333333334	1	10	8	3
58038	1667	HML	[HML]	0.7333333333333334	1	9	5	3
58039	1667	synergism	[synergism]	0.7333333333333334	1	9	5	3
58040	1667	renin	[renin]	0.7333333333333334	1	9	5	3
58041	1668	sites.	[sites.]	0.7250000000000001	1	9	7	4
58042	1669	2a	[2A]	0.7000000000000001	1	8	2	2
58043	1669	progress	[progress]	0.7000000000000001	1	8	7	7
58044	1669	Ag	[Ag]	0.7000000000000001	1	8	6	6
58045	1669	BL	[BL]	0.7000000000000001	1	8	4	4
58046	1669	DQ	[DQ]	0.7000000000000001	1	8	2	2
58047	1669	FN	[FN]	0.7000000000000001	1	8	2	2
58048	1669	IL	[IL]	0.7000000000000001	1	8	6	6
58049	1669	U3	[U3]	0.7000000000000001	1	8	2	2
58050	1669	Wp	[Wp]	0.7000000000000001	1	8	1	1
58051	1669	fold	[fold]	0.7000000000000001	1	8	7	7
58052	1669	gh	[GH]	0.7000000000000001	1	8	3	3
58053	1669	5-lipoxygenase	[5-lipoxygenase]	0.7000000000000001	1	8	2	2
58054	1669	T3SO4	[T3SO4]	0.7000000000000001	1	8	1	1
58055	1669	rhombotin	[rhombotin]	0.7000000000000001	1	8	3	3
58056	1669	pdgf(b)	[PDGF(B)]	0.7000000000000001	1	8	2	2
58057	1669	oriP	[oriP]	0.7000000000000001	1	8	2	2
58058	1669	B-myb	[B-myb]	0.7000000000000001	1	7	0	0
58059	1669	-beta	[-beta]	0.7000000000000001	1	8	2	2
58060	1669	dioxin	[dioxin]	0.7000000000000001	1	8	4	4
58061	1669	microglia	[microglia]	0.7000000000000001	1	7	0	0
58062	1669	application	[application]	0.7000000000000001	1	8	7	7
58063	1669	hypersensitivity	[hypersensitivity]	0.7000000000000001	1	8	3	3
58064	1669	EGR1	[EGR1]	0.7000000000000001	1	7	0	0
58065	1669	catalase	[catalase]	0.7000000000000001	1	9	4	2
58066	1669	-contain	[-containing]	0.7000000000000001	1	8	7	7
58067	1669	hgata-3	[hGATA-3]	0.7000000000000001	1	8	2	2
58068	1669	gold	[gold]	0.7000000000000001	1	8	4	4
58069	1669	raralpha	[RARalpha]	0.7000000000000001	1	8	4	4
58070	1669	HHV-6	[HHV-6]	0.7000000000000001	1	8	4	4
58071	1669	Smad6	[Smad6]	0.7000000000000001	1	8	2	2
58072	1669	Smad7	[Smad7]	0.7000000000000001	1	7	0	0
58073	1669	Bcl-3	[Bcl-3]	0.7000000000000001	1	7	0	0
58074	1669	pathways.	[pathways.]	0.7000000000000001	1	8	3	3
58075	1669	x-chromosome	[X-chromosome]	0.7000000000000001	1	8	4	4
58076	1669	nucleolin	[nucleolin]	0.7000000000000001	1	8	2	2
58077	1669	Bcl-xL	[Bcl-xL]	0.7000000000000001	1	7	0	0
58078	1669	hiv1	[HIV1]	0.7000000000000001	1	8	3	3
58079	1669	csf-1	[CSF-1]	0.7000000000000001	1	8	4	4
58080	1669	AhR	[AhR]	0.7000000000000001	1	9	2	1
58081	1669	E1a	[E1a]	0.7000000000000001	1	7	0	0
58082	1669	ptpase	[PTPase]	0.7000000000000001	1	8	2	2
58083	1669	parasite	[parasite]	0.7000000000000001	1	8	4	4
58084	1669	HIV-2	[HIV-2]	0.7000000000000001	1	7	0	0
58085	1669	IgE	[IgE]	0.7000000000000001	1	8	5	5
58086	1669	MBP	[MBP]	0.7000000000000001	1	8	1	1
58087	1669	Mac	[Mac]	0.7000000000000001	1	9	8	4
58088	1669	PHA	[PHA]	0.7000000000000001	1	8	3	3
58089	1669	PIH	[PIH]	0.7000000000000001	1	8	2	2
58090	1669	R24	[R24]	0.7000000000000001	1	8	2	2
58091	1669	Pax-5	[Pax-5]	0.7000000000000001	1	7	0	0
58092	1669	ROS	[ROS]	0.7000000000000001	1	9	6	3
58093	1669	Rho	[Rho]	0.7000000000000001	1	8	3	3
58094	1669	SML	[SML]	0.7000000000000001	1	8	2	2
58095	1669	Ramos	[Ramos]	0.7000000000000001	1	8	3	3
58096	1669	TPO	[TPO]	0.7000000000000001	1	7	0	0
58097	1669	RBP-Jkappa	[RBP-Jkappa]	0.7000000000000001	1	8	1	1
58098	1669	system.	[system.]	0.7000000000000001	1	8	2	2
58099	1669	determination	[determination]	0.7000000000000001	1	9	6	3
58100	1669	VZV	[VZV]	0.7000000000000001	1	8	5	5
58101	1669	phosphoinositide	[phosphoinositide]	0.7000000000000001	1	8	4	4
58102	1669	hybridoma	[hybridoma]	0.7000000000000001	1	8	6	6
58103	1669	Oct1	[Oct1]	0.7000000000000001	1	8	2	2
58104	1669	depression	[depression]	0.7000000000000001	1	8	5	5
58105	1669	isgf3	[ISGF3]	0.7000000000000001	1	8	2	2
58106	1669	bcr	[BCR]	0.7000000000000001	1	8	2	2
58107	1669	turn,	[turn,]	0.7000000000000001	1	7	0	0
58108	1669	heparin	[heparin]	0.7000000000000001	1	8	4	4
58109	1669	hie	[HIE]	0.7000000000000001	1	8	2	2
58110	1669	iNO	[iNO]	0.7000000000000001	1	8	2	2
58111	1669	hsv	[HSV]	0.7000000000000001	1	8	2	2
58112	1669	strike	[striking]	0.7000000000000001	1	7	0	0
58113	1669	il4	[IL4]	0.7000000000000001	1	8	2	2
58114	1669	ikk	[IKK]	0.7000000000000001	1	8	4	4
58115	1669	A-MYB	[A-MYB]	0.7000000000000001	1	8	2	2
58116	1669	age,	[age,]	0.7000000000000001	1	8	3	3
58117	1669	jak2	[JAK2]	0.7000000000000001	1	8	4	4
58118	1669	ng/ml	[ng/ml]	0.7000000000000001	1	8	5	5
58119	1669	pel	[PEL]	0.7000000000000001	1	8	3	3
58120	1669	rip	[RIP]	0.7000000000000001	1	8	3	3
58121	1669	microtubule	[microtubule]	0.7000000000000001	1	8	6	6
58122	1669	tam	[TAM]	0.7000000000000001	1	8	3	3
58123	1669	tre	[TRE]	0.7000000000000001	1	8	5	5
58124	1669	Takayasu	[Takayasu]	0.7000000000000001	1	7	0	0
58125	1669	IKKbeta	[IKKbeta]	0.7000000000000001	1	8	1	1
58126	1669	observations,	[observations,]	0.7000000000000001	1	8	3	3
58127	1669	resolution	[resolution]	0.7000000000000001	1	10	9	3
58128	1669	Grf40	[Grf40]	0.7000000000000001	1	8	4	4
58129	1669	HL60	[HL60]	0.7000000000000001	1	9	4	2
58130	1669	definition	[definition]	0.7000000000000001	1	8	8	8
58131	1669	HLA-DRA	[HLA-DRA]	0.7000000000000001	1	9	2	1
58132	1669	bcl6	[BCL6]	0.7000000000000001	1	8	3	3
58133	1669	site.	[site.]	0.7000000000000001	1	8	2	2
58134	1669	ubiquitin	[ubiquitin]	0.7000000000000001	1	8	1	1
58135	1669	neuroblastoma	[neuroblastoma]	0.7000000000000001	1	8	4	4
58136	1669	biopsy	[biopsy]	0.7000000000000001	1	8	5	5
58137	1669	radiotherapy	[radiotherapy]	0.7000000000000001	1	8	3	3
58138	1669	notch	[Notch]	0.7000000000000001	1	8	1	1
58139	1669	RT-PCR	[RT-PCR]	0.7000000000000001	1	10	3	1
58140	1669	prerequisite	[prerequisite]	0.7000000000000001	1	10	9	3
58141	1669	agents.	[agents.]	0.7000000000000001	1	8	4	4
58142	1669	ciprofloxacin	[ciprofloxacin]	0.7000000000000001	1	8	1	1
58143	1669	ricket	[rickets]	0.7000000000000001	1	8	3	3
58144	1669	cd86	[CD86]	0.7000000000000001	1	8	2	2
58145	1669	-produce	[-producing]	0.7000000000000001	1	8	4	4
58146	1669	vertebrate	[vertebrate]	0.7000000000000001	1	8	1	1
58147	1669	cdc2	[cdc2]	0.7000000000000001	1	10	3	1
58148	1669	hs-40	[HS-40]	0.7000000000000001	1	8	2	2
58149	1669	mammalian	[mammalian]	0.7000000000000001	1	8	2	2
58150	1669	Aldh1	[Aldh1]	0.7000000000000001	1	8	5	5
58151	1669	develop	[developing]	0.7000000000000001	1	8	2	2
58152	1669	life	[life]	0.7000000000000001	1	7	0	0
58153	1669	p39c-jun	[p39c-jun]	0.7000000000000001	1	8	3	3
58154	1669	Ets-1	[Ets-1]	0.7000000000000001	1	8	2	2
58155	1669	expression,	[expression,]	0.7000000000000001	1	8	1	1
58156	1669	lysopc	[lysoPC]	0.7000000000000001	1	8	2	2
58157	1669	organism	[organism]	0.7000000000000001	1	8	6	6
58158	1669	t-helper	[T-helper]	0.7000000000000001	1	8	2	2
58159	1669	hil-5	[hIL-5]	0.7000000000000001	1	8	1	1
58160	1669	IKKalpha	[IKKalpha]	0.7000000000000001	1	8	2	2
58161	1669	oct-2	[Oct-2]	0.7000000000000001	1	8	3	3
58162	1669	data	[Data]	0.7000000000000001	1	8	2	2
58163	1669	SRG3	[SRG3]	0.7000000000000001	1	8	1	1
58164	1669	mean	[mean]	0.7000000000000001	1	8	5	5
58165	1669	anemia	[anemia]	0.7000000000000001	1	8	5	5
58166	1669	dna,	[DNA,]	0.7000000000000001	1	7	0	0
58167	1669	days.	[days.]	0.7000000000000001	1	8	3	3
58168	1669	ml-9	[ML-9]	0.7000000000000001	1	8	1	1
58169	1669	NF-kappaB/Rel	[NF-kappaB/Rel]	0.7000000000000001	1	8	4	4
58170	1669	alpha-tocopherol	[alpha-tocopherol]	0.7000000000000001	1	8	5	5
58171	1669	lipid	[lipid]	0.7000000000000001	1	8	5	5
58172	1669	sickle	[sickle]	0.7000000000000001	1	9	4	2
58173	1669	ym268	[YM268]	0.7000000000000001	1	8	1	1
58174	1669	hmg-i(y)	[HMG-I(Y)]	0.7000000000000001	1	8	3	3
58175	1669	coordinate	[coordinate]	0.7000000000000001	1	8	3	3
58176	1669	bcl-xl	[Bcl-xL]	0.7000000000000001	1	9	6	3
58177	1669	e2f-1	[E2F-1]	0.7000000000000001	1	8	6	6
58178	1669	eklf	[EKLF]	0.7000000000000001	1	8	3	3
58179	1669	collagenase-1	[collagenase-1]	0.7000000000000001	1	8	3	3
58180	1669	gel-shift	[gel-shift]	0.7000000000000001	1	8	2	2
58181	1669	p100	[p100]	0.7000000000000001	1	8	4	4
58182	1669	cd8(+)	[CD8(+)]	0.7000000000000001	1	8	3	3
58183	1669	zipper	[zipper]	0.7000000000000001	1	8	6	6
58184	1669	nadph	[NADPH]	0.7000000000000001	1	9	6	3
58185	1669	excess	[excess]	0.7000000000000001	1	9	6	3
58186	1669	tissues.	[tissues.]	0.7000000000000001	1	8	3	3
58187	1669	Stat3alpha	[Stat3alpha]	0.7000000000000001	1	8	1	1
58188	1669	beta-chain	[beta-chain]	0.7000000000000001	1	8	7	7
58189	1669	nmol/l,	[nmol/L,]	0.7000000000000001	1	8	6	6
58190	1669	nucleus,	[nucleus,]	0.7000000000000001	1	8	1	1
58191	1669	pml/rar	[PML/RAR]	0.7000000000000001	1	8	5	5
58192	1669	CD11b	[CD11b]	0.7000000000000001	1	8	1	1
58193	1669	nmol/L)	[nmol/L)]	0.7000000000000001	1	8	6	6
58194	1669	anti-cd2	[anti-CD2]	0.7000000000000001	1	8	2	2
58195	1669	purification	[purification]	0.7000000000000001	1	9	6	3
58196	1669	asthmatics	[asthmatics]	0.7000000000000001	1	8	4	4
58197	1669	fish	[FISH]	0.7000000000000001	1	8	2	2
58198	1669	immunocytochemistry	[immunocytochemistry]	0.7000000000000001	1	8	3	3
58199	1670	killing	[killing]	0.6857142857142858	1	8	8	7
58200	1670	dependence	[dependence]	0.6857142857142858	1	8	8	7
58201	1670	insensitivity	[insensitivity]	0.6857142857142858	1	8	8	7
58202	1671	particle	[particle]	0.6833333333333333	1	8	7	6
58203	1671	alpha-chain	[alpha-chain]	0.6833333333333333	1	8	7	6
58204	1671	microM.	[microM.]	0.6833333333333333	1	8	7	6
58205	1671	sign	[sign]	0.6833333333333333	1	8	7	6
58206	1671	recovery	[recovery]	0.6833333333333333	1	8	7	6
58207	1672	platelet-activating	[platelet-activating]	0.68	1	8	6	5
58208	1672	fmol/mg	[fmol/mg]	0.68	1	8	6	5
58209	1672	Pan	[Pan]	0.68	1	8	6	5
58210	1672	transplantation	[transplantation]	0.68	1	8	6	5
58211	1672	extend	[extending]	0.68	1	8	6	5
58212	1672	Scatchard	[Scatchard]	0.68	1	8	6	5
58213	1672	analogue	[analogue]	0.68	1	8	6	5
58214	1672	location	[location]	0.68	1	8	6	5
58215	1673	FMS	[FMS]	0.675	1	8	5	4
58216	1673	helix	[helix]	0.675	1	8	5	4
58217	1673	src	[src]	0.675	1	8	5	4
58218	1673	nfat1	[NFAT1]	0.675	1	8	5	4
58219	1673	calyculin	[calyculin]	0.675	1	8	5	4
58220	1673	as2o3	[As2O3]	0.675	1	8	5	4
58221	1674	YJ	[YJ]	0.6666666666666667	1	8	4	3
58222	1674	zp	[Zp]	0.6666666666666667	1	8	4	3
58223	1674	ALY	[ALY]	0.6666666666666667	1	8	4	3
58224	1674	alpha-globin	[alpha-globin]	0.6666666666666667	1	8	4	3
58225	1674	atf-1	[ATF-1]	0.6666666666666667	1	8	4	3
58226	1674	neoplasm	[neoplasms]	0.6666666666666667	1	8	4	3
58227	1674	RAI	[RAI]	0.6666666666666667	1	8	4	3
58228	1674	SL3	[SL3]	0.6666666666666667	1	8	4	3
58229	1674	c-terminus	[C-terminus]	0.6666666666666667	1	8	4	3
58230	1674	5'HS3	[5'HS3]	0.6666666666666667	1	8	4	3
58231	1674	pwm	[PWM]	0.6666666666666667	1	8	4	3
58232	1674	retrovirus	[retrovirus]	0.6666666666666667	1	8	4	3
58233	1674	arsenic	[arsenic]	0.6666666666666667	1	8	4	3
58234	1674	envelope	[envelope]	0.6666666666666667	1	8	4	3
58235	1674	x-inactivation	[X-inactivation]	0.6666666666666667	1	8	4	3
58236	1674	coli	[coli]	0.6666666666666667	1	8	8	6
58237	1674	protein(s)	[protein(s)]	0.6666666666666667	1	8	4	3
58238	1675	tail	[tail]	0.6666666666666666	1	9	7	3
58239	1675	pertussis	[pertussis]	0.6666666666666666	1	9	7	3
58240	1675	effusion	[effusion]	0.6666666666666666	1	9	7	3
58241	1676	redundancy	[redundancy]	0.66	1	8	7	5
58242	1676	factor-1	[factor-1]	0.66	1	8	7	5
58243	1677	cr	[CR]	0.65	1	9	5	2
58244	1677	truncation	[truncation]	0.65	1	8	3	2
58245	1677	NIK	[NIK]	0.65	1	8	3	2
58246	1677	b104	[B104]	0.65	1	8	3	2
58247	1677	homeobox	[homeobox]	0.65	1	9	5	2
58248	1677	biology	[biology]	0.65	1	9	5	2
58249	1677	manner,	[manner,]	0.65	1	8	6	4
58250	1677	mad3	[MAD3]	0.65	1	8	3	2
58251	1677	interest	[interest]	0.65	1	8	6	4
58252	1677	anti-igm	[anti-IgM]	0.65	1	8	3	2
58253	1677	attention	[attention]	0.65	1	8	6	4
58254	1677	plzf-rar	[PLZF-RAR]	0.65	1	9	5	2
58255	1678	-stat	[-STAT]	0.6400000000000001	1	8	8	5
58256	1678	array	[array]	0.6400000000000001	1	8	8	5
58257	1678	CR1	[CR1]	0.6400000000000001	1	8	8	5
58258	1678	/Rel	[/Rel]	0.6400000000000001	1	8	8	5
58259	1678	terminus	[terminus]	0.6400000000000001	1	8	8	5
58260	1679	emergence	[emergence]	0.6333333333333334	1	9	8	3
58261	1679	alpha,25-(OH)2D3	[alpha,25-(OH)2D3]	0.6333333333333334	1	9	8	3
58262	1679	mobilization	[mobilization]	0.6333333333333334	1	9	8	3
58263	1680	creb/atf	[CREB/ATF]	0.6333333333333333	1	8	5	3
58264	1680	ptsd	[PTSD]	0.6333333333333333	1	8	5	3
58265	1680	design	[design]	0.6333333333333333	1	8	5	3
58266	1680	heterodimerization	[heterodimerization]	0.6333333333333333	1	8	5	3
58267	1680	Lipopolysaccharide	[Lipopolysaccharide]	0.6333333333333333	1	8	5	3
58268	1680	message	[message]	0.6333333333333333	1	8	5	3
58269	1680	media	[media]	0.6333333333333333	1	8	5	3
58270	1680	stabilization	[stabilization]	0.6333333333333333	1	8	5	3
58271	1681	enterotoxin	[enterotoxin]	0.625	1	8	7	4
58272	1681	index	[index]	0.625	1	8	7	4
58273	1682	V	[V]	0.6000000000000001	1	7	2	2
58274	1682	Z	[Z]	0.6000000000000001	1	7	3	3
58275	1682	time-	[time-]	0.6000000000000001	1	7	1	1
58276	1682	Tyk2	[Tyk2]	0.6000000000000001	1	7	1	1
58277	1682	attempt	[attempt]	0.6000000000000001	1	7	1	1
58278	1682	HL	[HL]	0.6000000000000001	1	7	5	5
58279	1682	NB	[NB]	0.6000000000000001	1	6	0	0
58280	1682	T3	[T3]	0.6000000000000001	1	7	1	1
58281	1682	dc	[DCs]	0.6000000000000001	1	6	0	0
58282	1682	fp	[FP]	0.6000000000000001	1	7	2	2
58283	1682	hm	[Hm]	0.6000000000000001	1	7	2	2
58284	1682	ms	[MS]	0.6000000000000001	1	7	1	1
58285	1682	p4	[P4]	0.6000000000000001	1	7	1	1
58286	1682	pb	[PB]	0.6000000000000001	1	7	3	3
58287	1682	ro	[Ro]	0.6000000000000001	1	7	3	3
58288	1682	sr	[SR]	0.6000000000000001	1	7	3	3
58289	1682	wp	[Wp]	0.6000000000000001	1	7	1	1
58290	1682	b/rel	[B/Rel]	0.6000000000000001	1	7	3	3
58291	1682	sense	[sense]	0.6000000000000001	1	7	5	5
58292	1682	Interferon	[Interferon]	0.6000000000000001	1	7	5	5
58293	1682	procedure	[procedure]	0.6000000000000001	1	7	4	4
58294	1682	(range,	[(range,]	0.6000000000000001	1	7	5	5
58295	1682	promoter.	[promoter.]	0.6000000000000001	1	7	2	2
58296	1682	cell-cycle	[cell-cycle]	0.6000000000000001	1	7	1	1
58297	1682	gal4	[GAL4]	0.6000000000000001	1	7	3	3
58298	1682	v-Abl	[v-Abl]	0.6000000000000001	1	7	3	3
58299	1682	vitd3	[VitD3]	0.6000000000000001	1	7	4	4
58300	1682	cysteamine	[cysteamine]	0.6000000000000001	1	7	2	2
58301	1682	mechanism(s)	[mechanism(s)]	0.6000000000000001	1	7	3	3
58302	1682	ICSAT	[ICSAT]	0.6000000000000001	1	7	1	1
58303	1682	Azeptin	[Azeptin]	0.6000000000000001	1	6	0	0
58304	1682	elastase	[elastase]	0.6000000000000001	1	7	2	2
58305	1682	OTF-2	[OTF-2]	0.6000000000000001	1	7	3	3
58306	1682	reservoir	[reservoir]	0.6000000000000001	1	7	5	5
58307	1682	gp41	[gp41]	0.6000000000000001	1	7	3	3
58308	1682	pathology	[pathology]	0.6000000000000001	1	7	6	6
58309	1682	ovulation	[ovulation]	0.6000000000000001	1	6	0	0
58310	1682	pp52	[pp52]	0.6000000000000001	1	6	0	0
58311	1682	pool	[pool]	0.6000000000000001	1	7	5	5
58312	1682	thrombopoietin	[thrombopoietin]	0.6000000000000001	1	7	3	3
58313	1682	diabete	[diabetes]	0.6000000000000001	1	7	3	3
58314	1682	(s)	[(s)]	0.6000000000000001	1	7	2	2
58315	1682	IFN-beta	[IFN-beta]	0.6000000000000001	1	7	3	3
58316	1682	elongation	[elongation]	0.6000000000000001	1	7	3	3
58317	1682	samples.	[samples.]	0.6000000000000001	1	7	2	2
58318	1682	autocrine	[autocrine]	0.6000000000000001	1	7	3	3
58319	1682	pcd41	[pCD41]	0.6000000000000001	1	7	4	4
58320	1682	duration	[duration]	0.6000000000000001	1	8	4	2
58321	1682	bufalin	[bufalin]	0.6000000000000001	1	7	3	3
58322	1682	alpha-	[alpha-]	0.6000000000000001	1	7	5	5
58323	1682	prednisolone	[prednisolone]	0.6000000000000001	1	7	3	3
58324	1682	alpha-tcp	[alpha-tcp]	0.6000000000000001	1	6	0	0
58325	1682	inhibition.	[inhibition.]	0.6000000000000001	1	7	1	1
58326	1682	events.	[events.]	0.6000000000000001	1	7	4	4
58327	1682	cross-talk	[cross-talk]	0.6000000000000001	1	7	5	5
58328	1682	overlap	[overlapping]	0.6000000000000001	1	7	2	2
58329	1682	nur77	[nur77]	0.6000000000000001	1	7	4	4
58330	1682	irf-2	[IRF-2]	0.6000000000000001	1	7	3	3
58331	1682	CBP	[CBP]	0.6000000000000001	1	7	2	2
58332	1682	CIF	[CIF]	0.6000000000000001	1	7	3	3
58333	1682	Bik	[Bik]	0.6000000000000001	1	6	0	0
58334	1682	CRF	[CRF]	0.6000000000000001	1	7	2	2
58335	1682	CVZ	[CVZ]	0.6000000000000001	1	7	5	5
58336	1682	[3H]thymidine	[[3H]thymidine]	0.6000000000000001	1	7	4	4
58337	1682	DQB	[DQB]	0.6000000000000001	1	7	3	3
58338	1682	CpG	[CpG]	0.6000000000000001	1	7	1	1
58339	1682	Ctx	[Ctx]	0.6000000000000001	1	6	0	0
58340	1682	DZA	[DZA]	0.6000000000000001	1	6	0	0
58341	1682	EBF	[EBF]	0.6000000000000001	1	8	2	1
58342	1682	EL4	[EL4]	0.6000000000000001	1	7	1	1
58343	1682	HEL	[HEL]	0.6000000000000001	1	7	3	3
58344	1682	IKK	[IKK]	0.6000000000000001	1	7	2	2
58345	1682	treatment,	[treatment,]	0.6000000000000001	1	7	1	1
58346	1682	pulse	[pulse]	0.6000000000000001	1	7	5	5
58347	1682	IkB	[IkB]	0.6000000000000001	1	7	2	2
58348	1682	LAM	[LAM]	0.6000000000000001	1	7	1	1
58349	1682	NB4	[NB4]	0.6000000000000001	1	7	2	2
58350	1682	NLS	[NLS]	0.6000000000000001	1	7	1	1
58351	1682	Nmi	[Nmi]	0.6000000000000001	1	7	1	1
58352	1682	PRL	[PRL]	0.6000000000000001	1	7	2	2
58353	1682	clearance	[clearance]	0.6000000000000001	1	7	4	4
58354	1682	tnfalpha	[TNFalpha]	0.6000000000000001	1	7	5	5
58355	1682	rank	[RANK]	0.6000000000000001	1	7	2	2
58356	1682	rescue	[rescue]	0.6000000000000001	1	7	4	4
58357	1682	cd11c	[CD11c]	0.6000000000000001	1	7	1	1
58358	1682	thymidine	[thymidine]	0.6000000000000001	1	7	6	6
58359	1682	shear	[shear]	0.6000000000000001	1	7	3	3
58360	1682	cd56+	[CD56+]	0.6000000000000001	1	7	4	4
58361	1682	NF-AT1	[NF-AT1]	0.6000000000000001	1	7	1	1
58362	1682	tamoxifen	[tamoxifen]	0.6000000000000001	1	7	3	3
58363	1682	cd95l	[CD95L]	0.6000000000000001	1	7	3	3
58364	1682	triflusal	[triflusal]	0.6000000000000001	1	7	1	1
58365	1682	example,	[example,]	0.6000000000000001	1	7	2	2
58366	1682	conformation	[conformation]	0.6000000000000001	1	7	4	4
58367	1682	ad5	[Ad5]	0.6000000000000001	1	7	2	2
58368	1682	abs	[Abs]	0.6000000000000001	1	7	5	5
58369	1682	all	[ALL]	0.6000000000000001	1	7	2	2
58370	1682	bcd	[Bcd]	0.6000000000000001	1	7	3	3
58371	1682	blk	[blk]	0.6000000000000001	1	7	2	2
58372	1682	cap	[cap]	0.6000000000000001	1	7	1	1
58373	1682	dse	[DSE]	0.6000000000000001	1	7	5	5
58374	1682	gag	[GAG]	0.6000000000000001	1	7	3	3
58375	1682	gut	[gut]	0.6000000000000001	1	7	5	5
58376	1682	hbd	[HBD]	0.6000000000000001	1	7	3	3
58377	1682	htr	[hTR]	0.6000000000000001	1	7	2	2
58378	1682	runt	[runt]	0.6000000000000001	1	7	6	6
58379	1682	coagulation	[coagulation]	0.6000000000000001	1	7	2	2
58380	1682	control.	[control.]	0.6000000000000001	1	7	2	2
58381	1682	lai	[LAI]	0.6000000000000001	1	7	3	3
58382	1682	BCL-2	[BCL-2]	0.6000000000000001	1	7	2	2
58383	1682	elam-1	[ELAM-1]	0.6000000000000001	1	7	7	7
58384	1682	mm)	[mM)]	0.6000000000000001	1	7	6	6
58385	1682	mpl	[MPL]	0.6000000000000001	1	7	4	4
58386	1682	nm)	[nM)]	0.6000000000000001	1	7	5	5
58387	1682	nos	[NOS]	0.6000000000000001	1	7	6	6
58388	1682	orf	[ORF]	0.6000000000000001	1	7	4	4
58389	1682	ro(ssa)	[Ro(SSA)]	0.6000000000000001	1	6	0	0
58390	1682	pc4	[PC4]	0.6000000000000001	1	7	2	2
58391	1682	pax	[Pax]	0.6000000000000001	1	6	0	0
58392	1682	HB24	[HB24]	0.6000000000000001	1	8	4	2
58393	1682	rex	[rex]	0.6000000000000001	1	7	1	1
58394	1682	alas	[ALAS]	0.6000000000000001	1	7	3	3
58395	1682	C3a(desArg)	[C3a(desArg)]	0.6000000000000001	1	7	1	1
58396	1682	tcc	[TCC]	0.6000000000000001	1	7	4	4
58397	1682	tpo	[TPO]	0.6000000000000001	1	7	3	3
58398	1682	tsh	[TSH]	0.6000000000000001	1	7	3	3
58399	1682	preeclampsia	[preeclampsia]	0.6000000000000001	1	7	2	2
58400	1682	udg	[UDG]	0.6000000000000001	1	7	2	2
58401	1682	timp-1	[TIMP-1]	0.6000000000000001	1	7	3	3
58402	1682	xpb	[XPB]	0.6000000000000001	1	7	2	2
58403	1682	induction,	[induction,]	0.6000000000000001	1	7	4	4
58404	1682	virus.	[virus.]	0.6000000000000001	1	6	0	0
58405	1682	sigm	[sIgM]	0.6000000000000001	1	7	3	3
58406	1682	etiology	[etiology]	0.6000000000000001	1	7	6	6
58407	1682	scavenger	[scavenger]	0.6000000000000001	1	7	4	4
58408	1682	sv40	[SV40]	0.6000000000000001	1	7	2	2
58409	1682	Spi-C	[Spi-C]	0.6000000000000001	1	7	2	2
58410	1682	transcription-polymerase	[transcription-polymerase]	0.6000000000000001	1	7	2	2
58411	1682	IARC	[IARC]	0.6000000000000001	1	7	4	4
58412	1682	cytochrome	[cytochrome]	0.6000000000000001	1	7	2	2
58413	1682	sds-page	[SDS-PAGE]	0.6000000000000001	1	6	0	0
58414	1682	effort	[effort]	0.6000000000000001	1	6	0	0
58415	1682	mantle	[mantle]	0.6000000000000001	1	7	2	2
58416	1682	bzip	[bZIP]	0.6000000000000001	1	7	5	5
58417	1682	AIR-1	[AIR-1]	0.6000000000000001	1	7	1	1
58418	1682	oncogenesis	[oncogenesis]	0.6000000000000001	1	7	2	2
58419	1682	traz	[TRAFs]	0.6000000000000001	1	7	4	4
58420	1682	downstream	[downstream]	0.6000000000000001	1	7	4	4
58421	1682	c-fos/c-jun	[c-fos/c-jun]	0.6000000000000001	1	7	3	3
58422	1682	selenium	[selenium]	0.6000000000000001	1	7	2	2
58423	1682	alanine	[alanine]	0.6000000000000001	1	7	2	2
58424	1682	vanadate	[vanadate]	0.6000000000000001	1	7	3	3
58425	1682	correlate	[correlate]	0.6000000000000001	1	7	7	7
58426	1682	cell.	[cell.]	0.6000000000000001	1	7	3	3
58427	1682	HMG-I	[HMG-I]	0.6000000000000001	1	6	0	0
58428	1682	deregulation	[deregulation]	0.6000000000000001	1	8	8	4
58429	1682	friend	[Friend]	0.6000000000000001	1	7	1	1
58430	1682	autoantigen	[autoantigen]	0.6000000000000001	1	7	3	3
58431	1682	stat2	[STAT2]	0.6000000000000001	1	7	1	1
58432	1682	loci	[loci]	0.6000000000000001	1	7	6	6
58433	1682	Hox11	[Hox11]	0.6000000000000001	1	7	2	2
58434	1682	steroid/thyroid	[steroid/thyroid]	0.6000000000000001	1	6	0	0
58435	1682	adhesive	[adhesive]	0.6000000000000001	1	7	5	5
58436	1682	intensity	[intensity]	0.6000000000000001	1	9	6	2
58437	1682	leukotriene	[leukotriene]	0.6000000000000001	1	7	2	2
58438	1682	CNI-1493	[CNI-1493]	0.6000000000000001	1	6	0	0
58439	1682	p56lck	[p56lck]	0.6000000000000001	1	7	2	2
58440	1682	uterine	[uterine]	0.6000000000000001	1	7	2	2
58441	1682	[3H]dexamethasone	[[3H]dexamethasone]	0.6000000000000001	1	7	3	3
58442	1682	toxicity	[toxicity]	0.6000000000000001	1	7	5	5
58443	1682	autoimmunity	[autoimmunity]	0.6000000000000001	1	6	0	0
58444	1682	15-lipoxygenase	[15-lipoxygenase]	0.6000000000000001	1	7	3	3
58445	1682	vdre	[VDRE]	0.6000000000000001	1	7	3	3
58446	1682	TCEd	[TCEd]	0.6000000000000001	1	7	4	4
58447	1682	view	[view]	0.6000000000000001	1	9	6	2
58448	1682	cos-7	[COS-7]	0.6000000000000001	1	7	2	2
58449	1682	encoding	[encoding]	0.6000000000000001	1	7	5	5
58450	1682	sterol	[sterol]	0.6000000000000001	1	7	3	3
58451	1682	gamma-ifn	[gamma-IFN]	0.6000000000000001	1	7	3	3
58452	1682	tryptophan	[tryptophan]	0.6000000000000001	1	7	1	1
58453	1682	CAML	[CAML]	0.6000000000000001	1	7	3	3
58454	1682	bandshift	[bandshift]	0.6000000000000001	1	7	5	5
58455	1682	controls,	[controls,]	0.6000000000000001	1	7	1	1
58456	1682	result,	[result,]	0.6000000000000001	1	6	0	0
58457	1682	chimera	[chimera]	0.6000000000000001	1	6	0	0
58458	1682	monocyte-macrophage	[monocyte-macrophage]	0.6000000000000001	1	7	2	2
58459	1682	CCAAT	[CCAAT]	0.6000000000000001	1	7	1	1
58460	1682	p21(waf1/cip1)	[p21(WAF1/CIP1)]	0.6000000000000001	1	7	3	3
58461	1682	loss-of-function	[loss-of-function]	0.6000000000000001	1	7	2	2
58462	1682	sclerosis	[sclerosis]	0.6000000000000001	1	7	6	6
58463	1682	keratinocyte	[keratinocyte]	0.6000000000000001	1	7	3	3
58464	1682	CoCl2	[CoCl2]	0.6000000000000001	1	7	1	1
58465	1682	eth1	[eTh1]	0.6000000000000001	1	7	2	2
58466	1682	family,	[family,]	0.6000000000000001	1	7	3	3
58467	1682	review,	[review,]	0.6000000000000001	1	6	0	0
58468	1682	SOCS-3	[SOCS-3]	0.6000000000000001	1	7	2	2
58469	1682	metabolism	[metabolism]	0.6000000000000001	1	7	6	6
58470	1682	substance	[substances]	0.6000000000000001	1	7	6	6
58471	1682	cbp/p300	[CBP/p300]	0.6000000000000001	1	6	0	0
58472	1682	p70(s6k)	[p70(s6k)]	0.6000000000000001	1	7	1	1
58473	1682	hypermutation	[hypermutation]	0.6000000000000001	1	7	5	5
58474	1682	curcumin	[curcumin]	0.6000000000000001	1	7	2	2
58475	1682	traf3	[TRAF3]	0.6000000000000001	1	7	3	3
58476	1682	antiandrogen	[antiandrogen]	0.6000000000000001	1	7	4	4
58477	1683	half	[half]	0.5833333333333334	1	7	7	6
58478	1683	labeling	[labeling]	0.5833333333333334	1	7	7	6
58479	1683	manifestation	[manifestation]	0.5833333333333334	1	7	7	6
58480	1683	focus	[focus]	0.5833333333333334	1	7	7	6
58481	1683	Zta	[Zta]	0.5833333333333334	1	7	7	6
58482	1683	constituent	[constituent]	0.5833333333333334	1	7	7	6
58483	1683	behavior	[behavior]	0.5833333333333334	1	7	7	6
58484	1684	gy	[Gy]	0.58	1	7	6	5
58485	1684	senescence	[senescence]	0.58	1	7	6	5
58486	1684	hyperparathyroidism	[hyperparathyroidism]	0.58	1	7	6	5
58487	1684	atrophy	[atrophy]	0.58	1	7	6	5
58488	1684	CTLA-4	[CTLA-4]	0.58	1	7	6	5
58489	1685	sucrose	[sucrose]	0.5750000000000001	1	7	5	4
58490	1685	effect,	[effect,]	0.5750000000000001	1	7	5	4
58491	1685	Wurzburg	[Wurzburg]	0.5750000000000001	1	7	5	4
58492	1685	icsat	[ICSAT]	0.5750000000000001	1	7	5	4
58493	1685	tcrzeta	[TCRzeta]	0.5750000000000001	1	7	5	4
58494	1685	Bmax	[Bmax]	0.5750000000000001	1	7	5	4
58495	1685	hours,	[hours,]	0.5750000000000001	1	7	5	4
58496	1685	mechanism.	[mechanism.]	0.5750000000000001	1	7	5	4
58497	1686	bm	[BM]	0.5666666666666668	1	7	4	3
58498	1686	TRE	[TRE]	0.5666666666666668	1	7	4	3
58499	1686	HUVECs	[HUVECs]	0.5666666666666668	1	7	4	3
58500	1687	conversion	[conversion]	0.5599999999999999	1	7	7	5
58501	1687	contribute	[contributing]	0.5599999999999999	1	7	7	5
58502	1687	efficiency	[efficiency]	0.5599999999999999	1	7	7	5
58503	1688	G.	[G.]	0.55	1	7	6	4
58504	1688	X2	[X2]	0.55	1	7	3	2
58505	1688	heterozygosity	[heterozygosity]	0.55	1	7	6	4
58506	1688	pdbu	[PDBu]	0.55	1	7	3	2
58507	1688	acetyl	[acetyl]	0.55	1	10	9	2
58508	1688	Pit-1	[Pit-1]	0.55	1	7	3	2
58509	1688	electromobility	[electromobility]	0.55	1	8	5	2
58510	1688	rflp	[RFLP]	0.55	1	7	3	2
58511	1688	pao	[PAO]	0.55	1	7	3	2
58512	1688	wt1	[WT1]	0.55	1	7	3	2
58513	1688	HL-60	[HL-60]	0.55	1	8	5	2
58514	1688	reconstitution	[reconstitution]	0.55	1	9	7	2
58515	1688	ltb4	[LTB4]	0.55	1	7	3	2
58516	1688	inheritance	[inheritance]	0.55	1	7	3	2
58517	1689	participation	[participation]	0.5333333333333334	1	8	8	3
58518	1689	incorporation	[incorporation]	0.5333333333333334	1	8	8	3
58519	1690	snrna	[snRNA]	0.5333333333333333	1	7	5	3
58520	1690	c-erbA/TR	[c-erbA/TR]	0.5333333333333333	1	7	5	3
58521	1690	culture,	[culture,]	0.5333333333333333	1	7	5	3
58522	1690	discovery	[discovery]	0.5333333333333333	1	7	5	3
58523	1690	b-related	[B-related]	0.5333333333333333	1	7	5	3
58524	1690	LCLs	[LCLs]	0.5333333333333333	1	7	5	3
58525	1691	mechanisms.	[mechanisms.]	0.525	1	7	7	4
58526	1692	D	[D]	0.5	1	6	1	1
58527	1692	t	[t]	0.5	1	6	5	5
58528	1692	z	[Z]	0.5	1	6	2	2
58529	1692	(r	[(r]	0.5	1	5	0	0
58530	1692	rxr-alpha	[RXR-alpha]	0.5	1	6	4	4
58531	1692	A1	[A1]	0.5	1	6	4	4
58532	1692	Ab	[Ab]	0.5	1	6	3	3
58533	1692	E1	[E1]	0.5	1	6	3	3
58534	1692	FL	[FL]	0.5	1	6	2	2
58535	1692	GG	[GG]	0.5	1	5	0	0
58536	1692	GH	[GH]	0.5	1	6	1	1
58537	1692	IK	[IK]	0.5	1	5	0	0
58538	1692	Kd	[Kd]	0.5	1	6	1	1
58539	1692	Mo	[Mo]	0.5	1	6	3	3
58540	1692	P-	[P-]	0.5	1	6	2	2
58541	1692	RI	[RI]	0.5	1	6	6	6
58542	1692	S.	[S.]	0.5	1	6	2	2
58543	1692	S6	[S6]	0.5	1	6	1	1
58544	1692	SM	[SM]	0.5	1	6	1	1
58545	1692	TN	[TN]	0.5	1	6	2	2
58546	1692	ab	[Ab]	0.5	1	6	4	4
58547	1692	bl	[BL]	0.5	1	6	5	5
58548	1692	bq	[BQ]	0.5	1	5	0	0
58549	1692	cd	[CD]	0.5	1	5	0	0
58550	1692	cf	[CF]	0.5	1	6	1	1
58551	1692	dg	[DG]	0.5	1	6	1	1
58552	1692	fosb	[FOSB]	0.5	1	6	3	3
58553	1692	gp	[GP]	0.5	1	6	3	3
58554	1692	iv	[IV]	0.5	1	6	4	4
58555	1692	no	[NO]	0.5	1	7	4	2
58556	1692	pa	[PA]	0.5	1	6	1	1
58557	1692	qr	[QR]	0.5	1	6	3	3
58558	1692	x2	[X2]	0.5	1	6	3	3
58559	1692	okt3	[OKT3]	0.5	1	6	1	1
58560	1692	raf-1	[Raf-1]	0.5	1	6	3	3
58561	1692	tegument	[tegument]	0.5	1	6	4	4
58562	1692	AML1b	[AML1b]	0.5	1	6	2	2
58563	1692	NFKB2	[NFKB2]	0.5	1	6	4	4
58564	1692	ML-9	[ML-9]	0.5	1	6	1	1
58565	1692	calmodulin	[calmodulin]	0.5	1	6	2	2
58566	1692	STAT-1	[STAT-1]	0.5	1	6	1	1
58567	1692	library	[library]	0.5	1	6	5	5
58568	1692	huaec	[HUAECs]	0.5	1	5	0	0
58569	1692	Cu2+	[Cu2+]	0.5	1	5	0	0
58570	1692	xp-d	[XP-D]	0.5	1	6	2	2
58571	1692	LOX-1	[LOX-1]	0.5	1	6	1	1
58572	1692	tad-a	[TAD-A]	0.5	1	5	0	0
58573	1692	Tpl-2	[Tpl-2]	0.5	1	9	4	1
58574	1692	isoforms,	[isoforms,]	0.5	1	6	5	5
58575	1692	c/ebpalpha	[C/EBPalpha]	0.5	1	6	4	4
58576	1692	C-rich	[C-rich]	0.5	1	5	0	0
58577	1692	literature	[literature]	0.5	1	6	2	2
58578	1692	associate	[associate]	0.5	1	6	3	3
58579	1692	abrogation	[abrogation]	0.5	1	6	4	4
58580	1692	gdsp	[GDSP]	0.5	1	6	2	2
58581	1692	g(s)alpha	[G(S)alpha]	0.5	1	6	2	2
58582	1692	RALDH2	[RALDH2]	0.5	1	6	1	1
58583	1692	neutralize	[neutralizing]	0.5	1	6	1	1
58584	1692	fluticasone	[fluticasone]	0.5	1	6	4	4
58585	1692	furthermore,	[Furthermore,]	0.5	1	6	4	4
58586	1692	ru486	[RU486]	0.5	1	6	2	2
58587	1692	BRLF1	[BRLF1]	0.5	1	6	1	1
58588	1692	phop	[phoP]	0.5	1	6	2	2
58589	1692	budesonide	[budesonide]	0.5	1	6	2	2
58590	1692	pma-	[PMA-]	0.5	1	6	2	2
58591	1692	pp65	[pp65]	0.5	1	5	0	0
58592	1692	aggregation	[aggregation]	0.5	1	6	4	4
58593	1692	EBNA3C	[EBNA3C]	0.5	1	5	0	0
58594	1692	degradation.	[degradation.]	0.5	1	6	2	2
58595	1692	differ	[differing]	0.5	1	6	6	6
58596	1692	nf-at1	[NF-AT1]	0.5	1	5	0	0
58597	1692	pnu156804	[PNU156804]	0.5	1	6	3	3
58598	1692	dnd39	[DND39]	0.5	1	5	0	0
58599	1692	novel,	[novel,]	0.5	1	6	3	3
58600	1692	percent	[percent]	0.5	1	6	6	6
58601	1692	nf-gm2	[NF-GM2]	0.5	1	5	0	0
58602	1692	hb24	[HB24]	0.5	1	6	4	4
58603	1692	counterpart	[counterpart]	0.5	1	6	6	6
58604	1692	t-pll	[T-PLL]	0.5	1	6	3	3
58605	1692	heme	[heme]	0.5	1	5	0	0
58606	1692	activin	[activin]	0.5	1	6	3	3
58607	1692	etoposide	[etoposide]	0.5	1	6	1	1
58608	1692	pecam-1	[PECAM-1]	0.5	1	6	4	4
58609	1692	HMG-I(Y)	[HMG-I(Y)]	0.5	1	6	1	1
58610	1692	fkbp51	[FKBP51]	0.5	1	5	0	0
58611	1692	coupling	[coupling]	0.5	1	6	6	6
58612	1692	ceramide	[ceramide]	0.5	1	6	2	2
58613	1692	events,	[events,]	0.5	1	6	4	4
58614	1692	regimen	[regimen]	0.5	1	6	3	3
58615	1692	neoplasia	[neoplasia]	0.5	1	6	3	3
58616	1692	A6H	[A6H]	0.5	1	5	0	0
58617	1692	lineages.	[lineages.]	0.5	1	6	3	3
58618	1692	AZT	[AZT]	0.5	1	6	1	1
58619	1692	monocytoid	[monocytoid]	0.5	1	6	3	3
58620	1692	C26	[C26]	0.5	1	5	0	0
58621	1692	dose-response	[dose-response]	0.5	1	6	4	4
58622	1692	CAG	[CAG]	0.5	1	6	1	1
58623	1692	Btk	[Btk]	0.5	1	6	3	3
58624	1692	CaM	[CaM]	0.5	1	6	3	3
58625	1692	c-Rel/p65	[c-Rel/p65]	0.5	1	6	2	2
58626	1692	DQ2	[DQ2]	0.5	1	6	2	2
58627	1692	E47	[E47]	0.5	1	6	1	1
58628	1692	EB1	[EB1]	0.5	1	6	2	2
58629	1692	OKT3	[OKT3]	0.5	1	6	1	1
58630	1692	b-lymphoid	[B-lymphoid]	0.5	1	6	3	3
58631	1692	GM3	[GM3]	0.5	1	6	2	2
58632	1692	GM2	[GM2]	0.5	1	6	1	1
58633	1692	GcR	[GcR]	0.5	1	6	3	3
58634	1692	IDC	[IDC]	0.5	1	6	1	1
58635	1692	Rac-1	[Rac-1]	0.5	1	6	2	2
58636	1692	ISO	[ISO]	0.5	1	6	1	1
58637	1692	IgH	[IgH]	0.5	1	5	0	0
58638	1692	LCL	[LCL]	0.5	1	6	3	3
58639	1692	LSF	[LSF]	0.5	1	6	2	2
58640	1692	NH2	[NH2]	0.5	1	6	1	1
58641	1692	c-kit	[c-kit]	0.5	1	6	1	1
58642	1692	PB1	[PB1]	0.5	1	5	0	0
58643	1692	pre-exist	[pre-existing]	0.5	1	5	0	0
58644	1692	malaria	[malaria]	0.5	1	6	3	3
58645	1692	suffer	[suffering]	0.5	1	6	2	2
58646	1692	idea	[idea]	0.5	1	6	2	2
58647	1692	S9a	[S9a]	0.5	1	6	2	2
58648	1692	glucocorticosteroids	[glucocorticosteroids]	0.5	1	5	0	0
58649	1692	SCC	[SCC]	0.5	1	6	2	2
58650	1692	SIT	[SIT]	0.5	1	6	3	3
58651	1692	hexon	[hexon]	0.5	1	5	0	0
58652	1692	TEC	[TEC]	0.5	1	6	1	1
58653	1692	TP1	[TP1]	0.5	1	6	2	2
58654	1692	TcR	[TcR]	0.5	1	6	2	2
58655	1692	am580	[AM580]	0.5	1	6	1	1
58656	1692	USA	[USA]	0.5	1	6	4	4
58657	1692	ZII	[ZII]	0.5	1	6	2	2
58658	1692	sequenced.	[sequenced.]	0.5	1	5	0	0
58659	1692	Danazol	[Danazol]	0.5	1	5	0	0
58660	1692	rhesus	[rhesus]	0.5	1	6	2	2
58661	1692	p62c-fo	[p62c-fos]	0.5	1	7	4	2
58662	1692	methov	[METHODS]	0.5	1	6	2	2
58663	1692	ap2	[AP2]	0.5	1	5	0	0
58664	1692	c5a	[C5a]	0.5	1	5	0	0
58665	1692	atp	[ATP]	0.5	1	6	4	4
58666	1692	cbp	[CBP]	0.5	1	6	3	3
58667	1692	H2O2	[H2O2]	0.5	1	6	1	1
58668	1692	chi	[chi]	0.5	1	5	0	0
58669	1692	platelet-activate	[platelet-activating]	0.5	1	6	1	1
58670	1692	fms	[FMS]	0.5	1	6	2	2
58671	1692	hbv	[HBV]	0.5	1	7	4	2
58672	1692	glioblastoma	[glioblastoma]	0.5	1	6	3	3
58673	1692	ikb	[IkB]	0.5	1	5	0	0
58674	1692	ferritin	[ferritin]	0.5	1	6	2	2
58675	1692	lbp	[LBP]	0.5	1	6	5	5
58676	1692	NGFI-A/Egr-1	[NGFI-A/Egr-1]	0.5	1	5	0	0
58677	1692	myb	[myb]	0.5	1	7	2	1
58678	1692	jak1	[JAK1]	0.5	1	6	2	2
58679	1692	allergy	[allergy]	0.5	1	6	1	1
58680	1692	nm.	[nM.]	0.5	1	6	5	5
58681	1692	issue	[issue]	0.5	1	6	5	5
58682	1692	tetracycline	[tetracycline]	0.5	1	6	2	2
58683	1692	consequence,	[consequence,]	0.5	1	6	1	1
58684	1692	fgf-1	[FGF-1]	0.5	1	6	1	1
58685	1692	psa	[PSA]	0.5	1	6	2	2
58686	1692	c-fm	[c-fms]	0.5	1	6	3	3
58687	1692	I(kappa)B(alpha)	[I(kappa)B(alpha)]	0.5	1	6	2	2
58688	1692	HePTP	[HePTP]	0.5	1	6	1	1
58689	1692	tgf	[TGF]	0.5	1	6	1	1
58690	1692	thr	[THR]	0.5	1	6	4	4
58691	1692	import	[import]	0.5	1	9	8	2
58692	1692	gsk-3beta	[GSK-3beta]	0.5	1	6	3	3
58693	1692	mixture	[mixture]	0.5	1	8	6	2
58694	1692	adenylate	[adenylate]	0.5	1	6	2	2
58695	1692	monocytes.	[monocytes.]	0.5	1	6	1	1
58696	1692	HOCl	[HOCl]	0.5	1	6	2	2
58697	1692	sp-1	[SP-1]	0.5	1	6	3	3
58698	1692	incidence	[incidence]	0.5	1	7	6	3
58699	1692	jund	[junD]	0.5	1	5	0	0
58700	1692	-cat	[-CAT]	0.5	1	6	6	6
58701	1692	displacement	[displacement]	0.5	1	6	6	6
58702	1692	p47phox	[p47phox]	0.5	1	6	1	1
58703	1692	exchange	[exchange]	0.5	1	6	4	4
58704	1692	HSF1	[HSF1]	0.5	1	5	0	0
58705	1692	TRAF3	[TRAF3]	0.5	1	5	0	0
58706	1692	TRAF6	[TRAF6]	0.5	1	6	1	1
58707	1692	p27kip1	[p27Kip1]	0.5	1	6	2	2
58708	1692	GrpL	[GrpL]	0.5	1	6	2	2
58709	1692	gland	[gland]	0.5	1	6	5	5
58710	1692	TINUR	[TINUR]	0.5	1	5	0	0
58711	1692	nfkb2	[NFKB2]	0.5	1	6	6	6
58712	1692	athlete	[athletes]	0.5	1	5	0	0
58713	1692	lining	[lining]	0.5	1	7	4	2
58714	1692	biomarker	[biomarker]	0.5	1	6	2	2
58715	1692	endocrine	[endocrine]	0.5	1	6	3	3
58716	1692	genotype	[genotype]	0.5	1	6	3	3
58717	1692	molecule.	[molecule.]	0.5	1	5	0	0
58718	1692	experiments,	[experiments,]	0.5	1	6	5	5
58719	1692	regulation.	[regulation.]	0.5	1	6	1	1
58720	1692	growth,	[growth,]	0.5	1	6	1	1
58721	1692	n-acetylcysteine	[N-acetylcysteine]	0.5	1	6	1	1
58722	1692	Cbl-b	[Cbl-b]	0.5	1	6	1	1
58723	1692	RFX1	[RFX1]	0.5	1	6	1	1
58724	1692	fmol/10(6)	[fmol/10(6)]	0.5	1	6	6	6
58725	1692	placebo	[placebo]	0.5	1	6	4	4
58726	1692	N-acetylcysteine	[N-acetylcysteine]	0.5	1	6	1	1
58727	1692	rela(p65)	[RelA(p65)]	0.5	1	6	3	3
58728	1692	process,	[process,]	0.5	1	6	1	1
58729	1692	tshr	[TSHR]	0.5	1	6	4	4
58730	1692	caat	[CAAT]	0.5	1	6	1	1
58731	1692	cd21	[CD21]	0.5	1	6	3	3
58732	1692	cd13	[CD13]	0.5	1	5	0	0
58733	1692	cdk4	[CDK4]	0.5	1	6	2	2
58734	1692	tsg101	[TSG101]	0.5	1	6	4	4
58735	1692	-induce	[-inducing]	0.5	1	6	5	5
58736	1692	land	[LANDs]	0.5	1	6	2	2
58737	1692	ap3-l	[AP3-L]	0.5	1	6	1	1
58738	1692	retroviruse	[retroviruses]	0.5	1	6	4	4
58739	1692	regions.	[regions.]	0.5	1	6	4	4
58740	1692	mAECA	[mAECA]	0.5	1	6	1	1
58741	1692	META(D+)	[META(D+)]	0.5	1	6	2	2
58742	1692	detail	[detail]	0.5	1	6	3	3
58743	1692	p13mtcp1	[p13MTCP1]	0.5	1	6	3	3
58744	1692	CACCC	[CACCC]	0.5	1	6	2	2
58745	1692	p50/p50	[p50/p50]	0.5	1	6	1	1
58746	1692	proliferate	[proliferating]	0.5	1	6	2	2
58747	1692	PGG-Glucan	[PGG-Glucan]	0.5	1	6	2	2
58748	1692	category	[Category]	0.5	1	6	5	5
58749	1692	gcrbeta	[GCRbeta]	0.5	1	5	0	0
58750	1692	interferon-alpha	[interferon-alpha]	0.5	1	6	3	3
58751	1692	E(gre)	[E(gre)]	0.5	1	6	2	2
58752	1692	p38alpha	[p38alpha]	0.5	1	6	4	4
58753	1692	CD28RE	[CD28RE]	0.5	1	6	1	1
58754	1692	factors.	[factors.]	0.5	1	6	2	2
58755	1692	carboxylesterase	[carboxylesterase]	0.5	1	6	3	3
58756	1692	t-lineage	[T-lineage]	0.5	1	6	2	2
58757	1692	Ca(2+)	[Ca(2+)]	0.5	1	6	2	2
58758	1692	preterm	[preterm]	0.5	1	6	4	4
58759	1692	SV40	[SV40]	0.5	1	6	1	1
58760	1692	ligand,	[ligand,]	0.5	1	6	5	5
58761	1692	BCL6	[BCL6]	0.5	1	7	2	1
58762	1692	BCL2	[BCL2]	0.5	1	7	4	2
58763	1692	bcr1/25	[BCR1/25]	0.5	1	6	1	1
58764	1692	Ad12	[Ad12]	0.5	1	6	4	4
58765	1692	Jak/Stat	[Jak/Stat]	0.5	1	6	2	2
58766	1692	50-kDa	[50-kDa]	0.5	1	5	0	0
58767	1692	mek1	[MEK1]	0.5	1	6	3	3
58768	1692	rejection	[rejection]	0.5	1	6	1	1
58769	1692	vary	[varying]	0.5	1	6	3	3
58770	1692	receptor,	[receptor,]	0.5	1	6	2	2
58771	1692	Staurosporine	[Staurosporine]	0.5	1	6	3	3
58772	1692	micromolar	[micromolar]	0.5	1	6	3	3
58773	1692	dprl	[dPRL]	0.5	1	6	1	1
58774	1692	Furthermore,	[Furthermore,]	0.5	1	6	6	6
58775	1692	ip-10	[IP-10]	0.5	1	6	3	3
58776	1692	concern	[concerning]	0.5	1	6	3	3
58777	1692	concept	[concept]	0.5	1	6	5	5
58778	1692	il-1ri	[IL-1RI]	0.5	1	6	2	2
58779	1692	elution	[elution]	0.5	1	6	1	1
58780	1692	guanine	[guanine]	0.5	1	6	4	4
58781	1692	combination,	[combination,]	0.5	1	6	2	2
58782	1692	il-12r	[IL-12R]	0.5	1	6	3	3
58783	1692	MM-LDL	[MM-LDL]	0.5	1	6	3	3
58784	1692	tcr/cd3	[TCR/CD3]	0.5	1	6	1	1
58785	1692	TNFR	[TNFR]	0.5	1	5	0	0
58786	1692	modulate	[modulating]	0.5	1	6	2	2
58787	1692	mucosa	[mucosa]	0.5	1	6	5	5
58788	1692	TRAF	[TRAF]	0.5	1	6	3	3
58789	1692	conservation	[conservation]	0.5	1	6	4	4
58790	1692	cadmium	[cadmium]	0.5	1	6	1	1
58791	1692	CALM	[CALM]	0.5	1	5	0	0
58792	1692	hirsutism	[hirsutism]	0.5	1	6	1	1
58793	1692	hsp60	[Hsp60]	0.5	1	6	4	4
58794	1692	morning	[morning]	0.5	1	6	2	2
58795	1692	bcl-xL	[bcl-xL]	0.5	1	6	3	3
58796	1692	(nfat)	[(NFAT)]	0.5	1	6	3	3
58797	1692	icrf-193	[ICRF-193]	0.5	1	5	0	0
58798	1692	nk3.3	[NK3.3]	0.5	1	6	2	2
58799	1692	tumor-draining	[tumor-draining]	0.5	1	6	1	1
58800	1692	adipocyte	[adipocyte]	0.5	1	6	2	2
58801	1692	alpha-lipoic	[alpha-lipoic]	0.5	1	9	4	1
58802	1692	monocyte-to-macrophage	[monocyte-to-macrophage]	0.5	1	5	0	0
58803	1692	receptors.	[receptors.]	0.5	1	6	3	3
58804	1692	receptors,	[receptors,]	0.5	1	6	3	3
58805	1692	pp90rsk	[pp90rsk]	0.5	1	6	2	2
58806	1692	CHEMR1	[CHEMR1]	0.5	1	6	1	1
58807	1692	pilot	[PILOT]	0.5	1	6	3	3
58808	1692	erk1	[ERK1]	0.5	1	6	2	2
58809	1692	years,	[years,]	0.5	1	6	4	4
58810	1692	electrophoresis	[electrophoresis]	0.5	1	6	6	6
58811	1692	subtype	[subtype]	0.5	1	6	6	6
58812	1692	lysp100	[LYSP100]	0.5	1	5	0	0
58813	1692	PECAM-1	[PECAM-1]	0.5	1	6	2	2
58814	1692	interleukin-5	[interleukin-5]	0.5	1	6	4	4
58815	1692	oligomer	[oligomer]	0.5	1	6	4	4
58816	1692	responses.	[responses.]	0.5	1	6	2	2
58817	1692	Calcineurin	[Calcineurin]	0.5	1	6	1	1
58818	1692	Philadelphia	[Philadelphia]	0.5	1	5	0	0
58819	1692	collagen	[collagen]	0.5	1	6	5	5
58820	1692	immunotherapy	[immunotherapy]	0.5	1	6	3	3
58821	1692	hsf2-alpha	[HSF2-alpha]	0.5	1	6	4	4
58822	1692	IL-11	[IL-11]	0.5	1	6	2	2
58823	1692	LYSP100	[LYSP100]	0.5	1	6	2	2
58824	1692	trans	[trans]	0.5	1	6	3	3
58825	1692	oct2	[Oct2]	0.5	1	6	3	3
58826	1692	oleate	[oleate]	0.5	1	5	0	0
58827	1692	ketoconazole	[ketoconazole]	0.5	1	6	1	1
58828	1693	beta-cell	[beta-cell]	0.48	1	6	6	5
58829	1693	sphingomyelinase	[sphingomyelinase]	0.48	1	6	6	5
58830	1694	om10.1	[OM10.1]	0.47500000000000003	1	6	5	4
58831	1694	picture	[picture]	0.47500000000000003	1	6	5	4
58832	1694	grade	[grade]	0.47500000000000003	1	6	5	4
58833	1694	network	[network]	0.47500000000000003	1	6	5	4
58834	1694	nf-	[NF-]	0.47500000000000003	1	6	5	4
58835	1694	rev	[Rev]	0.47500000000000003	1	6	5	4
58836	1694	kind	[kinds]	0.47500000000000003	1	6	5	4
58837	1694	b-like	[B-like]	0.47500000000000003	1	6	5	4
58838	1695	granulocyte/macrophage	[granulocyte/macrophage]	0.46666666666666673	1	6	4	3
58839	1695	tetanus	[tetanus]	0.46666666666666673	1	6	4	3
58840	1695	concentrations.	[concentrations.]	0.46666666666666673	1	6	4	3
58841	1695	pafr	[PAFR]	0.46666666666666673	1	6	4	3
58842	1695	ga-binding	[GA-binding]	0.46666666666666673	1	6	4	3
58843	1695	crosslinking	[crosslinking]	0.46666666666666673	1	6	4	3
58844	1695	mip-1	[MIP-1]	0.46666666666666673	1	6	4	3
58845	1695	hmr	[hMR]	0.46666666666666673	1	6	4	3
58846	1695	hiv-tf1	[HIV-TF1]	0.46666666666666673	1	6	4	3
58847	1695	sox9	[SOX9]	0.46666666666666673	1	6	4	3
58848	1695	differanisole	[Differanisole]	0.46666666666666673	1	6	4	3
58849	1695	p80c-rel	[p80c-rel]	0.46666666666666673	1	6	4	3
58850	1695	glial	[glial]	0.46666666666666673	1	6	4	3
58851	1695	pseudohypoaldosteronism	[pseudohypoaldosteronism]	0.46666666666666673	1	6	4	3
58852	1695	-receptor	[-receptor]	0.46666666666666673	1	6	4	3
58853	1695	RFX5	[RFX5]	0.46666666666666673	1	6	4	3
58854	1695	ctcf	[CTCF]	0.46666666666666673	1	6	4	3
58855	1695	trimer	[trimer]	0.46666666666666673	1	6	4	3
58856	1695	alkaline	[alkaline]	0.46666666666666673	1	6	4	3
58857	1695	il-10r	[IL-10R]	0.46666666666666673	1	6	4	3
58858	1695	(il)	[(IL)]	0.46666666666666673	1	6	4	3
58859	1695	CD40L	[CD40L]	0.46666666666666673	1	6	4	3
58860	1696	spite	[spite]	0.4666666666666666	1	7	7	3
58861	1697	hamster	[hamster]	0.45	1	7	5	2
58862	1697	ln	[LN]	0.45	1	6	3	2
58863	1697	/stat	[/STAT]	0.45	1	9	9	2
58864	1697	gc-box	[GC-box]	0.45	1	6	3	2
58865	1697	multimer	[multimer]	0.45	1	6	3	2
58866	1697	action.	[action.]	0.45	1	6	3	2
58867	1697	CR3	[CR3]	0.45	1	6	3	2
58868	1697	sensitization	[sensitization]	0.45	1	6	3	2
58869	1697	NIH	[NIH]	0.45	1	6	3	2
58870	1697	ie62	[IE62]	0.45	1	6	3	2
58871	1697	cd68+	[CD68+]	0.45	1	6	3	2
58872	1697	agreement	[agreement]	0.45	1	8	7	2
58873	1697	lncap	[LNCaP]	0.45	1	6	3	2
58874	1697	Flow	[Flow]	0.45	1	8	7	2
58875	1697	mad-3	[MAD-3]	0.45	1	6	3	2
58876	1697	lymphotoxin	[lymphotoxin]	0.45	1	6	3	2
58877	1697	pka	[PKA]	0.45	1	7	5	2
58878	1697	sry	[SRY]	0.45	1	6	3	2
58879	1697	outgrowth	[outgrowth]	0.45	1	6	6	4
58880	1697	injection	[injection]	0.45	1	6	6	4
58881	1697	lymphoblast	[lymphoblast]	0.45	1	6	3	2
58882	1697	transient-transfection	[transient-transfection]	0.45	1	6	3	2
58883	1697	IRAK	[IRAK]	0.45	1	6	3	2
58884	1697	remodeling	[remodeling]	0.45	1	6	6	4
58885	1697	(tnf)-alpha	[(TNF)-alpha]	0.45	1	6	3	2
58886	1697	metallothionein	[metallothionein]	0.45	1	6	3	2
58887	1697	STAT1alpha	[STAT1alpha]	0.45	1	6	3	2
58888	1698	time,	[time,]	0.43333333333333335	1	6	5	3
58889	1698	beta-estradiol	[beta-estradiol]	0.43333333333333335	1	6	5	3
58890	1698	viability	[viability]	0.43333333333333335	1	6	5	3
58891	1698	infarction	[infarction]	0.43333333333333335	1	6	5	3
58892	1698	criterion	[criteria]	0.43333333333333335	1	6	5	3
58893	1698	question	[question]	0.43333333333333335	1	6	5	3
58894	1698	extinction	[extinction]	0.43333333333333335	1	6	5	3
58895	1698	Interleukin-6	[Interleukin-6]	0.43333333333333335	1	6	5	3
58896	1699	W	[W]	0.4	1	4	0	0
58897	1699	time.	[time.]	0.4	1	5	3	3
58898	1699	pancrea	[pancreas]	0.4	1	5	4	4
58899	1699	(n	[(n]	0.4	1	5	1	1
58900	1699	BHRF1	[BHRF1]	0.4	1	5	1	1
58901	1699	trend	[trend]	0.4	1	5	5	5
58902	1699	B7	[B7]	0.4	1	5	3	3
58903	1699	Cp	[Cp]	0.4	1	5	1	1
58904	1699	G0	[G0]	0.4	1	5	3	3
58905	1699	H9	[H9]	0.4	1	5	2	2
58906	1699	J.	[J.]	0.4	1	5	4	4
58907	1699	LP	[LP]	0.4	1	5	1	1
58908	1699	M7	[M7]	0.4	1	5	3	3
58909	1699	ChtM	[ChtM]	0.4	1	5	1	1
58910	1699	Mn	[Mn]	0.4	1	5	1	1
58911	1699	P0	[P0]	0.4	1	4	0	0
58912	1699	P1	[P1]	0.4	1	5	2	2
58913	1699	P;	[h;]	0.4	1	5	5	5
58914	1699	Zp	[Zp]	0.4	1	5	3	3
58915	1699	h9	[H9]	0.4	1	4	0	0
58916	1699	gd	[GD]	0.4	1	5	3	3
58917	1699	fork	[fork]	0.4	1	4	0	0
58918	1699	MEK1	[MEK1]	0.4	1	5	2	2
58919	1699	m;	[M;]	0.4	1	5	3	3
58920	1699	ls	[LS]	0.4	1	4	0	0
58921	1699	p3	[P3]	0.4	1	4	0	0
58922	1699	DNA.	[DNA.]	0.4	1	5	1	1
58923	1699	nitrogen	[nitrogen]	0.4	1	5	2	2
58924	1699	ICAM-I	[ICAM-I]	0.4	1	5	2	2
58925	1699	catecholamine	[catecholamine]	0.4	1	5	2	2
58926	1699	xist	[XIST]	0.4	1	5	2	2
58927	1699	purine	[purine]	0.4	1	5	2	2
58928	1699	culminate	[culminating]	0.4	1	5	3	3
58929	1699	N-WASP	[N-WASP]	0.4	1	5	2	2
58930	1699	survival.	[survival.]	0.4	1	4	0	0
58931	1699	gamma/delta	[gamma/delta]	0.4	1	5	1	1
58932	1699	initiator	[initiator]	0.4	1	5	3	3
58933	1699	hlh-2	[hLH-2]	0.4	1	5	1	1
58934	1699	dehydroepiandrosterone	[dehydroepiandrosterone]	0.4	1	5	2	2
58935	1699	TNFR1	[TNFR1]	0.4	1	5	1	1
58936	1699	RARalpha	[RARalpha]	0.4	1	5	5	5
58937	1699	motor	[motor]	0.4	1	5	1	1
58938	1699	B-lymphoblastoid	[B-lymphoblastoid]	0.4	1	5	1	1
58939	1699	dna-protein	[DNA-protein]	0.4	1	5	3	3
58940	1699	OBF-1	[OBF-1]	0.4	1	5	2	2
58941	1699	gc-r	[GC-R]	0.4	1	5	2	2
58942	1699	emphasis	[emphasis]	0.4	1	5	2	2
58943	1699	PML-RAR	[PML-RAR]	0.4	1	5	1	1
58944	1699	BRCA1	[BRCA1]	0.4	1	5	1	1
58945	1699	EBS2	[EBS2]	0.4	1	4	0	0
58946	1699	staurosporine	[staurosporine]	0.4	1	5	3	3
58947	1699	Pervanadate	[Pervanadate]	0.4	1	4	0	0
58948	1699	HIV-TF1	[HIV-TF1]	0.4	1	5	1	1
58949	1699	frameshift	[frameshift]	0.4	1	5	3	3
58950	1699	retention	[retention]	0.4	1	6	6	3
58951	1699	proband	[proband]	0.4	1	5	2	2
58952	1699	phoq	[phoQ]	0.4	1	5	2	2
58953	1699	goal	[goal]	0.4	1	5	5	5
58954	1699	NF-M	[NF-M]	0.4	1	5	2	2
58955	1699	myometrium	[myometrium]	0.4	1	4	0	0
58956	1699	NF90	[NF90]	0.4	1	4	0	0
58957	1699	antibody,	[antibody,]	0.4	1	5	2	2
58958	1699	Hsp70	[Hsp70]	0.4	1	5	1	1
58959	1699	cck(b)	[CCK(B)]	0.4	1	4	0	0
58960	1699	kilodalton	[kilodalton]	0.4	1	5	5	5
58961	1699	maturation,	[maturation,]	0.4	1	5	3	3
58962	1699	preparation	[Preparation]	0.4	1	5	5	5
58963	1699	1beta	[1beta]	0.4	1	6	6	3
58964	1699	microM,	[microM,]	0.4	1	5	5	5
58965	1699	e2a-hlf	[E2A-HLF]	0.4	1	5	2	2
58966	1699	(1)	[(1)]	0.4	1	5	1	1
58967	1699	GCRbeta	[GCRbeta]	0.4	1	5	3	3
58968	1699	peripheral-blood	[peripheral-blood]	0.4	1	5	2	2
58969	1699	fashion.	[fashion.]	0.4	1	5	5	5
58970	1699	situation	[situation]	0.4	1	5	3	3
58971	1699	solution.	[solution.]	0.4	1	5	1	1
58972	1699	TFIIA	[TFIIA]	0.4	1	5	2	2
58973	1699	organization	[organization]	0.4	1	5	4	4
58974	1699	immunostaining	[immunostaining]	0.4	1	5	5	5
58975	1699	alone.	[alone.]	0.4	1	5	2	2
58976	1699	cytolysis	[cytolysis]	0.4	1	5	2	2
58977	1699	chemotaxis	[chemotaxis]	0.4	1	7	3	1
58978	1699	allograft	[allograft]	0.4	1	5	1	1
58979	1699	c-Maf	[c-Maf]	0.4	1	4	0	0
58980	1699	26s	[26S]	0.4	1	5	2	2
58981	1699	metalloproteinase	[metalloproteinase]	0.4	1	5	2	2
58982	1699	v-abl	[v-Abl]	0.4	1	4	0	0
58983	1699	c-Raf	[c-Raf]	0.4	1	5	1	1
58984	1699	alpha,	[alpha,]	0.4	1	5	2	2
58985	1699	Egr-2	[Egr-2]	0.4	1	5	1	1
58986	1699	th1/th2	[Th1/Th2]	0.4	1	5	2	2
58987	1699	hl-60/vinc	[HL-60/vinc]	0.4	1	4	0	0
58988	1699	hiv-	[HIV-]	0.4	1	5	1	1
58989	1699	inhibitor,	[inhibitor,]	0.4	1	4	0	0
58990	1699	assays.	[assays.]	0.4	1	5	2	2
58991	1699	v-atpase	[V-ATPase]	0.4	1	5	1	1
58992	1699	FISH	[FISH]	0.4	1	5	1	1
58993	1699	hnf1	[HNF1]	0.4	1	6	2	1
58994	1699	AMI	[AMI]	0.4	1	6	2	1
58995	1699	immunoblotting	[immunoblotting]	0.4	1	5	2	2
58996	1699	ASA	[ASA]	0.4	1	4	0	0
58997	1699	ht-2	[HT-2]	0.4	1	5	2	2
58998	1699	Ad5	[Ad5]	0.4	1	5	2	2
58999	1699	BHA	[BHA]	0.4	1	5	1	1
59000	1699	BLS	[BLS]	0.4	1	5	1	1
59001	1699	Akv	[Akv]	0.4	1	5	2	2
59002	1699	Ala	[Ala]	0.4	1	5	1	1
59003	1699	hgm-csf	[hGM-CSF]	0.4	1	4	0	0
59004	1699	finding,	[finding,]	0.4	1	5	1	1
59005	1699	hsf2	[HSF2]	0.4	1	4	0	0
59006	1699	hsf3	[HSF3]	0.4	1	6	2	1
59007	1699	CHD	[CHD]	0.4	1	5	2	2
59008	1699	CIS	[CIS]	0.4	1	5	1	1
59009	1699	G0S2	[G0S2]	0.4	1	5	4	4
59010	1699	CNS	[CNS]	0.4	1	5	2	2
59011	1699	BACKGROUND:	[BACKGROUND:]	0.4	1	5	1	1
59012	1699	CXC	[CXC]	0.4	1	5	2	2
59013	1699	isomerase	[isomerase]	0.4	1	5	3	3
59014	1699	pml/raralpha	[PML/RARalpha]	0.4	1	5	2	2
59015	1699	p65/p50	[P65/P50]	0.4	1	5	1	1
59016	1699	corticosterone	[corticosterone]	0.4	1	5	3	3
59017	1699	Chr	[Chr]	0.4	1	5	3	3
59018	1699	DR3	[DR3]	0.4	1	5	4	4
59019	1699	ECS	[ECS]	0.4	1	5	3	3
59020	1699	oxidation	[oxidation]	0.4	1	5	5	5
59021	1699	mip-1alpha	[MIP-1alpha]	0.4	1	5	3	3
59022	1699	v-src	[v-src]	0.4	1	5	2	2
59023	1699	FCM	[FCM]	0.4	1	5	2	2
59024	1699	Eed	[Eed]	0.4	1	5	2	2
59025	1699	Erk	[Erk]	0.4	1	5	3	3
59026	1699	dysfunction	[dysfunction]	0.4	1	5	5	5
59027	1699	NF-MATp35	[NF-MATp35]	0.4	1	5	2	2
59028	1699	raw264.7	[RAW264.7]	0.4	1	5	1	1
59029	1699	HBD	[HBD]	0.4	1	4	0	0
59030	1699	danazol	[danazol]	0.4	1	5	2	2
59031	1699	IRE	[IRE]	0.4	1	5	1	1
59032	1699	icam-i	[ICAM-I]	0.4	1	5	1	1
59033	1699	atf-2	[ATF-2]	0.4	1	5	2	2
59034	1699	c-erbA	[c-erbA]	0.4	1	5	2	2
59035	1699	rar-rxr	[RAR-RXR]	0.4	1	5	3	3
59036	1699	LIM	[LIM]	0.4	1	5	2	2
59037	1699	OSE2	[OSE2]	0.4	1	4	0	0
59038	1699	Namalwa	[Namalwa]	0.4	1	4	0	0
59039	1699	MLL	[MLL]	0.4	1	5	1	1
59040	1699	MNP	[MNP]	0.4	1	5	2	2
59041	1699	Lyn	[Lyn]	0.4	1	4	0	0
59042	1699	MDMac	[MDMac]	0.4	1	5	3	3
59043	1699	hepor	[hEpoR]	0.4	1	5	1	1
59044	1699	NIP	[NIP]	0.4	1	5	1	1
59045	1699	NPC	[NPC]	0.4	1	5	3	3
59046	1699	NXS	[NXS]	0.4	1	5	1	1
59047	1699	-resistant	[-resistant]	0.4	1	5	4	4
59048	1699	OKA	[OKA]	0.4	1	5	3	3
59049	1699	chaffeensis	[chaffeensis]	0.4	1	5	2	2
59050	1699	PAO	[PAO]	0.4	1	5	1	1
59051	1699	c-maf	[c-Maf]	0.4	1	5	1	1
59052	1699	x-ray	[X-ray]	0.4	1	5	3	3
59053	1699	PyG	[PyG]	0.4	1	5	1	1
59054	1699	patient'	[patient's]	0.4	1	5	2	2
59055	1699	RGD	[RGD]	0.4	1	4	0	0
59056	1699	RII	[RII]	0.4	1	4	0	0
59057	1699	iddm	[IDDM]	0.4	1	5	1	1
59058	1699	SH2	[SH2]	0.4	1	5	2	2
59059	1699	SPD	[SPD]	0.4	1	5	2	2
59060	1699	Sci	[Sci]	0.4	1	4	0	0
59061	1699	Ter	[Ter]	0.4	1	4	0	0
59062	1699	Ki-67	[Ki-67]	0.4	1	5	2	2
59063	1699	gata1	[GATA1]	0.4	1	5	2	2
59064	1699	arrest	[arrest]	0.4	1	5	2	2
59065	1699	system,	[system,]	0.4	1	5	1	1
59066	1699	housekeeping	[housekeeping]	0.4	1	5	2	2
59067	1699	cd16-	[CD16-]	0.4	1	5	3	3
59068	1699	HLA-Cw*0702	[HLA-Cw*0702]	0.4	1	4	0	0
59069	1699	XLH	[XLH]	0.4	1	5	1	1
59070	1699	atopy	[atopy]	0.4	1	4	0	0
59071	1699	stage.	[stage.]	0.4	1	5	3	3
59072	1699	dose-	[dose-]	0.4	1	5	1	1
59073	1699	PAEC	[PAEC]	0.4	1	5	2	2
59074	1699	Zap	[Zap]	0.4	1	5	1	1
59075	1699	lymphocytes.	[lymphocytes.]	0.4	1	5	2	2
59076	1699	isoleucine	[isoleucine]	0.4	1	5	2	2
59077	1699	drugs.	[drugs.]	0.4	1	5	2	2
59078	1699	sIgD	[sIgD]	0.4	1	5	2	2
59079	1699	rakfkqllq	[RAKFKQLLQ]	0.4	1	5	2	2
59080	1699	cells;	[cells;]	0.4	1	5	3	3
59081	1699	gynecomastia	[gynecomastia]	0.4	1	5	1	1
59082	1699	PEBP2betaMYH11	[PEBP2betaMYH11]	0.4	1	4	0	0
59083	1699	il-16	[IL-16]	0.4	1	4	0	0
59084	1699	il-15	[IL-15]	0.4	1	4	0	0
59085	1699	a-t	[A-T]	0.4	1	5	2	2
59086	1699	IL-10R	[IL-10R]	0.4	1	4	0	0
59087	1699	a6h	[A6H]	0.4	1	5	2	2
59088	1699	PI3K	[PI3K]	0.4	1	5	3	3
59089	1699	symmetry	[symmetry]	0.4	1	5	3	3
59090	1699	asm	[ASM]	0.4	1	4	0	0
59091	1699	NF-GM2	[NF-GM2]	0.4	1	4	0	0
59092	1699	cp1	[CP1]	0.4	1	4	0	0
59093	1699	cos	[COS]	0.4	1	5	1	1
59094	1699	domains,	[domains,]	0.4	1	5	3	3
59095	1699	pyrimidine	[pyrimidine]	0.4	1	4	0	0
59096	1699	dp1	[DP1]	0.4	1	4	0	0
59097	1699	dpm	[dpm]	0.4	1	5	4	4
59098	1699	eed	[Eed]	0.4	1	5	2	2
59099	1699	islet	[islet]	0.4	1	5	3	3
59100	1699	physiology	[physiology]	0.4	1	5	2	2
59101	1699	fcr	[FcR]	0.4	1	5	3	3
59102	1699	form,	[form,]	0.4	1	5	2	2
59103	1699	gct	[GCT]	0.4	1	5	3	3
59104	1699	IL-2Rbeta	[IL-2Rbeta]	0.4	1	5	1	1
59105	1699	haemopoietic	[haemopoietic]	0.4	1	4	0	0
59106	1699	master	[master]	0.4	1	4	0	0
59107	1699	ion	[ion]	0.4	1	5	2	2
59108	1699	ipr	[Ipr]	0.4	1	4	0	0
59109	1699	mitogenesis	[mitogenesis]	0.4	1	5	2	2
59110	1699	kb)	[kb)]	0.4	1	5	4	4
59111	1699	gst-pi	[GST-pi]	0.4	1	5	2	2
59112	1699	affinity.	[affinity.]	0.4	1	5	2	2
59113	1699	computer	[computer]	0.4	1	5	2	2
59114	1699	PRDII	[PRDII]	0.4	1	5	1	1
59115	1699	mitogen-	[mitogen-]	0.4	1	4	0	0
59116	1699	mnc	[MNC]	0.4	1	5	2	2
59117	1699	mub	[muB]	0.4	1	4	0	0
59118	1699	p23	[p23]	0.4	1	5	1	1
59119	1699	p55	[p55]	0.4	1	4	0	0
59120	1699	p60	[p60]	0.4	1	5	2	2
59121	1699	p85	[p85]	0.4	1	5	1	1
59122	1699	pco	[PCOS]	0.4	1	5	1	1
59123	1699	pih	[PIH]	0.4	1	5	1	1
59124	1699	pkr	[PKR]	0.4	1	5	4	4
59125	1699	pp1	[PP1]	0.4	1	5	4	4
59126	1699	pol	[pol]	0.4	1	4	0	0
59127	1699	ppt	[ppt]	0.4	1	5	3	3
59128	1699	topoisomerase	[topoisomerase]	0.4	1	5	4	4
59129	1699	s49	[S49]	0.4	1	4	0	0
59130	1699	rbp	[RBP]	0.4	1	5	2	2
59131	1699	rhu	[rhu]	0.4	1	5	1	1
59132	1699	ros	[ROS]	0.4	1	5	2	2
59133	1699	t3r	[T3R]	0.4	1	5	4	4
59134	1699	clonotype	[clonotype]	0.4	1	5	3	3
59135	1699	AML1/ETO	[AML1/ETO]	0.4	1	5	2	2
59136	1699	cytometry	[cytometry]	0.4	1	5	5	5
59137	1699	cytochalasin	[cytochalasin]	0.4	1	5	2	2
59138	1699	p21(ras)	[p21(ras)]	0.4	1	4	0	0
59139	1699	trx	[Trx]	0.4	1	5	2	2
59140	1699	synergize	[synergize]	0.4	1	6	2	1
59141	1699	vav	[Vav]	0.4	1	5	2	2
59142	1699	NS-Meg	[NS-Meg]	0.4	1	5	2	2
59143	1699	Delta	[Delta]	0.4	1	4	0	0
59144	1699	synthase	[synthase]	0.4	1	5	3	3
59145	1699	vpr	[vpr]	0.4	1	5	2	2
59146	1699	way	[way]	0.4	1	5	3	3
59147	1699	joint	[joint]	0.4	1	5	1	1
59148	1699	saccharomy	[Saccharomyces]	0.4	1	5	1	1
59149	1699	defense	[defense]	0.4	1	5	3	3
59150	1699	trypsin	[trypsin]	0.4	1	5	2	2
59151	1699	HIV1	[HIV1]	0.4	1	5	1	1
59152	1699	ubiquitinylation	[ubiquitinylation]	0.4	1	6	4	2
59153	1699	mechanisms,	[mechanisms,]	0.4	1	5	4	4
59154	1699	pg490	[PG490]	0.4	1	4	0	0
59155	1699	hypercalcemia	[hypercalcemia]	0.4	1	5	1	1
59156	1699	peri-kappa	[peri-kappa]	0.4	1	5	1	1
59157	1699	(tcr)	[(TCR)]	0.4	1	5	4	4
59158	1699	vessel	[vessel]	0.4	1	5	4	4
59159	1699	u/ml	[U/ml]	0.4	1	5	4	4
59160	1699	machinery	[machinery]	0.4	1	5	3	3
59161	1699	rel-a	[Rel-A]	0.4	1	5	2	2
59162	1699	TRAF1	[TRAF1]	0.4	1	5	2	2
59163	1699	T-lymphocyte	[T-lymphocyte]	0.4	1	4	0	0
59164	1699	colitis	[colitis]	0.4	1	6	4	2
59165	1699	Abelson	[Abelson]	0.4	1	4	0	0
59166	1699	inhibitors,	[inhibitors,]	0.4	1	4	0	0
59167	1699	rj2.2.5	[RJ2.2.5]	0.4	1	4	0	0
59168	1699	Proc	[Proc]	0.4	1	4	0	0
59169	1699	phorbol-12-myristate	[phorbol-12-myristate]	0.4	1	4	0	0
59170	1699	pregnancy,	[pregnancy,]	0.4	1	4	0	0
59171	1699	kbf1	[KBF1]	0.4	1	5	2	2
59172	1699	NF-muNR	[NF-muNR]	0.4	1	5	2	2
59173	1699	germ-line	[germ-line]	0.4	1	5	1	1
59174	1699	prevention	[prevention]	0.4	1	10	6	1
59175	1699	Stat-3	[Stat-3]	0.4	1	5	3	3
59176	1699	kda.	[kDa.]	0.4	1	5	5	5
59177	1699	doses.	[doses.]	0.4	1	5	5	5
59178	1699	disease,	[disease,]	0.4	1	5	1	1
59179	1699	parathyroid	[parathyroid]	0.4	1	4	0	0
59180	1699	hsf2-beta	[HSF2-beta]	0.4	1	5	1	1
59181	1699	BMLF1	[BMLF1]	0.4	1	5	3	3
59182	1699	non-T	[non-T]	0.4	1	5	2	2
59183	1699	tbp7	[TBP7]	0.4	1	4	0	0
59184	1699	sequence.	[sequence.]	0.4	1	5	2	2
59185	1699	sequence,	[sequence,]	0.4	1	5	2	2
59186	1699	alpha-helice	[alpha-helices]	0.4	1	5	4	4
59187	1699	follow-up	[follow-up]	0.4	1	5	2	2
59188	1699	effectiveness	[effectiveness]	0.4	1	6	6	3
59189	1699	DMDTC	[DMDTC]	0.4	1	4	0	0
59190	1699	E-box	[E-box]	0.4	1	4	0	0
59191	1699	lymphomagenesis	[lymphomagenesis]	0.4	1	4	0	0
59192	1699	IL13	[IL13]	0.4	1	4	0	0
59193	1699	brca2	[BRCA2]	0.4	1	5	2	2
59194	1699	MDS1/EVI1	[MDS1/EVI1]	0.4	1	4	0	0
59195	1699	HLA-DO	[HLA-DO]	0.4	1	5	1	1
59196	1699	HLA-DR	[HLA-DR]	0.4	1	5	3	3
59197	1699	HBxAg	[HBxAg]	0.4	1	4	0	0
59198	1699	gp91phox	[gp91phox]	0.4	1	5	3	3
59199	1699	development,	[development,]	0.4	1	5	3	3
59200	1699	tpck	[TPCK]	0.4	1	4	0	0
59201	1699	N-acetyl-L-cysteine	[N-acetyl-L-cysteine]	0.4	1	6	4	2
59202	1699	thyroglobulin	[thyroglobulin]	0.4	1	5	2	2
59203	1699	ISRE	[ISRE]	0.4	1	9	5	1
59204	1699	adjuvant	[adjuvant]	0.4	1	5	4	4
59205	1699	trep	[TREp]	0.4	1	5	1	1
59206	1699	brlf1	[BRLF1]	0.4	1	5	1	1
59207	1699	IL-4Ralpha	[IL-4Ralpha]	0.4	1	5	2	2
59208	1699	ng/ml).	[ng/mL).]	0.4	1	5	1	1
59209	1699	peroxisome	[Peroxisome]	0.4	1	6	6	3
59210	1699	artery	[artery]	0.4	1	5	3	3
59211	1699	gliadin	[gliadin]	0.4	1	5	1	1
59212	1699	RPMI	[RPMI]	0.4	1	4	0	0
59213	1699	template	[template]	0.4	1	5	3	3
59214	1699	cd43	[CD43]	0.4	1	5	4	4
59215	1699	role.	[role.]	0.4	1	5	3	3
59216	1699	epsilon26	[epsilon26]	0.4	1	5	4	4
59217	1699	Tyloxapol	[Tyloxapol]	0.4	1	4	0	0
59218	1699	erratum	[erratum]	0.4	1	5	1	1
59219	1699	cho-cd80	[CHO-CD80]	0.4	1	5	5	5
59220	1699	cis-	[cis-]	0.4	1	5	2	2
59221	1699	tfiih	[TFIIH]	0.4	1	5	3	3
59222	1699	cell,	[cell,]	0.4	1	5	3	3
59223	1699	frame	[frame]	0.4	1	5	4	4
59224	1699	trans-	[trans-]	0.4	1	5	1	1
59225	1699	analysis.	[analysis.]	0.4	1	5	1	1
59226	1699	granulopoiesis	[granulopoiesis]	0.4	1	5	1	1
59227	1699	drug.	[drug.]	0.4	1	5	1	1
59228	1699	lymphotropic	[lymphotropic]	0.4	1	6	4	2
59229	1699	ventilation	[ventilation]	0.4	1	7	6	2
59230	1699	water	[water]	0.4	1	5	4	4
59231	1699	irradiation	[irradiation]	0.4	1	5	2	2
59232	1699	MHC-I	[MHC-I]	0.4	1	5	2	2
59233	1699	Teflon	[Teflon]	0.4	1	5	2	2
59234	1699	pi3-k	[PI3-K]	0.4	1	6	2	1
59235	1699	unit	[unit]	0.4	1	5	5	5
59236	1699	tgf-alpha	[TGF-alpha]	0.4	1	5	2	2
59237	1699	triiodothyronine	[triiodothyronine]	0.4	1	5	3	3
59238	1699	C/EBPalpha	[C/EBPalpha]	0.4	1	5	1	1
59239	1699	T/NK	[T/NK]	0.4	1	4	0	0
59240	1699	osteoarthritis	[osteoarthritis]	0.4	1	4	0	0
59241	1699	mammal	[Mammal]	0.4	1	5	3	3
59242	1699	SP-1	[SP-1]	0.4	1	4	0	0
59243	1699	potassium	[potassium]	0.4	1	5	1	1
59244	1699	date	[date]	0.4	1	5	1	1
59245	1699	factors,	[factors,]	0.4	1	5	4	4
59246	1699	capability	[capability]	0.4	1	5	4	4
59247	1699	myeloblast	[myeloblast]	0.4	1	5	4	4
59248	1699	neonate	[neonate]	0.4	1	5	1	1
59249	1699	tissue-	[tissue-]	0.4	1	5	2	2
59250	1699	BASH	[BASH]	0.4	1	5	2	2
59251	1699	interactions.	[interactions.]	0.4	1	5	2	2
59252	1699	IRF-2	[IRF-2]	0.4	1	5	1	1
59253	1699	modulator	[modulator]	0.4	1	5	4	4
59254	1699	FECa2+	[FECa2+]	0.4	1	4	0	0
59255	1699	date,	[date,]	0.4	1	4	0	0
59256	1699	(il-2)	[(IL-2)]	0.4	1	5	4	4
59257	1699	Acad	[Acad]	0.4	1	4	0	0
59258	1699	mdhm	[MDHM]	0.4	1	4	0	0
59259	1699	hyponatremia	[hyponatremia]	0.4	1	5	2	2
59260	1699	codon	[codon]	0.4	1	5	5	5
59261	1699	microenvironment	[microenvironment]	0.4	1	5	1	1
59262	1699	dlcl	[DLCL]	0.4	1	4	0	0
59263	1699	KBF1	[KBF1]	0.4	1	5	1	1
59264	1699	gp130	[gp130]	0.4	1	5	1	1
59265	1699	components.	[components.]	0.4	1	5	5	5
59266	1699	min)	[min)]	0.4	1	5	5	5
59267	1699	BFU-E	[BFU-E]	0.4	1	5	3	3
59268	1699	Sp1urday	[Sp1-]	0.4	1	4	0	0
59269	1699	prednisone	[prednisone]	0.4	1	5	2	2
59270	1699	mt-2	[MT-2]	0.4	1	5	2	2
59271	1699	limit	[limit]	0.4	1	5	4	4
59272	1699	GATA3	[GATA3]	0.4	1	5	3	3
59273	1699	cox-2	[COX-2]	0.4	1	5	1	1
59274	1699	karyotype	[karyotype]	0.4	1	5	3	3
59275	1699	TLR2	[TLR2]	0.4	1	4	0	0
59276	1699	Urapidil	[Urapidil]	0.4	1	4	0	0
59277	1699	vsmc	[VSMCs]	0.4	1	5	4	4
59278	1699	ebna	[EBNA]	0.4	1	5	1	1
59279	1699	c-sis/pdgb	[c-sis/PDGF-B]	0.4	1	4	0	0
59280	1699	1a9-m	[1A9-M]	0.4	1	5	2	2
59281	1699	MIP-1	[MIP-1]	0.4	1	6	2	1
59282	1699	hsp27	[HSP27]	0.4	1	5	2	2
59283	1699	t-lymphoid	[T-lymphoid]	0.4	1	5	1	1
59284	1699	complexes.	[complexes.]	0.4	1	5	3	3
59285	1699	egr2	[EGR2]	0.4	1	5	2	2
59286	1699	CD70	[CD70]	0.4	1	4	0	0
59287	1699	signaling.	[signaling.]	0.4	1	5	2	2
59288	1699	thymoma	[thymoma]	0.4	1	5	1	1
59289	1699	neighbor	[neighboring]	0.4	1	4	0	0
59290	1699	Thrombopoietin	[Thrombopoietin]	0.4	1	5	1	1
59291	1699	ACH-2	[ACH-2]	0.4	1	5	1	1
59292	1699	el-4	[EL-4]	0.4	1	5	2	2
59293	1699	ISGF3	[ISGF3]	0.4	1	5	2	2
59294	1699	need	[need]	0.4	1	6	6	3
59295	1699	factor(	[factor(s)]	0.4	1	5	4	4
59296	1699	factor.	[factor.]	0.4	1	5	1	1
59297	1699	monoamine	[monoamine]	0.4	1	5	2	2
59298	1699	ngal	[NGAL]	0.4	1	5	1	1
59299	1699	SR-BP	[SR-BP]	0.4	1	5	3	3
59300	1699	g0s2	[G0S2]	0.4	1	5	2	2
59301	1699	contraction	[contraction]	0.4	1	5	2	2
59302	1699	Biol	[Biol]	0.4	1	4	0	0
59303	1699	testing	[testing]	0.4	1	5	5	5
59304	1699	NF(P)	[NF(P)]	0.4	1	6	2	1
59305	1699	comedo	[comedo]	0.4	1	5	2	2
59306	1699	adrenal	[adrenal]	0.4	1	4	0	0
59307	1699	eth2	[eTh2]	0.4	1	6	2	1
59308	1699	model,	[model,]	0.4	1	5	1	1
59309	1699	hypothyroidism	[hypothyroidism]	0.4	1	5	2	2
59310	1699	years)	[years)]	0.4	1	5	2	2
59311	1699	p300	[p300]	0.4	1	4	0	0
59312	1699	cd34+thy-1+	[CD34+Thy-1+]	0.4	1	4	0	0
59313	1699	CRM1	[CRM1]	0.4	1	5	1	1
59314	1699	others.	[others.]	0.4	1	5	1	1
59315	1699	clinic	[clinic]	0.4	1	4	0	0
59316	1699	alpha-IFN	[alpha-IFN]	0.4	1	5	1	1
59317	1699	testis	[testis]	0.4	1	5	3	3
59318	1699	29-kDa	[29-kDa]	0.4	1	4	0	0
59319	1699	(hiv-1)	[(HIV-1)]	0.4	1	5	4	4
59320	1699	nucleus.	[nucleus.]	0.4	1	6	2	1
59321	1699	interleukin-7	[interleukin-7]	0.4	1	5	1	1
59322	1699	BamHI	[BamHI]	0.4	1	4	0	0
59323	1699	issue,	[issue,]	0.4	1	4	0	0
59324	1699	CD11c	[CD11c]	0.4	1	5	1	1
59325	1699	megakaryocytic	[megakaryocytic]	0.4	1	5	2	2
59326	1699	history	[history]	0.4	1	5	4	4
59327	1699	9-cis-ra	[9-cis-RA]	0.4	1	5	1	1
59328	1699	acting	[acting]	0.4	1	5	4	4
59329	1699	L-selectin	[L-selectin]	0.4	1	4	0	0
59330	1699	fate	[fate]	0.4	1	5	4	4
59331	1699	RanBP1	[RanBP1]	0.4	1	4	0	0
59332	1699	p40tax	[p40tax]	0.4	1	6	2	1
59333	1699	hbxag	[HBxAg]	0.4	1	5	1	1
59334	1699	parallel,	[parallel,]	0.4	1	5	1	1
59335	1699	cepharanthine	[cepharanthine]	0.4	1	5	3	3
59336	1699	ut-7/gm	[UT-7/GM]	0.4	1	5	2	2
59337	1699	function,	[function,]	0.4	1	5	3	3
59338	1699	homodimerization	[homodimerization]	0.4	1	5	2	2
59339	1699	gradient	[gradient]	0.4	1	5	5	5
59340	1699	tramp	[TRAMP]	0.4	1	5	4	4
59341	1699	Jagged1	[Jagged1]	0.4	1	6	2	1
59342	1699	response,	[response,]	0.4	1	5	5	5
59343	1699	hallmark	[hallmark]	0.4	1	6	6	3
59344	1700	dysplasia	[dysplasia]	0.375	1	5	5	4
59345	1700	fashion,	[fashion,]	0.375	1	5	5	4
59346	1700	levels.	[levels.]	0.375	1	5	5	4
59347	1700	groove	[groove]	0.375	1	5	5	4
59348	1700	synovial	[synovial]	0.375	1	5	5	4
59349	1700	improvement	[improvement]	0.375	1	5	5	4
59350	1700	predictor	[predictor]	0.375	1	5	5	4
59351	1700	overproduction	[overproduction]	0.375	1	5	5	4
59352	1700	disappearance	[disappearance]	0.375	1	5	5	4
59353	1701	dissection	[dissection]	0.3666666666666667	1	5	4	3
59354	1701	TK	[TK]	0.3666666666666667	1	5	4	3
59355	1701	transcription-PCR	[transcription-PCR]	0.3666666666666667	1	5	4	3
59356	1701	G28-5	[G28-5]	0.3666666666666667	1	5	4	3
59357	1701	spread	[spread]	0.3666666666666667	1	5	4	3
59358	1701	g-csfr	[G-CSFR]	0.3666666666666667	1	5	4	3
59359	1701	cl-01	[CL-01]	0.3666666666666667	1	5	4	3
59360	1701	(igh)	[(IgH)]	0.3666666666666667	1	5	4	3
59361	1701	leader	[leader]	0.3666666666666667	1	5	4	3
59362	1701	advance	[advances]	0.3666666666666667	1	5	4	3
59363	1701	description	[description]	0.3666666666666667	1	5	4	3
59364	1701	MPD	[MPD]	0.3666666666666667	1	5	4	3
59365	1701	diseases.	[diseases.]	0.3666666666666667	1	5	4	3
59366	1701	atg	[ATG]	0.3666666666666667	1	5	4	3
59367	1701	bronchiti	[bronchitis]	0.3666666666666667	1	5	4	3
59368	1701	PD98059	[PD98059]	0.3666666666666667	1	5	4	3
59369	1701	strand	[strand]	0.3666666666666667	1	5	4	3
59370	1701	affinity,	[affinity,]	0.3666666666666667	1	5	4	3
59371	1701	nno	[nNOS]	0.3666666666666667	1	5	4	3
59372	1701	tmd	[TMD]	0.3666666666666667	1	5	4	3
59373	1701	cd45r0	[CD45R0]	0.3666666666666667	1	5	4	3
59374	1701	cortivazol	[cortivazol]	0.3666666666666667	1	5	4	3
59375	1701	electron	[electron]	0.3666666666666667	1	5	4	3
59376	1701	mother	[mother]	0.3666666666666667	1	5	4	3
59377	1701	internalization	[internalization]	0.3666666666666667	1	5	4	3
59378	1701	ATGCAAAT	[ATGCAAAT]	0.3666666666666667	1	5	4	3
59379	1701	weeks.	[weeks.]	0.3666666666666667	1	5	4	3
59380	1701	prognosis	[prognosis]	0.3666666666666667	1	5	4	3
59381	1701	node	[node]	0.3666666666666667	1	5	4	3
59382	1701	necessity	[necessity]	0.3666666666666667	1	5	4	3
59383	1702	Ii	[Ii]	0.35000000000000003	1	5	3	2
59384	1702	pu	[Pu]	0.35000000000000003	1	5	3	2
59385	1702	glucocorticosteroid	[glucocorticosteroid]	0.35000000000000003	1	5	3	2
59386	1702	Bcl-x	[Bcl-x]	0.35000000000000003	1	5	3	2
59387	1702	DRE	[DRE]	0.35000000000000003	1	5	3	2
59388	1702	HB9	[HB9]	0.35000000000000003	1	5	3	2
59389	1702	wound	[wound]	0.35000000000000003	1	5	3	2
59390	1702	ORF	[ORF]	0.35000000000000003	1	5	3	2
59391	1702	stimulator	[stimulator]	0.35000000000000003	1	6	5	2
59392	1702	Vitamin	[Vitamin]	0.35000000000000003	1	6	5	2
59393	1702	adenoviruse	[adenoviruses]	0.35000000000000003	1	5	3	2
59394	1702	ctll-2	[CTLL-2]	0.35000000000000003	1	5	3	2
59395	1702	tip	[Tip]	0.35000000000000003	1	5	3	2
59396	1702	virtue	[virtue]	0.35000000000000003	1	7	7	2
59397	1702	gamma-	[gamma-]	0.35000000000000003	1	5	3	2
59398	1702	bhrf1	[BHRF1]	0.35000000000000003	1	5	3	2
59399	1702	pneumophila	[pneumophila]	0.35000000000000003	1	5	3	2
59400	1702	BMRF1	[BMRF1]	0.35000000000000003	1	5	3	2
59401	1702	uf-1	[UF-1]	0.35000000000000003	1	5	3	2
59402	1702	pcd/dcoh	[PCD/DCoH]	0.35000000000000003	1	5	3	2
59403	1702	activator,	[activator,]	0.35000000000000003	1	5	3	2
59404	1702	dermatitis	[dermatitis]	0.35000000000000003	1	5	3	2
59405	1702	dibutyryl	[dibutyryl]	0.35000000000000003	1	6	5	2
59406	1702	propagation	[propagation]	0.35000000000000003	1	5	3	2
59407	1702	lineage-	[lineage-]	0.35000000000000003	1	5	3	2
59408	1702	cholera	[cholera]	0.35000000000000003	1	5	3	2
59409	1702	G(S)alpha	[G(S)alpha]	0.35000000000000003	1	5	3	2
59410	1702	(ig)	[(Ig)]	0.35000000000000003	1	5	3	2
59411	1702	relapse	[relapse]	0.35000000000000003	1	5	3	2
59412	1702	integrity	[integrity]	0.35000000000000003	1	5	3	2
59413	1703	runner	[runner]	0.3333333333333333	1	5	5	3
59414	1703	manipulation	[manipulation]	0.3333333333333333	1	5	5	3
59415	1703	SRE	[SRE]	0.3333333333333333	1	5	5	3
59416	1703	rnase	[RNase]	0.3333333333333333	1	5	5	3
59417	1703	htlv-ii	[HTLV-II]	0.3333333333333333	1	5	5	3
59418	1703	2,3,7,8-tetrachlorodibenzo-p-dioxin	[2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.3333333333333333	1	5	5	3
59419	1703	sarcoma	[sarcoma]	0.3333333333333333	1	5	5	3
59420	1704	j	[J]	0.30000000000000004	1	4	3	3
59421	1704	(a	[(A]	0.30000000000000004	1	4	1	1
59422	1704	monoblast	[monoblast]	0.30000000000000004	1	4	1	1
59423	1704	childhood	[childhood]	0.30000000000000004	1	4	2	2
59424	1704	Fabry	[Fabry]	0.30000000000000004	1	4	1	1
59425	1704	nonresponder	[nonresponders]	0.30000000000000004	1	4	2	2
59426	1704	CL	[CL]	0.30000000000000004	1	3	0	0
59427	1704	DM	[DM]	0.30000000000000004	1	3	0	0
59428	1704	DR	[DR]	0.30000000000000004	1	5	2	1
59429	1704	H2	[H2]	0.30000000000000004	1	3	0	0
59430	1704	MDHM	[MDHM]	0.30000000000000004	1	4	3	3
59431	1704	HF	[HF]	0.30000000000000004	1	4	2	2
59432	1704	L.	[L.]	0.30000000000000004	1	4	2	2
59433	1704	L2	[L2]	0.30000000000000004	1	4	1	1
59434	1704	KV	[KV]	0.30000000000000004	1	4	3	3
59435	1704	LN	[LN]	0.30000000000000004	1	3	0	0
59436	1704	M1	[M1]	0.30000000000000004	1	4	2	2
59437	1704	Mr	[Mr]	0.30000000000000004	1	3	0	0
59438	1704	PF	[PF]	0.30000000000000004	1	3	0	0
59439	1704	Pb	[Pb]	0.30000000000000004	1	4	3	3
59440	1704	Qp	[Qp]	0.30000000000000004	1	3	0	0
59441	1704	T.	[T.]	0.30000000000000004	1	4	1	1
59442	1704	Sp	[Sp]	0.30000000000000004	1	4	2	2
59443	1704	foam	[foam]	0.30000000000000004	1	5	2	1
59444	1704	X1	[X1]	0.30000000000000004	1	4	2	2
59445	1704	u1a/u1b	[U1A/U1B]	0.30000000000000004	1	4	1	1
59446	1704	b7	[B7]	0.30000000000000004	1	4	1	1
59447	1704	ao	[AO]	0.30000000000000004	1	3	0	0
59448	1704	transrepression	[transrepression]	0.30000000000000004	1	4	1	1
59449	1704	IFNalpha-	[IFNalpha-]	0.30000000000000004	1	3	0	0
59450	1704	df	[df]	0.30000000000000004	1	3	0	0
59451	1704	dr	[DR]	0.30000000000000004	1	4	1	1
59452	1704	hb	[Hb]	0.30000000000000004	1	4	2	2
59453	1704	hs	[HS]	0.30000000000000004	1	4	2	2
59454	1704	m,	[M,]	0.30000000000000004	1	4	2	2
59455	1704	xcid	[XCID]	0.30000000000000004	1	3	0	0
59456	1704	ng	[ng]	0.30000000000000004	1	4	4	4
59457	1704	p0	[P0]	0.30000000000000004	1	4	3	3
59458	1704	pf	[PF]	0.30000000000000004	1	4	1	1
59459	1704	pp	[pp]	0.30000000000000004	1	4	1	1
59460	1704	t4	[T4]	0.30000000000000004	1	4	3	3
59461	1704	se	[se]	0.30000000000000004	1	6	3	1
59462	1704	x1	[X1]	0.30000000000000004	1	4	1	1
59463	1704	hcd57	[HCD57]	0.30000000000000004	1	4	2	2
59464	1704	yj	[YJ]	0.30000000000000004	1	3	0	0
59465	1704	molecules,	[molecules,]	0.30000000000000004	1	4	3	3
59466	1704	DMSO	[DMSO]	0.30000000000000004	1	4	2	2
59467	1704	Kmone	[Km]	0.30000000000000004	1	4	1	1
59468	1704	ftoc	[FTOC]	0.30000000000000004	1	4	1	1
59469	1704	dihydroxyvitamin	[dihydroxyvitamin]	0.30000000000000004	1	4	2	2
59470	1704	E2A-	[E2A-]	0.30000000000000004	1	5	2	1
59471	1704	myeloperoxidase	[myeloperoxidase]	0.30000000000000004	1	4	2	2
59472	1704	fy*b	[FY*B]	0.30000000000000004	1	4	1	1
59473	1704	MMTV	[MMTV]	0.30000000000000004	1	4	2	2
59474	1704	EKLF-/-	[EKLF-/-]	0.30000000000000004	1	3	0	0
59475	1704	sp140	[Sp140]	0.30000000000000004	1	4	1	1
59476	1704	VIIa	[VIIa]	0.30000000000000004	1	4	1	1
59477	1704	xp-b	[XP-B]	0.30000000000000004	1	4	1	1
59478	1704	17-bp	[17-bp]	0.30000000000000004	1	3	0	0
59479	1704	TNFRI	[TNFRI]	0.30000000000000004	1	4	1	1
59480	1704	repertoire	[repertoire]	0.30000000000000004	1	4	2	2
59481	1704	leukocyte-type	[leukocyte-type]	0.30000000000000004	1	4	1	1
59482	1704	promoter,	[promoter,]	0.30000000000000004	1	4	1	1
59483	1704	thyroidectomy	[thyroidectomy]	0.30000000000000004	1	3	0	0
59484	1704	bmrf1	[BMRF1]	0.30000000000000004	1	4	2	2
59485	1704	MTCP1	[MTCP1]	0.30000000000000004	1	4	1	1
59486	1704	Flexi-12	[Flexi-12]	0.30000000000000004	1	3	0	0
59487	1704	competence	[competence]	0.30000000000000004	1	4	2	2
59488	1704	transmigration	[transmigration]	0.30000000000000004	1	4	1	1
59489	1704	ICK-1	[ICK-1]	0.30000000000000004	1	3	0	0
59490	1704	MTHC	[MTHC]	0.30000000000000004	1	4	1	1
59491	1704	Lt-4	[Lt-4]	0.30000000000000004	1	4	1	1
59492	1704	variability	[variability]	0.30000000000000004	1	4	4	4
59493	1704	termination	[termination]	0.30000000000000004	1	4	4	4
59494	1704	viral	[viral]	0.30000000000000004	1	4	2	2
59495	1704	35-kDa	[35-kDa]	0.30000000000000004	1	3	0	0
59496	1704	il-1alpha	[IL-1alpha]	0.30000000000000004	1	4	2	2
59497	1704	ivs1-10t-->c	[IVS1-10T-->C]	0.30000000000000004	1	4	1	1
59498	1704	barrier	[barrier]	0.30000000000000004	1	4	1	1
59499	1704	RanQ69L	[RanQ69L]	0.30000000000000004	1	3	0	0
59500	1704	non-hodgkin'	[non-Hodgkin's]	0.30000000000000004	1	4	3	3
59501	1704	STAT5b	[STAT5b]	0.30000000000000004	1	4	1	1
59502	1704	STAT5A	[STAT5A]	0.30000000000000004	1	4	2	2
59503	1704	up-regulate	[up-regulate]	0.30000000000000004	1	4	3	3
59504	1704	macrophage-differentiation	[macrophage-differentiation]	0.30000000000000004	1	4	1	1
59505	1704	EA/S	[EA/S]	0.30000000000000004	1	3	0	0
59506	1704	cryptococcus	[Cryptococcus]	0.30000000000000004	1	4	1	1
59507	1704	monolayer	[monolayers]	0.30000000000000004	1	4	3	3
59508	1704	circumstances,	[circumstances,]	0.30000000000000004	1	4	2	2
59509	1704	EBS1	[EBS1]	0.30000000000000004	1	3	0	0
59510	1704	vivo;	[vivo;]	0.30000000000000004	1	3	0	0
59511	1704	availability	[availability]	0.30000000000000004	1	6	6	2
59512	1704	pc-3	[PC-3]	0.30000000000000004	1	4	1	1
59513	1704	parp	[PARP]	0.30000000000000004	1	4	3	3
59514	1704	MC903	[MC903]	0.30000000000000004	1	4	1	1
59515	1704	pbsc	[PBSC]	0.30000000000000004	1	3	0	0
59516	1704	stretch	[stretch]	0.30000000000000004	1	4	3	3
59517	1704	PG490	[PG490]	0.30000000000000004	1	4	1	1
59518	1704	-3gamma	[-3gamma]	0.30000000000000004	1	3	0	0
59519	1704	shuttling	[shuttling]	0.30000000000000004	1	4	3	3
59520	1704	zeta-globin	[zeta-globin]	0.30000000000000004	1	3	0	0
59521	1704	ghost	[ghost]	0.30000000000000004	1	4	1	1
59522	1704	glia	[glia]	0.30000000000000004	1	4	1	1
59523	1704	fusion,	[fusion,]	0.30000000000000004	1	3	0	0
59524	1704	yb-1	[YB-1]	0.30000000000000004	1	4	3	3
59525	1704	5'-UTR	[5'-UTR]	0.30000000000000004	1	4	1	1
59526	1704	5-LOX	[5-LOX]	0.30000000000000004	1	3	0	0
59527	1704	TCRzeta	[TCRzeta]	0.30000000000000004	1	6	3	1
59528	1704	latter	[latter]	0.30000000000000004	1	3	0	0
59529	1704	hgata-4	[hGATA-4]	0.30000000000000004	1	3	0	0
59530	1704	well.	[well.]	0.30000000000000004	1	3	0	0
59531	1704	cipro	[cipro]	0.30000000000000004	1	4	2	2
59532	1704	subunits.	[subunits.]	0.30000000000000004	1	4	2	2
59533	1704	myd88	[MyD88]	0.30000000000000004	1	4	1	1
59534	1704	pkc,	[PKC,]	0.30000000000000004	1	3	0	0
59535	1704	survivalepromot	[survival-promoting]	0.30000000000000004	1	3	0	0
59536	1704	r-pk	[R-PK]	0.30000000000000004	1	3	0	0
59537	1704	pmnc	[PMNCs]	0.30000000000000004	1	4	3	3
59538	1704	evolution	[evolution]	0.30000000000000004	1	4	2	2
59539	1704	mycobacteria	[mycobacteria]	0.30000000000000004	1	4	2	2
59540	1704	ionizing	[ionizing]	0.30000000000000004	1	4	2	2
59541	1704	pp2a	[PP2A]	0.30000000000000004	1	4	1	1
59542	1704	coordination	[coordination]	0.30000000000000004	1	5	4	2
59543	1704	differential	[differential]	0.30000000000000004	1	3	0	0
59544	1704	ERK2	[ERK2]	0.30000000000000004	1	4	2	2
59545	1704	(+)	[(+)]	0.30000000000000004	1	4	1	1
59546	1704	decoy	[decoy]	0.30000000000000004	1	3	0	0
59547	1704	cross	[cross]	0.30000000000000004	1	3	0	0
59548	1704	pthrp	[PTHrP]	0.30000000000000004	1	4	2	2
59549	1704	varicella-zoster	[varicella-zoster]	0.30000000000000004	1	3	0	0
59550	1704	phorbol-12-myristate-13-acetate	[phorbol-12-myristate-13-acetate]	0.30000000000000004	1	3	0	0
59551	1704	(hpa)	[(HPA)]	0.30000000000000004	1	4	1	1
59552	1704	c5b-9	[C5b-9]	0.30000000000000004	1	4	1	1
59553	1704	KBF1/p50	[KBF1/p50]	0.30000000000000004	1	4	2	2
59554	1704	promoter-reporter	[promoter-reporter]	0.30000000000000004	1	4	3	3
59555	1704	(phase	[(phase]	0.30000000000000004	1	4	1	1
59556	1704	ut-7/gmt	[UT-7/GMT]	0.30000000000000004	1	4	2	2
59557	1704	pkb/akt	[PKB/Akt]	0.30000000000000004	1	4	3	3
59558	1704	beta2	[beta2]	0.30000000000000004	1	4	1	1
59559	1704	epsilon-	[epsilon-]	0.30000000000000004	1	4	2	2
59560	1704	functionality	[functionality]	0.30000000000000004	1	4	1	1
59561	1704	AG-490	[AG-490]	0.30000000000000004	1	4	1	1
59562	1704	3-o-methyl-d-glucose	[3-O-methyl-D-glucose]	0.30000000000000004	1	4	1	1
59563	1704	delay	[delay]	0.30000000000000004	1	4	1	1
59564	1704	transferase	[transferase]	0.30000000000000004	1	4	3	3
59565	1704	haec	[HAEC]	0.30000000000000004	1	4	2	2
59566	1704	cyclase	[cyclase]	0.30000000000000004	1	4	2	2
59567	1704	Interleukin-10	[Interleukin-10]	0.30000000000000004	1	8	5	1
59568	1704	hematopoietin	[hematopoietin]	0.30000000000000004	1	4	1	1
59569	1704	hl-60-c15	[HL-60-C15]	0.30000000000000004	1	3	0	0
59570	1704	systems,	[systems,]	0.30000000000000004	1	4	3	3
59571	1704	ERK1/2	[ERK1/2]	0.30000000000000004	1	4	2	2
59572	1704	STAT4	[STAT4]	0.30000000000000004	1	4	2	2
59573	1704	STAT2	[STAT2]	0.30000000000000004	1	3	0	0
59574	1704	sla-dq	[SLA-DQ]	0.30000000000000004	1	4	2	2
59575	1704	sla-dr	[SLA-DR]	0.30000000000000004	1	4	1	1
59576	1704	monocytic/macrophage	[monocytic/macrophage]	0.30000000000000004	1	3	0	0
59577	1704	alpha2	[alpha2]	0.30000000000000004	1	5	2	1
59578	1704	cases.	[cases.]	0.30000000000000004	1	4	2	2
59579	1704	U/ml,	[U/ml,]	0.30000000000000004	1	4	2	2
59580	1704	v-erb	[v-erb]	0.30000000000000004	1	4	1	1
59581	1704	temperature	[temperature]	0.30000000000000004	1	4	4	4
59582	1704	coping	[coping]	0.30000000000000004	1	4	1	1
59583	1704	BCP-ALL	[BCP-ALL]	0.30000000000000004	1	3	0	0
59584	1704	border	[border]	0.30000000000000004	1	4	3	3
59585	1704	Egr-3	[Egr-3]	0.30000000000000004	1	4	2	2
59586	1704	plant	[plant]	0.30000000000000004	1	4	1	1
59587	1704	levels,	[levels,]	0.30000000000000004	1	4	3	3
59588	1704	pokeweed	[pokeweed]	0.30000000000000004	1	3	0	0
59589	1704	c-type	[C-type]	0.30000000000000004	1	3	0	0
59590	1704	palindrome	[palindrome]	0.30000000000000004	1	4	4	4
59591	1704	cooperativity	[cooperativity]	0.30000000000000004	1	4	4	4
59592	1704	quality	[quality]	0.30000000000000004	1	4	3	3
59593	1704	Science	[Science]	0.30000000000000004	1	4	1	1
59594	1704	glycine	[glycine]	0.30000000000000004	1	3	0	0
59595	1704	FHIT	[FHIT]	0.30000000000000004	1	3	0	0
59596	1704	migrate	[migrating]	0.30000000000000004	1	4	4	4
59597	1704	ubiquitination	[ubiquitination]	0.30000000000000004	1	4	1	1
59598	1704	laz3/bcl6	[LAZ3/BCL6]	0.30000000000000004	1	4	2	2
59599	1704	case,	[case,]	0.30000000000000004	1	4	1	1
59600	1704	complication	[complications]	0.30000000000000004	1	4	3	3
59601	1704	action,	[action,]	0.30000000000000004	1	5	4	2
59602	1704	v-myb	[v-myb]	0.30000000000000004	1	4	1	1
59603	1704	5-lox	[5-LOX]	0.30000000000000004	1	4	2	2
59604	1704	rwleu-4	[RWLeu-4]	0.30000000000000004	1	5	2	1
59605	1704	A20	[A20]	0.30000000000000004	1	3	0	0
59606	1704	latency.	[latency.]	0.30000000000000004	1	4	3	3
59607	1704	5'-utr	[5'-UTR]	0.30000000000000004	1	4	2	2
59608	1704	ADT	[ADT]	0.30000000000000004	1	4	3	3
59609	1704	ALD	[ALD]	0.30000000000000004	1	3	0	0
59610	1704	mzf-2	[MZF-2]	0.30000000000000004	1	5	4	2
59611	1704	ATP	[ATP]	0.30000000000000004	1	3	0	0
59612	1704	BDP	[BDP]	0.30000000000000004	1	4	1	1
59613	1704	BMT	[BMT]	0.30000000000000004	1	4	1	1
59614	1704	a-myb	[A-myb]	0.30000000000000004	1	4	3	3
59615	1704	regulate	[regulating]	0.30000000000000004	1	4	4	4
59616	1704	Bak	[Bak]	0.30000000000000004	1	4	2	2
59617	1704	CD7	[CD7]	0.30000000000000004	1	3	0	0
59618	1704	Bax	[Bax]	0.30000000000000004	1	4	1	1
59619	1704	GM-CSFRalpha	[GM-CSFRalpha]	0.30000000000000004	1	3	0	0
59620	1704	CSF	[CSF]	0.30000000000000004	1	4	2	2
59621	1704	CTF	[CTF]	0.30000000000000004	1	3	0	0
59622	1704	state,	[state,]	0.30000000000000004	1	4	4	4
59623	1704	t(17;19)	[t(17;19)]	0.30000000000000004	1	4	1	1
59624	1704	DFX	[DFX]	0.30000000000000004	1	5	2	1
59625	1704	DOX	[DOX]	0.30000000000000004	1	4	2	2
59626	1704	E74	[E74]	0.30000000000000004	1	4	2	2
59627	1704	CyA	[CyA]	0.30000000000000004	1	3	0	0
59628	1704	r-hTBP-1	[r-hTBP-1]	0.30000000000000004	1	3	0	0
59629	1704	stat-1	[STAT-1]	0.30000000000000004	1	4	4	4
59630	1704	stat-3	[Stat-3]	0.30000000000000004	1	3	0	0
59631	1704	ERP	[ERP]	0.30000000000000004	1	4	2	2
59632	1704	placenta	[placenta]	0.30000000000000004	1	3	0	0
59633	1704	FCS	[FCS]	0.30000000000000004	1	3	0	0
59634	1704	FGF	[FGF]	0.30000000000000004	1	4	2	2
59635	1704	cellular	[cellular]	0.30000000000000004	1	4	2	2
59636	1704	cocktail	[cocktail]	0.30000000000000004	1	4	4	4
59637	1704	GR6	[GR6]	0.30000000000000004	1	4	1	1
59638	1704	IL-2Ralpha	[IL-2Ralpha]	0.30000000000000004	1	4	2	2
59639	1704	FTOC	[FTOC]	0.30000000000000004	1	3	0	0
59640	1704	PRRIII	[PRRIII]	0.30000000000000004	1	3	0	0
59641	1704	HSF	[HSF]	0.30000000000000004	1	4	2	2
59642	1704	HSV	[HSV]	0.30000000000000004	1	4	1	1
59643	1704	HTB	[HTB]	0.30000000000000004	1	3	0	0
59644	1704	HVS	[HVS]	0.30000000000000004	1	4	3	3
59645	1704	binding.	[binding.]	0.30000000000000004	1	4	2	2
59646	1704	IBD	[IBD]	0.30000000000000004	1	4	3	3
59647	1704	IBF	[IBF]	0.30000000000000004	1	3	0	0
59648	1704	IBR	[IBR]	0.30000000000000004	1	3	0	0
59649	1704	hypo	[hypo]	0.30000000000000004	1	4	1	1
59650	1704	mature	[maturing]	0.30000000000000004	1	4	1	1
59651	1704	19-bp	[19-bp]	0.30000000000000004	1	4	1	1
59652	1704	IgG	[IgG]	0.30000000000000004	1	3	0	0
59653	1704	FUra	[FUra]	0.30000000000000004	1	3	0	0
59654	1704	sport	[sport]	0.30000000000000004	1	3	0	0
59655	1704	KG1	[KG1]	0.30000000000000004	1	4	2	2
59656	1704	KOX	[KOX]	0.30000000000000004	1	4	3	3
59657	1704	Z/c-myb	[Z/c-myb]	0.30000000000000004	1	3	0	0
59658	1704	FY*B	[FY*B]	0.30000000000000004	1	3	0	0
59659	1704	LAL	[LAL]	0.30000000000000004	1	4	4	4
59660	1704	ATF/CREB	[ATF/CREB]	0.30000000000000004	1	4	2	2
59661	1704	reversion	[reversion]	0.30000000000000004	1	4	3	3
59662	1704	autophosphorylation	[autophosphorylation]	0.30000000000000004	1	4	2	2
59663	1704	MBC	[MBC]	0.30000000000000004	1	4	1	1
59664	1704	hLH-2	[hLH-2]	0.30000000000000004	1	3	0	0
59665	1704	ril-12	[rIL-12]	0.30000000000000004	1	3	0	0
59666	1704	MDP	[MDP]	0.30000000000000004	1	3	0	0
59667	1704	MEL	[MEL]	0.30000000000000004	1	4	1	1
59668	1704	MLV	[MLV]	0.30000000000000004	1	4	2	2
59669	1704	Max	[Max]	0.30000000000000004	1	3	0	0
59670	1704	NDP	[NDP]	0.30000000000000004	1	4	1	1
59671	1704	NF-	[NF-]	0.30000000000000004	1	4	1	1
59672	1704	OTF2	[OTF2]	0.30000000000000004	1	3	0	0
59673	1704	NK-	[NK-]	0.30000000000000004	1	4	3	3
59674	1704	Mol	[Mol]	0.30000000000000004	1	3	0	0
59675	1704	radioligand	[radioligand]	0.30000000000000004	1	4	2	2
59676	1704	PML/RAR	[PML/RAR]	0.30000000000000004	1	4	1	1
59677	1704	post-gc	[post-GC]	0.30000000000000004	1	4	1	1
59678	1704	P/I	[P/I]	0.30000000000000004	1	3	0	0
59679	1704	PBM	[PBM]	0.30000000000000004	1	4	1	1
59680	1704	methionine	[methionine]	0.30000000000000004	1	3	0	0
59681	1704	-4gamma	[-4gamma]	0.30000000000000004	1	3	0	0
59682	1704	sequestration	[sequestration]	0.30000000000000004	1	4	3	3
59683	1704	PTK	[PTK]	0.30000000000000004	1	4	2	2
59684	1704	Ara-C	[Ara-C]	0.30000000000000004	1	3	0	0
59685	1704	caspase-3	[caspase-3]	0.30000000000000004	1	4	2	2
59686	1704	bowel	[bowel]	0.30000000000000004	1	4	1	1
59687	1704	PEBP2/CBF	[PEBP2/CBF]	0.30000000000000004	1	4	1	1
59688	1704	PuF	[PuF]	0.30000000000000004	1	3	0	0
59689	1704	patient.	[patient.]	0.30000000000000004	1	4	3	3
59690	1704	REV	[REV]	0.30000000000000004	1	4	2	2
59691	1704	trans-activate	[trans-activating]	0.30000000000000004	1	4	1	1
59692	1704	SNE	[SNE]	0.30000000000000004	1	4	3	3
59693	1704	gamma-interferon	[gamma-interferon]	0.30000000000000004	1	4	3	3
59694	1704	Sp140	[Sp140]	0.30000000000000004	1	3	0	0
59695	1704	TCC	[TCC]	0.30000000000000004	1	3	0	0
59696	1704	THP	[THP]	0.30000000000000004	1	3	0	0
59697	1704	Shc	[Shc]	0.30000000000000004	1	3	0	0
59698	1704	TMD	[TMD]	0.30000000000000004	1	3	0	0
59699	1704	TR2	[TR2]	0.30000000000000004	1	3	0	0
59700	1704	TRs	[TRs]	0.30000000000000004	1	4	3	3
59701	1704	lipoxygenase	[lipoxygenase]	0.30000000000000004	1	4	2	2
59702	1704	properties	[properties,]	0.30000000000000004	1	4	4	4
59703	1704	dutpase	[dUTPase]	0.30000000000000004	1	4	3	3
59704	1704	USF	[USF]	0.30000000000000004	1	4	1	1
59705	1704	pentoxifylline	[pentoxifylline]	0.30000000000000004	1	4	2	2
59706	1704	p50/rela(p65)	[p50/RelA(p65)]	0.30000000000000004	1	3	0	0
59707	1704	cd23b	[CD23b]	0.30000000000000004	1	3	0	0
59708	1704	interpretation	[interpretation]	0.30000000000000004	1	4	4	4
59709	1704	cd106	[CD106]	0.30000000000000004	1	4	1	1
59710	1704	cd11a	[CD11a]	0.30000000000000004	1	4	2	2
59711	1704	approach,	[approach,]	0.30000000000000004	1	4	4	4
59712	1704	p75tnf-r	[p75TNF-R]	0.30000000000000004	1	4	1	1
59713	1704	72-kDa	[72-kDa]	0.30000000000000004	1	3	0	0
59714	1704	pocket	[pocket]	0.30000000000000004	1	3	0	0
59715	1704	coincubation	[coincubation]	0.30000000000000004	1	5	4	2
59716	1704	Wnt	[Wnt]	0.30000000000000004	1	4	1	1
59717	1704	gingival	[gingival]	0.30000000000000004	1	5	2	1
59718	1704	sibling	[sibling]	0.30000000000000004	1	4	2	2
59719	1704	Pax-5a	[Pax-5a]	0.30000000000000004	1	3	0	0
59720	1704	Pax-5e	[Pax-5e]	0.30000000000000004	1	3	0	0
59721	1704	thalassemia	[thalassemia]	0.30000000000000004	1	4	1	1
59722	1704	osteocalcin	[osteocalcin]	0.30000000000000004	1	4	1	1
59723	1704	PBSC	[PBSC]	0.30000000000000004	1	4	2	2
59724	1704	rutin	[rutin]	0.30000000000000004	1	3	0	0
59725	1704	pi3-kinase	[PI3-kinase]	0.30000000000000004	1	4	2	2
59726	1704	co-expression	[Co-expression]	0.30000000000000004	1	5	4	2
59727	1704	4e-bp1	[4E-BP1]	0.30000000000000004	1	4	2	2
59728	1704	LITAF	[LITAF]	0.30000000000000004	1	4	1	1
59729	1704	metastase	[metastases]	0.30000000000000004	1	3	0	0
59730	1704	calpain	[calpain]	0.30000000000000004	1	4	1	1
59731	1704	level,	[level,]	0.30000000000000004	1	4	4	4
59732	1704	Tal-1	[Tal-1]	0.30000000000000004	1	4	3	3
59733	1704	mimicry	[mimicry]	0.30000000000000004	1	4	2	2
59734	1704	nih-3t3	[NIH-3T3]	0.30000000000000004	1	3	0	0
59735	1704	il-2-	[IL-2-]	0.30000000000000004	1	4	1	1
59736	1704	sequences.	[sequences.]	0.30000000000000004	1	4	2	2
59737	1704	ach-2	[ACH-2]	0.30000000000000004	1	4	2	2
59738	1704	groups,	[groups,]	0.30000000000000004	1	4	4	4
59739	1704	IL-12R	[IL-12R]	0.30000000000000004	1	4	2	2
59740	1704	JAK-1	[JAK-1]	0.30000000000000004	1	3	0	0
59741	1704	IL-2-R	[IL-2-R]	0.30000000000000004	1	3	0	0
59742	1704	b29	[B29]	0.30000000000000004	1	4	2	2
59743	1704	secretion.	[secretion.]	0.30000000000000004	1	3	0	0
59744	1704	baseline.	[baseline.]	0.30000000000000004	1	3	0	0
59745	1704	Arnhl	[ARNHL]	0.30000000000000004	1	3	0	0
59746	1704	adt	[ADT]	0.30000000000000004	1	3	0	0
59747	1704	ags	[AGS]	0.30000000000000004	1	4	3	3
59748	1704	c-c	[C-C]	0.30000000000000004	1	4	2	2
59749	1704	alu	[Alu]	0.30000000000000004	1	4	1	1
59750	1704	bed	[bed]	0.30000000000000004	1	4	1	1
59751	1704	antigen,	[antigen,]	0.30000000000000004	1	3	0	0
59752	1704	cag	[CAG]	0.30000000000000004	1	4	1	1
59753	1704	cbl	[Cbl]	0.30000000000000004	1	4	2	2
59754	1704	divergence	[divergence]	0.30000000000000004	1	4	3	3
59755	1704	cis	[cis]	0.30000000000000004	1	4	1	1
59756	1704	FosB	[FosB]	0.30000000000000004	1	3	0	0
59757	1704	(HIV)	[(HIV)]	0.30000000000000004	1	4	3	3
59758	1704	con	[Con]	0.30000000000000004	1	4	1	1
59759	1704	cpo	[CPO]	0.30000000000000004	1	4	2	2
59760	1704	cys	[CYS]	0.30000000000000004	1	3	0	0
59761	1704	embryogenesis	[embryogenesis]	0.30000000000000004	1	4	2	2
59762	1704	maximum	[maximum]	0.30000000000000004	1	4	3	3
59763	1704	dioxyvit	[dioxyvit]	0.30000000000000004	1	4	2	2
59764	1704	dtc	[DTCs]	0.30000000000000004	1	3	0	0
59765	1704	egl	[eGLs]	0.30000000000000004	1	4	1	1
59766	1704	el4	[EL4]	0.30000000000000004	1	4	2	2
59767	1704	eml	[EML]	0.30000000000000004	1	5	2	1
59768	1704	g0s	[G0S]	0.30000000000000004	1	4	2	2
59769	1704	mar-bp1	[MAR-BP1]	0.30000000000000004	1	4	1	1
59770	1704	erp	[ERP]	0.30000000000000004	1	3	0	0
59771	1704	fat	[fat]	0.30000000000000004	1	4	1	1
59772	1704	flc	[FLCs]	0.30000000000000004	1	4	3	3
59773	1704	gd3	[GD3]	0.30000000000000004	1	4	3	3
59774	1704	gch	[GCH]	0.30000000000000004	1	4	2	2
59775	1704	(nf)-kappab	[(NF)-kappaB]	0.30000000000000004	1	4	3	3
59776	1704	gst	[GST]	0.30000000000000004	1	4	3	3
59777	1704	hsf	[HSF]	0.30000000000000004	1	4	2	2
59778	1704	hsp	[HSP]	0.30000000000000004	1	4	3	3
59779	1704	mac-1	[Mac-1]	0.30000000000000004	1	3	0	0
59780	1704	RelA(p65)	[RelA(p65)]	0.30000000000000004	1	4	2	2
59781	1704	ibd	[IBD]	0.30000000000000004	1	4	1	1
59782	1704	ibr	[IBR]	0.30000000000000004	1	4	1	1
59783	1704	ilf	[ILFs]	0.30000000000000004	1	4	1	1
59784	1704	KH1060	[KH1060]	0.30000000000000004	1	3	0	0
59785	1704	ach2	[Ach2]	0.30000000000000004	1	4	3	3
59786	1704	isg	[ISG]	0.30000000000000004	1	5	2	1
59787	1704	kD.	[kD.]	0.30000000000000004	1	4	2	2
59788	1704	HSV-2	[HSV-2]	0.30000000000000004	1	3	0	0
59789	1704	HSV-1	[HSV-1]	0.30000000000000004	1	3	0	0
59790	1704	Shigella	[Shigella]	0.30000000000000004	1	4	2	2
59791	1704	patients'	[patients']	0.30000000000000004	1	4	2	2
59792	1704	dimethyl	[dimethyl]	0.30000000000000004	1	4	2	2
59793	1704	lac	[lac]	0.30000000000000004	1	4	3	3
59794	1704	lak	[LAK]	0.30000000000000004	1	5	2	1
59795	1704	lat	[LAT]	0.30000000000000004	1	4	2	2
59796	1704	lcl	[LCLs]	0.30000000000000004	1	4	1	1
59797	1704	contrary,	[contrary,]	0.30000000000000004	1	3	0	0
59798	1704	ser-727	[ser-727]	0.30000000000000004	1	3	0	0
59799	1704	maeca	[mAECA]	0.30000000000000004	1	4	2	2
59800	1704	mua	[muA]	0.30000000000000004	1	3	0	0
59801	1704	fludarabine	[fludarabine]	0.30000000000000004	1	4	3	3
59802	1704	ner	[NER]	0.30000000000000004	1	4	1	1
59803	1704	p15	[p15]	0.30000000000000004	1	3	0	0
59804	1704	p45	[p45]	0.30000000000000004	1	4	2	2
59805	1704	p56	[p56]	0.30000000000000004	1	4	1	1
59806	1704	hyperkalemia	[hyperkalemia]	0.30000000000000004	1	4	1	1
59807	1704	cck-8	[CCK-8]	0.30000000000000004	1	3	0	0
59808	1704	oap	[OAP]	0.30000000000000004	1	3	0	0
59809	1704	homo-	[homo-]	0.30000000000000004	1	4	2	2
59810	1704	pbm	[PBM]	0.30000000000000004	1	4	1	1
59811	1704	toll-like	[toll-like]	0.30000000000000004	1	4	2	2
59812	1704	pgn	[PGN]	0.30000000000000004	1	4	3	3
59813	1704	plc	[PLC]	0.30000000000000004	1	4	2	2
59814	1704	salivary	[salivary]	0.30000000000000004	1	4	1	1
59815	1704	latent,	[latent,]	0.30000000000000004	1	4	2	2
59816	1704	agent,	[agent,]	0.30000000000000004	1	4	2	2
59817	1704	sIg	[sIg]	0.30000000000000004	1	4	3	3
59818	1704	rho	[Rho]	0.30000000000000004	1	4	1	1
59819	1704	rp1	[RP1]	0.30000000000000004	1	4	1	1
59820	1704	alf1	[ALF1]	0.30000000000000004	1	4	3	3
59821	1704	se,	[se,]	0.30000000000000004	1	4	2	2
59822	1704	lfa-1	[LFA-1]	0.30000000000000004	1	3	0	0
59823	1704	x-scid	[X-SCID]	0.30000000000000004	1	4	2	2
59824	1704	P/CAF	[P/CAF]	0.30000000000000004	1	3	0	0
59825	1704	ssb	[SSB]	0.30000000000000004	1	4	1	1
59826	1704	transformation.	[transformation.]	0.30000000000000004	1	4	3	3
59827	1704	syk	[Syk]	0.30000000000000004	1	4	2	2
59828	1704	ttg	[tTG]	0.30000000000000004	1	4	3	3
59829	1704	cd45ra	[CD45RA]	0.30000000000000004	1	4	1	1
59830	1704	IP-10	[IP-10]	0.30000000000000004	1	3	0	0
59831	1704	vWf	[vWf]	0.30000000000000004	1	3	0	0
59832	1704	il-4ralpha	[IL-4Ralpha]	0.30000000000000004	1	3	0	0
59833	1704	vkc	[VKC]	0.30000000000000004	1	4	2	2
59834	1704	YY-1	[YY-1]	0.30000000000000004	1	4	1	1
59835	1704	sem,	[SEM,]	0.30000000000000004	1	6	6	2
59836	1704	Gene	[Gene]	0.30000000000000004	1	4	3	3
59837	1704	methods,	[methods,]	0.30000000000000004	1	4	4	4
59838	1704	t(15;17)	[t(15;17)]	0.30000000000000004	1	3	0	0
59839	1704	induction.	[induction.]	0.30000000000000004	1	4	2	2
59840	1704	ba/f3	[Ba/F3]	0.30000000000000004	1	4	1	1
59841	1704	rar-alpha	[RAR-alpha]	0.30000000000000004	1	4	3	3
59842	1704	EGR-1	[EGR-1]	0.30000000000000004	1	4	1	1
59843	1704	Pax5	[Pax5]	0.30000000000000004	1	5	2	1
59844	1704	atll	[ATLL]	0.30000000000000004	1	3	0	0
59845	1704	CRO-AP/5	[CRO-AP/5]	0.30000000000000004	1	3	0	0
59846	1704	lambda5	[lambda5]	0.30000000000000004	1	3	0	0
59847	1704	virus,	[virus,]	0.30000000000000004	1	4	2	2
59848	1704	sigma	[sigma]	0.30000000000000004	1	4	1	1
59849	1704	tr2re-	[TR2RE-]	0.30000000000000004	1	3	0	0
59850	1704	donovani	[donovani]	0.30000000000000004	1	3	0	0
59851	1704	lactosylceramide	[lactosylceramide]	0.30000000000000004	1	3	0	0
59852	1704	cem-c7	[CEM-C7]	0.30000000000000004	1	4	3	3
59853	1704	ref-1	[REF-1]	0.30000000000000004	1	4	1	1
59854	1704	cd4-8-	[CD4-8-]	0.30000000000000004	1	6	6	2
59855	1704	tuberculosis.	[tuberculosis.]	0.30000000000000004	1	3	0	0
59856	1704	sp-a	[SP-A]	0.30000000000000004	1	4	3	3
59857	1704	choice	[choice]	0.30000000000000004	1	4	3	3
59858	1704	Delta19	[Delta19]	0.30000000000000004	1	3	0	0
59859	1704	HSF2	[HSF2]	0.30000000000000004	1	3	0	0
59860	1704	HSF3	[HSF3]	0.30000000000000004	1	3	0	0
59861	1704	mutation.	[mutation.]	0.30000000000000004	1	3	0	0
59862	1704	srg3	[SRG3]	0.30000000000000004	1	3	0	0
59863	1704	TRE-1	[TRE-1]	0.30000000000000004	1	4	1	1
59864	1704	nonexpress	[nonexpressing]	0.30000000000000004	1	3	0	0
59865	1704	Group	[Group]	0.30000000000000004	1	3	0	0
59866	1704	rhinitis	[rhinitis]	0.30000000000000004	1	6	3	1
59867	1704	cdc42	[Cdc42]	0.30000000000000004	1	4	2	2
59868	1704	transcripts.	[transcripts.]	0.30000000000000004	1	4	3	3
59869	1704	v3-bh10	[V3-BH10]	0.30000000000000004	1	3	0	0
59870	1704	follicle	[follicles]	0.30000000000000004	1	4	4	4
59871	1704	site,	[site,]	0.30000000000000004	1	4	3	3
59872	1704	microorganism	[microorganisms]	0.30000000000000004	1	3	0	0
59873	1704	-epsilon	[-epsilon]	0.30000000000000004	1	4	2	2
59874	1704	(tnf)	[(TNF)]	0.30000000000000004	1	4	3	3
59875	1704	heptamer	[heptamer]	0.30000000000000004	1	3	0	0
59876	1704	12-o-tetradecanoylphorbol	[12-O-tetradecanoylphorbol]	0.30000000000000004	1	4	1	1
59877	1704	criteria,	[criteria,]	0.30000000000000004	1	4	4	4
59878	1704	genital	[genital]	0.30000000000000004	1	4	2	2
59879	1704	pkc-epsilon	[PKC-epsilon]	0.30000000000000004	1	4	1	1
59880	1704	(U937)	[(U937)]	0.30000000000000004	1	4	4	4
59881	1704	intestine	[intestine]	0.30000000000000004	1	4	3	3
59882	1704	Theileria	[Theileria]	0.30000000000000004	1	4	2	2
59883	1704	40-kda	[40-kDa]	0.30000000000000004	1	3	0	0
59884	1704	Thrombin	[Thrombin]	0.30000000000000004	1	3	0	0
59885	1704	lox-1	[LOX-1]	0.30000000000000004	1	4	1	1
59886	1704	c/ebpbeta	[C/EBPbeta]	0.30000000000000004	1	4	2	2
59887	1704	(cat)	[(CAT)]	0.30000000000000004	1	4	3	3
59888	1704	alpha-galactosidase	[alpha-galactosidase]	0.30000000000000004	1	4	1	1
59889	1704	kruppel-like	[Kruppel-like]	0.30000000000000004	1	5	4	2
59890	1704	plasmodium	[Plasmodium]	0.30000000000000004	1	3	0	0
59891	1704	[3H]	[[3H]]	0.30000000000000004	1	4	4	4
59892	1704	subregion	[subregions]	0.30000000000000004	1	4	4	4
59893	1704	dehydrogenase	[dehydrogenase]	0.30000000000000004	1	4	3	3
59894	1704	XIC/XIST	[XIC/XIST]	0.30000000000000004	1	4	3	3
59895	1704	tnfr1	[TNFR1]	0.30000000000000004	1	3	0	0
59896	1704	Zap-70	[Zap-70]	0.30000000000000004	1	3	0	0
59897	1704	taxi	[TaxI]	0.30000000000000004	1	4	2	2
59898	1704	anti-IgM	[anti-IgM]	0.30000000000000004	1	3	0	0
59899	1704	(type	[(type]	0.30000000000000004	1	4	1	1
59900	1704	sjogren'	[Sjogren's]	0.30000000000000004	1	4	2	2
59901	1704	tced	[TCEd]	0.30000000000000004	1	4	2	2
59902	1704	SERCA	[SERCA]	0.30000000000000004	1	4	3	3
59903	1704	Tcf-1	[Tcf-1]	0.30000000000000004	1	3	0	0
59904	1704	RBTN-2	[RBTN-2]	0.30000000000000004	1	4	1	1
59905	1704	ecv304	[ECV304]	0.30000000000000004	1	3	0	0
59906	1704	IHES	[IHES]	0.30000000000000004	1	4	2	2
59907	1704	II-2	[II-2]	0.30000000000000004	1	3	0	0
59908	1704	obf-1	[OBF-1]	0.30000000000000004	1	4	2	2
59909	1704	hb-egf	[HB-EGF]	0.30000000000000004	1	4	2	2
59910	1704	CaMKIV/Gr	[CaMKIV/Gr]	0.30000000000000004	1	3	0	0
59911	1704	IL-9	[IL-9]	0.30000000000000004	1	4	1	1
59912	1704	inhibit	[inhibiting]	0.30000000000000004	1	3	0	0
59913	1704	IL1B	[IL1B]	0.30000000000000004	1	3	0	0
59914	1704	IL2R	[IL2R]	0.30000000000000004	1	4	2	2
59915	1704	heat-shock	[heat-shock]	0.30000000000000004	1	4	2	2
59916	1704	competitor	[competitor]	0.30000000000000004	1	4	2	2
59917	1704	anti-AIM	[anti-AIM]	0.30000000000000004	1	4	1	1
59918	1704	polyadenylation	[polyadenylation]	0.30000000000000004	1	4	2	2
59919	1704	hyperthermia	[hyperthermia]	0.30000000000000004	1	4	1	1
59920	1704	HLA-A3	[HLA-A3]	0.30000000000000004	1	3	0	0
59921	1704	HLA-DM	[HLA-DM]	0.30000000000000004	1	4	2	2
59922	1704	cf11/cd18	[CD11/CD18]	0.30000000000000004	1	3	0	0
59923	1704	HLA-DQ	[HLA-DQ]	0.30000000000000004	1	4	1	1
59924	1704	skewing	[skewing]	0.30000000000000004	1	4	1	1
59925	1704	subfamily	[subfamily]	0.30000000000000004	1	4	2	2
59926	1704	PKB/Akt	[PKB/Akt]	0.30000000000000004	1	4	2	2
59927	1704	agents,	[agents,]	0.30000000000000004	1	4	4	4
59928	1704	tnf-	[TNF-]	0.30000000000000004	1	4	1	1
59929	1704	cd8(+)-t-cell	[CD8(+)-T-cell]	0.30000000000000004	1	4	3	3
59930	1704	tr75	[TR75]	0.30000000000000004	1	4	3	3
59931	1704	megakaryocytopoiesis	[megakaryocytopoiesis]	0.30000000000000004	1	4	1	1
59932	1704	hormone.	[hormone.]	0.30000000000000004	1	4	1	1
59933	1704	(ctl)	[(CTL)]	0.30000000000000004	1	4	3	3
59934	1704	trap	[TRAP]	0.30000000000000004	1	3	0	0
59935	1704	caev	[CAEV]	0.30000000000000004	1	3	0	0
59936	1704	caml	[CAML]	0.30000000000000004	1	4	2	2
59937	1704	manlam	[ManLAM]	0.30000000000000004	1	4	1	1
59938	1704	syncytia	[syncytia]	0.30000000000000004	1	4	2	2
59939	1704	cd27	[CD27]	0.30000000000000004	1	4	2	2
59940	1704	cd33	[CD33]	0.30000000000000004	1	4	1	1
59941	1704	cd71	[CD71]	0.30000000000000004	1	3	0	0
59942	1704	normal	[normals]	0.30000000000000004	1	4	1	1
59943	1704	cd54	[CD54]	0.30000000000000004	1	4	1	1
59944	1704	gtpase	[GTPase]	0.30000000000000004	1	4	1	1
59945	1704	cdk2	[cdk2]	0.30000000000000004	1	3	0	0
59946	1704	arrangement	[arrangement]	0.30000000000000004	1	4	4	4
59947	1704	hs-72	[HS-72]	0.30000000000000004	1	4	1	1
59948	1704	noncomedo	[noncomedo]	0.30000000000000004	1	4	1	1
59949	1704	NF-AT-binding	[NF-AT-binding]	0.30000000000000004	1	3	0	0
59950	1704	tyk2	[tyk2]	0.30000000000000004	1	5	2	1
59951	1704	trophoblast	[trophoblast]	0.30000000000000004	1	4	1	1
59952	1704	ACLA	[ACLA]	0.30000000000000004	1	4	1	1
59953	1704	cho-cd86	[CHO-CD86]	0.30000000000000004	1	4	2	2
59954	1704	cho/	[CHO/]	0.30000000000000004	1	4	1	1
59955	1704	105-kDa	[105-kDa]	0.30000000000000004	1	4	1	1
59956	1704	hhv-8	[HHV-8]	0.30000000000000004	1	4	2	2
59957	1704	-3beta	[-3beta]	0.30000000000000004	1	3	0	0
59958	1704	aml1/eto	[AML1/ETO]	0.30000000000000004	1	4	2	2
59959	1704	AF10	[AF10]	0.30000000000000004	1	4	3	3
59960	1704	gamma-gene	[gamma-gene]	0.30000000000000004	1	3	0	0
59961	1704	12-lipoxygenase	[12-lipoxygenase]	0.30000000000000004	1	3	0	0
59962	1704	tfiia	[TFIIA]	0.30000000000000004	1	3	0	0
59963	1704	protein/dna	[protein/DNA]	0.30000000000000004	1	4	1	1
59964	1704	autologous	[autologous]	0.30000000000000004	1	6	3	1
59965	1704	SIVsmmPBj14	[SIVsmmPBj14]	0.30000000000000004	1	4	1	1
59966	1704	xanthomatosis	[xanthomatosis]	0.30000000000000004	1	4	1	1
59967	1704	clue	[clue]	0.30000000000000004	1	4	4	4
59968	1704	cmat	[CMAT]	0.30000000000000004	1	3	0	0
59969	1704	heavy-chain	[heavy-chain]	0.30000000000000004	1	4	4	4
59970	1704	cemxl74	[CEMxl74]	0.30000000000000004	1	3	0	0
59971	1704	zymogen	[zymogen]	0.30000000000000004	1	3	0	0
59972	1704	e1c3	[E1C3]	0.30000000000000004	1	3	0	0
59973	1704	Trident	[Trident]	0.30000000000000004	1	4	2	2
59974	1704	co-immunoprecipitation	[co-immunoprecipitation]	0.30000000000000004	1	4	3	3
59975	1704	glycation	[glycation]	0.30000000000000004	1	4	1	1
59976	1704	e2f4	[E2F4]	0.30000000000000004	1	3	0	0
59977	1704	e2f1	[E2F1]	0.30000000000000004	1	4	3	3
59978	1704	CCAAT/enhancer-binding	[CCAAT/enhancer-binding]	0.30000000000000004	1	3	0	0
59979	1704	SBMA	[SBMA]	0.30000000000000004	1	4	1	1
59980	1704	"octamer"	["octamer"]	0.30000000000000004	1	4	2	2
59981	1704	SCMV	[SCMV]	0.30000000000000004	1	3	0	0
59982	1704	GIG18	[GIG18]	0.30000000000000004	1	3	0	0
59983	1704	CONCLUSION.	[CONCLUSION.]	0.30000000000000004	1	3	0	0
59984	1704	Flutamide	[Flutamide]	0.30000000000000004	1	4	3	3
59985	1704	Interleukin-4	[Interleukin-4]	0.30000000000000004	1	7	4	1
59986	1704	B4-2	[B4-2]	0.30000000000000004	1	4	1	1
59987	1704	lps-	[LPS-]	0.30000000000000004	1	4	1	1
59988	1704	BEAD-1	[BEAD-1]	0.30000000000000004	1	3	0	0
59989	1704	haemin	[haemin]	0.30000000000000004	1	3	0	0
59990	1704	Also,	[Also,]	0.30000000000000004	1	4	3	3
59991	1704	minutes.	[minutes.]	0.30000000000000004	1	4	4	4
59992	1704	24-hydroxylase	[24-hydroxylase]	0.30000000000000004	1	6	3	1
59993	1704	periodontitis	[periodontitis]	0.30000000000000004	1	3	0	0
59994	1704	deltorphin	[deltorphin]	0.30000000000000004	1	3	0	0
59995	1704	nucleoside	[nucleoside]	0.30000000000000004	1	4	2	2
59996	1704	principle	[principle]	0.30000000000000004	1	4	3	3
59997	1704	Ba/F3	[Ba/F3]	0.30000000000000004	1	4	3	3
59998	1704	Richter'	[Richter's]	0.30000000000000004	1	3	0	0
59999	1704	imbalance	[imbalance]	0.30000000000000004	1	4	3	3
60000	1704	type-ii	[type-II]	0.30000000000000004	1	3	0	0
60001	1704	NF-chi	[NF-chi]	0.30000000000000004	1	5	4	2
60002	1704	words)	[WORDS)]	0.30000000000000004	1	27	24	1
60003	1704	mosaic	[mosaic]	0.30000000000000004	1	4	3	3
60004	1704	SP-A	[SP-A]	0.30000000000000004	1	3	0	0
60005	1704	32dcl3	[32Dcl3]	0.30000000000000004	1	4	1	1
60006	1704	NLPHD	[NLPHD]	0.30000000000000004	1	4	1	1
60007	1704	darc	[DARC]	0.30000000000000004	1	4	1	1
60008	1704	lef/tcf	[LEF/TCF]	0.30000000000000004	1	3	0	0
60009	1704	hinge	[hinge]	0.30000000000000004	1	3	0	0
60010	1704	phosphorylating	[phosphorylating]	0.30000000000000004	1	3	0	0
60011	1704	activating	[activating]	0.30000000000000004	1	4	3	3
60012	1704	GM-kappa	[GM-kappa]	0.30000000000000004	1	4	1	1
60013	1704	dest	[DESTs]	0.30000000000000004	1	4	3	3
60014	1704	migrating	[migrating]	0.30000000000000004	1	3	0	0
60015	1704	mol/L)	[mol/L)]	0.30000000000000004	1	4	3	3
60016	1704	gene.	[gene.]	0.30000000000000004	1	6	3	1
60017	1704	Cortivazol	[Cortivazol]	0.30000000000000004	1	4	1	1
60018	1704	ligand.	[ligand.]	0.30000000000000004	1	4	2	2
60019	1704	Elk-1	[Elk-1]	0.30000000000000004	1	3	0	0
60020	1704	proil-1	[proIL-1]	0.30000000000000004	1	3	0	0
60021	1704	G0/G1	[G0/G1]	0.30000000000000004	1	4	1	1
60022	1704	p3hr1	[P3HR1]	0.30000000000000004	1	3	0	0
60023	1704	oxidase	[oxidase]	0.30000000000000004	1	6	6	2
60024	1704	eicosanoid	[eicosanoids]	0.30000000000000004	1	3	0	0
60025	1704	hemoglobinization	[hemoglobinization]	0.30000000000000004	1	3	0	0
60026	1704	pathway,	[pathway,]	0.30000000000000004	1	4	2	2
60027	1704	/rxr	[/RXR]	0.30000000000000004	1	4	4	4
60028	1704	vaccine	[vaccine]	0.30000000000000004	1	4	1	1
60029	1704	mice	[Mice]	0.30000000000000004	1	4	1	1
60030	1704	ml-1	[ML-1]	0.30000000000000004	1	4	4	4
60031	1704	probability	[probability]	0.30000000000000004	1	4	4	4
60032	1704	single-copy	[single-copy]	0.30000000000000004	1	3	0	0
60033	1704	present,	[present,]	0.30000000000000004	1	3	0	0
60034	1704	hypergammaglobulinemia	[hypergammaglobulinemia]	0.30000000000000004	1	3	0	0
60035	1704	drip	[DRIP]	0.30000000000000004	1	3	0	0
60036	1704	BALB/c	[BALB/c]	0.30000000000000004	1	4	3	3
60037	1704	eTh2	[eTh2]	0.30000000000000004	1	3	0	0
60038	1704	mmp9	[MMP9]	0.30000000000000004	1	3	0	0
60039	1704	Tepoxalin	[Tepoxalin]	0.30000000000000004	1	4	1	1
60040	1704	alphabeta	[alphabeta]	0.30000000000000004	1	3	0	0
60041	1704	possibility,	[possibility,]	0.30000000000000004	1	4	1	1
60042	1704	Stat3gamma	[Stat3gamma]	0.30000000000000004	1	3	0	0
60043	1704	CaM-AI	[CaM-AI]	0.30000000000000004	1	3	0	0
60044	1704	immunogenicity	[immunogenicity]	0.30000000000000004	1	4	2	2
60045	1704	mmp-9	[MMP-9]	0.30000000000000004	1	4	3	3
60046	1704	e3330	[E3330]	0.30000000000000004	1	3	0	0
60047	1704	micromol/L	[micromol/L]	0.30000000000000004	1	4	3	3
60048	1704	notch1	[NOTCH1]	0.30000000000000004	1	4	2	2
60049	1704	plb-985	[PLB-985]	0.30000000000000004	1	4	3	3
60050	1704	December	[Dec]	0.30000000000000004	1	4	4	4
60051	1704	comments]	[comments]]	0.30000000000000004	1	4	1	1
60052	1704	MIBP1	[MIBP1]	0.30000000000000004	1	3	0	0
60053	1704	GATA-4	[GATA-4]	0.30000000000000004	1	4	1	1
60054	1704	assessment	[assessment]	0.30000000000000004	1	4	4	4
60055	1704	line,	[line,]	0.30000000000000004	1	3	0	0
60056	1704	c-erbB2	[c-erbB2]	0.30000000000000004	1	4	1	1
60057	1704	mtbe	[MTBE]	0.30000000000000004	1	3	0	0
60058	1704	spironolactone	[spironolactone]	0.30000000000000004	1	3	0	0
60059	1704	channel	[channel]	0.30000000000000004	1	4	3	3
60060	1704	peritoneal	[peritoneal]	0.30000000000000004	1	4	2	2
60061	1704	Site	[Site]	0.30000000000000004	1	4	3	3
60062	1704	TLCK	[TLCK]	0.30000000000000004	1	3	0	0
60063	1704	illness	[illness]	0.30000000000000004	1	4	2	2
60064	1704	diesel	[diesel]	0.30000000000000004	1	3	0	0
60065	1704	populations,	[populations,]	0.30000000000000004	1	4	4	4
60066	1704	receptor-1	[receptor-1]	0.30000000000000004	1	4	2	2
60067	1704	p-creb	[P-CREB]	0.30000000000000004	1	4	2	2
60068	1704	that:	[that:]	0.30000000000000004	1	4	1	1
60069	1704	ec50	[EC50]	0.30000000000000004	1	3	0	0
60070	1704	Moloney	[Moloney]	0.30000000000000004	1	3	0	0
60071	1704	hepatoma	[hepatoma]	0.30000000000000004	1	4	1	1
60072	1704	GABPalpha	[GABPalpha]	0.30000000000000004	1	3	0	0
60073	1704	pyrrolidinedithiocarbamate	[pyrrolidinedithiocarbamate]	0.30000000000000004	1	3	0	0
60074	1704	TIMP-1	[TIMP-1]	0.30000000000000004	1	4	3	3
60075	1704	Sos1	[Sos1]	0.30000000000000004	1	3	0	0
60076	1704	pervanadate	[pervanadate]	0.30000000000000004	1	3	0	0
60077	1704	inversion	[inversion]	0.30000000000000004	1	4	2	2
60078	1704	peroxidase	[peroxidase]	0.30000000000000004	1	4	3	3
60079	1704	CAEV	[CAEV]	0.30000000000000004	1	4	1	1
60080	1704	LNCaP	[LNCaP]	0.30000000000000004	1	4	1	1
60081	1704	sites/cell	[sites/cell]	0.30000000000000004	1	5	4	2
60082	1704	replicate	[replicating]	0.30000000000000004	1	3	0	0
60083	1704	Band	[Band]	0.30000000000000004	1	4	2	2
60084	1704	CD23	[CD23]	0.30000000000000004	1	4	2	2
60085	1704	th2-type	[Th2-type]	0.30000000000000004	1	3	0	0
60086	1704	specimen	[specimens]	0.30000000000000004	1	4	2	2
60087	1704	knowledge,	[knowledge,]	0.30000000000000004	1	4	2	2
60088	1704	(bhlh)	[(bHLH)]	0.30000000000000004	1	4	3	3
60089	1704	pml/rar-alpha	[pml/RAR-alpha]	0.30000000000000004	1	3	0	0
60090	1704	tested,	[tested,]	0.30000000000000004	1	4	2	2
60091	1704	grade,	[grade,]	0.30000000000000004	1	4	1	1
60092	1704	second	[second]	0.30000000000000004	1	4	2	2
60093	1704	emsa	[EMSAs]	0.30000000000000004	1	11	8	1
60094	1704	Rhom-2	[Rhom-2]	0.30000000000000004	1	4	1	1
60095	1704	CK-1	[CK-1]	0.30000000000000004	1	3	0	0
60096	1704	CKII	[CKII]	0.30000000000000004	1	4	3	3
60097	1704	CLE0	[CLE0]	0.30000000000000004	1	4	1	1
60098	1704	CLEO	[CLEO]	0.30000000000000004	1	4	2	2
60099	1704	pre-T	[pre-T]	0.30000000000000004	1	4	3	3
60100	1704	hugata-3	[huGATA-3]	0.30000000000000004	1	4	2	2
60101	1704	CMAT	[CMAT]	0.30000000000000004	1	3	0	0
60102	1704	immunology	[immunology]	0.30000000000000004	1	4	4	4
60103	1704	bcl-x	[bcl-x]	0.30000000000000004	1	4	2	2
60104	1704	monokine	[monokine]	0.30000000000000004	1	4	3	3
60105	1704	pp70s6k	[pp70S6K]	0.30000000000000004	1	3	0	0
60106	1704	polycythemia	[polycythemia]	0.30000000000000004	1	4	3	3
60107	1704	resident	[resident]	0.30000000000000004	1	4	3	3
60108	1704	p107	[p107]	0.30000000000000004	1	4	2	2
60109	1704	p130	[p130]	0.30000000000000004	1	3	0	0
60110	1704	NF-KB	[NF-KB]	0.30000000000000004	1	4	2	2
60111	1704	model.	[model.]	0.30000000000000004	1	4	2	2
60112	1704	thrombosis	[thrombosis]	0.30000000000000004	1	4	1	1
60113	1704	cd8(-)	[CD8(-)]	0.30000000000000004	1	4	1	1
60114	1704	ets1	[ETS1]	0.30000000000000004	1	4	4	4
60115	1704	NF-YB	[NF-YB]	0.30000000000000004	1	4	1	1
60116	1704	paxillin	[paxillin]	0.30000000000000004	1	3	0	0
60117	1704	elements,	[elements,]	0.30000000000000004	1	4	3	3
60118	1704	80-kd	[80-kD]	0.30000000000000004	1	3	0	0
60119	1704	novo	[novo]	0.30000000000000004	1	4	1	1
60120	1704	b95-8	[B95-8]	0.30000000000000004	1	4	3	3
60121	1704	nadir	[nadir]	0.30000000000000004	1	3	0	0
60122	1704	cd3+/cd4+	[CD3+/CD4+]	0.30000000000000004	1	3	0	0
60123	1704	prime	[Priming]	0.30000000000000004	1	6	6	2
60124	1704	tissues,	[tissues,]	0.30000000000000004	1	4	3	3
60125	1704	p50b	[p50B]	0.30000000000000004	1	3	0	0
60126	1704	p50-	[p50-]	0.30000000000000004	1	4	1	1
60127	1704	(gc)	[(GC)]	0.30000000000000004	1	4	2	2
60128	1704	BZLF-1	[BZLF-1]	0.30000000000000004	1	4	3	3
60129	1704	LFA-3	[LFA-3]	0.30000000000000004	1	4	2	2
60130	1704	LFA-I	[LFA-I]	0.30000000000000004	1	3	0	0
60131	1704	nmol/l)	[nmol/l)]	0.30000000000000004	1	4	3	3
60132	1704	FGF-1	[FGF-1]	0.30000000000000004	1	4	3	3
60133	1704	29-kda	[29-kDa]	0.30000000000000004	1	4	2	2
60134	1704	surround	[surrounding]	0.30000000000000004	1	4	2	2
60135	1704	synthetase	[synthetase]	0.30000000000000004	1	4	3	3
60136	1704	X-SCID	[X-SCID]	0.30000000000000004	1	4	1	1
60137	1704	proof	[proof]	0.30000000000000004	1	4	2	2
60138	1704	nmol/L;	[nmol/L;]	0.30000000000000004	1	4	3	3
60139	1704	NF-kappaB/NFAT	[NF-kappaB/NFAT]	0.30000000000000004	1	4	1	1
60140	1704	Stat2	[Stat2]	0.30000000000000004	1	3	0	0
60141	1704	hbsag	[HBsAg]	0.30000000000000004	1	3	0	0
60142	1704	epo-r	[Epo-R]	0.30000000000000004	1	4	2	2
60143	1704	regression	[regression]	0.30000000000000004	1	4	2	2
60144	1704	resection	[resection]	0.30000000000000004	1	4	3	3
60145	1704	fasL	[fasL]	0.30000000000000004	1	4	1	1
60146	1704	exclusion	[exclusion]	0.30000000000000004	1	4	4	4
60147	1704	triglyceride	[triglyceride]	0.30000000000000004	1	3	0	0
60148	1704	DeltaE	[DeltaE]	0.30000000000000004	1	4	1	1
60149	1704	subline	[subline]	0.30000000000000004	1	3	0	0
60150	1704	clinician	[clinicians]	0.30000000000000004	1	3	0	0
60151	1704	IL-2-	[IL-2-]	0.30000000000000004	1	4	2	2
60152	1704	IL-16	[IL-16]	0.30000000000000004	1	3	0	0
60153	1704	IL-7R	[IL-7R]	0.30000000000000004	1	4	1	1
60154	1704	(th)	[(Th)]	0.30000000000000004	1	5	4	2
60155	1704	CD95L	[CD95L]	0.30000000000000004	1	3	0	0
60156	1704	fhit	[FHIT]	0.30000000000000004	1	4	1	1
60157	1704	varicella	[varicella]	0.30000000000000004	1	4	1	1
60158	1704	pai-1	[PAI-1]	0.30000000000000004	1	4	2	2
60159	1704	il-2rbeta	[IL-2Rbeta]	0.30000000000000004	1	4	2	2
60160	1704	oct1	[Oct1]	0.30000000000000004	1	3	0	0
60161	1704	tract	[tract]	0.30000000000000004	1	4	3	3
60162	1704	trace	[trace]	0.30000000000000004	1	4	2	2
60163	1704	traf1	[TRAF1]	0.30000000000000004	1	4	1	1
60164	1704	prototype	[prototype]	0.30000000000000004	1	4	1	1
60165	1704	paracrine	[paracrine]	0.30000000000000004	1	4	2	2
60166	1704	molt-4	[Molt-4]	0.30000000000000004	1	4	1	1
60167	1704	h-rs	[H-RS]	0.30000000000000004	1	4	2	2
60168	1704	MARs	[MARs]	0.30000000000000004	1	3	0	0
60169	1704	tre-1	[TRE-1]	0.30000000000000004	1	4	2	2
60170	1705	preference	[preference]	0.2666666666666667	1	4	4	3
60171	1705	spacing	[spacing]	0.2666666666666667	1	4	4	3
60172	1705	quantification	[quantification]	0.2666666666666667	1	4	4	3
60173	1705	mycoplasma	[Mycoplasma]	0.2666666666666667	1	4	4	3
60174	1705	reversal	[reversal]	0.2666666666666667	1	4	4	3
60175	1705	hnf-1	[HNF-1]	0.2666666666666667	1	4	4	3
60176	1705	-STAT	[-STAT]	0.2666666666666667	1	4	4	3
60177	1705	t-leukemia	[T-leukemia]	0.2666666666666667	1	4	4	3
60178	1705	severity	[severity]	0.2666666666666667	1	4	4	3
60179	1705	selectivity	[selectivity]	0.2666666666666667	1	4	4	3
60180	1705	utility	[utility]	0.2666666666666667	1	4	4	3
60181	1705	asp	[Asp]	0.2666666666666667	1	4	4	3
60182	1705	unresponsiveness	[unresponsiveness]	0.2666666666666667	1	4	4	3
60183	1705	hyporesponsiveness	[hyporesponsiveness]	0.2666666666666667	1	4	4	3
60184	1705	m(r)	[M(r)]	0.2666666666666667	1	4	4	3
60185	1705	knockout	[knockout]	0.2666666666666667	1	4	4	3
60186	1705	proximity	[proximity]	0.2666666666666667	1	4	4	3
60187	1705	transgene	[transgene]	0.2666666666666667	1	4	4	3
60188	1705	search	[search]	0.2666666666666667	1	4	4	3
60189	1705	load	[load]	0.2666666666666667	1	4	4	3
60190	1705	hierarchy	[hierarchy]	0.2666666666666667	1	4	4	3
60191	1705	MZF-2	[MZF-2]	0.2666666666666667	1	4	4	3
60192	1705	monomer	[monomer]	0.2666666666666667	1	4	4	3
60193	1705	hcd57-srei	[HCD57-SREI]	0.2666666666666667	1	4	4	3
60194	1705	Toll	[Toll]	0.2666666666666667	1	4	4	3
60195	1706	as	[AS]	0.25	1	5	5	2
60196	1706	dp	[DP]	0.25	1	4	3	2
60197	1706	tax-express	[Tax-expressing]	0.25	1	4	3	2
60198	1706	elimination	[elimination]	0.25	1	4	3	2
60199	1706	EL-4	[EL-4]	0.25	1	4	3	2
60200	1706	glutamine	[glutamine]	0.25	1	4	3	2
60201	1706	cd3epsilon	[CD3epsilon]	0.25	1	4	3	2
60202	1706	restoration	[Restoration]	0.25	1	5	5	2
60203	1706	utilization	[utilization]	0.25	1	4	3	2
60204	1706	B*CaM-K	[B*CaM-K]	0.25	1	4	3	2
60205	1706	dayus-	[day,]	0.25	1	4	3	2
60206	1706	protein-protein	[protein-protein]	0.25	1	4	3	2
60207	1706	coculture	[coculture]	0.25	1	4	3	2
60208	1706	co-stimulation	[Co-stimulation]	0.25	1	4	3	2
60209	1706	(irf)	[(IRF)]	0.25	1	4	3	2
60210	1706	coreceptor	[coreceptor]	0.25	1	4	3	2
60211	1706	diseases,	[diseases,]	0.25	1	4	3	2
60212	1706	ifngr1	[IFNGR1]	0.25	1	4	3	2
60213	1706	cns	[CNS]	0.25	1	4	3	2
60214	1706	hml	[HML]	0.25	1	4	3	2
60215	1706	Fusion	[Fusion]	0.25	1	5	5	2
60216	1706	pAT	[pAT]	0.25	1	4	3	2
60217	1706	ptt	[PTT]	0.25	1	4	3	2
60218	1706	duplication	[duplication]	0.25	1	4	3	2
60219	1706	vca	[VCA]	0.25	1	4	3	2
60220	1706	Pbx1	[Pbx1]	0.25	1	4	3	2
60221	1706	p50p50	[p50p50]	0.25	1	4	3	2
60222	1706	classification	[classification]	0.25	1	4	3	2
60223	1706	kda)	[kDa)]	0.25	1	4	3	2
60224	1706	orientation	[orientation]	0.25	1	4	3	2
60225	1706	arginine	[arginine]	0.25	1	4	3	2
60226	1706	calf	[calf]	0.25	1	4	3	2
60227	1706	stain	[staining]	0.25	1	4	3	2
60228	1706	/eto	[/ETO]	0.25	1	5	5	2
60229	1706	/p50	[/p50]	0.25	1	4	3	2
60230	1706	interdomain	[interdomain]	0.25	1	4	3	2
60231	1706	hypercalciuria	[hypercalciuria]	0.25	1	4	3	2
60232	1706	wortmannin	[wortmannin]	0.25	1	4	3	2
60233	1706	(bp)	[(bp)]	0.25	1	4	3	2
60234	1706	csf-1r	[CSF-1R]	0.25	1	4	3	2
60235	1706	alpha,25(OH)2D3	[alpha,25(OH)2D3]	0.25	1	4	3	2
60236	1706	phenylarsine	[phenylarsine]	0.25	1	4	3	2
60237	1707	U	[U]	0.2	1	3	2	2
60238	1707	-nf-kappa	[-NF-kappa]	0.2	1	3	2	2
60239	1707	22-bp	[22-bp]	0.2	1	2	0	0
60240	1707	Ci-I	[Ci-I]	0.2	1	2	0	0
60241	1707	-c	[-C]	0.2	1	4	2	1
60242	1707	1a	[1A]	0.2	1	3	2	2
60243	1707	Chem	[Chem]	0.2	1	4	4	2
60244	1707	B3	[B3]	0.2	1	2	0	0
60245	1707	C4	[C4]	0.2	1	2	0	0
60246	1707	BW	[BW]	0.2	1	3	2	2
60247	1707	CN	[CN]	0.2	1	3	1	1
60248	1707	CR	[CR]	0.2	1	3	2	2
60249	1707	CS	[CS]	0.2	1	3	1	1
60250	1707	D5	[D5]	0.2	1	2	0	0
60251	1707	DS	[DS]	0.2	1	3	1	1
60252	1707	E6	[E6]	0.2	1	3	2	2
60253	1707	E7	[E7]	0.2	1	2	0	0
60254	1707	EM	[EM]	0.2	1	2	0	0
60255	1707	GS	[GS]	0.2	1	2	0	0
60256	1707	Hb	[Hb]	0.2	1	3	1	1
60257	1707	IV	[IV]	0.2	1	2	0	0
60258	1707	KA	[KA]	0.2	1	2	0	0
60259	1707	KB	[KB]	0.2	1	2	0	0
60260	1707	L1	[L1]	0.2	1	3	1	1
60261	1707	BOB.1/OBF.1	[BOB.1/OBF.1]	0.2	1	3	1	1
60262	1707	LT	[LT]	0.2	1	2	0	0
60263	1707	trial	[trial]	0.2	1	3	3	3
60264	1707	MR	[MR]	0.2	1	3	2	2
60265	1707	MS	[MS]	0.2	1	3	2	2
60266	1707	N9	[N9]	0.2	1	2	0	0
60267	1707	P7	[P7]	0.2	1	2	0	0
60268	1707	PD	[PD]	0.2	1	3	2	2
60269	1707	Ox	[Ox]	0.2	1	3	1	1
60270	1707	RM	[RM]	0.2	1	3	1	1
60271	1707	S1	[S1]	0.2	1	3	1	1
60272	1707	ST	[ST]	0.2	1	3	1	1
60273	1707	TS	[TS]	0.2	1	3	1	1
60274	1707	TT	[TT]	0.2	1	2	0	0
60275	1707	Tx	[Tx]	0.2	1	2	0	0
60276	1707	VD	[VD]	0.2	1	2	0	0
60277	1707	XY	[XY]	0.2	1	2	0	0
60278	1707	a2	[A2]	0.2	1	3	1	1
60279	1707	ac	[AC]	0.2	1	2	0	0
60280	1707	c-	[c-]	0.2	1	2	0	0
60281	1707	c1	[C1]	0.2	1	3	1	1
60282	1707	be	[r]	0.2	1	2	0	0
60283	1707	bv	[BV]	0.2	1	3	2	2
60284	1707	cs	[CS]	0.2	1	3	1	1
60285	1707	e7	[E7]	0.2	1	3	2	2
60286	1707	partner	[partner]	0.2	1	3	3	3
60287	1707	dn	[DN]	0.2	1	3	1	1
60288	1707	h2	[H2]	0.2	1	3	1	1
60289	1707	h5	[H5]	0.2	1	3	1	1
60290	1707	h7	[H7]	0.2	1	3	1	1
60291	1707	gf	[GF]	0.2	1	3	2	2
60292	1707	gt	[GT]	0.2	1	3	3	3
60293	1707	id	[Id]	0.2	1	3	1	1
60294	1707	nih3t3	[NIH3T3]	0.2	1	3	1	1
60295	1707	m)	[M)]	0.2	1	3	2	2
60296	1707	m2	[M2]	0.2	1	2	0	0
60297	1707	m7	[M7]	0.2	1	3	1	1
60298	1707	n:	[N:]	0.2	1	3	2	2
60299	1707	p1	[P1]	0.2	1	2	0	0
60300	1707	invertebrate	[invertebrate]	0.2	1	2	0	0
60301	1707	ox	[Ox]	0.2	1	2	0	0
60302	1707	META	[META]	0.2	1	3	2	2
60303	1707	s6	[S6]	0.2	1	3	1	1
60304	1707	oppose	[opposing]	0.2	1	3	1	1
60305	1707	t1	[T1]	0.2	1	2	0	0
60306	1707	t2	[T2]	0.2	1	2	0	0
60307	1707	(EBV)	[(EBV)]	0.2	1	3	2	2
60308	1707	sm	[SM]	0.2	1	3	3	3
60309	1707	v3	[V3]	0.2	1	2	0	0
60310	1707	ts	[TS]	0.2	1	3	2	2
60311	1707	x-	[X-]	0.2	1	2	0	0
60312	1707	rac-1	[Rac-1]	0.2	1	3	1	1
60313	1707	DLCL	[DLCL]	0.2	1	3	2	2
60314	1707	yt	[YT]	0.2	1	2	0	0
60315	1707	diagnosis.	[diagnosis.]	0.2	1	2	0	0
60316	1707	cis-act	[cis-acting]	0.2	1	2	0	0
60317	1707	molecules.	[molecules.]	0.2	1	3	1	1
60318	1707	immunophenotype	[immunophenotype]	0.2	1	4	4	2
60319	1707	0.2-kb	[0.2-kb]	0.2	1	2	0	0
60320	1707	trough	[trough]	0.2	1	2	0	0
60321	1707	MGUS	[MGUS]	0.2	1	2	0	0
60322	1707	DNA,	[DNA,]	0.2	1	3	2	2
60323	1707	gata-1.05	[GATA-1.05]	0.2	1	2	0	0
60324	1707	repression,	[repression,]	0.2	1	2	0	0
60325	1707	article	[article)]	0.2	1	2	0	0
60326	1707	molecule-1	[molecule-1]	0.2	1	3	2	2
60327	1707	DOR1	[DOR1]	0.2	1	3	1	1
60328	1707	tfiiib	[TFIIIB]	0.2	1	2	0	0
60329	1707	ionize	[ionizing]	0.2	1	3	3	3
60330	1707	E1C3	[E1C3]	0.2	1	2	0	0
60331	1707	molar	[molar]	0.2	1	2	0	0
60332	1707	aneuploidy	[aneuploidy]	0.2	1	2	0	0
60333	1707	VDRE	[VDRE]	0.2	1	2	0	0
60334	1707	E1a-	[E1a-]	0.2	1	3	1	1
60335	1707	p50urelb	[p50/RelB]	0.2	1	2	0	0
60336	1707	MKK3	[MKK3]	0.2	1	3	2	2
60337	1707	consequences.	[consequences.]	0.2	1	2	0	0
60338	1707	receptor-bearing	[receptor-bearing]	0.2	1	2	0	0
60339	1707	titer	[titer]	0.2	1	3	3	3
60340	1707	Prostaglandin	[Prostaglandin]	0.2	1	3	1	1
60341	1707	concentrations,	[concentrations,]	0.2	1	3	2	2
60342	1707	bmlf1	[BMLF1]	0.2	1	2	0	0
60343	1707	ifn-u937	[IFN-U937]	0.2	1	4	4	2
60344	1707	virion	[virion]	0.2	1	3	1	1
60345	1707	cis-tran	[cis-trans]	0.2	1	3	1	1
60346	1707	HL-60/vinc	[HL-60/vinc]	0.2	1	2	0	0
60347	1707	hcleo	[hCLEO]	0.2	1	2	0	0
60348	1707	promotion	[promotion]	0.2	1	4	2	1
60349	1707	pax-5d	[Pax-5d]	0.2	1	2	0	0
60350	1707	phenomenon,	[phenomenon,]	0.2	1	2	0	0
60351	1707	phenomenon.	[phenomenon.]	0.2	1	2	0	0
60352	1707	85-kDa	[85-kDa]	0.2	1	3	1	1
60353	1707	survival,	[survival,]	0.2	1	3	1	1
60354	1707	pax-8	[Pax-8]	0.2	1	2	0	0
60355	1707	mds1/evi1	[MDS1/EVI1]	0.2	1	3	1	1
60356	1707	IFN-gamma-	[IFN-gamma-]	0.2	1	3	1	1
60357	1707	3BP2	[3BP2]	0.2	1	2	0	0
60358	1707	sp100	[SP100]	0.2	1	3	1	1
60359	1707	single-chain	[single-chain]	0.2	1	2	0	0
60360	1707	osf2	[OSF2]	0.2	1	2	0	0
60361	1707	calcium-	[calcium-]	0.2	1	3	1	1
60362	1707	Toremifene	[Toremifene]	0.2	1	2	0	0
60363	1707	tf.viia	[TF.VIIa]	0.2	1	2	0	0
60364	1707	scatchard	[Scatchard]	0.2	1	2	0	0
60365	1707	STAT3alpha	[STAT3alpha]	0.2	1	3	2	2
60366	1707	ki-67	[Ki-67]	0.2	1	3	3	3
60367	1707	clones,	[clones,]	0.2	1	2	0	0
60368	1707	hyperaldosteronism	[hyperaldosteronism]	0.2	1	3	2	2
60369	1707	tad-b	[TAD-B]	0.2	1	3	1	1
60370	1707	Hashimoto	[Hashimoto]	0.2	1	3	1	1
60371	1707	element,	[element,]	0.2	1	3	1	1
60372	1707	MT-I	[MT-I]	0.2	1	2	0	0
60373	1707	MT-2	[MT-2]	0.2	1	2	0	0
60374	1707	t(3;3)(q21;q26)	[t(3;3)(q21;q26)]	0.2	1	2	0	0
60375	1707	MTBE	[MTBE]	0.2	1	3	2	2
60376	1707	probes.	[probes.]	0.2	1	2	0	0
60377	1707	cohort	[cohort]	0.2	1	3	2	2
60378	1707	isoproterenol	[isoproterenol]	0.2	1	3	1	1
60379	1707	mn-sod	[Mn-SOD]	0.2	1	4	4	2
60380	1707	endothelial-leukocyte	[endothelial-leukocyte]	0.2	1	3	1	1
60381	1707	stimulus-	[stimulus-]	0.2	1	2	0	0
60382	1707	cd33+,	[CD33+,]	0.2	1	3	1	1
60383	1707	VP16	[VP16]	0.2	1	3	1	1
60384	1707	tachycardia	[tachycardia]	0.2	1	2	0	0
60385	1707	proteinase	[proteinase]	0.2	1	3	1	1
60386	1707	correlation,	[correlation,]	0.2	1	3	2	2
60387	1707	MVEC	[MVEC]	0.2	1	3	2	2
60388	1707	gasd	[GASd]	0.2	1	2	0	0
60389	1707	carbimazole	[carbimazole]	0.2	1	2	0	0
60390	1707	antibiotic	[antibiotic]	0.2	1	3	1	1
60391	1707	positivity	[positivity]	0.2	1	3	3	3
60392	1707	ddpcr	[DDPCR]	0.2	1	3	1	1
60393	1707	IVS1-10T-->C	[IVS1-10T-->C]	0.2	1	2	0	0
60394	1707	STAT5a	[STAT5a]	0.2	1	2	0	0
60395	1707	u9-iiib	[U9-IIIB]	0.2	1	2	0	0
60396	1707	musculin	[musculin]	0.2	1	3	2	2
60397	1707	disulfide	[disulfide]	0.2	1	3	3	3
60398	1707	rel/nf-kappab	[Rel/NF-kappaB]	0.2	1	2	0	0
60399	1707	EA-D	[EA-D]	0.2	1	3	2	2
60400	1707	V3-BH10	[V3-BH10]	0.2	1	3	1	1
60401	1707	isoflavone	[isoflavone]	0.2	1	3	2	2
60402	1707	monocyte-	[monocyte-]	0.2	1	2	0	0
60403	1707	germ	[germ]	0.2	1	4	4	2
60404	1707	thalassaemia	[thalassaemia]	0.2	1	3	1	1
60405	1707	CMPD1	[CMPD1]	0.2	1	2	0	0
60406	1707	decidualization	[decidualization]	0.2	1	2	0	0
60407	1707	MKP-1	[MKP-1]	0.2	1	2	0	0
60408	1707	tyloxapol	[tyloxapol]	0.2	1	3	1	1
60409	1707	25(oh)2d3	[25(OH)2D3]	0.2	1	4	2	1
60410	1707	obscure.	[obscure.]	0.2	1	2	0	0
60411	1707	pbgd	[PBGD]	0.2	1	3	1	1
60412	1707	pd-c	[Pd-C]	0.2	1	2	0	0
60413	1707	article,	[article,]	0.2	1	2	0	0
60414	1707	pcdd	[PCDDs/PCDFs]	0.2	1	3	1	1
60415	1707	dinucleotide	[dinucleotide]	0.2	1	3	2	2
60416	1707	pcna	[PCNA]	0.2	1	2	0	0
60417	1707	ICSBP	[ICSBP]	0.2	1	3	1	1
60418	1707	butyrate	[butyrate]	0.2	1	2	0	0
60419	1707	region/leucine	[region/leucine]	0.2	1	2	0	0
60420	1707	3h-dexamethasone	[3H-dexamethasone]	0.2	1	2	0	0
60421	1707	radioreceptor	[radioreceptor]	0.2	1	3	1	1
60422	1707	Octamer	[Octamer]	0.2	1	3	2	2
60423	1707	ad5e1a	[Ad5E1A]	0.2	1	3	2	2
60424	1707	tat-i	[tat-I]	0.2	1	2	0	0
60425	1707	hMNL	[hMNL]	0.2	1	3	2	2
60426	1707	peer	[PEER]	0.2	1	2	0	0
60427	1707	N-Oct-3	[N-Oct-3]	0.2	1	2	0	0
60428	1707	substitute	[substitute]	0.2	1	3	3	3
60429	1707	OTF-1	[OTF-1]	0.2	1	2	0	0
60430	1707	insect	[insect]	0.2	1	2	0	0
60431	1707	LT-alpha1beta2	[LT-alpha1beta2]	0.2	1	2	0	0
60432	1707	insert	[insert]	0.2	1	3	1	1
60433	1707	bromodomain	[bromodomain]	0.2	1	2	0	0
60434	1707	albuminuria	[albuminuria]	0.2	1	2	0	0
60435	1707	well,	[well,]	0.2	1	3	1	1
60436	1707	tsh-r	[TSH-R]	0.2	1	4	2	1
60437	1707	piec	[PIEC]	0.2	1	3	3	3
60438	1707	concanavalin	[concanavalin]	0.2	1	3	1	1
60439	1707	hRAR	[hRAR]	0.2	1	2	0	0
60440	1707	gpix	[GPIX]	0.2	1	3	1	1
60441	1707	ketone	[ketone]	0.2	1	2	0	0
60442	1707	subunits,	[subunits,]	0.2	1	3	2	2
60443	1707	laminin	[laminin]	0.2	1	2	0	0
60444	1707	glomerulonephritis	[glomerulonephritis]	0.2	1	3	2	2
60445	1707	promoter/enhancer	[promoter/enhancer]	0.2	1	3	2	2
60446	1707	pkc-	[PKC-]	0.2	1	4	2	1
60447	1707	hSIE	[hSIE]	0.2	1	2	0	0
60448	1707	dihydrofolate	[dihydrofolate]	0.2	1	2	0	0
60449	1707	leukaemias	[leukaemias]	0.2	1	3	1	1
60450	1707	Sjogren'	[Sjogren's]	0.2	1	3	1	1
60451	1707	phagocytosing	[phagocytosing]	0.2	1	2	0	0
60452	1707	pathogens,	[pathogens,]	0.2	1	3	2	2
60453	1707	plap	[PLAP]	0.2	1	3	2	2
60454	1707	jun-D	[jun-D]	0.2	1	3	1	1
60455	1707	days),	[days),]	0.2	1	2	0	0
60456	1707	mNFATc	[mNFATc]	0.2	1	4	2	1
60457	1707	grpl	[GrpL]	0.2	1	2	0	0
60458	1707	POUHD	[POUHD]	0.2	1	2	0	0
60459	1707	bronchoalveolar	[bronchoalveolar]	0.2	1	3	1	1
60460	1707	po-b	[PO-B]	0.2	1	3	2	2
60461	1707	corepressor	[corepressor]	0.2	1	2	0	0
60462	1707	humans,	[humans,]	0.2	1	2	0	0
60463	1707	phenotype,	[phenotype,]	0.2	1	3	1	1
60464	1707	phenotype.	[phenotype.]	0.2	1	3	1	1
60465	1707	EMSAs	[EMSAs]	0.2	1	3	2	2
60466	1707	LYL-1	[LYL-1]	0.2	1	2	0	0
60467	1707	maturation.	[maturation.]	0.2	1	2	0	0
60468	1707	degradation,	[degradation,]	0.2	1	3	3	3
60469	1707	EBNA-5	[EBNA-5]	0.2	1	2	0	0
60470	1707	ERK1	[ERK1]	0.2	1	3	1	1
60471	1707	Wilms'	[Wilms']	0.2	1	3	1	1
60472	1707	thapsigargin	[thapsigargin]	0.2	1	3	2	2
60473	1707	protein-binding	[protein-binding]	0.2	1	3	2	2
60474	1707	NM23	[NM23]	0.2	1	2	0	0
60475	1707	medicine	[medicine]	0.2	1	3	3	3
60476	1707	kinetics,	[kinetics,]	0.2	1	3	3	3
60477	1707	kinetics.	[kinetics.]	0.2	1	3	3	3
60478	1707	rhabdomyosarcomas	[rhabdomyosarcomas]	0.2	1	2	0	0
60479	1707	potential.	[potential.]	0.2	1	3	3	3
60480	1707	pi-3,4,5-p3	[PI-3,4,5-P3]	0.2	1	2	0	0
60481	1707	(KD	[(KD]	0.2	1	3	1	1
60482	1707	Molt-4	[Molt-4]	0.2	1	3	2	2
60483	1707	(a)	[(A)]	0.2	1	3	2	2
60484	1707	pt).	[PT).]	0.2	1	2	0	0
60485	1707	hdmec	[HDMEC]	0.2	1	3	3	3
60486	1707	(kd	[(Kd]	0.2	1	2	0	0
60487	1707	EVI1	[EVI1]	0.2	1	3	1	1
60488	1707	erk-2	[ERK-2]	0.2	1	3	1	1
60489	1707	giant	[giant]	0.2	1	3	3	3
60490	1707	NH2Cl	[NH2Cl]	0.2	1	2	0	0
60491	1707	3bp2	[3BP2]	0.2	1	3	2	2
60492	1707	detail.	[detail.]	0.2	1	2	0	0
60493	1707	9cisra	[9cisRA]	0.2	1	3	2	2
60494	1707	RFX-B	[RFX-B]	0.2	1	2	0	0
60495	1707	starting	[starting]	0.2	1	3	1	1
60496	1707	d20s5	[D20S5]	0.2	1	2	0	0
60497	1707	[3h]-dexamethasone	[[3H]-dexamethasone]	0.2	1	2	0	0
60498	1707	ciprofibrate	[ciprofibrate]	0.2	1	3	1	1
60499	1707	stoichiometry	[stoichiometry]	0.2	1	3	1	1
60500	1707	il-4re	[IL-4RE]	0.2	1	3	2	2
60501	1707	p49/p65	[p49/p65]	0.2	1	3	1	1
60502	1707	G1-to-	[G1-to-S]	0.2	1	2	0	0
60503	1707	Jun/Fos	[Jun/Fos]	0.2	1	3	3	3
60504	1707	-dp	[-DP]	0.2	1	3	1	1
60505	1707	-dq	[-DQ]	0.2	1	3	2	2
60506	1707	-gr	[-GR]	0.2	1	3	3	3
60507	1707	underlie	[underlying]	0.2	1	2	0	0
60508	1707	algorithm	[algorithm]	0.2	1	3	1	1
60509	1707	Rel/NF-kappaB	[Rel/NF-kappaB]	0.2	1	2	0	0
60510	1707	immunomodulating	[immunomodulating]	0.2	1	2	0	0
60511	1707	immunoreaction	[immunoreaction]	0.2	1	3	3	3
60512	1707	pybf	[PYBF]	0.2	1	2	0	0
60513	1707	MCP-1	[MCP-1]	0.2	1	3	1	1
60514	1707	crystal	[crystal]	0.2	1	3	3	3
60515	1707	cytokines,	[cytokines,]	0.2	1	3	3	3
60516	1707	ionomycine	[ionomycine]	0.2	1	2	0	0
60517	1707	hair	[hair]	0.2	1	3	2	2
60518	1707	harc	[HAECs]	0.2	1	2	0	0
60519	1707	granulocyte-	[granulocyte-]	0.2	1	2	0	0
60520	1707	RelA/p65	[RelA/p65]	0.2	1	2	0	0
60521	1707	Galectin-3	[Galectin-3]	0.2	1	2	0	0
60522	1707	zk157202	[ZK157202]	0.2	1	2	0	0
60523	1707	hcss	[HCSs]	0.2	1	3	2	2
60524	1707	40s	[40S]	0.2	1	2	0	0
60525	1707	sb203580	[SB203580]	0.2	1	3	1	1
60526	1707	Thy-1	[Thy-1]	0.2	1	3	1	1
60527	1707	xscid	[XSCID]	0.2	1	4	2	1
60528	1707	/cd70	[/CD70]	0.2	1	4	4	2
60529	1707	head	[head]	0.2	1	3	2	2
60530	1707	/cd25	[/CD25]	0.2	1	2	0	0
60531	1707	thrombospondin	[thrombospondin]	0.2	1	3	1	1
60532	1707	hely	[HEL/S]	0.2	1	2	0	0
60533	1707	nf-il6beta	[NF-IL6beta]	0.2	1	3	1	1
60534	1707	hepo	[hEpo]	0.2	1	2	0	0
60535	1707	camp-	[cAMP-]	0.2	1	2	0	0
60536	1707	differences,	[differences,]	0.2	1	3	1	1
60537	1707	c5mj2	[C5MJ2]	0.2	1	2	0	0
60538	1707	nonresponsiveness	[nonresponsiveness]	0.2	1	2	0	0
60539	1707	casein	[casein]	0.2	1	4	2	1
60540	1707	cases)	[cases)]	0.2	1	3	2	2
60541	1707	htlv-i(+)	[HTLV-I(+)]	0.2	1	2	0	0
60542	1707	OCIM1	[OCIM1]	0.2	1	2	0	0
60543	1707	translation.	[translation.]	0.2	1	2	0	0
60544	1707	phenomena.	[phenomena.]	0.2	1	3	2	2
60545	1707	stp-c488	[STP-C488]	0.2	1	3	1	1
60546	1707	quantity	[quantities]	0.2	1	3	3	3
60547	1707	vsmc-myc	[VSMC-myc]	0.2	1	2	0	0
60548	1707	NFATc.beta	[NFATc.beta]	0.2	1	4	2	1
60549	1707	E-selectin	[E-selectin]	0.2	1	2	0	0
60550	1707	intervene	[intervening]	0.2	1	2	0	0
60551	1707	phosphatidylserine	[phosphatidylserine]	0.2	1	3	2	2
60552	1707	inhibitor.	[inhibitor.]	0.2	1	2	0	0
60553	1707	presentation.	[presentation.]	0.2	1	3	2	2
60554	1707	Akt/PKB	[Akt/PKB]	0.2	1	2	0	0
60555	1707	nlphd	[NLPHD]	0.2	1	3	3	3
60556	1707	immunomodulator	[immunomodulator]	0.2	1	2	0	0
60557	1707	il-9ralpha	[IL-9Ralpha]	0.2	1	2	0	0
60558	1707	destruction	[destruction]	0.2	1	3	1	1
60559	1707	c-Raf-1	[c-Raf-1]	0.2	1	2	0	0
60560	1707	(dissociation	[(dissociation]	0.2	1	3	2	2
60561	1707	-mRNA	[-mRNA]	0.2	1	3	2	2
60562	1707	extravasation	[extravasation]	0.2	1	2	0	0
60563	1707	fetal/adult	[fetal/adult]	0.2	1	2	0	0
60564	1707	/protein	[/protein]	0.2	1	3	2	2
60565	1707	antibodies	[antibodies,]	0.2	1	3	1	1
60566	1707	fkbp52	[FKBP52]	0.2	1	2	0	0
60567	1707	ews/fli-1	[EWS/FLI-1]	0.2	1	2	0	0
60568	1707	autoantibody	[autoantibodies]	0.2	1	3	2	2
60569	1707	OCTA	[OCTA]	0.2	1	3	1	1
60570	1707	5'-deletion	[5'-deletion]	0.2	1	3	3	3
60571	1707	polyclonal	[polyclonal]	0.2	1	2	0	0
60572	1707	LT-kappa	[LT-kappa]	0.2	1	2	0	0
60573	1707	ATF/CRE	[ATF/CRE]	0.2	1	3	1	1
60574	1707	hocl	[HOCl]	0.2	1	3	1	1
60575	1707	FKBP	[FKBP]	0.2	1	2	0	0
60576	1707	coimmunoprecipitation	[coimmunoprecipitation]	0.2	1	2	0	0
60577	1707	cro-ap/3	[CRO-AP/3]	0.2	1	2	0	0
60578	1707	rxr-rxr	[RXR-RXR]	0.2	1	3	2	2
60579	1707	j393	[J393]	0.2	1	2	0	0
60580	1707	factor(s),	[factor(s),]	0.2	1	2	0	0
60581	1707	pebp2/cbf	[PEBP2/CBF]	0.2	1	3	3	3
60582	1707	alphaIIb	[alphaIIb]	0.2	1	2	0	0
60583	1707	alpha-naphthyl	[alpha-naphthyl]	0.2	1	2	0	0
60584	1707	FLRE	[FLRE]	0.2	1	3	1	1
60585	1707	A-T	[A-T]	0.2	1	3	1	1
60586	1707	AGS	[AGS]	0.2	1	3	2	2
60587	1707	socs-1	[SOCS-1]	0.2	1	3	1	1
60588	1707	transferrin	[transferrin]	0.2	1	3	1	1
60589	1707	priming,	[priming,]	0.2	1	2	0	0
60590	1707	priming.	[priming.]	0.2	1	2	0	0
60591	1707	ATF	[ATF]	0.2	1	3	2	2
60592	1707	hrar	[hRAR]	0.2	1	2	0	0
60593	1707	condition,	[condition,]	0.2	1	2	0	0
60594	1707	stem-loop	[stem-loop]	0.2	1	2	0	0
60595	1707	BCS	[BCS]	0.2	1	3	2	2
60596	1707	Ad2	[Ad2]	0.2	1	3	1	1
60597	1707	BR3	[BR3]	0.2	1	2	0	0
60598	1707	BSO	[BSO]	0.2	1	2	0	0
60599	1707	Arg	[Arg]	0.2	1	3	1	1
60600	1707	calcineurin-	[calcineurin-]	0.2	1	2	0	0
60601	1707	BZ1	[BZ1]	0.2	1	2	0	0
60602	1707	CAM	[CAMs]	0.2	1	3	1	1
60603	1707	e(gre)	[E(gre)]	0.2	1	3	3	3
60604	1707	p300/cbp	[p300/CBP]	0.2	1	2	0	0
60605	1707	FOSB	[FOSB]	0.2	1	3	1	1
60606	1707	CLC	[CLC]	0.2	1	2	0	0
60607	1707	XCID	[XCID]	0.2	1	2	0	0
60608	1707	s194	[S194]	0.2	1	3	2	2
60609	1707	sperm	[sperm]	0.2	1	3	3	3
60610	1707	DBF	[DBF]	0.2	1	4	2	1
60611	1707	AP-1-	[AP-1-]	0.2	1	3	1	1
60612	1707	Cbf	[Cbf]	0.2	1	2	0	0
60613	1707	DEN	[DEN]	0.2	1	2	0	0
60614	1707	G2/M	[G2/M]	0.2	1	2	0	0
60615	1707	DHS	[DHS]	0.2	1	3	2	2
60616	1707	antagonists,	[antagonists,]	0.2	1	3	1	1
60617	1707	rPRL	[rPRL]	0.2	1	2	0	0
60618	1707	DPA	[DPA]	0.2	1	3	1	1
60619	1707	E1B	[E1B]	0.2	1	3	2	2
60620	1707	DPD	[DPD]	0.2	1	3	2	2
60621	1707	DQ8	[DQ8]	0.2	1	2	0	0
60622	1707	DSE	[DSE]	0.2	1	3	1	1
60623	1707	CBF1/RBP-Jkappa	[CBF1/RBP-Jkappa]	0.2	1	3	1	1
60624	1707	backbone	[backbone]	0.2	1	2	0	0
60625	1707	EC1	[EC1]	0.2	1	2	0	0
60626	1707	EDN	[EDN]	0.2	1	2	0	0
60627	1707	reticulum	[reticulum]	0.2	1	3	2	2
60628	1707	ap-1-binding	[AP-1-binding]	0.2	1	3	2	2
60629	1707	death.	[death.]	0.2	1	3	2	2
60630	1707	FAB	[FAB]	0.2	1	2	0	0
60631	1707	spondyloarthropathyathypathyartypathyartypathyarty	[spondyloarthropathies]	0.2	1	2	0	0
60632	1707	FcgammaRI	[FcgammaRI]	0.2	1	3	1	1
60633	1707	EpoR	[EpoR]	0.2	1	2	0	0
60634	1707	Egr	[Egr]	0.2	1	3	1	1
60635	1707	c/ebpepsilon	[C/EBPepsilon]	0.2	1	2	0	0
60636	1707	slap-130	[SLAP-130]	0.2	1	4	2	1
60637	1707	FOS	[FOS]	0.2	1	3	1	1
60638	1707	k-562	[K-562]	0.2	1	2	0	0
60639	1707	sr-bp	[SR-BP]	0.2	1	3	2	2
60640	1707	c-erb	[c-erb]	0.2	1	4	2	1
60641	1707	non-hodgkin	[non-Hodgkin]	0.2	1	3	1	1
60642	1707	IFNalpha	[IFNalpha]	0.2	1	3	1	1
60643	1707	GAD	[GAD]	0.2	1	2	0	0
60644	1707	FcR	[FcR]	0.2	1	2	0	0
60645	1707	GH3	[GH3]	0.2	1	2	0	0
60646	1707	GM5	[GM5]	0.2	1	2	0	0
60647	1707	GRR	[GRR]	0.2	1	3	1	1
60648	1707	thyrotropin	[thyrotropin]	0.2	1	3	1	1
60649	1707	TcR/CD3	[TcR/CD3]	0.2	1	2	0	0
60650	1707	Erk2	[Erk2]	0.2	1	3	1	1
60651	1707	HBx	[HBx]	0.2	1	3	1	1
60652	1707	HDL	[HDL]	0.2	1	2	0	0
60653	1707	HLH	[HLH]	0.2	1	3	1	1
60654	1707	HMG	[HMG]	0.2	1	3	1	1
60655	1707	HPC	[HPC]	0.2	1	4	2	1
60656	1707	HRF	[HRF]	0.2	1	3	1	1
60657	1707	HZF	[HZF]	0.2	1	3	1	1
60658	1707	organism.	[organism.]	0.2	1	2	0	0
60659	1707	binding,	[binding,]	0.2	1	3	2	2
60660	1707	HbF	[HbF]	0.2	1	3	2	2
60661	1707	ICI	[ICI]	0.2	1	3	2	2
60662	1707	IE2	[IE2]	0.2	1	2	0	0
60663	1707	perpetuation	[perpetuation]	0.2	1	3	2	2
60664	1707	IL4	[IL4]	0.2	1	3	1	1
60665	1707	menopause	[menopause]	0.2	1	3	1	1
60666	1707	Percoll	[Percoll]	0.2	1	2	0	0
60667	1707	daughter	[daughter]	0.2	1	3	2	2
60668	1707	re/ap	[RE/AP]	0.2	1	3	1	1
60669	1707	receptor-effector	[receptor-effector]	0.2	1	2	0	0
60670	1707	IRF	[IRF]	0.2	1	3	1	1
60671	1707	trans-factor	[trans-factor]	0.2	1	2	0	0
60672	1707	episode	[episode]	0.2	1	3	2	2
60673	1707	IgM	[IgM]	0.2	1	2	0	0
60674	1707	bfu-e	[BFU-E]	0.2	1	3	2	2
60675	1707	Ipr	[Ipr]	0.2	1	2	0	0
60676	1707	would	[d]	0.2	1	3	2	2
60677	1707	JUN	[JUN]	0.2	1	2	0	0
60678	1707	Ito	[Ito]	0.2	1	2	0	0
60679	1707	PNU156804	[PNU156804]	0.2	1	2	0	0
60680	1707	morphology.	[morphology.]	0.2	1	2	0	0
60681	1707	NF-IL6beta	[NF-IL6beta]	0.2	1	2	0	0
60682	1707	TSG101	[TSG101]	0.2	1	3	1	1
60683	1707	Nov2	[Nov2]	0.2	1	2	0	0
60684	1707	Jul	[Jul]	0.2	1	3	2	2
60685	1707	NF-IL-6	[NF-IL-6]	0.2	1	2	0	0
60686	1707	FY*A	[FY*A]	0.2	1	2	0	0
60687	1707	LAI	[LAI]	0.2	1	2	0	0
60688	1707	LBR	[LBR]	0.2	1	3	1	1
60689	1707	LDL	[LDL]	0.2	1	2	0	0
60690	1707	augment	[augment]	0.2	1	3	1	1
60691	1707	LMP	[LMP]	0.2	1	3	1	1
60692	1707	M22	[M22]	0.2	1	2	0	0
60693	1707	GenBank	[GenBank]	0.2	1	2	0	0
60694	1707	Immunol	[Immunol]	0.2	1	3	3	3
60695	1707	organisms.	[organisms.]	0.2	1	2	0	0
60696	1707	zearalenone	[zearalenone]	0.2	1	2	0	0
60697	1707	nf-x2	[NF-X2]	0.2	1	3	1	1
60698	1707	e-protein	[E-protein]	0.2	1	3	1	1
60699	1707	tcell	[Tcell]	0.2	1	3	2	2
60700	1707	MDS	[MDS]	0.2	1	2	0	0
60701	1707	OSF2	[OSF2]	0.2	1	2	0	0
60702	1707	MKK	[MKK]	0.2	1	3	2	2
60703	1707	MLR	[MLR]	0.2	1	3	2	2
60704	1707	MNC	[MNC]	0.2	1	3	2	2
60705	1707	MPE	[MPE]	0.2	1	3	1	1
60706	1707	MPL	[MPL]	0.2	1	3	1	1
60707	1707	lpr/lpr	[lpr/lpr]	0.2	1	2	0	0
60708	1707	sivmac239	[SIVmac239]	0.2	1	3	1	1
60709	1707	NCL	[NCL]	0.2	1	3	1	1
60710	1707	NGF	[NGF]	0.2	1	3	1	1
60711	1707	NHL	[NHL]	0.2	1	4	2	1
60712	1707	NKL	[NKL]	0.2	1	2	0	0
60713	1707	NOS	[NOS]	0.2	1	2	0	0
60714	1707	gain-of-function	[gain-of-function]	0.2	1	2	0	0
60715	1707	NR2	[NR2]	0.2	1	2	0	0
60716	1707	NRE	[NRE]	0.2	1	2	0	0
60717	1707	acetyl-transferase	[acetyl-transferase]	0.2	1	3	3	3
60718	1707	B-lymphocyte	[B-lymphocyte]	0.2	1	3	1	1
60719	1707	Myb	[Myb]	0.2	1	2	0	0
60720	1707	cyclic-AMP	[cyclic-AMP]	0.2	1	2	0	0
60721	1707	Nb2	[Nb2]	0.2	1	3	2	2
60722	1707	dr-nm23	[DR-nm23]	0.2	1	3	2	2
60723	1707	XP-B	[XP-B]	0.2	1	2	0	0
60724	1707	R7-57	[R7-57]	0.2	1	2	0	0
60725	1707	PAM	[PAM]	0.2	1	3	1	1
60726	1707	PIF	[PIF]	0.2	1	3	1	1
60727	1707	PKA	[PKA]	0.2	1	2	0	0
60728	1707	POU	[POU]	0.2	1	3	1	1
60729	1707	perspective	[perspective]	0.2	1	3	3	3
60730	1707	degree,	[degree,]	0.2	1	3	3	3
60731	1707	silencing.	[silencing.]	0.2	1	2	0	0
60732	1707	PWM	[PWM]	0.2	1	3	1	1
60733	1707	distress	[distress]	0.2	1	5	3	1
60734	1707	id-3	[Id-3]	0.2	1	3	3	3
60735	1707	predisposition	[predisposition]	0.2	1	3	3	3
60736	1707	strength	[strength]	0.2	1	3	3	3
60737	1707	ie-1	[IE-1]	0.2	1	3	1	1
60738	1707	RBC	[RBC]	0.2	1	3	3	3
60739	1707	RBD	[RBD]	0.2	1	3	2	2
60740	1707	icp0	[ICP0]	0.2	1	2	0	0
60741	1707	patient,	[patient,]	0.2	1	2	0	0
60742	1707	IFN-U937	[IFN-U937]	0.2	1	3	2	2
60743	1707	RIA	[RIA]	0.2	1	3	1	1
60744	1707	S1'	[S1']	0.2	1	2	0	0
60745	1707	e-box	[E-box]	0.2	1	3	3	3
60746	1707	virulence	[virulence]	0.2	1	3	1	1
60747	1707	110-kda	[110-kDa]	0.2	1	2	0	0
60748	1707	cachexia	[cachexia]	0.2	1	2	0	0
60749	1707	SAA	[SAA]	0.2	1	3	2	2
60750	1707	SAC	[SAC]	0.2	1	2	0	0
60751	1707	SAF	[SAF]	0.2	1	2	0	0
60752	1707	macrolide	[macrolide]	0.2	1	2	0	0
60753	1707	Rac	[Rac]	0.2	1	3	1	1
60754	1707	Ran	[Ran]	0.2	1	3	2	2
60755	1707	anaphylatoxin	[anaphylatoxin]	0.2	1	3	3	3
60756	1707	SEB	[SEB]	0.2	1	3	2	2
60757	1707	SIV	[SIV]	0.2	1	3	1	1
60758	1707	SJO	[SJO]	0.2	1	3	1	1
60759	1707	SSE	[SSE]	0.2	1	2	0	0
60760	1707	TBP	[TBP]	0.2	1	2	0	0
60761	1707	cerulein	[cerulein]	0.2	1	2	0	0
60762	1707	TIS	[TIS]	0.2	1	2	0	0
60763	1707	TNT	[TNT]	0.2	1	2	0	0
60764	1707	phosphoserine	[phosphoserine]	0.2	1	2	0	0
60765	1707	bronchiolitis	[bronchiolitis]	0.2	1	3	1	1
60766	1707	gender	[Gender]	0.2	1	3	2	2
60767	1707	cavity	[cavity]	0.2	1	2	0	0
60768	1707	PI3-K	[PI3-K]	0.2	1	3	1	1
60769	1707	usefulness	[usefulness]	0.2	1	3	2	2
60770	1707	myosin	[myosin]	0.2	1	2	0	0
60771	1707	cd1a+	[CD1a+]	0.2	1	2	0	0
60772	1707	cd1a-	[CD1a-]	0.2	1	2	0	0
60773	1707	hhv-6(gs)	[HHV-6(GS)]	0.2	1	3	1	1
60774	1707	GCII	[GCII]	0.2	1	3	1	1
60775	1707	feasibility	[feasibility]	0.2	1	3	3	3
60776	1707	protoenhancer	[protoenhancers]	0.2	1	3	2	2
60777	1707	stat3alpha	[STAT3alpha]	0.2	1	2	0	0
60778	1707	GDSP	[GDSP]	0.2	1	2	0	0
60779	1707	cd41a	[CD41a]	0.2	1	2	0	0
60780	1707	ca(2+)-dependent	[Ca(2+)-dependent]	0.2	1	2	0	0
60781	1707	entity	[entity]	0.2	1	3	3	3
60782	1707	tetrazolium	[tetrazolium]	0.2	1	3	2	2
60783	1707	Fabricius	[Fabricius]	0.2	1	2	0	0
60784	1707	XCI	[XCI]	0.2	1	3	1	1
60785	1707	dq3.2	[DQ3.2]	0.2	1	2	0	0
60786	1707	lithium	[lithium]	0.2	1	3	1	1
60787	1707	il15	[IL15]	0.2	1	2	0	0
60788	1707	Arp2/3	[Arp2/3]	0.2	1	2	0	0
60789	1707	cd62e	[CD62E]	0.2	1	3	1	1
60790	1707	[ca2+]i	[[Ca2+]i]	0.2	1	3	2	2
60791	1707	reason	[reason]	0.2	1	4	2	1
60792	1707	Yae	[Yae]	0.2	1	2	0	0
60793	1707	iHIV-1	[iHIV-1]	0.2	1	2	0	0
60794	1707	rel/	[rel/]	0.2	1	2	0	0
60795	1707	epinephrine	[epinephrine]	0.2	1	2	0	0
60796	1707	tonsillar	[tonsillar]	0.2	1	3	3	3
60797	1707	ZIP	[ZIP]	0.2	1	2	0	0
60798	1707	Pax-5b	[Pax-5b]	0.2	1	3	2	2
60799	1707	interleukin-13	[interleukin-13]	0.2	1	3	3	3
60800	1707	interleukin-12	[interleukin-12]	0.2	1	3	2	2
60801	1707	motifs,	[motifs,]	0.2	1	2	0	0
60802	1707	motifs.	[motifs.]	0.2	1	2	0	0
60803	1707	PI3-kinase	[PI3-kinase]	0.2	1	2	0	0
60804	1707	antithyroid	[antithyroid]	0.2	1	2	0	0
60805	1707	selection.	[selection.]	0.2	1	3	1	1
60806	1707	C3H-gld/gld	[C3H-gld/gld]	0.2	1	2	0	0
60807	1707	cultures,	[cultures,]	0.2	1	2	0	0
60808	1707	PBMo	[PBMo]	0.2	1	2	0	0
60809	1707	GIRE	[GIRE]	0.2	1	3	3	3
60810	1707	enhance	[enhancing]	0.2	1	3	1	1
60811	1707	CD2:lymphocyte	[CD2:lymphocyte]	0.2	1	2	0	0
60812	1707	4e-bp2	[4E-BP2]	0.2	1	3	1	1
60813	1707	cd3-cd16+	[CD3-CD16+]	0.2	1	3	2	2
60814	1707	NF-ATn	[NF-ATn]	0.2	1	2	0	0
60815	1707	iono	[iono]	0.2	1	3	1	1
60816	1707	riia	[RIIA]	0.2	1	3	3	3
60817	1707	NF-AT3	[NF-AT3]	0.2	1	2	0	0
60818	1707	NF-AT2	[NF-AT2]	0.2	1	2	0	0
60819	1707	NF-AT4	[NF-AT4]	0.2	1	3	1	1
60820	1707	down'	[Down's]	0.2	1	3	1	1
60821	1707	H-RS	[H-RS]	0.2	1	2	0	0
60822	1707	methyl	[methyl]	0.2	1	2	0	0
60823	1707	il-6r	[IL-6R]	0.2	1	2	0	0
60824	1707	-bearing	[-bearing]	0.2	1	3	3	3
60825	1707	il-4-	[IL-4-]	0.2	1	3	2	2
60826	1707	il-11	[IL-11]	0.2	1	2	0	0
60827	1707	apoptosis.	[apoptosis.]	0.2	1	3	1	1
60828	1707	apoptosis,	[apoptosis,]	0.2	1	2	0	0
60829	1707	sequences,	[sequences,]	0.2	1	2	0	0
60830	1707	group.	[group.]	0.2	1	3	1	1
60831	1707	moiety	[moiety]	0.2	1	3	3	3
60832	1707	A-CRF	[A-CRF]	0.2	1	3	1	1
60833	1707	IL-13R	[IL-13R]	0.2	1	2	0	0
60834	1707	a20	[A20]	0.2	1	2	0	0
60835	1707	JAK-3	[JAK-3]	0.2	1	2	0	0
60836	1707	irak	[IRAK]	0.2	1	2	0	0
60837	1707	attention.	[attention.]	0.2	1	2	0	0
60838	1707	cd56+,	[CD56+,]	0.2	1	3	2	2
60839	1707	b-1	[B-1]	0.2	1	2	0	0
60840	1707	kilobase	[kilobase]	0.2	1	2	0	0
60841	1707	b27	[B27]	0.2	1	2	0	0
60842	1707	captopril	[captopril]	0.2	1	3	1	1
60843	1707	IL-1RI	[IL-1RI]	0.2	1	3	1	1
60844	1707	unit-erythroid	[unit-erythroid]	0.2	1	2	0	0
60845	1707	aes	[AES]	0.2	1	2	0	0
60846	1707	mrp14	[MRP14]	0.2	1	3	3	3
60847	1707	ahr	[AhR]	0.2	1	2	0	0
60848	1707	genome.	[genome.]	0.2	1	2	0	0
60849	1707	CHO-DR/	[CHO-DR/]	0.2	1	2	0	0
60850	1707	Arnica	[Arnica]	0.2	1	2	0	0
60851	1707	atl	[ATL]	0.2	1	2	0	0
60852	1707	enhancer/promoter	[enhancer/promoter]	0.2	1	2	0	0
60853	1707	adherent	[adherent]	0.2	1	2	0	0
60854	1707	haemoglobin	[haemoglobin]	0.2	1	3	1	1
60855	1707	display	[display]	0.2	1	3	3	3
60856	1707	heterokaryon	[heterokaryon]	0.2	1	3	2	2
60857	1707	ikk-alpha	[IKK-alpha]	0.2	1	2	0	0
60858	1707	GPIX	[GPIX]	0.2	1	3	1	1
60859	1707	bad	[Bad]	0.2	1	2	0	0
60860	1707	bal	[BAL]	0.2	1	3	1	1
60861	1707	bha	[BHA]	0.2	1	3	2	2
60862	1707	bp.	[bp.]	0.2	1	3	1	1
60863	1707	antigen-	[antigen-]	0.2	1	2	0	0
60864	1707	tfiiib90	[TFIIIB90]	0.2	1	2	0	0
60865	1707	serum-contain	[serum-containing]	0.2	1	2	0	0
60866	1707	ca.	[ca.]	0.2	1	2	0	0
60867	1707	PKC-	[PKC-]	0.2	1	2	0	0
60868	1707	cfp	[CFP]	0.2	1	2	0	0
60869	1707	cho	[CHO]	0.2	1	3	2	2
60870	1707	Surprisingly,	[Surprisingly,]	0.2	1	3	3	3
60871	1707	e47	[E47]	0.2	1	3	1	1
60872	1707	fos-B	[fos-B]	0.2	1	2	0	0
60873	1707	CTLA4Ig	[CTLA4Ig]	0.2	1	2	0	0
60874	1707	asthma.	[asthma.]	0.2	1	2	0	0
60875	1707	Tat-I	[Tat-I]	0.2	1	2	0	0
60876	1707	hxbp-1	[hXBP-1]	0.2	1	3	1	1
60877	1707	dcs	[DCS]	0.2	1	2	0	0
60878	1707	buthionine	[buthionine]	0.2	1	2	0	0
60879	1707	dha	[DHA]	0.2	1	3	1	1
60880	1707	dhs	[DHS]	0.2	1	3	3	3
60881	1707	die	[dying]	0.2	1	3	2	2
60882	1707	dil	[DIL]	0.2	1	3	2	2
60883	1707	uterus	[uterus]	0.2	1	2	0	0
60884	1707	PMA-	[PMA-]	0.2	1	2	0	0
60885	1707	1,25-dihydroxycholecalciferol	[1,25-dihydroxycholecalciferol]	0.2	1	3	3	3
60886	1707	PML/	[PML/]	0.2	1	2	0	0
60887	1707	eic	[EIC]	0.2	1	3	1	1
60888	1707	GST-	[GST-]	0.2	1	3	1	1
60889	1707	dna-cellulose	[DNA-cellulose]	0.2	1	4	4	2
60890	1707	env	[env]	0.2	1	3	2	2
60891	1707	mifepristone	[mifepristone]	0.2	1	2	0	0
60892	1707	er-	[ER-]	0.2	1	3	2	2
60893	1707	cemx174	[CEMx174]	0.2	1	2	0	0
60894	1707	gas-motif	[GAS-motif]	0.2	1	3	1	1
60895	1707	fcs	[FCS]	0.2	1	3	2	2
60896	1707	hyperadhesion	[hyperadhesion]	0.2	1	2	0	0
60897	1707	precursors.	[precursors.]	0.2	1	3	1	1
60898	1707	fyn	[fyn]	0.2	1	2	0	0
60899	1707	(NF)-kappaB	[(NF)-kappaB]	0.2	1	2	0	0
60900	1707	gam	[GAM]	0.2	1	2	0	0
60901	1707	deamidation	[deamidation]	0.2	1	2	0	0
60902	1707	G-CSFR	[G-CSFR]	0.2	1	2	0	0
60903	1707	70-bp	[70-bp]	0.2	1	2	0	0
60904	1707	hb9	[HB9]	0.2	1	3	1	1
60905	1707	hbx	[HBx]	0.2	1	2	0	0
60906	1707	hck	[hck]	0.2	1	3	1	1
60907	1707	delta-ALA	[delta-ALA]	0.2	1	2	0	0
60908	1707	extent.	[extent.]	0.2	1	3	3	3
60909	1707	hpr	[hPR]	0.2	1	3	1	1
60910	1707	hpv	[HPV]	0.2	1	3	2	2
60911	1707	hs1	[HS1]	0.2	1	3	2	2
60912	1707	gata-2/er	[GATA-2/ER]	0.2	1	2	0	0
60913	1707	flagella	[flagella]	0.2	1	2	0	0
60914	1707	ie2	[IE2]	0.2	1	3	1	1
60915	1707	Sendai	[Sendai]	0.2	1	2	0	0
60916	1707	iga	[IgA]	0.2	1	3	1	1
60917	1707	igd	[IgD]	0.2	1	3	1	1
60918	1707	acne	[acne]	0.2	1	2	0	0
60919	1707	antiphosphotyrosine	[antiphosphotyrosine]	0.2	1	3	1	1
60920	1707	PRRI	[PRRI]	0.2	1	2	0	0
60921	1707	pioglitazone	[pioglitazone]	0.2	1	2	0	0
60922	1707	salmonella	[Salmonella]	0.2	1	2	0	0
60923	1707	insufficiency	[insufficiency]	0.2	1	3	3	3
60924	1707	kb.	[kb.]	0.2	1	3	3	3
60925	1707	kd.	[kd.]	0.2	1	3	2	2
60926	1707	kca	[KCa]	0.2	1	2	0	0
60927	1707	m).	[M).]	0.2	1	3	1	1
60928	1707	T-all	[T-ALL]	0.2	1	3	1	1
60929	1707	17beta-HSD	[17beta-HSD]	0.2	1	3	2	2
60930	1707	other,	[other,]	0.2	1	3	1	1
60931	1707	NFIL-2A	[NFIL-2A]	0.2	1	2	0	0
60932	1707	NFIL-2B	[NFIL-2B]	0.2	1	2	0	0
60933	1707	cells/mm2,	[cells/mm2,]	0.2	1	4	2	1
60934	1707	lam	[LAM]	0.2	1	2	0	0
60935	1707	detergent	[detergent]	0.2	1	3	2	2
60936	1707	om-10.1	[OM-10.1]	0.2	1	3	2	2
60937	1707	chemoattract	[chemoattractants]	0.2	1	3	2	2
60938	1707	lyn	[lyn]	0.2	1	3	2	2
60939	1707	aminothiol	[aminothiol]	0.2	1	2	0	0
60940	1707	mcr	[MCR]	0.2	1	3	1	1
60941	1707	mel	[MEL]	0.2	1	3	1	1
60942	1707	met	[MET]	0.2	1	3	1	1
60943	1707	mie	[MIE]	0.2	1	3	3	3
60944	1707	mnl	[MNL]	0.2	1	2	0	0
60945	1707	mnp	[MNP]	0.2	1	2	0	0
60946	1707	age.	[age.]	0.2	1	3	2	2
60947	1707	age-	[age-]	0.2	1	3	1	1
60948	1707	nck	[nck]	0.2	1	2	0	0
60949	1707	ndp	[NDP]	0.2	1	3	2	2
60950	1707	net	[net]	0.2	1	2	0	0
60951	1707	proline	[proline]	0.2	1	3	1	1
60952	1707	transduce	[transduce]	0.2	1	3	1	1
60953	1707	nkl	[NKL]	0.2	1	3	2	2
60954	1707	p/i	[P/I]	0.2	1	3	2	2
60955	1707	p19	[P19]	0.2	1	2	0	0
60956	1707	nrd	[NRDS]	0.2	1	3	1	1
60957	1707	p63	[p63]	0.2	1	2	0	0
60958	1707	p70	[p70]	0.2	1	3	1	1
60959	1707	sodium-proton-antiport	[sodium-proton-antiport]	0.2	1	2	0	0
60960	1707	Cross	[Cross]	0.2	1	3	3	3
60961	1707	nwp	[NWP]	0.2	1	3	2	2
60962	1707	NF(kappa)B	[NF(kappa)B]	0.2	1	2	0	0
60963	1707	owl	[owl]	0.2	1	3	1	1
60964	1707	pag	[pag]	0.2	1	3	2	2
60965	1707	pas	[PAS]	0.2	1	2	0	0
60966	1707	pcv	[PCVs]	0.2	1	3	1	1
60967	1707	gf109203x	[GF109203X]	0.2	1	3	1	1
60968	1707	php	[PHP]	0.2	1	3	1	1
60969	1707	pig	[pig]	0.2	1	3	1	1
60970	1707	pip	[Pip]	0.2	1	3	3	3
60971	1707	pos	[POS]	0.2	1	3	2	2
60972	1707	poz	[POZ]	0.2	1	3	2	2
60973	1707	pth	[pTh]	0.2	1	3	1	1
60974	1707	selectin	[selectin]	0.2	1	3	2	2
60975	1707	PYBF	[PYBF]	0.2	1	3	1	1
60976	1707	proil-1beta	[proIL-1beta]	0.2	1	2	0	0
60977	1707	health	[health]	0.2	1	3	2	2
60978	1707	rac	[Rac]	0.2	1	3	1	1
60979	1707	rag	[RAG]	0.2	1	3	3	3
60980	1707	C-JUN	[C-JUN]	0.2	1	3	3	3
60981	1707	sivsmmpbj14	[SIVsmmPBj14]	0.2	1	2	0	0
60982	1707	young.	[young.]	0.2	1	2	0	0
60983	1707	rpo	[rpoS]	0.2	1	3	1	1
60984	1707	IFNgamma-	[IFNgamma-]	0.2	1	3	1	1
60985	1707	rt-	[RT-]	0.2	1	3	2	2
60986	1707	host,	[host,]	0.2	1	2	0	0
60987	1707	Tyr-492	[Tyr-492]	0.2	1	2	0	0
60988	1707	Tyr-493	[Tyr-493]	0.2	1	2	0	0
60989	1707	NADPH	[NADPH]	0.2	1	2	0	0
60990	1707	novelty	[novelty]	0.2	1	2	0	0
60991	1707	staphylococcus	[Staphylococcus]	0.2	1	3	1	1
60992	1707	80-kDa	[80-kDa]	0.2	1	2	0	0
60993	1707	sac	[SAC]	0.2	1	3	1	1
60994	1707	scd	[SCD]	0.2	1	2	0	0
60995	1707	ser	[Ser]	0.2	1	3	1	1
60996	1707	sh3	[SH3]	0.2	1	3	1	1
60997	1707	sfv	[sFv]	0.2	1	2	0	0
60998	1707	millileter	[ml]	0.2	1	3	3	3
60999	1707	siv	[SIV]	0.2	1	3	2	2
61000	1707	parasitemia	[parasitemia]	0.2	1	2	0	0
61001	1707	HCMV	[HCMV]	0.2	1	3	1	1
61002	1707	valine	[valine]	0.2	1	3	1	1
61003	1707	tec	[TEC]	0.2	1	3	2	2
61004	1707	65-kD	[65-kD]	0.2	1	2	0	0
61005	1707	tr2	[TR2]	0.2	1	2	0	0
61006	1707	trp	[TRP]	0.2	1	3	1	1
61007	1707	tsc	[TSC]	0.2	1	2	0	0
61008	1707	tur	[TUR]	0.2	1	3	2	2
61009	1707	participate	[participating]	0.2	1	3	3	3
61010	1707	participant	[participant]	0.2	1	3	3	3
61011	1707	house	[house]	0.2	1	2	0	0
61012	1707	antiestrogen	[antiestrogens]	0.2	1	3	1	1
61013	1707	subjects,	[subjects,]	0.2	1	3	1	1
61014	1707	subjects.	[subjects.]	0.2	1	3	2	2
61015	1707	scid	[SCID]	0.2	1	3	1	1
61016	1707	delineation	[delineation]	0.2	1	3	3	3
61017	1707	environment	[environment]	0.2	1	3	1	1
61018	1707	uremia	[uremia]	0.2	1	2	0	0
61019	1707	vwf	[vWf]	0.2	1	3	1	1
61020	1707	both).	[both).]	0.2	1	2	0	0
61021	1707	RXR-alpha	[RXR-alpha]	0.2	1	3	1	1
61022	1707	ccr-4	[CCR-4]	0.2	1	3	2	2
61023	1707	IFN(alpha)	[IFN(alpha)]	0.2	1	2	0	0
61024	1707	sem)	[SEM)]	0.2	1	3	2	2
61025	1707	methods.	[methods.]	0.2	1	3	3	3
61026	1707	-signal	[-signal]	0.2	1	3	3	3
61027	1707	chamissonolid	[chamissonolid]	0.2	1	2	0	0
61028	1707	Notch-1	[Notch-1]	0.2	1	2	0	0
61029	1707	sera	[sera]	0.2	1	4	4	2
61030	1707	lamina	[lamina]	0.2	1	2	0	0
61031	1707	Exosurf	[Exosurf]	0.2	1	3	1	1
61032	1707	surfaces.	[surfaces.]	0.2	1	2	0	0
61033	1707	c/ebp-	[C/EBP-]	0.2	1	2	0	0
61034	1707	peroxide	[peroxide]	0.2	1	2	0	0
61035	1707	zip	[ZIP]	0.2	1	2	0	0
61036	1707	Pan/	[Pan/]	0.2	1	3	1	1
61037	1707	atf1	[ATF1]	0.2	1	3	1	1
61038	1707	Sox-4	[Sox-4]	0.2	1	2	0	0
61039	1707	pro-il-16	[pro-IL-16]	0.2	1	3	1	1
61040	1707	shp2	[SHP2]	0.2	1	3	2	2
61041	1707	Turner	[Turner]	0.2	1	3	1	1
61042	1707	fibroblasts,	[fibroblasts,]	0.2	1	2	0	0
61043	1707	sigd-	[sIgD-]	0.2	1	2	0	0
61044	1707	pg/ml	[pg/mL]	0.2	1	3	2	2
61045	1707	PRRII	[PRRII]	0.2	1	2	0	0
61046	1707	sigm-	[sIgM-]	0.2	1	3	1	1
61047	1707	opening	[opening]	0.2	1	3	3	3
61048	1707	mapkk-1	[MAPKK-1]	0.2	1	3	2	2
61049	1707	HMBA	[HMBA]	0.2	1	3	1	1
61050	1707	Ciprofloxacin	[Ciprofloxacin]	0.2	1	2	0	0
61051	1707	monocytes/	[monocytes/]	0.2	1	2	0	0
61052	1707	monocytes,	[monocytes,]	0.2	1	2	0	0
61053	1707	itf-2	[ITF-2]	0.2	1	2	0	0
61054	1707	itf-1	[ITF-1]	0.2	1	2	0	0
61055	1707	subdomain	[subdomains]	0.2	1	3	2	2
61056	1707	pp-2a	[PP-2A]	0.2	1	3	1	1
61057	1707	bZIP	[bZIP]	0.2	1	2	0	0
61058	1707	infections.	[infections.]	0.2	1	3	2	2
61059	1707	asparagine	[asparagine]	0.2	1	3	1	1
61060	1707	sideroblast	[sideroblasts]	0.2	1	4	2	1
61061	1707	leishmania	[Leishmania]	0.2	1	2	0	0
61062	1707	probe.	[probe.]	0.2	1	3	1	1
61063	1707	significance.	[significance.]	0.2	1	4	4	2
61064	1707	12-bp	[12-bp]	0.2	1	3	1	1
61065	1707	3t3-l1	[3T3-L1]	0.2	1	3	1	1
61066	1707	palmitate	[palmitate]	0.2	1	2	0	0
61067	1707	hiv-ltr	[HIV-LTR]	0.2	1	2	0	0
61068	1707	N19RhoA	[N19RhoA]	0.2	1	2	0	0
61069	1707	elderly.	[elderly.]	0.2	1	2	0	0
61070	1707	astrocytomas	[astrocytomas]	0.2	1	3	1	1
61071	1707	(th2)	[(Th2)]	0.2	1	4	4	2
61072	1707	PhoP	[PhoP]	0.2	1	3	1	1
61073	1707	Ficoll	[Ficoll]	0.2	1	2	0	0
61074	1707	elisa	[ELISA]	0.2	1	2	0	0
61075	1707	anthracycline	[anthracycline]	0.2	1	3	1	1
61076	1707	HRBC	[HRBC]	0.2	1	2	0	0
61077	1707	GPIIb	[GPIIb]	0.2	1	3	1	1
61078	1707	plastic.	[plastic.]	0.2	1	3	1	1
61079	1707	guinea	[guinea]	0.2	1	3	1	1
61080	1707	stat-1alpha	[STAT-1alpha]	0.2	1	3	3	3
61081	1707	TRAIL	[TRAIL]	0.2	1	3	1	1
61082	1707	TRADD	[TRADD]	0.2	1	2	0	0
61083	1707	cognate	[cognate]	0.2	1	2	0	0
61084	1707	sris	[SRIs]	0.2	1	2	0	0
61085	1707	hla-a3	[HLA-A3]	0.2	1	2	0	0
61086	1707	ilt-mat	[ILT-mat]	0.2	1	2	0	0
61087	1707	troglitazone	[troglitazone]	0.2	1	3	1	1
61088	1707	proerythroblast	[proerythroblasts]	0.2	1	2	0	0
61089	1707	angiogenesis	[angiogenesis]	0.2	1	3	2	2
61090	1707	NK3.3	[NK3.3]	0.2	1	2	0	0
61091	1707	spreading.	[spreading.]	0.2	1	2	0	0
61092	1707	Addisonian	[Addisonian]	0.2	1	2	0	0
61093	1707	baby	[baby]	0.2	1	3	1	1
61094	1707	curry	[curry]	0.2	1	2	0	0
61095	1707	macaque	[macaque]	0.2	1	2	0	0
61096	1707	kruppel-type	[Kruppel-type]	0.2	1	2	0	0
61097	1707	dibenzofuran	[dibenzofurans]	0.2	1	2	0	0
61098	1707	ru38486	[RU38486]	0.2	1	4	2	1
61099	1707	paclitaxel	[paclitaxel]	0.2	1	3	2	2
61100	1707	aml-1	[AML-1]	0.2	1	2	0	0
61101	1707	assumption	[assumption]	0.2	1	2	0	0
61102	1707	renal	[renal]	0.2	1	3	1	1
61103	1707	bcl2	[BCL2]	0.2	1	3	3	3
61104	1707	La(SSB)	[La(SSB)]	0.2	1	3	1	1
61105	1707	ataxia	[ataxia]	0.2	1	3	2	2
61106	1707	succinimide	[succinimide]	0.2	1	3	2	2
61107	1707	Nur77	[Nur77]	0.2	1	2	0	0
61108	1707	rar(alpha)	[RAR(alpha)]	0.2	1	3	3	3
61109	1707	Kinase	[Kinase]	0.2	1	3	3	3
61110	1707	bead	[bead]	0.2	1	3	3	3
61111	1707	cd3-epsilon	[CD3-epsilon]	0.2	1	3	1	1
61112	1707	aml1b	[AML1b]	0.2	1	2	0	0
61113	1707	LTalpha	[LTalpha]	0.2	1	2	0	0
61114	1707	c1-c3	[C1-C3]	0.2	1	2	0	0
61115	1707	endothelial-RAW264.7	[endothelial-RAW264.7]	0.2	1	2	0	0
61116	1707	sedimentation	[sedimentation]	0.2	1	3	2	2
61117	1707	min/l;	[min/L;]	0.2	1	2	0	0
61118	1707	factor-IL6	[factor-IL6]	0.2	1	3	2	2
61119	1707	Fludarabine	[Fludarabine]	0.2	1	2	0	0
61120	1707	avidity	[avidity]	0.2	1	3	1	1
61121	1707	Cepharanthine	[Cepharanthine]	0.2	1	3	1	1
61122	1707	size,	[size,]	0.2	1	3	1	1
61123	1707	Nucleolin	[Nucleolin]	0.2	1	2	0	0
61124	1707	bl-2	[BL-2]	0.2	1	2	0	0
61125	1707	p50/c-Rel	[p50/c-Rel]	0.2	1	3	2	2
61126	1707	anti-Fos	[anti-Fos]	0.2	1	2	0	0
61127	1707	40-kDa	[40-kDa]	0.2	1	2	0	0
61128	1707	host-cell	[host-cell]	0.2	1	2	0	0
61129	1707	IFN-alpha/beta	[IFN-alpha/beta]	0.2	1	2	0	0
61130	1707	nh2cl	[NH2Cl]	0.2	1	3	2	2
61131	1707	Acanthamoeba	[Acanthamoeba]	0.2	1	2	0	0
61132	1707	5'hs3	[5'HS3]	0.2	1	3	1	1
61133	1707	World	[World]	0.2	1	6	4	1
61134	1707	blr2	[BLR2]	0.2	1	3	1	1
61135	1707	blr1	[BLR1]	0.2	1	3	2	2
61136	1707	bmax	[Bmax]	0.2	1	2	0	0
61137	1707	MS-2gamma	[MS-2gamma]	0.2	1	2	0	0
61138	1707	TNFRp55	[TNFRp55]	0.2	1	2	0	0
61139	1707	reticulocyte-type	[reticulocyte-type]	0.2	1	2	0	0
61140	1707	70Z/3	[70Z/3]	0.2	1	2	0	0
61141	1707	IE-1	[IE-1]	0.2	1	2	0	0
61142	1707	experiments.	[experiments.]	0.2	1	2	0	0
61143	1707	Jeg-3	[Jeg-3]	0.2	1	2	0	0
61144	1707	2.3-kb	[2.3-kb]	0.2	1	3	1	1
61145	1707	bond	[bond]	0.2	1	3	1	1
61146	1707	damage	[damage]	0.2	1	3	2	2
61147	1707	tcrg	[TCRG]	0.2	1	3	2	2
61148	1707	zeta-chain	[zeta-chain]	0.2	1	2	0	0
61149	1707	receptor-ligand	[receptor-ligand]	0.2	1	3	1	1
61150	1707	p42/44	[p42/44]	0.2	1	2	0	0
61151	1707	disable	[disabling]	0.2	1	3	2	2
61152	1707	E2a-Pbx1	[E2a-Pbx1]	0.2	1	3	1	1
61153	1707	attack	[attack]	0.2	1	3	3	3
61154	1707	lt-alpha1beta2	[LT-alpha1beta2]	0.2	1	3	2	2
61155	1707	Fy(a-b-)	[Fy(a-b-)]	0.2	1	2	0	0
61156	1707	tes2	[TES2]	0.2	1	3	1	1
61157	1707	brdu	[BrdU]	0.2	1	3	1	1
61158	1707	RANKL	[RANKL]	0.2	1	3	2	2
61159	1707	originate	[originating]	0.2	1	3	3	3
61160	1707	growth.	[growth.]	0.2	1	2	0	0
61161	1707	d5g6	[D5G6]	0.2	1	2	0	0
61162	1707	Hodgkin'	[Hodgkin's]	0.2	1	3	2	2
61163	1707	option	[option]	0.2	1	3	3	3
61164	1707	dilution	[dilution]	0.2	1	3	3	3
61165	1707	thp1	[THP1]	0.2	1	2	0	0
61166	1707	GC-box	[GC-box]	0.2	1	2	0	0
61167	1707	IKK2	[IKK2]	0.2	1	2	0	0
61168	1707	c-erba/tr-alpha	[c-erbA/TR-alpha]	0.2	1	3	2	2
61169	1707	ccaat/enhancer	[CCAAT/enhancer]	0.2	1	2	0	0
61170	1707	IM-9	[IM-9]	0.2	1	2	0	0
61171	1707	c-ErbB	[c-ErbB]	0.2	1	3	1	1
61172	1707	glut4	[GLUT4]	0.2	1	2	0	0
61173	1707	anti-NF-ATp	[anti-NF-ATp]	0.2	1	2	0	0
61174	1707	B/MAD-3	[B/MAD-3]	0.2	1	2	0	0
61175	1707	yield	[yield]	0.2	1	3	2	2
61176	1707	toremifene	[toremifene]	0.2	1	2	0	0
61177	1707	nm23-h2	[nm23-H2]	0.2	1	3	2	2
61178	1707	structure-function	[structure-function]	0.2	1	3	1	1
61179	1707	pg/ml).	[pg/ml).]	0.2	1	2	0	0
61180	1707	immobilization	[immobilization]	0.2	1	3	2	2
61181	1707	IkappaB-alphaS32/36A	[IkappaB-alphaS32/36A]	0.2	1	3	2	2
61182	1707	TAL-1	[TAL-1]	0.2	1	2	0	0
61183	1707	mononucleosis	[mononucleosis]	0.2	1	3	2	2
61184	1707	centre	[centre]	0.2	1	2	0	0
61185	1707	species.	[species.]	0.2	1	3	2	2
61186	1707	species,	[species,]	0.2	1	3	3	3
61187	1707	breakdown	[breakdown]	0.2	1	3	3	3
61188	1707	boundary	[boundary]	0.2	1	3	1	1
61189	1707	inactivate	[inactivating]	0.2	1	2	0	0
61190	1707	T-lymphocytes	[T-lymphocytes]	0.2	1	2	0	0
61191	1707	xanthine	[xanthine]	0.2	1	3	3	3
61192	1707	euthyroid	[euthyroid]	0.2	1	3	1	1
61193	1707	IRBP	[IRBP]	0.2	1	2	0	0
61194	1707	process;	[process;]	0.2	1	2	0	0
61195	1707	regimens.	[regimens.]	0.2	1	2	0	0
61196	1707	tr55	[TR55]	0.2	1	3	3	3
61197	1707	Dezube	[Dezube]	0.2	1	2	0	0
61198	1707	tnfrp55	[TNFRp55]	0.2	1	3	1	1
61199	1707	exocytosis	[exocytosis]	0.2	1	2	0	0
61200	1707	infant	[infant]	0.2	1	3	3	3
61201	1707	HsN3	[HsN3]	0.2	1	2	0	0
61202	1707	pos-1	[POS-1]	0.2	1	3	2	2
61203	1707	25(oh)d3	[25(OH)D3]	0.2	1	3	1	1
61204	1707	couple	[couple]	0.2	1	3	3	3
61205	1707	simplex	[simplex]	0.2	1	3	3	3
61206	1707	caii	[CAII]	0.2	1	3	1	1
61207	1707	self-antigen	[self-antigen]	0.2	1	3	2	2
61208	1707	SLAP-130	[SLAP-130]	0.2	1	2	0	0
61209	1707	newborn	[newborn]	0.2	1	3	2	2
61210	1707	cooperativity,	[cooperativity,]	0.2	1	2	0	0
61211	1707	motif.	[motif.]	0.2	1	2	0	0
61212	1707	cd26	[CD26]	0.2	1	3	1	1
61213	1707	cd3-	[CD3-]	0.2	1	2	0	0
61214	1707	-gene	[-gene]	0.2	1	3	3	3
61215	1707	cd4-	[CD4-]	0.2	1	3	1	1
61216	1707	cd56	[CD56]	0.2	1	3	1	1
61217	1707	subtotal	[subtotal]	0.2	1	2	0	0
61218	1707	macrophage-CSF	[macrophage-CSF]	0.2	1	3	3	3
61219	1707	apoplexy	[apoplexy]	0.2	1	2	0	0
61220	1707	ccl4	[CCl4]	0.2	1	3	1	1
61221	1707	inv(16)(p13;q22)	[Inv(16)(p13;q22)]	0.2	1	2	0	0
61222	1707	STP-C488	[STP-C488]	0.2	1	2	0	0
61223	1707	anion	[anion]	0.2	1	3	2	2
61224	1707	vesicle	[vesicle]	0.2	1	3	2	2
61225	1707	92-kDa	[92-kDa]	0.2	1	2	0	0
61226	1707	ap-1-	[AP-1-]	0.2	1	3	1	1
61227	1707	ap-1,	[AP-1,]	0.2	1	2	0	0
61228	1707	e(2)	[E(2)]	0.2	1	3	1	1
61229	1707	esterase	[esterase]	0.2	1	3	3	3
61230	1707	monochloramine	[Monochloramine]	0.2	1	3	2	2
61231	1707	pouhd	[POUHD]	0.2	1	3	1	1
61232	1707	(ltr)	[(LTR)]	0.2	1	3	3	3
61233	1707	role,	[role,]	0.2	1	3	3	3
61234	1707	M-CRF	[M-CRF]	0.2	1	2	0	0
61235	1707	okt8+	[OKT8+]	0.2	1	2	0	0
61236	1707	ctll-r8	[CTLL-R8]	0.2	1	2	0	0
61237	1707	wbFos	[wbFos]	0.2	1	2	0	0
61238	1707	fmol/million	[fmol/million]	0.2	1	3	2	2
61239	1707	scavenging	[scavenging]	0.2	1	3	2	2
61240	1707	transactivation,	[transactivation,]	0.2	1	2	0	0
61241	1707	hypercortisolaemia	[hypercortisolaemia]	0.2	1	2	0	0
61242	1707	cho-cd14	[CHO-CD14]	0.2	1	3	2	2
61243	1707	lacz	[lacZ]	0.2	1	4	2	1
61244	1707	pathogenesis.	[pathogenesis.]	0.2	1	3	1	1
61245	1707	caprine	[caprine]	0.2	1	2	0	0
61246	1707	induce	[inducing]	0.2	1	3	2	2
61247	1707	accounting	[accounting]	0.2	1	3	2	2
61248	1707	erythroid,	[erythroid,]	0.2	1	2	0	0
61249	1707	fibre	[fibre]	0.2	1	2	0	0
61250	1707	alphaiibbeta3	[alphaIIbbeta3]	0.2	1	3	2	2
61251	1707	p50/rela	[p50/RelA]	0.2	1	2	0	0
61252	1707	anti-estrogen	[anti-estrogen]	0.2	1	3	1	1
61253	1707	ZRE-B	[ZRE-B]	0.2	1	2	0	0
61254	1707	-signaling	[-signaling]	0.2	1	3	3	3
61255	1707	fluoroquinolone	[fluoroquinolone]	0.2	1	2	0	0
61256	1707	tetrahydrobiopterin	[tetrahydrobiopterin]	0.2	1	3	1	1
61257	1707	pgd41	[pGD41]	0.2	1	2	0	0
61258	1707	regions,	[regions,]	0.2	1	2	0	0
61259	1707	MYH11	[MYH11]	0.2	1	3	1	1
61260	1707	passage	[passage]	0.2	1	3	2	2
61261	1707	SIVmac239	[SIVmac239]	0.2	1	3	1	1
61262	1707	micrograms/ml	[micrograms/ml]	0.2	1	3	3	3
61263	1707	field	[field]	0.2	1	3	2	2
61264	1707	bja-b	[BJA-B]	0.2	1	2	0	0
61265	1707	cirrhosis	[cirrhosis]	0.2	1	3	2	2
61266	1707	oca-b	[OCA-B]	0.2	1	2	0	0
61267	1707	8-bromo-cAMP	[8-bromo-cAMP]	0.2	1	2	0	0
61268	1707	obstacle	[obstacle]	0.2	1	3	3	3
61269	1707	prognosis.	[prognosis.]	0.2	1	3	1	1
61270	1707	prognosis,	[prognosis,]	0.2	1	3	3	3
61271	1707	sex-determine	[sex-determining]	0.2	1	2	0	0
61272	1707	clusters.	[clusters.]	0.2	1	2	0	0
61273	1707	m-tat/epo	[M-TAT/EPO]	0.2	1	2	0	0
61274	1707	(1-231)-mediated	[(1-231)-mediated]	0.2	1	3	2	2
61275	1707	PU-SF	[PU-SF]	0.2	1	3	1	1
61276	1707	consideration	[consideration]	0.2	1	3	3	3
61277	1707	evasion	[evasion]	0.2	1	3	3	3
61278	1707	p3hr-1	[P3HR-1]	0.2	1	2	0	0
61279	1707	3'-utr	[3'-UTR]	0.2	1	3	2	2
61280	1707	quiescence	[quiescence]	0.2	1	2	0	0
61281	1707	p50-nf-kappa	[p50-NF-kappa]	0.2	1	2	0	0
61282	1707	ALAS	[ALAS]	0.2	1	3	1	1
61283	1707	instance	[instance]	0.2	1	3	3	3
61284	1707	(about	[(about]	0.2	1	2	0	0
61285	1707	crel	[cRel]	0.2	1	2	0	0
61286	1707	cref	[CREF]	0.2	1	3	2	2
61287	1707	fractionation	[fractionation]	0.2	1	3	3	3
61288	1707	micromol/L;	[micromol/L;]	0.2	1	3	3	3
61289	1707	micromol/L,	[micromol/L,]	0.2	1	3	2	2
61290	1707	Class	[Class]	0.2	1	4	4	2
61291	1707	iu/ml),	[IU/mL),]	0.2	1	2	0	0
61292	1707	SDS-polyacrylamide	[SDS-polyacrylamide]	0.2	1	3	1	1
61293	1707	hypercortisolism	[hypercortisolism]	0.2	1	3	2	2
61294	1707	legionella	[Legionella]	0.2	1	2	0	0
61295	1707	cpkc-betaii	[cPKC-betaII]	0.2	1	2	0	0
61296	1707	adult.	[adult.]	0.2	1	2	0	0
61297	1707	(signal	[(signal]	0.2	1	3	3	3
61298	1707	SD),	[SD),]	0.2	1	2	0	0
61299	1707	GIG10	[GIG10]	0.2	1	2	0	0
61300	1707	NK-kappa	[NK-kappa]	0.2	1	3	2	2
61301	1707	pseudomonas	[Pseudomonas]	0.2	1	2	0	0
61302	1707	plc-gamma1	[PLC-gamma1]	0.2	1	2	0	0
61303	1707	splenocyte	[splenocyte]	0.2	1	3	2	2
61304	1707	paradigm	[paradigm]	0.2	1	3	3	3
61305	1707	look	[Looking]	0.2	1	3	3	3
61306	1707	HUMARA	[HUMARA]	0.2	1	2	0	0
61307	1707	compound,	[compound,]	0.2	1	2	0	0
61308	1707	erythroid/megakaryocytic	[erythroid/megakaryocytic]	0.2	1	2	0	0
61309	1707	Interleukin-1	[Interleukin-1]	0.2	1	3	1	1
61310	1707	Interleukin-7	[Interleukin-7]	0.2	1	3	1	1
61311	1707	Interleukin-5	[Interleukin-5]	0.2	1	4	4	2
61312	1707	disorder.	[disorder.]	0.2	1	2	0	0
61313	1707	Il-2	[Il-2]	0.2	1	3	2	2
61314	1707	MnlI-AluI	[MnlI-AluI]	0.2	1	3	1	1
61315	1707	phosphorylated,	[phosphorylated,]	0.2	1	2	0	0
61316	1707	Ig/EBP-1	[Ig/EBP-1]	0.2	1	2	0	0
61317	1707	leukemic	[leukemic]	0.2	1	3	1	1
61318	1707	restimulation	[restimulation]	0.2	1	3	3	3
61319	1707	proto-enhancer	[proto-enhancer]	0.2	1	3	1	1
61320	1707	ocim1	[OCIM1]	0.2	1	3	2	2
61321	1707	JNK1	[JNK1]	0.2	1	2	0	0
61322	1707	SHP1	[SHP1]	0.2	1	3	1	1
61323	1707	Interferon-alpha	[Interferon-alpha]	0.2	1	3	2	2
61324	1707	placentae	[placentae]	0.2	1	2	0	0
61325	1707	XSCID	[XSCID]	0.2	1	2	0	0
61326	1707	alpha-interferon	[alpha-interferon]	0.2	1	3	1	1
61327	1707	zymosan	[zymosan]	0.2	1	3	1	1
61328	1707	surrogate	[surrogate]	0.2	1	3	1	1
61329	1707	front	[front]	0.2	1	4	4	2
61330	1707	elf-2b	[elf-2b]	0.2	1	2	0	0
61331	1707	elf-2a	[elf-2a]	0.2	1	2	0	0
61332	1707	/cd3	[/CD3]	0.2	1	3	2	2
61333	1707	cdr2-loop	[CDR2-loop]	0.2	1	2	0	0
61334	1707	macrophages.	[macrophages.]	0.2	1	3	2	2
61335	1707	coincident	[coincident]	0.2	1	3	2	2
61336	1707	lysine	[lysine]	0.2	1	2	0	0
61337	1707	m2-type	[M2-type]	0.2	1	2	0	0
61338	1707	impdh	[IMPDH]	0.2	1	2	0	0
61339	1707	oligo	[oligo]	0.2	1	3	1	1
61340	1707	lipocalin	[lipocalin]	0.2	1	3	3	3
61341	1707	ligands.	[ligands.]	0.2	1	3	2	2
61342	1707	ligands,	[ligands,]	0.2	1	3	2	2
61343	1707	mut-i	[mut-I]	0.2	1	3	1	1
61344	1707	TNFR:Fc	[TNFR:Fc]	0.2	1	2	0	0
61345	1707	tumor.	[tumor.]	0.2	1	3	1	1
61346	1707	association.	[association.]	0.2	1	2	0	0
61347	1707	enzyme.	[enzyme.]	0.2	1	3	2	2
61348	1707	conjugation	[conjugation]	0.2	1	3	2	2
61349	1707	cell-cell	[cell-cell]	0.2	1	3	2	2
61350	1707	mutant.	[mutant.]	0.2	1	2	0	0
61351	1707	TGF-beta1	[TGF-beta1]	0.2	1	2	0	0
61352	1707	CCAAT/enhancer	[CCAAT/enhancer]	0.2	1	3	2	2
61353	1707	32dc13	[32Dc13]	0.2	1	3	1	1
61354	1707	return	[return]	0.2	1	4	2	1
61355	1707	cyclooxygenase	[cyclooxygenase]	0.2	1	2	0	0
61356	1707	resynthesis	[resynthesis]	0.2	1	2	0	0
61357	1707	endonuclease	[endonuclease]	0.2	1	3	1	1
61358	1707	protein-tyrosine	[protein-tyrosine]	0.2	1	3	1	1
61359	1707	RpoN	[RpoN]	0.2	1	2	0	0
61360	1707	jagged1	[jagged1]	0.2	1	3	3	3
61361	1707	g0s24	[G0S24]	0.2	1	2	0	0
61362	1707	tissue.	[tissue.]	0.2	1	2	0	0
61363	1707	myb:maf	[Myb:Maf]	0.2	1	2	0	0
61364	1707	LAZ3/BCL6	[LAZ3/BCL6]	0.2	1	3	1	1
61365	1707	dep-	[DEP-]	0.2	1	4	2	1
61366	1707	store	[stores]	0.2	1	3	3	3
61367	1707	doxorubicin	[doxorubicin]	0.2	1	3	1	1
61368	1707	xenopus	[Xenopus]	0.2	1	3	1	1
61369	1707	cytoskeleton	[cytoskeleton]	0.2	1	3	3	3
61370	1707	mb-1	[mb-1]	0.2	1	3	1	1
61371	1707	t(x;14)	[t(X;14)]	0.2	1	3	1	1
61372	1707	amebiasis	[amebiasis]	0.2	1	2	0	0
61373	1707	thiamine	[thiamine]	0.2	1	3	1	1
61374	1707	SP1/Egr-1	[SP1/Egr-1]	0.2	1	2	0	0
61375	1707	man.	[man.]	0.2	1	2	0	0
61376	1707	granuloma	[granuloma]	0.2	1	3	2	2
61377	1707	configuration	[configuration]	0.2	1	3	3	3
61378	1707	dhea	[DHEA]	0.2	1	3	1	1
61379	1707	dl343	[dl343]	0.2	1	2	0	0
61380	1707	pcdd/pcdf	[PCDD/PCDF]	0.2	1	2	0	0
61381	1707	C-terminus	[C-terminus]	0.2	1	2	0	0
61382	1707	U-373	[U-373]	0.2	1	2	0	0
61383	1707	additive	[additive]	0.2	1	2	0	0
61384	1707	mcm6	[MCM6]	0.2	1	4	2	1
61385	1707	(ec50	[(EC50]	0.2	1	2	0	0
61386	1707	January	[January]	0.2	1	3	3	3
61387	1707	(il-6)	[(IL-6)]	0.2	1	3	3	3
61388	1707	50-kda	[50-kDa]	0.2	1	3	2	2
61389	1707	xeroderma	[xeroderma]	0.2	1	3	1	1
61390	1707	pkc-alpha	[PKC-alpha]	0.2	1	3	2	2
61391	1707	icr27tk.3	[ICR27TK.3]	0.2	1	3	1	1
61392	1707	"fetal"	["fetal"]	0.2	1	2	0	0
61393	1707	population.	[population.]	0.2	1	3	1	1
61394	1707	sjogrens'	[Sjogrens']	0.2	1	2	0	0
61395	1707	Reed-Sternberg	[Reed-Sternberg]	0.2	1	3	2	2
61396	1707	Survanta	[Survanta]	0.2	1	3	1	1
61397	1707	product,	[product,]	0.2	1	2	0	0
61398	1707	75-kDa	[75-kDa]	0.2	1	2	0	0
61399	1707	kit225	[Kit225]	0.2	1	2	0	0
61400	1707	band-shift	[band-shift]	0.2	1	3	1	1
61401	1707	rbtn-2	[RBTN-2]	0.2	1	3	1	1
61402	1707	proliferate.	[proliferate.]	0.2	1	2	0	0
61403	1707	perforin	[perforin]	0.2	1	2	0	0
61404	1707	dna-	[DNA-]	0.2	1	2	0	0
61405	1707	dp-1	[DP-1]	0.2	1	2	0	0
61406	1707	kasumi-1	[Kasumi-1]	0.2	1	2	0	0
61407	1707	18C7	[18C7]	0.2	1	2	0	0
61408	1707	equilibrium	[equilibrium]	0.2	1	2	0	0
61409	1707	-zeta	[-zeta]	0.2	1	3	1	1
61410	1707	vcam	[VCAM]	0.2	1	3	1	1
61411	1707	colostrum	[colostrum]	0.2	1	2	0	0
61412	1707	dq0302	[DQ0302]	0.2	1	3	2	2
61413	1707	corticotropin	[corticotropin]	0.2	1	2	0	0
61414	1707	lysozyme	[lysozyme]	0.2	1	3	1	1
61415	1707	pd98059	[PD98059]	0.2	1	3	3	3
61416	1707	BLR1	[BLR1]	0.2	1	3	1	1
61417	1707	dqa1	[DQA1]	0.2	1	2	0	0
61418	1707	pre-treatment	[pre-treatment]	0.2	1	3	3	3
61419	1707	unknown.	[unknown.]	0.2	1	2	0	0
61420	1707	mediate	[mediating]	0.2	1	3	2	2
61421	1707	investigator	[investigators]	0.2	1	3	2	2
61422	1707	microtitre	[microtitre]	0.2	1	2	0	0
61423	1707	NF-kappaB-	[NF-kappaB-]	0.2	1	3	1	1
61424	1707	NF-kappaB1	[NF-kappaB1]	0.2	1	3	1	1
61425	1707	TCRalpha	[TCRalpha]	0.2	1	2	0	0
61426	1707	A1-VDR	[A1-VDR]	0.2	1	2	0	0
61427	1707	BOX1	[BOX1]	0.2	1	3	1	1
61428	1707	mo7e	[MO7e]	0.2	1	3	2	2
61429	1707	Sc-I	[Sc-I]	0.2	1	2	0	0
61430	1707	ca(2+)-atpase	[Ca(2+)-ATPase]	0.2	1	3	2	2
61431	1707	UCSD-AML1	[UCSD-AML1]	0.2	1	2	0	0
61432	1707	camp-response	[cAMP-response]	0.2	1	2	0	0
61433	1707	surface.	[surface.]	0.2	1	3	2	2
61434	1707	life,	[life,]	0.2	1	2	0	0
61435	1707	27-kda	[27-kDa]	0.2	1	3	1	1
61436	1707	lifer	[livers]	0.2	1	3	2	2
61437	1707	autosome	[autosome]	0.2	1	3	2	2
61438	1707	donors,	[donors,]	0.2	1	2	0	0
61439	1707	downmodulation	[downmodulation]	0.2	1	3	2	2
61440	1707	hairy	[hairy]	0.2	1	2	0	0
61441	1707	dutp	[dUTP]	0.2	1	2	0	0
61442	1707	slide	[slide]	0.2	1	3	1	1
61443	1707	TES1	[TES1]	0.2	1	3	2	2
61444	1707	TES2	[TES2]	0.2	1	2	0	0
61445	1707	homocysteine	[homocysteine]	0.2	1	2	0	0
61446	1707	SIVmac	[SIVmac]	0.2	1	2	0	0
61447	1707	AML-1B	[AML-1B]	0.2	1	2	0	0
61448	1707	mpro	[MPRO]	0.2	1	3	1	1
61449	1707	N-acetyl-cysteine	[N-acetyl-cysteine]	0.2	1	2	0	0
61450	1707	il-2-r	[IL-2-R]	0.2	1	2	0	0
61451	1707	cho/cd14	[CHO/CD14]	0.2	1	2	0	0
61452	1707	ms-2	[MS-2]	0.2	1	3	1	1
61453	1707	aml1/mds1/evi1	[AML1/MDS1/EVI1]	0.2	1	3	2	2
61454	1707	island	[island]	0.2	1	3	3	3
61455	1707	inducers,	[inducers,]	0.2	1	3	1	1
61456	1707	Arnt	[Arnt]	0.2	1	2	0	0
61457	1707	mt-i	[MT-I]	0.2	1	2	0	0
61458	1707	go-6976	[Go-6976]	0.2	1	2	0	0
61459	1707	C5b6	[C5b6]	0.2	1	2	0	0
61460	1707	serum-free	[serum-free]	0.2	1	3	1	1
61461	1707	mycotoxin	[mycotoxins]	0.2	1	2	0	0
61462	1707	Ile50	[Ile50]	0.2	1	2	0	0
61463	1707	mu/l	[mU/L]	0.2	1	3	3	3
61464	1707	SDS-PAGE	[SDS-PAGE]	0.2	1	3	2	2
61465	1707	kappab3	[kappaB3]	0.2	1	2	0	0
61466	1707	Stat3beta	[Stat3beta]	0.2	1	2	0	0
61467	1707	mv).	[mV).]	0.2	1	2	0	0
61468	1707	forms,	[forms,]	0.2	1	2	0	0
61469	1707	prediction	[prediction]	0.2	1	3	2	2
61470	1707	AuTG	[AuTG]	0.2	1	3	1	1
61471	1707	serotonin	[serotonin]	0.2	1	2	0	0
61472	1707	L243	[L243]	0.2	1	2	0	0
61473	1707	AU-DD	[AU-DD]	0.2	1	2	0	0
61474	1707	HSF2-beta	[HSF2-beta]	0.2	1	2	0	0
61475	1707	saturate	[saturating]	0.2	1	2	0	0
61476	1707	combination.	[combination.]	0.2	1	2	0	0
61477	1707	mue3	[muE3]	0.2	1	2	0	0
61478	1707	phytohaemagglutinin	[phytohaemagglutinin]	0.2	1	3	1	1
61479	1707	12-o-tetradecanoyl	[12-O-tetradecanoyl]	0.2	1	3	2	2
61480	1707	carborane	[carborane]	0.2	1	2	0	0
61481	1707	x2bp	[X2BP]	0.2	1	2	0	0
61482	1707	problem,	[problem,]	0.2	1	2	0	0
61483	1707	zk161422	[ZK161422]	0.2	1	3	2	2
61484	1707	nf-il-6	[NF-IL-6]	0.2	1	3	1	1
61485	1707	cd3/cd28	[CD3/CD28]	0.2	1	2	0	0
61486	1707	pressure-stretch	[pressure-stretching]	0.2	1	2	0	0
61487	1707	ea-d	[EA-D]	0.2	1	3	2	2
61488	1707	5-fold	[5-fold]	0.2	1	2	0	0
61489	1707	BZLF	[BZLF]	0.2	1	3	1	1
61490	1707	isoform,	[isoform,]	0.2	1	3	1	1
61491	1707	TNF-	[TNF-]	0.2	1	2	0	0
61492	1707	reagent	[reagents]	0.2	1	3	3	3
61493	1707	promoter-enhancer	[promoter-enhancer]	0.2	1	3	2	2
61494	1707	filament	[filament]	0.2	1	3	2	2
61495	1707	context.	[context.]	0.2	1	2	0	0
61496	1707	(with	[(with]	0.2	1	3	1	1
61497	1707	type,	[type,]	0.2	1	3	3	3
61498	1707	myf3	[myf3]	0.2	1	2	0	0
61499	1707	emanate	[emanating]	0.2	1	3	2	2
61500	1707	hyperplasia	[hyperplasia]	0.2	1	3	3	3
61501	1707	fluorescent	[fluorescent]	0.2	1	2	0	0
61502	1707	retrodifferentiation	[retrodifferentiation]	0.2	1	2	0	0
61503	1707	Edelta	[Edelta]	0.2	1	3	1	1
61504	1707	module	[module]	0.2	1	3	3	3
61505	1707	S-X-Y	[S-X-Y]	0.2	1	2	0	0
61506	1707	medium.	[medium.]	0.2	1	3	1	1
61507	1707	ebs1	[EBS1]	0.2	1	2	0	0
61508	1707	Sos2	[Sos2]	0.2	1	2	0	0
61509	1707	TREp	[TREp]	0.2	1	3	1	1
61510	1707	plb-iiib	[PLB-IIIB]	0.2	1	2	0	0
61511	1707	myelodysplasia	[myelodysplasia]	0.2	1	2	0	0
61512	1707	survey	[survey]	0.2	1	4	4	2
61513	1707	determine	[determining]	0.2	1	3	1	1
61514	1707	mip-1beta	[MIP-1beta]	0.2	1	2	0	0
61515	1707	these	[theses]	0.2	1	2	0	0
61516	1707	CAAX	[CAAX]	0.2	1	2	0	0
61517	1707	thiazolidinedion	[thiazolidinediones]	0.2	1	2	0	0
61518	1707	apo-1	[APO-1]	0.2	1	2	0	0
61519	1707	compete	[competing]	0.2	1	3	1	1
61520	1707	efcs	[(FCS+)]	0.2	1	3	2	2
61521	1707	deviation	[deviation]	0.2	1	3	3	3
61522	1707	mef2c	[MEF2C]	0.2	1	3	3	3
61523	1707	CArG	[CArG]	0.2	1	2	0	0
61524	1707	intervention	[intervention]	0.2	1	3	3	3
61525	1707	egfr	[EGFR]	0.2	1	3	1	1
61526	1707	egr1	[EGR1]	0.2	1	4	2	1
61527	1707	nail	[nail]	0.2	1	2	0	0
61528	1707	CD4+	[CD4+]	0.2	1	2	0	0
61529	1707	CD36	[CD36]	0.2	1	3	1	1
61530	1707	CD34	[CD34]	0.2	1	3	1	1
61531	1707	egta	[EGTA]	0.2	1	3	2	2
61532	1707	name	[name]	0.2	1	3	1	1
61533	1707	CD48	[CD48]	0.2	1	3	2	2
61534	1707	CD69	[CD69]	0.2	1	2	0	0
61535	1707	CD86	[CD86]	0.2	1	2	0	0
61536	1707	CD95	[CD95]	0.2	1	3	2	2
61537	1707	sulfhydryl	[sulfhydryl]	0.2	1	3	1	1
61538	1707	TDAG51	[TDAG51]	0.2	1	2	0	0
61539	1707	human,	[human,]	0.2	1	3	1	1
61540	1707	1,25(OH)2D3	[1,25(OH)2D3]	0.2	1	2	0	0
61541	1707	leukocyte-platelet	[leukocyte-platelet]	0.2	1	5	3	1
61542	1707	namely,	[namely,]	0.2	1	2	0	0
61543	1707	mitochondria	[mitochondria]	0.2	1	2	0	0
61544	1707	signaling,	[signaling,]	0.2	1	2	0	0
61545	1707	diapedesis	[diapedesis]	0.2	1	3	1	1
61546	1707	EBNA1	[EBNA1]	0.2	1	2	0	0
61547	1707	sialyltransferase	[sialyltransferase]	0.2	1	3	3	3
61548	1707	fragmentation	[fragmentation]	0.2	1	3	1	1
61549	1707	hl-60r	[HL-60R]	0.2	1	3	1	1
61550	1707	neck	[neck]	0.2	1	2	0	0
61551	1707	CYP1A1	[CYP1A1]	0.2	1	3	1	1
61552	1707	LBF7	[LBF7]	0.2	1	2	0	0
61553	1707	LBF4	[LBF4]	0.2	1	2	0	0
61554	1707	suggestion	[suggestion]	0.2	1	3	2	2
61555	1707	transfection.	[transfection.]	0.2	1	3	1	1
61556	1707	factor-	[factor-]	0.2	1	3	3	3
61557	1707	MRP14	[MRP14]	0.2	1	2	0	0
61558	1707	emcv	[EMCV]	0.2	1	3	1	1
61559	1707	21-bp	[21-bp]	0.2	1	2	0	0
61560	1707	mense	[menses]	0.2	1	3	3	3
61561	1707	RFLAT-1	[RFLAT-1]	0.2	1	3	2	2
61562	1707	carboxy	[carboxy]	0.2	1	3	2	2
61563	1707	these,	[these,]	0.2	1	2	0	0
61564	1707	way,	[way,]	0.2	1	3	1	1
61565	1707	g2/m	[G2/M]	0.2	1	2	0	0
61566	1707	v-(d)-j	[V-(D)-J]	0.2	1	2	0	0
61567	1707	(memory)	[(memory)]	0.2	1	3	2	2
61568	1707	enhancer.	[enhancer.]	0.2	1	2	0	0
61569	1707	fkhrl1	[fkhrl1]	0.2	1	3	2	2
61570	1707	-alpha	[-alpha]	0.2	1	3	2	2
61571	1707	Kcat	[Kcat]	0.2	1	2	0	0
61572	1707	G0S24	[G0S24]	0.2	1	2	0	0
61573	1707	difficulty	[difficulty]	0.2	1	3	2	2
61574	1707	limitation	[limitation]	0.2	1	3	1	1
61575	1707	hbcl6	[hBCL6]	0.2	1	2	0	0
61576	1707	colony-forming	[colony-forming]	0.2	1	2	0	0
61577	1707	dimaprit	[dimaprit]	0.2	1	2	0	0
61578	1707	nm),	[nM),]	0.2	1	3	2	2
61579	1707	UAS3	[UAS3]	0.2	1	2	0	0
61580	1707	UAS2	[UAS2]	0.2	1	3	1	1
61581	1707	UAS1	[UAS1]	0.2	1	3	2	2
61582	1707	pim-1	[pim-1]	0.2	1	4	2	1
61583	1707	soluble	[Soluble]	0.2	1	3	3	3
61584	1707	caenorhabditis	[Caenorhabditis]	0.2	1	3	1	1
61585	1707	repeats,	[repeats,]	0.2	1	2	0	0
61586	1707	COOH	[COOH]	0.2	1	2	0	0
61587	1707	COS7	[COS7]	0.2	1	2	0	0
61588	1707	nmol	[nmol]	0.2	1	3	3	3
61589	1707	leukaemogenesis	[leukaemogenesis]	0.2	1	2	0	0
61590	1707	(and	[(and]	0.2	1	3	1	1
61591	1707	USF/c-Myc	[USF/c-Myc]	0.2	1	3	1	1
61592	1707	mBob1	[mBob1]	0.2	1	2	0	0
61593	1707	TaqI	[TaqI]	0.2	1	3	1	1
61594	1707	Lyonization	[Lyonization]	0.2	1	2	0	0
61595	1707	Ribophorin	[Ribophorin]	0.2	1	2	0	0
61596	1707	sites/cell),	[sites/cell),]	0.2	1	2	0	0
61597	1707	mnp-1	[MNP-1]	0.2	1	3	1	1
61598	1707	NF-Y-	[NF-Y-]	0.2	1	2	0	0
61599	1707	NF-YA	[NF-YA]	0.2	1	3	1	1
61600	1707	NF-X2	[NF-X2]	0.2	1	3	1	1
61601	1707	communication,	[communication,]	0.2	1	2	0	0
61602	1707	metal	[metal]	0.2	1	2	0	0
61603	1707	splenomegaly	[splenomegaly]	0.2	1	2	0	0
61604	1707	grip-1	[GRIP-1]	0.2	1	2	0	0
61605	1707	blocking	[blocking]	0.2	1	3	1	1
61606	1707	METHOD:	[METHOD:]	0.2	1	3	1	1
61607	1707	thus,	[thus,]	0.2	1	3	1	1
61608	1707	Fra-1	[Fra-1]	0.2	1	3	1	1
61609	1707	140-kDa	[140-kDa]	0.2	1	2	0	0
61610	1707	kappaB-	[kappaB-]	0.2	1	3	1	1
61611	1707	(er)	[(ER)]	0.2	1	3	2	2
61612	1707	CTCF	[CTCF]	0.2	1	3	1	1
61613	1707	CCK-8	[CCK-8]	0.2	1	2	0	0
61614	1707	nt3r	[NT3R]	0.2	1	3	1	1
61615	1707	p65-	[p65-]	0.2	1	2	0	0
61616	1707	vicinity	[vicinity]	0.2	1	2	0	0
61617	1707	il-1rii	[IL-1RII]	0.2	1	3	2	2
61618	1707	operate	[operating]	0.2	1	3	2	2
61619	1707	hGATA-3	[hGATA-3]	0.2	1	3	1	1
61620	1707	triplex	[triplex]	0.2	1	3	3	3
61621	1707	processing.	[processing.]	0.2	1	2	0	0
61622	1707	signal-transduce	[signal-transducing]	0.2	1	3	1	1
61623	1707	fibrogenesis	[fibrogenesis]	0.2	1	2	0	0
61624	1707	Ro-VDR	[Ro-VDR]	0.2	1	3	1	1
61625	1707	16-bp	[16-bp]	0.2	1	2	0	0
61626	1707	nf-kappab/ntat	[NF-kappaB/NFAT]	0.2	1	3	1	1
61627	1707	nude	[nude]	0.2	1	2	0	0
61628	1707	(ii)	[(ii)]	0.2	1	3	3	3
61629	1707	y315	[Y315]	0.2	1	2	0	0
61630	1707	y319	[Y319]	0.2	1	2	0	0
61631	1707	beta-interferon	[beta-interferon]	0.2	1	2	0	0
61632	1707	alignment	[alignment]	0.2	1	3	3	3
61633	1707	pancreatitis	[pancreatitis]	0.2	1	3	2	2
61634	1707	responses,	[responses,]	0.2	1	2	0	0
61635	1707	phospholipid	[phospholipid]	0.2	1	3	2	2
61636	1707	vitellogenin	[vitellogenin]	0.2	1	3	1	1
61637	1707	purpose:	[PURPOSE:]	0.2	1	2	0	0
61638	1707	hyaluronic	[hyaluronic]	0.2	1	2	0	0
61639	1707	amino-	[amino-]	0.2	1	3	3	3
61640	1707	mechanism,	[mechanism,]	0.2	1	3	3	3
61641	1707	alpha-granule	[alpha-granules]	0.2	1	2	0	0
61642	1707	StatG	[StatG]	0.2	1	2	0	0
61643	1707	Canventol	[Canventol]	0.2	1	2	0	0
61644	1707	E220K	[E220K]	0.2	1	2	0	0
61645	1707	HOX11	[HOX11]	0.2	1	2	0	0
61646	1707	nf-at-1	[NF-AT-1]	0.2	1	3	2	2
61647	1707	LysoPC	[LysoPC]	0.2	1	2	0	0
61648	1707	aberrancy	[aberrancies]	0.2	1	4	4	2
61649	1707	Oct-2b	[Oct-2B]	0.2	1	2	0	0
61650	1707	fadd	[FADD]	0.2	1	2	0	0
61651	1707	c-Fos/c-Jun	[c-Fos/c-Jun]	0.2	1	2	0	0
61652	1707	myeloproliferative	[myeloproliferative]	0.2	1	2	0	0
61653	1707	fk-506	[FK-506]	0.2	1	3	1	1
61654	1707	deficiency-heat	[deficiency-heat]	0.2	1	2	0	0
61655	1707	c-raf-1	[c-Raf-1]	0.2	1	2	0	0
61656	1707	glycerol	[glycerol]	0.2	1	2	0	0
61657	1707	vasculopathy	[vasculopathy]	0.2	1	3	1	1
61658	1707	pac-1	[PAC-1]	0.2	1	2	0	0
61659	1707	laboratory,	[laboratory,]	0.2	1	2	0	0
61660	1707	homing	[homing]	0.2	1	3	3	3
61661	1707	lectins	[lectins]	0.2	1	4	2	1
61662	1707	metastasis	[metastasis]	0.2	1	3	1	1
61663	1707	character	[character]	0.2	1	3	3	3
61664	1707	fev1	[FEV1]	0.2	1	3	1	1
61665	1707	CBP/p300	[CBP/p300]	0.2	1	2	0	0
61666	1707	variants.	[variants.]	0.2	1	2	0	0
61667	1707	in-vitro	[in-vitro]	0.2	1	2	0	0
61668	1707	IL-2/	[IL-2/]	0.2	1	2	0	0
61669	1707	IL-6-	[IL-6-]	0.2	1	2	0	0
61670	1707	bursa	[bursa]	0.2	1	3	2	2
61671	1707	subgroup.	[subgroup.]	0.2	1	2	0	0
61672	1707	(tf)	[(TF)]	0.2	1	3	3	3
61673	1707	(the	[(the]	0.2	1	3	2	2
61674	1707	(two	[(two]	0.2	1	3	1	1
61675	1707	Similarly,	[Similarly,]	0.2	1	3	3	3
61676	1707	chick	[chick]	0.2	1	2	0	0
61677	1707	DCoH	[DCoH]	0.2	1	3	1	1
61678	1707	myricetin	[myricetin]	0.2	1	3	1	1
61679	1707	[3h]1,25(oh)2d3	[[3H]1,25(OH)2D3]	0.2	1	2	0	0
61680	1707	basophilia	[basophilia]	0.2	1	3	1	1
61681	1707	traf6	[TRAF6]	0.2	1	3	3	3
61682	1707	pathogenicity	[pathogenicity]	0.2	1	3	2	2
61683	1707	E(2)	[E(2)]	0.2	1	2	0	0
61684	1707	conalbumin	[conalbumin]	0.2	1	2	0	0
61685	1707	analogy	[analogy]	0.2	1	2	0	0
61686	1707	-luciferase	[-luciferase]	0.2	1	3	1	1
61687	1707	ecto-5'-NT	[ecto-5'-NT]	0.2	1	2	0	0
61688	1707	regulator,	[regulator,]	0.2	1	3	2	2
61689	1707	compounds,	[compounds,]	0.2	1	3	3	3
61690	1707	NFATx	[NFATx]	0.2	1	3	2	2
61691	1707	trifluoromethylketones	[Trifluoromethylketones]	0.2	1	2	0	0
61692	1707	lt-293	[LT-293]	0.2	1	3	1	1
61693	1708	F	[F]	0.15000000000000002	1	3	3	2
61694	1708	average	[average]	0.15000000000000002	1	3	3	2
61695	1708	PMLRAR	[PMLRAR]	0.15000000000000002	1	3	3	2
61696	1708	glycophorin	[glycophorin]	0.15000000000000002	1	3	3	2
61697	1708	under-representation	[under-representation]	0.15000000000000002	1	3	3	2
61698	1708	lactone	[lactones]	0.15000000000000002	1	3	3	2
61699	1708	phosphatidyl	[phosphatidyl]	0.15000000000000002	1	3	3	2
61700	1708	MoAb	[MoAb]	0.15000000000000002	1	3	3	2
61701	1708	histolytica	[histolytica]	0.15000000000000002	1	3	3	2
61702	1708	/nf-kappa	[/NF-kappa]	0.15000000000000002	1	3	3	2
61703	1708	19K	[19K]	0.15000000000000002	1	3	3	2
61704	1708	convergence	[convergence]	0.15000000000000002	1	3	3	2
61705	1708	x2-box	[X2-box]	0.15000000000000002	1	3	3	2
61706	1708	microM),	[microM),]	0.15000000000000002	1	3	3	2
61707	1708	down-modulation	[down-modulation]	0.15000000000000002	1	3	3	2
61708	1708	beas-2b	[BEAS-2B]	0.15000000000000002	1	3	3	2
61709	1708	ec-mn	[EC-Mn]	0.15000000000000002	1	3	3	2
61710	1708	B-1	[B-1]	0.15000000000000002	1	3	3	2
61711	1708	quantitation	[Quantitation]	0.15000000000000002	1	3	3	2
61712	1708	neutrophils.	[neutrophils.]	0.15000000000000002	1	3	3	2
61713	1708	kit/il-4r	[kit/IL-4R]	0.15000000000000002	1	3	3	2
61714	1708	volunteers.	[volunteers.]	0.15000000000000002	1	3	3	2
61715	1708	attenuation	[Attenuation]	0.15000000000000002	1	3	3	2
61716	1708	ires	[IRES]	0.15000000000000002	1	3	3	2
61717	1708	adp	[ADP]	0.15000000000000002	1	3	3	2
61718	1708	dna	[DNAs]	0.15000000000000002	1	3	3	2
61719	1708	ems	[EMS]	0.15000000000000002	1	3	3	2
61720	1708	h),	[h),]	0.15000000000000002	1	3	3	2
61721	1708	phi	[phi]	0.15000000000000002	1	3	3	2
61722	1708	(bal)	[(BAL)]	0.15000000000000002	1	3	3	2
61723	1708	retardation	[retardation]	0.15000000000000002	1	3	3	2
61724	1708	Cooperation	[Cooperation]	0.15000000000000002	1	3	3	2
61725	1708	p70(S6)-kinase	[p70(S6)-kinase]	0.15000000000000002	1	3	3	2
61726	1708	ontogeny	[ontogeny]	0.15000000000000002	1	3	3	2
61727	1708	processes,	[processes,]	0.15000000000000002	1	3	3	2
61728	1708	tnfr	[TNFR]	0.15000000000000002	1	3	3	2
61729	1708	cocultivation	[cocultivation]	0.15000000000000002	1	3	3	2
61730	1708	clustering	[clustering]	0.15000000000000002	1	3	3	2
61731	1708	co-treatment	[Co-treatment]	0.15000000000000002	1	3	3	2
61732	1708	lytic	[lytic]	0.15000000000000002	1	3	3	2
61733	1708	polyacrylamide	[polyacrylamide]	0.15000000000000002	1	3	3	2
61734	1708	Interleukin-3	[Interleukin-3]	0.15000000000000002	1	3	3	2
61735	1708	/stat5	[/STAT5]	0.15000000000000002	1	3	3	2
61736	1708	withdrawal	[withdrawal]	0.15000000000000002	1	3	3	2
61737	1708	toxin	[toxins]	0.15000000000000002	1	3	3	2
61738	1708	delta-aminolevulinate	[delta-aminolevulinate]	0.15000000000000002	1	3	3	2
61739	1708	100%	[100%]	0.15000000000000002	1	3	3	2
61740	1708	mcm5	[MCM5]	0.15000000000000002	1	3	3	2
61741	1708	mono	[Mono]	0.15000000000000002	1	3	3	2
61742	1708	granulomato	[granulomatoses]	0.15000000000000002	1	3	3	2
61743	1708	Granulocyte-macrophage	[Granulocyte-macrophage]	0.15000000000000002	1	3	3	2
61744	1708	implications.	[implications.]	0.15000000000000002	1	3	3	2
61745	1708	eotaxin	[eotaxin]	0.15000000000000002	1	3	3	2
61746	1708	paraparesis	[paraparesis]	0.15000000000000002	1	3	3	2
61747	1708	(il)-1	[(IL)-1]	0.15000000000000002	1	3	3	2
61748	1708	neuron	[neurons]	0.15000000000000002	1	3	3	2
61749	1708	(il)-10	[(IL)-10]	0.15000000000000002	1	3	3	2
61750	1708	tobacco	[Tobacco]	0.15000000000000002	1	3	3	2
61751	1708	anf-e2	[aNF-E2]	0.15000000000000002	1	3	3	2
61752	1708	serotype	[serotypes]	0.15000000000000002	1	3	3	2
61753	1709	(ap)-1	[(AP)-1]	0.1	1	2	1	1
61754	1709	E	[E]	0.1	1	1	0	0
61755	1709	K	[K]	0.1	1	1	0	0
61756	1709	f	[F]	0.1	1	1	0	0
61757	1709	k	[K]	0.1	1	2	1	1
61758	1709	er-alpha	[ER-alpha]	0.1	1	1	0	0
61759	1709	fli-1	[Fli-1]	0.1	1	2	1	1
61760	1709	(3;21)(q26;q22)	[(3;21)(q26;q22)]	0.1	1	1	0	0
61761	1709	igh-enhancer	[IgH-enhancer]	0.1	1	1	0	0
61762	1709	channels.	[channels.]	0.1	1	1	0	0
61763	1709	tracer,	[tracer,]	0.1	1	1	0	0
61764	1709	HB-EGF	[HB-EGF]	0.1	1	2	2	2
61765	1709	bw5147	[BW5147]	0.1	1	1	0	0
61766	1709	dithiocarbamate	[dithiocarbamates]	0.1	1	2	2	2
61767	1709	specificities.	[specificities.]	0.1	1	2	1	1
61768	1709	specificities,	[specificities,]	0.1	1	2	2	2
61769	1709	dehydroascorbate	[dehydroascorbate]	0.1	1	1	0	0
61770	1709	5'-ggcaccctttga-3'	[5'-GGCACCCTTTGA-3']	0.1	1	1	0	0
61771	1709	(4	[(4]	0.1	1	1	0	0
61772	1709	gata-1(c)	[GATA-1(c)]	0.1	1	1	0	0
61773	1709	monensine	[monensine]	0.1	1	1	0	0
61774	1709	mg/24h;	[mg/24h;]	0.1	1	2	1	1
61775	1709	repeats).	[repeats).]	0.1	1	2	1	1
61776	1709	-66-bp	[-66-bp]	0.1	1	1	0	0
61777	1709	beta-hydroxysteroid	[beta-hydroxysteroid]	0.1	1	2	1	1
61778	1709	nm23/ndp	[nm23/NDP]	0.1	1	1	0	0
61779	1709	3B	[3B]	0.1	1	1	0	0
61780	1709	3a	[3A]	0.1	1	1	0	0
61781	1709	3c	[3C]	0.1	1	1	0	0
61782	1709	4X	[4X]	0.1	1	1	0	0
61783	1709	4c	[4C]	0.1	1	2	1	1
61784	1709	4s	[4S]	0.1	1	1	0	0
61785	1709	5x	[5X]	0.1	1	1	0	0
61786	1709	9j	[9J]	0.1	1	1	0	0
61787	1709	9s	[9S]	0.1	1	2	1	1
61788	1709	hospital,	[hospital,]	0.1	1	1	0	0
61789	1709	A.	[A.]	0.1	1	2	1	1
61790	1709	AC	[AC]	0.1	1	1	0	0
61791	1709	B-	[B-]	0.1	1	1	0	0
61792	1709	B.	[B.]	0.1	1	1	0	0
61793	1709	AS	[AS]	0.1	1	1	0	0
61794	1709	W696-bp	[3696-bp]	0.1	1	1	0	0
61795	1709	BB	[BB]	0.1	1	1	0	0
61796	1709	BK	[BK]	0.1	1	2	1	1
61797	1709	C-	[C-]	0.1	1	2	1	1
61798	1709	BM	[BM]	0.1	1	1	0	0
61799	1709	tautomycin	[tautomycin]	0.1	1	1	0	0
61800	1709	BP	[BP]	0.1	1	1	0	0
61801	1709	C1	[C1]	0.1	1	1	0	0
61802	1709	BQ	[BQ]	0.1	1	2	1	1
61803	1709	stat5a/b	[STAT5a/b]	0.1	1	1	0	0
61804	1709	C2	[C2]	0.1	1	1	0	0
61805	1709	C3	[C3]	0.1	1	2	1	1
61806	1709	CC	[CC]	0.1	1	1	0	0
61807	1709	CF	[CF]	0.1	1	1	0	0
61808	1709	antidepressant	[antidepressant]	0.1	1	2	2	2
61809	1709	immunosuppressants.	[immunosuppressants.]	0.1	1	1	0	0
61810	1709	protein-coding	[protein-coding]	0.1	1	1	0	0
61811	1709	DD	[DD]	0.1	1	2	2	2
61812	1709	DE	[DE]	0.1	1	1	0	0
61813	1709	E4	[E4]	0.1	1	1	0	0
61814	1709	DU	[DU]	0.1	1	1	0	0
61815	1709	FH	[FH]	0.1	1	2	1	1
61816	1709	FP	[FP]	0.1	1	1	0	0
61817	1709	G2	[G2]	0.1	1	1	0	0
61818	1709	GD	[GD]	0.1	1	1	0	0
61819	1709	GP	[GP]	0.1	1	2	1	1
61820	1709	H4	[H4]	0.1	1	2	1	1
61821	1709	GT	[GT]	0.1	1	3	2	1
61822	1709	H7	[H7]	0.1	1	1	0	0
61823	1709	occupation	[occupation]	0.1	1	2	2	2
61824	1709	HM	[HM]	0.1	1	1	0	0
61825	1709	IH	[IH]	0.1	1	2	2	2
61826	1709	Ib	[Ib]	0.1	1	2	2	2
61827	1709	JH	[JH]	0.1	1	1	0	0
61828	1709	JM	[JM]	0.1	1	1	0	0
61829	1709	JY	[JY]	0.1	1	1	0	0
61830	1709	L-	[L-]	0.1	1	1	0	0
61831	1709	KS	[KS]	0.1	1	1	0	0
61832	1709	CFU-GEMM/	[CFU-GEMM/]	0.1	1	1	0	0
61833	1709	Ka	[Ka]	0.1	1	1	0	0
61834	1709	Ku	[Ku]	0.1	1	2	1	1
61835	1709	La	[La]	0.1	1	1	0	0
61836	1709	MF	[MF]	0.1	1	1	0	0
61837	1709	MG	[MG]	0.1	1	2	1	1
61838	1709	MN	[MN]	0.1	1	1	0	0
61839	1709	'aged'	['aged']	0.1	1	1	0	0
61840	1709	NL	[NL]	0.1	1	2	1	1
61841	1709	Ml	[Mls]	0.1	1	1	0	0
61842	1709	Cyclin	[Cyclin]	0.1	1	2	1	1
61843	1709	calcium-mobilize	[calcium-mobilizing]	0.1	1	1	0	0
61844	1709	OP	[OP]	0.1	1	1	0	0
61845	1709	P2	[P2]	0.1	1	1	0	0
61846	1709	P8	[P8]	0.1	1	1	0	0
61847	1709	13-myristate	[13-myristate]	0.1	1	1	0	0
61848	1709	PA	[PA]	0.1	1	1	0	0
61849	1709	PB	[PB]	0.1	1	1	0	0
61850	1709	rhythmicity	[rhythmicity]	0.1	1	2	1	1
61851	1709	R-	[R-]	0.1	1	1	0	0
61852	1709	R.	[R.]	0.1	1	1	0	0
61853	1709	RJ	[RJ]	0.1	1	2	1	1
61854	1709	RO	[RO]	0.1	1	1	0	0
61855	1709	S2	[S2]	0.1	1	1	0	0
61856	1709	RT	[RT]	0.1	1	1	0	0
61857	1709	SB	[SB]	0.1	1	2	2	2
61858	1709	T,	[T,]	0.1	1	1	0	0
61859	1709	SS	[SS]	0.1	1	2	1	1
61860	1709	Dihuang	[Dihuang]	0.1	1	1	0	0
61861	1709	TH	[TH]	0.1	1	1	0	0
61862	1709	TR	[TR]	0.1	1	2	2	2
61863	1709	U5	[U5]	0.1	1	1	0	0
61864	1709	UP	[UP]	0.1	1	2	2	2
61865	1709	V3	[V3]	0.1	1	2	1	1
61866	1709	VI	[VI]	0.1	1	1	0	0
61867	1709	VR	[VR]	0.1	1	2	1	1
61868	1709	porphobilinogen	[porphobilinogen]	0.1	1	1	0	0
61869	1709	foci	[foci]	0.1	1	2	2	2
61870	1709	WY	[WY]	0.1	1	2	1	1
61871	1709	XP	[XP]	0.1	1	3	2	1
61872	1709	ZI	[ZI]	0.1	1	1	0	0
61873	1709	95-bp	[95-bp]	0.1	1	1	0	0
61874	1709	proIL-1	[proIL-1]	0.1	1	1	0	0
61875	1709	a)	[A)]	0.1	1	2	1	1
61876	1709	b3	[B3]	0.1	1	1	0	0
61877	1709	b4	[B4]	0.1	1	2	1	1
61878	1709	c,	[C,]	0.1	1	2	1	1
61879	1709	c3	[C3]	0.1	1	2	1	1
61880	1709	c7	[C7]	0.1	1	2	1	1
61881	1709	bb	[Bb]	0.1	1	2	1	1
61882	1709	d1	[D1]	0.1	1	1	0	0
61883	1709	br	[BRs]	0.1	1	2	1	1
61884	1709	cb	[CB]	0.1	1	2	2	2
61885	1709	cl	[CL]	0.1	1	2	1	1
61886	1709	cm	[CM]	0.1	1	2	1	1
61887	1709	e3	[E3]	0.1	1	2	1	1
61888	1709	e4	[E4]	0.1	1	1	0	0
61889	1709	ct	[CT]	0.1	1	2	1	1
61890	1709	dd	[Dd]	0.1	1	1	0	0
61891	1709	de	[DE]	0.1	1	1	0	0
61892	1709	ea	[EA]	0.1	1	1	0	0
61893	1709	ep	[Ep]	0.1	1	2	2	2
61894	1709	g3	[G3]	0.1	1	1	0	0
61895	1709	secretory/transport	[secretory/transport]	0.1	1	1	0	0
61896	1709	h-	[H-]	0.1	1	1	0	0
61897	1709	gb	[gB]	0.1	1	2	1	1
61898	1709	Lck-	[Lck-]	0.1	1	1	0	0
61899	1709	gi	[Gi]	0.1	1	2	1	1
61900	1709	gs	[GS]	0.1	1	2	2	2
61901	1709	MEK2	[MEK2]	0.1	1	1	0	0
61902	1709	ib	[Ib]	0.1	1	3	2	1
61903	1709	ic	[IC]	0.1	1	1	0	0
61904	1709	ix	[IX]	0.1	1	1	0	0
61905	1709	m4	[M4]	0.1	1	1	0	0
61906	1709	Caspase	[Caspase]	0.1	1	1	0	0
61907	1709	n-	[N-]	0.1	1	2	1	1
61908	1709	lp	[lp]	0.1	1	1	0	0
61909	1709	mw	[MW]	0.1	1	1	0	0
61910	1709	mz	[MZ]	0.1	1	1	0	0
61911	1709	ne	[NE]	0.1	1	2	1	1
61912	1709	p5	[P5]	0.1	1	2	1	1
61913	1709	p6	[P6]	0.1	1	1	0	0
61914	1709	p9	[P9]	0.1	1	1	0	0
61915	1709	ps	[PS]	0.1	1	1	0	0
61916	1709	s)	[s)]	0.1	1	1	0	0
61917	1709	rd	[RD]	0.1	1	1	0	0
61918	1709	t)	[T)]	0.1	1	1	0	0
61919	1709	rj	[RJ]	0.1	1	1	0	0
61920	1709	t,	[T,]	0.1	1	1	0	0
61921	1709	DQB-W	[DQB-W]	0.1	1	1	0	0
61922	1709	rs	[RS]	0.1	1	3	2	1
61923	1709	rt	[RT]	0.1	1	2	1	1
61924	1709	sb	[SB]	0.1	1	2	2	2
61925	1709	sf	[SFs]	0.1	1	2	2	2
61926	1709	v-	[v-]	0.1	1	1	0	0
61927	1709	tt	[TT]	0.1	1	1	0	0
61928	1709	bactericidal/permeability-increasing	[bactericidal/permeability-increasing]	0.1	1	1	0	0
61929	1709	up	[UP]	0.1	1	2	1	1
61930	1709	morphogen	[morphogen]	0.1	1	2	2	2
61931	1709	wk	[wk]	0.1	1	2	2	2
61932	1709	xi	[Xi]	0.1	1	2	2	2
61933	1709	xp	[Xp]	0.1	1	1	0	0
61934	1709	compensation	[compensation]	0.1	1	1	0	0
61935	1709	Wuchereria	[Wuchereria]	0.1	1	1	0	0
61936	1709	c57mg	[C57MG]	0.1	1	1	0	0
61937	1709	chemotherapy.	[chemotherapy.]	0.1	1	1	0	0
61938	1709	fluorouracil	[fluorouracil]	0.1	1	1	0	0
61939	1709	/ap-1	[/AP-1]	0.1	1	2	2	2
61940	1709	d20s58	[D20S58]	0.1	1	1	0	0
61941	1709	d20s56	[D20S56]	0.1	1	1	0	0
61942	1709	d20s57	[D20S57]	0.1	1	1	0	0
61943	1709	scya3r	[Scya3r]	0.1	1	1	0	0
61944	1709	bisindolylmaleimide	[bisindolylmaleimide]	0.1	1	1	0	0
61945	1709	d20s41	[D20S41]	0.1	1	1	0	0
61946	1709	d20s42	[D20S42]	0.1	1	1	0	0
61947	1709	(ap-1)	[(AP-1)]	0.1	1	2	2	2
61948	1709	H-CAM	[H-CAM]	0.1	1	1	0	0
61949	1709	diagnosis,	[diagnosis,]	0.1	1	1	0	0
61950	1709	IgH-luciferase	[IgH-luciferase]	0.1	1	1	0	0
61951	1709	d20s18	[D20S18]	0.1	1	1	0	0
61952	1709	d20s17	[D20S17]	0.1	1	1	0	0
61953	1709	rag-1	[RAG-1]	0.1	1	1	0	0
61954	1709	cd4-cd8-	[CD4-CD8-]	0.1	1	2	1	1
61955	1709	-chloramphenicol	[-chloramphenicol]	0.1	1	2	1	1
61956	1709	overview,	[overview,]	0.1	1	1	0	0
61957	1709	Kit225	[Kit225]	0.1	1	1	0	0
61958	1709	CD3/TCR	[CD3/TCR]	0.1	1	1	0	0
61959	1709	m1-cat	[M1-CAT]	0.1	1	1	0	0
61960	1709	Zif-268	[Zif-268]	0.1	1	1	0	0
61961	1709	dynes/cm2).	[dynes/cm2).]	0.1	1	1	0	0
61962	1709	schizosaccharome	[Schizosaccharomyces]	0.1	1	2	1	1
61963	1709	hla-c	[HLA-C]	0.1	1	1	0	0
61964	1709	integrin-containing	[integrin-containing]	0.1	1	1	0	0
61965	1709	5'-monophosphate	[5'-monophosphate]	0.1	1	1	0	0
61966	1709	neoglucogenesis	[neoglucogenesis]	0.1	1	1	0	0
61967	1709	adults.	[adults.]	0.1	1	3	2	1
61968	1709	puzzle	[puzzle]	0.1	1	2	2	2
61969	1709	x-thr-pro	[X-Thr-Pro]	0.1	1	1	0	0
61970	1709	VASP	[VASP]	0.1	1	1	0	0
61971	1709	HuT102	[HuT102]	0.1	1	1	0	0
61972	1709	old)	[old)]	0.1	1	1	0	0
61973	1709	sensorgram	[sensorgrams]	0.1	1	1	0	0
61974	1709	(-445/-366)	[(-445/-366)]	0.1	1	1	0	0
61975	1709	hemopoiesis,	[hemopoiesis,]	0.1	1	1	0	0
61976	1709	repression.	[repression.]	0.1	1	2	1	1
61977	1709	BEAS-2B	[BEAS-2B]	0.1	1	1	0	0
61978	1709	Alagille	[Alagille]	0.1	1	2	1	1
61979	1709	past,	[past,]	0.1	1	1	0	0
61980	1709	DHL-9	[DHL-9]	0.1	1	1	0	0
61981	1709	adapter	[adapter]	0.1	1	2	1	1
61982	1709	(evi1)	[(EVI1)]	0.1	1	1	0	0
61983	1709	AML-1	[AML-1]	0.1	1	1	0	0
61984	1709	(b-cll)	[(B-CLL)]	0.1	1	2	1	1
61985	1709	)/mac-1	[)/MAC-1]	0.1	1	1	0	0
61986	1709	ggggactttccg	[GGGGACTTTCCG]	0.1	1	1	0	0
61987	1709	Y-box	[Y-box]	0.1	1	2	1	1
61988	1709	signal.	[signal.]	0.1	1	1	0	0
61989	1709	ras(g12v)	[Ras(G12V)]	0.1	1	1	0	0
61990	1709	DP-1	[DP-1]	0.1	1	1	0	0
61991	1709	reality,	[reality,]	0.1	1	1	0	0
61992	1709	VCAM	[VCAM]	0.1	1	1	0	0
61993	1709	NF.kappa	[NF.kappa]	0.1	1	2	1	1
61994	1709	1alpha,25(oh)2-lumisterol3	[1alpha,25(OH)2-lumisterol3]	0.1	1	1	0	0
61995	1709	MIP1	[MIP1]	0.1	1	1	0	0
61996	1709	view.	[view.]	0.1	1	1	0	0
61997	1709	molt4	[MOLT4]	0.1	1	2	2	2
61998	1709	polymorphonuclear	[polymorphonuclear]	0.1	1	1	0	0
61999	1709	c-Rel/	[c-Rel/]	0.1	1	2	2	2
62000	1709	E1A-	[E1A-]	0.1	1	1	0	0
62001	1709	PMLRARalpha	[PMLRARalpha]	0.1	1	1	0	0
62002	1709	-cd25+,	[-CD25+,]	0.1	1	1	0	0
62003	1709	microsequence	[microsequence]	0.1	1	1	0	0
62004	1709	c-Rel-	[c-Rel-]	0.1	1	1	0	0
62005	1709	Fr35-II	[Fr35-II]	0.1	1	1	0	0
62006	1709	E2F-4	[E2F-4]	0.1	1	1	0	0
62007	1709	E2F-I	[E2F-I]	0.1	1	1	0	0
62008	1709	ciglitazone	[ciglitazone]	0.1	1	1	0	0
62009	1709	stringency	[stringency]	0.1	1	2	2	2
62010	1709	Erbstatin	[Erbstatin]	0.1	1	1	0	0
62011	1709	cd28rc	[CD28RC]	0.1	1	2	1	1
62012	1709	16HBE	[16HBE]	0.1	1	1	0	0
62013	1709	/c-Jun	[/c-Jun]	0.1	1	2	2	2
62014	1709	r7-57	[R7-57]	0.1	1	1	0	0
62015	1709	cyp1a1	[CYP1A1]	0.1	1	2	1	1
62016	1709	DQB1	[DQB1]	0.1	1	1	0	0
62017	1709	DQA1	[DQA1]	0.1	1	2	2	2
62018	1709	Dexter-type	[Dexter-type]	0.1	1	1	0	0
62019	1709	E2F4	[E2F4]	0.1	1	1	0	0
62020	1709	p90(rsk)	[p90(rsk)]	0.1	1	2	1	1
62021	1709	aminolaevulinic	[aminolaevulinic]	0.1	1	1	0	0
62022	1709	(i.e.	[(i.e.]	0.1	1	2	1	1
62023	1709	Dopamine	[Dopamine]	0.1	1	1	0	0
62024	1709	iu/ml)	[IU/mL)]	0.1	1	1	0	0
62025	1709	iu/ml.	[IU/mL.]	0.1	1	1	0	0
62026	1709	hygromycin	[hygromycin]	0.1	1	2	1	1
62027	1709	fura	[FUra]	0.1	1	1	0	0
62028	1709	MKK4	[MKK4]	0.1	1	1	0	0
62029	1709	myelin	[myelin]	0.1	1	1	0	0
62030	1709	orphan	[orphan]	0.1	1	4	3	1
62031	1709	importance.	[importance.]	0.1	1	2	1	1
62032	1709	E2RE	[E2RE]	0.1	1	1	0	0
62033	1709	ML-1	[ML-1]	0.1	1	1	0	0
62034	1709	[3h]dexamethasone	[[3H]dexamethasone]	0.1	1	3	2	1
62035	1709	19-noraldosterone	[19-noraldosterone]	0.1	1	1	0	0
62036	1709	z-29	[Z-29]	0.1	1	1	0	0
62037	1709	viability,	[viability,]	0.1	1	2	1	1
62038	1709	alteration.	[alteration.]	0.1	1	1	0	0
62039	1709	IVS1-10TC	[IVS1-10TC]	0.1	1	1	0	0
62040	1709	titre	[titre]	0.1	1	2	1	1
62041	1709	hAEC.	[hAEC.]	0.1	1	1	0	0
62042	1709	receptor-containing	[receptor-containing]	0.1	1	1	0	0
62043	1709	orientations.	[orientations.]	0.1	1	1	0	0
62044	1709	aggregation.	[aggregation.]	0.1	1	1	0	0
62045	1709	MLL/	[MLL/]	0.1	1	1	0	0
62046	1709	extract,	[extract,]	0.1	1	2	1	1
62047	1709	IFN-gammaR	[IFN-gammaR]	0.1	1	2	2	2
62048	1709	concentrations;	[concentrations;]	0.1	1	2	2	2
62049	1709	cd4(-)cd8(-)	[CD4(-)CD8(-)]	0.1	1	4	3	1
62050	1709	HTLV-I(+)	[HTLV-I(+)]	0.1	1	1	0	0
62051	1709	Ras-Raf-1-MAP	[Ras-Raf-1-MAP]	0.1	1	1	0	0
62052	1709	vitronectin	[vitronectin]	0.1	1	1	0	0
62053	1709	Hungary.	[Hungary.]	0.1	1	1	0	0
62054	1709	Hungary,	[Hungary,]	0.1	1	1	0	0
62055	1709	ara-c	[Ara-C]	0.1	1	2	1	1
62056	1709	runoff	[runoff]	0.1	1	1	0	0
62057	1709	(Kruskal-Wallis)	[(Kruskal-Wallis)]	0.1	1	1	0	0
62058	1709	times.	[times.]	0.1	1	2	2	2
62059	1709	(pha-	[(PHA-]	0.1	1	1	0	0
62060	1709	flt-3	[flt-3]	0.1	1	2	1	1
62061	1709	purity	[purity]	0.1	1	2	1	1
62062	1709	meta(p)	[META(P)]	0.1	1	1	0	0
62063	1709	MMP9	[MMP9]	0.1	1	1	0	0
62064	1709	p55tnf-r	[p55TNF-R]	0.1	1	1	0	0
62065	1709	STAT-3	[STAT-3]	0.1	1	1	0	0
62066	1709	STAT-6	[STAT-6]	0.1	1	2	1	1
62067	1709	3-o-mg	[3-O-MG]	0.1	1	2	1	1
62068	1709	Kennedy'	[Kennedy's]	0.1	1	1	0	0
62069	1709	ionophore.	[ionophore.]	0.1	1	1	0	0
62070	1709	pedigree.	[pedigree.]	0.1	1	1	0	0
62071	1709	STAT1-	[STAT1-]	0.1	1	1	0	0
62072	1709	pax-5e	[Pax-5e]	0.1	1	1	0	0
62073	1709	pax-5a	[Pax-5a]	0.1	1	1	0	0
62074	1709	pax-5b	[Pax-5b]	0.1	1	1	0	0
62075	1709	orf2	[ORF2]	0.1	1	2	1	1
62076	1709	syndecan-1	[syndecan-1]	0.1	1	1	0	0
62077	1709	CrmA	[CrmA]	0.1	1	1	0	0
62078	1709	encephalomyocarditis	[Encephalomyocarditis]	0.1	1	2	1	1
62079	1709	pax-2	[Pax-2]	0.1	1	2	2	2
62080	1709	rflat-1	[RFLAT-1]	0.1	1	1	0	0
62081	1709	fluids.	[fluids.]	0.1	1	1	0	0
62082	1709	surrogate"	[surrogate"]	0.1	1	1	0	0
62083	1709	proto-oncoprotein	[proto-oncoprotein]	0.1	1	2	2	2
62084	1709	MODY	[MODY]	0.1	1	1	0	0
62085	1709	S.D.Hayward,	[S.D.Hayward,]	0.1	1	1	0	0
62086	1709	MOPC	[MOPC]	0.1	1	2	1	1
62087	1709	serum-response	[serum-response]	0.1	1	1	0	0
62088	1709	jcam1	[JCaM1]	0.1	1	2	1	1
62089	1709	'stressful'	['stressful']	0.1	1	1	0	0
62090	1709	encounter	[encounter]	0.1	1	2	2	2
62091	1709	parameters,	[parameters,]	0.1	1	2	1	1
62092	1709	kda/65	[kDa/65]	0.1	1	1	0	0
62093	1709	alpha-tubulin	[alpha-tubulin]	0.1	1	1	0	0
62094	1709	infectivity,	[infectivity,]	0.1	1	1	0	0
62095	1709	tuberculin	[tuberculin]	0.1	1	1	0	0
62096	1709	otf1	[OTF1]	0.1	1	2	1	1
62097	1709	p50/p65-	[p50/p65-]	0.1	1	1	0	0
62098	1709	cloned,	[cloned,]	0.1	1	2	1	1
62099	1709	BcLF1	[BcLF1]	0.1	1	1	0	0
62100	1709	(EML)	[(EML)]	0.1	1	1	0	0
62101	1709	P56lck	[p56lck]	0.1	1	1	0	0
62102	1709	MPRO	[MPRO]	0.1	1	1	0	0
62103	1709	fmol/mg).	[fmol/mg).]	0.1	1	1	0	0
62104	1709	5'-end	[5'-end]	0.1	1	2	1	1
62105	1709	mip-1beta,	[MIP-1beta,]	0.1	1	1	0	0
62106	1709	-bear	[-bearing]	0.1	1	2	1	1
62107	1709	gh/prl-	[GH/PRL-]	0.1	1	1	0	0
62108	1709	bcl-x(l)	[Bcl-x(L)]	0.1	1	2	1	1
62109	1709	(primary	[(primary]	0.1	1	1	0	0
62110	1709	monoblastoid	[monoblastoid]	0.1	1	1	0	0
62111	1709	immunoreactivity,	[immunoreactivity,]	0.1	1	1	0	0
62112	1709	isopropylidine	[isopropylidine]	0.1	1	1	0	0
62113	1709	mapped.	[mapped.]	0.1	1	2	1	1
62114	1709	favour	[favour]	0.1	1	1	0	0
62115	1709	YT-N17	[YT-N17]	0.1	1	2	1	1
62116	1709	(pll)	[(PLL)]	0.1	1	1	0	0
62117	1709	FasL-	[FasL-]	0.1	1	1	0	0
62118	1709	FasL.	[FasL.]	0.1	1	1	0	0
62119	1709	Qi-invigorating	[Qi-invigorating]	0.1	1	1	0	0
62120	1709	cd45r0+	[CD45R0+]	0.1	1	1	0	0
62121	1709	xq28	[Xq28]	0.1	1	1	0	0
62122	1709	phenylalanine	[phenylalanine]	0.1	1	2	1	1
62123	1709	proteic	[proteic]	0.1	1	1	0	0
62124	1709	organization,	[organization,]	0.1	1	1	0	0
62125	1709	la(ssb)	[La(SSB)]	0.1	1	1	0	0
62126	1709	qil-2re	[mIL-2rE]	0.1	1	1	0	0
62127	1709	protect	[protecting]	0.1	1	2	1	1
62128	1709	RRLPIF	[RRLPIF]	0.1	1	1	0	0
62129	1709	rap30	[RAP30]	0.1	1	1	0	0
62130	1709	-oestrogen	[-oestrogen]	0.1	1	2	1	1
62131	1709	histogenesis	[histogenesis]	0.1	1	4	3	1
62132	1709	rap74	[RAP74]	0.1	1	1	0	0
62133	1709	cd45ro+	[CD45RO+]	0.1	1	2	2	2
62134	1709	exposure,	[exposure,]	0.1	1	1	0	0
62135	1709	microgram	[micrograms]	0.1	1	2	2	2
62136	1709	depth.	[depth.]	0.1	1	1	0	0
62137	1709	promoter-	[promoter-]	0.1	1	2	1	1
62138	1709	MS-2	[MS-2]	0.1	1	1	0	0
62139	1709	treponema	[Treponema]	0.1	1	2	1	1
62140	1709	Dimethyldithiocarbamate	[Dimethyldithiocarbamate]	0.1	1	1	0	0
62141	1709	reactivation.	[reactivation.]	0.1	1	1	0	0
62142	1709	reactivation,	[reactivation,]	0.1	1	1	0	0
62143	1709	cem-3r43	[CEM-3R43]	0.1	1	1	0	0
62144	1709	DNA-PK(CS)	[DNA-PK(CS)]	0.1	1	2	1	1
62145	1709	element/	[element/]	0.1	1	1	0	0
62146	1709	cd45ra+	[CD45RA+]	0.1	1	2	1	1
62147	1709	NFKB2(p49/p52)	[NFKB2(p49/p52)]	0.1	1	1	0	0
62148	1709	connect	[connecting]	0.1	1	1	0	0
62149	1709	382/ec1	[382/EC1]	0.1	1	1	0	0
62150	1709	sertraline	[sertraline]	0.1	1	2	2	2
62151	1709	F774L	[F774L]	0.1	1	1	0	0
62152	1709	own,	[own,]	0.1	1	1	0	0
62153	1709	own.	[own.]	0.1	1	2	1	1
62154	1709	oft-2	[OFT-2]	0.1	1	1	0	0
62155	1709	cytochemistry	[cytochemistry]	0.1	1	1	0	0
62156	1709	83-kDa	[83-kDa]	0.1	1	1	0	0
62157	1709	cytofluorometry	[cytofluorometry]	0.1	1	1	0	0
62158	1709	BRLF1/BZLF1	[BRLF1/BZLF1]	0.1	1	1	0	0
62159	1709	wet-to-dry	[wet-to-dry]	0.1	1	1	0	0
62160	1709	isoforms.	[isoforms.]	0.1	1	2	1	1
62161	1709	division.	[division.]	0.1	1	1	0	0
62162	1709	area.	[area.]	0.1	1	2	1	1
62163	1709	cd4+/cd45ro	[CD4+/CD45RO]	0.1	1	1	0	0
62164	1709	dmdtc	[DMDTC]	0.1	1	2	2	2
62165	1709	ghf-1	[GHF-1]	0.1	1	1	0	0
62166	1709	MTS1	[MTS1]	0.1	1	1	0	0
62167	1709	Irish/German	[Irish/German]	0.1	1	1	0	0
62168	1709	rhtnf-alpha	[rhTNF-alpha]	0.1	1	1	0	0
62169	1709	extrauterine	[extrauterine]	0.1	1	1	0	0
62170	1709	phagocyte/neutrophil	[phagocyte/neutrophil]	0.1	1	1	0	0
62171	1709	B)/Rel	[B)/Rel]	0.1	1	1	0	0
62172	1709	carcinogenesis.	[carcinogenesis.]	0.1	1	1	0	0
62173	1709	spleen.	[spleen.]	0.1	1	1	0	0
62174	1709	stimulus.	[stimulus.]	0.1	1	1	0	0
62175	1709	Zfp36	[Zfp36]	0.1	1	1	0	0
62176	1709	rights	[Rights]	0.1	1	1	0	0
62177	1709	ML-1a	[ML-1a]	0.1	1	2	1	1
62178	1709	E3330	[E3330]	0.1	1	1	0	0
62179	1709	properties.	[properties.]	0.1	1	2	2	2
62180	1709	prickle	[prickle]	0.1	1	1	0	0
62181	1709	lineage-determinetermining	[lineage-determining]	0.1	1	1	0	0
62182	1709	gain	[gain]	0.1	1	2	2	2
62183	1709	distinction	[distinction]	0.1	1	2	1	1
62184	1709	actions,	[actions,]	0.1	1	2	2	2
62185	1709	actions.	[actions.]	0.1	1	1	0	0
62186	1709	Culture	[Culture]	0.1	1	2	2	2
62187	1709	hypercholesteremia	[hypercholesteremia]	0.1	1	1	0	0
62188	1709	Gy/min	[Gy/min]	0.1	1	1	0	0
62189	1709	chemr1	[CHEMR1]	0.1	1	1	0	0
62190	1709	pharmacology]	[pharmacology]]	0.1	1	1	0	0
62191	1709	atopic	[atopic]	0.1	1	2	1	1
62192	1709	/sra1	[/SRA1]	0.1	1	1	0	0
62193	1709	Indeed,	[Indeed,]	0.1	1	2	2	2
62194	1709	Tpp17	[Tpp17]	0.1	1	1	0	0
62195	1709	modulating	[modulating]	0.1	1	1	0	0
62196	1709	Disease	[Disease]	0.1	1	2	2	2
62197	1709	aims:	[AIMS:]	0.1	1	1	0	0
62198	1709	acid-response	[acid-response]	0.1	1	1	0	0
62199	1709	tethering	[tethering]	0.1	1	2	2	2
62200	1709	Lung	[Lung]	0.1	1	2	2	2
62201	1709	complex).	[complex).]	0.1	1	1	0	0
62202	1709	25-hydroxyvitamin	[25-hydroxyvitamin]	0.1	1	3	2	1
62203	1709	3,4-dichloroisocoumarin	[3,4-dichloroisocoumarin]	0.1	1	1	0	0
62204	1709	STAT5B	[STAT5B]	0.1	1	1	0	0
62205	1709	(camp)-dependent	[(cAMP)-dependent]	0.1	1	1	0	0
62206	1709	gcii	[GCII]	0.1	1	2	1	1
62207	1709	Triptolide	[Triptolide]	0.1	1	1	0	0
62208	1709	anti-cd	[anti-CD4]	0.1	1	2	1	1
62209	1709	ebna2-ebna6	[EBNA2-EBNA6]	0.1	1	1	0	0
62210	1709	lymphoid/	[lymphoid/]	0.1	1	1	0	0
62211	1709	esters.	[esters.]	0.1	1	1	0	0
62212	1709	counteract	[counteracting]	0.1	1	1	0	0
62213	1709	Interferon-beta	[Interferon-beta]	0.1	1	1	0	0
62214	1709	constitutive,	[constitutive,]	0.1	1	2	1	1
62215	1709	noncode	[noncoding]	0.1	1	2	1	1
62216	1709	(obese	[(obese]	0.1	1	1	0	0
62217	1709	TCRhigh	[TCRhigh]	0.1	1	2	1	1
62218	1709	alpha,alpha'-dipyridyl	[alpha,alpha'-dipyridyl]	0.1	1	1	0	0
62219	1709	g-csf-r	[G-CSF-R]	0.1	1	2	1	1
62220	1709	independence	[independence]	0.1	1	2	2	2
62221	1709	anti-Fc	[anti-Fc]	0.1	1	1	0	0
62222	1709	ICRF-193	[ICRF-193]	0.1	1	1	0	0
62223	1709	gf-1	[GF-1]	0.1	1	1	0	0
62224	1709	anti-STAT	[anti-STAT]	0.1	1	1	0	0
62225	1709	inducibility/cell	[inducibility/cell]	0.1	1	1	0	0
62226	1709	arise	[arising]	0.1	1	2	2	2
62227	1709	pp70(s6k)	[pp70(s6k)]	0.1	1	1	0	0
62228	1709	rats.	[rats.]	0.1	1	1	0	0
62229	1709	dibenzo-p-dioxin	[dibenzo-p-dioxins]	0.1	1	2	1	1
62230	1709	SAP-1	[SAP-1]	0.1	1	1	0	0
62231	1709	Bcl-X(L)	[Bcl-X(L)]	0.1	1	1	0	0
62232	1709	4-bp	[4-bp]	0.1	1	1	0	0
62233	1709	autokinase	[autokinase]	0.1	1	1	0	0
62234	1709	nonactivate	[nonactivating]	0.1	1	1	0	0
62235	1709	menstrual	[menstrual]	0.1	1	2	1	1
62236	1709	Tyr477	[Tyr477]	0.1	1	1	0	0
62237	1709	investigation,	[investigation,]	0.1	1	2	1	1
62238	1709	investigation.	[investigation.]	0.1	1	2	2	2
62239	1709	Genbank	[Genbank]	0.1	1	1	0	0
62240	1709	obesity.	[obesity.]	0.1	1	1	0	0
62241	1709	architecture	[architecture]	0.1	1	2	2	2
62242	1709	C57BL/10	[C57BL/10]	0.1	1	1	0	0
62243	1709	afternoon	[Afternoon]	0.1	1	2	1	1
62244	1709	interruption	[interruption]	0.1	1	2	2	2
62245	1709	viruses,	[viruses,]	0.1	1	2	1	1
62246	1709	mg-132	[MG-132]	0.1	1	2	2	2
62247	1709	433-442a	[433-442A]	0.1	1	1	0	0
62248	1709	nm23h2	[Nm23H2]	0.1	1	1	0	0
62249	1709	reporter.	[reporter.]	0.1	1	1	0	0
62250	1709	oncogenicity	[Oncogenicity]	0.1	1	2	2	2
62251	1709	gh-n	[GH-N]	0.1	1	1	0	0
62252	1709	Tyr396	[Tyr396]	0.1	1	1	0	0
62253	1709	tal1-	[TAL1-]	0.1	1	1	0	0
62254	1709	seminoma	[seminoma]	0.1	1	2	1	1
62255	1709	ICP36	[ICP36]	0.1	1	1	0	0
62256	1709	vivo:	[vivo:]	0.1	1	1	0	0
62257	1709	microE5/kappa	[microE5/kappa]	0.1	1	2	1	1
62258	1709	EBV-	[EBV-]	0.1	1	1	0	0
62259	1709	Can/Nup214.	[Can/Nup214.]	0.1	1	1	0	0
62260	1709	CTLL-2	[CTLL-2]	0.1	1	2	2	2
62261	1709	Lyme	[Lyme]	0.1	1	1	0	0
62262	1709	beta-methyl	[beta-methyl]	0.1	1	1	0	0
62263	1709	staurosporin,	[staurosporin,]	0.1	1	1	0	0
62264	1709	deoxyribonuclease	[deoxyribonuclease]	0.1	1	2	2	2
62265	1709	bacterial	[bacterial]	0.1	1	1	0	0
62266	1709	iexl320g	[IEXL320G]	0.1	1	1	0	0
62267	1709	flagellum	[flagellum]	0.1	1	2	1	1
62268	1709	sexes.	[sexes.]	0.1	1	1	0	0
62269	1709	arnhl	[ARNHL]	0.1	1	2	1	1
62270	1709	at2.5	[AT2.5]	0.1	1	1	0	0
62271	1709	goiter	[goiter]	0.1	1	2	1	1
62272	1709	PtdIns	[PtdIns]	0.1	1	1	0	0
62273	1709	BRL49653	[BRL49653]	0.1	1	2	1	1
62274	1709	Wingless/Wnt	[Wingless/Wnt]	0.1	1	1	0	0
62275	1709	pain	[pain]	0.1	1	1	0	0
62276	1709	cd34+thy-1-cd45ra-	[CD34+Thy-1-CD45RA-]	0.1	1	1	0	0
62277	1709	ED50	[ED50]	0.1	1	1	0	0
62278	1709	pil-5(-511)luc	[pIL-5(-511)Luc]	0.1	1	1	0	0
62279	1709	mpc11	[MPC11]	0.1	1	2	1	1
62280	1709	xscid,	[XSCID,]	0.1	1	1	0	0
62281	1709	KIAA0144	[KIAA0144]	0.1	1	1	0	0
62282	1709	pax5	[Pax5]	0.1	1	1	0	0
62283	1709	/beta	[/beta]	0.1	1	2	2	2
62284	1709	SAPKs	[SAPKs]	0.1	1	1	0	0
62285	1709	protein-affinity	[protein-affinity]	0.1	1	1	0	0
62286	1709	co-transfection.	[co-transfection.]	0.1	1	1	0	0
62287	1709	(sscp)	[(SSCP)]	0.1	1	2	2	2
62288	1709	[vol/vol])	[[vol/vol])]	0.1	1	1	0	0
62289	1709	Arg271Trp	[Arg271Trp]	0.1	1	1	0	0
62290	1709	anhydrase	[anhydrase]	0.1	1	1	0	0
62291	1709	hla-a2+,	[HLA-A2+,]	0.1	1	1	0	0
62292	1709	p300/cbp-type	[p300/CBP-type]	0.1	1	1	0	0
62293	1709	HLA-DRbeta	[HLA-DRbeta]	0.1	1	1	0	0
62294	1709	repeat-chloramphenicol	[repeat-chloramphenicol]	0.1	1	1	0	0
62295	1709	appear	[appearing]	0.1	1	2	2	2
62296	1709	megakaryoblastic	[megakaryoblastic]	0.1	1	2	2	2
62297	1709	constitutive	[constitutive]	0.1	1	1	0	0
62298	1709	pbmo	[PBMo]	0.1	1	2	1	1
62299	1709	prebed	[prebed]	0.1	1	1	0	0
62300	1709	mineralization	[mineralization]	0.1	1	1	0	0
62301	1709	drand_	[DRA/DQB]	0.1	1	1	0	0
62302	1709	v-Jun	[v-Jun]	0.1	1	1	0	0
62303	1709	pbx1	[PBX1]	0.1	1	1	0	0
62304	1709	eig)-secreting	[(Ig)-secreting]	0.1	1	2	1	1
62305	1709	Bt2cAMP	[Bt2cAMP]	0.1	1	1	0	0
62306	1709	transcription-1alpha	[transcription-1alpha]	0.1	1	1	0	0
62307	1709	at464	[AT464]	0.1	1	1	0	0
62308	1709	Int-2	[Int-2]	0.1	1	1	0	0
62309	1709	microg/ml).	[microg/ml).]	0.1	1	1	0	0
62310	1709	WGATAR	[WGATAR]	0.1	1	2	1	1
62311	1709	p55tnf-r.	[p55TNF-R.]	0.1	1	1	0	0
62312	1709	thalassemias	[thalassemias]	0.1	1	1	0	0
62313	1709	exchange.	[exchange.]	0.1	1	1	0	0
62314	1709	exposures.	[exposures.]	0.1	1	2	2	2
62315	1709	stress,	[stress,]	0.1	1	1	0	0
62316	1709	stress-	[stress-]	0.1	1	1	0	0
62317	1709	stress.	[stress.]	0.1	1	2	1	1
62318	1709	cd1+relb+	[CD1+RelB+]	0.1	1	2	1	1
62319	1709	hemoglobinopathybthybinobinybinybinybinybinie	[hemoglobinopathies]	0.1	1	2	2	2
62320	1709	verprolin-homology	[verprolin-homology]	0.1	1	1	0	0
62321	1709	hla-dr+	[HLA-DR+]	0.1	1	1	0	0
62322	1709	hla-dr3	[HLA-DR3]	0.1	1	1	0	0
62323	1709	cysteine-	[cysteine-]	0.1	1	1	0	0
62324	1709	hla-dmb	[HLA-DMB]	0.1	1	1	0	0
62325	1709	electrochemistry	[electrochemistry]	0.1	1	1	0	0
62326	1709	(n-oct)	[(N-Oct)]	0.1	1	1	0	0
62327	1709	expand	[expanding]	0.1	1	2	2	2
62328	1709	AP-1/octamer	[AP-1/octamer]	0.1	1	1	0	0
62329	1709	potency.	[potency.]	0.1	1	1	0	0
62330	1709	nf-kappab/rel	[NF-kappaB/Rel]	0.1	1	1	0	0
62331	1709	abundance,	[abundance,]	0.1	1	1	0	0
62332	1709	TAP1-/-	[TAP1-/-]	0.1	1	1	0	0
62333	1709	postactivation	[postactivation]	0.1	1	1	0	0
62334	1709	PFP9a20	[PFP9a20]	0.1	1	2	1	1
62335	1709	pea3	[PEA3]	0.1	1	1	0	0
62336	1709	32Dcl3	[32Dcl3]	0.1	1	2	2	2
62337	1709	Deltorphin	[Deltorphin]	0.1	1	1	0	0
62338	1709	recurrence	[recurrence]	0.1	1	2	2	2
62339	1709	ezrin	[ezrin]	0.1	1	1	0	0
62340	1709	(+44),	[(+44),]	0.1	1	1	0	0
62341	1709	erythropoietin-	[erythropoietin-]	0.1	1	1	0	0
62342	1709	mek1s218/222a	[MEK1S218/222A]	0.1	1	1	0	0
62343	1709	A.Garzino-Demo,	[A.Garzino-Demo,]	0.1	1	1	0	0
62344	1709	RNase	[RNase]	0.1	1	2	1	1
62345	1709	mcfffas	[MCF-Fas]	0.1	1	2	2	2
62346	1709	digestion	[digestion]	0.1	1	2	2	2
62347	1709	graves'	[Graves']	0.1	1	2	1	1
62348	1709	chronicity	[chronicity]	0.1	1	1	0	0
62349	1709	60-kda	[60-kDa]	0.1	1	1	0	0
62350	1709	megakaryopoiesis	[megakaryopoiesis]	0.1	1	1	0	0
62351	1709	EGTA	[EGTA]	0.1	1	1	0	0
62352	1709	cd30+,	[CD30+,]	0.1	1	1	0	0
62353	1709	Dev.	[Dev.]	0.1	1	1	0	0
62354	1709	hla-b27	[HLA-B27]	0.1	1	1	0	0
62355	1709	method.	[method.]	0.1	1	1	0	0
62356	1709	method,	[method,]	0.1	1	1	0	0
62357	1709	injury.	[injury.]	0.1	1	1	0	0
62358	1709	contexts,	[contexts,]	0.1	1	1	0	0
62359	1709	hut78	[HUT78]	0.1	1	1	0	0
62360	1709	trolox	[trolox]	0.1	1	1	0	0
62361	1709	anion-exchange	[anion-exchange]	0.1	1	1	0	0
62362	1709	IKK-beta	[IKK-beta]	0.1	1	2	1	1
62363	1709	alpha-chemokine	[alpha-chemokine]	0.1	1	1	0	0
62364	1709	b-lymphoblastoid	[B-lymphoblastoid]	0.1	1	2	1	1
62365	1709	trans-act	[trans-acting]	0.1	1	1	0	0
62366	1709	i.p.	[i.p.]	0.1	1	1	0	0
62367	1709	markers,	[markers,]	0.1	1	2	2	2
62368	1709	Eotaxin	[Eotaxin]	0.1	1	1	0	0
62369	1709	60-kDa	[60-kDa]	0.1	1	1	0	0
62370	1709	limitations.	[limitations.]	0.1	1	2	2	2
62371	1709	autoinhibitory	[autoinhibitory]	0.1	1	2	1	1
62372	1709	rNF-IL6	[rNF-IL6]	0.1	1	1	0	0
62373	1709	eia).	[EIA).]	0.1	1	1	0	0
62374	1709	lighting	[lighting]	0.1	1	2	1	1
62375	1709	(tcr-alpha)	[(TCR-alpha)]	0.1	1	1	0	0
62376	1709	pgf2	[PGF2]	0.1	1	1	0	0
62377	1709	weakly,	[weakly,]	0.1	1	1	0	0
62378	1709	MEDLINE	[MEDLINE]	0.1	1	1	0	0
62379	1709	p24rex	[p24rex]	0.1	1	2	1	1
62380	1709	gamma-activate	[gamma-activating]	0.1	1	1	0	0
62381	1709	pi-3	[PI-3]	0.1	1	1	0	0
62382	1709	eklf-/-	[EKLF-/-]	0.1	1	1	0	0
62383	1709	SupT1	[SupT1]	0.1	1	1	0	0
62384	1709	POS-1	[POS-1]	0.1	1	1	0	0
62385	1709	ERbeta	[ERbeta]	0.1	1	2	1	1
62386	1709	IL-2mRNA	[IL-2mRNA]	0.1	1	2	1	1
62387	1709	AF-10	[AF-10]	0.1	1	1	0	0
62388	1709	akt/pkb	[Akt/PKB]	0.1	1	2	1	1
62389	1709	pha-	[PHA-]	0.1	1	1	0	0
62390	1709	pha/	[PHA/]	0.1	1	1	0	0
62391	1709	deletion.	[deletion.]	0.1	1	1	0	0
62392	1709	v-Myb	[v-Myb]	0.1	1	1	0	0
62393	1709	oligopeptide	[oligopeptides]	0.1	1	2	1	1
62394	1709	(ie62)	[(IE62)]	0.1	1	1	0	0
62395	1709	gp55	[gp55]	0.1	1	1	0	0
62396	1709	hgata-1	[hGATA-1]	0.1	1	1	0	0
62397	1709	hgata-2	[hGATA-2]	0.1	1	1	0	0
62398	1709	efficacy,	[efficacy,]	0.1	1	1	0	0
62399	1709	efficacy.	[efficacy.]	0.1	1	1	0	0
62400	1709	Spi-1/	[Spi-1/]	0.1	1	2	1	1
62401	1709	Jak-1	[Jak-1]	0.1	1	1	0	0
62402	1709	Jak-3	[Jak-3]	0.1	1	1	0	0
62403	1709	polyamide	[polyamides]	0.1	1	1	0	0
62404	1709	goat	[goat]	0.1	1	1	0	0
62405	1709	pibf	[PIBF]	0.1	1	2	1	1
62406	1709	126+/-11%,	[126+/-11%,]	0.1	1	1	0	0
62407	1709	zre-b	[ZRE-B]	0.1	1	2	2	2
62408	1709	"natural"	["natural"]	0.1	1	1	0	0
62409	1709	pili	[pili]	0.1	1	2	1	1
62410	1709	"stress"	["stress"]	0.1	1	1	0	0
62411	1709	hbmp-2	[hBMP-2]	0.1	1	1	0	0
62412	1709	c-ABL	[c-ABL]	0.1	1	1	0	0
62413	1709	aureus	[aureus]	0.1	1	2	2	2
62414	1709	ELAM	[ELAM]	0.1	1	2	1	1
62415	1709	moreover,	[moreover,]	0.1	1	2	1	1
62416	1709	VpreB	[VpreB]	0.1	1	1	0	0
62417	1709	ELF1	[ELF1]	0.1	1	1	0	0
62418	1709	ib-ix-v	[Ib-IX-V]	0.1	1	1	0	0
62419	1709	Helenalin	[Helenalin]	0.1	1	2	1	1
62420	1709	NFKB	[NFKB]	0.1	1	1	0	0
62421	1709	stresses,	[stresses,]	0.1	1	1	0	0
62422	1709	antibody.	[antibody.]	0.1	1	1	0	0
62423	1709	dna-binding/dimerization	[DNA-binding/dimerization]	0.1	1	1	0	0
62424	1709	laminar	[laminar]	0.1	1	1	0	0
62425	1709	antitumour	[antitumour]	0.1	1	1	0	0
62426	1709	subunits;	[subunits;]	0.1	1	1	0	0
62427	1709	stat1alpha	[STAT1alpha]	0.1	1	2	1	1
62428	1709	EMCV	[EMCV]	0.1	1	1	0	0
62429	1709	pkc.	[PKC.]	0.1	1	1	0	0
62430	1709	scm-1beta	[SCM-1beta]	0.1	1	1	0	0
62431	1709	(cox-2)	[(COX-2)]	0.1	1	1	0	0
62432	1709	calmette-guerin	[Calmette-Guerin]	0.1	1	2	2	2
62433	1709	preosteoclast	[preosteoclast]	0.1	1	1	0	0
62434	1709	pm).	[pM).]	0.1	1	1	0	0
62435	1709	d1/cdr2-loop	[D1/CDR2-loop]	0.1	1	1	0	0
62436	1709	taxol	[Taxol]	0.1	1	1	0	0
62437	1709	lysophospholipid	[lysophospholipid]	0.1	1	2	1	1
62438	1709	case-control	[case-control]	0.1	1	2	1	1
62439	1709	activities,	[activities,]	0.1	1	2	1	1
62440	1709	activities.	[activities.]	0.1	1	2	1	1
62441	1709	NFkB	[NFkB]	0.1	1	2	1	1
62442	1709	hT86	[hT86]	0.1	1	1	0	0
62443	1709	F.R.	[F.R.]	0.1	1	1	0	0
62444	1709	p13MTCP1	[p13MTCP1]	0.1	1	1	0	0
62445	1709	Graves'	[Graves']	0.1	1	1	0	0
62446	1709	deiodination	[deiodination]	0.1	1	1	0	0
62447	1709	Concern	[Concerning]	0.1	1	1	0	0
62448	1709	Miyatake	[Miyatake]	0.1	1	1	0	0
62449	1709	element-containing	[element-containing]	0.1	1	1	0	0
62450	1709	Phosphatidylserine	[Phosphatidylserine]	0.1	1	1	0	0
62451	1709	gata-4	[GATA-4]	0.1	1	2	1	1
62452	1709	medulla	[medulla]	0.1	1	2	1	1
62453	1709	grb2	[Grb2]	0.1	1	1	0	0
62454	1709	Hsp60	[Hsp60]	0.1	1	1	0	0
62455	1709	etoposide-	[etoposide-]	0.1	1	1	0	0
62456	1709	nfatx1	[NFATx1]	0.1	1	1	0	0
62457	1709	nfatx2	[NFATx2]	0.1	1	1	0	0
62458	1709	nfatx3	[NFATx3]	0.1	1	1	0	0
62459	1709	gram	[g]	0.1	1	2	2	2
62460	1709	sevenfold,	[sevenfold,]	0.1	1	1	0	0
62461	1709	Sephadex	[Sephadex]	0.1	1	1	0	0
62462	1709	Norepinephrine	[Norepinephrine]	0.1	1	1	0	0
62463	1709	play	[play]	0.1	1	1	0	0
62464	1709	spermatogonia	[spermatogonia]	0.1	1	1	0	0
62465	1709	days).	[days).]	0.1	1	1	0	0
62466	1709	(high	[(high]	0.1	1	2	2	2
62467	1709	p10-->r	[P10-->R]	0.1	1	2	2	2
62468	1709	blood-glucose	[blood-glucose]	0.1	1	1	0	0
62469	1709	Comparison	[Comparison]	0.1	1	18	17	1
62470	1709	alphacd28	[alphaCD28]	0.1	1	1	0	0
62471	1709	106-kDa	[106-kDa]	0.1	1	1	0	0
62472	1709	c/ebP-binding	[C/EBP-binding]	0.1	1	1	0	0
62473	1709	fibric	[fibric]	0.1	1	2	2	2
62474	1709	fibrin	[fibrin]	0.1	1	2	1	1
62475	1709	'octamer'	['octamer']	0.1	1	1	0	0
62476	1709	costimulus	[costimulus]	0.1	1	2	1	1
62477	1709	mmol/L	[mmol/L]	0.1	1	2	1	1
62478	1709	plzf	[PLZF]	0.1	1	1	0	0
62479	1709	3h-aldosterone	[3H-aldosterone]	0.1	1	1	0	0
62480	1709	pdgf-b	[PDGF-B]	0.1	1	1	0	0
62481	1709	birth,	[birth,]	0.1	1	1	0	0
62482	1709	p65-rela	[p65-RelA]	0.1	1	1	0	0
62483	1709	seborrheic	[seborrheic]	0.1	1	1	0	0
62484	1709	harbor	[harboring]	0.1	1	1	0	0
62485	1709	phorbolmyristate-acetate	[phorbolmyristate-acetate]	0.1	1	1	0	0
62486	1709	Lac-.	[Lac-.]	0.1	1	1	0	0
62487	1709	nonpeptidyl	[nonpeptidyl]	0.1	1	1	0	0
62488	1709	pml/	[pml/]	0.1	1	1	0	0
62489	1709	dqa1*0501/dqb1*0201	[DQA1*0501/DQB1*0201]	0.1	1	2	1	1
62490	1709	non-express	[non-expressing]	0.1	1	1	0	0
62491	1709	agent(s)	[agent(s)]	0.1	1	1	0	0
62492	1709	h1285	[H1285]	0.1	1	1	0	0
62493	1709	nonpregnancy	[nonpregnancy]	0.1	1	1	0	0
62494	1709	620-bp	[620-bp]	0.1	1	1	0	0
62495	1709	(tnf)-receptor	[(TNF)-receptor]	0.1	1	1	0	0
62496	1709	ingestion	[ingestion]	0.1	1	1	0	0
62497	1709	Third	[Third]	0.1	1	1	0	0
62498	1709	decay	[decay]	0.1	1	2	1	1
62499	1709	20-kda	[20-kDa]	0.1	1	1	0	0
62500	1709	Paclitaxel	[Paclitaxel]	0.1	1	1	0	0
62501	1709	immunoaffinity	[immunoaffinity]	0.1	1	1	0	0
62502	1709	Arrednf-at	[ARRE/NF-AT]	0.1	1	1	0	0
62503	1709	alpha-thrombin	[alpha-thrombin]	0.1	1	2	1	1
62504	1709	phenotypic	[phenotypic]	0.1	1	1	0	0
62505	1709	(catalytic)	[(catalytic)]	0.1	1	1	0	0
62506	1709	EPOR	[EPOR]	0.1	1	2	1	1
62507	1709	infectivity	[infectivity]	0.1	1	2	1	1
62508	1709	pp36	[pp36]	0.1	1	1	0	0
62509	1709	epithelia	[epithelia]	0.1	1	1	0	0
62510	1709	epidemic,	[epidemic,]	0.1	1	1	0	0
62511	1709	thrombopoiesis	[thrombopoiesis]	0.1	1	1	0	0
62512	1709	Hodgkin	[Hodgkin]	0.1	1	1	0	0
62513	1709	kilodaltons),	[kilodaltons),]	0.1	1	1	0	0
62514	1709	t)6gg-3'	[T)6GG-3']	0.1	1	1	0	0
62515	1709	(hlh)	[(HLH)]	0.1	1	1	0	0
62516	1709	pbsct	[PBSCT]	0.1	1	1	0	0
62517	1709	polarization	[polarization]	0.1	1	1	0	0
62518	1709	(after	[(after]	0.1	1	2	1	1
62519	1709	exophthalmo	[exophthalmos]	0.1	1	1	0	0
62520	1709	poly	[poly]	0.1	1	2	2	2
62521	1709	icenko-	[Icenko-]	0.1	1	2	2	2
62522	1709	potentiate	[potentiating]	0.1	1	1	0	0
62523	1709	MIP-1alpha	[MIP-1alpha]	0.1	1	2	1	1
62524	1709	sense,	[sense,]	0.1	1	2	2	2
62525	1709	hypocomplementemia	[hypocomplementemia]	0.1	1	1	0	0
62526	1709	concurrence	[concurrence]	0.1	1	1	0	0
62527	1709	ggaaaa	[GGAAAA]	0.1	1	1	0	0
62528	1709	Th1/Th2	[Th1/Th2]	0.1	1	1	0	0
62529	1709	Th1/Th0	[Th1/Th0]	0.1	1	1	0	0
62530	1709	syndrome,	[syndrome,]	0.1	1	1	0	0
62531	1709	EBNA-1	[EBNA-1]	0.1	1	1	0	0
62532	1709	April	[Apr]	0.1	1	2	2	2
62533	1709	sensor	[sensor]	0.1	1	2	2	2
62534	1709	point.	[point.]	0.1	1	2	1	1
62535	1709	ERG2	[ERG2]	0.1	1	1	0	0
62536	1709	bhlf1/noti	[BHLF1/NotI]	0.1	1	1	0	0
62537	1709	menadione	[menadione]	0.1	1	1	0	0
62538	1709	(hmg)	[(HMG)]	0.1	1	2	2	2
62539	1709	alphacd3	[alphaCD3]	0.1	1	2	1	1
62540	1709	(10	[(10]	0.1	1	1	0	0
62541	1709	monoclonal	[monoclonal]	0.1	1	2	1	1
62542	1709	p50/p105-NF-kappa	[p50/p105-NF-kappa]	0.1	1	1	0	0
62543	1709	(4-	[(4-]	0.1	1	1	0	0
62544	1709	tnfr-1	[TNFR-1]	0.1	1	2	2	2
62545	1709	ikk-beta	[IKK-beta]	0.1	1	2	1	1
62546	1709	b/mad-3	[B/MAD-3]	0.1	1	1	0	0
62547	1709	mellitus	[mellitus]	0.1	1	1	0	0
62548	1709	dihydrotestosterone	[dihydrotestosterone]	0.1	1	2	1	1
62549	1709	lt-betar	[LT-betaR]	0.1	1	1	0	0
62550	1709	neoformans,	[neoformans,]	0.1	1	1	0	0
62551	1709	-cat+	[-CAT+]	0.1	1	1	0	0
62552	1709	(D.	[(D.]	0.1	1	1	0	0
62553	1709	normal.	[normal.]	0.1	1	1	0	0
62554	1709	protein-1alpha	[protein-1alpha]	0.1	1	2	2	2
62555	1709	anti-cd4-fitc	[anti-CD4-FITC]	0.1	1	1	0	0
62556	1709	Basophil	[Basophils]	0.1	1	1	0	0
62557	1709	g-->t	[G-->T]	0.1	1	1	0	0
62558	1709	DQA1*0201/DQB1*0201	[DQA1*0201/DQB1*0201]	0.1	1	1	0	0
62559	1709	reflex-tachycardia	[reflex-tachycardia]	0.1	1	1	0	0
62560	1709	(R2	[(R2]	0.1	1	1	0	0
62561	1709	(hour	[(hour]	0.1	1	2	1	1
62562	1709	status.	[status.]	0.1	1	1	0	0
62563	1709	r59z	[R59Z]	0.1	1	2	2	2
62564	1709	changes,	[changes,]	0.1	1	2	1	1
62565	1709	NFAT4/x	[NFAT4/x]	0.1	1	1	0	0
62566	1709	syncytium	[syncytium]	0.1	1	1	0	0
62567	1709	(Z)	[(Z)]	0.1	1	1	0	0
62568	1709	serine-36	[serine-36]	0.1	1	1	0	0
62569	1709	(-579)	[(-579)]	0.1	1	1	0	0
62570	1709	c5b-7	[C5b-7]	0.1	1	2	2	2
62571	1709	c5b-8	[C5b-8]	0.1	1	1	0	0
62572	1709	nf-at/	[NF-AT/]	0.1	1	1	0	0
62573	1709	pre-	[pre-]	0.1	1	1	0	0
62574	1709	avidity,	[avidity,]	0.1	1	1	0	0
62575	1709	(b)	[(B)]	0.1	1	2	1	1
62576	1709	prdi	[PRDI]	0.1	1	2	1	1
62577	1709	11-base-pair	[11-base-pair]	0.1	1	1	0	0
62578	1709	(aa	[(aa]	0.1	1	1	0	0
62579	1709	(an	[(an]	0.1	1	2	2	2
62580	1709	staging,	[staging,]	0.1	1	1	0	0
62581	1709	(FL),	[(FL),]	0.1	1	1	0	0
62582	1709	prl-	[PRL-]	0.1	1	1	0	0
62583	1709	prog	[Prog]	0.1	1	1	0	0
62584	1709	(ki	[(Ki]	0.1	1	1	0	0
62585	1709	microgram/mL)	[microgram/mL)]	0.1	1	1	0	0
62586	1709	(mr	[(Mr]	0.1	1	1	0	0
62587	1709	absence.	[absence.]	0.1	1	1	0	0
62588	1709	cholecystokinin	[cholecystokinin]	0.1	1	1	0	0
62589	1709	(t3	[(T3]	0.1	1	1	0	0
62590	1709	hmg-y	[HMG-Y]	0.1	1	1	0	0
62591	1709	hmg-i	[HMG-I]	0.1	1	2	2	2
62592	1709	(up	[(up]	0.1	1	1	0	0
62593	1709	haloperidol	[haloperidol]	0.1	1	1	0	0
62594	1709	Jun/Jun	[Jun/Jun]	0.1	1	1	0	0
62595	1709	replication,	[replication,]	0.1	1	2	2	2
62596	1709	solution,	[solution,]	0.1	1	2	2	2
62597	1709	claims,	[claims,]	0.1	1	1	0	0
62598	1709	nk-like	[NK-like]	0.1	1	1	0	0
62599	1709	hyperpolarization	[hyperpolarization]	0.1	1	2	1	1
62600	1709	nf-chi	[NF-chi]	0.1	1	2	2	2
62601	1709	project	[project]	0.1	1	1	0	0
62602	1709	NP-1	[NP-1]	0.1	1	1	0	0
62603	1709	NP-5	[NP-5]	0.1	1	1	0	0
62604	1709	co-activator	[co-activator]	0.1	1	2	2	2
62605	1709	microgram/ml)	[microgram/ml)]	0.1	1	2	1	1
62606	1709	TFIIH	[TFIIH]	0.1	1	1	0	0
62607	1709	daidzein	[daidzein]	0.1	1	1	0	0
62608	1709	hydroxylamine	[hydroxylamine]	0.1	1	1	0	0
62609	1709	tal-15'	[tal-15']	0.1	1	1	0	0
62610	1709	results.	[results.]	0.1	1	2	2	2
62611	1709	TNFalpha-	[TNFalpha-]	0.1	1	1	0	0
62612	1709	crude	[crude]	0.1	1	2	1	1
62613	1709	erythropoeitin	[erythropoeitin]	0.1	1	1	0	0
62614	1709	ptca	[PTCA]	0.1	1	2	1	1
62615	1709	d20z1	[D20Z1]	0.1	1	1	0	0
62616	1709	p21(waf1/cip1	[p21(WAF1/CIP1]	0.1	1	1	0	0
62617	1709	pu.1/spi-1	[PU.1/Spi-1]	0.1	1	2	2	2
62618	1709	hiv-ltr/tat	[HIV-LTR/tat]	0.1	1	1	0	0
62619	1709	ggggaatctccc	[GGGGAATCTCCC]	0.1	1	1	0	0
62620	1709	Oleate	[Oleate]	0.1	1	1	0	0
62621	1709	osteoprotegerin	[osteoprotegerin]	0.1	1	1	0	0
62622	1709	iodide	[iodide]	0.1	1	1	0	0
62623	1709	5'-gggcgg	[5'-GGGCGG]	0.1	1	1	0	0
62624	1709	1311-base	[1311-base]	0.1	1	1	0	0
62625	1709	22-kDa	[22-kDa]	0.1	1	1	0	0
62626	1709	immune-endocrine	[immune-endocrine]	0.1	1	1	0	0
62627	1709	detail,	[detail,]	0.1	1	1	0	0
62628	1709	beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.1	1	1	0	0
62629	1709	P450IA1	[P450IA1]	0.1	1	1	0	0
62630	1709	beta1	[beta1]	0.1	1	1	0	0
62631	1709	rolling,	[rolling,]	0.1	1	1	0	0
62632	1709	granulocyte/monocyte	[granulocyte/monocyte]	0.1	1	1	0	0
62633	1709	palmar	[palmar]	0.1	1	1	0	0
62634	1709	iodine	[iodine]	0.1	1	2	2	2
62635	1709	biphasic:	[biphasic:]	0.1	1	1	0	0
62636	1709	Mole	[Mol.]	0.1	1	1	0	0
62637	1709	cd68(+)	[CD68(+)]	0.1	1	1	0	0
62638	1709	connection	[connection]	0.1	1	2	2	2
62639	1709	B-lymphocytes	[B-lymphocytes]	0.1	1	1	0	0
62640	1709	-2a	[-2A]	0.1	1	1	0	0
62641	1709	BJA-B	[BJA-B]	0.1	1	2	1	1
62642	1709	CCACC/Sp1	[CCACC/Sp1]	0.1	1	2	1	1
62643	1709	src-family	[Src-family]	0.1	1	1	0	0
62644	1709	mutated)	[mutated)]	0.1	1	1	0	0
62645	1709	yr).	[yr).]	0.1	1	1	0	0
62646	1709	p450ia1	[P450IA1]	0.1	1	1	0	0
62647	1709	c-MYC	[c-MYC]	0.1	1	1	0	0
62648	1709	neuropeptide	[neuropeptide]	0.1	1	2	1	1
62649	1709	decades.	[decades.]	0.1	1	1	0	0
62650	1709	glycoconjugate	[glycoconjugates]	0.1	1	1	0	0
62651	1709	Yoshida,	[Yoshida,]	0.1	1	1	0	0
62652	1709	ataxia-telangiectasia	[ataxia-telangiectasia]	0.1	1	2	1	1
62653	1709	Thapsigargin	[Thapsigargin]	0.1	1	2	1	1
62654	1709	hyperthyroid	[hyperthyroid]	0.1	1	1	0	0
62655	1709	PKC/Ras	[PKC/Ras]	0.1	1	1	0	0
62656	1709	Gliotoxin	[Gliotoxin]	0.1	1	1	0	0
62657	1709	evening	[evening]	0.1	1	1	0	0
62658	1709	forkhead	[forkhead]	0.1	1	1	0	0
62659	1709	HeLaS3	[HeLaS3]	0.1	1	1	0	0
62660	1709	-h2	[-H2]	0.1	1	1	0	0
62661	1709	HL-60/vinc/R	[HL-60/vinc/R]	0.1	1	2	1	1
62662	1709	t(y;15)/45,x	[t(Y;15)/45,X]	0.1	1	1	0	0
62663	1709	-lp	[-LP]	0.1	1	1	0	0
62664	1709	desferrioxamine	[desferrioxamine]	0.1	1	2	1	1
62665	1709	NF-AT-Oct	[NF-AT-Oct]	0.1	1	2	1	1
62666	1709	5'hs	[5'HS]	0.1	1	2	1	1
62667	1709	immuno-deficiency	[immuno-deficiency]	0.1	1	1	0	0
62668	1709	double-stimulation	[Double-stimulation]	0.1	1	1	0	0
62669	1709	POU(H)	[POU(H)]	0.1	1	1	0	0
62670	1709	luman	[lumen]	0.1	1	2	2	2
62671	1709	adhere	[adhering]	0.1	1	1	0	0
62672	1709	(rprl)	[(rPRL)]	0.1	1	1	0	0
62673	1709	rakfkqll	[RAKFKQLL]	0.1	1	1	0	0
62674	1709	p-bromophenacyl-bromide	[p-bromophenacyl-bromide]	0.1	1	1	0	0
62675	1709	Domain	[Domain]	0.1	1	2	1	1
62676	1709	targets.	[targets.]	0.1	1	1	0	0
62677	1709	feca2+	[FECa2+]	0.1	1	1	0	0
62678	1709	68-kDa	[68-kDa]	0.1	1	1	0	0
62679	1709	nf-il4	[NF-IL4]	0.1	1	2	2	2
62680	1709	V14Rho	[V14Rho]	0.1	1	2	1	1
62681	1709	Vmax	[Vmax]	0.1	1	2	1	1
62682	1709	gig18	[GIG18]	0.1	1	2	1	1
62683	1709	adenoid	[adenoids]	0.1	1	1	0	0
62684	1709	cytokines:	[cytokines:]	0.1	1	1	0	0
62685	1709	UT-7/GM	[UT-7/GM]	0.1	1	1	0	0
62686	1709	motility	[motility]	0.1	1	1	0	0
62687	1709	Gudmundsson,	[Gudmundsson,]	0.1	1	1	0	0
62688	1709	RAW264.7	[RAW264.7]	0.1	1	1	0	0
62689	1709	s-adenosylhomocysteine	[S-adenosylhomocysteine]	0.1	1	1	0	0
62690	1709	Dihydroxyvitamin	[Dihydroxyvitamin]	0.1	1	2	1	1
62691	1709	ionomycin,	[ionomycin,]	0.1	1	1	0	0
62692	1709	immunoelectron	[Immunoelectron]	0.1	1	2	1	1
62693	1709	tripartite	[tripartite]	0.1	1	1	0	0
62694	1709	Interleukin-12	[Interleukin-12]	0.1	1	4	3	1
62695	1709	(1-231)	[(1-231)]	0.1	1	1	0	0
62696	1709	193-bp	[193-bp]	0.1	1	1	0	0
62697	1709	microgram/day	[microgram/day]	0.1	1	1	0	0
62698	1709	skw6.4	[SKW6.4]	0.1	1	2	1	1
62699	1709	hematopoietic	[hematopoietic]	0.1	1	1	0	0
62700	1709	Mg/dl),	[mg/dl),]	0.1	1	1	0	0
62701	1709	cytokine-produce-pduce-pduce-prine-prine-prine-pri	[cytokine-producing]	0.1	1	1	0	0
62702	1709	CES-2	[CES-2]	0.1	1	1	0	0
62703	1709	beta-gene	[beta-gene]	0.1	1	1	0	0
62704	1709	pulse-treatment	[pulse-treatment]	0.1	1	1	0	0
62705	1709	26S	[26S]	0.1	1	1	0	0
62706	1709	BALF2	[BALF2]	0.1	1	1	0	0
62707	1709	myelopoiesis,	[myelopoiesis,]	0.1	1	1	0	0
62708	1709	rbtn2	[RBTN2]	0.1	1	1	0	0
62709	1709	MS-2beta	[MS-2beta]	0.1	1	1	0	0
62710	1709	alphaIIbH	[alphaIIbH]	0.1	1	2	2	2
62711	1709	differentiation;	[differentiation;]	0.1	1	1	0	0
62712	1709	uptake,	[uptake,]	0.1	1	1	0	0
62713	1709	benzoquinone	[benzoquinone]	0.1	1	1	0	0
62714	1709	(70z/3)	[(70Z/3)]	0.1	1	1	0	0
62715	1709	1d4	[1D4]	0.1	1	1	0	0
62716	1709	agarose	[agarose]	0.1	1	1	0	0
62717	1709	nrf-1/alpha-pal	[NRF-1/alpha-Pal]	0.1	1	1	0	0
62718	1709	3-methylcholanthrene	[3-methylcholanthrene]	0.1	1	2	1	1
62719	1709	ATF-2/JUN	[ATF-2/JUN]	0.1	1	1	0	0
62720	1709	reversible.	[reversible.]	0.1	1	1	0	0
62721	1709	specificity,	[specificity,]	0.1	1	2	2	2
62722	1709	specificity.	[specificity.]	0.1	1	2	2	2
62723	1709	graft	[graft]	0.1	1	2	2	2
62724	1709	R-394	[R-394]	0.1	1	1	0	0
62725	1709	cd2019	[CD2019]	0.1	1	1	0	0
62726	1709	B95-8	[B95-8]	0.1	1	2	1	1
62727	1709	cyto-differentiaterentiating	[cyto-differentiating]	0.1	1	2	1	1
62728	1709	a1/bfl-1	[A1/Bfl-1]	0.1	1	1	0	0
62729	1709	consolidation	[consolidation]	0.1	1	2	1	1
62730	1709	implantation	[implantation]	0.1	1	2	1	1
62731	1709	"late"	["late"]	0.1	1	1	0	0
62732	1709	C-site	[C-site]	0.1	1	2	1	1
62733	1709	delta-globin	[delta-globin]	0.1	1	1	0	0
62734	1709	catalyst	[catalyst]	0.1	1	2	1	1
62735	1709	assay.	[assay.]	0.1	1	2	1	1
62736	1709	tat-binding	[Tat-binding]	0.1	1	1	0	0
62737	1709	Anergy	[Anergy]	0.1	1	1	0	0
62738	1709	Rhabdomyosarcomas	[Rhabdomyosarcomas]	0.1	1	1	0	0
62739	1709	hypokalemia	[hypokalemia]	0.1	1	2	1	1
62740	1709	immunoradiometric	[immunoradiometric]	0.1	1	1	0	0
62741	1709	clipping	[clipping]	0.1	1	1	0	0
62742	1709	monitoring	[monitoring]	0.1	1	2	2	2
62743	1709	N-Myc	[N-Myc]	0.1	1	1	0	0
62744	1709	CD20(B1)	[CD20(B1)]	0.1	1	1	0	0
62745	1709	sulphamethoxazole	[sulphamethoxazole]	0.1	1	2	1	1
62746	1709	presence,	[presence,]	0.1	1	1	0	0
62747	1709	presence.	[presence.]	0.1	1	1	0	0
62748	1709	5'-	[5'-]	0.1	1	1	0	0
62749	1709	soccer	[soccer]	0.1	1	1	0	0
62750	1709	'converted'	['converted']	0.1	1	1	0	0
62751	1709	Cysteine	[Cysteine]	0.1	1	1	0	0
62752	1709	3kb	[3kb]	0.1	1	1	0	0
62753	1709	erythropoiesis.	[erythropoiesis.]	0.1	1	2	1	1
62754	1709	storage	[storage]	0.1	1	1	0	0
62755	1709	/cd28	[/CD28]	0.1	1	2	1	1
62756	1709	/cd3,	[/CD3,]	0.1	1	1	0	0
62757	1709	pmol/L;	[pmol/L;]	0.1	1	2	2	2
62758	1709	megakaryopoiesis/	[megakaryopoiesis/]	0.1	1	1	0	0
62759	1709	FACS	[FACS]	0.1	1	1	0	0
62760	1709	donor,	[donor,]	0.1	1	1	0	0
62761	1709	donor)	[donor)]	0.1	1	1	0	0
62762	1709	arthritis,	[arthritis,]	0.1	1	1	0	0
62763	1709	helm	[helm]	0.1	1	1	0	0
62764	1709	CEM-C7	[CEM-C7]	0.1	1	2	2	2
62765	1709	sound	[sound]	0.1	1	1	0	0
62766	1709	observation.	[observation.]	0.1	1	2	1	1
62767	1709	q23-31	[q23-31]	0.1	1	1	0	0
62768	1709	intraspecy	[intraspecies]	0.1	1	1	0	0
62769	1709	gc-motif	[GC-motif]	0.1	1	1	0	0
62770	1709	alpha)	[alpha)]	0.1	1	1	0	0
62771	1709	alpha4	[alpha4]	0.1	1	1	0	0
62772	1709	3,4-diacetoxy	[3,4-diacetoxy]	0.1	1	1	0	0
62773	1709	MBP-HBD	[MBP-HBD]	0.1	1	1	0	0
62774	1709	papillomaviruse	[papillomaviruses]	0.1	1	2	1	1
62775	1709	c-erbA/T3	[c-erbA/T3]	0.1	1	1	0	0
62776	1709	"giant"	["giant"]	0.1	1	1	0	0
62777	1709	Pentoxifylline	[Pentoxifylline]	0.1	1	2	2	2
62778	1709	glucuronide	[glucuronides]	0.1	1	2	1	1
62779	1709	moesin	[moesin]	0.1	1	1	0	0
62780	1709	labile	[labile]	0.1	1	1	0	0
62781	1709	109203x	[109203X]	0.1	1	1	0	0
62782	1709	phop/phoq	[phoP/phoQ]	0.1	1	1	0	0
62783	1709	deoxidizing	[deoxidizing]	0.1	1	1	0	0
62784	1709	subject.	[subject.]	0.1	1	1	0	0
62785	1709	transcription)	[transcription)]	0.1	1	2	2	2
62786	1709	accelerate	[accelerating]	0.1	1	1	0	0
62787	1709	Carter,	[Carter,]	0.1	1	1	0	0
62788	1709	cyp-40	[CyP-40]	0.1	1	1	0	0
62789	1709	Indomethacin	[Indomethacin]	0.1	1	1	0	0
62790	1709	safety	[safety]	0.1	1	2	1	1
62791	1709	N-Oct	[N-Oct]	0.1	1	2	1	1
62792	1709	hmrp8	[hMRP8]	0.1	1	1	0	0
62793	1709	FCS-	[FCS-]	0.1	1	1	0	0
62794	1709	transformant	[transformant]	0.1	1	2	1	1
62795	1709	[il-2]-dependent	[[IL-2]-dependent]	0.1	1	1	0	0
62796	1709	East	[East]	0.1	1	1	0	0
62797	1709	aminotriazole	[aminotriazole]	0.1	1	1	0	0
62798	1709	apolar	[apolar]	0.1	1	1	0	0
62799	1709	coupling.	[coupling.]	0.1	1	1	0	0
62800	1709	signal-transducing	[signal-transducing]	0.1	1	2	1	1
62801	1709	stimulants.	[stimulants.]	0.1	1	1	0	0
62802	1709	immunosuppression.	[immunosuppression.]	0.1	1	2	1	1
62803	1709	immunosuppression:	[immunosuppression:]	0.1	1	1	0	0
62804	1709	anoxia	[anoxia]	0.1	1	2	1	1
62805	1709	nonlymphoid	[nonlymphoid]	0.1	1	2	2	2
62806	1709	(free)	[(free)]	0.1	1	1	0	0
62807	1709	dichloromethylene	[dichloromethylene]	0.1	1	1	0	0
62808	1709	nitroblue	[nitroblue]	0.1	1	2	1	1
62809	1709	(maximal	[(maximal]	0.1	1	2	2	2
62810	1709	a-crf	[A-CRF]	0.1	1	1	0	0
62811	1709	mhc/peptide	[MHC/peptide]	0.1	1	1	0	0
62812	1709	active.	[active.]	0.1	1	1	0	0
62813	1709	38-kd	[38-kD]	0.1	1	1	0	0
62814	1709	(g/kg/h)	[(g/kg/h)]	0.1	1	1	0	0
62815	1709	)/rel	[)/Rel]	0.1	1	2	2	2
62816	1709	microM).	[microM).]	0.1	1	2	1	1
62817	1709	plate	[plate]	0.1	1	1	0	0
62818	1709	adipogenesis	[adipogenesis]	0.1	1	1	0	0
62819	1709	erythroid-lineage	[erythroid-lineage]	0.1	1	1	0	0
62820	1709	post-PMA	[post-PMA]	0.1	1	1	0	0
62821	1709	inhibition,	[inhibition,]	0.1	1	2	1	1
62822	1709	b1/p50	[B1/p50]	0.1	1	1	0	0
62823	1709	nk-cell	[NK-cell]	0.1	1	1	0	0
62824	1709	NF-AT/AP-1	[NF-AT/AP-1]	0.1	1	1	0	0
62825	1709	down-regulate	[down-regulates]	0.1	1	1	0	0
62826	1709	absorbance	[absorbance]	0.1	1	1	0	0
62827	1709	P3HR-1	[P3HR-1]	0.1	1	1	0	0
62828	1709	outcome.	[outcome.]	0.1	1	2	1	1
62829	1709	leucin-zipper	[leucin-zipper]	0.1	1	1	0	0
62830	1709	cercopithicine	[cercopithicine]	0.1	1	2	1	1
62831	1709	tenacious,	[tenacious,]	0.1	1	1	0	0
62832	1709	vitality	[vitality]	0.1	1	1	0	0
62833	1709	keratoacanthomas	[keratoacanthomas]	0.1	1	2	1	1
62834	1709	(scid-husint)	[(SCID-HU-INT)]	0.1	1	1	0	0
62835	1709	alpha/mad-3	[alpha/MAD-3]	0.1	1	1	0	0
62836	1709	n-oct-factor	[N-Oct-factors]	0.1	1	1	0	0
62837	1709	patient/histopathology	[patient/histopathology]	0.1	1	1	0	0
62838	1709	phenotypes.	[phenotypes.]	0.1	1	2	1	1
62839	1709	NF-activated	[NF-activated]	0.1	1	1	0	0
62840	1709	17beta-(3H)	[17beta-(3H)]	0.1	1	1	0	0
62841	1709	1.955-kb	[1.955-kb]	0.1	1	1	0	0
62842	1709	CREB-1	[CREB-1]	0.1	1	1	0	0
62843	1709	(ice)	[(ICE)]	0.1	1	1	0	0
62844	1709	wp-34)	[WP-34)]	0.1	1	1	0	0
62845	1709	feb;16(2):735]	[Feb;16(2):735]]	0.1	1	1	0	0
62846	1709	(b-2)	[(B-2)]	0.1	1	1	0	0
62847	1709	eicosanoid,	[eicosanoid,]	0.1	1	1	0	0
62848	1709	circulation	[circulation]	0.1	1	2	2	2
62849	1709	coengagement	[coengagement]	0.1	1	1	0	0
62850	1709	mol/microgram	[mol/microgram]	0.1	1	1	0	0
62851	1709	NF-kB2/p52.	[NF-kB2/p52.]	0.1	1	1	0	0
62852	1709	24r-hydroxylase	[24R-hydroxylase]	0.1	1	1	0	0
62853	1709	hTLR2	[hTLR2]	0.1	1	2	1	1
62854	1709	aldosteronism	[aldosteronism]	0.1	1	1	0	0
62855	1709	(id50	[(ID50]	0.1	1	1	0	0
62856	1709	inv(14)(q11;q32)	[inv(14)(q11;q32)]	0.1	1	1	0	0
62857	1709	AP1/c-jun	[AP1/c-jun]	0.1	1	1	0	0
62858	1709	carboxy-terminus	[carboxy-terminus]	0.1	1	1	0	0
62859	1709	delta99	[delta99]	0.1	1	1	0	0
62860	1709	notch-1	[notch-1]	0.1	1	2	2	2
62861	1709	promoters,	[promoters,]	0.1	1	2	1	1
62862	1709	promoters.	[promoters.]	0.1	1	1	0	0
62863	1709	iNOS	[iNOS]	0.1	1	2	2	2
62864	1709	leukaemia/lymphoma	[leukaemia/lymphoma]	0.1	1	1	0	0
62865	1709	iron-sulfur	[iron-sulfur]	0.1	1	1	0	0
62866	1709	position.	[position.]	0.1	1	2	2	2
62867	1709	kd:2.92	[Kd:2.92]	0.1	1	1	0	0
62868	1709	expansion)	[expansion)]	0.1	1	2	2	2
62869	1709	irak2	[IRAK2]	0.1	1	1	0	0
62870	1709	/chloramphenicol	[/chloramphenicol]	0.1	1	1	0	0
62871	1709	NaOV	[NaOV]	0.1	1	2	1	1
62872	1709	BCR-ABL	[BCR-ABL]	0.1	1	1	0	0
62873	1709	contention	[contention]	0.1	1	1	0	0
62874	1709	stimulators,	[stimulators,]	0.1	1	1	0	0
62875	1709	hypercholesterolemia	[hypercholesterolemia]	0.1	1	1	0	0
62876	1709	assays,	[assays,]	0.1	1	1	0	0
62877	1709	(minute	[(minutes)]	0.1	1	1	0	0
62878	1709	hmba	[HMBA]	0.1	1	3	2	1
62879	1709	FICZ	[FICZ]	0.1	1	2	1	1
62880	1709	polyposis	[polyposis]	0.1	1	2	2	2
62881	1709	3H-thymidine	[3H-thymidine]	0.1	1	1	0	0
62882	1709	20-epi	[20-epi]	0.1	1	1	0	0
62883	1709	fkbp12	[FKBP12]	0.1	1	2	1	1
62884	1709	fkbp54	[FKBP54]	0.1	1	1	0	0
62885	1709	thioredoxin	[thioredoxin]	0.1	1	2	2	2
62886	1709	flurbiprofen	[flurbiprofen]	0.1	1	1	0	0
62887	1709	p50/65	[p50/65]	0.1	1	1	0	0
62888	1709	rantes,	[RANTES,]	0.1	1	1	0	0
62889	1709	itself,	[itself,]	0.1	1	1	0	0
62890	1709	cGATA-3	[cGATA-3]	0.1	1	1	0	0
62891	1709	interphase	[interphase]	0.1	1	2	1	1
62892	1709	d-ribose	[D-ribose]	0.1	1	1	0	0
62893	1709	AAGTGA	[AAGTGA]	0.1	1	1	0	0
62894	1709	hnf3	[HNF3]	0.1	1	2	1	1
62895	1709	cut-off	[cut-off]	0.1	1	1	0	0
62896	1709	fosd-c	[fos,]	0.1	1	1	0	0
62897	1709	rxr-rar	[RXR-RAR]	0.1	1	1	0	0
62898	1709	[3h]progesterone-mbp-hbd	[[3H]progesterone-MBP-HBD]	0.1	1	1	0	0
62899	1709	findings.	[findings.]	0.1	1	2	2	2
62900	1709	receptors/cell),	[receptors/cell),]	0.1	1	1	0	0
62901	1709	OCT-1	[OCT-1]	0.1	1	1	0	0
62902	1709	hiv-enhancer	[HIV-enhancer]	0.1	1	1	0	0
62903	1709	hoci	[HOCI]	0.1	1	1	0	0
62904	1709	BSLF2	[BSLF2]	0.1	1	1	0	0
62905	1709	syk-family	[Syk-family]	0.1	1	1	0	0
62906	1709	DU-145	[DU-145]	0.1	1	2	1	1
62907	1709	ceanorhabditis	[Ceanorhabditis]	0.1	1	1	0	0
62908	1709	pu.1-/-	[PU.1-/-]	0.1	1	1	0	0
62909	1709	gamma-promoter	[gamma-promoter]	0.1	1	2	1	1
62910	1709	pan-T-lineage	[pan-T-lineage]	0.1	1	1	0	0
62911	1709	cro-ap/5	[CRO-AP/5]	0.1	1	1	0	0
62912	1709	homo	[homo]	0.1	1	2	2	2
62913	1709	holo	[holo]	0.1	1	1	0	0
62914	1709	3'-region	[3'-region]	0.1	1	2	1	1
62915	1709	heat-	[heat-]	0.1	1	1	0	0
62916	1709	burst-forming	[burst-forming]	0.1	1	1	0	0
62917	1709	Xenopus	[Xenopus]	0.1	1	1	0	0
62918	1709	astrocytoma	[astrocytoma]	0.1	1	2	2	2
62919	1709	region:	[region:]	0.1	1	1	0	0
62920	1709	Tyrosines	[Tyrosines]	0.1	1	1	0	0
62921	1709	cytokeratin	[cytokeratins]	0.1	1	1	0	0
62922	1709	aggregate	[aggregate]	0.1	1	1	0	0
62923	1709	hpfh	[HPFH]	0.1	1	2	1	1
62924	1709	Boyden	[Boyden]	0.1	1	1	0	0
62925	1709	hplc	[HPLC]	0.1	1	2	1	1
62926	1709	nasopharyngeal	[nasopharyngeal]	0.1	1	1	0	0
62927	1709	willebrand	[Willebrand]	0.1	1	2	1	1
62928	1709	rakpgdp	[Rap1GDP]	0.1	1	1	0	0
62929	1709	dimethylsulfoxide	[dimethylsulfoxide]	0.1	1	2	1	1
62930	1709	p-nitrophenyl	[p-nitrophenyl]	0.1	1	1	0	0
62931	1709	A-F	[A-F]	0.1	1	1	0	0
62932	1709	A/G	[A/G]	0.1	1	1	0	0
62933	1709	Messenger	[Messenger]	0.1	1	2	1	1
62934	1709	hypoglycemia	[hypoglycemia]	0.1	1	2	2	2
62935	1709	Val10-Gln22	[Val10-Gln22]	0.1	1	1	0	0
62936	1709	lysosome	[lysosomes]	0.1	1	1	0	0
62937	1709	p93fe	[p93fes]	0.1	1	2	1	1
62938	1709	glycosidase	[glycosidase]	0.1	1	1	0	0
62939	1709	dominant-act	[dominant-acting]	0.1	1	1	0	0
62940	1709	Ca2+-	[Ca2+-]	0.1	1	1	0	0
62941	1709	AAV	[AAV]	0.1	1	1	0	0
62942	1709	(iii)	[(iii)]	0.1	1	1	0	0
62943	1709	AD1	[AD1]	0.1	1	1	0	0
62944	1709	AD2	[AD2]	0.1	1	1	0	0
62945	1709	ADP	[ADP]	0.1	1	1	0	0
62946	1709	AES	[AES]	0.1	1	2	1	1
62947	1709	AFR	[AFR]	0.1	1	2	1	1
62948	1709	ikappabbeta	[IkappaBbeta]	0.1	1	2	1	1
62949	1709	socs-3	[SOCS-3]	0.1	1	2	1	1
62950	1709	AIM	[AIM]	0.1	1	1	0	0
62951	1709	AL1	[AL1]	0.1	1	1	0	0
62952	1709	B-2	[B-2]	0.1	1	1	0	0
62953	1709	ANG	[ANG]	0.1	1	2	2	2
62954	1709	AMs	[AMs]	0.1	1	2	1	1
62955	1709	over-ride	[over-riding]	0.1	1	1	0	0
62956	1709	AP3	[AP3]	0.1	1	1	0	0
62957	1709	repeat-luciferase	[repeat-luciferase]	0.1	1	1	0	0
62958	1709	ATD	[ATD]	0.1	1	1	0	0
62959	1709	AUG	[AUG]	0.1	1	3	2	1
62960	1709	trimester	[trimester]	0.1	1	1	0	0
62961	1709	condition.	[condition.]	0.1	1	1	0	0
62962	1709	hrbc	[HRBC]	0.1	1	2	1	1
62963	1709	RU-486	[RU-486]	0.1	1	2	1	1
62964	1709	IFN-alpha-	[IFN-alpha-]	0.1	1	1	0	0
62965	1709	IFN-alpha5	[IFN-alpha5]	0.1	1	1	0	0
62966	1709	s.c.	[s.c.]	0.1	1	1	0	0
62967	1709	BAT	[BAT]	0.1	1	1	0	0
62968	1709	2-methylhistamine	[2-methylhistamine]	0.1	1	1	0	0
62969	1709	BCC	[BCC]	0.1	1	1	0	0
62970	1709	Abl	[Abl]	0.1	1	2	1	1
62971	1709	Abs	[Abs]	0.1	1	2	1	1
62972	1709	ht29	[HT29]	0.1	1	2	1	1
62973	1709	c6.1b/mtcp1	[c6.1B/MTCP1]	0.1	1	1	0	0
62974	1709	BH1	[BH1]	0.1	1	1	0	0
62975	1709	BH2	[BH2]	0.1	1	1	0	0
62976	1709	Ags	[Ags]	0.1	1	1	0	0
62977	1709	chloride	[chloride]	0.1	1	1	0	0
62978	1709	abi.,	[A.I.,]	0.1	1	1	0	0
62979	1709	BP2	[BP2]	0.1	1	1	0	0
62980	1709	cd3h12	[cD3H12]	0.1	1	1	0	0
62981	1709	BR4	[BR4]	0.1	1	1	0	0
62982	1709	C3H	[C3H]	0.1	1	1	0	0
62983	1709	hsc/	[HSC/]	0.1	1	1	0	0
62984	1709	calcineurin,	[calcineurin,]	0.1	1	2	2	2
62985	1709	BUD	[BUD]	0.1	1	1	0	0
62986	1709	creation	[creation]	0.1	1	1	0	0
62987	1709	banding	[banding]	0.1	1	2	1	1
62988	1709	BXB	[BXB]	0.1	1	1	0	0
62989	1709	stress-inducing	[stress-inducing]	0.1	1	1	0	0
62990	1709	KN-62	[KN-62]	0.1	1	1	0	0
62991	1709	15-deoxy-delta12,14-prostaglandin	[15-deoxy-delta12,14-prostaglandin]	0.1	1	1	0	0
62992	1709	hsie	[hSIE]	0.1	1	2	1	1
62993	1709	proof-of-principle	[proof-of-principle]	0.1	1	1	0	0
62994	1709	akata	[Akata]	0.1	1	1	0	0
62995	1709	kinases,	[kinases,]	0.1	1	2	2	2
62996	1709	kinases.	[kinases.]	0.1	1	2	1	1
62997	1709	G1/S	[G1/S]	0.1	1	2	1	1
62998	1709	G0S3	[G0S3]	0.1	1	2	1	1
62999	1709	Bis	[Bis]	0.1	1	2	1	1
63000	1709	CMF	[CMF]	0.1	1	2	1	1
63001	1709	FKHRL1P2	[FKHRL1P2]	0.1	1	1	0	0
63002	1709	CR2	[CR2]	0.1	1	1	0	0
63003	1709	Val837	[Val837]	0.1	1	1	0	0
63004	1709	CRC	[CRC]	0.1	1	1	0	0
63005	1709	Leu122	[Leu122]	0.1	1	1	0	0
63006	1709	liquid-suspension	[liquid-suspension]	0.1	1	1	0	0
63007	1709	versatility	[versatility]	0.1	1	2	2	2
63008	1709	centuries.	[centuries.]	0.1	1	1	0	0
63009	1709	opinion	[opinion]	0.1	1	1	0	0
63010	1709	DCR	[DCR]	0.1	1	2	1	1
63011	1709	AP-1/	[AP-1/]	0.1	1	1	0	0
63012	1709	DEM	[DEM]	0.1	1	2	1	1
63013	1709	DES	[DES]	0.1	1	2	1	1
63014	1709	DFC	[DFC]	0.1	1	2	1	1
63015	1709	DFR	[DFR]	0.1	1	1	0	0
63016	1709	a-ring	[A-ring]	0.1	1	1	0	0
63017	1709	DHA	[DHA]	0.1	1	1	0	0
63018	1709	prudence	[prudence]	0.1	1	1	0	0
63019	1709	acetylation	[Acetylation]	0.1	1	2	2	2
63020	1709	Nacetylcysteine	[Nacetylcysteine]	0.1	1	1	0	0
63021	1709	DMP	[DMP]	0.1	1	1	0	0
63022	1709	DP1	[DP1]	0.1	1	1	0	0
63023	1709	E12	[E12]	0.1	1	1	0	0
63024	1709	E15	[E15]	0.1	1	1	0	0
63025	1709	E14	[E14]	0.1	1	1	0	0
63026	1709	Fcgamma	[Fcgamma]	0.1	1	2	1	1
63027	1709	DR1	[DR1]	0.1	1	1	0	0
63028	1709	Cox	[Cox]	0.1	1	2	1	1
63029	1709	cd4/cd8	[CD4/CD8]	0.1	1	1	0	0
63030	1709	DSL	[DSL]	0.1	1	1	0	0
63031	1709	DTC	[DTC]	0.1	1	1	0	0
63032	1709	DTT	[DTT]	0.1	1	1	0	0
63033	1709	elderly	[elderly]	0.1	1	2	1	1
63034	1709	PMA/ionomycin	[PMA/ionomycin]	0.1	1	1	0	0
63035	1709	(2E)-3-[5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-	[(2E)-3-[5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-]	0.1	1	1	0	0
63036	1709	fluctuation	[fluctuations]	0.1	1	2	2	2
63037	1709	wt/vol)	[wt/vol)]	0.1	1	1	0	0
63038	1709	(tcr)-associated	[(TCR)-associated]	0.1	1	1	0	0
63039	1709	SLEDAI	[SLEDAI]	0.1	1	1	0	0
63040	1709	fever	[fever]	0.1	1	1	0	0
63041	1709	26-kDa	[26-kDa]	0.1	1	1	0	0
63042	1709	ECP	[ECP]	0.1	1	1	0	0
63043	1709	Fos/Jun	[Fos/Jun]	0.1	1	1	0	0
63044	1709	EGF	[EGF]	0.1	1	2	2	2
63045	1709	p42/p44	[p42/p44]	0.1	1	1	0	0
63046	1709	d.d.richman,	[D.D.Richman,]	0.1	1	1	0	0
63047	1709	EIA	[EIA]	0.1	1	1	0	0
63048	1709	EIC	[EIC]	0.1	1	1	0	0
63049	1709	stat-5	[STAT-5]	0.1	1	1	0	0
63050	1709	intermediate	[intermediate]	0.1	1	2	2	2
63051	1709	aitl/gc	[AITL/GC]	0.1	1	2	1	1
63052	1709	thiazolidinedione	[thiazolidinedione]	0.1	1	1	0	0
63053	1709	staphylococci	[staphylococci]	0.1	1	1	0	0
63054	1709	Erythropoietin	[Erythropoietin]	0.1	1	2	2	2
63055	1709	ER+	[ER+]	0.1	1	1	0	0
63056	1709	pmol/mg.	[pmol/mg.]	0.1	1	1	0	0
63057	1709	fetus	[fetus]	0.1	1	2	1	1
63058	1709	stat3-	[STAT3-]	0.1	1	1	0	0
63059	1709	stat1-	[STAT1-]	0.1	1	1	0	0
63060	1709	c-cbl	[c-Cbl]	0.1	1	1	0	0
63061	1709	Proc.Natl.Acad.Sci.USA	[Proc.Natl.Acad.Sci.USA]	0.1	1	1	0	0
63062	1709	Nm23H2	[Nm23H2]	0.1	1	2	2	2
63063	1709	g-actin	[G-actin]	0.1	1	1	0	0
63064	1709	cellularity	[cellularity]	0.1	1	2	2	2
63065	1709	Hematology	[Hematology]	0.1	1	1	0	0
63066	1709	challenge.	[challenge.]	0.1	1	2	1	1
63067	1709	paraffin-embedded)	[paraffin-embedded)]	0.1	1	1	0	0
63068	1709	FL,	[FL,]	0.1	1	1	0	0
63069	1709	G.,	[G.,]	0.1	1	2	1	1
63070	1709	contaminant	[contaminant]	0.1	1	2	2	2
63071	1709	unit-granulocyte-macrophage	[unit-granulocyte-macrophage]	0.1	1	1	0	0
63072	1709	FOG	[FOG]	0.1	1	2	1	1
63073	1709	Env	[Env]	0.1	1	1	0	0
63074	1709	G2S	[G2S]	0.1	1	1	0	0
63075	1709	Esc	[Esc]	0.1	1	1	0	0
63076	1709	6-k-PGF1	[6-k-PGF1]	0.1	1	1	0	0
63077	1709	G75	[G75]	0.1	1	2	1	1
63078	1709	G76	[G76]	0.1	1	2	1	1
63079	1709	FVA	[FVA]	0.1	1	1	0	0
63080	1709	GAS	[GAS]	0.1	1	2	1	1
63081	1709	GCA	[GCA]	0.1	1	2	1	1
63082	1709	GCH	[GCH]	0.1	1	1	0	0
63083	1709	c-fgr	[c-fgr]	0.1	1	1	0	0
63084	1709	GCS	[GCS]	0.1	1	1	0	0
63085	1709	nephropathy	[nephropathy]	0.1	1	6	5	1
63086	1709	lipopeptide	[lipopeptides]	0.1	1	2	2	2
63087	1709	H-7	[H-7]	0.1	1	1	0	0
63088	1709	GM1	[GM1]	0.1	1	1	0	0
63089	1709	hnf-6	[HNF-6]	0.1	1	1	0	0
63090	1709	H/C	[H/C]	0.1	1	1	0	0
63091	1709	actinomycin-D	[actinomycin-D]	0.1	1	1	0	0
63092	1709	GPA	[GPA]	0.1	1	2	2	2
63093	1709	GSH	[GSH]	0.1	1	1	0	0
63094	1709	GRs	[GRs]	0.1	1	1	0	0
63095	1709	egf-gp130	[EGF-gp130]	0.1	1	1	0	0
63096	1709	ErbB	[ErbB]	0.1	1	1	0	0
63097	1709	Fyb	[Fyb]	0.1	1	1	0	0
63098	1709	Fyn	[Fyn]	0.1	1	1	0	0
63099	1709	tacrolimus	[tacrolimus]	0.1	1	2	1	1
63100	1709	(+)-skf	[(+)-SKF]	0.1	1	2	1	1
63101	1709	particulate	[particulate]	0.1	1	1	0	0
63102	1709	Pan-2	[Pan-2]	0.1	1	1	0	0
63103	1709	HDN	[HDN]	0.1	1	1	0	0
63104	1709	HEB	[HEB]	0.1	1	1	0	0
63105	1709	35S-TR:	[35S-TR:]	0.1	1	1	0	0
63106	1709	I),	[I),]	0.1	1	1	0	0
63107	1709	Gen	[Gen]	0.1	1	2	2	2
63108	1709	HHT	[HHT]	0.1	1	1	0	0
63109	1709	celiac	[celiac]	0.1	1	1	0	0
63110	1709	C-type	[C-type]	0.1	1	1	0	0
63111	1709	functions,	[functions,]	0.1	1	2	1	1
63112	1709	functions.	[functions.]	0.1	1	1	0	0
63113	1709	(arre)/nuclear	[(ARRE)/nuclear]	0.1	1	1	0	0
63114	1709	Gln	[Gln]	0.1	1	2	1	1
63115	1709	HOX	[HOX]	0.1	1	1	0	0
63116	1709	zn2+	[Zn2+]	0.1	1	1	0	0
63117	1709	HTC	[HTC]	0.1	1	1	0	0
63118	1709	HSs	[HSs]	0.1	1	2	1	1
63119	1709	HUT	[HUT]	0.1	1	1	0	0
63120	1709	activation:	[activation:]	0.1	1	1	0	0
63121	1709	Nmax	[Nmax]	0.1	1	1	0	0
63122	1709	ICN	[ICN]	0.1	1	1	0	0
63123	1709	abnormality.	[abnormality.]	0.1	1	1	0	0
63124	1709	hematopoietin/cytokine	[hematopoietin/cytokine]	0.1	1	1	0	0
63125	1709	keratoconjunctivitis	[keratoconjunctivitis]	0.1	1	2	2	2
63126	1709	Hha	[Hha]	0.1	1	1	0	0
63127	1709	s727	[S727]	0.1	1	1	0	0
63128	1709	J-C	[J-C]	0.1	1	1	0	0
63129	1709	ILs	[ILs]	0.1	1	2	1	1
63130	1709	Hlf	[Hlf]	0.1	1	1	0	0
63131	1709	IP9	[IP9]	0.1	1	1	0	0
63132	1709	Leu42-Pro49	[Leu42-Pro49]	0.1	1	1	0	0
63133	1709	Phagocytosis	[Phagocytosis]	0.1	1	1	0	0
63134	1709	IRS	[IRS]	0.1	1	1	0	0
63135	1709	NC2.10	[NC2.10]	0.1	1	1	0	0
63136	1709	jejunostomy	[jejunostomy]	0.1	1	1	0	0
63137	1709	MyD88	[MyD88]	0.1	1	1	0	0
63138	1709	anxiety	[anxiety]	0.1	1	1	0	0
63139	1709	episome	[episome]	0.1	1	2	2	2
63140	1709	NRE-2a	[NRE-2a]	0.1	1	1	0	0
63141	1709	world	[world]	0.1	1	2	2	2
63142	1709	CD43/leukosialin	[CD43/leukosialin]	0.1	1	2	2	2
63143	1709	poxvirus	[poxvirus]	0.1	1	1	0	0
63144	1709	adjunct	[adjunct]	0.1	1	1	0	0
63145	1709	exhibit	[exhibit]	0.1	1	1	0	0
63146	1709	icam-3	[ICAM-3]	0.1	1	1	0	0
63147	1709	lesions,	[lesions,]	0.1	1	1	0	0
63148	1709	Id1	[Id1]	0.1	1	1	0	0
63149	1709	ribonuclease	[ribonuclease]	0.1	1	2	1	1
63150	1709	Ig,	[Ig,]	0.1	1	1	0	0
63151	1709	IgA	[IgA]	0.1	1	1	0	0
63152	1709	IgD	[IgD]	0.1	1	1	0	0
63153	1709	Leu765	[Leu765]	0.1	1	1	0	0
63154	1709	NRE-II	[NRE-II]	0.1	1	2	1	1
63155	1709	Ets-	[Ets-]	0.1	1	1	0	0
63156	1709	WiDr	[WiDr]	0.1	1	1	0	0
63157	1709	Ets1	[Ets1]	0.1	1	1	0	0
63158	1709	Ile	[Ile]	0.1	1	2	1	1
63159	1709	concentration-	[concentration-]	0.1	1	1	0	0
63160	1709	K46	[K46]	0.1	1	1	0	0
63161	1709	K3T	[K3T]	0.1	1	1	0	0
63162	1709	concentration,	[concentration,]	0.1	1	2	1	1
63163	1709	hoffmeyer,	[Hoffmeyer,]	0.1	1	1	0	0
63164	1709	Th2-type	[Th2-type]	0.1	1	1	0	0
63165	1709	beta-sheet	[beta-sheet]	0.1	1	1	0	0
63166	1709	nadph-oxidase	[NADPH-oxidase]	0.1	1	1	0	0
63167	1709	70/z3-derived	[70/Z3-derived]	0.1	1	1	0	0
63168	1709	KCa	[KCa]	0.1	1	1	0	0
63169	1709	L&H	[L&H]	0.1	1	2	2	2
63170	1709	morphology,	[morphology,]	0.1	1	2	2	2
63171	1709	atf1-	[ATF1-]	0.1	1	1	0	0
63172	1709	Tis-8	[Tis-8]	0.1	1	1	0	0
63173	1709	gp+e-86	[GP+E-86]	0.1	1	1	0	0
63174	1709	4,5-dihydro	[4,5-dihydro]	0.1	1	1	0	0
63175	1709	hCLEO	[hCLEO]	0.1	1	2	1	1
63176	1709	t-cell-activateivg	[T-cell-activating]	0.1	1	2	1	1
63177	1709	dapsone	[dapsone]	0.1	1	1	0	0
63178	1709	transfectin	[transfectin]	0.1	1	1	0	0
63179	1709	AITL/GC	[AITL/GC]	0.1	1	2	2	2
63180	1709	Eryf-1	[Eryf-1]	0.1	1	1	0	0
63181	1709	Tcells	[Tcells]	0.1	1	1	0	0
63182	1709	Jnk	[Jnk]	0.1	1	1	0	0
63183	1709	L23	[L23]	0.1	1	2	1	1
63184	1709	zona	[zona]	0.1	1	1	0	0
63185	1709	zone	[zone]	0.1	1	3	2	1
63186	1709	interest,	[interest,]	0.1	1	1	0	0
63187	1709	minutes).	[minutes).]	0.1	1	2	1	1
63188	1709	osteoblast	[osteoblasts]	0.1	1	1	0	0
63189	1709	Nov1	[Nov1]	0.1	1	2	1	1
63190	1709	FK-506	[FK-506]	0.1	1	1	0	0
63191	1709	division	[divisions]	0.1	1	2	1	1
63192	1709	ry13-7410)	[RO13-7410)]	0.1	1	1	0	0
63193	1709	(rna)	[(RNA)]	0.1	1	2	2	2
63194	1709	PG-B6p	[PG-B6p]	0.1	1	1	0	0
63195	1709	LAT	[LAT]	0.1	1	2	1	1
63196	1709	Porphyromonas	[Porphyromonas]	0.1	1	2	1	1
63197	1709	LCD	[LCD]	0.1	1	2	1	1
63198	1709	LCK	[LCK]	0.1	1	1	0	0
63199	1709	LDP	[LDP]	0.1	1	2	1	1
63200	1709	polya+	[polyA+]	0.1	1	1	0	0
63201	1709	ORF1	[ORF1]	0.1	1	1	0	0
63202	1709	branching	[branching]	0.1	1	1	0	0
63203	1709	LGL	[LGL]	0.1	1	2	1	1
63204	1709	ORFs	[ORFs]	0.1	1	1	0	0
63205	1709	categories:	[categories:]	0.1	1	1	0	0
63206	1709	Bfl-1/A1	[Bfl-1/A1]	0.1	1	1	0	0
63207	1709	humoral-	[humoral-]	0.1	1	1	0	0
63208	1709	humoral,	[humoral,]	0.1	1	1	0	0
63209	1709	RAW264	[RAW264]	0.1	1	1	0	0
63210	1709	M.,	[M.,]	0.1	1	1	0	0
63211	1709	B/rel	[B/rel]	0.1	1	2	2	2
63212	1709	M10	[M10]	0.1	1	2	1	1
63213	1709	lmp1-	[LMP1-]	0.1	1	1	0	0
63214	1709	(t1/2	[(T1/2]	0.1	1	1	0	0
63215	1709	M47	[M47]	0.1	1	2	1	1
63216	1709	LUF	[LUF]	0.1	1	1	0	0
63217	1709	"stem	["stem]	0.1	1	1	0	0
63218	1709	-1280	[-1280]	0.1	1	1	0	0
63219	1709	ca(2+)-ionophore	[Ca(2+)-ionophore]	0.1	1	1	0	0
63220	1709	discrimination	[discrimination]	0.1	1	2	2	2
63221	1709	neutrophilia	[neutrophilia]	0.1	1	3	2	1
63222	1709	nf-ya	[NF-YA]	0.1	1	1	0	0
63223	1709	non-smoker	[non-smokers]	0.1	1	1	0	0
63224	1709	La(	[La(]	0.1	1	1	0	0
63225	1709	MAZ	[MAZ]	0.1	1	1	0	0
63226	1709	alphaIIbbeta3	[alphaIIbbeta3]	0.1	1	1	0	0
63227	1709	LeR	[LeR]	0.1	1	1	0	0
63228	1709	MGC	[MGC]	0.1	1	1	0	0
63229	1709	Leu	[Leu]	0.1	1	2	2	2
63230	1709	MLA	[MLA]	0.1	1	1	0	0
63231	1709	nf-e1	[NF-E1]	0.1	1	2	2	2
63232	1709	DNase-I-hypersensitive	[DNase-I-hypersensitive]	0.1	1	1	0	0
63233	1709	Sialoadhesin	[Sialoadhesin]	0.1	1	2	1	1
63234	1709	T-helper	[T-helper]	0.1	1	1	0	0
63235	1709	MMs	[MMs]	0.1	1	1	0	0
63236	1709	here,	[here,]	0.1	1	2	1	1
63237	1709	Lyt	[Lyt]	0.1	1	1	0	0
63238	1709	diacylglycerol	[diacylglycerol]	0.1	1	2	1	1
63239	1709	NAF	[NAF]	0.1	1	2	2	2
63240	1709	RasN17	[RasN17]	0.1	1	1	0	0
63241	1709	heptp	[HePTP]	0.1	1	1	0	0
63242	1709	tcf-2	[TCF-2]	0.1	1	1	0	0
63243	1709	May	[May]	0.1	1	1	0	0
63244	1709	Mch	[Mch]	0.1	1	2	2	2
63245	1709	OTF1	[OTF1]	0.1	1	1	0	0
63246	1709	OTFs	[OTFs]	0.1	1	1	0	0
63247	1709	NFs	[NFs]	0.1	1	1	0	0
63248	1709	IkappaBs	[IkappaBs]	0.1	1	1	0	0
63249	1709	cut/cdp	[cut/CDP]	0.1	1	1	0	0
63250	1709	HUAECs	[HUAECs]	0.1	1	1	0	0
63251	1709	NK/	[NK/]	0.1	1	1	0	0
63252	1709	NK:	[NK:]	0.1	1	1	0	0
63253	1709	prodrug	[prodrugs]	0.1	1	1	0	0
63254	1709	costimulatory	[costimulatory]	0.1	1	1	0	0
63255	1709	NMR	[NMR]	0.1	1	2	1	1
63256	1709	t(3;3)	[t(3;3)]	0.1	1	1	0	0
63257	1709	hes-1	[HES-1]	0.1	1	1	0	0
63258	1709	Mpl	[Mpl]	0.1	1	1	0	0
63259	1709	NRL	[NRL]	0.1	1	2	2	2
63260	1709	NTF	[NTF]	0.1	1	1	0	0
63261	1709	ramification	[ramifications]	0.1	1	2	2	2
63262	1709	Myc	[Myc]	0.1	1	1	0	0
63263	1709	phytohemagglutinin-	[phytohemagglutinin-]	0.1	1	1	0	0
63264	1709	OAP	[OAP]	0.1	1	1	0	0
63265	1709	NaB	[NaB]	0.1	1	1	0	0
63266	1709	both)	[both)]	0.1	1	1	0	0
63267	1709	both,	[both,]	0.1	1	2	1	1
63268	1709	tissue-infiltrating	[tissue-infiltrating]	0.1	1	1	0	0
63269	1709	DQA1*0501/DQB1*0302	[DQA1*0501/DQB1*0302]	0.1	1	1	0	0
63270	1709	myeloid/NK	[myeloid/NK]	0.1	1	1	0	0
63271	1709	OSM	[OSM]	0.1	1	1	0	0
63272	1709	zebrafish	[zebrafish]	0.1	1	1	0	0
63273	1709	OTF	[OTF]	0.1	1	1	0	0
63274	1709	MiniMACS	[MiniMACS]	0.1	1	1	0	0
63275	1709	97-kDa	[97-kDa]	0.1	1	2	1	1
63276	1709	-/st	[-/ST]	0.1	1	1	0	0
63277	1709	mesencephalon	[mesencephalon]	0.1	1	1	0	0
63278	1709	capacitance	[Capacitance]	0.1	1	1	0	0
63279	1709	30-kd	[30-kD]	0.1	1	1	0	0
63280	1709	acetaminophen-	[acetaminophen-]	0.1	1	1	0	0
63281	1709	PAS	[PAS]	0.1	1	2	1	1
63282	1709	PC4	[PC4]	0.1	1	1	0	0
63283	1709	accompany	[accompanying]	0.1	1	1	0	0
63284	1709	conformation.	[conformation.]	0.1	1	1	0	0
63285	1709	PDN	[PDN]	0.1	1	1	0	0
63286	1709	syn-1	[syn-1]	0.1	1	2	2	2
63287	1709	brushing,	[brushing,]	0.1	1	1	0	0
63288	1709	mda-mb-231	[MDA-MB-231]	0.1	1	1	0	0
63289	1709	PGN	[PGN]	0.1	1	2	1	1
63290	1709	PKB	[PKB]	0.1	1	2	1	1
63291	1709	immunochemistry	[immunochemistry]	0.1	1	1	0	0
63292	1709	PP1	[PP1]	0.1	1	2	2	2
63293	1709	marmoset	[marmoset]	0.1	1	2	1	1
63294	1709	PSA	[PSA]	0.1	1	1	0	0
63295	1709	PTF	[PTF]	0.1	1	2	1	1
63296	1709	PTT	[PTT]	0.1	1	2	1	1
63297	1709	Spi-1/PU.1	[Spi-1/PU.1]	0.1	1	2	1	1
63298	1709	ME1a1	[ME1a1]	0.1	1	1	0	0
63299	1709	hyper-	[hyper-]	0.1	1	2	1	1
63300	1709	flunisolide	[flunisolide]	0.1	1	1	0	0
63301	1709	c-mpl	[c-Mpl]	0.1	1	2	2	2
63302	1709	30-bp	[30-bp]	0.1	1	1	0	0
63303	1709	rbpi21	[rBPI21]	0.1	1	3	2	1
63304	1709	rkgsssnepssd	[RKGSSSNEPSSD]	0.1	1	1	0	0
63305	1709	iblp	[IBLP]	0.1	1	2	1	1
63306	1709	PhK	[PhK]	0.1	1	1	0	0
63307	1709	myogenesis	[myogenesis]	0.1	1	2	1	1
63308	1709	haematopoiesis	[haematopoiesis]	0.1	1	2	1	1
63309	1709	Herpesviruses	[Herpesviruses]	0.1	1	1	0	0
63310	1709	mice.	[mice.]	0.1	1	1	0	0
63311	1709	account.	[account.]	0.1	1	1	0	0
63312	1709	mmol/l;	[mmol/l;]	0.1	1	1	0	0
63313	1709	icer	[ICER]	0.1	1	1	0	0
63314	1709	caspase-6	[caspase-6]	0.1	1	1	0	0
63315	1709	ifngamma	[IFNgamma]	0.1	1	2	1	1
63316	1709	RAZ	[RAZ]	0.1	1	1	0	0
63317	1709	APO-1/Fas	[APO-1/Fas]	0.1	1	2	1	1
63318	1709	REX	[REX]	0.1	1	1	0	0
63319	1709	icss	[ICSs]	0.1	1	2	2	2
63320	1709	icsa	[IcsA]	0.1	1	2	2	2
63321	1709	RIC	[RIC]	0.1	1	2	2	2
63322	1709	RP1	[RP1]	0.1	1	2	2	2
63323	1709	S1T	[S1T]	0.1	1	1	0	0
63324	1709	t3-response	[T3-responses]	0.1	1	1	0	0
63325	1709	p21ha-ras	[p21Ha-ras]	0.1	1	1	0	0
63326	1709	thiol-reduce	[thiol-reducing]	0.1	1	1	0	0
63327	1709	idbp	[IDBP]	0.1	1	2	1	1
63328	1709	rotamase	[rotamase]	0.1	1	2	1	1
63329	1709	SCM-1	[SCM-1]	0.1	1	2	1	1
63330	1709	MAPKK-1	[MAPKK-1]	0.1	1	1	0	0
63331	1709	flrgraygl	[FLRGRAYGL]	0.1	1	1	0	0
63332	1709	second,	[second,]	0.1	1	1	0	0
63333	1709	(seconds)	[(seconds)]	0.1	1	1	0	0
63334	1709	mmol/L.	[mmol/L.]	0.1	1	1	0	0
63335	1709	SBA	[SBA]	0.1	1	2	1	1
63336	1709	SBE	[SBE]	0.1	1	1	0	0
63337	1709	hypereosinophilic	[hypereosinophilic]	0.1	1	1	0	0
63338	1709	Rap	[Rap]	0.1	1	1	0	0
63339	1709	Rat	[Rat]	0.1	1	2	2	2
63340	1709	hiv-1-	[HIV-1-]	0.1	1	1	0	0
63341	1709	SDS	[SDS]	0.1	1	1	0	0
63342	1709	SF,	[SF,]	0.1	1	1	0	0
63343	1709	SF2	[SF2]	0.1	1	1	0	0
63344	1709	SH3	[SH3]	0.1	1	1	0	0
63345	1709	SFs	[SFs]	0.1	1	1	0	0
63346	1709	Rev	[Rev]	0.1	1	2	2	2
63347	1709	SIR	[SIR]	0.1	1	1	0	0
63348	1709	termini	[termini]	0.1	1	2	2	2
63349	1709	lyso-platelet-activating	[lyso-platelet-activating]	0.1	1	1	0	0
63350	1709	pma-)	[PMA-)]	0.1	1	1	0	0
63351	1709	SKW	[SKW]	0.1	1	1	0	0
63352	1709	paf-receptor	[PAF-receptor]	0.1	1	2	1	1
63353	1709	laevis	[laevis]	0.1	1	1	0	0
63354	1709	SP6	[SP6]	0.1	1	1	0	0
63355	1709	32.2-kda	[32.2-kDa]	0.1	1	1	0	0
63356	1709	T24	[T24]	0.1	1	1	0	0
63357	1709	SRI	[SRI]	0.1	1	2	1	1
63358	1709	mixture,	[mixture,]	0.1	1	1	0	0
63359	1709	STP	[STP]	0.1	1	1	0	0
63360	1709	helice	[helices]	0.1	1	1	0	0
63361	1709	Rta	[Rta]	0.1	1	3	2	1
63362	1709	COOH-	[COOH-]	0.1	1	1	0	0
63363	1709	ppar-gamma	[PPAR-gamma]	0.1	1	1	0	0
63364	1709	GABP	[GABP]	0.1	1	2	2	2
63365	1709	p53-/-	[p53-/-]	0.1	1	1	0	0
63366	1709	recipient	[recipient]	0.1	1	2	2	2
63367	1709	TCE	[TCE]	0.1	1	2	1	1
63368	1709	methodology	[methodology]	0.1	1	1	0	0
63369	1709	zxda	[ZXDA]	0.1	1	1	0	0
63370	1709	zxdb	[ZXDB]	0.1	1	1	0	0
63371	1709	TGF	[TGF]	0.1	1	2	1	1
63372	1709	THR	[THR]	0.1	1	1	0	0
63373	1709	cytochemical	[cytochemical]	0.1	1	1	0	0
63374	1709	non-T-lymphote	[non-T-lymphocytes]	0.1	1	1	0	0
63375	1709	(ada)	[(ADA)]	0.1	1	1	0	0
63376	1709	ikappab-alphas32/36a	[IkappaB-alphaS32/36A]	0.1	1	2	1	1
63377	1709	c8-c7	[C8-C7]	0.1	1	1	0	0
63378	1709	U1B	[U1B]	0.1	1	1	0	0
63379	1709	beta,19-epoxy-4,21-dihydroxypregn-4-ene-3,20-dione	[beta,19-epoxy-4,21-dihydroxypregn-4-ene-3,20-dione]	0.1	1	1	0	0
63380	1709	g(anh)mtetra	[G(Anh)MTetra]	0.1	1	1	0	0
63381	1709	Spl	[Spl]	0.1	1	2	2	2
63382	1709	TRP	[TRP]	0.1	1	1	0	0
63383	1709	"adult"	["adult"]	0.1	1	2	2	2
63384	1709	U4A	[U4A]	0.1	1	1	0	0
63385	1709	TSC	[TSC]	0.1	1	2	1	1
63386	1709	TTP	[TTP]	0.1	1	1	0	0
63387	1709	U89	[U89]	0.1	1	1	0	0
63388	1709	disorders:	[disorders:]	0.1	1	1	0	0
63389	1709	UBP	[UBP]	0.1	1	1	0	0
63390	1709	LY294002	[LY294002]	0.1	1	2	1	1
63391	1709	disorders,	[disorders,]	0.1	1	1	0	0
63392	1709	ifn-	[IFN-]	0.1	1	1	0	0
63393	1709	Taq	[Taq]	0.1	1	1	0	0
63394	1709	Tax	[Tax]	0.1	1	1	0	0
63395	1709	ifna	[IFNA]	0.1	1	2	1	1
63396	1709	2.0-kb	[2.0-kb]	0.1	1	1	0	0
63397	1709	Tcf	[Tcf]	0.1	1	2	2	2
63398	1709	Tef	[Tef]	0.1	1	1	0	0
63399	1709	Th0	[Th0]	0.1	1	1	0	0
63400	1709	cpkc-alpha	[cPKC-alpha]	0.1	1	2	1	1
63401	1709	S.E.DeRocco,	[S.E.DeRocco,]	0.1	1	1	0	0
63402	1709	hiv-hd	[HIV-HD]	0.1	1	2	2	2
63403	1709	URS	[URS]	0.1	1	1	0	0
63404	1709	share	[share]	0.1	1	1	0	0
63405	1709	hydroxyurea	[hydroxyurea]	0.1	1	1	0	0
63406	1709	deprivation	[deprivation]	0.1	1	2	2	2
63407	1709	Trx	[Trx]	0.1	1	1	0	0
63408	1709	iga+	[IgA+]	0.1	1	1	0	0
63409	1709	hippocampus	[hippocampus]	0.1	1	2	1	1
63410	1709	maintain	[maintaining]	0.1	1	1	0	0
63411	1709	igf2	[IGF2]	0.1	1	1	0	0
63412	1709	nucleoporin	[nucleoporin]	0.1	1	2	2	2
63413	1709	lymphadenopathy	[lymphadenopathy]	0.1	1	1	0	0
63414	1709	rac1	[Rac1]	0.1	1	1	0	0
63415	1709	calycin	[calycin]	0.1	1	1	0	0
63416	1709	cd28+	[CD28+]	0.1	1	1	0	0
63417	1709	cd27+	[CD27+]	0.1	1	2	1	1
63418	1709	cd27-	[CD27-]	0.1	1	1	0	0
63419	1709	VD3	[VD3]	0.1	1	1	0	0
63420	1709	cbp35	[CBP35]	0.1	1	1	0	0
63421	1709	800-base	[800-base]	0.1	1	1	0	0
63422	1709	GD1a	[GD1a]	0.1	1	1	0	0
63423	1709	cosmid	[cosmid]	0.1	1	2	1	1
63424	1709	95-kDa	[95-kDa]	0.1	1	1	0	0
63425	1709	rapl	[Rapl]	0.1	1	1	0	0
63426	1709	stability.	[stability.]	0.1	1	1	0	0
63427	1709	rare	[RAREs]	0.1	1	2	1	1
63428	1709	110-130-kDa	[110-130-kDa]	0.1	1	1	0	0
63429	1709	pou[h]	[POU[H]]	0.1	1	1	0	0
63430	1709	r-h-tbp-1	[r-h-TBP-1]	0.1	1	1	0	0
63431	1709	phosphatidylinositide	[Phosphatidylinositides]	0.1	1	2	1	1
63432	1709	genera	[genera]	0.1	1	1	0	0
63433	1709	essay	[essays]	0.1	1	1	0	0
63434	1709	[3H]calcitriol	[[3H]calcitriol]	0.1	1	1	0	0
63435	1709	islets.	[islets.]	0.1	1	1	0	0
63436	1709	COS-1	[COS-1]	0.1	1	2	2	2
63437	1709	cd19+	[CD19+]	0.1	1	1	0	0
63438	1709	Tyr-128	[Tyr-128]	0.1	1	1	0	0
63439	1709	squelching	[squelching]	0.1	1	2	2	2
63440	1709	Tyr-113	[Tyr-113]	0.1	1	1	0	0
63441	1709	Val	[Val]	0.1	1	2	1	1
63442	1709	p105/	[p105/]	0.1	1	1	0	0
63443	1709	p90rsk	[p90RSK]	0.1	1	1	0	0
63444	1709	subgroups,	[subgroups,]	0.1	1	1	0	0
63445	1709	Notch1/TAN-1	[Notch1/TAN-1]	0.1	1	1	0	0
63446	1709	cd14+	[CD14+]	0.1	1	2	1	1
63447	1709	cd14-	[CD14-]	0.1	1	1	0	0
63448	1709	X-Y	[X-Y]	0.1	1	1	0	0
63449	1709	cd437	[CD437]	0.1	1	1	0	0
63450	1709	cd45-	[CD45-]	0.1	1	2	1	1
63451	1709	cd40-	[CD40-]	0.1	1	1	0	0
63452	1709	v.cholera.	[V.cholera.]	0.1	1	1	0	0
63453	1709	young	[young]	0.1	1	1	0	0
63454	1709	culturing	[culturing]	0.1	1	1	0	0
63455	1709	Antiandrogens	[Antiandrogens]	0.1	1	1	0	0
63456	1709	th0-type	[Th0-type]	0.1	1	1	0	0
63457	1709	reside	[residing]	0.1	1	2	2	2
63458	1709	pmlrar	[PMLRAR]	0.1	1	1	0	0
63459	1709	cd49f	[CD49f]	0.1	1	1	0	0
63460	1709	HL-60-	[HL-60-]	0.1	1	1	0	0
63461	1709	<3),3	[<3),]	0.1	1	1	0	0
63462	1709	cd30l	[CD30L]	0.1	1	1	0	0
63463	1709	dq3.1	[DQ3.1]	0.1	1	1	0	0
63464	1709	dq3.3	[DQ3.3]	0.1	1	1	0	0
63465	1709	sodium/proton	[sodium/proton]	0.1	1	2	1	1
63466	1709	XPB	[XPB]	0.1	1	1	0	0
63467	1709	XPD	[XPD]	0.1	1	2	1	1
63468	1709	XPG	[XPG]	0.1	1	1	0	0
63469	1709	Wp,	[Wp,]	0.1	1	1	0	0
63470	1709	cd33+	[CD33+]	0.1	1	1	0	0
63471	1709	cd336	[CD336]	0.1	1	1	0	0
63472	1709	sensitize	[sensitizing]	0.1	1	1	0	0
63473	1709	STLV-I	[STLV-I]	0.1	1	2	1	1
63474	1709	beginning	[beginning]	0.1	1	1	0	0
63475	1709	cd30+	[CD30+]	0.1	1	1	0	0
63476	1709	dominant-negative,	[dominant-negative,]	0.1	1	1	0	0
63477	1709	P.G.,	[P.G.,]	0.1	1	1	0	0
63478	1709	lyt-10	[lyt-10]	0.1	1	2	1	1
63479	1709	YAC	[YAC]	0.1	1	1	0	0
63480	1709	Nuclease	[Nuclease]	0.1	1	1	0	0
63481	1709	foci,	[foci,]	0.1	1	2	1	1
63482	1709	tubal	[tubal]	0.1	1	1	0	0
63483	1709	cd367	[CD367]	0.1	1	1	0	0
63484	1709	cd38+	[CD38+]	0.1	1	2	2	2
63485	1709	Z/R	[Z/R]	0.1	1	1	0	0
63486	1709	cd68-	[CD68-]	0.1	1	2	2	2
63487	1709	Z29	[Z29]	0.1	1	1	0	0
63488	1709	BLIN-1	[BLIN-1]	0.1	1	2	1	1
63489	1709	interleukin-15	[interleukin-15]	0.1	1	1	0	0
63490	1709	c-fos)	[c-fos)]	0.1	1	1	0	0
63491	1709	ebna3c	[EBNA3C]	0.1	1	2	1	1
63492	1709	c-fos.	[c-fos.]	0.1	1	1	0	0
63493	1709	Interferon-gamma	[Interferon-gamma]	0.1	1	2	2	2
63494	1709	cd62l	[CD62L]	0.1	1	1	0	0
63495	1709	PKC-zeta	[PKC-zeta]	0.1	1	1	0	0
63496	1709	molybdate	[molybdate]	0.1	1	1	0	0
63497	1709	scm-1-producer	[SCM-1-producer]	0.1	1	2	1	1
63498	1709	ikk2	[IKK2]	0.1	1	2	1	1
63499	1709	GH-V	[GH-V]	0.1	1	1	0	0
63500	1709	nf(kappa)b	[NF(kappa)B]	0.1	1	2	2	2
63501	1709	PAFR	[PAFR]	0.1	1	2	1	1
63502	1709	debate	[debate]	0.1	1	1	0	0
63503	1709	sequela	[sequela]	0.1	1	2	2	2
63504	1709	Kaposi's	[Kaposi's]	0.1	1	2	1	1
63505	1709	k-ra	[K-RAS]	0.1	1	1	0	0
63506	1709	fmol/mg)	[fmol/mg)]	0.1	1	1	0	0
63507	1709	fmol/mg.	[fmol/mg.]	0.1	1	1	0	0
63508	1709	alpha2beta1	[alpha2beta1]	0.1	1	1	0	0
63509	1709	phrase	[phrases]	0.1	1	1	0	0
63510	1709	FDCP-2	[FDCP-2]	0.1	1	1	0	0
63511	1709	Pax-5d	[Pax-5d]	0.1	1	2	1	1
63512	1709	interleukin-11	[interleukin-11]	0.1	1	2	1	1
63513	1709	sheep	[sheep]	0.1	1	1	0	0
63514	1709	il-12p40	[IL-12p40]	0.1	1	1	0	0
63515	1709	[4]	[[4]]	0.1	1	1	0	0
63516	1709	SCL/Tal1	[SCL/Tal1]	0.1	1	1	0	0
63517	1709	Rat-1	[Rat-1]	0.1	1	2	1	1
63518	1709	cycling	[cycling]	0.1	1	2	2	2
63519	1709	reverse-transcriptase	[reverse-transcriptase]	0.1	1	1	0	0
63520	1709	programme	[programme]	0.1	1	2	1	1
63521	1709	azelastine	[azelastine]	0.1	1	2	2	2
63522	1709	opioid	[opioid]	0.1	1	2	1	1
63523	1709	lymphocytes,	[lymphocytes,]	0.1	1	2	1	1
63524	1709	immunophilin-drug	[immunophilin-drug]	0.1	1	1	0	0
63525	1709	Zfh	[Zfh]	0.1	1	1	0	0
63526	1709	Virol	[Virol]	0.1	1	1	0	0
63527	1709	TAFII105	[TAFII105]	0.1	1	1	0	0
63528	1709	PC12	[PC12]	0.1	1	1	0	0
63529	1709	Wortmannin,	[Wortmannin,]	0.1	1	1	0	0
63530	1709	(+)-pentazocine	[(+)-pentazocine]	0.1	1	2	1	1
63531	1709	rfx5	[RFX5]	0.1	1	1	0	0
63532	1709	rfx1	[RFX1]	0.1	1	1	0	0
63533	1709	monoblastic	[monoblastic]	0.1	1	1	0	0
63534	1709	calcium-ionophore	[calcium-ionophore]	0.1	1	1	0	0
63535	1709	PBYF	[PBYF]	0.1	1	1	0	0
63536	1709	mini-	[mini-]	0.1	1	1	0	0
63537	1709	b7.1	[B7.1]	0.1	1	1	0	0
63538	1709	site-forming	[site-forming]	0.1	1	1	0	0
63539	1709	acid-alpha	[acid-alpha]	0.1	1	1	0	0
63540	1709	secosterol	[secosterol]	0.1	1	1	0	0
63541	1709	k197	[K197S]	0.1	1	1	0	0
63542	1709	Arg551	[Arg551]	0.1	1	2	1	1
63543	1709	chi2);	[chi2);]	0.1	1	1	0	0
63544	1709	metamorphosis	[metamorphosis]	0.1	1	1	0	0
63545	1709	eradication	[eradication]	0.1	1	1	0	0
63546	1709	cd3-t-cell	[CD3-T-cell]	0.1	1	1	0	0
63547	1709	(mmtv)	[(MMTV)]	0.1	1	1	0	0
63548	1709	t(10;11)(p13;q14)	[t(10;11)(p13;q14)]	0.1	1	1	0	0
63549	1709	amino-acid	[amino-acid]	0.1	1	1	0	0
63550	1709	COX-2	[COX-2]	0.1	1	1	0	0
63551	1709	DQalpha	[DQalpha]	0.1	1	1	0	0
63552	1709	cd79b	[CD79b]	0.1	1	1	0	0
63553	1709	protozoan	[protozoan]	0.1	1	1	0	0
63554	1709	T-PLL	[T-PLL]	0.1	1	2	1	1
63555	1709	cd4-bearing	[CD4-bearing]	0.1	1	1	0	0
63556	1709	drugs,	[drugs,]	0.1	1	2	1	1
63557	1709	mrl-lpr/lpr	[MRL-lpr/lpr]	0.1	1	2	1	1
63558	1709	ccrf-cem	[CCRF-CEM]	0.1	1	1	0	0
63559	1709	Rch1/importin	[Rch1/importin]	0.1	1	1	0	0
63560	1709	PDBu	[PDBu]	0.1	1	2	1	1
63561	1709	hydrolase	[hydrolase]	0.1	1	2	1	1
63562	1709	70-kda	[70-kDa]	0.1	1	1	0	0
63563	1709	Karsenty,	[Karsenty,]	0.1	1	1	0	0
63564	1709	200-bp	[200-bp]	0.1	1	1	0	0
63565	1709	cross-linking.	[cross-linking.]	0.1	1	1	0	0
63566	1709	M.Malnati,	[M.Malnati,]	0.1	1	1	0	0
63567	1709	[3H]aldosterone	[[3H]aldosterone]	0.1	1	1	0	0
63568	1709	neuroendocrine	[neuroendocrine]	0.1	1	1	0	0
63569	1709	/il-7r	[/IL-7R]	0.1	1	2	1	1
63570	1709	myeloid-	[myeloid-]	0.1	1	1	0	0
63571	1709	washout	[washout]	0.1	1	1	0	0
63572	1709	dna-laddering	[DNA-laddering]	0.1	1	1	0	0
63573	1709	NF-ATs	[NF-ATs]	0.1	1	1	0	0
63574	1709	cells'	[cells']	0.1	1	1	0	0
63575	1709	(aml)	[(AML)]	0.1	1	2	2	2
63576	1709	ion.	[ion.]	0.1	1	1	0	0
63577	1709	erythroblastosis	[erythroblastosis]	0.1	1	1	0	0
63578	1709	carcinogenesis	[carcinogenesis]	0.1	1	2	1	1
63579	1709	il-9r	[IL-9R]	0.1	1	1	0	0
63580	1709	NF-AT-	[NF-AT-]	0.1	1	1	0	0
63581	1709	pdgf[b]	[PDGF[B]]	0.1	1	1	0	0
63582	1709	isozyme	[isozyme]	0.1	1	2	2	2
63583	1709	H-7,	[H-7,]	0.1	1	1	0	0
63584	1709	Pbeta	[Pbeta]	0.1	1	1	0	0
63585	1709	Japan,	[Japan,]	0.1	1	1	0	0
63586	1709	lipids.	[lipids.]	0.1	1	1	0	0
63587	1709	ttcaaag	[TTCAAAG]	0.1	1	1	0	0
63588	1709	Clone-13,	[Clone-13,]	0.1	1	1	0	0
63589	1709	12-o-tetradecanoyl-phorbol-13-acetate	[12-O-tetradecanoyl-phorbol-13-acetate]	0.1	1	2	1	1
63590	1709	matrice	[matrices]	0.1	1	2	2	2
63591	1709	neglect	[neglect]	0.1	1	1	0	0
63592	1709	VLA-4/	[VLA-4/]	0.1	1	1	0	0
63593	1709	5869-bp	[5869-bp]	0.1	1	1	0	0
63594	1709	alcoholics	[alcoholics]	0.1	1	1	0	0
63595	1709	microarchitecture	[microarchitecture]	0.1	1	2	2	2
63596	1709	superinduction	[superinduction]	0.1	1	2	1	1
63597	1709	GLRP	[GLRP]	0.1	1	1	0	0
63598	1709	translocations.	[translocations.]	0.1	1	1	0	0
63599	1709	il-7-	[IL-7-]	0.1	1	1	0	0
63600	1709	il-5-	[IL-5-]	0.1	1	1	0	0
63601	1709	atl-16t	[ATL-16T]	0.1	1	2	2	2
63602	1709	NH2-terminal	[NH2-terminal]	0.1	1	1	0	0
63603	1709	il-3,	[IL-3,]	0.1	1	2	1	1
63604	1709	il-3-	[IL-3-]	0.1	1	1	0	0
63605	1709	il-2+	[IL-2+]	0.1	1	1	0	0
63606	1709	il-1-	[IL-1-]	0.1	1	1	0	0
63607	1709	substSpl2	[substSpl2]	0.1	1	2	2	2
63608	1709	bamhi-q	[BamHI-Q]	0.1	1	2	1	1
63609	1709	EBER-1	[EBER-1]	0.1	1	1	0	0
63610	1709	ctll2	[CTLL2]	0.1	1	1	0	0
63611	1709	environment,	[environment,]	0.1	1	1	0	0
63612	1709	plcgamma1	[PLCgamma1]	0.1	1	1	0	0
63613	1709	PGI2	[PGI2]	0.1	1	1	0	0
63614	1709	fragment.	[fragment.]	0.1	1	1	0	0
63615	1709	c-jun/c-fo	[c-Jun/c-Fos]	0.1	1	1	0	0
63616	1709	coregulator	[coregulator]	0.1	1	2	2	2
63617	1709	P2l(ras)	[p2l(ras)]	0.1	1	1	0	0
63618	1709	a10	[A10]	0.1	1	1	0	0
63619	1709	a/t	[A/T]	0.1	1	2	2	2
63620	1709	IL-12-	[IL-12-]	0.1	1	1	0	0
63621	1709	IL-13-	[IL-13-]	0.1	1	1	0	0
63622	1709	IL-10-	[IL-10-]	0.1	1	1	0	0
63623	1709	(cd45ro+)	[(CD45RO+)]	0.1	1	2	1	1
63624	1709	arre-2	[ARRE-2]	0.1	1	1	0	0
63625	1709	irf-	[IRF-]	0.1	1	2	2	2
63626	1709	ciclosporin	[ciclosporin]	0.1	1	1	0	0
63627	1709	stomach	[stomach]	0.1	1	1	0	0
63628	1709	t(9;22)(q34;q11)	[t(9;22)(q34;q11)]	0.1	1	1	0	0
63629	1709	ic50)	[IC50)]	0.1	1	1	0	0
63630	1709	cre-loxP	[cre-loxP]	0.1	1	1	0	0
63631	1709	gag-pol	[gag-pol]	0.1	1	1	0	0
63632	1709	NF-IL4	[NF-IL4]	0.1	1	1	0	0
63633	1709	E4bp4	[E4bp4]	0.1	1	2	1	1
63634	1709	approaches;	[approaches;]	0.1	1	1	0	0
63635	1709	approaches.	[approaches.]	0.1	1	2	2	2
63636	1709	b-2	[B-2]	0.1	1	1	0	0
63637	1709	clb-cd28/1	[CLB-CD28/1]	0.1	1	1	0	0
63638	1709	t(3;21)(q26;q22)	[t(3;21)(q26;q22)]	0.1	1	1	0	0
63639	1709	marrow.	[marrow.]	0.1	1	1	0	0
63640	1709	isg54	[ISG54]	0.1	1	1	0	0
63641	1709	substSp34	[substSp34]	0.1	1	1	0	0
63642	1709	isg15	[ISG15]	0.1	1	2	1	1
63643	1709	camkiv	[CaMKIV]	0.1	1	2	1	1
63644	1709	(apc)	[(APC)]	0.1	1	1	0	0
63645	1709	DQbeta	[DQbeta]	0.1	1	2	1	1
63646	1709	(apl)	[(APL)]	0.1	1	3	2	1
63647	1709	Jurkat-tat	[Jurkat-tat]	0.1	1	1	0	0
63648	1709	peroxisome-proliferator	[peroxisome-proliferator]	0.1	1	1	0	0
63649	1709	aav	[AAV]	0.1	1	1	0	0
63650	1709	neurite	[neurite]	0.1	1	1	0	0
63651	1709	ad2	[Ad2]	0.1	1	2	1	1
63652	1709	gp350/220	[gp350/220]	0.1	1	1	0	0
63653	1709	ace	[ACE]	0.1	1	1	0	0
63654	1709	ach	[ACH]	0.1	1	2	1	1
63655	1709	cleavage.	[cleavage.]	0.1	1	1	0	0
63656	1709	ada	[ADA]	0.1	1	2	2	2
63657	1709	xenobiotics	[xenobiotics]	0.1	1	1	0	0
63658	1709	t1/2	[t1/2]	0.1	1	2	1	1
63659	1709	afr	[AFR]	0.1	1	1	0	0
63660	1709	shp-1	[SHP-1]	0.1	1	2	1	1
63661	1709	air	[air]	0.1	1	2	2	2
63662	1709	al1	[AL1]	0.1	1	1	0	0
63663	1709	ratio,	[ratio,]	0.1	1	1	0	0
63664	1709	ratio.	[ratio.]	0.1	1	1	0	0
63665	1709	ala	[Ala]	0.1	1	1	0	0
63666	1709	anh	[ANH]	0.1	1	1	0	0
63667	1709	tunel	[TUNEL]	0.1	1	1	0	0
63668	1709	increase-ratio	[increase-ratios]	0.1	1	1	0	0
63669	1709	c57	[C57]	0.1	1	1	0	0
63670	1709	mesenchymal	[mesenchymal]	0.1	1	1	0	0
63671	1709	at1	[AT1]	0.1	1	1	0	0
63672	1709	hypoactivity	[hypoactivity]	0.1	1	1	0	0
63673	1709	ata	[ATA]	0.1	1	1	0	0
63674	1709	atd	[ATD]	0.1	1	2	1	1
63675	1709	acid.	[acid.]	0.1	1	2	1	1
63676	1709	Smu/Sepsilon	[Smu/Sepsilon]	0.1	1	1	0	0
63677	1709	att	[ATT]	0.1	1	1	0	0
63678	1709	IL-1ra	[IL-1ra]	0.1	1	1	0	0
63679	1709	f(5,55)	[F(5,55)]	0.1	1	1	0	0
63680	1709	auc	[AUC]	0.1	1	2	1	1
63681	1709	avp	[AVP]	0.1	1	1	0	0
63682	1709	rna.	[RNA.]	0.1	1	2	1	1
63683	1709	mrna.	[mRNA.]	0.1	1	1	0	0
63684	1709	TFIIHwt	[TFIIHwt]	0.1	1	2	1	1
63685	1709	NRE-I	[NRE-I]	0.1	1	2	2	2
63686	1709	bak	[bak]	0.1	1	1	0	0
63687	1709	bax	[bax]	0.1	1	1	0	0
63688	1709	adenovirus-	[adenovirus-]	0.1	1	1	0	0
63689	1709	Alone,	[Alone,]	0.1	1	2	1	1
63690	1709	zinc-binding	[zinc-binding]	0.1	1	1	0	0
63691	1709	(ars)	[(AES)]	0.1	1	1	0	0
63692	1709	stimulations.	[stimulations.]	0.1	1	1	0	0
63693	1709	bdp	[BDP]	0.1	1	1	0	0
63694	1709	log10kd	[log10Kd]	0.1	1	1	0	0
63695	1709	reexpression	[reexpression]	0.1	1	2	2	2
63696	1709	blp	[BLPs]	0.1	1	2	1	1
63697	1709	d1/	[D1/]	0.1	1	1	0	0
63698	1709	bmt	[BMT]	0.1	1	2	2	2
63699	1709	bp-	[BP-]	0.1	1	1	0	0
63700	1709	bp1	[BP1]	0.1	1	2	1	1
63701	1709	bp2	[BP2]	0.1	1	1	0	0
63702	1709	chaperone	[chaperone]	0.1	1	2	1	1
63703	1709	bpi	[BPI]	0.1	1	1	0	0
63704	1709	serine-threonine	[serine-threonine]	0.1	1	2	1	1
63705	1709	infiltrates.	[infiltrates.]	0.1	1	1	0	0
63706	1709	(are)	[(are)]	0.1	1	1	0	0
63707	1709	bsa	[BSA]	0.1	1	1	0	0
63708	1709	5'-ctcagga-3'	[5'-CTCAGGA-3']	0.1	1	1	0	0
63709	1709	bso	[BSO]	0.1	1	2	2	2
63710	1709	bud	[BUD]	0.1	1	2	1	1
63711	1709	pharmacogenetics	[pharmacogenetics]	0.1	1	1	0	0
63712	1709	bz1	[BZ1]	0.1	1	2	1	1
63713	1709	Wortmannin	[Wortmannin]	0.1	1	1	0	0
63714	1709	nature.	[nature.]	0.1	1	1	0	0
63715	1709	transcriptase-polymerase	[transcriptase-polymerase]	0.1	1	3	2	1
63716	1709	can	[Ca]	0.1	1	1	0	0
63717	1709	roi-	[ROI-]	0.1	1	1	0	0
63718	1709	cat	[cat]	0.1	1	2	1	1
63719	1709	cax	[CAX]	0.1	1	1	0	0
63720	1709	ifn-alpha/beta	[IFN-alpha/beta]	0.1	1	2	1	1
63721	1709	PKCs	[PKCs]	0.1	1	1	0	0
63722	1709	reticuloendotheliosis	[Reticuloendotheliosis]	0.1	1	2	1	1
63723	1709	cdk	[cdk]	0.1	1	2	1	1
63724	1709	adulthood.	[adulthood.]	0.1	1	1	0	0
63725	1709	apolipoprotein	[apolipoprotein]	0.1	1	1	0	0
63726	1709	4-exon	[4-exon]	0.1	1	1	0	0
63727	1709	cid	[CID]	0.1	1	1	0	0
63728	1709	derangement	[derangements]	0.1	1	1	0	0
63729	1709	e12	[E12]	0.1	1	1	0	0
63730	1709	HK666	[HK666]	0.1	1	1	0	0
63731	1709	production,	[production,]	0.1	1	2	2	2
63732	1709	production.	[production.]	0.1	1	3	2	1
63733	1709	csf	[CSFs]	0.1	1	2	1	1
63734	1709	fenofibrate	[fenofibrate]	0.1	1	1	0	0
63735	1709	Phe50-Tyr65	[Phe50-Tyr65]	0.1	1	1	0	0
63736	1709	fibromyalgia	[fibromyalgia]	0.1	1	2	1	1
63737	1709	domains.	[domains.]	0.1	1	2	1	1
63738	1709	PLAP	[PLAP]	0.1	1	1	0	0
63739	1709	da.	[Da.]	0.1	1	1	0	0
63740	1709	Ets-1,	[Ets-1,]	0.1	1	1	0	0
63741	1709	dbd	[DBD]	0.1	1	2	2	2
63742	1709	dbp	[Dbp]	0.1	1	1	0	0
63743	1709	r-activating	[R-activating]	0.1	1	1	0	0
63744	1709	des	[DES]	0.1	1	1	0	0
63745	1709	dfs	[DFS]	0.1	1	1	0	0
63746	1709	chemiluminescence	[chemiluminescence]	0.1	1	1	0	0
63747	1709	n-acetyl-l-cysteine	[N-acetyl-L-cysteine]	0.1	1	2	1	1
63748	1709	rprl	[rPRL]	0.1	1	1	0	0
63749	1709	dp2	[DP2]	0.1	1	2	2	2
63750	1709	il-beta	[IL-beta]	0.1	1	1	0	0
63751	1709	retinoid-X	[retinoid-X]	0.1	1	1	0	0
63752	1709	t47d	[T47D]	0.1	1	1	0	0
63753	1709	microg/ml.	[microg/ml.]	0.1	1	1	0	0
63754	1709	dst	[DST]	0.1	1	2	2	2
63755	1709	allele:	[allele:]	0.1	1	1	0	0
63756	1709	dtt	[DTT]	0.1	1	1	0	0
63757	1709	diethylstilbestrol	[diethylstilbestrol]	0.1	1	2	1	1
63758	1709	partition	[partition]	0.1	1	1	0	0
63759	1709	dxm	[DXM]	0.1	1	2	1	1
63760	1709	Pebp2/Cbf	[Pebp2/Cbf]	0.1	1	1	0	0
63761	1709	pip/lsirf	[Pip/LSIRF]	0.1	1	1	0	0
63762	1709	PMA+	[PMA+]	0.1	1	1	0	0
63763	1709	immunotoxicity	[immunotoxicity]	0.1	1	2	1	1
63764	1709	covalent	[covalent]	0.1	1	1	0	0
63765	1709	Charcot-Leyden	[Charcot-Leyden]	0.1	1	1	0	0
63766	1709	aberration	[aberrations]	0.1	1	2	2	2
63767	1709	ef1	[EF1]	0.1	1	2	1	1
63768	1709	egr	[Egr]	0.1	1	2	1	1
63769	1709	GSSG	[GSSG]	0.1	1	1	0	0
63770	1709	PMNs	[PMNs]	0.1	1	2	1	1
63771	1709	KB-enhancer	[KB-enhancer]	0.1	1	1	0	0
63772	1709	base-pair	[base-pair]	0.1	1	1	0	0
63773	1709	g/g	[g/g]	0.1	1	2	2	2
63774	1709	g1-	[G1-]	0.1	1	1	0	0
63775	1709	g1,	[G1,]	0.1	1	1	0	0
63776	1709	hmg-box	[HMG-box]	0.1	1	2	1	1
63777	1709	ep4	[EP4]	0.1	1	1	0	0
63778	1709	er+	[ER+]	0.1	1	2	2	2
63779	1709	Mann-Whitney	[Mann-Whitney]	0.1	1	1	0	0
63780	1709	p21/cip1	[p21/Cip1]	0.1	1	1	0	0
63781	1709	apo-1/cd95	[Apo-1/CD95]	0.1	1	1	0	0
63782	1709	carotid	[carotid]	0.1	1	2	1	1
63783	1709	-protein	[-protein]	0.1	1	2	1	1
63784	1709	poly(A)	[poly(A)]	0.1	1	2	1	1
63785	1709	NFAT4/NFATx/NFATc3	[NFAT4/NFATx/NFATc3]	0.1	1	1	0	0
63786	1709	fak	[FAK]	0.1	1	2	1	1
63787	1709	fc3	[FC3]	0.1	1	2	1	1
63788	1709	p-toluenesulfonic	[p-toluenesulfonic]	0.1	1	1	0	0
63789	1709	oTAFII110	[oTAFII110]	0.1	1	1	0	0
63790	1709	h).	[h).]	0.1	1	1	0	0
63791	1709	PO-B	[PO-B]	0.1	1	2	1	1
63792	1709	hog-1	[HOG-1]	0.1	1	1	0	0
63793	1709	h-7	[H-7]	0.1	1	2	1	1
63794	1709	eukaryote	[eukaryotes]	0.1	1	2	1	1
63795	1709	haptenation	[haptenation]	0.1	1	2	1	1
63796	1709	transcription-enhancer	[transcription-enhancer]	0.1	1	1	0	0
63797	1709	fly	[fly]	0.1	1	1	0	0
63798	1709	h19	[H19]	0.1	1	1	0	0
63799	1709	perforin-	[perforin-expressing]	0.1	1	1	0	0
63800	1709	e2f-1/dp1	[E2F-1/DP1]	0.1	1	1	0	0
63801	1709	fus	[fuses]	0.1	1	1	0	0
63802	1709	fvc	[FVC]	0.1	1	1	0	0
63803	1709	precursors,	[precursors,]	0.1	1	1	0	0
63804	1709	alg-4	[ALG-4]	0.1	1	1	0	0
63805	1709	NF-E2/AP1	[NF-E2/AP1]	0.1	1	2	1	1
63806	1709	deltaSpi-B	[deltaSpi-B]	0.1	1	1	0	0
63807	1709	gad	[GAD]	0.1	1	2	1	1
63808	1709	gcR	[gcR]	0.1	1	1	0	0
63809	1709	tata-binding	[TATA-binding]	0.1	1	2	2	2
63810	1709	gdp	[GDP]	0.1	1	1	0	0
63811	1709	i/y	[I/Y]	0.1	1	1	0	0
63812	1709	PP2A	[PP2A]	0.1	1	1	0	0
63813	1709	granulocyte-colony	[granulocyte-colony]	0.1	1	1	0	0
63814	1709	gpx	[GPX]	0.1	1	2	1	1
63815	1709	POUs	[POUs]	0.1	1	1	0	0
63816	1709	hTR	[hTR]	0.1	1	2	1	1
63817	1709	E6-AP	[E6-AP]	0.1	1	1	0	0
63818	1709	gtt	[GTT]	0.1	1	1	0	0
63819	1709	death),	[death),]	0.1	1	1	0	0
63820	1709	histidine	[histidine]	0.1	1	1	0	0
63821	1709	mad3/	[MAD3/]	0.1	1	1	0	0
63822	1709	pigment	[pigment]	0.1	1	2	1	1
63823	1709	dna-binding/immunoprecipitation	[DNA-binding/immunoprecipitation]	0.1	1	1	0	0
63824	1709	bicoid	[Bicoid]	0.1	1	1	0	0
63825	1709	the/thf	[THE/THF]	0.1	1	2	1	1
63826	1709	measure	[measure]	0.1	1	3	2	1
63827	1709	hd1	[HD1]	0.1	1	1	0	0
63828	1709	hd6	[HD6]	0.1	1	2	1	1
63829	1709	maltose	[Maltose]	0.1	1	2	1	1
63830	1709	heb	[HEB]	0.1	1	2	1	1
63831	1709	hel	[HEL]	0.1	1	1	0	0
63832	1709	diclofenac	[diclofenac]	0.1	1	1	0	0
63833	1709	hip	[hip]	0.1	1	1	0	0
63834	1709	hit	[HIT]	0.1	1	1	0	0
63835	1709	hlh	[HLH]	0.1	1	2	2	2
63836	1709	hmd	[HMDS]	0.1	1	2	2	2
63837	1709	32-kDa	[32-kDa]	0.1	1	1	0	0
63838	1709	IL-2Rgamma	[IL-2Rgamma]	0.1	1	1	0	0
63839	1709	-Ile	[-Ile]	0.1	1	2	2	2
63840	1709	hnf	[HNF]	0.1	1	2	1	1
63841	1709	cross-competition	[Cross-competition]	0.1	1	2	2	2
63842	1709	hsc	[HSC]	0.1	1	2	2	2
63843	1709	D.G.Tenen,	[D.G.Tenen,]	0.1	1	1	0	0
63844	1709	htb	[HTB]	0.1	1	2	1	1
63845	1709	hum	[Hum]	0.1	1	1	0	0
63846	1709	mac-2	[Mac-2]	0.1	1	1	0	0
63847	1709	inv(16)(p13q22)	[inv(16)(p13q22)]	0.1	1	1	0	0
63848	1709	bursal	[bursal]	0.1	1	1	0	0
63849	1709	3'NF-E2/AP1	[3'NF-E2/AP1]	0.1	1	1	0	0
63850	1709	phytohemaglutinin	[phytohemaglutinin]	0.1	1	1	0	0
63851	1709	VDDR-II	[VDDR-II]	0.1	1	1	0	0
63852	1709	jun/fo	[jun/fos]	0.1	1	2	1	1
63853	1709	ice	[ICE]	0.1	1	2	1	1
63854	1709	ie,	[ie,]	0.1	1	1	0	0
63855	1709	icn	[ICN]	0.1	1	2	1	1
63856	1709	hdl-cholesterol	[HDL-cholesterol]	0.1	1	1	0	0
63857	1709	(subst)	[(subst)]	0.1	1	1	0	0
63858	1709	ii)	[II)]	0.1	1	2	2	2
63859	1709	il5	[IL5]	0.1	1	1	0	0
63860	1709	Cipro	[Cipro]	0.1	1	1	0	0
63861	1709	control,	[control,]	0.1	1	1	0	0
63862	1709	Kruppel-like	[Kruppel-like]	0.1	1	1	0	0
63863	1709	ish	[ISH]	0.1	1	2	1	1
63864	1709	p70s6k	[p70S6K]	0.1	1	1	0	0
63865	1709	transcription-activateactivateactivateactivating	[transcription-activating]	0.1	1	1	0	0
63866	1709	itt	[ITT]	0.1	1	1	0	0
63867	1709	55-kDa	[55-kDa]	0.1	1	1	0	0
63868	1709	Jun-D	[Jun-D]	0.1	1	1	0	0
63869	1709	mar;10(3):399]	[Mar;10(3):399]]	0.1	1	1	0	0
63870	1709	acla	[ACLA]	0.1	1	1	0	0
63871	1709	X2-box	[X2-box]	0.1	1	1	0	0
63872	1709	throughput	[throughput]	0.1	1	1	0	0
63873	1709	distance	[distance]	0.1	1	1	0	0
63874	1709	PRL-	[PRL-]	0.1	1	1	0	0
63875	1709	microg/10(6)	[microg/10(6)]	0.1	1	1	0	0
63876	1709	differentiation/maturation	[differentiation/maturation]	0.1	1	1	0	0
63877	1709	rvlp	[RVLP]	0.1	1	3	2	1
63878	1709	aborter	[aborters]	0.1	1	2	2	2
63879	1709	treatments.	[treatments.]	0.1	1	1	0	0
63880	1709	fast-migrate	[fast-migrating]	0.1	1	1	0	0
63881	1709	bFGF	[bFGF]	0.1	1	1	0	0
63882	1709	basic-leucine	[basic-leucine]	0.1	1	1	0	0
63883	1709	validity	[validity]	0.1	1	1	0	0
63884	1709	prooxidant	[prooxidants]	0.1	1	1	0	0
63885	1709	af-1	[AF-1]	0.1	1	2	1	1
63886	1709	af-2	[AF-2]	0.1	1	2	1	1
63887	1709	"instability"	["instability"]	0.1	1	1	0	0
63888	1709	af10	[AF10]	0.1	1	1	0	0
63889	1709	cis-activation	[cis-activation]	0.1	1	2	1	1
63890	1709	Hdg-1	[Hdg-1]	0.1	1	1	0	0
63891	1709	cbf1/rbp-jkappa	[CBF1/RBP-Jkappa]	0.1	1	2	1	1
63892	1709	retinoids.	[retinoids.]	0.1	1	1	0	0
63893	1709	kbf	[KBF]	0.1	1	1	0	0
63894	1709	anti-rabbit	[anti-rabbit]	0.1	1	1	0	0
63895	1709	[TNF],	[[TNF],]	0.1	1	1	0	0
63896	1709	biologist	[biologists]	0.1	1	1	0	0
63897	1709	virus-i	[virus-I]	0.1	1	2	2	2
63898	1709	taxreb	[TaxREB]	0.1	1	1	0	0
63899	1709	virus-1	[virus-1]	0.1	1	1	0	0
63900	1709	xic/xist	[XIC/XIST]	0.1	1	2	2	2
63901	1709	kit	[kit]	0.1	1	2	2	2
63902	1709	e1b-19	[E1B-19]	0.1	1	2	1	1
63903	1709	m.,	[M.,]	0.1	1	1	0	0
63904	1709	m/l	[M/l]	0.1	1	1	0	0
63905	1709	kmo	[KMO]	0.1	1	1	0	0
63906	1709	m10	[M10]	0.1	1	2	1	1
63907	1709	co-ordinate	[co-ordinate]	0.1	1	1	0	0
63908	1709	SMAD3	[SMAD3]	0.1	1	1	0	0
63909	1709	m22	[M22]	0.1	1	2	1	1
63910	1709	retinoidal	[retinoidal]	0.1	1	1	0	0
63911	1709	kos	[KOS]	0.1	1	1	0	0
63912	1709	kox	[KOX]	0.1	1	2	1	1
63913	1709	anti-tumor	[anti-tumor]	0.1	1	1	0	0
63914	1709	m67	[M67]	0.1	1	1	0	0
63915	1709	phenylpyrazolo	[phenylpyrazolo]	0.1	1	1	0	0
63916	1709	patients,	[patients,]	0.1	1	1	0	0
63917	1709	patients.	[patients.]	0.1	1	2	1	1
63918	1709	patients;	[patients;]	0.1	1	1	0	0
63919	1709	PTCA	[PTCA]	0.1	1	1	0	0
63920	1709	holo-	[holo-]	0.1	1	1	0	0
63921	1709	lal	[LAL]	0.1	1	1	0	0
63922	1709	rela/nfkappab1	[RelA/NFkappaB1]	0.1	1	1	0	0
63923	1709	contransfection	[contransfection]	0.1	1	1	0	0
63924	1709	mEI	[mEI]	0.1	1	2	1	1
63925	1709	nf-matp35	[NF-MATp35]	0.1	1	1	0	0
63926	1709	cryptococcosis	[cryptococcosis]	0.1	1	1	0	0
63927	1709	PU-1	[PU-1]	0.1	1	1	0	0
63928	1709	postreceptor	[postreceptor]	0.1	1	1	0	0
63929	1709	flexi-12	[Flexi-12]	0.1	1	1	0	0
63930	1709	chemoattrant	[Chemoattractants]	0.1	1	1	0	0
63931	1709	lmo	[LMO]	0.1	1	2	1	1
63932	1709	log	[log]	0.1	1	1	0	0
63933	1709	lox	[lox]	0.1	1	1	0	0
63934	1709	smad1/smad5	[Smad1/Smad5]	0.1	1	1	0	0
63935	1709	lpr	[lpr]	0.1	1	2	1	1
63936	1709	c(h)	[C(H)]	0.1	1	1	0	0
63937	1709	excretion,	[excretion,]	0.1	1	1	0	0
63938	1709	HT93A	[HT93A]	0.1	1	1	0	0
63939	1709	bHLH	[bHLH]	0.1	1	2	1	1
63940	1709	CD3-epsilon	[CD3-epsilon]	0.1	1	1	0	0
63941	1709	receptor/CD3	[receptor/CD3]	0.1	1	2	1	1
63942	1709	813-bp	[813-bp]	0.1	1	1	0	0
63943	1709	maf	[Maf]	0.1	1	1	0	0
63944	1709	(ltr)-ifna2	[(LTR)-IFNA2]	0.1	1	1	0	0
63945	1709	mbc	[MBC]	0.1	1	2	1	1
63946	1709	ctla4ig	[CTLA4Ig]	0.1	1	1	0	0
63947	1709	(1325(oh)2d3)	[(1,25(OH)2D3)]	0.1	1	1	0	0
63948	1709	mgc	[MGC]	0.1	1	2	2	2
63949	1709	mig	[mig]	0.1	1	1	0	0
63950	1709	mix	[MIX]	0.1	1	1	0	0
63951	1709	Nicoletti	[Nicoletti]	0.1	1	1	0	0
63952	1709	mm6	[MM6]	0.1	1	1	0	0
63953	1709	mlv	[MLVs]	0.1	1	2	2	2
63954	1709	dna-mobility	[DNA-mobility]	0.1	1	1	0	0
63955	1709	Baseler,	[Baseler,]	0.1	1	1	0	0
63956	1709	OspA	[OspA]	0.1	1	3	2	1
63957	1709	OspB	[OspB]	0.1	1	1	0	0
63958	1709	agar	[agar]	0.1	1	1	0	0
63959	1709	mol	[mol]	0.1	1	1	0	0
63960	1709	consistence,	[consistence,]	0.1	1	1	0	0
63961	1709	mpd	[MPDs]	0.1	1	2	2	2
63962	1709	mt4	[MT4]	0.1	1	1	0	0
63963	1709	msv	[MSV]	0.1	1	2	1	1
63964	1709	mv;	[mV;]	0.1	1	1	0	0
63965	1709	growth-factor	[growth-factor]	0.1	1	1	0	0
63966	1709	antibody-MR	[antibody-MR]	0.1	1	1	0	0
63967	1709	myc	[Myc]	0.1	1	1	0	0
63968	1709	oap/octamer	[OAP/octamer]	0.1	1	1	0	0
63969	1709	mzf	[MZF]	0.1	1	1	0	0
63970	1709	emerge	[emerging]	0.1	1	2	1	1
63971	1709	renaturation	[renaturation]	0.1	1	2	1	1
63972	1709	na+	[Na+]	0.1	1	2	1	1
63973	1709	Strasser	[Strasser]	0.1	1	1	0	0
63974	1709	n-formyl-methionyl-leucyl-phenylalanine	[N-formyl-methionyl-leucyl-phenylalanine]	0.1	1	2	2	2
63975	1709	dexamethasone,	[dexamethasone,]	0.1	1	1	0	0
63976	1709	gonadotropin	[gonadotropin]	0.1	1	2	1	1
63977	1709	promoter/reporter	[promoter/reporter]	0.1	1	2	2	2
63978	1709	nh2	[NH2]	0.1	1	1	0	0
63979	1709	nik	[NIK]	0.1	1	2	2	2
63980	1709	nip	[NIP]	0.1	1	2	2	2
63981	1709	cobalt,	[cobalt,]	0.1	1	1	0	0
63982	1709	atheroma	[atheroma]	0.1	1	2	1	1
63983	1709	p49	[p49]	0.1	1	1	0	0
63984	1709	p48	[p48]	0.1	1	3	2	1
63985	1709	nrl	[NRL]	0.1	1	1	0	0
63986	1709	p62	[p62]	0.1	1	1	0	0
63987	1709	p75	[p75]	0.1	1	3	2	1
63988	1709	ntf	[NTF]	0.1	1	2	1	1
63989	1709	ntp	[NTPs]	0.1	1	1	0	0
63990	1709	brother	[brother]	0.1	1	2	1	1
63991	1709	survivor	[survivor]	0.1	1	1	0	0
63992	1709	burden	[burden]	0.1	1	1	0	0
63993	1709	oct	[OCT]	0.1	1	1	0	0
63994	1709	amiloride	[amiloride]	0.1	1	1	0	0
63995	1709	s-phase	[S-phase]	0.1	1	2	1	1
63996	1709	autoinduction.	[autoinduction.]	0.1	1	1	0	0
63997	1709	odn	[ODNs]	0.1	1	1	0	0
63998	1709	peak,	[peak,]	0.1	1	1	0	0
63999	1709	oka	[OKA]	0.1	1	1	0	0
64000	1709	cation	[cations]	0.1	1	2	2	2
64001	1709	olp	[/LPS]	0.1	1	1	0	0
64002	1709	growth-transforme	[growth-transforming]	0.1	1	1	0	0
64003	1709	smoker	[smokers]	0.1	1	2	1	1
64004	1709	pRB	[pRB]	0.1	1	1	0	0
64005	1709	os.	[OS.]	0.1	1	1	0	0
64006	1709	Xq13	[Xq13]	0.1	1	1	0	0
64007	1709	osm	[OSM]	0.1	1	2	2	2
64008	1709	otf	[OTF]	0.1	1	1	0	0
64009	1709	rel/nuclear	[Rel/nuclear]	0.1	1	1	0	0
64010	1709	international-toxicity	[International-Toxicity]	0.1	1	1	0	0
64011	1709	phosphoform	[phosphoform]	0.1	1	1	0	0
64012	1709	cytotoxicity,	[cytotoxicity,]	0.1	1	1	0	0
64013	1709	GOS19	[GOS19]	0.1	1	1	0	0
64014	1709	aims	[Aims]	0.1	1	2	1	1
64015	1709	c-11	[C-11]	0.1	1	2	1	1
64016	1709	C5b-7	[C5b-7]	0.1	1	1	0	0
64017	1709	C5b-9	[C5b-9]	0.1	1	1	0	0
64018	1709	(band	[(band]	0.1	1	1	0	0
64019	1709	pan	[pan]	0.1	1	1	0	0
64020	1709	par	[PAR]	0.1	1	2	1	1
64021	1709	pcd	[PCD]	0.1	1	2	1	1
64022	1709	pcl	[PCL]	0.1	1	1	0	0
64023	1709	candidate,	[candidate,]	0.1	1	1	0	0
64024	1709	pdn	[PDN]	0.1	1	1	0	0
64025	1709	pdp	[PDP]	0.1	1	1	0	0
64026	1709	pet	[pets]	0.1	1	1	0	0
64027	1709	pfo	[/Fos]	0.1	1	2	1	1
64028	1709	preorder	[pre]	0.1	1	1	0	0
64029	1709	pit	[pits]	0.1	1	1	0	0
64030	1709	pm)	[pM)]	0.1	1	2	2	2
64031	1709	r24	[R24]	0.1	1	2	2	2
64032	1709	pod	[PODs]	0.1	1	1	0	0
64033	1709	5'HS2	[5'HS2]	0.1	1	4	3	1
64034	1709	ppb	[PPB]	0.1	1	2	2	2
64035	1709	ppe	[PPE]	0.1	1	2	1	1
64036	1709	pt)	[PT)]	0.1	1	1	0	0
64037	1709	cleft	[cleft]	0.1	1	2	1	1
64038	1709	pxp	[PXP]	0.1	1	1	0	0
64039	1709	pu-box	[PU-box]	0.1	1	1	0	0
64040	1709	m.hall,	[M.Hall,]	0.1	1	1	0	0
64041	1709	7-bp	[7-bp]	0.1	1	1	0	0
64042	1709	LAMPf	[LAMPf]	0.1	1	2	1	1
64043	1709	Sulindac	[sulindac]	0.1	1	1	0	0
64044	1709	ccl4-	[CCl4-]	0.1	1	1	0	0
64045	1709	c-rel-like	[c-Rel-like]	0.1	1	1	0	0
64046	1709	dimethylpimelimidate	[dimethylpimelimidate]	0.1	1	1	0	0
64047	1709	protein-dna	[Protein-DNA]	0.1	1	2	2	2
64048	1709	HAEC	[HAEC]	0.1	1	1	0	0
64049	1709	cd8+cd18bright	[CD8+CD18bright]	0.1	1	2	1	1
64050	1709	rad	[RAD]	0.1	1	1	0	0
64051	1709	raf	[raf]	0.1	1	1	0	0
64052	1709	rh-	[Rh-]	0.1	1	1	0	0
64053	1709	tumeric	[tumeric]	0.1	1	1	0	0
64054	1709	bacillus	[bacillus]	0.1	1	1	0	0
64055	1709	(il-2r)	[(IL-2R)]	0.1	1	3	2	1
64056	1709	h2b-2	[H2B-2]	0.1	1	1	0	0
64057	1709	lifelong,	[lifelong,]	0.1	1	1	0	0
64058	1709	t3,	[T3,]	0.1	1	1	0	0
64059	1709	t4)	[T4)]	0.1	1	1	0	0
64060	1709	X-inactivation	[X-inactivation]	0.1	1	1	0	0
64061	1709	EA-D/BHLF1/NotI	[EA-D/BHLF1/NotI]	0.1	1	1	0	0
64062	1709	isomers,	[isomers,]	0.1	1	1	0	0
64063	1709	(6,7-3h)	[(6,7-3H)]	0.1	1	1	0	0
64064	1709	all.	[all.]	0.1	1	1	0	0
64065	1709	insulin-	[insulin-]	0.1	1	1	0	0
64066	1709	nerve	[nerve]	0.1	1	2	1	1
64067	1709	saa	[SAA]	0.1	1	2	2	2
64068	1709	sequester	[sequestering]	0.1	1	1	0	0
64069	1709	sap	[SAP]	0.1	1	1	0	0
64070	1709	ro47-5944	[Ro47-5944]	0.1	1	1	0	0
64071	1709	14.3-kda	[14.3-kDa]	0.1	1	1	0	0
64072	1709	see	[SEE]	0.1	1	1	0	0
64073	1709	wheat	[wheat]	0.1	1	2	1	1
64074	1709	sem	[SEM]	0.1	1	2	1	1
64075	1709	lfa-i	[LFA-I]	0.1	1	1	0	0
64076	1709	HC11	[HC11]	0.1	1	1	0	0
64077	1709	IFP53	[IFP53]	0.1	1	1	0	0
64078	1709	stroma	[stroma]	0.1	1	5	4	1
64079	1709	shc	[Shc]	0.1	1	2	1	1
64080	1709	MNP-1	[MNP-1]	0.1	1	2	1	1
64081	1709	MNP-2	[MNP-2]	0.1	1	2	1	1
64082	1709	sil	[SIL]	0.1	1	1	0	0
64083	1709	fivefold	[fivefold]	0.1	1	1	0	0
64084	1709	eosinophils,	[eosinophils,]	0.1	1	1	0	0
64085	1709	skw	[SKW]	0.1	1	2	1	1
64086	1709	so,	[so,]	0.1	1	1	0	0
64087	1709	smx	[SMX]	0.1	1	2	1	1
64088	1709	sne	[SNE]	0.1	1	1	0	0
64089	1709	sp3	[Sp3]	0.1	1	1	0	0
64090	1709	u1a	[U1A]	0.1	1	1	0	0
64091	1709	soc	[SOCS]	0.1	1	1	0	0
64092	1709	103-amino-acid	[103-amino-acid]	0.1	1	1	0	0
64093	1709	sod	[SOD]	0.1	1	2	2	2
64094	1709	leukemogenicity	[leukemogenicity]	0.1	1	1	0	0
64095	1709	major,	[major,]	0.1	1	1	0	0
64096	1709	5-bromo-2'-deoxyuridine	[5-bromo-2'-deoxyuridine]	0.1	1	1	0	0
64097	1709	u86	[U86]	0.1	1	1	0	0
64098	1709	cyclotetrapeptide	[cyclotetrapeptide]	0.1	1	1	0	0
64099	1709	transformation,	[transformation,]	0.1	1	1	0	0
64100	1709	(g-csf)	[(G-CSF)]	0.1	1	1	0	0
64101	1709	amol	[amol]	0.1	1	2	1	1
64102	1709	mrna-type	[mRNA-type]	0.1	1	1	0	0
64103	1709	RAKFKQLLQ	[RAKFKQLLQ]	0.1	1	1	0	0
64104	1709	tab	[TAB]	0.1	1	1	0	0
64105	1709	taf	[TAF]	0.1	1	2	2	2
64106	1709	80-kda	[80-kDa]	0.1	1	1	0	0
64107	1709	tag	[TAG]	0.1	1	1	0	0
64108	1709	tap	[Tap]	0.1	1	2	1	1
64109	1709	tc2	[Tc2]	0.1	1	1	0	0
64110	1709	anti-kappa	[anti-kappa]	0.1	1	1	0	0
64111	1709	tbg	[TBG]	0.1	1	1	0	0
64112	1709	naive,	[naive,]	0.1	1	1	0	0
64113	1709	tds	[TDS]	0.1	1	2	2	2
64114	1709	65-kd	[65-kD]	0.1	1	1	0	0
64115	1709	th0	[Th0]	0.1	1	1	0	0
64116	1709	tgd	[TZDs]	0.1	1	1	0	0
64117	1709	synergist	[synergist]	0.1	1	1	0	0
64118	1709	churg-strauss	[Churg-Strauss]	0.1	1	1	0	0
64119	1709	gggatttcacc	[GGGATTTCACC]	0.1	1	1	0	0
64120	1709	thp	[THP]	0.1	1	2	1	1
64121	1709	pu.1/pip	[PU.1/Pip]	0.1	1	1	0	0
64122	1709	tlr	[TLRs]	0.1	1	2	1	1
64123	1709	sapk	[SAPK]	0.1	1	1	0	0
64124	1709	tp1	[TP1]	0.1	1	2	1	1
64125	1709	tp2	[TP2]	0.1	1	1	0	0
64126	1709	negative-act	[negative-acting]	0.1	1	1	0	0
64127	1709	2.6-kilobase	[2.6-kilobase]	0.1	1	1	0	0
64128	1709	ap-3	[AP-3]	0.1	1	1	0	0
64129	1709	ap-5	[AP-5]	0.1	1	1	0	0
64130	1709	irf-1/isgf2	[IRF-1/ISGF2]	0.1	1	1	0	0
64131	1709	immunolabeling	[immunolabeling]	0.1	1	4	3	1
64132	1709	lethality	[Lethality]	0.1	1	2	1	1
64133	1709	hour)	[hour)]	0.1	1	1	0	0
64134	1709	oncogene-expressing	[oncogene-expressing]	0.1	1	1	0	0
64135	1709	antigen-present	[antigen-presenting]	0.1	1	1	0	0
64136	1709	protein/activation	[protein/activation]	0.1	1	2	2	2
64137	1709	Rel/NF-kappa	[Rel/NF-kappa]	0.1	1	4	3	1
64138	1709	deterioration	[deterioration]	0.1	1	2	1	1
64139	1709	MEK1/MEK2	[MEK1/MEK2]	0.1	1	1	0	0
64140	1709	mande	[mande]	0.1	1	1	0	0
64141	1709	three,	[three,]	0.1	1	2	1	1
64142	1709	vWF	[vWF]	0.1	1	2	2	2
64143	1709	doxycycline	[doxycycline]	0.1	1	1	0	0
64144	1709	(il-2),	[(IL-2),]	0.1	1	1	0	0
64145	1709	(kb),	[(kb),]	0.1	1	1	0	0
64146	1709	ku812f	[KU812F]	0.1	1	1	0	0
64147	1709	cd4+cd28null	[CD4+CD28null]	0.1	1	1	0	0
64148	1709	sch.	[Sch.]	0.1	1	1	0	0
64149	1709	l-34	[L-34]	0.1	1	1	0	0
64150	1709	l-29	[L-29]	0.1	1	1	0	0
64151	1709	erythroleukemic	[erythroleukemic]	0.1	1	1	0	0
64152	1709	scmv	[SCMV]	0.1	1	2	1	1
64153	1709	x2-	[X2-]	0.1	1	1	0	0
64154	1709	PU.1/Spi-1	[PU.1/Spi-1]	0.1	1	1	0	0
64155	1709	von	[von]	0.1	1	2	1	1
64156	1709	pseudoautosomal	[pseudoautosomal]	0.1	1	1	0	0
64157	1709	c2h2	[C2H2]	0.1	1	2	1	1
64158	1709	thyroidism	[thyroidism]	0.1	1	2	2	2
64159	1709	768-bp	[768-bp]	0.1	1	1	0	0
64160	1709	timp-2	[TIMP-2]	0.1	1	1	0	0
64161	1709	diphenylhexatriene	[diphenylhexatriene]	0.1	1	1	0	0
64162	1709	flies,	[flies,]	0.1	1	1	0	0
64163	1709	pg-b6	[PG-B6]	0.1	1	1	0	0
64164	1709	cr2/cd21	[CR2/CD21]	0.1	1	1	0	0
64165	1709	field.	[field.]	0.1	1	1	0	0
64166	1709	pyruvate	[pyruvate]	0.1	1	2	1	1
64167	1709	proteins;	[proteins;]	0.1	1	1	0	0
64168	1709	proteins:	[proteins:]	0.1	1	1	0	0
64169	1709	win	[WIN]	0.1	1	3	2	1
64170	1709	y.,	[Y.,]	0.1	1	1	0	0
64171	1709	"housekeeping"	["housekeeping"]	0.1	1	1	0	0
64172	1709	Bmax).	[Bmax).]	0.1	1	1	0	0
64173	1709	wnt	[Wnt]	0.1	1	1	0	0
64174	1709	transducer	[transducer]	0.1	1	2	2	2
64175	1709	p50-p65	[p50-p65]	0.1	1	2	1	1
64176	1709	ccr-1	[CCR-1]	0.1	1	1	0	0
64177	1709	p50-p56	[p50-p56]	0.1	1	1	0	0
64178	1709	nonstimulate	[nonstimulating]	0.1	1	1	0	0
64179	1709	g2715t	[G2715T]	0.1	1	1	0	0
64180	1709	HTLV-III	[HTLV-III]	0.1	1	1	0	0
64181	1709	PTPase	[PTPase]	0.1	1	1	0	0
64182	1709	id-3l	[Id-3L]	0.1	1	2	2	2
64183	1709	documented	[documented)]	0.1	1	1	0	0
64184	1709	helicase	[helicase]	0.1	1	1	0	0
64185	1709	sedimenting	[sedimenting]	0.1	1	2	1	1
64186	1709	l-pk	[L-PK]	0.1	1	1	0	0
64187	1709	interferon-beta	[interferon-beta]	0.1	1	1	0	0
64188	1709	alpha-subunit	[alpha-subunit]	0.1	1	2	1	1
64189	1709	xp/	[XP/]	0.1	1	1	0	0
64190	1709	z29	[Z29]	0.1	1	1	0	0
64191	1709	defence	[defence]	0.1	1	2	2	2
64192	1709	are,	[are,]	0.1	1	1	0	0
64193	1709	sex-	[sex-]	0.1	1	1	0	0
64194	1709	success	[success]	0.1	1	2	1	1
64195	1709	12/15-lipoxygenase	[12/15-lipoxygenase]	0.1	1	2	2	2
64196	1709	trans-dimer	[trans-dimer]	0.1	1	2	1	1
64197	1709	rel/nfkappab	[Rel/NFkappaB]	0.1	1	1	0	0
64198	1709	framework	[framework]	0.1	1	2	1	1
64199	1709	arnt	[Arnt]	0.1	1	1	0	0
64200	1709	3.8-kb	[3.8-kb]	0.1	1	1	0	0
64201	1709	tumorigenicity	[tumorigenicity]	0.1	1	2	2	2
64202	1709	yac	[YAC]	0.1	1	2	2	2
64203	1709	microvessel	[microvessel]	0.1	1	2	2	2
64204	1709	tgf-beta2	[TGF-beta2]	0.1	1	1	0	0
64205	1709	protein-3	[protein-3]	0.1	1	1	0	0
64206	1709	protein-2	[protein-2]	0.1	1	2	2	2
64207	1709	beta-lipoprotein	[beta-lipoproteins]	0.1	1	1	0	0
64208	1709	alternative	[alternative]	0.1	1	2	1	1
64209	1709	pp125fak	[pp125FAK]	0.1	1	1	0	0
64210	1709	pleckstrin-homology	[pleckstrin-homology]	0.1	1	1	0	0
64211	1709	IL-1/tumor	[IL-1/tumor]	0.1	1	1	0	0
64212	1709	marck	[MARCKS]	0.1	1	1	0	0
64213	1709	tartrate	[tartrate]	0.1	1	1	0	0
64214	1709	observations.	[observations.]	0.1	1	1	0	0
64215	1709	question,	[question,]	0.1	1	1	0	0
64216	1709	pzvb10	[pZVB10]	0.1	1	2	1	1
64217	1709	pzvb70	[pZVB70]	0.1	1	2	1	1
64218	1709	Helices	[Helices]	0.1	1	1	0	0
64219	1709	"N-end	["N-end]	0.1	1	1	0	0
64220	1709	boundaries.	[boundaries.]	0.1	1	1	0	0
64221	1709	195-kd	[195-kD]	0.1	1	1	0	0
64222	1709	phyto-	[phyto-]	0.1	1	1	0	0
64223	1709	dna-recognition	[DNA-recognition]	0.1	1	1	0	0
64224	1709	HIV-	[HIV-]	0.1	1	1	0	0
64225	1709	pro-opiomelanocortin	[pro-opiomelanocortin]	0.1	1	1	0	0
64226	1709	mercury	[mercury]	0.1	1	1	0	0
64227	1709	atf/	[ATF/]	0.1	1	2	2	2
64228	1709	pressures;	[pressures;]	0.1	1	1	0	0
64229	1709	G(d1a),	[G(d1a),]	0.1	1	1	0	0
64230	1709	(d.e.	[(D.E.]	0.1	1	1	0	0
64231	1709	mol/L);	[mol/L);]	0.1	1	1	0	0
64232	1709	mol/L).	[mol/L).]	0.1	1	1	0	0
64233	1709	months)	[months)]	0.1	1	2	1	1
64234	1709	GSH:oxidized	[GSH:oxidized]	0.1	1	1	0	0
64235	1709	ubiquitinylating	[ubiquitinylating]	0.1	1	1	0	0
64236	1709	CRO-AP/3	[CRO-AP/3]	0.1	1	2	1	1
64237	1709	jnk2	[JNK2]	0.1	1	1	0	0
64238	1709	jnk1	[JNK1]	0.1	1	2	1	1
64239	1709	shbg	[SHBG]	0.1	1	1	0	0
64240	1709	shed	[shed]	0.1	1	1	0	0
64241	1709	t(X;14)(q28;q11)	[t(X;14)(q28;q11)]	0.1	1	1	0	0
64242	1709	l227	[L227]	0.1	1	1	0	0
64243	1709	G0-->S	[G0-->S]	0.1	1	1	0	0
64244	1709	show	[shows]	0.1	1	2	2	2
64245	1709	hil-4r	[hIL-4R]	0.1	1	2	1	1
64246	1709	auc;	[AUC;]	0.1	1	1	0	0
64247	1709	atttgcat	[ATTTGCAT]	0.1	1	2	2	2
64248	1709	Lactobacilli	[Lactobacilli]	0.1	1	1	0	0
64249	1709	project.	[project.]	0.1	1	1	0	0
64250	1709	(scm-1)/lymphotactin	[(SCM-1)/lymphotactin]	0.1	1	1	0	0
64251	1709	bacille	[bacille]	0.1	1	1	0	0
64252	1709	ku812	[KU812]	0.1	1	1	0	0
64253	1709	aunt	[aunt]	0.1	1	1	0	0
64254	1709	f(ab')2	[F(ab')2]	0.1	1	1	0	0
64255	1709	sig+	[sIg+]	0.1	1	1	0	0
64256	1709	autg	[AuTG]	0.1	1	1	0	0
64257	1709	Saos-2	[Saos-2]	0.1	1	1	0	0
64258	1709	morbidity	[morbidity]	0.1	1	2	1	1
64259	1709	react	[reacting]	0.1	1	2	1	1
64260	1709	Estrogens]	[Estrogens]]	0.1	1	1	0	0
64261	1709	deletion/substitution	[deletion/substitution]	0.1	1	1	0	0
64262	1709	ERalpha	[ERalpha]	0.1	1	1	0	0
64263	1709	inositoltrisphosphate	[inositoltrisphosphate]	0.1	1	1	0	0
64264	1709	GTPase	[GTPase]	0.1	1	1	0	0
64265	1709	apocynin	[apocynin]	0.1	1	1	0	0
64266	1709	p47(phox)	[p47(phox)]	0.1	1	1	0	0
64267	1709	HLA-DQA1*0501/DQB1*0302	[HLA-DQA1*0501/DQB1*0302]	0.1	1	1	0	0
64268	1709	Ldb-1	[Ldb-1]	0.1	1	1	0	0
64269	1709	5'-ggaacctccccc-3'	[5'-GGAACCTCCCCC-3']	0.1	1	1	0	0
64270	1709	platelet-progenitor	[platelet-progenitor]	0.1	1	1	0	0
64271	1709	manuscript,	[manuscript,]	0.1	1	1	0	0
64272	1709	Pro641	[Pro641]	0.1	1	1	0	0
64273	1709	Pro639	[Pro639]	0.1	1	1	0	0
64274	1709	l428	[L428]	0.1	1	1	0	0
64275	1709	cem-c1	[CEM-C1]	0.1	1	1	0	0
64276	1709	beta-subunit	[beta-subunit]	0.1	1	1	0	0
64277	1709	mechanisms;	[mechanisms;]	0.1	1	2	1	1
64278	1709	mechanisms:	[mechanisms:]	0.1	1	1	0	0
64279	1709	propranolol	[propranolol]	0.1	1	2	1	1
64280	1709	radioassay	[radioassay]	0.1	1	2	2	2
64281	1709	Jakdstat	[JAK/STAT]	0.1	1	1	0	0
64282	1709	loci,	[loci,]	0.1	1	1	0	0
64283	1709	pleckstrin	[pleckstrin]	0.1	1	2	2	2
64284	1709	tepoxalin,	[tepoxalin,]	0.1	1	2	1	1
64285	1709	support,	[support,]	0.1	1	2	1	1
64286	1709	12-O-tetradecanoyl	[12-O-tetradecanoyl]	0.1	1	2	1	1
64287	1709	reactions.	[reactions.]	0.1	1	1	0	0
64288	1709	nonresponders.	[nonresponders.]	0.1	1	2	1	1
64289	1709	nmol/L	[nmol/L]	0.1	1	2	2	2
64290	1709	techniques:	[techniques:]	0.1	1	1	0	0
64291	1709	techniques.	[techniques.]	0.1	1	2	1	1
64292	1709	axin	[axin]	0.1	1	1	0	0
64293	1709	organs.	[organs.]	0.1	1	1	0	0
64294	1709	h2o2-	[H2O2-]	0.1	1	1	0	0
64295	1709	"SFS"	["SFS"]	0.1	1	1	0	0
64296	1709	Eicosanoids	[Eicosanoids]	0.1	1	2	1	1
64297	1709	DQ0302	[DQ0302]	0.1	1	1	0	0
64298	1709	sn50	[SN50]	0.1	1	2	1	1
64299	1709	microenvironment-directed,	[microenvironment-directed,]	0.1	1	1	0	0
64300	1709	u.v.	[u.v.]	0.1	1	1	0	0
64301	1709	201-bp	[201-bp]	0.1	1	1	0	0
64302	1709	immunopathology	[immunopathology]	0.1	1	1	0	0
64303	1709	significance]	[significance]]	0.1	1	1	0	0
64304	1709	probe,	[probe,]	0.1	1	2	1	1
64305	1709	beta-chemokine	[beta-chemokine]	0.1	1	2	1	1
64306	1709	dermis	[dermis]	0.1	1	1	0	0
64307	1709	Palpha	[Palpha]	0.1	1	1	0	0
64308	1709	complex,	[complex,]	0.1	1	1	0	0
64309	1709	adenocarcinoma	[adenocarcinoma]	0.1	1	1	0	0
64310	1709	differentiation/activation	[differentiation/activation]	0.1	1	1	0	0
64311	1709	beta-actin	[beta-actin]	0.1	1	1	0	0
64312	1709	Trapoxin	[Trapoxin]	0.1	1	1	0	0
64313	1709	(3h)-e2	[(3H)-E2]	0.1	1	1	0	0
64314	1709	linearity	[linearity]	0.1	1	1	0	0
64315	1709	p38delta	[p38delta]	0.1	1	1	0	0
64316	1709	HPFH	[HPFH]	0.1	1	1	0	0
64317	1709	euthyroidism	[euthyroidism]	0.1	1	1	0	0
64318	1709	ng/mL),	[ng/mL),]	0.1	1	2	2	2
64319	1709	super-induction	[super-induction]	0.1	1	1	0	0
64320	1709	carbon-20	[carbon-20]	0.1	1	1	0	0
64321	1709	ar/tr2/ar	[AR/TR2/AR]	0.1	1	1	0	0
64322	1709	sulfate	[sulfate]	0.1	1	2	1	1
64323	1709	elderly,	[elderly,]	0.1	1	1	0	0
64324	1709	okt3/pma	[OKT3/PMA]	0.1	1	1	0	0
64325	1709	pre-activation	[pre-activation]	0.1	1	1	0	0
64326	1709	Maria,	[Maria,]	0.1	1	1	0	0
64327	1709	sp1-	[Sp1-]	0.1	1	1	0	0
64328	1709	sp1.	[Sp1.]	0.1	1	1	0	0
64329	1709	(th1)	[(Th1)]	0.1	1	3	2	1
64330	1709	continue	[continuing]	0.1	1	2	1	1
64331	1709	-bsa	[-BSA]	0.1	1	1	0	0
64332	1709	hyperthyroidism	[hyperthyroidism]	0.1	1	2	1	1
64333	1709	Leu-7+	[Leu-7+]	0.1	1	1	0	0
64334	1709	(m.a.	[(M.A.]	0.1	1	1	0	0
64335	1709	l929	[L929]	0.1	1	1	0	0
64336	1709	sos1	[SOS1]	0.1	1	2	1	1
64337	1709	Pili	[Pili]	0.1	1	1	0	0
64338	1709	S-G2/M	[S-G2/M]	0.1	1	1	0	0
64339	1709	(88%)	[(88%),]	0.1	1	1	0	0
64340	1709	integer	[integer]	0.1	1	1	0	0
64341	1709	oap40	[OAP40]	0.1	1	1	0	0
64342	1709	conflict	[conflicting]	0.1	1	1	0	0
64343	1709	hit-t15	[HIT-T15]	0.1	1	1	0	0
64344	1709	nfat4	[NFAT4]	0.1	1	1	0	0
64345	1709	nfat3	[NFAT3]	0.1	1	1	0	0
64346	1709	U/ml),	[U/ml),]	0.1	1	2	1	1
64347	1709	pseudo-tumor	[pseudo-tumor]	0.1	1	1	0	0
64348	1709	nfatx	[NFATx]	0.1	1	1	0	0
64349	1709	derivation	[derivation]	0.1	1	2	2	2
64350	1709	redistribution	[redistribution]	0.1	1	2	2	2
64351	1709	ep<0.05)	[(P<0.05)]	0.1	1	1	0	0
64352	1709	-1053/+34	[-1053/+34]	0.1	1	1	0	0
64353	1709	signal-mediating	[signal-mediating]	0.1	1	1	0	0
64354	1709	R-PK	[R-PK]	0.1	1	1	0	0
64355	1709	g0-g1	[G0-G1]	0.1	1	1	0	0
64356	1709	Bob1,	[Bob1,]	0.1	1	1	0	0
64357	1709	canrenone	[canrenone]	0.1	1	2	1	1
64358	1709	ribosome	[ribosome]	0.1	1	2	1	1
64359	1709	plastic,	[plastic,]	0.1	1	1	0	0
64360	1709	NF-ATc/p	[NF-ATc/p]	0.1	1	1	0	0
64361	1709	cepharantha	[cepharantha]	0.1	1	1	0	0
64362	1709	duration.	[duration.]	0.1	1	1	0	0
64363	1709	pg/ml;	[pg/ml;]	0.1	1	2	2	2
64364	1709	preleukemia	[preleukemia]	0.1	1	1	0	0
64365	1709	HSFE	[HSFE]	0.1	1	2	1	1
64366	1709	tubule	[tubules]	0.1	1	3	2	1
64367	1709	yang-deficiency	[yang-deficiency]	0.1	1	2	1	1
64368	1709	resuscitation.	[resuscitation.]	0.1	1	1	0	0
64369	1709	i-kappa	[I-kappa]	0.1	1	1	0	0
64370	1709	transrepression.	[transrepression.]	0.1	1	1	0	0
64371	1709	erk1/2	[ERK1/2]	0.1	1	2	1	1
64372	1709	transcription-activation	[transcription-activation]	0.1	1	1	0	0
64373	1709	TRAF5	[TRAF5]	0.1	1	1	0	0
64374	1709	mutation,	[mutation,]	0.1	1	1	0	0
64375	1709	h3-antagonist	[H3-antagonist]	0.1	1	1	0	0
64376	1709	delta383	[delta383]	0.1	1	1	0	0
64377	1709	cAMP	[cAMP]	0.1	1	2	2	2
64378	1709	m-crf	[M-CRF]	0.1	1	1	0	0
64379	1709	u-373	[U-373]	0.1	1	1	0	0
64380	1709	Throger	[Thr]	0.1	1	2	2	2
64381	1709	TRAMP	[TRAMP]	0.1	1	1	0	0
64382	1709	corticotropin-releasing	[corticotropin-releasing]	0.1	1	1	0	0
64383	1709	cytoplasmic,	[cytoplasmic,]	0.1	1	1	0	0
64384	1709	blastocysts,	[blastocysts,]	0.1	1	1	0	0
64385	1709	monocyte/macrophages	[Monocyte/macrophages]	0.1	1	1	0	0
64386	1709	Vbeta	[Vbeta]	0.1	1	2	1	1
64387	1709	monocyte/macrophage-	[monocyte/macrophage-]	0.1	1	1	0	0
64388	1709	conformer	[conformer]	0.1	1	2	1	1
64389	1709	venous	[venous]	0.1	1	2	2	2
64390	1709	hla-a2	[HLA-A2]	0.1	1	1	0	0
64391	1709	(cb50)	[(CB50)]	0.1	1	1	0	0
64392	1709	cdc-2	[cdc-2]	0.1	1	1	0	0
64393	1709	time-dependent,	[time-dependent,]	0.1	1	1	0	0
64394	1709	ZR-75-1	[ZR-75-1]	0.1	1	2	1	1
64395	1709	vaccination	[vaccination]	0.1	1	3	2	1
64396	1709	discharge.	[discharge.]	0.1	1	1	0	0
64397	1709	pebp-2alpha	[PEBP-2alpha]	0.1	1	1	0	0
64398	1709	R/U5	[R/U5]	0.1	1	1	0	0
64399	1709	pigeon	[pigeon]	0.1	1	1	0	0
64400	1709	micron/ml	[micron/ml]	0.1	1	1	0	0
64401	1709	anti-MHC	[anti-MHC]	0.1	1	2	2	2
64402	1709	dbf-site	[DBF-sites]	0.1	1	1	0	0
64403	1709	Arg143Gln	[Arg143Gln]	0.1	1	1	0	0
64404	1709	gammaR1	[gammaR1]	0.1	1	2	2	2
64405	1709	receptor-mediated	[receptor-mediated]	0.1	1	1	0	0
64406	1709	baf3	[BAF3]	0.1	1	2	2	2
64407	1709	lef1/bcf1	[LEF1/BCF1]	0.1	1	1	0	0
64408	1709	bait	[bait]	0.1	1	2	2	2
64409	1709	LT-producing	[LT-producing]	0.1	1	1	0	0
64410	1709	p49(100)	[p49(100)]	0.1	1	1	0	0
64411	1709	number.	[number.]	0.1	1	1	0	0
64412	1709	basc	[BASC]	0.1	1	1	0	0
64413	1709	transcripts,	[transcripts,]	0.1	1	2	2	2
64414	1709	p65:p50	[p65:p50]	0.1	1	1	0	0
64415	1709	stop	[stop]	0.1	1	2	1	1
64416	1709	characterize	[characterizing]	0.1	1	1	0	0
64417	1709	nfil2	[NFIL2]	0.1	1	2	2	2
64418	1709	mesenchyme	[mesenchyme]	0.1	1	1	0	0
64419	1709	HLA-DMB	[HLA-DMB]	0.1	1	1	0	0
64420	1709	Rho-family	[Rho-family]	0.1	1	1	0	0
64421	1709	anti-Fas-	[anti-Fas-]	0.1	1	1	0	0
64422	1709	HLA-DR4	[HLA-DR4]	0.1	1	1	0	0
64423	1709	complement,	[complement,]	0.1	1	1	0	0
64424	1709	HLA-DQB	[HLA-DQB]	0.1	1	1	0	0
64425	1709	acetylsalicylic	[Acetylsalicylic]	0.1	1	2	1	1
64426	1709	entrance	[entrance]	0.1	1	1	0	0
64427	1709	SH2-deleted	[SH2-deleted]	0.1	1	1	0	0
64428	1709	aml1-	[AML1-]	0.1	1	1	0	0
64429	1709	values.	[values.]	0.1	1	2	2	2
64430	1709	N-IRAK	[N-IRAK]	0.1	1	1	0	0
64431	1709	delta-	[delta-]	0.1	1	2	2	2
64432	1709	b-alpha/mad-3	[B-alpha/MAD-3]	0.1	1	1	0	0
64433	1709	sum,	[sum,]	0.1	1	1	0	0
64434	1709	situ,	[situ,]	0.1	1	1	0	0
64435	1709	NFATp/AP-1	[NFATp/AP-1]	0.1	1	2	1	1
64436	1709	suggest,	[suggest,]	0.1	1	1	0	0
64437	1709	cofilin-homology	[cofilin-homology]	0.1	1	1	0	0
64438	1709	bcr1	[bcr1]	0.1	1	2	1	1
64439	1709	xp11be	[XP11BE]	0.1	1	1	0	0
64440	1709	tetrahexamer	[tetrahexamer]	0.1	1	2	2	2
64441	1709	GH4C1	[GH4C1]	0.1	1	1	0	0
64442	1709	isolation.	[isolation.]	0.1	1	1	0	0
64443	1709	phosphopeptide	[phosphopeptide]	0.1	1	2	1	1
64444	1709	isomerization	[isomerization]	0.1	1	1	0	0
64445	1709	hla-dp	[HLA-DP]	0.1	1	1	0	0
64446	1709	hla-do	[HLA-DO]	0.1	1	1	0	0
64447	1709	hla-dm	[HLA-DM]	0.1	1	2	1	1
64448	1709	chromium-release	[chromium-release]	0.1	1	1	0	0
64449	1709	FLICE	[FLICE]	0.1	1	1	0	0
64450	1709	inhibitors.	[inhibitors.]	0.1	1	2	2	2
64451	1709	inhibitory)	[inhibitory)]	0.1	1	1	0	0
64452	1709	inhibitory,	[inhibitory,]	0.1	1	1	0	0
64453	1709	structure-activity	[structure-activity]	0.1	1	1	0	0
64454	1709	(placebo:	[(placebo:]	0.1	1	1	0	0
64455	1709	swi3	[SWI3]	0.1	1	2	2	2
64456	1709	swi2	[SWI2]	0.1	1	1	0	0
64457	1709	cell-to-cell	[cell-to-cell]	0.1	1	2	1	1
64458	1709	colour	[colour]	0.1	1	1	0	0
64459	1709	km-h2	[KM-H2]	0.1	1	1	0	0
64460	1709	colon,	[colon,]	0.1	1	1	0	0
64461	1709	(tre)-like	[(TRE)-like]	0.1	1	1	0	0
64462	1709	RARalpha403	[RARalpha403]	0.1	1	1	0	0
64463	1709	(t-pll)	[(T-PLL)]	0.1	1	1	0	0
64464	1709	qi-invigorate	[qi-invigorating]	0.1	1	1	0	0
64465	1709	ikkalpha	[IKKalpha]	0.1	1	1	0	0
64466	1709	radioimmune	[radioimmune]	0.1	1	1	0	0
64467	1709	amyloid-beta	[amyloid-beta]	0.1	1	1	0	0
64468	1709	anlage	[anlage]	0.1	1	2	2	2
64469	1709	AP-1(I,II,III)	[AP-1(I,II,III)]	0.1	1	1	0	0
64470	1709	xenotransplantation	[xenotransplantation]	0.1	1	2	1	1
64471	1709	(icam-1luc)	[(ICAM-1LUC)]	0.1	1	1	0	0
64472	1709	lps-lp	[LPS-LPS]	0.1	1	1	0	0
64473	1709	hypophosphatemia	[hypophosphatemia]	0.1	1	2	1	1
64474	1709	interferon-y	[interferon-y]	0.1	1	1	0	0
64475	1709	Prog	[Prog]	0.1	1	2	1	1
64476	1709	ca(2+)-	[Ca(2+)-]	0.1	1	1	0	0
64477	1709	mononulear	[mononulear]	0.1	1	1	0	0
64478	1709	FcepsilonRI	[FcepsilonRI]	0.1	1	1	0	0
64479	1709	(pbmc)	[(PBMC)]	0.1	1	1	0	0
64480	1709	ovulatory.	[ovulatory.]	0.1	1	1	0	0
64481	1709	kb),	[kb),]	0.1	1	1	0	0
64482	1709	Heinz	[Heinz]	0.1	1	2	2	2
64483	1709	GGGGCTGTCCC	[GGGGCTGTCCC]	0.1	1	1	0	0
64484	1709	fibrosarcoma	[fibrosarcoma]	0.1	1	2	2	2
64485	1709	pxqxt/s-containing	[PXQXT/S-containing]	0.1	1	1	0	0
64486	1709	DR11(+)	[DR11(+)]	0.1	1	1	0	0
64487	1709	pregnancy.	[pregnancy.]	0.1	1	1	0	0
64488	1709	substrate.	[substrate.]	0.1	1	2	1	1
64489	1709	loss.	[loss.]	0.1	1	1	0	0
64490	1709	costimulation.	[costimulation.]	0.1	1	1	0	0
64491	1709	Aldosterone	[Aldosterone]	0.1	1	1	0	0
64492	1709	PstI	[PstI]	0.1	1	1	0	0
64493	1709	analogues.	[analogues.]	0.1	1	1	0	0
64494	1709	Chlamydia	[Chlamydia]	0.1	1	2	2	2
64495	1709	metal-ion	[metal-ion]	0.1	1	2	1	1
64496	1709	blast-crisis	[blast-crisis]	0.1	1	1	0	0
64497	1709	PuB1	[PuB1]	0.1	1	1	0	0
64498	1709	PuB2	[PuB2]	0.1	1	1	0	0
64499	1709	(RNA)	[(RNA)]	0.1	1	1	0	0
64500	1709	dosing	[dosing]	0.1	1	1	0	0
64501	1709	SMase	[SMase]	0.1	1	1	0	0
64502	1709	Toronto,	[Toronto,]	0.1	1	1	0	0
64503	1709	anti-Tat	[anti-Tat]	0.1	1	1	0	0
64504	1709	mumol/L	[mumol/L]	0.1	1	2	1	1
64505	1709	papilloma	[papilloma]	0.1	1	2	1	1
64506	1709	anti-TNF	[anti-TNF]	0.1	1	1	0	0
64507	1709	gamma-1	[gamma-1]	0.1	1	1	0	0
64508	1709	(auto)immune	[(auto)immune]	0.1	1	1	0	0
64509	1709	hirudin	[hirudin]	0.1	1	1	0	0
64510	1709	Stat5b	[Stat5b]	0.1	1	1	0	0
64511	1709	carboxyl-	[carboxyl-]	0.1	1	1	0	0
64512	1709	RXR-RXR	[RXR-RXR]	0.1	1	2	1	1
64513	1709	neomycin-resistance	[neomycin-resistance]	0.1	1	1	0	0
64514	1709	N-formyl-methionyl-leucyl-phenylalanine	[N-formyl-methionyl-leucyl-phenylalanine]	0.1	1	1	0	0
64515	1709	-priming	[-priming]	0.1	1	1	0	0
64516	1709	(ablating	[(ablating]	0.1	1	1	0	0
64517	1709	NF-AT/AP-1-binding	[NF-AT/AP-1-binding]	0.1	1	2	1	1
64518	1709	protozoa	[protozoa]	0.1	1	1	0	0
64519	1709	Egr-1/	[Egr-1/]	0.1	1	1	0	0
64520	1709	truncate	[truncating]	0.1	1	2	1	1
64521	1709	alpha-hydroxymethyl,	[alpha-hydroxymethyl,]	0.1	1	1	0	0
64522	1709	Ca(2+)-	[Ca(2+)-]	0.1	1	2	1	1
64523	1709	1753-bp	[1753-bp]	0.1	1	1	0	0
64524	1709	Ascorbate	[Ascorbate]	0.1	1	1	0	0
64525	1709	endoglycosidase	[endoglycosidase]	0.1	1	1	0	0
64526	1709	p50/NF-kappa	[p50/NF-kappa]	0.1	1	1	0	0
64527	1709	pdx-1/ipf1/stf-1	[PDX-1/IPF1/STF-1]	0.1	1	1	0	0
64528	1709	RXR-RAR	[RXR-RAR]	0.1	1	1	0	0
64529	1709	xenograft	[xenograft]	0.1	1	3	2	1
64530	1709	c81-66-45	[C81-66-45]	0.1	1	1	0	0
64531	1709	min/L,	[min/L,]	0.1	1	1	0	0
64532	1709	microa	[microA]	0.1	1	2	1	1
64533	1709	estrogen-	[estrogen-]	0.1	1	1	0	0
64534	1709	precipitation	[precipitation]	0.1	1	2	2	2
64535	1709	ATP/Mg2+	[ATP/Mg2+]	0.1	1	1	0	0
64536	1709	RAG-1	[RAG-1]	0.1	1	1	0	0
64537	1709	RAG-2	[RAG-2]	0.1	1	1	0	0
64538	1709	bl30	[BL30]	0.1	1	1	0	0
64539	1709	(Martin	[(Martin]	0.1	1	1	0	0
64540	1709	bl2,	[BL2,]	0.1	1	1	0	0
64541	1709	units-erythroid	[units-erythroid]	0.1	1	1	0	0
64542	1709	myocyte-enhancer	[myocyte-enhancer]	0.1	1	1	0	0
64543	1709	LBP-1	[LBP-1]	0.1	1	2	1	1
64544	1709	beta,19-epoxy-4-hydroxypregnane-3,20-dione	[beta,19-epoxy-4-hydroxypregnane-3,20-dione]	0.1	1	1	0	0
64545	1709	redox.	[redox.]	0.1	1	1	0	0
64546	1709	breast-conservervest-cserveng	[breast-conserving]	0.1	1	2	1	1
64547	1709	alphav5	[alpha,25]	0.1	1	2	2	2
64548	1709	3d-nmr	[3D-NMR]	0.1	1	1	0	0
64549	1709	thyrocyte	[thyrocyte]	0.1	1	2	1	1
64550	1709	[3h]	[[3H]]	0.1	1	2	2	2
64551	1709	pd-98059	[PD-98059]	0.1	1	1	0	0
64552	1709	S-phase	[S-phase]	0.1	1	1	0	0
64553	1709	Scya3r2	[Scya3r2]	0.1	1	1	0	0
64554	1709	antiro	[anti-Fos]	0.1	1	1	0	0
64555	1709	design:	[DESIGN:]	0.1	1	2	2	2
64556	1709	(cbf)	[(CBF)]	0.1	1	1	0	0
64557	1709	ro-vdr	[Ro-VDR]	0.1	1	1	0	0
64558	1709	C-fos	[C-fos]	0.1	1	1	0	0
64559	1709	shp2-interacting	[SHP2-interacting]	0.1	1	1	0	0
64560	1709	sesquiterpene	[sesquiterpene]	0.1	1	1	0	0
64561	1709	kg-1	[KG-1]	0.1	1	2	1	1
64562	1709	proteoglycan	[proteoglycan]	0.1	1	2	1	1
64563	1709	personality	[personality]	0.1	1	1	0	0
64564	1709	autoimmunity,	[autoimmunity,]	0.1	1	1	0	0
64565	1709	helenalin	[helenalin]	0.1	1	2	2	2
64566	1709	atl-1k	[ATL-1K]	0.1	1	1	0	0
64567	1709	qualitative,	[qualitative,]	0.1	1	2	2	2
64568	1709	5'hs2	[5'HS2]	0.1	1	1	0	0
64569	1709	tumor/growth	[tumor/growth]	0.1	1	1	0	0
64570	1709	THP-1-	[THP-1-]	0.1	1	1	0	0
64571	1709	Aspirin	[Aspirin]	0.1	1	1	0	0
64572	1709	urine	[urine]	0.1	1	2	1	1
64573	1709	lines.	[lines.]	0.1	1	2	1	1
64574	1709	NF-muE3	[NF-muE3]	0.1	1	1	0	0
64575	1709	PIN*POINT	[PIN*POINT]	0.1	1	1	0	0
64576	1709	bryostatin	[bryostatin]	0.1	1	2	1	1
64577	1709	govern	[governing]	0.1	1	1	0	0
64578	1709	multifactor	[Multifactor]	0.1	1	1	0	0
64579	1709	sister	[sister]	0.1	1	2	2	2
64580	1709	reoxygenation	[reoxygenation]	0.1	1	2	1	1
64581	1709	m-tat	[M-TAT]	0.1	1	2	2	2
64582	1709	IBMX	[IBMX]	0.1	1	1	0	0
64583	1709	PAX-5	[PAX-5]	0.1	1	1	0	0
64584	1709	hyperphosphorylation	[hyperphosphorylation]	0.1	1	2	1	1
64585	1709	(two-	[(two-]	0.1	1	1	0	0
64586	1709	o-tetradecanoylphorbol	[o-tetradecanoylphorbol]	0.1	1	1	0	0
64587	1709	mutants.	[mutants.]	0.1	1	2	2	2
64588	1709	mutants,	[mutants,]	0.1	1	2	2	2
64589	1709	5-hydroxyeicosatetraenoic	[5-hydroxyeicosatetraenoic]	0.1	1	2	1	1
64590	1709	requirement.	[requirement.]	0.1	1	1	0	0
64591	1709	taci	[TACI]	0.1	1	2	1	1
64592	1709	factor-IL-6beta	[factor-IL-6beta]	0.1	1	2	2	2
64593	1709	ICP0	[ICP0]	0.1	1	1	0	0
64594	1709	ICP4	[ICP4]	0.1	1	1	0	0
64595	1709	hnf-3alpha	[HNF-3alpha]	0.1	1	1	0	0
64596	1709	variance,	[variance,]	0.1	1	2	1	1
64597	1709	ICSs	[ICSs]	0.1	1	1	0	0
64598	1709	Inv(16)(p13;q22)	[Inv(16)(p13;q22)]	0.1	1	1	0	0
64599	1709	taqi	[TaqI]	0.1	1	1	0	0
64600	1709	nmol/L).	[nmol/L).]	0.1	1	1	0	0
64601	1709	nmol/L),	[nmol/L),]	0.1	1	2	2	2
64602	1709	tat-expressing	[Tat-expressing]	0.1	1	1	0	0
64603	1709	18-hydroxyprogesterone	[18-hydroxyprogesterone]	0.1	1	1	0	0
64604	1709	HLA-A2-restricted,	[HLA-A2-restricted,]	0.1	1	1	0	0
64605	1709	IDDM	[IDDM]	0.1	1	1	0	0
64606	1709	codeletion	[codeletion]	0.1	1	2	1	1
64607	1709	tbar	[TBARS]	0.1	1	1	0	0
64608	1709	Balb/c3T3	[Balb/c3T3]	0.1	1	1	0	0
64609	1709	Ca(2+)-activated	[Ca(2+)-activated]	0.1	1	1	0	0
64610	1709	mtcp1	[MTCP1]	0.1	1	1	0	0
64611	1709	anti-Jun	[anti-Jun]	0.1	1	2	1	1
64612	1709	molecule,	[molecule,]	0.1	1	2	1	1
64613	1709	thrombomodulin	[thrombomodulin]	0.1	1	1	0	0
64614	1709	cd34+thy-l-cd45ra+	[CD34+Thy-l-CD45RA+]	0.1	1	1	0	0
64615	1709	processes.	[processes.]	0.1	1	2	1	1
64616	1709	Here,	[Here,]	0.1	1	2	1	1
64617	1709	tcf1	[TCF1]	0.1	1	1	0	0
64618	1709	ischemia/reperfusion	[ischemia/reperfusion]	0.1	1	1	0	0
64619	1709	hormone-related	[hormone-related]	0.1	1	2	1	1
64620	1709	FcRFgamma	[FcRFgamma]	0.1	1	1	0	0
64621	1709	box1	[box1]	0.1	1	2	1	1
64622	1709	-vdr	[-VDR]	0.1	1	2	2	2
64623	1709	o,o'-bismyristoyl	[o,o'-bismyristoyl]	0.1	1	1	0	0
64624	1709	determined.	[determined.]	0.1	1	1	0	0
64625	1709	tcr-	[TCR-]	0.1	1	1	0	0
64626	1709	tcr+	[TCR+]	0.1	1	2	2	2
64627	1709	Gal4-	[Gal4-]	0.1	1	2	1	1
64628	1709	mosaicism	[Mosaicism]	0.1	1	2	2	2
64629	1709	reduce	[reducing]	0.1	1	1	0	0
64630	1709	mbob1	[mBob1]	0.1	1	1	0	0
64631	1709	pxqxt/	[PXQXT/S]	0.1	1	2	2	2
64632	1709	rar/rxr	[RAR/RXR]	0.1	1	1	0	0
64633	1709	du-145	[DU-145]	0.1	1	1	0	0
64634	1709	express	[expressing]	0.1	1	1	0	0
64635	1709	Fenton	[Fenton]	0.1	1	1	0	0
64636	1709	bcr1/9	[BCR1/9]	0.1	1	1	0	0
64637	1709	(lak)	[(LAK)]	0.1	1	2	1	1
64638	1709	IFN.	[IFN.]	0.1	1	1	0	0
64639	1709	receptor/progesterone	[receptor/progesterone]	0.1	1	1	0	0
64640	1709	IFNA	[IFNA]	0.1	1	2	1	1
64641	1709	5'nf-e2/ap1	[5'NF-E2/AP1]	0.1	1	1	0	0
64642	1709	ileum	[ileum]	0.1	1	2	1	1
64643	1709	C-myb	[C-myb]	0.1	1	1	0	0
64644	1709	fk506.	[FK506.]	0.1	1	1	0	0
64645	1709	cRel	[cRel]	0.1	1	1	0	0
64646	1709	allergen.	[allergen.]	0.1	1	1	0	0
64647	1709	gynecomastias	[gynecomastias]	0.1	1	1	0	0
64648	1709	Ad5wt	[Ad5wt]	0.1	1	1	0	0
64649	1709	alpha-locus	[alpha-locus]	0.1	1	1	0	0
64650	1709	(1.3-fold)	[(1.3-fold)]	0.1	1	1	0	0
64651	1709	(chr)	[(Chr)]	0.1	1	1	0	0
64652	1709	tomography	[tomography]	0.1	1	1	0	0
64653	1709	Hela	[Hela]	0.1	1	2	1	1
64654	1709	mol/l),	[mol/L),]	0.1	1	1	0	0
64655	1709	lmp-2a	[LMP-2A]	0.1	1	1	0	0
64656	1709	TAD-A	[TAD-A]	0.1	1	1	0	0
64657	1709	supine	[supine]	0.1	1	1	0	0
64658	1709	mip-1alpha,	[MIP-1alpha,]	0.1	1	1	0	0
64659	1709	5007+2insA	[5007+2insA]	0.1	1	1	0	0
64660	1709	kb-like	[kB-like]	0.1	1	1	0	0
64661	1709	RARS	[RARS]	0.1	1	1	0	0
64662	1709	RARA	[RARA]	0.1	1	2	1	1
64663	1709	Pindolol	[Pindolol]	0.1	1	1	0	0
64664	1709	adherence,	[adherence,]	0.1	1	1	0	0
64665	1709	RARs	[RARs]	0.1	1	1	0	0
64666	1709	bruton'	[Bruton's]	0.1	1	1	0	0
64667	1709	kappaB-alpha	[kappaB-alpha]	0.1	1	2	2	2
64668	1709	transrepressor	[transrepressor]	0.1	1	1	0	0
64669	1709	switching	[Switching]	0.1	1	1	0	0
64670	1709	cdc10/ankyrin	[cdc10/ankyrin]	0.1	1	1	0	0
64671	1709	II).	[II).]	0.1	1	1	0	0
64672	1709	disrupt	[disrupting]	0.1	1	1	0	0
64673	1709	aging,	[aging,]	0.1	1	1	0	0
64674	1709	t-test	[t-test]	0.1	1	1	0	0
64675	1709	glycosylation	[glycosylation]	0.1	1	1	0	0
64676	1709	m.w.	[m.w.]	0.1	1	1	0	0
64677	1709	th1-	[Th1-]	0.1	1	2	1	1
64678	1709	phase-1	[phase-1]	0.1	1	2	2	2
64679	1709	Hypercortisolaemia	[Hypercortisolaemia]	0.1	1	1	0	0
64680	1709	laminin-	[laminin-]	0.1	1	1	0	0
64681	1709	note,	[note,]	0.1	1	1	0	0
64682	1709	1-oleoyl-2-acetyl-sn-glycerol	[1-oleoyl-2-acetyl-sn-glycerol]	0.1	1	1	0	0
64683	1709	Megakaryocytic	[Megakaryocytic]	0.1	1	1	0	0
64684	1709	sc170	[Sc170]	0.1	1	1	0	0
64685	1709	inv(3)(q21q26)	[inv(3)(q21q26)]	0.1	1	1	0	0
64686	1709	mycoestrogen	[mycoestrogens]	0.1	1	1	0	0
64687	1709	HeLa-cell	[HeLa-cell]	0.1	1	1	0	0
64688	1709	mkp-1	[MKP-1]	0.1	1	2	1	1
64689	1709	Seiki,	[Seiki,]	0.1	1	1	0	0
64690	1709	hGM-CSF	[hGM-CSF]	0.1	1	1	0	0
64691	1709	growth-inhibition	[growth-inhibition]	0.1	1	1	0	0
64692	1709	chickens,	[chickens,]	0.1	1	1	0	0
64693	1709	E.Kieff,	[E.Kieff,]	0.1	1	1	0	0
64694	1709	sepsis.	[sepsis.]	0.1	1	2	1	1
64695	1709	vdrnuc	[VDRnuc]	0.1	1	1	0	0
64696	1709	Ac-DEVD-fmk	[Ac-DEVD-fmk]	0.1	1	1	0	0
64697	1709	etiology,	[etiology,]	0.1	1	1	0	0
64698	1709	test.	[test.]	0.1	1	1	0	0
64699	1709	protocol	[protocol]	0.1	1	2	1	1
64700	1709	candidiasis	[candidiasis]	0.1	1	1	0	0
64701	1709	c-fps/fe	[c-fps/fes]	0.1	1	1	0	0
64702	1709	relationship,	[relationship,]	0.1	1	1	0	0
64703	1709	two-phase	[two-phase]	0.1	1	1	0	0
64704	1709	gliotoxin	[gliotoxin]	0.1	1	1	0	0
64705	1709	influx	[influx]	0.1	1	2	2	2
64706	1709	(cll)	[(CLL)]	0.1	1	1	0	0
64707	1709	adaptation	[adaptation]	0.1	1	2	2	2
64708	1709	wild-	[wild-]	0.1	1	1	0	0
64709	1709	300-bp	[300-bp]	0.1	1	1	0	0
64710	1709	Abbott	[Abbott]	0.1	1	1	0	0
64711	1709	embryocarcinoma	[embryocarcinoma]	0.1	1	1	0	0
64712	1709	signal-transduction	[signal-transduction]	0.1	1	2	1	1
64713	1709	receptor-dependent,	[receptor-dependent,]	0.1	1	1	0	0
64714	1709	edge:	[edge:]	0.1	1	2	1	1
64715	1709	cmmol	[CMMoL]	0.1	1	1	0	0
64716	1709	synergism,	[synergism,]	0.1	1	1	0	0
64717	1709	arteritis-SCID	[arteritis-SCID]	0.1	1	1	0	0
64718	1709	sh2-containing	[SH2-containing]	0.1	1	1	0	0
64719	1709	biscoclaurine	[biscoclaurine]	0.1	1	2	1	1
64720	1709	cd13/apn	[CD13/APN]	0.1	1	1	0	0
64721	1709	normalize	[normalizing]	0.1	1	2	1	1
64722	1709	bulk	[bulk]	0.1	1	2	1	1
64723	1709	O-side	[O-side]	0.1	1	1	0	0
64724	1709	lower-affinity	[lower-affinity]	0.1	1	1	0	0
64725	1709	acyclovir	[acyclovir]	0.1	1	1	0	0
64726	1709	ccaat-box	[CCAAT-box]	0.1	1	2	1	1
64727	1709	wt-19	[WT-19]	0.1	1	1	0	0
64728	1709	but,	[but,]	0.1	1	1	0	0
64729	1709	inhibin	[inhibin]	0.1	1	2	1	1
64730	1709	/enhancer	[/enhancer]	0.1	1	2	2	2
64731	1709	timp	[TIMP]	0.1	1	1	0	0
64732	1709	IL4R	[IL4R]	0.1	1	2	1	1
64733	1709	icr27	[ICR27]	0.1	1	1	0	0
64734	1709	triangle	[triangle]	0.1	1	1	0	0
64735	1709	interleukin-1beta-converting	[interleukin-1beta-converting]	0.1	1	1	0	0
64736	1709	(aim)/	[(AIM)/]	0.1	1	1	0	0
64737	1709	thrombogenesis	[thrombogenesis]	0.1	1	1	0	0
64738	1709	foregoing	[foregoing]	0.1	1	1	0	0
64739	1709	cytospin	[cytospin]	0.1	1	2	1	1
64740	1709	opportunity	[opportunity]	0.1	1	1	0	0
64741	1709	metamyelocyte	[metamyelocytes]	0.1	1	1	0	0
64742	1709	platelet-activating-factor	[platelet-activating-factor]	0.1	1	1	0	0
64743	1709	REVs	[REVs]	0.1	1	1	0	0
64744	1709	tracking	[tracking]	0.1	1	1	0	0
64745	1709	tarsal	[tarsal]	0.1	1	1	0	0
64746	1709	gel-retardation	[gel-retardation]	0.1	1	2	1	1
64747	1709	RFLP	[RFLP]	0.1	1	1	0	0
64748	1709	lipoproteins.	[lipoproteins.]	0.1	1	1	0	0
64749	1709	Tcl-5	[Tcl-5]	0.1	1	1	0	0
64750	1709	(8;21)(q22;q22)	[(8;21)(q22;q22)]	0.1	1	1	0	0
64751	1709	+/ebv-	[+/EBV-]	0.1	1	1	0	0
64752	1709	-encode	[-encoding]	0.1	1	2	2	2
64753	1709	glut1	[GLUT1]	0.1	1	1	0	0
64754	1709	anti-NF-ATc	[anti-NF-ATc]	0.1	1	1	0	0
64755	1709	pfp5a	[PFP5a]	0.1	1	2	2	2
64756	1709	cd95/apo-1	[CD95/APO-1]	0.1	1	2	2	2
64757	1709	anti-CD2	[anti-CD2]	0.1	1	1	0	0
64758	1709	chan'su	[chan'su]	0.1	1	1	0	0
64759	1709	lyso-phospholipid	[lyso-phospholipids]	0.1	1	1	0	0
64760	1709	inducibility.	[inducibility.]	0.1	1	1	0	0
64761	1709	inducibility,	[inducibility,]	0.1	1	1	0	0
64762	1709	four-fold,	[four-fold,]	0.1	1	1	0	0
64763	1709	84-kda	[84-kDa]	0.1	1	1	0	0
64764	1709	gamma-herpesvirus	[gamma-herpesvirus]	0.1	1	2	1	1
64765	1709	A549	[A549]	0.1	1	1	0	0
64766	1709	turnover,	[turnover,]	0.1	1	1	0	0
64767	1709	Heterokaryons	[Heterokaryons]	0.1	1	1	0	0
64768	1709	Naringenin,	[Naringenin,]	0.1	1	1	0	0
64769	1709	tumor-bearing	[tumor-bearing]	0.1	1	1	0	0
64770	1709	RXR-beta	[RXR-beta]	0.1	1	1	0	0
64771	1709	Garcia-Cozar,	[Garcia-Cozar,]	0.1	1	1	0	0
64772	1709	correction	[correction]	0.1	1	2	2	2
64773	1709	AACAAAG	[AACAAAG]	0.1	1	1	0	0
64774	1709	hormonocyte	[hormonocytes]	0.1	1	1	0	0
64775	1709	factor-DNA	[factor-DNA]	0.1	1	2	1	1
64776	1709	tlck	[TLCK]	0.1	1	1	0	0
64777	1709	surfactant'	[surfactant's]	0.1	1	1	0	0
64778	1709	GTP-GDP	[GTP-GDP]	0.1	1	1	0	0
64779	1709	kt-3	[KT-3]	0.1	1	1	0	0
64780	1709	tcf/lef	[TCF/LEF]	0.1	1	1	0	0
64781	1709	telangiectasia	[telangiectasia]	0.1	1	2	2	2
64782	1709	H+-ATPase	[H+-ATPase]	0.1	1	1	0	0
64783	1709	sulindac	[sulindac]	0.1	1	1	0	0
64784	1709	Src-family	[Src-family]	0.1	1	1	0	0
64785	1709	metabolism,	[metabolism,]	0.1	1	1	0	0
64786	1709	1.4-kb	[1.4-kb]	0.1	1	1	0	0
64787	1709	light-chain	[light-chain]	0.1	1	2	1	1
64788	1709	18-oh-b	[18-OH-B]	0.1	1	2	1	1
64789	1709	deletions.	[deletions.]	0.1	1	2	1	1
64790	1709	glucocorticoid-	[glucocorticoid-]	0.1	1	2	1	1
64791	1709	DDPCR	[DDPCR]	0.1	1	1	0	0
64792	1709	chromatin.	[chromatin.]	0.1	1	1	0	0
64793	1709	threefold)	[threefold)]	0.1	1	1	0	0
64794	1709	threefold.	[threefold.]	0.1	1	1	0	0
64795	1709	apr;17(4):2351]	[Apr;17(4):2351]]	0.1	1	1	0	0
64796	1709	study:	[STUDY:]	0.1	1	1	0	0
64797	1709	anti-HLA-DR	[anti-HLA-DR]	0.1	1	1	0	0
64798	1709	104-bp	[104-bp]	0.1	1	1	0	0
64799	1709	TAL-2	[TAL-2]	0.1	1	1	0	0
64800	1709	therapy.	[therapy.]	0.1	1	1	0	0
64801	1709	thymopoiesis	[thymopoiesis]	0.1	1	2	2	2
64802	1709	bzlf	[BZLF]	0.1	1	2	1	1
64803	1709	tnf)	[TNF)]	0.1	1	1	0	0
64804	1709	super-shift	[Super-shift]	0.1	1	2	2	2
64805	1709	fibromatosis	[fibromatosis]	0.1	1	1	0	0
64806	1709	tnf,	[TNF,]	0.1	1	1	0	0
64807	1709	devd-p-nitroanilide	[DEVD-p-nitroanilide]	0.1	1	1	0	0
64808	1709	(Mantel-Cox)	[(Mantel-Cox)]	0.1	1	1	0	0
64809	1709	IKK-alpha	[IKK-alpha]	0.1	1	1	0	0
64810	1709	nonsense	[nonsense]	0.1	1	1	0	0
64811	1709	(K(m)	[(K(m)]	0.1	1	1	0	0
64812	1709	cd38(-)	[CD38(-)]	0.1	1	1	0	0
64813	1709	z-lll-h	[Z-LLL-H]	0.1	1	2	1	1
64814	1709	13-kb	[13-kb]	0.1	1	1	0	0
64815	1709	t(3;14)(q27;q11)	[t(3;14)(q27;q11)]	0.1	1	2	1	1
64816	1709	/DNA	[/DNA]	0.1	1	2	2	2
64817	1709	BCR1/25	[BCR1/25]	0.1	1	1	0	0
64818	1709	profilin	[profilin]	0.1	1	1	0	0
64819	1709	Kidney-tonifying	[Kidney-tonifying]	0.1	1	1	0	0
64820	1709	1-(5-Isoquinolinylsulphonyl)-2-methylpiperazine	[1-(5-Isoquinolinylsulphonyl)-2-methylpiperazine]	0.1	1	1	0	0
64821	1709	toll	[toll]	0.1	1	2	1	1
64822	1709	estriol	[estriol]	0.1	1	1	0	0
64823	1709	anchor	[anchor]	0.1	1	2	1	1
64824	1709	lyf-1	[LyF-1]	0.1	1	1	0	0
64825	1709	toto	[toto,]	0.1	1	1	0	0
64826	1709	p40-kappaB	[p40-kappaB]	0.1	1	1	0	0
64827	1709	arachidonate	[arachidonate]	0.1	1	2	1	1
64828	1709	Grb2-like	[Grb2-like]	0.1	1	1	0	0
64829	1709	development;	[development;]	0.1	1	1	0	0
64830	1709	jpx-9	[JPX-9]	0.1	1	1	0	0
64831	1709	diamide	[diamide]	0.1	1	2	1	1
64832	1709	schizophrenia	[schizophrenia]	0.1	1	1	0	0
64833	1709	IRES	[IRES]	0.1	1	2	2	2
64834	1709	parallel	[parallel]	0.1	1	3	2	1
64835	1709	PMA/anti-CD28	[PMA/anti-CD28]	0.1	1	1	0	0
64836	1709	antiprogestagen	[antiprogestagens]	0.1	1	1	0	0
64837	1709	milliliter	[milliliter]	0.1	1	1	0	0
64838	1709	Oestradiol	[Oestradiol]	0.1	1	1	0	0
64839	1709	liposome	[Liposomes]	0.1	1	2	1	1
64840	1709	fraction,	[fraction,]	0.1	1	1	0	0
64841	1709	Agamma-	[Agamma-]	0.1	1	1	0	0
64842	1709	I(kappa)B	[I(kappa)B]	0.1	1	1	0	0
64843	1709	over-expression	[over-expression]	0.1	1	4	3	1
64844	1709	embryogenesis,	[embryogenesis,]	0.1	1	1	0	0
64845	1709	12,13-phorbol	[12,13-phorbol]	0.1	1	1	0	0
64846	1709	hence,	[hence,]	0.1	1	2	2	2
64847	1709	autoregulatory	[autoregulatory]	0.1	1	2	2	2
64848	1709	36-kDa	[36-kDa]	0.1	1	1	0	0
64849	1709	lactobacilli	[Lactobacilli]	0.1	1	1	0	0
64850	1709	dihydro	[dihydro]	0.1	1	1	0	0
64851	1709	M-TAT/EPO	[M-TAT/EPO]	0.1	1	1	0	0
64852	1709	dna-streptavidin	[DNA-streptavidin]	0.1	1	1	0	0
64853	1709	tre,	[TRE,]	0.1	1	1	0	0
64854	1709	tre1	[TRE1]	0.1	1	2	1	1
64855	1709	centrocyte	[centrocytes]	0.1	1	1	0	0
64856	1709	S.R.and	[S.R.and]	0.1	1	1	0	0
64857	1709	carboxy-	[carboxy-]	0.1	1	1	0	0
64858	1709	(40-48%	[(40-48%]	0.1	1	1	0	0
64859	1709	(impdh)	[(IMPDH)]	0.1	1	1	0	0
64860	1709	n-wasp	[N-WASP]	0.1	1	2	1	1
64861	1709	tsap	[TSAP]	0.1	1	2	1	1
64862	1709	progestin	[progestin]	0.1	1	1	0	0
64863	1709	phosphorylation.	[phosphorylation.]	0.1	1	1	0	0
64864	1709	pentazocine	[pentazocine]	0.1	1	2	1	1
64865	1709	placement	[placement]	0.1	1	1	0	0
64866	1709	multidrug	[multidrug]	0.1	1	1	0	0
64867	1709	a1-vdr	[A1-VDR]	0.1	1	1	0	0
64868	1709	organogenesis	[organogenesis]	0.1	1	2	2	2
64869	1709	S107	[S107]	0.1	1	1	0	0
64870	1709	ROS)	[ROS)]	0.1	1	1	0	0
64871	1709	INF-gamma	[INF-gamma]	0.1	1	1	0	0
64872	1709	47-bp	[47-bp]	0.1	1	1	0	0
64873	1709	18-deoxy-19-noraldosterone	[18-deoxy-19-noraldosterone]	0.1	1	1	0	0
64874	1709	alpha/AML-1	[alpha/AML-1]	0.1	1	2	2	2
64875	1709	deoxycorticosterone	[deoxycorticosterone]	0.1	1	1	0	0
64876	1709	spi-1/pu.1	[Spi-1/PU.1]	0.1	1	2	1	1
64877	1709	weakness	[weakness]	0.1	1	1	0	0
64878	1709	S194	[S194]	0.1	1	1	0	0
64879	1709	3,5,3'-triiodothyronine	[3,5,3'-triiodothyronine]	0.1	1	1	0	0
64880	1709	inositol-1,4,5-trisphosphate	[inositol-1,4,5-trisphosphate]	0.1	1	1	0	0
64881	1709	cell-like,n	[cell-like,]	0.1	1	1	0	0
64882	1709	choice.	[choice.]	0.1	1	1	0	0
64883	1709	choice;	[choice;]	0.1	1	1	0	0
64884	1709	59-kda	[59-kDa]	0.1	1	2	1	1
64885	1709	usage	[usage]	0.1	1	2	2	2
64886	1709	transfer.	[transfer.]	0.1	1	1	0	0
64887	1709	carg	[CArG]	0.1	1	2	1	1
64888	1709	care	[care]	0.1	1	1	0	0
64889	1709	CREB-	[CREB-]	0.1	1	1	0	0
64890	1709	immunofluorescence,	[immunofluorescence,]	0.1	1	1	0	0
64891	1709	Gzero/G1	[Gzero/G1]	0.1	1	1	0	0
64892	1709	chaperoning	[chaperoning]	0.1	1	1	0	0
64893	1709	3'-CAGGTG	[3'-CAGGTG]	0.1	1	1	0	0
64894	1709	instillation	[instillation]	0.1	1	2	2	2
64895	1709	lysophospholipid.	[lysophospholipid.]	0.1	1	1	0	0
64896	1709	g1/g0	[G1/G0]	0.1	1	1	0	0
64897	1709	ifn-gammar	[IFN-gammaR]	0.1	1	2	1	1
64898	1709	47-kd	[47-kD]	0.1	1	1	0	0
64899	1709	gad-creb	[GAD-CREB]	0.1	1	1	0	0
64900	1709	cd3/	[CD3/]	0.1	1	1	0	0
64901	1709	Schneider	[Schneider]	0.1	1	2	2	2
64902	1709	alterations.	[alterations.]	0.1	1	2	1	1
64903	1709	electron-transport	[electron-transport]	0.1	1	1	0	0
64904	1709	crossreact	[crossreacting]	0.1	1	1	0	0
64905	1709	cd37	[CD37]	0.1	1	1	0	0
64906	1709	del(17)(q25)	[del(17)(q25)]	0.1	1	1	0	0
64907	1709	cd68	[CD68]	0.1	1	1	0	0
64908	1709	rhombotin-2	[rhombotin-2]	0.1	1	1	0	0
64909	1709	cd3r	[CD3R]	0.1	1	1	0	0
64910	1709	cd61	[CD61]	0.1	1	1	0	0
64911	1709	cd62	[CD62]	0.1	1	2	1	1
64912	1709	cd8-	[CD8-]	0.1	1	2	1	1
64913	1709	artery-SCID	[artery-SCID]	0.1	1	1	0	0
64914	1709	responsiveness.	[responsiveness.]	0.1	1	1	0	0
64915	1709	granulocty	[granuloctyes]	0.1	1	1	0	0
64916	1709	motion	[motion]	0.1	1	1	0	0
64917	1709	gggaactacc	[GGGAACTACC]	0.1	1	1	0	0
64918	1709	atf4/creb2	[ATF4/CREB2]	0.1	1	1	0	0
64919	1709	Sp1-binding	[Sp1-binding]	0.1	1	1	0	0
64920	1709	picornavirus	[picornavirus]	0.1	1	1	0	0
64921	1709	hypotheses,	[hypotheses,]	0.1	1	2	1	1
64922	1709	t/nk-cell	[T/NK-cell]	0.1	1	2	1	1
64923	1709	IL-4RE	[IL-4RE]	0.1	1	1	0	0
64924	1709	Zinc	[Zinc]	0.1	1	1	0	0
64925	1709	F.Lori,	[F.Lori,]	0.1	1	1	0	0
64926	1709	Megakaryocyte/Platelet-specific	[Megakaryocyte/Platelet-specific]	0.1	1	1	0	0
64927	1709	(SIV)	[(SIV)]	0.1	1	1	0	0
64928	1709	Ser184	[Ser184]	0.1	1	2	1	1
64929	1709	hTAFII130	[hTAFII130]	0.1	1	1	0	0
64930	1709	worker	[workers]	0.1	1	2	1	1
64931	1709	ingredient	[ingredient]	0.1	1	2	1	1
64932	1709	nfil3/e4bp4	[NFIL3/E4BP4]	0.1	1	2	2	2
64933	1709	polymer	[polymer]	0.1	1	1	0	0
64934	1709	h(+)-atpase	[H(+)-ATPase]	0.1	1	2	1	1
64935	1709	lymphoid/myeloid	[lymphoid/myeloid]	0.1	1	1	0	0
64936	1709	tfe-3	[TFE-3]	0.1	1	1	0	0
64937	1709	BglII	[BglII]	0.1	1	1	0	0
64938	1709	leucine-zipper	[leucine-zipper]	0.1	1	1	0	0
64939	1709	avidin	[avidin]	0.1	1	1	0	0
64940	1709	cdk6	[cdk6]	0.1	1	2	1	1
64941	1709	transcription/repair	[transcription/repair]	0.1	1	1	0	0
64942	1709	antidsdna	[antidsDNA]	0.1	1	1	0	0
64943	1709	(luc)	[(Luc)]	0.1	1	1	0	0
64944	1709	ngfi-a/egr-1	[NGFI-A/Egr-1]	0.1	1	1	0	0
64945	1709	PBMCs	[PBMCs]	0.1	1	1	0	0
64946	1709	twhf	[TWHf]	0.1	1	1	0	0
64947	1709	stages:	[stages:]	0.1	1	2	2	2
64948	1709	stages,	[stages,]	0.1	1	1	0	0
64949	1709	stages.	[stages.]	0.1	1	2	1	1
64950	1709	pma/a23187	[PMA/A23187]	0.1	1	1	0	0
64951	1709	disomy	[disomy]	0.1	1	2	2	2
64952	1709	1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine	[1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine]	0.1	1	1	0	0
64953	1709	exception,	[exception,]	0.1	1	2	1	1
64954	1709	silence	[silencing]	0.1	1	1	0	0
64955	1709	immunocytochemical	[immunocytochemical]	0.1	1	1	0	0
64956	1709	(Chang	[(Chang]	0.1	1	1	0	0
64957	1709	erbstatin	[erbstatin]	0.1	1	1	0	0
64958	1709	subfragment	[subfragment]	0.1	1	1	0	0
64959	1709	tip-associated	[Tip-associated]	0.1	1	1	0	0
64960	1709	SOCS/	[SOCS/]	0.1	1	1	0	0
64961	1709	IL-4-binding	[IL-4-binding]	0.1	1	1	0	0
64962	1709	cess	[CESS]	0.1	1	1	0	0
64963	1709	switching.	[switching.]	0.1	1	2	1	1
64964	1709	wy14643	[WY14643]	0.1	1	1	0	0
64965	1709	leiomyoma	[leiomyoma]	0.1	1	3	2	1
64966	1709	bis(maltolato)oxovanadium-iv	[bis(maltolato)oxovanadium-IV]	0.1	1	1	0	0
64967	1709	oligomerization	[oligomerization]	0.1	1	4	3	1
64968	1709	Zn++	[Zn++]	0.1	1	1	0	0
64969	1709	/calcium	[/calcium]	0.1	1	2	2	2
64970	1709	muramyldipeptide	[muramyldipeptide]	0.1	1	1	0	0
64971	1709	deposition	[deposition]	0.1	1	1	0	0
64972	1709	BRLF-1	[BRLF-1]	0.1	1	1	0	0
64973	1709	J.Jhan	[J.Jhan]	0.1	1	2	2	2
64974	1709	hosts.	[hosts.]	0.1	1	1	0	0
64975	1709	rectifier	[rectifier]	0.1	1	1	0	0
64976	1709	Hyon	[Hyon]	0.1	1	2	1	1
64977	1709	interassay	[interassay]	0.1	1	2	1	1
64978	1709	hut102	[HuT102]	0.1	1	1	0	0
64979	1709	anti-silencer	[anti-silencer]	0.1	1	1	0	0
64980	1709	1beta,25-dihydroxyvitamin	[1beta,25-dihydroxyvitamin]	0.1	1	1	0	0
64981	1709	deoxynucleotidyl	[deoxynucleotidyl]	0.1	1	1	0	0
64982	1709	Ser-36	[Ser-36]	0.1	1	1	0	0
64983	1709	Rp-cAMP-	[Rp-cAMP-]	0.1	1	1	0	0
64984	1709	adenomyosis	[adenomyosis]	0.1	1	1	0	0
64985	1709	cd34(2+)/cd38-	[CD34(2+)/CD38-]	0.1	1	1	0	0
64986	1709	NF-kappa(b)	[NF-kappa(B)]	0.1	1	1	0	0
64987	1709	(pou[s])	[(POU[S])]	0.1	1	1	0	0
64988	1709	VDR-RXR	[VDR-RXR]	0.1	1	1	0	0
64989	1709	fiber	[fiber]	0.1	1	2	2	2
64990	1709	cgmp	[cGMP]	0.1	1	1	0	0
64991	1709	RAR-alpha	[RAR-alpha]	0.1	1	1	0	0
64992	1709	lam-	[LAM-]	0.1	1	1	0	0
64993	1709	october	[october]	0.1	1	1	0	0
64994	1709	hypothesis.	[hypothesis.]	0.1	1	1	0	0
64995	1709	norepinephrine	[norepinephrine]	0.1	1	1	0	0
64996	1709	ACTH	[ACTH]	0.1	1	1	0	0
64997	1709	Raf1/MEK1/	[Raf1/MEK1/]	0.1	1	1	0	0
64998	1709	phorbol-di-butyrate	[phorbol-di-butyrate]	0.1	1	1	0	0
64999	1709	67-kDa	[67-kDa]	0.1	1	1	0	0
65000	1709	/PHA	[/PHA]	0.1	1	1	0	0
65001	1709	nuclearity,	[nuclearity,]	0.1	1	1	0	0
65002	1709	proximal,	[proximal,]	0.1	1	1	0	0
65003	1709	chi2	[chi2]	0.1	1	2	2	2
65004	1709	flowerhead	[flowerheads]	0.1	1	1	0	0
65005	1709	average,	[average,]	0.1	1	1	0	0
65006	1709	lbf3	[LBF3]	0.1	1	1	0	0
65007	1709	lbf6	[LBF6]	0.1	1	1	0	0
65008	1709	lbf7	[LBF7]	0.1	1	1	0	0
65009	1709	lbf5	[LBF5]	0.1	1	1	0	0
65010	1709	micrograms/ml).	[micrograms/ml).]	0.1	1	1	0	0
65011	1709	pretreatment.	[pretreatment.]	0.1	1	1	0	0
65012	1709	permissivity	[permissivity]	0.1	1	2	1	1
65013	1709	n-ac-leu-leu-norleucinal	[N-Ac-Leu-Leu-norleucinal]	0.1	1	1	0	0
65014	1709	comigrate	[comigrating]	0.1	1	1	0	0
65015	1709	segregation	[segregation]	0.1	1	2	2	2
65016	1709	AECA	[AECA]	0.1	1	1	0	0
65017	1709	K-RAS	[K-RAS]	0.1	1	1	0	0
65018	1709	purine-box	[purine-box]	0.1	1	1	0	0
65019	1709	ck-1	[CK-1]	0.1	1	1	0	0
65020	1709	cip1	[Cip1]	0.1	1	1	0	0
65021	1709	1-beta-d-arabinofuranosylcytosine	[1-beta-D-arabinofuranosylcytosine]	0.1	1	1	0	0
65022	1709	fibronectin-	[fibronectin-]	0.1	1	1	0	0
65023	1709	fibronectin,	[fibronectin,]	0.1	1	1	0	0
65024	1709	drip205	[DRIP205]	0.1	1	1	0	0
65025	1709	Louckes	[Louckes]	0.1	1	1	0	0
65026	1709	cis.	[cis.]	0.1	1	1	0	0
65027	1709	armamentarium	[armamentarium]	0.1	1	1	0	0
65028	1709	workload	[workload]	0.1	1	1	0	0
65029	1709	respectively).	[respectively).]	0.1	1	2	2	2
65030	1709	respectively),	[respectively),]	0.1	1	2	2	2
65031	1709	ehrlichiosis	[ehrlichiosis]	0.1	1	2	1	1
65032	1709	Jaks/stat	[Jaks/Stats]	0.1	1	1	0	0
65033	1709	PL/IM	[PL/IM]	0.1	1	1	0	0
65034	1709	(dq2.1)-restricted,	[(DQ2.1)-restricted,]	0.1	1	1	0	0
65035	1709	wbJun	[wbJun]	0.1	1	1	0	0
65036	1709	t-lymphotropic	[T-lymphotropic]	0.1	1	1	0	0
65037	1709	mcl-1	[mcl-1]	0.1	1	1	0	0
65038	1709	autopsy	[autopsy]	0.1	1	1	0	0
65039	1709	yros)	[(ROS)]	0.1	1	1	0	0
65040	1709	alzheimer'	[Alzheimer's]	0.1	1	1	0	0
65041	1709	rfx-b	[RFX-B]	0.1	1	1	0	0
65042	1709	drive	[drive]	0.1	1	1	0	0
65043	1709	tfiie	[TFIIE]	0.1	1	2	2	2
65044	1709	Gq/G11	[Gq/G11]	0.1	1	1	0	0
65045	1709	dt-40	[DT-40]	0.1	1	1	0	0
65046	1709	9-bp	[9-bp]	0.1	1	1	0	0
65047	1709	transactivator-encoding	[transactivator-encoding]	0.1	1	1	0	0
65048	1709	e-cm	[E-CM]	0.1	1	1	0	0
65049	1709	long-last	[long-lasting]	0.1	1	1	0	0
65050	1709	bipartite	[bipartite]	0.1	1	1	0	0
65051	1709	GAL4-EBNA3C	[GAL4-EBNA3C]	0.1	1	1	0	0
65052	1709	lef1	[LEF1]	0.1	1	1	0	0
65053	1709	CTLL-2/	[CTLL-2/]	0.1	1	1	0	0
65054	1709	NF-AT-1	[NF-AT-1]	0.1	1	1	0	0
65055	1709	hypothese	[hypotheses]	0.1	1	2	1	1
65056	1709	mmol/l),	[mmol/l),]	0.1	1	1	0	0
65057	1709	tandem,	[tandem,]	0.1	1	1	0	0
65058	1709	SIVmac251	[SIVmac251]	0.1	1	2	1	1
65059	1709	peptidoglycan	[peptidoglycan]	0.1	1	2	2	2
65060	1709	Ferriman-Gallwey	[Ferriman-Gallwey]	0.1	1	1	0	0
65061	1709	dupuytren'	[Dupuytren's]	0.1	1	1	0	0
65062	1709	35-amino	[35-amino]	0.1	1	1	0	0
65063	1709	important,	[important,]	0.1	1	1	0	0
65064	1709	il-1-ra	[IL-1-RA]	0.1	1	1	0	0
65065	1709	cyclin/cdk	[cyclin/cdks]	0.1	1	2	1	1
65066	1709	season	[season]	0.1	1	1	0	0
65067	1709	s-lb1	[S-LB1]	0.1	1	2	2	2
65068	1709	clip	[CLIP]	0.1	1	2	1	1
65069	1709	gcr-beta	[GCR-beta]	0.1	1	2	1	1
65070	1709	cytosolic	[cytosolic]	0.1	1	2	2	2
65071	1709	glutaminyl-ttg	[glutaminyl-tTG]	0.1	1	1	0	0
65072	1709	micrograms/mL	[micrograms/mL]	0.1	1	2	2	2
65073	1709	clsm	[CLSM]	0.1	1	2	1	1
65074	1709	65-kilodalton	[65-kilodalton]	0.1	1	1	0	0
65075	1709	estradiol,	[estradiol,]	0.1	1	1	0	0
65076	1709	issue),	[issue),]	0.1	1	1	0	0
65077	1709	[3H]1	[[3H]1]	0.1	1	1	0	0
65078	1709	cell"	[cell"]	0.1	1	2	1	1
65079	1709	invert	[inverting]	0.1	1	1	0	0
65080	1709	prestimulation	[prestimulation]	0.1	1	1	0	0
65081	1709	PTHrP	[PTHrP]	0.1	1	1	0	0
65082	1709	drug-immunophilin	[drug-immunophilin]	0.1	1	2	1	1
65083	1709	Sephacryl	[Sephacryl]	0.1	1	1	0	0
65084	1709	3h-e2	[3H-E2]	0.1	1	1	0	0
65085	1709	92-bp	[92-bp]	0.1	1	1	0	0
65086	1709	phosphatidylcholine	[phosphatidylcholine]	0.1	1	1	0	0
65087	1709	HMG-1	[HMG-1]	0.1	1	1	0	0
65088	1709	reconstitution,	[reconstitution,]	0.1	1	1	0	0
65089	1709	HMG1B	[HMG1B]	0.1	1	1	0	0
65090	1709	NAD(P)H:quinone	[NAD(P)H:quinone]	0.1	1	2	1	1
65091	1709	repair/transcription	[repair/transcription]	0.1	1	1	0	0
65092	1709	67-bp	[67-bp]	0.1	1	1	0	0
65093	1709	lipoarabinomannan	[lipoarabinomannan]	0.1	1	2	2	2
65094	1709	nonalcoholic	[nonalcoholics]	0.1	1	1	0	0
65095	1709	bait.	[bait.]	0.1	1	1	0	0
65096	1709	er-beta	[ER-beta]	0.1	1	1	0	0
65097	1709	mangabey	[mangabey]	0.1	1	3	2	1
65098	1709	naturally-occurg	[naturally-occurring]	0.1	1	1	0	0
65099	1709	Id-3	[Id-3]	0.1	1	1	0	0
65100	1709	N-tosylphenylalanine	[N-tosylphenylalanine]	0.1	1	1	0	0
65101	1709	(timp)-1	[(TIMP)-1]	0.1	1	1	0	0
65102	1709	anti-	[anti-]	0.1	1	1	0	0
65103	1709	ebv-bhrf1	[EBV-BHRF1]	0.1	1	1	0	0
65104	1709	trance	[TRANCE]	0.1	1	1	0	0
65105	1709	rap1gtp	[Rap1GTP]	0.1	1	1	0	0
65106	1709	correspondent	[correspondent]	0.1	1	1	0	0
65107	1709	ISGF3gamma.	[ISGF3gamma.]	0.1	1	1	0	0
65108	1709	m-tat/gm-csf	[M-TAT/GM-CSF]	0.1	1	3	2	1
65109	1709	e1a-	[E1a-]	0.1	1	2	1	1
65110	1709	coat	[coat]	0.1	1	1	0	0
65111	1709	authors'	[authors']	0.1	1	1	0	0
65112	1709	bioavailability	[bioavailability]	0.1	1	2	1	1
65113	1709	code	[codes]	0.1	1	2	2	2
65114	1709	Hardy-Weinberg	[Hardy-Weinberg]	0.1	1	1	0	0
65115	1709	proposal	[proposal]	0.1	1	1	0	0
65116	1709	TCRgamma	[TCRgamma]	0.1	1	1	0	0
65117	1709	domain,	[domain,]	0.1	1	2	1	1
65118	1709	radioimmunoassay	[radioimmunoassay]	0.1	1	1	0	0
65119	1709	TNF-alpha-	[TNF-alpha-]	0.1	1	2	1	1
65120	1709	haploinsufficiency,	[haploinsufficiency,]	0.1	1	1	0	0
65121	1709	cona	[ConA]	0.1	1	1	0	0
65122	1709	nonsecret	[nonsecreting]	0.1	1	1	0	0
65123	1709	ikkbeta	[IKKbeta]	0.1	1	2	1	1
65124	1709	cyclin-dependent	[cyclin-dependent]	0.1	1	2	1	1
65125	1709	bioflavonoid	[bioflavonoids]	0.1	1	1	0	0
65126	1709	kappa3	[kappa3]	0.1	1	1	0	0
65127	1709	kappay	[kappaY]	0.1	1	2	1	1
65128	1709	tyrosine-phosphorylated	[tyrosine-phosphorylated]	0.1	1	1	0	0
65129	1709	(mapk	[(MAPK]	0.1	1	1	0	0
65130	1709	live	[living]	0.1	1	1	0	0
65131	1709	e2a-	[E2A-]	0.1	1	2	2	2
65132	1709	ALF1	[ALF1]	0.1	1	1	0	0
65133	1709	MOLT-4	[MOLT-4]	0.1	1	2	1	1
65134	1709	hybridisation	[hybridisation]	0.1	1	1	0	0
65135	1709	Act-1	[Act-1]	0.1	1	1	0	0
65136	1709	reorganization	[reorganization]	0.1	1	1	0	0
65137	1709	burkitt'	[Burkitt's]	0.1	1	2	1	1
65138	1709	oropharynx	[oropharynx]	0.1	1	1	0	0
65139	1709	(mab)	[(MAb)]	0.1	1	1	0	0
65140	1709	possible.	[possible.]	0.1	1	1	0	0
65141	1709	oligosaccharide	[oligosaccharide]	0.1	1	1	0	0
65142	1709	cocultures,	[cocultures,]	0.1	1	1	0	0
65143	1709	g-protein	[G-protein]	0.1	1	2	1	1
65144	1709	mumol/L).	[mumol/L).]	0.1	1	1	0	0
65145	1709	analysis:	[analysis:]	0.1	1	2	1	1
65146	1709	anti-CD2-FITC	[anti-CD2-FITC]	0.1	1	1	0	0
65147	1709	route	[route]	0.1	1	2	2	2
65148	1709	Ser-727	[Ser-727]	0.1	1	1	0	0
65149	1709	cimetidine	[cimetidine]	0.1	1	1	0	0
65150	1709	b6d2f1	[B6D2F1]	0.1	1	1	0	0
65151	1709	Chemokines	[Chemokines]	0.1	1	1	0	0
65152	1709	lklf	[LKLF]	0.1	1	1	0	0
65153	1709	p50/p85	[p50/p85]	0.1	1	1	0	0
65154	1709	H5sub304	[H5sub304]	0.1	1	2	2	2
65155	1709	factor-beta	[factor-beta]	0.1	1	2	2	2
65156	1709	bamhi	[BamHI]	0.1	1	1	0	0
65157	1709	sp1/ap-2	[Sp1/AP-2]	0.1	1	2	1	1
65158	1709	SAPK	[SAPK]	0.1	1	2	2	2
65159	1709	b-lineage	[B-lineage]	0.1	1	1	0	0
65160	1709	charybdotoxin	[charybdotoxin]	0.1	1	2	1	1
65161	1709	4-trifluoromethyl	[4-trifluoromethyl]	0.1	1	1	0	0
65162	1709	childrens'	[childrens']	0.1	1	2	1	1
65163	1709	IgA1	[IgA1]	0.1	1	1	0	0
65164	1709	micromol/L.	[micromol/L.]	0.1	1	2	2	2
65165	1709	lysophosphatidylcholine	[lysophosphatidylcholine]	0.1	1	2	1	1
65166	1709	tnfr:fc	[TNFR:Fc]	0.1	1	1	0	0
65167	1709	ru-486	[RU-486]	0.1	1	2	2	2
65168	1709	e214k	[E214K]	0.1	1	2	1	1
65169	1709	p67srf	[p67SRF]	0.1	1	1	0	0
65170	1709	interaction.	[interaction.]	0.1	1	1	0	0
65171	1709	interaction,	[interaction,]	0.1	1	1	0	0
65172	1709	coculture,n	[coculture,]	0.1	1	1	0	0
65173	1709	immunohistology	[immunohistology]	0.1	1	2	1	1
65174	1709	picogram	[picogram]	0.1	1	1	0	0
65175	1709	ANX5	[ANX5]	0.1	1	1	0	0
65176	1709	Pebp2	[Pebp2]	0.1	1	2	1	1
65177	1709	Elastatinal	[Elastatinal]	0.1	1	1	0	0
65178	1709	-flanking	[-flanking]	0.1	1	1	0	0
65179	1709	visualization	[visualization]	0.1	1	3	2	1
65180	1709	s-nitrosylation	[S-nitrosylation]	0.1	1	1	0	0
65181	1709	microg/ml)/mn2+	[microg/ml)/Mn2+]	0.1	1	1	0	0
65182	1709	enhanson	[enhanson]	0.1	1	1	0	0
65183	1709	multisubunit	[multisubunit]	0.1	1	1	0	0
65184	1709	components/pathways	[components/pathways]	0.1	1	1	0	0
65185	1709	B104	[B104]	0.1	1	1	0	0
65186	1709	lmo2	[Lmo2]	0.1	1	1	0	0
65187	1709	degranulation	[degranulation]	0.1	1	1	0	0
65188	1709	human-peripheral-blood	[human-peripheral-blood]	0.1	1	1	0	0
65189	1709	heredity	[heredity]	0.1	1	1	0	0
65190	1709	Raf1	[Raf1]	0.1	1	1	0	0
65191	1709	SCID	[SCID]	0.1	1	2	1	1
65192	1709	promonocyte	[promonocyte]	0.1	1	1	0	0
65193	1709	TH1-to-TH2	[TH1-to-TH2]	0.1	1	1	0	0
65194	1709	homodimerize	[homodimerizing]	0.1	1	1	0	0
65195	1709	oct1.2	[Oct1.2]	0.1	1	1	0	0
65196	1709	vh-to-dhjh	[VH-to-DHJH]	0.1	1	1	0	0
65197	1709	7td1	[7TD1]	0.1	1	1	0	0
65198	1709	triple	[triple]	0.1	1	2	2	2
65199	1709	Cyclosporin	[Cyclosporin]	0.1	1	7	6	1
65200	1709	chemoattractant	[chemoattractant]	0.1	1	3	2	1
65201	1709	65-kDa	[65-kDa]	0.1	1	2	1	1
65202	1709	Saimiri	[Saimiri]	0.1	1	2	1	1
65203	1709	cv-1	[CV-1]	0.1	1	1	0	0
65204	1709	53-kd	[53-kD]	0.1	1	1	0	0
65205	1709	stati	[STATI]	0.1	1	1	0	0
65206	1709	Ets-2	[Ets-2]	0.1	1	1	0	0
65207	1709	transcription-3	[transcription-3]	0.1	1	2	2	2
65208	1709	Jun/AP-1	[Jun/AP-1]	0.1	1	1	0	0
65209	1709	cyto-differentiating	[cyto-differentiating]	0.1	1	1	0	0
65210	1709	Alpha	[Alpha]	0.1	1	1	0	0
65211	1709	consume	[consuming]	0.1	1	1	0	0
65212	1709	uncertain,	[uncertain,]	0.1	1	1	0	0
65213	1709	colleague	[colleagues]	0.1	1	1	0	0
65214	1709	28-bp	[28-bp]	0.1	1	1	0	0
65215	1709	e232k	[E232K]	0.1	1	1	0	0
65216	1709	acquisition	[acquisition]	0.1	1	6	5	1
65217	1709	factor-chi	[factor-chi]	0.1	1	1	0	0
65218	1709	diversification	[diversification]	0.1	1	2	1	1
65219	1709	glucocorticoid-receptors	[glucocorticoid-receptors]	0.1	1	1	0	0
65220	1709	IL-13Ralpha1	[IL-13Ralpha1]	0.1	1	1	0	0
65221	1709	chain-break	[chain-breaking]	0.1	1	1	0	0
65222	1709	SEK/	[SEK/]	0.1	1	1	0	0
65223	1709	compound.	[compound.]	0.1	1	1	0	0
65224	1709	e220k	[E220K]	0.1	1	2	1	1
65225	1709	crisp-3	[CRISP-3]	0.1	1	1	0	0
65226	1709	GHF-1/Pit-1	[GHF-1/Pit-1]	0.1	1	1	0	0
65227	1709	SIVmacMER	[SIVmacMER]	0.1	1	1	0	0
65228	1709	ARDS	[ARDS]	0.1	1	2	1	1
65229	1709	AREs	[AREs]	0.1	1	1	0	0
65230	1709	+50bp	[+50bp]	0.1	1	1	0	0
65231	1709	Interleukin-2	[Interleukin-2]	0.1	1	5	4	1
65232	1709	p.g.whether	[P.G.whether]	0.1	1	1	0	0
65233	1709	macrophage-	[macrophage-]	0.1	1	1	0	0
65234	1709	protein/protein	[protein/protein]	0.1	1	1	0	0
65235	1709	transfusion	[transfusion]	0.1	1	1	0	0
65236	1709	disorder:	[disorder:]	0.1	1	1	0	0
65237	1709	cd4+cd45r0+	[CD4+CD45R0+]	0.1	1	1	0	0
65238	1709	AP-1(I,II,III),	[AP-1(I,II,III),]	0.1	1	1	0	0
65239	1709	s-x-y	[S-X-Y]	0.1	1	1	0	0
65240	1709	questions.	[questions.]	0.1	1	1	0	0
65241	1709	IkKs	[IKKs]	0.1	1	1	0	0
65242	1709	NFIL3/E4BP4	[NFIL3/E4BP4]	0.1	1	1	0	0
65243	1709	ul50	[UL50]	0.1	1	1	0	0
65244	1709	ul49	[UL49]	0.1	1	1	0	0
65245	1709	topic	[topic]	0.1	1	1	0	0
65246	1709	olf-1	[Olf-1]	0.1	1	1	0	0
65247	1709	pacemaker	[pacemaker]	0.1	1	2	2	2
65248	1709	microsome	[microsomes]	0.1	1	2	2	2
65249	1709	hepatotoxicity	[hepatotoxicity]	0.1	1	1	0	0
65250	1709	immortalize	[immortalizing]	0.1	1	1	0	0
65251	1709	phenol/chloroform	[phenol/chloroform]	0.1	1	1	0	0
65252	1709	M-TAT	[M-TAT]	0.1	1	1	0	0
65253	1709	membrane-spanning	[membrane-spanning]	0.1	1	1	0	0
65254	1709	Rel,	[Rel,]	0.1	1	1	0	0
65255	1709	makaume	[makeup,]	0.1	1	1	0	0
65256	1709	lysoPC	[lysoPC]	0.1	1	1	0	0
65257	1709	Res.	[Res.]	0.1	1	1	0	0
65258	1709	hydrolyse	[hydrolyse]	0.1	1	1	0	0
65259	1709	h-2kb	[H-2Kb]	0.1	1	1	0	0
65260	1709	ATF1	[ATF1]	0.1	1	1	0	0
65261	1709	ATF2	[ATF2]	0.1	1	1	0	0
65262	1709	tumour.	[tumour.]	0.1	1	1	0	0
65263	1709	adduct	[adducts]	0.1	1	1	0	0
65264	1709	il-12/10(6)	[IL-12/10(6)]	0.1	1	1	0	0
65265	1709	ATLL	[ATLL]	0.1	1	2	1	1
65266	1709	little,	[little,]	0.1	1	1	0	0
65267	1709	90-kDa	[90-kDa]	0.1	1	1	0	0
65268	1709	Pax-gene	[Pax-gene]	0.1	1	1	0	0
65269	1709	JNKs	[JNKs]	0.1	1	1	0	0
65270	1709	meta(d+)	[META(D+)]	0.1	1	1	0	0
65271	1709	oncology	[oncology]	0.1	1	1	0	0
65272	1709	Fast-Green/Neutral-Red	[Fast-Green/Neutral-Red]	0.1	1	1	0	0
65273	1709	reasons,	[reasons,]	0.1	1	1	0	0
65274	1709	cyclophilin/calcineurin	[cyclophilin/calcineurin]	0.1	1	1	0	0
65275	1709	J393/	[J393/]	0.1	1	2	1	1
65276	1709	thr729-leu765	[Thr729-Leu765]	0.1	1	1	0	0
65277	1709	Ionomycin	[Ionomycin]	0.1	1	1	0	0
65278	1709	SHP2	[SHP2]	0.1	1	1	0	0
65279	1709	t(9;14)(p13;q32)	[t(9;14)(p13;q32)]	0.1	1	1	0	0
65280	1709	anti-D	[anti-D]	0.1	1	2	2	2
65281	1709	anti-I	[anti-I]	0.1	1	1	0	0
65282	1709	anti-P	[anti-P]	0.1	1	1	0	0
65283	1709	hydrolysis	[hydrolysis]	0.1	1	2	2	2
65284	1709	56-59-kilodalton	[56-59-kilodalton]	0.1	1	1	0	0
65285	1709	alpha-methyl-1	[alpha-methyl-1]	0.1	1	1	0	0
65286	1709	(+))	[(+))]	0.1	1	1	0	0
65287	1709	(+)/	[(+)/]	0.1	1	1	0	0
65288	1709	lsp1	[LSP1]	0.1	1	2	2	2
65289	1709	based	[BASED]	0.1	1	1	0	0
65290	1709	mc1627	[MC1627]	0.1	1	1	0	0
65291	1709	Ri-I	[Ri-I]	0.1	1	2	1	1
65292	1709	cytokine-encoding	[cytokine-encoding]	0.1	1	1	0	0
65293	1709	SH3-deleted	[SH3-deleted]	0.1	1	1	0	0
65294	1709	(vdr)	[(VDR)]	0.1	1	1	0	0
65295	1709	motif-1/lymphotactin	[motif-1/lymphotactin]	0.1	1	1	0	0
65296	1709	pIL-5(-511)Luc	[pIL-5(-511)Luc]	0.1	1	1	0	0
65297	1709	placenta,	[placenta,]	0.1	1	1	0	0
65298	1709	conjugation.	[conjugation.]	0.1	1	1	0	0
65299	1709	nakao,	[Nakao,]	0.1	1	1	0	0
65300	1709	SK&F	[SK&F]	0.1	1	2	2	2
65301	1709	radical	[radicals]	0.1	1	2	1	1
65302	1709	JPX9	[JPX9]	0.1	1	1	0	0
65303	1709	RhoA	[RhoA]	0.1	1	1	0	0
65304	1709	zeta-	[zeta-]	0.1	1	1	0	0
65305	1709	cell-specific.	[cell-specific.]	0.1	1	1	0	0
65306	1709	purine-box/arre/nf-at	[purine-box/ARRE/NF-AT]	0.1	1	1	0	0
65307	1709	childhood.	[childhood.]	0.1	1	1	0	0
65308	1709	childhood,	[childhood,]	0.1	1	1	0	0
65309	1709	pulse/chase-experiments	[pulse/chase-experiments]	0.1	1	1	0	0
65310	1709	heterocomplex	[heterocomplexes]	0.1	1	2	1	1
65311	1709	protein;	[protein;]	0.1	1	1	0	0
65312	1709	plastic	[plastic]	0.1	1	2	1	1
65313	1709	/cat	[/CAT]	0.1	1	2	2	2
65314	1709	rhodamine	[rhodamine]	0.1	1	1	0	0
65315	1709	cotton	[cotton]	0.1	1	1	0	0
65316	1709	animals.	[animals.]	0.1	1	2	1	1
65317	1709	animals,	[animals,]	0.1	1	1	0	0
65318	1709	hemin-	[hemin-]	0.1	1	1	0	0
65319	1709	mumol	[mumol]	0.1	1	1	0	0
65320	1709	gamma-IFN	[gamma-IFN]	0.1	1	1	0	0
65321	1709	PTPases	[PTPases]	0.1	1	1	0	0
65322	1709	[3h]testosterone	[[3H]testosterone]	0.1	1	1	0	0
65323	1709	rhom-2	[Rhom-2]	0.1	1	2	1	1
65324	1709	dc-t-cell	[DC-T-cell]	0.1	1	1	0	0
65325	1709	counter-anion	[counter-anion]	0.1	1	1	0	0
65326	1709	JRFL	[JRFL]	0.1	1	1	0	0
65327	1709	(mnl)	[(MNL)]	0.1	1	2	2	2
65328	1709	phd/ttc	[PHD/TTC]	0.1	1	1	0	0
65329	1709	4-phorbol	[4-phorbol]	0.1	1	1	0	0
65330	1709	traffic	[traffic]	0.1	1	2	2	2
65331	1709	oxidants,	[oxidants,]	0.1	1	1	0	0
65332	1709	(97%),	[(97%),]	0.1	1	1	0	0
65333	1709	gamma-interferon-	[gamma-interferon-]	0.1	1	1	0	0
65334	1709	lysing	[lysing]	0.1	1	1	0	0
65335	1709	granulocytes.	[granulocytes.]	0.1	1	2	1	1
65336	1709	granulocytes,	[granulocytes,]	0.1	1	1	0	0
65337	1709	lysis,	[lysis,]	0.1	1	1	0	0
65338	1709	dysrhythmia	[dysrhythmia]	0.1	1	1	0	0
65339	1709	stat-binding	[STAT-binding]	0.1	1	2	2	2
65340	1709	ly+)	[ly+)]	0.1	1	1	0	0
65341	1709	ed-40515(+)	[ED-40515(+)]	0.1	1	1	0	0
65342	1709	thrombocytopenia	[thrombocytopenia]	0.1	1	2	1	1
65343	1709	locus.	[locus.]	0.1	1	3	2	1
65344	1709	RalGDS	[RalGDS]	0.1	1	1	0	0
65345	1709	hypotension	[hypotension]	0.1	1	1	0	0
65346	1709	exhaust	[exhaust]	0.1	1	2	2	2
65347	1709	mc1288	[MC1288]	0.1	1	1	0	0
65348	1709	tolerance,	[tolerance,]	0.1	1	1	0	0
65349	1709	K562	[K562]	0.1	1	2	2	2
65350	1709	interspecy	[Interspecies]	0.1	1	2	2	2
65351	1709	SRF/NFkappaB-like	[SRF/NFkappaB-like]	0.1	1	1	0	0
65352	1709	serum.	[serum.]	0.1	1	1	0	0
65353	1709	serum,	[serum,]	0.1	1	2	1	1
65354	1709	serum-	[serum-]	0.1	1	1	0	0
65355	1709	crossover	[crossover]	0.1	1	1	0	0
65356	1709	[3h]aldosterone	[[3H]aldosterone]	0.1	1	2	1	1
65357	1709	/erk	[/ERK]	0.1	1	2	2	2
65358	1709	A.S.Fauci,	[A.S.Fauci,]	0.1	1	1	0	0
65359	1709	epicardium	[epicardium]	0.1	1	1	0	0
65360	1709	t(17;19)(q22;p13)	[t(17;19)(q22;p13)]	0.1	1	1	0	0
65361	1709	cell-matrix	[cell-matrix]	0.1	1	1	0	0
65362	1709	transcription-regulategulate	[transcription-regulating]	0.1	1	1	0	0
65363	1709	g2/m-	[G2/M-]	0.1	1	1	0	0
65364	1709	alloantigen	[alloantigens]	0.1	1	1	0	0
65365	1709	b-all	[B-ALL]	0.1	1	1	0	0
65366	1709	15d-PGJ(2)	[15d-PGJ(2)]	0.1	1	2	1	1
65367	1709	(0/8	[(0/8]	0.1	1	1	0	0
65368	1709	crohn'	[Crohn's]	0.1	1	2	1	1
65369	1709	ternary	[ternary]	0.1	1	1	0	0
65370	1709	formulation	[formulation]	0.1	1	2	2	2
65371	1709	patency	[patency]	0.1	1	1	0	0
65372	1709	Ras-like	[Ras-like]	0.1	1	1	0	0
65373	1709	use,	[use,]	0.1	1	1	0	0
65374	1709	hiv/siv	[HIV/SIV]	0.1	1	1	0	0
65375	1709	(10)	[(10)]	0.1	1	1	0	0
65376	1709	decade	[decade]	0.1	1	2	2	2
65377	1709	hilar	[hilar]	0.1	1	1	0	0
65378	1709	CRISP-3	[CRISP-3]	0.1	1	1	0	0
65379	1709	trinucleotide	[trinucleotide]	0.1	1	2	1	1
65380	1709	cytodifferentiation	[cytodifferentiation]	0.1	1	1	0	0
65381	1709	dorsal	[Dorsal]	0.1	1	1	0	0
65382	1709	(STAT)	[(STAT)]	0.1	1	1	0	0
65383	1709	oct2b	[Oct2B]	0.1	1	1	0	0
65384	1709	regeneration	[regeneration]	0.1	1	1	0	0
65385	1709	pparalpha	[PPARalpha]	0.1	1	2	2	2
65386	1709	megakaryoblastic/erythroid	[megakaryoblastic/erythroid]	0.1	1	1	0	0
65387	1709	[125i]-	[[125I]-]	0.1	1	1	0	0
65388	1709	RXR-RARalpha403	[RXR-RARalpha403]	0.1	1	1	0	0
65389	1709	Hashimoto'	[Hashimoto's]	0.1	1	2	1	1
65390	1709	decay)	[decay)]	0.1	1	1	0	0
65391	1709	circumstance	[circumstance]	0.1	1	2	1	1
65392	1709	mutant,	[mutant,]	0.1	1	2	1	1
65393	1709	CD28RC	[CD28RC]	0.1	1	1	0	0
65394	1709	Elf-2	[Elf-2]	0.1	1	1	0	0
65395	1709	RU486	[RU486]	0.1	1	1	0	0
65396	1709	factors:	[factors:]	0.1	1	1	0	0
65397	1709	biotin-	[biotin-]	0.1	1	1	0	0
65398	1709	particles,	[particles,]	0.1	1	1	0	0
65399	1709	HEB-1	[HEB-1]	0.1	1	1	0	0
65400	1709	gm-csf-	[GM-CSF-]	0.1	1	1	0	0
65401	1709	e74-like	[E74-like]	0.1	1	1	0	0
65402	1709	[3h]ru-1881	[[3H]RU-1881]	0.1	1	1	0	0
65403	1709	mosaicism,	[mosaicism,]	0.1	1	1	0	0
65404	1709	beta-adrenoreceptor	[beta-adrenoreceptor]	0.1	1	1	0	0
65405	1709	hiv-1-ltr	[HIV-1-LTR]	0.1	1	2	2	2
65406	1709	ribonucleic	[ribonucleic]	0.1	1	3	2	1
65407	1709	5'-ggccaatggg-3'	[5'-GGCCAATGGG-3']	0.1	1	1	0	0
65408	1709	dispensable.	[dispensable.]	0.1	1	1	0	0
65409	1709	tgase	[TGase]	0.1	1	2	1	1
65410	1709	(-365/-264)	[(-365/-264)]	0.1	1	1	0	0
65411	1709	Locus	[Locus]	0.1	1	2	2	2
65412	1709	aes1/2	[AES1/2]	0.1	1	1	0	0
65413	1709	GATA-1.05	[GATA-1.05]	0.1	1	1	0	0
65414	1709	people	[people]	0.1	1	1	0	0
65415	1709	SRE-	[SRE-]	0.1	1	1	0	0
65416	1709	(3H)	[(3H)]	0.1	1	1	0	0
65417	1709	3'-untranslated	[3'-untranslated]	0.1	1	1	0	0
65418	1709	HNF-4alpha	[HNF-4alpha]	0.1	1	1	0	0
65419	1709	JY25	[JY25]	0.1	1	1	0	0
65420	1709	[125i]t3	[[125I]T3]	0.1	1	1	0	0
65421	1709	RpoS	[RpoS]	0.1	1	2	1	1
65422	1709	dl-nf	[dl-NF]	0.1	1	1	0	0
65423	1709	glutathione-s-transferase	[Glutathione-S-transferase]	0.1	1	2	2	2
65424	1709	Nup475	[Nup475]	0.1	1	1	0	0
65425	1709	cd65s+	[CD65s+]	0.1	1	1	0	0
65426	1709	105-kd	[105-kD]	0.1	1	1	0	0
65427	1709	SSCP	[SSCP]	0.1	1	1	0	0
65428	1709	transgenesis	[transgenesis]	0.1	1	1	0	0
65429	1709	1-bp	[1-bp]	0.1	1	1	0	0
65430	1709	BA92	[BA92]	0.1	1	1	0	0
65431	1709	130-kD	[130-kD]	0.1	1	1	0	0
65432	1709	tracer	[tracer]	0.1	1	1	0	0
65433	1709	130-kd	[130-kD]	0.1	1	1	0	0
65434	1709	-inducible	[-inducible]	0.1	1	1	0	0
65435	1709	1-kb	[1-kb]	0.1	1	2	1	1
65436	1709	depression.	[depression.]	0.1	1	1	0	0
65437	1709	living	[living]	0.1	1	1	0	0
65438	1709	anergy.	[anergy.]	0.1	1	1	0	0
65439	1709	anergy,	[anergy,]	0.1	1	1	0	0
65440	1709	65-kda	[65-kDa]	0.1	1	1	0	0
65441	1709	NOTCH1	[NOTCH1]	0.1	1	2	1	1
65442	1709	p50/p65/c-Rel	[p50/p65/c-Rel]	0.1	1	1	0	0
65443	1709	Per-Arnt-Sim	[Per-Arnt-Sim]	0.1	1	1	0	0
65444	1709	intron-exon	[intron-exon]	0.1	1	2	1	1
65445	1709	III),	[III),]	0.1	1	1	0	0
65446	1709	I-kappa	[I-kappa]	0.1	1	1	0	0
65447	1709	buffer,	[buffer,]	0.1	1	1	0	0
65448	1709	dg75	[DG75]	0.1	1	1	0	0
65449	1709	disuse	[disuse]	0.1	1	1	0	0
65450	1709	mol/L.	[mol/L.]	0.1	1	1	0	0
65451	1709	subset,	[subset,]	0.1	1	1	0	0
65452	1709	HpaII	[HpaII]	0.1	1	2	1	1
65453	1709	recall	[recall]	0.1	1	1	0	0
65454	1709	DNasel	[DNasel]	0.1	1	1	0	0
65455	1709	chelating	[chelating]	0.1	1	1	0	0
65456	1709	qakwrlqtl	[QAKWRLQTL]	0.1	1	1	0	0
65457	1709	hl-60/vinc/r	[HL-60/vinc/R]	0.1	1	2	1	1
65458	1709	dq2-anchor	[DQ2-anchor]	0.1	1	1	0	0
65459	1709	ensue	[ensuing]	0.1	1	2	1	1
65460	1709	airflow	[airflow]	0.1	1	1	0	0
65461	1709	B-cells.	[B-cells.]	0.1	1	1	0	0
65462	1709	resurgence	[resurgence]	0.1	1	1	0	0
65463	1709	repeat-KB	[repeat-KB]	0.1	1	1	0	0
65464	1709	gene-	[gene-]	0.1	1	1	0	0
65465	1709	gene'	[gene's]	0.1	1	1	0	0
65466	1709	annulata	[annulata]	0.1	1	1	0	0
65467	1709	sterol-	[sterol-]	0.1	1	1	0	0
65468	1709	undecapeptide	[undecapeptide]	0.1	1	1	0	0
65469	1709	R217A	[R217A]	0.1	1	1	0	0
65470	1709	adulthood	[adulthood]	0.1	1	2	1	1
65471	1709	tetrahydrobiopterin)	[tetrahydrobiopterin)]	0.1	1	1	0	0
65472	1709	mab.	[mAb.]	0.1	1	1	0	0
65473	1709	epicardin/capsulin/Pod-1	[epicardin/capsulin/Pod-1]	0.1	1	1	0	0
65474	1709	biochemistry	[biochemistry]	0.1	1	1	0	0
65475	1709	counterbalance	[counterbalance]	0.1	1	1	0	0
65476	1709	Phytohemagglutinin	[Phytohemagglutinin]	0.1	1	2	2	2
65477	1709	ad2/ad12	[Ad2/Ad12]	0.1	1	1	0	0
65478	1709	p388d1	[P388D1]	0.1	1	1	0	0
65479	1709	subunit,	[subunit,]	0.1	1	2	1	1
65480	1709	r-htbp-1	[r-hTBP-1]	0.1	1	2	1	1
65481	1709	malt	[MALT]	0.1	1	1	0	0
65482	1709	nonproliferateraterateratiferatiferatiferatiferati	[nonproliferating]	0.1	1	1	0	0
65483	1709	Orkin,	[Orkin,]	0.1	1	1	0	0
65484	1709	granulosa	[Granulosa]	0.1	1	2	1	1
65485	1709	pha-p	[PHA-p]	0.1	1	1	0	0
65486	1709	dhcc	[DHCC]	0.1	1	2	1	1
65487	1709	p8mtcp1	[p8MTCP1]	0.1	1	1	0	0
65488	1709	vincristine	[vincristine]	0.1	1	2	2	2
65489	1709	NF-kappaB-binding	[NF-kappaB-binding]	0.1	1	2	1	1
65490	1709	/p65	[/p65]	0.1	1	3	2	1
65491	1709	pharmacokinetics	[pharmacokinetics]	0.1	1	2	1	1
65492	1709	quantitative,	[quantitative,]	0.1	1	1	0	0
65493	1709	cocl2	[CoCl2]	0.1	1	1	0	0
65494	1709	NFKB1(p50).	[NFKB1(p50).]	0.1	1	1	0	0
65495	1709	dl312	[dl312]	0.1	1	1	0	0
65496	1709	needle	[needle]	0.1	1	1	0	0
65497	1709	EB1089	[EB1089]	0.1	1	1	0	0
65498	1709	mbp-	[MBP-]	0.1	1	1	0	0
65499	1709	Phorbol-12-myristate-13-acetate	[Phorbol-12-myristate-13-acetate]	0.1	1	1	0	0
65500	1709	pyrilamine	[pyrilamine]	0.1	1	2	2	2
65501	1709	Figure	[figure]	0.1	1	1	0	0
65502	1709	rifn-alpha	[rIFN-alpha]	0.1	1	1	0	0
65503	1709	il2rbeta	[IL2Rbeta]	0.1	1	1	0	0
65504	1709	Runt	[Runt]	0.1	1	1	0	0
65505	1709	section	[sections]	0.1	1	2	2	2
65506	1709	oncoproteins,	[oncoproteins,]	0.1	1	1	0	0
65507	1709	diet	[diet]	0.1	1	2	1	1
65508	1709	Myb-Et	[Myb-Ets]	0.1	1	1	0	0
65509	1709	cytokine.	[cytokine.]	0.1	1	1	0	0
65510	1709	il-6-type	[IL-6-type]	0.1	1	1	0	0
65511	1709	notion.	[notion.]	0.1	1	1	0	0
65512	1709	notion,	[notion,]	0.1	1	1	0	0
65513	1709	137c	[137Cs]	0.1	1	1	0	0
65514	1709	anti-cd3epsilon	[anti-CD3epsilon]	0.1	1	1	0	0
65515	1709	TCF-1/LEF-1	[TCF-1/LEF-1]	0.1	1	1	0	0
65516	1709	elongation.	[elongation.]	0.1	1	1	0	0
65517	1709	Acta	[Acta]	0.1	1	1	0	0
65518	1709	OCT-1/OAF	[OCT-1/OAF]	0.1	1	1	0	0
65519	1709	bladder	[bladder]	0.1	1	1	0	0
65520	1709	/pka	[/PKA]	0.1	1	2	2	2
65521	1709	unstained.	[unstained.]	0.1	1	1	0	0
65522	1709	nuclease	[nuclease]	0.1	1	2	2	2
65523	1709	Rel-B	[Rel-B]	0.1	1	2	1	1
65524	1709	ifngamma-a	[IFNgamma-]	0.1	1	1	0	0
65525	1709	rar-beta	[RAR-beta]	0.1	1	2	1	1
65526	1709	recruiting	[recruiting]	0.1	1	1	0	0
65527	1709	dihydropyrimidine	[dihydropyrimidine]	0.1	1	2	1	1
65528	1709	mid-age	[mid-age]	0.1	1	1	0	0
65529	1709	reactivity:	[reactivity:]	0.1	1	1	0	0
65530	1709	ptf-oct-1-dna	[PTF-Oct-1-DNA]	0.1	1	1	0	0
65531	1709	R272A	[R272A]	0.1	1	1	0	0
65532	1709	scanning	[scanning]	0.1	1	2	2	2
65533	1709	population,	[population,]	0.1	1	2	2	2
65534	1709	Fibronectin	[Fibronectin]	0.1	1	1	0	0
65535	1709	(segment	[(segments]	0.1	1	1	0	0
65536	1709	"nonresponsive"	["nonresponsive"]	0.1	1	1	0	0
65537	1709	ICSAT/Pip/LSIRF	[ICSAT/Pip/LSIRF]	0.1	1	1	0	0
65538	1709	mg).	[mg).]	0.1	1	1	0	0
65539	1709	trapoxin	[trapoxin]	0.1	1	1	0	0
65540	1709	predominance	[predominance]	0.1	1	4	3	1
65541	1709	-gamma	[-gamma]	0.1	1	2	1	1
65542	1709	Nalm-6	[Nalm-6]	0.1	1	1	0	0
65543	1709	Northern	[Northern]	0.1	1	1	0	0
65544	1709	Cdc42	[Cdc42]	0.1	1	1	0	0
65545	1709	rpose	[RpoS]	0.1	1	2	1	1
65546	1709	succinate	[succinate]	0.1	1	1	0	0
65547	1709	hepa-1	[Hepa-1]	0.1	1	1	0	0
65548	1709	25-ohd	[25-OHD]	0.1	1	1	0	0
65549	1709	wd-40	[WD-40]	0.1	1	1	0	0
65550	1709	sulfoxide	[sulfoxide]	0.1	1	2	2	2
65551	1709	gp39-cd8	[gp39-CD8]	0.1	1	1	0	0
65552	1709	151-bp	[151-bp]	0.1	1	1	0	0
65553	1709	proliferator	[proliferator]	0.1	1	2	2	2
65554	1709	(5118),	[(5/18),]	0.1	1	1	0	0
65555	1709	protodrug	[protodrug]	0.1	1	1	0	0
65556	1709	recessiveness	[recessiveness]	0.1	1	1	0	0
65557	1709	senescence.	[senescence.]	0.1	1	2	1	1
65558	1709	G.Peters,	[G.Peters,]	0.1	1	1	0	0
65559	1709	lymphoproliferation	[lymphoproliferation]	0.1	1	1	0	0
65560	1709	slb-i	[SLB-I]	0.1	1	1	0	0
65561	1709	myelomonoblast	[myelomonoblasts]	0.1	1	1	0	0
65562	1709	enzymes,	[enzymes,]	0.1	1	1	0	0
65563	1709	R294A	[R294A]	0.1	1	1	0	0
65564	1709	studies.	[studies.]	0.1	1	2	1	1
65565	1709	-300bp	[-300bp]	0.1	1	1	0	0
65566	1709	18-hydroxy-corticosterone	[18-hydroxy-corticosterone]	0.1	1	1	0	0
65567	1709	Jak-	[Jak-]	0.1	1	1	0	0
65568	1709	virus-transform	[virus-transforming]	0.1	1	1	0	0
65569	1709	tcccctcccct	[TCCCCTCCCCT]	0.1	1	1	0	0
65570	1709	20-bp	[20-bp]	0.1	1	1	0	0
65571	1709	cys2-xaa12-his2	[Cys2-Xaa12-His2]	0.1	1	1	0	0
65572	1709	rhabdomyosarcoma	[rhabdomyosarcoma]	0.1	1	2	2	2
65573	1709	hypothyroid	[hypothyroid]	0.1	1	1	0	0
65574	1709	access	[Access]	0.1	1	2	2	2
65575	1709	BJAB	[BJAB]	0.1	1	2	1	1
65576	1709	pre-b-	[pre-B-]	0.1	1	1	0	0
65577	1709	Pseudohypoaldosteronism	[Pseudohypoaldosteronism]	0.1	1	1	0	0
65578	1709	days'	[days']	0.1	1	1	0	0
65579	1709	basis,	[basis,]	0.1	1	1	0	0
65580	1709	herpesviruse	[herpesviruses]	0.1	1	2	2	2
65581	1709	scl/tal1	[SCL/Tal1]	0.1	1	1	0	0
65582	1709	trifluoperazine	[trifluoperazine]	0.1	1	1	0	0
65583	1709	pairwise	[pairwise]	0.1	1	1	0	0
65584	1709	TL-Mor	[TL-Mor]	0.1	1	1	0	0
65585	1709	Elf-2b	[Elf-2b]	0.1	1	1	0	0
65586	1709	hacat	[HaCaT]	0.1	1	1	0	0
65587	1709	52-kDa	[52-kDa]	0.1	1	1	0	0
65588	1709	OBF-1/Bob1/OCA-B	[OBF-1/Bob1/OCA-B]	0.1	1	1	0	0
65589	1709	phenol	[phenol]	0.1	1	2	1	1
65590	1709	beta-tubulin	[beta-tubulin]	0.1	1	1	0	0
65591	1709	ouabain	[ouabain]	0.1	1	2	1	1
65592	1709	tata-box	[TATA-box]	0.1	1	2	2	2
65593	1709	dor1	[DOR1]	0.1	1	2	1	1
65594	1709	Asp838	[Asp838]	0.1	1	1	0	0
65595	1709	relative	[relatives]	0.1	1	2	1	1
65596	1709	down	[Down]	0.1	1	1	0	0
65597	1709	/a23187	[/A23187]	0.1	1	2	2	2
65598	1709	calmodulin-	[calmodulin-]	0.1	1	1	0	0
65599	1709	angiotensin	[angiotensin]	0.1	1	2	1	1
65600	1709	miss	[missing]	0.1	1	1	0	0
65601	1709	trans-activating	[trans-activating]	0.1	1	1	0	0
65602	1709	Mutagenesis	[Mutagenesis]	0.1	1	2	1	1
65603	1709	mite	[mite]	0.1	1	1	0	0
65604	1709	pulsewise	[pulsewise]	0.1	1	1	0	0
65605	1709	d-box	[D-box]	0.1	1	1	0	0
65606	1709	dr+4	[DR+4]	0.1	1	1	0	0
65607	1709	dr+2	[DR+2]	0.1	1	1	0	0
65608	1709	p14TCL1	[p14TCL1]	0.1	1	1	0	0
65609	1709	(egf)	[(EGF)]	0.1	1	1	0	0
65610	1709	Lactobacilli,	[Lactobacilli,]	0.1	1	1	0	0
65611	1709	cd49d/cd29	[CD49d/CD29]	0.1	1	1	0	0
65612	1709	nk/lgl	[NK/LGL]	0.1	1	1	0	0
65613	1709	ZEBRA,	[ZEBRA,]	0.1	1	1	0	0
65614	1709	ml-3	[ML-3]	0.1	1	1	0	0
65615	1709	BLPs	[BLPs]	0.1	1	1	0	0
65616	1709	BLR2	[BLR2]	0.1	1	2	2	2
65617	1709	scm-1	[SCM-1]	0.1	1	1	0	0
65618	1709	gamma-radiation	[gamma-radiation]	0.1	1	1	0	0
65619	1709	KG-1	[KG-1]	0.1	1	1	0	0
65620	1709	(3h)-thymidine	[(3H)-thymidine]	0.1	1	1	0	0
65621	1709	exon:intron	[exon:intron]	0.1	1	2	1	1
65622	1709	detected,	[detected,]	0.1	1	1	0	0
65623	1709	LMP2B	[LMP2B]	0.1	1	1	0	0
65624	1709	synergistic,	[synergistic,]	0.1	1	1	0	0
65625	1709	FKBP51	[FKBP51]	0.1	1	2	1	1
65626	1709	sre/carg	[SRE/CArG]	0.1	1	1	0	0
65627	1709	TL-Om1	[TL-Om1]	0.1	1	1	0	0
65628	1709	class.	[class.]	0.1	1	1	0	0
65629	1709	class,	[class,]	0.1	1	1	0	0
65630	1709	immunity.	[immunity.]	0.1	1	1	0	0
65631	1709	color	[color]	0.1	1	2	2	2
65632	1709	PLZF-RAR	[PLZF-RAR]	0.1	1	3	2	1
65633	1709	mds1-	[MDS1-]	0.1	1	1	0	0
65634	1709	phka1	[PHKA1]	0.1	1	1	0	0
65635	1709	mkk3	[MKK3]	0.1	1	1	0	0
65636	1709	(B),	[(B),]	0.1	1	1	0	0
65637	1709	cycle.	[cycle.]	0.1	1	2	1	1
65638	1709	cycle:	[cycle:]	0.1	1	1	0	0
65639	1709	31747a	[31747A]	0.1	1	2	2	2
65640	1709	myristoyl	[myristoyl]	0.1	1	2	2	2
65641	1709	Slp-76	[Slp-76]	0.1	1	1	0	0
65642	1709	intron/exon	[intron/exon]	0.1	1	1	0	0
65643	1709	POZ/Zinc	[POZ/Zinc]	0.1	1	1	0	0
65644	1709	b/c-rel	[B/c-Rel]	0.1	1	2	1	1
65645	1709	nf-kappab2	[NF-kappaB2]	0.1	1	1	0	0
65646	1709	camp-phosphodiesterase	[cAMP-phosphodiesterase]	0.1	1	1	0	0
65647	1709	(eklf)	[(EKLF)]	0.1	1	1	0	0
65648	1709	c/ebp-beta	[C/EBP-beta]	0.1	1	2	1	1
65649	1709	jak/stat	[JAK/STAT]	0.1	1	2	2	2
65650	1709	T-cell	[T-cell]	0.1	1	2	1	1
65651	1709	nNOS	[nNOS]	0.1	1	1	0	0
65652	1709	erythroleukaemia	[erythroleukaemia]	0.1	1	1	0	0
65653	1709	African	[Africans]	0.1	1	2	1	1
65654	1709	TFG-beta	[TFG-beta]	0.1	1	1	0	0
65655	1709	phosphocreatine	[phosphocreatine]	0.1	1	2	2	2
65656	1709	NF-kappaB/	[NF-kappaB/]	0.1	1	2	1	1
65657	1709	NF-kappaB.	[NF-kappaB.]	0.1	1	1	0	0
65658	1709	NF-kappaB2	[NF-kappaB2]	0.1	1	1	0	0
65659	1709	1.7-kb	[1.7-kb]	0.1	1	1	0	0
65660	1709	ATF-2	[ATF-2]	0.1	1	1	0	0
65661	1709	cyclooxygenase-2	[cyclooxygenase-2]	0.1	1	2	1	1
65662	1709	formyl-met-leu-phe	[formyl-met-leu-phe]	0.1	1	1	0	0
65663	1709	indication	[indication]	0.1	1	2	2	2
65664	1709	activation-inducer	[activation-inducer]	0.1	1	1	0	0
65665	1709	garlic	[garlic]	0.1	1	1	0	0
65666	1709	ca2+-mediated	[Ca2+-mediated]	0.1	1	1	0	0
65667	1709	accessibility	[accessibility]	0.1	1	1	0	0
65668	1709	Dalton	[Dalton]	0.1	1	1	0	0
65669	1709	nondivide	[Nondividing]	0.1	1	2	2	2
65670	1709	AML1/ETO(MTG8)	[AML1/ETO(MTG8)]	0.1	1	1	0	0
65671	1709	(CB)	[(CB)]	0.1	1	2	1	1
65672	1709	microsatellite	[microsatellite]	0.1	1	2	2	2
65673	1709	27-kDa	[27-kDa]	0.1	1	1	0	0
65674	1709	serpentine	[serpentine]	0.1	1	1	0	0
65675	1709	spermatogenesis	[spermatogenesis]	0.1	1	1	0	0
65676	1709	TCDD	[TCDD]	0.1	1	1	0	0
65677	1709	delta-domain	[delta-domain]	0.1	1	2	1	1
65678	1709	TCF-2	[TCF-2]	0.1	1	1	0	0
65679	1709	IRS-1	[IRS-1]	0.1	1	1	0	0
65680	1709	Asp584	[Asp584]	0.1	1	1	0	0
65681	1709	noninduction	[noninduction]	0.1	1	1	0	0
65682	1709	mmtv	[MMTV]	0.1	1	2	2	2
65683	1709	alpha-lbd	[alpha-LBD]	0.1	1	1	0	0
65684	1709	t(11;17)(q23;q21)	[t(11;17)(q23;q21)]	0.1	1	1	0	0
65685	1709	polymyxin	[polymyxin]	0.1	1	1	0	0
65686	1709	(CR)	[(CR)]	0.1	1	1	0	0
65687	1709	c.h.r.)	[C.H.R.)]	0.1	1	1	0	0
65688	1709	daunomycin	[daunomycin]	0.1	1	1	0	0
65689	1709	tafii32	[TAFII32]	0.1	1	1	0	0
65690	1709	defect(s)	[defect(s)]	0.1	1	2	2	2
65691	1709	steroid-thyroid	[steroid-thyroid]	0.1	1	1	0	0
65692	1709	previously.	[previously.]	0.1	1	1	0	0
65693	1709	HLA-DQ3.2	[HLA-DQ3.2]	0.1	1	1	0	0
65694	1709	precipitin	[precipitins]	0.1	1	1	0	0
65695	1709	donors.	[donors.]	0.1	1	2	1	1
65696	1709	bal-17	[BAL-17]	0.1	1	1	0	0
65697	1709	discrepancy	[discrepancy]	0.1	1	2	2	2
65698	1709	1,25-Dihydroxyvitamin	[1,25-Dihydroxyvitamin]	0.1	1	6	5	1
65699	1709	such,	[such,]	0.1	1	1	0	0
65700	1709	Platelet	[Platelet]	0.1	1	1	0	0
65701	1709	C2H2	[C2H2]	0.1	1	1	0	0
65702	1709	possibility.	[possibility.]	0.1	1	1	0	0
65703	1709	F-actin	[F-actin]	0.1	1	1	0	0
65704	1709	sn-50	[SN-50]	0.1	1	1	0	0
65705	1709	dump	[dUMP]	0.1	1	1	0	0
65706	1709	C3/5	[C3/5]	0.1	1	2	1	1
65707	1709	molt	[Molt]	0.1	1	2	1	1
65708	1709	teniposide	[teniposide]	0.1	1	1	0	0
65709	1709	androgen-	[androgen-]	0.1	1	1	0	0
65710	1709	(kappa	[(kappa]	0.1	1	2	2	2
65711	1709	ApaI	[ApaI]	0.1	1	1	0	0
65712	1709	jurkat-t	[Jurkat-T]	0.1	1	2	2	2
65713	1709	Ar-5	[Ar-5]	0.1	1	1	0	0
65714	1709	S-LB1	[S-LB1]	0.1	1	2	1	1
65715	1709	confluency,	[confluency,]	0.1	1	1	0	0
65716	1709	Aes1/2	[AES1/2]	0.1	1	2	1	1
65717	1709	TFE3	[TFE3]	0.1	1	1	0	0
65718	1709	e2f-dna	[E2F-DNA]	0.1	1	1	0	0
65719	1709	cells).	[cells).]	0.1	1	2	2	2
65720	1709	Ro(SSA)	[Ro(SSA)]	0.1	1	1	0	0
65721	1709	alone)e	[alone)]	0.1	1	1	0	0
65722	1709	impromidine	[impromidine]	0.1	1	1	0	0
65723	1709	ms-5	[MS-5]	0.1	1	1	0	0
65724	1709	cyproterone,	[cyproterone,]	0.1	1	1	0	0
65725	1709	reactvation	[reactvation]	0.1	1	1	0	0
65726	1709	footprint.	[footprint.]	0.1	1	1	0	0
65727	1709	(7/20)	[(7/20)]	0.1	1	1	0	0
65728	1709	CHO-CD86	[CHO-CD86]	0.1	1	1	0	0
65729	1709	expectation	[expectation]	0.1	1	1	0	0
65730	1709	cos-1	[COS-1]	0.1	1	2	1	1
65731	1709	suramin	[suramin]	0.1	1	1	0	0
65732	1709	scaffold	[scaffold]	0.1	1	1	0	0
65733	1709	features.	[features.]	0.1	1	2	2	2
65734	1709	inducers.	[inducers.]	0.1	1	2	1	1
65735	1709	weight,	[weight,]	0.1	1	1	0	0
65736	1709	mrp8	[MRP8]	0.1	1	1	0	0
65737	1709	mumol/L,	[mumol/L,]	0.1	1	1	0	0
65738	1709	mumol/L)	[mumol/L)]	0.1	1	2	1	1
65739	1709	nonmacrophage	[nonmacrophage]	0.1	1	1	0	0
65740	1709	IL-1beta-	[IL-1beta-]	0.1	1	2	1	1
65741	1709	cni-1493	[CNI-1493]	0.1	1	1	0	0
65742	1709	HNP-1	[HNP-1]	0.1	1	1	0	0
65743	1709	dyad	[dyad]	0.1	1	1	0	0
65744	1709	(proto)oncogenes	[(proto)oncogenes]	0.1	1	1	0	0
65745	1709	L-N-monomethyl-arginine	[L-N-monomethyl-arginine]	0.1	1	1	0	0
65746	1709	dibutyric	[dibutyric]	0.1	1	1	0	0
65747	1709	line.	[line.]	0.1	1	1	0	0
65748	1709	ym-268	[YM-268]	0.1	1	1	0	0
65749	1709	druilkience	[drug,]	0.1	1	2	1	1
65750	1709	ra/vd	[RA/VD]	0.1	1	1	0	0
65751	1709	AML1/MDS1/EVI1	[AML1/MDS1/EVI1]	0.1	1	1	0	0
65752	1709	J.C.Alwine,	[J.C.Alwine,]	0.1	1	1	0	0
65753	1709	disturbance	[Disturbance]	0.1	1	3	2	1
65754	1709	rCTLA4Ig	[rCTLA4Ig]	0.1	1	1	0	0
65755	1709	15-LO	[15-LO]	0.1	1	2	1	1
65756	1709	hla-molecule	[HLA-molecules]	0.1	1	1	0	0
65757	1709	factor/DNA	[factor/DNA]	0.1	1	1	0	0
65758	1709	Marek's	[Marek's]	0.1	1	1	0	0
65759	1709	sugar	[sugar]	0.1	1	2	2	2
65760	1709	eosinophilopoiesis	[eosinophilopoiesis]	0.1	1	1	0	0
65761	1709	former	[former]	0.1	1	1	0	0
65762	1709	(erk)	[(ERK)]	0.1	1	3	2	1
65763	1709	mthc	[MTHC]	0.1	1	1	0	0
65764	1709	il-2/il-15	[IL-2/IL-15]	0.1	1	1	0	0
65765	1709	forms.	[forms.]	0.1	1	1	0	0
65766	1709	L227	[L227]	0.1	1	1	0	0
65767	1709	il-18-	[IL-18-]	0.1	1	1	0	0
65768	1709	il-15r	[IL-15R]	0.1	1	1	0	0
65769	1709	vp22	[VP22]	0.1	1	2	1	1
65770	1709	PKC/Ras-	[PKC/Ras-]	0.1	1	1	0	0
65771	1709	postvaccine	[postvaccine]	0.1	1	1	0	0
65772	1709	il-12-	[IL-12-]	0.1	1	1	0	0
65773	1709	gpibalpha	[GPIbalpha]	0.1	1	1	0	0
65774	1709	RelA.p50	[RelA.p50]	0.1	1	1	0	0
65775	1709	heterozygote	[heterozygote]	0.1	1	2	1	1
65776	1709	GATA-	[GATA-]	0.1	1	1	0	0
65777	1709	GATA1	[GATA1]	0.1	1	1	0	0
65778	1709	i-factor	[I-factor]	0.1	1	2	1	1
65779	1709	cd11b+	[CD11b+]	0.1	1	2	1	1
65780	1709	extinguishing	[extinguishing]	0.1	1	1	0	0
65781	1709	RU38486	[RU38486]	0.1	1	1	0	0
65782	1709	Ad2/Ad12	[Ad2/Ad12]	0.1	1	1	0	0
65783	1709	monocytes-macrophages;	[monocytes-macrophages;]	0.1	1	1	0	0
65784	1709	mSin3	[mSin3]	0.1	1	1	0	0
65785	1709	hsf-1	[HSF-1]	0.1	1	2	1	1
65786	1709	adipocytes.	[adipocytes.]	0.1	1	1	0	0
65787	1709	stable.	[stable.]	0.1	1	1	0	0
65788	1709	hdlm-1	[HDLM-1]	0.1	1	2	1	1
65789	1709	surgery,	[surgery,]	0.1	1	1	0	0
65790	1709	(esc)	[(esc)]	0.1	1	1	0	0
65791	1709	slope	[slope]	0.1	1	1	0	0
65792	1709	tetrahydrocortisol	[tetrahydrocortisol]	0.1	1	2	1	1
65793	1709	HLA-DRalpha	[HLA-DRalpha]	0.1	1	1	0	0
65794	1709	VCAM-	[VCAM-]	0.1	1	1	0	0
65795	1709	event,	[event,]	0.1	1	1	0	0
65796	1709	alkylation	[alkylation]	0.1	1	1	0	0
65797	1709	phenylpyrazol	[phenylpyrazol]	0.1	1	1	0	0
65798	1709	(Kd)	[(Kd)]	0.1	1	2	1	1
65799	1709	pro-interleukin-1beta	[pro-interleukin-1beta]	0.1	1	1	0	0
65800	1709	peritoneum	[peritoneum]	0.1	1	1	0	0
65801	1709	problem:	[PROBLEM:]	0.1	1	1	0	0
65802	1709	nf-il2a	[NF-IL2A]	0.1	1	1	0	0
65803	1709	TLR4	[TLR4]	0.1	1	1	0	0
65804	1709	hpp-cfc	[HPP-CFC]	0.1	1	1	0	0
65805	1709	postinduction	[postinduction]	0.1	1	1	0	0
65806	1709	int-2	[int-2]	0.1	1	1	0	0
65807	1709	KSHV	[KSHV]	0.1	1	2	2	2
65808	1709	deactivate	[deactivating]	0.1	1	2	1	1
65809	1709	CD4(+)	[CD4(+)]	0.1	1	1	0	0
65810	1709	TFIIIA	[TFIIIA]	0.1	1	1	0	0
65811	1709	osteoporosis	[osteoporosis]	0.1	1	1	0	0
65812	1709	forskolin,	[forskolin,]	0.1	1	1	0	0
65813	1709	relatedness	[relatedness]	0.1	1	2	2	2
65814	1709	"semimature"	["semimature"]	0.1	1	1	0	0
65815	1709	(NF)	[(NF)]	0.1	1	2	2	2
65816	1709	isoform.	[isoform.]	0.1	1	1	0	0
65817	1709	TNF,	[TNF,]	0.1	1	2	1	1
65818	1709	170-kd	[170-kD]	0.1	1	1	0	0
65819	1709	CD2/CD4-positive,	[CD2/CD4-positive,]	0.1	1	1	0	0
65820	1709	pre-incubation	[Pre-incubation]	0.1	1	2	2	2
65821	1709	context,	[context,]	0.1	1	2	1	1
65822	1709	mortality	[mortality]	0.1	1	1	0	0
65823	1709	SKF525a	[SKF525a]	0.1	1	1	0	0
65824	1709	myb,	[myb,]	0.1	1	1	0	0
65825	1709	initiating	[initiating]	0.1	1	1	0	0
65826	1709	myf5	[myf5]	0.1	1	1	0	0
65827	1709	myf6	[myf6]	0.1	1	1	0	0
65828	1709	obesity	[obesity]	0.1	1	2	2	2
65829	1709	GTGGGAA	[GTGGGAA]	0.1	1	1	0	0
65830	1709	EBERs	[EBERs]	0.1	1	2	1	1
65831	1709	BamHI-Q	[BamHI-Q]	0.1	1	1	0	0
65832	1709	myod	[MyoD]	0.1	1	1	0	0
65833	1709	allergen	[allergen]	0.1	1	1	0	0
65834	1709	Extract	[Extract]	0.1	1	2	1	1
65835	1709	anti-jund	[anti-JunD]	0.1	1	1	0	0
65836	1709	ctg-motif	[CTG-motif]	0.1	1	1	0	0
65837	1709	neurotoxin	[neurotoxin]	0.1	1	2	2	2
65838	1709	propidium	[propidium]	0.1	1	2	1	1
65839	1709	U/mL	[U/mL]	0.1	1	1	0	0
65840	1709	ICR-27	[ICR-27]	0.1	1	1	0	0
65841	1709	type-C	[type-C]	0.1	1	1	0	0
65842	1709	(cd33,	[(CD33,]	0.1	1	1	0	0
65843	1709	(PB)	[(PB)]	0.1	1	1	0	0
65844	1709	25-kDa	[25-kDa]	0.1	1	1	0	0
65845	1709	Estrone	[Estrone]	0.1	1	1	0	0
65846	1709	vaso-occlusion	[vaso-occlusion]	0.1	1	1	0	0
65847	1709	(Bt2)	[(Bt2)]	0.1	1	1	0	0
65848	1709	TPEN	[TPEN]	0.1	1	1	0	0
65849	1709	stationary-phase	[stationary-phase]	0.1	1	1	0	0
65850	1709	chimpanzee	[chimpanzee]	0.1	1	1	0	0
65851	1709	bv173	[BV173]	0.1	1	1	0	0
65852	1709	Sp-1	[Sp-1]	0.1	1	1	0	0
65853	1709	target-	[target-]	0.1	1	1	0	0
65854	1709	Sp1/	[Sp1/]	0.1	1	1	0	0
65855	1709	ms2-hbx	[MS2-HBx]	0.1	1	1	0	0
65856	1709	IL-6/interferon-gamma	[IL-6/interferon-gamma]	0.1	1	1	0	0
65857	1709	Sp3,	[Sp3,]	0.1	1	1	0	0
65858	1709	cluster,	[cluster,]	0.1	1	1	0	0
65859	1709	eber	[EBERs]	0.1	1	1	0	0
65860	1709	Ca2+-ATPase	[Ca2+-ATPase]	0.1	1	1	0	0
65861	1709	chrysotile	[Chrysotile]	0.1	1	1	0	0
65862	1709	allergy,	[allergy,]	0.1	1	1	0	0
65863	1709	medium,	[medium,]	0.1	1	1	0	0
65864	1709	ebs2	[EBS2]	0.1	1	1	0	0
65865	1709	ed50	[ED50]	0.1	1	2	1	1
65866	1709	allergy]	[allergy]]	0.1	1	1	0	0
65867	1709	medium;	[medium;]	0.1	1	1	0	0
65868	1709	self-ag	[self-Ags]	0.1	1	1	0	0
65869	1709	(exp.	[(Exp.]	0.1	1	1	0	0
65870	1709	controversy	[controversy]	0.1	1	2	1	1
65871	1709	down-regulation,	[down-regulation,]	0.1	1	1	0	0
65872	1709	June	[June]	0.1	1	1	0	0
65873	1709	mobilities,	[mobilities,]	0.1	1	1	0	0
65874	1709	IcsA-	[IcsA-]	0.1	1	1	0	0
65875	1709	(p105)	[(p105)]	0.1	1	1	0	0
65876	1709	chloroquine	[chloroquine]	0.1	1	1	0	0
65877	1709	ad5e1a-peptide	[Ad5E1A-peptide]	0.1	1	1	0	0
65878	1709	super	[super]	0.1	1	1	0	0
65879	1709	U373	[U373]	0.1	1	3	2	1
65880	1709	Sox4	[Sox4]	0.1	1	1	0	0
65881	1709	complexity	[complexity]	0.1	1	3	2	1
65882	1709	subepithelium	[subepithelium]	0.1	1	1	0	0
65883	1709	silica	[silica]	0.1	1	1	0	0
65884	1709	Listeria	[Listeria]	0.1	1	1	0	0
65885	1709	(ifn)-gamma	[(IFN)-gamma]	0.1	1	2	2	2
65886	1709	h1-histamine	[H1-histamine]	0.1	1	1	0	0
65887	1709	oxypurinol	[Oxypurinol]	0.1	1	1	0	0
65888	1709	jak-1	[JAK-1]	0.1	1	1	0	0
65889	1709	gestation	[gestation]	0.1	1	1	0	0
65890	1709	(irf)-1	[(IRF)-1]	0.1	1	1	0	0
65891	1709	mineralocorticoids	[Mineralocorticoids]	0.1	1	1	0	0
65892	1709	c-site	[C-site]	0.1	1	1	0	0
65893	1709	have,	[have,]	0.1	1	1	0	0
65894	1709	persist	[persisting]	0.1	1	1	0	0
65895	1709	country	[country]	0.1	1	1	0	0
65896	1709	crossreaction	[crossreactions]	0.1	1	1	0	0
65897	1709	crossreacting	[crossreacting]	0.1	1	1	0	0
65898	1709	rhizome	[rhizome]	0.1	1	1	0	0
65899	1709	TSC2	[TSC2]	0.1	1	2	1	1
65900	1709	exist	[existing]	0.1	1	1	0	0
65901	1709	control).	[control).]	0.1	1	1	0	0
65902	1709	activin-	[activin-]	0.1	1	1	0	0
65903	1709	death-prom	[death-promoting]	0.1	1	1	0	0
65904	1709	2-bp	[2-bp]	0.1	1	1	0	0
65905	1709	VLA-5	[VLA-5]	0.1	1	1	0	0
65906	1709	TSHR	[TSHR]	0.1	1	2	2	2
65907	1709	x;17	[X;17]	0.1	1	2	1	1
65908	1709	beta-promoter	[beta-promoter]	0.1	1	2	1	1
65909	1709	9,11-dihydro	[9,11-dihydro]	0.1	1	1	0	0
65910	1709	c-jun,	[c-jun,]	0.1	1	1	0	0
65911	1709	c-jun/	[c-jun/]	0.1	1	1	0	0
65912	1709	c-jun-	[c-Jun-]	0.1	1	1	0	0
65913	1709	2-kb	[2-kb]	0.1	1	1	0	0
65914	1709	2-me	[2-ME]	0.1	1	1	0	0
65915	1709	CAAT	[CAAT]	0.1	1	1	0	0
65916	1709	FcepsilonRIIb	[FcepsilonRIIb]	0.1	1	1	0	0
65917	1709	monocty	[monoctyes]	0.1	1	1	0	0
65918	1709	CAII	[CAII]	0.1	1	2	1	1
65919	1709	p130/rb2	[p130/Rb2]	0.1	1	1	0	0
65920	1709	24,25-dihydroxy-vitamin	[24,25-dihydroxy-vitamin]	0.1	1	1	0	0
65921	1709	embryo	[embryo]	0.1	1	2	2	2
65922	1709	Phe774	[Phe774]	0.1	1	1	0	0
65923	1709	Ras(G12V)	[Ras(G12V)]	0.1	1	1	0	0
65924	1709	them,	[them,]	0.1	1	1	0	0
65925	1709	Edman	[Edman]	0.1	1	1	0	0
65926	1709	carboxyl-terminus	[carboxyl-terminus]	0.1	1	2	2	2
65927	1709	explant	[explants]	0.1	1	1	0	0
65928	1709	kindred,	[kindred,]	0.1	1	1	0	0
65929	1709	non-receptor	[non-receptor]	0.1	1	1	0	0
65930	1709	respectively,	[respectively,]	0.1	1	2	2	2
65931	1709	Lef/Tcf	[Lef/Tcf]	0.1	1	1	0	0
65932	1709	gluco-	[gluco-]	0.1	1	1	0	0
65933	1709	Krox-24	[Krox-24]	0.1	1	1	0	0
65934	1709	anoxia/reoxygenation	[anoxia/reoxygenation]	0.1	1	2	1	1
65935	1709	reporter-gene	[reporter-gene]	0.1	1	1	0	0
65936	1709	camp-response-element-binding	[cAMP-response-element-binding]	0.1	1	1	0	0
65937	1709	tether	[tether]	0.1	1	1	0	0
65938	1709	491-amino-acid	[491-amino-acid]	0.1	1	1	0	0
65939	1709	setting	[setting]	0.1	1	2	2	2
65940	1709	dqa1*0201/dqb1*0201	[DQA1*0201/DQB1*0201]	0.1	1	2	2	2
65941	1709	controls;	[controls;]	0.1	1	1	0	0
65942	1709	fourier	[Fourier]	0.1	1	1	0	0
65943	1709	controls)	[controls)]	0.1	1	1	0	0
65944	1709	nip-2	[Nip-2]	0.1	1	1	0	0
65945	1709	gos19.1	[GOS19.1]	0.1	1	1	0	0
65946	1709	zvad-fmk	[zVAD-FMK]	0.1	1	1	0	0
65947	1709	tnf-alpha-	[TNF-alpha-]	0.1	1	2	1	1
65948	1709	v14rho	[V14Rho]	0.1	1	2	2	2
65949	1709	nacl	[NaCl]	0.1	1	1	0	0
65950	1709	CD+8	[CD+8]	0.1	1	1	0	0
65951	1709	types.	[types.]	0.1	1	1	0	0
65952	1709	CD16	[CD16]	0.1	1	1	0	0
65953	1709	CD15	[CD15]	0.1	1	2	2	2
65954	1709	CD29	[CD29]	0.1	1	1	0	0
65955	1709	CD27	[CD27]	0.1	1	3	2	1
65956	1709	CD25	[CD25]	0.1	1	1	0	0
65957	1709	CD21	[CD21]	0.1	1	2	1	1
65958	1709	defens	[defense.]	0.1	1	1	0	0
65959	1709	CD45	[CD45]	0.1	1	2	1	1
65960	1709	CD43	[CD43]	0.1	1	2	1	1
65961	1709	CD54	[CD54]	0.1	1	1	0	0
65962	1709	serine-727	[serine-727]	0.1	1	1	0	0
65963	1709	CD71	[CD71]	0.1	1	1	0	0
65964	1709	retinoic-acid	[retinoic-acid]	0.1	1	2	1	1
65965	1709	CD8+	[CD8+]	0.1	1	1	0	0
65966	1709	choriocarcinoma	[choriocarcinoma]	0.1	1	2	1	1
65967	1709	ISG15	[ISG15]	0.1	1	1	0	0
65968	1709	glycogen	[glycogen]	0.1	1	2	2	2
65969	1709	hypercorticism	[hypercorticism]	0.1	1	1	0	0
65970	1709	(tcr)-	[(TCR)-]	0.1	1	1	0	0
65971	1709	lineage.	[lineage.]	0.1	1	2	1	1
65972	1709	NFATc.alpha	[NFATc.alpha]	0.1	1	1	0	0
65973	1709	ectopic	[ectopic]	0.1	1	1	0	0
65974	1709	p-145	[p-145]	0.1	1	1	0	0
65975	1709	CCl4	[CCl4]	0.1	1	1	0	0
65976	1709	lac-Z	[lac-Z]	0.1	1	2	1	1
65977	1709	hydroxyl	[hydroxyl]	0.1	1	1	0	0
65978	1709	(il)-8	[(IL)-8]	0.1	1	2	2	2
65979	1709	(il)-4	[(IL)-4]	0.1	1	2	1	1
65980	1709	nd10	[ND10s]	0.1	1	1	0	0
65981	1709	immunosupershift	[immunosupershift]	0.1	1	1	0	0
65982	1709	Pro24Leu	[Pro24Leu]	0.1	1	1	0	0
65983	1709	cell-receptor	[cell-receptor]	0.1	1	1	0	0
65984	1709	behaviour	[behaviour]	0.1	1	2	2	2
65985	1709	poly[d(i-c)]	[poly[d(I-C)]]	0.1	1	1	0	0
65986	1709	ccgccc	[CCGCCC]	0.1	1	2	1	1
65987	1709	energy	[Energy]	0.1	1	2	2	2
65988	1709	ibuprofen	[ibuprofen]	0.1	1	1	0	0
65989	1709	cardiomyocyte	[cardiomyocytes]	0.1	1	1	0	0
65990	1709	amplicon	[amplicon]	0.1	1	2	2	2
65991	1709	56-kDa	[56-kDa]	0.1	1	1	0	0
65992	1709	EBNAs	[EBNAs]	0.1	1	2	1	1
65993	1709	metalloproteinases-1	[metalloproteinases-1]	0.1	1	1	0	0
65994	1709	anti-p65	[anti-p65]	0.1	1	1	0	0
65995	1709	Bcl6	[Bcl6]	0.1	1	2	1	1
65996	1709	asn240-leu335	[Asn240-Leu335]	0.1	1	1	0	0
65997	1709	virus-host	[virus-host]	0.1	1	1	0	0
65998	1709	B-ALL	[B-ALL]	0.1	1	1	0	0
65999	1709	TUNEL	[TUNEL]	0.1	1	2	2	2
66000	1709	third	[third]	0.1	1	1	0	0
66001	1709	p50/p65-nf-kappab	[p50/p65-NF-kappaB]	0.1	1	1	0	0
66002	1709	Taturday	[Tat.]	0.1	1	1	0	0
66003	1709	exon,	[exon,]	0.1	1	2	2	2
66004	1709	AP-1/c-jun	[AP-1/c-jun]	0.1	1	1	0	0
66005	1709	tubulointerstitium	[tubulointerstitium]	0.1	1	1	0	0
66006	1709	Fy(b-)	[Fy(b-)]	0.1	1	1	0	0
66007	1709	nf45	[NF45]	0.1	1	1	0	0
66008	1709	suppression.	[suppression.]	0.1	1	1	0	0
66009	1709	apoaldosterone	[apoaldosterone]	0.1	1	1	0	0
66010	1709	TYK2	[TYK2]	0.1	1	1	0	0
66011	1709	nf90	[NF90]	0.1	1	1	0	0
66012	1709	theory	[theory]	0.1	1	2	2	2
66013	1709	immunosenescence	[immunosenescence]	0.1	1	1	0	0
66014	1709	DCoH-HNF-1	[DCoH-HNF-1]	0.1	1	1	0	0
66015	1709	splice/polyadenylation	[splice/polyadenylation]	0.1	1	1	0	0
66016	1709	branch	[branch]	0.1	1	1	0	0
66017	1709	tataaa	[TATAAA]	0.1	1	1	0	0
66018	1709	neca	[NECA]	0.1	1	1	0	0
66019	1709	CaM/CN-	[CaM/CN-]	0.1	1	1	0	0
66020	1709	paucity	[paucity]	0.1	1	1	0	0
66021	1709	na(+)-h(+)-antiport	[Na(+)-H(+)-antiport]	0.1	1	1	0	0
66022	1709	golgi	[Golgi]	0.1	1	1	0	0
66023	1709	Beth	[Beth]	0.1	1	1	0	0
66024	1709	default	[default]	0.1	1	1	0	0
66025	1709	B-lymphoid	[B-lymphoid]	0.1	1	1	0	0
66026	1709	black	[blacks]	0.1	1	2	2	2
66027	1709	5-aminolevulinate	[5-aminolevulinate]	0.1	1	2	1	1
66028	1709	new,	[new,]	0.1	1	1	0	0
66029	1709	B-lymphoma	[B-lymphoma]	0.1	1	1	0	0
66030	1709	quercetin	[quercetin]	0.1	1	2	1	1
66031	1709	elf1	[ELF1]	0.1	1	1	0	0
66032	1709	Id-bHLH	[Id-bHLH]	0.1	1	1	0	0
66033	1709	Germline	[Germline]	0.1	1	2	2	2
66034	1709	MAR-BP1	[MAR-BP1]	0.1	1	1	0	0
66035	1709	LM-PCR	[LM-PCR]	0.1	1	1	0	0
66036	1709	LBF3	[LBF3]	0.1	1	1	0	0
66037	1709	LBF2	[LBF2]	0.1	1	1	0	0
66038	1709	LBF6	[LBF6]	0.1	1	1	0	0
66039	1709	LBF5	[LBF5]	0.1	1	1	0	0
66040	1709	5-[p-methoxyphenyl]-3H-1,2-dithiol-3-thione	[5-[p-methoxyphenyl]-3H-1,2-dithiol-3-thione]	0.1	1	1	0	0
66041	1709	gastroenterology	[gastroenterology]	0.1	1	2	1	1
66042	1709	nh2-	[NH2-]	0.1	1	2	2	2
66043	1709	Evi-1	[Evi-1]	0.1	1	1	0	0
66044	1709	G-CSF-R	[G-CSF-R]	0.1	1	1	0	0
66045	1709	dephosphorylation.	[dephosphorylation.]	0.1	1	1	0	0
66046	1709	-GGAT-	[-GGAT-]	0.1	1	1	0	0
66047	1709	base-substitution	[base-substitution]	0.1	1	1	0	0
66048	1709	ltr-cat	[LTR-CAT]	0.1	1	1	0	0
66049	1709	Jak/STAT	[Jak/STAT]	0.1	1	1	0	0
66050	1709	immunocyte	[immunocytes]	0.1	1	1	0	0
66051	1709	transfection,	[transfection,]	0.1	1	1	0	0
66052	1709	PXQXT/S	[PXQXT/S]	0.1	1	2	1	1
66053	1709	proviruse	[proviruses]	0.1	1	2	1	1
66054	1709	fragmented,	[fragmented,]	0.1	1	1	0	0
66055	1709	271c	[271C]	0.1	1	3	2	1
66056	1709	inosine-5'-monophosphate	[inosine-5'-monophosphate]	0.1	1	1	0	0
66057	1709	inactivity	[inactivity]	0.1	1	2	1	1
66058	1709	3H-triamcinolone	[3H-triamcinolone]	0.1	1	1	0	0
66059	1709	Finally,	[Finally,]	0.1	1	2	2	2
66060	1709	nitro	[nitro]	0.1	1	1	0	0
66061	1709	structure/function	[Structure/function]	0.1	1	2	2	2
66062	1709	ii-like	[II-like]	0.1	1	2	2	2
66063	1709	differentiate/mature	[differentiate/mature]	0.1	1	1	0	0
66064	1709	t-cell-leukemia	[T-cell-leukemia]	0.1	1	2	1	1
66065	1709	rhil-2	[rhIL-2]	0.1	1	1	0	0
66066	1709	t(17;19)-bearing	[t(17;19)-bearing]	0.1	1	1	0	0
66067	1709	i-kappabbeta	[I-kappaBbeta]	0.1	1	1	0	0
66068	1709	Tamoxifen	[Tamoxifen]	0.1	1	2	1	1
66069	1709	LD78	[LD78]	0.1	1	1	0	0
66070	1709	Rhom-3	[Rhom-3]	0.1	1	1	0	0
66071	1709	apoptosisprone	[apoptosisprone]	0.1	1	1	0	0
66072	1709	ferric	[ferric]	0.1	1	1	0	0
66073	1709	HIV-LTR	[HIV-LTR]	0.1	1	1	0	0
66074	1709	smase	[SMase]	0.1	1	2	2	2
66075	1709	ubiquination	[ubiquination]	0.1	1	1	0	0
66076	1709	pituitary	[pituitary]	0.1	1	3	2	1
66077	1709	involution	[involution]	0.1	1	2	2	2
66078	1709	mg132	[MG132]	0.1	1	1	0	0
66079	1709	whole-blood	[whole-blood]	0.1	1	2	1	1
66080	1709	HNF-1alpha	[HNF-1alpha]	0.1	1	1	0	0
66081	1709	period,	[period,]	0.1	1	2	2	2
66082	1709	Triflusal	[Triflusal]	0.1	1	1	0	0
66083	1709	period.	[period.]	0.1	1	2	2	2
66084	1709	500-bp	[500-bp]	0.1	1	2	1	1
66085	1709	AIDS-GR	[AIDS-GR]	0.1	1	1	0	0
66086	1709	smad2	[Smad2]	0.1	1	1	0	0
66087	1709	ast/alt	[AST/ALT]	0.1	1	1	0	0
66088	1709	hypothalamus	[hypothalamus]	0.1	1	3	2	1
66089	1709	enhancer/	[enhancer/]	0.1	1	1	0	0
66090	1709	enhancer,	[enhancer,]	0.1	1	2	2	2
66091	1709	hemoglobin,	[hemoglobin,]	0.1	1	1	0	0
66092	1709	enhancer;	[enhancer;]	0.1	1	1	0	0
66093	1709	94-kd	[94-kD]	0.1	1	1	0	0
66094	1709	myelodysplastic	[myelodysplastic]	0.1	1	1	0	0
66095	1709	oligos.	[oligos.]	0.1	1	1	0	0
66096	1709	annexin	[annexin]	0.1	1	2	1	1
66097	1709	ALG-4	[ALG-4]	0.1	1	1	0	0
66098	1709	gst-construct	[GST-construct]	0.1	1	1	0	0
66099	1709	LEF1	[LEF1]	0.1	1	1	0	0
66100	1709	ORF-A	[ORF-A]	0.1	1	1	0	0
66101	1709	SFLLRNP	[SFLLRNP]	0.1	1	1	0	0
66102	1709	substrates.	[substrates.]	0.1	1	2	1	1
66103	1709	mg/kg	[mg/kg]	0.1	1	1	0	0
66104	1709	Hematology.	[Hematology.]	0.1	1	1	0	0
66105	1709	mouse.	[mouse.]	0.1	1	1	0	0
66106	1709	D.Schwartz,	[D.Schwartz,]	0.1	1	1	0	0
66107	1709	prdii	[PRDII]	0.1	1	2	1	1
66108	1709	RE/AP	[RE/AP]	0.1	1	2	1	1
66109	1709	monocyte-type	[monocyte-type]	0.1	1	1	0	0
66110	1709	zpcat	[ZpCat]	0.1	1	1	0	0
66111	1709	HA1004	[HA1004]	0.1	1	1	0	0
66112	1709	p21rex	[p21rex]	0.1	1	1	0	0
66113	1709	p105/p50	[p105/p50]	0.1	1	2	1	1
66114	1709	caspase-3/cpp32	[caspase-3/CPP32]	0.1	1	1	0	0
66115	1709	bleed	[bleeding]	0.1	1	1	0	0
66116	1709	er+:	[ER+:]	0.1	1	1	0	0
66117	1709	'perfect'	['perfect']	0.1	1	1	0	0
66118	1709	Ras/Raf/ERK	[Ras/Raf/ERK]	0.1	1	1	0	0
66119	1709	CCACC	[CCACC]	0.1	1	1	0	0
66120	1709	mg/day)	[mg/day)]	0.1	1	2	1	1
66121	1709	stearic)	[stearic)]	0.1	1	1	0	0
66122	1709	Iepsilon	[Iepsilon]	0.1	1	2	1	1
66123	1709	Paget's	[Paget's]	0.1	1	1	0	0
66124	1709	recurrence,	[recurrence,]	0.1	1	1	0	0
66125	1709	EBV-B	[EBV-B]	0.1	1	1	0	0
66126	1709	ubiquitin-	[ubiquitin-]	0.1	1	1	0	0
66127	1709	pre-i	[PRE-I]	0.1	1	1	0	0
66128	1709	bcl2+	[BCL2+]	0.1	1	1	0	0
66129	1709	adult-t-cell-leukemia	[adult-T-cell-leukemia]	0.1	1	1	0	0
66130	1709	gcr-alpha	[GCR-alpha]	0.1	1	1	0	0
66131	1709	627-bp	[627-bp]	0.1	1	1	0	0
66132	1709	aldehyde	[aldehyde]	0.1	1	1	0	0
66133	1709	order:	[order:]	0.1	1	1	0	0
66134	1709	erbA	[erbA]	0.1	1	1	0	0
66135	1709	CNBr	[CNBr]	0.1	1	1	0	0
66136	1709	merge	[merging]	0.1	1	1	0	0
66137	1709	vulnerability	[vulnerability]	0.1	1	1	0	0
66138	1709	Hut102	[Hut102]	0.1	1	1	0	0
66139	1709	erg2	[ERG2]	0.1	1	1	0	0
66140	1709	co-receptor	[co-receptor]	0.1	1	2	1	1
66141	1709	merit	[merit]	0.1	1	2	2	2
66142	1709	CNI-	[CNI-]	0.1	1	1	0	0
66143	1709	rna-packaging	[RNA-packaging]	0.1	1	1	0	0
66144	1709	polysaccharide	[polysaccharide]	0.1	1	2	1	1
66145	1709	CNS:	[CNS:]	0.1	1	1	0	0
66146	1709	smear	[smear]	0.1	1	1	0	0
66147	1709	M(r)	[M(r)]	0.1	1	1	0	0
66148	1709	nf-kappab-p105/p50	[NF-kappaB-p105/p50]	0.1	1	1	0	0
66149	1709	gp91-phox	[gp91-phox]	0.1	1	1	0	0
66150	1709	(position	[(positions]	0.1	1	2	1	1
66151	1709	eightfold	[eightfold]	0.1	1	2	1	1
66152	1709	ribonucleoprotein	[ribonucleoprotein]	0.1	1	1	0	0
66153	1709	MAD-3	[MAD-3]	0.1	1	1	0	0
66154	1709	CP-2	[CP-2]	0.1	1	1	0	0
66155	1709	(ad)	[(Ad)]	0.1	1	2	2	2
66156	1709	p15,	[P15,]	0.1	1	1	0	0
66157	1709	20-epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(oh)2-vitamin	[20-Epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(OH)2-vitamin]	0.1	1	1	0	0
66158	1709	RJ2.2.5	[RJ2.2.5]	0.1	1	1	0	0
66159	1709	subcloning	[subcloning]	0.1	1	1	0	0
66160	1709	PKCalpha	[PKCalpha]	0.1	1	2	1	1
66161	1709	tumor-eradicate	[tumor-eradicating]	0.1	1	1	0	0
66162	1709	anti-hgh	[anti-hGH]	0.1	1	1	0	0
66163	1709	/rela	[/RelA]	0.1	1	2	2	2
66164	1709	(auc	[(AUC]	0.1	1	2	2	2
66165	1709	AIDS-C	[AIDS-C]	0.1	1	2	1	1
66166	1709	TaxI	[TaxI]	0.1	1	1	0	0
66167	1709	sites/cell).	[sites/cell).]	0.1	1	1	0	0
66168	1709	Rh:33	[Rh:33]	0.1	1	1	0	0
66169	1709	np-2	[NP-2]	0.1	1	1	0	0
66170	1709	mnp-2	[MNP-2]	0.1	1	2	1	1
66171	1709	11alpha,13-dihydrohelenalin	[11alpha,13-dihydrohelenalin]	0.1	1	1	0	0
66172	1709	-90/-79	[-90/-79]	0.1	1	1	0	0
66173	1709	kh1060	[KH1060]	0.1	1	2	1	1
66174	1709	igm-secreting	[IgM-secreting]	0.1	1	1	0	0
66175	1709	(bl)	[(BL)]	0.1	1	3	2	1
66176	1709	malignancy,	[malignancy,]	0.1	1	1	0	0
66177	1709	p288	[P288S]	0.1	1	1	0	0
66178	1709	(bzip)	[(bZIP)]	0.1	1	1	0	0
66179	1709	synthesis.	[synthesis.]	0.1	1	2	2	2
66180	1709	(amino	[(amino]	0.1	1	1	0	0
66181	1709	nk-kappa	[NK-kappa]	0.1	1	2	1	1
66182	1709	hours'	[hours']	0.1	1	1	0	0
66183	1709	(but	[(but]	0.1	1	1	0	0
66184	1709	manuscript	[manuscript]	0.1	1	1	0	0
66185	1709	[E(spl)]	[[E(spl)]]	0.1	1	1	0	0
66186	1709	ACT-1	[ACT-1]	0.1	1	1	0	0
66187	1709	(tnf-alpha)	[(TNF-alpha)]	0.1	1	2	1	1
66188	1709	family.	[family.]	0.1	1	1	0	0
66189	1709	lamin	[lamin]	0.1	1	2	1	1
66190	1709	(cd)	[(CD)]	0.1	1	1	0	0
66191	1709	researcher	[researchers]	0.1	1	2	1	1
66192	1709	years.	[years.]	0.1	1	2	1	1
66193	1709	b-specific	[B-specific]	0.1	1	2	1	1
66194	1709	funcion	[funcion]	0.1	1	1	0	0
66195	1709	mortality.	[mortality.]	0.1	1	1	0	0
66196	1709	not)	[not)]	0.1	1	1	0	0
66197	1709	note	[note]	0.1	1	1	0	0
66198	1709	Zebra	[Zebra]	0.1	1	2	1	1
66199	1709	Box1	[Box1]	0.1	1	1	0	0
66200	1709	together,	[together,]	0.1	1	1	0	0
66201	1709	Mi-2-HDAC	[Mi-2-HDAC]	0.1	1	1	0	0
66202	1709	conclusion:	[CONCLUSION:]	0.1	1	1	0	0
66203	1709	conclusion.	[conclusion.]	0.1	1	1	0	0
66204	1709	CREM	[CREM]	0.1	1	2	1	1
66205	1709	hormone.2+o	[hormone.2+o]	0.1	1	1	0	0
66206	1709	evi1	[EVI1]	0.1	1	1	0	0
66207	1709	HLA/peptide	[HLA/peptide]	0.1	1	1	0	0
66208	1709	antioxidant.	[antioxidant.]	0.1	1	1	0	0
66209	1709	review.	[review.]	0.1	1	1	0	0
66210	1709	NFAT1/	[NFAT1/]	0.1	1	1	0	0
66211	1709	(day	[(day]	0.1	1	2	1	1
66212	1709	others,	[others,]	0.1	1	2	1	1
66213	1709	evolution,	[evolution,]	0.1	1	1	0	0
66214	1709	(dn)	[(DN)]	0.1	1	1	0	0
66215	1709	RWLeu-4	[RWLeu-4]	0.1	1	1	0	0
66216	1709	excision	[excision]	0.1	1	2	1	1
66217	1709	(ds)	[(ds)]	0.1	1	1	0	0
66218	1709	jurkat-tag	[Jurkat-TAg]	0.1	1	1	0	0
66219	1709	TL-Om1,	[TL-Om1,]	0.1	1	1	0	0
66220	1709	(f:m	[(F:M]	0.1	1	1	0	0
66221	1709	conclusions:	[CONCLUSIONS:]	0.1	1	2	1	1
66222	1709	kappaB3	[kappaB3]	0.1	1	1	0	0
66223	1709	kappaB/	[kappaB/]	0.1	1	1	0	0
66224	1709	monocytes-macrophages	[monocytes-macrophages]	0.1	1	2	1	1
66225	1709	(Chr)	[(Chr)]	0.1	1	1	0	0
66226	1709	aetiology	[aetiology]	0.1	1	2	2	2
66227	1709	pleiotropy	[pleiotropy]	0.1	1	1	0	0
66228	1709	performance	[performance]	0.1	1	2	2	2
66229	1709	(es)	[(ES)]	0.1	1	2	1	1
66230	1709	peptidyl	[peptidyl]	0.1	1	1	0	0
66231	1709	4-hydroxytamoxifen	[4-hydroxytamoxifen]	0.1	1	1	0	0
66232	1709	nras	[NRAS]	0.1	1	1	0	0
66233	1709	laser	[laser]	0.1	1	2	1	1
66234	1709	modify	[modifying]	0.1	1	1	0	0
66235	1709	courses.	[courses.]	0.1	1	1	0	0
66236	1709	vulvar	[vulvar]	0.1	1	1	0	0
66237	1709	pseudo-hypoaldosteronism	[pseudo-hypoaldosteronism]	0.1	1	2	2	2
66238	1709	(fh)	[(FH)]	0.1	1	1	0	0
66239	1709	p65(	[p65(]	0.1	1	1	0	0
66240	1709	non-t-cell	[non-T-cells]	0.1	1	1	0	0
66241	1709	sds-gel	[SDS-gel]	0.1	1	1	0	0
66242	1709	temperature,	[temperature,]	0.1	1	1	0	0
66243	1709	fy(b-)	[Fy(b-)]	0.1	1	1	0	0
66244	1709	(for	[(for]	0.1	1	2	2	2
66245	1709	peptide,	[peptide,]	0.1	1	1	0	0
66246	1709	SOCS-1	[SOCS-1]	0.1	1	1	0	0
66247	1709	Lysis	[Lysis]	0.1	1	1	0	0
66248	1709	gm2/gc-box	[GM2/GC-box]	0.1	1	1	0	0
66249	1709	CD-40	[CD-40]	0.1	1	1	0	0
66250	1709	ones,	[ones,]	0.1	1	2	2	2
66251	1709	33-kDa	[33-kDa]	0.1	1	1	0	0
66252	1709	ManLAM	[ManLAM]	0.1	1	1	0	0
66253	1709	CV-1	[CV-1]	0.1	1	1	0	0
66254	1709	ones.	[ones.]	0.1	1	2	2	2
66255	1709	hGATA-4	[hGATA-4]	0.1	1	1	0	0
66256	1709	BsmI	[BsmI]	0.1	1	1	0	0
66257	1709	pebp2beta	[Pebp2beta]	0.1	1	1	0	0
66258	1709	octanucleotide	[octanucleotide]	0.1	1	1	0	0
66259	1709	dr3-type	[DR3-type]	0.1	1	1	0	0
66260	1709	dicysteine	[dicysteine]	0.1	1	1	0	0
66261	1709	prolongation	[prolongation]	0.1	1	2	2	2
66262	1709	triplet	[triplet]	0.1	1	1	0	0
66263	1709	tester	[tester]	0.1	1	3	2	1
66264	1709	buffy	[buffy]	0.1	1	1	0	0
66265	1709	y128	[Y128]	0.1	1	1	0	0
66266	1709	processing,	[processing,]	0.1	1	1	0	0
66267	1709	(gr)	[(GR)]	0.1	1	2	2	2
66268	1709	(gs)	[(GS)]	0.1	1	2	2	2
66269	1709	anti-mbp	[anti-MBP]	0.1	1	1	0	0
66270	1709	departure	[departure]	0.1	1	1	0	0
66271	1709	HaCaT	[HaCaT]	0.1	1	1	0	0
66272	1709	13-kilobase-pair	[13-kilobase-pair]	0.1	1	1	0	0
66273	1709	centrifugation	[centrifugation]	0.1	1	2	2	2
66274	1709	(MHC)	[(MHC)]	0.1	1	2	1	1
66275	1709	pou-domain	[POU-domain]	0.1	1	1	0	0
66276	1709	NF-AT/AP-1-	[NF-AT/AP-1-]	0.1	1	1	0	0
66277	1709	atl16t(-)	[ATL16T(-)]	0.1	1	2	1	1
66278	1709	(from	[(from]	0.1	1	1	0	0
66279	1709	Glu30-Leu41	[Glu30-Leu41]	0.1	1	1	0	0
66280	1709	2-deoxyglucose	[2-deoxyglucose]	0.1	1	1	0	0
66281	1709	[3h]thymidine	[[3H]thymidine]	0.1	1	1	0	0
66282	1709	LPMC	[LPMC]	0.1	1	2	1	1
66283	1709	thapsigargin)	[thapsigargin)]	0.1	1	1	0	0
66284	1709	pentadecamer	[pentadecamer]	0.1	1	1	0	0
66285	1709	retinaldehyde	[retinaldehyde]	0.1	1	2	1	1
66286	1709	hyperimmunoglobulin	[hyperimmunoglobulin]	0.1	1	1	0	0
66287	1709	undernutrition	[undernutrition]	0.1	1	1	0	0
66288	1709	TFIIHmut	[TFIIHmut]	0.1	1	2	1	1
66289	1709	interval	[intervals]	0.1	1	2	2	2
66290	1709	(ie)	[(IE)]	0.1	1	1	0	0
66291	1709	smoking	[smoking]	0.1	1	1	0	0
66292	1709	AM580	[AM580]	0.1	1	3	2	1
66293	1709	Murine	[Murine]	0.1	1	2	1	1
66294	1709	chemiluminescent	[chemiluminescent]	0.1	1	1	0	0
66295	1709	nitrofurantoin	[nitrofurantoin]	0.1	1	1	0	0
66296	1709	synteny	[synteny]	0.1	1	2	2	2
66297	1709	UL21	[UL21]	0.1	1	1	0	0
66298	1709	u/ml.	[U/ml.]	0.1	1	2	2	2
66299	1709	dimers.	[dimers.]	0.1	1	1	0	0
66300	1709	p50/nf-kappa	[p50/NF-kappa]	0.1	1	1	0	0
66301	1709	interleukin-9	[interleukin-9]	0.1	1	1	0	0
66302	1709	dehydration	[dehydration]	0.1	1	1	0	0
66303	1709	NFATc-	[NFATc-]	0.1	1	1	0	0
66304	1709	Cp/Wp	[Cp/Wp]	0.1	1	1	0	0
66305	1709	t(14;14)	[t(14;14)]	0.1	1	2	1	1
66306	1709	Concanavalin	[Concanavalin]	0.1	1	2	1	1
66307	1709	grave'	[Grave's]	0.1	1	1	0	0
66308	1709	-biotin	[-biotin]	0.1	1	2	2	2
66309	1709	individuals.	[individuals.]	0.1	1	1	0	0
66310	1709	individuals,	[individuals,]	0.1	1	2	2	2
66311	1709	(jn)	[(JN)]	0.1	1	1	0	0
66312	1709	rel/stat	[Rel/STAT]	0.1	1	1	0	0
66313	1709	NFATx4	[NFATx4]	0.1	1	1	0	0
66314	1709	NFATx2	[NFATx2]	0.1	1	2	2	2
66315	1709	CaMKIV	[CaMKIV]	0.1	1	1	0	0
66316	1709	a-binding	[A-binding]	0.1	1	1	0	0
66317	1709	CYC1	[CYC1]	0.1	1	1	0	0
66318	1709	log10mbc	[log10MBC]	0.1	1	1	0	0
66319	1709	(class	[(class]	0.1	1	1	0	0
66320	1709	NFATp-	[NFATp-]	0.1	1	1	0	0
66321	1709	egr-3	[egr-3]	0.1	1	1	0	0
66322	1709	TF.VIIa	[TF.VIIa]	0.1	1	1	0	0
66323	1709	(kb)	[(kb)]	0.1	1	2	2	2
66324	1709	divide	[dividing]	0.1	1	2	1	1
66325	1709	(kd)	[(kD)]	0.1	1	1	0	0
66326	1709	CD11a	[CD11a]	0.1	1	1	0	0
66327	1709	HTLV-I-LTR-CAT	[HTLV-I-LTR-CAT]	0.1	1	1	0	0
66328	1709	Dithiocarbamates	[Dithiocarbamates]	0.1	1	2	2	2
66329	1709	immunophenotypic	[immunophenotypic]	0.1	1	1	0	0
66330	1709	(alone	[(alone]	0.1	1	1	0	0
66331	1709	beta-gal	[beta-gal]	0.1	1	2	1	1
66332	1709	nmol/L.	[nmol/L.]	0.1	1	2	2	2
66333	1709	octamer,	[octamer,]	0.1	1	1	0	0
66334	1709	hyaluronan	[hyaluronan]	0.1	1	2	1	1
66335	1709	procedure.	[procedure.]	0.1	1	2	2	2
66336	1709	egr2,	[EGR2,]	0.1	1	1	0	0
66337	1709	promoter-luciferase	[promoter-luciferase]	0.1	1	2	2	2
66338	1709	State	[States]	0.1	1	1	0	0
66339	1709	Statl	[Statl]	0.1	1	1	0	0
66340	1709	CD28,	[CD28,]	0.1	1	1	0	0
66341	1709	(hiv)-1	[(HIV)-1]	0.1	1	2	2	2
66342	1709	LIM-only	[LIM-only]	0.1	1	1	0	0
66343	1709	zymosan-	[zymosan-]	0.1	1	1	0	0
66344	1709	basement	[Basement]	0.1	1	1	0	0
66345	1709	sulfatase	[sulfatase]	0.1	1	1	0	0
66346	1709	15-amino	[15-amino]	0.1	1	2	1	1
66347	1709	x50-7	[X50-7]	0.1	1	1	0	0
66348	1709	layer	[layer]	0.1	1	2	2	2
66349	1709	/peptide	[/peptide]	0.1	1	2	2	2
66350	1709	attachment	[attachment]	0.1	1	2	1	1
66351	1709	gC2-	[gC2-]	0.1	1	1	0	0
66352	1709	hypomelanosis	[hypomelanosis]	0.1	1	2	1	1
66353	1709	anti-cd70	[anti-CD70]	0.1	1	1	0	0
66354	1709	parental	[parental]	0.1	1	1	0	0
66355	1709	(mf)	[(MF)]	0.1	1	1	0	0
66356	1709	signal-transming	[signal-transmitting]	0.1	1	1	0	0
66357	1709	beta-(1,3)-glucan	[beta-(1,3)-glucan]	0.1	1	2	2	2
66358	1709	ligand-receptor	[ligand-receptor]	0.1	1	1	0	0
66359	1709	anti-cd3-	[anti-CD3-]	0.1	1	1	0	0
66360	1709	anti-cd3/	[anti-CD3/]	0.1	1	1	0	0
66361	1709	anti-cd40	[Anti-CD40]	0.1	1	1	0	0
66362	1709	lipase	[lipase]	0.1	1	1	0	0
66363	1709	testis-derermine	[testis-determining]	0.1	1	1	0	0
66364	1709	colimycin	[colimycin]	0.1	1	1	0	0
66365	1709	CD34+	[CD34+]	0.1	1	2	1	1
66366	1709	DQ3.3	[DQ3.3]	0.1	1	1	0	0
66367	1709	DQ3.2	[DQ3.2]	0.1	1	1	0	0
66368	1709	interleukin-1alpha	[interleukin-1alpha]	0.1	1	2	1	1
66369	1709	ac-devd-cho	[Ac-DEVD-CHO]	0.1	1	1	0	0
66370	1709	deoxyguanosine	[deoxyguanosine]	0.1	1	1	0	0
66371	1709	gD2-	[gD2-]	0.1	1	1	0	0
66372	1709	9-cis-RA	[9-cis-RA]	0.1	1	1	0	0
66373	1709	response-1	[response-1]	0.1	1	2	2	2
66374	1709	pheochromocytoma	[pheochromocytoma]	0.1	1	1	0	0
66375	1709	fas-	[Fas-]	0.1	1	1	0	0
66376	1709	following.	[following.]	0.1	1	1	0	0
66377	1709	following:	[following:]	0.1	1	2	1	1
66378	1709	75-kD	[75-kD]	0.1	1	1	0	0
66379	1709	sediment	[sedimenting]	0.1	1	1	0	0
66380	1709	(non	[(non]	0.1	1	1	0	0
66381	1709	Olf-1	[Olf-1]	0.1	1	1	0	0
66382	1709	(p50	[(p50]	0.1	1	1	0	0
66383	1709	trophoblast,	[trophoblast,]	0.1	1	1	0	0
66384	1709	autoradiography	[autoradiography]	0.1	1	1	0	0
66385	1709	trapping	[trapping]	0.1	1	2	1	1
66386	1709	procedures,	[procedures,]	0.1	1	1	0	0
66387	1709	supine:	[supine:]	0.1	1	1	0	0
66388	1709	t-cell-	[T-cell-]	0.1	1	1	0	0
66389	1709	pou-homeodomain	[POU-homeodomain]	0.1	1	1	0	0
66390	1709	nucleoli	[nucleoli]	0.1	1	1	0	0
66391	1709	caution.	[caution.]	0.1	1	1	0	0
66392	1709	diamide,	[diamide,]	0.1	1	1	0	0
66393	1709	ecd45ra+)	[(CD45RA+)]	0.1	1	2	1	1
66394	1709	"physiologic"	["physiologic"]	0.1	1	1	0	0
66395	1709	(r129c)	[(R129C)]	0.1	1	2	1	1
66396	1709	RanBP2	[RanBP2]	0.1	1	2	1	1
66397	1709	tissular	[tissular]	0.1	1	1	0	0
66398	1709	erythroleukemias	[erythroleukemias]	0.1	1	1	0	0
66399	1709	metastasis-suppressor	[metastasis-suppressor]	0.1	1	1	0	0
66400	1709	anti-dnp	[anti-DNP]	0.1	1	1	0	0
66401	1709	glomerular	[glomerular]	0.1	1	1	0	0
66402	1709	fcs+	[FCS+]	0.1	1	1	0	0
66403	1709	doxepin	[doxepin]	0.1	1	1	0	0
66404	1709	(dprl)	[(dPRL)]	0.1	1	1	0	0
66405	1709	gst-pi-	[GST-pi-]	0.1	1	1	0	0
66406	1709	(po2	[(PO2]	0.1	1	1	0	0
66407	1709	breast-cancer	[breast-cancer]	0.1	1	1	0	0
66408	1709	2M-1	[2M-1]	0.1	1	2	1	1
66409	1709	Rel/kappaB	[Rel/kappaB]	0.1	1	2	1	1
66410	1709	constraint	[constraints]	0.1	1	2	2	2
66411	1709	Torr,	[Torr,]	0.1	1	1	0	0
66412	1709	bt2camp	[Bt2cAMP]	0.1	1	2	1	1
66413	1709	sites/cell,	[sites/cell,]	0.1	1	2	2	2
66414	1709	sites/cell)	[sites/cell)]	0.1	1	1	0	0
66415	1709	GASd/EBSd	[GASd/EBSd]	0.1	1	2	1	1
66416	1709	sites/cell.	[sites/cell.]	0.1	1	1	0	0
66417	1709	kB-like	[kB-like]	0.1	1	1	0	0
66418	1709	Nature	[Nature]	0.1	1	2	1	1
66419	1709	SLA-DR	[SLA-DR]	0.1	1	1	0	0
66420	1709	SLA-DQ	[SLA-DQ]	0.1	1	1	0	0
66421	1709	medication.	[medication.]	0.1	1	1	0	0
66422	1709	immunopoiesis	[immunopoiesis]	0.1	1	1	0	0
66423	1709	135-(oh)2d3	[1,25-(OH)2D3]	0.1	1	2	1	1
66424	1709	chem.	[Chem.]	0.1	1	1	0	0
66425	1709	non-tumor	[non-tumor]	0.1	1	1	0	0
66426	1709	USF/	[USF/]	0.1	1	1	0	0
66427	1709	USF-	[USF-]	0.1	1	1	0	0
66428	1709	USF2	[USF2]	0.1	1	1	0	0
66429	1709	[corticoid	[[Corticoids]	0.1	1	1	0	0
66430	1709	IkappaBepsilon	[IkappaBepsilon]	0.1	1	1	0	0
66431	1709	hemostasis	[hemostasis]	0.1	1	1	0	0
66432	1709	avidin-biotin	[avidin-biotin]	0.1	1	1	0	0
66433	1709	y;15	[Y;15]	0.1	1	1	0	0
66434	1709	instances.	[instances.]	0.1	1	2	2	2
66435	1709	T-leukemia	[T-leukemia]	0.1	1	1	0	0
66436	1709	CREB/ATF-1	[CREB/ATF-1]	0.1	1	1	0	0
66437	1709	oxLDL	[oxLDL]	0.1	1	1	0	0
66438	1709	GATA-3/ER	[GATA-3/ER]	0.1	1	1	0	0
66439	1709	G-rich	[G-rich]	0.1	1	1	0	0
66440	1709	glycemic	[glycemic]	0.1	1	1	0	0
66441	1709	collaboration	[collaboration]	0.1	1	2	2	2
66442	1709	subsets,	[subsets,]	0.1	1	2	1	1
66443	1709	methotrexate	[methotrexate]	0.1	1	1	0	0
66444	1709	aminoenhancer	[Aminoenhancer]	0.1	1	1	0	0
66445	1709	DAPI	[DAPI]	0.1	1	1	0	0
66446	1709	5'-cc(a	[5'-CC(A]	0.1	1	1	0	0
66447	1709	(rel	[(Rel]	0.1	1	1	0	0
66448	1709	DARC	[DARC]	0.1	1	1	0	0
66449	1709	parallel.	[parallel.]	0.1	1	1	0	0
66450	1709	e-cadherin	[E-cadherin]	0.1	1	1	0	0
66451	1709	coregulators.	[coregulators.]	0.1	1	1	0	0
66452	1709	MHC-peptide	[MHC-peptide]	0.1	1	2	1	1
66453	1709	TAFII32	[TAFII32]	0.1	1	2	2	2
66454	1709	(t3)	[(T3)]	0.1	1	1	0	0
66455	1709	(rt)	[(RT)]	0.1	1	2	1	1
66456	1709	macrophage/monocyte	[macrophage/monocyte]	0.1	1	1	0	0
66457	1709	risk,	[risk,]	0.1	1	1	0	0
66458	1709	CCATATATGG	[CCATATATGG]	0.1	1	1	0	0
66459	1709	lim-hox	[LIM-Hox]	0.1	1	1	0	0
66460	1709	(Jurkat)	[(Jurkat)]	0.1	1	1	0	0
66461	1709	flask	[flasks]	0.1	1	1	0	0
66462	1709	c-rel-	[c-Rel-]	0.1	1	1	0	0
66463	1709	variants,	[variants,]	0.1	1	2	2	2
66464	1709	Rpd3p	[Rpd3p]	0.1	1	1	0	0
66465	1709	c-rel/	[c-Rel/]	0.1	1	2	1	1
66466	1709	burgdorferi	[burgdorferi]	0.1	1	1	0	0
66467	1709	IL-1/	[IL-1/]	0.1	1	1	0	0
66468	1709	IL-18	[IL-18]	0.1	1	1	0	0
66469	1709	IL-4-	[IL-4-]	0.1	1	1	0	0
66470	1709	hemizygosity	[hemizygosity]	0.1	1	1	0	0
66471	1709	IL-7-	[IL-7-]	0.1	1	1	0	0
66472	1709	Moreover,	[Moreover,]	0.1	1	2	2	2
66473	1709	Callithrix	[Callithrix]	0.1	1	2	1	1
66474	1709	alternate	[alternating]	0.1	1	1	0	0
66475	1709	trifluoromethylketone	[trifluoromethylketone]	0.1	1	1	0	0
66476	1709	tgacgtca	[TGACGTCA]	0.1	1	1	0	0
66477	1709	ng/10(6)	[ng/10(6)]	0.1	1	2	2	2
66478	1709	myogenin	[myogenin]	0.1	1	1	0	0
66479	1709	immaturity	[immaturity]	0.1	1	1	0	0
66480	1709	tcf-1/lef-1	[TCF-1/LEF-1]	0.1	1	1	0	0
66481	1709	nucleoplasm	[nucleoplasm]	0.1	1	1	0	0
66482	1709	ligase	[ligase]	0.1	1	2	1	1
66483	1709	gamma-Interferon	[gamma-Interferon]	0.1	1	1	0	0
66484	1709	(tcr	[(TCR]	0.1	1	1	0	0
66485	1709	hemopoietin	[hemopoietins]	0.1	1	2	1	1
66486	1709	exercise)	[exercise)]	0.1	1	1	0	0
66487	1709	ttcttctaattaa	[TTCTTCTAATTAA]	0.1	1	1	0	0
66488	1709	htlr2	[hTLR2]	0.1	1	2	1	1
66489	1709	cd8alpha/il-4ralpha	[CD8alpha/IL-4Ralpha]	0.1	1	1	0	0
66490	1709	stat1-containing	[STAT1-containing]	0.1	1	1	0	0
66491	1709	gralpha	[GRalpha]	0.1	1	1	0	0
66492	1709	SH-SY5Y	[SH-SY5Y]	0.1	1	1	0	0
66493	1709	htoll	[hToll]	0.1	1	2	1	1
66494	1709	charcoal	[charcoal]	0.1	1	1	0	0
66495	1709	hematopoiesis.	[hematopoiesis.]	0.1	1	1	0	0
66496	1709	455-bp	[455-bp]	0.1	1	1	0	0
66497	1709	IFN-gammaRalpha	[IFN-gammaRalpha]	0.1	1	1	0	0
66498	1709	gal4-p65(286-551)	[GAL4-p65(286-551)]	0.1	1	1	0	0
66499	1709	non-Hodgkin'	[non-Hodgkin's]	0.1	1	1	0	0
66500	1709	A-to-G	[A-to-G]	0.1	1	1	0	0
66501	1709	(uc)	[(UC)]	0.1	1	1	0	0
66502	1709	dopamine,	[dopamine,]	0.1	1	1	0	0
66503	1709	'latency	['latency]	0.1	1	2	1	1
66504	1709	hIRAK	[hIRAK]	0.1	1	2	2	2
66505	1709	(pp-1)	[(PP-1)]	0.1	1	1	0	0
66506	1709	p16(ink4a)	[p16(INK4A)]	0.1	1	2	1	1
66507	1709	2-3-fold,	[2-3-fold,]	0.1	1	1	0	0
66508	1709	fide	[fide]	0.1	1	1	0	0
66509	1709	zymography	[zymography]	0.1	1	1	0	0
66510	1709	-activate	[-activating]	0.1	1	2	1	1
66511	1709	hypertensive	[hypertensives]	0.1	1	2	1	1
66512	1709	-d421a	[-D421A]	0.1	1	1	0	0
66513	1709	positioning	[positioning]	0.1	1	2	2	2
66514	1709	REF-1	[REF-1]	0.1	1	1	0	0
66515	1709	pharmacodynamics	[pharmacodynamics]	0.1	1	1	0	0
66516	1709	polyether	[polyether]	0.1	1	1	0	0
66517	1709	anti-cd8-fitc	[anti-CD8-FITC]	0.1	1	1	0	0
66518	1709	thymus.	[thymus.]	0.1	1	1	0	0
66519	1709	reference	[reference]	0.1	1	2	2	2
66520	1709	oligodeoxynucleotides	[oligodeoxynucleotides]	0.1	1	2	2	2
66521	1709	traf5	[TRAF5]	0.1	1	1	0	0
66522	1709	vaccinia	[vaccinia]	0.1	1	1	0	0
66523	1709	parathyroidectomy,	[parathyroidectomy,]	0.1	1	1	0	0
66524	1709	mr-count	[MR-count]	0.1	1	1	0	0
66525	1709	analog0	[analog,]	0.1	1	1	0	0
66526	1709	B-alpha	[B-alpha]	0.1	1	1	0	0
66527	1709	anti-allergy	[anti-allergy]	0.1	1	1	0	0
66528	1709	c-ring	[C-ring]	0.1	1	1	0	0
66529	1709	LT-betaR	[LT-betaR]	0.1	1	1	0	0
66530	1709	emigration	[emigration]	0.1	1	1	0	0
66531	1709	mody1	[MODY1]	0.1	1	1	0	0
66532	1709	speculation	[speculation]	0.1	1	1	0	0
66533	1709	OAP40	[OAP40]	0.1	1	2	1	1
66534	1709	fas/apo-1/cd95-	[Fas/APO-1/CD95-]	0.1	1	1	0	0
66535	1709	identification,	[identification,]	0.1	1	1	0	0
66536	1709	compounds.	[compounds.]	0.1	1	1	0	0
66537	1709	regulatory	[regulatory]	0.1	1	2	2	2
66538	1709	structures,	[structures,]	0.1	1	1	0	0
66539	1709	gata-2/estrogen	[GATA-2/estrogen]	0.1	1	1	0	0
66540	1709	J.Menezes,	[J.Menezes,]	0.1	1	1	0	0
66541	1709	ultrafiltration	[ultrafiltration]	0.1	1	1	0	0
66542	1709	compounds'	[compounds']	0.1	1	1	0	0
66543	1709	sites,	[sites,]	0.1	1	2	1	1
66544	1709	NFATd	[NFATd]	0.1	1	1	0	0
66545	1709	NFAT4	[NFAT4]	0.1	1	4	3	1
66546	1709	NFAT2	[NFAT2]	0.1	1	3	2	1
66547	1709	NFATC	[NFATC]	0.1	1	1	0	0
66548	1709	tyrosine-containing	[tyrosine-containing]	0.1	1	1	0	0
66549	1709	sites]	[sites]]	0.1	1	1	0	0
66550	1709	desulfation	[desulfation]	0.1	1	1	0	0
66551	1709	Oct-4	[Oct-4]	0.1	1	1	0	0
66552	1709	Oct-6	[Oct-6]	0.1	1	1	0	0
66553	1709	MAP-	[MAP-]	0.1	1	1	0	0
66554	1709	clonogenicity	[clonogenicity]	0.1	1	1	0	0
66555	1709	Oct2ba	[Oct2ba]	0.1	1	1	0	0
66556	1709	MAPk	[MAPk]	0.1	1	1	0	0
66557	1709	Oct2ab	[Oct2ab]	0.1	1	1	0	0
66558	1709	migration-pe	[migration-promoting]	0.1	1	1	0	0
66559	1709	functioning	[functioning]	0.1	1	2	1	1
66560	1709	flap	[FLAP]	0.1	1	2	2	2
66561	1709	alphaiibh	[alphaIIbH]	0.1	1	1	0	0
66562	1709	suggest	[suggesting]	0.1	1	1	0	0
66563	1709	NF-microB-binding	[NF-microB-binding]	0.1	1	1	0	0
66564	1709	Sentman	[Sentman]	0.1	1	1	0	0
66565	1709	Oct2a	[Oct2a]	0.1	1	1	0	0
66566	1709	Oct2b	[Oct2b]	0.1	1	1	0	0
66567	1709	DHCC	[DHCC]	0.1	1	1	0	0
66568	1710	glucocorticoid receptor from the nonresponder	[glucocorticoid receptors from the nonresponders]	0.0	5	1	1	1
66569	1710	two polypeptide	[two polypeptides]	0.0	2	2	2	1
66570	1710	linkage between t-cell cell development	[linkage between T-cell cell development]	0.0	5	1	1	1
66571	1710	genomic segment	[genomic segment]	0.0	2	1	1	1
66572	1710	dna-binding assay with form	[DNA-binding assays with forms]	0.0	4	1	1	1
66573	1710	aml m4 without abnormality	[AML M4 without abnormalities]	0.0	4	1	1	1
66574	1710	equal, unequal expression	[equal, unequal expression]	0.0	3	1	1	1
66575	1710	additional costimulatory signal	[additional costimulatory signal]	0.0	3	1	1	1
66576	1710	Bacterial lipopolysaccharide (lps)-mediated immune response	[Bacterial lipopolysaccharide (LPS)-mediated immune responses]	0.0	5	1	1	1
66577	1710	endothelial gene product	[endothelial gene products]	0.0	3	1	1	1
66578	1710	13 man	[13 men]	0.0	2	1	1	1
66579	1710	produce less concurrent enhancement	[producing less concurrent enhancement]	0.0	4	1	1	1
66580	1710	DNA topoisomerase	[DNA topoisomerase]	0.0	2	1	1	1
66581	1710	lymphocyte by class	[lymphocytes by class]	0.0	3	1	1	1
66582	1710	comparable formation ifn-gamma-activated sequence-binding complex	[comparable formation IFN-gamma-activated sequence-binding complexes]	0.0	5	1	1	1
66583	1710	aspect of cytokine network	[aspects of cytokine networks]	0.0	4	1	1	1
66584	1710	latency in certain monocytic cell	[latency in certain monocytic cells]	0.0	5	1	1	1
66585	1710	formation of acid-reactive substance	[formation of acid-reactive substances]	0.0	4	1	1	1
66586	1710	class expression in this lines.	[class expression in these lines.]	0.0	5	1	1	1
66587	1710	lineage specific gene	[lineage specific gene]	0.0	3	1	1	1
66588	1710	regulate hiv-1 gene expression	[regulating HIV-1 gene expression]	0.0	4	1	1	1
66589	1710	mrna level for M-CSF	[mRNA levels for M-CSF]	0.0	4	1	1	1
66590	1710	suggest a requirement for optimal function	[suggesting a requirement for optimal function]	0.0	6	1	1	1
66591	1710	cbp/p300 coactivator protein	[CBP/p300 coactivator proteins]	0.0	3	1	1	1
66592	1710	H	[H]	0.0	1	1	1	1
66593	1710	tnf-alpha mrna induction like induction	[TNF-alpha mRNA induction like induction]	0.0	5	1	1	1
66594	1710	nuclear receptor receptor gamma	[nuclear receptor receptor gamma]	0.0	4	1	1	1
66595	1710	source of MHC ii transcript	[source of MHC II transcripts]	0.0	5	1	1	1
66596	1710	variation in environmental lighting	[variations in environmental lighting]	0.0	4	1	1	1
66597	1710	effect on ige synthesis	[effect on IgE synthesis]	0.0	4	1	1	1
66598	1710	hormonal interaction	[Hormonal interactions]	0.0	2	1	1	1
66599	1710	include fibroblast	[including fibroblasts]	0.0	2	1	1	1
66600	1710	activation in response to pma/a23187	[activation in response to PMA/A23187]	0.0	5	1	1	1
66601	1710	novel mechanism of inhibition	[novel mechanisms of inhibition]	0.0	4	1	1	1
66602	1710	7 MRD -positive MRD	[7 MRD -positive MRD]	0.0	4	1	1	1
66603	1710	Ad5 E1A	[Ad5 E1A]	0.0	2	1	1	1
66604	1710	chain-breaking antioxidant	[chain-breaking antioxidants]	0.0	2	1	1	1
66605	1710	effect on IKK	[effect on IKK]	0.0	3	1	1	1
66606	1710	alpha, 25-dihydroxyvitamin D3 a inducer	[alpha, 25-dihydroxyvitamin D3 a inducer]	0.0	5	1	1	1
66607	1710	clinical use for the treatment	[clinical use for the treatment]	0.0	5	1	1	1
66608	1710	cell cycle kinetic	[cell cycle kinetics]	0.0	3	1	1	1
66609	1710	mAECA to ec	[mAECA to EC]	0.0	3	1	1	1
66610	1710	inhibition of transcriptional activation	[inhibition of transcriptional activation]	0.0	4	1	1	1
66611	1710	generation of immunity against pathogen	[generation of immunity against pathogens]	0.0	5	1	1	1
66612	1710	t-cell killer T/NK	[T-cell killer T/NK]	0.0	3	1	1	1
66613	1710	mouse Chr 11	[mouse Chr 11]	0.0	3	1	1	1
66614	1710	other herpesviruse	[other herpesviruses]	0.0	2	1	1	1
66615	1710	HLA-A2-restricted, CTL clone	[HLA-A2-restricted, CTL clone]	0.0	3	1	1	1
66616	1710	most antigen (include smooth muscle actin	[most antigens (including smooth muscle actin]	0.0	6	1	1	1
66617	1710	consequence, the result	[consequence, the result]	0.0	3	1	1	1
66618	1710	hsv-2 epitope mapping	[HSV-2 epitope mapping]	0.0	3	1	1	1
66619	1710	monocytic activity	[monocytic activity]	0.0	2	1	1	1
66620	1710	promoter specificity	[promoter specificity]	0.0	2	1	1	1
66621	1710	patient during relapse,	[patient during relapse,]	0.0	3	1	1	1
66622	1710	therapeutic value alter immune response	[therapeutic value altering immune responses]	0.0	5	1	1	1
66623	1710	-flanking sequence	[-flanking sequence]	0.0	2	1	1	1
66624	1710	infection of myelomonoblastic cell	[infection of myelomonoblastic cells]	0.0	4	1	1	1
66625	1710	insulin on the power	[insulin on the power]	0.0	4	1	1	1
66626	1710	dephosphorylation at phosphoserine residue	[dephosphorylation at phosphoserine residues]	0.0	4	1	1	1
66627	1710	mutation in lymphoid cell	[mutations in lymphoid cells]	0.0	4	1	1	1
66628	1710	mechanism regulate human apoptosis	[mechanisms regulating human apoptosis]	0.0	4	1	1	1
66629	1710	expression of NF-kappaB	[expression of NF-kappaB]	0.0	3	1	1	1
66630	1710	function of NF-kappaB	[functions of NF-kappaB]	0.0	3	1	1	1
66631	1710	stable expression in jurkat-t cell	[stable expression in Jurkat-T cells]	0.0	5	1	1	1
66632	1710	human monocyte extract	[human monocyte extracts]	0.0	3	1	1	1
66633	1710	region with general cofactor	[regions with general cofactors]	0.0	4	1	1	1
66634	1710	transcription in murine lymphocyte by ciprofloxacin	[transcription in murine lymphocytes by ciprofloxacin]	0.0	6	1	1	1
66635	1710	common downstream signal event	[common downstream signaling events]	0.0	4	1	1	1
66636	1710	stimulation of a human t-cell clone	[Stimulation of a human T-cell clone]	0.0	6	1	1	1
66637	1710	induction of the enzyme	[induction of the enzyme]	0.0	4	1	1	1
66638	1710	type of stimulus	[types of stimuli]	0.0	3	1	1	1
66639	1710	euthymic patient than in person	[euthymic patients than in persons]	0.0	5	1	1	1
66640	1710	low, physiological concentration	[low, physiological concentrations]	0.0	3	2	2	1
66641	1710	gene therapy protocol utilize vector	[gene therapy protocols utilizing vectors]	0.0	5	1	1	1
66642	1710	Exclusive expression of WT1	[Exclusive expression of WT1]	0.0	4	1	1	1
66643	1710	receptor affinity (Kd)	[receptor affinity (Kd)]	0.0	3	1	1	1
66644	1710	Bipotential killer	[Bipotential killer]	0.0	2	1	1	1
66645	1710	three candidate gene hepatic nuclear factor	[three candidate genes hepatic nuclear factor]	0.0	6	1	1	1
66646	1710	minimum sequence	[minimum sequence]	0.0	2	1	1	1
66647	1710	2 T cell growth erratum	[2 T cell growth erratum]	0.0	5	1	1	1
66648	1710	surface of lymphocyte	[surface of lymphocytes]	0.0	3	1	1	1
66649	1710	inhibited, growth	[inhibited, growth]	0.0	2	1	1	1
66650	1710	distinct domain of the interaction	[distinct domains of the interaction]	0.0	5	1	1	1
66651	1710	subclone into CAT expression vector	[Subcloning into CAT expression vectors]	0.0	5	1	1	1
66652	1710	nf-kappab/rel protein	[NF-kappaB/Rel proteins]	0.0	2	1	1	1
66653	1710	gamma-ifn responsive gene over-express monocyte	[gamma-IFN responsive genes over-expressing monocytes]	0.0	5	1	1	1
66654	1710	least three complex	[least three complexes]	0.0	3	1	1	1
66655	1710	mechanism underlie endothelial cell activation	[mechanisms underlying endothelial cell activation]	0.0	5	1	1	1
66656	1710	production of the p75tnf-r in mouse	[production of the p75TNF-R in mice]	0.0	6	1	1	1
66657	1710	major complex class molecule	[major complex class molecules]	0.0	4	1	1	1
66658	1710	influence of local estrogen metabolism	[influence of local estrogen metabolism]	0.0	5	1	1	1
66659	1710	bind affinity kd	[binding affinity Kd]	0.0	3	1	1	1
66660	1710	stimulation of spleen cell	[stimulations of spleen cells]	0.0	4	1	1	1
66661	1710	ra-mediated type ii	[RA-mediated type II]	0.0	3	1	1	1
66662	1710	nf-kappa b protein in thymocyte	[NF-kappa B proteins in thymocytes]	0.0	5	1	1	1
66663	1710	granularity	[granularity]	0.0	1	1	1	1
66664	1710	one possibility	[One possibility]	0.0	2	1	1	1
66665	1710	downstream globin gene	[downstream globin genes]	0.0	3	1	1	1
66666	1710	codon of exon 1	[codon of exon 1]	0.0	4	1	1	1
66667	1710	cleavage product of kda after induction	[cleavage products of kDa after induction]	0.0	6	1	1	1
66668	1710	second inducible pathway	[second inducible pathway]	0.0	3	1	1	1
66669	1710	functional role in the domain	[functional role in the domain]	0.0	5	1	1	1
66670	1710	role in thymic maturation	[role in thymic maturation]	0.0	4	1	1	1
66671	1710	cell with nef gene	[cells with nef genes]	0.0	4	1	1	1
66672	1710	transcriptional regulator of cytokine receptor genes,	[transcriptional regulators of cytokine receptor genes,]	0.0	6	1	1	1
66673	1710	non-cross-resisting agent	[non-cross-resisting agents]	0.0	2	1	1	1
66674	1710	mediate the negative activity	[mediating the negative activity]	0.0	4	1	1	1
66675	1710	carry defect in the choice	[carrying defect in the choice]	0.0	5	1	1	1
66676	1710	treatment for 4 weeks.	[treatment for 4 weeks.]	0.0	4	1	1	1
66677	1710	CCAAT element present	[CCAAT element present]	0.0	3	1	1	1
66678	1710	type-specific t-cell clone reactive	[type-specific T-cell clone reactive]	0.0	4	1	1	1
66679	1710	intact mononuclear leukocyte	[intact mononuclear leukocytes]	0.0	3	1	1	1
66680	1710	effect on cytokine production in monocyte	[effects on cytokine production in monocytes]	0.0	6	1	1	1
66681	1710	common therapeutic use as agent	[common therapeutic use as agents]	0.0	5	1	1	1
66682	1710	least two pathway	[least two pathways]	0.0	3	1	1	1
66683	1710	thereby allow translocation	[thereby allowing translocation]	0.0	3	1	1	1
66684	1710	low concentration mol/L)	[Low concentrations mol/L)]	0.0	3	1	1	1
66685	1710	bind in a tax -dependent manner	[binding in a Tax -dependent manner]	0.0	6	1	1	1
66686	1710	NF-kappa B protein	[NF-kappa B proteins]	0.0	3	1	1	1
66687	1710	thereby amplify expression of high-affinity receptor	[thereby amplifying expression of high-affinity receptor]	0.0	6	1	1	1
66688	1710	il-10 stat protein	[IL-10 STAT protein]	0.0	3	1	1	1
66689	1710	seven ebv gastric carcinoma tissue	[seven EBV gastric carcinoma tissues]	0.0	5	1	1	1
66690	1710	channels,	[channels,]	0.0	1	1	1	1
66691	1710	NB4 apl cell	[NB4 APL cells]	0.0	3	1	1	1
66692	1710	p65 mrna (75 versus minutes).	[p65 mRNA (75 vs minutes).]	0.0	5	1	1	1
66693	1710	change in one set	[changes in one set]	0.0	4	1	1	1
66694	1710	cytoplasmic reservoir	[cytoplasmic reservoir]	0.0	2	1	1	1
66695	1710	compare the expression	[comparing the expression]	0.0	3	1	1	1
66696	1710	human tsh receptor	[human TSH receptor]	0.0	3	1	1	1
66697	1710	DNase 1 site	[DNase 1 sites]	0.0	3	1	1	1
66698	1710	difference in glucocorticoid sensitivity	[differences in glucocorticoid sensitivity]	0.0	4	1	1	1
66699	1710	expression of bcl2	[expression of bcl2]	0.0	3	1	1	1
66700	1710	JNK the map	[JNK the MAP]	0.0	3	1	1	1
66701	1710	quantitative dnase footprinting	[quantitative DNase footprinting]	0.0	3	1	1	1
66702	1710	several area	[several areas]	0.0	2	1	1	1
66703	1710	putative cancer related loci relevant	[putative cancer related loci relevant]	0.0	5	1	1	1
66704	1710	camp-response element CRE TGACGTCA	[cAMP-response element CRE TGACGTCA]	0.0	4	1	1	1
66705	1710	down-modulation of hpc growth	[down-modulation of HPC growth]	0.0	4	1	1	1
66706	1710	step of ebv infection	[steps of EBV infection]	0.0	4	1	1	1
66707	1710	comprise a ab fragment	[comprising an Ab fragment]	0.0	4	1	1	1
66708	1710	for cloning rrna	[for cloning mRNAs]	0.0	3	1	1	1
66709	1710	sites/cell significant	[sites/cell significant]	0.0	2	1	1	1
66710	1710	rapid action of nf-kappa b	[rapid action of NF-kappa B]	0.0	5	1	1	1
66711	1710	binding heterodimers, at times.	[binding heterodimers, at times.]	0.0	4	1	1	1
66712	1710	binding capacity (4978+/-391	[Binding capacity (4978+/-391]	0.0	3	1	1	1
66713	1710	endothelial cell HAEC	[endothelial cells HAEC]	0.0	3	1	1	1
66714	1710	interleukin-2 promoter activation	[interleukin-2 promoter activation]	0.0	3	1	1	1
66715	1710	loss of precursor cell	[loss of precursor cells]	0.0	4	1	1	1
66716	1710	reading frame with a homeobox	[reading frame with a homeobox]	0.0	5	1	1	1
66717	1710	0.23 p	[0.23, P]	0.0	2	1	1	1
66718	1710	treatment of nfatp from ht-2 cell	[Treatment of NFATp from HT-2 cells]	0.0	6	1	1	1
66719	1710	ltr contain nf-kappa b element	[LTRs containing NF-kappa B elements]	0.0	5	1	1	1
66720	1710	consider the strong effect	[Considering the strong effect]	0.0	4	1	1	1
66721	1710	apolar substitution	[apolar substitutions]	0.0	2	1	1	1
66722	1710	induction of nf-kb binding protein	[induction of NF-kB binding proteins]	0.0	5	1	1	1
66723	1710	nuclear factor kappab kinase NIK	[nuclear factor kappaB kinase NIK]	0.0	5	1	1	1
66724	1710	content of t3, 4) dysfunction hypophyseal	[content of T3, 4) dysfunction hypophyseal]	0.0	6	1	1	1
66725	1710	as the probe,	[as the probe,]	0.0	3	1	1	1
66726	1710	parathyroid hormone-related protein pthrp	[parathyroid hormone-related protein PTHrP]	0.0	4	1	1	1
66727	1710	Appraisal of therapeutic index	[Appraisal of therapeutic index]	0.0	4	1	1	1
66728	1710	type-specific clone	[type-specific clone]	0.0	2	1	1	1
66729	1710	functional diversification of a number	[functional diversification of a number]	0.0	5	1	1	1
66730	1710	select set	[select set]	0.0	2	1	1	1
66731	1710	encode jun-B	[encoding jun-B]	0.0	2	1	1	1
66732	1710	primary event	[primary event]	0.0	2	1	1	1
66733	1710	diverse group of chemical	[diverse group of chemicals]	0.0	4	1	1	1
66734	1710	negative regulation in fibroblast	[negative regulation in fibroblasts]	0.0	4	1	1	1
66735	1710	Spi-1 in this cell	[Spi-1 in these cells]	0.0	4	1	1	1
66736	1710	substantial clinical importance for counseling.	[substantial clinical importance for counseling.]	0.0	5	1	1	1
66737	1710	adjacent augmentative cis element	[adjacent augmentative cis elements]	0.0	4	1	1	1
66738	1710	signal event dependent on the presence	[signaling events dependent on the presence]	0.0	6	1	1	1
66739	1710	STAT1 alpha activation	[STAT1 alpha activation]	0.0	3	1	1	1
66740	1710	element alpha/delta	[element alpha/delta]	0.0	2	1	1	1
66741	1710	low cd4+ cell count	[low CD4+ cell counts]	0.0	4	1	1	1
66742	1710	capacity of early progenitor cell	[capacity of early progenitor cells]	0.0	5	1	1	1
66743	1710	pathophysiology on the role	[pathophysiology on the role]	0.0	4	1	1	1
66744	1710	follow treatment of 6tg1.1 cell	[Following treatment of 6TG1.1 cells]	0.0	5	1	1	1
66745	1710	hrbc antibody production	[HRBC antibody production]	0.0	3	1	1	1
66746	1710	minute of stimulation.	[min of stimulation.]	0.0	3	1	1	1
66747	1710	primitive stem cell	[primitive stem cells]	0.0	3	1	1	1
66748	1710	binding of three distinct complex	[binding of three distinct complexes]	0.0	5	1	1	1
66749	1710	narrowing of this repertoire	[narrowing of this repertoire]	0.0	4	1	1	1
66750	1710	tamarin receptor	[tamarin receptors]	0.0	2	2	2	1
66751	1710	human immunodeficiency virus type-1 transcription	[Human immunodeficiency virus type-1 transcription]	0.0	5	1	1	1
66752	1710	alpha, 25-Dihydroxyvitamin D3	[alpha, 25-Dihydroxyvitamin D3]	0.0	3	1	1	1
66753	1710	acid differentiation	[acid differentiation]	0.0	2	1	1	1
66754	1710	interleukin-2 (il-2) gene expression	[interleukin-2 (IL-2) gene expression]	0.0	4	1	1	1
66755	1710	occupancy heterodimer	[occupancy heterodimers]	0.0	2	1	1	1
66756	1710	optimal slp-76 function,	[optimal SLP-76 function,]	0.0	3	1	1	1
66757	1710	disorder involve defective sexual differentiation	[disorders involving defective sexual differentiation]	0.0	5	1	1	1
66758	1710	activity on leukemia cell line	[activity on leukemia cell lines]	0.0	5	1	1	1
66759	1710	differentiation block by AML1a	[differentiation block by AML1a]	0.0	4	1	1	1
66760	1710	Bcd a proto-oncogene	[Bcd a proto-oncogene]	0.0	3	1	1	1
66761	1710	competition by bhlh protein	[competition by bHLH proteins]	0.0	4	1	1	1
66762	1710	express ad2/ad12 hybrid e1a gene product	[expressing Ad2/Ad12 hybrid E1A gene products]	0.0	6	1	1	1
66763	1710	major histocompatibility class gene	[major histocompatibility class genes]	0.0	4	1	1	1
66764	1710	related kinase inhibitor active	[related kinase inhibitor active]	0.0	4	1	1	1
66765	1710	over-lapping set of gene	[over-lapping sets of genes]	0.0	4	1	1	1
66766	1710	measure the contribution of macrophage	[measuring the contribution of macrophages]	0.0	5	1	1	1
66767	1710	healthy volunteer without disorder	[healthy volunteers without disorders]	0.0	4	1	1	1
66768	1710	G1-regulating protein	[G1-regulating proteins]	0.0	2	1	1	1
66769	1710	generation enhance activity	[generation enhancing activity]	0.0	3	1	1	1
66770	1710	difference between stimuli,	[difference between stimuli,]	0.0	3	1	1	1
66771	1710	major signal cascade	[major signal cascades]	0.0	3	1	1	1
66772	1710	translocation of isoform	[translocation of isoforms]	0.0	3	1	1	1
66773	1710	icam-1 rrna	[ICAM-1 mRNAs]	0.0	2	1	1	1
66774	1710	cr in human leukocyte	[CR in human leukocytes]	0.0	4	1	1	1
66775	1710	cell mature.	[cells mature.]	0.0	2	1	1	1
66776	1710	intact microtubule	[intact microtubules]	0.0	2	1	1	1
66777	1710	blood pb DC	[blood PB DC]	0.0	3	1	1	1
66778	1710	two x-inactivation pattern	[two X-inactivation patterns]	0.0	3	1	1	1
66779	1710	(HIV) terminal repeat LTR	[(HIV) terminal repeat LTR]	0.0	4	1	1	1
66780	1710	57 substitution in a HLA-DQ3.2 molecule	[57 substitution in an HLA-DQ3.2 molecule]	0.0	6	1	1	1
66781	1710	however, culture condition	[however, cultures conditions]	0.0	3	1	1	1
66782	1710	terminal repeat hiv-1-ltr CAT construct	[terminal repeat HIV-1-LTR CAT constructs]	0.0	5	1	1	1
66783	1710	two site at position -50	[two sites at positions -50]	0.0	5	1	1	1
66784	1710	leucocyte genomic dna	[leucocyte genomic DNAs]	0.0	3	1	1	1
66785	1710	relatedness to a transcription factor	[relatedness to a transcription factor]	0.0	5	1	1	1
66786	1710	expression of transcription	[expression of transcription]	0.0	3	1	1	1
66787	1710	pha abs	[PHA Abs]	0.0	2	1	1	1
66788	1710	complex group of response	[complex group of responses]	0.0	4	1	1	1
66789	1710	immune-mediated lysis	[immune-mediated lysis]	0.0	2	1	1	1
66790	1710	possible presence	[possible presence]	0.0	2	2	2	1
66791	1710	apparent difference	[apparent differences]	0.0	2	1	1	1
66792	1710	degree of androgen insensitivity	[degrees of androgen insensitivity]	0.0	4	1	1	1
66793	1710	infiltrate of human disease	[infiltrates of human diseases]	0.0	4	1	1	1
66794	1710	pre-exist complex	[pre-existing complex]	0.0	2	1	1	1
66795	1710	mlv transcription in cell line	[MLV transcription in cell lines]	0.0	5	1	1	1
66796	1710	bind power	[binding power]	0.0	2	1	1	1
66797	1710	arbitrary units, p	[arbitrary units, P]	0.0	3	1	1	1
66798	1710	constitutively significant level	[constitutively significant levels]	0.0	3	1	1	1
66799	1710	8, fibrous histiocytoma 6, rhabdomyosarcoma	[8, fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
66800	1710	thyrotropin (tsh)	[thyrotropin (TSH)]	0.0	2	1	1	1
66801	1710	inducer in cell	[inducer in cells]	0.0	3	1	1	1
66802	1710	HTLV-I mt-2 cell	[HTLV-I MT-2 cells]	0.0	3	1	1	1
66803	1710	TNFRp55-/-mutant	[TNFRp55-/-mutant]	0.0	1	1	1	1
66804	1710	three experimental series: at subject	[three experimental series: at subjects]	0.0	5	1	1	1
66805	1710	expression of set at stage	[expression of sets at stages]	0.0	5	1	1	1
66806	1710	activation of interaction	[activation of interactions]	0.0	3	1	1	1
66807	1710	jagged1 transcript	[jagged1 transcripts]	0.0	2	1	1	1
66808	1710	two distinct pathways:	[two distinct pathways:]	0.0	3	1	1	1
66809	1710	ELK-1	[ELK-1]	0.0	1	1	1	1
66810	1710	achieve ebv activation	[achieving EBV activation]	0.0	3	1	1	1
66811	1710	integral component of glutathione peroxidase	[integral component of glutathione peroxidase]	0.0	5	1	1	1
66812	1710	synergism between TNF-alpha	[synergism between TNF-alpha]	0.0	3	1	1	1
66813	1710	most cell lines, protein	[most cell lines, proteins]	0.0	4	1	1	1
66814	1710	number with menopausal type diabete	[number with menopausal type diabetes]	0.0	5	1	1	1
66815	1710	degradation mechanism	[degradation mechanism]	0.0	2	1	1	1
66816	1710	nine woman with spontaneous abortion	[nine women with spontaneous abortion]	0.0	5	1	1	1
66817	1710	latency in b cell	[latency in B cells]	0.0	4	1	1	1
66818	1710	reach a maximum min,	[reaching a maximum min,]	0.0	4	1	1	1
66819	1710	binding affinity.	[binding affinity.]	0.0	2	1	1	1
66820	1710	statistically-significant difference	[statistically-significant differences]	0.0	2	1	1	1
66821	1710	however, three order of magnitude	[however, three orders of magnitude]	0.0	5	1	1	1
66822	1710	hbx protein	[HBx protein]	0.0	2	1	1	1
66823	1710	F.Barre-Sinoussi,	[F.Barre-Sinoussi,]	0.0	1	1	1	1
66824	1710	CREB family	[CREB family]	0.0	2	1	1	1
66825	1710	ap-1-like site	[AP-1-like site]	0.0	2	1	1	1
66826	1710	activity downstream of ZEBRA	[activities downstream of ZEBRA]	0.0	4	1	1	1
66827	1710	regulator of platelet production	[regulator of platelet production]	0.0	4	1	1	1
66828	1710	target of ebna2 activity	[target of EBNA2 activity]	0.0	4	1	1	1
66829	1710	percentage of acute leukemia	[percentage of acute leukemias]	0.0	4	1	1	1
66830	1710	unoccupied 135eoh)2d3 receptor	[unoccupied 1,25(OH)2D3 receptor]	0.0	3	1	1	1
66831	1710	type ii tax protein	[type II Tax proteins]	0.0	4	1	1	1
66832	1710	microg/100 millileter at P;	[microg/100 ml at h;]	0.0	4	1	1	1
66833	1710	tbp related	[TBP related]	0.0	2	1	1	1
66834	1710	b-related transcription	[B-related transcription]	0.0	2	1	1	1
66835	1710	number of T cell	[numbers of T cells]	0.0	4	1	1	1
66836	1710	fine granularity	[fine granularity]	0.0	2	1	1	1
66837	1710	adipocyte fatty	[adipocyte fatty]	0.0	2	1	1	1
66838	1710	base-pair sequence	[base-pair sequence]	0.0	2	1	1	1
66839	1710	suggest mechanism of action,	[suggesting mechanisms of action,]	0.0	4	1	1	1
66840	1710	extent on cd8+ t-lymphocyte	[extent on CD8+ T-lymphocytes]	0.0	4	1	1	1
66841	1710	regulatory domain (prd) ii binding protein	[regulatory domain (PRD) II binding proteins]	0.0	6	1	1	1
66842	1710	include tradd	[including TRADD]	0.0	2	1	1	1
66843	1710	stimulation of procoagulant activity	[stimulation of procoagulant activity]	0.0	4	1	1	1
66844	1710	sedentary control person	[sedentary control persons]	0.0	3	1	1	1
66845	1710	certain response gene	[certain response genes]	0.0	3	1	1	1
66846	1710	context of sequence	[context of sequences]	0.0	3	1	1	1
66847	1710	characteristic similar	[characteristics similar]	0.0	2	1	1	1
66848	1710	identical five motif	[identical five motif]	0.0	3	1	1	1
66849	1710	amount of e2	[amounts of E2]	0.0	3	1	1	1
66850	1710	few epitope	[few epitopes]	0.0	2	1	1	1
66851	1710	Jul 15;163(2):1091]	[Jul 15;163(2):1091]]	0.0	2	1	1	1
66852	1710	pretreatment 5-day human monocyte-derived macrophage	[Pretreatment 5-day human monocyte-derived macrophages]	0.0	5	1	1	1
66853	1710	level of nuclear of p50	[levels of nuclear of p50]	0.0	5	1	1	1
66854	1710	4 beta-phorbol 12-myristate	[4 beta-phorbol 12-myristate]	0.0	3	1	1	1
66855	1710	downstream activation by covalent modification	[downstream activation by covalent modification]	0.0	5	1	1	1
66856	1710	insufficiency M-CRF	[insufficiency M-CRF]	0.0	2	1	1	1
66857	1710	il-2 responsiveness	[IL-2 responsiveness]	0.0	2	1	1	1
66858	1710	vcam-1 promoter reporter gene construct	[VCAM-1 promoter reporter gene constructs]	0.0	5	1	1	1
66859	1710	t-cell-line-expressing CD4 receptor	[T-cell-line-expressing CD4 receptors]	0.0	3	1	1	1
66860	1710	same phenomenon	[same phenomenon]	0.0	2	1	1	1
66861	1710	effectiveness of therapy in patient	[effectiveness of therapy in patients]	0.0	5	1	1	1
66862	1710	t3 microgram dna).	[T3 micrograms DNA).]	0.0	3	1	1	1
66863	1710	human lung fibroblast	[human lung fibroblasts]	0.0	3	1	1	1
66864	1710	expression of p50 homodimer in monocyte	[expression of p50 homodimer in monocytes]	0.0	6	1	1	1
66865	1710	redundancy among NGFI-B/nur77 family	[redundancy among NGFI-B/nur77 family]	0.0	4	1	1	1
66866	1710	definitive hematopoiesis	[definitive hematopoiesis]	0.0	2	1	1	1
66867	1710	distinct specificity	[distinct specificities]	0.0	2	1	1	1
66868	1710	two potential factor	[two potential factor]	0.0	3	1	1	1
66869	1710	epithelial cell response to amebic infection	[epithelial cell responses to amebic infection]	0.0	6	1	1	1
66870	1710	nfat target gene	[NFAT target genes]	0.0	3	1	1	1
66871	1710	correlation of ebv infection	[correlation of EBV infection]	0.0	4	1	1	1
66872	1710	evidence at proximal bind element	[Evidence at proximal binding element]	0.0	5	1	1	1
66873	1710	mutation of the DBF ap3-l site	[mutation of the DBF AP3-L site]	0.0	6	1	1	1
66874	1710	study of transgenic mouse	[study of transgenic mice]	0.0	4	1	1	1
66875	1710	low-level activation	[low-level activation]	0.0	2	1	1	1
66876	1710	leukemic DNA	[leukemic DNA]	0.0	2	1	1	1
66877	1710	use cos-7 cell	[using COS-7 cells]	0.0	3	1	1	1
66878	1710	profound conformational change	[profound conformational change]	0.0	3	1	1	1
66879	1710	inducible form a response	[inducible form a response]	0.0	4	1	1	1
66880	1710	factor-kappa b by lipoprotein	[factor-kappa B by lipoprotein]	0.0	4	1	1	1
66881	1710	12-lipoxygenase activity than cell	[12-lipoxygenase activity than cells]	0.0	4	1	1	1
66882	1710	-dq beta	[-DQ beta]	0.0	2	1	1	1
66883	1710	proximity at position 61	[proximity at position 61]	0.0	4	1	1	1
66884	1710	tax transactivation	[Tax transactivation]	0.0	2	1	1	1
66885	1710	replication T-tropic isolate	[replication T-tropic isolate]	0.0	3	1	1	1
66886	1710	promoter region with respect	[promoter region with respect]	0.0	4	1	1	1
66887	1710	tyrosine kinase lck	[tyrosine kinases lck]	0.0	3	1	1	1
66888	1710	none to slightly on basal cell	[none to slightly on basal cells]	0.0	6	1	1	1
66889	1710	antipeptide	[antipeptide]	0.0	1	1	1	1
66890	1710	major histocompatibility class molecule	[major histocompatibility class molecules]	0.0	4	1	1	1
66891	1710	human fibronectin receptor	[human fibronectin receptor]	0.0	3	1	1	1
66892	1710	hsp70 protein	[HSP70 protein]	0.0	2	1	1	1
66893	1710	formation of distinct mitogen-inducible complex	[formation of distinct mitogen-inducible complexes]	0.0	5	1	1	1
66894	1710	intense melanosis	[intense melanosis]	0.0	2	1	1	1
66895	1710	murine b-cell specific coactivator	[murine B-cell specific coactivator]	0.0	4	1	1	1
66896	1710	target cell sensitization	[target cell sensitization]	0.0	3	1	1	1
66897	1710	remission of the preleukemic state	[remissions of the preleukemic state]	0.0	5	1	1	1
66898	1710	constitutively produce p40	[constitutively producing p40]	0.0	3	1	1	1
66899	1710	lysis of cell	[lysis of cells]	0.0	3	1	1	1
66900	1710	"octamer" binding protein	["octamer" binding proteins]	0.0	3	1	1	1
66901	1710	transcription of gene encode	[transcription of genes encoding]	0.0	4	1	1	1
66902	1710	biochemical lesion with advance age	[biochemical lesions with advancing age]	0.0	5	1	1	1
66903	1710	such as c-myc	[such as c-myc]	0.0	3	1	1	1
66904	1710	combination cytokine	[combination cytokine]	0.0	2	1	1	1
66905	1710	novel kRAB-containing zinc finger gene	[novel KRAB-containing zinc finger genes]	0.0	5	1	1	1
66906	1710	mix study of cytosol	[mixing studies of cytosol]	0.0	4	1	1	1
66907	1710	modulation of nf-kappab	[modulation of NF-kappaB]	0.0	3	1	1	1
66908	1710	p 0.01, young vs. old)	[P 0.01, young vs. old)]	0.0	5	1	1	1
66909	1710	enhancement of the MRP14 promoter	[enhancement of the MRP14 promoter]	0.0	5	1	1	1
66910	1710	understanding of the regulation with emphasis	[understanding of the regulation with emphasis]	0.0	6	1	1	1
66911	1710	different concentration of ald	[different concentrations of ALD]	0.0	4	1	1	1
66912	1710	antigen-specific memory	[antigen-specific memory]	0.0	2	1	1	1
66913	1710	fragment extend nucleotide	[fragment extending nucleotides]	0.0	3	1	1	1
66914	1710	stress than peroxidation	[stress than peroxidation]	0.0	3	1	1	1
66915	1710	RB expression vector	[RB expression vectors]	0.0	3	1	1	1
66916	1710	stimulation protein	[Stimulation protein]	0.0	2	1	1	1
66917	1710	two nonsteroidal anti-inflammatory drug	[two nonsteroidal anti-inflammatory drugs]	0.0	4	1	1	1
66918	1710	genetic basis	[genetic basis]	0.0	2	1	1	1
66919	1710	mechanism of growth inhibition	[mechanisms of growth inhibition]	0.0	4	1	1	1
66920	1710	respect to phase	[respect to phases]	0.0	3	1	1	1
66921	1710	control patient	[control patients]	0.0	2	1	1	1
66922	1710	IFN induction of resistance	[IFN induction of resistance]	0.0	4	1	1	1
66923	1710	response to secondary infection	[response to secondary infections]	0.0	4	1	1	1
66924	1710	iv isoform	[IV isoforms]	0.0	2	1	1	1
66925	1710	gammadelta T	[gammadelta T]	0.0	2	1	1	1
66926	1710	BCL2 checkpoint	[BCL2 checkpoint]	0.0	2	1	1	1
66927	1710	pharmacological concentration to 10 &mgr;m)	[pharmacological concentrations to 10 &mgr;M)]	0.0	5	1	1	1
66928	1710	accumulation of cyclic AMP camp	[accumulation of cyclic AMP cAMP]	0.0	5	1	1	1
66929	1710	extract from RAW cell	[extracts from RAW cells]	0.0	4	1	1	1
66930	1710	blood mononuclear cell proliferation from patient	[blood mononuclear cell proliferation from patients]	0.0	6	1	1	1
66931	1710	function of the receptor	[function of the receptor]	0.0	4	1	1	1
66932	1710	cluster analysis of potential nfat element	[cluster analysis of potential NFAT elements]	0.0	6	1	1	1
66933	1710	TCR/CD3 complex	[TCR/CD3 complex]	0.0	2	1	1	1
66934	1710	two distinct mitogen-inducible complex	[two distinct mitogen-inducible complexes]	0.0	4	1	1	1
66935	1710	myelomonocytic cell specific gene	[myelomonocytic cell specific genes]	0.0	4	1	1	1
66936	1710	domain of il-7r alpha	[domains of IL-7R alpha]	0.0	4	1	1	1
66937	1710	C-terminal zinc-finger motif	[C-terminal zinc-finger motifs]	0.0	3	1	1	1
66938	1710	1 -induced, cell-T-cell syncytia	[1 -induced, cell-T-cell syncytia]	0.0	4	1	1	1
66939	1710	end result	[end result]	0.0	2	1	1	1
66940	1710	young (mean	[young (mean]	0.0	2	1	1	1
66941	1710	difference in pattern	[differences in patterns]	0.0	3	1	1	1
66942	1710	various stress agent	[Various stress agents]	0.0	3	1	1	1
66943	1710	kappa activity	[kappa activity]	0.0	2	1	1	1
66944	1710	survival of pbl	[survival of PBL]	0.0	3	1	1	1
66945	1710	+/- fmol	[+/- fmol]	0.0	2	1	1	1
66946	1710	implication for specificity	[implications for specificity]	0.0	3	1	1	1
66947	1710	tissue specific,	[tissue specific,]	0.0	2	1	1	1
66948	1710	activator function af-1	[activator functions AF-1]	0.0	3	1	1	1
66949	1710	point in the inflammatory response	[point in the inflammatory response]	0.0	5	1	1	1
66950	1710	level of trap	[levels of TRAP]	0.0	3	1	1	1
66951	1710	state of adrenal cortex	[state of adrenal cortex]	0.0	4	1	1	1
66952	1710	significance of mutation	[significance of mutations]	0.0	3	1	1	1
66953	1710	CREB/ATF family of transcription	[CREB/ATF family of transcription]	0.0	4	1	1	1
66954	1710	member of the jun/fo family	[members of the jun/fos family]	0.0	5	1	1	1
66955	1710	immune glomerulopathy glomerulonephritis	[immune glomerulopathy glomerulonephritis]	0.0	3	1	1	1
66956	1710	primary activation, with phytohemagglutinin	[primary activation, with phytohemagglutinin]	0.0	4	1	1	1
66957	1710	narrowing	[narrowing]	0.0	1	1	1	1
66958	1710	level of ca2+	[level of Ca2+]	0.0	3	1	1	1
66959	1710	lack of recognition	[Lack of recognition]	0.0	3	1	1	1
66960	1710	proviral latency in cell	[proviral latency in cells]	0.0	4	1	1	1
66961	1710	exposure to multiple signals,	[exposure to multiple signals,]	0.0	4	1	1	1
66962	1710	T enhancer 14 kb upstream	[T enhancer 14 kb upstream]	0.0	5	1	1	1
66963	1710	transfection of erythroleukemia cell	[transfection of erythroleukemia cells]	0.0	4	1	1	1
66964	1710	orf a tegument protein	[ORF an tegument protein]	0.0	4	1	1	1
66965	1710	binding to the LAL promoter	[binding to the LAL promoter]	0.0	5	1	1	1
66966	1710	direct percutaneous coronary angioplasty PTCA	[direct percutaneous coronary angioplasty PTCA]	0.0	5	1	1	1
66967	1710	clone of two line	[clones of two lines]	0.0	4	1	1	1
66968	1710	encode oct-binding factor a novel protein	[encoding Oct-binding factor a novel protein]	0.0	6	1	1	1
66969	1710	phosphatase mkp-1	[phosphatase MKP-1]	0.0	2	1	1	1
66970	1710	TNF-alpha localization	[TNF-alpha localization]	0.0	2	1	1	1
66971	1710	course of the disease	[course of the disease.]	0.0	4	1	1	1
66972	1710	decline in T cell	[decline in T cells]	0.0	4	1	1	1
66973	1710	disorder present in early infancy	[disorder presenting in early infancy]	0.0	5	1	1	1
66974	1710	induction of phase protein	[induction of phase proteins]	0.0	4	1	1	1
66975	1710	use a bind assay with [3H]dexamethasone	[using a binding assay with [3H]dexamethasone]	0.0	6	1	1	1
66976	1710	prointerleukin 1 beta gene	[prointerleukin 1 beta gene]	0.0	4	2	2	1
66977	1710	capacity of 8e51 cell	[capacity of 8e51 cells]	0.0	4	1	1	1
66978	1710	case of T cell leukemia/lymphoma	[cases of T cell leukemia/lymphoma]	0.0	5	1	1	1
66979	1710	indicate the important role	[indicating the important role]	0.0	4	1	1	1
66980	1710	potential application to the study	[potential application to the study]	0.0	5	1	1	1
66981	1710	EBV anti-Z Epstein-Barr activator zebra	[EBV anti-Z Epstein-Barr activator ZEBRA]	0.0	5	1	1	1
66982	1710	various fundamental processes,	[various fundamental processes,]	0.0	3	1	1	1
66983	1710	(3	[(3]	0.0	1	1	1	1
66984	1710	antibody Lt-4	[antibody Lt-4]	0.0	2	1	1	1
66985	1710	result in translocation	[resulting in translocation]	0.0	3	1	1	1
66986	1710	uptake with failure A-CRF	[uptake with failure A-CRF]	0.0	4	1	1	1
66987	1710	(B	[(B]	0.0	1	1	1	1
66988	1710	induction of rela(p65) during differentiation	[Induction of relA(p65) during differentiation]	0.0	5	1	1	1
66989	1710	marker of monocytic differentiation	[markers of monocytic differentiation]	0.0	4	1	1	1
66990	1710	stimulus notably bacterial product	[stimuli notably bacterial products]	0.0	4	1	1	1
66991	1710	(E	[(E]	0.0	1	1	1	1
66992	1710	high intracellular level	[high intracellular levels]	0.0	3	2	2	1
66993	1710	suggest a role for this region	[suggesting a role for this region]	0.0	6	1	1	1
66994	1710	estrogen induction	[Estrogen induction]	0.0	2	2	2	1
66995	1710	special culture condition and/or cytokine	[special cultures conditions and/or cytokine]	0.0	5	1	1	1
66996	1710	fmol/10(6) cell respectively,	[fmol/10(6) cells respectively,]	0.0	3	1	1	1
66997	1710	progression from infection	[progression from infection]	0.0	3	1	1	1
66998	1710	region ii -119	[region II -119]	0.0	3	1	1	1
66999	1710	interleukin-1 receptor synthesis	[interleukin-1 receptor synthesis]	0.0	3	1	1	1
67000	1710	important role in the expression	[important role in the expression]	0.0	5	1	1	1
67001	1710	only in patient	[only in patients]	0.0	3	1	1	1
67002	1710	down-regulation of ICAM-I	[down-regulation of ICAM-I]	0.0	3	1	1	1
67003	1710	unexpected observation with the previous finding	[unexpected observations with the previous findings]	0.0	6	1	1	1
67004	1710	feature of erythroid differentiation	[features of erythroid differentiation]	0.0	4	1	1	1
67005	1710	src gene family	[src gene family]	0.0	3	1	1	1
67006	1710	up-regulation of htr beta	[up-regulation of hTR beta]	0.0	4	1	1	1
67007	1710	use pkc NF-kappa b inhibitors, pentoxifylline	[using PKC NF-kappa B inhibitors, pentoxifylline]	0.0	6	1	1	1
67008	1710	patient allergic	[patients allergic]	0.0	2	1	1	1
67009	1710	monocyte binding to cell harc	[monocyte binding to cells HAECs]	0.0	5	1	1	1
67010	1710	regulation of th1 cytokine gene	[regulation of Th1 cytokine genes]	0.0	5	1	1	1
67011	1710	pan-1	[Pan-1]	0.0	1	1	1	1
67012	1710	negative modulator of LMP1 (1-231)-mediated	[negative modulator of LMP1 (1-231)-mediated]	0.0	5	1	1	1
67013	1710	insensitivity with expression	[insensitivity with expression]	0.0	3	1	1	1
67014	1710	competition with gene	[competition with genes]	0.0	3	1	1	1
67015	1710	variation in expression	[variation in expression]	0.0	3	1	1	1
67016	1710	two main activity i.e. transactivation	[two main activities i.e. transactivation]	0.0	5	1	1	1
67017	1710	factor binding site	[factor binding sites]	0.0	3	1	1	1
67018	1710	repeats), 66%	[repeats), 66%]	0.0	2	1	1	1
67019	1710	represent activation and/or differentiation stage	[representing activation and/or differentiation stages]	0.0	5	1	1	1
67020	1710	mouse pro-B cell line	[mouse pro-B cell lines]	0.0	4	1	1	1
67021	1710	cultivation	[cultivation]	0.0	1	1	1	1
67022	1710	lead to a protection	[leading to a protection]	0.0	4	1	1	1
67023	1710	(b) subunit	[(B) subunit]	0.0	2	1	1	1
67024	1710	cd20-cat	[CD20-CAT]	0.0	1	1	1	1
67025	1710	analysis of the rdna	[analysis of the cDNAs]	0.0	4	1	1	1
67026	1710	repression of the transcription factor gata-1	[repression of the transcription factor GATA-1]	0.0	6	1	1	1
67027	1710	negative respond element	[negative responding elements]	0.0	3	1	1	1
67028	1710	tissue from woman undergo elective termination	[Tissues from women undergoing elective termination]	0.0	6	1	1	1
67029	1710	sesquiterpene lactone from Arnica	[sesquiterpene lactone from Arnica]	0.0	4	1	1	1
67030	1710	38 b	[38 B]	0.0	2	1	1	1
67031	1710	5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8)	[5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8)]	0.0	4	1	1	1
67032	1710	factor nk-kappa b	[factors NK-kappa B]	0.0	3	1	1	1
67033	1710	low binding affinity RBA	[low binding affinities RBA]	0.0	4	1	1	1
67034	1710	differentiation-dependent receptor gamma ppargamma expression	[differentiation-dependent receptor gamma PPARgamma expression]	0.0	5	1	1	1
67035	1710	T lymphocyte cell line	[T lymphocyte cell line]	0.0	4	1	1	1
67036	1710	formation of the transactivate nuclear factor	[formation of the transactivating nuclear factor]	0.0	6	1	1	1
67037	1710	accessible cell model	[accessible cell model]	0.0	3	1	1	1
67038	1710	replication of the genome	[replication of the genome]	0.0	4	1	1	1
67039	1710	prolonged pressure-stretch strain	[prolonged pressure-stretching strain]	0.0	3	1	1	1
67040	1710	different combination of this transcription factor	[different combinations of these transcription factors]	0.0	6	1	1	1
67041	1710	successful production	[successful production]	0.0	2	1	1	1
67042	1710	repeats),	[repeats),]	0.0	1	1	1	1
67043	1710	successful immune response	[successful immune response]	0.0	3	1	1	1
67044	1710	recognition of self ligand	[recognition of self, ligands]	0.0	4	1	1	1
67045	1710	member of immediate gene	[members of immediate genes]	0.0	4	1	1	1
67046	1710	glucocorticoid therapy for disease	[glucocorticoid therapy for diseases]	0.0	4	1	1	1
67047	1710	hydroxyurea in human k562 cell	[hydroxyurea in human K562 cells]	0.0	5	1	1	1
67048	1710	status of current knowledge concern	[status of current knowledge concerning]	0.0	5	1	1	1
67049	1710	any, effect	[any, effect]	0.0	2	1	1	1
67050	1710	h in this cell	[h in these cells]	0.0	4	1	1	1
67051	1710	homologous gene encode scm-1alpha	[homologous genes encoding SCM-1alpha]	0.0	4	1	1	1
67052	1710	relationship between the variants,	[relationship between the variants,]	0.0	4	1	1	1
67053	1710	fasl gene activation	[FasL gene activation]	0.0	3	1	1	1
67054	1710	co-stimulatory agent	[co-stimulatory agent]	0.0	2	1	1	1
67055	1710	however, order potent than H 1285	[however, orders potent than H 1285]	0.0	6	1	1	1
67056	1710	position in the TCR	[position in the TCR]	0.0	4	1	1	1
67057	1710	acid-Schiff	[acid-Schiff]	0.0	1	1	1	1
67058	1710	parathyroid hormone-related protein pthrp promoter	[parathyroid hormone-related protein PTHrP promoter]	0.0	5	1	1	1
67059	1710	cyclin/cdk kinase complex	[cyclin/cdks kinase complexes]	0.0	3	1	1	1
67060	1710	-t	[-T]	0.0	1	1	1	1
67061	1710	A cya	[A CyA]	0.0	2	1	1	1
67062	1710	production of IgE	[production of IgE]	0.0	3	1	1	1
67063	1710	/I	[/I]	0.0	1	1	1	1
67064	1710	sensitive technique	[sensitive techniques]	0.0	2	1	1	1
67065	1710	linear DNA	[linear DNA]	0.0	2	1	1	1
67066	1710	0,	[0,]	0.0	1	1	1	1
67067	1710	clinical gene therapy trials,	[clinical gene therapy trials,]	0.0	4	1	1	1
67068	1710	dose of lps ng/ml)	[dose of LPS ng/ml)]	0.0	4	1	1	1
67069	1710	25-dihydroxy	[25-dihydroxy]	0.0	1	1	1	1
67070	1710	level of gag p24	[levels of gag p24]	0.0	4	1	1	1
67071	1710	red blood cell hrbc	[red blood cells HRBC]	0.0	4	1	1	1
67072	1710	type of hematopoietic cell line	[types of hematopoietic cell lines]	0.0	5	1	1	1
67073	1710	evidence inflammatory mediator	[evidence inflammatory mediators]	0.0	3	1	1	1
67074	1710	retinoic acid during maturation	[retinoic acid during maturation]	0.0	4	1	1	1
67075	1710	immediate-early specific gene	[immediate-early specific genes]	0.0	3	1	1	1
67076	1710	intense staining in comedo	[intense staining in comedo]	0.0	4	1	1	1
67077	1710	evidence rate-limiting for human lymphocyte activation	[Evidence rate-limiting for human lymphocyte activation]	0.0	6	1	1	1
67078	1710	rhabdomyosarcoma leiomyosarcoma liposarcoma	[rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	3	1	1	1
67079	1710	/i	[/I]	0.0	1	3	3	1
67080	1710	thymus section	[thymus sections]	0.0	2	1	1	1
67081	1710	evidence for a sensitive pathway distinct	[evidence for an sensitive pathway distinct]	0.0	6	1	1	1
67082	1710	analysis of the cell origin	[analysis of the cell origin]	0.0	5	1	1	1
67083	1710	10 patient with affinity to glucocorticoid	[10 patients with affinity to glucocorticoids]	0.0	6	1	1	1
67084	1710	property of HIV-TF1	[properties of HIV-TF1]	0.0	3	1	1	1
67085	1710	gene include interferon factor	[genes including interferon factor]	0.0	4	1	1	1
67086	1710	factor-kappaB a activator	[factor-kappaB a activator]	0.0	3	1	1	1
67087	1710	c5b-7 on target cell during inflammation	[C5b-7 on target cells during inflammation]	0.0	6	1	1	1
67088	1710	subsequent adhesion in tnf-treated vein cell	[subsequent adhesion in TNF-treated vein cells]	0.0	6	1	1	1
67089	1710	statistically significant difference	[statistically significant difference]	0.0	3	1	1	1
67090	1710	obvious merit in long	[obvious merit in long-term]	0.0	4	1	1	1
67091	1710	importance of BCL2	[importance of BCL2]	0.0	3	1	1	1
67092	1710	patient with CLL express er	[patients with CLL express ER]	0.0	5	1	1	1
67093	1710	E1A susceptibility	[E1A susceptibility]	0.0	2	1	1	1
67094	1710	il-2 tyrosine phosphorylation	[IL-2 tyrosine phosphorylation]	0.0	3	1	1	1
67095	1710	identity to gene product	[identity to gene products]	0.0	4	1	1	1
67096	1710	activation of this reporter	[activation of this reporter]	0.0	4	1	1	1
67097	1710	xenograft rejection	[xenograft rejection]	0.0	2	1	1	1
67098	1710	hormone-inducible protein in transfection	[hormone-inducible proteins in transfection]	0.0	4	1	1	1
67099	1710	blood urea	[blood urea]	0.0	2	1	1	1
67100	1710	2B	[2B]	0.0	1	1	1	1
67101	1710	tcp 72 h),	[TCP 72 h),]	0.0	3	1	1	1
67102	1710	differentiative activity	[differentiative activities]	0.0	2	1	1	1
67103	1710	1h	[1H]	0.0	1	1	1	1
67104	1710	involve genetic alteration	[involving genetic alterations]	0.0	3	1	1	1
67105	1710	fold increase of c-fo expression	[fold increase of c-fos expression]	0.0	5	1	1	1
67106	1710	activation in natural killer cell	[Activation in natural killer cells]	0.0	5	1	1	1
67107	1710	92-kda protein in normal monocyte	[92-kDa protein in normal monocytes]	0.0	5	1	1	1
67108	1710	exposure with il-4	[exposure with IL-4]	0.0	3	1	1	1
67109	1710	monoclonal origin,	[monoclonal origin,]	0.0	2	1	1	1
67110	1710	stimulation in control	[stimulation in controls]	0.0	3	1	1	1
67111	1710	cotransfection with a combination	[cotransfection with a combination]	0.0	4	1	1	1
67112	1710	usf-related transcription	[USF-related transcription]	0.0	2	1	1	1
67113	1710	transient cotransfection in sense orientation together	[Transient cotransfection in sense orientation together]	0.0	6	1	1	1
67114	1710	model of lineage	[Models of lineage]	0.0	3	1	1	1
67115	1710	protein during human hematopoiesis	[proteins during human hematopoiesis]	0.0	4	1	1	1
67116	1710	GM-CSF blood polymorphonuclear leukocyte pmn activation	[GM-CSF blood polymorphonuclear leukocytes PMN activation]	0.0	6	1	1	1
67117	1710	number of sequence	[number of sequences]	0.0	3	1	1	1
67118	1710	inhibition of NFAT gene expression	[inhibition of NFAT gene expression]	0.0	5	1	1	1
67119	1710	Coxriber J.Leahy,	[Cox, J.Leahy,]	0.0	2	1	1	1
67120	1710	signal in vivo modulation	[signal in vivo modulation]	0.0	4	1	1	1
67121	1710	fas ligand on cytotoxic lymphocyte	[Fas ligand on cytotoxic lymphocytes]	0.0	5	1	1	1
67122	1710	component of each complex	[components of each complexes]	0.0	4	1	1	1
67123	1710	low level of IFN a constitutively,	[low levels of IFN A constitutively,]	0.0	6	1	1	1
67124	1710	activity in transgenic mouse	[activity in transgenic mice]	0.0	4	1	1	1
67125	1710	immediate-early gene include interleukin-2 IL-2	[immediate-early genes including interleukin-2 IL-2]	0.0	5	1	1	1
67126	1710	study: lymphocyte from pregnant woman	[STUDY: lymphocytes from pregnant women]	0.0	5	1	1	1
67127	1710	nf-at binding activity	[NF-AT binding activity]	0.0	3	1	1	1
67128	1710	identification of two regulatory element	[Identification of two regulatory elements]	0.0	5	1	1	1
67129	1710	immediate-early protein bzlf1	[immediate-early protein BZLF1]	0.0	3	1	1	1
67130	1710	350 kb	[350 kb]	0.0	2	1	1	1
67131	1710	dose result p50 on tissue oligonucleotide	[doses resulting p50 on tissue oligonucleotide]	0.0	6	1	1	1
67132	1710	Furthermore, S9a	[Furthermore, S9a]	0.0	2	1	1	1
67133	1710	NH2 terminus	[NH2 terminus]	0.0	2	1	1	1
67134	1710	phenotype in a spectrum	[phenotypes in a spectrum]	0.0	4	1	1	1
67135	1710	a/r cell	[A/R cells]	0.0	2	1	1	1
67136	1710	yeast cell resistant	[yeast cells resistant]	0.0	3	1	1	1
67137	1710	primary syndrome MDS in stage	[primary syndromes MDS in stage]	0.0	5	1	1	1
67138	1710	implicate this region	[implicating this region]	0.0	3	1	1	1
67139	1710	severe immunodeficiency x-scid	[severe immunodeficiency X-SCID]	0.0	3	1	1	1
67140	1710	il-1- function	[IL-1- function]	0.0	2	1	1	1
67141	1710	MZF-1 transcriptional regulation	[MZF-1 transcriptional regulation]	0.0	3	1	1	1
67142	1710	HLA class molecule	[HLA class molecules]	0.0	3	1	1	1
67143	1710	3 month of therapy	[3 months of therapy]	0.0	4	1	1	1
67144	1710	functional role of PML	[functional role of PML]	0.0	4	1	1	1
67145	1710	woman (11 second	[women (11 second]	0.0	3	1	1	1
67146	1710	5a	[5a]	0.0	1	1	1	1
67147	1710	early commitment step	[earliest commitment step]	0.0	3	1	1	1
67148	1710	use of the Oct2a Oct2b isoform	[use of the Oct2a Oct2b isoforms]	0.0	6	1	1	1
67149	1710	effect on the development of endometriosis	[effects on the development of endometriosis]	0.0	6	1	1	1
67150	1710	novel, proteasome	[novel, proteasome]	0.0	2	1	1	1
67151	1710	kilometer tax1 antigen	[kd tax1 antigen]	0.0	3	1	1	1
67152	1710	5s	[5S]	0.0	1	1	1	1
67153	1710	Nuclear factor kappa b heterodimer	[Nuclear factor kappa B heterodimer]	0.0	5	1	1	1
67154	1710	hypothesis for the etiology	[hypothesis for the etiology]	0.0	4	1	1	1
67155	1710	potent oncogene,	[potent oncogene,]	0.0	2	1	1	1
67156	1710	DNA binding of the coactivator oca-b	[DNA binding of the coactivator OCA-B]	0.0	6	1	1	1
67157	1710	contain consensus c/ebp site	[containing consensus C/EBP sites]	0.0	4	1	1	1
67158	1710	evidence key mediator	[evidence key mediators]	0.0	3	1	1	1
67159	1710	death domain another member	[death domain Another member]	0.0	4	1	1	1
67160	1710	differentiation in the cell line k562	[differentiation in the cell line K562]	0.0	6	1	1	1
67161	1710	almost complete tolerance of mouse	[almost complete tolerance of mice]	0.0	5	1	1	1
67162	1710	use in cardiac transplant medicine	[use in cardiac transplant medicine]	0.0	5	1	1	1
67163	1710	alteration in affinity between ligand	[alteration in affinity between ligand]	0.0	5	1	1	1
67164	1710	involvement of the receptor	[involvement of the receptor]	0.0	4	1	1	1
67165	1710	factor eklf	[factor EKLF]	0.0	2	1	1	1
67166	1710	eightfold amount of nf-at a member	[eightfold amounts of NF-AT a member]	0.0	6	1	1	1
67167	1710	kappab DNA	[kappaB DNA]	0.0	2	1	1	1
67168	1710	marker for activation, differentiation,	[markers for activation, differentiation,]	0.0	4	1	1	1
67169	1710	antioxidant pyrrolidine dithiocarbarmate	[antioxidant pyrrolidine dithiocarbarmate]	0.0	3	1	1	1
67170	1710	exposure of Jurkat cell	[exposure of Jurkat cells]	0.0	4	1	1	1
67171	1710	flow cytometry analysis,	[flow cytometry analysis,]	0.0	3	1	1	1
67172	1710	regulatory loop	[regulatory loop]	0.0	2	1	1	1
67173	1710	also no correlation of the level	[Also no correlations of the levels]	0.0	6	1	1	1
67174	1710	activation 1 gene transcription	[Activation 1 gene transcription]	0.0	4	1	1	1
67175	1710	swi3 protein	[SWI3 protein]	0.0	2	1	1	1
67176	1710	fresh BL case	[fresh BL case]	0.0	3	1	1	1
67177	1710	promoter for B-cell marker	[promoters for B-cell markers]	0.0	4	1	1	1
67178	1710	down-regulation of granzyme b expression	[Down-regulation of granzyme B expression]	0.0	5	1	1	1
67179	1710	association in NF-kappa b moiety	[Association in NF-kappa B moieties]	0.0	5	1	1	1
67180	1710	t-cell effect together	[T-cell effects together]	0.0	3	1	1	1
67181	1710	immunoglobulin light-chain enhancer	[immunoglobulin light-chain enhancer]	0.0	3	1	1	1
67182	1710	cd4+ th cell	[CD4+ Th cells]	0.0	3	1	1	1
67183	1710	cd23 of epsilon transcript	[CD23 of epsilon transcripts]	0.0	4	1	1	1
67184	1710	factor contain c-rel-like protein	[factor containing c-Rel-like proteins]	0.0	4	1	1	1
67185	1710	thus, aberration	[Thus, aberrations]	0.0	2	1	1	1
67186	1710	apc for vzv peptide after immunization.	[APC for VZV peptides after immunization.]	0.0	6	1	1	1
67187	1710	17 kb	[17 kb]	0.0	2	1	1	1
67188	1710	Schizosaccharomyces	[Schizosaccharomyces]	0.0	1	1	1	1
67189	1710	more glucocorticoid	[more glucocorticoids]	0.0	2	1	1	1
67190	1710	respiratory distress syndrome ARDS	[respiratory distress syndrome ARDS]	0.0	4	1	1	1
67191	1710	vitamin d3-responsive element	[vitamin D3-responsive element]	0.0	3	1	1	1
67192	1710	delicate balance between regulatory mechanism	[delicate balance between regulatory mechanisms]	0.0	5	1	1	1
67193	1710	Monoallelic expression a paradigm	[Monoallelic expression a paradigm]	0.0	4	1	1	1
67194	1710	JAK3 immunodeficiency lymphocyte	[JAK3 immunodeficiency lymphocytes]	0.0	3	1	1	1
67195	1710	new homeobox gene	[new homeobox gene]	0.0	3	1	1	1
67196	1710	contrast, development	[contrast, development]	0.0	2	1	1	1
67197	1710	property of killer	[properties of killer]	0.0	3	1	1	1
67198	1710	function infiltrate cd4-bearing T cell	[functions infiltrating CD4-bearing T cells]	0.0	5	1	1	1
67199	1710	role in vertebrate regulation	[role in vertebrate regulation]	0.0	4	1	1	1
67200	1710	rhythm of hepatic gr	[rhythm of hepatic GR]	0.0	4	1	1	1
67201	1710	cover the 491-amino-acid sequence of ie-1	[covering the 491-amino-acid sequence of IE-1]	0.0	6	1	1	1
67202	1710	lymphocyte predominance subtype NLPHD	[lymphocyte predominance subtype NLPHD]	0.0	4	1	1	1
67203	1710	96 -chaperoned peptide	[96 -chaperoned peptides]	0.0	3	1	1	1
67204	1710	Study during aging: evidence	[Studies during aging: evidence]	0.0	4	1	1	1
67205	1710	ratio of reduced:oxidized glutathione	[ratio of reduced:oxidized glutathione]	0.0	4	1	1	1
67206	1710	leukemic cell infiltration	[leukemic cell infiltration]	0.0	3	1	1	1
67207	1710	potential role of the anaphylatoxin	[potential role of the anaphylatoxins]	0.0	5	1	1	1
67208	1710	indicate a pattern of GRbeta activity	[indicating a pattern of GRbeta activity]	0.0	6	1	1	1
67209	1710	sk-n-be(2) cell protein kinase c	[SK-N-Be(2) cells protein kinase C]	0.0	5	1	1	1
67210	1710	bp upstream of the gata-binding site	[bp upstream of the GATA-binding site]	0.0	6	1	1	1
67211	1710	prolonged degradation of ikappab-alpha	[prolonged degradation of IkappaB-alpha]	0.0	4	1	1	1
67212	1710	1 receptor il-1r	[1 receptor IL-1R]	0.0	3	1	1	1
67213	1710	transfection assay with egr-1 promoter fragment	[transfection assays with EGR-1 promoter fragments]	0.0	6	1	1	1
67214	1710	promyelocytic leukemia (apl) cell	[promyelocytic leukemia (APL) cells]	0.0	4	2	2	1
67215	1710	expression of the transrepressive activity	[expression of the transrepressive activity]	0.0	5	1	1	1
67216	1710	t-cell line with rearrangement	[T-cell lines with rearrangements]	0.0	4	1	1	1
67217	1710	dl312 virus	[dl312 virus]	0.0	2	1	1	1
67218	1710	failure of the mutant endotoxin	[failure of the mutant endotoxin]	0.0	5	1	1	1
67219	1710	human prostatic cell	[Human prostatic cells]	0.0	3	1	1	1
67220	1710	early findings.	[earlier findings.]	0.0	2	1	1	1
67221	1710	threshold concentration	[threshold concentration]	0.0	2	1	1	1
67222	1710	functional receptor.	[functional receptor.]	0.0	2	1	1	1
67223	1710	patient with promyelocytic leukaemia	[patient with promyelocytic leukaemia]	0.0	4	1	1	1
67224	1710	treatment of Jurkat cell	[Treatment of Jurkat cells]	0.0	4	1	1	1
67225	1710	autopsy tissue	[autopsy tissues]	0.0	2	1	1	1
67226	1710	inhibition of nf-kappa b mobilization	[inhibition of NF-kappa B mobilization]	0.0	5	1	1	1
67227	1710	tf gene in cell	[TF gene in cells]	0.0	4	1	1	1
67228	1710	expression bzlf1 transactivator protein in leukoplakia	[expression BZLF1 transactivator protein in leukoplakia]	0.0	6	1	1	1
67229	1710	substantial proportion of subject	[substantial proportion of subjects]	0.0	4	1	1	1
67230	1710	(i.e. growth	[(i.e. growth]	0.0	2	1	1	1
67231	1710	results: incubation of whole blood	[RESULTS: Incubation of whole blood]	0.0	5	1	1	1
67232	1710	E1A induction of cellular susceptibility	[E1A induction of cellular susceptibility]	0.0	5	1	1	1
67233	1710	kd nmol/L) versus 8.9+/-1.2 nmol/L)	[Kd nmol/L) versus 8.9+/-1.2 nmol/L)]	0.0	5	1	1	1
67234	1710	distinct element act independently	[distinct elements acting independently]	0.0	4	1	1	1
67235	1710	implication for therapy of hematopoietic tumor	[implications for therapy of hematopoietic tumors]	0.0	6	1	1	1
67236	1710	include epithelia	[including epithelia]	0.0	2	1	1	1
67237	1710	full-length gag/pol	[full-length gag/pol]	0.0	2	1	1	1
67238	1710	negative transgenic mouse	[negative transgenic mice]	0.0	3	1	1	1
67239	1710	(succinimide)	[(succinimide)]	0.0	1	1	1	1
67240	1710	phenomenon of costimulation	[phenomenon of costimulation]	0.0	3	1	1	1
67241	1710	acid treatment of the U937 cell	[acid treatment of the U937 cells]	0.0	6	1	1	1
67242	1710	BSAP a regulator	[BSAP a regulator]	0.0	3	1	1	1
67243	1710	use pd-98059 two inhibitor	[using PD-98059 two inhibitors]	0.0	4	1	1	1
67244	1710	bacterial endotoxin Escherichia coli lps micrograms/kg).	[bacterial endotoxin Escherichia coli LPS micrograms/kg).]	0.0	6	1	1	1
67245	1710	Finally, CD40 ligation	[Finally, CD40 ligation]	0.0	3	1	1	1
67246	1710	gene characteristic	[genes characteristic]	0.0	2	1	1	1
67247	1710	ligation of fas	[Ligation of Fas]	0.0	3	1	1	1
67248	1710	c-fo c-jun p39c-jun gene	[c-fos c-jun p39c-jun genes]	0.0	4	1	1	1
67249	1710	treatment with concentration	[treatments with concentrations]	0.0	3	1	1	1
67250	1710	various activators, include J2	[various activators, including J2]	0.0	4	1	1	1
67251	1710	patient in short-term (st;	[patients in short-term (ST;]	0.0	4	1	1	1
67252	1710	t-lymphocyte from VZV immune donor	[T-lymphocytes from VZV immune donors]	0.0	5	1	1	1
67253	1710	subset of b lymphocytes.	[subset of B lymphocytes.]	0.0	4	1	1	1
67254	1710	hmd similar to bacterial lipopolysaccharide	[HMDS similar to bacterial lipopolysaccharide]	0.0	5	1	1	1
67255	1710	mechanism of bind affinity	[mechanism of binding affinity]	0.0	4	1	1	1
67256	1710	six antigen EBNA	[six antigens EBNA]	0.0	3	1	1	1
67257	1710	white pulp	[white pulp]	0.0	2	1	1	1
67258	1710	regulatory factor (irf) family	[regulatory factor (IRF) family]	0.0	4	1	1	1
67259	1710	level of xenobiotic response activity	[levels of xenobiotic response activity]	0.0	5	1	1	1
67260	1710	wild-type RXR	[wild-type RXR]	0.0	2	1	1	1
67261	1710	body temperature	[body temperature]	0.0	2	1	1	1
67262	1710	identify target for this transcription factors,	[identifying targets for these transcription factors,]	0.0	6	1	1	1
67263	1710	B)	[B)]	0.0	1	1	1	1
67264	1710	B,	[B,]	0.0	1	1	1	1
67265	1710	western blotting of hematopoietic population	[Western blotting of hematopoietic populations]	0.0	5	1	1	1
67266	1710	B/	[B/]	0.0	1	1	1	1
67267	1710	structurally related cation	[Structurally related cations]	0.0	3	1	1	1
67268	1710	jun/fo response gene expression	[jun/fos response gene expression]	0.0	4	1	1	1
67269	1710	AU	[AU]	0.0	1	1	1	1
67270	1710	patient with deficiency syndrome	[patients with deficiency syndromes]	0.0	4	1	1	1
67271	1710	genome-positive b cell by herpesvirus hhv-6	[genome-positive B cells by herpesvirus HHV-6]	0.0	6	1	1	1
67272	1710	agent, 1 alpha,25-dihydroxycholecalciferol dhcc	[agent, 1 alpha,25-dihydroxycholecalciferol DHCC]	0.0	4	1	1	1
67273	1710	promoter activation by CD40 ligand	[promoter activation by CD40 ligand]	0.0	5	1	1	1
67274	1710	model use mpl concentration	[model using MPL concentrations]	0.0	4	1	1	1
67275	1710	viral protein epitope	[viral protein epitopes]	0.0	3	1	1	1
67276	1710	paradigm for the haploinsufficiency	[paradigm for the haploinsufficiency]	0.0	4	1	1	1
67277	1710	leukaemia AML	[leukaemia AML]	0.0	2	1	1	1
67278	1710	expression by transformation	[expression by transformation]	0.0	3	1	1	1
67279	1710	3 gene expression	[3 gene expression]	0.0	3	1	1	1
67280	1710	remission CR	[remission CR]	0.0	2	1	1	1
67281	1710	element hsie	[element hSIE]	0.0	2	1	1	1
67282	1710	hd CHD	[HD CHD]	0.0	2	1	1	1
67283	1710	C7	[C7]	0.0	1	2	2	1
67284	1710	C;	[C;]	0.0	1	1	1	1
67285	1710	cd34+ cord	[CD34+ cord]	0.0	2	1	1	1
67286	1710	CD	[CD]	0.0	1	1	1	1
67287	1710	sulfate-polyacrylamide	[sulfate-polyacrylamide]	0.0	1	1	1	1
67288	1710	5669 binding site	[5669 binding sites]	0.0	3	1	1	1
67289	1710	circulate primary T cell	[circulating primary T cells]	0.0	4	1	1	1
67290	1710	differential nf-kappa b gene expression	[differential NF-kappa B gene expression]	0.0	5	1	1	1
67291	1710	CM	[CM]	0.0	1	1	1	1
67292	1710	differential accumulation	[differential accumulation]	0.0	2	1	1	1
67293	1710	D1	[D1]	0.0	1	1	1	1
67294	1710	wild-type level of gene expression	[wild-type levels of gene expression]	0.0	5	1	1	1
67295	1710	D2	[D2]	0.0	1	1	1	1
67296	1710	(6 wk RA	[(6 wk RA]	0.0	3	1	1	1
67297	1710	length of tnf-alpha promoter enhancer element	[lengths of TNF-alpha promoter enhancer elements]	0.0	6	1	1	1
67298	1710	use a panel of antisera	[Using a panel of antisera]	0.0	5	1	1	1
67299	1710	population t-cell killer population	[populations T-cell killer populations]	0.0	4	1	1	1
67300	1710	mechanism for trans-activation	[mechanism for trans-activation]	0.0	3	1	1	1
67301	1710	include hydroxyanisole	[including hydroxyanisole]	0.0	2	1	1	1
67302	1710	replication of immunodeficiency virus-1	[Replication of immunodeficiency virus-1]	0.0	4	1	1	1
67303	1710	gcrbeta -immunoreactive cell	[GCRbeta -immunoreactive cells]	0.0	3	1	1	1
67304	1710	DN	[DN]	0.0	1	1	1	1
67305	1710	b-cell-derived subtype	[B-cell-derived subtype]	0.0	2	1	1	1
67306	1710	nf-kappa b translocation result	[NF-kappa B translocation results]	0.0	4	1	1	1
67307	1710	functional nuclear factor kB element	[functional nuclear factor kB elements]	0.0	5	1	1	1
67308	1710	response to the stimulus	[response to the stimuli]	0.0	4	1	1	1
67309	1710	three-dimensional resonance spectroscopy	[three-dimensional resonance spectroscopy]	0.0	3	1	1	1
67310	1710	Addition of platelet	[Addition of platelets]	0.0	3	1	1	1
67311	1710	several cell-specific transcription factor	[several cell-specific transcription factors]	0.0	4	1	1	1
67312	1710	hsv-2 cd4+ antigen	[HSV-2 CD4+ antigens]	0.0	3	1	1	1
67313	1710	ca(2+) pathway alone	[Ca(2+) pathways alone]	0.0	3	1	1	1
67314	1710	tnf-alpha endothelial cell	[TNF-alpha endothelial cells]	0.0	3	1	1	1
67315	1710	adhesion to cell	[adhesion to cells]	0.0	3	1	1	1
67316	1710	role of all-tran acid atra	[role of all-trans acid ATRA]	0.0	5	1	1	1
67317	1710	(2.5 ng/mL), interleukin-3	[(2.5 ng/mL), interleukin-3]	0.0	3	1	1	1
67318	1710	ES	[ES]	0.0	1	1	1	1
67319	1710	content of vacuolar h+-atpase v-atpase	[content of vacuolar H+-ATPase V-ATPase]	0.0	5	1	1	1
67320	1710	hiv lymph node	[HIV lymph nodes]	0.0	3	1	1	1
67321	1710	loop length	[loop length]	0.0	2	1	1	1
67322	1710	fetal calf efcs clonogenic culture	[fetal calf (FCS+) clonogenic culture]	0.0	5	1	1	1
67323	1710	namely activator protein-1 ap-1 factor	[namely activator protein-1 AP-1 factor]	0.0	5	1	1	1
67324	1710	FI	[FI]	0.0	1	1	1	1
67325	1710	combination of transfection	[combination of transfection]	0.0	3	1	1	1
67326	1710	FK	[FK]	0.0	1	2	2	1
67327	1710	carbonic anhydrase ii caii	[carbonic anhydrase II CAII]	0.0	4	1	1	1
67328	1710	subsequent activation JAK stat signal pathway	[subsequent activation JAK STAT signaling pathway]	0.0	6	1	1	1
67329	1710	spastic paraparesis/ htlv-i myelopathy	[spastic paraparesis/ HTLV-I myelopathy]	0.0	4	1	1	1
67330	1710	differentiation to the lineage (with	[differentiation to the lineage (with]	0.0	5	1	1	1
67331	1710	GM	[GM]	0.0	1	1	1	1
67332	1710	binding in response to PMA	[binding in response to PMA]	0.0	5	1	1	1
67333	1710	four novel, sequence variant	[four novel, sequence variants]	0.0	4	1	1	1
67334	1710	c-fps/fe protooncogene	[c-fps/fes protooncogene]	0.0	2	1	1	1
67335	1710	translocation of factor	[translocation of factor]	0.0	3	1	1	1
67336	1710	hemopoietic progenitor to cell DC	[hemopoietic progenitors to cells DC]	0.0	5	1	1	1
67337	1710	anti-apoptotic effect on cd34+ cell	[anti-apoptotic effects on CD34+ cells]	0.0	5	1	1	1
67338	1710	corticosteroid receptor in mononuclear leukocyte	[corticosteroid receptors in mononuclear leukocytes]	0.0	5	1	1	1
67339	1710	increase during exposure	[increasing during exposure]	0.0	3	1	1	1
67340	1710	overcome cellular block	[overcoming cellular blocks]	0.0	3	1	1	1
67341	1710	synthesis of il-6 protein	[synthesis of IL-6 protein]	0.0	4	1	1	1
67342	1710	g0s2 expression by CsA	[G0S2 expression by CsA]	0.0	4	1	1	1
67343	1710	gm-csf growth	[GM-CSF growth]	0.0	2	1	1	1
67344	1710	I2	[I2]	0.0	1	1	1	1
67345	1710	blot analysis of mouse tissue	[blot analysis of mouse tissues]	0.0	5	1	1	1
67346	1710	AP1 binding site	[AP1 binding site]	0.0	3	1	1	1
67347	1710	cell type follow stable expression	[cell types following stable expression]	0.0	5	1	1	1
67348	1710	Gy	[Gy]	0.0	1	1	1	1
67349	1710	dose of budesonide bud	[doses of budesonide BUD]	0.0	4	1	1	1
67350	1710	recovery from lysate	[recovery from lysates]	0.0	3	1	1	1
67351	1710	immune reactivity of neonate	[immune reactivity of neonates]	0.0	4	1	1	1
67352	1710	31 kda in 12-o-tetradecanoyl-phorbol-13-acetate	[31 kDa in 12-O-tetradecanoyl-phorbol-13-acetate]	0.0	4	1	1	1
67353	1710	ligand for acid receptor rar	[ligands for acid receptors RARs]	0.0	5	1	1	1
67354	1710	receptor gamma chain	[receptor gamma chain]	0.0	3	1	1	1
67355	1710	cytokine production by human monocyte	[cytokine production by human monocytes]	0.0	5	1	1	1
67356	1710	768-bp region	[768-bp region]	0.0	2	1	1	1
67357	1710	J2	[J2]	0.0	1	1	1	1
67358	1710	constitutive expression of NF-kappaB/Rel family	[constitutive expression of NF-kappaB/Rel family]	0.0	5	1	1	1
67359	1710	suppress at least two pathway essential	[suppressing at least two pathways essential]	0.0	6	1	1	1
67360	1710	increase evidence key mediator	[increasing evidence key mediators]	0.0	4	1	1	1
67361	1710	clonogenic capacity	[clonogenic capacity]	0.0	2	1	1	1
67362	1710	HER-2/neu	[HER-2/neu]	0.0	1	1	1	1
67363	1710	various kind of hematopoietic cell	[various kinds of hematopoietic cells]	0.0	5	1	1	1
67364	1710	unit monocyte cfu-m	[unit monocyte CFU-M]	0.0	3	1	1	1
67365	1710	three experimental series:	[three experimental series:]	0.0	3	1	1	1
67366	1710	evaluate epithelium	[evaluating epithelium]	0.0	2	1	1	1
67367	1710	JN	[JN]	0.0	1	1	1	1
67368	1710	dose-dependent shift from erythroid	[dose-dependent shift from erythroid]	0.0	4	1	1	1
67369	1710	manner indistinguishable	[manner indistinguishable]	0.0	2	1	1	1
67370	1710	also NF-kappa b	[also NF-kappa B]	0.0	3	1	1	1
67371	1710	b series resistant cell	[B series resistant cells]	0.0	4	1	1	1
67372	1710	type ii receptor gcii	[type II receptor GCII]	0.0	4	1	1	1
67373	1710	genetic analysis of LTR mutation	[genetic analyses of LTR mutations]	0.0	5	1	1	1
67374	1710	e-box in MLV regulation	[E-boxes in MLV regulation]	0.0	4	1	1	1
67375	1710	protein in T cell	[proteins in T cells]	0.0	4	1	1	1
67376	1710	EBV anti-Z Epstein-Barr activator	[EBV anti-Z Epstein-Barr activator]	0.0	4	1	1	1
67377	1710	mm) in vitro,	[mM) in vitro,]	0.0	3	1	1	1
67378	1710	supramaximal dose	[supramaximal dose]	0.0	2	1	1	1
67379	1710	autoregulation by multiple inhibitor	[Autoregulation by multiple inhibitors]	0.0	4	1	1	1
67380	1710	spectrum of retroviruse	[spectrum of retroviruses]	0.0	3	1	1	1
67381	1710	expression of tax in CTLL-2	[expression of Tax in CTLL-2]	0.0	5	1	1	1
67382	1710	Separate Cox analysis for patient	[Separate Cox analysis for patients]	0.0	5	1	1	1
67383	1710	congenital defect in aspect	[congenital defects in aspects]	0.0	4	1	1	1
67384	1710	similar pattern in T cell	[similar pattern in T cells]	0.0	5	1	1	1
67385	1710	presence of a transcriptional element	[presence of a transcriptional element]	0.0	5	1	1	1
67386	1710	lineage (with phorbol ester	[lineage (with phorbol esters]	0.0	4	1	1	1
67387	1710	useful experimental system	[useful experimental system]	0.0	3	1	1	1
67388	1710	protein of the erythrocytic lineage	[protein of the erythrocytic lineage]	0.0	5	1	1	1
67389	1710	anabolic/catabolic balance	[anabolic/catabolic balance]	0.0	2	1	1	1
67390	1710	(gh3)	[(GH3)]	0.0	1	1	1	1
67391	1710	histiocytoma rhabdomyosarcoma leiomyosarcoma	[histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	3	1	1	1
67392	1710	AS oligonucleotide C-JUN as oligonucleotide	[AS oligonucleotides C-JUN AS oligonucleotides]	0.0	5	1	1	1
67393	1710	peripheral blood apparently healthy volunteer	[peripheral blood apparently healthy volunteers]	0.0	5	1	1	1
67394	1710	pebp2betamyh11	[PEBP2betaMYH11]	0.0	1	1	1	1
67395	1710	transcript of the type er	[transcripts of the type ER]	0.0	5	1	1	1
67396	1710	HTLV-I cord blood lymphocyte	[HTLV-I cord blood lymphocytes]	0.0	4	1	1	1
67397	1710	Ko	[Ko]	0.0	1	1	1	1
67398	1710	M2	[M2]	0.0	1	1	1	1
67399	1710	step for the inactivation	[steps for the inactivation]	0.0	4	1	1	1
67400	1710	M3	[M3]	0.0	1	1	1	1
67401	1710	M4	[M4]	0.0	1	1	1	1
67402	1710	nonatopic control subject ige	[nonatopic control subjects IgE]	0.0	4	1	1	1
67403	1710	rapid twofold increase from patient	[rapid twofold increase from patients]	0.0	5	1	1	1
67404	1710	Eighteen hirsute patient with mense	[Eighteen hirsute patients with menses]	0.0	5	1	1	1
67405	1710	fibroblast reveal a redundancy	[fibroblasts revealing an redundancy.]	0.0	4	1	1	1
67406	1710	LZ	[LZ]	0.0	1	1	1	1
67407	1710	follow pkc activation	[following PKC activation]	0.0	3	1	1	1
67408	1710	N,	[N,]	0.0	1	1	1	1
67409	1710	monocytic cell transcriptional induction of collagenase	[Monocytic cell transcriptional induction of collagenase]	0.0	6	1	1	1
67410	1710	regulate stat serine phosphorylation	[regulating STAT serine phosphorylation]	0.0	4	1	1	1
67411	1710	NFATx1 translocation	[NFATx1 translocation]	0.0	2	1	1	1
67412	1710	reduction for er gene	[reduction for ER gene]	0.0	4	1	1	1
67413	1710	interaction between human gata-1	[interaction between human GATA-1]	0.0	4	1	1	1
67414	1710	primary human NK cell	[primary human NK cells]	0.0	4	1	1	1
67415	1710	evidence of hypermutation	[evidence of hypermutation]	0.0	3	1	1	1
67416	1710	same nuclear protein	[same nuclear proteins]	0.0	3	1	1	1
67417	1710	(ic50 ng/ml)	[(IC50 ng/mL)]	0.0	2	1	1	1
67418	1710	role of c/ebp protein	[role of C/EBP proteins]	0.0	4	1	1	1
67419	1710	activation of the beta-globin promoter	[activation of the beta-globin promoter]	0.0	5	1	1	1
67420	1710	1 (hiv-1) infection	[1 (HIV-1) infection]	0.0	3	1	1	1
67421	1710	stimulation mono Mac	[Stimulation Mono Mac]	0.0	3	1	1	1
67422	1710	pattern of inheritance	[pattern of inheritance]	0.0	3	1	1	1
67423	1710	Mc	[Mc]	0.0	1	1	1	1
67424	1710	other protein of the cascade	[other proteins of the cascade]	0.0	5	1	1	1
67425	1710	mediator of activation	[mediator of activation]	0.0	3	1	1	1
67426	1710	induction protein 10 follow differentiation	[induction protein 10 following differentiation]	0.0	5	1	1	1
67427	1710	dominant negative mouse	[dominant negative mice]	0.0	3	1	1	1
67428	1710	ptk inhibitor herbimycin	[PTK inhibitor herbimycin]	0.0	3	1	1	1
67429	1710	ec epitope	[EC epitope]	0.0	2	1	1	1
67430	1710	allow activation of NF-kappa b	[allowing activation of NF-kappa B]	0.0	5	1	1	1
67431	1710	positive role for GATA-1	[positive role for GATA-1]	0.0	4	1	1	1
67432	1710	daily resistant sr	[daily resistant SR]	0.0	3	1	1	1
67433	1710	sequence (start at 532,	[sequences (starting at 532,]	0.0	4	1	1	1
67434	1710	nature of the measure	[nature of the measures]	0.0	4	1	1	1
67435	1710	three distinct transcription factor creb/atf	[three distinct transcription factors CREB/ATF]	0.0	5	1	1	1
67436	1710	c-jun signal	[c-jun signaling]	0.0	2	1	1	1
67437	1710	nuclear factor-kappaB translocation in lipopolysaccharide monocyte	[nuclear factor-kappaB translocation in lipopolysaccharide monocytes]	0.0	6	1	1	1
67438	1710	cortisol feedback	[cortisol feedback]	0.0	2	1	1	1
67439	1710	heterodimer nf-kappa b p50/p65	[heterodimer NF-kappa B p50/p65]	0.0	4	1	1	1
67440	1710	(hour 48)	[(hour 48)]	0.0	2	1	1	1
67441	1710	40-50% decrease	[40-50% decrease]	0.0	2	1	1	1
67442	1710	activate the transcription factor nfat factor	[activating the transcription factor NFAT factor]	0.0	6	1	1	1
67443	1710	detection of various intracellular signal protein	[Detection of various intracellular signaling proteins]	0.0	6	1	1	1
67444	1710	thymidine kinase reporter construct	[thymidine kinase reporter construct]	0.0	4	1	1	1
67445	1710	expression of STAT factor	[expression of STAT factor]	0.0	4	1	1	1
67446	1710	isotype-specific activator	[isotype-specific activator]	0.0	2	1	1	1
67447	1710	902 antibody	[902 antibody]	0.0	2	1	1	1
67448	1710	PI	[PI]	0.0	1	1	1	1
67449	1710	regulator nuclear factor-kappaB	[regulator nuclear factor-kappaB]	0.0	3	1	1	1
67450	1710	fetal thymocyte development after inhibition	[fetal thymocyte development after inhibition]	0.0	5	1	1	1
67451	1710	hormone condition	[hormone conditions]	0.0	2	1	1	1
67452	1710	range to 55 kd, result	[ranging to 55 kD, resulting]	0.0	5	1	1	1
67453	1710	tal1 activation in this patient	[TAL1 activation in these patients]	0.0	5	1	1	1
67454	1710	Subunit S6	[Subunit S6]	0.0	2	1	1	1
67455	1710	colony-stimulating factor colony-stimumulatelany-stg factor	[colony-stimulating factor colony-stimulating factor]	0.0	4	1	1	1
67456	1710	transition from latency	[transition from latency]	0.0	3	1	1	1
67457	1710	segment in Ag	[segments in Ag]	0.0	3	1	1	1
67458	1710	two other anti-inflammatory drug	[two other anti-inflammatory drugs]	0.0	4	1	1	1
67459	1710	degradation of the factor	[degradation of the factor]	0.0	4	1	1	1
67460	1710	myelomonocytic leukemia cmmol with eosinophilia	[myelomonocytic leukemia CMMoL with eosinophilia]	0.0	5	1	1	1
67461	1710	substance such as formylpeptide lps	[substances such as formylpeptides LPS]	0.0	5	1	1	1
67462	1710	encompass	[encompassing]	0.0	1	1	1	1
67463	1710	ifn-gamma to eosinophil	[IFN-gamma to eosinophils]	0.0	3	1	1	1
67464	1710	glucose toxicity	[glucose toxicity]	0.0	2	1	1	1
67465	1710	effect of corticosteroid	[effects of corticosteroids]	0.0	3	1	1	1
67466	1710	u-937 human cell	[U-937 human cells]	0.0	3	1	1	1
67467	1710	erythroid specific enhancer upstream	[erythroid specific enhancer upstream]	0.0	4	1	1	1
67468	1710	transcription factor nf-kappab regulation during obstruction	[Transcription factor NF-kappaB regulation during obstruction]	0.0	6	1	1	1
67469	1710	activity of this promoter	[activity of this promoter]	0.0	4	1	1	1
67470	1710	such as lps as stimuli.	[such as LPS as stimuli.]	0.0	5	1	1	1
67471	1710	effect of lps antibody	[effects of LPS antibodies]	0.0	4	1	1	1
67472	1710	include myeloid leukaemia	[including myeloid leukaemia]	0.0	3	2	2	1
67473	1710	nuclear stat6	[nuclear STAT6]	0.0	2	1	1	1
67474	1710	express t-cell leukemia virus type	[expressing T-cell leukemia virus type]	0.0	5	1	1	1
67475	1710	APL patient refractory	[APL patients refractory]	0.0	3	1	1	1
67476	1710	N-terminal serine	[N-terminal serines]	0.0	2	1	1	1
67477	1710	induction of hiv-1 gene expression	[Induction of HIV-1 gene expression]	0.0	5	1	1	1
67478	1710	low affinities.	[lower affinities.]	0.0	2	1	1	1
67479	1710	cytokine-stimulated saphenous vein cell	[cytokine-stimulated saphenous vein cells]	0.0	4	1	1	1
67480	1710	SD	[SD]	0.0	1	1	1	1
67481	1710	SF	[SF]	0.0	1	1	1	1
67482	1710	follow IL-2 stimulation	[following IL-2 stimulation]	0.0	3	1	1	1
67483	1710	SH	[SH]	0.0	1	1	1	1
67484	1710	change in membrane order	[change in membrane order]	0.0	4	1	1	1
67485	1710	function for the lineage	[function for the lineages]	0.0	4	1	1	1
67486	1710	generate a effective response	[generating an effective response]	0.0	4	1	1	1
67487	1710	immunodeficiency virus type 1 tat protein	[immunodeficiency virus type 1 Tat protein]	0.0	6	1	1	1
67488	1710	gradually accumulating, tyrosine	[gradually accumulating, tyrosine]	0.0	3	1	1	1
67489	1710	cho-cd86 stimulation.	[CHO-CD86 stimulation.]	0.0	2	1	1	1
67490	1710	human alphaiibbeta3	[human alphaIIbbeta3]	0.0	2	1	1	1
67491	1710	Paradoxical priming effect	[Paradoxical priming effects]	0.0	3	1	1	1
67492	1710	component of the activity	[component of the activity]	0.0	4	1	1	1
67493	1710	(0.1 nmol/L to mumol/L)	[(0.1 nmol/L to mumol/L)]	0.0	4	1	1	1
67494	1710	U.	[U.]	0.0	1	1	1	1
67495	1710	complex pu-sf	[complex PU-SF]	0.0	2	1	1	1
67496	1710	clearance of leukocyte by phagocyte	[clearance of leukocytes by phagocytes]	0.0	5	1	1	1
67497	1710	lipid-associated membrane protein	[lipid-associated membrane proteins]	0.0	3	1	1	1
67498	1710	steroid/thyroid hormone	[steroid/thyroid hormone]	0.0	2	1	1	1
67499	1710	FN action,	[FN action,]	0.0	2	1	1	1
67500	1710	two rdna with identity the sub-unit	[two cDNAs with identity the sub-unit]	0.0	6	1	1	1
67501	1710	However, combination	[However, combination]	0.0	2	1	1	1
67502	1710	related kinase	[related kinase]	0.0	2	1	1	1
67503	1710	J2 in human macrophage	[J2 in human macrophages]	0.0	4	1	1	1
67504	1710	anti-early antigen ea anti-viral antigen	[anti-early antigen EA anti-viral antigen]	0.0	5	1	1	1
67505	1710	-resistant variant	[-resistant variants]	0.0	2	1	1	1
67506	1710	isoforms, b	[isoforms, B]	0.0	2	1	1	1
67507	1710	stat in human T	[STATs in human T]	0.0	4	1	1	1
67508	1710	recombinant zebra protein	[recombinant ZEBRA protein]	0.0	3	1	1	1
67509	1710	first result	[first results]	0.0	2	2	2	1
67510	1710	receptor-mediated mechanism	[receptor-mediated mechanism]	0.0	2	1	1	1
67511	1710	cyclosporin nuclear factor-AT response element	[cyclosporin nuclear factor-AT response element]	0.0	5	1	1	1
67512	1710	sequence-specific dna-binding characteristic at low abundance	[sequence-specific DNA-binding characteristics at low abundance]	0.0	6	1	1	1
67513	1710	unchanged level	[unchanged level]	0.0	2	1	1	1
67514	1710	proinflammatory cytokine mrna expression in monocyte	[proinflammatory cytokine mRNA expression in monocytes]	0.0	6	1	1	1
67515	1710	W.	[W.]	0.0	1	1	1	1
67516	1710	endogenous peripheral function	[endogenous peripheral function]	0.0	3	1	1	1
67517	1710	one aspect	[One aspect]	0.0	2	1	1	1
67518	1710	response to the stimuli,	[response to the stimuli,]	0.0	4	1	1	1
67519	1710	syndrome MDS	[syndromes MDS]	0.0	2	1	1	1
67520	1710	A-T patient	[A-T patients]	0.0	2	1	1	1
67521	1710	evidence regard the role of macrophage	[evidence regarding the role of macrophages]	0.0	6	1	1	1
67522	1710	response to the stimuli.	[response to the stimuli.]	0.0	4	1	1	1
67523	1710	different hormone compound	[different hormone compounds]	0.0	3	1	1	1
67524	1710	potential role of I(kappa)B(alpha)	[potential role of I(kappa)B(alpha)]	0.0	4	1	1	1
67525	1710	receptors/cell; controls, +/-	[receptors/cell; controls, +/-]	0.0	3	1	1	1
67526	1710	redox equilibrium tend	[redox equilibrium tending]	0.0	3	1	1	1
67527	1710	5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation	[5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation]	0.0	5	1	1	1
67528	1710	3' xpb helicase	[3' XPB helicase]	0.0	3	1	1	1
67529	1710	killer cell activity in response	[killer cell activity in response]	0.0	5	1	1	1
67530	1710	inducible transcription factor site	[inducible transcription factor sites]	0.0	4	1	1	1
67531	1710	one component	[one component]	0.0	2	1	1	1
67532	1710	triangle uplngfr EGFP	[triangle upLNGFR EGFP]	0.0	3	1	1	1
67533	1710	cortisol patient	[cortisol patients]	0.0	2	1	1	1
67534	1710	effect on the transcriptional activation	[effect on the transcriptional activation]	0.0	5	1	1	1
67535	1710	factor kappa b activity	[factor kappa B activity]	0.0	4	1	1	1
67536	1710	initial evidence	[initial evidence]	0.0	2	1	1	1
67537	1710	il-4 transcription factor	[IL-4 transcription factor]	0.0	3	1	1	1
67538	1710	overexpression of p16	[overexpression of p16]	0.0	3	1	1	1
67539	1710	transcriptional regulator of cytokine genes,	[transcriptional regulators of cytokine genes,]	0.0	5	1	1	1
67540	1710	culture of mm cell	[culture of MM cells]	0.0	4	1	1	1
67541	1710	inducible degradation	[inducible degradation]	0.0	2	4	4	1
67542	1710	differentiation of haematopoietic cell	[differentiation of haematopoietic cells]	0.0	4	1	1	1
67543	1710	CONCLUSIONS: gcs of AITL/GC	[CONCLUSIONS: GCs of AITL/GC]	0.0	4	1	1	1
67544	1710	ii) of protein kinase	[II) of protein kinase]	0.0	4	1	1	1
67545	1710	t-cell-specific regulator	[T-cell-specific regulator]	0.0	2	1	1	1
67546	1710	role in, il-2	[role in, IL-2]	0.0	3	1	1	1
67547	1710	three natural gata element	[three natural GATA elements]	0.0	4	1	1	1
67548	1710	conservation.	[conservation.]	0.0	1	1	1	1
67549	1710	induction in human peripheral blood monocyte	[Induction in human peripheral blood monocytes]	0.0	6	1	1	1
67550	1710	high dose (more than mol/L)	[higher dose (more than mol/L)]	0.0	5	1	1	1
67551	1710	variation among the samples.	[variation among the samples.]	0.0	4	1	1	1
67552	1710	Xi	[Xi]	0.0	1	1	1	1
67553	1710	distal nuclear factor (NF)-AT AP-1/Octamer UPS	[distal nuclear factor (NF)-AT AP-1/Octamer UPS]	0.0	6	1	1	1
67554	1710	overexpression of gal4 -p65(286-551)-mediated transcription	[overexpression of GAL4 -p65(286-551)-mediated transcription]	0.0	5	1	1	1
67555	1710	analysis of mrna from ECs	[analysis of mRNA from ECs]	0.0	5	1	1	1
67556	1710	signal-dependent activation	[signal-dependent activation]	0.0	2	1	1	1
67557	1710	induction of the luciferase gene	[induction of the luciferase gene]	0.0	5	1	1	1
67558	1710	thrombospondin tsp	[thrombospondin TSP]	0.0	2	1	1	1
67559	1710	(five patient with microgram/day for month	[(five patients with microgram/day for month]	0.0	6	1	1	1
67560	1710	ongoing transcription	[ongoing transcription]	0.0	2	1	1	1
67561	1710	specific binding to response element	[specific binding to response element]	0.0	5	1	1	1
67562	1710	element in the immunodeficiency virus repeat	[elements in the immunodeficiency virus repeat]	0.0	6	1	1	1
67563	1710	significant decline in activity	[significant decline in activity]	0.0	4	1	1	1
67564	1710	atll cell	[ATLL cells]	0.0	2	2	2	1
67565	1710	constitutive activation of NF-kB in thymocyte	[Constitutive activation of NF-kB in thymocytes]	0.0	6	1	1	1
67566	1710	NF-kappaB reporter gene	[NF-kappaB reporter gene]	0.0	3	1	1	1
67567	1710	ebv b-lymphoblastoid cell line	[EBV B-lymphoblastoid cell lines]	0.0	4	1	1	1
67568	1710	/peptide density	[/peptide density]	0.0	2	1	1	1
67569	1710	examine in embryonic stem cell	[examining in embryonic stem cells]	0.0	5	1	1	1
67570	1710	three independent fusions.	[three independent fusions.]	0.0	3	1	1	1
67571	1710	human autosomal disease xeroderma pigmentosum	[human autosomal disease xeroderma pigmentosum]	0.0	5	1	1	1
67572	1710	transcription tyrosine phosphorylation	[transcription tyrosine phosphorylation]	0.0	3	1	1	1
67573	1710	strain of transgenic mouse	[strain of transgenic mice]	0.0	4	1	1	1
67574	1710	importance in t-cell activation	[importance in T-cell activation]	0.0	4	1	1	1
67575	1710	unicellular-unilineage erythropoietic culture molecular analysis	[Unicellular-unilineage erythropoietic cultures molecular analysis]	0.0	5	1	1	1
67576	1710	factor kappa B NF-kappaB site	[factor kappa B NF-kappaB site]	0.0	5	1	1	1
67577	1710	effect of catecholamine	[effects of catecholamine]	0.0	3	1	1	1
67578	1710	two immunosuppressive agent	[two immunosuppressive agents]	0.0	3	1	1	1
67579	1710	CD28 responsive element	[CD28 responsive element]	0.0	3	1	1	1
67580	1710	thromboxane receptor gene promoter/	[thromboxane receptor gene promoter/]	0.0	4	1	1	1
67581	1710	define a deletion hotspot	[defining a deletion hotspot]	0.0	4	1	1	1
67582	1710	mechanism of il-5 synthesis a study	[mechanisms of IL-5 synthesis a study]	0.0	6	1	1	1
67583	1710	culture of epithelial cell	[cultures of epithelial cells]	0.0	4	1	1	1
67584	1710	effect on the antiapoptotic property	[effect on the antiapoptotic property]	0.0	5	1	1	1
67585	1710	putative sex-determine gene	[putative sex-determining gene]	0.0	3	1	1	1
67586	1710	expression of the ah receptor gene	[expression of the Ah receptor gene]	0.0	6	1	1	1
67587	1710	translational regulation	[translational regulation]	0.0	2	1	1	1
67588	1710	low level alpha-naphthyl-acetate-esterase naf-r-nse	[low levels alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	4	1	1	1
67589	1710	bipartite dna-binding structure	[bipartite DNA-binding structure]	0.0	3	1	1	1
67590	1710	zymosan cell	[zymosan cells]	0.0	2	1	1	1
67591	1710	encode the hepatocyte factor HNF-1alpha	[encoding the hepatocyte factors HNF-1alpha]	0.0	5	1	1	1
67592	1710	intracellular accumulation	[intracellular accumulation]	0.0	2	2	2	1
67593	1710	treatment of t- lymphocyte	[treatment of T- lymphocytes]	0.0	4	1	1	1
67594	1710	feature of resistance to glucocorticoid	[features of resistance to glucocorticoids]	0.0	5	1	1	1
67595	1710	cd14 5'	[CD14 5']	0.0	2	1	1	1
67596	1710	166 female aged between 8	[166 females aged between 8]	0.0	5	1	1	1
67597	1710	large sequence in each	[larger sequences in each]	0.0	4	1	1	1
67598	1710	cell feature	[cell features]	0.0	2	1	1	1
67599	1710	receive 5-fluorouracil FUra	[receiving 5-fluorouracil FUra]	0.0	3	1	1	1
67600	1710	chromosomes,	[chromosomes,]	0.0	1	1	1	1
67601	1710	chromosomes.	[chromosomes.]	0.0	1	1	1	1
67602	1710	promoter methylation	[promoter methylation]	0.0	2	1	1	1
67603	1710	comparative sequence analysis of HS	[Comparative sequence analysis of HS]	0.0	5	1	1	1
67604	1710	e1a-binding protein other	[E1A-binding protein other]	0.0	3	1	1	1
67605	1710	nuclear vitamin d receptor	[nuclear vitamin D receptor]	0.0	4	1	1	1
67606	1710	full-length ciita construct	[full-length CIITA constructs]	0.0	3	1	1	1
67607	1710	physiologic significance	[physiologic significance]	0.0	2	1	1	1
67608	1710	ppargamma agonist	[PPARgamma agonists]	0.0	2	1	1	1
67609	1710	effect on other transcription factor	[effect on other transcription factors]	0.0	5	1	1	1
67610	1710	control group (4462	[control group (4462]	0.0	3	1	1	1
67611	1710	new function	[new functions]	0.0	2	1	1	1
67612	1710	nitric oxide a microbicidal pathway	[nitric oxide a microbicidal pathway]	0.0	5	1	1	1
67613	1710	land structure	[LANDs structures]	0.0	2	1	1	1
67614	1710	low molecular weight species	[lower molecular weight species]	0.0	4	1	1	1
67615	1710	nf-kappa b activity, p65 complex	[NF-kappa B activity, p65 complexes]	0.0	5	1	1	1
67616	1710	CD30 (tnf) receptor family,	[CD30 (TNF) receptor family,]	0.0	4	1	1	1
67617	1710	M47 mutation	[M47 mutation]	0.0	2	1	1	1
67618	1710	activation after CD40 trigger of monocyte	[Activation after CD40 triggering of monocytes]	0.0	6	1	1	1
67619	1710	often converge in pathway	[often converging in pathways]	0.0	4	1	1	1
67620	1710	include the CD34 promoter	[including the CD34 promoter]	0.0	4	1	1	1
67621	1710	a4	[A4]	0.0	1	1	1	1
67622	1710	cotransfection of JAK3 with IL-4 stat	[Cotransfection of JAK3 with IL-4 Stat]	0.0	6	1	1	1
67623	1710	role in human monocyte	[roles in human monocytes]	0.0	4	1	1	1
67624	1710	normal blood pb DC	[normal blood PB DC]	0.0	4	1	1	1
67625	1710	signal mediator in human cell	[signaling mediators in human cells]	0.0	5	1	1	1
67626	1710	case with a reaction	[case with a reaction]	0.0	4	1	1	1
67627	1710	ap-1 reporter construct	[AP-1 reporter constructs]	0.0	3	1	1	1
67628	1710	almost complete inhibition	[almost complete inhibition]	0.0	3	1	1	1
67629	1710	simultaneous exposure together with il-4	[simultaneous exposure together with IL-4]	0.0	5	1	1	1
67630	1710	relevant interaction	[relevant interaction]	0.0	2	1	1	1
67631	1710	b/	[B/]	0.0	1	1	1	1
67632	1710	induction of a t-cell response	[induction of a T-cell response]	0.0	5	1	1	1
67633	1710	bicycle ergometer)	[bicycle ergometer)]	0.0	2	1	1	1
67634	1710	leukemia cell line reh	[leukemia cell line REH]	0.0	4	1	1	1
67635	1710	expression of the IL-4 gene,	[expression of the IL-4 gene,]	0.0	5	1	1	1
67636	1710	human U2 rna(snrna)-encoding gene	[human U2 RNA(snRNA)-encoding gene]	0.0	4	1	1	1
67637	1710	A1 constitutive protein	[A1 constitutive proteins]	0.0	3	1	1	1
67638	1710	bq cytotoxicity	[BQ cytotoxicity]	0.0	2	1	1	1
67639	1710	one form of BLS	[one form of BLS]	0.0	4	1	1	1
67640	1710	millileter at 10:00 P;	[ml at 10:00 h;]	0.0	4	1	1	1
67641	1710	immunologic mediator	[immunologic mediator]	0.0	2	1	1	1
67642	1710	minutes) to acid washed,	[minutes) to acid washed,]	0.0	4	1	1	1
67643	1710	function in LTB4 adhesive interaction	[function in LTB4 adhesive interactions]	0.0	5	1	1	1
67644	1710	two reading frame orf of hhv-6	[two reading frames ORFs of HHV-6]	0.0	6	1	1	1
67645	1710	enhancer positive element	[enhancer positive element]	0.0	3	1	1	1
67646	1710	leukemia chimera	[leukemia chimera]	0.0	2	1	1	1
67647	1710	role of a downstream sequence	[role of a downstream sequence]	0.0	5	1	1	1
67648	1710	seven half-site for receptor/progesterone receptor binding	[seven half-sites for receptor/progesterone receptor binding]	0.0	6	1	1	1
67649	1710	asthma patient with expiratory volume	[asthma patients with expiratory volume]	0.0	5	1	1	1
67650	1710	phosphorylation of the sp1 protein	[phosphorylation of the Sp1 protein]	0.0	5	1	1	1
67651	1710	lymphocyte of healthy woman	[lymphocytes of healthy women]	0.0	4	1	1	1
67652	1710	cellular factor icp0	[cellular factor ICP0]	0.0	3	1	1	1
67653	1710	stage -specific expression	[stage -specific expression]	0.0	3	1	1	1
67654	1710	b-cell transcription	[B-cell transcription]	0.0	2	1	1	1
67655	1710	reverse-transcription pcr differential display	[reverse-transcription PCR differential display]	0.0	4	1	1	1
67656	1710	requirement provide one explanation	[requirement providing one explanation]	0.0	4	1	1	1
67657	1710	ch	[CH]	0.0	1	1	1	1
67658	1710	infiltration of tumor	[infiltration of tumor]	0.0	3	1	1	1
67659	1710	regulatory protein in eukaryote	[regulatory proteins in eukaryotes]	0.0	4	1	1	1
67660	1710	monoblast differentiation	[monoblast differentiation]	0.0	2	1	1	1
67661	1710	fraction of peripheral blood cell	[fraction of peripheral blood cells]	0.0	5	1	1	1
67662	1710	decrease from the membrane form	[decrease from the membrane forms]	0.0	5	1	1	1
67663	1710	water phorbol ester	[water phorbol esters]	0.0	3	1	1	1
67664	1710	cu	[Cu]	0.0	1	1	1	1
67665	1710	glucocorticoid-sensitive t-cell line 6tg1.1	[glucocorticoid-sensitive T-cell line 6TG1.1]	0.0	4	1	1	1
67666	1710	6-keto-PGF1	[6-keto-PGF1]	0.0	1	1	1	1
67667	1710	antigen presenting cell	[Antigen Presenting Cells]	0.0	3	1	1	1
67668	1710	interleukin-7 signal acute leukemia cell	[Interleukin-7 signaling acute leukemia cells]	0.0	5	1	1	1
67669	1710	induce tal-1 protein expression in tissue	[inducing tal-1 protein expression in tissues]	0.0	6	1	1	1
67670	1710	function of each	[function of each]	0.0	3	1	1	1
67671	1710	most interestingly, expression of cd95	[Most interestingly, expression of CD95]	0.0	5	1	1	1
67672	1710	vcam-1 adhesion molecule-1 promoter	[VCAM-1 adhesion molecule-1 promoters]	0.0	4	1	1	1
67673	1710	patient +/-	[patients +/-]	0.0	2	1	1	1
67674	1710	E2F dna-binding activity	[E2F DNA-binding activities]	0.0	3	1	1	1
67675	1710	f9	[F9]	0.0	1	1	1	1
67676	1710	molecular mediator of immunotoxicity	[molecular mediator of immunotoxicity]	0.0	4	1	1	1
67677	1710	Thus, p21ras regulation	[Thus, p21ras regulation]	0.0	3	1	1	1
67678	1710	indicate predominantly negative regulation	[indicating predominantly negative regulation]	0.0	4	1	1	1
67679	1710	pregerminal center	[pregerminal center]	0.0	2	1	1	1
67680	1710	bcl-6 in development	[BCL-6 in development]	0.0	3	1	1	1
67681	1710	em	[EM]	0.0	1	1	1	1
67682	1710	contrast, cd19 cross-linking	[contrast, CD19 cross-linking]	0.0	3	1	1	1
67683	1710	cell culture from 7 12	[cell cultures from 7 12]	0.0	5	1	1	1
67684	1710	activation of Stat 5b in progenitor	[Activation of Stat 5b in progenitors]	0.0	6	1	1	1
67685	1710	region contain repeat DR	[region containing repeats DR]	0.0	4	1	1	1
67686	1710	recloning	[recloning]	0.0	1	1	1	1
67687	1710	treatment with a concentration	[Treatment with an concentration]	0.0	4	1	1	1
67688	1710	proliferator-activated receptor ppar	[proliferator-activated receptor PPAR]	0.0	3	1	1	1
67689	1710	Hodgkin' disease marker	[Hodgkin's disease marker]	0.0	3	1	1	1
67690	1710	gE	[gE]	0.0	1	1	1	1
67691	1710	h)	[h)]	0.0	1	2	2	1
67692	1710	fh	[FH]	0.0	1	1	1	1
67693	1710	enhancer sequence for stat5	[enhancer sequences for STAT5]	0.0	4	1	1	1
67694	1710	h,	[Z,]	0.0	1	1	1	1
67695	1710	nuclear factor in function	[nuclear factors in functions]	0.0	4	1	1	1
67696	1710	fibrosarcoma 8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma 8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
67697	1710	cell tropic	[cell tropic]	0.0	2	1	1	1
67698	1710	fibrosarcoma malignant histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma malignant histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
67699	1710	fr	[FR]	0.0	1	1	1	1
67700	1710	h4	[H4]	0.0	1	2	2	1
67701	1710	reduction in hsp70 production	[reduction in hsp70 production]	0.0	4	1	1	1
67702	1710	serine-specific protein kinase	[serine-specific protein kinases]	0.0	3	1	1	1
67703	1710	study of G0S2	[studies of G0S2]	0.0	3	1	1	1
67704	1710	vitro, six nuclear antigen EBNAs	[vitro, six nuclear antigens EBNAs]	0.0	5	1	1	1
67705	1710	chromosomal translocation result in expression	[Chromosomal translocation resulting in expression]	0.0	5	1	1	1
67706	1710	combination of monoclonal reagent	[combination of monoclonal reagents]	0.0	4	1	1	1
67707	1710	gg	[GG]	0.0	1	1	1	1
67708	1710	multiple mutation cluster in the region	[multiple mutations clustering in the region]	0.0	6	1	1	1
67709	1710	restoration of content	[restoration of content]	0.0	3	1	1	1
67710	1710	go	[Go]	0.0	1	1	1	1
67711	1710	also no significant correlation	[Also no significant correlations]	0.0	4	1	1	1
67712	1710	regulation role of physical interaction	[Regulation role of physical interactions]	0.0	5	1	1	1
67713	1710	NF-kappa b transcriptional activator precursor	[NF-kappa B transcriptional activator precursor]	0.0	5	1	1	1
67714	1710	stimulation of lymphoid cell	[Stimulation of lymphoid cells]	0.0	4	1	1	1
67715	1710	regulate a b gene	[regulating a B gene]	0.0	4	1	1	1
67716	1710	cell lack receptor.	[cells lacking receptor.]	0.0	3	1	1	1
67717	1710	carotid artery	[carotid artery]	0.0	2	1	1	1
67718	1710	transfection with LMP1 expression vector	[transfection with LMP1 expression vector]	0.0	5	1	1	1
67719	1710	(also in umbilical arterial endothelial cell	[(also in umbilical arterial endothelial cells]	0.0	6	1	1	1
67720	1710	activity of activator protein-1	[activity of activator protein-1]	0.0	4	1	1	1
67721	1710	1.8 kilobasis	[1.8 kilobases]	0.0	2	1	1	1
67722	1710	intracellular messenger in c-fo	[intracellular messengers in c-Fos]	0.0	4	1	1	1
67723	1710	level of camp	[levels of cAMP]	0.0	3	1	1	1
67724	1710	status the role	[status the roles]	0.0	3	1	1	1
67725	1710	establish mnda expression	[establishing MNDA expression]	0.0	3	1	1	1
67726	1710	il	[ILs]	0.0	1	1	1	1
67727	1710	primate with resistance	[primates with resistance]	0.0	3	1	1	1
67728	1710	suppress gabp binding	[suppressing GABP binding]	0.0	3	1	1	1
67729	1710	human granulocyte/macrophage-colony factor gm-csf	[human granulocyte/macrophage-colony factor GM-CSF]	0.0	4	1	1	1
67730	1710	differentiate in response to retinoic acid	[differentiating in response to retinoic acid]	0.0	6	1	1	1
67731	1710	necessity for control	[necessity for control]	0.0	3	1	1	1
67732	1710	kB	[kB]	0.0	1	1	1	1
67733	1710	significant proliferation capacity in comparison	[significant proliferation capacity in comparison]	0.0	5	1	1	1
67734	1710	lps tf expression of monocyte	[LPS TF expression of monocytes]	0.0	5	1	1	1
67735	1710	GCR-beta cell than gc-sensitive asthmatics	[GCR-beta cells than GC-sensitive asthmatics]	0.0	5	1	1	1
67736	1710	however, alteration	[however, alterations]	0.0	2	1	1	1
67737	1710	New knowledge	[New knowledge]	0.0	2	1	1	1
67738	1710	characteristic of ef1	[characteristics of EF1]	0.0	3	1	1	1
67739	1710	interaction of CD2	[interaction of CD2]	0.0	3	1	1	1
67740	1710	healthy laboratory employees.	[healthy laboratory employees.]	0.0	3	1	1	1
67741	1710	major epitope	[major epitopes]	0.0	2	1	1	1
67742	1710	patient with wk RA	[patients with wk RA]	0.0	4	1	1	1
67743	1710	gene other	[genes other]	0.0	2	1	1	1
67744	1710	binding of [3h]dexamethasone	[binding of [3H]dexamethasone]	0.0	3	1	1	1
67745	1710	three membrane protein	[three membrane proteins]	0.0	3	1	1	1
67746	1710	positive selection antigen-driven expansion)	[positive selection antigen-driven expansion)]	0.0	4	1	1	1
67747	1710	vitro cleavage of p65	[vitro cleavage of p65]	0.0	4	1	1	1
67748	1710	+/- 11.0%).	[+/- 11.0%).]	0.0	2	1	1	1
67749	1710	stage specificities.	[stage specificities.]	0.0	2	1	1	1
67750	1710	role regulate il-4 transcription	[role regulating IL-4 transcription]	0.0	4	1	1	1
67751	1710	limbic brain structure	[limbic brain structure]	0.0	3	1	1	1
67752	1710	observation with the finding	[observations with the findings]	0.0	4	1	1	1
67753	1710	addition to generation	[addition to generation]	0.0	3	1	1	1
67754	1710	axillary lymph	[axillary lymph]	0.0	2	1	1	1
67755	1710	binding to tax -responsive element 1	[Binding to Tax -responsive element 1]	0.0	6	1	1	1
67756	1710	cell develop	[cells developing]	0.0	2	1	1	1
67757	1710	2 subject in two patient	[2 subjects in two patients]	0.0	5	1	1	1
67758	1710	assumptions,	[assumptions,]	0.0	1	1	1	1
67759	1710	il-6 during h	[IL-6 during h]	0.0	3	1	1	1
67760	1710	24 pregnant woman (11 second	[24 pregnant women (11 second]	0.0	5	1	1	1
67761	1710	activation of other gene	[activation of other genes]	0.0	4	1	1	1
67762	1710	b/rel nuclear activity	[B/Rel nuclear activity]	0.0	3	1	1	1
67763	1710	mucosa-associated tissue	[mucosa-associated tissue]	0.0	2	1	1	1
67764	1710	various genes,	[Various genes,]	0.0	2	1	1	1
67765	1710	strong expression occur	[strongest expression occurring]	0.0	3	1	1	1
67766	1710	mn	[Mn]	0.0	1	1	1	1
67767	1710	kinetic (high turnover) property identical	[kinetic (high turnover) properties identical]	0.0	5	1	1	1
67768	1710	transcription factor egr-1	[transcription factor egr-1]	0.0	3	1	1	1
67769	1710	Thus, NF-kappa B a activator	[Thus, NF-kappa B a activator]	0.0	5	1	1	1
67770	1710	non professional apc fibroblast	[non professional APCs fibroblasts]	0.0	4	1	1	1
67771	1710	fetal muscle	[fetal muscle]	0.0	2	1	1	1
67772	1710	stat complex in BCP-ALL cell	[STAT complexes in BCP-ALL cells]	0.0	5	1	1	1
67773	1710	(from hour 1	[(from hours 1]	0.0	3	1	1	1
67774	1710	mitochondrial potential delta	[Mitochondrial potential delta]	0.0	3	1	1	1
67775	1710	positive staining in the nuclei	[positive staining in the nuclei]	0.0	5	1	1	1
67776	1710	p,	[P,]	0.0	1	1	1	1
67777	1710	role of degradation	[role of degradation]	0.0	3	1	1	1
67778	1710	immunomodulatory role	[immunomodulatory role]	0.0	2	1	1	1
67779	1710	bovine artery cell	[bovine artery cells]	0.0	3	1	1	1
67780	1710	probably at a site	[probably at a site]	0.0	4	1	1	1
67781	1710	1beta gene	[1beta gene]	0.0	2	1	1	1
67782	1710	renal cell ganglioside	[Renal cell gangliosides]	0.0	3	1	1	1
67783	1710	pI	[pI]	0.0	1	1	1	1
67784	1710	unexpected variability	[unexpected variability]	0.0	2	1	1	1
67785	1710	induce acute distress syndrome	[inducing acute distress syndrome]	0.0	4	1	1	1
67786	1710	or	[OR]	0.0	1	1	1	1
67787	1710	breakpoint 11 range from q13	[breakpoints 11 ranging from q13]	0.0	5	1	1	1
67788	1710	Grb2-associated tyrosine protein	[Grb2-associated tyrosine protein]	0.0	3	1	1	1
67789	1710	primate.	[primate.]	0.0	1	1	1	1
67790	1710	bipartite localization signal	[bipartite localization signal]	0.0	3	1	1	1
67791	1710	multiple antigen-specific reactivity at level	[multiple antigen-specific reactivities at levels]	0.0	5	1	1	1
67792	1710	churg-strauss syndrome	[Churg-Strauss syndrome]	0.0	2	1	1	1
67793	1710	coordinate activation effect	[coordinate activation effects]	0.0	3	1	1	1
67794	1710	p55/p75 early late	[p55/p75 early late]	0.0	3	1	1	1
67795	1710	1 to 7.5 mm)	[1 to 7.5 mM)]	0.0	4	1	1	1
67796	1710	dead cell at day	[dead cells at day]	0.0	4	1	1	1
67797	1710	androgen receptor humara	[androgen receptor HUMARA]	0.0	3	1	1	1
67798	1710	HBxAg -specific stimulation	[HBxAg -specific stimulation]	0.0	3	1	1	1
67799	1710	class molecule on antigen-presenting cell	[class molecules on antigen-presenting cells]	0.0	5	1	1	1
67800	1710	cd14 ag	[CD14 Ag]	0.0	2	1	1	1
67801	1710	activation of factor kappa b NFkappaB	[activation of factor kappa B NFkappaB]	0.0	6	1	1	1
67802	1710	ebv-infected lymphoblastoid cell	[EBV-infected lymphoblastoid cells]	0.0	3	1	1	1
67803	1710	t-cell killer T/NK population	[T-cell killer T/NK populations]	0.0	4	1	1	1
67804	1710	Effect of glucocorticoid on endogenous function	[Effects of glucocorticoids on endogenous function]	0.0	6	1	1	1
67805	1710	pt	[PT]	0.0	1	1	1	1
67806	1710	expression of the il-1ri	[expression of the IL-1RI]	0.0	4	1	1	1
67807	1710	decrease cortisol ratio	[decrease cortisol ratio]	0.0	3	1	1	1
67808	1710	downregulation of the gr	[downregulation of the GR]	0.0	4	1	1	1
67809	1710	bufalin in u937 cell	[bufalin in U937 cells]	0.0	4	1	1	1
67810	1710	necessary cofactor for nf-kappab activation	[necessary cofactor for NF-kappaB activation]	0.0	5	1	1	1
67811	1710	IL-2 regulator	[IL-2 regulators]	0.0	2	1	1	1
67812	1710	tnf-alpha factor-kappa b	[TNF-alpha factor-kappa B]	0.0	3	1	1	1
67813	1710	property of the protein	[property of the protein]	0.0	4	1	1	1
67814	1710	vitro, six nuclear antigen	[vitro, six nuclear antigens]	0.0	4	1	1	1
67815	1710	activation of stat5 homologue in addition	[activation of STAT5 homologues in addition]	0.0	6	1	1	1
67816	1710	healthy subject fmol/10(6) cell	[healthy subjects fmol/10(6) cells]	0.0	4	1	1	1
67817	1710	induction by factor in monocyte	[Induction by factor in monocytes]	0.0	5	1	1	1
67818	1710	region of HLA-DQB	[regions of HLA-DQB]	0.0	3	1	1	1
67819	1710	s3	[S3]	0.0	1	1	1	1
67820	1710	further emphasize the antiatherosclerotic potential	[further emphasizing the antiatherosclerotic potential]	0.0	5	1	1	1
67821	1710	cell aggregation.	[cell aggregation.]	0.0	2	1	1	1
67822	1710	direct CTL control	[direct CTL control]	0.0	3	1	1	1
67823	1710	considerable datum	[considerable data]	0.0	2	1	1	1
67824	1710	important step in cell systems.	[important step in cell systems.]	0.0	5	1	1	1
67825	1710	lef-1 -interact protein	[LEF-1 -interacting protein]	0.0	3	1	1	1
67826	1710	least six isomorph of p56	[least six isomorphs of p56]	0.0	5	1	1	1
67827	1710	fmol/mg of protein	[fmol/mg of protein]	0.0	3	1	1	1
67828	1710	evidence of change.	[evidence of change.]	0.0	3	1	1	1
67829	1710	adhesion of polymorphonuclear cell	[adhesion of polymorphonuclear cells]	0.0	4	1	1	1
67830	1710	c-jun promoter construct	[c-jun promoter constructs]	0.0	3	1	1	1
67831	1710	molecular weight in the range kd.	[molecular weights in the range kd.]	0.0	6	1	1	1
67832	1710	cells, in cell culture	[cells, in cell culture]	0.0	4	1	1	1
67833	1710	induction of taxi	[Induction of TaxI]	0.0	3	1	1	1
67834	1710	zygous	[zygous]	0.0	1	1	1	1
67835	1710	affinity, squirrel monkey	[affinity, squirrel monkey]	0.0	3	1	1	1
67836	1710	two dna-binding subunit	[two DNA-binding subunits]	0.0	3	1	1	1
67837	1710	patient with inflammatory disease	[patients with inflammatory diseases]	0.0	4	1	1	1
67838	1710	multiple microbiological antigen	[multiple microbiological antigens]	0.0	3	1	1	1
67839	1710	noncatalytic N terminus	[noncatalytic N terminus]	0.0	3	1	1	1
67840	1710	indicate importance in the expression	[indicating importance in the expression]	0.0	5	1	1	1
67841	1710	sh	[SH]	0.0	1	1	1	1
67842	1710	effect on the gene expression	[effects on the gene expression]	0.0	5	1	1	1
67843	1710	low level.	[low level.]	0.0	2	2	2	1
67844	1710	CFU-GEMM/ bfu-e/cfu-m shift	[CFU-GEMM/ BFU-E/CFU-M shift]	0.0	3	1	1	1
67845	1710	unique phosphopeptide	[unique phosphopeptides]	0.0	2	1	1	1
67846	1710	MHC class ii gene activation	[MHC class II gene activation]	0.0	5	1	1	1
67847	1710	consecutive glutamine residue	[consecutive glutamine residues]	0.0	3	1	1	1
67848	1710	natural history of disease	[natural history of disease.]	0.0	4	1	1	1
67849	1710	dissociation stimulation,	[Dissociation stimulation,]	0.0	2	1	1	1
67850	1710	indicate the absence	[indicating the absence]	0.0	3	1	1	1
67851	1710	type of lymphoid cell line	[types of lymphoid cell lines]	0.0	5	1	1	1
67852	1710	small exon span kb	[small exons spanning kb]	0.0	4	1	1	1
67853	1710	cell with MM-LDL	[cells with MM-LDL]	0.0	3	1	1	1
67854	1710	macrophage response	[macrophage response]	0.0	2	1	1	1
67855	1710	dihydropyrimidine dehydrogenase the enzyme	[dihydropyrimidine dehydrogenase the enzyme]	0.0	4	1	1	1
67856	1710	trigger in the presence antibody	[triggering in the presence antibodies]	0.0	5	1	1	1
67857	1710	two different activation domain	[two different activation domains]	0.0	4	1	1	1
67858	1710	TCL1 oncogene expression	[TCL1 oncogene expression]	0.0	3	1	1	1
67859	1710	lentiviruse	[lentiviruses]	0.0	1	1	1	1
67860	1710	antioxidant therapy	[antioxidant therapies.]	0.0	2	1	1	1
67861	1710	tumor-specific rearrangement	[tumor-specific rearrangements]	0.0	2	1	1	1
67862	1710	immediate serum gene	[immediate serum genes]	0.0	3	1	1	1
67863	1710	evidence for distinct signal pathway	[Evidence for distinct signaling pathways]	0.0	5	1	1	1
67864	1710	controls; p	[controls; P]	0.0	2	1	1	1
67865	1710	primarily a feature	[primarily a feature]	0.0	3	1	1	1
67866	1710	effector molecule granzyme b	[effector molecules granzyme B]	0.0	4	1	1	1
67867	1710	rest human pbl	[resting human PBL]	0.0	3	1	1	1
67868	1710	slightly on basal cell	[slightly on basal cells]	0.0	4	1	1	1
67869	1710	other cell types:	[other cell types:]	0.0	3	1	1	1
67870	1710	uv	[uv]	0.0	1	1	1	1
67871	1710	activation of intracellular biochemical event	[activation of intracellular biochemical events]	0.0	5	1	1	1
67872	1710	acute leukemia particularly the variant	[acute leukemia particularly the variant]	0.0	5	1	1	1
67873	1710	target the GATA-1 gene	[targeting the GATA-1 gene]	0.0	4	1	1	1
67874	1710	IL-2 responsiveness on the hand,	[IL-2 responsiveness on the hand,]	0.0	5	1	1	1
67875	1710	association with T cell	[association with T cells]	0.0	4	1	1	1
67876	1710	phase-2 response	[phase-2 response]	0.0	2	1	1	1
67877	1710	physiological concentration (10(-9)-10(-7)	[physiological concentration (10(-9)-10(-7)]	0.0	3	1	1	1
67878	1710	encode IL-2	[encoding IL-2]	0.0	2	1	1	1
67879	1710	lead to accessibility	[leading to accessibility]	0.0	3	1	1	1
67880	1710	expression of Duffy protein	[expression of Duffy protein]	0.0	4	1	1	1
67881	1710	activation-induced phosphorylation	[activation-induced phosphorylation]	0.0	2	1	1	1
67882	1710	cytokine profile of blood cell	[Cytokine profiles of blood cells]	0.0	5	1	1	1
67883	1710	fibroblast reveal a functional redundancy	[fibroblasts revealing an functional redundancy.]	0.0	5	1	1	1
67884	1710	particularly the microgranular variant	[particularly the microgranular variant]	0.0	4	1	1	1
67885	1710	10 hiv-infected patient with receptor affinity	[10 HIV-infected patients with receptor affinity]	0.0	6	1	1	1
67886	1710	HTLV-I trans-activator p40tax	[HTLV-I trans-activator p40tax]	0.0	3	1	1	1
67887	1710	5'-deletion fragment	[5'-deletion fragments]	0.0	2	1	1	1
67888	1710	electrophoretic mobility shift assay,	[electrophoretic mobility shift assay,]	0.0	4	1	1	1
67889	1710	ifn-gamma -produce	[IFN-gamma -producing]	0.0	2	1	1	1
67890	1710	human myeloid cell polymorphonuclear granulocyte	[human myeloid cells polymorphonuclear granulocytes]	0.0	5	1	1	1
67891	1710	67-kDa precursor protein pro-il-16	[67-kDa precursor protein pro-IL-16]	0.0	4	1	1	1
67892	1710	medullary	[medullary]	0.0	1	1	1	1
67893	1710	(2) configuration	[(2) configuration]	0.0	2	1	1	1
67894	1710	activation by a combination	[activation by a combination]	0.0	4	1	1	1
67895	1710	IL-2 pi	[IL-2 PI]	0.0	2	1	1	1
67896	1710	bronchial asthma BA	[bronchial asthma BA]	0.0	3	1	1	1
67897	1710	single-chain ab fragment	[single-chain Ab fragment]	0.0	3	1	1	1
67898	1710	xy	[XY]	0.0	1	1	1	1
67899	1710	stress this mouse	[stressing these mice]	0.0	3	1	1	1
67900	1710	immunodeficiency virus hiv expression	[immunodeficiency virus HIV expression]	0.0	4	1	1	1
67901	1710	prognosis, include estrogen	[prognosis, including estrogen]	0.0	3	1	1	1
67902	1710	repeat of glutamine residue	[repeat of glutamine residues]	0.0	4	1	1	1
67903	1710	serine in the N terminus	[serines in the N terminus]	0.0	5	1	1	1
67904	1710	similar degree tested: dephosphorylation	[similar degree tested: dephosphorylation]	0.0	4	1	1	1
67905	1710	transient overexpression of inactive mutant	[Transient overexpression of inactive mutants]	0.0	5	1	1	1
67906	1710	-dependent cell line	[-dependent cell line]	0.0	3	1	1	1
67907	1710	origin for maintenance during latency	[origin for maintenance during latency]	0.0	5	1	1	1
67908	1710	relative affinity (at sevenfold) 3.	[relative affinity (at sevenfold) 3.]	0.0	5	1	1	1
67909	1710	cytoplasmic pool	[cytoplasmic pool]	0.0	2	1	1	1
67910	1710	human myeloid progenitor cell	[human myeloid progenitor cells]	0.0	4	1	1	1
67911	1710	40-fold follow okadaic acid exposure	[40-fold following okadaic acid exposure]	0.0	5	1	1	1
67912	1710	functional motif in the enhancer	[functional motifs in the enhancers]	0.0	5	1	1	1
67913	1710	cell adhesion,	[cell adhesion,]	0.0	2	1	1	1
67914	1710	zn	[Zn]	0.0	1	1	1	1
67915	1710	Interfollicular	[Interfollicular]	0.0	1	1	1	1
67916	1710	trans-activation of a IL-4 reporter	[trans-activation of an IL-4 reporter]	0.0	5	1	1	1
67917	1710	multiple inactivate nucleotide substitution	[multiple inactivating nucleotide substitutions]	0.0	4	1	1	1
67918	1710	different combination of disable mutation	[different combinations of disabling mutations]	0.0	5	1	1	1
67919	1710	participation of AMP	[participation of AMP]	0.0	3	1	1	1
67920	1710	breakage	[breakage]	0.0	1	1	1	1
67921	1710	effect on complex in T cell	[effects on complexes in T cells]	0.0	6	1	1	1
67922	1710	myeloproliferative disorder in down' syndrome tmd	[myeloproliferative disorder in Down's syndrome TMD]	0.0	6	2	2	1
67923	1710	control determinant	[controlling determinant]	0.0	2	1	1	1
67924	1710	approach study protein-protein interaction	[approach studying protein-protein interactions]	0.0	4	1	1	1
67925	1710	lymphocyte in sle	[lymphocytes in SLE]	0.0	3	1	1	1
67926	1710	pou(s)	[POU(S)]	0.0	1	1	1	1
67927	1710	EBV antigen one of the gene	[EBV antigen one of the genes]	0.0	6	1	1	1
67928	1710	protein, Sp1	[protein, Sp1]	0.0	2	1	1	1
67929	1710	several new function such as downregulation	[Several new functions such as downregulation]	0.0	6	1	1	1
67930	1710	release growth arrest;	[releasing growth arrest;]	0.0	3	1	1	1
67931	1710	Neurath,	[Neurath,]	0.0	1	1	1	1
67932	1710	primary normal b-cell	[primary normal B-cells]	0.0	3	1	1	1
67933	1710	transcription factor bsap in h-rs cell	[transcription factor BSAP in H-RS cells]	0.0	6	1	1	1
67934	1710	case-control study of population	[case-control studies of populations]	0.0	4	1	1	1
67935	1710	high-proliferative colony-forming cell	[high-proliferative colony-forming cells]	0.0	3	1	1	1
67936	1710	dna-binding of Stat	[DNA-binding of Stat]	0.0	3	1	1	1
67937	1710	tumor defense	[tumor defense]	0.0	2	1	1	1
67938	1710	factor of T cell activation.	[factor of T cell activation.]	0.0	5	1	1	1
67939	1710	late expression pattern from the virus,	[late expression patterns from the virus,]	0.0	6	1	1	1
67940	1710	kinase with activation	[kinases with activation]	0.0	3	1	1	1
67941	1710	impaired ligand-induced plasticity	[impaired ligand-induced plasticity]	0.0	3	1	1	1
67942	1710	mechanism of cell infiltration	[mechanism of cell infiltration]	0.0	4	1	1	1
67943	1710	production of Fos	[production of Fos]	0.0	3	1	1	1
67944	1710	interpretation of result	[interpretation of results]	0.0	3	1	1	1
67945	1710	tissue site	[tissue sites]	0.0	2	1	1	1
67946	1710	THP-1 mature cell line	[THP-1 mature cell line]	0.0	4	1	1	1
67947	1710	unidentified ets-like factor	[unidentified ETS-like factors]	0.0	3	1	1	1
67948	1710	block of granulocytic differentiation	[Block of granulocytic differentiation]	0.0	4	1	1	1
67949	1710	insertion of amino acid	[insertion of amino acids]	0.0	4	1	1	1
67950	1710	three site for factor	[three sites for factors]	0.0	4	1	1	1
67951	1710	ras-related protein (rap) in platelet membrane	[Ras-related protein (Rap) in platelet membranes]	0.0	6	1	1	1
67952	1710	part, by transcriptional activation.	[part, by transcriptional activation.]	0.0	4	1	1	1
67953	1710	population of mouse	[populations of mice]	0.0	3	1	1	1
67954	1710	generation compound	[generation compound]	0.0	2	1	1	1
67955	1710	cell a component of atheroma	[cells a component of atheroma]	0.0	5	1	1	1
67956	1710	divide single cell	[dividing single cells]	0.0	3	1	1	1
67957	1710	tissue turnover,	[tissue turnover,]	0.0	2	1	1	1
67958	1710	acute myeloid patient aml cases)	[acute myeloid patients AML cases)]	0.0	5	1	1	1
67959	1710	initial viral gene promoter	[initial viral gene promoter]	0.0	4	1	1	1
67960	1710	vascular adhesion molecule-1 on vein cell	[vascular adhesion molecule-1 on vein cells]	0.0	6	1	1	1
67961	1710	day 12 fetal liver	[day 12 fetal liver]	0.0	4	1	1	1
67962	1710	high activity of the activator	[high activities of the activators]	0.0	5	1	1	1
67963	1710	molecule such as glucocorticoid	[molecules such as glucocorticoid]	0.0	4	1	1	1
67964	1710	regulatory region of the Akv	[regulatory regions of the Akv]	0.0	5	1	1	1
67965	1710	vector-mediated transduction into this hl-60r subclone	[vector-mediated transduction into this HL-60R subclone]	0.0	6	1	1	1
67966	1710	ability of type	[ability of type]	0.0	3	1	1	1
67967	1710	tyrosine stat1 protein kda protein	[tyrosine stat1 proteins kDa proteins]	0.0	5	1	1	1
67968	1710	IL-6 alone	[IL-6 alone]	0.0	2	1	1	1
67969	1710	oligonucleotide homologous	[oligonucleotides homologous]	0.0	2	1	1	1
67970	1710	I trans-activator antigen	[I trans-activator antigen]	0.0	3	1	1	1
67971	1710	interaction with the regulatory element	[interaction with the regulatory element]	0.0	5	1	1	1
67972	1710	frequent hypermutation in follicular lymphoma (25	[frequent hypermutation in follicular lymphoma (25]	0.0	6	1	1	1
67973	1710	gamma(c) receptor subunit	[gamma(c) receptor subunit]	0.0	3	1	1	1
67974	1710	likely factor	[likely factor]	0.0	2	1	1	1
67975	1710	retinoic acid receptor alpha locus	[retinoic acid receptor alpha locus]	0.0	5	1	1	1
67976	1710	term culture u-937 cell	[term culture U-937 cells]	0.0	4	1	1	1
67977	1710	NF-kB in human thymocyte	[NF-kB in human thymocytes]	0.0	4	1	1	1
67978	1710	drosophila toll protein	[Drosophila toll protein]	0.0	3	1	1	1
67979	1710	two rna gene	[two RNA genes]	0.0	3	1	1	1
67980	1710	vitro exposure of cell	[vitro exposure of cells]	0.0	4	1	1	1
67981	1710	various set of cell hybrid	[various sets of cell hybrids]	0.0	5	1	1	1
67982	1710	other major subpopulation	[other major subpopulation]	0.0	3	1	1	1
67983	1710	series of clone	[series of clones]	0.0	3	1	1	1
67984	1710	encode the histone deacetylase subunit	[encoding the histone deacetylase subunit]	0.0	5	1	1	1
67985	1710	29 labial salivary gland biopsy	[29 labial salivary gland biopsies]	0.0	5	1	1	1
67986	1710	gata-3 expression	[GATA-3 expression]	0.0	2	1	1	1
67987	1710	biological function of e2a-hlf	[biological function of E2A-HLF]	0.0	4	1	1	1
67988	1710	challenge during pregnancy	[challenge during pregnancy]	0.0	3	1	1	1
67989	1710	T cell surface receptor	[T cell surface receptors]	0.0	4	1	1	1
67990	1710	t(15;17) promyelocytic leukemia	[t(15;17) promyelocytic leukemia]	0.0	3	1	1	1
67991	1710	human myeloid differentiation antigen	[human myeloid differentiation antigen]	0.0	4	1	1	1
67992	1710	tyrosine substrate	[tyrosine substrates]	0.0	2	1	1	1
67993	1710	Differential induction	[Differential induction]	0.0	2	3	3	1
67994	1710	core 5'-ggaa-3'	[core 5'-GGAA-3']	0.0	2	1	1	1
67995	1710	study of the molecular defect(s)	[study of the molecular defect(s)]	0.0	5	1	1	1
67996	1710	up-regulation in human T lymphocyte	[Up-regulation in human T lymphocytes]	0.0	5	1	1	1
67997	1710	response involve proliferation	[responses involving proliferation]	0.0	3	1	1	1
67998	1710	critical threshold level	[critical threshold levels]	0.0	3	1	1	1
67999	1710	Comparison of retinoic acid as inducer	[Comparison of retinoic acid as inducers]	0.0	6	1	1	1
68000	1710	mineralocorticoid receptor in leukocyte in patient	[mineralocorticoid receptors in leukocytes in patients]	0.0	6	1	1	1
68001	1710	amount of active nf-kappa b	[amount of active NF-kappa B]	0.0	5	1	1	1
68002	1710	distal factor NF-AT	[distal factor NF-AT]	0.0	3	1	1	1
68003	1710	breast duct in the vicinity	[breast ducts in the vicinity]	0.0	5	1	1	1
68004	1710	nuclear nf-kappa b of gene	[nuclear NF-kappa B of genes]	0.0	5	1	1	1
68005	1710	CD28 of naive T lymphocyte	[CD28 of naive T lymphocytes]	0.0	5	1	1	1
68006	1710	mutation within two C/EBP site	[mutations within two C/EBP sites]	0.0	5	1	1	1
68007	1710	gr with kinetic	[GR with kinetics]	0.0	3	1	1	1
68008	1710	hiv-1 nef	[HIV-1 Nef]	0.0	2	1	1	1
68009	1710	sem).	[SEM).]	0.0	1	1	1	1
68010	1710	infection b cell	[infection B cells]	0.0	3	1	1	1
68011	1710	cases, a potential regulator	[cases, a potential regulator]	0.0	4	1	1	1
68012	1710	clinical observation	[clinical observations]	0.0	2	1	1	1
68013	1710	transcription with the W-X-Y	[transcription with the W-X-Y]	0.0	4	1	1	1
68014	1710	b/gc-box	[B/GC-box]	0.0	1	1	1	1
68015	1710	response to recombinant glycoprotein b	[responses to recombinant glycoprotein B]	0.0	5	1	1	1
68016	1710	shp2-interacting adaptor protein SIT	[SHP2-interacting adaptor protein SIT]	0.0	4	1	1	1
68017	1710	inflammation, for rheumatoid synovitis,	[inflammation, for rheumatoid synovitis,]	0.0	4	1	1	1
68018	1710	regulation of factor kappa b	[regulation of factor kappa B]	0.0	5	1	1	1
68019	1710	control peptide	[Control peptides]	0.0	2	1	1	1
68020	1710	factor to the Egr-1 site	[factors to the Egr-1 sites]	0.0	5	1	1	1
68021	1710	proliferative samples, activity of egl	[proliferative samples, activity of eGLs]	0.0	5	1	1	1
68022	1710	erythroid alas isozyme	[erythroid ALAS isozyme]	0.0	3	1	1	1
68023	1710	many effect	[Many effects]	0.0	2	1	1	1
68024	1710	erythroid specific enhancer	[erythroid specific enhancer]	0.0	3	1	1	1
68025	1710	regulation of several genes.	[regulation of several genes.]	0.0	4	1	1	1
68026	1710	transcription of effector	[transcription of effector]	0.0	3	1	1	1
68027	1710	cobalt chloride signal lead	[Cobalt chloride signaling leading]	0.0	4	1	1	1
68028	1710	antibody against the gene product	[antibodies against the gene product]	0.0	5	1	1	1
68029	1710	T cell lysate	[T cell lysates]	0.0	3	1	1	1
68030	1710	crossreactivity with the vitamin d receptor	[crossreactivity with the vitamin D receptor]	0.0	6	1	1	1
68031	1710	activation of b gene	[activation of B genes]	0.0	4	1	1	1
68032	1710	B-cell lymphocytic leukemia (b-cll) cell	[B-cell lymphocytic leukemia (B-CLL) cells]	0.0	5	1	1	1
68033	1710	regulate protein as stimulus	[regulating proteins as stimuli]	0.0	4	1	1	1
68034	1710	basal activity a activator	[basal activity a activator]	0.0	4	1	1	1
68035	1710	interaction of EBNA-2	[interaction of EBNA-2]	0.0	3	1	1	1
68036	1710	tyrosine kinase hck	[tyrosine kinase hck]	0.0	3	1	1	1
68037	1710	patient with diseases.	[patients with diseases.]	0.0	3	1	1	1
68038	1710	immune deficiency syndrome	[immune deficiency syndrome]	0.0	3	2	2	1
68039	1710	cellular source for mediator	[cellular source for mediators]	0.0	4	1	1	1
68040	1710	chronic lymphatic leukemia	[chronic lymphatic leukemia]	0.0	3	1	1	1
68041	1710	tsg101 gene	[TSG101 genes]	0.0	2	1	1	1
68042	1710	tarsal biopsy from seven patient	[tarsal biopsies from seven patients]	0.0	5	1	1	1
68043	1710	vital importance during illness.	[vital importance during illness.]	0.0	4	1	1	1
68044	1710	long effect of treatment	[long-term effects of treatment]	0.0	4	1	1	1
68045	1710	single tr TREp complex	[single TR TREp complex]	0.0	4	1	1	1
68046	1710	sequence-specific triplex	[sequence-specific triplex]	0.0	2	1	1	1
68047	1710	secretion of chemotactic protein-1 mcp-1	[secretion of chemotactic protein-1 MCP-1]	0.0	5	1	1	1
68048	1710	ehuaess)	[(HUAECs)]	0.0	1	1	1	1
68049	1710	cotransfection of gamma B*CaM-K	[Cotransfection of gamma B*CaM-K]	0.0	4	1	1	1
68050	1710	culture with the stimulants.	[culture with the stimulants.]	0.0	4	1	1	1
68051	1710	blastic transformation in myelogenous leukemia	[blastic transformation in myelogenous leukemia]	0.0	5	1	1	1
68052	1710	method for specific down-regulation	[methods for specific down-regulation]	0.0	4	1	1	1
68053	1710	sequence (bp -88	[sequences (bp -88]	0.0	3	1	1	1
68054	1710	identical sequence CCGAAACTGAAAAGG	[identical sequence CCGAAACTGAAAAGG]	0.0	3	1	1	1
68055	1710	t-cell-specific activator tcf-1 t-cell factor-1	[T-cell-specific activator TCF-1 T-Cell Factor-1]	0.0	5	1	1	1
68056	1710	ebv activation	[EBV activation]	0.0	2	1	1	1
68057	1710	sequence homology with gene	[sequence homology with genes]	0.0	4	1	1	1
68058	1710	repeat of amino acid	[repeats of amino acids]	0.0	4	1	1	1
68059	1710	treatment of monocyte with phorbol-13-acetate tpa	[Treatment of monocytes with phorbol-13-acetate TPA]	0.0	6	1	1	1
68060	1710	importantly, additional testing of a set	[Importantly, additional testing of a set]	0.0	6	1	1	1
68061	1710	role of factor-DNA complex	[role of factor-DNA complexes]	0.0	4	1	1	1
68062	1710	24 pregnant woman first, second	[24 pregnant women first, second]	0.0	5	1	1	1
68063	1710	erythroid nuclear factor-DNA complex	[erythroid nuclear factor-DNA complexes]	0.0	4	1	1	1
68064	1710	total asthmatic patient	[total asthmatic patients]	0.0	3	1	1	1
68065	1710	property in vitro	[properties in vitro]	0.0	3	1	1	1
68066	1710	12-o-tetradecanoylphorbol-13-acetate represses, gene expression	[12-O-tetradecanoylphorbol-13-acetate represses, gene expression]	0.0	4	1	1	1
68067	1710	high content of gcr	[higher content of GCR]	0.0	4	1	1	1
68068	1710	human Chinese hamster ovary fibroblast	[human Chinese hamster ovary fibroblasts]	0.0	5	1	1	1
68069	1710	inhibition of the uptake of 3-o-methyl-d-glucose	[inhibition of the uptake of 3-O-methyl-D-glucose]	0.0	6	1	1	1
68070	1710	endogenous ikappab kinase signalsome activation	[endogenous IkappaB kinase signalsome activation]	0.0	5	1	1	1
68071	1710	clone from the centre	[clones from the centre]	0.0	4	1	1	1
68072	1710	etiologic agent of ehrlichiosis	[etiologic agent of ehrlichiosis]	0.0	4	1	1	1
68073	1710	weight gain (pre)	[weight gain (pre)]	0.0	3	1	1	1
68074	1710	activation in intact T cell	[activation in intact T cells]	0.0	5	1	1	1
68075	1710	however, (66 millileter	[However, (66 ml]	0.0	3	1	1	1
68076	1710	endothelial cell ECs in hypoxia	[endothelial cells ECs in hypoxia]	0.0	5	1	1	1
68077	1710	basis interfere	[basis interfering]	0.0	2	1	1	1
68078	1710	extrarenal, cell	[extrarenal, cells]	0.0	2	1	1	1
68079	1710	use a nf-kappab oligoprobe	[using a NF-kappaB oligoprobe]	0.0	4	1	1	1
68080	1710	other ion	[other ions]	0.0	2	1	1	1
68081	1710	5 red blood cell	[5 red blood cells]	0.0	4	1	1	1
68082	1710	function in lymphoid development	[function in lymphoid development]	0.0	4	1	1	1
68083	1710	nucleotide IP9	[nucleotides IP9]	0.0	2	1	1	1
68084	1710	effect on the disease	[effect on the disease.]	0.0	4	1	1	1
68085	1710	cell-specific factor otf2	[cell-specific factor OTF2]	0.0	3	1	1	1
68086	1710	moreover, cyclosporine	[Moreover, cyclosporine]	0.0	2	1	1	1
68087	1710	cellular programme	[cellular programme]	0.0	2	1	1	1
68088	1710	-PhoQ	[-PhoQ]	0.0	1	1	1	1
68089	1710	function test	[Function tests]	0.0	2	1	1	1
68090	1710	proteolysis of the carboxyl terminus	[proteolysis of the carboxyl terminus]	0.0	5	1	1	1
68091	1710	high expression level of c-myc	[high expression level of c-myc]	0.0	5	1	1	1
68092	1710	receptor on human leukocyte hml	[receptors on human leukocytes HML]	0.0	5	1	1	1
68093	1710	functional importance of the aCT-1-activating region	[functional importance of the ACT-1-activating region]	0.0	6	1	1	1
68094	1710	down-regulate the immune response to hiv-1	[down-regulating the immune response to HIV-1]	0.0	6	1	1	1
68095	1710	pathologic process	[pathologic processes]	0.0	2	1	1	1
68096	1710	terminal repeat activity in human T	[terminal repeat activity in human T]	0.0	6	1	1	1
68097	1710	therapeutic use	[therapeutic use]	0.0	2	1	1	1
68098	1710	clonality analysis simultaneous study of clonality	[Clonality analysis simultaneous study of clonality]	0.0	6	1	1	1
68099	1710	pattern of variation	[patterns of variation]	0.0	3	1	1	1
68100	1710	mechanism of steroid action a type	[mechanisms of steroid action a type]	0.0	6	1	1	1
68101	1710	treatment (day 0 hpc with alpha-pml	[treatment (day 0 HPCs with alpha-PML]	0.0	6	1	1	1
68102	1710	control in B-cell development	[control in B-cell development]	0.0	4	1	1	1
68103	1710	model clarify the pathogenesis	[model clarifying the pathogenesis]	0.0	4	1	1	1
68104	1710	region of other human sequence	[regions of other human sequences]	0.0	5	1	1	1
68105	1710	mutant tax	[mutant Tax]	0.0	2	1	1	1
68106	1710	flt-3 ligand	[Flt-3 ligand]	0.0	2	1	1	1
68107	1710	0.5-fold)	[0.5-fold)]	0.0	1	1	1	1
68108	1710	IFN gene promoter	[IFN gene promoters]	0.0	3	1	1	1
68109	1710	fas promoter activation	[fas promoter activation]	0.0	3	1	1	1
68110	1710	RA time-response	[RA time-response]	0.0	2	1	1	1
68111	1710	f(ab')2 fragment of monoclonal CR1	[F(ab')2 fragments of monoclonal CR1]	0.0	5	1	1	1
68112	1710	induction of factor-kappa b	[induction of factor-kappa B]	0.0	4	1	1	1
68113	1710	molecules:	[molecules:]	0.0	1	1	1	1
68114	1710	higher-molecular-weight species	[Higher-molecular-weight species]	0.0	2	1	1	1
68115	1710	mental illness involve response to stress	[mental illness involving responses to stress]	0.0	6	1	1	1
68116	1710	progesterone-mediated immunosuppression: inhibition	[progesterone-mediated immunosuppression: inhibition]	0.0	3	1	1	1
68117	1710	peptide inhibitor	[peptide inhibitor]	0.0	2	2	2	1
68118	1710	gene effect MHC antigen expression	[gene effects MHC antigen expression]	0.0	5	1	1	1
68119	1710	capacity of human receptor	[capacity of human receptor]	0.0	4	1	1	1
68120	1710	regulation of human interleukin IL-2 gene	[regulation of human interleukin IL-2 gene]	0.0	6	1	1	1
68121	1710	expression leukocyte protein of kilodaltons),	[expression leukocyte protein of kilodaltons),]	0.0	5	1	1	1
68122	1710	precursor to plasma cell	[precursors to plasma cells]	0.0	4	1	1	1
68123	1710	recombinant fragment of bactericidal/permeability-increasing protein	[recombinant fragment of bactericidal/permeability-increasing protein]	0.0	5	1	1	1
68124	1710	previously unrecognized mechanism	[previously unrecognized mechanism]	0.0	3	1	1	1
68125	1710	myeloid cell i.e. neutrophilic granulocyte	[myeloid cells i.e. neutrophilic granulocytes]	0.0	5	1	1	1
68126	1710	lymph node with hyperplasia	[lymph nodes with hyperplasia]	0.0	4	1	1	1
68127	1710	expression on human malignant melanoma	[expression on human malignant melanomas]	0.0	5	1	1	1
68128	1710	contrast to transcriptional activation	[contrast to transcriptional activation]	0.0	4	1	1	1
68129	1710	T-lymphocyte cell line Molt-4	[T-lymphocyte cell line Molt-4]	0.0	4	1	1	1
68130	1710	value in untreated depressed patient	[values in untreated depressed patients]	0.0	5	1	1	1
68131	1710	myelogenous leukemia patient	[myelogenous leukemia patients]	0.0	3	2	2	1
68132	1710	fluorochrome	[fluorochrome]	0.0	1	1	1	1
68133	1710	c-jun promoter element	[c-jun promoter element]	0.0	3	1	1	1
68134	1710	(lytic)	[(lytic)]	0.0	1	1	1	1
68135	1710	cell growth inhibitor	[cell growth inhibitors]	0.0	3	1	1	1
68136	1710	ubiquitin-carrier	[ubiquitin-carrier]	0.0	1	1	1	1
68137	1710	broad sense,	[broader sense,]	0.0	2	1	1	1
68138	1710	mild down-regulation in hypercortisolemic patient	[mild down-regulation in hypercortisolemic patients]	0.0	5	1	1	1
68139	1710	modification of nuclear protein	[modification of nuclear proteins]	0.0	4	1	1	1
68140	1710	purine region	[purine region]	0.0	2	1	1	1
68141	1710	overexpression of udg	[Overexpression of UDG]	0.0	3	1	1	1
68142	1710	response in rheumatoid arthritis	[response in rheumatoid arthritis]	0.0	4	1	1	1
68143	1710	CTL line	[CTL lines]	0.0	2	1	1	1
68144	1710	Furthermore, retinoic acid receptor RAR	[Furthermore, retinoic acid receptor RAR]	0.0	5	1	1	1
68145	1710	induction of bcl-x(l) expression through nf-kappab	[Induction of Bcl-x(L) expression through NF-kappaB]	0.0	6	1	1	1
68146	1710	studies, cell mono	[studies, cells Mono]	0.0	3	1	1	1
68147	1710	mineralocorticoid receptor count	[mineralocorticoid receptor count]	0.0	3	1	1	1
68148	1710	long-lasting csf-1 proliferation	[long-lasting CSF-1 proliferation]	0.0	3	1	1	1
68149	1710	dose within P;	[dose within h;]	0.0	3	1	1	1
68150	1710	grow cell line	[growing cell line]	0.0	3	1	1	1
68151	1710	consolidate the switch	[consolidating the switch]	0.0	3	1	1	1
68152	1710	confirm the involvement	[confirming the involvement]	0.0	3	1	1	1
68153	1710	mol/microgram rna respectively, corresponding	[mol/microgram RNA respectively, corresponding]	0.0	4	1	1	1
68154	1710	action of acid on hematopoiesis	[action of acid on hematopoiesis]	0.0	5	1	1	1
68155	1710	activity of 125d3	[activities of 1,25D3]	0.0	3	1	1	1
68156	1710	exogenous growth stimulus	[exogenous growth stimuli]	0.0	3	1	1	1
68157	1710	il-4 of multiple gene	[IL-4 of multiple genes]	0.0	4	1	1	1
68158	1710	pattern of kappa B-specific activity	[pattern of kappa B-specific activity]	0.0	5	1	1	1
68159	1710	other factors,	[other factors,]	0.0	2	1	1	1
68160	1710	analyze the effect of il-2	[analyzing the effects of IL-2]	0.0	5	1	1	1
68161	1710	membrane receptor a kda protein	[membrane receptors a kDa protein]	0.0	5	1	1	1
68162	1710	platelet extract	[platelet extracts]	0.0	2	1	1	1
68163	1710	high (p	[higher (P]	0.0	2	1	1	1
68164	1710	stimulus response	[stimulus response]	0.0	2	1	1	1
68165	1710	enzyme in the pathway	[enzymes in the pathway]	0.0	4	1	1	1
68166	1710	inhibitor in pbmc	[inhibitor in PBMC]	0.0	3	1	1	1
68167	1710	pharmacodynamic response versus dose	[pharmacodynamic responses versus doses]	0.0	4	1	1	1
68168	1710	occur breakdown product	[occurring breakdown product]	0.0	3	1	1	1
68169	1710	manner in vitro.	[manner in vitro.]	0.0	3	1	1	1
68170	1710	element inducible	[element inducible]	0.0	2	1	1	1
68171	1710	synthetic peptide represent acid sequence	[synthetic peptides representing acid sequences]	0.0	5	1	1	1
68172	1710	negligible level	[negligible levels]	0.0	2	1	1	1
68173	1710	ebv -positive tumour tissue	[EBV -positive tumour tissues]	0.0	4	1	1	1
68174	1710	new option	[new option]	0.0	2	1	1	1
68175	1710	contrast to the main mediator	[contrast to the main mediators]	0.0	5	1	1	1
68176	1710	indicate the role	[indicating the role]	0.0	3	1	1	1
68177	1710	large colony mm)	[large colonies mm)]	0.0	3	1	1	1
68178	1710	two novel 9-bp motif	[two novel 9-bp motifs]	0.0	4	1	1	1
68179	1710	proliferation (71%) iddm subject 8	[proliferation (71%) IDDM subjects 8]	0.0	5	1	1	1
68180	1710	relative mass (50k)	[relative mass (50K)]	0.0	3	1	1	1
68181	1710	so-called mobility group (hmg) box	[so-called mobility group (HMG) box]	0.0	5	1	1	1
68182	1710	axis in adult rat	[axis in adult rats]	0.0	4	1	1	1
68183	1710	domain of Oct2	[domain of Oct2]	0.0	3	1	1	1
68184	1710	gene in megakaryoblastic leukaemia	[genes in megakaryoblastic leukaemia]	0.0	4	1	1	1
68185	1710	terminate activity	[terminating activity]	0.0	2	1	1	1
68186	1710	activation of factor in a pathway	[Activation of factor in A pathway]	0.0	6	1	1	1
68187	1710	t-cell receptor-CD3 complex	[T-cell receptor-CD3 complex]	0.0	3	1	1	1
68188	1710	cell-specific enhancer	[cell-specific enhancer]	0.0	2	1	1	1
68189	1710	sequester bhlh target	[sequestering bHLH targets]	0.0	3	1	1	1
68190	1710	ap-1 site II,	[AP-1 sites II,]	0.0	3	1	1	1
68191	1710	concentration of tfiiib molecule	[concentration of TFIIIB molecules]	0.0	4	1	1	1
68192	1710	cellular event to endothelial cell	[cellular event to endothelial cells]	0.0	5	1	1	1
68193	1710	latency into the cycle	[latency into the cycle]	0.0	4	1	1	1
68194	1710	EBNA-2 element	[EBNA-2 element]	0.0	2	1	1	1
68195	1710	33 hypercalciuric patient	[33 hypercalciuric patients]	0.0	3	1	1	1
68196	1710	analysis of the specific methylation	[Analysis of the specific methylation]	0.0	5	1	1	1
68197	1710	addition of ligand	[addition of ligand]	0.0	3	1	1	1
68198	1710	expression of matrix metalloproteinase factor ap-1	[expression of matrix metalloproteinase factor AP-1]	0.0	6	1	1	1
68199	1710	HTLV-I activator tax	[HTLV-I activator tax]	0.0	3	1	1	1
68200	1710	light chain gene enhancer	[light chain gene enhancers]	0.0	4	1	1	1
68201	1710	up-regulation by ketoconazole treatment,	[up-regulation by ketoconazole treatment,]	0.0	4	1	1	1
68202	1710	expression of other cytokine	[expression of other cytokines]	0.0	4	1	1	1
68203	1710	reactivity to a progesterone monoclonal antibody	[Reactivity to a progesterone monoclonal antibody]	0.0	6	1	1	1
68204	1710	chimeric transcriptional properties unlike nuclear oncoprotein	[chimeric transcriptional properties, unlike nuclear oncoproteins]	0.0	6	1	1	1
68205	1710	expression inducible protein ip-10	[Expression inducible protein IP-10]	0.0	4	1	1	1
68206	1710	human mcm5 promoter	[Human MCM5 promoters]	0.0	3	1	1	1
68207	1710	notable participant	[notable participant]	0.0	2	1	1	1
68208	1710	region of the domain	[region of the domain]	0.0	4	1	1	1
68209	1710	cell line of T lineage	[cell lines of T lineage]	0.0	5	1	1	1
68210	1710	cdr2-loop in extracellular domain	[CDR2-loop in extracellular domain]	0.0	4	1	1	1
68211	1710	medium, cem-c7 cell	[medium, CEM-C7 cells]	0.0	3	1	1	1
68212	1710	Effect of ara-c	[Effects of Ara-C]	0.0	3	1	1	1
68213	1710	human matrix metalloproteinase mmp9	[human matrix metalloproteinase MMP9]	0.0	4	1	1	1
68214	1710	t(15;17) acute leukemia	[t(15;17) acute leukemia]	0.0	3	1	1	1
68215	1710	other nf-kappab protein	[other NF-kappaB proteins]	0.0	3	1	1	1
68216	1710	second, in contrast to result	[Second, in contrast to results]	0.0	5	1	1	1
68217	1710	protein (rap) 1	[protein (Rap) 1]	0.0	3	1	1	1
68218	1710	surface ganglioside	[surface ganglioside]	0.0	2	1	1	1
68219	1710	U2 dna-protein	[U2 DNA-protein]	0.0	2	1	1	1
68220	1710	cytokine in parallel	[cytokines in parallel]	0.0	3	1	1	1
68221	1710	characterization of the elk-1 promoter	[Characterization of the elk-1 promoter]	0.0	5	1	1	1
68222	1710	region of the IL3 promoter	[region of the IL3 promoter]	0.0	5	1	1	1
68223	1710	increase nuclear factor	[increasing nuclear factor]	0.0	3	1	1	1
68224	1710	regulation a study with IL-4	[regulation a study with IL-4]	0.0	5	1	1	1
68225	1710	pattern of expression of function-related gene	[patterns of expression of function-related genes]	0.0	6	1	1	1
68226	1710	postnatally, die by 8	[postnatally, dying by 8]	0.0	4	1	1	1
68227	1710	role for the zebra protein	[role for the ZEBRA protein]	0.0	5	1	1	1
68228	1710	neutrophil accumulation	[Neutrophil accumulation]	0.0	2	1	1	1
68229	1710	molecular target for signalling process	[molecular targets for signalling processes]	0.0	5	1	1	1
68230	1710	expression in blood lymphocyte from adults.	[Expression in blood lymphocytes from adults.]	0.0	6	1	1	1
68231	1710	flow-cytometric assay	[flow-cytometric assay]	0.0	2	1	1	1
68232	1710	more common syndrome	[more common syndrome]	0.0	3	1	1	1
68233	1710	(mean of two assays), a value	[(mean of two assays), a value]	0.0	6	1	1	1
68234	1710	Hox11 mouse	[Hox11 mice]	0.0	2	2	2	1
68235	1710	bhrf1 a Epstein-Barr virus early-lytic-cycle protein	[BHRF1 an Epstein-Barr virus early-lytic-cycle protein]	0.0	6	1	1	1
68236	1710	protein with a domain	[proteins with a domain]	0.0	4	1	1	1
68237	1710	key nuclear factor in function	[key nuclear factors in functions]	0.0	5	1	1	1
68238	1710	circulate dendritic cell	[Circulating dendritic cells]	0.0	3	1	1	1
68239	1710	emphasize the potential of lipid antioxidant	[emphasizing the potential of lipid antioxidants]	0.0	6	1	1	1
68240	1710	least 130 kb	[least 130 kb]	0.0	3	1	1	1
68241	1710	anti- TNF-alpha hiv-1 long repeat	[anti- TNF-alpha HIV-1 long repeat]	0.0	5	1	1	1
68242	1710	tumor in vivo	[tumors in vivo]	0.0	3	1	1	1
68243	1710	alternatively, through antagonism	[alternatively, through antagonism]	0.0	3	1	1	1
68244	1710	process essential	[processes essential]	0.0	2	1	1	1
68245	1710	resolution of inflammatory disease	[resolution of inflammatory diseases]	0.0	4	1	1	1
68246	1710	two protein kda	[two proteins kDa]	0.0	3	1	1	1
68247	1710	EBNA-2 -positive -negative extract	[EBNA-2 -positive -negative extracts]	0.0	4	1	1	1
68248	1710	class complex gene transcription	[class complex gene transcription]	0.0	4	1	1	1
68249	1710	pathology LP	[pathology LP]	0.0	2	1	1	1
68250	1710	effect include change	[effects including changes]	0.0	3	1	1	1
68251	1710	transfection under control of virus	[transfection under control of virus]	0.0	5	1	1	1
68252	1710	four bzip transcription factor	[four bZIP transcription factors]	0.0	4	1	1	1
68253	1710	immediate gene of human cytomegalovirus	[immediate genes of human cytomegalovirus]	0.0	5	1	1	1
68254	1710	e2a helix-loop-helix protein	[E2A helix-loop-helix proteins]	0.0	3	1	1	1
68255	1710	constitutive expression of specific interferon isotype	[Constitutive expression of specific interferon isotypes]	0.0	6	1	1	1
68256	1710	sexual dimorphism	[sexual dimorphism]	0.0	2	1	1	1
68257	1710	transcription of important hematopoietic gene	[transcription of important hematopoietic genes]	0.0	5	1	1	1
68258	1710	isoform of the element modulator CREM	[isoforms of the element modulator CREM]	0.0	6	1	1	1
68259	1710	receptor in cortisol resistance	[receptor in cortisol resistance]	0.0	4	1	1	1
68260	1710	study responsiveness in vitro to transactivator	[studying responsiveness in vitro to transactivators]	0.0	6	1	1	1
68261	1710	type 2 effector function	[type 2 effector function]	0.0	4	1	1	1
68262	1710	yield of viral protein	[yields of viral proteins]	0.0	4	1	1	1
68263	1710	important component lead to activation	[important component leading to activation]	0.0	5	1	1	1
68264	1710	region of other sequence	[regions of other sequences]	0.0	4	1	1	1
68265	1710	cellular susceptibility	[cellular susceptibility]	0.0	2	1	1	1
68266	1710	expression after brdu incorporation	[Expression after BrdU incorporation]	0.0	4	1	1	1
68267	1710	screen of atopic individual	[screening of atopic individuals]	0.0	4	1	1	1
68268	1710	cutaneous T	[cutaneous T]	0.0	2	1	1	1
68269	1710	50% dose within P;	[50% dose within h;]	0.0	4	1	1	1
68270	1710	two overlapping cosmid	[two overlapping cosmids]	0.0	3	1	1	1
68271	1710	respectively), indicate a rate in 80.5%	[respectively), indicating an rate in 80.5%]	0.0	6	1	1	1
68272	1710	long-lived state	[long-lived state]	0.0	2	1	1	1
68273	1710	comprise a ab variable fragment	[comprising an Ab variable fragment]	0.0	5	1	1	1
68274	1710	six to 8 week	[Six to 8 weeks]	0.0	4	2	2	1
68275	1710	t-cell leukemia virus type element	[T-cell leukemia virus type element]	0.0	5	1	1	1
68276	1710	ovary (stage	[ovary (stage]	0.0	2	1	1	1
68277	1710	activation by deletion	[activation by deletions]	0.0	3	1	1	1
68278	1710	model accounting for the haploinsufficiency	[models accounting for the haploinsufficiency]	0.0	5	1	1	1
68279	1710	develop T cell	[developing T cells]	0.0	3	1	1	1
68280	1710	type of breast carcinoma	[types of breast carcinoma]	0.0	4	1	1	1
68281	1710	modulate agent, alpha,25-dihydroxycholecalciferol dhcc	[modulating agent, alpha,25-dihydroxycholecalciferol DHCC]	0.0	4	1	1	1
68282	1710	granzyme b expression	[granzyme B expression]	0.0	3	1	1	1
68283	1710	receptor related	[receptor related]	0.0	2	1	1	1
68284	1710	treatment for asthma	[treatment for asthma]	0.0	3	1	1	1
68285	1710	evidence jak1 to il-2r beta	[evidence JAK1 to IL-2R beta]	0.0	5	1	1	1
68286	1710	effect on the proliferation of lymphocyte	[effects on the proliferation of lymphocytes]	0.0	6	1	1	1
68287	1710	involvement of acid receptor	[involvement of acid receptors]	0.0	4	1	1	1
68288	1710	neutrophil -endothelial adhesion response	[neutrophil -endothelial adhesion response]	0.0	4	1	1	1
68289	1710	heart, spleen, of the animals.	[heart, spleen, of the animals.]	0.0	5	1	1	1
68290	1710	incorporate multiple antigen	[incorporating multiple antigens]	0.0	3	1	1	1
68291	1710	unidentified target gene	[unidentified target genes]	0.0	3	1	1	1
68292	1710	exposure of aortic endothelial cell	[exposure of aortic endothelial cells]	0.0	5	1	1	1
68293	1710	biochemical analysis on b-cll cell	[biochemical analysis on B-CLL cells]	0.0	5	1	1	1
68294	1710	study cytokine regulation in normal monocyte	[studying cytokine regulation in normal monocytes]	0.0	6	1	1	1
68295	1710	function of oct-1 /oca-b	[function of Oct-1 /OCA-B]	0.0	4	1	1	1
68296	1710	48 patient	[48 patients]	0.0	2	1	1	1
68297	1710	treatment of cell with lps	[Treatment of cells with LPS]	0.0	5	1	1	1
68298	1710	ebv binding on rest b cell	[EBV binding on resting B cells]	0.0	6	1	1	1
68299	1710	lead to low production of c-Jun	[leading to lower production of c-Jun]	0.0	6	1	1	1
68300	1710	(Kd) of the fms nmol/l)	[(Kd) of the FMS nmol/l)]	0.0	5	1	1	1
68301	1710	large t-cell population	[large T-cell population]	0.0	3	1	1	1
68302	1710	oxidant acid hocl mm)	[oxidant acid HOCl mM)]	0.0	4	1	1	1
68303	1710	mechanism of the SCM-1 gene	[mechanism of the SCM-1 genes]	0.0	5	1	1	1
68304	1710	Genes	[Genes]	0.0	1	1	1	1
68305	1710	13 zinc finger	[13 zinc fingers]	0.0	3	1	1	1
68306	1710	transcriptionally-active conformation in cell	[transcriptionally-active conformation in cells]	0.0	4	1	1	1
68307	1710	important role in vivo	[important roles in vivo]	0.0	4	1	1	1
68308	1710	mechanism regulate sensitivity	[mechanism regulating sensitivity]	0.0	3	1	1	1
68309	1710	maintenance of nuclear nf-kappa b	[maintenance of nuclear NF-kappa B]	0.0	5	1	1	1
68310	1710	filopodia	[filopodia]	0.0	1	1	1	1
68311	1710	effect of a formulation	[effect of a formulation]	0.0	4	1	1	1
68312	1710	concentration of metabolite of oxygen	[concentrations of metabolites of oxygen]	0.0	5	1	1	1
68313	1710	all, adenovirus type	[all, adenovirus types]	0.0	3	1	1	1
68314	1710	response to CD3 ab	[response to CD3 Ab]	0.0	4	1	1	1
68315	1710	3 colony-stimulating factor	[3 colony-stimulating factor]	0.0	3	1	1	1
68316	1710	result in level	[resulting in levels]	0.0	3	1	1	1
68317	1710	interferon-gamma in human peripheral blood lymphocyte	[interferon-gamma in human peripheral blood lymphocytes]	0.0	6	1	1	1
68318	1710	cell resistance	[cell resistance]	0.0	2	1	1	1
68319	1710	saphenous	[saphenous]	0.0	1	1	1	1
68320	1710	action of concentration of gc	[action of concentration of GC]	0.0	5	1	1	1
68321	1710	presence of (il)-2	[presence of (IL)-2]	0.0	3	1	1	1
68322	1710	hla-dr-restricted T lymphocyte	[HLA-DR-restricted T lymphocytes]	0.0	3	1	1	1
68323	1710	oligonucleotide ao	[oligonucleotides AO]	0.0	2	1	1	1
68324	1710	reactivation from latency	[reactivation from latency]	0.0	3	1	1	1
68325	1710	humara loci	[HUMARA loci]	0.0	2	1	1	1
68326	1710	exhibit behavior	[exhibiting behavior]	0.0	2	1	1	1
68327	1710	constitutive, C2	[constitutive, C2]	0.0	2	1	1	1
68328	1710	presence of (il)-4	[presence of (IL)-4]	0.0	3	1	1	1
68329	1710	family, gata-3	[family, GATA-3]	0.0	2	1	1	1
68330	1710	islet expression study	[islet expression studies]	0.0	3	1	1	1
68331	1710	parathyroid gland of animal	[parathyroid glands of animals]	0.0	4	2	2	1
68332	1710	nature of GATA-1	[nature of GATA-1]	0.0	3	1	1	1
68333	1710	three cellular transcription factor	[three cellular transcription factors]	0.0	4	1	1	1
68334	1710	gamma-ifn signal	[gamma-IFN signaling]	0.0	2	1	1	1
68335	1710	replication of human immunodeficiency virus type-1	[Replication of human immunodeficiency virus type-1]	0.0	6	1	1	1
68336	1710	acute lymphoblastic leukemia t-all	[acute lymphoblastic leukemia T-ALL]	0.0	4	1	1	1
68337	1710	virologic subtype	[virologic subtypes]	0.0	2	1	1	1
68338	1710	exercise to maximal	[exercise to maximal]	0.0	3	1	1	1
68339	1710	inactive mutant of Raf-1	[inactive mutants of Raf-1]	0.0	4	1	1	1
68340	1710	region Chr 9	[region Chr 9]	0.0	3	1	1	1
68341	1710	15 micrograms/ml	[15 micrograms/ml]	0.0	2	1	1	1
68342	1710	LCL population	[LCL populations]	0.0	2	1	1	1
68343	1710	Raf-1 kinase activity maximum at minute	[Raf-1 kinase activity maximum at min]	0.0	6	1	1	1
68344	1710	use conditions, distinct complex	[Using conditions, distinct complexes]	0.0	4	1	1	1
68345	1710	successful generation	[successful generation]	0.0	2	1	1	1
68346	1710	paracrine manner	[paracrine manner]	0.0	2	1	1	1
68347	1710	IL 6 igm production	[IL 6 IgM production]	0.0	4	1	1	1
68348	1710	gene for ice	[gene for ICE]	0.0	3	1	1	1
68349	1710	cell transcription factor ef1	[cell transcription factor EF1]	0.0	4	1	1	1
68350	1710	sequence analysis between show	[sequence analysis between shows]	0.0	4	1	1	1
68351	1710	mrna use a assay	[mRNA using a assay]	0.0	4	1	1	1
68352	1710	corticosteroid methyl prednisolone for days.	[corticosteroid methyl prednisolone for days.]	0.0	5	1	1	1
68353	1710	Jak1 intracellular signal	[Jak1 intracellular signals]	0.0	3	1	1	1
68354	1710	circulate human leukocyte	[circulating human leukocytes]	0.0	3	1	1	1
68355	1710	diverse response	[diverse responses]	0.0	2	1	1	1
68356	1710	various molecular alteration responsible	[various molecular alterations responsible]	0.0	4	1	1	1
68357	1710	wp activity by interference	[Wp activity by interference]	0.0	4	1	1	1
68358	1710	grow in the initial stage	[growing in the initial stages]	0.0	5	1	1	1
68359	1710	region responsive to glucocorticoid	[region responsive to glucocorticoids]	0.0	4	1	1	1
68360	1710	basis for the tissue-specific expression	[basis for the tissue-specific expression]	0.0	5	1	1	1
68361	1710	transcriptional upregulation	[transcriptional upregulation]	0.0	2	1	1	1
68362	1710	mouse GM-CSF	[mouse GM-CSF]	0.0	2	1	1	1
68363	1710	cell formation	[cell formation]	0.0	2	1	1	1
68364	1710	early samples, activity of egl	[early samples, activity of eGLs]	0.0	5	1	1	1
68365	1710	diffusible protein such as e-selectin	[Diffusible proteins such as E-selectin]	0.0	5	1	1	1
68366	1710	significant inactivation inconsistent	[significant inactivation inconsistent]	0.0	3	1	1	1
68367	1710	study on peripheral blood lymphocyte culture	[studies on peripheral blood lymphocyte cultures]	0.0	6	1	1	1
68368	1710	immunodeficiency virus SIV	[immunodeficiency virus SIV]	0.0	3	1	1	1
68369	1710	CsA synthesis	[CsA synthesis]	0.0	2	1	1	1
68370	1710	TRAIL apoptosis -induce ligand	[TRAIL apoptosis -inducing ligand]	0.0	4	1	1	1
68371	1710	three sp site	[three Sp sites]	0.0	3	1	1	1
68372	1710	sequence include kb of DNA	[sequence including kb of DNA]	0.0	5	1	1	1
68373	1710	cd3r element	[CD3R element]	0.0	2	1	1	1
68374	1710	t3r in lymphocyte	[T3R in lymphocytes]	0.0	3	1	1	1
68375	1710	gene mechanism	[gene mechanisms]	0.0	2	1	1	1
68376	1710	severe hyperkalemia	[severe hyperkalemia]	0.0	2	1	1	1
68377	1710	ro5-3335	[Ro5-3335]	0.0	1	1	1	1
68378	1710	continuous nuclear expression of a protein	[continuous nuclear expression of an protein]	0.0	6	1	1	1
68379	1710	p65 subunit enf)-kappa b	[p65 subunit (NF)-kappa B]	0.0	4	1	1	1
68380	1710	region of several gene	[regions of several genes]	0.0	4	1	1	1
68381	1710	correlation between lymphocytic infiltration	[correlation between lymphocytic infiltration]	0.0	4	1	1	1
68382	1710	various mode of regulation	[Various modes of regulation]	0.0	4	1	1	1
68383	1710	already addition	[already addition]	0.0	2	1	1	1
68384	1710	24 healthy woman first, second	[24 healthy women first, second]	0.0	5	1	1	1
68385	1710	blood lymphocyte with hiv-1	[blood lymphocytes with HIV-1]	0.0	4	1	1	1
68386	1710	tail of il-4ralpha	[tail of IL-4Ralpha]	0.0	3	1	1	1
68387	1710	diffuse lymphoma	[diffuse lymphomas]	0.0	2	1	1	1
68388	1710	apparently due to the desensitization	[apparently due to the desensitization]	0.0	5	1	1	1
68389	1710	T lymphocyte culture	[T lymphocyte cultures]	0.0	3	1	1	1
68390	1710	nuclear protein from IARC	[nuclear proteins from IARC]	0.0	4	1	1	1
68391	1710	kinetic a finding	[kinetics a finding]	0.0	3	1	1	1
68392	1710	Epo-dependent cell line, ut-7	[Epo-dependent cell line, UT-7]	0.0	4	1	1	1
68393	1710	interval during treatment.	[intervals during treatment.]	0.0	3	1	1	1
68394	1710	moreover, alteration	[Moreover, alteration]	0.0	2	1	1	1
68395	1710	patient with renal cell carcinoma	[patients with renal cell carcinomas]	0.0	5	2	2	1
68396	1710	1,25-dihydroxyvitamin D3 in monocyte	[1,25-dihydroxyvitamin D3 in monocytes]	0.0	4	1	1	1
68397	1710	important mediator in the response	[important mediators in the response]	0.0	5	1	1	1
68398	1710	promoter Palpha	[promoters Palpha]	0.0	2	1	1	1
68399	1710	unknown host event	[unknown host events]	0.0	3	1	1	1
68400	1710	CD40 human MMs	[CD40 human MMs]	0.0	3	1	1	1
68401	1710	own autoimmune serum	[own autoimmune serum]	0.0	3	1	1	1
68402	1710	16.5 nmol/L)	[16.5 nmol/L)]	0.0	2	1	1	1
68403	1710	tetracycline trans-activator protein	[tetracycline trans-activator protein]	0.0	3	1	1	1
68404	1710	small apolar substitution alpha-methyl, alpha-fluoromethyl	[Small apolar substitutions alpha-methyl, alpha-fluoromethyl]	0.0	5	1	1	1
68405	1710	regulate this early response	[regulating this early response]	0.0	4	1	1	1
68406	1710	Chronic immunodeficiency virus type	[Chronic immunodeficiency virus type]	0.0	4	1	1	1
68407	1710	ros activity	[ROS activity]	0.0	2	1	1	1
68408	1710	pld activation,	[PLD activation,]	0.0	2	1	1	1
68409	1710	normal sensitivity	[normal sensitivity]	0.0	2	1	1	1
68410	1710	six line by expression	[six lines by expression]	0.0	4	1	1	1
68411	1710	endotoxin lps	[endotoxin LPS]	0.0	2	1	1	1
68412	1710	ebv b lymphoid cell	[EBV B lymphoid cells]	0.0	4	1	1	1
68413	1710	other lung cell type	[Other lung cell types]	0.0	4	1	1	1
68414	1710	androgen receptor (ar)	[androgen receptor (AR)]	0.0	3	1	1	1
68415	1710	E74 site	[E74 site]	0.0	2	1	1	1
68416	1710	hiv-1 long repeat transcription in monocyte	[HIV-1 long repeat transcription in monocytes]	0.0	6	1	1	1
68417	1710	receptor isoform	[receptor isoforms]	0.0	2	1	1	1
68418	1710	reduction in T lymphocyte	[reduction in T lymphocytes]	0.0	4	1	1	1
68419	1710	adipocyte differentiation through receptor gamma	[adipocyte differentiation through receptor gamma]	0.0	5	1	1	1
68420	1710	role of acid atra	[role of acid ATRA]	0.0	4	1	1	1
68421	1710	(il)-2 gene	[(IL)-2 gene]	0.0	2	1	1	1
68422	1710	regulator factor enf)-kappa b	[regulator factor (NF)-kappa B]	0.0	4	1	1	1
68423	1710	(pcr)	[(PCR)]	0.0	1	1	1	1
68424	1710	T cell growth erratum	[T cell growth erratum]	0.0	4	1	1	1
68425	1710	mutation change	[mutation changing]	0.0	2	1	1	1
68426	1710	20- great affinity	[20- greater affinity]	0.0	3	1	1	1
68427	1710	significant fold increase	[significant fold increase]	0.0	3	1	1	1
68428	1710	proteolysis assay ligand binding affinity	[proteolysis assaying ligand binding affinities]	0.0	5	1	1	1
68429	1710	proportion of acid	[proportions of acids]	0.0	3	1	1	1
68430	1710	cotransfection with c-fo	[cotransfections with c-fos]	0.0	3	1	1	1
68431	1710	region of the gamma-gene	[region of the gamma-gene]	0.0	4	1	1	1
68432	1710	pp56(lck) mutant lack the catalytic domain	[pp56(lck) mutants lacking the catalytic domain]	0.0	6	1	1	1
68433	1710	mediate thymocyte apoptosis,	[mediating thymocyte apoptosis,]	0.0	3	1	1	1
68434	1710	class I-restricted CTL	[class I-restricted CTLs]	0.0	3	1	1	1
68435	1710	characterization of HZF 11-42	[characterization of HZF 11-42]	0.0	4	1	1	1
68436	1710	peripheral leukocyte of healthy male	[peripheral leukocytes of healthy males]	0.0	5	1	1	1
68437	1710	dependent adhesion of cell	[dependent adhesion of cells]	0.0	4	1	1	1
68438	1710	lack er peptide	[lacking ER peptides]	0.0	3	1	1	1
68439	1710	pebp2 alpha a aml1	[PEBP2 alpha A AML1]	0.0	4	1	1	1
68440	1710	permit the release of functional nf-kappab	[permitting the release of functional NF-kappaB]	0.0	6	1	1	1
68441	1710	three alpha-helice with a proportion	[three alpha-helices with a proportion]	0.0	5	1	1	1
68442	1710	follow exposure to 12-o-tetradecanoylphorbol-13-acetate tpa	[following exposures to 12-O-tetradecanoylphorbol-13-acetate TPA]	0.0	5	1	1	1
68443	1710	il-2 blockade in T cell clone	[IL-2 blockade in T cell clones]	0.0	6	1	1	1
68444	1710	receptor by glucocorticoid	[receptor by glucocorticoids]	0.0	3	1	1	1
68445	1710	monocytic gene tnf-alpha	[monocytic genes TNF-alpha]	0.0	3	1	1	1
68446	1710	suggest a effect of B7	[suggesting a effect of B7]	0.0	5	1	1	1
68447	1710	Non-steroidal drug	[Non-steroidal drugs]	0.0	2	1	1	1
68448	1710	gamma- antibody	[gamma- antibodies]	0.0	2	1	1	1
68449	1710	interferon gamma IFNgamma a activator	[interferon gamma IFNgamma a activator]	0.0	5	1	1	1
68450	1710	expression of CD40 on melanoma	[expression of CD40 on melanomas]	0.0	5	1	1	1
68451	1710	homozygous codeletion	[homozygous codeletion]	0.0	2	1	1	1
68452	1710	powerful activator of factor	[powerful activators of factors]	0.0	4	1	1	1
68453	1710	PMA pathway	[PMA pathway]	0.0	2	1	1	1
68454	1710	activation of Epstein-Barr virus replication	[activation of Epstein-Barr virus replication]	0.0	5	1	1	1
68455	1710	p-selectin translocation a transcription factor	[P-selectin translocation a transcription factor]	0.0	5	1	1	1
68456	1710	human red blood cell hrbc	[human red blood cells HRBC]	0.0	5	1	1	1
68457	1710	biphasic activation	[biphasic activation]	0.0	2	1	1	1
68458	1710	31834500), (range,	[3183-4450), (range,]	0.0	2	1	1	1
68459	1710	more infiltrate melanoma	[more infiltrating melanomas]	0.0	3	1	1	1
68460	1710	cytosine binding	[cytosine binding]	0.0	2	1	1	1
68461	1710	pattern of expression of gene	[patterns of expression of genes]	0.0	5	1	1	1
68462	1710	cloning a slp-76 phosphoprotein	[cloning a SLP-76 phosphoprotein]	0.0	4	1	1	1
68463	1710	chromosome 4	[chromosome 4]	0.0	2	1	1	1
68464	1710	degree dephosphorylation	[degree dephosphorylation]	0.0	2	1	1	1
68465	1710	number of kinases, include PKC	[number of kinases, including PKC]	0.0	5	1	1	1
68466	1710	other steroid include DHEA sulfate	[other steroids including DHEA sulfate]	0.0	5	1	1	1
68467	1710	chromosome 1	[chromosome 1]	0.0	2	1	1	1
68468	1710	-restricted fashion	[-restricted fashion]	0.0	2	1	1	1
68469	1710	competition analysis consensus sequence oligonucleotide	[competition analysis consensus sequence oligonucleotides]	0.0	5	1	1	1
68470	1710	linkage of er codon polymorphism	[linkage of ER codon polymorphism]	0.0	5	1	1	1
68471	1710	less rt-pcr product	[less RT-PCR product]	0.0	3	1	1	1
68472	1710	matrix component	[matrix components]	0.0	2	1	1	1
68473	1710	designation	[designation]	0.0	1	1	1	1
68474	1710	gene of the Rel family	[genes of the Rel family]	0.0	5	1	1	1
68475	1710	heterozygous DNA variation 2418delA	[heterozygous DNA variations 2418delA]	0.0	4	1	1	1
68476	1710	physico-chemical parameter	[physico-chemical parameters]	0.0	2	1	1	1
68477	1710	regulatory unit consist	[regulatory unit consisting]	0.0	3	1	1	1
68478	1710	transduce a raralpha	[transducing a RARalpha]	0.0	3	1	1	1
68479	1710	producer of IL-2	[producers of IL-2]	0.0	3	1	1	1
68480	1710	bcl-6 phenotype	[BCL-6 phenotype]	0.0	2	1	1	1
68481	1710	gamma activation site probe	[gamma activation site probe]	0.0	4	1	1	1
68482	1710	(encoding	[(encoding]	0.0	1	1	1	1
68483	1710	agent on human cell activation	[agents on human cell activation]	0.0	5	1	1	1
68484	1710	apoptosis in murine thymoma cell	[apoptosis in murine thymoma cells]	0.0	5	1	1	1
68485	1710	support a receptor-mediated mechanism	[supporting a receptor-mediated mechanism]	0.0	4	1	1	1
68486	1710	GC with a ill-defined border	[GC with an ill-defined border]	0.0	5	1	1	1
68487	1710	aortic cell harc	[aortic cells HAECs]	0.0	3	1	1	1
68488	1710	tlr by microbial lipoprotein	[TLRs by microbial lipoproteins]	0.0	4	1	1	1
68489	1710	IL-3 colony-stimumulatelany-stg factor two complex	[IL-3 colony-stimulating factor two complexes]	0.0	5	1	1	1
68490	1710	breast tumor lymphocyte brtal	[breast tumor lymphocytes BRTAL]	0.0	4	1	1	1
68491	1710	However, sequence specificity	[However, sequence specificity]	0.0	3	1	1	1
68492	1710	mobility kd)	[mobility kD)]	0.0	2	1	1	1
68493	1710	regulation of nf kappab	[regulation of NF kappaB]	0.0	4	1	1	1
68494	1710	blood b lymphocyte	[blood B lymphocytes]	0.0	3	1	1	1
68495	1710	binding capacity mbc	[binding capacity MBC]	0.0	3	1	1	1
68496	1710	reading frame of amino acid	[reading frame of amino acids]	0.0	5	2	2	1
68497	1710	mediator pathways.	[mediator pathways.]	0.0	2	1	1	1
68498	1710	nfat complex formation	[NFAT complex formation]	0.0	3	1	1	1
68499	1710	much high intracellular activity	[much higher intracellular activity]	0.0	4	1	1	1
68500	1710	results: in blood of woman	[RESULTS: In blood of women]	0.0	5	1	1	1
68501	1710	factor GM-CSF	[factor GM-CSF]	0.0	2	1	1	1
68502	1710	NF-kappaB function as a proapoptotic factor	[NF-kappaB functions as a proapoptotic factor]	0.0	6	1	1	1
68503	1710	undetected gene product	[undetected gene products]	0.0	3	1	1	1
68504	1710	diverse syndrome include disease	[diverse syndromes including diseases]	0.0	4	1	1	1
68505	1710	parameter of the molecular protein	[parameters of the molecular proteins]	0.0	5	1	1	1
68506	1710	thus indicate sensitive	[thus indicating sensitive]	0.0	3	1	1	1
68507	1710	disorder patient	[disorder patients]	0.0	2	1	1	1
68508	1710	cellular pkc activity	[cellular PKC activity]	0.0	3	1	1	1
68509	1710	Karyotypic detection of chromosomal abnormality	[Karyotypic detection of chromosomal abnormalities]	0.0	5	1	1	1
68510	1710	distinct heteromeric complex	[distinct heteromeric complexes]	0.0	3	1	1	1
68511	1710	certain cytokine	[certain cytokines]	0.0	2	1	1	1
68512	1710	expression of c-rel/p50 heterodimer	[expression of c-Rel/p50 heterodimers]	0.0	4	1	1	1
68513	1710	human b-cell lymphoma especially lymphoma	[human B-cell lymphomas especially lymphomas]	0.0	5	1	1	1
68514	1710	4 nm growth factor	[4 nM growth factor]	0.0	4	1	1	1
68515	1710	heterodimerization of c-Jun	[heterodimerization of c-Jun]	0.0	3	1	1	1
68516	1710	high-density pbmc culture	[high-density PBMC cultures]	0.0	3	1	1	1
68517	1710	integrin-containing focal adhesion	[integrin-containing focal adhesions]	0.0	3	1	1	1
68518	1710	rate of synthesis	[rate of synthesis]	0.0	3	1	1	1
68519	1710	receptor binding specificity cd336	[receptor binding specificity CD336]	0.0	4	1	1	1
68520	1710	recurrent abnormality in disorder	[recurrent abnormality in disorders]	0.0	4	1	1	1
68521	1710	use as a crosslinker	[use as a crosslinker]	0.0	4	1	1	1
68522	1710	inhibition by a form of calcineurin	[Inhibition by a form of calcineurin]	0.0	6	1	1	1
68523	1710	palindrome alone	[palindrome alone]	0.0	2	1	1	1
68524	1710	Intimate interaction between hemopoietic stem cell	[Intimate interactions between hemopoietic stem cells]	0.0	6	1	1	1
68525	1710	presence of normal granulocyte	[presence of normal granulocytes]	0.0	4	1	1	1
68526	1710	essential protein for the replication	[essential protein for the replication]	0.0	5	1	1	1
68527	1710	patient 3 years)	[patients 3 years)]	0.0	3	1	1	1
68528	1710	t-cell precursor in bone marrow	[T-cell precursors in bone marrow]	0.0	5	1	1	1
68529	1710	fkbp cDNA	[FKBP cDNA]	0.0	2	1	1	1
68530	1710	cessation	[cessation]	0.0	1	1	1	1
68531	1710	reporter gata-1/lacz gene	[reporter GATA-1/lacZ genes]	0.0	3	1	1	1
68532	1710	stimulator of monocyte	[stimulator of monocytes]	0.0	3	1	1	1
68533	1710	viral transactivator zebra	[viral transactivator ZEBRA]	0.0	3	1	1	1
68534	1710	L-selectin gene in cell	[L-selectin gene in cells]	0.0	4	1	1	1
68535	1710	ptdin 3-kinase in Ras	[PtdIns 3-kinase in Ras]	0.0	4	1	1	1
68536	1710	other mediator	[other mediators]	0.0	2	2	2	1
68537	1710	function of T lymphocyte	[function of T lymphocytes]	0.0	4	1	1	1
68538	1710	prolonged exposure of aortic cell	[prolonged exposure of aortic cells]	0.0	5	1	1	1
68539	1710	activation of the long terminal repeat	[activation of the long terminal repeat]	0.0	6	1	1	1
68540	1710	switch -to adult expression	[switch -to adult expression]	0.0	4	1	1	1
68541	1710	use stringent systems,	[using stringent systems,]	0.0	3	1	1	1
68542	1710	structure distinct from the annular structure	[structures distinct from the annular structures]	0.0	6	1	1	1
68543	1710	suggest a mixture	[suggesting a mixture]	0.0	3	1	1	1
68544	1710	observation on Tcf-1 mouse	[observations on Tcf-1 mice]	0.0	4	1	1	1
68545	1710	content of t3, dysfunction	[content of T3, dysfunction]	0.0	4	1	1	1
68546	1710	defective nuclear translocation	[defective nuclear translocation]	0.0	3	1	1	1
68547	1710	activator protein BSAP	[activator protein BSAP]	0.0	3	2	2	1
68548	1710	NK/T cell progenitor	[NK/T cell progenitors]	0.0	3	1	1	1
68549	1710	affect growth of cell type	[affecting growth of cell types]	0.0	5	1	1	1
68550	1710	Specifically, removal	[Specifically, removal]	0.0	2	1	1	1
68551	1710	form of active transcription factor creb	[forms of active transcription factor CREB]	0.0	6	1	1	1
68552	1710	myelopoiesis in cell	[myelopoiesis in cells]	0.0	3	1	1	1
68553	1710	induce expression in lymphoblastoid cell	[inducing expression in lymphoblastoid cells]	0.0	5	1	1	1
68554	1710	finding, experiment	[finding, experiments]	0.0	2	1	1	1
68555	1710	MLV transcriptional activity	[MLV transcriptional activity]	0.0	3	1	1	1
68556	1710	oxidant signal	[oxidant signaling]	0.0	2	1	1	1
68557	1710	AM580 a derivative of acid	[AM580 a derivative of acid]	0.0	5	1	1	1
68558	1710	receptor /cell for type	[receptors /cell for type]	0.0	4	1	1	1
68559	1710	class histocompatibility complex gene DPA	[class histocompatibility complex gene DPA]	0.0	5	1	1	1
68560	1710	stat5 to all	[STAT5 to all]	0.0	3	1	1	1
68561	1710	(b) level	[(b) levels]	0.0	2	1	1	1
68562	1710	hyperreactive pituitary adrenocorticotropic hormone release	[hyperreactive pituitary adrenocorticotropic hormone release]	0.0	5	1	1	1
68563	1710	potent stimulator of monocyte	[potent stimulator of monocytes]	0.0	4	1	1	1
68564	1710	112 patient	[112 patients]	0.0	2	1	1	1
68565	1710	ag amino	[Ag amino]	0.0	2	1	1	1
68566	1710	human vein cell huvec monolayer	[human vein cell HUVEC monolayers]	0.0	5	1	1	1
68567	1710	cytokine-stimulated umbilical vein cell HUVEC	[cytokine-stimulated umbilical vein cells HUVEC]	0.0	5	1	1	1
68568	1710	disease-resistant mangabey	[disease-resistant mangabeys]	0.0	2	1	1	1
68569	1710	return after P.	[returning after h.]	0.0	3	1	1	1
68570	1710	interleukin -9-mediate cell proliferation	[interleukin -9-mediated cell proliferation]	0.0	4	1	1	1
68571	1710	tract infection	[tract infection]	0.0	2	1	1	1
68572	1710	inducible genes,	[inducible genes,]	0.0	2	1	1	1
68573	1710	expression of inflammatory gene	[expression of inflammatory genes]	0.0	4	1	1	1
68574	1710	ebv-transformed b cell line	[EBV-transformed B cell lines]	0.0	4	1	1	1
68575	1710	encode for myeloperoxidase	[encoding for myeloperoxidase]	0.0	3	1	1	1
68576	1710	human cell THP-1	[human cells THP-1]	0.0	3	1	1	1
68577	1710	result of blood pressure measurement	[results of blood pressure measurements]	0.0	5	1	1	1
68578	1710	activation of human blood T lymphoblast	[activation of human blood T lymphoblasts]	0.0	6	1	1	1
68579	1710	media-stimulated t-cell	[media-stimulated T-cells]	0.0	2	1	1	1
68580	1710	cytokine release from cell	[cytokine release from cells]	0.0	4	1	1	1
68581	1710	time of monocyte in culture	[time of monocytes in culture]	0.0	5	1	1	1
68582	1710	non-mammalian cytokine gene mapped.	[non-mammalian cytokine gene mapped.]	0.0	4	1	1	1
68583	1710	regulation of human interleukin 2 gene	[regulation of human interleukin 2 gene]	0.0	6	1	1	1
68584	1710	signalling complex	[signalling complexes]	0.0	2	1	1	1
68585	1710	regulator nuclear factor	[regulator nuclear factor]	0.0	3	1	1	1
68586	1710	MHC class ii gene transcription one	[MHC class II gene transcription one]	0.0	6	1	1	1
68587	1710	(i) level of oncogene transcript	[(i) levels of oncogene transcripts]	0.0	5	1	1	1
68588	1710	elucidate the mechanism	[elucidating the mechanisms]	0.0	3	1	1	1
68589	1710	complex process involve interaction	[complex process involving interactions]	0.0	4	1	1	1
68590	1710	thus a potential target	[thus a potential target]	0.0	4	1	1	1
68591	1710	two potential factor (NF)-kappaB binding site	[two potential factor (NF)-kappaB binding sites]	0.0	6	1	1	1
68592	1710	copyright by the Society of Hematology.	[Copyright by The Society of Hematology.]	0.0	6	1	1	1
68593	1710	proportion to dp2	[proportion to DP2]	0.0	3	1	1	1
68594	1710	viral terminal repeat LTR	[viral terminal repeat LTR]	0.0	4	5	5	1
68595	1710	tyrosine-based inhibition motif.	[tyrosine-based inhibition motif.]	0.0	3	1	1	1
68596	1710	hypersensitive site (HS 2)	[hypersensitive site (HS 2)]	0.0	4	1	1	1
68597	1710	t-cell from individual with pathology	[T-cells from individuals with pathology]	0.0	5	1	1	1
68598	1710	nfat -dependent expression	[NFAT -dependent expression]	0.0	3	1	1	1
68599	1710	influence on susceptibility	[Influence on susceptibility]	0.0	3	1	1	1
68600	1710	regulate a critical b gene	[regulating a critical B gene]	0.0	5	1	1	1
68601	1710	combination of anti-Tat intrabody	[combination of anti-Tat intrabodies]	0.0	4	1	1	1
68602	1710	GATA1 transcription factor	[GATA1 transcription factor]	0.0	3	1	1	1
68603	1710	g protein activation	[G protein activation]	0.0	3	1	1	1
68604	1710	(ie) response gene	[(IE) response genes]	0.0	3	1	1	1
68605	1710	response to differentiation	[response to differentiation]	0.0	3	1	1	1
68606	1710	twice/d,	[twice/d,]	0.0	1	1	1	1
68607	1710	use the region	[Using the region]	0.0	3	1	1	1
68608	1710	pml expression by interferon	[PML expression by interferons]	0.0	4	1	1	1
68609	1710	cell with 135-(oh)2d3	[cells with 1,25-(OH)2D3]	0.0	3	1	1	1
68610	1710	starting with a molecular clone	[Starting with a molecular clone]	0.0	5	1	1	1
68611	1710	clone cell	[clone cells]	0.0	2	1	1	1
68612	1710	cytoplasmic location:	[cytoplasmic location:]	0.0	2	1	1	1
68613	1710	production of interleukin-12 IL-12	[production of interleukin-12 IL-12]	0.0	4	1	1	1
68614	1710	amino acid peptide encompass	[amino acid peptides encompassing]	0.0	4	1	1	1
68615	1710	comparison with donor	[comparison with donors]	0.0	3	1	1	1
68616	1710	However, replication	[However, replication]	0.0	2	1	1	1
68617	1710	promoter dependent on the binding	[promoter dependent on the binding]	0.0	5	1	1	1
68618	1710	3' c/ebp site	[3' C/EBP sites]	0.0	3	1	1	1
68619	1710	highlight putative loci relevant	[highlighting putative loci relevant]	0.0	4	1	1	1
68620	1710	immuno-pathological condition such as disease	[immuno-pathological conditions such as diseases]	0.0	5	1	1	1
68621	1710	patient (17	[patients (17]	0.0	2	1	1	1
68622	1710	dominant IkappaB mutant	[dominant IkappaB mutant]	0.0	3	1	1	1
68623	1710	Deoxycholate	[Deoxycholate]	0.0	1	2	2	1
68624	1710	SLP-76 leukocyte protein	[SLP-76 leukocyte protein]	0.0	3	1	1	1
68625	1710	localize to genital hsv lesion	[localizing to genital HSV lesions]	0.0	5	1	1	1
68626	1710	deficient proliferative ability	[deficient proliferative ability]	0.0	3	1	1	1
68627	1710	transcription factor of the nfat family	[Transcription factors of the NFAT family]	0.0	6	1	1	1
68628	1710	utilize vector	[utilizing vectors]	0.0	2	1	1	1
68629	1710	nephew	[nephew]	0.0	1	1	1	1
68630	1710	role in low vcam-1 expression	[role in low VCAM-1 expression]	0.0	5	1	1	1
68631	1710	normal counterpart to chronic leukemia	[normal counterpart to chronic leukemias]	0.0	5	1	1	1
68632	1710	formation of two distinct complex	[formation of two distinct complexes]	0.0	5	1	1	1
68633	1710	repression"	[repression"]	0.0	1	1	1	1
68634	1710	p4 nfat	[P4 NFAT]	0.0	2	1	1	1
68635	1710	Ki-67 staining	[Ki-67 staining]	0.0	2	1	1	1
68636	1710	peptide micrograms),	[peptide micrograms),]	0.0	2	1	1	1
68637	1710	activity of a CD40-specific single-chain Fv	[activity of a CD40-specific single-chain Fv]	0.0	6	1	1	1
68638	1710	cell surface maturation-specific antigen	[cell surface maturation-specific antigens]	0.0	4	1	1	1
68639	1710	vitamin D3 metabolite 1,25-dihydroxycholecalciferol 135(oh)2d3	[vitamin D3 metabolite 1,25-dihydroxycholecalciferol 1,25(OH)2D3]	0.0	5	1	1	1
68640	1710	tissue-specific primary response	[tissue-specific primary response]	0.0	3	1	1	1
68641	1710	marker Neo(r)	[marker Neo(r)]	0.0	2	1	1	1
68642	1710	live-attenuated immunodeficiency virus hiv	[Live-attenuated immunodeficiency viruses HIVs]	0.0	4	1	1	1
68643	1710	only differentiate	[only differentiating]	0.0	2	1	1	1
68644	1710	concentration inhibit ige synthesis (10(-10)	[concentrations inhibiting IgE synthesis (10(-10)]	0.0	5	1	1	1
68645	1710	advance in regulation	[advances in regulation]	0.0	3	1	1	1
68646	1710	localization of this protein	[localization of these proteins]	0.0	4	1	1	1
68647	1710	mobility assay	[mobility assays]	0.0	2	1	1	1
68648	1710	maintain variation in the class molecule	[maintaining variation in the class molecule]	0.0	6	1	1	1
68649	1710	use the region as the bait	[Using the region as the bait]	0.0	6	1	1	1
68650	1710	-interaction	[-interaction]	0.0	1	1	1	1
68651	1710	individual of particular histocompatibility (mhc) haplotype	[individuals of particular histocompatibility (MHC) haplotypes]	0.0	6	1	1	1
68652	1710	LTR activity in	[LTR activity in]	0.0	3	1	1	1
68653	1710	only the immunodominant epitope	[only the immunodominant epitope]	0.0	4	1	1	1
68654	1710	analysis of mrna from hypoxic ECs	[analysis of mRNA from hypoxic ECs]	0.0	6	1	1	1
68655	1710	study of the functional immunity	[studies of the functional immunity]	0.0	5	1	1	1
68656	1710	strong transactivator	[strong transactivator]	0.0	2	1	1	1
68657	1710	latent epitope	[latent epitopes]	0.0	2	1	1	1
68658	1710	however, target for PI3K	[However, targets for PI3K]	0.0	4	1	1	1
68659	1710	Potent inhibition of hiv type	[Potent inhibition of HIV type]	0.0	5	1	1	1
68660	1710	multiple critical element	[multiple critical elements]	0.0	3	1	1	1
68661	1710	mouse raw264.7	[mouse RAW264.7]	0.0	2	1	1	1
68662	1710	induction infection	[Induction infection]	0.0	2	1	1	1
68663	1710	role induction	[role induction]	0.0	2	1	1	1
68664	1710	pathway regulate integrin gene expression	[pathway regulating integrin gene expression]	0.0	5	1	1	1
68665	1710	expression analysis in cell	[expression analyses in cells]	0.0	4	1	1	1
68666	1710	leukemia/lymphoma line	[leukemia/lymphoma lines]	0.0	2	1	1	1
68667	1710	interferon regulatory factor 2 gene	[interferon regulatory factor 2 gene]	0.0	5	1	1	1
68668	1710	potencies,	[potencies,]	0.0	1	1	1	1
68669	1710	receptor-triggered biochemical events,	[receptor-triggered biochemical events,]	0.0	3	1	1	1
68670	1710	very low level of hiv production	[very low levels of HIV production]	0.0	6	1	1	1
68671	1710	peripheral-blood lymphocyte	[peripheral-blood lymphocytes]	0.0	2	1	1	1
68672	1710	upregulation of epsilon germline transcription	[upregulation of epsilon germline transcription]	0.0	5	1	1	1
68673	1710	human cytomegalovirus binding	[Human cytomegalovirus binding]	0.0	3	1	1	1
68674	1710	factor NFs	[factors NFs]	0.0	2	1	1	1
68675	1710	10 year Gail risk probability)	[10 year Gail risk probability)]	0.0	5	1	1	1
68676	1710	failure patient	[failure patients]	0.0	2	1	1	1
68677	1710	study from laboratory	[studies from laboratory]	0.0	3	1	1	1
68678	1710	early g1 protein	[early G1 proteins]	0.0	3	1	1	1
68679	1710	monocytic characteristic	[monocytic characteristics]	0.0	2	1	1	1
68680	1710	calcemic effect	[calcemic effects]	0.0	2	1	1	1
68681	1710	cotransfection with IL-4 stat	[Cotransfection with IL-4 Stat]	0.0	4	1	1	1
68682	1710	detection of signal protein	[Detection of signaling proteins]	0.0	4	1	1	1
68683	1710	novel T element	[novel T element]	0.0	3	1	1	1
68684	1710	novel cellular tip-associated protein	[novel cellular Tip-associated protein]	0.0	4	1	1	1
68685	1710	stage-specific gene expression	[stage-specific gene expression]	0.0	3	1	1	1
68686	1710	addition, this age-related decrease	[addition, this age-related decrease]	0.0	4	1	1	1
68687	1710	notion direct substrate in cells.	[notion direct substrates in cells.]	0.0	5	1	1	1
68688	1710	stress-induced down-regulation of response	[stress-induced down-regulation of responses]	0.0	4	1	1	1
68689	1710	block MKK activity	[blocking MKK activity]	0.0	3	1	1	1
68690	1710	breakpoint 130 kb	[breakpoints 130 kb]	0.0	3	1	1	1
68691	1710	activation of host intracellular event	[Activation of host intracellular events]	0.0	5	1	1	1
68692	1710	triiodothyronine mononuclear leukocyte receptor kinetic	[triiodothyronine mononuclear leukocyte receptor kinetics]	0.0	5	1	1	1
68693	1710	myeloid lineage development	[myeloid lineage development]	0.0	3	1	1	1
68694	1710	range of biological effect related	[range of biological effects related]	0.0	5	1	1	1
68695	1710	substitution in the peptide	[substitution in the peptide]	0.0	4	1	1	1
68696	1710	10 patient with affinity	[10 patients with affinity]	0.0	4	1	1	1
68697	1710	chymotryptic activity independent	[chymotryptic activity independent]	0.0	3	1	1	1
68698	1710	results: neutrophil adhesion to corneal cell	[RESULTS: Neutrophil adhesion to corneal cells]	0.0	6	1	1	1
68699	1710	c/ebP-binding site bp	[C/EBP-binding site bp]	0.0	3	1	1	1
68700	1710	respect use a assay	[respect using a assay]	0.0	4	1	1	1
68701	1710	T cell of individual	[T cells of individuals]	0.0	4	1	1	1
68702	1710	alpha-chain of il-2ralpha	[alpha-chain of IL-2Ralpha]	0.0	3	1	1	1
68703	1710	(from hour 1 of the enzyme	[(from hours 1 of the enzyme]	0.0	6	1	1	1
68704	1710	anti-estrogen toremifene therapy	[anti-estrogen toremifene therapy]	0.0	3	1	1	1
68705	1710	involve the arm of chromosome 11	[involving the arm of chromosome 11]	0.0	6	1	1	1
68706	1710	role of promoter sequence	[role of promoter sequences]	0.0	4	1	1	1
68707	1710	approximately 80% treatment	[approximately 80% treatment]	0.0	3	1	1	1
68708	1710	stimulation of b-cell from B-CLL patient	[stimulation of B-cells from B-CLL patients]	0.0	6	1	1	1
68709	1710	cancer therapy	[cancer therapy]	0.0	2	1	1	1
68710	1710	transactivate nuclear factor	[transactivating nuclear factor]	0.0	3	1	1	1
68711	1710	two other nonselective RAR ligand	[two other nonselective RAR ligands]	0.0	5	1	1	1
68712	1710	subsequent analysis of transcription factor generation	[subsequent analysis of transcription factor generation]	0.0	6	1	1	1
68713	1710	results: neutrophil adhesion to endothelial cell	[RESULTS: Neutrophil adhesion to endothelial cells]	0.0	6	1	1	1
68714	1710	stimulation with growth factor	[stimulation with growth factors]	0.0	4	1	1	1
68715	1710	olr1	[OLR1]	0.0	1	1	1	1
68716	1710	sites/cell respectively, p	[sites/cell respectively, P]	0.0	3	1	1	1
68717	1710	pathophysiology of myeloid leukaemia	[pathophysiology of myeloid leukaemia]	0.0	4	1	1	1
68718	1710	release of il-4	[release of IL-4]	0.0	3	1	1	1
68719	1710	10 micrograms/mL etoposide	[10 micrograms/mL etoposide]	0.0	3	1	1	1
68720	1710	important molecule capable	[important molecule capable]	0.0	3	1	1	1
68721	1710	UAS1 -140	[UAS1 -140]	0.0	2	1	1	1
68722	1710	Differential autoregulation of glucocorticoid receptor expression	[Differential autoregulation of glucocorticoid receptor expression]	0.0	6	1	1	1
68723	1710	semen	[semen]	0.0	1	1	1	1
68724	1710	SLP-76 two hematopoietic cell molecule	[SLP-76 two hematopoietic cell molecules]	0.0	5	1	1	1
68725	1710	weak complex resemble nuclear factor	[weak complex resembling nuclear factor]	0.0	5	1	1	1
68726	1710	gata element of hiv-1 repeat	[GATA elements of HIV-1 repeat]	0.0	5	1	1	1
68727	1710	c-myb target gene	[c-Myb target genes]	0.0	3	1	1	1
68728	1710	hladq	[HLADQ]	0.0	1	1	1	1
68729	1710	stat transducer of transcription)	[STAT transducers of transcription)]	0.0	4	1	1	1
68730	1710	datum available relate ros activity	[data available relating ROS activity]	0.0	5	1	1	1
68731	1710	rapid dominance	[rapid dominance]	0.0	2	1	1	1
68732	1710	immunodeficiency virus type cell	[immunodeficiency virus type cells]	0.0	4	1	1	1
68733	1710	11 copy	[11 copies]	0.0	2	1	1	1
68734	1710	chromosome 11 at band 11p15	[chromosome 11 at band 11p15]	0.0	5	1	1	1
68735	1710	various breakpoint on chromosome	[various breakpoints on chromosome]	0.0	4	1	1	1
68736	1710	(6 wk to mo)	[(6 wk to mo)]	0.0	4	1	1	1
68737	1710	have a -rich region	[having a -rich region]	0.0	4	1	1	1
68738	1710	previous hour earlier) exposure	[previous hours earlier) exposure]	0.0	4	1	1	1
68739	1710	Rather,	[Rather,]	0.0	1	1	1	1
68740	1710	cellular mediator of tip function	[cellular mediator of Tip function]	0.0	5	1	1	1
68741	1710	activation via this pathway	[activation via this pathway]	0.0	4	1	1	1
68742	1710	expression of a viral protein	[expression of a viral protein]	0.0	5	1	1	1
68743	1710	secretion of chemotactic protein-1	[secretion of chemotactic protein-1]	0.0	4	1	1	1
68744	1710	sense, in situation	[sense, in situations]	0.0	3	1	1	1
68745	1710	g-csfr nfs-60 cell	[G-CSFR NFS-60 cells]	0.0	3	1	1	1
68746	1710	poor response	[poor response]	0.0	2	1	1	1
68747	1710	protein gata-1	[protein GATA-1]	0.0	2	1	1	1
68748	1710	promoter BMRF1	[promoter BMRF1]	0.0	2	1	1	1
68749	1710	co-cultured epithelial cell	[co-cultured epithelial cells]	0.0	3	1	1	1
68750	1710	efficient phosphorylation	[efficient phosphorylation]	0.0	2	1	1	1
68751	1710	four near-perfect direct repeat of bp	[four near-perfect direct repeats of bp]	0.0	6	1	1	1
68752	1710	nuclear factor (NF)-AT NF-AT	[nuclear factor (NF)-AT NF-AT]	0.0	4	1	1	1
68753	1710	human prolactin gene transcription	[human prolactin gene transcription]	0.0	4	1	1	1
68754	1710	substitution binding	[substitution binding]	0.0	2	1	1	1
68755	1710	promoter for marker include CD2	[promoters for markers including CD2]	0.0	5	1	1	1
68756	1710	positive regulatory role	[positive regulatory role]	0.0	3	1	1	1
68757	1710	level fluoride-resistant- alpha-naphthyl-acetate-esterase naf-r-nse	[levels fluoride-resistant- alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	4	1	1	1
68758	1710	sensitivity to Bcl-2	[sensitivity to Bcl-2]	0.0	3	1	1	1
68759	1710	specific power of receptor	[specific power of receptor]	0.0	4	1	1	1
68760	1710	PML body PML NBs	[PML bodies PML NBs]	0.0	4	1	1	1
68761	1710	moreover, the factor	[Moreover, the factor]	0.0	3	1	1	1
68762	1710	distinct il-4 signal pathway	[distinct IL-4 signaling pathways]	0.0	4	1	1	1
68763	1710	nf-m promoter construct	[NF-M promoter constructs]	0.0	3	1	1	1
68764	1710	neu-related lipocalin NRL	[neu-related lipocalin NRL]	0.0	3	1	1	1
68765	1710	one important factor	[one important factor]	0.0	3	1	1	1
68766	1710	competitive transcription polymerase chain reaction	[competitive transcription polymerase chain reaction]	0.0	5	1	1	1
68767	1710	determine the regulation of this promoter	[determining the regulation of this promoter]	0.0	6	1	1	1
68768	1710	categories: induction	[categories: induction]	0.0	2	1	1	1
68769	1710	Recently, activation	[Recently, activation]	0.0	2	1	1	1
68770	1710	pseudogene	[pseudogenes]	0.0	1	1	1	1
68771	1710	full-length hiv transcript	[full-length HIV transcripts]	0.0	3	1	1	1
68772	1710	monocyte-macrophage lineage-associated surface antigen	[monocyte-macrophage lineage-associated surface antigen]	0.0	4	1	1	1
68773	1710	three additional agent	[Three additional agents]	0.0	3	1	1	1
68774	1710	stat5b in erythroid precursor	[STAT5B in erythroid precursors]	0.0	4	1	1	1
68775	1710	2 myeloid progenitor cell	[2 myeloid progenitor cells]	0.0	4	1	1	1
68776	1710	exception, and/or with secretory/transport functions.	[exception, and/or with secretory/transport functions.]	0.0	5	1	1	1
68777	1710	vein cell huvec monolayer	[vein cell HUVEC monolayers]	0.0	4	1	1	1
68778	1710	2.3 0.9 (1.1-4.4) fmol/10(7) cell	[2.3 0.9 (1.1-4.4) fmol/10(7) cells]	0.0	5	3	3	1
68779	1710	cooperative model	[cooperative model]	0.0	2	1	1	1
68780	1710	percutaneous transluminal angioplasty PTCA	[percutaneous transluminal angioplasty PTCA]	0.0	4	1	1	1
68781	1710	stimulate factor	[stimulating factor]	0.0	2	1	1	1
68782	1710	muscle gene	[muscle genes]	0.0	2	1	1	1
68783	1710	class ii histocompatibility gene hla-dra	[class II histocompatibility gene HLA-DRA]	0.0	5	1	1	1
68784	1710	kinases, include PKC	[kinases, including PKC]	0.0	3	1	1	1
68785	1710	child with the sign	[children with the signs]	0.0	4	1	1	1
68786	1710	survival of cell undergo apoptosis	[survival of cells undergoing apoptosis]	0.0	5	1	1	1
68787	1710	novel RAR antagonist er27191	[novel RAR antagonist ER27191]	0.0	4	1	1	1
68788	1710	42 month (range,	[42 months (range,]	0.0	3	1	1	1
68789	1710	evidence the only CsA component	[evidence the only CsA component]	0.0	5	1	1	1
68790	1710	cell surface recognition	[cell surface recognition]	0.0	3	1	1	1
68791	1710	role of multiple sites.	[role of multiple sites.]	0.0	4	1	1	1
68792	1710	receptor engagement by ligands,	[receptor engagement by ligands,]	0.0	4	1	1	1
68793	1710	glycosylphosphatidylinositol-linked antigen	[glycosylphosphatidylinositol-linked antigen]	0.0	2	1	1	1
68794	1710	cell in the liver	[cells in the liver]	0.0	4	1	1	1
68795	1710	JAK phosphorylation	[JAK phosphorylation]	0.0	2	1	1	1
68796	1710	absence pu.1	[absence PU.1]	0.0	2	1	1	1
68797	1710	main feature of senescence	[main feature of senescence]	0.0	4	1	1	1
68798	1710	74 bp upstream	[74 bp upstream]	0.0	3	1	1	1
68799	1710	hugata-3 transcription factor	[huGATA-3 transcription factor]	0.0	3	1	1	1
68800	1710	+/- 237 ng/10(6) cells)	[+/- 237 ng/10(6) cells)]	0.0	4	1	1	1
68801	1710	relation to major histocompatibility class	[relation to major histocompatibility classes]	0.0	5	1	1	1
68802	1710	mediator expression	[mediator expression]	0.0	2	1	1	1
68803	1710	activation-dependent hs1 phosphorylation	[activation-dependent HS1 phosphorylation]	0.0	3	1	1	1
68804	1710	respectively, indicate a affinity of sr-bp	[respectively, indicating an affinity of SR-BP]	0.0	6	1	1	1
68805	1710	conversion from latent	[conversion from latent]	0.0	3	1	1	1
68806	1710	plasma membrane fraction from leukocyte	[plasma membrane fractions from leukocytes]	0.0	5	1	1	1
68807	1710	hacat cell	[HaCaT cells]	0.0	2	1	1	1
68808	1710	induction monoclonal antibody	[Induction monoclonal antibodies]	0.0	3	1	1	1
68809	1710	high weight form	[higher weight forms]	0.0	3	1	1	1
68810	1710	implicate cyclophilin b in calcium signalling	[implicating cyclophilin B in calcium signalling]	0.0	6	1	1	1
68811	1710	early biochemical events,	[early biochemical events,]	0.0	3	1	1	1
68812	1710	transcription transcription	[transcription transcription]	0.0	2	1	1	1
68813	1710	nuclear extract with dmdtc	[nuclear extracts with DMDTC]	0.0	4	1	1	1
68814	1710	electrolyte response in human leukocyte	[electrolyte response in human leukocytes]	0.0	5	1	1	1
68815	1710	chicken gata-1	[chicken GATA-1]	0.0	2	1	1	1
68816	1710	expression of gamma-ifn gene over-express monocyte	[Expression of gamma-IFN genes over-expressing monocytes]	0.0	6	1	1	1
68817	1710	partial monosomy of loci on chromosome	[partial monosomy of loci on chromosome]	0.0	6	1	1	1
68818	1710	b coactivator protein	[B coactivator protein]	0.0	3	1	1	1
68819	1710	characterisation	[characterisation]	0.0	1	1	1	1
68820	1710	high level capable	[higher levels capable]	0.0	3	1	1	1
68821	1710	5'-gttaaggttcgtaggtcatgga-3'	[5'-GTTAAGGTTCGTAGGTCATGGA-3']	0.0	1	1	1	1
68822	1710	expression activator protein-1 factor il-6	[expression activator protein-1 factor IL-6]	0.0	5	1	1	1
68823	1710	level of nf-atp capable of binding	[levels of NF-ATp capable of binding]	0.0	6	1	1	1
68824	1710	g-csf cell g-csf	[G-CSF cells G-CSF]	0.0	3	1	1	1
68825	1710	induce transcription c-fo	[inducing transcription c-fos]	0.0	3	1	1	1
68826	1710	disulfide-linked glycoprotein	[disulfide-linked glycoprotein]	0.0	2	1	1	1
68827	1710	region -1168	[regions -1168]	0.0	2	1	1	1
68828	1710	extensive purification by several cycle	[extensive purification by several cycles]	0.0	5	1	1	1
68829	1710	dose response	[dose response]	0.0	2	1	1	1
68830	1710	maintain variation at this position	[maintaining variation at this position]	0.0	5	1	1	1
68831	1710	subdominant latent cycle reactivity undetectable	[subdominant latent cycle reactivities undetectable]	0.0	5	1	1	1
68832	1710	somatic hypermutation of ig gene	[somatic hypermutation of Ig genes]	0.0	5	1	1	1
68833	1710	b activation of immunoglobulin promoter	[B activation of immunoglobulin promoters]	0.0	5	1	1	1
68834	1710	inadequate response to therapy	[inadequate response to therapy]	0.0	4	1	1	1
68835	1710	transcriptional regulation of erythroid gene expression	[Transcriptional regulation of erythroid gene expression]	0.0	6	1	1	1
68836	1710	fetal thymocyte development	[fetal thymocyte development]	0.0	3	1	1	1
68837	1710	cDNA end analysis	[cDNA ends analysis]	0.0	3	1	1	1
68838	1710	transcriptional induction of cytokine	[transcriptional induction of cytokine]	0.0	4	1	1	1
68839	1710	leukocyte of 12 ad patient	[leukocytes of 12 AD patients]	0.0	5	1	1	1
68840	1710	thymocyte development after inhibition	[thymocyte development after inhibition]	0.0	4	1	1	1
68841	1710	different response in pbmo cell	[different responses in PBMo cells]	0.0	5	1	1	1
68842	1710	gc b-cell	[GC B-cell]	0.0	2	1	1	1
68843	1710	control at 14.7118.7,	[control at 14.7-18.7,]	0.0	3	1	1	1
68844	1710	aids therapeutics	[AIDS therapeutics]	0.0	2	1	1	1
68845	1710	mol/L 9-cis RA	[mol/L 9-cis RA]	0.0	3	1	1	1
68846	1710	(p low	[(P lower]	0.0	2	1	1	1
68847	1710	imply a role in differentiation event	[implying a role in differentiation events]	0.0	6	1	1	1
68848	1710	modulate gata-1 activity	[modulating GATA-1 activity]	0.0	3	1	1	1
68849	1710	lymphoid-enhancer	[lymphoid-enhancer]	0.0	1	1	1	1
68850	1710	Functional block	[Functional block]	0.0	2	1	1	1
68851	1710	leucocyte in man with gynecomastia	[leucocytes in men with gynecomastia]	0.0	5	1	1	1
68852	1710	immunological parameter restoration of content	[immunological parameters restoration of content]	0.0	5	1	1	1
68853	1710	tumor cell of a cancer patient	[tumor cells of a cancer patient]	0.0	6	1	1	1
68854	1710	regulation of the il-5 gene	[regulation of the IL-5 gene]	0.0	5	1	1	1
68855	1710	induction of a set	[induction of a set]	0.0	4	1	1	1
68856	1710	nm 1 alpha,25-dihydroxyvitamin D3 D3	[nM 1 alpha,25-dihydroxyvitamin D3 D3]	0.0	5	1	1	1
68857	1710	deletion of the macrophage	[deletion of the macrophage]	0.0	4	1	1	1
68858	1710	staining of thymus section use abs	[staining of thymus sections using Abs]	0.0	6	1	1	1
68859	1710	clear correlation	[clear correlation]	0.0	2	1	1	1
68860	1710	protein of the same family	[proteins of the same family]	0.0	5	1	1	1
68861	1710	immunodeficiency virus hiv-1 long repeat	[immunodeficiency virus HIV-1 long repeat]	0.0	5	1	1	1
68862	1710	biogenesis of secondary organ	[biogenesis of secondary organs]	0.0	4	1	1	1
68863	1710	resection of the ileum	[resection of the ileum]	0.0	4	1	1	1
68864	1710	coamplification	[coamplification]	0.0	1	1	1	1
68865	1710	related immunoglobulin g fc receptor	[related immunoglobulin G Fc receptors]	0.0	5	1	1	1
68866	1710	Gal4-Elf-1 fusion protein	[Gal4-Elf-1 fusion proteins]	0.0	3	1	1	1
68867	1710	major complex (MHC) class promoter	[major complex (MHC) class promoters]	0.0	5	1	1	1
68868	1710	novel cDNA clone kb)	[novel cDNA clone kb)]	0.0	4	1	1	1
68869	1710	expression nonproliferateraterateratiferatiferatiferatiferati b cell	[expression nonproliferating B cells]	0.0	4	1	1	1
68870	1710	promyelocytic myeloblastic leukemia cell	[promyelocytic myeloblastic leukemia cells]	0.0	4	1	1	1
68871	1710	several transcription factor include AP-1	[several transcription factors including AP-1]	0.0	5	1	1	1
68872	1710	apoptosis in lymphoblastoid wild-type CD4 receptor	[apoptosis in lymphoblastoid wild-type CD4 receptors]	0.0	6	1	1	1
68873	1710	different origin	[different origin]	0.0	2	1	1	1
68874	1710	lymphocytic mineralocorticoid receptor	[lymphocytic mineralocorticoid receptors]	0.0	3	1	1	1
68875	1710	nuclear extract from ECs	[nuclear extracts from ECs]	0.0	4	1	1	1
68876	1710	T culture system	[T culture system]	0.0	3	1	1	1
68877	1710	agonist-induced cell adhesion to cell	[agonist-induced cell adhesion to cells]	0.0	5	1	1	1
68878	1710	deletion into the promoter	[deletions into the promoter]	0.0	4	1	1	1
68879	1710	cAMP-dependent reporter gene	[cAMP-dependent reporter genes]	0.0	3	1	1	1
68880	1710	Epstein-Barr virus strain	[Epstein-Barr virus strain]	0.0	3	1	1	1
68881	1710	select b gene	[select B genes]	0.0	3	1	1	1
68882	1710	various chronic disease four	[various chronic diseases four]	0.0	4	1	1	1
68883	1710	further structure-based enhancement	[further structure-based enhancement]	0.0	3	1	1	1
68884	1710	low dissociation constant for aldosterone	[low dissociation constant for aldosterone]	0.0	5	1	1	1
68885	1710	cyp1a1 gene expression	[CYP1A1 gene expression]	0.0	3	1	1	1
68886	1710	peptide delivery	[peptide delivery]	0.0	2	1	1	1
68887	1710	day of costimulation	[days of costimulation]	0.0	3	1	1	1
68888	1710	important role in dysregulation	[important role in dysregulation]	0.0	4	1	1	1
68889	1710	anhydrase caii a gene	[anhydrase CAII a gene]	0.0	4	1	1	1
68890	1710	major regulator of the homing	[major regulator of the homing]	0.0	5	1	1	1
68891	1710	such as the tubule	[such as the tubules]	0.0	4	1	1	1
68892	1710	result of the gssg deficiency	[results of the GSSG deficiency]	0.0	5	1	1	1
68893	1710	lack of correspondence with common variant	[lack of correspondence with common variants]	0.0	6	1	1	1
68894	1710	t-cell leukemia virus tax protein	[T-cell leukemia virus tax protein]	0.0	5	1	1	1
68895	1710	information from calcium-mobilize receptor	[information from calcium-mobilizing receptors]	0.0	4	1	1	1
68896	1710	breast tissue abnormality	[breast tissue abnormalities]	0.0	3	1	1	1
68897	1710	binding of a factor pu.1	[binding of a factor PU.1]	0.0	5	1	1	1
68898	1710	activity concomitant	[activity concomitant]	0.0	2	1	1	1
68899	1710	several erythroid-specific cis-acting element	[several erythroid-specific cis-acting elements]	0.0	4	1	1	1
68900	1710	human tr beta	[Human TR beta]	0.0	3	1	1	1
68901	1710	phorbol acetate PMA nf-kappa b	[phorbol acetate PMA NF-kappa B]	0.0	5	1	1	1
68902	1710	DNA binding of BSAP	[DNA binding of BSAP]	0.0	4	1	1	1
68903	1710	(C/EBP)	[(C/EBP)]	0.0	1	1	1	1
68904	1710	histocompatibility class invariant-chain gene	[histocompatibility class invariant-chain gene]	0.0	4	1	1	1
68905	1710	high circulate level	[high circulating levels]	0.0	3	1	1	1
68906	1710	(p<.001) in untreated patient	[(P<.001) in untreated patients]	0.0	4	1	1	1
68907	1710	growth factor beta tgf-beta	[growth factor beta TGF-beta]	0.0	4	1	1	1
68908	1710	mechanism of down-regulation	[mechanism of down-regulation]	0.0	3	3	3	1
68909	1710	half-life of mrna (75	[half-life of mRNA (75]	0.0	4	1	1	1
68910	1710	prevent the tyrosine phosphorylation a component	[preventing the tyrosine phosphorylation a component]	0.0	6	1	1	1
68911	1710	recombinant ssb	[recombinant SSB]	0.0	2	1	1	1
68912	1710	activation of a number	[activation of a number]	0.0	4	1	1	1
68913	1710	activation in tax-express T cell	[activation in Tax-expressing T cells]	0.0	5	1	1	1
68914	1710	Retinoic acid treatment granulocyte recovery.	[Retinoic acid treatment granulocyte recovery.]	0.0	5	1	1	1
68915	1710	nm for (+)-pentazocine	[nM for (+)-pentazocine]	0.0	3	1	1	1
68916	1710	bhrf1 a Epstein-Barr virus ebv protein	[BHRF1 an Epstein-Barr virus EBV protein]	0.0	6	1	1	1
68917	1710	tcp (200 microM,	[TCP (200 microM,]	0.0	3	1	1	1
68918	1710	down-regulatory effect.	[down-regulatory effect.]	0.0	2	1	1	1
68919	1710	somatic mutation cluster	[somatic mutations clustering]	0.0	3	1	1	1
68920	1710	suppressor gene nm23-h1	[suppressor genes nm23-H1]	0.0	3	1	1	1
68921	1710	antigen bzlf1	[antigen BZLF1]	0.0	2	1	1	1
68922	1710	antigen-specific t-cell	[antigen-specific T-cells]	0.0	2	1	1	1
68923	1710	large diffusion of ones.	[large diffusion of ones.]	0.0	4	1	1	1
68924	1710	incubation of l540 cell	[incubation of L540 cells]	0.0	4	1	1	1
68925	1710	hour at 42 degree c,	[hours at 42 degrees C,]	0.0	5	1	1	1
68926	1710	IL-4 gene -311ctcccttct-303	[IL-4 gene -311CTCCCTTCT-303]	0.0	3	1	1	1
68927	1710	signal,	[signal,]	0.0	1	1	1	1
68928	1710	sites/cell respectively, with the gcr	[sites/cell respectively, with the GCR]	0.0	5	1	1	1
68929	1710	high potential hpp- 47.10 cell	[high potential HPP- 47.10 cells]	0.0	5	1	1	1
68930	1710	group of female	[group of females]	0.0	3	1	1	1
68931	1710	inhibition of the generation	[inhibition of the generation]	0.0	4	1	1	1
68932	1710	Stable expression of rev protein	[Stable expression of Rev protein]	0.0	5	1	1	1
68933	1710	marmoset t-lymphocyte transformation	[marmoset T-lymphocyte transformation]	0.0	3	1	1	1
68934	1710	signal for T cell activation	[signal for T cell activation]	0.0	5	1	1	1
68935	1710	however, millileter at P;	[However, ml at h;]	0.0	4	1	1	1
68936	1710	immunologically important transcription factor	[immunologically important transcription factor]	0.0	4	1	1	1
68937	1710	CD28 promoter	[CD28 promoter]	0.0	2	1	1	1
68938	1710	IkappaB alpha phosphorylation	[IkappaB alpha phosphorylation]	0.0	3	1	1	1
68939	1710	percent of nonresponders.	[percent of nonresponders.]	0.0	3	1	1	1
68940	1710	primary defect in x-linked ricket	[primary defect in X-linked rickets]	0.0	5	1	1	1
68941	1710	pml leukemia	[PML leukemia]	0.0	2	1	1	1
68942	1710	supernatant fluid from RCC explant	[supernatant fluid from RCC explants]	0.0	5	1	1	1
68943	1710	suggest cooperative action	[suggesting cooperative action]	0.0	3	1	1	1
68944	1710	potential inhibition	[potential inhibition]	0.0	2	1	1	1
68945	1710	chronic leukaemias	[chronic leukaemias]	0.0	2	1	1	1
68946	1710	level capable	[levels capable]	0.0	2	1	1	1
68947	1710	site for ccaat-box binding factor	[sites for CCAAT-box binding factors]	0.0	5	1	1	1
68948	1710	single methionine codon-initiated reading frame	[single methionine codon-initiated reading frame]	0.0	5	1	1	1
68949	1710	subtype of hodgkin' disease	[subtypes of Hodgkin's disease]	0.0	4	1	1	1
68950	1710	nuclear translocation of the p50	[nuclear translocation of the p50]	0.0	5	1	1	1
68951	1710	mean type	[mean type]	0.0	2	1	1	1
68952	1710	effect in the HLA-Cw*0702 system	[effects in the HLA-Cw*0702 system]	0.0	5	1	1	1
68953	1710	activity concomitant to a inhibition	[activity concomitant to an inhibition]	0.0	5	1	1	1
68954	1710	furthermore, hmg-i(y)	[Furthermore, HMG-I(Y)]	0.0	2	1	1	1
68955	1710	activation by tcr signal	[activation by TCR signals]	0.0	4	1	1	1
68956	1710	rarely er	[rarely ER]	0.0	2	1	1	1
68957	1710	massive enhancement HL cell differentiated)	[massive enhancement HL cells differentiated)]	0.0	5	1	1	1
68958	1710	vector contain kappab site	[vectors containing kappaB sites]	0.0	4	1	1	1
68959	1710	inhibition of Tat activation	[inhibition of Tat activation]	0.0	4	1	1	1
68960	1710	result in phosphorylation of dna-binding protein	[resulting in phosphorylation of DNA-binding proteins]	0.0	6	1	1	1
68961	1710	respective response element	[respective response elements]	0.0	3	1	1	1
68962	1710	span nucleotide	[spanning nucleotides]	0.0	2	1	1	1
68963	1710	kbf1/p50	[KBF1/p50]	0.0	1	1	1	1
68964	1710	land electron-dense structure distinct	[LANDs electron-dense structures distinct]	0.0	4	1	1	1
68965	1710	gene in four cell line	[genes in four cell lines]	0.0	5	1	1	1
68966	1710	human immunodeficiency virus expression	[Human immunodeficiency virus expression]	0.0	4	1	1	1
68967	1710	effect on immune response	[effects on immune responses]	0.0	4	1	1	1
68968	1710	therefore a good candidate	[Therefore a good candidate]	0.0	4	1	1	1
68969	1710	nevertheless, high, concentration of RA	[Nevertheless, high, concentrations of RA]	0.0	5	1	1	1
68970	1710	rna polymerase ii transcription factor	[RNA polymerase II transcription factor]	0.0	5	1	1	1
68971	1710	hiv-1 ltr	[HIV-1 LTRs]	0.0	2	1	1	1
68972	1710	Interdomain	[Interdomain]	0.0	1	1	1	1
68973	1710	also in individual as control	[also in individuals as control]	0.0	5	1	1	1
68974	1710	contrast, ap-1 from cell	[contrast, AP-1 from cells]	0.0	4	1	1	1
68975	1710	involvement of this intracellular messenger	[involvement of these intracellular messengers]	0.0	5	1	1	1
68976	1710	regulation by member	[regulation by members]	0.0	3	1	1	1
68977	1710	level of nf-kappa b complex	[levels of NF-kappa B complex]	0.0	5	1	1	1
68978	1710	activation of a T cell	[activation of a T cell]	0.0	5	1	1	1
68979	1710	tissue-specific expression of cd14	[tissue-specific expression of CD14]	0.0	4	1	1	1
68980	1710	endocrine cell complex formation	[endocrine cell complex formation]	0.0	4	1	1	1
68981	1710	major regulatory role	[major regulatory role]	0.0	3	1	1	1
68982	1710	activator (s)	[activator (s)]	0.0	2	1	1	1
68983	1710	Minimal residual disease with pml/rar alpha	[Minimal residual disease with PML/RAR alpha]	0.0	6	1	1	1
68984	1710	gas-like dna-protein binding complex	[GAS-like DNA-protein binding complexes]	0.0	4	1	1	1
68985	1710	redox status fos	[redox status FOS]	0.0	3	1	1	1
68986	1710	include aml with immature morphology aml	[including AML with immature morphology AML]	0.0	6	1	1	1
68987	1710	10 differentiation	[10 differentiation]	0.0	2	1	1	1
68988	1710	expression of gamma-interferon	[Expression of gamma-interferon]	0.0	3	1	1	1
68989	1710	effusion lymphoma pel	[effusion lymphoma PEL]	0.0	3	1	1	1
68990	1710	cell-mediated immunity against many pathogen	[cell-mediated immunity against many pathogens]	0.0	5	1	1	1
68991	1710	receptor to factor	[receptors to factor]	0.0	3	1	1	1
68992	1710	AMP inhibition of transcription	[AMP inhibition of transcription]	0.0	4	1	1	1
68993	1710	level in 9 keratoacanthomas	[levels in 9 keratoacanthomas]	0.0	4	1	1	1
68994	1710	widespread extinction of other gene	[widespread extinction of other genes]	0.0	5	1	1	1
68995	1710	Epstein-Barr virus nuclear antigen 2 ebna-2	[Epstein-Barr virus nuclear antigen 2 EBNA-2]	0.0	6	1	1	1
68996	1710	positive domain (prd) binding protein	[positive domain (PRD) binding proteins]	0.0	5	1	1	1
68997	1710	dramatic shift from erythroid	[dramatic shift from erythroid]	0.0	4	1	1	1
68998	1710	region of the b2 gene	[region of the B2 gene]	0.0	5	1	1	1
68999	1710	E1A -conserved region	[E1A -conserved regions]	0.0	3	1	1	1
69000	1710	association of signal transducing protein	[association of signal transducing proteins]	0.0	5	1	1	1
69001	1710	contain near-perfect repeat of bp	[containing near-perfect repeats of bp]	0.0	5	1	1	1
69002	1710	cell adhesion in response	[cell adhesion in response]	0.0	4	1	1	1
69003	1710	often converge	[often converging]	0.0	2	1	1	1
69004	1710	important fundamental insight	[important fundamental insights]	0.0	3	1	1	1
69005	1710	only in a manner	[only in a manner]	0.0	4	1	1	1
69006	1710	activation in human lymphoblastoid cell	[Activation in human lymphoblastoid cells]	0.0	5	1	1	1
69007	1710	predict the occurrence	[predicting the occurrence]	0.0	3	1	1	1
69008	1710	western blotting (rna) blotting assay	[Western blotting (RNA) blotting assays]	0.0	5	1	1	1
69009	1710	elastase inhibitor guamerin-derived peptide	[elastase inhibitor guamerin-derived peptide]	0.0	4	1	1	1
69010	1710	Fifteen patient with sepsis	[Fifteen patients with sepsis]	0.0	4	1	1	1
69011	1710	Addition to the intermediate thymocyte culture	[Addition to the intermediate thymocyte cultures]	0.0	6	1	1	1
69012	1710	woman in health	[women in health]	0.0	3	1	1	1
69013	1710	importance of this protein	[importance of these proteins]	0.0	4	1	1	1
69014	1710	leukocyte clearance	[leukocyte clearance]	0.0	2	1	1	1
69015	1710	nadph-oxidase component	[NADPH-oxidase component]	0.0	2	1	1	1
69016	1710	exposure of cell type	[Exposure of cell types]	0.0	4	1	1	1
69017	1710	constitutive b activity	[constitutive B activity]	0.0	3	1	1	1
69018	1710	activation the initial viral gene promoter	[activation the initial viral gene promoter]	0.0	6	1	1	1
69019	1710	instillation into rat	[instillation into rats]	0.0	3	1	1	1
69020	1710	deletional vcam-1 promoter construct	[deletional VCAM-1 promoter constructs]	0.0	4	1	1	1
69021	1710	lung nf-kappab	[lung NF-kappaB]	0.0	2	1	1	1
69022	1710	temporary, condition	[temporary, conditions]	0.0	2	1	1	1
69023	1710	active p65( rela )/p50 heterodimer	[active p65( RelA )/p50 heterodimers]	0.0	5	1	1	1
69024	1710	produce inhibition ic50	[producing inhibition IC50]	0.0	3	1	1	1
69025	1710	interleukin 2 (il-2) enhancer	[interleukin 2 (IL-2) enhancer]	0.0	4	1	1	1
69026	1710	secret prl	[secreting PRL]	0.0	2	1	1	1
69027	1710	encode interferon (ifn) consensus	[encoding interferon (IFN) consensus]	0.0	4	1	1	1
69028	1710	activity of c-jun,	[activity of c-Jun,]	0.0	3	1	1	1
69029	1710	two pan-1 respectively),	[two Pan-1 respectively),]	0.0	3	1	1	1
69030	1710	twhf extract	[TWHf extract]	0.0	2	1	1	1
69031	1710	growth response gene (maximal	[growth response genes (maximal]	0.0	4	1	1	1
69032	1710	systemic effect on function	[systemic effects on function]	0.0	4	1	1	1
69033	1710	labial minor salivary gland biopsy	[labial minor salivary gland biopsies]	0.0	5	1	1	1
69034	1710	fraction of HML	[fractions of HML]	0.0	3	1	1	1
69035	1710	erythroid enhancer	[erythroid enhancer]	0.0	2	1	1	1
69036	1710	population of people	[populations of people]	0.0	3	1	1	1
69037	1710	rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation	[rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation]	0.0	6	1	1	1
69038	1710	carcinoma (npc) cell	[carcinoma (NPC) cells]	0.0	3	1	1	1
69039	1710	SIE gas motif	[SIE GAS motif]	0.0	3	1	1	1
69040	1710	early G1-regulating protein	[early G1-regulating proteins]	0.0	3	1	1	1
69041	1710	differential purpose in view.	[differential purposes in view.]	0.0	4	1	1	1
69042	1710	dose of microgram	[dose of micrograms]	0.0	3	1	1	1
69043	1710	spontaneous lymphocyte proliferation in control	[spontaneous lymphocyte proliferation in controls]	0.0	5	1	1	1
69044	1710	import of NF-ATc	[import of NF-ATc]	0.0	3	2	2	1
69045	1710	variability even to the agent	[variability even to the agents]	0.0	5	1	1	1
69046	1710	-resistant cell	[-resistant cells]	0.0	2	1	1	1
69047	1710	blood apparently healthy volunteer	[blood apparently healthy volunteers]	0.0	4	1	1	1
69048	1710	consistent involvement	[consistent involvement]	0.0	2	1	1	1
69049	1710	level of oncogene transcript	[levels of oncogene transcripts]	0.0	4	1	1	1
69050	1710	addition of ref-1 from monocyte	[addition of REF-1 from monocytes]	0.0	5	1	1	1
69051	1710	two glial cell	[two glial cells]	0.0	3	1	1	1
69052	1710	receive il-2 immunotherapy	[receiving IL-2 immunotherapy]	0.0	3	1	1	1
69053	1710	use tf antibody	[using TF antibody]	0.0	3	1	1	1
69054	1710	two sequence	[two sequences]	0.0	2	1	1	1
69055	1710	autosomal sex reversal	[autosomal sex reversal]	0.0	3	1	1	1
69056	1710	virus p5 promoter	[virus P5 promoter]	0.0	3	1	1	1
69057	1710	number eutopic endometrium	[numbers eutopic endometrium]	0.0	3	1	1	1
69058	1710	unique region	[unique region]	0.0	2	1	1	1
69059	1710	initial level	[initial levels]	0.0	2	1	1	1
69060	1710	carry kb 5'-flanking DNA	[carrying kb 5'-flanking DNA]	0.0	4	1	1	1
69061	1710	four near-perfect repeat of 21 bp	[four near-perfect repeats of 21 bp]	0.0	6	1	1	1
69062	1710	side-effect	[side-effects]	0.0	1	1	1	1
69063	1710	several cytokine by monocyte	[several cytokines by monocytes]	0.0	4	1	1	1
69064	1710	potential in response	[potential in response]	0.0	3	1	1	1
69065	1710	cells, DNA binding activity	[cells, DNA binding activity]	0.0	4	1	1	1
69066	1710	pancrea development in general.	[pancreas development in general.]	0.0	4	1	1	1
69067	1710	effect either on the b29 promoter	[effect either on the B29 promoter]	0.0	6	1	1	1
69068	1710	related result	[related results]	0.0	2	1	1	1
69069	1710	5'-deletion construct	[5'-deletion constructs]	0.0	2	1	1	1
69070	1710	effect of the c-11 analog	[effects of the C-11 analogs]	0.0	5	1	1	1
69071	1710	immature cell StatG	[immature cells StatG]	0.0	3	1	1	1
69072	1710	role of tumor necrosis factor factor	[Role of tumor necrosis factor factors]	0.0	6	1	1	1
69073	1710	such as downregulation	[such as downregulation]	0.0	3	1	1	1
69074	1710	t3r alteration circulate lymphocyte	[T3R alterations circulating lymphocytes]	0.0	4	1	1	1
69075	1710	possible consequence	[possible consequences]	0.0	2	1	1	1
69076	1710	stroma a differentiation process	[stroma a differentiation process]	0.0	4	1	1	1
69077	1710	Novel membrane receptor	[Novel membrane receptors]	0.0	3	1	1	1
69078	1710	expression of proinflammatory gene	[expression of proinflammatory genes]	0.0	4	1	1	1
69079	1710	activate many	[activating many]	0.0	2	1	1	1
69080	1710	repeat type 1	[repeat type 1]	0.0	3	1	1	1
69081	1710	mediate growth	[mediating growth]	0.0	2	1	1	1
69082	1710	inducible cyclosporin dnase i-hypersensitive site	[inducible cyclosporin DNase I-hypersensitive site]	0.0	5	1	1	1
69083	1710	part of large palindromic sequence	[part of larger palindromic sequences]	0.0	5	1	1	1
69084	1710	classic prednisolone	[classic prednisolone]	0.0	2	1	1	1
69085	1710	irf-1 interferon factor	[IRF-1 interferon factor]	0.0	3	1	1	1
69086	1710	octamer-dependent enhancer element	[octamer-dependent enhancer elements]	0.0	3	1	1	1
69087	1710	subunits; independent genes, nfkb1	[subunits; independent genes, NFKB1]	0.0	4	1	1	1
69088	1710	chicken shc homologue	[chicken Shc homologue]	0.0	3	1	1	1
69089	1710	amount of il-8	[amounts of IL-8]	0.0	3	1	1	1
69090	1710	amount of il-2	[amounts of IL-2]	0.0	3	1	1	1
69091	1710	involvement of hcmv in tumorigenesis	[involvement of HCMV in tumorigenesis]	0.0	5	1	1	1
69092	1710	carbinolamine	[carbinolamine]	0.0	1	1	1	1
69093	1710	Stat6 Jurkat T cell	[Stat6 Jurkat T cells]	0.0	4	1	1	1
69094	1710	selective role for traf6	[selective role for TRAF6]	0.0	4	1	1	1
69095	1710	SIT interact adaptor protein	[SIT interacting adaptor protein]	0.0	4	1	1	1
69096	1710	tcp (200 72 h),	[TCP (200 72 h),]	0.0	4	1	1	1
69097	1710	Differentiation-associated expression of the Epstein-Barr virus	[Differentiation-associated expression of the Epstein-Barr virus]	0.0	6	1	1	1
69098	1710	Potential role	[Potential role]	0.0	2	1	1	1
69099	1710	Conversely, rs cell	[Conversely, RS cells]	0.0	3	1	1	1
69100	1710	three element within the enhancer	[three elements within the enhancer]	0.0	5	1	1	1
69101	1710	four independent methods,	[four independent methods,]	0.0	3	1	1	1
69102	1710	wt1 in fibroblast	[WT1 in fibroblasts]	0.0	3	1	1	1
69103	1710	one parent	[one parent]	0.0	2	1	1	1
69104	1710	role of Egr-2	[Role of Egr-2]	0.0	3	1	1	1
69105	1710	htlv-i(+) t-cell line	[HTLV-I(+) T-cell lines]	0.0	3	1	1	1
69106	1710	76 kD	[76 kD]	0.0	2	1	1	1
69107	1710	very early stage cell	[very early stage cells]	0.0	4	1	1	1
69108	1710	nf-kappab activation repeat	[NF-kappaB activation repeat]	0.0	3	1	1	1
69109	1710	relatively few steroid-regulated gene	[relatively few steroid-regulated genes]	0.0	4	1	1	1
69110	1710	transcription factor pit-1	[transcription factor Pit-1]	0.0	3	1	1	1
69111	1710	cell-encoded gene	[cell-encoded genes]	0.0	2	1	1	1
69112	1710	erythroid-specific dnase site-forming element	[erythroid-specific DNase site-forming element]	0.0	4	1	1	1
69113	1710	DQB-W region	[DQB-W region]	0.0	2	1	1	1
69114	1710	b-like site 5'-cggagtttcc-3'	[B-like site 5'-CGGAGTTTCC-3']	0.0	3	1	1	1
69115	1710	unrelated Japanese child	[unrelated Japanese children]	0.0	3	1	1	1
69116	1710	cell mthc	[cells MTHC]	0.0	2	1	1	1
69117	1710	also with ankyrin motif-rich protein	[also with ankyrin motif-rich proteins]	0.0	5	1	1	1
69118	1710	49 healthy aged subject yr)	[49 healthy aged subjects yr)]	0.0	5	1	1	1
69119	1710	IL-6 level	[IL-6 levels]	0.0	2	1	1	1
69120	1710	gm-csf promoter-	[GM-CSF promoter-]	0.0	2	1	1	1
69121	1710	nip -mediated repression	[NIP -mediated repression]	0.0	3	1	1	1
69122	1710	localization of NF-AT	[localization of NF-AT]	0.0	3	1	1	1
69123	1710	zinc finger gene MZF-1	[zinc finger gene MZF-1]	0.0	4	1	1	1
69124	1710	pathway of apoptosis by cytokine	[pathways of apoptosis by cytokines]	0.0	5	1	1	1
69125	1710	skewer	[skewer]	0.0	1	1	1	1
69126	1710	key sensor	[key sensor]	0.0	2	1	1	1
69127	1710	human adult globin	[human adult globin]	0.0	3	1	1	1
69128	1710	erythroid-specific rrna	[erythroid-specific mRNAs]	0.0	2	1	1	1
69129	1710	little evidence	[little evidence]	0.0	2	1	1	1
69130	1710	lupus erythematosus patient	[lupus erythematosus patients]	0.0	3	1	1	1
69131	1710	b chemokine IL-8	[B chemokine IL-8]	0.0	3	1	1	1
69132	1710	hgm-csf -dependent cell proliferation	[hGM-CSF -dependent cell proliferation]	0.0	4	1	1	1
69133	1710	ch gene	[CH genes]	0.0	2	1	1	1
69134	1710	participation of the regulatory element	[participation of the regulatory element]	0.0	5	1	1	1
69135	1710	co-activation	[co-activation]	0.0	1	2	2	1
69136	1710	analysis of this cell	[analysis of these cells]	0.0	4	1	1	1
69137	1710	replicative form of Epstein-Barr DNA	[replicative form of Epstein-Barr DNA]	0.0	5	1	1	1
69138	1710	one molecule	[one molecule]	0.0	2	1	1	1
69139	1710	increase in the mbc	[increase in the MBC]	0.0	4	1	1	1
69140	1710	stage of embryonic development	[stage of embryonic development]	0.0	4	1	1	1
69141	1710	E1B-	[E1B-]	0.0	1	1	1	1
69142	1710	gene in differentiation	[gene in differentiation]	0.0	3	1	1	1
69143	1710	DNA-protein formation with member	[DNA-protein formation with members]	0.0	4	1	1	1
69144	1710	stimulation of CD40	[Stimulation of CD40]	0.0	3	1	1	1
69145	1710	ifn-gamma up-regulation	[IFN-gamma up-regulation]	0.0	2	1	1	1
69146	1710	site alpha-	[site alpha-]	0.0	2	1	1	1
69147	1710	distinct ligand-induced, docking site	[distinct ligand-induced, docking sites]	0.0	4	1	1	1
69148	1710	multiple reactivity	[multiple reactivities]	0.0	2	1	1	1
69149	1710	human adenovirus type e1a-region	[human adenovirus type E1A-region]	0.0	4	1	1	1
69150	1710	constitutive binding in unactivated extract	[constitutive binding in unactivated extracts]	0.0	5	1	1	1
69151	1710	nm less than 0.01).	[nM less than 0.01).]	0.0	4	1	1	1
69152	1710	effector plasmid express trx	[effector plasmid expressing Trx]	0.0	4	1	1	1
69153	1710	class isotype	[class isotypes]	0.0	2	1	1	1
69154	1710	footprint than the fetal globin	[footprints than the fetal globin]	0.0	5	1	1	1
69155	1710	level of hepor expression	[levels of hEpoR expression]	0.0	4	1	1	1
69156	1710	hemopoietic growth	[hemopoietic growth]	0.0	2	1	1	1
69157	1710	frequently occur	[frequently occurring]	0.0	2	1	1	1
69158	1710	several feature include sensitivity	[several features including sensitivity]	0.0	4	1	1	1
69159	1710	endothelial cell-monocyte (ec-mn) adhesion	[endothelial cell-monocyte (EC-Mn) adhesion]	0.0	4	1	1	1
69160	1710	thus establish NF-kappaB as a factor	[thus establishing NF-kappaB as a factor]	0.0	6	1	1	1
69161	1710	1 terminal	[1 terminal]	0.0	2	2	2	1
69162	1710	genuine hugata-3	[genuine huGATA-3]	0.0	2	1	1	1
69163	1710	sequence of gene	[sequences of genes]	0.0	3	1	1	1
69164	1710	contain near-perfect repeat	[containing near-perfect repeats]	0.0	3	1	1	1
69165	1710	self renewal of normal progenitor	[Self renewal of normal progenitors]	0.0	5	1	1	1
69166	1710	transcription from immediate gene	[transcription from immediate genes]	0.0	4	1	1	1
69167	1710	92-kda protein in human monocyte	[92-kDa protein in human monocytes]	0.0	5	1	1	1
69168	1710	fmol/10(7) cell 0.011	[fmol/10(7) cells 0.001),]	0.0	3	1	1	1
69169	1710	cell in s.c. lymph nodes;	[cells in s.c. lymph nodes;]	0.0	5	1	1	1
69170	1710	down-regulation of transcriptional factor	[down-regulation of transcriptional factors]	0.0	4	1	1	1
69171	1710	cytotoxic T lymphocyte (ctl) epitope	[cytotoxic T lymphocyte (CTL) epitopes]	0.0	5	1	1	1
69172	1710	Strikingly, deletion of C-terminal residue	[Strikingly, deletion of C-terminal residues]	0.0	5	1	1	1
69173	1710	alcohol-induced regulation of factor-kappa beta	[Alcohol-induced regulation of factor-kappa beta]	0.0	5	1	1	1
69174	1710	acute leukemia evi1 fusion respectively,	[acute leukemia EVI1 fusions respectively,]	0.0	5	1	1	1
69175	1710	convey protection against a signal	[conveying protection against an signal]	0.0	5	1	1	1
69176	1710	T J.Jhan	[T J.Jhan]	0.0	2	1	1	1
69177	1710	accessory receptor	[accessory receptors]	0.0	2	1	1	1
69178	1710	anti-microbial function	[anti-microbial functions]	0.0	2	1	1	1
69179	1710	nuclear nf-kb activity	[nuclear NF-kB activity]	0.0	3	1	1	1
69180	1710	mutant of shp1	[mutants of SHP1]	0.0	3	1	1	1
69181	1710	apparent function of this protein	[apparent function of this protein]	0.0	5	1	1	1
69182	1710	arthritis, binding of NF-kappa b	[arthritis, binding of NF-kappa B]	0.0	5	1	1	1
69183	1710	Oct-1 phenotype	[Oct-1 phenotype]	0.0	2	1	1	1
69184	1710	Comparison of primary sensitization with response	[Comparison of primary sensitization with responses]	0.0	6	1	1	1
69185	1710	tnf-related apoptosis -induce ligand	[TNF-related apoptosis -inducing ligand]	0.0	4	1	1	1
69186	1710	different subpopulation of lymphocyte	[different subpopulations of lymphocytes]	0.0	4	1	1	1
69187	1710	increase in cell surface.	[increase in cell surface.]	0.0	4	1	1	1
69188	1710	subtle alteration in regulatory sequence	[subtle alterations in regulatory sequences]	0.0	5	1	1	1
69189	1710	mutant of SIVmacMER	[mutants of SIVmacMER]	0.0	3	1	1	1
69190	1710	functional role in hematopoiesis	[functional role in hematopoiesis]	0.0	4	1	1	1
69191	1710	receptor changes, oppose	[receptor changes, opposing]	0.0	3	1	1	1
69192	1710	regulation of this promoter	[regulation of this promoter]	0.0	4	1	1	1
69193	1710	Lymphocytic level	[Lymphocytic levels]	0.0	2	1	1	1
69194	1710	subdivide the subject in age group	[subdividing the subjects in age groups]	0.0	6	1	1	1
69195	1710	little consistent effect	[little consistent effect]	0.0	3	1	1	1
69196	1710	ad5e1a tumor	[Ad5E1A tumors]	0.0	2	1	1	1
69197	1710	gene include gm-csf	[genes including GM-CSF]	0.0	3	1	1	1
69198	1710	response to the extracellular signal	[response to the extracellular signal]	0.0	5	1	1	1
69199	1710	structural analysis of the rdna	[structural analysis of the cDNAs]	0.0	5	1	1	1
69200	1710	new isoform of the transcription factor	[new isoforms of the transcription factor]	0.0	6	1	1	1
69201	1710	activation of a enhancer element	[activation of an enhancer element]	0.0	5	1	1	1
69202	1710	Study of the kinetic	[Studies of the kinetics]	0.0	4	1	1	1
69203	1710	oct-2 DNA binding activity	[Oct-2 DNA binding activity]	0.0	4	1	1	1
69204	1710	suppression to the endothelium by dexamethasone	[Suppression to the endothelium by dexamethasone]	0.0	6	1	1	1
69205	1710	t-cell line Wurzburg	[T-cell lines Wurzburg]	0.0	3	1	1	1
69206	1710	cell extract of T cell	[cell extracts of T cells]	0.0	5	1	1	1
69207	1710	other reactive oxygen species	[other reactive oxygen species]	0.0	4	1	1	1
69208	1710	case with tmd in this study.	[cases with TMD in this study.]	0.0	6	1	1	1
69209	1710	BZLF1 component of diverse clonotype	[BZLF1 component of diverse clonotypes]	0.0	5	1	1	1
69210	1710	type, eay	[type, EA/S]	0.0	2	1	1	1
69211	1710	work implicate zebra	[work implicating ZEBRA]	0.0	3	1	1	1
69212	1710	nfatp migration	[NFATp migration]	0.0	2	1	1	1
69213	1710	activation of primary T lymphocyte	[activation of primary T lymphocytes]	0.0	5	1	1	1
69214	1710	redox equilibrium tend toward oxidation	[redox equilibrium tending toward oxidation]	0.0	5	1	1	1
69215	1710	ebv transcriptional program	[EBV transcriptional program]	0.0	3	2	2	1
69216	1710	factor to site	[factor to site]	0.0	3	1	1	1
69217	1710	ap-1 tre	[AP-1 TRE]	0.0	2	1	1	1
69218	1710	lymphocyte activator sox-4	[lymphocyte activator Sox-4]	0.0	3	1	1	1
69219	1710	expression of ciita complex surface protein	[expression of CIITA complex surface proteins]	0.0	6	1	1	1
69220	1710	comparison to T lymphocyte	[comparison to T lymphocytes]	0.0	4	1	1	1
69221	1710	pp1 calyculin a	[PP1/PP2A calyculin A]	0.0	3	1	1	1
69222	1710	common abnormality	[common abnormalities]	0.0	2	1	1	1
69223	1710	autocrine activation	[Autocrine activation]	0.0	2	1	1	1
69224	1710	runting,	[runting,]	0.0	1	1	1	1
69225	1710	proinflammatory cytokine mrna expression	[proinflammatory cytokine mRNA expression]	0.0	4	1	1	1
69226	1710	establish due to expression	[establishing due to expression]	0.0	4	1	1	1
69227	1710	induction of a vitamin d receptor	[Induction of a vitamin D receptor]	0.0	6	1	1	1
69228	1710	inhibition of gata1 mrna induction	[inhibition of GATA1 mRNA induction]	0.0	5	1	1	1
69229	1710	mab over a period	[mAbs over a period]	0.0	4	1	1	1
69230	1710	-20 GATA binding site	[-20 GATA binding site]	0.0	4	1	1	1
69231	1710	ap-1 October	[AP-1 Oct]	0.0	2	1	1	1
69232	1710	patient 3 to 15 years)	[patients 3 to 15 years)]	0.0	5	1	1	1
69233	1710	only weak inhibition of the generation	[only weak inhibition of the generation]	0.0	6	1	1	1
69234	1710	site for ebf homologous sequence	[sites for EBF homologous sequences]	0.0	5	1	1	1
69235	1710	F mutant	[F mutant]	0.0	2	1	1	1
69236	1710	P-like element-binding complex	[P-like element-binding complexes]	0.0	3	1	1	1
69237	1710	microg/ml)/mn2+ (50 microM)	[microg/ml)/Mn2+ (50 microM)]	0.0	3	1	1	1
69238	1710	selective effect of agent	[Selective effects of agents]	0.0	4	1	1	1
69239	1710	(post)	[(post)]	0.0	1	1	1	1
69240	1710	regulation flow-induced haec vcam-1 expression	[Regulation flow-induced HAEC VCAM-1 expression]	0.0	5	1	1	1
69241	1710	hla binding	[HLA binding]	0.0	2	1	1	1
69242	1710	ino synthase ino	[iNO synthase iNOS]	0.0	3	1	1	1
69243	1710	chloram-phenicol acetyltransferase (cat) construct	[chloram-phenicol acetyltransferase (CAT) constructs]	0.0	4	1	1	1
69244	1710	labial salivary gland of patient	[labial salivary glands of patients]	0.0	5	1	1	1
69245	1710	include autoimmunity	[including autoimmunity]	0.0	2	1	1	1
69246	1710	po-b DNA binding	[PO-B DNA binding]	0.0	3	1	1	1
69247	1710	spectrum of differentiation	[spectrum of differentiation]	0.0	3	1	1	1
69248	1710	include ETS1	[including ETS1]	0.0	2	1	1	1
69249	1710	signal-dependent nf-kappa b activation	[signal-dependent NF-kappa B activation]	0.0	4	1	1	1
69250	1710	functionally related hepatocyte factor	[functionally related hepatocyte factors]	0.0	4	1	1	1
69251	1710	quantification by polymerase chain reaction lack	[Quantification by polymerase chain reaction lack]	0.0	6	1	1	1
69252	1710	activation by beta-phorbol 12-myristate 13-acetate	[activation by beta-phorbol 12-myristate 13-acetate]	0.0	5	1	1	1
69253	1710	other cytokine receptors,	[other cytokine receptors,]	0.0	3	1	1	1
69254	1710	loss of sensitivity	[loss of sensitivity]	0.0	3	1	1	1
69255	1710	architecture for antigen processing	[architecture for antigen processing]	0.0	4	1	1	1
69256	1710	rh- VDR	[Rh- VDR]	0.0	2	1	1	1
69257	1710	autosomal xy sex reversal	[autosomal XY sex reversal]	0.0	4	1	1	1
69258	1710	plasmid contain part	[plasmids containing parts]	0.0	3	1	1	1
69259	1710	several zinc finger gene	[several zinc finger genes]	0.0	4	1	1	1
69260	1710	cell of the central system	[cells of the central system]	0.0	5	1	1	1
69261	1710	use a incompetent human g-csfr mutant	[Using a incompetent human G-CSFR mutant]	0.0	6	1	1	1
69262	1710	phorbol ester concentration,	[phorbol ester concentration,]	0.0	3	1	1	1
69263	1710	DRE 1 protein, p37	[DRE 1 protein, p37]	0.0	4	1	1	1
69264	1710	tethering by p-selectin translocation	[tethering by P-selectin translocation]	0.0	4	1	1	1
69265	1710	lineage-specific factor act	[lineage-specific factor acting]	0.0	3	1	1	1
69266	1710	METHODS: lymphocytic cell line	[METHODS: lymphocytic cell lines]	0.0	4	1	1	1
69267	1710	retinoid-X receptor alpha	[retinoid-X receptor alpha]	0.0	3	1	1	1
69268	1710	megakaryocytic pathway by phorbol acetate	[megakaryocytic pathway by phorbol acetate]	0.0	5	1	1	1
69269	1710	ikappabalpha kinase p90(rsk)	[IkappaBalpha kinase p90(rsk)]	0.0	3	1	1	1
69270	1710	IL-6 kappa	[IL-6 kappa]	0.0	2	1	1	1
69271	1710	flow with dysmenorrhoea	[flow with dysmenorrhoea]	0.0	3	1	1	1
69272	1710	expression of slp-76 leukocyte protein	[expression of SLP-76 leukocyte protein]	0.0	5	1	1	1
69273	1710	potentiation of clearance	[potentiation of clearance]	0.0	3	1	1	1
69274	1710	member of the Bcl-2 family	[members of the Bcl-2 family]	0.0	5	1	1	1
69275	1710	use a approach	[using a approach]	0.0	3	1	1	1
69276	1710	Leu-7+ killer cell	[Leu-7+ killer cells]	0.0	3	1	1	1
69277	1710	tissue undergo elective termination	[Tissues undergoing elective termination]	0.0	4	1	1	1
69278	1710	prime from cellular signal to	[priming from cellular signal to]	0.0	5	1	1	1
69279	1710	tip-associated protein tap	[Tip-associated protein Tap]	0.0	3	1	1	1
69280	1710	infectious hiv-1 provirus	[infectious HIV-1 provirus]	0.0	3	1	1	1
69281	1710	identification of more specific inhibitor	[Identification of more specific inhibitors]	0.0	5	1	1	1
69282	1710	receptor determination a clue	[receptor determination a clue]	0.0	4	1	1	1
69283	1710	blocker	[blocker]	0.0	1	1	1	1
69284	1710	significant decrease in state kappa	[significant decrease in state kappa]	0.0	5	1	1	1
69285	1710	hiv transcript of virus particle	[HIV transcripts of virus particles]	0.0	5	1	1	1
69286	1710	other possible targets,	[other possible targets,]	0.0	3	1	1	1
69287	1710	dp2 -353 bp	[DP2 -353 bp]	0.0	3	1	1	1
69288	1710	prednisone PDN	[prednisone PDN]	0.0	2	1	1	1
69289	1710	effect on target cell	[effect on target cells]	0.0	4	1	1	1
69290	1710	thymocyte nuclei	[thymocyte nuclei]	0.0	2	1	1	1
69291	1710	extract secret el4 cell	[extracts secreting El4 cells]	0.0	4	1	1	1
69292	1710	type include chronic myeloid leukaemia	[types including chronic myeloid leukaemia]	0.0	5	2	2	1
69293	1710	+/- fmol/10(7) pbmc fmol/10(7) pbmc	[+/- fmol/10(7) PBMC fmol/10(7) PBMC]	0.0	5	1	1	1
69294	1710	proline domain	[proline domain]	0.0	2	1	1	1
69295	1710	cooperative binding elf-1	[cooperative binding Elf-1]	0.0	3	1	1	1
69296	1710	immune system target	[immune system targets]	0.0	3	1	1	1
69297	1710	include domain	[including domains]	0.0	2	1	1	1
69298	1710	393 amino acid tramp	[393 amino acid TRAMP]	0.0	4	1	1	1
69299	1710	ten healthy volunteer	[ten healthy volunteers]	0.0	3	1	1	1
69300	1710	use a flow-cytometric assay	[Using a flow-cytometric assay]	0.0	4	1	1	1
69301	1710	g1 cell cycle regulatory function	[G1 cell cycle regulatory function]	0.0	5	1	1	1
69302	1710	sunlight	[sunlight]	0.0	1	1	1	1
69303	1710	influence inflammatory disease	[influencing inflammatory disease]	0.0	3	1	1	1
69304	1710	nuclear factor-KB NF-kappa b result	[nuclear factor-KB NF-kappa B resulting]	0.0	5	1	1	1
69305	1710	use the binding assay	[using the binding assay]	0.0	4	1	1	1
69306	1710	-chelating	[-chelating]	0.0	1	1	1	1
69307	1710	manner analogous	[manner analogous]	0.0	2	1	1	1
69308	1710	genuine site	[genuine site]	0.0	2	1	1	1
69309	1710	affinity than atra	[affinity than ATRA]	0.0	3	1	1	1
69310	1710	patient with ricket	[patients with rickets]	0.0	3	1	1	1
69311	1710	regulation of a variety	[regulation of a variety]	0.0	4	1	1	1
69312	1710	rectifier K+ channel	[rectifier K+ channel]	0.0	3	1	1	1
69313	1710	interleukin-2 reporter gene	[interleukin-2 reporter gene]	0.0	3	1	1	1
69314	1710	differentiate towards the eosinophil lineage	[differentiating towards the eosinophil lineages]	0.0	5	1	1	1
69315	1710	negative domain	[negative domain]	0.0	2	1	1	1
69316	1710	expression jun	[expression jun]	0.0	2	1	1	1
69317	1710	protein-dna complex	[Protein-DNA complexes]	0.0	2	1	1	1
69318	1710	competition with transcription factor	[competition with transcription factors]	0.0	4	1	1	1
69319	1710	follow immunization	[following immunization]	0.0	2	1	1	1
69320	1710	diverse function	[diverse functions]	0.0	2	1	1	1
69321	1710	major cell wall component	[major cell wall component]	0.0	4	1	1	1
69322	1710	viral DNA polymerase inhibitor	[viral DNA polymerase inhibitor]	0.0	4	1	1	1
69323	1710	mode of stress.	[modes of stress.]	0.0	3	1	1	1
69324	1710	stimulation of interleukin-8 production protein	[Stimulation of interleukin-8 production protein]	0.0	5	1	1	1
69325	1710	"instability" motif	["instability" motif]	0.0	2	1	1	1
69326	1710	cell type throughout the body,	[cell types throughout the body,]	0.0	5	1	1	1
69327	1710	therapeutic effect of arsenic trioxide	[therapeutic effect of arsenic trioxide]	0.0	5	1	1	1
69328	1710	real-time blood pressure monitor	[real-time blood pressure monitor]	0.0	4	1	1	1
69329	1710	strain express PhoQ	[strains expressing PhoQ]	0.0	3	1	1	1
69330	1710	role of hsf1	[role of HSF1]	0.0	3	1	1	1
69331	1710	inhibition of NFATp/AP-1 formation	[inhibition of NFATp/AP-1 formation]	0.0	4	1	1	1
69332	1710	protease activation of nf-kappa b	[protease activation of NF-kappa B]	0.0	5	1	1	1
69333	1710	novel protein mar-bp1	[novel protein MAR-BP1]	0.0	3	1	1	1
69334	1710	small mutation	[small mutations]	0.0	2	1	1	1
69335	1710	U2 enhancer construction	[U2 enhancer constructions]	0.0	3	1	1	1
69336	1710	primary culture of T lymphocyte	[primary cultures of T lymphocytes]	0.0	5	1	1	1
69337	1710	region of base order-dependent stem-loop potential	[Regions of base order-dependent stem-loop potential]	0.0	6	1	1	1
69338	1710	total ca2+	[total Ca2+]	0.0	2	1	1	1
69339	1710	unrelated child with hormone deficiency	[unrelated children with hormone deficiency]	0.0	5	1	1	1
69340	1710	lead to gene regulatory response	[leading to gene regulatory responses]	0.0	5	1	1	1
69341	1710	(b-2) lymphocyte	[(B-2) lymphocytes]	0.0	2	1	1	1
69342	1710	role convert signal	[role converting signals]	0.0	3	1	1	1
69343	1710	synergistic enhancement	[synergistic enhancement]	0.0	2	1	1	1
69344	1710	function in differentiation	[function in differentiation]	0.0	3	1	1	1
69345	1710	protein synthesis,	[protein synthesis,]	0.0	2	1	1	1
69346	1710	response in leishmania-infected cell	[responses in leishmania-infected cells]	0.0	4	1	1	1
69347	1710	protein synthesis.	[protein synthesis.]	0.0	2	1	1	1
69348	1710	defective production of cytokine	[defective production of cytokines]	0.0	4	1	1	1
69349	1710	CEM-ICR leukemic lymphoblast a clone	[CEM-ICR leukemic lymphoblasts a clone]	0.0	5	1	1	1
69350	1710	example glucocorticoid receptor	[example glucocorticoid receptors]	0.0	3	1	1	1
69351	1710	contain CRE	[containing CRE]	0.0	2	1	1	1
69352	1710	hiv-1 rna	[HIV-1 RNA]	0.0	2	1	1	1
69353	1710	NF-kappaB inhibitory subunit	[NF-kappaB inhibitory subunits]	0.0	3	1	1	1
69354	1710	nm D3	[nM D3]	0.0	2	3	3	1
69355	1710	chemotactic adhesive ICAM-1 property of cell	[chemotactic adhesive ICAM-1 properties of cells]	0.0	6	1	1	1
69356	1710	b cell transcription factor bsap	[B cell transcription factor BSAP]	0.0	5	1	1	1
69357	1710	tf activity of monocyte	[TF activity of monocytes]	0.0	4	1	1	1
69358	1710	negative effect on the promoter	[negative effects on the promoters]	0.0	5	1	1	1
69359	1710	inflammatory arthritis	[inflammatory arthritis]	0.0	2	3	3	1
69360	1710	current understanding with emphasis	[current understanding with emphasis]	0.0	4	1	1	1
69361	1710	effector on activity	[effector on activity]	0.0	3	1	1	1
69362	1710	sequence in a region ii	[sequences in a region II]	0.0	5	1	1	1
69363	1710	murine Th1	[murine Th1]	0.0	2	1	1	1
69364	1710	RAR alpha alone	[RAR alpha alone]	0.0	3	1	1	1
69365	1710	two model of a opposite situation	[two models of an opposite situation]	0.0	6	1	1	1
69366	1710	effect of 1 alpha,25-(OH)2D3 analog	[effects of 1 alpha,25-(OH)2D3 analogs]	0.0	5	1	1	1
69367	1710	initiation of encephalomyocarditis virus	[initiation of encephalomyocarditis virus]	0.0	4	1	1	1
69368	1710	only transactivation	[only transactivation]	0.0	2	1	1	1
69369	1710	direct repeat DR	[direct repeats DR]	0.0	3	1	1	1
69370	1710	class transcription factor	[class transcription factors]	0.0	3	1	1	1
69371	1710	intermediate step in the processing,	[intermediate step in the processing,]	0.0	5	1	1	1
69372	1710	90 degree with helice	[90 degrees with helices]	0.0	4	1	1	1
69373	1710	element of hiv-1	[element of HIV-1]	0.0	3	1	1	1
69374	1710	wild-type level U2	[wild-type levels U2]	0.0	3	1	1	1
69375	1710	mg bolus late in volunteer	[mg bolus later) in volunteers]	0.0	5	1	1	1
69376	1710	ebf sequence	[EBF sequences]	0.0	2	1	1	1
69377	1710	interfere with this process	[interfering with these processes]	0.0	4	1	1	1
69378	1710	weak activation of NFkappaB	[weak activation of NFkappaB]	0.0	4	1	1	1
69379	1710	t3 binding capacity MBC	[T3 binding capacity MBC]	0.0	4	1	1	1
69380	1710	contain b DNA binding site	[containing B DNA binding sites]	0.0	5	1	1	1
69381	1710	span base pair	[spanning base pairs]	0.0	3	1	1	1
69382	1710	on/off switch	[on/off switches]	0.0	2	1	1	1
69383	1710	inhibitor of mek1 in vitro	[inhibitor of MEK1 in vitro]	0.0	5	1	1	1
69384	1710	ciita promoter suppression	[CIITA promoter suppression]	0.0	3	1	1	1
69385	1710	20 nmol/l, incubation time	[20 nmol/l, incubation time]	0.0	4	1	1	1
69386	1710	immune responsiveness by il-10	[immune responsiveness by IL-10]	0.0	4	1	1	1
69387	1710	expression of actin	[expression of actin]	0.0	3	1	1	1
69388	1710	(pbmc) hGR level	[(PBMC) hGR levels]	0.0	3	1	1	1
69389	1710	concentration of D3 receptor effect	[concentration of D3 receptors effect]	0.0	5	1	1	1
69390	1710	two potential domain	[two potential domains]	0.0	3	1	1	1
69391	1710	gamma activation	[gamma activation]	0.0	2	1	1	1
69392	1710	molecular function of Oct2	[molecular function of Oct2]	0.0	4	1	1	1
69393	1710	Colinear	[Colinear]	0.0	1	1	1	1
69394	1710	immunodeficiency virus type provirus	[immunodeficiency virus type provirus]	0.0	4	1	1	1
69395	1710	capsid antigen staining	[capsid antigen staining]	0.0	3	1	1	1
69396	1710	natural killer cell by IL-2	[natural killer cells by IL-2]	0.0	5	1	1	1
69397	1710	expression of the peak	[expression of the peak]	0.0	4	1	1	1
69398	1710	T lymphocyte a ISGF3 response	[T lymphocytes an ISGF3 response]	0.0	5	1	1	1
69399	1710	immunoglobulin chain enhancer igh-enhancer	[immunoglobulin chain enhancer IgH-enhancer]	0.0	4	1	1	1
69400	1710	factor to 10, as	[factor to 10, as]	0.0	4	1	1	1
69401	1710	effect of D3 dioxyvit	[effect of D3 dioxyvit]	0.0	4	1	1	1
69402	1710	decrease in interleukin (il-2)	[decrease in interleukin (IL-2)]	0.0	4	1	1	1
69403	1710	transcriptional activity follow PMA	[transcriptional activity following PMA]	0.0	4	1	1	1
69404	1710	activation by stimulus in neutrophil	[Activation by stimuli in neutrophils]	0.0	5	1	1	1
69405	1710	B-cell marker include vpreb1	[B-cell markers including VpreB1]	0.0	4	1	1	1
69406	1710	crucial role in the differentiation	[crucial role in the differentiation]	0.0	5	1	1	1
69407	1710	Cbf alpha subunit	[Cbf alpha subunit]	0.0	3	1	1	1
69408	1710	chemoattractant cytokine chemokine	[chemoattractant cytokine chemokine]	0.0	3	1	1	1
69409	1710	jurkat cell T lymphocyte	[Jurkat cells T lymphocytes]	0.0	4	1	1	1
69410	1710	subfragment (c26)	[subfragment (C26)]	0.0	2	1	1	1
69411	1710	camp inhibition	[cAMP inhibition]	0.0	2	1	1	1
69412	1710	result in thrombocytopenia	[resulting in thrombocytopenia]	0.0	3	1	1	1
69413	1710	factor determine gene activation	[factor determining gene activation]	0.0	4	1	1	1
69414	1710	demonstrate a in vitro substrate	[demonstrating an in vitro substrate]	0.0	5	1	1	1
69415	1710	NF-kappa b p50 /p50 homodimer	[NF-kappa B p50 /p50 homodimer]	0.0	5	1	1	1
69416	1710	Src homology domain	[Src homology domain]	0.0	3	1	1	1
69417	1710	isolation for zinc finger protein	[Isolation for zinc finger proteins]	0.0	5	1	1	1
69418	1710	irf-1 interferon regulatory factor	[IRF-1 interferon regulatory factor]	0.0	4	1	1	1
69419	1710	(mhc) class molecule	[(MHC) class molecules]	0.0	3	1	1	1
69420	1710	increase notably phospholipase c	[increase notably phospholipase C]	0.0	4	1	1	1
69421	1710	maximum stimulation use ng/ml	[maximum stimulation using ng/ml]	0.0	4	1	1	1
69422	1710	80.2 15.5 (p 0.05, p 0.01	[80.2 15.5 (P 0.05, P 0.01]	0.0	6	1	1	1
69423	1710	h9 T	[H9 T]	0.0	2	1	1	1
69424	1710	late h2a-2	[late H2A-2]	0.0	2	1	1	1
69425	1710	tgf-beta mrna	[TGF-beta mRNA]	0.0	2	1	1	1
69426	1710	tissue from this mouse	[tissues from these mice]	0.0	4	1	1	1
69427	1710	malignant histiocytoma 6, rhabdomyosarcoma	[malignant histiocytoma 6, rhabdomyosarcoma]	0.0	4	1	1	1
69428	1710	ptdin binding	[PtdIns binding]	0.0	2	1	1	1
69429	1710	affinity of heterodimeric NFKB2 p49	[affinity of heterodimeric NFKB2 p49]	0.0	5	1	1	1
69430	1710	use two pkc inhibitors, pentoxifylline PTX	[using two PKC inhibitors, pentoxifylline PTX]	0.0	6	1	1	1
69431	1710	human blood mononuclear cell pbmc	[human blood mononuclear cells PBMC]	0.0	5	6	6	1
69432	1710	blood cell culture in 50	[blood cell cultures in 50]	0.0	5	1	1	1
69433	1710	peripheral lymph node	[peripheral lymph nodes]	0.0	3	1	1	1
69434	1710	antigen in lymphocyte reaction	[antigen in lymphocyte reactions]	0.0	4	1	1	1
69435	1710	efficient induction of activation	[efficient induction of activation]	0.0	4	1	1	1
69436	1710	viable erythroid cell a phenotype	[viable erythroid cells a phenotype]	0.0	5	1	1	1
69437	1710	affinity consistent with biological effect	[affinity consistent with biological effects]	0.0	5	1	1	1
69438	1710	effect of ras	[effects of Ras]	0.0	3	1	1	1
69439	1710	suppression of nf-kappa b	[suppression of NF-kappa B]	0.0	4	1	1	1
69440	1710	RNA display DD	[RNA display DD]	0.0	3	1	1	1
69441	1710	functionally important b cell-specific co-activator	[functionally important B cell-specific co-activator]	0.0	5	1	1	1
69442	1710	SH2 domain-contain protein slp-76	[SH2 domain-containing protein SLP-76]	0.0	4	1	1	1
69443	1710	protein of the regulatory cascade	[proteins of the regulatory cascade]	0.0	5	1	1	1
69444	1710	adult blood cell	[adult blood cells]	0.0	3	1	1	1
69445	1710	level of receptor in mononuclear leucocyte	[levels of receptor in mononuclear leucocytes]	0.0	6	1	1	1
69446	1710	first year	[first year]	0.0	2	1	1	1
69447	1710	Bal 31	[Bal 31]	0.0	2	1	1	1
69448	1710	proper hormone-dependent expression	[proper hormone-dependent expression]	0.0	3	1	1	1
69449	1710	implication of t3r alteration	[implications of T3R alterations]	0.0	4	1	1	1
69450	1710	especially with marker as Ki-67 staining	[especially with markers as Ki-67 staining]	0.0	6	1	1	1
69451	1710	use a BK virus vector	[using a BK virus vector]	0.0	5	1	1	1
69452	1710	exogenous expression	[exogenous expression]	0.0	2	1	1	1
69453	1710	low transactivation activity	[lower transactivation activity]	0.0	3	1	1	1
69454	1710	negative mutant of the IL-1	[negative mutants of the IL-1]	0.0	5	1	1	1
69455	1710	role of a site	[role of an site]	0.0	4	1	1	1
69456	1710	Phosphatidyl inositol 3-kinase	[Phosphatidyl inositol 3-kinase]	0.0	3	1	1	1
69457	1710	(oh)2d3	[(OH)2D3]	0.0	1	1	1	1
69458	1710	carry mutation in the part	[carrying mutations in the part]	0.0	5	1	1	1
69459	1710	VDR CDNA	[VDR CDNA]	0.0	2	1	1	1
69460	1710	protein from IARC	[proteins from IARC]	0.0	3	1	1	1
69461	1710	assays), a value	[assays), a value]	0.0	3	1	1	1
69462	1710	expression ciita	[expression CIITA]	0.0	2	1	1	1
69463	1710	exclusive selectivity for aldosterone	[exclusive selectivity for aldosterone]	0.0	4	1	1	1
69464	1710	common detectable abnormality	[common detectable abnormalities]	0.0	3	1	1	1
69465	1710	translocation of factor nf-kappa b	[translocation of factor NF-kappa B]	0.0	5	1	1	1
69466	1710	granulocyte-macrophage CSF gene	[granulocyte-macrophage CSF gene]	0.0	3	1	1	1
69467	1710	hhv-8 +/ebv+	[HHV-8 +/EBV+]	0.0	2	1	1	1
69468	1710	IL-2 transformation step of t-cell	[IL-2 transformation steps of T-cells]	0.0	5	1	1	1
69469	1710	motheaten mouse	[motheaten mice]	0.0	2	1	1	1
69470	1710	reactive hyperplasia fh	[reactive hyperplasia FH]	0.0	3	1	1	1
69471	1710	thus any cellular defect lead	[thus any cellular defect leading]	0.0	5	1	1	1
69472	1710	potent activator of T lymphocyte	[potent activator of T lymphocytes]	0.0	5	1	1	1
69473	1710	element regulate il-4 gene expression	[elements regulating IL-4 gene expression]	0.0	5	1	1	1
69474	1710	T cell homeostasis	[T cell homeostasis]	0.0	3	1	1	1
69475	1710	only a cd8(+)-t-cell epitope	[only a CD8(+)-T-cell epitopes]	0.0	4	1	1	1
69476	1710	depend on the type	[Depending on the type]	0.0	4	1	1	1
69477	1710	suggest a key role	[suggesting a key role]	0.0	4	1	1	1
69478	1710	target of positive signal	[target of positive signals]	0.0	4	1	1	1
69479	1710	however, three order of magnitude potent	[however, three orders of magnitude potent]	0.0	6	1	1	1
69480	1710	factor-like growth	[factor-like growth]	0.0	2	2	2	1
69481	1710	structure distinct from the structure characteristic	[structures distinct from the structures characteristic]	0.0	6	1	1	1
69482	1710	presenter of antigen	[presenters of antigen]	0.0	3	1	1	1
69483	1710	activity of transcription factor NFkappaB	[activities of transcription factors NFkappaB]	0.0	5	1	1	1
69484	1710	JNK /sapk activation	[JNK /SAPK activation]	0.0	3	1	1	1
69485	1710	signal transducer of transcription-3	[signal transducer of transcription-3]	0.0	4	1	1	1
69486	1710	u/ml IFN gamma	[U/ml IFN gamma]	0.0	3	1	1	1
69487	1710	implicate this region in DNA	[implicating this region in DNA]	0.0	5	1	1	1
69488	1710	press.	[Press.]	0.0	1	16	16	1
69489	1710	trigger for the expression	[trigger for the expression]	0.0	4	1	1	1
69490	1710	collagen such as the skin	[collagen such as the skin]	0.0	5	1	1	1
69491	1710	atf/ creb recognition	[ATF/ CREB recognition]	0.0	3	1	1	1
69492	1710	property of glucocorticoid	[property of glucocorticoids]	0.0	3	1	1	1
69493	1710	significant variable predict NK activity	[significant variable predicting NK activity]	0.0	5	1	1	1
69494	1710	flexible mechanism	[flexible mechanism]	0.0	2	1	1	1
69495	1710	patient with primary syndrome	[patients with primary syndromes]	0.0	4	1	1	1
69496	1710	kinetic sivmac239	[kinetics SIVmac239]	0.0	2	1	1	1
69497	1710	both, cell	[both, cells]	0.0	2	1	1	1
69498	1710	signal for chemoattract	[signaling for chemoattractants]	0.0	3	1	1	1
69499	1710	less a-myb rna	[less A-myb RNA]	0.0	3	1	1	1
69500	1710	expense of key reactivities.	[expense of key reactivities.]	0.0	4	1	1	1
69501	1710	effect of adenovirus on gene activation	[Effect of adenovirus on gene activation]	0.0	6	1	1	1
69502	1710	acute injury in rat lung	[Acute injury in rat lung]	0.0	5	1	1	1
69503	1710	significant decrease monocyte il-1ra secretion	[significant decrease monocyte IL-1ra secretion]	0.0	5	1	1	1
69504	1710	role regulate interferon (ifn)-gamma production	[role regulating interferon (IFN)-gamma production]	0.0	5	1	1	1
69505	1710	tumor necrosis gene	[tumor necrosis genes]	0.0	3	1	1	1
69506	1710	level of tyrosine kinase activity	[levels of tyrosine kinase activity]	0.0	5	1	1	1
69507	1710	human pml expression	[human PML expression]	0.0	3	1	1	1
69508	1710	Study during evidence	[Studies during evidence]	0.0	3	1	1	1
69509	1710	early stage.	[early stage.]	0.0	2	1	1	1
69510	1710	distinct effect on pattern increase	[distinct effect on patterns increase]	0.0	5	1	1	1
69511	1710	relative efficiency	[relative efficiency]	0.0	2	1	1	1
69512	1710	important regulator in t-cell activation	[important regulator in T-cell activation]	0.0	5	1	1	1
69513	1710	unfractionated peripheral blood cell	[unfractionated peripheral blood cells]	0.0	4	1	1	1
69514	1710	92 base pair	[92 base pairs]	0.0	3	1	1	1
69515	1710	factor CBF	[factor CBF]	0.0	2	1	1	1
69516	1710	Glucocorticoid resistance in patient	[Glucocorticoid resistance in patients]	0.0	4	1	1	1
69517	1710	stable derivative of retinoic acid	[stable derivative of retinoic acid]	0.0	5	1	1	1
69518	1710	ikappab-alpha in cell	[IkappaB-alpha in cells]	0.0	3	1	1	1
69519	1710	calcium increase	[calcium increase]	0.0	2	1	1	1
69520	1710	coordinate the activity	[coordinating the activity]	0.0	3	1	1	1
69521	1710	finding, co-transfection	[finding, co-transfection]	0.0	2	1	1	1
69522	1710	use a negative form	[using a negative form]	0.0	4	1	1	1
69523	1710	exon 7	[exon 7]	0.0	2	1	1	1
69524	1710	peripheral blood volunteer (86 man	[peripheral blood volunteers (86 men]	0.0	5	1	1	1
69525	1710	protein x box protein hxbp-1	[protein X box protein hXBP-1]	0.0	5	1	1	1
69526	1710	moderate correlation between affinity	[moderate correlation between affinity]	0.0	4	1	1	1
69527	1710	modulation by transfer of IkappaB-alpha	[modulation by transfer of IkappaB-alpha]	0.0	5	1	1	1
69528	1710	cell nfat	[cell NFAT]	0.0	2	1	1	1
69529	1710	element OSE2	[elements OSE2]	0.0	2	1	1	1
69530	1710	inhibition of the igg (from	[inhibition of the IgG (from]	0.0	5	1	1	1
69531	1710	gm-csf lineage	[GM-CSF lineage]	0.0	2	1	1	1
69532	1710	PMA/ionomycin factor	[PMA/ionomycin factors]	0.0	2	1	1	1
69533	1710	activation of a reporter	[activation of a reporter]	0.0	4	1	1	1
69534	1710	utilize the steroid antagonist	[utilizing the steroid antagonist]	0.0	4	1	1	1
69535	1710	inhibit the capacity	[inhibiting the capacity]	0.0	3	1	1	1
69536	1710	two different system	[two different systems]	0.0	3	1	1	1
69537	1710	molecular aspect	[molecular aspects]	0.0	2	1	1	1
69538	1710	evidence for activity at element	[Evidence for activity at element]	0.0	5	1	1	1
69539	1710	four anonymous probe	[four anonymous probes]	0.0	3	1	1	1
69540	1710	exon V	[exon V]	0.0	2	1	1	1
69541	1710	impaired thymocyte development after efficient inhibition	[Impaired thymocyte development after efficient inhibition]	0.0	6	1	1	1
69542	1710	various human line u937	[various human lines U937]	0.0	4	1	1	1
69543	1710	inhibit dissociation of hGR	[inhibiting dissociation of hGR]	0.0	4	1	1	1
69544	1710	increase in ca2+ concentration	[increase in Ca2+ concentration]	0.0	4	1	1	1
69545	1710	fkbp12 /fk506	[FKBP12 /FK506]	0.0	2	1	1	1
69546	1710	tsh receptor tsh-r cDNA probe	[TSH receptor TSH-R cDNA probe]	0.0	5	1	1	1
69547	1710	tgf-beta 1	[TGF-beta 1]	0.0	2	1	1	1
69548	1710	(0/33)	[(0/33)]	0.0	1	1	1	1
69549	1710	spite of association however,	[spite of association however,]	0.0	4	1	1	1
69550	1710	resistant	[resistant]	0.0	1	1	1	1
69551	1710	cell-associated recognition	[cell-associated recognition]	0.0	2	1	1	1
69552	1710	overall blood histamine response	[overall blood histamine response]	0.0	4	1	1	1
69553	1710	slow decline	[slower decline]	0.0	2	1	1	1
69554	1710	gene regulation by repression"	[gene regulation by repression"]	0.0	4	1	1	1
69555	1710	protein kinase C dependent	[protein kinase C dependent]	0.0	4	1	1	1
69556	1710	cd3-cd16+ killer( NK	[CD3-CD16+ killer( NK]	0.0	3	1	1	1
69557	1710	rational strategy manipulate response	[rational strategies manipulating responses]	0.0	4	1	1	1
69558	1710	large genomic IL-4 region	[large genomic IL-4 regions]	0.0	4	1	1	1
69559	1710	tumor development	[tumor development]	0.0	2	1	1	1
69560	1710	include some Jewish group	[including some Jewish groups]	0.0	4	1	1	1
69561	1710	novel activate region	[novel activating region]	0.0	3	1	1	1
69562	1710	cytosolic nf-kappa b	[cytosolic NF-kappa B]	0.0	3	1	1	1
69563	1710	inducible promoter activation	[inducible promoter activation]	0.0	3	1	1	1
69564	1710	transcription of transformation,	[transcription of transformation,]	0.0	3	1	1	1
69565	1710	manner, with a inhibition	[manner, with a inhibition]	0.0	4	1	1	1
69566	1710	utilization of stat protein	[utilization of STAT proteins]	0.0	4	1	1	1
69567	1710	multiple nf-atc isoform	[Multiple NF-ATc isoforms]	0.0	3	1	1	1
69568	1710	background: Study	[BACKGROUND: Studies]	0.0	2	1	1	1
69569	1710	family of trans-acting factor	[family of trans-acting factors]	0.0	4	1	1	1
69570	1710	viral membrane protein	[viral membrane protein]	0.0	3	1	1	1
69571	1710	suggest a property	[suggesting a property]	0.0	3	1	1	1
69572	1710	much low extent	[much lower extent]	0.0	3	1	1	1
69573	1710	degree of glycosylation	[degree of glycosylation]	0.0	3	1	1	1
69574	1710	alternative splicing (R) rna	[Alternative splicing (R) RNA]	0.0	4	1	1	1
69575	1710	PMA factor	[PMA factor]	0.0	2	1	1	1
69576	1710	response in gene expression	[responses in gene expression]	0.0	4	1	1	1
69577	1710	primary peripheral cell	[primary peripheral cells]	0.0	3	1	1	1
69578	1710	accumulation of the rrna	[accumulation of the mRNAs]	0.0	4	1	1	1
69579	1710	maturation of a cell line	[maturation of a cell line]	0.0	5	1	1	1
69580	1710	proximal flank region	[proximal flanking region]	0.0	3	1	1	1
69581	1710	glucocorticosteroid binding assay	[glucocorticosteroid binding assay]	0.0	3	1	1	1
69582	1710	expression of many important protein	[expression of many important proteins]	0.0	5	1	1	1
69583	1710	factor-KB NF-kappa b result	[factor-KB NF-kappa B resulting]	0.0	4	1	1	1
69584	1710	25-hydroxyvitamin D3 24-hydroxylase	[25-hydroxyvitamin D3 24-hydroxylase]	0.0	3	1	1	1
69585	1710	three approaches.	[three approaches.]	0.0	2	1	1	1
69586	1710	acting Stat-3 isoform	[acting Stat-3 isoform]	0.0	3	1	1	1
69587	1710	nfat-binding element P0	[NFAT-binding elements P0]	0.0	3	1	1	1
69588	1710	activation of the interleukin-2 gene	[activation of the interleukin-2 gene]	0.0	5	1	1	1
69589	1710	trigger with CD3	[triggering with CD3]	0.0	3	1	1	1
69590	1710	gene in linkage	[gene in linkage]	0.0	3	1	1	1
69591	1710	activation of the il-4 promoter	[activation of the IL-4 promoter]	0.0	5	1	1	1
69592	1710	level of antibodies patient	[levels of antibodies, patients]	0.0	4	1	1	1
69593	1710	fuse	[fusing]	0.0	1	1	1	1
69594	1710	early production	[early production]	0.0	2	1	1	1
69595	1710	methov with factor	[METHODS with factor]	0.0	3	1	1	1
69596	1710	include interferon gamma	[including interferon gamma]	0.0	3	1	1	1
69597	1710	inhibitory effect of infection	[inhibitory effect of infection]	0.0	4	1	1	1
69598	1710	encode oct-binding factor obf-1 a protein	[encoding Oct-binding factor OBF-1 a protein]	0.0	6	1	1	1
69599	1710	trigger of pathway	[triggering of pathways]	0.0	3	1	1	1
69600	1710	only the pair mrna	[only the pair mRNA]	0.0	4	1	1	1
69601	1710	cd34+ hemopoietic progenitor cell HPC	[CD34+ hemopoietic progenitor cells HPC]	0.0	5	1	1	1
69602	1710	erythropoietin induction	[Erythropoietin induction]	0.0	2	1	1	1
69603	1710	ligand ro47-5944	[ligand Ro47-5944]	0.0	2	1	1	1
69604	1710	colony-forming cell	[colony-forming cells]	0.0	2	1	1	1
69605	1710	important implication for the treatment	[important implications for the treatment]	0.0	5	1	1	1
69606	1710	4 prolymphocytic leukemia	[4 prolymphocytic leukemias]	0.0	3	1	1	1
69607	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	6	1	1	1
69608	1710	interaction with Oct-1	[interaction with Oct-1]	0.0	3	1	1	1
69609	1710	nonactivate dna-binding domain	[nonactivating DNA-binding domain]	0.0	3	1	1	1
69610	1710	gram of salt	[g of salt]	0.0	3	1	1	1
69611	1710	three different cell type	[three different cell types]	0.0	4	1	1	1
69612	1710	high, concentration of RA to &mgr;m)	[high, concentrations of RA to &mgr;M)]	0.0	6	1	1	1
69613	1710	mg of the antioxidant thioctic acid	[mg of the antioxidant thioctic acid]	0.0	6	1	1	1
69614	1710	leukocyte glucocorticoid receptor binding characteristic	[leukocyte glucocorticoid receptor binding characteristics]	0.0	5	1	1	1
69615	1710	lmp gene	[LMP gene]	0.0	2	1	1	1
69616	1710	putative new retrovirus	[putative new retrovirus]	0.0	3	1	1	1
69617	1710	transient expression assay in cell culture	[transient expression assay in cell cultures]	0.0	6	1	1	1
69618	1710	stage of B-cell development	[stage of B-cell development]	0.0	4	1	1	1
69619	1710	Benzene toxicity	[Benzene toxicity]	0.0	2	1	1	1
69620	1710	arm encompass band	[arm encompassing bands]	0.0	3	1	1	1
69621	1710	(ccrf-cem) t-cell line	[(CCRF-CEM) T-cell lines]	0.0	3	1	1	1
69622	1710	such as STAT	[such as STAT]	0.0	3	1	1	1
69623	1710	information about the molecular mechanism	[information about the molecular mechanisms]	0.0	5	1	1	1
69624	1710	pp70s6k activation	[pp70S6K activation]	0.0	2	1	1	1
69625	1710	association of a t-cell transcription factor	[association of a T-cell transcription factor]	0.0	6	1	1	1
69626	1710	indicate important	[indicating important]	0.0	2	1	1	1
69627	1710	135(oh)2d3 receptor from patient	[1,25(OH)2D3 receptors from patients]	0.0	4	1	1	1
69628	1710	human differentiation antigen	[human differentiation antigen]	0.0	3	1	1	1
69629	1710	amlcg86/92	[AMLCG86/92]	0.0	1	1	1	1
69630	1710	nf-kappab activation in monocyte	[NF-kappaB activation in monocytes]	0.0	4	1	1	1
69631	1710	up-regulating	[up-regulating]	0.0	1	1	1	1
69632	1710	formation of binding heterodimers,	[formation of binding heterodimers,]	0.0	4	1	1	1
69633	1710	one biomarker between the risk	[one biomarkers between the risk]	0.0	5	1	1	1
69634	1710	cause glucocorticoid resistance	[causing glucocorticoid resistance]	0.0	3	1	1	1
69635	1710	expression by dexamethasone	[expression by dexamethasone]	0.0	3	1	1	1
69636	1710	asthma BA	[asthma BA]	0.0	2	1	1	1
69637	1710	1alpha,25(oh)2-lumisterol3 nb4 leukemia cell for differentiation	[1alpha,25(OH)2-lumisterol3 NB4 leukemia cells for differentiation]	0.0	6	1	1	1
69638	1710	adenovirus 2 ad2 infection	[adenovirus 2 Ad2 infection]	0.0	4	1	1	1
69639	1710	hhv-8 +/ebv- pel	[HHV-8 +/EBV- PEL]	0.0	3	1	1	1
69640	1710	Lin-	[Lin-]	0.0	1	1	1	1
69641	1710	least three category cell-specific factor	[least three categories cell-specific factors]	0.0	5	1	1	1
69642	1710	germline activation	[germline activation]	0.0	2	1	1	1
69643	1710	major component of human atheroma	[major component of human atheroma]	0.0	5	1	1	1
69644	1710	dsm-iii-r criterion	[DSM-III-R criteria]	0.0	2	1	1	1
69645	1710	macrophage marker CD14	[macrophage markers CD14]	0.0	3	1	1	1
69646	1710	delta-aminolevulinate synthase mrna level	[delta-aminolevulinate synthase mRNA levels]	0.0	4	1	1	1
69647	1710	RB protein expression	[RB protein expression]	0.0	3	1	1	1
69648	1710	function for cd44	[function for CD44]	0.0	3	1	1	1
69649	1710	transform activity in cell culture	[transforming activity in cell culture]	0.0	5	1	1	1
69650	1710	traf binding sequence	[TRAF binding sequences]	0.0	3	1	1	1
69651	1710	function of CD28	[function of CD28]	0.0	3	1	1	1
69652	1710	bacille calmette-guerin vaccine	[bacille Calmette-Guerin vaccine]	0.0	3	1	1	1
69653	1710	oestrogen receptor variant	[oestrogen receptor variants]	0.0	3	1	1	1
69654	1710	acute leukaemia (aml) blast	[acute leukaemia (AML) blasts]	0.0	4	1	1	1
69655	1710	survival idfs)	[survival (DFS)]	0.0	2	1	1	1
69656	1710	(i) constitutive level	[(i) constitutive levels]	0.0	3	1	1	1
69657	1710	gynecomastia (rs	[gynecomastia (Rs]	0.0	2	1	1	1
69658	1710	evidence key inflammatory mediator	[evidence key inflammatory mediators]	0.0	4	1	1	1
69659	1710	isolation of dendritic cell	[Isolation of dendritic cells]	0.0	4	1	1	1
69660	1710	expression of cytokine profile	[expression of cytokine profiles]	0.0	4	1	1	1
69661	1710	T enhancer kb upstream	[T enhancer kb upstream]	0.0	4	1	1	1
69662	1710	more mature double-positive population	[more mature double-positive populations]	0.0	4	1	1	1
69663	1710	polymorphic tandem repeat	[polymorphic tandem repeat]	0.0	3	1	1	1
69664	1710	gene activity -contain plasmid	[gene activity -containing plasmids]	0.0	4	1	1	1
69665	1710	anti- stat (signal transducer	[anti- STAT (signal transducers]	0.0	4	1	1	1
69666	1710	precipitate Stat-3 from nuclear extract	[precipitating Stat-3 from nuclear extracts]	0.0	5	1	1	1
69667	1710	dose of t3 (10(-10) mol/L).	[dose of T3 (10(-10) mol/L).]	0.0	5	1	1	1
69668	1710	stat5b in human erythroid precursor	[STAT5B in human erythroid precursors]	0.0	5	1	1	1
69669	1710	thus, coupling	[Thus, coupling]	0.0	2	1	1	1
69670	1710	such as tax	[such as Tax]	0.0	3	1	1	1
69671	1710	Jeg-3 human choriocarcinoma-induced immunosuppression downregulation	[Jeg-3 human choriocarcinoma-induced immunosuppression downregulation]	0.0	5	1	1	1
69672	1710	ambiguity intrinsic	[ambiguities intrinsic]	0.0	2	1	1	1
69673	1710	DNA ladder	[DNA ladder]	0.0	2	1	1	1
69674	1710	NFkappaB entry	[NFkappaB entry]	0.0	2	1	1	1
69675	1710	also significantly (p 0.025) low	[also significantly (P 0.025) lower]	0.0	5	1	1	1
69676	1710	porcine aortic cell	[Porcine aortic cells]	0.0	3	1	1	1
69677	1710	phosphatidylinositol-3,4,5-trisphosphate pi-3,4,5-p3 concentration in cell	[phosphatidylinositol-3,4,5-trisphosphate PI-3,4,5-P3 concentration in cells]	0.0	5	1	1	1
69678	1710	differentiation of th2 cells.	[differentiation of Th2 cells.]	0.0	4	1	1	1
69679	1710	respond to granulocyte/ factor	[responding to granulocyte/ factor]	0.0	4	1	1	1
69680	1710	MHC class extinction	[MHC class extinction]	0.0	3	1	1	1
69681	1710	class transplantation gene	[class transplantation gene]	0.0	3	1	1	1
69682	1710	encode a dna-binding protein protein	[encoding a DNA-binding protein protein]	0.0	5	1	1	1
69683	1710	unrecognized mutation	[unrecognized mutation]	0.0	2	1	1	1
69684	1710	n-acetylcysteine inhibition e-selectin	[N-acetylcysteine inhibition E-selectin]	0.0	3	1	1	1
69685	1710	transfection in this cell line	[transfections in these cell lines]	0.0	5	1	1	1
69686	1710	various molecular alteration	[various molecular alterations]	0.0	3	1	1	1
69687	1710	signal alone without signal tcr signal	[signal alone without signal TCR signal]	0.0	6	1	1	1
69688	1710	model 5 infection	[model 5 infection]	0.0	3	1	1	1
69689	1710	human cell in culture.	[human cells in culture.]	0.0	4	1	1	1
69690	1710	alteration,	[alteration,]	0.0	1	1	1	1
69691	1710	cycle infectious progeny virus expression	[cycle infectious progeny virus expression]	0.0	5	1	1	1
69692	1710	ifi in addition	[IFNs in addition]	0.0	3	1	1	1
69693	1710	resolution of whole cell extract	[Resolution of whole cell extract]	0.0	5	1	1	1
69694	1710	plant kingdom,	[plant kingdom,]	0.0	2	1	1	1
69695	1710	BHA a phenolic, chain-break antioxidant	[BHA a phenolic, chain-breaking antioxidant]	0.0	5	1	1	1
69696	1710	activation on transcription from region	[activation on transcription from regions]	0.0	5	1	1	1
69697	1710	6tg1.1 resistant icr27tk.3	[6TG1.1 resistant ICR27TK.3]	0.0	3	1	1	1
69698	1710	two isoform of STAT5	[two isoforms of STAT5]	0.0	4	1	1	1
69699	1710	rate corresponding	[rates corresponding]	0.0	2	1	1	1
69700	1710	transcript for IP-10	[transcripts for IP-10]	0.0	3	1	1	1
69701	1710	murine acute leukemia	[murine acute leukemia]	0.0	3	1	1	1
69702	1710	protein differ	[proteins differing]	0.0	2	1	1	1
69703	1710	Native PTF	[Native PTF]	0.0	2	1	1	1
69704	1710	interferon-gamma-induced factor	[Interferon-gamma-induced factor]	0.0	2	1	1	1
69705	1710	effect of GRalpha	[effects of GRalpha]	0.0	3	1	1	1
69706	1710	nm than 0.01).	[nM than 0.01).]	0.0	3	1	1	1
69707	1710	transient shuttling	[transient shuttling]	0.0	2	1	1	1
69708	1710	pretreatment monocyte-derived macrophage	[Pretreatment monocyte-derived macrophages]	0.0	3	1	1	1
69709	1710	tpa differentiation of the c-jun gene	[TPA differentiation of the c-jun genes]	0.0	6	1	1	1
69710	1710	min), c-jun,	[min), c-jun,]	0.0	2	1	1	1
69711	1710	decrease atpase activity	[decrease ATPase activities]	0.0	3	1	1	1
69712	1710	BMLF1 of the six protein	[BMLF1 of the six proteins]	0.0	5	1	1	1
69713	1710	single cell level	[single cell level]	0.0	3	1	1	1
69714	1710	total serum ige	[total serum IgE]	0.0	3	1	1	1
69715	1710	thus, differentiation of b cell	[Thus, differentiation of B cells]	0.0	5	1	1	1
69716	1710	BCL2 checkpoint eventuate	[BCL2 checkpoint eventuating]	0.0	3	1	1	1
69717	1710	low content of t3, 4) dysfunction	[low content of T3, 4) dysfunction]	0.0	6	1	1	1
69718	1710	transcription of erythroid gene	[transcription of erythroid genes]	0.0	4	1	1	1
69719	1710	thrombin generation by apoptotic muscle cell	[Thrombin generation by apoptotic muscle cells]	0.0	6	1	1	1
69720	1710	B29 minimal promoter	[B29 minimal promoter]	0.0	3	1	1	1
69721	1710	IL-12 receptor beta subunit binding	[IL-12 receptor beta subunit binding]	0.0	5	1	1	1
69722	1710	lack the primary binding site	[lacking the primary binding site]	0.0	5	1	1	1
69723	1710	alpha2 integrin gene expression	[alpha2 integrin gene expression]	0.0	4	1	1	1
69724	1710	cd14 cell surface	[CD14 cell surface]	0.0	3	1	1	1
69725	1710	relevance of cytokine therapy	[relevance of cytokine therapy]	0.0	4	1	1	1
69726	1710	control serum ige level	[controlling serum IgE levels]	0.0	4	1	1	1
69727	1710	subunit of molecular mass	[subunits of molecular mass]	0.0	4	1	1	1
69728	1710	recurrent genital herpes simplex virus	[recurrent genital herpes simplex virus]	0.0	5	1	1	1
69729	1710	human lung	[human lung]	0.0	2	1	1	1
69730	1710	clinical predictor for the course	[clinical predictor for the course]	0.0	5	1	1	1
69731	1710	article, regulation	[article, regulation]	0.0	2	1	1	1
69732	1710	rate of moderate grade	[rate of moderate grades]	0.0	4	1	1	1
69733	1710	regulator of immunoregulatory	[regulators of immunoregulatory]	0.0	3	1	1	1
69734	1710	repeat of immunodeficiency virus 1	[repeat of immunodeficiency virus 1]	0.0	5	1	1	1
69735	1710	27 child aged year	[27 children aged years]	0.0	4	1	1	1
69736	1710	profoundly decreased, z-lll-h transcriptional activity	[profoundly decreased, Z-LLL-H transcriptional activity]	0.0	5	1	1	1
69737	1710	convert	[converting]	0.0	1	1	1	1
69738	1710	induction of gene in cell	[induction of genes in cells]	0.0	5	1	1	1
69739	1710	steroid-induced rebound,	[steroid-induced rebound,]	0.0	2	1	1	1
69740	1710	mechanism of interleukin-10 inhibition	[Mechanism of interleukin-10 inhibition]	0.0	4	1	1	1
69741	1710	transformation effector site TES2	[transformation effector site TES2]	0.0	4	1	1	1
69742	1710	cd38(-) cell differentiate in culture	[CD38(-) cells differentiating in cultures]	0.0	5	1	1	1
69743	1710	three-dimensional nuclear magnetic resonance spectroscopy	[three-dimensional nuclear magnetic resonance spectroscopy]	0.0	5	1	1	1
69744	1710	U1 line	[U1 lines]	0.0	2	1	1	1
69745	1710	transformation effector site TES1	[transformation effector site TES1]	0.0	4	1	1	1
69746	1710	contain the ciita coding sequence	[containing the CIITA coding sequence]	0.0	5	1	1	1
69747	1710	effect on il-1 antagonist secretion	[effect on IL-1 antagonist secretion]	0.0	5	1	1	1
69748	1710	feature of a x-linked immunodeficiency disease	[features of a X-linked immunodeficiency disease]	0.0	6	1	1	1
69749	1710	modulation by the endogenous thyroid hormone	[Modulation by the endogenous thyroid hormone]	0.0	6	1	1	1
69750	1710	intracellular bacterium	[intracellular bacterium]	0.0	2	1	1	1
69751	1710	similarly in human alveolar macrophage	[similarly in human alveolar macrophages]	0.0	5	1	1	1
69752	1710	enhancement of the uptake of neutrophil	[enhancement of the uptake of neutrophils]	0.0	6	1	1	1
69753	1710	involvement of amp-dependent protein kinase	[Involvement of AMP-dependent protein kinases]	0.0	5	1	1	1
69754	1710	mutate at the end	[mutating at the end]	0.0	4	1	1	1
69755	1710	phase of the cycle.	[phase of the cycle.]	0.0	4	1	1	1
69756	1710	morphology loosely cell	[morphology loosely cells]	0.0	3	1	1	1
69757	1710	cortisol in the media	[cortisol in the media]	0.0	4	1	1	1
69758	1710	excess of corticosteroid cushingd' syndrome	[excess of corticosteroids Cushing's syndrome]	0.0	5	1	1	1
69759	1710	affect 135eoh)2d3 uptake	[affecting 1,25(OH)2D3 uptake]	0.0	3	1	1	1
69760	1710	1 mm) in vitro,	[1 mM) in vitro,]	0.0	4	1	1	1
69761	1710	NF-kappa b -dependent-gene	[NF-kappa B -dependent-genes]	0.0	3	1	1	1
69762	1710	consequent formation	[consequent formation]	0.0	2	1	1	1
69763	1710	cell a phenotype	[cells a phenotype]	0.0	3	1	1	1
69764	1710	moreover, nf-atp mouse	[Moreover, NF-ATp mice]	0.0	3	1	1	1
69765	1710	basal expression in cell	[basal expression in cells]	0.0	4	1	1	1
69766	1710	differentiate in response to acid	[differentiating in response to acid]	0.0	5	1	1	1
69767	1710	paracrine effect	[paracrine effect]	0.0	2	1	1	1
69768	1710	GCR in Yang deficient patient	[GCR in Yang deficient patients]	0.0	5	1	1	1
69769	1710	many cell-specific gene	[many cell-specific genes]	0.0	3	1	1	1
69770	1710	cell-specific bifunctional role	[Cell-specific bifunctional role]	0.0	3	1	1	1
69771	1710	intracellular oxidant generation	[intracellular oxidant generation]	0.0	3	1	1	1
69772	1710	end of cag repeat	[end of CAG repeats]	0.0	4	1	1	1
69773	1710	then interleukin (il)-10 blocking factor pibf	[then interleukin (IL)-10 blocking factor PIBF]	0.0	6	1	1	1
69774	1710	sap kinase	[SAP kinases]	0.0	2	1	1	1
69775	1710	prb of form 3	[pRb of Form 3]	0.0	4	1	1	1
69776	1710	assay with synthetic peptide	[assay with synthetic peptides]	0.0	4	1	1	1
69777	1710	evidence of tumor progression	[evidence of tumor progression]	0.0	4	1	1	1
69778	1710	binding to dna.	[binding to DNA.]	0.0	3	1	1	1
69779	1710	gc phenotype	[GC phenotype]	0.0	2	1	1	1
69780	1710	factor kappa b nf kappa b	[factor kappa B NF kappa B]	0.0	6	2	2	1
69781	1710	ori1yt	[ORI1yt]	0.0	1	1	1	1
69782	1710	member the homolog	[members the homolog]	0.0	3	1	1	1
69783	1710	e1a sequences.	[E1a sequences.]	0.0	2	1	1	1
69784	1710	complex function	[complex functions]	0.0	2	1	1	1
69785	1710	adrenocorticotropic hormone	[adrenocorticotropic hormone]	0.0	2	1	1	1
69786	1710	cover the 491-amino-acid sequence	[covering the 491-amino-acid sequence]	0.0	4	1	1	1
69787	1710	region important, through interaction with Oct-1	[regions important, through interaction with Oct-1]	0.0	6	1	1	1
69788	1710	part, induce expression of socs-1	[part, inducing expression of SOCS-1]	0.0	5	1	1	1
69789	1710	patient with a survival	[patients with a survival]	0.0	4	2	2	1
69790	1710	factor bind to site b	[factors binding to site B]	0.0	5	1	1	1
69791	1710	addition of oligonucleotide	[addition of oligonucleotides]	0.0	3	1	1	1
69792	1710	long terminal repeat activity	[long terminal repeat activity]	0.0	4	1	1	1
69793	1710	Bmax in pbmc	[Bmax in PBMC]	0.0	3	1	1	1
69794	1710	myelodysplastic syndrome in advanced stage	[myelodysplastic syndromes in advanced stage]	0.0	5	1	1	1
69795	1710	significant amount additionally, costimulation with anti-CD3	[significant amounts additionally, costimulation with anti-CD3]	0.0	6	1	1	1
69796	1710	mycoplasma fermentans-derived material MDHM	[Mycoplasma fermentans-derived material MDHM]	0.0	4	1	1	1
69797	1710	binding to dna,	[binding to DNA,]	0.0	3	1	1	1
69798	1710	homology to the BH1 domain	[homology to the BH1 domains]	0.0	5	1	1	1
69799	1710	such form lack a portion	[such forms lacking a portion]	0.0	5	1	1	1
69800	1710	b line	[B line]	0.0	2	1	1	1
69801	1710	region in Jurkat	[region in Jurkat]	0.0	3	1	1	1
69802	1710	mechanical stress	[mechanical stress]	0.0	2	1	1	1
69803	1710	use the sequence oligonucleotide as probe	[using the sequence oligonucleotides as probes]	0.0	6	1	1	1
69804	1710	constitutive enhancement	[constitutive enhancement]	0.0	2	1	1	1
69805	1710	gene in adult cell	[gene in adult cells]	0.0	4	1	1	1
69806	1710	effect on this signal	[effects on these signals]	0.0	4	1	1	1
69807	1710	factor bind to site C	[Factors binding to site C]	0.0	5	1	1	1
69808	1710	m, clinical serum concentration	[M, clinical serum concentration]	0.0	4	1	1	1
69809	1710	serum ige in subject	[serum IgE in subjects]	0.0	4	1	1	1
69810	1710	interaction of 135(oh)2d3 with receptor	[interaction of 1,25(OH)2D3 with receptor]	0.0	5	1	1	1
69811	1710	only inhibition	[only inhibition]	0.0	2	1	1	1
69812	1710	role for oxidant generation	[role for oxidant generation]	0.0	4	1	1	1
69813	1710	regulators/adapter	[regulators/adapters]	0.0	1	1	1	1
69814	1710	phorbol-13-acetate tpa	[phorbol-13-acetate TPA]	0.0	2	1	1	1
69815	1710	competition curve	[competition curves]	0.0	2	1	1	1
69816	1710	downregulate the activity of IKK	[downregulating the activity of IKK]	0.0	5	1	1	1
69817	1710	ligation i	[ligation I]	0.0	2	1	1	1
69818	1710	red cell gene	[red cell genes]	0.0	3	1	1	1
69819	1710	kill by lymphocyte	[killing by lymphocytes]	0.0	3	1	1	1
69820	1710	exocrine precursor	[exocrine precursor]	0.0	2	1	1	1
69821	1710	activation of this factor	[activation of this factor]	0.0	4	1	1	1
69822	1710	rhythm of gr	[rhythm of GR]	0.0	3	1	1	1
69823	1710	stimulation by CBF alpha 2-451	[stimulation by CBF alpha 2-451]	0.0	5	1	1	1
69824	1710	(hbcl6)	[(hBCL6)]	0.0	1	1	1	1
69825	1710	infiltrate cell	[infiltrating cells]	0.0	2	1	1	1
69826	1710	human peripheral cell pbmc	[human peripheral cells PBMC]	0.0	4	1	1	1
69827	1710	plasma growth	[plasma growth]	0.0	2	1	1	1
69828	1710	modulation by the thyroid hormone	[Modulation by the thyroid hormone]	0.0	5	1	1	1
69829	1710	stat6 by il-4	[STAT6 by IL-4]	0.0	3	2	2	1
69830	1710	molecular partners, include k protein	[molecular partners, including K protein]	0.0	5	1	1	1
69831	1710	association GATA binding site	[association GATA binding sites]	0.0	4	1	1	1
69832	1710	leukemic factor	[leukemic factor]	0.0	2	2	2	1
69833	1710	encode for certain growth factor	[encoding for certain growth factors]	0.0	5	1	1	1
69834	1710	regulation of the transcription factor elf-1	[Regulation of the transcription factor Elf-1]	0.0	6	1	1	1
69835	1710	activation signal to b cell	[activation signals to B cells]	0.0	5	1	1	1
69836	1710	t-lymphotropic virus type htlv-1 model	[T-lymphotropic virus type HTLV-1 model]	0.0	5	1	1	1
69837	1710	Duffy-negative black	[Duffy-negative blacks]	0.0	2	1	1	1
69838	1710	dominant mutant of the IL-1 signal	[dominant mutants of the IL-1 signaling]	0.0	6	1	1	1
69839	1710	mobility (approximately kd)	[mobility (approximately kD)]	0.0	3	1	1	1
69840	1710	cd4-cd8- T lymphocyte precursor	[CD4-CD8- T lymphocyte precursors]	0.0	4	1	1	1
69841	1710	polymerase chain reaction RT-PCR	[polymerase chain reaction RT-PCR]	0.0	4	1	1	1
69842	1710	two nucleoprotein complex	[two nucleoprotein complexes]	0.0	3	1	1	1
69843	1710	suggest a role in the activation	[suggesting a role in the activation]	0.0	6	1	1	1
69844	1710	lead to modulation	[leading to modulation]	0.0	3	1	1	1
69845	1710	nm23-h2hi	[nm23-H2His]	0.0	1	1	1	1
69846	1710	cytotoxic effector function	[cytotoxic effector function]	0.0	3	1	1	1
69847	1710	IRF-1 -dependent pathway	[IRF-1 -dependent pathway]	0.0	3	1	1	1
69848	1710	normal lung fibroblast	[normal lung fibroblasts]	0.0	3	1	1	1
69849	1710	protein kinase activity in b lymphocyte	[protein kinase activities in B lymphocytes]	0.0	6	1	1	1
69850	1710	fas ligand FasL on lymphocyte	[Fas ligand FasL on lymphocytes]	0.0	5	1	1	1
69851	1710	NKL NK cell line	[NKL NK cell line]	0.0	4	1	1	1
69852	1710	14 pr patient	[14 PR patients]	0.0	3	1	1	1
69853	1710	h after stimulation.	[h after stimulation.]	0.0	3	1	1	1
69854	1710	region in the viral promoter	[regions in the viral promoter]	0.0	5	1	1	1
69855	1710	decrease of tcrzeta	[decreases of TCRzeta]	0.0	3	1	1	1
69856	1710	early regulator	[early regulators]	0.0	2	1	1	1
69857	1710	factor independent	[factor independent]	0.0	2	1	1	1
69858	1710	analysis apoptosis	[analysis apoptosis]	0.0	2	1	1	1
69859	1710	cis-acting control	[cis-acting control]	0.0	2	1	1	1
69860	1710	direct transcriptional repressive effect	[direct transcriptional repressive effect]	0.0	4	1	1	1
69861	1710	therapy in the treatment	[therapy in the treatment]	0.0	4	1	1	1
69862	1710	promoter region -620 to +34	[promoter region -620 to +34]	0.0	5	1	1	1
69863	1710	induce expression of nf-kappa b	[inducing expression of NF-kappa B]	0.0	5	1	1	1
69864	1710	activation on the dprl promoter	[activation on the dPRL promoter]	0.0	5	1	1	1
69865	1710	roughly in two categories: induction	[roughly in two categories: induction]	0.0	5	1	1	1
69866	1710	decrease dna-dependent atpase activity	[decrease DNA-dependent ATPase activities]	0.0	4	1	1	1
69867	1710	regulation of BZLF1 transcription	[regulation of BZLF1 transcription]	0.0	4	1	1	1
69868	1710	modulation of factor bind	[modulation of factors binding]	0.0	4	1	1	1
69869	1710	adenovirus type 5 e1a-region	[adenovirus type 5 E1A-region]	0.0	4	1	1	1
69870	1710	2-hydroxy-4-trifluoromethylbenzoic	[2-hydroxy-4-trifluoromethylbenzoic]	0.0	1	1	1	1
69871	1710	(B cells)	[(B cells)]	0.0	2	1	1	1
69872	1710	lack xist expression with phenotypes.	[lacking XIST expression with phenotypes.]	0.0	5	1	1	1
69873	1710	relationship between receptor to glucocorticoid therapy	[Relationship between receptor to glucocorticoid therapy]	0.0	6	1	1	1
69874	1710	49 female patient	[49 female patients]	0.0	3	1	1	1
69875	1710	cardiac transplant medicine	[cardiac transplant medicine]	0.0	3	1	1	1
69876	1710	carbon-20 position	[carbon-20 position]	0.0	2	1	1	1
69877	1710	vitro fibroblast binding	[vitro fibroblast binding]	0.0	3	1	1	1
69878	1710	antibody level	[antibody levels]	0.0	2	1	1	1
69879	1710	x inactivation result	[X inactivation resulting]	0.0	3	1	1	1
69880	1710	short-term effect of glucocorticoid	[short-term effects of glucocorticoids]	0.0	4	1	1	1
69881	1710	antibody to NF-kappa b subunit	[antibodies to NF-kappa B subunits]	0.0	5	1	1	1
69882	1710	two receptor binding site	[two receptor binding sites]	0.0	4	1	1	1
69883	1710	blue tetrazolium	[blue tetrazolium]	0.0	2	1	1	1
69884	1710	keratoconjunctivitis vkc a eosinophilic disease	[keratoconjunctivitis VKC an eosinophilic disease.]	0.0	5	1	1	1
69885	1710	protein, hstat5	[protein, hStat5]	0.0	2	1	1	1
69886	1710	major regulatory factor	[major regulatory factor]	0.0	3	1	1	1
69887	1710	importance during illness.	[importance during illness.]	0.0	3	1	1	1
69888	1710	lack the gene	[lacking the gene]	0.0	3	1	1	1
69889	1710	variety of tissue	[variety of tissues]	0.0	3	1	1	1
69890	1710	integrin cell adhesion to fibronectin	[integrin cell adhesion to fibronectin]	0.0	5	1	1	1
69891	1710	normal vdr-rxr heterodimer binding	[normal VDR-RXR heterodimer binding]	0.0	4	1	1	1
69892	1710	severe anorexia nervosa	[severe anorexia nervosa]	0.0	3	1	1	1
69893	1710	lmp-1 protein level	[LMP-1 protein levels]	0.0	3	1	1	1
69894	1710	blot analysis of nuclear extract	[blot analysis of nuclear extracts]	0.0	5	1	1	1
69895	1710	nf-kappab protein p52	[NF-kappaB proteins p52]	0.0	3	1	1	1
69896	1710	+/- 8 nmol	[+/- 8 nmol]	0.0	3	1	1	1
69897	1710	sixteen patient aged 16-27 years, (range	[Sixteen patients aged 16-27 years, (ranging]	0.0	6	1	1	1
69898	1710	IL-1 gene expression	[IL-1 gene expression]	0.0	3	1	1	1
69899	1710	treatment of acute attack	[treatment of acute attacks]	0.0	4	1	1	1
69900	1710	same protein	[same proteins]	0.0	2	1	1	1
69901	1710	single major tr	[single major TR]	0.0	3	1	1	1
69902	1710	tpa mitogen	[TPA mitogen]	0.0	2	1	1	1
69903	1710	genotypic marker for a region	[genotypic markers for an region]	0.0	5	1	1	1
69904	1710	role as a regulator,	[role as a regulator,]	0.0	4	1	1	1
69905	1710	236 ng/ml)	[236 ng/mL)]	0.0	2	1	1	1
69906	1710	pathogenesis of B-cell lymphoma	[pathogenesis of B-cell lymphoma]	0.0	4	1	1	1
69907	1710	common member of the cascade	[common members of the cascade]	0.0	5	1	1	1
69908	1710	lymphoid nuclear factor in vivo	[lymphoid nuclear factor in vivo]	0.0	5	1	1	1
69909	1710	substrate recognition by loci	[substrate recognition by loci]	0.0	4	1	1	1
69910	1710	fourteen percent	[Fourteen percent]	0.0	2	1	1	1
69911	1710	concentration of insulin	[concentrations of insulin]	0.0	3	1	1	1
69912	1710	own study on culture	[own studies on cultures]	0.0	4	1	1	1
69913	1710	particular, occur	[particular, occurring]	0.0	2	1	1	1
69914	1710	difference in the spacing	[differences in the spacing]	0.0	4	1	1	1
69915	1710	RA -dependent differentiation	[RA -dependent differentiation]	0.0	3	1	1	1
69916	1710	ap-1/tpa responsive element	[AP-1/TPA responsive elements]	0.0	3	1	1	1
69917	1710	mutation of tyrosine	[Mutation of tyrosines]	0.0	3	1	1	1
69918	1710	only tyrosine phosphorylation of Janus kinase	[only tyrosine phosphorylation of Janus kinases]	0.0	6	1	1	1
69919	1710	cooperation between Spi-1 (r129c)	[cooperation between Spi-1 (R129C)]	0.0	4	1	1	1
69920	1710	p16 in lymphocyte	[p16 in lymphocytes]	0.0	3	1	1	1
69921	1710	peripheral human monocyte pbm	[peripheral human monocytes PBM]	0.0	4	1	1	1
69922	1710	activity RAR gamma tgase	[activity RAR gamma TGase]	0.0	4	1	1	1
69923	1710	result (average gr concentration 7131	[results (average GR concentration 7131]	0.0	5	1	1	1
69924	1710	hour time culture for mcp-1	[hours time culture for MCP-1]	0.0	5	1	1	1
69925	1710	whole spectrum of differentiation	[whole spectrum of differentiation]	0.0	4	1	1	1
69926	1710	human T cell proliferation	[human T cell proliferation]	0.0	4	1	1	1
69927	1710	interaction of a matrix attachment region	[interaction of a matrix attachment region]	0.0	6	1	1	1
69928	1710	low 24-hour urinary cortisol excretion	[low 24-hour urinary cortisol excretion]	0.0	5	1	1	1
69929	1710	state level of E-selectin mrna	[state levels of E-selectin mRNA]	0.0	5	1	1	1
69930	1710	B surface molecule CD40	[B surface molecule CD40]	0.0	4	1	1	1
69931	1710	e1 oligonucleotide	[E1 oligonucleotide]	0.0	2	1	1	1
69932	1710	'pre-activation'	['pre-activation']	0.0	1	1	1	1
69933	1710	regulate matrix attachment	[regulating matrix attachment]	0.0	3	1	1	1
69934	1710	panel of lymphocyte	[panel of lymphocytes]	0.0	3	1	1	1
69935	1710	receptor signal	[receptor signal]	0.0	2	1	1	1
69936	1710	NF-IL6 site	[NF-IL6 sites]	0.0	2	1	1	1
69937	1710	loss of cytolytic susceptibility	[Loss of cytolytic susceptibility]	0.0	4	1	1	1
69938	1710	fragment contain regulatory sequence	[fragments containing regulatory sequences]	0.0	4	1	1	1
69939	1710	underlie lymphocyte action	[underlying lymphocyte action]	0.0	3	1	1	1
69940	1710	elastatinal	[elastatinal]	0.0	1	1	1	1
69941	1710	regulation role of multiple regulatory sites.	[regulation role of multiple regulatory sites.]	0.0	6	1	1	1
69942	1710	mechanism for immune suppression	[mechanism for immune suppression]	0.0	4	1	1	1
69943	1710	pokeweed mitogen pwm	[pokeweed mitogen PWM]	0.0	3	1	1	1
69944	1710	latent membrane protein-1 lmp-1	[latent membrane protein-1 LMP-1]	0.0	4	1	1	1
69945	1710	mobility gel	[mobility gel]	0.0	2	1	1	1
69946	1710	possibly in the survival	[possibly in the survival]	0.0	4	1	1	1
69947	1710	+/- 3.7%	[+/- 3.7%]	0.0	2	1	1	1
69948	1710	very low sp1 activity	[very low SP1 activity]	0.0	4	1	1	1
69949	1710	positive chronic leukemia	[positive chronic leukemia]	0.0	3	1	1	1
69950	1710	Ii chain loading	[Ii chain loading]	0.0	3	1	1	1
69951	1710	freely exchangeable ca2+ feca2+	[freely exchangeable Ca2+ FECa2+]	0.0	4	1	1	1
69952	1710	hormone-mediated survival	[hormone-mediated survival]	0.0	2	1	1	1
69953	1710	patient with primary cirrhosis	[patient with primary cirrhosis]	0.0	4	1	1	1
69954	1710	activation by lipopolysaccharide in leukocyte	[Activation by lipopolysaccharide in leukocytes]	0.0	5	1	1	1
69955	1710	cell death in T lymphocyte	[cell death in T lymphocytes]	0.0	5	1	1	1
69956	1710	precise definition of the role	[precise definition of the role]	0.0	5	1	1	1
69957	1710	exon of the c-myc gene	[exon of the c-myc gene]	0.0	5	1	1	1
69958	1710	box antiserum	[box antiserum]	0.0	2	1	1	1
69959	1710	probe react	[probe reacting]	0.0	2	1	1	1
69960	1710	cd4+ t-cell clonal line	[CD4+ T-cell clonal lines]	0.0	4	1	1	1
69961	1710	glucocorticoid in leukemia of childhood.	[glucocorticoids in leukemia of childhood.]	0.0	5	1	1	1
69962	1710	many c-11-substituted alpha,25-(OH)2D3 analog	[many C-11-substituted alpha,25-(OH)2D3 analogs]	0.0	4	1	1	1
69963	1710	NFkappaB site within the HCMV version,	[NFkappaB sites within the HCMV version,]	0.0	6	1	1	1
69964	1710	activator of monocyte	[activator of monocytes]	0.0	3	1	1	1
69965	1710	factor the other ccgccc	[factor the other CCGCCC]	0.0	4	1	1	1
69966	1710	T cell thymic progenitor	[T cell thymic progenitors]	0.0	4	1	1	1
69967	1710	parental Jak1 -express counterpart	[parental Jak1 -expressing counterpart]	0.0	4	1	1	1
69968	1710	resistance to tumor necrosis factor	[Resistance to tumor necrosis factor]	0.0	5	1	1	1
69969	1710	effect on RA differentiation	[effects on RA differentiation]	0.0	4	1	1	1
69970	1710	CK-1/CK-2	[CK-1/CK-2]	0.0	1	1	1	1
69971	1710	stimulation with (il-6) a immunoregulatory cytokine	[stimulation with (IL-6) an immunoregulatory cytokine]	0.0	6	1	1	1
69972	1710	encode ciita	[encoding CIITA]	0.0	2	1	1	1
69973	1710	healthy aged subject (62-97 yr)	[healthy aged subjects (62-97 yr)]	0.0	5	1	1	1
69974	1710	contain as little as ng	[containing as little as ng]	0.0	5	1	1	1
69975	1710	full-length SCL protein	[full-length SCL protein]	0.0	3	1	1	1
69976	1710	role of 135(oh)2d3 receptor	[role of 1,25(OH)2D3 receptors]	0.0	4	1	1	1
69977	1710	one member capable	[one members capable]	0.0	3	1	1	1
69978	1710	incubation of T cell	[incubation of T cells]	0.0	4	1	1	1
69979	1710	Interleukin signal	[Interleukin signaling]	0.0	2	1	1	1
69980	1710	relatively early event in maturation	[relatively early events in maturation]	0.0	5	1	1	1
69981	1710	20 patient undergo ptca	[20 patients undergoing PTCA]	0.0	4	1	1	1
69982	1710	promoter between basis	[promoter between bases]	0.0	3	1	1	1
69983	1710	high levels,	[high levels,]	0.0	2	1	1	1
69984	1710	gel shift assay study	[Gel shift assay studies]	0.0	4	1	1	1
69985	1710	factor bind C not 4681	[Factors binding C nt 4681]	0.0	5	1	1	1
69986	1710	fuse each to the domain	[fusing each to the domain]	0.0	5	1	1	1
69987	1710	activation of the leukocyte integrin gene	[activation of the leukocyte integrin genes]	0.0	6	1	1	1
69988	1710	nuclei of cell types.	[nuclei of cell types.]	0.0	4	1	1	1
69989	1710	activation of JAK /stat pathway	[activation of JAK /STAT pathway]	0.0	5	1	1	1
69990	1710	i.e., granulocyte-colony-stimulating factor	[i.e., granulocyte-colony-stimulating factor]	0.0	3	1	1	1
69991	1710	trigger of the interleukin-6 gene	[Triggering of the interleukin-6 gene]	0.0	5	1	1	1
69992	1710	igh promoter	[IgH promoter]	0.0	2	1	1	1
69993	1710	22-bp duplication	[22-bp duplication]	0.0	2	1	1	1
69994	1710	interleukin cd28-responsive complex	[interleukin CD28-responsive complex]	0.0	3	1	1	1
69995	1710	six-base-pair consensus sequence	[six-base-pair consensus sequence]	0.0	3	1	1	1
69996	1710	average angle	[average angle]	0.0	2	1	1	1
69997	1710	factor for the constitutive expression	[factor for the constitutive expression]	0.0	5	1	1	1
69998	1710	chemotherapeutic potential in hiv-1 patient	[chemotherapeutic potential in HIV-1 patients]	0.0	5	1	1	1
69999	1710	concentration of peptide ligand	[concentrations of peptide ligand]	0.0	4	1	1	1
70000	1710	retinoblastoma prb	[retinoblastoma pRb]	0.0	2	1	1	1
70001	1710	receptor characteristic in monocyte	[receptor characteristics in monocytes]	0.0	4	1	1	1
70002	1710	pih group	[PIH group]	0.0	2	1	1	1
70003	1710	effect of pha	[effect of PHA]	0.0	3	1	1	1
70004	1710	clarify the chronological sequence of event	[clarifying the chronological sequence of events]	0.0	6	1	1	1
70005	1710	use the same dose	[using the same dose]	0.0	4	1	1	1
70006	1710	dose of flutamide	[doses of flutamide]	0.0	3	1	1	1
70007	1710	human breast carcinoma cell line	[human breast carcinoma cell line]	0.0	5	1	1	1
70008	1710	myeloid cell of mouse	[myeloid cells of mice]	0.0	4	1	1	1
70009	1710	strong ca2+ response	[strong Ca2+ responses]	0.0	3	1	1	1
70010	1710	evidence for the modulation by mechanism	[evidence for the modulation by mechanisms]	0.0	6	1	1	1
70011	1710	ST remission	[ST remission]	0.0	2	1	1	1
70012	1710	candidate compound for herpes simplex vaccine	[candidate compounds for herpes simplex vaccines]	0.0	6	1	1	1
70013	1710	megakaryocytic lineage cell p45 mrna	[megakaryocytic lineage cells p45 mRNA]	0.0	5	1	1	1
70014	1710	'master regulator	['master regulators]	0.0	2	1	1	1
70015	1710	change in long-distance runner	[changes in long-distance runner]	0.0	4	1	1	1
70016	1710	atypical abnormal eosinophil	[atypical abnormal eosinophils]	0.0	3	1	1	1
70017	1710	first- relative;	[first- relative;]	0.0	2	1	1	1
70018	1710	however, a much good transactivator	[However, a much better transactivator]	0.0	5	1	1	1
70019	1710	protein expression gag	[protein expression Gag]	0.0	3	1	1	1
70020	1710	evidence identical proteins, differ	[evidence identical proteins, differing]	0.0	4	1	1	1
70021	1710	cell lack endogenous receptor.	[cells lacking endogenous receptor.]	0.0	4	1	1	1
70022	1710	involvement of dendritic cell	[involvement of dendritic cells]	0.0	4	1	1	1
70023	1710	NK cytolytic activity	[NK cytolytic activities]	0.0	3	1	1	1
70024	1710	contain as little as bp	[containing as little as bp]	0.0	5	1	1	1
70025	1710	3-hydroxy-3-methylglutaryl	[3-hydroxy-3-methylglutaryl]	0.0	1	1	1	1
70026	1710	fluorescent probe react	[fluorescent probe reacting]	0.0	3	1	1	1
70027	1710	MHC class ligand	[MHC class ligands]	0.0	3	1	1	1
70028	1710	trans-active locus	[trans-active locus]	0.0	2	1	1	1
70029	1710	3 goiter	[3 goiter]	0.0	2	1	1	1
70030	1710	depression of type I receptor	[depression of Type I receptors]	0.0	5	1	1	1
70031	1710	deactivation of phagocyte	[Deactivation of phagocytes]	0.0	3	1	1	1
70032	1710	concentration of 10(-6) m	[concentrations of 10(-6) M]	0.0	4	1	1	1
70033	1710	calcium dephosphorylation of nfat	[calcium dephosphorylation of NFAT]	0.0	4	1	1	1
70034	1710	papillomavirus e6	[papillomavirus E6]	0.0	2	1	1	1
70035	1710	dictate pattern	[dictating patterns]	0.0	2	1	1	1
70036	1710	nf-kappa b -binding element	[NF-kappa B -binding elements]	0.0	4	1	1	1
70037	1710	reflect the binding	[reflecting the binding]	0.0	3	1	1	1
70038	1710	il-10 gene	[IL-10 genes]	0.0	2	1	1	1
70039	1710	cofactor for nos activity	[cofactor for NOS activity]	0.0	4	1	1	1
70040	1710	measure the phosphatidylinositol-3,4,5-trisphosphate concentration	[measuring the phosphatidylinositol-3,4,5-trisphosphate concentration]	0.0	4	1	1	1
70041	1710	herpes simplex virus type hsv-1	[herpes simplex virus type HSV-1]	0.0	5	1	1	1
70042	1710	productive form	[productive form]	0.0	2	1	1	1
70043	1710	anhydrase caii	[anhydrase CAII]	0.0	2	1	1	1
70044	1710	Zfh-1	[Zfh-1]	0.0	1	1	1	1
70045	1710	preincubation in u-937	[Preincubation in U-937]	0.0	3	1	1	1
70046	1710	induction jurkat	[Induction Jurkat]	0.0	2	1	1	1
70047	1710	p50 nf-kappab heterodimer binding	[p50 NF-kappaB heterodimer binding]	0.0	4	1	1	1
70048	1710	establish pbmc culture in small colony	[establishing PBMC cultures in small colonies]	0.0	6	1	1	1
70049	1710	human dendritic cell (dc)	[human dendritic cells (DC)]	0.0	4	1	1	1
70050	1710	monoclonal model of center maturation	[monoclonal model of center maturation]	0.0	5	1	1	1
70051	1710	regulatory element nre	[regulatory element NRE]	0.0	3	1	1	1
70052	1710	autoregulatory inhibitor	[autoregulatory inhibitor]	0.0	2	1	1	1
70053	1710	17 case of ebv-positive bl	[17 cases of EBV-positive BL]	0.0	5	1	1	1
70054	1710	blood human monocyte	[blood human monocytes]	0.0	3	1	1	1
70055	1710	follow cell stimulation.	[following cell stimulation.]	0.0	3	1	1	1
70056	1710	low fat level	[low fat level]	0.0	3	1	1	1
70057	1710	CONCLUSIONS: level	[CONCLUSIONS: Levels]	0.0	2	1	1	1
70058	1710	inhibitor of serine/threonine phosphatase	[inhibitors of serine/threonine phosphatases]	0.0	4	1	1	1
70059	1710	iib (gpiib)	[IIb (GPIIb)]	0.0	2	1	1	1
70060	1710	nf-kappab oligoprobe	[NF-kappaB oligoprobe]	0.0	2	1	1	1
70061	1710	action of nm23 protein on induction	[action of nm23 proteins on induction]	0.0	6	1	1	1
70062	1710	factor (NF)-AT NF-AT AP-1/Octamer	[factor (NF)-AT NF-AT AP-1/Octamer]	0.0	4	1	1	1
70063	1710	generation of cell-mediated immunity	[generation of cell-mediated immunity]	0.0	4	1	1	1
70064	1710	grade, DNA	[grade, DNA]	0.0	2	2	2	1
70065	1710	evidence flexible	[evidence flexible]	0.0	2	1	1	1
70066	1710	mineralocorticoid receptor mr	[mineralocorticoid receptor MR]	0.0	3	1	1	1
70067	1710	urinary cortisol excretion in subject	[urinary cortisol excretion in subjects]	0.0	5	1	1	1
70068	1710	erythrocyte protein to GATA site	[erythrocyte proteins to GATA sites]	0.0	5	1	1	1
70069	1710	replication in vitro	[replication in vitro]	0.0	3	1	1	1
70070	1710	regulation during cell differentiation	[regulation during cell differentiation]	0.0	4	1	1	1
70071	1710	cell at day	[cells at day]	0.0	3	1	1	1
70072	1710	further support a receptor-mediated mechanism	[further supporting a receptor-mediated mechanism]	0.0	5	1	1	1
70073	1710	zip binding site	[ZIP binding sites]	0.0	3	1	1	1
70074	1710	regulator of a set	[regulator of a set]	0.0	4	1	1	1
70075	1710	tcr-beta/tcr-delta knockout mouse	[TCR-beta/TCR-delta knockout mice]	0.0	3	1	1	1
70076	1710	pathophysiology of chronic leukaemia	[pathophysiology of chronic leukaemia]	0.0	4	1	1	1
70077	1710	sensitive target fibroblast	[sensitive target fibroblasts]	0.0	3	1	1	1
70078	1710	lysis of hpv cell	[lysis of HPV cells]	0.0	4	1	1	1
70079	1710	lymphoid aggregate formation	[lymphoid aggregate formation]	0.0	3	1	1	1
70080	1710	hybrid reporter construct	[hybrid reporter constructs]	0.0	3	1	1	1
70081	1710	plasminogen activator inhibitor type	[plasminogen activator inhibitor type]	0.0	4	1	1	1
70082	1710	expression for receptor	[expression for receptor]	0.0	3	1	1	1
70083	1710	rapid transcriptional activation independent	[rapid transcriptional activation independent]	0.0	4	1	1	1
70084	1710	two potent inhibitor	[two potent inhibitors]	0.0	3	1	1	1
70085	1710	MHC molecule	[MHC molecules]	0.0	2	2	2	1
70086	1710	4 kb	[4 kb]	0.0	2	1	1	1
70087	1710	acquisition of marker	[acquisition of markers]	0.0	3	1	1	1
70088	1710	inhibition by the drug acyclovir	[inhibition by the drug acyclovir]	0.0	5	1	1	1
70089	1710	expression of tax1	[expression of tax1]	0.0	3	1	1	1
70090	1710	corresponding section	[corresponding sections]	0.0	2	1	1	1
70091	1710	cytoplasmic domain of factor	[cytoplasmic domain of factor]	0.0	4	1	1	1
70092	1710	4 mM	[4 mM]	0.0	2	1	1	1
70093	1710	involve a modulation	[involving a modulation]	0.0	3	1	1	1
70094	1710	total of severe, nonsmok patient	[total of severe, nonsmoking patients]	0.0	5	1	1	1
70095	1710	factor with the exception	[factors with the exception]	0.0	4	1	1	1
70096	1710	rapamycin -resistant	[rapamycin -resistant]	0.0	2	1	1	1
70097	1710	result in promoter activation	[resulting in promoter activation]	0.0	4	1	1	1
70098	1710	analogue effect	[analogue effects]	0.0	2	1	1	1
70099	1710	normal adult peripheral blood lymphocyte sample	[normal adult peripheral blood lymphocyte samples]	0.0	6	1	1	1
70100	1710	clarify the sequence of biochemical event	[clarifying the sequence of biochemical events]	0.0	6	1	1	1
70101	1710	currently the subject of study.	[currently the subject of study.]	0.0	5	1	1	1
70102	1710	RB cell	[RB cells]	0.0	2	1	1	1
70103	1710	great affinity consistent with effect	[greater affinity consistent with effects]	0.0	5	1	1	1
70104	1710	gy result	[Gy results]	0.0	2	1	1	1
70105	1710	cytokine redundancy	[cytokine redundancy]	0.0	2	1	1	1
70106	1710	msr ligand,	[MSR ligand,]	0.0	2	1	1	1
70107	1710	potent activity at concentration low	[potent activity at concentrations lower]	0.0	5	1	1	1
70108	1710	infection genetic analysis LTR	[Infection genetic analyses LTR]	0.0	4	1	1	1
70109	1710	Novel membrane receptor a kda protein	[Novel membrane receptors a kDa protein]	0.0	6	1	1	1
70110	1710	cellular gene mechanism	[cellular gene mechanisms]	0.0	3	1	1	1
70111	1710	coexpression in cell line	[Coexpression in cell lines]	0.0	4	1	1	1
70112	1710	thyroid hormone alone	[Thyroid hormone alone]	0.0	3	1	1	1
70113	1710	chimeric receptor contain the domain	[chimeric receptor containing the domain]	0.0	5	1	1	1
70114	1710	Polyaromatic hydrocarbons pah	[Polyaromatic hydrocarbons PAHs]	0.0	3	1	1	1
70115	1710	binding to cell line bear dqa1*0201	[Binding to cell lines bearing DQA1*0201]	0.0	6	1	1	1
70116	1710	mechanism of human il-5 synthesis	[mechanisms of human IL-5 synthesis]	0.0	5	1	1	1
70117	1710	high level of nuclear of p50	[high levels of nuclear of p50]	0.0	6	1	1	1
70118	1710	novel quinone derivative	[novel quinone derivative]	0.0	3	1	1	1
70119	1710	degradation of the cytosolic inhibitor	[degradation of the cytosolic inhibitor]	0.0	5	1	1	1
70120	1710	molecule S9a	[molecule S9a]	0.0	2	1	1	1
70121	1710	create a novel, carboxy terminus	[creating a novel, carboxy terminus]	0.0	5	1	1	1
70122	1710	nuclear translocation of member	[nuclear translocation of members]	0.0	4	1	1	1
70123	1710	pan/e2a	[Pan/E2A]	0.0	1	1	1	1
70124	1710	great ap-1 -binding activity of protein	[greater AP-1 -binding activity of proteins]	0.0	6	1	1	1
70125	1710	consist of homodimer	[consisting of homodimers]	0.0	3	1	1	1
70126	1710	gamma-gene 5'-untranslated region	[gamma-gene 5'-untranslated region]	0.0	3	1	1	1
70127	1710	Jun oncogene family member	[Jun oncogene family members]	0.0	4	1	1	1
70128	1710	expression stat5 rrna	[expression STAT5 mRNAs]	0.0	3	1	1	1
70129	1710	change in affinity	[change in affinity]	0.0	3	1	1	1
70130	1710	pyrimidine-rich region upstream	[pyrimidine-rich region upstream]	0.0	3	1	1	1
70131	1710	key role of PML	[key role of PML]	0.0	4	1	1	1
70132	1710	events, antibody	[events, antibodies]	0.0	2	1	1	1
70133	1710	HLA-DR cd4(+) t-cell response	[HLA-DR CD4(+) T-cell response]	0.0	4	1	1	1
70134	1710	immature single positive cell	[immature single positive cells]	0.0	4	1	1	1
70135	1710	Ciprofibrate a peroxisome proliferator	[Ciprofibrate an peroxisome proliferator]	0.0	4	1	1	1
70136	1710	contain as a enhancer copy	[containing as an enhancer copies]	0.0	5	1	1	1
70137	1710	patient with biliary cirrhosis	[patient with biliary cirrhosis]	0.0	4	1	1	1
70138	1710	Biologic effect	[Biologic effects]	0.0	2	1	1	1
70139	1710	real-time study	[real-time study]	0.0	2	1	1	1
70140	1710	variability.	[variability.]	0.0	1	1	1	1
70141	1710	late induction	[later induction]	0.0	2	1	1	1
70142	1710	pu-sf	[PU-SF]	0.0	1	1	1	1
70143	1710	insert sequence (start	[inserting sequences (starting]	0.0	3	1	1	1
70144	1710	killing effect	[killing effect]	0.0	2	1	1	1
70145	1710	nuclear translocation of kappab-binding protein	[nuclear translocation of kappaB-binding proteins]	0.0	5	1	1	1
70146	1710	encompass a positive element NF-AT-1	[encompassing an positive element NF-AT-1]	0.0	5	1	1	1
70147	1710	arm of the hmg box	[arm of the HMG box]	0.0	5	1	1	1
70148	1710	octamerlike motif	[octamerlike motifs]	0.0	2	1	1	1
70149	1710	protein crossreactive	[proteins crossreactive]	0.0	2	1	1	1
70150	1710	16.5 13.51 nmol/L)	[16.5 13.51 nmol/L)]	0.0	3	1	1	1
70151	1710	specifically the failure	[specifically the failure]	0.0	3	1	1	1
70152	1710	interleukin il-10 receptor	[interleukin IL-10 receptor]	0.0	3	1	1	1
70153	1710	different transduction pathway	[different transduction pathways]	0.0	3	1	1	1
70154	1710	gamma-gene region UTR	[gamma-gene region UTR]	0.0	3	1	1	1
70155	1710	step in the shaping	[step in the shaping]	0.0	4	1	1	1
70156	1710	activation reporter	[activation reporters]	0.0	2	1	1	1
70157	1710	virus enhancer	[virus enhancer]	0.0	2	1	1	1
70158	1710	n: 2.7+/-2.0)	[N: 2.7+/-2.0)]	0.0	2	1	1	1
70159	1710	class dimer	[class dimers]	0.0	2	1	1	1
70160	1710	latent membrane protein 1 lmp-1	[latent membrane protein 1 LMP-1]	0.0	5	1	1	1
70161	1710	hydrophobic domain with eight transmembrane segment	[hydrophobic domain with eight transmembrane segments]	0.0	6	1	1	1
70162	1710	expression in sle of polyomavirus t-antigen	[expression in SLE of polyomavirus T-antigen]	0.0	6	1	1	1
70163	1710	level for protein-1 another member	[levels for protein-1 another member]	0.0	5	1	1	1
70164	1710	repeat of 21 bp	[repeats of 21 bp]	0.0	4	1	1	1
70165	1710	site-specific property for E2A- HLF	[site-specific properties for E2A- HLF]	0.0	5	1	1	1
70166	1710	cell (apc) morphology	[cell (APC) morphology]	0.0	3	1	1	1
70167	1710	overexpression of form of IKK alpha	[Overexpression of forms of IKK alpha]	0.0	6	1	1	1
70168	1710	suggest some misfunction	[suggesting some misfunction]	0.0	3	1	1	1
70169	1710	p55/p75	[p55/p75]	0.0	1	1	1	1
70170	1710	cell stage of differentiation,	[cells stage of differentiation,]	0.0	4	1	1	1
70171	1710	replication in myelo- cell	[replication in myelo- cells]	0.0	4	1	1	1
70172	1710	symptoms.	[symptoms.]	0.0	1	1	1	1
70173	1710	suggest a regulatory role	[suggesting a regulatory role]	0.0	4	1	1	1
70174	1710	Nuclear 3,5,3'-triiodothyronine receptor circulate human lymphocyte	[Nuclear 3,5,3'-triiodothyronine receptors circulating human lymphocytes]	0.0	6	1	1	1
70175	1710	human T cell line IARC	[human T cell line IARC]	0.0	5	1	1	1
70176	1710	bind protein LR1	[binding protein LR1]	0.0	3	1	1	1
70177	1710	express (mhc) class ii gene	[expressing (MHC) class II genes]	0.0	5	1	1	1
70178	1710	expression on enhancerless plasmid	[expression on enhancerless plasmids]	0.0	4	1	1	1
70179	1710	6- stimulation	[6- stimulation]	0.0	2	1	1	1
70180	1710	homology with p13mtcp1	[homology with p13MTCP1]	0.0	3	1	1	1
70181	1710	Ca(2+) factor NF-ATp	[Ca(2+) factor NF-ATp]	0.0	3	1	1	1
70182	1710	ig sIg	[Ig sIg]	0.0	2	1	1	1
70183	1710	slp-76 interleukin (il)-2 promoter	[SLP-76 interleukin (IL)-2 promoter]	0.0	4	1	1	1
70184	1710	significantly high (p<.001) in patient	[significantly higher (P<.001) in patients]	0.0	5	1	1	1
70185	1710	pro-B-cell leukemia	[pro-B-cell leukemia]	0.0	2	1	1	1
70186	1710	effect on c-jun kinase	[effects on c-Jun kinase]	0.0	4	1	1	1
70187	1710	two distinct, novel inhibitor	[two distinct, novel inhibitors]	0.0	4	1	1	1
70188	1710	level of this marker	[levels of these markers]	0.0	4	1	1	1
70189	1710	1,25-dihydroxycholecalciferol calcitriol	[1,25-dihydroxycholecalciferol calcitriol]	0.0	2	1	1	1
70190	1710	140-kDa surface antigen	[140-kDa surface antigen]	0.0	3	1	1	1
70191	1710	evidence for regulation specific	[evidence for regulation specific]	0.0	4	1	1	1
70192	1710	ATL patient ng/ml)	[ATL patients ng/mL)]	0.0	3	1	1	1
70193	1710	negative allele Raf	[negative allele Raf]	0.0	3	1	1	1
70194	1710	Tcf-1 transcription	[Tcf-1 transcription]	0.0	2	1	1	1
70195	1710	gene fra-1	[gene fra-1]	0.0	2	1	1	1
70196	1710	hyperplastic center	[hyperplastic centers]	0.0	2	1	1	1
70197	1710	human intestinal cell response	[Human intestinal cell responses]	0.0	4	1	1	1
70198	1710	release by the addition	[release by the addition]	0.0	4	1	1	1
70199	1710	detection of estrogen receptor	[detection of estrogen receptors]	0.0	4	1	1	1
70200	1710	IEF-1 a pancreatic beta-cell complex	[IEF-1 a pancreatic beta-cell complex]	0.0	5	1	1	1
70201	1710	observation in man	[observations in men]	0.0	3	1	1	1
70202	1710	interferon ifn-alpha	[interferons IFN-alpha]	0.0	2	1	1	1
70203	1710	normal b-cell	[normal B-cells]	0.0	2	1	1	1
70204	1710	angle of about 90 degree	[angle of about 90 degrees]	0.0	5	1	1	1
70205	1710	(predominant	[(predominant]	0.0	1	1	1	1
70206	1710	mineralocorticoid effector	[Mineralocorticoid effector]	0.0	2	1	1	1
70207	1710	enhancer element in b cell	[enhancer elements in B cells]	0.0	5	1	1	1
70208	1710	promoter ap-1 -binding site	[promoter AP-1 -binding site]	0.0	4	1	1	1
70209	1710	thalassemia patient with high HbF production	[thalassemia patient with high HbF production]	0.0	6	1	1	1
70210	1710	drug action	[drug action]	0.0	2	1	1	1
70211	1710	molecular cloning of a cDNA	[Molecular cloning of a cDNA]	0.0	5	1	1	1
70212	1710	contain bp of 5' -flanking sequence	[containing bp of 5' -flanking sequence]	0.0	6	1	1	1
70213	1710	activity of heparin	[activity of heparin]	0.0	3	1	1	1
70214	1710	v-erb a function	[v-erb A function]	0.0	3	2	2	1
70215	1710	of binding to rna	[of binding to RNA]	0.0	4	1	1	1
70216	1710	germinal center of organ	[germinal center of organs]	0.0	4	1	1	1
70217	1710	responsiveness less than 0.01).	[responsiveness less than 0.01).]	0.0	4	1	1	1
70218	1710	optimal il-4 -signal	[optimal IL-4 -signaling]	0.0	3	1	1	1
70219	1710	il-6-responsive colony-forming unit	[IL-6-responsive colony-forming units]	0.0	3	1	1	1
70220	1710	tyrosine residue Tyr427	[tyrosine residues Tyr427]	0.0	3	1	1	1
70221	1710	new class	[new class]	0.0	2	1	1	1
70222	1710	cord lymphocyte maximum c-fo expression	[cord lymphocyte maximum c-fos expression]	0.0	5	1	1	1
70223	1710	76 kilodaltons),	[76 kilodaltons),]	0.0	2	1	1	1
70224	1710	most transcript deletion	[most transcript deletions]	0.0	3	1	1	1
70225	1710	domain of Oct-2	[domain of Oct-2]	0.0	3	1	1	1
70226	1710	copy of brca1	[copy of BRCA1]	0.0	3	1	1	1
70227	1710	such as e-selectin	[such as E-selectin]	0.0	3	1	1	1
70228	1710	nuclear factor hnf3 beta	[nuclear factor HNF3 beta]	0.0	4	1	1	1
70229	1710	antigen receptor signal transduction	[antigen receptor signal transduction]	0.0	4	1	1	1
70230	1710	Translational initiation mrna	[Translational initiation mRNA]	0.0	3	1	1	1
70231	1710	ebv latent gene	[EBV latent genes]	0.0	3	1	1	1
70232	1710	Ovarian T lymphocyte	[Ovarian T lymphocytes]	0.0	3	1	1	1
70233	1710	role in shear-induced vcam-1 expression	[role in shear-induced VCAM-1 expression]	0.0	5	1	1	1
70234	1710	12-O-tetradecanoylphorbol-13-acetate differentiation,	[12-O-tetradecanoylphorbol-13-acetate differentiation,]	0.0	2	1	1	1
70235	1710	complementarity for residue 57	[complementarity for residue 57]	0.0	4	1	1	1
70236	1710	such as distress syndrome	[such as distress syndrome]	0.0	4	1	1	1
70237	1710	subject down-regulated Bmax after DEX	[subjects down-regulated Bmax after DEX]	0.0	5	1	1	1
70238	1710	regulate enhancement	[regulating enhancement]	0.0	2	1	1	1
70239	1710	herpesvirus saimiry a virus	[Herpesvirus saimiri an virus]	0.0	4	1	1	1
70240	1710	transactivation in Jurkat T cell	[Transactivation in Jurkat T cells]	0.0	5	1	1	1
70241	1710	events: the CsA -sensitive translocation	[events: the CsA -sensitive translocation]	0.0	5	1	1	1
70242	1710	murine pro-B	[murine pro-B]	0.0	2	1	1	1
70243	1710	binding characteristic of the receptor	[Binding characteristics of the receptor]	0.0	5	1	1	1
70244	1710	kd value for cortisol	[Kd values for cortisol]	0.0	4	1	1	1
70245	1710	functional role for otf-2	[functional role for OTF-2]	0.0	4	1	1	1
70246	1710	underlying degree	[underlying degree]	0.0	2	1	1	1
70247	1710	secretion of amount of IFN.	[secretion of amounts of IFN.]	0.0	5	1	1	1
70248	1710	develop human T lymphocyte erratum	[developing human T lymphocytes erratum]	0.0	5	1	1	1
70249	1710	nonphlogistic phagocytosis of leukocyte	[nonphlogistic phagocytosis of leukocytes]	0.0	4	1	1	1
70250	1710	lymphoid precursor cell	[lymphoid precursor cells]	0.0	3	1	1	1
70251	1710	spacings.	[spacings.]	0.0	1	1	1	1
70252	1710	regulation in monocytic cell line	[regulation in monocytic cell lines]	0.0	5	1	1	1
70253	1710	Trx-expressing plasmid	[Trx-expressing plasmid]	0.0	2	1	1	1
70254	1710	oxygen intermediate as messenger	[oxygen intermediates as messengers]	0.0	4	1	1	1
70255	1710	signal requirement by blot	[Signal requirements by blots]	0.0	4	1	1	1
70256	1710	seven healthy woman	[seven healthy women]	0.0	3	1	1	1
70257	1710	expression of lymphoid marker	[expression of lymphoid markers]	0.0	4	1	1	1
70258	1710	1 years.	[1 years.]	0.0	2	1	1	1
70259	1710	only relative binding affinity	[only relative binding affinities]	0.0	4	1	1	1
70260	1710	osteoclast-like multinucleated giant cell	[osteoclast-like multinucleated giant cells]	0.0	4	1	1	1
70261	1710	vivo role	[vivo role]	0.0	2	2	2	1
70262	1710	allow testing of the effect	[allowing testing of the effects]	0.0	5	1	1	1
70263	1710	uninduced extract, indicate regulation	[uninduced extract, indicating regulation]	0.0	4	1	1	1
70264	1710	intracellular traf2	[intracellular TRAF2]	0.0	2	1	1	1
70265	1710	apoptosis signal pathway with differential sensitivity	[apoptosis signaling pathways with differential sensitivity]	0.0	6	1	1	1
70266	1710	antitumour DNA topoisomerase	[antitumour DNA topoisomerase]	0.0	3	1	1	1
70267	1710	influence on the transcriptional activity	[influence on the transcriptional activity]	0.0	5	1	1	1
70268	1710	expression of this r-pk minimal promoter	[expression of this R-PK minimal promoter]	0.0	6	1	1	1
70269	1710	binding of Sp1 in unactivated extract	[binding of Sp1 in unactivated extracts]	0.0	6	1	1	1
70270	1710	retinoid-resistant cell line	[retinoid-resistant cell line]	0.0	3	1	1	1
70271	1710	tcr activation of factor	[TCR activation of factor]	0.0	4	1	1	1
70272	1710	47.10 cell (3-5%)	[47.10 cells (3-5%)]	0.0	3	1	1	1
70273	1710	nf-kappa b dissociation	[NF-kappa B dissociation]	0.0	3	1	1	1
70274	1710	breaks.	[breaks.]	0.0	1	1	1	1
70275	1710	high-proliferative colony-forming cell hppecfcs	[high-proliferative colony-forming cells HPP-CFCs]	0.0	4	1	1	1
70276	1710	mononuclear cell with interleukin-4 il-4	[mononuclear cells with interleukin-4 IL-4]	0.0	5	1	1	1
70277	1710	camp-responsive element CRE	[cAMP-responsive elements CRE]	0.0	3	1	1	1
70278	1710	CD14 cell line	[CD14 cell line]	0.0	3	1	1	1
70279	1710	line of cell THP-1	[line of cells THP-1]	0.0	4	1	1	1
70280	1710	constitutively active promoter	[constitutively active promoter]	0.0	3	1	1	1
70281	1710	amount of active creb protein	[amounts of active CREB protein]	0.0	5	1	1	1
70282	1710	anti-class i monoclonal antibody	[anti-class I monoclonal antibody]	0.0	4	1	1	1
70283	1710	conversion of group	[conversion of group]	0.0	3	1	1	1
70284	1710	embryonic kidney 293 cell	[embryonic kidney 293 cells]	0.0	4	1	1	1
70285	1710	series (a) of -resistant variant	[series (A) of -resistant variants]	0.0	5	1	1	1
70286	1710	Fusion of the portion	[Fusion of the portion]	0.0	4	1	1	1
70287	1710	hang drop-mediated transfer	[Hanging drop-mediated transfer]	0.0	3	1	1	1
70288	1710	nonsmok asthmatic patient	[nonsmoking asthmatic patients]	0.0	3	1	1	1
70289	1710	occur at minute 1) after reoxygenation	[occurring at minutes 1) after reoxygenation]	0.0	6	1	1	1
70290	1710	61 pmol/L;	[61 pmol/L;]	0.0	2	1	1	1
70291	1710	stimulator of monocyte cause secretion	[stimulator of monocytes causing secretion]	0.0	5	1	1	1
70292	1710	human chromosome 11 at band	[human chromosome 11 at band]	0.0	5	1	1	1
70293	1710	stringency of latency	[stringency of latency]	0.0	3	1	1	1
70294	1710	invertebrate transcription factor	[invertebrate transcription factors]	0.0	3	1	1	1
70295	1710	rna production in U937 cell	[RNA production in U937 cells]	0.0	5	1	1	1
70296	1710	ikkbeta cellular	[IKKbeta cellular]	0.0	2	1	1	1
70297	1710	na(+)-h+	[Na(+)-H+]	0.0	1	1	1	1
70298	1710	cytokine-stimulated human vein cell HUVEC	[cytokine-stimulated human vein cells HUVEC]	0.0	5	1	1	1
70299	1710	vaccine for this alpha-herpesviruse	[vaccine for these alpha-herpesviruses]	0.0	4	1	1	1
70300	1710	Avian erythroblast	[Avian erythroblasts]	0.0	2	1	1	1
70301	1710	DPA gene	[DPA gene]	0.0	2	1	1	1
70302	1710	offspring	[offspring]	0.0	1	2	2	1
70303	1710	follicular cell lymphoma	[follicular cell lymphomas]	0.0	3	1	1	1
70304	1710	fy(b-) phenotype	[Fy(b-) phenotypes]	0.0	2	1	1	1
70305	1710	presence of phorbol 12-myristate	[presence of phorbol 12-myristate]	0.0	4	1	1	1
70306	1710	n-acetyl-l-cysteine antioxidant	[N-acetyl-L-cysteine antioxidant]	0.0	2	1	1	1
70307	1710	adhesion at mM.	[adhesion at mM.]	0.0	3	1	1	1
70308	1710	mental illness involve inadequate response	[mental illness involving inadequate responses]	0.0	5	1	1	1
70309	1710	unstable untreated asthmatic patient	[unstable untreated asthmatic patients]	0.0	4	1	1	1
70310	1710	interleukin-2 deprivation	[interleukin-2 deprivation]	0.0	2	1	1	1
70311	1710	prior incubation	[prior incubation]	0.0	2	1	1	1
70312	1710	include integrin alpha	[including integrin alpha]	0.0	3	1	1	1
70313	1710	ability -express cell	[abilities -expressing cells]	0.0	3	1	1	1
70314	1710	proteolytic activation	[proteolytic activation]	0.0	2	1	1	1
70315	1710	Epstein-Barr virus antigen EBNA-2	[Epstein-Barr virus antigen EBNA-2]	0.0	4	1	1	1
70316	1710	basophilia in acute leukaemia	[basophilia in acute leukaemia]	0.0	4	1	1	1
70317	1710	transcription factor vp16	[transcription factor VP16]	0.0	3	1	1	1
70318	1710	human interleukin 2 IL-2 gene	[human interleukin 2 IL-2 gene]	0.0	5	1	1	1
70319	1710	treatment of human T cell	[Treatment of human T cells]	0.0	5	1	1	1
70320	1710	step identify a disorder	[step identifying a disorder]	0.0	4	1	1	1
70321	1710	significant new insight into the interaction	[significant new insights into the interactions]	0.0	6	1	1	1
70322	1710	three class ii gene	[three class II genes]	0.0	4	1	1	1
70323	1710	dayus- glucocorticoid therapy	[day, glucocorticoid therapy]	0.0	3	1	1	1
70324	1710	induce a cytokine cascade	[inducing a cytokine cascade]	0.0	4	1	1	1
70325	1710	culture analysis of gene expression	[cultures analysis of gene expression]	0.0	5	1	1	1
70326	1710	monocyte-type colony	[monocyte-type colonies]	0.0	2	1	1	1
70327	1710	culture-adapted fibroblast	[culture-adapted fibroblasts]	0.0	2	1	1	1
70328	1710	EBV nuclear protein transactivator	[EBV nuclear protein transactivator]	0.0	4	1	1	1
70329	1710	expression of the c-fe gene	[expression of the c-fes gene]	0.0	5	1	1	1
70330	1710	actual target	[actual target]	0.0	2	1	1	1
70331	1710	hiv monocyte	[HIV monocytes]	0.0	2	1	1	1
70332	1710	terminal insert exon	[terminal insert exon]	0.0	3	1	1	1
70333	1710	importance for genetic counseling.	[importance for genetic counseling.]	0.0	4	1	1	1
70334	1710	eosinophil granule major protein	[eosinophil granule major protein]	0.0	4	2	2	1
70335	1710	adult blood cell HPFH	[adult blood cells HPFH]	0.0	4	1	1	1
70336	1710	selection of therapeutic strategy	[selection of therapeutic strategies]	0.0	4	1	1	1
70337	1710	factor-IL6 binding site	[factor-IL6 binding site]	0.0	3	1	1	1
70338	1710	recurrent theme	[recurrent theme]	0.0	2	1	1	1
70339	1710	allele t	[allele t]	0.0	2	1	1	1
70340	1710	two major subunit of NF-kappaB	[two major subunits of NF-kappaB]	0.0	5	1	1	1
70341	1710	repression of the gene	[repression of the gene]	0.0	4	2	2	1
70342	1710	phenotypic changes,	[phenotypic changes,]	0.0	2	1	1	1
70343	1710	agent retinoic acid	[agent retinoic acid]	0.0	3	1	1	1
70344	1710	rrna for granule protein	[mRNAs for granule proteins]	0.0	4	1	1	1
70345	1710	nh2- domain	[NH2- domains]	0.0	2	1	1	1
70346	1710	tyrosine y113	[tyrosines Y113]	0.0	2	1	1	1
70347	1710	critical step in the initiation	[critical step in the initiation]	0.0	5	1	1	1
70348	1710	reduce the yield of viral protein	[reducing the yields of viral proteins]	0.0	6	1	1	1
70349	1710	14 patient with active sle	[14 patients with active SLE]	0.0	5	1	1	1
70350	1710	related kinase inhibitor less active	[related kinase inhibitor less active]	0.0	5	1	1	1
70351	1710	human primary b cell	[human primary B cells]	0.0	4	1	1	1
70352	1710	49 case of B-cell leukemia	[49 cases of B-cell leukemia]	0.0	5	1	1	1
70353	1710	aml m4 with atypical abnormal eosinophil	[AML M4 with atypical abnormal eosinophils]	0.0	6	1	1	1
70354	1710	c motif-1/lymphotactin promoter	[C motif-1/lymphotactin promoter]	0.0	3	1	1	1
70355	1710	function from the histocompatibility complex	[function from the histocompatibility complex]	0.0	5	1	1	1
70356	1710	candidate for a new, member	[candidate for a new, member]	0.0	5	1	1	1
70357	1710	rakfkqllq -specific CTL precursor frequency	[RAKFKQLLQ -specific CTL precursor frequency]	0.0	5	1	1	1
70358	1710	5' site	[5' site]	0.0	2	1	1	1
70359	1710	tnf-related apoptosis ligand	[TNF-related apoptosis ligand]	0.0	3	1	1	1
70360	1710	fibroblast ref52	[fibroblast REF52]	0.0	2	1	1	1
70361	1710	length promoter	[length promoter]	0.0	2	1	1	1
70362	1710	adenovirus e1b promoter-luciferase gene	[adenovirus E1B promoter-luciferase gene]	0.0	4	1	1	1
70363	1710	implication for NF-kappa b	[implications for NF-kappa B]	0.0	4	1	1	1
70364	1710	nonfinger region of clone	[nonfinger region of clone]	0.0	4	1	1	1
70365	1710	additionally, costimulation with anti-CD3	[additionally, costimulation with anti-CD3]	0.0	4	1	1	1
70366	1710	residual disease of patient with leukemia	[residual disease of patients with leukemia]	0.0	6	1	1	1
70367	1710	anemia in mouse	[anemia in mice]	0.0	3	1	1	1
70368	1710	expression of the activity	[expression of the activity]	0.0	4	1	1	1
70369	1710	pathogenesis of keratoconjunctivitis vkc	[pathogenesis of keratoconjunctivitis VKC]	0.0	4	1	1	1
70370	1710	protein set in motion a series	[proteins setting in motion a series]	0.0	6	1	1	1
70371	1710	hpv-16	[HPV-16]	0.0	1	1	1	1
70372	1710	primary breast cancer sample	[primary breast cancer samples]	0.0	4	1	1	1
70373	1710	use a excess	[using an excess]	0.0	3	1	1	1
70374	1710	hpv-18	[HPV-18]	0.0	1	1	1	1
70375	1710	tobacco smoke ts	[Tobacco smoke TS]	0.0	3	1	1	1
70376	1710	other adaptor	[other adaptors]	0.0	2	1	1	1
70377	1710	connection with impaired induction	[connection with impaired induction]	0.0	4	1	1	1
70378	1710	bind activity of nf-il6	[binding activity of NF-IL6]	0.0	4	1	1	1
70379	1710	mechanism of target cell lysis	[mechanism of target cell lysis]	0.0	5	1	1	1
70380	1710	adenylyl cyclase by pretreatment	[adenylyl cyclase by pretreatment]	0.0	4	1	1	1
70381	1710	new, clinically relevant compound	[new, clinically relevant compounds]	0.0	4	1	1	1
70382	1710	cytomegalovirus ie2 protein	[cytomegalovirus IE2 protein]	0.0	3	1	1	1
70383	1710	uptake with hyperparathyroidism	[uptake with hyperparathyroidism]	0.0	3	1	1	1
70384	1710	interaction with specific region	[interaction with specific regions]	0.0	4	1	1	1
70385	1710	granulocyte/macrophage-colony stimulate factor gm-csf	[granulocyte/macrophage-colony stimulating factor GM-CSF]	0.0	4	1	1	1
70386	1710	cis-acting element of gene	[cis-acting elements of genes]	0.0	4	1	1	1
70387	1710	tnf-beta	[TNF-beta]	0.0	1	1	1	1
70388	1710	encode the tata-box binding protein	[encoding the TATA-box binding protein]	0.0	5	1	1	1
70389	1710	dimerization with RelA(p65)	[Dimerization with RelA(p65)]	0.0	3	1	1	1
70390	1710	assay procedure use zebra protein	[assay procedure using ZEBRA protein]	0.0	5	1	1	1
70391	1710	benign tissue	[benign tissues]	0.0	2	1	1	1
70392	1710	molecular mechanism of proliferation cessation	[molecular mechanisms of proliferation cessation]	0.0	5	1	1	1
70393	1710	transfection under control	[transfection under control]	0.0	3	1	1	1
70394	1710	binding assay use c-c chemokine	[Binding assays using C-C chemokines]	0.0	5	1	1	1
70395	1710	synergistic activation by CD40 ligand	[synergistic activation by CD40 ligand]	0.0	5	1	1	1
70396	1710	flow conditions.	[flow conditions.]	0.0	2	1	1	1
70397	1710	high spi-1	[high Spi-1]	0.0	2	1	1	1
70398	1710	unit granulocyte-macrophage	[unit granulocyte-macrophage]	0.0	2	1	1	1
70399	1710	therefore, inactivation	[Therefore, inactivation]	0.0	2	1	1	1
70400	1710	evasion of immune response	[evasion of immune responses]	0.0	4	1	1	1
70401	1710	signal-regulated kinase pathway	[signal-regulated kinase pathway]	0.0	3	1	1	1
70402	1710	vzv product of orf	[VZV product of ORF]	0.0	4	1	1	1
70403	1710	significance of c-rel involvement	[significance of c-Rel involvement]	0.0	4	1	1	1
70404	1710	early (2-6 h) effect	[early (2-6 h) effects]	0.0	4	1	1	1
70405	1710	thereby promote mm cell growth	[thereby promoting MM cell growth]	0.0	5	1	1	1
70406	1710	ubiquitous transcription factor Oct1	[ubiquitous transcription factors Oct1]	0.0	4	1	1	1
70407	1710	respect to dissociation capacity,	[respect to dissociation capacity,]	0.0	4	1	1	1
70408	1710	tr2 orphan receptor	[TR2 orphan receptor]	0.0	3	1	1	1
70409	1710	novel isoform, oct2ab	[novel isoform, Oct2ab]	0.0	3	1	1	1
70410	1710	sites/cell statistically significant	[sites/cell statistically significant]	0.0	3	1	1	1
70411	1710	genetic alterations.	[genetic alterations.]	0.0	2	1	1	1
70412	1710	pbl from individual	[PBL from individuals]	0.0	3	1	1	1
70413	1710	Specific effect	[Specific effect]	0.0	2	1	1	1
70414	1710	number of regulatory sequence similar	[number of regulatory sequences similar]	0.0	5	1	1	1
70415	1710	leucocyte-activating property of mcp-1	[leucocyte-activating properties of MCP-1]	0.0	4	1	1	1
70416	1710	runting, skin	[runting, skin]	0.0	2	1	1	1
70417	1710	cases, a heterodimer	[cases, a heterodimer]	0.0	3	1	1	1
70418	1710	Sp site	[Sp sites]	0.0	2	1	1	1
70419	1710	-dependent cell adhesion to fibronectin	[-dependent cell adhesion to fibronectin]	0.0	5	1	1	1
70420	1710	retinoic acid washed,	[retinoic acid washed,]	0.0	3	1	1	1
70421	1710	specificity of regulator	[specificity of regulators]	0.0	3	1	1	1
70422	1710	significant difference between the patient	[significant difference between the patients]	0.0	5	1	1	1
70423	1710	4922 (range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564	[4922 (range, 4484-5643),]	0.0	3	1	1	1
70424	1710	acute injury with alpha-tocopherol	[acute injury with alpha-tocopherol]	0.0	4	1	1	1
70425	1710	primary defect	[primary defect]	0.0	2	1	1	1
70426	1710	fixative-sensitive a formalin-resistant epitope	[fixative-sensitive a formalin-resistant epitope]	0.0	4	1	1	1
70427	1710	pattern use extract	[pattern using extracts]	0.0	3	1	1	1
70428	1710	shock gene	[shock genes]	0.0	2	1	1	1
70429	1710	differentiative fate	[differentiative fate]	0.0	2	1	1	1
70430	1710	positive clone	[positive clones]	0.0	2	1	1	1
70431	1710	potency of class compounds, 20-epi	[potency of class compounds, 20-epi]	0.0	5	1	1	1
70432	1710	precursor p105	[precursor p105]	0.0	2	1	1	1
70433	1710	typical Th1-dominated chronic inflammation	[typical Th1-dominated chronic inflammation]	0.0	4	1	1	1
70434	1710	other strain	[other strains]	0.0	2	1	1	1
70435	1710	interactor (s) limit	[interactor (s) limits]	0.0	3	1	1	1
70436	1710	transient cotransfection together with a plasmid	[Transient cotransfection together with a plasmid]	0.0	6	1	1	1
70437	1710	potential of lipid antioxidant	[potential of lipid antioxidants]	0.0	4	1	1	1
70438	1710	two NF-IL6 binding site	[two NF-IL6 binding sites]	0.0	4	1	1	1
70439	1710	contribution gene product to the activation	[contribution gene products to the activation]	0.0	6	1	1	1
70440	1710	ZEB a vertebrate homolog	[ZEB a vertebrate homolog]	0.0	4	1	1	1
70441	1710	aminolaevulinic acid synthase alas-e activity	[aminolaevulinic acid synthase ALAS-E activity]	0.0	5	1	1	1
70442	1710	regulation of nuclear regulatory factor-kappa beta	[regulation of nuclear regulatory factor-kappa beta]	0.0	6	1	1	1
70443	1710	beta cd49d/cd29 costimulation	[beta CD49d/CD29 costimulation]	0.0	3	1	1	1
70444	1710	human umbilical vein cell CoCl2	[human umbilical vein cells CoCl2]	0.0	5	1	1	1
70445	1710	common therapeutic use	[common therapeutic use]	0.0	3	1	1	1
70446	1710	DTCs	[DTCs]	0.0	1	1	1	1
70447	1710	domain with eight putative segment	[domain with eight putative segments]	0.0	5	1	1	1
70448	1710	ifi IFN-alpha/beta	[IFNs IFN-alpha/beta]	0.0	2	1	1	1
70449	1710	regulation positive effect	[regulation positive effects]	0.0	3	1	1	1
70450	1710	number of pbmc	[number of PBMC]	0.0	3	1	1	1
70451	1710	expression of negative mapkk-1	[Expression of negative MAPKK-1]	0.0	4	1	1	1
70452	1710	effect of c-11-substituted alpha,25-(OH)2D3 analog	[effects of C-11-substituted alpha,25-(OH)2D3 analogs]	0.0	5	1	1	1
70453	1710	rheumatoid joint	[rheumatoid joint]	0.0	2	1	1	1
70454	1710	preparation,	[preparation,]	0.0	1	1	1	1
70455	1710	uptake of 135(oh)2d3	[uptake of 1,25(OH)2D3]	0.0	3	1	1	1
70456	1710	rel/nuclear factor kappab nf-kappab factor	[Rel/nuclear factor kappaB NF-kappaB factors]	0.0	5	1	1	1
70457	1710	preparation.	[preparation.]	0.0	1	1	1	1
70458	1710	activity in aged long-distance runner	[activity in aged long-distance runner]	0.0	5	1	1	1
70459	1710	base exchange by conformational polymorphism	[base exchanges by conformational polymorphism]	0.0	5	1	1	1
70460	1710	cytomegalovirus binding to monocyte	[cytomegalovirus binding to monocytes]	0.0	4	1	1	1
70461	1710	25% cells).	[25% cells).]	0.0	2	1	1	1
70462	1710	evidence a result	[evidence a result]	0.0	3	1	1	1
70463	1710	expression of specific set	[expression of specific sets]	0.0	4	1	1	1
70464	1710	Grb2 sh3-binding protein	[Grb2 SH3-binding proteins]	0.0	3	1	1	1
70465	1710	affinity on blood mononuclear cell	[affinity on blood mononuclear cells]	0.0	5	1	1	1
70466	1710	Chronic hiv-1 infection	[Chronic HIV-1 infection]	0.0	3	1	1	1
70467	1710	cd23 a common b	[CD23 a common B]	0.0	4	1	1	1
70468	1710	glucocorticoid-receptors in chronic failure patient	[glucocorticoid-receptors in chronic failure patients]	0.0	5	1	1	1
70469	1710	same mechanism	[same mechanisms]	0.0	2	1	1	1
70470	1710	overexpression in Jurkat cell	[overexpression in Jurkat cells]	0.0	4	1	1	1
70471	1710	regulate transcription in monocytic cell	[regulating transcription in monocytic cells]	0.0	5	1	1	1
70472	1710	class ii major histocompatibility promoter	[class II major histocompatibility promoters]	0.0	5	1	1	1
70473	1710	expression of a calcineurin cn	[Expression of a calcineurin CN]	0.0	5	1	1	1
70474	1710	decrease in the plasma sialyltransferase	[decrease in the plasma sialyltransferase]	0.0	5	1	1	1
70475	1710	pp-2a kinase	[PP-2A kinases]	0.0	2	1	1	1
70476	1710	number from 3	[number from 3]	0.0	3	1	1	1
70477	1710	follow CMV infection	[following CMV infection]	0.0	3	1	1	1
70478	1710	cd15 on monocyte	[CD15 on monocytes]	0.0	3	1	1	1
70479	1710	aml m4 without abnormal eosinophil	[AML M4 without abnormal eosinophils]	0.0	5	1	1	1
70480	1710	b cell-specific activation	[B cell-specific activation]	0.0	3	1	1	1
70481	1710	dq2-anchor residue	[DQ2-anchor residues]	0.0	2	1	1	1
70482	1710	transcription factor indicator	[transcription factor indicators]	0.0	3	1	1	1
70483	1710	nef phosphorylation	[Nef phosphorylation]	0.0	2	1	1	1
70484	1710	signal abnormality	[signaling abnormalities]	0.0	2	1	1	1
70485	1710	b dimer	[B dimers]	0.0	2	1	1	1
70486	1710	viral protein and/or	[viral proteins and/or]	0.0	3	1	1	1
70487	1710	effect of sac	[effects of SAC]	0.0	3	1	1	1
70488	1710	STAT5-	[STAT5-]	0.0	1	1	1	1
70489	1710	difference wild-type	[difference wild-type]	0.0	2	1	1	1
70490	1710	pd195599	[PD195599]	0.0	1	1	1	1
70491	1710	Consequently, T lymphocyte present	[Consequently, T lymphocytes present]	0.0	4	1	1	1
70492	1710	steroid-responsive cell use mrna display	[steroid-responsive cells using mRNA display]	0.0	5	1	1	1
70493	1710	regulation of nuclear factor-kappa beta	[regulation of nuclear factor-kappa beta]	0.0	5	1	1	1
70494	1710	treatment of hiv-infected pbmc	[Treatment of HIV-infected PBMC]	0.0	4	1	1	1
70495	1710	outcome of disease	[outcome of diseases]	0.0	3	1	1	1
70496	1710	lysis by killer cell	[lysis by killer cells]	0.0	4	1	1	1
70497	1710	linear correlation,	[linear correlation,]	0.0	2	1	1	1
70498	1710	however a very strong association	[however a very strong association]	0.0	5	1	1	1
70499	1710	homodimeric glycoprotein	[homodimeric glycoprotein]	0.0	2	1	1	1
70500	1710	vitro from cell	[vitro from cells]	0.0	3	1	1	1
70501	1710	signal in peripheral blood mononuclear cell	[signalling in peripheral blood mononuclear cells]	0.0	6	1	1	1
70502	1710	transcription factor in differentiation	[transcription factors in differentiation]	0.0	4	1	1	1
70503	1710	unstimulated human jurkat T cell	[unstimulated human Jurkat T cells]	0.0	5	1	1	1
70504	1710	current understanding	[current understanding]	0.0	2	3	3	1
70505	1710	amino-terminal domain of amino acid	[amino-terminal domain of amino acids]	0.0	5	1	1	1
70506	1710	pattern of kappa dna-binding activity	[pattern of kappa DNA-binding activity]	0.0	5	1	1	1
70507	1710	9.36 1.17 nm, bmax	[9.36 1.17 nM, Bmax]	0.0	4	1	1	1
70508	1710	multiple, distinct dna-binding protein	[multiple, distinct DNA-binding proteins]	0.0	4	1	1	1
70509	1710	polyamine pattern	[polyamine pattern]	0.0	2	2	2	1
70510	1710	cd23 transcript	[CD23 transcripts]	0.0	2	1	1	1
70511	1710	(p<.001) in untreated euthymic patient	[(P<.001) in untreated euthymic patients]	0.0	5	1	1	1
70512	1710	human m-csf receptor promoter	[human M-CSF receptor promoter]	0.0	4	1	1	1
70513	1710	culture lack fresh cell	[cultures lacking fresh cells]	0.0	4	1	1	1
70514	1710	enzyme independent	[enzyme independent]	0.0	2	1	1	1
70515	1710	elk-1 point	[Elk-1 pointing]	0.0	2	1	1	1
70516	1710	sk-n-be(2)	[SK-N-Be(2)]	0.0	1	1	1	1
70517	1710	participation of region	[participation of regions]	0.0	3	1	1	1
70518	1710	human islet encode jun-B	[human islet encoding jun-B]	0.0	4	1	1	1
70519	1710	use a specific nfatp antibody	[using a specific NFATp antibody]	0.0	5	1	1	1
70520	1710	one form	[one form]	0.0	2	1	1	1
70521	1710	il-2+ cell	[IL-2+ cells]	0.0	2	1	1	1
70522	1710	multiple signal protein	[multiple signaling proteins]	0.0	3	1	1	1
70523	1710	element of the IL-4 promoter	[elements of the IL-4 promoter]	0.0	5	1	1	1
70524	1710	loss encode a factor	[loss encoding a factor]	0.0	4	1	1	1
70525	1710	trigger of several pathway	[triggering of several pathways]	0.0	4	1	1	1
70526	1710	colour fish analysis use probe	[colour FISH analysis using probes]	0.0	5	1	1	1
70527	1710	characterization of this cell	[characterization of these cells]	0.0	4	1	1	1
70528	1710	extract, indicate regulation	[extract, indicating regulation]	0.0	3	1	1	1
70529	1710	il-1 antagonist secretion	[IL-1 antagonist secretion]	0.0	3	1	1	1
70530	1710	translocation of Rel-B	[translocation of Rel-B]	0.0	3	1	1	1
70531	1710	role of this different protein	[role of these different proteins]	0.0	5	1	1	1
70532	1710	surface MHC class expression	[surface MHC class expression]	0.0	4	1	1	1
70533	1710	Crkl	[Crkl]	0.0	1	1	1	1
70534	1710	site 4481	[site 4481]	0.0	2	1	1	1
70535	1710	notable exception	[notable exception]	0.0	2	1	1	1
70536	1710	micron/ml tumor necrosis factor alpha	[micron/ml tumor necrosis factor alpha]	0.0	5	1	1	1
70537	1710	B7 molecule	[B7 molecule]	0.0	2	1	1	1
70538	1710	promoter region (-36 with respect	[promoter region (-36 with respect]	0.0	5	1	1	1
70539	1710	suppression of endogenous corticosterone	[suppression of endogenous corticosterone]	0.0	4	1	1	1
70540	1710	mouse transgenic	[mice transgenic]	0.0	2	1	1	1
70541	1710	unexpected expression	[Unexpected expression]	0.0	2	2	2	1
70542	1710	level of otf-2	[levels of OTF-2]	0.0	3	1	1	1
70543	1710	myb expression	[myb expression]	0.0	2	1	1	1
70544	1710	secretory phase	[secretory phase]	0.0	2	1	1	1
70545	1710	factor.kappa b activation	[factor.kappa B activation]	0.0	3	1	1	1
70546	1710	increase in serine phosphorylation	[increase in serine phosphorylation]	0.0	4	1	1	1
70547	1710	transcriptional regulation during differentiation	[Transcriptional regulation during differentiation]	0.0	4	1	1	1
70548	1710	simultaneous early expression	[simultaneous early expression]	0.0	3	1	1	1
70549	1710	expression of lymphokine of cytokine	[expression of lymphokines of cytokines]	0.0	5	1	1	1
70550	1710	antigen-specific reactivity at level	[antigen-specific reactivities at levels]	0.0	4	1	1	1
70551	1710	factor-activated T cell	[factor-activated T cells]	0.0	3	1	1	1
70552	1710	prior modification toward reduction	[prior modification toward reduction]	0.0	4	1	1	1
70553	1710	two transcription factor Oct1	[two transcription factors Oct1]	0.0	4	1	1	1
70554	1710	cellular event to cell	[cellular event to cells]	0.0	4	1	1	1
70555	1710	transcript for the chemokine	[transcripts for the chemokines]	0.0	4	1	1	1
70556	1710	three category factor such as Oct-2A	[three categories factors such as Oct-2A]	0.0	6	1	1	1
70557	1710	Comparison of KG1	[Comparison of KG1]	0.0	3	1	1	1
70558	1710	additional staining with a small panel	[additional staining with a small panel]	0.0	6	1	1	1
70559	1710	rate limit in remodeling	[rate limiting in remodeling]	0.0	4	1	1	1
70560	1710	t-helper cell cytokine	[T-helper cell cytokines]	0.0	3	1	1	1
70561	1710	dysregulation immunodeficiency virus type 1 hiv-1	[dysregulation immunodeficiency virus type 1 HIV-1]	0.0	6	1	1	1
70562	1710	rest human umbilical vein cell	[resting human umbilical vein cells]	0.0	5	1	1	1
70563	1710	explore physical signal pathway	[exploring physical signaling pathways]	0.0	4	1	1	1
70564	1710	follow factor treatment of human neutrophils.	[following factor treatment of human neutrophils.]	0.0	6	1	1	1
70565	1710	expression of the promoter	[expression of the promoter]	0.0	4	1	1	1
70566	1710	additional structural role	[additional structural role]	0.0	3	1	1	1
70567	1710	blood lymphocyte from 9/19 ss patient	[blood lymphocytes from 9/19 SS patients]	0.0	6	1	1	1
70568	1710	protease inhibitor on the disease	[protease inhibitors on the disease]	0.0	5	1	1	1
70569	1710	effect of treatment with dose	[effects of treatment with doses]	0.0	5	1	1	1
70570	1710	single immediate-early protein	[single immediate-early protein]	0.0	3	1	1	1
70571	1710	pathway for periodontal tissue damage	[pathways for periodontal tissue damage]	0.0	5	1	1	1
70572	1710	non major complex way	[non major complex way]	0.0	4	1	1	1
70573	1710	role of interaction between elf-1	[role of interactions between Elf-1]	0.0	5	1	1	1
70574	1710	kappa b-binding factor	[kappa B-binding factors]	0.0	3	1	1	1
70575	1710	nuclear factor proximal NF-AT AP-1/Octamer UPS	[nuclear factor proximal NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
70576	1710	morphology loosely adherent cell	[morphology loosely adherent cells]	0.0	4	1	1	1
70577	1710	suggest a normal function	[suggesting a normal function]	0.0	4	1	1	1
70578	1710	beta-cell type-specific complex	[beta-cell type-specific complex]	0.0	3	1	1	1
70579	1710	wild-type Itk	[wild-type Itk]	0.0	2	1	1	1
70580	1710	outside-in signal	[outside-in signals]	0.0	2	1	1	1
70581	1710	(auc of 211 +/- nmol	[(AUC of 211 +/- nmol]	0.0	5	1	1	1
70582	1710	concentration to 10 &mgr;m)	[concentrations to 10 &mgr;M)]	0.0	4	1	1	1
70583	1710	specific lysosomal protein myeloperoxidase mpo	[specific lysosomal proteins myeloperoxidase MPO]	0.0	5	1	1	1
70584	1710	translocation result	[translocation resulting]	0.0	2	1	1	1
70585	1710	reading frame a	[reading frames A]	0.0	3	1	1	1
70586	1710	effect of arsenic trioxide As2O3	[effect of arsenic trioxide As2O3]	0.0	5	1	1	1
70587	1710	phytohaemagglutinin pha leucine	[phytohaemagglutinin PHA leucine]	0.0	3	1	1	1
70588	1710	negative element from bp	[negative element from bp]	0.0	4	1	1	1
70589	1710	critical regulatory mechanism	[critical regulatory mechanism]	0.0	3	1	1	1
70590	1710	NF-kappaB a LPS member	[NF-kappaB an LPS member]	0.0	4	1	1	1
70591	1710	s-100 protein	[S-100 proteins]	0.0	2	1	1	1
70592	1710	cd34+ cell g-csf cell	[CD34+ cells G-CSF cells]	0.0	4	1	1	1
70593	1710	subsequent activation JAK stat	[subsequent activation JAK STAT]	0.0	4	1	1	1
70594	1710	assembly tcc c5b-7	[Assembly TCC C5b-7]	0.0	3	1	1	1
70595	1710	replicative capacity in t-cell type	[replicative capacities in T-cell types]	0.0	5	1	1	1
70596	1710	involve the arm of chromosome	[involving the arm of chromosome]	0.0	5	1	1	1
70597	1710	expression regulation	[expression regulation]	0.0	2	1	1	1
70598	1710	(auc of +/- 8 nmol	[(AUC of +/- 8 nmol]	0.0	5	1	1	1
70599	1710	colony-stimumulatelany-stg factor protein	[colony-stimulating factor protein]	0.0	3	1	1	1
70600	1710	HLA-Cw*0702 system beta	[HLA-Cw*0702 system beta]	0.0	3	1	1	1
70601	1710	c-terminal serine proline region	[C-terminal serine proline region]	0.0	4	1	1	1
70602	1710	-restricted T	[-restricted T]	0.0	2	1	1	1
70603	1710	rest human lymphocyte from peripheral blood	[resting human lymphocytes from peripheral blood]	0.0	6	1	1	1
70604	1710	cell of mouse	[cells of mice]	0.0	3	1	1	1
70605	1710	absence of competition	[absence of competition]	0.0	3	1	1	1
70606	1710	receptor in blood leucocyte	[receptor in blood leucocyte]	0.0	4	1	1	1
70607	1710	uncoupling	[uncoupling]	0.0	1	2	2	1
70608	1710	evidence a result of activation	[evidence a result of activation]	0.0	5	1	1	1
70609	1710	day in serum	[days in serum]	0.0	3	1	1	1
70610	1710	synergy between Raf	[synergy between Raf]	0.0	3	1	1	1
70611	1710	histocompatibility complex class ii immunodeficiency	[histocompatibility complex class II immunodeficiency]	0.0	5	1	1	1
70612	1710	active infection	[active infection]	0.0	2	1	1	1
70613	1710	novel function in erythroid differentiation	[novel function in erythroid differentiation]	0.0	5	1	1	1
70614	1710	vitro, underline the role	[vitro, underlining the role]	0.0	4	1	1	1
70615	1710	calcineurin -binding peptide	[calcineurin -binding peptide]	0.0	3	1	1	1
70616	1710	DNase I mapping	[DNase I mapping]	0.0	3	1	1	1
70617	1710	inhibition of monoclonal antibody t-cell proliferation	[Inhibition of monoclonal antibody T-cell proliferation]	0.0	6	1	1	1
70618	1710	potential index	[potential index]	0.0	2	1	1	1
70619	1710	many pathogens,	[many pathogens,]	0.0	2	1	1	1
70620	1710	optimization	[optimization]	0.0	1	1	1	1
70621	1710	inflammatory cytokine in cell	[inflammatory cytokines in cells]	0.0	4	1	1	1
70622	1710	allergic airway hyperresponsiveness	[allergic airway hyperresponsiveness]	0.0	3	1	1	1
70623	1710	weak negative correlation	[weak negative correlation]	0.0	3	1	1	1
70624	1710	IL-5 promoter/enhancer luciferase gene construct	[IL-5 promoter/enhancer luciferase gene construct]	0.0	5	1	1	1
70625	1710	structurally distinct, inhibitor of NFAT transcription	[structurally distinct, inhibitors of NFAT transcription]	0.0	6	1	1	1
70626	1710	demonstration in ht-2 cell	[demonstration in HT-2 cells]	0.0	4	1	1	1
70627	1710	rapamycin pathway in the control	[rapamycin pathways in the control]	0.0	5	1	1	1
70628	1710	level gr expression in cell	[level GR expression in cells]	0.0	5	1	1	1
70629	1710	immunocytochemistry; 200 fmol/mg protein	[immunocytochemistry; 200 fmol/mg protein]	0.0	4	1	1	1
70630	1710	signal transducer of transcription 1	[signal transducer of transcription 1]	0.0	5	1	1	1
70631	1710	sequence-specific DNA binding	[Sequence-specific DNA binding]	0.0	3	2	2	1
70632	1710	comprise a single-chain ab variable fragment	[comprising an single-chain Ab variable fragment]	0.0	6	1	1	1
70633	1710	erythroid 5-aminolevulinate	[erythroid 5-aminolevulinate]	0.0	2	1	1	1
70634	1710	fungal c8-c7 sterol isomerase	[fungal C8-C7 sterol isomerase]	0.0	4	1	1	1
70635	1710	interestingly, a potent transcriptional activator	[Interestingly, a potent transcriptional activator]	0.0	5	1	1	1
70636	1710	thus lead	[thus leading]	0.0	2	1	1	1
70637	1710	expression of the surface marker	[expression of the surface markers]	0.0	5	1	1	1
70638	1710	high efficacy of the drug	[high efficacy of the drug]	0.0	5	1	1	1
70639	1710	reactivation of gene expression through inhibition	[reactivation of gene expression through inhibition]	0.0	6	1	1	1
70640	1710	+/- 0.4 fmol	[+/- 0.4 fmol]	0.0	3	1	1	1
70641	1710	level consist	[level consisting]	0.0	2	1	1	1
70642	1710	potent activity at concentration 100-fold low	[potent activity at concentrations 100-fold lower]	0.0	6	1	1	1
70643	1710	nf-kappab binding activity in extract	[NF-kappaB binding activity in extracts]	0.0	5	1	1	1
70644	1710	effect in the HLA-Cw*0702 system beta	[effects in the HLA-Cw*0702 system beta]	0.0	6	1	1	1
70645	1710	most erythroblastic cell line	[most erythroblastic cell lines]	0.0	4	1	1	1
70646	1710	domain from GAL4 activator	[domain from GAL4 activators]	0.0	4	1	1	1
70647	1710	nuclear expression activation	[nuclear expression activation]	0.0	3	1	1	1
70648	1710	F.M in ach2 cell	[F.M in Ach2 cells]	0.0	4	1	1	1
70649	1710	various rheumatic disease (12:	[various rheumatic diseases (12:]	0.0	4	1	1	1
70650	1710	ligand to nuclear receptor	[ligands to nuclear receptors]	0.0	4	1	1	1
70651	1710	ro(ssa) response	[Ro(SSA) response]	0.0	2	1	1	1
70652	1710	factor with mobilities,	[factors with mobilities,]	0.0	3	1	1	1
70653	1710	expression of gamma-interferon inducible protein ip-10	[Expression of gamma-interferon inducible protein IP-10]	0.0	6	1	1	1
70654	1710	five repeat	[five repeats]	0.0	2	1	1	1
70655	1710	low weight species	[lower weight species]	0.0	3	1	1	1
70656	1710	related disorder involve sexual differentiation	[related disorders involving sexual differentiation]	0.0	5	1	1	1
70657	1710	examination of 18 aml sample	[Examination of 18 AML samples]	0.0	5	1	1	1
70658	1710	cell sorting	[Cell sorting]	0.0	2	1	1	1
70659	1710	mediate responsiveness in the cns	[mediating responsiveness in the CNS]	0.0	5	1	1	1
70660	1710	upregulation of cytokine	[upregulation of cytokines]	0.0	3	1	1	1
70661	1710	IL-4 regulation of tgf-alpha expression	[IL-4 regulation of TGF-alpha expression]	0.0	5	1	1	1
70662	1710	step in the lysis	[steps in the lysis]	0.0	4	1	1	1
70663	1710	myeloid cell i.e. granulocyte pmn	[myeloid cells i.e. granulocytes PMN]	0.0	5	1	1	1
70664	1710	yeast transcriptional regulator	[yeast transcriptional regulator]	0.0	3	1	1	1
70665	1710	JCam cell	[JCam cells]	0.0	2	1	1	1
70666	1710	adult before overnight dst	[adults before overnight DST]	0.0	4	1	1	1
70667	1710	critical regulatory interaction	[critical regulatory interaction]	0.0	3	1	1	1
70668	1710	t-cell virus type htlv-1 tax	[T-cell virus type HTLV-1 Tax]	0.0	5	1	1	1
70669	1710	600 mg	[600 mg]	0.0	2	1	1	1
70670	1710	cd34+ hemopoietic progenitor cell	[CD34+ hemopoietic progenitor cells]	0.0	4	1	1	1
70671	1710	nucleotide DR3	[nucleotides DR3]	0.0	2	1	1	1
70672	1710	hiv-1 burden	[HIV-1 burden]	0.0	2	1	1	1
70673	1710	wild-type level of snrna	[wild-type levels of snRNA]	0.0	4	1	1	1
70674	1710	c-rel gene	[c-rel gene]	0.0	2	2	2	1
70675	1710	appropriate control	[appropriate controls]	0.0	2	1	1	1
70676	1710	herpesvirus a T virus	[herpesvirus a T virus]	0.0	4	1	1	1
70677	1710	temperature-induced down-regulation in patient with sepsis	[Temperature-induced down-regulation in patients with sepsis]	0.0	6	1	1	1
70678	1710	form in the regulation	[forms in the regulation]	0.0	4	1	1	1
70679	1710	activity for neutrophil	[activity for neutrophils]	0.0	3	1	1	1
70680	1710	apparent m.w.	[apparent m.w.]	0.0	2	1	1	1
70681	1710	3-o-methyl-d	[3-O-methyl-D]	0.0	1	1	1	1
70682	1710	initiation of malignancy	[initiation of malignancy]	0.0	3	1	1	1
70683	1710	and, in the carboxy-terminus	[and, in the carboxy-terminus]	0.0	4	1	1	1
70684	1710	encode the related hepatocyte factor	[encoding the related hepatocyte factors]	0.0	5	1	1	1
70685	1710	tyrosine auto/transphosphorylation	[tyrosine auto/transphosphorylation]	0.0	2	1	1	1
70686	1710	T lymphocyte with	[T lymphocytes with]	0.0	3	1	1	1
70687	1710	hormone treatment	[hormone treatment]	0.0	2	1	1	1
70688	1710	aberrant expression gene in mouse	[aberrant expression gene in mice]	0.0	5	1	1	1
70689	1710	suggest surrogate for the study	[suggesting surrogates for the study]	0.0	5	1	1	1
70690	1710	gene expression in tumour cell	[gene expression in tumour cells]	0.0	5	1	1	1
70691	1710	transfection study in HeLa cell	[transfection studies in HeLa cells]	0.0	5	1	1	1
70692	1710	proteic inhibitor	[proteic inhibitor]	0.0	2	1	1	1
70693	1710	involve retinoblastoma protein	[involving retinoblastoma protein]	0.0	3	1	1	1
70694	1710	cytokine receptor signal	[cytokine receptor signaling]	0.0	3	1	1	1
70695	1710	diagnostic value of D3 calcitriol determination	[diagnostic value of D3 calcitriol determination]	0.0	6	1	1	1
70696	1710	activator produce a 50-fold induction	[activator producing a 50-fold induction]	0.0	5	1	1	1
70697	1710	factor for the establishment	[factor for the establishment]	0.0	4	1	1	1
70698	1710	likewise, reporter gene assay	[Likewise, reporter gene assays]	0.0	4	1	1	1
70699	1710	648 bp	[648 bp]	0.0	2	1	1	1
70700	1710	synoviocyte	[synoviocytes]	0.0	1	1	1	1
70701	1710	formation sequence-binding complex contain STAT3	[formation sequence-binding complexes containing STAT3]	0.0	5	1	1	1
70702	1710	different concentration	[different concentrations]	0.0	2	3	3	1
70703	1710	Comparison of the combination gc	[Comparison of the combinations GC]	0.0	5	1	1	1
70704	1710	interleukin 1 receptor superfamily	[interleukin 1 receptor superfamily]	0.0	4	1	1	1
70705	1710	transcription factor NF-E1	[transcription factor NF-E1]	0.0	3	1	1	1
70706	1710	egf-gp130 receptor	[EGF-gp130 receptor]	0.0	2	1	1	1
70707	1710	background of the glucose toxicity	[background of the glucose toxicity]	0.0	5	1	1	1
70708	1710	Mutated ciita construct	[Mutated CIITA constructs]	0.0	3	1	1	1
70709	1710	type of histocompatibility class immunodeficiency	[type of histocompatibility class immunodeficiency]	0.0	5	1	1	1
70710	1710	enhancement of adipocyte differentiation	[enhancement of adipocyte differentiation]	0.0	4	1	1	1
70711	1710	further consideration as tumor ag	[further consideration as tumor Ag]	0.0	5	1	1	1
70712	1710	ML-1 myeloblastic leukemia cell	[ML-1 myeloblastic leukemia cells]	0.0	4	1	1	1
70713	1710	T lineage differentiation	[T lineage differentiation]	0.0	3	1	1	1
70714	1710	vivo anti-inflammatory effect	[vivo anti-inflammatory effects]	0.0	3	1	1	1
70715	1710	ability of Ras	[ability of Ras]	0.0	3	1	1	1
70716	1710	mutant of Raf-1	[mutants of Raf-1]	0.0	3	1	1	1
70717	1710	tyr-705	[Tyr-705]	0.0	1	1	1	1
70718	1710	wd-40 repeat in the c-terminal half	[WD-40 repeats in the C-terminal half]	0.0	6	1	1	1
70719	1710	(0/3) carrier	[(0/3) carriers]	0.0	2	1	1	1
70720	1710	disorder a challenging clinical problem	[disorders a challenging clinical problem]	0.0	5	1	1	1
70721	1710	block nf-kappab through overexpression	[blocking NF-kappaB through overexpression]	0.0	4	1	1	1
70722	1710	putative binding sequence for transcription factor	[putative binding sequences for transcription factors]	0.0	6	1	1	1
70723	1710	effect of vd3	[effects of VD3]	0.0	3	1	1	1
70724	1710	polar substitution 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[polar substitutions 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	5	1	1	1
70725	1710	nuclei of unstimulated pbl	[Nuclei of unstimulated PBL]	0.0	4	1	1	1
70726	1710	cell subtype	[cell subtype]	0.0	2	1	1	1
70727	1710	effect of myristic acetate	[effect of myristic acetate]	0.0	4	1	1	1
70728	1710	tcr /cd28 costimulation	[TCR /CD28 costimulation]	0.0	3	1	1	1
70729	1710	binding to different icss	[binding to different ICSs]	0.0	4	1	1	1
70730	1710	leucocyte-activating property	[leucocyte-activating properties]	0.0	2	1	1	1
70731	1710	binding site per cell; mean	[binding sites per cell; mean]	0.0	5	1	1	1
70732	1710	phosphorylation of JunB	[phosphorylation of JunB]	0.0	3	1	1	1
70733	1710	type include myeloid leukaemia CML	[types including myeloid leukaemia CML]	0.0	5	2	2	1
70734	1710	patient with type ii diabete	[patients with type II diabetes]	0.0	5	1	1	1
70735	1710	critical role convert extracellular signal	[critical role converting extracellular signals]	0.0	5	1	1	1
70736	1710	3' 5' xpb helicase	[3' 5' XPB helicase]	0.0	4	1	1	1
70737	1710	use mobility shift assay from patient	[using mobility shift assays from patients]	0.0	6	1	1	1
70738	1710	several generation	[several generations]	0.0	2	1	1	1
70739	1710	human thyroid fragment	[human thyroid fragments]	0.0	3	1	1	1
70740	1710	six full cell cycle	[six full cell cycle]	0.0	4	1	1	1
70741	1710	electron microscopy on intact cell	[electron microscopy on intact cells]	0.0	5	1	1	1
70742	1710	thus, change	[Thus, changes]	0.0	2	1	1	1
70743	1710	extracellular pool	[extracellular pools]	0.0	2	1	1	1
70744	1710	molecular target of drug	[molecular target of drugs]	0.0	4	1	1	1
70745	1710	search Ag	[searching Ag]	0.0	2	1	1	1
70746	1710	human interferon beta	[human interferon beta]	0.0	3	1	1	1
70747	1710	mouse lack mature T cell	[mice lacking mature T cells]	0.0	5	1	1	1
70748	1710	staining of thymus section	[staining of thymus sections]	0.0	4	1	1	1
70749	1710	change in set of phosphoprotein	[changes in set of phosphoproteins]	0.0	5	1	1	1
70750	1710	moiety of molecules.	[moiety of molecules.]	0.0	3	1	1	1
70751	1710	transcriptional regulation of genes.	[transcriptional regulation of genes.]	0.0	4	1	1	1
70752	1710	efficient precursor	[efficient precursors]	0.0	2	1	1	1
70753	1710	rela homodimer	[RelA homodimer]	0.0	2	1	1	1
70754	1710	vitro transcription of cDNA	[vitro transcription of cDNA]	0.0	4	1	1	1
70755	1710	produce stimulation at lower,	[producing stimulation at lower,]	0.0	4	1	1	1
70756	1710	(bhlh) transcription factor	[(bHLH) transcription factors]	0.0	3	1	1	1
70757	1710	high potential cell	[high potential cells]	0.0	3	1	1	1
70758	1710	period in cell	[periods in cells]	0.0	3	1	1	1
70759	1710	mean level of gcr	[mean level of GcR]	0.0	4	1	1	1
70760	1710	adhesion in vein cell	[adhesion in vein cells]	0.0	4	1	1	1
70761	1710	heterologous syncytia	[heterologous syncytia]	0.0	2	1	1	1
70762	1710	induction by immunodeficiency virus	[Induction by immunodeficiency virus]	0.0	4	1	1	1
70763	1710	significant gap in understanding	[significant gaps in understanding]	0.0	4	1	1	1
70764	1710	inhibition of transcriptional protein	[inhibition of transcriptional proteins]	0.0	4	1	1	1
70765	1710	erythroid cell population	[erythroid cell populations]	0.0	3	1	1	1
70766	1710	n-myc	[N-myc]	0.0	1	1	1	1
70767	1710	central role in growth transformation	[central role in growth transformation]	0.0	5	1	1	1
70768	1710	macrophage CSF gene result	[macrophage CSF gene resulting]	0.0	4	1	1	1
70769	1710	weight gain +/- 2126 (pre)	[weight gain +/- 2126 (pre)]	0.0	5	1	1	1
70770	1710	p23 a molecule	[p23 a molecule]	0.0	3	1	1	1
70771	1710	show a increase	[showing a increase]	0.0	3	1	1	1
70772	1710	involvement of NF-chi b	[Involvement of NF-chi B]	0.0	4	1	1	1
70773	1710	first-degree relative of IDDM subject	[first-degree relatives of IDDM subjects]	0.0	5	1	1	1
70774	1710	distinguished: 1) sign of primary hypothyroidism	[distinguished: 1) signs of primary hypothyroidism]	0.0	6	1	1	1
70775	1710	intercellular signalling system	[intercellular signalling systems]	0.0	3	1	1	1
70776	1710	trigger for the inducible expression	[trigger for the inducible expression]	0.0	5	1	1	1
70777	1710	lipopolysaccharide macrophage	[lipopolysaccharide macrophages]	0.0	2	1	1	1
70778	1710	interaction between the gene promoter	[interaction between the gene promoter]	0.0	5	1	1	1
70779	1710	fetal cell line	[fetal cell line]	0.0	3	1	1	1
70780	1710	majority of t-cell leukemia	[majority of T-cell leukemias]	0.0	4	1	1	1
70781	1710	level of reporter gene activity	[levels of reporter gene activity]	0.0	5	1	1	1
70782	1710	tight control	[tight control]	0.0	2	1	1	1
70783	1710	role of sites.	[role of sites.]	0.0	3	1	1	1
70784	1710	only significant systemic effect on function	[only significant systemic effects on function]	0.0	6	1	1	1
70785	1710	accumulation for elam-1 of elam-1 (ic50	[accumulation for ELAM-1 of ELAM-1 (IC50]	0.0	6	1	1	1
70786	1710	leukocyte function	[leukocyte function]	0.0	2	2	2	1
70787	1710	Vitamin e therapy	[Vitamin E therapy]	0.0	3	1	1	1
70788	1710	63% identity	[63% identity]	0.0	2	1	1	1
70789	1710	Rapid ca2+-mediated activation in platelet	[Rapid Ca2+-mediated activation in platelets]	0.0	5	1	1	1
70790	1710	corticosensitivity	[corticosensitivity]	0.0	1	1	1	1
70791	1710	negative form of Raf-1	[negative form of Raf-1]	0.0	4	1	1	1
70792	1710	optimal concentration	[optimal concentration]	0.0	2	1	1	1
70793	1710	unidentified c-c chemokine	[unidentified C-C chemokine]	0.0	3	1	1	1
70794	1710	Humara	[Humara]	0.0	1	1	1	1
70795	1710	specific uptake with hyperparathyroidism php	[specific uptake with hyperparathyroidism PHP]	0.0	5	1	1	1
70796	1710	variant translocation in a patient	[variant translocation in a patient]	0.0	5	1	1	1
70797	1710	carry ig chain sequence	[carrying Ig chain sequences]	0.0	4	1	1	1
70798	1710	type-C retroviruse	[type-C retroviruses]	0.0	2	1	1	1
70799	1710	mononuclear leukocyte from 11 subject	[mononuclear leukocytes from 11 subjects]	0.0	5	1	1	1
70800	1710	multiple inhibitor	[multiple inhibitors]	0.0	2	1	1	1
70801	1710	stimulation with 8-bromo-cAMP	[stimulation with 8-bromo-cAMP]	0.0	3	1	1	1
70802	1710	interferon factor-1	[interferon factor-1]	0.0	2	1	1	1
70803	1710	transcription-activation element with enhancer-like characteristic	[transcription-activation element with enhancer-like characteristics]	0.0	5	1	1	1
70804	1710	value at hour	[value at hour]	0.0	3	1	1	1
70805	1710	bright foci	[bright foci]	0.0	2	1	1	1
70806	1710	c57 mice.	[C57 mice.]	0.0	2	1	1	1
70807	1710	kilometer tnf receptor	[kd TNF receptor]	0.0	3	1	1	1
70808	1710	cd19 cross-linking in cell	[CD19 cross-linking in cells]	0.0	4	1	1	1
70809	1710	samples, activity from non-pregnant endometrium	[samples, activity from non-pregnant endometrium]	0.0	5	1	1	1
70810	1710	stable e1a expression	[stable E1A expression]	0.0	3	1	1	1
70811	1710	fetal erythroid cell line	[fetal erythroid cell line]	0.0	4	1	1	1
70812	1710	factor-kappaB control	[factor-kappaB control]	0.0	2	1	1	1
70813	1710	level of cd45	[levels of CD45]	0.0	3	1	1	1
70814	1710	activation of zeta role	[activation of zeta role]	0.0	4	1	1	1
70815	1710	clone with ltr	[clones with LTRs]	0.0	3	1	1	1
70816	1710	release of the silencing	[release of the silencing]	0.0	4	1	1	1
70817	1710	act as transcription factor	[acting as transcription factors]	0.0	4	1	1	1
70818	1710	rhythm the fractional inhibition	[rhythms the fractional inhibition]	0.0	4	1	1	1
70819	1710	level of epo-r mrna	[levels of Epo-R mRNA]	0.0	4	1	1	1
70820	1710	infectivity to P. falciparum	[infectivity to P. falciparum]	0.0	4	1	1	1
70821	1710	expression by human T helper cell	[expression by human T helper cells]	0.0	6	1	1	1
70822	1710	value in depressed patient	[values in depressed patients]	0.0	4	1	1	1
70823	1710	stat1 -dependent gene transcription	[STAT1 -dependent gene transcription]	0.0	4	1	1	1
70824	1710	t-cell inhibitory effect with PGE2	[T-cell inhibitory effects with PGE2]	0.0	5	1	1	1
70825	1710	human herpesvirus a T virus	[Human herpesvirus a T virus]	0.0	5	1	1	1
70826	1710	primary case of acute leukaemia	[primary cases of acute leukaemia]	0.0	5	1	1	1
70827	1710	NF-kappaB/Rel member predominantly c-rel	[NF-kappaB/Rel members predominantly c-Rel]	0.0	4	1	1	1
70828	1710	nmol/l, control	[nmol/l, control]	0.0	2	1	1	1
70829	1710	isolation of a human cDNA	[Isolation of a human cDNA]	0.0	5	1	1	1
70830	1710	subsequent monocytic cell adhesion to cell	[subsequent monocytic cell adhesion to cells]	0.0	6	1	1	1
70831	1710	M3 cell	[M3 cells]	0.0	2	1	1	1
70832	1710	action a gata site at -59/-54,	[action a GATA site at -59/-54,]	0.0	6	1	1	1
70833	1710	region of base stem-loop potential	[Regions of base stem-loop potential]	0.0	5	1	1	1
70834	1710	promoter activity a coreceptor	[promoter activity a coreceptor]	0.0	4	2	2	1
70835	1710	paraparesis/	[paraparesis/]	0.0	1	1	1	1
70836	1710	sjogren' syndrome (ss)	[Sjogren's syndrome (SS)]	0.0	3	1	1	1
70837	1710	NK/ T cell	[NK/ T cells]	0.0	3	1	1	1
70838	1710	cyclosporin A lesion formation	[cyclosporin A lesion formation]	0.0	4	1	1	1
70839	1710	oncoprotein e2a-hlf	[oncoprotein E2A-HLF]	0.0	2	2	2	1
70840	1710	unusual repeat	[unusual repeat]	0.0	2	1	1	1
70841	1710	two form of type 2	[two forms of type 2]	0.0	5	1	1	1
70842	1710	variable response to u/ml interleukin-2	[variable response to U/ml interleukin-2]	0.0	5	1	1	1
70843	1710	encompass a region of both isoform	[encompassing a region of both isoforms]	0.0	6	1	1	1
70844	1710	leukocyte population in endometrium	[leukocyte populations in endometrium]	0.0	4	1	1	1
70845	1710	development of neoplasia	[development of neoplasia]	0.0	3	1	1	1
70846	1710	factor with affinity	[factors with affinity]	0.0	3	1	1	1
70847	1710	selective increase	[selective increase]	0.0	2	1	1	1
70848	1710	covariant analysis	[covariant analysis]	0.0	2	1	1	1
70849	1710	alpha granule	[alpha granules]	0.0	2	1	1	1
70850	1710	k562 cell with downregulation	[K562 cells with downregulation]	0.0	4	1	1	1
70851	1710	166 healthy female	[166 healthy females]	0.0	3	1	1	1
70852	1710	heavy chain gene enhancer	[heavy chain gene enhancer]	0.0	4	1	1	1
70853	1710	(pkc)	[(PKC)]	0.0	1	1	1	1
70854	1710	negative version of TRAF6	[negative version of TRAF6]	0.0	4	1	1	1
70855	1710	cell of labial salivary gland	[cells of labial salivary glands]	0.0	5	1	1	1
70856	1710	distinct set at stage	[distinct sets at stages]	0.0	4	1	1	1
70857	1710	promoter contain a site	[promoter containing a site]	0.0	4	1	1	1
70858	1710	allergen provocation	[allergen provocation]	0.0	2	1	1	1
70859	1710	t-cell leukemia human T cell	[T-cell leukemia human T cells]	0.0	5	1	1	1
70860	1710	basic region	[basic region]	0.0	2	1	1	1
70861	1710	HS-40 enhancer region	[HS-40 enhancer region]	0.0	3	1	1	1
70862	1710	new DNA binding protein	[new DNA binding proteins]	0.0	4	1	1	1
70863	1710	regulatory unit	[regulatory unit]	0.0	2	1	1	1
70864	1710	raralpha exhibit activity	[RARalpha exhibiting activity]	0.0	3	1	1	1
70865	1710	inhibitory effect of antioxidant	[inhibitory effects of antioxidants]	0.0	4	1	1	1
70866	1710	cytokine to cells.	[cytokines to cells.]	0.0	3	1	1	1
70867	1710	differentiation of pluripotent progenitor	[differentiation of pluripotent progenitors]	0.0	4	1	1	1
70868	1710	regulation by HLA-DO	[regulation by HLA-DO]	0.0	3	1	1	1
70869	1710	include tyrosine phosphorylation of jak3	[including tyrosine phosphorylation of JAK3]	0.0	5	1	1	1
70870	1710	monocyte chemoattractant protein	[monocyte chemoattractant protein]	0.0	3	1	1	1
70871	1710	cross-link on the surface	[Cross-linking on the surface]	0.0	4	1	1	1
70872	1710	identification a T lymphocyte-specific transcription factor	[Identification a T lymphocyte-specific transcription factor]	0.0	6	1	1	1
70873	1710	13 adult	[13 adults]	0.0	2	1	1	1
70874	1710	high-level replication primary isolate	[high-level replication primary isolate]	0.0	4	1	1	1
70875	1710	alpha thf/thf (0.35; ratios.	[alpha THF/THF (0.35; ratios.]	0.0	4	1	1	1
70876	1710	pituitary-dependent cushingd'	[pituitary-dependent Cushing's]	0.0	2	1	1	1
70877	1710	virol.	[Virol.]	0.0	1	1	1	1
70878	1710	receptor GCR in leukocyte	[receptors GCR in leukocytes]	0.0	4	1	1	1
70879	1710	core NFAT	[core NFAT]	0.0	2	1	1	1
70880	1710	nfat complex present	[NFAT complexes present]	0.0	3	1	1	1
70881	1710	contrast, addition of ligand	[contrast, addition of ligand]	0.0	4	1	1	1
70882	1710	cushingd' syndrome type corticosteroid receptor	[Cushing's syndrome Type corticosteroid receptors]	0.0	5	1	1	1
70883	1710	NF(P) a factor specific	[NF(P) a factor specific]	0.0	4	2	2	1
70884	1710	ifna synthesis	[IFNA synthesis]	0.0	2	1	1	1
70885	1710	homodimer with heterodimer	[homodimers with heterodimers]	0.0	3	1	1	1
70886	1710	STAT3 activation	[STAT3 activation]	0.0	2	1	1	1
70887	1710	glucocorticoid receptor ro	[glucocorticoid receptors Ro]	0.0	3	1	1	1
70888	1710	comparison with control	[comparison with controls]	0.0	3	1	1	1
70889	1710	VZV gE	[VZV gE]	0.0	2	1	1	1
70890	1710	early rna splicing pattern	[Early RNA splicing patterns]	0.0	4	1	1	1
70891	1710	lymphocyte receptor isoform	[lymphocyte receptor isoforms]	0.0	3	1	1	1
70892	1710	novel octamer-DNA binding protein	[novel octamer-DNA binding proteins]	0.0	4	1	1	1
70893	1710	12 hour of treatment	[12 hours of treatment]	0.0	4	1	1	1
70894	1710	escape	[Escape]	0.0	1	1	1	1
70895	1710	correspondence	[correspondence]	0.0	1	1	1	1
70896	1710	reduction of progenitor	[reduction of progenitors]	0.0	3	1	1	1
70897	1710	response by NK cell	[response by NK cells]	0.0	4	1	1	1
70898	1710	approximately 10-fold reduction	[approximately 10-fold reduction]	0.0	3	1	1	1
70899	1710	set of pi3-k construct	[set of PI3-K constructs]	0.0	4	1	1	1
70900	1710	Effect of alpha-lipoic acid	[Effects of alpha-lipoic acid]	0.0	4	1	1	1
70901	1710	hsv-2 epitope	[HSV-2 epitope]	0.0	2	1	1	1
70902	1710	quiescent b-lymphocyte	[quiescent B-lymphocytes]	0.0	2	1	1	1
70903	1710	interferon factor 2	[interferon factor 2]	0.0	3	1	1	1
70904	1710	sequence-specific dna-binding characteristic at abundance	[sequence-specific DNA-binding characteristics at abundance]	0.0	5	1	1	1
70905	1710	cd19 signaling,	[CD19 signaling,]	0.0	2	1	1	1
70906	1710	gc therapy	[GC therapy]	0.0	2	1	1	1
70907	1710	localization of gr	[localization of GR]	0.0	3	1	1	1
70908	1710	change in the cellular adhesion	[changes in the cellular adhesion]	0.0	5	1	1	1
70909	1710	first non-mammalian cytokine gene	[first non-mammalian cytokine gene]	0.0	4	1	1	1
70910	1710	purification of human ptf	[purification of human PTF]	0.0	4	1	1	1
70911	1710	rate in neutrophilic granulocyte	[rate in neutrophilic granulocytes]	0.0	4	1	1	1
70912	1710	suppression of synthesis,	[suppression of synthesis,]	0.0	3	1	1	1
70913	1710	methods, include pcr with pair	[methods, including PCR with pairs]	0.0	5	1	1	1
70914	1710	fact, under condition	[fact, under conditions]	0.0	3	1	1	1
70915	1710	kinase (tk)	[kinase (TK)]	0.0	2	1	1	1
70916	1710	use vector contain kappab site	[using vectors containing kappaB sites]	0.0	5	1	1	1
70917	1710	inhibition after withdrawal	[inhibition after withdrawal]	0.0	3	1	1	1
70918	1710	factor kappab NF-kappaB	[factor kappaB NF-kappaB]	0.0	3	2	2	1
70919	1710	such as growth factor b subunit	[such as growth factor B subunit]	0.0	6	1	1	1
70920	1710	suppression in T cell	[Suppression in T cells]	0.0	4	1	1	1
70921	1710	co-expression of pu.1 in nonlymphoid cell	[Co-expression of PU.1 in nonlymphoid cells]	0.0	6	1	1	1
70922	1710	(p less than 0.05, p 0.01	[(P less than 0.05, P 0.01]	0.0	6	1	1	1
70923	1710	fate of cell-specific transcription factor	[fate of cell-specific transcription factors]	0.0	5	1	1	1
70924	1710	adjacent motif	[adjacent motif]	0.0	2	1	1	1
70925	1710	fosb gene G0S3	[FOSB gene G0S3]	0.0	3	1	1	1
70926	1710	tissue resistance	[tissue resistance]	0.0	2	1	1	1
70927	1710	functional element include binding site	[functional elements including binding sites]	0.0	5	1	1	1
70928	1710	only use bacterial constituent	[only using bacterial constituents]	0.0	4	1	1	1
70929	1710	encode b-binding-proteins use the yeast system	[encoding B-binding-proteins using the yeast system]	0.0	6	1	1	1
70930	1710	level of mrna for chemotactic protein-1	[levels of mRNA for chemotactic protein-1]	0.0	6	1	1	1
70931	1710	unicellular-unilineage erythropoietic culture analysis	[Unicellular-unilineage erythropoietic cultures analysis]	0.0	4	1	1	1
70932	1710	tight control of production	[tight control of production]	0.0	4	1	1	1
70933	1710	thymocyte with autologous cell	[thymocytes with autologous cells]	0.0	4	1	1	1
70934	1710	kappa e3'	[kappa E3']	0.0	2	1	1	1
70935	1710	transcription factor pilot	[transcription factor PILOT]	0.0	3	1	1	1
70936	1710	memory response	[memory response]	0.0	2	1	1	1
70937	1710	kda repressor protein	[kDA repressor protein]	0.0	3	1	1	1
70938	1710	result of trial	[results of trials]	0.0	3	1	1	1
70939	1710	atra case	[ATRA cases]	0.0	2	1	1	1
70940	1710	only level of amplification	[only levels of amplification]	0.0	4	1	1	1
70941	1710	host defense in the lung	[host defense in the lung]	0.0	5	1	1	1
70942	1710	effect on nf-kappab activation	[effect on NF-kappaB activation]	0.0	4	1	1	1
70943	1710	degree (or lack	[degree (or lack]	0.0	3	1	1	1
70944	1710	overexpression in some cell line	[Overexpression in some cell lines]	0.0	5	1	1	1
70945	1710	mimetic molecule	[mimetic molecule]	0.0	2	1	1	1
70946	1710	antitumour DNA topoisomerase inhibitor with mechanism	[antitumour DNA topoisomerase inhibitors with mechanisms]	0.0	6	1	1	1
70947	1710	151 bp of 5'-flanking sequence	[151 bp of 5'-flanking sequences]	0.0	5	1	1	1
70948	1710	many problem	[many problems.]	0.0	2	1	1	1
70949	1710	displacement implication for specificity	[Displacement implications for specificity]	0.0	4	1	1	1
70950	1710	incubation of cell with oleate	[Incubation of cells with oleate]	0.0	5	1	1	1
70951	1710	include nf- il-6	[including NF- IL-6]	0.0	3	1	1	1
70952	1710	blood-derived monocyte pbm	[blood-derived monocytes PBM]	0.0	3	1	1	1
70953	1710	mouse to infection	[mice to infection]	0.0	3	1	1	1
70954	1710	suggest marker	[suggesting markers]	0.0	2	1	1	1
70955	1710	defective translocation of this receptor,	[defective translocation of this receptor,]	0.0	5	1	1	1
70956	1710	several site	[several sites]	0.0	2	1	1	1
70957	1710	cd3+cd28-induced interleukin-2 production	[CD3+CD28-induced interleukin-2 production]	0.0	3	1	1	1
70958	1710	myeloid differentiation a novel model	[myeloid differentiation a novel model]	0.0	5	1	1	1
70959	1710	cDNA sequence tag from thymocyte cell	[cDNA sequence tags from thymocyte cells]	0.0	6	1	1	1
70960	1710	addition to the culture medium	[addition to the culture medium]	0.0	5	1	1	1
70961	1710	injection to adult mouse	[Injection to adult mice]	0.0	4	1	1	1
70962	1710	t- chronic leukemia arise	[T- chronic leukemias arising]	0.0	4	1	1	1
70963	1710	immunoreaction MLR	[immunoreactions MLR]	0.0	2	1	1	1
70964	1710	cyp1a1 gene expression in human cell	[CYP1A1 gene expression in human cells]	0.0	6	1	1	1
70965	1710	adhesion molecule-1 induction by PMA	[adhesion molecule-1 induction by PMA]	0.0	5	1	1	1
70966	1710	ICK-1A	[ICK-1A]	0.0	1	1	1	1
70967	1710	gata-1 allele, consequently lead to severity	[GATA-1 allele, consequently leading to severity]	0.0	6	1	1	1
70968	1710	erythroid-lineage cell	[erythroid-lineage cells]	0.0	2	1	1	1
70969	1710	similar susceptibility with respect	[similar susceptibility with respect]	0.0	4	1	1	1
70970	1710	characteristic marker of u-937 cell differentiation	[characteristic markers of U-937 cell differentiation]	0.0	6	1	1	1
70971	1710	transactivation capacity of nuclear factor	[transactivation capacity of nuclear factor]	0.0	5	1	1	1
70972	1710	patient with lupus erythematosus sle	[patients with lupus erythematosus SLE]	0.0	5	3	3	1
70973	1710	leukocyte pmn adhesion to huvec	[leukocyte PMN adhesion to HUVECs]	0.0	5	1	1	1
70974	1710	T cell line CTLL-2	[T cell line CTLL-2]	0.0	4	1	1	1
70975	1710	essential rise	[essential rise]	0.0	2	1	1	1
70976	1710	ica-positive relative	[ICA-positive relatives]	0.0	2	1	1	1
70977	1710	change in immunophilin	[changes in immunophilins]	0.0	3	1	1	1
70978	1710	repeat DR of bp	[repeats DR of bp]	0.0	4	1	1	1
70979	1710	3 time	[3 times]	0.0	2	1	1	1
70980	1710	latent, transformation-associated viral gene	[latent, transformation-associated viral genes]	0.0	4	1	1	1
70981	1710	NF-kappaB effect of FCM	[NF-kappaB effect of FCM]	0.0	4	1	1	1
70982	1710	hypothesis nuclear factor	[hypothesis nuclear factors]	0.0	3	1	1	1
70983	1710	limited requirement in this system.	[limited requirement in this system.]	0.0	5	1	1	1
70984	1710	heavy-chain igh gene rearrangement	[heavy-chain IgH gene rearrangement]	0.0	4	1	1	1
70985	1710	TNFalpha nfkappab activity	[TNFalpha NFkappaB activity]	0.0	3	1	1	1
70986	1710	domain with transmembrane segment	[domain with transmembrane segments]	0.0	4	1	1	1
70987	1710	integrin beta	[integrin beta]	0.0	2	1	1	1
70988	1710	15- reduction in expression	[15- reduction in expression]	0.0	4	1	1	1
70989	1710	human leukemic t-cell line	[human leukemic T-cell line]	0.0	4	1	1	1
70990	1710	inducer of ifn-gamma gene expression	[inducers of IFN-gamma gene expression]	0.0	5	1	1	1
70991	1710	IgE germline promoter	[IgE germline promoter]	0.0	3	1	1	1
70992	1710	method of study: for assessment	[METHOD OF STUDY: For assessment]	0.0	5	1	1	1
70993	1710	huvec protein	[HUVEC proteins]	0.0	2	1	1	1
70994	1710	concentration of antioxidant	[concentrations of antioxidants]	0.0	3	1	1	1
70995	1710	nf-y activity	[NF-Y activity]	0.0	2	1	1	1
70996	1710	factor kappa b NF kappa b	[factor kappa B NF kappa B]	0.0	6	1	1	1
70997	1710	ligand binding affinity of receptor	[ligand binding affinities of receptors]	0.0	5	1	1	1
70998	1710	cell clone express level	[cell clones expressing levels]	0.0	4	1	1	1
70999	1710	regulation in primary human T lymphocyte	[regulation in primary human T lymphocytes]	0.0	6	1	1	1
71000	1710	1 aneusomy	[1 aneusomy]	0.0	2	1	1	1
71001	1710	prolonged exposure of human aortic cell	[prolonged exposure of human aortic cells]	0.0	6	1	1	1
71002	1710	mechanism involve factor	[mechanism involving factor]	0.0	3	1	1	1
71003	1710	number (6500+/-1001	[number (6500+/-1001]	0.0	2	1	1	1
71004	1710	kappab activity	[kappaB activity]	0.0	2	1	1	1
71005	1710	aiolo transcription	[Aiolos transcription]	0.0	2	1	1	1
71006	1710	drug on hiv-1	[drugs on HIV-1]	0.0	3	1	1	1
71007	1710	b1 vitellogenin gene	[B1 vitellogenin gene]	0.0	3	1	1	1
71008	1710	expression of physiological level	[expression of physiological levels]	0.0	4	1	1	1
71009	1710	mutation at site	[Mutations at sites]	0.0	3	1	1	1
71010	1710	role maintain a load	[role maintaining a load]	0.0	4	1	1	1
71011	1710	bovine artery cell from oxidant injury	[bovine artery cells from oxidant injury]	0.0	6	1	1	1
71012	1710	(up to +/-	[(up to +/-]	0.0	3	1	1	1
71013	1710	Chr 20 centromere	[Chr 20 centromere]	0.0	3	1	1	1
71014	1710	strategy like the one	[strategy like the one]	0.0	4	1	1	1
71015	1710	second abnormality	[second abnormality]	0.0	2	1	1	1
71016	1710	IL-4 region	[IL-4 regions]	0.0	2	1	1	1
71017	1710	anti- il-6 monoclonal antibody	[anti- IL-6 monoclonal antibody]	0.0	4	1	1	1
71018	1710	hil-4r alpha	[hIL-4R alpha]	0.0	2	1	1	1
71019	1710	point toward defect in the activation	[pointing toward defects in the activation]	0.0	6	1	1	1
71020	1710	T cell line molt-4	[T cell line Molt-4]	0.0	4	1	1	1
71021	1710	context of enhancer-binding protein	[context of enhancer-binding proteins]	0.0	4	1	1	1
71022	1710	g-protein-coupled chemoattractant receptor	[G-protein-coupled chemoattractant receptors]	0.0	3	1	1	1
71023	1710	human colony-stimulating factor receptor g-csf-r	[human colony-stimulating factor receptor G-CSF-R]	0.0	5	1	1	1
71024	1710	cells; ubiquitously active factor	[cells; ubiquitously active factors]	0.0	4	1	1	1
71025	1710	expression of cell surface antigen	[expression of cell surface antigens]	0.0	5	1	1	1
71026	1710	mechanism change of the receptor.	[Mechanism changes of the receptor.]	0.0	5	1	1	1
71027	1710	low ifn-gamma level	[low IFN-gamma levels]	0.0	3	1	1	1
71028	1710	property of the ion.	[properties of the ion.]	0.0	4	1	1	1
71029	1710	erythrocyte in the blood	[erythrocytes in the blood]	0.0	4	1	1	1
71030	1710	family A-myb	[family A-myb]	0.0	2	1	1	1
71031	1710	rna splice of basis	[RNA splice of bases]	0.0	4	1	1	1
71032	1710	form of Ig chain	[form of Ig chain]	0.0	4	1	1	1
71033	1710	concurrent addition (in the form	[concurrent addition (in the form]	0.0	5	1	1	1
71034	1710	(bcp-all)	[(BCP-ALL)]	0.0	1	1	1	1
71035	1710	acquisition of feature	[acquisition of features]	0.0	3	1	1	1
71036	1710	significantly (p<.001) in untreated euthymic patient	[significantly (P<.001) in untreated euthymic patients]	0.0	6	1	1	1
71037	1710	cellular 25(oh)d3 uptake	[cellular 25(OH)D3 uptake]	0.0	3	1	1	1
71038	1710	lymphoma precursor	[lymphoma precursor]	0.0	2	1	1	1
71039	1710	t-lineage lymphocyte	[T-lineage lymphocytes]	0.0	2	1	1	1
71040	1710	phenolic, antioxidant	[phenolic, antioxidant]	0.0	2	1	1	1
71041	1710	transcription-3 STAT3	[transcription-3 STAT3]	0.0	2	1	1	1
71042	1710	series: at normal subject	[series: at normal subjects]	0.0	4	1	1	1
71043	1710	study of mouse	[study of mice]	0.0	3	1	1	1
71044	1710	implicate the involvement	[implicating the involvement]	0.0	3	1	1	1
71045	1710	search Ag for potential protein segment	[searching Ag for potential protein segments]	0.0	6	1	1	1
71046	1710	interferon (ifn) consensus	[interferon (IFN) consensus]	0.0	3	1	1	1
71047	1710	viral reverse transcriptase	[viral reverse transcriptase]	0.0	3	1	1	1
71048	1710	Comparison with response	[Comparison with responses]	0.0	3	1	1	1
71049	1710	form of mzf protein mzf-2	[form of MZF protein MZF-2]	0.0	5	1	1	1
71050	1710	induce characteristic of b cell	[inducing characteristics of B cells]	0.0	5	1	1	1
71051	1710	vitamin d -resistant cell extract	[vitamin D -resistant cell extract]	0.0	5	1	1	1
71052	1710	anti-sense	[anti-sense]	0.0	1	1	1	1
71053	1710	antigen anti-viral capsid antigen	[antigen anti-viral capsid antigen]	0.0	4	1	1	1
71054	1710	downstream parathyroid hormone-related protein promoter	[downstream parathyroid hormone-related protein promoter]	0.0	5	1	1	1
71055	1710	72-kilodalton major protein	[72-kilodalton major protein]	0.0	3	1	1	1
71056	1710	ability of nuclear receptor	[ability of nuclear receptors]	0.0	4	1	1	1
71057	1710	CMV immediate gene product expression	[CMV immediate gene product expression]	0.0	5	1	1	1
71058	1710	activation ie, the expression	[activation ie, the expression]	0.0	4	1	1	1
71059	1710	new target	[new targets]	0.0	2	1	1	1
71060	1710	individual from the group),	[individuals from the group),]	0.0	4	1	1	1
71061	1710	moreover, transfection of Daudi cell	[Moreover, transfection of Daudi cells]	0.0	5	1	1	1
71062	1710	h post-PMA	[h post-PMA]	0.0	2	1	1	1
71063	1710	symbiotic, relationship in tonsil	[symbiotic, relationship in tonsils]	0.0	4	1	1	1
71064	1710	eosinophilic inflammation of asthma	[eosinophilic inflammation of asthma]	0.0	4	2	2	1
71065	1710	chromogenic assay	[chromogenic assay]	0.0	2	1	1	1
71066	1710	interaction with human vein cell	[interaction with human vein cells]	0.0	5	1	1	1
71067	1710	such as mg2+	[such as Mg2+]	0.0	3	1	1	1
71068	1710	entry of hiv cell	[entry of HIV cells]	0.0	4	1	1	1
71069	1710	vitronectin receptor VR	[vitronectin receptor VR]	0.0	3	1	1	1
71070	1710	protein for NF kappa b	[protein for NF kappa B]	0.0	5	1	1	1
71071	1710	receive 5-fluorouracil	[receiving 5-fluorouracil]	0.0	2	1	1	1
71072	1710	equivalent increase in calcium ion	[equivalent increase in calcium ions]	0.0	5	1	1	1
71073	1710	immune response with agent	[immune response with agents]	0.0	4	1	1	1
71074	1710	1 receptor superfamily	[1 receptor superfamily]	0.0	3	1	1	1
71075	1710	phosphatase-positive multinucleated giant cell	[phosphatase-positive multinucleated giant cells]	0.0	4	1	1	1
71076	1710	exposure of endothelial cell	[exposure of endothelial cells]	0.0	4	1	1	1
71077	1710	activation of transcriptional protein	[activation of transcriptional proteins]	0.0	4	1	1	1
71078	1710	Ras signal	[Ras signaling]	0.0	2	1	1	1
71079	1710	bzlf cell lysate	[BZLF cell lysates]	0.0	3	1	1	1
71080	1710	function of ability	[function of ability]	0.0	3	1	1	1
71081	1710	ligation by abs ligand	[Ligation by Abs ligand]	0.0	4	1	1	1
71082	1710	adhesion molecule in endothelial cell	[adhesion molecules in endothelial cells]	0.0	5	1	1	1
71083	1710	(il-2rbeta)/il-4ralpha	[(IL-2Rbeta)/IL-4Ralpha]	0.0	1	1	1	1
71084	1710	infectivity.	[infectivity.]	0.0	1	1	1	1
71085	1710	course of pathogenic infections.	[course of pathogenic infections.]	0.0	4	1	1	1
71086	1710	b activity a preliminary report.	[B activity a preliminary report.]	0.0	5	1	1	1
71087	1710	intrahepatic lymphoid follicle ILF	[Intrahepatic lymphoid follicle ILF]	0.0	4	1	1	1
71088	1710	requirement for c-myb	[requirement for c-Myb]	0.0	3	1	1	1
71089	1710	fmol/mg protein (mean of independent assays),	[fmol/mg protein (mean of independent assays),]	0.0	6	1	1	1
71090	1710	involvement of phosphatidylinositol 3-kinase	[Involvement of phosphatidylinositol 3-kinase]	0.0	4	1	1	1
71091	1710	Culture in m 9-cis RA together	[Culture in M 9-cis RA together]	0.0	6	1	1	1
71092	1710	hence translocation	[hence translocation]	0.0	2	1	1	1
71093	1710	12-0-tetradecanoyl phorbol-13-acetate for h	[12-0-tetradecanoyl phorbol-13-acetate for h]	0.0	4	1	1	1
71094	1710	regulation of cell adhesion molecule-1 vcam-1	[regulation of cell adhesion molecule-1 VCAM-1]	0.0	6	1	1	1
71095	1710	major complex class ii	[major complex class II]	0.0	4	1	1	1
71096	1710	case of cell lymphoma	[cases of cell lymphomas]	0.0	4	1	1	1
71097	1710	factor in normal human monocyte	[factor in normal human monocytes]	0.0	5	1	1	1
71098	1710	untrained male volunteer	[untrained male volunteers]	0.0	3	1	1	1
71099	1710	effect on vcam-1 expression	[effect on VCAM-1 expression]	0.0	4	1	1	1
71100	1710	significantly (p<.001)	[significantly (P<.001)]	0.0	2	1	1	1
71101	1710	regulatory protein nf-kappab	[regulatory protein NF-kappaB]	0.0	3	1	1	1
71102	1710	lps concentration	[LPS concentrations]	0.0	2	1	1	1
71103	1710	protein-DNA interaction assay	[protein-DNA interaction assays]	0.0	3	1	1	1
71104	1710	clinical responsiveness less than 0.01).	[clinical responsiveness less than 0.01).]	0.0	5	1	1	1
71105	1710	human nm23 -h1	[human nm23 -H1]	0.0	3	1	1	1
71106	1710	sign of illness	[signs of illness]	0.0	3	1	1	1
71107	1710	15 day	[15 days]	0.0	2	1	1	1
71108	1710	Study with vein segment	[Studies with vein segments]	0.0	4	1	1	1
71109	1710	il-5 expression	[IL-5 expression]	0.0	2	1	1	1
71110	1710	murine interleukin (il)-2	[murine interleukin (IL)-2]	0.0	3	1	1	1
71111	1710	(b) conjugation to the precursor	[(b) conjugation to the precursor]	0.0	5	1	1	1
71112	1710	early mouse development in system	[early mouse development in system]	0.0	5	1	1	1
71113	1710	myeloid-cell-specific gene such as fibroblast	[myeloid-cell-specific genes such as fibroblasts]	0.0	5	1	1	1
71114	1710	femaless with the syndromee	[females) with the syndrome.]	0.0	4	1	1	1
71115	1710	induce fasL reporter construct	[inducing fasL reporter constructs]	0.0	4	1	1	1
71116	1710	structure of the end	[structure of the end]	0.0	4	1	1	1
71117	1710	type interferon ifn-gamma	[type interferon IFN-gamma]	0.0	3	1	1	1
71118	1710	loss of tgf-beta growth inhibition	[loss of TGF-beta growth inhibition]	0.0	5	1	1	1
71119	1710	element binding protein	[element binding protein]	0.0	3	1	1	1
71120	1710	element in the IL-4 promoter	[element in the IL-4 promoter]	0.0	5	1	1	1
71121	1710	lipopolysaccharide lps activation system	[lipopolysaccharide LPS activation system]	0.0	4	1	1	1
71122	1710	cytoplasmic protein extract	[Cytoplasmic protein extracts]	0.0	3	1	1	1
71123	1710	mechanism of gc of dose	[mechanisms of GC of doses]	0.0	5	1	1	1
71124	1710	patient with acute myeloid leukaemia	[patients with acute myeloid leukaemia]	0.0	5	1	1	1
71125	1710	dimerization of NF-KB2	[Dimerization of NF-KB2]	0.0	3	1	1	1
71126	1710	dexamethasone test	[dexamethasone test]	0.0	2	1	1	1
71127	1710	copyright by the Society	[Copyright by The Society]	0.0	4	2	2	1
71128	1710	factor (NF)-AT NF-AT AP-1/Octamer UPS	[factor (NF)-AT NF-AT AP-1/Octamer UPS]	0.0	5	1	1	1
71129	1710	produce p40	[producing p40]	0.0	2	1	1	1
71130	1710	replication human immunodeficiency virus	[Replication human immunodeficiency viruses]	0.0	4	1	1	1
71131	1710	dephosphorylation of zap-70	[Dephosphorylation of ZAP-70]	0.0	3	1	1	1
71132	1710	position on the molecule.	[position on the molecule.]	0.0	4	1	1	1
71133	1710	serve	[serving]	0.0	1	1	1	1
71134	1710	profound implication	[profound implication]	0.0	2	1	1	1
71135	1710	oligonucleotide homologous to each	[oligonucleotides homologous to each]	0.0	4	1	1	1
71136	1710	addition to the isoform	[addition to the isoform]	0.0	4	1	1	1
71137	1710	novel disulfide-linked dimer	[novel disulfide-linked dimer]	0.0	3	1	1	1
71138	1710	type ikk2	[type IKK2]	0.0	2	1	1	1
71139	1710	(monocytoid) b	[(monocytoid) B]	0.0	2	1	1	1
71140	1710	action between a element CPRE	[action between an element CPRE]	0.0	5	1	1	1
71141	1710	METHODS: during a placebo-controlled crossover study	[METHODS: During a placebo-controlled crossover study]	0.0	6	1	1	1
71142	1710	such as adult distress syndrome ards	[such as adult distress syndrome ARDS]	0.0	6	1	1	1
71143	1710	Antisense oligonucleotide	[Antisense oligonucleotides]	0.0	2	1	1	1
71144	1710	effect of udg	[effect of UDG]	0.0	3	1	1	1
71145	1710	increase half-life	[increasing half-life]	0.0	2	1	1	1
71146	1710	reverse transcriptase-polymerase chain reaction	[reverse transcriptase-polymerase chain reaction]	0.0	4	1	1	1
71147	1710	role of p38	[role of p38]	0.0	3	1	1	1
71148	1710	two activator RelA	[two activators RelA]	0.0	3	1	1	1
71149	1710	simian virus enhancer	[simian virus enhancer]	0.0	3	1	1	1
71150	1710	map kinase kinase-3 a activator	[MAP kinase kinase-3 a activator]	0.0	5	1	1	1
71151	1710	exception of one patient	[exception of one patient]	0.0	4	1	1	1
71152	1710	tyrosine within the region y145	[tyrosine within the region Y145]	0.0	5	1	1	1
71153	1710	er associate	[ER associate]	0.0	2	1	1	1
71154	1710	B7-independent T cell	[B7-independent T cell]	0.0	3	1	1	1
71155	1710	typical inflammation	[typical inflammation]	0.0	2	1	1	1
71156	1710	mature double-positive population	[mature double-positive populations]	0.0	3	1	1	1
71157	1710	transcription 3 Stat3	[transcription 3 Stat3]	0.0	3	1	1	1
71158	1710	target in ebv cell	[targets in EBV cells]	0.0	4	1	1	1
71159	1710	previously unrecognized mechanism regulate sensitivity	[previously unrecognized mechanism regulating sensitivity]	0.0	5	1	1	1
71160	1710	number of immunoregulatory gene	[number of immunoregulatory genes]	0.0	4	1	1	1
71161	1710	follow resection of the ileum	[following resection of the ileum]	0.0	5	1	1	1
71162	1710	hdmec thp-1 cell	[HDMEC THP-1 cells]	0.0	3	1	1	1
71163	1710	neutralize tumor necrosis factor	[neutralizing tumor necrosis factor]	0.0	4	1	1	1
71164	1710	healthy woman (11	[healthy women (11]	0.0	3	1	1	1
71165	1710	twin pair	[twin pair]	0.0	2	1	1	1
71166	1710	low risk control	[low risk controls]	0.0	3	1	1	1
71167	1710	sensitive blot assay	[sensitive blot assay]	0.0	3	1	1	1
71168	1710	binding of ligand	[binding of ligands]	0.0	3	1	1	1
71169	1710	sufficient th2 cell differentiation	[sufficient Th2 cell differentiation]	0.0	4	1	1	1
71170	1710	selective reduction	[selective reduction]	0.0	2	1	1	1
71171	1710	TNF-alpha hiv-1 long repeat LTR	[TNF-alpha HIV-1 long repeat LTR]	0.0	5	1	1	1
71172	1710	gene expression of monocyte protein-1	[gene expression of monocyte protein-1]	0.0	5	1	1	1
71173	1710	all-tran acid treatment in leukemia	[all-trans acid treatment in leukemia]	0.0	5	1	1	1
71174	1710	fetal hemoglobin production	[fetal hemoglobin production]	0.0	3	1	1	1
71175	1710	TNFR superfamily	[TNFR superfamily]	0.0	2	2	2	1
71176	1710	parva-transformed T	[parva-transformed T]	0.0	2	2	2	1
71177	1710	classical features: implications.	[classical features: implications.]	0.0	3	1	1	1
71178	1710	very low dissociation constant	[very low dissociation constant]	0.0	4	1	1	1
71179	1710	new group of eukaryotic protein	[new group of eukaryotic proteins]	0.0	5	1	1	1
71180	1710	elastase inhibitor peptide	[elastase inhibitor peptide]	0.0	3	1	1	1
71181	1710	initiation by RNA polymerase ii	[initiation by RNA polymerase II]	0.0	5	1	1	1
71182	1710	T enhancer of cd3-epsilon.	[T enhancer of CD3-epsilon.]	0.0	4	1	1	1
71183	1710	analysis apoptosis in CD4 receptor	[analysis apoptosis in CD4 receptors]	0.0	5	1	1	1
71184	1710	variant of nephrotic syndrome	[variants of nephrotic syndrome]	0.0	4	1	1	1
71185	1710	2 subunit CBF alpha	[2 subunit CBF alpha]	0.0	4	1	1	1
71186	1710	effect of tnf	[effects of TNF]	0.0	3	1	1	1
71187	1710	activator META	[activator META]	0.0	2	1	1	1
71188	1710	level of protein kinase	[levels of protein kinase]	0.0	4	1	1	1
71189	1710	requirement for this c-jun response,	[requirements for this c-Jun response,]	0.0	5	1	1	1
71190	1710	striking downregulation	[striking downregulation]	0.0	2	1	1	1
71191	1710	hypermutation in lymphoma (25 of 59	[hypermutation in lymphoma (25 of 59]	0.0	6	1	1	1
71192	1710	atf/creb	[ATF/CREB]	0.0	1	1	1	1
71193	1710	transgene dose-dependent reduction	[transgene dose-dependent reduction]	0.0	3	1	1	1
71194	1710	nf-at transactivation	[NF-AT transactivation]	0.0	2	1	1	1
71195	1710	Erythropoietin the regulator	[Erythropoietin the regulator]	0.0	3	1	1	1
71196	1710	study in immunodeficiency virus patient	[studies in immunodeficiency virus patients]	0.0	5	1	1	1
71197	1710	serca	[SERCA]	0.0	1	1	1	1
71198	1710	anti-cd3 monoclonal antibody t-cell proliferation	[anti-CD3 monoclonal antibody T-cell proliferation]	0.0	5	1	1	1
71199	1710	domain act in actin polymerization	[domains acting in actin polymerization]	0.0	5	1	1	1
71200	1710	overcome block	[overcoming blocks]	0.0	2	1	1	1
71201	1710	transcription factor of the nfat	[Transcription factors of the NFAT]	0.0	5	1	1	1
71202	1710	postcapillary venule	[postcapillary venules]	0.0	2	1	1	1
71203	1710	inhibition by the AMP signal pathway	[Inhibition by the AMP signaling pathway]	0.0	6	1	1	1
71204	1710	cell malignancy	[cell malignancies]	0.0	2	1	1	1
71205	1710	underlie the il-7 effect	[underlying the IL-7 effect]	0.0	4	1	1	1
71206	1710	similar, high affinity binding	[similar, high affinity binding]	0.0	4	1	1	1
71207	1710	generation of family	[generations of families]	0.0	3	1	1	1
71208	1710	rante promoter activity	[RANTES promoter activity]	0.0	3	1	1	1
71209	1710	homo- stat1 alpha	[homo- STAT1 alpha]	0.0	3	1	1	1
71210	1710	receptor (tcr)	[receptor (TCR)]	0.0	2	1	1	1
71211	1710	exposure of human aortic endothelial cell	[exposure of human aortic endothelial cells]	0.0	6	1	1	1
71212	1710	interferon factor 2 gene	[interferon factor 2 gene]	0.0	4	1	1	1
71213	1710	amount of nf-kappa b binding proteins,	[amounts of NF-kappa B binding proteins,]	0.0	6	1	1	1
71214	1710	involvement of a protein	[involvement of an protein]	0.0	4	1	1	1
71215	1710	component of the anti-inflammatory activity	[component of the anti-inflammatory activity]	0.0	5	1	1	1
71216	1710	interaction with ligand LFA-3	[interaction with ligand LFA-3]	0.0	4	1	1	1
71217	1710	important role in inducible expression	[important role in inducible expression]	0.0	5	1	1	1
71218	1710	sign of dysplasia	[signs of dysplasia]	0.0	3	1	1	1
71219	1710	growth factor-beta family	[growth factor-beta family]	0.0	3	1	1	1
71220	1710	description of a agent	[description of an agent]	0.0	4	1	1	1
71221	1710	il-5 t-cell clone	[IL-5 T-cell clones]	0.0	3	1	1	1
71222	1710	identification of recurrent abnormality	[identification of recurrent abnormalities]	0.0	4	1	1	1
71223	1710	treatment of gp160	[treatment of gp160]	0.0	3	1	1	1
71224	1710	86 woman with mpd	[86 women with MPDs]	0.0	4	1	1	1
71225	1710	only in a weak reactivation	[only in a weak reactivation]	0.0	5	1	1	1
71226	1710	low mobility ap-1	[low mobility AP-1]	0.0	3	1	1	1
71227	1710	recombinant nfatp	[recombinant NFATp]	0.0	2	1	1	1
71228	1710	dnase 1 hypersensitivity	[DNase 1 hypersensitivity]	0.0	3	1	1	1
71229	1710	regulator of the transcription factor	[regulators of the transcription factor]	0.0	5	1	1	1
71230	1710	class DNA binding factor	[class DNA binding factors]	0.0	4	1	1	1
71231	1710	hpc potential colony-forming cell hppecfcs	[HPCs potential colony-forming cells HPP-CFCs]	0.0	5	1	1	1
71232	1710	137c gamma ray	[137Cs gamma rays]	0.0	3	1	1	1
71233	1710	methylation I site	[Methylation I sites]	0.0	3	1	1	1
71234	1710	relative under-representation	[Relative under-representation]	0.0	2	1	1	1
71235	1710	significative change	[significative changes]	0.0	2	1	1	1
71236	1710	specific protein myeloperoxidase	[specific proteins myeloperoxidase]	0.0	3	1	1	1
71237	1710	nuclear translocation of protein kinase	[nuclear translocation of protein kinase]	0.0	5	1	1	1
71238	1710	commitment step	[commitment step]	0.0	2	1	1	1
71239	1710	requirement for oxidative event	[requirement for oxidative events]	0.0	4	1	1	1
71240	1710	other b cell-encoded gene	[other B cell-encoded genes]	0.0	4	1	1	1
71241	1710	18 unrelated case of tsc	[18 unrelated cases of TSC]	0.0	5	1	1	1
71242	1710	effect of gp130	[effect of gp130]	0.0	3	1	1	1
71243	1710	translational level	[translational level]	0.0	2	2	2	1
71244	1710	flexi-12 delivery to blast	[Flexi-12 delivery to blasts]	0.0	4	1	1	1
71245	1710	role initiate t-cell activation	[role initiating T-cell activation]	0.0	4	1	1	1
71246	1710	killer population	[killer populations]	0.0	2	1	1	1
71247	1710	80.2 (p less than 0.05, p	[80.2 (P less than 0.05, P]	0.0	6	1	1	1
71248	1710	Theileria parva	[Theileria parva]	0.0	2	1	1	1
71249	1710	regulate the expression of t-cell gene	[regulating the expression of T-cell genes]	0.0	6	1	1	1
71250	1710	agonist activity in tissue	[agonist activity in tissue]	0.0	4	1	1	1
71251	1710	pulmonary macrophage	[pulmonary macrophages]	0.0	2	1	1	1
71252	1710	activation nf-kappa b	[activation NF-kappa B]	0.0	3	1	1	1
71253	1710	non-PRL-secreting cell	[non-PRL-secreting cells]	0.0	2	1	1	1
71254	1710	anti- ap-1 -binding activity in cell	[anti- AP-1 -binding activity in cells]	0.0	6	1	1	1
71255	1710	role of NF-kappa b dimerization	[role of NF-kappa B dimerization]	0.0	5	1	1	1
71256	1710	several potential pathway for tissue damage	[several potential pathways for tissue damage]	0.0	6	1	1	1
71257	1710	v-abl kinase	[v-Abl kinase]	0.0	2	1	1	1
71258	1710	pharmacokinetic	[Pharmacokinetic]	0.0	1	1	1	1
71259	1710	two distinguishable gr abnormalities: 15	[two distinguishable GR abnormalities: 15]	0.0	5	1	1	1
71260	1710	cd8+ leukocyte	[CD8+ leukocytes]	0.0	2	1	1	1
71261	1710	stage of b-lymphocyte	[stages of B-lymphocyte]	0.0	3	1	1	1
71262	1710	immunodeficiency virus type 1 hiv	[immunodeficiency virus type 1 HIV]	0.0	5	1	1	1
71263	1710	enhancement of potency of this compound	[enhancement of potency of these compounds]	0.0	6	1	1	1
71264	1710	take change	[taking changes]	0.0	2	1	1	1
71265	1710	free tissue damage	[free tissue damage]	0.0	3	1	1	1
71266	1710	thp-1 a cell line	[THP-1 a cell line]	0.0	4	1	1	1
71267	1710	prointerleukin 1	[prointerleukin 1]	0.0	2	1	1	1
71268	1710	vascular adhesion molecule-1	[vascular adhesion molecule-1]	0.0	3	1	1	1
71269	1710	oxidation of SMX to metabolite	[oxidation of SMX to metabolites]	0.0	5	1	1	1
71270	1710	mol/L 9-cis RA (12 hours)	[mol/L 9-cis RA (12 hours)]	0.0	5	1	1	1
71271	1710	effect of gp160	[effect of gp160]	0.0	3	3	3	1
71272	1710	DC rdna	[DC cDNAs]	0.0	2	1	1	1
71273	1710	dual color	[dual color]	0.0	2	1	1	1
71274	1710	include interferon-gamma ifn-gamma	[including interferon-gamma IFN-gamma]	0.0	3	1	1	1
71275	1710	same time.	[same time.]	0.0	2	1	1	1
71276	1710	pivotal role of RXR	[pivotal role of RXR]	0.0	4	1	1	1
71277	1710	role on gr activation	[role on GR activation]	0.0	4	1	1	1
71278	1710	shift follow pkc activation	[shift following PKC activation]	0.0	4	1	1	1
71279	1710	1.16 arbitrary units, p	[1.16 arbitrary units, P]	0.0	4	1	1	1
71280	1710	increase in hiv production	[increase in HIV production]	0.0	4	1	1	1
71281	1710	central role in regulation	[central role in regulation]	0.0	4	1	1	1
71282	1710	effect gene expression	[effects gene expression]	0.0	3	1	1	1
71283	1710	20- great affinity consistent	[20- greater affinity consistent]	0.0	4	1	1	1
71284	1710	three DNA binding complex	[three DNA binding complexes]	0.0	4	1	1	1
71285	1710	GrpL a Grb2 adaptor protein	[GrpL a Grb2 adaptor protein]	0.0	5	1	1	1
71286	1710	retinoic acid on embryonic/fetal hematopoiesis	[retinoic acid on embryonic/fetal hematopoiesis]	0.0	5	1	1	1
71287	1710	rest human vein cell HUVEC	[resting human vein cells HUVEC]	0.0	5	1	1	1
71288	1710	/monocytic hpc growth	[/monocytic HPC growth]	0.0	3	1	1	1
71289	1710	Differential regulation a comparative study	[Differential regulation a comparative study]	0.0	5	1	1	1
71290	1710	expression a human homeobox gene	[expression a human homeobox gene]	0.0	5	1	1	1
71291	1710	pathway for mineralocorticoid action	[pathway for mineralocorticoid action]	0.0	4	1	1	1
71292	1710	gel shift datum	[gel shift data.]	0.0	3	1	1	1
71293	1710	tight complex	[tight complex]	0.0	2	2	2	1
71294	1710	differentiate agent acid RA	[differentiating agent acid RA]	0.0	4	1	1	1
71295	1710	dimethylsulfoxide dmso	[dimethylsulfoxide DMSO]	0.0	2	1	1	1
71296	1710	region of the protein	[region of the protein]	0.0	4	1	1	1
71297	1710	property of stage cell	[properties of stage cells]	0.0	4	1	1	1
71298	1710	target binding in vitro.	[target binding in vitro.]	0.0	4	1	1	1
71299	1710	pu.1 function as activator	[PU.1 function as activators]	0.0	4	1	1	1
71300	1710	alter weak, interaction	[altering weak, interactions]	0.0	3	1	1	1
71301	1710	oxidant activity.	[oxidant activity.]	0.0	2	1	1	1
71302	1710	inducible binding of nf-kappab heterodimer	[inducible binding of NF-kappaB heterodimers]	0.0	5	1	1	1
71303	1710	contrast, expression of dominant mutant	[contrast, expression of dominant mutants]	0.0	5	1	1	1
71304	1710	production of cyclin D3	[production of cyclin D3]	0.0	4	1	1	1
71305	1710	pbmc specimen from healthy adult	[PBMC specimens from healthy adults]	0.0	5	2	2	1
71306	1710	dnase site	[DNase site]	0.0	2	1	1	1
71307	1710	malignant fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[malignant fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
71308	1710	pml/rar-alpha peptide	[pml/RAR-alpha peptides]	0.0	2	1	1	1
71309	1710	defective survival of thymocyte	[Defective survival of thymocytes]	0.0	4	1	1	1
71310	1710	Balb/c3T3 cell	[Balb/c3T3 cells]	0.0	2	1	1	1
71311	1710	major property	[major properties]	0.0	2	1	1	1
71312	1710	HBxAg synthetic polypeptide	[HBxAg synthetic polypeptides]	0.0	3	1	1	1
71313	1710	period in myeloid cell	[periods in myeloid cells]	0.0	4	1	1	1
71314	1710	protein kinase family MAPK	[protein kinase family MAPK]	0.0	4	1	1	1
71315	1710	dose-dependence	[Dose-dependence]	0.0	1	1	1	1
71316	1710	molecular mechanism a type of cross-talk	[Molecular mechanisms a type of cross-talk]	0.0	6	1	1	1
71317	1710	nitroblue tetrazolium cell	[nitroblue tetrazolium cells]	0.0	3	1	1	1
71318	1710	(post) sites/cell,	[(post) sites/cell,]	0.0	2	1	1	1
71319	1710	3863 basis	[3863 bases]	0.0	2	1	1	1
71320	1710	other gene related	[other genes related]	0.0	3	1	1	1
71321	1710	active raf-1	[active Raf-1]	0.0	2	1	1	1
71322	1710	development of m-tat cell	[development of M-TAT cells]	0.0	4	1	1	1
71323	1710	CRE reporter	[CRE reporter]	0.0	2	1	1	1
71324	1710	cell basis	[cell basis]	0.0	2	1	1	1
71325	1710	effect on cell	[effects on cells]	0.0	3	1	1	1
71326	1710	internalization of antigen from surface.	[internalization of antigen from surface.]	0.0	5	1	1	1
71327	1710	dependent signal transduction pathway	[dependent signal transduction pathways]	0.0	4	1	1	1
71328	1710	conjunctival biopsy from patient with vkc	[conjunctival biopsies from patients with VKC]	0.0	6	1	1	1
71329	1710	role in erythroid differentiation event	[role in erythroid differentiation events]	0.0	5	1	1	1
71330	1710	enhancement of ifn-gamma production	[enhancement of IFN-gamma production]	0.0	4	1	1	1
71331	1710	class ii transplantation gene	[class II transplantation gene]	0.0	4	1	1	1
71332	1710	constitutive nf-kappab activation	[constitutive NF-kappaB activation]	0.0	3	1	1	1
71333	1710	ubiquitous component within 30 minute	[ubiquitous component within 30 min]	0.0	5	1	1	1
71334	1710	Oct-2 cis-regulatory function element.	[Oct-2 cis-regulatory function element.]	0.0	4	1	1	1
71335	1710	competitive binding profile	[competitive binding profile]	0.0	3	1	1	1
71336	1710	HTLV-1 human T	[HTLV-1 human T]	0.0	3	1	1	1
71337	1710	sensitivity to other, agent	[sensitivity to other, agents]	0.0	4	1	1	1
71338	1710	detectable calm	[detectable CALM]	0.0	2	1	1	1
71339	1710	interferon-gamma in peripheral blood lymphocyte	[interferon-gamma in peripheral blood lymphocytes]	0.0	5	1	1	1
71340	1710	case for tsc2 mutation	[cases for TSC2 mutations]	0.0	4	1	1	1
71341	1710	cytosolic component of the factor	[cytosolic component of the factor]	0.0	5	1	1	1
71342	1710	lipid-soluble, antioxidant	[lipid-soluble, antioxidant]	0.0	2	1	1	1
71343	1710	single point estimation	[Single point estimation]	0.0	3	1	1	1
71344	1710	phase of sepsis	[phase of sepsis]	0.0	3	2	2	1
71345	1710	dimeric activator protein-1	[dimeric activator protein-1]	0.0	3	1	1	1
71346	1710	activator in cell line	[activator in cell lines]	0.0	4	1	1	1
71347	1710	simian CMV by treatment	[simian CMV by treatment]	0.0	4	1	1	1
71348	1710	least six octamer binding protein	[least six octamer binding proteins]	0.0	5	1	1	1
71349	1710	region of PU.1	[region of PU.1]	0.0	3	1	1	1
71350	1710	dna-binding subunit of NF-kappa b	[DNA-binding subunit of NF-kappa B]	0.0	5	1	1	1
71351	1710	suggest a migration of T cell	[suggesting an migration of T cells]	0.0	6	1	1	1
71352	1710	alternative phagocyte	[alternative phagocytes]	0.0	2	1	1	1
71353	1710	(47 repeats),	[(47 repeats),]	0.0	2	1	1	1
71354	1710	potential reading frame orf a	[potential reading frames ORFs A]	0.0	5	1	1	1
71355	1710	express high kinase activity as deficient	[expressing high kinase activity as deficient]	0.0	6	1	1	1
71356	1710	double-label immunogold electron microscopy on cell	[double-labeling immunogold electron microscopy on cells]	0.0	6	1	1	1
71357	1710	intact carboxyl-terminal segment	[intact carboxyl-terminal segment]	0.0	3	1	1	1
71358	1710	induction of Mn sod in monocyte	[Induction of Mn SOD in monocytes]	0.0	6	1	1	1
71359	1710	alpha-methyl-1 alpha,25-(OH)2D3	[alpha-methyl-1 alpha,25-(OH)2D3]	0.0	2	1	1	1
71360	1710	six isomorph by gel analysis	[six isomorphs by gel analysis]	0.0	5	1	1	1
71361	1710	cell adhesion molecule-1 gene	[cell adhesion molecule-1 gene]	0.0	4	2	2	1
71362	1710	(nk) T cell library	[(NK) T cell library]	0.0	4	1	1	1
71363	1710	element 1 tre-1	[element 1 TRE-1]	0.0	3	1	1	1
71364	1710	initial latent gene promoter	[initial latent gene promoter]	0.0	4	1	1	1
71365	1710	Differential activation	[Differential activation]	0.0	2	1	1	1
71366	1710	Spl binding	[Spl binding]	0.0	2	1	1	1
71367	1710	polymorphism to physiological condition	[polymorphism to physiological conditions]	0.0	4	1	1	1
71368	1710	Challenge develop therapeutic strategy	[Challenges developing therapeutic strategies]	0.0	4	1	1	1
71369	1710	recombinant human dimeric tnf receptor	[recombinant human dimeric TNF receptor]	0.0	5	1	1	1
71370	1710	concern the role	[concerning the role]	0.0	3	1	1	1
71371	1710	Pb at relevant concentration	[Pb at relevant concentrations]	0.0	4	1	1	1
71372	1710	islet b cell	[islet B cell]	0.0	3	1	1	1
71373	1710	distinguished: 1) biochemical sign of hypothyroidism	[distinguished: 1) biochemical signs of hypothyroidism]	0.0	6	1	1	1
71374	1710	(1.8 kb)	[(1.8 kb)]	0.0	2	1	1	1
71375	1710	case of bl by immunohistology	[cases of BL by immunohistology]	0.0	5	1	1	1
71376	1710	inducible expression comments]	[Inducible expression comments]]	0.0	3	1	1	1
71377	1710	inhibitory ras mutant	[inhibitory ras mutant]	0.0	3	1	1	1
71378	1710	distinguished: 1) biochemical sign	[distinguished: 1) biochemical signs]	0.0	4	1	1	1
71379	1710	factor kappa B NFkappaB	[Factor kappa B NFkappaB]	0.0	4	1	1	1
71380	1710	one event to cell ECs	[one event to cells ECs]	0.0	5	1	1	1
71381	1710	near-perfect direct repeat of bp	[near-perfect direct repeats of bp]	0.0	5	1	1	1
71382	1710	dna-binding characteristics,	[DNA-binding characteristics,]	0.0	2	1	1	1
71383	1710	expression protein aml1/mds1/evi1	[expression protein AML1/MDS1/EVI1]	0.0	3	1	1	1
71384	1710	woman with spontaneous abortion	[women with spontaneous abortion]	0.0	4	1	1	1
71385	1710	DNasel site within the GM-CSF enhancer	[DNasel sites within the GM-CSF enhancer]	0.0	6	1	1	1
71386	1710	growth response protein egr-1	[growth response protein EGR-1]	0.0	4	1	1	1
71387	1710	similar degree dephosphorylation	[similar degree dephosphorylation]	0.0	3	1	1	1
71388	1710	include fcepsilonriib	[including FcepsilonRIIb]	0.0	2	1	1	1
71389	1710	week (>26	[weeks (>26]	0.0	2	1	1	1
71390	1710	GC box	[GC box]	0.0	2	1	1	1
71391	1710	migration through unstimulated huvec monolayer	[migration through unstimulated HUVEC monolayers]	0.0	5	1	1	1
71392	1710	mg/kg iv	[mg/kg IV]	0.0	2	1	1	1
71393	1710	diacetate	[diacetate]	0.0	1	1	1	1
71394	1710	38 glutamine residue	[38 glutamine residues]	0.0	3	1	1	1
71395	1710	direct sequencing of the genome	[Direct sequencing of the genomes]	0.0	5	1	1	1
71396	1710	stimulation of actin assembly	[stimulation of actin assembly]	0.0	4	1	1	1
71397	1710	there, wild-type clone	[there, wild-type clones]	0.0	3	1	1	1
71398	1710	cell adhesion molecule surface expression	[cell adhesion molecule surface expression]	0.0	5	1	1	1
71399	1710	JNK transcriptional activation	[JNK transcriptional activation]	0.0	3	1	1	1
71400	1710	STAT3 by IFN-gamma	[STAT3 by IFN-gamma]	0.0	3	1	1	1
71401	1710	production of 24,25-dihydroxy-vitamin D3 2422(oh)2d3	[production of 24,25-dihydroxy-vitamin D3 24,25(OH)2D3]	0.0	5	1	1	1
71402	1710	24 pregnant woman 10 second	[24 pregnant women 10 second]	0.0	5	1	1	1
71403	1710	C-terminal residue	[C-terminal residues]	0.0	2	1	1	1
71404	1710	gel electrophoresis	[Gel electrophoresis]	0.0	2	1	1	1
71405	1710	(viability great	[(viability greater]	0.0	2	1	1	1
71406	1710	cycling T	[cycling T]	0.0	2	1	1	1
71407	1710	(pma)	[(PMA)]	0.0	1	1	1	1
71408	1710	cases, 19	[cases, 19]	0.0	2	1	1	1
71409	1710	recent developments, include the identification	[recent developments, including the identification]	0.0	5	1	1	1
71410	1710	further information on the event	[further information on the events]	0.0	5	1	1	1
71411	1710	polypeptide of the srg3	[polypeptide of the SRG3]	0.0	4	1	1	1
71412	1710	lectins on c-fo protein level	[lectins on c-Fos protein levels]	0.0	5	1	1	1
71413	1710	expression of the response gene	[expression of the response genes]	0.0	5	1	1	1
71414	1710	glucocorticoid responsiveness of human mononuclear leukocyte	[glucocorticoid responsiveness of human mononuclear leukocytes]	0.0	6	1	1	1
71415	1710	24-hour cortisol excretion in subject	[24-hour cortisol excretion in subjects]	0.0	5	1	1	1
71416	1710	hybridisation method	[hybridisation method]	0.0	2	1	1	1
71417	1710	high capacity NF-kappaB	[high capacity NF-kappaB]	0.0	3	1	1	1
71418	1710	any, basal activity a transcriptional activator	[any, basal activity a transcriptional activator]	0.0	6	1	1	1
71419	1710	negative atra receptor (rar) gene	[negative ATRA receptor (RAR) gene]	0.0	5	1	1	1
71420	1710	soluble protein	[soluble protein]	0.0	2	1	1	1
71421	1710	quantitation of beta 1	[Quantitation of beta 1]	0.0	4	1	1	1
71422	1710	major MHC class ii gene	[major MHC class II genes]	0.0	5	1	1	1
71423	1710	mononuclear cell from subject	[mononuclear cells from subjects]	0.0	4	1	1	1
71424	1710	killer (nk) activity variance	[killer (NK) activity variance]	0.0	4	1	1	1
71425	1710	erythroid cell in transgenic mouse	[erythroid cells in transgenic mice]	0.0	5	1	1	1
71426	1710	inhibit endothelial activation	[inhibiting endothelial activation]	0.0	3	1	1	1
71427	1710	500-bp il-5 gene segment	[500-bp IL-5 gene segment]	0.0	4	1	1	1
71428	1710	exposure to the drug	[exposure to the drug]	0.0	4	1	1	1
71429	1710	nitric oxide a feedback inhibitor	[nitric oxide an feedback inhibitor]	0.0	5	1	1	1
71430	1710	mucosa-associated tissue malt lymphoma	[mucosa-associated tissue MALT lymphoma]	0.0	4	1	1	1
71431	1710	b cell proliferation and/or differentiation	[B cell proliferation and/or differentiation]	0.0	5	1	1	1
71432	1710	rather important marker	[rather important markers]	0.0	3	1	1	1
71433	1710	sulfhydryl group	[sulfhydryl groups]	0.0	2	1	1	1
71434	1710	major aspect	[major aspects]	0.0	2	1	1	1
71435	1710	hsp60 in vein endothelial cell huvec	[Hsp60 in vein endothelial cells HUVECs]	0.0	6	1	1	1
71436	1710	bacterial blood	[bacterial blood]	0.0	2	1	1	1
71437	1710	umbilical vein cell huvec monolayer	[umbilical vein cell HUVEC monolayers]	0.0	5	1	1	1
71438	1710	aspect of differentiation	[aspects of differentiation]	0.0	3	1	1	1
71439	1710	human immunodeficiency virus terminal repeat	[human immunodeficiency virus terminal repeat]	0.0	5	3	3	1
71440	1710	bfu-e response to erythropoietin	[BFU-E response to erythropoietin]	0.0	4	1	1	1
71441	1710	eightfold low amount of nf-at	[eightfold lower amounts of NF-AT]	0.0	5	1	1	1
71442	1710	cd13lo, cd15lo, cd34+/-, hla-dr	[CD13lo, CD15lo, CD34+/-, HLA-DR]	0.0	4	1	1	1
71443	1710	ability of active ras	[ability of active Ras]	0.0	4	1	1	1
71444	1710	important physiological trigger	[important physiological trigger]	0.0	3	1	1	1
71445	1710	transform property of the virus	[transforming properties of the virus]	0.0	5	1	1	1
71446	1710	disease due to molecular mimicry	[disease due to molecular mimicry]	0.0	5	1	1	1
71447	1710	-dependent reporter construct in mrl-lpr/lpr	[-dependent reporter constructs in MRL-lpr/lpr]	0.0	5	1	1	1
71448	1710	common disorder,	[common disorder,]	0.0	2	1	1	1
71449	1710	t-lymphocyte anergy in	[T-lymphocyte anergy in]	0.0	3	1	1	1
71450	1710	iv drug abuser with immunodeficiency syndrome	[iv drug abusers with immunodeficiency syndrome]	0.0	6	1	1	1
71451	1710	murine macrophage inflammatory protein alpha	[Murine macrophage inflammatory protein alpha]	0.0	5	1	1	1
71452	1710	family form of inheritance	[families: forms of inheritance]	0.0	4	1	1	1
71453	1710	datum support a model	[data supporting a model]	0.0	4	1	1	1
71454	1710	lymphocyte express socs-3	[lymphocytes expressing SOCS-3]	0.0	3	1	1	1
71455	1710	ifn-induced tyrosine phosphorylation	[IFN-induced tyrosine phosphorylation]	0.0	3	1	1	1
71456	1710	x inactivation status	[X inactivation status]	0.0	3	1	1	1
71457	1710	ubiquitous cyclic element	[ubiquitous cyclic element]	0.0	3	1	1	1
71458	1710	signal event in proliferate cell	[signaling events in proliferating cells]	0.0	5	1	1	1
71459	1710	include factor	[including factor]	0.0	2	1	1	1
71460	1710	state level of cd19 mrna	[state levels of CD19 mRNA]	0.0	5	1	1	1
71461	1710	factor-mu regulator NF-muNR	[factor-mu regulator NF-muNR]	0.0	3	1	1	1
71462	1710	rearrangement in the different ape	[rearrangements in the different apes]	0.0	5	1	1	1
71463	1710	nuclear rna (snrna) gene	[nuclear RNA (snRNA) genes]	0.0	4	1	1	1
71464	1710	inflammatory synovial fluid	[inflammatory synovial fluids]	0.0	3	1	1	1
71465	1710	eight volunteer	[Eight volunteers]	0.0	2	1	1	1
71466	1710	expression of mhc-class	[expression of MHC-class]	0.0	3	1	1	1
71467	1710	blood lymphocyte from adults.	[blood lymphocytes from adults.]	0.0	4	1	1	1
71468	1710	her-2/neu protein	[HER-2/neu protein]	0.0	2	1	1	1
71469	1710	characterization of lymphoma cell line	[characterization of lymphoma cell lines]	0.0	5	1	1	1
71470	1710	evidence for involvement in regulation	[evidence for involvement in regulation]	0.0	5	1	1	1
71471	1710	NF-kappa b /p65 heterodimer	[NF-kappa B /p65 heterodimer]	0.0	4	2	2	1
71472	1710	cd14 cho/ cd14	[CD14 CHO/ CD14]	0.0	3	1	1	1
71473	1710	range to mammal	[ranging to mammals]	0.0	3	1	1	1
71474	1710	peak expiratory	[peak expiratory]	0.0	2	1	1	1
71475	1710	means of rhodamine staining	[means of rhodamine staining]	0.0	4	1	1	1
71476	1710	distinct region important, respectively, through interaction	[distinct regions important, respectively, through interaction]	0.0	6	1	1	1
71477	1710	nuclear component after activation	[nuclear component after activation]	0.0	4	1	1	1
71478	1710	unsuppressed T cell	[unsuppressed T cells]	0.0	3	1	1	1
71479	1710	lymphocyte in 14 sle (92.9%)	[lymphocytes in 14 SLE (92.9%)]	0.0	5	1	1	1
71480	1710	cd3/t-cell antigen receptor	[CD3/T-cell antigen receptor]	0.0	3	1	1	1
71481	1710	distinct element within the enhancer	[distinct elements within the enhancer]	0.0	5	1	1	1
71482	1710	proliferative response to level equivalent	[proliferative response to levels equivalent]	0.0	5	1	1	1
71483	1710	58 bronchial asthma child aged	[58 bronchial asthma children aged]	0.0	5	1	1	1
71484	1710	repressor of the c-myc	[repressor of the c-myc]	0.0	4	1	1	1
71485	1710	first description,	[first description,]	0.0	2	1	1	1
71486	1710	activation in human natural killer cell	[Activation in human natural killer cells]	0.0	6	1	1	1
71487	1710	early production interleukin 2	[early production interleukin 2]	0.0	4	1	1	1
71488	1710	inflammatory mediator during syphilis disease	[inflammatory mediators during syphilis disease]	0.0	5	1	1	1
71489	1710	malignancy human melanoma	[malignancy human melanomas]	0.0	3	1	1	1
71490	1710	various biochemical lesion	[various biochemical lesions]	0.0	3	1	1	1
71491	1710	most antigen (include muscle actin	[most antigens (including muscle actin]	0.0	5	1	1	1
71492	1710	t(14;14) translocation	[t(14;14) translocation]	0.0	2	2	2	1
71493	1710	restimulation of human th2 line	[restimulation of human Th2 lines]	0.0	5	1	1	1
71494	1710	TPA-GR	[TPA-GR]	0.0	1	1	1	1
71495	1710	carry multiple copy	[carrying multiple copies]	0.0	3	1	1	1
71496	1710	type of E-box consensus motif	[types of E-box consensus motifs]	0.0	5	1	1	1
71497	1710	ca2+ load in platelet	[Ca2+ load in platelets]	0.0	4	1	1	1
71498	1710	activity tag capable of activation	[activity TAG capable of activation]	0.0	5	1	1	1
71499	1710	concomitant engagement	[concomitant engagement]	0.0	2	1	1	1
71500	1710	sex m	[sexes M]	0.0	2	1	1	1
71501	1710	use of stabilizer like beta	[use of stabilizers like beta]	0.0	5	1	1	1
71502	1710	distinct enhancer element	[distinct enhancer elements]	0.0	3	1	1	1
71503	1710	factor 1 csf-1	[factor 1 CSF-1]	0.0	3	1	1	1
71504	1710	new avenue in leukemia	[new avenue in leukemia]	0.0	4	1	1	1
71505	1710	helical turn	[helical turns]	0.0	2	1	1	1
71506	1710	idiopathic bowel disease	[idiopathic bowel diseases]	0.0	3	1	1	1
71507	1710	marker for promyelocytic leukemia	[marker for promyelocytic leukemia]	0.0	4	1	1	1
71508	1710	y196a	[Y196A]	0.0	1	1	1	1
71509	1710	egl from samples, activity	[eGLs from samples, activity]	0.0	4	1	1	1
71510	1710	glucocorticoid AIDS-C	[glucocorticoids AIDS-C]	0.0	2	1	1	1
71511	1710	mu/l insulin	[mU/L insulin]	0.0	2	1	1	1
71512	1710	year of relationship	[years of relationship]	0.0	3	1	1	1
71513	1710	positive effect of ap-1 protein	[positive effects of AP-1 proteins]	0.0	5	1	1	1
71514	1710	series of case	[series of cases]	0.0	3	1	1	1
71515	1710	human T cell response	[human T cell responses]	0.0	4	1	1	1
71516	1710	10 U/ml, 6	[10 U/ml, 6]	0.0	3	1	1	1
71517	1710	Study during evidence for ikappab-alpha phosphorylation	[Studies during evidence for IkappaB-alpha phosphorylation]	0.0	6	1	1	1
71518	1710	promoter in expression experiment	[promoter in expression experiments]	0.0	4	1	1	1
71519	1710	crossreacting protein	[crossreacting protein]	0.0	2	1	1	1
71520	1710	beta (p75)	[beta (p75)]	0.0	2	1	1	1
71521	1710	Grb2 adaptor protein	[Grb2 adaptor protein]	0.0	3	1	1	1
71522	1710	heterozygous DNA variation 2418delA in tumor	[heterozygous DNA variations 2418delA in tumor]	0.0	6	1	1	1
71523	1710	addition, extract	[addition, extracts]	0.0	2	1	1	1
71524	1710	analysis of sensorgram with hugata-3	[analysis of sensorgrams with huGATA-3]	0.0	5	1	1	1
71525	1710	flank region of kb	[flanking region of kb]	0.0	4	1	1	1
71526	1710	scant cytoplasm with granularity	[scant cytoplasm with granularity]	0.0	4	1	1	1
71527	1710	nf-kappab complex	[NF-kappaB complexes]	0.0	2	1	1	1
71528	1710	secretion of monocyte protein-1	[secretion of monocyte protein-1]	0.0	4	1	1	1
71529	1710	mediator of regulatory interaction	[mediators of regulatory interactions]	0.0	4	1	1	1
71530	1710	localization of both factor	[localization of both factors]	0.0	4	1	1	1
71531	1710	margin	[margins]	0.0	1	1	1	1
71532	1710	50 kda protein	[50 kDa protein]	0.0	3	1	1	1
71533	1710	tissue type; level	[tissue type; levels]	0.0	3	1	1	1
71534	1710	Specific formation between the type	[Specific formation between the type]	0.0	5	1	1	1
71535	1710	SAPK /jnk	[SAPK /JNK]	0.0	2	1	1	1
71536	1710	flexi-12 delivery	[Flexi-12 delivery]	0.0	2	1	1	1
71537	1710	metabolite of vitamin d,	[metabolite of vitamin D,]	0.0	4	1	1	1
71538	1710	costimulation-induced protein kinase mapk activation	[costimulation-induced protein kinase MAPK activation]	0.0	5	1	1	1
71539	1710	Minimal disease in leukemia	[Minimal disease in leukemia]	0.0	4	1	1	1
71540	1710	calcium immediate-early gene induction in lymphocyte	[Calcium immediate-early gene induction in lymphocytes]	0.0	6	1	1	1
71541	1710	hormone response	[hormone response]	0.0	2	2	2	1
71542	1710	child with renal deterioration	[children with renal deteriorations]	0.0	4	1	1	1
71543	1710	thus, tax through enhancement	[Thus, Tax through enhancement]	0.0	4	1	1	1
71544	1710	negative mutant mek1s218/222a	[negative mutant MEK1S218/222A]	0.0	3	1	1	1
71545	1710	component of the network	[components of the network]	0.0	4	1	1	1
71546	1710	defective production type	[defective production type]	0.0	3	1	1	1
71547	1710	two distinct, inhibitor	[two distinct, inhibitors]	0.0	3	1	1	1
71548	1710	pretreatment of "semimature" human macrophage	[Pretreatment of "semimature" human macrophages]	0.0	5	1	1	1
71549	1710	express MHC class	[expressing MHC class]	0.0	3	1	1	1
71550	1710	human leukocyte of donor	[human leukocytes of donors]	0.0	4	1	1	1
71551	1710	Phorbol	[Phorbol]	0.0	1	1	1	1
71552	1710	factor activity by interaction	[factor activity by interaction]	0.0	4	1	1	1
71553	1710	transient stimulation of quiescent b lymphocyte	[Transient stimulation of quiescent B lymphocytes]	0.0	6	1	1	1
71554	1710	stimulation with a cocktail of anti-CD40	[stimulation with a cocktail of anti-CD40]	0.0	6	1	1	1
71555	1710	blood stem cell PBSC	[blood stem cells PBSC]	0.0	4	1	1	1
71556	1710	signal converge in intracellular pathway	[signals converging in intracellular pathways]	0.0	5	1	1	1
71557	1710	multiple reactivity at least as high	[multiple reactivities at least as high]	0.0	6	1	1	1
71558	1710	nf-kappab activation lung,	[NF-kappaB activation lung,]	0.0	3	1	1	1
71559	1710	restimulation of T	[Restimulation of T]	0.0	3	1	1	1
71560	1710	class ii histocompatibility gene DPA	[class II histocompatibility gene DPA]	0.0	5	1	1	1
71561	1710	induce reporter construct	[inducing reporter constructs]	0.0	3	1	1	1
71562	1710	qualitative heterogeneity	[qualitative heterogeneity]	0.0	2	1	1	1
71563	1710	one model, polymorphism	[one model, polymorphisms]	0.0	3	1	1	1
71564	1710	distinct factor with different mobilities,	[distinct factors with different mobilities,]	0.0	5	1	1	1
71565	1710	DNA apoptosis a response	[DNA apoptosis a response]	0.0	4	1	1	1
71566	1710	cell type-specific permissiveness	[cell type-specific permissiveness]	0.0	3	1	1	1
71567	1710	regulator of hiv-1 replication	[regulators of HIV-1 replication]	0.0	4	1	1	1
71568	1710	U937 lymphoma cell	[U937 lymphoma cells]	0.0	3	1	1	1
71569	1710	fact, bone marrow cell	[fact, bone marrow cells]	0.0	4	1	1	1
71570	1710	increase half-life min.	[increasing half-life min.]	0.0	3	1	1	1
71571	1710	factor granulocyte-macrophage factor proliferation	[factor granulocyte-macrophage factor proliferation]	0.0	4	1	1	1
71572	1710	135eoh)2d3 metabolite	[1,25(OH)2D3 metabolite]	0.0	2	1	1	1
71573	1710	three bp element	[three bp elements]	0.0	3	1	1	1
71574	1710	k protein	[K protein]	0.0	2	1	1	1
71575	1710	protein nf-kappa	[protein NF-kappa]	0.0	2	1	1	1
71576	1710	fas -regulatory gene	[Fas -regulatory gene]	0.0	3	1	1	1
71577	1710	transcription in the absence	[transcription in the absence]	0.0	4	1	1	1
71578	1710	selective removal from the USA fraction	[selective removal from the USA fraction]	0.0	6	1	1	1
71579	1710	ehrlichiosis in the State	[ehrlichiosis in the States]	0.0	4	1	1	1
71580	1710	only x1-	[only X1-]	0.0	2	1	1	1
71581	1710	human reticulocyte-type 15-lipoxygenase	[human reticulocyte-type 15-lipoxygenase]	0.0	3	1	1	1
71582	1710	cell of most patient	[cells of most patients]	0.0	4	1	1	1
71583	1710	negative ras	[negative Ras]	0.0	2	1	1	1
71584	1710	CD40 stimulation of monocyte	[CD40 stimulation of monocytes]	0.0	4	1	1	1
71585	1710	IL-4 substrate	[IL-4 substrates]	0.0	2	1	1	1
71586	1710	neutralize abs to basic growth factor	[neutralizing Abs to basic growth factor]	0.0	6	1	1	1
71587	1710	negative rac	[negative Rac]	0.0	2	1	1	1
71588	1710	homeostasis by apoptosis	[homeostasis by apoptosis]	0.0	3	1	1	1
71589	1710	DNA from blood leukocyte of patient	[DNA from blood leukocytes of patients]	0.0	6	1	1	1
71590	1710	couple from approximately -500 bp	[Coupling from approximately -500 bp]	0.0	5	1	1	1
71591	1710	make interruption	[making interruption]	0.0	2	1	1	1
71592	1710	alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	3	1	1	1
71593	1710	Genetic characterization binding to element 1	[Genetic characterization Binding to element 1]	0.0	6	1	1	1
71594	1710	use the indexing term	[using the indexing terms]	0.0	4	1	1	1
71595	1710	22 t-cell malignancy	[22 T-cell malignancies]	0.0	3	1	1	1
71596	1710	high level of chromosome translocation	[high level of chromosome translocations]	0.0	5	1	1	1
71597	1710	truly uncommon phenomenon in woman	[truly uncommon phenomenon in women]	0.0	5	1	1	1
71598	1710	erythroblast express the mouse epor (r129c)	[erythroblasts expressing the mouse EpoR (R129C)]	0.0	6	1	1	1
71599	1710	substitution alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[substitutions alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	4	1	1	1
71600	1710	transcriptional activation of viral promoter	[transcriptional activation of viral promoters]	0.0	5	1	1	1
71601	1710	observation of expression with the finding	[observations of expression with the findings]	0.0	6	1	1	1
71602	1710	dnasei	[DNaseI]	0.0	1	1	1	1
71603	1710	human T-lymphocyte cell line	[human T-lymphocyte cell line]	0.0	4	1	1	1
71604	1710	myeloid cell in vivo	[myeloid cells in vivo]	0.0	4	1	1	1
71605	1710	three multi-protein complex	[three multi-protein complexes]	0.0	3	1	1	1
71606	1710	report of a ef1 activity	[report of an EF1 activity]	0.0	5	1	1	1
71607	1710	2 T cell growth	[2 T cell growth]	0.0	4	1	1	1
71608	1710	distal factor NF-AT AP-1/Octamer	[distal factor NF-AT AP-1/Octamer]	0.0	4	1	1	1
71609	1710	molecular weight species	[molecular weight species]	0.0	3	1	1	1
71610	1710	Dehydroepiandrosterone the predominant androgen	[Dehydroepiandrosterone the predominant androgen]	0.0	4	1	1	1
71611	1710	other nuclear factor	[other nuclear factors]	0.0	3	1	1	1
71612	1710	VZV immune human donor	[VZV immune human donors]	0.0	4	1	1	1
71613	1710	hirsute patient with regular mense	[hirsute patients with regular menses]	0.0	5	1	1	1
71614	1710	isomorph of p56 by gel analysis	[isomorphs of p56 by gel analysis]	0.0	6	1	1	1
71615	1710	role for pao phosphatase	[role for PAO phosphatase]	0.0	4	1	1	1
71616	1710	constitutive association in pro-B cell	[Constitutive association in pro-B cells]	0.0	5	1	1	1
71617	1710	independent form of collaboration	[independent forms of collaboration]	0.0	4	1	1	1
71618	1710	SIV terminal repeat	[SIV terminal repeat]	0.0	3	1	1	1
71619	1710	additional distinguishing characteristic	[additional distinguishing characteristic]	0.0	3	1	1	1
71620	1710	major site within the regulatory element	[major sites within the regulatory element]	0.0	6	1	1	1
71621	1710	Concomitant downregulation in a plasmacytoma implication	[Concomitant downregulation in a plasmacytoma implications]	0.0	6	1	1	1
71622	1710	factor bind C	[Factors binding C]	0.0	3	1	1	1
71623	1710	induce the degradation	[inducing the degradation]	0.0	3	1	1	1
71624	1710	phenomenon await further elucidation.	[phenomenon awaiting further elucidation.]	0.0	4	1	1	1
71625	1710	immunohistochemical evidence of proliferative activity	[Immunohistochemical evidence of proliferative activity]	0.0	5	1	1	1
71626	1710	sugar moiety	[sugar moiety]	0.0	2	1	1	1
71627	1710	cytotoxicity program	[cytotoxicity programs]	0.0	2	1	1	1
71628	1710	blood urea nitrogen	[blood urea nitrogen]	0.0	3	1	1	1
71629	1710	gene under factor-kappaB control	[genes under factor-kappaB control]	0.0	4	1	1	1
71630	1710	five target the membrane glycoprotein cd36	[five targets the membrane glycoprotein CD36]	0.0	6	1	1	1
71631	1710	CoCl2 hypoxia	[CoCl2 hypoxia]	0.0	2	1	1	1
71632	1710	additional complex contain tr alpha	[additional complexes containing TR alpha]	0.0	5	1	1	1
71633	1710	isoform-specific C-terminal antibody	[isoform-specific C-terminal antibodies]	0.0	3	1	1	1
71634	1710	2418delA	[2418delA]	0.0	1	1	1	1
71635	1710	efficient promoter	[efficient promoters]	0.0	2	1	1	1
71636	1710	cushingoid	[Cushingoid]	0.0	1	1	1	1
71637	1710	period of days.	[period of days.]	0.0	3	1	1	1
71638	1710	increase il-2 transcription	[increasing IL-2 transcription]	0.0	3	1	1	1
71639	1710	nmol/L; p	[nmol/L; P]	0.0	2	1	1	1
71640	1710	heterodimeric nfkb2 p49	[heterodimeric NFKB2 p49]	0.0	3	1	1	1
71641	1710	primate with glucocorticoid resistance	[primates with glucocorticoid resistance]	0.0	4	1	1	1
71642	1710	involvement in the pge2 effect	[involvement in the PGE2 effect]	0.0	5	1	1	1
71643	1710	less adhesion molecule-1	[lesser adhesion molecule-1]	0.0	3	1	1	1
71644	1710	c/ebpalpha transcription,	[C/EBPalpha transcription,]	0.0	2	1	1	1
71645	1710	grade).	[grade).]	0.0	1	1	1	1
71646	1710	two transcriptional element promoter,	[Two transcriptional elements promoter,]	0.0	4	1	1	1
71647	1710	airway cell of asthma	[airway cells of asthma]	0.0	4	1	1	1
71648	1710	cd14 activation of transcription factor	[CD14 activation of transcription factors]	0.0	5	1	1	1
71649	1710	sequence for gene expression	[sequence for gene expression]	0.0	4	1	1	1
71650	1710	lps activation in monocyte/macrophage cell	[LPS activation in monocyte/macrophage cells]	0.0	5	1	1	1
71651	1710	two other synthetic RAR ligand	[two other synthetic RAR ligands]	0.0	5	1	1	1
71652	1710	ovarian tumor cell	[ovarian tumor cells]	0.0	3	1	1	1
71653	1710	interleukin 3 survival of lymphocyte	[interleukin 3 survival of lymphocytes]	0.0	5	1	1	1
71654	1710	4.27 (range, 4-.11),	[4.27 (range, 4-5.13),]	0.0	3	1	1	1
71655	1710	efficacy in treatment in child	[efficacy in treatment in children]	0.0	5	1	1	1
71656	1710	important source	[important source]	0.0	2	1	1	1
71657	1710	MHC class antigen induction	[MHC class antigen induction]	0.0	4	1	1	1
71658	1710	ebf sequence on chromosome	[EBF sequences on Chromosome]	0.0	4	1	1	1
71659	1710	response to all-tran acid	[response to all-trans acid]	0.0	4	1	1	1
71660	1710	taxi gene	[TaxI gene]	0.0	2	1	1	1
71661	1710	essential regulatory protein	[essential regulatory protein]	0.0	3	1	1	1
71662	1710	alpha-globin gene expression	[alpha-globin gene expression]	0.0	3	1	1	1
71663	1710	gap in understanding	[gaps in understanding]	0.0	3	1	1	1
71664	1710	concentration of 1,25-dihydroxyvitamin D3 receptor effect	[concentration of 1,25-dihydroxyvitamin D3 receptors effect]	0.0	6	1	1	1
71665	1710	capacity secondary	[capacity secondary]	0.0	2	1	1	1
71666	1710	role in biological rhythm	[role in biological rhythms]	0.0	4	1	1	1
71667	1710	expression of c-erba/tr-alpha	[expression of c-erbA/TR-alpha]	0.0	3	1	1	1
71668	1710	vary conditions,	[varying conditions,]	0.0	2	1	1	1
71669	1710	differentiation of M1 cell	[differentiation of M1 cells]	0.0	4	1	1	1
71670	1710	flutamide on parameter	[flutamide on parameters]	0.0	3	1	1	1
71671	1710	healthy female aged between 8	[healthy females aged between 8]	0.0	5	1	1	1
71672	1710	oncogene of erythroblastosis virus	[oncogene of erythroblastosis virus]	0.0	4	1	1	1
71673	1710	various breakpoint 11	[various breakpoints 11]	0.0	3	1	1	1
71674	1710	only the 5' base pair	[only the 5' base pairs]	0.0	5	1	1	1
71675	1710	potent proinflammatory cytokine mrna expression	[potent proinflammatory cytokine mRNA expression]	0.0	5	1	1	1
71676	1710	none of the other site	[None of the other sites]	0.0	5	1	1	1
71677	1710	histologic grade	[histologic grade]	0.0	2	1	1	1
71678	1710	short C terminus	[short C terminus]	0.0	3	1	1	1
71679	1710	subsequent addition	[subsequent addition]	0.0	2	1	1	1
71680	1710	case of chronic leukemia CLL	[cases of chronic leukemia CLL]	0.0	5	1	1	1
71681	1710	(respective mean values:	[(respective mean values:]	0.0	3	1	1	1
71682	1710	airway epithelial cell from asthmatics	[airway epithelial cells from asthmatics]	0.0	5	1	1	1
71683	1710	calcineurin phosphatase	[calcineurin phosphatase]	0.0	2	1	1	1
71684	1710	49 case of B-cell lymphocytic leukemia	[49 cases of B-cell lymphocytic leukemia]	0.0	6	1	1	1
71685	1710	hgata-3 T	[hGATA-3 T]	0.0	2	2	2	1
71686	1710	protein segment	[protein segments]	0.0	2	1	1	1
71687	1710	thus prevent induction of cytokine	[thus preventing induction of cytokine]	0.0	5	1	1	1
71688	1710	three, rare heterozygous DNA variation 2418delA	[three, rare heterozygous DNA variations 2418delA]	0.0	6	1	1	1
71689	1710	associate with TNFR factor	[associating with TNFR factors]	0.0	4	1	1	1
71690	1710	micrograms/ml each transferrin	[micrograms/ml each transferrin]	0.0	3	1	1	1
71691	1710	tdag51	[TDAG51]	0.0	1	1	1	1
71692	1710	spatial alignment	[spatial alignment]	0.0	2	1	1	1
71693	1710	functional expression on melanoma MMs	[functional expression on melanomas MMs]	0.0	5	1	1	1
71694	1710	enhancer by ap-1	[enhancer by AP-1]	0.0	3	1	1	1
71695	1710	dna-dependent atpase activity	[DNA-dependent ATPase activities]	0.0	3	1	1	1
71696	1710	h of activation.	[h of activation.]	0.0	3	1	1	1
71697	1710	completely inhibit vdrnrar- vdre formation	[completely inhibiting VDR-RXR- VDRE formation]	0.0	5	1	1	1
71698	1710	Likewise, activation	[Likewise, activation]	0.0	2	1	1	1
71699	1710	nuclear factor (NF)-kappaB sequence	[nuclear factor (NF)-kappaB sequence]	0.0	4	1	1	1
71700	1710	human virus type htlv-1 tax	[human virus type HTLV-1 Tax]	0.0	5	1	1	1
71701	1710	susceptible target cell	[susceptible target cells]	0.0	3	1	1	1
71702	1710	mechanism explain the differentiation status	[mechanism explaining the differentiation status]	0.0	5	1	1	1
71703	1710	disorder a problem	[disorders a problem]	0.0	3	1	1	1
71704	1710	cis-acting element responsible for the expression	[cis-acting elements responsible for the expression]	0.0	6	1	1	1
71705	1710	related retinoic acid receptor	[related retinoic acid receptor]	0.0	4	1	1	1
71706	1710	NF-kappaB in MNC extract	[NF-kappaB in MNC extracts]	0.0	4	1	1	1
71707	1710	lymphocyte proliferation in 13 healthy control	[lymphocyte proliferation in 13 healthy controls]	0.0	6	1	1	1
71708	1710	type tgase up-regulation	[type TGase up-regulation]	0.0	3	1	1	1
71709	1710	regulation effect of treatment	[Regulation effects of treatment]	0.0	4	1	1	1
71710	1710	phosphorylation of a Elk-1 fusion protein	[phosphorylation of an Elk-1 fusion protein]	0.0	6	1	1	1
71711	1710	region UAS3	[regions UAS3]	0.0	2	1	1	1
71712	1710	2 IL2	[2 IL2]	0.0	2	1	1	1
71713	1710	cytogenetic abnormality highlight novel loci	[cytogenetic abnormalities highlighting novel loci]	0.0	5	1	1	1
71714	1710	leukocyte chemoattract	[leukocyte chemoattractants]	0.0	2	1	1	1
71715	1710	6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	5	1	1	1
71716	1710	component of the NB	[component of the NB]	0.0	4	1	1	1
71717	1710	analysis of creb mutant	[Analysis of CREB mutants]	0.0	4	1	1	1
71718	1710	m phi uptake of cell	[M phi uptake of cells]	0.0	5	1	1	1
71719	1710	Comparison of acid as inducer	[Comparison of acid as inducers]	0.0	5	1	1	1
71720	1710	NF-kappa b consist	[NF-kappa B consisting]	0.0	3	1	1	1
71721	1710	transcript, a transcription factor with function	[transcript, a transcription factor with functions]	0.0	6	1	1	1
71722	1710	complex interplay of element	[complex interplay of elements]	0.0	4	1	1	1
71723	1710	activation of member	[activation of members]	0.0	3	1	1	1
71724	1710	such as bacterial formylpeptide lps	[such as bacterial formylpeptides LPS]	0.0	5	1	1	1
71725	1710	NF-kappa b by interleukin	[NF-kappa B by interleukin]	0.0	4	1	1	1
71726	1710	expression of different gene	[expression of different genes]	0.0	4	1	1	1
71727	1710	E220K ubiquitinylation in the heterodimer	[E220K ubiquitinylation in the heterodimer]	0.0	5	1	1	1
71728	1710	human islet	[human islet]	0.0	2	1	1	1
71729	1710	least three complex RFX	[least three complexes RFX]	0.0	4	1	1	1
71730	1710	thus prevent transcriptional induction of cytokine	[thus preventing transcriptional induction of cytokine]	0.0	6	1	1	1
71731	1710	particular emphasis	[particular emphasis]	0.0	2	1	1	1
71732	1710	study on the expression	[studies on the expression]	0.0	4	1	1	1
71733	1710	genome-positive b cell by human herpesvirus	[genome-positive B cells by human herpesvirus]	0.0	6	1	1	1
71734	1710	analysis with butyrate esterase staining	[analysis with butyrate esterase staining]	0.0	5	1	1	1
71735	1710	mzf protein mzf-2	[MZF protein MZF-2]	0.0	3	1	1	1
71736	1710	extract of pmn	[extracts of PMN]	0.0	3	1	1	1
71737	1710	However, B	[However, B]	0.0	2	1	1	1
71738	1710	b-cell-specific b29 gene	[B-cell-specific B29 gene]	0.0	3	1	1	1
71739	1710	N-Oct protein	[N-Oct proteins]	0.0	2	1	1	1
71740	1710	immune hyperactivation of T cell	[Immune hyperactivation of T cells]	0.0	5	1	1	1
71741	1710	screen by rt-pcr	[screening by RT-PCR]	0.0	3	1	1	1
71742	1710	fibrosarcoma 8, fibrous histiocytoma rhabdomyosarcoma	[fibrosarcoma 8, fibrous histiocytoma rhabdomyosarcoma]	0.0	5	1	1	1
71743	1710	truncation mutant of TRAF6	[truncation mutant of TRAF6]	0.0	4	1	1	1
71744	1710	cooperation of factor	[cooperation of factors]	0.0	3	1	1	1
71745	1710	NF-kappaB subunit in mnc lysate	[NF-kappaB subunit in MNC lysates]	0.0	5	1	1	1
71746	1710	I interferon to specific receptor	[I interferon to specific receptors]	0.0	5	1	1	1
71747	1710	eotaxin gene expression	[eotaxin gene expression]	0.0	3	1	1	1
71748	1710	viral replication in monocyte	[viral replication in monocytes]	0.0	4	1	1	1
71749	1710	different method	[different methods]	0.0	2	1	1	1
71750	1710	interferon (ifn) consensus sequence-bind protein	[interferon (IFN) consensus sequence-binding protein]	0.0	5	1	1	1
71751	1710	(lymphocyte)	[(lymphocyte)]	0.0	1	1	1	1
71752	1710	several function	[Several functions]	0.0	2	1	1	1
71753	1710	absence of tnf-alpha	[absence of TNF-alpha]	0.0	3	1	1	1
71754	1710	rodent gene	[rodent gene]	0.0	2	1	1	1
71755	1710	consensus CKII site	[consensus CKII site]	0.0	3	1	1	1
71756	1710	MAP- Erk cascade	[MAP- Erk cascade]	0.0	3	1	1	1
71757	1710	ten in-vitro-stimulated adult blood lymphocyte sample	[ten in-vitro-stimulated adult blood lymphocyte samples]	0.0	6	1	1	1
71758	1710	enhancement of the uptake	[enhancement of the uptake]	0.0	4	1	1	1
71759	1710	b-cell-specific cofactor in concert	[B-cell-specific cofactors in concert]	0.0	4	1	1	1
71760	1710	binding similarly to the result	[Binding similarly to the results]	0.0	5	1	1	1
71761	1710	secretion level	[secretion levels]	0.0	2	1	1	1
71762	1710	sea urchin binding site	[sea urchin binding sites]	0.0	4	1	1	1
71763	1710	tissue-specific interindividual variation	[tissue-specific interindividual variation]	0.0	3	1	1	1
71764	1710	th2 level	[Th2 levels]	0.0	2	1	1	1
71765	1710	unresponsiveness for activation of this pathway	[Unresponsiveness for activation of this pathway]	0.0	6	1	1	1
71766	1710	support for the hypothesis	[support for the hypothesis]	0.0	4	1	1	1
71767	1710	analysis of the extract with antibody	[Analysis of the extracts with antibodies]	0.0	6	1	1	1
71768	1710	even 10(-10) mol/L	[even 10(-10) mol/L]	0.0	3	1	1	1
71769	1710	orf 62 a tegument protein	[ORF 62 an tegument protein]	0.0	5	1	1	1
71770	1710	point assay of receptor gr	[point assay of receptors GR]	0.0	5	1	1	1
71771	1710	-resistant human ecem) cell	[-resistant human (CEM) cells]	0.0	4	1	1	1
71772	1710	prolonged stimulation of b-2 cell	[prolonged stimulation of B-2 cells]	0.0	5	1	1	1
71773	1710	suppression of c-jun by oligonucleotide	[Suppression of c-jun by oligonucleotides]	0.0	5	1	1	1
71774	1710	local modulation of myelopoiesis	[local modulation of myelopoiesis]	0.0	4	1	1	1
71775	1710	endothelium-derived factor	[endothelium-derived factors]	0.0	2	1	1	1
71776	1710	superoxide dismutase a enzyme	[superoxide dismutase a enzyme]	0.0	4	1	1	1
71777	1710	focus on study	[focus on studies]	0.0	3	1	1	1
71778	1710	growth cell line express the epor	[growth cell lines expressing the EPOR]	0.0	6	1	1	1
71779	1710	increase in il-8 messenger rna mrna	[increases in IL-8 messenger RNA mRNA]	0.0	6	1	1	1
71780	1710	infection with the immunodeficiency virus hiv	[Infection with the immunodeficiency virus HIV]	0.0	6	1	1	1
71781	1710	90 degree	[90 degrees]	0.0	2	1	1	1
71782	1710	vascular endothelium,	[vascular endothelium,]	0.0	2	1	1	1
71783	1710	micromol/L for >24 hours, oleate	[micromol/L for >24 hours, oleate]	0.0	5	1	1	1
71784	1710	bind the alpha receptor	[binding the alpha receptor]	0.0	4	1	1	1
71785	1710	functionally distinct epitope	[functionally distinct epitopes]	0.0	3	1	1	1
71786	1710	ciprofloxacin micrograms/ml)	[ciprofloxacin micrograms/ml)]	0.0	2	1	1	1
71787	1710	cdc42 effector n-wasp	[CDC42 effector N-WASP]	0.0	3	1	1	1
71788	1710	11 index hypercalciuric patient	[11 index hypercalciuric patients]	0.0	4	1	1	1
71789	1710	dominant mutant pathway include myd88	[dominant mutants pathway including MyD88]	0.0	5	1	1	1
71790	1710	prevent activation in response	[preventing activation in response]	0.0	4	1	1	1
71791	1710	low the/thf 1.87+/-0.36)	[low THE/THF 1.87+/-0.36)]	0.0	3	1	1	1
71792	1710	effect on type	[effects on type]	0.0	3	1	1	1
71793	1710	corresponding to the TFIIIA zinc-finger consensus	[corresponding to the TFIIIA zinc-finger consensus]	0.0	6	1	1	1
71794	1710	assay in extrinsic asthmatics	[assay in extrinsic asthmatics]	0.0	4	1	1	1
71795	1710	transactivation capacity	[transactivation capacity]	0.0	2	1	1	1
71796	1710	tandem array range in number	[tandem arrays ranging in number]	0.0	5	1	1	1
71797	1710	globin regulatory element	[globin regulatory element]	0.0	3	1	1	1
71798	1710	other proliferator receptor ppar	[Other proliferator receptor PPAR]	0.0	4	1	1	1
71799	1710	stimulation of the CD3	[stimulation of the CD3]	0.0	4	1	1	1
71800	1710	egr-1 rna	[Egr-1 RNA]	0.0	2	1	1	1
71801	1710	female year	[female years]	0.0	2	1	1	1
71802	1710	leukocyte lineage	[leukocyte lineages]	0.0	2	1	1	1
71803	1710	osteoprotegerin ligand	[osteoprotegerin ligand]	0.0	2	1	1	1
71804	1710	activity in extract	[activity in extracts]	0.0	3	1	1	1
71805	1710	translocation in myeloproliferative disorder	[translocations in myeloproliferative disorders]	0.0	4	1	1	1
71806	1710	include the Sp1 element	[including the Sp1 element]	0.0	4	1	1	1
71807	1710	(apparent	[(apparent]	0.0	1	2	2	1
71808	1710	subclone into ltr-driven CAT expression vector	[Subcloning into LTR-driven CAT expression vectors]	0.0	6	1	1	1
71809	1710	further factor protein	[further factor proteins]	0.0	3	1	1	1
71810	1710	effect on tnf-alpha secretion	[effect on TNF-alpha secretion]	0.0	4	1	1	1
71811	1710	colony-stimumulatelany-stg factor 1	[colony-stimulating factor 1]	0.0	3	1	1	1
71812	1710	Rel -/- T cell culture	[Rel -/- T cell cultures]	0.0	5	1	1	1
71813	1710	ebv binding to cellular receptor	[EBV binding to cellular receptor]	0.0	5	1	1	1
71814	1710	identification of the sequence	[identification of the sequence]	0.0	4	1	1	1
71815	1710	clonal expansion)	[clonal expansion)]	0.0	2	1	1	1
71816	1710	nucleotide change	[nucleotide changes]	0.0	2	1	1	1
71817	1710	41 exon	[41 exons]	0.0	2	1	1	1
71818	1710	addition a complex	[addition a complex]	0.0	3	1	1	1
71819	1710	bind to GATA-1 motif	[binding to GATA-1 motifs]	0.0	4	1	1	1
71820	1710	135-(oh)2d3 receptors;	[1,25-(OH)2D3 receptors;]	0.0	2	1	1	1
71821	1710	property of the virus	[properties of the virus]	0.0	4	1	1	1
71822	1710	nf-kappab in cell follow hydrocortisone injection	[NF-kappaB in cells following hydrocortisone injection]	0.0	6	1	1	1
71823	1710	element in basophil	[element in basophils]	0.0	3	1	1	1
71824	1710	control (p 0.05)	[control (P 0.05)]	0.0	3	1	1	1
71825	1710	effect on normal hematopoiesis	[effects on normal hematopoiesis]	0.0	4	1	1	1
71826	1710	lack of correspondence	[lack of correspondence]	0.0	3	1	1	1
71827	1710	tcf-1 T cell factor	[TCF-1 T cell factor]	0.0	4	1	1	1
71828	1710	alpha 4 beta	[alpha 4 beta]	0.0	3	3	3	1
71829	1710	induction of oxygen intermediate	[induction of oxygen intermediates]	0.0	4	1	1	1
71830	1710	immediate gene in T cell	[immediate gene in T cells]	0.0	5	1	1	1
71831	1710	at1 receptor	[AT1 receptor]	0.0	2	1	1	1
71832	1710	Authentic NFAT	[Authentic NFAT]	0.0	2	1	1	1
71833	1710	absence of activation,	[absence of activation,]	0.0	3	1	1	1
71834	1710	counterpart to human leukemia	[counterpart to human leukemias]	0.0	4	1	1	1
71835	1710	inhibition in t-cell line	[Inhibition in T-cell lines]	0.0	4	1	1	1
71836	1710	stimulation with cytokine	[stimulation with cytokines]	0.0	3	1	1	1
71837	1710	effect on factor-kappaB nf-kappab regulation	[effects on factor-kappaB NF-kappaB regulation]	0.0	5	1	1	1
71838	1710	novel, -rich carboxy terminus	[novel, -rich carboxy terminus]	0.0	4	1	1	1
71839	1710	MHC class density on the APC	[MHC class density on the APC]	0.0	6	1	1	1
71840	1710	yield and/or	[yield and/or]	0.0	2	1	1	1
71841	1710	binding of GABPalpha	[binding of GABPalpha]	0.0	3	1	1	1
71842	1710	transcription of several cellular gene	[transcription of several cellular genes]	0.0	5	1	1	1
71843	1710	c-c chemokine receptor	[C-C chemokine receptor]	0.0	3	1	1	1
71844	1710	tyr-492	[Tyr-492]	0.0	1	1	1	1
71845	1710	mitogenic effect on the proliferation	[mitogenic effects on the proliferation]	0.0	5	1	1	1
71846	1710	acidic terminal segment	[acidic terminal segment]	0.0	3	1	1	1
71847	1710	endothelial activation a direct vascular mechanism	[endothelial activation A direct vascular mechanism]	0.0	6	1	1	1
71848	1710	management of disease	[management of diseases]	0.0	3	1	1	1
71849	1710	astroglioma	[astroglioma]	0.0	1	1	1	1
71850	1710	high radiosensitivity	[high radiosensitivity]	0.0	2	1	1	1
71851	1710	patient with bronchiti	[patients with bronchitis]	0.0	3	1	1	1
71852	1710	salicylic acid inhibition of NF-kappaB	[salicylic acid inhibition of NF-kappaB]	0.0	5	1	1	1
71853	1710	characterization of this promoter	[characterization of this promoter]	0.0	4	1	1	1
71854	1710	minus value	[minus values]	0.0	2	1	1	1
71855	1710	amount of iron	[amount of iron]	0.0	3	1	1	1
71856	1710	coactivator of LEF-1	[coactivator of LEF-1]	0.0	3	1	1	1
71857	1710	differentiation-dependent proliferator-activated receptor gamma ppargamma expression	[differentiation-dependent proliferator-activated receptor gamma PPARgamma expression]	0.0	6	1	1	1
71858	1710	(pml)	[(PML)]	0.0	1	1	1	1
71859	1710	v-Fos protein	[v-Fos protein]	0.0	2	1	1	1
71860	1710	vitro growth assay	[vitro growth assays]	0.0	3	1	1	1
71861	1710	effect of notch-1 on apoptosis	[effects of notch-1 on apoptosis]	0.0	5	1	1	1
71862	1710	beta antibody	[beta antibody]	0.0	2	2	2	1
71863	1710	glucocorticoid reduction	[glucocorticoid reduction]	0.0	2	1	1	1
71864	1710	group of hypercortisolemic patient one	[groups of hypercortisolemic patients one]	0.0	5	1	1	1
71865	1710	control of various gene	[control of various genes]	0.0	4	1	1	1
71866	1710	I gamma sequence	[I gamma sequence]	0.0	3	1	1	1
71867	1710	47-bp sequence position	[47-bp sequence positions]	0.0	3	1	1	1
71868	1710	200 mu/l	[200 mU/L]	0.0	2	1	1	1
71869	1710	time of 25 h (viability great	[times of 25 h (viability greater]	0.0	6	1	1	1
71870	1710	normal adult differentiation	[normal adult differentiation]	0.0	3	1	1	1
71871	1710	apl phenotype,	[APL phenotype,]	0.0	2	1	1	1
71872	1710	-driven chloramphenicol acetyltransferase	[-driven chloramphenicol acetyltransferase]	0.0	3	1	1	1
71873	1710	marker of promyelocytic leukemia apl	[markers of promyelocytic leukemias APLs]	0.0	5	1	1	1
71874	1710	antigen staining with bz1 reactivity	[antigen staining with BZ1 reactivity]	0.0	5	1	1	1
71875	1710	ltr contain one b element	[LTRs containing one B elements]	0.0	5	1	1	1
71876	1710	study use antibody against brdu	[studies using antibodies against BrdU]	0.0	5	1	1	1
71877	1710	trigger (s)	[triggering (s)]	0.0	2	1	1	1
71878	1710	immunodominant cycle epitope	[immunodominant cycle epitopes]	0.0	3	1	1	1
71879	1710	patient with lymphatic leukemia CLL	[patients with lymphatic leukemia CLL]	0.0	5	1	1	1
71880	1710	healthy aged subject yr)	[healthy aged subjects yr)]	0.0	4	1	1	1
71881	1710	binding of ebna-2 type	[binding of EBNA-2 type]	0.0	4	1	1	1
71882	1710	T-helper 0 subset	[T-helper 0 subset]	0.0	3	1	1	1
71883	1710	mucosa-associated lymphoid tissue malt lymphoma	[mucosa-associated lymphoid tissue MALT lymphoma]	0.0	5	1	1	1
71884	1710	expression of the glucocorticoid receptor isoform	[expression of the glucocorticoid receptor isoforms]	0.0	6	1	1	1
71885	1710	context [il-2]-dependent ht-2 line	[context [IL-2]-dependent HT-2 line]	0.0	4	1	1	1
71886	1710	young sister	[young sister]	0.0	2	1	1	1
71887	1710	number of promoter	[number of promoters]	0.0	3	1	1	1
71888	1710	variable proportion	[variable proportions]	0.0	2	1	1	1
71889	1710	oxygen release	[oxygen release]	0.0	2	1	1	1
71890	1710	direct the action of NK cell	[directing the action of NK cells]	0.0	6	1	1	1
71891	1710	inhibitor of ca(2+)-atpase	[inhibitor of Ca(2+)-ATPase]	0.0	3	1	1	1
71892	1710	CD4 subset of thymocyte	[CD4 subset of thymocytes]	0.0	4	1	1	1
71893	1710	cd56+ cd16+ natural killer cell	[CD56+ CD16+ natural killer cells]	0.0	5	1	1	1
71894	1710	demonstration of gene expression	[Demonstration of gene expression]	0.0	4	1	1	1
71895	1710	DNA binding, mutant	[DNA binding, mutants]	0.0	3	1	1	1
71896	1710	28-bp core	[28-bp core]	0.0	2	1	1	1
71897	1710	focus on the difference	[focusing on the differences]	0.0	4	1	1	1
71898	1710	acid (dna) protein	[acid (DNA) proteins]	0.0	3	1	1	1
71899	1710	activation c-Jun n-terminal kinase	[activation c-Jun N-terminal kinase]	0.0	4	1	1	1
71900	1710	preassociation	[Preassociation]	0.0	1	1	1	1
71901	1710	accurate model	[accurate model]	0.0	2	1	1	1
71902	1710	encode a membrane protein	[encoding an membrane protein]	0.0	4	1	1	1
71903	1710	adaptive response	[adaptive response]	0.0	2	1	1	1
71904	1710	follow exposure to 12-o-tetradecanoylphorbol-13-acetate	[following exposures to 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
71905	1710	20-methyl analogue	[20-methyl analogues]	0.0	2	1	1	1
71906	1710	chronic disorder a challenging problem	[chronic disorders a challenging problem]	0.0	5	1	1	1
71907	1710	consequence at a early stage	[consequences at an early stage]	0.0	5	1	1	1
71908	1710	adult mouse tissue include organ	[adult mouse tissues including organs]	0.0	5	1	1	1
71909	1710	Chinese hamster ovary cell express alphaiibbeta3	[Chinese hamster ovary cells expressing alphaIIbbeta3]	0.0	6	1	1	1
71910	1710	inducible complex resemble nuclear factor	[inducible complex resembling nuclear factor]	0.0	5	1	1	1
71911	1710	family of agent	[family of agents]	0.0	3	1	1	1
71912	1710	g-csf cell	[G-CSF cells]	0.0	2	1	1	1
71913	1710	series of variable	[series of variables]	0.0	3	1	1	1
71914	1710	illness involve inadequate response	[illness involving inadequate responses]	0.0	4	1	1	1
71915	1710	leukocyte from young person	[leukocytes from young persons]	0.0	4	1	1	1
71916	1710	level of cell	[level of cells]	0.0	3	2	2	1
71917	1710	mechanism a type	[mechanisms a type]	0.0	3	1	1	1
71918	1710	mnda mrna in monocyte	[MNDA mRNA in monocytes]	0.0	4	1	1	1
71919	1710	CD3/T cell receptor	[CD3/T cell receptor]	0.0	3	1	1	1
71920	1710	potent inhibitor of b activation	[potent inhibitor of B activation]	0.0	5	1	1	1
71921	1710	various condition of biomedical importance.	[various conditions of biomedical importance.]	0.0	5	1	1	1
71922	1710	mechanism of adherence to cell	[mechanisms of adherence to cells]	0.0	5	1	1	1
71923	1710	overexpression in Saos 2 cell	[Overexpression in Saos 2 cells]	0.0	5	1	1	1
71924	1710	RA vitd3	[RA VitD3]	0.0	2	1	1	1
71925	1710	reticulum ca2+-atpase SERCA	[reticulum Ca2+-ATPase SERCA]	0.0	3	1	1	1
71926	1710	treatment with two schedule (five patient	[Treatment with two schedules (five patients]	0.0	6	1	1	1
71927	1710	lymph-node	[lymph-node]	0.0	1	1	1	1
71928	1710	-contain leukocyte protein more tightly	[-containing leukocyte protein more tightly]	0.0	5	1	1	1
71929	1710	mechanism for n-acetylcysteine inhibition cytokine-induced e-selectin	[mechanisms for N-acetylcysteine inhibition cytokine-induced E-selectin]	0.0	6	1	1	1
71930	1710	employed, incorporate microbiological antigen	[employed, incorporating microbiological antigens]	0.0	4	1	1	1
71931	1710	precursor interleukin-1	[precursor interleukin-1]	0.0	2	1	1	1
71932	1710	target of antiinflammatory drug	[target of antiinflammatory drugs]	0.0	4	1	1	1
71933	1710	copy of the nf-at site	[copies of the NF-AT site]	0.0	5	1	1	1
71934	1710	transcription of oxide synthase	[transcription of oxide synthase]	0.0	4	1	1	1
71935	1710	two novel inhibitor	[two novel inhibitors]	0.0	3	1	1	1
71936	1710	acetate-A23187	[acetate-A23187]	0.0	1	1	1	1
71937	1710	expression of IL-2 regulator	[expression of IL-2 regulators]	0.0	4	1	1	1
71938	1710	certain level	[certain level]	0.0	2	1	1	1
71939	1710	tissue from woman undergo termination	[Tissues from women undergoing termination]	0.0	5	1	1	1
71940	1710	model for hemopoietic lineage restriction	[model for hemopoietic lineage restriction]	0.0	5	1	1	1
71941	1710	Calcitriol a hematolymphopoietrope	[Calcitriol a hematolymphopoietrope]	0.0	3	1	1	1
71942	1710	positive parental cell line	[positive parental cell line]	0.0	4	1	1	1
71943	1710	reading frame of nucleotide	[reading frame of nucleotides]	0.0	4	1	1	1
71944	1710	beta-globin promoter chromatin structure	[beta-globin promoter chromatin structure]	0.0	4	1	1	1
71945	1710	arrest differentiation of cell progenitor	[arresting differentiation of cell progenitors]	0.0	5	1	1	1
71946	1710	adhesion-dependent, ifn-gamma manner	[adhesion-dependent, IFN-gamma manner]	0.0	3	1	1	1
71947	1710	four NF-kappaB complex	[four NF-kappaB complexes]	0.0	3	1	1	1
71948	1710	lack the antigen	[lacking the antigen]	0.0	3	1	1	1
71949	1710	functional nuclear factor kB NF-kB element	[functional nuclear factor kB NF-kB elements]	0.0	6	1	1	1
71950	1710	Candida	[Candida]	0.0	1	4	4	1
71951	1710	receptor in repression	[receptor in repression]	0.0	3	1	1	1
71952	1710	minute posttreatment) relative	[minutes posttreatment) relative]	0.0	3	1	1	1
71953	1710	Kappa-B	[Kappa-B]	0.0	1	1	1	1
71954	1710	T cell receptor responsiveness	[T cell receptor responsiveness]	0.0	4	1	1	1
71955	1710	region include CBF	[regions including CBF]	0.0	3	1	1	1
71956	1710	il-4 promoter construct in cotransfection	[IL-4 promoter constructs in cotransfection]	0.0	5	1	1	1
71957	1710	pts; fluticasone: 1.55 pts)	[pts; fluticasone: 1.55 pts)]	0.0	4	1	1	1
71958	1710	promoter analysis of a element	[promoter analysis of an element]	0.0	5	1	1	1
71959	1710	disease such as distress syndrome	[diseases such as distress syndrome]	0.0	5	1	1	1
71960	1710	il-6 chloramphenicol transferase	[IL-6 chloramphenicol transferase]	0.0	3	1	1	1
71961	1710	rapid action of mineralocorticoid	[rapid actions of mineralocorticoids]	0.0	4	1	1	1
71962	1710	monocyte-macrophage colony stimulate	[monocyte-macrophage colony stimulating]	0.0	3	1	1	1
71963	1710	cysteine-rich domain lack sequence similarity	[cysteine-rich domain lacking sequence similarity]	0.0	5	1	1	1
71964	1710	contain complex	[containing complexes]	0.0	2	1	1	1
71965	1710	NK ec activation	[NK EC activation]	0.0	3	1	1	1
71966	1710	expression activation	[expression activation]	0.0	2	1	1	1
71967	1710	autoimmune thyroid disease: coregulation	[autoimmune thyroid disease: coregulation]	0.0	4	1	1	1
71968	1710	mononuclear cell reaction high grade	[mononuclear cell reaction high grade]	0.0	5	1	1	1
71969	1710	immunocytochemistry; fmol/mg protein by eia).	[immunocytochemistry; fmol/mg protein by EIA).]	0.0	5	1	1	1
71970	1710	characteristic of carcinoma	[characteristics of carcinomas]	0.0	3	1	1	1
71971	1710	paracrine action of tnf-alpha	[paracrine action of TNF-alpha]	0.0	4	1	1	1
71972	1710	hiv-1 nef expression	[HIV-1 Nef expression]	0.0	3	1	1	1
71973	1710	rapid analysis for diagnosis, counseling,	[rapid analysis for diagnosis, counseling,]	0.0	5	1	1	1
71974	1710	ganglioside as cell membrane constituent	[gangliosides as cell membrane constituents]	0.0	5	1	1	1
71975	1710	mm) of ethanol treatment in vitro	[mM) of ethanol treatment in vitro]	0.0	6	1	1	1
71976	1710	redox sensitivity,	[redox sensitivity,]	0.0	2	1	1	1
71977	1710	microg/g	[microg/g]	0.0	1	1	1	1
71978	1710	component of NF-ATc	[component of NF-ATc]	0.0	3	1	1	1
71979	1710	CArG motif	[CArG motif]	0.0	2	1	1	1
71980	1710	terminus of the protein.	[terminus of the protein.]	0.0	4	1	1	1
71981	1710	equal amount	[equal amounts]	0.0	2	1	1	1
71982	1710	protein/activation transcription factor family	[protein/activation transcription factor family]	0.0	4	1	1	1
71983	1710	oligomerization to a dna-binding trimer	[oligomerization to a DNA-binding trimer]	0.0	5	1	1	1
71984	1710	encode granule protein	[encoding granule proteins]	0.0	3	1	1	1
71985	1710	monolayer in assay	[monolayers in assays]	0.0	3	1	1	1
71986	1710	activation of STAT3 by IFN-gamma	[activation of STAT3 by IFN-gamma]	0.0	5	1	1	1
71987	1710	major recent developments, include the identification	[Major recent developments, including the identification]	0.0	6	1	1	1
71988	1710	expression a T cell-specific factor	[expression a T cell-specific factor]	0.0	5	1	1	1
71989	1710	Acanthamoeba castellanii	[Acanthamoeba castellanii]	0.0	2	1	1	1
71990	1710	functional cooperativity	[functional cooperativity]	0.0	2	1	1	1
71991	1710	transactivation by the human ciita	[transactivation by the human CIITA]	0.0	5	1	1	1
71992	1710	18 patient with leukaemia	[18 patients with leukaemia]	0.0	4	1	1	1
71993	1710	Ml antigen	[Mls antigens]	0.0	2	1	1	1
71994	1710	express high level of exogenous bcl-2	[expressing high levels of exogenous Bcl-2]	0.0	6	1	1	1
71995	1710	many year of relationship	[many years of relationship]	0.0	4	1	1	1
71996	1710	two gr bind abnormalities: 15	[two GR binding abnormalities: 15]	0.0	5	1	1	1
71997	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation]	0.0	5	1	1	1
71998	1710	role of paf	[role of PAF]	0.0	3	1	1	1
71999	1710	intranasal fluticasone propionate	[intranasal fluticasone propionate]	0.0	3	1	1	1
72000	1710	one palindrome	[one palindrome]	0.0	2	1	1	1
72001	1710	granulocyte factor granulocyte-macrophage factor	[granulocyte factor granulocyte-macrophage factor]	0.0	4	1	1	1
72002	1710	type ii estrogenic receptor	[Type II estrogenic receptors]	0.0	4	1	1	1
72003	1710	good candidate	[good candidate]	0.0	2	1	1	1
72004	1710	high affinity receptor for 1,25-dihydroxycholecalciferol	[High affinity receptors for 1,25-dihydroxycholecalciferol]	0.0	5	1	1	1
72005	1710	transcription factor Tax1	[transcription factor Tax1]	0.0	3	1	1	1
72006	1710	also constitutive activity concomitant	[also constitutive activity concomitant]	0.0	4	1	1	1
72007	1710	t-cell from individual with pathology LP	[T-cells from individuals with pathology LP]	0.0	6	1	1	1
72008	1710	e3 construct	[E3 constructs]	0.0	2	1	1	1
72009	1710	glycoprotein ix promoter	[glycoprotein IX promoter]	0.0	3	1	1	1
72010	1710	use a fragment of k protein	[Using a fragment of K protein]	0.0	6	1	1	1
72011	1710	agonistic property	[agonistic properties]	0.0	2	1	1	1
72012	1710	GTP-GDP state	[GTP-GDP state]	0.0	2	1	1	1
72013	1710	acetyl salicylic acid inhibition	[acetyl salicylic acid inhibition]	0.0	4	1	1	1
72014	1710	Glycoprotein	[Glycoprotein]	0.0	1	1	1	1
72015	1710	(NF) activation	[(NF) activation]	0.0	2	1	1	1
72016	1710	kd value of nm	[Kd values of nM]	0.0	4	1	1	1
72017	1710	expression of thrombospondin	[expression of thrombospondin]	0.0	3	1	1	1
72018	1710	pmol/L; in pregnant woman	[pmol/L; in pregnant women]	0.0	4	1	1	1
72019	1710	cellular redox	[cellular redox]	0.0	2	1	1	1
72020	1710	c-jun kinase	[c-Jun kinase]	0.0	2	1	1	1
72021	1710	condition of the PBMC	[conditions of the PBMC]	0.0	4	1	1	1
72022	1710	Stat3 signal	[Stat3 signals]	0.0	2	1	1	1
72023	1710	embryonic stem (es) cell	[embryonic stem (ES) cells]	0.0	4	1	1	1
72024	1710	common element response element	[common element Response Element]	0.0	4	1	1	1
72025	1710	replacement suggest a additional role	[Replacement suggesting an additional role]	0.0	5	1	1	1
72026	1710	explore stress-induced signal pathway	[exploring stress-induced signaling pathways]	0.0	4	1	1	1
72027	1710	1a promoter	[1A promoter]	0.0	2	1	1	1
72028	1710	impaired response in cell	[impaired responses in cells]	0.0	4	1	1	1
72029	1710	acid metabolism	[acid metabolism]	0.0	2	1	1	1
72030	1710	principal ligand	[principal ligands]	0.0	2	1	1	1
72031	1710	htafii105	[hTAFII105]	0.0	1	1	1	1
72032	1710	IL-1RII	[IL-1RII]	0.0	1	2	2	1
72033	1710	120 kd)	[120 kD)]	0.0	2	1	1	1
72034	1710	kg/m2)	[kg/m2),]	0.0	1	1	1	1
72035	1710	replication of immunodeficiency virus type-1	[Replication of immunodeficiency virus type-1]	0.0	5	1	1	1
72036	1710	product of PML-RAR alpha	[product of PML-RAR alpha]	0.0	4	1	1	1
72037	1710	entire NH2 domain	[entire NH2 domain]	0.0	3	1	1	1
72038	1710	establish the effectiveness	[establishing the effectiveness]	0.0	3	1	1	1
72039	1710	Culture in 5 m 9-cis RA	[Culture in 5 M 9-cis RA]	0.0	6	1	1	1
72040	1710	myeloid cytokine receptor	[myeloid cytokine receptors]	0.0	3	1	1	1
72041	1710	treatment with anti-immunoglobulin m	[Treatment with anti-immunoglobulin M]	0.0	4	1	1	1
72042	1710	CD40 cross-link link	[CD40 cross-linking link]	0.0	3	1	1	1
72043	1710	activity -convert enzyme family protease inhibitor	[activity -converting enzyme family protease inhibitors]	0.0	6	1	1	1
72044	1710	mrna from hypoxic ECs	[mRNA from hypoxic ECs]	0.0	4	1	1	1
72045	1710	gene encode EBNA 2	[gene encoding EBNA 2]	0.0	4	1	1	1
72046	1710	intracellular signal cascade	[intracellular signaling cascades]	0.0	3	1	1	1
72047	1710	hiv- replication	[HIV- replication]	0.0	2	1	1	1
72048	1710	IkappaB molecule	[IkappaB molecule]	0.0	2	1	1	1
72049	1710	htafii130	[hTAFII130]	0.0	1	1	1	1
72050	1710	2 beta zero- thalassemia patient	[2 beta zero- thalassemia patients]	0.0	5	1	1	1
72051	1710	undergo activation	[undergoing activation]	0.0	2	1	1	1
72052	1710	contrast to the endotoxin,	[contrast to the endotoxin,]	0.0	4	1	1	1
72053	1710	SCL helix-loop-helix transcription factor	[SCL helix-loop-helix transcription factors]	0.0	4	1	1	1
72054	1710	interference of RU	[interference of RU]	0.0	3	1	1	1
72055	1710	binding of several transcription factor essential	[binding of several transcription factors essential]	0.0	6	1	1	1
72056	1710	two class mutant cell line	[two class mutant cell lines]	0.0	5	1	1	1
72057	1710	difference in value of cancer patient	[Differences in values of cancer patients]	0.0	6	1	1	1
72058	1710	serum calcitriol	[serum calcitriol]	0.0	2	1	1	1
72059	1710	clonal pattern	[clonal pattern]	0.0	2	1	1	1
72060	1710	corticosterone in plasma	[corticosterone in plasma]	0.0	3	1	1	1
72061	1710	stimulation of the immunodeficiency virus type	[Stimulation of the immunodeficiency virus type]	0.0	6	1	1	1
72062	1710	dead cell at day 6;	[dead cells at day 6;]	0.0	5	1	1	1
72063	1710	vitro suppression	[vitro suppression]	0.0	2	1	1	1
72064	1710	redox state.	[redox state.]	0.0	2	1	1	1
72065	1710	b cell enhancer site	[B cell enhancer sites]	0.0	4	1	1	1
72066	1710	hormone-related protein gene promoter	[hormone-related protein gene promoter]	0.0	4	1	1	1
72067	1710	basic region/leucine zipper domain	[basic region/leucine zipper domain]	0.0	4	1	1	1
72068	1710	antibody antibody mab	[antibodies antibodies mAbs]	0.0	3	1	1	1
72069	1710	uptake of 3-o-methyl-d-glucose	[uptake of 3-O-methyl-D-glucose]	0.0	3	1	1	1
72070	1710	eight peptide	[eight peptides]	0.0	2	1	1	1
72071	1710	sideroblast in patient	[sideroblasts in patients]	0.0	3	1	1	1
72072	1710	multiple cell culture	[multiple cell culture]	0.0	3	1	1	1
72073	1710	monocyte activation.	[monocyte activation.]	0.0	2	1	1	1
72074	1710	patient (age 25-79)	[patients (age 25-79)]	0.0	3	1	1	1
72075	1710	reticulum ser ca2+-atpase SERCA	[reticulum SER Ca2+-ATPase SERCA]	0.0	4	1	1	1
72076	1710	human p75tnf-r in mouse	[human p75TNF-R in mice]	0.0	4	1	1	1
72077	1710	mycoestrogen none	[mycoestrogens none]	0.0	2	1	1	1
72078	1710	increase relative	[increase relative]	0.0	2	1	1	1
72079	1710	ad e1a sequence in the epithelium	[Ad E1a sequences in the epithelium]	0.0	6	1	1	1
72080	1710	p80c-rel a proto-oncogene	[p80c-rel a proto-oncogene]	0.0	3	1	1	1
72081	1710	3-week course	[3-week course]	0.0	2	1	1	1
72082	1710	activation globin promoter role	[activation globin promoter role]	0.0	4	1	1	1
72083	1710	nf-at activity among T cell	[NF-AT activity among T cells]	0.0	5	1	1	1
72084	1710	p45 nf-e2 mrna	[P45 NF-E2 mRNA]	0.0	3	1	1	1
72085	1710	patient with CLL rarely er	[patients with CLL rarely ER]	0.0	5	1	1	1
72086	1710	direct correlation between infiltration	[direct correlation between infiltration]	0.0	4	1	1	1
72087	1710	nf-kappab-like site	[NF-kappaB-like site]	0.0	2	1	1	1
72088	1710	adhesion at approximately 20 mM.	[adhesion at approximately 20 mM.]	0.0	5	1	1	1
72089	1710	different activation domain	[different activation domains]	0.0	3	1	1	1
72090	1710	skw cell with IL	[SKW cells with IL]	0.0	4	1	1	1
72091	1710	strategy manipulate immune response	[strategies manipulating immune responses]	0.0	4	1	1	1
72092	1710	phosphorylation the activity	[phosphorylation the activity]	0.0	3	1	1	1
72093	1710	tissue-specific site	[tissue-specific site]	0.0	2	1	1	1
72094	1710	infection of human blood lymphocyte	[Infection of human blood lymphocytes]	0.0	5	1	1	1
72095	1710	rapid increase from asthmatic patient	[rapid increase from asthmatic patients]	0.0	5	1	1	1
72096	1710	lymphoid t-cell proliferation	[lymphoid T-cell proliferations]	0.0	3	1	1	1
72097	1710	important human mediator	[important human mediator]	0.0	3	1	1	1
72098	1710	mass-to-charge ratio	[mass-to-charge ratio]	0.0	2	1	1	1
72099	1710	glucocorticosteroid receptor number	[glucocorticosteroid receptor number]	0.0	3	1	1	1
72100	1710	dependence conditions.	[dependence conditions.]	0.0	2	1	1	1
72101	1710	megakaryocytic transcript	[megakaryocytic transcripts]	0.0	2	1	1	1
72102	1710	use a polymerase chain method	[using a polymerase chain method]	0.0	5	1	1	1
72103	1710	nm23 -h1	[nm23 -H1]	0.0	2	1	1	1
72104	1710	Natural variant	[Natural variants]	0.0	2	1	1	1
72105	1710	increase expression along the erythroid pathway	[increasing expression along the erythroid pathway]	0.0	6	1	1	1
72106	1710	woman without diabete	[women without diabetes]	0.0	3	1	1	1
72107	1710	nontoxic concentration of metabolite of oxygen	[nontoxic concentrations of metabolites of oxygen]	0.0	6	1	1	1
72108	1710	apoptosis in hiv-infected cell induce apoptosis	[apoptosis in HIV-infected cells inducing apoptosis]	0.0	6	1	1	1
72109	1710	translocation of individual member	[translocation of individual members]	0.0	4	1	1	1
72110	1710	death signal	[death signals]	0.0	2	1	1	1
72111	1710	affinity binding of the radioligand	[affinity binding of the radioligand]	0.0	5	1	1	1
72112	1710	interleukin-2 il-2 growth	[interleukin-2 IL-2 growth]	0.0	3	1	1	1
72113	1710	chemotactic migration ChtM of human leukocyte	[chemotactic migration ChtM of human leukocytes]	0.0	6	1	1	1
72114	1710	block for alpha,25-dihydroxyvitamin D3 gene regulation	[block for alpha,25-dihydroxyvitamin D3 gene regulation]	0.0	6	1	1	1
72115	1710	rate of degradation	[rate of degradation]	0.0	3	1	1	1
72116	1710	part due to ability	[part due to ability]	0.0	4	1	1	1
72117	1710	allele loss 20q	[allele loss 20q]	0.0	3	1	1	1
72118	1710	C/EBPdelta NF-IL6beta	[C/EBPdelta NF-IL6beta]	0.0	2	1	1	1
72119	1710	basis in a patient	[basis in a patient]	0.0	4	1	1	1
72120	1710	analysis of the IL-4 down-regulatory effect	[analysis of the IL-4 down-regulatory effect]	0.0	6	1	1	1
72121	1710	human cord T lymphocyte	[human cord T lymphocytes]	0.0	4	1	1	1
72122	1710	overexpression a active version of c-Raf	[Overexpression a active version of c-Raf]	0.0	6	1	1	1
72123	1710	alpha403	[alpha403]	0.0	1	1	1	1
72124	1710	(interquartile range).	[(interquartile range).]	0.0	2	1	1	1
72125	1710	complex contain tr alpha 1	[complexes containing TR alpha 1]	0.0	5	1	1	1
72126	1710	cell-mediated immunity against pathogen	[cell-mediated immunity against pathogens]	0.0	4	1	1	1
72127	1710	framework signal	[framework signaling]	0.0	2	1	1	1
72128	1710	beta-estradiol e2	[beta-estradiol E2]	0.0	2	1	1	1
72129	1710	herpesvirus system herpes simplex	[herpesvirus systems herpes simplex]	0.0	4	1	1	1
72130	1710	diverse species	[diverse species]	0.0	2	1	1	1
72131	1710	express CD80	[expressing CD80]	0.0	2	1	1	1
72132	1710	inflammatory cytokine in epithelial cell	[inflammatory cytokines in epithelial cells]	0.0	5	1	1	1
72133	1710	aspect of interaction between nervous system	[aspects of interaction between nervous systems]	0.0	6	1	1	1
72134	1710	1.42 m-1	[1.42 M-1]	0.0	2	1	1	1
72135	1710	other cells; active factor	[other cells; active factors]	0.0	4	1	1	1
72136	1710	rd cell	[RD cells]	0.0	2	1	1	1
72137	1710	cooperative effect	[cooperative effect]	0.0	2	1	1	1
72138	1710	mutant progenitor cell	[mutant progenitor cells]	0.0	3	1	1	1
72139	1710	10(2) cell in vitro.	[10(2) cells in vitro.]	0.0	4	1	1	1
72140	1710	malignant lymphocytic cell	[malignant lymphocytic cells]	0.0	3	1	1	1
72141	1710	PI3-kinase /pkb/akt pathway	[PI3-kinase /PKB/Akt pathway]	0.0	3	1	1	1
72142	1710	i ifi in addition to IL-12	[I IFNs in addition to IL-12]	0.0	6	1	1	1
72143	1710	variable degree of staining.	[variable degrees of staining.]	0.0	4	1	1	1
72144	1710	substance such as bacterial formylpeptide	[substances such as bacterial formylpeptides]	0.0	5	1	1	1
72145	1710	damage in t-cell tumor	[damage in T-cell tumors]	0.0	4	1	1	1
72146	1710	lymphoma,	[lymphoma,]	0.0	1	1	1	1
72147	1710	NF-AT1 transcription	[NF-AT1 transcription]	0.0	2	1	1	1
72148	1710	expression of endothelial gene product	[expression of endothelial gene products]	0.0	5	1	1	1
72149	1710	co-transfection with mutant TNFRI	[Co-transfection with mutant TNFRI]	0.0	4	1	1	1
72150	1710	component of immunity	[component of immunity]	0.0	3	1	1	1
72151	1710	phosphate-supplemented patient 2.7)	[phosphate-supplemented patients 2.7)]	0.0	3	1	1	1
72152	1710	transcriptional pattern similar	[transcriptional pattern similar]	0.0	3	1	1	1
72153	1710	ligation of receptor	[ligation of receptors]	0.0	3	1	1	1
72154	1710	atherosclerotic plaque development	[atherosclerotic plaque development]	0.0	3	1	1	1
72155	1710	IFN factor 1 promoter	[IFN factor 1 promoter]	0.0	4	1	1	1
72156	1710	multiple biological activity	[multiple biological activities]	0.0	3	1	1	1
72157	1710	convert ligand-receptor interaction into functional modulation	[converting ligand-receptor interactions into functional modulation]	0.0	6	1	1	1
72158	1710	involve proviral clone	[involving proviral clones]	0.0	3	1	1	1
72159	1710	susceptibility in case-control study	[susceptibility in case-control studies]	0.0	4	1	1	1
72160	1710	Oct-1 binding protein	[Oct-1 binding proteins]	0.0	3	1	1	1
72161	1710	viral protein expression	[viral protein expression]	0.0	3	1	1	1
72162	1710	role in induction	[role in induction]	0.0	3	1	1	1
72163	1710	mediator like IL	[mediators like IL]	0.0	3	1	1	1
72164	1710	expression of a b-cell-specific transcription factor	[expression of a B-cell-specific transcription factor]	0.0	6	1	1	1
72165	1710	analysis of T	[analysis of T]	0.0	3	1	1	1
72166	1710	signal property	[signaling properties]	0.0	2	1	1	1
72167	1710	include NF-kappa b	[including NF-kappa B]	0.0	3	1	1	1
72168	1710	pkc of camp	[PKC of cAMP]	0.0	3	1	1	1
72169	1710	expression of interleukin-1	[expression of interleukin-1]	0.0	3	1	1	1
72170	1710	expression of interleukin-2	[expression of interleukin-2]	0.0	3	1	1	1
72171	1710	activator protein transcription factor	[activator protein transcription factors]	0.0	4	1	1	1
72172	1710	unilineage erythroid culture	[unilineage erythroid cultures]	0.0	3	1	1	1
72173	1710	evidence for the time	[evidence for the time]	0.0	4	1	1	1
72174	1710	human virus type htlv-1	[human virus type HTLV-1]	0.0	4	1	1	1
72175	1710	component of latent memory	[components of latent memory]	0.0	4	1	1	1
72176	1710	protein in eukaryote	[proteins in eukaryotes]	0.0	3	1	1	1
72177	1710	Wingless/Wnt signal	[Wingless/Wnt signal]	0.0	2	1	1	1
72178	1710	1-wk course of prednisone	[1-wk course of prednisone]	0.0	4	1	1	1
72179	1710	significantly favorable course	[significantly favorable course]	0.0	3	1	1	1
72180	1710	identical concentration of the compound	[identical concentrations of the compound]	0.0	5	1	1	1
72181	1710	two major difference	[two major differences]	0.0	3	1	1	1
72182	1710	portion of p105	[portion of p105]	0.0	3	1	1	1
72183	1710	s-phase fraction	[S-phase fraction]	0.0	2	1	1	1
72184	1710	highlight putative cancer related loci	[highlighting putative cancer related loci]	0.0	5	1	1	1
72185	1710	alone combination	[alone combination]	0.0	2	1	1	1
72186	1710	light of use	[light of use]	0.0	3	1	1	1
72187	1710	most prominent member	[most prominent members]	0.0	3	1	1	1
72188	1710	however, a good transactivator	[However, a better transactivator]	0.0	4	1	1	1
72189	1710	different subtype hhv-8 +/ebv- pel	[different subtypes HHV-8 +/EBV- PEL]	0.0	5	1	1	1
72190	1710	Spi-1 (r129c)	[Spi-1 (R129C)]	0.0	2	1	1	1
72191	1710	+/- fmol/10(7) pbmc versus 4.43 fmol/10(7)	[+/- fmol/10(7) PBMC vs 4.43 fmol/10(7)]	0.0	6	1	1	1
72192	1710	suppressor-inducer T	[suppressor-inducer T]	0.0	2	1	1	1
72193	1710	306 +/- 168)	[306 +/- 168)]	0.0	3	1	1	1
72194	1710	dna-binding activity, suggest essential	[DNA-binding activity, suggesting essential]	0.0	4	1	1	1
72195	1710	exposure of human endothelial cell	[exposure of human endothelial cells]	0.0	5	1	1	1
72196	1710	monocytic production	[monocytic production]	0.0	2	1	1	1
72197	1710	binding of human il-2	[binding of human IL-2]	0.0	4	1	1	1
72198	1710	dn fashion	[DN fashion]	0.0	2	1	1	1
72199	1710	binding antibody specific	[binding antibodies specific]	0.0	3	1	1	1
72200	1710	human class transactivator	[human class transactivator]	0.0	3	1	1	1
72201	1710	gamma-Interferon resistance to D3	[gamma-Interferon resistance to D3]	0.0	4	1	1	1
72202	1710	different response of cell	[different response of cells]	0.0	4	1	1	1
72203	1710	rel/nf-kappab -dependent induction	[Rel/NF-kappaB -dependent induction]	0.0	3	1	1	1
72204	1710	beta gene promoter	[beta gene promoter]	0.0	3	1	1	1
72205	1710	majority of aml m4eo	[majority of AML M4Eo]	0.0	4	1	1	1
72206	1710	uptake of [3h]1,25(oh)2d3 by PBMC	[uptake of [3H]1,25(OH)2D3 by PBMC]	0.0	5	1	1	1
72207	1710	co-expression in cell reporter plasmid	[Co-expression in cells reporter plasmids]	0.0	5	1	1	1
72208	1710	over-expression of this protein	[over-expression of this protein]	0.0	4	1	1	1
72209	1710	various kappa b motif	[various kappa B motifs]	0.0	4	1	1	1
72210	1710	potential protein segment	[potential protein segments]	0.0	3	1	1	1
72211	1710	form of leukemia include leukemia	[forms of leukemia including leukemia]	0.0	5	1	1	1
72212	1710	probe study signal transduction	[probes studying signal transduction]	0.0	4	1	1	1
72213	1710	platelet monoamine oxidase	[platelet monoamine oxidase]	0.0	3	1	1	1
72214	1710	upregulation adhesion molecule-1	[upregulation adhesion molecule-1]	0.0	3	1	1	1
72215	1710	increase in CAT activity	[Increases in CAT activity]	0.0	4	1	1	1
72216	1710	mature human myeloid cell	[mature human myeloid cells]	0.0	4	1	1	1
72217	1710	protein-1 activation	[protein-1 activation]	0.0	2	1	1	1
72218	1710	dominance of pathway	[dominance of pathway]	0.0	3	1	1	1
72219	1710	eadp-ribose)	[(ADP-ribose)]	0.0	1	1	1	1
72220	1710	even low dose	[even lower doses]	0.0	3	1	1	1
72221	1710	interaction with hormone receptor	[interaction with hormone receptors]	0.0	4	1	1	1
72222	1710	evidence of the coexpression	[evidence of the coexpression]	0.0	4	1	1	1
72223	1710	STAT protein in T cell	[STAT proteins in T cells]	0.0	5	1	1	1
72224	1710	clinical feature of resistance to glucocorticoid	[clinical features of resistance to glucocorticoids]	0.0	6	1	1	1
72225	1710	order the concentration	[orders the concentration]	0.0	3	1	1	1
72226	1710	binding to the interleukin-4 element	[binding to the interleukin-4 element]	0.0	5	1	1	1
72227	1710	1) inhibition of growth depletion	[1) inhibition of growth depletion]	0.0	5	1	1	1
72228	1710	mutation of the VDR	[mutations of the VDR]	0.0	4	1	1	1
72229	1710	role of the ap-1	[role of the AP-1]	0.0	4	1	1	1
72230	1710	control level by inhibitor	[control level by inhibitor]	0.0	4	1	1	1
72231	1710	inhibitor of protein phosphatase pp1	[inhibitor of protein phosphatases PP1/PP2A]	0.0	5	1	1	1
72232	1710	pretreatment of hl-60 cell	[Pretreatment of HL-60 cells]	0.0	4	1	1	1
72233	1710	effect show specific	[effect showing specific]	0.0	3	1	1	1
72234	1710	potent drug	[potent drug]	0.0	2	1	1	1
72235	1710	present hla molecule	[presenting HLA molecule]	0.0	3	1	1	1
72236	1710	hormone compound	[hormone compounds]	0.0	2	1	1	1
72237	1710	IL-2 prl dna-binding protein	[IL-2 PRL DNA-binding proteins]	0.0	4	1	1	1
72238	1710	major portion of the domain	[major portion of the domain]	0.0	5	1	1	1
72239	1710	lysis of the -resistant cell	[lysis of the -resistant cells]	0.0	5	1	1	1
72240	1710	complementarity for residue	[complementarity for residue]	0.0	3	1	1	1
72241	1710	epidemiologic feature with ebv include tumorigenesis.	[epidemiologic features with EBV including tumorigenesis.]	0.0	6	1	1	1
72242	1710	neutralize IL-6 abs	[neutralizing IL-6 Abs]	0.0	3	1	1	1
72243	1710	thus, genetic aberration	[Thus, genetic aberrations]	0.0	3	1	1	1
72244	1710	gene, transcript isolation of a transcript	[gene, transcripts isolation of an transcript]	0.0	6	1	1	1
72245	1710	distinct pattern of signal	[distinct patterns of signaling]	0.0	4	1	1	1
72246	1710	physiological function	[physiological functions]	0.0	2	1	1	1
72247	1710	frequent maternal expression	[frequent maternal expression]	0.0	3	1	1	1
72248	1710	such as dermatitis	[such as dermatitis]	0.0	3	1	1	1
72249	1710	dominant ikappabalpha	[dominant IkappaBalpha]	0.0	2	1	1	1
72250	1710	interleukin-1 signal	[interleukin-1 signaling]	0.0	2	1	1	1
72251	1710	fecal sodium loss	[fecal sodium losses]	0.0	3	1	1	1
72252	1710	cortisol BA	[cortisol BA]	0.0	2	1	1	1
72253	1710	hereditary disorder present in infancy	[hereditary disorder presenting in infancy]	0.0	5	1	1	1
72254	1710	early treatment with alpha-pml	[early treatment with alpha-PML]	0.0	4	1	1	1
72255	1710	domain 1 d1	[domain 1 D1]	0.0	3	1	1	1
72256	1710	recombinant thioredoxin T cell factor	[recombinant thioredoxin T cell factor]	0.0	5	1	1	1
72257	1710	regulation of cytokine gene expression	[regulation of cytokine gene expression]	0.0	5	1	1	1
72258	1710	b alpha evidence for a pathway	[B alpha evidence for an pathway]	0.0	6	1	1	1
72259	1710	disposition of sulphamethoxazole implication for hypersensitivity	[disposition of sulphamethoxazole implications for hypersensitivity]	0.0	6	1	1	1
72260	1710	include a heterodimer from extract consist	[including a heterodimer from extracts consisting]	0.0	6	1	1	1
72261	1710	however, three order	[however, three orders]	0.0	3	1	1	1
72262	1710	pkc- activation of ERK	[PKC- activation of ERK]	0.0	4	1	1	1
72263	1710	spectrum bind property	[spectrum binding properties]	0.0	3	1	1	1
72264	1710	hiv-1 strain	[HIV-1 strain]	0.0	2	1	1	1
72265	1710	adrenal androgen level	[adrenal androgen levels]	0.0	3	1	1	1
72266	1710	effect of ketoconazole	[effects of ketoconazole]	0.0	3	1	1	1
72267	1710	stimuli, lipopolysaccharide	[stimuli, lipopolysaccharide]	0.0	2	1	1	1
72268	1710	phospholipase c-gamma1	[phospholipase C-gamma1]	0.0	2	1	1	1
72269	1710	strategy use pkc inhibitors, pentoxifylline	[strategy using PKC inhibitors, pentoxifylline]	0.0	5	1	1	1
72270	1710	NF-kappa b inhibitor b epsilon	[NF-kappa B inhibitor B epsilon]	0.0	5	1	1	1
72271	1710	activation of lymphocyte	[activation of lymphocytes]	0.0	3	1	1	1
72272	1710	class ii histocompatibility complex promoter	[class II histocompatibility complex promoters]	0.0	5	1	1	1
72273	1710	lef/tcf factor	[LEF/TCF factors]	0.0	2	1	1	1
72274	1710	Rapid ca2+-mediated activation of Rap1	[Rapid Ca2+-mediated activation of Rap1]	0.0	5	1	1	1
72275	1710	age dependence	[age dependence]	0.0	2	1	1	1
72276	1710	other T cell activity	[other T cell activities]	0.0	4	1	1	1
72277	1710	concentration in vitro,	[concentrations in vitro,]	0.0	3	1	1	1
72278	1710	support previous hypothesis	[supporting previous hypothesis]	0.0	3	1	1	1
72279	1710	constitutive phosphorylation usually, STAT3	[Constitutive phosphorylation usually, STAT3]	0.0	4	1	1	1
72280	1710	establish high-density pbmc culture	[establishing high-density PBMC cultures]	0.0	4	1	1	1
72281	1710	tpa factor protein OAP40	[TPA factor protein OAP40]	0.0	4	1	1	1
72282	1710	thus form a system	[thus forming a system]	0.0	4	1	1	1
72283	1710	3.8-kb fragment	[3.8-kb fragment]	0.0	2	1	1	1
72284	1710	process of normal differentiation	[processes of normal differentiation]	0.0	4	1	1	1
72285	1710	cause of primary cortisol resistance	[cause of primary cortisol resistance]	0.0	5	1	1	1
72286	1710	mrna expression at mumol/L pdtc	[mRNA expression at mumol/L PDTC]	0.0	5	1	1	1
72287	1710	determine function	[determining function]	0.0	2	1	1	1
72288	1710	lack the transcriptional activator function	[lacking the transcriptional activator functions]	0.0	5	1	1	1
72289	1710	increase in il-8 messenger rna	[increases in IL-8 messenger RNA]	0.0	5	1	1	1
72290	1710	more than 5.6 kb	[more than 5.6 kb]	0.0	4	1	1	1
72291	1710	minimal activation	[minimal activation]	0.0	2	1	1	1
72292	1710	IL-2 activation	[IL-2 activation]	0.0	2	1	1	1
72293	1710	discordant xenograft rejection	[discordant xenograft rejection]	0.0	3	1	1	1
72294	1710	hcmv glycoprotein	[HCMV glycoproteins]	0.0	2	1	1	1
72295	1710	relationship between risk	[relationship between risk]	0.0	3	1	1	1
72296	1710	nf-kappa B/Rel activity	[NF-kappa B/Rel activity]	0.0	3	1	1	1
72297	1710	position of nucleotide	[position of nucleotides]	0.0	3	1	1	1
72298	1710	binding characteristic	[Binding characteristics]	0.0	2	1	1	1
72299	1710	s-allyl	[S-allyl]	0.0	1	1	1	1
72300	1710	contrast to u937 cell	[contrast to U937 cells]	0.0	4	1	1	1
72301	1710	pou transcription	[POU transcription]	0.0	2	1	1	1
72302	1710	eight patient years)	[Eight patients years)]	0.0	3	1	1	1
72303	1710	thymocyte in transgenic mouse	[thymocytes in transgenic mice]	0.0	4	1	1	1
72304	1710	cell polypryrimidine-binding factor	[cells polypryrimidine-binding factor]	0.0	3	1	1	1
72305	1710	activity in the presence	[activity in the presence]	0.0	4	1	1	1
72306	1710	endometrium during the cycle	[endometrium during the cycle]	0.0	4	1	1	1
72307	1710	adhesion in vein endothelial cell HUVECs	[adhesion in vein endothelial cells HUVECs]	0.0	6	1	1	1
72308	1710	ets-1 function	[ets-1 functions]	0.0	2	1	1	1
72309	1710	induction of p40	[induction of p40]	0.0	3	1	1	1
72310	1710	fmol/mg protein of estrogen receptor	[fmol/mg protein of estrogen receptor]	0.0	5	1	1	1
72311	1710	human epstein-barr virus b lymphocyte	[human Epstein-Barr virus B lymphocytes]	0.0	5	1	1	1
72312	1710	abrogate kappab	[abrogates kappaB]	0.0	2	1	1	1
72313	1710	protein binding site for Sp1	[protein binding sites for Sp1]	0.0	5	1	1	1
72314	1710	macrophage procoagulant activity	[macrophage procoagulant activity]	0.0	3	1	1	1
72315	1710	corneal cell	[corneal cells]	0.0	2	2	2	1
72316	1710	(2-6 h) effect	[(2-6 h) effects]	0.0	3	1	1	1
72317	1710	alpha in the NH2-terminal residue	[alpha in the NH2-terminal residues]	0.0	5	1	1	1
72318	1710	encode a seven receptor	[encoding a seven receptor]	0.0	4	1	1	1
72319	1710	basis for mimicry	[basis for mimicry]	0.0	3	1	1	1
72320	1710	second peak at h	[second peak at h]	0.0	4	1	1	1
72321	1710	expression of differentiation-associated phenotype	[expression of differentiation-associated phenotypes]	0.0	4	1	1	1
72322	1710	type estrogenic receptor	[Type estrogenic receptors]	0.0	3	1	1	1
72323	1710	interaction circulate T cell	[interactions circulating T cells]	0.0	4	1	1	1
72324	1710	mycoplasma material MDHM	[Mycoplasma material MDHM]	0.0	3	1	1	1
72325	1710	post-gc b	[post-GC B]	0.0	2	1	1	1
72326	1710	platelet for 6 hours,	[platelets for 6 hours,]	0.0	4	1	1	1
72327	1710	immunization with adenovirus,	[immunization with adenovirus,]	0.0	3	1	1	1
72328	1710	J2 in monocyte-derived macrophage	[J2 in monocyte-derived macrophages]	0.0	4	1	1	1
72329	1710	two promoter Palpha	[two promoters Palpha]	0.0	3	1	1	1
72330	1710	comparison to variant	[comparison to variants]	0.0	3	1	1	1
72331	1710	imbalanced expression	[Imbalanced expression]	0.0	2	2	2	1
72332	1710	/anti-cd28 T lymphocyte with il-7	[/anti-CD28 T lymphocytes with IL-7]	0.0	5	1	1	1
72333	1710	model of myeloid differentiation.	[model of myeloid differentiation.]	0.0	4	1	1	1
72334	1710	expression of human factor-1 receptor	[expression of human factor-1 receptor]	0.0	5	1	1	1
72335	1710	propagate the inactive state,	[propagating the inactive state,]	0.0	4	1	1	1
72336	1710	loss of transactivation,	[loss of transactivation,]	0.0	3	1	1	1
72337	1710	presence of bind site	[presence of binding sites]	0.0	4	1	1	1
72338	1710	contrast, level	[contrast, levels]	0.0	2	1	1	1
72339	1710	splenic erythroblast	[splenic erythroblasts]	0.0	2	1	1	1
72340	1710	hypoxic induction of gene expression	[Hypoxic induction of gene expression]	0.0	5	1	1	1
72341	1710	expression of recombination	[expression of recombination]	0.0	3	1	1	1
72342	1710	complex with two class of receptor	[complexes with two classes of receptors]	0.0	6	1	1	1
72343	1710	tal-1 animal	[tal-1 animals]	0.0	2	1	1	1
72344	1710	only through evaluation	[Only through evaluation]	0.0	3	1	1	1
72345	1710	kinetic a finding inconsistent	[kinetics a finding inconsistent]	0.0	4	1	1	1
72346	1710	protein-coding region	[protein-coding region]	0.0	2	1	1	1
72347	1710	concentration of ethanol	[concentrations of ethanol]	0.0	3	1	1	1
72348	1710	one explanation for toxicity	[one explanation for toxicities]	0.0	4	1	1	1
72349	1710	rare disorder present in infancy	[rare disorder presenting in infancy]	0.0	5	1	1	1
72350	1710	granurocyte	[granurocytes]	0.0	1	1	1	1
72351	1710	amino acid c-terminal	[amino acids C-terminal]	0.0	3	1	1	1
72352	1710	fas ligand fasl	[Fas ligand FasL]	0.0	3	1	1	1
72353	1710	gas DNA binding	[GAS DNA binding]	0.0	3	1	1	1
72354	1710	highlight putative loci	[highlighting putative loci]	0.0	3	1	1	1
72355	1710	fresh leukemic cell stage of differentiation,	[fresh leukemic cells stage of differentiation,]	0.0	6	1	1	1
72356	1710	means assess cell proliferation.	[means assessing cell proliferation.]	0.0	4	1	1	1
72357	1710	rat ventral prostate tissue	[rat ventral prostate tissue]	0.0	4	1	1	1
72358	1710	contrast a site	[contrast a site]	0.0	3	2	2	1
72359	1710	thus, development of m-tat cell	[Thus, development of M-TAT cells]	0.0	5	1	1	1
72360	1710	control the development	[controlling the development]	0.0	3	1	1	1
72361	1710	low production	[lower production]	0.0	2	1	1	1
72362	1710	Ig class	[Ig class]	0.0	2	1	1	1
72363	1710	50 nm alpha,25-dihydroxyvitamin D3 D3	[50 nM alpha,25-dihydroxyvitamin D3 D3]	0.0	5	1	1	1
72364	1710	HBx peptide elisa	[HBx peptide ELISAs]	0.0	3	1	1	1
72365	1710	one type-specific t-cell clone reactive	[one type-specific T-cell clone reactive]	0.0	5	1	1	1
72366	1710	consensus sequence gene exhibit	[consensus sequences gene exhibits]	0.0	4	1	1	1
72367	1710	level in monocytic than cell	[levels in monocytic than cells]	0.0	5	1	1	1
72368	1710	reduction in lymphocyte	[reduction in lymphocytes]	0.0	3	1	1	1
72369	1710	woman young than mcr	[women younger than MCR]	0.0	4	1	1	1
72370	1710	difference in transcriptional enhancer	[Differences in transcriptional enhancers]	0.0	4	1	1	1
72371	1710	dose rate	[dose rate]	0.0	2	1	1	1
72372	1710	residue kinetic analysis	[residues Kinetic analysis]	0.0	3	1	1	1
72373	1710	8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate	[8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate]	0.0	1	1	1	1
72374	1710	Intimate interaction between stem cell	[Intimate interactions between stem cells]	0.0	5	1	1	1
72375	1710	role in the inflammatory cascade	[role in the inflammatory cascade]	0.0	5	1	1	1
72376	1710	h of culture.	[h of culture.]	0.0	3	1	1	1
72377	1710	immunoblotting of fraction	[immunoblotting of fractions]	0.0	3	1	1	1
72378	1710	multiple stimulus	[multiple stimuli]	0.0	2	1	1	1
72379	1710	il-6 mrna level	[IL-6 mRNA levels]	0.0	3	1	1	1
72380	1710	oxygen formation in T cell	[oxygen formation in T cells]	0.0	5	1	1	1
72381	1710	il-4-induced tyrosine phosphorylation of intracellular substrate	[IL-4-induced tyrosine phosphorylation of intracellular substrates]	0.0	6	1	1	1
72382	1710	tyrosine protein	[tyrosine protein]	0.0	2	1	1	1
72383	1710	modulate effect of RA	[modulating effects of RA]	0.0	4	1	1	1
72384	1710	Ii kappa	[Ii kappa]	0.0	2	1	1	1
72385	1710	mutant form of DeltaE	[mutant form of DeltaE]	0.0	4	1	1	1
72386	1710	affinity for interleukin-6 IL-6	[affinity for interleukin-6 IL-6]	0.0	4	1	1	1
72387	1710	Glucocorticoid hormone suppression	[Glucocorticoid hormone suppression]	0.0	3	1	1	1
72388	1710	probes,	[probes,]	0.0	1	1	1	1
72389	1710	staining comparable	[staining comparable]	0.0	2	1	1	1
72390	1710	encode a transcription factor	[encoding a transcription factor]	0.0	4	1	1	1
72391	1710	nfkb2 induction of c-rel	[NFKB2 induction of c-Rel]	0.0	4	1	1	1
72392	1710	effect on OCA-B -dependent transcription	[effect on OCA-B -dependent transcription]	0.0	5	1	1	1
72393	1710	medium cm	[medium CM]	0.0	2	1	1	1
72394	1710	effect of il-10 on lipopolysaccharide	[effect of IL-10 on lipopolysaccharide]	0.0	5	1	1	1
72395	1710	differentiation of red cell progenitor	[differentiation of red cell progenitors]	0.0	5	1	1	1
72396	1710	mechanism for the induction	[mechanism for the induction]	0.0	4	1	1	1
72397	1710	histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	5	1	1	1
72398	1710	competition between general transcriptional activator RelA	[competition between general transcriptional activators RelA]	0.0	6	1	1	1
72399	1710	however, treatment	[However, treatment]	0.0	2	1	1	1
72400	1710	proliferative potential in response	[proliferative potential in response]	0.0	4	1	1	1
72401	1710	cpo gene between cell	[CPO gene between cells]	0.0	4	1	1	1
72402	1710	extensive granulopoiesis postnatally, typically die days.	[extensive granulopoiesis postnatally, typically dying days.]	0.0	6	1	1	1
72403	1710	b-cell response	[B-cell response]	0.0	2	1	1	1
72404	1710	bind site for cellular factor	[binding sites for cellular factors]	0.0	5	1	1	1
72405	1710	nine different cDNA clone	[nine different cDNA clones]	0.0	4	1	1	1
72406	1710	low range for age,	[lower range for age,]	0.0	4	1	1	1
72407	1710	cell outgrowth	[cell outgrowth]	0.0	2	1	1	1
72408	1710	normal cell in vitro.	[normal cells in vitro.]	0.0	4	1	1	1
72409	1710	originate 204 bp upstream	[originating 204 bp upstream]	0.0	4	1	1	1
72410	1710	potential measure	[potential measures]	0.0	2	1	1	1
72411	1710	cell line K562	[cell lines K562]	0.0	3	1	1	1
72412	1710	phenotypically distinct type of macrophage	[phenotypically distinct types of macrophages]	0.0	5	1	1	1
72413	1710	micromol/(mg	[micromol/(mg]	0.0	1	1	1	1
72414	1710	type interferon ifn-alpha/beta	[type interferons IFN-alpha/beta]	0.0	3	1	1	1
72415	1710	transactivation type ii tax protein	[Transactivation type II Tax proteins]	0.0	5	1	1	1
72416	1710	such as the uterus myometrium	[such as the uterus myometrium]	0.0	5	1	1	1
72417	1710	integer number	[integer numbers]	0.0	2	1	1	1
72418	1710	early event in transformation	[early event in transformation]	0.0	4	1	1	1
72419	1710	3'-untranslated region polymorphism lack	[3'-untranslated region polymorphisms lack]	0.0	4	1	1	1
72420	1710	CD40 domain truncation	[CD40 domain truncation]	0.0	3	1	1	1
72421	1710	oncogene expression	[oncogene expression]	0.0	2	1	1	1
72422	1710	immunosorbent assay with peptide	[immunosorbent assay with peptides]	0.0	4	1	1	1
72423	1710	patient with melanoma RCC	[patients with melanoma RCC]	0.0	4	1	1	1
72424	1710	indicate a rate of apoptosis	[indicating an rate of apoptosis]	0.0	5	1	1	1
72425	1710	event coincide with the release	[events coinciding with the release]	0.0	5	1	1	1
72426	1710	adrenocorticotropic hormone acth release	[adrenocorticotropic hormone ACTH release]	0.0	4	1	1	1
72427	1710	(RNA) blot of various mouse tissue	[(RNA) blots of various mouse tissues]	0.0	6	1	1	1
72428	1710	(pfge)	[(PFGE)]	0.0	1	1	1	1
72429	1710	co-stimulation with concentration	[Co-stimulation with concentrations]	0.0	3	1	1	1
72430	1710	72 hour	[72 hours]	0.0	2	1	1	1
72431	1710	/p21rex	[/p21rex]	0.0	1	1	1	1
72432	1710	heterozygosity at marker	[heterozygosity at markers]	0.0	3	1	1	1
72433	1710	incubation with dose	[incubation with doses]	0.0	3	1	1	1
72434	1710	blood lymphocyte bronchial asthma	[blood lymphocytes bronchial asthma]	0.0	4	1	1	1
72435	1710	many kind include ionizing radiation.	[many kinds including ionizing radiation.]	0.0	5	1	1	1
72436	1710	least one sp site	[least one Sp site]	0.0	4	1	1	1
72437	1710	proliferation, cytotoxicity, tumor necrosis factor	[proliferation, cytotoxicity, tumor necrosis factor]	0.0	5	1	1	1
72438	1710	partial monosomy	[partial monosomy]	0.0	2	1	1	1
72439	1710	co-stimulation of t-lymphocyte	[Co-stimulation of T-lymphocytes]	0.0	3	1	1	1
72440	1710	jun-B the nuclear transcription protein	[jun-B the nuclear transcription protein]	0.0	5	1	1	1
72441	1710	c-rel/p50	[c-Rel/p50]	0.0	1	1	1	1
72442	1710	expression protein a stat1alpha -responsive gene	[Expression protein a STAT1alpha -responsive gene]	0.0	6	1	1	1
72443	1710	further information	[further information]	0.0	2	1	1	1
72444	1710	activity of promoter in fibroblast	[activity of promoters in fibroblasts]	0.0	5	1	1	1
72445	1710	promoter-driven beta-galactosidase gene	[promoter-driven beta-galactosidase gene]	0.0	3	1	1	1
72446	1710	suggest operational in T lymphocyte	[suggesting operational in T lymphocytes]	0.0	5	1	1	1
72447	1710	affinity for aldosterone	[affinity for aldosterone]	0.0	3	1	1	1
72448	1710	prime from signal in vivo modulation	[priming from signal in vivo modulation]	0.0	6	1	1	1
72449	1710	cytoplasmic state	[cytoplasmic state]	0.0	2	1	1	1
72450	1710	mol/L for pbmc	[mol/L for PBMC]	0.0	3	1	1	1
72451	1710	mature lymphocyte	[Mature lymphocytes]	0.0	2	1	1	1
72452	1710	human mononuclear leukocyte of healthy donor	[human mononuclear leukocytes of healthy donors]	0.0	6	1	1	1
72453	1710	-ligand interaction	[-ligand interactions]	0.0	2	1	1	1
72454	1710	direct role	[direct role]	0.0	2	1	1	1
72455	1710	production of the p75tnf-r	[production of the p75TNF-R]	0.0	4	1	1	1
72456	1710	very low, concentration of aldosterone	[very low, concentrations of aldosterone]	0.0	5	2	2	1
72457	1710	expression of coactivator bob.1/obf.1 comments]	[expression of coactivator BOB.1/OBF.1 comments]]	0.0	5	1	1	1
72458	1710	hierarchy of transcriptional control	[hierarchy of transcriptional control]	0.0	4	1	1	1
72459	1710	il-6 in pbmc	[IL-6 in PBMCs]	0.0	3	1	1	1
72460	1710	activation-inducible protein	[activation-inducible proteins]	0.0	2	1	1	1
72461	1710	case of selection	[case of selection]	0.0	3	1	1	1
72462	1710	ability of defensin	[ability of defensins]	0.0	3	1	1	1
72463	1710	myeloid u-937 cell	[myeloid U-937 cells]	0.0	3	1	1	1
72464	1710	mononuclear cell of transplant recipient	[mononuclear cells of transplant recipients]	0.0	5	1	1	1
72465	1710	tyrosine kinase p59fyn	[tyrosine kinase p59fyn]	0.0	3	1	1	1
72466	1710	extensive alternative splicing	[extensive alternative splicing]	0.0	3	1	1	1
72467	1710	complex contain stat4 with stat1 alpha	[complexes containing STAT4 with STAT1 alpha]	0.0	6	1	1	1
72468	1710	action in T cell	[action in T cells]	0.0	4	1	1	1
72469	1710	prostaglandin pge2 in monocyte	[prostaglandin PGE2 in monocytes]	0.0	4	1	1	1
72470	1710	previously, a factor irf-1 interferon factor	[Previously, a factor IRF-1 interferon factor]	0.0	6	1	1	1
72471	1710	experiment with cytokine	[experiments with cytokines]	0.0	3	1	1	1
72472	1710	several round	[several round]	0.0	2	1	1	1
72473	1710	Differential regulation in monocytic cell line	[Differential regulation in monocytic cell lines]	0.0	6	1	1	1
72474	1710	AP-2 consensus	[AP-2 consensus]	0.0	2	1	1	1
72475	1710	signal for AP-1	[signal for AP-1]	0.0	3	1	1	1
72476	1710	T lymphocytes.	[T lymphocytes.]	0.0	2	1	1	1
72477	1710	kinase receptor	[kinase receptors]	0.0	2	1	1	1
72478	1710	T lymphocytes,	[T lymphocytes,]	0.0	2	1	1	1
72479	1710	1-long repeat hiv-1-ltr	[1-long repeat HIV-1-LTR]	0.0	3	1	1	1
72480	1710	extract from Daudi cell	[extract from Daudi cells]	0.0	4	1	1	1
72481	1710	effect on SIVmac replication	[effects on SIVmac replication]	0.0	4	1	1	1
72482	1710	umbilical vein cell monolayer	[umbilical vein cell monolayers]	0.0	4	1	1	1
72483	1710	lack of significant level	[lack of significant levels]	0.0	4	1	1	1
72484	1710	site of gc production	[site of GC production]	0.0	4	1	1	1
72485	1710	different levels,	[different levels,]	0.0	2	1	1	1
72486	1710	nuclei of pbl	[Nuclei of PBL]	0.0	3	1	1	1
72487	1710	regulate the cell death pathway	[regulating the cell death pathway]	0.0	5	1	1	1
72488	1710	therapeutic drug for disease	[therapeutic drugs for diseases]	0.0	4	1	1	1
72489	1710	regulate the growth of cell	[regulating the growth of cells]	0.0	5	1	1	1
72490	1710	site of gc production sialoadhesin	[site of GC production sialoadhesin]	0.0	5	1	1	1
72491	1710	novel molecule	[novel molecule]	0.0	2	1	1	1
72492	1710	5% serum	[5% serum]	0.0	2	1	1	1
72493	1710	Epstein-Barr virus tumor in patient	[Epstein-Barr virus tumors in patients]	0.0	5	1	1	1
72494	1710	Intracellular deletion variant of tlr2	[Intracellular deletion variants of TLR2]	0.0	5	1	1	1
72495	1710	Tax1 transcription factor	[Tax1 transcription factors]	0.0	3	1	1	1
72496	1710	member after CD40 induction	[members after CD40 induction]	0.0	4	1	1	1
72497	1710	nuclear resonance spectroscopy	[nuclear resonance spectroscopy]	0.0	3	1	1	1
72498	1710	expression in blood monocyte	[expression in blood monocytes]	0.0	4	1	1	1
72499	1710	nfat activation,	[NFAT activation,]	0.0	2	1	1	1
72500	1710	monolayer of vein cell	[monolayers of vein cells]	0.0	4	1	1	1
72501	1710	role of AMP response	[Role of AMP response]	0.0	4	1	1	1
72502	1710	high level of nfat activity	[high levels of NFAT activities]	0.0	5	1	1	1
72503	1710	important molecular mediator	[important molecular mediator]	0.0	3	1	1	1
72504	1710	proinflammatory lymphokine interleukin-1beta	[proinflammatory lymphokine interleukin-1beta]	0.0	3	1	1	1
72505	1710	camp -dependent regulation of proenkephalin effect	[cAMP -dependent regulation of proenkephalin effects]	0.0	6	1	1	1
72506	1710	nuclear translocation of this member	[nuclear translocation of these members]	0.0	5	1	1	1
72507	1710	rank tail	[RANK tail]	0.0	2	1	1	1
72508	1710	kinase pathway SAPK /jnk	[kinase pathway SAPK /JNK]	0.0	4	1	1	1
72509	1710	camp regulatory element	[cAMP regulatory element]	0.0	3	1	1	1
72510	1710	9-bp motif with high homology	[9-bp motifs with high homology]	0.0	5	1	1	1
72511	1710	expression of ifn-alpha5	[expression of IFN-alpha5]	0.0	3	1	1	1
72512	1710	dominant negative effector	[dominant negative effector]	0.0	3	1	1	1
72513	1710	master gene control the expression	[master gene controlling the expression]	0.0	5	1	1	1
72514	1710	analysis with a transient expression assay	[analysis with a transient expression assay]	0.0	6	1	1	1
72515	1710	regulation of signal transduction	[regulation of signal transduction]	0.0	4	1	1	1
72516	1710	DNA motif within the ECS	[DNA motifs within the ECS]	0.0	5	1	1	1
72517	1710	hmg box related	[HMG box related]	0.0	3	1	1	1
72518	1710	alpha thf/thf ratios.	[alpha THF/THF ratios.]	0.0	3	1	1	1
72519	1710	kd (30.3+/-2.5 versus 19.2+/-2.4 nmol/L) nmol/L)	[Kd (30.3+/-2.5 versus 19.2+/-2.4 nmol/L) nmol/L)]	0.0	6	1	1	1
72520	1710	great than 10-fold activity.	[greater than 10-fold activity.]	0.0	4	1	1	1
72521	1710	il-10 suppression	[IL-10 suppression]	0.0	2	1	1	1
72522	1710	hepatic factor 3 beta	[hepatic factor 3 beta]	0.0	4	1	1	1
72523	1710	dysplasia cmpd1	[dysplasia CMPD1]	0.0	2	1	1	1
72524	1710	negative regulatory DNA sequence	[negative regulatory DNA sequences]	0.0	4	1	1	1
72525	1710	2-50 gy result	[2-50 Gy results]	0.0	3	1	1	1
72526	1710	role in culture	[role in cultures]	0.0	3	1	1	1
72527	1710	role of ppargamma	[role of PPARgamma]	0.0	3	1	1	1
72528	1710	contain different gene element	[containing different gene elements]	0.0	4	1	1	1
72529	1710	calcium-dependent, cyclosporin-sensitive, modification	[calcium-dependent, cyclosporin-sensitive, modification]	0.0	3	1	1	1
72530	1710	[H-2k]	[[H-2k]]	0.0	1	1	1	1
72531	1710	effector of non-cytotoxic lmp-1 signal	[effector of non-cytotoxic LMP-1 signaling]	0.0	5	1	1	1
72532	1710	hemopoi-etic cell	[hemopoi-etic cells]	0.0	2	1	1	1
72533	1710	treatment hpc	[treatment HPCs]	0.0	2	1	1	1
72534	1710	fundamental insight into the molecular mechanism	[fundamental insights into the molecular mechanisms]	0.0	6	1	1	1
72535	1710	(i.p.)	[(i.p.)]	0.0	1	1	1	1
72536	1710	glycoprotein b	[glycoprotein B]	0.0	2	1	1	1
72537	1710	glycoprotein c	[glycoprotein C]	0.0	2	1	1	1
72538	1710	CD95 ligand promoter.	[CD95 ligand promoter.]	0.0	3	1	1	1
72539	1710	er staining	[ER staining]	0.0	2	1	1	1
72540	1710	important pathway lead to modulation	[important pathway leading to modulation]	0.0	5	1	1	1
72541	1710	human CLEO element	[human CLEO element]	0.0	3	1	1	1
72542	1710	more substitution alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[more substitutions alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	4	1	1	1
72543	1710	many year of symbiotic, relationship	[many years of symbiotic, relationship]	0.0	5	1	1	1
72544	1710	maintenance of pregnancy,	[maintenance of pregnancy,]	0.0	3	1	1	1
72545	1710	keratin	[keratin]	0.0	1	1	1	1
72546	1710	diverse cell type	[diverse cell types]	0.0	3	1	1	1
72547	1710	high dose result in suppression	[High doses resulting in suppression]	0.0	5	1	1	1
72548	1710	carboxyl-terminal peptide	[carboxyl-terminal peptide]	0.0	2	1	1	1
72549	1710	heterodimerization of VDR	[heterodimerization of VDR]	0.0	3	1	1	1
72550	1710	however, substitution	[However, substitution]	0.0	2	1	1	1
72551	1710	utilize this sequence	[utilizing this sequence]	0.0	3	1	1	1
72552	1710	importantly, C-JUN as oligonucleotide	[importantly, C-JUN AS oligonucleotides]	0.0	4	1	1	1
72553	1710	also in development	[also in development]	0.0	3	1	1	1
72554	1710	look back	[Looking back]	0.0	2	1	1	1
72555	1710	inactivation in cell	[inactivation in cells]	0.0	3	1	1	1
72556	1710	gross level	[gross levels]	0.0	2	1	1	1
72557	1710	complex model	[complex model]	0.0	2	1	1	1
72558	1710	splicing of exon 10	[splicing of exon 10]	0.0	4	1	1	1
72559	1710	affinity to NF-kappa b	[affinity to NF-kappa B]	0.0	4	1	1	1
72560	1710	bind selectivity for aldosterone	[binding selectivity for aldosterone]	0.0	4	1	1	1
72561	1710	select aberration in the apoptotic pathway	[select aberrations in the apoptotic pathway]	0.0	6	1	1	1
72562	1710	umbilical vein ec	[umbilical vein EC]	0.0	3	1	1	1
72563	1710	activation of human primary t-lymphocyte	[activation of human primary T-lymphocytes]	0.0	5	1	1	1
72564	1710	human interleukin-4	[human interleukin-4]	0.0	2	1	1	1
72565	1710	human interleukin-5	[human interleukin-5]	0.0	2	1	1	1
72566	1710	ligand up-regulated monocyte gene expression	[ligands up-regulated monocyte gene expression]	0.0	5	1	1	1
72567	1710	increase in intracellular-free calcium ion	[increase in intracellular-free calcium ions]	0.0	5	1	1	1
72568	1710	DNA binding, activation	[DNA binding, activation]	0.0	3	1	1	1
72569	1710	human interleukin-3	[human interleukin-3]	0.0	2	1	1	1
72570	1710	cycle reactivity undetectable in LCL population	[cycle reactivities undetectable in LCL populations]	0.0	6	1	1	1
72571	1710	number of estrogen receptor	[number of estrogen receptors]	0.0	4	3	3	1
72572	1710	use a lymphoma-derived hybridoma	[using a lymphoma-derived hybridoma]	0.0	4	1	1	1
72573	1710	pretreatment with microm OP for hour	[Pretreatment with microM OP for hr,]	0.0	6	1	1	1
72574	1710	direct contribution to rheumatoid arthritis	[direct contribution to rheumatoid arthritis]	0.0	5	1	1	1
72575	1710	development of human pathology	[development of human pathologies]	0.0	4	1	1	1
72576	1710	peripheral blood lymphocyte with cysteamine	[peripheral blood lymphocytes with cysteamine]	0.0	5	1	1	1
72577	1710	examine	[examining]	0.0	1	1	1	1
72578	1710	synteny with mouse chromosome	[synteny with mouse chromosome]	0.0	4	1	1	1
72579	1710	abolish acute injury	[abolishing acute injury]	0.0	3	1	1	1
72580	1710	analysis of megakaryocyte	[analysis of megakaryocytes]	0.0	3	1	1	1
72581	1710	cooh-terminal domain of Oct-2	[COOH-terminal domain of Oct-2]	0.0	4	1	1	1
72582	1710	activity within this cell	[activities within these cells]	0.0	4	1	1	1
72583	1710	incubation of cell line	[incubation of cell line]	0.0	4	1	1	1
72584	1710	use amount of recombinant nfatp	[using amounts of recombinant NFATp]	0.0	5	1	1	1
72585	1710	dexamethasone on the production	[dexamethasone on the production]	0.0	4	1	1	1
72586	1710	29 asthma patient with expiratory volume	[29 asthma patients with expiratory volume]	0.0	6	1	1	1
72587	1710	overall activity	[overall activity]	0.0	2	1	1	1
72588	1710	however, the enhancer	[however, the enhancer]	0.0	3	1	1	1
72589	1710	leukocyte protein kda)	[leukocyte protein kDa)]	0.0	3	1	1	1
72590	1710	lak cell-mediated lysis	[LAK cell-mediated lysis]	0.0	3	1	1	1
72591	1710	control the tissue-specific expression	[controlling the tissue-specific expression]	0.0	4	1	1	1
72592	1710	signal in primary precursor	[signaling in primary precursors]	0.0	4	1	1	1
72593	1710	octamer protein	[octamer protein]	0.0	2	1	1	1
72594	1710	dl312 virus defective	[dl312 virus defective]	0.0	3	1	1	1
72595	1710	produce a induction within hour	[producing a induction within hour]	0.0	5	1	1	1
72596	1710	E1A induction of cellular susceptibility kill	[E1A induction of cellular susceptibility killing]	0.0	6	1	1	1
72597	1710	pi3-kinase pathway	[PI3-kinase pathway]	0.0	2	1	1	1
72598	1710	competition /p65	[competition /p65]	0.0	2	1	1	1
72599	1710	two child	[two children]	0.0	2	2	2	1
72600	1710	activation of a protein related	[Activation of a protein related]	0.0	5	1	1	1
72601	1710	constitute model for the marker	[constituting models for the markers]	0.0	5	1	1	1
72602	1710	fundamental difference	[fundamental differences]	0.0	2	1	1	1
72603	1710	proximal octamer	[proximal octamer]	0.0	2	1	1	1
72604	1710	mechanism control E2F transcriptional activity	[mechanism controlling E2F transcriptional activity]	0.0	5	1	1	1
72605	1710	filarial t-cell	[filarial T-cells]	0.0	2	1	1	1
72606	1710	proliferative potential hpp- cell	[proliferative potential HPP- cells]	0.0	4	1	1	1
72607	1710	14.6 +/-	[14.6 +/-]	0.0	2	1	1	1
72608	1710	carboxyl-terminal segment	[carboxyl-terminal segment]	0.0	2	1	1	1
72609	1710	cloning of a lymphoid-restricted gene	[cloning of a lymphoid-restricted gene]	0.0	5	1	1	1
72610	1710	complex regulatory function	[complex regulatory functions]	0.0	3	1	1	1
72611	1710	time-dependent release	[time-dependent release]	0.0	2	1	1	1
72612	1710	binding power	[binding power]	0.0	2	1	1	1
72613	1710	least two distinct activity	[least two distinct activities]	0.0	4	1	1	1
72614	1710	Pb at concentration	[Pb at concentrations]	0.0	3	1	1	1
72615	1710	two ubiquitous transcription factor	[two ubiquitous transcription factors]	0.0	4	1	1	1
72616	1710	degenerative tropical paraparesis tsp	[degenerative tropical paraparesis TSP]	0.0	4	1	1	1
72617	1710	susceptibility to infections.	[susceptibility to infections.]	0.0	3	1	1	1
72618	1710	tumor in Group B.	[tumors in Group B.]	0.0	4	1	1	1
72619	1710	ligand, start	[ligand, starting]	0.0	2	1	1	1
72620	1710	center cell origin	[center cell origin]	0.0	3	1	1	1
72621	1710	strong staining for nf-kappabp65	[stronger staining for NF-kappaBp65]	0.0	4	1	1	1
72622	1710	effect of anti-estrogen therapy	[effect of anti-estrogen therapy]	0.0	4	1	1	1
72623	1710	involvement in activation	[Involvement in activation]	0.0	3	1	1	1
72624	1710	activation of the repeat type	[activation of the repeat type]	0.0	5	1	1	1
72625	1710	map region 0.30 to 0.46	[map regions 0.30 to 0.46]	0.0	5	1	1	1
72626	1710	mediate early response	[mediating early responses]	0.0	3	1	1	1
72627	1710	four protein complex a ubiquitous factor	[four protein complexes a ubiquitous factor]	0.0	6	1	1	1
72628	1710	effect in vivo,	[effect in vivo,]	0.0	3	1	1	1
72629	1710	rest blood mononuclear cell pbmc	[resting blood mononuclear cells PBMCs]	0.0	5	1	1	1
72630	1710	primarily by a mechanism	[primarily by a mechanism]	0.0	4	1	1	1
72631	1710	erythrocyte-specific anhydrase a gene	[erythrocyte-specific anhydrase a gene]	0.0	4	1	1	1
72632	1710	two nonstructural trans-acting gene	[two nonstructural trans-acting genes]	0.0	4	1	1	1
72633	1710	classical site	[classical site]	0.0	2	1	1	1
72634	1710	il-1 beta huvec by 56%	[IL-1 beta HUVEC by 56%]	0.0	5	1	1	1
72635	1710	mutagenesis analysis	[mutagenesis analyses]	0.0	2	1	1	1
72636	1710	30-fold	[30-fold]	0.0	1	1	1	1
72637	1710	down-regulation of immunogenic protein in lymphoma	[Down-regulation of immunogenic proteins in lymphoma]	0.0	6	1	1	1
72638	1710	tyrosine phosphorylation follow ptk activation	[tyrosine phosphorylation following PTK activation]	0.0	5	1	1	1
72639	1710	gabp alpha/gabp beta	[GABP alpha/GABP beta]	0.0	3	1	1	1
72640	1710	substnfkappab approximately substSpl2	[substNFkappaB approximately substSpl2]	0.0	3	1	1	1
72641	1710	biochemical consequence	[biochemical consequences]	0.0	2	1	1	1
72642	1710	cd95 transcription	[CD95 transcription]	0.0	2	1	1	1
72643	1710	3-o-methyl-d-glucose transport in leukocyte	[3-O-methyl-D-glucose transport in leukocyte]	0.0	4	1	1	1
72644	1710	Differentiation-associated expression bzlf1 transactivator protein	[Differentiation-associated expression BZLF1 transactivator protein]	0.0	5	1	1	1
72645	1710	region contain direct repeat DR	[region containing direct repeats DR]	0.0	5	1	1	1
72646	1710	mapping of the requirement	[Mapping of the requirements]	0.0	4	1	1	1
72647	1710	mouse with cd3epsilon gene	[mice with CD3epsilon gene]	0.0	4	1	1	1
72648	1710	prostate-specific antigen psa	[prostate-specific antigen PSA]	0.0	3	1	1	1
72649	1710	mutation of mds1/evi1	[mutations of MDS1/EVI1]	0.0	3	1	1	1
72650	1710	week after RAI therapy	[weeks after RAI therapy]	0.0	4	1	1	1
72651	1710	relative level in monocytic	[relative levels in monocytic]	0.0	4	1	1	1
72652	1710	TNF-alpha nuclear localization in memory	[TNF-alpha nuclear localization in memory]	0.0	5	1	1	1
72653	1710	critical serine phosphorylation site	[critical serine phosphorylation site]	0.0	4	1	1	1
72654	1710	response result neutrophil-mediated tissue damage	[response resulting neutrophil-mediated tissue damage]	0.0	5	1	1	1
72655	1710	-bind	[-binding]	0.0	1	1	1	1
72656	1710	inhibition replication by a combination	[Inhibition replication by a combination]	0.0	5	1	1	1
72657	1710	CCAAT/enhancer -binding protein form binding	[CCAAT/enhancer -binding protein form binding]	0.0	5	1	1	1
72658	1710	candidate gene hepatic factor hnf3 beta	[candidate genes hepatic factor HNF3 beta]	0.0	6	1	1	1
72659	1710	role for autocrine tnf-alpha secretion	[role for autocrine TNF-alpha secretion]	0.0	5	1	1	1
72660	1710	use a negative ikappabalpha	[using a negative IkappaBalpha]	0.0	4	1	1	1
72661	1710	LMP1 chimera	[LMP1 chimera]	0.0	2	1	1	1
72662	1710	control of c-Jun	[control of c-Jun]	0.0	3	1	1	1
72663	1710	elk-1 point in the activation	[Elk-1 pointing in the activation]	0.0	5	1	1	1
72664	1710	vitro, viral antigen EBNAs	[vitro, viral antigens EBNAs]	0.0	4	1	1	1
72665	1710	htlv-i p40tax	[HTLV-I p40tax]	0.0	2	1	1	1
72666	1710	VDR /drip interaction	[VDR /DRIP interactions]	0.0	3	1	1	1
72667	1710	TCL1 expression in aids-related lymphoma	[TCL1 expression in AIDS-related lymphomas]	0.0	5	1	1	1
72668	1710	delineate the role in pathophysiological condition	[delineating the roles in pathophysiological conditions]	0.0	6	1	1	1
72669	1710	rheumatic disease (12: four	[rheumatic diseases (12: four]	0.0	4	1	1	1
72670	1710	multiple somatic mutation cluster	[multiple somatic mutations clustering]	0.0	4	1	1	1
72671	1710	grbeta expression	[GRbeta expression]	0.0	2	1	1	1
72672	1710	t-cell-specific activation	[T-cell-specific activation]	0.0	2	1	1	1
72673	1710	immunodeficiency disease (scid)	[immunodeficiency disease (SCID)]	0.0	3	1	1	1
72674	1710	constitutive localization	[constitutive localization]	0.0	2	3	3	1
72675	1710	number of mutation	[number of mutations]	0.0	3	1	1	1
72676	1710	HTLV-I t-cell	[HTLV-I T-cells]	0.0	2	1	1	1
72677	1710	occur in a number	[occurring in a number]	0.0	4	1	1	1
72678	1710	nuclear factor nf-il6 (position	[nuclear factor NF-IL6 (positions]	0.0	4	1	1	1
72679	1710	episode of infection	[episodes of infections]	0.0	3	1	1	1
72680	1710	(range, 5.66-10)	[(range, 5.66-10),]	0.0	2	1	1	1
72681	1710	pathogenesis of severe immunodeficiency	[pathogenesis of severe immunodeficiency]	0.0	4	1	1	1
72682	1710	examination of Stat6 activity	[Examination of Stat6 activity]	0.0	4	1	1	1
72683	1710	22-bp sequence duplication	[22-bp sequence duplication]	0.0	3	1	1	1
72684	1710	have a biopsy as treatment	[having an biopsy as treatment]	0.0	5	1	1	1
72685	1710	receptor level in blood leukocyte	[receptor levels in blood leukocytes]	0.0	5	1	1	1
72686	1710	relevance of this alteration	[relevance of these alterations]	0.0	4	1	1	1
72687	1710	th2 cell th1 cell	[Th2 cells Th1 cells]	0.0	4	1	1	1
72688	1710	rel homology	[Rel homology]	0.0	2	1	1	1
72689	1710	factor of T cell activation	[factor of T cells activation]	0.0	5	1	1	1
72690	1710	pretreatment human macrophage	[Pretreatment human macrophages]	0.0	3	1	1	1
72691	1710	phenotypic characteristic of monocytic differentiation	[phenotypic characteristics of monocytic differentiation]	0.0	5	1	1	1
72692	1710	involvement of the mineralocorticoid receptor	[involvement of the mineralocorticoid receptor]	0.0	5	1	1	1
72693	1710	effectiveness of human ciita	[effectiveness of human CIITA]	0.0	4	1	1	1
72694	1710	concentration consistent	[concentrations consistent]	0.0	2	1	1	1
72695	1710	connection with glucocorticoid induction	[connection with glucocorticoid induction]	0.0	4	1	1	1
72696	1710	functional role of specific factor-DNA complex	[functional role of specific factor-DNA complexes]	0.0	6	1	1	1
72697	1710	g/g of rna	[g/g of RNA]	0.0	3	1	1	1
72698	1710	aml1/mds1/evi1 block differentiation result	[AML1/MDS1/EVI1 blocks differentiation resulting]	0.0	4	1	1	1
72699	1710	belong to the factor	[belonging to the factor]	0.0	4	1	1	1
72700	1710	treatment of malignant disorder	[treatment of malignant disorders]	0.0	4	1	1	1
72701	1710	infiltrate carcinoma	[infiltrating carcinomas]	0.0	2	1	1	1
72702	1710	avidity, CD8 contribution compensate	[avidity, CD8 contribution compensating]	0.0	4	1	1	1
72703	1710	immunoglobulin igh gene rearrangement	[immunoglobulin IgH gene rearrangement]	0.0	4	1	1	1
72704	1710	beta integrin	[beta integrins]	0.0	2	1	1	1
72705	1710	factor-kappaB translocation in lipopolysaccharide	[factor-kappaB translocation in lipopolysaccharide]	0.0	4	1	1	1
72706	1710	indicate regulation of the promoter	[indicating regulation of the promoter]	0.0	5	1	1	1
72707	1710	two region in the cytoplasmic domain	[two regions in the cytoplasmic domain]	0.0	6	1	1	1
72708	1710	moiety of active molecules.	[moiety of active molecules.]	0.0	4	1	1	1
72709	1710	transcription of class ii gene	[transcription of class II genes]	0.0	5	1	1	1
72710	1710	inefficient inducer	[inefficient inducer]	0.0	2	1	1	1
72711	1710	binary switch	[binary switch]	0.0	2	1	1	1
72712	1710	specifically in cell in vivo	[specifically in cells in vivo]	0.0	5	1	1	1
72713	1710	nf-kappab in human cell	[NF-kappaB in human cells]	0.0	4	1	1	1
72714	1710	exposure of u-937 cell	[exposure of U-937 cells]	0.0	4	1	1	1
72715	1710	role of ligand	[role of ligand]	0.0	3	1	1	1
72716	1710	promonocytic leukemia	[promonocytic leukemia]	0.0	2	1	1	1
72717	1710	moreover, mrna	[Moreover, mRNA]	0.0	2	1	1	1
72718	1710	represent endocrine lineage	[representing endocrine lineages]	0.0	3	1	1	1
72719	1710	microtitre assay system	[microtitre assay system]	0.0	3	2	2	1
72720	1710	Glucocorticosteroid	[Glucocorticosteroid]	0.0	1	1	1	1
72721	1710	few subject	[fewer subjects]	0.0	2	1	1	1
72722	1710	receptor -ligand	[receptor -ligand]	0.0	2	1	1	1
72723	1710	c-235	[C-235]	0.0	1	1	1	1
72724	1710	direct interaction between the receptor	[direct interaction between the receptor]	0.0	5	1	1	1
72725	1710	difference in enhancer of hiv-1	[Differences in enhancers of HIV-1]	0.0	5	1	1	1
72726	1710	xpa through XPG	[XPA through XPG]	0.0	3	1	1	1
72727	1710	anti- ebv antibody titre	[anti- EBV antibody titres]	0.0	4	1	1	1
72728	1710	mechanism a type of cross-talk	[mechanisms a type of cross-talk]	0.0	5	1	1	1
72729	1710	two potent AS oligonucleotide	[two potent AS oligonucleotides]	0.0	4	1	1	1
72730	1710	1 LMP1	[1 LMP1]	0.0	2	1	1	1
72731	1710	Th2 differentiation defect	[Th2 differentiation defect]	0.0	3	1	1	1
72732	1710	heterogeneity of t-cell	[heterogeneity of T-cells]	0.0	3	1	1	1
72733	1710	background: macrophage	[BACKGROUND: macrophages]	0.0	2	1	1	1
72734	1710	regulatory system of WT1	[regulatory system of WT1]	0.0	4	1	1	1
72735	1710	protein module	[protein module]	0.0	2	1	1	1
72736	1710	receptor for various chemokine	[receptor for various chemokines]	0.0	4	1	1	1
72737	1710	multinuclearity	[multinuclearity]	0.0	1	1	1	1
72738	1710	carboxyl-terminal domain of cd36	[carboxyl-terminal domain of CD36]	0.0	4	1	1	1
72739	1710	mutational analysis for diagnosis, counseling,	[mutational analysis for diagnosis, counseling,]	0.0	5	1	1	1
72740	1710	bcl-2 mrna	[bcl-2 mRNA]	0.0	2	1	1	1
72741	1710	interleukin-10 receptor domain	[interleukin-10 receptor domain]	0.0	3	1	1	1
72742	1710	binding of c-Rel present	[binding of c-Rel present]	0.0	4	1	1	1
72743	1710	separate cis-acting element	[separate cis-acting elements]	0.0	3	1	1	1
72744	1710	mutation cluster in the region	[mutations clustering in the region]	0.0	5	1	1	1
72745	1710	factor-kappa b mobilization	[factor-kappa B mobilization]	0.0	3	2	2	1
72746	1710	induction of dna-binding activity	[induction of DNA-binding activities]	0.0	4	1	1	1
72747	1710	form with a differentiation block	[form with a differentiation block]	0.0	5	1	1	1
72748	1710	activity of the regulatory gene	[activity of the regulatory genes]	0.0	5	1	1	1
72749	1710	prointerleukin	[prointerleukin]	0.0	1	2	2	1
72750	1710	control point	[control point]	0.0	2	2	2	1
72751	1710	several pathway for tissue damage	[several pathways for tissue damage]	0.0	5	1	1	1
72752	1710	stage of maturation.	[stage of maturation.]	0.0	3	1	1	1
72753	1710	activation of signal-regulated kinase	[activation of signal-regulated kinases]	0.0	4	1	1	1
72754	1710	interest of this project	[interest of this project]	0.0	4	1	1	1
72755	1710	2 pre-B acute leukemia all	[2 pre-B acute leukemia ALL]	0.0	5	1	1	1
72756	1710	regulation of the machinery specific	[regulation of the machinery specific]	0.0	5	1	1	1
72757	1710	respectively) increase	[respectively) increase]	0.0	2	1	1	1
72758	1710	contain two cysteine -rich region	[containing two cysteine -rich regions]	0.0	5	1	1	1
72759	1710	delta 5' region extend from -500	[delta 5' regions extending from -500]	0.0	6	1	1	1
72760	1710	preassociation of stat1 in signalling complex	[Preassociation of STAT1 in signalling complexes]	0.0	6	1	1	1
72761	1710	nuclear factor-KB result	[nuclear factor-KB resulting]	0.0	3	1	1	1
72762	1710	ectopic id1	[ectopic Id1]	0.0	2	1	1	1
72763	1710	domain LCD motif	[domains LCD motifs]	0.0	3	1	1	1
72764	1710	cell dexamethasone	[cell dexamethasone]	0.0	2	1	1	1
72765	1710	AP-1/Octamer	[AP-1/Octamer]	0.0	1	1	1	1
72766	1710	signal agent	[signalling agents]	0.0	2	1	1	1
72767	1710	association with NF-kappaB inhibition	[association with NF-kappaB inhibition]	0.0	4	1	1	1
72768	1710	mrna level in lipopolysaccharide	[mRNA levels in lipopolysaccharide]	0.0	4	1	1	1
72769	1710	kv1.3 component of KV current	[Kv1.3 components of KV current]	0.0	5	1	1	1
72770	1710	15 cell divisions,	[15 cell divisions,]	0.0	3	1	1	1
72771	1710	wild-type human leukemic ecem) cell	[wild-type human leukemic (CEM) cells]	0.0	5	1	1	1
72772	1710	ATF family	[ATF family]	0.0	2	1	1	1
72773	1710	concordance	[concordance]	0.0	1	1	1	1
72774	1710	cofactor BOB.1/OBF.1	[cofactor BOB.1/OBF.1]	0.0	2	1	1	1
72775	1710	contrast, two nonsteroidal drug	[contrast, two nonsteroidal drugs]	0.0	4	1	1	1
72776	1710	downregulation of Wilms' tumor gene	[Downregulation of Wilms' tumor gene]	0.0	5	1	1	1
72777	1710	age-related decrease by human T cell	[Age-related decreases by human T cells]	0.0	6	1	1	1
72778	1710	globular, structure distinct	[globular, structures distinct]	0.0	3	1	1	1
72779	1710	AS oligonucleotide	[AS oligonucleotides]	0.0	2	1	1	1
72780	1710	Comparison human sequence	[Comparison human sequences]	0.0	3	1	1	1
72781	1710	antigen carriage.	[antigen carriage.]	0.0	2	1	1	1
72782	1710	woman with reactive thrombocytosis	[women with reactive thrombocytosis]	0.0	4	1	1	1
72783	1710	distinct mitogen-inducible complex	[distinct mitogen-inducible complexes]	0.0	3	1	1	1
72784	1710	cytokine of T lymphocyte	[cytokine of T lymphocytes]	0.0	4	1	1	1
72785	1710	spleen,	[spleen,]	0.0	1	1	1	1
72786	1710	human soluble dimeric tnf receptor	[human soluble dimeric TNF receptor]	0.0	5	1	1	1
72787	1710	particularly in the initial stage	[particularly in the initial stages]	0.0	5	1	1	1
72788	1710	stimulus,	[stimulus,]	0.0	1	1	1	1
72789	1710	region of clone 18	[region of clone 18]	0.0	4	1	1	1
72790	1710	three, rare DNA variation in tumor	[three, rare DNA variations in tumor]	0.0	6	1	1	1
72791	1710	vivo activity.	[vivo activity.]	0.0	2	1	1	1
72792	1710	level of IFN a constitutively,	[levels of IFN A constitutively,]	0.0	5	1	1	1
72793	1710	majority of human disease syndrome	[majority of human disease syndromes]	0.0	5	1	1	1
72794	1710	trigger into changes, include repression	[triggering into changes, including repression]	0.0	5	1	1	1
72795	1710	expression of the dominant interfere	[expression of the dominant interfering]	0.0	5	1	1	1
72796	1710	proliferation response	[proliferation response]	0.0	2	1	1	1
72797	1710	sh2 domain-binding phosphotyrosine-based motif	[SH2 domain-binding phosphotyrosine-based motifs]	0.0	4	1	1	1
72798	1710	equimolar heterodimerization	[equimolar heterodimerization]	0.0	2	1	1	1
72799	1710	several low weight adaptor protein	[several low weight adaptor proteins]	0.0	5	1	1	1
72800	1710	id3 mrna increase,	[Id3 mRNA increase,]	0.0	3	1	1	1
72801	1710	pregnancy, lymphocyte	[pregnancy, lymphocyte]	0.0	2	1	1	1
72802	1710	calcium absorption	[calcium absorption]	0.0	2	1	1	1
72803	1710	lung cell type such as cell	[lung cell types such as cells]	0.0	6	1	1	1
72804	1710	c-fo region	[c-fos region]	0.0	2	1	1	1
72805	1710	blood hormone	[blood hormone]	0.0	2	1	1	1
72806	1710	protein latent infection membrane protein	[protein latent infection membrane protein]	0.0	5	1	1	1
72807	1710	entire catalytic domain	[entire catalytic domain]	0.0	3	1	1	1
72808	1710	factor in vivo	[factor in vivo]	0.0	3	1	1	1
72809	1710	suggest a role in repression genes.	[suggesting a role in repression genes.]	0.0	6	1	1	1
72810	1710	nm, p	[nM, P]	0.0	2	1	1	1
72811	1710	pml-rar a form	[PML-RAR an form]	0.0	3	1	1	1
72812	1710	multiple somatic mutation cluster a encoding	[multiple somatic mutations clustering a encoding]	0.0	6	1	1	1
72813	1710	include lymphoid cell	[including lymphoid cells]	0.0	3	1	1	1
72814	1710	colony-stimulating factor (g-csf) receptor	[colony-stimulating factor (G-CSF) receptor]	0.0	4	1	1	1
72815	1710	T protein neg-1	[T protein Neg-1]	0.0	3	1	1	1
72816	1710	promote mm cell growth via mechanisms;	[promoting MM cell growth via mechanisms;]	0.0	6	1	1	1
72817	1710	additional, binding.	[additional, binding.]	0.0	2	1	1	1
72818	1710	addition of microm pdtc	[addition of microM PDTC]	0.0	4	1	1	1
72819	1710	regulate the stringency of latency	[regulating the stringency of latency]	0.0	5	1	1	1
72820	1710	potentially dominant negative pi3-k construct	[potentially dominant negative PI3-K constructs]	0.0	5	1	1	1
72821	1710	bcl6 gene	[BCL6 gene]	0.0	2	1	1	1
72822	1710	role convert signal into event	[role converting signals into events]	0.0	5	1	1	1
72823	1710	mediator of cell-mediated tcell rescue	[mediator of cell-mediated Tcell rescue]	0.0	5	1	1	1
72824	1710	coactivator Bob1	[coactivator Bob1]	0.0	2	1	1	1
72825	1710	ah receptor c12 cell line	[Ah receptor c12 cell lines]	0.0	5	1	1	1
72826	1710	Ca2+ signal-dependent element obligatory	[Ca2+ signal-dependent element obligatory]	0.0	4	1	1	1
72827	1710	apoptosis in t-cell hybridoma	[apoptosis in T-cell hybridomas]	0.0	4	1	1	1
72828	1710	dilution assay	[dilution assays]	0.0	2	1	1	1
72829	1710	antecedent activation of protein tyrosine kinase	[antecedent activation of protein tyrosine kinases]	0.0	6	1	1	1
72830	1710	defect in the synthesis	[defects in the synthesis]	0.0	4	1	1	1
72831	1710	only the single mutation of R-276	[only the single mutations of R-276]	0.0	6	1	1	1
72832	1710	population in patient	[populations in patients]	0.0	3	1	1	1
72833	1710	Janus kinase 3 jak3 activity	[Janus kinase 3 JAK3 activity]	0.0	5	1	1	1
72834	1710	Effect modulation of function	[Effects modulation of functions]	0.0	4	1	1	1
72835	1710	cytoplasmic 105k precursor p105	[cytoplasmic 105K precursor p105]	0.0	4	1	1	1
72836	1710	receptor mr in mononuclear leucocyte	[receptor MR in mononuclear leucocytes]	0.0	5	1	1	1
72837	1710	differentiation program of progenitor	[differentiation program of progenitors]	0.0	4	1	1	1
72838	1710	cell ec activation	[cell EC activation]	0.0	3	1	1	1
72839	1710	transduce this effect	[transducing this effect]	0.0	3	1	1	1
72840	1710	STAT1 nuclear import	[STAT1 nuclear import]	0.0	3	1	1	1
72841	1710	vascular occlusion a cause	[vascular occlusion a cause]	0.0	4	1	1	1
72842	1710	expression of transcript	[expression of transcripts]	0.0	3	1	1	1
72843	1710	disruption of a sequence motif	[disruption of a sequence motif]	0.0	5	1	1	1
72844	1710	patient in LT	[patients in LT]	0.0	3	1	1	1
72845	1710	immunodeficiency virus type 1 (hiv-1) infection	[immunodeficiency virus type 1 (HIV-1) infection]	0.0	6	1	1	1
72846	1710	presence in this cells.	[presence in these cells.]	0.0	4	1	1	1
72847	1710	requirement in development	[requirement in development]	0.0	3	1	1	1
72848	1710	endogenous TRs	[endogenous TRs]	0.0	2	1	1	1
72849	1710	live-attenuated hiv	[live-attenuated HIVs]	0.0	2	1	1	1
72850	1710	ebv zebra gene	[EBV Zebra gene]	0.0	3	1	1	1
72851	1710	effect of interleukin-10 il-10	[effects of interleukin-10 IL-10]	0.0	4	1	1	1
72852	1710	sexual difference	[sexual difference]	0.0	2	1	1	1
72853	1710	differentiation of precursor cell line	[differentiation of precursor cell lines]	0.0	5	1	1	1
72854	1710	effect of dioxyvit	[effect of dioxyvit]	0.0	3	1	1	1
72855	1710	nuclear translocation of c-Rel heterodimer	[nuclear translocation of c-Rel heterodimers]	0.0	5	1	1	1
72856	1710	20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2	[20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2]	0.0	1	1	1	1
72857	1710	temporal change	[temporal changes]	0.0	2	1	1	1
72858	1710	precursor cell by acid metabolism	[precursor cells by acid metabolism]	0.0	5	1	1	1
72859	1710	lytic cycle promoter	[lytic cycle promoters]	0.0	3	1	1	1
72860	1710	signal through CD40	[Signaling through CD40]	0.0	3	1	1	1
72861	1710	expression of cell surface molecules,	[expression of cell surface molecules,]	0.0	5	1	1	1
72862	1710	basal cell carcinoma bcc	[basal cell carcinomas BCCs]	0.0	4	1	1	1
72863	1710	short arm encompass band	[short arm encompassing bands]	0.0	4	1	1	1
72864	1710	cell possible enhancement	[cells possible enhancement]	0.0	3	1	1	1
72865	1710	initiation of the ebv lytic cycle	[initiation of the EBV lytic cycle]	0.0	6	1	1	1
72866	1710	leukemia AML	[leukemia AML]	0.0	2	3	3	1
72867	1710	dose of autg	[doses of AuTG]	0.0	3	1	1	1
72868	1710	hiv-hd express CD40	[HIV-HD express CD40]	0.0	3	1	1	1
72869	1710	gene transfer of IkappaB-alpha	[gene transfer of IkappaB-alpha]	0.0	4	1	1	1
72870	1710	regulation of th cell development	[regulation of Th cell development]	0.0	5	1	1	1
72871	1710	one target	[one target]	0.0	2	1	1	1
72872	1710	simian immunodeficiency virus SIVmac251	[simian immunodeficiency virus SIVmac251]	0.0	4	1	1	1
72873	1710	thereby provide a basis for mimicry	[thereby providing a basis for mimicry]	0.0	6	1	1	1
72874	1710	anionic domain	[anionic domain]	0.0	2	1	1	1
72875	1710	proliferation of blood mononuclear cell	[proliferation of blood mononuclear cells]	0.0	5	1	1	1
72876	1710	use a transcription-pcr-based approach	[using a transcription-PCR-based approach]	0.0	4	1	1	1
72877	1710	nfatp from untreated ht-2 cell	[NFATp from untreated HT-2 cells]	0.0	5	1	1	1
72878	1710	+/lt	[+/LT]	0.0	1	1	1	1
72879	1710	sucrose density gradient	[sucrose density gradients]	0.0	3	1	1	1
72880	1710	red cell during experimental anemia	[red cells during experimental anemia]	0.0	5	1	1	1
72881	1710	lytic viral promoter	[lytic viral promoters]	0.0	3	1	1	1
72882	1710	rapid response	[rapid responses]	0.0	2	1	1	1
72883	1710	lung tissue	[lung tissue]	0.0	2	1	1	1
72884	1710	large effect.	[large effect.]	0.0	2	1	1	1
72885	1710	signal 2 signal alone	[signal 2 signal alone]	0.0	4	1	1	1
72886	1710	immature human myeloid cell	[immature human myeloid cells]	0.0	4	1	1	1
72887	1710	affinities:	[affinities:]	0.0	1	1	1	1
72888	1710	ad5e1a CTL activity	[Ad5E1A CTL activity]	0.0	3	1	1	1
72889	1710	affinities.	[affinities.]	0.0	1	1	1	1
72890	1710	derivative alpha b5a	[derivative alpha B5A]	0.0	3	1	1	1
72891	1710	repression of il-2	[repression of IL-2]	0.0	3	1	1	1
72892	1710	contain only -73 bp	[containing only -73 bp]	0.0	4	1	1	1
72893	1710	LYSP100 domain land	[LYSP100 domains LANDs]	0.0	3	1	1	1
72894	1710	are: (memory) T cell cd4+cd45r0+cd45ra-cd29highcd11a+	[are: (memory) T cells CD4+CD45R0+CD45RA-CD29highCD11a+]	0.0	5	1	1	1
72895	1710	constitutive DNA-protein interaction	[constitutive DNA-protein interactions]	0.0	3	1	1	1
72896	1710	induction of wp activity	[induction of Wp activity]	0.0	4	1	1	1
72897	1710	virus peptide in vitro	[virus peptides in vitro]	0.0	4	1	1	1
72898	1710	presentation by HLA DQ2 heterodimer	[presentation by HLA DQ2 heterodimers]	0.0	5	1	1	1
72899	1710	Differential activation during eosinophil differentiation	[Differential activation during eosinophil differentiation]	0.0	5	1	1	1
72900	1710	activation of Jak tyrosine kinase	[activation of Jak tyrosine kinases]	0.0	5	1	1	1
72901	1710	gene transcriptional inhibition	[gene transcriptional inhibition]	0.0	3	1	1	1
72902	1710	equimolar ratio, c-erbA activity	[equimolar ratio, c-erbA activity]	0.0	4	1	1	1
72903	1710	pseudo-hypoaldosteronism level	[pseudo-hypoaldosteronism level]	0.0	2	1	1	1
72904	1710	relative affinity of regulatory element	[Relative affinities of regulatory elements]	0.0	5	1	1	1
72905	1710	common signal pathway in human neutrophil	[Common signaling pathways in human neutrophils]	0.0	6	1	1	1
72906	1710	model for gene expression	[model for gene expression]	0.0	4	1	1	1
72907	1710	intercellular adhesion molecule-1 gene expression	[intercellular adhesion molecule-1 gene expression]	0.0	5	1	1	1
72908	1710	synthesis of tumor necrosis factor-alpha	[synthesis of tumor necrosis factor-alpha]	0.0	5	1	1	1
72909	1710	hiv type 1 transcription	[HIV type 1 transcription]	0.0	4	1	1	1
72910	1710	role in the process related	[role in the processes related]	0.0	5	1	1	1
72911	1710	administration of thioredoxin	[administration of thioredoxin]	0.0	3	1	1	1
72912	1710	nuclear RA receptor	[nuclear RA receptors]	0.0	3	1	1	1
72913	1710	E2F-1 gene	[E2F-1 gene]	0.0	2	1	1	1
72914	1710	similarity with respect	[similarities with respect]	0.0	3	1	1	1
72915	1710	monocyte mitochondrial	[monocyte mitochondrial]	0.0	2	1	1	1
72916	1710	v-erbA oncogene	[v-erbA oncogene]	0.0	2	1	1	1
72917	1710	high prevalence	[high prevalence]	0.0	2	1	1	1
72918	1710	patient in ST	[patients in ST]	0.0	3	1	1	1
72919	1710	suppression of b activity	[suppression of B activity]	0.0	4	1	1	1
72920	1710	type 1 immunodeficiency virus	[type 1 immunodeficiency virus]	0.0	4	1	1	1
72921	1710	CD4 t-cell clone	[CD4 T-cell clones]	0.0	3	1	1	1
72922	1710	Also, (10(-10) mol/L) in combination	[Also, (10(-10) mol/L) in combination]	0.0	5	1	1	1
72923	1710	pu.1 mrna	[PU.1 mRNA]	0.0	2	1	1	1
72924	1710	VDR level	[VDR levels]	0.0	2	1	1	1
72925	1710	use a reverse polymerase chain method	[using a reverse polymerase chain method]	0.0	6	1	1	1
72926	1710	level of adult beta-globin expression	[levels of adult beta-globin expression]	0.0	5	1	1	1
72927	1710	wy14,643	[Wy14,643]	0.0	1	1	1	1
72928	1710	2 ng cell per millileter	[2 ng cells per ml]	0.0	5	1	1	1
72929	1710	role of interleukin-1	[role of interleukin-1]	0.0	3	1	1	1
72930	1710	use extract from normal human eosinophil	[using extracts from normal human eosinophils]	0.0	6	1	1	1
72931	1710	high-level il-4 production	[high-level IL-4 production]	0.0	3	1	1	1
72932	1710	Ca2+ serine-threonine phosphatase calcineurin	[Ca2+ serine-threonine phosphatase calcineurin]	0.0	4	1	1	1
72933	1710	T cell receptor mouse	[T cell receptor mice]	0.0	4	1	1	1
72934	1710	step of signal transduction	[step of signal transduction]	0.0	4	1	1	1
72935	1710	encode the N terminus	[encoding the N terminus]	0.0	4	1	1	1
72936	1710	HLA class fashion	[HLA class fashion]	0.0	3	1	1	1
72937	1710	association of deletion	[association of deletions]	0.0	3	1	1	1
72938	1710	expression hour	[expression hr]	0.0	2	1	1	1
72939	1710	molecular action in the immune system	[Molecular actions in the immune system]	0.0	6	1	1	1
72940	1710	activation via cooperative nf-kappa b	[activation via cooperative NF-kappa B]	0.0	5	1	1	1
72941	1710	transcription, thereby amplify expression of receptor	[transcription, thereby amplifying expression of receptor]	0.0	6	1	1	1
72942	1710	expression of the luciferase reporter gene	[expression of the luciferase reporter gene]	0.0	6	1	1	1
72943	1710	increase extracellular concentration of cysteine	[increasing extracellular concentrations of cysteine]	0.0	5	1	1	1
72944	1710	intracellular signalling network	[intracellular signalling network]	0.0	3	1	1	1
72945	1710	23 P.	[23 h.]	0.0	2	1	1	1
72946	1710	activation of form of stat3 stat3alpha	[activation of forms of STAT3 STAT3alpha]	0.0	6	1	1	1
72947	1710	information on the molecular event	[information on the molecular events]	0.0	5	1	1	1
72948	1710	differentiation of human cd34+ cell	[differentiation of human CD34+ cells]	0.0	5	1	1	1
72949	1710	costimulation with anti-CD3	[costimulation with anti-CD3]	0.0	3	1	1	1
72950	1710	elk-1 transcription in	[elk-1 transcription in]	0.0	3	1	1	1
72951	1710	factor to ZII	[factors to ZII]	0.0	3	1	1	1
72952	1710	new cell line keep erythroid-specific property	[new cell lines keeping erythroid-specific properties]	0.0	6	1	1	1
72953	1710	suffer from cushingd' syndrome	[suffering from Cushing's syndrome]	0.0	4	1	1	1
72954	1710	level of fasL mrna	[levels of fasL mRNA]	0.0	4	1	1	1
72955	1710	probe include sequence	[probe including sequences]	0.0	3	1	1	1
72956	1710	two forms:	[two forms:]	0.0	2	1	1	1
72957	1710	respect to the factor	[respect to the factors]	0.0	4	1	1	1
72958	1710	effect of three loop peptide	[effect of three loop peptides]	0.0	5	1	1	1
72959	1710	induction of tnf-alpha transcription	[induction of TNF-alpha transcription]	0.0	4	1	1	1
72960	1710	previous study pertain to macrophage response	[previous studies pertaining to macrophage response]	0.0	6	1	1	1
72961	1710	dihydropyrimidine dehydrogenase the initial enzyme	[dihydropyrimidine dehydrogenase the initial enzyme]	0.0	5	1	1	1
72962	1710	suggest a molecule during a phase	[suggesting a molecule during a phase]	0.0	6	1	1	1
72963	1710	mononuclear cell follow hydrocortisone injection	[mononuclear cells following hydrocortisone injection]	0.0	5	1	1	1
72964	1710	PMA induction of factor	[PMA induction of factor]	0.0	4	1	1	1
72965	1710	amino-acid motif	[amino-acid motif]	0.0	2	1	1	1
72966	1710	rele family protein	[rel family proteins]	0.0	3	1	1	1
72967	1710	regulation during monocytic differentiation of cell	[regulation during monocytic differentiation of cells]	0.0	6	1	1	1
72968	1710	effect of interleukin-13	[effects of interleukin-13]	0.0	3	1	1	1
72969	1710	bp for binding.	[bp for binding.]	0.0	3	1	1	1
72970	1710	immunoprecipitated nfatp	[immunoprecipitated NFATp]	0.0	2	1	1	1
72971	1710	-47 upstream	[-47 upstream]	0.0	2	1	1	1
72972	1710	effect of interleukin-10	[effects of interleukin-10]	0.0	3	1	1	1
72973	1710	effect of interleukin-11	[effects of interleukin-11]	0.0	3	1	1	1
72974	1710	feature characteristic of a ganglioside	[features characteristic of a ganglioside]	0.0	5	1	1	1
72975	1710	subsequent adherence of leukocyte	[subsequent adherence of leukocytes]	0.0	4	1	1	1
72976	1710	(t4) thyrotropin (tsh) level	[(T4) thyrotropin (TSH) levels]	0.0	4	1	1	1
72977	1710	estrogen 10(-10)-(-6)	[estrogen 10(-10)-(-6)]	0.0	2	1	1	1
72978	1710	mouse thymus cDNA	[mouse thymus cDNA]	0.0	3	1	1	1
72979	1710	promoter deletion analysis	[promoter deletion analyses]	0.0	3	1	1	1
72980	1710	factor regulate a b gene	[factor regulating a B gene]	0.0	5	1	1	1
72981	1710	competitive reverse transcription pcr	[competitive reverse transcription PCR]	0.0	4	1	1	1
72982	1710	tolerance of mouse	[tolerance of mice]	0.0	3	1	1	1
72983	1710	myeloid blast	[myeloid blasts]	0.0	2	1	1	1
72984	1710	encode human ciita	[encoding human CIITA]	0.0	3	1	1	1
72985	1710	gr gene under the control	[GR gene under the control]	0.0	5	1	1	1
72986	1710	fasl -dependent reporter construct	[FasL -dependent reporter constructs]	0.0	4	1	1	1
72987	1710	alpha /mad-3	[alpha /MAD-3]	0.0	2	1	1	1
72988	1710	immediate-early transactivator BZLF1	[immediate-early transactivators BZLF1]	0.0	3	1	1	1
72989	1710	constitutive nuclear translocation a member	[constitutive nuclear translocation a member]	0.0	5	1	1	1
72990	1710	recently circulate	[recently circulating]	0.0	2	2	2	1
72991	1710	TCR CD3/CD28	[TCR CD3/CD28]	0.0	2	1	1	1
72992	1710	heteromeric kappa b-binding complex	[heteromeric kappa B-binding complexes]	0.0	4	1	1	1
72993	1710	low number (positive)	[low number (positive)]	0.0	3	1	1	1
72994	1710	potential therapeutic target in state	[potential therapeutic target in states]	0.0	5	1	1	1
72995	1710	ii kappa b-1	[Ii kappa B-1]	0.0	3	1	1	1
72996	1710	add exogenous ttg	[adding exogenous tTG]	0.0	3	1	1	1
72997	1710	dose-dependent inhibition of b mobilization	[dose-dependent inhibition of B mobilization]	0.0	5	1	1	1
72998	1710	use transfection assay	[using transfection assays]	0.0	3	1	1	1
72999	1710	ii kappa b-2	[Ii kappa B-2]	0.0	3	1	1	1
73000	1710	murine p388 macrophage	[murine P388 macrophages]	0.0	3	1	1	1
73001	1710	induction by macrophage factor	[Induction by macrophage factor]	0.0	4	1	1	1
73002	1710	single serine residue	[single serine residue]	0.0	3	1	1	1
73003	1710	support DNA binding than antagonist	[supporting DNA binding than antagonist]	0.0	5	1	1	1
73004	1710	transfection overexpression of type	[transfection overexpression of type]	0.0	4	1	1	1
73005	1710	vitamin a	[vitamin A]	0.0	2	1	1	1
73006	1710	centromere specific probe for chromosome	[centromere specific probes for chromosomes]	0.0	5	1	1	1
73007	1710	study responsiveness to viral transactivator	[studying responsiveness to viral transactivators]	0.0	5	1	1	1
73008	1710	vitamin e	[vitamin E]	0.0	2	1	1	1
73009	1710	proline-rich sequence motif	[proline-rich sequence motif]	0.0	3	1	1	1
73010	1710	gail	[Gail]	0.0	1	1	1	1
73011	1710	cause glucocorticoid resistance in primate	[causing glucocorticoid resistance in primates]	0.0	5	1	1	1
73012	1710	comparison with prognostic criteria]	[comparison with prognostic criteria]]	0.0	4	1	1	1
73013	1710	favorable course	[favorable course]	0.0	2	1	1	1
73014	1710	include change in gene expression,	[including changes in gene expression,]	0.0	5	1	1	1
73015	1710	T lymphocyte response in persistent type	[T lymphocyte response in persistent type]	0.0	6	1	1	1
73016	1710	patient (23.1%, p	[patients (23.1%, P]	0.0	3	1	1	1
73017	1710	5'-tgcgtca-3'	[5'-TGCGTCA-3']	0.0	1	1	1	1
73018	1710	reduce the response	[reducing the response]	0.0	3	1	1	1
73019	1710	phenotype than the parental myeloblast	[phenotype than the parental myeloblasts]	0.0	5	1	1	1
73020	1710	repressor of transcription	[repressor of transcription]	0.0	3	1	1	1
73021	1710	suggest a role for pao phosphatase	[suggesting a role for PAO phosphatase]	0.0	6	1	1	1
73022	1710	cause retarded mobility	[causing retarded mobility]	0.0	3	1	1	1
73023	1710	such silencing of gene expression	[Such silencing of gene expression]	0.0	5	1	1	1
73024	1710	Leu-7+ killer cell less	[Leu-7+ killer cells less]	0.0	4	1	1	1
73025	1710	matrix protein	[matrix protein]	0.0	2	1	1	1
73026	1710	hlp-1	[HLP-1]	0.0	1	1	1	1
73027	1710	evidence in anergic T cell	[Evidence in anergic T cells]	0.0	5	1	1	1
73028	1710	GM-CSF promoter element responsible	[GM-CSF promoter element responsible]	0.0	4	1	1	1
73029	1710	negative mutant of the IL-1 signal	[negative mutants of the IL-1 signaling]	0.0	6	1	1	1
73030	1710	sister of patient	[sister of patient]	0.0	3	1	1	1
73031	1710	use reporter construct	[using reporter constructs]	0.0	3	1	1	1
73032	1710	continuous administration	[continuous administration]	0.0	2	1	1	1
73033	1710	12 nonspecific hyperplasia fh	[12 nonspecific hyperplasia FH]	0.0	4	1	1	1
73034	1710	co-expression of pu.1	[Co-expression of PU.1]	0.0	3	1	1	1
73035	1710	acute myeloid leukemia gene	[acute myeloid leukemia gene]	0.0	4	1	1	1
73036	1710	proximal mechanism	[proximal mechanisms]	0.0	2	1	1	1
73037	1710	fourfold susceptibility to malaria	[fourfold susceptibility to malaria]	0.0	4	1	1	1
73038	1710	site at position -67 bp	[site at position -67 bp]	0.0	5	1	1	1
73039	1710	complement receptor-1 CR1	[complement receptor-1 CR1]	0.0	3	1	1	1
73040	1710	inhibition during the second A/R challenge	[Inhibition during the second A/R challenge]	0.0	6	1	1	1
73041	1710	activation of unknown host event	[Activation of unknown host events]	0.0	5	1	1	1
73042	1710	cd95l expression	[CD95L expression]	0.0	2	1	1	1
73043	1710	proinflammatory transcription factor factor-kappaB	[proinflammatory transcription factor factor-kappaB]	0.0	4	1	1	1
73044	1710	yy1 class	[YY1 class]	0.0	2	1	1	1
73045	1710	basis for the similarity	[basis for the similarities]	0.0	4	1	1	1
73046	1710	decrease by human T cell	[decreases by human T cells]	0.0	5	1	1	1
73047	1710	effect of ectopic expression	[effects of ectopic expression]	0.0	4	1	1	1
73048	1710	use a receptor system	[using a receptor system]	0.0	4	1	1	1
73049	1710	impact on the activation status	[impact on the activation status]	0.0	5	1	1	1
73050	1710	mutation of the octamer-binding site	[Mutations of the octamer-binding site]	0.0	5	1	1	1
73051	1710	bcl-2 expression take	[Bcl-2 expression take]	0.0	3	1	1	1
73052	1710	molecular action	[Molecular actions]	0.0	2	2	2	1
73053	1710	negligible effect	[negligible effects]	0.0	2	1	1	1
73054	1710	reduce status	[reducing status]	0.0	2	1	1	1
73055	1710	rapid turnover the I	[rapid turnover the I]	0.0	4	1	1	1
73056	1710	AP-1 site at bp	[AP-1 site at bp]	0.0	4	2	2	1
73057	1710	vcam-1 promoter	[VCAM-1 promoter]	0.0	2	1	1	1
73058	1710	cellular expression	[cellular expression]	0.0	2	2	2	1
73059	1710	synergistic action CPRE GGACTACAG at -49/41	[synergistic action CPRE GGACTACAG at -49/-41,]	0.0	6	1	1	1
73060	1710	disease of patient with acute leukemia	[disease of patients with acute leukemia]	0.0	6	1	1	1
73061	1710	rigid,	[rigid,]	0.0	1	1	1	1
73062	1710	ability of ras	[ability of Ras]	0.0	3	1	1	1
73063	1710	correlation.	[correlation.]	0.0	1	1	1	1
73064	1710	macrophage in lesion	[macrophages in lesions]	0.0	3	1	1	1
73065	1710	IL-2 control	[IL-2 control]	0.0	2	1	1	1
73066	1710	variance	[variance]	0.0	1	1	1	1
73067	1710	matrix metalloproteinase factor	[matrix metalloproteinase factor]	0.0	3	1	1	1
73068	1710	hla-dq class ii subset	[HLA-DQ class II subset]	0.0	4	1	1	1
73069	1710	epo hcd57 erythroid cell	[EPO HCD57 erythroid cells]	0.0	4	1	1	1
73070	1710	characterization of the variant allele	[characterization of the variant allele]	0.0	5	1	1	1
73071	1710	(3h)-thymidine incorporation into DNA	[(3H)-thymidine incorporation into DNA]	0.0	4	1	1	1
73072	1710	number in secretory phase	[numbers in secretory phase]	0.0	4	1	1	1
73073	1710	Prostaglandin E2 a pleiotropic molecule	[Prostaglandin E2 a pleiotropic molecule]	0.0	5	1	1	1
73074	1710	HeLa cervical carcinoma cell	[HeLa cervical carcinoma cells]	0.0	4	1	1	1
73075	1710	inhibitor of tnf-alpha	[inhibitor of TNF-alpha]	0.0	3	1	1	1
73076	1710	sem) for control	[SEM) for controls]	0.0	3	1	1	1
73077	1710	aml m4 with abnormal eosinophil	[AML M4 with abnormal eosinophils]	0.0	5	1	1	1
73078	1710	pi3-k construct comprise domain	[PI3-K constructs comprising domains]	0.0	4	1	1	1
73079	1710	putative oncogene bcl-3	[putative oncogene bcl-3]	0.0	3	1	1	1
73080	1710	morphogen in development,	[morphogen in development,]	0.0	3	1	1	1
73081	1710	partners,	[partners,]	0.0	1	1	1	1
73082	1710	hiv- 1 replication	[HIV- 1 replication]	0.0	3	1	1	1
73083	1710	membrane proline-rich domain	[membrane proline-rich domain]	0.0	3	1	1	1
73084	1710	EBV cascade	[EBV cascade]	0.0	2	1	1	1
73085	1710	one member of this family, gata-3	[One member of this family, GATA-3]	0.0	6	1	1	1
73086	1710	musculin expression	[musculin expression]	0.0	2	1	1	1
73087	1710	tissue lymphoma (19	[tissue lymphoma (19]	0.0	3	1	1	1
73088	1710	mcd14 membrane cd14	[mCD14 membrane CD14]	0.0	3	1	1	1
73089	1710	least one type-specific clone	[least one type-specific clone]	0.0	4	1	1	1
73090	1710	addition (in the form chloride	[addition (in the form chloride]	0.0	5	1	1	1
73091	1710	haec vcam-1 expression	[HAEC VCAM-1 expression]	0.0	3	1	1	1
73092	1710	cycle gene include brlf1	[cycle genes including BRLF1]	0.0	4	1	1	1
73093	1710	M-CSF expression of the fos-related gene	[M-CSF expression of the fos-related gene]	0.0	6	1	1	1
73094	1710	stress agent	[stress agents]	0.0	2	1	1	1
73095	1710	cross-link of this lymphocyte-specific protein	[Cross-linking of this lymphocyte-specific protein]	0.0	5	1	1	1
73096	1710	physical interaction between Ets	[Physical interactions between Ets]	0.0	4	1	1	1
73097	1710	mapping of this site	[mapping of this site]	0.0	4	1	1	1
73098	1710	use pd-98059 two inhibitor kinase upstream	[using PD-98059 two inhibitors kinase upstream]	0.0	6	1	1	1
73099	1710	molecular weight dextran sulfate hmd	[molecular weight dextran sulfate HMDS]	0.0	5	1	1	1
73100	1710	(pre)	[(pre)]	0.0	1	1	1	1
73101	1710	majority of erythroid gene	[majority of erythroid genes]	0.0	4	1	1	1
73102	1710	dissociation of the NF-kappa B	[dissociation of the NF-kappa B]	0.0	5	1	1	1
73103	1710	Soluble tumor necrosis	[Soluble tumor necrosis]	0.0	3	1	1	1
73104	1710	Class cell MHC class ii	[Class cell MHC class II]	0.0	5	1	1	1
73105	1710	expression leukocyte protein a adaptor protein	[expression leukocyte protein a adaptor protein]	0.0	6	1	1	1
73106	1710	suppression of the response	[suppression of the response]	0.0	4	1	1	1
73107	1710	protein kinase C phosphorylation site	[protein kinase C phosphorylation site]	0.0	5	1	1	1
73108	1710	together with difference	[together with differences]	0.0	3	1	1	1
73109	1710	b /p65	[B /p65]	0.0	2	1	1	1
73110	1710	(35 min) submaximal exercise ppe	[(35 min) submaximal exercise PPE]	0.0	5	1	1	1
73111	1710	DRA expression in b cell	[DRA expression in B cells]	0.0	5	1	1	1
73112	1710	role of stat5 in normal monocyte	[roles of STAT5 in normal monocytes]	0.0	6	1	1	1
73113	1710	more recent study	[more recent studies]	0.0	3	1	1	1
73114	1710	vitamin cell line u937	[vitamin cell line U937]	0.0	4	1	1	1
73115	1710	human tf gene	[human TF gene]	0.0	3	1	1	1
73116	1710	constant (Kd) nmol/l)	[constant (Kd) nmol/l)]	0.0	3	1	1	1
73117	1710	activation of protein	[activation of proteins]	0.0	3	1	1	1
73118	1710	various disease (12: four	[various diseases (12: four]	0.0	4	1	1	1
73119	1710	1 alpha, 25-Dihydroxyvitamin D3	[1 alpha, 25-Dihydroxyvitamin D3]	0.0	4	1	1	1
73120	1710	blast use virus	[blasts using virus]	0.0	3	1	1	1
73121	1710	six tandem repeat	[Six tandem repeats]	0.0	3	1	1	1
73122	1710	use DNA template contain copy	[using DNA templates containing copies]	0.0	5	1	1	1
73123	1710	mcr young than 40.	[MCR younger than 40.]	0.0	4	1	1	1
73124	1710	protein fraction from S. cerevisiae	[protein fraction from S. cerevisiae]	0.0	5	1	1	1
73125	1710	RU-486 microM),	[RU-486 microM),]	0.0	2	1	1	1
73126	1710	two-dimensional phosphopeptide map	[Two-dimensional phosphopeptide maps]	0.0	3	1	1	1
73127	1710	hiv hyperplastic lymph node	[HIV hyperplastic lymph nodes]	0.0	4	1	1	1
73128	1710	proteolysis of androgen -bound receptor protein	[proteolysis of androgen -bound receptor protein]	0.0	6	1	1	1
73129	1710	control kd:2.92	[controls Kd:2.92]	0.0	2	1	1	1
73130	1710	role of stat5 in monocyte	[roles of STAT5 in monocytes]	0.0	5	1	1	1
73131	1710	characterization of nf(p)	[Characterization of NF(P)]	0.0	3	1	1	1
73132	1710	potent inhibitor of apoptosis	[potent inhibitor of apoptosis]	0.0	4	1	1	1
73133	1710	Tepoxalin a enzyme inhibitor	[Tepoxalin a enzyme inhibitor]	0.0	4	1	1	1
73134	1710	over-lapping set	[over-lapping sets]	0.0	2	1	1	1
73135	1710	Comparison of group 1 sequence	[Comparison of group 1 sequences]	0.0	5	1	1	1
73136	1710	reexpression of human MHC class gene	[reexpression of human MHC class genes]	0.0	6	1	1	1
73137	1710	[3H]VD3	[[3H]VD3]	0.0	1	1	1	1
73138	1710	Differential induction (ifn)-inducible protein	[Differential induction (IFN)-inducible protein]	0.0	4	1	1	1
73139	1710	properties unlike nuclear oncoprotein	[properties, unlike nuclear oncoproteins]	0.0	4	1	1	1
73140	1710	>10 mm,	[>10 mM,]	0.0	2	1	1	1
73141	1710	oncogenic form of notch1	[Oncogenic forms of NOTCH1]	0.0	4	1	1	1
73142	1710	inhibitor kappab alpha	[inhibitor kappaB alpha]	0.0	3	1	1	1
73143	1710	induction of IkappaBalpha	[induction of IkappaBalpha]	0.0	3	1	1	1
73144	1710	instillation of IL-6	[instillation of IL-6]	0.0	3	1	1	1
73145	1710	ligand on monocyte	[ligands on monocytes]	0.0	3	1	1	1
73146	1710	role for c/ebp beta	[role for C/EBP beta]	0.0	4	1	1	1
73147	1710	expression of IL-4	[expression of IL-4]	0.0	3	1	1	1
73148	1710	modification of protein kinase	[modification of protein kinases]	0.0	4	1	1	1
73149	1710	corresponding binding at kd-value	[corresponding binding at Kd-values]	0.0	4	1	1	1
73150	1710	Biologic effect on primary human NK	[Biologic effects on primary human NK]	0.0	6	1	1	1
73151	1710	E-protein family member	[E-protein family members]	0.0	3	1	1	1
73152	1710	least two pan-1	[least two Pan-1]	0.0	3	1	1	1
73153	1710	activation of the terminal repeat	[activation of the terminal repeat]	0.0	5	1	1	1
73154	1710	thyroid hormone t3	[Thyroid hormone T3]	0.0	3	1	1	1
73155	1710	binding of extract	[binding of extracts]	0.0	3	1	1	1
73156	1710	lead to production	[leading to production]	0.0	3	1	1	1
73157	1710	repeat sequence diversity	[repeat sequence diversity]	0.0	3	1	1	1
73158	1710	pg490 inhibition	[PG490 inhibition]	0.0	2	1	1	1
73159	1710	possible role for G(Anh)MTetra	[possible role for G(Anh)MTetra]	0.0	4	1	1	1
73160	1710	addition, deletion	[addition, deletion]	0.0	2	1	1	1
73161	1710	nuclear factor-AT response	[nuclear factor-AT response]	0.0	3	1	1	1
73162	1710	association of JAK1 in pro-B cell	[association of JAK1 in pro-B cells]	0.0	6	1	1	1
73163	1710	adherent population	[adherent population]	0.0	2	1	1	1
73164	1710	certain class	[Certain classes]	0.0	2	1	1	1
73165	1710	clonality analysis of refractory anemia	[Clonality analysis of refractory anemia]	0.0	5	1	1	1
73166	1710	promoter /enhancer region	[promoter /enhancer region]	0.0	3	1	1	1
73167	1710	engagement of the cd3.tcr complex	[engagement of the CD3.TcR complex]	0.0	5	1	1	1
73168	1710	nef gene express nef	[nef genes expressing Nefs]	0.0	4	1	1	1
73169	1710	expression of a mutant	[expression of a mutant]	0.0	4	1	1	1
73170	1710	many kidney disease	[many kidney diseases]	0.0	3	1	1	1
73171	1710	testosterone receptor in plasma membrane	[testosterone receptors in plasma membranes]	0.0	5	1	1	1
73172	1710	anaplastic astrocytomas /glioblastomas	[anaplastic astrocytomas /glioblastomas]	0.0	3	1	1	1
73173	1710	thymocyte from the medulla	[thymocytes from the medulla]	0.0	4	1	1	1
73174	1710	true IL-12 stage	[true IL-12 stage]	0.0	3	1	1	1
73175	1710	new potential antirheumatic	[new potential antirheumatic]	0.0	3	1	1	1
73176	1710	dominant form of aml1	[dominant form of AML1]	0.0	4	1	1	1
73177	1710	thyroid hormone th	[thyroid hormone TH]	0.0	3	1	1	1
73178	1710	heterocomplex with stat1	[heterocomplexes with STAT1]	0.0	3	1	1	1
73179	1710	several other cell-encoded gene	[several other cell-encoded genes]	0.0	4	1	1	1
73180	1710	gm-csf gene activation	[GM-CSF gene activation]	0.0	3	1	1	1
73181	1710	pattern use nuclear extract	[pattern using nuclear extracts]	0.0	4	1	1	1
73182	1710	mouse thymoma	[Mouse thymoma]	0.0	2	1	1	1
73183	1710	level nf-kappab	[level NF-kappaB]	0.0	2	1	1	1
73184	1710	gp 160 extract	[gp 160 extracts]	0.0	3	1	1	1
73185	1710	significantly low transcription enhancement	[significantly lower transcription enhancement]	0.0	4	1	1	1
73186	1710	mineralocorticoid receptor on leukocyte hml	[mineralocorticoid receptors on leukocytes HML]	0.0	5	1	1	1
73187	1710	/erythroid /monocytic hpc growth	[/erythroid /monocytic HPC growth]	0.0	4	1	1	1
73188	1710	responsiveness leukemia	[responsiveness leukemia]	0.0	2	1	1	1
73189	1710	least two complex	[least two complexes]	0.0	3	1	1	1
73190	1710	protein lef-1	[proteins LEF-1]	0.0	2	1	1	1
73191	1710	induce transcription of the proto-oncogent	[inducing transcription of the proto-oncogenes]	0.0	5	1	1	1
73192	1710	Genetic characterization of transactivation binding	[Genetic characterization of transactivation Binding]	0.0	5	1	1	1
73193	1710	important effector	[important effector]	0.0	2	1	1	1
73194	1710	large body	[large body]	0.0	2	1	1	1
73195	1710	test of receptor	[test of receptors]	0.0	3	1	1	1
73196	1710	two mrna species	[two mRNA species]	0.0	3	1	1	1
73197	1710	treatment of vein cell huvec monolayer	[Treatment of vein cell HUVEC monolayers]	0.0	6	1	1	1
73198	1710	inhibit the capacity of T cell	[inhibiting the capacity of T cells]	0.0	6	1	1	1
73199	1710	Furthermore, treatment of nuclear extract	[Furthermore, treatment of nuclear extracts]	0.0	5	1	1	1
73200	1710	mitogen-inducible, kappa b-binding protein	[mitogen-inducible, kappa B-binding protein]	0.0	4	1	1	1
73201	1710	ebv -positive gastric carcinoma tissue	[EBV -positive gastric carcinoma tissues]	0.0	5	1	1	1
73202	1710	serum-grown hl60 cell	[serum-grown HL60 cells]	0.0	3	1	1	1
73203	1710	strain of hiv-1 up to 10000-fold	[strains of HIV-1 up to 10,000-fold]	0.0	6	1	1	1
73204	1710	rel protein p50	[Rel proteins p50]	0.0	3	1	1	1
73205	1710	keratoconjunctivitis a disease	[keratoconjunctivitis an disease.]	0.0	3	1	1	1
73206	1710	healthy pregnant woman first, second	[healthy pregnant women first, second]	0.0	5	1	1	1
73207	1710	implication in biomedical research	[implication in biomedical research]	0.0	4	1	1	1
73208	1710	oct-1 protein	[Oct-1 protein]	0.0	2	1	1	1
73209	1710	costimulation with CD28 MoAb	[Costimulation with CD28 MoAb]	0.0	4	1	1	1
73210	1710	acid-induced expression	[acid-induced expression]	0.0	2	1	1	1
73211	1710	(p great	[(P greater]	0.0	2	1	1	1
73212	1710	duration of this response	[duration of this response]	0.0	4	1	1	1
73213	1710	increase in ca2+ concentration ca2+	[increase in Ca2+ concentration Ca2+]	0.0	5	1	1	1
73214	1710	other components.	[other components.]	0.0	2	1	1	1
73215	1710	molecular mass of the two	[molecular masses of the two]	0.0	5	1	1	1
73216	1710	100 mumol/L)	[100 mumol/L)]	0.0	2	1	1	1
73217	1710	virus reactivation in rest pbmc	[virus reactivation in resting PBMCs]	0.0	5	1	1	1
73218	1710	IFNA cell	[IFNA cells]	0.0	2	1	1	1
73219	1710	amino acid (aa)	[amino acids (aa)]	0.0	3	1	1	1
73220	1710	1.54 nm (mean	[1.54 nM (mean]	0.0	3	1	1	1
73221	1710	membrane domain	[membrane domain]	0.0	2	1	1	1
73222	1710	common control mechanism	[common control mechanisms]	0.0	3	1	1	1
73223	1710	gene [Cao Proc.Natl.Acad.Sci.USA	[gene [Cao Proc.Natl.Acad.Sci.USA]	0.0	3	1	1	1
73224	1710	macromolecule	[macromolecule]	0.0	1	1	1	1
73225	1710	NF-kB to site	[NF-kB to sites]	0.0	3	1	1	1
73226	1710	Tpp47	[Tpp47]	0.0	1	1	1	1
73227	1710	bimodal increase	[bimodal increase]	0.0	2	1	1	1
73228	1710	suggest cooperativity in the estrogenic response	[suggesting cooperativity in the estrogenic response]	0.0	6	1	1	1
73229	1710	examination of aml sample by EMSA	[Examination of AML samples by EMSA]	0.0	6	1	1	1
73230	1710	substnfkappab approximately substSp23	[substNFkappaB approximately substSp23]	0.0	3	1	1	1
73231	1710	cooperation between the hsv-1-activated cellular factor	[cooperation between the HSV-1-activated cellular factor]	0.0	6	1	1	1
73232	1710	contain little 50 ng	[containing little 50 ng]	0.0	4	1	1	1
73233	1710	expression of pu.1 in xenopus embryo	[expression of PU.1 in Xenopus embryos]	0.0	6	1	1	1
73234	1710	allele in progenitor	[alleles in progenitors]	0.0	3	1	1	1
73235	1710	cellular component of the immunoreaction	[cellular components of the immunoreaction]	0.0	5	1	1	1
73236	1710	vivo in C/EBPalpha mouse	[vivo in C/EBPalpha mice]	0.0	4	1	1	1
73237	1710	cellular regulation	[Cellular regulation]	0.0	2	1	1	1
73238	1710	melanogaster	[melanogaster]	0.0	1	1	1	1
73239	1710	48-hr antigen t-cell	[48-hr antigen T-cells]	0.0	3	1	1	1
73240	1710	lymph node involvement (p	[lymph node involvement (P]	0.0	4	1	1	1
73241	1710	E1A region	[E1A regions]	0.0	2	1	1	1
73242	1710	treatment with microm sodium orthovanadate	[Treatment with microM sodium orthovanadate]	0.0	5	1	1	1
73243	1710	consensus kappab	[consensus kappaB]	0.0	2	1	1	1
73244	1710	immunosuppressive and/or cytokine	[immunosuppressive and/or cytokine]	0.0	3	1	1	1
73245	1710	th2 cell differentiation switch	[Th2 cell differentiation switching]	0.0	4	1	1	1
73246	1710	phosphatidylinositol-3,4,5-trisphosphate pi-3,4,5-p3 concentration	[phosphatidylinositol-3,4,5-trisphosphate PI-3,4,5-P3 concentration]	0.0	3	1	1	1
73247	1710	reveal a redundancy	[revealing an redundancy.]	0.0	3	1	1	1
73248	1710	prominent enzyme in the pathway	[prominent enzymes in the pathway]	0.0	5	1	1	1
73249	1710	type of epstein-barr virus latency	[type of Epstein-Barr virus latency]	0.0	5	1	1	1
73250	1710	maturation, result	[maturation, resulting]	0.0	2	1	1	1
73251	1710	dehydroepiandrosterone binding activity	[dehydroepiandrosterone binding activity]	0.0	3	1	1	1
73252	1710	factor ms-2	[factor MS-2]	0.0	2	1	1	1
73253	1710	pbmc resistance	[PBMC resistance]	0.0	2	1	1	1
73254	1710	5'-cggagtttcc-3'	[5'-CGGAGTTTCC-3']	0.0	1	1	1	1
73255	1710	b otf-2	[B OTF-2]	0.0	2	1	1	1
73256	1710	alpha,25-(OH)2D3 cell of the T	[alpha,25-(OH)2D3 cells of the T]	0.0	5	1	1	1
73257	1710	series of deletion derivative	[series of deletion derivatives]	0.0	4	1	1	1
73258	1710	enhancer hs-40	[enhancer HS-40]	0.0	2	1	1	1
73259	1710	cell-specific nuclear factor-DNA complex	[cell-specific nuclear factor-DNA complexes]	0.0	4	1	1	1
73260	1710	pretreatment with il-8	[pretreatment with IL-8]	0.0	3	1	1	1
73261	1710	kd (30.3+/-2.5	[Kd (30.3+/-2.5]	0.0	2	1	1	1
73262	1710	cell growth-regulated expression of mcm5	[Cell growth-regulated expression of MCM5]	0.0	5	1	1	1
73263	1710	2 micrograms/day	[2 micrograms/day]	0.0	2	1	1	1
73264	1710	cell of tissue from patient	[cells of tissue from patients]	0.0	5	1	1	1
73265	1710	nf-kappab ikappab-alphas32/36a	[NF-kappaB IkappaB-alphaS32/36A]	0.0	2	1	1	1
73266	1710	acid (dna) bind protein exhibit change	[acid (DNA) binding proteins exhibiting changes]	0.0	6	1	1	1
73267	1710	mean dissociation (kd)	[mean dissociation (KD)]	0.0	3	1	1	1
73268	1710	potential immunogenicity	[potential immunogenicity]	0.0	2	1	1	1
73269	1710	role in the pathophysiology	[role in the pathophysiology]	0.0	4	2	2	1
73270	1710	isoform a	[isoform A]	0.0	2	1	1	1
73271	1710	phop gene	[phoP gene]	0.0	2	1	1	1
73272	1710	glucocorticoid receptor by glucocorticoid	[glucocorticoid receptor by glucocorticoids]	0.0	4	1	1	1
73273	1710	reporter gene strategy	[reporter gene strategy]	0.0	3	1	1	1
73274	1710	lineage follow exposure	[lineage following exposures]	0.0	3	1	1	1
73275	1710	pathogenesis of the immunodeficiency	[pathogenesis of the immunodeficiency]	0.0	4	1	1	1
73276	1710	concomitant migration of monocyte	[concomitant migration of monocytes]	0.0	4	1	1	1
73277	1710	first peak	[first peak]	0.0	2	1	1	1
73278	1710	specificity for various kappa b motif	[specificities for various kappa B motifs]	0.0	6	1	1	1
73279	1710	express HLA dr11	[expressing HLA DR11]	0.0	3	1	1	1
73280	1710	antigen-driven clonal expansion) (by stimulation lead	[antigen-driven clonal expansion) (by stimulation leading]	0.0	6	1	1	1
73281	1710	encompass nucleotide -135 to -176	[encompassing nucleotides -135 to -176]	0.0	5	1	1	1
73282	1710	major complex way	[major complex way]	0.0	3	1	1	1
73283	1710	mediate fasl expression	[mediating FasL expression]	0.0	3	1	1	1
73284	1710	inactive, enhancer transcript	[inactive, enhancer transcripts]	0.0	3	1	1	1
73285	1710	acth stimulation	[ACTH stimulation]	0.0	2	1	1	1
73286	1710	direct percutaneous coronary angioplasty	[direct percutaneous coronary angioplasty]	0.0	4	1	1	1
73287	1710	process unique to specific stimulus	[process unique to specific stimuli]	0.0	5	1	1	1
73288	1710	analysis of immunodeficiency virus apoptosis	[analysis of immunodeficiency virus apoptosis]	0.0	5	1	1	1
73289	1710	transient increase peak	[transient increase peaking]	0.0	3	1	1	1
73290	1710	lps abs	[LPS Abs]	0.0	2	1	1	1
73291	1710	expression whereas expression of a mutant	[expression whereas expression of a mutant]	0.0	6	1	1	1
73292	1710	human b-cell by ebv	[human B-cells by EBV]	0.0	4	1	1	1
73293	1710	hpa abnormality	[HPA abnormalities]	0.0	2	1	1	1
73294	1710	dissociation constant (Kd) nmol/l)	[dissociation constant (Kd) nmol/l)]	0.0	4	1	1	1
73295	1710	antagonist spironolactone	[antagonist spironolactone]	0.0	2	1	1	1
73296	1710	normal T cell responsiveness	[normal T cell responsiveness]	0.0	4	1	1	1
73297	1710	leiomyosarcoma	[leiomyosarcoma]	0.0	1	1	1	1
73298	1710	presence of tandem array	[presence of tandem arrays]	0.0	4	1	1	1
73299	1710	functional responsiveness	[functional responsiveness]	0.0	2	1	1	1
73300	1710	n-formyl-methionine-leucine-phenyl-alanine	[N-formyl-methionine-leucine-phenyl-alanine]	0.0	1	1	1	1
73301	1710	structure function	[Structure function]	0.0	2	1	1	1
73302	1710	Study on RA time-response	[Studies on RA time-response]	0.0	4	1	1	1
73303	1710	mediate early inflammatory response	[mediating early inflammatory responses]	0.0	4	1	1	1
73304	1710	common pathway for B-cell activation	[common pathway for B-cell activation]	0.0	5	1	1	1
73305	1710	AMP response element-bind protein complex	[AMP response element-binding protein complexes]	0.0	5	1	1	1
73306	1710	granulopoiesis postnatally, typically die	[granulopoiesis postnatally, typically dying]	0.0	4	1	1	1
73307	1710	finally, study a series	[Finally, studying a series]	0.0	4	1	1	1
73308	1710	interleukin 6 gene	[interleukin 6 gene]	0.0	3	1	1	1
73309	1710	(range, 3413 (range,	[(range, 3413 (range,]	0.0	3	1	1	1
73310	1710	differential role of Spi-1	[differential role of Spi-1]	0.0	4	1	1	1
73311	1710	(571 ng/ml)	[(571 ng/mL)]	0.0	2	1	1	1
73312	1710	age-associated impairment in T cell	[age-associated impairments in T cells]	0.0	5	1	1	1
73313	1710	two negative pathway	[two negative pathways]	0.0	3	1	1	1
73314	1710	relationship between binding	[relationship between binding]	0.0	3	1	1	1
73315	1710	physiologic switch	[physiologic switch]	0.0	2	1	1	1
73316	1710	analysis of 10 pair	[Analysis of 10 pairs]	0.0	4	1	1	1
73317	1710	precursor in culture.	[precursors in culture.]	0.0	3	1	1	1
73318	1710	dna-binding hmg box	[DNA-binding HMG box]	0.0	3	1	1	1
73319	1710	ATL-16T	[ATL-16T]	0.0	1	1	1	1
73320	1710	comparative mapping in the great ape	[Comparative mapping in the great apes]	0.0	6	1	1	1
73321	1710	new hematopoietic transcription factor	[new hematopoietic transcription factor]	0.0	4	1	1	1
73322	1710	housekeeping gene	[housekeeping genes]	0.0	2	2	2	1
73323	1710	immunodominant region	[immunodominant region]	0.0	2	1	1	1
73324	1710	(prd)	[(PRD)]	0.0	1	1	1	1
73325	1710	effect of e3330 on activation	[effect of E3330 on activation]	0.0	5	1	1	1
73326	1710	predict the occurrence of proliferations.	[predicting the occurrence of proliferations.]	0.0	5	1	1	1
73327	1710	kappa site	[kappa site]	0.0	2	1	1	1
73328	1710	[3h] dexamethasone binding in preparation	[[3H] dexamethasone binding in preparations]	0.0	5	1	1	1
73329	1710	ionize radiation exposure	[ionizing radiation exposure]	0.0	3	1	1	1
73330	1710	latent nf-kappa b	[latent NF-kappa B]	0.0	3	1	1	1
73331	1710	basal phosphorylation STAT3	[basal phosphorylation STAT3]	0.0	3	1	1	1
73332	1710	hardly any binding	[hardly any binding]	0.0	3	1	1	1
73333	1710	production of interleukin-12 a signal	[production of interleukin-12 a signal]	0.0	5	1	1	1
73334	1710	localization of I(kappa)B(alpha) in PBL	[localization of I(kappa)B(alpha) in PBL]	0.0	5	1	1	1
73335	1710	0.7 micromol/(mg protein.	[0.7 micromol/(mg protein.]	0.0	3	1	1	1
73336	1710	protein (c/ebp) epsilon	[protein (C/EBP) epsilon]	0.0	3	1	1	1
73337	1710	cell to 10(-9) m/l calcitriol	[cells to 10(-9) M/l calcitriol]	0.0	5	1	1	1
73338	1710	two human line	[two human lines]	0.0	3	1	1	1
73339	1710	E15 liver	[E15 liver]	0.0	2	1	1	1
73340	1710	ln T cell	[LN T cells]	0.0	3	1	1	1
73341	1710	most other antigen (include muscle actin	[most other antigens (including muscle actin]	0.0	6	1	1	1
73342	1710	undifferentiated non-PRL-secreting endometrial cell	[undifferentiated non-PRL-secreting endometrial cells]	0.0	4	1	1	1
73343	1710	T cell-independent	[T cell-independent]	0.0	2	1	1	1
73344	1710	hyperadhesivity of huvec to neutrophil	[hyperadhesivity of HUVECs to neutrophils]	0.0	5	1	1	1
73345	1710	vascular occlusion	[vascular occlusion]	0.0	2	1	1	1
73346	1710	effect of hemin tpa induction	[effects of hemin TPA induction]	0.0	5	1	1	1
73347	1710	array of response	[array of responses]	0.0	3	1	1	1
73348	1710	type 2 response	[type 2 responses]	0.0	3	1	1	1
73349	1710	inflammatory mediator by bronchial cell	[inflammatory mediators by bronchial cells]	0.0	5	1	1	1
73350	1710	fluoride-resistant- alpha-naphthyl-acetate-esterase	[fluoride-resistant- alpha-naphthyl-acetate-esterase]	0.0	2	1	1	1
73351	1710	percoll gradient	[Percoll gradients]	0.0	2	1	1	1
73352	1710	sn50 peptide	[SN50 peptide]	0.0	2	1	1	1
73353	1710	translocation double-stranded oligonucleotide	[translocation double-stranded oligonucleotides]	0.0	3	1	1	1
73354	1710	control less than 0.001).	[controls less than 0.001).]	0.0	4	1	1	1
73355	1710	addition transform growth factor-beta	[addition transforming growth factor-beta]	0.0	4	1	1	1
73356	1710	pathway for tissue damage	[pathways for tissue damage]	0.0	4	1	1	1
73357	1710	c-myb targets,	[c-Myb targets,]	0.0	2	1	1	1
73358	1710	nip-2 protein	[Nip-2 protein]	0.0	2	1	1	1
73359	1710	primary human erythroid cell	[primary human erythroid cells]	0.0	4	1	1	1
73360	1710	transcriptional factor ap-1	[transcriptional factors AP-1]	0.0	3	1	1	1
73361	1710	leukaemia PML	[leukaemia PML]	0.0	2	1	1	1
73362	1710	two carcinoma	[two carcinomas]	0.0	2	1	1	1
73363	1710	inhibition of ino synthase activity	[Inhibition of iNO synthase activity]	0.0	5	1	1	1
73364	1710	impaired silencing	[Impaired silencing]	0.0	2	1	1	1
73365	1710	effect of acid on apoptosis	[effects of acid on apoptosis]	0.0	5	1	1	1
73366	1710	distinct region important, respectively,	[distinct regions important, respectively,]	0.0	4	1	1	1
73367	1710	IL-2 -dependent transformation step	[IL-2 -dependent transformation steps]	0.0	4	1	1	1
73368	1710	pseudo-hypoaldosteronism follow resection	[pseudo-hypoaldosteronism following resection]	0.0	3	1	1	1
73369	1710	jak3 /stat5a/b signal transduction	[JAK3 /STAT5a/b signal transduction]	0.0	4	1	1	1
73370	1710	tcp microM, 72 h),	[TCP microM, 72 h),]	0.0	4	1	1	1
73371	1710	vimentin level	[vimentin levels]	0.0	2	1	1	1
73372	1710	cd19 mrna	[CD19 mRNA]	0.0	2	1	1	1
73373	1710	myeloid differentiation antigen	[myeloid differentiation antigen]	0.0	3	1	1	1
73374	1710	STAT1 activation role of adhesion molecule	[STAT1 activation role of adhesion molecules]	0.0	6	1	1	1
73375	1710	il-3 murine pro-B cell	[IL-3 murine pro-B cells]	0.0	4	1	1	1
73376	1710	identical amino-acid motif	[identical amino-acid motif]	0.0	3	1	1	1
73377	1710	extracellular event	[extracellular events]	0.0	2	1	1	1
73378	1710	transduce tat	[transducing tat]	0.0	2	1	1	1
73379	1710	novel regulator of transcription	[novel regulator of transcription]	0.0	4	1	1	1
73380	1710	sequencing of the product	[sequencing of the product]	0.0	4	1	1	1
73381	1710	have a effect	[having a effect]	0.0	3	1	1	1
73382	1710	diversity among that clone	[diversity among those clones]	0.0	4	1	1	1
73383	1710	calcineurin substrate	[calcineurin substrate]	0.0	2	1	1	1
73384	1710	mutation in the AP-1 site	[mutations in the AP-1 site]	0.0	5	1	1	1
73385	1710	patient with vddr-ii	[patients with VDDR-II]	0.0	3	1	1	1
73386	1710	affinity (3.93+/-0.89	[affinity (3.93+/-0.89]	0.0	2	1	1	1
73387	1710	uremic animal	[uremic animals]	0.0	2	2	2	1
73388	1710	interaction with two sequence-specific protein	[interaction with two sequence-specific proteins]	0.0	5	1	1	1
73389	1710	initial ebv program	[initial EBV program]	0.0	3	1	1	1
73390	1710	calcitriol (final ethanol concentration v/v)	[calcitriol (final ethanol concentration v/v)]	0.0	5	1	1	1
73391	1710	Gene for a tissue-specific activator ebf	[Gene for a tissue-specific activator EBF]	0.0	6	1	1	1
73392	1710	leukocyte of healthy male	[leukocytes of healthy males]	0.0	4	1	1	1
73393	1710	role of various cis-act element	[role of various cis-acting elements]	0.0	5	1	1	1
73394	1710	distinct family RA receptor rar	[distinct families RA receptors RARs]	0.0	5	1	1	1
73395	1710	potential advantage of pbsct	[potential advantages of PBSCT]	0.0	4	1	1	1
73396	1710	severe leukopenia in transgenic	[severe leukopenia in transgenic]	0.0	4	1	1	1
73397	1710	detectable effect on hiv replication	[detectable effect on HIV replication]	0.0	5	1	1	1
73398	1710	integration of human t-cell-leukemia virus type	[integration of human T-cell-leukemia virus type]	0.0	6	1	1	1
73399	1710	Janus kinase phosphorylation induction	[Janus kinase phosphorylation induction]	0.0	4	1	1	1
73400	1710	prevention of atherogenesis	[prevention of atherogenesis]	0.0	3	1	1	1
73401	1710	ica-positive first-degree relative of IDDM subject	[ICA-positive first-degree relatives of IDDM subjects]	0.0	6	1	1	1
73402	1710	ast/alt level	[AST/ALT levels]	0.0	2	1	1	1
73403	1710	differentiation-dependent receptor gamma	[differentiation-dependent receptor gamma]	0.0	3	1	1	1
73404	1710	complex a	[complex a]	0.0	2	1	1	1
73405	1710	bind to PRE-I	[binding to PRE-I]	0.0	3	1	1	1
73406	1710	Polyaromatic hydrocarbons	[Polyaromatic hydrocarbons]	0.0	2	1	1	1
73407	1710	TRAIL apoptosis -induce ligand a dil	[TRAIL apoptosis -inducing ligand a DIL]	0.0	6	1	1	1
73408	1710	cross-link of this protein	[Cross-linking of this protein]	0.0	4	1	1	1
73409	1710	Significantly, expression	[Significantly, expression]	0.0	2	1	1	1
73410	1710	major costimulatory signal	[major costimulatory signal]	0.0	3	1	1	1
73411	1710	immortalization by Epstein-Barr virus	[immortalization by Epstein-Barr virus]	0.0	4	1	1	1
73412	1710	128 bp	[128 bp]	0.0	2	1	1	1
73413	1710	(mean of two assays),	[(mean of two assays),]	0.0	4	1	1	1
73414	1710	DNA transfection of gene	[DNA transfections of gene]	0.0	4	1	1	1
73415	1710	contact identical	[contacts identical]	0.0	2	1	1	1
73416	1710	mlv transcription	[MLV transcription]	0.0	2	1	1	1
73417	1710	alter other pathway lead	[altering other pathways leading]	0.0	4	1	1	1
73418	1710	powerful suppressor	[powerful suppressors]	0.0	2	1	1	1
73419	1710	AMP -responsive element activation	[AMP -responsive element activation]	0.0	4	1	1	1
73420	1710	expression inducible protein	[Expression inducible protein]	0.0	3	1	1	1
73421	1710	post- pha stimulation	[post- PHA stimulation]	0.0	3	1	1	1
73422	1710	(mean of independent assays),	[(mean of independent assays),]	0.0	4	1	1	1
73423	1710	cell with the gtpase ran	[cells with the GTPase Ran]	0.0	5	1	1	1
73424	1710	immediate-early gene in monocyte	[immediate-early gene in monocytes]	0.0	4	1	1	1
73425	1710	human lox-1 gene symbol olr1	[human LOX-1 gene symbol OLR1]	0.0	5	1	1	1
73426	1710	mrna of three protein	[mRNA of three proteins]	0.0	4	1	1	1
73427	1710	induce the expansion	[inducing the expansion]	0.0	3	1	1	1
73428	1710	contrast, two nonsteroidal anti-inflammatory drug	[contrast, two nonsteroidal anti-inflammatory drugs]	0.0	5	1	1	1
73429	1710	such as the nervous system	[such as the nervous system]	0.0	5	1	1	1
73430	1710	apoptotic event	[apoptotic events]	0.0	2	1	1	1
73431	1710	activation of factor ap-1	[activation of factors AP-1]	0.0	4	1	1	1
73432	1710	er monocyte	[ER monocytes]	0.0	2	1	1	1
73433	1710	coordinate expression	[coordinate expression]	0.0	2	4	4	1
73434	1710	two distinct protein	[two distinct proteins]	0.0	3	1	1	1
73435	1710	shear stress flow pattern	[shear stress flow patterns]	0.0	4	1	1	1
73436	1710	export nfat nuclear factor	[export NFAT nuclear factor]	0.0	4	1	1	1
73437	1710	c-11-substituted 1 alpha,25-(OH)2D3 analog	[C-11-substituted 1 alpha,25-(OH)2D3 analogs]	0.0	4	1	1	1
73438	1710	low level in b-cell line	[low levels in B-cell lines]	0.0	5	1	1	1
73439	1710	dissociation constant for aldosterone	[dissociation constant for aldosterone]	0.0	4	1	1	1
73440	1710	use of animal	[use of animals]	0.0	3	1	1	1
73441	1710	ifn-gamma activation site-like sequence	[IFN-gamma activation site-like sequence]	0.0	4	1	1	1
73442	1710	antigen receptor bcr	[antigen receptor BCR]	0.0	3	1	1	1
73443	1710	form of (free) e2f	[forms of (free) E2F]	0.0	4	1	1	1
73444	1710	expose vein endothelial cell	[Exposing vein endothelial cells]	0.0	4	1	1	1
73445	1710	paf receptor transcript	[PAF receptor transcript]	0.0	3	1	1	1
73446	1710	glucocorticoid for a degree	[glucocorticoids for an degree]	0.0	4	1	1	1
73447	1710	G(m1)	[G(m1)]	0.0	1	1	1	1
73448	1710	blast use adeno-associated virus	[blasts using adeno-associated virus]	0.0	4	1	1	1
73449	1710	inhibition of inflammatory cytokine production	[inhibition of inflammatory cytokine production]	0.0	5	1	1	1
73450	1710	production of cytokine interleukin-2	[production of cytokines interleukin-2]	0.0	4	1	1	1
73451	1710	apoptosis-resistant t-cell transfectant	[apoptosis-resistant T-cell transfectants]	0.0	3	1	1	1
73452	1710	complex ap-1	[complex AP-1]	0.0	2	1	1	1
73453	1710	effect than the rapid response	[effects than the rapid responses]	0.0	5	1	1	1
73454	1710	hsv-1 recombinant virus	[HSV-1 recombinant virus]	0.0	3	1	1	1
73455	1710	RI gas binding	[RI GAS binding]	0.0	3	1	1	1
73456	1710	complex with two class	[complexes with two classes]	0.0	4	1	1	1
73457	1710	induction of resistance	[induction of resistance]	0.0	3	2	2	1
73458	1710	region of the IL-3 gene 5'	[regions of the IL-3 gene 5']	0.0	6	1	1	1
73459	1710	degree tested: dephosphorylation	[degree tested: dephosphorylation]	0.0	3	1	1	1
73460	1710	calcineurin (a) subunit	[calcineurin (A) subunit]	0.0	3	1	1	1
73461	1710	significant depression I receptor	[significant depression I receptors]	0.0	4	1	1	1
73462	1710	context-dependent coactivator of LEF-1	[context-dependent coactivator of LEF-1]	0.0	4	1	1	1
73463	1710	lymphoma (25	[lymphoma (25]	0.0	2	1	1	1
73464	1710	circulate leukocyte of donor of sexes.	[circulating leukocytes of donors of sexes.]	0.0	6	1	1	1
73465	1710	growth of this fibroblast	[growth of these fibroblasts]	0.0	4	1	1	1
73466	1710	sequence in promoter	[sequences in promoters]	0.0	3	1	1	1
73467	1710	contain the negative element NREs	[containing the negative elements NREs]	0.0	5	1	1	1
73468	1710	site transform protein lmp1	[site transforming protein LMP1]	0.0	4	1	1	1
73469	1710	export nuclear factor of T cell	[export nuclear factor of T cells]	0.0	6	1	1	1
73470	1710	in-vitro-stimulated normal blood lymphocyte sample	[in-vitro-stimulated normal blood lymphocyte samples]	0.0	5	1	1	1
73471	1710	express mutant	[expressing mutants]	0.0	2	1	1	1
73472	1710	cell cycle signal	[cell cycle signaling]	0.0	3	1	1	1
73473	1710	distal ccaat box upstream	[distal CCAAT box upstream]	0.0	4	1	1	1
73474	1710	pag activation	[pag activation]	0.0	2	1	1	1
73475	1710	lymphoma (19	[lymphoma (19]	0.0	2	1	1	1
73476	1710	preincubation,	[preincubation,]	0.0	1	1	1	1
73477	1710	notion of the conservation	[notion of the conservation]	0.0	4	1	1	1
73478	1710	previous transfection study	[Previous transfection studies]	0.0	3	1	1	1
73479	1710	presence of concentration	[presence of concentrations]	0.0	3	1	1	1
73480	1710	blockade of granulocytic differentiation	[blockade of granulocytic differentiation]	0.0	4	1	1	1
73481	1710	cell type-specific formation	[cell type-specific formation]	0.0	3	1	1	1
73482	1710	eosinophil in wound healing	[eosinophils in wound healing]	0.0	4	1	1	1
73483	1710	four direct repeat of bp	[four direct repeats of bp]	0.0	5	1	1	1
73484	1710	promoter-distal site	[promoter-distal site]	0.0	2	1	1	1
73485	1710	nuclear factor from THP-1	[nuclear factor from THP-1]	0.0	4	1	1	1
73486	1710	several role	[Several roles]	0.0	2	1	1	1
73487	1710	retinoid with receptor binding specificity	[retinoids with receptor binding specificity]	0.0	5	1	1	1
73488	1710	I trans-activator tax1	[I trans-activator tax1]	0.0	3	1	1	1
73489	1710	VCAM promoter	[VCAM promoter]	0.0	2	1	1	1
73490	1710	affinity (at sevenfold) 3.	[affinity (at sevenfold) 3.]	0.0	4	1	1	1
73491	1710	research on cell therapy,	[research on cell therapy,]	0.0	4	1	1	1
73492	1710	human b-cell lymphoma	[human B-cell lymphomas]	0.0	3	1	1	1
73493	1710	create a novel, -rich carboxy terminus	[creating a novel, -rich carboxy terminus]	0.0	6	1	1	1
73494	1710	mildly oxldl	[Mildly oxLDLs]	0.0	2	1	1	1
73495	1710	NK-chi	[NK-chi]	0.0	1	1	1	1
73496	1710	use constituent	[using constituents]	0.0	2	1	1	1
73497	1710	domain (prd) binding protein	[domain (PRD) binding proteins]	0.0	4	1	1	1
73498	1710	ecreb)/cctivating transcription factor	[(CREB)/activating transcription factor]	0.0	3	1	1	1
73499	1710	abundant production of tenacious, protease	[abundant production of tenacious, protease]	0.0	5	1	1	1
73500	1710	brief review of property	[brief review of properties]	0.0	4	1	1	1
73501	1710	many aspect	[many aspects]	0.0	2	2	2	1
73502	1710	activation of RE/AP	[activation of RE/AP]	0.0	3	1	1	1
73503	1710	three complex RFX	[three complexes RFX]	0.0	3	1	1	1
73504	1710	air-1	[AIR-1]	0.0	1	1	1	1
73505	1710	encompass a positive element	[encompassing an positive element]	0.0	4	1	1	1
73506	1710	presumably through interaction	[presumably through interaction]	0.0	3	1	1	1
73507	1710	consist of residue	[consisting of residues]	0.0	3	1	1	1
73508	1710	activity of preexisting nf-il6	[activity of preexisting NF-IL6]	0.0	4	1	1	1
73509	1710	upstream region -1168 to -440	[upstream regions -1168 to -440]	0.0	5	1	1	1
73510	1710	trans-activate protein in transient transfection	[trans-activating proteins in transient transfection]	0.0	5	1	1	1
73511	1710	anti-class i antibody	[anti-class I antibody]	0.0	3	1	1	1
73512	1710	bronchial asthma child aged years.	[bronchial asthma children aged years.]	0.0	5	1	1	1
73513	1710	taci antibody	[TACI antibodies]	0.0	2	1	1	1
73514	1710	stage of differentiation,	[stage of differentiation,]	0.0	3	1	1	1
73515	1710	modest inhibitor in blood lymphocyte culture	[modest inhibitors in blood lymphocyte cultures]	0.0	6	1	1	1
73516	1710	a oncoprotein	[A oncoprotein]	0.0	2	1	1	1
73517	1710	steroid-regulated apoptosis in thymoma cell	[steroid-regulated apoptosis in thymoma cells]	0.0	5	1	1	1
73518	1710	hog-1 (p38) mapk	[HOG-1 (p38) MAPk]	0.0	3	1	1	1
73519	1710	accumulation of mrna I	[accumulation of mRNA I]	0.0	4	1	1	1
73520	1710	stimulation with a peptide	[stimulation with a peptide]	0.0	4	1	1	1
73521	1710	effect on cell adhesion	[effects on cell adhesion]	0.0	4	1	1	1
73522	1710	number of erythroid-specific genes,	[number of erythroid-specific genes,]	0.0	4	1	1	1
73523	1710	migration rate by cortisol	[migration rate by cortisol]	0.0	4	1	1	1
73524	1710	stimulation of cell with interleukin-1beta	[Stimulation of cells with interleukin-1beta]	0.0	5	1	1	1
73525	1710	level of amplification of each oncogene	[levels of amplification of each oncogene]	0.0	6	1	1	1
73526	1710	other prolyl isomerase inhibitor	[other prolyl isomerase inhibitors]	0.0	4	1	1	1
73527	1710	icam-1 -dependent adhesivity toward leukocyte	[ICAM-1 -dependent adhesivity toward leukocytes]	0.0	5	1	1	1
73528	1710	switch in development	[switching in development]	0.0	3	1	1	1
73529	1710	effect on the gene' inducibility	[effect on the gene's inducibility]	0.0	5	1	1	1
73530	1710	structural homology between this gene	[structural homologies between these genes]	0.0	5	1	1	1
73531	1710	use t-lymphocyte	[using T-lymphocytes]	0.0	2	1	1	1
73532	1710	death domain death receptor DR3	[death domain death receptor DR3]	0.0	5	1	1	1
73533	1710	identification of residual disease	[identification of residual disease]	0.0	4	1	1	1
73534	1710	thus, difference	[Thus, differences]	0.0	2	1	1	1
73535	1710	CD28 response transcription factor	[CD28 response transcription factor]	0.0	4	1	1	1
73536	1710	peripheral b cell	[peripheral B cells]	0.0	3	2	2	1
73537	1710	such as protein kinase c	[such as protein kinase C]	0.0	5	1	1	1
73538	1710	inhibitory process	[inhibitory process]	0.0	2	1	1	1
73539	1710	effector of gata-1 signal	[effector of GATA-1 signals]	0.0	4	1	1	1
73540	1710	cellular redox status.	[cellular redox status.]	0.0	3	1	1	1
73541	1710	physiological process	[physiological process]	0.0	2	1	1	1
73542	1710	involve the x chromosome	[involving the X chromosome]	0.0	4	1	1	1
73543	1710	potential colony-forming cell hppecfcs	[potential colony-forming cells HPP-CFCs]	0.0	4	1	1	1
73544	1710	factors, include ap-1	[factors, including AP-1]	0.0	3	1	1	1
73545	1710	replacement suggest a role	[Replacement suggesting an role]	0.0	4	1	1	1
73546	1710	expression of a activity	[expression of a activity]	0.0	4	1	1	1
73547	1710	anti-fa	[anti-Fas]	0.0	1	1	1	1
73548	1710	macrophage tissue factor expression	[macrophage tissue factor expression]	0.0	4	1	1	1
73549	1710	alpha-rb	[alpha-Rb]	0.0	1	1	1	1
73550	1710	[3h]dihydrotestosterone	[[3H]dihydrotestosterone]	0.0	1	1	1	1
73551	1710	live, hiv-1	[live, HIV-1]	0.0	2	1	1	1
73552	1710	clinically sensitive myelogenous leukemia patient	[clinically sensitive myelogenous leukemia patients]	0.0	5	1	1	1
73553	1710	study use a form Max	[studies using a form Max]	0.0	5	1	1	1
73554	1710	neutrophil with factor g-csf	[neutrophils with factor G-CSF]	0.0	4	1	1	1
73555	1710	formation of transcription factor complex	[formation of transcription factor complexes]	0.0	5	1	1	1
73556	1710	major regulatory region	[major regulatory region]	0.0	3	1	1	1
73557	1710	crh gene promoter	[CRH gene promoter]	0.0	3	1	1	1
73558	1710	important marker	[important markers]	0.0	2	1	1	1
73559	1710	bind the interferon-inducible regulatory element	[binding the interferon-inducible regulatory element]	0.0	5	1	1	1
73560	1710	hiv-1 transcription on DNA	[HIV-1 transcription on DNA]	0.0	4	1	1	1
73561	1710	type ifi	[type IFNs]	0.0	2	1	1	1
73562	1710	interaction between NF-kappa B	[interaction between NF-kappa B]	0.0	4	1	1	1
73563	1710	double time,	[doubling time,]	0.0	2	1	1	1
73564	1710	effect by means	[effect by means]	0.0	3	1	1	1
73565	1710	cell other	[cells other]	0.0	2	1	1	1
73566	1710	hepatitis c	[hepatitis C]	0.0	2	6	6	1
73567	1710	two functional factor kB NF-kB element	[two functional factor kB NF-kB elements]	0.0	6	1	1	1
73568	1710	hypothesis key nuclear factor	[hypothesis key nuclear factors]	0.0	4	1	1	1
73569	1710	circadian rhythm of hepatic gr	[circadian rhythm of hepatic GR]	0.0	5	1	1	1
73570	1710	peripheral blood cell use dexamethasone	[peripheral blood cells using dexamethasone]	0.0	5	1	1	1
73571	1710	alpha -globin	[alpha -globin]	0.0	2	1	1	1
73572	1710	suppress pathway essential for this stage	[suppressing pathways essential for this stage]	0.0	6	1	1	1
73573	1710	antibody-mediated cross-linking tyrosine phosphorylation	[antibody-mediated cross-linking tyrosine phosphorylation]	0.0	4	1	1	1
73574	1710	activation by the antigen receptor	[Activation by the antigen receptor]	0.0	5	1	1	1
73575	1710	blood cell response to lipopolysaccharide	[blood cell responses to lipopolysaccharide]	0.0	5	1	1	1
73576	1710	various cellular stress agent	[Various cellular stress agents]	0.0	4	1	1	1
73577	1710	minimal region	[minimal region]	0.0	2	1	1	1
73578	1710	binding to cellular receptors.	[binding to cellular receptors.]	0.0	4	1	1	1
73579	1710	immune deficiency virus type hiv-1	[immune deficiency virus type HIV-1]	0.0	5	1	1	1
73580	1710	key molecular mechanism	[key molecular mechanism]	0.0	3	1	1	1
73581	1710	two element in the tsp promoter,	[Two elements in the TSP promoter,]	0.0	6	1	1	1
73582	1710	partial explanation	[partial explanation]	0.0	2	1	1	1
73583	1710	feature with human ebv	[features with human EBV]	0.0	4	1	1	1
73584	1710	patient with pulmonary disease tuberculosis	[patients with pulmonary diseases tuberculosis]	0.0	5	1	1	1
73585	1710	cross-talking among adhesion molecule	[cross-talking among adhesion molecules]	0.0	4	1	1	1
73586	1710	messenger generation	[messenger generation]	0.0	2	1	1	1
73587	1710	constitutive, expression of type interferon	[constitutive, expression of type interferon]	0.0	5	1	1	1
73588	1710	growth response gene egr-1	[growth response gene egr-1]	0.0	4	1	1	1
73589	1710	mrp14 migration inhibitory related protein	[MRP14 migration inhibitory related protein]	0.0	5	1	1	1
73590	1710	mutation in gene	[mutations in gene]	0.0	3	1	1	1
73591	1710	linkage between t-cell	[linkage between T-cell]	0.0	3	1	1	1
73592	1710	interphase nuclei	[interphase nuclei]	0.0	2	1	1	1
73593	1710	activation of intracellular signal cascade	[activation of intracellular signaling cascades]	0.0	5	1	1	1
73594	1710	differentiation marker,	[differentiation marker,]	0.0	2	1	1	1
73595	1710	-protein kinase inhibitor	[-protein kinase inhibitor]	0.0	3	1	1	1
73596	1710	BMLF1 of the protein	[BMLF1 of the proteins]	0.0	4	1	1	1
73597	1710	co-expression with a c-fo	[co-expression with a c-Fos]	0.0	4	1	1	1
73598	1710	level of xenobiotic response	[levels of xenobiotic response]	0.0	4	1	1	1
73599	1710	cd3+ cell (2.2%	[CD3+ cells (2.2%]	0.0	3	1	1	1
73600	1710	also at the level	[also at the level]	0.0	4	1	1	1
73601	1710	pre-mrna	[pre-mRNA]	0.0	1	1	1	1
73602	1710	important role for tcf-1	[important role for TCF-1]	0.0	4	1	1	1
73603	1710	packaging of viral particles, integration	[Packaging of viral particles, integration]	0.0	5	1	1	1
73604	1710	inhibitory effect of CaM-K	[inhibitory effect of CaM-K]	0.0	4	1	1	1
73605	1710	i interferon ifn-alpha/beta	[I interferons IFN-alpha/beta]	0.0	3	1	1	1
73606	1710	potency on dexamethasone stimulation	[potency on dexamethasone stimulation]	0.0	4	1	1	1
73607	1710	effect on pattern increase	[effect on patterns increase]	0.0	4	1	1	1
73608	1710	BA overexpression of gene	[BA overexpression of genes]	0.0	4	1	1	1
73609	1710	stimulation on immunogenic melanoma	[Stimulation on immunogenic melanomas]	0.0	4	1	1	1
73610	1710	abundance in a wide variety	[abundance in a wide variety]	0.0	5	1	1	1
73611	1710	express LMP1 in a range	[expressing LMP1 in a range]	0.0	5	1	1	1
73612	1710	mature monocytic phenotype	[mature monocytic phenotype]	0.0	3	1	1	1
73613	1710	40-fold high activity	[40-fold higher activity]	0.0	3	1	1	1
73614	1710	anti- antibody	[anti- antibody]	0.0	2	1	1	1
73615	1710	hla-b8-restricted epitope	[HLA-B8-restricted epitopes]	0.0	2	1	1	1
73616	1710	hpr cDNA region-specific probe	[hPR cDNA region-specific probes]	0.0	4	1	1	1
73617	1710	putative zinc finger domain	[putative zinc finger domains]	0.0	4	1	1	1
73618	1710	surrogate for the study of activation	[surrogates for the study of activation]	0.0	6	1	1	1
73619	1710	establish pbmc culture in mediuhd colony	[establishing PBMC cultures in medium, colonies]	0.0	6	1	1	1
73620	1710	200 fmol/mg protein	[200 fmol/mg protein]	0.0	3	1	1	1
73621	1710	relevant interaction between the kinase	[relevant interaction between the kinase]	0.0	5	1	1	1
73622	1710	most World primate nwp	[Most World primate NWP]	0.0	4	1	1	1
73623	1710	exposure to radiation	[exposure to radiation]	0.0	3	1	1	1
73624	1710	tail,	[tail,]	0.0	1	1	1	1
73625	1710	135eoh)2d3 ]receptor	[1,25(OH)2D3 ]receptor]	0.0	2	1	1	1
73626	1710	base pair -1	[base pairs -1]	0.0	3	1	1	1
73627	1710	secretion of TNF	[Secretion of TNF]	0.0	3	1	1	1
73628	1710	only slightly on basal cell	[only slightly on basal cells]	0.0	5	1	1	1
73629	1710	patient in long 3 years)	[patients in long-term 3 years)]	0.0	5	1	1	1
73630	1710	-induced,	[-induced,]	0.0	1	1	1	1
73631	1710	characterization of the activity	[characterization of the activity]	0.0	4	1	1	1
73632	1710	tumor necrosis factor-alpha element	[tumor necrosis factor-alpha elements]	0.0	4	1	1	1
73633	1710	bind site for factor	[binding sites for factors]	0.0	4	1	1	1
73634	1710	molecule for the organogenesis	[molecule for the organogenesis]	0.0	4	1	1	1
73635	1710	mp dose	[MP dose]	0.0	2	1	1	1
73636	1710	Saos cell	[Saos cells]	0.0	2	1	1	1
73637	1710	receptor in blood mononuclear leukocyte	[receptor in blood mononuclear leukocytes]	0.0	5	1	1	1
73638	1710	induction of differentiation of hl-60	[induction of differentiation of HL-60]	0.0	5	1	1	1
73639	1710	b cell factor EBF	[B cell factor EBF]	0.0	4	1	1	1
73640	1710	new antiapoptotic role	[new antiapoptotic role]	0.0	3	1	1	1
73641	1710	show the bcl-6	[showing the BCL-6]	0.0	3	1	1	1
73642	1710	comparable sensitivity for detection	[comparable sensitivity for detection]	0.0	4	1	1	1
73643	1710	induce protein expression in lymphoid tissue	[inducing protein expression in lymphoid tissues]	0.0	6	1	1	1
73644	1710	plasma cell line,	[plasma cell line,]	0.0	3	1	1	1
73645	1710	expression of nuclear factor kappab nf-kappab	[expression of nuclear factor kappaB NF-kappaB]	0.0	6	1	1	1
73646	1710	depletion A1	[depletion A1]	0.0	2	1	1	1
73647	1710	fibronectin with vla-5 receptor	[fibronectin with VLA-5 receptor]	0.0	4	1	1	1
73648	1710	catalyze the exchange from class molecule	[catalyzing the exchange from class molecules]	0.0	6	1	1	1
73649	1710	dna-binding factor specific to cell	[DNA-binding factor specific to cells]	0.0	5	1	1	1
73650	1710	acute leukemia m2-type cell line	[acute leukemia M2-type cell line]	0.0	5	1	1	1
73651	1710	transient upregulation	[transient upregulation]	0.0	2	1	1	1
73652	1710	kda glial repressor protein	[kDA glial repressor protein]	0.0	4	1	1	1
73653	1710	human cell clone	[human cell clone]	0.0	3	1	1	1
73654	1710	lymphoblast express level	[lymphoblasts expressing levels]	0.0	3	1	1	1
73655	1710	absolute block in maturation	[absolute block in maturation]	0.0	4	1	1	1
73656	1710	pge2 action	[PGE2 action]	0.0	2	1	1	1
73657	1710	proliferative potential cell	[proliferative potential cells]	0.0	3	1	1	1
73658	1710	wild-type hiv	[wild-type HIV]	0.0	2	1	1	1
73659	1710	platelet igg receptor	[platelet IgG receptor]	0.0	3	1	1	1
73660	1710	enhance inactivation through binding	[enhancing inactivation through binding]	0.0	4	1	1	1
73661	1710	expression of the map phosphatase	[Expression of the MAP phosphatase]	0.0	5	1	1	1
73662	1710	distal factor (NF)-AT NF-AT	[distal factor (NF)-AT NF-AT]	0.0	4	1	1	1
73663	1710	main activity i.e. transactivation	[main activities i.e. transactivation]	0.0	4	1	1	1
73664	1710	Octamer-dependent activation	[Octamer-dependent activation]	0.0	2	1	1	1
73665	1710	minimal residual disease of patient	[minimal residual disease of patients]	0.0	5	1	1	1
73666	1710	more precisely similarity	[more precisely similarities]	0.0	3	1	1	1
73667	1710	gram metyrapone met	[g metyrapone MET]	0.0	3	1	1	1
73668	1710	combination of IL-2	[combination of IL-2]	0.0	3	1	1	1
73669	1710	isolation for the class ii transactivator	[Isolation for the class II transactivator]	0.0	6	1	1	1
73670	1710	two general activator	[two general activators]	0.0	3	1	1	1
73671	1710	base stem-loop potential	[base stem-loop potential]	0.0	3	1	1	1
73672	1710	heterogeneous ribonucleoprotein k protein	[heterogeneous ribonucleoprotein K protein]	0.0	4	1	1	1
73673	1710	response element binding	[response element binding]	0.0	3	1	1	1
73674	1710	stationary phase	[stationary phase]	0.0	2	1	1	1
73675	1710	binding site oligonucleotide	[binding site oligonucleotides]	0.0	3	1	1	1
73676	1710	spectrum of B-cell differentiation	[spectrum of B-cell differentiation]	0.0	4	1	1	1
73677	1710	h (viability great	[h (viability greater]	0.0	3	1	1	1
73678	1710	involve a interaction with type-ii EBS	[involving a interaction with type-II EBS]	0.0	6	1	1	1
73679	1710	activity of glucocorticoid transactivation	[activities of glucocorticoids transactivation]	0.0	4	1	1	1
73680	1710	isg15 mrna accumulation	[ISG15 mRNA accumulation]	0.0	3	1	1	1
73681	1710	distribution of human immunoglobulin gene	[distribution of human immunoglobulin genes]	0.0	5	1	1	1
73682	1710	subsequent step in the pathway	[subsequent steps in the pathway]	0.0	5	1	1	1
73683	1710	role maintain a viral load	[role maintaining a viral load]	0.0	5	1	1	1
73684	1710	redox equilibrium	[redox equilibrium]	0.0	2	1	1	1
73685	1710	accompany up-regulation consistent	[accompanying up-regulation consistent]	0.0	3	1	1	1
73686	1710	examination of aml sample	[Examination of AML samples]	0.0	4	1	1	1
73687	1710	implication for the treatment	[implications for the treatment]	0.0	4	1	1	1
73688	1710	therapeutic efficiency of glucocorticoid	[therapeutic efficiency of glucocorticoids]	0.0	4	1	1	1
73689	1710	blood.	[blood.]	0.0	1	1	1	1
73690	1710	death effector protease	[death effector proteases]	0.0	3	1	1	1
73691	1710	(i) transfection under control	[(i) transfection under control]	0.0	4	1	1	1
73692	1710	support of response	[support of responses]	0.0	3	1	1	1
73693	1710	hepatocyte nuclear factor-1 alpha	[Hepatocyte nuclear factor-1 alpha]	0.0	4	1	1	1
73694	1710	basic protein mbp	[basic protein MBP]	0.0	3	1	1	1
73695	1710	land structure distinct	[LANDs structures distinct]	0.0	3	1	1	1
73696	1710	inhibitor of DNA binding	[inhibitor of DNA binding]	0.0	4	1	1	1
73697	1710	effect of dioxyvit with correction	[effect of dioxyvit with correction]	0.0	5	1	1	1
73698	1710	binding consistent	[binding consistent]	0.0	2	1	1	1
73699	1710	loss analogous	[loss analogous]	0.0	2	1	1	1
73700	1710	atra -responsive APL	[ATRA -responsive APL]	0.0	3	1	1	1
73701	1710	IL-2 promoter construct	[IL-2 promoter construct]	0.0	3	1	1	1
73702	1710	984 binding site	[984 binding sites]	0.0	3	1	1	1
73703	1710	transcriptionally-active conformation	[transcriptionally-active conformation]	0.0	2	1	1	1
73704	1710	serum gene	[serum genes]	0.0	2	1	1	1
73705	1710	Negative regulation of interleukin gene	[Negative regulation of interleukin gene]	0.0	5	1	1	1
73706	1710	extract from ECs	[extracts from ECs]	0.0	3	1	1	1
73707	1710	ligand-induced, tyrosine-phosphorylated docking site	[ligand-induced, tyrosine-phosphorylated docking sites]	0.0	4	1	1	1
73708	1710	structural analysis of the first rdna	[structural analysis of the first cDNAs]	0.0	6	1	1	1
73709	1710	pkc- activation	[PKC- activation]	0.0	2	1	1	1
73710	1710	slightly high content	[slightly higher content]	0.0	3	1	1	1
73711	1710	furthermore, IL-18	[Furthermore, IL-18]	0.0	2	1	1	1
73712	1710	distinctive expression pattern	[Distinctive expression pattern]	0.0	3	1	1	1
73713	1710	production in blood monocyte	[production in blood monocytes]	0.0	4	1	1	1
73714	1710	isoform of the nfat	[isoform of the NFAT]	0.0	4	1	1	1
73715	1710	hyperplasia fh	[hyperplasia FH]	0.0	2	1	1	1
73716	1710	cho/ cd14 cell	[CHO/ CD14 cells]	0.0	3	2	2	1
73717	1710	aiolo	[Aiolos]	0.0	1	1	1	1
73718	1710	several other cell include monocyte	[several other cells including monocytes]	0.0	5	1	1	1
73719	1710	21-bp repeat tax-responsive element-1	[21-bp repeats Tax-responsive element-1]	0.0	4	1	1	1
73720	1710	analog of 1 alpha,25-dihydroxyvitamin D3	[Analogs of 1 alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
73721	1710	syndrome dcs	[syndrome DCS]	0.0	2	1	1	1
73722	1710	muscular atrophy a form	[muscular atrophy an form]	0.0	4	1	1	1
73723	1710	three-dimensional resonance 3d-nmr spectroscopy	[three-dimensional resonance 3D-NMR spectroscopy]	0.0	4	1	1	1
73724	1710	dna-binding fragment in yeast	[DNA-binding fragments in yeast]	0.0	4	1	1	1
73725	1710	additional open reading frame	[additional open reading frame]	0.0	4	1	1	1
73726	1710	two active element	[two active elements]	0.0	3	1	1	1
73727	1710	semiquantitative transcriptase polymerase chain reaction	[semiquantitative transcriptase polymerase chain reaction]	0.0	5	1	1	1
73728	1710	IL-1 response	[IL-1 response]	0.0	2	1	1	1
73729	1710	Epstein-Barr virus a herpesvirus	[Epstein-Barr virus an herpesvirus]	0.0	4	1	1	1
73730	1710	activation of interleukin-1beta il-1beta	[activation of interleukin-1beta IL-1beta]	0.0	4	1	1	1
73731	1710	two model of cell line	[two models of cell lines]	0.0	5	1	1	1
73732	1710	pretreatment of "semimature" 5-day human macrophage	[Pretreatment of "semimature" 5-day human macrophages]	0.0	6	1	1	1
73733	1710	nonspecific reactive hyperplasia fh	[nonspecific reactive hyperplasia FH]	0.0	4	1	1	1
73734	1710	amphipatic protein segment	[amphipatic protein segments]	0.0	3	1	1	1
73735	1710	inhibition of histamine	[inhibition of histamine]	0.0	3	1	1	1
73736	1710	generation of ca2+ ion	[generation of Ca2+ ions]	0.0	4	1	1	1
73737	1710	basal level in u937 cell	[basal levels in U937 cells]	0.0	5	1	1	1
73738	1710	immature myeloid cell StatG	[immature myeloid cells StatG]	0.0	4	1	1	1
73739	1710	factor-kappaB phenomenon	[factor-kappaB phenomenon]	0.0	2	1	1	1
73740	1710	two family acid receptor rar	[two families acid receptors RARs]	0.0	5	1	1	1
73741	1710	monoblast cell line u-937	[monoblast cell line U-937]	0.0	4	2	2	1
73742	1710	0.5 h with nm vd3	[0.5 h with nM VD3]	0.0	5	1	1	1
73743	1710	enhancer-binding factor	[enhancer-binding factor]	0.0	2	1	1	1
73744	1710	induction in a T cell	[induction in a T cell]	0.0	5	1	1	1
73745	1710	member the homolog c/ebp-beta NF-IL6	[members the homolog C/EBP-beta NF-IL6]	0.0	5	1	1	1
73746	1710	localization signal of rela	[localization signal of RelA]	0.0	4	1	1	1
73747	1710	function of such related protein	[function of such related proteins]	0.0	5	1	1	1
73748	1710	blood of this disorders,	[blood of these disorders,]	0.0	4	1	1	1
73749	1710	lead to NF-kappa b localization	[leading to NF-kappa B localization]	0.0	5	1	1	1
73750	1710	e2f activation	[E2F activation]	0.0	2	1	1	1
73751	1710	key regulator of blood T	[key regulators of blood T]	0.0	5	1	1	1
73752	1710	Messenger rna production coding	[Messenger RNA production coding]	0.0	4	1	1	1
73753	1710	blood;	[blood;]	0.0	1	1	1	1
73754	1710	18-hydroxycorticosterone	[18-hydroxycorticosterone]	0.0	1	1	1	1
73755	1710	regulate eotaxin gene expression and/or	[regulating eotaxin gene expression and/or]	0.0	5	1	1	1
73756	1710	potential significance.	[potential significance.]	0.0	2	1	1	1
73757	1710	human b-cell lymphoma diffuse lymphoma	[human B-cell lymphomas diffuse lymphomas]	0.0	5	1	1	1
73758	1710	analysis of general coactivator requirement	[analysis of general coactivator requirements]	0.0	5	1	1	1
73759	1710	factor of T pathway	[factors of T pathway]	0.0	4	1	1	1
73760	1710	granular lymphocyte LGL	[granular lymphocytes LGL]	0.0	3	1	1	1
73761	1710	lck mobility	[Lck mobility]	0.0	2	1	1	1
73762	1710	limbic-hippocampal type receptor gcii	[limbic-hippocampal type receptor GCII]	0.0	4	1	1	1
73763	1710	113 breast cancer patient	[113 breast cancer patients]	0.0	4	1	1	1
73764	1710	action promonocytic leukemia cell	[action promonocytic leukemia cells]	0.0	4	1	1	1
73765	1710	endothelial activation ie, the expression	[endothelial activation ie, the expression]	0.0	5	1	1	1
73766	1710	potent growth factor	[potent growth factor]	0.0	3	1	1	1
73767	1710	Sudan	[Sudan]	0.0	1	1	1	1
73768	1710	acute injury with alpha-tocopherol a scavenger	[acute injury with alpha-tocopherol a scavenger]	0.0	6	1	1	1
73769	1710	b lymphocyte from transgenic mouse	[B lymphocytes from transgenic mice]	0.0	5	1	1	1
73770	1710	alpha/beta	[alpha/beta]	0.0	1	1	1	1
73771	1710	50 ng of rna.	[50 ng of RNA.]	0.0	4	1	1	1
73772	1710	constitutive expression of cd69	[constitutive expression of CD69]	0.0	4	1	1	1
73773	1710	one event in plaque development	[one event in plaque development]	0.0	5	1	1	1
73774	1710	role in EPO differentiation	[roles in EPO differentiation]	0.0	4	1	1	1
73775	1710	primary human NK	[primary human NK]	0.0	3	1	1	1
73776	1710	suggest pha related	[suggesting PHA related]	0.0	3	1	1	1
73777	1710	lectin-type	[lectin-type]	0.0	1	1	1	1
73778	1710	pattern of p50	[patterns of p50]	0.0	3	1	1	1
73779	1710	key participant mediate the dysfunction	[key participants mediating the dysfunction]	0.0	5	1	1	1
73780	1710	pmol/L; in woman	[pmol/L; in women]	0.0	3	1	1	1
73781	1710	age-related reduction	[age-related reductions]	0.0	2	2	2	1
73782	1710	lymphoblastoid wild-type CD4 receptor	[lymphoblastoid wild-type CD4 receptors]	0.0	4	1	1	1
73783	1710	cyclosporin-sensitive, modification of NF-ATp	[cyclosporin-sensitive, modification of NF-ATp]	0.0	4	1	1	1
73784	1710	RANTES factor of late T Lymphocytes-1	[RANTES Factor of Late T Lymphocytes-1]	0.0	6	1	1	1
73785	1710	nuclease- site	[nuclease- site]	0.0	2	1	1	1
73786	1710	lack kinase activity	[lacking kinase activity]	0.0	3	1	1	1
73787	1710	hemoglobin production	[hemoglobin production]	0.0	2	1	1	1
73788	1710	insulin concentration change	[insulin concentration change]	0.0	3	1	1	1
73789	1710	category factor such as Oct-2A	[categories factors such as Oct-2A]	0.0	5	1	1	1
73790	1710	expression of nfkb2	[expression of NFKB2]	0.0	3	1	1	1
73791	1710	adhesion vein endothelial cell	[adhesion vein endothelial cells]	0.0	4	1	1	1
73792	1710	tax -independent binding of cellular factor	[Tax -independent binding of cellular factors]	0.0	6	1	1	1
73793	1710	cell of the system.	[cells of the system.]	0.0	4	1	1	1
73794	1710	rel family protein c-rel	[Rel family proteins c-Rel]	0.0	4	1	1	1
73795	1710	two pan-1	[two Pan-1]	0.0	2	1	1	1
73796	1710	activation include NF-kappa b	[activation including NF-kappa B]	0.0	4	1	1	1
73797	1710	tcr-regulated factor	[TCR-regulated factor]	0.0	2	1	1	1
73798	1710	novel mechanism of action	[novel mechanism of action]	0.0	4	1	1	1
73799	1710	selectivity of pf	[selectivity of PF]	0.0	3	1	1	1
73800	1710	precise abnormality	[precise abnormalities]	0.0	2	1	1	1
73801	1710	early apoptotic event in cells.	[early apoptotic events in cells.]	0.0	5	1	1	1
73802	1710	virus infectivity	[virus infectivity]	0.0	2	1	1	1
73803	1710	mutant defective	[mutant defective]	0.0	2	1	1	1
73804	1710	inhibition of chemotactic migration rate	[inhibition of chemotactic migration rate]	0.0	5	1	1	1
73805	1710	new element important	[new element important]	0.0	3	1	1	1
73806	1710	endogenous lt	[endogenous LT]	0.0	2	1	1	1
73807	1710	study indicate a important determinant	[studies indicating an important determinant]	0.0	5	1	1	1
73808	1710	protein expression in cell	[protein expression in cells]	0.0	4	1	1	1
73809	1710	background: inhibition of complement	[BACKGROUND: Inhibition of complement]	0.0	4	1	1	1
73810	1710	primary syndrome in advanced stage	[primary syndromes in advanced stage]	0.0	5	1	1	1
73811	1710	minute exposure to RA	[minutes exposure to RA]	0.0	4	1	1	1
73812	1710	limit in remodeling of tissue	[limiting in remodeling of tissues]	0.0	5	1	1	1
73813	1710	erythroid mrna steady-state level	[erythroid mRNA steady-state level]	0.0	4	1	1	1
73814	1710	mode of oxidative stress.	[modes of oxidative stress.]	0.0	4	1	1	1
73815	1710	overnight dst	[overnight DST]	0.0	2	1	1	1
73816	1710	hepor expression	[hEpoR expression]	0.0	2	1	1	1
73817	1710	semen sample	[semen sample]	0.0	2	1	1	1
73818	1710	T component nf-atp	[T component NF-ATp]	0.0	3	1	1	1
73819	1710	determinant for the death-prom activity	[determinant for the death-promoting activity]	0.0	5	1	1	1
73820	1710	stat3 of response gene	[STAT3 of response genes]	0.0	4	1	1	1
73821	1710	activate the transcription factor nuclear factor	[activating the transcription factor nuclear factor]	0.0	6	1	1	1
73822	1710	alternative splicing of exon	[Alternative splicing of exon]	0.0	4	1	1	1
73823	1710	strong preference	[strong preference]	0.0	2	1	1	1
73824	1710	hela-tat cell	[HeLa-tat cells]	0.0	2	1	1	1
73825	1710	ROI -form	[ROI -forming]	0.0	2	1	1	1
73826	1710	include enhancement	[including enhancement]	0.0	2	1	1	1
73827	1710	15000 receptors/cell,	[15,000 receptors/cell,]	0.0	2	1	1	1
73828	1710	synthetic thrombin receptor agonist peptide	[synthetic thrombin receptor agonist peptide]	0.0	5	1	1	1
73829	1710	8, malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[8, malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
73830	1710	human T cell modulation	[human T cells modulation]	0.0	4	1	1	1
73831	1710	cause resistance in neotropical primate	[causing resistance in neotropical primates]	0.0	5	1	1	1
73832	1710	colony-stimumulatelany-stg factor csf-1	[colony-stimulating factor CSF-1]	0.0	3	1	1	1
73833	1710	differentiation-inducing therapy of tumor	[differentiation-inducing therapy of tumors]	0.0	4	1	1	1
73834	1710	reactivity of neonate	[reactivity of neonates]	0.0	3	1	1	1
73835	1710	homeobox gene related to proboscipedia	[homeobox gene related to proboscipedia]	0.0	5	1	1	1
73836	1710	hil-5 -responsive cell line	[hIL-5 -responsive cell lines]	0.0	4	1	1	1
73837	1710	human vein endothelial cell huvec	[human vein endothelial cells HUVECs]	0.0	5	2	2	1
73838	1710	1 alpha,25-dihydroxyvitamin D3 in lymphocyte	[1 alpha,25-dihydroxyvitamin D3 in lymphocytes]	0.0	5	1	1	1
73839	1710	blood estrogen	[blood estrogen]	0.0	2	1	1	1
73840	1710	bind to glucocorticoid	[binding to glucocorticoid]	0.0	3	1	1	1
73841	1710	have a biopsy	[having an biopsy]	0.0	3	1	1	1
73842	1710	myeloid transcription factor	[myeloid transcription factor]	0.0	3	1	1	1
73843	1710	cytokine similar to IL-4	[cytokine similar to IL-4]	0.0	4	1	1	1
73844	1710	non-viral oncogene-expressing	[non-viral oncogene-expressing]	0.0	2	1	1	1
73845	1710	mrp14 macrophage migration protein	[MRP14 Macrophage migration protein]	0.0	4	1	1	1
73846	1710	accompany the turnover	[Accompanying the turnover]	0.0	3	1	1	1
73847	1710	cytokine affect growth	[cytokine affecting growth]	0.0	3	1	1	1
73848	1710	however, microg/100 millileter at 10:00 P;	[However, microg/100 ml at 10:00 h;]	0.0	6	1	1	1
73849	1710	hiv-1 infection of primary T cell	[HIV-1 infection of primary T cells]	0.0	6	1	1	1
73850	1710	ensure the differentiation	[ensuring the differentiation]	0.0	3	1	1	1
73851	1710	gata-1 allele, lead to variable severity	[GATA-1 allele, leading to variable severity]	0.0	6	1	1	1
73852	1710	+/- fmol/10(7) pbmc versus 4.43	[+/- fmol/10(7) PBMC vs 4.43]	0.0	5	1	1	1
73853	1710	information about the intracellular protein	[information about the intracellular proteins]	0.0	5	1	1	1
73854	1710	expression under the control	[expression under the control]	0.0	4	1	1	1
73855	1710	significance to aids patient with malignancy	[significance to AIDS patients with malignancies]	0.0	6	1	1	1
73856	1710	accurately, amount	[accurately, amounts]	0.0	2	1	1	1
73857	1710	cell line gp+e-86	[cell lines GP+E-86]	0.0	3	1	1	1
73858	1710	adhesion in human vein cell	[adhesion in human vein cells]	0.0	5	1	1	1
73859	1710	use T cell from donor	[using T cells from donors]	0.0	5	1	1	1
73860	1710	significant correlation between infiltration	[significant correlation between infiltration]	0.0	4	1	1	1
73861	1710	CD40 -ligand+ T	[CD40 -ligand+ T]	0.0	3	1	1	1
73862	1710	include some group	[including some groups]	0.0	3	1	1	1
73863	1710	major DNase-I hypersensitive site HS	[major DNase-I hypersensitive sites HS]	0.0	5	1	1	1
73864	1710	heavy-chain gene enhancer	[heavy-chain gene enhancer]	0.0	3	1	1	1
73865	1710	sr patient	[SR patients]	0.0	2	1	1	1
73866	1710	PKC fas expression	[PKC Fas expression]	0.0	3	1	1	1
73867	1710	time of h for culture	[times of h for cultures]	0.0	5	1	1	1
73868	1710	three distinct transcription factor	[three distinct transcription factors]	0.0	4	1	1	1
73869	1710	probably a target site for factor	[probably a target site for factors]	0.0	6	1	1	1
73870	1710	endogenous ikappab kinase activation	[endogenous IkappaB kinase activation]	0.0	4	1	1	1
73871	1710	use t-lymphocyte from VZV donor	[using T-lymphocytes from VZV donors]	0.0	5	1	1	1
73872	1710	tyrosine stat1 protein	[tyrosine stat1 proteins]	0.0	3	1	1	1
73873	1710	MF individual	[MF individuals]	0.0	2	1	1	1
73874	1710	globin gene delta	[globin genes delta]	0.0	3	1	1	1
73875	1710	hirsute patient with mense	[hirsute patients with menses]	0.0	4	1	1	1
73876	1710	homology in dna-binding domain	[homology in DNA-binding domains]	0.0	4	1	1	1
73877	1710	variable region promoter	[variable region promoters]	0.0	3	1	1	1
73878	1710	effect of NK granule	[effects of NK granules]	0.0	4	1	1	1
73879	1710	particular pattern	[particular pattern]	0.0	2	1	1	1
73880	1710	necessary signal component	[necessary signaling component]	0.0	3	1	1	1
73881	1710	presence of site	[presence of sites]	0.0	3	1	1	1
73882	1710	structural classification of IDC	[structural classification of IDC]	0.0	4	1	1	1
73883	1710	DC at effector site	[DC at effector sites]	0.0	4	1	1	1
73884	1710	receptor in growth	[receptors in growth]	0.0	3	1	1	1
73885	1710	transfection of mutant into jurkat T	[Transfection of mutants into Jurkat T]	0.0	6	1	1	1
73886	1710	inducible trans activation	[inducible trans activation]	0.0	3	1	1	1
73887	1710	suggest a involvement	[suggesting an involvement]	0.0	3	1	1	1
73888	1710	microB site	[microB sites]	0.0	2	1	1	1
73889	1710	(accessory	[(accessory]	0.0	1	1	1	1
73890	1710	skewing potential of il-12	[skewing potential of IL-12]	0.0	4	1	1	1
73891	1710	none of the compounds,	[none of the compounds,]	0.0	4	1	1	1
73892	1710	implication for autoimmunity	[implications for autoimmunity]	0.0	3	1	1	1
73893	1710	mix study	[mixing studies]	0.0	2	1	1	1
73894	1710	dimeric tnf receptor	[dimeric TNF receptor]	0.0	3	1	1	1
73895	1710	rapid posttranslational activation in response	[rapid posttranslational activation in response]	0.0	5	1	1	1
73896	1710	cd4+ t-cell	[CD4+ T-cells]	0.0	2	2	2	1
73897	1710	independency	[independency]	0.0	1	1	1	1
73898	1710	DNA cotransfection	[DNA cotransfection]	0.0	2	1	1	1
73899	1710	activation of the ap-1 site	[activation of the AP-1 site]	0.0	5	1	1	1
73900	1710	experiment compare binding	[experiments comparing binding]	0.0	3	1	1	1
73901	1710	two alpha-helice class MHC molecule	[two alpha-helices class MHC molecules]	0.0	5	1	1	1
73902	1710	stimulation in vitro,	[stimulations in vitro,]	0.0	3	1	1	1
73903	1710	related molecule	[related molecule]	0.0	2	1	1	1
73904	1710	sera (0/3) carrier (0/33)	[sera (0/3) carriers (0/33)]	0.0	4	1	1	1
73905	1710	thirteen preterm	[Thirteen preterms]	0.0	2	1	1	1
73906	1710	t-cell control.	[T-cell control.]	0.0	2	1	1	1
73907	1710	association of cytoplasmic carboxyl terminus	[association of cytoplasmic carboxyl terminus]	0.0	5	1	1	1
73908	1710	nearly all control mouse	[nearly all control mice]	0.0	4	1	1	1
73909	1710	kappa B/Rel nuclear activity lymphocyte	[kappa B/Rel nuclear activity lymphocytes]	0.0	5	1	1	1
73910	1710	poor glycemic control	[poor glycemic control]	0.0	3	1	1	1
73911	1710	arteritis	[arteritis]	0.0	1	1	1	1
73912	1710	late effect than the response	[later effects than the responses]	0.0	5	1	1	1
73913	1710	hgata-3 activation domain	[hGATA-3 activation domain]	0.0	3	1	1	1
73914	1710	cis-acting regulatory sequence	[cis-acting regulatory sequences]	0.0	3	1	1	1
73915	1710	hormone responsiveness	[hormone responsiveness]	0.0	2	1	1	1
73916	1710	IL-8 a potent factor	[IL-8 a potent factor]	0.0	4	1	1	1
73917	1710	analysis of the rdna HZF	[analysis of the cDNAs HZF]	0.0	5	1	1	1
73918	1710	fibrosarcoma malignant fibrous histiocytoma rhabdomyosarcoma	[fibrosarcoma malignant fibrous histiocytoma rhabdomyosarcoma]	0.0	5	1	1	1
73919	1710	inhibition depletion	[inhibition depletion]	0.0	2	1	1	1
73920	1710	HIV repeat reporter gene construct	[HIV repeat reporter gene construct]	0.0	5	1	1	1
73921	1710	normal diurnal decline	[normal diurnal decline]	0.0	3	1	1	1
73922	1710	nos nno	[NOS nNOS]	0.0	2	1	1	1
73923	1710	trigger molecule	[triggering molecule]	0.0	2	1	1	1
73924	1710	tumor-derived product from RCC explant	[Tumor-derived products from RCC explants]	0.0	5	1	1	1
73925	1710	histocompatibility complex MHC way	[histocompatibility complex MHC way]	0.0	4	1	1	1
73926	1710	antiserum (identical	[antiserum (identical]	0.0	2	1	1	1
73927	1710	human paf receptor transcript	[human PAF receptor transcript]	0.0	4	1	1	1
73928	1710	myeloid differentiation a experimental model	[myeloid differentiation a experimental model]	0.0	5	1	1	1
73929	1710	abnormal blast cell	[abnormal blast cells]	0.0	3	2	2	1
73930	1710	probability of interaction	[probability of interaction]	0.0	3	1	1	1
73931	1710	evidence for a strong component	[evidence for a strong component]	0.0	5	1	1	1
73932	1710	viral transactivator activity	[viral transactivator activity]	0.0	3	1	1	1
73933	1710	evaluation for the presence	[Evaluation for the presence]	0.0	4	1	1	1
73934	1710	kappa B NF-kappaB	[kappa B NF-kappaB]	0.0	3	1	1	1
73935	1710	notable exception lymphocyte	[notable exception lymphocytes]	0.0	3	1	1	1
73936	1710	immunoglobulin heavy-chain mrna in vivo	[immunoglobulin heavy-chain mRNA in vivo]	0.0	5	1	1	1
73937	1710	turnover of pre-	[turnover of pre-]	0.0	3	1	1	1
73938	1710	woman with hyperparathyroidism secondary	[women with hyperparathyroidism secondary]	0.0	4	1	1	1
73939	1710	patient' young brother,	[patient's younger brother,]	0.0	3	1	1	1
73940	1710	backbone vector alone	[backbone vector alone]	0.0	3	1	1	1
73941	1710	strong activate effect	[strong activating effects]	0.0	3	1	1	1
73942	1710	adrenocorticotropic hormone release in response	[adrenocorticotropic hormone release in response]	0.0	5	1	1	1
73943	1710	expression of p13mtcp1 normal tissue	[expression of p13MTCP1 normal tissues]	0.0	5	1	1	1
73944	1710	order less potent than H	[orders less potent than H]	0.0	5	1	1	1
73945	1710	constitutive overexpression of the L-selectin gene	[Constitutive overexpression of the L-selectin gene]	0.0	6	1	1	1
73946	1710	expression of own high-affinity receptor	[expression of own high-affinity receptor]	0.0	5	1	1	1
73947	1710	protein-protein level	[protein-protein level]	0.0	2	1	1	1
73948	1710	Platelet/endothelium interaction	[Platelet/endothelium interaction]	0.0	2	1	1	1
73949	1710	critical regulator of gene	[critical regulator of genes]	0.0	4	1	1	1
73950	1710	rank -dependent induction	[RANK -dependent induction]	0.0	3	1	1	1
73951	1710	test the effect of strategy	[testing the effects of strategies]	0.0	5	1	1	1
73952	1710	enhancer element activity under conditions.	[enhancer element activities under conditions.]	0.0	5	1	1	1
73953	1710	identification of a regulatory element	[Identification of a regulatory element]	0.0	5	1	1	1
73954	1710	cell of the lineage mature.	[cells of the lineage mature.]	0.0	5	1	1	1
73955	1710	gene by the nuclear factor	[genes by the nuclear factor]	0.0	5	1	1	1
73956	1710	EA-R	[EA-R]	0.0	1	1	1	1
73957	1710	dihuang	[dihuang]	0.0	1	1	1	1
73958	1710	immediate-early promoter	[immediate-early promoters]	0.0	2	1	1	1
73959	1710	mouse spleen in	[mice spleen in]	0.0	3	1	1	1
73960	1710	segregate the Chr 20	[segregating the Chr 20]	0.0	4	1	1	1
73961	1710	Challenge	[Challenges]	0.0	1	1	1	1
73962	1710	modes, like chemical induction, lytic superinfection	[modes, like chemical induction, lytic superinfection]	0.0	6	1	1	1
73963	1710	anti-p-selectin antibody monoclonal antibody	[anti-P-selectin antibodies monoclonal antibodies]	0.0	4	1	1	1
73964	1710	macrophage mdm	[macrophages MDMs]	0.0	2	2	2	1
73965	1710	characterization of a regulatory element	[characterization of a regulatory element]	0.0	5	1	1	1
73966	1710	pair of grade astrocytomas	[pairs of grade astrocytomas]	0.0	4	1	1	1
73967	1710	role in hiv regulation	[role in HIV regulation]	0.0	4	1	1	1
73968	1710	NF-kappaB effect of alpha-lipoate	[NF-kappaB effect of alpha-lipoate]	0.0	4	1	1	1
73969	1710	dexamethasone (ic50	[dexamethasone (IC50]	0.0	2	1	1	1
73970	1710	expression program	[expression program]	0.0	2	1	1	1
73971	1710	(p leukocyte adhesion	[(P leukocyte adhesion]	0.0	3	1	1	1
73972	1710	rapidak effect on electrolyte movement	[rapid, effects on electrolyte movements]	0.0	5	1	1	1
73973	1710	luciferase construct miss the region	[luciferase constructs missing the region]	0.0	5	1	1	1
73974	1710	I-kappa b	[I-kappa B]	0.0	2	1	1	1
73975	1710	taqi restriction	[TaqI restriction]	0.0	2	1	1	1
73976	1710	loss of cell production	[loss of cell production]	0.0	4	1	1	1
73977	1710	homologous member the homolog	[homologous members the homolog]	0.0	4	1	1	1
73978	1710	IL-5 promoter/enhancer	[IL-5 promoter/enhancer]	0.0	2	1	1	1
73979	1710	include aml with immature morphology	[including AML with immature morphology]	0.0	5	1	1	1
73980	1710	indicate negative regulation	[indicating negative regulation]	0.0	3	1	1	1
73981	1710	(pth)	[(pTh)]	0.0	1	1	1	1
73982	1710	expression of another viral protein	[expression of another viral protein]	0.0	5	1	1	1
73983	1710	whole-cell competitive radioassay use [3H]-dexamethasone	[whole-cell competitive radioassay using [3H]-dexamethasone]	0.0	5	1	1	1
73984	1710	cd23 a b	[CD23 a B]	0.0	3	1	1	1
73985	1710	associate with rip	[associates with RIP]	0.0	3	1	1	1
73986	1710	transcription of the genome	[transcription of the genome]	0.0	4	1	1	1
73987	1710	continue for hours.	[continuing for hours.]	0.0	3	1	1	1
73988	1710	human colony-stimumulatelany-stg factor-1 receptor	[human colony-stimulating factor-1 receptor]	0.0	4	1	1	1
73989	1710	indicate a role for calcitriol	[indicating a role for calcitriol]	0.0	5	1	1	1
73990	1710	misfunction	[misfunction]	0.0	1	1	1	1
73991	1710	promoter in the intron	[promoter in the intron]	0.0	4	1	1	1
73992	1710	human 5-aminolevulinate synthase	[Human 5-aminolevulinate synthase]	0.0	3	1	1	1
73993	1710	binding of elf-1 ap-1 transcription factor	[binding of Elf-1 AP-1 transcription factors]	0.0	6	1	1	1
73994	1710	subunits; five independent genes, nfkb1	[subunits; five independent genes, NFKB1]	0.0	5	1	1	1
73995	1710	myeloid-cell-specific expression	[myeloid-cell-specific expression]	0.0	2	1	1	1
73996	1710	eicosanoid synthesis from mammary cancer patient	[eicosanoid synthesis from mammary cancer patients]	0.0	6	1	1	1
73997	1710	25(oh)d3-24-hydroxylase	[25(OH)D3-24-hydroxylase]	0.0	1	1	1	1
73998	1710	high c-erb	[high c-erb]	0.0	2	2	2	1
73999	1710	tcell rescue	[Tcell rescue]	0.0	2	1	1	1
74000	1710	fuse the mouse t-lymphoma cell line	[fusing the mouse T-lymphoma cell line]	0.0	6	1	1	1
74001	1710	one event	[one event]	0.0	2	1	1	1
74002	1710	low level of transcription basal transcription	[Low levels of transcription basal transcription]	0.0	6	1	1	1
74003	1710	ltr with individual	[LTRs with individual]	0.0	3	1	1	1
74004	1710	activation of gene contain gata-responsive element	[activation of genes containing GATA-responsive elements]	0.0	6	1	1	1
74005	1710	increases.	[increases.]	0.0	1	1	1	1
74006	1710	leukocyte protein of kD slp-76	[leukocyte protein of kD SLP-76]	0.0	5	1	1	1
74007	1710	50 nm alpha,25-dihydroxyvitamin D3	[50 nM alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
74008	1710	wild-type tlr2	[wild-type TLR2]	0.0	2	1	1	1
74009	1710	glucocorticoid receptor mutant	[glucocorticoid receptor mutant]	0.0	3	1	1	1
74010	1710	pseudohypoaldosteronism with reduction	[pseudohypoaldosteronism with reduction]	0.0	3	1	1	1
74011	1710	immunoglobulin g igg fc receptor	[immunoglobulin G IgG Fc receptors]	0.0	5	1	1	1
74012	1710	contrast, inhibition beta of magnitude	[contrast, inhibition beta of magnitude]	0.0	5	1	1	1
74013	1710	number of marker	[number of markers]	0.0	3	1	1	1
74014	1710	nmol/L) versus 9.5+/-0.3 nmol/L)	[nmol/L) versus 9.5+/-0.3 nmol/L)]	0.0	4	1	1	1
74015	1710	specificity between all candidate	[specificity between all candidates]	0.0	4	1	1	1
74016	1710	interferon factor family transcription factor	[interferon factor family transcription factor]	0.0	5	1	1	1
74017	1710	characterization of protein in platelet	[Characterization of proteins in platelets]	0.0	5	1	1	1
74018	1710	-binding protein, p37	[-binding protein, p37]	0.0	3	1	1	1
74019	1710	strand conformation polymorphism (sscp) analysis	[strand conformation polymorphism (SSCP) analysis]	0.0	5	1	1	1
74020	1710	contain the transcription factor nf-y	[containing the transcription factor NF-Y]	0.0	5	1	1	1
74021	1710	caprine arthritis-encephalitis virus CAEV	[caprine arthritis-encephalitis virus CAEV]	0.0	4	1	1	1
74022	1710	week,	[week,]	0.0	1	1	1	1
74023	1710	NK function under condition	[NK functions under conditions]	0.0	4	1	1	1
74024	1710	regression analysis	[Regression analysis]	0.0	2	1	1	1
74025	1710	stable expression of HB24	[stable expression of HB24]	0.0	4	1	1	1
74026	1710	nuclearity, cover the surface	[nuclearity, covering the surface]	0.0	4	1	1	1
74027	1710	base pair bp	[base pairs bp]	0.0	3	1	1	1
74028	1710	accounting for 1% to 8%	[accounting for 1% to 8%]	0.0	5	1	1	1
74029	1710	2) biochemical sign	[2) biochemical signs]	0.0	3	1	1	1
74030	1710	specific uptake by PBMC	[specific uptake by PBMC]	0.0	4	1	1	1
74031	1710	intron of bcl-6	[intron of BCL-6]	0.0	3	1	1	1
74032	1710	complex with two different class	[complexes with two different classes]	0.0	5	1	1	1
74033	1710	encode receptor for D3	[encoding receptors for D3]	0.0	4	1	1	1
74034	1710	triple autoregulatory loop	[triple autoregulatory loop]	0.0	3	1	1	1
74035	1710	mechanism for the disruption	[mechanism for the disruption]	0.0	4	1	1	1
74036	1710	retinoid X receptor	[Retinoid X receptor]	0.0	3	1	1	1
74037	1710	change in pkc isoform	[Changes in PKC isoforms]	0.0	4	1	1	1
74038	1710	v3 loop monoclonal antibody	[V3 loop monoclonal antibody]	0.0	4	1	1	1
74039	1710	contrast, amount of the protein	[contrast, amounts of the protein]	0.0	5	1	1	1
74040	1710	npc cell line	[NPC cell lines]	0.0	3	1	1	1
74041	1710	alpha-helical domain	[alpha-helical domains]	0.0	2	1	1	1
74042	1710	subendothelium	[subendothelium]	0.0	1	1	1	1
74043	1710	lesion disrupt domain	[lesions disrupting domain]	0.0	3	1	1	1
74044	1710	human ah receptor mrna	[human Ah receptor mRNA]	0.0	4	1	1	1
74045	1710	rel macrophage	[Rel macrophages]	0.0	2	1	1	1
74046	1710	advancement	[advancement]	0.0	1	1	1	1
74047	1710	rna coding	[RNA coding]	0.0	2	1	1	1
74048	1710	use less stringent systems,	[using less stringent systems,]	0.0	4	1	1	1
74049	1710	nuclear localization of NFAT4	[nuclear localization of NFAT4]	0.0	4	1	1	1
74050	1710	cell gene expression	[cell gene expression]	0.0	3	1	1	1
74051	1710	pathway in monocyte	[pathways in monocytes]	0.0	3	1	1	1
74052	1710	dominant mutant form of component	[dominant mutant forms of components]	0.0	5	1	1	1
74053	1710	vary concentration microM)	[varying concentrations microM)]	0.0	3	1	1	1
74054	1710	v-Fos	[v-Fos]	0.0	1	1	1	1
74055	1710	rapid assessment	[rapid assessment]	0.0	2	1	1	1
74056	1710	irf-1 level	[IRF-1 levels]	0.0	2	1	1	1
74057	1710	DRA promoter (wild-type	[DRA promoter (wild-type]	0.0	3	1	1	1
74058	1710	precise mode	[precise mode]	0.0	2	1	1	1
74059	1710	chain gene enhancer by ETS-domain proteins.	[chain gene enhancer by ETS-domain proteins.]	0.0	6	1	1	1
74060	1710	premenopausal patient with cancer	[premenopausal patients with cancers]	0.0	4	1	1	1
74061	1710	c-fo control through b	[c-fos control through B]	0.0	4	1	1	1
74062	1710	sigm -crosslinking	[sIgM -crosslinking]	0.0	2	1	1	1
74063	1710	DNA sequence immediately adjacent	[DNA sequences immediately adjacent]	0.0	4	1	1	1
74064	1710	molt4 T cell	[MOLT4 T cell]	0.0	3	1	1	1
74065	1710	new controversies,	[new controversies,]	0.0	2	1	1	1
74066	1710	MTIIa	[MTIIa]	0.0	1	1	1	1
74067	1710	protein-binding site within the element	[protein-binding sites within the element]	0.0	5	1	1	1
74068	1710	vitro reconstitution	[vitro reconstitution]	0.0	2	1	1	1
74069	1710	utility of this fish technique	[utility of this FISH technique]	0.0	5	1	1	1
74070	1710	case of female twin	[case of female twins]	0.0	4	1	1	1
74071	1710	P0 element	[P0 elements]	0.0	2	1	1	1
74072	1710	regulation of gene expression in differentiation	[regulation of gene expression in differentiation]	0.0	6	1	1	1
74073	1710	negative activity of the region	[negative activity of the region]	0.0	5	1	1	1
74074	1710	binding of nf-kappa b	[binding of NF-kappa B]	0.0	4	1	1	1
74075	1710	deltanfkappabdeltasp1	[deltaNFkappaBdeltaSp1]	0.0	1	1	1	1
74076	1710	1 alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3	[1 alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3]	0.0	4	1	1	1
74077	1710	role in defense mechanism	[role in defense mechanisms]	0.0	4	1	1	1
74078	1710	positive, 1	[positive, 1]	0.0	2	1	1	1
74079	1710	ca2+ follow thapsigargin treatment	[Ca2+ following thapsigargin treatment]	0.0	4	1	1	1
74080	1710	gene important to biology,	[genes important to biology,]	0.0	4	1	1	1
74081	1710	disorder at this level.	[disorder at this level.]	0.0	4	1	1	1
74082	1710	enhancer in the b7.1 gene	[enhancer in the B7.1 gene]	0.0	5	1	1	1
74083	1710	molecular heterogeneity within muscle	[molecular heterogeneity within muscle]	0.0	4	1	1	1
74084	1710	cleavage by caspase during apoptosis	[Cleavage by caspases during apoptosis]	0.0	5	1	1	1
74085	1710	interleukin-1 alpha production	[interleukin-1 alpha production]	0.0	3	1	1	1
74086	1710	block a potential target	[blocking a potential target]	0.0	4	1	1	1
74087	1710	incidence of infection,	[incidence of infection,]	0.0	3	1	1	1
74088	1710	high-throughput assay	[high-throughput assay]	0.0	2	1	1	1
74089	1710	dysregulation immunodeficiency virus type	[dysregulation immunodeficiency virus type]	0.0	4	1	1	1
74090	1710	ligand am80	[ligand Am80]	0.0	2	1	1	1
74091	1710	[differential diagnostic value of receptor	[[Differential diagnostic value of receptors]	0.0	5	1	1	1
74092	1710	production of interleukin	[production of interleukin]	0.0	3	1	1	1
74093	1710	expression of the peak.	[expression of the peak.]	0.0	4	1	1	1
74094	1710	lineage-specific factor act on megakaryocytopoiesis	[lineage-specific factor acting on megakaryocytopoiesis]	0.0	5	1	1	1
74095	1710	PGE2 up-regulating effect	[PGE2 up-regulating effect]	0.0	3	1	1	1
74096	1710	few subject down-regulated Bmax after DEX	[fewer subjects down-regulated Bmax after DEX]	0.0	6	1	1	1
74097	1710	(range, (range, 4-.11),	[(range, (range, 4-5.13),]	0.0	3	1	1	1
74098	1710	water-soluble emulsion	[water-soluble emulsion]	0.0	2	1	1	1
74099	1710	tyrosine-phosphorylated peptide	[tyrosine-phosphorylated peptides]	0.0	2	1	1	1
74100	1710	EBV gene	[EBV genes]	0.0	2	1	1	1
74101	1710	overexpression of dr-nm23	[Overexpression of DR-nm23]	0.0	3	1	1	1
74102	1710	gene encode adhesion molecule	[genes encoding adhesion molecules]	0.0	4	1	1	1
74103	1710	fragment acid in 12	[fragment acids in 12]	0.0	4	1	1	1
74104	1710	Sp1 binding site bp	[Sp1 binding site bp]	0.0	4	1	1	1
74105	1710	40 promoter region in the u-937	[40 promoter regions in the U-937]	0.0	6	1	1	1
74106	1710	il-2 inhibition	[IL-2 inhibition]	0.0	2	1	1	1
74107	1710	degree to heat shock	[degree to heat shock]	0.0	4	1	1	1
74108	1710	-300bp of the promoter	[-300bp of the promoter]	0.0	4	1	1	1
74109	1710	association of a transcription factor	[association of a transcription factor]	0.0	5	1	1	1
74110	1710	(gm-csf)-	[(GM-CSF)-]	0.0	1	1	1	1
74111	1710	number of immature cell	[numbers of immature cells]	0.0	4	1	1	1
74112	1710	normal binding activity	[normal binding activities]	0.0	3	1	1	1
74113	1710	Epstein-Barr region (EBER) RNA-positive	[Epstein-Barr region (EBER) RNA-positive]	0.0	4	1	1	1
74114	1710	pregnant woman 10 second	[pregnant women 10 second]	0.0	4	1	1	1
74115	1710	important morphogen in vertebrate development,	[important morphogen in vertebrate development,]	0.0	5	1	1	1
74116	1710	copy of nf-kappa b site	[copies of NF-kappa B site]	0.0	5	1	1	1
74117	1710	monocyte with phorbol-13-acetate	[monocytes with phorbol-13-acetate]	0.0	3	1	1	1
74118	1710	lung inflammatory injury	[lung inflammatory injury]	0.0	3	1	1	1
74119	1710	145 prostate cancer	[145 prostate cancers]	0.0	3	1	1	1
74120	1710	b-lymphocyte by Epstein-Barr virus EBV	[B-lymphocytes by Epstein-Barr virus EBV]	0.0	5	1	1	1
74121	1710	histocompatibility complex (mhc) class ii gene	[histocompatibility complex (MHC) class II genes]	0.0	6	1	1	1
74122	1710	general consequence	[general consequence]	0.0	2	1	1	1
74123	1710	increase peak between 1-2 h.	[increase peaking between 1-2 h,]	0.0	5	1	1	1
74124	1710	/reporter	[/reporter]	0.0	1	1	1	1
74125	1710	Rel family	[Rel family]	0.0	2	1	1	1
74126	1710	specify affinity	[specifying affinity]	0.0	2	1	1	1
74127	1710	fluorescence in-situ hybridization technique	[fluorescence in-situ hybridization technique]	0.0	4	1	1	1
74128	1710	follow hiv infection	[following HIV infection]	0.0	3	2	2	1
74129	1710	tgf expression	[TGF expression]	0.0	2	1	1	1
74130	1710	removal of the sequence	[Removal of the sequences]	0.0	4	1	1	1
74131	1710	promoter retain this region.	[promoter retaining this region.]	0.0	4	1	1	1
74132	1710	first regulatory protein	[first regulatory protein]	0.0	3	1	1	1
74133	1710	transfection together	[Transfection together]	0.0	2	1	1	1
74134	1710	initial promoter	[initial promoter]	0.0	2	1	1	1
74135	1710	g1 cell	[G1 cell]	0.0	2	1	1	1
74136	1710	mononuclear cell activation	[mononuclear cell activation]	0.0	3	1	1	1
74137	1710	gsh -to-oxidized glutathione ratio	[GSH -to-oxidized glutathione ratio]	0.0	4	1	1	1
74138	1710	negative feedback of the axis	[negative feedback of the axis]	0.0	5	1	1	1
74139	1710	different ad group group A	[different Ad groups group A]	0.0	5	1	1	1
74140	1710	different ad group group C	[different Ad groups group C]	0.0	5	1	1	1
74141	1710	conjunctival biopsy from seven patient	[conjunctival biopsies from seven patients]	0.0	5	1	1	1
74142	1710	gr number with normal affinity	[GR number with normal affinity]	0.0	5	1	1	1
74143	1710	cell antibody from a patient	[cell antibodies from a patient]	0.0	5	1	1	1
74144	1710	critical determinant of the expression	[critical determinant of the expression]	0.0	5	1	1	1
74145	1710	T cell-specific gene	[T cell-specific genes]	0.0	3	1	1	1
74146	1710	blood t-cell	[blood T-cells]	0.0	2	1	1	1
74147	1710	differentiation of monoblastic leukemia u937 cell	[differentiation of monoblastic leukemia U937 cells]	0.0	6	1	1	1
74148	1710	underlie cell activation	[underlying cell activation]	0.0	3	1	1	1
74149	1710	acute patient cases)	[acute patients cases)]	0.0	3	1	1	1
74150	1710	patient with hypertension.	[patients with hypertension.]	0.0	3	1	1	1
74151	1710	T cell express MHC class ii	[T cells expressing MHC class II]	0.0	6	1	1	1
74152	1710	scavenging in unstimulated tnf- cell	[scavenging in unstimulated TNF- cells]	0.0	5	1	1	1
74153	1710	export receptor crm1	[export receptor CRM1]	0.0	3	1	1	1
74154	1710	structurally related divalent cation	[Structurally related divalent cations]	0.0	4	1	1	1
74155	1710	however, cell line with high potential	[However, cell lines with high potential]	0.0	6	1	1	1
74156	1710	RESULTS: maeca	[RESULTS: mAECA]	0.0	2	1	1	1
74157	1710	region in the cytoplasmic domain	[regions in the cytoplasmic domain]	0.0	5	1	1	1
74158	1710	pha normal human peripheral blood lymphocyte	[PHA normal human peripheral blood lymphocytes]	0.0	6	1	1	1
74159	1710	polymorphonuclear neutrophil migration during inflammation	[polymorphonuclear neutrophil migration during inflammation]	0.0	5	1	1	1
74160	1710	regulate the self-renewal capacity	[regulating the self-renewal capacity]	0.0	4	1	1	1
74161	1710	factor kappab kinase	[factor kappaB kinase]	0.0	3	1	1	1
74162	1710	level of p52	[levels of p52]	0.0	3	1	1	1
74163	1710	first DNA response element	[first DNA response element]	0.0	4	1	1	1
74164	1710	large substitution	[Large substitutions]	0.0	2	1	1	1
74165	1710	control expression of PECAM-1	[controlling expression of PECAM-1]	0.0	4	1	1	1
74166	1710	t-cell leukemia virus type trans-activator	[T-cell leukemia virus type trans-activator]	0.0	5	1	1	1
74167	1710	stringent regulation	[stringent regulation]	0.0	2	1	1	1
74168	1710	dysregulation human immunodeficiency virus type 1	[dysregulation human immunodeficiency virus type 1]	0.0	6	1	1	1
74169	1710	power of receptor gr	[power of receptor GR]	0.0	4	1	1	1
74170	1710	number of latent protein	[number of latent proteins]	0.0	4	1	1	1
74171	1710	126 amino acid	[126 amino acids]	0.0	3	1	1	1
74172	1710	platelet gpiib	[platelet GPIIb]	0.0	2	1	1	1
74173	1710	certain subpopulation	[Certain subpopulations]	0.0	2	1	1	1
74174	1710	tcp h),	[TCP h),]	0.0	2	1	1	1
74175	1710	critical effector	[critical effector]	0.0	2	1	1	1
74176	1710	regulator of the microenvironmental homing	[regulator of the microenvironmental homing]	0.0	5	1	1	1
74177	1710	level of active nf-kappa b complex	[levels of active NF-kappa B complex]	0.0	6	1	1	1
74178	1710	gear	[gears]	0.0	1	1	1	1
74179	1710	c5b-9 immunoprecipitate	[C5b-9 immunoprecipitates]	0.0	2	1	1	1
74180	1710	dimeric complex activator protein-1	[dimeric complex activator protein-1]	0.0	4	1	1	1
74181	1710	[3H]dexamethasone (p	[[3H]dexamethasone (P]	0.0	2	1	1	1
74182	1710	comparison of granulocyte DNA	[comparisons of granulocyte DNA]	0.0	4	1	1	1
74183	1710	apoptotic cascade lead	[apoptotic cascade leading]	0.0	3	1	1	1
74184	1710	regulate the maintenance	[regulating the maintenance]	0.0	3	1	1	1
74185	1710	binding of the two sh2 domain	[binding of the two SH2 domains]	0.0	6	1	1	1
74186	1710	eosinophil granule major protein mbp	[eosinophil granule major protein MBP]	0.0	5	2	2	1
74187	1710	murine cell raw264.7	[murine cells RAW264.7]	0.0	3	1	1	1
74188	1710	signal often converge	[signals often converging]	0.0	3	1	1	1
74189	1710	T cell-specific enhancer of murine	[T cell-specific enhancers of murine]	0.0	5	1	1	1
74190	1710	anti-runt box antiserum	[anti-runt box antiserum]	0.0	3	1	1	1
74191	1710	c-Jun kinase activation	[c-Jun kinase activation]	0.0	3	1	1	1
74192	1710	-body	[-body]	0.0	1	1	1	1
74193	1710	HsN3 proteasome subunit	[HsN3 proteasome subunit]	0.0	3	1	1	1
74194	1710	span kb	[spanning kb]	0.0	2	1	1	1
74195	1710	mutant with point mutation	[mutants with point mutations]	0.0	4	1	1	1
74196	1710	indicate critical for NFAT formation	[indicating critical for NFAT formation]	0.0	5	1	1	1
74197	1710	encode the related hepatocyte factor HNF-1alpha	[encoding the related hepatocyte factors HNF-1alpha]	0.0	6	1	1	1
74198	1710	/sv40	[/SV40]	0.0	1	1	1	1
74199	1710	pattern of expression,	[pattern of expression,]	0.0	3	1	1	1
74200	1710	production of interleukin colony-stimulating factor	[production of interleukin colony-stimulating factor]	0.0	5	1	1	1
74201	1710	glucocorticoid responsiveness of mononuclear leukocyte HML	[glucocorticoid responsiveness of mononuclear leukocytes HML]	0.0	6	1	1	1
74202	1710	relatively few gene	[relatively few genes]	0.0	3	1	1	1
74203	1710	interaction of retinoid	[interactions of retinoids]	0.0	3	1	1	1
74204	1710	3 IL3 gene expression	[3 IL3 gene expression]	0.0	4	1	1	1
74205	1710	increase from the intracellular	[increase from the intracellular]	0.0	4	1	1	1
74206	1710	role in t-cell-specific regulation	[role in T-cell-specific regulation]	0.0	4	1	1	1
74207	1710	phorbol myristate 13-acetate treatment	[phorbol myristate 13-acetate treatment]	0.0	4	1	1	1
74208	1710	two transduction pathway	[two transduction pathways]	0.0	3	1	1	1
74209	1710	JNK the map kinase	[JNK the MAP kinase]	0.0	4	1	1	1
74210	1710	transcriptase-polymerase chain reaction rt-pcr	[transcriptase-polymerase chain reaction RT-PCR]	0.0	4	1	1	1
74211	1710	effect on growth inhibition	[effect on growth inhibition]	0.0	4	1	1	1
74212	1710	little direct evidence regard the role	[little direct evidence regarding the role]	0.0	6	1	1	1
74213	1710	twelve normal cord blood	[twelve normal cord blood]	0.0	4	1	1	1
74214	1710	chemotherapy in a patient	[chemotherapy in a patient]	0.0	4	1	1	1
74215	1710	activity of tepoxalin	[activity of tepoxalin]	0.0	3	1	1	1
74216	1710	pluripotent progenitor to dendritic cell	[pluripotent progenitors to dendritic cells]	0.0	5	1	1	1
74217	1710	primary malignant melanoma	[primary malignant melanomas]	0.0	3	1	1	1
74218	1710	cold syndrome	[cold syndromes]	0.0	2	1	1	1
74219	1710	IL-2/ IFN alpha therapy	[IL-2/ IFN alpha therapy]	0.0	4	1	1	1
74220	1710	close, correlation	[close, correlation]	0.0	2	1	1	1
74221	1710	form include pre-B leukemia	[forms including pre-B leukemia]	0.0	4	1	1	1
74222	1710	effect on the dna-binding capacity	[effect on the DNA-binding capacity]	0.0	5	1	1	1
74223	1710	treatment of human t- lymphocyte	[treatment of human T- lymphocytes]	0.0	5	1	1	1
74224	1710	other characteristic	[other characteristics]	0.0	2	1	1	1
74225	1710	high level, expression	[high level, expression]	0.0	3	1	1	1
74226	1710	alphaIIb subunit	[alphaIIb subunit]	0.0	2	2	2	1
74227	1710	reduction of to 65%	[reduction of to 65%]	0.0	4	1	1	1
74228	1710	immunological consequence of gsh depletion	[immunological consequences of GSH depletion]	0.0	5	1	1	1
74229	1710	TF cognate cofactor	[TF cognate cofactor]	0.0	3	1	1	1
74230	1710	il-3 withdrawal	[IL-3 withdrawal]	0.0	2	1	1	1
74231	1710	include one strain	[including one strain]	0.0	3	1	1	1
74232	1710	monocytic cell to lipopolysaccharide lps	[monocytic cells to lipopolysaccharide LPS]	0.0	5	1	1	1
74233	1710	il-6 signal	[IL-6 signals]	0.0	2	1	1	1
74234	1710	interleukin receptor gamma chain	[interleukin receptor gamma chain]	0.0	4	1	1	1
74235	1710	protein crucial	[proteins crucial]	0.0	2	1	1	1
74236	1710	sterol dependent ldl-receptor gene transcription	[Sterol dependent LDL-receptor gene transcription]	0.0	5	1	1	1
74237	1710	mobilization of the factor	[mobilization of the factor]	0.0	4	1	1	1
74238	1710	lt tnf-beta	[LT TNF-beta]	0.0	2	1	1	1
74239	1710	ankyrin repeat region	[ankyrin repeat region]	0.0	3	1	1	1
74240	1710	microg/ml)/mn2+ microM) for 2 h	[microg/ml)/Mn2+ microM) for 2 h]	0.0	5	1	1	1
74241	1710	element NREs	[elements NREs]	0.0	2	1	1	1
74242	1710	factor in this region.	[factors in this region.]	0.0	4	1	1	1
74243	1710	expression in nonlymphoid cell	[Expression in nonlymphoid cells]	0.0	4	1	1	1
74244	1710	particularly the variant	[particularly the variant]	0.0	3	1	1	1
74245	1710	immunodeficiency syndrome therapy	[immunodeficiency syndrome therapy]	0.0	3	1	1	1
74246	1710	clone of CVZ -resistant cell	[clones of CVZ -resistant cells]	0.0	5	1	1	1
74247	1710	ifn-inducible gene product	[IFN-inducible gene products]	0.0	3	1	1	1
74248	1710	Molecular, evidence	[Molecular, evidence]	0.0	2	1	1	1
74249	1710	activation from patient receive il-2 immunotherapy	[activation from patients receiving IL-2 immunotherapy]	0.0	6	1	1	1
74250	1710	staining in 14.6 +/- 3.7%	[staining in 14.6 +/- 3.7%]	0.0	5	1	1	1
74251	1710	hyperdemarcation	[hyperdemarcation]	0.0	1	1	1	1
74252	1710	least creb- factor	[least CREB- factors]	0.0	3	1	1	1
74253	1710	respectively oppose	[respectively opposing]	0.0	2	1	1	1
74254	1710	interferon (ifn)-gamma production	[interferon (IFN)-gamma production]	0.0	3	1	1	1
74255	1710	granulopoiesis typically die days.	[granulopoiesis typically dying days.]	0.0	4	1	1	1
74256	1710	independent interaction	[independent interaction]	0.0	2	1	1	1
74257	1710	activity il-1	[activity IL-1]	0.0	2	1	1	1
74258	1710	TNFRI death domain	[TNFRI death domain]	0.0	3	1	1	1
74259	1710	T lymphocyte jurkat cell	[T lymphocyte Jurkat cells]	0.0	4	2	2	1
74260	1710	type of neoplasm	[types of neoplasms]	0.0	3	1	1	1
74261	1710	presence a transactivator	[presence a transactivator]	0.0	3	1	1	1
74262	1710	potent effect on T cell	[potent effects on T cells]	0.0	5	1	1	1
74263	1710	one such cofactor	[One such cofactor]	0.0	3	1	1	1
74264	1710	differentiation upon vd treatment	[differentiation upon VD treatment]	0.0	4	1	1	1
74265	1710	cortisol clearance	[cortisol clearance]	0.0	2	1	1	1
74266	1710	sib-pair analysis	[sib-pair analysis]	0.0	2	1	1	1
74267	1710	express major (mhc) class gene	[expressing major (MHC) class genes]	0.0	5	1	1	1
74268	1710	Ab cross-linking	[Ab cross-linking]	0.0	2	1	1	1
74269	1710	NK clearance	[NK clearance]	0.0	2	1	1	1
74270	1710	several weight adaptor protein	[several weight adaptor proteins]	0.0	4	1	1	1
74271	1710	different LTR vector	[different LTR vectors]	0.0	3	1	1	1
74272	1710	level in mature monocyte	[levels in mature monocytes]	0.0	4	1	1	1
74273	1710	danazol therapy	[danazol therapy]	0.0	2	1	1	1
74274	1710	several hbd subfragment	[several HBD subfragments]	0.0	3	1	1	1
74275	1710	only in b cell development	[only in B cell development]	0.0	5	1	1	1
74276	1710	member transcription factor family	[members transcription factor family]	0.0	4	1	1	1
74277	1710	turnover the I	[turnover the I]	0.0	3	1	1	1
74278	1710	target for the RAR alpha	[target for the RAR alpha]	0.0	5	1	1	1
74279	1710	more favorable activity profile	[more favorable activity profile]	0.0	4	1	1	1
74280	1710	borders.	[borders.]	0.0	1	1	1	1
74281	1710	concentration at the bacterial surface	[concentration at the bacterial surface]	0.0	5	1	1	1
74282	1710	interaction with the upstream element	[interaction with the upstream element]	0.0	5	1	1	1
74283	1710	bronchial (h292) cell-line dexamethasone basal	[bronchial (H292) cell-line dexamethasone basal]	0.0	5	1	1	1
74284	1710	cd37 b	[CD37 B]	0.0	2	1	1	1
74285	1710	domain with putative transmembrane segment	[domain with putative transmembrane segments]	0.0	5	1	1	1
74286	1710	cell line U1	[cell line U1]	0.0	3	1	1	1
74287	1710	suppress activation	[suppressing activation]	0.0	2	1	1	1
74288	1710	neutrophil binding by lps	[neutrophil binding by LPS]	0.0	4	1	1	1
74289	1710	normal healthy subject	[normal healthy subjects]	0.0	3	1	1	1
74290	1710	resonance 3d-nmr spectroscopy	[resonance 3D-NMR spectroscopy]	0.0	3	1	1	1
74291	1710	fivefold formation of substance	[fivefold formation of substances]	0.0	4	1	1	1
74292	1710	sole cause of growth	[sole cause of growth]	0.0	4	1	1	1
74293	1710	binding site for factor-kappaB	[binding site for factor-kappaB]	0.0	4	1	1	1
74294	1710	number in leucocyte in man	[number in leucocytes in men]	0.0	5	1	1	1
74295	1710	"stress" buffer,	["stress" buffer,]	0.0	2	1	1	1
74296	1710	copy upstream of a promoter	[copies upstream of a promoter]	0.0	5	1	1	1
74297	1710	antisera specific	[antisera specific]	0.0	2	1	1	1
74298	1710	resistance aids -c	[resistance AIDS -C]	0.0	3	1	1	1
74299	1710	circumstances.	[circumstances.]	0.0	1	1	1	1
74300	1710	increase half-life from 24	[increasing half-life from 24]	0.0	4	1	1	1
74301	1710	monoclonal antibody t-cell proliferation	[monoclonal antibody T-cell proliferation]	0.0	4	1	1	1
74302	1710	iv collagen	[IV collagen]	0.0	2	1	1	1
74303	1710	protein-binding site within the negative element	[protein-binding sites within the negative element]	0.0	6	1	1	1
74304	1710	multiple substitution	[multiple substitutions]	0.0	2	1	1	1
74305	1710	stat1 immune-response	[Stat1 immune-response]	0.0	2	1	1	1
74306	1710	monocyte)	[monocyte)]	0.0	1	1	1	1
74307	1710	transcriptional activation motif	[transcriptional activation motifs]	0.0	3	1	1	1
74308	1710	glucocorticoid affinity	[glucocorticoid affinity]	0.0	2	1	1	1
74309	1710	(>10 microm	[(>10 microM]	0.0	2	1	1	1
74310	1710	positive functional role	[positive functional role]	0.0	3	1	1	1
74311	1710	drug cyclosporine CsA	[drug cyclosporine CsA]	0.0	3	1	1	1
74312	1710	GM-CSF peripheral blood polymorphonuclear leukocyte activation	[GM-CSF peripheral blood polymorphonuclear leukocytes activation]	0.0	6	1	1	1
74313	1710	monocyte,	[monocyte,]	0.0	1	1	1	1
74314	1710	similar infection	[similar infection]	0.0	2	1	1	1
74315	1710	tnf-alpha -dose dependency	[TNF-alpha -dose dependency]	0.0	3	1	1	1
74316	1710	unrecognized property of glucocorticoid	[unrecognized property of glucocorticoids]	0.0	4	1	1	1
74317	1710	regulation in human lymphoid cell line	[regulation in human lymphoid cell lines]	0.0	6	1	1	1
74318	1710	GR -responsive element	[GR -responsive element]	0.0	3	1	1	1
74319	1710	region contain four repeat	[region containing four repeats]	0.0	4	1	1	1
74320	1710	cytosolic activation	[cytosolic activation]	0.0	2	1	1	1
74321	1710	cellularity)	[cellularity)]	0.0	1	1	1	1
74322	1710	Recent analysis	[Recent analysis]	0.0	2	1	1	1
74323	1710	activation of the p50 /p50 homodimer	[activation of the p50 /p50 homodimer]	0.0	6	1	1	1
74324	1710	mediate inflammatory response	[mediating inflammatory responses]	0.0	3	1	1	1
74325	1710	Pyrrolidine dithiocarbamate	[Pyrrolidine dithiocarbamate]	0.0	2	1	1	1
74326	1710	mechanism of vcam-1 induction	[mechanisms of VCAM-1 induction]	0.0	4	1	1	1
74327	1710	gene expression in myeloid cell	[gene expression in myeloid cells]	0.0	5	1	1	1
74328	1710	differ only at residue	[differing only at residue]	0.0	4	1	1	1
74329	1710	defect in fetal/neonatal t-cell activation	[defects in fetal/neonatal T-cell activation]	0.0	5	1	1	1
74330	1710	mutant of human Toll	[mutant of human Toll]	0.0	4	1	1	1
74331	1710	subdominant latent cycle reactivity though undetectable	[subdominant latent cycle reactivities though undetectable]	0.0	6	1	1	1
74332	1710	contrast, proviruse	[contrast, proviruses]	0.0	2	1	1	1
74333	1710	possibility of analysis	[possibility of analysis]	0.0	3	1	1	1
74334	1710	dominant activity	[dominant activity]	0.0	2	1	1	1
74335	1710	import of a transcription factor	[import of a transcription factor]	0.0	5	1	1	1
74336	1710	corresponding I gamma	[corresponding I gamma]	0.0	3	1	1	1
74337	1710	"late" T lymphocyte transcription factor	["late" T lymphocyte transcription factor]	0.0	5	1	1	1
74338	1710	signalling molecules.	[signalling molecules.]	0.0	2	1	1	1
74339	1710	mrna in human cell	[mRNA in human cells]	0.0	4	1	1	1
74340	1710	nuclear retention of VDR	[nuclear retention of VDR]	0.0	4	1	1	1
74341	1710	B-cell antigen receptor signal	[B-cell antigen receptor signals]	0.0	4	1	1	1
74342	1710	thymidine kinase regulation	[thymidine kinase regulation]	0.0	3	1	1	1
74343	1710	concomitant effect of antioxidant	[concomitant effects of antioxidants]	0.0	4	1	1	1
74344	1710	result in the interference	[resulting in the interference]	0.0	4	1	1	1
74345	1710	first 67 amino acid	[first 67 amino acids]	0.0	4	1	1	1
74346	1710	human immunodeficiency virus type hiv-1 factor	[Human immunodeficiency virus type HIV-1 factor]	0.0	6	1	1	1
74347	1710	sequence of pp65	[sequence of pp65]	0.0	3	1	1	1
74348	1710	same individuals,	[same individuals,]	0.0	2	1	1	1
74349	1710	lack of correspondence with allelic variant	[lack of correspondence with allelic variants]	0.0	6	1	1	1
74350	1710	inhibition of reporter activation	[inhibition of reporter activation]	0.0	4	1	1	1
74351	1710	leukocyte bind	[leukocytes binding]	0.0	2	1	1	1
74352	1710	1,25-dihydroxyvitamin d	[1,25-dihydroxyvitamin D]	0.0	2	1	1	1
74353	1710	different pattern of cytokine	[different patterns of cytokine]	0.0	4	1	1	1
74354	1710	5-dihydroxyvitamin	[5-dihydroxyvitamin]	0.0	1	1	1	1
74355	1710	16-18 h. treatment	[16-18 h, treatment]	0.0	3	1	1	1
74356	1710	novel negative regulator	[novel negative regulator]	0.0	3	1	1	1
74357	1710	mutation of Jak3 in a patient	[Mutation of Jak3 in a patient]	0.0	6	1	1	1
74358	1710	incubation with pha	[incubation with PHA]	0.0	3	1	1	1
74359	1710	Tat transactivation	[Tat transactivation]	0.0	2	1	1	1
74360	1710	stimulus product such as lipopolysaccharide	[stimuli products such as lipopolysaccharide]	0.0	5	1	1	1
74361	1710	pcr approach	[PCR approach]	0.0	2	1	1	1
74362	1710	acute reaction	[acute reactions]	0.0	2	1	1	1
74363	1710	DNA element within the repeat	[DNA elements within the repeat]	0.0	5	1	1	1
74364	1710	transformation through cytoplasmic tail	[transformation through cytoplasmic tail]	0.0	4	1	1	1
74365	1710	t (15;17) translocation	[t (15;17) translocation]	0.0	3	1	1	1
74366	1710	gammadelta	[gammadelta]	0.0	1	1	1	1
74367	1710	anti- TNF-alpha hiv-1 terminal repeat	[anti- TNF-alpha HIV-1 terminal repeat]	0.0	5	1	1	1
74368	1710	growth with herpesvirus saimiry	[growth with Herpesvirus saimiri]	0.0	4	1	1	1
74369	1710	azelastine hydrochloride	[azelastine hydrochloride]	0.0	2	1	1	1
74370	1710	Gene transcription	[Gene transcription]	0.0	2	1	1	1
74371	1710	antioxidant concentration high	[antioxidant concentrations high]	0.0	3	1	1	1
74372	1710	immunodeficiency virus terminal	[immunodeficiency virus terminal]	0.0	3	1	1	1
74373	1710	apoptosis in monocyte potential role	[apoptosis in monocytes potential role]	0.0	5	1	1	1
74374	1710	potential in a 68.5-kb segment	[potential in a 68.5-kb segment]	0.0	5	1	1	1
74375	1710	synthesis from cancer patient	[synthesis from cancer patients]	0.0	4	1	1	1
74376	1710	difference in the domain	[differences in the domain]	0.0	4	1	1	1
74377	1710	5' sequence kb)	[5' sequence kb)]	0.0	3	1	1	1
74378	1710	three different pathway	[three different pathways]	0.0	3	1	1	1
74379	1710	Differential induction protein follow differentiation	[Differential induction protein following differentiation]	0.0	5	1	1	1
74380	1710	endogenous virus, implicate sequence	[endogenous virus, implicating sequences]	0.0	4	1	1	1
74381	1710	activation of genes.	[activation of genes.]	0.0	3	1	1	1
74382	1710	i antibody	[I antibody]	0.0	2	1	1	1
74383	1710	cellular tumor necrosis factor	[cellular tumor necrosis factor]	0.0	4	1	1	1
74384	1710	cd86 two principal ligand	[CD86 two principal ligands]	0.0	4	1	1	1
74385	1710	various other condition	[various other conditions]	0.0	3	1	1	1
74386	1710	prolonged exposure of endothelial cell	[prolonged exposure of endothelial cells]	0.0	5	1	1	1
74387	1710	Indeed, gene expression	[Indeed, gene expression]	0.0	3	1	1	1
74388	1710	directly use TAP-deficient cell line	[directly using TAP-deficient cell lines]	0.0	5	1	1	1
74389	1710	nfil3/e4bp4 factor	[NFIL3/E4BP4 factor]	0.0	2	1	1	1
74390	1710	rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	4	1	1	1
74391	1710	inflammatory pathway	[inflammatory pathways]	0.0	2	1	1	1
74392	1710	abnormality in the etiology	[abnormalities in the etiology]	0.0	4	1	1	1
74393	1710	role in monocyte differentiation	[role in monocyte differentiation]	0.0	4	1	1	1
74394	1710	outcome of syndrome include disease	[outcome of syndromes including diseases]	0.0	5	1	1	1
74395	1710	contain tandem repeat	[containing tandem repeats]	0.0	3	1	1	1
74396	1710	antiinflammatory potential	[antiinflammatory potential]	0.0	2	1	1	1
74397	1710	transcription of cytokine	[transcription of cytokines]	0.0	3	1	1	1
74398	1710	cytokine production from T cell	[cytokine production from T cells]	0.0	5	1	1	1
74399	1710	beta 1 in T cell	[beta 1 in T cells]	0.0	5	1	1	1
74400	1710	interrupt the lps signal	[interrupting the LPS signal]	0.0	4	1	1	1
74401	1710	regulation of the composite octamer motif	[regulation of the composite octamer motif]	0.0	6	1	1	1
74402	1710	lymphocyte suppression	[lymphocyte suppression]	0.0	2	1	1	1
74403	1710	however a cofactor for nf-kappab activation	[However a cofactor for NF-kappaB activation]	0.0	6	1	1	1
74404	1710	p than 0.001)	[P than 0.001)]	0.0	3	1	1	1
74405	1710	safety phenotype of genome	[safety phenotype of genome]	0.0	4	1	1	1
74406	1710	demonstrate the importance of species	[demonstrating the importance of species]	0.0	5	1	1	1
74407	1710	labelling breaks.	[labelling breaks.]	0.0	2	1	1	1
74408	1710	Partial sequence from exon	[Partial sequences from exons]	0.0	4	1	1	1
74409	1710	line of CEM cell	[lines of CEM cells]	0.0	4	1	1	1
74410	1710	component of the floram	[component of the flora,]	0.0	4	1	1	1
74411	1710	end of ebv DNA	[ends of EBV DNA]	0.0	4	2	2	1
74412	1710	body in cell line	[bodies in cell lines]	0.0	4	1	1	1
74413	1710	corticosteroid resistance in asthma	[corticosteroid resistance in asthma]	0.0	4	2	2	1
74414	1710	nf-kappa b the activity	[NF-kappa B the activity]	0.0	4	1	1	1
74415	1710	33 pbmc specimen from adult	[33 PBMC specimens from adults]	0.0	5	2	2	1
74416	1710	natural hormone	[natural hormone]	0.0	2	1	1	1
74417	1710	type iia hyperlipidemia	[type IIa hyperlipidemia]	0.0	3	2	2	1
74418	1710	induction (ifn)-inducible protein 10 follow differentiation	[induction (IFN)-inducible protein 10 following differentiation]	0.0	6	1	1	1
74419	1710	42 gene HZF	[42 genes HZF]	0.0	3	1	1	1
74420	1710	supershift analysis use antibody	[supershift analysis using antibodies]	0.0	4	1	1	1
74421	1710	repressor region	[repressor region]	0.0	2	1	1	1
74422	1710	include expression of the genome	[including expression of the genome]	0.0	5	1	1	1
74423	1710	DNA sequence through homo-	[DNA sequences through homo-]	0.0	4	1	1	1
74424	1710	mast cell activation	[mast cell activation]	0.0	3	1	1	1
74425	1710	25- increase	[25- increase]	0.0	2	1	1	1
74426	1710	early gene of human cytomegalovirus	[early genes of human cytomegalovirus]	0.0	5	1	1	1
74427	1710	micromolar amount of pyrrolidine dithiocarbamate	[micromolar amounts of pyrrolidine dithiocarbamate]	0.0	5	1	1	1
74428	1710	embryonic muscle	[embryonic muscle]	0.0	2	1	1	1
74429	1710	competition between activator	[competition between activators]	0.0	3	1	1	1
74430	1710	high level expression	[high level expression]	0.0	3	1	1	1
74431	1710	use a whole-cell assay with [3H]dexamethasone	[using a whole-cell assay with [3H]dexamethasone]	0.0	6	1	1	1
74432	1710	acid receptor alpha locus	[acid receptor alpha locus]	0.0	4	1	1	1
74433	1710	intracellular protein eventually lead	[intracellular proteins eventually leading]	0.0	4	1	1	1
74434	1710	major histocompatibility molecule	[major histocompatibility molecules]	0.0	3	1	1	1
74435	1710	suggest a possible role for G(Anh)MTetra	[suggesting a possible role for G(Anh)MTetra]	0.0	6	1	1	1
74436	1710	long lymphoblastoid cell proliferation	[long-term lymphoblastoid cell proliferation]	0.0	4	1	1	1
74437	1710	percutaneous transluminal coronary angioplasty PTCA	[percutaneous transluminal coronary angioplasty PTCA]	0.0	5	1	1	1
74438	1710	CsA treatment Jurkat T cell line	[CsA treatment Jurkat T cell lines]	0.0	6	1	1	1
74439	1710	stimulation of chloramphenicol acetyltransferase activity	[stimulation of chloramphenicol acetyltransferase activity]	0.0	5	1	1	1
74440	1710	alteration of gene transcription	[Alteration of gene transcription]	0.0	4	1	1	1
74441	1710	human t-cell receptor	[human T-cell receptor]	0.0	3	1	1	1
74442	1710	combination lymphocyte binding,	[Combinations lymphocyte binding,]	0.0	3	1	1	1
74443	1710	gr protein	[GR protein]	0.0	2	1	1	1
74444	1710	mSin3 family	[mSin3 family]	0.0	2	1	1	1
74445	1710	immunohistochemical evidence of activity	[Immunohistochemical evidence of activity]	0.0	4	1	1	1
74446	1710	critical cytoplasmic domain	[Critical cytoplasmic domains]	0.0	3	1	1	1
74447	1710	unaffected family member	[unaffected family members]	0.0	3	1	1	1
74448	1710	Akv MLV activity	[Akv MLV activity]	0.0	3	1	1	1
74449	1710	t-lymphocyte via CD2	[T-lymphocytes via CD2]	0.0	3	1	1	1
74450	1710	cell for lysis	[cells for lysis]	0.0	3	1	1	1
74451	1710	determinant of cell proliferation	[determinant of cell proliferation]	0.0	4	1	1	1
74452	1710	endothelial production	[Endothelial production]	0.0	2	1	1	1
74453	1710	ion of masses;	[ions of masses;]	0.0	3	1	1	1
74454	1710	VDR coding region	[VDR coding region]	0.0	3	1	1	1
74455	1710	human coronary plaque	[human coronary plaques]	0.0	3	1	1	1
74456	1710	role of nuclear factor-DNA complex	[role of nuclear factor-DNA complexes]	0.0	5	1	1	1
74457	1710	inhibition instead of pp2a	[inhibition instead of PP2A]	0.0	4	1	1	1
74458	1710	binding of the sh2 domain	[binding of the SH2 domains]	0.0	5	1	1	1
74459	1710	aberrant activation	[aberrant activation]	0.0	2	1	1	1
74460	1710	year: 4.1	[year: 4.1]	0.0	2	1	1	1
74461	1710	terminal repeat type	[terminal repeat type]	0.0	3	1	1	1
74462	1710	depletion of Sp1 A1 from extract	[depletion of Sp1 A1 from extracts]	0.0	6	1	1	1
74463	1710	nf-kappab in Jurkat cell	[NF-kappaB in Jurkat cells]	0.0	4	1	1	1
74464	1710	transcription factor participate	[transcription factor participating]	0.0	3	1	1	1
74465	1710	metabolism in the asthmatics	[metabolism in the asthmatics]	0.0	4	1	1	1
74466	1710	involvement of follicular cell	[involvement of follicular cells]	0.0	4	1	1	1
74467	1710	free cortisol the number of receptor	[free cortisol the number of receptors]	0.0	6	1	1	1
74468	1710	quantification by competitive polymerase chain reaction	[Quantification by competitive polymerase chain reaction]	0.0	6	1	1	1
74469	1710	hiv transmission	[HIV transmission]	0.0	2	2	2	1
74470	1710	endothelium,	[endothelium,]	0.0	1	1	1	1
74471	1710	result in expression of downstream gene	[resulting in expression of downstream genes]	0.0	6	1	1	1
74472	1710	complex class ii transactivator	[complex class II transactivator]	0.0	4	1	1	1
74473	1710	transcriptional induction of several cytokine	[transcriptional induction of several cytokine]	0.0	5	1	1	1
74474	1710	surface antigen CD8	[surface antigen CD8]	0.0	3	1	1	1
74475	1710	endogenous IFN activity equivalent	[endogenous IFN activity equivalent]	0.0	4	1	1	1
74476	1710	axillary lymph node	[axillary lymph node]	0.0	3	1	1	1
74477	1710	G0 phase	[G0 phases]	0.0	2	1	1	1
74478	1710	possibility of a E1a- vector	[possibility of an E1a- vector]	0.0	5	1	1	1
74479	1710	RANTES factor of T Lymphocytes-1	[RANTES Factor of T Lymphocytes-1]	0.0	5	1	1	1
74480	1710	neutrophil by lps	[neutrophils by LPS]	0.0	3	1	1	1
74481	1710	immunoglobulin chain (igh) gene expression	[immunoglobulin chain (IgH) gene expression]	0.0	5	1	1	1
74482	1710	such as protein kinase-1	[such as protein kinase-1]	0.0	4	1	1	1
74483	1710	stoichiometry interact transcription factor	[stoichiometry interacting transcription factors]	0.0	4	1	1	1
74484	1710	2 microm mbp	[2 microM MBP]	0.0	3	1	1	1
74485	1710	vascular mechanism of a component	[vascular mechanism of a component]	0.0	5	1	1	1
74486	1710	inhibitor of activation	[inhibitors of activation]	0.0	3	1	1	1
74487	1710	artery-SCID chimera	[artery-SCID chimeras]	0.0	2	1	1	1
74488	1710	differentiation in this cells,	[differentiation in these cells,]	0.0	4	1	1	1
74489	1710	human heavy-chain gene enhancer	[human heavy-chain gene enhancer]	0.0	4	1	1	1
74490	1710	autokinase activity	[autokinase activity]	0.0	2	1	1	1
74491	1710	human locus control region	[human locus control region]	0.0	4	1	1	1
74492	1710	highly homologous gene	[highly homologous genes]	0.0	3	1	1	1
74493	1710	amyloid	[amyloid]	0.0	1	1	1	1
74494	1710	purification of this b-cell factor	[Purification of this B-cell factor]	0.0	5	1	1	1
74495	1710	two important class	[two important classes]	0.0	3	1	1	1
74496	1710	certain infectious disease	[certain infectious diseases]	0.0	3	1	1	1
74497	1710	extract-DNA	[extract-DNA]	0.0	1	2	2	1
74498	1710	camp inhibition of transcription	[cAMP inhibition of transcription]	0.0	4	1	1	1
74499	1710	treatment of hirsutism	[treatment of hirsutism]	0.0	3	2	2	1
74500	1710	average angle of degree	[average angle of degrees]	0.0	4	1	1	1
74501	1710	binding profile	[binding profile]	0.0	2	1	1	1
74502	1710	group of 36 control subject	[group of 36 control subjects]	0.0	5	1	1	1
74503	1710	beta-globin gene locus	[beta-globin gene locus]	0.0	3	2	2	1
74504	1710	lipid kinase	[lipid kinase]	0.0	2	1	1	1
74505	1710	six subregion	[six subregions]	0.0	2	1	1	1
74506	1710	exposure to 135-(oh)2d3	[exposure to 1,25-(OH)2D3]	0.0	3	1	1	1
74507	1710	detailed analysis of the rdna HZF	[Detailed analysis of the cDNAs HZF]	0.0	6	1	1	1
74508	1710	picture of hypercorticism	[picture of hypercorticism]	0.0	3	1	1	1
74509	1710	release of il-8 antigen	[release of IL-8 antigen]	0.0	4	1	1	1
74510	1710	view of a ligand-induced plasticity	[view of an ligand-induced plasticity]	0.0	5	1	1	1
74511	1710	comparison with drug	[comparison with drug]	0.0	3	1	1	1
74512	1710	il-8 antigen	[IL-8 antigen]	0.0	2	2	2	1
74513	1710	kappa b-alpha proteolysis	[kappa B-alpha proteolysis]	0.0	3	1	1	1
74514	1710	occasional GC with a border	[occasional GC with an border]	0.0	5	1	1	1
74515	1710	aldosterone effects.	[aldosterone effects.]	0.0	2	1	1	1
74516	1710	cd19 expression	[CD19 expression]	0.0	2	1	1	1
74517	1710	developmental stage-specificity	[developmental stage-specificity]	0.0	2	1	1	1
74518	1710	response to the immediate protein	[responses to the immediate proteins]	0.0	5	1	1	1
74519	1710	nuclear expression of a cytoplasmic protein	[nuclear expression of an cytoplasmic protein]	0.0	6	1	1	1
74520	1710	narrow range of avidity	[narrow range of avidity]	0.0	4	1	1	1
74521	1710	alpha-dihydroxycholecalciferol vitd3	[alpha-dihydroxycholecalciferol VitD3]	0.0	2	1	1	1
74522	1710	(7/8 patient positive	[(7/8 patients positive]	0.0	3	1	1	1
74523	1710	pml leukemia protein degradation	[PML leukemia protein degradation]	0.0	4	1	1	1
74524	1710	array of virus-encoded protein	[array of virus-encoded proteins]	0.0	4	1	1	1
74525	1710	IL-3 factor two complex in eosinophil	[IL-3 factor two complexes in eosinophils]	0.0	6	1	1	1
74526	1710	observation on the regulation of expression	[observations on the regulation of expression]	0.0	6	1	1	1
74527	1710	C terminus the isoforms, b	[C terminus the isoforms, B]	0.0	5	1	1	1
74528	1710	acute leukemia chimera	[acute leukemia chimera]	0.0	3	1	1	1
74529	1710	Ter 119 cell population	[Ter 119 cell population]	0.0	4	1	1	1
74530	1710	baf170	[BAF170]	0.0	1	1	1	1
74531	1710	kidney fibroblast	[kidney fibroblasts]	0.0	2	1	1	1
74532	1710	translocation involve 3q27	[translocation involving 3q27]	0.0	3	1	1	1
74533	1710	myeloid leukemia blast cell	[myeloid leukemia blast cells]	0.0	4	1	1	1
74534	1710	interaction of AML1 with BSAP	[interaction of AML1 with BSAP]	0.0	5	1	1	1
74535	1710	Jurkat leukemic T cell	[Jurkat leukemic T cells]	0.0	4	1	1	1
74536	1710	intrapulmonary instillation of liposome	[intrapulmonary instillation of liposomes]	0.0	4	1	1	1
74537	1710	normal cycle,	[normal cycle,]	0.0	2	1	1	1
74538	1710	two pp56(lck) mutant	[Two pp56(lck) mutants]	0.0	3	1	1	1
74539	1710	contact tcr	[contacting TCR]	0.0	2	1	1	1
74540	1710	rare cell	[rare cells]	0.0	2	1	1	1
74541	1710	survival of month (6-15	[survival of months (6-15]	0.0	4	1	1	1
74542	1710	man in woman	[men in women]	0.0	3	1	1	1
74543	1710	expression in human hematopoietic cell	[expression in human hematopoietic cells]	0.0	5	1	1	1
74544	1710	transcription factor Oct-2	[transcription factor Oct-2]	0.0	3	1	1	1
74545	1710	umbilical venous	[umbilical venous]	0.0	2	1	1	1
74546	1710	stimulation of monocytic cell	[stimulation of monocytic cells]	0.0	4	1	1	1
74547	1710	specific cytokine factor receptor	[specific cytokine factor receptors]	0.0	4	1	1	1
74548	1710	monocytic maturation of leukemia cell	[monocytic maturation of leukemia cells]	0.0	5	1	1	1
74549	1710	Comparison to virus peptide with response	[Comparison to virus peptides with responses]	0.0	6	1	1	1
74550	1710	Tyr427	[Tyr427]	0.0	1	1	1	1
74551	1710	antioxidant --including acid	[antioxidants --including acid]	0.0	3	1	1	1
74552	1710	hiv-1 monocytoid cell	[HIV-1 monocytoid cells]	0.0	3	1	1	1
74553	1710	immunodeficiency virus hiv replication	[immunodeficiency virus HIV replication]	0.0	4	1	1	1
74554	1710	one explanation important.	[one explanation important.]	0.0	3	1	1	1
74555	1710	event of tuberculosis infection	[events of tuberculosis infection]	0.0	4	1	1	1
74556	1710	deletion -70	[Deletion -70]	0.0	2	1	1	1
74557	1710	mode of stress	[modes of stress]	0.0	3	1	1	1
74558	1710	region sequence	[region sequence]	0.0	2	1	1	1
74559	1710	transformation of b cell with ebv	[transformation of B cells with EBV]	0.0	6	1	1	1
74560	1710	prb -e2f complex	[pRB -E2F complexes]	0.0	3	1	1	1
74561	1710	confirm the source	[confirming the source]	0.0	3	1	1	1
74562	1710	treatment of malignancy	[treatment of malignancies]	0.0	3	1	1	1
74563	1710	ERP a member	[ERP a member]	0.0	3	1	1	1
74564	1710	clue assess responsiveness to therapy	[clue assessing responsiveness to therapy]	0.0	5	1	1	1
74565	1710	half-site for glucocorticoid receptor/progesterone receptor binding	[half-sites for glucocorticoid receptor/progesterone receptor binding]	0.0	6	1	1	1
74566	1710	hla class ii antigen processing	[HLA class II antigen processing]	0.0	5	1	1	1
74567	1710	follow stimulation in control	[following stimulation in controls]	0.0	4	1	1	1
74568	1710	induction of phase protein in response	[induction of phase proteins in response]	0.0	6	1	1	1
74569	1710	patient with tuberculosis present	[patients with tuberculosis presenting]	0.0	4	1	1	1
74570	1710	terminal event	[terminal events]	0.0	2	1	1	1
74571	1710	percoll	[Percoll]	0.0	1	1	1	1
74572	1710	winged-helix transcription factor	[winged-helix transcription factor]	0.0	3	2	2	1
74573	1710	transcription of NF-kappa b -dependent-gene	[transcription of NF-kappa B -dependent-genes]	0.0	5	1	1	1
74574	1710	12-o-tetradecanoylphorbol-13-acetate mitogen tnf-alpha	[12-O-tetradecanoylphorbol-13-acetate mitogen TNF-alpha]	0.0	3	1	1	1
74575	1710	herpesvirus saimiry open reading frame	[herpesvirus saimiri open reading frame]	0.0	5	1	1	1
74576	1710	fp4-3'	[FP4-3']	0.0	1	1	1	1
74577	1710	thymocyte-specific gene	[thymocyte-specific gene]	0.0	2	1	1	1
74578	1710	24 hour time culture	[24 hours time culture]	0.0	4	2	2	1
74579	1710	80.2 (p p less than 0.01	[80.2 (P P less than 0.01]	0.0	6	1	1	1
74580	1710	peptide clip	[peptides CLIP]	0.0	2	1	1	1
74581	1710	depression I receptor	[depression I receptors]	0.0	3	1	1	1
74582	1710	signal follow CD40 stimulation	[signaling following CD40 stimulation]	0.0	4	1	1	1
74583	1710	result of aberrant splicing.	[result of aberrant splicing.]	0.0	4	1	1	1
74584	1710	repression direct inhibition	[repression direct inhibition]	0.0	3	1	1	1
74585	1710	B29 sequence	[B29 sequence]	0.0	2	1	1	1
74586	1710	recognize T antigen	[recognizing T antigen]	0.0	3	1	1	1
74587	1710	transfect T lymphocyte jurkat cell	[transfecting T lymphocyte Jurkat cells]	0.0	5	1	1	1
74588	1710	c-terminal tail	[C-terminal tail]	0.0	2	1	1	1
74589	1710	Concomitant downregulation implication for dysregulation	[Concomitant downregulation implications for dysregulation]	0.0	5	1	1	1
74590	1710	change in the transcription	[changes in the transcription]	0.0	4	1	1	1
74591	1710	12-o-tetradecanoyl 12-phorbol	[12-O-tetradecanoyl 12-phorbol]	0.0	2	1	1	1
74592	1710	favorable course (p chi2 test).	[favorable course (P chi2 test).]	0.0	5	1	1	1
74593	1710	region y145	[region Y145]	0.0	2	1	1	1
74594	1710	surface ganglioside erratum	[surface ganglioside erratum]	0.0	3	1	1	1
74595	1710	undergo selection	[undergoing selection]	0.0	2	1	1	1
74596	1710	Study with human vein segment	[Studies with human vein segments]	0.0	5	1	1	1
74597	1710	mass of the two proteins.	[masses of the two proteins.]	0.0	5	1	1	1
74598	1710	constitutive translocation	[constitutive translocation]	0.0	2	2	2	1
74599	1710	inducer of Fos kinase activity	[inducer of Fos kinase activity]	0.0	5	1	1	1
74600	1710	factor binding role in transient up-regulation	[factor binding role in transient up-regulation]	0.0	6	1	1	1
74601	1710	implication regard the use of agent	[implications regarding the use of agents]	0.0	6	1	1	1
74602	1710	reactivity at level	[reactivities at levels]	0.0	3	1	1	1
74603	1710	eotaxin gene	[eotaxin gene]	0.0	2	2	2	1
74604	1710	5'-most Ets site	[5'-most Ets site]	0.0	3	1	1	1
74605	1710	concept a distinct, b-cell-derived subtype	[concept an distinct, B-cell-derived subtype]	0.0	5	1	1	1
74606	1710	extensive N-terminal sequence homology	[extensive N-terminal sequence homology]	0.0	4	1	1	1
74607	1710	effect of phosphate supplementation	[effect of phosphate supplementation]	0.0	4	1	1	1
74608	1710	interaction between class promoter	[interactions between class promoters]	0.0	4	1	1	1
74609	1710	sensitivity for detection	[sensitivity for detection]	0.0	3	1	1	1
74610	1710	ten hiv-infected patient	[Ten HIV-infected patients]	0.0	3	1	1	1
74611	1710	concentration of dexamethasone binding site	[concentration of dexamethasone binding sites]	0.0	5	1	1	1
74612	1710	presence of the constitutive form	[presence of the constitutive form]	0.0	5	1	1	1
74613	1710	role in proliferative signal	[role in proliferative signaling]	0.0	4	1	1	1
74614	1710	microbial broth	[microbial broths]	0.0	2	1	1	1
74615	1710	active heterodimer follow time	[active heterodimers following time]	0.0	4	1	1	1
74616	1710	age-related decline in activity	[age-related decline in activity]	0.0	4	1	1	1
74617	1710	receptor during hypercortisolaemia	[receptors during hypercortisolaemia]	0.0	3	1	1	1
74618	1710	HBxAg -specific stimulation of blood cell	[HBxAg -specific stimulation of blood cells]	0.0	6	1	1	1
74619	1710	po2 approximately 14-18 Torr,	[PO2 approximately 14-18 Torr,]	0.0	4	1	1	1
74620	1710	evidence for a autoregulatory mechanism	[evidence for an autoregulatory mechanism]	0.0	5	1	1	1
74621	1710	msr promoter-reporter	[MSR promoter-reporter]	0.0	2	1	1	1
74622	1710	protein in extract of pmn	[protein in extracts of PMN]	0.0	5	1	1	1
74623	1710	survival of b cell	[survival of B cells]	0.0	4	1	1	1
74624	1710	lt gene expression	[LT gene expression]	0.0	3	1	1	1
74625	1710	Addition of thiol-reduce compounds,	[Addition of thiol-reducing compounds,]	0.0	4	1	1	1
74626	1710	activation of the v-j recombination	[activation of the V-J recombination]	0.0	5	1	1	1
74627	1710	analysis with isoform-specific antibody	[analysis with isoform-specific antibodies]	0.0	4	1	1	1
74628	1710	candidate gene hepatic factor	[candidate genes hepatic factor]	0.0	4	1	1	1
74629	1710	TNF-alpha hiv-1 long repeat LTR transcription	[TNF-alpha HIV-1 long repeat LTR transcription]	0.0	6	1	1	1
74630	1710	generation of reactive oxygen species	[generation of reactive oxygen species]	0.0	5	1	1	1
74631	1710	j393/ cd43	[J393/ CD43]	0.0	2	1	1	1
74632	1710	obligatory step	[obligatory steps]	0.0	2	1	1	1
74633	1710	factor with the pp52 promoter	[factors with the pp52 promoter]	0.0	5	1	1	1
74634	1710	enhancer regulatory element	[enhancer regulatory element]	0.0	3	1	1	1
74635	1710	affect the LTR	[affecting the LTR]	0.0	3	1	1	1
74636	1710	virus Akv	[virus Akv]	0.0	2	1	1	1
74637	1710	formalin-resistant epitope on the region	[formalin-resistant epitope on the region]	0.0	5	1	1	1
74638	1710	Toll protein	[Toll protein]	0.0	2	1	1	1
74639	1710	Biologic effect of il-13	[Biologic effects of IL-13]	0.0	4	1	1	1
74640	1710	induction of primary transformation	[induction of primary transformation]	0.0	4	1	1	1
74641	1710	control of replication	[control of replication]	0.0	3	1	1	1
74642	1710	effect of leukemia factor	[effects of leukemia factor]	0.0	4	1	1	1
74643	1710	obscure, line of investigation	[obscure, lines of investigation]	0.0	4	1	1	1
74644	1710	displacement implication	[Displacement implications]	0.0	2	1	1	1
74645	1710	study use ptf beta antibody	[studies using PTF beta antibodies]	0.0	5	1	1	1
74646	1710	impaired immunity	[impaired immunity]	0.0	2	1	1	1
74647	1710	specific uptake with failure	[specific uptake with failure]	0.0	4	1	1	1
74648	1710	expression of type interferon	[expression of type interferon]	0.0	4	1	1	1
74649	1710	ANG nf-kappab activation	[ANG NF-kappaB activation]	0.0	3	1	1	1
74650	1710	cell line of origin	[cell lines of origin]	0.0	4	1	1	1
74651	1710	macrophage activity	[macrophages activity]	0.0	2	1	1	1
74652	1710	replicative form of Epstein-Barr virus	[replicative form of Epstein-Barr virus]	0.0	5	1	1	1
74653	1710	multiple potential binding site	[multiple potential binding sites]	0.0	4	1	1	1
74654	1710	lps tolerance	[LPS tolerance]	0.0	2	1	1	1
74655	1710	receptor present in the cytoplasm	[receptors present in the cytoplasm]	0.0	5	1	1	1
74656	1710	specific context	[specific context]	0.0	2	1	1	1
74657	1710	Differentiation-dependent expression of a human carboxylesterase	[Differentiation-dependent expression of a human carboxylesterase]	0.0	6	1	1	1
74658	1710	common control mechanism in response	[common control mechanisms in response]	0.0	5	1	1	1
74659	1710	Tyr374	[Tyr374]	0.0	1	1	1	1
74660	1710	treatment in severe preeclampsia	[treatment in severe preeclampsia]	0.0	4	1	1	1
74661	1710	myelogenous leukaemia CML	[myelogenous leukaemia CML]	0.0	3	1	1	1
74662	1710	b cell precursor	[B cell precursor]	0.0	3	1	1	1
74663	1710	involve activation of form	[involving activation of forms]	0.0	4	1	1	1
74664	1710	2 h (and	[2 h (and]	0.0	3	1	1	1
74665	1710	two rdna with identity	[two cDNAs with identity]	0.0	4	1	1	1
74666	1710	repeats, bind	[repeats, bind]	0.0	2	1	1	1
74667	1710	expression use a BK virus vector	[expression using a BK virus vector]	0.0	6	1	1	1
74668	1710	several response include the activation	[Several responses including the activation]	0.0	5	1	1	1
74669	1710	activity of retinoic acid RA	[activities of retinoic acid RA]	0.0	5	1	1	1
74670	1710	site in the loci	[sites in the loci]	0.0	4	1	1	1
74671	1710	inhibitor of ptk genistein	[inhibitor of PTK genistein]	0.0	4	1	1	1
74672	1710	transcription factor C/EBPbeta	[transcription factors C/EBPbeta]	0.0	3	1	1	1
74673	1710	anti- TNF-alpha hiv-1 repeat transcription	[anti- TNF-alpha HIV-1 repeat transcription]	0.0	5	1	1	1
74674	1710	81% inhibition	[81% inhibition]	0.0	2	1	1	1
74675	1710	1,25-dihydroxyvitamin D3 in normal monocyte	[1,25-dihydroxyvitamin D3 in normal monocytes]	0.0	5	1	1	1
74676	1710	il-10 binding	[IL-10 binding]	0.0	2	1	1	1
74677	1710	shut-down	[shut-down]	0.0	1	1	1	1
74678	1710	peroxisome receptor gamma ppargamma	[peroxisome receptor gamma PPARgamma]	0.0	4	1	1	1
74679	1710	pregnant woman (11 10 second	[pregnant women (11 10 second]	0.0	5	1	1	1
74680	1710	concentration of ambient 125d3	[concentrations of ambient 1,25D3]	0.0	4	1	1	1
74681	1710	HIV region	[HIV region]	0.0	2	1	1	1
74682	1710	virus (sffv) envelope glycoprotein	[virus (SFFV) envelope glycoprotein]	0.0	4	1	1	1
74683	1710	393 amino acid	[393 amino acid]	0.0	3	1	1	1
74684	1710	induction of a inhibitory factor	[induction of a inhibitory factor]	0.0	5	1	1	1
74685	1710	NF-kappa /Rel	[NF-kappa /Rel]	0.0	2	1	1	1
74686	1710	especially aurothioglucose	[especially aurothioglucose]	0.0	2	1	1	1
74687	1710	demarcation	[demarcation]	0.0	1	1	1	1
74688	1710	pattern of alpha integrin	[pattern of alpha integrin]	0.0	4	1	1	1
74689	1710	same dose of anti-CD3	[same dose of anti-CD3]	0.0	4	1	1	1
74690	1710	GM-CSF promoter element	[GM-CSF promoter element]	0.0	3	1	1	1
74691	1710	presence of lipopolysaccharide	[presence of lipopolysaccharide]	0.0	3	1	1	1
74692	1710	activity of ifn-gamma	[activity of IFN-gamma]	0.0	3	1	1	1
74693	1710	heterodimeric complex	[heterodimeric complexes]	0.0	2	1	1	1
74694	1710	mechanism in the normal system	[mechanism in the normal system]	0.0	5	1	1	1
74695	1710	ifn-alpha in human T cell	[IFN-alpha in human T cells]	0.0	5	1	1	1
74696	1710	binding of several cell-specific transcription factor	[binding of several cell-specific transcription factors]	0.0	6	1	1	1
74697	1710	thus, select aberration	[Thus, select aberrations]	0.0	3	1	1	1
74698	1710	expression of hb24 a homeobox gene	[expression of HB24 a homeobox gene]	0.0	6	1	1	1
74699	1710	such as Syk	[such as Syk]	0.0	3	1	1	1
74700	1710	group at high risk	[group at high risk]	0.0	4	1	1	1
74701	1710	murine b-cell coactivator	[murine B-cell coactivator]	0.0	3	1	1	1
74702	1710	one gene, transcript	[One gene, transcripts]	0.0	3	1	1	1
74703	1710	huvec to neutrophil	[HUVECs to neutrophils]	0.0	3	1	1	1
74704	1710	selection of lac+clone out of transformant	[selection of Lac+clones out of transformants]	0.0	6	1	1	1
74705	1710	IL-13 by human monocyte	[IL-13 by human monocytes]	0.0	4	1	1	1
74706	1710	-inducible target gene	[-inducible target genes]	0.0	3	1	1	1
74707	1710	(ie-2)	[(IE-2)]	0.0	1	1	1	1
74708	1710	cooperation between the cellular factor	[cooperation between the cellular factor]	0.0	5	1	1	1
74709	1710	region (position -69	[region (positions -69]	0.0	3	1	1	1
74710	1710	response with a phorbol ester	[response with a phorbol ester]	0.0	5	1	1	1
74711	1710	extend base pair upstream	[extending base pairs upstream]	0.0	4	1	1	1
74712	1710	7.03 (range, 5.66-10) 4.27 (range, 4-.11),	[7.03 (range, 5.66-10), 4.27 (range, 4-5.13),]	0.0	6	1	1	1
74713	1710	interferon-gamma-induced factor role	[Interferon-gamma-induced factor role]	0.0	3	1	1	1
74714	1710	ppb for MTBE	[PPB for MTBE]	0.0	3	1	1	1
74715	1710	concentration of sodium	[concentrations of sodium]	0.0	3	1	1	1
74716	1710	methyl prednisolone 120 mg/day)	[methyl prednisolone 120 mg/day)]	0.0	4	1	1	1
74717	1710	genetic aberration in the apoptotic pathway	[genetic aberrations in the apoptotic pathway]	0.0	6	1	1	1
74718	1710	OBF-1 a b cell-specific coactivator	[OBF-1 a B cell-specific coactivator]	0.0	5	1	1	1
74719	1710	antisense oligomer target PML mrna	[antisense oligomers targeting PML mRNA]	0.0	5	1	1	1
74720	1710	cellular stress agent like radiation exposure	[cellular stress agents like radiation exposure]	0.0	6	1	1	1
74721	1710	h in HU cell	[h in HU cells]	0.0	4	1	1	1
74722	1710	new NH2 terminus	[new NH2 terminus]	0.0	3	1	1	1
74723	1710	cytotoxic T cell line	[cytotoxic T cell line]	0.0	4	1	1	1
74724	1710	mobility ap-1 binding activity	[mobility AP-1 binding activity]	0.0	4	1	1	1
74725	1710	feature occur in multiple family	[feature occurring in multiple families]	0.0	5	1	1	1
74726	1710	rapidly tyrosine-phosphorylated factor treatment	[rapidly tyrosine-phosphorylated factor treatment]	0.0	4	1	1	1
74727	1710	position -306 to -260	[positions -306 to -260]	0.0	4	1	1	1
74728	1710	level) for adenovirus DNA	[level) for adenovirus DNA]	0.0	4	2	2	1
74729	1710	preclinical rationale	[preclinical rationale]	0.0	2	1	1	1
74730	1710	Oct2a Oct2b isoform	[Oct2a Oct2b isoforms]	0.0	3	1	1	1
74731	1710	protein kinase C activation	[Protein kinase C activation]	0.0	4	1	1	1
74732	1710	co-expression in cell	[Co-expression in cells]	0.0	3	1	1	1
74733	1710	appearance of RelB	[appearance of RelB]	0.0	3	1	1	1
74734	1710	recognition within the karyophilic protein	[recognition within the karyophilic protein]	0.0	5	1	1	1
74735	1710	kinase C PKC transcription	[kinase C PKC transcription]	0.0	4	1	1	1
74736	1710	least 3-fold CAT activity	[least 3-fold CAT activity]	0.0	4	1	1	1
74737	1710	child with deterioration	[children with deteriorations]	0.0	3	1	1	1
74738	1710	implicate specific sequence in the control	[implicating specific sequences in the control]	0.0	6	1	1	1
74739	1710	moreover, supplement the culture with dose	[Moreover, supplementing the cultures with doses]	0.0	6	1	1	1
74740	1710	encode a potential transcription factor	[encoding a potential transcription factor]	0.0	5	1	1	1
74741	1710	use a palindromic nf-kappa b probe	[using a palindromic NF-kappa B probe]	0.0	6	1	1	1
74742	1710	vivo.	[vivo.]	0.0	1	1	1	1
74743	1710	true environment, experiment	[true environment, experiments]	0.0	3	1	1	1
74744	1710	tool for the mapping	[tool for the mapping]	0.0	4	1	1	1
74745	1710	depressive disorder: lack of evidence	[depressive disorder: lack of evidence]	0.0	5	1	1	1
74746	1710	include phorbol 13-acetate PMA	[including phorbol 13-acetate PMA]	0.0	4	1	1	1
74747	1710	protein 1 LMP1	[protein 1 LMP1]	0.0	3	1	1	1
74748	1710	e2f -contain complex	[E2F -containing complexes]	0.0	3	1	1	1
74749	1710	transcription of the wave,	[transcription of the wave,]	0.0	4	1	1	1
74750	1710	maturity-onset diabete of the young	[maturity-onset diabetes of the young]	0.0	5	1	1	1
74751	1710	effect of cell surface antigen	[effect of cell surface antigens]	0.0	5	1	1	1
74752	1710	normal myeloid differentiation	[normal myeloid differentiation]	0.0	3	1	1	1
74753	1710	high (66 millileter	[high (66 ml]	0.0	3	1	1	1
74754	1710	time per day	[times per day]	0.0	3	1	1	1
74755	1710	novel t-cell-specific transcriptional activator tcf-1	[novel T-cell-specific transcriptional activator TCF-1]	0.0	5	1	1	1
74756	1710	glycoprotein b gb	[glycoprotein B gB]	0.0	3	1	1	1
74757	1710	3 aml with myelomonocytic differentiation	[3 AML with myelomonocytic differentiation]	0.0	5	1	1	1
74758	1710	newborn disease	[newborn disease]	0.0	2	1	1	1
74759	1710	strength of this form	[strength of this form]	0.0	4	1	1	1
74760	1710	ifn-gamma colony-stimulating factor	[IFN-gamma colony-stimulating factor]	0.0	3	1	1	1
74761	1710	nm at 24 degree	[nM at 24 degrees]	0.0	4	1	1	1
74762	1710	intrinsic activity	[intrinsic activity]	0.0	2	1	1	1
74763	1710	expression of gamma-ifn responsive gene	[Expression of gamma-IFN responsive genes]	0.0	5	1	1	1
74764	1710	leukemia gene pml	[leukemia gene PML]	0.0	3	1	1	1
74765	1710	chrysotile b fr	[Chrysotile B FR]	0.0	3	1	1	1
74766	1710	length tf	[length TF]	0.0	2	1	1	1
74767	1710	ifn-gamma receptor activation	[IFN-gamma receptor activation]	0.0	3	1	1	1
74768	1710	frequency of response	[frequency of response]	0.0	3	1	1	1
74769	1710	specific substrate	[specific substrates]	0.0	2	1	1	1
74770	1710	factor-induced gene	[factor-induced genes]	0.0	2	1	1	1
74771	1710	vernal keratoconjunctivitis a eosinophilic disease	[vernal keratoconjunctivitis an eosinophilic disease.]	0.0	5	1	1	1
74772	1710	Alzheimer's disease	[Alzheimer's disease]	0.0	2	1	1	1
74773	1710	number of receptor gcr	[number of receptors GCR]	0.0	4	1	1	1
74774	1710	bcl-6 in normal development	[BCL-6 in normal development]	0.0	4	1	1	1
74775	1710	nuclear factor-kappaB transcription factor	[nuclear factor-kappaB transcription factors]	0.0	4	1	1	1
74776	1710	b production	[B production]	0.0	2	1	1	1
74777	1710	effect of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane	[effects of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane]	0.0	3	1	1	1
74778	1710	blood mononuclear cell of patient	[blood mononuclear cells of patients]	0.0	5	1	1	1
74779	1710	new analogue	[new analogue]	0.0	2	1	1	1
74780	1710	tnf-alpha independent	[TNF-alpha independent]	0.0	2	1	1	1
74781	1710	binding site on the human receptor	[binding sites on the human receptor]	0.0	6	1	1	1
74782	1710	new field in molecular immunology	[new field in molecular immunology]	0.0	5	1	1	1
74783	1710	IL-2 element	[IL-2 elements]	0.0	2	1	1	1
74784	1710	transcriptional protein nf-kappab	[transcriptional protein NF-kappaB]	0.0	3	1	1	1
74785	1710	decrease in interleukin	[decrease in interleukin]	0.0	3	1	1	1
74786	1710	apoptosis of progenitor cell	[apoptosis of progenitor cells]	0.0	4	1	1	1
74787	1710	24 woman first, second	[24 women first, second]	0.0	4	1	1	1
74788	1710	identical reaction	[identical reaction]	0.0	2	1	1	1
74789	1710	protein for the replication	[protein for the replication]	0.0	4	1	1	1
74790	1710	effective apc for vzv peptide	[effective APC for VZV peptides]	0.0	5	1	1	1
74791	1710	Cross competition	[Cross competition]	0.0	2	1	1	1
74792	1710	organ dysfunction	[organ dysfunction]	0.0	2	1	1	1
74793	1710	antigen-specific reactivity at level high	[antigen-specific reactivities at levels high]	0.0	5	1	1	1
74794	1710	alter weak, nonproductive interaction	[altering weak, nonproductive interactions]	0.0	4	1	1	1
74795	1710	choice between T cell	[choice between T cells]	0.0	4	1	1	1
74796	1710	important event in early signalling	[important event in early signalling]	0.0	5	1	1	1
74797	1710	protein necessary through the G1 phase	[proteins necessary through the G1 phase]	0.0	6	1	1	1
74798	1710	multinucleated cell from human monocyte	[multinucleated cells from human monocytes]	0.0	5	1	1	1
74799	1710	reticulum ca2+-atpase in platelet	[reticulum Ca2+-ATPase in platelets]	0.0	4	1	1	1
74800	1710	b origin	[B origin]	0.0	2	1	1	1
74801	1710	herpesvirus type-8 hhv-8	[herpesvirus type-8 HHV-8]	0.0	3	1	1	1
74802	1710	existence of a autoregulatory loop	[existence of a autoregulatory loop]	0.0	5	1	1	1
74803	1710	LH-20	[LH-20]	0.0	1	1	1	1
74804	1710	67-kDa precursor	[67-kDa precursor]	0.0	2	1	1	1
74805	1710	role of the chaperone hsp90	[roles of the chaperone hsp90]	0.0	5	1	1	1
74806	1710	subunit of mass 50000 (50k)	[subunits of mass 50,000 (50K)]	0.0	5	1	1	1
74807	1710	chromatin-assembled DNA	[chromatin-assembled DNA]	0.0	2	1	1	1
74808	1710	regard to expression	[regard to expression]	0.0	3	1	1	1
74809	1710	level for epithelial icam-1	[levels for epithelial ICAM-1]	0.0	4	1	1	1
74810	1710	inducible component after activation	[inducible component after activation]	0.0	4	1	1	1
74811	1710	IRE transcript	[IRE transcripts]	0.0	2	1	1	1
74812	1710	autologous blood stem cell transplantation PBSCT	[Autologous blood stem cell transplantation PBSCT]	0.0	6	1	1	1
74813	1710	relationship between late gene expression	[relationship between late gene expression]	0.0	5	1	1	1
74814	1710	expression in cell by cryptococcus neoforman	[expression in cells by Cryptococcus neoformans]	0.0	6	1	1	1
74815	1710	modulator (1-231)-mediated nf-kappab activation	[modulator (1-231)-mediated NF-kappaB activation]	0.0	4	1	1	1
74816	1710	inhibitor of apoptosis	[inhibitor of apoptosis]	0.0	3	1	1	1
74817	1710	b cell line bjab	[B cell line BJAB]	0.0	4	1	1	1
74818	1710	influence of activation on transcription	[influence of activation on transcription]	0.0	5	1	1	1
74819	1710	early gene expression	[early gene expression]	0.0	3	1	1	1
74820	1710	role in ebv transformation	[role in EBV transformation]	0.0	4	1	1	1
74821	1710	residue of the early protein	[residues of the early protein]	0.0	5	1	1	1
74822	1710	Cox analysis for premenopausal patient	[Cox analysis for premenopausal patients]	0.0	5	1	1	1
74823	1710	anti-Fc gamma R mab	[anti-Fc gamma R mAb]	0.0	4	1	1	1
74824	1710	rest state,	[resting state,]	0.0	2	1	1	1
74825	1710	ciita rdna	[CIITA cDNAs]	0.0	2	1	1	1
74826	1710	kinase C transcription	[kinase C transcription]	0.0	3	1	1	1
74827	1710	proportion of acidic residue	[proportion of acidic residues]	0.0	4	1	1	1
74828	1710	factor-kappaB induction evidence	[factor-kappaB induction evidence]	0.0	3	1	1	1
74829	1710	contrast, a mutant	[contrast, a mutant]	0.0	3	1	1	1
74830	1710	4111 ng/ml)	[4,111 ng/mL)]	0.0	2	1	1	1
74831	1710	two other ccgccc binding protein	[two other CCGCCC binding proteins]	0.0	5	1	1	1
74832	1710	expression of other early gene	[expression of other early genes]	0.0	5	1	1	1
74833	1710	DNA template	[DNA templates]	0.0	2	1	1	1
74834	1710	interact with interleukin-1	[interacting with interleukin-1]	0.0	3	1	1	1
74835	1710	glucose transporter	[glucose transporter]	0.0	2	1	1	1
74836	1710	ldl oxldl	[LDL oxLDL]	0.0	2	1	1	1
74837	1710	promoter area	[promoter area]	0.0	2	1	1	1
74838	1710	adenoviral transfer of IkappaB-alpha	[adenoviral transfer of IkappaB-alpha]	0.0	4	1	1	1
74839	1710	healthy subject in patient	[healthy subjects in patients]	0.0	4	1	1	1
74840	1710	Furthermore, expression of physiological level	[Furthermore, expression of physiological levels]	0.0	5	1	1	1
74841	1710	suggest dependent on structural constraint	[suggesting dependent on structural constraints]	0.0	5	1	1	1
74842	1710	rapid activation of gene	[rapid activation of genes]	0.0	4	1	1	1
74843	1710	bipartite structure	[bipartite structure]	0.0	2	1	1	1
74844	1710	fraction of the form	[fraction of the form]	0.0	4	1	1	1
74845	1710	implicate IL-4R	[implicating IL-4R]	0.0	2	1	1	1
74846	1710	multipotential fdcp-mix a4 cell	[multipotential FDCP-mix A4 cells]	0.0	4	1	1	1
74847	1710	molecule il-13r alpha1	[molecule IL-13R alpha1]	0.0	3	1	1	1
74848	1710	sequence in a gene	[sequence in a gene]	0.0	4	1	1	1
74849	1710	beta-globin promoter in cell	[beta-globin promoter in cells]	0.0	4	1	1	1
74850	1710	cell cycle protein	[cell cycle proteins]	0.0	3	1	1	1
74851	1710	function for the erythroid lineage	[function for the erythroid lineages]	0.0	5	1	1	1
74852	1710	hyperadhesivity of postanoxic huvec to neutrophil	[hyperadhesivity of postanoxic HUVECs to neutrophils]	0.0	6	1	1	1
74853	1710	60 mM d-ribose respectively.	[60 mM D-ribose respectively.]	0.0	4	1	1	1
74854	1710	understanding of t-cell differentiation	[understanding of T-cell differentiation]	0.0	4	1	1	1
74855	1710	enhancement HL cell	[enhancement HL cells]	0.0	3	1	1	1
74856	1710	inducible DNA	[inducible DNA]	0.0	2	1	1	1
74857	1710	p53-null cell highly resistant	[p53-null cells highly resistant]	0.0	4	1	1	1
74858	1710	monocyte tethering	[Monocyte tethering]	0.0	2	1	1	1
74859	1710	effect on the property	[effect on the property]	0.0	4	1	1	1
74860	1710	PKC with PMA	[PKC with PMA]	0.0	3	1	1	1
74861	1710	general mechanism	[general mechanism]	0.0	2	1	1	1
74862	1710	Effect of mitogenic agent upon action	[Effects of mitogenic agents upon action]	0.0	6	1	1	1
74863	1710	control of activity	[control of activity]	0.0	3	1	1	1
74864	1710	TCRzeta signal element	[TCRzeta signaling elements]	0.0	3	1	1	1
74865	1710	leukocyte from 11 abdominal subject	[leukocytes from 11 abdominal subjects]	0.0	5	1	1	1
74866	1710	helix-loop-helix bhlh motif contiguous	[helix-loop-helix bHLH motif contiguous]	0.0	4	1	1	1
74867	1710	suggest possible strategy for the detection	[suggesting possible strategies for the detection]	0.0	6	1	1	1
74868	1710	two compartments.	[two compartments.]	0.0	2	1	1	1
74869	1710	protection to T cell line	[protection to T cell lines]	0.0	5	1	1	1
74870	1710	regulator of human blood T	[regulators of human blood T]	0.0	5	1	1	1
74871	1710	component of promoter activity	[component of promoter activity]	0.0	4	1	1	1
74872	1710	immunostaining technique	[immunostaining technique]	0.0	2	1	1	1
74873	1710	NF-kappaB/Rel member	[NF-kappaB/Rel members]	0.0	2	1	1	1
74874	1710	infection with the human immunodeficiency virus	[Infection with the human immunodeficiency virus]	0.0	6	1	1	1
74875	1710	specific intracellular domain sequence	[specific intracellular domain sequences]	0.0	4	1	1	1
74876	1710	thus a potential target in state	[thus a potential target in states]	0.0	6	1	1	1
74877	1710	prolactin a peptide hormone	[prolactin a peptide hormone]	0.0	4	1	1	1
74878	1710	male with age distribution	[males with age distribution]	0.0	4	1	1	1
74879	1710	control vascular-specific expression	[controlling vascular-specific expression]	0.0	3	1	1	1
74880	1710	extend to -177 bp	[extending to -177 bp]	0.0	4	1	1	1
74881	1710	chemotactic protein-1 another member	[chemotactic protein-1 another member]	0.0	4	1	1	1
74882	1710	pathway of regulation	[pathway of regulation]	0.0	3	1	1	1
74883	1710	potency of class of analogue	[potency of class of analogues]	0.0	5	1	1	1
74884	1710	classical p50-p65 complex from pools,	[classical p50-p65 complex from pools,]	0.0	5	1	1	1
74885	1710	-contain leukocyte protein	[-containing leukocyte protein]	0.0	3	1	1	1
74886	1710	gr activation	[GR activation]	0.0	2	1	1	1
74887	1710	very low dissociation constant kd	[very low dissociation constant Kd]	0.0	5	1	1	1
74888	1710	lymphoid-specific responsiveness	[lymphoid-specific responsiveness]	0.0	2	1	1	1
74889	1710	Rapid shuttling of NF-AT in discrimination	[Rapid shuttling of NF-AT in discrimination]	0.0	6	1	1	1
74890	1710	positive cells, respectively),	[positive cells, respectively),]	0.0	3	1	1	1
74891	1710	thus establish a inverse relation	[thus establishing an inverse relation]	0.0	5	1	1	1
74892	1710	cytosine at position 1	[cytosine at position 1]	0.0	4	1	1	1
74893	1710	il-5 -specific mechanism	[IL-5 -specific mechanisms]	0.0	3	1	1	1
74894	1710	oxidative stress than peroxidation	[oxidative stress than peroxidation]	0.0	4	1	1	1
74895	1710	most IL-2 cell line	[most IL-2 cell lines]	0.0	4	1	1	1
74896	1710	human receptor hormone-binding domain	[human receptor hormone-binding domain]	0.0	4	1	1	1
74897	1710	corresponding mrna in cell	[corresponding mRNA in cells]	0.0	4	1	1	1
74898	1710	induction of the 16 promoter	[induction of the 16 promoter]	0.0	5	1	1	1
74899	1710	immediate gene transcription	[immediate gene transcription]	0.0	3	1	1	1
74900	1710	stromal tcell rescue from apoptosis	[stromal Tcell rescue from apoptosis]	0.0	5	1	1	1
74901	1710	Jeg-3 immunosuppression	[Jeg-3 immunosuppression]	0.0	2	1	1	1
74902	1710	strong affinity for the 12-bp insert	[strong affinity for the 12-bp insert]	0.0	6	1	1	1
74903	1710	quantity of nf-at	[quantities of NF-AT]	0.0	3	1	1	1
74904	1710	avian progenitor	[avian progenitors]	0.0	2	1	1	1
74905	1710	proliferator receptor ppar	[proliferator receptor PPAR]	0.0	3	1	1	1
74906	1710	hbd mutant	[HBD mutants]	0.0	2	1	1	1
74907	1710	4 prolymphocytic leukemia (pll)	[4 prolymphocytic leukemias (PLL)]	0.0	4	1	1	1
74908	1710	follow activation of U937 cell	[following activation of U937 cells]	0.0	5	1	1	1
74909	1710	receptor for the fc portion present	[Receptors for the Fc portion present]	0.0	6	1	1	1
74910	1710	patient with defect in t-cell signal	[patients with defects in T-cell signaling]	0.0	6	1	1	1
74911	1710	control the competence in response	[controlling the competence in response]	0.0	5	1	1	1
74912	1710	modes, like chemical induction, superinfection	[modes, like chemical induction, superinfection]	0.0	5	1	1	1
74913	1710	0.67 map unit	[0.67 map units]	0.0	3	1	1	1
74914	1710	opening of K+	[opening of K+]	0.0	3	1	1	1
74915	1710	prolactin interferon factor-1 gene	[prolactin interferon factor-1 gene]	0.0	4	1	1	1
74916	1710	haematopoietic line u937	[haematopoietic lines U937]	0.0	3	1	1	1
74917	1710	populations, include some Jewish group	[populations, including some Jewish groups]	0.0	5	1	1	1
74918	1710	thrombin generation by smooth muscle cell	[Thrombin generation by smooth muscle cells]	0.0	6	1	1	1
74919	1710	STAT3 alpha	[STAT3 alpha]	0.0	2	1	1	1
74920	1710	interaction with hsp90	[interaction with hsp90]	0.0	3	1	1	1
74921	1710	monocyte regulatory cytokine	[monocyte regulatory cytokine]	0.0	3	1	1	1
74922	1710	human lipopolysaccharide	[human lipopolysaccharide]	0.0	2	1	1	1
74923	1710	participation of the element	[participation of the element]	0.0	4	1	1	1
74924	1710	human embryonic zeta globin promoter	[human embryonic zeta globin promoter]	0.0	5	1	1	1
74925	1710	responsiveness chronic myelogenous leukemia	[responsiveness chronic myelogenous leukemia]	0.0	4	1	1	1
74926	1710	induction of gr mrna in cell	[induction of GR mRNA in cells]	0.0	6	1	1	1
74927	1710	requirement for optimal function	[requirement for optimal function]	0.0	4	1	1	1
74928	1710	enhance transcription of gene include IL-2	[enhancing transcription of genes including IL-2]	0.0	6	1	1	1
74929	1710	association of insensitivity	[Association of insensitivity]	0.0	3	1	1	1
74930	1710	transcriptional regulator factor	[transcriptional regulator factor]	0.0	3	1	1	1
74931	1710	interferon beta gene transcription	[interferon beta gene transcription]	0.0	4	1	1	1
74932	1710	intrinsic activity,	[intrinsic activity,]	0.0	2	1	1	1
74933	1710	use flow cytometric	[using flow cytometric]	0.0	3	1	1	1
74934	1710	d1/ cdr2-loop	[D1/ CDR2-loop]	0.0	2	1	1	1
74935	1710	first group),	[first group),]	0.0	2	1	1	1
74936	1710	anti-CD3 proliferation	[anti-CD3 proliferation]	0.0	2	1	1	1
74937	1710	induction differentiation of a monocyte	[induction differentiation of a monocyte]	0.0	5	1	1	1
74938	1710	erythroid burst-forming unit	[erythroid burst-forming units]	0.0	3	1	1	1
74939	1710	potent sequence	[potent sequence]	0.0	2	1	1	1
74940	1710	highly polymorphic tandem repeat	[highly polymorphic tandem repeat]	0.0	4	1	1	1
74941	1710	study the link between differentiation	[studying the link between differentiation]	0.0	5	1	1	1
74942	1710	neutrophilic cell	[neutrophilic cells]	0.0	2	1	1	1
74943	1710	interleukin (il) 4 gene	[interleukin (IL) 4 gene]	0.0	4	1	1	1
74944	1710	plate-bound anti-CD3 antibody mab	[plate-bound anti-CD3 antibody mAb]	0.0	4	1	1	1
74945	1710	pretranslational control mechanism	[pretranslational control mechanisms]	0.0	3	1	1	1
74946	1710	cell line NIH 3t3	[cell lines NIH 3T3]	0.0	4	1	1	1
74947	1710	normal counterpart to human leukemia	[normal counterpart to human leukemias]	0.0	5	1	1	1
74948	1710	up-regulate gene expression hiv-1 terminal repeat	[up-regulate gene expression HIV-1 terminal repeats]	0.0	6	1	1	1
74949	1710	activity in lymphoid cell	[activity in lymphoid cells]	0.0	4	1	1	1
74950	1710	acid a vitamin a derivative	[acid a vitamin A derivative]	0.0	5	1	1	1
74951	1710	suppress at least two pathway	[suppressing at least two pathways]	0.0	5	1	1	1
74952	1710	nf-il6 gene	[NF-IL6 gene]	0.0	2	1	1	1
74953	1710	lymphocyte-tropic strain of hiv-1	[lymphocyte-tropic strains of HIV-1]	0.0	4	1	1	1
74954	1710	induction of hiv-1 provirus	[induction of HIV-1 provirus]	0.0	4	1	1	1
74955	1710	atypical clinical feature	[atypical clinical features]	0.0	3	1	1	1
74956	1710	case of t-cell lymphoma with gcs	[cases of T-cell lymphoma with GCs]	0.0	6	1	1	1
74957	1710	interleukin a activator	[interleukin a activator]	0.0	3	1	1	1
74958	1710	multimerize the element	[multimerizing the elements]	0.0	3	1	1	1
74959	1710	use anti-ERK kinase antibody	[using anti-ERK kinase antibodies]	0.0	4	1	1	1
74960	1710	sla-dra	[SLA-DRA]	0.0	1	1	1	1
74961	1710	similar mechanism	[similar mechanisms]	0.0	2	1	1	1
74962	1710	hla class antigen expression	[HLA class antigens expression]	0.0	4	1	1	1
74963	1710	inhibition of phorbol ester nf-at activation	[inhibition of phorbol ester NF-AT activation]	0.0	6	1	1	1
74964	1710	transcription factor nf-il4	[transcription factor NF-IL4]	0.0	3	1	1	1
74965	1710	suggest a target for protein	[suggesting a target for proteins]	0.0	5	1	1	1
74966	1710	analysis of Epstein-Barr virus gene expression	[analysis of Epstein-Barr virus gene expression]	0.0	6	1	1	1
74967	1710	arthritis, binding	[arthritis, binding]	0.0	2	1	1	1
74968	1710	species of NFATc (of 110	[species of NFATc (of 110]	0.0	5	1	1	1
74969	1710	high dose result on tissue oligonucleotide	[High doses resulting on tissue oligonucleotide]	0.0	6	1	1	1
74970	1710	induction by interferon-gamma	[induction by interferon-gamma]	0.0	3	1	1	1
74971	1710	Culture in m 9-cis RA	[Culture in M 9-cis RA]	0.0	5	1	1	1
74972	1710	6 h peak at h.	[6 h peaks at h,]	0.0	5	1	1	1
74973	1710	role cause transformation	[role causing transformation]	0.0	3	1	1	1
74974	1710	3t3-l1 adipocyte	[3T3-L1 adipocytes]	0.0	2	2	2	1
74975	1710	trophoblast invasion	[trophoblast invasion]	0.0	2	1	1	1
74976	1710	positive regulator neutralize antibody	[positive regulator neutralizing antibodies]	0.0	4	1	1	1
74977	1710	concentration microM)	[concentrations microM)]	0.0	2	1	1	1
74978	1710	challenge cell	[challenging cells]	0.0	2	1	1	1
74979	1710	reduction in the induction	[reduction in the induction]	0.0	4	1	1	1
74980	1710	RA addition	[RA addition]	0.0	2	1	1	1
74981	1710	induction protein differentiation	[induction protein differentiation]	0.0	3	1	1	1
74982	1710	stimuli, tcr	[stimuli, TCR]	0.0	2	1	1	1
74983	1710	aberrancy important	[aberrancies important]	0.0	2	1	1	1
74984	1710	(ii) maintenance	[(ii) maintenance]	0.0	2	1	1	1
74985	1710	inducible promoter synergistic activation	[inducible promoter synergistic activation]	0.0	4	1	1	1
74986	1710	synergistic activity of Jun	[synergistic activity of Jun]	0.0	4	1	1	1
74987	1710	pagc	[pagC]	0.0	1	1	1	1
74988	1710	oncogene-initiated rat mammary carcinoma	[oncogene-initiated rat mammary carcinomas]	0.0	4	1	1	1
74989	1710	cell type to bacterial lipopolysaccharide	[cell types to bacterial lipopolysaccharide]	0.0	5	1	1	1
74990	1710	familial cancer patient	[familial cancer patient]	0.0	3	1	1	1
74991	1710	strong production	[strong production]	0.0	2	1	1	1
74992	1710	25 pregnancy by measurement	[25 pregnancies by measurement]	0.0	4	1	1	1
74993	1710	transmembrane potential delta	[transmembrane potential delta]	0.0	3	1	1	1
74994	1710	acute leukemia cell line thp-1	[acute leukemia cell line THP-1]	0.0	5	1	1	1
74995	1710	type of reactivity: il-13	[types of reactivity: IL-13]	0.0	4	1	1	1
74996	1710	additional putative sites.	[additional putative sites.]	0.0	3	1	1	1
74997	1710	red cell-specific activator	[red cell-specific activator]	0.0	3	1	1	1
74998	1710	datum support a new, model	[data supporting a new, model]	0.0	5	1	1	1
74999	1710	such cell surface molecule	[such cell surface molecules]	0.0	4	1	1	1
75000	1710	AP-1 by p21ras	[AP-1 by p21ras]	0.0	3	1	1	1
75001	1710	cell with fk506	[cells with FK506]	0.0	3	1	1	1
75002	1710	distinct family of factor	[distinct families of factors]	0.0	4	1	1	1
75003	1710	absorptive hypercalciuria condition	[Absorptive hypercalciuria condition]	0.0	3	1	1	1
75004	1710	little definite information about role	[little definite information about roles]	0.0	5	1	1	1
75005	1710	early signalling	[early signalling]	0.0	2	1	1	1
75006	1710	specific gene include interleukin-2	[specific genes including interleukin-2]	0.0	4	1	1	1
75007	1710	hydrocarbons pah	[hydrocarbons PAHs]	0.0	2	1	1	1
75008	1710	transfection analysis of the -66 region	[transfection analysis of the -66 region]	0.0	6	1	1	1
75009	1710	increase in m phi uptake	[increases in M phi uptake]	0.0	5	1	1	1
75010	1710	expression normal lymphoid tissue	[expression normal lymphoid tissues]	0.0	4	1	1	1
75011	1710	lymphoma rael	[lymphoma Rael]	0.0	2	1	1	1
75012	1710	Comparison to virus peptide by cell	[Comparison to virus peptides by cells]	0.0	6	1	1	1
75013	1710	use of agent	[use of agents]	0.0	3	1	1	1
75014	1710	minimal region responsible for expression	[minimal region responsible for expression]	0.0	5	1	1	1
75015	1710	production of double-positive population	[production of double-positive populations]	0.0	4	1	1	1
75016	1710	normal lymph node cell	[normal lymph node cells]	0.0	4	1	1	1
75017	1710	exon span 45 kb	[exons spanning 45 kb]	0.0	4	1	1	1
75018	1710	great low activity.	[greater lower activity.]	0.0	3	1	1	1
75019	1710	proximal enhancer	[proximal enhancer]	0.0	2	1	1	1
75020	1710	hypereosinophilic syndrome IHES	[hypereosinophilic syndrome IHES]	0.0	3	1	1	1
75021	1710	human monocyte il-1	[Human monocyte IL-1]	0.0	3	1	1	1
75022	1710	use human monocyte	[using human monocytes]	0.0	3	1	1	1
75023	1710	gp41 il-10 production	[gp41 IL-10 production]	0.0	3	1	1	1
75024	1710	Ran -binding domain of the nucleoporin	[Ran -binding domains of the nucleoporin]	0.0	6	1	1	1
75025	1710	suggest expression	[suggesting expression]	0.0	2	1	1	1
75026	1710	4) clone of CVZ cell	[4) clones of CVZ cells]	0.0	5	1	1	1
75027	1710	egr-1 mrna expression	[EGR-1 mRNA expression]	0.0	3	1	1	1
75028	1710	production in Jurkat cell	[production in Jurkat cells]	0.0	4	1	1	1
75029	1710	dominant mutant of the IL-1 pathway	[dominant mutants of the IL-1 pathway]	0.0	6	1	1	1
75030	1710	(45-50 min) in acid cell	[(45-50 min) in acid cells]	0.0	5	1	1	1
75031	1710	suggest a transcriptional repressive effect	[suggesting a transcriptional repressive effect]	0.0	5	1	1	1
75032	1710	important positive element	[important positive element]	0.0	3	1	1	1
75033	1710	x-linked atrophy a form	[X-linked atrophy an form]	0.0	4	1	1	1
75034	1710	reaction at stages.	[reactions at stages.]	0.0	3	1	1	1
75035	1710	invasive breast cancer	[invasive breast cancer]	0.0	3	1	1	1
75036	1710	expression a stat1alpha gene	[Expression a STAT1alpha gene]	0.0	4	1	1	1
75037	1710	hepatic nuclear factor	[hepatic nuclear factor]	0.0	3	1	1	1
75038	1710	two immediate-early transactivator	[two immediate-early transactivators]	0.0	3	1	1	1
75039	1710	regulator of class gene transcription	[regulator of class gene transcription]	0.0	5	1	1	1
75040	1710	protein tumor	[protein tumor]	0.0	2	1	1	1
75041	1710	serum concentration	[serum concentration]	0.0	2	1	1	1
75042	1710	substantial affect	[substantial affect]	0.0	2	1	1	1
75043	1710	two cysteine region	[two cysteine regions]	0.0	3	1	1	1
75044	1710	sixteen anorexic patient	[Sixteen anorexic patients]	0.0	3	1	1	1
75045	1710	expose vein cell to anoxia/reoxygenation	[Exposing vein cells to anoxia/reoxygenation]	0.0	5	1	1	1
75046	1710	entities.	[entities.]	0.0	1	1	1	1
75047	1710	binding site on the surface	[Binding sites on the surface]	0.0	5	1	1	1
75048	1710	reason(s)	[reason(s)]	0.0	1	1	1	1
75049	1710	bone cell line bms2.4	[bone cell line BMS2.4]	0.0	4	1	1	1
75050	1710	(aml) blast	[(AML) blasts]	0.0	2	1	1	1
75051	1710	bovine pulmonary artery endothelial cell	[bovine pulmonary artery endothelial cells]	0.0	5	1	1	1
75052	1710	tat activation in T cell	[Tat activation in T cells]	0.0	5	1	1	1
75053	1710	fiberoptic bronchoscopy with biopsy	[fiberoptic bronchoscopy with biopsy]	0.0	4	1	1	1
75054	1710	rearrangement in the great ape	[rearrangements in the great apes]	0.0	5	1	1	1
75055	1710	follow culture	[Following culture]	0.0	2	1	1	1
75056	1710	expression in human T cell	[Expression in human T cells]	0.0	5	1	1	1
75057	1710	Thrombopoietin the regulator	[Thrombopoietin the regulator]	0.0	3	1	1	1
75058	1710	cis-linked regulatory sequence	[cis-linked regulatory sequences]	0.0	3	1	1	1
75059	1710	means of a pathway	[means of an pathway]	0.0	4	1	1	1
75060	1710	50% displacement of estradiol	[50% displacement of estradiol]	0.0	4	1	1	1
75061	1710	potent inhibitory effect	[potent inhibitory effect]	0.0	3	1	1	1
75062	1710	inhibitor from NF-kappa b	[inhibitor from NF-kappa B]	0.0	4	1	1	1
75063	1710	use pkc inhibitors, pentoxifylline	[using PKC inhibitors, pentoxifylline]	0.0	4	1	1	1
75064	1710	T cell nfatc	[T cell NFATc]	0.0	3	1	1	1
75065	1710	chronic failure patient	[chronic failure patients]	0.0	3	1	1	1
75066	1710	Nonpituitary prolactin gene transcription	[Nonpituitary prolactin gene transcription]	0.0	4	1	1	1
75067	1710	lead by tax	[leading by Tax]	0.0	3	1	1	1
75068	1710	migration of T cell	[migration of T cells]	0.0	4	1	1	1
75069	1710	element for the transcriptional regulation	[element for the transcriptional regulation]	0.0	5	1	1	1
75070	1710	cytokine granulocyte/macrophage colony-stimulating factor	[cytokines granulocyte/macrophage colony-stimulating factor]	0.0	4	1	1	1
75071	1710	autoregulation of gr expression in cell	[autoregulation of GR expression in cells]	0.0	6	1	1	1
75072	1710	CTG-motif	[CTG-motif]	0.0	1	1	1	1
75073	1710	aldosterone in lymphocyte	[aldosterone in lymphocytes]	0.0	3	1	1	1
75074	1710	t-lymphocyte from individual with inflammatory disease	[T-lymphocytes from individuals with inflammatory disease]	0.0	6	1	1	1
75075	1710	cis-acting element of the factor gm-csf	[cis-acting elements of the factor GM-CSF]	0.0	6	1	1	1
75076	1710	concentration within the cultures.	[concentration within the cultures.]	0.0	4	1	1	1
75077	1710	murine transcription factor gene	[murine transcription factor gene]	0.0	4	1	1	1
75078	1710	ap1 binding	[AP1 binding]	0.0	2	1	1	1
75079	1710	activation of erythroid-specific gene	[activation of erythroid-specific genes]	0.0	4	1	1	1
75080	1710	pc60	[PC60]	0.0	1	1	1	1
75081	1710	adhesion umbilical vein cell	[adhesion umbilical vein cells]	0.0	4	1	1	1
75082	1710	intestinal cell apoptosis	[intestinal cell apoptosis]	0.0	3	1	1	1
75083	1710	10, leiomyosarcoma liposarcoma 5).	[10, leiomyosarcoma liposarcoma 5).]	0.0	4	1	1	1
75084	1710	year (mean	[yr (mean]	0.0	2	1	1	1
75085	1710	affinity for testosterone	[affinity for testosterone]	0.0	3	1	1	1
75086	1710	Lewis X antigen	[Lewis X antigen]	0.0	3	1	1	1
75087	1710	synergistic effect on cytotoxicity	[synergistic effect on cytotoxicity]	0.0	4	1	1	1
75088	1710	most lymphocyte line	[Most lymphocyte lines]	0.0	3	1	1	1
75089	1710	125d3 -priming stage	[1,25D3 -priming stage]	0.0	3	1	1	1
75090	1710	osteoprotegerin ligand OPGL	[osteoprotegerin ligand OPGL]	0.0	3	1	1	1
75091	1710	factor-kappaB activity	[factor-kappaB activity]	0.0	2	1	1	1
75092	1710	GM-CSF cell	[GM-CSF cells]	0.0	2	1	1	1
75093	1710	5' genomic clone	[5' genomic clone]	0.0	3	1	1	1
75094	1710	t-leukemia cell line	[T-leukemia cell lines]	0.0	3	1	1	1
75095	1710	SLP-76 hematopoietic cell molecule	[SLP-76 hematopoietic cell molecules]	0.0	4	1	1	1
75096	1710	long effect with low dose	[long-term effects with low doses]	0.0	5	1	1	1
75097	1710	target of this regulation in vivo	[target of this regulation in vivo]	0.0	6	1	1	1
75098	1710	sequence in the element	[sequence in the element]	0.0	4	1	1	1
75099	1710	interleukin-4 on endothelial cell	[interleukin-4 on endothelial cells]	0.0	4	1	1	1
75100	1710	intestinal cell response	[intestinal cell responses]	0.0	3	1	1	1
75101	1710	regulatory molecule during a phase	[regulatory molecule during a phase]	0.0	5	1	1	1
75102	1710	osteoblast extract-DNA complex	[osteoblast extract-DNA complexes]	0.0	3	1	1	1
75103	1710	effect relative	[effects relative]	0.0	2	1	1	1
75104	1710	cercopithicine herpesvirus herpesvirus papio	[cercopithicine herpesvirus herpesvirus papio]	0.0	4	1	1	1
75105	1710	gene in primary lymphoid cell	[genes in primary lymphoid cells]	0.0	5	1	1	1
75106	1710	suppression of nf-kappa b activity	[suppression of NF-kappa B activity]	0.0	5	1	1	1
75107	1710	substrate rap1	[substrates, Rap1]	0.0	2	1	1	1
75108	1710	three order of magnitude potent	[three orders of magnitude potent]	0.0	5	1	1	1
75109	1710	decrease in the component	[decreases in the components]	0.0	4	1	1	1
75110	1710	trigger CR1 cd35	[triggering CR1 CD35]	0.0	3	2	2	1
75111	1710	require more glucocorticoid	[requiring more glucocorticoids]	0.0	3	1	1	1
75112	1710	aim identify target	[aim identifying targets]	0.0	3	1	1	1
75113	1710	nonhematopoietic cell line 3t3	[nonhematopoietic cell lines 3T3]	0.0	4	1	1	1
75114	1710	expression of this cytokine gene	[expression of these cytokine genes]	0.0	5	1	1	1
75115	1710	molecular mechanism for the effect	[molecular mechanism for the effect]	0.0	5	1	1	1
75116	1710	e1b mutant genome	[E1B mutant genome]	0.0	3	1	1	1
75117	1710	il-2 target in lymphocyte	[IL-2 target in lymphocytes]	0.0	4	1	1	1
75118	1710	suggest primarily dependent on constraint	[suggesting primarily dependent on constraints]	0.0	5	1	1	1
75119	1710	chain gene enhancer by proteins.	[chain gene enhancer by proteins.]	0.0	5	1	1	1
75120	1710	27 child	[27 children]	0.0	2	1	1	1
75121	1710	encode hnf-3alpha	[encoding HNF-3alpha]	0.0	2	1	1	1
75122	1710	Thus, lps activation of cell	[Thus, LPS activation of cells]	0.0	5	1	1	1
75123	1710	role switch	[Role switching]	0.0	2	1	1	1
75124	1710	cell express CD40	[cells expressing CD40]	0.0	3	1	1	1
75125	1710	murine RA	[murine RA]	0.0	2	1	1	1
75126	1710	signal intermediate	[signaling intermediate]	0.0	2	1	1	1
75127	1710	combination pu.1 in cell	[combination PU.1 in cells]	0.0	4	1	1	1
75128	1710	pax1	[PAX1]	0.0	1	1	1	1
75129	1710	alpha mip-1 alpha	[alpha MIP-1 alpha]	0.0	3	1	1	1
75130	1710	fluticasone propionate in mucosa	[fluticasone propionate in mucosa]	0.0	4	1	1	1
75131	1710	encounter with antigen, cd4+ T	[encounter with antigen, CD4+ T]	0.0	5	1	1	1
75132	1710	supplement the culture with high dose	[supplementing the cultures with high doses]	0.0	6	1	1	1
75133	1710	firm basis for molecular mimicry	[firm basis for molecular mimicry]	0.0	5	1	1	1
75134	1710	PML/RAR alpha transcript	[PML/RAR alpha transcript]	0.0	3	1	1	1
75135	1710	chronic leukemia to combination chemotherapy	[chronic leukemia to combination chemotherapy]	0.0	5	1	1	1
75136	1710	9 adult	[9 adults]	0.0	2	1	1	1
75137	1710	nh2- terminal domain	[NH2- terminal domains]	0.0	3	1	1	1
75138	1710	single cd34+thy-1+ cell	[single CD34+Thy-1+ cells]	0.0	3	1	1	1
75139	1710	B/GC-box	[B/GC-box]	0.0	1	1	1	1
75140	1710	analysis of a occur mutation	[analysis of a occurring mutation]	0.0	5	1	1	1
75141	1710	-257 to +74 region	[-257 to +74 region]	0.0	4	1	1	1
75142	1710	share homology with Stat1	[share homology with Stat1]	0.0	4	1	1	1
75143	1710	ability of dexamethasone	[ability of dexamethasone]	0.0	3	1	1	1
75144	1710	receptor kinase	[receptor kinase]	0.0	2	1	1	1
75145	1710	pkc signal system	[PKC signaling systems]	0.0	3	1	1	1
75146	1710	cd14(+)	[CD14(+)]	0.0	1	1	1	1
75147	1710	weight form in cell line	[weight forms in cell lines]	0.0	5	1	1	1
75148	1710	thirty percent	[Thirty percent]	0.0	2	1	1	1
75149	1710	tnf-alpha mrna induction	[TNF-alpha mRNA induction]	0.0	3	2	2	1
75150	1710	binding of human il-2 to site	[binding of human IL-2 to site]	0.0	6	1	1	1
75151	1710	101pp erythroid-specific dnase site-forming element	[101bp, erythroid-specific DNase site-forming element]	0.0	5	1	1	1
75152	1710	SR-BP gene expression	[SR-BP gene expression]	0.0	3	1	1	1
75153	1710	common syndrome	[common syndrome]	0.0	2	1	1	1
75154	1710	protein such as soluble e-selectin	[proteins such as soluble E-selectin]	0.0	5	1	1	1
75155	1710	tax transform protein	[Tax transforming protein]	0.0	3	1	1	1
75156	1710	cd16 ligand	[CD16 ligands]	0.0	2	2	2	1
75157	1710	therapy in patient	[therapy in patients]	0.0	3	1	1	1
75158	1710	high concentration of native peptide	[high concentrations of native peptide]	0.0	5	1	1	1
75159	1710	granulocyte-macrophage CSF gm-csf gene	[granulocyte-macrophage CSF GM-CSF gene]	0.0	4	1	1	1
75160	1710	control-transduced pre-T cell	[control-transduced pre-T cells]	0.0	3	1	1	1
75161	1710	transcription factor nf-y	[transcription factor NF-Y]	0.0	3	1	1	1
75162	1710	tbp7 sequence	[TBP7 sequence]	0.0	2	1	1	1
75163	1710	effect (lps)-induced monocyte tnf-alpha production	[effect (LPS)-induced monocyte TNF-alpha production]	0.0	5	1	1	1
75164	1710	promote the selective NK clearance	[promoting the selective NK clearance]	0.0	5	1	1	1
75165	1710	tumor-draining lymph	[tumor-draining lymph]	0.0	2	1	1	1
75166	1710	role in early tissue damage	[role in early tissue damage]	0.0	5	1	1	1
75167	1710	disease in myelogenous leukemia	[disease in myelogenous leukemia]	0.0	4	1	1	1
75168	1710	disease for to 80%	[disease for to 80%]	0.0	4	1	1	1
75169	1710	general cellular transcription factor	[general cellular transcription factors]	0.0	4	1	1	1
75170	1710	oligonucleotide probe corresponding	[oligonucleotide probe corresponding]	0.0	3	1	1	1
75171	1710	exposure to level of ligand	[exposure to levels of ligand]	0.0	5	1	1	1
75172	1710	role of erk and/or p38	[roles of ERK and/or p38]	0.0	5	1	1	1
75173	1710	configuration of gm-csf	[configuration of GM-CSF]	0.0	3	1	1	1
75174	1710	C3H mouse	[C3H mice]	0.0	2	1	1	1
75175	1710	triepoxide	[triepoxide]	0.0	1	1	1	1
75176	1710	early treatment hpc with alpha-pml	[early treatment HPCs with alpha-PML]	0.0	5	1	1	1
75177	1710	suggest a aberrant consequence of memory	[suggesting an aberrant consequence of memory]	0.0	6	1	1	1
75178	1710	usually, STAT3	[usually, STAT3]	0.0	2	1	1	1
75179	1710	Cowan	[Cowan]	0.0	1	1	1	1
75180	1710	simian blood mononuclear cell	[simian blood mononuclear cells]	0.0	4	1	1	1
75181	1710	forty fms patient	[Forty FMS patients]	0.0	3	1	1	1
75182	1710	expression of gamma-ifn gene	[Expression of gamma-IFN genes]	0.0	4	1	1	1
75183	1710	proliferation of endothelial	[proliferation of endothelial]	0.0	3	1	1	1
75184	1710	transformation in myelogenous leukemia	[transformation in myelogenous leukemia]	0.0	4	1	1	1
75185	1710	disorders: xeroderma pigmentosum XP	[disorders: xeroderma pigmentosum XP]	0.0	4	1	1	1
75186	1710	log-fold glucocorticoid for a equivalent degree	[log-fold glucocorticoids for an equivalent degree]	0.0	6	1	1	1
75187	1710	non-B cell line	[non-B cell lines]	0.0	3	1	1	1
75188	1710	Rhombotin-2	[Rhombotin-2]	0.0	1	1	1	1
75189	1710	gene therapy trials,	[gene therapy trials,]	0.0	3	1	1	1
75190	1710	mediator of b cell growth	[mediator of B cell growth]	0.0	5	1	1	1
75191	1710	two healthy man	[two healthy men]	0.0	3	1	1	1
75192	1710	acute leukemia (apl) cell	[acute leukemia (APL) cells]	0.0	4	2	2	1
75193	1710	human b-cell lymphoma lymphoma	[human B-cell lymphomas lymphomas]	0.0	4	1	1	1
75194	1710	defective binding	[defective binding]	0.0	2	1	1	1
75195	1710	leukocyte undergo apoptosis	[leukocytes undergoing apoptosis]	0.0	3	1	1	1
75196	1710	shuttling of NF-AT	[shuttling of NF-AT]	0.0	3	1	1	1
75197	1710	property common to	[properties common to]	0.0	3	1	1	1
75198	1710	macrophage in activation of NF-kappaB	[macrophages in activation of NF-kappaB]	0.0	5	1	1	1
75199	1710	hiv infection of U937 cell	[HIV infection of U937 cells]	0.0	5	1	1	1
75200	1710	value as a "stress" buffer,	[value as a "stress" buffer,]	0.0	5	1	1	1
75201	1710	nm 12-o-tetradecanoylphorbol-13-acetate	[nM 12-O-tetradecanoylphorbol-13-acetate]	0.0	2	1	1	1
75202	1710	normal development of cell	[normal development of cells]	0.0	4	1	1	1
75203	1710	efficiently arrest differentiation of cell progenitor	[efficiently arresting differentiation of cell progenitors]	0.0	6	1	1	1
75204	1710	interleukin-2 a cytokine	[interleukin-2 a cytokine]	0.0	3	1	1	1
75205	1710	transformation of a cell	[transformation of a cell]	0.0	4	1	1	1
75206	1710	g1 phase gene	[G1 phase gene]	0.0	3	1	1	1
75207	1710	lps event	[LPS event]	0.0	2	1	1	1
75208	1710	inflammatory-type condition	[inflammatory-type conditions]	0.0	2	1	1	1
75209	1710	mechanism for il-10 suppression	[mechanism for IL-10 suppression]	0.0	4	1	1	1
75210	1710	estradiol inactivation	[estradiol inactivation]	0.0	2	1	1	1
75211	1710	translocation of stat3	[translocation of stat3]	0.0	3	3	3	1
75212	1710	criteria, include tyrosine phosphorylation	[criteria, including tyrosine phosphorylation]	0.0	4	1	1	1
75213	1710	translocation of stat6	[translocation of STAT6]	0.0	3	2	2	1
75214	1710	binding of several transcription factor	[binding of several transcription factors]	0.0	5	1	1	1
75215	1710	MHC hla-dra class gene	[MHC HLA-DRA class gene]	0.0	4	1	1	1
75216	1710	contrast to transient pattern	[contrast to transient pattern]	0.0	4	1	1	1
75217	1710	role transduce membrane-associated signal	[role transducing membrane-associated signals]	0.0	4	1	1	1
75218	1710	group of 33 patient	[group of 33 patients]	0.0	4	1	1	1
75219	1710	tcr-regulated ptk to signal pathway	[TCR-regulated PTKs to signaling pathways]	0.0	5	1	1	1
75220	1710	in-situ detection	[In-situ detection]	0.0	2	1	1	1
75221	1710	alpha 4 beta ligation	[alpha 4 beta ligation]	0.0	4	1	1	1
75222	1710	cell of the cerebral cortex	[cells of the cerebral cortex]	0.0	5	1	1	1
75223	1710	overexpression of hemoglobin	[overexpression of hemoglobin]	0.0	3	1	1	1
75224	1710	pu.1 Spi-1	[PU.1 Spi-1]	0.0	2	1	1	1
75225	1710	STAT1(alpha)	[STAT1(alpha)]	0.0	1	1	1	1
75226	1710	representative sample	[representative samples]	0.0	2	1	1	1
75227	1710	factor lymphocyte	[factor lymphocytes]	0.0	2	1	1	1
75228	1710	15-mer AS oligonucleotide	[15-mer AS oligonucleotides]	0.0	3	1	1	1
75229	1710	prospective trial	[prospective trial]	0.0	2	1	1	1
75230	1710	contrast to GATA-1	[contrast to GATA-1]	0.0	3	1	1	1
75231	1710	number of predictions.	[number of predictions.]	0.0	3	1	1	1
75232	1710	IRF-1 pathway	[IRF-1 pathway]	0.0	2	1	1	1
75233	1710	mouse DNA clone for CPO	[mouse DNA clones for CPO]	0.0	5	1	1	1
75234	1710	comparative analysis of nfat nuclear factor	[Comparative analysis of NFAT nuclear factor]	0.0	6	1	1	1
75235	1710	B-lymphoblastoid cell line from sclerosis patient	[B-lymphoblastoid cell lines from sclerosis patients]	0.0	6	1	1	1
75236	1710	two set of protein	[two sets of proteins]	0.0	4	1	1	1
75237	1710	human granulocyte colony-stimulating factor receptor	[human granulocyte colony-stimulating factor receptor]	0.0	5	1	1	1
75238	1710	two immediate-early transactivator BZLF1	[two immediate-early transactivators BZLF1]	0.0	4	1	1	1
75239	1710	terminal differentiation of mpro promyelocyte	[terminal differentiation of MPRO promyelocytes]	0.0	5	1	1	1
75240	1710	none of the three protein	[none of the three proteins]	0.0	5	1	1	1
75241	1710	link via the involvement	[link via the involvement]	0.0	4	1	1	1
75242	1710	monocyte to macrophage protein	[monocytes to macrophage proteins]	0.0	4	1	1	1
75243	1710	T cell-specific regulatory element	[T cell-specific regulatory element]	0.0	4	1	1	1
75244	1710	establish high-density pbmc culture (1.5	[establishing high-density PBMC cultures (1.5]	0.0	5	1	1	1
75245	1710	activation of two form of stat3	[activation of two forms of STAT3]	0.0	6	1	1	1
75246	1710	dominant-negative factor	[dominant-negative factor]	0.0	2	1	1	1
75247	1710	separation on two-lay percoll gradient	[separation on two-layer Percoll gradients]	0.0	5	1	1	1
75248	1710	susceptibility to pcdd with respect	[susceptibility to PCDDs/PCDFs with respect]	0.0	5	1	1	1
75249	1710	e-protein gene	[E-protein genes]	0.0	2	1	1	1
75250	1710	cell line Daudi	[cell lines Daudi]	0.0	3	1	1	1
75251	1710	-inducible DNA	[-inducible DNA]	0.0	2	1	1	1
75252	1710	constitutive basal phosphorylation of Jak3 STAT3	[Constitutive basal phosphorylation of Jak3 STAT3]	0.0	6	1	1	1
75253	1710	proinflammatory transcription factor nuclear factor-kappaB	[proinflammatory transcription factor nuclear factor-kappaB]	0.0	5	1	1	1
75254	1710	stabilization of the complex	[stabilization of the complexes]	0.0	4	2	2	1
75255	1710	MCM member	[MCM members,]	0.0	2	1	1	1
75256	1710	event of renal inflammation	[events of renal inflammation]	0.0	4	1	1	1
75257	1710	differentiation of U937 histiocytic lymphoma cell	[differentiation of U937 histiocytic lymphoma cells]	0.0	6	1	1	1
75258	1710	various cell lineage	[various cell lineages]	0.0	3	1	1	1
75259	1710	3 kda.	[3 kDa.]	0.0	2	1	1	1
75260	1710	differentiation, hiv transcription	[differentiation, HIV transcription]	0.0	3	1	1	1
75261	1710	include malignancy	[including malignancies]	0.0	2	1	1	1
75262	1710	c-fo expression in b-cell	[c-fos expression in B-cells]	0.0	4	1	1	1
75263	1710	cellular protein bind in a manner	[cellular proteins binding in a manner]	0.0	6	1	1	1
75264	1710	bind activity of b	[binding activity of B]	0.0	4	1	1	1
75265	1710	viruses, like the Herpesviruses	[viruses, like the Herpesviruses]	0.0	4	1	1	1
75266	1710	cyclosporin mutant in yeast	[cyclosporin mutants in yeast]	0.0	4	1	1	1
75267	1710	long-term inositol	[Long-term inositol]	0.0	2	1	1	1
75268	1710	domain of interleukin-9 receptor alpha chain	[domains of interleukin-9 receptor alpha chain]	0.0	6	1	1	1
75269	1710	various extracellular signal often converge	[Various extracellular signals often converging]	0.0	5	1	1	1
75270	1710	wound healing,	[wound healing,]	0.0	2	1	1	1
75271	1710	disorder: lack of evidence	[disorder: lack of evidence]	0.0	4	1	1	1
75272	1710	Stable expression	[Stable expression]	0.0	2	3	3	1
75273	1710	granule mediate early inflammatory response	[granules mediating early inflammatory responses]	0.0	5	1	1	1
75274	1710	APL blast available from patient	[APL blasts available from patients]	0.0	5	1	1	1
75275	1710	use the potent pkc inhibitor 31-8425	[using the potent PKC inhibitor 31-8425]	0.0	6	1	1	1
75276	1710	patient with dysplasia	[patients with dysplasia]	0.0	3	1	1	1
75277	1710	regulatory region of gene	[regulatory regions of genes]	0.0	4	1	1	1
75278	1710	primer product	[primer products]	0.0	2	1	1	1
75279	1710	step-wise	[step-wise]	0.0	1	1	1	1
75280	1710	a function in the cell	[A function in the cell]	0.0	5	1	1	1
75281	1710	hepatic injury with alpha-tocopherol a scavenger	[hepatic injury with alpha-tocopherol a scavenger]	0.0	6	1	1	1
75282	1710	iron result	[iron resulting]	0.0	2	1	1	1
75283	1710	competitive enzyme-linked assay	[competitive enzyme-linked assay]	0.0	3	1	1	1
75284	1710	regard, level	[regard, levels]	0.0	2	1	1	1
75285	1710	powerful inducer of granulocytic maturation	[powerful inducer of granulocytic maturation]	0.0	5	1	1	1
75286	1710	effect on marker	[effects on markers]	0.0	3	1	1	1
75287	1710	several human myeloid leukemia cell line	[Several human myeloid leukemia cell lines]	0.0	6	1	1	1
75288	1710	Epstein-Barr virus oncogene product	[Epstein-Barr virus oncogene product]	0.0	4	1	1	1
75289	1710	placental alkaline phosphatase reporter gene	[placental alkaline phosphatase reporter gene]	0.0	5	1	1	1
75290	1710	little nf kappa b p50	[little NF kappa B p50]	0.0	5	1	1	1
75291	1710	encompass a sequence within the stretch	[encompassing a sequence within the stretch]	0.0	6	1	1	1
75292	1710	TNF-alpha hiv-1 long repeat transcription	[TNF-alpha HIV-1 long repeat transcription]	0.0	5	1	1	1
75293	1710	proximal mouse Chr 11	[proximal mouse Chr 11]	0.0	4	1	1	1
75294	1710	kappaB-alpha IkappaB-alpha	[kappaB-alpha IkappaB-alpha]	0.0	2	1	1	1
75295	1710	inhibitor of GRalpha	[inhibitor of GRalpha]	0.0	3	1	1	1
75296	1710	neurologic dysfunction	[neurologic dysfunction]	0.0	2	1	1	1
75297	1710	trans-activation domain tad-b in peptide	[trans-activation domain TAD-B in peptide]	0.0	5	1	1	1
75298	1710	Comparison of group sequence	[Comparison of group sequences]	0.0	4	1	1	1
75299	1710	treatment with interferon alpha	[Treatment with interferon alpha]	0.0	4	1	1	1
75300	1710	isoform to IL-2-	[isoforms to IL-2-]	0.0	3	1	1	1
75301	1710	unrearranged TcR delta transcript	[unrearranged TcR delta transcripts]	0.0	4	1	1	1
75302	1710	optimal NK function under condition	[optimal NK functions under conditions]	0.0	5	1	1	1
75303	1710	association between hla class antigen	[Associations between HLA class antigens]	0.0	5	1	1	1
75304	1710	burst upon arachidonic acid stimulation	[burst upon arachidonic acid stimulation]	0.0	5	1	1	1
75305	1710	modulation by lps mab	[modulation by LPS mAbs]	0.0	4	1	1	1
75306	1710	atg to Rex function	[ATGs to Rex function]	0.0	4	1	1	1
75307	1710	induction 1 expression in monocytic cell	[Induction 1 expression in monocytic cells]	0.0	6	1	1	1
75308	1710	mammalian rna (snrna) gene	[mammalian RNA (snRNA) genes]	0.0	4	1	1	1
75309	1710	far the most potent site	[far the most potent site]	0.0	5	1	1	1
75310	1710	Rheumatoid arthritis	[Rheumatoid arthritis]	0.0	2	1	1	1
75311	1710	monocytic cell type-specific induction of collagenase	[Monocytic cell type-specific induction of collagenase]	0.0	6	1	1	1
75312	1710	response to the two protein	[responses to the two proteins]	0.0	5	1	1	1
75313	1710	role for radical	[role for radicals]	0.0	3	1	1	1
75314	1710	activity of retinoid	[activity of retinoids]	0.0	3	1	1	1
75315	1710	native receptor characteristics.	[native receptor characteristics.]	0.0	3	1	1	1
75316	1710	receptor antagonist RU 486.	[receptor antagonist RU 486.]	0.0	4	1	1	1
75317	1710	IL-10 concentration u/ml.	[IL-10 concentration U/ml.]	0.0	3	1	1	1
75318	1710	EBNA2 synthesis of IFN-beta mrna	[EBNA2 synthesis of IFN-beta mRNA]	0.0	5	1	1	1
75319	1710	leukocyte to serum	[leukocytes to serum]	0.0	3	1	1	1
75320	1710	tumor-specific response	[tumor-specific responses]	0.0	2	1	1	1
75321	1710	implication for a component	[implications for a component]	0.0	4	1	1	1
75322	1710	component within minute	[component within min]	0.0	3	1	1	1
75323	1710	cell-free supernatant	[cell-free supernatant]	0.0	2	1	1	1
75324	1710	D3 VDR	[D3 VDR]	0.0	2	1	1	1
75325	1710	sequence of the latter region	[sequences of the latter region]	0.0	5	1	1	1
75326	1710	active protein tyrosine kinase	[active protein tyrosine kinase]	0.0	4	1	1	1
75327	1710	common element within promoter	[common element within promoters]	0.0	4	1	1	1
75328	1710	region promoter	[region promoters]	0.0	2	1	1	1
75329	1710	result in divergent expression	[resulting in divergent expression]	0.0	4	1	1	1
75330	1710	action of dopamine in cell	[action of dopamine in cells]	0.0	5	1	1	1
75331	1710	glucose-stimulated insulin secretion	[glucose-stimulated insulin secretion]	0.0	3	1	1	1
75332	1710	(p p 0.01	[(P P 0.01]	0.0	3	1	1	1
75333	1710	sensor for vcam regulation	[sensor for VCAM regulation]	0.0	4	1	1	1
75334	1710	contrast to pattern of induction	[contrast to pattern of induction]	0.0	5	1	1	1
75335	1710	to: acute exposure	[to: acute exposure]	0.0	3	1	1	1
75336	1710	exposure to signals, include cytokine	[exposure to signals, including cytokines]	0.0	5	1	1	1
75337	1710	contrast, amount	[contrast, amounts]	0.0	2	1	1	1
75338	1710	1.955-kb segment	[1.955-kb segment]	0.0	2	1	1	1
75339	1710	potent cytokine mrna expression in monocyte	[potent cytokine mRNA expression in monocytes]	0.0	6	1	1	1
75340	1710	different part	[different parts]	0.0	2	1	1	1
75341	1710	CD3 event	[CD3 event]	0.0	2	1	1	1
75342	1710	involvement in the control	[involvement in the control]	0.0	4	1	1	1
75343	1710	inhibitor of MEK1 kinase upstream	[inhibitors of MEK1 kinase upstream]	0.0	5	1	1	1
75344	1710	10(-8) g/g	[10(-8) g/g]	0.0	2	1	1	1
75345	1710	NFIL3/E4BP4 transcription factor	[NFIL3/E4BP4 transcription factor]	0.0	3	1	1	1
75346	1710	alteration in affinity	[alteration in affinity]	0.0	3	1	1	1
75347	1710	signal pathway lead to the induction	[signaling pathways leading to the induction]	0.0	6	1	1	1
75348	1710	rest vein cell	[resting vein cells]	0.0	3	1	1	1
75349	1710	retrovirus (es)	[retrovirus (es)]	0.0	2	1	1	1
75350	1710	two chain	[two chains]	0.0	2	1	1	1
75351	1710	2% concentration	[2% concentration]	0.0	2	1	1	1
75352	1710	microgram/ml), expression	[microgram/ml), expression]	0.0	2	1	1	1
75353	1710	immunoglobulin gene within the nucleus	[immunoglobulin genes within the nucleus]	0.0	5	1	1	1
75354	1710	tyrosine-phosphorylated follow granulocyte-colony stimulate factor treatment	[tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment]	0.0	6	1	1	1
75355	1710	use ap1 protein	[using AP1 proteins]	0.0	3	1	1	1
75356	1710	high amount of v-erbA	[high amounts of v-erbA]	0.0	4	1	1	1
75357	1710	human monocyte with ifn-gamma	[human monocytes with IFN-gamma]	0.0	4	1	1	1
75358	1710	other receptor	[other receptors]	0.0	2	1	1	1
75359	1710	contain near-perfect direct repeat	[containing near-perfect direct repeats]	0.0	4	1	1	1
75360	1710	liver pcd/dcoh	[liver PCD/DCoH]	0.0	2	1	1	1
75361	1710	granulocyte antibody of clinical significance.	[granulocyte antibodies of clinical significance.]	0.0	5	1	1	1
75362	1710	tyrosine -phosphorylated protein	[tyrosine -phosphorylated protein]	0.0	3	1	1	1
75363	1710	epitope dendritic cell	[epitope dendritic cells]	0.0	3	1	1	1
75364	1710	systemic effect on adrenal function	[systemic effects on adrenal function]	0.0	5	1	1	1
75365	1710	component for production of il-2	[components for production of IL-2]	0.0	5	1	1	1
75366	1710	persistence of CTL clone	[persistence of CTL clones]	0.0	4	1	1	1
75367	1710	role for a novel octamer sequence	[Role for a novel octamer sequence]	0.0	6	1	1	1
75368	1710	promyelocytic leukemia hl-60 cell	[promyelocytic leukemia HL-60 cells]	0.0	4	3	3	1
75369	1710	bone marrow transplantation BMT	[bone marrow transplantation BMT]	0.0	4	1	1	1
75370	1710	second translocation	[second translocation]	0.0	2	1	1	1
75371	1710	mechanism underlie phenomena.	[mechanisms underlying phenomena.]	0.0	3	1	1	1
75372	1710	/nf-kappab1	[/NF-kappaB1]	0.0	1	1	1	1
75373	1710	absence of p50	[absence of p50]	0.0	3	1	1	1
75374	1710	there, dex -resistant clone	[there, dex -resistant clones]	0.0	4	1	1	1
75375	1710	stage of infection	[stages of infection]	0.0	3	3	3	1
75376	1710	assay volume	[assay volume]	0.0	2	1	1	1
75377	1710	aberrant expression of interferon factor	[aberrant expression of interferon factor]	0.0	5	1	1	1
75378	1710	response to alpha-IFN	[response to alpha-IFN]	0.0	3	1	1	1
75379	1710	inhibitory effect on gr transcription	[inhibitory effect on GR transcription]	0.0	5	1	1	1
75380	1710	tnf mrna expression	[TNF mRNA expression]	0.0	3	1	1	1
75381	1710	DNA-protein binding assay with extract	[DNA-protein binding assays with extracts]	0.0	5	1	1	1
75382	1710	activation of a infection	[activation of a infection]	0.0	4	1	1	1
75383	1710	cytokine important in the generation	[cytokine important in the generation]	0.0	5	1	1	1
75384	1710	variation in cortisol concentration	[variation in cortisol concentration]	0.0	4	1	1	1
75385	1710	silencer,	[silencer,]	0.0	1	1	1	1
75386	1710	result from healthy volunteer	[results from healthy volunteers]	0.0	4	1	1	1
75387	1710	less magnitude	[lesser magnitude]	0.0	2	1	1	1
75388	1710	protein contain domain	[protein containing domains]	0.0	3	1	1	1
75389	1710	daily oral replacement dose	[daily oral replacement dose]	0.0	4	1	1	1
75390	1710	expression of a mutation	[expression of a mutation]	0.0	4	1	1	1
75391	1710	long follow lps stimulation in addition	[longer following LPS stimulation in addition]	0.0	6	1	1	1
75392	1710	immunodeficiency virus-1 in T cell	[immunodeficiency virus-1 in T cells]	0.0	5	1	1	1
75393	1710	several t-cell-expressed cytokine	[several T-cell-expressed cytokines]	0.0	3	1	1	1
75394	1710	one SCC cell line	[one SCC cell line]	0.0	4	1	1	1
75395	1710	component,	[component,]	0.0	1	1	1	1
75396	1710	kda ca(2+)-atpase target	[kDa Ca(2+)-ATPase target]	0.0	3	1	1	1
75397	1710	glucocorticoid type receptor	[glucocorticoid type receptor]	0.0	3	1	1	1
75398	1710	particular, the pool	[particular, the pools]	0.0	3	1	1	1
75399	1710	synergy between il-12	[synergy between IL-12]	0.0	3	1	1	1
75400	1710	contrast, deletion of the portion	[contrast, deletion of the portion]	0.0	5	1	1	1
75401	1710	transcription factor factor of T cell	[Transcription factors factor of T cells]	0.0	6	1	1	1
75402	1710	factor such as Oct-2A	[factors such as Oct-2A]	0.0	4	1	1	1
75403	1710	m phi ingestion of erythrocyte	[M phi ingestion of erythrocytes]	0.0	5	1	1	1
75404	1710	platelet-endothelial cell adhesion molecule-1 phosphorylation	[platelet-endothelial cell adhesion molecule-1 phosphorylation]	0.0	5	1	1	1
75405	1710	oncogenic event in lymphoid tumor	[oncogenic events in lymphoid tumors]	0.0	5	1	1	1
75406	1710	factor Oct-1	[factor Oct-1]	0.0	2	1	1	1
75407	1710	histone deacetylase subunit hd1	[histone deacetylase subunit HD1]	0.0	4	1	1	1
75408	1710	number of receptor gcR	[number of receptors gcR]	0.0	4	1	1	1
75409	1710	histocompatibility -restricted fashion	[histocompatibility -restricted fashion]	0.0	3	1	1	1
75410	1710	basal total blood cell	[Basal total blood cell]	0.0	4	1	1	1
75411	1710	similarity in motif	[similarities in motifs]	0.0	3	1	1	1
75412	1710	leave nf-at transcription	[leaving NF-AT transcription]	0.0	3	1	1	1
75413	1710	provirus carry point mutation	[provirus carrying point mutations]	0.0	4	1	1	1
75414	1710	population progenitor	[populations progenitors]	0.0	2	1	1	1
75415	1710	Electrophoretic mobility shift ems	[Electrophoretic mobility shift EMS]	0.0	4	1	1	1
75416	1710	tumor with ki-67 proliferation index	[Tumors with Ki-67 proliferation indices]	0.0	5	1	1	1
75417	1710	encoding protein	[encoding proteins]	0.0	2	1	1	1
75418	1710	EBV response	[EBV response]	0.0	2	1	1	1
75419	1710	apparently the product of splicing	[apparently the products of splicing]	0.0	5	1	1	1
75420	1710	use a combination of reagent	[using a combination of reagents]	0.0	5	1	1	1
75421	1710	Wilms' tumor suppressor gene	[Wilms' tumor suppressor gene]	0.0	4	1	1	1
75422	1710	acute leukemia 1- respectively,	[acute leukemia 1- respectively,]	0.0	4	1	1	1
75423	1710	binding of the helix-loop-helix protein	[binding of the helix-loop-helix protein]	0.0	5	1	1	1
75424	1710	importance in lt gene expression	[importance in LT gene expression]	0.0	5	1	1	1
75425	1710	one mutant line	[one mutant line]	0.0	3	1	1	1
75426	1710	other structural homology	[other structural homologies]	0.0	3	1	1	1
75427	1710	g76:gpltplpv	[G76:GPLTPLPV]	0.0	1	1	1	1
75428	1710	population possible killer T/NK population	[populations possible killer T/NK populations]	0.0	5	1	1	1
75429	1710	only j393/ cd43	[only J393/ CD43]	0.0	3	1	1	1
75430	1710	mixture of ifn-gamma	[mixture of IFN-gamma]	0.0	3	1	1	1
75431	1710	tpa ca(2+) signal	[TPA Ca(2+) signals]	0.0	3	1	1	1
75432	1710	decrease in VDR level	[decrease in VDR levels]	0.0	4	1	1	1
75433	1710	development of culture of human megakaryocyte	[development of cultures of human megakaryocytes]	0.0	6	1	1	1
75434	1710	shift follow direct pkc activation	[shift following direct PKC activation]	0.0	5	1	1	1
75435	1710	C/EBPbeta NF-IL6	[C/EBPbeta NF-IL6]	0.0	2	1	1	1
75436	1710	donor for the assays.	[donors for the assays.]	0.0	4	1	1	1
75437	1710	effect of two type	[effects of two types]	0.0	4	1	1	1
75438	1710	ng of total rna.	[ng of total RNA.]	0.0	4	1	1	1
75439	1710	addition, il-2	[addition, IL-2]	0.0	2	1	1	1
75440	1710	form kinase C PKC transcription	[forms kinase C PKC transcription]	0.0	5	1	1	1
75441	1710	cell cycle regulator	[cell cycle regulators]	0.0	3	1	1	1
75442	1710	six motif	[six motifs]	0.0	2	1	1	1
75443	1710	four icss	[four ICSs]	0.0	2	1	1	1
75444	1710	diurnal rhythm of a response	[diurnal rhythms of a response]	0.0	5	1	1	1
75445	1710	domain of the interaction with hsp90	[domains of the interaction with hsp90]	0.0	6	1	1	1
75446	1710	treatment nb4	[Treatment NB4]	0.0	2	1	1	1
75447	1710	main difference between Ramos	[main difference between Ramos]	0.0	4	1	1	1
75448	1710	(1) substitution in the human counterpart	[(1) substitutions in the human counterpart]	0.0	6	1	1	1
75449	1710	immunodeficiency virus individual	[immunodeficiency virus individuals]	0.0	3	1	1	1
75450	1710	vitro immunization	[vitro immunization]	0.0	2	1	1	1
75451	1710	effect of 1,25-dihydroxyvitamin D3	[effect of 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
75452	1710	receptor-interacting protein	[receptor-interacting protein]	0.0	2	2	2	1
75453	1710	family of T cell transcription factor	[families of T cell transcription factors]	0.0	6	1	1	1
75454	1710	use recombination, eklf allele	[Using recombination, EKLF alleles]	0.0	4	1	1	1
75455	1710	subsequent cell adhesion to cell	[subsequent cell adhesion to cells]	0.0	5	1	1	1
75456	1710	fasl reporter construct in mrl-lpr/lpr	[FasL reporter constructs in MRL-lpr/lpr]	0.0	5	1	1	1
75457	1710	control of the e2f1 gene	[control of the E2F1 gene]	0.0	5	1	1	1
75458	1710	chemiluminescence assay	[chemiluminescence assays]	0.0	2	1	1	1
75459	1710	tyrosine phosphorylation of protein of mass	[tyrosine phosphorylation of proteins of mass]	0.0	6	1	1	1
75460	1710	disruption of beta	[Disruption of beta]	0.0	3	1	1	1
75461	1710	dephosphorylation at functional phosphoserine residue	[dephosphorylation at functional phosphoserine residues]	0.0	5	1	1	1
75462	1710	human endothelial cell harc	[human endothelial cells HAECs]	0.0	4	1	1	1
75463	1710	b element of immunodeficiency virus	[B elements of immunodeficiency virus]	0.0	5	1	1	1
75464	1710	integration to the genome of T	[integration to the genome of T]	0.0	6	1	1	1
75465	1710	oncoprotein Bcl-3	[oncoprotein Bcl-3]	0.0	2	1	1	1
75466	1710	cell (ec) surface	[cell (EC) surface]	0.0	3	1	1	1
75467	1710	3.7 s	[3.7 S]	0.0	2	1	1	1
75468	1710	risk: cell reaction	[risk: cell reaction]	0.0	3	1	1	1
75469	1710	human immunodeficiency virus hiv-1 repeat	[human immunodeficiency virus HIV-1 repeat]	0.0	5	1	1	1
75470	1710	T lymphocyte CTL	[T lymphocytes CTL]	0.0	3	1	1	1
75471	1710	3,5,3'-triiodothyronine receptor t3r circulate lymphocyte thyroidism	[3,5,3'-triiodothyronine receptors T3R circulating lymphocytes thyroidism]	0.0	6	1	1	1
75472	1710	human th cell	[human Th cells]	0.0	3	1	1	1
75473	1710	regulator of the viral cycle	[regulators of the viral cycle]	0.0	5	1	1	1
75474	1710	follow exposure of human platelet	[following exposure of human platelets]	0.0	5	1	1	1
75475	1710	CD28 -specific mab BW	[CD28 -specific mAb BW]	0.0	4	1	1	1
75476	1710	short treatment of T lymphocyte	[short treatment of T lymphocytes]	0.0	5	1	1	1
75477	1710	NF-kappa b p65 mutant	[NF-kappa B p65 mutants]	0.0	4	1	1	1
75478	1710	low affinity receptor	[low affinity receptor]	0.0	3	1	1	1
75479	1710	hypermutation in lymphoma (25	[hypermutation in lymphoma (25]	0.0	4	1	1	1
75480	1710	kd, result from splicing	[kD, resulting from splicing]	0.0	4	1	1	1
75481	1710	nef expression	[Nef expression]	0.0	2	1	1	1
75482	1710	addition, translation	[addition, translation]	0.0	2	1	1	1
75483	1710	leukemic cell stage	[leukemic cells stage]	0.0	3	1	1	1
75484	1710	NF-kappaB rank	[NF-kappaB RANK]	0.0	2	1	1	1
75485	1710	mechanism conformational change	[Mechanism conformational changes]	0.0	3	1	1	1
75486	1710	differential dependency	[differential dependency]	0.0	2	1	1	1
75487	1710	magnetic bead with DNA	[magnetic beads with DNA]	0.0	4	1	1	1
75488	1710	key transcriptional regulator	[key transcriptional regulator]	0.0	3	1	1	1
75489	1710	mark a transformation effector site	[marking a transformation effector site]	0.0	5	1	1	1
75490	1710	effect in Jurkat T cell	[effect in Jurkat T cells]	0.0	5	1	1	1
75491	1710	regulation of acid lipase	[regulation of acid lipase]	0.0	4	1	1	1
75492	1710	express histocompatibility (mhc) class ii gene	[expressing histocompatibility (MHC) class II genes]	0.0	6	1	1	1
75493	1710	expression follow the differentiation	[expression following the differentiation]	0.0	4	1	1	1
75494	1710	unknown cDNA sequence	[unknown cDNA sequences]	0.0	3	1	1	1
75495	1710	association between the response	[association between the response]	0.0	4	1	1	1
75496	1710	hydrophobic domain with eight putative segment	[hydrophobic domain with eight putative segments]	0.0	6	1	1	1
75497	1710	late induction of genes.	[later induction of genes.]	0.0	4	1	1	1
75498	1710	90% suppression	[90% suppression]	0.0	2	1	1	1
75499	1710	degradation rate	[degradation rate]	0.0	2	1	1	1
75500	1710	show only cross-reactivity	[showing only cross-reactivity]	0.0	3	1	1	1
75501	1710	ms disease	[MS disease]	0.0	2	1	1	1
75502	1710	lactose	[lactose]	0.0	1	1	1	1
75503	1710	mechanism of affinity	[mechanism of affinity]	0.0	3	1	1	1
75504	1710	examine ciita construct	[examining CIITA constructs]	0.0	3	1	1	1
75505	1710	infection of T cell	[infection of T cells]	0.0	4	1	1	1
75506	1710	defective replicative phenotype.	[defective replicative phenotype.]	0.0	3	1	1	1
75507	1710	definitive erythroid cell a phenotype	[definitive erythroid cells a phenotype]	0.0	5	1	1	1
75508	1710	TRE sites,	[TRE sites,]	0.0	2	1	1	1
75509	1710	complex formation between the type	[complex formation between the type]	0.0	5	1	1	1
75510	1710	antioxidant dimethyl sulfoxide	[antioxidant dimethyl sulfoxide]	0.0	3	1	1	1
75511	1710	efficient class ii processing	[efficient class II processing]	0.0	4	1	1	1
75512	1710	superantigen enterotoxin	[superantigen enterotoxin]	0.0	2	1	1	1
75513	1710	gamma activation site	[gamma activation site]	0.0	3	1	1	1
75514	1710	crossreact protein in normal lymphocyte	[crossreacting proteins in normal lymphocytes]	0.0	5	1	1	1
75515	1710	site of persistence	[site of persistence]	0.0	3	2	2	1
75516	1710	VDR 3'-utr haplotype	[VDR 3'-UTR haplotypes]	0.0	3	1	1	1
75517	1710	bind site for c-Myc	[binding site for c-Myc]	0.0	4	1	1	1
75518	1710	inhibit synthesis from the membrane form	[inhibiting synthesis from the membrane form]	0.0	6	1	1	1
75519	1710	activator of transcription STAT3	[activator of transcription STAT3]	0.0	4	1	1	1
75520	1710	(30 minutes) to all-tran acid washed,	[(30 minutes) to all-trans acid washed,]	0.0	6	1	1	1
75521	1710	nine 2.3-kb cDNA clone	[nine 2.3-kb cDNA clones]	0.0	4	1	1	1
75522	1710	determine the quality of the response	[determining the quality of the response]	0.0	6	1	1	1
75523	1710	association of CCACC/Sp1	[association of CCACC/Sp1]	0.0	3	1	1	1
75524	1710	se a oncogene,	[se a oncogene,]	0.0	3	1	1	1
75525	1710	effect related to the suppression	[effects related to the suppression]	0.0	5	1	1	1
75526	1710	culture of human megakaryocyte	[cultures of human megakaryocytes]	0.0	4	1	1	1
75527	1710	culture analysis	[cultures analysis]	0.0	2	1	1	1
75528	1710	thyroid tissue of patient	[thyroid tissue of patients]	0.0	4	1	1	1
75529	1710	serine-phenylalanine "SFS" domain similar	[serine-phenylalanine "SFS" domain similar]	0.0	4	1	1	1
75530	1710	maturation of lineage (day	[maturation of lineages (days]	0.0	4	1	1	1
75531	1710	abs ligand	[Abs ligand]	0.0	2	1	1	1
75532	1710	few genes,	[few genes,]	0.0	2	1	1	1
75533	1710	disorder include psoriasis	[disorders including psoriasis]	0.0	3	1	1	1
75534	1710	cellular binding protein	[cellular binding protein]	0.0	3	1	1	1
75535	1710	important role influence expression	[important role influencing expression]	0.0	4	1	1	1
75536	1710	appropriate control from the individuals,	[appropriate controls from the individuals,]	0.0	5	1	1	1
75537	1710	primary site of infection	[primary site of infection]	0.0	4	1	1	1
75538	1710	notable exception of b	[notable exception of B]	0.0	4	1	1	1
75539	1710	bind to the gata site	[binding to the GATA site]	0.0	5	1	1	1
75540	1710	major site within the negative element	[major sites within the negative element]	0.0	6	1	1	1
75541	1710	control: 46.26	[control: 46.26]	0.0	2	1	1	1
75542	1710	activation of two enzyme	[activation of two enzymes]	0.0	4	1	1	1
75543	1710	involvement at subregion	[Involvement at subregions]	0.0	3	1	1	1
75544	1710	various signal system	[various signaling systems]	0.0	3	1	1	1
75545	1710	binding of b transcription factor essential	[binding of B transcription factors essential]	0.0	6	1	1	1
75546	1710	Differential regulation a study with IL-4	[Differential regulation a study with IL-4]	0.0	6	1	1	1
75547	1710	growth regulatory signal	[growth regulatory signals]	0.0	3	1	1	1
75548	1710	NF-kappa b nuclear localization	[NF-kappa B nuclear localization]	0.0	4	1	1	1
75549	1710	role in wound healing	[roles in wound healing]	0.0	4	1	1	1
75550	1710	transcription of erythrocyte gene	[transcription of erythrocyte genes]	0.0	4	1	1	1
75551	1710	ic50 value for dexamethasone nmol/L)	[IC50 values for dexamethasone nmol/L)]	0.0	5	1	1	1
75552	1710	reactivity to the immunodominant cycle epitope	[reactivities to the immunodominant cycle epitopes]	0.0	6	1	1	1
75553	1710	series (b) of variants,	[series (B) of variants,]	0.0	4	1	1	1
75554	1710	function of activation of latency.	[functions of activation of latency.]	0.0	5	1	1	1
75555	1710	vitro, of a deletion	[vitro, of a deletion]	0.0	4	1	1	1
75556	1710	five family	[five families]	0.0	2	1	1	1
75557	1710	JAK3 type	[JAK3 Type]	0.0	2	1	1	1
75558	1710	transfect tumor cell	[transfecting tumor cells]	0.0	3	1	1	1
75559	1710	mediator in endothelial cell	[mediators in endothelial cells]	0.0	4	1	1	1
75560	1710	transcriptional regulating protein fos	[transcriptional regulating proteins Fos]	0.0	4	1	1	1
75561	1710	binding to wild-type	[binding to wild-type]	0.0	3	1	1	1
75562	1710	encode member of the BCL-2 family	[encoding members of the BCL-2 family]	0.0	6	1	1	1
75563	1710	pu.1 in nonmyeloid cell	[PU.1 in nonmyeloid cells]	0.0	4	1	1	1
75564	1710	expression in follicular center	[Expression in follicular center]	0.0	4	1	1	1
75565	1710	p75 tumor	[p75 tumor]	0.0	2	1	1	1
75566	1710	mechanism of developmental regulation	[mechanism of developmental regulation]	0.0	4	1	1	1
75567	1710	protein tissue	[protein tissue]	0.0	2	1	1	1
75568	1710	ic50 value nmol/L)	[IC50 values nmol/L)]	0.0	3	1	1	1
75569	1710	all-tran differentiation	[all-trans differentiation]	0.0	2	1	1	1
75570	1710	myelomonoblastic cell population	[myelomonoblastic cell population]	0.0	3	1	1	1
75571	1710	Nuclear factor-90	[Nuclear factor-90]	0.0	2	1	1	1
75572	1710	site of cancer	[site of cancer]	0.0	3	1	1	1
75573	1710	return to near-basal level	[returning to near-basal levels]	0.0	4	1	1	1
75574	1710	enigma	[enigma]	0.0	1	1	1	1
75575	1710	suggest gamma-ifn inhibition of 135eoh)2d3	[suggesting gamma-IFN inhibition of 1,25(OH)2D3]	0.0	5	1	1	1
75576	1710	gene transcription in t-cell	[gene transcription in T-cells]	0.0	4	1	1	1
75577	1710	chemotactic adhesive property	[chemotactic adhesive properties]	0.0	3	1	1	1
75578	1710	analysis of the HIV-1 LTR	[analyses of the HIV-1 LTR]	0.0	5	1	1	1
75579	1710	human umbilical vein segment	[human umbilical vein segments]	0.0	4	1	1	1
75580	1710	function for pkc isotype	[functions for PKC isotypes]	0.0	4	1	1	1
75581	1710	two patient with pseudohypoaldosteronism	[two patients with pseudohypoaldosteronism]	0.0	4	1	1	1
75582	1710	cytomegalovirus gene	[Cytomegalovirus genes]	0.0	2	1	1	1
75583	1710	malignant histiocytoma rhabdomyosarcoma leiomyosarcoma	[malignant histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	4	1	1	1
75584	1710	lysosomal serine protease	[lysosomal serine proteases]	0.0	3	1	1	1
75585	1710	erythrocyte ghost membrane	[erythrocyte ghost membrane]	0.0	3	2	2	1
75586	1710	inhibition occur	[inhibition occurring]	0.0	2	1	1	1
75587	1710	monocyte nf-kappab activation	[monocyte NF-kappaB activation]	0.0	3	1	1	1
75588	1710	gata element of hiv-1 long repeat	[GATA elements of HIV-1 long repeat]	0.0	6	1	1	1
75589	1710	inasmuch through opening	[Inasmuch through opening]	0.0	3	1	1	1
75590	1710	regulate the distribution in endothelial cell	[regulating the distribution in endothelial cells]	0.0	6	1	1	1
75591	1710	female patient present	[female patient presenting]	0.0	3	1	1	1
75592	1710	expression of nfat1	[expression of NFAT1]	0.0	3	1	1	1
75593	1710	dependent manner	[dependent manner]	0.0	2	1	1	1
75594	1710	accordingly, western blot with antibody	[Accordingly, Western blots with antibodies]	0.0	5	1	1	1
75595	1710	ALAS gene	[ALAS gene]	0.0	2	1	1	1
75596	1710	(latent)	[(latent)]	0.0	1	1	1	1
75597	1710	switch to lineage	[switching to lineages]	0.0	3	1	1	1
75598	1710	tyrosine kinase oncogene	[tyrosine kinase oncogene]	0.0	3	1	1	1
75599	1710	different condition in the presence	[different conditions in the presence]	0.0	5	1	1	1
75600	1710	two open reading frame of hhv-6	[two open reading frames of HHV-6]	0.0	6	1	1	1
75601	1710	low tcrzeta level 0.001)	[lower TCRzeta levels 0.001)]	0.0	4	1	1	1
75602	1710	down-regulation of Bcl-xL	[down-regulation of Bcl-xL]	0.0	3	1	1	1
75603	1710	level in mature erythrocyte	[levels in mature erythrocytes]	0.0	4	1	1	1
75604	1710	human receptor domain	[human receptor domain]	0.0	3	1	1	1
75605	1710	use ATL-16T extract	[using ATL-16T extract]	0.0	3	1	1	1
75606	1710	lack Ikaros transcription factor	[lacking Ikaros transcription factors]	0.0	4	1	1	1
75607	1710	gene inhibition during activation	[gene inhibition during activation]	0.0	4	1	1	1
75608	1710	Sp1/ Egr-1 site	[Sp1/ Egr-1 site]	0.0	3	1	1	1
75609	1710	hormone inhibition	[hormone inhibition]	0.0	2	1	1	1
75610	1710	cDNA clone encode a protein	[cDNA clone encoding a protein]	0.0	5	1	1	1
75611	1710	nuclear t3 receptor	[nuclear T3 receptor]	0.0	3	1	1	1
75612	1710	Extrarenal receptor-effector-mechor-mechanisms for aldosterone	[Extrarenal receptor-effector-mechanisms for aldosterone]	0.0	4	1	1	1
75613	1710	tpa nuclear factor octamer-associated protein	[TPA nuclear factor octamer-associated protein]	0.0	5	1	1	1
75614	1710	NFAT target	[NFAT targets]	0.0	2	1	1	1
75615	1710	hiv-1 laboratory isolate	[HIV-1 laboratory isolates]	0.0	3	1	1	1
75616	1710	runt polypeptide differentiate cell	[runt polypeptides differentiating cells]	0.0	4	1	1	1
75617	1710	(bind capacity	[(binding capacity]	0.0	2	1	1	1
75618	1710	element BEAD-1 block element alpha/delta	[element BEAD-1 blocking element alpha/delta]	0.0	5	1	1	1
75619	1710	suggest platelet production	[suggesting platelet production]	0.0	3	1	1	1
75620	1710	certain bone cell	[certain bone cells]	0.0	3	1	1	1
75621	1710	mimick into extravascular tissue	[mimicking into extravascular tissues]	0.0	4	1	1	1
75622	1710	low the/thf (0.24; alpha thf/thf	[low THE/THF (0.24; alpha THF/THF]	0.0	5	1	1	1
75623	1710	interfollicular zone cell	[interfollicular zone cells]	0.0	3	1	1	1
75624	1710	immature T cell	[immature T cells]	0.0	3	1	1	1
75625	1710	kappa B/Rel nuclear activity	[kappa B/Rel nuclear activity]	0.0	4	1	1	1
75626	1710	ligand to receptor	[ligands to receptors]	0.0	3	1	1	1
75627	1710	splicing in nfatx isoform	[splicing in NFATx isoforms]	0.0	4	1	1	1
75628	1710	number of diverse protein	[number of diverse proteins]	0.0	4	1	1	1
75629	1710	other strategy	[Other strategies]	0.0	2	1	1	1
75630	1710	control beta-actin	[control beta-actin]	0.0	2	1	1	1
75631	1710	nf-il-2b	[NF-IL-2B]	0.0	1	1	1	1
75632	1710	point in the activation of protein	[pointing in the activation of proteins]	0.0	6	1	1	1
75633	1710	severe degree in immunity	[severe degree in immunity]	0.0	4	1	1	1
75634	1710	fragment contain regulatory sequence from gene	[fragments containing regulatory sequences from genes]	0.0	6	1	1	1
75635	1710	domain of the tail	[domains of the tail]	0.0	4	1	1	1
75636	1710	class gene transcription factor	[class gene transcription factor]	0.0	4	1	1	1
75637	1710	understanding of opioid effect	[understanding of opioid effects]	0.0	4	1	1	1
75638	1710	human promonocytic leukemia cell	[human promonocytic leukemia cells]	0.0	4	1	1	1
75639	1710	serine kinase activity	[serine kinase activity]	0.0	3	1	1	1
75640	1710	case of overexpression	[cases of overexpression]	0.0	3	1	1	1
75641	1710	one blood donor	[one blood donor]	0.0	3	1	1	1
75642	1710	cholesterol synthesis in blood lymphocyte	[cholesterol synthesis in blood lymphocytes]	0.0	5	1	1	1
75643	1710	intracellular free ca2+ concentration ca2+	[intracellular free Ca2+ concentration Ca2+]	0.0	5	1	1	1
75644	1710	r-dependent enhancer activity	[R-dependent enhancer activity]	0.0	3	1	1	1
75645	1710	follow stable expression of hox11	[following stable expression of HOX11]	0.0	5	1	1	1
75646	1710	Ca2+ mobilization	[Ca2+ mobilization]	0.0	2	1	1	1
75647	1710	transcription of 2	[transcription of 2]	0.0	3	1	1	1
75648	1710	form in the cytoplasm	[form in the cytoplasm]	0.0	4	1	1	1
75649	1710	extracellular signal often converge in pathway	[extracellular signals often converging in pathways]	0.0	6	1	1	1
75650	1710	factor treatment of human neutrophils.	[factor treatment of human neutrophils.]	0.0	5	1	1	1
75651	1710	m-csf blood monocyte	[M-CSF blood monocytes]	0.0	3	1	1	1
75652	1710	heterozygous lymphocyte	[heterozygous lymphocytes]	0.0	2	1	1	1
75653	1710	particular nf-atp	[particular NF-ATp]	0.0	2	1	1	1
75654	1710	possibly through binding to a factor	[possibly through binding to an factor]	0.0	6	1	1	1
75655	1710	selective expression of cytokine	[selective expression of cytokines]	0.0	4	1	1	1
75656	1710	retinoic acid RA similar	[retinoic acid RA similar]	0.0	4	1	1	1
75657	1710	biopsy use a radioassay with [3h]-dexamethasone	[biopsies using a radioassay with [3H]-dexamethasone]	0.0	6	1	1	1
75658	1710	activity of ca(2+)-atpase	[activity of Ca(2+)-ATPase]	0.0	3	1	1	1
75659	1710	include the ca2+ /calmodulin-dependent protein kinase	[including the Ca2+ /calmodulin-dependent protein kinase]	0.0	6	1	1	1
75660	1710	repetitive activation	[repetitive activation]	0.0	2	1	1	1
75661	1710	serum-free contain media	[serum-free containing media]	0.0	3	1	1	1
75662	1710	girl	[girl]	0.0	1	1	1	1
75663	1710	risk groups.	[risk groups.]	0.0	2	1	1	1
75664	1710	deactivate effect	[deactivating effects]	0.0	2	1	1	1
75665	1710	class congenital immunodeficiency	[class congenital immunodeficiency]	0.0	3	1	1	1
75666	1710	development of acute leukemia	[development of acute leukemia]	0.0	4	1	1	1
75667	1710	lineage-specific expression,	[lineage-specific expression,]	0.0	2	1	1	1
75668	1710	alpha in the first NH2-terminal residue	[alpha in the first NH2-terminal residues]	0.0	6	1	1	1
75669	1710	such as THP1	[such as THP1]	0.0	3	1	1	1
75670	1710	production by b cell	[production by B cells]	0.0	4	1	1	1
75671	1710	nuclear factor (NF)-AT NF-AT AP-1/Octamer	[nuclear factor (NF)-AT NF-AT AP-1/Octamer]	0.0	5	1	1	1
75672	1710	several other marker	[several other markers]	0.0	3	1	1	1
75673	1710	terminal (940-984) region	[terminal (940-984) region]	0.0	3	1	1	1
75674	1710	emit in the uvb range	[emitting in the UVB range]	0.0	5	1	1	1
75675	1710	adhesion molecule-1 on human vein cell	[adhesion molecule-1 on human vein cells]	0.0	6	1	1	1
75676	1710	selective removal	[selective removal]	0.0	2	1	1	1
75677	1710	regulate the capacity	[regulating the capacity]	0.0	3	1	1	1
75678	1710	protein from soluble matrix preparation	[protein from soluble matrix preparations]	0.0	5	1	1	1
75679	1710	site for factor	[sites for factors]	0.0	3	1	1	1
75680	1710	culture media.	[culture media.]	0.0	2	1	1	1
75681	1710	dependency of b-lymphopoiesis	[dependency of B-lymphopoiesis]	0.0	3	1	1	1
75682	1710	cell to lipopolysaccharide	[cells to lipopolysaccharide]	0.0	3	1	1	1
75683	1710	individual response to the immediate protein	[individual responses to the immediate proteins]	0.0	6	1	1	1
75684	1710	normal value	[normal values]	0.0	2	1	1	1
75685	1710	alteration of the sequence at threonine	[alteration of the sequence at threonine]	0.0	6	1	1	1
75686	1710	loss of renal function	[loss of renal function]	0.0	4	1	1	1
75687	1710	inositol phosphate	[inositol phosphates]	0.0	2	2	2	1
75688	1710	leader sequence	[leader sequence]	0.0	2	1	1	1
75689	1710	difference in immortalization mechanism	[differences in immortalization mechanism]	0.0	4	1	1	1
75690	1710	Flow analysis	[Flow analysis]	0.0	2	1	1	1
75691	1710	tnf transgene	[TNF transgene]	0.0	2	1	1	1
75692	1710	R- inducible enhancer	[R- inducible enhancer]	0.0	3	1	1	1
75693	1710	roi- pathway in epithelial cell	[ROI- pathway in epithelial cells]	0.0	5	1	1	1
75694	1710	contact activation of NF-kappaB	[contact activation of NF-kappaB]	0.0	4	1	1	1
75695	1710	contrast a common site	[contrast a common site]	0.0	4	2	2	1
75696	1710	sterol sequence	[sterol sequence]	0.0	2	1	1	1
75697	1710	problem of emergence	[problem of emergence]	0.0	3	1	1	1
75698	1710	dominant negative allele Raf	[dominant negative allele Raf]	0.0	4	1	1	1
75699	1710	gene corresponding	[genes corresponding]	0.0	2	1	1	1
75700	1710	leukocyte of young subject	[leukocytes of young subjects]	0.0	4	1	1	1
75701	1710	hiv enhancer transcription	[HIV enhancer transcription]	0.0	3	1	1	1
75702	1710	multifactor cis-dominant regulation	[Multifactor cis-dominant regulation]	0.0	3	1	1	1
75703	1710	high-level bcl-6 expression	[high-level BCL-6 expression]	0.0	3	1	1	1
75704	1710	disease such as atopic dermatitis	[diseases such as atopic dermatitis]	0.0	5	1	1	1
75705	1710	thiol modify agent	[Thiol modifying agents]	0.0	3	1	1	1
75706	1710	domain of cyclophilin ligand	[domain of cyclophilin ligand]	0.0	4	1	1	1
75707	1710	mechanism involve nuclear factor	[mechanism involving nuclear factor]	0.0	4	1	1	1
75708	1710	effect of oxygen intermediate ROI	[effects of oxygen intermediates ROI]	0.0	5	1	1	1
75709	1710	characterization of the protein	[Characterization of the protein]	0.0	4	1	1	1
75710	1710	target plasmid	[target plasmids]	0.0	2	1	1	1
75711	1710	property of heat shock factor	[properties of heat shock factors]	0.0	5	1	1	1
75712	1710	formation of distinct complex	[formation of distinct complexes]	0.0	4	1	1	1
75713	1710	6 week after termination of treatment,	[6 weeks after termination of treatment,]	0.0	6	1	1	1
75714	1710	oligodeoxyribonucleotide contain a sp1-box 5'-gggcgg	[oligodeoxyribonucleotide containing an SP1-box 5'-GGGCGG]	0.0	5	1	1	1
75715	1710	scavenger macrophage	[scavenger macrophages]	0.0	2	1	1	1
75716	1710	impairment in the activation of ap-1	[impairments in the activation of AP-1]	0.0	6	1	1	1
75717	1710	one transcription start site	[One transcription start site]	0.0	4	1	1	1
75718	1710	beta-globin control region	[beta-globin control region]	0.0	3	1	1	1
75719	1710	1, 25-dihydroxyvitamin D3	[1, 25-dihydroxyvitamin D3]	0.0	3	1	1	1
75720	1710	ligand of TF	[ligands of TF]	0.0	3	1	1	1
75721	1710	atra-induced neutrophil differentiation	[ATRA-induced neutrophil differentiation]	0.0	3	1	1	1
75722	1710	oncogenic event in tumor	[oncogenic events in tumors]	0.0	4	1	1	1
75723	1710	evidence for the requirement	[evidence for the requirement]	0.0	4	1	1	1
75724	1710	contain nf-kappa b element	[containing NF-kappa B elements]	0.0	4	1	1	1
75725	1710	interleukin receptor beta chain	[interleukin receptor beta chain]	0.0	4	1	1	1
75726	1710	mechanism of genome evolution	[mechanism of genome evolution]	0.0	4	1	1	1
75727	1710	include human lymphoid cell	[including human lymphoid cells]	0.0	4	1	1	1
75728	1710	human cd4+ t-lymphocyte cell line	[human CD4+ T-lymphocyte cell line]	0.0	5	1	1	1
75729	1710	polyposis coli	[polyposis coli]	0.0	2	1	1	1
75730	1710	molecular weight adaptor protein	[molecular weight adaptor proteins]	0.0	4	1	1	1
75731	1710	determination in 10 child	[determination in 10 children]	0.0	4	1	1	1
75732	1710	Retinoic acid treatment recovery.	[Retinoic acid treatment recovery.]	0.0	4	1	1	1
75733	1710	m (igm)-, igd-,	[M (IgM)-, IgD-,]	0.0	3	1	1	1
75734	1710	immature normal cell	[immature normal cells]	0.0	3	1	1	1
75735	1710	primary RNA transcript	[primary RNA transcript]	0.0	3	1	1	1
75736	1710	supernatant fluid from cell carcinoma	[supernatant fluid from cell carcinomas]	0.0	5	1	1	1
75737	1710	significance of this model	[significance of this model]	0.0	4	1	1	1
75738	1710	long life span	[longer life span]	0.0	3	1	1	1
75739	1710	detect cytokine	[detecting cytokine]	0.0	2	1	1	1
75740	1710	lean body	[lean body]	0.0	2	1	1	1
75741	1710	aged subject yr)	[aged subjects yr)]	0.0	3	1	1	1
75742	1710	renal salt loss	[renal salt loss]	0.0	3	1	1	1
75743	1710	gene of the regulatory pair	[gene of the regulatory pair]	0.0	5	1	1	1
75744	1710	contain copy of the PRDII domain	[containing copies of the PRDII domain]	0.0	6	1	1	1
75745	1710	sensitivity (id50)	[Sensitivity (ID50)]	0.0	2	1	1	1
75746	1710	CONCLUSIONS: (1) gcs	[CONCLUSIONS: (1) GCs]	0.0	3	1	1	1
75747	1710	major protein-binding site	[major protein-binding sites]	0.0	3	1	1	1
75748	1710	expression result	[expression resulting]	0.0	2	1	1	1
75749	1710	pathway by Epo	[pathway by Epo]	0.0	3	1	1	1
75750	1710	use a dominant form Max	[using a dominant form Max]	0.0	5	1	1	1
75751	1710	piece of datum	[pieces of data]	0.0	3	1	1	1
75752	1710	2 ng of il-12/10(6) cell	[2 ng of IL-12/10(6) cells]	0.0	5	1	1	1
75753	1710	human clone	[human clones]	0.0	2	1	1	1
75754	1710	target in the il-2 gene	[target in the IL-2 gene]	0.0	5	1	1	1
75755	1710	cell wall,	[cell wall,]	0.0	2	1	1	1
75756	1710	competitor in cell	[competitor in cells]	0.0	3	1	1	1
75757	1710	activated, addition of rbpi21	[activated, addition of rBPI21]	0.0	4	1	1	1
75758	1710	flank region extend from -250 bp	[flanking regions extending from -250 bp]	0.0	6	1	1	1
75759	1710	correlation between the two methods.	[correlation between the two methods.]	0.0	5	1	1	1
75760	1710	colony-stimumulatelany-stg factor proliferation of cd34+ cell	[colony-stimulating factor proliferation of CD34+ cells]	0.0	6	1	1	1
75761	1710	suppression of the response during pregnancy	[suppression of the response during pregnancy]	0.0	6	1	1	1
75762	1710	EA-D promoter regulation by Z	[EA-D promoter regulation by Z]	0.0	5	1	1	1
75763	1710	patient with hypophosphatemic ricket	[patients with hypophosphatemic rickets]	0.0	4	1	1	1
75764	1710	map region 0.30	[map regions 0.30]	0.0	3	1	1	1
75765	1710	200 kb.	[200 kb.]	0.0	2	1	1	1
75766	1710	incubation of RU with dexamethasone	[incubation of RU with dexamethasone]	0.0	5	1	1	1
75767	1710	thus a target in state	[thus a target in states]	0.0	5	1	1	1
75768	1710	prevent the ifn-induced tyrosine phosphorylation	[preventing the IFN-induced tyrosine phosphorylation]	0.0	5	1	1	1
75769	1710	bioassay	[bioassay]	0.0	1	1	1	1
75770	1710	express exogenous bcl-2	[expressing exogenous Bcl-2]	0.0	3	1	1	1
75771	1710	understand the event	[understanding the events]	0.0	3	1	1	1
75772	1710	use a t-lymphocyte cell line	[using a T-lymphocyte cell line]	0.0	5	1	1	1
75773	1710	center of lymph node	[centers of lymph nodes]	0.0	4	1	1	1
75774	1710	lack antigen-presenting cell	[lacking antigen-presenting cells]	0.0	3	1	1	1
75775	1710	several leukemia cell line grow	[Several leukemia cell lines growing]	0.0	5	1	1	1
75776	1710	activity of tgf-beta	[activity of TGF-beta]	0.0	3	1	1	1
75777	1710	clustering of lesion	[clustering of lesions]	0.0	3	1	1	1
75778	1710	stress-induced susceptibility	[stress-induced susceptibility]	0.0	2	1	1	1
75779	1710	m2-type blast cell	[M2-type blast cells]	0.0	3	1	1	1
75780	1710	synergistic action CPRE at -49/41	[synergistic action CPRE at -49/-41,]	0.0	5	1	1	1
75781	1710	monocyte/macrophage phenotype	[monocyte/macrophage phenotype]	0.0	2	1	1	1
75782	1710	binding 5.5-fold	[binding 5.5-fold]	0.0	2	1	1	1
75783	1710	Sp1urday transcription factor maintain expression	[Sp1- transcription factors maintaining expression]	0.0	5	1	1	1
75784	1710	fast-migrate protein-DNA complex with mobility	[fast-migrating protein-DNA complexes with mobilities]	0.0	5	1	1	1
75785	1710	other cell include monocyte	[other cells including monocytes]	0.0	4	1	1	1
75786	1710	ebv carcinoma tissue for gene expression	[EBV carcinoma tissues for gene expression]	0.0	6	1	1	1
75787	1710	disease syndrome	[disease syndromes]	0.0	2	2	2	1
75788	1710	sequence identity in the C-terminal two-third	[sequence identity in the C-terminal two-thirds]	0.0	6	1	1	1
75789	1710	basal phosphorylation of Jak3 STAT3	[basal phosphorylation of Jak3 STAT3]	0.0	5	1	1	1
75790	1710	Jak1 proline-rich Box1 region	[Jak1 proline-rich Box1 region]	0.0	4	1	1	1
75791	1710	anti-hla class	[anti-HLA class]	0.0	2	1	1	1
75792	1710	presence of thapsigargin)	[presence of thapsigargin)]	0.0	3	1	1	1
75793	1710	gene of cytomegalovirus CMV	[genes of cytomegalovirus CMV]	0.0	4	1	1	1
75794	1710	direct assessment	[direct assessment]	0.0	2	1	1	1
75795	1710	analysis of close gene	[analysis of close genes]	0.0	4	1	1	1
75796	1710	protease expression vector	[protease expression vector]	0.0	3	1	1	1
75797	1710	several signal molecule	[several signaling molecules]	0.0	3	1	1	1
75798	1710	hla-dr-	[HLA-DR-]	0.0	1	1	1	1
75799	1710	cellular pathway	[Cellular pathways]	0.0	2	1	1	1
75800	1710	slight trend	[slight trends]	0.0	2	1	1	1
75801	1710	cause resistance in primate	[causing resistance in primates]	0.0	4	1	1	1
75802	1710	suggest a direct transcriptional repressive effect	[suggesting a direct transcriptional repressive effect]	0.0	6	1	1	1
75803	1710	Glucocorticoid receptor in blood lymphocyte	[Glucocorticoid receptors in blood lymphocytes]	0.0	5	1	1	1
75804	1710	large lymphocyte LGL	[large lymphocytes LGL]	0.0	3	1	1	1
75805	1710	major class molecule	[major class molecules]	0.0	3	1	1	1
75806	1710	quantification during differentiation of monocytic cell	[quantification during differentiation of monocytic cells]	0.0	6	1	1	1
75807	1710	approximately 1600 VDR by h	[approximately 1600 VDR by h]	0.0	5	1	1	1
75808	1710	ic50 value nmol/l,	[IC50 values nmol/L,]	0.0	3	1	1	1
75809	1710	absence in endometriotic lesion together	[absence in endometriotic lesions together]	0.0	5	1	1	1
75810	1710	cold aldosterone	[cold aldosterone]	0.0	2	1	1	1
75811	1710	260 +/-	[260 +/-]	0.0	2	1	1	1
75812	1710	Furthermore, transfection	[Furthermore, transfection]	0.0	2	1	1	1
75813	1710	BZLF1 expression	[BZLF1 expression]	0.0	2	1	1	1
75814	1710	aml-1 protein	[AML-1 proteins]	0.0	2	1	1	1
75815	1710	hla-dma	[HLA-DMA]	0.0	1	1	1	1
75816	1710	accumulation messenger rna (mrna)	[accumulation messenger RNA (mRNA)]	0.0	4	1	1	1
75817	1710	t-lineage cell population	[T-lineage cell populations]	0.0	3	1	1	1
75818	1710	cytoplasmic domain homologous	[cytoplasmic domain homologous]	0.0	3	1	1	1
75819	1710	ppargamma ligand	[PPARgamma ligand]	0.0	2	1	1	1
75820	1710	small second messenger response	[smaller second messenger response]	0.0	4	1	1	1
75821	1710	Addition of r-htbp-1 to U1 cell	[Addition of r-hTBP-1 to U1 cells]	0.0	6	1	1	1
75822	1710	morphology loosely cell with neurite process	[morphology loosely cells with neurite processes]	0.0	6	1	1	1
75823	1710	concept dependent	[concept dependent]	0.0	2	1	1	1
75824	1710	alone, provide further evidence	[alone, providing further evidence]	0.0	4	1	1	1
75825	1710	activator in a manner	[activator in a manner]	0.0	4	1	1	1
75826	1710	light zone	[light zone]	0.0	2	1	1	1
75827	1710	oct-binding	[Oct-binding]	0.0	1	1	1	1
75828	1710	only pu.1	[only PU.1]	0.0	2	1	1	1
75829	1710	pkc inhibitors, pentoxifylline	[PKC inhibitors, pentoxifylline]	0.0	3	1	1	1
75830	1710	rna -binding protein	[RNA -binding protein]	0.0	3	1	1	1
75831	1710	change with RU 486	[change with RU 486]	0.0	4	1	1	1
75832	1710	relation between parameter tsh-r	[relation between parameters TSH-R]	0.0	4	1	1	1
75833	1710	only a limited portion	[only a limited portion]	0.0	4	1	1	1
75834	1710	interleukin-4-induced transcription factor	[interleukin-4-induced transcription factor]	0.0	3	1	1	1
75835	1710	nf-kappa b in lymphoid extract	[NF-kappa B in lymphoid extracts]	0.0	5	1	1	1
75836	1710	secondary hyperparathyroidism to renal failure	[secondary hyperparathyroidism to renal failure]	0.0	5	1	1	1
75837	1710	highly permissive state	[highly permissive state]	0.0	3	1	1	1
75838	1710	novel clone	[novel clones]	0.0	2	1	1	1
75839	1710	acid lipase in monocyte	[acid lipase in monocytes]	0.0	4	1	1	1
75840	1710	jak1 to il-2r	[JAK1 to IL-2R]	0.0	3	1	1	1
75841	1710	indicate enhancement	[indicating enhancement]	0.0	2	1	1	1
75842	1710	characterization relationship to NF-kappa b	[Characterization relationship to NF-kappa B]	0.0	5	1	1	1
75843	1710	extracellular kinase in monocyte	[extracellular kinase in monocytes]	0.0	4	1	1	1
75844	1710	respectively, treatment	[respectively, treatment]	0.0	2	1	1	1
75845	1710	patient with 2 micrograms/day	[patients with 2 micrograms/day]	0.0	4	1	1	1
75846	1710	putative silencer of gene	[putative silencer of genes]	0.0	4	1	1	1
75847	1710	promoter 1b	[promoter 1b]	0.0	2	1	1	1
75848	1710	prototypic factor kappab	[prototypic factor kappaB]	0.0	3	1	1	1
75849	1710	activity of the regulatory region	[activity of the regulatory region]	0.0	5	1	1	1
75850	1710	interaction of stat5	[interaction of STAT5]	0.0	3	1	1	1
75851	1710	37 degree C	[37 degrees C]	0.0	3	1	1	1
75852	1710	-immunoreactive cell in peripheral blood	[-immunoreactive cells in peripheral blood]	0.0	5	1	1	1
75853	1710	SLP-76 a tyrosine protein	[SLP-76 a tyrosine protein]	0.0	4	1	1	1
75854	1710	up-regulation of VDR expression	[up-regulation of VDR expression]	0.0	4	1	1	1
75855	1710	long exposure	[long-term exposure]	0.0	2	1	1	1
75856	1710	three aspect	[Three aspects]	0.0	2	1	1	1
75857	1710	multiple cis element S	[multiple cis elements S]	0.0	4	1	1	1
75858	1710	cooperation with c-Myb	[cooperation with c-Myb]	0.0	3	1	1	1
75859	1710	growth factor-1 fgf-1	[growth factor-1 FGF-1]	0.0	3	1	1	1
75860	1710	h of autoinduction.	[h of autoinduction.]	0.0	3	1	1	1
75861	1710	depend on signal	[Depending on signals]	0.0	3	1	1	1
75862	1710	activator protein-1 factor nf-il6	[activator protein-1 factor NF-IL6]	0.0	4	1	1	1
75863	1710	contain binding site	[containing binding sites]	0.0	3	1	1	1
75864	1710	mobility (approximately 120 kd)	[mobility (approximately 120 kD)]	0.0	4	1	1	1
75865	1710	class ii major cell line	[class II major cell lines]	0.0	5	1	1	1
75866	1710	/cell for type	[/cell for type]	0.0	3	1	1	1
75867	1710	first demonstration of a inhibition	[first demonstration of a inhibition]	0.0	5	1	1	1
75868	1710	show a effect of hgata-3	[showing a effect of hGATA-3]	0.0	5	1	1	1
75869	1710	effect of adenovirus 2	[Effect of adenovirus 2]	0.0	4	1	1	1
75870	1710	part, on differential gene regulation	[part, on differential gene regulation]	0.0	5	1	1	1
75871	1710	extract from various cell line	[extracts from various cell lines]	0.0	5	1	1	1
75872	1710	export factor of T cell	[export factor of T cells]	0.0	5	1	1	1
75873	1710	family member in thymic development	[family members in thymic development]	0.0	5	1	1	1
75874	1710	crucial determinant process of differentiation	[crucial determinant processes of differentiation]	0.0	5	1	1	1
75875	1710	mzf-1 coding region	[MZF-1 coding region]	0.0	3	1	1	1
75876	1710	carry the cDNA	[carrying the cDNA]	0.0	3	1	1	1
75877	1710	background: patient	[BACKGROUND: Patients]	0.0	2	1	1	1
75878	1710	promyeloid leukemia cell	[promyeloid leukemia cells]	0.0	3	1	1	1
75879	1710	family with x-linked atrophy	[families with X-linked atrophy]	0.0	4	1	1	1
75880	1710	neutrophil apoptosis of function	[Neutrophil apoptosis of function]	0.0	4	1	1	1
75881	1710	j(2) 15d-PGJ(2)	[J(2) 15d-PGJ(2)]	0.0	2	1	1	1
75882	1710	counterpart to human chronic leukemia	[counterpart to human chronic leukemias]	0.0	5	1	1	1
75883	1710	such mutant line	[such mutant line]	0.0	3	1	1	1
75884	1710	DNA transfections.	[DNA transfections.]	0.0	2	1	1	1
75885	1710	biological role	[biological roles]	0.0	2	1	1	1
75886	1710	activity of regulatory element	[activity of regulatory elements]	0.0	4	1	1	1
75887	1710	novel Grb2 family member	[novel Grb2 family member]	0.0	4	1	1	1
75888	1710	concentration of alpha 4	[concentrations of alpha 4]	0.0	4	1	1	1
75889	1710	induction of set	[induction of sets]	0.0	3	1	1	1
75890	1710	Ikaros element	[Ikaros elements]	0.0	2	1	1	1
75891	1710	candidate gene hepatic nuclear factor beta	[candidate genes hepatic nuclear factor beta]	0.0	6	1	1	1
75892	1710	unspliced gag-pol mrna	[unspliced gag-pol mRNA]	0.0	3	1	1	1
75893	1710	reading frame in frame	[reading frame in frame]	0.0	4	1	1	1
75894	1710	nucleus of follicular cell	[nucleus of follicular cells]	0.0	4	1	1	1
75895	1710	TNF-alpha hiv-1 long terminal repeat transcription	[TNF-alpha HIV-1 long terminal repeat transcription]	0.0	6	1	1	1
75896	1710	Clone pAT	[Clone pAT]	0.0	2	1	1	1
75897	1710	suggest important in the increase	[suggesting important in the increase]	0.0	5	1	1	1
75898	1710	DRE regulatory sequence	[DRE regulatory sequence]	0.0	3	2	2	1
75899	1710	vitro, of a impaired deletion	[vitro, of a impaired deletion]	0.0	5	1	1	1
75900	1710	prevent activation of gene	[preventing activation of genes]	0.0	4	1	1	1
75901	1710	site for nuclear protein	[site for nuclear proteins]	0.0	4	1	1	1
75902	1710	three vzv donor	[Three VZV donors]	0.0	3	1	1	1
75903	1710	binding a element	[binding an element]	0.0	3	1	1	1
75904	1710	search Ag for protein segment	[searching Ag for protein segments]	0.0	5	1	1	1
75905	1710	ensure the differentiation in the stage	[ensuring the differentiation in the stages]	0.0	6	1	1	1
75906	1710	patient with condition	[patients with conditions]	0.0	3	1	1	1
75907	1710	two 5'-most carg sequence	[two 5'-most CArG sequences]	0.0	4	1	1	1
75908	1710	deletion of sequence upstream	[deletion of sequences upstream]	0.0	4	1	1	1
75909	1710	cellular level of receptor	[cellular levels of receptor]	0.0	4	1	1	1
75910	1710	chicken anemia	[chicken anemia]	0.0	2	1	1	1
75911	1710	subdomain of bob.1/obf.1	[subdomains of BOB.1/OBF.1]	0.0	3	1	1	1
75912	1710	pu box a DNA element	[Pu box an DNA element]	0.0	5	1	1	1
75913	1710	evidence a role in the regulation	[evidencing a role in the regulation]	0.0	6	1	1	1
75914	1710	ratio, c-erbA activity	[ratio, c-erbA activity]	0.0	3	1	1	1
75915	1710	viral, self ligand	[viral, self, ligands]	0.0	3	1	1	1
75916	1710	mammalian cell susceptibility	[mammalian cell susceptibility]	0.0	3	1	1	1
75917	1710	mass of 105 kda	[mass of 105 kDa]	0.0	4	1	1	1
75918	1710	consequent decrease in the level	[consequent decrease in the levels]	0.0	5	1	1	1
75919	1710	tumor activity	[Tumor activity]	0.0	2	1	1	1
75920	1710	predominantly T lymphotropic virus	[predominantly T lymphotropic virus]	0.0	4	1	1	1
75921	1710	signal pathway operate	[signaling pathways operating]	0.0	3	1	1	1
75922	1710	13 subject	[13 subjects]	0.0	2	1	1	1
75923	1710	endogenous c-fo mrna expression	[endogenous c-fos mRNA expression]	0.0	4	1	1	1
75924	1710	box in the sex-determine gene	[boxes in the sex-determining gene]	0.0	5	1	1	1
75925	1710	long repeat LTR of hiv-1	[long repeat LTR of HIV-1]	0.0	5	1	1	1
75926	1710	strong interaction	[strong interactions]	0.0	2	1	1	1
75927	1710	competition between two activator RelA	[competition between two activators RelA]	0.0	5	1	1	1
75928	1710	datum CD40 signal	[data, CD40 signals]	0.0	3	1	1	1
75929	1710	same four genes,	[same four genes,]	0.0	3	1	1	1
75930	1710	constitutive expression of colony-stimumulatelany-stg factor-1 receptor	[Constitutive expression of colony-stimulating factor-1 receptor]	0.0	6	1	1	1
75931	1710	tissue-type	[tissue-type]	0.0	1	1	1	1
75932	1710	multiple intracellular protein lead	[multiple intracellular proteins leading]	0.0	4	1	1	1
75933	1710	cyto-differentiating effect	[cyto-differentiating effects]	0.0	2	1	1	1
75934	1710	viral immediate-early protein bzlf1	[viral immediate-early protein BZLF1]	0.0	4	1	1	1
75935	1710	thp-1-hgh-transfected cell	[THP-1-hGH-transfected cells]	0.0	2	1	1	1
75936	1710	context T	[context T]	0.0	2	1	1	1
75937	1710	positive cooperativity in the response	[positive cooperativity in the response]	0.0	5	1	1	1
75938	1710	incubation of human T cell	[incubation of human T cells]	0.0	5	1	1	1
75939	1710	coupling to multiple pathway	[Coupling to multiple pathways]	0.0	4	1	1	1
75940	1710	content of t- lymphocyte	[content of T- lymphocytes]	0.0	4	1	1	1
75941	1710	only a cell	[Only a cells]	0.0	3	1	1	1
75942	1710	induction of cytokine expression in leukocyte	[Induction of cytokine expression in leukocytes]	0.0	6	1	1	1
75943	1710	three subtype of acid receptor RAR	[Three subtypes of acid receptors RAR]	0.0	6	1	1	1
75944	1710	expression to immunodeficiency virus type cell	[expression to immunodeficiency virus type cells]	0.0	6	1	1	1
75945	1710	mg of prednisolone	[mg of prednisolone]	0.0	3	1	1	1
75946	1710	apoptosis in wild-type CD4 receptor	[apoptosis in wild-type CD4 receptors]	0.0	5	1	1	1
75947	1710	breakpoint on chromosome range from q13	[breakpoints on chromosome ranging from q13]	0.0	6	1	1	1
75948	1710	duration of proliferation.	[duration of proliferation.]	0.0	3	1	1	1
75949	1710	early activator protein	[early activator protein]	0.0	3	1	1	1
75950	1710	corticosteroid methyl prednisolone 120 mg/day)	[corticosteroid methyl prednisolone 120 mg/day)]	0.0	5	1	1	1
75951	1710	constitutive degradation of inhibitor	[constitutive degradation of inhibitors]	0.0	4	1	1	1
75952	1710	human thp cell	[human THP cells]	0.0	3	1	1	1
75953	1710	point toward age-related defect	[pointing toward age-related defects]	0.0	4	1	1	1
75954	1710	immortalization of primary b-cell	[immortalization of primary B-cells]	0.0	4	1	1	1
75955	1710	active signal pathway	[active signaling pathways]	0.0	3	1	1	1
75956	1710	change of calcitriol receptor	[Changes of calcitriol receptors]	0.0	4	1	1	1
75957	1710	contain gene by the ubiquitous factor	[containing genes by the ubiquitous factor]	0.0	6	1	1	1
75958	1710	second enhancer element	[second enhancer element]	0.0	3	1	1	1
75959	1710	h2o2 nf-kappab activation	[H2O2 NF-kappaB activation]	0.0	3	1	1	1
75960	1710	enhancement of immunodeficiency virus 1 replication	[Enhancement of immunodeficiency virus 1 replication]	0.0	6	1	1	1
75961	1710	Class major histocompatibility (class ii) gene	[Class major histocompatibility (class II) genes]	0.0	6	1	1	1
75962	1710	region important, for recruitment	[regions important, for recruitment]	0.0	4	1	1	1
75963	1710	oxygen intermediate release	[oxygen intermediate release]	0.0	3	1	1	1
75964	1710	control gene expression	[controlling gene expression]	0.0	3	1	1	1
75965	1710	two nuclear factor kB element	[two nuclear factor kB elements]	0.0	5	1	1	1
75966	1710	11+/cd4+	[11+/CD4+]	0.0	1	1	1	1
75967	1710	ligand binding datum	[ligand binding data,]	0.0	3	1	1	1
75968	1710	many effector site	[many effector sites]	0.0	3	1	1	1
75969	1710	lps effects, ap-1	[LPS effects, AP-1]	0.0	3	1	1	1
75970	1710	peripheral blood lymphocyte with hiv-1	[peripheral blood lymphocytes with HIV-1]	0.0	5	1	1	1
75971	1710	other drug nsaid	[other drugs NSAIDs]	0.0	3	1	1	1
75972	1710	cellular gene molecule	[cellular gene molecules]	0.0	3	1	1	1
75973	1710	acid receptor alpha gene	[acid receptor alpha gene]	0.0	4	3	3	1
75974	1710	interleukin-10 receptor expression	[interleukin-10 receptor expression]	0.0	3	1	1	1
75975	1710	contain glucocorticoid receptor l753f	[containing glucocorticoid receptors L753F]	0.0	4	1	1	1
75976	1710	series of 350 case	[series of 350 cases]	0.0	4	1	1	1
75977	1710	occur in cell	[occurring in cells]	0.0	3	1	1	1
75978	1710	kappa b-like motif	[kappa B-like motifs]	0.0	3	1	1	1
75979	1710	protein (rap) in platelet membrane	[protein (Rap) in platelet membranes]	0.0	5	1	1	1
75980	1710	reverse-transcriptase polymerase chain reaction	[reverse-transcriptase polymerase chain reaction]	0.0	4	2	2	1
75981	1710	zipper transcription	[zipper transcription]	0.0	2	1	1	1
75982	1710	daily dose of microgram	[daily dose of micrograms]	0.0	4	1	1	1
75983	1710	b29 transcript	[B29 transcripts]	0.0	2	1	1	1
75984	1710	one subunit	[one subunit]	0.0	2	1	1	1
75985	1710	regulation of nf-kappa b activation	[regulation of NF-kappa B activation]	0.0	5	1	1	1
75986	1710	rule of assembly	[rules of assembly]	0.0	3	1	1	1
75987	1710	hsp expression	[Hsp expression]	0.0	2	1	1	1
75988	1710	polypeptide range from kda	[polypeptides ranging from kDa]	0.0	4	1	1	1
75989	1710	exclusive bind selectivity	[exclusive binding selectivity]	0.0	3	1	1	1
75990	1710	mass-to-charge ratio (m/z)	[mass-to-charge ratio (m/z)]	0.0	3	1	1	1
75991	1710	h at degree	[h at degrees]	0.0	3	1	1	1
75992	1710	ubiquitin -proteasome	[ubiquitin -proteasome]	0.0	2	2	2	1
75993	1710	target for oxidative signalling process	[targets for oxidative signalling processes]	0.0	5	1	1	1
75994	1710	udg on activity	[UDG on activity]	0.0	3	1	1	1
75995	1710	months).	[months).]	0.0	1	1	1	1
75996	1710	thymic maturation	[thymic maturation]	0.0	2	1	1	1
75997	1710	suppression continue for hours.	[suppression continuing for hours.]	0.0	4	1	1	1
75998	1710	region in vitro	[region in vitro]	0.0	3	1	1	1
75999	1710	contain the c-fo promoter in front	[containing the c-fos promoter in front]	0.0	6	1	1	1
76000	1710	13 amino acid	[13 amino acids]	0.0	3	1	1	1
76001	1710	c-Myb binding site	[c-Myb binding site]	0.0	3	1	1	1
76002	1710	nuclear translocation in T cell	[nuclear translocation in T cells]	0.0	5	1	1	1
76003	1710	61.0 dpm	[61.0 dpm]	0.0	2	1	1	1
76004	1710	human astrocyte	[human astrocytes]	0.0	2	1	1	1
76005	1710	c/ebp alpha transcription factor	[C/EBP alpha transcription factors]	0.0	4	1	1	1
76006	1710	molecular understanding of differentiation	[molecular understanding of differentiation]	0.0	4	1	1	1
76007	1710	il-6 transcription	[IL-6 transcription]	0.0	2	1	1	1
76008	1710	basal white blood cell	[Basal white blood cell]	0.0	4	1	1	1
76009	1710	evidence link abnormal behavior	[evidence linking abnormal behavior]	0.0	4	1	1	1
76010	1710	concentration M.	[concentration M.]	0.0	2	1	1	1
76011	1710	dox cell	[DOX cells]	0.0	2	1	1	1
76012	1710	stimulation of human tonsillar mononuclear cell	[Stimulation of human tonsillar mononuclear cells]	0.0	6	1	1	1
76013	1710	such as glycosidase activity	[such as glycosidase activities]	0.0	4	1	1	1
76014	1710	EBV protein EBNA-2 transactivator	[EBV protein EBNA-2 transactivator]	0.0	4	1	1	1
76015	1710	optimal transactivation	[optimal transactivation]	0.0	2	1	1	1
76016	1710	type a b ebv infection	[type A B EBV infection]	0.0	5	1	1	1
76017	1710	physiological regulation	[physiological regulation]	0.0	2	1	1	1
76018	1710	CTL epitope	[CTL epitope]	0.0	2	1	1	1
76019	1710	mechanism in acute infarction	[mechanism in acute infarction]	0.0	4	1	1	1
76020	1710	resistance to stress	[resistance to stress]	0.0	3	1	1	1
76021	1710	T cell with level	[T cells with levels]	0.0	4	1	1	1
76022	1710	encode a tfiid protein	[encoding a TFIID protein]	0.0	4	1	1	1
76023	1710	[3h]pyrilamine	[[3H]pyrilamine]	0.0	1	1	1	1
76024	1710	mineralocorticoid receptor in leucocyte	[mineralocorticoid receptor in leucocytes]	0.0	4	1	1	1
76025	1710	th development	[Th development]	0.0	2	1	1	1
76026	1710	only in two t-pll tumour	[only in two T-PLL tumours]	0.0	5	1	1	1
76027	1710	patient +/- 1.07	[patients +/- 1.07]	0.0	3	1	1	1
76028	1710	RA binding	[RA binding]	0.0	2	1	1	1
76029	1710	transcription factor include nuclear factor	[transcription factors including nuclear factor]	0.0	5	1	1	1
76030	1710	express PhoQ without PhoP	[expressing PhoQ without PhoP]	0.0	4	1	1	1
76031	1710	mechanism of a analogue	[mechanism of a analogue]	0.0	4	1	1	1
76032	1710	assay of pkc activity	[assays of PKC activity]	0.0	4	1	1	1
76033	1710	LTR sequence	[LTR sequence]	0.0	2	1	1	1
76034	1710	observation of paternal expression	[observations of paternal expression]	0.0	4	1	1	1
76035	1710	cell-monocyte	[cell-monocyte]	0.0	1	1	1	1
76036	1710	(R129C)	[(R129C)]	0.0	1	1	1	1
76037	1710	comparison, platelet activating factor	[comparison, platelet activating factor]	0.0	4	1	1	1
76038	1710	microm of the counter-anion thioglucose tg	[microM of the counter-anion thioglucose TG]	0.0	6	1	1	1
76039	1710	transcription follow ligand engagement	[transcription following ligand engagement]	0.0	4	1	1	1
76040	1710	human ghost membrane by glucocorticoid	[human ghost membrane by glucocorticoids]	0.0	5	1	1	1
76041	1710	induction condition	[induction conditions]	0.0	2	1	1	1
76042	1710	particular, tgf beta	[particular, TGF beta]	0.0	3	1	1	1
76043	1710	probability recur	[probability recurring]	0.0	2	1	1	1
76044	1710	PMA function	[PMA function]	0.0	2	1	1	1
76045	1710	especially diffuse lymphoma with a component	[especially diffuse lymphomas with a component]	0.0	6	1	1	1
76046	1710	mechanism of positive regulation	[mechanism of positive regulation]	0.0	4	1	1	1
76047	1710	lymphocyte in anorexia nervosa	[lymphocytes in anorexia nervosa]	0.0	4	1	1	1
76048	1710	response-1 gene expression in b cell	[response-1 gene expression in B cells]	0.0	6	1	1	1
76049	1710	single mrna transcript of kb.	[single mRNA transcript of kb.]	0.0	5	1	1	1
76050	1710	nuclear factor cell	[nuclear factor cells]	0.0	3	1	1	1
76051	1710	enlarge mass	[enlarging mass]	0.0	2	1	1	1
76052	1710	generation of T lymphocyte against epitope	[Generation of T lymphocytes against epitopes]	0.0	6	1	1	1
76053	1710	control of production	[control of production]	0.0	3	1	1	1
76054	1710	paf receptor	[PAF receptor]	0.0	2	1	1	1
76055	1710	rdna HZF	[cDNAs HZF]	0.0	2	1	1	1
76056	1710	new AMP response	[new AMP response]	0.0	3	1	1	1
76057	1710	hla -dq alpha	[HLA -DQ alpha]	0.0	3	1	1	1
76058	1710	high microg/100 millileter at 10:00 P;	[high microg/100 ml at 10:00 h;]	0.0	6	1	1	1
76059	1710	consist Raf-1	[consisting Raf-1]	0.0	2	1	1	1
76060	1710	many alpha,25-(OH)2D3 analog	[many alpha,25-(OH)2D3 analogs]	0.0	3	1	1	1
76061	1710	induction role	[induction role]	0.0	2	1	1	1
76062	1710	cell macrophage	[cells macrophages]	0.0	2	1	1	1
76063	1710	activation of jak-1	[activation of JAK-1]	0.0	3	1	1	1
76064	1710	E-dependent kinase	[E-dependent kinase]	0.0	2	1	1	1
76065	1710	intrauterine	[intrauterine]	0.0	1	1	1	1
76066	1710	conditional form	[conditional form]	0.0	2	1	1	1
76067	1710	m2 blast cell	[M2 blast cells]	0.0	3	1	1	1
76068	1710	suppression of stat1 activity.	[suppression of Stat1 activity.]	0.0	4	1	1	1
76069	1710	rapid intracellular formation	[rapid intracellular formation]	0.0	3	1	1	1
76070	1710	24 woman 10 second	[24 women 10 second]	0.0	4	1	1	1
76071	1710	e1 binding protein	[E1 binding protein]	0.0	3	1	1	1
76072	1710	e(2) murine line,	[E(2) murine line,]	0.0	3	1	1	1
76073	1710	two c-c chemokine receptor-like gene	[two C-C chemokine receptor-like genes]	0.0	5	1	1	1
76074	1710	various alteration responsible for the response	[various alterations responsible for the response]	0.0	6	1	1	1
76075	1710	region of the proteins.	[regions of the proteins.]	0.0	4	1	1	1
76076	1710	768-bp regulatory region	[768-bp regulatory region]	0.0	3	1	1	1
76077	1710	role regulate signal	[role regulating signaling]	0.0	3	1	1	1
76078	1710	nonsmok asthmatic patient with airway obstruction	[nonsmoking asthmatic patients with airways obstruction]	0.0	6	1	1	1
76079	1710	phosphatase-positive osteoclast-like multinucleated cell from monocyte	[phosphatase-positive osteoclast-like multinucleated cells from monocytes]	0.0	6	1	1	1
76080	1710	regulation of commitment	[Regulation of commitment]	0.0	3	1	1	1
76081	1710	DNase 1 hypersensitive site	[DNase 1 hypersensitive sites]	0.0	4	1	1	1
76082	1710	response to MDP	[response to MDP]	0.0	3	1	1	1
76083	1710	extrathymic development	[extrathymic development]	0.0	2	1	1	1
76084	1710	one first- relative;	[one first- relative;]	0.0	3	1	1	1
76085	1710	involvement in growth inhibition	[involvement in growth inhibition]	0.0	4	1	1	1
76086	1710	control of Bcl-2 expression by Aiolos	[control of Bcl-2 expression by Aiolos]	0.0	6	1	1	1
76087	1710	HNF-1 alpha	[HNF-1 alpha]	0.0	2	1	1	1
76088	1710	two Duffy polymorphic antigen	[two Duffy polymorphic antigens]	0.0	4	1	1	1
76089	1710	order complex contain hsp70	[order complex containing hsp70]	0.0	4	1	1	1
76090	1710	regulate the inducible expression	[regulating the inducible expression]	0.0	4	1	1	1
76091	1710	c-11-substituted alpha,25-(OH)2D3 analog	[C-11-substituted alpha,25-(OH)2D3 analogs]	0.0	3	1	1	1
76092	1710	engineering a vaccine	[engineering a vaccine]	0.0	3	1	1	1
76093	1710	include presentation, response with acid	[including presentation, response with acid]	0.0	5	1	1	1
76094	1710	examination of tissue	[Examination of tissues]	0.0	3	1	1	1
76095	1710	25-dihydroxyvitamin D3 135(oh)2d3	[25-dihydroxyvitamin D3 1,25(OH)2D3]	0.0	3	1	1	1
76096	1710	growth of a pre-B-cell variant line	[growth of a pre-B-cell variant line]	0.0	6	1	1	1
76097	1710	extinction of other b gene	[extinction of other B genes]	0.0	5	1	1	1
76098	1710	multiple gene reporter	[multiple gene reporters]	0.0	3	1	1	1
76099	1710	b /rel factor	[B /Rel factors]	0.0	3	1	1	1
76100	1710	45,x	[45,X]	0.0	1	1	1	1
76101	1710	transactivation of the membrane protein promoter	[transactivation of the membrane protein promoter]	0.0	6	1	1	1
76102	1710	class ii histocompatibility	[class II histocompatibility]	0.0	3	1	1	1
76103	1710	role of c-jun	[role of c-jun]	0.0	3	1	1	1
76104	1710	0.1 microm	[0.1 microM]	0.0	2	1	1	1
76105	1710	localization signal (89 to 106)	[localization signal (89 to 106)]	0.0	5	1	1	1
76106	1710	ability of cbl	[ability of Cbl]	0.0	3	1	1	1
76107	1710	physiologically relevant interaction	[physiologically relevant interaction]	0.0	3	1	1	1
76108	1710	il-6 kappa b binding factor	[IL-6 kappa B binding factor]	0.0	5	1	1	1
76109	1710	peripheral blood burst-forming unit-erythroid	[peripheral blood burst-forming unit-erythroid]	0.0	4	1	1	1
76110	1710	modest inhibitor of hiv-1 iiib replication	[modest inhibitors of HIV-1 IIIB replication]	0.0	6	1	1	1
76111	1710	contrast to identical experiment	[contrast to identical experiments]	0.0	4	1	1	1
76112	1710	two binding site on the receptor	[Two binding sites on the receptor]	0.0	6	1	1	1
76113	1710	ebna2 -oestrogen receptor	[EBNA2 -oestrogen receptor]	0.0	3	1	1	1
76114	1710	two subregion	[two subregions]	0.0	2	1	1	1
76115	1710	triiodothyronine t3 leukocyte receptor kinetic	[triiodothyronine T3 leukocyte receptor kinetics]	0.0	5	1	1	1
76116	1710	antioxidants, n-acetylcysteine	[antioxidants, N-acetylcysteine]	0.0	2	1	1	1
76117	1710	novel t-cell-specific transcriptional activator	[novel T-cell-specific transcriptional activator]	0.0	4	1	1	1
76118	1710	secondary hypothyroidism	[secondary hypothyroidism]	0.0	2	1	1	1
76119	1710	male breast cancer	[male breast cancer]	0.0	3	2	2	1
76120	1710	negative effector on dna-binding activity	[negative effector on DNA-binding activity]	0.0	5	1	1	1
76121	1710	transcriptional regulation of cell adhesion molecule	[transcriptional regulation of cell adhesion molecules]	0.0	6	1	1	1
76122	1710	2.0 0.8 nm less than 0.01).	[2.0 0.8 nM less than 0.01).]	0.0	6	1	1	1
76123	1710	circulate human lymphocyte in hyper-	[circulating human lymphocytes in hyper-]	0.0	5	1	1	1
76124	1710	target of the effect	[targets of the effects]	0.0	4	1	1	1
76125	1710	alpha thf/thf n: 0.92+/-0.42) ratios.	[alpha THF/THF N: 0.92+/-0.42) ratios.]	0.0	5	1	1	1
76126	1710	simian immunodeficiency virus variant	[simian immunodeficiency virus variant]	0.0	4	1	1	1
76127	1710	mature cell of the lineage	[maturing cells of the lineage]	0.0	5	1	1	1
76128	1710	initial diagnosis, counseling,	[initial diagnosis, counseling,]	0.0	3	1	1	1
76129	1710	transient overexpression of mutant	[Transient overexpression of mutants]	0.0	4	1	1	1
76130	1710	h-7 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine	[H-7 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine]	0.0	2	1	1	1
76131	1710	granzyme b gene promoter	[granzyme B gene promoter]	0.0	4	1	1	1
76132	1710	potent inhibitor of hiv-1 replication	[potent inhibitor of HIV-1 replication]	0.0	5	1	1	1
76133	1710	modulation of normal erythroid differentiation	[Modulation of normal erythroid differentiation]	0.0	5	1	1	1
76134	1710	Messenger RNA mrna	[Messenger RNA mRNA]	0.0	3	1	1	1
76135	1710	jak2 of stat5	[JAK2 of STAT5]	0.0	3	1	1	1
76136	1710	third patient	[third patient]	0.0	2	1	1	1
76137	1710	image analysis	[image analysis]	0.0	2	1	1	1
76138	1710	preterm suffer	[preterms suffering]	0.0	2	1	1	1
76139	1710	four protein complex	[four protein complexes]	0.0	3	1	1	1
76140	1710	pea1	[PEA1]	0.0	1	1	1	1
76141	1710	Consequently, inhibition of nf-kappab translocation	[Consequently, inhibition of NF-kappaB translocation]	0.0	5	1	1	1
76142	1710	activation of human macrophage by ventilation	[Activation of human macrophages by ventilation]	0.0	6	1	1	1
76143	1710	activate phorbol ester 12-o-tetradecanoylphorbol-13-acetate	[activating phorbol ester 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
76144	1710	c-fos-two component	[c-fos-two components]	0.0	2	1	1	1
76145	1710	Oct2-isoform expression	[Oct2-isoform expression]	0.0	2	1	1	1
76146	1710	blood burst-forming unit-erythroid bfu-e	[blood burst-forming unit-erythroid BFU-E]	0.0	4	1	1	1
76147	1710	model systems,	[model systems,]	0.0	2	1	1	1
76148	1710	regulator of cell growth	[regulators of cell growth]	0.0	4	1	1	1
76149	1710	25 h for serum-supplemented culture	[25 h for serum-supplemented cultures]	0.0	5	1	1	1
76150	1710	il-12r beta1 subunit	[IL-12R beta1 subunit]	0.0	3	1	1	1
76151	1710	malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	6	1	1	1
76152	1710	endothelial dysfunction.	[endothelial dysfunction.]	0.0	2	1	1	1
76153	1710	new cyclooxygenase/5-lipoxygenase compound	[new cyclooxygenase/5-lipoxygenase compound]	0.0	3	1	1	1
76154	1710	anti-tr55 antibody cross-linking	[Anti-TR55 antibody cross-linking]	0.0	3	1	1	1
76155	1710	simultaneous expression of BZLF-1	[simultaneous expression of BZLF-1]	0.0	4	1	1	1
76156	1710	DNA binding affinity	[DNA binding affinities]	0.0	3	1	1	1
76157	1710	24 h at dose	[24 h at doses]	0.0	4	1	1	1
76158	1710	globular, electron-dense structure	[globular, electron-dense structures]	0.0	3	1	1	1
76159	1710	leukaemia CML	[leukaemia CML]	0.0	2	1	1	1
76160	1710	proto-oncogene in the vicinity	[proto-oncogene in the vicinity]	0.0	4	1	1	1
76161	1710	1 year) in the continuous presence	[1 year) in the continuous presence]	0.0	6	1	1	1
76162	1710	thus prevent the expression	[thus preventing the expression]	0.0	4	1	1	1
76163	1710	EGFP	[EGFP]	0.0	1	1	1	1
76164	1710	EGFR	[EGFR]	0.0	1	1	1	1
76165	1710	absence of cortisol	[absence of cortisol]	0.0	3	1	1	1
76166	1710	activation gene family egr-1	[activation genes family egr-1]	0.0	4	1	1	1
76167	1710	IL-2 superinduction	[IL-2 superinduction]	0.0	2	1	1	1
76168	1710	point ylpq	[point YLPQ]	0.0	2	1	1	1
76169	1710	leukaemia CLL	[leukaemia CLL]	0.0	2	1	1	1
76170	1710	infectious disease tuberculosis	[infectious diseases tuberculosis]	0.0	3	1	1	1
76171	1710	new cell line keep property	[new cell lines keeping properties]	0.0	5	1	1	1
76172	1710	cell population (the cell lineage	[cell populations (the cell lineages]	0.0	5	1	1	1
76173	1710	independent cloning from cell	[independent cloning from cells]	0.0	4	1	1	1
76174	1710	thus establish the effectiveness of ciita	[thus establishing the effectiveness of CIITA]	0.0	6	1	1	1
76175	1710	regulation at the transcriptional level	[regulation at the transcriptional level]	0.0	5	1	1	1
76176	1710	functional unit	[functional unit]	0.0	2	1	1	1
76177	1710	very high level of bcl-2	[very high levels of Bcl-2]	0.0	5	1	1	1
76178	1710	suppression of b activation	[suppression of B activation]	0.0	4	1	1	1
76179	1710	hematopoietic protein- tyrosine phosphatase	[hematopoietic protein- tyrosine phosphatase]	0.0	4	1	1	1
76180	1710	breakpoint range from q13	[breakpoints ranging from q13]	0.0	4	1	1	1
76181	1710	mechanism of cell survival.	[mechanism of cell survival.]	0.0	4	1	1	1
76182	1710	effect of triptolide	[effect of triptolide]	0.0	3	1	1	1
76183	1710	(mhc) class ii antigen	[(MHC) class II antigens]	0.0	4	3	3	1
76184	1710	pathway include myd88	[pathway including MyD88]	0.0	3	1	1	1
76185	1710	tsap -binding	[TSAP -binding]	0.0	2	1	1	1
76186	1710	reason(s) for this change	[reason(s) for these changes]	0.0	4	1	1	1
76187	1710	pocket protein- e2f	[pocket protein- E2F]	0.0	3	1	1	1
76188	1710	mobility ap-1	[mobility AP-1]	0.0	2	1	1	1
76189	1710	t3 /100 microgram	[T3 /100 micrograms]	0.0	3	1	1	1
76190	1710	transcription factor IL-4STAT	[transcription factor IL-4STAT]	0.0	3	1	1	1
76191	1710	twenty-four hour treatment	[Twenty-four hour treatment]	0.0	3	1	1	1
76192	1710	only activity of nuclear extract	[only activity of nuclear extracts]	0.0	5	1	1	1
76193	1710	cd57+ cell	[CD57+ cells]	0.0	2	1	1	1
76194	1710	great selectivity	[greater selectivity]	0.0	2	1	1	1
76195	1710	significant proliferation recent-onset iddm subject 8	[significant proliferation recent-onset IDDM subjects 8]	0.0	6	1	1	1
76196	1710	defective production	[defective production]	0.0	2	1	1	1
76197	1710	the/thf (0.24;	[THE/THF (0.24;]	0.0	2	1	1	1
76198	1710	suggest a outward migration	[suggesting an outward migration]	0.0	4	1	1	1
76199	1710	clinically relevant concentration	[clinically relevant concentrations]	0.0	3	1	1	1
76200	1710	beta globin sequence	[beta globin sequence]	0.0	3	1	1	1
76201	1710	lymphocyte from rheumatoid arthritis patient	[lymphocytes from rheumatoid arthritis patients]	0.0	5	1	1	1
76202	1710	element promoter,	[elements promoter,]	0.0	2	1	1	1
76203	1710	understanding in the differentiation process	[understanding in the differentiation processes]	0.0	5	1	1	1
76204	1710	75-kDa cell-specific signal protein	[75-kDa cell-specific signaling protein]	0.0	4	1	1	1
76205	1710	T cell result	[T cells resulting]	0.0	3	1	1	1
76206	1710	(outer limits, 127	[(outer limits, 127]	0.0	3	1	1	1
76207	1710	intact GR domain	[intact GR domain]	0.0	3	1	1	1
76208	1710	neuronal	[Neuronal]	0.0	1	1	1	1
76209	1710	time point before the expression	[time points before the expression]	0.0	5	1	1	1
76210	1710	(activated) prb block transition	[(activated) pRB blocks transition]	0.0	4	1	1	1
76211	1710	(pomc)	[(POMC)]	0.0	1	1	1	1
76212	1710	basic, unphosphorylated 27-kda protein	[basic, unphosphorylated 27-kDa protein]	0.0	4	1	1	1
76213	1710	marker for personality characteristic	[marker for personality characteristics]	0.0	4	1	1	1
76214	1710	-inducing kinase	[-inducing kinase]	0.0	2	1	1	1
76215	1710	lyonization of normal cell	[lyonization of normal cells]	0.0	4	1	1	1
76216	1710	adhesion of cell human vein cell	[adhesion of cells human vein cells]	0.0	6	1	1	1
76217	1710	anergic T helper cell	[anergic T helper cells]	0.0	4	1	1	1
76218	1710	Japanese woman	[Japanese woman]	0.0	2	1	1	1
76219	1710	potent inhibitor of MEK1 kinase upstream	[potent inhibitors of MEK1 kinase upstream]	0.0	6	1	1	1
76220	1710	healthy non-pregnant woman	[healthy non-pregnant women]	0.0	3	1	1	1
76221	1710	concentration of etoposide (0.15 microM)	[concentrations of etoposide (0.15 microM)]	0.0	5	1	1	1
76222	1710	nuclear factor of t-cell	[nuclear factor of T-cells]	0.0	4	1	1	1
76223	1710	marker of acute leukemia apl	[markers of acute leukemias APLs]	0.0	5	1	1	1
76224	1710	two main goals:	[two main goals:]	0.0	3	1	1	1
76225	1710	regulation of the globin gene	[regulation of the globin genes]	0.0	5	1	1	1
76226	1710	significantly favorable course (p chi2	[significantly favorable course (P chi2]	0.0	5	1	1	1
76227	1710	alteration in resistance	[alterations in resistance]	0.0	3	1	1	1
76228	1710	deletion of a amino- (729-766)	[Deletions of a amino- (729-766)]	0.0	5	1	1	1
76229	1710	main target	[main target]	0.0	2	1	1	1
76230	1710	retinoid -dependent granulocytic marker	[retinoid -dependent granulocytic markers]	0.0	4	1	1	1
76231	1710	active ingredient mediate the effect	[active ingredients mediating the effect]	0.0	5	1	1	1
76232	1710	50-fold induction	[50-fold induction]	0.0	2	1	1	1
76233	1710	limited proteolysis of the terminus	[limited proteolysis of the terminus]	0.0	5	1	1	1
76234	1710	high-resolution mapping with DNase i	[high-resolution mapping with DNase I]	0.0	5	1	1	1
76235	1710	particular subgroup	[particular subgroup]	0.0	2	1	1	1
76236	1710	Correspondingly, transfection	[Correspondingly, transfection]	0.0	2	1	1	1
76237	1710	receptor loci	[receptor loci]	0.0	2	1	1	1
76238	1710	pattern of latency	[pattern of latency]	0.0	3	1	1	1
76239	1710	onset of symptom	[onset of symptoms]	0.0	3	1	1	1
76240	1710	engagement of cd15	[engagement of CD15]	0.0	3	1	1	1
76241	1710	period before development of symptom	[period before development of symptoms]	0.0	5	1	1	1
76242	1710	adherence of sickle blood cell	[adherence of sickle blood cells]	0.0	5	1	1	1
76243	1710	variety of b site	[variety of B sites]	0.0	4	1	1	1
76244	1710	heat-shock protein hsp90	[heat-shock protein hsp90]	0.0	3	1	1	1
76245	1710	Janus tyrosine kinase Jak	[Janus tyrosine kinases Jak]	0.0	4	1	1	1
76246	1710	activation of phosphatidylinositol 3-kinase pi3-kinase	[activation of phosphatidylinositol 3-kinase PI3-kinase]	0.0	5	1	1	1
76247	1710	genuine octamer-binding site	[genuine octamer-binding site]	0.0	3	1	1	1
76248	1710	repeat transcriptional activity	[repeat transcriptional activity]	0.0	3	1	1	1
76249	1710	extract from cells.	[extracts from cells.]	0.0	3	1	1	1
76250	1710	histiocytoma 6, rhabdomyosarcoma	[histiocytoma 6, rhabdomyosarcoma]	0.0	3	1	1	1
76251	1710	proportion of TCRhigh thymocyte	[proportion of TCRhigh thymocytes]	0.0	4	1	1	1
76252	1710	produce enhancement of lps uptake	[producing enhancement of LPS uptake]	0.0	5	1	1	1
76253	1710	b cell activator	[B cell activator]	0.0	3	1	1	1
76254	1710	hiv-1 terminal repeat promoter region	[HIV-1 terminal repeat promoter region]	0.0	5	1	1	1
76255	1710	dissect the event	[dissecting the events]	0.0	3	1	1	1
76256	1710	gene expression at stage	[gene expression at stages]	0.0	4	1	1	1
76257	1710	downstream kinase	[downstream kinases]	0.0	2	1	1	1
76258	1710	sk-n-be(2) cell	[SK-N-Be(2) cells]	0.0	2	1	1	1
76259	1710	heteromeric formation	[heteromeric formation]	0.0	2	1	1	1
76260	1710	gene (rag)-1	[gene (RAG)-1]	0.0	2	1	1	1
76261	1710	expression (m-csf) receptor	[expression (M-CSF) receptor]	0.0	3	1	1	1
76262	1710	hour pulse-treatment	[hour pulse-treatment]	0.0	2	1	1	1
76263	1710	c5a receptor	[C5a receptor]	0.0	2	1	1	1
76264	1710	genomic action of 1,25-dihydroxyvitamin D3	[genomic actions of 1,25-dihydroxyvitamin D3]	0.0	5	1	1	1
76265	1710	RESULTS: the number	[RESULTS: The number]	0.0	3	1	1	1
76266	1710	interleukin gene through interference	[interleukin gene through interference]	0.0	4	1	1	1
76267	1710	identity with the human I gamma	[identity with the human I gamma]	0.0	6	1	1	1
76268	1710	GRE binding	[GRE binding]	0.0	2	1	1	1
76269	1710	-353 to -304 bp	[-353 to -304 bp]	0.0	4	1	1	1
76270	1710	description of a region	[description of a region]	0.0	4	1	1	1
76271	1710	glutathione-s-transferase pi use immunocytochemical method	[glutathione-S-transferase pi using immunocytochemical methods]	0.0	5	1	1	1
76272	1710	portion in the cytoplasmic domain	[portion in the cytoplasmic domain]	0.0	5	1	1	1
76273	1710	involvement of a cofactor	[involvement of a cofactor]	0.0	4	1	1	1
76274	1710	amount nf-kappa b mrna	[amount NF-kappa B mRNA]	0.0	4	1	1	1
76275	1710	2) sign of secondary hypothyroidism	[2) signs of secondary hypothyroidism]	0.0	5	1	1	1
76276	1710	/kbf1	[/KBF1]	0.0	1	1	1	1
76277	1710	act at the level	[acting at the level]	0.0	4	1	1	1
76278	1710	endotoxin inflammation	[endotoxin inflammation]	0.0	2	1	1	1
76279	1710	human immunodeficiency virus-type hiv-1	[Human immunodeficiency virus-type HIV-1]	0.0	4	1	1	1
76280	1710	immature neutrophilic cell	[immature neutrophilic cells]	0.0	3	1	1	1
76281	1710	surface expression of cell adhesion molecule	[surface expression of cell adhesion molecules]	0.0	6	2	2	1
76282	1710	result (average gr concentration	[results (average GR concentration]	0.0	4	1	1	1
76283	1710	effect as on the regulation	[effects as on the regulation]	0.0	5	1	1	1
76284	1710	difference between the effect	[differences between the effect]	0.0	4	1	1	1
76285	1710	susceptibility of the elderly	[susceptibility of the elderly]	0.0	4	1	1	1
76286	1710	affinity with the correlation	[affinity with the correlation]	0.0	4	1	1	1
76287	1710	regulate biological function	[regulating biological functions]	0.0	3	1	1	1
76288	1710	binding of receptor	[binding of receptor]	0.0	3	1	1	1
76289	1710	macrophage by lipopolysaccharide lps	[macrophages by lipopolysaccharide LPS]	0.0	4	1	1	1
76290	1710	pattern of rdna	[pattern of cDNAs]	0.0	3	1	1	1
76291	1710	anomaly	[anomalies]	0.0	1	1	1	1
76292	1710	hemopoiesis, overexpression of gm-csf	[hemopoiesis, overexpression of GM-CSF]	0.0	4	1	1	1
76293	1710	similar DNA binding specificity	[similar DNA binding specificities]	0.0	4	1	1	1
76294	1710	reaction velocity (vmax)	[reaction velocity (Vmax)]	0.0	3	1	1	1
76295	1710	breakpoint kb	[breakpoints kb]	0.0	2	1	1	1
76296	1710	vitro from progenitor cell	[vitro from progenitor cells]	0.0	4	1	1	1
76297	1710	feature of peripheral resistance	[features of peripheral resistance]	0.0	4	1	1	1
76298	1710	regulation of hiv-1	[regulation of HIV-1]	0.0	3	1	1	1
76299	1710	tool predict the occurrence	[tool predicting the occurrence]	0.0	4	1	1	1
76300	1710	round of subcloning	[round of subcloning]	0.0	3	1	1	1
76301	1710	basis for il-4 gene expression	[basis for IL-4 gene expression]	0.0	5	1	1	1
76302	1710	mouse thymocyte	[mouse thymocyte]	0.0	2	1	1	1
76303	1710	expression of select gene	[expression of select genes]	0.0	4	1	1	1
76304	1710	so-called element	[so-called elements]	0.0	2	1	1	1
76305	1710	transcription of histocompatibility complex class gene	[transcription of histocompatibility complex class genes]	0.0	6	1	1	1
76306	1710	CD8 T lymphocyte	[CD8 T lymphocytes]	0.0	3	1	1	1
76307	1710	use a box antiserum	[using an box antiserum]	0.0	4	1	1	1
76308	1710	suppress transcription of gene	[suppressing transcription of genes]	0.0	4	1	1	1
76309	1710	detection selectively in extract	[detection selectively in extracts]	0.0	4	1	1	1
76310	1710	establish pbmc culture in adherent colony	[establishing PBMC cultures in adherent colonies]	0.0	6	1	1	1
76311	1710	individual from the first group),	[individuals from the first group),]	0.0	5	1	1	1
76312	1710	shaping	[shaping]	0.0	1	1	1	1
76313	1710	two class of abundant receptor	[two classes of abundant receptors]	0.0	5	1	1	1
76314	1710	pair phop	[pair phoP]	0.0	2	1	1	1
76315	1710	initially high expression	[initially high expression]	0.0	3	1	1	1
76316	1710	complex resemble nuclear factor	[complex resembling nuclear factor]	0.0	4	1	1	1
76317	1710	diurnal rhythmicity	[diurnal rhythmicity]	0.0	2	1	1	1
76318	1710	three mode of stress.	[three modes of stress.]	0.0	4	1	1	1
76319	1710	maternal expression in human placentae	[maternal expression in human placentae]	0.0	5	1	1	1
76320	1710	immunosuppression by cyclosporin A	[immunosuppression by cyclosporin A]	0.0	4	1	1	1
76321	1710	banding techniques,	[banding techniques,]	0.0	2	1	1	1
76322	1710	dendritic cell-based assay	[dendritic cell-based assay]	0.0	3	1	1	1
76323	1710	menstruate woman	[menstruating women]	0.0	2	1	1	1
76324	1710	overexpression of form	[Overexpression of forms]	0.0	3	1	1	1
76325	1710	potential cellular homologue	[potential cellular homologues]	0.0	3	1	1	1
76326	1710	feedback loop between hiv-1 infection	[feedback loop between HIV-1 infection]	0.0	5	1	1	1
76327	1710	proximal residue of the tail,	[proximal residues of the tail,]	0.0	5	1	1	1
76328	1710	1.16 arbitrary units,	[1.16 arbitrary units,]	0.0	3	1	1	1
76329	1710	p300/cbp-type coactivator	[p300/CBP-type coactivators]	0.0	2	1	1	1
76330	1710	egr-1 /rela synergy	[Egr-1 /RelA synergy]	0.0	3	1	1	1
76331	1710	tyrosine kinase gene	[tyrosine kinase genes]	0.0	3	1	1	1
76332	1710	Hypercortisolaemia,	[Hypercortisolaemia,]	0.0	1	1	1	1
76333	1710	gene in disorder	[genes in disorders]	0.0	3	1	1	1
76334	1710	climacteric syndrome patient	[climacteric syndrome patients]	0.0	3	1	1	1
76335	1710	estrogen bind	[estrogen binding]	0.0	2	1	1	1
76336	1710	extent as ifn-alpha	[extent as IFN-alpha]	0.0	3	1	1	1
76337	1710	hhv-8 +/ebv+ pel	[HHV-8 +/EBV+ PEL]	0.0	3	1	1	1
76338	1710	nf-kappab -contain nuclear extract	[NF-kappaB -containing nuclear extract]	0.0	4	1	1	1
76339	1710	p2 promoter	[P2 promoter]	0.0	2	1	1	1
76340	1710	thick tenacious, protease	[thick, tenacious, protease]	0.0	3	1	1	1
76341	1710	controls, white blood cell	[controls, white blood cell]	0.0	4	1	1	1
76342	1710	U-937 as a model	[U-937 as a model]	0.0	4	1	1	1
76343	1710	allele-specific regulatory system	[allele-specific regulatory system]	0.0	3	1	1	1
76344	1710	different species of heterodimer	[different species of heterodimers]	0.0	4	1	1	1
76345	1710	diagnosis of malignancy	[diagnosis of malignancies]	0.0	3	1	1	1
76346	1710	cp include the enhancer	[Cp including the enhancer]	0.0	4	1	1	1
76347	1710	bind to the -90/-79 sequence	[binding to the -90/-79 sequence]	0.0	5	1	1	1
76348	1710	suggest operational	[suggesting operational]	0.0	2	1	1	1
76349	1710	definite information about role	[definite information about roles]	0.0	4	1	1	1
76350	1710	interaction with the four-subunit ptf	[interaction with the four-subunit PTF]	0.0	5	1	1	1
76351	1710	patient with immunodeficiency X-SCID	[patients with immunodeficiency X-SCID]	0.0	4	1	1	1
76352	1710	Ig heavy chain sequence	[Ig heavy chain sequences]	0.0	4	1	1	1
76353	1710	decrease in function	[decrease in function]	0.0	3	1	1	1
76354	1710	Cbl homologue	[Cbl homologue]	0.0	2	1	1	1
76355	1710	t-cell-specific transcription factor nf-at	[T-cell-specific transcription factors NF-AT]	0.0	4	1	1	1
76356	1710	phosphorylation by protein kinase	[phosphorylation by protein kinase]	0.0	4	1	1	1
76357	1710	high metastatic capacity of cell	[high metastatic capacity of cells]	0.0	5	1	1	1
76358	1710	sulfoxide to phorbol myristate acetate	[sulfoxide to phorbol myristate acetate]	0.0	5	1	1	1
76359	1710	t1/2 of hour at pH	[t1/2 of hr at pH]	0.0	5	1	1	1
76360	1710	glutathione GSH	[glutathione GSH]	0.0	2	1	1	1
76361	1710	supratherapeutic concentration	[supratherapeutic concentrations]	0.0	2	1	1	1
76362	1710	infect baboon cercopithicine herpesvirus	[infecting baboons cercopithicine herpesvirus]	0.0	4	1	1	1
76363	1710	substitution alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[substitutions alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	3	1	1	1
76364	1710	affinity receptor for 1,25-dihydroxycholecalciferol	[affinity receptors for 1,25-dihydroxycholecalciferol]	0.0	4	1	1	1
76365	1710	major human glucocorticoid cortisol	[major human glucocorticoid cortisol]	0.0	4	1	1	1
76366	1710	0.8 microm	[0.8 microM]	0.0	2	1	1	1
76367	1710	terminal repeat (ltr) promoter	[terminal repeat (LTR) promoter]	0.0	4	1	1	1
76368	1710	Oct-2 -dependent function	[Oct-2 -dependent function]	0.0	3	1	1	1
76369	1710	NFAT element in promoter	[NFAT elements in promoters]	0.0	4	1	1	1
76370	1710	(i) acute transfection	[(i) Acute transfection]	0.0	3	1	1	1
76371	1710	less than 4 fmol/mg	[less than 4 fmol/mg]	0.0	4	1	1	1
76372	1710	nuclear nf-kappab in cell	[nuclear NF-kappaB in cells]	0.0	4	1	1	1
76373	1710	heat-labile serum factor	[heat-labile serum factor]	0.0	3	1	1	1
76374	1710	effect of cyclosporin a CsA	[effects of cyclosporin A CsA]	0.0	5	1	1	1
76375	1710	block translocation of the component	[block translocation of the component]	0.0	5	1	1	1
76376	1710	have a excisional biopsy as treatment	[having an excisional biopsy as treatment]	0.0	6	1	1	1
76377	1710	normal proliferation	[normal proliferation]	0.0	2	1	1	1
76378	1710	tuberculosis patient 0/3 sarcoidosis patient	[tuberculosis patients 0/3 sarcoidosis patients]	0.0	5	1	1	1
76379	1710	PPARalpha a regulator of atherogenesis	[PPARalpha a regulator of atherogenesis]	0.0	5	1	1	1
76380	1710	thymic population	[thymic populations]	0.0	2	1	1	1
76381	1710	expression of a gata-2/estrogen receptor chimera	[expression of a GATA-2/estrogen receptor chimera]	0.0	6	1	1	1
76382	1710	surface molecule	[surface molecule]	0.0	2	1	1	1
76383	1710	glucocorticoid receptor on leukocyte	[glucocorticoid receptors on leukocytes]	0.0	4	1	1	1
76384	1710	monoclonal cross-linking	[monoclonal cross-linking]	0.0	2	1	1	1
76385	1710	contain repeat of 15 amino acid	[containing repeats of 15 amino acids]	0.0	6	1	1	1
76386	1710	cell originate	[Cells originating]	0.0	2	1	1	1
76387	1710	search for constitutional loss of allele	[search for constitutional losses of allele]	0.0	6	1	1	1
76388	1710	Fos peptide	[Fos peptide]	0.0	2	1	1	1
76389	1710	receptor on peripheral leucocyte	[receptors on peripheral leucocytes]	0.0	4	1	1	1
76390	1710	glucocorticoid receptor blocker	[glucocorticoid receptor blocker]	0.0	3	1	1	1
76391	1710	sign of secondary hypothyroidism	[signs of secondary hypothyroidism]	0.0	4	1	1	1
76392	1710	alveolar collapse	[alveolar collapse]	0.0	2	1	1	1
76393	1710	reflect difference	[reflecting differences]	0.0	2	1	1	1
76394	1710	anti-CD28 mab	[anti-CD28 mAb]	0.0	2	1	1	1
76395	1710	arterial intima	[arterial intima]	0.0	2	1	1	1
76396	1710	+/- 29.8	[+/- 29.8]	0.0	2	1	1	1
76397	1710	ubiquitous activation	[ubiquitous activation]	0.0	2	1	1	1
76398	1710	acid stimulation	[acid stimulation]	0.0	2	1	1	1
76399	1710	evidence for a activate pathway distinct	[evidence for an activating pathway distinct]	0.0	6	1	1	1
76400	1710	lytic promoter	[lytic promoters]	0.0	2	1	1	1
76401	1710	ca2+-mediated activation of Rap1	[Ca2+-mediated activation of Rap1]	0.0	4	1	1	1
76402	1710	staining for NF-kappa b	[staining for NF-kappa B]	0.0	4	1	1	1
76403	1710	course of differentiation	[course of differentiation]	0.0	3	1	1	1
76404	1710	professional antigen present cell	[professional antigen presenting cells]	0.0	4	1	1	1
76405	1710	sex-and subject	[sex-and subjects]	0.0	2	1	1	1
76406	1710	mutant of type adenovirus ad5	[Mutants of type adenovirus Ad5]	0.0	5	1	1	1
76407	1710	VDR retention	[VDR retention]	0.0	2	1	1	1
76408	1710	part of the LTR region	[parts of the LTR region]	0.0	5	1	1	1
76409	1710	receptor in blood monocyte	[receptor in blood monocytes]	0.0	4	1	1	1
76410	1710	diverse receptor	[diverse receptors]	0.0	2	1	1	1
76411	1710	amino acid alteration	[amino acid alterations]	0.0	3	1	1	1
76412	1710	represent different stage from precursor	[representing different stages from precursors]	0.0	5	1	1	1
76413	1710	contain factor kappab complex	[containing factor kappaB complexes]	0.0	4	1	1	1
76414	1710	antibody pg-b6	[antibodies PG-B6]	0.0	2	1	1	1
76415	1710	concentration microM) of zinc sulfate	[concentrations microM) of zinc sulfate]	0.0	5	1	1	1
76416	1710	significant correlation between VDR concentration	[significant correlation between VDR concentration]	0.0	5	1	1	1
76417	1710	complex class DRA promoter occupancy	[complex class DRA promoter occupancy]	0.0	5	1	1	1
76418	1710	induce loss	[inducing loss]	0.0	2	1	1	1
76419	1710	human myeloid zinc finger protein	[Human myeloid zinc finger protein]	0.0	5	1	1	1
76420	1710	HLF protein	[HLF protein]	0.0	2	3	3	1
76421	1710	porcine cell PAEC	[Porcine cells PAEC]	0.0	3	1	1	1
76422	1710	impact of RXR	[impact of RXR]	0.0	3	1	1	1
76423	1710	LMP1 c-terminus	[LMP1 C-terminus]	0.0	2	1	1	1
76424	1710	receptor in the control	[receptor in the control]	0.0	4	1	1	1
76425	1710	creb camp regulatory element	[CREB cAMP regulatory element]	0.0	4	1	1	1
76426	1710	mutant macrophage-competent derivative of SIVmac239	[mutants macrophage-competent derivative of SIVmac239]	0.0	5	1	1	1
76427	1710	difference from the sequence	[differences from the sequence]	0.0	4	1	1	1
76428	1710	central importance	[central importance]	0.0	2	1	1	1
76429	1710	three pcr product	[Three PCR products]	0.0	3	1	1	1
76430	1710	Biologic effect on human NK	[Biologic effects on human NK]	0.0	5	1	1	1
76431	1710	asthma pathogenesis	[asthma pathogenesis]	0.0	2	1	1	1
76432	1710	methods, include pcr	[methods, including PCR]	0.0	3	1	1	1
76433	1710	bind to domain sequence	[binding to domain sequences]	0.0	4	1	1	1
76434	1710	addition to cell transformation	[addition to cell transformation]	0.0	4	1	1	1
76435	1710	CHO-DR/ B7	[CHO-DR/ B7]	0.0	2	1	1	1
76436	1710	dna-protein binding complex	[DNA-protein binding complexes]	0.0	3	1	1	1
76437	1710	search of a mechanism	[search of a mechanism]	0.0	4	1	1	1
76438	1710	high nuclear translocation of b	[higher nuclear translocation of B]	0.0	5	1	1	1
76439	1710	increase factor	[increasing factor]	0.0	2	1	1	1
76440	1710	t-cell lymphoma with center	[T-cell lymphoma with centers]	0.0	4	1	1	1
76441	1710	transformation in some neoplasia	[transformation in some neoplasias]	0.0	4	1	1	1
76442	1710	gamma-ifn inhibition	[gamma-IFN inhibition]	0.0	2	1	1	1
76443	1710	direct the synthesis of rna	[directing the synthesis of RNA]	0.0	5	1	1	1
76444	1710	multiple homo-	[multiple homo-]	0.0	2	1	1	1
76445	1710	case of b leukemia	[cases of B leukemias]	0.0	4	1	1	1
76446	1710	coiled-coil region	[coiled-coil region]	0.0	2	1	1	1
76447	1710	mechanism for the activation	[mechanism for the activation]	0.0	4	1	1	1
76448	1710	cells/tube	[cells/tube]	0.0	1	1	1	1
76449	1710	contain 151 bp	[containing 151 bp]	0.0	3	1	1	1
76450	1710	p50/p65 heterodimeric form	[p50/p65 heterodimeric form]	0.0	3	1	1	1
76451	1710	therefore, inhibition	[Therefore, inhibition]	0.0	2	1	1	1
76452	1710	hl-60 subclone	[HL-60 subclones]	0.0	2	1	1	1
76453	1710	pathophysiology of infection	[pathophysiology of infection]	0.0	3	1	1	1
76454	1710	relationship between rap1 protein phosphorylation	[Relationship between Rap1 protein phosphorylation]	0.0	5	1	1	1
76455	1710	uncouple of tyrosine kinase from plc-gamma1	[Uncoupling of tyrosine kinases from PLC-gamma1]	0.0	6	1	1	1
76456	1710	stat5b in primary erythroid precursor	[STAT5B in primary erythroid precursors]	0.0	5	1	1	1
76457	1710	various type include myeloid leukaemia	[various types including myeloid leukaemia]	0.0	5	2	2	1
76458	1710	human granulocyte/macrophage-colony factor	[human granulocyte/macrophage-colony factor]	0.0	3	1	1	1
76459	1710	important primary mechanism of insensitivity	[important primary mechanism of insensitivity]	0.0	5	1	1	1
76460	1710	lymphokine receptor gene	[lymphokine receptor genes]	0.0	3	1	1	1
76461	1710	propensity	[propensity]	0.0	1	1	1	1
76462	1710	transactivation by herpesvirus 6 hhv-6 strain	[Transactivation by herpesvirus 6 HHV-6 strains]	0.0	6	1	1	1
76463	1710	Stat3 isoform	[Stat3 isoform]	0.0	2	1	1	1
76464	1710	circulate leukemic T cell	[circulating leukemic T cells]	0.0	4	1	1	1
76465	1710	bone-sparing effect	[bone-sparing effect]	0.0	2	1	1	1
76466	1710	Staurosporine pentoxifylline NF-kappa b inhibitor	[Staurosporine pentoxifylline NF-kappa B inhibitor]	0.0	5	1	1	1
76467	1710	LFA-I beta chain	[LFA-I beta chain]	0.0	3	1	1	1
76468	1710	form of x-linked immunodeficiency	[form of X-linked immunodeficiency]	0.0	4	1	1	1
76469	1710	tal-1 protein expression	[tal-1 protein expression]	0.0	3	1	1	1
76470	1710	stage of B cell development	[stages of B cell development]	0.0	5	1	1	1
76471	1710	subclinical marker	[subclinical markers]	0.0	2	1	1	1
76472	1710	les-induced expression	[LPS-induced expression]	0.0	2	1	1	1
76473	1710	hallmark of t-lymphocyte activation	[hallmarks of T-lymphocyte activation]	0.0	4	1	1	1
76474	1710	g3 tumor with margin (31%	[G3 tumors with margins (31%]	0.0	5	1	1	1
76475	1710	several switch region	[several switch regions]	0.0	3	1	1	1
76476	1710	acute inflammatory injury	[Acute inflammatory injury]	0.0	3	1	1	1
76477	1710	protein dimerization domain hepatic factor	[protein dimerization domain hepatic factor]	0.0	5	1	1	1
76478	1710	signal by this receptor	[signaling by this receptor]	0.0	4	1	1	1
76479	1710	etiology of multiple sclerosis ms	[etiology of multiple sclerosis MS]	0.0	5	1	1	1
76480	1710	receptor in steroid-resistant asthma	[receptor in steroid-resistant asthma]	0.0	4	1	1	1
76481	1710	predominantly negative regulation	[predominantly negative regulation]	0.0	3	1	1	1
76482	1710	human cell line u-937	[human cell lines U-937]	0.0	4	1	1	1
76483	1710	e2f component	[E2F components]	0.0	2	1	1	1
76484	1710	redistribution of T cell	[redistribution of T cells]	0.0	4	1	1	1
76485	1710	loci relevant to pel	[loci relevant to PEL]	0.0	4	1	1	1
76486	1710	mechanism dependent	[mechanism dependent]	0.0	2	1	1	1
76487	1710	SRG3 mrna	[SRG3 mRNA]	0.0	2	1	1	1
76488	1710	outward migration of T cell	[outward migration of T cells]	0.0	5	1	1	1
76489	1710	potential antirheumatic	[potential antirheumatic]	0.0	2	1	1	1
76490	1710	ptf beta antibody	[PTF beta antibodies]	0.0	3	1	1	1
76491	1710	lyso-platelet-activating factor	[lyso-platelet-activating factor]	0.0	2	1	1	1
76492	1710	close relatedness	[close relatedness]	0.0	2	1	1	1
76493	1710	sequence DRE	[sequence DRE]	0.0	2	1	1	1
76494	1710	correlate to the current classification	[correlates to the current classification]	0.0	5	1	1	1
76495	1710	mrna species of 1.8 kilobasis	[mRNA species of 1.8 kilobases]	0.0	5	1	1	1
76496	1710	-DeltaSH2	[-DeltaSH2]	0.0	1	2	2	1
76497	1710	mucosa-associated lymphoid tissue lymphoma	[mucosa-associated lymphoid tissue lymphoma]	0.0	4	1	1	1
76498	1710	interaction with the transcriptional machinery.	[interaction with the transcriptional machinery.]	0.0	5	1	1	1
76499	1710	progression of responsiveness	[progression of responsiveness]	0.0	3	1	1	1
76500	1710	lymphocyte proliferation in 13 control	[lymphocyte proliferation in 13 controls]	0.0	5	1	1	1
76501	1710	c-jun y-peptide	[c-Jun Y-peptide]	0.0	2	1	1	1
76502	1710	species include human lymphoid cell	[species including human lymphoid cells]	0.0	5	1	1	1
76503	1710	physiological human glucocorticoid	[physiological human glucocorticoid]	0.0	3	1	1	1
76504	1710	lavage (bal) cell in tuberculosis	[lavage (BAL) cells in tuberculosis]	0.0	5	1	1	1
76505	1710	non professional apc	[non professional APCs]	0.0	3	1	1	1
76506	1710	activity of a ap-1-related protein	[activity of an AP-1-related protein]	0.0	5	1	1	1
76507	1710	role of signalling	[role of signalling]	0.0	3	1	1	1
76508	1710	aberrant consequence	[aberrant consequence]	0.0	2	1	1	1
76509	1710	induction in a human line jurkat	[Induction in a human line Jurkat]	0.0	6	1	1	1
76510	1710	Epstein-Barr virus EBV a gamma-herpesvirus	[Epstein-Barr virus EBV a gamma-herpesvirus]	0.0	5	1	1	1
76511	1710	early progenitor burst-form units-erythroid	[early progenitors burst-forming units-erythroid]	0.0	4	1	1	1
76512	1710	il-1 protein kinase	[IL-1 protein kinase]	0.0	3	1	1	1
76513	1710	Recent work from laboratory	[Recent work from laboratories]	0.0	4	1	1	1
76514	1710	unrecognized form	[unrecognized form]	0.0	2	2	2	1
76515	1710	dose of ionizing radiation	[doses of ionizing radiation]	0.0	4	1	1	1
76516	1710	lipopolysaccharide lps stimulation	[lipopolysaccharide LPS stimulation]	0.0	3	1	1	1
76517	1710	binding activity to CRE	[binding activity to CRE]	0.0	4	1	1	1
76518	1710	form of binding partner,	[form of binding partner,]	0.0	4	1	1	1
76519	1710	use a semen sample	[using a semen sample]	0.0	4	1	1	1
76520	1710	n-acetylcysteine inhibition cytokine-induced e-selectin	[N-acetylcysteine inhibition cytokine-induced E-selectin]	0.0	4	1	1	1
76521	1710	transactivation activity for the mbp promoter	[transactivation activity for the MBP promoter]	0.0	6	1	1	1
76522	1710	include 1 case without calm	[including 1 case without CALM]	0.0	5	1	1	1
76523	1710	negative gsk-3beta	[negative GSK-3beta]	0.0	2	1	1	1
76524	1710	carboxyl-terminal cytoplasmic segment on cd36	[carboxyl-terminal cytoplasmic segment on CD36]	0.0	5	1	1	1
76525	1710	target of PGE2	[targets of PGE2]	0.0	3	1	1	1
76526	1710	monocytic differentiation arrest	[monocytic differentiation arrest]	0.0	3	1	1	1
76527	1710	HHV-6 (gs) cDNA clone encode	[HHV-6 (GS) cDNA clone encoding]	0.0	5	1	1	1
76528	1710	classical NFkappaB site	[classical NFkappaB sites]	0.0	3	1	1	1
76529	1710	staining with Fast-Green/Neutral-Red	[staining with Fast-Green/Neutral-Red]	0.0	3	1	1	1
76530	1710	proliferative life span	[proliferative life span]	0.0	3	1	1	1
76531	1710	10 U/ml, h)	[10 U/ml, h)]	0.0	3	1	1	1
76532	1710	role of Aiolos	[role of Aiolos]	0.0	3	1	1	1
76533	1710	contrast, dominant rac	[contrast, dominant Rac]	0.0	3	1	1	1
76534	1710	transcription in the T	[transcription in the T]	0.0	4	1	1	1
76535	1710	strong, promoter activity	[strong, promoter activity]	0.0	3	1	1	1
76536	1710	Finally, transfection	[Finally, transfection]	0.0	2	1	1	1
76537	1710	support DNA binding than antagonist ru486	[supporting DNA binding than antagonist RU486]	0.0	6	1	1	1
76538	1710	induction of NF-ATc	[induction of NF-ATc]	0.0	3	1	1	1
76539	1710	granulocyte/macrophage-colony factor	[granulocyte/macrophage-colony factor]	0.0	2	1	1	1
76540	1710	progression of type of cancer	[progression of types of cancers]	0.0	5	2	2	1
76541	1710	breakpoint 11	[breakpoints 11]	0.0	2	1	1	1
76542	1710	synthesis in allergen-specific t-cell clone	[synthesis in allergen-specific T-cell clones]	0.0	5	1	1	1
76543	1710	Thus, NF-kappa B a transcriptional activator	[Thus, NF-kappa B a transcriptional activator]	0.0	6	1	1	1
76544	1710	activity of the hiv LTR	[activity of the HIV LTR]	0.0	5	1	1	1
76545	1710	PMA -inducible factor	[PMA -inducible factor]	0.0	3	1	1	1
76546	1710	plaque of coronary artery	[plaques of coronary arteries]	0.0	4	1	1	1
76547	1710	T cell control	[T cell controls]	0.0	3	1	1	1
76548	1710	b-cell progenitor	[B-cell progenitors]	0.0	2	1	1	1
76549	1710	site for phosphorylation by protein kinase	[sites for phosphorylation by protein kinase]	0.0	6	1	1	1
76550	1710	subset of CD4 T cell	[subsets of CD4 T cells]	0.0	5	1	1	1
76551	1710	defect in x-linked ricket	[defect in X-linked rickets]	0.0	4	1	1	1
76552	1710	near-perfect repeat DR of bp	[near-perfect repeats DR of bp]	0.0	5	1	1	1
76553	1710	tissue-specific rna polymerase transcription factor	[tissue-specific RNA polymerase transcription factor]	0.0	5	1	1	1
76554	1710	logarithmic phase	[logarithmic phase]	0.0	2	1	1	1
76555	1710	patient positive	[patients positive]	0.0	2	2	2	1
76556	1710	harbour herpesvirus type-8	[harbouring herpesvirus type-8]	0.0	3	1	1	1
76557	1710	murine GATA-1 Ie promoter	[murine GATA-1 IE promoter]	0.0	4	1	1	1
76558	1710	cytosolic receptor	[cytosolic receptors]	0.0	2	1	1	1
76559	1710	/luciferase	[/luciferase]	0.0	1	1	1	1
76560	1710	hour treatment with nm RA cell	[hour treatment with nM RA cells]	0.0	6	1	1	1
76561	1710	secretion of macrophage inflammatory protein-1alpha	[secretion of macrophage inflammatory protein-1alpha]	0.0	5	1	1	1
76562	1710	rna processing	[RNA processing]	0.0	2	1	1	1
76563	1710	(low affinity,	[(low affinity,]	0.0	2	1	1	1
76564	1710	fgf-1 signal	[FGF-1 signaling]	0.0	2	1	1	1
76565	1710	mechanism of viral latency	[mechanism of viral latency]	0.0	4	1	1	1
76566	1710	promoter-driven reporter	[promoter-driven reporter]	0.0	2	1	1	1
76567	1710	effect related to cell proliferation	[effects related to cell proliferation]	0.0	5	1	1	1
76568	1710	kD complex	[kD complex]	0.0	2	1	1	1
76569	1710	unexpectedly, expression	[unexpectedly, expression]	0.0	2	1	1	1
76570	1710	statg in normal human myeloid cell	[StatG in normal human myeloid cells]	0.0	6	1	1	1
76571	1710	fibrosarcoma malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[fibrosarcoma malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
76572	1710	c-fe gene	[c-fes gene]	0.0	2	2	2	1
76573	1710	further series of patient	[further series of patients]	0.0	4	1	1	1
76574	1710	24-hydroxylated metabolite more polar	[24-hydroxylated metabolites more polar]	0.0	4	1	1	1
76575	1710	nucleotide exchange factor Vav	[nucleotide exchange factor Vav]	0.0	4	1	1	1
76576	1710	mechanism in each cell type.	[mechanisms in each cell type.]	0.0	5	1	1	1
76577	1710	Fine mapping	[Fine mapping]	0.0	2	1	1	1
76578	1710	previously unrecognized function	[previously unrecognized function]	0.0	3	1	1	1
76579	1710	transcription of major complex class gene	[transcription of major complex class genes]	0.0	6	1	1	1
76580	1710	hematopoietic gene transcription	[hematopoietic gene transcription]	0.0	3	1	1	1
76581	1710	differentiation of HL-60 promyelocytic leukemia cell	[differentiation of HL-60 promyelocytic leukemia cells]	0.0	6	1	1	1
76582	1710	pre-bound transcription factor	[pre-bound transcription factors]	0.0	3	1	1	1
76583	1710	reverse primer adjacent	[reverse primer adjacent]	0.0	3	1	1	1
76584	1710	IL4R complex	[IL4R complex]	0.0	2	1	1	1
76585	1710	product of the translocation	[products of the translocation]	0.0	4	1	1	1
76586	1710	lipoarabinomannan manlam	[lipoarabinomannan ManLAM]	0.0	2	1	1	1
76587	1710	provide mechanism	[providing mechanism]	0.0	2	1	1	1
76588	1710	rest normal T cell	[resting normal T cells]	0.0	4	1	1	1
76589	1710	isolation for different zinc finger protein	[Isolation for different zinc finger proteins]	0.0	6	1	1	1
76590	1710	suppression of TNF	[suppression of TNF]	0.0	3	1	1	1
76591	1710	multiple antigen-specific reactivity	[multiple antigen-specific reactivities]	0.0	3	1	1	1
76592	1710	b-like site	[B-like site]	0.0	2	1	1	1
76593	1710	target of hiv infection	[targets of HIV infection]	0.0	4	1	1	1
76594	1710	degradation I kappa b alpha	[degradation I kappa B alpha]	0.0	5	1	1	1
76595	1710	use a genetic screen	[Using a genetic screen]	0.0	4	1	1	1
76596	1710	cell fusion between clone	[cell fusion between clone]	0.0	4	1	1	1
76597	1710	complementary single-residue substitution	[complementary single-residue substitution]	0.0	3	1	1	1
76598	1710	alpha-globin enhancer hs-40	[alpha-globin enhancer HS-40]	0.0	3	1	1	1
76599	1710	feasible manipulation	[feasible manipulation]	0.0	2	1	1	1
76600	1710	activation of biochemical event lead	[activation of biochemical events leading]	0.0	5	1	1	1
76601	1710	cytokine attract chemokine	[cytokines attracting chemokines]	0.0	3	1	1	1
76602	1710	promoter-enhancer induction	[promoter-enhancer induction]	0.0	2	1	1	1
76603	1710	creb-	[CREB-]	0.0	1	1	1	1
76604	1710	normal sequence	[normal sequences]	0.0	2	1	1	1
76605	1710	paf receptor transcript 1 leukocyte-type	[PAF receptor transcript 1 leukocyte-type]	0.0	5	1	1	1
76606	1710	VDR domain alone,	[VDR domain alone,]	0.0	3	1	1	1
76607	1710	glrp	[GLRP]	0.0	1	1	1	1
76608	1710	gene in primary cell	[genes in primary cells]	0.0	4	1	1	1
76609	1710	extract from cd16-	[extracts from CD16-]	0.0	3	1	1	1
76610	1710	three disease	[three diseases]	0.0	2	1	1	1
76611	1710	beta integrin with antibody	[beta integrins with antibodies]	0.0	4	1	1	1
76612	1710	glucocorticoid receptor in mononuclear cell	[glucocorticoid receptors in mononuclear cells]	0.0	5	1	1	1
76613	1710	Spi-B binding	[Spi-B binding]	0.0	2	1	1	1
76614	1710	efficient inhibitor	[efficient inhibitor]	0.0	2	1	1	1
76615	1710	cell rat fibroblast	[cells rat fibroblasts]	0.0	3	1	1	1
76616	1710	erythropoietin receptor signal	[erythropoietin receptor signaling]	0.0	3	1	1	1
76617	1710	influence on the induction	[influence on the induction]	0.0	4	1	1	1
76618	1710	ELAM-1	[ELAM-1]	0.0	1	1	1	1
76619	1710	disease xeroderma pigmentosum XP	[disease xeroderma pigmentosum XP]	0.0	4	1	1	1
76620	1710	low density lipoprotein inflammatory response	[low density lipoprotein inflammatory responses]	0.0	5	1	1	1
76621	1710	factor-kappa b by low-density lipoprotein	[factor-kappa B by low-density lipoprotein]	0.0	5	1	1	1
76622	1710	prip restriction fragment length polymorphism	[PRIP Restriction Fragment Length Polymorphism]	0.0	5	1	1	1
76623	1710	single retinoic acid response element	[single retinoic acid response element]	0.0	5	1	1	1
76624	1710	characterization of tissue expression	[characterization of tissue expression]	0.0	4	1	1	1
76625	1710	viral immediate-early transactivator	[viral immediate-early transactivator]	0.0	3	1	1	1
76626	1710	consider a element	[Considering a element]	0.0	3	1	1	1
76627	1710	il-2 blockade	[IL-2 blockade]	0.0	2	1	1	1
76628	1710	gene encode b-binding-proteins	[genes encoding B-binding-proteins]	0.0	3	1	1	1
76629	1710	role transduce distal signal	[role transducing distal signals]	0.0	4	1	1	1
76630	1710	regard t4	[regarding T4]	0.0	2	1	1	1
76631	1710	adult cd34+	[adult CD34+]	0.0	2	1	1	1
76632	1710	region of the c-myb	[region of the c-myb]	0.0	4	1	1	1
76633	1710	high mobility group (hmg) box	[high mobility group (HMG) box]	0.0	5	1	1	1
76634	1710	5'-most distal carg sequence	[5'-most distal CArG sequences]	0.0	4	1	1	1
76635	1710	TNFalpha inhibition	[TNFalpha inhibition]	0.0	2	1	1	1
76636	1710	several cytokine human interleukin	[several cytokines human interleukin]	0.0	4	1	1	1
76637	1710	apoptosis inhibition in malignant lymphocyte	[Apoptosis inhibition in malignant lymphocytes]	0.0	5	1	1	1
76638	1710	October transcription factor	[Oct transcription factor]	0.0	3	1	1	1
76639	1710	transcription factor contain zinc finger	[transcription factor containing zinc fingers]	0.0	5	1	1	1
76640	1710	nmol/L; diethylstilbestrol	[nmol/L; diethylstilbestrol]	0.0	2	1	1	1
76641	1710	c-myb site	[c-Myb sites]	0.0	2	1	1	1
76642	1710	different effect of agent	[different effects of agents]	0.0	4	1	1	1
76643	1710	also rapidak non-genomic effect	[also rapid, non-genomic effects]	0.0	4	1	1	1
76644	1710	lacz gene	[lacZ gene]	0.0	2	2	2	1
76645	1710	however, two immunosuppressive agent	[However, two immunosuppressive agents]	0.0	4	1	1	1
76646	1710	efficacy in child with deterioration	[efficacy in children with deteriorations]	0.0	5	1	1	1
76647	1710	acid RA treatment	[acid RA treatment]	0.0	3	1	1	1
76648	1710	conferr DNA binding in vivo	[conferring DNA binding in vivo]	0.0	5	1	1	1
76649	1710	thus, t-cell	[Thus, T-cells]	0.0	2	1	1	1
76650	1710	LEF-1 in vitro	[LEF-1 in vitro]	0.0	3	1	1	1
76651	1710	pbl-t	[PBL-T]	0.0	1	1	1	1
76652	1710	short cDNA sequence tag	[short cDNA sequence tags]	0.0	4	1	1	1
76653	1710	extracellular signal-regulated kinase pathway	[extracellular signal-regulated kinase pathway]	0.0	4	1	1	1
76654	1710	basophil cell return	[basophil cell return]	0.0	3	1	1	1
76655	1710	world primate	[World primates]	0.0	2	1	1	1
76656	1710	differential gene regulation	[differential gene regulation]	0.0	3	1	1	1
76657	1710	co-stimulation of t-lymphocyte occupancy	[Co-stimulation of T-lymphocytes occupancy]	0.0	4	1	1	1
76658	1710	cell with particle	[cells with particles]	0.0	3	1	1	1
76659	1710	-mobilize	[-mobilizing]	0.0	1	1	1	1
76660	1710	mutant with DNA sequence	[Mutants with DNA sequences]	0.0	4	1	1	1
76661	1710	transfection use reporter construct with multiple	[transfections using reporter constructs with multiples]	0.0	6	1	1	1
76662	1710	chain IgH	[chain IgH]	0.0	2	1	1	1
76663	1710	fibrosarcoma malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
76664	1710	impact binding	[impact binding]	0.0	2	1	1	1
76665	1710	oxygen -release of monocyte	[oxygen -release of monocytes]	0.0	4	1	1	1
76666	1710	twofold increase in GRE binding	[twofold increase in GRE binding]	0.0	5	1	1	1
76667	1710	receptor binding to region	[receptor binding to regions]	0.0	4	1	1	1
76668	1710	fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	6	1	1	1
76669	1710	units, p young	[units, P young]	0.0	3	1	1	1
76670	1710	metabolic status after surgery comparison	[metabolic status after surgery comparison]	0.0	5	1	1	1
76671	1710	transcription of the heavy-chain gene	[transcription of the heavy-chain gene]	0.0	5	1	1	1
76672	1710	increase in gene transcription	[increases in gene transcription]	0.0	4	1	1	1
76673	1710	MHC hla-dra class ii gene	[MHC HLA-DRA class II gene]	0.0	5	1	1	1
76674	1710	interaction of transcription factor pu.1 antagonism	[interaction of transcription factors PU.1 antagonism]	0.0	6	1	1	1
76675	1710	J delta	[J delta]	0.0	2	1	1	1
76676	1710	fetal protein	[fetal protein]	0.0	2	1	1	1
76677	1710	selective ligand for retinoic acid receptor	[selective ligands for retinoic acid receptors]	0.0	6	1	1	1
76678	1710	study use cell	[studies using cells]	0.0	3	1	1	1
76679	1710	-dependent activation of interleukin 2 gene	[-dependent activation of interleukin 2 gene]	0.0	6	1	1	1
76680	1710	consist of p50/p65 complex	[consisting of p50/p65 complexes]	0.0	4	1	1	1
76681	1710	continuous proliferation	[continuous proliferation]	0.0	2	1	1	1
76682	1710	kilometer tnf receptor tr75 expression	[kd TNF receptor TR75 expression]	0.0	5	1	1	1
76683	1710	human acid lipase LAL	[Human acid lipase LAL]	0.0	4	1	1	1
76684	1710	coinducer	[coinducer]	0.0	1	1	1	1
76685	1710	ebv- b	[EBV- B]	0.0	2	1	1	1
76686	1710	set a series	[setting a series]	0.0	3	1	1	1
76687	1710	RB sense,	[RB sense,]	0.0	2	1	1	1
76688	1710	acetate PMA	[acetate PMA]	0.0	2	1	1	1
76689	1710	related c-c chemokine gene	[related C-C chemokine genes]	0.0	4	1	1	1
76690	1710	er form	[ER forms]	0.0	2	1	1	1
76691	1710	human neonatal T lymphocyte	[human neonatal T lymphocytes]	0.0	4	1	1	1
76692	1710	99% suppression	[99% suppression]	0.0	2	2	2	1
76693	1710	transfection of trans-dominant expression vector	[Transfection of trans-dominant expression vectors]	0.0	5	1	1	1
76694	1710	thymocyte cell	[thymocyte cells]	0.0	2	1	1	1
76695	1710	gdsp a elastase inhibitor	[GDSP a elastase inhibitor]	0.0	4	1	1	1
76696	1710	infiltrate eosinophil	[infiltrating eosinophils]	0.0	2	1	1	1
76697	1710	major disorder in adolescent	[Major disorder in adolescents]	0.0	4	1	1	1
76698	1710	significant class of AIDS NHL	[significant class of AIDS NHL]	0.0	5	1	1	1
76699	1710	regulate a b gene blk	[regulating a B gene blk]	0.0	5	1	1	1
76700	1710	translocation of this member	[translocation of these members]	0.0	4	1	1	1
76701	1710	1e8 b cell line	[1E8 B cell line]	0.0	4	1	1	1
76702	1710	excision repair	[excision repair]	0.0	2	1	1	1
76703	1710	induction of stat1	[induction of STAT1]	0.0	3	1	1	1
76704	1710	neutrophil lipocalin NGAL	[Neutrophil lipocalin NGAL]	0.0	3	2	2	1
76705	1710	domains, a	[domains, A]	0.0	2	1	1	1
76706	1710	thus, competition between activator	[Thus, competition between activators]	0.0	4	1	1	1
76707	1710	relatively low number (positive)	[relatively low number (positive)]	0.0	4	1	1	1
76708	1710	effect of the pkc	[effects of the PKCs]	0.0	4	1	1	1
76709	1710	expression in the maintenance	[expression in the maintenance]	0.0	4	1	1	1
76710	1710	other member of the factor family	[other members of the factor family]	0.0	6	1	1	1
76711	1710	lack c/ebp site	[lacking C/EBP sites]	0.0	3	1	1	1
76712	1710	19 patient	[19 patients]	0.0	2	2	2	1
76713	1710	distal region Chr 9	[distal region Chr 9]	0.0	4	1	1	1
76714	1710	homologue of cyclosporin a	[homologues of cyclosporin A]	0.0	4	1	1	1
76715	1710	pHU-14	[pHU-14]	0.0	1	1	1	1
76716	1710	0.025) to il-1 beta	[0.025) to IL-1 beta]	0.0	4	1	1	1
76717	1710	reservoir for production in vivo,	[reservoir for production in vivo,]	0.0	5	1	1	1
76718	1710	only a amount	[only a amount]	0.0	3	2	2	1
76719	1710	hypertension PIH	[hypertension PIH]	0.0	2	2	2	1
76720	1710	determination in child	[determination in children]	0.0	3	1	1	1
76721	1710	thus positioning NFAT	[thus positioning NFAT]	0.0	3	1	1	1
76722	1710	potent antioxidant,	[potent antioxidant,]	0.0	2	2	2	1
76723	1710	adhesion molecule-1 expression in glial cell	[adhesion molecule-1 expression in glial cells]	0.0	6	1	1	1
76724	1710	genome positional homologue of herpesviruse	[genome positional homologues of herpesviruses]	0.0	5	1	1	1
76725	1710	formation of mitogen-inducible dna-binding complex	[formation of mitogen-inducible DNA-binding complexes]	0.0	5	1	1	1
76726	1710	consistent pattern	[consistent patterns]	0.0	2	1	1	1
76727	1710	vivo study deficient	[vivo studies deficient]	0.0	3	1	1	1
76728	1710	group of hypercalciuric patient	[group of hypercalciuric patients]	0.0	4	1	1	1
76729	1710	one member,	[One member,]	0.0	2	1	1	1
76730	1710	rapid regression	[rapid regression]	0.0	2	1	1	1
76731	1710	phagocyte activation	[phagocyte activation]	0.0	2	1	1	1
76732	1710	binding of three complex RFX	[binding of three complexes RFX]	0.0	5	1	1	1
76733	1710	fibrosarcoma 8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma 8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
76734	1710	requirement for function	[requirement for function]	0.0	3	1	1	1
76735	1710	method for down-regulation	[methods for down-regulation]	0.0	3	1	1	1
76736	1710	CD3 pathway	[CD3 pathway]	0.0	2	1	1	1
76737	1710	modulator of LMP1 (1-231)-mediated	[modulator of LMP1 (1-231)-mediated]	0.0	4	1	1	1
76738	1710	interleukin-12 expression	[Interleukin-12 expression]	0.0	2	1	1	1
76739	1710	binding antibody	[binding antibodies]	0.0	2	1	1	1
76740	1710	renaturation experiment	[renaturation experiments]	0.0	2	1	1	1
76741	1710	derivative alpha g2s	[derivative alpha G2S]	0.0	3	1	1	1
76742	1710	other reactive hyperplasias	[other reactive hyperplasias]	0.0	3	1	1	1
76743	1710	induce CAT activity fibrinogen for h.	[inducing CAT activity fibrinogen for h,]	0.0	6	1	1	1
76744	1710	degree of substrate specificity	[degree of substrate specificity]	0.0	4	1	1	1
76745	1710	encode cyclophilin b-binding-proteins	[encoding cyclophilin B-binding-proteins]	0.0	3	1	1	1
76746	1710	substitution on c-11 alpha,25-(OH)2D3	[substitutions on C-11 alpha,25-(OH)2D3]	0.0	4	1	1	1
76747	1710	mediator via binding	[mediators via binding]	0.0	3	1	1	1
76748	1710	b mobilization by aspirin	[B mobilization by aspirin]	0.0	4	1	1	1
76749	1710	variation in regulation	[variation in regulation]	0.0	3	1	1	1
76750	1710	receptor in the lymphocyte	[receptor in the lymphocytes]	0.0	4	1	1	1
76751	1710	growth inhibition of myeloid leukemia cell	[growth inhibition of myeloid leukemia cells]	0.0	6	1	1	1
76752	1710	agreement on the inflammatory pathogenesis	[agreement on the inflammatory pathogenesis]	0.0	5	1	1	1
76753	1710	epithelial stat1 control transcription factor	[epithelial Stat1 control transcription factors]	0.0	5	1	1	1
76754	1710	b p50 homodimer	[B p50 homodimers]	0.0	3	1	1	1
76755	1710	infection of tat- immunodeficiency virus analysis	[Infection of Tat- immunodeficiency viruses analyses]	0.0	6	1	1	1
76756	1710	land globular, electron-dense structure	[LANDs globular, electron-dense structures]	0.0	4	1	1	1
76757	1710	60 bp upstream from the enhancer	[60 bp upstream from the enhancer]	0.0	6	1	1	1
76758	1710	underlie this response	[underlying this response]	0.0	3	1	1	1
76759	1710	12 woman without diabete	[12 women without diabetes]	0.0	4	1	1	1
76760	1710	Jurkat T cell with mab	[Jurkat T cells with mAb]	0.0	5	1	1	1
76761	1710	15-base oligonucleotide	[15-base oligonucleotide]	0.0	2	1	1	1
76762	1710	serum cortisol level	[serum cortisol level]	0.0	3	1	1	1
76763	1710	mutant of IKKalpha	[mutants of IKKalpha]	0.0	3	1	1	1
76764	1710	activator of the viral repeat	[activator of the viral repeat]	0.0	5	1	1	1
76765	1710	corresponding to amino acid 199	[corresponding to amino acids 199]	0.0	5	1	1	1
76766	1710	human malignancy	[human malignancies]	0.0	2	1	1	1
76767	1710	DNA of the gene	[DNA of the gene]	0.0	4	1	1	1
76768	1710	abnormal nf-kappa b activity from patient	[Abnormal NF-kappa B activity from patients]	0.0	6	1	1	1
76769	1710	contrast, cell fusion	[contrast, cell fusion]	0.0	3	1	1	1
76770	1710	dominant negative HLH factor Id3	[dominant negative HLH factor Id3]	0.0	5	1	1	1
76771	1710	structure of the tissue	[structure of the tissues]	0.0	4	1	1	1
76772	1710	glucocorticoid on endogenous glucocorticoid function	[glucocorticoids on endogenous glucocorticoid function]	0.0	5	1	1	1
76773	1710	only binding affinity RBA	[only binding affinities RBA]	0.0	4	1	1	1
76774	1710	use magnetic separation	[using magnetic separation]	0.0	3	1	1	1
76775	1710	gene in fresh cell	[gene in fresh cells]	0.0	4	1	1	1
76776	1710	use the mobility shift assay	[using the mobility shift assay]	0.0	5	3	3	1
76777	1710	site of tuberculosis	[sites of tuberculosis]	0.0	3	1	1	1
76778	1710	variety of human cells,	[variety of human cells,]	0.0	4	1	1	1
76779	1710	activation of the il-2 receptor	[activation of the IL-2 receptor]	0.0	5	1	1	1
76780	1710	rapid phosphorylation of the three member	[rapid phosphorylation of the three members]	0.0	6	1	1	1
76781	1710	quantitative reverse transcription pcr	[quantitative reverse transcription PCR]	0.0	4	1	1	1
76782	1710	moreover, Tax1 expression of transcription factor	[Moreover, Tax1 expression of transcription factors]	0.0	6	1	1	1
76783	1710	affinity, capacity) binding site	[affinity, capacity) binding sites]	0.0	4	1	1	1
76784	1710	SL3 enhancer factor	[SL3 enhancer factor]	0.0	3	1	1	1
76785	1710	precise number	[precise number]	0.0	2	1	1	1
76786	1710	share homology	[share homology]	0.0	2	1	1	1
76787	1710	novel M(r)	[novel M(r)]	0.0	2	1	1	1
76788	1710	combination of gc olp	[combinations of GC /LPS]	0.0	4	1	1	1
76789	1710	effusion from 20 patient	[effusions from 20 patients]	0.0	4	1	1	1
76790	1710	cytokine assembly	[cytokines assembly]	0.0	2	1	1	1
76791	1710	measure postcapillary venule	[measuring postcapillary venules]	0.0	3	1	1	1
76792	1710	killer cell receptor	[killer cell receptors]	0.0	3	3	3	1
76793	1710	interleukin granulocyte-macrophage factor	[interleukin granulocyte-macrophage factor]	0.0	3	1	1	1
76794	1710	histocompatibility class gene expression	[histocompatibility class gene expression]	0.0	4	1	1	1
76795	1710	action a gata site	[action a GATA site]	0.0	4	1	1	1
76796	1710	colostrum inhibitory factor	[colostrum inhibitory factor]	0.0	3	1	1	1
76797	1710	use a competitive hybridization assay	[using a competitive hybridization assay]	0.0	5	1	1	1
76798	1710	e series	[E series]	0.0	2	1	1	1
76799	1710	parallel protein kinase pathway	[parallel protein kinase pathways]	0.0	4	1	1	1
76800	1710	substrate in cells.	[substrates in cells.]	0.0	3	1	1	1
76801	1710	one case with a negative reaction	[one case with a negative reaction]	0.0	6	1	1	1
76802	1710	estrogen-mediated activation	[estrogen-mediated activation]	0.0	2	1	1	1
76803	1710	nf-e2 expression in erythroid differentiation	[NF-E2 expression in erythroid differentiation]	0.0	5	1	1	1
76804	1710	RARS patient	[RARS patients]	0.0	2	1	1	1
76805	1710	phospholipase Cy1	[phospholipase Cy1]	0.0	2	1	1	1
76806	1710	induction differentiation of m2-type blast cell	[Induction differentiation of M2-type blast cells]	0.0	6	1	1	1
76807	1710	molecular mass (50k)	[molecular mass (50K)]	0.0	3	1	1	1
76808	1710	pluripotent progenitor	[pluripotent progenitors]	0.0	2	1	1	1
76809	1710	such as factor enf)-kappa b	[such as factor (NF)-kappa B]	0.0	5	1	1	1
76810	1710	mrna species of kilobasis	[mRNA species of kilobases]	0.0	4	1	1	1
76811	1710	similar susceptibility	[similar susceptibility]	0.0	2	1	1	1
76812	1710	tnfrp55 mouse strain	[TNFRp55 mouse strain]	0.0	3	1	1	1
76813	1710	several hallmark	[several hallmarks]	0.0	2	1	1	1
76814	1710	major complex class ii transactivator	[major complex class II transactivator]	0.0	5	1	1	1
76815	1710	transform protein LMP1	[transforming protein LMP1]	0.0	3	1	1	1
76816	1710	index of antioxidant	[index of antioxidants]	0.0	3	1	1	1
76817	1710	adherence/contact to cell in vessel	[adherence/contact to cells in vessel]	0.0	5	1	1	1
76818	1710	diabete diabete	[diabetes diabetes]	0.0	2	1	1	1
76819	1710	substantial activation of ap-1	[substantial activation of AP-1]	0.0	4	1	1	1
76820	1710	conflict result	[conflicting results]	0.0	2	1	1	1
76821	1710	t-cell-activating superantigen enterotoxin a	[T-cell-activating superantigen enterotoxin A]	0.0	4	1	1	1
76822	1710	clearly a transcription factor	[clearly a transcription factor]	0.0	4	1	1	1
76823	1710	synthetic lipid	[synthetic lipid]	0.0	2	1	1	1
76824	1710	moreover, virus	[Moreover, virus]	0.0	2	1	1	1
76825	1710	form of positive selection clonal expansion)	[forms of positive selection clonal expansion)]	0.0	6	1	1	1
76826	1710	uptake of neutrophil by phagocyte	[uptake of neutrophils by phagocytes]	0.0	5	1	1	1
76827	1710	two Burkitt' lymphoma b cell line	[two Burkitt's lymphoma B cell lines]	0.0	6	1	1	1
76828	1710	ca2+ feca2+	[Ca2+ FECa2+]	0.0	2	1	1	1
76829	1710	3.1+/-0.2 nmol/L)	[3.1+/-0.2 nmol/L)]	0.0	2	1	1	1
76830	1710	near-perfect repeat	[near-perfect repeats]	0.0	2	1	1	1
76831	1710	compound in the plant kingdom,	[compounds in the plant kingdom,]	0.0	5	1	1	1
76832	1710	concern the pathogenesis of endometriosis	[concerning the pathogenesis of endometriosis]	0.0	5	1	1	1
76833	1710	maintain the balance	[maintaining the balance]	0.0	3	1	1	1
76834	1710	promoter-reporter fusion	[promoter-reporter fusions]	0.0	2	1	1	1
76835	1710	homology with the IL-2 gene	[homology with the IL-2 gene]	0.0	5	1	1	1
76836	1710	background: hydrocarbons	[BACKGROUND: hydrocarbons]	0.0	2	1	1	1
76837	1710	cd4-igg	[CD4-IgG]	0.0	1	1	1	1
76838	1710	human il-7r alpha	[human IL-7R alpha]	0.0	3	1	1	1
76839	1710	glucocorticosteroid response	[glucocorticosteroid response]	0.0	2	1	1	1
76840	1710	rat microglia	[rat microglia]	0.0	2	2	2	1
76841	1710	nfatp antibody	[NFATp antibody]	0.0	2	1	1	1
76842	1710	tax with p100	[Tax with p100]	0.0	3	1	1	1
76843	1710	stage i-iii	[stage I-III]	0.0	2	1	1	1
76844	1710	factor for granulocyte	[factor for granulocytes]	0.0	3	1	1	1
76845	1710	immunodominant antigenic region	[immunodominant antigenic region]	0.0	3	1	1	1
76846	1710	mouse b cell transfectant	[mouse B cell transfectants]	0.0	4	1	1	1
76847	1710	c-myb binding site	[c-Myb binding site]	0.0	3	1	1	1
76848	1710	nanomolar concentration of the ligand,	[nanomolar concentrations of the ligand,]	0.0	5	1	1	1
76849	1710	myelomonocytic cell of the system.	[myelomonocytic cells of the system.]	0.0	5	1	1	1
76850	1710	Retinoic acid treatment of pml/raralpha mouse	[Retinoic acid treatment of PML/RARalpha mice]	0.0	6	1	1	1
76851	1710	cd15 cell	[CD15 cells]	0.0	2	1	1	1
76852	1710	treatment of myeloid leukemia cell	[treatment of myeloid leukemia cells]	0.0	5	1	1	1
76853	1710	interferon-gamma in human neutrophil	[interferon-gamma in human neutrophils]	0.0	4	1	1	1
76854	1710	histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	6	1	1	1
76855	1710	basic protein e2a	[basic proteins E2A]	0.0	3	1	1	1
76856	1710	lytic cycle epitope	[lytic cycle epitopes]	0.0	3	1	1	1
76857	1710	(HIV) long repeat LTR	[(HIV) long repeat LTR]	0.0	4	1	1	1
76858	1710	T cell leukemia virus-1	[T cell leukemia virus-1]	0.0	4	1	1	1
76859	1710	lack of correspondence with variant	[lack of correspondence with variants]	0.0	5	1	1	1
76860	1710	th2-type cytokine interleukin-4	[Th2-type cytokines interleukin-4]	0.0	3	1	1	1
76861	1710	pha normal peripheral blood lymphocyte	[PHA normal peripheral blood lymphocytes]	0.0	5	1	1	1
76862	1710	development of hematopoietic lineage	[development of hematopoietic lineages]	0.0	4	1	1	1
76863	1710	two kappa b-like motif at position	[Two kappa B-like motifs at positions]	0.0	6	1	1	1
76864	1710	enhancer element cd28re	[enhancer element CD28RE]	0.0	3	1	1	1
76865	1710	hla-dr/-dq	[HLA-DR/-DQ]	0.0	1	1	1	1
76866	1710	T cell leukemia virus-i	[T cell leukemia virus-I]	0.0	4	1	1	1
76867	1710	range to kd, result from splicing	[ranging to kD, resulting from splicing]	0.0	6	1	1	1
76868	1710	b cell-specific, DNA binding activity	[B cell-specific, DNA binding activity]	0.0	5	1	1	1
76869	1710	evidence of low activity	[evidence of low activity]	0.0	4	1	1	1
76870	1710	il-13 level	[IL-13 levels]	0.0	2	1	1	1
76871	1710	interaction between October factor	[interactions between Oct factors]	0.0	4	1	1	1
76872	1710	necrosis factor-alpha in cell	[necrosis factor-alpha in cells]	0.0	4	1	1	1
76873	1710	mrp14 migration inhibitory protein	[MRP14 migration inhibitory protein]	0.0	4	1	1	1
76874	1710	chemokine receptor blr2/ebi1	[chemokine receptor BLR2/EBI1]	0.0	3	1	1	1
76875	1710	cd95 ligand cd95l	[CD95 ligand CD95L]	0.0	3	1	1	1
76876	1710	b-cell-specific EB1 element	[B-cell-specific EB1 element]	0.0	3	1	1	1
76877	1710	allele loss on chromosome	[allele loss on chromosome]	0.0	4	1	1	1
76878	1710	type 2 cytokine	[type 2 cytokines]	0.0	3	1	1	1
76879	1710	binding site in peripheral leukocyte	[binding sites in peripheral leukocytes]	0.0	5	1	1	1
76880	1710	human epstein-barr virus	[human Epstein-Barr virus]	0.0	3	1	1	1
76881	1710	feature of all stage	[feature of all stages]	0.0	4	1	1	1
76882	1710	complex in eosinophil	[complexes in eosinophils]	0.0	3	1	1	1
76883	1710	vitro colony	[vitro colony]	0.0	2	1	1	1
76884	1710	origin of cytokine	[origin of cytokine]	0.0	3	1	1	1
76885	1710	expose human vein cell	[Exposing human vein cells]	0.0	4	1	1	1
76886	1710	presenting	[Presenting]	0.0	1	1	1	1
76887	1710	terminus of CIITA	[terminus of CIITA]	0.0	3	1	1	1
76888	1710	acid receptor-alpha	[acid receptor-alpha]	0.0	2	1	1	1
76889	1710	loop of kinase domain	[loop of kinase domain]	0.0	4	1	1	1
76890	1710	direct target gene	[direct target genes]	0.0	3	1	1	1
76891	1710	year:	[year:]	0.0	1	1	1	1
76892	1710	least in part, follow activation	[least in part, following activation]	0.0	5	1	1	1
76893	1710	number in phase endometrium	[numbers in phase endometrium]	0.0	4	1	1	1
76894	1710	status after surgery	[status after surgery]	0.0	3	1	1	1
76895	1710	multifactorial process	[multifactorial process]	0.0	2	1	1	1
76896	1710	anti- g-seropositive donor	[anti- G-seropositive donors]	0.0	3	1	1	1
76897	1710	ease of culture,	[ease of culture,]	0.0	3	1	1	1
76898	1710	year)	[year)]	0.0	1	1	1	1
76899	1710	useful biochemical marker	[useful biochemical marker]	0.0	3	1	1	1
76900	1710	t-cell killer population in the bm	[T-cell killer populations in the BM]	0.0	6	1	1	1
76901	1710	year,	[year,]	0.0	1	1	1	1
76902	1710	C/EBPalpha cell	[C/EBPalpha cells]	0.0	2	1	1	1
76903	1710	case of nasal lymphoma	[cases of nasal lymphoma]	0.0	4	1	1	1
76904	1710	complex with class	[complexes with classes]	0.0	3	1	1	1
76905	1710	negative modulator (1-231)-mediated	[negative modulator (1-231)-mediated]	0.0	3	1	1	1
76906	1710	cell differentiation into monocyte /macrophage	[cell differentiation into monocytes /macrophages]	0.0	5	1	1	1
76907	1710	normal Rh(D) cell	[normal Rh(D) cells]	0.0	3	1	1	1
76908	1710	seek support as a coping strategy,	[seeking support as a coping strategy,]	0.0	6	1	1	1
76909	1710	high percentage of leukemia	[high percentage of leukemias]	0.0	4	1	1	1
76910	1710	chronic myelomonocytic leukemia cmmol	[chronic myelomonocytic leukemia CMMoL]	0.0	4	1	1	1
76911	1710	inflammatory event in atherogenesis	[inflammatory events in atherogenesis]	0.0	4	1	1	1
76912	1710	morning-to-afternoon decline	[morning-to-afternoon decline]	0.0	2	1	1	1
76913	1710	nf-kappab transcription in cell	[NF-kappaB transcription in cells]	0.0	4	1	1	1
76914	1710	expression of coreceptor	[expression of coreceptors]	0.0	3	1	1	1
76915	1710	class ii mutant cell line	[class II mutant cell lines]	0.0	5	1	1	1
76916	1710	protein rna complex	[protein RNA complex]	0.0	3	1	1	1
76917	1710	role in regulation lymphocytes.	[Role in regulation lymphocytes.]	0.0	4	1	1	1
76918	1710	extent, b	[extent, B]	0.0	2	1	1	1
76919	1710	individual to disease	[individual to diseases]	0.0	3	1	1	1
76920	1710	(axillary	[(axillary]	0.0	1	1	1	1
76921	1710	mutant of type 5 adenovirus	[Mutants of type 5 adenovirus]	0.0	5	1	1	1
76922	1710	IL-2 cell antigen receptor complex induction	[IL-2 cell antigen receptor complex induction]	0.0	6	1	1	1
76923	1710	over-express monocyte	[over-expressing monocytes]	0.0	2	1	1	1
76924	1710	promoter for several B-cell marker	[promoters for several B-cell markers]	0.0	5	1	1	1
76925	1710	Grf40 a novel	[Grf40 A novel]	0.0	3	1	1	1
76926	1710	role on the differentiation	[role on the differentiation]	0.0	4	1	1	1
76927	1710	mutant of type 5 adenovirus ad5	[Mutants of type 5 adenovirus Ad5]	0.0	6	1	1	1
76928	1710	distinct subset with translocation	[distinct subsets with translocation]	0.0	4	1	1	1
76929	1710	sites/cell with the gcr on mnl	[sites/cell with the GCR on MNL]	0.0	6	1	1	1
76930	1710	related condition occur in patient	[related condition occurring in patients]	0.0	5	1	1	1
76931	1710	human vein endothelial cell monolayer	[human vein endothelial cell monolayers]	0.0	5	1	1	1
76932	1710	terminal repeat (ltr) region	[terminal repeat (LTR) region]	0.0	4	1	1	1
76933	1710	exclusively in the cytoplasm of lymphocyte	[exclusively in the cytoplasm of lymphocytes]	0.0	6	1	1	1
76934	1710	menstrual cycle,	[menstrual cycle,]	0.0	2	1	1	1
76935	1710	response to a fragment acid	[response to a fragment acids]	0.0	5	1	1	1
76936	1710	typical localization	[typical localization]	0.0	2	1	1	1
76937	1710	in-leucyl-tRNA	[in-leucyl-tRNA]	0.0	1	1	1	1
76938	1710	MRD -positive MRD relapsed.	[MRD -positive MRD relapsed.]	0.0	4	1	1	1
76939	1710	interleukin-3 macrophage colony-stimumulatelany-stg factor	[interleukin-3 macrophage colony-stimulating factor]	0.0	4	1	1	1
76940	1710	use a CD20 antibody	[using an CD20 antibody]	0.0	4	1	1	1
76941	1710	terminal repeat of immunodeficiency virus	[terminal repeat of immunodeficiency virus]	0.0	5	1	1	1
76942	1710	expense	[expense]	0.0	1	1	1	1
76943	1710	NTF interaction with cognate DNA element	[NTF interactions with cognate DNA elements]	0.0	6	1	1	1
76944	1710	many part	[many parts]	0.0	2	1	1	1
76945	1710	correlation alteration	[correlation alterations]	0.0	2	1	1	1
76946	1710	anti- icam-1 antibody	[anti- ICAM-1 antibodies]	0.0	3	1	1	1
76947	1710	defect in production of interleukin factor	[defects in production of interleukin factor]	0.0	6	1	1	1
76948	1710	ic50 value versus 3.1+/-0.2 nmol/L)	[IC50 values versus 3.1+/-0.2 nmol/L)]	0.0	5	1	1	1
76949	1710	;autosome	[;autosome]	0.0	1	1	1	1
76950	1710	vcam-1 intercellular adhesion molecule-1 promoter	[VCAM-1 intercellular adhesion molecule-1 promoters]	0.0	5	1	1	1
76951	1710	R.C. Gallo, Science 231:850-853,	[R.C. Gallo, Science 231:850-853,]	0.0	4	1	1	1
76952	1710	important class	[important classes]	0.0	2	1	1	1
76953	1710	gamma(c)-positive, alpha1 -negative daudi cell	[gamma(c)-positive, alpha1 -negative Daudi cells]	0.0	5	1	1	1
76954	1710	560 bp	[560 bp]	0.0	2	1	1	1
76955	1710	cell line mm6	[cell line MM6]	0.0	3	1	1	1
76956	1710	inhibitor of vascular inflammation	[inhibitor of vascular inflammation]	0.0	4	1	1	1
76957	1710	alpha1 daudi cell	[alpha1 Daudi cells]	0.0	3	1	1	1
76958	1710	late maturation	[late maturation]	0.0	2	1	1	1
76959	1710	sign of primary hypothyroidism	[signs of primary hypothyroidism]	0.0	4	1	1	1
76960	1710	dna-binding eukaryotic transcription factor	[DNA-binding eukaryotic transcription factors]	0.0	4	1	1	1
76961	1710	n-acetyl-l-cysteine nac antioxidant	[N-acetyl-L-cysteine NAC antioxidant]	0.0	3	1	1	1
76962	1710	member of this family, dimethyldithiocarbamate	[member of this family, dimethyldithiocarbamate]	0.0	5	1	1	1
76963	1710	kappab -mutated,	[kappaB -mutated,]	0.0	2	1	1	1
76964	1710	target cells.	[target cells.]	0.0	2	1	1	1
76965	1710	cell line NS-Meg	[cell line NS-Meg]	0.0	3	1	1	1
76966	1710	b cell-specific transcription	[B cell-specific transcription]	0.0	3	1	1	1
76967	1710	consider study in the context	[considering studies in the context]	0.0	5	1	1	1
76968	1710	cell induction of collagenase	[cell induction of collagenase]	0.0	4	1	1	1
76969	1710	pathway lead from monocytic cell	[pathway leading from monocytic cells]	0.0	5	1	1	1
76970	1710	substitution on c-11	[substitutions on C-11]	0.0	3	1	1	1
76971	1710	permanent overexpression	[permanent overexpression]	0.0	2	1	1	1
76972	1710	normal keratinocyte	[normal keratinocytes]	0.0	2	1	1	1
76973	1710	peak in response	[peaking in response]	0.0	3	1	1	1
76974	1710	cytokine receptor expression	[cytokine receptor expression]	0.0	3	1	1	1
76975	1710	study in human T cell line	[studies in human T cell lines]	0.0	6	1	1	1
76976	1710	cycle reactivity though rarely undetectable	[cycle reactivities though rarely undetectable]	0.0	5	1	1	1
76977	1710	gata-factor	[GATA-factor]	0.0	1	1	1	1
76978	1710	signal 1	[signal 1]	0.0	2	1	1	1
76979	1710	signal 2	[signal 2]	0.0	2	1	1	1
76980	1710	signal 3	[signaling 3]	0.0	2	1	1	1
76981	1710	almost complete elimination	[almost complete elimination]	0.0	3	1	1	1
76982	1710	phosphorylation of s6	[phosphorylation of S6]	0.0	3	1	1	1
76983	1710	HLA-DR3 with no apparent association	[HLA-DR3 with no apparent association]	0.0	5	1	1	1
76984	1710	especially the human homolog	[especially the human homolog]	0.0	4	1	1	1
76985	1710	Cbf alpha	[Cbf alpha]	0.0	2	1	1	1
76986	1710	as many as child aged year	[As many as children aged years]	0.0	6	1	1	1
76987	1710	gc-box binding activity A1	[GC-box binding activity A1]	0.0	4	1	1	1
76988	1710	interaction with dna-binding protein	[interaction with DNA-binding proteins]	0.0	4	1	1	1
76989	1710	undergo elective termination	[undergoing elective termination]	0.0	3	1	1	1
76990	1710	transactivator in HTLV-I	[transactivator in HTLV-I]	0.0	3	1	1	1
76991	1710	two isolate	[two isolates]	0.0	2	1	1	1
76992	1710	tata-box binding protein tfiib	[TATA-box binding protein TFIIB]	0.0	4	1	1	1
76993	1710	indicate a critical involvement	[indicating a critical involvement]	0.0	4	1	1	1
76994	1710	50 kD factor	[50 kD factor]	0.0	3	1	1	1
76995	1710	extent interleukin-1	[extent interleukin-1]	0.0	2	1	1	1
76996	1710	Nonradioactive quantification of expression during differentiation	[Nonradioactive quantification of expression during differentiation]	0.0	6	1	1	1
76997	1710	pi3k	[PI3K]	0.0	1	1	1	1
76998	1710	basal serum	[basal serum]	0.0	2	1	1	1
76999	1710	removal of class dimer	[removal of class dimers]	0.0	4	1	1	1
77000	1710	daltons.	[daltons.]	0.0	1	1	1	1
77001	1710	role in a context	[role in a context]	0.0	4	1	1	1
77002	1710	possible linkage polymorphism to condition	[possible linkage polymorphism to conditions]	0.0	5	1	1	1
77003	1710	cell growth in promyelocytic leukemia	[cell growth in promyelocytic leukemia]	0.0	5	1	1	1
77004	1710	matrix-bound RB	[matrix-bound RB]	0.0	2	1	1	1
77005	1710	respective function	[respective functions]	0.0	2	1	1	1
77006	1710	transcription factor hiv-tf1	[transcription factor HIV-TF1]	0.0	3	1	1	1
77007	1710	tyrosine phosphorylation of a protein	[tyrosine phosphorylation of a protein]	0.0	5	1	1	1
77008	1710	NF-kappaB -binding site 2	[NF-kappaB -binding site 2]	0.0	4	1	1	1
77009	1710	-contain activity	[-containing activity]	0.0	2	1	1	1
77010	1710	detrimental effect on OCA-B transcription	[detrimental effect on OCA-B transcription]	0.0	5	1	1	1
77011	1710	Active RelB	[Active RelB]	0.0	2	1	1	1
77012	1710	secretion of pge2 by macrophage	[secretion of PGE2 by macrophages]	0.0	5	1	1	1
77013	1710	follow expression in Jurkat T lymphocyte	[following expression in Jurkat T lymphocytes]	0.0	6	1	1	1
77014	1710	Functional analysis with a expression assay	[Functional analysis with a expression assay]	0.0	6	1	1	1
77015	1710	involve band	[involving band]	0.0	2	1	1	1
77016	1710	interestingly, the combination 25(oh)2d3	[Interestingly, the combination 25(OH)2D3]	0.0	4	1	1	1
77017	1710	cell belong	[cells belonging]	0.0	2	1	1	1
77018	1710	certain individual of (mhc) haplotype	[certain individuals of (MHC) haplotypes]	0.0	5	1	1	1
77019	1710	such as hiv infection	[such as HIV infection]	0.0	4	1	1	1
77020	1710	tsst-1	[TSST-1]	0.0	1	1	1	1
77021	1710	strict dependence of HS activity	[Strict dependence of HS activity]	0.0	5	1	1	1
77022	1710	viral oncoprotein	[viral oncoproteins]	0.0	2	1	1	1
77023	1710	mobility shift assay in pbmc	[mobility shift assays in PBMC]	0.0	5	1	1	1
77024	1710	il-6-responsive colony-forming unit in C/EBPalpha mouse	[IL-6-responsive colony-forming units in C/EBPalpha mice]	0.0	6	1	1	1
77025	1710	different route on signalling	[different routes on signalling]	0.0	4	1	1	1
77026	1710	however, latent, gene	[However, latent, genes]	0.0	3	1	1	1
77027	1710	other hallmark	[other hallmarks]	0.0	2	1	1	1
77028	1710	many gene important	[many genes important]	0.0	3	1	1	1
77029	1710	disruption of a membrane-proximal sequence motif	[disruption of a membrane-proximal sequence motif]	0.0	6	1	1	1
77030	1710	stimulation by eosinophil granule protein	[Stimulation by eosinophil granule protein]	0.0	5	1	1	1
77031	1710	enhance transcription of several gene	[enhancing transcription of several genes]	0.0	5	1	1	1
77032	1710	cytolytic action of cytotoxic protein	[cytolytic action of cytotoxic proteins]	0.0	5	1	1	1
77033	1710	lack sequence similarity	[lacking sequence similarity]	0.0	3	1	1	1
77034	1710	common cause	[common cause]	0.0	2	1	1	1
77035	1710	limiting-dilution	[limiting-dilution]	0.0	1	1	1	1
77036	1710	self antigens.	[self antigens.]	0.0	2	1	1	1
77037	1710	NFAT-1 site	[NFAT-1 site]	0.0	2	1	1	1
77038	1710	several response	[Several responses]	0.0	2	1	1	1
77039	1710	role of retinoic acid atra	[role of retinoic acid ATRA]	0.0	5	1	1	1
77040	1710	long-lasting effect	[long-lasting effect]	0.0	2	1	1	1
77041	1710	dose microm	[doses microM]	0.0	2	1	1	1
77042	1710	flow cytometric assay	[flow cytometric assays]	0.0	3	1	1	1
77043	1710	sensitive identification of gene hypermethylation	[sensitive identification of gene hypermethylation]	0.0	5	1	1	1
77044	1710	stage of the pathway	[stage of the pathway]	0.0	4	1	1	1
77045	1710	T cell receptor involvement	[T cell receptor involvement]	0.0	4	1	1	1
77046	1710	month 12 month	[months 12 months]	0.0	3	1	1	1
77047	1710	site between position	[site between positions]	0.0	3	1	1	1
77048	1710	activation in cell leukemia virus type	[activation in cell leukemia virus type]	0.0	6	1	1	1
77049	1710	globin gene in a environment	[globin genes in a environment]	0.0	5	1	1	1
77050	1710	primarily within RelB	[primarily within RelB]	0.0	3	1	1	1
77051	1710	relative formation of dimer	[relative formation of dimers]	0.0	4	1	1	1
77052	1710	adhesion in human vein cell HUVECs	[adhesion in human vein cells HUVECs]	0.0	6	1	1	1
77053	1710	use of u937 cell	[use of U937 cells]	0.0	4	1	1	1
77054	1710	modulation of E2F complex	[Modulation of E2F complexes]	0.0	4	1	1	1
77055	1710	expression experiment of 5'-deletion fragment	[expression experiments of 5'-deletion fragments]	0.0	5	1	1	1
77056	1710	hiv-1 iiib replication	[HIV-1 IIIB replication]	0.0	3	1	1	1
77057	1710	15.5 (p less than p	[15.5 (P less than P]	0.0	5	1	1	1
77058	1710	intrigue possibility the mechanism	[intriguing possibility the mechanism]	0.0	4	1	1	1
77059	1710	HLF ancillary domain	[HLF ancillary domain]	0.0	3	1	1	1
77060	1710	anti-early antigen ea capsid antigen vca	[anti-early antigen EA capsid antigen VCA]	0.0	6	1	1	1
77061	1710	indirect link	[indirect link]	0.0	2	1	1	1
77062	1710	correlation, indicate a subtle effect.	[correlation, indicating a subtle effect.]	0.0	5	1	1	1
77063	1710	rna (snrna)	[RNA (snRNA)]	0.0	2	1	1	1
77064	1710	contrast, at dose	[contrast, at doses]	0.0	3	1	1	1
77065	1710	include repression of cd95 transcription	[including repression of CD95 transcription]	0.0	5	1	1	1
77066	1710	cell line nb4	[cell lines NB4]	0.0	3	1	1	1
77067	1710	express human bcl2	[expressing human BCL2]	0.0	3	1	1	1
77068	1710	kda precursor	[kDa precursor]	0.0	2	1	1	1
77069	1710	gene product Egr-1	[gene product Egr-1]	0.0	3	1	1	1
77070	1710	cytoplasmic and/or receptor	[cytoplasmic and/or receptor]	0.0	3	1	1	1
77071	1710	ribosomal protein sequence	[ribosomal protein sequences]	0.0	3	1	1	1
77072	1710	distribution of human gene evidence	[distribution of human genes evidence]	0.0	5	1	1	1
77073	1710	interferon gamma IFNgamma	[interferon gamma IFNgamma]	0.0	3	1	1	1
77074	1710	101pp dnase hypersensitive site-forming element	[101bp, DNase hypersensitive site-forming element]	0.0	5	1	1	1
77075	1710	lipopolysaccharide u937 cell	[lipopolysaccharide U937 cells]	0.0	3	1	1	1
77076	1710	monocyte adhesion in umbilical vein cell	[monocyte adhesion in umbilical vein cells]	0.0	6	1	1	1
77077	1710	1,4,5-trisphosphate	[1,4,5-trisphosphate]	0.0	1	1	1	1
77078	1710	such hypermethylation-associated silencing	[Such hypermethylation-associated silencing]	0.0	3	1	1	1
77079	1710	interferon (ifn)-inducible protein ip-10	[interferon (IFN)-inducible protein IP-10]	0.0	4	1	1	1
77080	1710	number of regulatory element	[number of regulatory elements]	0.0	4	1	1	1
77081	1710	cell clone CEM C7	[cell clone CEM C7]	0.0	4	1	1	1
77082	1710	mcm6 promoter	[MCM6 promoter]	0.0	2	1	1	1
77083	1710	dnase 1 site-forming element HSFE	[DNase 1 site-forming element HSFE]	0.0	5	1	1	1
77084	1710	natural DNA response element	[natural DNA response element]	0.0	4	1	1	1
77085	1710	novel T element nre	[novel T element NRE]	0.0	4	1	1	1
77086	1710	phosphorylation of Jak2	[Phosphorylation of Jak2]	0.0	3	1	1	1
77087	1710	heterologous minimal promoter.	[heterologous minimal promoter.]	0.0	3	1	1	1
77088	1710	number of high affinity tnfrp75 molecule	[numbers of high affinity TNFRp75 molecules]	0.0	6	1	1	1
77089	1710	analysis of cis-linked sequence	[analysis of cis-linked sequences]	0.0	4	1	1	1
77090	1710	hb9 transcript	[HB9 transcripts]	0.0	2	1	1	1
77091	1710	basis in a patient with immunodeficiency	[basis in a patient with immunodeficiency]	0.0	6	1	1	1
77092	1710	anti-estrogen toremifene	[anti-estrogen toremifene]	0.0	2	1	1	1
77093	1710	cold air	[cold air]	0.0	2	1	1	1
77094	1710	putative ets binding site	[putative Ets binding sites]	0.0	4	1	1	1
77095	1710	human homolog of chicken nf-m	[human homolog of chicken NF-M]	0.0	5	1	1	1
77096	1710	inactive heterodimer	[inactive heterodimers]	0.0	2	1	1	1
77097	1710	use anti-ERK extracellular kinase antibody	[using anti-ERK extracellular kinase antibodies]	0.0	5	1	1	1
77098	1710	1) inhibition through adenosine triphosphate atp	[1) inhibition through adenosine triphosphate ATP]	0.0	6	1	1	1
77099	1710	action of 1,25-dihydroxyvitamin D3 (1325(oh)2d3)	[actions of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)]	0.0	5	1	1	1
77100	1710	biological activity of alpha-methyl-1 alpha,25-(OH)2D3	[biological activity of alpha-methyl-1 alpha,25-(OH)2D3]	0.0	5	1	1	1
77101	1710	motif characteristic	[motif characteristic]	0.0	2	1	1	1
77102	1710	death domain death domain	[death domain death domain]	0.0	4	1	1	1
77103	1710	activation of form 90-kda stat3alpha	[activation of forms 90-kDa STAT3alpha]	0.0	5	1	1	1
77104	1710	role in the host's defense	[role in the host's defense]	0.0	5	1	1	1
77105	1710	series of clinical variable	[series of clinical variables]	0.0	4	1	1	1
77106	1710	physiologic setting	[physiologic setting]	0.0	2	1	1	1
77107	1710	October factor gene	[Oct factor gene]	0.0	3	1	1	1
77108	1710	steroid (66.6	[steroids (66.6]	0.0	2	1	1	1
77109	1710	level alpha-naphthyl-acetate-esterase	[levels alpha-naphthyl-acetate-esterase]	0.0	2	1	1	1
77110	1710	little nfat transcriptional activity	[little NFAT transcriptional activity]	0.0	4	1	1	1
77111	1710	gel electrophoresis mobility shift	[Gel electrophoresis mobility shift]	0.0	4	1	1	1
77112	1710	(35 min) submaximal physical exercise	[(35 min) submaximal physical exercise]	0.0	5	1	1	1
77113	1710	thioctic	[thioctic]	0.0	1	1	1	1
77114	1710	21 bp element	[21 bp elements]	0.0	3	1	1	1
77115	1710	kda in 12-o-tetradecanoyl-phorbol-13-acetate	[kDa in 12-O-tetradecanoyl-phorbol-13-acetate]	0.0	3	1	1	1
77116	1710	leukemia acid receptor alpha	[leukemia acid receptor alpha]	0.0	4	1	1	1
77117	1710	a fail	[aa fail]	0.0	2	1	1	1
77118	1710	high affinity (at sevenfold)	[higher affinity (at sevenfold)]	0.0	4	1	1	1
77119	1710	development of nonlymphoid tumor	[development of nonlymphoid tumors]	0.0	4	1	1	1
77120	1710	bind site-specific property	[binding site-specific properties]	0.0	3	1	1	1
77121	1710	express cell surface glycophorin a GPA	[expressing cell surface glycophorin A GPA]	0.0	6	1	1	1
77122	1710	replication of the viral genome	[replication of the viral genome]	0.0	5	1	1	1
77123	1710	infection of mononuclear phagocyte	[infection of mononuclear phagocytes]	0.0	4	1	1	1
77124	1710	calcium-mobilize receptor to factor	[calcium-mobilizing receptors to factor]	0.0	4	1	1	1
77125	1710	-contact	[-contact]	0.0	1	1	1	1
77126	1710	less viral rna production	[less viral RNA production]	0.0	4	1	1	1
77127	1710	overrepresentation of aggressive type	[overrepresentation of aggressive types]	0.0	4	1	1	1
77128	1710	transcriptional regulation of retroviruse	[transcriptional regulation of retroviruses]	0.0	4	1	1	1
77129	1710	calcium protease	[calcium protease]	0.0	2	1	1	1
77130	1710	region of protein-DNA interaction	[region of protein-DNA interactions]	0.0	4	1	1	1
77131	1710	class complex promoter	[class complex promoters]	0.0	3	1	1	1
77132	1710	immunodeficiency virus type factor Nef	[immunodeficiency virus type factor Nef]	0.0	5	1	1	1
77133	1710	non- a-t	[non- A-T]	0.0	2	1	1	1
77134	1710	t-cell malignancy of stage	[T-cell malignancies of stages]	0.0	4	1	1	1
77135	1710	similar tyrosine motif	[similar tyrosine motifs]	0.0	3	1	1	1
77136	1710	causative agent of mononucleosis	[causative agent of mononucleosis]	0.0	4	1	1	1
77137	1710	-dependent activation of interleukin gene	[-dependent activation of interleukin gene]	0.0	5	1	1	1
77138	1710	cellular transactivation factor	[cellular transactivation factor]	0.0	3	1	1	1
77139	1710	monocyte with phorbol-13-acetate tpa	[monocytes with phorbol-13-acetate TPA]	0.0	4	1	1	1
77140	1710	exposure of CML cell	[Exposure of CML cells]	0.0	4	1	1	1
77141	1710	independent evidence	[independent evidences]	0.0	2	1	1	1
77142	1710	TFG-beta promoter	[TFG-beta promoter]	0.0	2	1	1	1
77143	1710	el4 6.1	[EL4 6.1]	0.0	2	1	1	1
77144	1710	regulation follow the trigger	[regulation following the triggering]	0.0	4	1	1	1
77145	1710	three order potent	[three orders potent]	0.0	3	1	1	1
77146	1710	precise role signal in lymphocyte	[precise roles signaling in lymphocytes]	0.0	5	1	1	1
77147	1710	alpha (tnf-alpha) il-6 rrna	[alpha (TNF-alpha) IL-6 mRNAs]	0.0	4	1	1	1
77148	1710	of induce lap as much	[of inducing LAP as much]	0.0	5	1	1	1
77149	1710	METHODS: case of Arnhl	[METHODS: cases of ARNHL]	0.0	4	1	1	1
77150	1710	kD slp-76	[kD SLP-76]	0.0	2	1	1	1
77151	1710	level of mineralocorticoid receptor	[levels of mineralocorticoid receptor]	0.0	4	1	1	1
77152	1710	mono Mac with lipopolysaccharide	[Mono Mac with lipopolysaccharide]	0.0	4	1	1	1
77153	1710	widespread extinction	[widespread extinction]	0.0	2	1	1	1
77154	1710	(R) rna	[(R) RNA]	0.0	2	1	1	1
77155	1710	several pathway for periodontal tissue damage	[several pathways for periodontal tissue damage]	0.0	6	1	1	1
77156	1710	binding of interferon-gamma ifn-gamma to receptor	[Binding of interferon-gamma IFN-gamma to receptor]	0.0	6	1	1	1
77157	1710	cd34+/-, hla-dr cd16	[CD34+/-, HLA-DR CD16]	0.0	3	1	1	1
77158	1710	differentiation of human cd34+ progenitor cell	[differentiation of human CD34+ progenitor cells]	0.0	6	1	1	1
77159	1710	expression of various immediate serum gene	[expression of various immediate serum genes]	0.0	6	1	1	1
77160	1710	pattern of synergy	[patterns of synergy]	0.0	3	1	1	1
77161	1710	combination of motility assay	[combination of motility assays]	0.0	4	1	1	1
77162	1710	p26rex /p24rex	[p26rex /p24rex]	0.0	2	1	1	1
77163	1710	activation of Stat in progenitor	[Activation of Stat in progenitors]	0.0	5	1	1	1
77164	1710	hematopoietic cell polypryrimidine-binding factor pybf	[hematopoietic cells polypryrimidine-binding factor PYBF]	0.0	5	1	1	1
77165	1710	principal cis-acting element	[principal cis-acting elements]	0.0	3	1	1	1
77166	1710	recombinant fragment lps expression	[recombinant fragment LPS expression]	0.0	4	1	1	1
77167	1710	activity-alpha gro-alpha	[activity-alpha GRO-alpha]	0.0	2	1	1	1
77168	1710	migration ChtM of leukocyte	[migration ChtM of leukocytes]	0.0	4	1	1	1
77169	1710	U2 small rna(snrna)-encoding gene	[U2 small RNA(snRNA)-encoding gene]	0.0	4	1	1	1
77170	1710	promotion of polymorphonuclear neutrophil migration	[promotion of polymorphonuclear neutrophil migration]	0.0	5	1	1	1
77171	1710	induction of endothelial icam-1	[induction of endothelial ICAM-1]	0.0	4	1	1	1
77172	1710	nf-kappab essential modulator),	[NF-kappaB essential modulator),]	0.0	3	1	1	1
77173	1710	also for region between -201	[also for regions between -201]	0.0	5	1	1	1
77174	1710	single dna-binding hmg box related	[single DNA-binding HMG box related]	0.0	5	1	1	1
77175	1710	JPX-9	[JPX-9]	0.0	1	1	1	1
77176	1710	autoregulation by inhibitor contain ankyrin motif	[Autoregulation by inhibitors containing ankyrin motifs]	0.0	6	1	1	1
77177	1710	HTLV-I taxi	[HTLV-I TaxI]	0.0	2	1	1	1
77178	1710	two rdna	[two cDNAs]	0.0	2	1	1	1
77179	1710	clonality analysis of anemia	[Clonality analysis of anemia]	0.0	4	1	1	1
77180	1710	thereby amplify expression of receptor	[thereby amplifying expression of receptor]	0.0	5	1	1	1
77181	1710	extend from approximately -250 bp	[extending from approximately -250 bp]	0.0	5	1	1	1
77182	1710	stable derivative of acid	[stable derivative of acid]	0.0	4	1	1	1
77183	1710	Positive regulation role of regulatory sites.	[Positive regulation role of regulatory sites.]	0.0	6	1	1	1
77184	1710	gr transcription from GRE	[GR transcription from GRE]	0.0	4	1	1	1
77185	1710	PPARalpha a regulator	[PPARalpha a regulator]	0.0	3	1	1	1
77186	1710	phi)	[phi)]	0.0	1	1	1	1
77187	1710	use lymphocyte model	[using lymphocyte models]	0.0	3	1	1	1
77188	1710	transcript,	[transcript,]	0.0	1	1	1	1
77189	1710	factor-kappaB induction of interleukin-8 gene expression	[factor-kappaB induction of interleukin-8 gene expression]	0.0	6	1	1	1
77190	1710	key sensor for vcam regulation	[key sensor for VCAM regulation]	0.0	5	1	1	1
77191	1710	role switch during initial stage	[Role switching during initial stages]	0.0	5	1	1	1
77192	1710	(include the VDR coding region	[(including the VDR coding region]	0.0	5	1	1	1
77193	1710	discussion of method	[discussion of methods]	0.0	3	1	1	1
77194	1710	CMV immediate gene product	[CMV immediate gene product]	0.0	4	1	1	1
77195	1710	early b lineage cell	[early B lineage cells]	0.0	4	1	1	1
77196	1710	human paf receptor transcript leukocyte-type	[human PAF receptor transcript leukocyte-type]	0.0	5	1	1	1
77197	1710	gene transcription by inhibition	[gene transcription by inhibition]	0.0	4	1	1	1
77198	1710	affinity for dna-binding than aml1b	[affinity for DNA-binding than AML1b]	0.0	5	1	1	1
77199	1710	interleukin-12 expression by transformation	[Interleukin-12 expression by transformation]	0.0	4	1	1	1
77200	1710	dependence in a cell line UT-7	[Dependence in a cell line UT-7]	0.0	6	1	1	1
77201	1710	ratio of bcl2+	[ratio of BCL2+]	0.0	3	1	1	1
77202	1710	detection in a patient with leukemia	[Detection in a patient with leukemia]	0.0	6	1	1	1
77203	1710	Epstein-Barr virus antigen bzlf1	[Epstein-Barr virus antigen BZLF1]	0.0	4	1	1	1
77204	1710	day post-stimulation	[days) post-stimulation]	0.0	2	1	1	1
77205	1710	marker of subpopulation of lymphocyte	[marker of subpopulations of lymphocytes]	0.0	5	1	1	1
77206	1710	respect to the protein, little	[respect to the protein, little]	0.0	5	1	1	1
77207	1710	approximately 70% sequence similarity	[approximately 70% sequence similarity]	0.0	4	1	1	1
77208	1710	constitutive activation of NFkappaB	[constitutive activation of NFkappaB]	0.0	4	1	1	1
77209	1710	cell undergo differentiation	[cells undergoing differentiation]	0.0	3	1	1	1
77210	1710	change in cortisol response.	[change in cortisol response.]	0.0	4	1	1	1
77211	1710	amebic infection of intestine	[amebic infection of intestine]	0.0	4	1	1	1
77212	1710	expression of ebf in nonlymphoid cell	[Expression of EBF in nonlymphoid cells]	0.0	6	1	1	1
77213	1710	factor present in cell	[factor present in cells]	0.0	4	1	1	1
77214	1710	leukocyte adhesion molecule ELAM	[leukocyte adhesion molecule ELAM]	0.0	4	1	1	1
77215	1710	correlation between the expression pattern	[correlation between the expression pattern]	0.0	5	1	1	1
77216	1710	co-transfection assay	[co-transfection assays]	0.0	2	1	1	1
77217	1710	site different	[site different]	0.0	2	1	1	1
77218	1710	expression rna	[expression RNAs]	0.0	2	1	1	1
77219	1710	differentiation of the cells.	[differentiation of the cells.]	0.0	4	1	1	1
77220	1710	affect proliferation	[affecting proliferation]	0.0	2	1	1	1
77221	1710	clonal line of CEM cell	[clonal lines of CEM cells]	0.0	5	1	1	1
77222	1710	dihydroxyvitamin d3,	[dihydroxyvitamin D3,]	0.0	2	1	1	1
77223	1710	human gata-3 factor	[human GATA-3 factors]	0.0	3	1	1	1
77224	1710	about 1.5-1.6 time	[about 1.5-1.6 times]	0.0	3	1	1	1
77225	1710	diagnostic value	[diagnostic value]	0.0	2	1	1	1
77226	1710	activator (stat) family of proteins.	[activators (STAT) family of proteins.]	0.0	5	1	1	1
77227	1710	Retroviral induction	[Retroviral induction]	0.0	2	1	1	1
77228	1710	patient with normal affinity	[patients with normal affinity]	0.0	4	1	1	1
77229	1710	evidence of hypermutation act	[evidence of hypermutation acting]	0.0	4	1	1	1
77230	1710	human CBFA2 locus	[human CBFA2 locus]	0.0	3	1	1	1
77231	1710	b expression of ig gene	[B expression of Ig genes]	0.0	5	1	1	1
77232	1710	involvement of camp signal	[involvement of cAMP signaling]	0.0	4	1	1	1
77233	1710	however, three order less potent	[however, three orders less potent]	0.0	5	1	1	1
77234	1710	act together in actin polymerization	[acting together in actin polymerization]	0.0	5	1	1	1
77235	1710	homodimer with transcriptionally active heterodimer	[homodimers with transcriptionally active heterodimers]	0.0	5	1	1	1
77236	1710	evidence identical proteins,	[evidence identical proteins,]	0.0	3	1	1	1
77237	1710	tradd protein	[TRADD protein]	0.0	2	1	1	1
77238	1710	morphology indicative	[morphology indicative]	0.0	2	1	1	1
77239	1710	conferr DNA binding by the receptor	[conferring DNA binding by the receptor]	0.0	6	1	1	1
77240	1710	dependent adhesion	[dependent adhesion]	0.0	2	1	1	1
77241	1710	produce outcomes,	[producing outcomes,]	0.0	2	1	1	1
77242	1710	inhibition in vivo effect	[Inhibition in vivo effect]	0.0	4	1	1	1
77243	1710	express LMP1	[expressing LMP1]	0.0	2	1	1	1
77244	1710	molecular mechanism underlie the translocation	[molecular mechanisms underlying the translocation]	0.0	5	1	1	1
77245	1710	SLP-76 cell molecule	[SLP-76 cell molecules]	0.0	3	1	1	1
77246	1710	provisional matrix	[provisional matrix]	0.0	2	1	1	1
77247	1710	molecular understanding of opioid effect	[molecular understanding of opioid effects]	0.0	5	1	1	1
77248	1710	temporal correlation	[temporal correlation]	0.0	2	1	1	1
77249	1710	intron of 1211	[introns of 1211]	0.0	3	1	1	1
77250	1710	functional role of Itk	[functional role of Itk]	0.0	4	1	1	1
77251	1710	two EBV-associated, hla-b8-restricted epitope	[two EBV-associated, HLA-B8-restricted epitopes]	0.0	4	1	1	1
77252	1710	ratio of bcl-2	[ratio of BCL-2]	0.0	3	1	1	1
77253	1710	corticoid receptor of blood lymphocyte	[corticoid receptors of blood lymphocytes]	0.0	5	1	1	1
77254	1710	information on the molecular event occur	[information on the molecular events occurring]	0.0	6	1	1	1
77255	1710	two subunit of relative mass	[two subunits of relative mass]	0.0	5	1	1	1
77256	1710	act on megakaryocytopoiesis	[acting on megakaryocytopoiesis]	0.0	3	1	1	1
77257	1710	nuclear factor with property	[nuclear factor with properties]	0.0	4	1	1	1
77258	1710	direct, effect of androgen	[direct, effects of androgens]	0.0	4	1	1	1
77259	1710	antiatherosclerotic potential of lipid antioxidant	[antiatherosclerotic potential of lipid antioxidants]	0.0	5	1	1	1
77260	1710	adenocarcinoma reactive chimeric monoclonal antibody	[adenocarcinoma reactive chimeric monoclonal antibody]	0.0	5	1	1	1
77261	1710	facilitate progression	[facilitating progression]	0.0	2	1	1	1
77262	1710	p50-p65 complex from pools,	[p50-p65 complex from pools,]	0.0	4	1	1	1
77263	1710	activity against ec HUVEC	[Activity against EC HUVEC]	0.0	4	1	1	1
77264	1710	rev protein in T cell	[Rev protein in T cells]	0.0	5	1	1	1
77265	1710	messenger rna (mrna)	[messenger RNA (mRNA)]	0.0	3	1	1	1
77266	1710	well-recognized adhesive role,	[well-recognized adhesive role,]	0.0	3	1	1	1
77267	1710	human thp-1 leukemia cell	[human THP-1 leukemia cells]	0.0	4	1	1	1
77268	1710	expression of 135eoh)2d3 receptor	[expression of 1,25(OH)2D3 receptor]	0.0	4	1	1	1
77269	1710	demonstrate a subdiploid population	[demonstrating a subdiploid population]	0.0	4	1	1	1
77270	1710	activity relative	[activity relative]	0.0	2	1	1	1
77271	1710	b-cell-specific displacement	[B-cell-specific displacement]	0.0	2	1	1	1
77272	1710	limbic-hippocampal type ii receptor gcii	[limbic-hippocampal type II receptor GCII]	0.0	5	1	1	1
77273	1710	elucidate the function of Cbl	[elucidating the function of Cbl]	0.0	5	1	1	1
77274	1710	acetic	[acetic]	0.0	1	1	1	1
77275	1710	extend 1053 base pair	[extending 1053 base pairs]	0.0	4	1	1	1
77276	1710	kruppel-like factor EKLF	[Kruppel-like factor EKLF]	0.0	3	2	2	1
77277	1710	generate a effective humoral response	[generating an effective humoral response]	0.0	5	1	1	1
77278	1710	non-classic target tissue	[non-classic target tissues]	0.0	3	1	1	1
77279	1710	base pair of sequence	[base pairs of sequence]	0.0	4	1	1	1
77280	1710	contain two b DNA binding site	[containing two B DNA binding sites]	0.0	6	1	1	1
77281	1710	mechanism signal in human eosinophil	[mechanisms signaling in human eosinophils]	0.0	5	1	1	1
77282	1710	tyrosine phosphorylation of ZAP-70	[tyrosine phosphorylation of ZAP-70]	0.0	4	1	1	1
77283	1710	correlation, with a value	[correlation, with an value]	0.0	4	1	1	1
77284	1710	tubulointerstitial disease under condition	[tubulointerstitial disease under conditions]	0.0	4	1	1	1
77285	1710	anti- tf antibody	[anti- TF antibody]	0.0	3	1	1	1
77286	1710	49 subject (62-97 yr)	[49 subjects (62-97 yr)]	0.0	4	1	1	1
77287	1710	co-expression of pu.1 in cell	[Co-expression of PU.1 in cells]	0.0	5	1	1	1
77288	1710	rhythm of a response	[rhythms of a response]	0.0	4	1	1	1
77289	1710	adhesion in tnf-treated vein cell	[adhesion in TNF-treated vein cells]	0.0	5	1	1	1
77290	1710	23 case of lymphoma NL	[23 cases of lymphoma NL]	0.0	5	1	1	1
77291	1710	ligation of the receptor	[ligation of the receptor]	0.0	4	1	1	1
77292	1710	infiltrate melanoma	[infiltrating melanomas]	0.0	2	1	1	1
77293	1710	mitogen-activated protein kinase activity	[mitogen-activated protein kinase activities]	0.0	4	1	1	1
77294	1710	preferential coupling of jak3	[preferential coupling of JAK3]	0.0	4	1	1	1
77295	1710	expression of stat4 protein	[expression of Stat4 proteins]	0.0	4	1	1	1
77296	1710	enhanced, 2 h of cd19 cross-linking	[enhanced, 2 h of CD19 cross-linking]	0.0	6	1	1	1
77297	1710	PMA T cell from a proportion	[PMA T cells from a proportion]	0.0	6	1	1	1
77298	1710	pro-interleukin 1beta	[pro-interleukin 1beta]	0.0	2	1	1	1
77299	1710	different myeloid stage	[different myeloid stages]	0.0	3	1	1	1
77300	1710	specific granule of the neutrophil	[specific granules of the neutrophil]	0.0	5	1	1	1
77301	1710	membrane-proximal portion in the domain	[membrane-proximal portion in the domain]	0.0	5	1	1	1
77302	1710	convey protection	[conveying protection]	0.0	2	1	1	1
77303	1710	treatment of vein endothelial cell monolayer	[Treatment of vein endothelial cell monolayers]	0.0	6	1	1	1
77304	1710	up-regulation of il-2 via nf-at	[up-regulation of IL-2 via NF-AT]	0.0	5	1	1	1
77305	1710	precursor level	[precursor levels]	0.0	2	1	1	1
77306	1710	endothelial muscle cell	[endothelial muscle cells]	0.0	3	1	1	1
77307	1710	leukotriene b4 LTB4 generation	[leukotriene B4 LTB4 generation]	0.0	4	1	1	1
77308	1710	cd34(+) bone marrow cell survival	[CD34(+) bone marrow cell survival]	0.0	5	1	1	1
77309	1710	putative metastatic suppressor gene	[putative metastatic suppressor genes]	0.0	4	1	1	1
77310	1710	biochemical modification	[biochemical modifications]	0.0	2	1	1	1
77311	1710	molecular framework	[molecular framework]	0.0	2	1	1	1
77312	1710	silencer of gene	[silencer of genes]	0.0	3	1	1	1
77313	1710	normal myeloid cell polymorphonuclear granulocyte	[normal myeloid cells polymorphonuclear granulocytes]	0.0	5	1	1	1
77314	1710	unexpected observation together with the finding	[unexpected observations together with the findings]	0.0	6	1	1	1
77315	1710	activation of proenkephalin transcription	[Activation of proenkephalin transcription]	0.0	4	1	1	1
77316	1710	effect of er alpha	[effect of ER alpha]	0.0	4	1	1	1
77317	1710	isolation for the class transactivator	[Isolation for the class transactivator]	0.0	5	1	1	1
77318	1710	differ in capacity	[differing in capacity]	0.0	3	1	1	1
77319	1710	i.e. polymorphonuclear granulocyte	[i.e. polymorphonuclear granulocytes]	0.0	3	1	1	1
77320	1710	-76 base pair	[-76 base pairs]	0.0	3	1	1	1
77321	1710	case of ige	[cases of IgE]	0.0	3	1	1	1
77322	1710	phenol extraction	[phenol extraction]	0.0	2	1	1	1
77323	1710	element 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Elements 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	5	1	1	1
77324	1710	limited expression	[limited expression]	0.0	2	1	1	1
77325	1710	effect of this stimulus	[effect of these stimuli]	0.0	4	1	1	1
77326	1710	B-lymphocyte cell cycle	[B-lymphocyte cell cycle]	0.0	3	1	1	1
77327	1710	IL-12 induction of ifn-gamma mrna	[IL-12 induction of IFN-gamma mRNA]	0.0	5	1	1	1
77328	1710	proteins; in	[proteins; in]	0.0	2	1	1	1
77329	1710	hematopoiesis translocation	[hematopoiesis translocations]	0.0	2	1	1	1
77330	1710	cell line, ut-7	[cell line, UT-7]	0.0	3	1	1	1
77331	1710	/heb protein	[/HEB proteins]	0.0	2	1	1	1
77332	1710	APL cell line UF-1	[APL cell line UF-1]	0.0	4	1	1	1
77333	1710	coding for amino acid	[coding for amino acids]	0.0	4	1	1	1
77334	1710	inhibition of the gut response	[Inhibition of the gut response]	0.0	5	1	1	1
77335	1710	repeat transactivation	[repeat transactivation]	0.0	2	1	1	1
77336	1710	2-globin	[2-globin]	0.0	1	2	2	1
77337	1710	pattern of calcium metabolism	[patterns of calcium metabolism]	0.0	4	1	1	1
77338	1710	(p<.001) in patient	[(P<.001) in patients]	0.0	3	1	1	1
77339	1710	region in gene (-276	[region in genes (-276]	0.0	4	1	1	1
77340	1710	trans-disulfide of thiamine disulfide tds	[trans-disulfide of thiamine disulfide TDS]	0.0	5	1	1	1
77341	1710	clonality analysis of anemia simultaneous study	[Clonality analysis of anemia simultaneous study]	0.0	6	1	1	1
77342	1710	establish a relation MHC	[establishing an relation MHC]	0.0	4	1	1	1
77343	1710	domain for receptor coupling	[domain for receptor coupling]	0.0	4	1	1	1
77344	1710	modification of serine-specific protein kinase	[modification of serine-specific protein kinases]	0.0	5	1	1	1
77345	1710	Mn-SOD	[Mn-SOD]	0.0	1	1	1	1
77346	1710	ap1 protein	[AP1 proteins]	0.0	2	1	1	1
77347	1710	new approach study interaction	[new approach studying interactions]	0.0	4	1	1	1
77348	1710	Finally, activation	[Finally, activation]	0.0	2	1	1	1
77349	1710	soluble cd4-igg	[soluble CD4-IgG]	0.0	2	1	1	1
77350	1710	several gene specific	[several genes specific]	0.0	3	1	1	1
77351	1710	use c-c chemokine in mammalian cell	[using C-C chemokines in mammalian cells]	0.0	6	1	1	1
77352	1710	association of X	[association of X]	0.0	3	1	1	1
77353	1710	nuclear expression human T cell	[nuclear expression human T cells]	0.0	5	1	1	1
77354	1710	ability of dna	[abilities of DNAs]	0.0	3	1	1	1
77355	1710	one-hybrid assay	[One-hybrid assays]	0.0	2	1	1	1
77356	1710	role in atherosclerosis	[role in atherosclerosis]	0.0	3	1	1	1
77357	1710	addition of cell	[addition of cells]	0.0	3	1	1	1
77358	1710	essential USA fraction	[essential USA fraction]	0.0	3	1	1	1
77359	1710	population killer population	[populations killer populations]	0.0	3	1	1	1
77360	1710	functional parameter	[functional parameters]	0.0	2	1	1	1
77361	1710	line of human cell	[line of human cells]	0.0	4	1	1	1
77362	1710	distinct activity in IL-4 T cell	[distinct activities in IL-4 T cells]	0.0	6	1	1	1
77363	1710	copy of 17-bp serum response factor	[copies of 17-bp serum response factor]	0.0	6	1	1	1
77364	1710	identify segment	[identifying segments]	0.0	2	1	1	1
77365	1710	allele allele ratio 3:1)	[allele allele ratio 3:1)]	0.0	4	1	1	1
77366	1710	course of replication	[course of replication]	0.0	3	1	1	1
77367	1710	implication for hypersensitivity	[implications for hypersensitivity]	0.0	3	1	1	1
77368	1710	deletion of a relatively short amino-	[Deletions of a relatively short amino-]	0.0	6	1	1	1
77369	1710	b binding	[B binding]	0.0	2	1	1	1
77370	1710	four animal	[four animals]	0.0	2	1	1	1
77371	1710	gene of human cytomegalovirus CMV	[genes of human cytomegalovirus CMV]	0.0	5	1	1	1
77372	1710	lead to nf-kappab activation	[leading to NF-kappaB activation]	0.0	4	1	1	1
77373	1710	tr beta mrna level	[TR beta mRNA levels]	0.0	4	1	1	1
77374	1710	absence of hgf	[absence of HGFs]	0.0	3	1	1	1
77375	1710	role in myeloid cell development	[role in myeloid cell development]	0.0	5	1	1	1
77376	1710	expression of beta-like globin gene	[expression of beta-like globin genes]	0.0	5	1	1	1
77377	1710	heavy-chain (igh) gene	[heavy-chain (IgH) gene]	0.0	3	1	1	1
77378	1710	direct transcriptional effect	[direct transcriptional effect]	0.0	3	1	1	1
77379	1710	express the e1a oncoprotein	[expressing the E1A oncoprotein]	0.0	4	1	1	1
77380	1710	repression of the interleukin-2 gene inhibition	[repression of the interleukin-2 gene inhibition]	0.0	6	1	1	1
77381	1710	CRE -contain	[CRE -containing]	0.0	2	1	1	1
77382	1710	combination of CD2	[combination of CD2]	0.0	3	1	1	1
77383	1710	binding of interferon IFN	[binding of interferon IFN]	0.0	4	1	1	1
77384	1710	transient pseudo-hypoaldosteronism level	[Transient pseudo-hypoaldosteronism level]	0.0	3	1	1	1
77385	1710	1 terminal repeat quasispecy	[1 terminal repeat quasispecies]	0.0	4	1	1	1
77386	1710	Peripheral leucocyte dna	[Peripheral leucocyte DNAs]	0.0	3	1	1	1
77387	1710	polypeptide of function	[polypeptide of function]	0.0	3	1	1	1
77388	1710	ectopic expression of pu.1	[ectopic expression of PU.1]	0.0	4	1	1	1
77389	1710	presence in Ca2+ medium	[presence in Ca2+ medium]	0.0	4	1	1	1
77390	1710	b-lymphocyte by Epstein-Barr virus	[B-lymphocytes by Epstein-Barr virus]	0.0	4	1	1	1
77391	1710	IL-16 promoter	[IL-16 promoter]	0.0	2	1	1	1
77392	1710	p 0.01, young	[P 0.01, young]	0.0	3	1	1	1
77393	1710	abnormality highlight novel loci relevant	[abnormalities highlighting novel loci relevant]	0.0	5	1	1	1
77394	1710	apparent dissociation rate	[apparent dissociation rate]	0.0	3	1	1	1
77395	1710	pigeon cytochrome c	[pigeon cytochrome c]	0.0	3	1	1	1
77396	1710	formation of stat complex	[formation of STAT complexes]	0.0	4	1	1	1
77397	1710	[correlation	[[Correlation]	0.0	1	1	1	1
77398	1710	20- oligonucleotide probe	[20-mer oligonucleotide probes]	0.0	3	1	1	1
77399	1710	accumulation of c-fo	[accumulation of c-fos]	0.0	3	1	1	1
77400	1710	v3 loop antibody 902 antibody	[V3 loop antibody 902 antibody]	0.0	5	1	1	1
77401	1710	upregulation of cell adhesion molecule-1	[upregulation of cell adhesion molecule-1]	0.0	5	1	1	1
77402	1710	genomic clone of herpesvirus-6	[genomic clones of herpesvirus-6]	0.0	4	1	1	1
77403	1710	general.	[general.]	0.0	1	1	1	1
77404	1710	normal myeloid cell granulocyte pmn	[normal myeloid cells granulocytes PMN]	0.0	5	1	1	1
77405	1710	potential open reading frame	[potential open reading frames]	0.0	4	1	1	1
77406	1710	culture of lymphocytic leukemia	[cultures of lymphocytic leukemia]	0.0	4	1	1	1
77407	1710	cd8(-) CD3 a role	[CD8(-) CD3 a role]	0.0	4	1	1	1
77408	1710	induction of stat	[induction of STATs]	0.0	3	1	1	1
77409	1710	potent impact	[potent impact]	0.0	2	1	1	1
77410	1710	dna-binding protein bind protein hxbp-1	[DNA-binding protein binding protein hXBP-1]	0.0	5	1	1	1
77411	1710	latter group	[latter group]	0.0	2	1	1	1
77412	1710	peripheral blood lymphocyte from young human	[peripheral blood lymphocytes from young humans]	0.0	6	1	1	1
77413	1710	CD28 itself,	[CD28 itself,]	0.0	2	1	1	1
77414	1710	unusually high proportion of cell	[unusually high proportion of cells]	0.0	5	1	1	1
77415	1710	three clone of hiv-1	[Three clones of HIV-1]	0.0	4	1	1	1
77416	1710	regulation of human interleukin gene	[regulation of human interleukin gene]	0.0	5	1	1	1
77417	1710	cyclooxygenase activity	[cyclooxygenase activity]	0.0	2	1	1	1
77418	1710	factor-kappaB -dependent induction	[factor-kappaB -dependent induction]	0.0	3	1	1	1
77419	1710	effect of n-acetyl-l-cysteine	[effects of N-acetyl-L-cysteine]	0.0	3	1	1	1
77420	1710	granulocyte/ factor	[granulocyte/ factor]	0.0	2	1	1	1
77421	1710	optimum time	[optimum time]	0.0	2	1	1	1
77422	1710	eiconsanoid	[eiconsanoids]	0.0	1	1	1	1
77423	1710	proteolysis-resistant factor-kappaB inhibitor IkappaB-alphaS32/36A	[proteolysis-resistant factor-kappaB inhibitor IkappaB-alphaS32/36A]	0.0	4	1	1	1
77424	1710	control reactvation of KSHV	[controlling reactvation of KSHV]	0.0	4	1	1	1
77425	1710	tip-associated protein	[Tip-associated protein]	0.0	2	1	1	1
77426	1710	corresponding to protein	[corresponding to proteins]	0.0	3	1	1	1
77427	1710	include the case	[including the case]	0.0	3	1	1	1
77428	1710	class ii cell line	[class II cell lines]	0.0	4	1	1	1
77429	1710	eighteen kox gene	[eighteen KOX genes]	0.0	3	1	1	1
77430	1710	finally, potential target	[Finally, potential targets]	0.0	3	1	1	1
77431	1710	first activation	[first activation]	0.0	2	1	1	1
77432	1710	relevance for disease	[relevance for disease]	0.0	3	1	1	1
77433	1710	extent, c-jun	[extent, c-Jun]	0.0	2	1	1	1
77434	1710	virus 40 SV40	[virus 40 SV40]	0.0	3	1	1	1
77435	1710	AM580 a retinobenzoic derivative	[AM580 a retinobenzoic derivative]	0.0	4	1	1	1
77436	1710	15.5 (p p less than 0.01	[15.5 (P P less than 0.01]	0.0	6	1	1	1
77437	1710	functional kappa b motif	[functional kappa B motif]	0.0	4	1	1	1
77438	1710	RA sensitivity of RA-resistant cell	[RA sensitivity of RA-resistant cells]	0.0	5	1	1	1
77439	1710	swi6/ankyrin	[SWI6/ankyrin]	0.0	1	1	1	1
77440	1710	phosphorylation of Jak3 usually, STAT3	[phosphorylation of Jak3 usually, STAT3]	0.0	5	1	1	1
77441	1710	range [1-3	[range [1-3]	0.0	2	1	1	1
77442	1710	gamma-Interferon resistance a mechanism	[gamma-Interferon resistance a mechanism]	0.0	4	1	1	1
77443	1710	apparent contradiction, expression	[apparent contradiction, expression]	0.0	3	1	1	1
77444	1710	b2 isoform	[B2 isoform]	0.0	2	1	1	1
77445	1710	ebv transactivator BZLF1	[EBV transactivators BZLF1]	0.0	3	1	1	1
77446	1710	gene include IL-2	[genes including IL-2]	0.0	3	1	1	1
77447	1710	results: in blood of healthy woman	[RESULTS: In blood of healthy women]	0.0	6	1	1	1
77448	1710	primary NK cell on stimulation	[primary NK cells on stimulation]	0.0	5	1	1	1
77449	1710	hiv-1 production in t-lymphoid	[HIV-1 production in T-lymphoid]	0.0	4	1	1	1
77450	1710	hpa system	[HPA system]	0.0	2	1	1	1
77451	1710	five dnase I hypersensitive site	[five DNase I hypersensitive sites]	0.0	5	1	1	1
77452	1710	accumulate datum	[Accumulating data]	0.0	2	1	1	1
77453	1710	transcript isolation of a transcript encode	[transcripts isolation of an transcript encoding]	0.0	6	1	1	1
77454	1710	reading frame orf a	[reading frames ORFs A]	0.0	4	1	1	1
77455	1710	level of trap alpha-naphthyl-acetate-esterase naf-r-nse	[levels of TRAP alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	5	1	1	1
77456	1710	RA-independent differentiation	[RA-independent differentiation]	0.0	2	1	1	1
77457	1710	nearby site	[nearby sites]	0.0	2	1	1	1
77458	1710	excess of endogenous corticosteroid	[excess of endogenous corticosteroids]	0.0	4	1	1	1
77459	1710	fluid from cell carcinoma	[fluid from cell carcinomas]	0.0	4	1	1	1
77460	1710	effect of interleukin-4 il-4	[effect of interleukin-4 IL-4]	0.0	4	1	1	1
77461	1710	mitogen-inducible gene product	[mitogen-inducible gene product]	0.0	3	1	1	1
77462	1710	assess cell proliferation.	[assessing cell proliferation.]	0.0	3	1	1	1
77463	1710	nuclear autoantigen la/ss-b	[nuclear autoantigen La/SS-B]	0.0	3	2	2	1
77464	1710	adenocarcinoma reactive monoclonal antibody ing-1	[adenocarcinoma reactive monoclonal antibody ING-1]	0.0	5	1	1	1
77465	1710	disorder present	[disorder presenting]	0.0	2	1	1	1
77466	1710	1.1 0.4 10(-18) mol/microgram rna corresponding	[1.1 0.4 10(-18) mol/microgram RNA corresponding]	0.0	6	1	1	1
77467	1710	cd14 coding sequence	[CD14 coding sequence]	0.0	3	1	1	1
77468	1710	tcr coengagement	[TCR coengagement]	0.0	2	1	1	1
77469	1710	plasmid contain bp of 5'-flanking sequence	[Plasmids containing bp of 5'-flanking sequences]	0.0	6	1	1	1
77470	1710	lipopolysaccharide (lps)-mediated immune response	[lipopolysaccharide (LPS)-mediated immune responses]	0.0	4	1	1	1
77471	1710	contrast, mutant p85 allele	[contrast, mutant p85 alleles]	0.0	4	1	1	1
77472	1710	stage of T lymphocyte development	[stages of T lymphocyte development]	0.0	5	1	1	1
77473	1710	comparison, a inducer	[comparison, a inducer]	0.0	3	1	1	1
77474	1710	Comparison to virus peptide in vitro	[Comparison to virus peptides in vitro]	0.0	6	1	1	1
77475	1710	(20 mg	[(20 mg]	0.0	2	1	1	1
77476	1710	mechanism for this steroid resistance	[mechanism for this steroid resistance]	0.0	5	1	1	1
77477	1710	aml m4 with eosinophil	[AML M4 with eosinophils]	0.0	4	1	1	1
77478	1710	Myb consensus site	[Myb consensus sites]	0.0	3	1	1	1
77479	1710	latent Epstein-Barr virus infection	[latent Epstein-Barr virus infection]	0.0	4	1	1	1
77480	1710	expression of sla-dr	[expression of SLA-DR]	0.0	3	1	1	1
77481	1710	(s) distinct	[(s) distinct]	0.0	2	1	1	1
77482	1710	patient 8.98	[patients 8.98]	0.0	2	1	1	1
77483	1710	tumor necrosis factor-alpha U/ml, 6	[tumor necrosis factor-alpha U/ml, 6]	0.0	5	1	1	1
77484	1710	molecular framework signal in phagocyte	[molecular framework signaling in phagocytes]	0.0	5	1	1	1
77485	1710	signal from patient with x-linked immunodeficiency	[signaling from patients with X-linked immunodeficiency]	0.0	6	1	1	1
77486	1710	NRE gamma	[NRE gamma]	0.0	2	1	1	1
77487	1710	differential inhibitory effect	[differential inhibitory effects]	0.0	3	1	1	1
77488	1710	cdna-transfected	[cDNA-transfected]	0.0	1	1	1	1
77489	1710	potent peptide chemoattractant	[potent peptide chemoattractant]	0.0	3	1	1	1
77490	1710	role in immune dysregulation	[role in immune dysregulation]	0.0	4	1	1	1
77491	1710	patient a decrease	[patients a decrease]	0.0	3	1	1	1
77492	1710	effect on mrna stability	[effect on mRNA stability]	0.0	4	1	1	1
77493	1710	LPS -responsive member	[LPS -responsive member]	0.0	3	1	1	1
77494	1710	Jak1 signal	[Jak1 signals]	0.0	2	1	1	1
77495	1710	range in human tissue	[range in human tissues]	0.0	4	1	1	1
77496	1710	liquid-suspension culture	[liquid-suspension culture]	0.0	2	1	1	1
77497	1710	recruitment of shp1	[recruitment of SHP1]	0.0	3	1	1	1
77498	1710	h9 T cell	[H9 T cells]	0.0	3	1	1	1
77499	1710	role of NF-kappaB	[role of NF-kappaB]	0.0	3	1	1	1
77500	1710	cofilin-homology sequence	[cofilin-homology sequence]	0.0	2	1	1	1
77501	1710	certain characteristic	[certain characteristics]	0.0	2	1	1	1
77502	1710	two phosphopeptide	[two phosphopeptides]	0.0	2	1	1	1
77503	1710	multiple	[multiples]	0.0	1	1	1	1
77504	1710	fibroblast line	[fibroblast lines]	0.0	2	1	1	1
77505	1710	factor kappab nf-kappab system	[factor kappaB NF-kappaB system]	0.0	4	1	1	1
77506	1710	other monocytic gene	[other monocytic genes]	0.0	3	1	1	1
77507	1710	exclusive fashion.	[exclusive fashion.]	0.0	2	1	1	1
77508	1710	GATA-3 site	[GATA-3 site]	0.0	2	1	1	1
77509	1710	chicken homolog	[chicken homolog]	0.0	2	1	1	1
77510	1710	human cell line UT-7	[human cell line UT-7]	0.0	4	1	1	1
77511	1710	thiol level	[thiol level]	0.0	2	1	1	1
77512	1710	formation by membrane protein gene	[formation by membrane protein gene]	0.0	5	1	1	1
77513	1710	10(-8) to 10(-7) g/g	[10(-8) to 10(-7) g/g]	0.0	4	1	1	1
77514	1710	regulation of intercellular adhesion molecule-1	[regulation of intercellular adhesion molecule-1]	0.0	5	1	1	1
77515	1710	Monoallelic expression	[Monoallelic expression]	0.0	2	2	2	1
77516	1710	detection of minimal residual disease	[Detection of minimal residual disease]	0.0	5	1	1	1
77517	1710	splice/polyadenylation event	[splice/polyadenylation events]	0.0	2	1	1	1
77518	1710	amount of ap-1	[amounts of AP-1]	0.0	3	1	1	1
77519	1710	leukemia cell line ut-7/gm	[leukemia cell line UT-7/GM]	0.0	4	1	1	1
77520	1710	feature of blastic transformation	[feature of blastic transformation]	0.0	4	1	1	1
77521	1710	5 u/ml of erythropoietin	[5 U/mL of erythropoietin]	0.0	4	1	1	1
77522	1710	serine protease inhibitor	[serine protease inhibitors]	0.0	3	1	1	1
77523	1710	b-cell factor EBF	[B-cell factor EBF]	0.0	3	1	1	1
77524	1710	abundant protein of 75	[abundant proteins of 75]	0.0	4	1	1	1
77525	1710	small lymphoma	[small lymphoma]	0.0	2	1	1	1
77526	1710	two-component	[two-component]	0.0	1	1	1	1
77527	1710	guamerin-derived synthetic peptide	[guamerin-derived synthetic peptide]	0.0	3	1	1	1
77528	1710	Oct2 cDNA	[Oct2 cDNA]	0.0	2	1	1	1
77529	1710	use a fragment as bait	[Using a fragment as bait]	0.0	5	1	1	1
77530	1710	analog rad	[analog RAD]	0.0	2	1	1	1
77531	1710	clustering of receptor	[clustering of receptors]	0.0	3	1	1	1
77532	1710	combination include CD28 signaling.	[combination including CD28 signaling.]	0.0	4	1	1	1
77533	1710	level expression of nf-kappa b promoter	[level expression of NF-kappa B promoters]	0.0	6	1	1	1
77534	1710	activation of human T lymphocyte	[activation of human T lymphocytes]	0.0	5	1	1	1
77535	1710	transcription factor necessary	[transcription factor necessary]	0.0	3	1	1	1
77536	1710	il-4 of gene in monocyte	[IL-4 of genes in monocytes]	0.0	5	1	1	1
77537	1710	activity in erythrocyte membrane	[activity in erythrocyte membranes]	0.0	4	1	1	1
77538	1710	involve shp2	[involving SHP2]	0.0	2	1	1	1
77539	1710	activity of NF-kappa B	[activity of NF-kappa B]	0.0	4	1	1	1
77540	1710	raise the activity	[raising the activity]	0.0	3	1	1	1
77541	1710	Glucocorticoid receptor on peripheral mononuclear	[Glucocorticoid receptors on peripheral mononuclear]	0.0	5	1	1	1
77542	1710	enhancer repressor overlap	[enhancer repressor overlap]	0.0	3	1	1	1
77543	1710	translocation of factor kappab nf-kappab	[translocation of factor kappaB NF-kappaB]	0.0	5	1	1	1
77544	1710	possibilities,	[possibilities,]	0.0	1	1	1	1
77545	1710	simply a function	[simply a function]	0.0	3	1	1	1
77546	1710	small substance	[small substances]	0.0	2	1	1	1
77547	1710	reporter chloramphenicol	[reporter chloramphenicol]	0.0	2	1	1	1
77548	1710	IL-1 protein kinase	[IL-1 protein kinase]	0.0	3	1	1	1
77549	1710	contain a reading frame	[containing an reading frame]	0.0	4	1	1	1
77550	1710	mutant nm23-h2hi protein	[mutant nm23-H2His protein]	0.0	3	1	1	1
77551	1710	efficient transcription in the absence	[Efficient transcription in the absence]	0.0	5	1	1	1
77552	1710	chimeric properties unlike oncoprotein	[chimeric properties, unlike oncoproteins]	0.0	4	1	1	1
77553	1710	responsiveness to prednisolone 0.01).	[responsiveness to prednisolone 0.01).]	0.0	4	1	1	1
77554	1710	range in number	[ranging in number]	0.0	3	1	1	1
77555	1710	granule of the human neutrophil	[granules of the human neutrophil]	0.0	5	1	1	1
77556	1710	NF-kappa B /Rel	[NF-kappa B /Rel]	0.0	3	1	1	1
77557	1710	overexpression of full-length alg-4 transcription	[Overexpression of full-length ALG-4 transcription]	0.0	5	1	1	1
77558	1710	86 control subject	[86 control subjects]	0.0	3	1	1	1
77559	1710	charcoal binding assay	[charcoal binding assay]	0.0	3	1	1	1
77560	1710	cell line hER	[cell line hER]	0.0	3	1	1	1
77561	1710	20-base pair sequence	[20-base pair sequence]	0.0	3	1	1	1
77562	1710	histocompatibility immune deficiency	[histocompatibility immune deficiency]	0.0	3	1	1	1
77563	1710	hours, level	[hours, levels]	0.0	2	1	1	1
77564	1710	th2-type cytokine	[Th2-type cytokines]	0.0	2	1	1	1
77565	1710	point assay of receptor	[point assay of receptors]	0.0	4	1	1	1
77566	1710	contain the protein	[containing the protein]	0.0	3	1	1	1
77567	1710	Stat5 /mek pathway	[Stat5 /MEK pathways]	0.0	3	1	1	1
77568	1710	base pair -1 to -275	[base pairs -1 to -275]	0.0	5	1	1	1
77569	1710	-receptor antagonist	[-receptor antagonist]	0.0	2	1	1	1
77570	1710	also in individual as normal control	[also in individuals as normal control]	0.0	6	1	1	1
77571	1710	chronic heart disease	[chronic heart disease]	0.0	3	2	2	1
77572	1710	b cell with ebv	[B cells with EBV]	0.0	4	1	1	1
77573	1710	splicing out of exon	[splicing out of exon]	0.0	4	1	1	1
77574	1710	activation of a CRE reporter plasmid	[activation of a CRE reporter plasmid]	0.0	6	1	1	1
77575	1710	one Ets binding site	[one Ets binding site]	0.0	4	1	1	1
77576	1710	activate effect of p65	[activating effects of p65]	0.0	4	1	1	1
77577	1710	link this class	[linking these classes]	0.0	3	1	1	1
77578	1710	function of this cis-acting site	[function of these cis-acting sites]	0.0	5	1	1	1
77579	1710	transactivator BZLF1 Z	[transactivators BZLF1 Z]	0.0	3	1	1	1
77580	1710	few gr	[fewer GR]	0.0	2	1	1	1
77581	1710	number of intracellular signal molecule	[number of intracellular signaling molecules]	0.0	5	1	1	1
77582	1710	dna-binding activity of three transcription factor	[DNA-binding activities of three transcription factors]	0.0	6	1	1	1
77583	1710	treatment, at regular interval week	[treatment, at regular intervals week]	0.0	5	1	1	1
77584	1710	ca2+-dependent signal	[Ca2+-dependent signal]	0.0	2	1	1	1
77585	1710	Peroxisomal proliferator-activated receptor gamma PPARgamma	[Peroxisomal proliferator-activated receptor gamma PPARgamma]	0.0	5	1	1	1
77586	1710	random x-inactivation	[random X-inactivation]	0.0	2	1	1	1
77587	1710	alpha-dihydrotestosterone	[alpha-dihydrotestosterone]	0.0	1	1	1	1
77588	1710	expression in leukaemic T cell	[Expression in leukaemic T cells]	0.0	5	1	1	1
77589	1710	axis activation during illness	[axis activation during illness]	0.0	4	1	1	1
77590	1710	analysis of immunodeficiency virus	[analysis of immunodeficiency virus]	0.0	4	1	1	1
77591	1710	cd45ra+ T	[CD45RA+ T]	0.0	2	1	1	1
77592	1710	size variant	[size variant]	0.0	2	1	1	1
77593	1710	response of type	[response of Type]	0.0	3	1	1	1
77594	1710	bioactivation of sulphamethoxazole	[Bioactivation of sulphamethoxazole]	0.0	3	1	1	1
77595	1710	tissue-specific transcriptional control of activity	[tissue-specific transcriptional control of activity]	0.0	5	1	1	1
77596	1710	salt loss lead	[salt loss leading]	0.0	3	1	1	1
77597	1710	follow expression of tax	[following expression of Tax]	0.0	4	1	1	1
77598	1710	alpha isozyme	[alpha isozymes]	0.0	2	1	1	1
77599	1710	linear correlation, with a value	[linear correlation, with an value]	0.0	5	1	1	1
77600	1710	platelet for hours,	[platelets for hours,]	0.0	3	1	1	1
77601	1710	noncontiguous region include the poz motif	[noncontiguous regions including the POZ motif]	0.0	6	1	1	1
77602	1710	patient with hepatitis c	[patients with hepatitis C]	0.0	4	5	5	1
77603	1710	majority of carcinoma	[majority of carcinomas]	0.0	3	1	1	1
77604	1710	difference between EBNA-2 -positive extract	[differences between EBNA-2 -positive extracts]	0.0	5	1	1	1
77605	1710	key functional role of PML	[key functional role of PML]	0.0	5	1	1	1
77606	1710	polyclonal signal	[polyclonal signals]	0.0	2	1	1	1
77607	1710	expression of BZLF-1	[expression of BZLF-1]	0.0	3	1	1	1
77608	1710	role of redox status	[role of redox status]	0.0	4	1	1	1
77609	1710	human umbilical arterial cell	[human umbilical arterial cells]	0.0	4	1	1	1
77610	1710	c-jun NH2-terminal mapk	[c-jun NH2-terminal MAPk]	0.0	3	1	1	1
77611	1710	epstein-barr virus b lymphocyte	[Epstein-Barr virus B lymphocytes]	0.0	4	1	1	1
77612	1710	role of PGE2	[role of PGE2]	0.0	3	1	1	1
77613	1710	stat3 activation with kinetic	[Stat3 activation with kinetics]	0.0	4	1	1	1
77614	1710	inhibition during lytic infection	[inhibition during lytic infection]	0.0	4	1	1	1
77615	1710	interaction with cellular protein	[interactions with cellular proteins]	0.0	4	1	1	1
77616	1710	Yin-Yang	[Yin-Yang]	0.0	1	2	2	1
77617	1710	IL-2 heterodimerization	[IL-2 heterodimerization]	0.0	2	1	1	1
77618	1710	panel of line represent stage	[panel of lines representing stages]	0.0	5	1	1	1
77619	1710	unrecognized element,	[unrecognized element,]	0.0	2	1	1	1
77620	1710	functional factor kB NF-kB element	[functional factor kB NF-kB elements]	0.0	5	1	1	1
77621	1710	action human promonocytic leukemia cell	[action human promonocytic leukemia cells]	0.0	5	1	1	1
77622	1710	unique characteristic among factor	[unique characteristic among factors]	0.0	4	1	1	1
77623	1710	mature cell line	[mature cell lines]	0.0	3	1	1	1
77624	1710	(64 8 mv), normalize	[(64 8 mV), normalizing]	0.0	4	1	1	1
77625	1710	potential application of this system	[potential application of this system]	0.0	5	1	1	1
77626	1710	stat pathway for cytokine	[STAT pathways for cytokine]	0.0	4	1	1	1
77627	1710	NFAT oligonucleotide	[NFAT oligonucleotide]	0.0	2	1	1	1
77628	1710	degree of autoregulation	[degree of autoregulation]	0.0	3	1	1	1
77629	1710	block uptake	[blocking uptake]	0.0	2	1	1	1
77630	1710	tg presentation	[TG presentation]	0.0	2	1	1	1
77631	1710	disease of kidney	[disease of kidney]	0.0	3	1	1	1
77632	1710	TRAF2 mutant	[TRAF2 mutant]	0.0	2	1	1	1
77633	1710	motif for ap-2	[motif for AP-2]	0.0	3	1	1	1
77634	1710	viral gene ORF 50	[viral gene ORF 50]	0.0	4	1	1	1
77635	1710	12-o-tetradecanoyl-phorbol-13	[12-O-tetradecanoyl-phorbol-13]	0.0	1	1	1	1
77636	1710	PKC subfamily	[PKC subfamilies]	0.0	2	1	1	1
77637	1710	b -induce agent	[B -inducing agents]	0.0	3	1	1	1
77638	1710	low base stem-loop potential	[low base stem-loop potential]	0.0	4	1	1	1
77639	1710	selection expansion)	[selection expansion)]	0.0	2	1	1	1
77640	1710	Oct-1 DNA binding	[Oct-1 DNA binding]	0.0	3	1	1	1
77641	1710	weight complex	[weight complex]	0.0	2	1	1	1
77642	1710	blood of 145	[blood of 145]	0.0	3	1	1	1
77643	1710	40 mM d-ribose	[40 mM D-ribose]	0.0	3	1	1	1
77644	1710	InterleUkin expression	[InterleUkin expression]	0.0	2	1	1	1
77645	1710	whole blood with PGG-Glucan	[whole blood with PGG-Glucan]	0.0	4	1	1	1
77646	1710	association with toxicity in a patient	[association with toxicity in a patient]	0.0	6	1	1	1
77647	1710	the/thf (0.24; n: alpha thf/thf	[THE/THF (0.24; N: alpha THF/THF]	0.0	5	1	1	1
77648	1710	red blood cell ss RBC	[red blood cells SS RBC]	0.0	5	1	1	1
77649	1710	T cell-specific negative element	[T cell-specific negative element]	0.0	4	1	1	1
77650	1710	MHC class Ii chain	[MHC class Ii chain]	0.0	4	1	1	1
77651	1710	time for 12	[times for 12]	0.0	3	1	1	1
77652	1710	infant brother	[infant brothers]	0.0	2	1	1	1
77653	1710	ca(2+) -dependent pathway alone	[Ca(2+) -dependent pathways alone]	0.0	4	1	1	1
77654	1710	low affinity to glucocorticoid AIDS-GR	[low affinity to glucocorticoids AIDS-GR]	0.0	5	1	1	1
77655	1710	dnase-i	[DNase-I]	0.0	1	1	1	1
77656	1710	endothelial tethering factor	[endothelial tethering factor]	0.0	3	1	1	1
77657	1710	upstream region (position -69	[upstream region (positions -69]	0.0	4	1	1	1
77658	1710	simultaneously; (3) non-dividing, pbl	[simultaneously; (3) non-dividing, PBL]	0.0	4	1	1	1
77659	1710	expansion) (by abortive stimulation	[expansion) (by abortive stimulation]	0.0	4	1	1	1
77660	1710	encompass a element	[encompassing an element]	0.0	3	1	1	1
77661	1710	Platelet factor	[Platelet Factor]	0.0	2	1	1	1
77662	1710	similar rhythm of gr	[similar rhythm of GR]	0.0	4	1	1	1
77663	1710	bcl-xL mediate cell survival	[bcl-xL mediating cell survival]	0.0	4	1	1	1
77664	1710	amino acid alanine	[amino acids alanine]	0.0	3	1	1	1
77665	1710	variant translocation in leukaemia	[variant translocation in leukaemia]	0.0	4	1	1	1
77666	1710	rise in c-myc mrna expression	[rise in c-myc mRNA expression]	0.0	5	1	1	1
77667	1710	primitive hpc potential colony-forming cell	[primitive HPCs potential colony-forming cells]	0.0	5	1	1	1
77668	1710	nf-kappab site present	[NF-kappaB sites present]	0.0	3	1	1	1
77669	1710	follow CD40 stimulation of monocyte	[following CD40 stimulation of monocytes]	0.0	5	1	1	1
77670	1710	IL-12 developmental stage involve expression	[IL-12 developmental stage involving expression]	0.0	5	1	1	1
77671	1710	significant correlation between lymphocytic infiltration	[significant correlation between lymphocytic infiltration]	0.0	5	1	1	1
77672	1710	day establish high-density pbmc culture	[days establishing high-density PBMC cultures]	0.0	5	1	1	1
77673	1710	dansylcadaverine	[dansylcadaverine]	0.0	1	1	1	1
77674	1710	effect on replication	[effects on replication]	0.0	3	1	1	1
77675	1710	affinity tnfrp75 molecule	[affinity TNFRp75 molecules]	0.0	3	1	1	1
77676	1710	circulate T cell with cell	[circulating T cells with cells]	0.0	5	1	1	1
77677	1710	replacement of the AP-1 site	[Replacement of the AP-1 sites]	0.0	5	1	1	1
77678	1710	cell-mediated tcell rescue	[cell-mediated Tcell rescue]	0.0	3	1	1	1
77679	1710	target structure the 72-kilodalton immediate-early protein	[Target structures the 72-kilodalton immediate-early protein]	0.0	6	1	1	1
77680	1710	binding of hmg-i(y)	[binding of HMG-I(Y)]	0.0	3	1	1	1
77681	1710	p21 Waf1	[p21 Waf1]	0.0	2	1	1	1
77682	1710	bind domain	[binding domain]	0.0	2	1	1	1
77683	1710	x-linked muscular atrophy a adult-onset form	[X-linked muscular atrophy an adult-onset form]	0.0	6	1	1	1
77684	1710	differentiation of pluripotent hemopoietic progenitor	[differentiation of pluripotent hemopoietic progenitors]	0.0	5	1	1	1
77685	1710	-neutralize antibody	[-neutralizing antibodies]	0.0	2	1	1	1
77686	1710	indicate a causal relationship	[indicating a causal relationship]	0.0	4	1	1	1
77687	1710	anti-p-selectin antibody antibody mab	[anti-P-selectin antibodies antibodies mAbs]	0.0	4	1	1	1
77688	1710	nuclear factor-kappa b site -85	[nuclear factor-kappa B site -85]	0.0	5	1	1	1
77689	1710	leukocyte in aging.	[leukocytes in aging.]	0.0	3	1	1	1
77690	1710	analysis of phosphotyrosine	[Analysis of phosphotyrosine]	0.0	3	1	1	1
77691	1710	immunofluorescence from five normal tonsil	[immunofluorescence from five normal tonsils]	0.0	5	1	1	1
77692	1710	cyclosporin a -sensitive induction	[cyclosporin A -sensitive induction]	0.0	4	1	1	1
77693	1710	aortic endothelial cell harc	[aortic endothelial cells HAECs]	0.0	4	1	1	1
77694	1710	mobility.	[mobility.]	0.0	1	1	1	1
77695	1710	il-5 transcription	[IL-5 transcription]	0.0	2	2	2	1
77696	1710	stimulate expression	[stimulating expression]	0.0	2	1	1	1
77697	1710	repeat hiv-1-ltr	[repeat HIV-1-LTR]	0.0	2	1	1	1
77698	1710	stage of maturation	[stage of maturation]	0.0	3	1	1	1
77699	1710	rna transcription assay	[RNA transcription assay]	0.0	3	1	1	1
77700	1710	etiology of sclerosis ms	[etiology of sclerosis MS]	0.0	4	1	1	1
77701	1710	interaction between the zinc finger domain	[interaction between the zinc finger domains]	0.0	6	1	1	1
77702	1710	response of the L-selectin promoter	[response of the L-selectin promoter]	0.0	5	1	1	1
77703	1710	new facet to understanding	[new facet to understanding]	0.0	4	1	1	1
77704	1710	role factor	[Role factors]	0.0	2	1	1	1
77705	1710	NF-kappaB/Rel transcription factor family	[NF-kappaB/Rel transcription factor family]	0.0	4	1	1	1
77706	1710	evidence for a considerable tissue-specific variation	[evidence for a considerable tissue-specific variation]	0.0	6	1	1	1
77707	1710	effect on primary NK	[effects on primary NK]	0.0	4	1	1	1
77708	1710	vertebrate transcriptional regulation	[vertebrate transcriptional regulation]	0.0	3	1	1	1
77709	1710	incubation in LDL	[incubation in LDL]	0.0	3	1	1	1
77710	1710	multiple gene product	[multiple gene products]	0.0	3	1	1	1
77711	1710	increase in homodimer	[increase in homodimers]	0.0	3	1	1	1
77712	1710	[regulatory effect of insulin	[[Regulatory effect of insulin]	0.0	4	1	1	1
77713	1710	non-cytotoxic dose microm	[non-cytotoxic doses microM]	0.0	3	1	1	1
77714	1710	appearance of p50/p65-nf-kappab	[appearance of p50/p65-NF-kappaB]	0.0	3	1	1	1
77715	1710	degradation of the i-kappa b	[degradation of the I-kappa B]	0.0	5	1	1	1
77716	1710	inhibitor contain ankyrin motif	[inhibitors containing ankyrin motifs]	0.0	4	1	1	1
77717	1710	RelA(p65) mrna	[RelA(p65) mRNA]	0.0	2	1	1	1
77718	1710	sequential deletion	[sequential deletions]	0.0	2	1	1	1
77719	1710	functional stimulation of monocyte	[functional stimulation of monocytes]	0.0	4	1	1	1
77720	1710	h of treatment	[h of treatment]	0.0	3	1	1	1
77721	1710	association latency in monocytic cell	[Association latency in monocytic cells]	0.0	5	1	1	1
77722	1710	uptake with advanced failure	[uptake with advanced failure]	0.0	4	1	1	1
77723	1710	potential advantage	[potential advantages]	0.0	2	1	1	1
77724	1710	contrast, cell line	[contrast, cell lines]	0.0	3	1	1	1
77725	1710	rprl footprint	[rPRL footprint]	0.0	2	1	1	1
77726	1710	dramatic increase in tyrosine phosphorylation	[dramatic increase in tyrosine phosphorylation]	0.0	5	1	1	1
77727	1710	high level of nuclear nf-atp capable	[higher levels of nuclear NF-ATp capable]	0.0	6	1	1	1
77728	1710	endometrial fragment	[endometrial fragments]	0.0	2	1	1	1
77729	1710	increase in the cytoplasmic ikappabalpha level	[increase in the cytoplasmic IkappaBalpha levels]	0.0	6	1	1	1
77730	1710	Functional association of Nmi	[Functional association of Nmi]	0.0	4	1	1	1
77731	1710	however, continuous treatment	[However, continuous treatments]	0.0	3	1	1	1
77732	1710	unique region contain four repeat	[unique region containing four repeats]	0.0	5	1	1	1
77733	1710	encompass band	[encompassing bands]	0.0	2	1	1	1
77734	1710	Study in semisolid culture	[Studies in semisolid culture]	0.0	4	1	1	1
77735	1710	gene expression 3 promoter	[gene expression 3 promoter]	0.0	4	1	1	1
77736	1710	socs3	[SOCS3]	0.0	1	1	1	1
77737	1710	common b	[common B]	0.0	2	1	1	1
77738	1710	presence of multiple critical element	[presence of multiple critical elements]	0.0	5	1	1	1
77739	1710	stimulation use ng/ml	[stimulation using ng/ml]	0.0	3	1	1	1
77740	1710	immunodeficiency virus contain enhancer/promoters	[immunodeficiency viruses containing enhancer/promoters]	0.0	4	1	1	1
77741	1710	Escherichia coli stress	[Escherichia coli stress]	0.0	3	1	1	1
77742	1710	repeat (ltr) of hiv-1	[repeat (LTR) of HIV-1]	0.0	4	1	1	1
77743	1710	immunodeficiency virus (HIV) type 1	[immunodeficiency virus (HIV) type 1]	0.0	5	1	1	1
77744	1710	cytokine interleukin-7 il-7	[cytokine interleukin-7 IL-7]	0.0	3	1	1	1
77745	1710	Retinoic acid-induced expression	[Retinoic acid-induced expression]	0.0	3	1	1	1
77746	1710	keratoconjunctivitis a allergic eosinophilic disease	[keratoconjunctivitis an allergic eosinophilic disease.]	0.0	5	1	1	1
77747	1710	mechanism of proteolysis	[mechanism of proteolysis]	0.0	3	1	1	1
77748	1710	induction of clonal anergy	[induction of clonal anergy]	0.0	4	1	1	1
77749	1710	binding site for activator protein BSAP	[binding sites for activator protein BSAP]	0.0	6	1	1	1
77750	1710	h from level	[h from levels]	0.0	3	1	1	1
77751	1710	rxr-alpha sequence	[RXR-alpha sequences]	0.0	2	1	1	1
77752	1710	modular structure with separable domain	[modular structure with separable domains]	0.0	5	1	1	1
77753	1710	non-polymorphic region of class molecule	[non-polymorphic regions of class molecules]	0.0	5	1	1	1
77754	1710	mechanism during t-cell activation	[mechanisms during T-cell activation]	0.0	4	1	1	1
77755	1710	favorable course (p	[favorable course (P]	0.0	3	1	1	1
77756	1710	T cell-specific function a notion	[T cell-specific function a notion]	0.0	5	1	1	1
77757	1710	23 amino acid	[23 amino acids]	0.0	3	1	1	1
77758	1710	expression of type	[expression of type]	0.0	3	1	1	1
77759	1710	RESULTS: six	[RESULTS: Six]	0.0	2	1	1	1
77760	1710	DNA-protein interaction involve factor	[DNA-protein interactions involving factor]	0.0	4	1	1	1
77761	1710	membrane proximal domain	[membrane proximal domain]	0.0	3	1	1	1
77762	1710	coligation	[Coligation]	0.0	1	1	1	1
77763	1710	domain of ZEBRA	[domain of ZEBRA]	0.0	3	1	1	1
77764	1710	pathophysiological background	[pathophysiological background]	0.0	2	1	1	1
77765	1710	several cis-acting element	[several cis-acting elements]	0.0	3	1	1	1
77766	1710	68 triple-labelling	[68 triple-labellings]	0.0	2	1	1	1
77767	1710	term treatment	[term treatment]	0.0	2	1	1	1
77768	1710	distal factor proximal NF-AT AP-1/Octamer	[distal factor proximal NF-AT AP-1/Octamer]	0.0	5	1	1	1
77769	1710	effect of CyA attributable	[effects of CyA attributable]	0.0	4	1	1	1
77770	1710	physiologically relevant inhibitor	[physiologically relevant inhibitor]	0.0	3	1	1	1
77771	1710	role in primary culture	[role in primary cultures]	0.0	4	1	1	1
77772	1710	D 4816	[D 4816]	0.0	2	1	1	1
77773	1710	CMV immediate cell	[CMV immediate cells]	0.0	3	1	1	1
77774	1710	expression -1	[expression -1]	0.0	2	1	1	1
77775	1710	10(-10) mol/L	[10(-10) mol/L]	0.0	2	1	1	1
77776	1710	cell line kg-1	[cell lines KG-1]	0.0	3	1	1	1
77777	1710	t- acute leukemia arise	[T- acute leukemias arising]	0.0	4	1	1	1
77778	1710	characteristic of promyelocyte	[characteristics of promyelocytes]	0.0	3	1	1	1
77779	1710	hiv-protease	[HIV-protease]	0.0	1	1	1	1
77780	1710	marker for cell	[marker for cells]	0.0	3	1	1	1
77781	1710	strong activator	[strong activator]	0.0	2	1	1	1
77782	1710	methionine codon-initiated open reading frame	[methionine codon-initiated open reading frame]	0.0	5	1	1	1
77783	1710	cell to condition	[cells to conditions]	0.0	3	1	1	1
77784	1710	type receptor in ovulation woman	[Type receptors in ovulation women]	0.0	5	1	1	1
77785	1710	1 aml m4 with eosinophil	[1 AML M4 with eosinophils]	0.0	5	1	1	1
77786	1710	cell growth-regulated expression	[Cell growth-regulated expression]	0.0	3	1	1	1
77787	1710	inducible nuclear form	[inducible nuclear form]	0.0	3	1	1	1
77788	1710	expression of the transcriptional element	[expression of the transcriptional elements]	0.0	5	1	1	1
77789	1710	corticoid	[corticoid]	0.0	1	1	1	1
77790	1710	expression in Hox11 mouse	[expression in Hox11 mice]	0.0	4	1	1	1
77791	1710	cytokine tumor necrosis	[cytokine tumor necrosis]	0.0	3	1	1	1
77792	1710	collectively, factor necessary	[Collectively, factor necessary]	0.0	3	1	1	1
77793	1710	certain individual of major (mhc) haplotype	[certain individuals of major (MHC) haplotypes]	0.0	6	1	1	1
77794	1710	45 kb of genomic DNA	[45 kb of genomic DNA]	0.0	5	1	1	1
77795	1710	Schizosaccharomyces pombe	[Schizosaccharomyces pombe]	0.0	2	1	1	1
77796	1710	reliable surrogate for the study	[reliable surrogates for the study]	0.0	5	1	1	1
77797	1710	often converge in common pathway	[often converging in common pathways]	0.0	5	1	1	1
77798	1710	seasonal variation in gr	[seasonal variation in GR]	0.0	4	1	1	1
77799	1710	the/thf (0.24; 1.87+/-0.36)	[THE/THF (0.24; 1.87+/-0.36)]	0.0	3	1	1	1
77800	1710	membrane antigen	[membrane antigens]	0.0	2	1	1	1
77801	1710	study, cotransfection	[study, cotransfection]	0.0	2	1	1	1
77802	1710	cell with interleukin-1beta il-1beta	[cells with interleukin-1beta IL-1beta]	0.0	4	1	1	1
77803	1710	166 healthy female aged	[166 healthy females aged]	0.0	4	1	1	1
77804	1710	replication in hela cell	[replication in HeLa cells]	0.0	4	1	1	1
77805	1710	difference in isoform expression pattern	[differences in isoform expression patterns]	0.0	5	1	1	1
77806	1710	sevenfold) of site	[sevenfold) of site]	0.0	3	1	1	1
77807	1710	threefold to fourfold 12-lipoxygenase activity	[threefold to fourfold 12-lipoxygenase activity]	0.0	5	1	1	1
77808	1710	alter signal transduction	[altering signal transduction]	0.0	3	1	1	1
77809	1710	distinct role for the form	[distinct roles for the forms]	0.0	5	1	1	1
77810	1710	eosinophil phenotype	[eosinophil phenotype]	0.0	2	1	1	1
77811	1710	administration of pcr	[administration of PCr]	0.0	3	1	1	1
77812	1710	(non-recurrent) tcr beta clonotype	[(non-recurrent) TCR beta clonotypes]	0.0	4	1	1	1
77813	1710	apparent size	[apparent size]	0.0	2	1	1	1
77814	1710	activation of factor-kappa b nf-kappa b	[activation of factor-kappa B NF-kappa B]	0.0	6	1	1	1
77815	1710	transactivation by herpesvirus 6 strain	[Transactivation by herpesvirus 6 strains]	0.0	5	1	1	1
77816	1710	4 kilobasis 5'	[4 kilobases 5']	0.0	3	1	1	1
77817	1710	induction I gene expression	[induction I gene expression]	0.0	4	1	1	1
77818	1710	significant change of specific binding	[significant changes of specific binding]	0.0	5	1	1	1
77819	1710	granulocyte-macrophage factor proliferation	[granulocyte-macrophage factor proliferation]	0.0	3	1	1	1
77820	1710	kinases/extracellular	[kinases/extracellular]	0.0	1	1	1	1
77821	1710	several transcriptional regulator	[several transcriptional regulators]	0.0	3	1	1	1
77822	1710	Dithiocarbamates a group of chemical	[Dithiocarbamates a group of chemicals]	0.0	5	1	1	1
77823	1710	effect of ifn-gamma on type	[effects of IFN-gamma on type]	0.0	5	1	1	1
77824	1710	human b-cell activation	[human B-cell activation]	0.0	3	1	1	1
77825	1710	NF kappa b like complex	[NF kappa B like complexes]	0.0	5	1	1	1
77826	1710	effector cell eTh1	[effector cells eTh1]	0.0	3	1	1	1
77827	1710	binding of three multi-protein complex	[binding of three multi-protein complexes]	0.0	5	1	1	1
77828	1710	various part	[various parts]	0.0	2	1	1	1
77829	1710	release during sepsis.	[release during sepsis.]	0.0	3	1	1	1
77830	1710	difference in the er transcript	[differences in the ER transcripts]	0.0	5	1	1	1
77831	1710	mutant pathway include myd88	[mutants pathway including MyD88]	0.0	4	1	1	1
77832	1710	mouse transgenic for csf-1r	[mice transgenic for CSF-1R]	0.0	4	1	1	1
77833	1710	VLA-4/ VCAM-1 pathway	[VLA-4/ VCAM-1 pathway]	0.0	3	1	1	1
77834	1710	detail of glucocorticoid hormone action	[details of glucocorticoid hormone action]	0.0	5	1	1	1
77835	1710	region contain repeat	[region containing repeats]	0.0	3	1	1	1
77836	1710	fate decision	[fate decisions]	0.0	2	1	1	1
77837	1710	modulate the expression only in cell	[modulating the expression only in cells]	0.0	6	1	1	1
77838	1710	carry the localization sequence	[carrying the localization sequence]	0.0	4	1	1	1
77839	1710	silencer extend bp	[silencer extending bp]	0.0	3	1	1	1
77840	1710	follow the trigger	[following the triggering]	0.0	3	1	1	1
77841	1710	well-defined, borders.	[well-defined, borders.]	0.0	2	1	1	1
77842	1710	production during T cell activation	[production during T cell activation]	0.0	5	1	1	1
77843	1710	receptor c-kit/epo-r	[receptors c-Kit/Epo-R]	0.0	2	1	1	1
77844	1710	T cell leukemia-derived factor	[T cell leukemia-derived factor]	0.0	4	1	1	1
77845	1710	role for Jagged1	[role for Jagged1]	0.0	3	1	1	1
77846	1710	regulation effect of ap-1 protein	[regulation effects of AP-1 proteins]	0.0	5	1	1	1
77847	1710	exogenous nf-kappab	[exogenous NF-kappaB]	0.0	2	1	1	1
77848	1710	cytogenetic abnormality highlight putative loci	[cytogenetic abnormalities highlighting putative loci]	0.0	5	1	1	1
77849	1710	C/EBPalpha -deficient cell	[C/EBPalpha -deficient cells]	0.0	3	1	1	1
77850	1710	Potential site ap1	[Potential sites AP1]	0.0	3	1	1	1
77851	1710	sodium in HML	[sodium in HML]	0.0	3	1	1	1
77852	1710	involve the synthesis	[involving the synthesis]	0.0	3	1	1	1
77853	1710	determination of hiv-1 viral burden	[determination of HIV-1 viral burden]	0.0	5	1	1	1
77854	1710	leukocyte of subject	[leukocytes of subjects]	0.0	3	1	1	1
77855	1710	three form of unbound (free) e2f	[three forms of unbound (free) E2F]	0.0	6	1	1	1
77856	1710	initiation of fibrin deposition	[initiation of fibrin deposition]	0.0	4	1	1	1
77857	1710	ebv entry	[EBV entry]	0.0	2	1	1	1
77858	1710	Paramyxovirus	[Paramyxovirus]	0.0	1	1	1	1
77859	1710	only the response	[only the response]	0.0	3	1	1	1
77860	1710	development of some lineage	[development of some lineages]	0.0	4	1	1	1
77861	1710	concentration of 10(-4)	[concentration of 10(-4)]	0.0	3	1	1	1
77862	1710	possibility use TAP-deficient cell line	[possibility using TAP-deficient cell lines]	0.0	5	1	1	1
77863	1710	CD28 itself, ligation	[CD28 itself, ligation]	0.0	3	1	1	1
77864	1710	affect cell fate	[affecting cell fate]	0.0	3	1	1	1
77865	1710	differentiation of u-937 cell by etoposide	[Differentiation of U-937 cells by etoposide]	0.0	6	1	1	1
77866	1710	requirement for additional interaction	[requirement for additional interactions]	0.0	4	1	1	1
77867	1710	half-site for receptor/progesterone receptor binding	[half-sites for receptor/progesterone receptor binding]	0.0	5	1	1	1
77868	1710	g3 tumor with positive margin	[G3 tumors with positive margins]	0.0	5	1	1	1
77869	1710	selective repressor	[selective repressor]	0.0	2	1	1	1
77870	1710	tissue rich	[tissues rich]	0.0	2	1	1	1
77871	1710	responsiveness to CMV	[responsiveness to CMV]	0.0	3	1	1	1
77872	1710	deletion of TSG101 the homolog	[deletions of TSG101 the homolog]	0.0	5	1	1	1
77873	1710	exclusively cytoplasmic precursor p105	[exclusively cytoplasmic precursor p105]	0.0	4	1	1	1
77874	1710	alpha,25-(OH)2D3 cell	[alpha,25-(OH)2D3 cells]	0.0	2	1	1	1
77875	1710	stati DNA	[STATI DNA]	0.0	2	1	1	1
77876	1710	use hiv long repeat -cat construct	[using HIV long repeat -CAT constructs]	0.0	6	1	1	1
77877	1710	NFAT-DNA	[NFAT-DNA]	0.0	1	1	1	1
77878	1710	involvement of alu sequence	[Involvement of Alu sequences]	0.0	4	1	1	1
77879	1710	only at amino termini	[only at amino termini]	0.0	4	1	1	1
77880	1710	transcription factor pat 225/egr1	[transcription factors pAT 225/EGR1]	0.0	4	1	1	1
77881	1710	apart the source of MHC transcript	[apart the source of MHC transcripts]	0.0	6	1	1	1
77882	1710	successful generation of receptor	[successful generation of receptors]	0.0	4	1	1	1
77883	1710	NF-kappaB inhibitory effect	[NF-kappaB inhibitory effect]	0.0	3	1	1	1
77884	1710	transcription-pcr-based approach	[transcription-PCR-based approach]	0.0	2	1	1	1
77885	1710	stimulation of neutrophil il-8 release	[stimulation of neutrophil IL-8 release]	0.0	5	1	1	1
77886	1710	Promiscuous activity of the terminal repeat	[Promiscuous activity of the terminal repeat]	0.0	6	1	1	1
77887	1710	hmg box related to box	[HMG box related to boxes]	0.0	5	1	1	1
77888	1710	factor-DNA complex	[factor-DNA complexes]	0.0	2	2	2	1
77889	1710	exact etiology of sclerosis ms	[exact etiology of sclerosis MS]	0.0	5	1	1	1
77890	1710	tpa on egr-1 transcription	[TPA on EGR-1 transcription]	0.0	4	1	1	1
77891	1710	dominant n17rac	[dominant N17Rac]	0.0	2	1	1	1
77892	1710	suppressor of porcine MHC class expression	[suppressors of porcine MHC class expression]	0.0	6	1	1	1
77893	1710	clinically relevant dose mm)	[clinically relevant dose mM)]	0.0	4	1	1	1
77894	1710	transcription factor to regulatory element	[transcription factors to regulatory elements]	0.0	5	1	1	1
77895	1710	activation of downstream kinase	[activation of downstream kinases]	0.0	4	1	1	1
77896	1710	selective activation of regulatory factor	[selective activation of regulatory factors]	0.0	5	1	1	1
77897	1710	mechanism of neutrophil adherence to cell	[mechanisms of neutrophil adherence to cells]	0.0	6	1	1	1
77898	1710	Peripheral lymphocyte from pregnant woman	[Peripheral lymphocytes from pregnant women]	0.0	5	1	1	1
77899	1710	acid 1-180) in 12	[acids 1-180) in 12]	0.0	4	1	1	1
77900	1710	existence of a triple loop	[existence of a triple loop]	0.0	5	1	1	1
77901	1710	study in immunodeficiency virus (hiv)-positive patient	[studies in immunodeficiency virus (HIV)-positive patients]	0.0	6	1	1	1
77902	1710	mnc from septic patient	[MNC from septic patients]	0.0	4	1	1	1
77903	1710	deletion mutant of the fas promoter	[deletion mutants of the fas promoter]	0.0	6	1	1	1
77904	1710	HLH factor	[HLH factor]	0.0	2	1	1	1
77905	1710	5 of evaluable cases,	[5 of evaluable cases,]	0.0	4	1	1	1
77906	1710	4% apoptotic cells;	[4% apoptotic cells;]	0.0	3	1	1	1
77907	1710	(free) e2f	[(free) E2F]	0.0	2	1	1	1
77908	1710	30%, overexpression in the risk woman	[30%, overexpression in the risk women]	0.0	6	1	1	1
77909	1710	P-4501A1 CYP1A1 activity	[P-4501A1 CYP1A1 activity]	0.0	3	1	1	1
77910	1710	potent stimulator cause secretion	[potent stimulator causing secretion]	0.0	4	1	1	1
77911	1710	fk506 a block translocation	[FK506 A block translocation]	0.0	4	1	1	1
77912	1710	helix-loop-helix-zipper	[helix-loop-helix-zipper]	0.0	1	1	1	1
77913	1710	whole-cell competitive bind radioassay	[whole-cell competitive binding radioassay]	0.0	4	1	1	1
77914	1710	activity capable of activation	[activity capable of activation]	0.0	4	1	1	1
77915	1710	blotting ultra-violet cross-linking study	[blotting UV cross-linking studies]	0.0	4	1	1	1
77916	1710	event lead to monocyte activation	[events leading to monocyte activation]	0.0	5	1	1	1
77917	1710	study pertain to macrophage response	[studies pertaining to macrophage response]	0.0	5	1	1	1
77918	1710	EGR1 subclone	[EGR1 subclone]	0.0	2	1	1	1
77919	1710	total of severe, patient	[total of severe, patients]	0.0	4	1	1	1
77920	1710	human proenkephalin	[human proenkephalin]	0.0	2	1	1	1
77921	1710	interferon isotype in blood leukocyte	[interferon isotypes in blood leukocytes]	0.0	5	1	1	1
77922	1710	antibody alphacd3	[antibody alphaCD3]	0.0	2	1	1	1
77923	1710	NF kappa b subunit	[NF kappa B subunit]	0.0	4	1	1	1
77924	1710	chromosomal 16 abnormality	[chromosomal 16 abnormalities]	0.0	3	1	1	1
77925	1710	rest blood T cell	[resting blood T cells]	0.0	4	2	2	1
77926	1710	nf-kappab n-terminal kinase	[NF-kappaB N-terminal kinase]	0.0	3	1	1	1
77927	1710	(G0) T	[(G0) T]	0.0	2	1	1	1
77928	1710	two responses, nf-kappab activation	[two responses, NF-kappaB activation]	0.0	4	1	1	1
77929	1710	rapid activation in response to signal	[rapid activation in response to signals]	0.0	6	1	1	1
77930	1710	monocyte/neutrophil elastase inhibitor mEI	[monocyte/neutrophil elastase inhibitor mEI]	0.0	4	1	1	1
77931	1710	foci of gata-1 fluorescence	[foci of GATA-1 fluorescence]	0.0	4	1	1	1
77932	1710	reach a peak	[reaching a peak]	0.0	3	1	1	1
77933	1710	direct exposure to nm 2,3,377-tc	[Direct exposure to nM 2,3,7,8-TCDD]	0.0	5	1	1	1
77934	1710	influence (t4) thyrotropin (tsh) level	[influence (T4) thyrotropin (TSH) levels]	0.0	5	1	1	1
77935	1710	expression of the laz3/bcl6 gene	[expression of the LAZ3/BCL6 gene]	0.0	5	1	1	1
77936	1710	contain vp16	[containing VP16]	0.0	2	1	1	1
77937	1710	involvement of cell FDC	[involvement of cells FDC]	0.0	4	1	1	1
77938	1710	h. spleen	[h, spleen]	0.0	2	1	1	1
77939	1710	secretory/transport functions.	[secretory/transport functions.]	0.0	2	1	1	1
77940	1710	encode a B7 molecule	[encoding a B7 molecule]	0.0	4	1	1	1
77941	1710	helper cell	[helper cell]	0.0	2	1	1	1
77942	1710	inactive, cytoplasmic complex	[inactive, cytoplasmic complex]	0.0	3	1	1	1
77943	1710	decrease in response	[decrease in response]	0.0	3	1	1	1
77944	1710	vdr-rxr	[VDR-RXR]	0.0	1	1	1	1
77945	1710	granulocyte antibody of potential significance.	[granulocyte antibodies of potential significance.]	0.0	5	1	1	1
77946	1710	expression by T helper cell	[expression by T helper cells]	0.0	5	1	1	1
77947	1710	binding to the symmetry element	[binding to the symmetry element]	0.0	5	1	1	1
77948	1710	thus a potential therapeutic target	[thus a potential therapeutic target]	0.0	5	1	1	1
77949	1710	Surprisingly, overexpression	[Surprisingly, overexpression]	0.0	2	1	1	1
77950	1710	blood lymphocyte pbl	[blood lymphocytes PBLs]	0.0	3	4	4	1
77951	1710	binding activity blood mononuclear cell	[binding activity blood mononuclear cells]	0.0	5	1	1	1
77952	1710	atopy gene	[atopy gene]	0.0	2	1	1	1
77953	1710	feature of mature monocyte/macrophage function	[features of mature monocyte/macrophage function]	0.0	5	1	1	1
77954	1710	gc asthmatics	[GC asthmatics]	0.0	2	1	1	1
77955	1710	expression tumor originate from cell	[expression tumors originating from cells]	0.0	5	1	1	1
77956	1710	cd4+ clone	[CD4+ clone]	0.0	2	1	1	1
77957	1710	gene expression during differentiation	[gene expression during differentiation]	0.0	4	1	1	1
77958	1710	transmit the result signal	[transmitting the resulting signal]	0.0	4	1	1	1
77959	1710	quieiescent patient p	[quieiescent patients P]	0.0	3	1	1	1
77960	1710	separate,	[separate,]	0.0	1	1	1	1
77961	1710	deletion of the portion	[deletion of the portion]	0.0	4	1	1	1
77962	1710	other cells;	[other cells;]	0.0	2	1	1	1
77963	1710	translocation signal	[translocation signals]	0.0	2	1	1	1
77964	1710	mimicry between gliadin peptide	[mimicry between gliadin peptides]	0.0	4	1	1	1
77965	1710	polymorphism in the HLA-DQ sequence	[polymorphisms in the HLA-DQ sequence]	0.0	5	1	1	1
77966	1710	stimulation with cho-dr enterotoxin a	[stimulation with CHO-DR enterotoxin A]	0.0	5	1	1	1
77967	1710	use analysis	[Using analyses]	0.0	2	1	1	1
77968	1710	regulation in the response	[regulation in the response]	0.0	4	1	1	1
77969	1710	inhibition 1 replication by a combination	[Inhibition 1 replication by a combination]	0.0	6	1	1	1
77970	1710	binding of calcineurin	[binding of calcineurin]	0.0	3	1	1	1
77971	1710	role as a distinct level	[role as a distinct level]	0.0	5	1	1	1
77972	1710	malignant cell of acute leukemia	[malignant cells of acute leukemia]	0.0	5	1	1	1
77973	1710	PML alpha expression in cell	[PML alpha expression in cells]	0.0	5	1	1	1
77974	1710	dissection of the base pair region	[dissection of the base pair region]	0.0	6	1	1	1
77975	1710	demonstrate a event.	[demonstrating an event.]	0.0	3	1	1	1
77976	1710	Furthermore, transcript	[Furthermore, transcripts]	0.0	2	1	1	1
77977	1710	link behavior of stat pathway	[linking behavior of STAT pathways]	0.0	5	1	1	1
77978	1710	secretion of antigen psa	[secretion of antigen PSA]	0.0	4	1	1	1
77979	1710	effect of cysteamine treatment	[effect of cysteamine treatment]	0.0	4	1	1	1
77980	1710	novel, frequently occur sequence variant	[novel, frequently occurring sequence variants]	0.0	5	1	1	1
77981	1710	induction of AP-1	[induction of AP-1]	0.0	3	1	1	1
77982	1710	factor-KB result	[factor-KB resulting]	0.0	2	1	1	1
77983	1710	recombinant timp-1	[recombinant TIMP-1]	0.0	2	1	1	1
77984	1710	important domain	[important domains]	0.0	2	1	1	1
77985	1710	DNA binding state	[DNA binding state]	0.0	3	1	1	1
77986	1710	promoter 21 bp repeat	[promoter 21 bp repeat]	0.0	4	1	1	1
77987	1710	41 small exon span kb	[41 small exons spanning kb]	0.0	5	1	1	1
77988	1710	include all-trans-retinoic acid	[including all-trans-retinoic acid]	0.0	3	1	1	1
77989	1710	induction of the adaptive response	[Induction of the adaptive response]	0.0	5	1	1	1
77990	1710	comparable formation sequence-binding complex contain STAT3	[comparable formation sequence-binding complexes containing STAT3]	0.0	6	1	1	1
77991	1710	histocompatibility (mhc) class antigen	[histocompatibility (MHC) class antigens]	0.0	4	2	2	1
77992	1710	activation of b regulatory element	[activation of B regulatory elements]	0.0	5	1	1	1
77993	1710	chimeric transcriptional properties unlike oncoprotein	[chimeric transcriptional properties, unlike oncoproteins]	0.0	5	1	1	1
77994	1710	strong association between amplification	[strong association between amplification]	0.0	4	1	1	1
77995	1710	mature phenotype	[mature phenotype]	0.0	2	1	1	1
77996	1710	[mechanism	[[Mechanism]	0.0	1	1	1	1
77997	1710	JAK stat	[JAK STAT]	0.0	2	1	1	1
77998	1710	indicate a requirement for protein-protein interaction	[indicating a requirement for protein-protein interactions]	0.0	6	1	1	1
77999	1710	class trans- activator	[class trans- activator]	0.0	3	1	1	1
78000	1710	resistance to infectious disease	[resistance to infectious diseases]	0.0	4	1	1	1
78001	1710	high, thus establish a relation	[high, thus establishing an relation]	0.0	5	1	1	1
78002	1710	informative patient	[informative patients]	0.0	2	1	1	1
78003	1710	monocytes: role	[monocytes: role]	0.0	2	1	1	1
78004	1710	treatment with different schedule (five patient	[Treatment with different schedules (five patients]	0.0	6	1	1	1
78005	1710	level mrna level	[levels mRNA levels]	0.0	3	1	1	1
78006	1710	low tcrzeta level (p	[lower TCRzeta levels (P]	0.0	4	1	1	1
78007	1710	exon genomic sequence	[exon genomic sequence]	0.0	3	1	1	1
78008	1710	inactivation of gene	[inactivation of genes]	0.0	3	1	1	1
78009	1710	regulation of specific genes.	[regulation of specific genes.]	0.0	4	1	1	1
78010	1710	presence of D3	[presence of D3]	0.0	3	1	1	1
78011	1710	thyroid disease: coregulation	[thyroid disease: coregulation]	0.0	3	1	1	1
78012	1710	leukemia gene AML1	[leukemia gene AML1]	0.0	3	1	1	1
78013	1710	relation to major histocompatibility complex class	[relation to major histocompatibility complex classes]	0.0	6	1	1	1
78014	1710	role in C3a enhancement	[role in C3a enhancement]	0.0	4	1	1	1
78015	1710	binding of protein, presumably Sp1	[binding of protein, presumably Sp1]	0.0	5	1	1	1
78016	1710	receptor antagonist ru38486	[receptor antagonist RU38486]	0.0	3	3	3	1
78017	1710	different form include pre-B leukemia	[different forms including pre-B leukemia]	0.0	5	1	1	1
78018	1710	suggest action of the receptor	[suggesting action of the receptors]	0.0	5	1	1	1
78019	1710	camp-response element CRE present	[cAMP-response element CRE present]	0.0	4	1	1	1
78020	1710	TNF-alpha induction	[TNF-alpha induction]	0.0	2	1	1	1
78021	1710	up-regulation of dehydroepiandrosterone binding activity	[Up-regulation of dehydroepiandrosterone binding activity]	0.0	5	1	1	1
78022	1710	very early activation	[very early activation]	0.0	3	1	1	1
78023	1710	monocytic cell adhesion in response	[Monocytic cell adhesion in response]	0.0	5	1	1	1
78024	1710	erythroid-specific gene in disorder	[erythroid-specific genes in disorders]	0.0	4	1	1	1
78025	1710	response of the anti-cd3-	[response of the anti-CD3-]	0.0	4	1	1	1
78026	1710	vascular endothelial muscle cell	[vascular endothelial muscle cells]	0.0	4	1	1	1
78027	1710	western blot with a antibody	[Western blot with an antibody]	0.0	5	1	1	1
78028	1710	complete haematological remission	[complete haematological remission]	0.0	3	2	2	1
78029	1710	expression of the b1 vitellogenin gene	[expression of the B1 vitellogenin gene]	0.0	6	1	1	1
78030	1710	granule from neutrophil	[granules from neutrophils]	0.0	3	1	1	1
78031	1710	EMBO	[EMBO]	0.0	1	1	1	1
78032	1710	pi3-k construct comprise individual domain	[PI3-K constructs comprising individual domains]	0.0	5	1	1	1
78033	1710	two Ets family member Ets-1	[Two Ets family members Ets-1]	0.0	5	1	1	1
78034	1710	decrease in induction of nfkappab	[decrease in induction of NFkappaB]	0.0	5	1	1	1
78035	1710	expression between Spi-B	[expression between Spi-B]	0.0	3	1	1	1
78036	1710	1,25-dihydroxy	[1,25-dihydroxy]	0.0	1	1	1	1
78037	1710	hiv promoter domain activity	[HIV promoter domain activity]	0.0	4	1	1	1
78038	1710	far the site	[far the site]	0.0	3	1	1	1
78039	1710	result via two C-terminal activating region	[resulting via two C-terminal activating regions]	0.0	6	1	1	1
78040	1710	significantly great migration through huvec monolayer	[significantly greater migration through HUVEC monolayers]	0.0	6	1	1	1
78041	1710	allele of the VDR gene	[alleles of the VDR gene]	0.0	5	1	1	1
78042	1710	T cell origin	[T cell origin]	0.0	3	1	1	1
78043	1710	N-acetyl-L-cysteine NAC a thiol-containing antioxidant	[N-acetyl-L-cysteine NAC a thiol-containing antioxidant]	0.0	5	1	1	1
78044	1710	unique c-terminus	[unique C-terminus]	0.0	2	1	1	1
78045	1710	granulocyte-macrophage colony stimulate	[Granulocyte-macrophage colony stimulating]	0.0	3	1	1	1
78046	1710	SCM-1 gene	[SCM-1 genes]	0.0	2	2	2	1
78047	1710	step in peripheral T cell	[step in peripheral T cells]	0.0	5	1	1	1
78048	1710	cd34+ erythroid progenitor cell	[CD34+ erythroid progenitor cells]	0.0	4	1	1	1
78049	1710	effect a effect	[effect an effect]	0.0	3	1	1	1
78050	1710	cdk inhibitor p21(waf1/cip1)	[cdk inhibitor p21(WAF1/CIP1)]	0.0	3	1	1	1
78051	1710	thus, type effector function	[Thus, type effector function]	0.0	4	1	1	1
78052	1710	transcriptase (rt) assay	[transcriptase (RT) assays]	0.0	3	1	1	1
78053	1710	contrast, level of the factor	[contrast, levels of the factor]	0.0	5	1	1	1
78054	1710	encode gamma-globin deaminase pbgd	[encoding gamma-globin deaminase PBGD]	0.0	4	1	1	1
78055	1710	somatic mutation in DNA	[somatic mutations in DNA]	0.0	4	1	1	1
78056	1710	indicate the active factor	[indicating the active factor]	0.0	4	1	1	1
78057	1710	order of human ghost membrane	[order of human ghost membrane]	0.0	5	2	2	1
78058	1710	(Ca2+)i	[(Ca2+)i]	0.0	1	1	1	1
78059	1710	hyperparathyroidism secondary to failure	[hyperparathyroidism secondary to failure]	0.0	4	1	1	1
78060	1710	regions, dp1 -140	[regions, DP1 -140]	0.0	3	1	1	1
78061	1710	foundation	[foundation]	0.0	1	1	1	1
78062	1710	span nucleotide -158	[spanning nucleotides -158]	0.0	3	1	1	1
78063	1710	7 mm cell line	[7 MM cell lines]	0.0	4	1	1	1
78064	1710	il-6 chloramphenicol	[IL-6 chloramphenicol]	0.0	2	1	1	1
78065	1710	human blood monocyte to macrophage	[human blood monocytes to macrophages]	0.0	5	1	1	1
78066	1710	pathway for the activity	[pathway for the activity]	0.0	4	1	1	1
78067	1710	stimulation by interferon	[stimulation by interferons]	0.0	3	1	1	1
78068	1710	regulate fas death a pathway	[regulating Fas death a pathway]	0.0	5	1	1	1
78069	1710	cytoplasmic pools,	[cytoplasmic pools,]	0.0	2	1	1	1
78070	1710	expression of tal-1 protein	[Expression of tal-1 proteins]	0.0	4	1	1	1
78071	1710	selective role of gata-4	[selective role of GATA-4]	0.0	4	1	1	1
78072	1710	(50k)	[(50K)]	0.0	1	1	1	1
78073	1710	separate signalling complex	[separate signalling complexes]	0.0	3	1	1	1
78074	1710	MBP promoter region	[MBP promoter region]	0.0	3	1	1	1
78075	1710	hormone-dependent expression	[hormone-dependent expression]	0.0	2	1	1	1
78076	1710	cell death pcd	[cell death PCD]	0.0	3	1	1	1
78077	1710	stimulator of il-12 production	[stimulators of IL-12 production]	0.0	4	1	1	1
78078	1710	fra-1 engagement	[fra-1 engagement]	0.0	2	1	1	1
78079	1710	gene in recurrent malignant astrocytomas	[genes in recurrent malignant astrocytomas]	0.0	5	1	1	1
78080	1710	level of ligand	[levels of ligand]	0.0	3	1	1	1
78081	1710	normal myeloid cell neutrophilic granulocyte	[normal myeloid cells neutrophilic granulocytes]	0.0	5	1	1	1
78082	1710	particular loci	[particular loci]	0.0	2	1	1	1
78083	1710	ad patient	[AD patients]	0.0	2	1	1	1
78084	1710	distinct immunophilin-drug complex	[distinct immunophilin-drug complexes]	0.0	3	1	1	1
78085	1710	27 combination	[27 combinations]	0.0	2	1	1	1
78086	1710	T cell repertoire development	[T cell repertoire development]	0.0	4	1	1	1
78087	1710	restriction fragment	[restriction fragment]	0.0	2	1	1	1
78088	1710	transcriptional regulation of gtp -cyclohydrolase	[transcriptional regulation of GTP -cyclohydrolase]	0.0	5	1	1	1
78089	1710	IgG immune	[IgG immune]	0.0	2	1	1	1
78090	1710	presence of a reservoir	[presence of a reservoir]	0.0	4	1	1	1
78091	1710	use of this agent	[use of this agent]	0.0	4	1	1	1
78092	1710	GM-CSF promoter CBF site	[GM-CSF promoter CBF site]	0.0	4	1	1	1
78093	1710	latent precursor isgf3 alpha	[latent precursors ISGF3 alpha]	0.0	4	1	1	1
78094	1710	evidence for a dysregulation	[evidence for a dysregulation]	0.0	4	1	1	1
78095	1710	expression of c-rel	[expression of c-Rel]	0.0	3	1	1	1
78096	1710	early-lytic-cycle protein with distant homology	[early-lytic-cycle protein with distant homology]	0.0	5	1	1	1
78097	1710	specific uptake with advanced failure	[specific uptake with advanced failure]	0.0	5	1	1	1
78098	1710	transcription of erythrocyte-specific gene	[transcription of erythrocyte-specific genes]	0.0	4	1	1	1
78099	1710	step of leukocyte adhesion	[step of leukocyte adhesion]	0.0	4	1	1	1
78100	1710	many populations,	[many populations,]	0.0	2	1	1	1
78101	1710	pm),	[pM),]	0.0	1	1	1	1
78102	1710	terminal 3'	[terminal 3']	0.0	2	1	1	1
78103	1710	kinase erk2	[kinase Erk2]	0.0	2	1	1	1
78104	1710	differential expression of the Ca2+ isoform	[differential expression of the Ca2+ isoforms]	0.0	6	1	1	1
78105	1710	recombination,	[recombination,]	0.0	1	1	1	1
78106	1710	down-regulation of activity	[down-regulation of activity]	0.0	3	1	1	1
78107	1710	determine the regulation in leukocyte lineage	[determining the regulation in leukocyte lineages]	0.0	6	1	1	1
78108	1710	patient with renal failure CRF	[patients with renal failure CRF]	0.0	5	1	1	1
78109	1710	alignment of this element	[alignment of these elements]	0.0	4	1	1	1
78110	1710	rest blood mononuclear cell of adult	[resting blood mononuclear cells of adults]	0.0	6	1	1	1
78111	1710	aspect of TCF-1	[aspects of TCF-1]	0.0	3	1	1	1
78112	1710	dehydroepiandrosterone modulation monocyte cytotoxicity	[Dehydroepiandrosterone modulation monocyte cytotoxicity]	0.0	4	1	1	1
78113	1710	monocytic differentiation via signal pathway	[monocytic differentiation via signaling pathways]	0.0	5	1	1	1
78114	1710	Nuclear b activity in T cell	[Nuclear B activity in T cells]	0.0	6	1	1	1
78115	1710	short tandem repeat CAG	[short tandem repeats CAG]	0.0	4	1	1	1
78116	1710	monocyte line	[monocyte line]	0.0	2	1	1	1
78117	1710	participate to switch	[participating to switch]	0.0	3	1	1	1
78118	1710	mouse macrophage RAW cell	[mouse macrophage RAW cells]	0.0	4	1	1	1
78119	1710	single gene ORF	[single gene ORF]	0.0	3	1	1	1
78120	1710	two protein in lymphocyte	[two proteins in lymphocytes]	0.0	4	1	1	1
78121	1710	nuclear morphology indicative of dysplasia	[nuclear morphology indicative of dysplasia]	0.0	5	1	1	1
78122	1710	NFeB	[NFeB]	0.0	1	1	1	1
78123	1710	phosphorylation at Throger 102	[phosphorylation at Thr 102]	0.0	4	1	1	1
78124	1710	sign of adrenal failure	[signs of adrenal failure]	0.0	4	1	1	1
78125	1710	2.0 nm	[2.0 nM]	0.0	2	1	1	1
78126	1710	regulatory element within the region	[regulatory elements within the region]	0.0	5	1	1	1
78127	1710	cell lines, tcf-1 expression	[cell lines, TCF-1 expression]	0.0	4	1	1	1
78128	1710	nine woman with abortion	[nine women with abortion]	0.0	4	1	1	1
78129	1710	(scid-husint) mouse	[(SCID-HU-INT) mice]	0.0	2	1	1	1
78130	1710	lymphotropic virus type htlv-1	[lymphotropic virus type HTLV-1]	0.0	4	1	1	1
78131	1710	involvement lymphocyte activation	[involvement lymphocyte activation]	0.0	3	1	1	1
78132	1710	(nk) minus T cell library	[(NK) minus T cell library]	0.0	5	1	1	1
78133	1710	impaired thymocyte development after inhibition	[Impaired thymocyte development after inhibition]	0.0	5	1	1	1
78134	1710	various alteration	[various alterations]	0.0	2	1	1	1
78135	1710	enhancement of lps uptake	[enhancement of LPS uptake]	0.0	4	1	1	1
78136	1710	different stimuli, include tumor necrosis factor	[different stimuli, including tumor necrosis factor]	0.0	6	1	1	1
78137	1710	retinoid granulocytic marker expression	[retinoid granulocytic markers expression]	0.0	4	1	1	1
78138	1710	32p-labeled oligonucleotide corresponding	[32P-labeled oligonucleotides corresponding]	0.0	3	1	1	1
78139	1710	degree of differentiation.	[degree of differentiation.]	0.0	3	1	1	1
78140	1710	overexpression of BXB a active version	[Overexpression of BXB a active version]	0.0	6	1	1	1
78141	1710	However, result	[However, results]	0.0	2	1	1	1
78142	1710	23 case	[23 cases]	0.0	2	1	1	1
78143	1710	presence of NE	[presence of NE]	0.0	3	1	1	1
78144	1710	[age-related change in lymphocyte	[[Age-related changes in lymphocytes]	0.0	4	1	1	1
78145	1710	suppression of NF-AT	[suppression of NF-AT]	0.0	3	1	1	1
78146	1710	embryonic zeta 2 globin gene	[embryonic zeta 2 globin gene]	0.0	5	1	1	1
78147	1710	indicator of progression from infection	[indicator of progression from infection]	0.0	5	1	1	1
78148	1710	several b-cell line	[several B-cell lines]	0.0	3	1	1	1
78149	1710	9.36 1.17 nm,	[9.36 1.17 nM,]	0.0	3	1	1	1
78150	1710	factors, in particular, cytokine	[factors, in particular, cytokines]	0.0	4	1	1	1
78151	1710	express a inactive form	[expressing a inactive form]	0.0	4	1	1	1
78152	1710	distal nuclear factor (NF)-AT	[distal nuclear factor (NF)-AT]	0.0	4	1	1	1
78153	1710	weight of 35 kD	[weights of 35 kD]	0.0	4	1	1	1
78154	1710	neutrophil lipocalin from human	[neutrophil lipocalin from humans]	0.0	4	1	1	1
78155	1710	cellular responses.	[cellular responses.]	0.0	2	1	1	1
78156	1710	marker of different subpopulation t-	[marker of different subpopulations T-]	0.0	5	1	1	1
78157	1710	recognition of a localization sequence NLS	[recognition of a localization sequence NLS]	0.0	6	1	1	1
78158	1710	immunodeficiency virus type hiv-1 tat	[immunodeficiency virus type HIV-1 Tat]	0.0	5	1	1	1
78159	1710	presence of TN	[presence of TN]	0.0	3	1	1	1
78160	1710	Progressive expression of cell surface antigen	[Progressive expression of cell surface antigens]	0.0	6	1	1	1
78161	1710	tight complex with class	[tight complexes with classes]	0.0	4	1	1	1
78162	1710	single c	[Single C]	0.0	2	1	1	1
78163	1710	chimeric	[chimeric]	0.0	1	1	1	1
78164	1710	key enzyme	[key enzyme]	0.0	2	1	1	1
78165	1710	protein bcl-xL	[protein bcl-xL]	0.0	2	1	1	1
78166	1710	bone cell line	[bone cell line]	0.0	3	1	1	1
78167	1710	support the relevance of no regulation	[supporting the relevance of NO regulation]	0.0	6	1	1	1
78168	1710	-conjugating	[-conjugating]	0.0	1	1	1	1
78169	1710	ro(ssa) antibody	[Ro(SSA) antibodies]	0.0	2	2	2	1
78170	1710	number of metalloproteinase activity	[number of metalloproteinase activities]	0.0	4	1	1	1
78171	1710	use ng/ml	[using ng/ml]	0.0	2	1	1	1
78172	1710	il-2 receptor complex	[IL-2 receptor complexes]	0.0	3	2	2	1
78173	1710	ptf gamma	[PTF gamma]	0.0	2	1	1	1
78174	1710	T lymphocyte population	[T lymphocyte populations]	0.0	3	1	1	1
78175	1710	dose of corticosteroid	[doses of corticosteroid]	0.0	3	1	1	1
78176	1710	culture conditions, bovine brain ganglioside	[culture conditions, bovine brain gangliosides]	0.0	5	1	1	1
78177	1710	protein-coding region of RP1	[protein-coding region of RP1]	0.0	4	1	1	1
78178	1710	expression of matrix metalloproteinase factor	[expression of matrix metalloproteinase factor]	0.0	5	1	1	1
78179	1710	directly modulate calcium	[directly modulating calcium]	0.0	3	1	1	1
78180	1710	hydrophobic domain with transmembrane segment	[hydrophobic domain with transmembrane segments]	0.0	5	1	1	1
78181	1710	t-cell-activating superantigen staphylococcal enterotoxin a	[T-cell-activating superantigen staphylococcal enterotoxin A]	0.0	5	1	1	1
78182	1710	include chemokine	[including chemokines]	0.0	2	1	1	1
78183	1710	terminal segment vca	[terminal segment VCA]	0.0	3	1	1	1
78184	1710	role in cooperative activation	[role in cooperative activation]	0.0	4	1	1	1
78185	1710	ec epitope bind specificity	[EC epitope binding specificity]	0.0	4	1	1	1
78186	1710	retroviral particle	[retroviral particles]	0.0	2	1	1	1
78187	1710	novel ca2+ step	[novel Ca2+ step]	0.0	3	1	1	1
78188	1710	inhibitor pp1 calyculin a	[inhibitor PP1/PP2A calyculin A]	0.0	4	1	1	1
78189	1710	patient with wk untreated RA	[patients with wk untreated RA]	0.0	5	1	1	1
78190	1710	silencer extend bp relative	[silencer extending bp relative]	0.0	4	1	1	1
78191	1710	10 epitopes.	[10 epitopes.]	0.0	2	1	1	1
78192	1710	cell characteristic	[cell characteristics]	0.0	2	1	1	1
78193	1710	considerations.	[considerations.]	0.0	1	1	1	1
78194	1710	mechanism underlie this anti-inflammatory capacity	[mechanisms underlying this anti-inflammatory capacity]	0.0	5	1	1	1
78195	1710	human gata-4 hgata-4	[human GATA-4 hGATA-4]	0.0	3	1	1	1
78196	1710	eklf-/- erythrocyte in animal	[EKLF-/- erythrocytes in animals]	0.0	4	1	1	1
78197	1710	capacity of T lymphocyte	[capacities of T lymphocytes]	0.0	4	1	1	1
78198	1710	microtitre assay system receptor concentration	[microtitre assay system receptor concentration]	0.0	5	1	1	1
78199	1710	presumably Sp1	[presumably Sp1]	0.0	2	1	1	1
78200	1710	signal to	[signal to]	0.0	2	1	1	1
78201	1710	E2A-HLF fusion protein	[E2A-HLF fusion protein]	0.0	3	1	1	1
78202	1710	cDNA encoding c/ebp-epsilon	[cDNA encoding C/EBP-epsilon]	0.0	3	1	1	1
78203	1710	almost exclusive selectivity for aldosterone	[almost exclusive selectivity for aldosterone]	0.0	5	1	1	1
78204	1710	c-fo transcript level	[c-fos transcript levels]	0.0	3	1	1	1
78205	1710	functionally related hepatocyte factor HNF-1alpha	[functionally related hepatocyte factors HNF-1alpha]	0.0	5	1	1	1
78206	1710	inherent resistance of T cell	[inherent resistance of T cells]	0.0	5	1	1	1
78207	1710	potent enhancer in	[potent enhancer in]	0.0	3	1	1	1
78208	1710	receptor -ligand binding study	[receptor -ligand binding studies]	0.0	4	1	1	1
78209	1710	Ikaros isoform	[Ikaros isoforms]	0.0	2	1	1	1
78210	1710	Granulocyte/macrophage	[Granulocyte/macrophage]	0.0	1	1	1	1
78211	1710	concomitant decrease in expression	[concomitant decrease in expression]	0.0	4	1	1	1
78212	1710	different 2.3-kb cDNA clone	[different 2.3-kb cDNA clones]	0.0	4	1	1	1
78213	1710	critical region with cofactor	[critical regions with cofactors]	0.0	4	1	1	1
78214	1710	steady-state protein level	[steady-state protein levels]	0.0	3	1	1	1
78215	1710	histocompatibility (MHC) class ii promoter	[histocompatibility (MHC) class II promoters]	0.0	5	1	1	1
78216	1710	healthy subject (62-97 yr)	[healthy subjects (62-97 yr)]	0.0	4	1	1	1
78217	1710	presence of complex involve GrpL	[presence of complexes involving GrpL]	0.0	5	1	1	1
78218	1710	least in part, induce expression	[least in part, inducing expression]	0.0	5	1	1	1
78219	1710	regulation of cellular processes,	[regulation of cellular processes,]	0.0	4	1	1	1
78220	1710	suppress factor-kappa b mobilization	[suppressing factor-kappa B mobilization]	0.0	4	1	1	1
78221	1710	homo- stat1 alpha consistent	[homo- STAT1 alpha consistent]	0.0	4	1	1	1
78222	1710	dna-binding fragment	[DNA-binding fragments]	0.0	2	1	1	1
78223	1710	bind to domain sequence contain phosphotyrosine	[binding to domain sequences containing phosphotyrosine]	0.0	6	1	1	1
78224	1710	patient with acute leukemia AML	[patients with acute leukemia AML]	0.0	5	1	1	1
78225	1710	substrate in proliferate cell	[substrates in proliferating cells]	0.0	4	1	1	1
78226	1710	activation of host event	[Activation of host events]	0.0	4	1	1	1
78227	1710	CMV gene product	[CMV gene product]	0.0	3	1	1	1
78228	1710	rapamycin pathway	[rapamycin pathways]	0.0	2	1	1	1
78229	1710	possibility of mutational analysis	[possibility of mutational analysis]	0.0	4	1	1	1
78230	1710	inflammatory stimulus in neutrophil	[inflammatory stimuli in neutrophils]	0.0	4	1	1	1
78231	1710	day 12 liver	[day 12 liver]	0.0	3	1	1	1
78232	1710	pertussis toxin -insensitive pathway	[pertussis toxin -insensitive pathway]	0.0	4	1	1	1
78233	1710	dissociation capacity,	[dissociation capacity,]	0.0	2	1	1	1
78234	1710	component of gammac promoter activity	[component of gammac promoter activity]	0.0	5	1	1	1
78235	1710	il-6 mm	[IL-6 MM]	0.0	2	1	1	1
78236	1710	CD15 engagement	[CD15 engagement]	0.0	2	1	1	1
78237	1710	activation the viral latent gene promoter	[activation the viral latent gene promoter]	0.0	6	1	1	1
78238	1710	positive staining for NF-kappa b	[positive staining for NF-kappa B]	0.0	5	1	1	1
78239	1710	23 cells, respectively),	[23 cells, respectively),]	0.0	3	1	1	1
78240	1710	extract of HUVEC	[extracts of HUVEC]	0.0	3	1	1	1
78241	1710	key control determinant	[key controlling determinant]	0.0	3	1	1	1
78242	1710	shock syndrome toxin-1 tsst-1	[shock syndrome toxin-1 TSST-1]	0.0	4	1	1	1
78243	1710	/Fas ligand FasL	[/Fas ligand FasL]	0.0	3	1	1	1
78244	1710	nuclear translocation of nfat factor	[nuclear translocation of NFAT factor]	0.0	5	2	2	1
78245	1710	friend leukemia cell flc	[Friend leukemia cells FLCs]	0.0	4	1	1	1
78246	1710	case-control study of three disease	[case-control studies of three diseases]	0.0	5	1	1	1
78247	1710	nucleotide number 5'-gttaaggttcgtaggtcatgga-3'	[nucleotide numbers 5'-GTTAAGGTTCGTAGGTCATGGA-3']	0.0	3	1	1	1
78248	1710	two transcriptional element in the tsp	[Two transcriptional elements in the TSP]	0.0	6	1	1	1
78249	1710	tpa nuclear factor protein	[TPA nuclear factor protein]	0.0	4	1	1	1
78250	1710	encode eosinophil granule protein	[encoding eosinophil granule proteins]	0.0	4	1	1	1
78251	1710	nuclear membrane protein	[nuclear membrane protein]	0.0	3	1	1	1
78252	1710	block abs	[blocking Abs]	0.0	2	1	1	1
78253	1710	mediate tyrosine phosphorylation events.	[mediating tyrosine phosphorylation events.]	0.0	4	1	1	1
78254	1710	line carry a LMP1 gene	[lines carrying an LMP1 gene]	0.0	5	1	1	1
78255	1710	cases, include case	[cases, including case]	0.0	3	1	1	1
78256	1710	pre-B-cell line	[pre-B-cell lines]	0.0	2	1	1	1
78257	1710	effect of acetylsalicylic acid	[effects of acetylsalicylic acid]	0.0	4	1	1	1
78258	1710	monozygotic (mz) twin	[monozygotic (MZ) twins]	0.0	3	1	1	1
78259	1710	(571 236 ng/ml) in plasma	[(571 236 ng/mL) in plasma]	0.0	5	1	1	1
78260	1710	site between position -53	[site between positions -53]	0.0	4	1	1	1
78261	1710	phase-1 neutrophil adhesion	[phase-1 neutrophil adhesion]	0.0	3	1	1	1
78262	1710	effect on promoter expression	[effects on promoter expression]	0.0	4	1	1	1
78263	1710	time-dependent binding	[time-dependent binding]	0.0	2	1	1	1
78264	1710	decrease for receptor mrna expression	[decrease for receptor mRNA expression]	0.0	5	1	1	1
78265	1710	group ii type MHC cid	[group II type MHC CID]	0.0	5	1	1	1
78266	1710	renin activity,	[renin activity,]	0.0	2	1	1	1
78267	1710	il-2 line	[IL-2 lines]	0.0	2	1	1	1
78268	1710	chemotactic migration of human leukocyte	[chemotactic migration of human leukocytes]	0.0	5	1	1	1
78269	1710	family of protein in eukaryote	[family of proteins in eukaryotes]	0.0	5	1	1	1
78270	1710	antiviral, cd8(+) CTL response	[antiviral, CD8(+) CTL responses]	0.0	4	1	1	1
78271	1710	phenotypic female with onset menarche	[phenotypic female with onset menarche]	0.0	5	1	1	1
78272	1710	reactive metabolite	[reactive metabolites]	0.0	2	2	2	1
78273	1710	induce the cycle	[inducing the cycle]	0.0	3	1	1	1
78274	1710	degradation by a phosphorylation-dependent signal	[degradation by a phosphorylation-dependent signal]	0.0	5	1	1	1
78275	1710	human t-cell line IARC	[human T-cell line IARC]	0.0	4	1	1	1
78276	1710	microm kn-62	[microM KN-62]	0.0	2	1	1	1
78277	1710	intracellular domain icn	[intracellular domain ICN]	0.0	3	1	1	1
78278	1710	SP1/Egr-1 binding site	[SP1/Egr-1 binding site]	0.0	3	1	1	1
78279	1710	analogous framework	[analogous framework]	0.0	2	1	1	1
78280	1710	nf-kappa b accumulation ready	[NF-kappa B accumulation ready]	0.0	4	1	1	1
78281	1710	basis of this induction	[basis of this induction]	0.0	4	1	1	1
78282	1710	Mn sod endotoxin induction	[Mn SOD endotoxin induction]	0.0	4	1	1	1
78283	1710	structure,	[structure,]	0.0	1	1	1	1
78284	1710	structure.	[structure.]	0.0	1	1	1	1
78285	1710	DNA replication in u937 cell	[DNA replication in U937 cells]	0.0	5	1	1	1
78286	1710	result of a pilot study	[results of a pilot study]	0.0	5	1	1	1
78287	1710	27-kDa form	[27-kDa form]	0.0	2	1	1	1
78288	1710	CFU-GEMM/ bfu-e/cfu-m	[CFU-GEMM/ BFU-E/CFU-M]	0.0	2	1	1	1
78289	1710	pathogens.	[pathogens.]	0.0	1	1	1	1
78290	1710	TNF nuclear factor-kappaB activation	[TNF nuclear factor-kappaB activation]	0.0	4	1	1	1
78291	1710	inhibitory effect of DEX together	[inhibitory effects of DEX together]	0.0	5	1	1	1
78292	1710	er27191	[ER27191]	0.0	1	1	1	1
78293	1710	genetic aberration in the pathway	[genetic aberrations in the pathway]	0.0	5	1	1	1
78294	1710	transactivator in T cell	[transactivator in T cells]	0.0	4	1	1	1
78295	1710	proliferation in response to a fragment	[proliferation in response to a fragment]	0.0	6	1	1	1
78296	1710	suicidal inversion	[suicidal inversion]	0.0	2	1	1	1
78297	1710	anti-tumor immunity	[anti-tumor immunity]	0.0	2	1	1	1
78298	1710	induction of monocytic differentiation infection	[Induction of monocytic differentiation infection]	0.0	5	1	1	1
78299	1710	interaction with a binding site	[interaction with a binding site]	0.0	5	1	1	1
78300	1710	develop mature T lymphocyte erratum	[developing mature T lymphocytes erratum]	0.0	5	1	1	1
78301	1710	abolish injury with alpha-tocopherol a scavenger	[abolishing injury with alpha-tocopherol a scavenger]	0.0	6	1	1	1
78302	1710	requirement of active ne	[requirement of active NE]	0.0	4	1	1	1
78303	1710	myelogenous leukemia 1- respectively,	[myelogenous leukemia 1- respectively,]	0.0	4	1	1	1
78304	1710	cerulein-induced pancreatitis in the rat	[cerulein-induced pancreatitis in the rat]	0.0	5	1	1	1
78305	1710	developmental stage homogeneity of cell	[developmental stage homogeneity of cells]	0.0	5	1	1	1
78306	1710	domain lack sequence similarity	[domain lacking sequence similarity]	0.0	4	1	1	1
78307	1710	member of the STAT	[member of the STAT]	0.0	4	1	1	1
78308	1710	also cytokine	[also cytokines]	0.0	2	1	1	1
78309	1710	human vein cell monolayer	[human vein cell monolayers]	0.0	4	1	1	1
78310	1710	receptor transcription	[receptor transcription]	0.0	2	1	1	1
78311	1710	arnt heterodimerization,	[Arnt heterodimerization,]	0.0	2	1	1	1
78312	1710	tcell rescue from apoptosis	[Tcell rescue from apoptosis]	0.0	4	1	1	1
78313	1710	immunodeficiency virus 1 hiv-1	[immunodeficiency virus 1 HIV-1]	0.0	4	1	1	1
78314	1710	activity of 11 alpha-methyl-1 alpha,25-(OH)2D3	[activity of 11 alpha-methyl-1 alpha,25-(OH)2D3]	0.0	5	1	1	1
78315	1710	minus oral value	[minus oral values]	0.0	3	1	1	1
78316	1710	such as uterus myometrium	[such as uterus myometrium]	0.0	4	1	1	1
78317	1710	sevenfold)	[sevenfold)]	0.0	1	1	1	1
78318	1710	series of construct	[series of constructs]	0.0	3	1	1	1
78319	1710	lps- signal	[LPS- signaling]	0.0	2	1	1	1
78320	1710	tumor antigen	[tumor antigens]	0.0	2	1	1	1
78321	1710	complex element	[complex element]	0.0	2	1	1	1
78322	1710	[regulation of cholesterol synthesis in hypercholesterolemia	[[Regulation of cholesterol synthesis in hypercholesterolemia]	0.0	6	1	1	1
78323	1710	5 fetal bovine serum	[5 fetal bovine serum]	0.0	4	1	1	1
78324	1710	cytokine on the activity	[cytokines on the activity]	0.0	4	1	1	1
78325	1710	cell culture of individual	[cell cultures of individuals]	0.0	4	1	1	1
78326	1710	information on the event	[information on the events]	0.0	4	1	1	1
78327	1710	transfection of expression vector of ras	[Transfection of expression vectors of ras]	0.0	6	1	1	1
78328	1710	concentration of D3 receptor in cell	[concentration of D3 receptors in cells]	0.0	6	1	1	1
78329	1710	cross-linking tgf-beta	[cross-linking TGF-beta]	0.0	2	1	1	1
78330	1710	autoregulation of glucocorticoid receptor expression	[autoregulation of glucocorticoid receptor expression]	0.0	5	1	1	1
78331	1710	activity of Bik	[activity of Bik]	0.0	3	1	1	1
78332	1710	p50/p65 form of NF-kappa b	[p50/p65 form of NF-kappa B]	0.0	5	1	1	1
78333	1710	only abundant activity	[only abundant activity]	0.0	3	1	1	1
78334	1710	MCM gene product	[MCM gene products]	0.0	3	1	1	1
78335	1710	lps concentration of micrograms/ml	[LPS concentrations of micrograms/ml]	0.0	4	1	1	1
78336	1710	protein exhibit Arre-2 binding activity	[proteins exhibiting ARRE-2 binding activity]	0.0	5	1	1	1
78337	1710	large number of response	[large number of responses]	0.0	4	1	1	1
78338	1710	role of AMP response element-binding protein	[Role of AMP response element-binding protein]	0.0	6	1	1	1
78339	1710	use of a recombinant virus	[use of an recombinant virus]	0.0	5	1	1	1
78340	1710	interaction of rank	[interaction of RANK]	0.0	3	1	1	1
78341	1710	dissociation from ig kappa b stimulation,	[Dissociation from Ig kappa B stimulation,]	0.0	6	1	1	1
78342	1710	effect of acid	[effect of acids]	0.0	3	2	2	1
78343	1710	gene on human chromosome	[genes on human chromosome]	0.0	4	1	1	1
78344	1710	treatment with retinoic acid RA	[treatment with retinoic acid RA]	0.0	5	1	1	1
78345	1710	'late'	['late']	0.0	1	1	1	1
78346	1710	level of nuclear factor	[Levels of nuclear factors]	0.0	4	1	1	1
78347	1710	transcriptional analysis of p40	[transcriptional analyses of p40]	0.0	4	1	1	1
78348	1710	inhibitor of protein phosphatase type	[inhibitors of protein phosphatase type]	0.0	5	1	1	1
78349	1710	specifically bind	[specifically binding]	0.0	2	1	1	1
78350	1710	[correlation with the hormonal state	[[Correlation with the hormonal state]	0.0	5	1	1	1
78351	1710	GM-kappa B/GC-box position	[GM-kappa B/GC-box positions]	0.0	3	1	1	1
78352	1710	0 hpc	[0 HPCs]	0.0	2	1	1	1
78353	1710	second, tyrphostin	[Second, tyrphostin]	0.0	2	1	1	1
78354	1710	patient with acute leukemia APL	[patients with acute leukemia APL]	0.0	5	1	1	1
78355	1710	adult red blood cell	[adult red blood cells]	0.0	4	1	1	1
78356	1710	accord to two exercise protocols:	[according to two exercise protocols:]	0.0	5	1	1	1
78357	1710	MRD -negative	[MRD -negative]	0.0	2	1	1	1
78358	1710	soluble tnf receptor rhu tnfr:fc	[soluble TNF receptor rhu TNFR:Fc]	0.0	5	1	1	1
78359	1710	A Ad12	[A Ad12]	0.0	2	1	1	1
78360	1710	immunoglobulin chain igh gene rearrangement	[immunoglobulin chain IgH gene rearrangement]	0.0	5	1	1	1
78361	1710	CD3 -dependent phosphorylation	[CD3 -dependent phosphorylation]	0.0	3	1	1	1
78362	1710	reverse polymerase chain method	[reverse polymerase chain method]	0.0	4	1	1	1
78363	1710	induction by hiv type 1 infection	[Induction by HIV type 1 infection]	0.0	6	1	1	1
78364	1710	regulation of the glycoprotein ix promoter	[Regulation of the glycoprotein IX promoter]	0.0	6	1	1	1
78365	1710	possible linkage 10 polymorphism	[possible linkage 10 polymorphism]	0.0	4	1	1	1
78366	1710	transcriptional activation the viral gene promoter	[transcriptional activation the viral gene promoter]	0.0	6	1	1	1
78367	1710	-stat3	[-STAT3]	0.0	1	1	1	1
78368	1710	apparent molecular size	[apparent molecular size]	0.0	3	1	1	1
78369	1710	involve sexual differentiation in karyotypic male	[involving sexual differentiation in karyotypic males]	0.0	6	1	1	1
78370	1710	feedback mechanism	[feedback mechanism]	0.0	2	1	1	1
78371	1710	blood plasma cortisol concentration	[blood plasma cortisol concentration]	0.0	4	1	1	1
78372	1710	evidence at proximal element	[Evidence at proximal element]	0.0	4	1	1	1
78373	1710	two-lay percoll gradient	[two-layer Percoll gradients]	0.0	3	1	1	1
78374	1710	cell count	[cell count]	0.0	2	1	1	1
78375	1710	gcr level	[GCR level]	0.0	2	1	1	1
78376	1710	human allergen-specific th cell	[human allergen-specific Th cells]	0.0	4	1	1	1
78377	1710	biological effect of pnu156804	[biological effect of PNU156804]	0.0	4	1	1	1
78378	1710	lps -binding protein	[LPS -binding protein]	0.0	3	1	1	1
78379	1710	phytohemagglutinin to CD3	[phytohemagglutinin to CD3]	0.0	3	1	1	1
78380	1710	also in the activation of carcinogen	[also in the activation of carcinogens]	0.0	6	1	1	1
78381	1710	inhibition of the uptake in leukocyte	[inhibition of the uptake in leukocytes]	0.0	6	1	1	1
78382	1710	stimulation by high dose of peptide	[Stimulation by high doses of peptide]	0.0	6	1	1	1
78383	1710	JNK kinase-related kinase	[JNK kinase-related kinase]	0.0	3	1	1	1
78384	1710	use ligand to acid receptor rar	[Using ligands to acid receptors RARs]	0.0	6	1	1	1
78385	1710	amino-terminal region amino acid 1-450	[amino-terminal region amino acids 1-450]	0.0	5	1	1	1
78386	1710	presence of fibrinogen	[presence of fibrinogen]	0.0	3	1	1	1
78387	1710	mechanism of drug action	[mechanism of drug action]	0.0	4	1	1	1
78388	1710	inhibitor of inflammation	[inhibitor of inflammation]	0.0	3	1	1	1
78389	1710	two distinct domains, a	[two distinct domains, A]	0.0	4	1	1	1
78390	1710	apoptosis in human monocyte role	[apoptosis in human monocytes role]	0.0	5	1	1	1
78391	1710	additional cofactor	[additional cofactors]	0.0	2	1	1	1
78392	1710	unusually high content	[unusually high content]	0.0	3	1	1	1
78393	1710	signal ag	[signaling Ag]	0.0	2	1	1	1
78394	1710	characterization of nf(p) the factor relationship	[Characterization of NF(P) the factor relationship]	0.0	6	1	1	1
78395	1710	myeloid cell StatG	[myeloid cells StatG]	0.0	3	1	1	1
78396	1710	signal transduction pathway in human monocyte	[Signal transduction pathways in human monocytes]	0.0	6	1	1	1
78397	1710	LMP promoter	[LMP promoter]	0.0	2	1	1	1
78398	1710	T beta	[T beta]	0.0	2	1	1	1
78399	1710	capability pre-treatment with gp160	[capabilities pre-treatment with gp160]	0.0	4	1	1	1
78400	1710	[Cao Proc.Natl.Acad.Sci.USA	[[Cao Proc.Natl.Acad.Sci.USA]	0.0	2	1	1	1
78401	1710	efficiently by H-8, a kinase inhibitor	[efficiently by H-8, a kinase inhibitor]	0.0	6	1	1	1
78402	1710	Retroviral vector-mediated transduction of RA receptor	[Retroviral vector-mediated transduction of RA receptor]	0.0	6	1	1	1
78403	1710	pml/ rar-alpha	[pml/ RAR-alpha]	0.0	2	1	1	1
78404	1710	ebv persistence	[EBV persistence]	0.0	2	1	1	1
78405	1710	ht-2 cell with calcineurin	[HT-2 cells with calcineurin]	0.0	4	1	1	1
78406	1710	granulocyte colony-stimulating factor colony-stimumulatelany-stg factor	[granulocyte colony-stimulating factor colony-stimulating factor]	0.0	5	1	1	1
78407	1710	rapidak accumulating, tyrosine	[rapid, accumulating, tyrosine]	0.0	3	1	1	1
78408	1710	structure of Oct-2a with domain	[structure of Oct-2a with domains]	0.0	5	1	1	1
78409	1710	dominant component of antigen-specific memory	[dominant components of antigen-specific memory]	0.0	5	1	1	1
78410	1710	jun-b	[Jun-B]	0.0	1	1	1	1
78411	1710	potential target of regulation	[potential targets of regulation]	0.0	4	1	1	1
78412	1710	maintain variation	[maintaining variation]	0.0	2	1	1	1
78413	1710	six volunteer	[six volunteers]	0.0	2	1	1	1
78414	1710	pha-blast	[PHA-blasts]	0.0	1	2	2	1
78415	1710	hemoglobin HbF production in adulthood	[hemoglobin HbF production in adulthood]	0.0	5	1	1	1
78416	1710	ebv infection (2/7), ebv reactivation	[EBV infection (2/7), EBV reactivation]	0.0	5	1	1	1
78417	1710	11 alpha-methyl-1 alpha,25-(OH)2D3	[11 alpha-methyl-1 alpha,25-(OH)2D3]	0.0	3	1	1	1
78418	1710	presenter	[presenters]	0.0	1	1	1	1
78419	1710	direct suppression during adenoviral infection	[Direct suppression during adenoviral infection]	0.0	5	1	1	1
78420	1710	two protein products, p27rex	[two protein products, p27rex]	0.0	4	1	1	1
78421	1710	modulate effect	[modulating effects]	0.0	2	1	1	1
78422	1710	isolation a transcription factor	[isolation a transcription factor]	0.0	4	1	1	1
78423	1710	selective modulation of nf-kappab	[selective modulation of NF-kappaB]	0.0	4	1	1	1
78424	1710	site of receptor	[sites of receptor]	0.0	3	1	1	1
78425	1710	inflammatory mechanism in epithelial cell	[inflammatory mechanisms in epithelial cells]	0.0	5	1	1	1
78426	1710	intracellular protein stat6	[intracellular protein Stat6]	0.0	3	1	1	1
78427	1710	transcription in response	[transcription in response]	0.0	3	1	1	1
78428	1710	also a inhibitor of cell	[also a inhibitor of cells]	0.0	5	1	1	1
78429	1710	cellular transcriptional nuclear factor-KB	[cellular transcriptional nuclear factor-KB]	0.0	4	1	1	1
78430	1710	palindromic arrangement	[palindromic arrangement]	0.0	2	1	1	1
78431	1710	hrar alpha-lbd	[hRAR alpha-LBD]	0.0	2	1	1	1
78432	1710	overexpress hIRAK a activation	[overexpressing hIRAK a activation]	0.0	4	1	1	1
78433	1710	expression in human promonocytic u937 cell	[Expression in human promonocytic U937 cells]	0.0	6	1	1	1
78434	1710	activity of CBF	[activity of CBF]	0.0	3	1	1	1
78435	1710	differentiation of cd34+ progenitor cell	[differentiation of CD34+ progenitor cells]	0.0	5	1	1	1
78436	1710	ceroid-lypofuscinosis NCL	[ceroid-lypofuscinosis NCL]	0.0	2	1	1	1
78437	1710	protein myeloperoxidase mpo	[proteins myeloperoxidase MPO]	0.0	3	1	1	1
78438	1710	case of ebv-positive endemic bl	[cases of EBV-positive endemic BL]	0.0	5	1	1	1
78439	1710	block factor of T lymphocyte nfat	[blocking factor of T lymphocytes NFAT]	0.0	6	1	1	1
78440	1710	evidence for distinct intracellular signal pathway	[Evidence for distinct intracellular signaling pathways]	0.0	6	1	1	1
78441	1710	effects, such as the activation	[effects, such as the activation]	0.0	5	1	1	1
78442	1710	beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer	[beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer]	0.0	4	1	1	1
78443	1710	other hallmark of t-lymphocyte activation	[other hallmarks of T-lymphocyte activation]	0.0	5	1	1	1
78444	1710	property of hepatic leukemia factor HLF	[properties of hepatic leukemia factor HLF]	0.0	6	1	1	1
78445	1710	probably due to difference	[probably due to differences]	0.0	4	1	1	1
78446	1710	8 cases, DNA	[8 cases, DNA]	0.0	3	1	1	1
78447	1710	infiltration of c-fos-positive lymphocyte	[infiltration of c-fos-positive lymphocytes]	0.0	4	1	1	1
78448	1710	translocation result in abnormal expression	[translocation resulting in abnormal expression]	0.0	5	1	1	1
78449	1710	difference in the mechanism(s)	[differences in the mechanism(s)]	0.0	4	1	1	1
78450	1710	evidence for involvement in transcriptional regulation	[evidence for involvement in transcriptional regulation]	0.0	6	1	1	1
78451	1710	gt11	[gt11]	0.0	1	1	1	1
78452	1710	modulation of erythroid differentiation	[Modulation of erythroid differentiation]	0.0	4	1	1	1
78453	1710	emission of a probe react	[emission of a probe reacting]	0.0	5	1	1	1
78454	1710	e1-binding	[E1-binding]	0.0	1	1	1	1
78455	1710	strong transactivation	[strong transactivation]	0.0	2	2	2	1
78456	1710	H.-M.Chen,	[H.-M.Chen,]	0.0	1	1	1	1
78457	1710	erythroid-specific property	[erythroid-specific properties]	0.0	2	1	1	1
78458	1710	implication for regulation of traf signal	[implications for regulation of TRAF signaling]	0.0	6	1	1	1
78459	1710	induction of early growth response	[induction of early growth response]	0.0	5	1	1	1
78460	1710	transcriptional regulation by IFNs	[transcriptional regulation by IFNs]	0.0	4	1	1	1
78461	1710	regulation of structure	[regulation of structure]	0.0	3	1	1	1
78462	1710	cyclic AMP -responsive sequence	[cyclic AMP -responsive sequence]	0.0	4	1	1	1
78463	1710	full-length human c/ebp-epsilon	[full-length human C/EBP-epsilon]	0.0	3	1	1	1
78464	1710	control of nuclear factor-kappa b activation	[control of nuclear factor-kappa B activation]	0.0	6	1	1	1
78465	1710	differentiation of p21	[differentiation of p21]	0.0	3	1	1	1
78466	1710	contain b dimer	[containing B dimers]	0.0	3	1	1	1
78467	1710	tumor necrosis factor 3	[tumor necrosis factor 3]	0.0	4	1	1	1
78468	1710	homology in domain	[homology in domains]	0.0	3	1	1	1
78469	1710	VitD3 receptor	[VitD3 receptor]	0.0	2	1	1	1
78470	1710	244b human lymphoblastoid cell	[244B human lymphoblastoid cells]	0.0	4	1	1	1
78471	1710	treatment (day 0 hpc	[treatment (day 0 HPCs]	0.0	4	1	1	1
78472	1710	stat1 alpha consistent with synergism	[STAT1 alpha consistent with synergism]	0.0	5	1	1	1
78473	1710	stably overexpress hIRAK a constitutive activation	[stably overexpressing hIRAK a constitutive activation]	0.0	6	1	1	1
78474	1710	normalize effect increase of ca2+	[normalizing effect increase of Ca2+]	0.0	5	1	1	1
78475	1710	N-terminal pou-specific domain	[N-terminal POU-specific domain]	0.0	3	1	1	1
78476	1710	ligand-induced transient membrane hyperpolarization	[ligand-induced transient membrane hyperpolarization]	0.0	4	1	1	1
78477	1710	tyrosine phosphorylation of Itk	[tyrosine phosphorylation of Itk]	0.0	4	1	1	1
78478	1710	drug interaction	[drug interactions]	0.0	2	1	1	1
78479	1710	inducer of hiv-ltr activation	[inducer of HIV-LTR activation]	0.0	4	1	1	1
78480	1710	proteasome degradation in T cell	[proteasome degradation in T cells]	0.0	5	1	1	1
78481	1710	bind to promoter element	[binding to promoter elements]	0.0	4	1	1	1
78482	1710	cotransfection of nf-kappa b	[Cotransfection of NF-kappa B]	0.0	4	1	1	1
78483	1710	modulator of LMP1	[modulator of LMP1]	0.0	3	1	1	1
78484	1710	other abnormality	[other abnormalities]	0.0	2	1	1	1
78485	1710	peripheral lymphocyte receptor	[peripheral lymphocyte receptors]	0.0	3	1	1	1
78486	1710	result in abnormal expression	[resulting in abnormal expression]	0.0	4	1	1	1
78487	1710	patient with inflammatory arthritis	[patients with inflammatory arthritis]	0.0	4	1	1	1
78488	1710	S107 cell	[S107 cells]	0.0	2	1	1	1
78489	1710	protein bind specifically	[proteins binding specifically]	0.0	3	1	1	1
78490	1710	two protein kD	[Two proteins kD]	0.0	3	1	1	1
78491	1710	regulator of the homing	[regulator of the homing]	0.0	4	1	1	1
78492	1710	(wt) cell	[(wt) cells]	0.0	2	1	1	1
78493	1710	control obese:	[controls obese:]	0.0	2	1	1	1
78494	1710	saphenous vein	[saphenous vein]	0.0	2	1	1	1
78495	1710	cytokine such as IL-4,	[cytokines such as IL-4,]	0.0	4	1	1	1
78496	1710	transcription of the gene cluster	[Transcription of the gene cluster]	0.0	5	1	1	1
78497	1710	sense sequence	[sense sequence]	0.0	2	1	1	1
78498	1710	transcription at late stage of differentiation	[transcription at late stages of differentiation]	0.0	6	1	1	1
78499	1710	lipopolysaccharide-activated human blood	[lipopolysaccharide-activated human blood]	0.0	3	1	1	1
78500	1710	terminus of pp52 mrna	[terminus of pp52 mRNA]	0.0	4	1	1	1
78501	1710	suggest responsible for the decrease	[suggesting responsible for the decrease]	0.0	5	1	1	1
78502	1710	use a pkc inhibitor	[Using a PKC inhibitor]	0.0	4	1	1	1
78503	1710	target of 1 alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3	[targets of 1 alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3]	0.0	6	1	1	1
78504	1710	contain 128 bp	[containing 128 bp]	0.0	3	1	1	1
78505	1710	plot	[plot]	0.0	1	2	2	1
78506	1710	gene-proximal element	[gene-proximal elements]	0.0	2	1	1	1
78507	1710	efficient competitors,	[efficient competitors,]	0.0	2	1	1	1
78508	1710	time, by a mechanism,	[time, by an mechanism,]	0.0	4	1	1	1
78509	1710	few week	[few weeks]	0.0	2	1	1	1
78510	1710	drive the progression	[driving the progression]	0.0	3	1	1	1
78511	1710	21.4-kb DNA clone	[21.4-kb DNA clone]	0.0	3	1	1	1
78512	1710	induction of protein	[induction of proteins]	0.0	3	2	2	1
78513	1710	one copy upstream	[one copies upstream]	0.0	3	1	1	1
78514	1710	several cell-encoded gene	[several cell-encoded genes]	0.0	3	1	1	1
78515	1710	GCR-beta gene	[GCR-beta gene]	0.0	2	1	1	1
78516	1710	case of atll	[cases of ATLL]	0.0	3	1	1	1
78517	1710	expose human umbilical vein endothelial cell	[Exposing human umbilical vein endothelial cells]	0.0	6	1	1	1
78518	1710	steady-state tnf-alpha mrna	[steady-state TNF-alpha mRNA]	0.0	3	1	1	1
78519	1710	C81-66-45	[C81-66-45]	0.0	1	1	1	1
78520	1710	o-phenanthroline metal-ion chelator on the induction	[o-phenanthroline metal-ion chelator on the induction]	0.0	6	1	1	1
78521	1710	response of T lymphocyte	[response of T lymphocytes]	0.0	4	1	1	1
78522	1710	intestinal cell response to infection	[intestinal cell responses to infection]	0.0	5	1	1	1
78523	1710	transactivation by human herpesvirus strain	[Transactivation by human herpesvirus strains]	0.0	5	1	1	1
78524	1710	methyl prednisolone	[methyl prednisolone]	0.0	2	1	1	1
78525	1710	trans-activation activity on promoter element	[trans-activation activities on promoter elements]	0.0	5	1	1	1
78526	1710	nuclei of uninfected cell	[nuclei of uninfected cells]	0.0	4	1	1	1
78527	1710	two distinct sequence-specific protein	[two distinct sequence-specific proteins]	0.0	4	1	1	1
78528	1710	interleukin T cell growth	[interleukin T cell growth]	0.0	4	1	1	1
78529	1710	hypolipidaemic peroxisome proliferator	[hypolipidaemic peroxisome proliferator]	0.0	3	1	1	1
78530	1710	characterization of nf(p) relationship	[Characterization of NF(P) relationship]	0.0	4	1	1	1
78531	1710	component of Gram-positive bacterium	[component of Gram-positive bacteria]	0.0	4	1	1	1
78532	1710	advantage of model	[advantage of model]	0.0	3	1	1	1
78533	1710	translocation of nf-kappa b p50/p65	[translocation of NF-kappa B p50/p65]	0.0	5	1	1	1
78534	1710	novel treatment	[novel treatments]	0.0	2	1	1	1
78535	1710	replacement in vitro	[replacement in vitro]	0.0	3	1	1	1
78536	1710	ldl receptor	[LDL receptor]	0.0	2	1	1	1
78537	1710	complex interaction occur	[complex interactions occurring]	0.0	3	1	1	1
78538	1710	only a portion of the domain	[only a portion of the domain]	0.0	6	1	1	1
78539	1710	age-related decline by T cell	[age-related decline by T cells]	0.0	5	1	1	1
78540	1710	trans-acting factor in lymphocyte	[trans-acting factors in lymphocytes]	0.0	4	1	1	1
78541	1710	key functional role in hematopoiesis	[key functional role in hematopoiesis]	0.0	5	1	1	1
78542	1710	HSV -specific CD4 T cell	[HSV -specific CD4 T cells]	0.0	5	1	1	1
78543	1710	Oct2-isoform	[Oct2-isoform]	0.0	1	1	1	1
78544	1710	hla peptide	[HLA peptide]	0.0	2	1	1	1
78545	1710	continuum	[continuum]	0.0	1	1	1	1
78546	1710	moreover, nf-atp mouse old	[Moreover, NF-ATp mice older]	0.0	4	1	1	1
78547	1710	lamin a	[lamin A]	0.0	2	1	1	1
78548	1710	reaction of the tumor	[reaction of the tumor]	0.0	4	1	1	1
78549	1710	extract from rest ml-1 cell	[extracts from resting ML-1 cells]	0.0	5	1	1	1
78550	1710	show only cross-reactivity at high concentration	[showing only cross-reactivity at high concentrations]	0.0	6	1	1	1
78551	1710	BA patient	[BA patients]	0.0	2	1	1	1
78552	1710	CD40 association	[CD40 association]	0.0	2	1	1	1
78553	1710	activity of promoter-reporter fusion	[activities of promoter-reporter fusions]	0.0	4	1	1	1
78554	1710	human B-cell transcription factor	[human B-cell transcription factor]	0.0	4	1	1	1
78555	1710	region contain near-perfect direct repeat	[region containing near-perfect direct repeats]	0.0	5	1	1	1
78556	1710	NFkappaB /inhibitor-kappaB system	[NFkappaB /inhibitor-kappaB system]	0.0	3	1	1	1
78557	1710	tcc mitotic signal	[TCC mitotic signaling]	0.0	3	1	1	1
78558	1710	activation, differentiation, in ilf	[activation, differentiation, in ILFs]	0.0	4	1	1	1
78559	1710	quantitative analysis with antibody	[quantitative analysis with antibodies]	0.0	4	1	1	1
78560	1710	study the mechanism responsible for downmodulation	[studying the mechanisms responsible for downmodulation]	0.0	6	1	1	1
78561	1710	nucleotide +13	[nucleotides +13]	0.0	2	1	1	1
78562	1710	tnf-alpha signal pathway	[TNF-alpha signaling pathways]	0.0	3	1	1	1
78563	1710	ultra-violet activation	[UV activation]	0.0	2	1	1	1
78564	1710	/c-ebp	[/C-EBP]	0.0	1	1	1	1
78565	1710	(i) suppression	[(i) suppression]	0.0	2	1	1	1
78566	1710	span base pair -1	[spanning base pairs -1]	0.0	4	1	1	1
78567	1710	CR1 of peripheral blood monocyte	[CR1 of peripheral blood monocytes]	0.0	5	1	1	1
78568	1710	treatment with units/ml recombinant m-csf	[Treatment with units/ml recombinant M-CSF]	0.0	5	1	1	1
78569	1710	CREB/ATF-1/CREM family member	[CREB/ATF-1/CREM family members]	0.0	3	1	1	1
78570	1710	evolutionary benefit	[evolutionary benefit]	0.0	2	1	1	1
78571	1710	fetal brain development due to challenge	[fetal brain development due to challenge]	0.0	6	1	1	1
78572	1710	il-1 necrosis factor	[IL-1 necrosis factor]	0.0	3	1	1	1
78573	1710	origin,	[origin,]	0.0	1	1	1	1
78574	1710	spectrum of antibody	[spectrum of antibodies]	0.0	3	1	1	1
78575	1710	virtue of affinity	[virtue of affinity]	0.0	3	1	1	1
78576	1710	such as transcription factor	[such as transcription factors]	0.0	4	1	1	1
78577	1710	fibrosarcoma malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrosarcoma malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
78578	1710	novel coupling between sIg protein	[novel coupling between sIg proteins]	0.0	5	1	1	1
78579	1710	flexneri	[flexneri]	0.0	1	1	1	1
78580	1710	mg/kg iv bolus dose of mpl	[mg/kg IV bolus doses of MPL]	0.0	6	1	1	1
78581	1710	similarly, a kinase-deficient mutant	[Similarly, a kinase-deficient mutant]	0.0	4	1	1	1
78582	1710	hiv- hd	[HIV- HD]	0.0	2	1	1	1
78583	1710	recognition within the protein	[recognition within the protein]	0.0	4	1	1	1
78584	1710	similar function	[similar function]	0.0	2	1	1	1
78585	1710	sp1-box 5'-gggcgg	[SP1-box 5'-GGGCGG]	0.0	2	1	1	1
78586	1710	activation in PBMC	[activation in PBMC]	0.0	3	1	1	1
78587	1710	expression of expression vector	[expression of expression vectors]	0.0	4	1	1	1
78588	1710	distal factor (NF)-AT AP-1/Octamer	[distal factor (NF)-AT AP-1/Octamer]	0.0	4	1	1	1
78589	1710	immunoglobulin chain gene	[immunoglobulin chain genes]	0.0	3	1	1	1
78590	1710	element alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Elements alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	4	1	1	1
78591	1710	characteristic domain	[characteristic domain]	0.0	2	1	1	1
78592	1710	Differential induction protein	[Differential induction protein]	0.0	3	1	1	1
78593	1710	tumor necrosis factor-alpha U/ml, h)	[tumor necrosis factor-alpha U/ml, h)]	0.0	5	1	1	1
78594	1710	human T lymphotropic	[Human T lymphotropic]	0.0	3	1	1	1
78595	1710	function of nm23 protein	[functions of nm23 proteins]	0.0	4	1	1	1
78596	1710	little cytokine	[little cytokines]	0.0	2	1	1	1
78597	1710	gr transcriptional activation of GRE	[GR transcriptional activation of GRE]	0.0	5	1	1	1
78598	1710	factor for eosinophil	[factor for eosinophils]	0.0	3	1	1	1
78599	1710	jun B	[jun B]	0.0	2	1	1	1
78600	1710	expression by Northern blot analysis	[expression by Northern blot analysis]	0.0	5	1	1	1
78601	1710	lead to monocyte activation	[leading to monocyte activation]	0.0	4	1	1	1
78602	1710	induction requirement in primary T cell	[Induction requirements in primary T cells]	0.0	6	1	1	1
78603	1710	immunodeficiency virus type 1 provirus	[immunodeficiency virus type 1 provirus]	0.0	5	1	1	1
78604	1710	role -sensitive induction	[role -sensitive induction]	0.0	3	1	1	1
78605	1710	monosomy of loci	[monosomy of loci]	0.0	3	1	1	1
78606	1710	association between expression	[Association between expression]	0.0	3	1	1	1
78607	1710	acute hbv infection	[acute HBV infection]	0.0	3	1	1	1
78608	1710	tyrosine phosphorylation of Jak	[tyrosine phosphorylation of Jak]	0.0	4	1	1	1
78609	1710	thus, inhibition	[Thus, inhibition]	0.0	2	1	1	1
78610	1710	role of iron	[role of iron]	0.0	3	1	1	1
78611	1710	Effect of prostaglandin e2	[Effects of prostaglandin E2]	0.0	4	1	1	1
78612	1710	steady-state mrna level in lipopolysaccharide	[steady-state mRNA levels in lipopolysaccharide]	0.0	5	1	1	1
78613	1710	influence on the differentiation	[influence on the differentiation]	0.0	4	1	1	1
78614	1710	regulatory protein network	[regulatory protein network]	0.0	3	1	1	1
78615	1710	pathway dependent on ROI production	[pathway dependent on ROI production]	0.0	5	1	1	1
78616	1710	specific regulation of promoter	[specific regulation of promoters]	0.0	4	1	1	1
78617	1710	drug discovery	[drug discovery]	0.0	2	1	1	1
78618	1710	pyrimidine element present	[pyrimidine elements present]	0.0	3	1	1	1
78619	1710	first intron in cells,	[first intron in cells,]	0.0	4	1	1	1
78620	1710	two 9-bp motif with homology	[two 9-bp motifs with homology]	0.0	5	1	1	1
78621	1710	DR11(+) APL patient	[DR11(+) APL patients]	0.0	3	1	1	1
78622	1710	activation of two form stat3alpha	[activation of two forms STAT3alpha]	0.0	5	1	1	1
78623	1710	dual effect on malignant lymphocyte	[dual effects on malignant lymphocytes]	0.0	5	1	1	1
78624	1710	several rearrangement	[several rearrangements]	0.0	2	1	1	1
78625	1710	injection in mouse	[injection in mice]	0.0	3	1	1	1
78626	1710	trans-acting activator	[trans-acting activator]	0.0	2	1	1	1
78627	1710	expression in hematopoietic stage	[expression in hematopoietic stages]	0.0	4	1	1	1
78628	1710	activation by t-cell leukemia virus type	[Activation by T-cell leukemia virus type]	0.0	6	1	1	1
78629	1710	ebna2 rrna	[EBNA2 mRNAs]	0.0	2	1	1	1
78630	1710	nervous (n-oct) protein	[nervous (N-Oct) proteins]	0.0	3	1	1	1
78631	1710	level of urinary cortisol	[levels of urinary cortisol]	0.0	4	1	1	1
78632	1710	NK clearance of human cell	[NK clearance of human cells]	0.0	5	1	1	1
78633	1710	12 reactive follicular hyperplasia	[12 reactive follicular hyperplasia]	0.0	4	1	1	1
78634	1710	histocompatibility class ii molecule	[histocompatibility class II molecules]	0.0	4	1	1	1
78635	1710	transcriptional activation of NF-kappaB	[transcriptional activation of NF-kappaB]	0.0	4	1	1	1
78636	1710	attenuation of live-hiv-1	[attenuation of live-HIV-1]	0.0	3	1	1	1
78637	1710	more extensive deletion	[More extensive deletion]	0.0	3	1	1	1
78638	1710	human haemopoietic cell of lineages.	[human haemopoietic cells of lineages.]	0.0	5	1	1	1
78639	1710	disruption epstein-barr virus	[disruption Epstein-Barr virus]	0.0	3	1	1	1
78640	1710	human cd3epsilon gene	[human CD3epsilon gene]	0.0	3	1	1	1
78641	1710	Recent analysis of mouse	[Recent analysis of mice]	0.0	4	1	1	1
78642	1710	PPARgamma a partner	[PPARgamma a partner]	0.0	3	1	1	1
78643	1710	toxic effect of LMP1	[toxic effects of LMP1]	0.0	4	1	1	1
78644	1710	library screening	[library screenings]	0.0	2	1	1	1
78645	1710	E-selectin surface expression	[E-selectin surface expression]	0.0	3	1	1	1
78646	1710	selection expansion) (by stimulation lead	[selection expansion) (by stimulation leading]	0.0	5	1	1	1
78647	1710	similar cd11b+ population in mouse	[similar CD11b+ populations in mice]	0.0	5	1	1	1
78648	1710	patient with disease (12: four	[patients with diseases (12: four]	0.0	5	1	1	1
78649	1710	hgmw-approved symbol olr1	[HGMW-approved symbol OLR1]	0.0	3	1	1	1
78650	1710	phagocytosis of neutrophil	[phagocytosis of neutrophils]	0.0	3	2	2	1
78651	1710	two kappa B-specific complex	[two kappa B-specific complexes]	0.0	4	1	1	1
78652	1710	model of adenovirus infection	[model of adenovirus infection]	0.0	4	1	1	1
78653	1710	counterpart of this b cell	[counterpart of these B cells]	0.0	5	1	1	1
78654	1710	pma+	[PMA+]	0.0	1	1	1	1
78655	1710	15% fetal calf serum	[15% fetal calf serum]	0.0	4	1	1	1
78656	1710	pathway essential	[pathways essential]	0.0	2	1	1	1
78657	1710	weak effect on hiv production	[weak effects on HIV production]	0.0	5	1	1	1
78658	1710	immunophenotypic correlate to the current classification	[immunophenotypic correlates to the current classification]	0.0	6	1	1	1
78659	1710	jurkat mouse el-4 cell pos-1 pos-1a	[Jurkat mouse EL-4 cells POS-1 POS-1a]	0.0	6	1	1	1
78660	1710	antigenic challenge,	[antigenic challenge,]	0.0	2	1	1	1
78661	1710	myeloid cell granulocyte	[myeloid cells granulocytes]	0.0	3	1	1	1
78662	1710	look in new approach treat IBD	[Looking in newer approaches treating IBD]	0.0	6	1	1	1
78663	1710	evidence for differential regulation specific	[evidence for differential regulation specific]	0.0	5	1	1	1
78664	1710	molecular mechanism underlie il-2 blockade	[molecular mechanism underlying IL-2 blockade]	0.0	5	1	1	1
78665	1710	number with aggregate formation	[numbers with aggregate formation]	0.0	4	1	1	1
78666	1710	chromosome band 11p15	[chromosome bands 11p15]	0.0	3	1	1	1
78667	1710	ca2+ in the dense tubules:	[Ca2+ in the dense tubules:]	0.0	5	1	1	1
78668	1710	icam-1 expression in cell	[ICAM-1 expression in cells]	0.0	4	1	1	1
78669	1710	mcd14 uptake produce less concurrent enhancement	[mCD14 uptake producing less concurrent enhancement]	0.0	6	1	1	1
78670	1710	G1-to- phase transition	[G1-to-S phase transition]	0.0	3	1	1	1
78671	1710	protein species of the family	[protein species of the family]	0.0	5	1	1	1
78672	1710	characterization of novel IL-2 inhibitor	[characterization of novel IL-2 inhibitors]	0.0	5	1	1	1
78673	1710	switch in b cell	[switching in B cells]	0.0	4	1	1	1
78674	1710	induce acute distress syndrome ARDS	[inducing acute distress syndrome ARDS]	0.0	5	1	1	1
78675	1710	innate defense mechanism	[innate defense mechanisms]	0.0	3	1	1	1
78676	1710	mutation of the DBF	[mutation of the DBF]	0.0	4	1	1	1
78677	1710	detection in non-erythroid cell	[Detection in non-erythroid cells]	0.0	4	1	1	1
78678	1710	heterodimerization of jak1	[heterodimerization of JAK1]	0.0	3	1	1	1
78679	1710	addition, cycle	[addition, cycle]	0.0	2	1	1	1
78680	1710	blood leukocyte from normal human	[blood leukocytes from normal humans]	0.0	5	1	1	1
78681	1710	mediator include instability	[mediators including instability]	0.0	3	1	1	1
78682	1710	coordination with factor	[coordination with factors]	0.0	3	1	1	1
78683	1710	gene transcription during induction of differentiation	[gene transcription during induction of differentiation]	0.0	6	1	1	1
78684	1710	role as a trans-activator	[role as a trans-activator]	0.0	4	1	1	1
78685	1710	adaptation in receptor number	[adaptation in receptor number]	0.0	4	1	1	1
78686	1710	(range, (range, 6.18 (range, 5.86-6.74) nm,	[(range, (range, 6.18 (range, 5.86-6.74) nM,]	0.0	6	1	1	1
78687	1710	different hil-5 -responsive cell line	[different hIL-5 -responsive cell lines]	0.0	5	1	1	1
78688	1710	role modulate immune function	[role modulating immune function]	0.0	4	1	1	1
78689	1710	alteration of the sequence	[alteration of the sequence]	0.0	4	1	1	1
78690	1710	role of ICSAT	[role of ICSAT]	0.0	3	1	1	1
78691	1710	surface icam-1 expression	[surface ICAM-1 expression]	0.0	3	1	1	1
78692	1710	production by cd4+ T lymphocyte	[production by CD4+ T lymphocytes]	0.0	5	1	1	1
78693	1710	gene such as ip-10	[genes such as IP-10]	0.0	4	1	1	1
78694	1710	several cytokine interleukin	[several cytokines interleukin]	0.0	3	1	1	1
78695	1710	tumor necrosis factor tnf	[tumor necrosis factor TNF]	0.0	4	1	1	1
78696	1710	retinoid differentiation marker	[retinoid differentiation markers]	0.0	3	1	1	1
78697	1710	stimulation of the lymphocyte	[stimulation of the lymphocytes]	0.0	4	1	1	1
78698	1710	paraffin section	[paraffin sections]	0.0	2	1	1	1
78699	1710	differentiation potential of normal cell	[differentiation potential of normal cells]	0.0	5	1	1	1
78700	1710	eosinophil infiltrate into different process	[eosinophils infiltrating into different processes]	0.0	5	1	1	1
78701	1710	distribution of gene evidence	[distribution of genes evidence]	0.0	4	1	1	1
78702	1710	pediatric sample	[pediatric samples]	0.0	2	2	2	1
78703	1710	lymphocyte of patient with rheumatoid arthritis	[Lymphocytes of patients with rheumatoid arthritis]	0.0	6	1	1	1
78704	1710	express the CD28 ligand	[expressing the CD28 ligands]	0.0	4	1	1	1
78705	1710	radiotherapy in human cell carcinoma	[radiotherapy in human cell carcinomas]	0.0	5	1	1	1
78706	1710	difference between astrocytomas /glioblastomas	[differences between astrocytomas /glioblastomas]	0.0	4	1	1	1
78707	1710	tgf-alpha expression	[TGF-alpha expression]	0.0	2	1	1	1
78708	1710	analysis protein	[Analysis proteins]	0.0	2	1	1	1
78709	1710	CONCLUSION: cytomegalovirus early gene product	[CONCLUSION: Cytomegalovirus early gene products]	0.0	5	1	1	1
78710	1710	intense phosphorylation	[intense phosphorylation]	0.0	2	1	1	1
78711	1710	factor (NF)-AT proximal NF-AT AP-1/Octamer UPS	[factor (NF)-AT proximal NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
78712	1710	activation-deficient receptor mutant	[activation-deficient receptor mutant]	0.0	3	1	1	1
78713	1710	following: increased; at the beginning	[following: increased; at the beginning]	0.0	5	1	1	1
78714	1710	normal condition	[normal conditions]	0.0	2	1	1	1
78715	1710	ad5 e1a protein	[Ad5 E1A protein]	0.0	3	1	1	1
78716	1710	rapid expansion of the number	[rapid expansion of the number]	0.0	5	1	1	1
78717	1710	growth of this culture-adapted fibroblast	[growth of these culture-adapted fibroblasts]	0.0	5	1	1	1
78718	1710	deterioration immunodeficiency virus type 1	[deterioration immunodeficiency virus type 1]	0.0	5	1	1	1
78719	1710	change in 17beta-HSD iv	[change in 17beta-HSD IV]	0.0	4	1	1	1
78720	1710	mAb l243	[mAb L243]	0.0	2	1	1	1
78721	1710	protein gal4-p65(286-551)	[protein GAL4-p65(286-551)]	0.0	2	1	1	1
78722	1710	coimmunoprecipitation experiment	[coimmunoprecipitation experiments]	0.0	2	1	1	1
78723	1710	cd20/b1	[CD20/B1]	0.0	1	1	1	1
78724	1710	expression on a population	[expression on a population]	0.0	4	1	1	1
78725	1710	major surface protein	[major surface proteins]	0.0	3	1	1	1
78726	1710	indicate heterogeneity within fetal muscle	[indicating heterogeneity within fetal muscle]	0.0	5	1	1	1
78727	1710	lymphocyte of patient with arthritis	[Lymphocytes of patients with arthritis]	0.0	5	1	1	1
78728	1710	cell-permeable sn50 peptide	[cell-permeable SN50 peptide]	0.0	3	1	1	1
78729	1710	macrophage AMs	[macrophages AMs]	0.0	2	1	1	1
78730	1710	globin expression	[globin expression]	0.0	2	1	1	1
78731	1710	gelatinase granule from neutrophil	[gelatinase granules from neutrophils]	0.0	4	1	1	1
78732	1710	vimentin level in cell	[vimentin levels in cells]	0.0	4	1	1	1
78733	1710	impaired expression	[impaired expression]	0.0	2	1	1	1
78734	1710	expression in three,	[expression in three,]	0.0	3	1	1	1
78735	1710	first visit,	[first visit,]	0.0	2	1	1	1
78736	1710	virus-exposed T cell	[virus-exposed T cells]	0.0	3	1	1	1
78737	1710	co-migrate with lef1/bcf1	[co-migrating with LEF1/BCF1]	0.0	3	1	1	1
78738	1710	activator protein-1 binding activity;	[activator protein-1 binding activity;]	0.0	4	1	1	1
78739	1710	role in the immortalization	[role in the immortalization]	0.0	4	1	1	1
78740	1710	atf-2 in S. cerevisiae	[ATF-2 in S. cerevisiae]	0.0	4	1	1	1
78741	1710	il-3 commitment lineage.	[IL-3 commitment lineage.]	0.0	3	1	1	1
78742	1710	activity of DEN	[activity of DEN]	0.0	3	1	1	1
78743	1710	factor FcRFgamma	[factor FcRFgamma]	0.0	2	1	1	1
78744	1710	competitive antagonist	[competitive antagonist]	0.0	2	1	1	1
78745	1710	element hSIE	[element hSIE]	0.0	2	1	1	1
78746	1710	molecular clone of hiv-1	[molecular clones of HIV-1]	0.0	4	1	1	1
78747	1710	Novel aldosterone receptor	[Novel aldosterone receptors]	0.0	3	1	1	1
78748	1710	t-cell-mediated disease	[T-cell-mediated diseases]	0.0	2	1	1	1
78749	1710	tre camp-responsive dse site	[TRE cAMP-responsive DSE sites]	0.0	4	1	1	1
78750	1710	use specific antisera	[using specific antisera]	0.0	3	1	1	1
78751	1710	five t-cell clone	[Five T-cell clones]	0.0	3	1	1	1
78752	1710	in-frame splicing	[in-frame splicing]	0.0	2	1	1	1
78753	1710	primary effect of this reagent	[primary effect of these reagents]	0.0	5	1	1	1
78754	1710	cytokine production by a endotoxin	[cytokine production by a endotoxin]	0.0	5	1	1	1
78755	1710	motif for Pit-1	[motifs for Pit-1]	0.0	3	1	1	1
78756	1710	(rna) blot	[(RNA) blots]	0.0	2	1	1	1
78757	1710	suggest important in lymphomagenesis	[suggesting important in lymphomagenesis]	0.0	4	1	1	1
78758	1710	c-fo /c-Jun heterodimer	[c-Fos /c-Jun heterodimers]	0.0	3	1	1	1
78759	1710	mab BW	[mAb BW]	0.0	2	1	1	1
78760	1710	interleukin production.	[interleukin production.]	0.0	2	1	1	1
78761	1710	involvement of tumor necrosis factor	[involvement of tumor necrosis factor]	0.0	5	1	1	1
78762	1710	effect in the eight patient	[effect in the eight patients]	0.0	5	1	1	1
78763	1710	improve the definition of clinical endpoint	[improving the definitions of clinical endpoints]	0.0	6	1	1	1
78764	1710	stimulate factor treatment of neutrophils.	[stimulating factor treatment of neutrophils.]	0.0	5	1	1	1
78765	1710	extracellular signal converge in common pathway	[extracellular signals converging in common pathways]	0.0	6	1	1	1
78766	1710	non-hodgkin' lymphoma AIDS NHL	[non-Hodgkin's lymphoma AIDS NHL]	0.0	4	1	1	1
78767	1710	Clinical deterioration immunodeficiency virus type	[Clinical deterioration immunodeficiency virus type]	0.0	5	1	1	1
78768	1710	extensive homology in domain	[extensive homology in domains]	0.0	4	1	1	1
78769	1710	t-cell leukemia patient	[T-cell leukemia patients]	0.0	3	1	1	1
78770	1710	EKLF to 5'HS2	[EKLF to 5'HS2]	0.0	3	1	1	1
78771	1710	EKLF to 5'HS3	[EKLF to 5'HS3]	0.0	3	2	2	1
78772	1710	therefore a EB1 b-cell-specific element	[therefore an EB1 B-cell-specific element]	0.0	5	1	1	1
78773	1710	prominent tyrosine phosphorylation	[prominent tyrosine phosphorylation]	0.0	3	1	1	1
78774	1710	mutation/deletion of NF-kappa b site basis	[mutation/deletion of NF-kappa B site bases]	0.0	6	1	1	1
78775	1710	use monocyte in 69% of comparison	[using monocytes in 69% of comparisons]	0.0	6	1	1	1
78776	1710	include expression	[including expression]	0.0	2	1	1	1
78777	1710	encode octamer-binding protein	[encoding octamer-binding proteins]	0.0	3	1	1	1
78778	1710	population of CD4 killer population	[populations of CD4 killer populations]	0.0	5	1	1	1
78779	1710	viral domain	[viral domain]	0.0	2	1	1	1
78780	1710	mediate induction	[mediating induction]	0.0	2	1	1	1
78781	1710	order the concentration of lps	[orders the concentration of LPS]	0.0	5	1	1	1
78782	1710	receptor in lymphocyte without change	[receptors in lymphocytes without changes]	0.0	5	1	1	1
78783	1710	also (p 0.025)	[also (P 0.025)]	0.0	3	1	1	1
78784	1710	(gm)-csf	[(GM)-CSF]	0.0	1	1	1	1
78785	1710	tax1 antigen	[tax1 antigens]	0.0	2	1	1	1
78786	1710	osteocalcine	[osteocalcine]	0.0	1	1	1	1
78787	1710	silent c-myc allele	[silent c-myc allele]	0.0	3	2	2	1
78788	1710	complex contain stat4 only, stat4	[complexes containing STAT4 only, STAT4]	0.0	5	1	1	1
78789	1710	nacl solution	[NaCl solution]	0.0	2	1	1	1
78790	1710	include anti-CD3	[including anti-CD3]	0.0	2	1	1	1
78791	1710	key event	[key event]	0.0	2	1	1	1
78792	1710	allergen-specific th cell	[allergen-specific Th cells]	0.0	3	1	1	1
78793	1710	insulin-gene regulation	[insulin-gene regulation]	0.0	2	1	1	1
78794	1710	mouse ccr-4	[mouse CCR-4]	0.0	2	1	1	1
78795	1710	POZ/Zinc finger repressor	[POZ/Zinc finger repressor]	0.0	3	1	1	1
78796	1710	binding of ap-1 transcription factor	[binding of AP-1 transcription factors]	0.0	5	1	1	1
78797	1710	spectrum of K+ channel	[spectrum of K+ channels]	0.0	4	1	1	1
78798	1710	Tat a activator	[Tat a activator]	0.0	3	1	1	1
78799	1710	immunodeficiency virus type (hiv-1) tat	[immunodeficiency virus type (HIV-1) Tat]	0.0	5	1	1	1
78800	1710	methods: blood monocyte	[METHODS: blood monocytes]	0.0	3	1	1	1
78801	1710	include stop codon mutant	[including stop codon mutants]	0.0	4	1	1	1
78802	1710	own localization	[own localization]	0.0	2	1	1	1
78803	1710	rate in cell	[rate in cells]	0.0	3	1	1	1
78804	1710	(hbb)-like	[(HBB)-like]	0.0	1	1	1	1
78805	1710	macrophage cell surface ags	[macrophage cell surface Ags]	0.0	4	1	1	1
78806	1710	trypan exclusion cell counting	[trypan exclusion cell counting]	0.0	4	1	1	1
78807	1710	direct interaction functional antagonism	[Direct interaction functional antagonism]	0.0	4	1	1	1
78808	1710	selective NK clearance of cell	[selective NK clearance of cells]	0.0	5	1	1	1
78809	1710	patient with CLL er	[patients with CLL ER]	0.0	4	1	1	1
78810	1710	synergism between distinct element	[Synergism between distinct elements]	0.0	4	1	1	1
78811	1710	upregulation intercellular adhesion molecule-1	[upregulation intercellular adhesion molecule-1]	0.0	4	1	1	1
78812	1710	possible role regulate e2f	[possible role regulating E2F]	0.0	4	1	1	1
78813	1710	other, non-cross-resisting agent	[other, non-cross-resisting agents]	0.0	3	1	1	1
78814	1710	deletion of the region of PU.1	[Deletion of the region of PU.1]	0.0	6	1	1	1
78815	1710	regulation of proenkephalin effect	[regulation of proenkephalin effects]	0.0	4	1	1	1
78816	1710	effect in the treatment	[effect in the treatment]	0.0	4	1	1	1
78817	1710	intact human mononuclear leukocyte	[intact human mononuclear leukocytes]	0.0	4	1	1	1
78818	1710	lesion in the development	[lesion in the development]	0.0	4	1	1	1
78819	1710	m10 CEM clone	[M10 CEM clones]	0.0	3	1	1	1
78820	1710	-132/+170)-reporter	[-132/+170)-reporter]	0.0	1	1	1	1
78821	1710	apoptotic effect	[apoptotic effect]	0.0	2	1	1	1
78822	1710	effect of retinoic acid	[effect of retinoic acids]	0.0	4	2	2	1
78823	1710	case of B-cell leukemia	[cases of B-cell leukemia]	0.0	4	1	1	1
78824	1710	interaction of hematopoietic transcription factor antagonism	[interaction of hematopoietic transcription factors antagonism]	0.0	6	1	1	1
78825	1710	efficient promoter in cell	[efficient promoters in cells]	0.0	4	1	1	1
78826	1710	2 human myeloid progenitor cell	[2 human myeloid progenitor cells]	0.0	5	1	1	1
78827	1710	case of B-cell leukemia CLL	[cases of B-cell leukemia CLL]	0.0	5	1	1	1
78828	1710	hiv repeat -cat construct	[HIV repeat -CAT constructs]	0.0	4	1	1	1
78829	1710	method for down-regulation of transcription factor	[methods for down-regulation of transcription factors]	0.0	6	1	1	1
78830	1710	maximum value	[maximum value]	0.0	2	1	1	1
78831	1710	similar signal mechanism	[similar signaling mechanisms]	0.0	3	1	1	1
78832	1710	pax protein	[Pax proteins]	0.0	2	1	1	1
78833	1710	optimal NK function	[optimal NK functions]	0.0	3	1	1	1
78834	1710	chronic rheumatic disease four	[chronic rheumatic diseases four]	0.0	4	1	1	1
78835	1710	blood volunteer	[blood volunteers]	0.0	2	1	1	1
78836	1710	ad group group C	[Ad groups group C]	0.0	4	1	1	1
78837	1710	hiv long terminal repeat transactivation	[HIV long terminal repeat transactivation]	0.0	5	1	1	1
78838	1710	u-937 cell to huvec	[U-937 cells to HUVECs]	0.0	4	1	1	1
78839	1710	10 U/ml,	[10 U/ml,]	0.0	2	1	1	1
78840	1710	ad group group A	[Ad groups group A]	0.0	4	1	1	1
78841	1710	soluble beta-(1,6)-branched glucose homopolymer	[soluble beta-(1,6)-branched glucose homopolymer]	0.0	4	1	1	1
78842	1710	variety of inducers,	[variety of inducers,]	0.0	3	1	1	1
78843	1710	umbilical vein cell HUVECs	[umbilical vein cells HUVECs]	0.0	4	2	2	1
78844	1710	clonal change	[clonal change]	0.0	2	1	1	1
78845	1710	response of cd4+	[responses of CD4+]	0.0	3	1	1	1
78846	1710	comparison no synthase gene	[comparison NO synthase genes]	0.0	4	1	1	1
78847	1710	compare binding	[comparing binding]	0.0	2	1	1	1
78848	1710	association with tradd	[association with TRADD]	0.0	3	1	1	1
78849	1710	ad2/ad12 hybrid e1a gene product	[Ad2/Ad12 hybrid E1A gene products]	0.0	5	1	1	1
78850	1710	good predictor for the course	[good predictor for the course]	0.0	5	1	1	1
78851	1710	1 tax transactivator	[1 tax transactivator]	0.0	3	1	1	1
78852	1710	tissue-specific stage-specific protein	[tissue-specific stage-specific protein]	0.0	3	1	1	1
78853	1710	cyclin/cdk complex	[cyclin/cdks complexes]	0.0	2	1	1	1
78854	1710	single protein fraction	[single protein fraction]	0.0	3	1	1	1
78855	1710	preterm of the latter group	[preterms of the latter group]	0.0	5	1	1	1
78856	1710	affinity of sr-bp high	[affinity of SR-BP higher]	0.0	4	1	1	1
78857	1710	adult-t-cell-leukemia cell line	[adult-T-cell-leukemia cell lines]	0.0	3	1	1	1
78858	1710	exception of patient	[exception of patient]	0.0	3	1	1	1
78859	1710	activation-dependent events: the CsA -sensitive translocation	[activation-dependent events: the CsA -sensitive translocation]	0.0	6	1	1	1
78860	1710	beta,19-epoxy-3-hydroxypregnan-20-one beta,19-epoxy-4-hydroxypregnane-3,20-dione	[beta,19-epoxy-3-hydroxypregnan-20-one beta,19-epoxy-4-hydroxypregnane-3,20-dione]	0.0	2	1	1	1
78861	1710	one end	[one end]	0.0	2	1	1	1
78862	1710	blood cell proliferation from patient	[blood cell proliferation from patients]	0.0	5	1	1	1
78863	1710	(il)-1beta CD40 trigger	[(IL)-1beta CD40 triggering]	0.0	3	1	1	1
78864	1710	rectal oral value	[rectal oral values]	0.0	3	1	1	1
78865	1710	site originate bp upstream	[sites originating bp upstream]	0.0	4	1	1	1
78866	1710	confirmation of the unique significance	[Confirmation of the unique significance]	0.0	5	1	1	1
78867	1710	17 case of endemic bl	[17 cases of endemic BL]	0.0	5	1	1	1
78868	1710	Minimal disease	[Minimal disease]	0.0	2	1	1	1
78869	1710	seven case	[seven cases]	0.0	2	1	1	1
78870	1710	role of the anaphylatoxin C5a	[role of the anaphylatoxins C5a]	0.0	5	1	1	1
78871	1710	transfer of tumor-draining lymph node	[transfer of tumor-draining lymph node]	0.0	5	1	1	1
78872	1710	Also, mol/L) in combination	[Also, mol/L) in combination]	0.0	4	1	1	1
78873	1710	response versus dose of methylprednisolone	[responses versus doses of methylprednisolone]	0.0	5	1	1	1
78874	1710	respond to cellular stimulation	[responding to cellular stimulation]	0.0	4	1	1	1
78875	1710	show specific	[showing specific]	0.0	2	1	1	1
78876	1710	C. pneumoniae-mediated activation of cell	[C. pneumoniae-mediated activation of cells]	0.0	5	1	1	1
78877	1710	plasma activity	[plasma activity]	0.0	2	1	1	1
78878	1710	model study alteration	[model studying alterations]	0.0	3	1	1	1
78879	1710	tumor immunohistochemical study	[tumor immunohistochemical studies]	0.0	3	1	1	1
78880	1710	nuclear activity	[nuclear activity]	0.0	2	2	2	1
78881	1710	Ter positive cell population	[Ter positive cell population]	0.0	4	1	1	1
78882	1710	bp EBNA2 region between -258	[bp EBNA2 region between -258]	0.0	5	1	1	1
78883	1710	b DNA	[B DNA]	0.0	2	1	1	1
78884	1710	hiv inhibition	[HIV inhibition]	0.0	2	1	1	1
78885	1710	gene encode cyclophilin b-binding-proteins	[genes encoding cyclophilin B-binding-proteins]	0.0	4	1	1	1
78886	1710	protein neg-2	[protein Neg-2]	0.0	2	1	1	1
78887	1710	distal nuclear factor NF-AT AP-1/Octamer	[distal nuclear factor NF-AT AP-1/Octamer]	0.0	5	1	1	1
78888	1710	OTF-2 expression vector	[OTF-2 expression vector]	0.0	3	1	1	1
78889	1710	leukemia cell with 12-o-tetradecanoylphorbol-13-acetate tpa	[leukemia cells with 12-O-tetradecanoylphorbol-13-acetate TPA]	0.0	5	1	1	1
78890	1710	BASH a novel	[BASH a novel]	0.0	3	1	1	1
78891	1710	neutrophil to cell	[neutrophils to cells]	0.0	3	1	1	1
78892	1710	protein (map) kinase pathway	[protein (MAP) kinase pathways]	0.0	4	1	1	1
78893	1710	nf-kb translocation	[NF-kB translocation]	0.0	2	1	1	1
78894	1710	b species in T cell	[B species in T cells]	0.0	5	1	1	1
78895	1710	high HbF production	[high HbF production]	0.0	3	1	1	1
78896	1710	expression p65 NF-kappa b subunit	[expression p65 NF-kappa B subunits]	0.0	5	1	1	1
78897	1710	mechanism regulate this response	[mechanisms regulating this response]	0.0	4	1	1	1
78898	1710	such as respiratory distress syndrome	[such as respiratory distress syndrome]	0.0	5	1	1	1
78899	1710	daily dose in treatment	[daily dose in treatment]	0.0	4	1	1	1
78900	1710	encode GATA-1	[encoding GATA-1]	0.0	2	1	1	1
78901	1710	LT promoter	[LT promoter]	0.0	2	1	1	1
78902	1710	distal factor (NF)-AT proximal NF-AT AP-1/Octamer	[distal factor (NF)-AT proximal NF-AT AP-1/Octamer]	0.0	6	1	1	1
78903	1710	binding of cellular transactivation factor	[binding of cellular transactivation factor]	0.0	5	1	1	1
78904	1710	friend virus (fva	[Friend virus (FVA]	0.0	3	1	1	1
78905	1710	consequence of cellular DNA damage	[consequence of cellular DNA damage]	0.0	5	1	1	1
78906	1710	Interferon regulatory factor 2	[Interferon regulatory factor 2]	0.0	4	1	1	1
78907	1710	abnormality of other gene	[abnormalities of other genes]	0.0	4	1	1	1
78908	1710	macrophage colony-stimumulatelany-stg factor in monocyte	[macrophage colony-stimulating factor in monocytes]	0.0	5	1	1	1
78909	1710	VCAM-1 promoter	[VCAM-1 promoter]	0.0	2	2	2	1
78910	1710	cytokine-stimulated umbilical vein cell	[cytokine-stimulated umbilical vein cells]	0.0	4	1	1	1
78911	1710	human impdh type gene	[human IMPDH type gene]	0.0	4	1	1	1
78912	1710	nkl cell	[NKL cells]	0.0	2	1	1	1
78913	1710	least three category of factor	[least three categories of factors]	0.0	5	1	1	1
78914	1710	pretreatment of ECs	[Pretreatment of ECs]	0.0	3	1	1	1
78915	1710	MARCKS -related protein	[MARCKS -related protein]	0.0	3	1	1	1
78916	1710	human interleukin 1beta	[human interleukin 1beta]	0.0	3	1	1	1
78917	1710	prominent binding	[prominent binding]	0.0	2	1	1	1
78918	1710	expression of the transcription factor Egr-1	[expression of the transcription factor Egr-1]	0.0	6	1	1	1
78919	1710	retention of VDR	[retention of VDR]	0.0	3	1	1	1
78920	1710	receptor antagonist RU 486	[receptor antagonist RU 486]	0.0	4	1	1	1
78921	1710	proteolytic digestion	[proteolytic digestion]	0.0	2	1	1	1
78922	1710	amylase	[amylase]	0.0	1	1	1	1
78923	1710	t-cell leukemia virus type-i	[T-cell leukemia virus type-I]	0.0	4	1	1	1
78924	1710	dna-binding hmg box related	[DNA-binding HMG box related]	0.0	4	1	1	1
78925	1710	occur in multiple distinct family	[occurring in multiple distinct families]	0.0	5	1	1	1
78926	1710	kappa b molecules.	[kappa B molecules.]	0.0	3	1	1	1
78927	1710	delivery carry the localization sequence	[delivery carrying the localization sequence]	0.0	5	1	1	1
78928	1710	basis of independent assay	[basis of independent assays]	0.0	4	1	1	1
78929	1710	protein, p37	[protein, p37]	0.0	2	1	1	1
78930	1710	current knowledge of the signal cascade	[current knowledge of the signaling cascade]	0.0	6	1	1	1
78931	1710	migration ChtM of human leukocyte	[migration ChtM of human leukocytes]	0.0	5	1	1	1
78932	1710	20-base pair upstream sequence	[20-base pair upstream sequence]	0.0	4	1	1	1
78933	1710	unrecognized composite binding site	[unrecognized composite binding site]	0.0	4	1	1	1
78934	1710	tarsal conjunctival biopsy from patient	[tarsal conjunctival biopsies from patients]	0.0	5	1	1	1
78935	1710	human mouse genomic sequence	[human mouse genomic sequences]	0.0	4	1	1	1
78936	1710	lymphoid cell-specific factor in vivo	[lymphoid cell-specific factor in vivo]	0.0	5	1	1	1
78937	1710	role in maturation for factor	[role in maturation for factors]	0.0	5	1	1	1
78938	1710	suggest possible new strategy	[suggesting possible new strategies]	0.0	4	1	1	1
78939	1710	differentiation of the parent ut-7/gm cell	[differentiation of the parent UT-7/GM cells]	0.0	6	1	1	1
78940	1710	same mechanism of proliferation cessation	[same mechanisms of proliferation cessation]	0.0	5	1	1	1
78941	1710	Simultaneously, T lymphocyte subset	[Simultaneously, T lymphocyte subsets]	0.0	4	1	1	1
78942	1710	such as gamma-globin delta-aminolevulinate synthase ALAS-E	[such as gamma-globin delta-aminolevulinate synthase ALAS-E]	0.0	6	1	1	1
78943	1710	AMP -responsive element CRE	[AMP -responsive element CRE]	0.0	4	2	2	1
78944	1710	lymphoid gene expression promoter	[Lymphoid gene expression promoter]	0.0	4	1	1	1
78945	1710	weight of kda	[weight of kDa]	0.0	3	1	1	1
78946	1710	human t-cell-leukemia virus type htlv-1	[human T-cell-leukemia virus type HTLV-1]	0.0	5	1	1	1
78947	1710	subunit IkappaB	[subunit IkappaB]	0.0	2	1	1	1
78948	1710	however, in contrast to lymphocyte	[However, in contrast to lymphocytes]	0.0	5	1	1	1
78949	1710	n-terminal half	[N-terminal half]	0.0	2	1	1	1
78950	1710	iv drug abuser	[iv drug abusers]	0.0	3	1	1	1
78951	1710	125i-labeled c-c chemokine	[125I-labeled C-C chemokines]	0.0	3	1	1	1
78952	1710	co-transfection of the promoter construct	[co-transfections of the promoter construct]	0.0	5	1	1	1
78953	1710	cleavage by caspase during B-cell apoptosis	[Cleavage by caspases during B-cell apoptosis]	0.0	6	1	1	1
78954	1710	promoter in erythroid cell	[promoter in erythroid cells]	0.0	4	1	1	1
78955	1710	evaluation of the role	[Evaluation of the role]	0.0	4	1	1	1
78956	1710	lymphocyte upon stimulation	[lymphocytes upon stimulation]	0.0	3	1	1	1
78957	1710	years, study of regulation	[years, studies of regulation]	0.0	4	1	1	1
78958	1710	antagonism by dexamethasone	[antagonism by dexamethasone]	0.0	3	1	1	1
78959	1710	phenylacetate	[phenylacetate]	0.0	1	1	1	1
78960	1710	result in a enhancement	[resulting in a enhancement]	0.0	4	1	1	1
78961	1710	lack of response to aldosterone	[lack of response to aldosterone]	0.0	5	1	1	1
78962	1710	phenotype'	[phenotype']	0.0	1	1	1	1
78963	1710	exclusive interaction	[exclusive interaction]	0.0	2	1	1	1
78964	1710	possibly lie	[possibly lying]	0.0	2	1	1	1
78965	1710	beta-phorbol 12-myristate 13-acetate	[beta-phorbol 12-myristate 13-acetate]	0.0	3	2	2	1
78966	1710	carboxy-terminal dimerization region	[carboxy-terminal dimerization region]	0.0	3	1	1	1
78967	1710	acute t-cell line	[acute T-cell line]	0.0	3	1	1	1
78968	1710	correlation with IL-2 production,	[correlation with IL-2 production,]	0.0	4	1	1	1
78969	1710	binding factor (dbf) site	[binding factor (DBF) site]	0.0	4	1	1	1
78970	1710	VitD3 response	[VitD3 response]	0.0	2	1	1	1
78971	1710	interrelation between the hypothalamic-pituitary-adrenal system	[Interrelations between the hypothalamic-pituitary-adrenal system]	0.0	5	1	1	1
78972	1710	event to endothelial cell	[event to endothelial cells]	0.0	4	1	1	1
78973	1710	bind assay with [3H]dexamethasone	[binding assay with [3H]dexamethasone]	0.0	4	1	1	1
78974	1710	intrinsic proliferative behavior	[intrinsic proliferative behavior]	0.0	3	1	1	1
78975	1710	two carg sequence	[two CArG sequences]	0.0	3	1	1	1
78976	1710	evidence for the modulation	[evidence for the modulation]	0.0	4	1	1	1
78977	1710	egr family	[Egr family]	0.0	2	1	1	1
78978	1710	accounting for 1%	[accounting for 1%]	0.0	3	1	1	1
78979	1710	intracellular cyclic AMP	[intracellular cyclic AMP]	0.0	3	1	1	1
78980	1710	STAT1 alpha	[STAT1 alpha]	0.0	2	1	1	1
78981	1710	kinase erk pathway	[kinase Erk pathway]	0.0	3	1	1	1
78982	1710	addition to the two complexess	[addition to the two complexes,]	0.0	5	1	1	1
78983	1710	however, T cell	[however, T cells]	0.0	3	1	1	1
78984	1710	concentration of glucocorticoid receptor	[concentration of glucocorticoid receptors]	0.0	4	1	1	1
78985	1710	phosphorylation in a cell-free system	[phosphorylation in a cell-free system]	0.0	5	1	1	1
78986	1710	injury in mouse	[injury in mice]	0.0	3	1	1	1
78987	1710	spectrum of retroviruse with potential	[spectrum of retroviruses with potential]	0.0	5	1	1	1
78988	1710	benzoic derivative of acid	[benzoic derivative of acid]	0.0	4	1	1	1
78989	1710	transcriptional response to activation	[transcriptional response to activation]	0.0	4	1	1	1
78990	1710	nfat -dependent expression of cytokine gene	[NFAT -dependent expression of cytokine genes]	0.0	6	1	1	1
78991	1710	activation at the time	[activation at the time]	0.0	4	1	1	1
78992	1710	wk to 12 mo) RA	[wk to 12 mo) RA]	0.0	5	1	1	1
78993	1710	tnf-treated human vein endothelial cell	[TNF-treated human vein endothelial cells]	0.0	5	1	1	1
78994	1710	phorbol ester -inducible neutrophil burst activation	[phorbol ester -inducible neutrophil burst activation]	0.0	6	1	1	1
78995	1710	exposure of cell to lipopolysaccharide lps	[Exposure of cells to lipopolysaccharide LPS]	0.0	6	1	1	1
78996	1710	[differential diagnostic value	[[Differential diagnostic value]	0.0	3	1	1	1
78997	1710	comparative analysis factor	[Comparative analysis factor]	0.0	3	1	1	1
78998	1710	erythroid 5-aminolevulinate synthase	[erythroid 5-aminolevulinate synthase]	0.0	3	1	1	1
78999	1710	binding of il-2 to bind site	[binding of IL-2 to binding site]	0.0	6	1	1	1
79000	1710	gene in hematopoietic progenitor cell	[genes in hematopoietic progenitor cells]	0.0	5	1	1	1
79001	1710	encode the Runt domain	[encoding the Runt domain]	0.0	4	1	1	1
79002	1710	activate transcription from class major promoter	[activating transcription from class major promoters]	0.0	6	1	1	1
79003	1710	new evidence	[new evidence]	0.0	2	1	1	1
79004	1710	ap-1/et	[AP-1/ets]	0.0	1	1	1	1
79005	1710	pathway with differential sensitivity	[pathways with differential sensitivity]	0.0	4	1	1	1
79006	1710	L-selectin mrna	[L-selectin mRNA]	0.0	2	1	1	1
79007	1710	coactivation by OCA-B	[Coactivation by OCA-B]	0.0	3	1	1	1
79008	1710	homodimerization of surface receptor consist	[homodimerization of surface receptors consisting]	0.0	5	1	1	1
79009	1710	feature of senescence	[feature of senescence]	0.0	3	1	1	1
79010	1710	component of recruitment	[component of recruitment]	0.0	3	1	1	1
79011	1710	CD40 gene	[CD40 gene]	0.0	2	1	1	1
79012	1710	Polymorphic nucleotide within the IL-4 promoter	[Polymorphic nucleotides within the IL-4 promoter]	0.0	6	1	1	1
79013	1710	gut hyperabsorption	[gut hyperabsorption]	0.0	2	1	1	1
79014	1710	constitute two model for the marker	[constituting two models for the markers]	0.0	6	1	1	1
79015	1710	transcriptional mechanism distinct	[transcriptional mechanism distinct]	0.0	3	1	1	1
79016	1710	38-kd murine map kinase	[38-kD murine MAP kinase]	0.0	4	1	1	1
79017	1710	activation of nuclear factor-kappaB by lipopolysaccharide	[Activation of nuclear factor-kappaB by lipopolysaccharide]	0.0	6	1	1	1
79018	1710	spatial distribution of gene evidence	[spatial distribution of genes evidence]	0.0	5	1	1	1
79019	1710	application.	[application.]	0.0	1	1	1	1
79020	1710	distinct epitope on the CD4 coreceptor	[distinct epitopes on the CD4 coreceptor]	0.0	6	1	1	1
79021	1710	major inhibitor	[major inhibitor]	0.0	2	1	1	1
79022	1710	complete remission CHR	[complete remission CHR]	0.0	3	2	2	1
79023	1710	method in cell mnc	[method in cells MNC]	0.0	4	1	1	1
79024	1710	regulation in human cells,	[regulation in human cells,]	0.0	4	1	1	1
79025	1710	very efficient precursor of DC	[very efficient precursors of DC]	0.0	5	1	1	1
79026	1710	loop in monocyte	[loop in monocytes]	0.0	3	1	1	1
79027	1710	500-fold excess	[500-fold excess]	0.0	2	1	1	1
79028	1710	acid receptor alpha RAR alpha	[acid receptor alpha RAR alpha]	0.0	5	1	1	1
79029	1710	avascular necrosis	[avascular necrosis]	0.0	2	1	1	1
79030	1710	glycation oxygen species	[glycation oxygen species]	0.0	3	1	1	1
79031	1710	electron-dense structure	[electron-dense structures]	0.0	2	1	1	1
79032	1710	case of ataxia-telangiectasia at	[cases of ataxia-telangiectasia AT]	0.0	4	1	1	1
79033	1710	activator of type-C retroviruse	[activator of type-C retroviruses]	0.0	4	1	1	1
79034	1710	resection of the ileum respond	[resection of the ileum responding]	0.0	5	1	1	1
79035	1710	very close homologue,	[very close homologue,]	0.0	3	1	1	1
79036	1710	gm-csf pmn	[GM-CSF PMN]	0.0	2	1	1	1
79037	1710	complex contain tr alpha	[complexes containing TR alpha]	0.0	4	1	1	1
79038	1710	inversion inv14(q11;q32.1)	[inversions inv14(q11;q32.1)]	0.0	2	1	1	1
79039	1710	complex role	[complex role]	0.0	2	1	1	1
79040	1710	Effect of diesel organic extract	[Effects of diesel organic extracts]	0.0	5	1	1	1
79041	1710	41-kDa protein	[41-kDa protein]	0.0	2	1	1	1
79042	1710	b-cell repertoire	[B-cell repertoire]	0.0	2	1	1	1
79043	1710	month of age, 10%	[months of age, 10%]	0.0	4	1	1	1
79044	1710	distinct apoptosis	[distinct apoptosis]	0.0	2	1	1	1
79045	1710	period years.	[period years.]	0.0	2	1	1	1
79046	1710	contain the 5' region	[containing the 5' region]	0.0	4	1	1	1
79047	1710	activity of nf-kappa b	[activity of NF-kappa B]	0.0	4	1	1	1
79048	1710	direct analysis with recombinant hugata-3	[Direct analysis with recombinant huGATA-3]	0.0	5	1	1	1
79049	1710	opposite receptor changes,	[opposite receptor changes,]	0.0	3	1	1	1
79050	1710	new leukemic entity	[new leukemic entity]	0.0	3	1	1	1
79051	1710	dominant form of Raf-1	[dominant form of Raf-1]	0.0	4	1	1	1
79052	1710	suppressor most notably	[suppressors most notably]	0.0	3	1	1	1
79053	1710	vitamin element vdre	[vitamin element VDRE]	0.0	3	1	1	1
79054	1710	growth factor release	[growth factor release]	0.0	3	1	1	1
79055	1710	12 nonspecific follicular hyperplasia fh	[12 nonspecific follicular hyperplasia FH]	0.0	5	1	1	1
79056	1710	significance of the differential expression	[significance of the differential expression]	0.0	5	1	1	1
79057	1710	presence of the form	[presence of the form]	0.0	4	1	1	1
79058	1710	feedback sensitivity	[feedback sensitivity]	0.0	2	1	1	1
79059	1710	oct-binding factor obf-1 a protein	[Oct-binding factor OBF-1 a protein]	0.0	5	1	1	1
79060	1710	investigate the nature of syndrome	[investigating the nature of syndromes]	0.0	5	1	1	1
79061	1710	shp2-interacting adaptor protein a dimer	[SHP2-interacting adaptor protein a dimer]	0.0	5	1	1	1
79062	1710	transient stimulation of c-jun	[transient stimulation of c-jun]	0.0	4	1	1	1
79063	1710	amount of glucocorticoid receptor	[amount of glucocorticoid receptors]	0.0	4	1	1	1
79064	1710	tool for sensitive monitoring	[tools for sensitive monitoring]	0.0	4	1	1	1
79065	1710	critical mechanism underlie the diversification	[critical mechanism underlying the diversification]	0.0	5	1	1	1
79066	1710	include alpha- globin	[including alpha- globin]	0.0	3	1	1	1
79067	1710	gene responsive	[genes responsive]	0.0	2	1	1	1
79068	1710	element of the HTLV-I enhancer	[elements of the HTLV-I enhancer]	0.0	5	1	1	1
79069	1710	group ii type	[group II type]	0.0	3	1	1	1
79070	1710	box in the gene sry	[boxes in the gene SRY]	0.0	5	1	1	1
79071	1710	regulation of octamer site	[regulation of octamer sites]	0.0	4	1	1	1
79072	1710	lps mab	[LPS mAbs]	0.0	2	1	1	1
79073	1710	frequent emergence of variant	[frequent emergence of variants]	0.0	4	1	1	1
79074	1710	expression of cd95	[expression of CD95]	0.0	3	1	1	1
79075	1710	c-fo c-jun gene	[c-fos c-jun genes]	0.0	3	1	1	1
79076	1710	absence in lesion	[absence in lesions]	0.0	3	1	1	1
79077	1710	increase indicate the important role	[increase indicating the important role]	0.0	5	1	1	1
79078	1710	microdeletion	[microdeletion]	0.0	1	2	2	1
79079	1710	inhibition by a antiinflammatory alkaloid cepharanthine	[inhibition by an antiinflammatory alkaloid cepharanthine]	0.0	6	1	1	1
79080	1710	acid-induced expression of CD38 antigen	[acid-induced expression of CD38 antigen]	0.0	5	1	1	1
79081	1710	PPARgamma a heterodimer partner	[PPARgamma a heterodimer partner]	0.0	4	1	1	1
79082	1710	mutant stock	[mutant stock]	0.0	2	1	1	1
79083	1710	nuclear factor in macrophage	[nuclear factors in macrophages]	0.0	4	1	1	1
79084	1710	exact defect(s) lead	[exact defect(s) leading]	0.0	3	1	1	1
79085	1710	human gene [Cao	[human gene [Cao]	0.0	3	1	1	1
79086	1710	er peptide	[ER peptides]	0.0	2	1	1	1
79087	1710	basic method for detection	[basic methods for detection]	0.0	4	1	1	1
79088	1710	cell as a model	[cells as a model]	0.0	4	1	1	1
79089	1710	high quality emotional support	[high quality emotional support]	0.0	4	1	1	1
79090	1710	several cell cycle-associated gene	[several cell cycle-associated genes]	0.0	4	1	1	1
79091	1710	autopresentation of peptide	[autopresentation of peptide]	0.0	3	1	1	1
79092	1710	tenfold increase in apoptosis	[tenfold increase in apoptosis]	0.0	4	1	1	1
79093	1710	only level of nuclear nf-kappa b	[only levels of nuclear NF-kappa B]	0.0	6	1	1	1
79094	1710	nuclear relb translocation	[nuclear RelB translocation]	0.0	3	1	1	1
79095	1710	HTLV-I terminal repeat LTR	[HTLV-I terminal repeat LTR]	0.0	4	1	1	1
79096	1710	response to the same signal	[response to the same signal]	0.0	5	1	1	1
79097	1710	role regulate signal by virtue	[role regulating signaling by virtue]	0.0	5	1	1	1
79098	1710	mouse resistant to dosage	[mice resistant to dosages]	0.0	4	1	1	1
79099	1710	cell with ptx	[cells with PTX]	0.0	3	1	1	1
79100	1710	human tumor necrosis factor binding protein-1	[human tumor necrosis factor binding protein-1]	0.0	6	1	1	1
79101	1710	contribution to the capacity	[Contribution to the capacity]	0.0	4	1	1	1
79102	1710	permit translocation	[permitting translocation]	0.0	2	1	1	1
79103	1710	property of killer NK	[properties of killer NK]	0.0	4	1	1	1
79104	1710	rxr-specific ligand	[RXR-specific ligand]	0.0	2	1	1	1
79105	1710	heterodimer follow time in culture	[heterodimers following time in culture]	0.0	5	1	1	1
79106	1710	precise mechanism lead	[precise mechanisms leading]	0.0	3	1	1	1
79107	1710	comparison of DNA	[comparisons of DNA]	0.0	3	1	1	1
79108	1710	hypertension mr status.	[hypertension MR status.]	0.0	3	1	1	1
79109	1710	optimum time of pretreatment	[optimum time of pretreatment]	0.0	4	1	1	1
79110	1710	staining with a panel	[staining with a panel]	0.0	4	1	1	1
79111	1710	icam-1 expression in endothelial cell	[ICAM-1 expression in endothelial cells]	0.0	5	1	1	1
79112	1710	abnormal camp activity	[abnormal cAMP activity]	0.0	3	1	1	1
79113	1710	PML alpha expression in promyelocytic cell	[PML alpha expression in promyelocytic cells]	0.0	6	1	1	1
79114	1710	thus, aberration in the pathway	[Thus, aberrations in the pathway]	0.0	5	1	1	1
79115	1710	suggest a similar role	[suggesting a similar role]	0.0	4	1	1	1
79116	1710	degree of immune suppression	[degree of immune suppression]	0.0	4	1	1	1
79117	1710	monoclonal antibody to BZLF1	[monoclonal antibody to BZLF1]	0.0	4	1	1	1
79118	1710	good transactivator in the presence	[better transactivator in the presence]	0.0	5	1	1	1
79119	1710	50% displacement of estradiol (cb50)	[50% displacement of estradiol (CB50)]	0.0	5	1	1	1
79120	1710	fosb/g0s3	[FOSB/G0S3]	0.0	1	1	1	1
79121	1710	1 gene	[1 gene]	0.0	2	1	1	1
79122	1710	TFE-3	[TFE-3]	0.0	1	1	1	1
79123	1710	differential role on the differentiation	[differential role on the differentiation]	0.0	5	1	1	1
79124	1710	belong to the nuclear factor	[belonging to the nuclear factor]	0.0	5	1	1	1
79125	1710	ongoing study of mouse	[ongoing study of mice]	0.0	4	1	1	1
79126	1710	pp2b	[PP2B]	0.0	1	1	1	1
79127	1710	high-level replication T-tropic primary isolate	[high-level replication T-tropic primary isolate]	0.0	5	1	1	1
79128	1710	oestrogen receptor analysis correlation of method	[Oestrogen receptor analysis correlation of methods]	0.0	6	1	1	1
79129	1710	inducibility on a promoter follow transfection	[inducibility on a promoter following transfection]	0.0	6	1	1	1
79130	1710	direct assessment of the role	[direct assessment of the roles]	0.0	5	1	1	1
79131	1710	genital herpes lesion	[genital herpes lesions]	0.0	3	1	1	1
79132	1710	adult before dst	[adults before DST]	0.0	3	1	1	1
79133	1710	trans relationship between gene expression	[trans relationship between gene expression]	0.0	5	1	1	1
79134	1710	case of tsc	[cases of TSC]	0.0	3	1	1	1
79135	1710	theoretical pathway of regulation	[theoretical pathway of regulation]	0.0	4	1	1	1
79136	1710	ethidium	[ethidium]	0.0	1	1	1	1
79137	1710	tnfrii	[TNFRII]	0.0	1	1	1	1
79138	1710	primary culture of cell	[primary cultures of cells]	0.0	4	1	1	1
79139	1710	complete suppression	[Complete suppression]	0.0	2	1	1	1
79140	1710	initiate signal pathway	[initiating signaling pathways]	0.0	3	1	1	1
79141	1710	level of cell surface molecules,	[levels of cell surface molecules,]	0.0	5	1	1	1
79142	1710	form of STAT-1	[forms of STAT-1]	0.0	3	1	1	1
79143	1710	ppargamma receptor gamma ppargamma expression	[PPARgamma receptor gamma PPARgamma expression]	0.0	5	1	1	1
79144	1710	sequence of pp65 on 10	[sequence of pp65 on 10]	0.0	5	1	1	1
79145	1710	contrast to induction by cytokine	[contrast to induction by cytokines]	0.0	5	1	1	1
79146	1710	peptidyl-prolyl bond	[peptidyl-prolyl bond]	0.0	2	1	1	1
79147	1710	pre-B-cell variant line	[pre-B-cell variant line]	0.0	3	1	1	1
79148	1710	moreover, deletion of nf-kappab site	[Moreover, deletion of NF-kappaB sites]	0.0	5	1	1	1
79149	1710	termination of uterine pregnancy	[termination of uterine pregnancy]	0.0	4	1	1	1
79150	1710	signal in mononuclear phagocyte	[signaling in mononuclear phagocytes]	0.0	4	1	1	1
79151	1710	limiting-dilution analysis	[limiting-dilution analysis]	0.0	2	1	1	1
79152	1710	hiv-1 burden in monocyte	[HIV-1 burden in monocytes]	0.0	4	1	1	1
79153	1710	trans-dominant negative expression vector	[trans-dominant negative expression vectors]	0.0	4	1	1	1
79154	1710	putative functional role	[putative functional role]	0.0	3	1	1	1
79155	1710	patient with acute myeloid leukemia	[patients with acute myeloid leukemia]	0.0	5	1	1	1
79156	1710	IL-6 kappa kappa b motif	[IL-6 kappa kappa B motifs]	0.0	5	1	1	1
79157	1710	d cyclin	[D cyclins]	0.0	2	1	1	1
79158	1710	ca2+ -modulate	[Ca2+ -modulating]	0.0	2	1	1	1
79159	1710	same transactivation ability	[same transactivation ability]	0.0	3	1	1	1
79160	1710	acute exposure to hydrogen peroxide	[acute exposure to hydrogen peroxide]	0.0	5	1	1	1
79161	1710	GRbeta expression vector	[GRbeta expression vector]	0.0	3	1	1	1
79162	1710	generation of molecular isoform	[generation of molecular isoforms]	0.0	4	1	1	1
79163	1710	effect inhibition of growth	[effects inhibition of growth]	0.0	4	1	1	1
79164	1710	t3 sulfate	[T3 sulfate]	0.0	2	1	1	1
79165	1710	EBV antigen one	[EBV antigen one]	0.0	3	1	1	1
79166	1710	rescue of the defect	[rescue of the defect]	0.0	4	1	1	1
79167	1710	exposure to nm vd3 for h	[Exposure to nM VD3 for h]	0.0	6	1	1	1
79168	1710	NK/T	[NK/T]	0.0	1	1	1	1
79169	1710	deregulation of gene	[deregulation of genes]	0.0	3	1	1	1
79170	1710	level of the signalsome component	[levels of the signalsome components]	0.0	5	1	1	1
79171	1710	predict NK activity	[predicting NK activity]	0.0	3	1	1	1
79172	1710	contain full cell cycle	[containing full cell cycle]	0.0	4	1	1	1
79173	1710	consist mainly of p50/p65 complex	[consisting mainly of p50/p65 complexes]	0.0	5	1	1	1
79174	1710	mobility of protein-DNA complex	[mobility of protein-DNA complexes]	0.0	4	1	1	1
79175	1710	contain mut-i kappa b	[containing mut-I kappa B]	0.0	4	2	2	1
79176	1710	mechanism of down-regulation of icam-i	[mechanism of down-regulation of ICAM-I]	0.0	5	1	1	1
79177	1710	different subpopulation t-	[different subpopulations T-]	0.0	3	1	1	1
79178	1710	novel RAR antagonist	[novel RAR antagonist]	0.0	3	1	1	1
79179	1710	Effect of cd45	[Effects of CD45]	0.0	3	1	1	1
79180	1710	number of normal granulocyte	[numbers of normal granulocytes]	0.0	4	1	1	1
79181	1710	use of dtc	[use of DTCs]	0.0	3	1	1	1
79182	1710	delta 5' flank region extend	[delta 5' flanking regions extending]	0.0	5	1	1	1
79183	1710	role of this kinase signal	[roles of this kinase signaling]	0.0	5	1	1	1
79184	1710	evidence a relevant role for NF-kappaB	[evidencing a relevant role for NF-kappaB]	0.0	6	1	1	1
79185	1710	regulate the synthesis	[regulating the synthesis]	0.0	3	1	1	1
79186	1710	primary infection.	[primary infection.]	0.0	2	1	1	1
79187	1710	acid (ra)	[acid (RA)]	0.0	2	1	1	1
79188	1710	exogenous gene in cell	[exogenous genes in cells]	0.0	4	1	1	1
79189	1710	radiation dose of Gy	[radiation dose of Gy]	0.0	4	1	1	1
79190	1710	element consistent with gene expression	[elements consistent with gene expression]	0.0	5	1	1	1
79191	1710	criteria, unbalanced inactivation	[criteria, unbalanced inactivation]	0.0	3	1	1	1
79192	1710	skin fibroblast with DNA	[skin fibroblasts with DNA]	0.0	4	1	1	1
79193	1710	stimulation to inhibition	[stimulation to inhibition]	0.0	3	1	1	1
79194	1710	dna-binding protein in T cell	[DNA-binding proteins in T cells]	0.0	5	1	1	1
79195	1710	gel-mobility	[gel-mobility]	0.0	1	1	1	1
79196	1710	suggest a divergence	[suggesting an divergence]	0.0	3	1	1	1
79197	1710	nineteen healthy woman	[nineteen healthy women]	0.0	3	1	1	1
79198	1710	cell adhesion molecule-1 vcam-1 expression	[cell adhesion molecule-1 VCAM-1 expression]	0.0	5	1	1	1
79199	1710	healthy control obese:	[healthy controls obese:]	0.0	3	1	1	1
79200	1710	CONCLUSION: cytomegalovirus	[CONCLUSION: Cytomegalovirus]	0.0	2	1	1	1
79201	1710	degradation a role in immune senescence	[degradation A role in immune senescence]	0.0	6	1	1	1
79202	1710	property of gene	[property of genes]	0.0	3	1	1	1
79203	1710	effect on degradation	[effect on degradation]	0.0	3	1	1	1
79204	1710	PGG-Glucan a glucose homopolymer	[PGG-Glucan a glucose homopolymer]	0.0	4	1	1	1
79205	1710	biologic inhibitory concentration	[biologic inhibitory concentrations]	0.0	3	1	1	1
79206	1710	kappab-responsive element of repeat	[kappaB-responsive elements of repeats]	0.0	4	1	1	1
79207	1710	about the early event	[about the early events]	0.0	4	1	1	1
79208	1710	(4%) clone from the b cell	[(4%) clones from the B cells]	0.0	6	1	1	1
79209	1710	nuclear factor kB regulatory element	[nuclear factor kB regulatory elements]	0.0	5	1	1	1
79210	1710	tethering factor	[tethering factor]	0.0	2	1	1	1
79211	1710	human cd34+ stem cell	[human CD34+ stem cells]	0.0	4	2	2	1
79212	1710	variety of stat	[variety of Stat]	0.0	3	1	1	1
79213	1710	Conversely, classic hd	[Conversely, classic HD]	0.0	3	1	1	1
79214	1710	recognize a acid epitope	[recognizing a acid epitope]	0.0	4	1	1	1
79215	1710	development of T cell	[development of T cells]	0.0	4	1	1	1
79216	1710	express dq0302 at pH	[expressing DQ0302 at pH]	0.0	4	1	1	1
79217	1710	TCP succinate (200	[TCP succinate (200]	0.0	3	1	1	1
79218	1710	plaque of artery	[plaques of arteries]	0.0	3	1	1	1
79219	1710	zymogen plasma	[zymogen plasma]	0.0	2	1	1	1
79220	1710	Essential role of alveolar macrophage	[Essential role of alveolar macrophages]	0.0	5	1	1	1
79221	1710	different level of motor activity	[different levels of motor activity]	0.0	5	1	1	1
79222	1710	lineage-specific determinant	[lineage-specific determinants]	0.0	2	1	1	1
79223	1710	effect of viral infection	[effect of viral infection]	0.0	4	1	1	1
79224	1710	response to inflammatory stimulus product	[response to inflammatory stimuli products]	0.0	5	1	1	1
79225	1710	myeloid leukemic blast use virus	[myeloid leukemic blasts using virus]	0.0	5	1	1	1
79226	1710	replication of gene	[replication of genes]	0.0	3	1	1	1
79227	1710	A/R challenge,	[A/R challenge,]	0.0	2	1	1	1
79228	1710	increase in human monocyte pdgf(b) mrna	[increase in human monocyte PDGF(B) mRNA]	0.0	6	1	1	1
79229	1710	cd56+, cd11a+, cd13lo, cd15lo,	[CD56+, CD11a+, CD13lo, CD15lo,]	0.0	4	1	1	1
79230	1710	sequence in each	[sequences in each]	0.0	3	1	1	1
79231	1710	p50 nfkappab1	[p50 NFkappaB1]	0.0	2	1	1	1
79232	1710	mouse carry the human irf-1 gene	[mice carrying the human IRF-1 gene]	0.0	6	1	1	1
79233	1710	least two sequence-specific protein	[least two sequence-specific proteins]	0.0	4	1	1	1
79234	1710	(Singh	[(Singh]	0.0	1	1	1	1
79235	1710	form of positive selection expansion)	[forms of positive selection expansion)]	0.0	5	1	1	1
79236	1710	detection in peripheral blood mononuclear cell	[Detection in peripheral blood mononuclear cells]	0.0	6	2	2	1
79237	1710	encompass a important positive element NF-AT-1	[encompassing an important positive element NF-AT-1]	0.0	6	1	1	1
79238	1710	immunodeficiency virus type infection	[immunodeficiency virus type infection]	0.0	4	1	1	1
79239	1710	underlie the activity	[underlying the activity]	0.0	3	1	1	1
79240	1710	signal protein include Vav	[signaling proteins including Vav]	0.0	4	1	1	1
79241	1710	b p65 DNA binding activity	[B p65 DNA binding activity]	0.0	5	1	1	1
79242	1710	peripheral blood a phenomenon	[peripheral blood a phenomenon]	0.0	4	1	1	1
79243	1710	quinone derivative	[quinone derivative]	0.0	2	1	1	1
79244	1710	endothelial cell gssg /gsh	[endothelial cell GSSG /GSH]	0.0	4	1	1	1
79245	1710	level of vascular cell adhesion molecule	[levels of vascular cell adhesion molecule]	0.0	6	1	1	1
79246	1710	change in the pancrea	[changes in the pancreas]	0.0	4	1	1	1
79247	1710	abnormal expression in Hox11 mouse	[abnormal expression in Hox11 mice]	0.0	5	1	1	1
79248	1710	other subpopulation the (dp) CD4	[other subpopulation the (DP) CD4]	0.0	5	1	1	1
79249	1710	expression of major histocompatibility surface protein	[expression of major histocompatibility surface proteins]	0.0	6	1	1	1
79250	1710	encode tissue-specific component	[encoding tissue-specific components]	0.0	3	1	1	1
79251	1710	I aldosterone receptor in mononuclear leucocyte	[I aldosterone receptors in mononuclear leucocytes]	0.0	6	1	1	1
79252	1710	avidity, CD8 contribution	[avidity, CD8 contribution]	0.0	3	1	1	1
79253	1710	NF-kappaB molecule IkappaBalpha	[NF-kappaB molecule IkappaBalpha]	0.0	3	1	1	1
79254	1710	MHC class Ii	[MHC class Ii]	0.0	3	1	1	1
79255	1710	myeloid/natural killer cell leukemia	[myeloid/natural killer cell leukemia]	0.0	4	1	1	1
79256	1710	fibroblast from patient	[fibroblasts from patients]	0.0	3	1	1	1
79257	1710	decrease in cytosolic level	[decrease in cytosolic levels]	0.0	4	1	1	1
79258	1710	promote the resolution of disease	[promoting the resolution of diseases]	0.0	5	1	1	1
79259	1710	mapping of hnf-6	[mapping of HNF-6]	0.0	3	1	1	1
79260	1710	VDR 3'-utr	[VDR 3'-UTR]	0.0	2	1	1	1
79261	1710	inducible ubiquitous nuclear component	[inducible ubiquitous nuclear component]	0.0	4	1	1	1
79262	1710	remission in patient with leukemia	[remission in patients with leukemia]	0.0	5	1	1	1
79263	1710	nucleotide change (with respect	[nucleotide changes (with respect]	0.0	4	1	1	1
79264	1710	different hormone gch	[Different hormones GCH]	0.0	3	1	1	1
79265	1710	MRD lt	[MRD LT]	0.0	2	1	1	1
79266	1710	Recognition of NFATp/AP-1 composite element	[Recognition of NFATp/AP-1 composite elements]	0.0	5	1	1	1
79267	1710	activation of lymphokine gene role	[Activation of lymphokine genes role]	0.0	5	1	1	1
79268	1710	IL3 promoter	[IL3 promoter]	0.0	2	1	1	1
79269	1710	little definite information	[little definite information]	0.0	3	1	1	1
79270	1710	modulate adhesion to matrix component	[modulating adhesion to matrix components]	0.0	5	1	1	1
79271	1710	suppress pathway	[suppressing pathways]	0.0	2	1	1	1
79272	1710	T cell activation at pH	[T cell activation at pH]	0.0	5	1	1	1
79273	1710	inflammatory injury in rat lung	[inflammatory injury in rat lung]	0.0	5	1	1	1
79274	1710	synthesis of two isoform	[synthesis of two isoforms]	0.0	4	1	1	1
79275	1710	little nfat activity	[little NFAT activity]	0.0	3	1	1	1
79276	1710	T/NK subset	[T/NK subsets]	0.0	2	1	1	1
79277	1710	cell from patient with rheumatoid	[cells from patients with rheumatoid]	0.0	5	1	1	1
79278	1710	normal human alveolar macrophage PAM	[Normal human alveolar macrophages PAM]	0.0	5	1	1	1
79279	1710	manipulate T cell response	[manipulating T cell responses]	0.0	4	1	1	1
79280	1710	neonatal respiratory distress syndrome	[neonatal respiratory distress syndrome]	0.0	4	1	1	1
79281	1710	overexpression of activation	[overexpression of activation]	0.0	3	1	1	1
79282	1710	5' terminus of pp52 mrna	[5' terminus of pp52 mRNA]	0.0	5	1	1	1
79283	1710	ikappab-alpha of nf-kappab	[IkappaB-alpha of NF-kappaB]	0.0	3	2	2	1
79284	1710	role activate transcription	[role activating transcription]	0.0	3	1	1	1
79285	1710	direct output	[direct output]	0.0	2	1	1	1
79286	1710	peptide show only cross-reactivity	[peptide showing only cross-reactivity]	0.0	4	1	1	1
79287	1710	activity of ap-1/tpa element	[activity of AP-1/TPA elements]	0.0	4	1	1	1
79288	1710	characteristic of ductal carcinoma	[characteristics of ductal carcinomas]	0.0	4	1	1	1
79289	1710	bl 41 cell	[BL 41 cells]	0.0	3	1	1	1
79290	1710	partitioning into blood cell	[Partitioning into blood cells]	0.0	4	1	1	1
79291	1710	cellular activation event occur	[cellular activation events occurring]	0.0	4	1	1	1
79292	1710	understanding of the effect	[understanding of the effects]	0.0	4	1	1	1
79293	1710	treatment of human leukemia hl-60 cell	[Treatment of human leukemia HL-60 cells]	0.0	6	1	1	1
79294	1710	dermatitis ad	[dermatitis AD]	0.0	2	1	1	1
79295	1710	region between the exon	[region between the exons]	0.0	4	1	1	1
79296	1710	average value from volunteer	[average values from volunteers]	0.0	4	1	1	1
79297	1710	recent study in T cell line	[recent studies in T cell lines]	0.0	6	1	1	1
79298	1710	detectable abnormality	[detectable abnormalities]	0.0	2	1	1	1
79299	1710	hsv-2 vp-16-derived peptide	[HSV-2 VP-16-derived peptide]	0.0	3	1	1	1
79300	1710	suboptimal activation C	[suboptimal activation C]	0.0	3	1	1	1
79301	1710	dominant mode	[dominant mode]	0.0	2	2	2	1
79302	1710	most antigen	[most antigens]	0.0	2	1	1	1
79303	1710	basophilia in leukaemia molecular analysis	[basophilia in leukaemia molecular analysis]	0.0	5	1	1	1
79304	1710	protein kinase c -zeta	[protein kinase C -zeta]	0.0	4	1	1	1
79305	1710	similarity with the v-rel oncogene product	[similarity with the v-rel oncogene product]	0.0	6	1	1	1
79306	1710	characteristic feature of differentiation	[characteristic features of differentiation]	0.0	4	1	1	1
79307	1710	inducible import	[inducible import]	0.0	2	2	2	1
79308	1710	proviral clone with ltr	[proviral clones with LTRs]	0.0	4	1	1	1
79309	1710	human il-10r	[human IL-10R]	0.0	2	1	1	1
79310	1710	staining for nf-kappabp65 than patient	[staining for NF-kappaBp65 than patients]	0.0	5	1	1	1
79311	1710	mm patient cell	[MM patient cells]	0.0	3	1	1	1
79312	1710	peptide 430-444,442A	[peptide 430-444,442A]	0.0	2	1	1	1
79313	1710	S-allyl	[S-allyl]	0.0	1	1	1	1
79314	1710	regulation nf-kappab	[Regulation NF-kappaB]	0.0	2	1	1	1
79315	1710	proviral transcription unit	[proviral transcription unit]	0.0	3	1	1	1
79316	1710	inducible transcriptional activation	[inducible transcriptional activation]	0.0	3	1	1	1
79317	1710	distinguish heterozygous carrier in androgen resistance	[distinguishing heterozygous carriers in androgen resistance]	0.0	6	1	1	1
79318	1710	proliferation in a manner	[proliferation in a manner]	0.0	4	1	1	1
79319	1710	17beta-estradiol E2	[17beta-estradiol E2]	0.0	2	1	1	1
79320	1710	follow 3-day exposure	[following 3-day exposures]	0.0	3	1	1	1
79321	1710	property of NF-kappa b	[properties of NF-kappa B]	0.0	4	1	1	1
79322	1710	map kinase kinase ERK	[MAP kinase kinase ERK]	0.0	4	1	1	1
79323	1710	phenomenon of resistance in disorder	[phenomenon of resistance in disorder]	0.0	5	1	1	1
79324	1710	antigen-driven expansion) (by abortive stimulation lead	[antigen-driven expansion) (by abortive stimulation leading]	0.0	6	1	1	1
79325	1710	translocation of hiv-1 transactivator	[translocation of HIV-1 transactivator]	0.0	4	1	1	1
79326	1710	many change in the form	[many changes in the form]	0.0	5	1	1	1
79327	1710	natural ligand to receptor	[natural ligands to receptors]	0.0	4	1	1	1
79328	1710	related receptor in leukocyte	[related receptors in leukocytes]	0.0	4	1	1	1
79329	1710	potent interleukin	[potent interleukin]	0.0	2	1	1	1
79330	1710	glycemic control in diabete mellitus patient	[glycemic control in diabetes mellitus patients]	0.0	6	1	1	1
79331	1710	binding of 135(oh)2d3	[binding of 1,25(OH)2D3]	0.0	3	1	1	1
79332	1710	promoter ISG15 LTR	[promoter ISG15 LTR]	0.0	3	1	1	1
79333	1710	family of receptor	[families of receptors]	0.0	3	1	1	1
79334	1710	complex mechanism	[complex mechanisms]	0.0	2	1	1	1
79335	1710	behaviour of Albuminemia platelet factor	[behaviour of Albuminemia Platelet Factor]	0.0	5	1	1	1
79336	1710	acid change	[acid change]	0.0	2	1	1	1
79337	1710	lack endogenous receptor.	[lacking endogenous receptor.]	0.0	3	1	1	1
79338	1710	level t-cell receptor (tcr)-zeta in 4	[levels T-cell receptor (TCR)-zeta in 4]	0.0	6	1	1	1
79339	1710	manner as class gene	[manner as class genes]	0.0	4	1	1	1
79340	1710	genome homologue	[genome homologues]	0.0	2	1	1	1
79341	1710	organisation exon	[organisation exons]	0.0	2	1	1	1
79342	1710	activity of environmental estrogen	[activities of environmental estrogens]	0.0	4	1	1	1
79343	1710	ra-induced down-modulation	[RA-induced down-modulation]	0.0	2	1	1	1
79344	1710	il-2 function	[IL-2 functions]	0.0	2	1	1	1
79345	1710	early apoptotic event	[early apoptotic events]	0.0	3	1	1	1
79346	1710	case of chronic lymphocytic leukemia	[cases of chronic lymphocytic leukemia]	0.0	5	1	1	1
79347	1710	death domain another -contain member	[death domain Another -containing member]	0.0	5	1	1	1
79348	1710	constitutively active form of calcineurin	[constitutively active form of calcineurin]	0.0	5	1	1	1
79349	1710	uptake with advanced chronic failure	[uptake with advanced chronic failure]	0.0	5	1	1	1
79350	1710	analysis viral latency	[analysis viral latency]	0.0	3	1	1	1
79351	1710	form in vitro.	[form in vitro.]	0.0	3	1	1	1
79352	1710	cell hybrid panel	[cell hybrid panels]	0.0	3	1	1	1
79353	1710	suboptimal activation of protein kinase	[suboptimal activation of protein kinase]	0.0	5	1	1	1
79354	1710	patient receive il-2 immunotherapy	[patients receiving IL-2 immunotherapy]	0.0	4	1	1	1
79355	1710	interestingly, early treatment hpc with alpha-pml	[Interestingly, early treatment HPCs with alpha-PML]	0.0	6	1	1	1
79356	1710	clinical outcome.	[clinical outcome.]	0.0	2	1	1	1
79357	1710	active, virus	[active, virus]	0.0	2	1	1	1
79358	1710	abnormal receptor on lymphocyte	[abnormal receptors on lymphocytes]	0.0	4	1	1	1
79359	1710	embryonal carcinoma cell line	[embryonal carcinoma cell line]	0.0	4	1	1	1
79360	1710	control line	[control lines]	0.0	2	1	1	1
79361	1710	stat1 protein start	[STAT1 protein starting]	0.0	3	1	1	1
79362	1710	expression of a hiv-1 terminal repeat	[expression of a HIV-1 terminal repeat]	0.0	6	1	1	1
79363	1710	effect of alpha-tocopherol alpha-tcp	[effect of alpha-tocopherol alpha-tcp]	0.0	4	1	1	1
79364	1710	many 1 alpha,25-(OH)2D3 analog	[many 1 alpha,25-(OH)2D3 analogs]	0.0	4	1	1	1
79365	1710	inducer of drip coactivator complex binding	[inducers of DRIP coactivator complex binding]	0.0	6	1	1	1
79366	1710	t-cell leukemia virus type i	[T-cell leukemia virus type I]	0.0	5	1	1	1
79367	1710	weakly with Jak3	[weakly with Jak3]	0.0	3	1	1	1
79368	1710	anti-cancer drug	[anti-cancer drug]	0.0	2	1	1	1
79369	1710	tnf-alpha protein comparable	[TNF-alpha protein comparable]	0.0	3	1	1	1
79370	1710	t-antigen	[T-antigen]	0.0	1	3	3	1
79371	1710	relationship between the two variants,	[relationship between the two variants,]	0.0	5	1	1	1
79372	1710	many more change	[many more changes]	0.0	3	1	1	1
79373	1710	Study on the activity	[Studies on the activity]	0.0	4	1	1	1
79374	1710	furthermore, 1,25-dihydroxyvitamin D3 a distinct agent	[Furthermore, 1,25-dihydroxyvitamin D3 a distinct agent]	0.0	6	1	1	1
79375	1710	thus, type 2	[Thus, type 2]	0.0	3	1	1	1
79376	1710	stage cell in the monocytic	[stage cells in the monocytic]	0.0	5	1	1	1
79377	1710	inhibition by cell	[Inhibition by cells]	0.0	3	1	1	1
79378	1710	cell express v-abl kinase activity	[cells expressing v-abl kinase activity]	0.0	5	1	1	1
79379	1710	depressive disorder MDD in adolescent	[depressive disorder MDD in adolescents]	0.0	5	1	1	1
79380	1710	intragenic deletion of TSG101 the homolog	[Intragenic deletions of TSG101 the homolog]	0.0	6	1	1	1
79381	1710	single cell assay	[Single cell assay]	0.0	3	1	1	1
79382	1710	treatment of pbmc	[Treatment of PBMC]	0.0	3	1	1	1
79383	1710	Functional expression	[Functional expression]	0.0	2	1	1	1
79384	1710	endothelial activation a vascular mechanism	[endothelial activation A vascular mechanism]	0.0	5	1	1	1
79385	1710	T cell activator protein-1	[T cells activator protein-1]	0.0	4	1	1	1
79386	1710	cell distribution.	[cell distribution.]	0.0	2	1	1	1
79387	1710	model for study in human	[model for studies in humans]	0.0	5	1	1	1
79388	1710	moreover, TCR phosphorylation	[Moreover, TCR phosphorylation]	0.0	3	1	1	1
79389	1710	activation of the latent provirus	[activation of the latent provirus]	0.0	5	1	1	1
79390	1710	radiation dose of 4,	[radiation doses of 4,]	0.0	4	1	1	1
79391	1710	response to ldl	[responses to LDL]	0.0	3	1	1	1
79392	1710	follow stimulation with agonist as lipopolysaccharide	[Following stimulation with agonists as lipopolysaccharide]	0.0	6	1	1	1
79393	1710	degradation machinery	[degradation machinery]	0.0	2	1	1	1
79394	1710	rdna with identity the catalytic sub-unit	[cDNAs with identity the catalytic sub-unit]	0.0	6	1	1	1
79395	1710	double-stranded RNA-dependent protein kinase	[double-stranded RNA-dependent protein kinase]	0.0	4	2	2	1
79396	1710	agent propidium iodide	[agents propidium iodide]	0.0	3	1	1	1
79397	1710	cis-activation of promoter	[cis-activation of promoter]	0.0	3	1	1	1
79398	1710	immune response in adult drosophila	[immune response in adult Drosophila]	0.0	5	1	1	1
79399	1710	long-last activation	[long-lasting activation]	0.0	2	1	1	1
79400	1710	Maximal accumulation of c-fo	[Maximal accumulation of c-fos]	0.0	4	1	1	1
79401	1710	induction by TAL1	[induction by TAL1]	0.0	3	1	1	1
79402	1710	leukocyte HML	[leukocytes HML]	0.0	2	3	3	1
79403	1710	block element alpha/delta	[blocking element alpha/delta]	0.0	3	1	1	1
79404	1710	Exclusive expression	[Exclusive expression]	0.0	2	1	1	1
79405	1710	high level of heat alkaline phosphatase	[high levels of heat alkaline phosphatase]	0.0	6	1	1	1
79406	1710	PMA u1 cell	[PMA U1 cells]	0.0	3	1	1	1
79407	1710	exonic splice site	[exonic splice site]	0.0	3	1	1	1
79408	1710	rapidak non-genomic effect	[rapid, non-genomic effects]	0.0	3	1	1	1
79409	1710	IL4R complex component	[IL4R complex components]	0.0	3	1	1	1
79410	1710	present with renal salt loss lead	[presenting with renal salt loss leading]	0.0	6	1	1	1
79411	1710	different aspect of tissue development	[different aspects of tissue development]	0.0	5	1	1	1
79412	1710	(i) level	[(i) levels]	0.0	2	1	1	1
79413	1710	important regulator of hematopoiesis	[important regulators of hematopoiesis]	0.0	4	1	1	1
79414	1710	propenoic acid	[propenoic acid]	0.0	2	1	1	1
79415	1710	time-dependent binding antibody	[time-dependent binding antibodies]	0.0	3	1	1	1
79416	1710	Effect of aldosterone on sodium	[Effects of aldosterone on sodium]	0.0	5	1	1	1
79417	1710	direct the action towards the cell	[directing the action towards the cells]	0.0	6	1	1	1
79418	1710	loss (il-6) receptor	[loss (IL-6) receptor]	0.0	3	1	1	1
79419	1710	beta-phorbol 12-myristate 13-acetate PMA addition	[beta-phorbol 12-myristate 13-acetate PMA addition]	0.0	5	1	1	1
79420	1710	e47 individually	[E47 individually]	0.0	2	1	1	1
79421	1710	oxidation with glucose oxidase	[oxidation with glucose oxidase]	0.0	4	1	1	1
79422	1710	fibroblast growth factor bFGF	[fibroblast growth factor bFGF]	0.0	4	1	1	1
79423	1710	source of interferon gamma	[source of interferon gamma]	0.0	4	1	1	1
79424	1710	abnormal adherence	[abnormal adherence]	0.0	2	1	1	1
79425	1710	umbilical vein segment	[umbilical vein segments]	0.0	3	1	1	1
79426	1710	transcription of a potent cytokine	[transcription of a potent cytokine]	0.0	5	1	1	1
79427	1710	chicken nf-m	[chicken NF-M]	0.0	2	1	1	1
79428	1710	epithelial cell interaction	[epithelial cell interaction]	0.0	3	1	1	1
79429	1710	leukocyte adhesion molecule e-selectin	[leukocyte adhesion molecules E-selectin]	0.0	4	1	1	1
79430	1710	characterization of novel IL-2 transcriptional inhibitor	[characterization of novel IL-2 transcriptional inhibitors]	0.0	6	1	1	1
79431	1710	effector protein	[effector proteins]	0.0	2	1	1	1
79432	1710	(0/3) carrier (0/33)	[(0/3) carriers (0/33)]	0.0	3	1	1	1
79433	1710	T-cell leukemia	[T-cell leukemia]	0.0	2	1	1	1
79434	1710	1 aml m2	[1 AML M2]	0.0	3	1	1	1
79435	1710	1 aml m4	[1 AML M4]	0.0	3	1	1	1
79436	1710	fibroblast phosphatidylinositol 3-kinase	[fibroblasts Phosphatidylinositol 3-kinase]	0.0	3	1	1	1
79437	1710	drosophila melanogaster sex comb	[Drosophila melanogaster sex combs]	0.0	4	1	1	1
79438	1710	Ca2+ medium	[Ca2+ medium]	0.0	2	1	1	1
79439	1710	mucosa-associated tissue lymphoma	[mucosa-associated tissue lymphoma]	0.0	3	1	1	1
79440	1710	over-representation of t2	[over-representation of T2]	0.0	3	1	1	1
79441	1710	variable region of mAb	[variable regions of mAb]	0.0	4	1	1	1
79442	1710	inhibition CD40 up-regulation	[Inhibition CD40 up-regulation]	0.0	3	1	1	1
79443	1710	constitutive MHC class gene activation	[constitutive MHC class gene activation]	0.0	5	1	1	1
79444	1710	e2f DNA	[E2F DNA]	0.0	2	1	1	1
79445	1710	[mechanism of action	[[Mechanism of action]	0.0	3	1	1	1
79446	1710	zinc finger protein binding site	[zinc finger protein binding site]	0.0	5	1	1	1
79447	1710	tip in jurkat-t cell	[Tip in Jurkat-T cells]	0.0	4	1	1	1
79448	1710	instillation of phosphonate-containing liposome	[instillation of phosphonate-containing liposomes]	0.0	4	1	1	1
79449	1710	promote the translocation	[promoting the translocation]	0.0	3	1	1	1
79450	1710	Effect of stress lead	[Effects of stress leading]	0.0	4	1	1	1
79451	1710	two gr abnormalities:	[two GR abnormalities:]	0.0	3	1	1	1
79452	1710	nonselective RAR ligand	[nonselective RAR ligands]	0.0	3	1	1	1
79453	1710	dose-dependent inhibition of b activation	[dose-dependent inhibition of B activation]	0.0	5	1	1	1
79454	1710	Acquisition	[Acquisition]	0.0	1	2	2	1
79455	1710	circulate human lymphocyte thyroidism	[circulating human lymphocytes thyroidism]	0.0	4	1	1	1
79456	1710	potentially important regulator	[potentially important regulator]	0.0	3	1	1	1
79457	1710	adenocarcinoma monoclonal antibody	[adenocarcinoma monoclonal antibody]	0.0	3	1	1	1
79458	1710	alpha-helical segment	[alpha-helical segments]	0.0	2	1	1	1
79459	1710	ig cross-linking	[Ig cross-linking]	0.0	2	1	1	1
79460	1710	gsh depletion	[GSH depletion]	0.0	2	1	1	1
79461	1710	mixture, p50 associate	[mixture, p50 associates]	0.0	3	1	1	1
79462	1710	pore	[pore]	0.0	1	2	2	1
79463	1710	8, histiocytoma rhabdomyosarcoma	[8, histiocytoma rhabdomyosarcoma]	0.0	3	1	1	1
79464	1710	comparison group of subject	[comparison group of subjects]	0.0	4	1	1	1
79465	1710	ventilatory strategy	[ventilatory strategies]	0.0	2	1	1	1
79466	1710	conclusion rate-limiting	[conclusion rate-limiting]	0.0	2	1	1	1
79467	1710	three region of the promoter UAS1	[three regions of the promoter UAS1]	0.0	6	1	1	1
79468	1710	grow family	[growing family]	0.0	2	1	1	1
79469	1710	calcineurin responsiveness	[calcineurin responsiveness]	0.0	2	1	1	1
79470	1710	follow cd19 cross-linking	[following CD19 cross-linking]	0.0	3	1	1	1
79471	1710	cytokine production by monocyte	[cytokine production by monocytes]	0.0	4	1	1	1
79472	1710	e1a sequence in the epithelium	[E1a sequences in the epithelium]	0.0	5	1	1	1
79473	1710	cell line bf24	[cell line BF24]	0.0	3	1	1	1
79474	1710	messenger in the induction	[messengers in the induction]	0.0	4	1	1	1
79475	1710	tyrosine motif include Y440	[tyrosine motif including Y440]	0.0	4	1	1	1
79476	1710	accounting for the requirement	[accounting for the requirements]	0.0	4	1	1	1
79477	1710	response pathway	[response pathways]	0.0	2	1	1	1
79478	1710	MDHM induction	[MDHM induction]	0.0	2	1	1	1
79479	1710	nb4 cell for differentiation	[NB4 cells for differentiation]	0.0	4	1	1	1
79480	1710	heterodimeric binding complex	[heterodimeric binding complex]	0.0	3	1	1	1
79481	1710	EBNA2 induction	[EBNA2 induction]	0.0	2	1	1	1
79482	1710	deletion with "stem cell" disorder	[deletions with "stem cell" disorders]	0.0	5	1	1	1
79483	1710	scm-1alpha	[SCM-1alpha]	0.0	1	1	1	1
79484	1710	cell type-specific complex	[cell type-specific complexes]	0.0	3	1	1	1
79485	1710	key cell cycle regulator	[key cell cycle regulators]	0.0	4	1	1	1
79486	1710	post	[Post]	0.0	1	1	1	1
79487	1710	use deoxyribonuclease dnase	[using deoxyribonuclease DNase]	0.0	3	1	1	1
79488	1710	only through the effect phorbol	[only through the effect phorbol]	0.0	5	1	1	1
79489	1710	inhibition of hiv infection	[inhibition of HIV infection]	0.0	4	1	1	1
79490	1710	corresponding to a increase	[corresponding to a increase]	0.0	4	1	1	1
79491	1710	sh2 domain-contain leukocyte protein	[SH2 domain-containing leukocyte protein]	0.0	4	1	1	1
79492	1710	t-cell-specific transcriptional activator	[T-cell-specific transcriptional activator]	0.0	3	1	1	1
79493	1710	knowledge of the signal cascade	[knowledge of the signaling cascade]	0.0	5	1	1	1
79494	1710	other a target,	[other a target,]	0.0	3	1	1	1
79495	1710	11+/cd4+ T lymphocyte	[11+/CD4+ T lymphocytes]	0.0	3	1	1	1
79496	1710	normal beta-cell function	[normal beta-cell function]	0.0	3	1	1	1
79497	1710	protein distinct	[proteins distinct]	0.0	2	1	1	1
79498	1710	active p50/p65 heterodimer	[active p50/p65 heterodimers]	0.0	3	1	1	1
79499	1710	oxidant stress lead to transendothelial migration	[oxidant stress leading to transendothelial migration]	0.0	6	1	1	1
79500	1710	alpha -globin promoter activity	[alpha -globin promoter activity]	0.0	4	1	1	1
79501	1710	the/thf n: alpha thf/thf n:	[THE/THF N: alpha THF/THF N:]	0.0	5	1	1	1
79502	1710	encode interleukin-2 a cytokine facilitate progression	[encoding interleukin-2 a cytokine facilitating progression]	0.0	6	1	1	1
79503	1710	target of regulatory signal	[target of regulatory signals]	0.0	4	1	1	1
79504	1710	protein kinase tyrosine phosphatase HePTP	[protein kinase tyrosine phosphatase HePTP]	0.0	5	1	1	1
79505	1710	encode the histone deacetylase catalytic subunit	[encoding the histone deacetylase catalytic subunit]	0.0	6	1	1	1
79506	1710	intrinsic apoptosis	[intrinsic apoptosis]	0.0	2	1	1	1
79507	1710	child aged 6 year with nephropathy	[children aged 6 years with nephropathies]	0.0	6	1	1	1
79508	1710	coactivator hbob1	[coactivator hBob1]	0.0	2	1	1	1
79509	1710	several intracellular signal protein	[Several intracellular signaling proteins]	0.0	4	1	1	1
79510	1710	glucocorticoid receptor transcription	[glucocorticoid receptor transcription]	0.0	3	1	1	1
79511	1710	interfere with event	[interfering with events]	0.0	3	1	1	1
79512	1710	dendritic-like cell in response	[dendritic-like cells in response]	0.0	4	1	1	1
79513	1710	function of AP-1 complex	[function of AP-1 complexes]	0.0	4	1	1	1
79514	1710	exclusion of NFAT4	[exclusion of NFAT4]	0.0	3	1	1	1
79515	1710	modification toward reduction	[modification toward reduction]	0.0	3	1	1	1
79516	1710	induction of interleukin-8 gene expression	[induction of interleukin-8 gene expression]	0.0	5	1	1	1
79517	1710	IL-2R expression	[IL-2R expression]	0.0	2	1	1	1
79518	1710	degree anti-CD3 interleukin-2 secretion	[degrees anti-CD3 interleukin-2 secretion]	0.0	4	1	1	1
79519	1710	xpb helicase	[XPB helicase]	0.0	2	1	1	1
79520	1710	active vitamin D3 metabolite	[active vitamin D3 metabolite]	0.0	4	1	1	1
79521	1710	erythroid nuclear protein	[erythroid nuclear proteins]	0.0	3	1	1	1
79522	1710	three protein of mass	[three proteins of mass]	0.0	4	1	1	1
79523	1710	(12/12 tuberculosis patient	[(12/12 tuberculosis patients]	0.0	3	1	1	1
79524	1710	receptor n-terminal domain	[receptor N-terminal domain]	0.0	3	1	1	1
79525	1710	Ets bind motif	[Ets binding motifs]	0.0	3	1	1	1
79526	1710	active nfat-like element	[active NFAT-like elements]	0.0	3	1	1	1
79527	1710	regulate the stringency	[regulating the stringency]	0.0	3	1	1	1
79528	1710	p49(100) DNA binding	[p49(100) DNA binding]	0.0	3	1	1	1
79529	1710	electrophoretic mobility kd)	[electrophoretic mobility kD)]	0.0	3	1	1	1
79530	1710	option alter the th1/th2 balance	[options altering the Th1/Th2 balance]	0.0	5	1	1	1
79531	1710	activation in vitro	[activation in vitro]	0.0	3	2	2	1
79532	1710	absence of challenge	[absence of challenge]	0.0	3	1	1	1
79533	1710	classic model	[classic models]	0.0	2	1	1	1
79534	1710	local estrogen metabolism	[local estrogen metabolism]	0.0	3	1	1	1
79535	1710	recent advance in understanding	[recent advances in understanding]	0.0	4	1	1	1
79536	1710	saturable capacity	[saturable capacity]	0.0	2	1	1	1
79537	1710	5'-most	[5'-most]	0.0	1	1	1	1
79538	1710	human immunodeficiency virus type provirus	[human immunodeficiency virus type provirus]	0.0	5	1	1	1
79539	1710	overlap palindrome	[overlapping palindromes]	0.0	2	1	1	1
79540	1710	nf-e2 ap-1	[NF-E2 AP-1]	0.0	2	1	1	1
79541	1710	iodine therapy	[iodine therapy]	0.0	2	1	1	1
79542	1710	8% dead cell	[8% dead cells]	0.0	3	1	1	1
79543	1710	throughput screen	[throughput screening]	0.0	2	1	1	1
79544	1710	major determinant of expression	[major determinant of expression]	0.0	4	1	1	1
79545	1710	expression of exogenous gene	[expression of exogenous genes]	0.0	4	1	1	1
79546	1710	domain of erythroid-specific chromatin structure	[domains of erythroid-specific chromatin structure]	0.0	5	1	1	1
79547	1710	"instability" motif attta	["instability" motif ATTTA]	0.0	3	1	1	1
79548	1710	partial disomy of sequence	[partial disomy of sequences]	0.0	4	1	1	1
79549	1710	early arrest	[early arrest]	0.0	2	1	1	1
79550	1710	translocation of NF-ATp a member	[translocation of NF-ATp a member]	0.0	5	1	1	1
79551	1710	syndromee	[syndrome.]	0.0	1	1	1	1
79552	1710	blood DC	[blood DC]	0.0	2	1	1	1
79553	1710	il-1ra mrna	[IL-1ra mRNA]	0.0	2	1	1	1
79554	1710	convert signal into biochemical event	[converting signals into biochemical events]	0.0	5	1	1	1
79555	1710	activation role of nuclear factor-DNA complex	[activation role of nuclear factor-DNA complexes]	0.0	6	1	1	1
79556	1710	influence of exposure	[influence of exposure]	0.0	3	1	1	1
79557	1710	stimulation of huvec	[Stimulation of HUVEC]	0.0	3	1	1	1
79558	1710	adenovirus vector	[adenovirus vectors]	0.0	2	1	1	1
79559	1710	clonal deletion of self-reactive T cell	[clonal deletion of self-reactive T cells]	0.0	6	1	1	1
79560	1710	analysis of close to 600 gene	[analysis of close to 600 genes]	0.0	6	1	1	1
79561	1710	specific translocation into the compartment	[specific translocation into the compartment]	0.0	5	1	1	1
79562	1710	late T Lymphocytes-1	[Late T Lymphocytes-1]	0.0	3	1	1	1
79563	1710	important inhibitor	[important inhibitor]	0.0	2	1	1	1
79564	1710	combine dexamethasone	[combining dexamethasone]	0.0	2	1	1	1
79565	1710	growth resistance to stress	[growth resistance to stress]	0.0	4	1	1	1
79566	1710	tissue-specific promoter region	[tissue-specific promoter region]	0.0	3	1	1	1
79567	1710	main mediator like IL	[main mediators like IL]	0.0	4	1	1	1
79568	1710	dose of 100 microgram	[dose of 100 micrograms]	0.0	4	1	1	1
79569	1710	use decrease	[using decrease]	0.0	2	1	1	1
79570	1710	long follow lps stimulation	[longer following LPS stimulation]	0.0	4	1	1	1
79571	1710	(940-984) region	[(940-984) region]	0.0	2	1	1	1
79572	1710	histocompatibility complex class molecule	[histocompatibility complex class molecules]	0.0	4	1	1	1
79573	1710	complex of m(r)	[complex of M(r)]	0.0	3	1	1	1
79574	1710	immunohistochemical staining with a small panel	[immunohistochemical staining with a small panel]	0.0	6	1	1	1
79575	1710	tropical paraparesis tsp	[tropical paraparesis TSP]	0.0	3	1	1	1
79576	1710	transcription factor factor-kappaB in monocyte	[transcription factor factor-kappaB in monocytes]	0.0	5	1	1	1
79577	1710	dna-binding activity of B-cell extract	[DNA-binding activity of B-cell extracts]	0.0	5	1	1	1
79578	1710	human alveolar macrophage PAM	[human alveolar macrophages PAM]	0.0	4	1	1	1
79579	1710	transcriptional proteins,	[transcriptional proteins,]	0.0	2	1	1	1
79580	1710	construction	[Construction]	0.0	1	1	1	1
79581	1710	patient with the syndrome	[patients with the syndrome]	0.0	4	1	1	1
79582	1710	proinflammatory regulator of the response	[proinflammatory regulators of the response]	0.0	5	1	1	1
79583	1710	collagenase induction	[collagenase induction]	0.0	2	1	1	1
79584	1710	block in appearance	[block in appearance]	0.0	3	1	1	1
79585	1710	role in inducible tnf-alpha expression	[role in inducible TNF-alpha expression]	0.0	5	1	1	1
79586	1710	granulopoiesis die by 8	[granulopoiesis dying by 8]	0.0	4	1	1	1
79587	1710	transfusion incompatibility	[transfusion incompatibility]	0.0	2	1	1	1
79588	1710	critical role induction of tnf-alpha	[critical role induction of TNF-alpha]	0.0	5	1	1	1
79589	1710	chromosomal copy	[chromosomal copy]	0.0	2	1	1	1
79590	1710	undetectable level in brain	[undetectable levels in brain]	0.0	4	1	1	1
79591	1710	SCID-HU-	[SCID-HU-]	0.0	1	1	1	1
79592	1710	cyclosporin factor-AT response element	[cyclosporin factor-AT response element]	0.0	4	1	1	1
79593	1710	cytokine gene specificity	[cytokine gene specificity]	0.0	3	1	1	1
79594	1710	notion multifactorial,	[notion multifactorial,]	0.0	2	1	1	1
79595	1710	saf-like transcription factor	[SAF-like transcription factor]	0.0	3	1	1	1
79596	1710	severe syndrome	[severe syndrome]	0.0	2	1	1	1
79597	1710	two different x-inactivation pattern	[two different X-inactivation patterns]	0.0	4	1	1	1
79598	1710	high concentration of the epitope	[high concentrations of the epitope]	0.0	5	1	1	1
79599	1710	22% probability	[22% probability]	0.0	2	1	1	1
79600	1710	thereby allow translocation into the nucleus	[thereby allowing translocation into the nucleus]	0.0	6	1	1	1
79601	1710	signal on b cell	[signaling on B cells]	0.0	4	1	1	1
79602	1710	secretion the product	[Secretion the product]	0.0	3	1	1	1
79603	1710	traditional medicine	[traditional medicine]	0.0	2	1	1	1
79604	1710	correlation to the expression	[correlation to the expression]	0.0	4	1	1	1
79605	1710	distal factor proximal NF-AT	[distal factor proximal NF-AT]	0.0	4	1	1	1
79606	1710	human il-2re	[human IL-2rE]	0.0	2	1	1	1
79607	1710	expression of the Ca2+ -independent isoform	[expression of the Ca2+ -independent isoforms]	0.0	6	1	1	1
79608	1710	hematopoietic cell line absent	[hematopoietic cell lines absent]	0.0	4	1	1	1
79609	1710	consecutive series	[consecutive series]	0.0	2	1	1	1
79610	1710	usefulness for the generation	[usefulness for the generation]	0.0	4	1	1	1
79611	1710	two domain act	[two domains acting]	0.0	3	1	1	1
79612	1710	normal pml	[normal pml]	0.0	2	1	1	1
79613	1710	breast tumor lymphocyte of peptide	[breast tumor lymphocytes of peptides]	0.0	5	1	1	1
79614	1710	functionally important ebf	[functionally important EBF]	0.0	3	1	1	1
79615	1710	overrepresentation of type	[overrepresentation of types]	0.0	3	1	1	1
79616	1710	use anti- tf antibody	[using anti- TF antibody]	0.0	4	1	1	1
79617	1710	tissue-infiltrating macrophage	[tissue-infiltrating macrophages]	0.0	2	1	1	1
79618	1710	role of the cell	[role of the cell]	0.0	4	1	1	1
79619	1710	early gene after kind	[early genes after kinds]	0.0	4	1	1	1
79620	1710	effect on hiv infection	[effects on HIV infection]	0.0	4	1	1	1
79621	1710	ikk complex protein transcription,	[IKK complex protein transcription,]	0.0	4	1	1	1
79622	1710	syk protein tyrosine kinase SIT	[syk protein tyrosine kinases SIT]	0.0	5	1	1	1
79623	1710	T-helper th0	[T-helper Th0]	0.0	2	1	1	1
79624	1710	contrast, nfat activation	[contrast, NFAT activation]	0.0	3	1	1	1
79625	1710	regulation switch to ige	[regulation switching to IgE]	0.0	4	1	1	1
79626	1710	expression for the protein	[Expression for the proteins]	0.0	4	1	1	1
79627	1710	peripheral human monocyte	[peripheral human monocytes]	0.0	3	1	1	1
79628	1710	cd3epsilon transgenic mouse line	[CD3epsilon transgenic mouse lines]	0.0	4	1	1	1
79629	1710	trans-activator tax	[trans-activator Tax]	0.0	2	1	1	1
79630	1710	effect of acetate PMA	[effect of acetate PMA]	0.0	4	1	1	1
79631	1710	high proportion of responder	[higher proportions of responders]	0.0	4	1	1	1
79632	1710	action blockade of primitive progenitor proliferation	[action blockade of primitive progenitor proliferation]	0.0	6	1	1	1
79633	1710	replication competence	[replication competence]	0.0	2	1	1	1
79634	1710	specificity of a response	[specificity of an response]	0.0	4	1	1	1
79635	1710	hepatic l-pk isozyme	[hepatic L-PK isozymes]	0.0	3	1	1	1
79636	1710	means understand the role	[means understanding the role]	0.0	4	1	1	1
79637	1710	significant inactivation inconsistent with the mechanism	[significant inactivation inconsistent with the mechanism]	0.0	6	1	1	1
79638	1710	action of acid on embryonic/fetal hematopoiesis	[action of acid on embryonic/fetal hematopoiesis]	0.0	6	1	1	1
79639	1710	ach functional molecular clone	[ACH functional molecular clone]	0.0	4	1	1	1
79640	1710	tcr beta clonotype	[TCR beta clonotypes]	0.0	3	1	1	1
79641	1710	12 rdna HZF	[12 cDNAs HZF]	0.0	3	1	1	1
79642	1710	binding activity of AP-1	[binding activities of AP-1]	0.0	4	1	1	1
79643	1710	clearly high translocation of b	[clearly higher translocation of B]	0.0	5	1	1	1
79644	1710	ligand monocyte gene expression	[ligands monocyte gene expression]	0.0	4	1	1	1
79645	1710	expression of the igh gene	[expression of the IgH gene]	0.0	5	1	1	1
79646	1710	late promoter-reporter fusion	[late promoter-reporter fusions]	0.0	3	1	1	1
79647	1710	na+/h(+)-exchanger	[Na+/H(+)-exchanger]	0.0	1	1	1	1
79648	1710	receptor site capable	[receptor sites capable]	0.0	3	1	1	1
79649	1710	infection of intestine	[infection of intestine]	0.0	3	1	1	1
79650	1710	reticulum ser	[reticulum SER]	0.0	2	1	1	1
79651	1710	contrast, roll	[contrast, rolling]	0.0	2	1	1	1
79652	1710	leucine zipper (bzip)	[leucine zipper (bZIP)]	0.0	3	1	1	1
79653	1710	immature mature T cell	[immature mature T cells]	0.0	4	1	1	1
79654	1710	adherence/contact	[adherence/contact]	0.0	1	1	1	1
79655	1710	stimulation of CD40 on melanoma	[Stimulation of CD40 on melanomas]	0.0	5	1	1	1
79656	1710	23 clearly positive cells, respectively),	[23 clearly positive cells, respectively),]	0.0	5	1	1	1
79657	1710	patient with fulminant hepatitis	[patients with fulminant hepatitis]	0.0	4	1	1	1
79658	1710	suggest a joint requirement for function	[suggesting a joint requirement for function]	0.0	6	1	1	1
79659	1710	3 h with mAb	[3 h with mAb]	0.0	4	1	1	1
79660	1710	amount of il-8 additionally, costimulation	[amounts of IL-8 additionally, costimulation]	0.0	5	1	1	1
79661	1710	receptor (gr) expression by ligand	[receptor (GR) expression by ligand]	0.0	5	1	1	1
79662	1710	major protein of kD	[major protein of kD]	0.0	4	1	1	1
79663	1710	binding of aldosterone to plasma membrane	[Binding of aldosterone to plasma membranes]	0.0	6	1	1	1
79664	1710	increase with a increase	[increase with a increase]	0.0	4	1	1	1
79665	1710	similar protein sequence	[similar protein sequences]	0.0	3	1	1	1
79666	1710	multimer of kappa 1-kappa	[multimers of kappa 1-kappa]	0.0	4	1	1	1
79667	1710	include corticosteroid	[including corticosteroids]	0.0	2	1	1	1
79668	1710	membrane hyperpolarization in b cell	[membrane hyperpolarization in B cells]	0.0	5	1	1	1
79669	1710	various v-atpase subunit	[various V-ATPase subunits]	0.0	3	1	1	1
79670	1710	infiltration in breast tumor	[infiltration in breast tumor]	0.0	4	1	1	1
79671	1710	intron of the CD4 gene	[intron of the CD4 gene]	0.0	5	1	1	1
79672	1710	ptk inhibitor	[PTK inhibitors]	0.0	2	1	1	1
79673	1710	u937 lymphoma cell	[U937 lymphoma cells]	0.0	3	1	1	1
79674	1710	injection.	[injection.]	0.0	1	1	1	1
79675	1710	effect on receptor (gr)	[effects on receptor (GR)]	0.0	4	1	1	1
79676	1710	effect all attributable to cn inhibition	[effects all attributable to CN inhibition]	0.0	6	1	1	1
79677	1710	combination with all-tran retinoic acid	[combination with all-trans retinoic acid]	0.0	5	1	1	1
79678	1710	inhibit cell death	[inhibiting cell death]	0.0	3	1	1	1
79679	1710	contain zinc-finger motif	[containing zinc-finger motifs]	0.0	3	1	1	1
79680	1710	ketoconazole treatment,	[ketoconazole treatment,]	0.0	2	1	1	1
79681	1710	such cytokine	[such cytokine]	0.0	2	2	2	1
79682	1710	novel, as effector molecule	[novel, as effector molecule]	0.0	4	1	1	1
79683	1710	erythroid differentiation of leukemia cell	[erythroid differentiation of leukemia cells]	0.0	5	1	1	1
79684	1710	antisense (as) phosphorothioate oligonucleotide	[antisense (AS) phosphorothioate oligonucleotides]	0.0	4	1	1	1
79685	1710	translocation involve the region	[translocations involving the regions]	0.0	4	1	1	1
79686	1710	coactivation definition	[Coactivation definition]	0.0	2	1	1	1
79687	1710	repression of the interleukin-2 gene	[repression of the interleukin-2 gene]	0.0	5	1	1	1
79688	1710	fluorescence anisotropy of diphenylhexatriene	[fluorescence anisotropy of diphenylhexatriene]	0.0	4	1	1	1
79689	1710	surprising finding	[surprising finding]	0.0	2	1	1	1
79690	1710	form of stat3 stat3alpha	[forms of STAT3 STAT3alpha]	0.0	4	1	1	1
79691	1710	maturation for factor	[maturation for factors]	0.0	3	1	1	1
79692	1710	several ifn-induced gene	[several IFN-induced genes]	0.0	3	1	1	1
79693	1710	Recently, fibromyalgia	[Recently, fibromyalgia]	0.0	2	1	1	1
79694	1710	model of signal transduction	[model of signal transduction]	0.0	4	1	1	1
79695	1710	cooperation of human factor	[cooperation of human factors]	0.0	4	1	1	1
79696	1710	point estimation of receptor	[point estimation of receptors]	0.0	4	1	1	1
79697	1710	two functional factor kB regulatory element	[two functional factor kB regulatory elements]	0.0	6	1	1	1
79698	1710	cascade within the minute	[cascade within the minutes]	0.0	4	1	1	1
79699	1710	clinical stigmata	[clinical stigmata]	0.0	2	1	1	1
79700	1710	-57-positive	[-57-positive]	0.0	1	1	1	1
79701	1710	specificity of ciita	[specificity of CIITA]	0.0	3	1	1	1
79702	1710	protein neg-2 binding	[protein Neg-2 binding]	0.0	3	1	1	1
79703	1710	apoptosis in monocyte	[apoptosis in monocytes]	0.0	3	1	1	1
79704	1710	cell adhesion to ec	[cell adhesion to EC]	0.0	4	1	1	1
79705	1710	stimulation of human mononuclear cell	[Stimulation of human mononuclear cells]	0.0	5	1	1	1
79706	1710	cell cycle -stimulatory activity	[cell cycle -stimulatory activity]	0.0	4	1	1	1
79707	1710	mcp-1 induction	[MCP-1 induction]	0.0	2	1	1	1
79708	1710	day of cycle one	[day of cycle one]	0.0	4	1	1	1
79709	1710	human homologue of Drosophila Toll	[human homologue of Drosophila Toll]	0.0	5	1	1	1
79710	1710	possible correlation with clinical variable	[possible correlation with clinical variables]	0.0	5	1	1	1
79711	1710	gold compound especially aurothioglucose	[gold compounds especially aurothioglucose]	0.0	4	1	1	1
79712	1710	gene specific for the erythroid	[genes specific for the erythroid]	0.0	5	1	1	1
79713	1710	presence of isoform	[presence of isoforms]	0.0	3	1	1	1
79714	1710	involvement in t-cell lymphotropic virus type	[Involvement in T-cell lymphotropic virus type]	0.0	6	1	1	1
79715	1710	administration for month	[Administration for month]	0.0	3	1	1	1
79716	1710	significant response	[significant response]	0.0	2	1	1	1
79717	1710	less concurrent enhancement	[less concurrent enhancement]	0.0	3	1	1	1
79718	1710	efficacy in patient	[efficacy in patients]	0.0	3	1	1	1
79719	1710	(cfu-gm)	[(CFU-GM)]	0.0	1	1	1	1
79720	1710	wk to mo) RA	[wk to mo) RA]	0.0	4	1	1	1
79721	1710	CD3 CD28	[CD3 CD28]	0.0	2	1	1	1
79722	1710	77 nucleotide upstream	[77 nucleotides upstream]	0.0	3	1	1	1
79723	1710	(1) nucleotide substitution in the counterpart	[(1) nucleotide substitutions in the counterpart]	0.0	6	1	1	1
79724	1710	differentiation of hel	[differentiation of HEL]	0.0	3	1	1	1
79725	1710	switch region bind protein	[switch region binding protein]	0.0	4	1	1	1
79726	1710	mainly lactone	[mainly lactones]	0.0	2	1	1	1
79727	1710	results: in peripheral blood of woman	[RESULTS: In peripheral blood of women]	0.0	6	1	1	1
79728	1710	Epstein-Barr virus replication	[Epstein-Barr virus replication]	0.0	3	1	1	1
79729	1710	-73 bp	[-73 bp]	0.0	2	1	1	1
79730	1710	relationship between glucocorticoid receptor to therapy	[Relationship between glucocorticoid receptor to therapy]	0.0	6	1	1	1
79731	1710	differentiation-dependent peroxisomal receptor gamma	[differentiation-dependent peroxisomal receptor gamma]	0.0	4	1	1	1
79732	1710	novel apoptosis-mediating receptor	[novel apoptosis-mediating receptor]	0.0	3	1	1	1
79733	1710	molecular interaction with prb	[molecular interaction with pRb]	0.0	4	1	1	1
79734	1710	follow resection	[following resection]	0.0	2	1	1	1
79735	1710	nuclear factor-kappa b site	[nuclear factor-kappa B site]	0.0	4	1	1	1
79736	1710	activation lck	[activation lck]	0.0	2	1	1	1
79737	1710	Potential role of a intronic sequence	[Potential role of a intronic sequence]	0.0	6	1	1	1
79738	1710	RFX5 fusion protein	[RFX5 fusion protein]	0.0	3	1	1	1
79739	1710	basis for induction	[basis for induction]	0.0	3	1	1	1
79740	1710	hormone receptor response	[hormone receptor response]	0.0	3	1	1	1
79741	1710	er positive cell	[ER positive cells]	0.0	3	1	1	1
79742	1710	granulocyte-colony factor treatment of human neutrophils.	[granulocyte-colony factor treatment of human neutrophils.]	0.0	6	1	1	1
79743	1710	marker of ovulation	[markers of ovulation]	0.0	3	1	1	1
79744	1710	inhibition by a form	[Inhibition by a form]	0.0	4	1	1	1
79745	1710	n-terminal peptide	[N-terminal peptide]	0.0	2	1	1	1
79746	1710	expression in human Jurkat T cell	[expression in human Jurkat T cells]	0.0	6	1	1	1
79747	1710	reversion of DRA promoter occupancy	[reversion of DRA promoter occupancy]	0.0	5	1	1	1
79748	1710	latent to infection	[latent to infection]	0.0	3	1	1	1
79749	1710	tsp 1 -chloramphenicol acetyltransferase construct	[TSP 1 -chloramphenicol acetyltransferase constructs]	0.0	5	1	1	1
79750	1710	death domain -contain receptor	[death domain -containing receptor]	0.0	4	1	1	1
79751	1710	incorporate microbiological antigen	[incorporating microbiological antigens]	0.0	3	1	1	1
79752	1710	tax expression on the interaction	[Tax expression on the interaction]	0.0	5	1	1	1
79753	1710	novel factor in bovine colostrum	[novel factor in bovine colostrum]	0.0	5	1	1	1
79754	1710	human homologue activation	[human homologue activation]	0.0	3	1	1	1
79755	1710	immunological marker	[immunological markers]	0.0	2	1	1	1
79756	1710	rat ref52 cell	[rat REF52 cells]	0.0	3	1	1	1
79757	1710	induction by cytokine	[induction by cytokines]	0.0	3	1	1	1
79758	1710	ten hiv-infected patient with normal affinity	[Ten HIV-infected patients with normal affinity]	0.0	6	1	1	1
79759	1710	addition of H2 agonist	[addition of H2 agonists]	0.0	4	1	1	1
79760	1710	results: co-culture	[RESULTS: Co-culture]	0.0	2	1	1	1
79761	1710	suppression by fluid	[Suppression by fluid]	0.0	3	1	1	1
79762	1710	tpa -inducible nuclear factor	[TPA -inducible nuclear factor]	0.0	4	1	1	1
79763	1710	region of the c-sis/pdgb promoter	[region of the c-sis/PDGF-B promoter]	0.0	5	1	1	1
79764	1710	domain of gamma(c)	[domain of gamma(c)]	0.0	3	1	1	1
79765	1710	regulation of il-6 gene expression	[regulation of IL-6 gene expression]	0.0	5	1	1	1
79766	1710	loss suggest of importance	[loss suggesting of importance]	0.0	4	1	1	1
79767	1710	binding of p50-p65 nf-kappab heterodimer	[binding of p50-p65 NF-kappaB heterodimers]	0.0	5	1	1	1
79768	1710	specific cell type	[specific cell types]	0.0	3	1	1	1
79769	1710	role in the rapid production	[role in the rapid production]	0.0	5	1	1	1
79770	1710	part, by a lack	[part, by a lack]	0.0	4	1	1	1
79771	1710	environmental estrogenic compound from plant source	[environmental estrogenic compounds from plant sources]	0.0	6	1	1	1
79772	1710	regulation of lymphocyte	[regulation of lymphocytes]	0.0	3	1	1	1
79773	1710	latent cycle reactivity to epitope undetectable	[latent cycle reactivities to epitopes undetectable]	0.0	6	1	1	1
79774	1710	CD40 -positive human MMs	[CD40 -positive human MMs]	0.0	4	1	1	1
79775	1710	several copy of the genome	[several copies of the genome]	0.0	5	1	1	1
79776	1710	such as the central system	[such as the central system]	0.0	5	1	1	1
79777	1710	Challenge develop new strategy	[Challenges developing new strategies]	0.0	4	1	1	1
79778	1710	developmental stage homogeneity of progenitor/precursor cell	[developmental stage homogeneity of progenitor/precursor cells]	0.0	6	1	1	1
79779	1710	factor of T cell protein	[factor of T cell proteins]	0.0	5	1	1	1
79780	1710	anti-mhc class antibody Ab	[anti-MHC class antibodies Ab]	0.0	4	1	1	1
79781	1710	only adhesion molecule-1	[only adhesion molecule-1]	0.0	3	1	1	1
79782	1710	cis-acting dominant effect	[cis-acting dominant effect]	0.0	3	1	1	1
79783	1710	important role transduce signal	[important role transducing signals]	0.0	4	1	1	1
79784	1710	NLSs	[NLSs]	0.0	1	1	1	1
79785	1710	type immunodeficiency virus	[type immunodeficiency virus]	0.0	3	1	1	1
79786	1710	cell number, from day	[cell number, from day]	0.0	4	1	1	1
79787	1710	receptor on leukocyte MNL	[receptors on leukocytes MNL]	0.0	4	1	1	1
79788	1710	presence with the property	[presence with the properties]	0.0	4	1	1	1
79789	1710	c-c chemokine receptor-like gene	[C-C chemokine receptor-like genes]	0.0	4	1	1	1
79790	1710	BZLF 1 trans-activator	[BZLF 1 trans-activator]	0.0	3	1	1	1
79791	1710	ah receptor cell line	[Ah receptor cell lines]	0.0	4	1	1	1
79792	1710	TIMP-1 suppression	[TIMP-1 suppression]	0.0	2	1	1	1
79793	1710	Ro 13-7410	[Ro 13-7410]	0.0	2	1	1	1
79794	1710	variant line 1a9-m	[variant line 1A9-M]	0.0	3	1	1	1
79795	1710	proteolysis of p65 during extraction	[proteolysis of p65 during extraction]	0.0	5	1	1	1
79796	1710	age group	[age groups]	0.0	2	1	1	1
79797	1710	inactivity of the progesterone	[inactivity of the progesterone]	0.0	4	1	1	1
79798	1710	p65 nf-kappa b subunit	[p65 NF-kappa B subunit]	0.0	4	1	1	1
79799	1710	protein products,	[protein products,]	0.0	2	1	1	1
79800	1710	co-cultured cell BEAS-2B	[co-cultured cells BEAS-2B]	0.0	3	1	1	1
79801	1710	synthesis of all cytokine	[synthesis of all cytokines]	0.0	4	1	1	1
79802	1710	impending immune response	[impending immune response]	0.0	3	1	1	1
79803	1710	tumor-draining ln	[tumor-draining LN]	0.0	2	1	1	1
79804	1710	dominant transgenic mouse	[dominant transgenic mice]	0.0	3	1	1	1
79805	1710	critical role regulate the response	[critical role regulating the response]	0.0	5	1	1	1
79806	1710	use two pkc inhibitors, pentoxifylline	[using two PKC inhibitors, pentoxifylline]	0.0	5	1	1	1
79807	1710	increase in permeability	[increase in permeability]	0.0	3	1	1	1
79808	1710	tat activation of LTR	[Tat activation of LTR]	0.0	4	1	1	1
79809	1710	primary rhesus monkey macrophage	[primary rhesus monkey macrophages]	0.0	4	1	1	1
79810	1710	human macrophage inflammatory protein-1alpha	[human macrophage inflammatory protein-1alpha]	0.0	4	1	1	1
79811	1710	Erythropoietin Epo the primary regulator	[Erythropoietin Epo the primary regulator]	0.0	5	1	1	1
79812	1710	silencing of globin expression	[Silencing of globin expression]	0.0	4	1	1	1
79813	1710	general agreement	[general agreement]	0.0	2	1	1	1
79814	1710	mechanism a cell line	[mechanisms a cell line]	0.0	4	1	1	1
79815	1710	(71%) iddm subject	[(71%) IDDM subjects]	0.0	3	1	1	1
79816	1710	bp repeat element	[bp repeat elements]	0.0	3	1	1	1
79817	1710	peak thrombin (pt) nmol/L.	[peak thrombin (PT) nmol/L.]	0.0	4	1	1	1
79818	1710	production of metabolite of oxygen	[production of metabolites of oxygen]	0.0	5	1	1	1
79819	1710	Interestingly, reexpression of MHC class gene	[Interestingly, reexpression of MHC class genes]	0.0	6	1	1	1
79820	1710	nucleotide insertion	[nucleotide insertion]	0.0	2	1	1	1
79821	1710	virulent mycobacteria	[virulent mycobacteria]	0.0	2	1	1	1
79822	1710	breast cancer of stage	[breast cancer of stages]	0.0	4	1	1	1
79823	1710	role induce Cepsilon germline transcript	[role inducing Cepsilon germline transcripts]	0.0	5	1	1	1
79824	1710	interferon-gamma-treated u937 cell	[interferon-gamma-treated U937 cells]	0.0	3	1	1	1
79825	1710	steroid-regulated gene	[steroid-regulated genes]	0.0	2	1	1	1
79826	1710	use p21ras	[using p21ras]	0.0	2	1	1	1
79827	1710	glyocophorin	[glyocophorin]	0.0	1	1	1	1
79828	1710	24 healthy woman (11	[24 healthy women (11]	0.0	4	1	1	1
79829	1710	binding of receptor to DNA	[binding of receptor to DNA]	0.0	5	1	1	1
79830	1710	oncoproteins, cell transformation,	[oncoproteins, cell transformation,]	0.0	3	1	1	1
79831	1710	child with adenoviral infection	[children with adenoviral infection]	0.0	4	2	2	1
79832	1710	avian erythroblast cell	[avian erythroblast cell]	0.0	3	1	1	1
79833	1710	nf-e2 expression in differentiation	[NF-E2 expression in differentiation]	0.0	4	1	1	1
79834	1710	subsequent activity	[subsequent activity]	0.0	2	1	1	1
79835	1710	ebv epithelial cell	[EBV epithelial cells]	0.0	3	1	1	1
79836	1710	NF-E1 ref respectively),	[NF-E1 refs respectively),]	0.0	3	1	1	1
79837	1710	VDJ recombination	[VDJ recombination]	0.0	2	1	1	1
79838	1710	NFAT-1 -dependent gene expression in mouse	[NFAT-1 -dependent gene expression in mice]	0.0	6	1	1	1
79839	1710	human element dna-probe	[human element DNA-probe]	0.0	3	1	1	1
79840	1710	applicability, allow testing	[applicability, allowing testing]	0.0	3	1	1	1
79841	1710	Dexamethasone Dex a hormone	[Dexamethasone Dex a hormone]	0.0	4	1	1	1
79842	1710	extend promoter region	[extending promoter regions]	0.0	3	1	1	1
79843	1710	approach study interaction	[approach studying interactions]	0.0	3	1	1	1
79844	1710	Specific formation between the type ii	[Specific formation between the type II]	0.0	6	1	1	1
79845	1710	formation of oxygen intermediate ROI	[Formation of oxygen intermediates ROI]	0.0	5	1	1	1
79846	1710	amount of transcriptionally active creb protein	[amounts of transcriptionally active CREB protein]	0.0	6	1	1	1
79847	1710	little effect on the minimal promoter	[little effect on the minimal promoter]	0.0	6	1	1	1
79848	1710	T manner	[T manner]	0.0	2	1	1	1
79849	1710	mechanism of EBNA2 transactivation	[mechanism of EBNA2 transactivation]	0.0	4	1	1	1
79850	1710	c-fm proto-oncogene	[c-fms proto-oncogene]	0.0	2	1	1	1
79851	1710	monocyte in culture	[monocytes in culture]	0.0	3	1	1	1
79852	1710	differential purpose	[differential purposes]	0.0	2	1	1	1
79853	1710	ikappab kinase ikk activation	[IkappaB kinase IKK activation]	0.0	4	1	1	1
79854	1710	line, re-expression of RB	[line, re-expression of RB]	0.0	4	1	1	1
79855	1710	signal pathway result via activating region	[signaling pathways resulting via activating regions]	0.0	6	1	1	1
79856	1710	hand, in culture	[hand, in cultures]	0.0	3	1	1	1
79857	1710	antioxidant sensitive activate pathway	[antioxidant sensitive activating pathway]	0.0	4	1	1	1
79858	1710	in-vitro cleavage of recombinant sp1	[In-vitro cleavage of recombinant SP1]	0.0	5	1	1	1
79859	1710	mechanism common	[mechanisms common]	0.0	2	1	1	1
79860	1710	possible hormonal dysregulation	[possible hormonal dysregulation]	0.0	3	1	1	1
79861	1710	role in ig class switch	[role in Ig class switching]	0.0	5	1	1	1
79862	1710	inhibit the phosphatase activity	[inhibiting the phosphatase activity]	0.0	4	1	1	1
79863	1710	6.5- to 8.5-fold induction	[6.5- to 8.5-fold induction]	0.0	4	1	1	1
79864	1710	activity in the cytosol	[activity in the cytosol]	0.0	4	1	1	1
79865	1710	bcl-6 protein on epidermis	[bcl-6 protein on epidermis]	0.0	4	1	1	1
79866	1710	(3) evidence of switch recombination	[(3) evidence of switch recombination]	0.0	5	1	1	1
79867	1710	patient proband nine	[patient proband nine]	0.0	3	1	1	1
79868	1710	macrophage factor in normal monocyte	[macrophage factor in normal monocytes]	0.0	5	1	1	1
79869	1710	modest translocation	[modest translocation]	0.0	2	1	1	1
79870	1710	use a antibody Lt-4	[Using a antibody Lt-4]	0.0	4	1	1	1
79871	1710	fibrosarcoma 8, malignant histiocytoma	[fibrosarcoma 8, malignant histiocytoma]	0.0	4	1	1	1
79872	1710	il-5 regulatory mechanism	[IL-5 regulatory mechanisms]	0.0	3	1	1	1
79873	1710	cell-T-cell	[cell-T-cell]	0.0	1	1	1	1
79874	1710	total blood cell	[total blood cell]	0.0	3	1	1	1
79875	1710	candidate oxygen species	[candidate oxygen species]	0.0	3	1	1	1
79876	1710	EBNA2 cis-element	[EBNA2 cis-element]	0.0	2	2	2	1
79877	1710	(HIV) long terminal repeat LTR	[(HIV) long terminal repeat LTR]	0.0	5	1	1	1
79878	1710	start at minute after stimulation.	[starting at min after stimulation.]	0.0	5	1	1	1
79879	1710	ifn-gamma icam-1 expression	[IFN-gamma ICAM-1 expression]	0.0	3	1	1	1
79880	1710	functional component	[functional component]	0.0	2	1	1	1
79881	1710	4922 (range,	[4922 (range,]	0.0	2	1	1	1
79882	1710	nuclear localization in PBL	[nuclear localization in PBL]	0.0	4	1	1	1
79883	1710	effective dose of t3 (10(-10)	[effective dose of T3 (10(-10)]	0.0	5	1	1	1
79884	1710	Differential utilization	[Differential utilization]	0.0	2	1	1	1
79885	1710	set of factor	[set of factor]	0.0	3	1	1	1
79886	1710	germline region promoter	[germline region promoters]	0.0	3	1	1	1
79887	1710	form include pre-B acute leukemia	[forms including pre-B acute leukemia]	0.0	5	1	1	1
79888	1710	RAR(alpha)	[RAR(alpha)]	0.0	1	1	1	1
79889	1710	role for the two form	[roles for the two forms]	0.0	5	1	1	1
79890	1710	Nuclear localization	[Nuclear localization]	0.0	2	3	3	1
79891	1710	involvement in human t-cell virus type	[Involvement in human T-cell virus type]	0.0	6	1	1	1
79892	1710	i.e. granulocyte	[i.e. granulocytes]	0.0	2	1	1	1
79893	1710	(sv40)	[(SV40)]	0.0	1	1	1	1
79894	1710	expression of recombination gene	[expression of recombination genes]	0.0	4	1	1	1
79895	1710	hyperreactive adrenocorticotropic hormone acth release	[hyperreactive adrenocorticotropic hormone ACTH release]	0.0	5	1	1	1
79896	1710	cell lineage during hematopoiesis	[cell lineages during hematopoiesis]	0.0	4	1	1	1
79897	1710	antitumor antibiotic	[antitumor antibiotic]	0.0	2	1	1	1
79898	1710	betaherpesvirus	[betaherpesvirus]	0.0	1	1	1	1
79899	1710	independent assays), a value	[independent assays), a value]	0.0	4	1	1	1
79900	1710	early sign of remission	[early sign of remission]	0.0	4	1	1	1
79901	1710	Spi-1 gene	[Spi-1 genes]	0.0	2	1	1	1
79902	1710	cf sputum	[CF sputum]	0.0	2	1	1	1
79903	1710	migration in vitro.	[migration in vitro.]	0.0	3	1	1	1
79904	1710	latent to active infection	[latent to active infection]	0.0	4	1	1	1
79905	1710	retinobenzoic derivative	[retinobenzoic derivative]	0.0	2	1	1	1
79906	1710	element for respective factor	[elements for respective factor]	0.0	4	1	1	1
79907	1710	similar (inhibitory) effect on differentiation	[similar (inhibitory) effects on differentiation]	0.0	5	1	1	1
79908	1710	transcriptional response to NF-kappa b	[transcriptional responses to NF-kappa B]	0.0	5	1	1	1
79909	1710	syk-family kinase in cell	[Syk-family kinases in cells]	0.0	4	1	1	1
79910	1710	m in a concentration-dependent manner	[M in a concentration-dependent manner]	0.0	5	1	1	1
79911	1710	three child with hormone deficiency	[three children with hormone deficiency]	0.0	5	1	1	1
79912	1710	dominant mutant NFAT delta418	[dominant mutant NFAT delta418]	0.0	4	1	1	1
79913	1710	require approximately 2 log-fold more glucocorticoid	[requiring approximately 2 log-fold more glucocorticoids]	0.0	6	1	1	1
79914	1710	controversies, one of the troublesome	[controversies, one of the troublesome]	0.0	5	1	1	1
79915	1710	induce transcription from ch gene	[inducing transcription from CH genes]	0.0	5	1	1	1
79916	1710	regulatory mobility group (hmg) protein	[regulatory mobility group (HMG) protein]	0.0	5	1	1	1
79917	1710	result production	[resulting production]	0.0	2	1	1	1
79918	1710	enhanced, 2 h	[enhanced, 2 h]	0.0	3	1	1	1
79919	1710	receptor-effector-mechor-mechanisms for aldosterone the sequence	[receptor-effector-mechanisms for aldosterone the sequence]	0.0	5	1	1	1
79920	1710	b cell specific transcription factor	[B cell specific transcription factor]	0.0	5	1	1	1
79921	1710	cd16 cell	[CD16 cells]	0.0	2	1	1	1
79922	1710	binding of the 50-kDa hlp-1 protein	[binding of the 50-kDa HLP-1 protein]	0.0	6	1	1	1
79923	1710	interrelationship between the two messenger	[interrelationship between the two messengers]	0.0	5	1	1	1
79924	1710	extensive apoptosis	[extensive apoptosis]	0.0	2	1	1	1
79925	1710	addition, N-acetyl-L-cysteine	[addition, N-acetyl-L-cysteine]	0.0	2	1	1	1
79926	1710	45 kb of DNA	[45 kb of DNA]	0.0	4	1	1	1
79927	1710	study use specific antibody	[study using specific antibodies]	0.0	4	1	1	1
79928	1710	role in immune inflammatory state	[role in immune inflammatory states]	0.0	5	1	1	1
79929	1710	closely related immunoglobulin g fc receptor	[closely related immunoglobulin G Fc receptors]	0.0	6	1	1	1
79930	1710	lymphatic leukemia CLL	[lymphatic leukemia CLL]	0.0	3	1	1	1
79931	1710	Sp1/NF-AT	[Sp1/NF-AT]	0.0	1	1	1	1
79932	1710	methylation in granulocyte	[methylation in granulocytes]	0.0	3	1	1	1
79933	1710	activation of the IL3 gene	[activation of the IL3 gene]	0.0	5	1	1	1
79934	1710	virus, implicate cis-active sequence	[virus, implicating cis-active sequences]	0.0	4	1	1	1
79935	1710	CD3-stimulated human T lymphocyte	[CD3-stimulated human T lymphocytes]	0.0	4	1	1	1
79936	1710	site of lytic ebv replication	[site of lytic EBV replication]	0.0	5	1	1	1
79937	1710	region amino acid of CBP	[region amino acids of CBP]	0.0	5	1	1	1
79938	1710	protein tcf-2 alpha	[protein TCF-2 alpha]	0.0	3	1	1	1
79939	1710	1) inhibition of growth	[1) inhibition of growth]	0.0	4	1	1	1
79940	1710	transcription factor activation protein	[transcription factor activation protein]	0.0	4	1	1	1
79941	1710	element in the first kb	[elements in the first kb]	0.0	5	1	1	1
79942	1710	subtle down-regulatory effect.	[subtle down-regulatory effect.]	0.0	3	1	1	1
79943	1710	modification arginine residue	[modification arginine residues]	0.0	3	1	1	1
79944	1710	thrombin receptor activation	[Thrombin receptor activation]	0.0	3	1	1	1
79945	1710	acid receptor pml-rar	[acid receptor PML-RAR]	0.0	3	1	1	1
79946	1710	blot analysis, immunostaining,	[blot analysis, immunostaining,]	0.0	3	1	1	1
79947	1710	probe react intracellularly	[probe reacting intracellularly]	0.0	3	1	1	1
79948	1710	complex to CRE	[complexes to CRE]	0.0	3	1	1	1
79949	1710	retrovirus-transduced version	[retrovirus-transduced version]	0.0	2	1	1	1
79950	1710	erythroblast stage	[erythroblast stage]	0.0	2	1	1	1
79951	1710	isotype class switch	[isotype class switching]	0.0	3	1	1	1
79952	1710	inhibition of b DNA binding activity	[inhibition of B DNA binding activity]	0.0	6	1	1	1
79953	1710	dependence of HS activity	[dependence of HS activity]	0.0	4	1	1	1
79954	1710	absence of glucocorticoid	[absence of glucocorticoid]	0.0	3	1	1	1
79955	1710	induction by dil	[induction by DILs]	0.0	3	1	1	1
79956	1710	human assay	[human assay]	0.0	2	1	1	1
79957	1710	mutation of Pax5	[mutation of Pax5]	0.0	3	1	1	1
79958	1710	specific transcription factor function	[specific transcription factor functions]	0.0	4	1	1	1
79959	1710	recurrent feature	[recurrent feature]	0.0	2	1	1	1
79960	1710	critical factor for the expression	[critical factor for the expression]	0.0	5	1	1	1
79961	1710	GGGAAATTCC	[GGGAAATTCC]	0.0	1	1	1	1
79962	1710	addition, amount	[addition, amounts]	0.0	2	1	1	1
79963	1710	translocation in Jurkat cell	[translocation in Jurkat cells]	0.0	4	1	1	1
79964	1710	retinoid with binding specificity	[retinoids with binding specificity]	0.0	4	1	1	1
79965	1710	DRA reporter	[DRA reporter]	0.0	2	1	1	1
79966	1710	latency type pattern	[latency type pattern]	0.0	3	1	1	1
79967	1710	c/ebp consensus binding site	[C/EBP consensus binding site]	0.0	4	1	1	1
79968	1710	high activity of this enzyme	[higher activity of this enzyme]	0.0	5	1	1	1
79969	1710	camp intracellular signal pathway	[cAMP intracellular signaling pathways]	0.0	4	1	1	1
79970	1710	T allele	[T allele]	0.0	2	1	1	1
79971	1710	LMP1 DNA fragment	[LMP1 DNA fragments]	0.0	3	1	1	1
79972	1710	context-restricted manner	[context-restricted manner]	0.0	2	1	1	1
79973	1710	activation of the cytokine tnf-alpha	[activation of the cytokines TNF-alpha]	0.0	5	1	1	1
79974	1710	promoter function of the flank region	[Promoter function of the flanking region]	0.0	6	1	1	1
79975	1710	x chromosome-containing sperm	[X chromosome-containing sperm]	0.0	3	1	1	1
79976	1710	downstream event important	[downstream events important]	0.0	3	1	1	1
79977	1710	resultant cell line	[resultant cell line]	0.0	3	1	1	1
79978	1710	retroviruse in T lymphocyte	[retroviruses in T lymphocytes]	0.0	4	1	1	1
79979	1710	lineage-restricted transactivator	[lineage-restricted transactivators]	0.0	2	1	1	1
79980	1710	previously unrecognized NFATp -binding site	[previously unrecognized NFATp -binding sites]	0.0	5	1	1	1
79981	1710	target for immunosuppression	[target for immunosuppression]	0.0	3	1	1	1
79982	1710	undifferentiated monocytic cell	[undifferentiated monocytic cells]	0.0	3	1	1	1
79983	1710	dnd39 cell with il-4	[DND39 cells with IL-4]	0.0	4	1	1	1
79984	1710	inter-relationship	[inter-relationship]	0.0	1	1	1	1
79985	1710	extent, the GPIIb promoter	[extent, the GPIIb promoter]	0.0	4	1	1	1
79986	1710	terminal neutrophil maturation	[terminal neutrophil maturation]	0.0	3	1	1	1
79987	1710	type cytokine il-4	[type cytokines IL-4]	0.0	3	1	1	1
79988	1710	differentiation inducer 12-o-tetradecanoylphorbol 13-acetate tpa	[differentiation inducers 12-O-tetradecanoylphorbol 13-acetate TPA]	0.0	5	1	1	1
79989	1710	b-cell response in intrahepatic follicle	[B-cell response in intrahepatic follicles]	0.0	5	1	1	1
79990	1710	amount of trypsin fragment	[amount of trypsin fragments]	0.0	4	1	1	1
79991	1710	cd3-cd16+ natural killer cell	[CD3-CD16+ natural killer cells]	0.0	4	1	1	1
79992	1710	constitutive expression of a factor	[constitutive expression of a factor]	0.0	5	1	1	1
79993	1710	ltr-driven CAT expression vector	[LTR-driven CAT expression vectors]	0.0	4	1	1	1
79994	1710	charcoal assay	[charcoal assay]	0.0	2	1	1	1
79995	1710	antigen level	[antigen level]	0.0	2	1	1	1
79996	1710	hiv long-terminal repeat transcription	[HIV long-terminal repeat transcription]	0.0	4	1	1	1
79997	1710	support a mechanism of cell survival.	[supporting a mechanism of cell survival.]	0.0	6	1	1	1
79998	1710	expression of bcl-6 protein tumor	[expression of bcl-6 protein tumors]	0.0	5	1	1	1
79999	1710	dUTPase	[dUTPase]	0.0	1	1	1	1
80000	1710	pattern of two transcription factor	[pattern of two transcription factors]	0.0	5	1	1	1
80001	1710	EBNA2 -dependent transcriptional induction	[EBNA2 -dependent transcriptional induction]	0.0	4	1	1	1
80002	1710	suggest the absence	[suggesting the absence]	0.0	3	1	1	1
80003	1710	molecular alteration responsible	[molecular alterations responsible]	0.0	3	1	1	1
80004	1710	ifn-gamma-activated sequence	[IFN-gamma-activated sequence]	0.0	2	1	1	1
80005	1710	utilize transfection assay	[Utilizing transfection assays]	0.0	3	1	1	1
80006	1710	less kda.	[less kDa.]	0.0	2	1	1	1
80007	1710	leukemia of childhood.	[leukemia of childhood.]	0.0	3	1	1	1
80008	1710	lymphocyte from blood	[lymphocytes from blood]	0.0	3	1	1	1
80009	1710	interaction between this neutrophil	[interaction between this neutrophils]	0.0	4	1	1	1
80010	1710	level in untreated u937 cell	[levels in untreated U937 cells]	0.0	5	1	1	1
80011	1710	feature of immune senescence.	[feature of immune senescence.]	0.0	4	1	1	1
80012	1710	degradation block the translocation	[degradation blocking the translocation]	0.0	4	1	1	1
80013	1710	role in monocyte	[roles in monocytes]	0.0	3	1	1	1
80014	1710	rapamycin-regulated signal	[rapamycin-regulated signals]	0.0	2	1	1	1
80015	1710	leukemic t-cell line 6tg1.1	[leukemic T-cell line 6TG1.1]	0.0	4	1	1	1
80016	1710	follow immunization of mouse	[following immunization of mice]	0.0	4	1	1	1
80017	1710	allele-specific expression in fibroblast	[allele-specific expression in fibroblasts]	0.0	4	1	1	1
80018	1710	intracellular cholesterol synthesis	[intracellular cholesterol synthesis]	0.0	3	1	1	1
80019	1710	Twenty-two difference from the sequence	[Twenty-two differences from the sequence]	0.0	5	1	1	1
80020	1710	alphacd3 stimulation	[alphaCD3 stimulation]	0.0	2	1	1	1
80021	1710	such as CD28	[such as CD28]	0.0	3	2	2	1
80022	1710	3 copy	[3 copies]	0.0	2	1	1	1
80023	1710	well-characterized, antioxidant	[well-characterized, antioxidant]	0.0	2	1	1	1
80024	1710	domain of the protein,	[domain of the protein,]	0.0	4	1	1	1
80025	1710	pathway in the cytokine network	[pathway in the cytokine network]	0.0	5	1	1	1
80026	1710	include benzoquinone	[including benzoquinone]	0.0	2	1	1	1
80027	1710	minimal maturation effect	[minimal maturation effect]	0.0	3	1	1	1
80028	1710	death of T lymphocyte	[death of T lymphocyte]	0.0	4	1	1	1
80029	1710	acute myelogenous leukemia 1- evi1 fusion	[acute myelogenous leukemia 1- EVI1 fusions]	0.0	6	1	1	1
80030	1710	alpha, 25-dihydroxyvitamin D3 on proliferation	[alpha, 25-dihydroxyvitamin D3 on proliferation]	0.0	5	1	1	1
80031	1710	resting human pbl	[resting human PBL]	0.0	3	1	1	1
80032	1710	response to lymphotropic virus type	[response to lymphotropic virus type]	0.0	5	1	1	1
80033	1710	follow time in culture	[following time in culture]	0.0	4	1	1	1
80034	1710	AMP production	[AMP production]	0.0	2	1	1	1
80035	1710	domain responsible	[domains responsible]	0.0	2	1	1	1
80036	1710	eneanalogue	[eneanalogues]	0.0	1	1	1	1
80037	1710	substitution in the TF site	[substitutions in the TF site]	0.0	5	1	1	1
80038	1710	agreement a accumulation of eosinophil	[agreement an accumulation of eosinophils]	0.0	5	1	1	1
80039	1710	different combination gc	[different combinations GC]	0.0	3	1	1	1
80040	1710	weight gain (14 2126 (pre)	[weight gain (14 2126 (pre)]	0.0	5	1	1	1
80041	1710	response to cellular activation	[response to cellular activation]	0.0	4	1	1	1
80042	1710	alter interaction at the x box	[altering interactions at the X boxes]	0.0	6	1	1	1
80043	1710	use extract from human eosinophil	[using extracts from human eosinophils]	0.0	5	1	1	1
80044	1710	portion in the domain	[portion in the domain]	0.0	4	1	1	1
80045	1710	mechanism signal in eosinophil	[mechanisms signaling in eosinophils]	0.0	4	1	1	1
80046	1710	Interleukin-2 promoter -reporter gene behavior	[Interleukin-2 promoter -reporter gene behavior]	0.0	5	1	1	1
80047	1710	response in peripheral T cell	[response in peripheral T cells]	0.0	5	1	1	1
80048	1710	grow leukemic cell line	[growing leukemic cell line]	0.0	4	1	1	1
80049	1710	phosphorylation of kinase	[phosphorylation of kinases]	0.0	3	1	1	1
80050	1710	cytokine T	[cytokine T]	0.0	2	1	1	1
80051	1710	tmd in this study.	[TMD in this study.]	0.0	4	1	1	1
80052	1710	analysis of the first 12 rdna	[analysis of the first 12 cDNAs]	0.0	6	1	1	1
80053	1710	inhibition by a alkaloid cepharanthine	[inhibition by an alkaloid cepharanthine]	0.0	5	1	1	1
80054	1710	differential rescue by cytokine	[differential rescue by cytokines]	0.0	4	1	1	1
80055	1710	haemopoietic cell of various lineages.	[haemopoietic cells of various lineages.]	0.0	5	1	1	1
80056	1710	human T lymphoid	[human T lymphoid]	0.0	3	1	1	1
80057	1710	new element important for expression	[new element important for expression]	0.0	5	1	1	1
80058	1710	trep -contain	[TREp -containing]	0.0	2	1	1	1
80059	1710	extract of Il-2	[extracts of Il-2]	0.0	3	1	1	1
80060	1710	ngal expression	[NGAL expression]	0.0	2	3	3	1
80061	1710	t3-responsive (gh3) cell	[T3-responsive (GH3) cells]	0.0	3	1	1	1
80062	1710	(R)	[(R)]	0.0	1	1	1	1
80063	1710	initial gene promoter	[initial gene promoter]	0.0	3	1	1	1
80064	1710	cooperation between the factor icp0	[cooperation between the factor ICP0]	0.0	5	1	1	1
80065	1710	(hox)	[(Hox)]	0.0	1	1	1	1
80066	1710	CsA on cell	[CsA on cells]	0.0	3	1	1	1
80067	1710	stimulation with gc	[Stimulation with GC]	0.0	3	1	1	1
80068	1710	+/- fmol/10(7) pbmc fmol/10(7)	[+/- fmol/10(7) PBMC fmol/10(7)]	0.0	4	1	1	1
80069	1710	m alphav5 dihydroxyvitamin D3 D3	[M alpha,25 dihydroxyvitamin D3 D3]	0.0	5	1	1	1
80070	1710	factor nf-il6 (position -153 to -145	[factor NF-IL6 (positions -153 to -145]	0.0	6	1	1	1
80071	1710	hla-dra mrna expression	[HLA-DRA mRNA expression]	0.0	3	1	1	1
80072	1710	IL-2 T cell line	[IL-2 T cell line]	0.0	4	1	1	1
80073	1710	mean group	[mean group]	0.0	2	1	1	1
80074	1710	response to extracellular cues,	[responses to extracellular cues,]	0.0	4	1	1	1
80075	1710	objective in the study	[objectives in the study]	0.0	4	1	1	1
80076	1710	number of receptor /cell	[number of receptors /cell]	0.0	4	1	1	1
80077	1710	induction of expression in leukocyte	[Induction of expression in leukocytes]	0.0	5	1	1	1
80078	1710	effect on level	[effect on levels]	0.0	3	1	1	1
80079	1710	mutant viral stock	[mutant viral stock]	0.0	3	1	1	1
80080	1710	cell types, oct-2 expression	[cell types, Oct-2 expression]	0.0	4	1	1	1
80081	1710	polypeptide of kda	[polypeptides of kDa]	0.0	3	1	1	1
80082	1710	long terminal repeat of hiv-1	[long terminal repeat of HIV-1]	0.0	5	1	1	1
80083	1710	one arm	[one arm]	0.0	2	1	1	1
80084	1710	cytoplasmic serine kinase	[cytoplasmic serine kinases]	0.0	3	1	1	1
80085	1710	apoptosis role of IL-1 beta	[apoptosis role of IL-1 beta]	0.0	5	1	1	1
80086	1710	adult genomic footprint	[adult genomic footprint]	0.0	3	1	1	1
80087	1710	means influence NFAT-1	[means influencing NFAT-1]	0.0	3	1	1	1
80088	1710	hepatocyte factor-1 alpha	[Hepatocyte factor-1 alpha]	0.0	3	1	1	1
80089	1710	therefore a target under condition	[therefore a target under conditions]	0.0	5	1	1	1
80090	1710	study the binding on membrane	[studying the binding on membranes]	0.0	5	1	1	1
80091	1710	novel 9-bp motif with high homology	[novel 9-bp motifs with high homology]	0.0	6	1	1	1
80092	1710	drive the progression of responsiveness	[driving the progression of responsiveness]	0.0	5	1	1	1
80093	1710	significance of mineralocorticoid receptor	[significance of mineralocorticoid receptors]	0.0	4	1	1	1
80094	1710	effector on activity of Oct-2	[effector on activity of Oct-2]	0.0	5	1	1	1
80095	1710	>50% of rap1	[>50% of Rap1]	0.0	3	1	1	1
80096	1710	effect of M-CSF	[effects of M-CSF]	0.0	3	1	1	1
80097	1710	group of U937 cell	[groups of U937 cells]	0.0	4	1	1	1
80098	1710	presence of peptide	[presence of peptides]	0.0	3	1	1	1
80099	1710	immunofluorescence from normal tonsil	[immunofluorescence from normal tonsils]	0.0	4	1	1	1
80100	1710	b5a cell	[B5A cells]	0.0	2	1	1	1
80101	1710	internalization of the bacterium	[internalization of the bacterium]	0.0	4	1	1	1
80102	1710	quantitative blotting	[quantitative blotting]	0.0	2	1	1	1
80103	1710	human vsmc	[human VSMCs]	0.0	2	1	1	1
80104	1710	ligand LFA-3	[ligand LFA-3]	0.0	2	1	1	1
80105	1710	start codon	[start codon]	0.0	2	1	1	1
80106	1710	native molecular weight of kD	[native molecular weights of kD]	0.0	5	1	1	1
80107	1710	stage- specific regulation	[stage- specific regulation]	0.0	3	1	1	1
80108	1710	induction of collagenase-1 transcription	[induction of collagenase-1 transcription]	0.0	4	1	1	1
80109	1710	regulate the capacity of progenitor cell	[regulating the capacity of progenitor cells]	0.0	6	1	1	1
80110	1710	viral gene effect	[viral gene effects]	0.0	3	1	1	1
80111	1710	four herpesviruse	[four herpesviruses]	0.0	2	1	1	1
80112	1710	fragment extend 2738 nucleotide	[fragment extending 2,738 nucleotides]	0.0	4	1	1	1
80113	1710	considerable change	[considerable change]	0.0	2	1	1	1
80114	1710	phosphatidylinositol 3-kinase activity in cell	[phosphatidylinositol 3-kinase activity in cells]	0.0	5	1	1	1
80115	1710	10(-8) mol/L for all-tran RA	[10(-8) mol/L for all-trans RA]	0.0	5	1	1	1
80116	1710	female year of age),	[female years of age),]	0.0	4	1	1	1
80117	1710	enhancement of ig-secreting cell	[enhancement of Ig-secreting cells]	0.0	4	1	1	1
80118	1710	regulate intracellular localization	[regulating intracellular localization]	0.0	3	1	1	1
80119	1710	finding in CLL	[finding in CLL]	0.0	3	1	1	1
80120	1710	potent antiproliferative effect	[potent antiproliferative effects]	0.0	3	1	1	1
80121	1710	high level of octamer transcription	[high levels of octamer transcription]	0.0	5	1	1	1
80122	1710	expression of type p53	[expression of type p53]	0.0	4	1	1	1
80123	1710	thus show essential	[thus showing essential]	0.0	3	1	1	1
80124	1710	two 9-bp motif (-90/-82 with homology	[two 9-bp motifs (-90/-82 with homology]	0.0	6	1	1	1
80125	1710	T alpha	[T alpha]	0.0	2	1	1	1
80126	1710	lox-1 gene symbol olr1	[LOX-1 gene symbol OLR1]	0.0	4	1	1	1
80127	1710	modulation by adenoviral transfer of IkappaB-alpha	[modulation by adenoviral transfer of IkappaB-alpha]	0.0	6	1	1	1
80128	1710	p24 production	[p24 production]	0.0	2	1	1	1
80129	1710	immune-response	[immune-response]	0.0	1	1	1	1
80130	1710	ubiquitin -carrier protein	[ubiquitin -carrier protein]	0.0	3	1	1	1
80131	1710	effect on lymphocyte 1) inhibition	[effects on lymphocytes 1) inhibition]	0.0	5	1	1	1
80132	1710	limit transcription factor	[limiting transcription factors]	0.0	3	1	1	1
80133	1710	oxide a autoregulatory feedback inhibitor	[oxide an autoregulatory feedback inhibitor]	0.0	5	1	1	1
80134	1710	transcription factor nuclear factor family	[Transcription factors nuclear factor family]	0.0	5	1	1	1
80135	1710	accumulation of unspliced mrna I	[accumulation of unspliced mRNA I]	0.0	5	1	1	1
80136	1710	uninfected blood monocyte from donor	[uninfected blood monocytes from donors]	0.0	5	1	1	1
80137	1710	normal igg	[normal IgG]	0.0	2	1	1	1
80138	1710	fdcp-mix a4 cell	[FDCP-mix A4 cells]	0.0	3	1	1	1
80139	1710	cell of synovial tissue	[cells of synovial tissue]	0.0	4	1	1	1
80140	1710	skw 6.4 cell with IL	[SKW 6.4 cells with IL]	0.0	5	1	1	1
80141	1710	276 mumol cortisol to subject	[276 mumol cortisol to subjects]	0.0	5	1	1	1
80142	1710	regulation in NK cell a study	[regulation in NK cells a study]	0.0	6	1	1	1
80143	1710	event in the progression	[event in the progression]	0.0	4	1	1	1
80144	1710	immunosuppressive cytokine tgf-beta 2	[immunosuppressive cytokine TGF-beta 2]	0.0	4	1	1	1
80145	1710	total serum ige in subject	[total serum IgE in subjects]	0.0	5	1	1	1
80146	1710	difference in the spectra of disease	[differences in the spectra of diseases]	0.0	6	1	1	1
80147	1710	cd14+ adherent monocyte	[CD14+ adherent monocytes]	0.0	3	1	1	1
80148	1710	generate only positive mechanism	[generating only positive mechanisms]	0.0	4	1	1	1
80149	1710	effect of DNA damage agent	[effects of DNA damaging agents]	0.0	5	1	1	1
80150	1710	MTHC in the presence	[MTHC in the presence]	0.0	4	1	1	1
80151	1710	together, substitution	[together, substitution]	0.0	2	1	1	1
80152	1710	nuclear expression by IL-4	[nuclear expression by IL-4]	0.0	4	1	1	1
80153	1710	pd098059	[PD098059]	0.0	1	1	1	1
80154	1710	activate transcription from the repeat	[activating transcription from the repeat]	0.0	5	1	1	1
80155	1710	-harbor	[-harboring]	0.0	1	2	2	1
80156	1710	primarily on the morphology	[primarily on the morphology]	0.0	4	1	1	1
80157	1710	continuous monitoring of the mother	[continuous monitoring of the mother]	0.0	5	1	1	1
80158	1710	spectra of disease	[spectra of diseases]	0.0	3	1	1	1
80159	1710	inappropriate activation	[inappropriate activation]	0.0	2	2	2	1
80160	1710	suppression of a differentiation program	[Suppression of a differentiation program]	0.0	5	1	1	1
80161	1710	interaction between two cell-specific coactivator	[interactions between two cell-specific coactivators]	0.0	5	1	1	1
80162	1710	contribute to response	[contributing to response]	0.0	3	1	1	1
80163	1710	specific induction during monocytic differentiation	[specific induction during monocytic differentiation]	0.0	5	1	1	1
80164	1710	silencing of the beta-globin promoter	[silencing of the beta-globin promoter]	0.0	5	1	1	1
80165	1710	pu.1-/- mouse	[PU.1-/- mice]	0.0	2	1	1	1
80166	1710	myeloid u-937 cell blood monocyte	[myeloid U-937 cells blood monocytes]	0.0	5	1	1	1
80167	1710	such as lipopolysaccharide the endotoxin	[such as lipopolysaccharide the endotoxin]	0.0	5	1	1	1
80168	1710	gene expression of receptor of differentiation	[gene expression of receptors of differentiation]	0.0	6	1	1	1
80169	1710	stat3 bcl2 downregulation	[Stat3 BCL2 downregulation]	0.0	3	1	1	1
80170	1710	monocyte protein-1 CC chemokine	[monocyte protein-1 CC chemokine]	0.0	4	1	1	1
80171	1710	involve the CBFA2 locus	[involving the CBFA2 locus]	0.0	4	1	1	1
80172	1710	7 MRD -positive	[7 MRD -positive]	0.0	3	1	1	1
80173	1710	E1A sensitization	[E1A sensitization]	0.0	2	1	1	1
80174	1710	play a role	[playing an role]	0.0	3	1	1	1
80175	1710	early inhibition	[early inhibition]	0.0	2	1	1	1
80176	1710	homolog c/ebp-beta NF-IL6	[homolog C/EBP-beta NF-IL6]	0.0	3	1	1	1
80177	1710	sp3 expression in the cell line	[Sp3 expression in the cell line]	0.0	6	1	1	1
80178	1710	allergen-specific th2 cell	[allergen-specific Th2 cells]	0.0	3	1	1	1
80179	1710	disease due to mimicry	[disease due to mimicry]	0.0	4	1	1	1
80180	1710	unrelated protein	[unrelated proteins]	0.0	2	1	1	1
80181	1710	molecular aspect of IBR/F	[molecular aspects of IBR/F]	0.0	4	1	1	1
80182	1710	transactivate hhv-6 (gs) gene fragment	[transactivating HHV-6 (GS) gene fragments]	0.0	5	1	1	1
80183	1710	treatment with oxldl	[treatment with oxLDL]	0.0	3	1	1	1
80184	1710	signals, nf kappa b	[signals, NF kappa B]	0.0	4	1	1	1
80185	1710	signal for erk activation	[signal for ERK activation]	0.0	4	1	1	1
80186	1710	I -182 to -162	[I -182 to -162]	0.0	4	1	1	1
80187	1710	comparison of the promoter	[comparison of the promoters]	0.0	4	1	1	1
80188	1710	phenomenon in normal woman	[phenomenon in normal women]	0.0	4	1	1	1
80189	1710	function other	[functions other]	0.0	2	1	1	1
80190	1710	pool of rela	[pool of RelA]	0.0	3	1	1	1
80191	1710	-myh11 positive,	[-MYH11 positive,]	0.0	2	1	1	1
80192	1710	DEX condition	[DEX condition]	0.0	2	1	1	1
80193	1710	T/NK checkpoint	[T/NK checkpoint]	0.0	2	1	1	1
80194	1710	avenue of therapy in leukemia	[avenue of therapy in leukemia]	0.0	5	1	1	1
80195	1710	overexpress hIRAK a weak constitutive activation	[overexpressing hIRAK a weak constitutive activation]	0.0	6	1	1	1
80196	1710	property common	[properties common]	0.0	2	1	1	1
80197	1710	.3; pt	[.3; PT]	0.0	2	1	1	1
80198	1710	15 cell divisions, corresponding	[15 cell divisions, corresponding]	0.0	4	1	1	1
80199	1710	prostate tumour cell	[prostate tumour cells]	0.0	3	1	1	1
80200	1710	clinical course 0.05, chi2 test).	[clinical course 0.05, chi2 test).]	0.0	5	1	1	1
80201	1710	differentiation of cd34+ progenitor cell HPC	[differentiation of CD34+ progenitor cells HPC]	0.0	6	1	1	1
80202	1710	binding to appropriate receptors.	[binding to appropriate receptors.]	0.0	4	1	1	1
80203	1710	essential genetic element	[essential genetic elements]	0.0	3	1	1	1
80204	1710	low dose of peptide micrograms),	[low doses of peptide micrograms),]	0.0	5	1	1	1
80205	1710	such as the induction	[such as the induction]	0.0	4	1	1	1
80206	1710	react with nuclei	[reacting with nuclei]	0.0	3	1	1	1
80207	1710	recognition by T lymphocyte	[recognition by T lymphocytes]	0.0	4	1	1	1
80208	1710	DNA domain of MyoD	[DNA domain of MyoD]	0.0	4	1	1	1
80209	1710	type receptor in 42 ovulation woman	[Type receptors in 42 ovulation women]	0.0	6	1	1	1
80210	1710	activation of cytokine-encoding gene	[activation of cytokine-encoding genes]	0.0	4	1	1	1
80211	1710	use a thymic hybridoma pc60	[using a thymic hybridoma PC60]	0.0	5	1	1	1
80212	1710	NF-kappa b binding sequence	[NF-kappa B binding sequence]	0.0	4	1	1	1
80213	1710	-76 nucleotide	[-76 nucleotides]	0.0	2	1	1	1
80214	1710	mrna at low level	[mRNA at low levels]	0.0	4	1	1	1
80215	1710	protein -408	[proteins -408]	0.0	2	1	1	1
80216	1710	alter the th1/th2 balance	[altering the Th1/Th2 balance]	0.0	4	1	1	1
80217	1710	circulate pmnc	[circulating PMNCs]	0.0	2	1	1	1
80218	1710	virtual absence	[virtual absence]	0.0	2	1	1	1
80219	1710	cell-specific factor in vivo	[cell-specific factor in vivo]	0.0	4	1	1	1
80220	1710	g1 protein	[G1 proteins]	0.0	2	1	1	1
80221	1710	26 s multicatalytic protease	[26 S multicatalytic proteases]	0.0	4	1	1	1
80222	1710	expression of coactivator bob.1/obf.1	[expression of coactivator BOB.1/OBF.1]	0.0	4	1	1	1
80223	1710	(bp	[(bp]	0.0	1	1	1	1
80224	1710	cytoplasmic domain of il-9ralpha	[cytoplasmic domain of IL-9Ralpha]	0.0	4	1	1	1
80225	1710	factor critical to T cell commitment	[factors critical to T cell commitment]	0.0	6	1	1	1
80226	1710	severely depressed patient	[severely depressed patients]	0.0	3	1	1	1
80227	1710	role of free tissue damage	[role of free tissue damage]	0.0	5	1	1	1
80228	1710	line represent stage of maturation,	[lines representing stages of maturation,]	0.0	5	1	1	1
80229	1710	progression of certain malignancy	[progression of certain malignancies]	0.0	4	1	1	1
80230	1710	transcription factor TCF-1	[transcription factors TCF-1]	0.0	3	1	1	1
80231	1710	inflammation of atopic asthma	[inflammation of atopic asthma]	0.0	4	2	2	1
80232	1710	contain the transcription factor	[containing the transcription factor]	0.0	4	1	1	1
80233	1710	tat- human immunodeficiency virus	[Tat- human immunodeficiency viruses]	0.0	4	1	1	1
80234	1710	result in the lysis of cell	[resulting in the lysis of cells]	0.0	6	1	1	1
80235	1710	dependent adhesion human umbilical vein cell	[dependent adhesion human umbilical vein cells]	0.0	6	1	1	1
80236	1710	prip	[PRIP]	0.0	1	1	1	1
80237	1710	addition to p300/cbp	[addition to p300/CBP]	0.0	3	1	1	1
80238	1710	nf-kappab-controlled reporter gene	[NF-kappaB-controlled reporter gene]	0.0	3	1	1	1
80239	1710	conjunction with overexpression	[conjunction with overexpression]	0.0	3	1	1	1
80240	1710	minute of il-5 stimulation	[min of IL-5 stimulation]	0.0	4	1	1	1
80241	1710	region/leucine zipper bzip domain	[region/leucine zipper bZIP domain]	0.0	4	1	1	1
80242	1710	moreover, il-10 effect	[Moreover, IL-10 effects]	0.0	3	1	1	1
80243	1710	ability -express fibroblastic cell	[abilities -expressing fibroblastic cells]	0.0	4	1	1	1
80244	1710	cellular dna-binding transcription factor	[cellular DNA-binding transcription factors]	0.0	4	1	1	1
80245	1710	exposure of hd6 cell	[exposure of HD6 cells]	0.0	4	1	1	1
80246	1710	novel function in differentiation	[novel function in differentiation]	0.0	4	1	1	1
80247	1710	effect on number	[effects on number]	0.0	3	1	1	1
80248	1710	therapeutic index of antioxidant	[therapeutic index of antioxidants]	0.0	4	1	1	1
80249	1710	initial induction	[initial induction]	0.0	2	1	1	1
80250	1710	rs cell of all category	[RS cells of all categories]	0.0	5	1	1	1
80251	1710	extend from the start site	[extending from the start site]	0.0	5	1	1	1
80252	1710	stimuli, indicate the factor	[stimuli, indicating the factor]	0.0	4	1	1	1
80253	1710	response in AMI	[responses in AMI]	0.0	3	1	1	1
80254	1710	AUG codon	[AUG codons]	0.0	2	1	1	1
80255	1710	instillation of IL-6 alone	[instillation of IL-6 alone]	0.0	4	1	1	1
80256	1710	understanding of the role	[understanding of the role]	0.0	4	1	1	1
80257	1710	two Ets family member	[Two Ets family members]	0.0	4	1	1	1
80258	1710	inhibitor of mapk kinase	[inhibitor of MAPK kinase]	0.0	4	1	1	1
80259	1710	adjacent region	[adjacent region]	0.0	2	1	1	1
80260	1710	thus lead to low production	[thus leading to lower production]	0.0	5	1	1	1
80261	1710	55 kd, result	[55 kD, resulting]	0.0	3	1	1	1
80262	1710	-cd40	[-CD40]	0.0	1	1	1	1
80263	1710	lps a nf-kappa b inducer	[LPS a NF-kappa B inducer]	0.0	5	1	1	1
80264	1710	involve aml1	[involving AML1]	0.0	2	1	1	1
80265	1710	CoCl2 signal direct expression	[CoCl2 signals directing expression]	0.0	4	1	1	1
80266	1710	basAl, adhesion at approximately 20 mM.	[basal, adhesion at approximately 20 mM.]	0.0	6	1	1	1
80267	1710	stimulation of phospholipase d	[stimulation of phospholipase D]	0.0	4	1	1	1
80268	1710	(h)	[(h)]	0.0	1	1	1	1
80269	1710	specific proliferation, cytotoxicity,	[specific proliferation, cytotoxicity,]	0.0	3	1	1	1
80270	1710	functionally distinct domains, a	[functionally distinct domains, A]	0.0	4	1	1	1
80271	1710	expression of atf-2	[Expression of ATF-2]	0.0	3	1	1	1
80272	1710	downstream effector of gata-1 signal	[downstream effector of GATA-1 signals]	0.0	5	1	1	1
80273	1710	cell death pathway	[cell death pathway]	0.0	3	1	1	1
80274	1710	supplement the culture	[supplementing the cultures]	0.0	3	1	1	1
80275	1710	T lymphocyte of sibling	[T lymphocytes of siblings]	0.0	4	1	1	1
80276	1710	mechanism underlie selective expression of cytokine	[mechanisms underlying selective expression of cytokines]	0.0	6	1	1	1
80277	1710	tumour progression	[tumour progression]	0.0	2	1	1	1
80278	1710	mutagenesis of the L1	[mutagenesis of the L1]	0.0	4	1	1	1
80279	1710	treatment of extract	[treatment of extracts]	0.0	3	1	1	1
80280	1710	MHC class compartment	[MHC class compartment]	0.0	3	2	2	1
80281	1710	several putative binding site	[several putative binding sites]	0.0	4	1	1	1
80282	1710	prl gene expression	[PRL gene expression]	0.0	3	2	2	1
80283	1710	modulate the expression in cell	[modulating the expression in cells]	0.0	5	1	1	1
80284	1710	inhibition by dexamethasone in vitro.	[inhibition by dexamethasone in vitro.]	0.0	5	1	1	1
80285	1710	slp-76 augmentation	[SLP-76 augmentation]	0.0	2	1	1	1
80286	1710	RA regulation	[RA regulation]	0.0	2	1	1	1
80287	1710	day 7 14	[day 7 14]	0.0	3	1	1	1
80288	1710	multiple tissue during murine embryogenesis	[multiple tissues during murine embryogenesis]	0.0	5	1	1	1
80289	1710	share homology at the phosphorylation site	[share homology at the phosphorylation site]	0.0	6	1	1	1
80290	1710	(if	[(if]	0.0	1	1	1	1
80291	1710	promyelocytic leukemia the microgranular variant	[promyelocytic leukemia the microgranular variant]	0.0	5	1	1	1
80292	1710	serum-activated Jurkat	[serum-activated Jurkat]	0.0	2	1	1	1
80293	1710	Sp1/NF-AT binding site	[Sp1/NF-AT binding sites]	0.0	3	1	1	1
80294	1710	G0 to S	[G0 to S]	0.0	3	1	1	1
80295	1710	in rest PBL	[in resting PBL]	0.0	3	1	1	1
80296	1710	h of PMA exposure	[h of PMA exposure]	0.0	4	1	1	1
80297	1710	otf-2 factor	[OTF-2 factor]	0.0	2	1	1	1
80298	1710	subsequent maintenance	[subsequent maintenance]	0.0	2	1	1	1
80299	1710	expression of "normal" lymphokine	[expression of "normal" lymphokines]	0.0	4	1	1	1
80300	1710	antagonism in the regulation	[antagonism in the regulation]	0.0	4	1	1	1
80301	1710	baboon	[baboons]	0.0	1	1	1	1
80302	1710	three patient with dysplasia	[three patients with dysplasia]	0.0	4	1	1	1
80303	1710	signal in neutrophils.	[signaling in neutrophils.]	0.0	3	1	1	1
80304	1710	expression of inhibitor	[expression of inhibitor]	0.0	3	1	1	1
80305	1710	microM, 72	[microM, 72]	0.0	2	1	1	1
80306	1710	box pdp motif	[box PDP motif]	0.0	3	1	1	1
80307	1710	transcription-polymerase chain reaction with rna	[transcription-polymerase chain reaction with RNA]	0.0	5	1	1	1
80308	1710	support hypothesis	[supporting hypothesis]	0.0	2	1	1	1
80309	1710	phenylarsine oxide a inhibitor	[phenylarsine oxide a inhibitor]	0.0	4	1	1	1
80310	1710	hppecfcs	[HPP-CFCs]	0.0	1	1	1	1
80311	1710	two-third of proteins.	[two-thirds of proteins.]	0.0	3	1	1	1
80312	1710	(m)	[(m)]	0.0	1	1	1	1
80313	1710	CMV scmv	[CMV SCMV]	0.0	2	1	1	1
80314	1710	Sendai virus	[Sendai virus]	0.0	2	1	1	1
80315	1710	expression of ebv gene	[expression of EBV genes]	0.0	4	1	1	1
80316	1710	datum implicate gata-1 function	[data implicating GATA-1 function]	0.0	4	1	1	1
80317	1710	cortisol the number of receptor ro	[cortisol the number of receptors Ro]	0.0	6	1	1	1
80318	1710	encode general initiation factor	[encoding general initiation factors]	0.0	4	1	1	1
80319	1710	Antioxidant-mediated inhibition	[Antioxidant-mediated inhibition]	0.0	2	1	1	1
80320	1710	open-reading frame	[open-reading frames]	0.0	2	1	1	1
80321	1710	suppressor notably	[suppressors notably]	0.0	2	1	1	1
80322	1710	resection margins: tumor	[resection margins: tumors]	0.0	3	1	1	1
80323	1710	inhibitor pp pp1 calyculin a	[inhibitor PPs PP1/PP2A calyculin A]	0.0	5	1	1	1
80324	1710	role in il-4 gene expression	[role in IL-4 gene expression]	0.0	5	1	1	1
80325	1710	about 25 h for culture	[about 25 h for cultures]	0.0	5	1	1	1
80326	1710	diffusion of biochemical ones.	[diffusion of biochemical ones.]	0.0	4	1	1	1
80327	1710	htlv-1-transfected T	[HTLV-1-transfected T]	0.0	2	1	1	1
80328	1710	analysis by Miyatake	[analysis by Miyatake]	0.0	3	1	1	1
80329	1710	murine thymocyte apoptosis,	[murine thymocyte apoptosis,]	0.0	3	1	1	1
80330	1710	dual colour fish analysis	[dual colour FISH analysis]	0.0	4	1	1	1
80331	1710	factor bind C 4681 to 4701	[Factors binding C 4681 to 4701]	0.0	6	1	1	1
80332	1710	10 microm sodium	[10 microM sodium]	0.0	3	1	1	1
80333	1710	il-7r function	[IL-7R function]	0.0	2	1	1	1
80334	1710	lps kappab transcription	[LPS kappaB transcription]	0.0	3	1	1	1
80335	1710	woman with hyperparathyroidism secondary to failure	[women with hyperparathyroidism secondary to failure]	0.0	6	1	1	1
80336	1710	similar MHC class ii-negative cell	[similar MHC class II-negative cells]	0.0	5	1	1	1
80337	1710	mutant hiv-1	[mutant HIV-1]	0.0	2	1	1	1
80338	1710	cd8+ T cell leukemia cell	[CD8+ T cell leukemia cells]	0.0	5	1	1	1
80339	1710	ten normal peripheral blood lymphocyte sample	[ten normal peripheral blood lymphocyte samples]	0.0	6	1	1	1
80340	1710	differentiation of hl-60 cell implication	[differentiation of HL-60 cells implications]	0.0	5	1	1	1
80341	1710	interleukin-2 IL2 a cytokine	[interleukin-2 IL2 a cytokine]	0.0	4	1	1	1
80342	1710	comparative analysis nuclear factor	[Comparative analysis nuclear factor]	0.0	4	1	1	1
80343	1710	nucleosome -assembly system	[nucleosome -assembly system]	0.0	3	1	1	1
80344	1710	effect in human T cell	[effects in human T cells]	0.0	5	1	1	1
80345	1710	SRI responder differ	[SRI responders differing]	0.0	3	1	1	1
80346	1710	majority of the population	[majority of the population]	0.0	4	1	1	1
80347	1710	cell expression of mcm5	[Cell expression of MCM5]	0.0	4	1	1	1
80348	1710	depressive disorder: lack	[depressive disorder: lack]	0.0	3	1	1	1
80349	1710	lymphocyte action	[lymphocyte action]	0.0	2	1	1	1
80350	1710	+/- 0.92 fmol/10(7)	[+/- 0.92 fmol/10(7)]	0.0	3	1	1	1
80351	1710	effect on thymidine incorporation	[effect on thymidine incorporation]	0.0	4	1	1	1
80352	1710	(on	[(on]	0.0	1	1	1	1
80353	1710	overexpression in the lymphoid cell line	[Overexpression in the lymphoid cell lines]	0.0	6	1	1	1
80354	1710	(or	[(or]	0.0	1	1	1	1
80355	1710	two form of type diabete	[two forms of type diabetes]	0.0	5	1	1	1
80356	1710	cloned, T lymphocyte	[Cloned, T lymphocytes]	0.0	3	1	1	1
80357	1710	woman with syndrome	[women with syndrome]	0.0	3	1	1	1
80358	1710	fc epsilonRII	[Fc epsilonRII]	0.0	2	1	1	1
80359	1710	-177 bp relative	[-177 bp relative]	0.0	3	1	1	1
80360	1710	hiv-infected patient with low receptor affinity	[HIV-infected patients with low receptor affinity]	0.0	6	1	1	1
80361	1710	possibility establish cell line	[possibility establishing cell lines]	0.0	4	1	1	1
80362	1710	suggest marker for a region	[suggesting markers for an region]	0.0	5	1	1	1
80363	1710	immunosuppressive agent cyclosporin A	[immunosuppressive agent cyclosporin A]	0.0	4	1	1	1
80364	1710	regulation by NFKB2	[regulation by NFKB2]	0.0	3	1	1	1
80365	1710	different lymphoid cell	[different lymphoid cells]	0.0	3	1	1	1
80366	1710	state mrna level equivalent	[state mRNA levels equivalent]	0.0	4	1	1	1
80367	1710	inhibit vdrnrar- vdre complex formation	[inhibiting VDR-RXR- VDRE complex formation]	0.0	5	1	1	1
80368	1710	CD40 ligand activation	[CD40 ligand activation]	0.0	3	1	1	1
80369	1710	rest T helper lymphocyte	[resting T helper lymphocytes]	0.0	4	1	1	1
80370	1710	elution conditions,	[elution conditions,]	0.0	2	1	1	1
80371	1710	overproduction a mechanism for trans-activation	[Overproduction a mechanism for trans-activation]	0.0	5	1	1	1
80372	1710	homeostatic switch	[homeostatic switch]	0.0	2	1	1	1
80373	1710	Conclusions: cell	[CONCLUSIONS: cells]	0.0	2	1	1	1
80374	1710	granulocyte factor colony-stimumulatelany-stg factor proliferation	[granulocyte factor colony-stimulating factor proliferation]	0.0	5	1	1	1
80375	1710	immature cd34+thy-1+ subset	[immature CD34+Thy-1+ subset]	0.0	3	1	1	1
80376	1710	effect of lipopolysaccharide factor	[effects of lipopolysaccharide factor]	0.0	4	1	1	1
80377	1710	positive selection expansion)	[positive selection expansion)]	0.0	3	1	1	1
80378	1710	class a msr	[class A MSR]	0.0	3	1	1	1
80379	1710	degree of mucosal inflammation	[degree of mucosal inflammation]	0.0	4	1	1	1
80380	1710	microg/ml in PMA u1 cell	[microg/ml in PMA U1 cells]	0.0	5	1	1	1
80381	1710	nfkappab activation after stimulation	[NFkappaB activation after stimulation]	0.0	4	1	1	1
80382	1710	autologous cell TEC	[autologous cells TEC]	0.0	3	1	1	1
80383	1710	important benefit	[important benefits]	0.0	2	1	1	1
80384	1710	chronic response in rheumatoid arthritis	[chronic response in rheumatoid arthritis]	0.0	5	1	1	1
80385	1710	transfection result	[transfection results]	0.0	2	1	1	1
80386	1710	limulus	[Limulus]	0.0	1	1	1	1
80387	1710	nucleoside diphosphate(ndp) kinase	[nucleoside diphosphate(NDP) kinase]	0.0	3	1	1	1
80388	1710	cocktail of granulocyte/macrophage factor	[cocktail of granulocyte/macrophage factor]	0.0	4	1	1	1
80389	1710	expression latent membrane protein 1 lmp-1	[Expression latent membrane protein 1 LMP-1]	0.0	6	1	1	1
80390	1710	il-2-alpha receptor expression	[IL-2-alpha receptor expression]	0.0	3	1	1	1
80391	1710	C base pair upstream	[C base pairs upstream]	0.0	4	1	1	1
80392	1710	-retinoid	[-retinoid]	0.0	1	1	1	1
80393	1710	activation the Janus kinase	[Activation the Janus kinase]	0.0	4	1	1	1
80394	1710	regulatory element NF-AT-1	[regulatory element NF-AT-1]	0.0	3	1	1	1
80395	1710	Jijoye	[Jijoye]	0.0	1	1	1	1
80396	1710	t-cell-specific regulation	[T-cell-specific regulation]	0.0	2	1	1	1
80397	1710	suggest a additional role	[suggesting an additional role]	0.0	4	1	1	1
80398	1710	regulate matrix attachment (Scheuermann, R. h.,	[regulating matrix attachment (Scheuermann, R. H.,]	0.0	6	1	1	1
80399	1710	low isoform	[lower isoforms]	0.0	2	1	1	1
80400	1710	directly repress Th1 development	[directly repressing Th1 development]	0.0	4	1	1	1
80401	1710	hour minute	[hr min]	0.0	2	1	1	1
80402	1710	classification of ivs1-10t-->c	[Classification of IVS1-10T-->C]	0.0	3	1	1	1
80403	1710	nuclear export complex	[nuclear export complexes]	0.0	3	1	1	1
80404	1710	thus, difference in the capacity	[Thus, differences in the capacity]	0.0	5	1	1	1
80405	1710	change in nature Arg91	[change in nature Arg91]	0.0	4	1	1	1
80406	1710	outcome in carcinoma	[outcome in carcinoma]	0.0	3	1	1	1
80407	1710	transient overexpression of mutant of Raf-1	[Transient overexpression of mutants of Raf-1]	0.0	6	1	1	1
80408	1710	anti-early antigen ea	[anti-early antigen EA]	0.0	3	1	1	1
80409	1710	6 Yang patient	[6 Yang patients]	0.0	3	1	1	1
80410	1710	cooperation among nf-kappa b-	[cooperation among NF-kappa B-]	0.0	4	1	1	1
80411	1710	heterogeneous population of /precursor grow	[heterogeneous populations of /precursors growing]	0.0	5	1	1	1
80412	1710	principle of Chinese medicine chan'su	[principle of Chinese medicine chan'su]	0.0	5	1	1	1
80413	1710	exclusive binding	[exclusive binding]	0.0	2	1	1	1
80414	1710	triptolide degradation of parp	[triptolide degradation of PARP]	0.0	4	1	1	1
80415	1710	human gammaherpesvirus	[human gammaherpesvirus]	0.0	2	1	1	1
80416	1710	effect in a macrophage cell line	[Effect in a macrophage cell line]	0.0	6	1	1	1
80417	1710	use nuclear extract from normal eosinophil	[using nuclear extracts from normal eosinophils]	0.0	6	1	1	1
80418	1710	large number of receptor	[large number of receptors]	0.0	4	1	1	1
80419	1710	mol/L for all-tran RA	[mol/L for all-trans RA]	0.0	4	1	1	1
80420	1710	take age-related change	[taking age-related changes]	0.0	3	1	1	1
80421	1710	cytoplasmic domain of cd36	[cytoplasmic domain of CD36]	0.0	4	1	1	1
80422	1710	other form of arthritis	[other forms of arthritis]	0.0	4	1	1	1
80423	1710	expression of a single immediate-early protein	[expression of a single immediate-early protein]	0.0	6	1	1	1
80424	1710	fr 101	[FR 101]	0.0	2	1	1	1
80425	1710	real effect	[real effect]	0.0	2	1	1	1
80426	1710	HIV1 infection	[HIV1 infection]	0.0	2	1	1	1
80427	1710	alteration in apparent affinity	[alteration in apparent affinity]	0.0	4	1	1	1
80428	1710	/9-cis	[/9-cis]	0.0	1	1	1	1
80429	1710	self renewal of progenitor	[Self renewal of progenitors]	0.0	4	1	1	1
80430	1710	tumor necrosis factor tnf binding protein-1	[tumor necrosis factor TNF binding protein-1]	0.0	6	1	1	1
80431	1710	expression of the tsc2 gene	[expression of the TSC2 gene]	0.0	5	1	1	1
80432	1710	form of Epstein-Barr virus DNA	[form of Epstein-Barr virus DNA]	0.0	5	1	1	1
80433	1710	thiol decrease,	[thiol decrease,]	0.0	2	1	1	1
80434	1710	direct control of Bcl-2 expression	[direct control of Bcl-2 expression]	0.0	5	1	1	1
80435	1710	exon to the region	[exon to the region]	0.0	4	1	1	1
80436	1710	binding of the protein hmg-i	[binding of the protein HMG-I]	0.0	5	1	1	1
80437	1710	(35 min) physical exercise at 70%	[(35 min) physical exercise at 70%]	0.0	6	1	1	1
80438	1710	patient with leukaemia AML	[patients with leukaemia AML]	0.0	4	1	1	1
80439	1710	granulocyte-colony factor treatment of neutrophils.	[granulocyte-colony factor treatment of neutrophils.]	0.0	5	1	1	1
80440	1710	case of promelocytic leukemia	[cases of promelocytic leukemia]	0.0	4	1	1	1
80441	1710	lymphocyte predominance hd	[lymphocyte predominance HD]	0.0	3	1	1	1
80442	1710	aspect of down-regulation	[aspect of down-regulation]	0.0	3	1	1	1
80443	1710	several other marker of prognosis,	[several other markers of prognosis,]	0.0	5	1	1	1
80444	1710	gene in four Epo-dependent cell line	[genes in four Epo-dependent cell lines]	0.0	6	1	1	1
80445	1710	granulocyte-macrophage CSF gm-csf	[granulocyte-macrophage CSF GM-CSF]	0.0	3	1	1	1
80446	1710	interferon-gamma activation of monocyte	[interferon-gamma activation of monocytes]	0.0	4	1	1	1
80447	1710	residue c-235	[residue C-235]	0.0	2	1	1	1
80448	1710	NF-kappaB p50	[NF-kappaB p50]	0.0	2	1	1	1
80449	1710	cell rescue of T cell	[cell rescue of T cells]	0.0	5	1	1	1
80450	1710	x-linked	[X-linked]	0.0	1	1	1	1
80451	1710	pre-existing, T factor	[pre-existing, T factor]	0.0	3	1	1	1
80452	1710	2000 mu/l	[2,000 mU/L]	0.0	2	1	1	1
80453	1710	protection employ nuclear extract	[protection employing nuclear extracts]	0.0	4	1	1	1
80454	1710	utility use lymphocyte model	[utility using lymphocyte models]	0.0	4	1	1	1
80455	1710	lack of responsiveness	[lack of responsiveness]	0.0	3	1	1	1
80456	1710	accumulation of AMP	[accumulation of AMP]	0.0	3	1	1	1
80457	1710	day 7 precursor	[day 7 precursors]	0.0	3	1	1	1
80458	1710	trigger by the l243	[Triggering by the L243]	0.0	4	1	1	1
80459	1710	serum testosterone	[serum testosterone]	0.0	2	1	1	1
80460	1710	ARRE-1	[ARRE-1]	0.0	1	1	1	1
80461	1710	expression of a single protein bzlf1	[expression of a single protein BZLF1]	0.0	6	1	1	1
80462	1710	fluid specimen	[fluid specimens]	0.0	2	1	1	1
80463	1710	switch during stage	[switching during stages]	0.0	3	1	1	1
80464	1710	low bone density in populations,	[low bone density in populations,]	0.0	5	1	1	1
80465	1710	form of Ras RasN17	[form of Ras RasN17]	0.0	4	1	1	1
80466	1710	early treatment (day hpc with alpha-pml	[early treatment (day HPCs with alpha-PML]	0.0	6	1	1	1
80467	1710	only in sequence	[only in sequence]	0.0	3	1	1	1
80468	1710	expression of adhesion molecule-1 in huvec	[expression of adhesion molecule-1 in HUVECs]	0.0	6	1	1	1
80469	1710	NF-kappa b mechanism	[NF-kappa B mechanisms]	0.0	3	1	1	1
80470	1710	ability,	[ability,]	0.0	1	1	1	1
80471	1710	gene TINUR	[gene TINUR]	0.0	2	1	1	1
80472	1710	factor bind to site C 4681	[Factors binding to site C 4681]	0.0	6	1	1	1
80473	1710	GC induction	[GC induction]	0.0	2	1	1	1
80474	1710	aetiology of endometriosis a disorder,	[aetiology of endometriosis a disorder,]	0.0	5	1	1	1
80475	1710	originate 204 bp	[originating 204 bp]	0.0	3	1	1	1
80476	1710	spectrum of g(s)alpha expression	[spectrum of G(S)alpha expression]	0.0	4	1	1	1
80477	1710	important class of signal molecule	[important classes of signaling molecules]	0.0	5	1	1	1
80478	1710	binding site for factor include NFAT-1	[binding sites for factors including NFAT-1]	0.0	6	1	1	1
80479	1710	fresh human epstein-barr virus b lymphocyte	[fresh human Epstein-Barr virus B lymphocytes]	0.0	6	1	1	1
80480	1710	2422-erh)2d3 synthesis	[24,25-(OH)2D3 synthesis]	0.0	2	1	1	1
80481	1710	9s untransformed receptor complex	[9S untransformed receptor complexes]	0.0	4	1	1	1
80482	1710	interplay of cis- element	[interplay of cis- elements]	0.0	4	1	1	1
80483	1710	purine-rich motif	[purine-rich motifs]	0.0	2	1	1	1
80484	1710	apoptosis in Burkitt lymphoma	[apoptosis in Burkitt lymphoma]	0.0	4	1	1	1
80485	1710	transcription factor such as factor	[transcription factors such as factor]	0.0	5	1	1	1
80486	1710	recognize component	[recognizing components]	0.0	2	1	1	1
80487	1710	sub-unit	[sub-unit]	0.0	1	1	1	1
80488	1710	Erythroid-specific rrna encode gamma-globin delta-aminolevulinate synthase	[Erythroid-specific mRNAs encoding gamma-globin delta-aminolevulinate synthase]	0.0	6	1	1	1
80489	1710	dna).	[DNA).]	0.0	1	1	1	1
80490	1710	release of vasoactive factor	[release of vasoactive factors]	0.0	4	1	1	1
80491	1710	relation to histocompatibility complex class	[relation to histocompatibility complex classes]	0.0	5	1	1	1
80492	1710	staining in +/-	[staining in +/-]	0.0	3	1	1	1
80493	1710	description, to knowledge, of element	[description, to knowledge, of elements]	0.0	5	1	1	1
80494	1710	level of beta-globin	[levels of beta-globin]	0.0	3	1	1	1
80495	1710	shuttling transcription factor	[shuttling transcription factor]	0.0	3	1	1	1
80496	1710	unbalanced inactivation	[unbalanced inactivation]	0.0	2	1	1	1
80497	1710	dqa1*0201	[DQA1*0201]	0.0	1	1	1	1
80498	1710	main transcription-activation element	[main transcription-activation element]	0.0	3	1	1	1
80499	1710	monocytic differentiation of myeloid cell	[monocytic differentiation of myeloid cells]	0.0	5	1	1	1
80500	1710	reduce component of KV current	[reducing components of KV current]	0.0	5	1	1	1
80501	1710	expression of class molecule	[expression of class molecules]	0.0	4	1	1	1
80502	1710	LT promoter LT-293	[LT promoter LT-293]	0.0	3	1	1	1
80503	1710	immune system a step	[immune system a step]	0.0	4	1	1	1
80504	1710	(10(-10) mol/L) in combination with RA	[(10(-10) mol/L) in combination with RA]	0.0	6	1	1	1
80505	1710	transient overexpression of Bcl-2	[Transient overexpression of Bcl-2]	0.0	4	1	1	1
80506	1710	consist of 32 male	[consisting of 32 males]	0.0	4	1	1	1
80507	1710	lead to the commitment	[leading to the commitment]	0.0	4	1	1	1
80508	1710	amount of CAT mrna	[amount of CAT mRNA]	0.0	4	1	1	1
80509	1710	patient with lymphocytic leukemia	[patients with lymphocytic leukemia]	0.0	4	1	1	1
80510	1710	demonstrate a consequence of DNA damage	[demonstrating a consequence of DNA damage]	0.0	6	1	1	1
80511	1710	proinflammatory transcription factor	[proinflammatory transcription factor]	0.0	3	1	1	1
80512	1710	reduce kv1.3 component	[reducing Kv1.3 components]	0.0	3	1	1	1
80513	1710	gene in the locus	[genes in the locus]	0.0	4	1	1	1
80514	1710	part of the anti-atherogenic effect	[part of the anti-atherogenic effect]	0.0	5	1	1	1
80515	1710	adenovirus type during year of relationship	[adenovirus types during years of relationship]	0.0	6	1	1	1
80516	1710	blood mononuclear precursor	[blood mononuclear precursors]	0.0	3	1	1	1
80517	1710	hyperparathyroidism secondary	[hyperparathyroidism secondary]	0.0	2	1	1	1
80518	1710	Fusion of subdomain	[Fusion of subdomains]	0.0	3	1	1	1
80519	1710	two protein- tyrosine kinase	[two protein- tyrosine kinases]	0.0	4	1	1	1
80520	1710	function of the chimeric protein	[function of the chimeric proteins]	0.0	5	1	1	1
80521	1710	high, pharmacological concentration to 10 &mgr;m)	[high, pharmacological concentrations to 10 &mgr;M)]	0.0	6	1	1	1
80522	1710	great proliferation rate with pha	[greater proliferation rate with PHA]	0.0	5	1	1	1
80523	1710	protein interaction necessary for regulation	[protein interactions necessary for regulation]	0.0	5	1	1	1
80524	1710	role in normal human monocyte	[roles in normal human monocytes]	0.0	5	1	1	1
80525	1710	cortical region	[cortical regions]	0.0	2	1	1	1
80526	1710	point estimation of receptor in lymphocyte	[point estimation of receptors in lymphocytes]	0.0	6	1	1	1
80527	1710	high ca2+ thapsigargin treatment	[high Ca2+ thapsigargin treatment]	0.0	4	1	1	1
80528	1710	thus any defect	[thus any defect]	0.0	3	1	1	1
80529	1710	various cellular processes,	[various cellular processes,]	0.0	3	1	1	1
80530	1710	cause of growth	[cause of growth]	0.0	3	1	1	1
80531	1710	signal transduction pathway,	[signal transduction pathway,]	0.0	3	1	1	1
80532	1710	population genetics	[population genetics]	0.0	2	1	1	1
80533	1710	malignant clone with pcr-based technique	[malignant clone with PCR-based techniques]	0.0	5	1	1	1
80534	1710	structural comparison	[structural comparison]	0.0	2	1	1	1
80535	1710	likely interpretation of result	[likely interpretation of results]	0.0	4	1	1	1
80536	1710	subset of normal b	[subset of normal B]	0.0	4	1	1	1
80537	1710	fibrosarcoma histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrosarcoma histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
80538	1710	binding of interleukin-2 IL-2	[binding of interleukin-2 IL-2]	0.0	4	1	1	1
80539	1710	cd138/ syndecan-1	[CD138/ syndecan-1]	0.0	2	1	1	1
80540	1710	glucocorticoid receptor/progesterone receptor binding	[glucocorticoid receptor/progesterone receptor binding]	0.0	4	1	1	1
80541	1710	DOX cell	[DOX cells]	0.0	2	1	1	1
80542	1710	amplification of cell	[amplification of cells]	0.0	3	1	1	1
80543	1710	induction of promoter activity	[induction of promoter activity]	0.0	4	1	1	1
80544	1710	inhibit the synthesis	[inhibiting the synthesis]	0.0	3	1	1	1
80545	1710	murine melanoma D5	[murine melanoma D5]	0.0	3	1	1	1
80546	1710	deletion terminal (940-984) region	[Deletions terminal (940-984) region]	0.0	4	1	1	1
80547	1710	protein), a rapid increase	[protein), a rapid increase]	0.0	4	1	1	1
80548	1710	Okadaic	[Okadaic]	0.0	1	7	7	1
80549	1710	neutrophilic maturation	[neutrophilic maturation]	0.0	2	1	1	1
80550	1710	interestingly, early treatment (day hpc	[Interestingly, early treatment (day HPCs]	0.0	5	1	1	1
80551	1710	function from proliferation	[functions from proliferation]	0.0	3	1	1	1
80552	1710	human primary t-lymphocyte	[human primary T-lymphocytes]	0.0	3	1	1	1
80553	1710	dramatic increase phospholipase c	[dramatic increase phospholipase C]	0.0	4	1	1	1
80554	1710	feature indistinguishable	[features indistinguishable]	0.0	2	1	1	1
80555	1710	nf-e2,	[NF-E2,]	0.0	1	1	1	1
80556	1710	c-terminal segment	[C-terminal segment]	0.0	2	1	1	1
80557	1710	EBNA 2	[EBNA 2]	0.0	2	1	1	1
80558	1710	i ifi in addition	[I IFNs in addition]	0.0	4	1	1	1
80559	1710	syncytium formation with cell	[syncytium formation with cells]	0.0	4	1	1	1
80560	1710	spermine	[spermine]	0.0	1	1	1	1
80561	1710	pre-B acute lymphoblastic leukemia all	[pre-B acute lymphoblastic leukemia ALL]	0.0	5	1	1	1
80562	1710	three individual with infection	[three individuals with infection]	0.0	4	1	1	1
80563	1710	inactive, monomeric form	[inactive, monomeric form]	0.0	3	1	1	1
80564	1710	addition, bronchoalveolar	[addition, bronchoalveolar]	0.0	2	1	1	1
80565	1710	likely interpretation	[likely interpretation]	0.0	2	1	1	1
80566	1710	immune response in human	[immune responses in humans]	0.0	4	1	1	1
80567	1710	organ culture	[organ culture]	0.0	2	3	3	1
80568	1710	glucocorticoid binding site on the gr	[glucocorticoid binding sites on the GR]	0.0	6	1	1	1
80569	1710	antigen ea anti-viral capsid antigen vca	[antigen EA anti-viral capsid antigen VCA]	0.0	6	1	1	1
80570	1710	previously, a factor	[Previously, a factor]	0.0	3	1	1	1
80571	1710	PMA ionomycin	[PMA ionomycin]	0.0	2	1	1	1
80572	1710	il-1beta mrna level in beas-2b cell	[IL-1beta mRNA levels in BEAS-2B cells]	0.0	6	1	1	1
80573	1710	main feature of cellular senescence	[main feature of cellular senescence]	0.0	5	1	1	1
80574	1710	T cell il-2 production	[T cell IL-2 production]	0.0	4	1	1	1
80575	1710	gene association	[genes association]	0.0	2	1	1	1
80576	1710	mechanism change	[Mechanism changes]	0.0	2	1	1	1
80577	1710	human cd3epsilon mouse line	[human CD3epsilon mouse lines]	0.0	4	1	1	1
80578	1710	therapeutic value alter pathologic immune response	[therapeutic value altering pathologic immune responses]	0.0	6	1	1	1
80579	1710	IL-2 tyrosine	[IL-2 tyrosine]	0.0	2	1	1	1
80580	1710	ca(2+)-mobilize	[Ca(2+)-mobilizing]	0.0	1	1	1	1
80581	1710	stimulation of pbl-t	[stimulation of PBL-T]	0.0	3	1	1	1
80582	1710	genomic DNA sequence upstream	[genomic DNA sequence upstream]	0.0	4	1	1	1
80583	1710	NK lysis	[NK lysis]	0.0	2	1	1	1
80584	1710	c57mg fibroblast cell	[C57MG fibroblast cells]	0.0	3	1	1	1
80585	1710	specific [3H]dexamethasone binding site	[specific [3H]dexamethasone binding sites]	0.0	4	1	1	1
80586	1710	appearance in cd4+ lymphocyte supt	[appearance in CD4+ lymphocytes SupT]	0.0	5	1	1	1
80587	1710	dichroism analysis	[dichroism analysis]	0.0	2	1	1	1
80588	1710	(hours)	[(hours)]	0.0	1	1	1	1
80589	1710	CsA associate with binding protein	[CsA associate with binding proteins]	0.0	5	1	1	1
80590	1710	end target	[end targets]	0.0	2	1	1	1
80591	1710	functional core	[functional core]	0.0	2	2	2	1
80592	1710	cyclosporin A cya lesion formation	[cyclosporin A CyA lesion formation]	0.0	5	1	1	1
80593	1710	endometriotic lesion together	[endometriotic lesions together]	0.0	3	1	1	1
80594	1710	growth resistance	[growth resistance]	0.0	2	1	1	1
80595	1710	modulate the differentiation	[modulating the differentiation]	0.0	3	1	1	1
80596	1710	follow adherence	[following adherence]	0.0	2	1	1	1
80597	1710	Differential regulation c-jun	[Differential regulation c-jun]	0.0	3	1	1	1
80598	1710	ig/tcr gene rearrangement	[Ig/TcR gene rearrangements]	0.0	3	1	1	1
80599	1710	administration of a oligonucleotide	[administration of an oligonucleotide]	0.0	4	1	1	1
80600	1710	redundant role in development	[redundant roles in development]	0.0	4	1	1	1
80601	1710	less extent the kD factor	[less extent the kD factor]	0.0	5	1	1	1
80602	1710	constitutive basal phosphorylation usually, STAT3	[Constitutive basal phosphorylation usually, STAT3]	0.0	5	1	1	1
80603	1710	enhance transcription	[enhancing transcription]	0.0	2	1	1	1
80604	1710	chemical nature Arg91	[chemical nature Arg91]	0.0	3	1	1	1
80605	1710	significantly (p 0.025)	[significantly (P 0.025)]	0.0	3	1	1	1
80606	1710	use ptf beta antibody	[using PTF beta antibodies]	0.0	4	1	1	1
80607	1710	activity of nf-il6	[activity of NF-IL6]	0.0	3	1	1	1
80608	1710	prevent tnf-alpha apoptosis efficiently	[preventing TNF-alpha apoptosis efficiently]	0.0	4	1	1	1
80609	1710	nearly complete resistance	[nearly complete resistance]	0.0	3	1	1	1
80610	1710	C3a(desArg) lps	[C3a(desArg) LPS]	0.0	2	1	1	1
80611	1710	thereby provide a structural basis	[thereby providing a structural basis]	0.0	5	1	1	1
80612	1710	overexpression of inactive mutant of Raf-1	[overexpression of inactive mutants of Raf-1]	0.0	6	1	1	1
80613	1710	sclerosis gene in tissue	[sclerosis gene in tissues]	0.0	4	1	1	1
80614	1710	receptor tnfr1 death domain protein tradd	[receptor TNFR1 death domain protein TRADD]	0.0	6	1	1	1
80615	1710	identity with the corresponding I gamma	[identity with the corresponding I gamma]	0.0	6	1	1	1
80616	1710	only use constituent such as lps	[only using constituents such as LPS]	0.0	6	1	1	1
80617	1710	Potential role of a sequence	[Potential role of a sequence]	0.0	5	1	1	1
80618	1710	3 survival	[3 survival]	0.0	2	1	1	1
80619	1710	minute at 37 degree	[min at 37 degrees]	0.0	4	1	1	1
80620	1710	binding parameter	[Binding parameters]	0.0	2	1	1	1
80621	1710	inclusion of microm RU	[inclusion of microM RU]	0.0	4	1	1	1
80622	1710	17beta-HSD iv mrna expression	[17beta-HSD IV mRNA expression]	0.0	4	1	1	1
80623	1710	intracellular receptor vitamin D3 receptor	[intracellular receptors vitamin D3 receptors]	0.0	5	1	1	1
80624	1710	direct percutaneous transluminal coronary angioplasty	[direct percutaneous transluminal coronary angioplasty]	0.0	5	1	1	1
80625	1710	hiv-1 harbor mutation	[HIV-1 harboring mutations]	0.0	3	1	1	1
80626	1710	simian virus SV40 region	[simian virus SV40 region]	0.0	4	1	1	1
80627	1710	sequestration of class heterodimer	[sequestration of class heterodimers]	0.0	4	1	1	1
80628	1710	several function such as downregulation	[Several functions such as downregulation]	0.0	5	1	1	1
80629	1710	human haematopoietic line u937	[human haematopoietic lines U937]	0.0	4	1	1	1
80630	1710	relatively late stage	[relatively late stage]	0.0	3	1	1	1
80631	1710	coordination with cell-specific factor	[coordination with cell-specific factors]	0.0	4	1	1	1
80632	1710	pathogenic role,	[pathogenic role,]	0.0	2	1	1	1
80633	1710	Nuclear factor-kappaB -dependent induction	[Nuclear factor-kappaB -dependent induction]	0.0	4	1	1	1
80634	1710	gene bzlf1	[genes BZLF1]	0.0	2	1	1	1
80635	1710	repeat activity in T	[repeat activity in T]	0.0	4	1	1	1
80636	1710	disorder euthymic,	[disorder euthymic,]	0.0	2	1	1	1
80637	1710	development of primary culture	[development of primary cultures]	0.0	4	1	1	1
80638	1710	imply a role for SCL	[implying a role for SCL]	0.0	5	1	1	1
80639	1710	monocyte adhesion in endothelial cell	[monocyte adhesion in endothelial cells]	0.0	5	1	1	1
80640	1710	include k protein	[including K protein]	0.0	3	1	1	1
80641	1710	saa gene	[SAA gene]	0.0	2	1	1	1
80642	1710	microgram/ml]	[microgram/ml]]	0.0	1	1	1	1
80643	1710	more specific inhibitor	[more specific inhibitors]	0.0	3	1	1	1
80644	1710	calcium -signal cyclophilin ligand	[calcium -signal cyclophilin ligand]	0.0	4	1	1	1
80645	1710	gh in obese patient	[GH in obese patient]	0.0	4	1	1	1
80646	1710	repressor activity of Eed	[repressor activity of Eed]	0.0	4	1	1	1
80647	1710	contain a additional site	[containing an additional site]	0.0	4	1	1	1
80648	1710	control gene transcription	[controlling gene transcription]	0.0	3	1	1	1
80649	1710	TFIID	[TFIID]	0.0	1	1	1	1
80650	1710	mutation in codon	[mutation in codon]	0.0	3	1	1	1
80651	1710	oligoclonal,	[oligoclonal,]	0.0	1	1	1	1
80652	1710	long maintenance	[long-term maintenance]	0.0	2	1	1	1
80653	1710	important new insight into role	[important new insights into role]	0.0	5	1	1	1
80654	1710	system a step	[system a step]	0.0	3	1	1	1
80655	1710	Separate Cox analysis	[Separate Cox analysis]	0.0	3	1	1	1
80656	1710	expression of a distinct subset	[expression of a distinct subset]	0.0	5	2	2	1
80657	1710	lack of feature in patient	[lack of features in patients]	0.0	5	1	1	1
80658	1710	shp2-interacting adaptor protein	[SHP2-interacting adaptor protein]	0.0	3	1	1	1
80659	1710	dbcamp	[dbcAMP]	0.0	1	1	1	1
80660	1710	in-vitro-stimulated adult peripheral blood lymphocyte sample	[in-vitro-stimulated adult peripheral blood lymphocyte samples]	0.0	6	1	1	1
80661	1710	RXR-RXR pathway	[RXR-RXR pathway]	0.0	2	1	1	1
80662	1710	role of specific nuclear factor-DNA complex	[role of specific nuclear factor-DNA complexes]	0.0	6	1	1	1
80663	1710	c-sis/platelet-derived growth factor-B proto-oncogene	[c-sis/platelet-derived growth factor-B proto-oncogene]	0.0	4	1	1	1
80664	1710	only dna-binding activity of extract	[only DNA-binding activity of extracts]	0.0	5	1	1	1
80665	1710	hiv-1 mutation within C/EBP site	[HIV-1 mutations within C/EBP sites]	0.0	5	1	1	1
80666	1710	monocytogent	[monocytogenes]	0.0	1	1	1	1
80667	1710	glucocorticoid in leukocyte from male	[glucocorticoids in leukocytes from males]	0.0	5	1	1	1
80668	1710	report in cell	[report in cells]	0.0	3	1	1	1
80669	1710	diffuse b-cell lymphoma	[diffuse B-cell lymphomas]	0.0	3	1	1	1
80670	1710	activation in response to signal	[activation in response to signals]	0.0	5	1	1	1
80671	1710	event in transformation	[event in transformation]	0.0	3	1	1	1
80672	1710	transcription isgf3	[transcription ISGF3]	0.0	2	1	1	1
80673	1710	rapidly tyrosine-phosphorylated follow stimulate factor treatment	[rapidly tyrosine-phosphorylated following stimulating factor treatment]	0.0	6	1	1	1
80674	1710	nuclear translocation factor	[nuclear translocation factor]	0.0	3	2	2	1
80675	1710	tcf-responsive gene	[Tcf-responsive genes]	0.0	2	1	1	1
80676	1710	neighbor sequence	[neighboring sequences]	0.0	2	1	1	1
80677	1710	transform growth factor-beta tgf-beta in relationship	[transforming growth factor-beta TGF-beta in relationship]	0.0	6	1	1	1
80678	1710	effect of a liposomal formulation	[effect of a liposomal formulation]	0.0	5	1	1	1
80679	1710	heat shock protein 60	[heat shock protein 60]	0.0	4	1	1	1
80680	1710	peritoneal macrophage by interleukin	[peritoneal macrophages by interleukins]	0.0	4	1	1	1
80681	1710	HL-60/vinc revertant line	[HL-60/vinc revertant line]	0.0	3	1	1	1
80682	1710	apoptosis in human neutrophil	[apoptosis in human neutrophils]	0.0	4	1	1	1
80683	1710	source of 135(oh)2d3 production	[source of 1,25(OH)2D3 production]	0.0	4	1	1	1
80684	1710	decidua	[decidua]	0.0	1	1	1	1
80685	1710	adhesion in umbilical vein endothelial cell	[adhesion in umbilical vein endothelial cells]	0.0	6	1	1	1
80686	1710	patient (58.3 2.7)	[patients (58.3 2.7)]	0.0	3	1	1	1
80687	1710	removal of class ii dimer	[removal of class II dimers]	0.0	5	1	1	1
80688	1710	myeloid nuclear differentiation antigen	[myeloid nuclear differentiation antigen]	0.0	4	1	1	1
80689	1710	especially diffuse lymphoma	[especially diffuse lymphomas]	0.0	3	1	1	1
80690	1710	molecular mechanism of t-lymphocyte anergy	[molecular mechanisms of T-lymphocyte anergy]	0.0	5	1	1	1
80691	1710	peripheral blood lymphocyte asthma	[peripheral blood lymphocytes asthma]	0.0	4	1	1	1
80692	1710	here, structure-function	[here, structure-function]	0.0	2	1	1	1
80693	1710	well in line with the notion	[well in line with the notion]	0.0	6	1	1	1
80694	1710	adhesion molecule in cell	[adhesion molecules in cells]	0.0	4	1	1	1
80695	1710	glutathione -depleting agent diethyl	[glutathione -depleting agent diethyl]	0.0	4	1	1	1
80696	1710	change in chemical nature	[change in chemical nature]	0.0	4	1	1	1
80697	1710	Interleukin (il) level	[Interleukin (IL) levels]	0.0	3	1	1	1
80698	1710	receptor on human mononuclear leukocyte	[receptors on human mononuclear leukocytes]	0.0	5	1	1	1
80699	1710	1,25 Dihydroxyvitamin D3	[1,25 Dihydroxyvitamin D3]	0.0	3	1	1	1
80700	1710	use different approach	[using different approaches]	0.0	3	1	1	1
80701	1710	untreated RA	[untreated RA]	0.0	2	1	1	1
80702	1710	observation with the previous finding	[observations with the previous findings]	0.0	5	1	1	1
80703	1710	suggest great than thought.	[suggesting greater than thought.]	0.0	4	1	1	1
80704	1710	perspective about mechanism	[perspectives about mechanisms]	0.0	3	1	1	1
80705	1710	class in vitro.	[classes in vitro.]	0.0	3	1	1	1
80706	1710	transfection of vcam-1 promoter construct	[transfection of VCAM-1 promoter constructs]	0.0	5	1	1	1
80707	1710	protect vascular injury	[protecting vascular injury]	0.0	3	1	1	1
80708	1710	critical guanine nucleotide	[critical guanine nucleotides]	0.0	3	1	1	1
80709	1710	human macrophage by ventilation	[human macrophages by ventilation]	0.0	4	1	1	1
80710	1710	control transcription via cis-acting element	[control transcription via cis-acting elements]	0.0	5	1	1	1
80711	1710	Lipopolysaccharide LPS stimulation	[Lipopolysaccharide LPS stimulation]	0.0	3	1	1	1
80712	1710	b-cell precursor	[B-cell precursors]	0.0	2	1	1	1
80713	1710	b cell membrane protein	[B cell membrane proteins]	0.0	4	1	1	1
80714	1710	factor/DNA interaction	[factor/DNA interactions]	0.0	2	1	1	1
80715	1710	-500 bp	[-500 bp]	0.0	2	1	1	1
80716	1710	activation domain requirement	[Activation domain requirements]	0.0	3	1	1	1
80717	1710	expression of gamma-ifn responsive gene monocyte	[Expression of gamma-IFN responsive genes monocytes]	0.0	6	1	1	1
80718	1710	property in endothelial cell	[properties in endothelial cells]	0.0	4	1	1	1
80719	1710	presence of a inducible pathway	[presence of a inducible pathway]	0.0	5	1	1	1
80720	1710	Extrarenal receptor-effector-mechor-mechanisms the sequence	[Extrarenal receptor-effector-mechanisms the sequence]	0.0	4	1	1	1
80721	1710	distinct nuclear factor with mobilities,	[distinct nuclear factors with mobilities,]	0.0	5	1	1	1
80722	1710	environment, experiment	[environment, experiments]	0.0	2	1	1	1
80723	1710	decline in glucocorticoid receptor concentration	[decline in glucocorticoid receptor concentrations]	0.0	5	1	1	1
80724	1710	class of dex -resistant clone	[classes of dex -resistant clones]	0.0	5	1	1	1
80725	1710	apc only after immunization.	[APC only after immunization.]	0.0	4	1	1	1
80726	1710	IL-12 signal pathway,	[IL-12 signaling pathway,]	0.0	3	1	1	1
80727	1710	Study with analogue	[Studies with analogues]	0.0	3	1	1	1
80728	1710	important step in the transition	[important step in the transition]	0.0	5	1	1	1
80729	1710	expression in promonocytic u937 cell	[Expression in promonocytic U937 cells]	0.0	5	1	1	1
80730	1710	two well-characterized Ets family member	[Two well-characterized Ets family members]	0.0	5	1	1	1
80731	1710	element at -1280	[element at -1280]	0.0	3	1	1	1
80732	1710	immunofluorescence study on population	[Immunofluorescence studies on populations]	0.0	4	1	1	1
80733	1710	IL-12 receptor beta subunit	[IL-12 receptor beta subunit]	0.0	4	1	1	1
80734	1710	metabolic cascade culminate	[metabolic cascade culminating]	0.0	3	1	1	1
80735	1710	effect on hematopoiesis	[effects on hematopoiesis]	0.0	3	1	1	1
80736	1710	cyclosporin -resistant mutant	[cyclosporin -resistant mutants]	0.0	3	1	1	1
80737	1710	AITL /gc	[AITL /GC]	0.0	2	1	1	1
80738	1710	marker after a great	[markers after a great]	0.0	4	1	1	1
80739	1710	10 cushingd'	[10 Cushing's]	0.0	2	1	1	1
80740	1710	cell microg/ml)/mn2+ microM) for 2 h	[Cells microg/ml)/Mn2+ microM) for 2 h]	0.0	6	1	1	1
80741	1710	dna-binding protein of the lineage	[DNA-binding protein of the lineage]	0.0	5	1	1	1
80742	1710	multiple protein lead	[multiple proteins leading]	0.0	3	1	1	1
80743	1710	inactive lyso-platelet-activating factor	[inactive lyso-platelet-activating factor]	0.0	3	1	1	1
80744	1710	overproduction in granulomato	[overproduction in granulomatoses]	0.0	3	1	1	1
80745	1710	interleukin 2 T cell growth	[interleukin 2 T cell growth]	0.0	5	1	1	1
80746	1710	component of U1	[components of U1]	0.0	3	1	1	1
80747	1710	transformation in leukemia	[transformation in leukemia]	0.0	3	1	1	1
80748	1710	rest vein endothelial cell	[resting vein endothelial cells]	0.0	4	1	1	1
80749	1710	HTLV-IIIB	[HTLV-IIIB]	0.0	1	1	1	1
80750	1710	detectable deviation in this variable	[detectable deviations in these variables]	0.0	5	1	1	1
80751	1710	th2 clone pos-1 pos-1b	[Th2 clones POS-1 POS-1b]	0.0	4	1	1	1
80752	1710	combination of acid	[combination of acid]	0.0	3	1	1	1
80753	1710	native molecular weight	[native molecular weights]	0.0	3	1	1	1
80754	1710	pebp2 alpha gene	[PEBP2 alpha genes]	0.0	3	1	1	1
80755	1710	nfatp from ht-2 cell	[NFATp from HT-2 cells]	0.0	4	1	1	1
80756	1710	parasite Theileria parva	[parasite Theileria parva]	0.0	3	1	1	1
80757	1710	regulatory region responsive	[regulatory region responsive]	0.0	3	1	1	1
80758	1710	decrease in pH	[decreases in pH]	0.0	3	1	1	1
80759	1710	recurrent abnormality highlight loci	[recurrent abnormalities highlighting loci]	0.0	4	1	1	1
80760	1710	direct phosphorylation	[direct phosphorylation]	0.0	2	1	1	1
80761	1710	interleukin-5 synthesis	[interleukin-5 synthesis]	0.0	2	1	1	1
80762	1710	source of antibody	[source of antibodies]	0.0	3	1	1	1
80763	1710	intravenous pretreatment	[intravenous pretreatment]	0.0	2	1	1	1
80764	1710	hiv-1 gp41 il-10 up-regulation	[HIV-1 gp41 IL-10 up-regulation]	0.0	4	1	1	1
80765	1710	Oct-2 function	[Oct-2 function]	0.0	2	1	1	1
80766	1710	constitute model for the three marker	[constituting models for the three markers]	0.0	6	1	1	1
80767	1710	mechanism for mineralocorticoid action	[mechanism for mineralocorticoid action]	0.0	4	1	1	1
80768	1710	+/- 0.49 nM;	[+/- 0.49 nM;]	0.0	3	1	1	1
80769	1710	Addition during the h	[Addition during the h]	0.0	4	1	1	1
80770	1710	ar in cancer lncap cell	[AR in cancer LNCaP cells]	0.0	5	1	1	1
80771	1710	mouse mutant	[mouse mutants]	0.0	2	1	1	1
80772	1710	hypereosinophilic disease	[hypereosinophilic diseases]	0.0	2	1	1	1
80773	1710	chimeric properties	[chimeric properties,]	0.0	2	1	1	1
80774	1710	fasl transcription	[FasL transcription]	0.0	2	1	1	1
80775	1710	Tat- hiv-1 with ltr	[Tat- HIV-1 with LTRs]	0.0	4	1	1	1
80776	1710	cell-to-cell contact activation	[Cell-to-cell contact activation]	0.0	3	1	1	1
80777	1710	value of receptor of D3 determination	[value of receptors of D3 determination]	0.0	6	1	1	1
80778	1710	class ii major gene transcription	[class II major gene transcription]	0.0	5	1	1	1
80779	1710	chain gene cluster	[chain gene cluster]	0.0	3	1	1	1
80780	1710	low affinity class	[lower affinity class]	0.0	3	1	1	1
80781	1710	distinct epitope	[distinct epitopes]	0.0	2	1	1	1
80782	1710	low surface icam-1 expression	[low surface ICAM-1 expression]	0.0	4	1	1	1
80783	1710	heat-shock for hour at degree	[Heat-shock for hours at degrees]	0.0	5	1	1	1
80784	1710	differentiation of human leukemia u937 cell	[differentiation of human leukemia U937 cells]	0.0	6	1	1	1
80785	1710	vesicle trafficking	[vesicle trafficking]	0.0	2	1	1	1
80786	1710	least two species,	[least two species,]	0.0	3	1	1	1
80787	1710	model of lineage switch	[Models of lineage switching]	0.0	4	1	1	1
80788	1710	individual property	[individual properties]	0.0	2	1	1	1
80789	1710	collagenase-1 promoter	[collagenase-1 promoter]	0.0	2	1	1	1
80790	1710	several regulatory mechanism	[several regulatory mechanisms]	0.0	3	1	1	1
80791	1710	effect of Ras	[effect of Ras]	0.0	3	1	1	1
80792	1710	several line of mouse	[several lines of mice]	0.0	4	1	1	1
80793	1710	(RNA) blot of adult mouse tissue	[(RNA) blots of adult mouse tissues]	0.0	6	1	1	1
80794	1710	potentially novel protein	[potentially novel proteins]	0.0	3	1	1	1
80795	1710	inhibitory capacity	[inhibitory capacity]	0.0	2	1	1	1
80796	1710	-secreting	[-secreting]	0.0	1	1	1	1
80797	1710	also against a excess	[also against an excess]	0.0	4	1	1	1
80798	1710	study on the rhythm	[study on the rhythm]	0.0	4	1	1	1
80799	1710	deaminase a enzyme	[deaminase an enzyme]	0.0	3	1	1	1
80800	1710	normal number of affinity tnfrp75 molecule	[normal numbers of affinity TNFRp75 molecules]	0.0	6	1	1	1
80801	1710	cell transfection involve deletion analysis	[cell transfection involving deletion analysis]	0.0	5	1	1	1
80802	1710	substantial nf-kappa b -binding activity	[substantial NF-kappa B -binding activity]	0.0	5	1	1	1
80803	1710	role of regulatory sites.	[role of regulatory sites.]	0.0	4	1	1	1
80804	1710	hpc high-proliferative potential colony-forming cell	[HPCs high-proliferative potential colony-forming cells]	0.0	5	1	1	1
80805	1710	activation involvement	[activation involvement]	0.0	2	1	1	1
80806	1710	bmt structure	[BMT structure]	0.0	2	1	1	1
80807	1710	b binding activity	[B binding activity]	0.0	3	1	1	1
80808	1710	sequence downstream element	[sequence downstream element]	0.0	3	1	1	1
80809	1710	tonically suppress nervous system	[tonically suppressing nervous system]	0.0	4	1	1	1
80810	1710	elaboration	[elaboration]	0.0	1	1	1	1
80811	1710	effect of expression	[effects of expression]	0.0	3	1	1	1
80812	1710	mediate transcriptional activation	[mediating transcriptional activation]	0.0	3	1	1	1
80813	1710	consist of nfkappab1	[consisting of NFkappaB1]	0.0	3	1	1	1
80814	1710	analysis apoptosis in wild-type CD4 receptor	[analysis apoptosis in wild-type CD4 receptors]	0.0	6	1	1	1
80815	1710	activation of the transcription factor indicator	[activation of the transcription factor indicators]	0.0	6	1	1	1
80816	1710	active ras	[active Ras]	0.0	2	1	1	1
80817	1710	study the mechanism of latency	[studying the mechanism of latency]	0.0	5	1	1	1
80818	1710	use retinoid with different binding specificity	[Using retinoids with different binding specificity]	0.0	6	1	1	1
80819	1710	T-helper 2 th2 subset	[T-helper 2 Th2 subset]	0.0	4	1	1	1
80820	1710	response in cases.	[response in cases.]	0.0	3	1	1	1
80821	1710	future gene therapy trials,	[future gene therapy trials,]	0.0	4	1	1	1
80822	1710	supernatant from cell	[supernatants from cells]	0.0	3	1	1	1
80823	1710	1-kb region	[1-kb region]	0.0	2	1	1	1
80824	1710	abnormal adherence of blood cell	[abnormal adherence of blood cells]	0.0	5	1	1	1
80825	1710	number in blood lymphocyte pbl	[numbers in blood lymphocytes PBL]	0.0	5	1	1	1
80826	1710	distinct entity	[distinct entity]	0.0	2	1	1	1
80827	1710	two- to fourfold increase	[two- to fourfold increase]	0.0	4	1	1	1
80828	1710	activity in long-distance runner	[activity in long-distance runner]	0.0	4	1	1	1
80829	1710	weak chi b formation	[weaker chi B formation]	0.0	4	1	1	1
80830	1710	spread on human cell	[spreading on human cells]	0.0	4	1	1	1
80831	1710	term priming.	[term priming.]	0.0	2	1	1	1
80832	1710	multiple element include binding site	[multiple elements including binding sites]	0.0	5	1	1	1
80833	1710	cloning of the 5' region	[Cloning of the 5' region]	0.0	5	1	1	1
80834	1710	macrophage-colony stimulate factor	[macrophage-colony stimulating factor]	0.0	3	1	1	1
80835	1710	end target of pathway	[end targets of pathway]	0.0	4	1	1	1
80836	1710	epidermal keratinocyte	[epidermal keratinocytes]	0.0	2	1	1	1
80837	1710	interval.	[interval.]	0.0	1	1	1	1
80838	1710	remainder	[remainders]	0.0	1	1	1	1
80839	1710	glucocorticoid receptor expression in t-	[glucocorticoid receptor expression in T-]	0.0	5	1	1	1
80840	1710	corresponding to the binding site	[corresponding to the binding sites]	0.0	5	1	1	1
80841	1710	weight transmembrane adaptor protein	[weight transmembrane adaptor proteins]	0.0	4	1	1	1
80842	1710	-synthesizing	[-synthesizing]	0.0	1	1	1	1
80843	1710	inherent problem	[inherent problems.]	0.0	2	1	1	1
80844	1710	gi/go protein	[Gi/Go protein]	0.0	2	1	1	1
80845	1710	Helenalin a sesquiterpene lactone from Arnica	[Helenalin an sesquiterpene lactone from Arnica]	0.0	6	1	1	1
80846	1710	treatment with 5-azacytidine re-expression of icam-i	[treatment with 5-azacytidine re-expression of ICAM-I]	0.0	6	1	1	1
80847	1710	molecular size of dalton	[molecular size of daltons]	0.0	4	1	1	1
80848	1710	kinase gamma B*CaM-K	[kinases gamma B*CaM-K]	0.0	3	1	1	1
80849	1710	non-pregnant endometrium during the cycle	[non-pregnant endometrium during the cycle]	0.0	5	1	1	1
80850	1710	PAS domain	[PAS domain]	0.0	2	1	1	1
80851	1710	transient disorder in down' syndrome tmd	[transient disorder in Down's syndrome TMD]	0.0	6	2	2	1
80852	1710	use 125i-labeled c-c chemokine	[using 125I-labeled C-C chemokines]	0.0	4	1	1	1
80853	1710	regulation in lymphoid cell line	[regulation in lymphoid cell lines]	0.0	5	1	1	1
80854	1710	hepatic factor beta hnf3 beta	[hepatic factor beta HNF3 beta]	0.0	5	1	1	1
80855	1710	growth factor-beta TGF-beta	[growth factor-beta TGF-beta]	0.0	3	2	2	1
80856	1710	e(gre) motif mediate transcriptional activation	[E(gre) motifs mediating transcriptional activation]	0.0	5	1	1	1
80857	1710	chronic (auto)immune inflammation	[chronic (auto)immune inflammation]	0.0	3	1	1	1
80858	1710	24 woman (11 second	[24 women (11 second]	0.0	4	1	1	1
80859	1710	CEM T	[CEM T]	0.0	2	1	1	1
80860	1710	er-: mda-mb-231	[ER-: MDA-MB-231]	0.0	2	1	1	1
80861	1710	conversion of E2	[Conversion of E2]	0.0	3	1	1	1
80862	1710	erythroid mel cell	[erythroid MEL cells]	0.0	3	1	1	1
80863	1710	portion of this sequence	[portion of this sequence]	0.0	4	1	1	1
80864	1710	treatment nb4 with interferon alpha	[Treatment NB4 with interferon alpha]	0.0	5	1	1	1
80865	1710	blood lactate concentration during MPE	[blood lactate concentrations during MPE]	0.0	5	1	1	1
80866	1710	class ii determinant	[class II determinants]	0.0	3	1	1	1
80867	1710	interleukin-4 IL-4 receptor	[interleukin-4 IL-4 receptor]	0.0	3	1	1	1
80868	1710	anti-fa antibody	[anti-Fas antibody]	0.0	2	1	1	1
80869	1710	molecular basis for induction	[molecular basis for induction]	0.0	4	1	1	1
80870	1710	cDNA cloning strategy	[cDNA cloning strategies]	0.0	3	1	1	1
80871	1710	PHA-stimulated pbl	[PHA-stimulated PBL]	0.0	2	1	1	1
80872	1710	undergo tnf-alpha apoptosis	[undergoing TNF-alpha apoptosis]	0.0	3	2	2	1
80873	1710	simultaneous activation of pkc	[simultaneous activation of PKC]	0.0	4	1	1	1
80874	1710	receptor in human mononuclear leukocyte	[receptors in human mononuclear leukocytes]	0.0	5	1	1	1
80875	1710	protein complex a factor	[protein complexes a factor]	0.0	4	1	1	1
80876	1710	pha human blood lymphocyte pbl	[PHA human blood lymphocytes PBL]	0.0	5	1	1	1
80877	1710	simultaneously; non-dividing, normal pbl	[simultaneously; non-dividing, normal PBL]	0.0	4	1	1	1
80878	1710	inducibility on a promoter	[inducibility on a promoter]	0.0	4	1	1	1
80879	1710	site of interaction	[site of interactions]	0.0	3	1	1	1
80880	1710	bivalent cation	[Bivalent cations]	0.0	2	1	1	1
80881	1710	opposite effect on monocytic differentiation	[opposite effects on monocytic differentiation]	0.0	5	1	1	1
80882	1710	involvement in translocation	[involvement in translocations]	0.0	3	1	1	1
80883	1710	hGR domain	[hGR domain]	0.0	2	1	1	1
80884	1710	receptor (tcr) variable region beta-chain family	[receptor (TCR) variable region beta-chain families]	0.0	6	1	1	1
80885	1710	identification in a background	[identification in a background]	0.0	4	1	1	1
80886	1710	immunodeficiency virus type 1 LTR	[immunodeficiency virus type 1 LTR]	0.0	5	1	1	1
80887	1710	fraction contain the protein Sp1	[fractions containing the protein Sp1]	0.0	5	1	1	1
80888	1710	stat5b tyrosine phosphorylation.	[STAT5b tyrosine phosphorylation.]	0.0	3	1	1	1
80889	1710	immediate response to IL-12	[immediate response to IL-12]	0.0	4	1	1	1
80890	1710	interleukin (il)-10 blocking factor pibf expression	[interleukin (IL)-10 blocking factor PIBF expression]	0.0	6	1	1	1
80891	1710	mouse overexpress icsat in lymphocyte	[mice overexpressing ICSAT in lymphocytes]	0.0	5	1	1	1
80892	1710	angioimmunoblastic t-cell lymphoma with center	[angioimmunoblastic T-cell lymphoma with centers]	0.0	5	1	1	1
80893	1710	pge2 synthesis	[PGE2 synthesis]	0.0	2	1	1	1
80894	1710	activation of this zymogen	[activation of this zymogen]	0.0	4	1	1	1
80895	1710	astroglioma cell line CRT	[astroglioma cell line CRT]	0.0	4	1	1	1
80896	1710	grf40 in jurkat cell	[Grf40 in Jurkat cells]	0.0	4	1	1	1
80897	1710	target for a screen	[targets for a screening]	0.0	4	1	1	1
80898	1710	triple-labelling with mab	[triple-labellings with mAbs]	0.0	3	1	1	1
80899	1710	binding of creb/atf-1	[binding of CREB/ATF-1]	0.0	3	1	1	1
80900	1710	p3a2 wing gene product	[P3A2 wing gene product]	0.0	4	1	1	1
80901	1710	result of redundancy	[result of redundancy]	0.0	3	1	1	1
80902	1710	9 keratoacanthomas kas	[9 keratoacanthomas KAs]	0.0	3	1	1	1
80903	1710	105-kDa protein	[105-kDa protein]	0.0	2	1	1	1
80904	1710	very small effect	[very small effect]	0.0	3	1	1	1
80905	1710	high-frequency rearrangement	[high-frequency rearrangement]	0.0	2	1	1	1
80906	1710	model for apl	[model for APL]	0.0	3	1	1	1
80907	1710	candidate gene factor beta hnf3 beta	[candidate genes factor beta HNF3 beta]	0.0	6	1	1	1
80908	1710	mature myeloid cell polymorphonuclear granulocyte	[mature myeloid cells polymorphonuclear granulocytes]	0.0	5	1	1	1
80909	1710	protein-beta	[protein-beta]	0.0	1	1	1	1
80910	1710	embryonic/fetal k562 cell	[embryonic/fetal K562 cells]	0.0	3	1	1	1
80911	1710	Ser386-Val525	[Ser386-Val525]	0.0	1	1	1	1
80912	1710	terminal differentiation of precursor cell line	[terminal differentiation of precursor cell lines]	0.0	6	1	1	1
80913	1710	77 +/-	[77 +/-]	0.0	2	1	1	1
80914	1710	day establish high-density pbmc culture (1.5	[days establishing high-density PBMC cultures (1.5]	0.0	6	1	1	1
80915	1710	possible mechanism of cellular transformation	[possible mechanism of cellular transformation]	0.0	5	1	1	1
80916	1710	hydrophobic, polypeptide of function	[hydrophobic, polypeptide of function]	0.0	4	1	1	1
80917	1710	increase in b	[increase in B]	0.0	3	1	1	1
80918	1710	m all-tran retinoic acid RA	[M all-trans retinoic acid RA]	0.0	5	1	1	1
80919	1710	importance in the immune system	[importance in the immune system]	0.0	5	1	1	1
80920	1710	pts;	[pts;]	0.0	1	1	1	1
80921	1710	suggest possible strategy	[suggesting possible strategies]	0.0	3	1	1	1
80922	1710	formalin-resistant epitope	[formalin-resistant epitope]	0.0	2	1	1	1
80923	1710	Rel/NF-kappaB gene	[Rel/NF-kappaB gene]	0.0	2	1	1	1
80924	1710	express the ebna2 protein	[expressing the EBNA2 protein]	0.0	4	1	1	1
80925	1710	action a gata site CPRE GGACTACAG	[action a GATA site CPRE GGACTACAG]	0.0	6	1	1	1
80926	1710	maximal lps induction	[maximal LPS induction]	0.0	3	1	1	1
80927	1710	lymphocyte-specific immunoglobulin mu gene enhancer	[lymphocyte-specific immunoglobulin mu gene enhancer]	0.0	5	1	1	1
80928	1710	inducible, CsA T cell factor	[inducible, CsA T cell factors]	0.0	5	1	1	1
80929	1710	full il-4 enhancement	[full IL-4 enhancement]	0.0	3	1	1	1
80930	1710	regulation by gene 4	[Regulation by gene 4]	0.0	4	1	1	1
80931	1710	role in normal hematopoiesis	[role in normal hematopoiesis]	0.0	4	1	1	1
80932	1710	a23187 PDBu/iono	[A23187 PDBu/iono]	0.0	2	1	1	1
80933	1710	capacity in different t-cell type	[capacities in different T-cell types]	0.0	5	1	1	1
80934	1710	NF-kappa b as inducible activator	[NF-kappa B as inducible activator]	0.0	5	1	1	1
80935	1710	activity of Jun	[activity of Jun]	0.0	3	1	1	1
80936	1710	metabolite polar	[metabolites polar]	0.0	2	1	1	1
80937	1710	transfection into b cell	[transfection into B cells]	0.0	4	1	1	1
80938	1710	elderly (mean years)	[elderly (mean years)]	0.0	3	1	1	1
80939	1710	full length tf	[full length TF]	0.0	3	1	1	1
80940	1710	follow factor treatment	[following factor treatment]	0.0	3	1	1	1
80941	1710	-dependent cell line m-tat	[-dependent cell line M-TAT]	0.0	4	1	1	1
80942	1710	development abnormality	[development abnormalities]	0.0	2	1	1	1
80943	1710	study of this protein,	[studies of this protein,]	0.0	4	1	1	1
80944	1710	TCR gene expression	[TCR gene expression]	0.0	3	1	1	1
80945	1710	900 normal x-chromosomes	[900 normal X-chromosomes]	0.0	3	1	1	1
80946	1710	activation of second messenger	[activation of second messengers]	0.0	4	1	1	1
80947	1710	engagement of this receptor.	[engagement of this receptor.]	0.0	4	1	1	1
80948	1710	expose human vein cell to anoxia/reoxygenation	[Exposing human vein cells to anoxia/reoxygenation]	0.0	6	1	1	1
80949	1710	cell with a retrovirus	[cells with a retrovirus]	0.0	4	1	1	1
80950	1710	goal of this study	[goal of this study]	0.0	4	1	1	1
80951	1710	level of Spi-B	[levels of Spi-B]	0.0	3	1	1	1
80952	1710	anti- il-1beta antibody	[anti- IL-1beta antibody]	0.0	3	1	1	1
80953	1710	ng/ml) in plasma	[ng/mL) in plasma]	0.0	3	1	1	1
80954	1710	fibrosarcoma histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	6	1	1	1
80955	1710	tramp a apoptosis-mediating receptor	[TRAMP a apoptosis-mediating receptor]	0.0	4	1	1	1
80956	1710	non-PRL-secreting stromal cell	[non-PRL-secreting stromal cells]	0.0	3	1	1	1
80957	1710	hiv-infected human T cell	[HIV-infected human T cells]	0.0	4	1	1	1
80958	1710	treatment of er- cell	[treatment of ER- cells]	0.0	4	1	1	1
80959	1710	antioxidant concentration	[antioxidant concentrations]	0.0	2	1	1	1
80960	1710	10 nm RA cell	[10 nM RA cells]	0.0	4	1	1	1
80961	1710	expression assay with plasmid	[expression assays with plasmids]	0.0	4	1	1	1
80962	1710	universal finding	[universal finding]	0.0	2	1	1	1
80963	1710	anti-tumour activity	[anti-tumour activity]	0.0	2	1	1	1
80964	1710	outgrowth of erythroid cell	[outgrowth of erythroid cells]	0.0	4	1	1	1
80965	1710	(p50/p65)- expression vector	[(p50/p65)- expression vectors]	0.0	3	1	1	1
80966	1710	IL-3 colony-stimumulatelany-stg factor dna-binding complex	[IL-3 colony-stimulating factor DNA-binding complexes]	0.0	5	1	1	1
80967	1710	downstream nf-kappab activation	[downstream NF-kappaB activation]	0.0	3	1	1	1
80968	1710	percentage infiltrate T cell	[percentage infiltrating T cells]	0.0	4	1	1	1
80969	1710	stretch with site	[stretches with sites]	0.0	3	1	1	1
80970	1710	activation of binding in lymphocyte	[activation of binding in lymphocytes]	0.0	5	1	1	1
80971	1710	perhaps by transcriptional regulation	[perhaps by transcriptional regulation]	0.0	4	1	1	1
80972	1710	role for IL-7 signal pathway	[role for IL-7 signaling pathways]	0.0	5	1	1	1
80973	1710	express egr-1 rna	[expressing Egr-1 RNA]	0.0	3	1	1	1
80974	1710	receptor type	[receptor type]	0.0	2	1	1	1
80975	1710	Tax1 a activator	[Tax1 a activator]	0.0	3	1	1	1
80976	1710	1-long repeat CAT construct	[1-long repeat CAT constructs]	0.0	4	1	1	1
80977	1710	huvec to human neutrophil	[HUVECs to human neutrophils]	0.0	4	1	1	1
80978	1710	NLS peptide-mediated disruption of the import	[NLS peptide-mediated disruption of the import]	0.0	6	1	1	1
80979	1710	10 nm 2,3,377-tc	[10 nM 2,3,7,8-TCDD]	0.0	3	1	1	1
80980	1710	T cell in this condition.	[T cells in this condition.]	0.0	5	1	1	1
80981	1710	latter factor for T cell	[latter factor for T cells]	0.0	5	1	1	1
80982	1710	breast cancer mcf-7 cell	[breast cancer MCF-7 cells]	0.0	4	1	1	1
80983	1710	antigen-specific reactivity at level as high	[antigen-specific reactivities at levels as high]	0.0	6	1	1	1
80984	1710	little alteration in apparent affinity	[little alteration in apparent affinity]	0.0	5	1	1	1
80985	1710	cell of the cell line	[cells of the cell line]	0.0	5	1	1	1
80986	1710	significantly more cortivazol than the cell	[significantly more cortivazol than the cells]	0.0	6	1	1	1
80987	1710	only a degree of transcription,	[only a degree of transcription,]	0.0	5	1	1	1
80988	1710	other viral activity downstream	[other viral activities downstream]	0.0	4	1	1	1
80989	1710	set of lymphokine gene	[set of lymphokine genes]	0.0	4	1	1	1
80990	1710	calcitriol ethanol concentration v/v)	[calcitriol ethanol concentration v/v)]	0.0	4	1	1	1
80991	1710	productive hiv infection,	[productive HIV infection,]	0.0	3	1	1	1
80992	1710	group c, adenovirus serotype 5	[Group C, adenovirus serotype 5]	0.0	5	1	1	1
80993	1710	binding of three complex	[binding of three complexes]	0.0	4	1	1	1
80994	1710	enhancer of interferon (ifn)-inducible	[enhancers of interferon (IFN)-inducible]	0.0	4	1	1	1
80995	1710	rhombotin family	[rhombotin family]	0.0	2	1	1	1
80996	1710	class gene regulation	[class gene regulation]	0.0	3	1	1	1
80997	1710	two band	[two bands]	0.0	2	1	1	1
80998	1710	microtitre assay	[microtitre assay]	0.0	2	1	1	1
80999	1710	implicate CAML	[implicating CAML]	0.0	2	1	1	1
81000	1710	morphologic feature membrane	[morphologic features membranes]	0.0	3	1	1	1
81001	1710	cluster of aromatic residue	[cluster of aromatic residues]	0.0	4	1	1	1
81002	1710	collagenase transcription in monocytic cell	[collagenase transcription in monocytic cells]	0.0	5	1	1	1
81003	1710	gata-1 allele, lead to anemic severity	[GATA-1 allele, leading to anemic severity]	0.0	6	1	1	1
81004	1710	major cellular component of atheroma	[major cellular component of atheroma]	0.0	5	1	1	1
81005	1710	first kb	[first kb]	0.0	2	1	1	1
81006	1710	peptide show cross-reactivity at concentration	[peptide showing cross-reactivity at concentrations]	0.0	5	1	1	1
81007	1710	taf of kda	[TAF of kDa]	0.0	3	1	1	1
81008	1710	hgata-3 binding	[hGATA-3 binding]	0.0	2	1	1	1
81009	1710	increase in beta-globin gene transcription	[increases in beta-globin gene transcription]	0.0	5	1	1	1
81010	1710	administration for hour	[administration for hours]	0.0	3	1	1	1
81011	1710	light of common therapeutic use	[light of common therapeutic use]	0.0	5	1	1	1
81012	1710	patient experience toxicity secondary	[patients experiencing toxicity secondary]	0.0	4	1	1	1
81013	1710	2.3 fmol/million cells;	[2.3 fmol/million cells;]	0.0	3	1	1	1
81014	1710	diameter,	[diameter,]	0.0	1	1	1	1
81015	1710	Nuclear factor-kappaB activation	[Nuclear factor-kappaB activation]	0.0	3	1	1	1
81016	1710	death receptor DR3	[death receptor DR3]	0.0	3	1	1	1
81017	1710	chronic state	[chronic state]	0.0	2	1	1	1
81018	1710	cell with p50	[Cells with p50]	0.0	3	1	1	1
81019	1710	elicit oxidative stress	[eliciting oxidative stress]	0.0	3	1	1	1
81020	1710	beta il-1 beta	[beta IL-1 beta]	0.0	3	2	2	1
81021	1710	multiple substrate in proliferate cell	[multiple substrates in proliferating cells]	0.0	5	1	1	1
81022	1710	effect on the migration	[effect on the migration]	0.0	4	1	1	1
81023	1710	fragment span nucleotide	[fragment spanning nucleotides]	0.0	3	1	1	1
81024	1710	use interleukin-2 sequence oligonucleotide probe	[using interleukin-2 sequence oligonucleotide probes]	0.0	5	1	1	1
81025	1710	also the homologue	[also the homologue]	0.0	3	1	1	1
81026	1710	15 to 22 cell divisions, corresponding	[15 to 22 cell divisions, corresponding]	0.0	6	1	1	1
81027	1710	active promoter region bp.	[active promoter region bp.]	0.0	4	1	1	1
81028	1710	two step	[two steps]	0.0	2	1	1	1
81029	1710	ATL patient 4111 ng/ml)	[ATL patients 4,111 ng/mL)]	0.0	4	1	1	1
81030	1710	action on U-937	[action on U-937]	0.0	3	1	1	1
81031	1710	cell death of b cell	[cell death of B cells]	0.0	5	1	1	1
81032	1710	(1.2-3.3) fmol/10(7) cell vs. fmol/10(7) cell	[(1.2-3.3) fmol/10(7) cells vs. fmol/10(7) cells]	0.0	6	1	1	1
81033	1710	cleavage during anti-igm-induced apoptosis	[Cleavage during anti-IgM-induced apoptosis]	0.0	4	1	1	1
81034	1710	activation by the trans-activator	[activation by the trans-activator]	0.0	4	1	1	1
81035	1710	Percoll density gradient	[Percoll density gradient]	0.0	3	1	1	1
81036	1710	process via recognition	[processes via recognition]	0.0	3	1	1	1
81037	1710	formation by extract	[formation by extracts]	0.0	3	1	1	1
81038	1710	potent inducer of drip coactivator binding	[potent inducers of DRIP coactivator binding]	0.0	6	1	1	1
81039	1710	background: arsenic trioxide	[BACKGROUND: Arsenic trioxide]	0.0	3	1	1	1
81040	1710	regulation in peripheral blood T cell	[regulation in peripheral blood T cells]	0.0	6	1	1	1
81041	1710	flexi-12 delivery to blast use virus	[Flexi-12 delivery to blasts using virus]	0.0	6	1	1	1
81042	1710	therapeutic modality	[therapeutic modality]	0.0	2	1	1	1
81043	1710	interleukin (il)-10 blocking factor	[interleukin (IL)-10 blocking factor]	0.0	4	1	1	1
81044	1710	competition /heb protein	[competition /HEB proteins]	0.0	3	1	1	1
81045	1710	regulator of stat6	[regulator of STAT6]	0.0	3	1	1	1
81046	1710	first bp	[first bp]	0.0	2	1	1	1
81047	1710	number in leucocyte in woman	[numbers in leucocytes in women]	0.0	5	1	1	1
81048	1710	activation of gene gene	[activation of genes genes]	0.0	4	1	1	1
81049	1710	AM580 a benzoic derivative of acid	[AM580 a benzoic derivative of acid]	0.0	6	1	1	1
81050	1710	P; binding of heterodimer	[h; binding of heterodimers]	0.0	4	1	1	1
81051	1710	ie, inhibition	[ie, inhibition]	0.0	2	1	1	1
81052	1710	parent with receptor binding	[parent with receptor binding]	0.0	4	1	1	1
81053	1710	dna-binding activity of nuclear extract	[DNA-binding activity of nuclear extracts]	0.0	5	1	1	1
81054	1710	vzv product	[VZV product]	0.0	2	1	1	1
81055	1710	human androgen receptor assay	[human androgen receptor assay]	0.0	4	1	1	1
81056	1710	target of AML1/ETO	[target of AML1/ETO]	0.0	3	1	1	1
81057	1710	blotting of hematopoietic population	[blotting of hematopoietic populations]	0.0	4	1	1	1
81058	1710	salt loss	[salt loss]	0.0	2	1	1	1
81059	1710	mature, T cell	[mature, T cells]	0.0	3	1	1	1
81060	1710	blood cell hrbc	[blood cells HRBC]	0.0	3	1	1	1
81061	1710	cleavage of transcription factor	[Cleavage of transcription factor]	0.0	4	1	1	1
81062	1710	-infected	[-infected]	0.0	1	2	2	1
81063	1710	VDR by 8 h	[VDR by 8 h]	0.0	4	1	1	1
81064	1710	androgen on cell	[androgens on cells]	0.0	3	1	1	1
81065	1710	culture molecular analysis of gene expression	[cultures molecular analysis of gene expression]	0.0	6	1	1	1
81066	1710	cd11b+ bone	[CD11b+ bone]	0.0	2	1	1	1
81067	1710	regulation of il-6 gene transcription	[regulation of IL-6 gene transcription]	0.0	5	1	1	1
81068	1710	kruppel-type zinc finger domain	[Kruppel-type zinc finger domains]	0.0	4	1	1	1
81069	1710	analysis of 1 signal molecule	[analysis of 1 signaling molecule]	0.0	5	1	1	1
81070	1710	feature in PML/RARalpha transgenic mouse	[features in PML/RARalpha transgenic mice]	0.0	5	1	1	1
81071	1710	nuclear binding protein kD	[nuclear binding proteins kD]	0.0	4	1	1	1
81072	1710	require log-fold glucocorticoid	[requiring log-fold glucocorticoids]	0.0	3	1	1	1
81073	1710	Epstein-Barr virus EBV the causative agent	[Epstein-Barr virus EBV the causative agent]	0.0	6	1	1	1
81074	1710	type of estrogen binding site	[types of estrogen binding sites]	0.0	5	1	1	1
81075	1710	candidate gene nuclear factor hnf3 beta	[candidate genes nuclear factor HNF3 beta]	0.0	6	1	1	1
81076	1710	Ca2+ ca2+	[Ca2+ Ca2+]	0.0	2	1	1	1
81077	1710	cd34(+) progenitor cell	[CD34(+) progenitor cells]	0.0	3	1	1	1
81078	1710	killing by cd8(+) T lymphocyte	[killing by CD8(+) T lymphocytes]	0.0	5	1	1	1
81079	1710	indicate fk506 -sensitive	[indicating FK506 -sensitive]	0.0	3	1	1	1
81080	1710	role in B-cell growth	[role in B-cell growth]	0.0	4	1	1	1
81081	1710	more recently circulate lymphocyte	[more recently circulating lymphocytes]	0.0	4	2	2	1
81082	1710	replication of the hiv-1	[replication of the HIV-1]	0.0	4	1	1	1
81083	1710	(fh) subject	[(FH) subjects]	0.0	2	1	1	1
81084	1710	characteristic at abundance in a variety	[characteristics at abundance in a variety]	0.0	6	1	1	1
81085	1710	i.e. 28 dayus- glucocorticoid therapy	[i.e. 28 day, glucocorticoid therapy]	0.0	5	1	1	1
81086	1710	b cell-specific gene blk	[B cell-specific gene blk]	0.0	4	1	1	1
81087	1710	gene in quiescent cell	[genes in quiescent cells]	0.0	4	1	1	1
81088	1710	thus, tal1	[Thus, TAL1]	0.0	2	1	1	1
81089	1710	protein-beta C/EBP-beta	[protein-beta C/EBP-beta]	0.0	2	1	1	1
81090	1710	cellular pathway for induction	[Cellular pathways for induction]	0.0	4	1	1	1
81091	1710	binding of ebna-2 type a	[binding of EBNA-2 type A]	0.0	5	1	1	1
81092	1710	combination with acid	[combination with acid]	0.0	3	1	1	1
81093	1710	transacting	[transacting]	0.0	1	1	1	1
81094	1710	activation of lytic promoter	[activation of lytic promoters]	0.0	4	1	1	1
81095	1710	suggest the presence of element	[suggesting the presence of elements]	0.0	5	1	1	1
81096	1710	subpopulation of worker	[subpopulations of workers]	0.0	3	1	1	1
81097	1710	various gene product from virus htlv-1	[Various gene products from viruses HTLV-1]	0.0	6	1	1	1
81098	1710	hexameric binding site	[hexameric binding sites]	0.0	3	1	1	1
81099	1710	course in patient	[course in patients]	0.0	3	1	1	1
81100	1710	specificity of the enhancer	[specificity of the enhancer]	0.0	4	1	1	1
81101	1710	increase in the density	[increase in the density]	0.0	4	1	1	1
81102	1710	2 gene enhancer	[2 gene enhancer]	0.0	3	1	1	1
81103	1710	2 h. induce CAT activity	[2 h, inducing CAT activity]	0.0	5	1	1	1
81104	1710	negative mutant of traf2	[negative mutant of TRAF2]	0.0	4	1	1	1
81105	1710	inhibit dissociation from heat shock protein	[inhibiting dissociation from heat shock protein]	0.0	6	1	1	1
81106	1710	cross-specy effectiveness of ciita	[cross-species effectiveness of CIITA]	0.0	4	1	1	1
81107	1710	weight of k.0	[weight of kd,]	0.0	3	1	1	1
81108	1710	(chi2=6.25,	[(chi2=6.25,]	0.0	1	1	1	1
81109	1710	novel tip-associated protein tap	[novel Tip-associated protein Tap]	0.0	4	1	1	1
81110	1710	withdrawal of il-2	[withdrawal of IL-2]	0.0	3	1	1	1
81111	1710	early step signal cascade	[early steps signaling cascade]	0.0	4	1	1	1
81112	1710	phosphatidylinositol 3-kinase binding site	[phosphatidylinositol 3-kinase binding site]	0.0	4	1	1	1
81113	1710	evidence at bind element p0	[Evidence at binding element P0]	0.0	5	1	1	1
81114	1710	association of traz with LMP1	[association of TRAFs with LMP1]	0.0	5	1	1	1
81115	1710	specific NF-kappaB complex	[specific NF-kappaB complexes]	0.0	3	1	1	1
81116	1710	inhibition include tumor necrosis factor-alpha	[inhibition including tumor necrosis factor-alpha]	0.0	5	1	1	1
81117	1710	further deletional mutagenesis analysis	[Further deletional mutagenesis analyses]	0.0	4	1	1	1
81118	1710	affinity for a sterol sequence	[affinity for a sterol sequence]	0.0	5	1	1	1
81119	1710	steroid dpm mg-1 cytosol protein	[steroids dpm mg-1 cytosol protein]	0.0	5	1	1	1
81120	1710	axis in rat	[axis in rats]	0.0	3	1	1	1
81121	1710	leukemic hl-60 cell	[leukemic HL-60 cells]	0.0	3	1	1	1
81122	1710	e1a-immortalized cell	[E1A-immortalized cells]	0.0	2	1	1	1
81123	1710	peroxide Wurzburg t-cell	[peroxide Wurzburg T-cells]	0.0	3	1	1	1
81124	1710	insight into a role for nf-kappab	[insight into a role for NF-kappaB]	0.0	6	1	1	1
81125	1710	TNFRp55-/-mutant mouse	[TNFRp55-/-mutant mice]	0.0	2	1	1	1
81126	1710	differentiation event	[differentiation events]	0.0	2	1	1	1
81127	1710	pnu156804 inhibition	[PNU156804 inhibition]	0.0	2	1	1	1
81128	1710	immunoreactivity of the subunit	[immunoreactivity of the subunits]	0.0	4	1	1	1
81129	1710	thapsigargin sensitive, ca2+	[thapsigargin sensitive, Ca2+]	0.0	3	1	1	1
81130	1710	treatment with alpha-pml	[treatment with alpha-PML]	0.0	3	1	1	1
81131	1710	memory cells,	[memory cells,]	0.0	2	1	1	1
81132	1710	cemx174 cell	[CEMx174 cells]	0.0	2	1	1	1
81133	1710	include polysaccharide specificity	[including polysaccharide specificity]	0.0	3	1	1	1
81134	1710	extensive component	[extensive component]	0.0	2	1	1	1
81135	1710	step in NF-kappa b activation	[step in NF-kappa B activation]	0.0	5	1	1	1
81136	1710	beta)	[beta)]	0.0	1	1	1	1
81137	1710	analysis of the proximal CD19 promoter	[analysis of the proximal CD19 promoter]	0.0	6	1	1	1
81138	1710	study gene regulation	[studying gene regulation]	0.0	3	1	1	1
81139	1710	two form of type	[two forms of type]	0.0	4	1	1	1
81140	1710	analogue of up pnu156804	[analogue of UP PNU156804]	0.0	4	1	1	1
81141	1710	line with the notion	[line with the notion]	0.0	4	1	1	1
81142	1710	treatment lymphocyte	[Treatment lymphocytes]	0.0	2	1	1	1
81143	1710	period of viral latency	[period of viral latency]	0.0	4	1	1	1
81144	1710	human sr-bp	[human SR-BP]	0.0	2	1	1	1
81145	1710	different amount of the isoform	[Different amounts of the isoforms]	0.0	5	1	1	1
81146	1710	mammalian runt product	[mammalian runt products]	0.0	3	1	1	1
81147	1710	process of hematopoietic cell	[process of hematopoietic cells]	0.0	4	1	1	1
81148	1710	measurement of the activity	[Measurement of the activity]	0.0	4	1	1	1
81149	1710	interaction between protein	[interactions between proteins]	0.0	3	1	1	1
81150	1710	transfection of expression vector together	[Transfection of expression vectors together]	0.0	5	1	1	1
81151	1710	phosphorylation at Throger	[phosphorylation at Thr]	0.0	3	1	1	1
81152	1710	Th2 subset	[Th2 subset]	0.0	2	1	1	1
81153	1710	feature include sensitivity	[features including sensitivity]	0.0	3	1	1	1
81154	1710	monocyte specificity,	[monocyte specificity,]	0.0	2	1	1	1
81155	1710	physical interaction between multiple ets	[physical interaction between multiple Ets]	0.0	5	1	1	1
81156	1710	kidney insufficiency	[kidney insufficiency]	0.0	2	3	3	1
81157	1710	n: excretion,	[N: excretion,]	0.0	2	1	1	1
81158	1710	control subject (24.6+/-2.4	[control subjects (24.6+/-2.4]	0.0	3	1	1	1
81159	1710	analyze the clonality	[analyzing the clonality]	0.0	3	1	1	1
81160	1710	tissue regulation of gene expression	[Tissue regulation of gene expression]	0.0	5	1	1	1
81161	1710	examination.	[examination.]	0.0	1	1	1	1
81162	1710	9s receptor complex	[9S receptor complexes]	0.0	3	1	1	1
81163	1710	act with calcium /calcineurin signal	[acting with calcium /calcineurin signals]	0.0	5	1	1	1
81164	1710	nonactive fragment	[nonactive fragments]	0.0	2	1	1	1
81165	1710	gcr regulation	[GcR regulation]	0.0	2	1	1	1
81166	1710	persistent replication	[persistent replication]	0.0	2	1	1	1
81167	1710	estimate	[estimate]	0.0	1	1	1	1
81168	1710	octamer -75 to -66	[octamer -75 to -66]	0.0	4	1	1	1
81169	1710	cooperation with factor	[cooperation with factors]	0.0	3	1	1	1
81170	1710	corresponding to partial sequence	[corresponding to partial sequences]	0.0	4	1	1	1
81171	1710	30-fold induction	[30-fold induction]	0.0	2	1	1	1
81172	1710	electrolyte transport	[electrolyte transport]	0.0	2	1	1	1
81173	1710	differentiation control of erythroblast	[differentiation control of erythroblasts]	0.0	4	1	1	1
81174	1710	differentiation of the mpro promyelocyte	[differentiation of the MPRO promyelocytes]	0.0	5	1	1	1
81175	1710	novel factor ms-2	[novel factor MS-2]	0.0	3	1	1	1
81176	1710	differential assembly of stat1 alpha	[differential assembly of STAT1 alpha]	0.0	5	1	1	1
81177	1710	absence for 32-36 day	[absence for 32-36 days]	0.0	4	1	1	1
81178	1710	acid RA a vitamin a derivative	[acid RA a vitamin A derivative]	0.0	6	1	1	1
81179	1710	occur at 30 minute 1)	[occurring at 30 minutes 1)]	0.0	5	1	1	1
81180	1710	efficiency for antagonist	[efficiency for antagonists]	0.0	3	1	1	1
81181	1710	highly specific lysosomal protein myeloperoxidase	[highly specific lysosomal proteins myeloperoxidase]	0.0	5	1	1	1
81182	1710	low level alpha-naphthyl-acetate-esterase	[low levels alpha-naphthyl-acetate-esterase]	0.0	3	1	1	1
81183	1710	mutation of the AP-1 site	[mutation of the AP-1 site]	0.0	5	1	1	1
81184	1710	t-cell phenotype	[T-cell phenotype]	0.0	2	1	1	1
81185	1710	Gene for a activator ebf	[Gene for a activator EBF]	0.0	5	1	1	1
81186	1710	TF catalytic cofactor	[TF catalytic cofactor]	0.0	3	1	1	1
81187	1710	capacity of glucocorticoid receptor	[capacity of glucocorticoid receptor]	0.0	4	1	1	1
81188	1710	cotransfection of tat cDNA together	[cotransfection of tat cDNA together]	0.0	5	1	1	1
81189	1710	significance of this finding	[significance of these findings]	0.0	4	1	1	1
81190	1710	severe inflammatory syndrome	[severe inflammatory syndrome]	0.0	3	1	1	1
81191	1710	pulp	[pulp]	0.0	1	1	1	1
81192	1710	x gene sequence in patient	[X gene sequence in patients]	0.0	5	1	1	1
81193	1710	ad vector lack antigen	[Ad vectors lacking antigens]	0.0	4	1	1	1
81194	1710	ic50 parameter	[IC50 parameters]	0.0	2	1	1	1
81195	1710	tissue-specific expression of cytokine	[tissue-specific expression of cytokines]	0.0	4	1	1	1
81196	1710	pathways,	[pathways,]	0.0	1	1	1	1
81197	1710	target for Oct2	[targets for Oct2]	0.0	3	1	1	1
81198	1710	biphasic,	[biphasic,]	0.0	1	1	1	1
81199	1710	use mutagenesis of HSs	[Using mutagenesis of HSs]	0.0	4	1	1	1
81200	1710	inhibition by a hormone receptor	[inhibition by a hormone receptor]	0.0	5	1	1	1
81201	1710	points),	[points),]	0.0	1	1	1	1
81202	1710	prototype class	[prototype class]	0.0	2	1	1	1
81203	1710	cell line HeLa	[cell lines HeLa]	0.0	3	1	1	1
81204	1710	pathways:	[pathways:]	0.0	1	1	1	1
81205	1710	lim-hox gene hlh-2	[LIM-Hox gene hLH-2]	0.0	3	1	1	1
81206	1710	manipulate pathological immune response	[manipulating pathological immune responses]	0.0	4	1	1	1
81207	1710	conferr il-2 responsiveness	[conferring IL-2 responsiveness]	0.0	3	1	1	1
81208	1710	well-characterized Ets family member Ets-1	[well-characterized Ets family members Ets-1]	0.0	5	1	1	1
81209	1710	evidence most likely identical proteins, differ	[evidence most likely identical proteins, differing]	0.0	6	1	1	1
81210	1710	regulator of blood T	[regulators of blood T]	0.0	4	1	1	1
81211	1710	feature nuclear membrane	[features nuclear membranes]	0.0	3	1	1	1
81212	1710	nonsmok patient	[nonsmoking patients]	0.0	2	1	1	1
81213	1710	human pterin carbinolamine	[human pterin carbinolamine]	0.0	3	1	1	1
81214	1710	leukocyte bind to glucocorticoid	[leukocytes binding to glucocorticoid]	0.0	4	1	1	1
81215	1710	intracellular ca2+ concentration ca2+	[intracellular Ca2+ concentration Ca2+]	0.0	4	1	1	1
81216	1710	study in non-epithelial cell	[studies in non-epithelial cells]	0.0	4	1	1	1
81217	1710	nf-kappab activation of hiv-1 long repeat	[NF-kappaB activation of HIV-1 long repeat]	0.0	6	1	1	1
81218	1710	concentration range nm.	[concentrations ranging nM.]	0.0	3	1	1	1
81219	1710	suppressor of the immune system notably	[suppressors of the immune system notably]	0.0	6	1	1	1
81220	1710	flutamide	[flutamide]	0.0	1	2	2	1
81221	1710	antigen-driven hypermutation of ig gene	[antigen-driven hypermutation of Ig genes]	0.0	5	1	1	1
81222	1710	cortical thymocyte	[cortical thymocytes]	0.0	2	1	1	1
81223	1710	-/-	[-/-]	0.0	1	1	1	1
81224	1710	eccrine poroma	[eccrine poromas]	0.0	2	1	1	1
81225	1710	monocyte in suspension	[monocytes in suspension]	0.0	3	1	1	1
81226	1710	two activity of glucocorticoid i.e. transactivation	[two activities of glucocorticoids i.e. transactivation]	0.0	6	1	1	1
81227	1710	alpha-globin gene expression during differentiation	[alpha-globin gene expression during differentiation]	0.0	5	1	1	1
81228	1710	cloning encode a chemokine receptor	[cloning encoding a chemokine receptor]	0.0	5	1	1	1
81229	1710	biopsy as treatment	[biopsy as treatment]	0.0	3	1	1	1
81230	1710	extensive purification	[extensive purification]	0.0	2	1	1	1
81231	1710	genotypic marker	[genotypic markers]	0.0	2	1	1	1
81232	1710	activation of stat5 protein	[activation of STAT5 proteins]	0.0	4	1	1	1
81233	1710	treatment with m all-tran retinoic acid	[treatment with M all-trans retinoic acid]	0.0	6	1	1	1
81234	1710	noncomedo status	[noncomedo status]	0.0	2	1	1	1
81235	1710	rapidly expand family	[rapidly expanding family]	0.0	3	1	1	1
81236	1710	current structural classification	[current structural classification]	0.0	3	1	1	1
81237	1710	cd138/	[CD138/]	0.0	1	1	1	1
81238	1710	other result	[other results]	0.0	2	1	1	1
81239	1710	phosphatase-positive giant cell from human monocyte	[phosphatase-positive giant cells from human monocytes]	0.0	6	1	1	1
81240	1710	treatment with 10(3) units/ml recombinant m-csf	[Treatment with 10(3) units/ml recombinant M-CSF]	0.0	6	1	1	1
81241	1710	rescue MHC thymocyte from cell death	[rescuing MHC thymocytes from cell death]	0.0	6	1	1	1
81242	1710	blood lymphocytes, expression	[blood lymphocytes, expression]	0.0	3	1	1	1
81243	1710	fc portion	[Fc portion]	0.0	2	1	1	1
81244	1710	absence of upstream	[absence of upstream]	0.0	3	1	1	1
81245	1710	primary effusion lymphoma cell line	[primary effusion lymphoma cell lines]	0.0	5	1	1	1
81246	1710	evidence for a form	[evidence for an form]	0.0	4	1	1	1
81247	1710	parp inactivation	[PARP inactivation]	0.0	2	1	1	1
81248	1710	synthetic agonist	[synthetic agonists]	0.0	2	1	1	1
81249	1710	h for culture (viability	[h for cultures (viability]	0.0	4	1	1	1
81250	1710	IL-2 prl protein	[IL-2 PRL proteins]	0.0	3	1	1	1
81251	1710	569 receptor	[569 receptors]	0.0	2	1	1	1
81252	1710	3 gene expression follow CD3	[3 gene expression following CD3]	0.0	5	1	1	1
81253	1710	association with tnfr factor TRAFs	[association with TNFR factors TRAFs]	0.0	5	1	1	1
81254	1710	mycobacterial infection [see	[mycobacterial infection [see]	0.0	3	1	1	1
81255	1710	cytokine rrna	[cytokine mRNAs]	0.0	2	1	1	1
81256	1710	induction include tissue factor	[induction including tissue factor]	0.0	4	1	1	1
81257	1710	193-bp region	[193-bp region]	0.0	2	1	1	1
81258	1710	early lytic cycle gene	[early lytic cycle genes]	0.0	4	1	1	1
81259	1710	HaCaT cell line primary blood lymphocyte	[HaCaT cell line primary blood lymphocytes]	0.0	6	1	1	1
81260	1710	some,	[some,]	0.0	1	1	1	1
81261	1710	treatment with m all-tran acid	[treatment with M all-trans acid]	0.0	5	1	1	1
81262	1710	class ii-	[class II-]	0.0	2	1	1	1
81263	1710	blockade use a negative ikappabalpha	[blockade using a negative IkappaBalpha]	0.0	5	1	1	1
81264	1710	inhibitor in a cell line	[inhibitor in a cell line]	0.0	5	1	1	1
81265	1710	continuous presence epo factor	[continuous presence EPO factor]	0.0	4	1	1	1
81266	1710	oxidant-induced nf-kappab activation	[oxidant-induced NF-kappaB activation]	0.0	3	1	1	1
81267	1710	b lymphocyte responsive to alpha,25(OH)2D3	[B lymphocytes responsive to alpha,25(OH)2D3]	0.0	5	1	1	1
81268	1710	class ii+	[class II+]	0.0	2	1	1	1
81269	1710	peripheral blood sample of female	[peripheral blood samples of females]	0.0	5	1	1	1
81270	1710	polypeptide flexi-12	[polypeptide Flexi-12]	0.0	2	1	1	1
81271	1710	ankyrin-rich inhibitory protein	[ankyrin-rich inhibitory proteins]	0.0	3	1	1	1
81272	1710	bind site for c/ebp protein	[binding sites for C/EBP proteins]	0.0	5	1	1	1
81273	1710	amoebocyte	[amoebocyte]	0.0	1	1	1	1
81274	1710	stimulation with C. neoforman	[Stimulation with C. neoformans]	0.0	4	1	1	1
81275	1710	Janus kinase (JAK)-1	[Janus kinase (JAK)-1]	0.0	3	1	1	1
81276	1710	major product	[major products]	0.0	2	1	1	1
81277	1710	direct temporal relationship	[direct temporal relationship]	0.0	3	1	1	1
81278	1710	heat shock protein hsp60	[heat shock protein Hsp60]	0.0	4	1	1	1
81279	1710	relative amount	[relative amount]	0.0	2	1	1	1
81280	1710	promising avenue in acute leukemia	[promising avenue in acute leukemia]	0.0	5	1	1	1
81281	1710	significantly early stage of development	[significantly earlier stages of development]	0.0	5	1	1	1
81282	1710	contain the extracellular domain of c-kit	[containing the extracellular domain of c-kit]	0.0	6	1	1	1
81283	1710	(memory) T cell cd4+cd45r0+cd45ra-cd29highcd11a+	[(memory) T cells CD4+CD45R0+CD45RA-CD29highCD11a+]	0.0	4	1	1	1
81284	1710	AP-1/octamer element	[AP-1/octamer element]	0.0	2	1	1	1
81285	1710	down-regulatory capacity	[down-regulatory capacity]	0.0	2	1	1	1
81286	1710	t-cell leukemia line jurkat cell	[T-cell leukemia line Jurkat cells]	0.0	5	1	1	1
81287	1710	evidence for induction	[Evidence for induction]	0.0	3	1	1	1
81288	1710	directions.	[directions.]	0.0	1	1	1	1
81289	1710	epitope cell dc	[epitope cells DCs]	0.0	3	1	1	1
81290	1710	two site within the negative element	[Two sites within the negative element]	0.0	6	1	1	1
81291	1710	same pattern	[same pattern]	0.0	2	1	1	1
81292	1710	signal in erythroid precursor	[signaling in erythroid precursors]	0.0	4	1	1	1
81293	1710	immunodeficiency virus vpr product	[immunodeficiency virus vpr product]	0.0	4	1	1	1
81294	1710	Peroxisomal proliferator-activated receptor gamma	[Peroxisomal proliferator-activated receptor gamma]	0.0	4	1	1	1
81295	1710	two distinct dna-binding protein	[two distinct DNA-binding proteins]	0.0	4	1	1	1
81296	1710	6 day in 5% serum	[6 days in 5% serum]	0.0	5	1	1	1
81297	1710	different modes, like chemical induction, superinfection	[Different modes, like chemical induction, superinfection]	0.0	6	1	1	1
81298	1710	viral ligand monocyte gene expression	[viral ligands monocyte gene expression]	0.0	5	1	1	1
81299	1710	patient express er	[patients express ER]	0.0	3	1	1	1
81300	1710	PMA agent	[PMA agents]	0.0	2	1	1	1
81301	1710	surface plasmon	[surface plasmon]	0.0	2	1	1	1
81302	1710	promoter proximal (pp) repeat	[promoter proximal (pp) repeat]	0.0	4	1	1	1
81303	1710	long-distance effect	[long-distance effect]	0.0	2	1	1	1
81304	1710	cd11b+ population in mouse	[CD11b+ populations in mice]	0.0	4	1	1	1
81305	1710	interleukin (il)-10 blocking factor expression	[interleukin (IL)-10 blocking factor expression]	0.0	5	1	1	1
81306	1710	-gene transcription	[-gene transcription]	0.0	2	1	1	1
81307	1710	1 bp deletion	[1 bp deletion]	0.0	3	1	1	1
81308	1710	blood sample in parallel,	[blood samples in parallel,]	0.0	4	1	1	1
81309	1710	nuclear factor AP-1/Octamer UPS	[nuclear factor AP-1/Octamer UPS]	0.0	4	1	1	1
81310	1710	hiv -gene expression	[HIV -gene expression]	0.0	3	1	1	1
81311	1710	(inhibitory)	[(inhibitory)]	0.0	1	1	1	1
81312	1710	second weak complex resemble factor	[second weak complex resembling factor]	0.0	5	1	1	1
81313	1710	ADT a glutathione antioxidant	[ADT a glutathione antioxidant]	0.0	4	1	1	1
81314	1710	novel treatment for disease	[novel treatments for diseases]	0.0	4	1	1	1
81315	1710	study, use human cd34+	[study, using human CD34+]	0.0	4	1	1	1
81316	1710	dsm-iii-r	[DSM-III-R]	0.0	1	1	1	1
81317	1710	existence as a subpopulation	[existence as a subpopulation]	0.0	4	1	1	1
81318	1710	expression of the factor Evi-1	[expression of the factors Evi-1]	0.0	5	1	1	1
81319	1710	particular histocompatibility (mhc) haplotype	[particular histocompatibility (MHC) haplotypes]	0.0	4	1	1	1
81320	1710	expression level of receptor	[expression levels of receptors]	0.0	4	1	1	1
81321	1710	80.2 (p p	[80.2 (P P]	0.0	3	1	1	1
81322	1710	patient rarely er	[patients rarely ER]	0.0	3	1	1	1
81323	1710	underlie immunosenescence	[underlying immunosenescence]	0.0	2	1	1	1
81324	1710	property in response	[properties in response]	0.0	3	1	1	1
81325	1710	defective hiv virus	[defective HIV virus]	0.0	3	1	1	1
81326	1710	patient with chronic arthritis	[patient with chronic arthritis]	0.0	4	1	1	1
81327	1710	negative form of Stat1alpha	[negative forms of Stat1alpha]	0.0	4	1	1	1
81328	1710	MHC class ii gene silencing	[MHC class II gene silencing]	0.0	5	1	1	1
81329	1710	subunit bipartite	[subunit bipartite]	0.0	2	1	1	1
81330	1710	protein), a increase in mad3 mrna	[protein), a increase in MAD3 mRNA]	0.0	6	1	1	1
81331	1710	oxygen scavenger enzyme catalase	[oxygen scavenger enzymes catalase]	0.0	4	1	1	1
81332	1710	cytosol of cell	[cytosol of cells]	0.0	3	1	1	1
81333	1710	small amount	[small amount]	0.0	2	2	2	1
81334	1710	surround zone	[surrounding zones]	0.0	2	1	1	1
81335	1710	microm at neutral pH	[microM at neutral pH]	0.0	4	1	1	1
81336	1710	cell adhesion molecule (vcam)-1	[cell adhesion molecule (VCAM)-1]	0.0	4	1	1	1
81337	1710	abnormality of/or	[abnormality of/or]	0.0	2	1	1	1
81338	1710	b-related sequence	[B-related sequence]	0.0	2	1	1	1
81339	1710	mouse mammary tumor terminal	[mouse mammary tumor terminal]	0.0	4	1	1	1
81340	1710	primitive hpc colony-forming cell	[primitive HPCs colony-forming cells]	0.0	4	1	1	1
81341	1710	active pkc	[active PKCs]	0.0	2	1	1	1
81342	1710	activity of JNK	[activity of JNK]	0.0	3	1	1	1
81343	1710	various B-cell line	[various B-cell lines]	0.0	3	1	1	1
81344	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD a inhibitor activation	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD an inhibitor activation]	0.0	5	1	1	1
81345	1710	many cytokine include the interferon	[many cytokines including the interferons]	0.0	5	1	1	1
81346	1710	molecule a protein	[molecule a protein]	0.0	3	1	1	1
81347	1710	activation of T cell through stimulation	[activation of T cells through stimulation]	0.0	6	1	1	1
81348	1710	kilobase (kb) fragment	[kilobase (kb) fragment]	0.0	3	1	1	1
81349	1710	receptor repression	[receptor repression]	0.0	2	1	1	1
81350	1710	replication defect for mutants.	[replication defects for mutants.]	0.0	4	1	1	1
81351	1710	tsp element	[TSP element]	0.0	2	1	1	1
81352	1710	proportion of control	[proportion of controls]	0.0	3	1	1	1
81353	1710	expression by transformation with Epstein-Barr virus	[expression by transformation with Epstein-Barr virus]	0.0	6	1	1	1
81354	1710	nucleotide-dependent kinases.	[nucleotide-dependent kinases.]	0.0	2	1	1	1
81355	1710	malignant fibrous histiocytoma	[malignant fibrous histiocytoma]	0.0	3	1	1	1
81356	1710	only activity of extract	[only activity of extracts]	0.0	4	1	1	1
81357	1710	catalyze the step	[catalyzing the step]	0.0	3	1	1	1
81358	1710	th2 line	[Th2 lines]	0.0	2	1	1	1
81359	1710	lysate use immunomagnetic separation	[lysates using immunomagnetic separation]	0.0	4	1	1	1
81360	1710	sequence regulatory element DRE	[sequence regulatory element DRE]	0.0	4	1	1	1
81361	1710	factor NF-kB	[factor NF-kB]	0.0	2	1	1	1
81362	1710	IL-3 colony-stimumulatelany-stg factor	[IL-3 colony-stimulating factor]	0.0	3	1	1	1
81363	1710	HBxAg stimulation of peripheral blood cell	[HBxAg stimulation of peripheral blood cells]	0.0	6	1	1	1
81364	1710	interaction with distinct dna-binding protein	[interaction with distinct DNA-binding proteins]	0.0	5	1	1	1
81365	1710	response to (il)-2	[response to (IL)-2]	0.0	3	1	1	1
81366	1710	POU motif	[POU motif]	0.0	2	1	1	1
81367	1710	reconstitution erk2 kinase activation	[Reconstitution Erk2 kinase activation]	0.0	4	1	1	1
81368	1710	molecular biology study	[molecular biology study]	0.0	3	1	1	1
81369	1710	immune-mediated disease	[immune-mediated disease]	0.0	2	1	1	1
81370	1710	cytogenetic change	[cytogenetic change]	0.0	2	1	1	1
81371	1710	similarly, covalent modification of sulfhydryl group	[Similarly, covalent modification of sulfhydryl groups]	0.0	6	1	1	1
81372	1710	stimulation synthesis.	[stimulation synthesis.]	0.0	2	1	1	1
81373	1710	novel class	[novel class]	0.0	2	3	3	1
81374	1710	human T transcription factor	[human T transcription factor]	0.0	4	1	1	1
81375	1710	constitutive translocation a member	[constitutive translocation a member]	0.0	4	1	1	1
81376	1710	infection with e1b mutant	[infection with E1B mutants]	0.0	4	1	1	1
81377	1710	anti- human immunodeficiency virus type	[anti- human immunodeficiency virus type]	0.0	5	1	1	1
81378	1710	oncogenic herpesvirus	[oncogenic herpesvirus]	0.0	2	1	1	1
81379	1710	hiv-1 cycle	[HIV-1 cycle]	0.0	2	1	1	1
81380	1710	PKB/Akt activity	[PKB/Akt activity]	0.0	2	1	1	1
81381	1710	evidence link behavior	[evidence linking behavior]	0.0	3	1	1	1
81382	1710	implication for B-cell specificity	[implications for B-cell specificity]	0.0	4	1	1	1
81383	1710	prolactin interferon regulatory factor-1 gene	[prolactin interferon regulatory factor-1 gene]	0.0	5	1	1	1
81384	1710	acetylation of factor activity	[Acetylation of factor activity]	0.0	4	1	1	1
81385	1710	constitutive level of oncogene transcript	[constitutive levels of oncogene transcripts]	0.0	5	1	1	1
81386	1710	serum element SRE present	[serum element SRE present]	0.0	4	1	1	1
81387	1710	AMP -responsive sequence	[AMP -responsive sequence]	0.0	3	1	1	1
81388	1710	creb camp element binding protein	[CREB cAMP element binding protein]	0.0	5	1	1	1
81389	1710	open reading frame of hhv-6	[open reading frames of HHV-6]	0.0	5	1	1	1
81390	1710	NF-AT assembly of transcription complex	[NF-AT assembly of transcription complexes]	0.0	5	1	1	1
81391	1710	region from cell	[region from cells]	0.0	3	1	1	1
81392	1710	transcription of the immunoglobulin gene	[transcription of the immunoglobulin gene]	0.0	5	1	1	1
81393	1710	electromobility shift	[electromobility shift]	0.0	2	3	3	1
81394	1710	down-regulation of nf-kappa b protein level	[Down-regulation of NF-kappa B protein levels]	0.0	6	1	1	1
81395	1710	3' region act	[3' regions acting]	0.0	3	1	1	1
81396	1710	colony size expansion)	[colony size expansion)]	0.0	3	1	1	1
81397	1710	expression of globin gene	[expression of globin genes]	0.0	4	1	1	1
81398	1710	(3 day with dimethylsulfoxide	[(3 days) with dimethylsulfoxide]	0.0	4	1	1	1
81399	1710	synergism between element	[Synergism between elements]	0.0	3	1	1	1
81400	1710	urban pollution	[urban pollution]	0.0	2	1	1	1
81401	1710	moreover, kappa 1-kappa	[Moreover, kappa 1-kappa]	0.0	3	1	1	1
81402	1710	repeat of 15 amino acid	[repeats of 15 amino acids]	0.0	5	1	1	1
81403	1710	carboxyl end	[carboxyl end]	0.0	2	1	1	1
81404	1710	STAT (signal transducer	[STAT (signal transducer]	0.0	3	1	1	1
81405	1710	5 mg bolus late	[5 mg bolus later)]	0.0	4	1	1	1
81406	1710	mechanism underlie cell activation	[mechanisms underlying cell activation]	0.0	4	1	1	1
81407	1710	anti- TNF-alpha hiv-1 repeat LTR	[anti- TNF-alpha HIV-1 repeat LTR]	0.0	5	1	1	1
81408	1710	many environmental factors,	[Many environmental factors,]	0.0	3	1	1	1
81409	1710	mobility gel shift assay	[mobility gel shift assay]	0.0	4	1	1	1
81410	1710	viral gene effect on class	[viral gene effects on class]	0.0	5	1	1	1
81411	1710	detectable basal phosphorylation of Jak3	[detectable basal phosphorylation of Jak3]	0.0	5	1	1	1
81412	1710	expression of ap1 reporter construct	[expression of AP1 reporter constructs]	0.0	5	1	1	1
81413	1710	enable transcriptional activation	[enabling transcriptional activation]	0.0	3	1	1	1
81414	1710	experience toxicity secondary	[experiencing toxicity secondary]	0.0	3	1	1	1
81415	1710	Translational initiation of encephalomyocarditis virus emcv	[Translational initiation of encephalomyocarditis virus EMCV]	0.0	6	1	1	1
81416	1710	treatment, 1 week	[treatment, 1 week]	0.0	3	1	1	1
81417	1710	interact adaptor protein	[interacting adaptor protein]	0.0	3	1	1	1
81418	1710	abnormally high expression	[abnormally high expression]	0.0	3	1	1	1
81419	1710	vessel wall	[vessel wall]	0.0	2	2	2	1
81420	1710	single case with eosinophil abnormality	[single case with eosinophil abnormalities]	0.0	5	1	1	1
81421	1710	nuclear protein from cell	[nuclear proteins from cells]	0.0	4	1	1	1
81422	1710	il-2 induction of ifn-gamma	[IL-2 induction of IFN-gamma]	0.0	4	1	1	1
81423	1710	suggest a mode	[suggesting a mode]	0.0	3	1	1	1
81424	1710	potentiation of activity	[potentiation of activity]	0.0	3	1	1	1
81425	1710	effect inhibition depletion	[effects inhibition depletion]	0.0	3	1	1	1
81426	1710	B-CLL patient	[B-CLL patients]	0.0	2	3	3	1
81427	1710	immunogenicity of protein epitope	[immunogenicity of protein epitopes]	0.0	4	1	1	1
81428	1710	transfection into jurkat T	[Transfection into Jurkat T]	0.0	4	1	1	1
81429	1710	[3H] dex	[[3H] Dex]	0.0	2	1	1	1
81430	1710	NF-AT -deficient mouse	[NF-AT -deficient mice]	0.0	3	1	1	1
81431	1710	classical features: clinical implications.	[classical features: clinical implications.]	0.0	4	1	1	1
81432	1710	6 h of ifn-alpha treatment	[6 h of IFN-alpha treatment]	0.0	5	1	1	1
81433	1710	hypothesis factor in function	[hypothesis factors in functions]	0.0	4	1	1	1
81434	1710	activity capable of transcriptional activation	[activity capable of transcriptional activation]	0.0	5	1	1	1
81435	1710	activate signal lead	[activating signals leading]	0.0	3	1	1	1
81436	1710	chromosome in polycythemia vera	[chromosome in polycythemia vera]	0.0	4	1	1	1
81437	1710	recent demonstration	[recent demonstration]	0.0	2	1	1	1
81438	1710	TREp complex	[TREp complex]	0.0	2	1	1	1
81439	1710	contain the gamma ECS	[containing the gamma ECS]	0.0	4	1	1	1
81440	1710	single point assay of receptor	[single point assay of receptors]	0.0	5	1	1	1
81441	1710	analysis of pair	[Analysis of pairs]	0.0	3	1	1	1
81442	1710	stimulation lead	[stimulation leading]	0.0	2	1	1	1
81443	1710	acute,	[acute,]	0.0	1	1	1	1
81444	1710	5 mg bolus	[5 mg bolus]	0.0	3	1	1	1
81445	1710	effect a integral component	[effects an integral component]	0.0	4	1	1	1
81446	1710	class ii major complex promoter	[class II major complex promoters]	0.0	5	1	1	1
81447	1710	signal by a variety of cytokine	[Signaling by a variety of cytokines]	0.0	6	1	1	1
81448	1710	affect transcription factor	[affecting transcription factors]	0.0	3	1	1	1
81449	1710	primary impairment	[primary impairment]	0.0	2	1	1	1
81450	1710	CBF alpha2 pebp2 alpha	[CBF alpha2 PEBP2 alpha]	0.0	4	1	1	1
81451	1710	lymphatic pathology LP	[lymphatic pathology LP]	0.0	3	1	1	1
81452	1710	few copy encode fkbp	[few copies encoding FKBP]	0.0	4	1	1	1
81453	1710	800-base pair	[800-base pair]	0.0	2	1	1	1
81454	1710	nuclear translocation of [3H]calcitriol/VDR	[nuclear translocation of [3H]calcitriol/VDR]	0.0	4	2	2	1
81455	1710	overexpression of acid receptor alpha	[overexpression of acid receptor alpha]	0.0	5	1	1	1
81456	1710	basic hlh protein	[basic HLH proteins]	0.0	3	1	1	1
81457	1710	t-cell in iddm	[T-cells in IDDM]	0.0	3	1	1	1
81458	1710	NRDS	[NRDS]	0.0	1	1	1	1
81459	1710	homology to the BH1 domain characteristic	[homology to the BH1 domains characteristic]	0.0	6	1	1	1
81460	1710	latter class	[latter class]	0.0	2	1	1	1
81461	1710	factor( binding to promoter DNA	[factor(s) binding to promoter DNA]	0.0	5	1	1	1
81462	1710	selective downregulation	[selective downregulation]	0.0	2	1	1	1
81463	1710	oligodeoxyribonudleotides	[oligodeoxyribonucleotides]	0.0	1	1	1	1
81464	1710	little effect on transcription factor	[little effect on transcription factors]	0.0	5	1	1	1
81465	1710	phorbol differentiation by dexamethasone	[phorbol differentiation by dexamethasone]	0.0	4	1	1	1
81466	1710	dna-binding activity of NF-kappa b complex	[DNA-binding activity of NF-kappa B complex]	0.0	6	1	1	1
81467	1710	(40 mg	[(40 mg]	0.0	2	1	1	1
81468	1710	ctcf activity	[CTCF activity]	0.0	2	1	1	1
81469	1710	high specificity for pkc,	[high specificity for PKC,]	0.0	4	1	1	1
81470	1710	Epstein-Barr virus early antigen component	[Epstein-Barr virus early antigen component]	0.0	5	1	1	1
81471	1710	blood cell hla b8+	[blood cells HLA B8+]	0.0	4	1	1	1
81472	1710	igg-aeca	[IgG-AECA]	0.0	1	1	1	1
81473	1710	5.7+/-0.3 nmol/L),	[5.7+/-0.3 nmol/L),]	0.0	2	1	1	1
81474	1710	1,24(oh)2-22-ene-24-cyclopropyl-vitamin	[1,24(OH)2-22-ene-24-cyclopropyl-vitamin]	0.0	1	1	1	1
81475	1710	change in expression	[changes in expression]	0.0	3	1	1	1
81476	1710	effect of this drug	[effects of these drugs]	0.0	4	1	1	1
81477	1710	cell malignancy nasopharyngeal carcinoma	[cell malignancies nasopharyngeal carcinoma]	0.0	4	1	1	1
81478	1710	NREs	[NREs]	0.0	1	1	1	1
81479	1710	pathogenicity of the virus	[pathogenicity of the viruses]	0.0	4	1	1	1
81480	1710	common messenger	[common messengers]	0.0	2	1	1	1
81481	1710	class major gene transcription	[class major gene transcription]	0.0	4	1	1	1
81482	1710	long follow lps stimulation in monocyte	[longer following LPS stimulation in monocytes]	0.0	6	1	1	1
81483	1710	B/Sp1	[B/Sp1]	0.0	1	1	1	1
81484	1710	important IL-2 element	[important IL-2 elements]	0.0	3	1	1	1
81485	1710	good transactivator of element-containing promoter	[better transactivator of element-containing promoters]	0.0	5	1	1	1
81486	1710	cell vulnerable	[cells vulnerable]	0.0	2	1	1	1
81487	1710	immunodeficiency virus hiv-1 terminal repeat	[immunodeficiency virus HIV-1 terminal repeat]	0.0	5	1	1	1
81488	1710	large region	[large region]	0.0	2	1	1	1
81489	1710	low dose of ionizing radiation gy	[lower doses of ionizing radiation Gy]	0.0	6	1	1	1
81490	1710	persistent relationship in human tonsil	[persistent relationship in human tonsils]	0.0	5	1	1	1
81491	1710	factor-kappaB nuclear translocation	[factor-kappaB nuclear translocation]	0.0	3	1	1	1
81492	1710	transcription in b lymphocyte	[transcription in B lymphocytes]	0.0	4	1	1	1
81493	1710	quantitative immunofluorescence	[quantitative immunofluorescence]	0.0	2	1	1	1
81494	1710	genomic response to 1,25-dihydroxyvitamin D3	[genomic response to 1,25-dihydroxyvitamin D3]	0.0	5	1	1	1
81495	1710	transcription of immunodeficiency virus-1	[transcription of immunodeficiency virus-1]	0.0	4	1	1	1
81496	1710	merit in long	[merit in long-term]	0.0	3	1	1	1
81497	1710	t-pll tumour from a-t patient	[T-PLL tumours from A-T patients]	0.0	5	1	1	1
81498	1710	several intracellular signalling molecule	[several intracellular signalling molecules]	0.0	4	1	1	1
81499	1710	anti- TNF-alpha hiv-1 long repeat LTR	[anti- TNF-alpha HIV-1 long repeat LTR]	0.0	6	1	1	1
81500	1710	nervous system CNS	[nervous system CNS]	0.0	3	3	3	1
81501	1710	pathway mediate shear- ec-mn adhesion	[pathways mediating shear- EC-Mn adhesion]	0.0	5	1	1	1
81502	1710	DC lineage	[DC lineage]	0.0	2	1	1	1
81503	1710	activate ARRE-1 site	[activating ARRE-1 site]	0.0	3	1	1	1
81504	1710	important component of the picture	[important component of the picture]	0.0	5	1	1	1
81505	1710	other toxin	[Other toxins]	0.0	2	1	1	1
81506	1710	spread of lymphoma of malignancy	[spread of lymphomas of malignancy]	0.0	5	1	1	1
81507	1710	mechanism of functional synergy	[mechanisms of functional synergy]	0.0	4	1	1	1
81508	1710	gene promoter in tgf-beta1	[gene promoters in TGF-beta1]	0.0	4	1	1	1
81509	1710	difference in activity	[differences in activity]	0.0	3	1	1	1
81510	1710	significantly (p low	[significantly (P lower]	0.0	3	1	1	1
81511	1710	10 microm at neutral pH	[10 microM at neutral pH]	0.0	5	1	1	1
81512	1710	accompany proliferation	[accompanying proliferation]	0.0	2	1	1	1
81513	1710	control by a inhibitory domain	[Control by a inhibitory domain]	0.0	5	1	1	1
81514	1710	labial salivary gland	[labial salivary glands]	0.0	3	2	2	1
81515	1710	1,25-dihydroxyvitamin D3 a agent	[1,25-dihydroxyvitamin D3 a agent]	0.0	4	1	1	1
81516	1710	role in lipopolysaccharide signal	[Role in lipopolysaccharide signaling]	0.0	4	1	1	1
81517	1710	local host defense	[local host defense]	0.0	3	1	1	1
81518	1710	induce CAT activity for h.	[inducing CAT activity for h,]	0.0	5	1	1	1
81519	1710	specifically in myeloid cell	[specifically in myeloid cells]	0.0	4	1	1	1
81520	1710	interleukin gene by glucocorticoid	[interleukin gene by glucocorticoids]	0.0	4	1	1	1
81521	1710	pbmc from individual	[PBMC from individuals]	0.0	3	1	1	1
81522	1710	rate in granulocyte	[rate in granulocytes]	0.0	3	1	1	1
81523	1710	et transcription factor binding site	[ets transcription factor binding sites]	0.0	5	1	1	1
81524	1710	dissociation constant kDa	[dissociation constants kDa]	0.0	3	1	1	1
81525	1710	inflammatory mediator by cell	[inflammatory mediators by cells]	0.0	4	1	1	1
81526	1710	nuclear export nfat factor	[nuclear export NFAT factor]	0.0	4	1	1	1
81527	1710	-type	[-type]	0.0	1	2	2	1
81528	1710	NF-kappa b -independent suppression	[NF-kappa B -independent suppression]	0.0	4	1	1	1
81529	1710	use a nucleotide sequence	[using a nucleotide sequence]	0.0	4	1	1	1
81530	1710	signal requirement for expression.	[signal requirement for expression.]	0.0	4	1	1	1
81531	1710	development of tumor	[development of tumors]	0.0	3	1	1	1
81532	1710	T alpha 1	[T alpha 1]	0.0	3	1	1	1
81533	1710	mrna for the LFA-I beta chain	[mRNA for the LFA-I beta chain]	0.0	6	1	1	1
81534	1710	130tl-as	[130TL-AS]	0.0	1	1	1	1
81535	1710	distinct dnase-i site	[Distinct DNase-I sites]	0.0	3	1	1	1
81536	1710	sialoglycoprotein	[sialoglycoprotein]	0.0	1	1	1	1
81537	1710	malignancy of CD4 T cell	[malignancy of CD4 T cells]	0.0	5	1	1	1
81538	1710	effect on il-12 production	[effects on IL-12 production]	0.0	4	1	1	1
81539	1710	Activation-dependent regulation	[Activation-dependent regulation]	0.0	2	1	1	1
81540	1710	human sequence element	[human sequence element]	0.0	3	1	1	1
81541	1710	evidence for negative cross-talk	[evidence for negative cross-talk]	0.0	4	1	1	1
81542	1710	level of constitutive hiv production	[levels of constitutive HIV production]	0.0	5	1	1	1
81543	1710	DNA position	[DNA positions]	0.0	2	1	1	1
81544	1710	regulation of cytokine production	[regulation of cytokine production]	0.0	4	1	1	1
81545	1710	Pills	[Pills]	0.0	1	1	1	1
81546	1710	child with variant of syndrome	[children with variants of syndrome]	0.0	5	1	1	1
81547	1710	(9.36 nm	[(9.36 nM]	0.0	2	1	1	1
81548	1710	glutathione-s-transferase pi gst-pi use method	[glutathione-S-transferase pi GST-pi using methods]	0.0	5	1	1	1
81549	1710	olfactory neuronal cell	[olfactory neuronal cells]	0.0	3	1	1	1
81550	1710	-NO	[-NO]	0.0	1	2	2	1
81551	1710	BH1 domain characteristic	[BH1 domains characteristic]	0.0	3	1	1	1
81552	1710	microm sodium	[microM sodium]	0.0	2	1	1	1
81553	1710	frequent hypermutation in lymphoma	[frequent hypermutation in lymphoma]	0.0	4	1	1	1
81554	1710	unique activation signal	[unique activation signals]	0.0	3	1	1	1
81555	1710	different strain	[different strains]	0.0	2	1	1	1
81556	1710	SRF/NFkappaB-like element	[SRF/NFkappaB-like element]	0.0	2	1	1	1
81557	1710	mobilization factor-kappa b nf-kappa b	[mobilization factor-kappa B NF-kappa B]	0.0	5	1	1	1
81558	1710	muscular atrophy	[muscular atrophy]	0.0	2	1	1	1
81559	1710	Sp100 a NB protein	[Sp100 a NB protein]	0.0	4	1	1	1
81560	1710	Ca(2+) factor	[Ca(2+) factor]	0.0	2	1	1	1
81561	1710	regulatory high mobility group	[regulatory high mobility group]	0.0	4	1	1	1
81562	1710	endogenous level	[endogenous levels]	0.0	2	1	1	1
81563	1710	activation by the alpha globin element	[activation by the alpha globin element]	0.0	6	1	1	1
81564	1710	macrophage by ventilation	[macrophages by ventilation]	0.0	3	1	1	1
81565	1710	use monocyte as apc	[using monocytes as APC]	0.0	4	1	1	1
81566	1710	minute of anoxia	[minutes of anoxia]	0.0	3	1	1	1
81567	1710	study with IL-4	[study with IL-4]	0.0	3	1	1	1
81568	1710	bp of the 3'-region	[bp of the 3'-region]	0.0	4	1	1	1
81569	1710	hpv type 16	[HPV type 16]	0.0	3	1	1	1
81570	1710	concept a subtype	[concept an subtype]	0.0	3	1	1	1
81571	1710	serine residue in id2	[serine residue in Id2]	0.0	4	1	1	1
81572	1710	activation a direct vascular mechanism	[activation A direct vascular mechanism]	0.0	5	1	1	1
81573	1710	il-2 promoter/reporter	[IL-2 promoter/reporter]	0.0	2	1	1	1
81574	1710	tf activation occur	[TF activation occurring]	0.0	3	1	1	1
81575	1710	x chromosome xi	[X chromosome Xi]	0.0	3	1	1	1
81576	1710	chronic disorder a clinical problem	[chronic disorders a clinical problem]	0.0	5	1	1	1
81577	1710	g-csf 8% cell	[G-CSF 8% cells]	0.0	3	1	1	1
81578	1710	periplasmic domain	[periplasmic domain]	0.0	2	1	1	1
81579	1710	core of the virus	[core of the virus]	0.0	4	1	1	1
81580	1710	tool for diagnosis.	[tool for diagnosis.]	0.0	3	1	1	1
81581	1710	only activity	[only activity]	0.0	2	1	1	1
81582	1710	differentiation primary response gene	[differentiation primary response gene]	0.0	4	1	1	1
81583	1710	have g3 tumor with positive margin	[having G3 tumors with positive margins]	0.0	6	1	1	1
81584	1710	epitope dendritic cell dc	[epitope dendritic cells DCs]	0.0	4	1	1	1
81585	1710	expression in stage	[expression in stages]	0.0	3	1	1	1
81586	1710	monolayer of vein endothelial cell	[monolayers of vein endothelial cells]	0.0	5	1	1	1
81587	1710	b cell mutant	[B cell mutant]	0.0	3	1	1	1
81588	1710	sequence 5'	[sequences 5']	0.0	2	1	1	1
81589	1710	expression in T lymphocyte	[expression in T lymphocytes]	0.0	4	1	1	1
81590	1710	sequence from the transcriptional start site	[sequences from the transcriptional start site]	0.0	6	1	1	1
81591	1710	line of investigation	[lines of investigation]	0.0	3	2	2	1
81592	1710	antioxidant include hydroxyanisole bha tetrahydropapaveroline	[antioxidants including hydroxyanisole BHA tetrahydropapaveroline]	0.0	5	1	1	1
81593	1710	monocyte adhesion tnf-alpha cell	[monocyte adhesion TNF-alpha cells]	0.0	4	1	1	1
81594	1710	protein in extract	[protein in extracts]	0.0	3	1	1	1
81595	1710	consider the strong positive effect	[Considering the strong positive effect]	0.0	5	1	1	1
81596	1710	World primate cell extract	[World primate cell extracts]	0.0	4	1	1	1
81597	1710	alter nonproductive interaction to interactions.	[altering nonproductive interactions to interactions.]	0.0	5	1	1	1
81598	1710	molecular weight stat5 isoform	[molecular weight STAT5 isoforms]	0.0	4	1	1	1
81599	1710	simian T cell leukemia virus type	[simian T cell leukemia virus type]	0.0	6	1	1	1
81600	1710	divalent cation like cobalt, nickel,	[divalent cations like cobalt, nickel,]	0.0	5	1	1	1
81601	1710	lymphocyte t3 receptor	[lymphocyte T3 receptor]	0.0	3	1	1	1
81602	1710	roi- -independent pathway in cell	[ROI- -independent pathway in cells]	0.0	5	1	1	1
81603	1710	IFN activity equivalent	[IFN activity equivalent]	0.0	3	1	1	1
81604	1710	expression of socs-1	[expression of SOCS-1]	0.0	3	1	1	1
81605	1710	cellular immune	[Cellular immune]	0.0	2	1	1	1
81606	1710	acid dependent signalling	[acid dependent signalling]	0.0	3	1	1	1
81607	1710	AP-1 generation	[AP-1 generation]	0.0	2	1	1	1
81608	1710	neonatal response to a challenge	[neonatal response to an challenge]	0.0	5	1	1	1
81609	1710	Gal/ER	[Gal/ER]	0.0	1	1	1	1
81610	1710	single strand nick	[single strand nicks]	0.0	3	1	1	1
81611	1710	different cell adhesion molecule	[different cell adhesion molecules]	0.0	4	2	2	1
81612	1710	controversies, one	[controversies, one]	0.0	2	1	1	1
81613	1710	peripheral monocyte extract	[peripheral monocyte extracts]	0.0	3	1	1	1
81614	1710	use the PL/IM 430 antibody	[using the PL/IM 430 antibody]	0.0	5	1	1	1
81615	1710	clear induction	[clear induction]	0.0	2	1	1	1
81616	1710	IL-2 event	[IL-2 events]	0.0	2	1	1	1
81617	1710	antagonism in the regulation during differentiation	[antagonism in the regulation during differentiation]	0.0	6	1	1	1
81618	1710	stimulation of primary b lymphocyte	[stimulation of primary B lymphocytes]	0.0	5	1	1	1
81619	1710	ten in-vitro-stimulated normal blood lymphocyte sample	[ten in-vitro-stimulated normal blood lymphocyte samples]	0.0	6	1	1	1
81620	1710	mutation cluster	[mutations clustering]	0.0	2	1	1	1
81621	1710	activity of a individual factor	[activity of an individual factor]	0.0	5	1	1	1
81622	1710	nf-kappa b nuclear activity	[NF-kappa B nuclear activity]	0.0	4	1	1	1
81623	1710	marker in group	[marker in groups]	0.0	3	1	1	1
81624	1710	germ-line mutation	[germ-line mutations]	0.0	2	1	1	1
81625	1710	product of alternative splicing	[products of alternative splicing]	0.0	4	1	1	1
81626	1710	(outer	[(outer]	0.0	1	1	1	1
81627	1710	cell during anemia	[cells during anemia]	0.0	3	1	1	1
81628	1710	hpc growth	[HPC growth]	0.0	2	1	1	1
81629	1710	therapeutic application	[therapeutic application]	0.0	2	1	1	1
81630	1710	er+: mcf-7	[ER+: MCF-7]	0.0	2	1	1	1
81631	1710	transcriptional suppressor protein	[transcriptional suppressor proteins]	0.0	3	1	1	1
81632	1710	Dehydroepiandrosterone DHEA	[Dehydroepiandrosterone DHEA]	0.0	2	1	1	1
81633	1710	activation of peripheral blood T cell	[activation of peripheral blood T cells]	0.0	6	1	1	1
81634	1710	nuclear staining in +/-	[nuclear staining in +/-]	0.0	4	1	1	1
81635	1710	analyze the effect on nk3.3 cell	[analyzing the effects on NK3.3 cells]	0.0	6	1	1	1
81636	1710	involve other steroid hormone	[involving other steroid hormones]	0.0	4	1	1	1
81637	1710	suggest a structural role	[suggesting an structural role]	0.0	4	1	1	1
81638	1710	multiple dna-binding transcription factor	[Multiple DNA-binding transcription factors]	0.0	4	1	1	1
81639	1710	TNF-alpha hiv-1 terminal repeat	[TNF-alpha HIV-1 terminal repeat]	0.0	4	1	1	1
81640	1710	non-tumorous cavity fluid	[non-tumorous cavity fluids]	0.0	3	1	1	1
81641	1710	formation of AMP response	[formation of AMP response]	0.0	4	1	1	1
81642	1710	bioassay for action	[bioassay for action]	0.0	3	1	1	1
81643	1710	human platelet-activating factor	[human platelet-activating factor]	0.0	3	1	1	1
81644	1710	inhibition of no synthase NOS	[Inhibition of NO synthase NOS]	0.0	5	1	1	1
81645	1710	unequal expression in three,	[unequal expression in three,]	0.0	4	1	1	1
81646	1710	devd-cleavable caspase activity	[DEVD-cleavable caspases activity]	0.0	3	1	1	1
81647	1710	regulation of granulocyte-macrophage	[regulation of granulocyte-macrophage]	0.0	3	1	1	1
81648	1710	patient with the disease	[patients with the disease]	0.0	4	1	1	1
81649	1710	state in mouse	[state in mice]	0.0	3	1	1	1
81650	1710	recombinant N-terminal fragment lps expression	[recombinant N-terminal fragment LPS expression]	0.0	5	1	1	1
81651	1710	decrease after pretreatment of huvec	[decrease after pretreatment of HUVEC]	0.0	5	1	1	1
81652	1710	however, analysis	[However, analysis]	0.0	2	2	2	1
81653	1710	inducibility of zp	[inducibility of Zp]	0.0	3	1	1	1
81654	1710	human lymphotropic virus	[Human lymphotropic virus]	0.0	3	1	1	1
81655	1710	affinity in New World primate	[affinity in New World primates]	0.0	5	1	1	1
81656	1710	15 nmol	[15 nmol]	0.0	2	1	1	1
81657	1710	dendritic cell level: association	[dendritic cell level: association]	0.0	4	1	1	1
81658	1710	alpha- ppar	[alpha- PPAR]	0.0	2	1	1	1
81659	1710	(scid)	[(SCID)]	0.0	1	1	1	1
81660	1710	synthetic peptide gdsp	[synthetic peptide GDSP]	0.0	3	1	1	1
81661	1710	only the two mutation of R-276	[only the two mutations of R-276]	0.0	6	1	1	1
81662	1710	cd34+ progenitor	[CD34+ progenitor]	0.0	2	1	1	1
81663	1710	extract of unstimulated T cell	[extracts of unstimulated T cells]	0.0	5	2	2	1
81664	1710	new, NF kappa b species	[new, NF kappa B species]	0.0	5	1	1	1
81665	1710	induce apoptosis in t-cell lineage	[inducing apoptosis in T-cell lineages]	0.0	5	1	1	1
81666	1710	tyrosine phosphorylation of Janus kinase JAK1	[tyrosine phosphorylation of Janus kinases JAK1]	0.0	6	1	1	1
81667	1710	generation of trigger molecule	[generation of triggering molecule]	0.0	4	1	1	1
81668	1710	tnf-alpha in rat	[TNF-alpha in rats]	0.0	3	1	1	1
81669	1710	transcription basal transcription	[transcription basal transcription]	0.0	3	1	1	1
81670	1710	constitutive, expression of type	[constitutive, expression of type]	0.0	4	1	1	1
81671	1710	correlation between high infiltration	[correlation between high infiltration]	0.0	4	1	1	1
81672	1710	cis- acting factor	[cis- acting factors]	0.0	3	1	1	1
81673	1710	respond in chronic hepatitis b patient	[responding in chronic hepatitis B patients]	0.0	6	1	1	1
81674	1710	coexpression in cell line lack Oct-2	[Coexpression in cell lines lacking Oct-2]	0.0	6	1	1	1
81675	1710	phospholipase d pld	[phospholipase D PLD]	0.0	3	1	1	1
81676	1710	interference activity	[interference activity]	0.0	2	1	1	1
81677	1710	samples,	[samples,]	0.0	1	1	1	1
81678	1710	receptor in human blood monocyte	[receptor in human blood monocytes]	0.0	5	1	1	1
81679	1710	interferon beta IFN-beta element	[interferon beta IFN-beta element]	0.0	4	1	1	1
81680	1710	effect in fibroblast	[effects in fibroblasts]	0.0	3	1	1	1
81681	1710	t-cell killer population	[T-cell killer populations]	0.0	3	1	1	1
81682	1710	amount of the various isoform	[amounts of the various isoforms]	0.0	5	1	1	1
81683	1710	dna-binding characteristic at low abundance	[DNA-binding characteristics at low abundance]	0.0	5	1	1	1
81684	1710	cytokine -produce	[cytokine -producing]	0.0	2	1	1	1
81685	1710	HLA-DR3 with no association	[HLA-DR3 with no association]	0.0	4	1	1	1
81686	1710	long last proliferation	[long lasting proliferation]	0.0	3	1	1	1
81687	1710	C5a stimulation	[C5a stimulation]	0.0	2	1	1	1
81688	1710	hand, interleukin	[hand, interleukin]	0.0	2	1	1	1
81689	1710	gamma-ifn inhibition transactivate function.	[gamma-IFN inhibition transactivating function.]	0.0	4	1	1	1
81690	1710	link Grb2 sh3-binding protein sos1	[linking Grb2 SH3-binding proteins SOS1]	0.0	5	1	1	1
81691	1710	direct relationship	[direct relationship]	0.0	2	1	1	1
81692	1710	form unit-erythroid cell	[forming unit-erythroid cells]	0.0	3	1	1	1
81693	1710	G protein family member	[G protein family member]	0.0	4	1	1	1
81694	1710	implication for replication	[Implications for replication]	0.0	3	1	1	1
81695	1710	significant amount in testis	[significant amounts in testis]	0.0	4	1	1	1
81696	1710	correlation, indicate a down-regulatory effect.	[correlation, indicating a down-regulatory effect.]	0.0	5	1	1	1
81697	1710	membrane viability,	[membrane viability,]	0.0	2	1	1	1
81698	1710	factor nf- cle0 gamma	[factor NF- CLE0 gamma]	0.0	4	1	1	1
81699	1710	patient about 1.5-1.6 time	[patients about 1.5-1.6 times]	0.0	4	1	1	1
81700	1710	loss of tgf-beta 1 growth inhibition	[loss of TGF-beta 1 growth inhibition]	0.0	6	1	1	1
81701	1710	principle target	[principle target]	0.0	2	1	1	1
81702	1710	p65:p50 heterodimer	[p65:p50 heterodimer]	0.0	2	1	1	1
81703	1710	transcription function	[transcription function]	0.0	2	1	1	1
81704	1710	new link	[new link]	0.0	2	1	1	1
81705	1710	nuclear protein act	[nuclear proteins acting]	0.0	3	1	1	1
81706	1710	carry Val	[carrying Val]	0.0	2	1	1	1
81707	1710	open reading frame of 1458	[open reading frame of 1,458]	0.0	5	1	1	1
81708	1710	central position	[central positions]	0.0	2	1	1	1
81709	1710	b DNA binding site	[B DNA binding sites]	0.0	4	1	1	1
81710	1710	vdr-rxr heterodimer binding	[VDR-RXR heterodimer binding]	0.0	3	1	1	1
81711	1710	most recipient	[most recipients]	0.0	2	1	1	1
81712	1710	study responsiveness in vitro	[studying responsiveness in vitro]	0.0	4	1	1	1
81713	1710	DNA binding in T cell	[DNA binding in T cells]	0.0	5	1	1	1
81714	1710	ldl putative molecule	[LDL putative molecule]	0.0	3	1	1	1
81715	1710	concomitant presence of MBP-HBD	[concomitant presence of MBP-HBD]	0.0	4	1	1	1
81716	1710	cytokine assembly contain complex capable	[cytokines assembly containing complexes capable]	0.0	5	1	1	1
81717	1710	ICAM-1 /beta fashion	[ICAM-1 /beta fashion]	0.0	3	1	1	1
81718	1710	pattern of expression in cell	[pattern of expression in cells]	0.0	5	1	1	1
81719	1710	instead a marker of other, polymorphism	[instead a marker(s) of other, polymorphisms]	0.0	6	1	1	1
81720	1710	epo granulocyte-macrophage colony-stimumulatelany-stg factor	[EPO granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
81721	1710	Class cell	[Class cell]	0.0	2	1	1	1
81722	1710	dex inhibition	[Dex inhibition]	0.0	2	1	1	1
81723	1710	insertion site in leukemia	[insertion site in leukemia]	0.0	4	1	1	1
81724	1710	expression of different cytokine gene	[expression of different cytokine genes]	0.0	5	1	1	1
81725	1710	element 1 alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[Elements 1 alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	0.0	6	1	1	1
81726	1710	level of beta-globin expression	[levels of beta-globin expression]	0.0	4	1	1	1
81727	1710	product of splicing	[products of splicing]	0.0	3	1	1	1
81728	1710	c-maf protein	[c-Maf protein]	0.0	2	1	1	1
81729	1710	STAT6 element	[STAT6 elements]	0.0	2	1	1	1
81730	1710	induction of hiv-1-	[induction of HIV-1-]	0.0	3	1	1	1
81731	1710	cyclosporin a induction	[cyclosporin A induction]	0.0	3	1	1	1
81732	1710	observations, coexpression	[observations, coexpression]	0.0	2	1	1	1
81733	1710	related divalent cation like cobalt, nickel,	[related divalent cations like cobalt, nickel,]	0.0	6	1	1	1
81734	1710	exclusively cytoplasmic precursor	[exclusively cytoplasmic precursor]	0.0	3	1	1	1
81735	1710	strong potential of am580	[strong potential of AM580]	0.0	4	1	1	1
81736	1710	human counterpart	[human counterpart]	0.0	2	1	1	1
81737	1710	other viral activity	[other viral activities]	0.0	3	1	1	1
81738	1710	three candidate genes.	[three candidate genes.]	0.0	3	1	1	1
81739	1710	potent effect of 9-cis-ra	[potent effect of 9-cis-RA]	0.0	4	1	1	1
81740	1710	shared, component of the receptor	[shared, component of the receptors]	0.0	5	1	1	1
81741	1710	requirement for interaction	[requirement for interactions]	0.0	3	1	1	1
81742	1710	deletion model	[deletion model]	0.0	2	1	1	1
81743	1710	years) subject	[years) subjects]	0.0	2	1	1	1
81744	1710	tyrosine phosphorylation of JAK2	[tyrosine phosphorylation of JAK2]	0.0	4	1	1	1
81745	1710	icam-1 surface	[ICAM-1 surface]	0.0	2	1	1	1
81746	1710	-do	[-DO]	0.0	1	1	1	1
81747	1710	moderate activation	[Moderate activation]	0.0	2	1	1	1
81748	1710	aetiology a disorder,	[aetiology a disorder,]	0.0	3	1	1	1
81749	1710	produce progeny at the same time.	[producing progeny at the same time.]	0.0	6	1	1	1
81750	1710	b cell from CLL patient	[B cells from CLL patients]	0.0	5	1	1	1
81751	1710	IL-4 down-regulatory effect	[IL-4 down-regulatory effect]	0.0	3	1	1	1
81752	1710	evidence rate-limiting for lymphocyte activation	[Evidence rate-limiting for lymphocyte activation]	0.0	5	1	1	1
81753	1710	threefold to high 12-lipoxygenase activity	[threefold to higher 12-lipoxygenase activity]	0.0	5	1	1	1
81754	1710	overexpression in the nuclei	[overexpression in the nuclei]	0.0	4	1	1	1
81755	1710	receptor to nuclear factor	[receptors to nuclear factor]	0.0	4	1	1	1
81756	1710	protein expression of signal molecule	[protein expression of signaling molecules]	0.0	5	1	1	1
81757	1710	knowledge on the mechanism	[knowledge on the mechanism]	0.0	4	1	1	1
81758	1710	transduction mutant exhibit a defect	[transduction mutant exhibiting a defect]	0.0	5	1	1	1
81759	1710	activin growth arrest	[activin growth arrest]	0.0	3	1	1	1
81760	1710	icrf-193 cell	[ICRF-193 cells]	0.0	2	1	1	1
81761	1710	contrast, rt-pcr analysis from reticulocyte	[contrast, RT-PCR analysis from reticulocytes]	0.0	5	1	1	1
81762	1710	association with p50	[association with p50]	0.0	3	1	1	1
81763	1710	naturally occur mutation t-c)	[naturally occurring mutation T-C)]	0.0	4	1	1	1
81764	1710	state of maturation	[state of maturation]	0.0	3	1	1	1
81765	1710	three day establish pbmc culture	[Three days establishing PBMC cultures]	0.0	5	1	1	1
81766	1710	potential use of tpo	[potential use of TPO]	0.0	4	1	1	1
81767	1710	human sterol element	[human sterol element]	0.0	3	1	1	1
81768	1710	effect of CaM-K ii	[effect of CaM-K II]	0.0	4	1	1	1
81769	1710	kD polypeptide	[kD polypeptide]	0.0	2	1	1	1
81770	1710	restimulated, however, T cell	[restimulated, however, T cells]	0.0	4	1	1	1
81771	1710	protein (residue	[protein (residues]	0.0	2	1	1	1
81772	1710	supraoptimal concentration	[supraoptimal concentrations]	0.0	2	1	1	1
81773	1710	only after immunization.	[only after immunization.]	0.0	3	1	1	1
81774	1710	oxygen species in disease	[oxygen species in diseases]	0.0	4	1	1	1
81775	1710	mature CD4 cd8(-) CD3	[mature CD4 CD8(-) CD3]	0.0	4	1	1	1
81776	1710	CD28 ab stimulation study	[CD28 Ab stimulation studies]	0.0	4	1	1	1
81777	1710	peripheral monocyte pbm	[peripheral monocytes PBM]	0.0	3	1	1	1
81778	1710	interleukin(IL)-2	[interleukin(IL)-2]	0.0	1	1	1	1
81779	1710	predominantly by cell of the lineage	[predominantly by cells of the lineage]	0.0	6	1	1	1
81780	1710	factor of T lymphocyte nfat	[factor of T lymphocytes NFAT]	0.0	5	1	1	1
81781	1710	insertion of copy	[insertion of copies]	0.0	3	1	1	1
81782	1710	implicate a number	[implicating a number]	0.0	3	1	1	1
81783	1710	explanation for mechanism-based toxicity	[explanation for mechanism-based toxicities]	0.0	4	1	1	1
81784	1710	multiple activity of acid RA	[multiple activities of acid RA]	0.0	5	1	1	1
81785	1710	th1 th2 type cytokine	[Th1 Th2 type cytokines]	0.0	4	1	1	1
81786	1710	patient with myeloid leukemia	[patients with myeloid leukemia]	0.0	4	1	1	1
81787	1710	mobility shift assay,	[mobility shift assay,]	0.0	3	1	1	1
81788	1710	so-called octamer transcription factor	[so-called octamer transcription factors]	0.0	4	1	1	1
81789	1710	presence of MBP-HBD	[presence of MBP-HBD]	0.0	3	1	1	1
81790	1710	fusion partner of AF10	[fusion partner of AF10]	0.0	4	1	1	1
81791	1710	lymphoid precursor of human	[lymphoid precursors of humans]	0.0	4	1	1	1
81792	1710	specificity of the protein	[specificity of the protein]	0.0	4	1	1	1
81793	1710	glucocorticoid binding site in leukocyte	[glucocorticoid binding sites in leukocytes]	0.0	5	1	1	1
81794	1710	splicing of the gc receptor gcr	[splicing of the GC receptor GCR]	0.0	6	1	1	1
81795	1710	competition between general activator RelA	[competition between general activators RelA]	0.0	5	1	1	1
81796	1710	monocyte of patient	[monocytes of patients]	0.0	3	1	1	1
81797	1710	depletion of Sp1 from extract	[depletion of Sp1 from extracts]	0.0	5	1	1	1
81798	1710	phosphatase-positive osteoclast-like cell from monocyte	[phosphatase-positive osteoclast-like cells from monocytes]	0.0	5	1	1	1
81799	1710	cell in transgenic mouse	[cells in transgenic mice]	0.0	4	1	1	1
81800	1710	5s rrna	[5S rRNA]	0.0	2	1	1	1
81801	1710	'aged' lymphocyte	['aged' lymphocytes]	0.0	2	1	1	1
81802	1710	produce p40 with ebv	[producing p40 with EBV]	0.0	4	1	1	1
81803	1710	high, establish a inverse relation	[high, establishing an inverse relation]	0.0	5	1	1	1
81804	1710	exogenous stimulus	[exogenous stimuli]	0.0	2	1	1	1
81805	1710	treatment of human disease	[treatment of human disease]	0.0	4	1	1	1
81806	1710	interestingly, expression	[interestingly, expression]	0.0	2	1	1	1
81807	1710	chemical-induced erythroleukemia cell line	[chemical-induced erythroleukemia cell lines]	0.0	4	1	1	1
81808	1710	alpha-naphthyl acetate esterase activity	[alpha-naphthyl acetate esterase activity]	0.0	4	1	1	1
81809	1710	cytokine during malignancy	[cytokines during malignancy]	0.0	3	1	1	1
81810	1710	apc after immunization.	[APC after immunization.]	0.0	3	1	1	1
81811	1710	trans-activate protein in transfection	[trans-activating proteins in transfection]	0.0	4	1	1	1
81812	1710	virologic subtype of pel	[virologic subtypes of PEL]	0.0	4	1	1	1
81813	1710	additional evidence a potent modulator	[additional evidence a potent modulator]	0.0	5	1	1	1
81814	1710	follow hiv infection of macrophage	[following HIV infection of macrophages]	0.0	5	1	1	1
81815	1710	nonresponsive hematopoietic progenitor with no potential	[nonresponsive hematopoietic progenitors with no potential]	0.0	6	1	1	1
81816	1710	transcriptional silencing of the CAT gene	[transcriptional silencing of the CAT gene]	0.0	6	1	1	1
81817	1710	use a yeast screen	[Using a yeast screen]	0.0	4	1	1	1
81818	1710	chromosome alteration	[chromosome alterations]	0.0	2	1	1	1
81819	1710	characteristic Th1-dominated (auto)immune inflammation	[characteristic Th1-dominated (auto)immune inflammation]	0.0	4	1	1	1
81820	1710	superantigen enterotoxin b SEB	[superantigen enterotoxin B SEB]	0.0	4	1	1	1
81821	1710	1 microm RU 38486	[1 microM RU 38486]	0.0	4	1	1	1
81822	1710	three human cell line	[three human cell lines]	0.0	4	1	1	1
81823	1710	Drosophila segment polarity	[Drosophila segment polarity]	0.0	3	1	1	1
81824	1710	cell to surface	[cells to surfaces]	0.0	3	1	1	1
81825	1710	distinct form of free e2f	[distinct forms of free E2F]	0.0	5	1	1	1
81826	1710	-m2	[-M2]	0.0	1	1	1	1
81827	1710	pml expression in hematopoiesis	[PML expression in hematopoiesis]	0.0	4	1	1	1
81828	1710	germline deletion	[germline deletions]	0.0	2	1	1	1
81829	1710	follow exposure of platelet to thrombin	[following exposure of platelets to thrombin]	0.0	6	1	1	1
81830	1710	expression assay in cell culture	[expression assay in cell cultures]	0.0	5	1	1	1
81831	1710	acid accumulation	[acid accumulation]	0.0	2	1	1	1
81832	1710	x-linked immunodeficiency x-scid	[X-linked immunodeficiency X-SCID]	0.0	3	1	1	1
81833	1710	c-terminal serine	[C-terminal serine]	0.0	2	1	1	1
81834	1710	four- to 10-fold great amount	[four- to 10-fold greater amounts]	0.0	5	1	1	1
81835	1710	Ad5E1A234-243	[Ad5E1A234-243]	0.0	1	1	1	1
81836	1710	activation of the CAT gene	[activation of the CAT gene]	0.0	5	1	1	1
81837	1710	rar-rxr response	[RAR-RXR response]	0.0	2	1	1	1
81838	1710	disease susceptibility	[disease susceptibility]	0.0	2	1	1	1
81839	1710	second protein,	[second protein,]	0.0	2	1	1	1
81840	1710	multiple antigen	[multiple antigens]	0.0	2	1	1	1
81841	1710	growth-related activity-alpha	[growth-related activity-alpha]	0.0	2	1	1	1
81842	1710	downregulation of WT1 during differentiation	[downregulation of WT1 during differentiation]	0.0	5	1	1	1
81843	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one a inhibitor of protein kinase	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one an inhibitor of protein kinase]	0.0	6	1	1	1
81844	1710	t-lymphotropic virus type htlv-1	[T-lymphotropic virus type HTLV-1]	0.0	4	1	1	1
81845	1710	cell by cyclosporin A	[cells by cyclosporin A]	0.0	4	1	1	1
81846	1710	uninfected pbmc	[uninfected PBMCs]	0.0	2	1	1	1
81847	1710	endocrine-lineage	[endocrine-lineage]	0.0	1	1	1	1
81848	1710	effect of Rho	[effect of Rho]	0.0	3	1	1	1
81849	1710	factor kappa b heterodimer of p50	[factor kappa B heterodimer of p50]	0.0	6	1	1	1
81850	1710	transient transfection use reporter construct	[Transient transfections using reporter constructs]	0.0	5	1	1	1
81851	1710	histocompatibility complex molecule	[histocompatibility complex molecules]	0.0	3	1	1	1
81852	1710	anti- csf-1r monoclonal antibody	[anti- CSF-1R monoclonal antibodies]	0.0	4	1	1	1
81853	1710	b-cell transcription factor Oct-2	[B-cell transcription factor Oct-2]	0.0	4	1	1	1
81854	1710	effective dose within P;	[effective dose within h;]	0.0	4	1	1	1
81855	1710	host t-cell surveillance	[host T-cell surveillance]	0.0	3	1	1	1
81856	1710	alone,	[alone,]	0.0	1	1	1	1
81857	1710	two raralpha	[two RARalpha]	0.0	2	1	1	1
81858	1710	T lymphocyte response to ad	[T lymphocyte response to Ad]	0.0	5	1	1	1
81859	1710	macrophage migration inhibitory protein	[Macrophage migration inhibitory protein]	0.0	4	1	1	1
81860	1710	c2h2-type	[C2H2-type]	0.0	1	1	1	1
81861	1710	woman (11	[women (11]	0.0	2	1	1	1
81862	1710	FL hematopoiesis	[FL hematopoiesis]	0.0	2	2	2	1
81863	1710	chromosomal il-16 gene	[chromosomal IL-16 gene]	0.0	3	1	1	1
81864	1710	two anti-MHC class	[Two anti-MHC class]	0.0	3	1	1	1
81865	1710	75-kDa cell-specific intracellular signal protein	[75-kDa cell-specific intracellular signaling protein]	0.0	5	1	1	1
81866	1710	incomplete degradation	[incomplete degradation]	0.0	2	1	1	1
81867	1710	level of a novel binding activity	[levels of a novel binding activity]	0.0	6	1	1	1
81868	1710	response in pbmo cell	[responses in PBMo cells]	0.0	4	1	1	1
81869	1710	chemical mismatch cleavage analysis	[chemical mismatch cleavage analysis]	0.0	4	1	1	1
81870	1710	two rna EBERs	[two RNAs EBERs]	0.0	3	1	1	1
81871	1710	anti CD20 antibody	[anti CD20 antibody]	0.0	3	1	1	1
81872	1710	-ox	[-Ox]	0.0	1	1	1	1
81873	1710	only low molecular weight species	[only lower molecular weight species]	0.0	5	1	1	1
81874	1710	activator protein-1 activity	[activator protein-1 activity]	0.0	3	1	1	1
81875	1710	proliferation of rest b lymphocyte	[proliferation of resting B lymphocytes]	0.0	5	1	1	1
81876	1710	such as distribution	[such as distribution]	0.0	3	1	1	1
81877	1710	potential of classic glucocorticoid	[potential of classic glucocorticoids]	0.0	4	1	1	1
81878	1710	RAR -selective antagonist	[RAR -selective antagonist]	0.0	3	1	1	1
81879	1710	response to erythropoietin	[response to erythropoietin]	0.0	3	1	1	1
81880	1710	log-fold glucocorticoid	[log-fold glucocorticoids]	0.0	2	1	1	1
81881	1710	pituitary adrenocorticotropic hormone	[pituitary adrenocorticotropic hormone]	0.0	3	1	1	1
81882	1710	distal nuclear factor proximal NF-AT	[distal nuclear factor proximal NF-AT]	0.0	5	1	1	1
81883	1710	10 to 100 nm	[10 to 100 nM]	0.0	4	1	1	1
81884	1710	intermediate thymocyte compartment	[intermediate thymocyte compartment]	0.0	3	1	1	1
81885	1710	LPS nuclear binding of factor-kappaB/Rel	[LPS nuclear binding of factor-kappaB/Rel]	0.0	5	1	1	1
81886	1710	shuttling of NFATp	[shuttling of NFATp]	0.0	3	1	1	1
81887	1710	13 patient with sle (0.2979	[13 patients with SLE (0.2979]	0.0	5	1	1	1
81888	1710	possible targets,	[possible targets,]	0.0	2	1	1	1
81889	1710	female (18 year	[female (18 years]	0.0	3	1	1	1
81890	1710	ionizing radiation 0.25-2.0 gy	[ionizing radiation 0.25-2.0 Gy]	0.0	4	1	1	1
81891	1710	more substitution alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[more substitutions alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	5	1	1	1
81892	1710	normal signal transduction	[normal signal transduction]	0.0	3	1	1	1
81893	1710	h2o2 scavenger pyrrolidine	[H2O2 scavenger pyrrolidine]	0.0	3	1	1	1
81894	1710	the/thf 1.87+/-0.36) alpha thf/thf ratios.	[THE/THF 1.87+/-0.36) alpha THF/THF ratios.]	0.0	5	1	1	1
81895	1710	characteristic histological feature	[characteristic histological features]	0.0	3	1	1	1
81896	1710	about two fold increase	[about two fold increase]	0.0	4	1	1	1
81897	1710	ALAS-E	[ALAS-E]	0.0	1	1	1	1
81898	1710	permanent occupancy enhancer by nf-kappa b	[Permanent occupancy enhancer by NF-kappa B]	0.0	6	1	1	1
81899	1710	rapid phosphorylation of member	[rapid phosphorylation of members]	0.0	4	1	1	1
81900	1710	glucocorticoid receptor binding in blood lymphocyte	[glucocorticoid receptor binding in blood lymphocytes]	0.0	6	1	1	1
81901	1710	induction of interferon (ifn)-inducible protein	[induction of interferon (IFN)-inducible protein]	0.0	5	1	1	1
81902	1710	nuclear nf-kappab level	[nuclear NF-kappaB levels]	0.0	3	1	1	1
81903	1710	Ig hypermutation process	[Ig hypermutation process]	0.0	3	1	1	1
81904	1710	acid (dna) protein exhibit change	[acid (DNA) proteins exhibiting changes]	0.0	5	1	1	1
81905	1710	component of KV	[components of KV]	0.0	3	1	1	1
81906	1710	preformed, heterodimeric nfkb2	[preformed, heterodimeric NFKB2]	0.0	3	1	1	1
81907	1710	control kappa b-alpha proteolysis	[Control kappa B-alpha proteolysis]	0.0	4	1	1	1
81908	1710	immunologic function	[immunologic function]	0.0	2	1	1	1
81909	1710	ebv program in T cell	[EBV program in T cells]	0.0	5	1	1	1
81910	1710	1 year)	[1 year)]	0.0	2	1	1	1
81911	1710	two different hil-5 cell line	[two different hIL-5 cell lines]	0.0	5	1	1	1
81912	1710	histocompatibility class chain promoter	[histocompatibility class chain promoter]	0.0	4	1	1	1
81913	1710	phagocyte/neutrophil series	[phagocyte/neutrophil series]	0.0	2	1	1	1
81914	1710	1 year:	[1 year:]	0.0	2	1	1	1
81915	1710	g1/g0 cell	[G1/G0 cells]	0.0	2	1	1	1
81916	1710	increase unresponsiveness	[increasing unresponsiveness]	0.0	2	1	1	1
81917	1710	abnormal sodium handling	[abnormal sodium handling]	0.0	3	1	1	1
81918	1710	enhancer by t-cell activator	[enhancers by T-cell activators]	0.0	4	1	1	1
81919	1710	mononuclear phagocyte with L. donovani	[mononuclear phagocytes with L. donovani]	0.0	5	1	1	1
81920	1710	index hypercalciuric patient	[index hypercalciuric patients]	0.0	3	1	1	1
81921	1710	nuclei of eosinophil	[nuclei of eosinophils]	0.0	3	1	1	1
81922	1710	protein glycation	[protein glycation]	0.0	2	1	1	1
81923	1710	mastectomy	[mastectomy]	0.0	1	1	1	1
81924	1710	effect hemin on the binding	[effects hemin on the binding]	0.0	5	1	1	1
81925	1710	cytokines: tnf	[cytokines: TNF]	0.0	2	1	1	1
81926	1710	various extracellular signal converge in pathway	[Various extracellular signals converging in pathways]	0.0	6	1	1	1
81927	1710	more indirect, alteration of the sequence	[more indirect, alteration of the sequence]	0.0	6	1	1	1
81928	1710	strategy persist lifelong, usually asymptomatically	[strategy persisting lifelong, usually asymptomatically]	0.0	5	1	1	1
81929	1710	phenotypic characteristic of differentiation	[phenotypic characteristics of differentiation]	0.0	4	1	1	1
81930	1710	146 female	[146 females]	0.0	2	1	1	1
81931	1710	hiv-1 infection a cytokine	[HIV-1 infection an cytokine]	0.0	4	1	1	1
81932	1710	infiltrate of gland	[infiltrates of glands]	0.0	3	1	1	1
81933	1710	mar-bp1 /enhancer interaction	[MAR-BP1 /enhancer interaction]	0.0	3	1	1	1
81934	1710	other unrecognized NFATp -binding site	[other unrecognized NFATp -binding sites]	0.0	5	1	1	1
81935	1710	uptake by macrophage	[uptake by macrophages]	0.0	3	1	1	1
81936	1710	sIg protein	[sIg proteins]	0.0	2	1	1	1
81937	1710	[25-140 ppt tcdd	[[25-140 ppt TCDD]	0.0	3	1	1	1
81938	1710	ongoing immune response with agent	[ongoing immune response with agents]	0.0	5	1	1	1
81939	1710	intestinal epithelial cell inflammatory response	[intestinal epithelial cell inflammatory responses]	0.0	5	1	1	1
81940	1710	control of normal cell	[control of normal cells]	0.0	4	1	1	1
81941	1710	u/ml interleukin-2	[U/ml interleukin-2]	0.0	2	1	1	1
81942	1710	healthy control (abdominal obese:	[healthy controls (abdominal obese:]	0.0	4	1	1	1
81943	1710	factor nf-kappab	[factor NF-kappaB]	0.0	2	1	1	1
81944	1710	simian virus (sv40) promoter	[simian virus (SV40) promoters]	0.0	4	1	1	1
81945	1710	defective survival of thymocyte in mouse	[Defective survival of thymocytes in mice]	0.0	6	1	1	1
81946	1710	c-Kit	[c-Kit]	0.0	1	1	1	1
81947	1710	biological characteristic of il-12	[biological characteristics of IL-12]	0.0	4	1	1	1
81948	1710	immune receptor risk rearrangement	[immune receptors risk rearrangements]	0.0	4	1	1	1
81949	1710	one major candidate	[one major candidate]	0.0	3	1	1	1
81950	1710	intracellular signal transduction molecule	[intracellular signal transduction molecules]	0.0	4	1	1	1
81951	1710	direct angioplasty PTCA	[direct angioplasty PTCA]	0.0	3	1	1	1
81952	1710	structural loci	[structural loci]	0.0	2	1	1	1
81953	1710	cellular content of h+-atpase v-atpase	[cellular content of H+-ATPase V-ATPase]	0.0	5	1	1	1
81954	1710	course of other infections.	[course of other infections.]	0.0	4	1	1	1
81955	1710	analysis of translocation of individual member	[Analyses of translocation of individual members]	0.0	6	1	1	1
81956	1710	include that encode cytokine	[including those encoding cytokines]	0.0	4	1	1	1
81957	1710	multi-protein complex RFX	[multi-protein complexes RFX]	0.0	3	1	1	1
81958	1710	malignant tissue tumor fibrosarcoma	[malignant tissue tumors fibrosarcoma]	0.0	4	1	1	1
81959	1710	contain the sre- binding site	[containing the SRE- binding sites]	0.0	5	1	1	1
81960	1710	methylprednisolone MPL	[methylprednisolone MPL]	0.0	2	1	1	1
81961	1710	receptor binding in leucocyte	[receptor binding in leucocytes]	0.0	4	1	1	1
81962	1710	expression of the nef gene	[expression of the nef gene]	0.0	5	1	1	1
81963	1710	mechanism of this difference	[mechanism of this difference]	0.0	4	1	1	1
81964	1710	consequence of lmp1 expression	[consequence of LMP1 expression]	0.0	4	1	1	1
81965	1710	characteristic of yj cell	[characteristics of YJ cells]	0.0	4	1	1	1
81966	1710	CD28 enhances,	[CD28 enhances,]	0.0	2	1	1	1
81967	1710	cell per millileter per 48 hr.	[cells per ml per 48 hr.]	0.0	6	1	1	1
81968	1710	various breakpoint on chromosome 11 range	[various breakpoints on chromosome 11 ranging]	0.0	6	1	1	1
81969	1710	9 iv drug abuser	[9 iv drug abusers]	0.0	4	1	1	1
81970	1710	-express human fibroblastic cell	[-expressing human fibroblastic cells]	0.0	4	1	1	1
81971	1710	other haematopoietic population	[other haematopoietic populations]	0.0	3	1	1	1
81972	1710	receptor to DNA	[receptor to DNA]	0.0	3	2	2	1
81973	1710	tyrosine kinase hck gene	[tyrosine kinase hck gene]	0.0	4	1	1	1
81974	1710	beta-phorbol 13-acetate	[beta-phorbol 13-acetate]	0.0	2	1	1	1
81975	1710	rate in 80.5%	[rate in 80.5%]	0.0	3	1	1	1
81976	1710	effect through binding on the DNA	[effects through binding on the DNA]	0.0	6	1	1	1
81977	1710	skewing potential	[skewing potential]	0.0	2	1	1	1
81978	1710	increase in the Kcat	[increase in the Kcat]	0.0	4	1	1	1
81979	1710	main reservoir	[main reservoirs]	0.0	2	1	1	1
81980	1710	factor from unstimulated,	[factors from unstimulated,]	0.0	3	1	1	1
81981	1710	Oligoclonal expansion	[Oligoclonal expansion]	0.0	2	1	1	1
81982	1710	encode cytoskeletal protein	[encoding cytoskeletal proteins]	0.0	3	1	1	1
81983	1710	pluripotent culture	[pluripotent cultures]	0.0	2	1	1	1
81984	1710	regulator of response	[regulator of responses]	0.0	3	1	1	1
81985	1710	viral capsid antigen staining	[viral capsid antigen staining]	0.0	4	1	1	1
81986	1710	thrombin receptor agonist	[thrombin receptor agonist]	0.0	3	1	1	1
81987	1710	expression for the protein in eosinophil	[Expression for the proteins in eosinophils]	0.0	6	1	1	1
81988	1710	oxidant hypochlorous acid hocl	[oxidant hypochlorous acid HOCl]	0.0	4	1	1	1
81989	1710	dominant regulatory effect	[dominant regulatory effect]	0.0	3	1	1	1
81990	1710	occur at minute after reoxygenation	[occurring at minutes after reoxygenation]	0.0	5	1	1	1
81991	1710	addition, activation	[addition, activation]	0.0	2	1	1	1
81992	1710	subunit 6	[subunit 6]	0.0	2	1	1	1
81993	1710	interact with motif in the cd3-epsilon	[interacting with motifs in the CD3-epsilon]	0.0	6	1	1	1
81994	1710	oxidative-stress transcription factor nf-kappab	[oxidative-stress transcription factor NF-kappaB]	0.0	4	1	1	1
81995	1710	only the association	[only the association]	0.0	3	1	1	1
81996	1710	underlie beneficial effect	[underlying beneficial effects]	0.0	3	1	1	1
81997	1710	oncogene c-fo	[oncogene c-fos]	0.0	2	1	1	1
81998	1710	primary mechanism	[primary mechanism]	0.0	2	1	1	1
81999	1710	include the tyrosine protein kinase	[including the tyrosine protein kinase]	0.0	5	1	1	1
82000	1710	addition IL 6 igm production	[addition IL 6 IgM production]	0.0	5	1	1	1
82001	1710	cd3+cd28-induced	[CD3+CD28-induced]	0.0	1	1	1	1
82002	1710	mouse p sequence	[mouse P sequence]	0.0	3	1	1	1
82003	1710	crucial factor for thymopoiesis	[crucial factor for thymopoiesis]	0.0	4	1	1	1
82004	1710	mammary cell grow	[mammary cells growing]	0.0	3	1	1	1
82005	1710	transcription follow engagement cell-to-cell	[transcription following engagement cell-to-cell]	0.0	4	1	1	1
82006	1710	provide a additional mechanism	[providing an additional mechanism]	0.0	4	1	1	1
82007	1710	also many cytokine	[also many cytokines]	0.0	3	1	1	1
82008	1710	explore the pathogenesis	[exploring the pathogenesis]	0.0	3	1	1	1
82009	1710	lmp1+ tumour cell	[LMP1+ tumour cells]	0.0	3	1	1	1
82010	1710	plasma repressor function suppressor	[plasma repressor function suppressor]	0.0	4	1	1	1
82011	1710	p young vs. old) from individual	[P young vs. old) from individuals]	0.0	6	1	1	1
82012	1710	role as a antagonist	[role as a antagonist]	0.0	4	1	1	1
82013	1710	Disease activity	[Disease Activity]	0.0	2	1	1	1
82014	1710	tcr beta-chain	[TCR beta-chain]	0.0	2	1	1	1
82015	1710	suggest a transcriptional effect	[suggesting a transcriptional effect]	0.0	4	1	1	1
82016	1710	concentration of RA mol/L)	[concentrations of RA mol/L)]	0.0	4	1	1	1
82017	1710	analysis of this system	[analysis of this system]	0.0	4	1	1	1
82018	1710	teratogenic effect	[teratogenic effects]	0.0	2	1	1	1
82019	1710	tpa addition to monocyte	[TPA addition to monocytes]	0.0	4	1	1	1
82020	1710	C epsilon gas binding complex	[C epsilon GAS binding complexes]	0.0	5	1	1	1
82021	1710	interference in dna-binding activity	[interference in DNA-binding activities]	0.0	4	1	1	1
82022	1710	develop system	[developing system]	0.0	2	1	1	1
82023	1710	2-fold increase in il-8 messenger rna	[2-fold increases in IL-8 messenger RNA]	0.0	6	1	1	1
82024	1710	incubation of blood mononuclear cell	[incubation of blood mononuclear cells]	0.0	5	1	1	1
82025	1710	pattern suggest a role	[pattern suggesting a role]	0.0	4	1	1	1
82026	1710	population of eosinophil	[population of eosinophils]	0.0	3	1	1	1
82027	1710	h at 37 degree	[h at 37 degrees]	0.0	4	1	1	1
82028	1710	glucocorticoid receptor of human leukocyte	[glucocorticoid receptor of human leukocytes]	0.0	5	1	1	1
82029	1710	induction of genes,	[induction of genes,]	0.0	3	1	1	1
82030	1710	induction of genes.	[induction of genes.]	0.0	3	1	1	1
82031	1710	domain -leucine zipper region	[domain -leucine zipper region]	0.0	4	1	1	1
82032	1710	similar level mrna level	[Similar levels mRNA levels]	0.0	4	1	1	1
82033	1710	affinity of the receptor together	[affinity of the receptor together]	0.0	5	1	1	1
82034	1710	malignant progression	[malignant progression]	0.0	2	1	1	1
82035	1710	seen, migration of filarial antigen t-cell	[seen, migration of filarial antigen T-cells]	0.0	6	1	1	1
82036	1710	specific regulation of repressor	[specific regulation of repressors]	0.0	4	1	1	1
82037	1710	oct-binding factor a novel protein	[Oct-binding factor a novel protein]	0.0	5	1	1	1
82038	1710	/c-jun	[/c-Jun]	0.0	1	2	2	1
82039	1710	import process	[import process]	0.0	2	1	1	1
82040	1710	osteosarcoma	[osteosarcoma]	0.0	1	1	1	1
82041	1710	c-myc PuF	[c-myc PuF]	0.0	2	1	1	1
82042	1710	abundant activity	[abundant activity]	0.0	2	1	1	1
82043	1710	8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	6	1	1	1
82044	1710	single tonsillar gc b cell	[single tonsillar GC B cells]	0.0	5	1	1	1
82045	1710	proximity to homologue	[proximity to homologues]	0.0	3	1	1	1
82046	1710	viral nuclear antigen EBNAs	[viral nuclear antigen EBNAs]	0.0	4	2	2	1
82047	1710	b-cell lymphoma lymphoma	[B-cell lymphomas lymphomas]	0.0	3	1	1	1
82048	1710	vivo to a short region	[vivo to a short region]	0.0	5	1	1	1
82049	1710	least a fraction	[least a fraction]	0.0	3	1	1	1
82050	1710	lncap cell line	[LNCaP cell line]	0.0	3	1	1	1
82051	1710	other lymphoid organ	[other lymphoid organs]	0.0	3	1	1	1
82052	1710	analogous region	[analogous regions]	0.0	2	1	1	1
82053	1710	capacity of human glucocorticoid receptor	[capacity of human glucocorticoid receptor]	0.0	5	1	1	1
82054	1710	mechanism underlie monocytic differentiation	[mechanisms underlying monocytic differentiation]	0.0	4	1	1	1
82055	1710	PML gene in normal hematopoiesis	[PML gene in normal hematopoiesis]	0.0	5	1	1	1
82056	1710	control this developmental choice	[controlling this developmental choice]	0.0	4	1	1	1
82057	1710	-417 to -207 region	[-417 to -207 region]	0.0	4	1	1	1
82058	1710	cell response to infection	[cell responses to infection]	0.0	4	1	1	1
82059	1710	little information about role	[little information about roles]	0.0	4	1	1	1
82060	1710	property of macrophage	[properties of macrophages]	0.0	3	2	2	1
82061	1710	growth-regulated expression of mcm5	[growth-regulated expression of MCM5]	0.0	4	1	1	1
82062	1710	oncogenic event in human tumor	[oncogenic events in human tumors]	0.0	5	1	1	1
82063	1710	presence of the -130 site	[presence of the -130 site]	0.0	5	1	1	1
82064	1710	D3 dioxyvit	[D3 dioxyvit]	0.0	2	1	1	1
82065	1710	collaboration of multiple protein	[collaboration of multiple proteins]	0.0	4	1	1	1
82066	1710	human CD40	[human CD40]	0.0	2	1	1	1
82067	1710	/atf-1	[/ATF-1]	0.0	1	1	1	1
82068	1710	vascular cell adhesion molecule vcam	[vascular cell adhesion molecule VCAM]	0.0	5	1	1	1
82069	1710	nf-y binding activity	[NF-Y binding activity]	0.0	3	1	1	1
82070	1710	.h1	[.H1]	0.0	1	1	1	1
82071	1710	opening of K+ channel	[opening of K+ channels]	0.0	4	1	1	1
82072	1710	wide variety include monocyte	[wide variety including monocytes]	0.0	4	1	1	1
82073	1710	uncommon phenomenon	[uncommon phenomenon]	0.0	2	1	1	1
82074	1710	Extrarenal receptor-effector-mechor-mechanisms	[Extrarenal receptor-effector-mechanisms]	0.0	2	1	1	1
82075	1710	casein kinase ii site	[casein kinase II sites]	0.0	4	1	1	1
82076	1710	dexamethasone a synthetic glucocorticoid	[dexamethasone a synthetic glucocorticoid]	0.0	4	1	1	1
82077	1710	evasion of the immune response	[evasion of the immune response]	0.0	5	1	1	1
82078	1710	disease subject	[disease subjects]	0.0	2	1	1	1
82079	1710	presence of regulatory element	[presence of regulatory elements]	0.0	4	1	1	1
82080	1710	extensive granulopoiesis die by 8	[extensive granulopoiesis dying by 8]	0.0	5	1	1	1
82081	1710	monocyte in vitro	[monocytes in vitro]	0.0	3	1	1	1
82082	1710	element binding protein creb	[element binding protein CREB]	0.0	4	1	1	1
82083	1710	oxygen species in the pathway	[oxygen species in the pathway]	0.0	5	1	1	1
82084	1710	CD18 expression	[CD18 expression]	0.0	2	1	1	1
82085	1710	provide a additional mechanism for effect	[providing an additional mechanism for effects]	0.0	6	1	1	1
82086	1710	induce protection in this cells.	[inducing protection in these cells.]	0.0	5	1	1	1
82087	1710	CD14 monocytic cell line	[CD14 monocytic cell line]	0.0	4	1	1	1
82088	1710	type of cancer	[types of cancers]	0.0	3	2	2	1
82089	1710	evidence of activity	[evidence of activity]	0.0	3	1	1	1
82090	1710	1 mM aminoguanidine	[1 mM aminoguanidine]	0.0	3	1	1	1
82091	1710	various type of cancer	[various types of cancers]	0.0	4	2	2	1
82092	1710	response of neonatal T cell	[response of neonatal T cells]	0.0	5	1	1	1
82093	1710	effect on organ	[effects on organs]	0.0	3	1	1	1
82094	1710	tax 12-myristate 13-acetate	[Tax 12-myristate 13-acetate]	0.0	3	1	1	1
82095	1710	follow expression of the protein	[following expression of the protein]	0.0	5	1	1	1
82096	1710	factor include Sp1	[factors including Sp1]	0.0	3	1	1	1
82097	1710	antigen-specific cd4(+) T cell line	[antigen-specific CD4(+) T cell lines]	0.0	5	1	1	1
82098	1710	two EBV-associated, latent epitope	[two EBV-associated, latent epitopes]	0.0	4	1	1	1
82099	1710	serine residue present	[serine residues present]	0.0	3	1	1	1
82100	1710	type response il-4	[type responses IL-4]	0.0	3	1	1	1
82101	1710	isolation a putative transcription factor	[isolation a putative transcription factor]	0.0	5	1	1	1
82102	1710	sequence ii	[sequence II]	0.0	2	1	1	1
82103	1710	neutralize il-6 monoclonal antibody MoAb	[neutralizing IL-6 monoclonal antibody MoAb]	0.0	5	1	1	1
82104	1710	activation by beta-amyloid peptide	[Activation by beta-amyloid peptides]	0.0	4	1	1	1
82105	1710	RNA display	[RNA display]	0.0	2	1	1	1
82106	1710	parameter of acute pancreatitis	[parameters of acute pancreatitis]	0.0	4	1	1	1
82107	1710	distinct docking site	[distinct docking sites]	0.0	3	1	1	1
82108	1710	effective cell function	[effective cell function]	0.0	3	1	1	1
82109	1710	group of 166 female	[group of 166 females]	0.0	4	1	1	1
82110	1710	synergy regulate IL-2 gene expression	[synergy regulating IL-2 gene expression]	0.0	5	1	1	1
82111	1710	beneficial effect in patient	[beneficial effect in patients]	0.0	4	1	1	1
82112	1710	transactivation of the nuclear factor	[transactivation of the nuclear factor]	0.0	5	1	1	1
82113	1710	show physical interaction	[showing physical interactions]	0.0	3	1	1	1
82114	1710	least a explanation	[least a explanation]	0.0	3	1	1	1
82115	1710	benefit.	[benefit.]	0.0	1	1	1	1
82116	1710	R-276	[R-276]	0.0	1	1	1	1
82117	1710	describe the stochastic activation	[describing the stochastic activation]	0.0	4	1	1	1
82118	1710	sequence kb	[sequence kb]	0.0	2	1	1	1
82119	1710	IRF family transcription factor	[IRF family transcription factor]	0.0	4	1	1	1
82120	1710	prostaglandin I2	[prostaglandin I2]	0.0	2	1	1	1
82121	1710	generation of molecule	[generation of molecule]	0.0	3	1	1	1
82122	1710	variety of site	[variety of sites]	0.0	3	1	1	1
82123	1710	mcd14 a cell-surface receptor	[mCD14 a cell-surface receptor]	0.0	4	1	1	1
82124	1710	component of the nuclear body	[components of the nuclear bodies]	0.0	5	1	1	1
82125	1710	sampling	[sampling]	0.0	1	1	1	1
82126	1710	main goals: (1)	[main goals: (1)]	0.0	3	1	1	1
82127	1710	also with other ankyrin motif-rich protein	[also with other ankyrin motif-rich proteins]	0.0	6	1	1	1
82128	1710	other gene such as IL-8	[other genes such as IL-8]	0.0	5	1	1	1
82129	1710	suboptimal activation with phorbol ester	[suboptimal activation with phorbol esters]	0.0	5	1	1	1
82130	1710	vitro to monocyte-derived macrophage	[vitro to monocyte-derived macrophages]	0.0	4	1	1	1
82131	1710	subtle difference in the regulation hiv-1	[subtle differences in the regulation HIV-1]	0.0	6	1	1	1
82132	1710	sensitivity to acid differentiation	[sensitivity to acid differentiation]	0.0	4	1	1	1
82133	1710	emergence of CTL follow administration	[emergence of CTLs following administrations]	0.0	5	1	1	1
82134	1710	DNA-protein formation	[DNA-protein formation]	0.0	2	1	1	1
82135	1710	phytohemagglutinin-stimulated blood lymphocyte culture	[phytohemagglutinin-stimulated blood lymphocyte cultures]	0.0	4	1	1	1
82136	1710	several feature include sensitivity to neuraminidase	[several features including sensitivity to neuraminidase]	0.0	6	1	1	1
82137	1710	additional complex formation in the presence	[additional complex formation in the presence]	0.0	6	1	1	1
82138	1710	many chronic disorder a problem	[many chronic disorders a problem]	0.0	5	1	1	1
82139	1710	marker expression	[markers expression]	0.0	2	1	1	1
82140	1710	culture in murine splenocyte	[culture in murine splenocytes]	0.0	4	1	1	1
82141	1710	least one gene	[least one gene]	0.0	3	1	1	1
82142	1710	two dna-binding complex in eosinophil	[two DNA-binding complexes in eosinophils]	0.0	5	1	1	1
82143	1710	c--responsive	[C--responsive]	0.0	1	1	1	1
82144	1710	inhibitor of the production	[inhibitors of the production]	0.0	4	1	1	1
82145	1710	chimeric surface receptor	[chimeric surface receptors]	0.0	3	1	1	1
82146	1710	three b clone	[three B clones]	0.0	3	1	1	1
82147	1710	m in a manner	[M in a manner]	0.0	4	1	1	1
82148	1710	myelogenous leukemia aml	[myelogenous leukemia AML]	0.0	3	1	1	1
82149	1710	group of cell lines,	[groups of cell lines,]	0.0	4	1	1	1
82150	1710	33 case of t-cell proliferation	[33 cases of T-cell proliferations]	0.0	5	1	1	1
82151	1710	pseudohypoaldosteronism in form	[Pseudohypoaldosteronism in forms]	0.0	3	1	1	1
82152	1710	soluble antioxidant	[soluble antioxidants]	0.0	2	1	1	1
82153	1710	region of several other sequence	[regions of several other sequences]	0.0	5	1	1	1
82154	1710	prostaglandin E2	[prostaglandin E2]	0.0	2	1	1	1
82155	1710	contrast, T cell from subject	[contrast, T cells from subjects]	0.0	5	1	1	1
82156	1710	effect on pdgf(b) mrna accumulation	[effect on PDGF(B) mRNA accumulation]	0.0	5	1	1	1
82157	1710	nf-kappab activation of long repeat	[NF-kappaB activation of long repeat]	0.0	5	1	1	1
82158	1710	activity of the MHC class	[activity of the MHC class]	0.0	5	1	1	1
82159	1710	acid treatment recovery.	[acid treatment recovery.]	0.0	3	1	1	1
82160	1710	phenotypic marker of osteoclast with nuclearity,	[phenotypic markers of osteoclasts with nuclearity,]	0.0	6	1	1	1
82161	1710	ifngr1 deletion hotspot	[IFNGR1 deletion hotspot]	0.0	3	1	1	1
82162	1710	full-length cDNA sequence	[full-length cDNA sequence]	0.0	3	2	2	1
82163	1710	over-expression of nf-kappa b gene	[over-expression of NF-kappa B genes]	0.0	5	1	1	1
82164	1710	human serum-inducible element dna-probe	[human serum-inducible element DNA-probe]	0.0	4	1	1	1
82165	1710	lead to gene transcription	[leading to gene transcription]	0.0	4	1	1	1
82166	1710	random needle aspiration	[random needle aspirations]	0.0	3	1	1	1
82167	1710	significant inflammatory activity	[significant inflammatory activity]	0.0	3	1	1	1
82168	1710	threonine residue	[threonine residue]	0.0	2	1	1	1
82169	1710	cell reaction mcr histologic grade	[cell reaction MCR histologic grade]	0.0	5	1	1	1
82170	1710	myeloid leukaemia (aml) blast	[myeloid leukaemia (AML) blasts]	0.0	4	1	1	1
82171	1710	targets,	[targets,]	0.0	1	1	1	1
82172	1710	binding of two complex	[binding of two complexes]	0.0	4	1	1	1
82173	1710	human ecem) cell	[human (CEM) cells]	0.0	3	1	1	1
82174	1710	apoptosis in human monocyte	[apoptosis in human monocytes]	0.0	4	1	1	1
82175	1710	diverse role	[diverse roles]	0.0	2	1	1	1
82176	1710	Ig variable chain sequence	[Ig variable chain sequences]	0.0	4	1	1	1
82177	1710	NLS receptor complex	[NLS receptor complex]	0.0	3	1	1	1
82178	1710	indicate a function of PPARalpha	[indicating a function of PPARalpha]	0.0	5	1	1	1
82179	1710	encompass a important regulatory element NF-AT-1	[encompassing an important regulatory element NF-AT-1]	0.0	6	1	1	1
82180	1710	subtle alteration	[subtle alterations]	0.0	2	1	1	1
82181	1710	determinant for b activation	[determinant for B activation]	0.0	4	1	1	1
82182	1710	2 hour at degree	[2 hours at degrees]	0.0	4	1	1	1
82183	1710	oral replacement dose	[oral replacement dose]	0.0	3	1	1	1
82184	1710	dg/sa	[DG/SA]	0.0	1	1	1	1
82185	1710	13 patient with sle	[13 patients with SLE]	0.0	4	1	1	1
82186	1710	nf-kappab site present at bp	[NF-kappaB sites present at bp]	0.0	5	1	1	1
82187	1710	t-cell pathway	[T-cell pathway]	0.0	2	1	1	1
82188	1710	membrane from human leukocyte	[membranes from human leukocytes]	0.0	4	1	1	1
82189	1710	region beta chain	[region beta chain]	0.0	3	1	1	1
82190	1710	cell lipid	[cell lipids]	0.0	2	2	2	1
82191	1710	mbp release	[MBP release]	0.0	2	1	1	1
82192	1710	erythroid enhancer in assay	[erythroid enhancer in assays]	0.0	4	1	1	1
82193	1710	human CD80	[human CD80]	0.0	2	1	1	1
82194	1710	to: exposure to hydrogen peroxide	[to: exposure to hydrogen peroxide]	0.0	5	1	1	1
82195	1710	leukemia (b-cll) cell	[leukemia (B-CLL) cells]	0.0	3	2	2	1
82196	1710	lack of natural killer cell	[lack of natural killer cells]	0.0	5	1	1	1
82197	1710	second essential regulatory element	[second essential regulatory element]	0.0	4	1	1	1
82198	1710	decrease monocyte il-1ra secretion	[decrease monocyte IL-1ra secretion]	0.0	4	1	1	1
82199	1710	development of specific human pathology	[development of specific human pathologies]	0.0	5	1	1	1
82200	1710	il-2re	[IL-2rE]	0.0	1	1	1	1
82201	1710	lps (100	[LPS (100]	0.0	2	1	1	1
82202	1710	bhlh-pas partner factor	[bHLH-PAS partner factor]	0.0	3	1	1	1
82203	1710	contain direct repeat	[containing direct repeats]	0.0	3	1	1	1
82204	1710	platelet/endothelial	[platelet/endothelial]	0.0	1	1	1	1
82205	1710	overexpression of ZEBRA, the product	[Overexpression of ZEBRA, the product]	0.0	5	1	1	1
82206	1710	self-perpetuation	[self-perpetuation]	0.0	1	1	1	1
82207	1710	currently the subject	[currently the subject]	0.0	3	1	1	1
82208	1710	potentiation by methylprednisolone	[potentiation by methylprednisolone]	0.0	3	1	1	1
82209	1710	sequence CCGAAACTGAAAAGG E6	[sequence CCGAAACTGAAAAGG E6]	0.0	3	1	1	1
82210	1710	line by expression	[lines by expression]	0.0	3	1	1	1
82211	1710	nf-atc isoform with transcriptional property	[NF-ATc isoforms with transcriptional properties]	0.0	5	1	1	1
82212	1710	cell type,	[cell type,]	0.0	2	1	1	1
82213	1710	human mono Mac cell	[human Mono Mac cells]	0.0	4	1	1	1
82214	1710	intact human platelet	[intact human platelets]	0.0	3	1	1	1
82215	1710	u1rnp	[U1RNP]	0.0	1	1	1	1
82216	1710	regard to weight	[regard to weight]	0.0	3	1	1	1
82217	1710	GCR binding affinity	[GCR binding affinity]	0.0	3	1	1	1
82218	1710	early response gene expression	[early response gene expression]	0.0	4	1	1	1
82219	1710	human pathology such as failure	[human pathologies such as failure]	0.0	5	1	1	1
82220	1710	sequential) presence	[sequential) presence]	0.0	2	1	1	1
82221	1710	patient with affinity to glucocorticoid AIDS-C	[patients with affinity to glucocorticoids AIDS-C]	0.0	6	1	1	1
82222	1710	domain of the human receptor	[domain of the human receptor]	0.0	5	1	1	1
82223	1710	ldl receptor gene	[LDL receptor gene]	0.0	3	1	1	1
82224	1710	patient time	[patients times]	0.0	2	1	1	1
82225	1710	mononuclear cell b cell	[mononuclear cells B cells]	0.0	4	1	1	1
82226	1710	concatameric DNA	[concatameric DNA]	0.0	2	1	1	1
82227	1710	nuclear abundance	[nuclear abundance]	0.0	2	2	2	1
82228	1710	individual cd4+ T cell	[individual CD4+ T cells]	0.0	4	1	1	1
82229	1710	effect of PDTC	[effect of PDTC]	0.0	3	1	1	1
82230	1710	transplantation through effect	[transplantation through effects]	0.0	3	1	1	1
82231	1710	biologic activity of acid	[biologic activities of acid]	0.0	4	1	1	1
82232	1710	island suggest expression	[island suggesting expression]	0.0	3	1	1	1
82233	1710	dysregulation in infection	[dysregulation in infection]	0.0	3	1	1	1
82234	1710	interaction with p100	[interaction with p100]	0.0	3	1	1	1
82235	1710	effect in leukemic cell	[effect in leukemic cells]	0.0	4	1	1	1
82236	1710	target for PI3K	[targets for PI3K]	0.0	3	1	1	1
82237	1710	series: at subject	[series: at subjects]	0.0	3	1	1	1
82238	1710	fmol/10(7) pbmc	[fmol/10(7) PBMC]	0.0	2	1	1	1
82239	1710	endogenous ikappab kinase	[endogenous IkappaB kinase]	0.0	3	1	1	1
82240	1710	dual signal requirement	[dual signal requirement]	0.0	3	1	1	1
82241	1710	(as) phosphorothioate oligonucleotide	[(AS) phosphorothioate oligonucleotides]	0.0	3	1	1	1
82242	1710	10 control	[10 controls]	0.0	2	1	1	1
82243	1710	large substitution on c-11 alpha,25-(OH)2D3	[Large substitutions on C-11 alpha,25-(OH)2D3]	0.0	5	1	1	1
82244	1710	convergence point	[convergence points]	0.0	2	1	1	1
82245	1710	nonspecific inhibitor of PKC	[nonspecific inhibitor of PKC]	0.0	4	1	1	1
82246	1710	TCR activation	[TCR activation]	0.0	2	1	1	1
82247	1710	suppression of NFkappaB entry	[suppression of NFkappaB entry]	0.0	4	1	1	1
82248	1710	use sequential deletion mutant	[Using sequential deletion mutants]	0.0	4	1	1	1
82249	1710	trophic effect result	[trophic effect resulting]	0.0	3	1	1	1
82250	1710	cotransfection in sense orientation	[cotransfection in sense orientation]	0.0	4	1	1	1
82251	1710	stat5b in precursor	[STAT5B in precursors]	0.0	3	1	1	1
82252	1710	Importantly, culture	[Importantly, culture]	0.0	2	1	1	1
82253	1710	peroxisome receptor alpha ligand WY	[peroxisome receptor alpha ligand WY]	0.0	5	1	1	1
82254	1710	subject young than year	[subjects younger than years]	0.0	4	1	1	1
82255	1710	Physiological concentration	[Physiological concentration]	0.0	2	2	2	1
82256	1710	influence of activation	[influence of activation]	0.0	3	1	1	1
82257	1710	event important in cd34+ hpc	[events important in CD34+ HPC]	0.0	5	1	1	1
82258	1710	proline- region	[proline- region]	0.0	2	1	1	1
82259	1710	further structure-based enhancement of potency	[further structure-based enhancement of potency]	0.0	5	1	1	1
82260	1710	biomarker between the high risk	[biomarkers between the high risk]	0.0	5	1	1	1
82261	1710	induction expression in cell	[Induction expression in cells]	0.0	4	1	1	1
82262	1710	excisional biopsy as treatment	[excisional biopsy as treatment]	0.0	4	1	1	1
82263	1710	interfere with calcium increase	[interfering with calcium increase]	0.0	4	1	1	1
82264	1710	CAT expression vector	[CAT expression vectors]	0.0	3	1	1	1
82265	1710	erythroid differentiation event	[erythroid differentiation events]	0.0	3	1	1	1
82266	1710	cytokine -modulate activity a new potential	[Cytokine -modulating activity a new potential]	0.0	6	1	1	1
82267	1710	repression through the cooperation	[Repression through the cooperation]	0.0	4	1	1	1
82268	1710	selective role in the regulation	[selective role in the regulation]	0.0	5	1	1	1
82269	1710	"SFS" domain similar	["SFS" domain similar]	0.0	3	1	1	1
82270	1710	nf-kappa b for efficient transcription,	[NF-kappa B for efficient transcription,]	0.0	5	1	1	1
82271	1710	incubation of human endothelial cell	[Incubation of human endothelial cells]	0.0	5	1	1	1
82272	1710	natural ligand LFA-3	[natural ligand LFA-3]	0.0	3	1	1	1
82273	1710	signal often converge in common pathway	[signals often converging in common pathways]	0.0	6	1	1	1
82274	1710	important bioinactivation mechanism	[important bioinactivation mechanism]	0.0	3	1	1	1
82275	1710	2 hour at 42 degree	[2 hours at 42 degrees]	0.0	5	1	1	1
82276	1710	significant decrease cortisol ratio	[significant decrease cortisol ratio]	0.0	4	1	1	1
82277	1710	composition in normal myeloid cell	[composition in normal myeloid cells]	0.0	5	1	1	1
82278	1710	activity of IKK	[activity of IKK]	0.0	3	1	1	1
82279	1710	mrna expression of protein	[mRNA expression of protein]	0.0	4	1	1	1
82280	1710	gm-csf il-4	[GM-CSF IL-4]	0.0	2	1	1	1
82281	1710	Leukotriene	[Leukotriene]	0.0	1	4	4	1
82282	1710	Gal4-Elf-1	[Gal4-Elf-1]	0.0	1	1	1	1
82283	1710	internal entry site rna-protein interaction	[internal entry site RNA-protein interactions]	0.0	5	1	1	1
82284	1710	weight gain	[weight gain]	0.0	2	1	1	1
82285	1710	drosophila melanogaster	[Drosophila melanogaster]	0.0	2	1	1	1
82286	1710	three protein lef-1	[three proteins LEF-1]	0.0	3	1	1	1
82287	1710	parameter of the protein sp	[parameters of the proteins SP]	0.0	5	1	1	1
82288	1710	intact egf-gp130 receptor	[intact EGF-gp130 receptor]	0.0	3	1	1	1
82289	1710	release expression by pbmc	[release expression by PBMCs]	0.0	4	1	1	1
82290	1710	hemolytic disease	[hemolytic disease]	0.0	2	1	1	1
82291	1710	/a1	[/A1]	0.0	1	1	1	1
82292	1710	population hematopoietic progenitor	[populations hematopoietic progenitors]	0.0	3	1	1	1
82293	1710	locus interrupt locus	[locus interrupting locus]	0.0	3	1	1	1
82294	1710	induction of interferon follow differentiation	[induction of interferon following differentiation]	0.0	5	1	1	1
82295	1710	300 amino acid	[300 amino acids]	0.0	3	1	1	1
82296	1710	T lymphocyte to anti-cd2	[T lymphocytes to anti-CD2]	0.0	4	1	1	1
82297	1710	factor-kappaB in memory	[factor-kappaB in memory]	0.0	3	1	1	1
82298	1710	resorption	[Resorption]	0.0	1	1	1	1
82299	1710	50 nm vd3	[50 nM VD3]	0.0	3	1	1	1
82300	1710	monophosphate	[monophosphate]	0.0	1	1	1	1
82301	1710	hybridize close	[hybridizes close]	0.0	2	1	1	1
82302	1710	decline in the proliferative capacity	[decline in the proliferative capacities]	0.0	5	1	1	1
82303	1710	sp100 homology region	[SP100 homology regions]	0.0	3	1	1	1
82304	1710	IL-1alpha gene	[IL-1alpha gene]	0.0	2	1	1	1
82305	1710	gas -motif sequence	[GAS -motif sequences]	0.0	3	1	1	1
82306	1710	encode interleukin-2 IL2	[encoding interleukin-2 IL2]	0.0	3	1	1	1
82307	1710	basis of dna-binding activity	[basis of DNA-binding activity]	0.0	4	1	1	1
82308	1710	classical feedback loop	[classical feedback loop]	0.0	3	1	1	1
82309	1710	Addition of tnf	[Addition of TNF]	0.0	3	1	1	1
82310	1710	progenitor to dendritic cell DC	[progenitors to dendritic cells DC]	0.0	5	1	1	1
82311	1710	activation involve transcript initiation	[activation involving transcript initiation]	0.0	4	1	1	1
82312	1710	untreated depressed patient with disorder	[untreated depressed patients with disorder]	0.0	5	1	1	1
82313	1710	conventional (b-2) lymphocyte	[conventional (B-2) lymphocytes]	0.0	3	1	1	1
82314	1710	deltaspi-B	[deltaspi-B]	0.0	1	1	1	1
82315	1710	effect on hsp gene expression	[effect on HSP gene expression]	0.0	5	1	1	1
82316	1710	Additionally, overexpression	[Additionally, overexpression]	0.0	2	1	1	1
82317	1710	girl with immunological feature	[girl with immunological features]	0.0	4	1	1	1
82318	1710	female with onset menarche	[female with onset menarche]	0.0	4	1	1	1
82319	1710	detection of transcription factor	[detection of transcription factors]	0.0	4	1	1	1
82320	1710	35-amino acid c terminus	[35-amino acid C terminus]	0.0	4	1	1	1
82321	1710	NF-kappaB transcription of cytokine	[NF-kappaB transcription of cytokines]	0.0	4	1	1	1
82322	1710	expression protein ip-10 a stat1alpha gene	[Expression protein IP-10 a STAT1alpha gene]	0.0	6	1	1	1
82323	1710	stage homogeneity of cell grow	[stage homogeneity of cells growing]	0.0	5	1	1	1
82324	1710	inflammatory microenvironment	[inflammatory microenvironment]	0.0	2	1	1	1
82325	1710	mol/L 9-cis RA hours)	[mol/L 9-cis RA hours)]	0.0	4	1	1	1
82326	1710	none to on epidermal basal cell	[none to on epidermal basal cells]	0.0	6	1	1	1
82327	1710	signal essential	[signals essential]	0.0	2	1	1	1
82328	1710	thus, competition between activator RelA	[Thus, competition between activators RelA]	0.0	5	1	1	1
82329	1710	reaction with probe.	[reaction with probe.]	0.0	3	1	1	1
82330	1710	glucocorticoid receptor binding in leukocyte	[glucocorticoid receptor binding in leukocytes]	0.0	5	1	1	1
82331	1710	packaging into the target genome,	[Packaging into the target genome,]	0.0	5	1	1	1
82332	1710	involvement of Stat3	[Involvement of Stat3]	0.0	3	1	1	1
82333	1710	expression of WT1 in fibroblast	[expression of WT1 in fibroblasts]	0.0	5	1	1	1
82334	1710	basic helix-loop-helix bhlh motif	[basic helix-loop-helix bHLH motif]	0.0	4	1	1	1
82335	1710	bone stromal cell line	[bone stromal cell line]	0.0	4	1	1	1
82336	1710	regulate aspect	[regulating aspects]	0.0	2	1	1	1
82337	1710	CD19 1e8 cell	[CD19 1E8 cells]	0.0	3	1	1	1
82338	1710	protein ie62	[protein IE62]	0.0	2	1	1	1
82339	1710	VDR in the absence	[VDR in the absence]	0.0	4	1	1	1
82340	1710	defect in transport	[defect in transport]	0.0	3	1	1	1
82341	1710	three category factor	[three categories factors]	0.0	3	1	1	1
82342	1710	/et	[/Ets]	0.0	1	1	1	1
82343	1710	bind affinity of the receptor	[binding affinity of the receptor]	0.0	5	1	1	1
82344	1710	pha peripheral blood lymphocyte	[PHA peripheral blood lymphocytes]	0.0	4	1	1	1
82345	1710	untreated patient than in person	[untreated patients than in persons]	0.0	5	1	1	1
82346	1710	gm-csf RA	[GM-CSF RA]	0.0	2	1	1	1
82347	1710	protein icsa	[protein IcsA]	0.0	2	1	1	1
82348	1710	induction E-selectin surface expression by TNF	[Induction E-selectin surface expression by TNF]	0.0	6	1	1	1
82349	1710	pathway in transformation by v-Abl	[pathways in transformation by v-Abl]	0.0	5	1	1	1
82350	1710	cell line follow stimulation.	[cell line following stimulation.]	0.0	4	1	1	1
82351	1710	level in this patient	[levels in these patients]	0.0	4	1	1	1
82352	1710	region of A-MYB responsible	[region of A-MYB responsible]	0.0	4	1	1	1
82353	1710	suppression during adenoviral infection	[suppression during adenoviral infection]	0.0	4	1	1	1
82354	1710	component in the pathogenesis	[component in the pathogenesis]	0.0	4	1	1	1
82355	1710	normal component of NF-AT	[normal components of NF-AT]	0.0	4	1	1	1
82356	1710	studies, cell	[studies, cells]	0.0	2	1	1	1
82357	1710	calcineurin activity	[calcineurin activity]	0.0	2	1	1	1
82358	1710	msr expression	[MSR expression]	0.0	2	1	1	1
82359	1710	similar susceptibility to pcdd	[similar susceptibility to PCDDs/PCDFs]	0.0	4	1	1	1
82360	1710	kappa b-like motif at position -98	[kappa B-like motifs at positions -98]	0.0	6	1	1	1
82361	1710	pattern at the level	[pattern at the level]	0.0	4	1	1	1
82362	1710	activation 1 enhancer	[Activation 1 enhancer]	0.0	3	1	1	1
82363	1710	two protein in normal lymphocyte	[two proteins in normal lymphocytes]	0.0	5	1	1	1
82364	1710	xanthine derivative	[xanthine derivative]	0.0	2	1	1	1
82365	1710	class histocompatibility -negative cell line	[class histocompatibility -negative cell lines]	0.0	5	1	1	1
82366	1710	cellular mediator	[cellular mediator]	0.0	2	1	1	1
82367	1710	surround the transcription start site	[surrounding the transcription start site]	0.0	5	1	1	1
82368	1710	spi-1 /PU.1	[Spi-1 /PU.1]	0.0	2	1	1	1
82369	1710	number of functional receptor	[numbers of functional receptors]	0.0	4	1	1	1
82370	1710	expression in human placentae	[expression in human placentae]	0.0	4	1	1	1
82371	1710	stress in plasma sample	[stress in plasma samples]	0.0	4	1	1	1
82372	1710	blood monocyte pbmo	[blood monocytes PBMo]	0.0	3	1	1	1
82373	1710	inhibition of the transcription	[inhibition of the transcription]	0.0	4	1	1	1
82374	1710	tumor cell growth.	[tumor cell growth.]	0.0	3	1	1	1
82375	1710	augmentation of nfat promoter activity	[augmentation of NFAT promoter activity]	0.0	5	1	1	1
82376	1710	characterization the factor	[Characterization the factor]	0.0	3	1	1	1
82377	1710	two separate cis-acting regulatory element	[two separate cis-acting regulatory elements]	0.0	5	1	1	1
82378	1710	cell extract from leukemia	[cell extracts from leukemia]	0.0	4	1	1	1
82379	1710	adult cell polypryrimidine-binding factor	[adult cells polypryrimidine-binding factor]	0.0	4	1	1	1
82380	1710	induction of the adhesion protein	[induction of the adhesion proteins]	0.0	5	1	1	1
82381	1710	effect of N-acetyl-L-cysteine a antioxidant	[effects of N-acetyl-L-cysteine a antioxidant]	0.0	5	1	1	1
82382	1710	protective immunity against tumor	[protective immunity against tumors]	0.0	4	1	1	1
82383	1710	reaction for HER-2/neu	[reactions for HER-2/neu]	0.0	3	1	1	1
82384	1710	evidence for a polyclonal etiology	[Evidence for a polyclonal etiology]	0.0	5	1	1	1
82385	1710	injection cd4+ t-cell deletion	[injections CD4+ T-cell deletion]	0.0	4	1	1	1
82386	1710	antigen cell APC	[antigen cells APC]	0.0	3	1	1	1
82387	1710	history of hiv-1 infection	[history of HIV-1 infection]	0.0	4	1	1	1
82388	1710	(il)-8 production	[(IL)-8 production]	0.0	2	1	1	1
82389	1710	18-20 peptide fragment	[18-20 peptide fragments]	0.0	3	1	1	1
82390	1710	underline a proliferation reduction mechanism	[underlining a proliferation reduction mechanism]	0.0	5	1	1	1
82391	1710	ratios,	[ratios,]	0.0	1	1	1	1
82392	1710	patient with leukaemia CLL	[patients with leukaemia CLL]	0.0	4	1	1	1
82393	1710	ratios.	[ratios.]	0.0	1	1	1	1
82394	1710	isoform expression	[isoform expression]	0.0	2	1	1	1
82395	1710	myeloid-specific surface marker	[myeloid-specific surface markers]	0.0	3	1	1	1
82396	1710	ctl-specific expression of perforin	[CTL-specific expression of perforin]	0.0	4	1	1	1
82397	1710	insufficient suppression	[insufficient suppression]	0.0	2	1	1	1
82398	1710	23 woman	[23 women]	0.0	2	2	2	1
82399	1710	continuous monitoring	[continuous monitoring]	0.0	2	1	1	1
82400	1710	bipotential cell population capable	[bipotential cell population capable]	0.0	4	1	1	1
82401	1710	novel gene encode a member	[novel gene encoding a member]	0.0	5	1	1	1
82402	1710	level of the rel-a protein	[levels of the Rel-A protein]	0.0	5	1	1	1
82403	1710	however, high (66 microg/100 millileter	[However, high (66 microg/100 ml]	0.0	5	1	1	1
82404	1710	transcription of numerous gene	[transcription of numerous genes]	0.0	4	1	1	1
82405	1710	macrophage in atheroma	[Macrophages in atheroma]	0.0	3	1	1	1
82406	1710	thus, stimulation	[Thus, stimulation]	0.0	2	1	1	1
82407	1710	T cell leukemia jurkat cell	[T cell leukemia Jurkat cells]	0.0	5	1	1	1
82408	1710	trans-activator promoter	[trans-activator promoter]	0.0	2	1	1	1
82409	1710	Fusion protein present in cell	[Fusion proteins present in cells]	0.0	5	1	1	1
82410	1710	potential value alter immune response	[potential value altering immune responses]	0.0	5	1	1	1
82411	1710	contain gamma-globin	[containing gamma-globin]	0.0	2	1	1	1
82412	1710	recombinant glycoprotein b	[recombinant glycoprotein B]	0.0	3	1	1	1
82413	1710	activation of factor-kappa b NF-kappa b	[activation of factor-kappa B NF-kappa B]	0.0	6	1	1	1
82414	1710	mutagenesis of the guanine nucleotide	[mutagenesis of the guanine nucleotides]	0.0	5	1	1	1
82415	1710	cell include blood mononuclear cell	[cells including blood mononuclear cells]	0.0	5	1	1	1
82416	1710	form lack a major portion	[forms lacking a major portion]	0.0	5	1	1	1
82417	1710	hl-60 subline with interleukin-5	[HL-60 sublines with interleukin-5]	0.0	4	1	1	1
82418	1710	glucocorticoid replacement	[glucocorticoid replacement]	0.0	2	1	1	1
82419	1710	glucocorticoid receptor to glucocorticoid therapy	[glucocorticoid receptor to glucocorticoid therapy]	0.0	5	1	1	1
82420	1710	expression of stat4 inducible protein	[expression of Stat4 inducible proteins]	0.0	5	1	1	1
82421	1710	unexpected expression of gene	[unexpected expression of genes]	0.0	4	1	1	1
82422	1710	2 enhancer activation	[2 enhancer activation]	0.0	3	1	1	1
82423	1710	PPARalpha a important regulator	[PPARalpha a important regulator]	0.0	4	1	1	1
82424	1710	such as transcription factor kappa beta	[such as transcription factor kappa beta]	0.0	6	1	1	1
82425	1710	prl expression	[PRL expression]	0.0	2	1	1	1
82426	1710	vitro immortalization	[vitro immortalization]	0.0	2	1	1	1
82427	1710	neoplastic clone in disorder	[neoplastic clone in disorders]	0.0	4	1	1	1
82428	1710	clone CEM c1	[clone CEM C1]	0.0	3	1	1	1
82429	1710	mrna isoform of 2.6 kb	[mRNA isoforms of 2.6 kb]	0.0	5	1	1	1
82430	1710	oligonucleotide contain nf-kappab binding sequence	[oligonucleotides containing NF-kappaB binding sequence]	0.0	5	1	1	1
82431	1710	transcriptional activation of zeta globin gene	[transcriptional activation of zeta globin gene]	0.0	6	1	1	1
82432	1710	component for production	[components for production]	0.0	3	1	1	1
82433	1710	nf-kappab -dependent activation 1 long repeat	[NF-kappaB -dependent activation 1 long repeat]	0.0	6	1	1	1
82434	1710	histidine-rich zinc finger domain	[histidine-rich zinc finger domains]	0.0	4	1	1	1
82435	1710	recombinant nf-kappab protein	[recombinant NF-kappaB proteins]	0.0	3	1	1	1
82436	1710	responsiveness to ifn-alpha	[responsiveness to IFN-alpha]	0.0	3	1	1	1
82437	1710	U937 monoblastic cell	[U937 monoblastic cells]	0.0	3	1	1	1
82438	1710	deletion region	[Deletions region]	0.0	2	1	1	1
82439	1710	quantitation of glucocorticoid receptor	[Quantitation of glucocorticoid receptors]	0.0	4	1	1	1
82440	1710	Defining target	[Defining targets]	0.0	2	1	1	1
82441	1710	example of IDC	[examples of IDC]	0.0	3	1	1	1
82442	1710	affinity (at sevenfold)	[affinity (at sevenfold)]	0.0	3	1	1	1
82443	1710	13S	[13S]	0.0	1	1	1	1
82444	1710	response to virus type	[response to virus type]	0.0	4	1	1	1
82445	1710	novel zinc finger gene	[novel zinc finger genes]	0.0	4	1	1	1
82446	1710	97 young (18- healthy volunteer	[97 young (18- healthy volunteers]	0.0	5	1	1	1
82447	1710	constitute two biological model	[constituting two biological models]	0.0	4	1	1	1
82448	1710	modification in the expression	[modification in the expression]	0.0	4	1	1	1
82449	1710	monocyte binding to aortic endothelial cell	[monocyte binding to aortic endothelial cells]	0.0	6	1	1	1
82450	1710	tcr-induced tyrosine phosphorylation	[TCR-induced tyrosine phosphorylation]	0.0	3	1	1	1
82451	1710	nuclear factor-kappaB binding site	[nuclear factor-kappaB binding site]	0.0	4	1	1	1
82452	1710	constitute biological model of a situation	[constituting biological models of an situation]	0.0	6	1	1	1
82453	1710	recruitment of factor	[recruitment of factors]	0.0	3	1	1	1
82454	1710	level of the form	[level of the form]	0.0	4	1	1	1
82455	1710	mol/L 135(oh)2d3	[mol/L 1,25(OH)2D3]	0.0	2	1	1	1
82456	1710	mechanism for induction	[mechanism for induction]	0.0	3	1	1	1
82457	1710	il-8 release	[IL-8 release]	0.0	2	1	1	1
82458	1710	sem body mass	[SEM body mass]	0.0	3	1	1	1
82459	1710	cell (th)	[cell (Th)]	0.0	2	1	1	1
82460	1710	rrna such as gamma-globin delta-aminolevulinate synthase	[mRNAs such as gamma-globin delta-aminolevulinate synthase]	0.0	6	1	1	1
82461	1710	tax-responsive element tre1	[Tax-responsive element TRE1]	0.0	3	1	1	1
82462	1710	15N	[15N]	0.0	1	1	1	1
82463	1710	envelope membrane	[envelope membrane]	0.0	2	2	2	1
82464	1710	only g/g of mrna	[only g/g of mRNA]	0.0	4	1	1	1
82465	1710	normal maturing granulocyte	[normal maturing granulocytes]	0.0	3	1	1	1
82466	1710	repressive effect.	[repressive effect.]	0.0	2	1	1	1
82467	1710	Grb2 -related adaptor protein	[Grb2 -related adaptor protein]	0.0	4	1	1	1
82468	1710	complete remission.	[complete remission.]	0.0	2	1	1	1
82469	1710	(71%) recent-onset iddm subject 8	[(71%) recent-onset IDDM subjects 8]	0.0	5	1	1	1
82470	1710	monocyte-conditioned medium	[monocyte-conditioned medium]	0.0	2	1	1	1
82471	1710	stimulus vitamin D3	[stimuli vitamin D3]	0.0	3	1	1	1
82472	1710	cytokine expression erratum	[cytokine expression erratum]	0.0	3	1	1	1
82473	1710	development of the disease	[development of the disease.]	0.0	4	1	1	1
82474	1710	effect of dioxyvit with simultaneous correction	[effect of dioxyvit with simultaneous correction]	0.0	6	1	1	1
82475	1710	oligomer target PML mrna	[oligomers targeting PML mRNA]	0.0	4	1	1	1
82476	1710	myb family	[myb family]	0.0	2	1	1	1
82477	1710	1) sign	[1) signs]	0.0	2	1	1	1
82478	1710	plasmodium vivax protein	[Plasmodium vivax protein]	0.0	3	1	1	1
82479	1710	activation in the lining,	[activation in the lining,]	0.0	4	1	1	1
82480	1710	provide a basis for mimicry	[providing a basis for mimicry]	0.0	5	1	1	1
82481	1710	factor from THP-1 cell	[factor from THP-1 cells]	0.0	4	1	1	1
82482	1710	major candidate	[major candidate]	0.0	2	1	1	1
82483	1710	NK cytolysis IFN cytoprotection	[NK cytolysis IFN cytoprotection]	0.0	4	1	1	1
82484	1710	regulator of cytokine receptor signal	[regulator of cytokine receptor signaling]	0.0	5	1	1	1
82485	1710	act concurrently	[acting concurrently]	0.0	2	1	1	1
82486	1710	kappa b-dependent gene	[kappa B-dependent genes]	0.0	3	1	1	1
82487	1710	Pb activation	[Pb activation]	0.0	2	1	1	1
82488	1710	Karyotypic detection of abnormality	[Karyotypic detection of abnormalities]	0.0	4	1	1	1
82489	1710	region element	[region elements]	0.0	2	1	1	1
82490	1710	ttg act	[tTG acting]	0.0	2	1	1	1
82491	1710	3) content	[3) content]	0.0	2	1	1	1
82492	1710	human library	[human library]	0.0	2	1	1	1
82493	1710	Jak1 Box1 region	[Jak1 Box1 region]	0.0	3	1	1	1
82494	1710	process involve interaction	[process involving interactions]	0.0	3	1	1	1
82495	1710	activation of granulocyte	[activation of granulocytes]	0.0	3	1	1	1
82496	1710	"pure" progenitor	["pure" progenitors]	0.0	2	1	1	1
82497	1710	etntri)	[(TNFRI)]	0.0	1	1	1	1
82498	1710	immunofluorescence method	[immunofluorescence method]	0.0	2	1	1	1
82499	1710	kinetic of tumor development	[kinetics of tumor development]	0.0	4	1	1	1
82500	1710	enhancer domain	[enhancer domain]	0.0	2	1	1	1
82501	1710	modulate release of vasoactive factor	[modulating release of vasoactive factors]	0.0	5	1	1	1
82502	1710	interferon-alpha tyrosine phosphorylation	[interferon-alpha tyrosine phosphorylation]	0.0	3	1	1	1
82503	1710	mature T cell in	[mature T cells in]	0.0	4	1	1	1
82504	1710	action of six flavonoid	[action of six flavonoids]	0.0	4	1	1	1
82505	1710	extra c-terminal peptide	[extra C-terminal peptides]	0.0	3	1	1	1
82506	1710	autoregulatory feedback inhibitor of inflammation	[autoregulatory feedback inhibitor of inflammation]	0.0	5	1	1	1
82507	1710	last proliferation	[lasting proliferation]	0.0	2	1	1	1
82508	1710	stimulation in the presence	[Stimulation in the presence]	0.0	4	1	1	1
82509	1710	experiment by others,	[experiments by others,]	0.0	3	1	1	1
82510	1710	approach significance	[approaching significance]	0.0	2	1	1	1
82511	1710	slp-76 phosphoprotein of kda.	[SLP-76 phosphoprotein of kDa.]	0.0	4	1	1	1
82512	1710	decreases.	[decreases.]	0.0	1	1	1	1
82513	1710	binding of b cell-specific transcription factor	[binding of B cell-specific transcription factors]	0.0	6	1	1	1
82514	1710	c-Mpl	[c-Mpl]	0.0	1	1	1	1
82515	1710	anti-oxidative effect	[anti-oxidative effect]	0.0	2	1	1	1
82516	1710	occlusion a cause of morbidity	[occlusion a cause of morbidity]	0.0	5	1	1	1
82517	1710	bone marrow cell with vector	[bone marrow cells with vector]	0.0	5	1	1	1
82518	1710	low extent than c-fo	[lower extent than c-fos]	0.0	4	1	1	1
82519	1710	GCR on MNL in Yang patient	[GCR on MNL in Yang patients]	0.0	6	1	1	1
82520	1710	role mediate response	[roles mediating responses]	0.0	3	1	1	1
82521	1710	apoptosis in lymphoblastoid cell	[apoptosis in lymphoblastoid cells]	0.0	4	1	1	1
82522	1710	over-representation in cancer patient	[over-representation in cancer patients]	0.0	4	1	1	1
82523	1710	effect of dexamethasone on eosinophil apoptosis	[effects of dexamethasone on eosinophil apoptosis]	0.0	6	1	1	1
82524	1710	elimination of suppression	[elimination of suppression]	0.0	3	1	1	1
82525	1710	regulation role of sites.	[regulation role of sites.]	0.0	4	1	1	1
82526	1710	specific oligonucleotide sequence	[specific oligonucleotide sequence]	0.0	3	1	1	1
82527	1710	comprise a anti-hapten single-chain ab fragment	[comprising an anti-hapten single-chain Ab fragment]	0.0	6	1	1	1
82528	1710	expression of colony-stimumulatelany-stg factor-1 receptor csf-1r	[expression of colony-stimulating factor-1 receptor CSF-1R]	0.0	6	1	1	1
82529	1710	increase of T cell activation	[increase of T cell activation]	0.0	5	1	1	1
82530	1710	patient with incomplete androgen insensitivity	[patient with incomplete androgen insensitivity]	0.0	5	1	1	1
82531	1710	high (p<.001) in untreated patient	[higher (P<.001) in untreated patients]	0.0	5	1	1	1
82532	1710	(tcr) region beta-chain family	[(TCR) region beta-chain families]	0.0	4	1	1	1
82533	1710	lps-responsive cell	[LPS-responsive cells]	0.0	2	1	1	1
82534	1710	carboxyl-terminal domain	[carboxyl-terminal domain]	0.0	2	1	1	1
82535	1710	human fibroblastic cell	[human fibroblastic cells]	0.0	3	1	1	1
82536	1710	log-fold more glucocorticoid for a degree	[log-fold more glucocorticoids for an degree]	0.0	6	1	1	1
82537	1710	effect either on the promoter	[effect either on the promoter]	0.0	5	1	1	1
82538	1710	monoallelic (3	[monoallelic (3]	0.0	2	1	1	1
82539	1710	inhibitory activity of peptide	[inhibitory activities of peptides]	0.0	4	1	1	1
82540	1710	specific oligonucleotide probe	[specific oligonucleotide probes]	0.0	3	1	1	1
82541	1710	factor promoter in T cell	[factor promoters in T cells]	0.0	5	1	1	1
82542	1710	glucocorticoid binding site on the receptor	[glucocorticoid binding sites on the receptor]	0.0	6	1	1	1
82543	1710	four protein-DNA complex	[Four protein-DNA complexes]	0.0	3	1	1	1
82544	1710	three, heterozygous DNA variation in tumor	[three, heterozygous DNA variations in tumor]	0.0	6	1	1	1
82545	1710	underline the central role	[underlining the central role]	0.0	4	1	1	1
82546	1710	cis-acting element of the collagenase promoter	[cis-acting elements of the collagenase promoter]	0.0	6	1	1	1
82547	1710	washed,	[washed,]	0.0	1	1	1	1
82548	1710	kd (30.3+/-2.5 nmol/L) nmol/L) for cortisol	[Kd (30.3+/-2.5 nmol/L) nmol/L) for cortisol]	0.0	6	1	1	1
82549	1710	binding of il-2 to site	[binding of IL-2 to site]	0.0	5	1	1	1
82550	1710	sequence divergence	[sequence divergence]	0.0	2	1	1	1
82551	1710	focus attention	[focusing attention]	0.0	2	1	1	1
82552	1710	prl response element	[PRL response elements]	0.0	3	1	1	1
82553	1710	alteration in regulatory sequence	[alterations in regulatory sequences]	0.0	4	1	1	1
82554	1710	effect on proliferation.	[effects on proliferation.]	0.0	3	1	1	1
82555	1710	potential mechanism for the activation	[potential mechanism for the activation]	0.0	5	1	1	1
82556	1710	dose microm in om10.1 cell	[doses microM in OM10.1 cells]	0.0	5	1	1	1
82557	1710	also in 10 individual as control	[also in 10 individuals as control]	0.0	6	1	1	1
82558	1710	such function	[Such function]	0.0	2	1	1	1
82559	1710	ebna-2 type a	[EBNA-2 type A]	0.0	3	1	1	1
82560	1710	patient with lupus erythematosus SLE	[patients with lupus erythematosus SLE]	0.0	5	1	1	1
82561	1710	regulation in vivo	[regulation in vivo]	0.0	3	1	1	1
82562	1710	mobility supershift	[mobility supershift]	0.0	2	1	1	1
82563	1710	spite of this downstream signalling,	[spite of this downstream signalling,]	0.0	5	1	1	1
82564	1710	t(8;21) acute leukemia aml	[t(8;21) acute leukemia AML]	0.0	4	1	1	1
82565	1710	adjacent pair upstream sequence	[adjacent pair upstream sequence]	0.0	4	1	1	1
82566	1710	species-specific regulation	[species-specific regulation]	0.0	2	1	1	1
82567	1710	fraction of bq cell	[fraction of BQ cells]	0.0	4	1	1	1
82568	1710	RBC with tcdd	[RBCs with TCDD]	0.0	3	1	1	1
82569	1710	small intestinal epithelium	[small intestinal epithelium]	0.0	3	1	1	1
82570	1710	evidence for coupling of receptor factor	[evidence for coupling of receptor factor]	0.0	6	1	1	1
82571	1710	provision of p65/p50 nf-kappab	[provision of p65/p50 NF-kappaB]	0.0	4	1	1	1
82572	1710	Burkitt' lymphoma receptor	[Burkitt's lymphoma receptor]	0.0	3	1	1	1
82573	1710	hematopoiesis of leukocyte	[hematopoiesis of leukocytes]	0.0	3	1	1	1
82574	1710	putative systemic disorder	[putative systemic disorder]	0.0	3	1	1	1
82575	1710	cytokine function of t-cell	[cytokine functions of T-cells]	0.0	4	1	1	1
82576	1710	hhv-6 T cell	[HHV-6 T cells]	0.0	3	1	1	1
82577	1710	IL-2 transcriptional inhibitor	[IL-2 transcriptional inhibitors]	0.0	3	1	1	1
82578	1710	"SFS" domain similar to part	["SFS" domain similar to part]	0.0	5	1	1	1
82579	1710	transglycosylase of Escherichia coli	[transglycosylase of Escherichia coli]	0.0	4	1	1	1
82580	1710	ratio of memory	[ratio of memory]	0.0	3	1	1	1
82581	1710	profound depression	[profound depression]	0.0	2	1	1	1
82582	1710	(1) multiple inactivate substitution	[(1) multiple inactivating substitutions]	0.0	4	1	1	1
82583	1710	factor in thymocyte	[factor in thymocytes]	0.0	3	1	1	1
82584	1710	four repeat DR	[four repeats DR]	0.0	3	1	1	1
82585	1710	source for mediator	[source for mediators]	0.0	3	1	1	1
82586	1710	gene IL-1beta	[genes IL-1beta]	0.0	2	1	1	1
82587	1710	so-called pu box	[so-called Pu box]	0.0	3	1	1	1
82588	1710	regulation of MHC class expression	[regulation of MHC class expression]	0.0	5	1	1	1
82589	1710	method for detection	[methods for detection]	0.0	3	1	1	1
82590	1710	number of affinity tnfrp75 molecule	[numbers of affinity TNFRp75 molecules]	0.0	5	1	1	1
82591	1710	tandem repeat CAG	[tandem repeats CAG]	0.0	3	1	1	1
82592	1710	model, experiment	[model, experiments]	0.0	2	1	1	1
82593	1710	region important, respectively, through interaction	[regions important, respectively, through interaction]	0.0	5	1	1	1
82594	1710	mp dose mg bolus)	[MP dose mg bolus)]	0.0	4	1	1	1
82595	1710	I il-1 receptor	[I IL-1 receptors]	0.0	3	1	1	1
82596	1710	nf-il6beta expression	[NF-IL6beta expression]	0.0	2	1	1	1
82597	1710	ref 1-3	[refs 1-3]	0.0	2	1	1	1
82598	1710	pg/ml; N supine	[pg/ml; N supine]	0.0	3	1	1	1
82599	1710	interaction with factor tafii250	[interaction with factor TAFII250]	0.0	4	1	1	1
82600	1710	csf-1 -dependent proliferation	[CSF-1 -dependent proliferation]	0.0	3	1	1	1
82601	1710	MIP1 alpha nuclear protein MNP	[MIP1 alpha nuclear protein MNP]	0.0	5	1	1	1
82602	1710	apolipoprotein a1,	[apolipoprotein A1,]	0.0	2	1	1	1
82603	1710	six patient from five family	[six patients from five families]	0.0	5	1	1	1
82604	1710	two different forms:	[two different forms:]	0.0	3	1	1	1
82605	1710	patient with chronic heart disease	[patients with chronic heart disease]	0.0	5	2	2	1
82606	1710	dyad symmetrical sequence	[dyad symmetrical sequence]	0.0	3	1	1	1
82607	1710	sulfonyl)-2-methylpiperazine	[sulfonyl)-2-methylpiperazine]	0.0	1	1	1	1
82608	1710	approach to hiv-2 infection	[approaches to HIV-2 infection]	0.0	4	1	1	1
82609	1710	presumably by inhibition	[presumably by inhibition]	0.0	3	1	1	1
82610	1710	assembly of stable adhesion	[assembly of stable adhesions]	0.0	4	1	1	1
82611	1710	Differential regulation in NK cell	[Differential regulation in NK cells]	0.0	5	1	1	1
82612	1710	involvement of a enhancer element	[Involvement of a enhancer element]	0.0	5	1	1	1
82613	1710	most frequent lesion	[most frequent lesion]	0.0	3	1	1	1
82614	1710	immunohistochemistry on a panel	[Immunohistochemistry on a panel]	0.0	4	1	1	1
82615	1710	T to C substitution	[T to C substitution]	0.0	4	1	1	1
82616	1710	interferon protein CXC chemokine	[interferon protein CXC chemokine]	0.0	4	1	1	1
82617	1710	viral promoter switch	[viral promoter switching]	0.0	3	1	1	1
82618	1710	pharmacological profile of sigma receptor	[pharmacological profile of sigma receptors]	0.0	5	1	1	1
82619	1710	nuclear t3r alteration	[nuclear T3R alterations]	0.0	3	1	1	1
82620	1710	triple loop in monocyte	[triple loop in monocytes]	0.0	4	1	1	1
82621	1710	5' site at position bp	[5' site at position bp]	0.0	5	1	1	1
82622	1710	sequence regulatory element	[sequence regulatory element]	0.0	3	1	1	1
82623	1710	anti-SSB T	[anti-SSB T]	0.0	2	1	1	1
82624	1710	primary physiological regulator	[primary physiological regulator]	0.0	3	1	1	1
82625	1710	Interleukin-13	[Interleukin-13]	0.0	1	1	1	1
82626	1710	negative dominant molecule	[negative dominant molecule]	0.0	3	1	1	1
82627	1710	chemotactic migration rate	[chemotactic migration rate]	0.0	3	2	2	1
82628	1710	component within 30 minute	[component within 30 min]	0.0	4	1	1	1
82629	1710	role of HTLV-I taxi	[role of HTLV-I TaxI]	0.0	4	1	1	1
82630	1710	Surprisingly, multimer	[Surprisingly, multimers]	0.0	2	1	1	1
82631	1710	T cell line of infant	[T cell lines of infants]	0.0	5	1	1	1
82632	1710	factor-kappaB/Rel	[factor-kappaB/Rel]	0.0	1	1	1	1
82633	1710	class ii complex gene transcription	[class II complex gene transcription]	0.0	5	1	1	1
82634	1710	distinct complex with protein	[distinct complexes with proteins]	0.0	4	1	1	1
82635	1710	p65 -mediated activation	[p65 -mediated activation]	0.0	3	1	1	1
82636	1710	c-myc transcription	[c-myc transcription]	0.0	2	1	1	1
82637	1710	alpha (tnf-alpha)	[alpha (TNF-alpha)]	0.0	2	1	1	1
82638	1710	positive,	[positive,]	0.0	1	1	1	1
82639	1710	nitric oxide guanine nucleotide exchange	[Nitric oxide guanine nucleotide exchange]	0.0	5	1	1	1
82640	1710	parallel differentiation.	[paralleling differentiation.]	0.0	2	1	1	1
82641	1710	class ii heterodimer	[class II heterodimers]	0.0	3	1	1	1
82642	1710	nf-kappa b in atherosclerotic lesion	[NF-kappa B in atherosclerotic lesions]	0.0	5	1	1	1
82643	1710	Interferon regulatory factor irf-2	[Interferon regulatory factor IRF-2]	0.0	4	1	1	1
82644	1710	expression in the hypothalamus	[expression in the hypothalamus]	0.0	4	1	1	1
82645	1710	complete tolerance of mouse	[complete tolerance of mice]	0.0	4	1	1	1
82646	1710	activity RARalpha403	[activity RARalpha403]	0.0	2	1	1	1
82647	1710	pathway dependent in cell	[pathway dependent in cells]	0.0	4	1	1	1
82648	1710	2a-sensitive	[2A-sensitive]	0.0	1	1	1	1
82649	1710	form of ferrous	[form of ferrous]	0.0	3	1	1	1
82650	1710	1G5	[1G5]	0.0	1	1	1	1
82651	1710	millileter per hr.	[ml per hr.]	0.0	3	1	1	1
82652	1710	proteolytic regulation	[proteolytic regulation]	0.0	2	1	1	1
82653	1710	type effector function	[type effector function]	0.0	3	1	1	1
82654	1710	lead from the receptor	[leading from the receptor]	0.0	4	1	1	1
82655	1710	level of nfat transcriptional activity	[levels of NFAT transcriptional activities]	0.0	5	1	1	1
82656	1710	transcriptional activation of element	[transcriptional activation of element]	0.0	4	1	1	1
82657	1710	myeloid patient aml	[myeloid patients AML]	0.0	3	1	1	1
82658	1710	15-lipoxygenase gene promoter	[15-lipoxygenase gene promoter]	0.0	3	1	1	1
82659	1710	stimulator of direct t-cell recognition	[stimulators of direct T-cell recognition]	0.0	5	1	1	1
82660	1710	death domain death receptor	[death domain death receptor]	0.0	4	1	1	1
82661	1710	subcellular distribution.	[subcellular distribution.]	0.0	2	1	1	1
82662	1710	competition with p50	[competition with p50]	0.0	3	1	1	1
82663	1710	two alpha-helice	[two alpha-helices]	0.0	2	1	1	1
82664	1710	class histocompatibility complex gene hla-dra	[class histocompatibility complex gene HLA-DRA]	0.0	5	1	1	1
82665	1710	rapid activation of the isoform	[rapid activation of the isoforms]	0.0	5	1	1	1
82666	1710	242 control subject	[242 control subjects]	0.0	3	1	1	1
82667	1710	remission follow atra treatment	[remission following ATRA treatment]	0.0	4	1	1	1
82668	1710	Itk immunoprecipitate	[Itk immunoprecipitate]	0.0	2	1	1	1
82669	1710	there, clone	[there, clones]	0.0	2	1	1	1
82670	1710	other variable serum calcitriol	[other variables serum calcitriol]	0.0	4	1	1	1
82671	1710	alpha beta ligation alone	[alpha beta ligation alone]	0.0	4	1	1	1
82672	1710	marmoset T lymphocyte	[marmoset T lymphocytes]	0.0	3	1	1	1
82673	1710	il-2-gene regulation	[IL-2-gene regulation]	0.0	2	1	1	1
82674	1710	importance of gamma(c)	[importance of gamma(c)]	0.0	3	1	1	1
82675	1710	point estimation of glucocorticoid receptor	[point estimation of glucocorticoid receptors]	0.0	5	1	1	1
82676	1710	HL-60 leukemia cell line	[HL-60 leukemia cell line]	0.0	4	1	1	1
82677	1710	gene expression during erythroid differentiation	[gene expression during erythroid differentiation]	0.0	5	1	1	1
82678	1710	lymphocyte-specific immunoglobulin mu	[lymphocyte-specific immunoglobulin mu]	0.0	3	1	1	1
82679	1710	regard to the release of mediator	[regarding to the release of mediators]	0.0	6	1	1	1
82680	1710	direct substrate	[direct substrates]	0.0	2	1	1	1
82681	1710	laser scanning microscopy clsm	[laser scanning microscopy CLSM]	0.0	4	1	1	1
82682	1710	mass of 155 kD.	[mass of 155 kD.]	0.0	4	1	1	1
82683	1710	2 h of PMA exposure	[2 h of PMA exposure]	0.0	5	1	1	1
82684	1710	absence of apparent abnormality	[absence of apparent abnormalities]	0.0	4	1	1	1
82685	1710	Ter 119 positive erythroid cell	[Ter 119 positive erythroid cells]	0.0	5	1	1	1
82686	1710	3-fold increase in gene transcription	[3-fold increases in gene transcription]	0.0	5	1	1	1
82687	1710	2 class	[2 classes]	0.0	2	1	1	1
82688	1710	T negative element	[T negative element]	0.0	3	1	1	1
82689	1710	single case	[single case]	0.0	2	1	1	1
82690	1710	enzyme of heme synthesis	[enzyme of heme synthesis]	0.0	4	1	1	1
82691	1710	jul;27(7):1830]	[Jul;27(7):1830]]	0.0	1	1	1	1
82692	1710	scavenger receptor	[scavenger receptor]	0.0	2	1	1	1
82693	1710	h- pgg-glucan to leukocyte membrane	[H- PGG-Glucan to leukocyte membranes]	0.0	5	1	1	1
82694	1710	bzip transcription factor	[bZIP transcription factors]	0.0	3	1	1	1
82695	1710	receptor-effector-mechor-mechanisms	[receptor-effector-mechanisms]	0.0	1	1	1	1
82696	1710	factor in PBL	[factors in PBL]	0.0	3	1	1	1
82697	1710	role of stat5 in human monocyte	[roles of STAT5 in human monocytes]	0.0	6	1	1	1
82698	1710	Comparison of constitutive enhancement	[Comparison of constitutive enhancement]	0.0	4	1	1	1
82699	1710	study, structure/function analysis	[study, structure/function analyses]	0.0	3	1	1	1
82700	1710	constitutive translocation of this member	[constitutive translocation of these members]	0.0	5	1	1	1
82701	1710	repeat type	[repeat type]	0.0	2	1	1	1
82702	1710	detailed analysis of the first rdna	[Detailed analysis of the first cDNAs]	0.0	6	1	1	1
82703	1710	provide explanation important.	[providing explanation important.]	0.0	3	1	1	1
82704	1710	erythroleukemia cell line k562	[erythroleukemia cell line K562]	0.0	4	1	1	1
82705	1710	only binding affinity RBA the high	[only binding affinities RBA the highest]	0.0	6	1	1	1
82706	1710	serine/threonine phosphatase -1	[serine/threonine phosphatases -1]	0.0	3	1	1	1
82707	1710	use a assay with [3H]dexamethasone	[using a assay with [3H]dexamethasone]	0.0	5	1	1	1
82708	1710	four patient with myelofibrosis	[four patients with myelofibrosis]	0.0	4	1	1	1
82709	1710	effect of il-13 on human NK	[effects of IL-13 on human NK]	0.0	6	1	1	1
82710	1710	four repeat of bp	[four repeats of bp]	0.0	4	1	1	1
82711	1710	6tg1.1 icr27tk.3 T cell	[6TG1.1 ICR27TK.3 T cells]	0.0	4	1	1	1
82712	1710	pr patient	[PR patients]	0.0	2	1	1	1
82713	1710	signal event related	[signaling events related]	0.0	3	1	1	1
82714	1710	target PML mrna alpha-PML	[targeting PML mRNA alpha-PML]	0.0	4	1	1	1
82715	1710	number of false prediction	[number of false predictions]	0.0	4	1	1	1
82716	1710	presence of the flagellum	[presence of the flagellum]	0.0	4	1	1	1
82717	1710	express the mouse epor (r129c)	[expressing the mouse EpoR (R129C)]	0.0	5	1	1	1
82718	1710	present a structure	[presenting a structure]	0.0	3	1	1	1
82719	1710	N-terminal deletion of CIITA	[N-terminal deletions of CIITA]	0.0	4	1	1	1
82720	1710	evidence likely identical proteins, differ	[evidence likely identical proteins, differing]	0.0	5	1	1	1
82721	1710	3-bp mutation	[3-bp mutation]	0.0	2	1	1	1
82722	1710	expression of the mouse perforin gene	[expression of the mouse perforin gene]	0.0	6	1	1	1
82723	1710	direct expression of vcam-1	[directing expression of VCAM-1]	0.0	4	1	1	1
82724	1710	induction of immediate early gene	[induction of immediate early genes]	0.0	5	1	1	1
82725	1710	p50.p65 heterodimer	[p50.p65 heterodimers]	0.0	2	1	1	1
82726	1710	32 male with age distribution	[32 males with age distribution]	0.0	5	1	1	1
82727	1710	potential of the virus	[potential of the virus]	0.0	4	1	1	1
82728	1710	center of peripheral organ	[center of peripheral organs]	0.0	4	1	1	1
82729	1710	virus-induced transformation	[virus-induced transformation]	0.0	2	1	1	1
82730	1710	phosphoprotein with dna-binding activity	[phosphoproteins with DNA-binding activity]	0.0	4	1	1	1
82731	1710	only a low degree	[only a low degree]	0.0	4	1	1	1
82732	1710	gene for gelatinase-associated lipocalin	[gene for gelatinase-associated lipocalin]	0.0	4	1	1	1
82733	1710	hbx-antigen	[HBx-antigen]	0.0	1	1	1	1
82734	1710	4 leukemia (pll)	[4 leukemias (PLL)]	0.0	3	1	1	1
82735	1710	site in the transcriptional enhancer	[sites in the transcriptional enhancer]	0.0	5	1	1	1
82736	1710	case cathepsin	[case cathepsin]	0.0	2	1	1	1
82737	1710	U1 U2 dna-protein complex	[U1 U2 DNA-protein complexes]	0.0	4	1	1	1
82738	1710	concentration of the parent peptide	[concentrations of the parent peptide]	0.0	5	1	1	1
82739	1710	form in four familiess	[form in four families,]	0.0	4	1	1	1
82740	1710	negative ikappabalpha	[negative IkappaBalpha]	0.0	2	1	1	1
82741	1710	DNA binding of the proto-oncoprotein ets-1	[DNA binding of the proto-oncoprotein ets-1]	0.0	6	1	1	1
82742	1710	signal-dependent activation in fibroblast	[signal-dependent activation in fibroblasts]	0.0	4	1	1	1
82743	1710	activation by this mutant form	[activation by this mutant form]	0.0	5	1	1	1
82744	1710	novel elastase inhibitor peptide	[novel elastase inhibitor peptide]	0.0	4	1	1	1
82745	1710	overexpression of mutant IkappaBalpha	[overexpression of mutant IkappaBalpha]	0.0	4	1	1	1
82746	1710	differ at amino termini	[differing at amino termini]	0.0	4	1	1	1
82747	1710	5 micrograms/ml	[5 micrograms/ml]	0.0	2	1	1	1
82748	1710	m(r) in ebna-2 cell extract	[M(r) in EBNA-2 cell extracts]	0.0	5	1	1	1
82749	1710	virus-immortalized b cell	[virus-immortalized B cells]	0.0	3	1	1	1
82750	1710	intercellular adhesion molecule-1 icam-1 expression	[intercellular adhesion molecule-1 ICAM-1 expression]	0.0	5	1	1	1
82751	1710	definite information	[definite information]	0.0	2	1	1	1
82752	1710	stimulatory activity of CREB	[stimulatory activity of CREB]	0.0	4	1	1	1
82753	1710	fluorescence [channels]	[fluorescence [channels]]	0.0	2	1	1	1
82754	1710	breast cancer case (33%)	[breast cancer cases (33%)]	0.0	4	1	1	1
82755	1710	level in keratoacanthomas	[levels in keratoacanthomas]	0.0	3	1	1	1
82756	1710	cell in the region,	[cells in the region,]	0.0	4	1	1	1
82757	1710	i BL cell	[I BL cells]	0.0	3	1	1	1
82758	1710	binding site,	[binding site,]	0.0	2	1	1	1
82759	1710	gc border	[GC borders]	0.0	2	1	1	1
82760	1710	footprint over the elements,	[footprints over the elements,]	0.0	4	1	1	1
82761	1710	receptor on lymphocyte from patient	[receptors on lymphocytes from patients]	0.0	5	1	1	1
82762	1710	translocation involve the gene	[translocations involving the genes]	0.0	4	1	1	1
82763	1710	min) exercise ppe at 70%	[min) exercise PPE at 70%]	0.0	5	1	1	1
82764	1710	up-regulated tgf-beta1 mrna	[up-regulated TGF-beta1 mRNA]	0.0	3	1	1	1
82765	1710	pharmacologic control of trans-gene expression	[Pharmacologic control of trans-gene expression]	0.0	5	1	1	1
82766	1710	major physiological glucocorticoid	[major physiological glucocorticoid]	0.0	3	1	1	1
82767	1710	high affinity (at least sevenfold)	[higher affinity (at least sevenfold)]	0.0	5	1	1	1
82768	1710	generate a response	[generating an response]	0.0	3	1	1	1
82769	1710	infiltration of htlv-1-infected T lymphocyte	[infiltration of HTLV-1-infected T lymphocytes]	0.0	5	1	1	1
82770	1710	biochemical basis for the regulation	[biochemical basis for the regulation]	0.0	5	1	1	1
82771	1710	abundant expression of transcription factor	[Abundant expression of transcription factor]	0.0	5	1	1	1
82772	1710	hypermutation in follicular lymphoma (25	[hypermutation in follicular lymphoma (25]	0.0	5	1	1	1
82773	1710	subject of controversy.	[subject of controversy.]	0.0	3	1	1	1
82774	1710	additional means	[additional means]	0.0	2	1	1	1
82775	1710	60 minute exposure	[60 minutes exposure]	0.0	3	1	1	1
82776	1710	myeloid surface marker	[myeloid surface markers]	0.0	3	1	1	1
82777	1710	none of the site	[None of the sites]	0.0	4	1	1	1
82778	1710	Positive regulation of the octamer motif	[Positive regulation of the octamer motif]	0.0	6	1	1	1
82779	1710	adhesion protein mac-1	[adhesion protein Mac-1]	0.0	3	1	1	1
82780	1710	intensive hybridization signal	[intensive hybridization signals]	0.0	3	1	1	1
82781	1710	short amino- (729-766)	[short amino- (729-766)]	0.0	3	1	1	1
82782	1710	ongoing hiv-1 replication	[ongoing HIV-1 replication]	0.0	3	1	1	1
82783	1710	two abundant protein kD	[Two abundant proteins kD]	0.0	4	1	1	1
82784	1710	protein kinase/c-Jun kinase	[protein kinase/c-Jun kinases]	0.0	3	1	1	1
82785	1710	vast majority of disease syndrome	[vast majority of disease syndromes]	0.0	5	1	1	1
82786	1710	effect of reactive oxygen intermediate	[effects of reactive oxygen intermediates]	0.0	5	1	1	1
82787	1710	region of RFX5	[regions of RFX5]	0.0	3	1	1	1
82788	1710	(il)-10 blocking factor expression immuno-cytochemistry	[(IL)-10 blocking factor expression immuno-cytochemistry]	0.0	5	1	1	1
82789	1710	deletion of 70z/3 sequence	[deletions of 70Z/3 sequences]	0.0	4	1	1	1
82790	1710	binding complex relative	[binding complexes relative]	0.0	3	1	1	1
82791	1710	steady-state fluorescence anisotropy	[steady-state fluorescence anisotropy]	0.0	3	1	1	1
82792	1710	interference of binding	[interference of binding]	0.0	3	1	1	1
82793	1710	991.9 ng/mL, respectively).	[991.9 ng/mL, respectively).]	0.0	3	1	1	1
82794	1710	cell by member	[cells by members]	0.0	3	1	1	1
82795	1710	human vein segment	[human vein segments]	0.0	3	1	1	1
82796	1710	androgen -bound receptor protein	[androgen -bound receptor protein]	0.0	4	1	1	1
82797	1710	signal in JAK3 -deficient immunodeficiency lymphocyte	[Signaling in JAK3 -deficient immunodeficiency lymphocytes]	0.0	6	1	1	1
82798	1710	igg fc gamma	[IgG Fc gamma]	0.0	3	1	1	1
82799	1710	effect on cd34+ cell g-csf	[effects on CD34+ cells G-CSF]	0.0	5	1	1	1
82800	1710	independent assays),	[independent assays),]	0.0	2	1	1	1
82801	1710	(approximately nm)	[(approximately nM)]	0.0	2	1	1	1
82802	1710	reactive CTL clone	[reactive CTL clones]	0.0	3	1	1	1
82803	1710	few il-12 target gene	[few IL-12 target genes]	0.0	4	1	1	1
82804	1710	rBPI21 a fragment lps E-selectin expression	[rBPI21 a fragment LPS E-selectin expression]	0.0	6	1	1	1
82805	1710	T medium	[T medium]	0.0	2	1	1	1
82806	1710	follow activation than control line	[following activation than control lines]	0.0	5	1	1	1
82807	1710	gata-1 binding	[GATA-1 binding]	0.0	2	1	1	1
82808	1710	2.5-kilobase	[2.5-kilobase]	0.0	1	1	1	1
82809	1710	colony stimulate activity	[colony stimulating activity]	0.0	3	1	1	1
82810	1710	3,5,3'-triiodothyronine receptor circulate lymphocyte	[3,5,3'-triiodothyronine receptors circulating lymphocytes]	0.0	4	1	1	1
82811	1710	silencer between bp	[silencer between bp]	0.0	3	1	1	1
82812	1710	(range from 11.1	[(ranging from 11.1]	0.0	3	1	1	1
82813	1710	signal in t-cell	[signalling in T-cells]	0.0	3	1	1	1
82814	1710	synthesis in t-cell clone	[synthesis in T-cell clones]	0.0	4	1	1	1
82815	1710	bovine serum	[bovine serum]	0.0	2	2	2	1
82816	1710	peroxisome receptor member	[Peroxisome receptors members]	0.0	3	1	1	1
82817	1710	factor factor proliferation	[factor factor proliferation]	0.0	3	1	1	1
82818	1710	immediate dephosphorylation	[immediate dephosphorylation]	0.0	2	1	1	1
82819	1710	regulator of nf-kappab	[regulator of NF-kappaB]	0.0	3	1	1	1
82820	1710	ltr contain b element	[LTRs containing B elements]	0.0	4	1	1	1
82821	1710	lineage (with	[lineage (with]	0.0	2	1	1	1
82822	1710	activation marker	[activation markers]	0.0	2	1	1	1
82823	1710	binding site in mononuclear leukocyte	[binding sites in mononuclear leukocytes]	0.0	5	1	1	1
82824	1710	transformation of lymphoid cell	[transformation of lymphoid cells]	0.0	4	1	1	1
82825	1710	amplification of allele	[amplification of allele]	0.0	3	1	1	1
82826	1710	variability of the history	[variability of the history]	0.0	4	1	1	1
82827	1710	protein x box bind protein	[protein X box binding protein]	0.0	5	1	1	1
82828	1710	b cell signal response	[B cell signaling responses]	0.0	4	1	1	1
82829	1710	product of microbial pathogen	[products of microbial pathogens]	0.0	4	1	1	1
82830	1710	immunohistochemistry with antibody	[immunohistochemistry with antibodies]	0.0	3	1	1	1
82831	1710	14 nonatopic control subject	[14 nonatopic control subjects]	0.0	4	1	1	1
82832	1710	prenatal challenge	[prenatal challenge]	0.0	2	1	1	1
82833	1710	defective differentiation	[defective differentiation]	0.0	2	1	1	1
82834	1710	SKW cell 0.011	[SKW cells 0.001),]	0.0	3	1	1	1
82835	1710	elevation of protein	[elevation of protein]	0.0	3	1	1	1
82836	1710	also a TFIID binding site	[also a TFIID binding site]	0.0	5	1	1	1
82837	1710	anti-igm stimulation of b lymphocyte	[anti-IgM stimulation of B lymphocytes]	0.0	5	1	1	1
82838	1710	T cell-specific enhancer kb upstream	[T cell-specific enhancer kb upstream]	0.0	5	1	1	1
82839	1710	Culture supernatant	[Culture supernatants]	0.0	2	1	1	1
82840	1710	implication for dysregulation	[implications for dysregulation]	0.0	3	1	1	1
82841	1710	alpha,25-(OH)2D3 analog	[alpha,25-(OH)2D3 analogs]	0.0	2	1	1	1
82842	1710	thymocyte with thymic cell TEC	[thymocytes with thymic cells TEC]	0.0	5	1	1	1
82843	1710	general principle a regulator	[general principle a regulator]	0.0	4	1	1	1
82844	1710	(NF)-kappaB consensus sequence	[(NF)-kappaB consensus sequence]	0.0	3	1	1	1
82845	1710	gamma(c) cytoplasmic domain	[gamma(c) cytoplasmic domain]	0.0	3	1	1	1
82846	1710	element of long repeat	[elements of long repeats]	0.0	4	1	1	1
82847	1710	involve ca2+ mobilization	[involving Ca2+ mobilization]	0.0	3	1	1	1
82848	1710	early gene transcription	[early gene transcription]	0.0	3	1	1	1
82849	1710	1 expression in cell	[1 expression in cells]	0.0	4	1	1	1
82850	1710	use high throughput screen	[using high throughput screening]	0.0	4	1	1	1
82851	1710	integrin tyrosine phosphorylation	[integrin tyrosine phosphorylation]	0.0	3	1	1	1
82852	1710	macrophage colony-stimumulatelany-stg factor protein	[macrophage colony-stimulating factor protein]	0.0	4	1	1	1
82853	1710	various transcription factor include factor	[various transcription factors including factor]	0.0	5	1	1	1
82854	1710	late gene expression in cell	[late gene expression in cells]	0.0	5	1	1	1
82855	1710	4 beta 1 cd49d/cd29 costimulation	[4 beta 1 CD49d/CD29 costimulation]	0.0	5	1	1	1
82856	1710	signal for abrogation	[signal for abrogation]	0.0	3	1	1	1
82857	1710	IKAROS/LYF-1	[IKAROS/LYF-1]	0.0	1	1	1	1
82858	1710	sodium/proton-exchanger	[sodium/proton-exchanger]	0.0	1	1	1	1
82859	1710	recombinant nm23 -h1	[recombinant nm23 -H1]	0.0	3	1	1	1
82860	1710	polyclonal pattern of x-inactivation	[polyclonal pattern of X-inactivation]	0.0	4	1	1	1
82861	1710	non-steroidal drug	[non-steroidal drugs]	0.0	2	1	1	1
82862	1710	protein phosphatase,	[protein phosphatase,]	0.0	2	1	1	1
82863	1710	use ad 2/5 primer	[Using Ad 2/5 primers]	0.0	4	1	1	1
82864	1710	digestion in uninduced hepatocyte	[digestion in uninduced hepatocytes]	0.0	4	1	1	1
82865	1710	CD28 -dependent induction	[CD28 -dependent induction]	0.0	3	1	1	1
82866	1710	differentiation/activation stimulus	[differentiation/activation stimuli]	0.0	2	1	1	1
82867	1710	cooperate nuclear transcription factor	[cooperating nuclear transcription factors]	0.0	4	1	1	1
82868	1710	immune-endocrine function	[immune-endocrine function]	0.0	2	1	1	1
82869	1710	deletion of exon	[deletions of exons]	0.0	3	1	1	1
82870	1710	RFX activity	[RFX activity]	0.0	2	1	1	1
82871	1710	highlight novel cancer related loci relevant	[highlighting novel cancer related loci relevant]	0.0	6	1	1	1
82872	1710	induce 135(oh)2d3 degradation	[inducing 1,25(OH)2D3 degradation]	0.0	3	1	1	1
82873	1710	indicate a involvement of Itk	[indicating a involvement of Itk]	0.0	5	1	1	1
82874	1710	set of band	[set of bands]	0.0	3	1	1	1
82875	1710	roset cd4+	[rosetting CD4+]	0.0	2	1	1	1
82876	1710	hiv-1 infection of T cell	[HIV-1 infection of T cells]	0.0	5	1	1	1
82877	1710	anti activity	[anti activity]	0.0	2	1	1	1
82878	1710	nonspecific stimulation, il-5 production	[nonspecific stimulation, IL-5 production]	0.0	4	1	1	1
82879	1710	PBMC from child with adenoviral infection	[PBMC from children with adenoviral infection]	0.0	6	2	2	1
82880	1710	fitc- lps	[FITC- LPS]	0.0	2	1	1	1
82881	1710	induction during monocytic differentiation	[induction during monocytic differentiation]	0.0	4	1	1	1
82882	1710	breakpoint 11 range	[breakpoints 11 ranging]	0.0	3	1	1	1
82883	1710	anti- CR1	[anti- CR1]	0.0	2	1	1	1
82884	1710	anti- CR3	[anti- CR3]	0.0	2	1	1	1
82885	1710	young rat	[young rats]	0.0	2	1	1	1
82886	1710	enzyme-linked assay with peptide	[enzyme-linked assay with peptides]	0.0	4	1	1	1
82887	1710	crossreact protein in human lymphocyte	[crossreacting proteins in human lymphocytes]	0.0	5	1	1	1
82888	1710	cushingd' syndrome type ii	[Cushing's syndrome Type II]	0.0	4	1	1	1
82889	1710	acidic protein	[acidic protein]	0.0	2	1	1	1
82890	1710	blood burst-forming unit-erythroid	[blood burst-forming unit-erythroid]	0.0	3	1	1	1
82891	1710	t-cell NFAT-1	[T-cells NFAT-1]	0.0	2	1	1	1
82892	1710	monocytoid u937 cell	[monocytoid U937 cells]	0.0	3	1	1	1
82893	1710	activity downstream	[activities downstream]	0.0	2	1	1	1
82894	1710	hiv infection,	[HIV infection,]	0.0	2	1	1	1
82895	1710	activation to a element	[Activation to a element]	0.0	4	1	1	1
82896	1710	response to D3 in monocyte	[response to D3 in monocytes]	0.0	5	1	1	1
82897	1710	low weight variant in monocyte	[lower weight variant in monocytes]	0.0	5	1	1	1
82898	1710	inhibition involvement of the receptor	[Inhibition involvement of the receptor]	0.0	5	1	1	1
82899	1710	c5b-7 on target cell	[C5b-7 on target cells]	0.0	4	1	1	1
82900	1710	activator produce a induction	[activator producing a induction]	0.0	4	1	1	1
82901	1710	factor (NF)-AT proximal NF-AT	[factor (NF)-AT proximal NF-AT]	0.0	4	1	1	1
82902	1710	NF-kappaB mechanism	[NF-kappaB mechanism]	0.0	2	1	1	1
82903	1710	drug such as salicylate	[drugs such as salicylates]	0.0	4	1	1	1
82904	1710	gene interleukin-2 IL2 a cytokine	[gene interleukin-2 IL2 a cytokine]	0.0	5	1	1	1
82905	1710	variety include T cell	[variety including T cells]	0.0	4	1	1	1
82906	1710	lineage retinoic acid	[lineage retinoic acid]	0.0	3	1	1	1
82907	1710	Pd-C hydrogenation	[Pd-C hydrogenation]	0.0	2	1	1	1
82908	1710	six individual	[six individuals]	0.0	2	1	1	1
82909	1710	protein in human T cell	[proteins in human T cells]	0.0	5	1	1	1
82910	1710	50% hcss	[50% HCSs]	0.0	2	1	1	1
82911	1710	b protein level	[B protein levels]	0.0	3	1	1	1
82912	1710	least several gene	[least several genes]	0.0	3	1	1	1
82913	1710	TAP-deficient cell line	[TAP-deficient cell lines]	0.0	3	1	1	1
82914	1710	prolonged exposure	[prolonged exposure]	0.0	2	1	1	1
82915	1710	activity il-1 in runner	[activity IL-1 in runner]	0.0	4	1	1	1
82916	1710	possibly evasion of response	[possibly evasion of responses]	0.0	4	1	1	1
82917	1710	response to stimulus in t-cell	[response to stimuli in T-cells]	0.0	5	1	1	1
82918	1710	IL-12 receptor beta 2 subunit	[IL-12 receptor beta 2 subunit]	0.0	5	1	1	1
82919	1710	impact for cell development	[impact for cell development]	0.0	4	1	1	1
82920	1710	approximately 20 mM.	[approximately 20 mM.]	0.0	3	1	1	1
82921	1710	integrin ligation	[integrin ligation]	0.0	2	1	1	1
82922	1710	ets-related protein elf-1	[Ets-related protein Elf-1]	0.0	3	1	1	1
82923	1710	neutrophil leukocyte	[neutrophils leukocytes]	0.0	2	1	1	1
82924	1710	14 patient with sle (0.9356	[14 patients with SLE (0.9356]	0.0	5	1	1	1
82925	1710	carry XIC/XIST	[carrying XIC/XIST]	0.0	2	1	1	1
82926	1710	enhancer upon overexpression	[enhancer upon overexpression]	0.0	3	1	1	1
82927	1710	individual to certain disease	[individual to certain diseases]	0.0	4	1	1	1
82928	1710	target complex binding	[target complex binding]	0.0	3	1	1	1
82929	1710	portion of the domain DeltaE	[portion of the domain DeltaE]	0.0	5	1	1	1
82930	1710	10% porcine serum (control)	[10% porcine serum (control)]	0.0	4	1	1	1
82931	1710	thp-1 macrophage cell	[THP-1 macrophage cells]	0.0	3	1	1	1
82932	1710	activity of nf-kb less	[activity of NF-kB less]	0.0	4	1	1	1
82933	1710	lymphotoxin-alpha gene	[lymphotoxin-alpha genes]	0.0	2	1	1	1
82934	1710	significant aldosterone binding at a weight	[significant aldosterone binding at a weight]	0.0	6	1	1	1
82935	1710	lymphocyte infiltration of the tumor	[lymphocyte infiltration of the tumor]	0.0	5	1	1	1
82936	1710	study in patient	[study in patients]	0.0	3	1	1	1
82937	1710	such as factor kappa b	[such as factor kappa B]	0.0	5	1	1	1
82938	1710	factor (irf) binding site	[factor (IRF) binding site]	0.0	4	1	1	1
82939	1710	3'-	[3'-]	0.0	1	1	1	1
82940	1710	presence of site for factor	[presence of sites for factors]	0.0	5	1	1	1
82941	1710	three zinc finger at the carboxyl-terminus	[three zinc fingers at the carboxyl-terminus]	0.0	6	1	1	1
82942	1710	use a adenovirus	[using a adenovirus]	0.0	3	1	1	1
82943	1710	consensus gata-binding site	[consensus GATA-binding sites]	0.0	3	1	1	1
82944	1710	mature normal myelomonocytic cell	[maturing normal myelomonocytic cells]	0.0	4	1	1	1
82945	1710	transfection of trans-dominant expression vector together	[Transfection of trans-dominant expression vectors together]	0.0	6	1	1	1
82946	1710	physical interaction between ets	[physical interaction between Ets]	0.0	4	1	1	1
82947	1710	oligomerization of a monomer	[oligomerization of an monomer]	0.0	4	1	1	1
82948	1710	jun/fo family	[jun/fos family]	0.0	2	1	1	1
82949	1710	wide variety in vivo	[wide variety in vivo]	0.0	4	1	1	1
82950	1710	various organelle	[various organelles]	0.0	2	1	1	1
82951	1710	modulate calcium	[modulating calcium]	0.0	2	1	1	1
82952	1710	basement membrane immunoreactivity for type	[Basement membrane immunoreactivity for type]	0.0	5	1	1	1
82953	1710	formation of new AMP response	[formation of new AMP response]	0.0	5	1	1	1
82954	1710	two form lack a portion	[two forms lacking a portion]	0.0	5	1	1	1
82955	1710	use antibody against subunit	[using antibodies against subunits]	0.0	4	1	1	1
82956	1710	step of transport	[step of transport]	0.0	3	1	1	1
82957	1710	competition between general activator	[competition between general activators]	0.0	4	1	1	1
82958	1710	inhibit generation of trigger molecule	[inhibiting generation of triggering molecule]	0.0	5	1	1	1
82959	1710	eight segment	[eight segments]	0.0	2	1	1	1
82960	1710	N-Oct factor	[N-Oct factors]	0.0	2	1	1	1
82961	1710	target to the progeny	[targeting to the progeny]	0.0	4	1	1	1
82962	1710	angioplasty	[angioplasty]	0.0	1	1	1	1
82963	1710	site of damage	[site of damage]	0.0	3	1	1	1
82964	1710	tolerance for human tcf-1	[tolerance for human TCF-1]	0.0	4	1	1	1
82965	1710	feature of cellular senescence	[feature of cellular senescence]	0.0	4	1	1	1
82966	1710	adult erythroid-specific footprint	[adult erythroid-specific footprint]	0.0	3	1	1	1
82967	1710	nuclear factor (ref. 1)	[nuclear factor (ref. 1)]	0.0	4	1	1	1
82968	1710	characterization of b-cell factor	[characterization of B-cell factor]	0.0	4	1	1	1
82969	1710	step-wise increase exercise	[step-wise increasing exercise]	0.0	3	1	1	1
82970	1710	cotton-top	[cotton-top]	0.0	1	1	1	1
82971	1710	role of protein tyrosine phosphatase	[role of protein tyrosine phosphatases]	0.0	5	1	1	1
82972	1710	phorbol-13-acetate for 4-24 h	[phorbol-13-acetate for 4-24 h]	0.0	4	1	1	1
82973	1710	respectively), indicate a rate	[respectively), indicating an rate]	0.0	4	1	1	1
82974	1710	gpc91-phox	[gpc91-phox]	0.0	1	1	1	1
82975	1710	action CPRE GGACTACAG	[action CPRE GGACTACAG]	0.0	3	1	1	1
82976	1710	oct-binding factor a protein	[Oct-binding factor a protein]	0.0	4	1	1	1
82977	1710	such as nuclear factor kappa b	[such as nuclear factor kappa B]	0.0	6	1	1	1
82978	1710	period of clinical latency	[period of clinical latency]	0.0	4	1	1	1
82979	1710	contain lck	[containing Lck]	0.0	2	1	1	1
82980	1710	upstream of the coding region	[upstream of the coding region]	0.0	5	1	1	1
82981	1710	clone-13 to the x2-box	[clone-13 to the X2-box]	0.0	4	1	1	1
82982	1710	activation of transcription factor by stimulus	[Activation of transcription factor by stimuli]	0.0	6	1	1	1
82983	1710	exclude targets,	[excluding targets,]	0.0	2	1	1	1
82984	1710	nonhematopoietic cell line NIH	[nonhematopoietic cell lines NIH]	0.0	4	1	1	1
82985	1710	region for il-2-r alpha	[region for IL-2-R alpha]	0.0	4	1	1	1
82986	1710	covalent modification of protein kinase	[covalent modification of protein kinases]	0.0	5	1	1	1
82987	1710	-contain complex	[-containing complex]	0.0	2	1	1	1
82988	1710	role augment antitumor immunity	[role augmenting antitumor immunity]	0.0	4	1	1	1
82989	1710	subunits; independent genes, nfkb1 p105	[subunits; independent genes, NFKB1 p105]	0.0	5	1	1	1
82990	1710	response to single versus dose	[responses to single versus doses]	0.0	5	1	1	1
82991	1710	il-1 beta huvec	[IL-1 beta HUVEC]	0.0	3	1	1	1
82992	1710	tissue factor tf expression	[Tissue factor TF expression]	0.0	4	1	1	1
82993	1710	inhibitor for s-adenosylhomocysteine hydrolase	[inhibitor for S-adenosylhomocysteine hydrolase]	0.0	4	1	1	1
82994	1710	hormonal situation	[hormonal situation]	0.0	2	1	1	1
82995	1710	patient with sjogren' syndrome (ss)	[patients with Sjogren's syndrome (SS)]	0.0	5	1	1	1
82996	1710	171.3 dpm	[171.3 dpm]	0.0	2	1	1	1
82997	1710	GCRbeta expression in asthma	[GCRbeta expression in asthma]	0.0	4	1	1	1
82998	1710	dramatic increase notably phospholipase c	[dramatic increase notably phospholipase C]	0.0	5	1	1	1
82999	1710	technique block nf-kappab through overexpression	[technique blocking NF-kappaB through overexpression]	0.0	5	1	1	1
83000	1710	low, physiological concentration of aldosterone	[low, physiological concentrations of aldosterone]	0.0	5	2	2	1
83001	1710	expression of high-affinity receptor	[expression of high-affinity receptor]	0.0	4	1	1	1
83002	1710	bone growth	[bone growth]	0.0	2	1	1	1
83003	1710	similar effects,	[similar effects,]	0.0	2	1	1	1
83004	1710	soluble CD40 ligand activation	[soluble CD40 ligand activation]	0.0	4	1	1	1
83005	1710	hiv-1 induction	[HIV-1 induction]	0.0	2	1	1	1
83006	1710	cocktail factor	[cocktail factor]	0.0	2	1	1	1
83007	1710	act outside Ig loci	[acting outside Ig loci]	0.0	4	1	1	1
83008	1710	hpc colony-forming cell hppecfcs	[HPCs colony-forming cells HPP-CFCs]	0.0	4	1	1	1
83009	1710	mucosal biopsy use a radioassay	[mucosal biopsies using a radioassay]	0.0	5	1	1	1
83010	1710	ATL cell line TL-OmI	[ATL cell lines TL-OmI]	0.0	4	1	1	1
83011	1710	elevation of lavage cellularity	[elevation of lavage cellularity]	0.0	4	1	1	1
83012	1710	action of GCH	[action of GCH]	0.0	3	1	1	1
83013	1710	molecular clone of HTLV-II	[molecular clone of HTLV-II]	0.0	4	1	1	1
83014	1710	nevertheless, high, concentration to 10 &mgr;m)	[Nevertheless, high, concentrations to 10 &mgr;M)]	0.0	6	1	1	1
83015	1710	beclomethasone	[beclomethasone]	0.0	1	1	1	1
83016	1710	nf-kb DNA binding	[NF-kB DNA binding]	0.0	3	1	1	1
83017	1710	infiltrate the tumor	[infiltrating the tumor]	0.0	3	1	1	1
83018	1710	Effect on blood mononuclear cell response	[Effects on blood mononuclear cell responses]	0.0	6	1	1	1
83019	1710	lung,	[lung,]	0.0	1	1	1	1
83020	1710	activity of factor (nf)-kappab	[activity of factor (NF)-kappaB]	0.0	4	1	1	1
83021	1710	systems.	[systems.]	0.0	1	1	1	1
83022	1710	leukocyte in patient	[leukocytes in patients]	0.0	3	1	1	1
83023	1710	nuclear extract from B	[nuclear extracts from B]	0.0	4	1	1	1
83024	1710	ras transformation of b lymphoblast	[Ras transformation of B lymphoblasts]	0.0	5	1	1	1
83025	1710	stress-activated protein kinase/c-Jun	[stress-activated protein kinase/c-Jun]	0.0	3	1	1	1
83026	1710	-independent pathway	[-independent pathways]	0.0	2	1	1	1
83027	1710	inhibition in vivo effect of formulation	[Inhibition in vivo effect of formulation]	0.0	6	1	1	1
83028	1710	specificity)	[specificity)]	0.0	1	1	1	1
83029	1710	GCR-beta -immunoreactive cell than asthmatics	[GCR-beta -immunoreactive cells than asthmatics]	0.0	5	1	1	1
83030	1710	cd11c promoter -luciferase	[CD11c promoter -luciferase]	0.0	3	1	1	1
83031	1710	less pronounced,	[less pronounced,]	0.0	2	1	1	1
83032	1710	affinity aldosterone	[affinity aldosterone]	0.0	2	1	1	1
83033	1710	negative form Max	[negative form Max]	0.0	3	1	1	1
83034	1710	apoptosis regulator	[apoptosis regulator]	0.0	2	1	1	1
83035	1710	sequence of bovine fkbp	[sequence of bovine FKBP]	0.0	4	1	1	1
83036	1710	inhibitor activation	[inhibitor activation]	0.0	2	1	1	1
83037	1710	two factor kB element	[two factor kB elements]	0.0	4	1	1	1
83038	1710	regeneration the cofactor	[regeneration the cofactor]	0.0	3	1	1	1
83039	1710	inhibitory role	[inhibitory role]	0.0	2	1	1	1
83040	1710	kind of receptor complexes:	[kinds of receptor complexes:]	0.0	4	1	1	1
83041	1710	independent cloning from olfactory neuronal cell	[independent cloning from olfactory neuronal cells]	0.0	6	1	1	1
83042	1710	CML cell	[CML cells]	0.0	2	1	1	1
83043	1710	gene after many kind	[genes after many kinds]	0.0	4	1	1	1
83044	1710	human p75tnf-r	[human p75TNF-R]	0.0	2	1	1	1
83045	1710	distinct subset of DLCL	[distinct subsets of DLCL]	0.0	4	1	1	1
83046	1710	GCR-beta cell than asthmatics	[GCR-beta cells than asthmatics]	0.0	4	1	1	1
83047	1710	durable inhibition of replication	[durable inhibition of replication]	0.0	4	1	1	1
83048	1710	several binding site for transcription factor	[several binding sites for transcription factors]	0.0	6	1	1	1
83049	1710	moreover, deletion	[Moreover, deletion]	0.0	2	1	1	1
83050	1710	murine protein, exogenous	[murine protein, exogenous]	0.0	3	1	1	1
83051	1710	cell of the cortex	[cells of the cortex]	0.0	4	1	1	1
83052	1710	CD38 marker	[CD38 markers]	0.0	2	1	1	1
83053	1710	p50 /p50	[p50 /p50]	0.0	2	1	1	1
83054	1710	subsequent treatment	[subsequent treatment]	0.0	2	1	1	1
83055	1710	ribosome binding	[ribosome binding]	0.0	2	1	1	1
83056	1710	profile of other gene	[profiles of other genes]	0.0	4	1	1	1
83057	1710	intact gata element	[intact GATA element]	0.0	3	1	1	1
83058	1710	ecto-5'-NT core promoter	[ecto-5'-NT core promoter]	0.0	3	1	1	1
83059	1710	caspase 1	[caspase 1]	0.0	2	1	1	1
83060	1710	caspase 7	[caspase 7]	0.0	2	1	1	1
83061	1710	activity of trans-activating factor	[activity of trans-activating factors]	0.0	4	1	1	1
83062	1710	uninfected T lymphocyte	[uninfected T lymphocytes]	0.0	3	1	1	1
83063	1710	portion of Sp140	[portion of Sp140]	0.0	3	1	1	1
83064	1710	imbalanced expression from a patient	[Imbalanced expression from a patient]	0.0	5	1	1	1
83065	1710	human acid lipase	[Human acid lipase]	0.0	3	1	1	1
83066	1710	pre-exist subunit	[pre-existing subunit]	0.0	2	1	1	1
83067	1710	protein crossreactive with the STAT family	[proteins crossreactive with the STAT family]	0.0	6	1	1	1
83068	1710	antagonist of E2	[antagonist of E2]	0.0	3	1	1	1
83069	1710	15-lipoxygenase gene promoter analysis	[15-lipoxygenase gene promoter analysis]	0.0	4	1	1	1
83070	1710	human gamma	[human gamma]	0.0	2	1	1	1
83071	1710	edge: effect of Ile50Val variant	[edge: effect of Ile50Val variant]	0.0	5	1	1	1
83072	1710	putative loop	[putative loop]	0.0	2	1	1	1
83073	1710	emergence follow multiple administration	[emergence following multiple administrations]	0.0	4	1	1	1
83074	1710	gtp-cyclohydrolase	[GTP-cyclohydrolase]	0.0	1	1	1	1
83075	1710	regulate the distribution	[regulating the distribution]	0.0	3	1	1	1
83076	1710	infection to aids	[infection to AIDS]	0.0	3	1	1	1
83077	1710	traf binding sequence in CD30	[TRAF binding sequences in CD30]	0.0	5	1	1	1
83078	1710	sp-a dose as low	[SP-A doses as low]	0.0	4	1	1	1
83079	1710	resection respond	[resection responding]	0.0	2	1	1	1
83080	1710	human monocyte tnf-alpha production	[human monocyte TNF-alpha production]	0.0	4	1	1	1
83081	1710	uptake with primary hyperparathyroidism php	[uptake with primary hyperparathyroidism PHP]	0.0	5	1	1	1
83082	1710	form of active transcription factor	[forms of active transcription factor]	0.0	5	1	1	1
83083	1710	trigger necrosis factor-alpha	[Triggering necrosis factor-alpha]	0.0	3	1	1	1
83084	1710	frequently, cd4+ T cell	[frequently, CD4+ T cells]	0.0	4	1	1	1
83085	1710	75% respectively,	[75% respectively,]	0.0	2	1	1	1
83086	1710	mitogen assay	[mitogen assay]	0.0	2	1	1	1
83087	1710	key negative regulator	[key negative regulator]	0.0	3	1	1	1
83088	1710	traf binding sequence in CD40	[TRAF binding sequences in CD40]	0.0	5	1	1	1
83089	1710	glucocorticoid receptor determination in patient	[glucocorticoid receptor determination in patients]	0.0	5	1	1	1
83090	1710	(ig) gene	[(Ig) genes]	0.0	2	1	1	1
83091	1710	receptor complex on MDMac	[receptor complex on MDMac]	0.0	4	1	1	1
83092	1710	1pk	[1pk]	0.0	1	2	2	1
83093	1710	ap-1 DNA	[AP-1 DNA]	0.0	2	2	2	1
83094	1710	8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
83095	1710	potent pkc inhibitor	[potent PKC inhibitor]	0.0	3	1	1	1
83096	1710	adhesive ICAM-1	[adhesive ICAM-1]	0.0	2	1	1	1
83097	1710	putative motif	[putative motifs]	0.0	2	1	1	1
83098	1710	human deficiency virus type	[human deficiency virus type]	0.0	4	1	1	1
83099	1710	CTL recognize tumor ag	[CTL recognizing tumor Ag]	0.0	4	1	1	1
83100	1710	transfection into human jurkat T	[Transfection into human Jurkat T]	0.0	5	1	1	1
83101	1710	glutamine residue	[glutamine residues]	0.0	2	1	1	1
83102	1710	(auc of 332	[(AUC of 332]	0.0	3	1	1	1
83103	1710	aspect of T lymphocyte development,	[aspects of T lymphocyte development,]	0.0	5	1	1	1
83104	1710	t-cell recognition	[T-cell recognition]	0.0	2	1	1	1
83105	1710	10 follow differentiation	[10 following differentiation]	0.0	3	1	1	1
83106	1710	transcriptase polymerase chain	[transcriptase polymerase chain]	0.0	3	1	1	1
83107	1710	male with similar age distribution	[males with similar age distribution]	0.0	5	1	1	1
83108	1710	sla-dra mrna induction	[SLA-DRA mRNA induction]	0.0	3	1	1	1
83109	1710	Twenty-two difference	[Twenty-two differences]	0.0	2	1	1	1
83110	1710	macrophage PAM	[macrophages PAM]	0.0	2	1	1	1
83111	1710	blood mononuclear cell in relation	[blood mononuclear cells in relation]	0.0	5	1	1	1
83112	1710	lesion together	[lesions together]	0.0	2	1	1	1
83113	1710	reverse-transcription pcr display	[reverse-transcription PCR display]	0.0	3	1	1	1
83114	1710	time of the normal control	[times of the normal controls]	0.0	5	1	1	1
83115	1710	three member	[three members]	0.0	2	1	1	1
83116	1710	start at day	[starting at day]	0.0	3	1	1	1
83117	1710	survival against apoptosis	[survival against apoptosis]	0.0	3	1	1	1
83118	1710	induced,	[induced,]	0.0	1	1	1	1
83119	1710	immune dysregulation	[immune dysregulation]	0.0	2	1	1	1
83120	1710	biological function in development	[biological function in development]	0.0	4	1	1	1
83121	1710	cellular source	[cellular source]	0.0	2	1	1	1
83122	1710	molecular consequence	[molecular consequences]	0.0	2	1	1	1
83123	1710	small basic potential phosphoprotein	[small basic potential phosphoprotein]	0.0	4	1	1	1
83124	1710	granulocyte functionality	[granulocyte functionality]	0.0	2	1	1	1
83125	1710	Reciprocally, inhibition	[Reciprocally, inhibition]	0.0	2	1	1	1
83126	1710	range of biological effect	[range of biological effects]	0.0	4	1	1	1
83127	1710	environmental contaminant	[environmental contaminant]	0.0	2	1	1	1
83128	1710	gene encode a component	[genes encoding a component]	0.0	4	1	1	1
83129	1710	regulation of m-csf expression role	[Regulation of M-CSF expression role]	0.0	5	1	1	1
83130	1710	AD1 transactivation domain	[AD1 transactivation domains]	0.0	3	1	1	1
83131	1710	interaction of CD2 with ligand LFA-3	[interaction of CD2 with ligand LFA-3]	0.0	6	1	1	1
83132	1710	production of level	[production of levels]	0.0	3	1	1	1
83133	1710	rest T cells,	[resting T cells,]	0.0	3	1	1	1
83134	1710	IL-2 promoter factor (NF)-AT	[IL-2 promoter factor (NF)-AT]	0.0	4	1	1	1
83135	1710	1st	[1st]	0.0	1	1	1	1
83136	1710	likely: correct fold	[likely: correct folding]	0.0	3	1	1	1
83137	1710	Finally, micromolar amount	[Finally, micromolar amounts]	0.0	3	1	1	1
83138	1710	involve the arm	[involving the arm]	0.0	3	1	1	1
83139	1710	consist after a observation period	[consisting after an observation period]	0.0	5	1	1	1
83140	1710	fetal thymic organ	[fetal thymic organ]	0.0	3	1	1	1
83141	1710	complex between the drug	[complex between the drug]	0.0	4	1	1	1
83142	1710	clinicopathological aspect	[clinicopathological aspects]	0.0	2	1	1	1
83143	1710	mechanism of rna	[mechanism of RNA]	0.0	3	1	1	1
83144	1710	transient transfectant with the CIITA construct	[Transient transfectants with the CIITA constructs]	0.0	6	1	1	1
83145	1710	HL 60 cell	[HL 60 cells]	0.0	3	1	1	1
83146	1710	response through form	[response through forms]	0.0	3	1	1	1
83147	1710	chronic mpd	[chronic MPDs]	0.0	2	1	1	1
83148	1710	interaction between two cell-specific transcriptional coactivator	[interactions between two cell-specific transcriptional coactivators]	0.0	6	1	1	1
83149	1710	il-2 upon stimulation,	[IL-2 upon stimulation,]	0.0	3	1	1	1
83150	1710	antigen EA-D	[antigen EA-D]	0.0	2	1	1	1
83151	1710	[3H]calcitriol/VDR	[[3H]calcitriol/VDR]	0.0	1	2	2	1
83152	1710	role in repression	[role in repression]	0.0	3	1	1	1
83153	1710	induction by IFN-gamma	[induction by IFN-gamma]	0.0	3	1	1	1
83154	1710	proteolysis profile	[proteolysis profile]	0.0	2	1	1	1
83155	1710	multiple region include the enhancer	[multiple regions including the enhancer]	0.0	5	1	1	1
83156	1710	step in the pathway	[steps in the pathway]	0.0	4	1	1	1
83157	1710	il-2 cytokine jak	[IL-2 cytokines JAKs]	0.0	3	1	1	1
83158	1710	oct-2 mrna	[Oct-2 mRNA]	0.0	2	1	1	1
83159	1710	spontaneous lymphoblastoid cell line	[spontaneous lymphoblastoid cell lines]	0.0	4	1	1	1
83160	1710	HBxAg stimulation of blood mononuclear cell	[HBxAg stimulation of blood mononuclear cells]	0.0	6	1	1	1
83161	1710	balance between repression	[balance between repression]	0.0	3	1	1	1
83162	1710	nucleolin expression construct	[nucleolin expression constructs]	0.0	3	1	1	1
83163	1710	anti-hapten single-chain ab fragment	[anti-hapten single-chain Ab fragment]	0.0	4	1	1	1
83164	1710	treatment with units/ml human recombinant m-csf	[Treatment with units/ml human recombinant M-CSF]	0.0	6	1	1	1
83165	1710	plasma acth	[plasma ACTH]	0.0	2	1	1	1
83166	1710	aberration in the apoptotic pathway	[aberrations in the apoptotic pathway]	0.0	5	1	1	1
83167	1710	sedimenting complex	[sedimenting complex]	0.0	2	1	1	1
83168	1710	notion substrate in cells.	[notion substrates in cells.]	0.0	4	1	1	1
83169	1710	addition of acid pa	[addition of acid PA]	0.0	4	1	1	1
83170	1710	B-lymphocyte development	[B-lymphocyte development]	0.0	2	1	1	1
83171	1710	isolate dest	[isolating DESTs]	0.0	2	1	1	1
83172	1710	five DNase-I site	[Five DNase-I sites]	0.0	3	1	1	1
83173	1710	structure with domain	[structure with domains]	0.0	3	1	1	1
83174	1710	blood polymorphonuclear cell	[blood polymorphonuclear cells]	0.0	3	1	1	1
83175	1710	u1 cell with r-h-tbp-1	[U1 cells with r-h-TBP-1]	0.0	4	1	1	1
83176	1710	controls, p	[controls, p]	0.0	2	1	1	1
83177	1710	alpha gene promoter	[alpha gene promoter]	0.0	3	2	2	1
83178	1710	-mcd14	[-mCD14]	0.0	1	2	2	1
83179	1710	umbilical vein endothelial cell HUVECs	[umbilical vein endothelial cells HUVECs]	0.0	5	2	2	1
83180	1710	regulatory protein distinct	[regulatory proteins distinct]	0.0	3	1	1	1
83181	1710	prototype stress hormone dexamethasone glucocorticoid	[prototype stress hormones dexamethasone glucocorticoid]	0.0	5	1	1	1
83182	1710	2 alpha	[2 alpha]	0.0	2	1	1	1
83183	1710	microm OP for hour	[microM OP for hr,]	0.0	4	1	1	1
83184	1710	paf receptor transcript 1	[PAF receptor transcript 1]	0.0	4	1	1	1
83185	1710	dysfunctional T cell in patient	[dysfunctional T cells in patients]	0.0	5	1	1	1
83186	1710	modulate gata-1 activity through interaction	[modulating GATA-1 activity through interaction]	0.0	5	1	1	1
83187	1710	third tyrosine within the region	[third tyrosine within the region]	0.0	5	1	1	1
83188	1710	ets-like factor present in Jurkat cell	[ETS-like factors present in Jurkat cells]	0.0	6	1	1	1
83189	1710	two other hla-b8-restricted latent epitope	[two other HLA-B8-restricted latent epitopes]	0.0	5	1	1	1
83190	1710	response of blood T cell	[response of blood T cells]	0.0	5	1	1	1
83191	1710	kda sterol element binding factor	[kDa sterol element binding factor]	0.0	5	1	1	1
83192	1710	cDNA microarray technology	[cDNA microarray technology]	0.0	3	1	1	1
83193	1710	mechanism of a new analogue	[mechanism of a new analogue]	0.0	5	1	1	1
83194	1710	EBV nuclear antigen one	[EBV nuclear antigen one]	0.0	4	1	1	1
83195	1710	cd44 transcription	[CD44 transcription]	0.0	2	1	1	1
83196	1710	receptor blocker RU43044	[receptor blocker RU43044]	0.0	3	1	1	1
83197	1710	protein elf-1	[protein Elf-1]	0.0	2	1	1	1
83198	1710	receptor in systemic lupus erythematosus	[receptors in systemic lupus erythematosus]	0.0	5	1	1	1
83199	1710	hour 1 of the membrane-bound enzyme	[hours 1 of the membrane-bound enzyme]	0.0	6	1	1	1
83200	1710	expression from REV ltr	[expression from REV LTRs]	0.0	4	1	1	1
83201	1710	methods, with eight pair	[methods, with eight pairs]	0.0	4	1	1	1
83202	1710	stress response of T lymphocyte	[Stress response of T lymphocytes]	0.0	5	1	1	1
83203	1710	class inducibility	[class inducibility]	0.0	2	1	1	1
83204	1710	exception of exon	[exceptions of exon]	0.0	3	1	1	1
83205	1710	dna-binding than aml1b	[DNA-binding than AML1b]	0.0	3	1	1	1
83206	1710	disorder ataxia telangiectasia	[disorder ataxia telangiectasia]	0.0	3	1	1	1
83207	1710	putative loci	[putative loci]	0.0	2	1	1	1
83208	1710	low affinity fc receptor	[low affinity Fc receptor]	0.0	4	1	1	1
83209	1710	differentiation of center b cell	[differentiation of center B cells]	0.0	5	1	1	1
83210	1710	contain hla dqa1*0501	[containing HLA DQA1*0501]	0.0	3	1	1	1
83211	1710	candidate repressor/activator	[candidate repressor/activator]	0.0	2	1	1	1
83212	1710	humoral, non-specific action	[humoral, non-specific actions]	0.0	3	1	1	1
83213	1710	bipartite acid response element	[bipartite acid response element]	0.0	4	1	1	1
83214	1710	gamma interferon signal	[gamma interferon signal]	0.0	3	1	1	1
83215	1710	lps-free condition	[LPS-free conditions]	0.0	2	1	1	1
83216	1710	target of oxygen intermediate	[target of oxygen intermediates]	0.0	4	1	1	1
83217	1710	tissue-specific region 5'	[tissue-specific region 5']	0.0	3	1	1	1
83218	1710	interferon-gamma receptor expression	[interferon-gamma receptor expression]	0.0	3	1	1	1
83219	1710	include response	[including response]	0.0	2	1	1	1
83220	1710	activity of the GCR	[activity of the GCR]	0.0	4	1	1	1
83221	1710	progression such that Th2 effect	[progression such that Th2 effects]	0.0	5	1	1	1
83222	1710	t/nk-cell lymphoma	[T/NK-cell lymphomas]	0.0	2	1	1	1
83223	1710	binding to TF cognate cofactor	[binding to TF cognate cofactor]	0.0	5	1	1	1
83224	1710	importance of the ratio	[importance of the ratio]	0.0	4	1	1	1
83225	1710	partial disomy	[partial disomy]	0.0	2	1	1	1
83226	1710	additional 6 month month	[additional 6 months months]	0.0	4	1	1	1
83227	1710	phosphatase-positive multinucleated cell	[phosphatase-positive multinucleated cells]	0.0	3	1	1	1
83228	1710	patient with bowel disease	[patients with bowel disease]	0.0	4	1	1	1
83229	1710	eight healthy male volunteer	[Eight healthy male volunteers]	0.0	4	1	1	1
83230	1710	genetic element support the expression	[genetic elements supporting the expression]	0.0	5	1	1	1
83231	1710	activation by cellular stimulus	[Activation by cellular stimuli]	0.0	4	1	1	1
83232	1710	mechanism in thymocyte	[mechanisms in thymocytes]	0.0	3	1	1	1
83233	1710	Study of islet culture	[Studies of islet cultures]	0.0	4	1	1	1
83234	1710	myeloid leukemia gene AML1	[myeloid leukemia gene AML1]	0.0	4	1	1	1
83235	1710	control regions,	[control regions,]	0.0	2	1	1	1
83236	1710	implicate the N-terminal hydrophilic domain	[implicating the N-terminal hydrophilic domain]	0.0	5	1	1	1
83237	1710	secondary tissue development	[secondary tissue development]	0.0	3	1	1	1
83238	1710	number of 135(oh)2d3 receptor	[number of 1,25(OH)2D3 receptors]	0.0	4	1	1	1
83239	1710	-dependent cell adhesion	[-dependent cell adhesion]	0.0	3	1	1	1
83240	1710	beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation of 3,21-diacetoxy-5 beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation of 3,21-diacetoxy-5 beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	6	1	1	1
83241	1710	increase amount of nfatp	[increasing amounts of NFATp]	0.0	4	1	1	1
83242	1710	mean value	[Mean values]	0.0	2	1	1	1
83243	1710	BL cell contain level of nf-kappab	[BL cells containing levels of NF-kappaB]	0.0	6	1	1	1
83244	1710	stimulate T cell blast	[stimulating T cell blasts]	0.0	4	1	1	1
83245	1710	exploration	[exploration]	0.0	1	1	1	1
83246	1710	transactivation by human herpesvirus 6 strain	[Transactivation by human herpesvirus 6 strains]	0.0	6	1	1	1
83247	1710	produce functional hiv tat protein	[producing functional HIV Tat protein]	0.0	5	1	1	1
83248	1710	concentration-dependent inhibition	[concentration-dependent inhibition]	0.0	2	1	1	1
83249	1710	internal functional promoter	[internal functional promoter]	0.0	3	1	1	1
83250	1710	NK-kappa b transcription factor	[NK-kappa B transcription factor]	0.0	4	1	1	1
83251	1710	cytokine for repeat transactivation	[cytokines for repeat transactivation]	0.0	4	1	1	1
83252	1710	expression of receptor GRs	[expression of receptors GRs]	0.0	4	1	1	1
83253	1710	polar substitution 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[polar substitutions 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	6	1	1	1
83254	1710	virus aav	[virus AAV]	0.0	2	1	1	1
83255	1710	activate protein-1 bind tpa responsive element	[Activating protein-1 binding TPA responsive elements]	0.0	6	1	1	1
83256	1710	2 pebp2	[2 PEBP2]	0.0	2	1	1	1
83257	1710	Progressive expression	[Progressive expression]	0.0	2	1	1	1
83258	1710	dimerize	[dimerizing]	0.0	1	1	1	1
83259	1710	expression of adherence-associated early gene	[expression of adherence-associated early genes]	0.0	5	1	1	1
83260	1710	two different negative pathway	[two different negative pathways]	0.0	4	1	1	1
83261	1710	protein-tyrosine kinase pathway	[protein-tyrosine kinase pathway]	0.0	3	1	1	1
83262	1710	primary hpp-cfc colony	[primary HPP-CFC colonies]	0.0	3	1	1	1
83263	1710	rat smooth muscle cell vsmc	[rat smooth muscle cells VSMCs]	0.0	5	1	1	1
83264	1710	immunodeficiency due to defective binding	[immunodeficiency due to defective binding]	0.0	5	1	1	1
83265	1710	PDBu/iono	[PDBu/iono]	0.0	1	1	1	1
83266	1710	interleukin-5 gene	[interleukin-5 gene]	0.0	2	1	1	1
83267	1710	tyrosine kinase from plc-gamma1	[tyrosine kinases from PLC-gamma1]	0.0	4	1	1	1
83268	1710	activation in neuroblastoma cell line	[Activation in neuroblastoma cell lines]	0.0	5	1	1	1
83269	1710	esterase activity	[esterase activity]	0.0	2	1	1	1
83270	1710	Cox multivariate analysis	[Cox multivariate analysis]	0.0	3	1	1	1
83271	1710	increase awareness of avascular necrosis	[increasing awareness of avascular necrosis]	0.0	5	1	1	1
83272	1710	regulatory mechanism for cytokine	[regulatory mechanism for cytokine]	0.0	4	1	1	1
83273	1710	synthetic metalloproteinase inhibitor	[synthetic metalloproteinase inhibitor]	0.0	3	1	1	1
83274	1710	induction of degradation.	[induction of degradation.]	0.0	3	1	1	1
83275	1710	module of promoter	[modules of promoters]	0.0	3	1	1	1
83276	1710	antibody-mediated cross-linking	[antibody-mediated cross-linking]	0.0	2	1	1	1
83277	1710	metal gold	[metal gold]	0.0	2	1	1	1
83278	1710	activity of Tat	[activity of Tat]	0.0	3	1	1	1
83279	1710	content of er	[contents of ER]	0.0	3	1	1	1
83280	1710	localization of NFAT4	[localization of NFAT4]	0.0	3	1	1	1
83281	1710	serine phosphorylation stat5	[serine phosphorylation Stat5]	0.0	3	1	1	1
83282	1710	line differ	[lines differing]	0.0	2	1	1	1
83283	1710	1r25-dihydroxy vitamin D3	[1,25-dihydroxy vitamin D3]	0.0	3	1	1	1
83284	1710	estradiol acting	[estradiol acting]	0.0	2	1	1	1
83285	1710	STATs	[STATs]	0.0	1	1	1	1
83286	1710	Peroxisomal receptor gamma	[Peroxisomal receptor gamma]	0.0	3	1	1	1
83287	1710	globin gene 10-50 kilobasis	[globin genes 10-50 kilobases]	0.0	4	1	1	1
83288	1710	activation 1 gene transcription during induction	[Activation 1 gene transcription during induction]	0.0	6	1	1	1
83289	1710	(il-6) a multipotential cytokine	[(IL-6) an multipotential cytokine]	0.0	4	1	1	1
83290	1710	secretion of factor	[secretion of factor]	0.0	3	1	1	1
83291	1710	cell cycle time	[cell cycle time]	0.0	3	1	1	1
83292	1710	function in the fine tuning	[function in the fine tuning]	0.0	5	1	1	1
83293	1710	2 expression in t-cell leukemia	[2 expression in T-cell leukemia]	0.0	5	1	1	1
83294	1710	anti-HLA-DR antibody mab	[anti-HLA-DR antibody mAb]	0.0	3	1	1	1
83295	1710	overexpression of SCL protein	[Overexpression of SCL protein]	0.0	4	1	1	1
83296	1710	nuclear factor bind specifically	[nuclear factors binding specifically]	0.0	4	1	1	1
83297	1710	two rna	[two RNAs]	0.0	2	1	1	1
83298	1710	specific element	[specific element]	0.0	2	1	1	1
83299	1710	mechanism underlie il-2 transcriptional blockade	[mechanism underlying IL-2 transcriptional blockade]	0.0	5	1	1	1
83300	1710	Ras-like gtpase	[Ras-like GTPase]	0.0	2	1	1	1
83301	1710	transactivation by herpesvirus 6 strain gs	[Transactivation by herpesvirus 6 strains GS]	0.0	6	1	1	1
83302	1710	especially lymphoma with a component	[especially lymphomas with a component]	0.0	5	1	1	1
83303	1710	follow treatment of cell	[Following treatment of cells]	0.0	4	1	1	1
83304	1710	cam-k	[CaM-K]	0.0	1	1	1	1
83305	1710	dual effect on lymphocyte	[dual effects on lymphocytes]	0.0	4	1	1	1
83306	1710	group of naturally-occurg compound	[group of naturally-occurring compounds]	0.0	4	1	1	1
83307	1710	CsA treatment	[CsA treatment]	0.0	2	1	1	1
83308	1710	(control versus estrogen	[(control vs estrogen]	0.0	3	1	1	1
83309	1710	migration alone,	[migration alone,]	0.0	2	1	1	1
83310	1710	human cell from blood	[human cells from blood]	0.0	4	1	1	1
83311	1710	synergize with signal	[synergizing with signals]	0.0	3	1	1	1
83312	1710	epitope in D1	[epitopes in D1]	0.0	3	1	1	1
83313	1710	strong potentiation	[strong potentiation]	0.0	2	1	1	1
83314	1710	agar) of CTLL-2/ tax	[agar) of CTLL-2/ Tax]	0.0	4	1	1	1
83315	1710	oligodeoxynucleotides target gata-1 nf-e2 protein	[oligodeoxynucleotides targeting GATA-1 NF-E2 proteins]	0.0	5	1	1	1
83316	1710	monocytic factor-kappa b	[monocytic factor-kappa B]	0.0	3	1	1	1
83317	1710	use hiv repeat -cat construct	[using HIV repeat -CAT constructs]	0.0	5	1	1	1
83318	1710	Subunit S6 a component	[Subunit S6 an component]	0.0	4	1	1	1
83319	1710	ectoderm	[ectoderm]	0.0	1	1	1	1
83320	1710	CC chemokine	[CC chemokine]	0.0	2	1	1	1
83321	1710	t-cell leukemia virus type ii	[T-cell leukemia virus type II]	0.0	5	1	1	1
83322	1710	cdna-transfected tf-1	[cDNA-transfected TF-1]	0.0	2	1	1	1
83323	1710	fragment of bactericidal/permeability-increasing protein bpi	[fragment of bactericidal/permeability-increasing protein BPI]	0.0	5	1	1	1
83324	1710	specific progeny	[specific progeny]	0.0	2	1	1	1
83325	1710	amino acid in the carboxyl-terminal end	[amino acids in the carboxyl-terminal end]	0.0	6	1	1	1
83326	1710	single serine residue Ser5	[single serine residue Ser5]	0.0	4	1	1	1
83327	1710	basic dbd adjacent	[basic DBD adjacent]	0.0	3	1	1	1
83328	1710	1-(5-chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine	[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine]	0.0	1	1	1	1
83329	1710	dose of radiation therapy	[doses of radiation therapy]	0.0	4	1	1	1
83330	1710	follow total adrenalectomy	[following total adrenalectomy]	0.0	3	1	1	1
83331	1710	distinct normalize effect on pattern	[distinct normalizing effect on patterns]	0.0	5	1	1	1
83332	1710	sequence-specific repressor	[sequence-specific repressor]	0.0	2	2	2	1
83333	1710	er upstream region	[ER upstream region]	0.0	3	1	1	1
83334	1710	role for p75tnf-r production	[role for p75TNF-R production]	0.0	4	1	1	1
83335	1710	U3 region regulatory domain	[U3 region regulatory domain]	0.0	4	1	1	1
83336	1710	case of small cell lymphoma	[cases of small cell lymphomas]	0.0	5	1	1	1
83337	1710	activity of transcriptional protein	[activity of transcriptional proteins]	0.0	4	1	1	1
83338	1710	d-binding	[D-binding]	0.0	1	1	1	1
83339	1710	assay,	[assay,]	0.0	1	2	2	1
83340	1710	response CSF	[response CSF]	0.0	2	1	1	1
83341	1710	adhesion assay	[Adhesion assays]	0.0	2	1	1	1
83342	1710	T lymphocyte with regulatory function	[T lymphocytes with regulatory functions]	0.0	5	1	1	1
83343	1710	overexpression of protein- tyrosine phosphatase heptp	[Overexpression of protein- tyrosine phosphatase HePTP]	0.0	6	1	1	1
83344	1710	mitogenic stimulation of blood mononuclear cell	[mitogenic stimulation of blood mononuclear cells]	0.0	6	1	1	1
83345	1710	0.05, increase	[0.05, increase]	0.0	2	1	1	1
83346	1710	Importantly, nucleoprotein extract	[Importantly, nucleoprotein extracts]	0.0	3	1	1	1
83347	1710	response to phorbol 13-acetate PMA	[response to phorbol 13-acetate PMA]	0.0	5	1	1	1
83348	1710	immunodeficiency virus type tat protein	[immunodeficiency virus type Tat protein]	0.0	5	1	1	1
83349	1710	stimulation by VitD3	[stimulation by VitD3]	0.0	3	1	1	1
83350	1710	two motif for Pit-1	[two motifs for Pit-1]	0.0	4	1	1	1
83351	1710	sequence from the c-terminus	[sequences from the C-terminus]	0.0	4	1	1	1
83352	1710	activity of Syk	[activity of Syk]	0.0	3	1	1	1
83353	1710	monocytic phenotype than the myeloblast	[monocytic phenotype than the myeloblasts]	0.0	5	1	1	1
83354	1710	b29 promoter	[B29 promoter]	0.0	2	1	1	1
83355	1710	normal menstrual	[normal menstrual]	0.0	2	1	1	1
83356	1710	highly specific protein myeloperoxidase	[highly specific proteins myeloperoxidase]	0.0	4	1	1	1
83357	1710	individual of major (mhc) haplotype	[individuals of major (MHC) haplotypes]	0.0	5	1	1	1
83358	1710	idiopathic inflammatory bowel disease	[idiopathic inflammatory bowel diseases]	0.0	4	1	1	1
83359	1710	effector of lmp-1	[effector of LMP-1]	0.0	3	1	1	1
83360	1710	increase in promoter strength	[increase in promoter strength]	0.0	4	1	1	1
83361	1710	clinical progression from infection	[clinical progression from infection]	0.0	4	1	1	1
83362	1710	molecular mechanism a novel type	[Molecular mechanisms a novel type]	0.0	5	1	1	1
83363	1710	class transcriptional mutant cell line	[class transcriptional mutant cell lines]	0.0	5	1	1	1
83364	1710	span kb of genomic DNA	[spanning kb of genomic DNA]	0.0	5	1	1	1
83365	1710	analysis of GR mrna	[analysis of GR mRNA]	0.0	4	1	1	1
83366	1710	-independent transactivation by Tat	[-independent transactivation by Tat]	0.0	4	1	1	1
83367	1710	mineralocorticoid (mr)	[mineralocorticoid (MR)]	0.0	2	1	1	1
83368	1710	initiation of actin assembly	[initiation of actin assembly]	0.0	4	1	1	1
83369	1710	activity of NF-kappa B/Rel complex	[activity of NF-kappa B/Rel complexes]	0.0	5	1	1	1
83370	1710	human control region	[human control region]	0.0	3	1	1	1
83371	1710	distribution between cytosol	[distribution between cytosol]	0.0	3	1	1	1
83372	1710	suggest a requirement	[suggesting a requirement]	0.0	3	1	1	1
83373	1710	line u937 in human fibroblast	[lines U937 in human fibroblasts]	0.0	5	1	1	1
83374	1710	icr-27	[ICR-27]	0.0	1	1	1	1
83375	1710	early differentiation stage	[early differentiation stages]	0.0	3	1	1	1
83376	1710	72-hr period	[72-hr period]	0.0	2	1	1	1
83377	1710	undetectable follow consolidation	[undetectable following consolidation]	0.0	3	1	1	1
83378	1710	pharmacological control	[Pharmacological control]	0.0	2	1	1	1
83379	1710	lesion in aspect	[lesions in aspects]	0.0	3	1	1	1
83380	1710	peripheral blood from healthy donor	[peripheral blood from healthy donors]	0.0	5	1	1	1
83381	1710	blood of type	[blood of types]	0.0	3	1	1	1
83382	1710	histocompatibility complex class gene	[histocompatibility complex class genes]	0.0	4	1	1	1
83383	1710	include sensitivity	[including sensitivity]	0.0	2	1	1	1
83384	1710	mechanism underlie the nuclear translocation	[mechanisms underlying the nuclear translocation]	0.0	5	1	1	1
83385	1710	somatic cell fusion	[somatic cell fusion]	0.0	3	1	1	1
83386	1710	two cis-acting elements,	[two cis-acting elements,]	0.0	3	1	1	1
83387	1710	mineralocorticoid receptor mr count	[mineralocorticoid receptor MR count]	0.0	4	1	1	1
83388	1710	grf40	[Grf40]	0.0	1	1	1	1
83389	1710	inhibition involvement	[Inhibition involvement]	0.0	2	1	1	1
83390	1710	expression of mnda in bone marrow	[expression of MNDA in bone marrow]	0.0	6	1	1	1
83391	1710	immunodeficiency virus type 1 factor Nef	[immunodeficiency virus type 1 factor Nef]	0.0	6	1	1	1
83392	1710	removal of additional residue	[removal of additional residues]	0.0	4	1	1	1
83393	1710	14 family member	[14 family members]	0.0	3	1	1	1
83394	1710	form heterodimer with the mutant	[forming heterodimers with the mutant]	0.0	5	1	1	1
83395	1710	transcriptional up-regulation of il-2	[transcriptional up-regulation of IL-2]	0.0	4	1	1	1
83396	1710	actions, raise the possibility	[actions, raising the possibility]	0.0	4	1	1	1
83397	1710	set of epitope	[set of epitopes]	0.0	3	1	1	1
83398	1710	various chain	[various chains]	0.0	2	1	1	1
83399	1710	proenkephalin transcription by JunD	[proenkephalin transcription by JunD]	0.0	4	1	1	1
83400	1710	effect of atra	[effects of ATRA]	0.0	3	1	1	1
83401	1710	500-bp fragment	[500-bp fragment]	0.0	2	1	1	1
83402	1710	suggest effective in the phase	[suggesting effective in the phase]	0.0	5	1	1	1
83403	1710	divergence of factor kappab	[divergence of factor kappaB]	0.0	4	1	1	1
83404	1710	certain immune response through effect	[certain immune responses through effects]	0.0	5	1	1	1
83405	1710	six ebv-encoded antigen EBNA	[six EBV-encoded antigens EBNA]	0.0	4	1	1	1
83406	1710	treatment of the mature b-cell line	[Treatment of the mature B-cell line]	0.0	6	1	1	1
83407	1710	distinct form of transcription factor	[distinct forms of transcription factor]	0.0	5	1	1	1
83408	1710	rearrangement of amino acid	[rearrangements of amino acids]	0.0	4	1	1	1
83409	1710	Effect of alpha, 25-dihydroxyvitamin D3	[Effects of alpha, 25-dihydroxyvitamin D3]	0.0	5	1	1	1
83410	1710	negative element NREs	[negative elements NREs]	0.0	3	1	1	1
83411	1710	il-16 expression	[IL-16 expression]	0.0	2	1	1	1
83412	1710	diverse receptor of differentiation	[diverse receptors of differentiation]	0.0	4	1	1	1
83413	1710	translation of the DNA	[translation of the DNA]	0.0	4	1	1	1
83414	1710	implication for the design of therapy	[implications for the design of therapy]	0.0	6	1	1	1
83415	1710	regulate apoptosis	[regulating apoptosis]	0.0	2	1	1	1
83416	1710	cd4+ lymphocyte supt	[CD4+ lymphocytes SupT]	0.0	3	1	1	1
83417	1710	cell b cell	[cells B cells]	0.0	3	1	1	1
83418	1710	emphasize the potential	[emphasizing the potential]	0.0	3	1	1	1
83419	1710	blood of atopic patient	[blood of atopic patients]	0.0	4	1	1	1
83420	1710	receptor mr in leucocyte	[receptor MR in leucocytes]	0.0	4	1	1	1
83421	1710	four methods,	[four methods,]	0.0	2	1	1	1
83422	1710	effect of leukemia factor LIF	[effects of leukemia factor LIF]	0.0	5	1	1	1
83423	1710	N-terminal trans-activation domain tad-a	[N-terminal trans-activation domain TAD-A]	0.0	4	1	1	1
83424	1710	fas ligand element FLRE	[Fas ligand element FLRE]	0.0	4	1	1	1
83425	1710	100-fold increase	[100-fold increase]	0.0	2	1	1	1
83426	1710	three different isoform	[Three different isoforms]	0.0	3	1	1	1
83427	1710	complex function in	[complex functions in]	0.0	3	1	1	1
83428	1710	stimulation with anti-CD3 tumor necrosis factor	[Stimulation with anti-CD3 tumor necrosis factor]	0.0	6	1	1	1
83429	1710	hyperparathyroidism to renal failure	[hyperparathyroidism to renal failure]	0.0	4	1	1	1
83430	1710	underlie selective expression of cytokine	[underlying selective expression of cytokines]	0.0	5	1	1	1
83431	1710	regulation of stat activity	[regulation of STAT activity]	0.0	4	1	1	1
83432	1710	lineage- stage- specific expression	[Lineage- stage- specific expression]	0.0	4	1	1	1
83433	1710	multipotent hpc growth	[multipotent HPC growth]	0.0	3	1	1	1
83434	1710	Tax1 a activator htlv-1 transcription	[Tax1 a activator HTLV-1 transcription]	0.0	5	1	1	1
83435	1710	use a E6 motif	[using a E6 motif]	0.0	4	1	1	1
83436	1710	the/thf (0.24; alpha thf/thf (0.35;	[THE/THF (0.24; alpha THF/THF (0.35;]	0.0	5	1	1	1
83437	1710	expression of gata-1	[expression of GATA-1]	0.0	3	1	1	1
83438	1710	certain immune response	[certain immune responses]	0.0	3	1	1	1
83439	1710	such as shock	[such as shock]	0.0	3	1	1	1
83440	1710	I kappa b beta pool	[I kappa B beta pools]	0.0	5	1	1	1
83441	1710	expression of gata-3	[expression of GATA-3]	0.0	3	1	1	1
83442	1710	limited portion of the domain	[limited portion of the domain]	0.0	5	1	1	1
83443	1710	catalyze the rate-limiting step	[catalyzing the rate-limiting step]	0.0	4	1	1	1
83444	1710	protein appearance	[protein appearance]	0.0	2	1	1	1
83445	1710	lead despite level of plasma aldosterone	[leading despite levels of plasma aldosterone]	0.0	6	1	1	1
83446	1710	hamster ovary fibroblast cho-cd14 cell	[hamster ovary fibroblasts CHO-CD14 cells]	0.0	5	1	1	1
83447	1710	NFAT -276	[NFAT -276]	0.0	2	1	1	1
83448	1710	important consequence for the function	[important consequences for the function]	0.0	5	1	1	1
83449	1710	suggest a repressive effect	[suggesting a repressive effect]	0.0	4	1	1	1
83450	1710	bulbar conjunctiva of patient	[bulbar conjunctiva of patients]	0.0	4	1	1	1
83451	1710	lac operator	[lac operator]	0.0	2	1	1	1
83452	1710	limited number of protein	[limited number of proteins]	0.0	4	1	1	1
83453	1710	receptor by T lymphocyte	[receptors by T lymphocytes]	0.0	4	1	1	1
83454	1710	hemoglobin production in adulthood	[hemoglobin production in adulthood]	0.0	4	1	1	1
83455	1710	key gene	[key genes]	0.0	2	1	1	1
83456	1710	replicative capacity NF-kappaB	[replicative capacity NF-kappaB]	0.0	3	1	1	1
83457	1710	involvement in mediate growth inhibition	[involvement in mediating growth inhibition]	0.0	5	1	1	1
83458	1710	angioimmunoblastic t-cell lymphoma with germinal center	[angioimmunoblastic T-cell lymphoma with germinal centers]	0.0	6	1	1	1
83459	1710	study of activation	[study of activation]	0.0	3	1	1	1
83460	1710	killer T/NK population in the bm	[killer T/NK populations in the BM]	0.0	6	1	1	1
83461	1710	recognition in hla-dq -specific response	[recognition in HLA-DQ -specific response]	0.0	5	1	1	1
83462	1710	other homology between this gene	[other homologies between these genes]	0.0	5	1	1	1
83463	1710	cross-linking of CD28	[cross-linking of CD28]	0.0	3	1	1	1
83464	1710	subtotal thyroidectomy	[subtotal thyroidectomy]	0.0	2	1	1	1
83465	1710	pre-incubation of nuclear extract	[pre-incubation of nuclear extracts]	0.0	4	1	1	1
83466	1710	c-fo protooncogene	[c-fos protooncogene]	0.0	2	1	1	1
83467	1710	hela-tat	[HeLa-tat]	0.0	1	1	1	1
83468	1710	c-myc mrna expression with Sjogren' syndromee	[c-myc mRNA expression with Sjogren's syndrome.]	0.0	6	1	1	1
83469	1710	interleukin-2 il-2 state	[interleukin-2 IL-2 state]	0.0	3	1	1	1
83470	1710	evidence for regulation of the machinery	[evidence for regulation of the machinery]	0.0	6	1	1	1
83471	1710	second inducible complex	[second inducible complex]	0.0	3	1	1	1
83472	1710	hcd57 cell	[HCD57 cells]	0.0	2	1	1	1
83473	1710	cd4-bearing T cell	[CD4-bearing T cells]	0.0	3	1	1	1
83474	1710	exposure dyn/cm2) for h.	[exposure dyn/cm2) for h,]	0.0	4	1	1	1
83475	1710	OM-10.1 model hiv-1 expression	[OM-10.1 model HIV-1 expression]	0.0	4	1	1	1
83476	1710	potential implication	[potential implications]	0.0	2	1	1	1
83477	1710	involvement in nfat activation	[Involvement in NFAT activation]	0.0	4	1	1	1
83478	1710	contain cepharanthine	[containing cepharanthine]	0.0	2	1	1	1
83479	1710	5'-truncation	[5'-truncations]	0.0	1	1	1	1
83480	1710	activity in U-373 MG cell	[activities in U-373 MG cells]	0.0	5	1	1	1
83481	1710	integrate the signal	[integrating the signal]	0.0	3	1	1	1
83482	1710	introduction of the plasmid	[Introduction of the plasmids]	0.0	4	1	1	1
83483	1710	direct vascular antiatherogenic mechanism	[direct vascular antiatherogenic mechanism]	0.0	4	1	1	1
83484	1710	determination in tissue sample	[determination in tissue samples]	0.0	4	1	1	1
83485	1710	tumor necrosis factor activation	[tumor necrosis factor activation]	0.0	4	1	1	1
83486	1710	m-csf gene in myelodysplastic syndrome	[M-CSF genes in myelodysplastic syndromes]	0.0	5	1	1	1
83487	1710	induction of cytolytic susceptibility	[induction of cytolytic susceptibility]	0.0	4	1	1	1
83488	1710	level 2	[levels 2]	0.0	2	1	1	1
83489	1710	mutation t-c) in the area	[mutation T-C) in the area]	0.0	5	1	1	1
83490	1710	concentration of reactive metabolite of oxygen	[concentrations of reactive metabolites of oxygen]	0.0	6	1	1	1
83491	1710	potential role signal pathway	[potential role signaling pathways]	0.0	4	1	1	1
83492	1710	role of physical interaction between elf-1	[role of physical interactions between Elf-1]	0.0	6	1	1	1
83493	1710	IL-4 receptor alpha-chain domain	[IL-4 receptor alpha-chain domain]	0.0	4	1	1	1
83494	1710	Glucocorticoid receptor concentration in leukocyte MNL	[Glucocorticoid receptor concentrations in leukocytes MNL]	0.0	6	1	1	1
83495	1710	complex in human eosinophil	[complexes in human eosinophils]	0.0	4	1	1	1
83496	1710	peak after 60 minute exposure	[peaking after 60 minutes exposure]	0.0	5	1	1	1
83497	1710	express very high level	[expressing very high levels]	0.0	4	1	1	1
83498	1710	nf-kappab suppression	[NF-kappaB suppression]	0.0	2	2	2	1
83499	1710	NF kappa	[NF kappa]	0.0	2	1	1	1
83500	1710	level in whole brain	[levels in whole brain]	0.0	4	1	1	1
83501	1710	minute post- pha stimulation,	[min post- PHA stimulation,]	0.0	4	1	1	1
83502	1710	binding two antibody	[binding two antibodies]	0.0	3	1	1	1
83503	1710	Epstein-Barr early region (EBER)	[Epstein-Barr early region (EBER)]	0.0	4	1	1	1
83504	1710	acid motif	[acid motif]	0.0	2	1	1	1
83505	1710	human cell in culture	[human cells in cultures]	0.0	4	1	1	1
83506	1710	IL-4 receptor engagement	[IL-4 receptor engagement]	0.0	3	1	1	1
83507	1710	study in extrarenal, cell	[studies in extrarenal, cells]	0.0	4	1	1	1
83508	1710	i.e. polymorphonuclear neutrophilic granulocyte	[i.e. polymorphonuclear neutrophilic granulocytes]	0.0	4	1	1	1
83509	1710	binding from lysate	[binding from lysates]	0.0	3	1	1	1
83510	1710	0.5 h of treatment	[0.5 h of treatment]	0.0	4	1	1	1
83511	1710	arm of the molecule.	[arm of the molecule.]	0.0	4	1	1	1
83512	1710	classification as a polymorphism	[Classification as a polymorphism]	0.0	4	1	1	1
83513	1710	monospecific antibody	[monospecific antibodies]	0.0	2	1	1	1
83514	1710	critical cytokine for repeat transactivation	[critical cytokines for repeat transactivation]	0.0	5	1	1	1
83515	1710	tal1 mrna	[TAL1 mRNA]	0.0	2	1	1	1
83516	1710	covalent modification of sulfhydryl group	[covalent modification of sulfhydryl groups]	0.0	5	1	1	1
83517	1710	49 aged subject	[49 aged subjects]	0.0	3	1	1	1
83518	1710	association of STAT3	[association of STAT3]	0.0	3	1	1	1
83519	1710	activator in nonlymphoid cell line	[activator in nonlymphoid cell lines]	0.0	5	1	1	1
83520	1710	constitutive expression from normal individual	[Constitutive expression from normal individuals]	0.0	5	1	1	1
83521	1710	rise to a last proliferation	[rise to a lasting proliferation]	0.0	5	1	1	1
83522	1710	new model of differentiation.	[new model of differentiation.]	0.0	4	1	1	1
83523	1710	use pkc inhibitors, pentoxifylline PTX	[using PKC inhibitors, pentoxifylline PTX]	0.0	5	1	1	1
83524	1710	cell-types.	[cell-types.]	0.0	1	1	1	1
83525	1710	respiratory burst upon acid stimulation	[respiratory burst upon acid stimulation]	0.0	5	1	1	1
83526	1710	camp-responsive element binding protein	[cAMP-responsive element binding protein]	0.0	4	1	1	1
83527	1710	change by tcdd	[changes by TCDD]	0.0	3	1	1	1
83528	1710	level of c-rel protein	[levels of c-Rel proteins]	0.0	4	1	1	1
83529	1710	hiv long terminal repeat activity	[HIV long terminal repeat activity]	0.0	5	1	1	1
83530	1710	(1) nucleotide substitution	[(1) nucleotide substitutions]	0.0	3	1	1	1
83531	1710	level of lucigenin-enhanced cl	[levels of lucigenin-enhanced CL]	0.0	4	1	1	1
83532	1710	transactivation by herpesvirus strain	[Transactivation by herpesvirus strains]	0.0	4	1	1	1
83533	1710	buthionine sulfoximine (an inhibitor	[buthionine sulfoximine (an inhibitor]	0.0	4	1	1	1
83534	1710	(i) patient with CLL rarely er	[(i) patients with CLL rarely ER]	0.0	6	1	1	1
83535	1710	interleukin-1beta in non-monocytic cells,	[interleukin-1beta in non-monocytic cells,]	0.0	4	1	1	1
83536	1710	study, analysis	[study, analysis]	0.0	2	1	1	1
83537	1710	use in tr2 orphan receptor	[using in TR2 orphan receptor]	0.0	5	1	1	1
83538	1710	lymphocyte g0/g1 switch gene homologous	[lymphocyte G0/G1 switch gene homologous]	0.0	5	1	1	1
83539	1710	disproportionate severity	[disproportionate severity]	0.0	2	1	1	1
83540	1710	Comparison as inducer of differentiation	[Comparison as inducers of differentiation]	0.0	5	1	1	1
83541	1710	succinimide derivative	[succinimide derivative]	0.0	2	1	1	1
83542	1710	suppression by supernatant fluid	[Suppression by supernatant fluid]	0.0	4	1	1	1
83543	1710	(hour 48) of the total, enzyme	[(hour 48) of the total, enzyme]	0.0	6	1	1	1
83544	1710	extract from monocyte	[extracts from monocytes]	0.0	3	2	2	1
83545	1710	transformation of other cell type	[transformation of other cell types]	0.0	5	1	1	1
83546	1710	17 case of bl	[17 cases of BL]	0.0	4	1	1	1
83547	1710	addition of nac to MLR	[addition of NAC to MLR]	0.0	5	1	1	1
83548	1710	map kinase phosphatase-1	[map kinase phosphatase-1]	0.0	3	1	1	1
83549	1710	PMA exposure	[PMA exposure]	0.0	2	1	1	1
83550	1710	NPC cell line	[NPC cell line]	0.0	3	1	1	1
83551	1710	il-2- transcription	[IL-2- transcription]	0.0	2	1	1	1
83552	1710	inhibitor in phytohemagglutinin-stimulated blood lymphocyte culture	[inhibitors in phytohemagglutinin-stimulated blood lymphocyte cultures]	0.0	6	1	1	1
83553	1710	factor necessary for expression	[factor necessary for expression]	0.0	4	1	1	1
83554	1710	activation signals,	[activation signals,]	0.0	2	1	1	1
83555	1710	content of t-	[content of T-]	0.0	3	1	1	1
83556	1710	j(2)	[J(2)]	0.0	1	1	1	1
83557	1710	model ags	[model Ags]	0.0	2	1	1	1
83558	1710	activation a mechanism of a component	[activation A mechanism of a component]	0.0	6	1	1	1
83559	1710	major (mhc) class molecule	[major (MHC) class molecules]	0.0	4	1	1	1
83560	1710	p50 component	[p50 component]	0.0	2	1	1	1
83561	1710	hyperplastic germinal center	[hyperplastic germinal centers]	0.0	3	1	1	1
83562	1710	tyrosine phosphorylation of crucial molecule	[tyrosine phosphorylation of crucial molecules]	0.0	5	1	1	1
83563	1710	major positive region	[major positive region]	0.0	3	1	1	1
83564	1710	b cell in organ	[B cells in organs]	0.0	4	1	1	1
83565	1710	incorporate antigen	[incorporating antigens]	0.0	2	1	1	1
83566	1710	treatment with 10 microm sodium orthovanadate	[Treatment with 10 microM sodium orthovanadate]	0.0	6	1	1	1
83567	1710	wide range of pathology	[wide range of pathologies]	0.0	4	1	1	1
83568	1710	nf(kappa)b Oct-1	[NF(kappa)B Oct-1]	0.0	2	1	1	1
83569	1710	1 ng/ml.	[1 ng/ml.]	0.0	2	1	1	1
83570	1710	PP1 -sensitive tyrosine	[PP1 -sensitive tyrosine]	0.0	3	1	1	1
83571	1710	express certain (tcr) region beta-chain family	[expressing certain (TCR) region beta-chain families]	0.0	6	1	1	1
83572	1710	JPX9 cell	[JPX9 cells]	0.0	2	1	1	1
83573	1710	cell-specific steroid-regulated gene	[cell-specific steroid-regulated genes]	0.0	3	1	1	1
83574	1710	signal transducer of transcription-1alpha	[signal transducer of transcription-1alpha]	0.0	4	1	1	1
83575	1710	contain little 50 ng of rna.	[containing little 50 ng of RNA.]	0.0	6	1	1	1
83576	1710	activation of the interleukin-2	[activation of the interleukin-2]	0.0	4	1	1	1
83577	1710	depend on localization	[depending on localization]	0.0	3	1	1	1
83578	1710	ifn-gamma responsiveness	[IFN-gamma responsiveness]	0.0	2	1	1	1
83579	1710	stimulation of neutrophil with factor	[Stimulation of neutrophils with factor]	0.0	5	1	1	1
83580	1710	X1-specific factor	[X1-specific factors]	0.0	2	1	1	1
83581	1710	human cd4+ T cell line	[human CD4+ T cell lines]	0.0	5	1	1	1
83582	1710	nuclear RA receptor rar	[nuclear RA receptors RARs]	0.0	4	1	1	1
83583	1710	transcription activator of viral gene	[transcription activator of viral genes]	0.0	5	1	1	1
83584	1710	silencer extend	[silencer extending]	0.0	2	1	1	1
83585	1710	glucocorticoid treatment for weeks.	[glucocorticoid treatment for weeks.]	0.0	4	1	1	1
83586	1710	element support the expression	[elements supporting the expression]	0.0	4	1	1	1
83587	1710	milligram of hydrocortisone	[milligram of hydrocortisone]	0.0	3	1	1	1
83588	1710	STAT1 nuclear import in T lymphocyte	[STAT1 nuclear import in T lymphocytes]	0.0	6	1	1	1
83589	1710	pmol/l;	[pmol/l;]	0.0	1	1	1	1
83590	1710	level induction	[level induction]	0.0	2	1	1	1
83591	1710	two nuclear nf-at complex	[two nuclear NF-AT complexes]	0.0	4	1	1	1
83592	1710	Specific rrna	[Specific mRNAs]	0.0	2	1	1	1
83593	1710	prenatal immune	[Prenatal immune]	0.0	2	1	1	1
83594	1710	two potential open reading frame orf	[two potential open reading frames ORFs]	0.0	6	1	1	1
83595	1710	kappa b alpha in monocyte	[kappa B alpha in monocytes]	0.0	5	1	1	1
83596	1710	cell types, include monocyte/macrophages	[cell types, including monocyte/macrophages]	0.0	4	1	1	1
83597	1710	factor-kappa b activity in T cell	[factor-kappa B activity in T cells]	0.0	6	1	1	1
83598	1710	T cell with mAb	[T cells with mAb]	0.0	4	1	1	1
83599	1710	hormone receptor coactivator activity	[hormone receptor coactivator activity]	0.0	4	1	1	1
83600	1710	however, simultaneous incubation of RU	[However, simultaneous incubation of RU]	0.0	5	1	1	1
83601	1710	simulate adrenal insufficiency	[simulating adrenal insufficiency]	0.0	3	1	1	1
83602	1710	two rna probe	[two RNA probes]	0.0	3	1	1	1
83603	1710	different ape	[different apes]	0.0	2	1	1	1
83604	1710	radical-generating system	[radical-generating systems]	0.0	2	1	1	1
83605	1710	contain tr alpha	[containing TR alpha]	0.0	3	1	1	1
83606	1710	regulator of this coupling.	[regulator of this coupling.]	0.0	4	1	1	1
83607	1710	vivo migration	[vivo migration]	0.0	2	1	1	1
83608	1710	competitor in intact cell	[competitor in intact cells]	0.0	4	1	1	1
83609	1710	patient with gc asthma	[Patients with GC asthma]	0.0	4	1	1	1
83610	1710	immunosuppressive activity of tgf-beta	[immunosuppressive activity of TGF-beta]	0.0	4	1	1	1
83611	1710	nfat-1 factor	[NFAT-1 factor]	0.0	2	1	1	1
83612	1710	subdominant cycle reactivity to epitope undetectable	[subdominant cycle reactivities to epitopes undetectable]	0.0	6	1	1	1
83613	1710	dopamine system	[dopamine system]	0.0	2	1	1	1
83614	1710	41 patient with carcinoma	[41 patients with carcinoma]	0.0	4	1	1	1
83615	1710	characteristic of such phagocyte system	[characteristics of such phagocyte system]	0.0	5	1	1	1
83616	1710	human t-cell acute leukemia t-all	[human T-cell acute leukemia T-ALL]	0.0	5	1	1	1
83617	1710	sh3-sh2-sh3	[SH3-SH2-SH3]	0.0	1	1	1	1
83618	1710	exon span kb	[exons spanning kb]	0.0	3	1	1	1
83619	1710	dor1 agonist	[DOR1 agonist]	0.0	2	1	1	1
83620	1710	binding of YY1 to a element	[Binding of YY1 to a element]	0.0	6	1	1	1
83621	1710	maturing	[maturing]	0.0	1	1	1	1
83622	1710	inactive, complex in cell	[inactive, complex in cells]	0.0	4	1	1	1
83623	1710	coexpression of HMG i/y	[Coexpression of HMG I/Y]	0.0	4	1	1	1
83624	1710	molecule during a phase	[molecule during a phase]	0.0	4	1	1	1
83625	1710	IL-2R enhancer	[IL-2R enhancer]	0.0	2	1	1	1
83626	1710	one type-specific t-cell clone	[one type-specific T-cell clone]	0.0	4	1	1	1
83627	1710	ligand bind	[ligand binding]	0.0	2	1	1	1
83628	1710	yet, for pathogens, the molecule	[Yet, for pathogens, the molecules]	0.0	5	1	1	1
83629	1710	active promoter region	[active promoter region]	0.0	3	1	1	1
83630	1710	transduction of signal lead	[transduction of signals leading]	0.0	4	1	1	1
83631	1710	also with ankyrin protein	[also with ankyrin proteins]	0.0	4	1	1	1
83632	1710	expression of nf-kappab in human monocyte	[expression of NF-kappaB in human monocytes]	0.0	6	1	1	1
83633	1710	receptor/progesterone receptor pr binding	[receptor/progesterone receptor PR binding]	0.0	4	1	1	1
83634	1710	background of cell	[background of cells]	0.0	3	1	1	1
83635	1710	mononuclear leukocyte from abdominal subject	[mononuclear leukocytes from abdominal subjects]	0.0	5	1	1	1
83636	1710	absence of mutation	[absence of mutation]	0.0	3	1	1	1
83637	1710	thus, coupling of ptk	[Thus, coupling of PTKs]	0.0	4	1	1	1
83638	1710	connective tissue diseases,	[connective tissue diseases,]	0.0	3	1	1	1
83639	1710	cellular mechanism contribute to inadequate response	[Cellular mechanisms contributing to inadequate response]	0.0	6	1	1	1
83640	1710	immunodeficiency virus type a regulatory protein	[immunodeficiency virus type an regulatory protein]	0.0	6	1	1	1
83641	1710	clone in disorder	[clone in disorders]	0.0	3	1	1	1
83642	1710	Glucocorticoid receptor on mononuclear	[Glucocorticoid receptors on mononuclear]	0.0	4	1	1	1
83643	1710	selective inhibition of pkc activity	[selective inhibition of PKC activity]	0.0	5	1	1	1
83644	1710	atopic th2 cell	[atopic Th2 cells]	0.0	3	1	1	1
83645	1710	(734 +/- ng/10(6) cells)	[(734 +/- ng/10(6) cells)]	0.0	4	1	1	1
83646	1710	T beta element	[T beta element]	0.0	3	1	1	1
83647	1710	clinically significant class	[clinically significant class]	0.0	3	1	1	1
83648	1710	control subject use technique	[control subjects using techniques]	0.0	4	1	1	1
83649	1710	rag-1 gene	[RAG-1 gene]	0.0	2	1	1	1
83650	1710	1 provirus	[1 provirus]	0.0	2	1	1	1
83651	1710	carboxyl-terminal region of p65	[carboxyl-terminal region of p65]	0.0	4	1	1	1
83652	1710	pthrp by tax	[PTHrP by Tax]	0.0	3	1	1	1
83653	1710	sarco(endo)plasmic reticulum ser ca2+-atpase	[sarco(endo)plasmic reticulum SER Ca2+-ATPase]	0.0	4	1	1	1
83654	1710	late time h)	[later times h)]	0.0	3	1	1	1
83655	1710	135eoh)2d3 receptor rna analysis	[1,25(OH)2D3 receptor RNA analysis]	0.0	4	1	1	1
83656	1710	JY25 b	[JY25 B]	0.0	2	1	1	1
83657	1710	two regulatory region PRRI	[two regulatory regions PRRI]	0.0	4	1	1	1
83658	1710	moreover, Tax1 expression	[Moreover, Tax1 expression]	0.0	3	1	1	1
83659	1710	whole-cell radioassay	[whole-cell radioassay]	0.0	2	1	1	1
83660	1710	important component of a response	[important component of a response]	0.0	5	1	1	1
83661	1710	pattern,	[pattern,]	0.0	1	1	1	1
83662	1710	pattern.	[pattern.]	0.0	1	1	1	1
83663	1710	cell with a mutant	[cells with a mutant]	0.0	4	1	1	1
83664	1710	alphav5 dihydroxyvitamin	[alpha,25 dihydroxyvitamin]	0.0	2	1	1	1
83665	1710	ad group group C Ad5	[Ad groups group C Ad5]	0.0	5	1	1	1
83666	1710	renin pg/ml;	[renin pg/ml;]	0.0	2	1	1	1
83667	1710	fluid from human cell carcinoma	[fluid from human cell carcinomas]	0.0	5	1	1	1
83668	1710	statg in myeloid cell	[StatG in myeloid cells]	0.0	4	1	1	1
83669	1710	50%	[50%]	0.0	1	1	1	1
83670	1710	competition ems	[Competition EMS]	0.0	2	1	1	1
83671	1710	(18- healthy volunteer	[(18- healthy volunteers]	0.0	3	1	1	1
83672	1710	20- oligonucleotide	[20-mer oligonucleotide]	0.0	2	1	1	1
83673	1710	immediate early serum responsive gene	[immediate early serum responsive genes]	0.0	5	1	1	1
83674	1710	yy-1	[YY-1]	0.0	1	1	1	1
83675	1710	fold decrease in expression.	[fold decrease in expression.]	0.0	4	1	1	1
83676	1710	also other dinucleotide trinucleotide repeat	[also other dinucleotide trinucleotide repeats]	0.0	5	1	1	1
83677	1710	role in function	[role in functions]	0.0	3	1	1	1
83678	1710	tcf-1 site	[TCF-1 site]	0.0	2	1	1	1
83679	1710	contain direct repeat of 21 bp	[containing direct repeats of 21 bp]	0.0	6	1	1	1
83680	1710	involution of corticosteroid receptor	[involution of corticosteroid receptors]	0.0	4	1	1	1
83681	1710	woman (11 10 second	[women (11 10 second]	0.0	4	1	1	1
83682	1710	ap-1(iii)	[AP-1(III)]	0.0	1	1	1	1
83683	1710	two set	[Two sets]	0.0	2	4	4	1
83684	1710	maturity	[maturity]	0.0	1	1	1	1
83685	1710	chains, the IL-4-binding IL-4Ralpha chain	[chains, the IL-4-binding IL-4Ralpha chain]	0.0	5	1	1	1
83686	1710	CONCLUSION: cytomegalovirus early gene product expression	[CONCLUSION: Cytomegalovirus early gene products expression]	0.0	6	1	1	1
83687	1710	Tat a activator of gene expression	[Tat a activator of gene expression]	0.0	6	1	1	1
83688	1710	regulation of various gene	[regulation of various genes]	0.0	4	1	1	1
83689	1710	effector th cell	[effector Th cells]	0.0	3	1	1	1
83690	1710	expression in several cell line	[expression in several cell lines]	0.0	5	1	1	1
83691	1710	Hsp60 T cell	[Hsp60 T cells]	0.0	3	1	1	1
83692	1710	element in the kb	[elements in the kb]	0.0	4	1	1	1
83693	1710	transcriptional activation of the receptor	[transcriptional activation of the receptor]	0.0	5	1	1	1
83694	1710	Intratracheal instillation into rat	[Intratracheal instillation into rats]	0.0	4	1	1	1
83695	1710	activity of hlh protein	[activities of HLH proteins]	0.0	4	1	1	1
83696	1710	defense mechanism against pathogen	[defense mechanisms against pathogens]	0.0	4	1	1	1
83697	1710	mucosa-associated lymphoid tissue	[mucosa-associated lymphoid tissue]	0.0	3	1	1	1
83698	1710	apoptosis of progenitor cells,	[apoptosis of progenitor cells,]	0.0	4	1	1	1
83699	1710	pathway of monocyte differentiation	[pathway of monocyte differentiation]	0.0	4	1	1	1
83700	1710	male with x-linked severe immunodeficiency	[Males with X-linked severe immunodeficiency]	0.0	5	1	1	1
83701	1710	surfactant' effect	[surfactant's effects]	0.0	2	1	1	1
83702	1710	interaction in patient with the syndrome	[interactions in patients with the syndrome]	0.0	6	1	1	1
83703	1710	role in ifn-alpha signal	[role in IFN-alpha signaling]	0.0	4	1	1	1
83704	1710	major protein complex	[major protein complex]	0.0	3	1	1	1
83705	1710	result of a transcription/repair deficiency	[result of a transcription/repair deficiency]	0.0	5	1	1	1
83706	1710	role maintain the level	[role maintaining the level]	0.0	4	1	1	1
83707	1710	t-cell malignancy of various stage	[T-cell malignancies of various stages]	0.0	5	1	1	1
83708	1710	more genetic change	[more genetic changes]	0.0	3	1	1	1
83709	1710	fourfold 12-lipoxygenase activity than cell	[fourfold 12-lipoxygenase activity than cells]	0.0	5	1	1	1
83710	1710	response include phytohemagglutinin	[response including phytohemagglutinin]	0.0	3	1	1	1
83711	1710	MHC class ii density	[MHC class II density]	0.0	4	1	1	1
83712	1710	indicate derivation	[indicating derivation]	0.0	2	1	1	1
83713	1710	breast recurrence in patient	[breast recurrence in patients]	0.0	4	1	1	1
83714	1710	human sterol element SRE	[human sterol element SRE]	0.0	4	1	1	1
83715	1710	/cd40	[/CD40]	0.0	1	1	1	1
83716	1710	alteration of the triplet	[alteration of the triplet]	0.0	4	1	1	1
83717	1710	-induced, dendritic cell-T-cell syncytia	[-induced, dendritic cell-T-cell syncytia]	0.0	4	1	1	1
83718	1710	mcr high grade	[MCR high grade]	0.0	3	1	1	1
83719	1710	PB1 nuclear protein complex	[PB1 nuclear protein complex]	0.0	4	1	1	1
83720	1710	LPS binding of nuclear factor-kappaB/Rel	[LPS binding of nuclear factor-kappaB/Rel]	0.0	5	1	1	1
83721	1710	protein, dpii,	[protein, DP-I,]	0.0	2	1	1	1
83722	1710	vivo expression	[vivo expression]	0.0	2	1	1	1
83723	1710	probable point	[probable point]	0.0	2	1	1	1
83724	1710	transcription complex tfiid	[transcription complex TFIID]	0.0	3	1	1	1
83725	1710	sp 1-binding	[Sp 1-binding]	0.0	2	1	1	1
83726	1710	loosely cell	[loosely cells]	0.0	2	1	1	1
83727	1710	inflammatory disorder a challenging problem	[inflammatory disorders a challenging problem]	0.0	5	1	1	1
83728	1710	NF-IL6 binding site	[NF-IL6 binding sites]	0.0	3	1	1	1
83729	1710	(il) 4 production by effector cell	[(IL) 4 production by effector cells]	0.0	6	1	1	1
83730	1710	transcription of a variety of gene	[transcription of a variety of genes]	0.0	6	1	1	1
83731	1710	activation-induced cell death	[activation-induced cell death]	0.0	3	1	1	1
83732	1710	3t3	[3T3]	0.0	1	4	4	1
83733	1710	after crosslinking	[after crosslinking]	0.0	2	1	1	1
83734	1710	ccaat box apparent	[CCAAT box apparent]	0.0	3	1	1	1
83735	1710	predominant transcript	[predominant transcript]	0.0	2	1	1	1
83736	1710	regulator of hiv-1 expression	[regulators of HIV-1 expression]	0.0	4	1	1	1
83737	1710	interleukin-5 synthesis in t-cell clone	[interleukin-5 synthesis in T-cell clones]	0.0	5	1	1	1
83738	1710	source of ROI	[source of ROIs]	0.0	3	1	1	1
83739	1710	addition, transcriptional activity	[addition, transcriptional activity]	0.0	3	1	1	1
83740	1710	important role in inflammatory state	[important role in inflammatory states]	0.0	5	1	1	1
83741	1710	further evidence for the translational suppression	[Further evidence for the translational suppression]	0.0	6	1	1	1
83742	1710	missense mutation	[missense mutation]	0.0	2	1	1	1
83743	1710	several different levels,	[several different levels,]	0.0	3	1	1	1
83744	1710	litaf mrna expression	[LITAF mRNA expression]	0.0	3	1	1	1
83745	1710	CD28 responsive complex	[CD28 responsive complex]	0.0	3	1	1	1
83746	1710	overexpression in red blood cell	[overexpression in red blood cells]	0.0	5	1	1	1
83747	1710	differentiation switch	[differentiation switch]	0.0	2	1	1	1
83748	1710	af-1 and/or af-2	[AF-1 and/or AF-2]	0.0	3	1	1	1
83749	1710	pre-B acute leukemia all	[pre-B acute leukemia ALL]	0.0	4	1	1	1
83750	1710	Long term culture	[Long term culture]	0.0	3	1	1	1
83751	1710	significantly (p less than 0.025) low	[significantly (P less than 0.025) lower]	0.0	6	1	1	1
83752	1710	results--reaction	[RESULTS--Reactions]	0.0	1	1	1	1
83753	1710	hla class antigen anti-HLA-DR antibody	[HLA class antigens anti-HLA-DR antibody]	0.0	5	1	1	1
83754	1710	thus, erythroid development	[Thus, erythroid development]	0.0	3	1	1	1
83755	1710	clearance of leukocyte	[clearance of leukocytes]	0.0	3	1	1	1
83756	1710	high level of nuclear	[high levels of nuclear]	0.0	4	1	1	1
83757	1710	effector of b-lymphocyte activation	[effector of B-lymphocyte activation]	0.0	4	1	1	1
83758	1710	use the human acid receptor alpha	[Using the human acid receptor alpha]	0.0	6	1	1	1
83759	1710	antisense rna probe	[antisense RNA probes]	0.0	3	1	1	1
83760	1710	erythroid cell-specific nuclear factor-DNA complex	[erythroid cell-specific nuclear factor-DNA complexes]	0.0	5	1	1	1
83761	1710	response through two form	[response through two forms]	0.0	4	1	1	1
83762	1710	differentiation to the lineage acid	[differentiation to the lineage acid]	0.0	5	1	1	1
83763	1710	supplementation	[supplementation]	0.0	1	1	1	1
83764	1710	type of myeloid leukemia	[type of myeloid leukemia]	0.0	4	1	1	1
83765	1710	adenovirus region 3	[adenovirus region 3]	0.0	3	1	1	1
83766	1710	cell messenger rna splicing	[cell messenger RNA splicing]	0.0	4	1	1	1
83767	1710	distinct stages:	[distinct stages:]	0.0	2	1	1	1
83768	1710	transcriptional upregulation of a carboxylesterase	[transcriptional upregulation of a carboxylesterase]	0.0	5	1	1	1
83769	1710	proteasome inhibitor n-acetyl-l-leucinyl-l-leucinyl-l-norleucinal	[proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal]	0.0	3	1	1	1
83770	1710	complex array	[complex array]	0.0	2	2	2	1
83771	1710	parallel activation function	[parallel activation functions]	0.0	3	1	1	1
83772	1710	proinflammatory effect of stress	[proinflammatory effects of stress]	0.0	4	1	1	1
83773	1710	arachidonic acid stimulation	[arachidonic acid stimulation]	0.0	3	1	1	1
83774	1710	E-selectin expression in cell	[E-selectin expression in cells]	0.0	4	1	1	1
83775	1710	beta-amyloid peptide	[beta-amyloid peptides]	0.0	2	1	1	1
83776	1710	-contain receptor	[-containing receptor]	0.0	2	1	1	1
83777	1710	loss of function	[loss of function]	0.0	3	1	1	1
83778	1710	activation of zeta globin promoter	[activation of zeta globin promoter]	0.0	5	1	1	1
83779	1710	disease in acute leukemia	[disease in acute leukemia]	0.0	4	1	1	1
83780	1710	enf)-kappa B/Rel activity	[(NF)-kappa B/Rel activity]	0.0	3	1	1	1
83781	1710	western promoter deletion analysis	[Western promoter deletion analyses]	0.0	4	1	1	1
83782	1710	upregulation of a human carboxylesterase	[upregulation of a human carboxylesterase]	0.0	5	1	1	1
83783	1710	imply a positive physiological role	[implying a positive physiological role]	0.0	5	1	1	1
83784	1710	immunohistochemistry with antibody against protein	[immunohistochemistry with antibodies against proteins]	0.0	5	1	1	1
83785	1710	22% probability recur by 5	[22% probability recurring by 5]	0.0	5	1	1	1
83786	1710	analysis take change into account.	[analysis taking changes into account.]	0.0	5	1	1	1
83787	1710	il-1-induced gene transcription	[IL-1-induced gene transcription]	0.0	3	1	1	1
83788	1710	11 aml m4eo	[11 AML M4Eo]	0.0	3	1	1	1
83789	1710	NF-kappaB-dependent	[NF-kappaB-dependent]	0.0	1	1	1	1
83790	1710	effect on a variety	[effects on a variety]	0.0	4	1	1	1
83791	1710	sla-dr expression	[SLA-DR expression]	0.0	2	1	1	1
83792	1710	alpha-methyl, 11 alpha-fluoromethyl	[alpha-methyl, 11 alpha-fluoromethyl]	0.0	3	1	1	1
83793	1710	potential reading frame	[potential reading frames]	0.0	3	1	1	1
83794	1710	monocytic cell line U	[monocytic cell line U]	0.0	4	1	1	1
83795	1710	adenylate cyclase inhibitor sq	[adenylate cyclase inhibitor SQ]	0.0	4	1	1	1
83796	1710	more than half	[More than half]	0.0	3	1	1	1
83797	1710	restrict hiv-1 gene expression	[restricting HIV-1 gene expression]	0.0	4	1	1	1
83798	1710	binding analysis	[binding analysis]	0.0	2	1	1	1
83799	1710	strong activate effect of p65	[strong activating effects of p65]	0.0	5	1	1	1
83800	1710	il-1ra secretion by cortisol	[IL-1ra secretion by cortisol]	0.0	4	1	1	1
83801	1710	N-terminal pou-specific domain POUs	[N-terminal POU-specific domain POUs]	0.0	4	1	1	1
83802	1710	donor'	[donor's]	0.0	1	1	1	1
83803	1710	action of CsA	[action of CsA]	0.0	3	1	1	1
83804	1710	expression of hiv-1 tat protein	[expression of HIV-1 tat protein]	0.0	5	1	1	1
83805	1710	cell line by acid	[cell line by acid]	0.0	4	1	1	1
83806	1710	dnd39 cell by il-4	[DND39 cells by IL-4]	0.0	4	1	1	1
83807	1710	produce virus	[producing virus]	0.0	2	1	1	1
83808	1710	nf-kappab pathway	[NF-kappaB pathway]	0.0	2	2	2	1
83809	1710	)/p50	[)/p50]	0.0	1	1	1	1
83810	1710	E1B mutant virus	[E1B mutant viruses]	0.0	3	1	1	1
83811	1710	many factors, in proinflammatory cytokine	[Many factors, in proinflammatory cytokines]	0.0	5	1	1	1
83812	1710	development of derivative	[development of derivatives]	0.0	3	1	1	1
83813	1710	diameter, corresponding	[diameter, corresponding]	0.0	2	1	1	1
83814	1710	profound switch	[profound switch]	0.0	2	1	1	1
83815	1710	bind RFX species	[binding RFX species]	0.0	3	1	1	1
83816	1710	activate transcription factor responsible	[activating transcription factors responsible]	0.0	4	1	1	1
83817	1710	level such as psoriasis	[levels such as psoriasis]	0.0	4	1	1	1
83818	1710	high molecular weight complex	[high molecular weight complex]	0.0	4	1	1	1
83819	1710	blood lymphocyte of both group	[blood lymphocytes of both groups]	0.0	5	1	1	1
83820	1710	response in adult drosophila	[response in adult Drosophila]	0.0	4	1	1	1
83821	1710	t-cell transfectant	[T-cell transfectants]	0.0	2	1	1	1
83822	1710	leukemic cell whatever stage of differentiation,	[leukemic cells whatever stage of differentiation,]	0.0	6	1	1	1
83823	1710	two hla-b8-restricted latent epitope	[two HLA-B8-restricted latent epitopes]	0.0	4	1	1	1
83824	1710	novel trans-activator	[novel trans-activator]	0.0	2	1	1	1
83825	1710	GATA-1 mrna	[GATA-1 mRNA]	0.0	2	1	1	1
83826	1710	MLA T cell line	[MLA T cell line]	0.0	4	1	1	1
83827	1710	6.04 fmol/10(6) cell	[6.04 fmol/10(6) cells]	0.0	3	1	1	1
83828	1710	Strikingly, blotting	[Strikingly, blotting]	0.0	2	1	1	1
83829	1710	discrete subregion	[discrete subregions]	0.0	2	1	1	1
83830	1710	architecture,	[architecture,]	0.0	1	1	1	1
83831	1710	more essential rise	[more essential rise]	0.0	3	1	1	1
83832	1710	target structure the 72-kilodalton protein	[Target structures the 72-kilodalton protein]	0.0	5	1	1	1
83833	1710	inhibition of il-12r beta	[inhibition of IL-12R beta]	0.0	4	1	1	1
83834	1710	173% increase	[173% increase]	0.0	2	1	1	1
83835	1710	main co-activator	[main co-activator]	0.0	2	1	1	1
83836	1710	arm of chromosome 11	[arm of chromosome 11]	0.0	4	1	1	1
83837	1710	arthritis.	[arthritis.]	0.0	1	1	1	1
83838	1710	uncouple in a slP-76-deficient T	[Uncoupling in an SLP-76-deficient T]	0.0	5	1	1	1
83839	1710	inhibition of dexamethasone binding	[Inhibition of dexamethasone binding]	0.0	4	1	1	1
83840	1710	response to virus type tax	[response to virus type Tax]	0.0	5	1	1	1
83841	1710	CD4+ T cell response	[CD4+ T cell responses]	0.0	4	1	1	1
83842	1710	corticosteroid methyl prednisolone 120	[corticosteroid methyl prednisolone 120]	0.0	4	1	1	1
83843	1710	property of hepatic leukemia factor	[properties of hepatic leukemia factor]	0.0	5	1	1	1
83844	1710	expression of protein in T cell	[Expression of proteins in T cells]	0.0	6	1	1	1
83845	1710	arm of chromosome 20	[arm of chromosome 20]	0.0	4	1	1	1
83846	1710	small lipophilic substance such as formylpeptide	[small lipophilic substances such as formylpeptides]	0.0	6	1	1	1
83847	1710	neutralize tnf-alpha antibody p24 antigen release	[neutralizing TNF-alpha antibodies p24 antigen release]	0.0	6	1	1	1
83848	1710	STAT1 homodimer	[STAT1 homodimers]	0.0	2	1	1	1
83849	1710	Rex trans-activation	[Rex trans-activation]	0.0	2	1	1	1
83850	1710	wild-type mutant form	[wild-type mutant forms]	0.0	3	1	1	1
83851	1710	dose (more than 10(-5) mol/L)	[dose (more than 10(-5) mol/L)]	0.0	5	1	1	1
83852	1710	potential health impact	[potential health impact]	0.0	3	1	1	1
83853	1710	SLP-76 cell specific molecule	[SLP-76 cell specific molecules]	0.0	4	1	1	1
83854	1710	outcome of exposure	[outcome of exposure]	0.0	3	1	1	1
83855	1710	cholecystokinin (cck(b)) receptor	[cholecystokinin (CCK(B)) receptor]	0.0	3	1	1	1
83856	1710	dexamethasone suppressibility	[dexamethasone suppressibility]	0.0	2	2	2	1
83857	1710	complete burst upon acid stimulation	[complete burst upon acid stimulation]	0.0	5	1	1	1
83858	1710	(i) transfection under control of virus	[(i) transfection under control of virus]	0.0	6	1	1	1
83859	1710	proliferation of antigen-activated human T cell	[proliferation of antigen-activated human T cells]	0.0	6	1	1	1
83860	1710	rIL-2	[rIL-2]	0.0	1	1	1	1
83861	1710	case with distinctive eosinophil abnormality	[case with distinctive eosinophil abnormalities]	0.0	5	1	1	1
83862	1710	bsap in a panel	[BSAP in a panel]	0.0	4	1	1	1
83863	1710	recognize this enhancer element	[recognizing this enhancer element]	0.0	4	1	1	1
83864	1710	role of the GASd/EBSd element	[role of the GASd/EBSd element]	0.0	5	1	1	1
83865	1710	cell induction	[cell induction]	0.0	2	1	1	1
83866	1710	cell with a rate epithelia	[cells with a rate epithelia]	0.0	5	1	1	1
83867	1710	paraparesis tsp	[paraparesis TSP]	0.0	2	1	1	1
83868	1710	immunohistological staining for nf-kappabp65	[immunohistological staining for NF-kappaBp65]	0.0	4	1	1	1
83869	1710	influence differential expression	[influencing differential expression]	0.0	3	1	1	1
83870	1710	wnt signal	[Wnt signaling]	0.0	2	1	1	1
83871	1710	transcriptional activation by CIITA	[transcriptional activation by CIITA]	0.0	4	1	1	1
83872	1710	rapid tyrosine phosphorylation of intracellular substrate	[rapid tyrosine phosphorylation of intracellular substrates]	0.0	6	1	1	1
83873	1710	dermal microvessel cell MVEC	[dermal microvessel cells MVEC]	0.0	4	1	1	1
83874	1710	synergistic action a gata site CPRE	[synergistic action a GATA site CPRE]	0.0	6	1	1	1
83875	1710	thus suggest a joint requirement	[thus suggesting a joint requirement]	0.0	5	1	1	1
83876	1710	E2F heterodimer in G0 phase	[E2F heterodimers in G0 phases]	0.0	5	1	1	1
83877	1710	p less than 0.001)	[P less than 0.001)]	0.0	4	1	1	1
83878	1710	terminal differentiation of precursors.	[terminal differentiation of precursors.]	0.0	4	1	1	1
83879	1710	acute monocytic leukemia cell line	[acute monocytic leukemia cell line]	0.0	5	1	1	1
83880	1710	b-reporter	[B-reporter]	0.0	1	1	1	1
83881	1710	class transplantation gene DRA	[class transplantation gene DRA]	0.0	4	1	1	1
83882	1710	upstream region at position	[upstream region at positions]	0.0	4	1	1	1
83883	1710	effect on two regulatory factor	[effects on two regulatory factors]	0.0	5	1	1	1
83884	1710	hiv terminal repeat LTR	[HIV terminal repeat LTR]	0.0	4	2	2	1
83885	1710	anti-e-selectin antibody	[anti-E-selectin antibody]	0.0	2	1	1	1
83886	1710	receptor isoforms,	[receptor isoforms,]	0.0	2	1	1	1
83887	1710	result in T cell	[resulting in T cells]	0.0	4	1	1	1
83888	1710	first residue	[first residues]	0.0	2	1	1	1
83889	1710	use as anti-inflammatory agent	[use as anti-inflammatory agents]	0.0	4	1	1	1
83890	1710	Octamer factor Oct-1 in nf-atp	[Octamer factors Oct-1 in NF-ATp]	0.0	5	1	1	1
83891	1710	complex sedimenting	[complex sedimenting]	0.0	2	1	1	1
83892	1710	delayed-early gene	[delayed-early genes]	0.0	2	1	1	1
83893	1710	site of inflammation by resident	[sites of inflammation by resident]	0.0	5	1	1	1
83894	1710	CEM subclone	[CEM subclones]	0.0	2	2	2	1
83895	1710	express T cell line	[expressing T cell lines]	0.0	4	1	1	1
83896	1710	heparin-binding growth factor-like growth factor	[heparin-binding growth factor-like growth factor]	0.0	5	1	1	1
83897	1710	cholesterol homeostasis	[cholesterol homeostasis]	0.0	2	1	1	1
83898	1710	young (18- female volunteer	[young (18- female volunteers]	0.0	4	1	1	1
83899	1710	progesterone suppression	[Progesterone suppression]	0.0	2	1	1	1
83900	1710	interaction with pkc signal system	[interactions with PKC signaling systems]	0.0	5	1	1	1
83901	1710	arbitrary units, p 0.01, young	[arbitrary units, P 0.01, young]	0.0	5	1	1	1
83902	1710	euthymic,	[euthymic,]	0.0	1	1	1	1
83903	1710	important insight into the mechanism	[important insights into the mechanisms]	0.0	5	1	1	1
83904	1710	observation,	[observation,]	0.0	1	1	1	1
83905	1710	th2 cells,	[Th2 cells,]	0.0	2	1	1	1
83906	1710	potential 47.10 cell	[potential 47.10 cells]	0.0	3	1	1	1
83907	1710	th2 cells.	[Th2 cells.]	0.0	2	1	1	1
83908	1710	two transcriptional factor	[two transcriptional factors]	0.0	3	1	1	1
83909	1710	study of peptide binding	[studies of peptide binding]	0.0	4	1	1	1
83910	1710	slow turnover	[slower turnover]	0.0	2	1	1	1
83911	1710	hiv-1 parasitism	[HIV-1 parasitism]	0.0	2	1	1	1
83912	1710	rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).	[rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).]	0.0	5	1	1	1
83913	1710	progressively enlarge mass	[progressively enlarging mass]	0.0	3	1	1	1
83914	1710	receptor 3'-untranslated region polymorphism	[receptor 3'-untranslated region polymorphisms]	0.0	4	1	1	1
83915	1710	i monoclonal antibody mab	[I monoclonal antibody mAb]	0.0	4	1	1	1
83916	1710	VCAM-1 antibody	[VCAM-1 antibody]	0.0	2	1	1	1
83917	1710	follow a genotype screen of volunteer	[Following an genotype screening of volunteers]	0.0	6	1	1	1
83918	1710	deletion variant	[deletion variants]	0.0	2	1	1	1
83919	1710	many aspect of the program	[many aspects of the program]	0.0	5	1	1	1
83920	1710	other chronic rheumatoid arthritis patient	[other chronic rheumatoid arthritis patients]	0.0	5	1	1	1
83921	1710	moreover, supplement the culture	[Moreover, supplementing the cultures]	0.0	4	1	1	1
83922	1710	t-cell lymphoma AITL	[T-cell lymphoma AITL]	0.0	3	1	1	1
83923	1710	stat protein include stat5a	[STAT proteins including STAT5a]	0.0	4	1	1	1
83924	1710	major protein in extract	[major protein in extracts]	0.0	4	1	1	1
83925	1710	induction of interferon differentiation	[induction of interferon differentiation]	0.0	4	1	1	1
83926	1710	approximately 2 mol/L	[approximately 2 mol/L]	0.0	3	1	1	1
83927	1710	biochemical modification responsible	[biochemical modifications responsible]	0.0	3	1	1	1
83928	1710	phenomenon in woman	[phenomenon in women]	0.0	3	1	1	1
83929	1710	level of hlh-2 expression	[levels of hLH-2 expression]	0.0	4	1	1	1
83930	1710	decrease in il-2 cell	[decrease in IL-2 cells]	0.0	4	1	1	1
83931	1710	monitor disease	[monitoring disease]	0.0	2	1	1	1
83932	1710	pgn phosphorylation	[PGN phosphorylation]	0.0	2	1	1	1
83933	1710	first intron (overall frequency:	[first intron (overall frequency:]	0.0	4	1	1	1
83934	1710	presence factor NF-kappa b	[presence factor NF-kappa B]	0.0	4	1	1	1
83935	1710	binding site on the glucocorticoid receptor	[binding sites on the glucocorticoid receptor]	0.0	6	1	1	1
83936	1710	holo drug	[holo drug]	0.0	2	1	1	1
83937	1710	case of B-cell chronic leukemia CLL	[cases of B-cell chronic leukemia CLL]	0.0	6	1	1	1
83938	1710	lead to NF-kappaB activation	[leading to NF-kappaB activation]	0.0	4	1	1	1
83939	1710	none to only slightly on cell	[none to only slightly on cells]	0.0	6	1	1	1
83940	1710	umbilical vein endothelial cell huvec	[umbilical vein endothelial cells HUVECs]	0.0	5	2	2	1
83941	1710	most proteins,	[most proteins,]	0.0	2	1	1	1
83942	1710	other e1a activities, sensitization	[other E1A activities, sensitization]	0.0	4	1	1	1
83943	1710	nonoverlapping epitope	[nonoverlapping epitopes]	0.0	2	1	1	1
83944	1710	v14rho construct	[V14Rho construct]	0.0	2	1	1	1
83945	1710	several line of mouse display expression	[several lines of mice displaying expression]	0.0	6	1	1	1
83946	1710	difference in the sequence with difference	[differences in the sequence with differences]	0.0	6	1	1	1
83947	1710	encode oct-binding factor obf-1	[encoding Oct-binding factor OBF-1]	0.0	4	1	1	1
83948	1710	expression of il-1alpha cell	[Expression of IL-1alpha cells]	0.0	4	1	1	1
83949	1710	region of the steroid hormone	[region of the steroid hormone]	0.0	5	1	1	1
83950	1710	exposure to sea	[exposure to SEA]	0.0	3	1	1	1
83951	1710	subsequent response	[subsequent responses]	0.0	2	1	1	1
83952	1710	resistant icr27tk.3 human T cell	[resistant ICR27TK.3 human T cells]	0.0	5	1	1	1
83953	1710	mutational removal	[Mutational removal]	0.0	2	1	1	1
83954	1710	necessity follow atra therapy	[necessity following ATRA therapy]	0.0	4	1	1	1
83955	1710	hormone-activated receptor binding to region	[hormone-activated receptor binding to regions]	0.0	5	1	1	1
83956	1710	rate of replication	[rate of replication]	0.0	3	1	1	1
83957	1710	facet to understanding	[facet to understanding]	0.0	3	1	1	1
83958	1710	1 h before il-4 stimulation	[1 h before IL-4 stimulation]	0.0	5	1	1	1
83959	1710	stage homogeneity	[stage homogeneity]	0.0	2	1	1	1
83960	1710	(3 day	[(3 days)]	0.0	2	1	1	1
83961	1710	factor receptor mrna	[factor receptor mRNA]	0.0	3	1	1	1
83962	1710	superoxide formation in the neutrophil	[superoxide formation in the neutrophils]	0.0	5	1	1	1
83963	1710	respect to suppression	[respect to suppression]	0.0	3	1	1	1
83964	1710	t-cell effect of DEX together	[T-cell effects of DEX together]	0.0	5	1	1	1
83965	1710	t-cell expansion	[T-cell expansion]	0.0	2	1	1	1
83966	1710	jak3 binding	[JAK3 binding]	0.0	2	1	1	1
83967	1710	Ca(2+)-dependent event	[Ca(2+)-dependent events]	0.0	2	1	1	1
83968	1710	1.4 nm aldosterone	[1.4 nM aldosterone]	0.0	3	1	1	1
83969	1710	two gr bind abnormalities:	[two GR binding abnormalities:]	0.0	4	1	1	1
83970	1710	effect of mpl	[effect of MPL]	0.0	3	1	1	1
83971	1710	leucine domain LCD motif	[leucine domains LCD motifs]	0.0	4	1	1	1
83972	1710	major histocompatibility (mhc) class ii gene	[major histocompatibility (MHC) class II genes]	0.0	6	1	1	1
83973	1710	translocation of nfat factor	[translocation of NFAT factor]	0.0	4	2	2	1
83974	1710	human immunodeficiency virus-1 enhancer	[human immunodeficiency virus-1 enhancer]	0.0	4	1	1	1
83975	1710	cell property	[cell properties]	0.0	2	1	1	1
83976	1710	15- reduction	[15- reduction]	0.0	2	1	1	1
83977	1710	consider the regulatory effect	[Considering the regulatory effect]	0.0	4	1	1	1
83978	1710	role of in steel factor	[role of in Steel factor]	0.0	5	1	1	1
83979	1710	six man	[six men]	0.0	2	1	1	1
83980	1710	low activation of glucocorticoid binding	[lower activation of glucocorticoid binding]	0.0	5	1	1	1
83981	1710	novel mechanism for mineralocorticoid action	[novel mechanism for mineralocorticoid action]	0.0	5	1	1	1
83982	1710	slp-76 phosphoprotein	[SLP-76 phosphoprotein]	0.0	2	1	1	1
83983	1710	typical inducer	[typical inducer]	0.0	2	1	1	1
83984	1710	antiviral function	[antiviral functions]	0.0	2	1	1	1
83985	1710	interaction of CD2 with natural ligand	[interaction of CD2 with natural ligand]	0.0	6	1	1	1
83986	1710	Hayata	[Hayata]	0.0	1	1	1	1
83987	1710	histocompatibility class transactivator	[histocompatibility class transactivator]	0.0	3	1	1	1
83988	1710	8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
83989	1710	thiol compound	[thiol compounds]	0.0	2	1	1	1
83990	1710	epo cell line ut-7	[EPO cell lines UT-7]	0.0	4	1	1	1
83991	1710	mean hTR beta	[mean hTR beta]	0.0	3	1	1	1
83992	1710	range of stimulation	[range of stimulation]	0.0	3	1	1	1
83993	1710	four distinct nuclear protein complex	[four distinct nuclear protein complexes]	0.0	5	1	1	1
83994	1710	stimulation of interleukin-8 production major protein	[Stimulation of interleukin-8 production major protein]	0.0	6	1	1	1
83995	1710	guamerin-derived peptide gdsp	[guamerin-derived peptide GDSP]	0.0	3	1	1	1
83996	1710	induction of immediate response gene	[Induction of immediate response genes]	0.0	5	1	1	1
83997	1710	i-kappabalpha level	[I-kappaBalpha levels]	0.0	2	1	1	1
83998	1710	box motif	[box motifs]	0.0	2	1	1	1
83999	1710	3' site within the context	[3' site within the context]	0.0	5	1	1	1
84000	1710	interleukin-2 signal in T cell	[interleukin-2 signaling in T cells]	0.0	5	1	1	1
84001	1710	high, establish a relation	[high, establishing an relation]	0.0	4	1	1	1
84002	1710	kda repressor protein glrp	[kDA repressor protein GLRP]	0.0	4	1	1	1
84003	1710	protein during hematopoiesis	[proteins during hematopoiesis]	0.0	3	1	1	1
84004	1710	intron/exon junctions,	[intron/exon junctions,]	0.0	2	1	1	1
84005	1710	accord to results, however,	[According to results, however,]	0.0	4	1	1	1
84006	1710	class iii gene transcription factor	[class III gene transcription factor]	0.0	5	1	1	1
84007	1710	nf-kappa b oligonucleotide	[NF-kappa B oligonucleotide]	0.0	3	1	1	1
84008	1710	potential therapeutic drug	[potential therapeutic drugs]	0.0	3	1	1	1
84009	1710	euthymic	[euthymic]	0.0	1	1	1	1
84010	1710	transcriptase polymerase	[transcriptase polymerase]	0.0	2	1	1	1
84011	1710	only a weak induction	[only a weak induction]	0.0	4	1	1	1
84012	1710	donor splice site	[donor splice site]	0.0	3	1	1	1
84013	1710	enhancement of dna-binding of e2f	[enhancement of DNA-binding of E2F]	0.0	5	1	1	1
84014	1710	mature t-cell proliferation	[mature T-cell proliferations]	0.0	3	1	1	1
84015	1710	increase to 15-fold)	[increase to 15-fold)]	0.0	3	1	1	1
84016	1710	translocation in neonatal T cell	[translocation in neonatal T cells]	0.0	5	1	1	1
84017	1710	primary case of myelogenous leukaemia	[primary cases of myelogenous leukaemia]	0.0	5	1	1	1
84018	1710	case of nasal lymphoma NL	[cases of nasal lymphoma NL]	0.0	5	1	1	1
84019	1710	induction of cytochrome P-4501A1 CYP1A1 activity	[Induction of cytochrome P-4501A1 CYP1A1 activity]	0.0	6	1	1	1
84020	1710	colony-stimumulatelany-stg factor 1 colony-stimulating factor	[colony-stimulating factor 1 colony-stimulating factor]	0.0	5	1	1	1
84021	1710	transfer of tumor-draining ln T cell	[transfer of tumor-draining LN T cells]	0.0	6	1	1	1
84022	1710	kill through target cell sensitization	[killing through target cell sensitization]	0.0	5	1	1	1
84023	1710	value for plasma aldosterone	[values for plasma aldosterone]	0.0	4	1	1	1
84024	1710	implication for the use of RA	[implications for the use of RA]	0.0	6	1	1	1
84025	1710	chemotherapy in a patient with APL	[chemotherapy in a patient with APL]	0.0	6	1	1	1
84026	1710	peripheral blood organ	[peripheral blood organs]	0.0	3	1	1	1
84027	1710	b-cell mitogenesis	[B-cell mitogenesis]	0.0	2	1	1	1
84028	1710	[regulation of intracellular cholesterol synthesis	[[Regulation of intracellular cholesterol synthesis]	0.0	5	1	1	1
84029	1710	action of the receptor	[action of the receptors]	0.0	4	1	1	1
84030	1710	tolerization	[tolerization]	0.0	1	1	1	1
84031	1710	vitro receptor binding study	[vitro receptor binding studies]	0.0	4	1	1	1
84032	1710	25 microm of the counter-anion thioglucose	[25 microM of the counter-anion thioglucose]	0.0	6	1	1	1
84033	1710	difference between the er content	[difference between the ER content]	0.0	5	1	1	1
84034	1710	two abnormality	[two abnormalities]	0.0	2	1	1	1
84035	1710	marker of early apoptotic event	[marker of early apoptotic events]	0.0	5	1	1	1
84036	1710	viral gene ORF	[viral gene ORF]	0.0	3	1	1	1
84037	1710	DNA transfection of receptor gene	[DNA transfections of receptor gene]	0.0	5	1	1	1
84038	1710	peptide a novel elastase inhibitor	[peptide a novel elastase inhibitor]	0.0	5	1	1	1
84039	1710	(stage	[(stage]	0.0	1	1	1	1
84040	1710	glucocorticoid in various disease	[glucocorticoids in various diseases]	0.0	4	1	1	1
84041	1710	other cell type follow expression	[other cell types following expression]	0.0	5	1	1	1
84042	1710	strong component	[strong component]	0.0	2	1	1	1
84043	1710	study of the immunity	[studies of the immunity]	0.0	4	1	1	1
84044	1710	clone with technique	[clone with techniques]	0.0	3	1	1	1
84045	1710	however, cell line with potential	[However, cell lines with potential]	0.0	5	1	1	1
84046	1710	furthermore, NF-kappaB transcriptional factor	[Furthermore, NF-kappaB transcriptional factor]	0.0	4	1	1	1
84047	1710	continuous expression of a protein	[continuous expression of an protein]	0.0	5	1	1	1
84048	1710	tnf factor 2 traf2	[TNF factor 2 TRAF2]	0.0	4	1	1	1
84049	1710	tnf factor 2 traf3	[TNF factor 2 TRAF3]	0.0	4	1	1	1
84050	1710	seventeen patient with syndrome	[seventeen patients with syndromes]	0.0	4	1	1	1
84051	1710	cis element within this region,	[cis elements within this region,]	0.0	5	1	1	1
84052	1710	retroviral transgene	[retroviral transgene]	0.0	2	1	1	1
84053	1710	contain a open reading frame	[containing an open reading frame]	0.0	5	1	1	1
84054	1710	chronological sequence of event	[chronological sequence of events]	0.0	4	1	1	1
84055	1710	hla-b8-restricted latent epitope	[HLA-B8-restricted latent epitopes]	0.0	3	1	1	1
84056	1710	spontaneous occurrence	[Spontaneous occurrence]	0.0	2	1	1	1
84057	1710	several distinct role	[Several distinct roles]	0.0	3	1	1	1
84058	1710	effect attributable	[effects attributable]	0.0	2	1	1	1
84059	1710	rare DNA variation in tumor	[rare DNA variations in tumor]	0.0	5	1	1	1
84060	1710	gene targeting,	[gene targeting,]	0.0	2	1	1	1
84061	1710	NF-kappaB/Rel member c-rel	[NF-kappaB/Rel members c-Rel]	0.0	3	1	1	1
84062	1710	jurkat lymphoblastic T cell	[Jurkat lymphoblastic T cells]	0.0	4	1	1	1
84063	1710	role SCL	[role SCL]	0.0	2	1	1	1
84064	1710	posttranslational activation in response to signal	[posttranslational activation in response to signals]	0.0	6	1	1	1
84065	1710	provide a regulatory point	[providing an regulatory point]	0.0	4	1	1	1
84066	1710	molecular mechanism of adherence to cell	[Molecular mechanisms of adherence to cells]	0.0	6	1	1	1
84067	1710	ets-related transcription factor Elf-1	[Ets-related transcription factor Elf-1]	0.0	4	1	1	1
84068	1710	lytic origin	[lytic origin]	0.0	2	1	1	1
84069	1710	non-cell-type-specific expression	[non-cell-type-specific expression]	0.0	2	1	1	1
84070	1710	hs transcription factor	[HS transcription factor]	0.0	3	1	1	1
84071	1710	serious problem for patient	[serious problem for patients]	0.0	4	1	1	1
84072	1710	target during cell cycle entry	[targets during cell cycle entry]	0.0	5	1	1	1
84073	1710	viscosity of fibrosis sputum	[viscosity of fibrosis sputum]	0.0	4	1	1	1
84074	1710	two family of transcriptional factor	[two families of transcriptional factors]	0.0	5	1	1	1
84075	1710	transcript of the normal type er	[transcripts of the normal type ER]	0.0	6	1	1	1
84076	1710	first trimester pregnancy	[first trimester pregnancies]	0.0	3	1	1	1
84077	1710	role in rante gene expression	[role in RANTES gene expression]	0.0	5	1	1	1
84078	1710	airway hyperresponsiveness on a background	[airway hyperresponsiveness on a background]	0.0	5	1	1	1
84079	1710	pleiotropic immunomodulatory molecule	[pleiotropic immunomodulatory molecule]	0.0	3	1	1	1
84080	1710	value of 1,25-dihydroxyvitamin D3 calcitriol determination	[value of 1,25-dihydroxyvitamin D3 calcitriol determination]	0.0	6	1	1	1
84081	1710	transcription of over-lapping set	[transcription of over-lapping sets]	0.0	4	1	1	1
84082	1710	significant systemic effect on function	[significant systemic effects on function]	0.0	5	1	1	1
84083	1710	epstein-barr virus latency	[Epstein-Barr virus latency]	0.0	3	1	1	1
84084	1710	granulopoiesis postnatally, typically die by 8	[granulopoiesis postnatally, typically dying by 8]	0.0	6	1	1	1
84085	1710	process of somatic hypermutation	[process of somatic hypermutation]	0.0	4	1	1	1
84086	1710	mobility 120 kd)	[mobility 120 kD)]	0.0	3	1	1	1
84087	1710	negative correlation between body temperature	[negative correlation between body temperature]	0.0	5	1	1	1
84088	1710	human blood monocytes.	[human blood monocytes.]	0.0	3	1	1	1
84089	1710	lead to virus reactivation	[leading to virus reactivation]	0.0	4	1	1	1
84090	1710	phagocytosis of apoptotic leukocyte	[phagocytosis of apoptotic leukocytes]	0.0	4	1	1	1
84091	1710	STAT binding sequence SBE	[STAT binding sequences SBE]	0.0	4	1	1	1
84092	1710	carboxyl-terminal portion	[carboxyl-terminal portion]	0.0	2	1	1	1
84093	1710	e.g. interleukin-3 macrophage factor	[e.g. interleukin-3 macrophage factor]	0.0	4	1	1	1
84094	1710	vitro clonal growth	[vitro clonal growth]	0.0	3	1	1	1
84095	1710	expression in human sle	[expression in human SLE]	0.0	4	1	1	1
84096	1710	low nuclear protein	[low nuclear proteins]	0.0	3	1	1	1
84097	1710	addition of the recombinant nf-y	[addition of the recombinant NF-Y]	0.0	5	1	1	1
84098	1710	arm of chromosome lp	[arm of chromosome lp]	0.0	4	1	1	1
84099	1710	lyonization of cell	[lyonization of cells]	0.0	3	1	1	1
84100	1710	cell type-specific complex formation	[cell type-specific complex formation]	0.0	4	1	1	1
84101	1710	p.o.,	[p.o.,]	0.0	1	1	1	1
84102	1710	further hour	[further hr]	0.0	2	1	1	1
84103	1710	oxide a powerful pathway	[oxide a powerful pathway]	0.0	4	1	1	1
84104	1710	involve modification and/or translocation	[involving modification and/or translocation]	0.0	4	1	1	1
84105	1710	pathogenic process similar to the disease	[pathogenic processes similar to the diseases]	0.0	6	1	1	1
84106	1710	relate the two nf-at complex	[relating the two NF-AT complexes]	0.0	5	1	1	1
84107	1710	receive therapy for systemic disease	[receiving therapy for systemic diseases]	0.0	5	1	1	1
84108	1710	survival within macrophage	[survival within macrophages]	0.0	3	1	1	1
84109	1710	10 P.	[10 h.]	0.0	2	1	1	1
84110	1710	cell with ifn-gamma	[cells with IFN-gamma]	0.0	3	1	1	1
84111	1710	papillomavirus-	[papillomavirus-]	0.0	1	1	1	1
84112	1710	participate quantitatively	[participating quantitatively]	0.0	2	1	1	1
84113	1710	Epstein-Barr virus EBV dutpase	[Epstein-Barr virus EBV dUTPase]	0.0	4	1	1	1
84114	1710	anti-hsp antibody	[anti-hsp antibody]	0.0	2	1	1	1
84115	1710	two other T cell line	[Two other T cell lines]	0.0	5	1	1	1
84116	1710	hypermethylation-associated silencing of gene expression	[hypermethylation-associated silencing of gene expression]	0.0	5	1	1	1
84117	1710	apparent dissociation constant of receptor	[apparent dissociation constant of receptor]	0.0	5	4	4	1
84118	1710	mol/L for RA	[mol/L for RA]	0.0	3	1	1	1
84119	1710	variant receptor transcript	[Variant receptor transcripts]	0.0	3	1	1	1
84120	1710	p45 lineage cell p45 mrna	[p45 lineage cells p45 mRNA]	0.0	5	1	1	1
84121	1710	contrast, at dose high	[contrast, at doses high]	0.0	4	1	1	1
84122	1710	tat activation	[Tat activation]	0.0	2	1	1	1
84123	1710	reticulocyte of the chimeric animal	[reticulocytes of the chimeric animals]	0.0	5	1	1	1
84124	1710	New datum	[New data]	0.0	2	1	1	1
84125	1710	caspase cleavage site	[caspase cleavage site]	0.0	3	1	1	1
84126	1710	calcitropic effect	[calcitropic effect]	0.0	2	1	1	1
84127	1710	nf.kappa b protein	[NF.kappa B proteins]	0.0	3	1	1	1
84128	1710	expression normal tissue	[expression normal tissues]	0.0	3	1	1	1
84129	1710	abnormal renal sodium handling	[abnormal renal sodium handling]	0.0	4	1	1	1
84130	1710	contain nf-kappa b	[containing NF-kappa B]	0.0	3	1	1	1
84131	1710	melanoma cell line	[melanoma cell lines]	0.0	3	1	1	1
84132	1710	natural environmental cycle	[natural environmental cycle]	0.0	3	1	1	1
84133	1710	arm x;17 translocation	[arm X;17 translocation]	0.0	3	1	1	1
84134	1710	two subunits, p50	[two subunits, p50]	0.0	3	1	1	1
84135	1710	induction of gene important	[induction of genes important]	0.0	4	1	1	1
84136	1710	selective modulation by transfer	[selective modulation by transfer]	0.0	4	1	1	1
84137	1710	property of steroidal effect	[properties of steroidal effects]	0.0	4	1	1	1
84138	1710	other genes,	[other genes,]	0.0	2	1	1	1
84139	1710	positive lymph node	[positive lymph nodes]	0.0	3	1	1	1
84140	1710	several human b-cell line	[several human B-cell lines]	0.0	4	1	1	1
84141	1710	factor AP-1	[factors AP-1]	0.0	2	1	1	1
84142	1710	various cells, use a antibody	[various cells, using a antibody]	0.0	5	1	1	1
84143	1710	nuclei in the cytoplasm	[nuclei in the cytoplasm]	0.0	4	1	1	1
84144	1710	corresponding to consensus binding site	[corresponding to consensus binding sites]	0.0	5	1	1	1
84145	1710	cell line with metastatic potential	[cell lines with metastatic potential]	0.0	5	1	1	1
84146	1710	functional analysis by Miyatake	[functional analysis by Miyatake]	0.0	4	1	1	1
84147	1710	two nf-kappa b site	[two NF-kappa B sites]	0.0	4	1	1	1
84148	1710	suggest due, in part,	[suggesting due, in part,]	0.0	4	2	2	1
84149	1710	success in the treatment of childhood	[success in the treatment of childhood]	0.0	6	1	1	1
84150	1710	variant translocation of (q27;q32)	[variant translocation of (q27;q32)]	0.0	4	1	1	1
84151	1710	DNA motif homologous	[DNA motifs homologous]	0.0	3	1	1	1
84152	1710	trend approach significance for patient	[trend approaching significance for patients]	0.0	5	1	1	1
84153	1710	direct effect on IRF-1	[direct effect on IRF-1]	0.0	4	1	1	1
84154	1710	a.m.	[a.m.]	0.0	1	1	1	1
84155	1710	rapidak increase	[rapid, increase]	0.0	2	1	1	1
84156	1710	protein bind to tre-1	[proteins binding to TRE-1]	0.0	4	1	1	1
84157	1710	viral transcription-activateactivateactivateactivating domain	[viral transcription-activating domain]	0.0	3	1	1	1
84158	1710	differentiation in T cell	[differentiation in T cells]	0.0	4	1	1	1
84159	1710	evaluation.	[evaluation.]	0.0	1	2	2	1
84160	1710	indicate molecular heterogeneity	[indicating molecular heterogeneity]	0.0	3	1	1	1
84161	1710	enhancement of dna-binding transactivate protein tax	[enhancement of DNA-binding transactivating protein Tax]	0.0	6	1	1	1
84162	1710	il-2 -secret	[IL-2 -secreting]	0.0	2	1	1	1
84163	1710	kappa activity a report.	[kappa activity a report.]	0.0	4	1	1	1
84164	1710	voltage-gated K+ channel	[voltage-gated K+ channels]	0.0	3	1	1	1
84165	1710	cho-dr	[CHO-DR]	0.0	1	1	1	1
84166	1710	Pentoxifylline for the treatment	[Pentoxifylline for the treatment]	0.0	4	1	1	1
84167	1710	various chronic disease (12: four	[various chronic diseases (12: four]	0.0	5	1	1	1
84168	1710	relate the nf-at complex	[relating the NF-AT complexes]	0.0	4	1	1	1
84169	1710	lymphoid/myeloid hybrid	[lymphoid/myeloid hybrid]	0.0	2	1	1	1
84170	1710	express the protein mds1/evi1 to factor	[expressing the protein MDS1/EVI1 to factors]	0.0	6	1	1	1
84171	1710	regulate a critical b gene blk	[regulating a critical B gene blk]	0.0	6	1	1	1
84172	1710	9/19 ss patient	[9/19 SS patients]	0.0	3	1	1	1
84173	1710	secretion level of interleukin-6	[secretion levels of interleukin-6]	0.0	4	1	1	1
84174	1710	Minimal residual disease	[Minimal residual disease]	0.0	3	1	1	1
84175	1710	Specific complex formation between the type	[Specific complex formation between the type]	0.0	6	1	1	1
84176	1710	addition the product of pld action	[addition the product of PLD action]	0.0	6	1	1	1
84177	1710	one complex	[one complex]	0.0	2	1	1	1
84178	1710	current scheme	[current scheme]	0.0	2	1	1	1
84179	1710	I ifi	[I IFNs]	0.0	2	1	1	1
84180	1710	immunoregulatory molecule	[immunoregulatory molecule]	0.0	2	1	1	1
84181	1710	kilometer fraction	[kd fractions]	0.0	2	1	1	1
84182	1710	translocation independent of calcium signal	[translocation independent of calcium signaling]	0.0	5	1	1	1
84183	1710	donor anti-pml/ rar-alpha cd4(+) t-cell clone	[donor anti-pml/ RAR-alpha CD4(+) T-cell clones]	0.0	6	1	1	1
84184	1710	avenue	[avenue]	0.0	1	1	1	1
84185	1710	hiv type transcription	[HIV type transcription]	0.0	3	1	1	1
84186	1710	dominant component of memory	[dominant components of memory]	0.0	4	1	1	1
84187	1710	endothelial leukocyte adhesion molecule	[endothelial leukocyte adhesion molecule]	0.0	4	1	1	1
84188	1710	carboxyl terminus ct	[carboxyl terminus CT]	0.0	3	1	1	1
84189	1710	originate from epidermal cell	[originating from epidermal cells]	0.0	4	1	1	1
84190	1710	Th0-like	[Th0-like]	0.0	1	1	1	1
84191	1710	t-helper-cell	[T-helper-cell]	0.0	1	1	1	1
84192	1710	G(S)alpha expression	[G(S)alpha expression]	0.0	2	3	3	1
84193	1710	qualitative aspect	[qualitative aspects]	0.0	2	1	1	1
84194	1710	ces-2 mediator	[CES-2 mediator]	0.0	2	1	1	1
84195	1710	peroxidation	[peroxidation]	0.0	1	4	4	1
84196	1710	functional alteration in the cells.	[functional alterations in the cells.]	0.0	5	1	1	1
84197	1710	probe specific for the region	[probes specific for the regions]	0.0	5	1	1	1
84198	1710	level, tissue-specific expression	[level, tissue-specific expression]	0.0	3	1	1	1
84199	1710	even level expression of this receptor	[even level expression of these receptors]	0.0	6	1	1	1
84200	1710	form of nf-kb	[form of NF-kB]	0.0	3	1	1	1
84201	1710	distinct form creb	[distinct forms CREB]	0.0	3	1	1	1
84202	1710	flank the base pair region	[flanking the base pair region]	0.0	5	1	1	1
84203	1710	same property regard phosphorylation	[same properties regarding phosphorylation]	0.0	4	1	1	1
84204	1710	wide role	[wider role]	0.0	2	1	1	1
84205	1710	frequent cause of morbidity	[frequent cause of morbidity]	0.0	4	1	1	1
84206	1710	induction of monocytic differentiation 1 infection	[Induction of monocytic differentiation 1 infection]	0.0	6	1	1	1
84207	1710	mimick in vivo migration into tissue	[mimicking in vivo migration into tissues]	0.0	6	1	1	1
84208	1710	ap-1-like site -187	[AP-1-like site -187]	0.0	3	1	1	1
84209	1710	IL-2 IFNgamma	[IL-2 IFNgamma]	0.0	2	1	1	1
84210	1710	EBNA-2 nuclear extract	[EBNA-2 nuclear extracts]	0.0	3	1	1	1
84211	1710	BSAP -binding site	[BSAP -binding sites]	0.0	3	1	1	1
84212	1710	binding of cognate factor	[binding of cognate factors]	0.0	4	1	1	1
84213	1710	effect of prednisone	[effects of prednisone]	0.0	3	1	1	1
84214	1710	Specific glucocorticoid binding at level	[Specific glucocorticoid binding at levels]	0.0	5	1	1	1
84215	1710	response il-4	[responses IL-4]	0.0	2	1	1	1
84216	1710	th2 type	[Th2 type]	0.0	2	1	1	1
84217	1710	A proliferate	[A proliferating]	0.0	2	1	1	1
84218	1710	mouse macrophage protein-1alpha receptor gene	[mouse macrophage protein-1alpha receptor gene]	0.0	5	1	1	1
84219	1710	only to the site	[only to the site]	0.0	4	1	1	1
84220	1710	T lymphocyte nfat	[T lymphocytes NFAT]	0.0	3	1	1	1
84221	1710	interleukin-2 expression a gene	[interleukin-2 expression a gene]	0.0	4	1	1	1
84222	1710	interleukin-1 beta messenger rna level	[interleukin-1 beta messenger RNA levels]	0.0	5	1	1	1
84223	1710	nf-kappab formation	[NF-kappaB formation]	0.0	2	1	1	1
84224	1710	group of industrial chemical	[group of industrial chemicals]	0.0	4	1	1	1
84225	1710	anticancer treatment	[anticancer treatment]	0.0	2	1	1	1
84226	1710	sensitivity to non-cross-resisting agent	[sensitivity to non-cross-resisting agents]	0.0	4	1	1	1
84227	1710	10-15 min,	[10-15 min,]	0.0	2	1	1	1
84228	1710	two immunophilin-drug complex	[two immunophilin-drug complexes]	0.0	3	1	1	1
84229	1710	cleavage by caspase	[Cleavage by caspases]	0.0	3	1	1	1
84230	1710	change in nf-kappa b	[change in NF-kappa B]	0.0	4	1	1	1
84231	1710	floram	[flora,]	0.0	1	1	1	1
84232	1710	cases;	[cases;]	0.0	1	1	1	1
84233	1710	human promyeloid leukemia cell	[human promyeloid leukemia cells]	0.0	4	1	1	1
84234	1710	1q12 region	[1q12 regions]	0.0	2	1	1	1
84235	1710	S6 kinase	[S6 kinase]	0.0	2	1	1	1
84236	1710	strike reduction	[striking reduction]	0.0	2	1	1	1
84237	1710	transient pattern of induction	[transient pattern of induction]	0.0	4	1	1	1
84238	1710	express form	[expressing forms]	0.0	2	1	1	1
84239	1710	delta globin regulatory region	[delta globin regulatory region]	0.0	4	1	1	1
84240	1710	daughter cell culture	[daughter cell culture]	0.0	3	1	1	1
84241	1710	biogenesis of lymphoid organ	[biogenesis of lymphoid organs]	0.0	4	1	1	1
84242	1710	SRF binding	[SRF binding]	0.0	2	1	1	1
84243	1710	concentration (10(-9)-10(-7) mol/L)	[concentration (10(-9)-10(-7) mol/L)]	0.0	3	1	1	1
84244	1710	inducible enhancer between nucleotide -299	[inducible enhancer between nucleotides -299]	0.0	5	1	1	1
84245	1710	nf-kappa b in lesion	[NF-kappa B in lesions]	0.0	4	1	1	1
84246	1710	regimen mg bolus	[regimen mg bolus]	0.0	3	1	1	1
84247	1710	endothelium by dexamethasone	[endothelium by dexamethasone]	0.0	3	1	1	1
84248	1710	jak1 in T lymphocyte	[JAK1 in T lymphocytes]	0.0	4	1	1	1
84249	1710	cell factor pybf	[cells factor PYBF]	0.0	3	1	1	1
84250	1710	alphav5 dihydroxyvitamin D3	[alpha,25 dihydroxyvitamin D3]	0.0	3	1	1	1
84251	1710	nuclear factor in PBL	[nuclear factors in PBL]	0.0	4	1	1	1
84252	1710	six unidentified factor	[six unidentified factors]	0.0	3	1	1	1
84253	1710	approximately 68 kda	[approximately 68 kDa]	0.0	3	1	1	1
84254	1710	association profile	[association profiles]	0.0	2	1	1	1
84255	1710	microg/100 millileter at 10:00 P;	[microg/100 ml at 10:00 h;]	0.0	5	1	1	1
84256	1710	T function a notion	[T function a notion]	0.0	4	1	1	1
84257	1710	strategy involve inhibition	[strategies involving inhibition]	0.0	3	1	1	1
84258	1710	requirement for activation	[requirements for activation]	0.0	3	1	1	1
84259	1710	antibody t-cell proliferation by dexamethasone	[antibody T-cell proliferation by dexamethasone]	0.0	5	1	1	1
84260	1710	antigen receptor element	[antigen receptor element]	0.0	3	1	1	1
84261	1710	mechanism for complex effect	[mechanism for complex effects]	0.0	4	1	1	1
84262	1710	cooperative interaction between cell-specific coactivator	[cooperative interactions between cell-specific coactivators]	0.0	5	1	1	1
84263	1710	glucocorticoid-resistant cell lack endogenous receptor.	[glucocorticoid-resistant cells lacking endogenous receptor.]	0.0	5	1	1	1
84264	1710	effect on c-jun	[effect on c-jun]	0.0	3	1	1	1
84265	1710	clonal disorder	[clonal disorder]	0.0	2	1	1	1
84266	1710	hepatic microsome in term culture	[Hepatic microsomes in term culture]	0.0	5	1	1	1
84267	1710	B alpha	[B alpha]	0.0	2	1	1	1
84268	1710	ikappabalpha mrna	[IkappaBalpha mRNA]	0.0	2	1	1	1
84269	1710	grow in culture,	[growing in culture,]	0.0	3	1	1	1
84270	1710	order potent	[orders potent]	0.0	2	1	1	1
84271	1710	grow in culture.	[growing in culture.]	0.0	3	1	1	1
84272	1710	hmrp8 promoter	[hMRP8 promoter]	0.0	2	1	1	1
84273	1710	pc-3 prostate cancer	[PC-3 prostate cancers]	0.0	3	1	1	1
84274	1710	stage of myeloid differentiation	[stages of myeloid differentiation]	0.0	4	1	1	1
84275	1710	other populations,	[other populations,]	0.0	2	1	1	1
84276	1710	trigger of CD40 signal pathway	[triggering of CD40 signaling pathway]	0.0	5	1	1	1
84277	1710	repress Th1 development	[repressing Th1 development]	0.0	3	1	1	1
84278	1710	replication of macrophage-tropic strain	[replication of macrophage-tropic strains]	0.0	4	1	1	1
84279	1710	272 receptor /cell for type i	[272 receptors /cell for type I]	0.0	6	1	1	1
84280	1710	importance of pi 3-kinase	[importance of PI 3-kinase]	0.0	4	1	1	1
84281	1710	induction surface expression	[Induction surface expression]	0.0	3	1	1	1
84282	1710	Addition during the last h	[Addition during the last h]	0.0	5	1	1	1
84283	1710	woman second	[women second]	0.0	2	1	1	1
84284	1710	partial correlation	[partial correlations]	0.0	2	1	1	1
84285	1710	residual disease in leukemia	[residual disease in leukemia]	0.0	4	1	1	1
84286	1710	activity of 135(oh)2d3	[activities of 1,25(OH)2D3]	0.0	3	1	1	1
84287	1710	regulator of atherogenesis	[regulator of atherogenesis]	0.0	3	1	1	1
84288	1710	interaction involve nuclear factor	[interactions involving nuclear factor]	0.0	4	1	1	1
84289	1710	model during the stage	[model during the stages]	0.0	4	1	1	1
84290	1710	5 steroid hormone anti-sera	[5 steroid hormone anti-sera]	0.0	4	1	1	1
84291	1710	signal by the g-csfr	[signaling by the G-CSFR]	0.0	4	1	1	1
84292	1710	regulation cytokine receptor expression	[Regulation cytokine receptor expression]	0.0	4	1	1	1
84293	1710	relative importance	[relative importance]	0.0	2	1	1	1
84294	1710	change in response	[change in response]	0.0	3	1	1	1
84295	1710	effect human monocyte tnf-alpha production	[effect human monocyte TNF-alpha production]	0.0	5	1	1	1
84296	1710	include presentation, response with retinoic acid	[including presentation, response with retinoic acid]	0.0	6	1	1	1
84297	1710	sv40 t-antigen	[SV40 T-antigen]	0.0	2	1	1	1
84298	1710	prognostic features: clinical implications.	[prognostic features: clinical implications.]	0.0	4	1	1	1
84299	1710	Proc.	[Proc.]	0.0	1	1	1	1
84300	1710	leukemia cell line uf-1	[leukemia cell line UF-1]	0.0	4	1	1	1
84301	1710	family of transcriptional factor	[families of transcriptional factors]	0.0	4	1	1	1
84302	1710	gamma-globin promoter /luciferase gene expression	[gamma-globin promoter /luciferase gene expression]	0.0	5	1	1	1
84303	1710	inhibition of regulatory protein	[inhibition of regulatory proteins]	0.0	4	1	1	1
84304	1710	then (il)-10 blocking factor	[then (IL)-10 blocking factor]	0.0	4	1	1	1
84305	1710	complex with the -70 gata site	[complex with the -70 GATA site]	0.0	6	1	1	1
84306	1710	induction of endothelial icam-1 role	[induction of endothelial ICAM-1 role]	0.0	5	1	1	1
84307	1710	site, meta(d-)	[site, META(D-)]	0.0	2	1	1	1
84308	1710	molecular mechanism for effect	[molecular mechanism for effects]	0.0	4	1	1	1
84309	1710	alter pathway	[altering pathways]	0.0	2	1	1	1
84310	1710	nuclear t3r mbc	[nuclear T3R MBC]	0.0	3	1	1	1
84311	1710	expression of a viral gene	[expression of a viral gene]	0.0	5	1	1	1
84312	1710	minimal nf-kappa b	[minimal NF-kappa B]	0.0	3	1	1	1
84313	1710	ki-67, cd23,	[Ki-67, CD23,]	0.0	2	1	1	1
84314	1710	DNase I site DHS	[DNase I site DHS]	0.0	4	1	1	1
84315	1710	event related to tolerance induction	[events related to tolerance induction]	0.0	5	1	1	1
84316	1710	coimmunoadsorption	[coimmunoadsorption]	0.0	1	1	1	1
84317	1710	apoptosis of T cell	[apoptosis of T cells]	0.0	4	1	1	1
84318	1710	signal pathways, lead	[signaling pathways, leading]	0.0	3	1	1	1
84319	1710	two different class	[two different classes]	0.0	3	1	1	1
84320	1710	however, millileter at 10:00 P;	[However, ml at 10:00 h;]	0.0	5	1	1	1
84321	1710	erythroblast cell	[erythroblast cell]	0.0	2	1	1	1
84322	1710	Epstein-Barr virus replicative gene expression	[Epstein-Barr virus replicative gene expression]	0.0	5	1	1	1
84323	1710	proliferative activity of breast cancer	[proliferative activity of breast cancers]	0.0	5	1	1	1
84324	1710	anti-ro(ssa)	[Anti-Ro(SSA)]	0.0	1	1	1	1
84325	1710	co-operative interaction between RA	[co-operative interactions between RA]	0.0	4	1	1	1
84326	1710	dominant RhoA mutant	[dominant RhoA mutant]	0.0	3	1	1	1
84327	1710	new enhancer element	[new enhancer element]	0.0	3	1	1	1
84328	1710	heme synthesis	[heme synthesis]	0.0	2	1	1	1
84329	1710	benefit for individual	[benefits for individuals]	0.0	3	1	1	1
84330	1710	mode of transcription	[mode of transcription]	0.0	3	1	1	1
84331	1710	myelomocytic cell line	[myelomocytic cell line]	0.0	3	1	1	1
84332	1710	overexpression in the high risk woman	[overexpression in the high risk women]	0.0	6	1	1	1
84333	1710	metabolic status in breast cancer patient	[metabolic status in breast cancer patients]	0.0	6	1	1	1
84334	1710	effect of many alpha,25-(OH)2D3 analog	[effects of many alpha,25-(OH)2D3 analogs]	0.0	5	1	1	1
84335	1710	transcription factor stat1 activity	[transcription factor Stat1 activity]	0.0	4	1	1	1
84336	1710	vivo, despite a entry	[vivo, despite an entry]	0.0	4	1	1	1
84337	1710	drug acyclovir	[drug acyclovir]	0.0	2	1	1	1
84338	1710	transcription factor include NF-AT	[transcription factors including NF-AT]	0.0	4	1	1	1
84339	1710	Cross titration analysis	[Cross titration analyses]	0.0	3	1	1	1
84340	1710	T lymphocytic cell line	[T lymphocytic cell line]	0.0	4	1	1	1
84341	1710	restimulated, T cell	[restimulated, T cells]	0.0	3	1	1	1
84342	1710	leukocyte chemoattract include chemokine	[leukocyte chemoattractants including chemokines]	0.0	4	1	1	1
84343	1710	M-CSF induction	[M-CSF induction]	0.0	2	1	1	1
84344	1710	70%	[70%]	0.0	1	1	1	1
84345	1710	double immunostaining technique	[double immunostaining technique]	0.0	3	1	1	1
84346	1710	htlv-i(-)	[HTLV-I(-)]	0.0	1	1	1	1
84347	1710	mechanism of phenotypic expression	[mechanism of phenotypic expression]	0.0	4	1	1	1
84348	1710	Sp1 factor Sp3ilday	[Sp1 factor Sp3]	0.0	3	1	1	1
84349	1710	several relevant compound	[Several relevant compounds]	0.0	3	1	1	1
84350	1710	interaction with the flank region	[interactions with the flanking regions]	0.0	5	1	1	1
84351	1710	modulatory effect of glucocorticoid	[Modulatory effects of glucocorticoids]	0.0	4	1	1	1
84352	1710	72 bp of -flanking sequence	[72 bp of -flanking sequence]	0.0	5	1	1	1
84353	1710	sensitivity of cells.	[sensitivity of cells.]	0.0	3	1	1	1
84354	1710	htlv-1 disease	[HTLV-1 diseases]	0.0	2	1	1	1
84355	1710	express a hiv virus	[expressing a HIV virus]	0.0	4	1	1	1
84356	1710	decrease in tnf-alpha factor-kappa b	[decrease in TNF-alpha factor-kappa B]	0.0	5	1	1	1
84357	1710	expression of various serum responsive gene	[expression of various serum responsive genes]	0.0	6	1	1	1
84358	1710	novel acid receptor	[novel acid receptor]	0.0	3	1	1	1
84359	1710	simultaneous exposure to CD40L together	[simultaneous exposure to CD40L together]	0.0	5	1	1	1
84360	1710	nuclear factor (nfat) family	[nuclear factor (NFAT) family]	0.0	4	1	1	1
84361	1710	Ca2+ -independent isoform	[Ca2+ -independent isoforms]	0.0	3	1	1	1
84362	1710	deletion derivative of the region	[deletion derivatives of the region]	0.0	5	1	1	1
84363	1710	(30 minutes) to acid washed,	[(30 minutes) to acid washed,]	0.0	5	1	1	1
84364	1710	CD28 augmentation	[CD28 augmentation]	0.0	2	1	1	1
84365	1710	MyoD	[MyoD]	0.0	1	1	1	1
84366	1710	two inducible nf-at complex	[two inducible NF-AT complexes]	0.0	4	1	1	1
84367	1710	vitamin d -resistant nwp	[vitamin D -resistant NWP]	0.0	4	1	1	1
84368	1710	three candidate gene nuclear factor	[three candidate genes nuclear factor]	0.0	5	1	1	1
84369	1710	two early gene	[two early genes]	0.0	3	1	1	1
84370	1710	multiple polypeptide	[multiple polypeptides]	0.0	2	1	1	1
84371	1710	prime with anti-cd28	[priming with anti-CD28]	0.0	3	1	1	1
84372	1710	growth factor-regulated signal pathway	[growth factor-regulated signaling pathway]	0.0	4	1	1	1
84373	1710	Paradoxically, removal	[Paradoxically, removal]	0.0	2	1	1	1
84374	1710	threonine residue at position 234	[threonine residue at position 234]	0.0	5	1	1	1
84375	1710	conservation connect	[conservation connecting]	0.0	2	1	1	1
84376	1710	major (mhc) class ii-like molecule	[major (MHC) class II-like molecule]	0.0	5	1	1	1
84377	1710	study on population of /precursor	[studies on populations of /precursors]	0.0	5	1	1	1
84378	1710	cd56 cell adhesion molecule	[CD56 cell adhesion molecule]	0.0	4	1	1	1
84379	1710	transfection datum	[transfection data.]	0.0	2	1	1	1
84380	1710	kd nmol/L) for cortisol	[Kd nmol/L) for cortisol]	0.0	4	1	1	1
84381	1710	catalytically active dimer	[catalytically active dimer]	0.0	3	1	1	1
84382	1710	pax-5 allele	[PAX-5 allele]	0.0	2	1	1	1
84383	1710	mammalian small rna (snrna) gene	[mammalian small RNA (snRNA) genes]	0.0	5	1	1	1
84384	1710	thus support a role	[thus supporting a role]	0.0	4	1	1	1
84385	1710	accurate initiation by RNA polymerase	[accurate initiation by RNA polymerase]	0.0	5	1	1	1
84386	1710	cell wall component of bacterium	[cell wall component of bacteria]	0.0	5	1	1	1
84387	1710	epithelium of 19 of normal	[epithelium of 19 of normals]	0.0	5	1	1	1
84388	1710	include septic shock	[including septic shock]	0.0	3	1	1	1
84389	1710	phosphorylation of numerous substrate	[phosphorylation of numerous substrates]	0.0	4	1	1	1
84390	1710	co-expression with a dominant c-fo	[co-expression with a dominant c-Fos]	0.0	5	1	1	1
84391	1710	gene (E box) sequence	[gene (E box) sequences]	0.0	4	1	1	1
84392	1710	mature c	[mature C]	0.0	2	1	1	1
84393	1710	evidence inflammatory mediator during syphilis disease	[evidence inflammatory mediators during syphilis disease]	0.0	6	1	1	1
84394	1710	different granule	[different granules]	0.0	2	1	1	1
84395	1710	epo -dependent differentiation	[Epo -dependent differentiation]	0.0	3	1	1	1
84396	1710	adjacent repeat region	[adjacent repeat region]	0.0	3	1	1	1
84397	1710	hormone-mediated gene regulation	[hormone-mediated gene regulation]	0.0	3	1	1	1
84398	1710	compete with MNP-2 for binding	[competing with MNP-2 for binding]	0.0	5	1	1	1
84399	1710	single amp-responsive element	[single AMP-responsive element]	0.0	3	1	1	1
84400	1710	c-Raf phosphorylation	[c-Raf phosphorylation]	0.0	2	1	1	1
84401	1710	change in gene topography	[changes in gene topography]	0.0	4	1	1	1
84402	1710	series of rna sample	[series of RNA samples]	0.0	4	1	1	1
84403	1710	IL-4 NAF IL-4 factor	[IL-4 NAF IL-4 factors]	0.0	4	1	1	1
84404	1710	corresponding to a amplification of cell	[corresponding to a amplification of cells]	0.0	6	1	1	1
84405	1710	combination of olp	[combinations of /LPS]	0.0	3	1	1	1
84406	1710	ccgccc binding protein	[CCGCCC binding proteins]	0.0	3	1	1	1
84407	1710	factor act	[factor acting]	0.0	2	1	1	1
84408	1710	murine macrophage inflammatory protein 1 alpha	[Murine macrophage inflammatory protein 1 alpha]	0.0	6	1	1	1
84409	1710	period of latency before development	[period of latency before development]	0.0	5	1	1	1
84410	1710	fluticasone propionate in subject	[fluticasone propionate in subjects]	0.0	4	1	1	1
84411	1710	run-on experiment	[run-on experiments]	0.0	2	3	3	1
84412	1710	3-fold range in tissue	[3-fold range in tissues]	0.0	4	1	1	1
84413	1710	mechanism unknown,	[mechanisms unknown,]	0.0	2	1	1	1
84414	1710	10 consecutive transplant recipient	[10 consecutive transplant recipients]	0.0	4	1	1	1
84415	1710	gene in helper T cell	[genes in helper T cells]	0.0	5	1	1	1
84416	1710	land globular, electron-dense structure distinct	[LANDs globular, electron-dense structures distinct]	0.0	5	1	1	1
84417	1710	increase during expression of this construct	[Increases during expression of these constructs]	0.0	6	1	1	1
84418	1710	islet culture	[islet cultures]	0.0	2	1	1	1
84419	1710	non-erythroid gene contain element	[non-erythroid genes containing elements]	0.0	4	1	1	1
84420	1710	regulator of cellular gene	[regulators of cellular genes]	0.0	4	1	1	1
84421	1710	case (6%)	[cases (6%)]	0.0	2	1	1	1
84422	1710	stimulation of LTR transcription	[stimulation of LTR transcription]	0.0	4	1	1	1
84423	1710	species range from plant	[species ranging from plants]	0.0	4	1	1	1
84424	1710	World Wide Web	[World Wide Web]	0.0	3	1	1	1
84425	1710	METHODS: seventeen	[METHODS: Seventeen]	0.0	2	1	1	1
84426	1710	four host protein p50	[four host proteins p50]	0.0	4	1	1	1
84427	1710	normal thyroid tissue of patient	[normal thyroid tissue of patients]	0.0	5	1	1	1
84428	1710	extend from cytoplasm	[extending from cytoplasm]	0.0	3	1	1	1
84429	1710	include a heterodimer from nuclear extract	[including a heterodimer from nuclear extracts]	0.0	6	1	1	1
84430	1710	endogenous IFN activity equivalent iu/ml.	[endogenous IFN activity equivalent IU/mL.]	0.0	5	1	1	1
84431	1710	hsp90 by a antibody	[hsp90 by a antibody]	0.0	4	1	1	1
84432	1710	bacteriophage lambda	[bacteriophage lambda]	0.0	2	1	1	1
84433	1710	acute leukemic blast use virus	[acute leukemic blasts using virus]	0.0	5	1	1	1
84434	1710	balance between positive mechanism	[balance between positive mechanisms]	0.0	4	1	1	1
84435	1710	steroid-MR	[steroid-MR]	0.0	1	1	1	1
84436	1710	gc enhancement	[GC enhancement]	0.0	2	1	1	1
84437	1710	encode gamma-globin deaminase	[encoding gamma-globin deaminase]	0.0	3	1	1	1
84438	1710	Retinoic acid modulation	[Retinoic acid modulation]	0.0	3	1	1	1
84439	1710	thus inhibit nf-kappab translocation	[thus inhibiting NF-kappaB translocation]	0.0	4	1	1	1
84440	1710	further, by mobility shift assay	[Further, by mobility shift assay]	0.0	5	1	1	1
84441	1710	change of glucocorticoid binding	[changes of glucocorticoid binding]	0.0	4	1	1	1
84442	1710	Neo(r)	[Neo(r)]	0.0	1	1	1	1
84443	1710	41-kDa	[41-kDa]	0.0	1	1	1	1
84444	1710	proinflammatory mediator leukotriene b4	[proinflammatory mediator leukotriene B4]	0.0	4	1	1	1
84445	1710	mixture gag	[mixture GAGs]	0.0	2	1	1	1
84446	1710	pathway as zap-70	[pathways as ZAP-70]	0.0	3	1	1	1
84447	1710	human immunodeficiency virus repeat	[human immunodeficiency virus repeat]	0.0	4	5	5	1
84448	1710	migration of 48-hr filarial antigen t-cell	[migration of 48-hr filarial antigen T-cells]	0.0	6	1	1	1
84449	1710	accumulating, long-lasting tyrosine	[accumulating, long-lasting tyrosine]	0.0	3	1	1	1
84450	1710	concentration in the luman	[concentration in the lumen]	0.0	4	1	1	1
84451	1710	astrocyte-derived kappa b-binding activity	[astrocyte-derived kappa B-binding activity]	0.0	4	1	1	1
84452	1710	basal cd23 expression	[basal CD23 expression]	0.0	3	1	1	1
84453	1710	combination of all-tran retinoic acid	[combination of all-trans retinoic acid]	0.0	5	2	2	1
84454	1710	a1.1	[A1.1]	0.0	1	1	1	1
84455	1710	stimulate cytokine production	[stimulating cytokine production]	0.0	3	1	1	1
84456	1710	normal epithelium	[normal epithelium]	0.0	2	1	1	1
84457	1710	responsive T cell	[responsive T cells]	0.0	3	1	1	1
84458	1710	human Mo	[human Mo]	0.0	2	1	1	1
84459	1710	Smmhc	[Smmhc]	0.0	1	1	1	1
84460	1710	(start at 532,	[(starting at 532,]	0.0	3	1	1	1
84461	1710	regulation hiv-1	[regulation HIV-1]	0.0	2	1	1	1
84462	1710	drug cyclosporine	[drug cyclosporine]	0.0	2	1	1	1
84463	1710	corresponding binding to plasma membrane	[corresponding binding to plasma membranes]	0.0	5	1	1	1
84464	1710	treatment of skw 6.4 cell	[Treatment of SKW 6.4 cells]	0.0	5	1	1	1
84465	1710	leukocyte from healthy male	[leukocytes from healthy males]	0.0	4	1	1	1
84466	1710	significance of extrarenal, mineralocorticoid receptor	[significance of extrarenal, mineralocorticoid receptors]	0.0	5	1	1	1
84467	1710	concentration of nf-atc	[concentrations of NF-ATc]	0.0	3	1	1	1
84468	1710	solution structure of a pou-specific homeodomain	[Solution structure of a POU-specific homeodomain]	0.0	6	1	1	1
84469	1710	intracellular signal protein such as CBL	[intracellular signaling proteins such as CBL]	0.0	6	1	1	1
84470	1710	immunoglobulin heavy chain region	[immunoglobulin heavy chain region]	0.0	4	1	1	1
84471	1710	transactivator BZLF1	[transactivators BZLF1]	0.0	2	1	1	1
84472	1710	value of a positive response	[value of a positive response]	0.0	5	1	1	1
84473	1710	role in the inducible expression	[role in the inducible expression]	0.0	5	1	1	1
84474	1710	at case	[AT cases]	0.0	2	1	1	1
84475	1710	many gene include alpha- globin	[many genes including alpha- globin]	0.0	5	1	1	1
84476	1710	glucocorticoid on lymphocyte activation	[glucocorticoids on lymphocyte activation]	0.0	4	1	1	1
84477	1710	molecular analysis apoptosis in CD4 receptor	[Molecular analysis apoptosis in CD4 receptors]	0.0	6	1	1	1
84478	1710	only the NF-kappa b homodimer	[only the NF-kappa B homodimer]	0.0	5	1	1	1
84479	1710	amino-terminal domain lack sequence similarity	[amino-terminal domain lacking sequence similarity]	0.0	5	1	1	1
84480	1710	together with the previous finding	[together with the previous findings]	0.0	5	1	1	1
84481	1710	10 mM	[10 mM]	0.0	2	1	1	1
84482	1710	retargeting	[retargeting]	0.0	1	1	1	1
84483	1710	abnormal binding	[abnormal binding]	0.0	2	1	1	1
84484	1710	lipopolysaccharide on gene expression	[lipopolysaccharide on gene expression]	0.0	4	1	1	1
84485	1710	cell nuclei	[cell nuclei]	0.0	2	1	1	1
84486	1710	two atf1 isoform	[two ATF1 isoforms]	0.0	3	1	1	1
84487	1710	clarify the pathogenesis	[clarifying the pathogenesis]	0.0	3	1	1	1
84488	1710	nuclear factor-kappaB translocation human monocyte	[nuclear factor-kappaB translocation human monocytes]	0.0	5	1	1	1
84489	1710	positive element active	[positive element active]	0.0	3	1	1	1
84490	1710	similar effect on nf-kappab transcription	[Similar effects on NF-kappaB transcription]	0.0	5	1	1	1
84491	1710	higher-affinity site	[higher-affinity site]	0.0	2	1	1	1
84492	1710	Blood	[Blood]	0.0	1	1	1	1
84493	1710	nf-at protein	[NF-AT protein]	0.0	2	1	1	1
84494	1710	plasma membrane from leukocyte	[plasma membranes from leukocytes]	0.0	4	1	1	1
84495	1710	protein complex Band a	[protein complex Band A]	0.0	4	1	1	1
84496	1710	12-24 h at a concentration	[12-24 h at a concentration]	0.0	5	1	1	1
84497	1710	transactivation I tax	[transactivation I tax]	0.0	3	1	1	1
84498	1710	significant amount additionally, costimulation	[significant amounts additionally, costimulation]	0.0	4	1	1	1
84499	1710	suppressive effect on thymidine incorporation	[suppressive effect on thymidine incorporation]	0.0	5	1	1	1
84500	1710	p.m.)	[p.m.)]	0.0	1	1	1	1
84501	1710	insertion of this promoter upstream	[Insertion of this promoter upstream]	0.0	5	1	1	1
84502	1710	vitamin d resistance	[vitamin D resistance]	0.0	3	1	1	1
84503	1710	interaction with sequence-specific dna-binding protein	[interaction with sequence-specific DNA-binding proteins]	0.0	5	1	1	1
84504	1710	cloning of gene by AU-motif-directed display	[Cloning of genes by AU-motif-directed display]	0.0	6	1	1	1
84505	1710	IL-4 gene of 10 kilobasis	[IL-4 gene of 10 kilobases]	0.0	5	1	1	1
84506	1710	translocation of c-rel/ p65 heterodimer	[translocation of c-Rel/ p65 heterodimers]	0.0	5	1	1	1
84507	1710	cellular background,	[cellular background,]	0.0	2	1	1	1
84508	1710	computer-assisted analysis	[Computer-assisted analysis]	0.0	2	1	1	1
84509	1710	Soluble tumor necrosis factor	[Soluble tumor necrosis factor]	0.0	4	1	1	1
84510	1710	anomalous activation of protein kinase	[anomalous activation of protein kinase]	0.0	5	1	1	1
84511	1710	Genetic characterization binding to element	[Genetic characterization Binding to element]	0.0	5	1	1	1
84512	1710	single immediate-early protein bzlf1	[single immediate-early protein BZLF1]	0.0	4	1	1	1
84513	1710	cascade of change	[cascade of changes]	0.0	3	1	1	1
84514	1710	T cell receptor-beta	[T cell receptor-beta]	0.0	3	1	1	1
84515	1710	replication of strain	[replication of strains]	0.0	3	1	1	1
84516	1710	cytotoxicity at concentration consistent	[cytotoxicity at concentrations consistent]	0.0	4	1	1	1
84517	1710	Dehydroepiandrosterone DHEA the androgen	[Dehydroepiandrosterone DHEA the androgen]	0.0	4	1	1	1
84518	1710	type of macrophage	[types of macrophages]	0.0	3	1	1	1
84519	1710	signal from patient with severe immunodeficiency	[signaling from patients with severe immunodeficiency]	0.0	6	1	1	1
84520	1710	-1-linked	[-1-linked]	0.0	1	1	1	1
84521	1710	differentiation of mouse erythroleukemia cell	[differentiation of mouse erythroleukemia cells]	0.0	5	1	1	1
84522	1710	leukemia 1- evi1 fusion	[leukemia 1- EVI1 fusions]	0.0	4	1	1	1
84523	1710	amino termini	[amino termini]	0.0	2	1	1	1
84524	1710	negative nf-il6 mutant	[negative NF-IL6 mutant]	0.0	3	1	1	1
84525	1710	site for OCTA enhancer activity	[site for OCTA enhancer activity]	0.0	5	1	1	1
84526	1710	essential feature	[essential feature]	0.0	2	1	1	1
84527	1710	cocktail of granulocyte/macrophage	[cocktail of granulocyte/macrophage]	0.0	3	1	1	1
84528	1710	negative regulatory process	[negative regulatory process]	0.0	3	1	1	1
84529	1710	adhesion with inhibition at mM.	[adhesion with inhibition at mM.]	0.0	5	1	1	1
84530	1710	cotransfection with a transdominant mutant	[Cotransfection with a transdominant mutant]	0.0	5	1	1	1
84531	1710	development of specific inflammatory pathology	[development of specific inflammatory pathologies]	0.0	5	1	1	1
84532	1710	result signal to a domain	[resulting signal to a domain]	0.0	5	1	1	1
84533	1710	presence of the ap-1-like site	[presence of the AP-1-like site]	0.0	5	1	1	1
84534	1710	gal4 site	[GAL4 sites]	0.0	2	1	1	1
84535	1710	20 subject	[20 subjects]	0.0	2	1	1	1
84536	1710	binding of the igh enhancer	[binding of the IgH enhancer]	0.0	5	1	1	1
84537	1710	[age-related change in receptor in lymphocyte	[[Age-related changes in receptors in lymphocytes]	0.0	6	1	1	1
84538	1710	virus-exposed cell from elderly donor	[virus-exposed cells from elderly donors]	0.0	5	1	1	1
84539	1710	anti- v3 loop antibody antibody	[anti- V3 loop antibody antibody]	0.0	5	1	1	1
84540	1710	culminate in cell with mrna encoding	[culminating in cells with mRNA encoding]	0.0	6	1	1	1
84541	1710	calcineurin a	[calcineurin A]	0.0	2	1	1	1
84542	1710	gain a understanding	[gaining a understanding]	0.0	3	1	1	1
84543	1710	protein (creb) factor	[protein (CREB) factors]	0.0	3	1	1	1
84544	1710	abortive stimulation	[abortive stimulation]	0.0	2	1	1	1
84545	1710	thereby modulate the expression	[thereby modulating the expression]	0.0	4	1	1	1
84546	1710	subdominant cycle reactivity to epitope	[subdominant cycle reactivities to epitopes]	0.0	5	1	1	1
84547	1710	dna-protein kinase DNA-PK(CS)	[DNA-protein kinase DNA-PK(CS)]	0.0	3	1	1	1
84548	1710	cortisol binding to receptor	[cortisol binding to receptors]	0.0	4	1	1	1
84549	1710	METHODS: E.	[METHODS: E.]	0.0	2	1	1	1
84550	1710	useful target	[useful target]	0.0	2	1	1	1
84551	1710	asymptomatic infection	[asymptomatic infection]	0.0	2	1	1	1
84552	1710	multiple stage of cell development	[multiple stages of cell development]	0.0	5	1	1	1
84553	1710	ciita cell hybrid	[CIITA cell hybrids]	0.0	3	1	1	1
84554	1710	phagocyte system	[phagocyte system]	0.0	2	1	1	1
84555	1710	promoter contain element	[promoter containing elements]	0.0	3	1	1	1
84556	1710	function of lymphocyte	[functions of lymphocytes]	0.0	3	1	1	1
84557	1710	Ran GTP association of CRM1	[Ran GTP association of CRM1]	0.0	5	1	1	1
84558	1710	JAK2 Janus kinase	[JAK2 Janus kinase]	0.0	3	1	1	1
84559	1710	IkappaB kinase activation	[IkappaB kinase activation]	0.0	3	1	1	1
84560	1710	transactivation domain of amino acid	[transactivation domain of amino acids]	0.0	5	1	1	1
84561	1710	erythropoietin receptor epo-r	[erythropoietin receptor Epo-R]	0.0	3	1	1	1
84562	1710	pp pp1 calyculin a	[PPs PP1/PP2A calyculin A]	0.0	4	1	1	1
84563	1710	activator protein ap-1 dna-binding activity	[activator protein AP-1 DNA-binding activity]	0.0	5	1	1	1
84564	1710	blot analysis of human DNA	[blot analysis of human DNA]	0.0	5	1	1	1
84565	1710	amount of rrna	[amounts of mRNAs]	0.0	3	1	1	1
84566	1710	gene encode for lymphokine	[genes encoding for lymphokines]	0.0	4	1	1	1
84567	1710	prognostic indicator in patient	[prognostic indicator in patients]	0.0	4	1	1	1
84568	1710	72-kilodalton immediate-early protein	[72-kilodalton immediate-early protein]	0.0	3	1	1	1
84569	1710	long terminal repeat promoter	[long terminal repeat promoter]	0.0	4	1	1	1
84570	1710	action of HePTP	[action of HePTP]	0.0	3	1	1	1
84571	1710	HUVECs 75%	[HUVECs 75%]	0.0	2	1	1	1
84572	1710	adhesion molecule-1 gene transcription	[adhesion molecule-1 gene transcription]	0.0	4	1	1	1
84573	1710	EBV early promoter	[EBV early promoter]	0.0	3	1	1	1
84574	1710	intraperitoneal injection in mouse	[intraperitoneal injection in mice]	0.0	4	1	1	1
84575	1710	marker of polymorphism	[marker(s) of polymorphisms]	0.0	3	1	1	1
84576	1710	addition of nm aldosterone	[addition of nM aldosterone]	0.0	4	1	1	1
84577	1710	advanced chronic renal failure A-CRF	[advanced chronic renal failure A-CRF]	0.0	5	1	1	1
84578	1710	NF-kappaB heterodimer	[NF-kappaB heterodimer]	0.0	2	1	1	1
84579	1710	granule protein ecp	[granule proteins ECP]	0.0	3	1	1	1
84580	1710	finding the infiltration	[finding the infiltration]	0.0	3	1	1	1
84581	1710	least 24 P.	[least 24 h.]	0.0	3	1	1	1
84582	1710	CVZ cell	[CVZ cells]	0.0	2	1	1	1
84583	1710	first objective	[first objective]	0.0	2	1	1	1
84584	1710	human myeloid cell granulocyte pmn	[human myeloid cells granulocytes PMN]	0.0	5	1	1	1
84585	1710	support a new, model	[supporting a new, model]	0.0	4	1	1	1
84586	1710	effect of ldl	[effects of LDL]	0.0	3	1	1	1
84587	1710	important aspect of hematopoiesis	[important aspects of hematopoiesis]	0.0	4	1	1	1
84588	1710	c-sis/platelet-derived growth factor-B	[c-sis/platelet-derived growth factor-B]	0.0	3	1	1	1
84589	1710	MHC class I class molecule	[MHC class I class molecules]	0.0	5	1	1	1
84590	1710	blockade of a signal	[blockade of a signal]	0.0	4	1	1	1
84591	1710	transcriptional regulator factor-kappaB nf-kappab	[transcriptional regulator factor-kappaB NF-kappaB]	0.0	4	1	1	1
84592	1710	binding of cell-specific transcription factor essential	[binding of cell-specific transcription factors essential]	0.0	6	1	1	1
84593	1710	gene family member	[gene family members]	0.0	3	1	1	1
84594	1710	effect on dna-binding activity	[effect on DNA-binding activities]	0.0	4	1	1	1
84595	1710	start at 30 minute	[starting at 30 min]	0.0	4	1	1	1
84596	1710	molecule of pkc-zeta	[molecule of PKC-zeta]	0.0	3	1	1	1
84597	1710	specific, time-dependent, activation	[specific, time-dependent, activation]	0.0	3	1	1	1
84598	1710	effect of angiotensin (ang)	[effect of angiotensin (ANG)]	0.0	4	1	1	1
84599	1710	multiple reactivity at level high	[multiple reactivities at levels high]	0.0	5	1	1	1
84600	1710	male with severe immunodeficiency	[Males with severe immunodeficiency]	0.0	4	1	1	1
84601	1710	distinct heteromeric complex with nuclear protein	[distinct heteromeric complexes with nuclear proteins]	0.0	6	1	1	1
84602	1710	expression of immediate early serum gene	[expression of immediate early serum genes]	0.0	6	1	1	1
84603	1710	cell line by immunoblotting	[cell lines by immunoblotting]	0.0	4	1	1	1
84604	1710	content of h+-atpase v-atpase	[content of H+-ATPase V-ATPase]	0.0	4	1	1	1
84605	1710	reticuloendotheliosis virus REV	[reticuloendotheliosis virus REV]	0.0	3	1	1	1
84606	1710	lymphocyte homing	[lymphocyte homing]	0.0	2	1	1	1
84607	1710	derivative of SIVmac239	[derivative of SIVmac239]	0.0	3	1	1	1
84608	1710	hybrid arise	[hybrids arising]	0.0	2	1	1	1
84609	1710	APL blast available from patient F.R.	[APL blasts available from patients F.R.]	0.0	6	1	1	1
84610	1710	exposure to shear dyn/cm2) haec	[exposure to shear dyn/cm2) HAEC]	0.0	5	1	1	1
84611	1710	early-onset type	[early-onset type]	0.0	2	1	1	1
84612	1710	IL-5 -inducible gene	[IL-5 -inducible genes]	0.0	3	1	1	1
84613	1710	IL-12R beta chain	[IL-12R beta chain]	0.0	3	1	1	1
84614	1710	abnormal regulation	[Abnormal regulation]	0.0	2	1	1	1
84615	1710	agent like diamide	[agents like diamide]	0.0	3	1	1	1
84616	1710	therapeutic value for disease	[therapeutic value for disease]	0.0	4	1	1	1
84617	1710	assay procedure use recombinant zebra protein	[assay procedure using recombinant ZEBRA protein]	0.0	6	1	1	1
84618	1710	human b-	[human B-]	0.0	2	1	1	1
84619	1710	different activation and/or differentiation stage	[different activation and/or differentiation stages]	0.0	5	1	1	1
84620	1710	(start	[(starting]	0.0	1	1	1	1
84621	1710	case of twin discordant	[case of twins discordant]	0.0	4	1	1	1
84622	1710	CD28 together	[CD28 together]	0.0	2	1	1	1
84623	1710	induction of AhR during differentiation	[induction of AhR during differentiation]	0.0	5	1	1	1
84624	1710	increase in number	[increase in numbers]	0.0	3	1	1	1
84625	1710	immunosuppression: inhibition	[immunosuppression: inhibition]	0.0	2	1	1	1
84626	1710	only inhibition of the generation	[only inhibition of the generation]	0.0	5	1	1	1
84627	1710	V3 loop	[V3 loop]	0.0	2	1	1	1
84628	1710	her-2/neu overexpression (57.3 +/-	[HER-2/neu overexpression (57.3 +/-]	0.0	4	1	1	1
84629	1710	calcineurin phosphatase activity	[calcineurin phosphatase activity]	0.0	3	1	1	1
84630	1710	nf-kappa b heteromer	[NF-kappa B heteromers]	0.0	3	1	1	1
84631	1710	alpha,25-dihydroxyvitamin D3 (vitd3)-induced monocytic differentiation	[alpha,25-dihydroxyvitamin D3 (VitD3)-induced monocytic differentiation]	0.0	5	1	1	1
84632	1710	specific response	[specific response]	0.0	2	1	1	1
84633	1710	action blockade of progenitor proliferation	[action blockade of progenitor proliferation]	0.0	5	1	1	1
84634	1710	expression along the pathway	[expression along the pathway]	0.0	4	1	1	1
84635	1710	immuno-pathological condition	[immuno-pathological conditions]	0.0	2	1	1	1
84636	1710	45-nucleotide sequence downstream element DRE	[45-nucleotide sequence downstream element DRE]	0.0	5	1	1	1
84637	1710	expression of MEK1 mutant	[Expression of MEK1 mutants]	0.0	4	1	1	1
84638	1710	unregulated expression a gene	[unregulated expression a gene]	0.0	4	1	1	1
84639	1710	signal of the immune system	[signal of the immune system]	0.0	5	1	1	1
84640	1710	loci relevant	[loci relevant]	0.0	2	1	1	1
84641	1710	(35 min) physical exercise ppe	[(35 min) physical exercise PPE]	0.0	5	1	1	1
84642	1710	other nervous tissue	[other nervous tissues]	0.0	3	1	1	1
84643	1710	costimulatory molecule in the activation	[costimulatory molecule in the activation]	0.0	5	1	1	1
84644	1710	appearance of marker	[appearance of markers]	0.0	3	1	1	1
84645	1710	b series cell	[B series cells]	0.0	3	1	1	1
84646	1710	transcriptional regulator of myeloid differentiation	[transcriptional regulator of myeloid differentiation]	0.0	5	1	1	1
84647	1710	activation of the NF-kappaB pathway	[Activation of the NF-kappaB pathway]	0.0	5	1	1	1
84648	1710	kind of il-4ralpha	[kinds of IL-4Ralpha]	0.0	3	1	1	1
84649	1710	anticancer	[anticancer]	0.0	1	1	1	1
84650	1710	regulation of colony-stimulating factor	[Regulation of colony-stimulating factor]	0.0	4	1	1	1
84651	1710	endometria	[endometria]	0.0	1	1	1	1
84652	1710	delta-globin region	[delta-globin region]	0.0	2	1	1	1
84653	1710	affinity CVZ binding site	[affinity CVZ binding site]	0.0	4	1	1	1
84654	1710	subdominant cycle reactivity though rarely undetectable	[subdominant cycle reactivities though rarely undetectable]	0.0	6	1	1	1
84655	1710	pxqxt/ core sequence	[PXQXT/S core sequence]	0.0	3	1	1	1
84656	1710	brief incubation	[brief incubation]	0.0	2	1	1	1
84657	1710	cell death program	[cell death program]	0.0	3	1	1	1
84658	1710	first experience	[first experiences]	0.0	2	1	1	1
84659	1710	activation of c-Jun function	[activation of c-Jun functions]	0.0	4	1	1	1
84660	1710	use of tpo	[use of TPO]	0.0	3	1	1	1
84661	1710	include interleukin-1	[including interleukin-1]	0.0	2	1	1	1
84662	1710	b cell tumor line	[B cell tumor lines]	0.0	4	1	1	1
84663	1710	include interleukin-2	[including interleukin-2]	0.0	2	1	1	1
84664	1710	number with alteration in apparent affinity	[numbers with alteration in apparent affinity]	0.0	6	1	1	1
84665	1710	specificity-conferring mechanism for mineralocorticoid action	[specificity-conferring mechanism for mineralocorticoid action]	0.0	5	1	1	1
84666	1710	such as cell adhesion molecule-1	[such as cell adhesion molecule-1]	0.0	5	1	1	1
84667	1710	plasmid contain sense rxr-alpha sequence	[plasmids containing sense RXR-alpha sequences]	0.0	5	1	1	1
84668	1710	amino acid long tramp	[amino acid long TRAMP]	0.0	4	1	1	1
84669	1710	drosophila homeobox	[Drosophila homeobox]	0.0	2	1	1	1
84670	1710	antisense oligo against hepatitis b virus	[antisense oligos against hepatitis B virus]	0.0	6	1	1	1
84671	1710	inhibition during the A/R challenge	[Inhibition during the A/R challenge]	0.0	5	1	1	1
84672	1710	adjuvant treatment	[adjuvant treatment]	0.0	2	1	1	1
84673	1710	immunodeficiency virus type hiv-1 negative factor	[immunodeficiency virus type HIV-1 negative factor]	0.0	6	1	1	1
84674	1710	adaptive change	[adaptive changes]	0.0	2	1	1	1
84675	1710	t(3;14)(q27;q11) rearrangement	[t(3;14)(q27;q11) rearrangement]	0.0	2	1	1	1
84676	1710	independent module	[independent module]	0.0	2	1	1	1
84677	1710	co-activator for the expression	[co-activator for the expression]	0.0	4	1	1	1
84678	1710	mechanism of a component	[mechanism of a component]	0.0	4	1	1	1
84679	1710	stimulation with all-tran acid RA	[stimulation with all-trans acid RA]	0.0	5	1	1	1
84680	1710	improvement in airflow	[improvements in airflow]	0.0	3	1	1	1
84681	1710	tbp related to tfiiib	[TBP related to TFIIIB]	0.0	4	1	1	1
84682	1710	effect of Dex on the avidity	[effects of Dex on the avidity]	0.0	6	1	1	1
84683	1710	independence of intracellular electrolyte	[independence of intracellular electrolytes]	0.0	4	1	1	1
84684	1710	EBV gene transcript bzlf1	[EBV gene transcripts BZLF1]	0.0	4	1	1	1
84685	1710	cooperative interaction between two transcriptional coactivator	[cooperative interactions between two transcriptional coactivators]	0.0	6	1	1	1
84686	1710	cytokine important	[cytokine important]	0.0	2	1	1	1
84687	1710	reach a maximum after h	[reaching a maximum after h]	0.0	5	1	1	1
84688	1710	regulatory DNA element present	[regulatory DNA element present]	0.0	4	1	1	1
84689	1710	c/ebP-binding site bp -90	[C/EBP-binding site bp -90]	0.0	4	1	1	1
84690	1710	expression of human factor-1 receptor csf-1r	[expression of human factor-1 receptor CSF-1R]	0.0	6	1	1	1
84691	1710	c-myb binding	[c-Myb binding]	0.0	2	1	1	1
84692	1710	regulation by trans-acting factor	[regulation by trans-acting factors]	0.0	4	1	1	1
84693	1710	contain a region.	[containing a region.]	0.0	3	1	1	1
84694	1710	/cell	[/cell]	0.0	1	1	1	1
84695	1710	level in b cell	[levels in B cells]	0.0	4	1	1	1
84696	1710	requirement for immunodeficiency virus	[requirement for immunodeficiency virus]	0.0	4	1	1	1
84697	1710	provirus establishment	[provirus establishment]	0.0	2	1	1	1
84698	1710	differentiation, with c-jun expression	[differentiation, with c-jun expression]	0.0	4	1	1	1
84699	1710	casein kinase CKII	[casein kinase CKII]	0.0	3	1	1	1
84700	1710	binding site on the gr	[binding sites on the GR]	0.0	5	1	1	1
84701	1710	8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
84702	1710	acetate Egr-1 mrna expression	[acetate Egr-1 mRNA expression]	0.0	4	1	1	1
84703	1710	CD20 antibody	[CD20 antibody]	0.0	2	1	1	1
84704	1710	protein kinase mapk activity	[protein kinase MAPK activities]	0.0	4	1	1	1
84705	1710	B-like	[B-like]	0.0	1	2	2	1
84706	1710	housekeeping alas precursor	[housekeeping ALAS precursor]	0.0	3	1	1	1
84707	1710	hour after the injection.	[hr after the injection.]	0.0	4	1	1	1
84708	1710	characterization identification of a pebp2/cbf site	[characterization identification of a PEBP2/CBF site]	0.0	6	1	1	1
84709	1710	phosphorothioate oligodeoxynucleotide	[phosphorothioate oligodeoxynucleotide]	0.0	2	1	1	1
84710	1710	hiv provirus	[HIV provirus]	0.0	2	1	1	1
84711	1710	representate the whole spectrum of differentiation	[representating the whole spectrum of differentiation]	0.0	6	1	1	1
84712	1710	NF-AT family	[NF-AT family]	0.0	2	2	2	1
84713	1710	analysis of the cellular function	[analysis of the cellular functions]	0.0	5	1	1	1
84714	1710	identification of abnormality	[identification of abnormalities]	0.0	3	1	1	1
84715	1710	amplification of allele allele ratio	[amplification of allele allele ratio]	0.0	5	1	1	1
84716	1710	population of cells,	[population of cells,]	0.0	3	1	1	1
84717	1710	interaction with traf protein	[interactions with TRAF proteins]	0.0	4	1	1	1
84718	1710	inhibit the phosphatase activity of calcineurin	[inhibiting the phosphatase activity of calcineurin]	0.0	6	1	1	1
84719	1710	promoter by transcription factor	[promoters by transcription factors]	0.0	4	1	1	1
84720	1710	cell of patient with ricket	[cells of patients with rickets]	0.0	5	1	1	1
84721	1710	method for detection of transcription factor	[methods for detection of transcription factors]	0.0	6	1	1	1
84722	1710	Suppressive effect	[Suppressive effects]	0.0	2	1	1	1
84723	1710	ic50 value of 31	[IC50 values of 31]	0.0	4	1	1	1
84724	1710	platelet (auc	[platelets (AUC]	0.0	2	1	1	1
84725	1710	p16 leukemia cell line	[p16 leukemia cell lines]	0.0	4	1	1	1
84726	1710	finding synergistic	[findings synergistic]	0.0	2	1	1	1
84727	1710	analysis of the first rdna HZF	[analysis of the first cDNAs HZF]	0.0	6	1	1	1
84728	1710	critical role of c-jun	[critical role of c-jun]	0.0	4	1	1	1
84729	1710	(oh)2d3 dioxyvit	[(OH)2D3 dioxyvit]	0.0	2	1	1	1
84730	1710	normal range for age,	[normal range for age,]	0.0	4	1	1	1
84731	1710	use extract from brain	[using extracts from brain]	0.0	4	1	1	1
84732	1710	hypothalamic-pituitary-adrenal system hpa	[hypothalamic-pituitary-adrenal system HPA]	0.0	3	1	1	1
84733	1710	USA component	[USA components]	0.0	2	1	1	1
84734	1710	induce transcription through element	[inducing transcription through elements]	0.0	4	1	1	1
84735	1710	concentration inhibit ige synthesis mol/L)	[concentrations inhibiting IgE synthesis mol/L)]	0.0	5	1	1	1
84736	1710	evidence for reactivity	[evidence for reactivity]	0.0	3	1	1	1
84737	1710	pertain	[pertaining]	0.0	1	1	1	1
84738	1710	50nm	[50nM]	0.0	1	1	1	1
84739	1710	-dependent modulation	[-dependent modulation]	0.0	2	1	1	1
84740	1710	protein kinase endothelial cell	[protein kinase endothelial cells]	0.0	4	1	1	1
84741	1710	such as 12-o-tetradecanoyl phorbol 13-acetate	[such as 12-O-tetradecanoyl phorbol 13-acetate]	0.0	5	1	1	1
84742	1710	modifier	[modifier]	0.0	1	1	1	1
84743	1710	genes, alpha	[genes, alpha]	0.0	2	1	1	1
84744	1710	mutant ebv	[mutant EBV]	0.0	2	1	1	1
84745	1710	T cell hybridoma model	[T cell hybridoma model]	0.0	4	1	1	1
84746	1710	contain stat4 only, stat4	[containing STAT4 only, STAT4]	0.0	4	1	1	1
84747	1710	adhesion molecule-1 cd62e	[adhesion molecule-1 CD62E]	0.0	3	1	1	1
84748	1710	ifn-alpha/b-stimulated early response gene	[IFN-alpha/B-stimulated early response genes]	0.0	4	1	1	1
84749	1710	human leukemia/lymphoma line	[human leukemia/lymphoma lines]	0.0	3	1	1	1
84750	1710	glucocorticoid type ii receptor	[glucocorticoid type II receptor]	0.0	4	1	1	1
84751	1710	level for protein-1	[levels for protein-1]	0.0	3	1	1	1
84752	1710	disorder present with salt loss	[disorder presenting with salt loss]	0.0	5	1	1	1
84753	1710	g/g of rna in cell-sorted monocyte	[g/g of RNA in cell-sorted monocytes]	0.0	6	1	1	1
84754	1710	immunoprecipitation study	[immunoprecipitation studies]	0.0	2	1	1	1
84755	1710	moreover, induction	[Moreover, induction]	0.0	2	2	2	1
84756	1710	activation functional role	[activation functional role]	0.0	3	1	1	1
84757	1710	initial expression	[initial expression]	0.0	2	1	1	1
84758	1710	large germline deletion	[Large germline deletions]	0.0	3	1	1	1
84759	1710	alternative splicing of exon 10	[Alternative splicing of exon 10]	0.0	5	1	1	1
84760	1710	distinct c-fos/c-jun promoter element	[distinct c-fos/c-jun promoter elements]	0.0	4	1	1	1
84761	1710	group of neoplasm	[group of neoplasms]	0.0	3	1	1	1
84762	1710	monocyte binding to fibronectin	[monocyte binding to fibronectin]	0.0	4	1	1	1
84763	1710	t-cell specific gene include interleukin-2	[T-cell specific genes including interleukin-2]	0.0	5	1	1	1
84764	1710	CPRE GGACTACAG at -49/41	[CPRE GGACTACAG at -49/-41,]	0.0	4	1	1	1
84765	1710	immediate early gene Ie	[immediate early genes IE]	0.0	4	1	1	1
84766	1710	GPIb-V-IX	[GPIb-V-IX]	0.0	1	1	1	1
84767	1710	ascorbate AFR act in system	[ascorbate AFR acts in systems]	0.0	5	1	1	1
84768	1710	induction by factor in human monocyte	[Induction by factor in human monocytes]	0.0	6	1	1	1
84769	1710	t-cell inhibitory effect of DEX	[T-cell inhibitory effects of DEX]	0.0	5	1	1	1
84770	1710	47 amino acid	[47 amino acids]	0.0	3	1	1	1
84771	1710	cycle reactivity to epitope though undetectable	[cycle reactivities to epitopes though undetectable]	0.0	6	1	1	1
84772	1710	concentration in this cell	[concentrations in these cells]	0.0	4	1	1	1
84773	1710	activity of PKC	[activity of PKC]	0.0	3	1	1	1
84774	1710	h in the presence	[h in the presence]	0.0	4	2	2	1
84775	1710	end growth	[end growth]	0.0	2	1	1	1
84776	1710	suggest possible mechanism	[suggesting possible mechanism]	0.0	3	1	1	1
84777	1710	trend approach significance	[trend approaching significance]	0.0	3	1	1	1
84778	1710	single-chain ab variable fragment	[single-chain Ab variable fragment]	0.0	4	1	1	1
84779	1710	inducible enhancer between nucleotide	[inducible enhancer between nucleotides]	0.0	4	1	1	1
84780	1710	metaphase analysis	[metaphase analysis]	0.0	2	1	1	1
84781	1710	blood from healthy donor	[blood from healthy donors]	0.0	4	1	1	1
84782	1710	three subtype of acid receptor	[Three subtypes of acid receptors]	0.0	5	1	1	1
84783	1710	t-cell-leukemia virus type 1 htlv-1	[T-cell-leukemia virus type 1 HTLV-1]	0.0	5	1	1	1
84784	1710	prolactin receptor	[prolactin receptor]	0.0	2	1	1	1
84785	1710	t3, 4) dysfunction	[T3, 4) dysfunction]	0.0	3	1	1	1
84786	1710	sequence at +265	[sequence at +265]	0.0	3	1	1	1
84787	1710	volunteer with hypertension.	[volunteers with hypertension.]	0.0	3	1	1	1
84788	1710	inhibition of hiv type	[inhibition of HIV type]	0.0	4	1	1	1
84789	1710	hematopoiesis of mature leukocyte	[hematopoiesis of mature leukocytes]	0.0	4	1	1	1
84790	1710	diagnostic purpose in view.	[diagnostic purposes in view.]	0.0	4	1	1	1
84791	1710	terminal differentiation in cell line	[terminal differentiation in cell lines]	0.0	5	1	1	1
84792	1710	type of granulomatous disease	[types of granulomatous disease]	0.0	4	1	1	1
84793	1710	membrane receptor a pathway	[Membrane receptors a pathway]	0.0	4	1	1	1
84794	1710	major late promoter erratum	[major late promoter erratum]	0.0	4	1	1	1
84795	1710	abnormality highlight loci relevant	[abnormalities highlighting loci relevant]	0.0	4	1	1	1
84796	1710	deviation of methylation	[deviation of methylation]	0.0	3	1	1	1
84797	1710	hybrid molecule	[hybrid molecule]	0.0	2	1	1	1
84798	1710	active activation domain,	[active activation domain,]	0.0	3	1	1	1
84799	1710	transcription initiation from cp	[transcription initiation from Cp]	0.0	4	1	1	1
84800	1710	distinct complex RFX	[distinct complexes RFX]	0.0	3	1	1	1
84801	1710	NK cell-mediated cytolysis	[NK cell-mediated cytolysis]	0.0	3	1	1	1
84802	1710	t-cell line IARC 301.5	[T-cell line IARC 301.5]	0.0	4	1	1	1
84803	1710	region in gene	[region in genes]	0.0	3	1	1	1
84804	1710	primary activation,	[primary activation,]	0.0	2	1	1	1
84805	1710	disruption the acidic activation domain	[disruptions the acidic activation domain]	0.0	5	1	1	1
84806	1710	normal golgi processing	[normal Golgi processing]	0.0	3	1	1	1
84807	1710	inactivation inconsistent	[inactivation inconsistent]	0.0	2	1	1	1
84808	1710	x element	[X element]	0.0	2	1	1	1
84809	1710	two distinguishable gr abnormalities:	[two distinguishable GR abnormalities:]	0.0	4	1	1	1
84810	1710	mab anti-CD40	[mAb anti-CD40]	0.0	2	1	1	1
84811	1710	(>1 mm)	[(>1 mm)]	0.0	2	1	1	1
84812	1710	cytokine signal cascade lead	[cytokine signaling cascade leading]	0.0	4	1	1	1
84813	1710	cis-acting DNA	[cis-acting DNA]	0.0	2	1	1	1
84814	1710	tissue-specific mechanism	[tissue-specific mechanisms]	0.0	2	1	1	1
84815	1710	likely identical proteins, differ in degree	[likely identical proteins, differing in degree]	0.0	6	1	1	1
84816	1710	chromatin domain	[chromatin domains]	0.0	2	1	1	1
84817	1710	IL-1/tumor necrosis element	[IL-1/tumor necrosis element]	0.0	3	1	1	1
84818	1710	process regulate the intensity	[process regulating the intensity]	0.0	4	1	1	1
84819	1710	urinary thf with the/thf	[urinary THF with THE/THF]	0.0	4	1	1	1
84820	1710	mouse transgenic line	[mouse transgenic lines]	0.0	3	1	1	1
84821	1710	pathway by phorbol myristic acetate	[pathway by phorbol myristic acetate]	0.0	5	1	1	1
84822	1710	cytokine interleukin-1 beta	[cytokines interleukin-1 beta]	0.0	3	1	1	1
84823	1710	feature of the rna	[feature of the RNA]	0.0	4	1	1	1
84824	1710	human serum-inducible element	[human serum-inducible element]	0.0	3	1	1	1
84825	1710	occur in family	[occurring in families]	0.0	3	1	1	1
84826	1710	corticosteroid-resistant (cr) subject	[corticosteroid-resistant (CR) subjects]	0.0	3	1	1	1
84827	1710	management of patient	[management of patients]	0.0	3	1	1	1
84828	1710	truncation analysis	[Truncation analyses]	0.0	2	1	1	1
84829	1710	reservoir of infection	[reservoir of infection]	0.0	3	1	1	1
84830	1710	equi-effective doses.	[equi-effective doses.]	0.0	2	1	1	1
84831	1710	binding to a nf-kappa factor	[binding to an NF-kappa factor]	0.0	5	1	1	1
84832	1710	expression of the c-jun	[expression of the c-Jun]	0.0	4	1	1	1
84833	1710	surface domain in solution,	[surface domain in solution,]	0.0	4	1	1	1
84834	1710	factor colony-stimumulatelany-stg factor	[factor colony-stimulating factor]	0.0	3	1	1	1
84835	1710	decrease use binding peptide	[decrease using binding peptides]	0.0	4	1	1	1
84836	1710	haemopoietic cell of lineages.	[haemopoietic cells of lineages.]	0.0	4	1	1	1
84837	1710	IFN alpha production by monocyte	[IFN alpha production by monocytes]	0.0	5	1	1	1
84838	1710	specific binding interaction	[specific binding interactions]	0.0	3	1	1	1
84839	1710	inhibition of fas killing	[inhibition of Fas killing]	0.0	4	1	1	1
84840	1710	human deficiency virus type hiv-1	[human deficiency virus type HIV-1]	0.0	5	1	1	1
84841	1710	surface ganglioside gd3	[surface ganglioside GD3]	0.0	3	1	1	1
84842	1710	other lymphocyte-specific gene	[other lymphocyte-specific genes]	0.0	3	1	1	1
84843	1710	form of Epstein-Barr virus EBV	[form of Epstein-Barr virus EBV]	0.0	5	1	1	1
84844	1710	b protein in extract	[B proteins in extracts]	0.0	4	1	1	1
84845	1710	mechanism involve a interaction	[mechanism involving a interaction]	0.0	4	1	1	1
84846	1710	dimerize with member	[dimerizing with members]	0.0	3	1	1	1
84847	1710	include receptor	[including receptor]	0.0	2	1	1	1
84848	1710	component of each P-like complex	[components of each P-like complexes]	0.0	5	1	1	1
84849	1710	suggest one mechanism	[suggesting one mechanism]	0.0	3	1	1	1
84850	1710	trigger include repression of cd95 transcription	[triggering including repression of CD95 transcription]	0.0	6	1	1	1
84851	1710	use the dose	[using the dose]	0.0	3	1	1	1
84852	1710	15 to 22 cell divisions,	[15 to 22 cell divisions,]	0.0	5	1	1	1
84853	1710	inappropriate binding	[inappropriate binding]	0.0	2	1	1	1
84854	1710	interleukin 2 a activator	[interleukin 2 a activator]	0.0	4	1	1	1
84855	1710	phorbol ester PMA in T	[phorbol esters PMA in T]	0.0	5	1	1	1
84856	1710	transactivation by human herpesvirus strain gs	[Transactivation by human herpesvirus strains GS]	0.0	6	1	1	1
84857	1710	comparison of the promoter for inducible	[comparison of the promoters for inducible]	0.0	6	1	1	1
84858	1710	tnf-alpha degradation in memory	[TNF-alpha degradation in memory]	0.0	4	1	1	1
84859	1710	porcine endothelial cell	[Porcine endothelial cells]	0.0	3	1	1	1
84860	1710	basis dna-binding characteristics,	[basis DNA-binding characteristics,]	0.0	3	1	1	1
84861	1710	reactivity of choice;	[reactivity of choice;]	0.0	3	1	1	1
84862	1710	rapid formation	[rapid formation]	0.0	2	1	1	1
84863	1710	seen, transendothelial migration	[seen, transendothelial migration]	0.0	3	1	1	1
84864	1710	role release a elongation block	[role releasing an elongation block]	0.0	5	1	1	1
84865	1710	name for flowerhead	[name for flowerheads]	0.0	3	1	1	1
84866	1710	whole peripheral venous blood from donor	[whole peripheral venous blood from donors]	0.0	6	1	1	1
84867	1710	region of complex class molecule	[regions of complex class molecules]	0.0	5	1	1	1
84868	1710	mouse EpoR	[mouse EpoR]	0.0	2	1	1	1
84869	1710	co-migrate	[co-migrating]	0.0	1	1	1	1
84870	1710	intact cells.	[intact cells.]	0.0	2	1	1	1
84871	1710	case of ebv-positive bl	[cases of EBV-positive BL]	0.0	4	1	1	1
84872	1710	interaction factor traz	[interaction factors TRAFs]	0.0	3	1	1	1
84873	1710	neonatal immune response	[neonatal immune response]	0.0	3	1	1	1
84874	1710	correlation between footprinting datum	[correlation between footprinting data]	0.0	4	1	1	1
84875	1710	acute blast use virus	[acute blasts using virus]	0.0	4	1	1	1
84876	1710	housekeeping alas mrna	[housekeeping ALAS mRNA]	0.0	3	1	1	1
84877	1710	c-Jun response	[c-Jun response]	0.0	2	1	1	1
84878	1710	lck-negative jcam1 cell	[Lck-negative JCaM1 cells]	0.0	3	1	1	1
84879	1710	inactive factor-kappaB in the cytosol	[inactive factor-kappaB in the cytosol]	0.0	5	1	1	1
84880	1710	sequential deletion mutant	[sequential deletion mutants]	0.0	3	1	1	1
84881	1710	contrast to pattern	[contrast to pattern]	0.0	3	1	1	1
84882	1710	dendritic cell FDC	[dendritic cells FDC]	0.0	3	2	2	1
84883	1710	encode a human tfiid protein	[encoding a human TFIID protein]	0.0	5	1	1	1
84884	1710	two form of early-onset type	[two forms of early-onset type]	0.0	5	1	1	1
84885	1710	allow for gene expression	[allowing for gene expression]	0.0	4	1	1	1
84886	1710	sequence homology to SWI3	[sequence homology to SWI3]	0.0	4	1	1	1
84887	1710	surrogate tg receptor on non-T	[surrogate TG receptors on non-T]	0.0	5	1	1	1
84888	1710	monocyte-specific function	[monocyte-specific function]	0.0	2	1	1	1
84889	1710	wt1 expression in hematopoietic cell	[WT1 expression in hematopoietic cells]	0.0	5	1	1	1
84890	1710	unit-erythroid (bfu-e) colony formation	[unit-erythroid (BFU-E) colony formation]	0.0	4	1	1	1
84891	1710	inhibition I type interferon	[Inhibition I type interferons]	0.0	4	1	1	1
84892	1710	encode receptor	[encoding receptors]	0.0	2	1	1	1
84893	1710	anti-CD28	[anti-CD28]	0.0	1	1	1	1
84894	1710	inhibition of DNA methyltransferase	[inhibition of DNA methyltransferase]	0.0	4	1	1	1
84895	1710	(p less than p 0.01	[(P less than P 0.01]	0.0	5	1	1	1
84896	1710	major putative site for E2F	[major putative site for E2F]	0.0	5	1	1	1
84897	1710	peptidylprolyl cis-tran isomerase distinct	[peptidylprolyl cis-trans isomerase distinct]	0.0	4	1	1	1
84898	1710	steroid hormone estrogen	[steroid hormones estrogen]	0.0	3	1	1	1
84899	1710	hence, induction	[Hence, induction]	0.0	2	1	1	1
84900	1710	potent activity low than cyclosporin a	[potent activity lower than cyclosporin A]	0.0	6	1	1	1
84901	1710	rapid decrease in level	[rapid decrease in levels]	0.0	4	1	1	1
84902	1710	cytogenetic examination of the patient' brother,	[Cytogenetic examination of the patient's brother,]	0.0	6	1	1	1
84903	1710	NE of platelet	[NE of platelets]	0.0	3	1	1	1
84904	1710	porcine cell line piec	[porcine cell line PIEC]	0.0	4	1	1	1
84905	1710	ifn-gamma level	[IFN-gamma levels]	0.0	2	1	1	1
84906	1710	consensus sequences, capable	[consensus sequences, capable]	0.0	3	1	1	1
84907	1710	effect on nf-kappab regulation	[effects on NF-kappaB regulation]	0.0	4	1	1	1
84908	1710	samples, activity of egl	[samples, activity of eGLs]	0.0	4	1	1	1
84909	1710	highlight loci relevant to pel	[highlighting loci relevant to PEL]	0.0	5	1	1	1
84910	1710	candidate gene hepatic nuclear factor	[candidate genes hepatic nuclear factor]	0.0	5	1	1	1
84911	1710	hormone erythropoietin Epo	[hormone erythropoietin Epo]	0.0	3	1	1	1
84912	1710	immunophenotypic correlate to the classification	[immunophenotypic correlates to the classification]	0.0	5	1	1	1
84913	1710	proliferative response to glycoprotein b	[proliferative responses to glycoprotein B]	0.0	5	1	1	1
84914	1710	level of nf kappa b	[levels of NF kappa B]	0.0	5	1	1	1
84915	1710	role in the signal pathway	[role in the signalling pathway]	0.0	5	1	1	1
84916	1710	induce differentiation with vitamin D3	[inducing differentiation with vitamin D3]	0.0	5	1	1	1
84917	1710	amount of stat5a /stat5b heterodimerization	[amounts of STAT5A /STAT5B heterodimerization]	0.0	5	1	1	1
84918	1710	affect synthesis	[affecting synthesis]	0.0	2	1	1	1
84919	1710	overexpression of RAR alpha	[overexpression of RAR alpha]	0.0	4	1	1	1
84920	1710	relationship between receptor to therapy	[Relationship between receptor to therapy]	0.0	5	1	1	1
84921	1710	marker of early event	[marker of early events]	0.0	4	1	1	1
84922	1710	use transfection	[Using transfection]	0.0	2	1	1	1
84923	1710	resection respond to salt supplementation	[resection responding to salt supplementation]	0.0	5	1	1	1
84924	1710	activation by AML1b	[activation by AML1b]	0.0	3	1	1	1
84925	1710	transcriptional regulator factor-kappaB	[transcriptional regulator factor-kappaB]	0.0	3	1	1	1
84926	1710	kilometer tumor	[kd tumor]	0.0	2	1	1	1
84927	1710	Y chromosome in ape	[Y chromosome in apes]	0.0	4	1	1	1
84928	1710	regard the clinical use	[regarding the clinical use]	0.0	4	1	1	1
84929	1710	b-lymphoid progenitor	[B-lymphoid progenitors]	0.0	2	1	1	1
84930	1710	demonstrate the potent activity of tgf-beta	[demonstrating the potent activity of TGF-beta]	0.0	6	1	1	1
84931	1710	possible mechanism underlie cell activation	[possible mechanisms underlying cell activation]	0.0	5	1	1	1
84932	1710	calcium level,	[calcium level,]	0.0	2	1	1	1
84933	1710	various probe	[various probes]	0.0	2	1	1	1
84934	1710	harbor mutation within C/EBP site	[harboring mutations within C/EBP sites]	0.0	5	1	1	1
84935	1710	nuclear ribonucleoprotein k	[nuclear ribonucleoprotein K]	0.0	3	1	1	1
84936	1710	complete respiratory burst	[complete respiratory burst]	0.0	3	1	1	1
84937	1710	various activation agent	[various activation agents]	0.0	3	1	1	1
84938	1710	control in vitro.	[controls in vitro.]	0.0	3	1	1	1
84939	1710	potential drug for disease	[potential drugs for diseases]	0.0	4	1	1	1
84940	1710	rela/nfkappab1 -binding activity	[RelA/NFkappaB1 -binding activity]	0.0	3	1	1	1
84941	1710	weak constitutive activation	[weak constitutive activation]	0.0	3	1	1	1
84942	1710	cell number, of culture,	[cell number, of culture,]	0.0	4	1	1	1
84943	1710	role of erythropoietin	[role of erythropoietin]	0.0	3	1	1	1
84944	1710	phorbol ester differentiation	[phorbol ester differentiation]	0.0	3	1	1	1
84945	1710	cortisol binding to receptor in patient	[cortisol binding to receptors in patients]	0.0	6	1	1	1
84946	1710	genetic analysis	[genetic analyses]	0.0	2	1	1	1
84947	1710	trans-activator protein bzlf1	[trans-activator protein BZLF1]	0.0	3	1	1	1
84948	1710	healthy control subject	[healthy control subjects]	0.0	3	2	2	1
84949	1710	sixth step	[sixth step]	0.0	2	1	1	1
84950	1710	demonstrate a consequence	[demonstrating a consequence]	0.0	3	1	1	1
84951	1710	little nf kappa b	[little NF kappa B]	0.0	4	1	1	1
84952	1710	b cell by stimulation	[B cells by stimulation]	0.0	4	1	1	1
84953	1710	receptor peroxisome receptor gamma	[receptor peroxisome receptor gamma]	0.0	4	1	1	1
84954	1710	differentiation implication	[differentiation implications]	0.0	2	1	1	1
84955	1710	fk506 protein	[FK506 protein]	0.0	2	1	1	1
84956	1710	indicate entry into the cycle	[indicating entry into the cycle]	0.0	5	1	1	1
84957	1710	switch from the eosinophil	[switching from the eosinophil]	0.0	4	1	1	1
84958	1710	fmol/mg protein by eia).	[fmol/mg protein by EIA).]	0.0	4	1	1	1
84959	1710	(irf) family transcription factor	[(IRF) family transcription factors]	0.0	4	1	1	1
84960	1710	tyrosine kinase receptor c-kit	[tyrosine kinase receptor c-Kit]	0.0	4	1	1	1
84961	1710	regulation in blood T cell	[regulation in blood T cells]	0.0	5	1	1	1
84962	1710	chain of receptor	[chains of receptor]	0.0	3	1	1	1
84963	1710	(2.2% of cd3+	[(2.2% of CD3+]	0.0	3	1	1	1
84964	1710	techniques: western blot	[techniques: Western blot]	0.0	3	1	1	1
84965	1710	cut-off values.	[cut-off values.]	0.0	2	1	1	1
84966	1710	suppression of t-cell immune response	[Suppression of T-cell immune responses]	0.0	5	1	1	1
84967	1710	gene encode primary granule protein ecp	[genes encoding primary granule proteins ECP]	0.0	6	1	1	1
84968	1710	mature normal myeloid cell granulocyte	[mature normal myeloid cells granulocytes]	0.0	5	1	1	1
84969	1710	e1a sequence in the respiratory epithelium	[E1a sequences in the respiratory epithelium]	0.0	6	1	1	1
84970	1710	strong binding to DNA	[strong binding to DNA]	0.0	4	1	1	1
84971	1710	MLV activity in cell line	[MLV activity in cell lines]	0.0	5	1	1	1
84972	1710	il-10 production by gp41	[IL-10 production by gp41]	0.0	4	1	1	1
84973	1710	enhancer-blocking element BEAD-1	[enhancer-blocking element BEAD-1]	0.0	3	1	1	1
84974	1710	injection of ccl4	[injection of CCl4]	0.0	3	1	1	1
84975	1710	4% mean percent	[4% mean percent]	0.0	3	1	1	1
84976	1710	peroxisome receptor-alpha	[Peroxisome receptor-alpha]	0.0	2	1	1	1
84977	1710	and/or slot blot technique	[and/or slot blot techniques]	0.0	4	1	1	1
84978	1710	element in the 0.2 kb	[elements in the 0.2 kb]	0.0	5	1	1	1
84979	1710	mosaic with regard	[mosaic with regard]	0.0	3	1	1	1
84980	1710	peripheral function	[peripheral function]	0.0	2	1	1	1
84981	1710	inhibition experiment	[inhibition experiments]	0.0	2	1	1	1
84982	1710	morphology cell with long neurite process	[morphology cells with long neurite processes]	0.0	6	1	1	1
84983	1710	b activation with inducer	[B activation with inducers]	0.0	4	1	1	1
84984	1710	hypothese concern the pathogenesis	[hypotheses concerning the pathogenesis]	0.0	4	1	1	1
84985	1710	distal site	[distal site]	0.0	2	1	1	1
84986	1710	functional differentiation marker	[functional differentiation markers]	0.0	3	1	1	1
84987	1710	interplay of protein	[interplay of proteins]	0.0	3	1	1	1
84988	1710	crossreactive recognition T lymphocyte clonotypes: implication	[Crossreactive recognition T lymphocyte clonotypes: implications]	0.0	6	1	1	1
84989	1710	binding to heterodimeric receptor	[Binding to heterodimeric receptor]	0.0	4	1	1	1
84990	1710	level of ifn-gamma secretion	[levels of IFN-gamma secretion]	0.0	4	1	1	1
84991	1710	treatment with subcytotoxic concentration	[treatments with subcytotoxic concentrations]	0.0	4	1	1	1
84992	1710	inhibitors, cyclosporin a	[inhibitors, cyclosporin A]	0.0	3	1	1	1
84993	1710	aberrant acid metabolism	[aberrant acid metabolism]	0.0	3	1	1	1
84994	1710	effect of p65	[effects of p65]	0.0	3	1	1	1
84995	1710	frequent molecular lesion	[frequent molecular lesion]	0.0	3	1	1	1
84996	1710	nf-il6 mutant	[NF-IL6 mutant]	0.0	2	1	1	1
84997	1710	distal T cell element	[distal T cell element]	0.0	4	1	1	1
84998	1710	O.J., Goldberg, a.l.,	[O.J., Goldberg, A.L.,]	0.0	3	1	1	1
84999	1710	method for assessment	[METHOD For assessment]	0.0	3	1	1	1
85000	1710	pathway during activation	[pathways during activation]	0.0	3	1	1	1
85001	1710	formation of homo- dimer	[formation of homo- dimers]	0.0	4	1	1	1
85002	1710	use the yeast system,	[using the yeast system,]	0.0	4	1	1	1
85003	1710	P. aeruginosa pak	[P. aeruginosa PAK]	0.0	3	1	1	1
85004	1710	hiv-1 gene transcription	[HIV-1 gene transcription]	0.0	3	1	1	1
85005	1710	extract of m-csf blood monocyte	[extracts of M-CSF blood monocytes]	0.0	5	1	1	1
85006	1710	regulation of interleukin	[regulation of interleukin]	0.0	3	1	1	1
85007	1710	bp -90	[bp -90]	0.0	2	1	1	1
85008	1710	activators,	[activators,]	0.0	1	1	1	1
85009	1710	two reading frame	[two reading frames]	0.0	3	3	3	1
85010	1710	means of blot	[means of blots]	0.0	3	1	1	1
85011	1710	unidentified factor present in Jurkat cell	[unidentified factors present in Jurkat cells]	0.0	6	1	1	1
85012	1710	114 patient	[114 patients]	0.0	2	1	1	1
85013	1710	inactivation of autosomal material	[inactivation of autosomal material]	0.0	4	1	1	1
85014	1710	ly294002 a inhibitor of pi3-kinase	[LY294002 a inhibitor of PI3-kinase]	0.0	5	1	1	1
85015	1710	chain-derived peptide	[chain-derived peptides]	0.0	2	1	1	1
85016	1710	mechanism underlie the diversification	[mechanism underlying the diversification]	0.0	4	1	1	1
85017	1710	largely through binding nf-kappa b	[largely through binding NF-kappa B]	0.0	5	1	1	1
85018	1710	weight of 59.5 kilometer	[weights of 59.5 kd]	0.0	4	1	1	1
85019	1710	adenovirus region 3 ES	[adenovirus region 3 ES]	0.0	4	1	1	1
85020	1710	pkc pathway	[PKC pathways]	0.0	2	1	1	1
85021	1710	Effect of intranasal glucocorticoid	[Effects of intranasal glucocorticoids]	0.0	4	1	1	1
85022	1710	t-cell-expressed cytokine gene	[T-cell-expressed cytokine genes]	0.0	3	1	1	1
85023	1710	simultaneous incubation	[simultaneous incubation]	0.0	2	1	1	1
85024	1710	transfectin experiments,	[transfectin experiments,]	0.0	2	1	1	1
85025	1710	emergence of CTL	[emergence of CTLs]	0.0	3	1	1	1
85026	1710	effect of SMX -no	[effects of SMX -NO]	0.0	4	1	1	1
85027	1710	cooperative binding of ap-1 transcription factor	[cooperative binding of AP-1 transcription factors]	0.0	6	1	1	1
85028	1710	fibrosarcoma fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
85029	1710	levels:	[levels:]	0.0	1	1	1	1
85030	1710	hydroxyurea in k562 cell differentiation	[hydroxyurea in K562 cells differentiation]	0.0	5	1	1	1
85031	1710	developments, include the identification	[developments, including the identification]	0.0	4	1	1	1
85032	1710	phase of the cycle	[phases of the cycle]	0.0	4	1	1	1
85033	1710	Sp1 -related factor	[Sp1 -related factor]	0.0	3	1	1	1
85034	1710	cytokine-stimulated vein endothelial cell	[cytokine-stimulated vein endothelial cells]	0.0	4	1	1	1
85035	1710	complete tolerance for tcf-1	[complete tolerance for TCF-1]	0.0	4	1	1	1
85036	1710	signal-coupled depletion	[signal-coupled depletion]	0.0	2	1	1	1
85037	1710	myristylation	[myristylation]	0.0	1	1	1	1
85038	1710	result in the absence of activity	[resulting in the absence of activity]	0.0	6	1	1	1
85039	1710	signal in precursor	[signaling in precursors]	0.0	3	1	1	1
85040	1710	human nf-kappa b	[human NF-kappa B]	0.0	3	1	1	1
85041	1710	biochemical mechanism regulate apoptosis	[biochemical mechanisms regulating apoptosis]	0.0	4	1	1	1
85042	1710	combination gc	[combinations GC]	0.0	2	1	1	1
85043	1710	il-12 mip-1alpha	[IL-12 MIP-1alpha]	0.0	2	1	1	1
85044	1710	mature, b cell	[mature, B cells]	0.0	3	1	1	1
85045	1710	value of acth	[values of ACTH]	0.0	3	1	1	1
85046	1710	modulate the expression of gene	[modulating the expression of genes]	0.0	5	1	1	1
85047	1710	dexamethasone of endotoxin inflammation	[dexamethasone of endotoxin inflammation]	0.0	4	1	1	1
85048	1710	unexpectedly, expression of another viral protein	[unexpectedly, expression of another viral protein]	0.0	6	1	1	1
85049	1710	partial functional disomy	[partial functional disomy]	0.0	3	1	1	1
85050	1710	presumably occur	[presumably occurring]	0.0	2	1	1	1
85051	1710	case of leukemia CLL	[cases of leukemia CLL]	0.0	4	1	1	1
85052	1710	tcr-beta/tcr-delta	[TCR-beta/TCR-delta]	0.0	1	1	1	1
85053	1710	regulation of proenkephalin by JunD effect	[regulation of proenkephalin by JunD effects]	0.0	6	1	1	1
85054	1710	crosslinker	[crosslinker]	0.0	1	1	1	1
85055	1710	export nfat factor of T cell	[export NFAT factor of T cells]	0.0	6	1	1	1
85056	1710	nfat-1 element	[NFAT-1 element]	0.0	2	1	1	1
85057	1710	result in protein	[resulting in proteins]	0.0	3	1	1	1
85058	1710	(range, 6.18 (range, 5.86-6.74) nm,	[(range, 6.18 (range, 5.86-6.74) nM,]	0.0	5	1	1	1
85059	1710	ap3-l site	[AP3-L site]	0.0	2	1	1	1
85060	1710	existence of kappa binding factor	[existence of kappa binding factors]	0.0	5	1	1	1
85061	1710	ap-1 -binding activity in cell	[AP-1 -binding activity in cells]	0.0	5	1	1	1
85062	1710	histocompatibility class ii transactivator	[histocompatibility class II transactivator]	0.0	4	1	1	1
85063	1710	region of b cell-specific gene	[regions of B cell-specific genes]	0.0	5	1	1	1
85064	1710	peripheral blood mononuclear precursor	[peripheral blood mononuclear precursors]	0.0	4	1	1	1
85065	1710	pbmc from subject	[PBMC from subjects]	0.0	3	1	1	1
85066	1710	factor of nadph oxidase	[factor of NADPH oxidase]	0.0	4	1	1	1
85067	1710	function in this process	[function in these processes]	0.0	4	1	1	1
85068	1710	are: helper-inducer (memory) T cell	[are: helper-inducer (memory) T cells]	0.0	5	1	1	1
85069	1710	development of complication	[development of complications]	0.0	3	1	1	1
85070	1710	stores.	[stores.]	0.0	1	1	1	1
85071	1710	initial program	[initial program]	0.0	2	1	1	1
85072	1710	b cell in thymus	[B cells in thymus]	0.0	4	1	1	1
85073	1710	domain of granulocyte-macrophage colony-stimumulatelany-stg factor	[domain of granulocyte-macrophage colony-stimulating factor]	0.0	5	1	1	1
85074	1710	polymorphonuclear leukocyte bind	[polymorphonuclear leukocytes binding]	0.0	3	1	1	1
85075	1710	expression of a thymocyte-specific gene	[expression of an thymocyte-specific gene]	0.0	5	1	1	1
85076	1710	eosinophil-depleted leukocyte	[Eosinophil-depleted leukocytes]	0.0	2	1	1	1
85077	1710	stimulus of the microenvironment	[stimuli of the microenvironment]	0.0	4	1	1	1
85078	1710	repression of globin	[repression of globin]	0.0	3	1	1	1
85079	1710	induce CAT activity 2) fibrinogen /mn2+	[inducing CAT activity 2) fibrinogen /Mn2+]	0.0	6	1	1	1
85080	1710	regulatory property of leukemia factor	[regulatory properties of leukemia factor]	0.0	5	1	1	1
85081	1710	tool for diagnosis	[tool for diagnosis]	0.0	3	1	1	1
85082	1710	C3a(desArg) lps mrna level	[C3a(desArg) LPS mRNA levels]	0.0	4	1	1	1
85083	1710	understanding of the pathway	[understanding of the pathways]	0.0	4	1	1	1
85084	1710	hypothesis key factor	[hypothesis key factors]	0.0	3	1	1	1
85085	1710	responsiveness of human leukocyte	[responsiveness of human leukocytes]	0.0	4	1	1	1
85086	1710	small deletion hotspot	[small deletion hotspot]	0.0	3	1	1	1
85087	1710	transcriptional nuclear factor-KB	[transcriptional nuclear factor-KB]	0.0	3	1	1	1
85088	1710	link between the il-2 teceptor	[link between the IL-2 teceptor]	0.0	5	1	1	1
85089	1710	inducible expression of coactivator bob.1/obf.1	[Inducible expression of coactivator BOB.1/OBF.1]	0.0	5	1	1	1
85090	1710	fibrosarcoma 8, malignant histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma 8, malignant histiocytoma 6, rhabdomyosarcoma]	0.0	6	1	1	1
85091	1710	primitive ones.	[primitive ones.]	0.0	2	1	1	1
85092	1710	repeat of human immunodeficiency virus	[repeat of human immunodeficiency virus]	0.0	5	1	1	1
85093	1710	two piece	[Two pieces]	0.0	2	1	1	1
85094	1710	N terminus with Erk	[N terminus with Erk]	0.0	4	1	1	1
85095	1710	low level of xenobiotic response activity	[low levels of xenobiotic response activity]	0.0	6	1	1	1
85096	1710	similar form	[similar forms]	0.0	2	1	1	1
85097	1710	as blood histamine	[as blood histamine]	0.0	3	1	1	1
85098	1710	single tal1 allele	[single TAL1 allele]	0.0	3	1	1	1
85099	1710	cellular immunoreaction	[cellular immunoreactions]	0.0	2	1	1	1
85100	1710	b cell-specific coactivator protein	[B cell-specific coactivator protein]	0.0	4	1	1	1
85101	1710	action of fgf-1	[action of FGF-1]	0.0	3	1	1	1
85102	1710	(approximately kd)	[(approximately kD)]	0.0	2	1	1	1
85103	1710	resemble factor of T cell NF-AT	[resembling factor of T cells NF-AT]	0.0	6	1	1	1
85104	1710	detection of adenovirus DNA	[Detection of adenovirus DNA]	0.0	4	2	2	1
85105	1710	subclone of the variant	[Subcloning of the variant]	0.0	4	1	1	1
85106	1710	Clinical outcome in carcinoma	[Clinical outcome in carcinoma]	0.0	4	1	1	1
85107	1710	cyclosporin a-sensitive factor-AT response element	[cyclosporin A-sensitive factor-AT response element]	0.0	5	1	1	1
85108	1710	basic (bhlh) protein e2a	[basic (bHLH) protein E2A]	0.0	4	1	1	1
85109	1710	accessory gene	[accessory genes]	0.0	2	1	1	1
85110	1710	least two pathway essential	[least two pathways essential]	0.0	4	1	1	1
85111	1710	unrecognized binding site	[unrecognized binding site]	0.0	3	1	1	1
85112	1710	expression of the signal transducer	[expression of the signal transducer]	0.0	5	1	1	1
85113	1710	sole basis	[sole basis]	0.0	2	1	1	1
85114	1710	develop nervous system CNS	[developing nervous system CNS]	0.0	4	1	1	1
85115	1710	T cell interleukin-2	[T cell interleukin-2]	0.0	3	1	1	1
85116	1710	ARH77 cell	[ARH77 cells]	0.0	2	1	1	1
85117	1710	upstream of a NF-AT site	[upstream of an NF-AT site]	0.0	5	1	1	1
85118	1710	survey in malignancy	[survey in malignancies]	0.0	3	1	1	1
85119	1710	hiv disease	[HIV disease]	0.0	2	1	1	1
85120	1710	phosphorylation of the inhibitor	[Phosphorylation of the inhibitor]	0.0	4	1	1	1
85121	1710	element within the region	[elements within the region]	0.0	4	1	1	1
85122	1710	monocyte differentiation into cell	[monocyte differentiation into cells]	0.0	4	1	1	1
85123	1710	p21ras signal act	[p21ras signals acting]	0.0	3	1	1	1
85124	1710	in-vitro cleavage	[In-vitro cleavage]	0.0	2	1	1	1
85125	1710	noncode region	[noncoding region]	0.0	2	1	1	1
85126	1710	rat fibroblast ref52 cell	[rat fibroblast REF52 cells]	0.0	4	1	1	1
85127	1710	il-4-induced tyrosine phosphorylation of substrate in	[IL-4-induced tyrosine phosphorylation of substrates in]	0.0	6	1	1	1
85128	1710	over-expression by stable transfection	[over-expression by stable transfection]	0.0	4	1	1	1
85129	1710	Ras RasN17	[Ras RasN17]	0.0	2	1	1	1
85130	1710	various glucocorticoid	[various glucocorticoids]	0.0	2	1	1	1
85131	1710	surrogate for the study	[surrogates for the study]	0.0	4	1	1	1
85132	1710	important b co-activator of A-MYB	[important B co-activator of A-MYB]	0.0	5	1	1	1
85133	1710	great proliferation rate	[greater proliferation rate]	0.0	3	1	1	1
85134	1710	exposure to tpo	[exposure to TPO]	0.0	3	1	1	1
85135	1710	two main activity of glucocorticoid	[two main activities of glucocorticoids]	0.0	5	1	1	1
85136	1710	express receptor (tcr) region beta-chain family	[expressing receptor (TCR) region beta-chain families]	0.0	6	1	1	1
85137	1710	time course analysis of egr-1 expression	[time course analysis of Egr-1 expression]	0.0	6	1	1	1
85138	1710	ccaat/enhancer-binding protein	[CCAAT/enhancer-binding protein]	0.0	2	1	1	1
85139	1710	factor (NF)-AT proximal NF-AT AP-1/Octamer	[factor (NF)-AT proximal NF-AT AP-1/Octamer]	0.0	5	1	1	1
85140	1710	blood cell use dexamethasone	[blood cells using dexamethasone]	0.0	4	1	1	1
85141	1710	T-helper th0 subset	[T-helper Th0 subset]	0.0	3	1	1	1
85142	1710	vary time of exposure	[varying times of exposure]	0.0	4	1	1	1
85143	1710	possible role in proliferation of cell	[Possible roles in proliferation of cells]	0.0	6	1	1	1
85144	1710	new potential	[new potential]	0.0	2	1	1	1
85145	1710	related cell type	[related cell types]	0.0	3	1	1	1
85146	1710	development of immunosuppressive therapy	[development of immunosuppressive therapies]	0.0	4	1	1	1
85147	1710	kb downstream from the polyadenylation site	[kb downstream from the polyadenylation site]	0.0	6	1	1	1
85148	1710	transactivation of the IL-2 promoter	[transactivation of the IL-2 promoter]	0.0	5	1	1	1
85149	1710	endogenous repeat activity	[endogenous repeat activity]	0.0	3	1	1	1
85150	1710	constitutive presence	[constitutive presence]	0.0	2	1	1	1
85151	1710	addition to the protein Oct-1	[addition to the proteins Oct-1]	0.0	5	1	1	1
85152	1710	hcmv immunoglobulin g-seropositive donor	[HCMV immunoglobulin G-seropositive donors]	0.0	4	1	1	1
85153	1710	regulate a critical b cell-specific gene	[regulating a critical B cell-specific gene]	0.0	6	1	1	1
85154	1710	lack of feature	[lack of features]	0.0	3	1	1	1
85155	1710	small tail	[small tail]	0.0	2	1	1	1
85156	1710	CsA blood concentration	[CsA blood concentrations]	0.0	3	1	1	1
85157	1710	deletion of the Sp site	[Deletion of the Sp sites]	0.0	5	1	1	1
85158	1710	two phenotypically distinct type	[two phenotypically distinct types]	0.0	4	1	1	1
85159	1710	IL-1beta stimulation of cell	[IL-1beta stimulation of cells]	0.0	4	1	1	1
85160	1710	high-level replication of human immunodeficiency virus	[High-level replication of human immunodeficiency virus]	0.0	6	1	1	1
85161	1710	IK stably	[IK stably]	0.0	2	1	1	1
85162	1710	progeny of human progenitor	[progeny of human progenitors]	0.0	4	1	1	1
85163	1710	encode a regulator of differentiation	[encoding a regulator of differentiation]	0.0	5	1	1	1
85164	1710	globular, structure distinct from the structure	[globular, structures distinct from the structures]	0.0	6	1	1	1
85165	1710	high concentration of NE	[high concentration of NE]	0.0	4	1	1	1
85166	1710	deletion region of the hbd fragment	[Deletions region of the HBD fragment]	0.0	6	1	1	1
85167	1710	h of stimulation with 8-bromo-cAMP	[h of stimulation with 8-bromo-cAMP]	0.0	5	1	1	1
85168	1710	lps induction of the TF promoter	[LPS induction of the TF promoter]	0.0	6	1	1	1
85169	1710	cell line represent pro-B	[cell lines representing pro-B]	0.0	4	1	1	1
85170	1710	several malignant b-cell line	[several malignant B-cell lines]	0.0	4	1	1	1
85171	1710	functional fashion.	[functional fashion.]	0.0	2	1	1	1
85172	1710	1,25-dihydroxyvitamin D2	[1,25-dihydroxyvitamin D2]	0.0	2	1	1	1
85173	1710	subline cell from patient	[sublining cells from patients]	0.0	4	1	1	1
85174	1710	E2F complex in haemopoietic cell	[E2F complex in haemopoietic cells]	0.0	5	1	1	1
85175	1710	DNA for human irf-2 gene	[DNA for human IRF-2 gene]	0.0	5	1	1	1
85176	1710	effect of nac	[effect of NAC]	0.0	3	1	1	1
85177	1710	(il)-1beta	[(IL)-1beta]	0.0	1	1	1	1
85178	1710	hla-dq class	[HLA-DQ class]	0.0	2	1	1	1
85179	1710	b2 gene	[B2 gene]	0.0	2	1	1	1
85180	1710	complete activation	[complete activation]	0.0	2	1	1	1
85181	1710	very efficient precursor in culture.	[very efficient precursors in culture.]	0.0	5	1	1	1
85182	1710	expression with kinetic a finding	[expression with kinetics a finding]	0.0	5	1	1	1
85183	1710	related disorder involve differentiation	[related disorders involving differentiation]	0.0	4	1	1	1
85184	1710	little effect either on the promoter	[little effect either on the promoter]	0.0	6	1	1	1
85185	1710	link between product	[link between products]	0.0	3	1	1	1
85186	1710	myelomonocytic cell line enhancement	[myelomonocytic cell line enhancement]	0.0	4	1	1	1
85187	1710	exposure at a dose rate	[exposure at a dose rate]	0.0	5	1	1	1
85188	1710	EBV product	[EBV product]	0.0	2	1	1	1
85189	1710	activation the gene promoter	[activation the gene promoter]	0.0	4	1	1	1
85190	1710	two binding protein (85 kD	[two binding proteins (85 kD]	0.0	5	1	1	1
85191	1710	two noncontiguous region	[two noncontiguous regions]	0.0	3	1	1	1
85192	1710	evening exposure	[evening exposure]	0.0	2	1	1	1
85193	1710	cn inhibition in human leukocyte	[CN inhibition in human leukocytes]	0.0	5	1	1	1
85194	1710	Retinoic acid a vitamin a derivative	[Retinoic acid a vitamin A derivative]	0.0	6	1	1	1
85195	1710	CD40-stimulated b cell	[CD40-stimulated B cells]	0.0	3	1	1	1
85196	1710	achieve efficient ebv activation	[achieving efficient EBV activation]	0.0	4	1	1	1
85197	1710	silencer mechanism	[silencer mechanism]	0.0	2	1	1	1
85198	1710	dna-binding study	[DNA-binding studies]	0.0	2	1	1	1
85199	1710	mononuclear leucocyte recruitment across endothelium	[mononuclear leucocyte recruitment across endothelium]	0.0	5	1	1	1
85200	1710	productive replicative form	[productive replicative form]	0.0	3	1	1	1
85201	1710	transcription factor-kappa b	[transcription factor-kappa B]	0.0	3	1	1	1
85202	1710	lipophilic substance such as bacterial formylpeptide	[lipophilic substances such as bacterial formylpeptides]	0.0	6	1	1	1
85203	1710	express histocompatibility complex (mhc) class gene	[expressing histocompatibility complex (MHC) class genes]	0.0	6	1	1	1
85204	1710	variety of species,	[variety of species,]	0.0	3	1	1	1
85205	1710	cysteine -rich region LIM domain	[cysteine -rich regions LIM domains]	0.0	5	1	1	1
85206	1710	consequence of mrna stabilization event	[consequence of mRNA stabilization events]	0.0	5	1	1	1
85207	1710	3 hour of cross-linking.	[3 hours of cross-linking.]	0.0	4	1	1	1
85208	1710	negative correlation,	[negative correlation,]	0.0	2	1	1	1
85209	1710	activation of cd95 ligand	[activation of CD95 ligand]	0.0	4	1	1	1
85210	1710	17-bp sequence	[17-bp sequence]	0.0	2	1	1	1
85211	1710	critical early event	[critical early event]	0.0	3	1	1	1
85212	1710	core of hs-40	[core of HS-40]	0.0	3	1	1	1
85213	1710	hematopoietic tyrosine	[hematopoietic tyrosine]	0.0	2	1	1	1
85214	1710	protein in normal T cell	[proteins in normal T cells]	0.0	5	1	1	1
85215	1710	biological significance in carcinogenesis	[biological significance in carcinogenesis]	0.0	4	1	1	1
85216	1710	antigen EBNA	[antigen EBNA]	0.0	2	2	2	1
85217	1710	receptor/progesterone receptor	[receptor/progesterone receptor]	0.0	2	1	1	1
85218	1710	transcription involvement	[transcription involvement]	0.0	2	1	1	1
85219	1710	two domain of the interaction	[two domains of the interaction]	0.0	5	1	1	1
85220	1710	any, basal activity a activator	[any, basal activity a activator]	0.0	5	1	1	1
85221	1710	ultimate outcome	[ultimate outcome]	0.0	2	1	1	1
85222	1710	methyl prednisolone mg/day)	[methyl prednisolone mg/day)]	0.0	3	1	1	1
85223	1710	factor critical to hiv-1 replication	[factors critical to HIV-1 replication]	0.0	5	1	1	1
85224	1710	(five patient with 0.5 microgram/day	[(five patients with 0.5 microgram/day]	0.0	5	1	1	1
85225	1710	erythropoietic culture	[erythropoietic cultures]	0.0	2	1	1	1
85226	1710	difference in the spectra	[differences in the spectra]	0.0	4	1	1	1
85227	1710	anti-mouse	[anti-mouse]	0.0	1	1	1	1
85228	1710	DNase I site mapping	[DNase I site mapping]	0.0	4	1	1	1
85229	1710	partial disomy of sequence on xp	[partial disomy of sequences on Xp]	0.0	6	1	1	1
85230	1710	delay of P.	[delay of h.]	0.0	3	1	1	1
85231	1710	protein of the lymphoid system	[protein of the lymphoid system]	0.0	5	1	1	1
85232	1710	primary involvement of type	[primary involvement of Type]	0.0	4	1	1	1
85233	1710	uptake with renal failure	[uptake with renal failure]	0.0	4	1	1	1
85234	1710	activity of twhf extract	[activity of TWHf extract]	0.0	4	1	1	1
85235	1710	lymphatic leukemia to combination chemotherapy	[lymphatic leukemia to combination chemotherapy]	0.0	5	1	1	1
85236	1710	2 h up to 250-fold	[2 h up to 250-fold]	0.0	5	1	1	1
85237	1710	very high amount	[very high amounts]	0.0	3	1	1	1
85238	1710	16-18 h. treatment of cell	[16-18 h, treatment of cells]	0.0	5	1	1	1
85239	1710	cr of gr in leukocyte	[CR of GR in leukocytes]	0.0	5	1	1	1
85240	1710	characterization of gelatinase granule	[characterization of gelatinase granules]	0.0	4	1	1	1
85241	1710	expression Oct2	[expression Oct2]	0.0	2	1	1	1
85242	1710	lineage development	[lineage development]	0.0	2	1	1	1
85243	1710	minimal cell-specific enhancer	[minimal cell-specific enhancer]	0.0	3	1	1	1
85244	1710	diabete diabete of the young	[diabetes diabetes of the young]	0.0	5	1	1	1
85245	1710	cell in hematopoietic lineage	[cells in hematopoietic lineage]	0.0	4	1	1	1
85246	1710	Northern blot analysis on tissue	[Northern blot analysis on tissues]	0.0	5	1	1	1
85247	1710	antibody bz1 to BZLF1	[antibody BZ1 to BZLF1]	0.0	4	1	1	1
85248	1710	platelet nmol	[platelets nmol]	0.0	2	1	1	1
85249	1710	even dose of ionizing radiation gy	[even doses of ionizing radiation Gy]	0.0	6	1	1	1
85250	1710	detectable ad e1a sequence	[detectable Ad E1a sequences]	0.0	4	1	1	1
85251	1710	inhibition of growth through adenosine triphosphate	[inhibition of growth through adenosine triphosphate]	0.0	6	1	1	1
85252	1710	14 normal subject	[14 normal subjects]	0.0	3	1	1	1
85253	1710	cellular activation in EL4 cell	[cellular activation in EL4 cells]	0.0	5	1	1	1
85254	1710	polypeptide product	[polypeptide product]	0.0	2	1	1	1
85255	1710	kappay element	[kappaY element]	0.0	2	1	1	1
85256	1710	basal activity in fibroblast	[basal activity in fibroblasts]	0.0	4	1	1	1
85257	1710	presence nuclear factor	[presence nuclear factor]	0.0	3	1	1	1
85258	1710	same signal requirement	[same signaling requirements]	0.0	3	1	1	1
85259	1710	report of NFAT	[report of NFAT]	0.0	3	1	1	1
85260	1710	rapid up-regulation of rp1 mrna	[rapid up-regulation of RP1 mRNA]	0.0	5	1	1	1
85261	1710	several criteria, include tyrosine phosphorylation	[several criteria, including tyrosine phosphorylation]	0.0	5	1	1	1
85262	1710	c/ebp beta staining	[C/EBP beta staining]	0.0	3	1	1	1
85263	1710	one transcription factor in h-rs cell	[one transcription factor in H-RS cells]	0.0	6	1	1	1
85264	1710	CD3(+),	[CD3(+),]	0.0	1	1	1	1
85265	1710	overexpression of calcineurin	[overexpression of calcineurin]	0.0	3	1	1	1
85266	1710	gata regulatory element of hiv-1 repeat	[GATA regulatory elements of HIV-1 repeat]	0.0	6	1	1	1
85267	1710	NF-kappa b localization	[NF-kappa B localization]	0.0	3	1	1	1
85268	1710	intact platelet	[intact platelets]	0.0	2	1	1	1
85269	1710	human granulocyte-macrophage CSF gene	[human granulocyte-macrophage CSF gene]	0.0	4	1	1	1
85270	1710	(also in endothelial cell	[(also in endothelial cells]	0.0	4	1	1	1
85271	1710	(p 0.05, p 0.01	[(P 0.05, P 0.01]	0.0	4	1	1	1
85272	1710	presenter of antigen in lymphocyte reaction	[presenters of antigen in lymphocyte reactions]	0.0	6	1	1	1
85273	1710	gene protein	[gene proteins]	0.0	2	1	1	1
85274	1710	high capacity of cell	[high capacity of cells]	0.0	4	1	1	1
85275	1710	effect during lung inflammatory injury	[effects during lung inflammatory injury]	0.0	5	1	1	1
85276	1710	tr75 surface	[TR75 surface]	0.0	2	1	1	1
85277	1710	cell particularly T cell	[cells particularly T cells]	0.0	4	1	1	1
85278	1710	RNA -dependent protein kinase	[RNA -dependent protein kinase]	0.0	4	1	1	1
85279	1710	high load	[high load]	0.0	2	1	1	1
85280	1710	expression gene in T lymphocyte	[expression genes in T lymphocytes]	0.0	5	1	1	1
85281	1710	internal site	[internal sites]	0.0	2	1	1	1
85282	1710	activator induce a cytokine cascade	[activator inducing a cytokine cascade]	0.0	5	1	1	1
85283	1710	control the competence	[controlling the competence]	0.0	3	1	1	1
85284	1710	pse of rna polymerase	[PSE of RNA polymerase]	0.0	4	1	1	1
85285	1710	assembly of adhesion	[assembly of adhesions]	0.0	3	1	1	1
85286	1710	cell population capable	[cell population capable]	0.0	3	1	1	1
85287	1710	hiv-1 iiib	[HIV-1 IIIB]	0.0	2	1	1	1
85288	1710	use a CD20 monoclonal antibody	[using an CD20 monoclonal antibody]	0.0	5	1	1	1
85289	1710	follow a injection	[following an injection]	0.0	3	1	1	1
85290	1710	arrest this immune response with agent	[arresting this immune response with agents]	0.0	6	1	1	1
85291	1710	NF-kappa B family	[NF-kappa B family]	0.0	3	3	3	1
85292	1710	low range ppt tcdd	[lower range ppt TCDD]	0.0	4	1	1	1
85293	1710	pharmacogenetic syndrome	[pharmacogenetic syndrome]	0.0	2	1	1	1
85294	1710	different gc at concentration	[different GC at concentrations]	0.0	4	1	1	1
85295	1710	survival factor for T cell	[survival factors for T cells]	0.0	5	1	1	1
85296	1710	herpesvirus 6 hhv-6 strain	[herpesvirus 6 HHV-6 strains]	0.0	4	1	1	1
85297	1710	level in U-937	[levels in U-937]	0.0	3	1	1	1
85298	1710	suffer from telangiectasia	[suffering from telangiectasia]	0.0	3	1	1	1
85299	1710	ligation by specific abs ligand	[Ligation by specific Abs ligand]	0.0	5	1	1	1
85300	1710	high level capable of binding	[higher levels capable of binding]	0.0	5	1	1	1
85301	1710	use digestion	[using digestion]	0.0	2	1	1	1
85302	1710	abnormality by classical metaphase analysis	[abnormalities by classical metaphase analysis]	0.0	5	1	1	1
85303	1710	population of T lymphocyte	[population of T lymphocytes]	0.0	4	1	1	1
85304	1710	bifunctional role on gr activation	[bifunctional role on GR activation]	0.0	5	1	1	1
85305	1710	62 (ie62) protein	[62 (IE62) protein]	0.0	3	1	1	1
85306	1710	manifestation of hiv-1	[manifestations of HIV-1]	0.0	3	1	1	1
85307	1710	2-hydroxy-4-trifluoromethylbenzoic acid	[2-hydroxy-4-trifluoromethylbenzoic acid]	0.0	2	1	1	1
85308	1710	likely cause of cortisol resistance	[likely cause of cortisol resistance]	0.0	5	1	1	1
85309	1710	primitive hpc colony-forming cell hppecfcs	[primitive HPCs colony-forming cells HPP-CFCs]	0.0	5	1	1	1
85310	1710	STAT regulatory factor	[STAT regulatory factor]	0.0	3	1	1	1
85311	1710	binding affinity RBA the high	[binding affinities RBA the highest]	0.0	5	1	1	1
85312	1710	mu/l concentration	[mU/L concentration]	0.0	2	1	1	1
85313	1710	-236/-145 e2re	[-236/-145 E2RE]	0.0	2	1	1	1
85314	1710	nuclear nf-at complex to NF-ATp	[nuclear NF-AT complexes to NF-ATp]	0.0	5	1	1	1
85315	1710	activation of a nuclear factor	[activation of a nuclear factor]	0.0	5	1	1	1
85316	1710	g-->t transversion	[G-->T transversion]	0.0	2	1	1	1
85317	1710	also a site for c-Myc	[also a site for c-Myc]	0.0	5	1	1	1
85318	1710	effector gene product	[effector gene products]	0.0	3	1	1	1
85319	1710	regulator of c-myb expression	[regulator of c-myb expression]	0.0	4	1	1	1
85320	1710	Rex production	[Rex production]	0.0	2	1	1	1
85321	1710	so-called element AREs	[so-called elements AREs]	0.0	3	1	1	1
85322	1710	b cell with il-6	[B cells with IL-6]	0.0	4	1	1	1
85323	1710	b cell with il-7	[B cells with IL-7]	0.0	4	1	1	1
85324	1710	EBNA2 -dependent synthesis of mrna	[EBNA2 -dependent synthesis of mRNA]	0.0	5	1	1	1
85325	1710	cell line NIH	[cell lines NIH]	0.0	3	1	1	1
85326	1710	Differential inhibition of Smad6	[Differential inhibition of Smad6]	0.0	4	1	1	1
85327	1710	u937 IFN-U937 cell	[U937 IFN-U937 cells]	0.0	3	1	1	1
85328	1710	maintenance without integration	[maintenance without integration]	0.0	3	1	1	1
85329	1710	component of KV current	[components of KV current]	0.0	4	1	1	1
85330	1710	complement of mouse globin gene	[complement of mouse globin genes]	0.0	5	1	1	1
85331	1710	155 residue	[155 residues]	0.0	2	1	1	1
85332	1710	activation, T	[activation, T]	0.0	2	1	1	1
85333	1710	thymocyte subpopulation	[thymocyte subpopulation]	0.0	2	1	1	1
85334	1710	activate protein-1 bind tpa element	[Activating protein-1 binding TPA elements]	0.0	5	1	1	1
85335	1710	level of nuclear nf-atp	[levels of nuclear NF-ATp]	0.0	4	1	1	1
85336	1710	time of about 25 h	[times of about 25 h]	0.0	5	1	1	1
85337	1710	receptor in long-distance runner	[receptor in long-distance runner]	0.0	4	1	1	1
85338	1710	removal encompass all	[removal encompassing all]	0.0	3	1	1	1
85339	1710	cell signal pathway	[cell signaling pathways]	0.0	3	1	1	1
85340	1710	prostaglandin I2 a strong regulator	[prostaglandin I2 a strong regulator]	0.0	5	1	1	1
85341	1710	element of terminal repeat	[elements of terminal repeats]	0.0	4	1	1	1
85342	1710	FAB type	[FAB types]	0.0	2	1	1	1
85343	1710	Epstein-Barr nuclear antigen	[Epstein-Barr nuclear antigen]	0.0	3	1	1	1
85344	1710	biphasic, produce stimulation	[biphasic, producing stimulation]	0.0	3	1	1	1
85345	1710	stimulation, il-5 production	[stimulation, IL-5 production]	0.0	3	1	1	1
85346	1710	moderate number	[moderate numbers]	0.0	2	1	1	1
85347	1710	difference between solution	[difference between solution]	0.0	3	1	1	1
85348	1710	repeat (ltr) region	[repeat (LTR) region]	0.0	3	1	1	1
85349	1710	early lytic cycle protein	[early lytic cycle proteins]	0.0	4	1	1	1
85350	1710	feature suggestive	[features suggestive]	0.0	2	1	1	1
85351	1710	cell function,	[cell function,]	0.0	2	1	1	1
85352	1710	vivo modulation of receptor mrna	[vivo modulation of receptor mRNA]	0.0	5	1	1	1
85353	1710	induction of acute phase protein	[induction of acute phase proteins]	0.0	5	1	1	1
85354	1710	role PMA differentiation	[role PMA differentiation]	0.0	3	1	1	1
85355	1710	interaction with effector protein	[interaction with effector proteins]	0.0	4	1	1	1
85356	1710	peak activity	[Peak activity]	0.0	2	1	1	1
85357	1710	prevention by cell	[prevention by cells]	0.0	3	1	1	1
85358	1710	oxidant hypochlorous acid 1 mm)	[oxidant hypochlorous acid 1 mM)]	0.0	5	1	1	1
85359	1710	control (10%, p less	[controls (10%, P less]	0.0	4	1	1	1
85360	1710	contrast, rac	[contrast, Rac]	0.0	2	1	1	1
85361	1710	role 3-kinase activation of epf	[role 3-kinase activation of E2Fs]	0.0	5	1	1	1
85362	1710	role of BHRF1 against apoptosis	[role of BHRF1 against apoptosis]	0.0	5	1	1	1
85363	1710	behavior of the majority	[behavior of the majority]	0.0	4	1	1	1
85364	1710	use zebra protein as antigen	[using ZEBRA protein as antigens]	0.0	5	1	1	1
85365	1710	sodium diclofenac	[sodium diclofenac]	0.0	2	1	1	1
85366	1710	determinant process of differentiation	[determinant processes of differentiation]	0.0	4	1	1	1
85367	1710	(outer limits, 127 to 283),	[(outer limits, 127 to 283),]	0.0	5	1	1	1
85368	1710	acetylation of erythroid factor activity	[Acetylation of erythroid factor activity]	0.0	5	1	1	1
85369	1710	addition, activity	[addition, activity]	0.0	2	1	1	1
85370	1710	level of receptor in lymphocyte	[levels of receptors in lymphocytes]	0.0	5	1	1	1
85371	1710	physical signal pathway	[physical signaling pathways]	0.0	3	1	1	1
85372	1710	Egr-1/ Sp1 site	[Egr-1/ Sp1 site]	0.0	3	1	1	1
85373	1710	rank induction of NF-kappaB	[RANK induction of NF-kappaB]	0.0	4	1	1	1
85374	1710	failure A-CRF with insufficiency	[failure A-CRF with insufficiency]	0.0	4	1	1	1
85375	1710	contain a gata-factor gata-1	[containing a GATA-factor GATA-1]	0.0	4	1	1	1
85376	1710	total mrna in lymphocyte	[total mRNA in lymphocytes]	0.0	4	1	1	1
85377	1710	sodium in patient with hypertension	[sodium in patients with hypertension]	0.0	5	1	1	1
85378	1710	respectively, reflect the level	[respectively, reflecting the levels]	0.0	4	1	1	1
85379	1710	factor hnf3 beta	[factor HNF3 beta]	0.0	3	1	1	1
85380	1710	viral isolate	[viral isolates]	0.0	2	1	1	1
85381	1710	family form	[families: forms]	0.0	2	1	1	1
85382	1710	lipoprotein modulation of nf-kappab activity	[lipoprotein modulation of NF-kappaB activity]	0.0	5	1	1	1
85383	1710	bronchial cell BEAS-2B	[bronchial cells BEAS-2B]	0.0	3	1	1	1
85384	1710	role in beta-cell function	[role in beta-cell function]	0.0	4	1	1	1
85385	1710	other intracellular signal protein	[other intracellular signaling proteins]	0.0	4	1	1	1
85386	1710	principal protein	[principal protein]	0.0	2	1	1	1
85387	1710	general octamer site transcription	[general octamer site transcription]	0.0	4	1	1	1
85388	1710	two family acid receptor	[two families acid receptors]	0.0	4	1	1	1
85389	1710	direct expression	[directing expression]	0.0	2	1	1	1
85390	1710	prb modification	[pRB modification]	0.0	2	1	1	1
85391	1710	background: acid	[BACKGROUND: acid]	0.0	2	1	1	1
85392	1710	hotspot for ifngr1 deletion	[hotspot for IFNGR1 deletions]	0.0	4	1	1	1
85393	1710	expression integrin	[expression integrins]	0.0	2	1	1	1
85394	1710	two 9-bp motif (-90/-82	[two 9-bp motifs (-90/-82]	0.0	4	1	1	1
85395	1710	involvement in nf-kappa b activation	[Involvement in NF-kappa B activation]	0.0	5	1	1	1
85396	1710	regulation of receptor effect	[Regulation of receptors effects]	0.0	4	1	1	1
85397	1710	distribution of the e-selectin	[distribution of the E-selectin]	0.0	4	1	1	1
85398	1710	cells, include precursor	[cells, including precursors]	0.0	3	1	1	1
85399	1710	use mobility shift assay in pbmc	[using mobility shift assays in PBMC]	0.0	6	1	1	1
85400	1710	protein tyrosine kinase(s)	[protein tyrosine kinase(s)]	0.0	3	1	1	1
85401	1710	Arnicae	[Arnicae]	0.0	1	1	1	1
85402	1710	limitation to potential antiviral effect	[limitation to potential antiviral effects]	0.0	5	1	1	1
85403	1710	modification of sulfhydryl group	[modification of sulfhydryl groups]	0.0	4	1	1	1
85404	1710	approach to the study of aspect	[approaches to the study of aspects]	0.0	6	1	1	1
85405	1710	critical c-myb binding site	[critical c-Myb binding site]	0.0	4	1	1	1
85406	1710	natural dominant HLH factor Id3	[natural dominant HLH factor Id3]	0.0	5	1	1	1
85407	1710	posttranscriptionally by DOX	[posttranscriptionally by DOX]	0.0	3	1	1	1
85408	1710	function at the level,	[function at the level,]	0.0	4	1	1	1
85409	1710	Chinese prescription	[Chinese prescription]	0.0	2	1	1	1
85410	1710	binding site for NF-E1 ref respectively),	[binding sites for NF-E1 refs respectively),]	0.0	6	1	1	1
85411	1710	T lymphotropic virus-i infection	[T lymphotropic virus-I infection]	0.0	4	1	1	1
85412	1710	further addition	[Further addition]	0.0	2	1	1	1
85413	1710	subsequent interaction	[subsequent interaction]	0.0	2	1	1	1
85414	1710	low-serum apoptosis	[low-serum apoptosis]	0.0	2	1	1	1
85415	1710	mycoplasma high-molecular-weight material MDHM	[Mycoplasma high-molecular-weight material MDHM]	0.0	4	1	1	1
85416	1710	m D3 induce differentiation	[M D3 inducing differentiation]	0.0	4	1	1	1
85417	1710	mac-1 cell surface	[Mac-1 cell surface]	0.0	3	1	1	1
85418	1710	signalling.	[signalling.]	0.0	1	1	1	1
85419	1710	colony-stimumulatelany-stg factor in monocyte	[colony-stimulating factor in monocytes]	0.0	4	1	1	1
85420	1710	T cell-specific protein	[T cell-specific protein]	0.0	3	1	1	1
85421	1710	pu.1 from extract	[PU.1 from extracts]	0.0	3	1	1	1
85422	1710	16 hour of exposure	[16 hr of exposure]	0.0	4	1	1	1
85423	1710	effect of the e2a moiety	[effect of the E2a moiety]	0.0	5	1	1	1
85424	1710	signalling,	[signalling,]	0.0	1	1	1	1
85425	1710	fas ligand expression	[Fas ligand expression]	0.0	3	1	1	1
85426	1710	blood relative	[blood relatives]	0.0	2	1	1	1
85427	1710	isolation of rdna	[isolation of cDNAs]	0.0	3	1	1	1
85428	1710	use a model	[using a model]	0.0	3	1	1	1
85429	1710	Fusion protein present	[Fusion proteins present]	0.0	3	1	1	1
85430	1710	wild type peptide	[wild type peptides]	0.0	3	1	1	1
85431	1710	several element in the region	[several elements in the region]	0.0	5	1	1	1
85432	1710	T cell protein binding	[T cell protein binding]	0.0	4	1	1	1
85433	1710	c-jun promoter (position	[c-jun promoter (positions]	0.0	3	1	1	1
85434	1710	selective modulation by transfer of IkappaB-alpha	[selective modulation by transfer of IkappaB-alpha]	0.0	6	1	1	1
85435	1710	pld activation	[PLD activation]	0.0	2	1	1	1
85436	1710	signals, such as activation	[signals, such as activation]	0.0	4	1	1	1
85437	1710	carry transgene in combination	[carrying transgenes in combinations]	0.0	4	1	1	1
85438	1710	result in nf-kappa b translocation	[resulting in NF-kappa B translocation]	0.0	5	1	1	1
85439	1710	Rel /nf-kappa b	[Rel /NF-kappa B]	0.0	3	1	1	1
85440	1710	background: hydrocarbons pah	[BACKGROUND: hydrocarbons PAHs]	0.0	3	1	1	1
85441	1710	ige production in asthma	[IgE production in asthma]	0.0	4	1	1	1
85442	1710	pharmacological basis interfere	[pharmacological basis interfering]	0.0	3	1	1	1
85443	1710	corticotropin-releasing hormone	[corticotropin-releasing hormone]	0.0	2	1	1	1
85444	1710	class snrna gene	[class snRNA genes]	0.0	3	1	1	1
85445	1710	pyrimidine catabolism	[pyrimidine catabolism]	0.0	2	2	2	1
85446	1710	loss of membrane viability,	[loss of membrane viability,]	0.0	4	1	1	1
85447	1710	calcium gene induction in lymphocyte	[Calcium gene induction in lymphocytes]	0.0	5	1	1	1
85448	1710	mol/L for all-tran RA (94%	[mol/L for all-trans RA (94%]	0.0	5	1	1	1
85449	1710	58 bronchial asthma child	[58 bronchial asthma children]	0.0	4	1	1	1
85450	1710	follow long expression	[following long-term expression]	0.0	3	1	1	1
85451	1710	encode kruppel-type zinc finger domain	[encoding Kruppel-type zinc finger domains]	0.0	5	1	1	1
85452	1710	independent role for p75tnf-r production	[independent role for p75TNF-R production]	0.0	5	1	1	1
85453	1710	negative variant	[negative variants]	0.0	2	1	1	1
85454	1710	single major start site	[single major start site]	0.0	4	1	1	1
85455	1710	glucocorticoid AIDS-GR	[glucocorticoids AIDS-GR]	0.0	2	1	1	1
85456	1710	microm dexamethasone	[microM dexamethasone]	0.0	2	1	1	1
85457	1710	ppar activator 15-deoxy-delta(12,14)-prostaglandin j(2)	[PPAR activators 15-deoxy-Delta(12,14)-prostaglandin J(2)]	0.0	4	1	1	1
85458	1710	mechanism of antiandrogen action	[Mechanism of antiandrogen action]	0.0	4	1	1	1
85459	1710	expression whereas expression	[expression whereas expression]	0.0	3	1	1	1
85460	1710	use decrease in the activity	[using decrease in the activity]	0.0	5	1	1	1
85461	1710	few virus-exposed cell from donor	[Fewer virus-exposed cells from donors]	0.0	5	1	1	1
85462	1710	bacterial cell wall breakdown product	[bacterial cell wall breakdown product]	0.0	5	1	1	1
85463	1710	lymphoblastoid CD4 receptor	[lymphoblastoid CD4 receptors]	0.0	3	1	1	1
85464	1710	selective lysis of cell	[selective lysis of cells]	0.0	4	1	1	1
85465	1710	rBPI21 a recombinant fragment lps expression	[rBPI21 a recombinant fragment LPS expression]	0.0	6	1	1	1
85466	1710	erythroid-specific aminolaevulinic acid synthase activity	[erythroid-specific aminolaevulinic acid synthase activity]	0.0	5	1	1	1
85467	1710	outer volume,	[outer volume,]	0.0	2	1	1	1
85468	1710	significant amount of il-8 costimulation	[significant amounts of IL-8 costimulation]	0.0	5	1	1	1
85469	1710	document	[document]	0.0	1	1	1	1
85470	1710	evidence for a bind site	[evidence for an binding site]	0.0	5	1	1	1
85471	1710	relationship with the change	[relationship with the changes]	0.0	4	2	2	1
85472	1710	novel T regulatory element	[novel T regulatory element]	0.0	4	1	1	1
85473	1710	least in part, by activation.	[least in part, by activation.]	0.0	5	1	1	1
85474	1710	maximal increase in c-fo (99+/-15	[maximal increases in c-fos (99+/-15]	0.0	5	1	1	1
85475	1710	importance of the aCT-1-activating region	[importance of the ACT-1-activating region]	0.0	5	1	1	1
85476	1710	endogenous ikappab kinase ikk	[endogenous IkappaB kinase IKK]	0.0	4	1	1	1
85477	1710	tsp gene to serum	[TSP gene to serum]	0.0	4	1	1	1
85478	1710	cell wall breakdown product	[cell wall breakdown product]	0.0	4	1	1	1
85479	1710	death receptor 3	[death receptor 3]	0.0	3	1	1	1
85480	1710	study responsiveness to two transactivator BZLF1	[studying responsiveness to two transactivators BZLF1]	0.0	6	1	1	1
85481	1710	Dexter-type culture	[Dexter-type culture]	0.0	2	1	1	1
85482	1710	member of the family,	[members of the family,]	0.0	4	1	1	1
85483	1710	one set	[one set]	0.0	2	1	1	1
85484	1710	independent role in the pathogenesis	[independent role in the pathogenesis]	0.0	5	1	1	1
85485	1710	eosinophil in cell	[eosinophils in cells]	0.0	3	1	1	1
85486	1710	dissociation of nf-kappa b translocation	[dissociation of NF-kappa B translocation]	0.0	5	1	1	1
85487	1710	neutrophil with granulocyte-colony stimulate factor	[neutrophils with granulocyte-colony stimulating factor]	0.0	5	1	1	1
85488	1710	express the ikappab	[expressing the IkappaB]	0.0	3	1	1	1
85489	1710	variation in the composition	[variations in the composition]	0.0	4	1	1	1
85490	1710	activation of jak kinase signal transducer	[activation of JAK kinases Signal transducers]	0.0	6	1	1	1
85491	1710	kb in	[kb in]	0.0	2	1	1	1
85492	1710	chain class switch recombination	[chain class switch recombination]	0.0	4	1	1	1
85493	1710	selective activation of stat5 homologue	[Selective activation of STAT5 homologues]	0.0	5	1	1	1
85494	1710	two other drug	[two other drugs]	0.0	3	1	1	1
85495	1710	base level	[base levels]	0.0	2	1	1	1
85496	1710	high concentration of foreign antigen	[high concentration of foreign antigen]	0.0	5	1	1	1
85497	1710	distribution of cell	[distribution of cells]	0.0	3	1	1	1
85498	1710	culture conditions, type	[culture conditions, type]	0.0	3	1	1	1
85499	1710	activation of the nuclear transcription factor	[activation of the nuclear transcription factor]	0.0	6	1	1	1
85500	1710	process of selection.	[process of selection.]	0.0	3	1	1	1
85501	1710	bind nuclear protein	[binding nuclear proteins]	0.0	3	1	1	1
85502	1710	RA uf-1 cell	[RA UF-1 cells]	0.0	3	1	1	1
85503	1710	v3 loop monoclonal antibody antibody	[V3 loop monoclonal antibody antibody]	0.0	5	1	1	1
85504	1710	mediator in dermal cell	[mediators in dermal cells]	0.0	4	1	1	1
85505	1710	(multivariate	[(multivariate]	0.0	1	1	1	1
85506	1710	experimental strategy	[experimental strategies]	0.0	2	1	1	1
85507	1710	feature occur in distinct family	[feature occurring in distinct families]	0.0	5	1	1	1
85508	1710	281 61 pmol/L; in woman	[281 61 pmol/L; in women]	0.0	5	1	1	1
85509	1710	silent mutation in breast tumor	[silent mutation in breast tumors]	0.0	5	1	1	1
85510	1710	series of mutant	[series of mutants]	0.0	3	1	1	1
85511	1710	IL-4 regulation	[IL-4 regulation]	0.0	2	1	1	1
85512	1710	effect of tgf-beta on factor	[effects of TGF-beta on factors]	0.0	5	1	1	1
85513	1710	uterus tumour leiomyoma	[uterus tumour leiomyoma]	0.0	3	2	2	1
85514	1710	test of glucocorticoid receptor	[test of glucocorticoid receptors]	0.0	4	1	1	1
85515	1710	35% decrease	[35% decrease]	0.0	2	1	1	1
85516	1710	-neutralize	[-neutralizing]	0.0	1	1	1	1
85517	1710	divergent reaction	[divergent reaction]	0.0	2	1	1	1
85518	1710	relevance for atherosclerotic disease	[relevance for atherosclerotic disease]	0.0	4	1	1	1
85519	1710	distinct family acid receptor	[distinct families acid receptors]	0.0	4	1	1	1
85520	1710	dna-binding subunit of relative mass	[DNA-binding subunits of relative mass]	0.0	5	1	1	1
85521	1710	human monocyte/neutrophil elastase inhibitor	[human monocyte/neutrophil elastase inhibitor]	0.0	4	1	1	1
85522	1710	use ar antibody	[using AR antibodies]	0.0	3	1	1	1
85523	1710	epithelial level	[epithelial levels]	0.0	2	1	1	1
85524	1710	malignant melanoma study	[malignant melanoma study]	0.0	3	1	1	1
85525	1710	leukocyte by proinflammatory stimulus	[leukocytes by proinflammatory stimuli]	0.0	4	1	1	1
85526	1710	Jun phosphorylation	[Jun phosphorylation]	0.0	2	1	1	1
85527	1710	inflammatory autoimmune disease	[inflammatory autoimmune diseases]	0.0	3	1	1	1
85528	1710	fresh cell whatever	[fresh cells whatever]	0.0	3	1	1	1
85529	1710	erythroid progenitor burst-form units-erythroid	[erythroid progenitors burst-forming units-erythroid]	0.0	4	1	1	1
85530	1710	bcr1 type	[bcr1 type]	0.0	2	1	1	1
85531	1710	platelet factor iv	[Platelet Factor IV]	0.0	3	1	1	1
85532	1710	antigen-induced allergic airway hyperresponsiveness	[antigen-induced allergic airway hyperresponsiveness]	0.0	4	1	1	1
85533	1710	IL-2 promoter-enhancer	[IL-2 promoter-enhancer]	0.0	2	1	1	1
85534	1710	impact to b cell	[impact to B cells]	0.0	4	1	1	1
85535	1710	expression of ebf in HeLa cell	[expression of EBF in HeLa cells]	0.0	6	1	1	1
85536	1710	terminal deoxynucleotidyl transferase labeling	[terminal deoxynucleotidyl transferase labeling]	0.0	4	1	1	1
85537	1710	synergism between two element during activation	[Synergism between two elements during activation]	0.0	6	1	1	1
85538	1710	ratio to cd3+ cell	[ratio to CD3+ cells]	0.0	4	1	1	1
85539	1710	transmission electron microscopy em	[transmission electron microscopy EM]	0.0	4	1	1	1
85540	1710	32p-probe	[32P-probe]	0.0	1	1	1	1
85541	1710	nonconsensus	[nonconsensus]	0.0	1	1	1	1
85542	1710	T cell event	[T cell events]	0.0	3	1	1	1
85543	1710	mrna in the neutrophil	[mRNA in the neutrophils]	0.0	4	1	1	1
85544	1710	indexing	[indexing]	0.0	1	1	1	1
85545	1710	subtype of lymphoma	[subtypes of lymphomas]	0.0	3	1	1	1
85546	1710	dioxyvit with simultaneous correction	[dioxyvit with simultaneous correction]	0.0	4	1	1	1
85547	1710	specific nf-kappa b activity	[specific NF-kappa B activity]	0.0	4	1	1	1
85548	1710	infiltrate into different process	[infiltrating into different processes]	0.0	4	1	1	1
85549	1710	substitution in a HLA-DQ3.2 molecule binding	[substitution in an HLA-DQ3.2 molecule binding]	0.0	6	1	1	1
85550	1710	dominant negative mapkk-1	[dominant negative MAPKK-1]	0.0	3	1	1	1
85551	1710	effect in bone protein-2-	[effects in bone protein-2-]	0.0	4	1	1	1
85552	1710	presentation,	[presentation,]	0.0	1	1	1	1
85553	1710	differentiation-dependent proliferator-activated receptor gamma expression	[differentiation-dependent proliferator-activated receptor gamma expression]	0.0	5	1	1	1
85554	1710	early passage cell	[early passage cells]	0.0	3	1	1	1
85555	1710	icam-1 expression.	[ICAM-1 expression.]	0.0	2	1	1	1
85556	1710	t-cell receptor tcr beta	[T-cell receptor TCR beta]	0.0	4	1	1	1
85557	1710	patient aged 16-27 years, (range	[patients aged 16-27 years, (ranging]	0.0	5	1	1	1
85558	1710	requirement for transcriptional activation	[requirements for transcriptional activation]	0.0	4	1	1	1
85559	1710	nature of cold syndrome	[nature of cold syndromes]	0.0	4	1	1	1
85560	1710	differentiation-associated gene	[differentiation-associated genes]	0.0	2	1	1	1
85561	1710	stimulation of human pbl-t	[stimulation of human PBL-T]	0.0	4	1	1	1
85562	1710	activity a intact autophosphorylation site	[activity an intact autophosphorylation site]	0.0	5	1	1	1
85563	1710	class IL transactivator	[class IL transactivator]	0.0	3	1	1	1
85564	1710	LYSP100 domain	[LYSP100 domains]	0.0	2	1	1	1
85565	1710	8 month	[8 months]	0.0	2	1	1	1
85566	1710	apoptosis in vitro.	[apoptosis in vitro.]	0.0	3	1	1	1
85567	1710	down-regulation of factor	[down-regulation of factors]	0.0	3	1	1	1
85568	1710	src kinase	[src kinase]	0.0	2	1	1	1
85569	1710	[correlation of infiltration	[[Correlation of infiltration]	0.0	3	1	1	1
85570	1710	number of receptor GCR	[number of receptors GCR]	0.0	4	1	1	1
85571	1710	Bcl-6 /cd20	[Bcl-6 /CD20]	0.0	2	1	1	1
85572	1710	dual mechanisms; inhibition	[dual mechanisms; inhibition]	0.0	3	1	1	1
85573	1710	novel inhibitor of NFAT transcription	[novel inhibitors of NFAT transcription]	0.0	5	1	1	1
85574	1710	analogous molecular framework	[analogous molecular framework]	0.0	3	1	1	1
85575	1710	interleukin-7 signal in b cell precursor	[Interleukin-7 signaling in B cell precursor]	0.0	6	1	1	1
85576	1710	inflammatory infiltrate of disease	[inflammatory infiltrates of diseases]	0.0	4	1	1	1
85577	1710	erythrocyte-specific carbonic anhydrase ii	[erythrocyte-specific carbonic anhydrase II]	0.0	4	1	1	1
85578	1710	matrix metalloproteinase mmp	[matrix metalloproteinases MMPs]	0.0	3	1	1	1
85579	1710	treatment of human vein cell monolayer	[Treatment of human vein cell monolayers]	0.0	6	1	1	1
85580	1710	acid receptor action	[acid receptor action]	0.0	3	1	1	1
85581	1710	antioxidant pathway	[antioxidant pathway]	0.0	2	1	1	1
85582	1710	step of nuclear export	[step of nuclear export]	0.0	4	1	1	1
85583	1710	nf-kappa b protein level	[NF-kappa B protein levels]	0.0	4	1	1	1
85584	1710	activation response element	[activation response element]	0.0	3	1	1	1
85585	1710	myelogenous leukemia evi1 fusion	[myelogenous leukemia EVI1 fusions]	0.0	4	1	1	1
85586	1710	effect of liuwei dihuang pill	[effect of liuwei dihuang pills]	0.0	5	1	1	1
85587	1710	phase of hiv-2 infection	[phase of HIV-2 infection]	0.0	4	1	1	1
85588	1710	site of DNA-protein interaction	[site of DNA-protein interactions]	0.0	4	1	1	1
85589	1710	induction kappa B/Rel nuclear activity lymphocyte	[Induction kappa B/Rel nuclear activity lymphocytes]	0.0	6	1	1	1
85590	1710	packaging into chromatin in vitro	[packaging into chromatin in vitro]	0.0	5	1	1	1
85591	1710	1 (egr-1) gene expression	[1 (EGR-1) gene expression]	0.0	4	1	1	1
85592	1710	regulatory sequence important	[regulatory sequences important]	0.0	3	1	1	1
85593	1710	individual' oxygen uptake	[individual's oxygen uptake]	0.0	3	1	1	1
85594	1710	transcription factor such as gata-1	[transcription factors such as GATA-1]	0.0	5	1	1	1
85595	1710	dissociation constant of nm	[dissociation constant of nM]	0.0	4	1	1	1
85596	1710	GM-CSF blood polymorphonuclear leukocyte pmn	[GM-CSF blood polymorphonuclear leukocytes PMN]	0.0	5	1	1	1
85597	1710	progress understand the regulation	[progress understanding the regulation]	0.0	4	1	1	1
85598	1710	protein bind c-fos/c-jun promoter element	[proteins binding c-fos/c-jun promoter elements]	0.0	5	1	1	1
85599	1710	antibody from normal, carrier	[antibodies from normal, carriers]	0.0	4	1	1	1
85600	1710	dissociation (Kd) nmol/l)	[dissociation (Kd) nmol/l)]	0.0	3	1	1	1
85601	1710	nevertheless, high, concentration to &mgr;m)	[Nevertheless, high, concentrations to &mgr;M)]	0.0	5	1	1	1
85602	1710	two signal for induction, PMA	[two signals for induction, PMA]	0.0	5	1	1	1
85603	1710	multiple DNA-protein complex with nuclear extract	[multiple DNA-protein complexes with nuclear extracts]	0.0	6	1	1	1
85604	1710	two inhibitor kinase upstream	[two inhibitors kinase upstream]	0.0	4	1	1	1
85605	1710	synergistic proinflammatory effect	[Synergistic proinflammatory effects]	0.0	3	1	1	1
85606	1710	lymphoid tissue development	[lymphoid tissue development]	0.0	3	1	1	1
85607	1710	np-tcii	[NP-TCII]	0.0	1	1	1	1
85608	1710	variety of sources.	[variety of sources.]	0.0	3	1	1	1
85609	1710	factor USF	[factor USF]	0.0	2	1	1	1
85610	1710	possibly a mature platelet function	[possibly a mature platelet function]	0.0	5	1	1	1
85611	1710	activation rna	[activation RNA]	0.0	2	1	1	1
85612	1710	expression in mouse tissue	[expression in mouse tissues]	0.0	4	1	1	1
85613	1710	two major stat complex	[two major STAT complexes]	0.0	4	1	1	1
85614	1710	effect of type in term	[effects of types in terms]	0.0	5	1	1	1
85615	1710	feedback regulation by means	[feedback regulation by means]	0.0	4	1	1	1
85616	1710	study the mechanism of differentiation	[studying the mechanisms of differentiation]	0.0	5	1	1	1
85617	1710	contradiction, expression	[contradiction, expression]	0.0	2	1	1	1
85618	1710	mechanism govern lineage switch	[mechanisms governing lineage switching]	0.0	4	1	1	1
85619	1710	substrate in	[substrates in]	0.0	2	1	1	1
85620	1710	20-kda protein	[20-kDa protein]	0.0	2	1	1	1
85621	1710	kappa b-1 in tnf-alpha promoter	[kappa B-1 in TNF-alpha promoter]	0.0	5	1	1	1
85622	1710	microbial pathogen	[microbial pathogens]	0.0	2	1	1	1
85623	1710	obtain probe	[obtaining probes]	0.0	2	1	1	1
85624	1710	ioct) protein	[(Oct) proteins]	0.0	2	1	1	1
85625	1710	reactivation by expression	[Reactivation by expression]	0.0	3	1	1	1
85626	1710	dna-binding protein x box protein	[DNA-binding protein X box protein]	0.0	5	1	1	1
85627	1710	gene of the pair phop	[gene of the pair phoP]	0.0	5	1	1	1
85628	1710	leucocyte in 12 woman	[leucocytes in 12 women]	0.0	4	1	1	1
85629	1710	alg-4 transcription	[ALG-4 transcription]	0.0	2	1	1	1
85630	1710	cell surface molecule in response	[cell surface molecules in responses]	0.0	5	1	1	1
85631	1710	potentially autoreactive T cell	[potentially autoreactive T cells]	0.0	4	1	1	1
85632	1710	principle of Chinese medicine	[principle of Chinese medicine]	0.0	4	1	1	1
85633	1710	Protection	[Protection]	0.0	1	1	1	1
85634	1710	cover the surface by 15	[covering the surface by 15]	0.0	5	1	1	1
85635	1710	two distinct sequence-specific dna-binding protein	[two distinct sequence-specific DNA-binding proteins]	0.0	5	1	1	1
85636	1710	host control by the factor	[Host control by the factor]	0.0	5	1	1	1
85637	1710	(i).poly	[(I).poly]	0.0	1	1	1	1
85638	1710	sequence in the region	[sequence in the region]	0.0	4	1	1	1
85639	1710	factor kB regulatory element	[factor kB regulatory elements]	0.0	4	1	1	1
85640	1710	pos-1 pos-1a	[POS-1 POS-1a]	0.0	2	1	1	1
85641	1710	pos-1 pos-1b	[POS-1 POS-1b]	0.0	2	1	1	1
85642	1710	six cell cycle	[six cell cycle]	0.0	3	1	1	1
85643	1710	5 infection	[5 infection]	0.0	2	1	1	1
85644	1710	accumulation in tissue.	[accumulation in tissue.]	0.0	3	1	1	1
85645	1710	adhesive property	[adhesive properties]	0.0	2	1	1	1
85646	1710	subject yr)	[subjects yr)]	0.0	2	1	1	1
85647	1710	effect on malignant lymphocyte 1) inhibition	[effects on malignant lymphocytes 1) inhibition]	0.0	6	1	1	1
85648	1710	molecular regulation	[Molecular regulation]	0.0	2	1	1	1
85649	1710	activation-responsive element	[activation-responsive element]	0.0	2	1	1	1
85650	1710	different NF-kappaB complex	[different NF-kappaB complexes]	0.0	3	1	1	1
85651	1710	interferon-gamma activation site-like	[interferon-gamma activation site-like]	0.0	3	1	1	1
85652	1710	T cell patient.	[T cells patient.]	0.0	3	1	1	1
85653	1710	suppression in T cell by fluid	[Suppression in T cells by fluid]	0.0	6	1	1	1
85654	1710	conformational change of the receptor.	[conformational changes of the receptor.]	0.0	5	1	1	1
85655	1710	early (2-6 h) pro-apoptotic effect	[early (2-6 h) pro-apoptotic effects]	0.0	5	1	1	1
85656	1710	lymphocyte sarcoidosis	[lymphocytes sarcoidosis]	0.0	2	1	1	1
85657	1710	activation of non-erythroid gene contain element	[activation of non-erythroid genes containing elements]	0.0	6	1	1	1
85658	1710	chromosome,	[chromosome,]	0.0	1	1	1	1
85659	1710	chemotactic activity	[chemotactic activity]	0.0	2	2	2	1
85660	1710	characteristic of zinc finger protein	[characteristics of zinc finger proteins]	0.0	5	1	1	1
85661	1710	(auc of +/-	[(AUC of +/-]	0.0	3	1	1	1
85662	1710	analysis with a expression assay	[analysis with a expression assay]	0.0	5	1	1	1
85663	1710	Hypothetically, on/off switch of transactivator	[Hypothetically, on/off switches of transactivators]	0.0	5	1	1	1
85664	1710	target of agent	[target of agents]	0.0	3	1	1	1
85665	1710	expression of the csf-1 receptor	[expression of the CSF-1 receptor]	0.0	5	1	1	1
85666	1710	megakaryocytic lineage cell	[megakaryocytic lineage cells]	0.0	3	1	1	1
85667	1710	IL-4 factor	[IL-4 factors]	0.0	2	1	1	1
85668	1710	effect on a number	[effects on a number]	0.0	4	1	1	1
85669	1710	role in species-specific regulation	[role in species-specific regulation]	0.0	4	1	1	1
85670	1710	coactivation definition of region	[Coactivation definition of regions]	0.0	4	1	1	1
85671	1710	quantification of receptor expression	[quantification of receptor expression]	0.0	4	1	1	1
85672	1710	two different approach	[two different approaches]	0.0	3	1	1	1
85673	1710	group of female aged years,	[group of females aged years,]	0.0	5	1	1	1
85674	1710	contain as little as	[containing as little as]	0.0	4	1	1	1
85675	1710	adhesion the endothelial tethering factor	[Adhesion the endothelial tethering factor]	0.0	5	1	1	1
85676	1710	recessive disease xeroderma pigmentosum	[recessive disease xeroderma pigmentosum]	0.0	4	1	1	1
85677	1710	suggest action of the two receptor	[suggesting action of the two receptors]	0.0	6	1	1	1
85678	1710	express receptor	[expressing receptors]	0.0	2	1	1	1
85679	1710	regulatory element for respective factor	[regulatory elements for respective factor]	0.0	5	1	1	1
85680	1710	exposure to CD40L	[exposure to CD40L]	0.0	3	1	1	1
85681	1710	alteration in sequence (affect expression	[alterations in sequences (affecting expression]	0.0	5	1	1	1
85682	1710	cell with a recombinant retrovirus	[cells with a recombinant retrovirus]	0.0	5	1	1	1
85683	1710	whole cell extract	[whole cell extract]	0.0	3	1	1	1
85684	1710	follow discontinuation of drug gcr count	[Following discontinuation of drugs GCR count]	0.0	6	1	1	1
85685	1710	several myeloid leukemia cell line grow	[Several myeloid leukemia cell lines growing]	0.0	6	1	1	1
85686	1710	5 m 9-cis RA	[5 M 9-cis RA]	0.0	4	1	1	1
85687	1710	relevant gene	[relevant genes]	0.0	2	1	1	1
85688	1710	correspondence with variant	[correspondence with variants]	0.0	3	1	1	1
85689	1710	spontaneous expression in sle	[spontaneous expression in SLE]	0.0	4	1	1	1
85690	1710	involve class CTL	[involving class CTLs]	0.0	3	1	1	1
85691	1710	twice daily resistant	[twice daily resistant]	0.0	3	1	1	1
85692	1710	3' 5'	[3' 5']	0.0	2	1	1	1
85693	1710	methyl prednisolone 120 for 10 days.	[methyl prednisolone 120 for 10 days.]	0.0	6	1	1	1
85694	1710	infection of phagocyte	[infection of phagocytes]	0.0	3	1	1	1
85695	1710	four proteins--a protein of kD	[four proteins--a protein of kD]	0.0	5	1	1	1
85696	1710	dose of peptide (10 micrograms),	[doses of peptide (10 micrograms),]	0.0	5	1	1	1
85697	1710	haplotype bat	[haplotypes BAt]	0.0	2	1	1	1
85698	1710	understanding of the potential	[understanding of the potential]	0.0	4	1	1	1
85699	1710	cell in the blood assay	[cells in the blood assays]	0.0	5	1	1	1
85700	1710	various cells,	[various cells,]	0.0	2	2	2	1
85701	1710	at1 receptor antagonist losartan	[AT1 receptor antagonist losartan]	0.0	4	1	1	1
85702	1710	lack alf1	[lacking ALF1]	0.0	2	1	1	1
85703	1710	further stimulation	[further stimulation]	0.0	2	1	1	1
85704	1710	five target for Oct2	[five targets for Oct2]	0.0	4	1	1	1
85705	1710	property of the blast cell	[properties of the blast cells]	0.0	5	1	1	1
85706	1710	yeast regulator	[yeast regulator]	0.0	2	1	1	1
85707	1710	at (on average during MPE	[AT (on average during MPE]	0.0	5	1	1	1
85708	1710	exclusive expression of vcam-1	[exclusive expression of VCAM-1]	0.0	4	1	1	1
85709	1710	bind to specific domain sequence	[binding to specific domain sequences]	0.0	5	1	1	1
85710	1710	increase of motor activity	[increase of motor activity]	0.0	4	1	1	1
85711	1710	blood lymphocyte leukemia B-CLL	[blood lymphocytes leukemia B-CLL]	0.0	4	1	1	1
85712	1710	feedback regulation of glucocorticoid synthesis	[feedback regulation of glucocorticoid synthesis]	0.0	5	1	1	1
85713	1710	two sequence-specific protein	[two sequence-specific proteins]	0.0	3	1	1	1
85714	1710	bp with one 12-bp insert	[bp with one 12-bp insert]	0.0	5	1	1	1
85715	1710	steroid aldosterone	[steroids aldosterone]	0.0	2	1	1	1
85716	1710	major promoter erratum	[major promoter erratum]	0.0	3	1	1	1
85717	1710	several region between -201	[several regions between -201]	0.0	4	1	1	1
85718	1710	cytoplasmic effector protein	[cytoplasmic effector proteins]	0.0	3	1	1	1
85719	1710	gr -dependent activation	[GR -dependent activation]	0.0	3	1	1	1
85720	1710	lck/fyn-	[Lck/Fyn-]	0.0	1	1	1	1
85721	1710	existence of a family	[existence of a family]	0.0	4	1	1	1
85722	1710	sequence for the expression	[sequence for the expression]	0.0	4	1	1	1
85723	1710	tight complex with class of receptor	[tight complexes with classes of receptors]	0.0	6	1	1	1
85724	1710	FcepsilonRIIb receptor cd23	[FcepsilonRIIb receptor CD23]	0.0	3	1	1	1
85725	1710	cd8+ T lymphocyte (ctl) repertoire	[CD8+ T lymphocyte (CTL) repertoire]	0.0	5	1	1	1
85726	1710	negative RhoA mutant	[negative RhoA mutant]	0.0	3	1	1	1
85727	1710	cell resistant to the effect	[cells resistant to the effects]	0.0	5	1	1	1
85728	1710	twofold increase).	[twofold increase).]	0.0	2	1	1	1
85729	1710	growth regulation	[Growth regulation]	0.0	2	1	1	1
85730	1710	inhibitor of transcription factor	[inhibitors of transcription factors]	0.0	4	1	1	1
85731	1710	stimulation of a t-cell clone	[Stimulation of a T-cell clone]	0.0	5	1	1	1
85732	1710	catalytic,	[catalytic,]	0.0	1	1	1	1
85733	1710	5-lox nf-kappab activation	[5-LOX NF-kappaB activation]	0.0	3	1	1	1
85734	1710	capacity, mobility	[capacity, mobility]	0.0	2	1	1	1
85735	1710	inherent resistance to hiv infection,	[inherent resistance to HIV infection,]	0.0	5	1	1	1
85736	1710	different Jak tyrosine kinase	[different Jak tyrosine kinases]	0.0	4	1	1	1
85737	1710	cancer case	[cancer cases]	0.0	2	1	1	1
85738	1710	lack the entire domain	[lacking the entire domain]	0.0	4	1	1	1
85739	1710	density lipoprotein response in cell	[density lipoprotein responses in cells]	0.0	5	1	1	1
85740	1710	two domain act in actin polymerization	[two domains acting in actin polymerization]	0.0	6	1	1	1
85741	1710	activation ap-1 transcription factor	[activation AP-1 transcription factors]	0.0	4	1	1	1
85742	1710	favorable course chi2 test).	[favorable course chi2 test).]	0.0	4	1	1	1
85743	1710	presence of 4-hydroxytamoxifen	[presence of 4-hydroxytamoxifen]	0.0	3	1	1	1
85744	1710	two different schedule of calcitriol	[two different schedules of calcitriol]	0.0	5	1	1	1
85745	1710	induce NF-kappaB in a cell line	[inducing NF-kappaB in a cell line]	0.0	6	1	1	1
85746	1710	lymphocytic leukaemia CLL	[lymphocytic leukaemia CLL]	0.0	3	1	1	1
85747	1710	early samples, activity	[early samples, activity]	0.0	3	1	1	1
85748	1710	proportion of elderly subject	[proportion of elderly subjects]	0.0	4	1	1	1
85749	1710	differentiation of human leukemic cell	[differentiation of human leukemic cells]	0.0	5	1	1	1
85750	1710	activation by a combination of phytohemagglutinin	[activation by a combination of phytohemagglutinin]	0.0	6	1	1	1
85751	1710	block of differentiation of 32dcl3 cell	[Block of differentiation of 32Dcl3 cells]	0.0	6	1	1	1
85752	1710	regulation of traf signal	[regulation of TRAF signaling]	0.0	4	1	1	1
85753	1710	release of a subunit	[release of an subunit]	0.0	4	1	1	1
85754	1710	computer algorithm	[computer algorithm]	0.0	2	1	1	1
85755	1710	amphipatic alpha-helical protein segment	[amphipatic alpha-helical protein segments]	0.0	4	1	1	1
85756	1710	beta-globin gene cluster	[beta-globin gene cluster]	0.0	3	1	1	1
85757	1710	complex exhibit a ap-1 specificity	[complexes exhibiting an AP-1 specificity]	0.0	5	1	1	1
85758	1710	inhibition of specific regulatory protein	[inhibition of specific regulatory proteins]	0.0	5	1	1	1
85759	1710	fluid monocyte	[fluid monocytes]	0.0	2	1	1	1
85760	1710	47-bp sequence position relative	[47-bp sequence positions relative]	0.0	4	1	1	1
85761	1710	(ifn)-activated NK cell	[(IFN)-activated NK cells]	0.0	3	1	1	1
85762	1710	finally 6 week after termination	[finally 6 weeks after termination]	0.0	5	1	1	1
85763	1710	hiv-2 gene expression by activation	[HIV-2 gene expression by activation]	0.0	5	1	1	1
85764	1710	tyrosine protein kinase activity	[tyrosine protein kinase activity]	0.0	4	1	1	1
85765	1710	(30 minutes) to all-tran retinoic acid	[(30 minutes) to all-trans retinoic acid]	0.0	6	1	1	1
85766	1710	depend	[depending]	0.0	1	1	1	1
85767	1710	role in vertebrate transcriptional regulation	[role in vertebrate transcriptional regulation]	0.0	5	1	1	1
85768	1710	mobility group 1 (hmg) box	[mobility group 1 (HMG) box]	0.0	5	1	1	1
85769	1710	dicoumarol a qr inhibitor	[dicoumarol a QR inhibitor]	0.0	4	1	1	1
85770	1710	(2/7),	[(2/7),]	0.0	1	1	1	1
85771	1710	984 binding site per nucleus	[984 binding sites per nucleus]	0.0	5	1	1	1
85772	1710	immunocytochemical analysis of mnda	[Immunocytochemical analysis of MNDA]	0.0	4	1	1	1
85773	1710	ZEBRA /EBV system	[ZEBRA /EBV system]	0.0	3	1	1	1
85774	1710	expression of ap1 reporter construct nm),	[expression of AP1 reporter constructs nM),]	0.0	6	1	1	1
85775	1710	important positive element NF-AT-1	[important positive element NF-AT-1]	0.0	4	1	1	1
85776	1710	class molecule on cell	[class molecules on cells]	0.0	4	1	1	1
85777	1710	regulation of normal progenitor	[regulation of normal progenitors]	0.0	4	1	1	1
85778	1710	Functional interaction	[Functional interaction]	0.0	2	1	1	1
85779	1710	significant proliferation in response	[significant proliferation in response]	0.0	4	1	1	1
85780	1710	suggest cooperative action of the receptor	[suggesting cooperative action of the receptors]	0.0	6	1	1	1
85781	1710	effect inhibition through adenosine triphosphate depletion	[effects inhibition through adenosine triphosphate depletion]	0.0	6	1	1	1
85782	1710	histocompatibility class molecule	[histocompatibility class molecules]	0.0	3	1	1	1
85783	1710	transfection of negative expression vector together	[Transfection of negative expression vectors together]	0.0	6	1	1	1
85784	1710	activator 4	[activator 4]	0.0	2	1	1	1
85785	1710	great ap-1 activity	[greater AP-1 activity]	0.0	3	1	1	1
85786	1710	majority of leukemia	[majority of leukemias]	0.0	3	1	1	1
85787	1710	change in receptor in leukocyte	[changes in receptors in leukocytes]	0.0	5	1	1	1
85788	1710	natural killer cell line	[natural killer cell line]	0.0	4	1	1	1
85789	1710	uncultured T cell	[uncultured T cells]	0.0	3	1	1	1
85790	1710	induce proliferation	[inducing proliferation]	0.0	2	1	1	1
85791	1710	multiple NF-kappa b related polypeptide	[multiple NF-kappa B related polypeptides]	0.0	5	1	1	1
85792	1710	coexpression of the gene	[Coexpression of the genes]	0.0	4	1	1	1
85793	1710	several cell-type-specific regulator	[several cell-type-specific regulators]	0.0	3	1	1	1
85794	1710	result in synthesis	[resulting in synthesis]	0.0	3	1	1	1
85795	1710	enhanceosome	[enhanceosome]	0.0	1	1	1	1
85796	1710	domain responsible for DNA binding	[domains responsible for DNA binding]	0.0	5	1	1	1
85797	1710	aldosterone derivative to fraction	[aldosterone derivative to fractions]	0.0	4	1	1	1
85798	1710	65 kda	[65 kDa]	0.0	2	1	1	1
85799	1710	similar response toward cytokine stimulation	[similar response toward cytokine stimulation]	0.0	5	1	1	1
85800	1710	MZF-1 regulation of this relevant promoter	[MZF-1 regulation of this relevant promoter]	0.0	6	1	1	1
85801	1710	morphological differentiation in normal cell	[morphological differentiation in normal cells]	0.0	5	1	1	1
85802	1710	Philips	[Philips]	0.0	1	1	1	1
85803	1710	antigen-driven somatic hypermutation	[antigen-driven somatic hypermutation]	0.0	3	1	1	1
85804	1710	hiv-1 blood	[HIV-1 blood]	0.0	2	1	1	1
85805	1710	tnf translation efficiency	[TNF translation efficiency]	0.0	3	1	1	1
85806	1710	hla stabilization experiment	[HLA stabilization experiments]	0.0	3	1	1	1
85807	1710	kg-1 myeloid leukemia cell	[KG-1 myeloid leukemia cells]	0.0	4	1	1	1
85808	1710	chemoattract at concentrations.	[chemoattractants at concentrations.]	0.0	3	1	1	1
85809	1710	postnatally, typically die days.	[postnatally, typically dying days.]	0.0	4	1	1	1
85810	1710	sample of blood	[samples of blood]	0.0	3	1	1	1
85811	1710	affinity of sr-bp	[affinity of SR-BP]	0.0	3	1	1	1
85812	1710	overexpression of ikappab-alpha in cell	[overexpression of IkappaB-alpha in cells]	0.0	5	1	1	1
85813	1710	splicing pre-mrna	[splicing pre-mRNA]	0.0	2	1	1	1
85814	1710	immune-mediated inflammation	[immune-mediated inflammation]	0.0	2	1	1	1
85815	1710	interaction with the transcription factor	[interaction with the transcription factor]	0.0	5	1	1	1
85816	1710	contribution to T expression	[contribution to T expression]	0.0	4	1	1	1
85817	1710	subsequent deletion	[subsequent deletion]	0.0	2	1	1	1
85818	1710	antitumour DNA topoisomerase ii inhibitor	[antitumour DNA topoisomerase II inhibitors]	0.0	5	1	1	1
85819	1710	porcine cell	[Porcine cells]	0.0	2	1	1	1
85820	1710	small adherent colony	[small adherent colonies]	0.0	3	1	1	1
85821	1710	lupus nephritis	[lupus nephritis]	0.0	2	2	2	1
85822	1710	HTLV-1 promoter.	[HTLV-1 promoter.]	0.0	2	1	1	1
85823	1710	gene expression in blood lymphocyte	[gene expression in blood lymphocytes]	0.0	5	1	1	1
85824	1710	AMP factor	[AMP factors]	0.0	2	1	1	1
85825	1710	baboon cercopithicine herpesvirus herpesvirus papio	[baboons cercopithicine herpesvirus herpesvirus papio]	0.0	5	1	1	1
85826	1710	stimulation in control from RCC patient	[stimulation in controls from RCC patients]	0.0	6	1	1	1
85827	1710	thymic organ culture	[thymic organ culture]	0.0	3	3	3	1
85828	1710	four patient in remission	[four patients in remission]	0.0	4	1	1	1
85829	1710	incubation (90-120	[incubation (90-120]	0.0	2	1	1	1
85830	1710	involvement of follicular cell FDC	[involvement of follicular cells FDC]	0.0	5	1	1	1
85831	1710	dense peroxidase-negative granule	[dense peroxidase-negative granules]	0.0	3	1	1	1
85832	1710	several other hallmark	[several other hallmarks]	0.0	3	1	1	1
85833	1710	formation of two dna-binding complex	[formation of two DNA-binding complexes]	0.0	5	1	1	1
85834	1710	second protein	[second protein]	0.0	2	1	1	1
85835	1710	rapid accumulation of high concentration	[rapid accumulation of high concentrations]	0.0	5	1	1	1
85836	1710	activity reticuloendotheliosis virus REV	[activity reticuloendotheliosis virus REV]	0.0	4	1	1	1
85837	1710	repressor molecule	[repressor molecule]	0.0	2	2	2	1
85838	1710	several anti-ig response element	[several anti-Ig response elements]	0.0	4	1	1	1
85839	1710	selection clonal expansion)	[selection clonal expansion)]	0.0	3	1	1	1
85840	1710	L132 cell	[L132 cells]	0.0	2	1	1	1
85841	1710	constitutive serine phosphorylation	[constitutive serine phosphorylation]	0.0	3	1	1	1
85842	1710	current understanding of the transcriptional regulation	[current understanding of the transcriptional regulation]	0.0	6	1	1	1
85843	1710	six C-terminal zinc-finger motif	[six C-terminal zinc-finger motifs]	0.0	4	1	1	1
85844	1710	provocative mechanism	[provocative mechanism]	0.0	2	1	1	1
85845	1710	alteration of cd19 gene expression	[alteration of CD19 gene expression]	0.0	5	1	1	1
85846	1710	dissociation rate of [3H]dexamethasone	[dissociation rate of [3H]dexamethasone]	0.0	4	1	1	1
85847	1710	amount of creb protein p-creb	[amounts of CREB protein P-CREB]	0.0	5	1	1	1
85848	1710	mobilization nuclear factor-kappa b	[mobilization nuclear factor-kappa B]	0.0	4	1	1	1
85849	1710	cord blood cd4+ T	[cord blood CD4+ T]	0.0	4	1	1	1
85850	1710	al1 virus stock	[AL1 virus stock]	0.0	3	1	1	1
85851	1710	enhancer -binding protein	[enhancer -binding proteins]	0.0	3	1	1	1
85852	1710	adult globin (hbb)	[adult globin (HBB)]	0.0	3	1	1	1
85853	1710	two cDNA sequence	[two cDNA sequences]	0.0	3	1	1	1
85854	1710	bioavailability from mononuclear cell	[bioavailability from mononuclear cells]	0.0	4	1	1	1
85855	1710	inducible nf-at complex	[inducible NF-AT complexes]	0.0	3	1	1	1
85856	1710	degenerative spastic paraparesis tsp	[degenerative spastic paraparesis TSP]	0.0	4	1	1	1
85857	1710	gene expression via binding	[gene expression via binding]	0.0	4	1	1	1
85858	1710	transcription factor a regulator	[transcription factor a regulator]	0.0	4	1	1	1
85859	1710	human interleukin-3 il-3	[human interleukin-3 IL-3]	0.0	3	1	1	1
85860	1710	induction of adhesion molecule	[Induction of adhesion molecules]	0.0	4	1	1	1
85861	1710	COS-1 cell co-express the il-10r	[COS-1 cells co-expressing the IL-10R]	0.0	5	1	1	1
85862	1710	leukocyte by phagocyte	[leukocytes by phagocytes]	0.0	3	1	1	1
85863	1710	effect inhibition through adenosine triphosphate	[effects inhibition through adenosine triphosphate]	0.0	5	1	1	1
85864	1710	cell line with epo	[cell line with Epo]	0.0	4	1	1	1
85865	1710	cd4(+) T cell line	[CD4(+) T cell lines]	0.0	4	1	1	1
85866	1710	inhibitor of the rotamase activity	[inhibitor of the rotamase activity]	0.0	5	1	1	1
85867	1710	roset around L&H cell	[rosetting around L&H cells]	0.0	4	1	1	1
85868	1710	glucocorticoid receptor in cell	[glucocorticoid receptors in cells]	0.0	4	1	1	1
85869	1710	gr in leukocyte	[GR in leukocytes]	0.0	3	1	1	1
85870	1710	abnormal activation	[Abnormal activation]	0.0	2	1	1	1
85871	1710	Epstein-Barr virus bmrf1 promoter	[Epstein-Barr virus BMRF1 promoter]	0.0	4	1	1	1
85872	1710	pathway in human monocyte	[pathways in human monocytes]	0.0	4	1	1	1
85873	1710	nfatp a cyclosporin-sensitive protein	[NFATp a cyclosporin-sensitive protein]	0.0	4	1	1	1
85874	1710	RBP-Jkappa response element	[RBP-Jkappa response elements]	0.0	3	1	1	1
85875	1710	human oncogene bcl-3	[human oncogene bcl-3]	0.0	3	1	1	1
85876	1710	variation of GR	[variation of GR]	0.0	3	1	1	1
85877	1710	localization of NFkappaB	[localization of NFkappaB]	0.0	3	1	1	1
85878	1710	transiently convert the transactivation	[transiently converting the transactivation]	0.0	4	1	1	1
85879	1710	transfection of mutant of IKKalpha	[Transfection of mutants of IKKalpha]	0.0	5	1	1	1
85880	1710	thus, qualitative difference	[Thus, qualitative differences]	0.0	3	1	1	1
85881	1710	viable T cell	[viable T cells]	0.0	3	1	1	1
85882	1710	benign uterus tumour	[benign uterus tumour]	0.0	3	2	2	1
85883	1710	human homolog c/ebp-beta NF-IL6	[human homolog C/EBP-beta NF-IL6]	0.0	4	1	1	1
85884	1710	three heat shock transcription factor	[three heat shock transcription factor]	0.0	5	1	1	1
85885	1710	respect by CIF	[respect by CIF]	0.0	3	1	1	1
85886	1710	receptor -dependent transcription	[receptor -dependent transcription]	0.0	3	1	1	1
85887	1710	combat Vietnam veteran	[combat Vietnam veterans]	0.0	3	1	1	1
85888	1710	region of sequence	[regions of sequences]	0.0	3	1	1	1
85889	1710	proliferation of antigen-activated T cell	[proliferation of antigen-activated T cells]	0.0	5	1	1	1
85890	1710	negative version	[negative version]	0.0	2	1	1	1
85891	1710	family protein c-rel	[family proteins c-Rel]	0.0	3	1	1	1
85892	1710	binding site in region	[binding site in regions]	0.0	4	1	1	1
85893	1710	transient increase peak in response	[transient increase peaking in response]	0.0	5	1	1	1
85894	1710	dna-binding small molecule	[DNA-binding small molecules]	0.0	3	1	1	1
85895	1710	23 to 40% cells, respectively),	[23 to 40% cells, respectively),]	0.0	5	1	1	1
85896	1710	E1A -negative,	[E1A -negative,]	0.0	2	1	1	1
85897	1710	thereby promote the translocation	[thereby promoting the translocation]	0.0	4	1	1	1
85898	1710	protein bind the regulatory element	[proteins binding the regulatory element]	0.0	5	1	1	1
85899	1710	existence of only a copy	[existence of only a copies]	0.0	5	1	1	1
85900	1710	traz coactivate nf-kappab	[TRAFs coactivating NF-kappaB]	0.0	3	1	1	1
85901	1710	population of type T cell	[population of type T cells]	0.0	5	1	1	1
85902	1710	range of inflammatory pathology	[range of inflammatory pathologies]	0.0	4	1	1	1
85903	1710	several casein kinase ii site (37	[several casein kinase II sites (37]	0.0	6	1	1	1
85904	1710	amino acid carboxy-terminus	[amino acid carboxy-terminus]	0.0	3	1	1	1
85905	1710	codon 10 site	[codon 10 site]	0.0	3	1	1	1
85906	1710	regulate biological function in this cells.	[regulating biological functions in these cells.]	0.0	6	1	1	1
85907	1710	inactive mutant	[inactive mutants]	0.0	2	1	1	1
85908	1710	skw cell with IL 6	[SKW cells with IL 6]	0.0	5	1	1	1
85909	1710	hybrid mrna level	[hybrid mRNA levels]	0.0	3	1	1	1
85910	1710	blood platelet with alpha-thrombin	[blood platelets with alpha-thrombin]	0.0	4	1	1	1
85911	1710	b lymphoblastoid cell line	[B lymphoblastoid cell line]	0.0	4	1	1	1
85912	1710	presence of intracellular receptor	[presence of intracellular receptors]	0.0	4	1	1	1
85913	1710	induction of hl-60	[Induction of HL-60]	0.0	3	1	1	1
85914	1710	pattern of cytokine secretion	[pattern of cytokine secretion]	0.0	4	1	1	1
85915	1710	bind motif for Pit-1	[binding motifs for Pit-1]	0.0	4	1	1	1
85916	1710	low level of transcription transcription	[Low levels of transcription transcription]	0.0	5	1	1	1
85917	1710	bind the element	[binding the element]	0.0	3	1	1	1
85918	1710	evidence for ikappab-alpha phosphorylation	[evidence for IkappaB-alpha phosphorylation]	0.0	4	1	1	1
85919	1710	100-500 microm OP for hour	[100-500 microM OP for hr,]	0.0	5	1	1	1
85920	1710	angle of degree with helice	[angle of degrees with helices]	0.0	5	1	1	1
85921	1710	400-fold excess	[400-fold excess]	0.0	2	1	1	1
85922	1710	human epidermal keratinocyte	[human epidermal keratinocytes]	0.0	3	1	1	1
85923	1710	form lack a portion	[forms lacking a portion]	0.0	4	1	1	1
85924	1710	long activation of primary t-lymphocyte	[long-term activation of primary T-lymphocytes]	0.0	5	1	1	1
85925	1710	thymic hybridoma pc60	[thymic hybridoma PC60]	0.0	3	1	1	1
85926	1710	role switch during stage of infection	[Role switching during stages of infection]	0.0	6	1	1	1
85927	1710	inhibition by the isoquinoline derivative H7	[Inhibition by the isoquinoline derivative H7]	0.0	6	1	1	1
85928	1710	enf-kappa	[(NF-kappa]	0.0	1	1	1	1
85929	1710	lymphocyte from the two	[lymphocytes from the two]	0.0	4	1	1	1
85930	1710	novel substoichiometric taf	[novel substoichiometric TAF]	0.0	3	1	1	1
85931	1710	cord samples.	[cord samples.]	0.0	2	1	1	1
85932	1710	mechanism control this choice	[mechanisms controlling this choice]	0.0	4	1	1	1
85933	1710	affinity on blood cell	[affinity on blood cells]	0.0	4	1	1	1
85934	1710	nuclear, acid (dna) protein exhibit change	[nuclear, acid (DNA) proteins exhibiting changes]	0.0	6	1	1	1
85935	1710	erythroid histone h5	[erythroid histone H5]	0.0	3	1	1	1
85936	1710	addition of icam-1 antibody	[addition of ICAM-1 antibodies]	0.0	4	1	1	1
85937	1710	especially the homolog c/ebp-beta NF-IL6	[especially the homolog C/EBP-beta NF-IL6]	0.0	5	1	1	1
85938	1710	activity of cyclosporine	[activity of cyclosporine]	0.0	3	1	1	1
85939	1710	dexamethasone in vitro fibroblast binding	[dexamethasone in vitro fibroblast binding]	0.0	5	1	1	1
85940	1710	(p13;q14)	[(p13;q14)]	0.0	1	1	1	1
85941	1710	tat mutant include stop codon mutant	[tat mutants including stop codon mutants]	0.0	6	1	1	1
85942	1710	lead to gene regulatory inhibitory response	[leading to gene regulatory inhibitory responses]	0.0	6	1	1	1
85943	1710	oncogenic virus of primate	[oncogenic virus of primates]	0.0	4	1	1	1
85944	1710	form of costimulation	[form of costimulation]	0.0	3	1	1	1
85945	1710	result of studies,	[Results of studies,]	0.0	3	1	1	1
85946	1710	monoamine oxidase b gene	[monoamine oxidase B gene]	0.0	4	2	2	1
85947	1710	one transformation effector site	[One transformation effector site]	0.0	4	1	1	1
85948	1710	participation of c-fo	[participation of c-Fos]	0.0	3	1	1	1
85949	1710	such as signal transducer	[such as signal transducer]	0.0	4	1	1	1
85950	1710	lymphokine interleukin-1beta	[lymphokine interleukin-1beta]	0.0	2	1	1	1
85951	1710	L.Szekely,	[L.Szekely,]	0.0	1	1	1	1
85952	1710	erythematosus	[erythematosus]	0.0	1	1	1	1
85953	1710	MCM gene	[MCM genes]	0.0	2	1	1	1
85954	1710	(66 millileter at 10:00 P;	[(66 ml at 10:00 h;]	0.0	5	1	1	1
85955	1710	express ebv during stage	[expressing EBV during stages]	0.0	4	1	1	1
85956	1710	creatinine	[creatinine]	0.0	1	1	1	1
85957	1710	microvessel endothelial cell hdmec	[microvessel endothelial cells HDMEC]	0.0	4	1	1	1
85958	1710	differential regulation of the machinery	[differential regulation of the machinery]	0.0	5	1	1	1
85959	1710	tat gene expression	[tat gene expression]	0.0	3	1	1	1
85960	1710	osteoclast-like cell from monocyte	[osteoclast-like cells from monocytes]	0.0	4	1	1	1
85961	1710	cd8alpha/il-4ralpha receptor	[CD8alpha/IL-4Ralpha receptor]	0.0	2	1	1	1
85962	1710	downstream nf-kappab activation of long repeat	[downstream NF-kappaB activation of long repeat]	0.0	6	1	1	1
85963	1710	lymphocyte of promyelocytic leukemia patient	[lymphocytes of promyelocytic leukemia patients]	0.0	5	1	1	1
85964	1710	bronchiti subject	[bronchitis subjects]	0.0	2	1	1	1
85965	1710	mixture of heparin with ifn-gamma	[mixture of heparin with IFN-gamma]	0.0	5	1	1	1
85966	1710	ikappab alpha kinase	[IkappaB alpha kinases]	0.0	3	1	1	1
85967	1710	lymphoid cell include cell	[lymphoid cells including cells]	0.0	4	1	1	1
85968	1710	role in the ligand-binding domain	[role in the ligand-binding domain]	0.0	5	1	1	1
85969	1710	target of alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3	[targets of alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3]	0.0	5	1	1	1
85970	1710	patient with pulmonary condition	[patients with pulmonary conditions]	0.0	4	1	1	1
85971	1710	protection from tcr-mediated apoptosis	[protection from TCR-mediated apoptosis]	0.0	4	1	1	1
85972	1710	human mononuclear leukocyte of male	[human mononuclear leukocytes of males]	0.0	5	1	1	1
85973	1710	positive regulatory domain (prd) binding protein	[positive regulatory domain (PRD) binding proteins]	0.0	6	1	1	1
85974	1710	p47phox patient	[p47phox patients]	0.0	2	1	1	1
85975	1710	use for the treatment	[use for the treatment]	0.0	4	1	1	1
85976	1710	SCL with proliferation	[SCL with proliferation]	0.0	3	1	1	1
85977	1710	screening	[Screening]	0.0	1	1	1	1
85978	1710	conditions, reagents,	[conditions, reagents,]	0.0	2	1	1	1
85979	1710	comparable formation sequence-binding complex	[comparable formation sequence-binding complexes]	0.0	4	1	1	1
85980	1710	cysteine-rich antigen segment	[cysteine-rich antigen segments]	0.0	3	1	1	1
85981	1710	downstream T	[downstream T]	0.0	2	1	1	1
85982	1710	potential in human skin cancer	[potential in human skin cancer]	0.0	5	1	1	1
85983	1710	activation of the factor by PGG-Glucan	[activation of the factor by PGG-Glucan]	0.0	6	1	1	1
85984	1710	contribution to the phenotype of SIVsmmPBj14	[contribution to the phenotype of SIVsmmPBj14]	0.0	6	1	1	1
85985	1710	pseudohypoaldosteronism in family different form	[Pseudohypoaldosteronism in families: different forms]	0.0	5	1	1	1
85986	1710	negative regulatory region responsive	[negative regulatory region responsive]	0.0	4	1	1	1
85987	1710	60 amino acid carboxy-terminus	[60 amino acid carboxy-terminus]	0.0	4	1	1	1
85988	1710	binding of il-2	[binding of IL-2]	0.0	3	1	1	1
85989	1710	motor neuron disease,	[motor neuron disease,]	0.0	3	1	1	1
85990	1710	blood precursor	[blood precursors]	0.0	2	1	1	1
85991	1710	advanced renal failure A-CRF	[advanced renal failure A-CRF]	0.0	4	1	1	1
85992	1710	nfat target	[NFAT target]	0.0	2	1	1	1
85993	1710	activation expression	[Activation expression]	0.0	2	1	1	1
85994	1710	leukemic cell stage of differentiation,	[leukemic cells stage of differentiation,]	0.0	5	1	1	1
85995	1710	T cell receptor responsive element	[T cell receptor responsive elements]	0.0	5	1	1	1
85996	1710	other human cell include monocyte	[other human cells including monocytes]	0.0	5	1	1	1
85997	1710	dominant form Max	[dominant form Max]	0.0	3	1	1	1
85998	1710	inhibitory effect a quinone derivative	[Inhibitory effect a quinone derivative]	0.0	5	1	1	1
85999	1710	involvement by a chromosomal translocation	[involvement by a chromosomal translocation]	0.0	5	1	1	1
86000	1710	CD40 b cell culture system	[CD40 B cell culture system]	0.0	5	1	1	1
86001	1710	IFN-gamma -responsive promoter	[IFN-gamma -responsive promoter]	0.0	3	1	1	1
86002	1710	"pure" hematopoietic progenitor	["pure" hematopoietic progenitors]	0.0	3	1	1	1
86003	1710	use transfection with a series	[Using transfection with a series]	0.0	5	1	1	1
86004	1710	eight putative segment	[eight putative segments]	0.0	3	1	1	1
86005	1710	endothelial adhesion molecule-1	[endothelial adhesion molecule-1]	0.0	3	1	1	1
86006	1710	various line u937 in fibroblast	[various lines U937 in fibroblasts]	0.0	5	1	1	1
86007	1710	regulation in human NK cell	[regulation in human NK cells]	0.0	5	1	1	1
86008	1710	function in erythroid differentiation	[function in erythroid differentiation]	0.0	4	1	1	1
86009	1710	peroxidase-antiperoxidase	[peroxidase-antiperoxidase]	0.0	1	1	1	1
86010	1710	contain cysteine region LIM domain	[containing cysteine regions LIM domains]	0.0	5	1	1	1
86011	1710	receptor (tnfr)-associated factor	[receptor (TNFR)-associated factors]	0.0	3	1	1	1
86012	1710	understand the molecular mechanism	[Understanding the molecular mechanisms]	0.0	4	1	1	1
86013	1710	important role in effect	[important role in effects]	0.0	4	1	1	1
86014	1710	oxidant injury	[oxidant injury]	0.0	2	1	1	1
86015	1710	effect on the morphology	[effect on the morphology]	0.0	4	1	1	1
86016	1710	soluble CD4 scd4	[soluble CD4 sCD4]	0.0	3	1	1	1
86017	1710	g/g of mrna in lymphocyte	[g/g of mRNA in lymphocytes]	0.0	5	1	1	1
86018	1710	dominant negative regulatory effect	[dominant negative regulatory effect]	0.0	4	1	1	1
86019	1710	sequence kb)	[sequence kb)]	0.0	2	1	1	1
86020	1710	additional regulatory sites.	[additional regulatory sites.]	0.0	3	1	1	1
86021	1710	cytokine profile of blood mononuclear cell	[Cytokine profiles of blood mononuclear cells]	0.0	6	1	1	1
86022	1710	low affinity il-2r	[low affinity IL-2Rs]	0.0	3	1	1	1
86023	1710	early diagnosis	[early diagnosis]	0.0	2	1	1	1
86024	1710	receptor in growth of cell	[receptors in growth of cells]	0.0	5	1	1	1
86025	1710	indicator of prognosis	[indicator of prognosis]	0.0	3	1	1	1
86026	1710	apparent kd of nm.	[apparent Kd of nM.]	0.0	4	1	1	1
86027	1710	16 (50%) first-degree relative	[16 (50%) first-degree relatives]	0.0	4	1	1	1
86028	1710	inconsistency	[inconsistencies]	0.0	1	1	1	1
86029	1710	IL-5 gene in eosinophil	[IL-5 genes in eosinophils]	0.0	4	1	1	1
86030	1710	role of the hs-40 motif	[roles of the HS-40 motifs]	0.0	5	1	1	1
86031	1710	tissue-specific variation	[tissue-specific variation]	0.0	2	1	1	1
86032	1710	tata element	[TATA elements]	0.0	2	1	1	1
86033	1710	simian virus 40 SV40	[simian virus 40 SV40]	0.0	4	1	1	1
86034	1710	value through down regulation	[value through down regulation]	0.0	4	1	1	1
86035	1710	only (il)-2-receptor expression	[only (IL)-2-receptor expression]	0.0	3	1	1	1
86036	1710	induction of tolerance	[induction of tolerance]	0.0	3	1	1	1
86037	1710	growth factor stimulus	[growth factor stimulus]	0.0	3	1	1	1
86038	1710	inducible nuclear import	[inducible nuclear import]	0.0	3	2	2	1
86039	1710	instead a marker of nearby polymorphism	[instead a marker(s) of nearby polymorphisms]	0.0	6	1	1	1
86040	1710	cover the sequence individual	[covering the sequence individuals]	0.0	4	1	1	1
86041	1710	strong effect of p65	[strong effects of p65]	0.0	4	1	1	1
86042	1710	never any effect	[never any effect]	0.0	3	1	1	1
86043	1710	transcription factor mef2c	[transcription factor MEF2C]	0.0	3	1	1	1
86044	1710	magnitude of this response	[magnitude of these responses]	0.0	4	1	1	1
86045	1710	0.05, p less than 0.01	[0.05, P less than 0.01]	0.0	5	1	1	1
86046	1710	effect of acetate	[effect of acetate]	0.0	3	1	1	1
86047	1710	intracellular calcium concentration ca2+ ]i	[intracellular calcium concentration Ca2+ ]i]	0.0	5	1	1	1
86048	1710	additional sites.	[additional sites.]	0.0	2	1	1	1
86049	1710	phorbol monocytic differentiation by dexamethasone	[phorbol monocytic differentiation by dexamethasone]	0.0	5	1	1	1
86050	1710	high quality support	[high quality support]	0.0	3	1	1	1
86051	1710	identification of Bcd	[Identification of Bcd]	0.0	3	1	1	1
86052	1710	mechanism against cell death	[mechanism against cell death]	0.0	4	1	1	1
86053	1710	avian erythroblast	[avian erythroblast]	0.0	2	1	1	1
86054	1710	selective force	[selective force]	0.0	2	1	1	1
86055	1710	expression by blotting	[expression by blotting]	0.0	3	1	1	1
86056	1710	adhesion vein cell	[adhesion vein cells]	0.0	3	1	1	1
86057	1710	physiological inhibitor	[physiological inhibitor]	0.0	2	1	1	1
86058	1710	individual with defect	[individuals with defects]	0.0	3	1	1	1
86059	1710	regulator of the basal promoter activity	[regulators of the basal promoter activity]	0.0	6	1	1	1
86060	1710	prostaglandin I2 a regulator	[prostaglandin I2 a regulator]	0.0	4	1	1	1
86061	1710	molecule with nf-kappa b	[molecule with NF-kappa B]	0.0	4	1	1	1
86062	1710	(pml) leucocyte	[(PML) leucocytes]	0.0	2	1	1	1
86063	1710	CR1 cd35	[CR1 CD35]	0.0	2	2	2	1
86064	1710	umbilical cell	[umbilical cells]	0.0	2	1	1	1
86065	1710	extract with antibody	[extracts with antibodies]	0.0	3	1	1	1
86066	1710	role of acid	[role of acid]	0.0	3	1	1	1
86067	1710	Circadian rhythm in glucocorticoid receptor	[Circadian rhythm in glucocorticoid receptor]	0.0	5	1	1	1
86068	1710	cell to bacterial lipopolysaccharide	[cells to bacterial lipopolysaccharide]	0.0	4	1	1	1
86069	1710	il-2 transcriptional blockade	[IL-2 transcriptional blockade]	0.0	3	1	1	1
86070	1710	interleukin-7 signal leukemia cell	[Interleukin-7 signaling leukemia cells]	0.0	4	1	1	1
86071	1710	action on cell (dc)	[action on cells (DC)]	0.0	4	1	1	1
86072	1710	result signal	[resulting signal]	0.0	2	1	1	1
86073	1710	p.m.) type	[p.m.) Type]	0.0	2	1	1	1
86074	1710	one relative;	[one relative;]	0.0	2	1	1	1
86075	1710	formation of substance tbar	[formation of substances TBARS]	0.0	4	1	1	1
86076	1710	c epsilon transcription	[C epsilon transcription]	0.0	3	1	1	1
86077	1710	human intestinal cell inflammatory response	[Human intestinal cell inflammatory responses]	0.0	5	1	1	1
86078	1710	regulation by messenger in b cell	[Regulation by messengers in B cells]	0.0	6	1	1	1
86079	1710	human erythroid 5-aminolevulinate synthase	[Human erythroid 5-aminolevulinate synthase]	0.0	4	1	1	1
86080	1710	different process	[different processes]	0.0	2	1	1	1
86081	1710	3.5 kb transcript	[3.5 kb transcript]	0.0	3	1	1	1
86082	1710	involve interaction between multiple regulatory element	[involving interactions between multiple regulatory elements]	0.0	6	1	1	1
86083	1710	similar weight	[similar weights]	0.0	2	1	1	1
86084	1710	prevent activation of gene contain element	[preventing activation of genes containing elements]	0.0	6	1	1	1
86085	1710	role of cis-act element	[role of cis-acting elements]	0.0	4	1	1	1
86086	1710	human MHC class gene transcription one	[Human MHC class gene transcription one]	0.0	6	1	1	1
86087	1710	factor Evi-1	[factors Evi-1]	0.0	2	1	1	1
86088	1710	cell number,	[cell number,]	0.0	2	1	1	1
86089	1710	drug resistant marker	[drug resistant marker]	0.0	3	1	1	1
86090	1710	interleukin-4 promoter activity	[interleukin-4 promoter activity]	0.0	3	1	1	1
86091	1710	substantial sequence similarity	[substantial sequence similarity]	0.0	3	1	1	1
86092	1710	hormonal metabolic status	[Hormonal metabolic status]	0.0	3	1	1	1
86093	1710	dissociation constant kd of nm	[dissociation constant Kd of nM]	0.0	5	1	1	1
86094	1710	tarsal biopsy from patient	[tarsal biopsies from patients]	0.0	4	1	1	1
86095	1710	predictive clue	[predictive clue]	0.0	2	1	1	1
86096	1710	diethylstilbestrol DES	[diethylstilbestrol DES]	0.0	2	1	1	1
86097	1710	immediate gene of cytomegalovirus	[immediate genes of cytomegalovirus]	0.0	4	1	1	1
86098	1710	VZV gE-HSV	[VZV gE-HSV]	0.0	2	1	1	1
86099	1710	family of proteins,	[family of proteins,]	0.0	3	1	1	1
86100	1710	tissue regulation	[Tissue regulation]	0.0	2	1	1	1
86101	1710	amide bond	[amide bond]	0.0	2	1	1	1
86102	1710	two viral transactivator	[two viral transactivators]	0.0	3	1	1	1
86103	1710	use defensin	[using defensins]	0.0	2	1	1	1
86104	1710	moreover, oligodeoxynucleotides target gata-1 nf-e2 protein	[Moreover, oligodeoxynucleotides targeting GATA-1 NF-E2 proteins]	0.0	6	1	1	1
86105	1710	immunoglobulin (ig) m	[immunoglobulin (Ig) M]	0.0	3	1	1	1
86106	1710	expression of cytolytic effector molecule	[expression of cytolytic effector molecules]	0.0	5	1	1	1
86107	1710	Potent inhibition by a alkaloid	[Potent inhibition by an alkaloid]	0.0	5	1	1	1
86108	1710	quantity of a number	[quantities of a number]	0.0	4	1	1	1
86109	1710	circulate cortisol concentration	[circulating cortisol concentrations]	0.0	3	1	1	1
86110	1710	shuttling in discrimination	[shuttling in discrimination]	0.0	3	1	1	1
86111	1710	glucocorticoid receptor complex in cytosol	[glucocorticoid receptor complexes in cytosol]	0.0	5	1	1	1
86112	1710	macrophage from normal individual	[macrophages from normal individuals]	0.0	4	1	1	1
86113	1710	amino-terminal rel-related domain	[amino-terminal Rel-related domain]	0.0	3	1	1	1
86114	1710	detectable effect in u937 cell	[detectable effect in U937 cells]	0.0	5	1	1	1
86115	1710	hiv expression by acid	[HIV expression by acid]	0.0	4	1	1	1
86116	1710	particle exposure of bm	[particle exposure of BM]	0.0	4	1	1	1
86117	1710	disparate stimulus-	[disparate stimulus-]	0.0	2	1	1	1
86118	1710	carboxyl-terminal cytoplasmic domain	[carboxyl-terminal cytoplasmic domain]	0.0	3	1	1	1
86119	1710	amount of jak3	[amount of JAK3]	0.0	3	1	1	1
86120	1710	beta-phorbol 12-myristate 13-acetate addition	[beta-phorbol 12-myristate 13-acetate addition]	0.0	4	1	1	1
86121	1710	diploid fibroblast	[diploid fibroblasts]	0.0	2	1	1	1
86122	1710	deletion of 346 residue	[deletion of 346 residues]	0.0	4	1	1	1
86123	1710	adhesion molecule-1 expression	[adhesion molecule-1 expression]	0.0	3	1	1	1
86124	1710	erythroid-specific dnase 1 site-forming element	[erythroid-specific DNase 1 site-forming element]	0.0	5	1	1	1
86125	1710	convert signal	[converting signals]	0.0	2	1	1	1
86126	1710	cellular protein Bik	[cellular protein Bik]	0.0	3	1	1	1
86127	1710	nuclear factor-mu regulator NF-muNR	[nuclear factor-mu regulator NF-muNR]	0.0	4	1	1	1
86128	1710	b cell from B-CLL patient	[B cells from B-CLL patients]	0.0	5	1	1	1
86129	1710	cotransfection of gamma	[Cotransfection of gamma]	0.0	3	1	1	1
86130	1710	B factor	[B factor]	0.0	2	1	1	1
86131	1710	class T cell line	[class T cell line]	0.0	4	1	1	1
86132	1710	pleiotropic regulator of gene	[pleiotropic regulator of genes]	0.0	4	1	1	1
86133	1710	series of centrifugation	[series of centrifugations]	0.0	3	1	1	1
86134	1710	early cytokine	[early cytokines]	0.0	2	1	1	1
86135	1710	platelet (auc of 332	[platelets (AUC of 332]	0.0	4	1	1	1
86136	1710	native terminal repeat LTR	[native terminal repeat LTR]	0.0	4	1	1	1
86137	1710	20- to 25-fold increase	[20- to 25-fold increase]	0.0	4	1	1	1
86138	1710	52 binding site	[52 binding sites]	0.0	3	1	1	1
86139	1710	different schedule of calcitriol	[different schedules of calcitriol]	0.0	4	1	1	1
86140	1710	rbtn-2 binding	[RBTN-2 binding]	0.0	2	1	1	1
86141	1710	tumor of the cavity	[tumors of the cavity]	0.0	4	1	1	1
86142	1710	tr beta	[TR beta]	0.0	2	1	1	1
86143	1710	two pkc substrate	[two PKC substrates]	0.0	3	1	1	1
86144	1710	il-9 cell growth	[IL-9 cell growth]	0.0	3	1	1	1
86145	1710	conformation in erythroid cell	[conformation in erythroid cells]	0.0	4	1	1	1
86146	1710	MAZ transcription	[MAZ transcription]	0.0	2	1	1	1
86147	1710	cognate DNA element	[cognate DNA elements]	0.0	3	1	1	1
86148	1710	jpx-9 cell	[JPX-9 cells]	0.0	2	1	1	1
86149	1710	specific glucocorticoid binding rhythm of adrenocorticotropin	[specific glucocorticoid binding rhythms of adrenocorticotropin]	0.0	6	1	1	1
86150	1710	mechanism for effect of aspirin	[mechanism for effects of aspirin]	0.0	5	1	1	1
86151	1710	similarly in normal macrophage	[similarly in normal macrophages]	0.0	4	1	1	1
86152	1710	spectrometry	[spectrometry]	0.0	1	1	1	1
86153	1710	subunit of a transcription factor tfiih	[subunits of a transcription factor TFIIH]	0.0	6	1	1	1
86154	1710	widespread applicability,	[widespread applicability,]	0.0	2	1	1	1
86155	1710	k562 cell differentiation	[K562 cells differentiation]	0.0	3	1	1	1
86156	1710	such as Epstein-Barr virus ebv	[such as Epstein-Barr virus EBV]	0.0	5	1	1	1
86157	1710	mrna level of v-atpase subunit	[mRNA levels of V-ATPase subunits]	0.0	5	1	1	1
86158	1710	22 t-cell malignancy of stage	[22 T-cell malignancies of stages]	0.0	5	1	1	1
86159	1710	1.8 +/-	[1.8 +/-]	0.0	2	1	1	1
86160	1710	transcriptional induction by phorbol ester	[transcriptional induction by phorbol esters]	0.0	5	1	1	1
86161	1710	variation of glucocorticoid in aged subject	[Variation of glucocorticoids in aged subjects]	0.0	6	1	1	1
86162	1710	rest normal human lymphocyte	[resting normal human lymphocytes]	0.0	4	1	1	1
86163	1710	E1a- vector replicate	[E1a- vector replicating]	0.0	3	1	1	1
86164	1710	cell population L&H cell	[cell population L&H cells]	0.0	4	1	1	1
86165	1710	microgram fluticasone propionate aqueous spray	[micrograms fluticasone propionate aqueous spray]	0.0	5	1	1	1
86166	1710	ANG ii nf-kappab activation	[ANG II NF-kappaB activation]	0.0	4	1	1	1
86167	1710	kappab3)	[kappaB3)]	0.0	1	1	1	1
86168	1710	effect of bdp	[effect of BDP]	0.0	3	1	1	1
86169	1710	vaccine development	[vaccine development]	0.0	2	1	1	1
86170	1710	distinct pattern of intracellular signal	[distinct patterns of intracellular signaling]	0.0	5	1	1	1
86171	1710	binding to MHC class ii molecule	[Binding to MHC class II molecules]	0.0	6	1	1	1
86172	1710	physicochemical property	[physicochemical properties]	0.0	2	1	1	1
86173	1710	endogenous cytokine gene	[endogenous cytokine genes]	0.0	3	1	1	1
86174	1710	signal agent in the regulation	[signalling agents in the regulation]	0.0	5	1	1	1
86175	1710	dna-binding transcription	[DNA-binding transcription]	0.0	2	1	1	1
86176	1710	use the ifn-gamma-activated sequence gas oligonucleotide	[using the IFN-gamma-activated sequence GAS oligonucleotides]	0.0	6	1	1	1
86177	1710	nuclear localization of NF-AT	[nuclear localization of NF-AT]	0.0	4	1	1	1
86178	1710	even after h	[even after h]	0.0	3	1	1	1
86179	1710	two form of collaboration	[two forms of collaboration]	0.0	4	1	1	1
86180	1710	mono Mac 6 cell	[Mono Mac 6 cells]	0.0	4	1	1	1
86181	1710	concentration of 1,25-dihydroxyvitamin D3 receptor	[concentration of 1,25-dihydroxyvitamin D3 receptors]	0.0	5	1	1	1
86182	1710	follow human CMV infection	[following human CMV infection]	0.0	4	1	1	1
86183	1710	lead to the entry of cell	[leading to the entry of cells]	0.0	6	1	1	1
86184	1710	cell line three	[cell lines three]	0.0	3	1	1	1
86185	1710	response in rheumatoid arthritis RA	[response in rheumatoid arthritis RA]	0.0	5	1	1	1
86186	1710	4 and,	[4 and,]	0.0	2	1	1	1
86187	1710	'silencer'	['silencer']	0.0	1	1	1	1
86188	1710	namely the immunoglobulin chain enhancer igh-enhancer	[namely the immunoglobulin chain enhancer IgH-enhancer]	0.0	6	1	1	1
86189	1710	whole venous blood	[whole venous blood]	0.0	3	1	1	1
86190	1710	isolation of sequence tag	[Isolation of sequence tags]	0.0	4	1	1	1
86191	1710	pathogenic process similar	[pathogenic processes similar]	0.0	3	1	1	1
86192	1710	Specific receptor	[Specific receptors]	0.0	2	1	1	1
86193	1710	two lymphoma cell line	[two lymphoma cell lines]	0.0	4	1	1	1
86194	1710	day establish pbmc culture (1.5	[days establishing PBMC cultures (1.5]	0.0	5	1	1	1
86195	1710	guideline related	[guidelines related]	0.0	2	1	1	1
86196	1710	apart from lymphocyte the source	[apart from lymphocytes the source]	0.0	5	1	1	1
86197	1710	rat pancrea	[rat pancreas]	0.0	2	1	1	1
86198	1710	toll-like receptor tlr2	[Toll-like receptor TLR2]	0.0	3	1	1	1
86199	1710	reactive oxygen release	[reactive oxygen release]	0.0	3	1	1	1
86200	1710	hormonal status	[Hormonal status]	0.0	2	1	1	1
86201	1710	proliferations.	[proliferations.]	0.0	1	1	1	1
86202	1710	2 globin promoter	[2 globin promoter]	0.0	3	1	1	1
86203	1710	breast tumor lymphocyte corresponding	[breast tumor lymphocytes corresponding]	0.0	4	1	1	1
86204	1710	mutation of stat-binding site	[mutation of STAT-binding sites]	0.0	4	1	1	1
86205	1710	counteract 5' regulatory DNA sequence	[counteracting 5' regulatory DNA sequences]	0.0	5	1	1	1
86206	1710	sphingomyelinase signal	[sphingomyelinase signals]	0.0	2	1	1	1
86207	1710	family with spinal atrophy	[families with spinal atrophy]	0.0	4	1	1	1
86208	1710	high level of ige	[high levels of IgE]	0.0	4	1	1	1
86209	1710	contain n-terminal peptide	[containing N-terminal peptide]	0.0	3	1	1	1
86210	1710	acid modulation of il-2 mrna production	[acid modulation of IL-2 mRNA production]	0.0	6	1	1	1
86211	1710	analysis latency	[analysis latency]	0.0	2	1	1	1
86212	1710	human zeta 2 globin promoter	[human zeta 2 globin promoter]	0.0	5	1	1	1
86213	1710	regulate human immunodeficiency virus persistence	[regulating human immunodeficiency virus persistence]	0.0	5	2	2	1
86214	1710	transcriptional silencing	[transcriptional silencing]	0.0	2	1	1	1
86215	1710	state kappa	[state kappa]	0.0	2	1	1	1
86216	1710	surface receptor consist	[surface receptors consisting]	0.0	3	1	1	1
86217	1710	other human cell	[other human cells]	0.0	3	1	1	1
86218	1710	activation follow tcr stimulation	[activation following TCR stimulation]	0.0	4	1	1	1
86219	1710	-182 base pair (bp))	[-182 base pairs (bp))]	0.0	4	1	1	1
86220	1710	transcription activity in vitro.	[transcription activity in vitro.]	0.0	4	1	1	1
86221	1710	true IL-12 stage involve expression	[true IL-12 stage involving expression]	0.0	5	1	1	1
86222	1710	Effect of alpha-lipoic acid on expression	[Effects of alpha-lipoic acid on expression]	0.0	6	1	1	1
86223	1710	transcription factor nf-kappab regulation	[Transcription factor NF-kappaB regulation]	0.0	4	1	1	1
86224	1710	distinctly different requirement for binding,	[distinctly different requirements for binding,]	0.0	5	1	1	1
86225	1710	hiv-1 transcription antibody	[HIV-1 transcription antibody]	0.0	3	1	1	1
86226	1710	state of hiv-1 infection	[state of HIV-1 infection]	0.0	4	1	1	1
86227	1710	Epstein Barr	[Epstein Barr]	0.0	2	1	1	1
86228	1710	plaque development	[plaque development]	0.0	2	1	1	1
86229	1710	monoclonal antibody mab phosphatidylinositol 3-kinase	[monoclonal antibody mAb phosphatidylinositol 3-kinase]	0.0	5	1	1	1
86230	1710	CREB/activating	[CREB/activating]	0.0	1	1	1	1
86231	1710	basis for this species specificity	[basis for this species specificity]	0.0	5	1	1	1
86232	1710	formation of DNase hypersensitive site	[formation of DNase hypersensitive sites]	0.0	5	1	1	1
86233	1710	specific; lps	[specific; LPS]	0.0	2	1	1	1
86234	1710	cell use mrna differential display	[cells using mRNA differential display]	0.0	5	1	1	1
86235	1710	adhesion molecule in human cell	[adhesion molecules in human cells]	0.0	5	1	1	1
86236	1710	human epithelial cell response to infection	[Human epithelial cell responses to infection]	0.0	6	1	1	1
86237	1710	a-t individual	[A-T individuals]	0.0	2	2	2	1
86238	1710	Stat3 recruitment by two docking site	[Stat3 recruitment by two docking sites]	0.0	6	1	1	1
86239	1710	pair of grade malignant astrocytomas	[pairs of grade malignant astrocytomas]	0.0	5	1	1	1
86240	1710	glucocorticoid binding at different level	[glucocorticoid binding at different levels]	0.0	5	1	1	1
86241	1710	induce transcription of the proto-oncogent c-fo	[inducing transcription of the proto-oncogenes c-fos]	0.0	6	1	1	1
86242	1710	production of oxide a pathway	[production of oxide a pathway]	0.0	5	1	1	1
86243	1710	structure-function study	[Structure-function studies]	0.0	2	1	1	1
86244	1710	evidence for the translational suppression	[evidence for the translational suppression]	0.0	5	1	1	1
86245	1710	human peripheral leucocyte in man	[human peripheral leucocytes in men]	0.0	5	1	1	1
86246	1710	cd19 cross-linking in BLIN-1 cell	[CD19 cross-linking in BLIN-1 cells]	0.0	5	1	1	1
86247	1710	mobility shift assay use protein extract	[mobility shift assays using protein extracts]	0.0	6	1	1	1
86248	1710	IL-2 translocation of the kda protein	[IL-2 translocation of the kDa protein]	0.0	6	1	1	1
86249	1710	circadian pacemaker of GR	[circadian pacemaker of GR]	0.0	4	1	1	1
86250	1710	type T lymphocyte	[type T lymphocytes]	0.0	3	1	1	1
86251	1710	expression of glucocorticoid receptor	[expression of glucocorticoid receptors]	0.0	4	1	1	1
86252	1710	carboxyl-terminal segment on cd36	[carboxyl-terminal segment on CD36]	0.0	4	1	1	1
86253	1710	incorporation into the MNL	[incorporation into the MNL]	0.0	4	1	1	1
86254	1710	ras oncogene transformation	[Ras oncogene transformation]	0.0	3	1	1	1
86255	1710	patient with dermatitis	[patients with dermatitis]	0.0	3	2	2	1
86256	1710	47-kda protein	[47-kDa protein]	0.0	2	1	1	1
86257	1710	one such mutant line	[one such mutant line]	0.0	4	1	1	1
86258	1710	pld activation under different conditions.	[PLD activation under different conditions.]	0.0	5	1	1	1
86259	1710	lymphocyte proliferation for the group	[lymphocyte proliferation for the group]	0.0	5	1	1	1
86260	1710	endogenous NFkappaB	[endogenous NFkappaB]	0.0	2	1	1	1
86261	1710	high proliferative potential hpp- cell	[high proliferative potential HPP- cells]	0.0	5	1	1	1
86262	1710	Th1-dominated inflammation	[Th1-dominated inflammation]	0.0	2	1	1	1
86263	1710	shift of Lck	[shift of Lck]	0.0	3	1	1	1
86264	1710	anhydrase ii a gene	[anhydrase II a gene]	0.0	4	1	1	1
86265	1710	expression of p16 in lymphocyte	[expression of p16 in lymphocytes]	0.0	5	1	1	1
86266	1710	cord lymphocyte c-fo expression (82+/-6	[cord lymphocyte c-fos expression (82+/-6]	0.0	5	1	1	1
86267	1710	granulocytic lineage (with	[granulocytic lineage (with]	0.0	3	1	1	1
86268	1710	immunogenetic basis	[immunogenetic basis]	0.0	2	1	1	1
86269	1710	(approximately nm) of calyculin a	[(approximately nM) of calyculin A]	0.0	5	1	1	1
86270	1710	use monocyte in 69%	[using monocytes in 69%]	0.0	4	1	1	1
86271	1710	variety of extract	[variety of extracts]	0.0	3	1	1	1
86272	1710	interleukin-3 macrophage factor	[interleukin-3 macrophage factor]	0.0	3	1	1	1
86273	1710	two class ii	[two class II]	0.0	3	1	1	1
86274	1710	erythrocyte gene	[erythrocyte genes]	0.0	2	1	1	1
86275	1710	study of early development	[study of early development]	0.0	4	1	1	1
86276	1710	physiological effect	[physiological effects]	0.0	2	1	1	1
86277	1710	collectively, transcriptional factor	[Collectively, transcriptional factor]	0.0	3	1	1	1
86278	1710	180 amino acid	[180 amino acids]	0.0	3	1	1	1
86279	1710	platelet (auc of 332 nmol	[platelets (AUC of 332 nmol]	0.0	5	1	1	1
86280	1710	model system examine change	[model system examining changes]	0.0	4	1	1	1
86281	1710	antibody against brdu	[antibodies against BrdU]	0.0	3	1	1	1
86282	1710	slP-76-deficient T	[SLP-76-deficient T]	0.0	2	1	1	1
86283	1710	bhrf1 early-lytic-cycle protein	[BHRF1 early-lytic-cycle protein]	0.0	3	1	1	1
86284	1710	range from mmol/L.	[ranging from mmol/L.]	0.0	3	1	1	1
86285	1710	approach to intervention.	[approach to intervention.]	0.0	3	1	1	1
86286	1710	weak interaction with the ptf	[weak interaction with the PTF]	0.0	5	1	1	1
86287	1710	stat5a DNA	[STAT5a DNA]	0.0	2	1	1	1
86288	1710	stable replication	[stable replication]	0.0	2	1	1	1
86289	1710	germ-line igh gene	[germ-line IgH genes]	0.0	3	1	1	1
86290	1710	Differential induction 10 follow differentiation	[Differential induction 10 following differentiation]	0.0	5	1	1	1
86291	1710	moreover, anti- TNF-alpha hiv-1 repeat	[Moreover, anti- TNF-alpha HIV-1 repeat]	0.0	5	1	1	1
86292	1710	effect on nfat activation	[effects on NFAT activation]	0.0	4	1	1	1
86293	1710	obstacle understand the signal event	[obstacle understanding the signaling events]	0.0	5	1	1	1
86294	1710	activity of topoisomerase in extract	[activity of topoisomerases in extracts]	0.0	5	1	1	1
86295	1710	occupancy of the enhancer heterodimer	[occupancy of the enhancer heterodimers]	0.0	5	1	1	1
86296	1710	immune modulate effect	[immune modulating effects]	0.0	3	1	1	1
86297	1710	related protein- tyrosine kinase	[related protein- tyrosine kinases]	0.0	4	1	1	1
86298	1710	range of gene	[range of genes]	0.0	3	1	1	1
86299	1710	closely related acid receptor	[closely related acid receptor]	0.0	4	1	1	1
86300	1710	additional agent	[additional agents]	0.0	2	1	1	1
86301	1710	encompass a regulatory element	[encompassing an regulatory element]	0.0	4	1	1	1
86302	1710	six discrete subregion	[six discrete subregions]	0.0	3	1	1	1
86303	1710	thp-1 a monocytic cell line	[THP-1 a monocytic cell line]	0.0	5	1	1	1
86304	1710	localization contain factor kappab NFkappaB complex	[localization containing factor kappaB NFkappaB complexes]	0.0	6	1	1	1
86305	1710	evidence a modulator	[evidence a modulator]	0.0	3	1	1	1
86306	1710	recruiting distinct histone deacetylase complex	[recruiting distinct histone deacetylase complexes]	0.0	5	1	1	1
86307	1710	similar region of other sequence	[similar regions of other sequences]	0.0	5	1	1	1
86308	1710	physiological cell death pathway	[physiological cell death pathway]	0.0	4	1	1	1
86309	1710	b co-activator	[B co-activator]	0.0	2	1	1	1
86310	1710	level of ikappabalpha mrna	[levels of IkappaBalpha mRNA]	0.0	4	1	1	1
86311	1710	phosphorylation of subunit	[phosphorylation of subunit]	0.0	3	1	1	1
86312	1710	pax-258	[Pax-258]	0.0	1	1	1	1
86313	1710	hsp60 in umbilical vein cell	[Hsp60 in umbilical vein cells]	0.0	5	1	1	1
86314	1710	prevent activation	[preventing activation]	0.0	2	3	3	1
86315	1710	suppress pathway essential	[suppressing pathways essential]	0.0	3	1	1	1
86316	1710	endometriosis at phase	[endometriosis at phases]	0.0	3	1	1	1
86317	1710	large substitution on c-11	[Large substitutions on C-11]	0.0	4	1	1	1
86318	1710	homing of b cell	[homing of B cells]	0.0	4	1	1	1
86319	1710	element of inducible t-cell gene	[elements of inducible T-cell genes]	0.0	5	1	1	1
86320	1710	low reporter mrna level	[low reporter mRNA levels]	0.0	4	1	1	1
86321	1710	gamma-ifn inhibition of 135eoh)2d3	[gamma-IFN inhibition of 1,25(OH)2D3]	0.0	4	1	1	1
86322	1710	binding site in regulatory region	[binding site in regulatory regions]	0.0	5	1	1	1
86323	1710	Rel domain	[Rel domain]	0.0	2	1	1	1
86324	1710	substnfkappab approximately substSpl2 substSp23	[substNFkappaB approximately substSpl2 substSp23]	0.0	4	1	1	1
86325	1710	action of MPL	[action of MPL]	0.0	3	1	1	1
86326	1710	high affinity for GRE site	[high affinity for GRE sites]	0.0	5	1	1	1
86327	1710	several pml/rar-alpha peptide	[several pml/RAR-alpha peptides]	0.0	3	1	1	1
86328	1710	20 residue	[20 residues]	0.0	2	1	1	1
86329	1710	platelet activate	[platelet activating]	0.0	2	2	2	1
86330	1710	cross-linking tgf-beta 1	[cross-linking TGF-beta 1]	0.0	3	1	1	1
86331	1710	YY-1 delta	[YY-1 delta]	0.0	2	1	1	1
86332	1710	event in the activation	[events in the activation]	0.0	4	1	1	1
86333	1710	replication of immunodeficiency virus in thymocyte	[replication of immunodeficiency virus in thymocytes]	0.0	6	1	1	1
86334	1710	scavenging property	[scavenging properties]	0.0	2	1	1	1
86335	1710	carry the irf-1 gene	[carrying the IRF-1 gene]	0.0	4	1	1	1
86336	1710	cd56 in blast	[CD56 in blasts]	0.0	3	1	1	1
86337	1710	factor in T cell	[factor in T cells]	0.0	4	1	1	1
86338	1710	understanding of B-cell development	[understanding of B-cell development]	0.0	4	1	1	1
86339	1710	hiv enhancer -dependent transcription	[HIV enhancer -dependent transcription]	0.0	4	1	1	1
86340	1710	cobalt chloride signal in endothelium	[Cobalt chloride signaling in endothelium]	0.0	5	1	1	1
86341	1710	terminal repeat site	[terminal repeat sites]	0.0	3	1	1	1
86342	1710	new transcription factor bind	[new transcription factor binding]	0.0	4	1	1	1
86343	1710	effectively, responder	[effectively, responders]	0.0	2	1	1	1
86344	1710	part by cell October factor	[part by cell Oct factors]	0.0	5	1	1	1
86345	1710	bifunctional regulator of growth	[bifunctional regulators of growth]	0.0	4	1	1	1
86346	1710	activation JAK stat	[activation JAK STAT]	0.0	3	1	1	1
86347	1710	promotor	[promotor]	0.0	1	1	1	1
86348	1710	tonically suppress central system	[tonically suppressing central system]	0.0	4	1	1	1
86349	1710	cell with a rapid rate	[cells with a rapid rate]	0.0	5	1	1	1
86350	1710	two (mz) twin	[two (MZ) twins]	0.0	3	1	1	1
86351	1710	diseases, include hematological malignancy	[diseases, including hematological malignancies]	0.0	4	1	1	1
86352	1710	e3 mrna level	[E3 mRNA levels]	0.0	3	1	1	1
86353	1710	express CAT	[expressing CAT]	0.0	2	1	1	1
86354	1710	mechanism govern the control	[mechanisms governing the control]	0.0	4	1	1	1
86355	1710	patient group.	[patient group.]	0.0	2	1	1	1
86356	1710	extensive homology	[extensive homology]	0.0	2	1	1	1
86357	1710	septic patient	[septic patients]	0.0	2	1	1	1
86358	1710	express a rev protein	[expressing a Rev protein]	0.0	4	1	1	1
86359	1710	formation of c-fo promoter sis-inducible element	[formation of c-fos promoter sis-inducible element]	0.0	6	1	1	1
86360	1710	ikappab kinase ikk	[IkappaB kinase IKK]	0.0	3	1	1	1
86361	1710	early generation	[early generation]	0.0	2	1	1	1
86362	1710	isoform in naive T cell	[isoforms in naive T cells]	0.0	5	1	1	1
86363	1710	proteolytic regulation of function.	[proteolytic regulation of function.]	0.0	4	1	1	1
86364	1710	interleukin-3 factor	[interleukin-3 factor]	0.0	2	1	1	1
86365	1710	change depend on the combination	[changing depending on the combination]	0.0	5	1	1	1
86366	1710	cell progression	[cell progression]	0.0	2	1	1	1
86367	1710	oxidative stress with oxygen formation	[Oxidative stress with oxygen formation]	0.0	5	1	1	1
86368	1710	report of chromosome abnormality	[reports of chromosome abnormalities]	0.0	4	1	1	1
86369	1710	concomitant decrease in ap-1	[concomitant decrease in AP-1]	0.0	4	1	1	1
86370	1710	delta K	[delta K]	0.0	2	3	3	1
86371	1710	group of race- control subject	[group of race- control subjects]	0.0	5	1	1	1
86372	1710	functional specificity of transcriptional regulator	[functional specificity of transcriptional regulators]	0.0	5	1	1	1
86373	1710	residue of the protein	[residues of the protein]	0.0	4	1	1	1
86374	1710	activation the weight variant	[activation the weight variant]	0.0	4	1	1	1
86375	1710	PKC stimulus	[PKC stimulus]	0.0	2	1	1	1
86376	1710	delta T	[delta T]	0.0	2	1	1	1
86377	1710	patient with various disease (12:	[patients with various diseases (12:]	0.0	5	1	1	1
86378	1710	early serum gene	[early serum genes]	0.0	3	1	1	1
86379	1710	inhibition of IL-4 gene expression	[Inhibition of IL-4 gene expression]	0.0	5	1	1	1
86380	1710	calcitonin	[calcitonin]	0.0	1	1	1	1
86381	1710	result in differentiation	[resulting in differentiation]	0.0	3	1	1	1
86382	1710	factor kappa b nf-kappa b activity	[factor kappa B NF-kappa B activity]	0.0	6	1	1	1
86383	1710	amount of stat1	[amounts of STAT1]	0.0	3	1	1	1
86384	1710	therefore a EB1 -responsive element	[therefore an EB1 -responsive element]	0.0	5	1	1	1
86385	1710	joint requirement	[joint requirement]	0.0	2	1	1	1
86386	1710	interferon-gamma in human blood lymphocyte	[interferon-gamma in human blood lymphocytes]	0.0	5	1	1	1
86387	1710	lysosomal protein myeloperoxidase mpo	[lysosomal proteins myeloperoxidase MPO]	0.0	4	1	1	1
86388	1710	response to medium	[response to medium]	0.0	3	1	1	1
86389	1710	direct analysis with hugata-3	[Direct analysis with huGATA-3]	0.0	4	1	1	1
86390	1710	glucocorticosteroid response element	[glucocorticosteroid response element]	0.0	3	1	1	1
86391	1710	IgH-luciferase construct	[IgH-luciferase construct]	0.0	2	1	1	1
86392	1710	abundant protein kD	[abundant proteins kD]	0.0	3	1	1	1
86393	1710	membrane g(s)alpha expression	[membrane G(S)alpha expression]	0.0	3	1	1	1
86394	1710	1.8 kb 5'	[1.8 kb 5']	0.0	3	1	1	1
86395	1710	land electron-dense structure	[LANDs electron-dense structures]	0.0	3	1	1	1
86396	1710	NFkappaB /inhibitor-kappaB	[NFkappaB /inhibitor-kappaB]	0.0	2	1	1	1
86397	1710	apoptotic muscle cell	[apoptotic muscle cells]	0.0	3	1	1	1
86398	1710	apoptosis potential role of IL-1 beta	[apoptosis potential role of IL-1 beta]	0.0	6	1	1	1
86399	1710	different cell include cell	[different cells including cells]	0.0	4	1	1	1
86400	1710	CD19 cell	[CD19 cells]	0.0	2	1	1	1
86401	1710	benign mammary tissue	[benign mammary tissue]	0.0	3	1	1	1
86402	1710	early b-cell development	[early B-cell development]	0.0	3	1	1	1
86403	1710	atopic dermatitis ad	[atopic dermatitis AD]	0.0	3	1	1	1
86404	1710	potent modulator	[potent modulator]	0.0	2	1	1	1
86405	1710	magnetic resonance	[magnetic resonance]	0.0	2	1	1	1
86406	1710	stat transducer	[STAT transducers]	0.0	2	1	1	1
86407	1710	prime by cytokine from signal	[priming by cytokines from signal]	0.0	5	1	1	1
86408	1710	concentration of foreign antigen	[concentration of foreign antigen]	0.0	4	1	1	1
86409	1710	human mononuclear	[human mononuclear]	0.0	2	1	1	1
86410	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione]	0.0	2	1	1	1
86411	1710	transcription differentiate monocyte	[transcription differentiating monocytes]	0.0	3	1	1	1
86412	1710	b cell by human herpesvirus hhv-6	[B cells by human herpesvirus HHV-6]	0.0	6	1	1	1
86413	1710	various function	[various functions]	0.0	2	1	1	1
86414	1710	competition between tpo	[competition between TPO]	0.0	3	1	1	1
86415	1710	b-driven	[B-driven]	0.0	1	1	1	1
86416	1710	T cell line IARC 301	[T cell line IARC 301]	0.0	5	1	1	1
86417	1710	number of important signal molecule	[number of important signaling molecules]	0.0	5	1	1	1
86418	1710	magnetic resonance 3d-nmr spectroscopy	[magnetic resonance 3D-NMR spectroscopy]	0.0	4	1	1	1
86419	1710	suggest pha	[suggesting PHA]	0.0	2	1	1	1
86420	1710	clinical significance of receptor determination	[clinical significance of receptor determination]	0.0	5	1	1	1
86421	1710	acute patient aml cases)	[acute patients AML cases)]	0.0	4	1	1	1
86422	1710	activation of specific program	[activation of specific programs]	0.0	4	1	1	1
86423	1710	peroxisome proliferator-activated receptor member	[Peroxisome proliferator-activated receptors members]	0.0	4	1	1	1
86424	1710	concentration of the compound.	[concentrations of the compound.]	0.0	4	1	1	1
86425	1710	glucocorticoid binding at level	[glucocorticoid binding at levels]	0.0	4	1	1	1
86426	1710	tnf effect	[TNF effects]	0.0	2	1	1	1
86427	1710	acid phosphatase (trap)-positive giant cell	[acid phosphatase (TRAP)-positive giant cells]	0.0	5	1	1	1
86428	1710	ebna-2 transactivation	[EBNA-2 transactivation]	0.0	2	1	1	1
86429	1710	suggest a effect on the activity	[suggesting a effect on the activity]	0.0	6	1	1	1
86430	1710	hla b8-restricted peptide	[HLA B8-restricted peptide]	0.0	3	1	1	1
86431	1710	immunogenic melanoma	[immunogenic melanomas]	0.0	2	1	1	1
86432	1710	Furthermore, activation	[Furthermore, activation]	0.0	2	1	1	1
86433	1710	translocation a member	[translocation a member]	0.0	3	1	1	1
86434	1710	activator of inflammation	[activator of inflammation]	0.0	3	1	1	1
86435	1710	activation of Jak tyrosine kinase T	[activation of Jak tyrosine kinases T]	0.0	6	1	1	1
86436	1710	10 microm sodium orthovanadate	[10 microM sodium orthovanadate]	0.0	4	1	1	1
86437	1710	requirement for the NF-kappa b	[requirement for the NF-kappa B]	0.0	5	1	1	1
86438	1710	augment replication	[augmenting replication]	0.0	2	1	1	1
86439	1710	delta k	[delta K]	0.0	2	1	1	1
86440	1710	involve interaction between positive transcriptional element	[involving interactions between positive transcriptional elements]	0.0	6	1	1	1
86441	1710	oligonucleotide GM3	[oligonucleotide GM3]	0.0	2	1	1	1
86442	1710	three candidate gene factor	[three candidate genes factor]	0.0	4	1	1	1
86443	1710	gc box binding protein	[GC box binding proteins]	0.0	4	1	1	1
86444	1710	addition of inhibitor	[addition of inhibitors]	0.0	3	1	1	1
86445	1710	period, cd41 immunofluorescence	[period, CD41 immunofluorescence]	0.0	3	1	1	1
86446	1710	particular value	[particular value]	0.0	2	1	1	1
86447	1710	toxicity secondary to dihydropyrimidine dehydrogenase deficiency	[toxicity secondary to dihydropyrimidine dehydrogenase deficiency]	0.0	6	1	1	1
86448	1710	six factor lbf2	[six factors LBF2]	0.0	3	1	1	1
86449	1710	brain structure	[brain structure]	0.0	2	1	1	1
86450	1710	(mean 78 years)	[(mean 78 years)]	0.0	3	1	1	1
86451	1710	induce Cepsilon germline transcript	[inducing Cepsilon germline transcripts]	0.0	4	1	1	1
86452	1710	combinatorial activation	[combinatorial activation]	0.0	2	1	1	1
86453	1710	cell type to lipopolysaccharide lps	[cell types to lipopolysaccharide LPS]	0.0	5	1	1	1
86454	1710	eig)-secreting cell in pokeweed mitogen	[(Ig)-secreting cells in pokeweed mitogen]	0.0	5	1	1	1
86455	1710	clinical responsiveness to prednisolone	[clinical responsiveness to prednisolone]	0.0	4	1	1	1
86456	1710	one in T cell	[one in T cells]	0.0	4	1	1	1
86457	1710	accordingly, western blot	[Accordingly, Western blots]	0.0	3	1	1	1
86458	1710	Eed gene expression during embryogenesis	[Eed gene expression during embryogenesis]	0.0	5	1	1	1
86459	1710	additional evidence a modulator	[additional evidence a modulator]	0.0	4	1	1	1
86460	1710	blotting (rna) blotting assay	[blotting (RNA) blotting assays]	0.0	4	1	1	1
86461	1710	mouse ets-1	[mouse ets-1]	0.0	2	1	1	1
86462	1710	FK506 -sensitive pathway	[FK506 -sensitive pathway]	0.0	3	1	1	1
86463	1710	envelope glycoprotein of hiv-1 gp160	[envelope glycoproteins of HIV-1 gp160]	0.0	5	1	1	1
86464	1710	promoter in the stage.	[promoter in the stage.]	0.0	4	1	1	1
86465	1710	addition in culture medium	[addition in culture medium]	0.0	4	1	1	1
86466	1710	factor protein to dna,	[factor proteins to DNA,]	0.0	4	1	1	1
86467	1710	interaction with the basal machinery.	[interaction with the basal machinery.]	0.0	5	1	1	1
86468	1710	incubation from individual	[incubation from individuals]	0.0	3	1	1	1
86469	1710	follow expression in vitro	[following expression in vitro]	0.0	4	1	1	1
86470	1710	week after RAI therapy the number	[weeks after RAI therapy the number]	0.0	6	1	1	1
86471	1710	immediate-early gene include interleukin-2	[immediate-early genes including interleukin-2]	0.0	4	1	1	1
86472	1710	complex with different class	[complexes with different classes]	0.0	4	1	1	1
86473	1710	toxicity in a patient	[toxicity in a patient]	0.0	4	1	1	1
86474	1710	vitro, platelet	[vitro, platelets]	0.0	2	1	1	1
86475	1710	stress-inducing signal during delivery and/or	[stress-inducing signals during delivery and/or]	0.0	5	1	1	1
86476	1710	obligatory requirement	[obligatory requirement]	0.0	2	1	1	1
86477	1710	u/ml in the c group; p	[U/mL in the C group; P]	0.0	6	1	1	1
86478	1710	inhibition in the presence	[Inhibition in the presence]	0.0	4	1	1	1
86479	1710	proliferation, cytotoxicity,	[proliferation, cytotoxicity,]	0.0	2	1	1	1
86480	1710	thyroid hormone element aggtcatgacct	[thyroid hormone element AGGTCATGACCT]	0.0	4	1	1	1
86481	1710	subsequent monocyte adhesion in cell	[subsequent monocyte adhesion in cells]	0.0	5	1	1	1
86482	1710	rna (snrna) gene	[RNA (snRNA) genes]	0.0	3	1	1	1
86483	1710	suggest still effective in the phase	[suggesting still effective in the phase]	0.0	6	1	1	1
86484	1710	murine transcription	[murine transcription]	0.0	2	1	1	1
86485	1710	activation a direct antiatherogenic mechanism	[activation A direct antiatherogenic mechanism]	0.0	5	1	1	1
86486	1710	murine macrophage protein alpha	[Murine macrophage protein alpha]	0.0	4	1	1	1
86487	1710	anti-ERK extracellular kinase antibody	[anti-ERK extracellular kinase antibodies]	0.0	4	1	1	1
86488	1710	single cyclic amp-responsive element	[single cyclic AMP-responsive element]	0.0	4	1	1	1
86489	1710	determinant for the activity	[determinant for the activity]	0.0	4	1	1	1
86490	1710	lack of cushingoid feature	[lack of cushingoid features]	0.0	4	1	1	1
86491	1710	correlation points), body mass	[correlation points), body mass]	0.0	4	1	1	1
86492	1710	control cd19 gene expression	[controlling CD19 gene expression]	0.0	4	1	1	1
86493	1710	three tnf cell line	[three TNF cell lines]	0.0	4	1	1	1
86494	1710	transcriptional regulation during differentiation of cell	[Transcriptional regulation during differentiation of cells]	0.0	6	1	1	1
86495	1710	peroxisome-proliferator receptor gamma a member	[peroxisome-proliferator receptor gamma a member]	0.0	5	1	1	1
86496	1710	considerable interindividual variation	[considerable interindividual variation]	0.0	3	1	1	1
86497	1710	case.	[case.]	0.0	1	1	1	1
86498	1710	primary approach	[primary approach]	0.0	2	1	1	1
86499	1710	process of aids pathogenesis	[process of AIDS pathogenesis]	0.0	4	1	1	1
86500	1710	evidence for involvement of gsk-3beta	[evidence for involvement of GSK-3beta]	0.0	5	1	1	1
86501	1710	relatively young (18- healthy volunteer	[relatively young (18- healthy volunteers]	0.0	5	1	1	1
86502	1710	expression of il-2r	[expression of IL-2R]	0.0	3	1	1	1
86503	1710	cell glutathione gsh	[cell glutathione GSH]	0.0	3	1	1	1
86504	1710	selective phosphatase inhibitor	[Selective phosphatase inhibitors]	0.0	3	1	1	1
86505	1710	prevalence of er	[prevalence of ER]	0.0	3	1	1	1
86506	1710	consequence include the possibility	[consequences including the possibility]	0.0	4	1	1	1
86507	1710	location:	[location:]	0.0	1	1	1	1
86508	1710	potential therapeutic index	[potential therapeutic index]	0.0	3	1	1	1
86509	1710	activator protein-1 AP-1 site	[activator protein-1 AP-1 site]	0.0	4	1	1	1
86510	1710	follow stimulation with agonist	[Following stimulation with agonists]	0.0	4	1	1	1
86511	1710	integral role	[integral role]	0.0	2	1	1	1
86512	1710	transcription of several important gene	[transcription of several important genes]	0.0	5	1	1	1
86513	1710	part, via activation	[part, via activation]	0.0	3	1	1	1
86514	1710	include instability	[including instability]	0.0	2	1	1	1
86515	1710	disease duration	[disease duration]	0.0	2	1	1	1
86516	1710	fibrosarcoma 8, histiocytoma	[fibrosarcoma 8, histiocytoma]	0.0	3	1	1	1
86517	1710	monocyte differentiation process	[monocyte differentiation process]	0.0	3	1	1	1
86518	1710	hot phenol extraction	[hot phenol extraction]	0.0	3	1	1	1
86519	1710	transfection of the porcine b-cell line	[transfection of the porcine B-cell line]	0.0	6	1	1	1
86520	1710	expression model	[expression model]	0.0	2	1	1	1
86521	1710	t(14;14)(q11;q32) chromosome translocation	[t(14;14)(q11;q32) chromosome translocation]	0.0	3	1	1	1
86522	1710	muscular atrophy a adult-onset form	[muscular atrophy an adult-onset form]	0.0	5	1	1	1
86523	1710	homologue of the rhombotin gene	[homologues of the rhombotin gene]	0.0	5	1	1	1
86524	1710	unknown protein	[unknown proteins]	0.0	2	1	1	1
86525	1710	pbl from different donor	[PBL from different donors]	0.0	4	1	1	1
86526	1710	events:	[events:]	0.0	1	1	1	1
86527	1710	events;	[events;]	0.0	1	1	1	1
86528	1710	-13- acetate	[-13- acetate]	0.0	2	1	1	1
86529	1710	tnf-alpha-activity	[TNF-alpha-activity]	0.0	1	1	1	1
86530	1710	memory T lymphocyte	[memory T lymphocytes]	0.0	3	1	1	1
86531	1710	implicate sequence in the control	[implicating sequences in the control]	0.0	5	1	1	1
86532	1710	experiments).	[experiments).]	0.0	1	1	1	1
86533	1710	considerable change in nature	[considerable change in nature]	0.0	4	1	1	1
86534	1710	Src family kinase	[Src family kinases]	0.0	3	1	1	1
86535	1710	Specific glucocorticoid binding	[Specific glucocorticoid binding]	0.0	3	1	1	1
86536	1710	effect of ald	[effect of ALD]	0.0	3	1	1	1
86537	1710	R.C. Gallo, Science	[R.C. Gallo, Science]	0.0	3	1	1	1
86538	1710	contributor	[contributor]	0.0	1	1	1	1
86539	1710	M10 cell line	[M10 cell lines]	0.0	3	1	1	1
86540	1710	tool for monitoring	[tools for monitoring]	0.0	3	1	1	1
86541	1710	cytokine promoter region	[cytokine promoter regions]	0.0	3	1	1	1
86542	1710	monocytic promoter activity	[monocytic promoter activity]	0.0	3	1	1	1
86543	1710	include adhesive molecule	[including adhesive molecules]	0.0	3	1	1	1
86544	1710	virion-associated protein	[virion-associated protein]	0.0	2	1	1	1
86545	1710	jak3 activation,	[JAK3 activation,]	0.0	2	1	1	1
86546	1710	critical downstream effector	[critical downstream effector]	0.0	3	1	1	1
86547	1710	immunodeficiency virus long terminal	[immunodeficiency virus long terminal]	0.0	4	1	1	1
86548	1710	Translational initiation of encephalomyocarditis virus mrna	[Translational initiation of encephalomyocarditis virus mRNA]	0.0	6	1	1	1
86549	1710	only a effect	[only a effect]	0.0	3	1	1	1
86550	1710	26 s protease	[26 S proteases]	0.0	3	1	1	1
86551	1710	role for otf-2	[role for OTF-2]	0.0	3	1	1	1
86552	1710	mediate shear- ec-mn adhesion	[mediating shear- EC-Mn adhesion]	0.0	4	1	1	1
86553	1710	pathway mediate low shear- ec-mn adhesion	[pathways mediating low shear- EC-Mn adhesion]	0.0	6	1	1	1
86554	1710	injection of red blood cell	[injection of red blood cells]	0.0	5	1	1	1
86555	1710	MNDA mrna level in monocyte	[MNDA mRNA level in monocytes]	0.0	5	1	1	1
86556	1710	regulation role of interaction between elf-1	[Regulation role of interactions between Elf-1]	0.0	6	1	1	1
86557	1710	respect to the protein,	[respect to the protein,]	0.0	4	1	1	1
86558	1710	element reporter gene	[element reporter gene]	0.0	3	1	1	1
86559	1710	acid sphingomyelinase	[acid sphingomyelinase]	0.0	2	1	1	1
86560	1710	activation of regulatory factor	[activation of regulatory factors]	0.0	4	1	1	1
86561	1710	p65 NF-kappa b subunit	[p65 NF-kappa B subunits]	0.0	4	1	1	1
86562	1710	pocket region	[pocket region]	0.0	2	1	1	1
86563	1710	physical proximity to the serine	[physical proximity to the serine]	0.0	5	1	1	1
86564	1710	presence 30 base pair	[presence 30 base pairs]	0.0	4	1	1	1
86565	1710	active lipid	[active lipids]	0.0	2	1	1	1
86566	1710	undetectable level of c-jun	[undetectable levels of c-jun]	0.0	4	1	1	1
86567	1710	cell line thp-1 cell	[cell line THP-1 cells]	0.0	4	1	1	1
86568	1710	ability, CBF beta	[ability, CBF beta]	0.0	3	1	1	1
86569	1710	subpopulation of t- lymphocyte	[subpopulations of T- lymphocytes]	0.0	4	1	1	1
86570	1710	Furthermore, treatment	[Furthermore, treatment]	0.0	2	1	1	1
86571	1710	usual mechanism of expression	[usual mechanism of expression]	0.0	4	1	1	1
86572	1710	gene movement	[gene movements]	0.0	2	1	1	1
86573	1710	expression of cDNA clone	[Expression of cDNA clones]	0.0	4	1	1	1
86574	1710	/pka activation	[/PKA activation]	0.0	2	1	1	1
86575	1710	227.0 dpm mg-1	[227.0 dpm mg-1]	0.0	3	1	1	1
86576	1710	permanent occupancy enhancer	[Permanent occupancy enhancer]	0.0	3	1	1	1
86577	1710	x-box	[X-box]	0.0	1	1	1	1
86578	1710	potential target in inflammatory state	[potential target in inflammatory states]	0.0	5	1	1	1
86579	1710	Sp1 Ap2 binding site/	[Sp1 Ap2 binding site/s]	0.0	4	1	1	1
86580	1710	nuclear factor kappab nf-kappab kinase	[nuclear factor kappaB NF-kappaB kinase]	0.0	5	1	1	1
86581	1710	9 young adult	[9 young adults]	0.0	3	1	1	1
86582	1710	fmol/million cells; p less	[fmol/million cells; P less]	0.0	4	1	1	1
86583	1710	intertypic recombinant virus	[intertypic recombinant virus]	0.0	3	1	1	1
86584	1710	concentration of cysteine	[concentrations of cysteine]	0.0	3	1	1	1
86585	1710	contain direct repeat DR	[containing direct repeats DR]	0.0	4	1	1	1
86586	1710	employ sequential deletion	[employing sequential deletions]	0.0	3	1	1	1
86587	1710	slow kinetics,	[slow kinetics,]	0.0	2	1	1	1
86588	1710	value alter pathologic immune response	[value altering pathologic immune responses]	0.0	5	1	1	1
86589	1710	na+ channel	[Na+ channel]	0.0	2	1	1	1
86590	1710	thymocyte in mouse	[thymocytes in mice]	0.0	3	1	1	1
86591	1710	facilitate entry	[facilitating entry]	0.0	2	1	1	1
86592	1710	binding domain of factor	[binding domains of factor]	0.0	4	1	1	1
86593	1710	role of the protein	[role of the proteins]	0.0	4	1	1	1
86594	1710	personality characteristic	[personality characteristics]	0.0	2	1	1	1
86595	1710	development of pathology	[development of pathologies]	0.0	3	1	1	1
86596	1710	important feature with this datum	[important features with these data.]	0.0	5	1	1	1
86597	1710	and/or specific compound	[and/or specific compound]	0.0	3	1	1	1
86598	1710	protein kinase CaM kinase	[protein kinase CaM kinase]	0.0	4	1	1	1
86599	1710	oct2b protein	[Oct2B protein]	0.0	2	1	1	1
86600	1710	bp a silencer	[bp a silencer]	0.0	3	1	1	1
86601	1710	expose umbilical vein cell huvec	[Exposing umbilical vein cells HUVECs]	0.0	5	1	1	1
86602	1710	differentiation/maturation process	[differentiation/maturation process]	0.0	2	1	1	1
86603	1710	inhibition of the generation enhance activity	[inhibition of the generation enhancing activity]	0.0	6	1	1	1
86604	1710	ald T cell	[ALD T cells]	0.0	3	1	1	1
86605	1710	display rt-pcr	[display RT-PCR]	0.0	2	1	1	1
86606	1710	further evidence for the local modulation	[further evidence for the local modulation]	0.0	6	1	1	1
86607	1710	express different ad2/ad12 e1a gene product	[expressing different Ad2/Ad12 E1A gene products]	0.0	6	1	1	1
86608	1710	ea-d promoter activity	[EA-D promoter activity]	0.0	3	1	1	1
86609	1710	correlation between the methods.	[correlation between the methods.]	0.0	4	1	1	1
86610	1710	receptors/cell; controls,	[receptors/cell; controls,]	0.0	2	1	1	1
86611	1710	detectable deviation	[detectable deviations]	0.0	2	1	1	1
86612	1710	binding of complex RFX	[binding of complexes RFX]	0.0	4	1	1	1
86613	1710	preliminary evidence for cross-talk	[preliminary evidence for cross-talk]	0.0	4	1	1	1
86614	1710	cyto-differentiaterentiating treatment of leukemia	[cyto-differentiating treatment of leukemia]	0.0	4	1	1	1
86615	1710	case of endemic bl	[cases of endemic BL]	0.0	4	1	1	1
86616	1710	inhibition of gsk-3beta	[inhibition of GSK-3beta]	0.0	3	1	1	1
86617	1710	NF-kappa b 32p-labelled oligonucleotide	[NF-kappa B 32P-labelled oligonucleotide]	0.0	4	1	1	1
86618	1710	however, activation from a position	[However, activation from a position]	0.0	5	1	1	1
86619	1710	variant of the hiv-1 terminal repeat	[variants of the HIV-1 terminal repeat]	0.0	6	1	1	1
86620	1710	two lck/fyn-	[two Lck/Fyn-]	0.0	2	1	1	1
86621	1710	kD polypeptide of nf-kb	[kD polypeptide of NF-kB]	0.0	4	1	1	1
86622	1710	simian virus enhancer activity	[simian virus enhancer activity]	0.0	4	1	1	1
86623	1710	extract upon translocation	[extracts upon translocation]	0.0	3	1	1	1
86624	1710	atpase activity	[ATPase activities]	0.0	2	1	1	1
86625	1710	semiquantitative rt-pcr analysis	[semiquantitative RT-PCR analysis]	0.0	3	1	1	1
86626	1710	activation of t-lymphocyte via CD2	[activation of T-lymphocytes via CD2]	0.0	5	1	1	1
86627	1710	nf-kappab activation of terminal repeat LTR	[NF-kappaB activation of terminal repeat LTR]	0.0	6	1	1	1
86628	1710	expression of the immediate-early factor	[expression of the immediate-early factor]	0.0	5	1	1	1
86629	1710	cell-free extract	[cell-free extracts]	0.0	2	1	1	1
86630	1710	monocyte-macrophage colony	[monocyte-macrophage colony]	0.0	2	1	1	1
86631	1710	activity of the conalbumin promoter	[activity of the conalbumin promoter]	0.0	5	1	1	1
86632	1710	tnf-treated human vein cell	[TNF-treated human vein cells]	0.0	4	1	1	1
86633	1710	positional effect relative	[positional effects relative]	0.0	3	1	1	1
86634	1710	Importantly, enhancement of the uptake	[Importantly, enhancement of the uptake]	0.0	5	1	1	1
86635	1710	c-Jun pc-fo	[c-Jun /c-Fos]	0.0	2	1	1	1
86636	1710	hiv-infected patient with low affinity	[HIV-infected patients with low affinity]	0.0	5	1	1	1
86637	1710	contrast to the result	[contrast to the result]	0.0	4	1	1	1
86638	1710	transfection of Daudi cell	[transfection of Daudi cells]	0.0	4	1	1	1
86639	1710	aldosterone from human leukocyte	[aldosterone from human leukocytes]	0.0	4	1	1	1
86640	1710	effect on cd11b	[effects on CD11b]	0.0	3	1	1	1
86641	1710	culture of megakaryocyte	[cultures of megakaryocytes]	0.0	3	1	1	1
86642	1710	characterization identification	[characterization identification]	0.0	2	1	1	1
86643	1710	z-lll-h activity in U937 monocyte	[Z-LLL-H activity in U937 monocytes]	0.0	5	1	1	1
86644	1710	Interestingly, alteration of the microb site	[Interestingly, alteration of the microB site]	0.0	6	1	1	1
86645	1710	isoform lack exon	[isoform lacking exon]	0.0	3	1	1	1
86646	1710	postnatally, die by 8 days.	[postnatally, dying by 8 days.]	0.0	5	1	1	1
86647	1710	rt-pcr analysis	[RT-PCR analysis]	0.0	2	1	1	1
86648	1710	demonstration crossreactivity	[Demonstration crossreactivity]	0.0	2	1	1	1
86649	1710	tnf-treated vein cell	[TNF-treated vein cells]	0.0	3	1	1	1
86650	1710	regulatory p sequence	[regulatory P sequence]	0.0	3	1	1	1
86651	1710	result via two activating region	[resulting via two activating regions]	0.0	5	1	1	1
86652	1710	deletion of NF-kappa b site basis	[deletion of NF-kappa B site bases]	0.0	6	1	1	1
86653	1710	current knowledge concern	[current knowledge concerning]	0.0	3	1	1	1
86654	1710	differentiation inhibitory	[differentiation inhibitory]	0.0	2	1	1	1
86655	1710	lymphocyte from stem cell	[lymphocytes from stem cells]	0.0	4	1	1	1
86656	1710	induction of nf-kappab gene expression	[Induction of NF-kappaB gene expression]	0.0	5	1	1	1
86657	1710	DC in skin	[DC in skin]	0.0	3	1	1	1
86658	1710	0.06 nm (mean	[0.06 nM (mean]	0.0	3	1	1	1
86659	1710	findings:	[findings:]	0.0	1	1	1	1
86660	1710	Intron-exon	[Intron-exon]	0.0	1	1	1	1
86661	1710	son of the twin sister	[son of the twin sister]	0.0	5	1	1	1
86662	1710	especially in the case	[especially in the case]	0.0	4	1	1	1
86663	1710	similar infection with a retrovirus	[similar infection with a retrovirus]	0.0	5	1	1	1
86664	1710	five potential target for Oct2	[five potential targets for Oct2]	0.0	5	1	1	1
86665	1710	NF-kappaB a transcriptional regulator of response	[NF-kappaB a transcriptional regulator of responses]	0.0	6	1	1	1
86666	1710	(35 min) exercise ppe	[(35 min) exercise PPE]	0.0	4	1	1	1
86667	1710	least one type-specific clone reactive	[least one type-specific clone reactive]	0.0	5	1	1	1
86668	1710	b lymphocyte from patient	[B lymphocytes from patients]	0.0	4	1	1	1
86669	1710	high (66 microg/100 millileter at P;	[high (66 microg/100 ml at h;]	0.0	6	1	1	1
86670	1710	activation of ig gene	[activation of Ig genes]	0.0	4	1	1	1
86671	1710	nearby site originate bp upstream	[nearby sites originating bp upstream]	0.0	5	1	1	1
86672	1710	regulate the inflammatory response	[regulating the inflammatory response]	0.0	4	1	1	1
86673	1710	PBMC from child with fatal infection	[PBMC from children with fatal infection]	0.0	6	2	2	1
86674	1710	negative process	[negative process]	0.0	2	1	1	1
86675	1710	phosphotyrosine antibody	[phosphotyrosine antibody]	0.0	2	1	1	1
86676	1710	characterization the nuclear factor relationship	[Characterization the nuclear factor relationship]	0.0	5	1	1	1
86677	1710	peripheral mononuclear leukocyte of male	[peripheral mononuclear leukocytes of males]	0.0	5	1	1	1
86678	1710	pattern of chromosome	[patterns of chromosome]	0.0	3	1	1	1
86679	1710	Tcf-1 transcription in T lymphocyte	[Tcf-1 transcription in T lymphocytes]	0.0	5	1	1	1
86680	1710	suboptimal activation C PKC	[suboptimal activation C PKC]	0.0	4	1	1	1
86681	1710	inhibition of antibody t-cell proliferation	[Inhibition of antibody T-cell proliferation]	0.0	5	1	1	1
86682	1710	promote the NK clearance	[promoting the NK clearance]	0.0	4	1	1	1
86683	1710	direct interaction of transcription factor antagonism	[Direct interaction of transcription factors antagonism]	0.0	6	1	1	1
86684	1710	dioxyvit with correction	[dioxyvit with correction]	0.0	3	1	1	1
86685	1710	use of based	[use of BASED]	0.0	3	1	1	1
86686	1710	cell with interleukin-1beta	[cells with interleukin-1beta]	0.0	3	1	1	1
86687	1710	thus, cosignaling	[Thus, cosignaling]	0.0	2	1	1	1
86688	1710	pathway of synthesis	[pathways of synthesis]	0.0	3	1	1	1
86689	1710	vein cell monolayer	[vein cell monolayers]	0.0	3	1	1	1
86690	1710	retention of p65	[retention of p65]	0.0	3	1	1	1
86691	1710	syndrome in stage	[syndromes in stage]	0.0	3	1	1	1
86692	1710	secret il-2 at a level	[secreting IL-2 at a level]	0.0	5	1	1	1
86693	1710	include y292	[including Y292]	0.0	2	1	1	1
86694	1710	level of pafr transcript	[levels of PAFR transcript]	0.0	4	1	1	1
86695	1710	transcriptional activation of reporter gene	[transcriptional activation of reporter genes]	0.0	5	1	1	1
86696	1710	intranasal glucocorticoid on function	[intranasal glucocorticoids on function]	0.0	4	1	1	1
86697	1710	hypercalcemic effect	[hypercalcemic effect]	0.0	2	1	1	1
86698	1710	methods, each	[methods, each]	0.0	2	1	1	1
86699	1710	activation of Wp, the gene promoter	[activation of Wp, the gene promoter]	0.0	6	1	1	1
86700	1710	role of specific factor-DNA complex	[role of specific factor-DNA complexes]	0.0	5	1	1	1
86701	1710	(except in obese patient	[(except in obese patient]	0.0	4	1	1	1
86702	1710	BLS genetic complementation group	[BLS genetic complementation groups]	0.0	4	1	1	1
86703	1710	very effective treatment	[very effective treatment]	0.0	3	1	1	1
86704	1710	activity of 129 breast cancer	[activity of 129 breast cancers]	0.0	5	1	1	1
86705	1710	stimulation of factor	[stimulation of factor]	0.0	3	1	1	1
86706	1710	(ifn)	[(IFN)]	0.0	1	1	1	1
86707	1710	overexpression peptide in jy25 cell	[Overexpression peptide in JY25 cells]	0.0	5	1	1	1
86708	1710	peripheral blood lymphocyte from individual	[peripheral blood lymphocytes from individuals]	0.0	5	1	1	1
86709	1710	expression cloning,	[expression cloning,]	0.0	2	1	1	1
86710	1710	breast cancer mortality rate	[breast cancer mortality rates]	0.0	4	1	1	1
86711	1710	6tg1.1 icr27tk.3 human T cell	[6TG1.1 ICR27TK.3 human T cells]	0.0	5	1	1	1
86712	1710	relevant inhibitor	[relevant inhibitor]	0.0	2	1	1	1
86713	1710	several set with residue kinetic analysis	[several sets with residues Kinetic analysis]	0.0	6	1	1	1
86714	1710	inhibitory effect of 9-cis-ra	[inhibitory effect of 9-cis-RA]	0.0	4	1	1	1
86715	1710	CD30 -dependent degradation	[CD30 -dependent degradation]	0.0	3	1	1	1
86716	1710	bifunctional regulator	[bifunctional regulator]	0.0	2	2	2	1
86717	1710	c-jun p39c-jun	[c-jun p39c-jun]	0.0	2	1	1	1
86718	1710	multiple reactivity high	[multiple reactivities high]	0.0	3	1	1	1
86719	1710	putative transmembrane segment	[putative transmembrane segments]	0.0	3	1	1	1
86720	1710	evidence of a interplay	[evidence of an interplay]	0.0	4	1	1	1
86721	1710	deficient activity	[deficient activity]	0.0	2	1	1	1
86722	1710	chain-specific mAb	[chain-specific mAb]	0.0	2	1	1	1
86723	1710	immortalize T cell	[immortalizing T cells]	0.0	3	1	1	1
86724	1710	new approach to the study	[new approaches to the study]	0.0	5	1	1	1
86725	1710	activation of a factor	[activation of a factor]	0.0	4	1	1	1
86726	1710	regulation of change	[regulation of changes]	0.0	3	1	1	1
86727	1710	BSAP a key regulator	[BSAP a key regulator]	0.0	4	1	1	1
86728	1710	role in t-cell activation	[role in T-cell activation]	0.0	4	1	1	1
86729	1710	extracellular matrix process	[extracellular matrix processes]	0.0	3	1	1	1
86730	1710	cyclic element CRE	[cyclic element CRE]	0.0	3	2	2	1
86731	1710	significant level of proto-oncogent c-jun	[significant levels of proto-oncogenes c-jun]	0.0	5	1	1	1
86732	1710	il-1 receptor type	[IL-1 receptor type]	0.0	3	1	1	1
86733	1710	human interleukin IL-2	[human interleukin IL-2]	0.0	3	1	1	1
86734	1710	b cell line AF10	[B cell lines AF10]	0.0	4	1	1	1
86735	1710	nuclear rna (snrna)	[nuclear RNA (snRNA)]	0.0	3	1	1	1
86736	1710	only the kd-restricted epitope	[only the Kd-restricted epitope]	0.0	4	1	1	1
86737	1710	sufficient number of glucocorticoid receptor	[sufficient numbers of glucocorticoid receptors]	0.0	5	1	1	1
86738	1710	spinal atrophy a form	[spinal atrophy an form]	0.0	4	1	1	1
86739	1710	common event in signalling	[common event in signalling]	0.0	4	1	1	1
86740	1710	Thy-1 promoter	[Thy-1 promoter]	0.0	2	1	1	1
86741	1710	Graves' patient	[Graves' patients]	0.0	2	1	1	1
86742	1710	upstream factor-kappa b site -85	[upstream factor-kappa B site -85]	0.0	5	1	1	1
86743	1710	stage of virus infection	[stages of virus infection]	0.0	4	1	1	1
86744	1710	disomy of sequence on xp	[disomy of sequences on Xp]	0.0	5	1	1	1
86745	1710	also constitutive hiv-enhancer activity concomitant	[also constitutive HIV-enhancer activity concomitant]	0.0	5	1	1	1
86746	1710	induction of nuclear factor	[Induction of nuclear factor]	0.0	4	1	1	1
86747	1710	age young	[age younger]	0.0	2	1	1	1
86748	1710	(also in cell	[(also in cells]	0.0	3	1	1	1
86749	1710	octamer-associated protein	[octamer-associated protein]	0.0	2	1	1	1
86750	1710	same transactivation ability as otf-2	[same transactivation ability as OTF-2]	0.0	5	1	1	1
86751	1710	dexamethasone suppressibility of incorporation	[dexamethasone suppressibility of incorporation]	0.0	4	1	1	1
86752	1710	rar(alpha) level	[RAR(alpha) levels]	0.0	2	1	1	1
86753	1710	such as gamma-globin delta-aminolevulinate synthase	[such as gamma-globin delta-aminolevulinate synthase]	0.0	5	1	1	1
86754	1710	monocyte use polyclonal tf antibody	[monocytes using polyclonal TF antibody]	0.0	5	1	1	1
86755	1710	electron-dense structure morphologically distinct	[electron-dense structures morphologically distinct]	0.0	4	1	1	1
86756	1710	adjacent kappa b site	[adjacent kappa B sites]	0.0	4	1	1	1
86757	1710	nuclear morphology indicative	[nuclear morphology indicative]	0.0	3	1	1	1
86758	1710	activation of monocytic cell	[Activation of monocytic cells]	0.0	4	1	1	1
86759	1710	cd8(+)-t-cell target	[CD8(+)-T-cell target]	0.0	2	1	1	1
86760	1710	early developmental stage	[early developmental stage]	0.0	3	1	1	1
86761	1710	[editorial]	[[editorial]]	0.0	1	1	1	1
86762	1710	type immunodeficiency virus hiv-1	[type immunodeficiency virus HIV-1]	0.0	4	1	1	1
86763	1710	pattern of alpha expression	[pattern of alpha expression]	0.0	4	1	1	1
86764	1710	IL-7 proliferation	[IL-7 proliferation]	0.0	2	1	1	1
86765	1710	extinction of gene	[extinction of genes]	0.0	3	1	1	1
86766	1710	NF-kappa b activator precursor	[NF-kappa B activator precursor]	0.0	4	1	1	1
86767	1710	4-phorbol 12-myristate 13-acetate	[4-phorbol 12-myristate 13-acetate]	0.0	3	1	1	1
86768	1710	primary peripheral cell PBMC	[primary peripheral cells PBMC]	0.0	4	1	1	1
86769	1710	patient with melanoma	[patients with melanoma]	0.0	3	1	1	1
86770	1710	component of long outgrowth	[component of long-term outgrowth]	0.0	4	1	1	1
86771	1710	encode relevant protein	[encoding relevant proteins]	0.0	3	1	1	1
86772	1710	allele regulation of Pax5	[allele regulation of Pax5]	0.0	4	2	2	1
86773	1710	heteromeric complex with protein	[heteromeric complexes with proteins]	0.0	4	1	1	1
86774	1710	patient with rhinitis.	[patients with rhinitis.]	0.0	3	1	1	1
86775	1710	retinoic acid receptor alpha rar-alpha	[retinoic acid receptor alpha RAR-alpha]	0.0	5	1	1	1
86776	1710	Prostaglandin E2 a immunomodulatory molecule	[Prostaglandin E2 a immunomodulatory molecule]	0.0	5	1	1	1
86777	1710	ki-67 antigen	[Ki-67 antigen]	0.0	2	1	1	1
86778	1710	human blood leukocyte	[human blood leukocytes]	0.0	3	1	1	1
86779	1710	cDNA sequence tag	[cDNA sequence tags]	0.0	3	1	1	1
86780	1710	Endocrine status change	[Endocrine status changes]	0.0	3	1	1	1
86781	1710	various process	[various processes]	0.0	2	1	1	1
86782	1710	abnormality gene in astrocytomas	[Abnormalities genes in astrocytomas]	0.0	4	1	1	1
86783	1710	contain ap-1 site	[containing AP-1 sites]	0.0	3	1	1	1
86784	1710	nf-matp35 induction	[NF-MATp35 induction]	0.0	2	1	1	1
86785	1710	expression of immunodeficiency virus hiv	[expression of immunodeficiency virus HIV]	0.0	5	1	1	1
86786	1710	datum along with other finding	[data, along with other findings]	0.0	5	1	1	1
86787	1710	p65 labeling	[p65 labeling]	0.0	2	1	1	1
86788	1710	antidsdna antibody	[antidsDNA antibody]	0.0	2	1	1	1
86789	1710	two pan-1 respectively), by the mechanism	[two Pan-1 respectively), by the mechanism]	0.0	6	1	1	1
86790	1710	contain four direct repeat of bp	[containing four direct repeats of bp]	0.0	6	1	1	1
86791	1710	activity of the long repeat	[activity of the long repeat]	0.0	5	1	1	1
86792	1710	signal costimulatory signal alone without signal	[signal costimulatory signal alone without signal]	0.0	6	1	1	1
86793	1710	activation gene transcription during induction	[Activation gene transcription during induction]	0.0	5	1	1	1
86794	1710	constitutive DNA binding activity consist	[Constitutive DNA binding activity consisting]	0.0	5	1	1	1
86795	1710	overview	[overview]	0.0	1	1	1	1
86796	1710	polyclonal etiology of fibromatosis	[polyclonal etiology of fibromatosis]	0.0	4	1	1	1
86797	1710	mitogenic stimulation of pbl-t	[mitogenic stimulation of PBL-T]	0.0	4	1	1	1
86798	1710	such as alpha, 25-dihydroxy vitamin D3	[such as alpha, 25-dihydroxy vitamin D3]	0.0	6	1	1	1
86799	1710	generation of oxygen species ROS)	[generation of oxygen species ROS)]	0.0	5	1	1	1
86800	1710	Staurosporine pentoxifylline	[Staurosporine pentoxifylline]	0.0	2	1	1	1
86801	1710	binding affinities: testosterone	[binding affinities: testosterone]	0.0	3	1	1	1
86802	1710	direct transluminal coronary angioplasty	[direct transluminal coronary angioplasty]	0.0	4	1	1	1
86803	1710	transcription factor oct2	[transcription factor Oct2]	0.0	3	1	1	1
86804	1710	same electrophoretic mobility kd)	[same electrophoretic mobility kD)]	0.0	4	1	1	1
86805	1710	beta in T cell	[beta in T cells]	0.0	4	1	1	1
86806	1710	Chemical cross-linking with 125i-labeled tgf-beta	[Chemical cross-linking with 125I-labeled TGF-beta]	0.0	5	1	1	1
86807	1710	signal molecule of ERK	[signaling molecules of ERK]	0.0	4	1	1	1
86808	1710	binding of factor protein	[binding of factor proteins]	0.0	4	1	1	1
86809	1710	cysteine-rich protein crisp-3	[cysteine-rich protein CRISP-3]	0.0	3	1	1	1
86810	1710	serial sectioning of micrometer	[Serial sectioning of micrometer]	0.0	4	1	1	1
86811	1710	activity reticuloendotheliosis virus	[activity reticuloendotheliosis virus]	0.0	3	1	1	1
86812	1710	viral survivalepromot protein	[viral survival-promoting proteins]	0.0	3	1	1	1
86813	1710	two system a cell line	[two systems a cell line]	0.0	5	1	1	1
86814	1710	show ptt shift	[showing PTT shifts]	0.0	3	1	1	1
86815	1710	separate element	[separate elements]	0.0	2	1	1	1
86816	1710	lymphoma of B-cell type	[lymphoma of B-cell type]	0.0	4	1	1	1
86817	1710	member share DNA binding specificity	[members sharing DNA binding specificities]	0.0	5	1	1	1
86818	1710	positive regulatory element NF-AT-1	[positive regulatory element NF-AT-1]	0.0	4	1	1	1
86819	1710	recessive form of inheritance	[recessive form of inheritance]	0.0	4	1	1	1
86820	1710	phenotypic female year of age),	[phenotypic female years of age),]	0.0	5	1	1	1
86821	1710	however, order of magnitude potent	[however, orders of magnitude potent]	0.0	5	1	1	1
86822	1710	cyclosporin-sensitive dna-binding protein	[cyclosporin-sensitive DNA-binding protein]	0.0	3	1	1	1
86823	1710	cell express level of bcl-2	[cells expressing levels of Bcl-2]	0.0	5	1	1	1
86824	1710	use dimethyl sulfate	[using dimethyl sulfate]	0.0	3	1	1	1
86825	1710	YY1 transcription factor	[YY1 transcription factor]	0.0	3	1	1	1
86826	1710	wild-type -resistant human ecem) cell	[wild-type -resistant human (CEM) cells]	0.0	5	1	1	1
86827	1710	other frame	[other frames]	0.0	2	1	1	1
86828	1710	inducer of collagenase expression in macrophage	[inducers of collagenase expression in macrophages]	0.0	6	1	1	1
86829	1710	c8-c7 sterol isomerase	[C8-C7 sterol isomerase]	0.0	3	1	1	1
86830	1710	DNA marker	[DNA markers]	0.0	2	1	1	1
86831	1710	structurally related cation like cobalt, nickel,	[Structurally related cations like cobalt, nickel,]	0.0	6	1	1	1
86832	1710	challenge for immunology	[challenge for immunology]	0.0	3	1	1	1
86833	1710	involve protein kinase C	[involving protein kinase C]	0.0	4	1	1	1
86834	1710	alpha-helice with a proportion	[alpha-helices with a proportion]	0.0	4	1	1	1
86835	1710	2 h of cd19 cross-linking	[2 h of CD19 cross-linking]	0.0	5	1	1	1
86836	1710	biological significance for mechanism	[biological significance for mechanisms]	0.0	4	1	1	1
86837	1710	tfiid binding site	[TFIID binding site]	0.0	3	1	1	1
86838	1710	HIV region LTR	[HIV region LTR]	0.0	3	1	1	1
86839	1710	interferon signal	[interferon signal]	0.0	2	1	1	1
86840	1710	considerably high proportion of responder	[Considerably higher proportions of responders]	0.0	5	1	1	1
86841	1710	33 absorptive patient	[33 absorptive patients]	0.0	3	1	1	1
86842	1710	high (KD	[higher (KD]	0.0	2	1	1	1
86843	1710	microsomal membrane	[microsomal membranes]	0.0	2	1	1	1
86844	1710	probability of relapse	[probability of relapse]	0.0	3	1	1	1
86845	1710	preeclamptic woman	[preeclamptic women]	0.0	2	1	1	1
86846	1710	antigen receptor bcr signal	[antigen receptor BCR signals]	0.0	4	1	1	1
86847	1710	receptor gcR in peripheral lymphocyte	[receptors gcR in peripheral lymphocytes]	0.0	5	1	1	1
86848	1710	m2-type cell	[M2-type cells]	0.0	2	1	1	1
86849	1710	menopausal woman without diabete	[menopausal women without diabetes]	0.0	4	1	1	1
86850	1710	furthermore, region ii sequence element	[Furthermore, region II sequence elements]	0.0	5	1	1	1
86851	1710	immunogold electron microscopy on cell	[immunogold electron microscopy on cells]	0.0	5	1	1	1
86852	1710	45-nucleotide sequence DRE to +240	[45-nucleotide sequence DRE to +240]	0.0	5	1	1	1
86853	1710	include myd88	[including MyD88]	0.0	2	1	1	1
86854	1710	irrespective of the position	[irrespective of the position]	0.0	4	1	1	1
86855	1710	c-terminal peptide of isoform	[C-terminal peptide of isoform]	0.0	4	1	1	1
86856	1710	specific lysosomal protein myeloperoxidase	[specific lysosomal proteins myeloperoxidase]	0.0	4	1	1	1
86857	1710	proboscipedia	[proboscipedia]	0.0	1	1	1	1
86858	1710	disruption epstein-barr virus ebv	[disruption Epstein-Barr virus EBV]	0.0	4	1	1	1
86859	1710	nf-kappab transcription factor binding site	[NF-kappaB transcription factor binding sites]	0.0	5	1	1	1
86860	1710	CML cell to ifn-alpha	[CML cells to IFN-alpha]	0.0	4	1	1	1
86861	1710	control individual	[control individuals]	0.0	2	1	1	1
86862	1710	limbic-hippocampal type receptor	[limbic-hippocampal type receptor]	0.0	3	1	1	1
86863	1710	shutdown	[shutdown]	0.0	1	1	1	1
86864	1710	increase in erythroid mrna level	[increase in erythroid mRNA level]	0.0	5	1	1	1
86865	1710	product of pld action	[product of PLD action]	0.0	4	1	1	1
86866	1710	three erp transcript	[three ERP transcripts]	0.0	3	1	1	1
86867	1710	taxi induction	[TaxI induction]	0.0	2	1	1	1
86868	1710	new era in research	[new era in research]	0.0	4	1	1	1
86869	1710	25 pregnancy	[25 pregnancies]	0.0	2	1	1	1
86870	1710	a23187.	[A23187.]	0.0	1	1	1	1
86871	1710	bp of DNA	[bp of DNA]	0.0	3	1	1	1
86872	1710	separation of beneficial	[separation of beneficial]	0.0	3	1	1	1
86873	1710	protective effect of notch-1	[Protective effects of notch-1]	0.0	4	1	1	1
86874	1710	nuclei of human lymphocyte	[nuclei of human lymphocytes]	0.0	4	1	1	1
86875	1710	nuclear factor beta	[nuclear factor beta]	0.0	3	1	1	1
86876	1710	form of selection expansion) (by stimulation	[forms of selection expansion) (by stimulation]	0.0	6	1	1	1
86877	1710	transcriptional stimulatory activity	[transcriptional stimulatory activity]	0.0	3	1	1	1
86878	1710	Janus kinase in glial cell	[Janus kinase in glial cells]	0.0	5	1	1	1
86879	1710	membrane-bound	[membrane-bound]	0.0	1	1	1	1
86880	1710	tax-responsive element necessary	[Tax-responsive element necessary]	0.0	3	1	1	1
86881	1710	lead to expression of different gene	[leading to expression of different genes]	0.0	6	1	1	1
86882	1710	nuclear factor contain c-rel-like protein	[nuclear factor containing c-Rel-like proteins]	0.0	5	1	1	1
86883	1710	molecular analysis of gene expression	[molecular analysis of gene expression]	0.0	5	1	1	1
86884	1710	relative affinity of transcriptional regulatory element	[Relative affinities of transcriptional regulatory elements]	0.0	6	1	1	1
86885	1710	mrna in the cell	[mRNA in the cells]	0.0	4	1	1	1
86886	1710	bal blood	[BAL blood]	0.0	2	1	1	1
86887	1710	MHC class ii-negative cell	[MHC class II-negative cells]	0.0	4	1	1	1
86888	1710	factor modulate the differentiation-dependent transcription	[factors modulating the differentiation-dependent transcription]	0.0	5	1	1	1
86889	1710	NF-kappa b sensitive	[NF-kappa B sensitive]	0.0	3	2	2	1
86890	1710	peptide ligand of tetanus toxoid	[peptide ligand of tetanus toxoid]	0.0	5	1	1	1
86891	1710	anti-SSB T cell	[anti-SSB T cells]	0.0	3	1	1	1
86892	1710	FOS family	[FOS family]	0.0	2	1	1	1
86893	1710	(b10)	[(B10)]	0.0	1	1	1	1
86894	1710	complex formation with member	[complex formation with members]	0.0	4	1	1	1
86895	1710	clinical syndrome	[clinical syndromes]	0.0	2	1	1	1
86896	1710	production of il-8 by ECs	[Production of IL-8 by ECs]	0.0	5	1	1	1
86897	1710	1,25-dihydroxyvitamin D3 erratum	[1,25-dihydroxyvitamin D3 erratum]	0.0	3	1	1	1
86898	1710	much high activity	[much higher activity]	0.0	3	1	1	1
86899	1710	receptor in hypertensive patient	[receptors in hypertensive patients]	0.0	4	1	1	1
86900	1710	receptor-ligand affinity,	[receptor-ligand affinity,]	0.0	2	1	1	1
86901	1710	condition in the presence	[conditions in the presence]	0.0	4	1	1	1
86902	1710	apoptosis in thymocyte	[apoptosis in thymocytes]	0.0	3	1	1	1
86903	1710	replicate hiv-1	[replicating HIV-1]	0.0	2	1	1	1
86904	1710	Tat-activated,	[Tat-activated,]	0.0	1	1	1	1
86905	1710	small reduction	[small reduction]	0.0	2	1	1	1
86906	1710	DEX (1.0 mg	[DEX (1.0 mg]	0.0	3	1	1	1
86907	1710	govern the response	[governing the response]	0.0	3	1	1	1
86908	1710	target spleen	[targeting spleen]	0.0	2	1	1	1
86909	1710	T cell with normal level	[T cells with normal levels]	0.0	5	1	1	1
86910	1710	identification of upstream element	[Identification of upstream elements]	0.0	4	1	1	1
86911	1710	short immunodominant region	[short immunodominant region]	0.0	3	1	1	1
86912	1710	structure characteristic	[structures characteristic]	0.0	2	1	1	1
86913	1710	quantification of vitamin d receptor mrna	[Quantification of vitamin D receptor mRNA]	0.0	6	1	1	1
86914	1710	factor NF-GM2	[factor NF-GM2]	0.0	2	1	1	1
86915	1710	additional factor for maximal activity	[additional factors for maximal activity]	0.0	5	1	1	1
86916	1710	10, granulocyte-macrophage colony-stimulating factor	[10, granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
86917	1710	grade of lymphocyte before radiotherapy	[grades of lymphocytes before radiotherapy]	0.0	5	1	1	1
86918	1710	implicate cyclophilin b in the absence	[implicating cyclophilin B in the absence]	0.0	6	1	1	1
86919	1710	inducible AP-1 family member	[inducible AP-1 family members]	0.0	4	1	1	1
86920	1710	human c-rel	[human c-Rel]	0.0	2	1	1	1
86921	1710	stimulation with (il-6) a cytokine	[stimulation with (IL-6) an cytokine]	0.0	5	1	1	1
86922	1710	four proteins--a protein of 52 kD	[four proteins--a protein of 52 kD]	0.0	6	1	1	1
86923	1710	h with methylprednisolone	[h with methylprednisolone]	0.0	3	1	1	1
86924	1710	[induction of apoptosis in lymphocyte	[[Induction of apoptosis in lymphocytes]	0.0	5	1	1	1
86925	1710	ifn-gamma up-regulation of mcp-1 production	[IFN-gamma up-regulation of MCP-1 production]	0.0	5	1	1	1
86926	1710	e1a protein in target	[E1A proteins in targets]	0.0	4	1	1	1
86927	1710	treatment tyrosine phosphorylation of protein substrate	[Treatment tyrosine phosphorylation of protein substrates]	0.0	6	1	1	1
86928	1710	last h	[last h]	0.0	2	1	1	1
86929	1710	concentration in infarction	[concentration in infarction]	0.0	3	1	1	1
86930	1710	Furthermore, acid receptor RAR alpha	[Furthermore, acid receptor RAR alpha]	0.0	5	1	1	1
86931	1710	model characterize NF-kappa b activation	[model characterizing NF-kappa B activation]	0.0	5	1	1	1
86932	1710	a.m. receptor	[a.m. receptors]	0.0	2	1	1	1
86933	1710	case of acute myeloid leukemia	[cases of acute myeloid leukemia]	0.0	5	1	1	1
86934	1710	SL3-3	[SL3-3]	0.0	1	1	1	1
86935	1710	activator of the light-chain enhancer	[activators of the light-chain enhancer]	0.0	5	1	1	1
86936	1710	role regulate e2f	[role regulating E2F]	0.0	3	1	1	1
86937	1710	b cell-specific enhancer	[B cell-specific enhancer]	0.0	3	1	1	1
86938	1710	critical role cause transformation	[critical role causing transformation]	0.0	4	1	1	1
86939	1710	two hematopoietic cell molecule	[two hematopoietic cell molecules]	0.0	4	1	1	1
86940	1710	psychiatric control	[psychiatric controls]	0.0	2	1	1	1
86941	1710	E1A -negative, cell line	[E1A -negative, cell lines]	0.0	4	1	1	1
86942	1710	blockade of the translocation	[blockade of the translocation]	0.0	4	1	1	1
86943	1710	biochemical response to IL-12	[biochemical response to IL-12]	0.0	4	1	1	1
86944	1710	corticotropin-releasing hormone gene promoter	[corticotropin-releasing hormone gene promoter]	0.0	4	1	1	1
86945	1710	sex reversal map 130 kb	[sex reversal map 130 kb]	0.0	5	1	1	1
86946	1710	treatment with mg flutamide	[treatment with mg flutamide]	0.0	4	1	1	1
86947	1710	steroid-sensitive asthmatic patient	[steroid-sensitive asthmatic patients]	0.0	3	1	1	1
86948	1710	7.03 (range, 5.66-10) (range,	[7.03 (range, 5.66-10), (range,]	0.0	4	1	1	1
86949	1710	good correlation, with a value	[good correlation, with an value]	0.0	5	1	1	1
86950	1710	difference in stat induction pattern	[differences in STAT induction patterns]	0.0	5	1	1	1
86951	1710	substantial clinical importance	[substantial clinical importance]	0.0	3	1	1	1
86952	1710	interleukin-2 gene induction	[interleukin-2 gene induction]	0.0	3	2	2	1
86953	1710	despite evidence	[Despite evidence]	0.0	2	1	1	1
86954	1710	experiment involve clone	[experiments involving clones]	0.0	3	1	1	1
86955	1710	dissociation of nf kappa b stimulation,	[Dissociation of NF kappa B stimulation,]	0.0	6	1	1	1
86956	1710	suggest the involvement	[suggesting the involvement]	0.0	3	2	2	1
86957	1710	control (10%, p	[controls (10%, P]	0.0	3	1	1	1
86958	1710	H+-ATPase b2 subunit	[H+-ATPase B2 subunit]	0.0	3	1	1	1
86959	1710	suggest a consequence	[suggesting an consequence]	0.0	3	1	1	1
86960	1710	year) in the continuous presence	[year) in the continuous presence]	0.0	5	1	1	1
86961	1710	491-amino-acid sequence	[491-amino-acid sequence]	0.0	2	1	1	1
86962	1710	thus prevent the expression of gene	[thus preventing the expression of genes]	0.0	6	1	1	1
86963	1710	action of retinoic acid on hematopoiesis	[action of retinoic acid on hematopoiesis]	0.0	6	1	1	1
86964	1710	direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin	[Direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.0	4	1	1	1
86965	1710	cd95 APO-1/Fas ligand	[CD95 APO-1/Fas ligand]	0.0	3	1	1	1
86966	1710	significant decrease in lps	[significant decrease in LPS]	0.0	4	1	1	1
86967	1710	chloramphenicol acetyltransferase expression construct	[Chloramphenicol acetyltransferase expression constructs]	0.0	4	1	1	1
86968	1710	resistant sr	[resistant SR]	0.0	2	1	1	1
86969	1710	predominantly activate effect	[predominantly activating effect]	0.0	3	1	1	1
86970	1710	activation of 3 gene expression	[activation of 3 gene expression]	0.0	5	1	1	1
86971	1710	decrease in (mr)	[decreases in (MR)]	0.0	3	1	1	1
86972	1710	simple way	[simplest way]	0.0	2	1	1	1
86973	1710	contrast to the c-terminus	[contrast to the C-terminus]	0.0	4	1	1	1
86974	1710	EPO differentiation	[EPO differentiation]	0.0	2	1	1	1
86975	1710	adhesion molecule for neutrophil	[adhesion molecules for neutrophils]	0.0	4	1	1	1
86976	1710	induction by macrophage-CSF M-CSF	[induction by macrophage-CSF M-CSF]	0.0	4	1	1	1
86977	1710	(rai)	[(RAI)]	0.0	1	1	1	1
86978	1710	transcriptional properties unlike nuclear oncoprotein	[transcriptional properties, unlike nuclear oncoproteins]	0.0	5	1	1	1
86979	1710	only factor	[only factor]	0.0	2	1	1	1
86980	1710	phenylarsine oxide a specific inhibitor	[phenylarsine oxide a specific inhibitor]	0.0	5	1	1	1
86981	1710	inhibitor pp1	[inhibitor PP1/PP2A]	0.0	2	1	1	1
86982	1710	express fibroblast	[expressing fibroblasts]	0.0	2	1	1	1
86983	1710	transcription regulatory factor	[transcription regulatory factor]	0.0	3	1	1	1
86984	1710	function at the hypothalamic level,	[function at the hypothalamic level,]	0.0	5	1	1	1
86985	1710	two allele in b-lymphoid progenitor	[two alleles in B-lymphoid progenitors]	0.0	5	1	1	1
86986	1710	loading	[loading]	0.0	1	1	1	1
86987	1710	following: increased;	[following: increased;]	0.0	2	1	1	1
86988	1710	accumulation of m-csf mrna	[accumulation of M-CSF mRNA]	0.0	4	1	1	1
86989	1710	individual with atrophy	[individual with atrophy]	0.0	3	1	1	1
86990	1710	step of nf-kappab activation	[steps of NF-kappaB activation]	0.0	4	1	1	1
86991	1710	pu box transactivation	[Pu box transactivation]	0.0	3	1	1	1
86992	1710	il-6 luciferase activity	[IL-6 luciferase activity]	0.0	3	2	2	1
86993	1710	E3-dependent ubiquitinylation	[E3-dependent ubiquitinylation]	0.0	2	1	1	1
86994	1710	regulation of this zinc-finger	[regulation of these zinc-finger]	0.0	4	1	1	1
86995	1710	aromatic residue	[aromatic residues]	0.0	2	1	1	1
86996	1710	cell-type lps	[cell-type LPS]	0.0	2	1	1	1
86997	1710	estrogen receptor beta	[estrogen receptor beta]	0.0	3	1	1	1
86998	1710	pre-B-cell stage of development	[pre-B-cell stage of development]	0.0	4	1	1	1
86999	1710	phorbol ester responsiveness	[phorbol ester responsiveness]	0.0	3	1	1	1
87000	1710	role in recognition	[role in recognition]	0.0	3	1	1	1
87001	1710	reduction of aldosterone receptor	[reduction of aldosterone receptors]	0.0	4	1	1	1
87002	1710	monocytic/myeloid cell line	[monocytic/myeloid cell lines]	0.0	3	1	1	1
87003	1710	contrast to the mediator	[contrast to the mediators]	0.0	4	1	1	1
87004	1710	core sp1	[core Sp1]	0.0	2	1	1	1
87005	1710	lps at a concentration	[LPS at a concentration]	0.0	4	1	1	1
87006	1710	early cell stage	[early cell stage]	0.0	3	1	1	1
87007	1710	osteoclast vitronectin receptor	[osteoclasts vitronectin receptor]	0.0	3	1	1	1
87008	1710	consequence at a stage	[consequences at an stage]	0.0	4	1	1	1
87009	1710	antiinflammatory alkaloid cepharanthine	[antiinflammatory alkaloid cepharanthine]	0.0	3	1	1	1
87010	1710	receptor-negative erythroblast	[receptor-negative erythroblasts]	0.0	2	1	1	1
87011	1710	sequencing amino acid	[sequencing amino acids]	0.0	3	1	1	1
87012	1710	element block element alpha/delta	[element blocking element alpha/delta]	0.0	4	1	1	1
87013	1710	immunopathogenesis	[immunopathogenesis]	0.0	1	1	1	1
87014	1710	Chinese hamster ovary fibroblast	[Chinese hamster ovary fibroblasts]	0.0	4	1	1	1
87015	1710	21 adult control	[21 adult controls]	0.0	3	1	1	1
87016	1710	T to C	[T to C]	0.0	3	1	1	1
87017	1710	active p65-50 heterodimer	[active p65-50 heterodimer]	0.0	3	1	1	1
87018	1710	ceramide release in apoptosis	[ceramide release in apoptosis]	0.0	4	1	1	1
87019	1710	role on gr -dependent activation	[role on GR -dependent activation]	0.0	5	1	1	1
87020	1710	anti- lps mab	[anti- LPS mAbs]	0.0	3	1	1	1
87021	1710	line of transgenic mouse display expression	[lines of transgenic mice displaying expression]	0.0	6	1	1	1
87022	1710	level low	[levels lower]	0.0	2	1	1	1
87023	1710	I gene expression by il-4	[I gene expression by IL-4]	0.0	5	1	1	1
87024	1710	macrophage-lymphocyte	[macrophage-lymphocyte]	0.0	1	1	1	1
87025	1710	comparison, RBA	[comparison, RBA]	0.0	2	1	1	1
87026	1710	tight correlation of hiv-1 induction	[tight correlation of HIV-1 induction]	0.0	5	1	1	1
87027	1710	kinase-deficient mutant of IKKalpha	[kinase-deficient mutants of IKKalpha]	0.0	4	1	1	1
87028	1710	human tshr domain	[human TSHR domain]	0.0	3	1	1	1
87029	1710	element 1 alpha,25-dihydroxyvitamin D3	[Elements 1 alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
87030	1710	e2f-1 in differentiation	[E2F-1 in differentiation]	0.0	3	1	1	1
87031	1710	functional immune deficiency virus type hiv-1	[functional immune deficiency virus type HIV-1]	0.0	6	1	1	1
87032	1710	few depressed subject	[fewer depressed subjects]	0.0	3	1	1	1
87033	1710	histocompatibility class ii gene	[histocompatibility class II genes]	0.0	4	1	1	1
87034	1710	human heavy-chain enhancer	[human heavy-chain enhancer]	0.0	3	1	1	1
87035	1710	use centromere probe	[using centromere probes]	0.0	3	1	1	1
87036	1710	vascular wall cell	[vascular wall cells]	0.0	3	1	1	1
87037	1710	p50/c-Rel in thymocyte	[p50/c-Rel in thymocytes]	0.0	3	1	1	1
87038	1710	human interferon beta regulatory element	[human interferon beta regulatory element]	0.0	5	1	1	1
87039	1710	level of ap-1	[levels of AP-1]	0.0	3	1	1	1
87040	1710	difference in mechanism	[differences in mechanisms]	0.0	3	1	1	1
87041	1710	apoptosis of malignant lymphoid cell	[apoptosis of malignant lymphoid cells]	0.0	5	1	1	1
87042	1710	latent cytoplasmic precursor	[latent cytoplasmic precursors]	0.0	3	1	1	1
87043	1710	hsp70b	[HSP70B]	0.0	1	1	1	1
87044	1710	lack endogenous functional receptor.	[lacking endogenous functional receptor.]	0.0	4	1	1	1
87045	1710	hydrophobic moiety	[hydrophobic moiety]	0.0	2	1	1	1
87046	1710	relative affinity of quercetin	[relative affinity of quercetin]	0.0	4	1	1	1
87047	1710	model of switch	[model of switching]	0.0	3	1	1	1
87048	1710	quality of the response	[quality of the response]	0.0	4	1	1	1
87049	1710	binding of peptide to cell line	[Binding of peptide to cell lines]	0.0	6	1	1	1
87050	1710	permissive condition	[permissive conditions]	0.0	2	1	1	1
87051	1710	pro-B cell line	[pro-B cell line]	0.0	3	1	1	1
87052	1710	color confocal microscopy	[color confocal microscopy]	0.0	3	1	1	1
87053	1710	mnda mrna variation	[MNDA mRNA variation]	0.0	3	1	1	1
87054	1710	offersugg a new aspect	[offersuggesting a new aspect]	0.0	4	1	1	1
87055	1710	human ALAS gene	[human ALAS gene]	0.0	3	1	1	1
87056	1710	binding to TF cofactor	[binding to TF cofactor]	0.0	4	1	1	1
87057	1710	repressor icer camp repressor	[repressor ICER cAMP repressor]	0.0	4	1	1	1
87058	1710	variable region beta chain	[variable region beta chain]	0.0	4	1	1	1
87059	1710	ptf a complex of subunit	[PTF a complex of subunits]	0.0	5	1	1	1
87060	1710	latency breaking	[Latency breaking]	0.0	2	1	1	1
87061	1710	study pertain to LPS	[studies pertaining to LPS]	0.0	4	1	1	1
87062	1710	level lps	[levels LPS]	0.0	2	1	1	1
87063	1710	virus contain the cytomegalovirus enhancer	[Viruses containing the cytomegalovirus enhancer]	0.0	5	1	1	1
87064	1710	disorder in down' syndrome tmd	[disorder in Down's syndrome TMD]	0.0	5	2	2	1
87065	1710	level binding protein	[levels binding proteins]	0.0	3	1	1	1
87066	1710	chromosome abnormality with loss	[Chromosome abnormalities with loss]	0.0	4	1	1	1
87067	1710	three major infectious disease	[three major infectious diseases]	0.0	4	1	1	1
87068	1710	stress gene	[stress genes]	0.0	2	1	1	1
87069	1710	detectable e1a sequence in the epithelium	[detectable E1a sequences in the epithelium]	0.0	6	1	1	1
87070	1710	normocalcemic patient	[normocalcemic patients]	0.0	2	2	2	1
87071	1710	3- increase	[3- increase]	0.0	2	1	1	1
87072	1710	myeloid/natural	[myeloid/natural]	0.0	1	1	1	1
87073	1710	alter interaction to strong interactions.	[altering interactions to strong interactions.]	0.0	5	1	1	1
87074	1710	association with Stat5	[association with Stat5]	0.0	3	1	1	1
87075	1710	replate	[replating]	0.0	1	1	1	1
87076	1710	surface expression of adhesion molecule-1 icam-1	[surface expression of adhesion molecule-1 ICAM-1]	0.0	6	1	1	1
87077	1710	triptolide degradation	[triptolide degradation]	0.0	2	1	1	1
87078	1710	site in the Epstein-Barr virus	[site in the Epstein-Barr virus]	0.0	5	1	1	1
87079	1710	lighting regimen	[lighting regimen]	0.0	2	1	1	1
87080	1710	stat1 control transcription factor	[Stat1 control transcription factors]	0.0	4	1	1	1
87081	1710	overall distribution	[overall distributions]	0.0	2	1	1	1
87082	1710	protein 3 crisp-3	[protein 3 CRISP-3]	0.0	3	1	1	1
87083	1710	affinity (at least sevenfold)	[affinity (at least sevenfold)]	0.0	4	1	1	1
87084	1710	rdna the sub-unit	[cDNAs the sub-unit]	0.0	3	1	1	1
87085	1710	new link via the involvement	[new link via the involvement]	0.0	5	1	1	1
87086	1710	expression p 0.005	[expression P 0.005,]	0.0	3	1	1	1
87087	1710	signal from this receptor	[signals from these receptors]	0.0	4	1	1	1
87088	1710	thp cell	[THP cells]	0.0	2	1	1	1
87089	1710	(outer limits,	[(outer limits,]	0.0	2	1	1	1
87090	1710	platelet-activating factor (paf)- receptor antagonist	[platelet-activating factor (PAF)- receptor antagonist]	0.0	5	1	1	1
87091	1710	stat in primary T	[STATs in primary T]	0.0	4	1	1	1
87092	1710	plasma sialyltransferase level	[Plasma sialyltransferase levels]	0.0	3	1	1	1
87093	1710	transcriptional activation of the cytokine	[transcriptional activation of the cytokines]	0.0	5	1	1	1
87094	1710	inflammatory cytokine gene include tnf	[inflammatory cytokine genes including TNF]	0.0	5	1	1	1
87095	1710	cycle progeny virus expression	[cycle progeny virus expression]	0.0	4	1	1	1
87096	1710	constitutive binding of Sp1	[constitutive binding of Sp1]	0.0	4	1	1	1
87097	1710	cellular factor-KB	[cellular factor-KB]	0.0	2	1	1	1
87098	1710	amino acid alteration within domain relative	[amino acid alterations within domain relative]	0.0	6	1	1	1
87099	1710	transactivate complex, factor	[transactivating complex, factor]	0.0	3	1	1	1
87100	1710	blockade of nfat activity by FK506	[blockade of NFAT activity by FK506]	0.0	6	1	1	1
87101	1710	first step-wise increase physical exercise	[first step-wise increasing physical exercise]	0.0	5	1	1	1
87102	1710	jun d proto-oncogent	[jun D proto-oncogenes]	0.0	3	1	1	1
87103	1710	Saos 2 cell	[Saos 2 cells]	0.0	3	1	1	1
87104	1710	almost complete tolerance	[almost complete tolerance]	0.0	3	1	1	1
87105	1710	30-40 torr),	[30-40 Torr),]	0.0	2	1	1	1
87106	1710	12 reactive hyperplasia	[12 reactive hyperplasia]	0.0	3	1	1	1
87107	1710	syk-family kinase	[Syk-family kinases]	0.0	2	1	1	1
87108	1710	potent inducer of differentiation	[potent inducer of differentiation]	0.0	4	1	1	1
87109	1710	modification of NF-ATp	[modification of NF-ATp]	0.0	3	1	1	1
87110	1710	accumulating, tyrosine	[accumulating, tyrosine]	0.0	2	1	1	1
87111	1710	slp-76 function	[SLP-76 function]	0.0	2	1	1	1
87112	1710	sequence from -repressible gene	[sequences from -repressible genes]	0.0	4	1	1	1
87113	1710	chronic failure A-CRF with insufficiency	[chronic failure A-CRF with insufficiency]	0.0	5	1	1	1
87114	1710	inhibit state ep<0.05)	[inhibiting state (P<0.05)]	0.0	3	1	1	1
87115	1710	epitopes.	[epitopes.]	0.0	1	1	1	1
87116	1710	visualization of chain gene	[visualization of chain genes]	0.0	4	1	1	1
87117	1710	sequence from glucocorticoid gene	[sequences from glucocorticoid genes]	0.0	4	1	1	1
87118	1710	h2 receptor desensitization	[H2 receptor desensitization]	0.0	3	1	1	1
87119	1710	6 day in human serum	[6 days in human serum]	0.0	5	1	1	1
87120	1710	current state of knowledge	[current state of knowledge]	0.0	4	1	1	1
87121	1710	datum on the signal	[data on the signals]	0.0	4	1	1	1
87122	1710	lymphoid component	[lymphoid components]	0.0	2	1	1	1
87123	1710	weight of 32, 36	[weights of 32, 36]	0.0	4	1	1	1
87124	1710	cellular gene include gm-csf	[cellular genes including GM-CSF]	0.0	4	1	1	1
87125	1710	even in response to acid	[even in response to acid]	0.0	5	1	1	1
87126	1710	mild down-regulation in patient	[mild down-regulation in patients]	0.0	4	1	1	1
87127	1710	receptor on leukocyte hml	[receptors on leukocytes HML]	0.0	4	1	1	1
87128	1710	activation in a p16(ink4a)-negative t-cell line	[Activation in a p16(INK4A)-negative T-cell line]	0.0	6	1	1	1
87129	1710	induce degradation	[inducing degradation]	0.0	2	1	1	1
87130	1710	marker of osteoclast with nuclearity,	[markers of osteoclasts with nuclearity,]	0.0	5	1	1	1
87131	1710	9 chromosome	[9 chromosome]	0.0	2	1	1	1
87132	1710	chromosome 1 abnormality with loss	[Chromosome 1 abnormalities with loss]	0.0	5	1	1	1
87133	1710	growth-transforme infection	[growth-transforming infection]	0.0	2	1	1	1
87134	1710	cell transcriptional induction of collagenase	[cell transcriptional induction of collagenase]	0.0	5	1	1	1
87135	1710	pretreatment human monocyte-derived macrophage	[Pretreatment human monocyte-derived macrophages]	0.0	4	1	1	1
87136	1710	mutation/deletion basis	[mutation/deletion bases]	0.0	2	1	1	1
87137	1710	level of aldosterone receptor	[level of aldosterone receptors]	0.0	4	1	1	1
87138	1710	Gardnerella vaginalis	[Gardnerella vaginalis]	0.0	2	1	1	1
87139	1710	potential for pathology such as disease	[potential for pathologies such as disease]	0.0	6	1	1	1
87140	1710	incubation of cell for hour	[Incubation of cells for hours]	0.0	5	1	1	1
87141	1710	functionally interact	[functionally interacting]	0.0	2	1	1	1
87142	1710	other arm	[other arm]	0.0	2	1	1	1
87143	1710	high throughput screen of broth	[high throughput screening of broths]	0.0	5	1	1	1
87144	1710	role of Jak3 in development	[role of Jak3 in development]	0.0	5	1	1	1
87145	1710	human thromboxane receptor	[human thromboxane receptor]	0.0	3	1	1	1
87146	1710	loss of recognition	[loss of recognition]	0.0	3	1	1	1
87147	1710	suggest a cooperative effect of B7	[suggesting a cooperative effect of B7]	0.0	6	1	1	1
87148	1710	virus-infected T cell	[virus-infected T cells]	0.0	3	1	1	1
87149	1710	65 kda p65	[65 kDa p65]	0.0	3	1	1	1
87150	1710	40s protein s6 kinase	[40S protein S6 kinase]	0.0	4	1	1	1
87151	1710	typical T cell cytokine	[typical T cell cytokine]	0.0	4	1	1	1
87152	1710	generation of messenger	[generation of messengers]	0.0	3	1	1	1
87153	1710	property of pre-exist mcp-1	[properties of pre-existing MCP-1]	0.0	4	1	1	1
87154	1710	stimulation, mrna	[stimulation, mRNA]	0.0	2	1	1	1
87155	1710	control of developmental process	[control of developmental processes]	0.0	4	1	1	1
87156	1710	adhesion molecule-1 cd106	[adhesion molecule-1 CD106]	0.0	3	1	1	1
87157	1710	mature monocyte/macrophage function	[mature monocyte/macrophage function]	0.0	3	1	1	1
87158	1710	Extrarenal receptor-effector-mechor-mechanisms the sequence of effect	[Extrarenal receptor-effector-mechanisms the sequence of effects]	0.0	6	1	1	1
87159	1710	NK activity variance	[NK activity variance]	0.0	3	1	1	1
87160	1710	construct contain deletion mutant	[constructs containing deletion mutants]	0.0	4	1	1	1
87161	1710	high level of all b	[high levels of all B]	0.0	5	1	1	1
87162	1710	constitutive association through the a	[constitutive association through the aa]	0.0	5	1	1	1
87163	1710	Ca2+/calmodulin-dependent protein phosphatase	[Ca2+/calmodulin-dependent protein phosphatase]	0.0	3	1	1	1
87164	1710	regulation a comparative study	[regulation a comparative study]	0.0	4	1	1	1
87165	1710	apoptotic cell within plaque	[Apoptotic cells within plaques]	0.0	4	1	1	1
87166	1710	hsv-1-activated factor	[HSV-1-activated factor]	0.0	2	1	1	1
87167	1710	suggest lack of (a) factor	[suggesting lack of (a) factor]	0.0	5	1	1	1
87168	1710	region(	[region(s)]	0.0	1	1	1	1
87169	1710	G0 phase transition	[G0 phase transition]	0.0	3	1	1	1
87170	1710	x-ray-treated human carcinoma cell line	[X-ray-treated human carcinoma cell line]	0.0	5	1	1	1
87171	1710	cis-acting effect on the trans-activation	[cis-acting effect on the trans-activation]	0.0	5	1	1	1
87172	1710	h. induce CAT activity costimulation	[h, inducing CAT activity costimulation]	0.0	5	1	1	1
87173	1710	expression by immune system cell	[expression by immune system cells]	0.0	5	1	1	1
87174	1710	leukemic cell line u-937	[leukemic cell lines U-937]	0.0	4	1	1	1
87175	1710	activator property in lymphoid cell	[activator properties in lymphoid cells]	0.0	5	1	1	1
87176	1710	10 patient with low affinity	[10 patients with low affinity]	0.0	5	1	1	1
87177	1710	certain aspect	[Certain aspects]	0.0	2	1	1	1
87178	1710	use a panel	[Using a panel]	0.0	3	2	2	1
87179	1710	third trimester),	[third trimester),]	0.0	2	1	1	1
87180	1710	AU-motif-directed display	[AU-motif-directed display]	0.0	2	1	1	1
87181	1710	paracrine action	[paracrine action]	0.0	2	1	1	1
87182	1710	early transcriptional regulation	[early transcriptional regulation]	0.0	3	1	1	1
87183	1710	UAS2 -352	[UAS2 -352]	0.0	2	1	1	1
87184	1710	Effect erythroid differentiation	[Effects erythroid differentiation]	0.0	3	1	1	1
87185	1710	productive cycle	[productive cycle]	0.0	2	1	1	1
87186	1710	x box-dependent pathway	[X box-dependent pathway]	0.0	3	1	1	1
87187	1710	human mononuclear leukocyte of patient	[human mononuclear leukocytes of patients]	0.0	5	1	1	1
87188	1710	common feature	[common feature]	0.0	2	2	2	1
87189	1710	hmd similar to lipopolysaccharide lps	[HMDS similar to lipopolysaccharide LPS]	0.0	5	1	1	1
87190	1710	pure differentiate progenitor	[pure differentiating progenitors]	0.0	3	1	1	1
87191	1710	extract of th1 clone	[extracts of Th1 clones]	0.0	4	1	1	1
87192	1710	inhibit ige synthesis (10(-10)	[inhibiting IgE synthesis (10(-10)]	0.0	4	1	1	1
87193	1710	oligonucleotide probe in tissue section	[oligonucleotide probes in tissue sections]	0.0	5	1	1	1
87194	1710	domain with sh2 phosphotyrosine-based motif	[domains with SH2 phosphotyrosine-based motifs]	0.0	5	1	1	1
87195	1710	Furthermore, replacement	[Furthermore, replacement]	0.0	2	1	1	1
87196	1710	single cell	[single cells]	0.0	2	1	1	1
87197	1710	mobility of extract-DNA complex	[mobilities of extract-DNA complexes]	0.0	4	1	1	1
87198	1710	(35 min) physical exercise	[(35 min) physical exercise]	0.0	4	1	1	1
87199	1710	8, malignant fibrous histiocytoma 6, rhabdomyosarcoma	[8, malignant fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	6	1	1	1
87200	1710	SLP-76 sh2 domain leukocyte protein kda)	[SLP-76 SH2 domain leukocyte protein kDa)]	0.0	6	1	1	1
87201	1710	normal nf-kappa b activation	[normal NF-kappa B activation]	0.0	4	1	1	1
87202	1710	IL-2 -inducible DNA binding activity	[IL-2 -inducible DNA binding activities]	0.0	5	1	1	1
87203	1710	observation period	[observation period]	0.0	2	1	1	1
87204	1710	potential for pathology	[potential for pathologies]	0.0	3	1	1	1
87205	1710	localization of NF-kappa b	[localization of NF-kappa B]	0.0	4	1	1	1
87206	1710	moment,	[moment,]	0.0	1	1	1	1
87207	1710	cellular activation follow viral binding	[cellular activation following viral binding]	0.0	5	1	1	1
87208	1710	space	[space]	0.0	1	2	2	1
87209	1710	genetic end target of pathway	[genetic end targets of pathway]	0.0	5	1	1	1
87210	1710	transcriptional regulation during monocytic differentiation	[Transcriptional regulation during monocytic differentiation]	0.0	5	1	1	1
87211	1710	specific proteasome inhibitor	[specific proteasome inhibitor]	0.0	3	1	1	1
87212	1710	cell (ec)	[cell (EC)]	0.0	2	1	1	1
87213	1710	select activity	[selecting activity]	0.0	2	1	1	1
87214	1710	frequently traffic	[frequently traffic]	0.0	2	1	1	1
87215	1710	procoagulant	[procoagulant]	0.0	1	1	1	1
87216	1710	myelomonocytic differentiation include 1 aml	[myelomonocytic differentiation including 1 AML]	0.0	5	1	1	1
87217	1710	group ebv genome	[group EBV genome]	0.0	3	1	1	1
87218	1710	2 yac	[2 YACs]	0.0	2	1	1	1
87219	1710	overcome several cellular block	[overcoming several cellular blocks]	0.0	4	1	1	1
87220	1710	target of the silencing.	[target of the silencing.]	0.0	4	1	1	1
87221	1710	consequence of mef2c activation	[consequence of MEF2C activation]	0.0	4	1	1	1
87222	1710	tryptophan solution	[tryptophan solutions]	0.0	2	1	1	1
87223	1710	site of reaction	[sites of reactions]	0.0	3	1	1	1
87224	1710	transformation in chronic myelogenous leukemia	[transformation in chronic myelogenous leukemia]	0.0	5	1	1	1
87225	1710	1 mmol/L.	[1 mmol/L.]	0.0	2	1	1	1
87226	1710	leukaemias /lymphomas	[leukaemias /lymphomas]	0.0	2	1	1	1
87227	1710	Th2-type cytokine	[Th2-type cytokines]	0.0	2	1	1	1
87228	1710	induction of c-fos/c-jun	[induction of c-fos/c-jun]	0.0	3	1	1	1
87229	1710	emulsion	[emulsion]	0.0	1	1	1	1
87230	1710	gamma-promoter activity	[gamma-promoter activity]	0.0	2	1	1	1
87231	1710	extract from k562 cell	[extracts from K562 cells]	0.0	4	1	1	1
87232	1710	receptor of peripheral blood leukocyte	[receptors of peripheral blood leukocytes]	0.0	5	1	1	1
87233	1710	activity of acid RA	[activities of acid RA]	0.0	4	1	1	1
87234	1710	T helper 1 (th1) cell	[T helper 1 (Th1) cells]	0.0	5	1	1	1
87235	1710	result in inactivity	[resulting in inactivity]	0.0	3	1	1	1
87236	1710	dual cyclooxygenase/5-lipoxygenase compound under investigation.	[dual cyclooxygenase/5-lipoxygenase compound under investigation.]	0.0	5	1	1	1
87237	1710	contrast, analysis	[contrast, analysis]	0.0	2	1	1	1
87238	1710	apoptotic change	[apoptotic changes]	0.0	2	1	1	1
87239	1710	competitive hybridization assay	[competitive hybridization assay]	0.0	3	1	1	1
87240	1710	vitamin d-resistant World primate cell	[vitamin D-resistant World primate cells]	0.0	5	1	1	1
87241	1710	genetic aberration	[genetic aberrations]	0.0	2	1	1	1
87242	1710	growth of a variant line 1a9-m	[growth of a variant line 1A9-M]	0.0	6	1	1	1
87243	1710	compensatory response of cell	[compensatory response of cells]	0.0	4	1	1	1
87244	1710	contrast to induction of stat	[contrast to induction of STATs]	0.0	5	1	1	1
87245	1710	sensitive identification in a background	[sensitive identification in a background]	0.0	5	1	1	1
87246	1710	functional domain responsible	[functional domains responsible]	0.0	3	1	1	1
87247	1710	importance of lesion in aspect	[importance of lesions in aspects]	0.0	5	1	1	1
87248	1710	normal development; addition to hpc	[normal development; addition to HPC]	0.0	5	1	1	1
87249	1710	physical interaction of tax	[physical interaction of Tax]	0.0	4	1	1	1
87250	1710	protein from matrix preparation	[protein from matrix preparations]	0.0	4	1	1	1
87251	1710	keep erythroid-specific property through the immortalization	[keeping erythroid-specific properties through the immortalization]	0.0	6	1	1	1
87252	1710	5' DNA of the gene	[5' DNA of the gene]	0.0	5	1	1	1
87253	1710	GAL4 DNA domain	[GAL4 DNA domain]	0.0	3	1	1	1
87254	1710	value of a response	[value of a response]	0.0	4	1	1	1
87255	1710	tyrosine phosphorylation of protein substrates.	[tyrosine phosphorylation of protein substrates.]	0.0	5	1	1	1
87256	1710	analysis of the sequence	[Analysis of the sequence]	0.0	4	1	1	1
87257	1710	obvious sequence similarity	[obvious sequence similarity]	0.0	3	1	1	1
87258	1710	CD28RE complex	[CD28RE complex]	0.0	2	1	1	1
87259	1710	induce the emergence	[inducing the emergence]	0.0	3	1	1	1
87260	1710	blood leukocyte content	[blood leukocyte content]	0.0	3	2	2	1
87261	1710	role of c-Jun	[role of c-Jun]	0.0	3	1	1	1
87262	1710	Effect of the myb expression	[Effects of the myb expression]	0.0	5	1	1	1
87263	1710	Ras pathway	[Ras pathway]	0.0	2	1	1	1
87264	1710	vivo DNA	[vivo DNA]	0.0	2	1	1	1
87265	1710	use throughput screen	[using throughput screening]	0.0	3	1	1	1
87266	1710	typical Th1-dominated inflammation	[typical Th1-dominated inflammation]	0.0	3	1	1	1
87267	1710	defect in the ability	[defects in the ability]	0.0	4	1	1	1
87268	1710	permanent control	[permanent control]	0.0	2	1	1	1
87269	1710	pre-B acute leukemia	[pre-B acute leukemia]	0.0	3	1	1	1
87270	1710	effect during acute lung inflammatory injury	[effects during acute lung inflammatory injury]	0.0	6	1	1	1
87271	1710	trifluoromethylketone inhibitor interleukin-1beta protein	[trifluoromethylketone inhibitors interleukin-1beta protein]	0.0	4	1	1	1
87272	1710	classical effects,	[classical effects,]	0.0	2	2	2	1
87273	1710	exposure to il-6	[exposure to IL-6]	0.0	3	1	1	1
87274	1710	provide a initial regulatory point	[providing an initial regulatory point]	0.0	5	1	1	1
87275	1710	Minimal disease in acute leukemia	[Minimal disease in acute leukemia]	0.0	5	1	1	1
87276	1710	addition to the octamer-binding protein	[addition to the octamer-binding proteins]	0.0	5	1	1	1
87277	1710	T cell from the transgenic mouse	[T cells from the transgenic mice]	0.0	6	1	1	1
87278	1710	regulation kappa b molecules.	[regulation kappa B molecules.]	0.0	4	1	1	1
87279	1710	p young vs. old) in pbl	[P young vs. old) in PBL]	0.0	6	1	1	1
87280	1710	production of interleukin 2 il-2	[production of interleukin 2 IL-2]	0.0	5	1	1	1
87281	1710	specific DNA binding capacity	[specific DNA binding capacity]	0.0	4	1	1	1
87282	1710	a gamma-globin gene	[A gamma-globin gene]	0.0	3	1	1	1
87283	1710	monocyte production	[monocyte production]	0.0	2	1	1	1
87284	1710	specific uptake with chronic failure	[specific uptake with chronic failure]	0.0	5	1	1	1
87285	1710	therapeutic target in inflammatory state	[therapeutic target in inflammatory states]	0.0	5	1	1	1
87286	1710	circulate lymphocyte in hyper- thyroidism	[circulating lymphocytes in hyper- thyroidism]	0.0	5	1	1	1
87287	1710	recognition of peptide	[recognition of peptides]	0.0	3	1	1	1
87288	1710	initiation of encephalomyocarditis virus emcv mrna	[initiation of encephalomyocarditis virus EMCV mRNA]	0.0	6	1	1	1
87289	1710	whole blood from donor	[whole blood from donors]	0.0	4	1	1	1
87290	1710	immune mechanism	[immune mechanisms]	0.0	2	1	1	1
87291	1710	even in a line	[even in a line]	0.0	4	1	1	1
87292	1710	produce a new human retrovirus	[producing a new human retrovirus]	0.0	5	1	1	1
87293	1710	cytopathic effect in T cell	[cytopathic effects in T cells]	0.0	5	1	1	1
87294	1710	human myeloid cell granulocyte	[human myeloid cells granulocytes]	0.0	4	1	1	1
87295	1710	critical determinant for the activity	[critical determinant for the activity]	0.0	5	1	1	1
87296	1710	membrane protein homolog	[membrane protein homologs]	0.0	3	1	1	1
87297	1710	CD40 by CD40 ligand	[CD40 by CD40 ligand]	0.0	4	1	1	1
87298	1710	minutes) to all-tran acid	[minutes) to all-trans acid]	0.0	4	1	1	1
87299	1710	four- amount of the kb transcript	[four- amounts of the kb transcript]	0.0	6	1	1	1
87300	1710	factor role in transient up-regulation	[factor role in transient up-regulation]	0.0	5	1	1	1
87301	1710	protein expression in tissue	[protein expression in tissues]	0.0	4	1	1	1
87302	1710	activation of the kinase erk2	[activation of the kinase Erk2]	0.0	5	1	1	1
87303	1710	human macrophage protein-1alpha	[human macrophage protein-1alpha]	0.0	3	1	1	1
87304	1710	anti-STAT antibody	[anti-STAT antibodies]	0.0	2	1	1	1
87305	1710	distant homology	[distant homology]	0.0	2	1	1	1
87306	1710	least three category	[least three categories]	0.0	3	1	1	1
87307	1710	normal woman age.	[normal women age.]	0.0	3	1	1	1
87308	1710	reporter activation	[reporter activation]	0.0	2	1	1	1
87309	1710	beta-(1,3)-glucan receptor	[beta-(1,3)-glucan receptor]	0.0	2	1	1	1
87310	1710	stimulation, two kappa B-specific complex	[stimulation, two kappa B-specific complexes]	0.0	5	1	1	1
87311	1710	instead a marker of polymorphism	[instead a marker(s) of polymorphisms]	0.0	5	1	1	1
87312	1710	presence in cytokine gene	[presence in cytokine genes]	0.0	4	1	1	1
87313	1710	simian cell line	[simian cell lines]	0.0	3	1	1	1
87314	1710	tripartite complex	[tripartite complex]	0.0	2	1	1	1
87315	1710	patient aml	[patients AML]	0.0	2	1	1	1
87316	1710	signal transduce	[signal transducing]	0.0	2	1	1	1
87317	1710	cytokine il-1	[cytokines IL-1]	0.0	2	1	1	1
87318	1710	aberrancy important for the induction	[aberrancies important for the induction]	0.0	5	1	1	1
87319	1710	potential target for hiv-1 therapy	[potential targets for HIV-1 therapy]	0.0	5	1	1	1
87320	1710	receptor contain the extracellular domain	[receptor containing the extracellular domain]	0.0	5	1	1	1
87321	1710	eight peptide represent acid sequence	[eight peptides representing acid sequences]	0.0	5	1	1	1
87322	1710	structural constraint	[structural constraints]	0.0	2	1	1	1
87323	1710	class molecule through the compartment	[class molecules through the compartment]	0.0	5	1	1	1
87324	1710	sequence from the TATA box	[Sequences from the TATA box]	0.0	5	1	1	1
87325	1710	position to -91	[positions to -91]	0.0	3	1	1	1
87326	1710	study to dq0302 molecule	[studies to DQ0302 molecules]	0.0	4	1	1	1
87327	1710	cover the sequence on 10 individual	[covering the sequence on 10 individuals]	0.0	6	1	1	1
87328	1710	requirement provide explanation	[requirement providing explanation]	0.0	3	1	1	1
87329	1710	function over the gene activation	[function over the gene activation]	0.0	5	1	1	1
87330	1710	action of S9a	[action of S9a]	0.0	3	1	1	1
87331	1710	cytokine cascade	[cytokine cascade]	0.0	2	1	1	1
87332	1710	significant class immunoblastic lymphoma plasmacytoid	[significant class immunoblastic lymphoma plasmacytoid]	0.0	5	1	1	1
87333	1710	alter weak, interaction to strong interactions.	[altering weak, interactions to strong interactions.]	0.0	6	1	1	1
87334	1710	other bone marrow	[other bone marrow]	0.0	3	1	1	1
87335	1710	vivo through a latent infection	[vivo through a latent infection]	0.0	5	1	1	1
87336	1710	5 Hashimoto patient	[5 Hashimoto patients]	0.0	3	1	1	1
87337	1710	thus, competition between general activator RelA	[Thus, competition between general activators RelA]	0.0	6	1	1	1
87338	1710	activation by interferon-gamma in human neutrophil	[activation by interferon-gamma in human neutrophils]	0.0	6	1	1	1
87339	1710	nuclear export of mrna	[nuclear export of mRNA]	0.0	4	1	1	1
87340	1710	level of stat6 protein	[Levels of Stat6 protein]	0.0	4	1	1	1
87341	1710	leukocyte of male	[leukocytes of males]	0.0	3	1	1	1
87342	1710	risk: mononuclear cell reaction	[risk: mononuclear cell reaction]	0.0	4	1	1	1
87343	1710	cell T cell	[cells T cells]	0.0	3	1	1	1
87344	1710	unique region contain near-perfect repeat	[unique region containing near-perfect repeats]	0.0	5	1	1	1
87345	1710	18 breast cancer case	[18 breast cancer cases]	0.0	4	1	1	1
87346	1710	study a series of patient	[studying a series of patients]	0.0	5	1	1	1
87347	1710	form of nf-kappab	[form of NF-kappaB]	0.0	3	1	1	1
87348	1710	show a direct effect	[showing a direct effect]	0.0	4	1	1	1
87349	1710	suppression downregulate the activity of IKK	[Suppression downregulating the activity of IKK]	0.0	6	1	1	1
87350	1710	expression at mrna level	[expression at mRNA levels]	0.0	4	1	1	1
87351	1710	addition, N-acetyl-L-cysteine NAC	[addition, N-acetyl-L-cysteine NAC]	0.0	3	1	1	1
87352	1710	3'-untranslated region polymorphism lack of effect	[3'-untranslated region polymorphisms lack of effect]	0.0	6	1	1	1
87353	1710	favorable clinical course	[favorable clinical course]	0.0	3	1	1	1
87354	1710	interaction in the gamma-globin promoter	[Interaction in the gamma-globin promoter]	0.0	5	1	1	1
87355	1710	biological principle a regulator	[biological principle a regulator]	0.0	4	1	1	1
87356	1710	post-transcriptional regulator i	[post-transcriptional regulator I]	0.0	3	1	1	1
87357	1710	hiv type protease activation of b	[HIV type protease activation of B]	0.0	6	1	1	1
87358	1710	However, retroviral transduction of gata-3	[However, retroviral transduction of GATA-3]	0.0	5	1	1	1
87359	1710	consider study	[considering studies]	0.0	2	1	1	1
87360	1710	association with cellular/molecular event	[association with cellular/molecular events]	0.0	4	1	1	1
87361	1710	western blotting of population	[Western blotting of populations]	0.0	4	1	1	1
87362	1710	three time per day	[three times per day]	0.0	4	1	1	1
87363	1710	action of nm23 protein	[action of nm23 proteins]	0.0	4	1	1	1
87364	1710	expression of bcl-x(l)	[expression of Bcl-x(L)]	0.0	3	1	1	1
87365	1710	activation of human macrophage	[Activation of human macrophages]	0.0	4	1	1	1
87366	1710	macrophage-CSF M-CSF in monocyte	[macrophage-CSF M-CSF in monocytes]	0.0	4	1	1	1
87367	1710	fibrous histiocytoma rhabdomyosarcoma	[fibrous histiocytoma rhabdomyosarcoma]	0.0	3	1	1	1
87368	1710	T-lymphocyte cell line	[T-lymphocyte cell line]	0.0	3	1	1	1
87369	1710	vitro, six viral nuclear antigen	[vitro, six viral nuclear antigens]	0.0	5	1	1	1
87370	1710	IRF-1 gas element	[IRF-1 GAS elements]	0.0	3	1	1	1
87371	1710	role in early hematopoiesis	[role in early hematopoiesis]	0.0	4	1	1	1
87372	1710	endobronchial biopsy	[endobronchial biopsy]	0.0	2	1	1	1
87373	1710	4.8%) center	[4.8%) center]	0.0	2	1	1	1
87374	1710	nf kappab enzyme ino	[NF kappaB enzyme iNOS]	0.0	4	1	1	1
87375	1710	event in agonist-induced signalling	[event in agonist-induced signalling]	0.0	4	1	1	1
87376	1710	clonally expand	[clonally expanding]	0.0	2	1	1	1
87377	1710	molecular mass kda	[molecular mass kDa]	0.0	3	1	1	1
87378	1710	role of the zip site	[role of the ZIP site]	0.0	5	1	1	1
87379	1710	sequence tag from cell	[sequence tags from cells]	0.0	4	1	1	1
87380	1710	Interleukin-12 IL-12 a cytokine	[Interleukin-12 IL-12 a cytokine]	0.0	4	1	1	1
87381	1710	lymphocyte of woman first, second	[lymphocytes of women first, second]	0.0	5	1	1	1
87382	1710	62 loss	[62 loss]	0.0	2	1	1	1
87383	1710	other type of process	[other types of processes]	0.0	4	1	1	1
87384	1710	evolutionary benefit for eukaryote	[evolutionary benefit for eukaryotes]	0.0	4	1	1	1
87385	1710	element in the promoter	[element in the promoter]	0.0	4	1	1	1
87386	1710	translocation of a zeta isoform	[translocation of a zeta isoform]	0.0	5	1	1	1
87387	1710	member of the BCL-2 family	[members of the BCL-2 family]	0.0	5	1	1	1
87388	1710	CIITA occupation	[CIITA occupation]	0.0	2	1	1	1
87389	1710	long repeat in T cell	[long repeat in T cells]	0.0	5	1	1	1
87390	1710	difference in pre- value	[Differences in pre- values]	0.0	4	1	1	1
87391	1710	continuous nf-kappa b translocation result p105	[continuous NF-kappa B translocation results p105]	0.0	6	1	1	1
87392	1710	cytolytic resistance	[cytolytic resistance]	0.0	2	3	3	1
87393	1710	sequence gas	[sequence GAS]	0.0	2	1	1	1
87394	1710	Recent evidence jak1 to il-2r beta	[Recent evidence JAK1 to IL-2R beta]	0.0	6	1	1	1
87395	1710	shock gene such as IL1B	[shock genes such as IL1B]	0.0	5	1	1	1
87396	1710	CEM c7	[CEM C7]	0.0	2	1	1	1
87397	1710	activation of transcriptional factor ap-1	[activation of transcriptional factors AP-1]	0.0	5	1	1	1
87398	1710	hamster ovary (cho) cell	[hamster ovary (CHO) cells]	0.0	4	1	1	1
87399	1710	four stimulus	[four stimuli]	0.0	2	1	1	1
87400	1710	interact with functional motif	[interacting with functional motifs]	0.0	4	1	1	1
87401	1710	increase in the hemoglobin concentration	[increase in the hemoglobin concentration]	0.0	5	1	1	1
87402	1710	follow adrenalectomy	[following adrenalectomy]	0.0	2	1	1	1
87403	1710	ar gene	[AR gene]	0.0	2	1	1	1
87404	1710	killer gene complex	[killer gene complex]	0.0	3	3	3	1
87405	1710	model for viral promoter switch	[model for viral promoter switching]	0.0	5	1	1	1
87406	1710	ap-1 -tre	[AP-1 -TRE]	0.0	2	1	1	1
87407	1710	contain the ubiquitous transcription factor nf-y	[containing the ubiquitous transcription factor NF-Y]	0.0	6	1	1	1
87408	1710	creb isoform with identical specificity	[CREB isoforms with identical specificities]	0.0	5	1	1	1
87409	1710	possible strategy for the detection	[possible strategies for the detection]	0.0	5	1	1	1
87410	1710	bhlh homo hetero dimer formation	[bHLH homo hetero dimer formation]	0.0	5	1	1	1
87411	1710	murine m	[murine M]	0.0	2	1	1	1
87412	1710	increase in state level ifn-gamma	[increase in state levels IFN-gamma]	0.0	5	1	1	1
87413	1710	analysis with cell	[Analyses with cells]	0.0	3	1	1	1
87414	1710	present with salt loss	[presenting with salt loss]	0.0	4	1	1	1
87415	1710	lack of killer cell	[lack of killer cells]	0.0	4	1	1	1
87416	1710	highlight novel loci relevant to pel	[highlighting novel loci relevant to PEL]	0.0	6	1	1	1
87417	1710	severe,	[severe,]	0.0	1	1	1	1
87418	1710	NF-kappaB subunit p65	[NF-kappaB subunit P65]	0.0	3	1	1	1
87419	1710	change of glucocorticoid receptor	[changes of glucocorticoid receptor]	0.0	4	1	1	1
87420	1710	subtle gene movement within that region	[subtle gene movements within those regions]	0.0	6	1	1	1
87421	1710	death-prom activity	[death-promoting activity]	0.0	2	1	1	1
87422	1710	IFN-alpha responsiveness myelogenous leukemia	[IFN-alpha responsiveness myelogenous leukemia]	0.0	4	1	1	1
87423	1710	inhibition of processing	[Inhibition of processing]	0.0	3	1	1	1
87424	1710	tract of woman	[tracts of women]	0.0	3	1	1	1
87425	1710	biochemical event lead to activation	[biochemical events leading to activation]	0.0	5	1	1	1
87426	1710	NF-activated T	[NF-activated T]	0.0	2	1	1	1
87427	1710	ras -dependent	[Ras -dependent]	0.0	2	1	1	1
87428	1710	12 child-bearing-age woman	[12 child-bearing-age women]	0.0	3	1	1	1
87429	1710	concentration range to 10(-6) M.	[concentrations ranging to 10(-6) M.]	0.0	5	1	1	1
87430	1710	Alpha-tocopherol treatment	[Alpha-tocopherol treatment]	0.0	2	1	1	1
87431	1710	cell lines, protein	[cell lines, proteins]	0.0	3	1	1	1
87432	1710	cytokine-stimulated vein endothelial cell HUVEC	[cytokine-stimulated vein endothelial cells HUVEC]	0.0	5	1	1	1
87433	1710	cockayne'	[Cockayne's]	0.0	1	1	1	1
87434	1710	-peptide	[-peptide]	0.0	1	1	1	1
87435	1710	3,605 984 binding site	[3,605 984 binding sites]	0.0	4	1	1	1
87436	1710	hb-egf expression	[HB-EGF expression]	0.0	2	1	1	1
87437	1710	g2, increase	[G2, increase]	0.0	2	1	1	1
87438	1710	activator protein-1 ap-1 nuclear factor il-6	[activator protein-1 AP-1 nuclear factor IL-6]	0.0	6	1	1	1
87439	1710	lmp-1 b cell	[LMP-1 B cells]	0.0	3	1	1	1
87440	1710	8 promoter activity	[8 promoter activity]	0.0	3	1	1	1
87441	1710	analysis latency in the tumour cell	[analysis latency in the tumour cells]	0.0	6	1	1	1
87442	1710	liver FL	[liver FL]	0.0	2	1	1	1
87443	1710	NF-kappaB activation in response	[NF-kappaB activation in response]	0.0	4	1	1	1
87444	1710	cell from 24% to 44%	[cells from 24% to 44%]	0.0	5	1	1	1
87445	1710	plasma membrane ca-atpase	[plasma membrane Ca-ATPase]	0.0	3	1	1	1
87446	1710	IL-12 stage involve expression	[IL-12 stage involving expression]	0.0	4	1	1	1
87447	1710	difference in binding	[Differences in binding]	0.0	3	1	1	1
87448	1710	interactor (s) limit transcription	[interactor (s) limits transcription]	0.0	4	1	1	1
87449	1710	role a gene in differentiation	[role a gene in differentiation]	0.0	5	1	1	1
87450	1710	region of the irf-1 5'-flanking	[regions of the IRF-1 5'-flanking]	0.0	5	1	1	1
87451	1710	ability of E1A	[abilities of E1A]	0.0	3	1	1	1
87452	1710	enhance effect of beta-estradiol	[Enhancing effect of beta-estradiol]	0.0	4	1	1	1
87453	1710	only g/g	[only g/g]	0.0	2	1	1	1
87454	1710	peripheral blood mononuclear cell of adult	[peripheral blood mononuclear cells of adults]	0.0	6	1	1	1
87455	1710	key role of erythropoietin	[key role of erythropoietin]	0.0	4	1	1	1
87456	1710	linker protein	[linker proteins]	0.0	2	2	2	1
87457	1710	p-nitrophenyl sulfatase activity	[p-nitrophenyl sulfatase activity]	0.0	3	1	1	1
87458	1710	fosb mrna	[FOSB mRNA]	0.0	2	1	1	1
87459	1710	lack the activator function af-1	[lacking the activator functions AF-1]	0.0	5	1	1	1
87460	1710	impact of EBNA-2	[impact of EBNA-2]	0.0	3	1	1	1
87461	1710	(rar)	[(RAR)]	0.0	1	1	1	1
87462	1710	cell from CLL patient	[cells from CLL patients]	0.0	4	1	1	1
87463	1710	only of the intracellular domain	[only of the intracellular domain]	0.0	5	1	1	1
87464	1710	obtain new probe specific	[obtaining new probes specific]	0.0	4	1	1	1
87465	1710	combination to ig isotype switch	[combination to Ig isotype switching]	0.0	5	1	1	1
87466	1710	NF-kappa b related polypeptide	[NF-kappa B related polypeptides]	0.0	4	1	1	1
87467	1710	maintenance of transcription	[maintenance of transcription]	0.0	3	1	1	1
87468	1710	rearrangement of one	[Rearrangement of one]	0.0	3	1	1	1
87469	1710	two region include the poz motif	[two regions including the POZ motif]	0.0	6	1	1	1
87470	1710	evidence for the relationship	[evidence for the relationship]	0.0	4	1	1	1
87471	1710	cell type-specific induction	[cell type-specific induction]	0.0	3	1	1	1
87472	1710	autosomal recessive disease	[autosomal recessive disease]	0.0	3	1	1	1
87473	1710	even a moderate increase	[Even a moderate increase]	0.0	4	1	1	1
87474	1710	95% decrease of activation	[95% decrease of activation]	0.0	4	1	1	1
87475	1710	activity of glucocorticoid i.e. transactivation	[activities of glucocorticoids i.e. transactivation]	0.0	5	1	1	1
87476	1710	mutation of the receptor	[mutation of the receptor]	0.0	4	2	2	1
87477	1710	specific binding site of receptor	[specific binding sites of receptors]	0.0	5	1	1	1
87478	1710	10(-12) g/g of total mrna	[10(-12) g/g of total mRNA]	0.0	5	1	1	1
87479	1710	differentiation-inducing capacity upon k562 cell	[differentiation-inducing capacity upon K562 cells]	0.0	5	1	1	1
87480	1710	T cell nf-at-1	[T cells NF-AT-1]	0.0	3	1	1	1
87481	1710	10% porcine serum	[10% porcine serum]	0.0	3	1	1	1
87482	1710	deoxyribonucleic acid (dna) protein	[deoxyribonucleic acid (DNA) proteins]	0.0	4	1	1	1
87483	1710	class trans-activator CIITA	[class trans-activator CIITA]	0.0	3	1	1	1
87484	1710	modes, like induction, superinfection with ebv	[modes, like induction, superinfection with EBV]	0.0	6	1	1	1
87485	1710	site of endogenous gc production	[site of endogenous GC production]	0.0	5	1	1	1
87486	1710	ecto-5'-NT mrna	[ecto-5'-NT mRNA]	0.0	2	1	1	1
87487	1710	sp1-binding	[Sp1-binding]	0.0	1	1	1	1
87488	1710	warm hcl	[warm HCl]	0.0	2	1	1	1
87489	1710	effect on malignant lymphocyte inhibition depletion	[effects on malignant lymphocytes inhibition depletion]	0.0	6	1	1	1
87490	1710	incubation with various concentration	[incubation with various concentrations]	0.0	4	1	1	1
87491	1710	pkc alpha	[PKC alpha]	0.0	2	1	1	1
87492	1710	addition of phosphatidic acid	[addition of phosphatidic acid]	0.0	4	1	1	1
87493	1710	induction of this il-2 enhancer	[Induction of this IL-2 enhancer]	0.0	5	1	1	1
87494	1710	stable integration	[stable integration]	0.0	2	1	1	1
87495	1710	erythroid-specific gene in acute leukaemia	[erythroid-specific genes in acute leukaemia]	0.0	5	1	1	1
87496	1710	tpa (0.5 microM)	[TPA (0.5 microM)]	0.0	3	1	1	1
87497	1710	less extent, ebv antigen	[lesser extent, EBV antigen]	0.0	4	1	1	1
87498	1710	Functional b-cell response in lymphoid follicle	[Functional B-cell response in lymphoid follicles]	0.0	6	1	1	1
87499	1710	PP1 tyrosine	[PP1 tyrosine]	0.0	2	1	1	1
87500	1710	case of hypersensitivity	[case of hypersensitivity]	0.0	3	1	1	1
87501	1710	exclude possible targets,	[excluding possible targets,]	0.0	3	1	1	1
87502	1710	heterogeneous pool	[heterogeneous pool]	0.0	2	1	1	1
87503	1710	system a key step	[system a key step]	0.0	4	1	1	1
87504	1710	cytotoxic property	[cytotoxic properties]	0.0	2	1	1	1
87505	1710	oxygen species generation	[oxygen species generation]	0.0	3	1	1	1
87506	1710	health impact on tissue	[health impact on tissues]	0.0	4	1	1	1
87507	1710	unit consist of the promoter	[unit consisting of the promoter]	0.0	5	1	1	1
87508	1710	Effect on expression of c-fo	[Effects on expression of c-fos]	0.0	5	1	1	1
87509	1710	oncogenic version	[oncogenic version]	0.0	2	1	1	1
87510	1710	cell clone express level of hsf2-alpha	[cell clones expressing levels of HSF2-alpha]	0.0	6	1	1	1
87511	1710	human lymphotropic virus type htlv-1	[human lymphotropic virus type HTLV-1]	0.0	5	1	1	1
87512	1710	underlie this process.	[underlying this process.]	0.0	3	1	1	1
87513	1710	retinoid with different receptor binding specificity	[retinoids with different receptor binding specificity]	0.0	6	1	1	1
87514	1710	component of the specific immunoreaction	[components of the specific immunoreaction]	0.0	5	1	1	1
87515	1710	molecular mechanism of action	[molecular mechanisms of action]	0.0	4	1	1	1
87516	1710	upregulation of this molecule	[upregulation of these molecules]	0.0	4	1	1	1
87517	1710	factor lbf2	[factors LBF2]	0.0	2	1	1	1
87518	1710	blast from patient	[blasts from patients]	0.0	3	1	1	1
87519	1710	very low constitutive level	[very low constitutive levels]	0.0	4	1	1	1
87520	1710	number of patient	[number of patients]	0.0	3	1	1	1
87521	1710	affinity for CAML	[affinity for CAML]	0.0	3	1	1	1
87522	1710	b differentiation in vivo;	[B differentiation in vivo;]	0.0	4	1	1	1
87523	1710	median year Gail risk probability)	[median year Gail risk probability)]	0.0	5	1	1	1
87524	1710	stat6-dna binding complex	[STAT6-DNA binding complexes]	0.0	3	1	1	1
87525	1710	characterization of protein in human platelet	[Characterization of proteins in human platelets]	0.0	6	1	1	1
87526	1710	latent membrane protein lmp-1	[latent membrane protein LMP-1]	0.0	4	1	1	1
87527	1710	prototype for b gene	[prototype for B genes]	0.0	4	1	1	1
87528	1710	CYP1A1 mrna	[CYP1A1 mRNA]	0.0	2	1	1	1
87529	1710	proximity to the TATA box	[proximity to the TATA box]	0.0	5	1	1	1
87530	1710	effect than on IKK-beta	[effect than on IKK-beta]	0.0	4	1	1	1
87531	1710	(n-oct) protein	[(N-Oct) proteins]	0.0	2	1	1	1
87532	1710	range from kD to kd, result	[ranging from kD to kD, resulting]	0.0	6	1	1	1
87533	1710	high retinoidal activity (agonist	[High retinoidal activity (agonist]	0.0	4	1	1	1
87534	1710	use peptide	[using peptides]	0.0	2	1	1	1
87535	1710	hypothesis responsible for expression	[hypothesis responsible for expression]	0.0	4	1	1	1
87536	1710	two mitogen-inducible complex	[two mitogen-inducible complexes]	0.0	3	1	1	1
87537	1710	recombinant Tat protein	[recombinant Tat protein]	0.0	3	1	1	1
87538	1710	inhibition of the uptake	[inhibition of the uptake]	0.0	4	1	1	1
87539	1710	node T	[node T]	0.0	2	1	1	1
87540	1710	express the receptor	[expressing the receptor]	0.0	3	1	1	1
87541	1710	-inducible interferon regulatory factor-1 gene	[-inducible interferon regulatory factor-1 gene]	0.0	5	1	1	1
87542	1710	gas DNA	[GAS DNA]	0.0	2	1	1	1
87543	1710	patient with low affinity	[patients with low affinity]	0.0	4	1	1	1
87544	1710	expression of the exon	[expression of the exon]	0.0	4	1	1	1
87545	1710	rel oncogene family	[rel oncogene family]	0.0	3	1	1	1
87546	1710	inducible expression of many gene	[inducible expression of many genes]	0.0	5	1	1	1
87547	1710	Chimeric oncoprotein	[Chimeric oncoprotein]	0.0	2	1	1	1
87548	1710	colony formation by progenitor	[colony formation by progenitors]	0.0	4	1	1	1
87549	1710	removal of Ii chain loading	[removal of Ii chain loading]	0.0	5	1	1	1
87550	1710	activity of the endogenous protein	[activity of the endogenous protein]	0.0	5	1	1	1
87551	1710	proteins: RXR a subunit	[proteins: RXR a subunit]	0.0	4	1	1	1
87552	1710	bind interaction	[binding interaction]	0.0	2	1	1	1
87553	1710	functional architecture	[functional architecture]	0.0	2	1	1	1
87554	1710	change in p-glycoprotein	[changes in P-glycoprotein]	0.0	3	1	1	1
87555	1710	atra-induced differentiation of hl60 cell	[ATRA-induced differentiation of HL60 cells]	0.0	5	1	1	1
87556	1710	lymph node of mouse	[lymph nodes of mice]	0.0	4	1	1	1
87557	1710	myeloperoxidase gene	[myeloperoxidase genes]	0.0	2	1	1	1
87558	1710	h follow lps addition to cell	[h following LPS addition to cells]	0.0	6	1	1	1
87559	1710	cell (dc)	[cells (DC)]	0.0	2	1	1	1
87560	1710	>50%	[>50%]	0.0	1	1	1	1
87561	1710	20 patient with lupus erythematosus	[20 patients with lupus erythematosus]	0.0	5	1	1	1
87562	1710	induce mnp-1 expression	[inducing MNP-1 expression]	0.0	3	1	1	1
87563	1710	receptor density; thus, patient	[receptor density; thus, patients]	0.0	4	1	1	1
87564	1710	gene, transcript	[gene, transcripts]	0.0	2	1	1	1
87565	1710	cooperative interaction between b cell-specific coactivator	[cooperative interactions between B cell-specific coactivators]	0.0	6	1	1	1
87566	1710	component in the diet	[component in the diet]	0.0	4	1	1	1
87567	1710	Myeloid	[Myeloid]	0.0	1	1	1	1
87568	1710	nuclear translocation of NF-kappaB complex	[nuclear translocation of NF-kappaB complexes]	0.0	5	1	1	1
87569	1710	domain contain full cell cycle	[domain containing full cell cycle]	0.0	5	1	1	1
87570	1710	three-dimensional positioning of (ig) gene	[three-dimensional positioning of (Ig) genes]	0.0	5	1	1	1
87571	1710	pathway to induction	[pathway to induction]	0.0	3	1	1	1
87572	1710	property of CsA	[properties of CsA]	0.0	3	1	1	1
87573	1710	bowel disease ulcerative colitis	[bowel diseases ulcerative colitis]	0.0	4	1	1	1
87574	1710	human interferon factor 2 gene	[Human interferon factor 2 gene]	0.0	5	1	1	1
87575	1710	cell in the biopsy	[cells in the biopsies]	0.0	4	1	1	1
87576	1710	cooperation binding sequence	[cooperation binding sequences]	0.0	3	1	1	1
87577	1710	early treatment hpc	[early treatment HPCs]	0.0	3	1	1	1
87578	1710	concentration at the surface	[concentration at the surface]	0.0	4	1	1	1
87579	1710	supernatants.	[supernatants.]	0.0	1	1	1	1
87580	1710	determine gene sry	[determining gene SRY]	0.0	3	1	1	1
87581	1710	cell cd34(2+)/cd38-	[cells CD34(2+)/CD38-]	0.0	2	1	1	1
87582	1710	cell important	[cells important]	0.0	2	1	1	1
87583	1710	ABC	[ABC]	0.0	1	1	1	1
87584	1710	transrepressive effect	[transrepressive effect]	0.0	2	1	1	1
87585	1710	alteration in receptor	[alterations in receptor]	0.0	3	1	1	1
87586	1710	assembly tcc c5b-7 on target cell	[Assembly TCC C5b-7 on target cells]	0.0	6	1	1	1
87587	1710	Subunit	[Subunit]	0.0	1	1	1	1
87588	1710	positioning of immunoglobulin (ig) gene	[positioning of immunoglobulin (Ig) genes]	0.0	5	1	1	1
87589	1710	endothelium-derived vasoactive factor	[endothelium-derived vasoactive factors]	0.0	3	1	1	1
87590	1710	differentiation of leukemia cell line u937	[differentiation of leukemia cell lines U937]	0.0	6	1	1	1
87591	1710	t3r mbc	[T3R MBC]	0.0	2	1	1	1
87592	1710	observation together with the previous finding	[observations together with the previous findings]	0.0	6	1	1	1
87593	1710	ligand-activatable, tyrosine-containing stat docking site	[ligand-activatable, tyrosine-containing STAT docking sites]	0.0	5	1	1	1
87594	1710	role of various regulatory element	[role of various regulatory elements]	0.0	5	1	1	1
87595	1710	nf-kappab kinase NIK	[NF-kappaB kinase NIK]	0.0	3	1	1	1
87596	1710	3 nucleotide	[3 nucleotides]	0.0	2	1	1	1
87597	1710	functional human immune deficiency virus type	[functional human immune deficiency virus type]	0.0	6	1	1	1
87598	1710	activity of the LTR	[activity of the LTR]	0.0	4	1	1	1
87599	1710	mimick into tissue	[mimicking into tissues]	0.0	3	1	1	1
87600	1710	differentiation via signal pathway	[differentiation via signaling pathways]	0.0	4	1	1	1
87601	1710	anti-proliferative effect	[anti-proliferative effects]	0.0	2	1	1	1
87602	1710	nf-kappab gene	[NF-kappaB genes]	0.0	2	1	1	1
87603	1710	recognition of viral, self ligand	[recognition of viral, self, ligands]	0.0	5	1	1	1
87604	1710	detection in cell of a factor	[Detection in cells of a factor]	0.0	6	1	1	1
87605	1710	Thapsigargin TG	[Thapsigargin TG]	0.0	2	1	1	1
87606	1710	contrast, acid accumulation	[contrast, acid accumulation]	0.0	3	1	1	1
87607	1710	only level of this protein	[only levels of this protein]	0.0	5	1	1	1
87608	1710	81% increment	[81% increment]	0.0	2	1	1	1
87609	1710	function of spi-1 /PU.1	[function of Spi-1 /PU.1]	0.0	4	1	1	1
87610	1710	regulation during cell death	[Regulation during cell death]	0.0	4	1	1	1
87611	1710	negative mutant pathway include myd88	[negative mutants pathway including MyD88]	0.0	5	1	1	1
87612	1710	prolonged exposure of human cell	[prolonged exposure of human cells]	0.0	5	1	1	1
87613	1710	EBV gene transcript	[EBV gene transcripts]	0.0	3	1	1	1
87614	1710	copy encode fkbp	[copies encoding FKBP]	0.0	3	1	1	1
87615	1710	promoter for ebna expression	[promoter for EBNA expression]	0.0	4	1	1	1
87616	1710	gene activation follow cd16 cross-linking	[gene activation following CD16 cross-linking]	0.0	5	1	1	1
87617	1710	only identify agents,	[only identifying agents,]	0.0	3	1	1	1
87618	1710	receptor in the CLL patient	[receptor in the CLL patients]	0.0	5	1	1	1
87619	1710	patient with rheumatoid	[patients with rheumatoid]	0.0	3	1	1	1
87620	1710	B-cell chronic leukemia (b-cll) cell	[B-cell chronic leukemia (B-CLL) cells]	0.0	5	1	1	1
87621	1710	abnormality in the DNA bind capability	[abnormalities in the DNA binding capability]	0.0	6	1	1	1
87622	1710	hiv-1 terminal repeat site	[HIV-1 terminal repeat sites]	0.0	4	1	1	1
87623	1710	human T lymphocyte erratum	[human T lymphocytes erratum]	0.0	4	1	1	1
87624	1710	increase in monocyte pdgf(b) mrna	[increase in monocyte PDGF(B) mRNA]	0.0	5	1	1	1
87625	1710	such as the one	[such as the one]	0.0	4	1	1	1
87626	1710	monocyte in a assay	[monocytes in a assay]	0.0	4	1	1	1
87627	1710	monocyte thp-1	[monocytes THP-1]	0.0	2	1	1	1
87628	1710	fusion/entry process	[fusion/entry process]	0.0	2	1	1	1
87629	1710	elucidate the function in tcr signal	[elucidating the function in TCR signaling]	0.0	6	1	1	1
87630	1710	human gata3	[human GATA3]	0.0	2	1	1	1
87631	1710	human kidney 293 cell	[human kidney 293 cells]	0.0	4	1	1	1
87632	1710	individual response to the two protein	[individual responses to the two proteins]	0.0	6	1	1	1
87633	1710	treatment of human b lymphocyte	[Treatment of human B lymphocytes]	0.0	5	1	1	1
87634	1710	treatment of T with ifn-alpha	[Treatment of T with IFN-alpha]	0.0	5	1	1	1
87635	1710	Junuary	[Jun-]	0.0	1	1	1	1
87636	1710	binding of member	[binding of members]	0.0	3	1	1	1
87637	1710	profound state	[profound state]	0.0	2	1	1	1
87638	1710	glucocorticoid at concentration	[glucocorticoids at concentrations]	0.0	3	1	1	1
87639	1710	histocompatibility (mhc) class gene expression	[histocompatibility (MHC) class gene expression]	0.0	5	1	1	1
87640	1710	relative affinity of element for factor	[Relative affinities of elements for factor]	0.0	6	1	1	1
87641	1710	antigen-driven expansion) (by stimulation	[antigen-driven expansion) (by stimulation]	0.0	4	1	1	1
87642	1710	3) deletion	[3) deletion]	0.0	2	1	1	1
87643	1710	receptors, induction protein kinase C	[receptors, induction protein kinase C]	0.0	5	1	1	1
87644	1710	use, CsA treatment	[use, CsA treatment]	0.0	3	1	1	1
87645	1710	HL-60/vinc revertant hl-60/vinc/r	[HL-60/vinc revertant HL-60/vinc/R]	0.0	3	1	1	1
87646	1710	contain mutant glucocorticoid receptor	[containing mutant glucocorticoid receptors]	0.0	4	1	1	1
87647	1710	two distinct domain of the interaction	[two distinct domains of the interaction]	0.0	6	1	1	1
87648	1710	SL3-3 murine leukemia retroviruse	[SL3-3 murine leukemia retroviruses]	0.0	4	1	1	1
87649	1710	only expression of the beta-casein gene	[only expression of the beta-casein gene]	0.0	6	1	1	1
87650	1710	b transcriptional activity	[B transcriptional activity]	0.0	3	1	1	1
87651	1710	whole cell lysate	[whole cell lysates]	0.0	3	1	1	1
87652	1710	peripheral venous blood from donor	[peripheral venous blood from donors]	0.0	5	1	1	1
87653	1710	double-stranded protein kinase	[double-stranded protein kinase]	0.0	3	2	2	1
87654	1710	ciita coding sequence	[CIITA coding sequence]	0.0	3	1	1	1
87655	1710	gamma interferon class	[gamma interferon class]	0.0	3	1	1	1
87656	1710	pb granulocyte	[PB granulocytes]	0.0	2	1	1	1
87657	1710	IL-4 mrna accumulation	[IL-4 mRNA accumulation]	0.0	3	1	1	1
87658	1710	transcription factor Trident	[transcription factor Trident]	0.0	3	2	2	1
87659	1710	human leukocyte of patient	[human leukocytes of patients]	0.0	4	1	1	1
87660	1710	different form of leukemia	[different forms of leukemia]	0.0	4	1	1	1
87661	1710	however, secretion of il-2	[However, secretion of IL-2]	0.0	4	1	1	1
87662	1710	normalize after delivery	[normalizing after delivery]	0.0	3	1	1	1
87663	1710	involvement of hcmv	[involvement of HCMV]	0.0	3	1	1	1
87664	1710	weight form	[weight forms]	0.0	2	1	1	1
87665	1710	oral value	[oral values]	0.0	2	1	1	1
87666	1710	distinct b-cell-specific cofactor	[distinct B-cell-specific cofactors]	0.0	3	1	1	1
87667	1710	result in the reexpression	[resulting in the reexpression]	0.0	4	1	1	1
87668	1710	cation like cobalt, nickel,	[cations like cobalt, nickel,]	0.0	4	1	1	1
87669	1710	(il-2r) receptor	[(IL-2R) receptors]	0.0	2	1	1	1
87670	1710	increase in subsequent adherence	[increase in subsequent adherence]	0.0	4	1	1	1
87671	1710	ets-1-containg complex c	[Ets-1-containing complex c]	0.0	3	1	1	1
87672	1710	old) from elderly individual	[old) from elderly individuals]	0.0	4	1	1	1
87673	1710	support a two-step model	[supporting a two-step model]	0.0	4	1	1	1
87674	1710	vitro, viral antigen	[vitro, viral antigens]	0.0	3	1	1	1
87675	1710	lining layer depth	[lining layer depth]	0.0	3	1	1	1
87676	1710	different cytokine gene	[different cytokine genes]	0.0	3	1	1	1
87677	1710	also rapid effect	[also rapid effects]	0.0	3	1	1	1
87678	1710	Degenerate primer corresponding	[Degenerate primers corresponding]	0.0	3	1	1	1
87679	1710	single type	[single type]	0.0	2	1	1	1
87680	1710	binding studies.	[binding studies.]	0.0	2	1	1	1
87681	1710	regulation cross-talk between stat5	[regulation cross-talk between STAT5]	0.0	4	1	1	1
87682	1710	VDR 3'-utr polymorphism	[VDR 3'-UTR polymorphisms]	0.0	3	1	1	1
87683	1710	differentiation activity	[differentiation activity]	0.0	2	2	2	1
87684	1710	abf-1	[ABF-1]	0.0	1	1	1	1
87685	1710	proximal 45 residue	[proximal 45 residues]	0.0	3	1	1	1
87686	1710	activator protein-1 ap-1 factor	[activator protein-1 AP-1 factor]	0.0	4	1	1	1
87687	1710	use transfectant	[using transfectants]	0.0	2	1	1	1
87688	1710	use anti-c/ebpbeta anti-c/ebpdelta	[Using anti-C/EBPbeta anti-C/EBPdelta]	0.0	3	1	1	1
87689	1710	represent stage of B-cell differentiation	[representing stages of B-cell differentiation]	0.0	5	1	1	1
87690	1710	regulation of receptor in human cell	[Regulation of receptors in human cells]	0.0	6	1	1	1
87691	1710	mononulear leukocyte	[mononulear leukocytes]	0.0	2	1	1	1
87692	1710	ikappab level	[IkappaB levels]	0.0	2	1	1	1
87693	1710	putative regulatory site	[putative regulatory sites]	0.0	3	1	1	1
87694	1710	killer(	[killer(]	0.0	1	1	1	1
87695	1710	AIDS iblp	[AIDS IBLP]	0.0	2	1	1	1
87696	1710	primarily a structural feature	[primarily a structural feature]	0.0	4	1	1	1
87697	1710	coordinate reduction in il-2 gene expression	[coordinate reductions in IL-2 gene expression]	0.0	6	1	1	1
87698	1710	latent cycle reactivity though rarely undetectable	[latent cycle reactivities though rarely undetectable]	0.0	6	1	1	1
87699	1710	immunosuppressive activity at concentration low	[immunosuppressive activity at concentrations lower]	0.0	5	1	1	1
87700	1710	promoter activity of the 1-kb fragment	[promoter activity of the 1-kb fragment]	0.0	6	1	1	1
87701	1710	study of cytosol	[studies of cytosol]	0.0	3	1	1	1
87702	1710	modulate immune function	[modulating immune function]	0.0	3	1	1	1
87703	1710	relevant compound	[relevant compounds]	0.0	2	1	1	1
87704	1710	genetic correlation	[genetic correlation]	0.0	2	1	1	1
87705	1710	erythroid enhancer upstream	[erythroid enhancer upstream]	0.0	3	1	1	1
87706	1710	early pro-apoptotic effect	[early pro-apoptotic effects]	0.0	3	1	1	1
87707	1710	S6 peptide	[S6 peptides]	0.0	2	1	1	1
87708	1710	fos-related gene	[fos-related gene]	0.0	2	1	1	1
87709	1710	11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	4	1	1	1
87710	1710	code for the enzyme	[coding for the enzyme]	0.0	4	1	1	1
87711	1710	1alpha,25-dihydroxyvitamin D3	[1alpha,25-dihydroxyvitamin D3]	0.0	2	1	1	1
87712	1710	however a association between amplification	[however a association between amplification]	0.0	5	1	1	1
87713	1710	cancer chemotherapy	[cancer chemotherapy]	0.0	2	1	1	1
87714	1710	apoptosis -induce	[apoptosis -inducing]	0.0	2	1	1	1
87715	1710	emerge family of protein	[emerging family of proteins]	0.0	4	1	1	1
87716	1710	b-lymphocyte transformation role	[B-lymphocyte transformation role]	0.0	3	1	1	1
87717	1710	ANH	[ANH]	0.0	1	1	1	1
87718	1710	case of chronic leukaemia	[cases of chronic leukaemia]	0.0	4	1	1	1
87719	1710	h2-antagonist cimetidine	[H2-antagonist cimetidine]	0.0	2	1	1	1
87720	1710	24 volunteer without disorder	[24 volunteers without disorders]	0.0	4	1	1	1
87721	1710	vitamin D3 responsiveness	[vitamin D3 responsiveness]	0.0	3	1	1	1
87722	1710	dose of IL-2	[doses of IL-2]	0.0	3	1	1	1
87723	1710	Duffy blood group	[Duffy blood group]	0.0	3	1	1	1
87724	1710	induction by lps	[induction by LPS]	0.0	3	1	1	1
87725	1710	person with chronic back pain	[persons with chronic back pain]	0.0	5	1	1	1
87726	1710	human antibody specific	[human antibody specific]	0.0	3	1	1	1
87727	1710	substantial decrease in (mr)	[substantial decreases in (MR)]	0.0	4	1	1	1
87728	1710	B10	[B10]	0.0	1	1	1	1
87729	1710	transcription from DNA	[transcription from DNA]	0.0	3	1	1	1
87730	1710	mediate in a variety	[mediating in a variety]	0.0	4	1	1	1
87731	1710	cellular receptors.	[cellular receptors.]	0.0	2	1	1	1
87732	1710	VCAM-1 antibody 1g11	[VCAM-1 antibody 1G11]	0.0	3	1	1	1
87733	1710	signal cascade like tnf-alpha	[signaling cascade like TNF-alpha]	0.0	4	1	1	1
87734	1710	lef-1 protein	[LEF-1 protein]	0.0	2	1	1	1
87735	1710	evidence for a considerable variation	[evidence for a considerable variation]	0.0	5	1	1	1
87736	1710	trigger (p	[Triggering (P]	0.0	2	1	1	1
87737	1710	contain near-perfect repeat DR	[containing near-perfect repeats DR]	0.0	4	1	1	1
87738	1710	metabolite of vitamin d	[metabolite of vitamin D]	0.0	4	1	1	1
87739	1710	mutation in human lymphoid cell	[mutations in human lymphoid cells]	0.0	5	1	1	1
87740	1710	individual in IL-2	[individuals in IL-2]	0.0	3	1	1	1
87741	1710	Ca2+ mobilization expression	[Ca2+ mobilization expression]	0.0	3	1	1	1
87742	1710	however, microg/100 millileter at P;	[However, microg/100 ml at h;]	0.0	5	1	1	1
87743	1710	pattern of tissue specificity	[patterns of tissue specificity]	0.0	4	1	1	1
87744	1710	(low affinity, capacity) binding site	[(low affinity, capacity) binding sites]	0.0	5	1	1	1
87745	1710	expression after influenza a virus infection	[Expression after influenza A virus infection]	0.0	6	1	1	1
87746	1710	pseudo-hypoaldosteronism follow resection normal level	[pseudo-hypoaldosteronism following resection normal level]	0.0	5	1	1	1
87747	1710	activation a direct vascular antiatherogenic mechanism	[activation A direct vascular antiatherogenic mechanism]	0.0	6	1	1	1
87748	1710	inhibition of specific transcriptional protein	[inhibition of specific transcriptional proteins]	0.0	5	1	1	1
87749	1710	CEM C7	[CEM C7]	0.0	2	1	1	1
87750	1710	responder in t-cell response	[responder in T-cell responses]	0.0	4	1	1	1
87751	1710	thr-15	[Thr-15]	0.0	1	1	1	1
87752	1710	subunit of relative mass (50k)	[subunits of relative mass (50K)]	0.0	5	1	1	1
87753	1710	implication regard the use	[implications regarding the use]	0.0	4	1	1	1
87754	1710	ets dna-binding domain	[ETS DNA-binding domain]	0.0	3	1	1	1
87755	1710	stat5 homologue in addition	[STAT5 homologues in addition]	0.0	4	1	1	1
87756	1710	possible strategy	[possible strategies]	0.0	2	1	1	1
87757	1710	range to kd, result	[ranging to kD, resulting]	0.0	4	1	1	1
87758	1710	terminal differentiation of lineage	[terminal differentiation of lineages]	0.0	4	1	1	1
87759	1710	mrna expression in huvec	[mRNA expression in HUVECs]	0.0	4	1	1	1
87760	1710	depend on the mode	[depending on the mode]	0.0	4	1	1	1
87761	1710	extract from primary T lymphocyte	[extracts from primary T lymphocytes]	0.0	5	1	1	1
87762	1710	hemoglobin accumulation	[hemoglobin accumulation]	0.0	2	1	1	1
87763	1710	g/g of total mrna	[g/g of total mRNA]	0.0	4	1	1	1
87764	1710	month (range, months).	[months (range, months).]	0.0	3	1	1	1
87765	1710	pseudo-hypoaldosteronism follow resection level	[pseudo-hypoaldosteronism following resection level]	0.0	4	1	1	1
87766	1710	component of a successful response	[component of a successful response]	0.0	5	1	1	1
87767	1710	mechanism lt gene induction	[mechanism LT gene induction]	0.0	4	1	1	1
87768	1710	multiple binding site for ms-2	[multiple binding sites for MS-2]	0.0	5	1	1	1
87769	1710	addition to a band	[addition to a band]	0.0	4	1	1	1
87770	1710	microm sodium orthovanadate NaOV	[microM sodium orthovanadate NaOV]	0.0	4	1	1	1
87771	1710	role in the action	[role in the actions]	0.0	4	1	1	1
87772	1710	2 protein	[2 protein]	0.0	2	1	1	1
87773	1710	formation of transcriptionally active complex	[formation of transcriptionally active complexes]	0.0	5	1	1	1
87774	1710	diversification of a limited number	[diversification of a limited number]	0.0	5	1	1	1
87775	1710	multiple biological response	[multiple biological responses]	0.0	3	1	1	1
87776	1710	il-4 in monocyte	[IL-4 in monocytes]	0.0	3	1	1	1
87777	1710	DCoH-HNF-1 alpha complex	[DCoH-HNF-1 alpha complex]	0.0	3	1	1	1
87778	1710	substrate by the G-CSFR	[substrates by the G-CSFR]	0.0	4	1	1	1
87779	1710	adenylate cyclase inhibitor	[adenylate cyclase inhibitor]	0.0	3	1	1	1
87780	1710	dissociation (Kd) of the fms	[dissociation (Kd) of the FMS]	0.0	5	1	1	1
87781	1710	three enhancer-binding protein	[three enhancer-binding proteins]	0.0	3	1	1	1
87782	1710	G(Anh)MTetra induction	[G(Anh)MTetra induction]	0.0	2	1	1	1
87783	1710	four distinct protein complex a factor	[four distinct protein complexes a factor]	0.0	6	1	1	1
87784	1710	cell by etoposide	[cells by etoposide]	0.0	3	1	1	1
87785	1710	important factor determine specific gene activation	[important factor determining specific gene activation]	0.0	6	1	1	1
87786	1710	essential nature	[essential nature]	0.0	2	1	1	1
87787	1710	look in approach treat IBD	[Looking in approaches treating IBD]	0.0	5	1	1	1
87788	1710	incubation of each from cos-7 cell	[Incubation of each from COS-7 cells]	0.0	6	1	1	1
87789	1710	bovine artery endothelial cell	[bovine artery endothelial cells]	0.0	4	1	1	1
87790	1710	detailed molecular analysis of deletion	[detailed molecular analysis of deletions]	0.0	5	1	1	1
87791	1710	exclude skewedness of x-inactivation	[excluding skewedness of X-inactivation]	0.0	4	1	1	1
87792	1710	belong by a mutant	[belonging by a mutant]	0.0	4	1	1	1
87793	1710	et site	[ets sites]	0.0	2	1	1	1
87794	1710	three region of the promoter	[three regions of the promoter]	0.0	5	1	1	1
87795	1710	myocyte	[myocytes]	0.0	1	1	1	1
87796	1710	b coactivator bob.1/obf.1	[B coactivator BOB.1/OBF.1]	0.0	3	1	1	1
87797	1710	lineages,	[lineages,]	0.0	1	1	1	1
87798	1710	high specificity	[high specificity]	0.0	2	1	1	1
87799	1710	hiv protease between phenylalanine	[HIV protease between phenylalanine]	0.0	4	1	1	1
87800	1710	level of ige in this patient	[levels of IgE in these patients]	0.0	6	1	1	1
87801	1710	vitro substrate	[vitro substrate]	0.0	2	1	1	1
87802	1710	stage of cell development	[stages of cell development]	0.0	4	1	1	1
87803	1710	similar set	[similar sets]	0.0	2	1	1	1
87804	1710	depolarization	[depolarization]	0.0	1	1	1	1
87805	1710	subset of b-cell neoplasia	[subset of B-cell neoplasias]	0.0	4	1	1	1
87806	1710	differentiation of u-937	[Differentiation of U-937]	0.0	3	1	1	1
87807	1710	effect nf-kappab DNA binding	[effect NF-kappaB DNA binding]	0.0	4	1	1	1
87808	1710	50% decrease	[50% decrease]	0.0	2	2	2	1
87809	1710	bhlh motif	[bHLH motif]	0.0	2	1	1	1
87810	1710	role in up-regulation in T cell	[Role in up-regulation in T cells]	0.0	6	1	1	1
87811	1710	overexpression a Ca2+/calmodulin-dependent protein phosphatase	[overexpression a Ca2+/calmodulin-dependent protein phosphatase]	0.0	5	1	1	1
87812	1710	candidate genes.	[candidate genes.]	0.0	2	1	1	1
87813	1710	implication of nuclear t3r alteration	[implications of nuclear T3R alterations]	0.0	5	1	1	1
87814	1710	arthritis-encephalitis	[arthritis-encephalitis]	0.0	1	1	1	1
87815	1710	possibly reflect difference	[possibly reflecting differences]	0.0	3	1	1	1
87816	1710	carboxyl-terminal peptide in jy25 cell	[carboxyl-terminal peptide in JY25 cells]	0.0	5	1	1	1
87817	1710	macrophage migration	[Macrophage migration]	0.0	2	1	1	1
87818	1710	result in severe thrombocytopenia	[resulting in severe thrombocytopenia]	0.0	4	1	1	1
87819	1710	liver of pu.1-/- mouse	[liver of PU.1-/- mice]	0.0	4	1	1	1
87820	1710	different class of abundant receptor	[different classes of abundant receptors]	0.0	5	1	1	1
87821	1710	rheumatoid synovial tissue	[rheumatoid synovial tissue]	0.0	3	1	1	1
87822	1710	two gel shift complex	[Two gel shift complexes]	0.0	4	1	1	1
87823	1710	body,	[body,]	0.0	1	1	1	1
87824	1710	chain igh	[chain IgH]	0.0	2	1	1	1
87825	1710	single complex	[single complex]	0.0	2	1	1	1
87826	1710	3 survival of lymphocyte	[3 survival of lymphocytes]	0.0	4	1	1	1
87827	1710	ebv-positive case	[EBV-positive cases]	0.0	2	1	1	1
87828	1710	therapy in leukocyte	[therapy in leukocytes]	0.0	3	1	1	1
87829	1710	1.5 gram metyrapone	[1.5 g metyrapone]	0.0	3	1	1	1
87830	1710	activation, coincident	[activation, coincident]	0.0	2	1	1	1
87831	1710	recruitment to inflammatory	[recruitment to inflammatory]	0.0	3	1	1	1
87832	1710	(66 microg/100 millileter at 10:00 P;	[(66 microg/100 ml at 10:00 h;]	0.0	6	1	1	1
87833	1710	more interest, ikappabalpha overexpression	[more interest, IkappaBalpha overexpression]	0.0	4	1	1	1
87834	1710	two- rise	[two- rise]	0.0	2	1	1	1
87835	1710	Bcl-6 expression in hyperplasia	[Bcl-6 expression in hyperplasia]	0.0	4	1	1	1
87836	1710	apoptosis progression	[apoptosis progression]	0.0	2	1	1	1
87837	1710	signal through tradd	[signaling through TRADD]	0.0	3	1	1	1
87838	1710	large diffusion	[large diffusion]	0.0	2	1	1	1
87839	1710	variety of disease state	[variety of disease states]	0.0	4	1	1	1
87840	1710	competitor of GcR in cell	[competitor of GcR in cells]	0.0	5	1	1	1
87841	1710	context of other protein	[context of other proteins]	0.0	4	1	1	1
87842	1710	Essential role of macrophage	[Essential role of macrophages]	0.0	4	1	1	1
87843	1710	minutes) to acid	[minutes) to acid]	0.0	3	1	1	1
87844	1710	secretion of MHC class expression	[secretion of MHC class expression]	0.0	5	1	1	1
87845	1710	Exclusive paternal expression	[Exclusive paternal expression]	0.0	3	1	1	1
87846	1710	vcam-1 activation	[VCAM-1 activation]	0.0	2	1	1	1
87847	1710	suggest of importance for the activity	[suggesting of importance for the activity]	0.0	6	1	1	1
87848	1710	very useful tool	[very useful tool]	0.0	3	1	1	1
87849	1710	C 2	[C 2]	0.0	2	1	1	1
87850	1710	endogenous terminal repeat transcriptional activity	[endogenous terminal repeat transcriptional activity]	0.0	5	1	1	1
87851	1710	effect on two transcriptional factor	[effects on two transcriptional factors]	0.0	5	1	1	1
87852	1710	most notably dendritic cell	[most notably dendritic cells]	0.0	4	1	1	1
87853	1710	present than for patient	[presenting than for patients]	0.0	4	1	1	1
87854	1710	transcription of htlv-i	[transcription of HTLV-I]	0.0	3	1	1	1
87855	1710	also with protein include the product	[also with proteins including the products]	0.0	6	1	1	1
87856	1710	Calcium/calmodulin-dependent protein kinase	[Calcium/calmodulin-dependent protein kinase]	0.0	3	1	1	1
87857	1710	also in mammary gland	[also in mammary glands]	0.0	4	1	1	1
87858	1710	carboxyl-terminal end	[carboxyl-terminal end]	0.0	2	1	1	1
87859	1710	stat protein phosphorylation	[STAT protein phosphorylation]	0.0	3	1	1	1
87860	1710	C T	[C T]	0.0	2	1	1	1
87861	1710	ebv -negative individual	[EBV -negative individuals]	0.0	3	1	1	1
87862	1710	transcriptase assay	[transcriptase assay]	0.0	2	2	2	1
87863	1710	inhibitors, cyclosporin a transform growth factor-beta	[inhibitors, cyclosporin A transforming growth factor-beta]	0.0	6	1	1	1
87864	1710	cellular defect lead	[cellular defect leading]	0.0	3	1	1	1
87865	1710	proliferation/differentiation	[proliferation/differentiation]	0.0	1	1	1	1
87866	1710	expression of interferon factor 1	[expression of interferon factor 1]	0.0	5	1	1	1
87867	1710	nuclear transcription protein	[nuclear transcription protein]	0.0	3	1	1	1
87868	1710	component of endothelial recruitment	[component of endothelial recruitment]	0.0	4	1	1	1
87869	1710	receptor hormone-binding domain	[receptor hormone-binding domain]	0.0	3	1	1	1
87870	1710	quantitative sba	[quantitative SBA]	0.0	2	1	1	1
87871	1710	such as nuclear factor	[such as nuclear factor]	0.0	4	1	1	1
87872	1710	already addition of rbpi21	[already addition of rBPI21]	0.0	4	1	1	1
87873	1710	'master	['master]	0.0	1	1	1	1
87874	1710	core sp1 consensus	[core Sp1 consensus]	0.0	3	1	1	1
87875	1710	potent vp16 transactivation domain	[potent VP16 transactivation domains]	0.0	4	1	1	1
87876	1710	BAL	[BAL]	0.0	1	1	1	1
87877	1710	functional role of cysteine	[functional role of cysteine]	0.0	4	1	1	1
87878	1710	percent-age	[percent-age]	0.0	1	1	1	1
87879	1710	1.54 0.06 nm	[1.54 0.06 nM]	0.0	3	1	1	1
87880	1710	NF-kappa B /rel binding site	[NF-kappa B /Rel binding sites]	0.0	5	1	1	1
87881	1710	one days'	[one days']	0.0	2	1	1	1
87882	1710	trans-acting regulatory gene	[trans-acting regulatory genes]	0.0	3	1	1	1
87883	1710	capacity)	[capacity)]	0.0	1	1	1	1
87884	1710	c-myc promoter construct	[c-myc promoter constructs]	0.0	3	1	1	1
87885	1710	fusion transcript RAZ	[fusion transcript RAZ]	0.0	3	1	1	1
87886	1710	Ab-	[Ab-]	0.0	1	1	1	1
87887	1710	three tissue	[three tissues]	0.0	2	1	1	1
87888	1710	unknown member	[unknown member]	0.0	2	1	1	1
87889	1710	acute (apl) cell line	[acute (APL) cell line]	0.0	4	1	1	1
87890	1710	effect of alpha,25-(OH)2D3 analog	[effects of alpha,25-(OH)2D3 analogs]	0.0	4	1	1	1
87891	1710	evidence of binding defect	[evidence of binding defect]	0.0	4	1	1	1
87892	1710	involvement of ion channel	[involvement of ion channels]	0.0	4	1	1	1
87893	1710	receptor in glucocorticoid apoptosis	[receptor in glucocorticoid apoptosis]	0.0	4	1	1	1
87894	1710	early event in cells.	[early events in cells.]	0.0	4	1	1	1
87895	1710	expression of the fusion	[expression of the fusion]	0.0	4	1	1	1
87896	1710	transactivation capacity of factor	[transactivation capacity of factor]	0.0	4	1	1	1
87897	1710	capacity,	[capacity,]	0.0	1	1	1	1
87898	1710	difference between Oct-1 factor	[differences between Oct-1 factors]	0.0	4	1	1	1
87899	1710	negative mapkk-1	[negative MAPKK-1]	0.0	2	1	1	1
87900	1710	hsp90 by a anti-hsp antibody	[hsp90 by a anti-hsp antibody]	0.0	5	1	1	1
87901	1710	encode a smooth muscle myosin chain	[encoding a smooth muscle myosin chain]	0.0	6	1	1	1
87902	1710	expression of pkc-alpha	[expression of PKC-alpha]	0.0	3	1	1	1
87903	1710	feature with human ebv include tumorigenesis.	[features with human EBV including tumorigenesis.]	0.0	6	1	1	1
87904	1710	single transcript of kilobasis	[single transcript of kilobases]	0.0	4	1	1	1
87905	1710	1 element	[1 element]	0.0	2	1	1	1
87906	1710	cyclic element-like sequence	[cyclic element-like sequence]	0.0	3	1	1	1
87907	1710	removal of the 67 amino acid	[removal of the 67 amino acids]	0.0	6	1	1	1
87908	1710	circulation follow lps	[circulation following LPS]	0.0	3	1	1	1
87909	1710	interleukin survival of lymphocyte	[interleukin survival of lymphocytes]	0.0	4	1	1	1
87910	1710	old ones,	[older ones,]	0.0	2	1	1	1
87911	1710	molecular site of steroid action.	[molecular site of steroid action.]	0.0	5	1	1	1
87912	1710	host protein p50	[host proteins p50]	0.0	3	1	1	1
87913	1710	one patient with androgen insensitivity	[One patient with androgen insensitivity]	0.0	5	1	1	1
87914	1710	creb/atf pathway	[CREB/ATF pathway]	0.0	2	1	1	1
87915	1710	14 individual	[14 individuals]	0.0	2	1	1	1
87916	1710	protein with only a domain	[proteins with only a domain]	0.0	5	1	1	1
87917	1710	further optimization	[Further optimization]	0.0	2	1	1	1
87918	1710	Ad3	[Ad3]	0.0	1	1	1	1
87919	1710	oxidoreductive regulation of nuclear factor	[Oxidoreductive regulation of nuclear factor]	0.0	5	1	1	1
87920	1710	two transcriptional element	[Two transcriptional elements]	0.0	3	1	1	1
87921	1710	lining layer	[lining layer]	0.0	2	1	1	1
87922	1710	persistent activation	[persistent activation]	0.0	2	1	1	1
87923	1710	vivo hla-dr	[vivo HLA-DR]	0.0	2	1	1	1
87924	1710	hamster ovary fibroblast	[hamster ovary fibroblasts]	0.0	3	1	1	1
87925	1710	10 micromol/L	[10 micromol/L]	0.0	2	1	1	1
87926	1710	early hematopoietic progenitor cell HPC	[early hematopoietic progenitor cells HPC]	0.0	5	1	1	1
87927	1710	DNA replication in cell line	[DNA replication in cell lines]	0.0	5	1	1	1
87928	1710	potent activator in cell line	[potent activator in cell lines]	0.0	5	1	1	1
87929	1710	possibly inhibit the activity	[possibly inhibiting the activity]	0.0	4	1	1	1
87930	1710	IL-4 control	[IL-4 control]	0.0	2	1	1	1
87931	1710	i of type receptor	[I of Type receptors]	0.0	4	1	1	1
87932	1710	ten patient with receptor affinity	[Ten patients with receptor affinity]	0.0	5	1	1	1
87933	1710	several new function of Ras	[Several new functions of Ras]	0.0	5	1	1	1
87934	1710	development into NK cell	[development into NK cells]	0.0	4	1	1	1
87935	1710	hrs.	[hrs.]	0.0	1	1	1	1
87936	1710	surface of allogeneic cell	[surface of allogeneic cells]	0.0	4	1	1	1
87937	1710	sessile peptide bond	[sessile peptide bond]	0.0	3	1	1	1
87938	1710	thus a therapeutic target	[thus a therapeutic target]	0.0	4	1	1	1
87939	1710	human serum-inducible element hSIE	[human serum-inducible element hSIE]	0.0	4	1	1	1
87940	1710	use of this agent in combination	[use of this agent in combination]	0.0	6	1	1	1
87941	1710	MHC class molecule on the surface	[MHC class molecules on the surface]	0.0	6	1	1	1
87942	1710	gammadelta-type T	[gammadelta-type T]	0.0	2	1	1	1
87943	1710	induce the viral cycle	[inducing the viral cycle]	0.0	4	1	1	1
87944	1710	dominant form of CBP	[dominant form of CBP]	0.0	4	1	1	1
87945	1710	c-akt	[c-Akt]	0.0	1	1	1	1
87946	1710	BH3	[BH3]	0.0	1	1	1	1
87947	1710	production of level of il-8	[production of levels of IL-8]	0.0	5	1	1	1
87948	1710	45-nucleotide sequence element	[45-nucleotide sequence element]	0.0	3	1	1	1
87949	1710	hypertension in woman	[hypertension in women]	0.0	3	1	1	1
87950	1710	megakaryocytic cell surface marker	[megakaryocytic cell surface markers]	0.0	4	1	1	1
87951	1710	cytokine chemokine important	[cytokine chemokine important]	0.0	3	1	1	1
87952	1710	transcriptional analysis	[transcriptional analyses]	0.0	2	1	1	1
87953	1710	hyperplasias	[hyperplasias]	0.0	1	2	2	1
87954	1710	physiological glucocorticoid cortisol	[physiological glucocorticoid cortisol]	0.0	3	1	1	1
87955	1710	mechanism control the pattern	[mechanisms controlling the pattern]	0.0	4	1	1	1
87956	1710	molecular mechanism (s) responsible	[molecular mechanism (s) responsible]	0.0	4	1	1	1
87957	1710	ectopic expression of the transcription factor	[ectopic expression of the transcription factor]	0.0	6	1	1	1
87958	1710	inhibition effect	[Inhibition effects]	0.0	2	1	1	1
87959	1710	yellow pigment	[yellow pigment]	0.0	2	1	1	1
87960	1710	end-end	[end-end]	0.0	1	1	1	1
87961	1710	express ebna2	[expressing EBNA2]	0.0	2	1	1	1
87962	1710	aurothioglucose AuTG	[aurothioglucose AuTG]	0.0	2	1	1	1
87963	1710	late-onset	[late-onset]	0.0	1	1	1	1
87964	1710	deletion of a short amino- (729-766)	[Deletions of a short amino- (729-766)]	0.0	6	1	1	1
87965	1710	human tonsillar gc b cell	[human tonsillar GC B cells]	0.0	5	1	1	1
87966	1710	Study on RA time-response in culture	[Studies on RA time-response in culture]	0.0	6	1	1	1
87967	1710	cytoplasmic domain heterogeneity	[Cytoplasmic domain heterogeneity]	0.0	3	1	1	1
87968	1710	synergy on target	[synergy on targets]	0.0	3	1	1	1
87969	1710	great than threefold increase	[greater than threefold increase]	0.0	4	1	1	1
87970	1710	chemical induction, superinfection	[chemical induction, superinfection]	0.0	3	1	1	1
87971	1710	p65 induction	[p65 induction]	0.0	2	1	1	1
87972	1710	dose in treatment	[dose in treatment]	0.0	3	1	1	1
87973	1710	agent on endothelial cell activation	[agents on endothelial cell activation]	0.0	5	1	1	1
87974	1710	value from volunteer	[values from volunteers]	0.0	3	1	1	1
87975	1710	kinase inhibitor less active	[kinase inhibitor less active]	0.0	4	1	1	1
87976	1710	cellular extraction	[cellular extraction]	0.0	2	1	1	1
87977	1710	small amount of p65	[small amount of P65]	0.0	4	2	2	1
87978	1710	mutation a encoding	[mutations a encoding]	0.0	3	1	1	1
87979	1710	subsequent adherence	[subsequent adherence]	0.0	2	1	1	1
87980	1710	rate of cholesterol synthesis	[rate of cholesterol synthesis]	0.0	4	1	1	1
87981	1710	aml1/mds1/evi1 block	[AML1/MDS1/EVI1 blocks]	0.0	2	1	1	1
87982	1710	analysis for diagnosis, counseling,	[analysis for diagnosis, counseling,]	0.0	4	1	1	1
87983	1710	gc of hsv-2	[gC of HSV-2]	0.0	3	1	1	1
87984	1710	anti-cd28 mab to cell	[anti-CD28 mAb to cells]	0.0	4	1	1	1
87985	1710	analysis of a mutation	[analysis of a mutation]	0.0	4	1	1	1
87986	1710	secretion of multiple cytokine	[secretion of multiple cytokines]	0.0	4	1	1	1
87987	1710	activation of egr-1 promoter-reporter construct	[activation of EGR-1 promoter-reporter constructs]	0.0	5	1	1	1
87988	1710	induction of VCAM-1 mrna	[induction of VCAM-1 mRNA]	0.0	4	1	1	1
87989	1710	blood lymphocyte culture	[blood lymphocyte cultures]	0.0	3	2	2	1
87990	1710	cellular mechanism contribute to response	[Cellular mechanisms contributing to response]	0.0	5	1	1	1
87991	1710	malignancy-associated defect	[malignancy-associated defect]	0.0	2	1	1	1
87992	1710	BKO	[BKO]	0.0	1	1	1	1
87993	1710	three cell type	[three cell types]	0.0	3	1	1	1
87994	1710	respectively, in fusions.	[respectively, in fusions.]	0.0	3	1	1	1
87995	1710	low level of nf-kappab	[low levels of NF-kappaB]	0.0	4	1	1	1
87996	1710	develop T lymphocyte erratum	[developing T lymphocytes erratum]	0.0	4	1	1	1
87997	1710	interaction in competition	[interaction in competition]	0.0	3	1	1	1
87998	1710	tcrzeta molecule	[TCRzeta molecules]	0.0	2	1	1	1
87999	1710	woman old than year	[women older than years]	0.0	4	1	1	1
88000	1710	clue for predisposition	[clue for predisposition]	0.0	3	1	1	1
88001	1710	Rel/ NF-kappa B family	[Rel/ NF-kappa B family]	0.0	4	1	1	1
88002	1710	partner of RXR	[partner of RXR]	0.0	3	1	1	1
88003	1710	two cosmid encode ciita	[two cosmids encoding CIITA]	0.0	4	1	1	1
88004	1710	phenotype into blood lymphocyte	[phenotypes into blood lymphocytes]	0.0	4	1	1	1
88005	1710	the/thf (0.24; 1.87+/-0.36) alpha thf/thf	[THE/THF (0.24; 1.87+/-0.36) alpha THF/THF]	0.0	5	1	1	1
88006	1710	exposure to a stimulus	[exposure to a stimulus]	0.0	4	1	1	1
88007	1710	tnf-alpha T lymphocyte	[TNF-alpha T lymphocytes]	0.0	3	1	1	1
88008	1710	trans HLA-DQ molecule	[trans HLA-DQ molecules]	0.0	3	1	1	1
88009	1710	triepoxide with property	[triepoxide with properties]	0.0	3	1	1	1
88010	1710	-rich region	[-rich region]	0.0	2	2	2	1
88011	1710	cell surface ganglioside	[cell surface ganglioside]	0.0	3	1	1	1
88012	1710	leukemic spread	[leukemic spread]	0.0	2	1	1	1
88013	1710	use a pulse	[using a pulse]	0.0	3	1	1	1
88014	1710	Am.	[Am.]	0.0	1	1	1	1
88015	1710	effective dose of t3 mol/L).	[effective dose of T3 mol/L).]	0.0	5	1	1	1
88016	1710	hour treatment	[hour treatment]	0.0	2	1	1	1
88017	1710	peripheral blood lymphocyte from adults.	[peripheral blood lymphocytes from adults.]	0.0	5	1	1	1
88018	1710	EB1 b-cell-specific element	[EB1 B-cell-specific element]	0.0	3	1	1	1
88019	1710	amount of active creb protein p-creb	[amounts of active CREB protein P-CREB]	0.0	6	1	1	1
88020	1710	free gene transcription in t-cell	[free gene transcription in T-cells]	0.0	5	1	1	1
88021	1710	phi) for h with methylprednisolone	[phi) for h with methylprednisolone]	0.0	5	1	1	1
88022	1710	EBV T cell	[EBV T cells]	0.0	3	1	1	1
88023	1710	little activity on the promoter	[little activity on the promoter]	0.0	5	1	1	1
88024	1710	expression of mcm5	[expression of MCM5]	0.0	3	1	1	1
88025	1710	determinant of the activity	[determinant of the activity]	0.0	4	1	1	1
88026	1710	differentiation by okadaic acid	[differentiation by okadaic acid]	0.0	4	1	1	1
88027	1710	scavenger of no through formation	[scavenger of NO through formation]	0.0	5	1	1	1
88028	1710	myb rna expression	[myb RNA expression]	0.0	3	1	1	1
88029	1710	step in T cell	[step in T cells]	0.0	4	1	1	1
88030	1710	(+)/ syn-1	[(+)/ syn-1]	0.0	2	1	1	1
88031	1710	sequence support replication	[sequences supporting replication]	0.0	3	1	1	1
88032	1710	major role in signal	[major role in signaling]	0.0	4	1	1	1
88033	1710	herpes virus transactivator	[herpes virus transactivator]	0.0	3	1	1	1
88034	1710	enhance transcription of cellular gene	[enhancing transcription of cellular genes]	0.0	5	1	1	1
88035	1710	mutant tumor necrosis factor receptor	[mutant tumor necrosis factor receptor]	0.0	5	1	1	1
88036	1710	binding to double-stranded DNA	[binding to double-stranded DNA]	0.0	4	1	1	1
88037	1710	butyric	[Butyric]	0.0	1	1	1	1
88038	1710	patient f.r., m.m., P.	[patients F.R., M.M., P.]	0.0	4	1	1	1
88039	1710	BP1	[BP1]	0.0	1	2	2	1
88040	1710	indicate critical	[indicating critical]	0.0	2	2	2	1
88041	1710	high potency synthetic glucocorticoid	[high potency synthetic glucocorticoid]	0.0	4	1	1	1
88042	1710	poxvirus protein	[poxvirus proteins]	0.0	2	1	1	1
88043	1710	hrxr	[hRXR]	0.0	1	1	1	1
88044	1710	VZV ie62ohsv	[VZV IE62-HSV]	0.0	2	1	1	1
88045	1710	removal of the negative effect	[removal of the negative effect]	0.0	5	1	1	1
88046	1710	similar form of immunodeficiency	[similar forms of immunodeficiency]	0.0	4	1	1	1
88047	1710	Ap2	[Ap2]	0.0	1	1	1	1
88048	1710	antigen ebna-5	[antigen EBNA-5]	0.0	2	1	1	1
88049	1710	Ap1	[Ap1]	0.0	1	1	1	1
88050	1710	volunteers, MRD +/lt patient	[volunteers, MRD +/LT patients]	0.0	4	1	1	1
88051	1710	immunodominant kd-restricted epitope	[immunodominant Kd-restricted epitope]	0.0	3	1	1	1
88052	1710	anti-viral effect	[anti-viral effects]	0.0	2	1	1	1
88053	1710	mechanism of lymphotoxin	[mechanism of lymphotoxin]	0.0	3	1	1	1
88054	1710	50 nm 1 alpha,25-dihydroxyvitamin D3	[50 nM 1 alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
88055	1710	two t-cell line Wurzburg	[two T-cell lines Wurzburg]	0.0	4	1	1	1
88056	1710	represent the fusion region	[representing the fusion region]	0.0	4	1	1	1
88057	1710	add b protein from cell	[Adding B protein from cells]	0.0	5	1	1	1
88058	1710	lymphoid cell with a retrovirus	[lymphoid cells with a retrovirus]	0.0	5	1	1	1
88059	1710	benzoic derivative	[benzoic derivative]	0.0	2	1	1	1
88060	1710	p53 tumor-suppressor	[p53 tumor-suppressor]	0.0	2	1	1	1
88061	1710	monocytic thp cell	[monocytic THP cells]	0.0	3	1	1	1
88062	1710	action of factor	[actions of factor]	0.0	3	1	1	1
88063	1710	antibody in EMSA	[antibodies in EMSA]	0.0	3	1	1	1
88064	1710	woman with endometriosis	[women with endometriosis]	0.0	3	1	1	1
88065	1710	domain of cd36	[domain of CD36]	0.0	3	1	1	1
88066	1710	category cell-specific factor such as Oct-2A	[categories cell-specific factors such as Oct-2A]	0.0	6	1	1	1
88067	1710	misfunction in the system	[misfunction in the systems]	0.0	4	1	1	1
88068	1710	activation through the B2 site	[activation through the B2 site]	0.0	5	1	1	1
88069	1710	kd, result from extensive splicing	[kD, resulting from extensive splicing]	0.0	5	1	1	1
88070	1710	weak inducible complex	[weak inducible complex]	0.0	3	1	1	1
88071	1710	processing by the hiv-1 protease	[Processing by the HIV-1 protease]	0.0	5	1	1	1
88072	1710	(64 mv),	[(64 mV),]	0.0	2	1	1	1
88073	1710	unique c-terminal domain	[unique C-terminal domain]	0.0	3	1	1	1
88074	1710	Coproporphyrinogen	[Coproporphyrinogen]	0.0	1	1	1	1
88075	1710	diverse syndrome include infectious disease	[diverse syndromes including infectious diseases]	0.0	5	1	1	1
88076	1710	target for SR 31747a	[target for SR 31747A]	0.0	4	1	1	1
88077	1710	candidate gene factor beta	[candidate genes factor beta]	0.0	4	1	1	1
88078	1710	presence of the site -187	[presence of the site -187]	0.0	5	1	1	1
88079	1710	(p50/p65)	[(p50/p65)]	0.0	1	1	1	1
88080	1710	number with lymphoid aggregate formation	[numbers with lymphoid aggregate formation]	0.0	5	1	1	1
88081	1710	form diabete diabete	[forms diabetes diabetes]	0.0	3	1	1	1
88082	1710	two major signal cascade	[two major signal cascades]	0.0	4	1	1	1
88083	1710	increase evidence key inflammatory mediator	[increasing evidence key inflammatory mediators]	0.0	5	1	1	1
88084	1710	fluid sf	[fluids SFs]	0.0	2	1	1	1
88085	1710	activity factor macrophage colony-stimulating factor	[activity factor macrophage colony-stimulating factor]	0.0	5	1	1	1
88086	1710	presence of specific receptor	[presence of specific receptors]	0.0	4	1	1	1
88087	1710	down-regulation of receptor mrna expression	[down-regulation of receptor mRNA expression]	0.0	5	1	1	1
88088	1710	NFAT binding	[NFAT binding]	0.0	2	1	1	1
88089	1710	patient with hypercholesteremia	[patients with hypercholesteremia]	0.0	3	1	1	1
88090	1710	partial suppression	[partial suppression]	0.0	2	2	2	1
88091	1710	Messenger RNA level	[Messenger RNA levels]	0.0	3	1	1	1
88092	1710	step of activation	[step of activation]	0.0	3	1	1	1
88093	1710	mrna differential display	[mRNA differential display]	0.0	3	2	2	1
88094	1710	four principal cis-acting element	[four principal cis-acting elements]	0.0	4	1	1	1
88095	1710	activation of phosphatidylinositol 3-kinase	[activation of phosphatidylinositol 3-kinase]	0.0	4	1	1	1
88096	1710	contain cepharanthine as a component,	[containing cepharanthine as a component,]	0.0	5	1	1	1
88097	1710	level of hb24 mrna	[levels of HB24 mRNA]	0.0	4	1	1	1
88098	1710	different structural domain include domain	[different structural domains including domains]	0.0	5	1	1	1
88099	1710	existence of B-specific binding factor	[existence of B-specific binding factors]	0.0	5	1	1	1
88100	1710	cell surface immunoglobulin	[cell surface immunoglobulin]	0.0	3	1	1	1
88101	1710	latter agents.	[latter agents.]	0.0	2	1	1	1
88102	1710	autoreactive thymocyte	[autoreactive thymocytes]	0.0	2	1	1	1
88103	1710	potent therapeutic agent	[potent therapeutic agents]	0.0	3	1	1	1
88104	1710	retinoic-acid receptor type	[retinoic-acid receptors type]	0.0	3	1	1	1
88105	1710	Blood 82,	[Blood 82,]	0.0	2	1	1	1
88106	1710	engagement of any	[Engagement of any]	0.0	3	1	1	1
88107	1710	only the epitope	[only the epitope]	0.0	3	1	1	1
88108	1710	combination of the protein	[combination of the proteins]	0.0	4	1	1	1
88109	1710	transfection experiment with expression vector	[transfection experiments with expression vectors]	0.0	5	1	1	1
88110	1710	activation by the spleen focus	[activation by the spleen focus]	0.0	5	1	1	1
88111	1710	Glucocorticoid resistance in patient with failure	[Glucocorticoid resistance in patients with failure]	0.0	6	1	1	1
88112	1710	sarcoma/leukemia virus ltr	[sarcoma/leukemia virus LTRs]	0.0	3	1	1	1
88113	1710	part, to a selective block	[part, to a selective block]	0.0	5	1	1	1
88114	1710	two monoclonal antibody specific	[two monoclonal antibodies specific]	0.0	4	1	1	1
88115	1710	human epsilon germline	[human epsilon germline]	0.0	3	1	1	1
88116	1710	immunization of tcf-1 mouse	[immunization of TCF-1 mice]	0.0	4	1	1	1
88117	1710	aberration in the pathway	[aberrations in the pathway]	0.0	4	1	1	1
88118	1710	year of persistent relationship	[years of persistent relationship]	0.0	4	1	1	1
88119	1710	apart the source	[apart the source]	0.0	3	1	1	1
88120	1710	embryonic kidney cell	[embryonic kidney cells]	0.0	3	1	1	1
88121	1710	scavenger of h2o2	[scavenger of H2O2]	0.0	3	1	1	1
88122	1710	two transcriptional activator	[two transcriptional activators]	0.0	3	1	1	1
88123	1710	control of factor-kappa b activation	[control of factor-kappa B activation]	0.0	5	1	1	1
88124	1710	subsequent transcriptional activity	[subsequent transcriptional activity]	0.0	3	1	1	1
88125	1710	induce distress syndrome ARDS	[inducing distress syndrome ARDS]	0.0	4	1	1	1
88126	1710	downstream sequence	[downstream sequence]	0.0	2	1	1	1
88127	1710	major -restricted fashion	[major -restricted fashion]	0.0	3	1	1	1
88128	1710	biological process via recognition	[biological processes via recognition]	0.0	4	1	1	1
88129	1710	activation of p50/c-Rel	[activation of p50/c-Rel]	0.0	3	1	1	1
88130	1710	cd3.tcr complex	[CD3.TcR complex]	0.0	2	1	1	1
88131	1710	necessity of continuous monitoring	[necessity of continuous monitoring]	0.0	4	1	1	1
88132	1710	relevant form of NHL	[relevant form of NHL]	0.0	4	1	1	1
88133	1710	recurrent feature occur	[recurrent feature occurring]	0.0	3	1	1	1
88134	1710	mutation on each allele:	[mutation on each allele:]	0.0	4	1	1	1
88135	1710	th2 cells, ectopic expression	[Th2 cells, ectopic expression]	0.0	4	1	1	1
88136	1710	region of the GPIIb gene	[region of the GPIIb gene]	0.0	5	1	1	1
88137	1710	expression of C/EBPbeta	[expressions of C/EBPbeta]	0.0	3	1	1	1
88138	1710	effect of 10(-12)	[effect of 10(-12)]	0.0	3	1	1	1
88139	1710	pathway (rather	[pathway (rather]	0.0	2	1	1	1
88140	1710	effect of estrogen e(2)	[effect of estrogen E(2)]	0.0	4	1	1	1
88141	1710	such as von willebrand factor	[such as von Willebrand factor]	0.0	5	1	1	1
88142	1710	tg receptor on t) cell	[TG receptors on T) cells]	0.0	5	1	1	1
88143	1710	regulatory sequence from glucocorticoid gene	[regulatory sequences from glucocorticoid genes]	0.0	5	1	1	1
88144	1710	vascular pathology	[vascular pathology]	0.0	2	1	1	1
88145	1710	-assembly system	[-assembly system]	0.0	2	1	1	1
88146	1710	TR:TRE complex	[TR:TRE complex]	0.0	2	1	1	1
88147	1710	initiation factor	[initiation factors]	0.0	2	2	2	1
88148	1710	neutrophil adherence to endothelial cell	[neutrophil adherence to endothelial cells]	0.0	5	1	1	1
88149	1710	cell-specific manner,	[cell-specific manner,]	0.0	2	1	1	1
88150	1710	ap-1 by PMA	[AP-1 by PMA]	0.0	3	2	2	1
88151	1710	include lymphatic organ	[including lymphatic organs]	0.0	3	1	1	1
88152	1710	localization of the unoccupied 135eoh)2d3 receptor	[localization of the unoccupied 1,25(OH)2D3 receptor]	0.0	6	1	1	1
88153	1710	nmol/l, incubation time	[nmol/l, incubation time]	0.0	3	1	1	1
88154	1710	gene expression via hormone-activated binding	[gene expression via hormone-activated binding]	0.0	5	1	1	1
88155	1710	effect on this apoptotic signal	[effects on these apoptotic signals]	0.0	5	1	1	1
88156	1710	gene on chromosome 11	[genes on chromosome 11]	0.0	4	1	1	1
88157	1710	only in u937 cell	[only in U937 cells]	0.0	4	1	1	1
88158	1710	furthermore, multimerized region	[Furthermore, multimerized region]	0.0	3	1	1	1
88159	1710	rapid non-genomic effect	[rapid non-genomic effects]	0.0	3	1	1	1
88160	1710	regulatory event in the thyrocyte	[regulatory events in the thyrocyte]	0.0	5	1	1	1
88161	1710	gag protein synthesis	[Gag protein synthesis]	0.0	3	1	1	1
88162	1710	present with IHES	[presenting with IHES]	0.0	3	2	2	1
88163	1710	(mef2)	[(MEF2)]	0.0	1	1	1	1
88164	1710	impairment of ap-1	[impairments of AP-1]	0.0	3	1	1	1
88165	1710	DNA fragment of 200 kb.	[DNA fragments of 200 kb.]	0.0	5	1	1	1
88166	1710	culture condition from pbmc	[culture conditions from PBMC]	0.0	4	1	1	1
88167	1710	rela p65	[RelA p65]	0.0	2	2	2	1
88168	1710	activity of enzyme	[activity of enzymes]	0.0	3	1	1	1
88169	1710	protein in EBNA-2 cell line	[proteins in EBNA-2 cell lines]	0.0	5	1	1	1
88170	1710	pathogenetic role	[pathogenetic roles]	0.0	2	1	1	1
88171	1710	regulation potential role of interaction	[Regulation potential role of interactions]	0.0	5	1	1	1
88172	1710	FK-506 CsA	[FK-506 CsA]	0.0	2	1	1	1
88173	1710	DNA replication such as HeLa	[DNA replication such as HeLa]	0.0	5	1	1	1
88174	1710	9-bp motif (-90/-82 with high homology	[9-bp motifs (-90/-82 with high homology]	0.0	6	1	1	1
88175	1710	cellular disposition implication for hypersensitivity	[Cellular disposition implications for hypersensitivity]	0.0	5	1	1	1
88176	1710	t-helper lymphocyte	[T-helper lymphocytes]	0.0	2	1	1	1
88177	1710	gamma response	[gamma response]	0.0	2	1	1	1
88178	1710	somewhat divergent region	[somewhat divergent region]	0.0	3	1	1	1
88179	1710	other polymorphic dinucleotide trinucleotide repeat	[other polymorphic dinucleotide trinucleotide repeats]	0.0	5	1	1	1
88180	1710	different intracellular signal pathway	[different intracellular signaling pathways]	0.0	4	1	1	1
88181	1710	concentration of hormone	[concentrations of hormone]	0.0	3	1	1	1
88182	1710	position of xic/xist	[position of XIC/XIST]	0.0	3	1	1	1
88183	1710	transcription follow engagement	[transcription following engagement]	0.0	3	1	1	1
88184	1710	five family with degree	[five families with degrees]	0.0	4	1	1	1
88185	1710	plzf-rar alpha on differentiation	[PLZF-RAR alpha on differentiation]	0.0	4	1	1	1
88186	1710	dimeric activator protein-1 ap-1	[dimeric activator protein-1 AP-1]	0.0	4	1	1	1
88187	1710	amount of IFN.	[amounts of IFN.]	0.0	3	1	1	1
88188	1710	induction of the response	[Induction of the response]	0.0	4	1	1	1
88189	1710	glucocorticoid receptor determination a clue	[glucocorticoid receptor determination a clue]	0.0	5	1	1	1
88190	1710	IL-16 gene	[IL-16 gene]	0.0	2	1	1	1
88191	1710	congruence between pbmc	[congruence between PBMC]	0.0	3	1	1	1
88192	1710	domain of hiv-1 transmembrane glycoprotein	[domain of HIV-1 transmembrane glycoprotein]	0.0	5	1	1	1
88193	1710	four nuclear protein complex	[four nuclear protein complexes]	0.0	4	1	1	1
88194	1710	vitamin d-binding protein	[vitamin D-binding protein]	0.0	3	1	1	1
88195	1710	Peptidoglycan PGN the cell wall component	[Peptidoglycan PGN the cell wall component]	0.0	6	1	1	1
88196	1710	seven unstable asthmatic patient	[seven unstable asthmatic patients]	0.0	4	1	1	1
88197	1710	pbmc specimen from adult	[PBMC specimens from adults]	0.0	4	2	2	1
88198	1710	x-chromosome material	[X-chromosome material]	0.0	2	1	1	1
88199	1710	understanding of early development	[understanding of early development]	0.0	4	1	1	1
88200	1710	CAK	[CAK]	0.0	1	1	1	1
88201	1710	zap-70-	[zap-70-]	0.0	1	1	1	1
88202	1710	encompass of this tyrosine residue	[encompassing of these tyrosine residues]	0.0	5	1	1	1
88203	1710	ppar activator j(2) Wyeth 14643	[PPAR activators J(2) Wyeth 14643]	0.0	5	1	1	1
88204	1710	s49 thymoma cell	[S49 thymoma cells]	0.0	3	1	1	1
88205	1710	retain full promoter activity	[retaining full promoter activity]	0.0	4	1	1	1
88206	1710	CAV	[CAV]	0.0	1	1	1	1
88207	1710	over-representation in ovarian cancer patient	[over-representation in ovarian cancer patients]	0.0	5	1	1	1
88208	1710	consecutive sample	[consecutive samples]	0.0	2	1	1	1
88209	1710	12-O-tetradecanoyl phorbol-13-acetate	[12-O-tetradecanoyl phorbol-13-acetate]	0.0	2	1	1	1
88210	1710	subdominant cycle reactivity undetectable	[subdominant cycle reactivities undetectable]	0.0	4	1	1	1
88211	1710	example interleukin-1	[example interleukin-1]	0.0	2	1	1	1
88212	1710	degradation of the inhibitor	[degradation of the inhibitor]	0.0	4	1	1	1
88213	1710	balance between oxidation	[balance between oxidation]	0.0	3	1	1	1
88214	1710	CBG	[CBG]	0.0	1	1	1	1
88215	1710	b cell protein 1/octamer-binding factor	[B cell protein 1/octamer-binding factor]	0.0	5	1	1	1
88216	1710	indicate a rate in 80.5%	[indicating an rate in 80.5%]	0.0	5	1	1	1
88217	1710	line u937 in fibroblast	[lines U937 in fibroblasts]	0.0	4	1	1	1
88218	1710	two dna-binding protein	[two DNA-binding proteins]	0.0	3	1	1	1
88219	1710	Bal	[Bal]	0.0	1	1	1	1
88220	1710	vitro cell	[vitro cell]	0.0	2	1	1	1
88221	1710	Drosophila sequence ttk	[Drosophila sequences ttk]	0.0	3	1	1	1
88222	1710	persistent relationship in tonsil	[persistent relationship in tonsils]	0.0	4	1	1	1
88223	1710	pseudohyperaldosteronism	[pseudohyperaldosteronism]	0.0	1	1	1	1
88224	1710	study 1,25-dihydroxyvitamin D3 calcitriol	[studying 1,25-dihydroxyvitamin D3 calcitriol]	0.0	4	1	1	1
88225	1710	ligand for retinoic acid receptor rar	[ligands for retinoic acid receptors RARs]	0.0	6	1	1	1
88226	1710	effect of androgen	[effects of androgens]	0.0	3	1	1	1
88227	1710	factor-kappa b NK-kappa b	[factor-kappa B NK-kappa B]	0.0	4	1	1	1
88228	1710	constitutive DNA-protein interaction involve factor	[constitutive DNA-protein interactions involving factor]	0.0	5	1	1	1
88229	1710	Ca(2+) phosphatase calcineurin	[Ca(2+) phosphatase calcineurin]	0.0	3	1	1	1
88230	1710	element in the promoter-proximal region	[elements in the promoter-proximal region]	0.0	5	1	1	1
88231	1710	Bcd	[Bcd]	0.0	1	1	1	1
88232	1710	treatment with two different schedule	[Treatment with two different schedules]	0.0	5	1	1	1
88233	1710	TNFalpha a cytokine	[TNFalpha a cytokine]	0.0	3	1	1	1
88234	1710	DQB1 polypeptide	[DQB1 polypeptide]	0.0	2	1	1	1
88235	1710	significant proliferation iddm subject	[significant proliferation IDDM subjects]	0.0	4	1	1	1
88236	1710	distinctly biphasic kinetic	[distinctly biphasic kinetics]	0.0	3	1	1	1
88237	1710	viral growth rate	[viral growth rate]	0.0	3	1	1	1
88238	1710	helix-loop-helix"	[helix-loop-helix"]	0.0	1	1	1	1
88239	1710	breast cancer antibody-dependent cellular cytotoxicity	[breast cancer antibody-dependent cellular cytotoxicity]	0.0	5	1	1	1
88240	1710	kinetic of c-jun induction by TPA	[kinetics of c-jun induction by TPA]	0.0	6	1	1	1
88241	1710	exert effects,	[exerting effects,]	0.0	2	1	1	1
88242	1710	also in target tissue	[also in target tissues]	0.0	4	1	1	1
88243	1710	oxidant-regulation in the intestine	[Oxidant-regulation in the intestine]	0.0	4	1	1	1
88244	1710	gcr treatment	[GCR treatment]	0.0	2	1	1	1
88245	1710	functional heterodimer with the mutant	[functional heterodimers with the mutant]	0.0	5	1	1	1
88246	1710	important trans-acting factor nf-kb	[important trans-acting factors NF-kB]	0.0	4	1	1	1
88247	1710	+/- 17 nmol	[+/- 17 nmol]	0.0	3	1	1	1
88248	1710	(ref.	[(ref.]	0.0	1	1	1	1
88249	1710	lytic replication of the genome	[lytic replication of the genome]	0.0	5	1	1	1
88250	1710	contrast, priming	[contrast, priming]	0.0	2	1	1	1
88251	1710	qp function, qp	[Qp function, Qp]	0.0	3	1	1	1
88252	1710	cellular protein p52	[cellular proteins p52]	0.0	3	1	1	1
88253	1710	transcription factor include sp1	[transcription factors including Sp1]	0.0	4	1	1	1
88254	1710	CD3 zeta	[CD3 zeta]	0.0	2	1	1	1
88255	1710	include case without calm	[including case without CALM]	0.0	4	1	1	1
88256	1710	such as phosphorylation,	[such as phosphorylation,]	0.0	3	1	1	1
88257	1710	xist locus on ring	[XIST locus on ring]	0.0	4	1	1	1
88258	1710	six transcription factor	[six transcription factors]	0.0	3	1	1	1
88259	1710	prolactin-responsive element	[prolactin-responsive elements]	0.0	2	1	1	1
88260	1710	beta,19-cyclopregn-5-ene-4,20-dione	[beta,19-cyclopregn-5-ene-4,20-dione]	0.0	1	1	1	1
88261	1710	perhaps in transformation	[perhaps in transformation]	0.0	3	1	1	1
88262	1710	distribution of immunoglobulin gene	[distribution of immunoglobulin genes]	0.0	4	1	1	1
88263	1710	phorbol-13-acetate	[phorbol-13-acetate]	0.0	1	1	1	1
88264	1710	four near-perfect repeat DR of bp	[four near-perfect repeats DR of bp]	0.0	6	1	1	1
88265	1710	previously, a enhancer between nucleotide -299	[Previously, an enhancer between nucleotides -299]	0.0	6	1	1	1
88266	1710	IL-3 factor two dna-binding complex	[IL-3 factor two DNA-binding complexes]	0.0	5	1	1	1
88267	1710	CHO	[CHO]	0.0	1	1	1	1
88268	1710	CHR	[CHR]	0.0	1	2	2	1
88269	1710	regulator of apoptosis	[regulator of apoptosis]	0.0	3	1	1	1
88270	1710	IL-1alpha kappab-like site -1065	[IL-1alpha kappaB-like sites -1,065]	0.0	4	1	1	1
88271	1710	327 a protein	[327 aa protein]	0.0	3	1	1	1
88272	1710	two copy	[two copies]	0.0	2	1	1	1
88273	1710	kb id-3 transcript	[kb Id-3 transcript]	0.0	3	1	1	1
88274	1710	gold compound contain divalent gold ion	[gold compound containing divalent gold ion]	0.0	6	1	1	1
88275	1710	protein -408 to -386	[proteins -408 to -386]	0.0	4	1	1	1
88276	1710	transform growth factor-beta in relationship	[transforming growth factor-beta in relationship]	0.0	5	1	1	1
88277	1710	alkaline phosphatase reporter gene	[alkaline phosphatase reporter gene]	0.0	4	1	1	1
88278	1710	study evidence for complex formation	[studies evidence for complex formation]	0.0	5	1	1	1
88279	1710	c/ebp motif	[C/EBP motif]	0.0	2	1	1	1
88280	1710	p45 nf-e2 expression	[p45 NF-E2 expression]	0.0	3	1	1	1
88281	1710	level for rearrangement	[level for rearrangement]	0.0	3	1	1	1
88282	1710	results: in studies,	[RESULTS: In studies,]	0.0	3	1	1	1
88283	1710	action of ifn-alpha	[action of IFN-alpha]	0.0	3	1	1	1
88284	1710	Waf1	[Waf1]	0.0	1	1	1	1
88285	1710	basal activity a potent activator	[basal activity a potent activator]	0.0	5	1	1	1
88286	1710	90 percent	[90 percent]	0.0	2	1	1	1
88287	1710	antihypertensive therapy with captopril	[antihypertensive therapy with captopril]	0.0	4	1	1	1
88288	1710	effect of plzf-rar alpha	[effect of PLZF-RAR alpha]	0.0	4	1	1	1
88289	1710	contain nf-kappab binding sequence	[containing NF-kappaB binding sequence]	0.0	4	1	1	1
88290	1710	addition to the complexess	[addition to the complexes,]	0.0	4	1	1	1
88291	1710	involvement of blr2	[involvement of BLR2]	0.0	3	1	1	1
88292	1710	black woman in health	[black women in health]	0.0	4	1	1	1
88293	1710	deletion model of mispair event	[deletion model of mispairing events]	0.0	5	1	1	1
88294	1710	catalytic domain of VIIa	[catalytic domain of VIIa]	0.0	4	1	1	1
88295	1710	dendritic cell development	[dendritic cell development]	0.0	3	1	1	1
88296	1710	mediate tyrosine phosphorylation of molecule	[mediating tyrosine phosphorylation of molecules]	0.0	5	1	1	1
88297	1710	inflammatory mediator include instability	[inflammatory mediators including instability]	0.0	4	1	1	1
88298	1710	leucocyte dna	[leucocyte DNAs]	0.0	2	1	1	1
88299	1710	difference in dose, route	[differences in dose, route]	0.0	4	1	1	1
88300	1710	diagnostic value of receptor	[diagnostic value of receptors]	0.0	4	1	1	1
88301	1710	counteract DNA sequence	[counteracting DNA sequences]	0.0	3	1	1	1
88302	1710	contrast, in a active state	[contrast, in a active state]	0.0	5	1	1	1
88303	1710	lysis synthetic substrate	[lysis synthetic substrate]	0.0	3	1	1	1
88304	1710	thus establish a inverse relation MHC	[thus establishing an inverse relation MHC]	0.0	6	1	1	1
88305	1710	sublethal irradiation	[sublethal irradiation]	0.0	2	1	1	1
88306	1710	EBNA2 transactivation	[EBNA2 transactivation]	0.0	2	1	1	1
88307	1710	decrease of il-2 production	[decreases of IL-2 production]	0.0	4	1	1	1
88308	1710	overexpression of a form of Rb	[Overexpression of a form of Rb]	0.0	6	1	1	1
88309	1710	great than mol/L for hydrocortisone	[greater than mol/L for hydrocortisone]	0.0	5	1	1	1
88310	1710	recently, leukocyte	[recently, leukocytes]	0.0	2	1	1	1
88311	1710	vehicle for delivery	[vehicle for delivery]	0.0	3	1	1	1
88312	1710	renal salt loss lead	[renal salt loss leading]	0.0	4	1	1	1
88313	1710	dominant negative mutant ikk1	[dominant negative mutant IKK1]	0.0	4	1	1	1
88314	1710	u-937 monoblast	[U-937 monoblasts]	0.0	2	1	1	1
88315	1710	considerable change in nature Arg91	[considerable change in nature Arg91]	0.0	5	1	1	1
88316	1710	improvement of therapy	[improvement of therapies]	0.0	3	1	1	1
88317	1710	common t-cell mitogen	[common T-cell mitogens]	0.0	3	1	1	1
88318	1710	patient with renal failure	[patients with renal failure]	0.0	4	1	1	1
88319	1710	considerable tissue-specific interindividual variation	[considerable tissue-specific interindividual variation]	0.0	4	1	1	1
88320	1710	salt bridge	[salt bridge]	0.0	2	1	1	1
88321	1710	additional NF-IL6 binding site	[additional NF-IL6 binding sites]	0.0	4	1	1	1
88322	1710	use a nf-kappa b oligonucleotide	[using a NF-kappa B oligonucleotide]	0.0	5	1	1	1
88323	1710	Bcl-x a molecule	[Bcl-x a molecule]	0.0	3	1	1	1
88324	1710	interaction of transcription factor antagonism	[interaction of transcription factors antagonism]	0.0	5	1	1	1
88325	1710	molecular nuclear protein sp	[molecular nuclear proteins SP]	0.0	4	1	1	1
88326	1710	cis-tran isomerase distinct	[cis-trans isomerase distinct]	0.0	3	1	1	1
88327	1710	p16 gene	[p16 genes]	0.0	2	1	1	1
88328	1710	antigen use T cell	[antigens using T cells]	0.0	4	1	1	1
88329	1710	same molecular mechanism	[same molecular mechanisms]	0.0	3	1	1	1
88330	1710	especially with marker of rate	[especially with markers of rate]	0.0	5	1	1	1
88331	1710	n-acetyl-L-cysteine a thiol antioxidant	[n-acetyl-L-cysteine a thiol antioxidant]	0.0	4	1	1	1
88332	1710	cell-specific synergistic activity	[cell-specific synergistic activity]	0.0	3	1	1	1
88333	1710	T cell specific expression:	[T cell specific expression:]	0.0	4	1	1	1
88334	1710	induction of interferon (ifn)-inducible protein differentiation	[induction of interferon (IFN)-inducible protein differentiation]	0.0	6	1	1	1
88335	1710	rBPI21 a recombinant fragment	[rBPI21 a recombinant fragment]	0.0	4	1	1	1
88336	1710	primarily through a pertussis toxin pathway	[primarily through a pertussis toxin pathway]	0.0	6	1	1	1
88337	1710	IL-2 promoter factor AP-1/Octamer	[IL-2 promoter factor AP-1/Octamer]	0.0	4	1	1	1
88338	1710	FIGURE	[FIGURE]	0.0	1	1	1	1
88339	1710	x1- box of HLA-DRA	[X1- boxes of HLA-DRA]	0.0	4	1	1	1
88340	1710	response of ECs	[responses of ECs]	0.0	3	1	1	1
88341	1710	use retinoid	[Using retinoids]	0.0	2	1	1	1
88342	1710	ebv expression	[EBV expression]	0.0	2	1	1	1
88343	1710	CPO	[CPO]	0.0	1	1	1	1
88344	1710	moreover, impaired activation	[Moreover, impaired activation]	0.0	3	1	1	1
88345	1710	temporal control	[temporal control]	0.0	2	2	2	1
88346	1710	cellular disposition of sulphamethoxazole implication	[Cellular disposition of sulphamethoxazole implications]	0.0	5	1	1	1
88347	1710	site within the negative regulatory element	[sites within the negative regulatory element]	0.0	6	1	1	1
88348	1710	complement receptor-1	[complement receptor-1]	0.0	2	1	1	1
88349	1710	intestinal hyperabsorption	[intestinal hyperabsorption]	0.0	2	1	1	1
88350	1710	remission in patient with acute leukemia	[remission in patients with acute leukemia]	0.0	6	1	1	1
88351	1710	o-phenanthroline OP	[o-phenanthroline OP]	0.0	2	1	1	1
88352	1710	four site	[four sites]	0.0	2	1	1	1
88353	1710	on b cell	[on B cells]	0.0	3	1	1	1
88354	1710	effector mechanism in disorder	[effector mechanism in disorders]	0.0	4	1	1	1
88355	1710	silence effect	[silencing effect]	0.0	2	1	1	1
88356	1710	nucleotide polymorphism (snp)	[nucleotide polymorphism (SNP)]	0.0	3	1	1	1
88357	1710	chain gene in b-lymphoid cell	[chain genes in B-lymphoid cells]	0.0	5	1	1	1
88358	1710	site kappa	[sites kappa]	0.0	2	1	1	1
88359	1710	adult hematopoietic cell	[adult hematopoietic cells]	0.0	3	1	1	1
88360	1710	contrast, integrin ligation	[contrast, integrin ligation]	0.0	3	1	1	1
88361	1710	intervene region upstream of switch	[intervening regions upstream of switch]	0.0	5	1	1	1
88362	1710	acute myeloid leukemic blast	[acute myeloid leukemic blasts]	0.0	4	1	1	1
88363	1710	D3 in normal monocyte	[D3 in normal monocytes]	0.0	4	1	1	1
88364	1710	unrelated child	[unrelated children]	0.0	2	1	1	1
88365	1710	interpretation a transcriptional response	[interpretation a transcriptional response]	0.0	4	1	1	1
88366	1710	least two protein	[least two proteins]	0.0	3	1	1	1
88367	1710	tsc2 sscp	[TSC2 SSCP]	0.0	2	1	1	1
88368	1710	murine protein,	[murine protein,]	0.0	2	1	1	1
88369	1710	significant level in myeloid cell	[significant levels in myeloid cells]	0.0	5	1	1	1
88370	1710	EBV antigen EBNA2	[EBV antigen EBNA2]	0.0	3	1	1	1
88371	1710	Fas Ligand	[Fas Ligand]	0.0	2	1	1	1
88372	1710	lineage markers;	[lineage markers;]	0.0	2	1	1	1
88373	1710	hpv type 16 hpv-16	[HPV type 16 HPV-16]	0.0	4	1	1	1
88374	1710	dermal endothelial cell	[dermal endothelial cells]	0.0	3	1	1	1
88375	1710	weakly in muscle	[weakly in muscle]	0.0	3	1	1	1
88376	1710	pel growth	[PEL growth]	0.0	2	1	1	1
88377	1710	case of chronic lymphocytic leukemia CLL	[cases of chronic lymphocytic leukemia CLL]	0.0	6	1	1	1
88378	1710	induction during anemia	[induction during anemia]	0.0	3	1	1	1
88379	1710	least some case	[least some cases]	0.0	3	1	1	1
88380	1710	jak1 beta	[JAK1 beta]	0.0	2	1	1	1
88381	1710	homolog c/ebp-beta	[homolog C/EBP-beta]	0.0	2	1	1	1
88382	1710	ebv include virus-induced tumorigenesis.	[EBV including virus-induced tumorigenesis.]	0.0	4	1	1	1
88383	1710	two dose of budesonide	[two doses of budesonide]	0.0	4	1	1	1
88384	1710	8 woman with hyperparathyroidism secondary	[8 women with hyperparathyroidism secondary]	0.0	5	1	1	1
88385	1710	uncouple in a T	[Uncoupling in an T]	0.0	4	1	1	1
88386	1710	region of mouse	[region of mouse]	0.0	3	1	1	1
88387	1710	one base substitution	[one base substitution]	0.0	3	1	1	1
88388	1710	such defect	[such defects]	0.0	2	1	1	1
88389	1710	tnf-alpha induction of hiv transcription	[TNF-alpha induction of HIV transcription]	0.0	5	1	1	1
88390	1710	granulocyte recovery.	[granulocyte recovery.]	0.0	2	1	1	1
88391	1710	remain c-terminal residue	[remaining C-terminal residues]	0.0	3	1	1	1
88392	1710	C/EBPalpha hematopoietic cell	[C/EBPalpha hematopoietic cells]	0.0	3	1	1	1
88393	1710	distal nuclear factor proximal NF-AT AP-1/Octamer	[distal nuclear factor proximal NF-AT AP-1/Octamer]	0.0	6	1	1	1
88394	1710	e(2) murine line, e(2)	[E(2) murine line, E(2)]	0.0	4	1	1	1
88395	1710	twenty two man aged	[Twenty two men aged]	0.0	4	1	1	1
88396	1710	include kb from the 5' region	[including kb from the 5' region]	0.0	6	1	1	1
88397	1710	nf kappa b p50	[NF kappa B p50]	0.0	4	1	1	1
88398	1710	such as aggregation	[such as aggregation]	0.0	3	1	1	1
88399	1710	tnf-alpha release in monocyte	[TNF-alpha release in monocytes]	0.0	4	5	5	1
88400	1710	cell express tdag51	[cells expressing TDAG51]	0.0	3	1	1	1
88401	1710	signal to a domain	[signal to a domain]	0.0	4	1	1	1
88402	1710	role for balance	[role for balance]	0.0	3	1	1	1
88403	1710	allele loss 20q in polycythemia vera	[allele loss 20q in polycythemia vera]	0.0	6	1	1	1
88404	1710	receptor mr status in leukocyte	[receptor MR status in leukocytes]	0.0	5	1	1	1
88405	1710	inducible inhibitory pathway	[inducible inhibitory pathway]	0.0	3	1	1	1
88406	1710	single positive cell	[single positive cells]	0.0	3	1	1	1
88407	1710	contrast, prostaglandin I2 a regulator	[contrast, prostaglandin I2 a regulator]	0.0	5	1	1	1
88408	1710	viral activity downstream of ZEBRA	[viral activities downstream of ZEBRA]	0.0	5	1	1	1
88409	1710	response through two independent form	[response through two independent forms]	0.0	5	1	1	1
88410	1710	blotting of fetal hematopoietic population	[blotting of fetal hematopoietic populations]	0.0	5	1	1	1
88411	1710	c-terminal amino acid of p70	[C-terminal amino acids of p70]	0.0	5	1	1	1
88412	1710	environmental estrogenic compound	[environmental estrogenic compounds]	0.0	3	1	1	1
88413	1710	anti- CD30 antibody,	[anti- CD30 antibody,]	0.0	3	1	1	1
88414	1710	activation of nfkappab	[activation of NFkappaB]	0.0	3	1	1	1
88415	1710	granulocyte- factor	[granulocyte- factor]	0.0	2	1	1	1
88416	1710	direct evidence of a role	[direct evidence of a role]	0.0	5	1	1	1
88417	1710	antibody cross-linking in U1 culture	[antibody cross-linking in U1 cultures]	0.0	5	1	1	1
88418	1710	cytoplasmic inhibitor contain ankyrin motif	[cytoplasmic inhibitors containing ankyrin motifs]	0.0	5	1	1	1
88419	1710	NF-kappaB a regulator	[NF-kappaB a regulator]	0.0	3	1	1	1
88420	1710	delineate the role of the proteasome	[delineating the roles of the proteasome]	0.0	6	1	1	1
88421	1710	acid treatment in promyelocytic leukemia	[acid treatment in promyelocytic leukemia]	0.0	5	1	1	1
88422	1710	matrix protein fibronectin FN	[matrix protein fibronectin FN]	0.0	4	1	1	1
88423	1710	myelomonoblastic cell population capable	[myelomonoblastic cell population capable]	0.0	4	1	1	1
88424	1710	effect VDR	[effects VDR]	0.0	2	1	1	1
88425	1710	Natl.	[Natl.]	0.0	1	1	1	1
88426	1710	standard consist of concentration	[standard consisting of concentrations]	0.0	4	1	1	1
88427	1710	double infection with virion	[double infection with virions]	0.0	4	1	1	1
88428	1710	octamer-like factor bind	[octamer-like factors binding]	0.0	3	1	1	1
88429	1710	result on human cell line	[results on human cell lines]	0.0	5	1	1	1
88430	1710	cytokine-induced vascular cell adhesion molecule-1 expression	[cytokine-induced vascular cell adhesion molecule-1 expression]	0.0	6	1	1	1
88431	1710	nf kappa b from the cytoplasm	[NF kappa B from the cytoplasm]	0.0	6	1	1	1
88432	1710	initial diagnosis, genetic counseling,	[initial diagnosis, genetic counseling,]	0.0	4	1	1	1
88433	1710	support DNA binding	[supporting DNA binding]	0.0	3	1	1	1
88434	1710	malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
88435	1710	Effect of diesel extract	[Effects of diesel extracts]	0.0	4	1	1	1
88436	1710	active calcineurin cn	[active calcineurin CN]	0.0	3	1	1	1
88437	1710	include a heterodimer	[including a heterodimer]	0.0	3	1	1	1
88438	1710	intermediate size range	[intermediate size range]	0.0	3	1	1	1
88439	1710	suggest essential for interaction	[suggesting essential for interaction]	0.0	4	1	1	1
88440	1710	various adhesion molecule	[various adhesion molecules]	0.0	3	1	1	1
88441	1710	two il-2 DNA enhancer element	[two IL-2 DNA enhancer elements]	0.0	5	1	1	1
88442	1710	cell pbmc	[cells PBMC]	0.0	2	1	1	1
88443	1710	Epstein-Barr virus tumor	[Epstein-Barr virus tumors]	0.0	3	1	1	1
88444	1710	CAML mutant	[CAML mutant]	0.0	2	1	1	1
88445	1710	Ets-family	[Ets-family]	0.0	1	1	1	1
88446	1710	expression of stat1	[expression of STAT1]	0.0	3	1	1	1
88447	1710	strong inhibitory activity	[stronger inhibitory activity]	0.0	3	1	1	1
88448	1710	pfp9a20	[PFP9a20]	0.0	1	1	1	1
88449	1710	distinct stat5 protein	[distinct STAT5 proteins]	0.0	3	1	1	1
88450	1710	normal pulmonary macrophage	[Normal pulmonary macrophages]	0.0	3	1	1	1
88451	1710	lead to expression of gene important	[leading to expression of genes important]	0.0	6	1	1	1
88452	1710	immunophilin immunosuppressant binding protein	[immunophilin immunosuppressant binding protein]	0.0	4	1	1	1
88453	1710	degree with helice	[degrees with helices]	0.0	3	1	1	1
88454	1710	inhibition of hsv-1 replication	[inhibition of HSV-1 replication]	0.0	4	1	1	1
88455	1710	major MHC class gene	[major MHC class genes]	0.0	4	1	1	1
88456	1710	accumulation of IL2 mrna	[accumulation of IL2 mRNA]	0.0	4	1	1	1
88457	1710	rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).	[rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).]	0.0	5	1	1	1
88458	1710	transcriptional activation reporter	[transcriptional activation reporters]	0.0	3	1	1	1
88459	1710	part of chromosome 14	[part of chromosome 14]	0.0	4	1	1	1
88460	1710	affect replication	[affecting replication]	0.0	2	1	1	1
88461	1710	number of neoplasm	[number of neoplasms]	0.0	3	1	1	1
88462	1710	amount of il-8 costimulation	[amounts of IL-8 costimulation]	0.0	4	1	1	1
88463	1710	beneficial effect on the development	[beneficial effect on the development]	0.0	5	1	1	1
88464	1710	plasma repressor function	[plasma repressor function]	0.0	3	1	1	1
88465	1710	expression pattern suggest a common property	[expression patterns suggesting a common property]	0.0	6	1	1	1
88466	1710	western blot assay	[Western blot assay]	0.0	3	1	1	1
88467	1710	include 3 kb of DNA	[including 3 kb of DNA]	0.0	5	1	1	1
88468	1710	proteins, differ in degree of glycosylation	[proteins, differing in degree of glycosylation]	0.0	6	1	1	1
88469	1710	typical localization of the 135eoh)2d3 receptor	[typical localization of the 1,25(OH)2D3 receptor]	0.0	6	1	1	1
88470	1710	three protein of 82	[three proteins of 82]	0.0	4	1	1	1
88471	1710	down-regulation of immunogenic protein	[Down-regulation of immunogenic proteins]	0.0	4	1	1	1
88472	1710	interaction of specific ags	[interaction of specific Ags]	0.0	4	1	1	1
88473	1710	microm as2o3	[microM As2O3]	0.0	2	1	1	1
88474	1710	most t-cell line	[most T-cell lines]	0.0	3	1	1	1
88475	1710	calcium ionophore in T cell	[calcium ionophore in T cells]	0.0	5	1	1	1
88476	1710	expression in human cell	[expression in human cells]	0.0	4	1	1	1
88477	1710	binding of pac-1 monoclonal antibody	[binding of PAC-1 monoclonal antibodies]	0.0	5	1	1	1
88478	1710	expression upon repression,	[expression upon repression,]	0.0	3	1	1	1
88479	1710	30 kb	[30 kb]	0.0	2	1	1	1
88480	1710	tissue-specific activator	[tissue-specific activator]	0.0	2	1	1	1
88481	1710	frequency of germ-line brca2 mutation	[frequency of germ-line BRCA2 mutations]	0.0	5	1	1	1
88482	1710	expression of tnf receptor	[expression of TNF receptors]	0.0	4	1	1	1
88483	1710	immunologic barrier	[immunologic barrier]	0.0	2	1	1	1
88484	1710	peritoneal macrophage of mouse	[Peritoneal macrophages of mice]	0.0	4	1	1	1
88485	1710	lymphoblastoid cell proliferation	[lymphoblastoid cell proliferation]	0.0	3	1	1	1
88486	1710	recent initiative	[recent initiative]	0.0	2	1	1	1
88487	1710	sensitivity to putatively non-cross-resisting agent	[sensitivity to putatively non-cross-resisting agents]	0.0	5	1	1	1
88488	1710	gene, transcript isolation	[gene, transcripts isolation]	0.0	3	1	1	1
88489	1710	binding media.	[binding media.]	0.0	2	1	1	1
88490	1710	maximal inhibition in pbmc	[maximal inhibition in PBMC]	0.0	4	1	1	1
88491	1710	early t-cell gene activation	[early T-cell gene activation]	0.0	4	1	1	1
88492	1710	only individual of major (mhc) haplotype	[only individuals of major (MHC) haplotypes]	0.0	6	1	1	1
88493	1710	only under growth condition	[only under growth conditions]	0.0	4	1	1	1
88494	1710	up-regulation consistent	[up-regulation consistent]	0.0	2	1	1	1
88495	1710	monoclonal antibody Lt-4	[monoclonal antibody Lt-4]	0.0	3	1	1	1
88496	1710	receptor oligomerization	[receptor oligomerization]	0.0	2	1	1	1
88497	1710	predominant synthesis of isoform	[predominant synthesis of isoforms]	0.0	4	1	1	1
88498	1710	treatment via suppression	[treatment via suppression]	0.0	3	1	1	1
88499	1710	t3r alteration	[T3R alterations]	0.0	2	1	1	1
88500	1710	Nuclear analysis	[Nuclear analyses]	0.0	2	1	1	1
88501	1710	high ability	[highest ability]	0.0	2	1	1	1
88502	1710	anti CD20 monoclonal antibody	[anti CD20 monoclonal antibody]	0.0	4	1	1	1
88503	1710	site of pkc responsiveness	[site of PKC responsiveness]	0.0	4	1	1	1
88504	1710	ebv mutant	[EBV mutants]	0.0	2	1	1	1
88505	1710	accumulation in the cells,	[accumulation in the cells,]	0.0	4	1	1	1
88506	1710	great affinity consistent	[greater affinity consistent]	0.0	3	1	1	1
88507	1710	ability of molecule	[ability of molecules]	0.0	3	1	1	1
88508	1710	important trans-acting factor	[important trans-acting factors]	0.0	3	1	1	1
88509	1710	regulatory effect on the trans-activation	[regulatory effect on the trans-activation]	0.0	5	1	1	1
88510	1710	substantial activation	[substantial activation]	0.0	2	1	1	1
88511	1710	distinct interference with dexamethasone	[distinct interference with dexamethasone]	0.0	4	1	1	1
88512	1710	oligodeoxynucleotides odn	[oligodeoxynucleotides ODNs]	0.0	2	1	1	1
88513	1710	bp repeat c1-c3	[bp repeats C1-C3]	0.0	3	1	1	1
88514	1710	probably in the suprachiasmatic nuclei	[probably in the suprachiasmatic nuclei]	0.0	5	1	1	1
88515	1710	disruption in a b-cell line	[disruption in a B-cell line]	0.0	5	1	1	1
88516	1710	DNA bind specificities,	[DNA binding specificities,]	0.0	3	1	1	1
88517	1710	tpa responsiveness in assay	[TPA responsiveness in assays]	0.0	4	1	1	1
88518	1710	phosphatase-positive osteoclast-like cell	[phosphatase-positive osteoclast-like cells]	0.0	3	1	1	1
88519	1710	human umbilical cord T	[human umbilical cord T]	0.0	4	1	1	1
88520	1710	significant proliferation recent-onset iddm subject	[significant proliferation recent-onset IDDM subjects]	0.0	5	1	1	1
88521	1710	activation of the factor completely,	[activation of the factor completely,]	0.0	5	1	1	1
88522	1710	cxcr4 promoter activity	[CXCR4 promoter activity]	0.0	3	1	1	1
88523	1710	alteration of order of ghost membrane	[Alteration of order of ghost membrane]	0.0	6	1	1	1
88524	1710	phenotype reversal of th2 cell	[phenotype reversal of Th2 cells]	0.0	5	1	1	1
88525	1710	ST patient	[ST patients]	0.0	2	1	1	1
88526	1710	mycoplasma-derived material mdhm	[mycoplasma-derived material MDHM]	0.0	3	1	1	1
88527	1710	non-irradiated cell line	[non-irradiated cell lines]	0.0	3	1	1	1
88528	1710	utilization of signal transduction pathway distinct	[utilization of signal transduction pathways distinct]	0.0	6	1	1	1
88529	1710	extract of anti- cd15 cell	[extracts of anti- CD15 cells]	0.0	5	1	1	1
88530	1710	first report of a activity	[first report of an activity]	0.0	5	1	1	1
88531	1710	tcrzeta expression	[TCRzeta expression]	0.0	2	1	1	1
88532	1710	partial independence from growth stimulus	[partial independence from growth stimuli]	0.0	5	1	1	1
88533	1710	gene-suppressive activity	[gene-suppressive activity]	0.0	2	1	1	1
88534	1710	suggest a possible role regulate e2f	[suggesting a possible role regulating E2F]	0.0	6	1	1	1
88535	1710	element of a NFATp/c	[elements of a NFATp/c]	0.0	4	1	1	1
88536	1710	gch compound	[GCH compounds]	0.0	2	1	1	1
88537	1710	analysis of replication	[analysis of replication]	0.0	3	1	1	1
88538	1710	of lap as much as am580	[of LAP as much as AM580]	0.0	6	1	1	1
88539	1710	human c/ebp-epsilon	[human C/EBP-epsilon]	0.0	2	1	1	1
88540	1710	Nb2 T cell	[Nb2 T cells]	0.0	3	1	1	1
88541	1710	(TNF) receptor family	[(TNF) receptor family]	0.0	3	1	1	1
88542	1710	pulse exposure of hl60	[Pulse exposure of HL60]	0.0	4	1	1	1
88543	1710	a of hhv-6	[A of HHV-6]	0.0	3	1	1	1
88544	1710	metabolic acidosis	[metabolic acidosis]	0.0	2	1	1	1
88545	1710	in-vitro-stimulated peripheral blood lymphocyte sample	[in-vitro-stimulated peripheral blood lymphocyte samples]	0.0	5	1	1	1
88546	1710	the/thf 1.87+/-0.36) alpha thf/thf n:	[THE/THF 1.87+/-0.36) alpha THF/THF N:]	0.0	5	1	1	1
88547	1710	transcription of mediator	[transcription of mediators]	0.0	3	1	1	1
88548	1710	6 day	[6 days]	0.0	2	1	1	1
88549	1710	nonsteroidal drug nsaid	[nonsteroidal drugs NSAIDs]	0.0	3	1	1	1
88550	1710	spi-1 mrna	[spi-1 mRNA]	0.0	2	1	1	1
88551	1710	tyrosine phosphorylation of protein substrate	[tyrosine phosphorylation of protein substrates]	0.0	5	1	1	1
88552	1710	AP-1,	[AP-1,]	0.0	1	1	1	1
88553	1710	stat1 alpha activation	[STAT1 alpha activation]	0.0	3	1	1	1
88554	1710	regulate the IL-12 signal pathway	[regulating the IL-12 signaling pathway]	0.0	5	1	1	1
88555	1710	key mediator during syphilis disease	[key mediators during syphilis disease]	0.0	5	1	1	1
88556	1710	incubation of cell with MM-LDL	[Incubation of cells with MM-LDL]	0.0	5	1	1	1
88557	1710	aeruginosa	[aeruginosa]	0.0	1	1	1	1
88558	1710	human lim-hox gene	[human LIM-Hox gene]	0.0	3	1	1	1
88559	1710	glutathione peroxidase gpx	[glutathione peroxidase GPX]	0.0	3	1	1	1
88560	1710	role in up-regulation of fas ligand	[Role in up-regulation of Fas ligand]	0.0	6	1	1	1
88561	1710	position p1	[position P1]	0.0	2	1	1	1
88562	1710	element-like sequence	[element-like sequence]	0.0	2	1	1	1
88563	1710	hormonal regulator	[hormonal regulators]	0.0	2	1	1	1
88564	1710	role in gene regulation.	[roles in gene regulation.]	0.0	4	1	1	1
88565	1710	paradigm for stat induction	[paradigm for STAT induction]	0.0	4	1	1	1
88566	1710	stimulus such as shock	[stimuli such as shock]	0.0	4	1	1	1
88567	1710	Jun pfo heterodimer	[Jun /Fos heterodimer]	0.0	3	1	1	1
88568	1710	method for relative quantification	[method for relative quantification]	0.0	4	1	1	1
88569	1710	blood cell receptor with body burdens.	[Blood cell receptors with body burdens.]	0.0	6	1	1	1
88570	1710	mechanism underlie ig gene extinction	[mechanism underlying Ig gene extinction]	0.0	5	1	1	1
88571	1710	activation by thrombin	[activation by thrombin]	0.0	3	2	2	1
88572	1710	only minimal activation	[only minimal activation]	0.0	3	1	1	1
88573	1710	cd44 promoter	[CD44 promoter]	0.0	2	1	1	1
88574	1710	Study from laboratory	[Studies from laboratory]	0.0	3	1	1	1
88575	1710	accumulation of various lesion	[accumulation of various lesions]	0.0	4	1	1	1
88576	1710	monocytic/myeloid leukemia-derived cell line	[monocytic/myeloid leukemia-derived cell lines]	0.0	4	1	1	1
88577	1710	more migrate b2 complex	[more migrating B2 complex]	0.0	4	1	1	1
88578	1710	disposition of sulphamethoxazole implication	[disposition of sulphamethoxazole implications]	0.0	4	1	1	1
88579	1710	recognition in hla-dq immune response	[recognition in HLA-DQ immune response]	0.0	5	1	1	1
88580	1710	representate the spectrum of B-cell differentiation	[representating the spectrum of B-cell differentiation]	0.0	6	1	1	1
88581	1710	localization of beta-catenin -lymphoid enhancer factor	[localization of beta-catenin -lymphoid enhancer factor]	0.0	6	1	1	1
88582	1710	activation a antiatherogenic mechanism	[activation A antiatherogenic mechanism]	0.0	4	1	1	1
88583	1710	T-helper 0 2 subset	[T-helper 0 2 subset]	0.0	4	1	1	1
88584	1710	EBNA-2 lmp-1 promoter	[EBNA-2 LMP-1 promoter]	0.0	3	1	1	1
88585	1710	proinflammatory effect of mechanical stress	[proinflammatory effects of mechanical stress]	0.0	5	1	1	1
88586	1710	response to stimulus notably product	[response to stimuli notably products]	0.0	5	1	1	1
88587	1710	ICAM-1 /beta 2 fashion	[ICAM-1 /beta 2 fashion]	0.0	4	1	1	1
88588	1710	Subcellular localization analysis in cells,	[Subcellular localization analysis in cells,]	0.0	5	1	1	1
88589	1710	factor to m rapid elevation	[factor to M rapid elevation]	0.0	5	1	1	1
88590	1710	-850 upstream	[-850 upstream]	0.0	2	1	1	1
88591	1710	suggest a physiologically relevant interaction	[suggesting a physiologically relevant interaction]	0.0	5	1	1	1
88592	1710	specificity of the heavy-chain enhancer	[specificity of the heavy-chain enhancer]	0.0	5	1	1	1
88593	1710	implication for some role of darc	[implications for some roles of DARC]	0.0	6	1	1	1
88594	1710	autosomal recessive pattern	[autosomal recessive pattern]	0.0	3	1	1	1
88595	1710	progesterone antagonist ru486	[progesterone antagonist RU486]	0.0	3	1	1	1
88596	1710	diesel extract on chemokine production	[diesel extracts on chemokine production]	0.0	5	1	1	1
88597	1710	approximately 1 P; immediate) binding	[approximately 1 h; immediate) binding]	0.0	5	1	1	1
88598	1710	cell of the human lineage	[cells of the human lineage]	0.0	5	1	1	1
88599	1710	activation of protein distinct	[activation of proteins distinct]	0.0	4	1	1	1
88600	1710	quantification of hiv rna	[quantification of HIV RNA]	0.0	4	1	1	1
88601	1710	immunodeficiency virus type hiv- 1 replication	[immunodeficiency virus type HIV- 1 replication]	0.0	6	1	1	1
88602	1710	agent for the treatment	[agents for the treatment]	0.0	4	1	1	1
88603	1710	alpha b5a	[alpha B5A]	0.0	2	1	1	1
88604	1710	b-cell by mutant virus	[B-cells by mutant virus]	0.0	4	1	1	1
88605	1710	selective chemical modification of lysine	[selective chemical modification of lysine]	0.0	5	1	1	1
88606	1710	combat Vietnam veteran with ptsd	[combat Vietnam veterans with PTSD]	0.0	5	1	1	1
88607	1710	however, a inhibition	[however, a inhibition]	0.0	3	1	1	1
88608	1710	STAT3 expression	[STAT3 expression]	0.0	2	1	1	1
88609	1710	ige synthesis (10(-10)	[IgE synthesis (10(-10)]	0.0	3	1	1	1
88610	1710	lymphocyte-specific member	[lymphocyte-specific member]	0.0	2	1	1	1
88611	1710	effect of rapamycin	[effects of rapamycin]	0.0	3	1	1	1
88612	1710	(sh2) domain	[(SH2) domain]	0.0	2	2	2	1
88613	1710	subsequent adhesion in vein cell HUVECs	[subsequent adhesion in vein cells HUVECs]	0.0	6	1	1	1
88614	1710	treatment with schedule (five patient	[Treatment with schedules (five patients]	0.0	5	1	1	1
88615	1710	homolog of a mouse gene	[homolog of a mouse gene]	0.0	5	1	1	1
88616	1710	differentiation induction system include hl-60	[differentiation induction systems including HL-60]	0.0	5	1	1	1
88617	1710	secretion of monocyte chemotactic protein-1	[secretion of monocyte chemotactic protein-1]	0.0	5	1	1	1
88618	1710	activation via release of a subunit	[activation via release of an subunit]	0.0	6	1	1	1
88619	1710	AP-1 transcription complex	[AP-1 transcription complex]	0.0	3	1	1	1
88620	1710	especially in organ	[especially in organs]	0.0	3	1	1	1
88621	1710	xenogeneic serum as a source	[xenogeneic serum as a source]	0.0	5	1	1	1
88622	1710	IFN-gamma complex	[IFN-gamma complex]	0.0	2	1	1	1
88623	1710	zymogen plasma factor VII	[zymogen plasma factors VII]	0.0	4	1	1	1
88624	1710	contain four repeat DR	[containing four repeats DR]	0.0	4	1	1	1
88625	1710	indicate virus transcription	[indicating virus transcription]	0.0	3	1	1	1
88626	1710	cell line deficient	[cell lines deficient]	0.0	3	1	1	1
88627	1710	encode component	[encoding components]	0.0	2	1	1	1
88628	1710	primary t-lymphocyte via CD2	[primary T-lymphocytes via CD2]	0.0	4	1	1	1
88629	1710	local metabolism of steroid	[local metabolism of steroids]	0.0	4	1	1	1
88630	1710	contrast, cd4+ T cell	[contrast, CD4+ T cells]	0.0	4	1	1	1
88631	1710	such as FcgammaRI	[such as FcgammaRI]	0.0	3	1	1	1
88632	1710	product of pathogen	[products of pathogens]	0.0	3	1	1	1
88633	1710	Cl-	[Cl-]	0.0	1	1	1	1
88634	1710	-contain intracellular molecule	[-containing intracellular molecules]	0.0	3	1	1	1
88635	1710	monocyte with 12-0-tetradecanoyl phorbol-13-acetate	[monocytes with 12-0-tetradecanoyl phorbol-13-acetate]	0.0	4	1	1	1
88636	1710	ionomycin myristate acetate	[ionomycin myristate acetate]	0.0	3	1	1	1
88637	1710	export of the shuttling transcription factor	[export of the shuttling transcription factor]	0.0	6	1	1	1
88638	1710	abundance in liver	[abundance in liver]	0.0	3	1	1	1
88639	1710	age range;	[age range;]	0.0	2	1	1	1
88640	1710	J Virol	[J Virol]	0.0	2	1	1	1
88641	1710	oncogenicity of papillomavirus-	[Oncogenicity of papillomavirus-]	0.0	3	1	1	1
88642	1710	integral component of the factor	[integral component of the factor]	0.0	5	1	1	1
88643	1710	virus gene expression	[virus gene expression]	0.0	3	1	1	1
88644	1710	Nuclear factor-kappaB -dependent induction evidence	[Nuclear factor-kappaB -dependent induction evidence]	0.0	5	1	1	1
88645	1710	weight of great	[weight of greater]	0.0	3	1	1	1
88646	1710	activation C PKC	[activation C PKC]	0.0	3	1	1	1
88647	1710	activity of a repeat	[activity of a repeat]	0.0	4	1	1	1
88648	1710	DMS	[DMS]	0.0	1	1	1	1
88649	1710	phagocyte with L. donovani	[phagocytes with L. donovani]	0.0	4	1	1	1
88650	1710	promoter region of two gene	[promoter regions of two genes]	0.0	5	1	1	1
88651	1710	40 kilometer	[40 kd]	0.0	2	1	1	1
88652	1710	polymorphic, short tandem repeat	[polymorphic, short tandem repeats]	0.0	4	1	1	1
88653	1710	size range (33-39	[size range (33-39]	0.0	3	1	1	1
88654	1710	Oct-2 cis-regulatory function	[Oct-2 cis-regulatory function]	0.0	3	1	1	1
88655	1710	allograft rejection after transplantation	[allograft rejection after transplantation]	0.0	4	1	1	1
88656	1710	rhesus monkey cercopithicine herpesvirus 15	[rhesus monkeys cercopithicine herpesvirus 15]	0.0	5	1	1	1
88657	1710	self ligand by human class	[self, ligands by human class]	0.0	5	1	1	1
88658	1710	DO-	[DO-]	0.0	1	1	1	1
88659	1710	approximately 1000 VDR by P.	[approximately 1000 VDR by h.]	0.0	5	1	1	1
88660	1710	most cycle gene	[most cycle genes]	0.0	3	1	1	1
88661	1710	character in abortion	[character in abortion]	0.0	3	1	1	1
88662	1710	deletion of nf-kappab site	[deletion of NF-kappaB sites]	0.0	4	1	1	1
88663	1710	analysis of the inactive methylation	[Analysis of the inactive methylation]	0.0	5	1	1	1
88664	1710	mammary cancer patient	[mammary cancer patients]	0.0	3	1	1	1
88665	1710	major developments,	[Major developments,]	0.0	2	1	1	1
88666	1710	patient with granulomatous disease tuberculosis	[patients with granulomatous diseases tuberculosis]	0.0	5	1	1	1
88667	1710	DZA on NF-kappaB activity	[DZA on NF-kappaB activity]	0.0	4	1	1	1
88668	1710	R-3-hydroxymyristate	[R-3-hydroxymyristate]	0.0	1	1	1	1
88669	1710	regard, anti-inflammatory cytokine	[regard, anti-inflammatory cytokines]	0.0	3	1	1	1
88670	1710	retinoid with binding specificity cd336	[retinoids with binding specificity CD336]	0.0	5	1	1	1
88671	1710	GCR in 6 Yang patient	[GCR in 6 Yang patients]	0.0	5	1	1	1
88672	1710	alteration, at threonine	[alteration, at threonine]	0.0	3	1	1	1
88673	1710	interaction with the receptor	[interactions with the receptor]	0.0	4	1	1	1
88674	1710	protein 2/core-binding	[protein 2/core-binding]	0.0	2	2	2	1
88675	1710	respiratory burst during phorbol differentiation	[respiratory burst during phorbol differentiation]	0.0	5	1	1	1
88676	1710	liposomal formulation of methylprednisolone	[liposomal formulation of methylprednisolone]	0.0	4	1	1	1
88677	1710	evidence for coupling	[evidence for coupling]	0.0	3	1	1	1
88678	1710	pattern of ebv gene expression	[pattern of EBV gene expression]	0.0	5	1	1	1
88679	1710	inhibition of vitamin d receptor expression	[inhibition of vitamin D receptor expression]	0.0	6	1	1	1
88680	1710	range of membrane g(s)alpha expression	[range of membrane G(S)alpha expression]	0.0	5	1	1	1
88681	1710	two complex in eosinophil	[two complexes in eosinophils]	0.0	4	1	1	1
88682	1710	C-terminal antibody	[C-terminal antibodies]	0.0	2	1	1	1
88683	1710	high activity in ocim1	[high activity in OCIM1]	0.0	4	1	1	1
88684	1710	facilitate the assembly of multiple protein	[facilitating the assembly of multiple proteins]	0.0	6	1	1	1
88685	1710	lysate use separation	[lysates using separation]	0.0	3	1	1	1
88686	1710	process similar to the disease	[processes similar to the diseases]	0.0	5	1	1	1
88687	1710	understanding of the molecular mechanism	[understanding of the molecular mechanisms]	0.0	5	1	1	1
88688	1710	comprise a minor b-cell component	[comprising a minor B-cell component]	0.0	5	1	1	1
88689	1710	range from 85 kda	[ranging from 85 kDa]	0.0	4	1	1	1
88690	1710	establish new cell line	[establishing new cell lines]	0.0	4	1	1	1
88691	1710	Con	[Con]	0.0	1	1	1	1
88692	1710	most function	[most functions]	0.0	2	1	1	1
88693	1710	effect with PGE2	[effects with PGE2]	0.0	3	1	1	1
88694	1710	major tegument protein ie62	[major tegument protein IE62]	0.0	4	1	1	1
88695	1710	cell-mediated immunity against infectious pathogen	[cell-mediated immunity against infectious pathogens]	0.0	5	1	1	1
88696	1710	concentration of RA inhibit ige synthesis	[concentrations of RA inhibiting IgE synthesis]	0.0	6	1	1	1
88697	1710	ALY lef-1 protein	[ALY LEF-1 protein]	0.0	3	1	1	1
88698	1710	lipoprotein oxldl	[lipoproteins oxLDLs]	0.0	2	1	1	1
88699	1710	+/- 0.92 fmol/10(7) pbmc	[+/- 0.92 fmol/10(7) PBMC]	0.0	4	1	1	1
88700	1710	immunoglobulin heavy-chain mrna	[immunoglobulin heavy-chain mRNA]	0.0	3	1	1	1
88701	1710	stat5a DNA binding	[STAT5a DNA binding]	0.0	3	1	1	1
88702	1710	cell with antibody (mab) 13b8-2	[cells with antibody (MAb) 13B8-2]	0.0	5	1	1	1
88703	1710	seven transmembrane receptor	[seven transmembrane receptor]	0.0	3	1	1	1
88704	1710	modulator of class antigen processing	[modulator of class antigen processing]	0.0	5	1	1	1
88705	1710	10 patient with cushingd' disease	[10 patients with Cushing's disease]	0.0	5	1	1	1
88706	1710	disease with rheumatoid arthritis five	[diseases with rheumatoid arthritis five]	0.0	5	1	1	1
88707	1710	result from mutation	[Results from mutations]	0.0	3	1	1	1
88708	1710	least one t-cell clone reactive	[least one T-cell clone reactive]	0.0	5	1	1	1
88709	1710	gata-factor gata-1	[GATA-factor GATA-1]	0.0	2	1	1	1
88710	1710	receptor determination a predictive clue	[receptor determination a predictive clue]	0.0	5	1	1	1
88711	1710	activator of the repeat	[activator of the repeat]	0.0	4	1	1	1
88712	1710	priming of monocyte with ifn-gamma	[Priming of monocytes with IFN-gamma]	0.0	5	1	1	1
88713	1710	mobility on sucrose gradients,	[mobility on sucrose gradients,]	0.0	4	1	1	1
88714	1710	hsv-specific cd4+ t-cell clone	[HSV-specific CD4+ T-cell clones]	0.0	4	1	1	1
88715	1710	similar activation transcription factor complex	[similar activation transcription factor complex]	0.0	5	1	1	1
88716	1710	effect of dexamethasone generation	[effect of dexamethasone generation]	0.0	4	1	1	1
88717	1710	unique activation	[unique activation]	0.0	2	1	1	1
88718	1710	hepatic factor 3 beta hnf3 beta	[hepatic factor 3 beta HNF3 beta]	0.0	6	1	1	1
88719	1710	agent on adhesion molecule	[agents on adhesion molecule]	0.0	4	1	1	1
88720	1710	constitutive activation in cell	[constitutive activation in cells]	0.0	4	1	1	1
88721	1710	extensive component eic	[extensive component EIC]	0.0	3	1	1	1
88722	1710	Ca2+ activation	[Ca2+ activation]	0.0	2	1	1	1
88723	1710	human c-type	[human C-type]	0.0	2	1	1	1
88724	1710	smoking patient	[smoking patients]	0.0	2	1	1	1
88725	1710	micrograms/day	[micrograms/day]	0.0	1	1	1	1
88726	1710	implication in research on cell therapy,	[implication in research on cell therapy,]	0.0	6	1	1	1
88727	1710	microb motif	[microB motif]	0.0	2	1	1	1
88728	1710	ppargamma receptor gamma expression	[PPARgamma receptor gamma expression]	0.0	4	1	1	1
88729	1710	receptor of form of 135(oh)2d3	[receptors of form of 1,25(OH)2D3]	0.0	5	1	1	1
88730	1710	human differentiation antigen MNDA	[human differentiation antigen MNDA]	0.0	4	1	1	1
88731	1710	response to a challenge	[response to an challenge]	0.0	4	1	1	1
88732	1710	ecd45ra+) T lymphocyte	[(CD45RA+) T lymphocytes]	0.0	3	1	1	1
88733	1710	Tax1 expression of transcription factor	[Tax1 expression of transcription factors]	0.0	5	1	1	1
88734	1710	enlarge vulvar mass	[enlarging vulvar mass]	0.0	3	1	1	1
88735	1710	also with other ankyrin protein	[also with other ankyrin proteins]	0.0	5	1	1	1
88736	1710	transcription factor at stage	[transcription factors at stages]	0.0	4	1	1	1
88737	1710	shutdown of synthesis	[shutdown of synthesis]	0.0	3	1	1	1
88738	1710	Th1-dominated chronic (auto)immune inflammation	[Th1-dominated chronic (auto)immune inflammation]	0.0	4	1	1	1
88739	1710	viral protein expression gag	[viral protein expression Gag]	0.0	4	1	1	1
88740	1710	presence of nf-e2 complex	[presence of NF-E2 complex]	0.0	4	1	1	1
88741	1710	bcl2 a oncogene	[bcl2 an oncogene]	0.0	3	1	1	1
88742	1710	suggest the target	[suggesting the target]	0.0	3	1	1	1
88743	1710	human lysosomal acid lipase	[Human lysosomal acid lipase]	0.0	4	1	1	1
88744	1710	enhancer by nf-kappab p50/p65	[enhancer by NF-kappaB p50/p65]	0.0	4	1	1	1
88745	1710	parallel activation	[parallel activation]	0.0	2	1	1	1
88746	1710	number of granule	[numbers of granules]	0.0	3	1	1	1
88747	1710	expression of diverse receptor of differentiation	[expression of diverse receptors of differentiation]	0.0	6	1	1	1
88748	1710	angiotensin (ang)	[angiotensin (ANG)]	0.0	2	1	1	1
88749	1710	redundancy of this transcription factor	[redundancy of these transcription factors]	0.0	5	1	1	1
88750	1710	CsA fk506 factor	[CsA FK506 factor]	0.0	3	1	1	1
88751	1710	site for depletion	[site for depletion]	0.0	3	1	1	1
88752	1710	new crucial element important	[new crucial element important]	0.0	4	1	1	1
88753	1710	significant amount of b	[significant amounts of B]	0.0	4	1	1	1
88754	1710	12-myristate 13-acetate PMA	[12-myristate 13-acetate PMA]	0.0	3	1	1	1
88755	1710	lytic reactivity	[lytic reactivities]	0.0	2	1	1	1
88756	1710	carry the taxi gene	[carrying the TaxI gene]	0.0	4	1	1	1
88757	1710	different sequence requirement	[Different sequence requirements]	0.0	3	1	1	1
88758	1710	stress-dependent activation	[stress-dependent activation]	0.0	2	1	1	1
88759	1710	cell reaction grade	[cell reaction grade]	0.0	3	1	1	1
88760	1710	class ii DRA promoter occupancy	[class II DRA promoter occupancy]	0.0	5	1	1	1
88761	1710	cell divisions, corresponding	[cell divisions, corresponding]	0.0	3	1	1	1
88762	1710	5' enhancer region	[5' enhancer region]	0.0	3	2	2	1
88763	1710	cell-surface heparan sulphate	[cell-surface heparan sulphate]	0.0	3	1	1	1
88764	1710	cell upon heat shock	[cells upon heat shock]	0.0	4	1	1	1
88765	1710	number of macrophage	[number of macrophages]	0.0	3	1	1	1
88766	1710	different subpopulation	[different subpopulations]	0.0	2	1	1	1
88767	1710	delta 5' flank region	[delta 5' flanking regions]	0.0	4	1	1	1
88768	1710	(PAS)	[(PAS)]	0.0	1	1	1	1
88769	1710	employ a lysis synthetic substrate	[employing a lysis synthetic substrate]	0.0	5	1	1	1
88770	1710	oxidant acid 1 mm)	[oxidant acid 1 mM)]	0.0	4	1	1	1
88771	1710	expression previously.	[expression previously.]	0.0	2	1	1	1
88772	1710	immediate target	[immediate target]	0.0	2	1	1	1
88773	1710	thin-layer chromatography tlc	[thin-layer chromatography TLC]	0.0	3	1	1	1
88774	1710	creb )/activating	[CREB )/activating]	0.0	2	1	1	1
88775	1710	c motif-1	[C motif-1]	0.0	2	1	1	1
88776	1710	caat box-like	[CAAT box-like]	0.0	2	1	1	1
88777	1710	interaction with vein cell HUVEC	[interaction with vein cells HUVEC]	0.0	5	1	1	1
88778	1710	low binding affinity RBA the high	[low binding affinities RBA the highest]	0.0	6	1	1	1
88779	1710	p27kip1 mrna	[p27Kip1 mRNA]	0.0	2	1	1	1
88780	1710	nonerythroid hl-60 cell	[nonerythroid HL-60 cells]	0.0	3	1	1	1
88781	1710	hormonal control of this promoter	[hormonal control of this promoter]	0.0	5	1	1	1
88782	1710	xist locus on tiny ring	[XIST locus on tiny ring]	0.0	5	1	1	1
88783	1710	proliferation, stat-5 induction	[proliferation, STAT-5 induction]	0.0	3	1	1	1
88784	1710	metabolite of oxygen	[metabolites of oxygen]	0.0	3	2	2	1
88785	1710	microm RU 38486	[microM RU 38486]	0.0	3	1	1	1
88786	1710	acquisition of sensitivity	[acquisition of sensitivity]	0.0	3	1	1	1
88787	1710	promoter in a chromatin configuration	[promoters in an chromatin configuration]	0.0	5	1	1	1
88788	1710	contain Tyr374	[containing Tyr374]	0.0	2	1	1	1
88789	1710	control E2F transcriptional activity	[controlling E2F transcriptional activity]	0.0	4	1	1	1
88790	1710	ls mutation -201	[LS mutations -201]	0.0	3	1	1	1
88791	1710	effect of p50/NF-kappa b homodimer	[effects of p50/NF-kappa B homodimers]	0.0	5	1	1	1
88792	1710	focus of this research	[focus of this research]	0.0	4	1	1	1
88793	1710	nuclear translocation nuclear factor	[nuclear translocation nuclear factor]	0.0	4	2	2	1
88794	1710	clinical effect	[clinical effects]	0.0	2	1	1	1
88795	1710	intact segment on cd36	[intact segment on CD36]	0.0	4	1	1	1
88796	1710	comprise a member	[comprising a member]	0.0	3	1	1	1
88797	1710	1 repeat in T cell	[1 repeat in T cells]	0.0	5	1	1	1
88798	1710	Markus	[Markus]	0.0	1	1	1	1
88799	1710	frequency of anti-SSB T cell	[frequency of anti-SSB T cells]	0.0	5	1	1	1
88800	1710	presentation of self-antigen	[presentation of self-antigen]	0.0	3	1	1	1
88801	1710	however, high millileter	[However, high ml]	0.0	3	1	1	1
88802	1710	form of heterodimeric binding partner,	[form of heterodimeric binding partner,]	0.0	5	1	1	1
88803	1710	fourfold 12-lipoxygenase activity	[fourfold 12-lipoxygenase activity]	0.0	3	1	1	1
88804	1710	lead to response	[leading to responses]	0.0	3	1	1	1
88805	1710	pcd/dcoh protein level	[PCD/DCoH protein level]	0.0	3	1	1	1
88806	1710	layer of the lesion	[layer of the lesion]	0.0	4	1	1	1
88807	1710	include possibly sp1 binding protein	[including possibly Sp1 binding proteins]	0.0	5	1	1	1
88808	1710	dna-binding alf1	[DNA-binding ALF1]	0.0	2	1	1	1
88809	1710	er content in lymphocyte of blood	[ER content in lymphocytes of blood]	0.0	6	1	1	1
88810	1710	gel shift complex	[gel shift complexes]	0.0	3	1	1	1
88811	1710	number of metabolite	[number of metabolites]	0.0	3	1	1	1
88812	1710	hematopoietic cell as a model	[hematopoietic cells as a model]	0.0	5	1	1	1
88813	1710	five dnase I	[five DNase I]	0.0	3	1	1	1
88814	1710	T cell from (mean years)	[T cells from (mean years)]	0.0	5	1	1	1
88815	1710	human vacuolar h(+)-atpase	[human vacuolar H(+)-ATPase]	0.0	3	1	1	1
88816	1710	temporal artery-SCID chimera for wk	[temporal artery-SCID chimeras for wk]	0.0	5	1	1	1
88817	1710	9.36 nm,	[9.36 nM,]	0.0	2	1	1	1
88818	1710	expression/repression of gene	[expression/repression of genes]	0.0	3	1	1	1
88819	1710	process dependent	[processes dependent]	0.0	2	1	1	1
88820	1710	Ter positive erythroid cell	[Ter positive erythroid cells]	0.0	4	1	1	1
88821	1710	adhesive ICAM-1 property of endothelial cell	[adhesive ICAM-1 properties of endothelial cells]	0.0	6	1	1	1
88822	1710	one target of this regulation	[one target of this regulation]	0.0	5	1	1	1
88823	1710	Dithiocarbamates DTC a group of chemical	[Dithiocarbamates DTC a group of chemicals]	0.0	6	1	1	1
88824	1710	relevant spectrum	[relevant spectrum]	0.0	2	1	1	1
88825	1710	platelet fibrinogen	[platelet fibrinogen]	0.0	2	1	1	1
88826	1710	central role in transcriptional regulation	[central role in transcriptional regulation]	0.0	5	1	1	1
88827	1710	beta promoter	[beta promoter]	0.0	2	1	1	1
88828	1710	stage-specific nuclear factor-DNA complex	[stage-specific nuclear factor-DNA complexes]	0.0	4	1	1	1
88829	1710	polypeptide of 50 kD	[polypeptides of 50 kD]	0.0	4	1	1	1
88830	1710	hyperaldosteronism pseudohyperaldosteronism	[hyperaldosteronism pseudohyperaldosteronism]	0.0	2	1	1	1
88831	1710	nature of syndrome	[nature of syndromes]	0.0	3	1	1	1
88832	1710	study individual	[study individuals]	0.0	2	1	1	1
88833	1710	part, due to inability	[part, due to inability]	0.0	4	1	1	1
88834	1710	(gst)-grb2	[(GST)-Grb2]	0.0	1	1	1	1
88835	1710	14-kd protein	[14-kD protein]	0.0	2	1	1	1
88836	1710	effect of glucocorticoid treatment	[effects of glucocorticoid treatment]	0.0	4	1	1	1
88837	1710	regulatory pathway involve kinase c	[regulatory pathways involving kinase C]	0.0	5	1	1	1
88838	1710	expression of nf-kappab in monocyte	[expression of NF-kappaB in monocytes]	0.0	5	1	1	1
88839	1710	interleukin-5 hil-5	[interleukin-5 hIL-5]	0.0	2	1	1	1
88840	1710	ikappab kinase activation in cell	[IkappaB kinase activation in cells]	0.0	5	1	1	1
88841	1710	ref respectively),	[refs respectively),]	0.0	2	1	1	1
88842	1710	cell transmembrane	[cell transmembrane]	0.0	2	1	1	1
88843	1710	factor granulocyte-macrophage factor	[factor granulocyte-macrophage factor]	0.0	3	1	1	1
88844	1710	distinct site	[distinct sites]	0.0	2	1	1	1
88845	1710	activation in erythroid progenitor	[Activation in erythroid progenitors]	0.0	4	1	1	1
88846	1710	hypermutation in follicular lymphoma	[hypermutation in follicular lymphoma]	0.0	4	1	1	1
88847	1710	cytochrome p-450	[cytochrome P-450]	0.0	2	1	1	1
88848	1710	contain nf-kappa b dimer	[containing NF-kappa B dimers]	0.0	4	1	1	1
88849	1710	human peripheral monocyte extract	[human peripheral monocyte extracts]	0.0	4	1	1	1
88850	1710	activation in interleukin-2 receptor expression	[Activation in interleukin-2 receptor expression]	0.0	5	1	1	1
88851	1710	weak cross-reactivity	[weak cross-reactivity]	0.0	2	1	1	1
88852	1710	yeast chromosome contig	[yeast chromosome contig]	0.0	3	1	1	1
88853	1710	expression of megakaryocytic lineage cell	[expression of megakaryocytic lineage cells]	0.0	5	1	1	1
88854	1710	pretreatment 5-day macrophage	[Pretreatment 5-day macrophages]	0.0	3	1	1	1
88855	1710	inhibitor of sphingomyelinase	[inhibitor of sphingomyelinase]	0.0	3	1	1	1
88856	1710	receptor in the peripheral lymphocyte	[receptor in the peripheral lymphocytes]	0.0	5	1	1	1
88857	1710	native receptor	[native receptor]	0.0	2	1	1	1
88858	1710	present study, use cd34+	[present study, using CD34+]	0.0	4	1	1	1
88859	1710	(non t)	[(non T)]	0.0	2	1	1	1
88860	1710	analysis apoptosis in lymphoblastoid CD4 receptor	[analysis apoptosis in lymphoblastoid CD4 receptors]	0.0	6	1	1	1
88861	1710	antibody Yae	[antibody Yae]	0.0	2	1	1	1
88862	1710	/nerve growth	[/nerve growth]	0.0	2	1	1	1
88863	1710	sharp contrast to cell	[sharp contrast to cells]	0.0	4	1	1	1
88864	1710	function of ebna2	[function of EBNA2]	0.0	3	1	1	1
88865	1710	antigen-specific reactivity high	[antigen-specific reactivities high]	0.0	3	1	1	1
88866	1710	occlusion a cause	[occlusion a cause]	0.0	3	1	1	1
88867	1710	inactivation of material	[inactivation of material]	0.0	3	1	1	1
88868	1710	dna-binding characteristic of ef1 at abundance	[DNA-binding characteristics of EF1 at abundance]	0.0	6	1	1	1
88869	1710	more extensive footprint	[more extensive footprints]	0.0	3	1	1	1
88870	1710	spontaneous lymphocyte proliferation in 13 control	[spontaneous lymphocyte proliferation in 13 controls]	0.0	6	1	1	1
88871	1710	parallel protein kinase signal pathway	[parallel protein kinase signaling pathways]	0.0	5	1	1	1
88872	1710	importance in the IL-7R complex	[importance in the IL-7R complex]	0.0	5	1	1	1
88873	1710	protein bzlf1	[protein BZLF1]	0.0	2	1	1	1
88874	1710	dr unit	[DR units]	0.0	2	1	1	1
88875	1710	substantial growth inhibition without evidence	[Substantial growth inhibition without evidence]	0.0	5	1	1	1
88876	1710	difference in this two related lineage	[differences in these two related lineages]	0.0	6	1	1	1
88877	1710	human immunodeficiency virus type 1 repeat	[human immunodeficiency virus type 1 repeats]	0.0	6	1	1	1
88878	1710	systemic hGR level between patient	[systemic hGR levels between patients]	0.0	5	1	1	1
88879	1710	binding site for NF-E1	[binding sites for NF-E1]	0.0	4	1	1	1
88880	1710	change in nature Arg91 one	[change in nature Arg91 one]	0.0	5	1	1	1
88881	1710	two additional complex	[two additional complexes]	0.0	3	1	1	1
88882	1710	only binding affinity	[only binding affinities]	0.0	3	1	1	1
88883	1710	sex-matched control with respect	[sex-matched controls with respect]	0.0	4	1	1	1
88884	1710	follow neutrophil stimulation	[Following neutrophil stimulation]	0.0	3	1	1	1
88885	1710	molecular dissection	[Molecular dissection]	0.0	2	1	1	1
88886	1710	cooperative interaction between coactivator	[cooperative interactions between coactivators]	0.0	4	1	1	1
88887	1710	dna-binding activity in t-cell	[DNA-binding activity in T-cells]	0.0	4	1	1	1
88888	1710	protein latent infection	[protein latent infection]	0.0	3	1	1	1
88889	1710	significant level in all population	[significant levels in all populations]	0.0	5	1	1	1
88890	1710	provide a point	[providing an point]	0.0	3	1	1	1
88891	1710	incubation of cell in hypoxia po2	[Incubation of cells in hypoxia PO2]	0.0	6	1	1	1
88892	1710	enhancer present	[enhancer present]	0.0	2	1	1	1
88893	1710	contrast, mutagenesis	[contrast, mutagenesis]	0.0	2	1	1	1
88894	1710	value at hour 12	[value at hour 12]	0.0	4	1	1	1
88895	1710	hypocortisolemia	[hypocortisolemia]	0.0	1	1	1	1
88896	1710	DNA sequence adjacent	[DNA sequences adjacent]	0.0	3	1	1	1
88897	1710	human t-lymphotropic virus type htlv-1	[human T-lymphotropic virus type HTLV-1]	0.0	5	1	1	1
88898	1710	fold decrease	[fold decrease]	0.0	2	1	1	1
88899	1710	middle-aged years) hypertensive	[middle-aged years) hypertensives]	0.0	3	1	1	1
88900	1710	effect of CD40 stimulation	[effect of CD40 stimulation]	0.0	4	1	1	1
88901	1710	46,x,-y,t(y;15)(q12;p13)/45,x cell line	[46,X,-Y,t(Y;15)(q12;p13)/45,X cell lines]	0.0	3	1	1	1
88902	1710	remarkable correlation between footprinting datum	[remarkable correlation between footprinting data]	0.0	5	1	1	1
88903	1710	expression of a active calcineurin	[Expression of a active calcineurin]	0.0	5	1	1	1
88904	1710	intermediary	[intermediary]	0.0	1	1	1	1
88905	1710	organizational pattern	[organizational pattern]	0.0	2	1	1	1
88906	1710	follow CD3	[following CD3]	0.0	2	1	1	1
88907	1710	follow CD2	[following CD2]	0.0	2	1	1	1
88908	1710	generation during the course	[generation during the course]	0.0	4	1	1	1
88909	1710	activator of transcription (stat) family	[activators of transcription (STAT) family]	0.0	5	1	1	1
88910	1710	interleukin 2 synthesis	[interleukin 2 synthesis]	0.0	3	1	1	1
88911	1710	blood of healthy woman	[blood of healthy women]	0.0	4	1	1	1
88912	1710	/cu2+	[/Cu2+]	0.0	1	1	1	1
88913	1710	exposure to low shear dyn/cm2)	[exposure to low shear dyn/cm2)]	0.0	5	1	1	1
88914	1710	cell killing.	[cell killing.]	0.0	2	1	1	1
88915	1710	negative mutant of Ras	[negative mutants of Ras]	0.0	4	1	1	1
88916	1710	powerful suppressor notably	[powerful suppressors notably]	0.0	3	1	1	1
88917	1710	il-13-induced factor	[IL-13-induced factors]	0.0	2	1	1	1
88918	1710	neuraminidase	[neuraminidase]	0.0	1	1	1	1
88919	1710	tested: dephosphorylation	[tested: dephosphorylation]	0.0	2	1	1	1
88920	1710	tyrosine kinase jak2	[tyrosine kinases JAK2]	0.0	3	1	1	1
88921	1710	negative influence	[negative influence]	0.0	2	2	2	1
88922	1710	TP1 gene	[TP1 gene]	0.0	2	1	1	1
88923	1710	abrogate interleukin-1beta gene transcription	[abrogating interleukin-1beta gene transcription]	0.0	4	1	1	1
88924	1710	up-regulation of the cd23 mrna	[up-regulation of the CD23 mRNA]	0.0	5	1	1	1
88925	1710	pml/rar alpha cell	[PML/RAR alpha cells]	0.0	3	1	1	1
88926	1710	40mer oligonucleotide from the 1st	[40mer oligonucleotides from the 1st]	0.0	5	1	1	1
88927	1710	arrest this ongoing immune response	[arresting this ongoing immune response]	0.0	5	1	1	1
88928	1710	look at success in approach	[Looking at successes in approaches]	0.0	5	1	1	1
88929	1710	diesel exhaust particle	[diesel exhaust particles]	0.0	3	1	1	1
88930	1710	composition in myeloid cell	[composition in myeloid cells]	0.0	4	1	1	1
88931	1710	hiv-1 terminal repeat transcription in monocyte	[HIV-1 terminal repeat transcription in monocytes]	0.0	6	1	1	1
88932	1710	33-47% identity	[33-47% identity]	0.0	2	1	1	1
88933	1710	combination necessarily include CD28 signaling.	[combination necessarily including CD28 signaling.]	0.0	5	1	1	1
88934	1710	two regulatory element (igh) enhancer	[two regulatory elements (IgH) enhancer]	0.0	5	1	1	1
88935	1710	adhesion molecule-1 on vein cell	[adhesion molecule-1 on vein cells]	0.0	5	1	1	1
88936	1710	phosphorylation-defective form	[phosphorylation-defective form]	0.0	2	1	1	1
88937	1710	several oncogene in cell lysis	[several oncogenes in cell lysis]	0.0	5	1	1	1
88938	1710	effect on mnp-1 expression,	[effect on MNP-1 expression,]	0.0	4	1	1	1
88939	1710	protein kinase inhibitor ha-1004	[protein kinase inhibitor HA-1004]	0.0	4	1	1	1
88940	1710	nf-kappab activation of immunodeficiency virus type	[NF-kappaB activation of immunodeficiency virus type]	0.0	6	1	1	1
88941	1710	stat1 in airway cell	[Stat1 in airway cells]	0.0	4	1	1	1
88942	1710	LTR size variant	[LTR size variants]	0.0	3	1	1	1
88943	1710	effect of constitutively active mutant	[effects of constitutively active mutants]	0.0	5	1	1	1
88944	1710	er mrna by transcription	[ER mRNA by transcription]	0.0	4	1	1	1
88945	1710	30 base pair	[30 base pairs]	0.0	3	1	1	1
88946	1710	thrombomodulin plasma	[thrombomodulin plasma]	0.0	2	1	1	1
88947	1710	signal from the t-cell receptor	[signal from the T-cell receptor]	0.0	5	1	1	1
88948	1710	presence of cell	[presence of cells]	0.0	3	1	1	1
88949	1710	show a 5- to 2-fold increase	[showing a 5- to 2-fold increase]	0.0	6	1	1	1
88950	1710	strong suppression of b activation	[strong suppression of B activation]	0.0	5	1	1	1
88951	1710	patient respond ifn-alpha	[patients responding IFN-alpha]	0.0	3	1	1	1
88952	1710	layer of hairy leukoplakia	[layers of hairy leukoplakia]	0.0	4	1	1	1
88953	1710	effect on RA -dependent differentiation	[effects on RA -dependent differentiation]	0.0	5	1	1	1
88954	1710	centromere probe	[centromere probes]	0.0	2	1	1	1
88955	1710	express a series	[expressing a series]	0.0	3	1	1	1
88956	1710	evaluation of evidence	[evaluation of evidence]	0.0	3	1	1	1
88957	1710	part of sequence in each	[part of sequences in each]	0.0	5	1	1	1
88958	1710	enhancer-binding factor lef-1	[enhancer-binding factor LEF-1]	0.0	3	1	1	1
88959	1710	quantitative transcription-PCR assay	[quantitative transcription-PCR assay]	0.0	3	1	1	1
88960	1710	length e2a cDNA	[length E2A cDNA]	0.0	3	1	1	1
88961	1710	leukaemia (aml) blast	[leukaemia (AML) blasts]	0.0	3	1	1	1
88962	1710	second element in the region	[second element in the region]	0.0	5	1	1	1
88963	1710	41 patient	[41 patients]	0.0	2	1	1	1
88964	1710	tyrosine phosphorylation of STAT1	[tyrosine phosphorylation of STAT1]	0.0	4	1	1	1
88965	1710	transcriptional 'silencer'	[transcriptional 'silencer']	0.0	2	1	1	1
88966	1710	molecule during a specific phase	[molecule during a specific phase]	0.0	5	1	1	1
88967	1710	F.M	[F.M]	0.0	1	1	1	1
88968	1710	activate the transcription	[activating the transcription]	0.0	3	2	2	1
88969	1710	EMS	[EMS]	0.0	1	1	1	1
88970	1710	use of stem cell	[use of stem cells]	0.0	4	1	1	1
88971	1710	effect on protein synthesis	[effects on protein synthesis]	0.0	4	1	1	1
88972	1710	variation in gr mrna expression	[variation in GR mRNA expression]	0.0	5	1	1	1
88973	1710	new, distinct entity	[new, distinct entity]	0.0	3	1	1	1
88974	1710	thus, competition between transcriptional activator	[Thus, competition between transcriptional activators]	0.0	5	1	1	1
88975	1710	myeloma line	[myeloma lines]	0.0	2	1	1	1
88976	1710	breast carcinoma cell line ZR-75-1	[breast carcinoma cell line ZR-75-1]	0.0	5	1	1	1
88977	1710	icam-1 surface protein	[ICAM-1 surface protein]	0.0	3	1	1	1
88978	1710	class major gene	[class major genes]	0.0	3	1	1	1
88979	1710	T transacting factor	[T transacting factors]	0.0	3	1	1	1
88980	1710	plate-bound anti-CD3 antibody	[plate-bound anti-CD3 antibody]	0.0	3	1	1	1
88981	1710	mechanism conformational change of the receptor.	[Mechanism conformational changes of the receptor.]	0.0	6	1	1	1
88982	1710	class lymphoma plasmacytoid AIDS iblp	[class lymphoma plasmacytoid AIDS IBLP]	0.0	5	1	1	1
88983	1710	ig-secreting cell	[Ig-secreting cells]	0.0	2	1	1	1
88984	1710	interaction with distinct coactivator	[interactions with distinct coactivators]	0.0	4	1	1	1
88985	1710	p50/rela(p65) heterodimer with the capacity	[p50/RelA(p65) heterodimers with the capacity]	0.0	5	1	1	1
88986	1710	inducible regulator of gene	[inducible regulators of genes]	0.0	4	1	1	1
88987	1710	i.e. granulocyte pmn	[i.e. granulocytes PMN]	0.0	3	1	1	1
88988	1710	cause secretion of mediator	[causing secretion of mediators]	0.0	4	1	1	1
88989	1710	transcriptional regulator of numerous gene	[transcriptional regulators of numerous genes]	0.0	5	1	1	1
88990	1710	production interleukin 2	[production interleukin 2]	0.0	3	1	1	1
88991	1710	response to cross-linking	[response to cross-linking]	0.0	3	1	1	1
88992	1710	treatment of blood lymphocyte with cysteamine	[Treatment of blood lymphocytes with cysteamine]	0.0	6	1	1	1
88993	1710	rxr 25-6603).	[RXRs 25-6603).]	0.0	2	1	1	1
88994	1710	potent cytokine mrna expression	[potent cytokine mRNA expression]	0.0	4	1	1	1
88995	1710	standard consist	[standard consisting]	0.0	2	1	1	1
88996	1710	dual stimulation	[dual stimulation]	0.0	2	1	1	1
88997	1710	androgen receptor humara gene	[androgen receptor HUMARA gene]	0.0	4	1	1	1
88998	1710	non-abortive infection	[non-abortive infections]	0.0	2	1	1	1
88999	1710	DLCL the form	[DLCL the form]	0.0	3	1	1	1
89000	1710	number of GCR in asthmatics	[number of GCR in asthmatics]	0.0	5	1	1	1
89001	1710	expression hours)	[expression hours)]	0.0	2	1	1	1
89002	1710	retention of the brca1 allele	[Retention of the BRCA1 allele]	0.0	5	1	1	1
89003	1710	b-cell factor ebf	[B-cell factor EBF]	0.0	3	2	2	1
89004	1710	pharmacological basis	[pharmacological basis]	0.0	2	1	1	1
89005	1710	c-jun rrna	[c-jun mRNAs]	0.0	2	1	1	1
89006	1710	participation of cis-acting regulatory element	[participation of cis-acting regulatory elements]	0.0	5	1	1	1
89007	1710	alpha beta ligation	[alpha beta ligation]	0.0	3	1	1	1
89008	1710	p3hr-1 strain	[P3HR-1 strain]	0.0	2	1	1	1
89009	1710	hormone gene	[hormone gene]	0.0	2	1	1	1
89010	1710	molecular defect(s)	[molecular defect(s)]	0.0	2	1	1	1
89011	1710	excessive expression of lymphokine	[excessive expression of lymphokines]	0.0	4	1	1	1
89012	1710	stat5-	[STAT5-]	0.0	1	1	1	1
89013	1710	new variant translocation in leukaemia	[new variant translocation in leukaemia]	0.0	5	1	1	1
89014	1710	ferritin expression	[ferritin expression]	0.0	2	1	1	1
89015	1710	light on the mechanism regulate apoptosis	[light on the mechanisms regulating apoptosis]	0.0	6	1	1	1
89016	1710	patient (range from 11.1	[patients (ranging from 11.1]	0.0	4	1	1	1
89017	1710	cytoplasmic terminus ct	[cytoplasmic terminus CT]	0.0	3	1	1	1
89018	1710	expression of PML/RARalpha	[expression of PML/RARalpha]	0.0	3	1	1	1
89019	1710	splenic t-lymphocyte culture	[splenic T-lymphocytes culture]	0.0	3	1	1	1
89020	1710	binding of transcription factor essential	[binding of transcription factors essential]	0.0	5	1	1	1
89021	1710	repeat quasispecy	[repeat quasispecies]	0.0	2	1	1	1
89022	1710	reduction in il-2r alpha	[reduction in IL-2R alpha]	0.0	4	1	1	1
89023	1710	stigmata	[stigmata]	0.0	1	1	1	1
89024	1710	unrecognized form of acute leukemia	[unrecognized form of acute leukemia]	0.0	5	2	2	1
89025	1710	structural complementarity for residue	[structural complementarity for residue]	0.0	4	1	1	1
89026	1710	regulation of the machinery	[regulation of the machinery]	0.0	4	1	1	1
89027	1710	documented significance	[documented) significance]	0.0	2	1	1	1
89028	1710	0.025) to il-1 beta huvec	[0.025) to IL-1 beta HUVEC]	0.0	5	1	1	1
89029	1710	significant correlation of the level	[significant correlations of the levels]	0.0	5	1	1	1
89030	1710	induction of the cycle	[induction of the cycle]	0.0	4	1	1	1
89031	1710	NF-kappaB gene expression	[NF-kappaB gene expression]	0.0	3	1	1	1
89032	1710	wide variety of disease state	[wide variety of disease states]	0.0	5	1	1	1
89033	1710	signal system lead	[signaling systems leading]	0.0	3	1	1	1
89034	1710	k562 cell erythroid differentiation	[K562 cells erythroid differentiation]	0.0	4	1	1	1
89035	1710	change in lymphocyte of person	[changes in lymphocytes of persons]	0.0	5	1	1	1
89036	1710	finally 6 week	[finally 6 weeks]	0.0	3	1	1	1
89037	1710	marker of u-937 cell differentiation	[markers of U-937 cell differentiation]	0.0	5	1	1	1
89038	1710	principal mediator of tcell rescue	[principal mediator of Tcell rescue]	0.0	5	1	1	1
89039	1710	study at the protein level	[study at the protein level]	0.0	5	1	1	1
89040	1710	protein/protein interaction	[protein/protein interactions]	0.0	2	1	1	1
89041	1710	hashimoto disease	[Hashimoto's disease]	0.0	2	1	1	1
89042	1710	stat1,	[STAT1,]	0.0	1	1	1	1
89043	1710	sulfonyl)-2-methylpiperazine a inhibitor	[sulfonyl)-2-methylpiperazine an inhibitor]	0.0	3	1	1	1
89044	1710	32-36 day	[32-36 days]	0.0	2	1	1	1
89045	1710	repeat element-1	[repeats element-1]	0.0	2	1	1	1
89046	1710	interaction with other protein	[interactions with other proteins]	0.0	4	1	1	1
89047	1710	sr-bp high for sr	[SR-BP higher for SR]	0.0	4	1	1	1
89048	1710	receptor expression in human t-	[receptor expression in human T-]	0.0	5	1	1	1
89049	1710	point toward defect	[pointing toward defects]	0.0	3	1	1	1
89050	1710	thus for monocyte infiltration in plaque	[thus for monocyte infiltration in plaques]	0.0	6	1	1	1
89051	1710	host control of hiv-1 parasitism	[Host control of HIV-1 parasitism]	0.0	5	1	1	1
89052	1710	proliferate hematopoietic cell	[proliferating hematopoietic cells]	0.0	3	1	1	1
89053	1710	special culture condition	[special cultures conditions]	0.0	3	1	1	1
89054	1710	respect to regulation	[respect to regulation]	0.0	3	1	1	1
89055	1710	EWG	[EWG]	0.0	1	1	1	1
89056	1710	patient with various disease four	[patients with various diseases four]	0.0	5	1	1	1
89057	1710	sclerosis gene tsc2	[sclerosis gene TSC2]	0.0	3	1	1	1
89058	1710	/anti-cd28 T lymphocyte	[/anti-CD28 T lymphocytes]	0.0	3	1	1	1
89059	1710	resistance in major disorder	[resistance in major disorder]	0.0	4	2	2	1
89060	1710	isoquinoline derivative	[isoquinoline derivative]	0.0	2	1	1	1
89061	1710	quantification of glucocorticoid expression during differentiation	[quantification of glucocorticoid expression during differentiation]	0.0	6	1	1	1
89062	1710	include allergy	[including allergy]	0.0	2	1	1	1
89063	1710	signal from patient with immunodeficiency	[signaling from patients with immunodeficiency]	0.0	5	1	1	1
89064	1710	moreover, M-CSF expression of the gene	[Moreover, M-CSF expression of the gene]	0.0	6	1	1	1
89065	1710	Differential induction of interferon protein	[Differential induction of interferon protein]	0.0	5	1	1	1
89066	1710	x box sequence	[X box sequences]	0.0	3	1	1	1
89067	1710	monocytic nuclear factor-kappa b	[monocytic nuclear factor-kappa B]	0.0	4	1	1	1
89068	1710	strict dependence activity	[Strict dependence activity]	0.0	3	1	1	1
89069	1710	abnormal protein expression	[abnormal protein expression]	0.0	3	1	1	1
89070	1710	225/EGR1	[225/EGR1]	0.0	1	1	1	1
89071	1710	3 autoantigen	[3 autoantigens]	0.0	2	1	1	1
89072	1710	nur77 mouse	[nur77 mice]	0.0	2	1	1	1
89073	1710	spi-b	[spi-B]	0.0	1	1	1	1
89074	1710	bone morphogenetic protein-	[bone morphogenetic protein-]	0.0	3	1	1	1
89075	1710	anti-Class ii	[anti-Class II]	0.0	2	1	1	1
89076	1710	emission	[emission]	0.0	1	1	1	1
89077	1710	onset within 1-2 min.	[onset within 1-2 min.]	0.0	4	1	1	1
89078	1710	cell stimulation	[cell stimulation]	0.0	2	1	1	1
89079	1710	express the dominant ikappab	[expressing the dominant IkappaB]	0.0	4	1	1	1
89080	1710	multiple DNA-protein complex with extract	[multiple DNA-protein complexes with extracts]	0.0	5	1	1	1
89081	1710	virus type HTLV-I	[virus type HTLV-I]	0.0	3	1	1	1
89082	1710	biological characteristic of carcinoma	[biological characteristics of carcinomas]	0.0	4	1	1	1
89083	1710	stimulation with different gc at concentration	[Stimulation with different GC at concentrations]	0.0	6	1	1	1
89084	1710	affinity column	[affinity column]	0.0	2	1	1	1
89085	1710	response by this mechanism	[responses by these mechanisms]	0.0	4	1	1	1
89086	1710	transfection study a e(2) receptor-negative line,	[transfection studies an E(2) receptor-negative line,]	0.0	6	1	1	1
89087	1710	binding motif of HS-40	[binding motifs of HS-40]	0.0	4	1	1	1
89088	1710	use immunocytochemical method	[using immunocytochemical methods]	0.0	3	1	1	1
89089	1710	g/g of total mrna in lymphocyte	[g/g of total mRNA in lymphocytes]	0.0	6	1	1	1
89090	1710	transcription factor- kappab activation	[transcription factor- kappaB activation]	0.0	4	1	1	1
89091	1710	-contain protein	[-containing proteins]	0.0	2	1	1	1
89092	1710	autoregulation in im-9 cell	[autoregulation in IM-9 cells]	0.0	4	1	1	1
89093	1710	maximal expression of cytokine	[maximal expression of cytokines]	0.0	4	1	1	1
89094	1710	signal converge in common intracellular pathway	[signals converging in common intracellular pathways]	0.0	6	1	1	1
89095	1710	induction of expression of phenotype	[induction of expression of phenotypes]	0.0	5	1	1	1
89096	1710	rna to SRG3 mrna	[RNA to SRG3 mRNA]	0.0	4	1	1	1
89097	1710	specific nuclear factor( binding	[specific nuclear factor(s) binding]	0.0	4	1	1	1
89098	1710	nonmatrix	[nonmatrix]	0.0	1	1	1	1
89099	1710	b differentiation	[B differentiation]	0.0	2	1	1	1
89100	1710	infection with the immunodeficiency virus	[Infection with the immunodeficiency virus]	0.0	5	1	1	1
89101	1710	stromal-derived cytokine interleukin-7	[stromal-derived cytokine interleukin-7]	0.0	3	1	1	1
89102	1710	induction of nf-kappa b/rel activity	[induction of NF-kappa B/Rel activity]	0.0	5	1	1	1
89103	1710	immediate-early viral transactivator BZLF1 Z	[immediate-early viral transactivators BZLF1 Z]	0.0	5	1	1	1
89104	1710	three candidate gene hepatic factor beta	[three candidate genes hepatic factor beta]	0.0	6	1	1	1
89105	1710	Communication	[Communication]	0.0	1	1	1	1
89106	1710	effect on basal level	[effect on basal levels]	0.0	4	1	1	1
89107	1710	ndp kinase expression	[NDP kinase expression]	0.0	3	1	1	1
89108	1710	ap-1 -binding activity in 1e8 cell	[AP-1 -binding activity in 1E8 cells]	0.0	6	1	1	1
89109	1710	camp -dependent pathway	[cAMP -dependent pathway]	0.0	3	1	1	1
89110	1710	target for CTL	[target for CTL]	0.0	3	1	1	1
89111	1710	express ad2/ad12 e1a gene product	[expressing Ad2/Ad12 E1A gene products]	0.0	5	1	1	1
89112	1710	regulatory process	[regulatory process]	0.0	2	1	1	1
89113	1710	increase in expression	[increase in expression]	0.0	3	1	1	1
89114	1710	indicate regulation	[indicating regulation]	0.0	2	1	1	1
89115	1710	alternative phagocyte glomerular mesangial cell	[alternative phagocytes glomerular mesangial cells]	0.0	5	1	1	1
89116	1710	Tepoxalin a enzyme inhibitor of cyclooxygenase	[Tepoxalin a enzyme inhibitor of cyclooxygenase]	0.0	6	1	1	1
89117	1710	2-3-fold decrease	[2-3-fold decrease]	0.0	2	1	1	1
89118	1710	further evidence for the modulation	[further evidence for the modulation]	0.0	5	1	1	1
89119	1710	hexamethylene	[hexamethylene]	0.0	1	2	2	1
89120	1710	Lewis X	[Lewis X]	0.0	2	1	1	1
89121	1710	distinct effect on pattern	[distinct effect on patterns]	0.0	4	1	1	1
89122	1710	effect of dopamine	[effect of dopamine]	0.0	3	1	1	1
89123	1710	prerequisite for differentiation	[prerequisite for differentiation]	0.0	3	1	1	1
89124	1710	fp treatment	[FP treatment]	0.0	2	1	1	1
89125	1710	unliganded receptor	[unliganded receptors]	0.0	2	1	1	1
89126	1710	h&e-stained section	[H&E-stained sections]	0.0	2	1	1	1
89127	1710	role in the life cycle	[role in the life cycle]	0.0	5	1	1	1
89128	1710	follow administration of ad vector	[following administrations of Ad vectors]	0.0	5	1	1	1
89129	1710	transcription-PCR assay for gene expression	[transcription-PCR assay for gene expression]	0.0	5	1	1	1
89130	1710	use hematopoietic progenitor cell HPC	[using hematopoietic progenitor cells HPC]	0.0	5	1	1	1
89131	1710	vitro study use recombinant p21ras	[vitro studies using recombinant p21ras]	0.0	5	1	1	1
89132	1710	inhibitor of mek1	[inhibitor of MEK1]	0.0	3	1	1	1
89133	1710	oncogene rel	[oncogene rel]	0.0	2	1	1	1
89134	1710	human matrix metalloproteinase 9	[human matrix metalloproteinase 9]	0.0	4	1	1	1
89135	1710	steroid antagonist	[steroid antagonist]	0.0	2	1	1	1
89136	1710	M-CSF expression	[M-CSF expression]	0.0	2	1	1	1
89137	1710	characteristic of htlv-i infection	[characteristic of HTLV-I infection]	0.0	4	1	1	1
89138	1710	interaction between transcript-2/leukocyte ig-like receptor	[Interaction between transcript-2/leukocyte Ig-like receptor]	0.0	5	1	1	1
89139	1710	molecular mechanism underlie selective expression	[Molecular mechanisms underlying selective expression]	0.0	5	1	1	1
89140	1710	incubation of cell in hypoxia	[Incubation of cells in hypoxia]	0.0	5	1	1	1
89141	1710	pattern of inhibition	[pattern of inhibition]	0.0	3	1	1	1
89142	1710	interleukin-9 receptor alpha chain	[interleukin-9 receptor alpha chain]	0.0	4	1	1	1
89143	1710	distinct normalize effect increase	[distinct normalizing effect increase]	0.0	4	1	1	1
89144	1710	contain bp of -flanking sequence	[containing bp of -flanking sequence]	0.0	5	1	1	1
89145	1710	deregulation of gene encode	[deregulation of genes encoding]	0.0	4	1	1	1
89146	1710	subject in patient	[subjects in patients]	0.0	3	1	1	1
89147	1710	treatment tur cell with okadaic acid	[Treatment TUR cells with okadaic acid]	0.0	6	1	1	1
89148	1710	primary sjogren' syndrome	[Primary Sjogren's syndrome]	0.0	3	1	1	1
89149	1710	tnf factor traf2 traf3	[TNF factor TRAF2 TRAF3]	0.0	4	1	1	1
89150	1710	zinc-finger motif	[zinc-finger motifs]	0.0	2	1	1	1
89151	1710	gene activator protein eklf	[gene activator protein EKLF]	0.0	4	1	1	1
89152	1710	RNA protein kinase	[RNA protein kinase]	0.0	3	1	1	1
89153	1710	(an enzyme	[(an enzyme]	0.0	2	1	1	1
89154	1710	also a potent scavenger	[also a potent scavenger]	0.0	4	1	1	1
89155	1710	effect on stat5b tyrosine phosphorylation.	[effect on STAT5b tyrosine phosphorylation.]	0.0	5	1	1	1
89156	1710	tissue homeostasis	[tissue homeostasis]	0.0	2	1	1	1
89157	1710	response to a cyclic load	[response to a cyclic load]	0.0	5	1	1	1
89158	1710	acute lymphoblastic t-cell line	[acute lymphoblastic T-cell line]	0.0	4	1	1	1
89159	1710	DQB X-box	[DQB X-box]	0.0	2	1	1	1
89160	1710	treatment with mutant form of lps	[Treatment with mutant forms of LPS]	0.0	6	1	1	1
89161	1710	nf-kappab p65	[NF-kappaB p65]	0.0	2	1	1	1
89162	1710	mediator in the inflammatory response	[mediators in the inflammatory response]	0.0	5	1	1	1
89163	1710	8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
89164	1710	various rheumatic disease four	[various rheumatic diseases four]	0.0	4	1	1	1
89165	1710	POUHD solution	[POUHD solution]	0.0	2	1	1	1
89166	1710	resistance to protease	[resistance to proteases]	0.0	3	1	1	1
89167	1710	basis for the regulation	[basis for the regulation]	0.0	4	1	1	1
89168	1710	encode a protein bind protein hxbp-1	[encoding a protein binding protein hXBP-1]	0.0	6	1	1	1
89169	1710	elusive oct2 target gene	[elusive Oct2 target genes]	0.0	4	1	1	1
89170	1710	thrombin generation	[Thrombin generation]	0.0	2	2	2	1
89171	1710	Ph' the hallmark	[Ph' the hallmark]	0.0	3	1	1	1
89172	1710	establish pbmc culture (1.5	[establishing PBMC cultures (1.5]	0.0	4	1	1	1
89173	1710	secondary hyperparathyroidism to failure	[secondary hyperparathyroidism to failure]	0.0	4	1	1	1
89174	1710	increase in the rate	[increase in the rate]	0.0	4	1	1	1
89175	1710	primary rodent cell	[primary rodent cells]	0.0	3	1	1	1
89176	1710	mutant incapable	[mutant incapable]	0.0	2	1	1	1
89177	1710	transcription binding site	[transcription binding sites]	0.0	3	1	1	1
89178	1710	nuclear transcriptional factor	[nuclear transcriptional factors]	0.0	3	1	1	1
89179	1710	constitutive expression of interferon isotype	[Constitutive expression of interferon isotypes]	0.0	5	1	1	1
89180	1710	binding to the glucocorticoid receptor	[binding to the glucocorticoid receptor]	0.0	5	1	1	1
89181	1710	distribution of immunoglobulin gene evidence	[distribution of immunoglobulin genes evidence]	0.0	5	1	1	1
89182	1710	functional context for activation	[functional context for activation]	0.0	4	1	1	1
89183	1710	bend in the DNA helix,	[bend in the DNA helix,]	0.0	5	1	1	1
89184	1710	very low, physiological concentration	[very low, physiological concentrations]	0.0	4	2	2	1
89185	1710	antibody monoclonal antibody phase-1 neutrophil adhesion	[antibodies monoclonal antibodies phase-1 neutrophil adhesion]	0.0	6	1	1	1
89186	1710	c-fo promoter activity	[c-fos promoter activity]	0.0	3	2	2	1
89187	1710	role for FGF receptor	[role for FGF receptors]	0.0	4	1	1	1
89188	1710	inefficient termination	[Inefficient termination]	0.0	2	1	1	1
89189	1710	basis for a hypothesis	[basis for an hypothesis]	0.0	4	1	1	1
89190	1710	single case of AML m4	[single case of AML M4]	0.0	5	1	1	1
89191	1710	provide the early transactivator bzlf1	[providing the early transactivator BZLF1]	0.0	5	1	1	1
89192	1710	characterization of Grb2-binding protein	[Characterization of Grb2-binding proteins]	0.0	4	1	1	1
89193	1710	impaired binding	[impaired binding]	0.0	2	1	1	1
89194	1710	specific signal for initiation.	[specific signals for initiation.]	0.0	4	1	1	1
89195	1710	Peripheral T	[Peripheral T]	0.0	2	1	1	1
89196	1710	histocompatibility class I molecule	[histocompatibility class I molecules]	0.0	4	1	1	1
89197	1710	tpa factor	[TPA factor]	0.0	2	1	1	1
89198	1710	activity of egl	[activity of eGLs]	0.0	3	1	1	1
89199	1710	ineffectiveness	[ineffectiveness]	0.0	1	2	2	1
89200	1710	abnormality of cellular receptor	[abnormalities of cellular receptors]	0.0	4	1	1	1
89201	1710	aortic ec activity	[aortic EC activity]	0.0	3	1	1	1
89202	1710	challenge,	[challenge,]	0.0	1	1	1	1
89203	1710	further information on the molecular event	[further information on the molecular events]	0.0	6	1	1	1
89204	1710	constitutive binding between JAK1	[constitutive binding between JAK1]	0.0	4	1	1	1
89205	1710	stat 6	[STAT 6]	0.0	2	1	1	1
89206	1710	stat 3	[STATs 3]	0.0	2	1	1	1
89207	1710	Ectopic expression	[Ectopic expression]	0.0	2	3	3	1
89208	1710	variant of Jurkat cell	[variants of Jurkat cells]	0.0	4	1	1	1
89209	1710	leukemia cell in bandshift assay	[leukemia cells in bandshift assays]	0.0	5	1	1	1
89210	1710	disposition implication for hypersensitivity	[disposition implications for hypersensitivity]	0.0	4	1	1	1
89211	1710	Differential induction of activity	[Differential induction of activities]	0.0	4	1	1	1
89212	1710	icam-1 message	[ICAM-1 message]	0.0	2	1	1	1
89213	1710	putative new human retrovirus	[putative new human retrovirus]	0.0	4	1	1	1
89214	1710	synergy in cd8+cd18bright T cell	[synergy in CD8+CD18bright T cells]	0.0	5	1	1	1
89215	1710	granulocytic lineage acid	[granulocytic lineage acid]	0.0	3	1	1	1
89216	1710	phosphatase-positive multinucleated cell from human monocyte	[phosphatase-positive multinucleated cells from human monocytes]	0.0	6	1	1	1
89217	1710	expression of th1/th2-like cytokine	[expression of Th1/Th2-like cytokines]	0.0	4	1	1	1
89218	1710	addition to adhesive role,	[addition to adhesive role,]	0.0	4	1	1	1
89219	1710	trigger (s) by CD40 ligand	[triggering (s) by CD40 ligands]	0.0	5	1	1	1
89220	1710	mechanism of proliferation cessation	[mechanisms of proliferation cessation]	0.0	4	1	1	1
89221	1710	block of transcription	[block of transcription]	0.0	3	1	1	1
89222	1710	member of the NFAT	[members of the NFAT]	0.0	4	1	1	1
89223	1710	near-perfect repeat DR of 21 bp	[near-perfect repeats DR of 21 bp]	0.0	6	1	1	1
89224	1710	kinase C	[kinase C]	0.0	2	1	1	1
89225	1710	property of the receptor gr	[properties of the receptors GR]	0.0	5	1	1	1
89226	1710	medium pge2	[medium PGE2]	0.0	2	1	1	1
89227	1710	induction 10 follow differentiation	[induction 10 following differentiation]	0.0	4	1	1	1
89228	1710	fosb gene	[FOSB gene]	0.0	2	2	2	1
89229	1710	signal transduction defect	[signal transduction defect]	0.0	3	1	1	1
89230	1710	mononitrosyl iron complex	[mononitrosyl iron complexes]	0.0	3	1	1	1
89231	1710	adhesion molecule-1 on umbilical vein cell	[adhesion molecule-1 on umbilical vein cells]	0.0	6	1	1	1
89232	1710	15.5 (p p	[15.5 (P P]	0.0	3	1	1	1
89233	1710	mar-binding protein from matrix preparation	[MAR-binding protein from matrix preparations]	0.0	5	1	1	1
89234	1710	consensus sequence G(or C)CTGTG	[consensus sequence G(or C)CTGTG]	0.0	4	1	1	1
89235	1710	promoter within the pcd41 sequence	[promoter within the pCD41 sequence]	0.0	5	1	1	1
89236	1710	precise role of this kinase	[precise roles of this kinase]	0.0	5	1	1	1
89237	1710	role in growth transformation	[role in growth transformation]	0.0	4	1	1	1
89238	1710	cell-b	[cell-B]	0.0	1	1	1	1
89239	1710	40-fold okadaic acid exposure	[40-fold okadaic acid exposure]	0.0	4	1	1	1
89240	1710	affinity site	[affinity site]	0.0	2	2	2	1
89241	1710	x pathway	[X pathway]	0.0	2	1	1	1
89242	1710	fourfold decrease in potency	[fourfold decrease in potency]	0.0	4	1	1	1
89243	1710	Janus family of kinase	[Janus family of kinases]	0.0	4	1	1	1
89244	1710	evaluate epithelium for the presence	[evaluating epithelium for the presence]	0.0	5	1	1	1
89245	1710	role alter the status	[role altering the status]	0.0	4	1	1	1
89246	1710	signal result in promoter activation	[signal resulting in promoter activation]	0.0	5	1	1	1
89247	1710	fibrosarcoma 8, histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma 8, histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
89248	1710	two family RA receptor	[two families RA receptors]	0.0	4	1	1	1
89249	1710	malignant transformation of lymphoid cell	[malignant transformation of lymphoid cells]	0.0	5	1	1	1
89250	1710	heterodimer p50/p65	[heterodimer p50/p65]	0.0	2	1	1	1
89251	1710	tax -responsive element 1 tre-1	[Tax -responsive element 1 TRE-1]	0.0	5	1	1	1
89252	1710	nucleotide dr+4	[nucleotides DR+4]	0.0	2	1	1	1
89253	1710	termination in the Jak3 JH4 domain	[termination in the Jak3 JH4 domain]	0.0	6	1	1	1
89254	1710	authors' observation	[authors' observations]	0.0	2	1	1	1
89255	1710	molecular cloning a slp-76 phosphoprotein	[molecular cloning a SLP-76 phosphoprotein]	0.0	5	1	1	1
89256	1710	mouse il-2	[mouse IL-2]	0.0	2	1	1	1
89257	1710	transcription (stat) activation pathway	[transcription (STAT) activation pathways]	0.0	4	1	1	1
89258	1710	protein-binding site within the regulatory element	[protein-binding sites within the regulatory element]	0.0	6	1	1	1
89259	1710	induce expression from cycle promoter	[inducing expression from cycle promoters]	0.0	5	1	1	1
89260	1710	different effect on the gene	[different effects on the genes]	0.0	5	1	1	1
89261	1710	closely related member	[closely related members]	0.0	3	1	1	1
89262	1710	anabolism	[anabolism]	0.0	1	1	1	1
89263	1710	contain as little as 50 ng	[containing as little as 50 ng]	0.0	6	1	1	1
89264	1710	Pyrrolidinedithiocarbamate	[Pyrrolidinedithiocarbamate]	0.0	1	1	1	1
89265	1710	h+-atpase v-atpase	[H+-ATPase V-ATPase]	0.0	2	1	1	1
89266	1710	tract with bv	[tracts with BV]	0.0	3	1	1	1
89267	1710	45 bp downstream	[45 bp downstream]	0.0	3	1	1	1
89268	1710	MHC class -cell	[MHC class -cells]	0.0	3	1	1	1
89269	1710	active SHP1 -DeltaSH2	[active SHP1 -DeltaSH2]	0.0	3	1	1	1
89270	1710	significant effect on basal level	[significant effect on basal levels]	0.0	5	1	1	1
89271	1710	NF-AT complex	[NF-AT complex]	0.0	2	1	1	1
89272	1710	NF-E1 ref 1-3	[NF-E1 refs 1-3]	0.0	3	1	1	1
89273	1710	early cycle gene	[early cycle genes]	0.0	3	1	1	1
89274	1710	calcitriol ethanol concentration 0.0001% v/v)	[calcitriol ethanol concentration 0.0001% v/v)]	0.0	5	1	1	1
89275	1710	transactivate protein tax	[transactivating protein Tax]	0.0	3	1	1	1
89276	1710	immunoglobulin igh locus	[immunoglobulin IgH locus]	0.0	3	1	1	1
89277	1710	four probe	[four probes]	0.0	2	1	1	1
89278	1710	response of blood cell	[responses of blood cells]	0.0	4	1	1	1
89279	1710	presence on Teflon	[presence on Teflon]	0.0	3	1	1	1
89280	1710	the/thf 1.87+/-0.36) alpha thf/thf	[THE/THF 1.87+/-0.36) alpha THF/THF]	0.0	4	1	1	1
89281	1710	direct evidence for the requirement	[direct evidence for the requirement]	0.0	5	1	1	1
89282	1710	twenty-seven patient	[Twenty-seven patients]	0.0	2	1	1	1
89283	1710	immune deficiency virus type 1 hiv-1	[immune deficiency virus type 1 HIV-1]	0.0	6	1	1	1
89284	1710	hexameric receptor binding site	[hexameric receptor binding sites]	0.0	4	1	1	1
89285	1710	factor bind 4681 to 4701	[Factors binding 4681 to 4701]	0.0	5	1	1	1
89286	1710	interact element	[interacting elements]	0.0	2	1	1	1
89287	1710	Scatchard analysis,	[Scatchard analysis,]	0.0	2	1	1	1
89288	1710	16 residue	[16 residues]	0.0	2	1	1	1
89289	1710	nf-at factor of T cell	[NF-AT factor of T cells]	0.0	5	1	1	1
89290	1710	various immediate serum gene	[various immediate serum genes]	0.0	4	1	1	1
89291	1710	development; addition of RA	[development; addition of RA]	0.0	4	1	1	1
89292	1710	interleukin receptor alpha-chain gene	[interleukin receptor alpha-chain gene]	0.0	4	2	2	1
89293	1710	role in the terminal differentiation	[role in the terminal differentiation]	0.0	5	1	1	1
89294	1710	G1,	[G1,]	0.0	1	1	1	1
89295	1710	loop peptide	[loop peptides]	0.0	2	1	1	1
89296	1710	homodimeric protein	[homodimeric proteins]	0.0	2	1	1	1
89297	1710	long repeat-luciferase construct	[long repeat-luciferase constructs]	0.0	3	1	1	1
89298	1710	incubation with the anti-rabbit hsp90 antibody	[incubation with the anti-rabbit hsp90 antibody]	0.0	6	1	1	1
89299	1710	cell),	[cell),]	0.0	1	1	1	1
89300	1710	cell).	[cell).]	0.0	1	1	1	1
89301	1710	possibly lie at the level	[possibly lying at the level]	0.0	5	1	1	1
89302	1710	suppressive effect of mpl	[suppressive effect of MPL]	0.0	4	1	1	1
89303	1710	migration rate of pmn	[migration rate of PMN]	0.0	4	1	1	1
89304	1710	cd34+thy-l-cd45ra+ subset	[CD34+Thy-l-CD45RA+ subset]	0.0	2	1	1	1
89305	1710	molecular link between product	[molecular link between products]	0.0	4	1	1	1
89306	1710	counter-anion thioglucose tg	[counter-anion thioglucose TG]	0.0	3	1	1	1
89307	1710	form of the nf-kappab inhibitor	[form of the NF-kappaB inhibitor]	0.0	5	1	1	1
89308	1710	nonproductive hiv-1 infection	[nonproductive HIV-1 infection]	0.0	3	1	1	1
89309	1710	aml -m1	[AML -M1]	0.0	2	1	1	1
89310	1710	pathogenesis of acute leukemia	[pathogenesis of acute leukemia]	0.0	4	2	2	1
89311	1710	Missense mutation	[Missense mutation]	0.0	2	1	1	1
89312	1710	IL-2 -secreting cell	[IL-2 -secreting cells]	0.0	3	1	1	1
89313	1710	patient suggest great than thought.	[patient suggesting greater than thought.]	0.0	5	1	1	1
89314	1710	region in the AIDS retrovirus	[region in the AIDS retrovirus]	0.0	5	1	1	1
89315	1710	progenitor cell growth	[progenitor cell growth]	0.0	3	1	1	1
89316	1710	two strain of hhv-6	[Two strains of HHV-6]	0.0	4	1	1	1
89317	1710	similar regulatory response	[similar regulatory response]	0.0	3	1	1	1
89318	1710	mapping study within the E1A gene	[mapping studies within the E1A gene]	0.0	6	1	1	1
89319	1710	other phenotypic characteristic of differentiation	[other phenotypic characteristics of differentiation]	0.0	5	1	1	1
89320	1710	48 hour time culture	[48 hours time culture]	0.0	4	2	2	1
89321	1710	microg/g tissue	[microg/g tissue]	0.0	2	1	1	1
89322	1710	(range, 4.27 (range, 4-.11),	[(range, 4.27 (range, 4-5.13),]	0.0	4	1	1	1
89323	1710	cck-8 effect	[CCK-8 effect]	0.0	2	1	1	1
89324	1710	approach treat IBD	[approaches treating IBD]	0.0	3	1	1	1
89325	1710	biological modification	[biological modifications]	0.0	2	1	1	1
89326	1710	human th2 clone	[human Th2 clones]	0.0	3	1	1	1
89327	1710	perhaps in B-cell transformation	[perhaps in B-cell transformation]	0.0	4	1	1	1
89328	1710	macrophage maturation,	[macrophage maturation,]	0.0	2	1	1	1
89329	1710	intravenous injection	[Intravenous injection]	0.0	2	1	1	1
89330	1710	association with disorder	[association with disorders]	0.0	3	1	1	1
89331	1710	FT4	[FT4]	0.0	1	1	1	1
89332	1710	Chignard, M. (1993)	[Chignard, M. (1993)]	0.0	3	1	1	1
89333	1710	receptor in lymphocyte in anorexia nervosa	[receptors in lymphocytes in anorexia nervosa]	0.0	6	1	1	1
89334	1710	class non-inducible RB tumor line	[class non-inducible RB tumor lines]	0.0	5	1	1	1
89335	1710	event in CD40 signal	[event in CD40 signaling]	0.0	4	1	1	1
89336	1710	b-acute leukemia	[B-acute leukemia]	0.0	2	1	1	1
89337	1710	high histologic grade	[high histologic grade]	0.0	3	1	1	1
89338	1710	migration response towards mcp-1	[migration response towards MCP-1]	0.0	4	1	1	1
89339	1710	role in cell type	[roles in cell types]	0.0	4	1	1	1
89340	1710	senescent T lymphocyte culture	[Senescent T lymphocyte cultures]	0.0	4	1	1	1
89341	1710	glucocorticoid -receptor antagonist	[glucocorticoid -receptor antagonist]	0.0	3	1	1	1
89342	1710	continuous presence of erythropoietin	[continuous presence of erythropoietin]	0.0	4	1	1	1
89343	1710	gene, suppressor of cytokine	[gene, suppressor of cytokine]	0.0	4	1	1	1
89344	1710	gata1 mrna induction	[GATA1 mRNA induction]	0.0	3	1	1	1
89345	1710	absence of any stimulus.	[absence of any stimulus.]	0.0	4	1	1	1
89346	1710	new field in immunology	[new field in immunology]	0.0	4	1	1	1
89347	1710	change in p21ras	[change in p21ras]	0.0	3	1	1	1
89348	1710	serine in the domain	[serine in the domain]	0.0	4	1	1	1
89349	1710	cis inactivation	[cis inactivation]	0.0	2	1	1	1
89350	1710	fourfold susceptibility in case-control study	[fourfold susceptibility in case-control studies]	0.0	5	1	1	1
89351	1710	several 4,19-substituted steroid	[Several 4,19-substituted steroids]	0.0	3	1	1	1
89352	1710	estrogen receptor er in monocyte	[estrogen receptor ER in monocytes]	0.0	5	1	1	1
89353	1710	contribution to the pathogenesis	[contribution to the pathogenesis]	0.0	4	1	1	1
89354	1710	somatic mutation a proto-oncogene encoding	[somatic mutations a proto-oncogene encoding]	0.0	5	1	1	1
89355	1710	huvec 75%	[HUVECs 75%]	0.0	2	1	1	1
89356	1710	irf- CAT	[IRF- CAT]	0.0	2	1	1	1
89357	1710	activity of SV40 promoter	[activities of SV40 promoter]	0.0	4	1	1	1
89358	1710	regulate normal differentiation	[regulating normal differentiation]	0.0	3	1	1	1
89359	1710	up-regulation of RB protein expression	[up-regulation of RB protein expression]	0.0	5	1	1	1
89360	1710	hierarchy of control	[hierarchy of control]	0.0	3	1	1	1
89361	1710	fragment of Oct-2	[fragment of Oct-2]	0.0	3	1	1	1
89362	1710	exhibit activity	[exhibiting activity]	0.0	2	1	1	1
89363	1710	oestrogen -receptive organ	[oestrogen -receptive organs]	0.0	3	1	1	1
89364	1710	day hematopoietic liver	[day hematopoietic liver]	0.0	3	1	1	1
89365	1710	match point mutation	[matching point mutations]	0.0	3	1	1	1
89366	1710	genetic characterization of the variant allele	[genetic characterization of the variant allele]	0.0	6	1	1	1
89367	1710	(6 wk to 12 mo)	[(6 wk to 12 mo)]	0.0	5	1	1	1
89368	1710	phenotypic marker of subpopulation t-	[phenotypic marker of subpopulations T-]	0.0	5	1	1	1
89369	1710	activation of interleukin gene expression	[activation of interleukin gene expression]	0.0	5	1	1	1
89370	1710	primary T cell from blood	[primary T cells from blood]	0.0	5	1	1	1
89371	1710	slight augmentation	[slight augmentation]	0.0	2	1	1	1
89372	1710	removal of residue	[removal of residues]	0.0	3	1	1	1
89373	1710	erythroid cell a phenotype	[erythroid cells a phenotype]	0.0	4	1	1	1
89374	1710	expression of a immediate-early protein bzlf1	[expression of a immediate-early protein BZLF1]	0.0	6	1	1	1
89375	1710	product of bzlf1	[product of BZLF1]	0.0	3	1	1	1
89376	1710	patient aged years, (range	[patients aged years, (ranging]	0.0	4	1	1	1
89377	1710	acylation	[Acylation]	0.0	1	1	1	1
89378	1710	early (ie62) protein vzv	[early (IE62) protein VZV]	0.0	4	1	1	1
89379	1710	NFAT delta418	[NFAT delta418]	0.0	2	1	1	1
89380	1710	effect 1) inhibition depletion	[effects 1) inhibition depletion]	0.0	4	1	1	1
89381	1710	t-cell activation: purification	[T-cell activation: purification]	0.0	3	1	1	1
89382	1710	element within the 5'-untranslated region	[elements within the 5'-untranslated region]	0.0	5	1	1	1
89383	1710	Ig chain switch region sequence	[Ig chain switch region sequences]	0.0	5	1	1	1
89384	1710	development in Hox11 null mouse	[development in Hox11 null mice]	0.0	5	1	1	1
89385	1710	region of 142 residue	[region of 142 residues]	0.0	4	1	1	1
89386	1710	gene in the cell	[genes in the cells]	0.0	4	1	1	1
89387	1710	membrane protein promoter	[membrane protein promoter]	0.0	3	1	1	1
89388	1710	transcription-activateactivateactivateactivating domain	[transcription-activating domain]	0.0	2	1	1	1
89389	1710	negative-acting element	[negative-acting elements]	0.0	2	1	1	1
89390	1710	lack exon 11	[lacking exon 11]	0.0	3	1	1	1
89391	1710	I (p55)	[I (p55)]	0.0	2	1	1	1
89392	1710	reduce component current	[reducing components current]	0.0	3	1	1	1
89393	1710	element upstream of -224	[element upstream of -224,]	0.0	4	1	1	1
89394	1710	permissive enhancer/ promoter interaction	[permissive enhancer/ promoter interaction]	0.0	4	1	1	1
89395	1710	promoter erratum	[promoter erratum]	0.0	2	1	1	1
89396	1710	fasl interaction	[FasL interaction]	0.0	2	1	1	1
89397	1710	important positive regulatory element	[important positive regulatory element]	0.0	4	1	1	1
89398	1710	responder ubiquitous oligopeptide	[responder ubiquitous oligopeptides]	0.0	3	1	1	1
89399	1710	dna-binding characteristic at abundance	[DNA-binding characteristics at abundance]	0.0	4	1	1	1
89400	1710	erythroid-specific aminolaevulinic acid synthase	[erythroid-specific aminolaevulinic acid synthase]	0.0	4	1	1	1
89401	1710	strength of T cell receptor tcr	[Strength of T cell receptor TCR]	0.0	6	1	1	1
89402	1710	colony size (10-fold expansion)	[colony size (10-fold expansion)]	0.0	4	1	1	1
89403	1710	sex-and age-matched subject	[sex-and age-matched subjects]	0.0	3	1	1	1
89404	1710	extent, b cell	[extent, B cells]	0.0	3	1	1	1
89405	1710	form lack the binding site	[forms lacking the binding site]	0.0	5	1	1	1
89406	1710	modulation of immune responsiveness	[modulation of immune responsiveness]	0.0	4	1	1	1
89407	1710	IL-4 substrate include JAK1	[IL-4 substrates including JAK1]	0.0	4	1	1	1
89408	1710	cells, use a monoclonal antibody	[cells, using a monoclonal antibody]	0.0	5	1	1	1
89409	1710	and/or paracrine	[and/or paracrine]	0.0	2	1	1	1
89410	1710	microg/mL lps	[microg/mL LPS]	0.0	2	1	1	1
89411	1710	transcription at late stage	[transcription at late stages]	0.0	4	1	1	1
89412	1710	transcription of nf-at transactivate pathway	[transcription of NF-AT transactivating pathways]	0.0	5	1	1	1
89413	1710	include the phenomenon	[including the phenomenon]	0.0	3	1	1	1
89414	1710	identification of recurrent cytogenetic abnormality	[identification of recurrent cytogenetic abnormalities]	0.0	5	1	1	1
89415	1710	octamer enhancer element	[octamer enhancer element]	0.0	3	1	1	1
89416	1710	treatment with CsA	[treatment with CsA]	0.0	3	1	1	1
89417	1710	alteration binding	[alterations binding]	0.0	2	1	1	1
89418	1710	cell polypryrimidine-binding factor pybf	[cells polypryrimidine-binding factor PYBF]	0.0	4	1	1	1
89419	1710	rare disorder present	[rare disorder presenting]	0.0	3	1	1	1
89420	1710	dimorphism	[dimorphism]	0.0	1	1	1	1
89421	1710	low molecular weight transmembrane adaptor protein	[low molecular weight transmembrane adaptor proteins]	0.0	6	1	1	1
89422	1710	b-binding-proteins	[B-binding-proteins]	0.0	1	1	1	1
89423	1710	component of the pathologic picture	[component of the pathologic picture]	0.0	5	1	1	1
89424	1710	energy substrate	[Energy substrates,]	0.0	2	1	1	1
89425	1710	lineage in cell line	[lineages in cell lines]	0.0	4	1	1	1
89426	1710	stat1 transcription	[STAT1 transcription]	0.0	2	1	1	1
89427	1710	NGAL tumor	[NGAL tumors]	0.0	2	1	1	1
89428	1710	plasma volume	[plasma volume]	0.0	2	1	1	1
89429	1710	(granulocytic differentiated)	[(granulocytic differentiated)]	0.0	2	1	1	1
89430	1710	apoptosis in eosinophil	[apoptosis in eosinophils]	0.0	3	1	1	1
89431	1710	induction of interleukin-12 p40 transcript	[Induction of interleukin-12 p40 transcript]	0.0	5	1	1	1
89432	1710	few years,	[few years,]	0.0	2	1	1	1
89433	1710	C/EBP-beta	[C/EBP-beta]	0.0	1	1	1	1
89434	1710	radical scavenging tnf- cell	[radical scavenging TNF- cells]	0.0	4	1	1	1
89435	1710	ep level	[Ep level]	0.0	2	1	1	1
89436	1710	treatment with DMP	[Treatment with DMP]	0.0	3	1	1	1
89437	1710	m, serum concentration	[M, serum concentration]	0.0	3	1	1	1
89438	1710	range from kD to 55 kd,	[ranging from kD to 55 kD,]	0.0	6	1	1	1
89439	1710	alteration in the cells.	[alterations in the cells.]	0.0	4	1	1	1
89440	1710	IL-1alpha kappab-like site -1065 to -1056	[IL-1alpha kappaB-like sites -1,065 to -1,056]	0.0	6	1	1	1
89441	1710	nb4 cell leukemia line	[NB4 cells leukemia line]	0.0	4	1	1	1
89442	1710	multipotential hemopoietic stem cell	[multipotential hemopoietic stem cells]	0.0	4	1	1	1
89443	1710	anti- ap-1 activity in 1e8 cell	[anti- AP-1 activity in 1E8 cells]	0.0	6	1	1	1
89444	1710	polyposis coli-binding gene family	[polyposis coli-binding gene family]	0.0	4	1	1	1
89445	1710	cis-acting element include a gata-1	[cis-acting elements including a GATA-1]	0.0	5	1	1	1
89446	1710	replicative property	[replicative properties]	0.0	2	1	1	1
89447	1710	methods, with pair of oligonucleotide	[methods, with pairs of oligonucleotides]	0.0	5	1	1	1
89448	1710	PRE-I enhancer	[PRE-I enhancer]	0.0	2	1	1	1
89449	1710	fibroblast medium	[fibroblast medium]	0.0	2	1	1	1
89450	1710	threshold for activation	[thresholds for activation]	0.0	3	1	1	1
89451	1710	identification of abnormality highlight loci	[identification of abnormalities highlighting loci]	0.0	5	1	1	1
89452	1710	level in hl60 cell	[levels in HL60 cells]	0.0	4	1	1	1
89453	1710	post-dose until h. spleen	[post-dosing until h, spleen]	0.0	4	1	1	1
89454	1710	peak after minute exposure	[peaking after minutes exposure]	0.0	4	1	1	1
89455	1710	activity of a template	[activity of a template]	0.0	4	1	1	1
89456	1710	Bcl-6 expression in reactive hyperplasia heterogeneity	[Bcl-6 expression in reactive hyperplasia heterogeneity]	0.0	6	1	1	1
89457	1710	dna-binding domain of member	[DNA-binding domains of members]	0.0	4	1	1	1
89458	1710	human autosomal recessive disease	[human autosomal recessive disease]	0.0	4	1	1	1
89459	1710	set of Janus kinase	[set of Janus kinases]	0.0	4	1	1	1
89460	1710	subunits; five genes, nfkb1 nfkb2	[subunits; five genes, NFKB1 NFKB2]	0.0	5	1	1	1
89461	1710	involvement signal	[involvement signaling]	0.0	2	1	1	1
89462	1710	case with thyroid gland	[case with thyroid gland]	0.0	4	1	1	1
89463	1710	gene expression pattern in mammary cell	[gene expression patterns in mammary cells]	0.0	6	1	1	1
89464	1710	macrophage by ventilation in vitro.	[macrophages by ventilation in vitro.]	0.0	5	1	1	1
89465	1710	hand, all b- case	[hand, all B- cases]	0.0	4	1	1	1
89466	1710	chronic disorder	[chronic disorders]	0.0	2	1	1	1
89467	1710	c-fo sense	[c-fos sense]	0.0	2	1	1	1
89468	1710	hematopoietic cell factor pybf	[hematopoietic cells factor PYBF]	0.0	4	1	1	1
89469	1710	distinct subunits; genes, nfkb1 nfkb2	[distinct subunits; genes, NFKB1 NFKB2]	0.0	5	1	1	1
89470	1710	more efficient interaction	[more efficient interaction]	0.0	3	1	1	1
89471	1710	promoter (-62	[promoter (-62]	0.0	2	1	1	1
89472	1710	delivery of nf-kappab	[delivery of NF-kappaB]	0.0	3	1	1	1
89473	1710	cell undergo tnf-alpha apoptosis	[cells undergoing TNF-alpha apoptosis]	0.0	4	2	2	1
89474	1710	rapid accumulation of concentration	[rapid accumulation of concentrations]	0.0	4	1	1	1
89475	1710	hiv -gene	[HIV -gene]	0.0	2	1	1	1
89476	1710	corresponding to a amplification	[corresponding to a amplification]	0.0	4	1	1	1
89477	1710	different stage of the cycle	[different stages of the cycle]	0.0	5	1	1	1
89478	1710	look at success in new approach	[Looking at successes in newer approaches]	0.0	6	1	1	1
89479	1710	ccgccc binding protein from cell	[CCGCCC binding proteins from cells]	0.0	5	1	1	1
89480	1710	inducer in all	[inducer in all]	0.0	3	1	1	1
89481	1710	BL case with bone marrow infiltration	[BL case with bone marrow infiltration]	0.0	6	1	1	1
89482	1710	CD4 gene transcription	[CD4 gene transcription]	0.0	3	1	1	1
89483	1710	low level of i(kappa)b(alpha)	[Low levels of I(kappa)B(alpha)]	0.0	4	1	1	1
89484	1710	effect together	[effects together]	0.0	2	1	1	1
89485	1710	spinous layer	[spinous layer]	0.0	2	1	1	1
89486	1710	effect to gabp alpha/gabp beta	[effect to GABP alpha/GABP beta]	0.0	5	1	1	1
89487	1710	T cell-specific function for TCF-1	[T cell-specific function for TCF-1]	0.0	5	1	1	1
89488	1710	acid receptor type alpha	[acid receptor type alpha]	0.0	4	1	1	1
89489	1710	PMA alpha activation of enf)-kappa b	[PMA alpha activation of (NF)-kappa B]	0.0	6	1	1	1
89490	1710	low level of nuclear nf-kappa b	[low levels of nuclear NF-kappa B]	0.0	6	1	1	1
89491	1710	two T cell line	[Two T cell lines]	0.0	4	1	1	1
89492	1710	extensive granulopoiesis	[extensive granulopoiesis]	0.0	2	1	1	1
89493	1710	receptor of form	[receptors of form]	0.0	3	1	1	1
89494	1710	effector proteins,	[effector proteins,]	0.0	2	1	1	1
89495	1710	intrinsic DNA binding affinity	[intrinsic DNA binding affinities]	0.0	4	1	1	1
89496	1710	Epstein-Barr virus transactivator	[Epstein-Barr virus transactivators]	0.0	3	1	1	1
89497	1710	human tnf transgene	[human TNF transgene]	0.0	3	1	1	1
89498	1710	instillation into normal rat	[instillation into normal rats]	0.0	4	1	1	1
89499	1710	three 21-bp repeat element-1	[three 21-bp repeats element-1]	0.0	4	1	1	1
89500	1710	control the pp52 promoter	[controlling the pp52 promoter]	0.0	4	1	1	1
89501	1710	case of lymphocytic leukaemias	[cases of lymphocytic leukaemias]	0.0	4	1	1	1
89502	1710	eukaryotic origin	[eukaryotic origin]	0.0	2	1	1	1
89503	1710	follow immortalization	[following immortalization]	0.0	2	1	1	1
89504	1710	decrease in b-cell mitogenesis	[decrease in B-cell mitogenesis]	0.0	4	1	1	1
89505	1710	Deoxycholate treatment	[Deoxycholate treatment]	0.0	2	2	2	1
89506	1710	blr2 gene	[BLR2 gene]	0.0	2	1	1	1
89507	1710	ec human bone marrow ec	[EC human bone marrow EC]	0.0	5	1	1	1
89508	1710	several important hematopoietic gene	[several important hematopoietic genes]	0.0	4	1	1	1
89509	1710	however, order less potent than H	[however, orders less potent than H]	0.0	6	1	1	1
89510	1710	low protein	[low proteins]	0.0	2	1	1	1
89511	1710	three DNA clone contain hhv-6(gs) fragment	[Three DNA clones containing HHV-6(GS) fragments]	0.0	6	1	1	1
89512	1710	immunodeficiency virus type-1 transcription role	[immunodeficiency virus type-1 transcription role]	0.0	5	1	1	1
89513	1710	maintenance of NK function	[maintenance of NK functions]	0.0	4	1	1	1
89514	1710	deletion of 5' nf-kappab site	[deletion of 5' NF-kappaB sites]	0.0	5	1	1	1
89515	1710	Fes	[Fes]	0.0	1	1	1	1
89516	1710	direct effect of pa	[direct effect of PA]	0.0	4	1	1	1
89517	1710	novel, carboxy terminus	[novel, carboxy terminus]	0.0	3	1	1	1
89518	1710	nf-kappab -dependent activation long terminal repeat	[NF-kappaB -dependent activation long terminal repeat]	0.0	6	1	1	1
89519	1710	result of clinical trial	[results of clinical trials]	0.0	4	1	1	1
89520	1710	antigen PSA	[antigen PSA]	0.0	2	1	1	1
89521	1710	nf-kappab -dependent	[NF-kappaB -dependent]	0.0	2	1	1	1
89522	1710	transactivation by nfat1	[Transactivation by NFAT1]	0.0	3	1	1	1
89523	1710	ligand-receptor interaction	[ligand-receptor interactions]	0.0	2	1	1	1
89524	1710	use of receptor binding study	[use of receptor binding studies]	0.0	5	1	1	1
89525	1710	correlation between chromosome alteration	[correlation between chromosome alterations]	0.0	4	1	1	1
89526	1710	human cd34+ cell	[human CD34+ cells]	0.0	3	1	1	1
89527	1710	antiserum against ifn-gamma	[antiserum against IFN-gamma]	0.0	3	1	1	1
89528	1710	most individual	[most individuals]	0.0	2	1	1	1
89529	1710	common use as agent	[common use as agents]	0.0	4	1	1	1
89530	1710	N-terminal domain POUs	[N-terminal domain POUs]	0.0	3	1	1	1
89531	1710	percent life span	[percent life span]	0.0	3	1	1	1
89532	1710	coactivation by OCA-B definition	[Coactivation by OCA-B definition]	0.0	4	1	1	1
89533	1710	il-4- gene expression	[IL-4- gene expression]	0.0	3	1	1	1
89534	1710	contain two repeat of amino acid	[containing two repeats of amino acids]	0.0	6	1	1	1
89535	1710	opening of Ca(2+)-stimulated K+	[opening of Ca(2+)-stimulated K+]	0.0	4	1	1	1
89536	1710	degree of nephropathy	[degree of nephropathy]	0.0	3	1	1	1
89537	1710	adhesive ICAM-1 property	[adhesive ICAM-1 properties]	0.0	3	1	1	1
89538	1710	herpesvirus a predominantly T lymphotropic virus	[herpesvirus a predominantly T lymphotropic virus]	0.0	6	1	1	1
89539	1710	distal promoter sequence	[distal promoter sequences]	0.0	3	1	1	1
89540	1710	myeloid differentiation from stem cell	[myeloid differentiation from stem cells]	0.0	5	1	1	1
89541	1710	calf efcs clonogenic culture	[calf (FCS+) clonogenic culture]	0.0	4	1	1	1
89542	1710	human SCL locus	[human SCL locus]	0.0	3	1	1	1
89543	1710	hsp60 in human vein endothelial cell	[Hsp60 in human vein endothelial cells]	0.0	6	1	1	1
89544	1710	sequence-binding complex contain STAT3 with complex	[sequence-binding complexes containing STAT3 with complexes]	0.0	6	1	1	1
89545	1710	use the region of Stat5b	[Using the region of Stat5b]	0.0	5	1	1	1
89546	1710	analysis of the MBP promoter region	[analysis of the MBP promoter region]	0.0	6	1	1	1
89547	1710	cleavage domain	[cleavage domain]	0.0	2	1	1	1
89548	1710	preclinical study of regimen	[preclinical studies of regimens]	0.0	4	1	1	1
89549	1710	cytosolic transcription	[cytosolic transcription]	0.0	2	1	1	1
89550	1710	lbp (14.7	[LBP (14.7]	0.0	2	1	1	1
89551	1710	overexpression a constitutive version	[Overexpression a constitutive version]	0.0	4	1	1	1
89552	1710	NK cell membrane-bound lt signal lead	[NK cell membrane-bound LT signals leading]	0.0	6	1	1	1
89553	1710	cell from other primate	[cells from other primates]	0.0	4	1	1	1
89554	1710	gene for neutrophil lipocalin	[gene for neutrophil lipocalin]	0.0	4	1	1	1
89555	1710	type include chronic leukaemia	[types including chronic leukaemia]	0.0	4	2	2	1
89556	1710	leukocyte hml	[leukocytes HML]	0.0	2	1	1	1
89557	1710	additional protein-DNA interaction	[Additional protein-DNA interactions]	0.0	3	1	1	1
89558	1710	mouse peritoneal macrophage	[mouse peritoneal macrophages]	0.0	3	1	1	1
89559	1710	previously unexpected variability	[previously unexpected variability]	0.0	3	1	1	1
89560	1710	factor/oncoprotein	[factor/oncoprotein]	0.0	1	2	2	1
89561	1710	somatic cell hybrid between IARC	[somatic cell hybrids between IARC]	0.0	5	1	1	1
89562	1710	initiator specify the terminus	[initiator specifying the terminus]	0.0	4	1	1	1
89563	1710	low number of false prediction	[lower number of false predictions]	0.0	5	1	1	1
89564	1710	effect with regard to expression	[effect with regard to expression]	0.0	5	1	1	1
89565	1710	Tandem	[Tandem]	0.0	1	1	1	1
89566	1710	protein act as positive transcription factor	[proteins acting as positive transcription factors]	0.0	6	1	1	1
89567	1710	expression of a cytoplasmic protein	[expression of an cytoplasmic protein]	0.0	5	1	1	1
89568	1710	expression in leukemic cell	[expression in leukemic cells]	0.0	4	1	1	1
89569	1710	b cell-specific co-activator	[B cell-specific co-activator]	0.0	3	1	1	1
89570	1710	Ras superfamily	[Ras superfamily]	0.0	2	1	1	1
89571	1710	vitro DNA	[vitro DNA]	0.0	2	1	1	1
89572	1710	regulatory factor for the expression	[regulatory factor for the expression]	0.0	5	1	1	1
89573	1710	none of the other regulatory site	[None of the other regulatory sites]	0.0	6	1	1	1
89574	1710	eight patient in long 3 years)	[Eight patients in long-term 3 years)]	0.0	6	1	1	1
89575	1710	member of the NFAT family	[members of the NFAT family]	0.0	5	2	2	1
89576	1710	adhesive molecule for leukocyte	[adhesive molecules for leukocytes]	0.0	4	1	1	1
89577	1710	receptor by thymic T lymphocyte	[receptors by thymic T lymphocytes]	0.0	5	1	1	1
89578	1710	class transcription factor RFX	[class transcription factors RFX]	0.0	4	1	1	1
89579	1710	demonstrate the activity of tgf-beta	[demonstrating the activity of TGF-beta]	0.0	5	1	1	1
89580	1710	lymphocyte by ags	[lymphocytes by Ags]	0.0	3	1	1	1
89581	1710	expression a new murine member	[expression a new murine member]	0.0	5	1	1	1
89582	1710	quantification of expression	[quantification of expression]	0.0	3	1	1	1
89583	1710	effect on gene activation	[Effect on gene activation]	0.0	4	1	1	1
89584	1710	many factors,	[Many factors,]	0.0	2	1	1	1
89585	1710	wide variety of cells,	[wide variety of cells,]	0.0	4	1	1	1
89586	1710	effect of a T immune response	[effects of a T immune response]	0.0	6	1	1	1
89587	1710	capacity of cd34+thy-1+ cell	[capacity of CD34+Thy-1+ cells]	0.0	4	1	1	1
89588	1710	degradation by a signal	[degradation by a signal]	0.0	4	1	1	1
89589	1710	t-cell transfectant with tax	[T-cell transfectants with Tax]	0.0	4	1	1	1
89590	1710	transactivation capacity of factor NF-AT	[transactivation capacity of factor NF-AT]	0.0	5	1	1	1
89591	1710	difference in transcriptional activity	[differences in transcriptional activity]	0.0	4	1	1	1
89592	1710	overlap antisense rna probe	[overlapping antisense RNA probes]	0.0	4	1	1	1
89593	1710	activity of JNK the map	[activity of JNK the MAP]	0.0	5	1	1	1
89594	1710	relation to plasma testosterone	[relation to plasma testosterone]	0.0	4	1	1	1
89595	1710	primate Y chromosome	[primate Y chromosomes]	0.0	3	1	1	1
89596	1710	blood of 145 volunteer	[blood of 145 volunteers]	0.0	4	1	1	1
89597	1710	molecule on normal lung fibroblast	[molecule on normal lung fibroblasts]	0.0	5	1	1	1
89598	1710	mitochondrial form of the erythroid	[mitochondrial forms of the erythroid]	0.0	5	1	1	1
89599	1710	Specific depletion	[Specific depletion]	0.0	2	1	1	1
89600	1710	cooperative activity	[cooperative activity]	0.0	2	1	1	1
89601	1710	expression p	[expression P]	0.0	2	1	1	1
89602	1710	gene encode interleukin-2 a cytokine	[gene encoding interleukin-2 a cytokine]	0.0	5	1	1	1
89603	1710	mannose endocytosis	[mannose endocytosis]	0.0	2	1	1	1
89604	1710	five healthy leukocyte antigen-B8	[Five healthy leukocyte antigen-B8]	0.0	4	1	1	1
89605	1710	pu.1 site adjacent	[PU.1 site adjacent]	0.0	3	1	1	1
89606	1710	combination isoform	[combination isoform]	0.0	2	1	1	1
89607	1710	chains,	[chains,]	0.0	1	1	1	1
89608	1710	pma/ca2+	[PMA/Ca2+]	0.0	1	1	1	1
89609	1710	treatment of gp160 with cd4-igg	[treatment of gp160 with CD4-IgG]	0.0	5	1	1	1
89610	1710	hypoxia, sickle blood cell	[hypoxia, sickle blood cells]	0.0	4	1	1	1
89611	1710	expression I	[expression I]	0.0	2	1	1	1
89612	1710	extent than aspirin	[extent than aspirin]	0.0	3	1	1	1
89613	1710	key enzyme for (il)-2	[key enzyme for (IL)-2]	0.0	4	1	1	1
89614	1710	CD3 depletion,	[CD3 depletion,]	0.0	2	1	1	1
89615	1710	genetic change in the form	[genetic changes in the form]	0.0	5	1	1	1
89616	1710	co-migrate on mobility shift analysis	[co-migrating on mobility shift analysis]	0.0	5	1	1	1
89617	1710	CD2 cross-linking phosphorylation	[CD2 cross-linking phosphorylation]	0.0	3	1	1	1
89618	1710	membrane protein gene protein	[membrane protein gene proteins]	0.0	4	1	1	1
89619	1710	interaction with octamer-bound Oct-1	[interaction with octamer-bound Oct-1]	0.0	4	1	1	1
89620	1710	affinity receptor VDR for 1,25-dihydroxycholecalciferol	[affinity receptors VDR for 1,25-dihydroxycholecalciferol]	0.0	5	1	1	1
89621	1710	control with the cytomegalovirus	[control with the cytomegalovirus]	0.0	4	1	1	1
89622	1710	respond ifn-alpha	[responding IFN-alpha]	0.0	2	1	1	1
89623	1710	expression 2	[expression 2]	0.0	2	1	1	1
89624	1710	expression from a patient with resistance	[expression from a patient with resistance]	0.0	6	1	1	1
89625	1710	level of the neuropeptide enkephalin	[levels of the neuropeptide enkephalin]	0.0	5	1	1	1
89626	1710	upstream region (position -69 responsive	[upstream region (positions -69 responsive]	0.0	5	1	1	1
89627	1710	adhesion after 3 h	[adhesion after 3 h]	0.0	4	1	1	1
89628	1710	antiapoptotic role for Notch-1	[antiapoptotic role for Notch-1]	0.0	4	1	1	1
89629	1710	contain the -257 region	[containing the -257 region]	0.0	4	1	1	1
89630	1710	nfatp induction	[NFATp induction]	0.0	2	1	1	1
89631	1710	mobility shift ems analysis utilize oligonucleotide	[mobility shift EMS analyses utilizing oligonucleotides]	0.0	6	1	1	1
89632	1710	to: exposure	[to: exposure]	0.0	2	1	1	1
89633	1710	5- to 2-fold increase	[5- to 2-fold increase]	0.0	4	1	1	1
89634	1710	follow administration	[following administrations]	0.0	2	1	1	1
89635	1710	cleavage stimulation factor	[cleavage stimulation factor]	0.0	3	1	1	1
89636	1710	generality	[generality]	0.0	1	2	2	1
89637	1710	microm for dutp	[microM for dUTP]	0.0	3	1	1	1
89638	1710	priming effect of il-10	[priming effects of IL-10]	0.0	4	1	1	1
89639	1710	contain four direct repeat DR	[containing four direct repeats DR]	0.0	5	1	1	1
89640	1710	tricyclic antidepressant of hypercortisolemia	[tricyclic antidepressants of hypercortisolemia]	0.0	4	1	1	1
89641	1710	human disease x-linked agammaglobulinemia	[human disease X-linked agammaglobulinemia]	0.0	4	1	1	1
89642	1710	hour of the enzyme	[hours of the enzyme]	0.0	4	1	1	1
89643	1710	endogenous ikk activity	[endogenous IKK activity]	0.0	3	1	1	1
89644	1710	simultaneous binding	[simultaneous binding]	0.0	2	1	1	1
89645	1710	GTP	[GTP]	0.0	1	1	1	1
89646	1710	RA RXR alpha	[RA RXR alpha]	0.0	3	1	1	1
89647	1710	Sublethal level	[Sublethal levels]	0.0	2	2	2	1
89648	1710	sequence at threonine	[sequence at threonine]	0.0	3	1	1	1
89649	1710	nuclear protein nf-kappa b	[nuclear proteins NF-kappa B]	0.0	4	1	1	1
89650	1710	formation of the complex, nuclear factor	[formation of the complex, nuclear factor]	0.0	6	1	1	1
89651	1710	FL progenitor colony-form unit monocyte	[FL progenitors colony-forming unit monocyte]	0.0	5	1	1	1
89652	1710	element identical	[element identical]	0.0	2	1	1	1
89653	1710	cyclin-dependent kinase inhibitor p21(waf1/cip1)	[cyclin-dependent kinase inhibitor p21(WAF1/CIP1)]	0.0	4	1	1	1
89654	1710	inhibitory effect gene expression	[inhibitory effects gene expression]	0.0	4	1	1	1
89655	1710	nucleotide insertion result	[nucleotide insertion resulting]	0.0	3	1	1	1
89656	1710	great ap-1 activity of protein	[greater AP-1 activity of proteins]	0.0	5	1	1	1
89657	1710	2.3 fmol/10(7) cell in control	[2.3 fmol/10(7) cells in controls]	0.0	5	3	3	1
89658	1710	linkage 10 polymorphism	[linkage 10 polymorphism]	0.0	3	1	1	1
89659	1710	decade.	[decade.]	0.0	1	1	1	1
89660	1710	binding factor present	[binding factors present]	0.0	3	1	1	1
89661	1710	three distinct complex RFX	[three distinct complexes RFX]	0.0	4	1	1	1
89662	1710	drug-free patient	[drug-free patients]	0.0	2	1	1	1
89663	1710	IL-12 IFN gene	[IL-12 IFN genes]	0.0	3	1	1	1
89664	1710	phorbol ester neutrophil	[phorbol ester neutrophil]	0.0	3	1	1	1
89665	1710	monocyte from hypercholesterolemic (fh) subject	[monocytes from hypercholesterolemic (FH) subjects]	0.0	5	1	1	1
89666	1710	umbilical vein cell CoCl2	[umbilical vein cells CoCl2]	0.0	4	1	1	1
89667	1710	classification as a polymorphism of BRCA1	[Classification as a polymorphism of BRCA1]	0.0	6	1	1	1
89668	1710	-dependent reporter	[-dependent reporter]	0.0	2	1	1	1
89669	1710	expression of PPARgamma a partner	[Expression of PPARgamma a partner]	0.0	5	1	1	1
89670	1710	transformation effector	[transformation effector]	0.0	2	1	1	1
89671	1710	defect in b- development	[defects in B- development]	0.0	4	1	1	1
89672	1710	selection expansion) (by stimulation	[selection expansion) (by stimulation]	0.0	4	1	1	1
89673	1710	8, histiocytoma	[8, histiocytoma]	0.0	2	1	1	1
89674	1710	particle rvlp by transmission electron microscopy	[particles RVLPs by transmission electron microscopy]	0.0	6	1	1	1
89675	1710	physiologic role of receptor	[physiologic role of receptors]	0.0	4	1	1	1
89676	1710	activate a DNA binding protein	[activating a DNA binding protein]	0.0	5	1	1	1
89677	1710	hour earlier) exposure	[hours earlier) exposure]	0.0	3	1	1	1
89678	1710	agreement on the pathogenesis	[agreement on the pathogenesis]	0.0	4	1	1	1
89679	1710	TATA binding factor	[TATA binding factor]	0.0	3	1	1	1
89680	1710	phenylarsine oxide pao	[phenylarsine oxide PAO]	0.0	3	1	1	1
89681	1710	interaction with other cellular protein	[interactions with other cellular proteins]	0.0	5	1	1	1
89682	1710	intrinsic potential	[intrinsic potential]	0.0	2	1	1	1
89683	1710	distribution,	[distribution,]	0.0	1	1	1	1
89684	1710	distribution.	[distribution.]	0.0	1	1	1	1
89685	1710	cell effector function	[cell effector function]	0.0	3	1	1	1
89686	1710	unique role	[unique role]	0.0	2	1	1	1
89687	1710	cytokine rescue	[Cytokine rescue]	0.0	2	1	1	1
89688	1710	B /Rel	[B /Rel]	0.0	2	1	1	1
89689	1710	subtype of retinoic acid receptor RAR	[subtypes of retinoic acid receptors RAR]	0.0	6	1	1	1
89690	1710	express this receptors, leukocyte	[expressing these receptors, leukocytes]	0.0	4	1	1	1
89691	1710	identical sequence within the promoter	[identical sequences within the promoter]	0.0	5	1	1	1
89692	1710	observation of expression	[observations of expression]	0.0	3	1	1	1
89693	1710	include sensitivity to neuraminidase	[including sensitivity to neuraminidase]	0.0	4	1	1	1
89694	1710	number of intragenic mutation	[number of intragenic mutations]	0.0	4	1	1	1
89695	1710	means of a autoregulatory pathway	[means of an autoregulatory pathway]	0.0	5	1	1	1
89696	1710	putative regulatory loop	[putative regulatory loop]	0.0	3	1	1	1
89697	1710	malignant histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma	[malignant histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
89698	1710	molecular mechanism govern lineage	[molecular mechanisms governing lineage]	0.0	4	1	1	1
89699	1710	dinucleotide repeat	[dinucleotide repeat]	0.0	2	1	1	1
89700	1710	possible paracrine effect	[possible paracrine effect]	0.0	3	1	1	1
89701	1710	other gene transcription	[other gene transcription]	0.0	3	1	1	1
89702	1710	early mouse development	[early mouse development]	0.0	3	1	1	1
89703	1710	insulin on receptor in leukocyte	[insulin on receptor in leukocytes]	0.0	5	1	1	1
89704	1710	granule protein gene	[granule protein gene]	0.0	3	1	1	1
89705	1710	include interferon regulatory factor	[including interferon regulatory factor]	0.0	4	1	1	1
89706	1710	conjugation of ubiquitin	[conjugation of ubiquitin]	0.0	3	1	1	1
89707	1710	infiltration in blood	[infiltration in blood]	0.0	3	1	1	1
89708	1710	ALY a coactivator of LEF-1	[ALY a coactivator of LEF-1]	0.0	5	1	1	1
89709	1710	development of multiple hematopoietic lineage	[development of multiple hematopoietic lineages]	0.0	5	1	1	1
89710	1710	transition from b cell	[transition from B cell]	0.0	4	1	1	1
89711	1710	effect of g-csf on cd34+ cell	[effects of G-CSF on CD34+ cells]	0.0	6	1	1	1
89712	1710	long latency	[longer latency]	0.0	2	1	1	1
89713	1710	dihydrochloride a inhibitor	[dihydrochloride an inhibitor]	0.0	3	1	1	1
89714	1710	Fya	[Fya]	0.0	1	1	1	1
89715	1710	saimiry	[saimiri]	0.0	1	1	1	1
89716	1710	apoptosis induce apoptosis in uninfected cell	[apoptosis inducing apoptosis in uninfected cells]	0.0	6	1	1	1
89717	1710	ribosomal binding	[ribosomal binding]	0.0	2	1	1	1
89718	1710	involvement I receptor	[involvement I receptors]	0.0	3	1	1	1
89719	1710	nf-kappab action	[NF-kappaB action]	0.0	2	1	1	1
89720	1710	center GC formation	[center GC formation]	0.0	3	1	1	1
89721	1710	il-1 lps	[IL-1 LPS]	0.0	2	1	1	1
89722	1710	West	[West]	0.0	1	1	1	1
89723	1710	regulation by apoptosis-linked gene	[Regulation by apoptosis-linked gene]	0.0	4	1	1	1
89724	1710	more durable inhibition of replication	[more durable inhibition of replication]	0.0	5	1	1	1
89725	1710	case of hodgkin' disease hd	[cases of Hodgkin's disease HD]	0.0	5	1	1	1
89726	1710	hiv-2 long terminal repeat	[HIV-2 long terminal repeat]	0.0	4	1	1	1
89727	1710	+/- 0.4	[+/- 0.4]	0.0	2	1	1	1
89728	1710	26 carcinoma patient	[26 carcinoma patients]	0.0	3	1	1	1
89729	1710	property of monocyte	[properties of monocytes]	0.0	3	1	1	1
89730	1710	viral rna	[viral RNA]	0.0	2	1	1	1
89731	1710	activity of e2f	[activity of E2F]	0.0	3	2	2	1
89732	1710	moreover, cotransfection	[Moreover, cotransfections]	0.0	2	1	1	1
89733	1710	transcription complex contain nfat-family protein	[transcription complexes containing NFAT-family proteins]	0.0	5	1	1	1
89734	1710	expression of the adhesion molecule	[expression of the adhesion molecules]	0.0	5	1	1	1
89735	1710	translocation of kappab-binding protein	[translocation of kappaB-binding proteins]	0.0	4	1	1	1
89736	1710	k562 extract	[K562 extracts]	0.0	2	1	1	1
89737	1710	patient with myeloid leukaemia	[patients with myeloid leukaemia]	0.0	4	1	1	1
89738	1710	type adenovirus	[type adenovirus]	0.0	2	1	1	1
89739	1710	overexpression by ATL cell	[overexpression by ATL cells]	0.0	4	1	1	1
89740	1710	negative c/ebp protein LIP	[negative C/EBP protein LIP]	0.0	4	1	1	1
89741	1710	regard phosphorylation	[regarding phosphorylation]	0.0	2	1	1	1
89742	1710	difference between h-rs cell	[difference between H-RS cells]	0.0	4	1	1	1
89743	1710	c/ebp-beta NF-IL6	[C/EBP-beta NF-IL6]	0.0	2	1	1	1
89744	1710	promoter for inducible	[promoters for inducible]	0.0	3	1	1	1
89745	1710	majority of tissue	[majority of tissues]	0.0	3	1	1	1
89746	1710	clone specific	[clone specific]	0.0	2	1	1	1
89747	1710	cytoplasmic calcium	[cytoplasmic calcium]	0.0	2	1	1	1
89748	1710	ap-1 by gp160	[AP-1 by gp160]	0.0	3	1	1	1
89749	1710	involvement of a second enhancer element	[Involvement of a second enhancer element]	0.0	6	1	1	1
89750	1710	physiologically relevant spectrum	[physiologically relevant spectrum]	0.0	3	1	1	1
89751	1710	receptor c alpha gene enhancer	[receptor C alpha gene enhancer]	0.0	5	1	1	1
89752	1710	cyclosporin human b	[cyclosporin human B]	0.0	3	1	1	1
89753	1710	complex with a intermediate mobility	[complex with an intermediate mobility]	0.0	5	1	1	1
89754	1710	monocyte infiltration in atherosclerotic plaque	[monocyte infiltration in atherosclerotic plaques]	0.0	5	1	1	1
89755	1710	surface receptor for igg	[surface receptor for IgG]	0.0	4	1	1	1
89756	1710	ikk protein transcription,	[IKK protein transcription,]	0.0	3	1	1	1
89757	1710	evidence for a additional site	[evidence for an additional site]	0.0	5	1	1	1
89758	1710	high level of nuclear nf-atp	[higher levels of nuclear NF-ATp]	0.0	5	1	1	1
89759	1710	range to 55 kd,	[ranging to 55 kD,]	0.0	4	1	1	1
89760	1710	upstream IL-2 response element	[upstream IL-2 response element]	0.0	4	1	1	1
89761	1710	presence of alpha-helice Val10-Gln22	[presence of alpha-helices Val10-Gln22]	0.0	4	1	1	1
89762	1710	II-specific transcription	[II-specific transcription]	0.0	2	1	1	1
89763	1710	treatment of Jurkat cell tyrosine phosphorylation	[Treatment of Jurkat cells tyrosine phosphorylation]	0.0	6	1	1	1
89764	1710	transcriptional proteins, the gata factor	[transcriptional proteins, the GATA factors]	0.0	5	1	1	1
89765	1710	cyclic AMP element -dependent activation	[Cyclic AMP element -dependent activation]	0.0	5	1	1	1
89766	1710	sh3-binding	[SH3-binding]	0.0	1	1	1	1
89767	1710	cytokine tested,	[cytokines tested,]	0.0	2	1	1	1
89768	1710	consequent function	[consequent function]	0.0	2	1	1	1
89769	1710	activation of erk kinase	[activation of ERK kinase]	0.0	4	1	1	1
89770	1710	young sister of patient	[young sister of patient]	0.0	4	1	1	1
89771	1710	replacement of p50 homodimer	[replacement of p50 homodimers]	0.0	4	1	1	1
89772	1710	one octamer motif	[one octamer motif]	0.0	3	1	1	1
89773	1710	color microscopy	[color microscopy]	0.0	2	1	1	1
89774	1710	few element	[few elements]	0.0	2	1	1	1
89775	1710	z bzlf1	[Z BZLF1]	0.0	2	1	1	1
89776	1710	safe peptide vaccine	[safe peptide vaccines]	0.0	3	1	1	1
89777	1710	cell transcription factor ets-1	[cell transcription factors Ets-1]	0.0	4	1	1	1
89778	1710	least several hematopoietic gene	[least several hematopoietic genes]	0.0	4	1	1	1
89779	1710	antibody (mab)	[antibody (MAb)]	0.0	2	1	1	1
89780	1710	bronchoscopy with biopsy	[bronchoscopy with biopsy]	0.0	3	1	1	1
89781	1710	cell adhesion of beta integrin	[cell adhesion of beta integrins]	0.0	5	1	1	1
89782	1710	element BEAD-1	[element BEAD-1]	0.0	2	1	1	1
89783	1710	increase in the intracellular level	[increase in the intracellular levels]	0.0	5	1	1	1
89784	1710	cell in large vessel	[cells in large vessel]	0.0	4	1	1	1
89785	1710	immunoglobulin g fc receptor	[immunoglobulin G Fc receptors]	0.0	4	1	1	1
89786	1710	long repeat transcription	[long repeat transcription]	0.0	3	1	1	1
89787	1710	kb upstream from the initiation site	[kb upstream from the initiation site]	0.0	6	1	1	1
89788	1710	result necessity	[resulting necessity]	0.0	2	1	1	1
89789	1710	5 red blood cell hrbc	[5 red blood cells HRBC]	0.0	5	1	1	1
89790	1710	ap1 transcription	[AP1 transcription]	0.0	2	2	2	1
89791	1710	source of interferon gamma IFNgamma	[source of interferon gamma IFNgamma]	0.0	5	1	1	1
89792	1710	patient aged 16-27 years,	[patients aged 16-27 years,]	0.0	4	1	1	1
89793	1710	c-terminal serine -rich region	[C-terminal serine -rich region]	0.0	4	1	1	1
89794	1710	HCS	[HCS]	0.0	1	1	1	1
89795	1710	cytokine release a critical step	[cytokine release a critical step]	0.0	5	1	1	1
89796	1710	selective blockade	[selective blockade]	0.0	2	1	1	1
89797	1710	qr inhibitor	[QR inhibitor]	0.0	2	1	1	1
89798	1710	other antigen	[other antigens]	0.0	2	1	1	1
89799	1710	undifferentiated non-PRL-secreting stromal cell	[undifferentiated non-PRL-secreting stromal cells]	0.0	4	1	1	1
89800	1710	bovine artery endothelial cell from injury	[bovine artery endothelial cells from injury]	0.0	6	1	1	1
89801	1710	b6d2f1 mouse	[B6D2F1 mouse]	0.0	2	1	1	1
89802	1710	factor lef-1	[factor LEF-1]	0.0	2	1	1	1
89803	1710	suggest a interaction between the kinase	[suggesting a interaction between the kinase]	0.0	6	1	1	1
89804	1710	underlie this effect of aldosterone	[underlying these effects of aldosterone]	0.0	5	1	1	1
89805	1710	Clinical deterioration	[Clinical deterioration]	0.0	2	1	1	1
89806	1710	little conservation	[little conservation]	0.0	2	1	1	1
89807	1710	HEK	[HEK]	0.0	1	1	1	1
89808	1710	effect of tat protein	[effect of Tat protein]	0.0	4	1	1	1
89809	1710	transcriptional activity of a nuclear factor	[transcriptional activity of an nuclear factor]	0.0	6	1	1	1
89810	1710	potential role of protein	[potential role of proteins]	0.0	4	1	1	1
89811	1710	compound in vitro.	[compound in vitro.]	0.0	3	1	1	1
89812	1710	ciita cDNA	[CIITA cDNA]	0.0	2	1	1	1
89813	1710	tnf-alpha factor-kappa b nf-kappa b	[TNF-alpha factor-kappa B NF-kappa B]	0.0	5	1	1	1
89814	1710	aids -gr patient	[AIDS -GR patients]	0.0	3	1	1	1
89815	1710	key mechanism	[key mechanism]	0.0	2	1	1	1
89816	1710	progenitor with no potential	[progenitors with no potential]	0.0	4	1	1	1
89817	1710	healthy man aged	[healthy men aged]	0.0	3	1	1	1
89818	1710	soluble surface domain	[soluble surface domain]	0.0	3	1	1	1
89819	1710	Ikaros protein	[Ikaros proteins]	0.0	2	1	1	1
89820	1710	serum as a source	[serum as a source]	0.0	4	1	1	1
89821	1710	inhibition to the cytoskeleton	[inhibition to the cytoskeleton]	0.0	4	1	1	1
89822	1710	interaction lead to cell death	[interaction leading to cell death]	0.0	5	1	1	1
89823	1710	MHC class 1	[MHC class 1]	0.0	3	1	1	1
89824	1710	TCP succinate	[TCP succinate]	0.0	2	1	1	1
89825	1710	lak lysis	[LAK lysis]	0.0	2	1	1	1
89826	1710	red blood cell HPFH	[red blood cells HPFH]	0.0	4	1	1	1
89827	1710	stimulation by eosinophil granule basic protein	[Stimulation by eosinophil granule basic protein]	0.0	6	1	1	1
89828	1710	three series: at (17 subject	[three series: at (17 subjects]	0.0	5	1	1	1
89829	1710	expression of rev protein	[expression of Rev protein]	0.0	4	1	1	1
89830	1710	HGF	[HGF]	0.0	1	1	1	1
89831	1710	DC characteristic of KG1 dendritic-like cell	[DC characteristics of KG1 dendritic-like cells]	0.0	6	1	1	1
89832	1710	ablation	[Ablation]	0.0	1	1	1	1
89833	1710	level 2 17	[levels 2 17]	0.0	3	1	1	1
89834	1710	IFN-gamma receptor	[IFN-gamma receptor]	0.0	2	1	1	1
89835	1710	footprint cell express the fetal	[footprinting cells expressing the fetal]	0.0	5	1	1	1
89836	1710	tyrosine phosphorylation of Tyk2	[tyrosine phosphorylation of Tyk2]	0.0	4	1	1	1
89837	1710	activation of the tissue factor gene	[activation of the tissue factor gene]	0.0	6	1	1	1
89838	1710	sertraline response in adolescent disorder	[sertraline response in adolescent disorder]	0.0	5	1	1	1
89839	1710	strong potential	[strong potential]	0.0	2	1	1	1
89840	1710	relationship to NF-kappa b	[relationship to NF-kappa B]	0.0	4	1	1	1
89841	1710	cell-specific gene include alpha- globin	[cell-specific genes including alpha- globin]	0.0	5	1	1	1
89842	1710	respect after transfection	[respect after transfection]	0.0	3	1	1	1
89843	1710	decrease in helicase atpase activity	[decrease in helicase ATPase activities]	0.0	5	1	1	1
89844	1710	competition study	[competition studies]	0.0	2	1	1	1
89845	1710	nmol/L) nmol/L)	[nmol/L) nmol/L)]	0.0	2	1	1	1
89846	1710	effect of environmental estrogen	[Effect of environmental estrogens]	0.0	4	1	1	1
89847	1710	17 kb of DNA	[17 kb of DNA]	0.0	4	1	1	1
89848	1710	feature of zinc finger protein	[feature of zinc finger proteins]	0.0	5	1	1	1
89849	1710	most hemopoietic lineage	[most hemopoietic lineages]	0.0	3	1	1	1
89850	1710	prognosis, with a mean survival	[prognosis, with a mean survival]	0.0	5	1	1	1
89851	1710	receptor on peripheral blood t-lymphocyte	[receptors on peripheral blood T-lymphocytes]	0.0	5	1	1	1
89852	1710	human immunodeficiency virus type LTR	[human immunodeficiency virus type LTR]	0.0	5	1	1	1
89853	1710	organ develops,	[organ develops,]	0.0	2	1	1	1
89854	1710	49 case of leukemia CLL	[49 cases of leukemia CLL]	0.0	5	1	1	1
89855	1710	phagocyte in M. tuberculosis infection	[phagocytes in M. tuberculosis infection]	0.0	5	1	1	1
89856	1710	peripheral blood NK cell	[peripheral blood NK cells]	0.0	4	1	1	1
89857	1710	body burden reference	[body burden reference]	0.0	3	1	1	1
89858	1710	e-selectin icam-1 induction	[E-selectin ICAM-1 induction]	0.0	3	1	1	1
89859	1710	disease (12: with rheumatoid arthritis	[diseases (12: with rheumatoid arthritis]	0.0	5	1	1	1
89860	1710	activation of Stat	[Activation of Stat]	0.0	3	1	1	1
89861	1710	express form in this cell line	[expressing forms in this cell line]	0.0	6	1	1	1
89862	1710	region of gene isg15	[region of gene ISG15]	0.0	4	1	1	1
89863	1710	differentiation in epidermal cell	[differentiation in epidermal cells]	0.0	4	1	1	1
89864	1710	lymphocyte of two sibling	[lymphocytes of two siblings]	0.0	4	1	1	1
89865	1710	monocytic cell adhesion to ec	[Monocytic cell adhesion to EC]	0.0	5	1	1	1
89866	1710	only the nfat complex	[only the NFAT complexes]	0.0	4	1	1	1
89867	1710	provide a mechanism for effect	[providing an mechanism for effects]	0.0	5	1	1	1
89868	1710	chemical modification of lysine	[chemical modification of lysine]	0.0	4	1	1	1
89869	1710	sequence homology with other gene	[sequence homology with other genes]	0.0	5	1	1	1
89870	1710	mu/l upper limit	[mU/L upper limit]	0.0	3	1	1	1
89871	1710	natural HLH factor Id3	[natural HLH factor Id3]	0.0	4	1	1	1
89872	1710	various signal converge in intracellular pathway	[Various signals converging in intracellular pathways]	0.0	6	1	1	1
89873	1710	interaction receptor-associated factor traz	[interaction receptor-associated factors TRAFs]	0.0	4	1	1	1
89874	1710	however, order of magnitude	[however, orders of magnitude]	0.0	4	1	1	1
89875	1710	differentiation increase of acid lipase expression	[differentiation increase of acid lipase expression]	0.0	6	1	1	1
89876	1710	employ a lysis substrate	[employing a lysis substrate]	0.0	4	1	1	1
89877	1710	bind element p0	[binding element P0]	0.0	3	1	1	1
89878	1710	normal blood b lymphocyte	[normal blood B lymphocytes]	0.0	4	1	1	1
89879	1710	occupancy 1 enhancer	[occupancy 1 enhancer]	0.0	3	1	1	1
89880	1710	IL-12 receptor IL-12R beta subunit	[IL-12 receptor IL-12R beta subunit]	0.0	5	1	1	1
89881	1710	increase suggestive	[increase suggestive]	0.0	2	1	1	1
89882	1710	cellular reduce status	[cellular reducing status]	0.0	3	1	1	1
89883	1710	mrna isoform	[mRNA isoforms]	0.0	2	1	1	1
89884	1710	hours' exposure	[hours' exposure]	0.0	2	1	1	1
89885	1710	role in the mechanism	[role in the mechanism]	0.0	4	1	1	1
89886	1710	association with phospholipid surface	[association with phospholipid surfaces]	0.0	4	1	1	1
89887	1710	transactivation in cell	[transactivation in cells]	0.0	3	1	1	1
89888	1710	inhibition motif.	[inhibition motif.]	0.0	2	1	1	1
89889	1710	feature of (nk) cell	[features of (NK) cells]	0.0	4	1	1	1
89890	1710	MHC class I	[MHC class I]	0.0	3	1	1	1
89891	1710	co-transfection with expression plasmid	[Co-transfections with expression plasmids]	0.0	4	1	1	1
89892	1710	inhibition of p24 antigen production	[inhibition of p24 antigen production]	0.0	5	1	1	1
89893	1710	messenger in anti-immunoglobulin-treated b cell	[messengers in anti-immunoglobulin-treated B cells]	0.0	5	1	1	1
89894	1710	reactivity of lymphocyte	[Reactivity of lymphocytes]	0.0	3	1	1	1
89895	1710	regulation of fas ligand expression	[Regulation of Fas ligand expression]	0.0	5	1	1	1
89896	1710	xenograft survival	[xenograft survival]	0.0	2	1	1	1
89897	1710	blotting of fetal population	[blotting of fetal populations]	0.0	4	1	1	1
89898	1710	onset of b activation	[onset of B activation]	0.0	4	1	1	1
89899	1710	absence by banding techniques,	[absence by banding techniques,]	0.0	4	1	1	1
89900	1710	I/Y	[I/Y]	0.0	1	2	2	1
89901	1710	mouse DNA clone	[mouse DNA clones]	0.0	3	1	1	1
89902	1710	presence of a strong element	[presence of a strong element]	0.0	5	1	1	1
89903	1710	mutation of cbp hat activity	[mutation of CBP HAT activity]	0.0	5	1	1	1
89904	1710	insulin tolerance	[insulin tolerance]	0.0	2	1	1	1
89905	1710	feedback inhibitor	[feedback inhibitor]	0.0	2	1	1	1
89906	1710	incorporation of [3h]thymidine	[incorporation of [3H]thymidine]	0.0	3	1	1	1
89907	1710	general transcription complex tfiid	[general transcription complex TFIID]	0.0	4	1	1	1
89908	1710	DNA binding activity consist of homodimer	[DNA binding activity consisting of homodimers]	0.0	6	1	1	1
89909	1710	CoCl2 signal direct expression of vcam-1	[CoCl2 signals directing expression of VCAM-1]	0.0	6	1	1	1
89910	1710	umbilical cord T lymphocyte	[umbilical cord T lymphocytes]	0.0	4	1	1	1
89911	1710	NF-kappa b block	[NF-kappa B block]	0.0	3	1	1	1
89912	1710	platelet gpiib gene	[platelet GPIIb gene]	0.0	3	1	1	1
89913	1710	encompass a important positive element	[encompassing an important positive element]	0.0	5	1	1	1
89914	1710	binding site on the human gr	[binding sites on the human GR]	0.0	6	1	1	1
89915	1710	mainly by DOX	[mainly by DOX]	0.0	3	1	1	1
89916	1710	vitamin d binding protein idbp	[vitamin D binding protein IDBP]	0.0	5	1	1	1
89917	1710	platelet (auc nmol	[platelets (AUC nmol]	0.0	3	1	1	1
89918	1710	lytic reactivity at level	[lytic reactivities at levels]	0.0	4	1	1	1
89919	1710	activity between the promoter	[activity between the promoters]	0.0	4	1	1	1
89920	1710	A/R huvec	[A/R HUVECs]	0.0	2	1	1	1
89921	1710	8% cell at day	[8% cells at day]	0.0	4	1	1	1
89922	1710	keep erythroid-specific property in vitro	[keeping erythroid-specific properties in vitro]	0.0	5	1	1	1
89923	1710	T element	[T element]	0.0	2	1	1	1
89924	1710	cell-type specificity, activation dependence,	[cell-type specificity, activation dependence,]	0.0	4	1	1	1
89925	1710	corresponding to a -2 molecule	[corresponding to an -2 molecules]	0.0	5	1	1	1
89926	1710	low production of c-Jun	[lower production of c-Jun]	0.0	4	1	1	1
89927	1710	other T cell inhibitory activity	[other T cell inhibitory activities]	0.0	5	1	1	1
89928	1710	distinct signal transmission pathway	[distinct signal transmission pathways]	0.0	4	1	1	1
89929	1710	dominant allele	[dominant allele]	0.0	2	1	1	1
89930	1710	competition between general transcriptional activator	[competition between general transcriptional activators]	0.0	5	1	1	1
89931	1710	renal failure A-CRF with insufficiency	[renal failure A-CRF with insufficiency]	0.0	5	1	1	1
89932	1710	many molecular mechanism	[many molecular mechanisms]	0.0	3	1	1	1
89933	1710	retinoblastoma protein prb	[retinoblastoma protein pRB]	0.0	3	1	1	1
89934	1710	multiple intracellular protein	[multiple intracellular proteins]	0.0	3	1	1	1
89935	1710	red activator	[red activator]	0.0	2	1	1	1
89936	1710	lack receptor.	[lacking receptor.]	0.0	2	1	1	1
89937	1710	translocation in a t-cell leukemia	[translocation in a T-cell leukemia]	0.0	5	1	1	1
89938	1710	modification of cytokine dysregulation	[modification of cytokine dysregulation]	0.0	4	1	1	1
89939	1710	phenotypic analysis of T	[phenotypic analysis of T]	0.0	4	1	1	1
89940	1710	dna-binding activity of ap-1	[DNA-binding activity of AP-1]	0.0	4	1	1	1
89941	1710	Prostaglandin E2 a molecule	[Prostaglandin E2 a molecule]	0.0	4	1	1	1
89942	1710	lymphoid leukemia cell line	[lymphoid leukemia cell lines]	0.0	4	1	1	1
89943	1710	HS1	[HS1]	0.0	1	4	4	1
89944	1710	RXR RAR agonist	[RXR RAR agonists]	0.0	3	1	1	1
89945	1710	constitutive level of nf kappa b	[constitutive levels of NF kappa B]	0.0	6	1	1	1
89946	1710	target experiment in the mouse	[targeting experiments in the mouse]	0.0	5	1	1	1
89947	1710	hyperparathyroidism secondary to renal failure	[hyperparathyroidism secondary to renal failure]	0.0	5	1	1	1
89948	1710	dominant negative form Max	[dominant negative form Max]	0.0	4	1	1	1
89949	1710	prolonged degradation	[prolonged degradation]	0.0	2	1	1	1
89950	1710	DNA-protein complex with Abs	[DNA-protein complexes with Abs]	0.0	4	1	1	1
89951	1710	HSI	[HSI]	0.0	1	1	1	1
89952	1710	three fusions.	[three fusions.]	0.0	2	1	1	1
89953	1710	element act independently	[elements acting independently]	0.0	3	1	1	1
89954	1710	MLV activity	[MLV activity]	0.0	2	1	1	1
89955	1710	protein in normal human lymphocyte	[proteins in normal human lymphocytes]	0.0	5	1	1	1
89956	1710	glucocorticoid-sensitive 6tg1.1 icr27tk.3 T cell	[glucocorticoid-sensitive 6TG1.1 ICR27TK.3 T cells]	0.0	5	1	1	1
89957	1710	loss of one allele	[losses of one allele]	0.0	4	1	1	1
89958	1710	well-known cell transformation	[well-known cell transformation]	0.0	3	1	1	1
89959	1710	binding of gata-1	[binding of GATA-1]	0.0	3	1	1	1
89960	1710	ad2/ad12 e1a gene product	[Ad2/Ad12 E1A gene products]	0.0	4	1	1	1
89961	1710	expression of heterodimer	[expression of heterodimers]	0.0	3	1	1	1
89962	1710	spastic paraparesis tsp	[spastic paraparesis TSP]	0.0	3	1	1	1
89963	1710	glucocorticoid on endogenous function	[glucocorticoids on endogenous function]	0.0	4	1	1	1
89964	1710	only certain individual	[only certain individuals]	0.0	3	1	1	1
89965	1710	high proliferative potential cell	[high proliferative potential cells]	0.0	4	1	1	1
89966	1710	individual with filaria-induced lymphatic pathology	[individuals with filaria-induced lymphatic pathology]	0.0	5	1	1	1
89967	1710	clonality analysis of anemia study	[Clonality analysis of anemia study]	0.0	5	1	1	1
89968	1710	distal purine box	[distal purine box]	0.0	3	1	1	1
89969	1710	stimulation of cell with lps	[stimulation of cells with LPS]	0.0	5	1	1	1
89970	1710	dose-dependent inhibition of nf-kappa b mobilization	[dose-dependent inhibition of NF-kappa B mobilization]	0.0	6	1	1	1
89971	1710	4 IL-4	[4 IL-4]	0.0	2	1	1	1
89972	1710	leukocyte membrane	[leukocyte membranes]	0.0	2	1	1	1
89973	1710	control of differentiation	[control of differentiation]	0.0	3	1	1	1
89974	1710	selective modulation of nf-kappab by transfer	[selective modulation of NF-kappaB by transfer]	0.0	6	1	1	1
89975	1710	chronic ebv infection (2/7), ebv reactivation	[chronic EBV infection (2/7), EBV reactivation]	0.0	6	1	1	1
89976	1710	term of affinity	[terms of affinity]	0.0	3	1	1	1
89977	1710	tat intracellular antibody intrabody	[Tat intracellular antibody intrabody]	0.0	4	1	1	1
89978	1710	role of PKC in induction	[role of PKC in induction]	0.0	5	1	1	1
89979	1710	also polymorphic dinucleotide trinucleotide repeat	[also polymorphic dinucleotide trinucleotide repeats]	0.0	5	1	1	1
89980	1710	nuclear map kinase phosphatase	[nuclear MAP kinase phosphatases]	0.0	4	1	1	1
89981	1710	many function of human macrophage	[many functions of human macrophages]	0.0	5	1	1	1
89982	1710	5 blood cell	[5 blood cells]	0.0	3	1	1	1
89983	1710	b cell ig production	[B cell Ig production]	0.0	4	1	1	1
89984	1710	related member	[related members]	0.0	2	1	1	1
89985	1710	finding related to support	[finding related to support]	0.0	4	1	1	1
89986	1710	considerable variation	[considerable variation]	0.0	2	1	1	1
89987	1710	two activating region	[two activating regions]	0.0	3	1	1	1
89988	1710	trans-activation domain in C-terminal peptide	[trans-activation domain in C-terminal peptide]	0.0	5	1	1	1
89989	1710	lead to separable gene response	[leading to separable gene responses]	0.0	5	1	1	1
89990	1710	control subject in patient	[control subjects in patients]	0.0	4	1	1	1
89991	1710	result of transcription	[result of transcription]	0.0	3	1	1	1
89992	1710	role in transient up-regulation	[role in transient up-regulation]	0.0	4	1	1	1
89993	1710	activation of the nf-kappab -like factor	[activation of the NF-kappaB -like factor]	0.0	6	1	1	1
89994	1710	specific enhancer upstream	[specific enhancer upstream]	0.0	3	1	1	1
89995	1710	ras in ras immunoprecipitate	[Ras in Ras immunoprecipitates]	0.0	4	1	1	1
89996	1710	intrafollicular t-cell population	[intrafollicular T-cell population]	0.0	3	1	1	1
89997	1710	use rbp	[using RBP]	0.0	2	1	1	1
89998	1710	undifferentiated human cell	[undifferentiated human cells]	0.0	3	1	1	1
89999	1710	glucocorticoid in monocytic thp cell	[glucocorticoids in monocytic THP cells]	0.0	5	1	1	1
90000	1710	same genes, suggest	[same genes, suggesting]	0.0	3	1	1	1
90001	1710	high level of hepor expression	[high levels of hEpoR expression]	0.0	5	1	1	1
90002	1710	prevent transcriptional induction of cytokine	[preventing transcriptional induction of cytokine]	0.0	5	1	1	1
90003	1710	acute promyelocytic leukemia (apl):	[acute promyelocytic leukemia (APL):]	0.0	4	1	1	1
90004	1710	unbound (free) e2f	[unbound (free) E2F]	0.0	3	1	1	1
90005	1710	8, malignant fibrous histiocytoma rhabdomyosarcoma	[8, malignant fibrous histiocytoma rhabdomyosarcoma]	0.0	5	1	1	1
90006	1710	patient with chronic rheumatic disease	[patients with chronic rheumatic diseases]	0.0	5	1	1	1
90007	1710	osteosarcoma Saos-2 cell	[osteosarcoma Saos-2 cells]	0.0	3	1	1	1
90008	1710	hiv-1 replication within a individual	[HIV-1 replication within an individual]	0.0	5	1	1	1
90009	1710	degree of deficiency	[degree of deficiency]	0.0	3	1	1	1
90010	1710	mean ic50 for the group	[mean IC50s for the group]	0.0	5	1	1	1
90011	1710	response to CoCl2	[response to CoCl2]	0.0	3	1	1	1
90012	1710	interaction of rank factor traz	[interaction of RANK factors TRAFs]	0.0	5	1	1	1
90013	1710	indicate the result of activation	[indicating the result of activation]	0.0	5	1	1	1
90014	1710	number of glucocorticoid receptor ro	[number of glucocorticoid receptors Ro]	0.0	5	1	1	1
90015	1710	casein kinase ii site (37	[casein kinase II sites (37]	0.0	5	1	1	1
90016	1710	cell (sites/cell)	[cell (sites/cell)]	0.0	2	1	1	1
90017	1710	Steady-state level of receptor rna	[Steady-state levels of receptor RNA]	0.0	5	1	1	1
90018	1710	position bp	[position bp]	0.0	2	1	1	1
90019	1710	fluoroquinolone antibiotic	[fluoroquinolone antibiotic]	0.0	2	1	1	1
90020	1710	activation from the germline promoter	[activation from the germline promoter]	0.0	5	1	1	1
90021	1710	antibody against transcription factor	[antibodies against transcription factors]	0.0	4	1	1	1
90022	1710	expression of icam-i gene	[expression of ICAM-I gene]	0.0	4	1	1	1
90023	1710	contribute to disease progression	[contributing to disease progression]	0.0	4	1	1	1
90024	1710	immunomodulatory effect	[immunomodulatory effects]	0.0	2	1	1	1
90025	1710	protein adenovirus e1b-19 kda	[proteins adenovirus E1B-19 kDa]	0.0	4	1	1	1
90026	1710	contain six zinc-finger motif	[containing six zinc-finger motifs]	0.0	4	1	1	1
90027	1710	0.15 nm	[0.15 nM]	0.0	2	1	1	1
90028	1710	(mbcl6)	[(mBCL6)]	0.0	1	1	1	1
90029	1710	HTLV-I transcription	[HTLV-I transcription]	0.0	2	1	1	1
90030	1710	also significantly (p	[also significantly (P]	0.0	3	1	1	1
90031	1710	involvement of the activity	[involvement of the activity]	0.0	4	1	1	1
90032	1710	lymphocyte of 24 woman	[lymphocytes of 24 women]	0.0	4	1	1	1
90033	1710	observation, together	[observation, together]	0.0	2	1	1	1
90034	1710	simian virus SV40	[simian virus SV40]	0.0	3	1	1	1
90035	1710	hiv-enhancer activity	[HIV-enhancer activity]	0.0	2	1	1	1
90036	1710	individual binding site	[individual binding sites]	0.0	3	1	1	1
90037	1710	protein capable to regulatory sequence	[proteins capable to regulatory sequences]	0.0	5	1	1	1
90038	1710	study of c-fos-positive lymphocyte	[study of c-fos-positive lymphocytes]	0.0	4	1	1	1
90039	1710	twin sister	[twin sister]	0.0	2	1	1	1
90040	1710	c-terminal serine proline -rich region	[C-terminal serine proline -rich region]	0.0	5	1	1	1
90041	1710	role enhance nf-kappa b activity	[role enhancing NF-kappa B activity]	0.0	5	1	1	1
90042	1710	transformation of b-cell precursor	[transformation of B-cell precursors]	0.0	4	1	1	1
90043	1710	reactivity as high	[reactivities as high]	0.0	3	1	1	1
90044	1710	signal by il-2 cytokine	[Signaling by IL-2 cytokines]	0.0	4	1	1	1
90045	1710	991.9 224 ng/mL,	[991.9 224 ng/mL,]	0.0	3	1	1	1
90046	1710	initial signal event	[initial signaling events]	0.0	3	1	1	1
90047	1710	65k subunit	[65K subunits]	0.0	2	1	1	1
90048	1710	indicate common in maturation	[indicating common in maturation]	0.0	4	1	1	1
90049	1710	PLZF POZ domain	[PLZF POZ domain]	0.0	3	1	1	1
90050	1710	severe (scid-husint) mouse	[severe (SCID-HU-INT) mice]	0.0	3	1	1	1
90051	1710	tumor aggressivity	[tumor aggressivity]	0.0	2	1	1	1
90052	1710	loss of interleukin 6	[loss of interleukin 6]	0.0	4	1	1	1
90053	1710	relation between high density lipoprotein	[relation between high density lipoprotein]	0.0	5	1	1	1
90054	1710	resolution of cell extract	[Resolution of cell extract]	0.0	4	1	1	1
90055	1710	mean percent inhibition	[mean percent inhibition]	0.0	3	1	1	1
90056	1710	IEF-1	[IEF-1]	0.0	1	1	1	1
90057	1710	human interferon factor gene	[Human interferon factor gene]	0.0	4	1	1	1
90058	1710	amount present	[amount present]	0.0	2	1	1	1
90059	1710	Additionally, preincubation with a peptide Arg-Gly-Asp	[Additionally, preincubation with a peptide Arg-Gly-Asp]	0.0	6	1	1	1
90060	1710	total number of receptor	[total number of receptors]	0.0	4	1	1	1
90061	1710	pharmacophore	[pharmacophore]	0.0	1	1	1	1
90062	1710	map kinase mapk	[MAP kinase MAPK]	0.0	3	1	1	1
90063	1710	phosphoserine mimetic	[phosphoserine mimetic]	0.0	2	1	1	1
90064	1710	second feature	[second feature]	0.0	2	1	1	1
90065	1710	chimeric transcriptional properties unlike other oncoprotein	[chimeric transcriptional properties, unlike other oncoproteins]	0.0	6	1	1	1
90066	1710	infiltration into various organs,	[infiltration into various organs,]	0.0	4	1	1	1
90067	1710	transcription of hematopoietic gene	[transcription of hematopoietic genes]	0.0	4	1	1	1
90068	1710	decrease in translation	[decrease in translation]	0.0	3	1	1	1
90069	1710	other MCM member	[other MCM members,]	0.0	3	1	1	1
90070	1710	human human cell	[human human cells]	0.0	3	1	1	1
90071	1710	IL-2 inhibitor	[IL-2 inhibitors]	0.0	2	1	1	1
90072	1710	expression of Epstein-Barr virus latent protein	[expression of Epstein-Barr virus latent proteins]	0.0	6	1	1	1
90073	1710	interferon (ifn)-inducible protein	[interferon (IFN)-inducible protein]	0.0	3	1	1	1
90074	1710	gr bind abnormalities: 15	[GR binding abnormalities: 15]	0.0	4	1	1	1
90075	1710	Half-maximal induction of gr mrna	[Half-maximal induction of GR mRNA]	0.0	5	1	1	1
90076	1710	nuclear inhibitory protein	[nuclear inhibitory protein]	0.0	3	1	1	1
90077	1710	severe disease	[severe disease]	0.0	2	1	1	1
90078	1710	SMX -no	[SMX -NO]	0.0	2	1	1	1
90079	1710	pbl of individual	[PBL of individuals]	0.0	3	1	1	1
90080	1710	adaptive immune system	[adaptive immune system]	0.0	3	1	1	1
90081	1710	T cell line myristate	[T cell line myristate]	0.0	4	1	1	1
90082	1710	comparison, other RBA	[comparison, other RBA]	0.0	3	1	1	1
90083	1710	add-back experiment	[Add-back experiments]	0.0	2	1	1	1
90084	1710	requirement for il-2	[requirement for IL-2]	0.0	3	1	1	1
90085	1710	synergism between two distinct element	[Synergism between two distinct elements]	0.0	5	1	1	1
90086	1710	course,	[course,]	0.0	1	1	1	1
90087	1710	45-nucleotide sequence	[45-nucleotide sequence]	0.0	2	1	1	1
90088	1710	rBPI21 a recombinant N-terminal fragment	[rBPI21 a recombinant N-terminal fragment]	0.0	5	1	1	1
90089	1710	replication of the hiv-1 b-laip	[replication of the HIV-1 B-LAIp]	0.0	5	1	1	1
90090	1710	transduction of signal	[transduction of signals]	0.0	3	1	1	1
90091	1710	acid similar to tumor necrosis factor-alpha	[acid similar to tumor necrosis factor-alpha]	0.0	6	1	1	1
90092	1710	breakpoint in this lymphoma	[breakpoint in these lymphomas]	0.0	4	1	1	1
90093	1710	sequence-bind protein	[sequence-binding protein]	0.0	2	1	1	1
90094	1710	term of the ability	[terms of the ability]	0.0	4	1	1	1
90095	1710	normal sensitivity to glucocorticoid	[normal sensitivity to glucocorticoids]	0.0	4	1	1	1
90096	1710	reconstitution of a processing system	[reconstitution of a processing system]	0.0	5	1	1	1
90097	1710	feedback regulation	[feedback regulation]	0.0	2	1	1	1
90098	1710	leukemic t-cell line	[leukemic T-cell line]	0.0	3	1	1	1
90099	1710	gc of dose	[GC of doses]	0.0	3	1	1	1
90100	1710	cellular apoptosis	[cellular apoptosis]	0.0	2	1	1	1
90101	1710	factor 4681	[Factors 4681]	0.0	2	1	1	1
90102	1710	encode the splice product	[encoding the splice products]	0.0	4	1	1	1
90103	1710	abnormality,	[abnormality,]	0.0	1	1	1	1
90104	1710	monocytic differentiation of HL-60 leukemia cell	[Monocytic differentiation of HL-60 leukemia cells]	0.0	6	1	1	1
90105	1710	tyrosine kinase Tec family	[tyrosine kinase Tec family]	0.0	4	1	1	1
90106	1710	antibody specific for the conformer	[antibodies specific for the conformers]	0.0	5	1	1	1
90107	1710	disease with rheumatoid arthritis	[diseases with rheumatoid arthritis]	0.0	4	1	1	1
90108	1710	involvement in lymphotropic virus type	[Involvement in lymphotropic virus type]	0.0	5	1	1	1
90109	1710	mature form of the erythroid	[mature forms of the erythroid]	0.0	5	1	1	1
90110	1710	er alpha	[ER alpha]	0.0	2	1	1	1
90111	1710	part, due to signalling system	[part, due to signalling systems]	0.0	5	1	1	1
90112	1710	exclusively in the cytoplasm	[exclusively in the cytoplasm]	0.0	4	1	1	1
90113	1710	aging syndrome	[aging syndromes]	0.0	2	2	2	1
90114	1710	however, removal	[however, removal]	0.0	2	1	1	1
90115	1710	DNA bind region specify affinity	[DNA binding region specifying affinity]	0.0	5	1	1	1
90116	1710	acid RA on hiv-1 expression	[acids RA on HIV-1 expression]	0.0	5	1	1	1
90117	1710	primary bone marrow culture	[primary bone marrow cultures]	0.0	4	1	1	1
90118	1710	vivo exposure	[vivo exposure]	0.0	2	1	1	1
90119	1710	pituitary peptide hormone	[pituitary peptide hormone]	0.0	3	1	1	1
90120	1710	lai replication in T cell	[LAI replication in T cells]	0.0	5	1	1	1
90121	1710	affinity to the vd receptor (vdr)	[affinity to the VD receptor (VDR)]	0.0	6	1	1	1
90122	1710	MRD -positive patient	[MRD -positive patients]	0.0	3	1	1	1
90123	1710	DLCL the clinically relevant form	[DLCL the clinically relevant form]	0.0	5	1	1	1
90124	1710	decreased, z-lll-h -insensitive activity	[decreased, Z-LLL-H -insensitive activity]	0.0	4	1	1	1
90125	1710	use histamine	[using histamine]	0.0	2	1	1	1
90126	1710	addition of antibody in culture medium	[addition of antibody in culture medium]	0.0	6	1	1	1
90127	1710	Stanley	[Stanley]	0.0	1	1	1	1
90128	1710	immunohistochemical, blotting (rna) blotting assay	[immunohistochemical, blotting (RNA) blotting assays]	0.0	5	1	1	1
90129	1710	role of Itk a member	[role of Itk a member]	0.0	5	1	1	1
90130	1710	new crucial element	[new crucial element]	0.0	3	1	1	1
90131	1710	4 h in endothelial cell	[4 h in endothelial cells]	0.0	5	1	1	1
90132	1710	superantigen staphylococcal enterotoxin b	[superantigen staphylococcal enterotoxin B]	0.0	4	1	1	1
90133	1710	superantigen staphylococcal enterotoxin a	[superantigen staphylococcal enterotoxin A]	0.0	4	1	1	1
90134	1710	two pathway operate	[two pathways operating]	0.0	3	1	1	1
90135	1710	7.0 kb of the sequence	[7.0 kb of the sequence]	0.0	5	1	1	1
90136	1710	activation through CD2 adhesion molecule	[Activation through CD2 adhesion molecules]	0.0	5	1	1	1
90137	1710	response of monocytes/macrophages	[responses of monocytes/macrophages]	0.0	3	1	1	1
90138	1710	thiazolidinedione derivative	[thiazolidinedione derivative]	0.0	2	1	1	1
90139	1710	Recombinant tumor necrosis factor binding protein-1	[Recombinant tumor necrosis factor binding protein-1]	0.0	6	1	1	1
90140	1710	two factor nf-il6	[Two factor NF-IL6]	0.0	3	1	1	1
90141	1710	HaCaT cell line blood lymphocyte	[HaCaT cell line blood lymphocytes]	0.0	5	1	1	1
90142	1710	pma-induced JNK activation	[PMA-induced JNK activation]	0.0	3	1	1	1
90143	1710	flexi-12 delivery to acute myeloid blast	[Flexi-12 delivery to acute myeloid blasts]	0.0	6	1	1	1
90144	1710	II,	[II,]	0.0	1	1	1	1
90145	1710	-mediated growth	[-mediated growth]	0.0	2	2	2	1
90146	1710	3.16 mg/24h; n: excretion,	[3.16 mg/24h; N: excretion,]	0.0	4	1	1	1
90147	1710	function of il-13	[function of IL-13]	0.0	3	1	1	1
90148	1710	combination with acid RA	[combination with acid RA]	0.0	4	1	1	1
90149	1710	aortic cell HAEC	[aortic cells HAEC]	0.0	3	1	1	1
90150	1710	result in the absence	[resulting in the absence]	0.0	4	1	1	1
90151	1710	important role mediate adhesion	[important role mediating adhesion]	0.0	4	1	1	1
90152	1710	domain act in insertional actin polymerization	[domains acting in insertional actin polymerization]	0.0	6	1	1	1
90153	1710	binding of distinct complex RFX	[binding of distinct complexes RFX]	0.0	5	1	1	1
90154	1710	plasma cysteine	[plasma cysteine]	0.0	2	1	1	1
90155	1710	2 weeks.	[2 weeks.]	0.0	2	1	1	1
90156	1710	particular tyrosine-containing stat docking site	[particular tyrosine-containing STAT docking sites]	0.0	5	1	1	1
90157	1710	aids patient with malignancy	[AIDS patients with malignancies]	0.0	4	1	1	1
90158	1710	abundant dna-binding activity of extract	[abundant DNA-binding activity of extracts]	0.0	5	1	1	1
90159	1710	blockade use a dominant negative ikappabalpha	[blockade using a dominant negative IkappaBalpha]	0.0	6	1	1	1
90160	1710	regulator of cytokine genes,	[regulators of cytokine genes,]	0.0	4	1	1	1
90161	1710	interaction between regulatory element	[interactions between regulatory elements]	0.0	4	1	1	1
90162	1710	overexpression of mutant	[overexpression of mutants]	0.0	3	1	1	1
90163	1710	3-fold increase	[3-fold increases]	0.0	2	1	1	1
90164	1710	accumulation for elam-1 of elam-1	[accumulation for ELAM-1 of ELAM-1]	0.0	5	1	1	1
90165	1710	such important mediator	[such important mediators]	0.0	3	1	1	1
90166	1710	v-Abl signal	[v-Abl signaling]	0.0	2	1	1	1
90167	1710	immunoprecipitation of the gp 160 extract	[Immunoprecipitation of the gp 160 extracts]	0.0	6	1	1	1
90168	1710	detectable phosphorylation	[detectable phosphorylation]	0.0	2	1	1	1
90169	1710	regulatory element for factor	[regulatory elements for factor]	0.0	4	1	1	1
90170	1710	erythroid stage-specific nuclear factor-DNA complex	[erythroid stage-specific nuclear factor-DNA complexes]	0.0	5	1	1	1
90171	1710	analysis of nfat nuclear factor	[analysis of NFAT nuclear factor]	0.0	5	1	1	1
90172	1710	human immunodeficiency virus-type 1	[Human immunodeficiency virus-type 1]	0.0	4	1	1	1
90173	1710	prolyl isomerase	[prolyl isomerases]	0.0	2	1	1	1
90174	1710	Differential regulation of 4e-bp1	[Differential regulation of 4E-BP1]	0.0	4	1	1	1
90175	1710	significant proliferation capacity	[significant proliferation capacity]	0.0	3	1	1	1
90176	1710	also with other motif-rich protein	[also with other motif-rich proteins]	0.0	5	1	1	1
90177	1710	female aged	[females aged]	0.0	2	1	1	1
90178	1710	transcription study	[transcription studies]	0.0	2	1	1	1
90179	1710	expression of several cytokine gene	[expression of several cytokine genes]	0.0	5	1	1	1
90180	1710	rest human vein endothelial cell	[resting human vein endothelial cells]	0.0	5	1	1	1
90181	1710	modulation of the CREB /atf-1 family	[modulation of the CREB /ATF-1 family]	0.0	6	1	1	1
90182	1710	gene regulation of the human h(+)-atpase	[gene regulation of the human H(+)-ATPase]	0.0	6	1	1	1
90183	1710	low-dose il-3	[low-dose IL-3]	0.0	2	1	1	1
90184	1710	cellular activator	[cellular activator]	0.0	2	1	1	1
90185	1710	more polar substitution alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[more polar substitutions alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	5	1	1	1
90186	1710	protein kinase C PKC isoenzyme	[protein kinase C PKC isoenzymes]	0.0	5	1	1	1
90187	1710	tnf-treated umbilical vein endothelial cell	[TNF-treated umbilical vein endothelial cells]	0.0	5	1	1	1
90188	1710	child with asthma	[children with asthma]	0.0	3	1	1	1
90189	1710	important pathway lead	[important pathway leading]	0.0	3	1	1	1
90190	1710	ILF	[ILF]	0.0	1	1	1	1
90191	1710	leukemia cell from a patient	[leukemia cells from a patient]	0.0	5	1	1	1
90192	1710	il-4 induction	[IL-4 induction]	0.0	2	1	1	1
90193	1710	immunosuppression: inhibition of K+ channel	[immunosuppression: inhibition of K+ channels]	0.0	5	1	1	1
90194	1710	J.,	[J.,]	0.0	1	1	1	1
90195	1710	production in vivo,	[production in vivo,]	0.0	3	1	1	1
90196	1710	calcium c-myc suppression	[calcium c-myc suppression]	0.0	3	1	1	1
90197	1710	T cell proliferation in the absence	[T cell proliferation in the absence]	0.0	6	1	1	1
90198	1710	ERK inhibitor pd98059	[ERK inhibitor PD98059]	0.0	3	1	1	1
90199	1710	impaired deletion	[impaired deletion]	0.0	2	1	1	1
90200	1710	down-regulation of ALY	[down-regulation of ALY]	0.0	3	1	1	1
90201	1710	Comparing the regulation of this zinc-finger	[Comparing the regulation of these zinc-finger]	0.0	6	1	1	1
90202	1710	nf-kappa b in ML-1a	[NF-kappa B in ML-1a]	0.0	4	1	1	1
90203	1710	signal through CD3	[signaling through CD3]	0.0	3	1	1	1
90204	1710	activation by beta-phorbol 13-acetate PMA	[activation by beta-phorbol 13-acetate PMA]	0.0	5	1	1	1
90205	1710	hypothalamic-pituitary-adrenal axis activation	[hypothalamic-pituitary-adrenal axis activation]	0.0	3	1	1	1
90206	1710	production of 3 colony-stimulating factor	[production of 3 colony-stimulating factor]	0.0	5	1	1	1
90207	1710	heart failure	[heart failure]	0.0	2	3	3	1
90208	1710	malaria [see comments]	[malaria [see comments]]	0.0	3	1	1	1
90209	1710	stat6 protein present	[Stat6 protein present]	0.0	3	1	1	1
90210	1710	addition to extract	[addition to extracts]	0.0	3	1	1	1
90211	1710	inflammatory disorder a problem	[inflammatory disorders a problem]	0.0	4	1	1	1
90212	1710	tissue-specific element	[tissue-specific element]	0.0	2	1	1	1
90213	1710	degradation of neutrophil	[degradation of neutrophils]	0.0	3	1	1	1
90214	1710	burst-forming unit BFU-E	[burst-forming units BFU-E]	0.0	3	1	1	1
90215	1710	inhibitor platelet-activating factor	[Inhibitors platelet-activating factor]	0.0	3	1	1	1
90216	1710	infiltrate tumour	[infiltrating tumours]	0.0	2	1	1	1
90217	1710	regulation during induction	[Regulation during induction]	0.0	3	1	1	1
90218	1710	two cluster	[Two clusters]	0.0	2	1	1	1
90219	1710	four b binding site	[four B binding sites]	0.0	4	1	1	1
90220	1710	lysis by cytolytic lymphocyte	[lysis by cytolytic lymphocytes]	0.0	4	1	1	1
90221	1710	T negative element nre	[T negative element NRE]	0.0	4	1	1	1
90222	1710	beta thalassemia patient without HbF	[beta thalassemia patients without HbF]	0.0	5	1	1	1
90223	1710	groups, sr	[groups, SR]	0.0	2	1	1	1
90224	1710	reactivity at level as high	[reactivities at levels as high]	0.0	5	1	1	1
90225	1710	difference 0.02) in the distribution	[difference 0.02) in the distribution]	0.0	5	1	1	1
90226	1710	action of other cytotoxic protein	[action of other cytotoxic proteins]	0.0	5	1	1	1
90227	1710	inhibition acid	[Inhibition acid]	0.0	2	1	1	1
90228	1710	domain of c-kit	[domain of c-kit]	0.0	3	1	1	1
90229	1710	specific elastase inhibitor	[specific elastase inhibitor]	0.0	3	1	1	1
90230	1710	bind media	[binding media]	0.0	2	1	1	1
90231	1710	constitutive expression of nf-kappab in monocyte	[constitutive expression of NF-kappaB in monocytes]	0.0	6	1	1	1
90232	1710	pathogenesis of synovitis	[pathogenesis of synovitis]	0.0	3	1	1	1
90233	1710	NK cell lysis	[NK cell lysis]	0.0	3	2	2	1
90234	1710	allele-specific expression in human fibroblast	[allele-specific expression in human fibroblasts]	0.0	5	1	1	1
90235	1710	FDC clusters, p50	[FDC clusters, p50]	0.0	3	1	1	1
90236	1710	precursor by insertion	[precursors by insertion]	0.0	3	1	1	1
90237	1710	g-csf cell at day	[G-CSF cells at day]	0.0	4	1	1	1
90238	1710	kb) in all tissue	[kb) in all tissues]	0.0	4	1	1	1
90239	1710	rapid modulation in response	[rapid modulation in response]	0.0	4	1	1	1
90240	1710	nucleotide relative	[nucleotides relative]	0.0	2	1	1	1
90241	1710	hematopoietic neoplasm	[hematopoietic neoplasms]	0.0	2	1	1	1
90242	1710	western blotting experiment	[Western blotting experiments]	0.0	3	1	1	1
90243	1710	calcineurin -dependent translocation	[calcineurin -dependent translocation]	0.0	3	1	1	1
90244	1710	enhancement of tnf-alpha production	[enhancement of TNF-alpha production]	0.0	4	1	1	1
90245	1710	recruitment to lesion	[recruitment to lesions]	0.0	3	1	1	1
90246	1710	CTL control in vivo	[CTL control in vivo]	0.0	4	1	1	1
90247	1710	model of the regulation	[model of the regulation]	0.0	4	1	1	1
90248	1710	density lipoprotein response	[density lipoprotein responses]	0.0	3	1	1	1
90249	1710	sterol regulatory sequence	[sterol regulatory sequence]	0.0	3	1	1	1
90250	1710	as tracer, mnl of subject	[as tracer, MNL of subjects]	0.0	5	1	1	1
90251	1710	normal exon sequence	[normal exon sequence]	0.0	3	1	1	1
90252	1710	presence of multiple cis element	[presence of multiple cis elements]	0.0	5	1	1	1
90253	1710	control expression in response	[controlling expression in response]	0.0	4	1	1	1
90254	1710	stimulation with peptide	[stimulation with peptide]	0.0	3	1	1	1
90255	1710	pbl sample	[PBL samples]	0.0	2	1	1	1
90256	1710	K+ channel KV	[K+ channels KV]	0.0	3	1	1	1
90257	1710	number in peripheral leucocyte	[number in peripheral leucocytes]	0.0	4	2	2	1
90258	1710	(i) patient rarely er	[(i) patients rarely ER]	0.0	4	1	1	1
90259	1710	coincubation of 35s- tr alpha	[coincubation of 35S- TR alpha]	0.0	5	1	1	1
90260	1710	level in neonatal T cell	[levels in neonatal T cells]	0.0	5	1	1	1
90261	1710	approximately eightfold low amount of nf-at	[approximately eightfold lower amounts of NF-AT]	0.0	6	1	1	1
90262	1710	cytokine dysregulation immunodeficiency virus type 1	[Cytokine dysregulation immunodeficiency virus type 1]	0.0	6	1	1	1
90263	1710	(tf) expression by blood monocyte	[(TF) expression by blood monocytes]	0.0	5	1	1	1
90264	1710	myeloproliferative disease mpd	[myeloproliferative diseases MPDs]	0.0	3	1	1	1
90265	1710	es-derived body	[ES-derived bodies]	0.0	2	1	1	1
90266	1710	15 patient in (st;	[15 patients in (ST;]	0.0	4	1	1	1
90267	1710	critical transcription factor for expression	[critical transcription factor for expression]	0.0	5	1	1	1
90268	1710	ISG	[ISG]	0.0	1	1	1	1
90269	1710	C-terminal homeodomain pouhd	[C-terminal homeodomain POUHD]	0.0	3	1	1	1
90270	1710	follow treatment with retinoic acid	[following treatment with retinoic acid]	0.0	5	1	1	1
90271	1710	abundance in blood mononuclear cell	[abundance in blood mononuclear cells]	0.0	5	1	1	1
90272	1710	high intracellular activity	[higher intracellular activity]	0.0	3	1	1	1
90273	1710	plasminogen	[plasminogen]	0.0	1	1	1	1
90274	1710	u937 transfectant	[U937 transfectants]	0.0	2	1	1	1
90275	1710	t-cell from individual with lymphatic pathology	[T-cells from individuals with lymphatic pathology]	0.0	6	1	1	1
90276	1710	divergence in cytokine profile	[divergence in cytokine profiles]	0.0	4	1	1	1
90277	1710	Protein kinase C	[Protein kinase C]	0.0	3	1	1	1
90278	1710	histiocytoma rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma	[histiocytoma rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
90279	1710	ITT	[ITT]	0.0	1	1	1	1
90280	1710	antiviral effect of antioxidant therapy	[antiviral effects of antioxidant therapies.]	0.0	5	1	1	1
90281	1710	hypothalamic-pituitary-adrenal axis activation during illness	[hypothalamic-pituitary-adrenal axis activation during illness]	0.0	5	1	1	1
90282	1710	represent the new NH2 terminus	[representing the new NH2 terminus]	0.0	5	1	1	1
90283	1710	such silencing	[Such silencing]	0.0	2	1	1	1
90284	1710	macrophage in the gland,y	[macrophages in the gland,]	0.0	4	1	1	1
90285	1710	nuclear factor present	[nuclear factor present]	0.0	3	1	1	1
90286	1710	dominant negative mutant pathway	[dominant negative mutants pathway]	0.0	4	1	1	1
90287	1710	tal1/scl	[TAL1/SCL]	0.0	1	1	1	1
90288	1710	kappa b motif activity	[kappa B motif activity]	0.0	4	1	1	1
90289	1710	nuclear factor proximal NF-AT AP-1/Octamer	[nuclear factor proximal NF-AT AP-1/Octamer]	0.0	5	1	1	1
90290	1710	immunoglobulin chain igh enhancer	[immunoglobulin chain IgH enhancer]	0.0	4	1	1	1
90291	1710	T cell leukemia ATL	[T cell leukemia ATL]	0.0	4	1	1	1
90292	1710	pathogenesis of inflammation	[pathogenesis of inflammation]	0.0	3	1	1	1
90293	1710	T cell a transcription factor	[T cells a transcription factor]	0.0	5	1	1	1
90294	1710	il-6-responsive element	[IL-6-responsive elements]	0.0	2	1	1	1
90295	1710	bp of sequence	[bp of sequence]	0.0	3	1	1	1
90296	1710	multidrug resistance	[multidrug resistance]	0.0	2	1	1	1
90297	1710	high expression of the signal transducer	[high expression of the signal transducer]	0.0	6	1	1	1
90298	1710	part of the sequence	[parts of the sequence]	0.0	4	1	1	1
90299	1710	protein protein hxbp-1	[protein protein hXBP-1]	0.0	3	1	1	1
90300	1710	molecular genetic basis	[molecular genetic basis]	0.0	3	1	1	1
90301	1710	prostate epithelia	[prostate epithelia]	0.0	2	1	1	1
90302	1710	pathway of Tat activation	[pathway of Tat activation]	0.0	4	1	1	1
90303	1710	use anti-Class monoclonal antibody	[using anti-Class monoclonal antibodies]	0.0	4	1	1	1
90304	1710	level of intracellular ROI	[levels of intracellular ROI]	0.0	4	1	1	1
90305	1710	class gene transactivator	[class gene transactivator]	0.0	3	1	1	1
90306	1710	understanding of development	[understanding of development]	0.0	3	1	1	1
90307	1710	pmol/L (p than 0.025).	[pmol/L (P than 0.025).]	0.0	4	1	1	1
90308	1710	coupling of tcr-regulated ptk	[coupling of TCR-regulated PTKs]	0.0	4	1	1	1
90309	1710	sickle erythrocyte	[sickle erythrocytes]	0.0	2	1	1	1
90310	1710	cells, fludarabine	[cells, fludarabine]	0.0	2	1	1	1
90311	1710	significant correlation points), body mass	[significant correlation points), body mass]	0.0	5	1	1	1
90312	1710	such as okadaic acid	[such as okadaic acid]	0.0	4	1	1	1
90313	1710	level of nf-kappab subunit plb-985	[levels of NF-kappaB subunits PLB-985]	0.0	5	1	1	1
90314	1710	moreover, TNF-alpha hiv-1 repeat	[Moreover, TNF-alpha HIV-1 repeat]	0.0	4	1	1	1
90315	1710	bolus	[bolus]	0.0	1	1	1	1
90316	1710	certain fatty acid	[certain fatty acids]	0.0	3	1	1	1
90317	1710	3D-NMR study	[3D-NMR studies]	0.0	2	1	1	1
90318	1710	up-regulation consistent with a need	[up-regulation consistent with a need]	0.0	5	1	1	1
90319	1710	element alpha/delta 1	[element alpha/delta 1]	0.0	3	1	1	1
90320	1710	identical concentration	[identical concentrations]	0.0	2	2	2	1
90321	1710	human interferon regulatory factor gene	[Human interferon regulatory factor gene]	0.0	5	1	1	1
90322	1710	stimulatory effect on the transcription	[stimulatory effect on the transcription]	0.0	5	1	1	1
90323	1710	mean type ii	[mean type II]	0.0	3	1	1	1
90324	1710	(ire)	[(IRE)]	0.0	1	1	1	1
90325	1710	fatigue	[fatigue]	0.0	1	1	1	1
90326	1710	stage- specific manner	[stage- specific manner]	0.0	3	1	1	1
90327	1710	2 subject	[2 subjects]	0.0	2	1	1	1
90328	1710	certain mediator	[certain mediators]	0.0	2	1	1	1
90329	1710	cell effector	[cell effector]	0.0	2	1	1	1
90330	1710	four binding site for nuclear protein	[four binding sites for nuclear proteins]	0.0	6	1	1	1
90331	1710	transendothelial migration of antigen t-cell	[transendothelial migration of antigen T-cells]	0.0	5	1	1	1
90332	1710	useful technique for the measurement	[useful technique for the measurement]	0.0	5	1	1	1
90333	1710	human epsilon-globin gene	[human epsilon-globin gene]	0.0	3	1	1	1
90334	1710	therefore a target	[therefore a target]	0.0	3	1	1	1
90335	1710	amino acid-rich par	[amino acid-rich PAR]	0.0	3	1	1	1
90336	1710	constitutive phosphorylation of Jak3 usually, STAT3	[Constitutive phosphorylation of Jak3 usually, STAT3]	0.0	6	1	1	1
90337	1710	mutant ikk1	[mutant IKK1]	0.0	2	1	1	1
90338	1710	cd3epsilon transgenic mouse	[CD3epsilon transgenic mice]	0.0	3	1	1	1
90339	1710	X inactivation analysis evidence	[X inactivation analysis evidence]	0.0	4	1	1	1
90340	1710	activation of cAMP-dependent reporter gene	[activation of cAMP-dependent reporter genes]	0.0	5	1	1	1
90341	1710	XIST	[XIST]	0.0	1	1	1	1
90342	1710	surface expression alpha subunit	[surface expression alpha subunit]	0.0	4	1	1	1
90343	1710	functional characteristic	[functional characteristics]	0.0	2	1	1	1
90344	1710	ap-1 -binding activity of protein	[AP-1 -binding activity of proteins]	0.0	5	1	1	1
90345	1710	gene fall	[genes falling]	0.0	2	1	1	1
90346	1710	hybridization accessibility	[hybridization accessibility]	0.0	2	1	1	1
90347	1710	lipoarabinomannan manlam of mycobacterium tuberculosis	[lipoarabinomannan ManLAM of Mycobacterium tuberculosis]	0.0	5	1	1	1
90348	1710	rapid response, reach a maximum	[rapid response, reaching a maximum]	0.0	5	1	1	1
90349	1710	subnuclear domain	[subnuclear domain]	0.0	2	1	1	1
90350	1710	reporter gene expression in erythroleukemia cell	[reporter gene expression in erythroleukemia cells]	0.0	6	1	1	1
90351	1710	bipartite interleukin-4 receptor	[bipartite interleukin-4 receptor]	0.0	3	1	1	1
90352	1710	form of selection expansion)	[forms of selection expansion)]	0.0	4	1	1	1
90353	1710	protein with a programme	[protein with a programme]	0.0	4	1	1	1
90354	1710	sex reversal map kb	[sex reversal map kb]	0.0	4	1	1	1
90355	1710	211 +/- 8 nmol	[211 +/- 8 nmol]	0.0	4	1	1	1
90356	1710	activation of zeta 2 globin gene	[activation of zeta 2 globin gene]	0.0	6	1	1	1
90357	1710	blood histamine response	[blood histamine response]	0.0	3	1	1	1
90358	1710	alternative transcript	[alternative transcript]	0.0	2	1	1	1
90359	1710	guardian	[guardian]	0.0	1	1	1	1
90360	1710	beta- versus globin chain	[beta- versus globin chains]	0.0	4	1	1	1
90361	1710	cell v-atpase content	[cell V-ATPase content]	0.0	3	1	1	1
90362	1710	position of exon	[position of exon]	0.0	3	1	1	1
90363	1710	differentiation of pth cell	[differentiation of pTh cells]	0.0	4	1	1	1
90364	1710	load in vivo	[load in vivo]	0.0	3	1	1	1
90365	1710	dose of autg microm	[doses of AuTG microM]	0.0	4	1	1	1
90366	1710	various diseases, include malignancy	[various diseases, including malignancies]	0.0	4	1	1	1
90367	1710	Recombinant caspase	[Recombinant caspase]	0.0	2	1	1	1
90368	1710	low level of ifn-gamma	[low levels of IFN-gamma]	0.0	4	1	1	1
90369	1710	factor modulate the transcription	[factors modulating the transcription]	0.0	4	1	1	1
90370	1710	contrast to experiment with intact	[contrast to experiments with intact]	0.0	5	1	1	1
90371	1710	use conditions, three distinct complex	[Using conditions, three distinct complexes]	0.0	5	1	1	1
90372	1710	conjunctival biopsy from patient	[conjunctival biopsies from patients]	0.0	4	1	1	1
90373	1710	nuclear binding protein (85 kD	[nuclear binding proteins (85 kD]	0.0	5	1	1	1
90374	1710	cross-talk with the calcineurin-	[cross-talk with the calcineurin-]	0.0	4	1	1	1
90375	1710	two distinct signal transmission pathway	[Two distinct signal transmission pathways]	0.0	5	1	1	1
90376	1710	underlie the nuclear translocation of b	[underlying the nuclear translocation of B]	0.0	6	1	1	1
90377	1710	keep property	[keeping properties]	0.0	2	1	1	1
90378	1710	uncommon phenomenon in normal woman	[uncommon phenomenon in normal women]	0.0	5	1	1	1
90379	1710	nineteen woman aged	[nineteen women aged]	0.0	3	1	1	1
90380	1710	basic fibroblast growth factor	[basic fibroblast growth factor]	0.0	4	1	1	1
90381	1710	blood leukocyte in patient	[blood leukocytes in patients]	0.0	4	2	2	1
90382	1710	interrelationship between the messenger Ca2+	[interrelationship between the messengers Ca2+]	0.0	5	1	1	1
90383	1710	treatment of u1 cell	[Treatment of U1 cells]	0.0	4	1	1	1
90384	1710	affinity consistent with effect	[affinity consistent with effects]	0.0	4	1	1	1
90385	1710	hematopoietic cell polypryrimidine-binding factor	[hematopoietic cells polypryrimidine-binding factor]	0.0	4	1	1	1
90386	1710	il-10 regulation	[IL-10 regulation]	0.0	2	1	1	1
90387	1710	adequacy	[adequacy]	0.0	1	1	1	1
90388	1710	epitope cell	[epitope cells]	0.0	2	1	1	1
90389	1710	stat1 by tax	[STAT1 by Tax]	0.0	3	1	1	1
90390	1710	modulation in response	[modulation in response]	0.0	3	1	1	1
90391	1710	alpha receptor	[alpha receptor]	0.0	2	1	1	1
90392	1710	antibody from healthy carrier	[antibodies from healthy carriers]	0.0	4	1	1	1
90393	1710	promoter activity in k562 cell	[promoter activity in K562 cells]	0.0	5	1	1	1
90394	1710	bronchial asthmatic subject	[bronchial asthmatic subjects]	0.0	3	1	1	1
90395	1710	stimulus in t-cell	[stimuli in T-cells]	0.0	3	1	1	1
90396	1710	use a dominant negative form	[using a dominant negative form]	0.0	5	1	1	1
90397	1710	enhancer position	[enhancer position]	0.0	2	1	1	1
90398	1710	promoter synergistic activation	[promoter synergistic activation]	0.0	3	1	1	1
90399	1710	hiv1 macrophage	[HIV1 macrophages]	0.0	2	1	1	1
90400	1710	activity of ap1	[activity of AP1]	0.0	3	1	1	1
90401	1710	apoptosis signal pathway	[apoptosis signaling pathways]	0.0	3	1	1	1
90402	1710	contrast to hypotheses,	[contrast to hypotheses,]	0.0	3	1	1	1
90403	1710	band p11.23	[bands p11.23]	0.0	2	1	1	1
90404	1710	cytoplasmic domain of factor gm-csf	[cytoplasmic domain of factor GM-CSF]	0.0	5	1	1	1
90405	1710	integrin cd11b	[integrin CD11b]	0.0	2	1	1	1
90406	1710	patient with infections.	[patients with infections.]	0.0	3	1	1	1
90407	1710	gene contain gata-responsive element	[genes containing GATA-responsive elements]	0.0	4	1	1	1
90408	1710	binding site for Oct2	[binding sites for Oct2]	0.0	4	1	1	1
90409	1710	decrease to addition	[decrease to addition]	0.0	3	1	1	1
90410	1710	b species	[B species]	0.0	2	1	1	1
90411	1710	increase with peak at h	[increase with peaks at h]	0.0	5	1	1	1
90412	1710	initial infection in most individual	[initial infection in most individuals]	0.0	5	1	1	1
90413	1710	heat-labile serum factor (s)	[heat-labile serum factor (s)]	0.0	4	1	1	1
90414	1710	other lung disease	[other lung diseases]	0.0	3	1	1	1
90415	1710	recombinant mouse strain	[recombinant mouse strains]	0.0	3	1	1	1
90416	1710	evidence for involvement of NF-kappa b	[evidence for involvement of NF-kappa B]	0.0	6	1	1	1
90417	1710	selective expression by T helper cell	[Selective expression by T helper cells]	0.0	6	1	1	1
90418	1710	permanent occupancy 1 enhancer	[Permanent occupancy 1 enhancer]	0.0	4	1	1	1
90419	1710	premature onset of feature	[premature onset of features]	0.0	4	1	1	1
90420	1710	distinct apoptotic pathway	[distinct apoptotic pathways]	0.0	3	1	1	1
90421	1710	NF-kappaB complex in function	[NF-kappaB complexes in functions]	0.0	4	1	1	1
90422	1710	pax gene in the system	[Pax genes in the system]	0.0	5	1	1	1
90423	1710	negative mutant of NIK	[negative mutants of NIK]	0.0	4	1	1	1
90424	1710	Ca2+ pkc isoform	[Ca2+ PKC isoforms]	0.0	3	1	1	1
90425	1710	underlie expression	[underlying expression]	0.0	2	1	1	1
90426	1710	intracellular signal pathway in neutrophil	[intracellular signaling pathways in neutrophils]	0.0	5	1	1	1
90427	1710	remission CHR	[remission CHR]	0.0	2	2	2	1
90428	1710	activation of blood T lymphoblast	[activation of blood T lymphoblasts]	0.0	5	1	1	1
90429	1710	3 to 5 day	[3 to 5 days]	0.0	4	1	1	1
90430	1710	two tandem cysteine LIM domain	[two tandem cysteine LIM domains]	0.0	5	1	1	1
90431	1710	substrate recognition	[substrate recognition]	0.0	2	1	1	1
90432	1710	activation of gene contain element	[activation of genes containing elements]	0.0	5	1	1	1
90433	1710	differentiation program of normal progenitor	[differentiation program of normal progenitors]	0.0	5	1	1	1
90434	1710	crucial determinant govern process	[crucial determinant governing processes]	0.0	4	1	1	1
90435	1710	wt1 expression in cell	[WT1 expression in cells]	0.0	4	1	1	1
90436	1710	several class ii DNA binding factor	[several class II DNA binding factors]	0.0	6	1	1	1
90437	1710	human gene [Cao Proc.Natl.Acad.Sci.USA	[human gene [Cao Proc.Natl.Acad.Sci.USA]	0.0	4	1	1	1
90438	1710	use the PL/IM monoclonal antibody	[using the PL/IM monoclonal antibody]	0.0	5	1	1	1
90439	1710	mesoderm	[mesoderm]	0.0	1	1	1	1
90440	1710	molecular cloning encode a chemokine receptor	[Molecular cloning encoding a chemokine receptor]	0.0	6	1	1	1
90441	1710	69-bp promoter fragment	[69-bp promoter fragment]	0.0	3	1	1	1
90442	1710	version of c-Raf	[version of c-Raf]	0.0	3	2	2	1
90443	1710	inhibition of NFATp/AP-1 complex formation	[inhibition of NFATp/AP-1 complex formation]	0.0	5	1	1	1
90444	1710	measure cellular incorporation	[measuring cellular incorporation]	0.0	3	1	1	1
90445	1710	t-cell lymphotropic virus type 1	[T-cell lymphotropic virus type 1]	0.0	5	1	1	1
90446	1710	branch site	[branch site]	0.0	2	1	1	1
90447	1710	event in maturation	[events in maturation]	0.0	3	1	1	1
90448	1710	sequence (affect expression	[sequences (affecting expression]	0.0	3	1	1	1
90449	1710	cooperation with tnf-alpha	[cooperation with TNF-alpha]	0.0	3	1	1	1
90450	1710	migration of intrafollicular T cell	[migration of intrafollicular T cells]	0.0	5	1	1	1
90451	1710	edge: expression	[edge: expression]	0.0	2	1	1	1
90452	1710	NF-kappaB dna-binding complex	[NF-kappaB DNA-binding complexes]	0.0	3	1	1	1
90453	1710	bypass the need	[bypassing the need]	0.0	3	1	1	1
90454	1710	virus type i promoter	[virus type I promoter]	0.0	4	1	1	1
90455	1710	Chr 9	[Chr 9]	0.0	2	1	1	1
90456	1710	similarity to AP-1	[similarities to AP-1]	0.0	3	1	1	1
90457	1710	target of this positive/negative regulation	[target of this positive/negative regulation]	0.0	5	1	1	1
90458	1710	use the pkc inhibitor	[using the PKC inhibitor]	0.0	4	1	1	1
90459	1710	pathophysiology of hypertension	[pathophysiology of hypertension]	0.0	3	1	1	1
90460	1710	future research	[future research]	0.0	2	1	1	1
90461	1710	42.2% 135-(oh)2d3 induction	[42.2% 1,25-(OH)2D3 induction]	0.0	3	1	1	1
90462	1710	inhibition of the VLA-4/ VCAM-1 pathway	[inhibition of the VLA-4/ VCAM-1 pathway]	0.0	6	1	1	1
90463	1710	dynamic	[dynamics]	0.0	1	1	1	1
90464	1710	naturally occur sequence variation	[naturally occurring sequence variation]	0.0	4	1	1	1
90465	1710	critical role -sensitive induction	[critical role -sensitive induction]	0.0	4	1	1	1
90466	1710	chicken erythrocyte factor 70 kda)	[chicken erythrocyte factor 70 kDa)]	0.0	5	1	1	1
90467	1710	OPGL	[OPGL]	0.0	1	1	1	1
90468	1710	expression of a sv40 T antigen	[expression of a SV40 T antigen]	0.0	6	2	2	1
90469	1710	level of transcription basal transcription	[levels of transcription basal transcription]	0.0	5	1	1	1
90470	1710	VCAM-1 promoter construct	[VCAM-1 promoter constructs]	0.0	3	1	1	1
90471	1710	3,5,3'-triiodothyronine receptor t3r circulate lymphocyte	[3,5,3'-triiodothyronine receptors T3R circulating lymphocytes]	0.0	5	1	1	1
90472	1710	mechanisms; inhibition of a set	[mechanisms; inhibition of a set]	0.0	5	1	1	1
90473	1710	three major disease tuberculosis	[three major diseases tuberculosis]	0.0	4	1	1	1
90474	1710	JH2	[JH2]	0.0	1	1	1	1
90475	1710	lps -mcd14 binding response	[LPS -mCD14 binding responses]	0.0	4	1	1	1
90476	1710	JH4	[JH4]	0.0	1	1	1	1
90477	1710	study in murine T cell line	[studies in murine T cell lines]	0.0	6	1	1	1
90478	1710	interaction for function.	[interactions for function.]	0.0	3	1	1	1
90479	1710	cytokine function	[cytokine functions]	0.0	2	1	1	1
90480	1710	group of disorder	[group of disorders]	0.0	3	1	1	1
90481	1710	Differential presentation of peptide	[Differential presentation of peptide]	0.0	4	1	1	1
90482	1710	host control	[Host control]	0.0	2	1	1	1
90483	1710	three-dimensional nuclear resonance spectroscopy	[three-dimensional nuclear resonance spectroscopy]	0.0	4	1	1	1
90484	1710	maf family protein	[Maf family protein]	0.0	3	1	1	1
90485	1710	uncouple cell.	[Uncoupling cell.]	0.0	2	1	1	1
90486	1710	10(-7) m alphav5 dihydroxyvitamin D3	[10(-7) M alpha,25 dihydroxyvitamin D3]	0.0	5	1	1	1
90487	1710	integration to the genome	[integration to the genome]	0.0	4	1	1	1
90488	1710	young subject type ii	[young subjects Type II]	0.0	4	1	1	1
90489	1710	receptor presence	[receptor presence]	0.0	2	1	1	1
90490	1710	distinct subset include fcepsilonriib	[distinct subset including FcepsilonRIIb]	0.0	4	1	1	1
90491	1710	number sites/cell	[number sites/cell]	0.0	2	1	1	1
90492	1710	12 month of age,	[12 months of age,]	0.0	4	1	1	1
90493	1710	non-clonal, component	[non-clonal, component]	0.0	2	1	1	1
90494	1710	ecreb)/cctivating	[(CREB)/activating]	0.0	1	1	1	1
90495	1710	isomerase-1	[isomerase-1]	0.0	1	1	1	1
90496	1710	effect of Dexamethasone	[effect of Dexamethasone]	0.0	3	1	1	1
90497	1710	incubation from cos-7 cell	[Incubation from COS-7 cells]	0.0	4	1	1	1
90498	1710	nm, bmax +/-	[nM, Bmax +/-]	0.0	3	1	1	1
90499	1710	inducible gene include the enhancer	[inducible genes including the enhancer]	0.0	5	1	1	1
90500	1710	difference in hdac-containing repressor complex	[differences in HDAC-containing repressor complexes]	0.0	5	1	1	1
90501	1710	use luciferase construct	[using luciferase constructs]	0.0	3	1	1	1
90502	1710	caat box-like motif	[CAAT box-like motifs]	0.0	3	1	1	1
90503	1710	technique of analysis	[technique of analysis]	0.0	3	1	1	1
90504	1710	NFAT transcription	[NFAT transcription]	0.0	2	1	1	1
90505	1710	control of cellular proliferation	[control of cellular proliferation]	0.0	4	1	1	1
90506	1710	human virus type tax	[human virus type Tax]	0.0	4	1	1	1
90507	1710	mediuhd adherent colony	[medium, adherent colonies]	0.0	3	1	1	1
90508	1710	oncostatin	[oncostatin]	0.0	1	1	1	1
90509	1710	egr-1 transgene hl-60egr-1	[Egr-1 transgene HL-60Egr-1]	0.0	3	1	1	1
90510	1710	expression of human colony-stimumulatelany-stg factor-1 receptor	[expression of human colony-stimulating factor-1 receptor]	0.0	6	1	1	1
90511	1710	a-myb rna	[A-myb RNA]	0.0	2	1	1	1
90512	1710	pro-x-pro	[Pro-X-Pro]	0.0	1	1	1	1
90513	1710	icam-1 cd54	[ICAM-1 CD54]	0.0	2	1	1	1
90514	1710	stage-specificity of PYBF	[stage-specificity of PYBF]	0.0	3	1	1	1
90515	1710	unrelated case	[unrelated cases]	0.0	2	1	1	1
90516	1710	assay in cell	[assay in cells]	0.0	3	1	1	1
90517	1710	potential core recognition	[potential core recognition]	0.0	3	1	1	1
90518	1710	expression of kappa b-dependent gene	[expression of kappa B-dependent genes]	0.0	5	1	1	1
90519	1710	cytotoxic response	[cytotoxic response]	0.0	2	1	1	1
90520	1710	tradd residue 296	[TRADD residues 296]	0.0	3	1	1	1
90521	1710	RA nm)	[RA nM)]	0.0	2	1	1	1
90522	1710	tradd residue 294	[TRADD residues 294]	0.0	3	1	1	1
90523	1710	unrelated family	[unrelated families]	0.0	2	1	1	1
90524	1710	constitutive expression in b lymphoblast	[constitutive expression in B lymphoblasts]	0.0	5	1	1	1
90525	1710	proximal residue of the cytoplasmic tail,	[proximal residues of the cytoplasmic tail,]	0.0	6	1	1	1
90526	1710	mutation of the proximal,	[mutations of the proximal,]	0.0	4	1	1	1
90527	1710	regulation of the inhibitor,	[regulation of the inhibitor,]	0.0	4	1	1	1
90528	1710	formation of thiobarbituric substance	[formation of thiobarbituric substances]	0.0	4	1	1	1
90529	1710	protein hxbp-1	[protein hXBP-1]	0.0	2	1	1	1
90530	1710	grade (p	[grade (P]	0.0	2	1	1	1
90531	1710	aberrant lpr	[aberrant lpr]	0.0	2	1	1	1
90532	1710	thyroid fragment by blot analysis	[thyroid fragments by blot analysis]	0.0	5	1	1	1
90533	1710	dqa1*0501/dqb1*0201 heterodimer	[DQA1*0501/DQB1*0201 heterodimers]	0.0	2	1	1	1
90534	1710	member of a group	[members of a group]	0.0	4	1	1	1
90535	1710	induction of c-fos/c-jun gene	[induction of c-fos/c-jun genes]	0.0	4	1	1	1
90536	1710	edge: dominant effect	[edge: dominant effect]	0.0	3	1	1	1
90537	1710	mutant of the IL-1 signal pathway	[mutants of the IL-1 signaling pathway]	0.0	6	1	1	1
90538	1710	substantial molar amount	[substantial molar amounts]	0.0	3	1	1	1
90539	1710	normal brca1 allele	[normal BRCA1 allele]	0.0	3	1	1	1
90540	1710	structure analysis	[structure analysis]	0.0	2	1	1	1
90541	1710	therefore action throughout the vasculature	[therefore actions throughout the vasculature]	0.0	5	1	1	1
90542	1710	additional, rapamycin -sensitive pathway	[additional, rapamycin -sensitive pathways]	0.0	4	1	1	1
90543	1710	skf525a	[SKF525a]	0.0	1	1	1	1
90544	1710	c-jun mapk jnk	[c-jun MAPk JNKs]	0.0	3	1	1	1
90545	1710	intracellular AMP	[intracellular AMP]	0.0	2	1	1	1
90546	1710	leukocyte MNL from 11 subject	[leukocytes MNL from 11 subjects]	0.0	5	1	1	1
90547	1710	rhythm of glucocorticoid receptor in leukocyte	[rhythm of glucocorticoid receptors in leukocytes]	0.0	6	1	1	1
90548	1710	post-transcriptional regulator	[post-transcriptional regulator]	0.0	2	1	1	1
90549	1710	[correlation with the state	[[Correlation with the state]	0.0	4	1	1	1
90550	1710	isoflavone glucuronide	[isoflavone glucuronides]	0.0	2	1	1	1
90551	1710	24,25-dihydroxyvitamin D3 dioxyvit	[24,25-dihydroxyvitamin D3 dioxyvit]	0.0	3	1	1	1
90552	1710	thymus section use abs	[thymus sections using Abs]	0.0	4	1	1	1
90553	1710	Also, (10(-10) mol/L)	[Also, (10(-10) mol/L)]	0.0	3	1	1	1
90554	1710	high ki-67 proliferation index	[high Ki-67 proliferation indices]	0.0	4	1	1	1
90555	1710	cd5+ b	[CD5+ B]	0.0	2	1	1	1
90556	1710	immune response of blood mononuclear cell	[Immune response of blood mononuclear cells]	0.0	6	1	1	1
90557	1710	transduce adaptor molecule	[transducing adaptor molecule]	0.0	3	1	1	1
90558	1710	vitro-translated pu.1 from extract	[vitro-translated PU.1 from extracts]	0.0	4	1	1	1
90559	1710	putative glycolipid	[putative glycolipid]	0.0	2	1	1	1
90560	1710	relation to classical prognostic features: implications.	[relations to classical prognostic features: implications.]	0.0	6	1	1	1
90561	1710	NF-kappaB nuclear transcription	[NF-kappaB nuclear transcription]	0.0	3	1	1	1
90562	1710	expression a paradigm	[expression a paradigm]	0.0	3	1	1	1
90563	1710	cocultivation r59z activator cell	[cocultivation R59Z activator cells]	0.0	4	1	1	1
90564	1710	inclusion	[inclusion]	0.0	1	4	4	1
90565	1710	agent cyclosporin a ecsa)	[agents cyclosporin A (CsA)]	0.0	4	1	1	1
90566	1710	enhancer element in non b cell	[enhancer elements in non B cells]	0.0	6	1	1	1
90567	1710	class antibody Ab	[class antibodies Ab]	0.0	3	1	1	1
90568	1710	class ii major complex gene	[class II major complex genes]	0.0	5	1	1	1
90569	1710	encode the Epstein-Barr virus EBV	[encoding the Epstein-Barr virus EBV]	0.0	5	1	1	1
90570	1710	association of traz	[association of TRAFs]	0.0	3	1	1	1
90571	1710	candidate gene factor hnf3 beta	[candidate genes factor HNF3 beta]	0.0	5	1	1	1
90572	1710	IL-4 down-regulated mrna accumulation	[IL-4 down-regulated mRNA accumulation]	0.0	4	1	1	1
90573	1710	one event to cell	[one event to cells]	0.0	4	1	1	1
90574	1710	five major DNase-I site HS	[Five major DNase-I sites HS]	0.0	5	1	1	1
90575	1710	t(15;17) acute leukemia APL	[t(15;17) acute leukemia APL]	0.0	4	1	1	1
90576	1710	0.5 nm	[0.5 nM]	0.0	2	1	1	1
90577	1710	il-5 -specific regulatory mechanism	[IL-5 -specific regulatory mechanisms]	0.0	4	1	1	1
90578	1710	nf-kappab activity in this thymocyte	[NF-kappaB activity in these thymocytes]	0.0	5	1	1	1
90579	1710	0.5 ng	[0.5 ng]	0.0	2	1	1	1
90580	1710	electrophoretic mobility (approximately kd)	[electrophoretic mobility (approximately kD)]	0.0	4	1	1	1
90581	1710	binding of nf-atp	[binding of NF-ATp]	0.0	3	1	1	1
90582	1710	mediate immune responsiveness	[mediating immune responsiveness]	0.0	3	1	1	1
90583	1710	leukocyte from abdominal obese subject	[leukocytes from abdominal obese subjects]	0.0	5	1	1	1
90584	1710	translocation adjacent	[translocation adjacent]	0.0	2	1	1	1
90585	1710	calcium-stimulated, cyclosporin a induction	[calcium-stimulated, cyclosporin A induction]	0.0	4	1	1	1
90586	1710	two interleukin ILs	[two interleukins ILs]	0.0	3	1	1	1
90587	1710	conjunctiva	[conjunctiva]	0.0	1	1	1	1
90588	1710	loss of stat1	[loss of STAT1]	0.0	3	1	1	1
90589	1710	type 2a	[type 2A]	0.0	2	1	1	1
90590	1710	concentration with a onset	[concentrations with an onset]	0.0	4	2	2	1
90591	1710	(endothelial)	[(endothelial)]	0.0	1	1	1	1
90592	1710	effect of sp	[effect of SP]	0.0	3	1	1	1
90593	1710	gm-csf -mediated growth	[GM-CSF -mediated growth]	0.0	3	1	1	1
90594	1710	different 5' truncation mutant	[different 5' truncation mutants]	0.0	4	1	1	1
90595	1710	retinoid X receptor activation of RXR	[Retinoid X receptor activation of RXR]	0.0	6	1	1	1
90596	1710	two potent inhibitor of MEK1	[two potent inhibitors of MEK1]	0.0	5	1	1	1
90597	1710	activation by sp-a dose as low	[Activation by SP-A doses as low]	0.0	6	1	1	1
90598	1710	ki-67 values.	[Ki-67 values.]	0.0	2	1	1	1
90599	1710	squirrel monkey gr	[squirrel monkey GR]	0.0	3	1	1	1
90600	1710	Prostaglandin E2	[Prostaglandin E2]	0.0	2	1	1	1
90601	1710	effect of pa	[effect of PA]	0.0	3	1	1	1
90602	1710	macrophage from individual	[macrophages from individuals]	0.0	3	1	1	1
90603	1710	encompass a common region	[encompassing a common region]	0.0	4	1	1	1
90604	1710	microgram fluticasone propionate aqueous nasal spray	[micrograms fluticasone propionate aqueous nasal spray]	0.0	6	1	1	1
90605	1710	undergo negative selection	[undergoing negative selection]	0.0	3	1	1	1
90606	1710	enhancement of expression	[Enhancement of expression]	0.0	3	1	1	1
90607	1710	molecular weight of kilometer	[molecular weights of kd]	0.0	4	1	1	1
90608	1710	mcd14 uptake produce enhancement	[mCD14 uptake producing enhancement]	0.0	4	1	1	1
90609	1710	express LMP1 from a promoter	[expressing LMP1 from a promoter]	0.0	5	1	1	1
90610	1710	inhibition beta of less magnitude	[inhibition beta of lesser magnitude]	0.0	5	1	1	1
90611	1710	relationship between the exchangeable ca2+	[relationship between the exchangeable Ca2+]	0.0	5	1	1	1
90612	1710	costimulation by EC	[costimulation by EC]	0.0	3	1	1	1
90613	1710	+/- fmol/10(7)	[+/- fmol/10(7)]	0.0	2	1	1	1
90614	1710	contrast to experiment	[contrast to experiments]	0.0	3	1	1	1
90615	1710	malfunction of the response	[malfunction of the response]	0.0	4	1	1	1
90616	1710	tshr domain	[TSHR domain]	0.0	2	1	1	1
90617	1710	t-cell receptor gene	[T-cell receptor genes]	0.0	3	1	1	1
90618	1710	inducible protein kinase c activity	[inducible protein kinase C activity]	0.0	5	1	1	1
90619	1710	cell pivotal in the regulation	[cells pivotal in the regulation]	0.0	5	1	1	1
90620	1710	8, malignant histiocytoma	[8, malignant histiocytoma]	0.0	3	1	1	1
90621	1710	retinoic acid atra washed,	[retinoic acid ATRA washed,]	0.0	4	1	1	1
90622	1710	approximately -250 bp	[approximately -250 bp]	0.0	3	1	1	1
90623	1710	pattern of factor binding	[pattern of factor binding]	0.0	4	1	1	1
90624	1710	early treatment (day hpc	[early treatment (day HPCs]	0.0	4	1	1	1
90625	1710	assess the risk	[assessing the risk]	0.0	3	1	1	1
90626	1710	mononuclear blood cell	[mononuclear blood cell]	0.0	3	1	1	1
90627	1710	evidence for cross-talk	[evidence for cross-talk]	0.0	3	1	1	1
90628	1710	role of this octamer motif	[role of this octamer motif]	0.0	5	1	1	1
90629	1710	member of the regulatory factor	[member of the regulatory factor]	0.0	5	1	1	1
90630	1710	knock-out	[knock-out]	0.0	1	1	1	1
90631	1710	transactivation by recombinant nfat1	[Transactivation by recombinant NFAT1]	0.0	4	1	1	1
90632	1710	microm of the counter-anion thioglucose	[microM of the counter-anion thioglucose]	0.0	5	1	1	1
90633	1710	chemotactic migration of leukocyte to serum	[chemotactic migration of leukocytes to serum]	0.0	6	1	1	1
90634	1710	(il-6) a cytokine	[(IL-6) an cytokine]	0.0	3	1	1	1
90635	1710	two related c-c chemokine gene	[two related C-C chemokine genes]	0.0	5	1	1	1
90636	1710	malignant cell population	[malignant cell population]	0.0	3	1	1	1
90637	1710	inhibit the generation	[inhibiting the generation]	0.0	3	1	1	1
90638	1710	use a screen assay	[Using a screening assay]	0.0	4	1	1	1
90639	1710	(p less than 0.05, p	[(P less than 0.05, P]	0.0	5	1	1	1
90640	1710	only a copy encode fkbp	[only a copies encoding FKBP]	0.0	5	1	1	1
90641	1710	dependence of HS	[dependence of HS]	0.0	3	1	1	1
90642	1710	same pathway as zap-70	[same pathways as ZAP-70]	0.0	4	1	1	1
90643	1710	pathophysiology of asthma	[pathophysiology of asthma]	0.0	3	1	1	1
90644	1710	two b inducer	[two B inducers]	0.0	3	1	1	1
90645	1710	structurally unique raralpha	[structurally unique RARalpha]	0.0	3	1	1	1
90646	1710	protein translation start atg	[protein translation start ATG]	0.0	4	1	1	1
90647	1710	target specificity	[target specificity]	0.0	2	1	1	1
90648	1710	relative contribution to pel growth	[relative contribution to PEL growth]	0.0	5	1	1	1
90649	1710	cellular cholesterol homeostasis	[cellular cholesterol homeostasis]	0.0	3	1	1	1
90650	1710	identification of a positive element	[Identification of a positive element]	0.0	5	1	1	1
90651	1710	three loop peptide	[three loop peptides]	0.0	3	1	1	1
90652	1710	fibrosarcomas	[fibrosarcomas]	0.0	1	1	1	1
90653	1710	expression of mrna for receptor	[expression of mRNA for receptor]	0.0	5	1	1	1
90654	1710	transcription in vivo	[transcription in vivo]	0.0	3	1	1	1
90655	1710	clinically relevant form of NHL	[clinically relevant form of NHL]	0.0	5	1	1	1
90656	1710	serum total thyroxine	[serum total thyroxine]	0.0	3	1	1	1
90657	1710	nuclear extract from cell line	[nuclear extracts from cell lines]	0.0	5	1	1	1
90658	1710	hla-dr- a previously unrecognized form	[HLA-DR- a previously unrecognized form]	0.0	5	1	1	1
90659	1710	novel flow-cytometric assay	[novel flow-cytometric assay]	0.0	3	1	1	1
90660	1710	immunodeficiency virus type 1 progeny	[immunodeficiency virus type 1 progeny]	0.0	5	1	1	1
90661	1710	cd86 principal ligand	[CD86 principal ligands]	0.0	3	1	1	1
90662	1710	three transcription factor creb/atf	[three transcription factors CREB/ATF]	0.0	4	1	1	1
90663	1710	PML alpha expression in myeloid cell	[PML alpha expression in myeloid cells]	0.0	6	1	1	1
90664	1710	hiv- hd express	[HIV- HD express]	0.0	3	1	1	1
90665	1710	absence in the FMS group	[absence in the FMS group]	0.0	5	1	1	1
90666	1710	induction of set of gene	[induction of sets of genes]	0.0	5	1	1	1
90667	1710	different glucocorticoid hormone	[Different glucocorticoid hormones]	0.0	3	1	1	1
90668	1710	previous study pertain	[previous studies pertaining]	0.0	3	1	1	1
90669	1710	distinct immunostaining against 1	[distinct immunostaining against 1]	0.0	4	1	1	1
90670	1710	define the characteristic of phagocyte system	[defining the characteristics of phagocyte system]	0.0	6	1	1	1
90671	1710	theoretical potential	[theoretical potential]	0.0	2	1	1	1
90672	1710	member the homolog c/ebp-beta	[members the homolog C/EBP-beta]	0.0	4	1	1	1
90673	1710	dose rate Gy/min	[dose rate Gy/min]	0.0	3	1	1	1
90674	1710	matter	[matter]	0.0	1	1	1	1
90675	1710	transcriptional factor-KB NF-kappa b	[transcriptional factor-KB NF-kappa B]	0.0	4	1	1	1
90676	1710	half of the cell	[half of the cells]	0.0	4	1	1	1
90677	1710	occur frameshift mutation	[occurring frameshift mutation]	0.0	3	1	1	1
90678	1710	only through the effect	[only through the effect]	0.0	4	1	1	1
90679	1710	result in selective activation	[resulting in selective activation]	0.0	4	1	1	1
90680	1710	JNK signal	[JNK signal]	0.0	2	2	2	1
90681	1710	abnormality of gene related	[abnormalities of genes related]	0.0	4	1	1	1
90682	1710	contain the consensus GRE	[containing the consensus GRE]	0.0	4	1	1	1
90683	1710	two major site	[Two major sites]	0.0	3	1	1	1
90684	1710	produce	[producing]	0.0	1	1	1	1
90685	1710	IkappaBalpha kinase	[IkappaBalpha kinase]	0.0	2	1	1	1
90686	1710	human t-cell lymphoblastic leukemia t-all	[human T-cell lymphoblastic leukemia T-ALL]	0.0	5	1	1	1
90687	1710	procedure suitable	[procedure suitable]	0.0	2	1	1	1
90688	1710	effect on immune function	[effect on immune functions]	0.0	4	1	1	1
90689	1710	hormonal regulation of t3r	[hormonal regulation of T3R]	0.0	4	1	1	1
90690	1710	apoptosis-mediating	[apoptosis-mediating]	0.0	1	1	1	1
90691	1710	activity on the promoter	[activity on the promoter]	0.0	4	1	1	1
90692	1710	dendritic cell (dc)	[dendritic cells (DC)]	0.0	3	1	1	1
90693	1710	target spleen with mpl	[targeting spleen with MPL]	0.0	4	1	1	1
90694	1710	suppressor t-lymphocyte	[suppressor T-lymphocytes]	0.0	2	1	1	1
90695	1710	common binding site	[common binding site]	0.0	3	1	1	1
90696	1710	p50 heterodimer	[p50 heterodimers]	0.0	2	1	1	1
90697	1710	aberrant splicing	[Aberrant splicing]	0.0	2	1	1	1
90698	1710	adhesion molecule (icam)-1	[adhesion molecule (ICAM)-1]	0.0	3	1	1	1
90699	1710	mutation event	[mutation events]	0.0	2	1	1	1
90700	1710	illness.	[illness.]	0.0	1	1	1	1
90701	1710	constitutive expression of human factor-1 receptor	[Constitutive expression of human factor-1 receptor]	0.0	6	1	1	1
90702	1710	epo signal mechanism	[Epo signaling mechanisms]	0.0	3	1	1	1
90703	1710	reservoir for production	[reservoir for production]	0.0	3	1	1	1
90704	1710	stimulation"	[stimulation"]	0.0	1	1	1	1
90705	1710	range from kD	[ranging from kD]	0.0	3	1	1	1
90706	1710	mobility-shift analysis	[mobility-shift analysis]	0.0	2	1	1	1
90707	1710	disease onset,	[disease onset,]	0.0	2	1	1	1
90708	1710	C/EBP-epsilon	[C/EBP-epsilon]	0.0	1	1	1	1
90709	1710	variant with sp1 site	[variant with Sp1 sites]	0.0	4	1	1	1
90710	1710	bzlf1 in trans	[BZLF1 in trans]	0.0	3	1	1	1
90711	1710	only level activity	[only level activity]	0.0	3	1	1	1
90712	1710	suggest persistence despite onset	[suggesting persistence despite onset]	0.0	4	1	1	1
90713	1710	erythroblast from mouse	[erythroblasts from mice]	0.0	3	1	1	1
90714	1710	case-control study of infectious disease	[case-control studies of infectious diseases]	0.0	5	1	1	1
90715	1710	potential homologue	[potential homologues]	0.0	2	1	1	1
90716	1710	place round nucleus	[placed, round nucleus]	0.0	3	1	1	1
90717	1710	encode mouse oct2	[encoding mouse Oct2]	0.0	3	1	1	1
90718	1710	site (-579)	[site (-579)]	0.0	2	1	1	1
90719	1710	hiv type infection	[HIV type infection]	0.0	3	1	1	1
90720	1710	surface expression of icam-1	[Surface expression of ICAM-1]	0.0	4	2	2	1
90721	1710	renal failure patient	[renal failure patients]	0.0	3	1	1	1
90722	1710	cd4+ cd8int/- cell	[CD4+ CD8int/- cells]	0.0	3	1	1	1
90723	1710	effect of dm	[effect of DM]	0.0	3	1	1	1
90724	1710	characterization of transactivation binding of tax	[characterization of transactivation Binding of Tax]	0.0	6	1	1	1
90725	1710	anti-viral antigen vca	[anti-viral antigen VCA]	0.0	3	1	1	1
90726	1710	several B-cell marker	[several B-cell markers]	0.0	3	1	1	1
90727	1710	indicator in patient	[indicator in patients]	0.0	3	1	1	1
90728	1710	respectively, corresponding to a molecule	[respectively, corresponding to an molecules]	0.0	5	1	1	1
90729	1710	gene in leukemic cell	[gene in leukemic cells]	0.0	4	1	1	1
90730	1710	hormone status	[hormone status]	0.0	2	1	1	1
90731	1710	SAA promoter sequence	[SAA promoter sequence]	0.0	3	1	1	1
90732	1710	healthy individual as normal control	[healthy individuals as normal control]	0.0	5	1	1	1
90733	1710	KCl	[KCl]	0.0	1	1	1	1
90734	1710	AM580 a stable benzoic derivative	[AM580 a stable benzoic derivative]	0.0	5	1	1	1
90735	1710	only of the domain icn	[only of the domain ICN]	0.0	5	1	1	1
90736	1710	increase (up to 15-fold)	[increase (up to 15-fold)]	0.0	4	1	1	1
90737	1710	sequence analysis of nine cDNA clone	[Sequence analysis of nine cDNA clones]	0.0	6	1	1	1
90738	1710	dihydrochloride h7	[dihydrochloride H7]	0.0	2	1	1	1
90739	1710	important pathogen	[important pathogen]	0.0	2	1	1	1
90740	1710	macrophage in intrapulmonary activation	[macrophages in intrapulmonary activation]	0.0	4	1	1	1
90741	1710	describe the activation	[describing the activation]	0.0	3	1	1	1
90742	1710	understanding of the action of glucocorticoid	[understanding of the action of glucocorticoids]	0.0	6	1	1	1
90743	1710	copy of the octamer site	[copy of the octamer site]	0.0	5	1	1	1
90744	1710	12% increase	[12% increase]	0.0	2	1	1	1
90745	1710	benefit in this patient	[benefit in these patients]	0.0	4	1	1	1
90746	1710	sensitivity to dexamethasone	[sensitivity to dexamethasone]	0.0	3	1	1	1
90747	1710	two specific inhibitor	[two specific inhibitors]	0.0	3	1	1	1
90748	1710	tyrosine phosphorylation of the factor stat-1alpha	[tyrosine phosphorylation of the factor STAT-1alpha]	0.0	6	1	1	1
90749	1710	membrane-spanning domain	[membrane-spanning domains]	0.0	2	1	1	1
90750	1710	subtraction	[subtraction]	0.0	1	1	1	1
90751	1710	inhibitory drug interaction	[Inhibitory drug interactions]	0.0	3	1	1	1
90752	1710	two similar proteins, cyclophilin	[two similar proteins, cyclophilin]	0.0	4	1	1	1
90753	1710	develop new strategy	[developing new strategies]	0.0	3	1	1	1
90754	1710	hsv-1-activated factor icp0	[HSV-1-activated factor ICP0]	0.0	3	1	1	1
90755	1710	tsc2 gene expression in autopsy- tissue	[TSC2 gene expression in autopsy- tissues]	0.0	6	1	1	1
90756	1710	double-positive (dp) CD4	[double-positive (DP) CD4]	0.0	3	1	1	1
90757	1710	cortisol excretion in subject	[cortisol excretion in subjects]	0.0	4	1	1	1
90758	1710	kinase ikappab kinase alpha	[kinases IkappaB kinase alpha]	0.0	4	1	1	1
90759	1710	DNA demethylation	[DNA demethylation]	0.0	2	1	1	1
90760	1710	patient in the clearance	[patients in the clearance]	0.0	4	1	1	1
90761	1710	study on culture	[studies on cultures]	0.0	3	1	1	1
90762	1710	late gene expression in glial cell	[late gene expression in glial cells]	0.0	6	1	1	1
90763	1710	effect of this interaction	[effects of these interactions]	0.0	4	1	1	1
90764	1710	family of factor RA receptor	[families of factors RA receptors]	0.0	5	1	1	1
90765	1710	minutes) to acid atra washed,	[minutes) to acid ATRA washed,]	0.0	5	1	1	1
90766	1710	activation of the htlv-i enhancer	[activation of the HTLV-I enhancer]	0.0	5	1	1	1
90767	1710	Jew	[Jews]	0.0	1	1	1	1
90768	1710	768-bp upstream regulatory region	[768-bp upstream regulatory region]	0.0	4	1	1	1
90769	1710	rare variant translocation	[rare variant translocations]	0.0	3	1	1	1
90770	1710	specific mutation	[specific mutations]	0.0	2	1	1	1
90771	1710	employ nuclear extract from B	[employing nuclear extracts from B]	0.0	5	1	1	1
90772	1710	inhibition of phorbol monocytic differentiation	[Inhibition of phorbol monocytic differentiation]	0.0	5	1	1	1
90773	1710	Thus, p21ras regulation of nfat	[Thus, p21ras regulation of NFAT]	0.0	5	1	1	1
90774	1710	genomic rearrangement corresponding to transcript	[genomic rearrangements corresponding to transcripts]	0.0	5	1	1	1
90775	1710	human cell ECs in hypoxia	[human cells ECs in hypoxia]	0.0	5	1	1	1
90776	1710	considerable protection from apoptosis	[considerable protection from apoptosis]	0.0	4	1	1	1
90777	1710	virus exposure	[virus exposure]	0.0	2	1	1	1
90778	1710	H7-inhibitable pathway	[H7-inhibitable pathway]	0.0	2	1	1	1
90779	1710	two protein sequence	[two protein sequences]	0.0	3	1	1	1
90780	1710	effect on the reporter cell	[effect on the reporter cells]	0.0	5	1	1	1
90781	1710	platelet from euthymic patient	[platelets from euthymic patients]	0.0	4	1	1	1
90782	1710	major source	[major source]	0.0	2	1	1	1
90783	1710	phosphorylation in cell	[Phosphorylation in cells]	0.0	3	1	1	1
90784	1710	histocompatibility complex surface protein	[histocompatibility complex surface proteins]	0.0	4	1	1	1
90785	1710	analysis of DNA fragment	[analyses of DNA fragments]	0.0	4	1	1	1
90786	1710	nuclear factor-IL6 motif	[nuclear factor-IL6 motifs]	0.0	3	1	1	1
90787	1710	effect on pattern increase of ca2+	[effect on patterns increase of Ca2+]	0.0	6	1	1	1
90788	1710	role deliver the activation signal	[role delivering the activation signal]	0.0	5	1	1	1
90789	1710	4 transcript	[4 transcripts]	0.0	2	1	1	1
90790	1710	isoforms, a short form, stat3beta	[isoforms, a short form, Stat3beta]	0.0	5	1	1	1
90791	1710	appearance of a nuclear factor bind	[appearance of an nuclear factor binding]	0.0	6	1	1	1
90792	1710	induction 1 infection of cell	[Induction 1 infection of cells]	0.0	5	1	1	1
90793	1710	RNA -dependent manner	[RNA -dependent manner]	0.0	3	1	1	1
90794	1710	alpha beta 1 ligation alone	[alpha beta 1 ligation alone]	0.0	5	1	1	1
90795	1710	human cell in liquid culture	[human cells in liquid cultures]	0.0	5	1	1	1
90796	1710	chicken erythrocyte factor mass,	[chicken erythrocyte factor mass,]	0.0	4	1	1	1
90797	1710	human immunodeficiency virus type tat protein	[human immunodeficiency virus type Tat protein]	0.0	6	1	1	1
90798	1710	bear dqa1*0201/dqb1*0201	[bearing DQA1*0201/DQB1*0201]	0.0	2	1	1	1
90799	1710	limit of er content	[limit of ER content]	0.0	4	1	1	1
90800	1710	activation of pkc of camp	[activation of PKC of cAMP]	0.0	5	1	1	1
90801	1710	include the retinoblastoma protein	[including the retinoblastoma protein]	0.0	4	1	1	1
90802	1710	response to PMA together	[response to PMA together]	0.0	4	1	1	1
90803	1710	new field	[new field]	0.0	2	1	1	1
90804	1710	interaction of AML1	[interaction of AML1]	0.0	3	1	1	1
90805	1710	role of EGR1 in regulation lymphocytes.	[Role of EGR1 in regulation lymphocytes.]	0.0	6	1	1	1
90806	1710	Burkitt' lymphoma BL cell lines,	[Burkitt's lymphoma BL cell lines,]	0.0	5	1	1	1
90807	1710	surface expression of cd25	[surface expression of CD25]	0.0	4	1	1	1
90808	1710	appearance of a inducible factor bind	[appearance of an inducible factor binding]	0.0	6	1	1	1
90809	1710	transfection of p50	[transfection of p50]	0.0	3	1	1	1
90810	1710	role for monocyte protein-1 secretion	[role for monocyte protein-1 secretion]	0.0	5	1	1	1
90811	1710	monocytic cell a cellular component	[monocytic cells a cellular component]	0.0	5	1	1	1
90812	1710	nevertheless, high, pharmacological concentration of RA	[Nevertheless, high, pharmacological concentrations of RA]	0.0	6	1	1	1
90813	1710	mutation of Jak3	[Mutation of Jak3]	0.0	3	1	1	1
90814	1710	obvious regulation	[obvious regulation]	0.0	2	1	1	1
90815	1710	cross-linking of MHC class molecule	[cross-linking of MHC class molecules]	0.0	5	1	1	1
90816	1710	histocompatibility (mhc) class ii gene	[histocompatibility (MHC) class II genes]	0.0	5	3	3	1
90817	1710	protein/activating transcription factor	[protein/activating transcription factor]	0.0	3	1	1	1
90818	1710	hiv-2 terminal repeat	[HIV-2 terminal repeat]	0.0	3	1	1	1
90819	1710	activation of a gene in 3q21	[Activation of a gene in 3q21]	0.0	6	1	1	1
90820	1710	rate-limiting step in T cell	[rate-limiting step in T cells]	0.0	5	1	1	1
90821	1710	cell carcinoma-derived ganglioside	[cell carcinoma-derived gangliosides]	0.0	3	1	1	1
90822	1710	observation demonstrate the activity	[observations demonstrating the activity]	0.0	4	1	1	1
90823	1710	cell in growth	[cells in growth]	0.0	3	1	1	1
90824	1710	analysis of 20q deletion	[analysis of 20q deletions]	0.0	4	1	1	1
90825	1710	transcriptional activation independent	[transcriptional activation independent]	0.0	3	1	1	1
90826	1710	unequivocal evidence	[unequivocal evidence]	0.0	2	1	1	1
90827	1710	response in human mononuclear leukocyte	[response in human mononuclear leukocytes]	0.0	5	1	1	1
90828	1710	analysis -contain protein	[Analysis -containing proteins]	0.0	3	1	1	1
90829	1710	reservoir of p50/rela(p65) complex	[reservoir of p50/RelA(p65) complexes]	0.0	4	1	1	1
90830	1710	especially the number	[especially the number]	0.0	3	1	1	1
90831	1710	(stat) protein	[(Stat) protein]	0.0	2	1	1	1
90832	1710	KMT	[KMT]	0.0	1	1	1	1
90833	1710	potentially self-reactive T cell	[potentially self-reactive T cells]	0.0	4	1	1	1
90834	1710	sequence element dse	[sequence elements DSE]	0.0	3	1	1	1
90835	1710	10(-8) m,	[10(-8) M,]	0.0	2	1	1	1
90836	1710	female by the humara method	[females by the HUMARA method]	0.0	5	1	1	1
90837	1710	target cell with virus	[target cells with viruses]	0.0	4	1	1	1
90838	1710	T cell of RCC	[T cells of RCC]	0.0	4	1	1	1
90839	1710	preincubation of cell only in u-937	[Preincubation of cells only in U-937]	0.0	6	1	1	1
90840	1710	rearrangement to 21-acetoxy-11	[rearrangement to 21-acetoxy-11]	0.0	3	1	1	1
90841	1710	c-rel-like protein	[c-Rel-like proteins]	0.0	2	1	1	1
90842	1710	glucocorticoid hormone action	[glucocorticoid hormone action]	0.0	3	1	1	1
90843	1710	transformation of early b-cell precursor	[transformation of early B-cell precursors]	0.0	5	1	1	1
90844	1710	transactivator activity	[transactivator activity]	0.0	2	1	1	1
90845	1710	hl-60 cell hl-60/vinc,	[HL-60 cells HL-60/vinc,]	0.0	3	1	1	1
90846	1710	migrate complex pu-sf	[migrating complex PU-SF]	0.0	3	1	1	1
90847	1710	tat gene hela-tat cell	[tat gene HeLa-tat cells]	0.0	4	1	1	1
90848	1710	explanation for the perpetuation	[explanation for the perpetuation]	0.0	4	1	1	1
90849	1710	related disorder involve defective differentiation	[related disorders involving defective differentiation]	0.0	5	1	1	1
90850	1710	interleukin-7 signal lymphoblastic leukemia cell	[Interleukin-7 signaling lymphoblastic leukemia cells]	0.0	5	1	1	1
90851	1710	chloramphenicol acetyltransferase assay after transient cotransfection	[Chloramphenicol acetyltransferase assay after transient cotransfection]	0.0	6	1	1	1
90852	1710	coat protein	[coat protein]	0.0	2	1	1	1
90853	1710	signal PMA	[signal PMA]	0.0	2	1	1	1
90854	1710	inflammatory cytokine in bronchial cell	[inflammatory cytokines in bronchial cells]	0.0	5	1	1	1
90855	1710	expression interleukin	[expression interleukin]	0.0	2	1	1	1
90856	1710	five copy of nf-kappa b site	[five copies of NF-kappa B site]	0.0	6	1	1	1
90857	1710	preparation from rat tissue	[preparations from rat tissues]	0.0	4	1	1	1
90858	1710	intracellular generation	[intracellular generation]	0.0	2	1	1	1
90859	1710	role mediate in a variety	[role mediating in a variety]	0.0	5	1	1	1
90860	1710	activation of the nf-kappab system	[activation of the NF-kappaB system]	0.0	5	1	1	1
90861	1710	role of this gene	[role of these genes]	0.0	4	1	1	1
90862	1710	use a vector.	[using a vector.]	0.0	3	1	1	1
90863	1710	detection of this protein	[detection of this protein]	0.0	4	1	1	1
90864	1710	unrecognized function for pi 3-kinase	[unrecognized function for PI 3-kinase]	0.0	5	1	1	1
90865	1710	NF-kappa b p65 activation	[NF-kappa B p65 activation]	0.0	4	1	1	1
90866	1710	Thus, TNF alpha	[Thus, TNF alpha]	0.0	3	1	1	1
90867	1710	only low weight species of 24	[only lower weight species of 24]	0.0	6	1	1	1
90868	1710	distinct region important,	[distinct regions important,]	0.0	3	1	1	1
90869	1710	transcription factor contain cysteine region	[transcription factor containing cysteine regions]	0.0	5	1	1	1
90870	1710	importantly, additional testing	[Importantly, additional testing]	0.0	3	1	1	1
90871	1710	protein partner	[protein partners]	0.0	2	1	1	1
90872	1710	highlight putative novel loci	[highlighting putative novel loci]	0.0	4	1	1	1
90873	1710	anti-hapten ab variable fragment	[anti-hapten Ab variable fragment]	0.0	4	1	1	1
90874	1710	overlap rna probe	[overlapping RNA probes]	0.0	3	1	1	1
90875	1710	interest:	[interest:]	0.0	1	1	1	1
90876	1710	exact mechanism underlie this capacity	[exact mechanisms underlying this capacity]	0.0	5	1	1	1
90877	1710	u937 cell to ECs	[U937 cells to ECs]	0.0	4	1	1	1
90878	1710	activator of (mhc) class gene	[activator of (MHC) class genes]	0.0	5	1	1	1
90879	1710	t-cell il-5 synthesis	[T-cell IL-5 synthesis]	0.0	3	1	1	1
90880	1710	interest.	[interest.]	0.0	1	1	1	1
90881	1710	cis-acting effect	[cis-acting effect]	0.0	2	1	1	1
90882	1710	cis-acting element of the factor	[cis-acting elements of the factor]	0.0	5	1	1	1
90883	1710	transformation of the stroma	[transformation of the stroma]	0.0	4	1	1	1
90884	1710	putative site for E2F	[putative site for E2F]	0.0	4	1	1	1
90885	1710	NF-kappaB -binding sequence	[NF-kappaB -binding sequence]	0.0	3	1	1	1
90886	1710	use tetanus toxoid specific T lymphocyte	[Using tetanus toxoid specific T lymphocytes]	0.0	6	1	1	1
90887	1710	gata3 gene	[GATA3 gene]	0.0	2	2	2	1
90888	1710	absolute master gene	[absolute master gene]	0.0	3	1	1	1
90889	1710	express the appropriate region beta chain	[expressing the appropriate region beta chain]	0.0	6	1	1	1
90890	1710	morning plasma	[morning plasma]	0.0	2	1	1	1
90891	1710	effect of ts	[effects of TS]	0.0	3	1	1	1
90892	1710	extinction of several other gene	[extinction of several other genes]	0.0	5	1	1	1
90893	1710	overexpression in tumor cell	[Overexpression in tumor cells]	0.0	4	1	1	1
90894	1710	signal often converge in pathway	[signals often converging in pathways]	0.0	5	1	1	1
90895	1710	gene product EA-R	[gene products EA-R]	0.0	3	1	1	1
90896	1710	direct exposure to 10 nm	[Direct exposure to 10 nM]	0.0	5	1	1	1
90897	1710	platelet thromboxane	[platelet thromboxane]	0.0	2	1	1	1
90898	1710	activation of the gene enhancer	[activation of the gene enhancer]	0.0	5	1	1	1
90899	1710	transactivation of pthrp	[Transactivation of PTHrP]	0.0	3	1	1	1
90900	1710	lymphoid factor lef-1	[Lymphoid factor LEF-1]	0.0	3	1	1	1
90901	1710	specific uptake of 3h-labelled 135(oh)2d3	[specific uptake of 3H-labelled 1,25(OH)2D3]	0.0	5	1	1	1
90902	1710	multiparameter	[multiparameter]	0.0	1	1	1	1
90903	1710	cell inflammatory response to amebic infection	[cell inflammatory responses to amebic infection]	0.0	6	1	1	1
90904	1710	anti-early antigen capsid antigen vca	[anti-early antigen capsid antigen VCA]	0.0	5	1	1	1
90905	1710	induction by binding	[Induction by binding]	0.0	3	1	1	1
90906	1710	various early serum responsive gene	[various early serum responsive genes]	0.0	5	1	1	1
90907	1710	airway secretion	[airway secretions]	0.0	2	1	1	1
90908	1710	thyroid disease:	[thyroid disease:]	0.0	2	1	1	1
90909	1710	two main activity transactivation	[two main activities transactivation]	0.0	4	1	1	1
90910	1710	effect of n-acetyl-l-cysteine antioxidant	[effects of N-acetyl-L-cysteine antioxidant]	0.0	4	1	1	1
90911	1710	gelatinase-associated lipocalin	[gelatinase-associated lipocalin]	0.0	2	1	1	1
90912	1710	involve differentiation in male	[involving differentiation in males]	0.0	4	1	1	1
90913	1710	up-regulate gene expression	[up-regulate gene expression]	0.0	3	1	1	1
90914	1710	effect 1) inhibition through adenosine triphosphate	[effects 1) inhibition through adenosine triphosphate]	0.0	6	1	1	1
90915	1710	profile of gene	[profiles of genes]	0.0	3	1	1	1
90916	1710	also in maintenance of transcription	[also in maintenance of transcription]	0.0	5	1	1	1
90917	1710	overlap ifngr1 frameshift deletion	[overlapping IFNGR1 frameshift deletions]	0.0	4	1	1	1
90918	1710	antibody antibody phase-1 neutrophil adhesion	[antibodies antibodies phase-1 neutrophil adhesion]	0.0	5	1	1	1
90919	1710	clinical problem	[clinical problem]	0.0	2	2	2	1
90920	1710	DNA in vitro.	[DNA in vitro.]	0.0	3	1	1	1
90921	1710	nuclear factor with different mobilities,	[nuclear factors with different mobilities,]	0.0	5	1	1	1
90922	1710	il-4 receptor stimulation	[IL-4 receptor stimulation]	0.0	3	1	1	1
90923	1710	functional capability	[functional capabilities]	0.0	2	1	1	1
90924	1710	additional testing of a set	[additional testing of a set]	0.0	5	1	1	1
90925	1710	treatment irrespective	[treatment irrespective]	0.0	2	1	1	1
90926	1710	Kasumi-1 cell	[Kasumi-1 cells]	0.0	2	1	1	1
90927	1710	diverse phenotype	[diverse phenotypes]	0.0	2	1	1	1
90928	1710	change of specific binding	[changes of specific binding]	0.0	4	1	1	1
90929	1710	pathway as the way accounting	[pathway as the way accounting]	0.0	5	1	1	1
90930	1710	healthy untrained volunteer	[healthy untrained volunteers]	0.0	3	1	1	1
90931	1710	response to four different stimulus	[response to four different stimuli]	0.0	5	1	1	1
90932	1710	analysis of LTR mutation	[analyses of LTR mutations]	0.0	4	1	1	1
90933	1710	loss of susceptibility	[Loss of susceptibility]	0.0	3	1	1	1
90934	1710	high nuclear translocation	[higher nuclear translocation]	0.0	3	1	1	1
90935	1710	immunodeficiency virus type hiv-1 replication	[immunodeficiency virus type HIV-1 replication]	0.0	5	1	1	1
90936	1710	100 patient	[100 patients]	0.0	2	1	1	1
90937	1710	tissue differentiation	[tissue differentiation]	0.0	2	1	1	1
90938	1710	remission.	[remission.]	0.0	1	1	1	1
90939	1710	NK T cell	[NK T cells]	0.0	3	1	1	1
90940	1710	PMA for 24 h.	[PMA for 24 h,]	0.0	4	1	1	1
90941	1710	encode region of RFX5	[encoding regions of RFX5]	0.0	4	1	1	1
90942	1710	domain sequence contain phosphotyrosine	[domain sequences containing phosphotyrosine]	0.0	4	1	1	1
90943	1710	dna-binding complex in eosinophil	[DNA-binding complexes in eosinophils]	0.0	4	1	1	1
90944	1710	phosphorylation of the three member	[phosphorylation of the three members]	0.0	5	1	1	1
90945	1710	end-effector	[end-effectors]	0.0	1	1	1	1
90946	1710	syndrome include disease	[syndromes including diseases]	0.0	3	1	1	1
90947	1710	drug doxorubicin	[drug doxorubicin]	0.0	2	1	1	1
90948	1710	several new, relevant compound	[Several new, relevant compounds]	0.0	4	1	1	1
90949	1710	fusion follow translocation in leukemia	[fusion following translocations in leukemias]	0.0	5	1	1	1
90950	1710	regular mense	[regular menses]	0.0	2	1	1	1
90951	1710	proximity to the serine	[proximity to the serine]	0.0	4	1	1	1
90952	1710	il-2r beta asn240-leu335	[IL-2R beta Asn240-Leu335]	0.0	3	1	1	1
90953	1710	uptake of [3h]1,25(oh)2d3	[uptake of [3H]1,25(OH)2D3]	0.0	3	1	1	1
90954	1710	sterol- VDR complex	[sterol- VDR complex]	0.0	3	1	1	1
90955	1710	important autoregulatory inhibitor	[important autoregulatory inhibitor]	0.0	3	1	1	1
90956	1710	apoptosis m.tremblay, j.exp.med.183:39-48,	[apoptosis M.Tremblay, J.Exp.Med.183:39-48,]	0.0	3	1	1	1
90957	1710	include acid	[including acid]	0.0	2	1	1	1
90958	1710	differentiation-dependent change	[differentiation-dependent changes]	0.0	2	1	1	1
90959	1710	same arrangement	[same arrangement]	0.0	2	1	1	1
90960	1710	multiple nonlymphoid tissue	[multiple nonlymphoid tissues]	0.0	3	1	1	1
90961	1710	link between production of mediator	[link between production of mediators]	0.0	5	1	1	1
90962	1710	nf-kappab regulation of fibrosis during obstruction	[NF-kappaB regulation of fibrosis during obstruction]	0.0	6	1	1	1
90963	1710	effect of flavonoid	[effects of flavonoids]	0.0	3	1	1	1
90964	1710	include 20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2 5-dihydroxyvitamin D3	[including 20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2 5-dihydroxyvitamin D3]	0.0	4	1	1	1
90965	1710	cycle reactivity to epitope rarely undetectable	[cycle reactivities to epitopes rarely undetectable]	0.0	6	1	1	1
90966	1710	lead onto the surface	[leading onto the surface]	0.0	4	1	1	1
90967	1710	phosphorylation to serine	[phosphorylation to serines]	0.0	3	1	1	1
90968	1710	prevent nuclear translocation	[preventing nuclear translocation]	0.0	3	2	2	1
90969	1710	rest human blood monocyte	[resting human blood monocytes]	0.0	4	1	1	1
90970	1710	filarial antigen-specific t-cell	[filarial antigen-specific T-cells]	0.0	3	1	1	1
90971	1710	ng/ml of il-10	[ng/ml of IL-10]	0.0	3	1	1	1
90972	1710	RA gene	[RA genes]	0.0	2	1	1	1
90973	1710	tnfr factor	[TNFR factors]	0.0	2	1	1	1
90974	1710	immature single cell	[immature single cells]	0.0	3	1	1	1
90975	1710	constitutive b translocation	[constitutive B translocation]	0.0	3	1	1	1
90976	1710	lipoarabinomannan LAM from the cell wall,	[lipoarabinomannan LAM from the cell wall,]	0.0	6	1	1	1
90977	1710	contain phosphotyrosine	[containing phosphotyrosine]	0.0	2	1	1	1
90978	1710	G-rich motif	[G-rich motifs]	0.0	2	1	1	1
90979	1710	two system	[two systems]	0.0	2	1	1	1
90980	1710	ensue gene activation	[ensuing gene activation]	0.0	3	1	1	1
90981	1710	action on erythropoiesis	[action on erythropoiesis]	0.0	3	1	1	1
90982	1710	HL 60 cell differentiated)	[HL 60 cells differentiated)]	0.0	4	1	1	1
90983	1710	CsA -resistant synthesis	[CsA -resistant synthesis]	0.0	3	1	1	1
90984	1710	shp2-interacting transmembrane adaptor protein a dimer	[SHP2-interacting transmembrane adaptor protein a dimer]	0.0	6	1	1	1
90985	1710	signal transduction of il-5	[signal transduction of IL-5]	0.0	4	1	1	1
90986	1710	two potent agent	[two potent agents]	0.0	3	1	1	1
90987	1710	cyclin/cdk cyclin-dependent kinase	[cyclin/cdks cyclin-dependent kinase]	0.0	3	1	1	1
90988	1710	hiv adenopathy	[HIV adenopathy]	0.0	2	1	1	1
90989	1710	multifactorial process affect transcription factor	[multifactorial process affecting transcription factors]	0.0	5	1	1	1
90990	1710	(viability	[(viability]	0.0	1	1	1	1
90991	1710	leukotriene B4 LTB4 a mediator	[leukotriene B4 LTB4 a mediator]	0.0	5	1	1	1
90992	1710	form of peripheral resistance	[form of peripheral resistance]	0.0	4	1	1	1
90993	1710	component of the receptor il-2	[component of the receptors IL-2]	0.0	5	1	1	1
90994	1710	transcription factor under condition	[transcription factors under conditions]	0.0	4	1	1	1
90995	1710	high value in patient	[higher values in patients]	0.0	4	1	1	1
90996	1710	2 production.	[2 production.]	0.0	2	1	1	1
90997	1710	oestrogen antagonist	[oestrogen antagonist]	0.0	2	1	1	1
90998	1710	six unidentified factor lbf2	[six unidentified factors LBF2]	0.0	4	1	1	1
90999	1710	cleavage product of 68 kda	[cleavage products of 68 kDa]	0.0	5	1	1	1
91000	1710	SDS-PAGE analysis	[SDS-PAGE analysis]	0.0	2	1	1	1
91001	1710	autologous lymphoblastoid	[autologous lymphoblastoid]	0.0	2	1	1	1
91002	1710	RA subclone	[RA subclone]	0.0	2	1	1	1
91003	1710	specific granule mediate inflammatory response	[specific granules mediating inflammatory responses]	0.0	5	1	1	1
91004	1710	encode the Epstein-Barr virus	[encoding the Epstein-Barr virus]	0.0	4	1	1	1
91005	1710	B-cell chronic leukaemias	[B-cell chronic leukaemias]	0.0	3	1	1	1
91006	1710	biochemical lesion	[biochemical lesions]	0.0	2	1	1	1
91007	1710	expression activate gene	[expression activating genes]	0.0	3	1	1	1
91008	1710	affect distribution.	[affecting distribution.]	0.0	2	1	1	1
91009	1710	LAK	[LAK]	0.0	1	1	1	1
91010	1710	(auto)immune inflammation	[(auto)immune inflammation]	0.0	2	1	1	1
91011	1710	addition of gm-csf	[addition of GM-CSF]	0.0	3	1	1	1
91012	1710	twofold increase from steroid-sensitive patient	[twofold increase from steroid-sensitive patients]	0.0	5	1	1	1
91013	1710	course of prednisone	[course of prednisone]	0.0	3	1	1	1
91014	1710	tpa responsive element TRE	[TPA responsive elements TRE]	0.0	4	1	1	1
91015	1710	binding to tax -responsive element	[Binding to Tax -responsive element]	0.0	5	1	1	1
91016	1710	sensitivity to differentiation effect	[sensitivity to differentiation effect]	0.0	4	1	1	1
91017	1710	construct of human RAR alpha	[construct of human RAR alpha]	0.0	5	1	1	1
91018	1710	result, mutation	[result, mutation]	0.0	2	1	1	1
91019	1710	early B-cell differentiation	[early B-cell differentiation]	0.0	3	1	1	1
91020	1710	follow genetic alteration	[following genetic alterations]	0.0	3	1	1	1
91021	1710	4-carboranyl-substituted compound	[4-carboranyl-substituted compounds]	0.0	2	1	1	1
91022	1710	[rh]-dex-bind	[[3H]-DEX-binding]	0.0	1	1	1	1
91023	1710	mechanism of phagocytosis	[mechanism of phagocytosis]	0.0	3	1	1	1
91024	1710	expression of ap-1 protein.	[expression of AP-1 protein.]	0.0	4	1	1	1
91025	1710	coexpression of calcineurin	[coexpression of calcineurin]	0.0	3	1	1	1
91026	1710	tat affinity column	[Tat affinity column]	0.0	3	1	1	1
91027	1710	borrelia	[Borrelia]	0.0	1	2	2	1
91028	1710	potent repressor icer	[potent repressor ICER]	0.0	3	1	1	1
91029	1710	tissue tumor fibrosarcoma	[tissue tumors fibrosarcoma]	0.0	3	1	1	1
91030	1710	enhancer with distinct domains, a	[enhancer with distinct domains, A]	0.0	5	1	1	1
91031	1710	sequence of the cd69 gene,	[sequences of the CD69 gene,]	0.0	5	1	1	1
91032	1710	dissociation signal in neutrophils.	[Dissociation signaling in neutrophils.]	0.0	4	1	1	1
91033	1710	expression human I	[expression human I]	0.0	3	1	1	1
91034	1710	all-tran acid washed,	[all-trans acid washed,]	0.0	3	1	1	1
91035	1710	receptor gr binding from ms patient	[receptor GR binding from MS patients]	0.0	6	1	1	1
91036	1710	h287a	[H287A]	0.0	1	1	1	1
91037	1710	ORF2	[ORF2]	0.0	1	1	1	1
91038	1710	blood-derived human monocyte pbm	[blood-derived human monocytes PBM]	0.0	4	1	1	1
91039	1710	stimulation with different gc	[Stimulation with different GC]	0.0	4	1	1	1
91040	1710	works? with a therapy as specific	[works? with a therapy as specific]	0.0	6	1	1	1
91041	1710	cross-linking of cd44 on synovial cell	[Cross-linking of CD44 on synovial cells]	0.0	6	1	1	1
91042	1710	measure decay after addition	[measuring decay after addition]	0.0	4	1	1	1
91043	1710	IL-12R complex	[IL-12R complex]	0.0	2	1	1	1
91044	1710	breast cancer target	[breast cancer target]	0.0	3	1	1	1
91045	1710	adhesion, nf-kappab activation	[adhesion, NF-kappaB activation]	0.0	3	1	1	1
91046	1710	patient with hypercholesteremia of type	[patients with hypercholesteremia of type]	0.0	5	1	1	1
91047	1710	transcription factor of possible importance	[transcription factors of possible importance]	0.0	5	1	1	1
91048	1710	naive cell along the Th1	[naive cells along the Th1]	0.0	5	1	1	1
91049	1710	interaction with a receptor.	[interaction with a receptor.]	0.0	4	1	1	1
91050	1710	only significant effect on function	[only significant effects on function]	0.0	5	1	1	1
91051	1710	divergent effect on gene expression	[divergent effects on gene expression]	0.0	5	1	1	1
91052	1710	extract, indicate negative regulation	[extract, indicating negative regulation]	0.0	4	1	1	1
91053	1710	fish technique	[FISH technique]	0.0	2	1	1	1
91054	1710	infiltrate of exocrine gland	[infiltrates of exocrine glands]	0.0	4	1	1	1
91055	1710	depressed subject down-regulated Bmax	[depressed subjects down-regulated Bmax]	0.0	4	1	1	1
91056	1710	patient with chronic leukaemia	[patients with chronic leukaemia]	0.0	4	1	1	1
91057	1710	specific DNA target sequence	[specific DNA target sequences]	0.0	4	1	1	1
91058	1710	DNA virus	[DNA viruses]	0.0	2	1	1	1
91059	1710	patient with disorder euthymic,	[patients with disorder euthymic,]	0.0	4	1	1	1
91060	1710	formation between T ag	[formation between T ag]	0.0	4	1	1	1
91061	1710	change consistent with apoptosis	[changes consistent with apoptosis]	0.0	4	1	1	1
91062	1710	DC characteristic of KG1 cell	[DC characteristics of KG1 cells]	0.0	5	1	1	1
91063	1710	blood of elderly subject	[blood of elderly subjects]	0.0	4	1	1	1
91064	1710	first limitation	[first limitation]	0.0	2	1	1	1
91065	1710	overexpression of grf40 in jurkat cell	[Overexpression of Grf40 in Jurkat cells]	0.0	6	1	1	1
91066	1710	exquisite sensitivity	[exquisite sensitivity]	0.0	2	1	1	1
91067	1710	two cell-specific transcription factor	[two cell-specific transcription factors]	0.0	4	1	1	1
91068	1710	two immediate-early viral transactivator BZLF1	[two immediate-early viral transactivators BZLF1]	0.0	5	1	1	1
91069	1710	SH2 domain-contain protein 76	[SH2 domain-containing protein 76]	0.0	4	1	1	1
91070	1710	binding site for nuclear factor-kappaB	[binding site for nuclear factor-kappaB]	0.0	5	1	1	1
91071	1710	monocyte-derived m	[monocyte-derived M]	0.0	2	1	1	1
91072	1710	anti-CD3 /anti-cd3+ anti-cd28 stimulation	[anti-CD3 /anti-CD3+ anti-CD28 stimulation]	0.0	4	1	1	1
91073	1710	interleukin-6 (il-6) gene	[interleukin-6 (IL-6) gene]	0.0	3	1	1	1
91074	1710	functional differentiation	[functional differentiation]	0.0	2	1	1	1
91075	1710	transient cotransfection with a plasmid	[Transient cotransfection with a plasmid]	0.0	5	1	1	1
91076	1710	such as icam1	[such as ICAM1]	0.0	3	1	1	1
91077	1710	characterization of a element	[characterization of a element]	0.0	4	1	1	1
91078	1710	suppression of anti-porcine t-cell immune response	[Suppression of anti-porcine T-cell immune responses]	0.0	6	1	1	1
91079	1710	level of mineralocorticoid receptor in leucocyte	[levels of mineralocorticoid receptor in leucocytes]	0.0	6	1	1	1
91080	1710	binding of [3H]dexamethasone (p	[binding of [3H]dexamethasone (P]	0.0	4	1	1	1
91081	1710	tpa factor protein	[TPA factor protein]	0.0	3	1	1	1
91082	1710	AML1/ETO transcript	[AML1/ETO transcript]	0.0	2	1	1	1
91083	1710	Adherence-dependent increase in monocyte pdgf(b) mrna	[Adherence-dependent increase in monocyte PDGF(B) mRNA]	0.0	6	1	1	1
91084	1710	coding sequence of mrna	[coding sequence of mRNA]	0.0	4	1	1	1
91085	1710	tissue malt	[tissue MALT]	0.0	2	1	1	1
91086	1710	develop response	[developing response]	0.0	2	1	1	1
91087	1710	M-CSF expression of the gene	[M-CSF expression of the gene]	0.0	5	1	1	1
91088	1710	induction in a human t-cell line	[Induction in a human T-cell line]	0.0	6	1	1	1
91089	1710	myeloid cell polymorphonuclear neutrophilic granulocyte	[myeloid cells polymorphonuclear neutrophilic granulocytes]	0.0	5	1	1	1
91090	1710	endogenous corticosteroid	[endogenous corticosteroids]	0.0	2	1	1	1
91091	1710	mismatch	[mismatch]	0.0	1	1	1	1
91092	1710	cytosolic preparation	[cytosolic preparations]	0.0	2	1	1	1
91093	1710	fractional inhibition of migration rate	[fractional inhibition of migration rate]	0.0	5	1	1	1
91094	1710	presence a good transactivator	[presence a better transactivator]	0.0	4	1	1	1
91095	1710	peptide show only weak cross-reactivity	[peptide showing only weak cross-reactivity]	0.0	5	1	1	1
91096	1710	own expression	[own expression]	0.0	2	1	1	1
91097	1710	different sequence requirement for expression	[Different sequence requirements for expression]	0.0	5	1	1	1
91098	1710	intranuclear environment	[intranuclear environment]	0.0	2	1	1	1
91099	1710	suggest a negative regulatory domain	[suggesting a negative regulatory domain]	0.0	5	1	1	1
91100	1710	active c-fos/c-jun ap-1	[active c-Fos/c-Jun AP-1]	0.0	3	1	1	1
91101	1710	arrest differentiation of red cell progenitor	[arresting differentiation of red cell progenitors]	0.0	6	1	1	1
91102	1710	mechanism in myocardial infarction	[mechanism in myocardial infarction]	0.0	4	1	1	1
91103	1710	significantly (p leukocyte adhesion in respect	[significantly (P leukocyte adhesion in respect]	0.0	6	1	1	1
91104	1710	interaction between b cell-specific transcriptional coactivator	[interactions between B cell-specific transcriptional coactivators]	0.0	6	1	1	1
91105	1710	early (ie62) protein	[early (IE62) protein]	0.0	3	1	1	1
91106	1710	tcf-1 mouse	[TCF-1 mice]	0.0	2	1	1	1
91107	1710	gold compound aurothioglucose contain gold ion	[gold compounds aurothioglucose containing gold ion]	0.0	6	1	1	1
91108	1710	p21ras effector	[p21ras effector]	0.0	2	1	1	1
91109	1710	binding to consensus sequence	[binding to consensus sequence]	0.0	4	1	1	1
91110	1710	endogenous corticosterone	[endogenous corticosterone]	0.0	2	1	1	1
91111	1710	strong suppression	[strong suppression]	0.0	2	1	1	1
91112	1710	mediator in cell	[mediators in cells]	0.0	3	1	1	1
91113	1710	healthy human leukocyte antigen-B8	[healthy human leukocyte antigen-B8]	0.0	4	1	1	1
91114	1710	endogenous long terminal repeat activity	[endogenous long terminal repeat activity]	0.0	5	1	1	1
91115	1710	role integrate the signal	[role integrating the signal]	0.0	4	1	1	1
91116	1710	involvement in il-10 up-regulation	[Involvement in IL-10 up-regulation]	0.0	4	1	1	1
91117	1710	nineteen woman	[nineteen women]	0.0	2	1	1	1
91118	1710	activation of nfat	[activation of NFAT]	0.0	3	1	1	1
91119	1710	most likely components.	[most likely components.]	0.0	3	1	1	1
91120	1710	specific antibody against transcription factor	[specific antibodies against transcription factors]	0.0	5	1	1	1
91121	1710	follow discontinuation	[Following discontinuation]	0.0	2	1	1	1
91122	1710	normal alveolar macrophage PAM	[Normal alveolar macrophages PAM]	0.0	4	1	1	1
91123	1710	secondary messenger	[secondary messenger]	0.0	2	1	1	1
91124	1710	level of pge2 bind	[levels of PGE2 bind]	0.0	4	1	1	1
91125	1710	estrogen unit	[estrogen unit]	0.0	2	1	1	1
91126	1710	human cell in hypoxia	[human cells in hypoxia]	0.0	4	1	1	1
91127	1710	level of p56(lck)	[levels of p56(lck)]	0.0	3	1	1	1
91128	1710	formation of binding heterodimers, at times.	[formation of binding heterodimers, at times.]	0.0	6	1	1	1
91129	1710	pretreatment of "semimature" 5-day macrophage	[Pretreatment of "semimature" 5-day macrophages]	0.0	5	1	1	1
91130	1710	strategy persist lifelong, asymptomatically	[strategy persisting lifelong, asymptomatically]	0.0	4	1	1	1
91131	1710	consider group together	[considering groups together]	0.0	3	1	1	1
91132	1710	cell inflammatory response	[cell inflammatory responses]	0.0	3	1	1	1
91133	1710	phenotype of SIVsmmPBj14	[phenotype of SIVsmmPBj14]	0.0	3	1	1	1
91134	1710	adult cd34+ bone marrow cell	[adult CD34+ bone marrow cells]	0.0	5	1	1	1
91135	1710	human stat protein	[human Stat proteins]	0.0	3	1	1	1
91136	1710	nuclear factor-kappaB control	[nuclear factor-kappaB control]	0.0	3	1	1	1
91137	1710	kappaB-regulated luciferase encoding vector	[kappaB-regulated luciferase encoding vector]	0.0	4	1	1	1
91138	1710	confirm a transcription factor	[confirming a transcription factor]	0.0	4	1	1	1
91139	1710	determinant of the ability	[determinants of the ability]	0.0	4	1	1	1
91140	1710	target structure the major immediate-early protein	[Target structures the major immediate-early protein]	0.0	6	1	1	1
91141	1710	supernatant from dep-pah-activated cell	[supernatants from DEP-PAH-activated cells]	0.0	4	1	1	1
91142	1710	physical proximity at position	[physical proximity at position]	0.0	4	1	1	1
91143	1710	subject type	[subjects Type]	0.0	2	1	1	1
91144	1710	phorbol myristate acetate-	[phorbol myristate acetate-]	0.0	3	1	1	1
91145	1710	pancreatic beta-cell type-specific complex	[pancreatic beta-cell type-specific complex]	0.0	4	1	1	1
91146	1710	thereby suggest a posttranscriptional mechanism	[thereby suggesting a posttranscriptional mechanism]	0.0	5	1	1	1
91147	1710	lmp1+	[LMP1+]	0.0	1	1	1	1
91148	1710	produce a 50-fold induction	[producing a 50-fold induction]	0.0	4	1	1	1
91149	1710	unexpected observation of paternal expression	[unexpected observations of paternal expression]	0.0	5	1	1	1
91150	1710	liver function	[liver function]	0.0	2	1	1	1
91151	1710	transcriptional effect on the promoter	[transcriptional effects on the promoters]	0.0	5	1	1	1
91152	1710	induction of 2422-erh)2d3 synthesis	[Induction of 24,25-(OH)2D3 synthesis]	0.0	4	1	1	1
91153	1710	follow-up of patient	[Follow-up of patient]	0.0	3	1	1	1
91154	1710	same group	[same group]	0.0	2	1	1	1
91155	1710	effect of leukotriene B4 LTB4	[effect of leukotriene B4 LTB4]	0.0	5	1	1	1
91156	1710	nf-e2 protein	[NF-E2 proteins]	0.0	2	2	2	1
91157	1710	expression during monocytic differentiation	[Expression during monocytic differentiation]	0.0	4	1	1	1
91158	1710	[effect of therapy	[[Effect of therapy]	0.0	3	1	1	1
91159	1710	exclusive expression on T cell	[exclusive expression on T cells]	0.0	5	1	1	1
91160	1710	5'-deletion mutation	[5'-deletion mutations]	0.0	2	1	1	1
91161	1710	transcription of the reporter gene	[transcription of the reporter gene]	0.0	5	1	1	1
91162	1710	antagonist to the activity	[antagonist to the activities]	0.0	4	1	1	1
91163	1710	several t-cell-expressed cytokine interleukin	[several T-cell-expressed cytokines interleukin]	0.0	4	1	1	1
91164	1710	x-inactivation center	[X-inactivation center]	0.0	2	1	1	1
91165	1710	LTR region	[LTR region]	0.0	2	1	1	1
91166	1710	regions, dp1 -140 bp	[regions, DP1 -140 bp]	0.0	4	1	1	1
91167	1710	recent identification of transcription factor	[recent identification of transcription factors]	0.0	5	1	1	1
91168	1710	role in myeloid differentiation	[role in myeloid differentiation]	0.0	4	1	1	1
91169	1710	however, high (66 millileter	[However, high (66 ml]	0.0	4	1	1	1
91170	1710	close homologue, KIAA0144	[close homologue, KIAA0144]	0.0	3	1	1	1
91171	1710	pathway for B-cell activation	[pathway for B-cell activation]	0.0	4	1	1	1
91172	1710	xist gene	[XIST gene]	0.0	2	1	1	1
91173	1710	NF-kappa b probe	[NF-kappa B probe]	0.0	3	1	1	1
91174	1710	human immunodeficiency virus type (hiv-1) tat	[Human immunodeficiency virus type (HIV-1) Tat]	0.0	6	1	1	1
91175	1710	significant effect on function	[significant effects on function]	0.0	4	1	1	1
91176	1710	direct stimulation	[direct stimulation]	0.0	2	1	1	1
91177	1710	competition for binding	[competition for binding]	0.0	3	1	1	1
91178	1710	production of mature population	[production of mature populations]	0.0	4	1	1	1
91179	1710	other mononuclear cell	[other mononuclear cells]	0.0	3	1	1	1
91180	1710	cytokine-induced ec-mn adhesion	[cytokine-induced EC-Mn adhesion]	0.0	3	1	1	1
91181	1710	injection of blood cell hrbc	[injection of blood cells HRBC]	0.0	5	1	1	1
91182	1710	level of bcl-2	[level of bcl-2]	0.0	3	2	2	1
91183	1710	activation the latent gene promoter	[activation the latent gene promoter]	0.0	5	1	1	1
91184	1710	BL case	[BL case]	0.0	2	1	1	1
91185	1710	inhibitory concentration of mp value	[inhibitory concentrations of MP values]	0.0	5	1	1	1
91186	1710	acid-synthesizing enzyme aldehyde dehydrogenase	[acid-synthesizing enzyme aldehyde dehydrogenase]	0.0	4	1	1	1
91187	1710	major depressive disorder: lack	[major depressive disorder: lack]	0.0	4	1	1	1
91188	1710	blot with a N-terminal antibody	[blot with an N-terminal antibody]	0.0	5	1	1	1
91189	1710	bacteriophage	[bacteriophage]	0.0	1	1	1	1
91190	1710	differentiation in vitro	[differentiation in vitro]	0.0	3	1	1	1
91191	1710	interferon IFN gene transfer	[interferon IFN gene transfer]	0.0	4	1	1	1
91192	1710	binding I interferon	[Binding I interferon]	0.0	3	1	1	1
91193	1710	consider the positive effect	[Considering the positive effect]	0.0	4	1	1	1
91194	1710	xeroderma pigmentosum XP	[xeroderma pigmentosum XP]	0.0	3	1	1	1
91195	1710	receptor/ gr	[receptor/s GR]	0.0	2	1	1	1
91196	1710	reaction with er	[reaction with ER]	0.0	3	1	1	1
91197	1710	susceptibility of the mouse	[susceptibility of the mice]	0.0	4	1	1	1
91198	1710	major target of oxygen intermediate	[major target of oxygen intermediates]	0.0	5	1	1	1
91199	1710	activity kbf1/p50	[activity KBF1/p50]	0.0	2	1	1	1
91200	1710	inflammatory disease in Japan, cepharanthine	[inflammatory diseases in Japan, cepharanthine]	0.0	5	1	1	1
91201	1710	preincubation with a peptide Arg-Gly-Asp	[preincubation with a peptide Arg-Gly-Asp]	0.0	5	1	1	1
91202	1710	modular structure with domain	[modular structure with domains]	0.0	4	1	1	1
91203	1710	continuous expression of a cytoplasmic protein	[continuous expression of an cytoplasmic protein]	0.0	6	1	1	1
91204	1710	involvement of calcineurin	[involvement of calcineurin]	0.0	3	1	1	1
91205	1710	distinct cell type	[distinct cell types]	0.0	3	1	1	1
91206	1710	complex devoid	[complexes devoid]	0.0	2	1	1	1
91207	1710	small nuclear rna (snrna) gene	[small nuclear RNA (snRNA) genes]	0.0	5	1	1	1
91208	1710	lead to low production	[leading to lower production]	0.0	4	1	1	1
91209	1710	element important	[element important]	0.0	2	1	1	1
91210	1710	proteolysis during cellular extraction	[proteolysis during cellular extraction]	0.0	4	1	1	1
91211	1710	group low dissociation	[groups lower dissociation]	0.0	3	1	1	1
91212	1710	fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	5	1	1	1
91213	1710	acid on po-b	[acid on PO-B]	0.0	3	1	1	1
91214	1710	response to pathogen	[response to pathogens]	0.0	3	1	1	1
91215	1710	interaction with b coactivator	[interactions with B coactivators]	0.0	4	1	1	1
91216	1710	(25 mm) of acute ethanol treatment	[(25 mM) of acute ethanol treatment]	0.0	6	1	1	1
91217	1710	photoaffinity labeling	[Photoaffinity labeling]	0.0	2	1	1	1
91218	1710	-oppose	[-opposing]	0.0	1	1	1	1
91219	1710	specific effect	[specific effects]	0.0	2	1	1	1
91220	1710	use a molecular clone of HTLV-II	[using an molecular clone of HTLV-II]	0.0	6	1	1	1
91221	1710	2 receptor alpha subunit	[2 receptor alpha subunit]	0.0	4	1	1	1
91222	1710	TAL1 scl) gene	[TAL1 SCL) gene]	0.0	3	1	1	1
91223	1710	adeno-associated virus aav	[adeno-associated virus AAV]	0.0	3	1	1	1
91224	1710	balance between mechanism	[balance between mechanisms]	0.0	3	1	1	1
91225	1710	means of a inducible pathway	[means of an inducible pathway]	0.0	5	1	1	1
91226	1710	use as anti-inflammatory /hypereosinophilic agent	[use as anti-inflammatory /hypereosinophilic agents]	0.0	5	1	1	1
91227	1710	primarily at stage of b-lymphocyte development	[primarily at stages of B-lymphocyte development]	0.0	6	1	1	1
91228	1710	potential pathway for periodontal tissue damage	[potential pathways for periodontal tissue damage]	0.0	6	1	1	1
91229	1710	role regulate cell-cycle progression	[role regulating cell-cycle progression]	0.0	4	1	1	1
91230	1710	function of accessory cell	[functions of accessory cells]	0.0	4	1	1	1
91231	1710	cortex in spinal cord	[cortex in spinal cord]	0.0	4	1	1	1
91232	1710	regulate cp activity	[regulating Cp activity]	0.0	3	1	1	1
91233	1710	tyrosine phosphorylation of set	[tyrosine phosphorylation of sets]	0.0	4	1	1	1
91234	1710	24 healthy woman second	[24 healthy women second]	0.0	4	1	1	1
91235	1710	evidence for a sequence of event	[evidence for a sequence of events]	0.0	6	1	1	1
91236	1710	x gene sequence	[X gene sequence]	0.0	3	1	1	1
91237	1710	five cis-acting region	[five cis-acting regions]	0.0	3	1	1	1
91238	1710	regulator of b-cell development	[regulator of B-cell development]	0.0	4	1	1	1
91239	1710	PPARalpha a important regulator of atherogenesis	[PPARalpha a important regulator of atherogenesis]	0.0	6	1	1	1
91240	1710	proliferation capacity in comparison	[proliferation capacity in comparison]	0.0	4	1	1	1
91241	1710	role as a regulatory mechanism	[role as a regulatory mechanism]	0.0	5	1	1	1
91242	1710	regulator of transcription during b-cell maturation	[regulators of transcription during B-cell maturation]	0.0	6	1	1	1
91243	1710	generation of no	[generation of NO]	0.0	3	1	1	1
91244	1710	illness involve response	[illness involving responses]	0.0	3	1	1	1
91245	1710	mrna (75	[mRNA (75]	0.0	2	1	1	1
91246	1710	interleukin-2-independent growth	[interleukin-2-independent growth]	0.0	2	1	1	1
91247	1710	function as a factor	[functioning as a factor]	0.0	4	1	1	1
91248	1710	two distal carg sequence	[two distal CArG sequences]	0.0	4	1	1	1
91249	1710	primary NK	[primary NK]	0.0	2	1	1	1
91250	1710	ro(ssa) patient	[Ro(SSA) patients]	0.0	2	1	1	1
91251	1710	oligomer to p65	[oligomers to p65]	0.0	3	1	1	1
91252	1710	antibody of potential significance.	[antibodies of potential significance.]	0.0	4	1	1	1
91253	1710	cell line in to group	[cell lines in to group]	0.0	5	1	1	1
91254	1710	process require interaction	[process requiring interaction]	0.0	3	1	1	1
91255	1710	simultaneous treatment with dexamethasone	[simultaneous treatment with dexamethasone]	0.0	4	1	1	1
91256	1710	lectin to human blood cell	[lectin to human blood cells]	0.0	5	1	1	1
91257	1710	oct-2 DNA	[Oct-2 DNA]	0.0	2	1	1	1
91258	1710	effect on marker of PMA differentiation;	[effects on markers of PMA differentiation;]	0.0	6	1	1	1
91259	1710	role in the calcium-mediated, cyclosporin	[role in the calcium-mediated, cyclosporin]	0.0	5	1	1	1
91260	1710	only abundant activity of extract	[only abundant activity of extracts]	0.0	5	1	1	1
91261	1710	antibody mAECA	[antibodies mAECA]	0.0	2	1	1	1
91262	1710	monocyte nf-kappab	[monocyte NF-kappaB]	0.0	2	1	1	1
91263	1710	gata-1 binding site	[GATA-1 binding site]	0.0	3	1	1	1
91264	1710	further knowledge	[further knowledge]	0.0	2	1	1	1
91265	1710	-deficient T	[-deficient T]	0.0	2	1	1	1
91266	1710	number include that cytokine	[number including those cytokines]	0.0	4	1	1	1
91267	1710	Recent progress	[Recent progress]	0.0	2	1	1	1
91268	1710	physiological limit	[physiological limit]	0.0	2	1	1	1
91269	1710	pp56(lck) molecule	[pp56(lck) molecule]	0.0	2	1	1	1
91270	1710	initial decline in blood histamine	[initial decline in blood histamine]	0.0	5	1	1	1
91271	1710	(5118), ebv infection (2/7), ebv reactivation	[(5/18), EBV infection (2/7), EBV reactivation]	0.0	6	1	1	1
91272	1710	concentration of smx -nhoh	[concentrations of SMX -NHOH]	0.0	4	1	1	1
91273	1710	PBMC from child	[PBMC from children]	0.0	3	2	2	1
91274	1710	EBV nuclear antigen	[EBV nuclear antigen]	0.0	3	1	1	1
91275	1710	supplement the datum	[Supplementing the data]	0.0	3	1	1	1
91276	1710	expression of receptor beta	[expression of receptor beta]	0.0	4	1	1	1
91277	1710	AP-1 type	[AP-1 type]	0.0	2	1	1	1
91278	1710	family of immunosuppressant	[family of immunosuppressants]	0.0	3	1	1	1
91279	1710	aids -related Epstein-Barr virus	[AIDS -related Epstein-Barr virus]	0.0	4	1	1	1
91280	1710	involve a bind interaction	[involving a binding interaction]	0.0	4	1	1	1
91281	1710	specificity similar	[specificity similar]	0.0	2	2	2	1
91282	1710	extrarenal, mineralocorticoid receptor	[extrarenal, mineralocorticoid receptors]	0.0	3	1	1	1
91283	1710	factor irf-1 interferon factor 1	[factor IRF-1 interferon factor 1]	0.0	5	1	1	1
91284	1710	control collagenase transcription in cell	[controlling collagenase transcription in cells]	0.0	5	1	1	1
91285	1710	two mutation of R-276	[two mutations of R-276]	0.0	4	1	1	1
91286	1710	nf-yb	[NF-YB]	0.0	1	1	1	1
91287	1710	r-pk minimal promoter	[R-PK minimal promoter]	0.0	3	1	1	1
91288	1710	stat1 alpha in primary NK cell	[STAT1 alpha in primary NK cells]	0.0	6	1	1	1
91289	1710	presence of IkappaBbeta	[presence of IkappaBbeta]	0.0	3	1	1	1
91290	1710	contact with factor	[contacts with factors]	0.0	3	1	1	1
91291	1710	further evidence to observation	[further evidence to observations]	0.0	4	1	1	1
91292	1710	effect on VCAM-1 gene transcription	[effects on VCAM-1 gene transcription]	0.0	5	1	1	1
91293	1710	expression of mnda	[expression of MNDA]	0.0	3	1	1	1
91294	1710	study: lymphocyte from woman	[STUDY: lymphocytes from women]	0.0	4	1	1	1
91295	1710	NH2 amino acid sequence analysis	[NH2 amino acid sequence analysis]	0.0	5	1	1	1
91296	1710	silencing of fetal globin expression	[Silencing of fetal globin expression]	0.0	5	1	1	1
91297	1710	h. induce CAT activity /mn2+	[h, inducing CAT activity /Mn2+]	0.0	5	1	1	1
91298	1710	location: rest memory T cell	[location: resting memory T cells]	0.0	5	1	1	1
91299	1710	independent signal	[independent signal]	0.0	2	1	1	1
91300	1710	simian peripheral blood mononuclear cell	[simian peripheral blood mononuclear cells]	0.0	5	1	1	1
91301	1710	response to virus type htlv-1	[response to virus type HTLV-1]	0.0	5	1	1	1
91302	1710	action of acid blockade	[action of acid blockade]	0.0	4	1	1	1
91303	1710	colony-stimulating factor production	[colony-stimulating factor production]	0.0	3	1	1	1
91304	1710	HTLV-I promoter.	[HTLV-I promoter.]	0.0	2	1	1	1
91305	1710	factor-kappaB a transcriptional activator	[factor-kappaB a transcriptional activator]	0.0	4	1	1	1
91306	1710	classical ar	[classical AR]	0.0	2	1	1	1
91307	1710	erythroblast co-express Spi-1	[erythroblasts co-expressing Spi-1]	0.0	3	1	1	1
91308	1710	vivo of Fos	[vivo of Fos]	0.0	3	1	1	1
91309	1710	difference of the a6h molecule	[differences of the A6H molecule]	0.0	5	1	1	1
91310	1710	rna activity of promoter-enhancer.	[RNA activity of promoter-enhancer.]	0.0	4	1	1	1
91311	1710	biochemical sign of secondary hypothyroidism	[biochemical signs of secondary hypothyroidism]	0.0	5	1	1	1
91312	1710	marker of different subpopulation	[marker of different subpopulations]	0.0	4	1	1	1
91313	1710	antecedent activation	[antecedent activation]	0.0	2	1	1	1
91314	1710	patient without tal1 rearrangement	[patients without TAL1 rearrangements]	0.0	4	1	1	1
91315	1710	regulatory region include CBF	[regulatory regions including CBF]	0.0	4	1	1	1
91316	1710	hypothesis of direct, effect	[hypothesis of direct, effects]	0.0	4	1	1	1
91317	1710	event lymphocyte action	[event lymphocyte action]	0.0	3	1	1	1
91318	1710	production of mcp-1	[production of MCP-1]	0.0	3	1	1	1
91319	1710	anti- cd15 cell	[anti- CD15 cells]	0.0	3	1	1	1
91320	1710	aspect of pathogenesis	[aspects of pathogenesis]	0.0	3	1	1	1
91321	1710	b/rel activity in T lymphocyte	[B/Rel activity in T lymphocytes]	0.0	5	1	1	1
91322	1710	dominant HLH factor Id3	[dominant HLH factor Id3]	0.0	4	1	1	1
91323	1710	study of the inhibitory activity	[Study of the inhibitory activities]	0.0	5	1	1	1
91324	1710	fragment of a kb sequence	[Fragments of a kb sequence]	0.0	5	1	1	1
91325	1710	octamerlike sequence	[octamerlike sequence]	0.0	2	1	1	1
91326	1710	binding of the ap1 factor	[binding of the AP1 factors]	0.0	5	1	1	1
91327	1710	MCR	[MCR]	0.0	1	1	1	1
91328	1710	mapping by in vivo footprinting	[mapping by in vivo footprinting]	0.0	5	1	1	1
91329	1710	suggest a target for cellular protein	[suggesting a target for cellular proteins]	0.0	6	1	1	1
91330	1710	detailed understanding	[detailed understanding]	0.0	2	1	1	1
91331	1710	BL cell	[BL cells]	0.0	2	1	1	1
91332	1710	encompass a positive regulatory element NF-AT-1	[encompassing an positive regulatory element NF-AT-1]	0.0	6	1	1	1
91333	1710	fluid of agent(s)	[fluid of agent(s)]	0.0	3	1	1	1
91334	1710	gc-sensitive asthmatics	[GC-sensitive asthmatics]	0.0	2	1	1	1
91335	1710	mucosa-associated lymphoid tissue malt lymphoma (19	[mucosa-associated lymphoid tissue MALT lymphoma (19]	0.0	6	1	1	1
91336	1710	oncogene bcl-3	[oncogene bcl-3]	0.0	2	1	1	1
91337	1710	balance between type	[balance between type]	0.0	3	1	1	1
91338	1710	3 -stat5a pathway	[3 -STAT5a pathway]	0.0	3	1	1	1
91339	1710	mediator in human endothelial cell	[mediators in human endothelial cells]	0.0	5	1	1	1
91340	1710	growth of virus	[growth of viruses]	0.0	3	1	1	1
91341	1710	control with respect to dissociation capacity,	[controls with respect to dissociation capacity,]	0.0	6	1	1	1
91342	1710	infection of blood lymphocyte	[Infection of blood lymphocytes]	0.0	4	1	1	1
91343	1710	LMP1 expression vector	[LMP1 expression vector]	0.0	3	1	1	1
91344	1710	deoxynucleotidyl transferase labeling of DNA fragment	[deoxynucleotidyl transferase labeling of DNA fragments]	0.0	6	1	1	1
91345	1710	distinct DNA binding complex	[distinct DNA binding complexes]	0.0	4	1	1	1
91346	1710	globin cluster	[globin cluster]	0.0	2	1	1	1
91347	1710	/threonine protein phosphorylation	[/threonine protein phosphorylation]	0.0	3	1	1	1
91348	1710	rdna with identity	[cDNAs with identity]	0.0	3	1	1	1
91349	1710	translation start	[translation start]	0.0	2	1	1	1
91350	1710	putative human homolog	[putative human homolog]	0.0	3	1	1	1
91351	1710	DNA-relaxing activity in extract	[DNA-relaxing activity in extracts]	0.0	4	1	1	1
91352	1710	oligomer representative of the vdre	[oligomers representative of the VDREs]	0.0	5	1	1	1
91353	1710	activation at the IFN-gamma receptor	[activation at the IFN-gamma receptor]	0.0	5	1	1	1
91354	1710	average during MPE	[average during MPE]	0.0	3	1	1	1
91355	1710	effect of the cytokine interleukin	[effects of the cytokine interleukin]	0.0	5	1	1	1
91356	1710	suggest a direct repressive effect	[suggesting a direct repressive effect]	0.0	5	1	1	1
91357	1710	down-regulation of the receptor in patient	[down-regulation of the receptor in patients]	0.0	6	1	1	1
91358	1710	conclusion a signal component	[conclusion a signaling component]	0.0	4	1	1	1
91359	1710	versatile cellular switch	[versatile cellular switch]	0.0	3	1	1	1
91360	1710	transcriptionally inactive allele	[transcriptionally inactive alleles]	0.0	3	1	1	1
91361	1710	human SCL	[human SCL]	0.0	2	1	1	1
91362	1710	arm of Chr 20	[arm of Chr 20]	0.0	4	1	1	1
91363	1710	2 synthesis	[2 synthesis]	0.0	2	1	1	1
91364	1710	receptor synthesis	[receptor synthesis]	0.0	2	1	1	1
91365	1710	reach a peak after stimulation	[reaching a peak after stimulation]	0.0	5	1	1	1
91366	1710	remarkable correlation	[remarkable correlation]	0.0	2	1	1	1
91367	1710	control (HIV) terminal repeat	[control (HIV) terminal repeat]	0.0	4	1	1	1
91368	1710	one mechanism for activation	[one mechanism for activation]	0.0	4	1	1	1
91369	1710	lymphoid factor contain c-rel-like protein	[lymphoid factor containing c-Rel-like proteins]	0.0	5	1	1	1
91370	1710	lymphoma of type	[lymphoma of type]	0.0	3	1	1	1
91371	1710	expression of all gene	[Expression of all genes]	0.0	4	1	1	1
91372	1710	NFATx1 nuclear translocation	[NFATx1 nuclear translocation]	0.0	3	1	1	1
91373	1710	immunoglobulin eig)-secreting cell	[immunoglobulin (Ig)-secreting cells]	0.0	3	1	1	1
91374	1710	9 adult before overnight dst	[9 adults before overnight DST]	0.0	5	1	1	1
91375	1710	robust phosphorylation	[robust phosphorylation]	0.0	2	1	1	1
91376	1710	Glucocorticoid receptor in patient	[Glucocorticoid receptor in patients]	0.0	4	1	1	1
91377	1710	culture supernatant of cell	[culture supernatants of cells]	0.0	4	1	1	1
91378	1710	new experimental system	[new experimental system]	0.0	3	1	1	1
91379	1710	repressor complex	[repressor complexes]	0.0	2	1	1	1
91380	1710	97 (18- healthy female volunteer	[97 (18- healthy female volunteers]	0.0	5	1	1	1
91381	1710	assessment of the functional role	[assessment of the functional roles]	0.0	5	1	1	1
91382	1710	591/EGR2	[591/EGR2]	0.0	1	1	1	1
91383	1710	IkappaBalpha kinase (ikk)	[IkappaBalpha kinase (IKK)]	0.0	3	1	1	1
91384	1710	leukemia cell of DNA topoisomerase inhibitor	[leukemia cells of DNA topoisomerase inhibitors]	0.0	6	1	1	1
91385	1710	expression of fmol/mg	[expression of fmol/mg]	0.0	3	1	1	1
91386	1710	state of immune hyperactivation	[state of immune hyperactivation]	0.0	4	1	1	1
91387	1710	inhibition evidence for two lck/fyn-	[inhibition evidence for two Lck/Fyn-]	0.0	5	1	1	1
91388	1710	induction (ifn)-inducible protein follow differentiation	[induction (IFN)-inducible protein following differentiation]	0.0	5	1	1	1
91389	1710	positive chronic myelogenous leukemia	[positive chronic myelogenous leukemia]	0.0	4	1	1	1
91390	1710	single nucleotide insertion	[single nucleotide insertion]	0.0	3	1	1	1
91391	1710	gene hypermethylation	[gene hypermethylation]	0.0	2	1	1	1
91392	1710	glucocorticoid responsiveness of cd4+ t-cell line	[glucocorticoid responsiveness of CD4+ T-cell lines]	0.0	6	1	1	1
91393	1710	activation of cytokine gene	[activation of cytokine genes]	0.0	4	1	1	1
91394	1710	binding of cell-specific transcription factor	[binding of cell-specific transcription factors]	0.0	5	1	1	1
91395	1710	IFN stimulus	[IFN stimulus]	0.0	2	1	1	1
91396	1710	gammac response	[gammac responses]	0.0	2	1	1	1
91397	1710	growth factor receptor transcript	[growth factor receptor transcripts]	0.0	4	1	1	1
91398	1710	half-life of p65 mrna	[half-life of p65 mRNA]	0.0	4	1	1	1
91399	1710	eccrine	[eccrine]	0.0	1	1	1	1
91400	1710	number of target gene	[number of target genes]	0.0	4	1	1	1
91401	1710	two immediate protein BZLF1	[two immediate proteins BZLF1]	0.0	4	1	1	1
91402	1710	regulator for myeloid cell differentiation	[regulator for myeloid cell differentiation]	0.0	5	1	1	1
91403	1710	disease such as dermatitis	[diseases such as dermatitis]	0.0	4	1	1	1
91404	1710	activation synthetase (oas) gene expression	[activation synthetase (OAS) gene expression]	0.0	5	1	1	1
91405	1710	much the abundant protein.	[much the abundant protein.]	0.0	4	1	1	1
91406	1710	18-hydroxy-corticosterone 18-oh-b level	[18-hydroxy-corticosterone 18-OH-B levels]	0.0	3	1	1	1
91407	1710	specific pathology	[specific pathologies]	0.0	2	1	1	1
91408	1710	independent assay	[independent assays]	0.0	2	1	1	1
91409	1710	coronary atherosclerotic plaque	[coronary atherosclerotic plaques]	0.0	3	1	1	1
91410	1710	flow analysis	[flow analysis]	0.0	2	3	3	1
91411	1710	novel mechanism for action	[novel mechanism for action]	0.0	4	1	1	1
91412	1710	role of gata-1	[Role of GATA-1]	0.0	3	1	1	1
91413	1710	role of gata-4	[role of GATA-4]	0.0	3	1	1	1
91414	1710	control of protein necessary	[control of proteins necessary]	0.0	4	1	1	1
91415	1710	IL-13Ralpha1 chain	[IL-13Ralpha1 chain]	0.0	2	1	1	1
91416	1710	two class of cytosolic receptor	[two classes of cytosolic receptors]	0.0	5	1	1	1
91417	1710	increase in p105 mrna	[increase in p105 mRNA]	0.0	4	1	1	1
91418	1710	Recent isolation	[Recent isolation]	0.0	2	1	1	1
91419	1710	study of follicular border	[study of follicular borders]	0.0	4	1	1	1
91420	1710	connection with induction	[connection with induction]	0.0	3	1	1	1
91421	1710	woman aged	[women aged]	0.0	2	1	1	1
91422	1710	especially with marker of mitotic rate	[especially with markers of mitotic rate]	0.0	6	1	1	1
91423	1710	recent identification	[recent identification]	0.0	2	1	1	1
91424	1710	event in cells.	[events in cells.]	0.0	3	1	1	1
91425	1710	ALY a novel	[ALY a novel]	0.0	3	1	1	1
91426	1710	exon 10	[exon 10]	0.0	2	1	1	1
91427	1710	expression in erythroid precursor	[expression in erythroid precursors]	0.0	4	1	1	1
91428	1710	bioactivation	[Bioactivation]	0.0	1	1	1	1
91429	1710	continuously grow cell line	[continuously growing cell line]	0.0	4	1	1	1
91430	1710	site for ebf sequence on chromosome	[sites for EBF sequences on Chromosome]	0.0	6	1	1	1
91431	1710	peak CsA drug level	[peak CsA drug levels]	0.0	4	1	1	1
91432	1710	change in androgen binding site	[changes in androgen binding sites]	0.0	5	1	1	1
91433	1710	low dose of ionizing radiation	[lower doses of ionizing radiation]	0.0	5	1	1	1
91434	1710	virus replication.	[virus replication.]	0.0	2	1	1	1
91435	1710	patient with disease (12:	[patients with diseases (12:]	0.0	4	1	1	1
91436	1710	major (mhc) class antigen	[major (MHC) class antigens]	0.0	4	3	3	1
91437	1710	overlapping cosmid	[overlapping cosmids]	0.0	2	1	1	1
91438	1710	class ii DNA binding factor	[class II DNA binding factors]	0.0	5	1	1	1
91439	1710	human cd34(+) progenitor cell	[human CD34(+) progenitor cells]	0.0	4	1	1	1
91440	1710	haplotype analysis	[Haplotype analysis]	0.0	2	1	1	1
91441	1710	comparison with protease-treated extract	[comparison with protease-treated extracts]	0.0	4	1	1	1
91442	1710	low gr number with affinity	[low GR number with affinity]	0.0	5	1	1	1
91443	1710	use throughput screen of microbial broth	[using throughput screening of microbial broths]	0.0	6	1	1	1
91444	1710	temporal relationship	[temporal relationship]	0.0	2	1	1	1
91445	1710	perhaps due to a chromatin structure	[perhaps due to a chromatin structure]	0.0	6	1	1	1
91446	1710	subpopulation of cd4+ cell	[subpopulation of CD4+ cells]	0.0	4	1	1	1
91447	1710	three 29-kda protein	[three 29-kDa proteins]	0.0	3	1	1	1
91448	1710	overexpression 1 peptide	[Overexpression 1 peptide]	0.0	3	1	1	1
91449	1710	decrease the amount	[decreasing the amount]	0.0	3	1	1	1
91450	1710	progenitor cell HPC	[progenitor cells HPC]	0.0	3	1	1	1
91451	1710	multiple event along the pathway	[multiple events along the pathways]	0.0	5	1	1	1
91452	1710	peak content	[peak content]	0.0	2	1	1	1
91453	1710	synthesis of (il)-6	[synthesis of (IL)-6]	0.0	3	1	1	1
91454	1710	treatment of immunoprecipitated nfatp	[Treatment of immunoprecipitated NFATp]	0.0	4	1	1	1
91455	1710	transcription factor c-Jun	[transcription factors c-Jun]	0.0	3	1	1	1
91456	1710	region upstream from HBD	[region upstream from HBD]	0.0	4	1	1	1
91457	1710	block this crucial element	[blocking these crucial elements]	0.0	4	1	1	1
91458	1710	steroid binding site	[steroid binding sites]	0.0	3	1	1	1
91459	1710	mean fluorescence intensity	[mean fluorescence intensity]	0.0	3	1	1	1
91460	1710	sox9 coding sequence polymorphism	[SOX9 coding sequence polymorphism]	0.0	4	1	1	1
91461	1710	nonsmok patient with airway obstruction	[nonsmoking patients with airways obstruction]	0.0	5	1	1	1
91462	1710	other functional region	[other functional regions]	0.0	3	1	1	1
91463	1710	42 different gene HZF	[42 different genes HZF]	0.0	4	1	1	1
91464	1710	encode a kappa b protein	[encoding a kappa B protein]	0.0	5	1	1	1
91465	1710	first contrast IL-12 IFN gene	[first contrasting IL-12 IFN genes]	0.0	5	1	1	1
91466	1710	transcription factor such as gata-1 common	[transcription factors such as GATA-1 common]	0.0	6	1	1	1
91467	1710	cys gsh human blood cell	[CYS GSH human blood cells]	0.0	5	1	1	1
91468	1710	jeg-3	[JEG-3]	0.0	1	1	1	1
91469	1710	nonphlogistic clearance of leukocyte	[nonphlogistic clearance of leukocytes]	0.0	4	1	1	1
91470	1710	Janus kinase jak	[Janus kinases JAKs]	0.0	3	1	1	1
91471	1710	clone with proliferative response	[Clones with proliferative responses]	0.0	4	1	1	1
91472	1710	capacity of I(kappa)B(alpha)	[capacity of I(kappa)B(alpha)]	0.0	3	1	1	1
91473	1710	induction by human immunodeficiency virus	[Induction by human immunodeficiency virus]	0.0	5	1	1	1
91474	1710	corticosteroid receptor glucocorticoid receptor hgr	[corticosteroid receptors glucocorticoid receptors hGRs]	0.0	5	1	1	1
91475	1710	responsiveness to lps	[responsiveness to LPS]	0.0	3	1	1	1
91476	1710	apparent correlation	[apparent correlation]	0.0	2	1	1	1
91477	1710	b heteromer	[B heteromers]	0.0	2	1	1	1
91478	1710	protein in transient transfection	[proteins in transient transfection]	0.0	4	1	1	1
91479	1710	eventual progression	[eventual progression]	0.0	2	1	1	1
91480	1710	Clinical feature of a immunodeficiency disease	[Clinical features of a immunodeficiency disease]	0.0	6	1	1	1
91481	1710	9-bp motif (-90/-82 with homology	[9-bp motifs (-90/-82 with homology]	0.0	5	1	1	1
91482	1710	results: factor (nf)-kappab	[RESULTS: factor (NF)-kappaB]	0.0	3	1	1	1
91483	1710	stimulation basic protein	[Stimulation basic protein]	0.0	3	1	1	1
91484	1710	expression of obf-1 in HeLa cell	[expression of OBF-1 in HeLa cells]	0.0	6	1	1	1
91485	1710	b target	[B target]	0.0	2	1	1	1
91486	1710	inhibitor in om10.1 cell	[inhibitor in OM10.1 cells]	0.0	4	1	1	1
91487	1710	affect the chymotryptic activity independent	[affecting the chymotryptic activity independent]	0.0	5	1	1	1
91488	1710	woman age.	[women age.]	0.0	2	1	1	1
91489	1710	response to a load	[response to a load]	0.0	4	1	1	1
91490	1710	negative c-fo	[negative c-Fos]	0.0	2	2	2	1
91491	1710	uncouple	[Uncoupling]	0.0	1	1	1	1
91492	1710	least four cis-acting element	[least four cis-acting elements]	0.0	4	1	1	1
91493	1710	expression inducible protein a stat1alpha gene	[Expression inducible protein a STAT1alpha gene]	0.0	6	1	1	1
91494	1710	eosinophil-specific gene encode granule protein ecp	[eosinophil-specific genes encoding granule proteins ECP]	0.0	6	1	1	1
91495	1710	murine lymphocyte by ciprofloxacin	[murine lymphocytes by ciprofloxacin]	0.0	4	1	1	1
91496	1710	inflammation,	[inflammation,]	0.0	1	1	1	1
91497	1710	inflammation.	[inflammation.]	0.0	1	1	1	1
91498	1710	result in cell-monocyte (ec-mn) adhesion	[resulting in cell-monocyte (EC-Mn) adhesion]	0.0	5	1	1	1
91499	1710	MHC class gene silencing	[MHC class gene silencing]	0.0	4	1	1	1
91500	1710	control the step	[controlling the steps]	0.0	3	1	1	1
91501	1710	therapy in peripheral leukocyte	[therapy in peripheral leukocytes]	0.0	4	1	1	1
91502	1710	tetrahydrocortisone 3.16 mg/24h;	[tetrahydrocortisone 3.16 mg/24h;]	0.0	3	1	1	1
91503	1710	igg fc receptor	[IgG Fc receptors]	0.0	3	1	1	1
91504	1710	presence of a loop	[presence of an loop]	0.0	4	1	1	1
91505	1710	very mild down-regulation in patient	[very mild down-regulation in patients]	0.0	5	1	1	1
91506	1710	kb upstream,	[kb upstream,]	0.0	2	1	1	1
91507	1710	mediators, include growth factor	[mediators, including growth factors]	0.0	4	1	1	1
91508	1710	granulocyte colony-stimulating factor granulocyte-macrophage colony-stimumulatelany-stg factor	[granulocyte colony-stimulating factor granulocyte-macrophage colony-stimulating factor]	0.0	6	1	1	1
91509	1710	periodic acid-Schiff	[periodic acid-Schiff]	0.0	2	1	1	1
91510	1710	soft tissue tumor fibrosarcoma	[soft tissue tumors fibrosarcoma]	0.0	4	1	1	1
91511	1710	determinant of megakaryocytic gene expression	[determinants of megakaryocytic gene expression]	0.0	5	1	1	1
91512	1710	lactone such as helenalin	[lactones such as helenalin]	0.0	4	1	1	1
91513	1710	therefore a target for drug therapy	[therefore a target for drug therapy]	0.0	6	1	1	1
91514	1710	deterioration immunodeficiency virus type 1 hiv-1	[deterioration immunodeficiency virus type 1 HIV-1]	0.0	6	1	1	1
91515	1710	stress response in T lymphocyte	[stress response in T lymphocytes]	0.0	5	1	1	1
91516	1710	open reading frame of 342	[open reading frame of 342]	0.0	5	1	1	1
91517	1710	endothelial cell in culture,	[endothelial cells in culture,]	0.0	4	1	1	1
91518	1710	primary stimulation	[primary stimulations]	0.0	2	1	1	1
91519	1710	T phagocytic lineage	[T phagocytic lineage]	0.0	3	1	1	1
91520	1710	anti-inflammatory (non t) effect	[anti-inflammatory (non T) effects]	0.0	4	1	1	1
91521	1710	two activity on T cell	[two activities on T cells]	0.0	5	1	1	1
91522	1710	80.2 (p 0.05, p 0.01	[80.2 (P 0.05, P 0.01]	0.0	5	1	1	1
91523	1710	cell of T phagocytic lineage	[cells of T phagocytic lineage]	0.0	5	1	1	1
91524	1710	activation of nonreceptor protein tyrosine kinase	[Activation of nonreceptor protein tyrosine kinases]	0.0	6	1	1	1
91525	1710	PKC-zeta overexpression	[PKC-zeta overexpression]	0.0	2	1	1	1
91526	1710	specific antibody from normal, carrier	[specific antibodies from normal, carriers]	0.0	5	1	1	1
91527	1710	cd3/t-cell	[CD3/T-cell]	0.0	1	1	1	1
91528	1710	other gene on human chromosome	[other genes on human chromosome]	0.0	5	1	1	1
91529	1710	rna in monocyte	[RNA in monocytes]	0.0	3	1	1	1
91530	1710	Regulatory effect during acute lung injury	[Regulatory effects during acute lung injury]	0.0	6	1	1	1
91531	1710	MYC	[MYC]	0.0	1	1	1	1
91532	1710	ccaat box upstream of cp	[CCAAT box upstream of Cp]	0.0	5	1	1	1
91533	1710	production of high level	[production of high levels]	0.0	4	1	1	1
91534	1710	Here, cytokine activation	[Here, cytokine activation]	0.0	3	1	1	1
91535	1710	twenty-seven patient with tumor	[Twenty-seven patients with tumors]	0.0	4	1	1	1
91536	1710	response to a recombinant fragment	[response to a recombinant fragment]	0.0	5	1	1	1
91537	1710	positive sample of 80	[positive samples of 80]	0.0	4	1	1	1
91538	1710	gene in progenitor cell	[genes in progenitor cells]	0.0	4	1	1	1
91539	1710	up-regulation of the signal transducer	[up-regulation of the signal transducer]	0.0	5	1	1	1
91540	1710	several response to ultra-violet irradiation	[Several responses to UV irradiation]	0.0	5	1	1	1
91541	1710	stimulus-induced ikappabalpha degradation	[stimulus-induced IkappaBalpha degradation]	0.0	3	1	1	1
91542	1710	survivalepromot protein Epstein Barr	[survival-promoting proteins Epstein Barr]	0.0	4	1	1	1
91543	1710	cause a bp truncation	[causing a bp truncation]	0.0	4	1	1	1
91544	1710	role of a sequence	[role of a sequence]	0.0	4	1	1	1
91545	1710	regulatory factor-1 irf-1 gene	[regulatory factor-1 IRF-1 gene]	0.0	4	1	1	1
91546	1710	incubation of cell with antibody	[Incubation of cells with antibody]	0.0	5	1	1	1
91547	1710	expression in sle	[expression in SLE]	0.0	3	1	1	1
91548	1710	gene in cell type	[genes in cell types]	0.0	4	1	1	1
91549	1710	apoptosis suppressor	[apoptosis suppressor]	0.0	2	2	2	1
91550	1710	control gene	[control gene]	0.0	2	1	1	1
91551	1710	multiple lytic antigen-specific reactivity high	[multiple lytic antigen-specific reactivities high]	0.0	5	1	1	1
91552	1710	circadian modification	[circadian modification]	0.0	2	1	1	1
91553	1710	acidic amino acid-rich	[acidic amino acid-rich]	0.0	3	1	1	1
91554	1710	expression of RXR	[expression of RXR]	0.0	3	1	1	1
91555	1710	decrease of aml1 /eto transcript	[decrease of AML1 /ETO transcripts]	0.0	5	1	1	1
91556	1710	inhibition of tnf-alpha production by cell	[Inhibition of TNF-alpha production by cells]	0.0	6	1	1	1
91557	1710	crosslinkage	[crosslinkage]	0.0	1	1	1	1
91558	1710	injury with alpha-tocopherol a free scavenger	[injury with alpha-tocopherol a free scavenger]	0.0	6	1	1	1
91559	1710	QUK splice pattern	[QUK splice pattern]	0.0	3	1	1	1
91560	1710	non-cytotoxic dose	[non-cytotoxic doses]	0.0	2	1	1	1
91561	1710	distinct pattern of signal for chemoattract	[distinct patterns of signaling for chemoattractants]	0.0	6	1	1	1
91562	1710	form include pre-B lymphoblastic leukemia	[forms including pre-B lymphoblastic leukemia]	0.0	5	1	1	1
91563	1710	disulfide bridge	[disulfide bridges]	0.0	2	1	1	1
91564	1710	role for pao -sensitive phosphatase	[role for PAO -sensitive phosphatase]	0.0	5	1	1	1
91565	1710	aspect include presentation, response to treatment	[aspects including presentation, response to treatment]	0.0	6	1	1	1
91566	1710	restimulated, anergic T cell	[restimulated, anergic T cells]	0.0	4	1	1	1
91567	1710	cytoplasmic segment on cd36	[cytoplasmic segment on CD36]	0.0	4	1	1	1
91568	1710	domain of 300 amino acid	[domain of 300 amino acids]	0.0	5	1	1	1
91569	1710	contain p130	[containing p130]	0.0	2	1	1	1
91570	1710	time (12-24	[times (12-24]	0.0	2	1	1	1
91571	1710	cell type gene	[cell type gene]	0.0	3	1	1	1
91572	1710	case with function thyroid gland	[case with functioning thyroid gland]	0.0	5	1	1	1
91573	1710	young (18- to 35-year-old) volunteer	[young (18- to 35-year-old) volunteers]	0.0	5	1	1	1
91574	1710	correlation between c-fo expression	[correlation between c-fos expression]	0.0	4	1	1	1
91575	1710	distinct immunostaining	[distinct immunostaining]	0.0	2	1	1	1
91576	1710	protein in EBNA-2 -positive cell line	[proteins in EBNA-2 -positive cell lines]	0.0	6	1	1	1
91577	1710	(tf) expression	[(TF) expression]	0.0	2	1	1	1
91578	1710	down-regulation of transcription factor	[down-regulation of transcription factors]	0.0	4	1	1	1
91579	1710	blood island	[blood islands]	0.0	2	1	1	1
91580	1710	DNA sequence motif	[DNA sequence motifs]	0.0	3	1	1	1
91581	1710	GH effect	[GH effect]	0.0	2	1	1	1
91582	1710	addition of ebv protein	[addition of EBV proteins]	0.0	4	1	1	1
91583	1710	open reading frame orf of hhv-6	[open reading frames ORFs of HHV-6]	0.0	6	1	1	1
91584	1710	(for class ii	[(for class II]	0.0	3	1	1	1
91585	1710	86 patient	[86 patients]	0.0	2	1	1	1
91586	1710	human microvessel endothelial cell MVEC	[human microvessel endothelial cells MVEC]	0.0	5	1	1	1
91587	1710	differential stimulation	[differential stimulation]	0.0	2	1	1	1
91588	1710	signal event result	[signaling events resulting]	0.0	3	1	1	1
91589	1710	sequence within the so-called element AREs	[sequences within the so-called elements AREs]	0.0	6	1	1	1
91590	1710	pulmonary macrophage PAM	[pulmonary macrophages PAM]	0.0	3	1	1	1
91591	1710	mineralocorticoid receptor on leukocyte	[mineralocorticoid receptors on leukocytes]	0.0	4	1	1	1
91592	1710	as little as bp	[as little as bp]	0.0	4	1	1	1
91593	1710	positive mechanism during t-cell activation	[positive mechanisms during T-cell activation]	0.0	5	1	1	1
91594	1710	lps-stimulated 264.7 cell	[LPS-stimulated 264.7 cells]	0.0	3	1	1	1
91595	1710	toremifene therapy	[toremifene therapy]	0.0	2	1	1	1
91596	1710	infection analysis LTR	[Infection analyses LTR]	0.0	3	1	1	1
91597	1710	transcription initiation in cell-free extract	[transcription initiation in cell-free extracts]	0.0	5	1	1	1
91598	1710	only low relative binding affinity RBA	[only low relative binding affinities RBA]	0.0	6	1	1	1
91599	1710	ifn-alpha5	[IFN-alpha5]	0.0	1	1	1	1
91600	1710	switch gear during t-cell maturation	[Switching gears during T-cell maturation]	0.0	5	1	1	1
91601	1710	DNA intercalate	[DNA intercalating]	0.0	2	1	1	1
91602	1710	SV40 early promoter	[SV40 early promoter]	0.0	3	1	1	1
91603	1710	use the puc 1.77 probe	[using the pUC 1.77 probes]	0.0	5	1	1	1
91604	1710	encompass of this two tyrosine residue	[encompassing of these two tyrosine residues]	0.0	6	1	1	1
91605	1710	immunodeficiency virus type hiv	[immunodeficiency virus type HIV]	0.0	4	1	1	1
91606	1710	activation by 4 beta-phorbol 12-myristate	[activation by 4 beta-phorbol 12-myristate]	0.0	5	1	1	1
91607	1710	dose DEX	[doses DEX]	0.0	2	1	1	1
91608	1710	subunit in particular,	[subunit in particular,]	0.0	3	1	1	1
91609	1710	Jak 2 -STAT pathway	[Jak 2 -STAT pathway]	0.0	4	1	1	1
91610	1710	Stat6 Jurkat cell	[Stat6 Jurkat cells]	0.0	3	1	1	1
91611	1710	two unique raralpha	[two unique RARalpha]	0.0	3	1	1	1
91612	1710	signalling molecule brid the generation	[signalling molecules bridging the generation]	0.0	5	1	1	1
91613	1710	HBxAg stimulation of blood cell	[HBxAg stimulation of blood cells]	0.0	5	1	1	1
91614	1710	glutathione -s-transferase gst assay	[glutathione -S-transferase GST assay]	0.0	4	1	1	1
91615	1710	expression of a otherwise cytoplasmic protein	[expression of an otherwise cytoplasmic protein]	0.0	6	1	1	1
91616	1710	practice	[practice]	0.0	1	1	1	1
91617	1710	distinct isoform	[distinct isoforms]	0.0	2	1	1	1
91618	1710	two functional nuclear factor kB element	[two functional nuclear factor kB elements]	0.0	6	1	1	1
91619	1710	transcription of the nuclear proto-oncogent	[transcription of the nuclear proto-oncogenes]	0.0	5	1	1	1
91620	1710	ZEB repressor	[ZEB repressor]	0.0	2	1	1	1
91621	1710	increase over placebo-treated subject	[increase over placebo-treated subjects]	0.0	4	1	1	1
91622	1710	signal result in T cell	[signal resulting in T cells]	0.0	5	1	1	1
91623	1710	amino acid domain BH3	[amino acid domain BH3]	0.0	4	1	1	1
91624	1710	culture of leukemia	[cultures of leukemia]	0.0	3	1	1	1
91625	1710	comparable level of tax expression	[comparable levels of tax expression]	0.0	5	1	1	1
91626	1710	five human leukocyte antigen-B8	[Five human leukocyte antigen-B8]	0.0	4	1	1	1
91627	1710	cdk2 construct	[cdk2 construct]	0.0	2	1	1	1
91628	1710	minimal level	[minimal levels]	0.0	2	1	1	1
91629	1710	t-cell (tcr) variable region beta-chain family	[T-cell (TCR) variable region beta-chain families]	0.0	6	1	1	1
91630	1710	intragenic deletion the human homolog	[Intragenic deletions the human homolog]	0.0	5	1	1	1
91631	1710	crossreact protein in normal human lymphocyte	[crossreacting proteins in normal human lymphocytes]	0.0	6	1	1	1
91632	1710	laboratory isolate	[laboratory isolates]	0.0	2	1	1	1
91633	1710	suggest a migration	[suggesting an migration]	0.0	3	1	1	1
91634	1710	heterodimer consist	[heterodimer consisting]	0.0	2	1	1	1
91635	1710	bhlh target	[bHLH targets]	0.0	2	1	1	1
91636	1710	challenge by lps	[challenge by LPS]	0.0	3	1	1	1
91637	1710	twofold,	[twofold,]	0.0	1	1	1	1
91638	1710	24 hours,	[24 hours,]	0.0	2	1	1	1
91639	1710	bind element	[binding element]	0.0	2	1	1	1
91640	1710	1.0 micrograms/ml	[1.0 micrograms/ml]	0.0	2	1	1	1
91641	1710	anti- il-6 antibody MoAb	[anti- IL-6 antibody MoAb]	0.0	4	1	1	1
91642	1710	hsp60 in umbilical vein cell huvec	[Hsp60 in umbilical vein cells HUVECs]	0.0	6	1	1	1
91643	1710	addition, lack	[addition, lack]	0.0	2	1	1	1
91644	1710	dose of methylprednisolone	[doses of methylprednisolone]	0.0	3	1	1	1
91645	1710	cell permeable inhibitory peptide	[cell permeable inhibitory peptide]	0.0	4	1	1	1
91646	1710	level of the protein	[levels of the protein]	0.0	4	1	1	1
91647	1710	expression during cell cycle progression	[Expression during cell cycle progression]	0.0	5	1	1	1
91648	1710	therefore action	[therefore actions]	0.0	2	1	1	1
91649	1710	40 sample	[40 samples]	0.0	2	2	2	1
91650	1710	comparable event	[comparable events]	0.0	2	1	1	1
91651	1710	progressive 5'-deletion construct	[progressive 5'-deletion constructs]	0.0	3	1	1	1
91652	1710	healthy pregnant woman (11	[healthy pregnant women (11]	0.0	4	1	1	1
91653	1710	common polymorphism	[common polymorphisms]	0.0	2	1	1	1
91654	1710	alpha motif	[alpha motif]	0.0	2	1	1	1
91655	1710	/erythroid hpc growth	[/erythroid HPC growth]	0.0	3	1	1	1
91656	1710	clinical action	[clinical action]	0.0	2	1	1	1
91657	1710	granulocyte-colony factor g-csf	[granulocyte-colony factor G-CSF]	0.0	3	1	1	1
91658	1710	NF1	[NF1]	0.0	1	1	1	1
91659	1710	expression in a t-cell line	[expression in a T-cell line]	0.0	5	1	1	1
91660	1710	"stress" buffer, related	["stress" buffer, related]	0.0	3	1	1	1
91661	1710	double-stranded RNA protein kinase	[double-stranded RNA protein kinase]	0.0	4	1	1	1
91662	1710	responsiveness to prednisolone	[responsiveness to prednisolone]	0.0	3	1	1	1
91663	1710	cycle protein	[cycle proteins]	0.0	2	1	1	1
91664	1710	effect on gene activation in monocyte	[Effect on gene activation in monocytes]	0.0	6	1	1	1
91665	1710	expression of surface protein	[expression of surface proteins]	0.0	4	1	1	1
91666	1710	differentiation to the lineage	[differentiation to the lineage]	0.0	4	1	1	1
91667	1710	negative form of Ras	[negative form of Ras]	0.0	4	1	1	1
91668	1710	significantly (p 0.025) low	[significantly (P 0.025) lower]	0.0	4	1	1	1
91669	1710	murine member	[murine member]	0.0	2	1	1	1
91670	1710	main activity of glucocorticoid i.e. transactivation	[main activities of glucocorticoids i.e. transactivation]	0.0	6	1	1	1
91671	1710	several day result	[several days, resulting]	0.0	3	1	1	1
91672	1710	nucleolin component	[nucleolin component]	0.0	2	1	1	1
91673	1710	-to-oxidized glutathione	[-to-oxidized glutathione]	0.0	2	1	1	1
91674	1710	interleukin-6 from m	[interleukin-6 from M]	0.0	3	1	1	1
91675	1710	fos/cun-contain	[Fos/Jun-containing]	0.0	1	1	1	1
91676	1710	two transcriptional activator RelA	[two transcriptional activators RelA]	0.0	4	1	1	1
91677	1710	transcription factor bind sites,	[transcription factor binding sites,]	0.0	4	1	1	1
91678	1710	inhibition by sodium salicylate	[Inhibition by sodium salicylate]	0.0	4	1	1	1
91679	1710	distribution of myeloid cytokine receptor	[distribution of myeloid cytokine receptors]	0.0	5	1	1	1
91680	1710	intense viral transcription	[intense viral transcription]	0.0	3	1	1	1
91681	1710	h(+)-atpase v-atpase	[H(+)-ATPase V-ATPase]	0.0	2	1	1	1
91682	1710	self-tolerance.	[self-tolerance.]	0.0	1	1	1	1
91683	1710	aminolaevulinic acid synthase alas-e	[aminolaevulinic acid synthase ALAS-E]	0.0	4	1	1	1
91684	1710	other inhibitor of ptpase	[other inhibitors of PTPase]	0.0	4	1	1	1
91685	1710	overexpress hIRAK a weak activation	[overexpressing hIRAK a weak activation]	0.0	5	1	1	1
91686	1710	Germline C	[Germline C]	0.0	2	1	1	1
91687	1710	control of Bcl-2 expression	[control of Bcl-2 expression]	0.0	4	1	1	1
91688	1710	Potent inhibition by a alkaloid cepharanthine	[Potent inhibition by an alkaloid cepharanthine]	0.0	6	1	1	1
91689	1710	effect on macrophage	[effects on macrophages]	0.0	3	1	1	1
91690	1710	exon 7a	[exon 7a]	0.0	2	1	1	1
91691	1710	such as histocompatibility complex (mhc) class	[such as histocompatibility complex (MHC) class]	0.0	6	1	1	1
91692	1710	common target for protein	[common target for proteins]	0.0	4	1	1	1
91693	1710	mutant of the IL-1 pathway	[mutants of the IL-1 pathway]	0.0	5	1	1	1
91694	1710	N terminus of Oct-2a	[N terminus of Oct-2a]	0.0	4	1	1	1
91695	1710	susceptibility to apoptosis	[susceptibility to apoptosis]	0.0	3	1	1	1
91696	1710	gamma-Interferon resistance to D3 in monocyte	[gamma-Interferon resistance to D3 in monocytes]	0.0	6	1	1	1
91697	1710	unique fashion.	[unique fashion.]	0.0	2	1	1	1
91698	1710	prevalence in female	[prevalence in females]	0.0	3	1	1	1
91699	1710	15-lox gene	[15-lox gene]	0.0	2	1	1	1
91700	1710	methov of umbilical vein cell	[METHODS of umbilical vein cells]	0.0	5	1	1	1
91701	1710	alkaline phosphatase plap reporter gene	[alkaline phosphatase PLAP reporter gene]	0.0	5	1	1	1
91702	1710	stage of female development	[stage of female development]	0.0	4	1	1	1
91703	1710	addition of the intron	[addition of the intron]	0.0	4	1	1	1
91704	1710	determine the steady-state fluorescence anisotropy dph	[determining the steady-state fluorescence anisotropy DPH]	0.0	6	1	1	1
91705	1710	plausibility of this claims,	[plausibility of these claims,]	0.0	4	1	1	1
91706	1710	peripheral blood of 145	[peripheral blood of 145]	0.0	4	1	1	1
91707	1710	free cortisol the number	[free cortisol the number]	0.0	4	1	1	1
91708	1710	two nuclear factor (NF)-kappaB binding site	[two nuclear factor (NF)-kappaB binding sites]	0.0	6	1	1	1
91709	1710	regulatory effect of this element	[regulatory effect of this element]	0.0	5	1	1	1
91710	1710	ige 112+/-28	[IgE 112+/-28]	0.0	2	1	1	1
91711	1710	even after covariant analysis take change	[even after covariant analysis taking changes]	0.0	6	1	1	1
91712	1710	erythroid development; addition	[erythroid development; addition]	0.0	3	1	1	1
91713	1710	amount of Oct-1 protein	[amounts of Oct-1 proteins]	0.0	4	1	1	1
91714	1710	multiple susceptibility gene	[multiple susceptibility genes]	0.0	3	1	1	1
91715	1710	JNK kinase	[JNK kinase]	0.0	2	1	1	1
91716	1710	24 woman (11	[24 women (11]	0.0	3	1	1	1
91717	1710	corresponding to a factor	[corresponding to a factor]	0.0	4	1	1	1
91718	1710	use lps	[using LPS]	0.0	2	1	1	1
91719	1710	operational characteristic of phagocyte system	[operational characteristics of phagocyte system]	0.0	5	1	1	1
91720	1710	T-tropic isolate	[T-tropic isolate]	0.0	2	1	1	1
91721	1710	general inhibitor	[general inhibitor]	0.0	2	1	1	1
91722	1710	insensitivity of arterial endothelium	[insensitivity of arterial endothelium]	0.0	4	1	1	1
91723	1710	possible approach	[possible approaches]	0.0	2	1	1	1
91724	1710	lymphocyte-specific factor bind	[lymphocyte-specific factors binding]	0.0	3	1	1	1
91725	1710	binding of the individual protein	[binding of the individual proteins]	0.0	5	1	1	1
91726	1710	replication rate	[replication rate]	0.0	2	1	1	1
91727	1710	asthma patient	[asthma patients]	0.0	2	1	1	1
91728	1710	thereby amplify expression	[thereby amplifying expression]	0.0	3	1	1	1
91729	1710	binding of this peptide	[binding of these peptides]	0.0	4	1	1	1
91730	1710	encompass this site 4481	[encompassing this site 4481]	0.0	4	1	1	1
91731	1710	irs-2	[IRS-2]	0.0	1	1	1	1
91732	1710	deliver the activation signal	[delivering the activation signal]	0.0	4	1	1	1
91733	1710	platelet patient	[platelets patients]	0.0	2	1	1	1
91734	1710	expression of a form of calcineurin	[expression of a form of calcineurin]	0.0	6	1	1	1
91735	1710	th2-specific expression	[Th2-specific expression]	0.0	2	1	1	1
91736	1710	appreciable level	[appreciable level]	0.0	2	1	1	1
91737	1710	immunodeficiency virus type (hiv-1) therapy	[immunodeficiency virus type (HIV-1) therapy]	0.0	5	1	1	1
91738	1710	culture of thymic cell TEC	[cultures of thymic cells TEC]	0.0	5	1	1	1
91739	1710	immunosuppressant cyclosporin A	[immunosuppressants cyclosporin A]	0.0	3	3	3	1
91740	1710	leukocyte from this patient	[leukocytes from this patient]	0.0	4	1	1	1
91741	1710	monocytic maturation	[monocytic maturation]	0.0	2	1	1	1
91742	1710	high variation	[high variation]	0.0	2	1	1	1
91743	1710	complex by anti-peptide antibody	[complexes by anti-peptide antibodies]	0.0	4	1	1	1
91744	1710	expression of nf-kappab in primary monocyte	[expression of NF-kappaB in primary monocytes]	0.0	6	1	1	1
91745	1710	early sign	[early sign]	0.0	2	1	1	1
91746	1710	50-500 microm pdtc	[50-500 microM PDTC]	0.0	3	1	1	1
91747	1710	immunization with peptide	[immunization with peptides]	0.0	3	1	1	1
91748	1710	isolation of cDNA clone	[Isolation of cDNA clones]	0.0	4	1	1	1
91749	1710	i.e. the activation	[i.e. the activation]	0.0	3	1	1	1
91750	1710	inhibit translocation of c-Rel /p65 heterodimer	[inhibiting translocation of c-Rel /p65 heterodimers]	0.0	6	1	1	1
91751	1710	release of functional nf-kappab	[release of functional NF-kappaB]	0.0	4	1	1	1
91752	1710	T cell receptor tcr element	[T cell receptor TcR elements]	0.0	5	1	1	1
91753	1710	b enhancer element	[B enhancer elements]	0.0	3	1	1	1
91754	1710	t3 binding capacity	[T3 binding capacity]	0.0	3	1	1	1
91755	1710	coordinate the activity of element	[coordinating the activity of elements]	0.0	5	1	1	1
91756	1710	sex-related influence	[Sex-related influences]	0.0	2	1	1	1
91757	1710	CXCR4	[CXCR4]	0.0	1	2	2	1
91758	1710	CholecystokininB receptor	[CholecystokininB receptor]	0.0	2	1	1	1
91759	1710	O2-	[O2-]	0.0	1	1	1	1
91760	1710	stat1 gene	[STAT1 genes]	0.0	2	1	1	1
91761	1710	two DNA topoisomerase inhibitor	[two DNA topoisomerase inhibitors]	0.0	4	1	1	1
91762	1710	feedback of the axis	[feedback of the axis]	0.0	4	1	1	1
91763	1710	aberrancy in protein	[aberrancies in proteins]	0.0	3	1	1	1
91764	1710	synthesis of derivative	[Synthesis of derivatives]	0.0	3	1	1	1
91765	1710	incubation with ifn-gamma	[incubation with IFN-gamma]	0.0	3	1	1	1
91766	1710	two cell	[two cells]	0.0	2	1	1	1
91767	1710	gata-1 allele, lead	[GATA-1 allele, leading]	0.0	3	1	1	1
91768	1710	human alas mrna	[human ALAS mRNA]	0.0	3	1	1	1
91769	1710	binding of a protein	[binding of a protein]	0.0	4	1	1	1
91770	1710	lymphocyte transcriptional activator	[lymphocyte transcriptional activator]	0.0	3	1	1	1
91771	1710	Functional analysis of regulatory sequence	[Functional analysis of regulatory sequences]	0.0	5	1	1	1
91772	1710	open reading frame of nucleotide	[open reading frame of nucleotides]	0.0	5	1	1	1
91773	1710	response to cell activation	[responses to cell activation]	0.0	4	1	1	1
91774	1710	runt product	[runt products]	0.0	2	1	1	1
91775	1710	effect of dexamethasone dm generation	[effect of dexamethasone DM generation]	0.0	5	1	1	1
91776	1710	factor bind 4681	[Factors binding 4681]	0.0	3	1	1	1
91777	1710	gc production	[GC production]	0.0	2	1	1	1
91778	1710	adhesion in tnf-treated umbilical vein cell	[adhesion in TNF-treated umbilical vein cells]	0.0	6	1	1	1
91779	1710	low level t-cell receptor (tcr)-zeta	[low levels T-cell receptor (TCR)-zeta]	0.0	5	1	1	1
91780	1710	maturation, result in thrombocytopenia	[maturation, resulting in thrombocytopenia]	0.0	4	1	1	1
91781	1710	proportion of cd4+	[proportion of CD4+]	0.0	3	1	1	1
91782	1710	difference in transactivation	[differences in transactivation]	0.0	3	1	1	1
91783	1710	target for immunodeficiency virus type	[target for immunodeficiency virus type]	0.0	5	1	1	1
91784	1710	apparent dual function	[apparent dual function]	0.0	3	1	1	1
91785	1710	contain the factor-kappa b phase-2 response	[containing the factor-kappa B phase-2 response]	0.0	6	1	1	1
91786	1710	use a screen in yeast,	[Using a screen in yeast,]	0.0	5	1	1	1
91787	1710	increase of b DNA binding	[increase of B DNA binding]	0.0	5	1	1	1
91788	1710	second inducible complex resemble factor	[second inducible complex resembling factor]	0.0	5	1	1	1
91789	1710	pih group (148	[PIH group (148]	0.0	3	1	1	1
91790	1710	various type include leukaemia	[various types including leukaemia]	0.0	4	2	2	1
91791	1710	pkc inhibition	[PKC inhibition]	0.0	2	1	1	1
91792	1710	breakpoint range to q23	[breakpoints ranging to q23]	0.0	4	1	1	1
91793	1710	tyrosine phosphorylation in cell	[tyrosine phosphorylation in cells]	0.0	4	1	1	1
91794	1710	subdominant cycle reactivity rarely undetectable	[subdominant cycle reactivities rarely undetectable]	0.0	5	1	1	1
91795	1710	overall change	[overall changes]	0.0	2	1	1	1
91796	1710	number of controls.	[number of controls.]	0.0	3	1	1	1
91797	1710	granulopoiesis die by 8 days.	[granulopoiesis dying by 8 days.]	0.0	5	1	1	1
91798	1710	low extent	[lower extent]	0.0	2	1	1	1
91799	1710	incorporate multiple microbiological antigen	[incorporating multiple microbiological antigens]	0.0	4	1	1	1
91800	1710	step of NF-kappa b induction	[step of NF-kappa B induction]	0.0	5	1	1	1
91801	1710	target of vector	[targeting of vectors]	0.0	3	1	1	1
91802	1710	OCA-B transcription	[OCA-B transcription]	0.0	2	1	1	1
91803	1710	identification in the initiation site	[Identification in the initiation site]	0.0	5	1	1	1
91804	1710	major difference in immortalization mechanism	[major differences in immortalization mechanism]	0.0	5	1	1	1
91805	1710	1) biochemical sign of hypothyroidism	[1) biochemical signs of hypothyroidism]	0.0	5	1	1	1
91806	1710	molecular mimicry in disease	[molecular mimicry in disease]	0.0	4	1	1	1
91807	1710	60-kda precursor	[60-kDa precursor]	0.0	2	1	1	1
91808	1710	change in aged runner	[changes in aged runner]	0.0	4	1	1	1
91809	1710	production of oxygen species	[production of oxygen species]	0.0	4	1	1	1
91810	1710	complex with a mobility	[complex with an mobility]	0.0	4	1	1	1
91811	1710	(p less than 0.025) low	[(P less than 0.025) lower]	0.0	5	1	1	1
91812	1710	binding to androgen receptor	[binding to androgen receptor]	0.0	4	1	1	1
91813	1710	pathway lead from cell	[pathway leading from cells]	0.0	4	1	1	1
91814	1710	bed rest)	[bed rest)]	0.0	2	1	1	1
91815	1710	high level of camp	[high levels of cAMP]	0.0	4	1	1	1
91816	1710	treatment with DMP prior to treatment	[Treatment with DMP prior to treatment]	0.0	6	1	1	1
91817	1710	nuclear, deoxyribonucleic acid (dna) bind protein	[nuclear, deoxyribonucleic acid (DNA) binding proteins]	0.0	6	1	1	1
91818	1710	brainstem	[brainstem]	0.0	1	1	1	1
91819	1710	consequence of immunological memory	[consequence of immunological memory]	0.0	4	1	1	1
91820	1710	woman with a seminoma	[woman with a seminoma]	0.0	4	1	1	1
91821	1710	anti- stat transducer of transcription)	[anti- STAT transducers of transcription)]	0.0	5	1	1	1
91822	1710	hiv-1(bal)	[HIV-1(BaL)]	0.0	1	1	1	1
91823	1710	eight form	[eight forms]	0.0	2	1	1	1
91824	1710	autoinduction of receptor expression	[autoinduction of receptor expression]	0.0	4	1	1	1
91825	1710	Bufalin	[Bufalin]	0.0	1	1	1	1
91826	1710	Thrombopoietin TPO the physiological regulator	[Thrombopoietin TPO the physiological regulator]	0.0	5	1	1	1
91827	1710	promote the generation	[promoting the generation]	0.0	3	1	1	1
91828	1710	neutral sphingomyelinase	[neutral sphingomyelinase]	0.0	2	1	1	1
91829	1710	gs in primary T lymphocyte	[GS in primary T lymphocytes]	0.0	5	1	1	1
91830	1710	two promoters, anf-e2 promoter	[two promoters, aNF-E2 promoter]	0.0	4	1	1	1
91831	1710	metaphase	[metaphase]	0.0	1	1	1	1
91832	1710	new antibody mab	[new antibody mAb]	0.0	3	1	1	1
91833	1710	135eoh)2d3 -vdr interaction	[1,25(OH)2D3 -VDR interaction]	0.0	3	1	1	1
91834	1710	structurally related kinase inhibitor active	[structurally related kinase inhibitor active]	0.0	5	1	1	1
91835	1710	relative role	[relative role]	0.0	2	1	1	1
91836	1710	preincubation of the DNA	[preincubation of the DNA]	0.0	4	1	1	1
91837	1710	NK cell-derived granule than cell	[NK cell-derived granules than cells]	0.0	5	1	1	1
91838	1710	transactivation property	[transactivation properties]	0.0	2	1	1	1
91839	1710	Recent evidence for a preferential coupling	[Recent evidence for a preferential coupling]	0.0	6	1	1	1
91840	1710	minus T	[minus T]	0.0	2	1	1	1
91841	1710	enhancement of DNA binding capacity	[enhancement of DNA binding capacity]	0.0	5	1	1	1
91842	1710	subunit in platelet	[subunits in platelets]	0.0	3	1	1	1
91843	1710	antibody bz1	[antibody BZ1]	0.0	2	1	1	1
91844	1710	direct molecular effect VDR	[direct molecular effects VDR]	0.0	4	1	1	1
91845	1710	GM-CSF -dependent proliferation	[GM-CSF -dependent proliferation]	0.0	3	1	1	1
91846	1710	transcriptional activity of a protein	[transcriptional activity of an protein]	0.0	5	1	1	1
91847	1710	position -306 relative to the atg	[positions -306 relative to the ATG]	0.0	6	1	1	1
91848	1710	il-5 stimulation	[IL-5 stimulation]	0.0	2	1	1	1
91849	1710	receptor constant	[receptors constant]	0.0	2	1	1	1
91850	1710	immunoprecipitated nfatp from ht-2 cell	[immunoprecipitated NFATp from HT-2 cells]	0.0	5	1	1	1
91851	1710	repression of immunodeficiency virus type	[Repression of immunodeficiency virus type]	0.0	5	1	1	1
91852	1710	linker substitution (LS) mutation (relative	[linker substitution (LS) mutations (relative]	0.0	5	1	1	1
91853	1710	only signal PMA	[only signal PMA]	0.0	3	1	1	1
91854	1710	intranasal glucocorticoid on peripheral function	[intranasal glucocorticoids on peripheral function]	0.0	5	1	1	1
91855	1710	low epithelial layer	[lower epithelial layers]	0.0	3	1	1	1
91856	1710	ca2+ concentration ca2+	[Ca2+ concentration Ca2+]	0.0	3	1	1	1
91857	1710	expression of target gene	[expression of target genes]	0.0	4	1	1	1
91858	1710	delta-globin gene promoter	[delta-globin gene promoter]	0.0	3	1	1	1
91859	1710	Ectopic overexpression	[Ectopic overexpression]	0.0	2	1	1	1
91860	1710	metabolic consequence	[metabolic consequences]	0.0	2	1	1	1
91861	1710	study responsiveness to transactivator BZLF1	[studying responsiveness to transactivators BZLF1]	0.0	5	1	1	1
91862	1710	similar spectrum	[similar spectrum]	0.0	2	1	1	1
91863	1710	potency of this compound	[potency of these compounds]	0.0	4	1	1	1
91864	1710	measure the phosphatidylinositol-3,4,5-trisphosphate pi-3,4,5-p3 concentration	[measuring the phosphatidylinositol-3,4,5-trisphosphate PI-3,4,5-P3 concentration]	0.0	5	1	1	1
91865	1710	peripheral blood polymorphonuclear cell	[peripheral blood polymorphonuclear cells]	0.0	4	1	1	1
91866	1710	activation of PKB/Akt	[activations of PKB/Akt]	0.0	3	1	1	1
91867	1710	hormonal status after conservative surgery	[Hormonal status after conservative surgery]	0.0	5	1	1	1
91868	1710	level of udg expression	[levels of UDG expression]	0.0	4	1	1	1
91869	1710	study of the activity of peptide	[Study of the activities of peptides]	0.0	6	1	1	1
91870	1710	FL monocytic progenitor colony-form unit monocyte	[FL monocytic progenitors colony-forming unit monocyte]	0.0	6	1	1	1
91871	1710	erythroid pathway by treatment	[erythroid pathway by treatment]	0.0	4	1	1	1
91872	1710	human toll-like receptor-2	[human Toll-like receptor-2]	0.0	3	1	1	1
91873	1710	BB genotype	[BB genotype]	0.0	2	1	1	1
91874	1710	phosphorylated, zinc finger transcription factor	[phosphorylated, zinc finger transcription factor]	0.0	5	1	1	1
91875	1710	thymocyte with autologous cell TEC	[thymocytes with autologous cells TEC]	0.0	5	1	1	1
91876	1710	Arrednf-at site	[ARRE/NF-AT site]	0.0	2	1	1	1
91877	1710	elevation of expression	[elevation of expression]	0.0	3	1	1	1
91878	1710	mp value	[MP values]	0.0	2	1	1	1
91879	1710	interleukin-8 secretion	[interleukin-8 secretion]	0.0	2	1	1	1
91880	1710	dna-binding site specificity	[DNA-binding site specificity]	0.0	3	1	1	1
91881	1710	mature cell a phenotype	[mature cells a phenotype]	0.0	4	1	1	1
91882	1710	arrest assay	[arrest assay]	0.0	2	1	1	1
91883	1710	activation of camp pathway	[activation of cAMP pathways]	0.0	4	1	1	1
91884	1710	gene transcription, protein synthesis	[gene transcription, protein synthesis]	0.0	4	1	1	1
91885	1710	such as interleukin	[such as interleukin]	0.0	3	1	1	1
91886	1710	phosphatase-positive osteoclast-like multinucleated giant cell	[phosphatase-positive osteoclast-like multinucleated giant cells]	0.0	5	1	1	1
91887	1710	multiple effector pathway	[multiple effector pathways]	0.0	3	1	1	1
91888	1710	t-cell region	[T-cell regions]	0.0	2	1	1	1
91889	1710	procoagulant activity	[procoagulant activity]	0.0	2	1	1	1
91890	1710	extract from Ipr cd4-8- T cell	[extracts from Ipr CD4-8- T cells]	0.0	6	1	1	1
91891	1710	histocompatibility (mhc) class gene	[histocompatibility (MHC) class genes]	0.0	4	4	4	1
91892	1710	apoptosis-linked gene	[apoptosis-linked gene]	0.0	2	1	1	1
91893	1710	effect of RA on hematopoiesis	[effects of RA on hematopoiesis]	0.0	5	1	1	1
91894	1710	nuclear grade (p	[nuclear grade (P]	0.0	3	1	1	1
91895	1710	effect of SR 31747a	[effect of SR 31747A]	0.0	4	1	1	1
91896	1710	natural antagonist	[natural antagonist]	0.0	2	1	1	1
91897	1710	1-long terminal repeat CAT construct	[1-long terminal repeat CAT constructs]	0.0	5	1	1	1
91898	1710	permissive state	[permissive state]	0.0	2	1	1	1
91899	1710	differential priming	[differential priming]	0.0	2	1	1	1
91900	1710	role in the survival	[role in the survival]	0.0	4	1	1	1
91901	1710	negative element nre	[negative element NRE]	0.0	3	1	1	1
91902	1710	anti-early antigen anti-viral capsid antigen	[anti-early antigen anti-viral capsid antigen]	0.0	5	1	1	1
91903	1710	importance during critical illness.	[importance during critical illness.]	0.0	4	1	1	1
91904	1710	mutation of R-276 to alanine	[mutations of R-276 to alanine]	0.0	5	1	1	1
91905	1710	negative region responsive	[negative region responsive]	0.0	3	1	1	1
91906	1710	internalization from surface.	[internalization from surface.]	0.0	3	1	1	1
91907	1710	survival in medium	[survival in medium]	0.0	3	1	1	1
91908	1710	pure progenitor	[pure progenitors]	0.0	2	1	1	1
91909	1710	dose-dependent reduction	[dose-dependent reduction]	0.0	2	1	1	1
91910	1710	minimal disease in patient	[minimal disease in patients]	0.0	4	1	1	1
91911	1710	three isoforms, pax-5b	[three isoforms, Pax-5b]	0.0	3	1	1	1
91912	1710	sulfoxide-induced mel cell	[sulfoxide-induced MEL cells]	0.0	3	1	1	1
91913	1710	various gene product	[Various gene products]	0.0	3	1	1	1
91914	1710	initial infection in individual	[initial infection in individuals]	0.0	4	1	1	1
91915	1710	pcl gamma tyrosine phosphorylation	[PCL gamma tyrosine phosphorylation]	0.0	4	1	1	1
91916	1710	inhibition of p24 production	[inhibition of p24 production]	0.0	4	1	1	1
91917	1710	induction in apoptosis-resistant t-cell transfectant	[Induction in apoptosis-resistant T-cell transfectants]	0.0	5	1	1	1
91918	1710	g transcription factor activation	[G transcription factor activation]	0.0	4	1	1	1
91919	1710	low capacity	[Low capacity]	0.0	2	1	1	1
91920	1710	receptor (gr) expression	[receptor (GR) expression]	0.0	3	1	1	1
91921	1710	down-modulation of multipotent hpc growth	[down-modulation of multipotent HPC growth]	0.0	5	1	1	1
91922	1710	two element in the tsp	[Two elements in the TSP]	0.0	5	1	1	1
91923	1710	vd receptor VDR	[VD receptor VDR]	0.0	3	1	1	1
91924	1710	family with degree	[families with degrees]	0.0	3	1	1	1
91925	1710	minor susceptibility gene	[minor susceptibility genes]	0.0	3	1	1	1
91926	1710	ribosomal entry site rna-protein interaction	[ribosomal entry site RNA-protein interactions]	0.0	5	1	1	1
91927	1710	human cytomegalovirus immediate-early enhancer	[human cytomegalovirus immediate-early enhancer]	0.0	4	1	1	1
91928	1710	anti- TNF-alpha hiv-1 terminal repeat LTR	[anti- TNF-alpha HIV-1 terminal repeat LTR]	0.0	6	1	1	1
91929	1710	regulator in turn	[regulators in turn]	0.0	3	1	1	1
91930	1710	great deal	[great deal]	0.0	2	1	1	1
91931	1710	informative probe specific for the deletion	[informative probes specific for the deletion]	0.0	6	1	1	1
91932	1710	use lt	[using LT]	0.0	2	1	1	1
91933	1710	direct repeat DR of 21 bp	[direct repeats DR of 21 bp]	0.0	6	1	1	1
91934	1710	pre-treatment with gp160	[pre-treatment with gp160]	0.0	3	1	1	1
91935	1710	seven ebv -positive carcinoma tissue	[seven EBV -positive carcinoma tissues]	0.0	5	1	1	1
91936	1710	include the early induction	[including the early induction]	0.0	4	1	1	1
91937	1710	analysis of transcription factor generation	[analysis of transcription factor generation]	0.0	5	1	1	1
91938	1710	24 to 72 h	[24 to 72 h]	0.0	4	1	1	1
91939	1710	molecular heterogeneity within fetal muscle	[molecular heterogeneity within fetal muscle]	0.0	5	1	1	1
91940	1710	heterogeneous population of /precursor	[heterogeneous populations of /precursors]	0.0	4	1	1	1
91941	1710	(20 microM, 72	[(20 microM, 72]	0.0	3	1	1	1
91942	1710	all, adenovirus type during year	[all, adenovirus types during years]	0.0	5	1	1	1
91943	1710	cell express kinase activity	[cells expressing kinase activity]	0.0	4	1	1	1
91944	1710	STAT3 DNA	[STAT3 DNA]	0.0	2	1	1	1
91945	1710	suppression of transcription	[suppression of transcription]	0.0	3	1	1	1
91946	1710	alternative mechanism of action	[alternative mechanism of action]	0.0	4	1	1	1
91947	1710	cells, factor	[cells, factors]	0.0	2	1	1	1
91948	1710	one sp site	[one Sp site]	0.0	3	1	1	1
91949	1710	macrophage protein (mip)-1alpha	[macrophage protein (MIP)-1alpha]	0.0	3	1	1	1
91950	1710	pha leucine	[PHA leucine]	0.0	2	1	1	1
91951	1710	new insight into the interaction	[new insights into the interactions]	0.0	5	1	1	1
91952	1710	region to the first exon,	[region to the first exon,]	0.0	5	1	1	1
91953	1710	ODN	[ODN]	0.0	1	1	1	1
91954	1710	encode a protein of kda	[encoding a protein of kDa]	0.0	5	1	1	1
91955	1710	binding site for NF-E1 ref 1-3	[binding sites for NF-E1 refs 1-3]	0.0	6	1	1	1
91956	1710	chromosomal rearrangement	[chromosomal rearrangements]	0.0	2	1	1	1
91957	1710	venous huvec	[venous HUVECs]	0.0	2	1	1	1
91958	1710	mean of er content	[mean of ER content]	0.0	4	1	1	1
91959	1710	initiator specify the 5' terminus	[initiator specifying the 5' terminus]	0.0	5	1	1	1
91960	1710	minimal effect on gene expression	[minimal effects on gene expression]	0.0	5	1	1	1
91961	1710	effect on nfat	[effect on NFAT]	0.0	3	1	1	1
91962	1710	dissociation of the Jak kinase pathway	[Dissociation of the Jak kinase pathway]	0.0	6	1	1	1
91963	1710	factor-90 of t-cell	[factor-90 of T-cells]	0.0	3	1	1	1
91964	1710	Rap binding domain	[Rap binding domain]	0.0	3	1	1	1
91965	1710	ultimately, the property	[ultimately, the properties]	0.0	3	1	1	1
91966	1710	protein with similar weight	[proteins with similar weights]	0.0	4	1	1	1
91967	1710	number of potential regulatory sequence	[number of potential regulatory sequences]	0.0	5	1	1	1
91968	1710	B-cell leukemia cell	[B-cell leukemia cells]	0.0	3	1	1	1
91969	1710	inhibition by the drug cyclosporin a	[Inhibition by the drugs cyclosporin A]	0.0	6	1	1	1
91970	1710	induce the degradation of inhibitor	[inducing the degradation of inhibitors]	0.0	5	1	1	1
91971	1710	leukemia-specific translocation	[leukemia-specific translocations]	0.0	2	1	1	1
91972	1710	effector cd4+ T helper	[effector CD4+ T helper]	0.0	4	1	1	1
91973	1710	number of progenitor cell	[number of progenitor cells]	0.0	4	1	1	1
91974	1710	such as h2o2	[such as H2O2]	0.0	3	1	1	1
91975	1710	rel-related domain of amino acid	[Rel-related domain of amino acids]	0.0	5	1	1	1
91976	1710	cell with feature	[cells with features]	0.0	3	1	1	1
91977	1710	case-control study of African population	[case-control studies of African populations]	0.0	5	2	2	1
91978	1710	human 1beta gene	[human 1beta gene]	0.0	3	1	1	1
91979	1710	CD40 cytoplasmic domain truncation	[CD40 cytoplasmic domain truncation]	0.0	4	1	1	1
91980	1710	Internal labeling	[Internal labeling]	0.0	2	1	1	1
91981	1710	mutation on any	[mutation on any]	0.0	3	1	1	1
91982	1710	activity on the threshold	[activity on the threshold]	0.0	4	1	1	1
91983	1710	chain enhancer igh-enhancer	[chain enhancer IgH-enhancer]	0.0	3	1	1	1
91984	1710	Flow cell sorting	[Flow cell sorting]	0.0	3	1	1	1
91985	1710	promoter expression	[promoter expression]	0.0	2	1	1	1
91986	1710	evidence for repression in T cell	[Evidence for repression in T cells]	0.0	6	1	1	1
91987	1710	alpha globin regulatory element	[alpha globin regulatory element]	0.0	4	2	2	1
91988	1710	RESULTS: Hypercortisolaemia,	[RESULTS: Hypercortisolaemia,]	0.0	2	1	1	1
91989	1710	hypothesis requirement	[hypothesis requirements]	0.0	2	1	1	1
91990	1710	effect of DEX with PGE2	[effects of DEX with PGE2]	0.0	5	1	1	1
91991	1710	disease under condition	[disease under conditions]	0.0	3	1	1	1
91992	1710	longitudinal study	[longitudinal study]	0.0	2	1	1	1
91993	1710	cell with p50/p65	[cells with p50/p65]	0.0	3	1	1	1
91994	1710	phagocyte in vitro.	[phagocytes in vitro.]	0.0	3	1	1	1
91995	1710	molecular understanding	[molecular understanding]	0.0	2	2	2	1
91996	1710	49 case of B-cell chronic leukemia	[49 cases of B-cell chronic leukemia]	0.0	6	1	1	1
91997	1710	use this cytokine	[using this cytokine]	0.0	3	1	1	1
91998	1710	class ii RB tumor line	[class II RB tumor lines]	0.0	5	1	1	1
91999	1710	use a 32p-probe	[using a 32P-probe]	0.0	3	1	1	1
92000	1710	potential target under condition	[potential target under conditions]	0.0	4	1	1	1
92001	1710	rapid analysis	[rapid analysis]	0.0	2	1	1	1
92002	1710	significant role in binding	[significant role in binding]	0.0	4	1	1	1
92003	1710	autosomal mode of transmission	[autosomal mode of transmission]	0.0	4	2	2	1
92004	1710	putative retrovirus (es)	[putative retrovirus (es)]	0.0	3	1	1	1
92005	1710	reason for the oncogenicity	[reasons for the oncogenicities]	0.0	4	1	1	1
92006	1710	incubation with rabbit reticulocyte lysate	[incubation with rabbit reticulocyte lysate]	0.0	5	1	1	1
92007	1710	induction (ifn)-inducible protein	[induction (IFN)-inducible protein]	0.0	3	1	1	1
92008	1710	levels, include suppression	[levels, including suppression]	0.0	3	1	1	1
92009	1710	express some characteristic	[expressing some characteristics]	0.0	3	1	1	1
92010	1710	domain of hrar alpha	[domain of hRAR alpha]	0.0	4	1	1	1
92011	1710	peripheral leucocyte in 12 woman	[peripheral leucocytes in 12 women]	0.0	5	1	1	1
92012	1710	immunoglobulin major (mhc) gene	[immunoglobulin major (MHC) genes]	0.0	4	1	1	1
92013	1710	presence in a setting	[presence in a setting]	0.0	4	1	1	1
92014	1710	regulation of the BZLF1 promoter	[Regulation of the BZLF1 promoter]	0.0	5	1	1	1
92015	1710	nm23 gene product	[nm23 gene product]	0.0	3	1	1	1
92016	1710	propagate the state,	[propagating the state,]	0.0	3	1	1	1
92017	1710	integrin on neutrophil granulocyte	[integrins on neutrophil granulocytes]	0.0	4	1	1	1
92018	1710	messenger Ca2+	[messengers Ca2+]	0.0	2	1	1	1
92019	1710	neutralize anti- il-6 antibody MoAb	[neutralizing anti- IL-6 antibody MoAb]	0.0	5	1	1	1
92020	1710	common component	[common component]	0.0	2	1	1	1
92021	1710	g c content	[G C content]	0.0	3	1	1	1
92022	1710	0.7 (1.2-3.3) fmol/10(7) cell	[0.7 (1.2-3.3) fmol/10(7) cells]	0.0	4	1	1	1
92023	1710	significantly (p<.001) in euthymic patient	[significantly (P<.001) in euthymic patients]	0.0	5	1	1	1
92024	1710	rolling, adhesion, of leukocyte	[rolling, adhesion, of leukocytes]	0.0	4	1	1	1
92025	1710	expression of factor kappab	[expression of factor kappaB]	0.0	4	1	1	1
92026	1710	acetylsalicylate	[acetylsalicylate]	0.0	1	1	1	1
92027	1710	versatile switch	[versatile switch]	0.0	2	1	1	1
92028	1710	expression of a endogenous gene	[expression of an endogenous gene]	0.0	5	1	1	1
92029	1710	Promiscuous transcriptional activity reticuloendotheliosis virus REV	[Promiscuous transcriptional activity reticuloendotheliosis virus REV]	0.0	6	1	1	1
92030	1710	CEM c1 cell	[CEM C1 cells]	0.0	3	1	1	1
92031	1710	gene truncation result	[gene truncation resulting]	0.0	3	1	1	1
92032	1710	means of splicing	[means of splicing]	0.0	3	1	1	1
92033	1710	normal circulate monocyte	[normal circulating monocytes]	0.0	3	1	1	1
92034	1710	related condition occur	[related condition occurring]	0.0	3	1	1	1
92035	1710	recombinant nf-y	[recombinant NF-Y]	0.0	2	1	1	1
92036	1710	factor include sp1	[factors including Sp1]	0.0	3	1	1	1
92037	1710	inhibitory, form	[inhibitory, form]	0.0	2	1	1	1
92038	1710	MHC class gene in rj	[MHC class genes in RJ]	0.0	5	1	1	1
92039	1710	involve inhibition	[involving inhibition]	0.0	2	1	1	1
92040	1710	phop/phoq virulence regulon	[phoP/phoQ virulence regulon]	0.0	3	1	1	1
92041	1710	molecular alteration responsible for the response	[molecular alterations responsible for the response]	0.0	6	1	1	1
92042	1710	nf-kappa b promoter	[NF-kappa B promoters]	0.0	3	1	1	1
92043	1710	several levels, include suppression	[several levels, including suppression]	0.0	4	1	1	1
92044	1710	radioassay use [3H]-dexamethasone	[radioassay using [3H]-dexamethasone]	0.0	3	1	1	1
92045	1710	CsA translocation	[CsA translocation]	0.0	2	1	1	1
92046	1710	secretion of pge2 in response	[secretion of PGE2 in response]	0.0	5	1	1	1
92047	1710	activation during tpa-	[activation during TPA-]	0.0	3	1	1	1
92048	1710	cross-react	[cross-reacting]	0.0	1	1	1	1
92049	1710	11 amino acid	[11 amino acids]	0.0	3	1	1	1
92050	1710	iv isoform of beta-hydroxysteroid dehydrogenase	[IV isoforms of beta-hydroxysteroid dehydrogenase]	0.0	5	1	1	1
92051	1710	steroid-regulated gene network	[steroid-regulated gene networks]	0.0	3	1	1	1
92052	1710	correlation of activity of retinoid	[Correlation of activity of retinoids]	0.0	5	1	1	1
92053	1710	proviruse carry mutation	[proviruses carrying mutations]	0.0	3	1	1	1
92054	1710	expression of gene in leukaemia	[Expression of genes in leukaemia]	0.0	5	1	1	1
92055	1710	DRA gene sequence	[DRA gene sequences]	0.0	3	1	1	1
92056	1710	pkc inhibitor 31-8425	[PKC inhibitor 31-8425]	0.0	3	1	1	1
92057	1710	1 hour minute	[1 hr min]	0.0	3	1	1	1
92058	1710	pretreatment 5-day human macrophage	[Pretreatment 5-day human macrophages]	0.0	4	1	1	1
92059	1710	SK&F 96365,	[SK&F 96365,]	0.0	2	1	1	1
92060	1710	role b cell maturation	[role B cell maturation]	0.0	4	1	1	1
92061	1710	soluble product	[soluble products]	0.0	2	1	1	1
92062	1710	five tandem repeat	[five tandem repeats]	0.0	3	1	1	1
92063	1710	class transactivator mrna expression	[class transactivator mRNA expression]	0.0	4	1	1	1
92064	1710	arginine element	[arginine element]	0.0	2	1	1	1
92065	1710	degradation a role	[degradation A role]	0.0	3	1	1	1
92066	1710	-resistant human leukemic ecem) cell	[-resistant human leukemic (CEM) cells]	0.0	5	1	1	1
92067	1710	produce enhancement	[producing enhancement]	0.0	2	1	1	1
92068	1710	Minimal residual disease in leukemia	[Minimal residual disease in leukemia]	0.0	5	1	1	1
92069	1710	early stage of t-cell development	[earlier stages of T-cell development]	0.0	5	1	1	1
92070	1710	T cell expression	[T cell expression]	0.0	3	2	2	1
92071	1710	Prostaglandin E2 PGE2 a molecule	[Prostaglandin E2 PGE2 a molecule]	0.0	5	1	1	1
92072	1710	expression of the macrophage colony-stimulating factor	[expression of the macrophage colony-stimulating factor]	0.0	6	1	1	1
92073	1710	follow intracranial inoculation	[Following intracranial inoculation]	0.0	3	1	1	1
92074	1710	analysis of deletion	[analysis of deletions]	0.0	3	1	1	1
92075	1710	IL-2 cyclosporin	[IL-2 cyclosporin]	0.0	2	1	1	1
92076	1710	autocrine and/or	[autocrine and/or]	0.0	2	1	1	1
92077	1710	structurally distinct, novel inhibitor	[structurally distinct, novel inhibitors]	0.0	4	1	1	1
92078	1710	basement membrane immunoreactivity iv collagen	[Basement membrane immunoreactivity IV collagen]	0.0	5	1	1	1
92079	1710	polyclonal level,	[polyclonal level,]	0.0	2	1	1	1
92080	1710	transcriptional activity of the terminal repeat	[transcriptional activity of the terminal repeat]	0.0	6	1	1	1
92081	1710	pure hematopoietic progenitor	[pure hematopoietic progenitors]	0.0	3	1	1	1
92082	1710	ubiquitin carrier	[ubiquitin carrier]	0.0	2	1	1	1
92083	1710	two other latent epitope	[two other latent epitopes]	0.0	4	1	1	1
92084	1710	healthy female aged years,	[healthy females aged years,]	0.0	4	1	1	1
92085	1710	certain infections.	[certain infections.]	0.0	2	1	1	1
92086	1710	binding consistent with site	[binding consistent with sites]	0.0	4	1	1	1
92087	1710	Stat3-like protein	[Stat3-like protein]	0.0	2	1	1	1
92088	1710	striking downregulation of the gr	[striking downregulation of the GR]	0.0	5	1	1	1
92089	1710	vitamin d binding protein	[vitamin D binding protein]	0.0	4	1	1	1
92090	1710	CD30 with a CD30 monoclonal antibody,	[CD30 with an CD30 monoclonal antibody,]	0.0	6	1	1	1
92091	1710	two gene encode scm-1alpha	[two genes encoding SCM-1alpha]	0.0	4	1	1	1
92092	1710	11.8 fmol/mg protein (mean of assays),	[11.8 fmol/mg protein (mean of assays),]	0.0	6	1	1	1
92093	1710	same property	[same properties]	0.0	2	1	1	1
92094	1710	U 937	[U 937]	0.0	2	1	1	1
92095	1710	utilize a series	[utilizing a series]	0.0	3	1	1	1
92096	1710	native weight of 35 kD	[native weights of 35 kD]	0.0	5	1	1	1
92097	1710	membrane protein 1 -driven activation	[membrane protein 1 -driven activation]	0.0	5	1	1	1
92098	1710	-/lt	[-/LT]	0.0	1	1	1	1
92099	1710	expose human umbilical vein cell	[Exposing human umbilical vein cells]	0.0	5	1	1	1
92100	1710	stimulus elicit oxidative stress	[stimuli eliciting oxidative stress]	0.0	4	1	1	1
92101	1710	-resistant leukemic ecem) cell	[-resistant leukemic (CEM) cells]	0.0	4	1	1	1
92102	1710	n: 2.7+/-2.0) excretion,	[N: 2.7+/-2.0) excretion,]	0.0	3	1	1	1
92103	1710	primary myelodysplastic syndrome MDS	[primary myelodysplastic syndromes MDS]	0.0	4	1	1	1
92104	1710	raldh2	[RALDH2]	0.0	1	1	1	1
92105	1710	tyrosine-phosphorylated follow factor treatment	[tyrosine-phosphorylated following factor treatment]	0.0	4	1	1	1
92106	1710	272 receptor	[272 receptors]	0.0	2	1	1	1
92107	1710	immunological feature	[immunological features]	0.0	2	1	1	1
92108	1710	ap-1 induction	[AP-1 induction]	0.0	2	1	1	1
92109	1710	h-chain	[H-chain]	0.0	1	2	2	1
92110	1710	ctg-monomer	[CTG-monomer]	0.0	1	1	1	1
92111	1710	-13-	[-13-]	0.0	1	1	1	1
92112	1710	facilitate the collaboration of protein	[facilitating the collaboration of proteins]	0.0	5	1	1	1
92113	1710	c-myb gene product	[c-myb gene product]	0.0	3	1	1	1
92114	1710	many growth cell line	[many growth cell lines]	0.0	4	1	1	1
92115	1710	transcriptional inhibition	[transcriptional inhibition]	0.0	2	1	1	1
92116	1710	interassay coefficient	[interassay coefficient]	0.0	2	1	1	1
92117	1710	cell surface recognition event	[cell surface recognition events]	0.0	4	1	1	1
92118	1710	h lag,	[h lag,]	0.0	2	1	1	1
92119	1710	two gr abnormalities: 15	[two GR abnormalities: 15]	0.0	4	1	1	1
92120	1710	bind to this sequence	[binding to this sequence]	0.0	4	1	1	1
92121	1710	bacterial product such as lipopolysaccharide lps	[bacterial products such as lipopolysaccharide LPS]	0.0	6	1	1	1
92122	1710	marker of ovulation after a great	[markers of ovulation after a great]	0.0	6	1	1	1
92123	1710	bHLH domain	[bHLH domain]	0.0	2	1	1	1
92124	1710	encode a dna-binding protein x box	[encoding a DNA-binding protein X box]	0.0	6	1	1	1
92125	1710	lead to cell death	[leading to cell death]	0.0	4	1	1	1
92126	1710	negative modulator nf-kappab activation	[negative modulator NF-kappaB activation]	0.0	4	1	1	1
92127	1710	large cohort of patient	[large cohorts of patients]	0.0	4	1	1	1
92128	1710	binding of the four complex	[Binding of the four complexes]	0.0	5	1	1	1
92129	1710	analysis of the IL-4 effect	[analysis of the IL-4 effect]	0.0	5	1	1	1
92130	1710	rel/nuclear factor kappab	[Rel/nuclear factor kappaB]	0.0	3	1	1	1
92131	1710	structural change	[structural changes]	0.0	2	1	1	1
92132	1710	a6h antigen	[A6H antigen]	0.0	2	1	1	1
92133	1710	role of Stat1alpha	[roles of Stat1alpha]	0.0	3	1	1	1
92134	1710	mutant e6	[mutant E6]	0.0	2	1	1	1
92135	1710	control determinant of recognition	[controlling determinant of recognition]	0.0	4	1	1	1
92136	1710	second, TRE	[Second, TRE]	0.0	2	1	1	1
92137	1710	second protein, most likely dpii,	[second protein, most likely DP-I,]	0.0	5	1	1	1
92138	1710	infiltrate and/or cavity	[infiltrates and/or cavities]	0.0	3	1	1	1
92139	1710	Differential induction differentiation	[Differential induction differentiation]	0.0	3	1	1	1
92140	1710	affinity (at least sevenfold) 3.	[affinity (at least sevenfold) 3.]	0.0	5	1	1	1
92141	1710	CEM-ICR 27 leukemic lymphoblast	[CEM-ICR 27 leukemic lymphoblasts]	0.0	4	1	1	1
92142	1710	product of member	[products of members]	0.0	3	1	1	1
92143	1710	regard, cytokine	[regard, cytokines]	0.0	2	1	1	1
92144	1710	affinity BSAP site	[affinity BSAP site]	0.0	3	1	1	1
92145	1710	herpesvirus system	[herpesvirus systems]	0.0	2	1	1	1
92146	1710	gene technology	[gene technology]	0.0	2	1	1	1
92147	1710	immunodeficiency virus (HIV) type	[immunodeficiency virus (HIV) type]	0.0	4	1	1	1
92148	1710	110-kDa	[110-kDa]	0.0	1	1	1	1
92149	1710	woman young than mcr young	[women younger than MCR younger]	0.0	5	1	1	1
92150	1710	monocyte maturation	[monocyte maturation]	0.0	2	1	1	1
92151	1710	microg/10(6) cells.	[microg/10(6) cells.]	0.0	2	1	1	1
92152	1710	demonstrate the importance	[demonstrating the importance]	0.0	3	1	1	1
92153	1710	nuclear distribution	[nuclear distribution]	0.0	2	1	1	1
92154	1710	c-terminal peptide of 128	[C-terminal peptides of 128]	0.0	4	1	1	1
92155	1710	use b-	[Using B-]	0.0	2	1	1	1
92156	1710	nuclear extract from mt-2 cell	[nuclear extract from MT-2 cells]	0.0	5	1	1	1
92157	1710	expression of cell surface maturation-specific antigen	[expression of cell surface maturation-specific antigens]	0.0	6	1	1	1
92158	1710	involvement of stat	[involvement of STATs]	0.0	3	1	1	1
92159	1710	organizer	[organizer]	0.0	1	1	1	1
92160	1710	increase concentration of cysteine	[increasing concentrations of cysteine]	0.0	4	1	1	1
92161	1710	molecular mechanism underlie expression of cytokine	[Molecular mechanisms underlying expression of cytokines]	0.0	6	1	1	1
92162	1710	contain four near-perfect direct repeat	[containing four near-perfect direct repeats]	0.0	5	1	1	1
92163	1710	interaction between various protein	[interactions between various proteins]	0.0	4	1	1	1
92164	1710	activity, DNA sequence specificity,	[activity, DNA sequence specificity,]	0.0	4	1	1	1
92165	1710	80% identity	[80% identity]	0.0	2	1	1	1
92166	1710	inhibition by il-10	[Inhibition by IL-10]	0.0	3	1	1	1
92167	1710	latent membrane protein homolog	[latent membrane protein homologs]	0.0	4	1	1	1
92168	1710	new, ubiquitous transcription factor	[new, ubiquitous transcription factors]	0.0	4	1	1	1
92169	1710	role factor in nf-kappab activation	[Role factors in NF-kappaB activation]	0.0	5	1	1	1
92170	1710	marker of promyelocytic leukemia	[markers of promyelocytic leukemias]	0.0	4	1	1	1
92171	1710	adenocarcinoma human-mouse monoclonal antibody	[adenocarcinoma human-mouse monoclonal antibody]	0.0	4	1	1	1
92172	1710	role in ebv-induced growth transformation	[role in EBV-induced growth transformation]	0.0	5	1	1	1
92173	1710	type of IDC	[type of IDC]	0.0	3	1	1	1
92174	1710	nuclear access	[nuclear access]	0.0	2	1	1	1
92175	1710	icsat expression	[ICSAT expression]	0.0	2	1	1	1
92176	1710	Strikingly, deletion of residue	[Strikingly, deletion of residues]	0.0	4	1	1	1
92177	1710	resolution through chromatographic step	[Resolution through chromatographic steps]	0.0	4	1	1	1
92178	1710	series: at (17 subject	[series: at (17 subjects]	0.0	4	1	1	1
92179	1710	disorder in woman	[disorders in women]	0.0	3	1	1	1
92180	1710	inhibition of translocation of Rap1	[inhibition of translocation of Rap1]	0.0	5	1	1	1
92181	1710	24r-hydroxylase activity	[24R-hydroxylase activity]	0.0	2	1	1	1
92182	1710	transcription-regulategulate protein	[transcription-regulating proteins]	0.0	2	1	1	1
92183	1710	occupancy enhancer	[occupancy enhancer]	0.0	2	1	1	1
92184	1710	600 nm, respectively, in monocyte	[600 nM, respectively, in monocytes]	0.0	5	1	1	1
92185	1710	addition, T	[addition, T]	0.0	2	1	1	1
92186	1710	stochastic activation of other gene	[stochastic activation of other genes]	0.0	5	1	1	1
92187	1710	lead to e2f activation	[leading to E2F activation]	0.0	4	1	1	1
92188	1710	pyrimidine -rich element	[pyrimidine -rich elements]	0.0	3	1	1	1
92189	1710	activation of carcinogen	[activation of carcinogens]	0.0	3	1	1	1
92190	1710	blood lymphocyte from normal individual	[blood lymphocytes from normal individuals]	0.0	5	1	1	1
92191	1710	past few year	[past few years]	0.0	3	1	1	1
92192	1710	Ig superfamily	[Ig superfamily]	0.0	2	1	1	1
92193	1710	promonocytic cells.	[promonocytic cells.]	0.0	2	1	1	1
92194	1710	depressed subject	[depressed subjects]	0.0	2	1	1	1
92195	1710	various construct	[various constructs]	0.0	2	1	1	1
92196	1710	stimulation U1	[stimulation U1]	0.0	2	1	1	1
92197	1710	occurrence of apoptosis	[occurrence of apoptosis]	0.0	3	1	1	1
92198	1710	ifn-gamma colony-stimulating factor gm-csf	[IFN-gamma colony-stimulating factor GM-CSF]	0.0	4	1	1	1
92199	1710	event in atherosclerotic plaque development	[event in atherosclerotic plaque development]	0.0	5	1	1	1
92200	1710	CBF beta positive, 1	[CBF beta positive, 1]	0.0	4	1	1	1
92201	1710	cytokine neutrophil chemoattractant cinc	[cytokine neutrophil chemoattractant CINC]	0.0	4	1	1	1
92202	1710	contain the domain of c-kit	[containing the domain of c-kit]	0.0	5	1	1	1
92203	1710	Specific glucocorticoid binding at different level	[Specific glucocorticoid binding at different levels]	0.0	6	1	1	1
92204	1710	counter-anion thioglucose	[counter-anion thioglucose]	0.0	2	1	1	1
92205	1710	typical bind pattern	[typical binding pattern]	0.0	3	1	1	1
92206	1710	treatment with warm hcl	[Treatment with warm HCl]	0.0	4	1	1	1
92207	1710	induce icam-1 expression.	[inducing ICAM-1 expression.]	0.0	3	1	1	1
92208	1710	very efficient precursor	[very efficient precursors]	0.0	3	1	1	1
92209	1710	terminal step	[terminal step]	0.0	2	2	2	1
92210	1710	nuclear abundance of vd receptor	[nuclear abundance of VD receptor]	0.0	5	1	1	1
92211	1710	nf-kappab gene expression	[NF-kappaB gene expression]	0.0	3	1	1	1
92212	1710	anti-CD3 tumor necrosis factor	[anti-CD3 tumor necrosis factor]	0.0	4	1	1	1
92213	1710	histogenesis of lymphoma	[histogenesis of lymphomas]	0.0	3	1	1	1
92214	1710	high weight complex	[high weight complex]	0.0	3	1	1	1
92215	1710	infectious hiv-1 clone	[infectious HIV-1 clone]	0.0	3	1	1	1
92216	1710	proliferation of erythroblast	[proliferation of erythroblasts]	0.0	3	1	1	1
92217	1710	dendritic process extend	[dendritic processes extending]	0.0	3	1	1	1
92218	1710	epithelium of cd patient	[epithelium of CD patients]	0.0	4	1	1	1
92219	1710	observation with the finding of expression	[observations with the findings of expression]	0.0	6	1	1	1
92220	1710	member of NF-AT	[members of NF-AT]	0.0	3	1	1	1
92221	1710	production by L-N-monomethyl-arginine	[production by L-N-monomethyl-arginine]	0.0	3	1	1	1
92222	1710	gingival fibroblast HF	[gingival fibroblasts HF]	0.0	3	1	1	1
92223	1710	Strober	[Strober]	0.0	1	1	1	1
92224	1710	adhesive response	[adhesive response]	0.0	2	1	1	1
92225	1710	need for RB expression	[need for RB expression]	0.0	4	1	1	1
92226	1710	encompass a important positive regulatory element	[encompassing an important positive regulatory element]	0.0	6	1	1	1
92227	1710	95 sample	[95 samples]	0.0	2	1	1	1
92228	1710	dnase hypersensitivity	[DNase hypersensitivity]	0.0	2	1	1	1
92229	1710	synthetic nf-kappab promoter	[synthetic NF-kappaB promoter]	0.0	3	1	1	1
92230	1710	association in pro-B cell	[association in pro-B cells]	0.0	4	1	1	1
92231	1710	IkappaBalpha protein,	[IkappaBalpha protein,]	0.0	2	1	1	1
92232	1710	inhibitor IkappaBalpha	[inhibitor IkappaBalpha]	0.0	2	1	1	1
92233	1710	association of cytokine pattern	[association of cytokine patterns]	0.0	4	1	1	1
92234	1710	(5118), ebv infection	[(5/18), EBV infection]	0.0	3	1	1	1
92235	1710	human ifngr1 deletion hotspot	[human IFNGR1 deletion hotspot]	0.0	4	1	1	1
92236	1710	DNA electrophoresis mobility	[DNA electrophoresis mobility]	0.0	3	1	1	1
92237	1710	expression of exogenous gene in cell	[expression of exogenous genes in cells]	0.0	6	1	1	1
92238	1710	(fc) b cell	[(FC) B cells]	0.0	3	1	1	1
92239	1710	element in the chicken IL2 promoter	[elements in the chicken IL2 promoter]	0.0	6	1	1	1
92240	1710	induction of reactive oxygen intermediate	[induction of reactive oxygen intermediates]	0.0	5	1	1	1
92241	1710	use kappaB- Sp1 concatamer	[using kappaB- Sp1 concatamers]	0.0	4	1	1	1
92242	1710	new role for Notch-1	[new role for Notch-1]	0.0	4	1	1	1
92243	1710	c-mim	[c-mim]	0.0	1	1	1	1
92244	1710	feature with ebv	[features with EBV]	0.0	3	1	1	1
92245	1710	antibody against -binding (creb) protein	[Antibodies against -binding (CREB) protein]	0.0	5	1	1	1
92246	1710	level of interleukin	[levels of interleukin]	0.0	3	1	1	1
92247	1710	cell of adult t-cell leukemia	[cells of adult T-cell leukemia]	0.0	5	1	1	1
92248	1710	thp-1 promonocytic cell	[THP-1 promonocytic cells]	0.0	3	1	1	1
92249	1710	4.3 pts; fluticasone: 2.4 pts)	[4.3 pts; fluticasone: 2.4 pts)]	0.0	5	1	1	1
92250	1710	recombinant gp41 aa565-647	[recombinant gp41 aa565-647]	0.0	3	1	1	1
92251	1710	action of flavonoid	[action of flavonoids]	0.0	3	1	1	1
92252	1710	concomitant down-regulation	[concomitant down-regulation]	0.0	2	1	1	1
92253	1710	form of free e2f	[forms of free E2F]	0.0	4	1	1	1
92254	1710	factor gene	[factor gene]	0.0	2	1	1	1
92255	1710	inactivation inconsistent with the mechanism	[inactivation inconsistent with the mechanism]	0.0	5	1	1	1
92256	1710	DRE to +240	[DRE to +240]	0.0	3	1	1	1
92257	1710	molecular mechanism signal in eosinophil	[molecular mechanisms signaling in eosinophils]	0.0	5	1	1	1
92258	1710	transactivation potential of bsap	[transactivation potential of BSAP]	0.0	4	1	1	1
92259	1710	rheumatoid tissue	[rheumatoid tissue]	0.0	2	1	1	1
92260	1710	cell mimick clonal cell growth	[cells mimicking clonal cell growth]	0.0	5	1	1	1
92261	1710	involve the addition	[involving the addition]	0.0	3	1	1	1
92262	1710	major coat protein	[major coat protein]	0.0	3	1	1	1
92263	1710	individual protein factor	[individual protein factors]	0.0	3	1	1	1
92264	1710	expansion) (by stimulation lead	[expansion) (by stimulation leading]	0.0	4	1	1	1
92265	1710	activity on the SL3 enhancer	[activity on the SL3 enhancer]	0.0	5	1	1	1
92266	1710	M.C.Re,	[M.C.Re,]	0.0	1	1	1	1
92267	1710	GM-CSF enhancer	[GM-CSF enhancer]	0.0	2	1	1	1
92268	1710	factor of T cell NFATp	[factor of T cells NFATp]	0.0	5	2	2	1
92269	1710	pathway of T cell death	[pathway of T cell death]	0.0	5	1	1	1
92270	1710	involve differentiation in karyotypic male	[involving differentiation in karyotypic males]	0.0	5	1	1	1
92271	1710	ifnalpha-stimulated tyrosine phosphorylation	[IFNalpha-stimulated tyrosine phosphorylation]	0.0	3	1	1	1
92272	1710	weight of 50 kda	[weight of 50 kDa]	0.0	4	1	1	1
92273	1710	human homolog of nrl	[human homolog of NRL]	0.0	4	1	1	1
92274	1710	species range	[species ranging]	0.0	2	1	1	1
92275	1710	direct circulate leukocyte	[directing circulating leukocytes]	0.0	3	1	1	1
92276	1710	bp of 5' -flanking sequence	[bp of 5' -flanking sequence]	0.0	5	1	1	1
92277	1710	retinoid X receptor RXR	[Retinoid X receptor RXR]	0.0	4	1	1	1
92278	1710	activation of the human gene promoter	[Activation of the human gene promoter]	0.0	6	1	1	1
92279	1710	haematopoietic line	[haematopoietic lines]	0.0	2	1	1	1
92280	1710	one factor in human macrophage	[one factors in human macrophages]	0.0	5	1	1	1
92281	1710	activator phytohemagglutinin pha	[activator phytohemagglutinin PHA]	0.0	3	1	1	1
92282	1710	aids-gr patient	[AIDS-GR patients]	0.0	2	1	1	1
92283	1710	bind specifically after ltb4 stimulation	[binding specifically after LTB4 stimulation]	0.0	5	1	1	1
92284	1710	lupus T	[lupus T]	0.0	2	1	1	1
92285	1710	initial enzyme of catabolism	[initial enzyme of catabolism]	0.0	4	1	1	1
92286	1710	G1 to S	[G1 to S]	0.0	3	2	2	1
92287	1710	(a) of variant	[(A) of variants]	0.0	3	1	1	1
92288	1710	distinct cell complex	[distinct cell complexes]	0.0	3	1	1	1
92289	1710	antioxidant --including ascorbic acid	[antioxidants --including ascorbic acid]	0.0	4	1	1	1
92290	1710	many tissue	[many tissues]	0.0	2	1	1	1
92291	1710	nf-kappa b motif L2	[NF-kappa B motif L2]	0.0	4	1	1	1
92292	1710	nf-kappa b motif L1	[NF-kappa B motif L1]	0.0	4	1	1	1
92293	1710	immediate availability	[immediate availability]	0.0	2	1	1	1
92294	1710	include the tumor necrosis factor	[including the tumor necrosis factor]	0.0	5	1	1	1
92295	1710	protein from nuclear matrix preparation	[protein from nuclear matrix preparations]	0.0	5	1	1	1
92296	1710	pleural effusion from 20 patient	[Pleural effusions from 20 patients]	0.0	5	1	1	1
92297	1710	hormone-activated receptor binding	[hormone-activated receptor binding]	0.0	3	1	1	1
92298	1710	of binding to p element	[of binding to P elements]	0.0	5	1	1	1
92299	1710	only in a redox status	[only in an redox status]	0.0	5	1	1	1
92300	1710	deletion of the hgata-3 activation domain	[deletion of the hGATA-3 activation domain]	0.0	6	1	1	1
92301	1710	prolonged exposure of endothelial cell HAEC	[prolonged exposure of endothelial cells HAEC]	0.0	6	1	1	1
92302	1710	regulatory mechanism in the system	[regulatory mechanism in the system]	0.0	5	1	1	1
92303	1710	tumor vaccine	[tumor vaccines]	0.0	2	1	1	1
92304	1710	part of the R- inducible enhancer	[part of the R- inducible enhancer]	0.0	6	1	1	1
92305	1710	immunosorbent assay procedure use zebra protein	[immunosorbent assay procedure using ZEBRA protein]	0.0	6	1	1	1
92306	1710	candidate gene factor 3 beta	[candidate genes factor 3 beta]	0.0	5	1	1	1
92307	1710	55-kDa isoform	[55-kDa isoform]	0.0	2	1	1	1
92308	1710	act of each control expression	[acting of each control expression]	0.0	5	1	1	1
92309	1710	administration of mumol cortisol to subject	[administration of mumol cortisol to subjects]	0.0	6	1	1	1
92310	1710	unique involvement in growth inhibition	[unique involvement in growth inhibition]	0.0	5	1	1	1
92311	1710	translocation of nfat nuclear factor	[translocation of NFAT nuclear factor]	0.0	5	2	2	1
92312	1710	affinity of squirrel monkey gr	[affinity of squirrel monkey GR]	0.0	5	1	1	1
92313	1710	all-tran acid atra washed,	[all-trans acid ATRA washed,]	0.0	4	1	1	1
92314	1710	preincubation with a synthetic peptide Arg-Gly-Asp	[preincubation with a synthetic peptide Arg-Gly-Asp]	0.0	6	1	1	1
92315	1710	phenotype of Nef	[phenotypes of Nef]	0.0	3	1	1	1
92316	1710	exon contain a region (4c)	[exon containing a region (4c)]	0.0	5	1	1	1
92317	1710	protein latent	[protein latent]	0.0	2	1	1	1
92318	1710	regulate functionality	[regulating functionality]	0.0	2	1	1	1
92319	1710	ascorbate radical AFR act	[ascorbate radical AFR acts]	0.0	4	1	1	1
92320	1710	cytoplasmic inhibitory molecule	[cytoplasmic inhibitory molecules]	0.0	3	1	1	1
92321	1710	result tissue damage	[resulting tissue damage]	0.0	3	1	1	1
92322	1710	Indeed, pc2	[Indeed, PC2]	0.0	2	1	1	1
92323	1710	Glucocorticoid gc	[Glucocorticoid GC]	0.0	2	1	1	1
92324	1710	potentiate activity of NE	[potentiating activity of NE]	0.0	4	1	1	1
92325	1710	carg sequence	[CArG sequences]	0.0	2	1	1	1
92326	1710	extra-renal production	[extra-renal production]	0.0	2	1	1	1
92327	1710	TGF elisa	[TGF ELISAs]	0.0	2	1	1	1
92328	1710	extensive mutagenesis	[Extensive mutagenesis]	0.0	2	1	1	1
92329	1710	combination with all-tran acid	[combination with all-trans acid]	0.0	4	1	1	1
92330	1710	112 patient with disorder euthymic,	[112 patients with disorder euthymic,]	0.0	5	1	1	1
92331	1710	interleukin-10 stat molecule	[interleukin-10 STAT molecules]	0.0	3	1	1	1
92332	1710	LTR reporter construct	[LTR reporter constructs]	0.0	3	1	1	1
92333	1710	high, concentration to &mgr;m)	[high, concentrations to &mgr;M)]	0.0	4	1	1	1
92334	1710	dnase-i hypersensitive site	[DNase-I hypersensitive sites]	0.0	3	1	1	1
92335	1710	agonist activity,	[agonist activity,]	0.0	2	1	1	1
92336	1710	sprue	[sprue]	0.0	1	1	1	1
92337	1710	use the dose of anti-CD3	[using the dose of anti-CD3]	0.0	5	1	1	1
92338	1710	transrepression of the il-2 gene	[transrepression of the IL-2 gene]	0.0	5	1	1	1
92339	1710	dose of 3.5-10 nm	[dose of 3.5-10 nM]	0.0	4	1	1	1
92340	1710	phase of growth	[phase of growth]	0.0	3	1	1	1
92341	1710	Glucocorticoid receptor on human mononuclear	[Glucocorticoid receptors on human mononuclear]	0.0	5	1	1	1
92342	1710	culture lack antigen-presenting cell	[cultures lacking antigen-presenting cells]	0.0	4	1	1	1
92343	1710	region extend from -250 bp	[regions extending from -250 bp]	0.0	5	1	1	1
92344	1710	gr -dependent transcriptional activation	[GR -dependent transcriptional activation]	0.0	4	1	1	1
92345	1710	srf/ ets element	[SRF/ ETS element]	0.0	3	1	1	1
92346	1710	virologic subtype hhv-8 +/ebv- pel	[virologic subtypes HHV-8 +/EBV- PEL]	0.0	5	1	1	1
92347	1710	PKR	[PKR]	0.0	1	1	1	1
92348	1710	the/thf (0.24; alpha thf/thf ratios.	[THE/THF (0.24; alpha THF/THF ratios.]	0.0	5	1	1	1
92349	1710	new dual cyclooxygenase/5-lipoxygenase compound	[new dual cyclooxygenase/5-lipoxygenase compound]	0.0	4	1	1	1
92350	1710	cytokine-induced immunodeficiency virus type	[cytokine-induced immunodeficiency virus type]	0.0	4	1	1	1
92351	1710	resistance to tricyclic antidepressant	[resistance to tricyclic antidepressants]	0.0	4	1	1	1
92352	1710	clinically distinct stages: a chronic	[clinically distinct stages: a chronic]	0.0	5	1	1	1
92353	1710	blood monocyte from patient	[Blood monocytes from patients]	0.0	4	1	1	1
92354	1710	design of the trial	[design of the trials]	0.0	4	1	1	1
92355	1710	detailed analysis of 20q deletion	[detailed analysis of 20q deletions]	0.0	5	1	1	1
92356	1710	coactivator requirement	[coactivator requirements]	0.0	2	1	1	1
92357	1710	subtle modification	[subtle modifications]	0.0	2	1	1	1
92358	1710	position to -195	[positions to -195]	0.0	3	1	1	1
92359	1710	protein bind the interferon-inducible element	[proteins binding the interferon-inducible element]	0.0	5	1	1	1
92360	1710	two spindle-shaped carcinoma	[two spindle-shaped carcinomas]	0.0	3	1	1	1
92361	1710	two subunit of NF-kappaB	[two subunits of NF-kappaB]	0.0	4	1	1	1
92362	1710	only that lymphocyte	[only those lymphocytes]	0.0	3	1	1	1
92363	1710	balance of stat1 activity	[balance of Stat1 activity]	0.0	4	1	1	1
92364	1710	augment uptake	[augmenting uptake]	0.0	2	1	1	1
92365	1710	thrombin inducibility	[thrombin inducibility]	0.0	2	1	1	1
92366	1710	specifically in cell of the lineage	[specifically in cells of the lineage]	0.0	6	1	1	1
92367	1710	blood lymphocyte generation	[blood lymphocytes Generation]	0.0	3	1	1	1
92368	1710	quantitatively similar reduction	[quantitatively similar reduction]	0.0	3	1	1	1
92369	1710	hsp60 in vein cell huvec	[Hsp60 in vein cells HUVECs]	0.0	5	1	1	1
92370	1710	patient with myeloid leukaemia AML	[patients with myeloid leukaemia AML]	0.0	5	1	1	1
92371	1710	link between epo mechanism	[link between Epo mechanisms]	0.0	4	1	1	1
92372	1710	human mononuclear cell with interleukin-4	[human mononuclear cells with interleukin-4]	0.0	5	1	1	1
92373	1710	representate the whole spectrum	[representating the whole spectrum]	0.0	4	1	1	1
92374	1710	expression of TNF	[expression of TNF]	0.0	3	1	1	1
92375	1710	adult t-cell leukemia/lymphoma	[adult T-cell leukemia/lymphoma]	0.0	3	1	1	1
92376	1710	main piece of datum	[main pieces of data]	0.0	4	1	1	1
92377	1710	also no significant partial correlation	[Also no significant partial correlations]	0.0	5	1	1	1
92378	1710	response to activating agents.	[response to activating agents.]	0.0	4	1	1	1
92379	1710	lactoferrin	[lactoferrin]	0.0	1	1	1	1
92380	1710	translocation of NFkappaB	[translocation of NFkappaB]	0.0	3	2	2	1
92381	1710	comprise a anti-hapten ab fragment	[comprising an anti-hapten Ab fragment]	0.0	5	1	1	1
92382	1710	two major subunit	[two major subunits]	0.0	3	1	1	1
92383	1710	Bcl-6 expression in follicular hyperplasia heterogeneity	[Bcl-6 expression in follicular hyperplasia heterogeneity]	0.0	6	1	1	1
92384	1710	hematopoietic property	[hematopoietic properties]	0.0	2	1	1	1
92385	1710	stat1 gene transcription in resting	[STAT1 gene transcription in resting]	0.0	5	1	1	1
92386	1710	novel target for manipulation	[novel targets for manipulation]	0.0	4	1	1	1
92387	1710	library of rdna	[library of cDNAs]	0.0	3	1	1	1
92388	1710	tnf-alpha protein to level	[TNF-alpha protein to levels]	0.0	4	1	1	1
92389	1710	receptor /cell for type i	[receptors /cell for type I]	0.0	5	1	1	1
92390	1710	natural cycle	[natural cycle]	0.0	2	1	1	1
92391	1710	alternative pax-5 transcript	[alternative Pax-5 transcripts]	0.0	3	1	1	1
92392	1710	bioinactivation mechanism	[bioinactivation mechanism]	0.0	2	1	1	1
92393	1710	cotton-top tamarin	[cotton-top tamarin]	0.0	2	1	1	1
92394	1710	domain the ligand-binding domain	[domains the ligand-binding domain]	0.0	4	1	1	1
92395	1710	POZ	[POZ]	0.0	1	1	1	1
92396	1710	cooperative action	[cooperative action]	0.0	2	1	1	1
92397	1710	disease state	[disease states]	0.0	2	1	1	1
92398	1710	agonistic monoclonal antibody	[agonistic monoclonal antibody]	0.0	3	1	1	1
92399	1710	two general transcription factor	[two general transcription factors]	0.0	4	1	1	1
92400	1710	LMP1 ct a	[LMP1 CT aa]	0.0	3	1	1	1
92401	1710	marker for t-derived cell	[marker for T-derived cells]	0.0	4	1	1	1
92402	1710	two goals:	[two goals:]	0.0	2	1	1	1
92403	1710	suggest cross-talk	[suggesting cross-talk]	0.0	2	1	1	1
92404	1710	promoter without the W box	[promoters without the W box]	0.0	5	1	1	1
92405	1710	mcd14 ligand in	[mCD14 ligands in]	0.0	3	1	1	1
92406	1710	construct into bone marrow cell	[construct into bone marrow cells]	0.0	5	1	1	1
92407	1710	pit-1 pit-1b	[Pit-1 Pit-1b]	0.0	2	1	1	1
92408	1710	oligonucleotide corresponding to sequence	[oligonucleotides corresponding to sequences]	0.0	4	1	1	1
92409	1710	45-nucleotide sequence element DRE	[45-nucleotide sequence element DRE]	0.0	4	1	1	1
92410	1710	cellular,	[cellular,]	0.0	1	1	1	1
92411	1710	calcium-dependent, posttranslational modification	[calcium-dependent, posttranslational modification]	0.0	3	1	1	1
92412	1710	50 ng	[50 ng]	0.0	2	1	1	1
92413	1710	50 nm	[50 nM]	0.0	2	1	1	1
92414	1710	stress condition	[stress conditions]	0.0	2	1	1	1
92415	1710	factor-kappaB activation in human monocyte	[factor-kappaB activation in human monocytes]	0.0	5	1	1	1
92416	1710	-resistant T	[-resistant T]	0.0	2	1	1	1
92417	1710	protein and/or viral DNA	[proteins and/or viral DNA]	0.0	4	1	1	1
92418	1710	USF- promoter	[USF- promoters]	0.0	2	1	1	1
92419	1710	structurally related kinase inhibitor	[structurally related kinase inhibitor]	0.0	4	1	1	1
92420	1710	human immunodeficiency virus apoptosis m.tremblay,	[human immunodeficiency virus apoptosis M.Tremblay,]	0.0	5	1	1	1
92421	1710	receptor allele	[receptor allele]	0.0	2	1	1	1
92422	1710	regulate different biological function	[regulating different biological functions]	0.0	4	1	1	1
92423	1710	only high level	[only high levels]	0.0	3	1	1	1
92424	1710	encode oct-binding factor 1 obf-1	[encoding Oct-binding factor 1 OBF-1]	0.0	5	1	1	1
92425	1710	cell type hela cell	[cell types HeLa cells]	0.0	4	1	1	1
92426	1710	cytokine -mRNA	[cytokine -mRNA]	0.0	2	1	1	1
92427	1710	other traf-binding member	[other TRAF-binding members]	0.0	3	1	1	1
92428	1710	rearrangement corresponding to transcript	[rearrangements corresponding to transcripts]	0.0	4	1	1	1
92429	1710	Differentiation-dependent expression of a carboxylesterase	[Differentiation-dependent expression of a carboxylesterase]	0.0	5	1	1	1
92430	1710	lymphocyte factor	[lymphocyte factors]	0.0	2	1	1	1
92431	1710	glucocorticosteroid response element ngre	[glucocorticosteroid response element nGRE]	0.0	4	1	1	1
92432	1710	GATA-3 enhancer activity	[GATA-3 enhancer activity]	0.0	3	1	1	1
92433	1710	various transcription factor	[various transcription factors]	0.0	3	3	3	1
92434	1710	range of avidity	[range of avidity]	0.0	3	1	1	1
92435	1710	PRE	[PRE]	0.0	1	1	1	1
92436	1710	LCR holocomplex	[LCR holocomplex]	0.0	2	1	1	1
92437	1710	significant class lymphoma plasmacytoid	[significant class lymphoma plasmacytoid]	0.0	4	1	1	1
92438	1710	HaCaT cell line human blood lymphocyte	[HaCaT cell line human blood lymphocytes]	0.0	6	1	1	1
92439	1710	gp160 for 4 h	[gp160 for 4 h]	0.0	4	1	1	1
92440	1710	beta gene	[beta genes]	0.0	2	1	1	1
92441	1710	a (of ebv type	[A (of EBV type]	0.0	4	1	1	1
92442	1710	positive regulation in T cell	[positive regulation in T cells]	0.0	5	1	1	1
92443	1710	EBNA2 monoclonal antibody	[EBNA2 monoclonal antibodies]	0.0	3	1	1	1
92444	1710	inhibition of magnitude	[inhibition of magnitude]	0.0	3	1	1	1
92445	1710	position to -108	[positions to -108]	0.0	3	1	1	1
92446	1710	endothelial cell glutathione	[endothelial cell glutathione]	0.0	3	1	1	1
92447	1710	collection	[collection]	0.0	1	1	1	1
92448	1710	persistent latency	[persistent latency]	0.0	2	1	1	1
92449	1710	cell infiltration with necrosis	[cell infiltration with necrosis]	0.0	4	1	1	1
92450	1710	trans- dominant inhibitor	[trans- dominant inhibitor]	0.0	3	1	1	1
92451	1710	activity of granulocyte-macrophage colony-stimumulatelany-stg factor	[activity of granulocyte-macrophage colony-stimulating factor]	0.0	5	1	1	1
92452	1710	bp region	[bp region]	0.0	2	1	1	1
92453	1710	relb -ck1 gene	[RelB -CK1 gene]	0.0	3	1	1	1
92454	1710	PTX	[PTX]	0.0	1	1	1	1
92455	1710	early regulator of the cycle	[early regulators of the cycle]	0.0	5	1	1	1
92456	1710	initial phase of interleukin-2	[initial phase of interleukin-2]	0.0	4	1	1	1
92457	1710	ino synthase	[iNO synthase]	0.0	2	1	1	1
92458	1710	dead cell at day 6; g-csf	[dead cells at day 6; G-CSF]	0.0	6	1	1	1
92459	1710	nuclear expression of factor kappab activation	[nuclear expression of factor kappaB activation]	0.0	6	1	1	1
92460	1710	blood lymphocyte asthma BA	[blood lymphocytes asthma BA]	0.0	4	1	1	1
92461	1710	fos-related Ag	[Fos-related Ag]	0.0	2	1	1	1
92462	1710	high (p<.001)	[higher (P<.001)]	0.0	2	1	1	1
92463	1710	effect on (<2 gene expression	[effect on (<2 gene expression]	0.0	5	1	1	1
92464	1710	concept a histogenetically distinct, subtype	[concept an histogenetically distinct, subtype]	0.0	5	1	1	1
92465	1710	cell StatG	[cells StatG]	0.0	2	1	1	1
92466	1710	rather, analysis	[Rather, analysis]	0.0	2	1	1	1
92467	1710	variety of transcriptional protein	[variety of transcriptional proteins]	0.0	4	1	1	1
92468	1710	pha treatment	[PHA treatment]	0.0	2	1	1	1
92469	1710	nf-kappab activation of hiv-1 repeat	[NF-kappaB activation of HIV-1 repeat]	0.0	5	1	1	1
92470	1710	change of receptor	[changes of receptor]	0.0	3	1	1	1
92471	1710	signal event in cell	[signaling events in cells]	0.0	4	1	1	1
92472	1710	immune glomerulopathy	[immune glomerulopathy]	0.0	2	1	1	1
92473	1710	abnormality gene in malignant astrocytomas	[Abnormalities genes in malignant astrocytomas]	0.0	5	1	1	1
92474	1710	factor-kappa beta enf-kappa	[factor-kappa beta (NF-kappa]	0.0	3	1	1	1
92475	1710	PBMC of woman	[PBMC of women]	0.0	3	1	1	1
92476	1710	mar-binding protein	[MAR-binding protein]	0.0	2	1	1	1
92477	1710	several other cell type	[several other cell types]	0.0	4	1	1	1
92478	1710	chronic autoimmune disease	[chronic autoimmune disease]	0.0	3	2	2	1
92479	1710	correlation of the level b4	[correlations of the levels B4]	0.0	5	1	1	1
92480	1710	putative membrane-spanning domain	[putative membrane-spanning domains]	0.0	3	1	1	1
92481	1710	profilin-like functional fashion.	[profilin-like functional fashion.]	0.0	3	1	1	1
92482	1710	release of endothelium-derived factor	[release of endothelium-derived factors]	0.0	4	1	1	1
92483	1710	distinct effect on the activity	[distinct effects on the activity]	0.0	5	1	1	1
92484	1710	8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	5	1	1	1
92485	1710	cell of tissue	[cells of tissue]	0.0	3	1	1	1
92486	1710	lack antigenic er peptide	[lacking antigenic ER peptides]	0.0	4	1	1	1
92487	1710	protein capable to sequence	[proteins capable to sequences]	0.0	4	1	1	1
92488	1710	friend leukemia	[Friend leukemia]	0.0	2	1	1	1
92489	1710	lymph node at surgery	[lymph nodes at surgery]	0.0	4	1	1	1
92490	1710	little activity	[little activity]	0.0	2	1	1	1
92491	1710	level in group	[levels in groups]	0.0	3	1	1	1
92492	1710	endothelial protein such as e-selectin	[endothelial proteins such as E-selectin]	0.0	5	1	1	1
92493	1710	important event	[important event]	0.0	2	1	1	1
92494	1710	effect 1) inhibition of growth	[effects 1) inhibition of growth]	0.0	5	1	1	1
92495	1710	manipulation of mammary cell	[manipulations of mammary cells]	0.0	4	1	1	1
92496	1710	etiologies.	[etiologies.]	0.0	1	1	1	1
92497	1710	strain of tal-1 mouse	[strain of tal-1 mice]	0.0	4	1	1	1
92498	1710	use mpl concentration as a input	[using MPL concentrations as an input]	0.0	6	1	1	1
92499	1710	activation after ligation	[Activation after ligation]	0.0	3	1	1	1
92500	1710	Cell. Biol. 8:5581-5587,	[Cell. Biol. 8:5581-5587,]	0.0	3	1	1	1
92501	1710	combination with retinoic acid RA	[combination with retinoic acid RA]	0.0	5	1	1	1
92502	1710	ratio (m/z)	[ratio (m/z)]	0.0	2	1	1	1
92503	1710	indicate apparently independent	[indicating apparently independent]	0.0	3	1	1	1
92504	1710	exogenous c-fo	[exogenous c-fos]	0.0	2	1	1	1
92505	1710	stat5 protein by il-5	[STAT5 proteins by IL-5]	0.0	4	1	1	1
92506	1710	marker of apoptotic event	[marker of apoptotic events]	0.0	4	1	1	1
92507	1710	encode a muscle myosin chain	[encoding a muscle myosin chain]	0.0	5	1	1	1
92508	1710	short analog	[short analog]	0.0	2	1	1	1
92509	1710	contribution of macrophage	[contribution of macrophages]	0.0	3	1	1	1
92510	1710	nf-kappa b -like factor evidence	[NF-kappa B -like factor evidence]	0.0	5	1	1	1
92511	1710	amino acid difference Ser551	[amino acid differences Ser551]	0.0	4	1	1	1
92512	1710	predominant nf-kappa b species	[predominant NF-kappa B species]	0.0	4	1	1	1
92513	1710	oestrogen receptor analysis in lymphocytic leukemia	[Oestrogen receptor analysis in lymphocytic leukemia]	0.0	6	1	1	1
92514	1710	complex with class of cytosolic receptor	[complexes with classes of cytosolic receptors]	0.0	6	1	1	1
92515	1710	27-kda protein	[27-kDa protein]	0.0	2	1	1	1
92516	1710	weak inducible complex resemble factor	[weak inducible complex resembling factor]	0.0	5	1	1	1
92517	1710	role of p70(s6k)	[role of p70(s6k)]	0.0	3	1	1	1
92518	1710	prostaglandin I2 a negative regulator	[prostaglandin I2 a negative regulator]	0.0	5	1	1	1
92519	1710	macrophage-colony stimulate	[macrophage-colony stimulating]	0.0	2	2	2	1
92520	1710	mmol/L buthionine	[mmol/L buthionine]	0.0	2	1	1	1
92521	1710	normal myeloid cell i.e. granulocyte	[normal myeloid cells i.e. granulocytes]	0.0	5	1	1	1
92522	1710	alpha-helix	[alpha-helix]	0.0	1	1	1	1
92523	1710	beta-catenin -lymphoid enhancer factor	[beta-catenin -lymphoid enhancer factor]	0.0	4	1	1	1
92524	1710	reduce the yield of structural protein	[reducing the yields of structural proteins]	0.0	6	1	1	1
92525	1710	whole sequence	[whole sequences]	0.0	2	1	1	1
92526	1710	Differential interaction of factor	[Differential interaction of factors]	0.0	4	2	2	1
92527	1710	portion of c/ebp-epsilon	[portion of C/EBP-epsilon]	0.0	3	1	1	1
92528	1710	comprehensive screen	[comprehensive screening]	0.0	2	1	1	1
92529	1710	diffusible endothelial protein such as e-selectin	[Diffusible endothelial proteins such as E-selectin]	0.0	6	1	1	1
92530	1710	v-atpase b	[V-ATPase B]	0.0	2	1	1	1
92531	1710	differ from dq3.2 at residue	[differing from DQ3.2 at residue]	0.0	5	1	1	1
92532	1710	evidence for a tissue-specific variation	[evidence for a tissue-specific variation]	0.0	5	1	1	1
92533	1710	enhancer site	[enhancer site]	0.0	2	1	1	1
92534	1710	1/oct coactivator from b cell	[1/Oct coactivator from B cells]	0.0	5	1	1	1
92535	1710	50 nm 1	[50 nM 1]	0.0	3	1	1	1
92536	1710	compound, ru24858	[compound, RU24858]	0.0	2	1	1	1
92537	1710	c-jun component	[c-Jun component]	0.0	2	1	1	1
92538	1710	human granulocyte/macrophage-colony stimulate factor	[human granulocyte/macrophage-colony stimulating factor]	0.0	4	1	1	1
92539	1710	Biological marker	[Biological markers]	0.0	2	1	1	1
92540	1710	inhibition of IL-10 c-fo expression	[inhibition of IL-10 c-fos expression]	0.0	5	1	1	1
92541	1710	range include interferon-gamma ifn-gamma	[range including interferon-gamma IFN-gamma]	0.0	4	1	1	1
92542	1710	camp in the presence	[cAMP in the presence]	0.0	4	1	1	1
92543	1710	PU.1 (the	[PU.1 (the]	0.0	2	1	1	1
92544	1710	pp2a inhibitor	[PP2A inhibitors]	0.0	2	1	1	1
92545	1710	kit proliferation	[Kit proliferation]	0.0	2	1	1	1
92546	1710	benzoic derivative of retinoic acid	[benzoic derivative of retinoic acid]	0.0	5	1	1	1
92547	1710	(20 microM, h),	[(20 microM, h),]	0.0	3	1	1	1
92548	1710	novel gene product related	[novel gene product related]	0.0	4	1	1	1
92549	1710	e1a protein	[E1A proteins]	0.0	2	1	1	1
92550	1710	wild type phenotype	[wild type phenotypes]	0.0	3	1	1	1
92551	1710	viral repeat LTR	[viral repeat LTR]	0.0	3	5	5	1
92552	1710	gamma-interferon gamma-ifn	[gamma-interferon gamma-IFN]	0.0	2	1	1	1
92553	1710	T cell factor 1	[T cell factor 1]	0.0	4	1	1	1
92554	1710	cysteine-rich protein	[cysteine-rich protein]	0.0	2	1	1	1
92555	1710	four proteins--a major protein of kD	[four proteins--a major protein of kD]	0.0	6	1	1	1
92556	1710	part, on gene regulation	[part, on gene regulation]	0.0	4	1	1	1
92557	1710	megakaryocytic gene in four cell line	[megakaryocytic genes in four cell lines]	0.0	6	1	1	1
92558	1710	MHC class ii gene transcription	[MHC class II gene transcription]	0.0	5	1	1	1
92559	1710	importance in the expression	[importance in the expression]	0.0	4	1	1	1
92560	1710	peripheral blood of pregnant woman	[peripheral blood of pregnant women]	0.0	5	1	1	1
92561	1710	role for oxidant stress	[role for oxidant stress]	0.0	4	1	1	1
92562	1710	binding capacity of the nt3r value	[binding capacity of the NT3R values]	0.0	6	1	1	1
92563	1710	up-regulation during monocytic cell maturation	[up-regulation during monocytic cell maturation]	0.0	5	1	1	1
92564	1710	tnf receptor rhu tnfr:fc	[TNF receptor rhu TNFR:Fc]	0.0	4	1	1	1
92565	1710	region sequence element	[region sequence elements]	0.0	3	1	1	1
92566	1710	use nuclear extract from eosinophil	[using nuclear extracts from eosinophils]	0.0	5	1	1	1
92567	1710	form of cellular collaboration	[forms of cellular collaboration]	0.0	4	1	1	1
92568	1710	NF-kappa b p50 /p50	[NF-kappa B p50 /p50]	0.0	4	1	1	1
92569	1710	size of 37745 dalton	[size of 37,745 daltons]	0.0	4	1	1	1
92570	1710	signal costimulatory signal	[signal costimulatory signal]	0.0	3	1	1	1
92571	1710	sensitive pathway	[sensitive pathway]	0.0	2	1	1	1
92572	1710	nf-at -like response element	[NF-AT -like response element]	0.0	4	1	1	1
92573	1710	two categories: induction	[two categories: induction]	0.0	3	1	1	1
92574	1710	important regulator during b-cell maturation	[important regulators during B-cell maturation]	0.0	5	1	1	1
92575	1710	traf-binding member of the TNFR superfamily	[TRAF-binding members of the TNFR superfamily]	0.0	6	1	1	1
92576	1710	cd4+ T cell clone tcc	[CD4+ T cell clones TCC]	0.0	5	1	1	1
92577	1710	number of gr in leukocyte	[number of GR in leukocytes]	0.0	5	1	1	1
92578	1710	expression of factor kappab nf-kappab activation	[expression of factor kappaB NF-kappaB activation]	0.0	6	1	1	1
92579	1710	association of insensitivity with expression	[Association of insensitivity with expression]	0.0	5	1	1	1
92580	1710	Lymphotoxin-alpha LTalpha	[Lymphotoxin-alpha LTalpha]	0.0	2	1	1	1
92581	1710	localize cis-element	[localizing cis-elements]	0.0	2	1	1	1
92582	1710	decrease in CAT activity	[decrease in CAT activity]	0.0	4	1	1	1
92583	1710	rat muscle cell	[rat muscle cells]	0.0	3	1	1	1
92584	1710	correspondence with common variant	[correspondence with common variants]	0.0	4	1	1	1
92585	1710	CD3/TCR complex	[CD3/TCR complex]	0.0	2	1	1	1
92586	1710	inhibition of the NF-kappaB pathway	[Inhibition of the NF-kappaB pathway]	0.0	5	1	1	1
92587	1710	g-csfr mutant	[G-CSFR mutant]	0.0	2	1	1	1
92588	1710	tissue-specific late histone h2a-2 gene	[tissue-specific late histone H2A-2 genes]	0.0	5	1	1	1
92589	1710	heparin-binding growth growth factor HB-EGF	[heparin-binding growth growth factor HB-EGF]	0.0	5	1	1	1
92590	1710	defect,	[defect,]	0.0	1	1	1	1
92591	1710	one obese patient	[one obese patient]	0.0	3	1	1	1
92592	1710	protein EBNA-2	[protein EBNA-2]	0.0	2	1	1	1
92593	1710	susceptibility to pcdd	[susceptibility to PCDDs/PCDFs]	0.0	3	1	1	1
92594	1710	-assembly	[-assembly]	0.0	1	1	1	1
92595	1710	activator ebf	[activator EBF]	0.0	2	1	1	1
92596	1710	interleukin-7 signal acute lymphoblastic leukemia cell	[Interleukin-7 signaling acute lymphoblastic leukemia cells]	0.0	6	1	1	1
92597	1710	result to sunlight	[resulting to sunlight]	0.0	3	1	1	1
92598	1710	p65 protein	[p65 protein]	0.0	2	1	1	1
92599	1710	mature p50 subunit	[mature p50 subunit]	0.0	3	1	1	1
92600	1710	expression of human immunodeficiency virus	[expression of human immunodeficiency virus]	0.0	5	1	1	1
92601	1710	25-dihydroxyvitamin D3 receptor	[25-dihydroxyvitamin D3 receptor]	0.0	3	1	1	1
92602	1710	semisolid culture	[semisolid culture]	0.0	2	1	1	1
92603	1710	distinct sequence-specific dna-binding protein	[distinct sequence-specific DNA-binding proteins]	0.0	4	1	1	1
92604	1710	interfere with the cell cycle progression	[interfering with the cell cycle progression]	0.0	6	1	1	1
92605	1710	cytotoxicity against autologous cell	[cytotoxicity against autologous cells]	0.0	4	1	1	1
92606	1710	addition act	[addition acting]	0.0	2	1	1	1
92607	1710	Ph'	[Ph']	0.0	1	1	1	1
92608	1710	hl-60 cell with tpa	[HL-60 cells with TPA]	0.0	4	1	1	1
92609	1710	histocompatibility (MHC) class ii gene	[histocompatibility (MHC) class II genes]	0.0	5	1	1	1
92610	1710	mostly from increase	[mostly from increases]	0.0	3	1	1	1
92611	1710	Epstein-Barr virus antigen 2 ebna-2	[Epstein-Barr virus antigen 2 EBNA-2]	0.0	5	1	1	1
92612	1710	26 cell carcinoma SCC	[26 cell carcinomas SCCs]	0.0	4	1	1	1
92613	1710	than in cell	[than in cells]	0.0	3	1	1	1
92614	1710	early tissue damage	[early tissue damage]	0.0	3	1	1	1
92615	1710	domain of HS-40	[domains of HS-40]	0.0	3	1	1	1
92616	1710	ap-1 component	[AP-1 component]	0.0	2	1	1	1
92617	1710	myeloid differentiation antigen MNDA	[myeloid differentiation antigen MNDA]	0.0	4	1	1	1
92618	1710	il-2 by T lymphocyte	[IL-2 by T lymphocytes]	0.0	4	1	1	1
92619	1710	1 minute of activation,	[1 min of activation,]	0.0	4	1	1	1
92620	1710	involve clone	[involving clones]	0.0	2	1	1	1
92621	1710	expression of reporter gene	[expression of reporter genes]	0.0	4	1	1	1
92622	1710	abnormal pattern	[abnormal pattern]	0.0	2	1	1	1
92623	1710	selection of lmp1	[selection of LMP1]	0.0	3	1	1	1
92624	1710	3) failure	[3) failure]	0.0	2	1	1	1
92625	1710	activation of NF-kB in human thymocyte	[activation of NF-kB in human thymocytes]	0.0	6	1	1	1
92626	1710	signal-related kinase n-terminal kinase	[signal-related kinase N-terminal kinase]	0.0	4	1	1	1
92627	1710	er transcript	[ER transcripts]	0.0	2	1	1	1
92628	1710	2 pre-B lymphoblastic leukemia	[2 pre-B lymphoblastic leukemia]	0.0	4	1	1	1
92629	1710	induction by macrophage colony-stimumulatelany-stg factor	[Induction by macrophage colony-stimulating factor]	0.0	5	1	1	1
92630	1710	number of positive prediction	[number of positive predictions]	0.0	4	1	1	1
92631	1710	cell layer	[cell layer]	0.0	2	1	1	1
92632	1710	significance in patient	[significance in patients]	0.0	3	1	1	1
92633	1710	tissue specificity in this organisms.	[tissue specificity in these organisms.]	0.0	5	1	1	1
92634	1710	However, transduction	[However, transduction]	0.0	2	1	1	1
92635	1710	acute onset	[acute onset]	0.0	2	2	2	1
92636	1710	encode a muscle myosin heavy chain	[encoding a muscle myosin heavy chain]	0.0	6	1	1	1
92637	1710	transcription from promoter in b lymphocyte	[transcription from promoters in B lymphocytes]	0.0	6	1	1	1
92638	1710	transcription factor use ubiquitinylating enzyme	[transcription factors using ubiquitinylating enzymes]	0.0	5	1	1	1
92639	1710	grow list of molecule	[growing list of molecules]	0.0	4	1	1	1
92640	1710	distinguishing characteristic	[distinguishing characteristic]	0.0	2	1	1	1
92641	1710	increase indicate the role	[increase indicating the role]	0.0	4	1	1	1
92642	1710	incubation of cell with antibody (mab)	[Incubation of cells with antibody (MAb)]	0.0	6	1	1	1
92643	1710	role in pancreatic beta-cell function	[role in pancreatic beta-cell function]	0.0	5	1	1	1
92644	1710	ras-related protein (rap)	[Ras-related protein (Rap)]	0.0	3	1	1	1
92645	1710	analysis of ca2+ mobilization	[Analysis of Ca2+ mobilization]	0.0	4	1	1	1
92646	1710	DC in normal skin	[DC in normal skin]	0.0	4	1	1	1
92647	1710	12.1 1.3, respectively),	[12.1 1.3, respectively),]	0.0	3	1	1	1
92648	1710	export from the nucleus	[export from the nucleus]	0.0	4	1	1	1
92649	1710	carboxy terminal insert	[carboxy terminal insert]	0.0	3	1	1	1
92650	1710	pha normal blood lymphocyte pbl	[PHA normal blood lymphocytes PBL]	0.0	5	1	1	1
92651	1710	two trans-acting gene	[two trans-acting genes]	0.0	3	1	1	1
92652	1710	B-cell line represent different stage	[B-cell lines representing different stages]	0.0	5	1	1	1
92653	1710	namely activator protein-1 ap-1 nuclear factor	[namely activator protein-1 AP-1 nuclear factor]	0.0	6	1	1	1
92654	1710	safe hiv	[safer HIVs]	0.0	2	1	1	1
92655	1710	different mobility	[different mobilities]	0.0	2	1	1	1
92656	1710	multiple antigen-specific reactivity high	[multiple antigen-specific reactivities high]	0.0	4	1	1	1
92657	1710	second, independent, b-cell line	[second, independent, B-cell line]	0.0	4	1	1	1
92658	1710	pathway regulate alpha2 gene expression	[pathway regulating alpha2 gene expression]	0.0	5	1	1	1
92659	1710	7.03 (range, 5.66-10) (range, 4-.11),	[7.03 (range, 5.66-10), (range, 4-5.13),]	0.0	5	1	1	1
92660	1710	antigen/chemokine	[antigen/chemokine]	0.0	1	1	1	1
92661	1710	EBV origin of replication.	[EBV origin of replication.]	0.0	4	1	1	1
92662	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	5	1	1	1
92663	1710	18,21-anhydroaldosterone	[18,21-anhydroaldosterone]	0.0	1	1	1	1
92664	1710	cd38(-) cell differentiate in unilineage culture	[CD38(-) cells differentiating in unilineage cultures]	0.0	6	1	1	1
92665	1710	only positive mechanism control the competence	[only positive mechanisms controlling the competence]	0.0	6	1	1	1
92666	1710	weak staining	[weak staining]	0.0	2	1	1	1
92667	1710	number (positive)	[number (positive)]	0.0	2	1	1	1
92668	1710	differentiation-inducing activity of retinoid	[differentiation-inducing activity of retinoids]	0.0	4	1	1	1
92669	1710	[3H]thymidine proliferation assay	[[3H]thymidine proliferation assay]	0.0	3	1	1	1
92670	1710	hiv-infected human cell	[HIV-infected human cells]	0.0	3	1	1	1
92671	1710	rapid effect on electrolyte movement	[rapid effects on electrolyte movements]	0.0	5	1	1	1
92672	1710	other T cell line	[other T cell lines]	0.0	4	1	1	1
92673	1710	muscle myosin heavy chain Smmhc	[muscle myosin heavy chain Smmhc]	0.0	5	1	1	1
92674	1710	study variation in gene expression pattern	[studying variation in gene expression patterns]	0.0	6	1	1	1
92675	1710	protein kinase activation in monocyte	[protein kinase activation in monocytes]	0.0	5	1	1	1
92676	1710	thus any defect lead	[thus any defect leading]	0.0	4	1	1	1
92677	1710	down' syndrome tmd	[Down's syndrome TMD]	0.0	3	2	2	1
92678	1710	ebv receptor	[EBV receptor]	0.0	2	1	1	1
92679	1710	first stat family member	[first STAT family member]	0.0	4	1	1	1
92680	1710	six wd-40 repeat	[six WD-40 repeats]	0.0	3	1	1	1
92681	1710	mass of the two	[masses of the two]	0.0	4	1	1	1
92682	1710	Tax1 pathway	[Tax1 pathway]	0.0	2	1	1	1
92683	1710	coupling of receptor factor	[coupling of receptor factor]	0.0	4	1	1	1
92684	1710	seventeen patient with syndrome MDS	[seventeen patients with syndromes MDS]	0.0	5	1	1	1
92685	1710	adjuvant tamoxifen	[adjuvant tamoxifen]	0.0	2	1	1	1
92686	1710	tnf-alpha release from blood monocyte	[TNF-alpha release from blood monocytes]	0.0	5	1	1	1
92687	1710	ebv memory response	[EBV memory response]	0.0	3	1	1	1
92688	1710	alter the status	[altering the status]	0.0	3	1	1	1
92689	1710	namely activator protein-1 nuclear factor	[namely activator protein-1 nuclear factor]	0.0	5	1	1	1
92690	1710	binding of pac-1 antibody	[binding of PAC-1 antibodies]	0.0	4	1	1	1
92691	1710	different manner	[different manner]	0.0	2	1	1	1
92692	1710	Ca2+ mobilization expression of c-fo mrna	[Ca2+ mobilization expression of c-fos mRNA]	0.0	6	1	1	1
92693	1710	25 h for culture	[25 h for cultures]	0.0	4	1	1	1
92694	1710	co-stimulation of microglia	[Co-stimulation of microglia]	0.0	3	1	1	1
92695	1710	stimulus in human neutrophils.	[stimuli in human neutrophils.]	0.0	4	1	1	1
92696	1710	effect of B7	[effect of B7]	0.0	3	1	1	1
92697	1710	A1 protein	[A1 proteins]	0.0	2	1	1	1
92698	1710	mispair	[mispairing]	0.0	1	1	1	1
92699	1710	breast cancer cellular cytotoxicity facilitate antibody	[breast cancer cellular cytotoxicity facilitating antibody]	0.0	6	1	1	1
92700	1710	cell sorting of bone marrow	[Cell sorting of bone marrow]	0.0	5	1	1	1
92701	1710	sensitive measurement	[sensitive measurement]	0.0	2	1	1	1
92702	1710	proliferation in the absence	[proliferation in the absence]	0.0	4	1	1	1
92703	1710	caspase-1	[caspase-1]	0.0	1	1	1	1
92704	1710	role a lymphoid-restricted gene	[role a lymphoid-restricted gene]	0.0	4	1	1	1
92705	1710	consist of concentration	[consisting of concentrations]	0.0	3	1	1	1
92706	1710	absence of il-13r	[absence of IL-13R]	0.0	3	1	1	1
92707	1710	expression of various serum gene	[expression of various serum genes]	0.0	5	1	1	1
92708	1710	Kaposi's sarcoma herpesvirus infection	[Kaposi's sarcoma herpesvirus infection]	0.0	4	1	1	1
92709	1710	hiv-enhancer activity concomitant to a inhibition	[HIV-enhancer activity concomitant to an inhibition]	0.0	6	1	1	1
92710	1710	only negligible activity	[only negligible activity]	0.0	3	1	1	1
92711	1710	(ig) gene within the nucleus	[(Ig) genes within the nucleus]	0.0	5	1	1	1
92712	1710	base pair bp of DNA	[base pairs bp of DNA]	0.0	5	1	1	1
92713	1710	pertain to macrophage response	[pertaining to macrophage response]	0.0	4	1	1	1
92714	1710	phorbol ester neutrophil respiratory burst activation	[phorbol ester neutrophil respiratory burst activation]	0.0	6	1	1	1
92715	1710	cyclic AMP protein kinase	[cyclic AMP protein kinase]	0.0	4	1	1	1
92716	1710	glucocorticoid-sensitive cell before steroid treatment	[glucocorticoid-sensitive cells before steroid treatment]	0.0	5	1	1	1
92717	1710	regulate the distribution receptor in cell	[regulating the distribution receptors in cells]	0.0	6	1	1	1
92718	1710	c-myc mrna expression in salivary gland	[c-myc mRNA expression in salivary glands]	0.0	6	1	1	1
92719	1710	c/ebp medial	[C/EBP medial]	0.0	2	1	1	1
92720	1710	cell in the central system	[cells in the central system]	0.0	5	1	1	1
92721	1710	possibly homodimer	[possibly homodimers]	0.0	2	1	1	1
92722	1710	NF-kappa b-related transcription factor	[NF-kappa B-related transcription factors]	0.0	4	1	1	1
92723	1710	filament protein vimentin	[filament protein vimentin]	0.0	3	1	1	1
92724	1710	technique for the sensitive measurement	[technique for the sensitive measurement]	0.0	5	1	1	1
92725	1710	other primate with resistance	[other primates with resistance]	0.0	4	1	1	1
92726	1710	carboxylesterase in cell	[carboxylesterase in cells]	0.0	3	1	1	1
92727	1710	IFN increase	[IFN increase]	0.0	2	1	1	1
92728	1710	supershif the DNA-protein complex	[supershifting the DNA-protein complexes]	0.0	4	1	1	1
92729	1710	Nonradioactive quantification of glucocorticoid receptor expression	[Nonradioactive quantification of glucocorticoid receptor expression]	0.0	6	1	1	1
92730	1710	isomer	[isomer]	0.0	1	1	1	1
92731	1710	influence on the binding	[influence on the binding]	0.0	4	1	1	1
92732	1710	nk/lgl cell	[NK/LGL cells]	0.0	2	1	1	1
92733	1710	GATA-1 mutant mouse	[GATA-1 mutant mouse]	0.0	3	1	1	1
92734	1710	factor nf-at	[factor NF-AT]	0.0	2	1	1	1
92735	1710	two other epitope	[two other epitopes]	0.0	3	1	1	1
92736	1710	ataxia-telangiectasia at	[ataxia-telangiectasia AT]	0.0	2	1	1	1
92737	1710	sera of ebv -negative individual	[sera of EBV -negative individuals]	0.0	5	1	1	1
92738	1710	ca2+ thapsigargin treatment	[Ca2+ thapsigargin treatment]	0.0	3	1	1	1
92739	1710	Functional analysis of thp-1 cell	[Functional analysis of THP-1 cells]	0.0	5	1	1	1
92740	1710	agent for aids	[agents for AIDS]	0.0	3	1	1	1
92741	1710	important mechanism of androgen insensitivity	[important mechanism of androgen insensitivity]	0.0	5	1	1	1
92742	1710	lead to adhesion onto the surface	[leading to adhesion onto the surface]	0.0	6	1	1	1
92743	1710	molecular analysis of 20q deletion	[molecular analysis of 20q deletions]	0.0	5	1	1	1
92744	1710	entamoeba	[Entamoeba]	0.0	1	1	1	1
92745	1710	igg level	[IgG levels]	0.0	2	1	1	1
92746	1710	QUK	[QUK]	0.0	1	1	1	1
92747	1710	disorder present in infancy	[disorder presenting in infancy]	0.0	4	1	1	1
92748	1710	R. h.,	[R. H.,]	0.0	2	1	1	1
92749	1710	nucleoprotein dna-binding activity	[nucleoprotein DNA-binding activities]	0.0	3	1	1	1
92750	1710	subsequent replacement	[subsequent replacement]	0.0	2	1	1	1
92751	1710	oxidoreductive regulation kappa b	[Oxidoreductive regulation kappa B]	0.0	4	1	1	1
92752	1710	6.04 fmol/10(6) cell respectively,	[6.04 fmol/10(6) cells respectively,]	0.0	4	1	1	1
92753	1710	well-standardized criteria, inactivation	[well-standardized criteria, inactivation]	0.0	3	1	1	1
92754	1710	mm) of ethanol treatment	[mM) of ethanol treatment]	0.0	4	1	1	1
92755	1710	evidence a result of distinct activation	[evidence a result of distinct activation]	0.0	6	1	1	1
92756	1710	class iii gene	[class III gene]	0.0	3	1	1	1
92757	1710	(mnl) of patient	[(MNL) of patients]	0.0	3	1	1	1
92758	1710	EBNA2 -dependent induction	[EBNA2 -dependent induction]	0.0	3	1	1	1
92759	1710	adhesion in umbilical vein cell	[adhesion in umbilical vein cells]	0.0	5	1	1	1
92760	1710	suggest a posttranscriptional mechanism	[suggesting a posttranscriptional mechanism]	0.0	4	1	1	1
92761	1710	erythroid marker expression	[erythroid markers expression]	0.0	3	1	1	1
92762	1710	kda polypeptide	[kDa polypeptides]	0.0	2	1	1	1
92763	1710	model accounting	[models accounting]	0.0	2	1	1	1
92764	1710	carboxylesterase gene	[carboxylesterase gene]	0.0	2	1	1	1
92765	1710	hiv-1 cell line	[HIV-1 cell lines]	0.0	3	1	1	1
92766	1710	use a human g-csfr mutant	[Using a human G-CSFR mutant]	0.0	5	1	1	1
92767	1710	T cell-specific negative element nre	[T cell-specific negative element NRE]	0.0	5	1	1	1
92768	1710	macrophage-colony	[macrophage-colony]	0.0	1	2	2	1
92769	1710	involve interaction between element	[involving interactions between elements]	0.0	4	1	1	1
92770	1710	mice,	[mice,]	0.0	1	1	1	1
92771	1710	regulation in U937 cell	[regulation in U937 cells]	0.0	4	1	1	1
92772	1710	adjacent kidney tissue	[adjacent kidney tissue]	0.0	3	1	1	1
92773	1710	site of group c infection	[site of group C infection]	0.0	5	2	2	1
92774	1710	status of current knowledge	[status of current knowledge]	0.0	4	1	1	1
92775	1710	receptor alpha il-2r alpha	[receptor alpha IL-2R alpha]	0.0	4	1	1	1
92776	1710	protein kinase c phorbol ester	[protein kinase C phorbol ester]	0.0	5	1	1	1
92777	1710	U1 cell by lps	[U1 cells by LPS]	0.0	4	1	1	1
92778	1710	transduction of RA receptor RAR alpha	[transduction of RA receptor RAR alpha]	0.0	6	1	1	1
92779	1710	monocyte mn superoxide dismutase	[monocyte Mn superoxide dismutase]	0.0	4	1	1	1
92780	1710	class ii-negative b cell line	[class II-negative B cell lines]	0.0	5	1	1	1
92781	1710	presence of three site	[presence of three sites]	0.0	4	1	1	1
92782	1710	tolerance in T lymphocyte	[tolerance in T lymphocytes]	0.0	4	1	1	1
92783	1710	hsp90 by a monoclonal antibody	[hsp90 by a monoclonal antibody]	0.0	5	1	1	1
92784	1710	complicated assay	[complicated assay]	0.0	2	1	1	1
92785	1710	immunoglobulin chain (igh) promoter	[immunoglobulin chain (IgH) promoter]	0.0	4	1	1	1
92786	1710	disorder a challenging problem	[disorders a challenging problem]	0.0	4	1	1	1
92787	1710	activity of a factor	[activity of an factor]	0.0	4	1	1	1
92788	1710	individual of particular major (mhc) haplotype	[individuals of particular major (MHC) haplotypes]	0.0	6	1	1	1
92789	1710	treatment with E2 alone	[treatment with E2 alone]	0.0	4	1	1	1
92790	1710	risk: cell reaction mcr grade	[risk: cell reaction MCR grade]	0.0	5	1	1	1
92791	1710	histocompatibility (MHC) class gene	[histocompatibility (MHC) class genes]	0.0	4	1	1	1
92792	1710	involvement of follicular dendritic cell	[involvement of follicular dendritic cells]	0.0	5	1	1	1
92793	1710	interleukin (il) 4 production	[interleukin (IL) 4 production]	0.0	4	1	1	1
92794	1710	actin motility	[actin motility]	0.0	2	1	1	1
92795	1710	property similar	[properties similar]	0.0	2	1	1	1
92796	1710	two day of treatment	[two days of treatment]	0.0	4	1	1	1
92797	1710	cbl-b	[Cbl-b]	0.0	1	1	1	1
92798	1710	histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	4	1	1	1
92799	1710	HIV long terminal	[HIV long terminal]	0.0	3	1	1	1
92800	1710	dysregulation immunodeficiency virus type hiv-1	[dysregulation immunodeficiency virus type HIV-1]	0.0	5	1	1	1
92801	1710	taf of 105 kda	[TAF of 105 kDa]	0.0	4	1	1	1
92802	1710	Ad5E1A	[Ad5E1A]	0.0	1	2	2	1
92803	1710	control b29 gene expression	[controlling B29 gene expression]	0.0	4	1	1	1
92804	1710	differential response creb	[differential response CREB]	0.0	3	1	1	1
92805	1710	transcriptional activation of 2 gene	[transcriptional activation of 2 gene]	0.0	5	1	1	1
92806	1710	harbor a beta-globin yeast chromosome transgene	[harboring a beta-globin yeast chromosome transgene]	0.0	6	1	1	1
92807	1710	differentiate agent acid	[differentiating agent acid]	0.0	3	1	1	1
92808	1710	GM-CSF cell line	[GM-CSF cell line]	0.0	3	1	1	1
92809	1710	pdbu cell	[PDBu cells]	0.0	2	1	1	1
92810	1710	gata element of the repeat site	[GATA elements of the repeat sites]	0.0	6	1	1	1
92811	1710	LT-betaR TNF receptor system	[LT-betaR TNF receptor systems]	0.0	4	1	1	1
92812	1710	proliferation in response iddm subject 8	[proliferation in response IDDM subjects 8]	0.0	6	1	1	1
92813	1710	expression of viral coreceptor	[expression of viral coreceptors]	0.0	4	1	1	1
92814	1710	thymidine kinase mrna expression	[thymidine kinase mRNA expression]	0.0	4	1	1	1
92815	1710	occur in cell of transplant recipient	[occurring in cells of transplant recipients]	0.0	6	1	1	1
92816	1710	activity of the bcl-2 promoter	[activity of the bcl-2 promoter]	0.0	5	1	1	1
92817	1710	response element in the promoter	[response elements in the promoter]	0.0	5	1	1	1
92818	1710	region of immunoglobulin (mhc) gene	[regions of immunoglobulin (MHC) genes]	0.0	5	1	1	1
92819	1710	failure of T cell	[failure of T cells]	0.0	4	1	1	1
92820	1710	effect of this immunosuppressive reagent	[effect of these immunosuppressive reagents]	0.0	5	1	1	1
92821	1710	gene exhibit	[gene exhibits]	0.0	2	1	1	1
92822	1710	function of closely related protein	[function of closely related proteins]	0.0	5	1	1	1
92823	1710	ligand-induced activation of smad protein	[ligand-induced activation of Smad proteins]	0.0	5	1	1	1
92824	1710	major histocompatibility class ii immunodeficiency	[major histocompatibility class II immunodeficiency]	0.0	5	1	1	1
92825	1710	more substitution 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[more substitutions 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	5	1	1	1
92826	1710	cd8(-) CD3 a critical role	[CD8(-) CD3 a critical role]	0.0	5	1	1	1
92827	1710	zap-70 responsiveness	[ZAP-70 responsiveness]	0.0	2	1	1	1
92828	1710	second weak inducible complex	[second weak inducible complex]	0.0	4	1	1	1
92829	1710	same set of word	[same set of words]	0.0	4	1	1	1
92830	1710	generation of response in human	[generation of responses in humans]	0.0	5	1	1	1
92831	1710	significantly favorable clinical course chi2	[significantly favorable clinical course chi2]	0.0	5	1	1	1
92832	1710	endometrium from woman	[endometrium from women]	0.0	3	1	1	1
92833	1710	immunodeficiency syndrome (aids) vaccine	[Immunodeficiency Syndrome (AIDS) vaccine]	0.0	4	1	1	1
92834	1710	co-operativity	[co-operativity]	0.0	1	1	1	1
92835	1710	dual effect on lymphocyte 1) inhibition	[dual effects on lymphocytes 1) inhibition]	0.0	6	1	1	1
92836	1710	many (bhlh) transcription factor	[many (bHLH) transcription factors]	0.0	4	1	1	1
92837	1710	induction in a line jurkat	[Induction in a line Jurkat]	0.0	5	1	1	1
92838	1710	factor nf-kb	[factor NF-kB]	0.0	2	1	1	1
92839	1710	function of intact USA	[function of intact USA]	0.0	4	1	1	1
92840	1710	phosphatidylinositol 3-kinase pi3-kinase	[phosphatidylinositol 3-kinase PI3-kinase]	0.0	3	1	1	1
92841	1710	circulate cell DC	[Circulating cells DC]	0.0	3	1	1	1
92842	1710	(mz) twin	[(MZ) twins]	0.0	2	1	1	1
92843	1710	adenovirus type e1a-region	[adenovirus type E1A-region]	0.0	3	1	1	1
92844	1710	20-methyl analogue of dihydroxyvitamin D3	[20-methyl analogues of dihydroxyvitamin D3]	0.0	5	1	1	1
92845	1710	change in cell gssg /gsh	[changes in cell GSSG /GSH]	0.0	5	1	1	1
92846	1710	healthy woman second	[healthy women second]	0.0	3	1	1	1
92847	1710	quiescent simian blood mononuclear cell	[quiescent simian blood mononuclear cells]	0.0	5	1	1	1
92848	1710	morphology by means	[morphology by means]	0.0	3	1	1	1
92849	1710	alternative "targets" eosinophil	[alternative "targets" eosinophils]	0.0	3	1	1	1
92850	1710	modification of lysine	[modification of lysine]	0.0	3	1	1	1
92851	1710	ifn-gamma-activated sequence-binding complex contain STAT3 alone	[IFN-gamma-activated sequence-binding complexes containing STAT3 alone]	0.0	6	1	1	1
92852	1710	member (irf) family	[member (IRF) family]	0.0	3	1	1	1
92853	1710	10 pair	[10 pairs]	0.0	2	1	1	1
92854	1710	capacity secondary to phosphatidylserine exposure	[capacity secondary to phosphatidylserine exposure]	0.0	5	1	1	1
92855	1710	primary human melanoma	[primary human melanomas]	0.0	3	1	1	1
92856	1710	tpo ut-7/gmt cell	[TPO UT-7/GMT cells]	0.0	3	1	1	1
92857	1710	MIP1 alpha nuclear protein	[MIP1 alpha nuclear protein]	0.0	4	1	1	1
92858	1710	negative fashion,	[negative fashion,]	0.0	2	1	1	1
92859	1710	expression on plasmid	[expression on plasmids]	0.0	3	1	1	1
92860	1710	JAK3 type signal pathway	[JAK3 Type signaling pathway]	0.0	4	1	1	1
92861	1710	sizes.	[sizes.]	0.0	1	1	1	1
92862	1710	alpha interferon	[alpha interferon]	0.0	2	1	1	1
92863	1710	alpha g2s	[alpha G2S]	0.0	2	1	1	1
92864	1710	concentration of aldosterone	[concentrations of aldosterone]	0.0	3	2	2	1
92865	1710	hl-60 cell with acid	[HL-60 cells with acid]	0.0	4	1	1	1
92866	1710	addition to IL-12	[addition to IL-12]	0.0	3	1	1	1
92867	1710	genetic correlation with class expression	[genetic correlation with class expression]	0.0	5	1	1	1
92868	1710	CAT mrna	[CAT mRNA]	0.0	2	1	1	1
92869	1710	interferon-gamma-induced intercellular adhesion molecule-1 gene transcription	[interferon-gamma-induced intercellular adhesion molecule-1 gene transcription]	0.0	6	1	1	1
92870	1710	repression of cytokine gene transcription	[repression of cytokine gene transcription]	0.0	5	1	1	1
92871	1710	hemopoietic stem cell	[hemopoietic stem cells]	0.0	3	1	1	1
92872	1710	RBA	[RBA]	0.0	1	1	1	1
92873	1710	highly potent inhibitor of replication	[highly potent inhibitor of replication]	0.0	5	1	1	1
92874	1710	activation of interleukin-1beta	[activation of interleukin-1beta]	0.0	3	1	1	1
92875	1710	myb site	[Myb sites]	0.0	2	1	1	1
92876	1710	proliferation in megakaryocyte	[proliferation in megakaryocytes]	0.0	3	1	1	1
92877	1710	genetic target for factor	[genetic target for factor]	0.0	4	1	1	1
92878	1710	RBP	[RBP]	0.0	1	1	1	1
92879	1710	expression of major cytokine	[expression of major cytokines]	0.0	4	1	1	1
92880	1710	nf-at transcription responsive	[NF-AT transcription responsive]	0.0	3	1	1	1
92881	1710	activation of zeta 2 globin promoter	[activation of zeta 2 globin promoter]	0.0	6	1	1	1
92882	1710	50% reduction,	[50% reduction,]	0.0	2	1	1	1
92883	1710	study in extra-renal, nonepithelial cell	[studies in extra-renal, nonepithelial cells]	0.0	5	1	1	1
92884	1710	pre-culture condition	[pre-culture conditions]	0.0	2	1	1	1
92885	1710	none of the enhancer-binding protein lef-1	[none of the enhancer-binding proteins LEF-1]	0.0	6	1	1	1
92886	1710	stimulation on human malignant melanoma	[Stimulation on human malignant melanomas]	0.0	5	1	1	1
92887	1710	effect of SR	[effect of SR]	0.0	3	1	1	1
92888	1710	interaction factor	[interaction factors]	0.0	2	1	1	1
92889	1710	mid-S	[mid-S]	0.0	1	1	1	1
92890	1710	use a sensitive blot assay	[using a sensitive blot assay]	0.0	5	1	1	1
92891	1710	suggest present in b cell	[suggesting present in B cells]	0.0	5	1	1	1
92892	1710	involve class I-restricted CTL	[involving class I-restricted CTLs]	0.0	4	1	1	1
92893	1710	use the potent pkc inhibitor ro	[using the potent PKC inhibitor Ro]	0.0	6	1	1	1
92894	1710	stage-specific regulation	[stage-specific regulation]	0.0	2	1	1	1
92895	1710	e-selectin induction.	[E-selectin induction.]	0.0	2	1	1	1
92896	1710	type of differentiation	[type of differentiation]	0.0	3	1	1	1
92897	1710	two signal cascade	[two signal cascades]	0.0	3	1	1	1
92898	1710	establish NF-kappaB as a proapoptotic factor	[establishing NF-kappaB as a proapoptotic factor]	0.0	6	1	1	1
92899	1710	human macrophage-colony stimulate factor promoter	[human macrophage-colony stimulating factor promoter]	0.0	5	1	1	1
92900	1710	75-kDa intracellular signal protein	[75-kDa intracellular signaling protein]	0.0	4	1	1	1
92901	1710	form of immunodeficiency SCID	[forms of immunodeficiency SCID]	0.0	4	1	1	1
92902	1710	completion	[completion]	0.0	1	1	1	1
92903	1710	cell surface antigene	[cell surface antigenes]	0.0	3	1	1	1
92904	1710	pyrimidine element 5'-pyctttg-3'	[pyrimidine elements 5'-PyCTTTG-3']	0.0	3	1	1	1
92905	1710	p45 subunit	[p45 subunit]	0.0	2	1	1	1
92906	1710	defect in production	[defects in production]	0.0	3	1	1	1
92907	1710	IARC cell	[IARC cells]	0.0	2	1	1	1
92908	1710	icam-1 surface protein in cell	[ICAM-1 surface protein in cells]	0.0	5	1	1	1
92909	1710	inhibition of this pathway	[inhibition of this pathway]	0.0	4	1	1	1
92910	1710	icp4	[ICP4]	0.0	1	2	2	1
92911	1710	tuberculosis df,	[tuberculosis df,]	0.0	2	1	1	1
92912	1710	only a small region	[Only a small region]	0.0	4	1	1	1
92913	1710	role in hepatitis b	[role in hepatitis B]	0.0	4	1	1	1
92914	1710	strike insensitivity of endothelium	[striking insensitivity of endothelium]	0.0	4	1	1	1
92915	1710	use recombinant p21ras	[using recombinant p21ras]	0.0	3	1	1	1
92916	1710	role in activation of interactions.	[role in activation of interactions.]	0.0	5	1	1	1
92917	1710	potent molecule	[potent molecule]	0.0	2	1	1	1
92918	1710	physical interaction between October factor	[physical interactions between Oct factors]	0.0	5	1	1	1
92919	1710	homotypic cell adhesion,	[homotypic cell adhesion,]	0.0	3	1	1	1
92920	1710	strong production of interleukin il-2	[strong production of interleukin IL-2]	0.0	5	1	1	1
92921	1710	underlie this association	[underlying this association]	0.0	3	1	1	1
92922	1710	minutes) to retinoic acid atra washed,	[minutes) to retinoic acid ATRA washed,]	0.0	6	1	1	1
92923	1710	function of Cbl	[function of Cbl]	0.0	3	1	1	1
92924	1710	interleukin-2 IL-2 receptor alpha chain	[interleukin-2 IL-2 receptor alpha chain]	0.0	5	1	1	1
92925	1710	1600 VDR by h	[1600 VDR by h]	0.0	4	1	1	1
92926	1710	hormonal interaction in patient	[Hormonal interactions in patients]	0.0	4	1	1	1
92927	1710	key mediator of neuroendocrine-immune interaction	[key mediators of neuroendocrine-immune interactions]	0.0	5	1	1	1
92928	1710	however, high microg/100 millileter at P;	[However, high microg/100 ml at h;]	0.0	6	1	1	1
92929	1710	nucleotide sequence to the domain	[nucleotide sequence to the domain]	0.0	5	1	1	1
92930	1710	regulatory element in b-cell line	[regulatory element in B-cell lines]	0.0	5	1	1	1
92931	1710	29-kDa fragment	[29-kDa fragment]	0.0	2	1	1	1
92932	1710	other gene on chromosome	[other genes on chromosome]	0.0	4	1	1	1
92933	1710	cytotoxic lymphocyte against peptide	[cytotoxic lymphocytes against peptides]	0.0	4	1	1	1
92934	1710	patient with preeclampsia before month	[patients with preeclampsia before months]	0.0	5	1	1	1
92935	1710	site around position	[sites around positions]	0.0	3	1	1	1
92936	1710	growth-affecting gene	[growth-affecting genes]	0.0	2	1	1	1
92937	1710	follow antigen stimulation	[following antigen stimulation]	0.0	3	1	1	1
92938	1710	treatment of u-937 cell	[Treatment of U-937 cells]	0.0	4	1	1	1
92939	1710	effect on the expression of lymphokine	[effects on the expression of lymphokines]	0.0	6	1	1	1
92940	1710	mibp1	[MIBP1]	0.0	1	1	1	1
92941	1710	oct-binding factor obf-1 a novel protein	[Oct-binding factor OBF-1 a novel protein]	0.0	6	1	1	1
92942	1710	gene for lipocalin	[gene for lipocalin]	0.0	3	1	1	1
92943	1710	synergism with Oct-2	[synergism with Oct-2]	0.0	3	1	1	1
92944	1710	Furthermore, expression	[Furthermore, expression]	0.0	2	3	3	1
92945	1710	fp microg	[FP microg]	0.0	2	1	1	1
92946	1710	system study the link	[system studying the link]	0.0	4	1	1	1
92947	1710	antibody of potential clinical significance.	[antibodies of potential clinical significance.]	0.0	5	1	1	1
92948	1710	basis for th1- gene expression	[basis for Th1- gene expression]	0.0	5	1	1	1
92949	1710	serotype belong to subgroup	[serotypes belonging to subgroups]	0.0	4	1	1	1
92950	1710	viral pathway	[viral pathway]	0.0	2	1	1	1
92951	1710	mrp14 macrophage migration inhibitory protein	[MRP14 Macrophage migration inhibitory protein]	0.0	5	1	1	1
92952	1710	RI-	[RI-]	0.0	1	1	1	1
92953	1710	-300 region	[-300 region]	0.0	2	1	1	1
92954	1710	inhibition of 90%.	[inhibition of 90%.]	0.0	3	1	1	1
92955	1710	packaging	[Packaging]	0.0	1	2	2	1
92956	1710	Interestingly, coincubation	[Interestingly, coincubation]	0.0	2	1	1	1
92957	1710	Third Monoclonal Workshop	[Third Monoclonal Workshop]	0.0	3	1	1	1
92958	1710	component of glutathione peroxidase gpx	[component of glutathione peroxidase GPX]	0.0	5	1	1	1
92959	1710	human microvessel endothelial cell hdmec	[human microvessel endothelial cells HDMEC]	0.0	5	1	1	1
92960	1710	antigen, cd4+ T	[antigen, CD4+ T]	0.0	3	1	1	1
92961	1710	patient with reversible airway obstruction	[patients with reversible airways obstruction]	0.0	5	1	1	1
92962	1710	(auc of 211 +/-	[(AUC of 211 +/-]	0.0	4	1	1	1
92963	1710	extract of pbmc	[extracts of PBMC]	0.0	3	1	1	1
92964	1710	population of 2 T cell	[population of 2 T cells]	0.0	5	1	1	1
92965	1710	low level of viral transcription	[Low levels of viral transcription]	0.0	5	1	1	1
92966	1710	exposure to level	[exposure to levels]	0.0	3	1	1	1
92967	1710	amount of the isoform	[amounts of the isoforms]	0.0	4	1	1	1
92968	1710	human peripheral cell PBMC	[human peripheral cells PBMC]	0.0	4	1	1	1
92969	1710	anti-tr55 antibody	[anti-TR55 antibody]	0.0	2	1	1	1
92970	1710	positive selection.	[positive selection.]	0.0	2	1	1	1
92971	1710	distal site (-579)	[distal site (-579)]	0.0	3	1	1	1
92972	1710	difference in the regulation hiv-1	[differences in the regulation HIV-1]	0.0	5	1	1	1
92973	1710	surface ag	[surface Ag]	0.0	2	1	1	1
92974	1710	alpha in the NH2-terminal 29 residue	[alpha in the NH2-terminal 29 residues]	0.0	6	1	1	1
92975	1710	two property	[two properties]	0.0	2	1	1	1
92976	1710	280 bp upstream	[280 bp upstream]	0.0	3	1	1	1
92977	1710	glucocorticoid on the rate	[glucocorticoids on the rate]	0.0	4	1	1	1
92978	1710	suppression of lai replication	[suppression of LAI replication]	0.0	4	1	1	1
92979	1710	interleukin IL-2 gene by glucocorticoid	[interleukin IL-2 gene by glucocorticoids]	0.0	5	1	1	1
92980	1710	patient aml (10 cases)	[patients AML (10 cases)]	0.0	4	1	1	1
92981	1710	activator protein-1 -dependent transcription	[activator protein-1 -dependent transcription]	0.0	4	1	1	1
92982	1710	nf-kappab activation of repeat LTR	[NF-kappaB activation of repeat LTR]	0.0	5	1	1	1
92983	1710	functional binding site	[functional binding sites]	0.0	3	1	1	1
92984	1710	gene expression by Pb	[gene expression by Pb]	0.0	4	1	1	1
92985	1710	essential element support the expression	[essential elements supporting the expression]	0.0	5	1	1	1
92986	1710	Addition of compounds, such as l-cystine	[Addition of compounds, such as L-cystine]	0.0	6	1	1	1
92987	1710	type Mo	[type Mo]	0.0	2	1	1	1
92988	1710	activate the b domain	[activating the B domain]	0.0	4	1	1	1
92989	1710	potent anti-proliferative effect	[potent anti-proliferative effects]	0.0	3	1	1	1
92990	1710	single mp dose	[single MP dose]	0.0	3	1	1	1
92991	1710	antagonization	[antagonization]	0.0	1	1	1	1
92992	1710	acute lymphoblastic leukemia chimera	[acute lymphoblastic leukemia chimera]	0.0	4	1	1	1
92993	1710	other monocytic/myeloid cell line	[other monocytic/myeloid cell lines]	0.0	4	1	1	1
92994	1710	aids-related effusion lymphoma	[AIDS-related effusion lymphoma]	0.0	3	1	1	1
92995	1710	significantly more glucocorticoid receptor	[significantly more glucocorticoid receptors]	0.0	4	1	1	1
92996	1710	effect of HU	[effects of HU]	0.0	3	1	1	1
92997	1710	sulphamethoxazole SMX	[sulphamethoxazole SMX]	0.0	2	1	1	1
92998	1710	expression of gene important	[expression of genes important]	0.0	4	1	1	1
92999	1710	antioxidant sensitive pathway distinct	[antioxidant sensitive pathway distinct]	0.0	4	1	1	1
93000	1710	soluble interleukin-2	[soluble interleukin-2]	0.0	2	1	1	1
93001	1710	association components.	[association components.]	0.0	2	1	1	1
93002	1710	role in ligand binding	[role in ligand binding]	0.0	4	1	1	1
93003	1710	expression of ah receptor	[Expression of Ah receptor]	0.0	4	1	1	1
93004	1710	participation of two cis-acting element	[participation of two cis-acting elements]	0.0	5	1	1	1
93005	1710	mimicry involve class CTL	[mimicry involving class CTLs]	0.0	4	1	1	1
93006	1710	enhancer in the human gene	[enhancer in the human gene]	0.0	5	1	1	1
93007	1710	human disease xeroderma pigmentosum XP	[human disease xeroderma pigmentosum XP]	0.0	5	1	1	1
93008	1710	determine specific gene activation	[determining specific gene activation]	0.0	4	1	1	1
93009	1710	unusual repeat of glutamine residue	[unusual repeat of glutamine residues]	0.0	5	1	1	1
93010	1710	underlie the translocation of nf-kappa b	[underlying the translocation of NF-kappa B]	0.0	6	1	1	1
93011	1710	mg bolus late	[mg bolus later)]	0.0	3	1	1	1
93012	1710	interestingly, a activator in cell line	[Interestingly, a activator in cell lines]	0.0	6	1	1	1
93013	1710	formation in the presence of NE	[formation in the presence of NE]	0.0	6	1	1	1
93014	1710	span the nucleotide	[spanning the nucleotides]	0.0	3	1	1	1
93015	1710	nf-kappab activation 1 terminal repeat	[NF-kappaB activation 1 terminal repeat]	0.0	5	1	1	1
93016	1710	shortly after engagement	[shortly after engagement]	0.0	3	1	1	1
93017	1710	suggest a mode of action	[suggesting a mode of action]	0.0	5	1	1	1
93018	1710	several other human cell	[several other human cells]	0.0	4	1	1	1
93019	1710	adult beta-globin expression	[adult beta-globin expression]	0.0	3	1	1	1
93020	1710	regulator of leukemia virus type	[regulator of leukemia virus type]	0.0	5	1	1	1
93021	1710	transcription 3 STAT3	[transcription 3 STAT3]	0.0	3	1	1	1
93022	1710	kappa B/Rel activity lymphocyte	[kappa B/Rel activity lymphocytes]	0.0	4	1	1	1
93023	1710	molecular analysis of human immunodeficiency virus	[Molecular analysis of human immunodeficiency virus]	0.0	6	1	1	1
93024	1710	subtle difference in the regulation	[subtle differences in the regulation]	0.0	5	1	1	1
93025	1710	Furthermore, level	[Furthermore, levels]	0.0	2	1	1	1
93026	1710	abnormality highlight putative loci relevant	[abnormalities highlighting putative loci relevant]	0.0	5	1	1	1
93027	1710	bacterial antigen	[bacterial antigens]	0.0	2	1	1	1
93028	1710	use a form	[using a form]	0.0	3	1	1	1
93029	1710	native-Western analysis	[native-Western analyses]	0.0	2	1	1	1
93030	1710	glucocorticoid-dependent stimulation	[glucocorticoid-dependent stimulation]	0.0	2	1	1	1
93031	1710	unique role of NFAT1	[unique role of NFAT1]	0.0	4	1	1	1
93032	1710	12-24 h	[12-24 h]	0.0	2	1	1	1
93033	1710	vertebrate regulation	[vertebrate regulation]	0.0	2	1	1	1
93034	1710	S2'	[S2']	0.0	1	1	1	1
93035	1710	hetero	[hetero]	0.0	1	1	1	1
93036	1710	blot analysis use anti-ERK antibody	[blot analysis using anti-ERK antibodies]	0.0	5	1	1	1
93037	1710	receptor concentration in mnl	[receptor concentrations in MNL]	0.0	4	1	1	1
93038	1710	relative resistance	[relative resistance]	0.0	2	1	1	1
93039	1710	binding site for nuclear protein	[binding sites for nuclear proteins]	0.0	5	1	1	1
93040	1710	two isoforms, a form, stat3beta	[two isoforms, a form, Stat3beta]	0.0	5	1	1	1
93041	1710	constitutive phosphorylation proteins; in	[constitutive phosphorylation proteins; in]	0.0	4	1	1	1
93042	1710	[3H]-dexamethasone	[[3H]-dexamethasone]	0.0	1	1	1	1
93043	1710	glucocorticoid receptor blocker RU43044	[glucocorticoid receptor blocker RU43044]	0.0	4	1	1	1
93044	1710	endothelial smooth muscle cell	[endothelial smooth muscle cells]	0.0	4	1	1	1
93045	1710	diagnostic value of 1,25-dihydroxyvitamin D3 determination	[diagnostic value of 1,25-dihydroxyvitamin D3 determination]	0.0	6	1	1	1
93046	1710	constitutive localization of NF-AT	[constitutive localization of NF-AT]	0.0	4	1	1	1
93047	1710	interaction with phospholipase Cy1	[interaction with phospholipase Cy1]	0.0	4	1	1	1
93048	1710	high salt concentration m nacl	[high salt concentrations M NaCl]	0.0	5	1	1	1
93049	1710	small effect	[small effect]	0.0	2	1	1	1
93050	1710	tyrosine stat1 protein 91 kda protein	[tyrosine stat1 proteins 91 kDa proteins]	0.0	6	1	1	1
93051	1710	follow CD4 oligomerization	[following CD4 oligomerization]	0.0	3	1	1	1
93052	1710	monocyte to m-csf	[monocytes to M-CSF]	0.0	3	1	1	1
93053	1710	diffuse cell subtype	[diffuse cell subtype]	0.0	3	1	1	1
93054	1710	response to antigen proceed	[response to antigen proceeds]	0.0	4	1	1	1
93055	1710	reversal from stimulation	[reversal from stimulation]	0.0	3	1	1	1
93056	1710	lps induction of the TNF-alpha promoter	[LPS induction of the TNF-alpha promoter]	0.0	6	1	1	1
93057	1710	detection in a patient by rt-pcr	[Detection in a patient by RT-PCR]	0.0	6	1	1	1
93058	1710	difference in value	[Differences in values]	0.0	3	1	1	1
93059	1710	approximately 90% inhibition	[approximately 90% inhibition]	0.0	3	1	1	1
93060	1710	monocyte -macrophage	[monocyte -macrophages]	0.0	2	1	1	1
93061	1710	use interferon gene transfer	[using interferon gene transfer]	0.0	4	1	1	1
93062	1710	combination of drug	[combinations of drugs]	0.0	3	1	1	1
93063	1710	induction of mrna	[induction of mRNA]	0.0	3	1	1	1
93064	1710	structure of the lymphoid tissue	[structure of the lymphoid tissues]	0.0	5	1	1	1
93065	1710	eightfold low amount a member	[eightfold lower amounts a member]	0.0	5	1	1	1
93066	1710	21-bp repeat element-1	[21-bp repeats element-1]	0.0	3	1	1	1
93067	1710	erythroid cell in lineage	[erythroid cells in lineage]	0.0	4	1	1	1
93068	1710	NFAT inhibitor	[NFAT inhibitor]	0.0	2	1	1	1
93069	1710	activation of the nfkappab	[activation of the NFkappaB]	0.0	4	1	1	1
93070	1710	phase of friend leukemia	[phase of Friend leukemia]	0.0	4	1	1	1
93071	1710	molecular mediator	[molecular mediator]	0.0	2	1	1	1
93072	1710	monocyte binding to human aortic cell	[monocyte binding to human aortic cells]	0.0	6	1	1	1
93073	1710	inducible, T enhancer of murine	[inducible, T enhancers of murine]	0.0	5	1	1	1
93074	1710	two multicopy enhancer motif	[Two multicopy enhancer motifs]	0.0	4	1	1	1
93075	1710	therapeutic use as anti-inflammatory agent	[therapeutic use as anti-inflammatory agents]	0.0	5	1	1	1
93076	1710	receptor density	[receptor density]	0.0	2	1	1	1
93077	1710	leukaemic transformation of b-cell precursor	[leukaemic transformation of B-cell precursors]	0.0	5	1	1	1
93078	1710	primary virus carrier	[primary virus carriers]	0.0	3	1	1	1
93079	1710	dysregulation of monocytic factor-kappa b	[Dysregulation of monocytic factor-kappa B]	0.0	5	1	1	1
93080	1710	analogous molecular framework signal	[analogous molecular framework signaling]	0.0	4	1	1	1
93081	1710	different ad2/ad12 e1a gene product	[different Ad2/Ad12 E1A gene products]	0.0	5	1	1	1
93082	1710	cytosolic glucocorticoid receptor	[cytosolic glucocorticoid receptors]	0.0	3	1	1	1
93083	1710	combination between ifi	[combinations between IFNs]	0.0	3	1	1	1
93084	1710	La mRNA	[La mRNA]	0.0	2	1	1	1
93085	1710	reduce component	[reducing components]	0.0	2	1	1	1
93086	1710	type er	[type ER]	0.0	2	1	1	1
93087	1710	mode of hla-dra expression	[modes of HLA-DRA expression]	0.0	4	1	1	1
93088	1710	Zn++ ion	[Zn++ ions]	0.0	2	1	1	1
93089	1710	tyrphostin	[tyrphostin]	0.0	1	1	1	1
93090	1710	agonist,	[agonist,]	0.0	1	1	1	1
93091	1710	various chronic rheumatic disease	[various chronic rheumatic diseases]	0.0	4	1	1	1
93092	1710	hiv-2 terminal repeat LTR	[HIV-2 terminal repeat LTR]	0.0	4	1	1	1
93093	1710	half-site for receptor/progesterone receptor pr binding	[half-sites for receptor/progesterone receptor PR binding]	0.0	6	1	1	1
93094	1710	status of the HS2 enhancer	[status of the HS2 enhancer]	0.0	5	1	1	1
93095	1710	24 healthy pregnant woman second	[24 healthy pregnant women second]	0.0	5	1	1	1
93096	1710	include peripheral cell from normal individual	[including peripheral cells from normal individuals]	0.0	6	1	1	1
93097	1710	large case-control study of disease	[large case-control studies of diseases]	0.0	5	1	1	1
93098	1710	clinical initiative	[clinical initiative]	0.0	2	1	1	1
93099	1710	bhrf1 protein with homology	[BHRF1 protein with homology]	0.0	4	1	1	1
93100	1710	new eosinophil cell line	[new eosinophil cell line]	0.0	4	1	1	1
93101	1710	role for icam-1	[roles for ICAM-1]	0.0	3	1	1	1
93102	1710	T cell factor-1	[T cell factor-1]	0.0	3	1	1	1
93103	1710	inducer of maturation	[inducer of maturation]	0.0	3	1	1	1
93104	1710	decreased, z-lll-h transcriptional activity	[decreased, Z-LLL-H transcriptional activity]	0.0	4	1	1	1
93105	1710	t-lymphotropic virus type model	[T-lymphotropic virus type model]	0.0	4	1	1	1
93106	1710	different developmental stage	[different developmental stages]	0.0	3	1	1	1
93107	1710	luciferase in this cell	[luciferase in these cells]	0.0	4	1	1	1
93108	1710	consolidation with chemotherapy	[consolidation with chemotherapy]	0.0	3	1	1	1
93109	1710	PMA -pha	[PMA -PHA]	0.0	2	1	1	1
93110	1710	two regions, dp1 -140 to -92	[Two regions, DP1 -140 to -92]	0.0	6	1	1	1
93111	1710	immunofluorescence from normal human tonsil	[immunofluorescence from normal human tonsils]	0.0	5	1	1	1
93112	1710	Nonimmunoglobulin	[Nonimmunoglobulin]	0.0	1	1	1	1
93113	1710	individual of particular (mhc) haplotype	[individuals of particular (MHC) haplotypes]	0.0	5	1	1	1
93114	1710	-insensitive asthma	[-insensitive asthma]	0.0	2	1	1	1
93115	1710	40 nucleotide	[40 nucleotides]	0.0	2	1	1	1
93116	1710	protect b cell from apoptosis	[protecting B cells from apoptosis]	0.0	5	1	1	1
93117	1710	1 peptide in jy25 cell	[1 peptide in JY25 cells]	0.0	5	1	1	1
93118	1710	GRE oligonucleotide drive chloramphenicol acetyl-transferase expression	[GRE oligonucleotides driving chloramphenicol acetyl-transferase expression]	0.0	6	1	1	1
93119	1710	report of a -like activity	[report of an -like activity]	0.0	5	1	1	1
93120	1710	glucocorticoid therapy in mononuclear leukocyte	[glucocorticoid therapy in mononuclear leukocytes]	0.0	5	1	1	1
93121	1710	neutralize anti- il-6 monoclonal antibody	[neutralizing anti- IL-6 monoclonal antibody]	0.0	5	1	1	1
93122	1710	such as dibutyryl camp	[such as dibutyryl cAMP]	0.0	4	1	1	1
93123	1710	expression of the exon of E1A	[expression of the exon of E1A]	0.0	6	1	1	1
93124	1710	also in individual	[also in individuals]	0.0	3	1	1	1
93125	1710	nfkb2 p52 form, induction	[NFKB2 p52 form, induction]	0.0	4	1	1	1
93126	1710	oxidative stress such as cytokine	[oxidative stress such as cytokines]	0.0	5	1	1	1
93127	1710	infection in most individual	[infection in most individuals]	0.0	4	1	1	1
93128	1710	alpha-globin chain	[alpha-globin chains]	0.0	2	1	1	1
93129	1710	significant factor in nf-kappab activation	[significant factor in NF-kappaB activation]	0.0	5	1	1	1
93130	1710	almost no effect	[almost no effect]	0.0	3	1	1	1
93131	1710	signal in primary erythroid precursor	[signaling in primary erythroid precursors]	0.0	5	1	1	1
93132	1710	gata/er factor	[GATA/ER factors]	0.0	2	1	1	1
93133	1710	malignant histiocytoma	[malignant histiocytoma]	0.0	2	1	1	1
93134	1710	adhesion of sulfoxide	[adhesion of sulfoxide]	0.0	3	1	1	1
93135	1710	increase infiltrate (p less than 0.02).	[increasing infiltrate (P less than 0.02).]	0.0	6	1	1	1
93136	1710	agent of human ehrlichiosis	[agent of human ehrlichiosis]	0.0	4	1	1	1
93137	1710	formation of oxygen intermediate after stress	[Formation of oxygen intermediates after stress]	0.0	6	1	1	1
93138	1710	subsequent challenge	[subsequent challenges]	0.0	2	1	1	1
93139	1710	addition to Oct2	[addition to Oct2]	0.0	3	1	1	1
93140	1710	assay ELISA with peptide	[assay ELISA with peptides]	0.0	4	1	1	1
93141	1710	exposure of human endothelial cell HAEC	[exposure of human endothelial cells HAEC]	0.0	6	1	1	1
93142	1710	mechanism govern proliferation	[mechanisms governing proliferation]	0.0	3	1	1	1
93143	1710	contrast, engagement of the tcr	[contrast, engagement of the TCR]	0.0	5	1	1	1
93144	1710	interleukin survival	[interleukin survival]	0.0	2	1	1	1
93145	1710	subsequent cell adhesion	[subsequent cell adhesion]	0.0	3	1	1	1
93146	1710	include the possibility	[including the possibility]	0.0	3	1	1	1
93147	1710	vitro model,	[vitro model,]	0.0	2	1	1	1
93148	1710	long-lasting tyrosine	[long-lasting tyrosine]	0.0	2	1	1	1
93149	1710	response to a prolonged load	[response to a prolonged load]	0.0	5	1	1	1
93150	1710	cellular component of atheroma	[cellular component of atheroma]	0.0	4	1	1	1
93151	1710	adhesion to huvec	[adhesion to HUVECs]	0.0	3	1	1	1
93152	1710	chimeric promoter upstream	[chimeric promoter upstream]	0.0	3	1	1	1
93153	1710	E-box-dependent bhlh homo-	[E-box-dependent bHLH homo-]	0.0	3	1	1	1
93154	1710	granulocyte factor granulocyte-macrophage colony-stimumulatelany-stg factor	[granulocyte factor granulocyte-macrophage colony-stimulating factor]	0.0	5	1	1	1
93155	1710	2 ng cell	[2 ng cells]	0.0	3	1	1	1
93156	1710	breakpoint.	[breakpoint.]	0.0	1	1	1	1
93157	1710	acid-synthesizing enzyme aldehyde dehydrogenase Aldh1	[acid-synthesizing enzyme aldehyde dehydrogenase Aldh1]	0.0	5	1	1	1
93158	1710	monocytic differentiation of hl-60	[monocytic differentiation of HL-60]	0.0	4	1	1	1
93159	1710	lack xist expression from three female	[lacking XIST expression from three females]	0.0	6	1	1	1
93160	1710	calcium -mobilize potency as vd	[calcium -mobilizing potency as VD]	0.0	5	1	1	1
93161	1710	function for Trident	[function for Trident]	0.0	3	1	1	1
93162	1710	probably compete for binding	[probably competing for binding]	0.0	4	1	1	1
93163	1710	autoimmunity in mouse	[autoimmunity in mice]	0.0	3	1	1	1
93164	1710	bacterial lysate use separation	[bacterial lysates using separation]	0.0	4	1	1	1
93165	1710	il-5 -produce cell line	[IL-5 -producing cell line]	0.0	4	1	1	1
93166	1710	CD19 gene	[CD19 gene]	0.0	2	1	1	1
93167	1710	subsequent determination of hiv-1 burden	[subsequent determination of HIV-1 burden]	0.0	5	1	1	1
93168	1710	5 region	[5 regions]	0.0	2	1	1	1
93169	1710	(tgf)-beta1	[(TGF)-beta1]	0.0	1	1	1	1
93170	1710	precursor at a stage	[precursor at an stage]	0.0	4	1	1	1
93171	1710	significant positive correlation	[significant positive correlation]	0.0	3	1	1	1
93172	1710	blot analysis use antibody against subunit	[Blot analysis using antibodies against subunits]	0.0	6	1	1	1
93173	1710	vitro, nuclear antigen	[vitro, nuclear antigens]	0.0	3	1	1	1
93174	1710	i-kappa b	[I-kappa B]	0.0	2	1	1	1
93175	1710	Protein	[Protein]	0.0	1	1	1	1
93176	1710	alone, provide evidence to the notion	[alone, providing evidence to the notion]	0.0	6	1	1	1
93177	1710	low-level constitutive expression	[low-level constitutive expression]	0.0	3	1	1	1
93178	1710	treat hl-60 cell	[treating HL-60 cells]	0.0	3	1	1	1
93179	1710	T cell of SL3	[T cells of SL3]	0.0	4	1	1	1
93180	1710	idiopathic bowel disease colitis	[idiopathic bowel diseases colitis]	0.0	4	1	1	1
93181	1710	cyto-differentiating effect on leukemia cell	[cyto-differentiating effects on leukemia cells]	0.0	5	1	1	1
93182	1710	normally menstruate woman	[normally menstruating women]	0.0	3	1	1	1
93183	1710	similar interaction	[similar interactions]	0.0	2	1	1	1
93184	1710	il-1 beta message level	[IL-1 beta message levels]	0.0	4	1	1	1
93185	1710	ga-binding protein alpha	[GA-binding protein alpha]	0.0	3	1	1	1
93186	1710	expression of NF-kappa b p65	[expression of NF-kappa B p65]	0.0	5	1	1	1
93187	1710	mature Burkitt lymphoma cell	[mature Burkitt lymphoma cell]	0.0	4	1	1	1
93188	1710	characterization of transactivation binding to element	[characterization of transactivation Binding to element]	0.0	6	1	1	1
93189	1710	exon span 45 kb of DNA	[exons spanning 45 kb of DNA]	0.0	6	1	1	1
93190	1710	protein (rap) 1 in platelet membrane	[protein (Rap) 1 in platelet membranes]	0.0	6	1	1	1
93191	1710	phase-dependent resistance	[phase-dependent resistance]	0.0	2	1	1	1
93192	1710	elucidation.	[elucidation.]	0.0	1	1	1	1
93193	1710	small colony	[small colonies]	0.0	2	1	1	1
93194	1710	chromosome abnormality with loss of 1p36	[Chromosome abnormalities with loss of 1p36]	0.0	6	1	1	1
93195	1710	extinction of b gene	[extinction of B genes]	0.0	4	1	1	1
93196	1710	Rb-	[Rb-]	0.0	1	1	1	1
93197	1710	complex in extract	[complexes in extracts]	0.0	3	1	1	1
93198	1710	probably compete with MNP-2	[probably competing with MNP-2]	0.0	4	1	1	1
93199	1710	most isolate	[most isolates]	0.0	2	1	1	1
93200	1710	expression of a hiv-1 repeat	[expression of a HIV-1 repeat]	0.0	5	1	1	1
93201	1710	surface profile	[surface profile]	0.0	2	1	1	1
93202	1710	normal x-chromosomes	[normal X-chromosomes]	0.0	2	1	1	1
93203	1710	RAR alpha -LBD	[RAR alpha -LBD]	0.0	3	1	1	1
93204	1710	receptor-mediated effect of androgen	[receptor-mediated effects of androgens]	0.0	4	1	1	1
93205	1710	peripheral-blood monocyte	[peripheral-blood monocytes]	0.0	2	1	1	1
93206	1710	function of the promoter	[function of the promoter]	0.0	4	1	1	1
93207	1710	influence of factor	[influence of factor]	0.0	3	1	1	1
93208	1710	possibly cell	[possibly cells]	0.0	2	1	1	1
93209	1710	mense of days'	[menses of days']	0.0	3	1	1	1
93210	1710	Ca(2+)-independent activity	[Ca(2+)-independent activity]	0.0	2	1	1	1
93211	1710	estrogen -binding site	[estrogen -binding sites]	0.0	3	1	1	1
93212	1710	Pollio,	[Pollio,]	0.0	1	1	1	1
93213	1710	region of IL-2 gene	[region of IL-2 gene]	0.0	4	1	1	1
93214	1710	indicate a involvement in the stage	[indicating a involvement in the stage]	0.0	6	1	1	1
93215	1710	significantly (p less than 0.025)	[significantly (P less than 0.025)]	0.0	5	1	1	1
93216	1710	formation of active complex	[formation of active complexes]	0.0	4	1	1	1
93217	1710	EBNA-2 -negative nuclear extract	[EBNA-2 -negative nuclear extracts]	0.0	4	1	1	1
93218	1710	complete elimination	[complete elimination]	0.0	2	1	1	1
93219	1710	cytokine by DC	[cytokines by DC]	0.0	3	1	1	1
93220	1710	pro-myelocytic leukaemia gene product	[pro-myelocytic leukaemia gene product]	0.0	4	1	1	1
93221	1710	high, thus establish a inverse relation	[high, thus establishing an inverse relation]	0.0	6	1	1	1
93222	1710	agonistic antibody	[agonistic antibody]	0.0	2	1	1	1
93223	1710	250 microm	[250 microM]	0.0	2	1	1	1
93224	1710	passage clinical strains.	[passage clinical strains.]	0.0	3	1	1	1
93225	1710	inhibit synthesis	[inhibiting synthesis]	0.0	2	1	1	1
93226	1710	immunodeficiency virus type-2 gene expression	[immunodeficiency virus type-2 gene expression]	0.0	5	1	1	1
93227	1710	coincide	[coinciding]	0.0	1	1	1	1
93228	1710	protein of b cell	[protein of B cells]	0.0	4	1	1	1
93229	1710	synthetic ceramide analog	[synthetic ceramide analog]	0.0	3	1	1	1
93230	1710	human HSs	[human HSs]	0.0	2	1	1	1
93231	1710	NF-kappa b activator	[NF-kappa B activator]	0.0	3	1	1	1
93232	1710	IL-3 factor complex include Stat1 alpha	[IL-3 factor complexes including Stat1 alpha]	0.0	6	1	1	1
93233	1710	hiv expression in u1 cell	[HIV expression in U1 cells]	0.0	5	1	1	1
93234	1710	involvement of ca2+	[Involvement of Ca2+]	0.0	3	1	1	1
93235	1710	evidence for a antioxidant sensitive pathway	[evidence for an antioxidant sensitive pathway]	0.0	6	1	1	1
93236	1710	nm at degree	[nM at degrees]	0.0	3	1	1	1
93237	1710	effect at concentration	[effect at concentrations]	0.0	3	1	1	1
93238	1710	binding of NF-kappa Bp65	[binding of NF-kappa Bp65]	0.0	4	1	1	1
93239	1710	murine tcf-1	[murine TCF-1]	0.0	2	1	1	1
93240	1710	monocyte to endothelium	[monocytes to endothelium]	0.0	3	1	1	1
93241	1710	growth factor HGF requirement	[growth factor HGF requirement]	0.0	4	1	1	1
93242	1710	variant translocation in leukaemia characterization	[variant translocation in leukaemia characterization]	0.0	5	1	1	1
93243	1710	translocation of hiv-1 tat	[translocation of HIV-1 Tat]	0.0	4	1	1	1
93244	1710	resistance against apoptosis	[resistance against apoptosis]	0.0	3	1	1	1
93245	1710	bone density in populations,	[bone density in populations,]	0.0	4	1	1	1
93246	1710	nuclei of the spinous layer	[nuclei of the spinous layer]	0.0	5	1	1	1
93247	1710	cross-linking on rheumatoid synovial cell	[Cross-linking on rheumatoid synovial cells]	0.0	5	1	1	1
93248	1710	confocal immunocytochemistry	[confocal immunocytochemistry]	0.0	2	1	1	1
93249	1710	such change in tr expression	[such changes in TR expression]	0.0	5	1	1	1
93250	1710	genomic sterol regulatory element	[genomic sterol regulatory element]	0.0	4	1	1	1
93251	1710	high metastatic capacity	[high metastatic capacity]	0.0	3	1	1	1
93252	1710	pmn-mediated lung injury	[PMN-mediated lung injury]	0.0	3	1	1	1
93253	1710	mitotic rate epithelia	[mitotic rate epithelia]	0.0	3	1	1	1
93254	1710	additive combination	[additive combination]	0.0	2	1	1	1
93255	1710	fulminant hepatitis	[fulminant hepatitis]	0.0	2	1	1	1
93256	1710	human immunodeficiency virus type negative factor	[Human immunodeficiency virus type negative factor]	0.0	6	1	1	1
93257	1710	thp-1 cell at clinically relevant doses.	[THP-1 cells at clinically relevant doses.]	0.0	6	1	1	1
93258	1710	observation from the authors' laboratory	[observations from the authors' laboratory]	0.0	5	1	1	1
93259	1710	human nfil3/e4bp4 cDNA	[human NFIL3/E4BP4 cDNA]	0.0	3	1	1	1
93260	1710	intracellular event lead	[intracellular events leading]	0.0	3	1	1	1
93261	1710	nuclear factor Kappa-B	[nuclear factor Kappa-B]	0.0	3	1	1	1
93262	1710	Res	[Res]	0.0	1	1	1	1
93263	1710	grow particularly in the initial stage	[growing particularly in the initial stages]	0.0	6	1	1	1
93264	1710	four complementation group	[Four complementation groups]	0.0	3	1	1	1
93265	1710	vdrnrar- vdre complex formation	[VDR-RXR- VDRE complex formation]	0.0	4	1	1	1
93266	1710	binding repressor	[binding repressor]	0.0	2	1	1	1
93267	1710	insert sequence (start at 532,	[inserting sequences (starting at 532,]	0.0	5	1	1	1
93268	1710	use hsv-1 recombinant virus	[using HSV-1 recombinant virus]	0.0	4	1	1	1
93269	1710	only in a context	[only in a context]	0.0	4	1	1	1
93270	1710	B cell-specific factor OTF-2	[B cell-specific factor OTF-2]	0.0	4	1	1	1
93271	1710	kD purified.	[kD purified.]	0.0	2	1	1	1
93272	1710	preincubation of cell with endotoxin lipopolysaccharide	[Preincubation of cells with endotoxin lipopolysaccharide]	0.0	6	1	1	1
93273	1710	carry transgene	[carrying transgenes]	0.0	2	1	1	1
93274	1710	expression pattern from the endogenous virus,	[expression patterns from the endogenous virus,]	0.0	6	1	1	1
93275	1710	induction in Jurkat t-cell	[induction in Jurkat T-cells]	0.0	4	1	1	1
93276	1710	effect on immediate-early gene expression	[effect on immediate-early gene expression]	0.0	5	1	1	1
93277	1710	11.8 fmol/mg protein of estrogen receptor	[11.8 fmol/mg protein of estrogen receptor]	0.0	6	1	1	1
93278	1710	SIE	[SIE]	0.0	1	1	1	1
93279	1710	tbp tfiib	[TBP TFIIB]	0.0	2	1	1	1
93280	1710	additional finding	[additional finding]	0.0	2	1	1	1
93281	1710	indicate aetiology	[indicating aetiologies]	0.0	2	1	1	1
93282	1710	further protein fraction	[further protein fraction]	0.0	3	1	1	1
93283	1710	region important, respectively, for recruitment	[regions important, respectively, for recruitment]	0.0	5	1	1	1
93284	1710	tgf-beta receptor profile	[TGF-beta receptor profile]	0.0	3	1	1	1
93285	1710	RA uf-1 cell toward granulocyte	[RA UF-1 cells toward granulocytes]	0.0	5	1	1	1
93286	1710	activator protein-binding site	[activator protein-binding site]	0.0	3	2	2	1
93287	1710	patient with the autoimmune disease	[patients with the autoimmune disease]	0.0	5	1	1	1
93288	1710	oestrogen receptor analysis in leukemia correlation	[Oestrogen receptor analysis in leukemia correlation]	0.0	6	1	1	1
93289	1710	respond to stimulation	[responding to stimulation]	0.0	3	1	1	1
93290	1710	one factor in macrophage	[one factors in macrophages]	0.0	4	1	1	1
93291	1710	protein to the promoter	[proteins to the promoter]	0.0	4	1	1	1
93292	1710	RA -resistant uf-1 cell	[RA -resistant UF-1 cells]	0.0	4	1	1	1
93293	1710	subdominant reactivities.	[subdominant reactivities.]	0.0	2	1	1	1
93294	1710	distal nuclear factor AP-1/Octamer UPS	[distal nuclear factor AP-1/Octamer UPS]	0.0	5	1	1	1
93295	1710	Arai,	[Arai,]	0.0	1	1	1	1
93296	1710	tax function	[Tax function]	0.0	2	1	1	1
93297	1710	site induce the expansion	[site inducing the expansion]	0.0	4	1	1	1
93298	1710	allelic family	[allelic families]	0.0	2	1	1	1
93299	1710	possibility of inactivation	[possibility of inactivation]	0.0	3	1	1	1
93300	1710	cortex in cord	[cortex in cord]	0.0	3	1	1	1
93301	1710	different icss	[different ICSs]	0.0	2	1	1	1
93302	1710	retrovirus-like particle by transmission electron microscopy	[retrovirus-like particles by transmission electron microscopy]	0.0	6	1	1	1
93303	1710	anti- TNF-alpha hiv-1 repeat	[anti- TNF-alpha HIV-1 repeat]	0.0	4	1	1	1
93304	1710	Long term	[Long term]	0.0	2	1	1	1
93305	1710	reading frame of hhv-6	[reading frames of HHV-6]	0.0	4	1	1	1
93306	1710	novel activator	[novel activator]	0.0	2	1	1	1
93307	1710	alcoholic extract form	[Alcoholic extracts form]	0.0	3	1	1	1
93308	1710	even after analysis take age-related change	[even after analysis taking age-related changes]	0.0	6	1	1	1
93309	1710	virus-exposed T	[virus-exposed T]	0.0	2	1	1	1
93310	1710	available mab	[available mAb]	0.0	2	1	1	1
93311	1710	chemoattract at relevant concentrations.	[chemoattractants at relevant concentrations.]	0.0	4	1	1	1
93312	1710	(i) c-fo transcript level	[(i) c-fos transcript levels]	0.0	4	1	1	1
93313	1710	distinct stages: a chronic	[distinct stages: a chronic]	0.0	4	1	1	1
93314	1710	slow rate	[slow rate]	0.0	2	1	1	1
93315	1710	gene expression from the Epstein-Barr virus	[gene expression from the Epstein-Barr virus]	0.0	6	1	1	1
93316	1710	exon 1-8	[exons 1-8]	0.0	2	1	1	1
93317	1710	normal regulation in b cell	[normal regulation in B cells]	0.0	5	1	1	1
93318	1710	evidence for a autosomal recessive form	[evidence for an autosomal recessive form]	0.0	6	1	1	1
93319	1710	receptor antagonist RU 38486	[receptor antagonist RU 38486]	0.0	4	1	1	1
93320	1710	pattern of induction	[pattern of induction]	0.0	3	1	1	1
93321	1710	expression of a immediate-early protein	[expression of a immediate-early protein]	0.0	5	1	1	1
93322	1710	insulin on the bind power	[insulin on the binding power]	0.0	5	1	1	1
93323	1710	inhibition by a combination	[Inhibition by a combination]	0.0	4	1	1	1
93324	1710	relation to prognostic features: clinical implications.	[relations to prognostic features: clinical implications.]	0.0	6	1	1	1
93325	1710	camp element binding protein	[cAMP element binding protein]	0.0	4	1	1	1
93326	1710	promoter region bp.	[promoter region bp.]	0.0	3	1	1	1
93327	1710	stimulation of cells.	[stimulation of cells.]	0.0	3	1	1	1
93328	1710	receptor on alveolar lymphocyte	[receptors on alveolar lymphocytes]	0.0	4	1	1	1
93329	1710	weak, nonproductive interaction	[weak, nonproductive interactions]	0.0	3	1	1	1
93330	1710	inhibition of GRalpha transactivation	[inhibition of GRalpha transactivation]	0.0	4	1	1	1
93331	1710	activator (stat) family	[activators (STAT) family]	0.0	3	1	1	1
93332	1710	extracellular signal converge in intracellular pathway	[extracellular signals converging in intracellular pathways]	0.0	6	1	1	1
93333	1710	protein network	[protein network]	0.0	2	1	1	1
93334	1710	lysosomal acid lipase lal	[lysosomal acid lipase LAL]	0.0	4	1	1	1
93335	1710	function in the system	[function in the system]	0.0	4	1	1	1
93336	1710	tax-expressing	[Tax-expressing]	0.0	1	1	1	1
93337	1710	mrna expression in thp-1 cell	[mRNA expression in THP-1 cells]	0.0	5	1	1	1
93338	1710	all-tran acid at dose	[all-trans acid at doses]	0.0	4	1	1	1
93339	1710	microg/ml)/mn2+ (50 microM) for h	[microg/ml)/Mn2+ (50 microM) for h]	0.0	5	1	1	1
93340	1710	normal epithelial cell	[normal epithelial cells]	0.0	3	1	1	1
93341	1710	after crosslinking of a ngf-r	[after crosslinking of a NGF-R]	0.0	5	1	1	1
93342	1710	two TcR delta transcript	[Two TcR delta transcripts]	0.0	4	1	1	1
93343	1710	units, p 0.01, young	[units, P 0.01, young]	0.0	4	1	1	1
93344	1710	potential in the treatment	[potential in the treatment]	0.0	4	1	1	1
93345	1710	interaction with other cytokine	[interactions with other cytokines]	0.0	4	1	1	1
93346	1710	potential for mutation expansion	[potential for mutation expansion]	0.0	4	1	1	1
93347	1710	selectively in extract	[selectively in extracts]	0.0	3	1	1	1
93348	1710	e1a-region	[E1A-region]	0.0	1	1	1	1
93349	1710	presence of granulocyte	[presence of granulocytes]	0.0	3	1	1	1
93350	1710	acid oxygenation	[acid oxygenation]	0.0	2	1	1	1
93351	1710	delta 5' region extend promoter region	[delta 5' regions extending promoter regions]	0.0	6	1	1	1
93352	1710	map kinase pathway	[MAP kinase pathway]	0.0	3	1	1	1
93353	1710	rest human lymphocyte	[resting human lymphocytes]	0.0	3	1	1	1
93354	1710	sequence contiguous	[sequences contiguous]	0.0	2	1	1	1
93355	1710	labile inhibitor.	[labile inhibitor.]	0.0	2	1	1	1
93356	1710	affect the expression of cytokine	[affecting the expression of cytokines]	0.0	5	1	1	1
93357	1710	mutagenesis of human HSs	[mutagenesis of human HSs]	0.0	4	1	1	1
93358	1710	cofactor for gata3	[cofactors for GATA3]	0.0	3	1	1	1
93359	1710	pkc substrate	[PKC substrates]	0.0	2	2	2	1
93360	1710	frequent use	[frequent use]	0.0	2	1	1	1
93361	1710	dq0302 molecule	[DQ0302 molecules]	0.0	2	1	1	1
93362	1710	enzyme level	[enzyme levels]	0.0	2	1	1	1
93363	1710	human umbilical vein cell huvec	[human umbilical vein cells HUVECs]	0.0	5	2	2	1
93364	1710	sequence at bp	[sequence at bp]	0.0	3	1	1	1
93365	1710	Thus, lps activation of human cell	[Thus, LPS activation of human cells]	0.0	6	1	1	1
93366	1710	ra-mediated type tgase up-regulation	[RA-mediated type TGase up-regulation]	0.0	4	1	1	1
93367	1710	exon 112	[exons 112]	0.0	2	1	1	1
93368	1710	factor-kappaB NFkappaB in memory	[factor-kappaB NFkappaB in memory]	0.0	4	1	1	1
93369	1710	fundamental insight into the mechanism	[fundamental insights into the mechanisms]	0.0	5	1	1	1
93370	1710	prolonged exposure of human endothelial cell	[prolonged exposure of human endothelial cells]	0.0	6	1	1	1
93371	1710	response to adenovirus antigen	[responses to adenovirus antigen]	0.0	4	1	1	1
93372	1710	membrane system	[membrane system]	0.0	2	1	1	1
93373	1710	patient with glomerulonephritis	[patients with glomerulonephritis]	0.0	3	1	1	1
93374	1710	antibody from carrier	[antibodies from carriers]	0.0	3	1	1	1
93375	1710	overexpression CN	[overexpression CN]	0.0	2	1	1	1
93376	1710	kappa b free	[kappa B free]	0.0	3	1	1	1
93377	1710	binding to the domain	[binding to the domain]	0.0	4	1	1	1
93378	1710	immortalization of progenitor	[immortalization of progenitors]	0.0	3	1	1	1
93379	1710	prototype stress hormone dexamethasone	[prototype stress hormones dexamethasone]	0.0	4	1	1	1
93380	1710	45-nucleotide sequence downstream element	[45-nucleotide sequence downstream element]	0.0	4	1	1	1
93381	1710	downregulation of ap-1	[Downregulation of AP-1]	0.0	3	1	1	1
93382	1710	transcription of important gene	[transcription of important genes]	0.0	4	1	1	1
93383	1710	consequence follow genetic alteration	[consequences following genetic alterations]	0.0	4	1	1	1
93384	1710	promyeloid	[promyeloid]	0.0	1	2	2	1
93385	1710	contribute to the expression	[contributing to the expression]	0.0	4	1	1	1
93386	1710	peripheral blood monocyte Mo	[peripheral blood monocytes Mo]	0.0	4	1	1	1
93387	1710	dose dexamethasone therapy	[dose dexamethasone therapy]	0.0	3	1	1	1
93388	1710	hl-60 leukemic cell	[HL-60 leukemic cells]	0.0	3	1	1	1
93389	1710	cell by cryptococcus neoforman	[cells by Cryptococcus neoformans]	0.0	4	1	1	1
93390	1710	T cell receptor gamma	[T cell receptor gamma]	0.0	4	1	1	1
93391	1710	cell of the innate system	[cells of the innate system]	0.0	5	1	1	1
93392	1710	fibrous histiocytoma 6, rhabdomyosarcoma	[fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	4	1	1	1
93393	1710	(il) production	[(IL) production]	0.0	2	1	1	1
93394	1710	basal t-cell lymphotropic virus type	[basal T-cell lymphotropic virus type]	0.0	5	1	1	1
93395	1710	transcriptional status	[transcriptional status]	0.0	2	1	1	1
93396	1710	transient transfection of HEK cell	[transient transfection of HEK cells]	0.0	5	1	1	1
93397	1710	multidrug resistance on 12-o-tetradecanoylphorbol-13-acetate	[multidrug resistance on 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
93398	1710	relatively early event	[relatively early events]	0.0	3	1	1	1
93399	1710	transactivation of the BMRF1 promoter	[transactivation of the BMRF1 promoter]	0.0	5	1	1	1
93400	1710	T helper (th2) cell	[T helper (Th2) cells]	0.0	4	1	1	1
93401	1710	recruitment to atherosclerotic lesion	[recruitment to atherosclerotic lesions]	0.0	4	1	1	1
93402	1710	mechanism regulate this inflammatory response	[mechanisms regulating this inflammatory response]	0.0	5	1	1	1
93403	1710	two principal ligand	[two principal ligands]	0.0	3	1	1	1
93404	1710	convert ligand-receptor interaction	[converting ligand-receptor interactions]	0.0	3	1	1	1
93405	1710	member of the IL-8 family	[members of the IL-8 family]	0.0	5	1	1	1
93406	1710	Nuclear extract from zymosan cell	[Nuclear extracts from zymosan cells]	0.0	5	1	1	1
93407	1710	secretion of matrix metalloproteinase	[secretion of matrix metalloproteinases]	0.0	4	1	1	1
93408	1710	activation of thymocyte	[Activation of thymocytes]	0.0	3	1	1	1
93409	1710	GASd/EBSd element	[GASd/EBSd element]	0.0	2	1	1	1
93410	1710	test of this hypothesis,	[test of this hypothesis,]	0.0	4	1	1	1
93411	1710	CRF patient fmol/10(6) cell respectively,	[CRF patients fmol/10(6) cells respectively,]	0.0	5	1	1	1
93412	1710	overexpression of udg in Saos cell	[Overexpression of UDG in Saos cells]	0.0	6	1	1	1
93413	1710	distinctive pattern of b activation	[distinctive patterns of B activation]	0.0	5	1	1	1
93414	1710	involve hiv	[involving HIV]	0.0	2	1	1	1
93415	1710	IL-2 independent cell line	[IL-2 independent cell lines]	0.0	4	1	1	1
93416	1710	human zeta 2 globin gene	[human zeta 2 globin gene]	0.0	5	1	1	1
93417	1710	proviral latency in certain cell	[proviral latency in certain cells]	0.0	5	1	1	1
93418	1710	phenylalanine 112	[phenylalanine 112]	0.0	2	1	1	1
93419	1710	structural basis for molecular mimicry	[structural basis for molecular mimicry]	0.0	5	1	1	1
93420	1710	somatic cell	[somatic cells]	0.0	2	1	1	1
93421	1710	long transcript	[long transcripts]	0.0	2	1	1	1
93422	1710	synergism during activation by the trans-activator	[Synergism during activation by the trans-activator]	0.0	6	1	1	1
93423	1710	(bp -88	[(bp -88]	0.0	2	1	1	1
93424	1710	hybridization analysis of a cDNA library	[hybridization analysis of a cDNA library]	0.0	6	1	1	1
93425	1710	understanding of the clinical action	[understanding of the clinical action]	0.0	5	1	1	1
93426	1710	cellular transcriptional nuclear factor-KB result	[cellular transcriptional nuclear factor-KB resulting]	0.0	5	1	1	1
93427	1710	dose of dexamethasone DEX	[doses of dexamethasone DEX]	0.0	4	1	1	1
93428	1710	similarity to binding site	[similarity to binding sites]	0.0	4	1	1	1
93429	1710	thus, type	[Thus, type]	0.0	2	1	1	1
93430	1710	92 base pair bp	[92 base pairs bp]	0.0	4	1	1	1
93431	1710	polyclonal process	[polyclonal process]	0.0	2	1	1	1
93432	1710	site for c/ebp protein	[sites for C/EBP proteins]	0.0	4	1	1	1
93433	1710	hiv- 1	[HIV- 1]	0.0	2	1	1	1
93434	1710	spleen, of the transgenic animals.	[spleen, of the transgenic animals.]	0.0	5	1	1	1
93435	1710	transcript from homologue	[transcripts from homologue]	0.0	3	1	1	1
93436	1710	exercise at 70% of oxygen uptake)	[exercises at 70% of oxygen uptake)]	0.0	6	1	1	1
93437	1710	weight of kilometer	[weights of kd]	0.0	3	1	1	1
93438	1710	pts; fluticasone: 2.4 1.55 pts)	[pts; fluticasone: 2.4 1.55 pts)]	0.0	5	1	1	1
93439	1710	retinoid differentiation therapy in leukemia	[Retinoid differentiation therapy in leukemia]	0.0	5	1	1	1
93440	1710	dnase 1 hypersensitivity extend	[DNase 1 hypersensitivity extending]	0.0	4	1	1	1
93441	1710	two such form	[two such forms]	0.0	3	1	1	1
93442	1710	acetylation of factor activity by interaction	[Acetylation of factor activity by interaction]	0.0	6	1	1	1
93443	1710	Aclacinomycin	[Aclacinomycin]	0.0	1	1	1	1
93444	1710	CBF beta-myh11	[CBF beta-MYH11]	0.0	2	1	1	1
93445	1710	IL-8 a factor	[IL-8 a factor]	0.0	3	1	1	1
93446	1710	two c-c chemokine gene	[two C-C chemokine genes]	0.0	4	1	1	1
93447	1710	disturbance of the system	[disturbances of the system]	0.0	4	1	1	1
93448	1710	complex group	[complex group]	0.0	2	1	1	1
93449	1710	MHC class homologous protein	[MHC class homologous proteins]	0.0	4	1	1	1
93450	1710	two activation domain at the N	[two activation domains at the N]	0.0	6	1	1	1
93451	1710	cell transcription factor pu.1	[cell transcription factor PU.1]	0.0	4	1	1	1
93452	1710	4-exon structure	[4-exon structure]	0.0	2	1	1	1
93453	1710	interleukin-13 gene	[interleukin-13 genes]	0.0	2	1	1	1
93454	1710	adult footprint	[adult footprint]	0.0	2	1	1	1
93455	1710	study 1,25-dihydroxyvitamin D3 in lymphocyte	[studying 1,25-dihydroxyvitamin D3 in lymphocytes]	0.0	5	1	1	1
93456	1710	acute blast	[acute blasts]	0.0	2	1	1	1
93457	1710	most study	[Most studies]	0.0	2	1	1	1
93458	1710	highly potent inducer	[highly potent inducers]	0.0	3	1	1	1
93459	1710	expression of gcrbeta	[expression of GCRbeta]	0.0	3	1	1	1
93460	1710	outgrowth of cell line	[outgrowth of cell lines]	0.0	4	1	1	1
93461	1710	two t-pll tumour	[two T-PLL tumours]	0.0	3	1	1	1
93462	1710	Stepwise deletion into the promoter	[Stepwise deletions into the promoter]	0.0	5	1	1	1
93463	1710	blood eosinophilia	[blood eosinophilia]	0.0	2	1	1	1
93464	1710	Sp100	[Sp100]	0.0	1	1	1	1
93465	1710	thereby amplify expression of own receptor	[thereby amplifying expression of own receptor]	0.0	6	1	1	1
93466	1710	A-CRF with renal insufficiency	[A-CRF with renal insufficiency]	0.0	4	1	1	1
93467	1710	nk-like cell line	[NK-like cell line]	0.0	3	1	1	1
93468	1710	higher-molecular-weight species of NFATc	[Higher-molecular-weight species of NFATc]	0.0	4	1	1	1
93469	1710	15 stimulation of activity,	[15 stimulation of activity,]	0.0	4	1	1	1
93470	1710	expression of FOS	[expression of FOS]	0.0	3	1	1	1
93471	1710	concentration (21.7	[concentration (21.7]	0.0	2	1	1	1
93472	1710	monitoring of the preeclamptic mother	[monitoring of the preeclamptic mother]	0.0	5	1	1	1
93473	1710	volunteer man	[volunteers men]	0.0	2	1	1	1
93474	1710	inhibitor include pervanadate	[inhibitors including pervanadate]	0.0	3	1	1	1
93475	1710	adaptive change in tr expression	[adaptive changes in TR expression]	0.0	5	1	1	1
93476	1710	patient with heart disease	[patients with heart disease]	0.0	4	3	3	1
93477	1710	metastatic capacity of cell	[metastatic capacity of cells]	0.0	4	1	1	1
93478	1710	cytoplasmic/nuclear signal	[cytoplasmic/nuclear signaling]	0.0	2	1	1	1
93479	1710	enhancement 1 replication	[Enhancement 1 replication]	0.0	3	1	1	1
93480	1710	tbp mutant defective	[TBP mutant defective]	0.0	3	1	1	1
93481	1710	normotensive volunteer with hypertension.	[normotensive volunteers with hypertension.]	0.0	4	1	1	1
93482	1710	(p 0.01) leukocyte adhesion in respect	[(P 0.01) leukocyte adhesion in respect]	0.0	6	1	1	1
93483	1710	Fas /Fas ligand interaction	[Fas /Fas ligand interaction]	0.0	4	1	1	1
93484	1710	general feature	[general features]	0.0	2	1	1	1
93485	1710	effect on nf-kappab transcription	[effects on NF-kappaB transcription]	0.0	4	1	1	1
93486	1710	oligo against hepatitis b virus hbv	[oligos against hepatitis B virus HBV]	0.0	6	1	1	1
93487	1710	t3 syndrome	[T3 syndrome]	0.0	2	1	1	1
93488	1710	change the relative proportion	[changing the relative proportions]	0.0	4	1	1	1
93489	1710	acute patient aml (10 cases)	[acute patients AML (10 cases)]	0.0	5	1	1	1
93490	1710	molecule this group	[molecule this group]	0.0	3	1	1	1
93491	1710	role of serine/threonine phosphatase	[role of serine/threonine phosphatases]	0.0	4	1	1	1
93492	1710	receptor in lymphocyte of subject	[receptors in lymphocytes of subjects]	0.0	5	1	1	1
93493	1710	Antisense inhibition	[Antisense inhibition]	0.0	2	1	1	1
93494	1710	simian virus region	[simian virus region]	0.0	3	1	1	1
93495	1710	protein bsap/pax5	[protein BSAP/PAX5]	0.0	2	1	1	1
93496	1710	pld pathway,	[PLD pathway,]	0.0	2	1	1	1
93497	1710	such as Oct-2A	[such as Oct-2A]	0.0	3	1	1	1
93498	1710	factor binding role in up-regulation	[factor binding role in up-regulation]	0.0	5	1	1	1
93499	1710	transcript encode	[transcript encoding]	0.0	2	1	1	1
93500	1710	increase in il-6 mrna level	[increase in IL-6 mRNA levels]	0.0	5	1	1	1
93501	1710	factor 1 macrophage colony-stimulating factor	[factor 1 macrophage colony-stimulating factor]	0.0	5	1	1	1
93502	1710	c-kit ligand	[c-kit ligand]	0.0	2	1	1	1
93503	1710	spectrum with vary potential	[spectrum with varying potential]	0.0	4	1	1	1
93504	1710	nonactive dna-binding fragment	[nonactive DNA-binding fragments]	0.0	3	1	1	1
93505	1710	inhibition of tlr2	[inhibition of TLR2]	0.0	3	1	1	1
93506	1710	approximately substnfkappab approximately substSpl2 substSp23	[approximately substNFkappaB approximately substSpl2 substSp23]	0.0	5	1	1	1
93507	1710	adhesion of T cell	[adhesion of T cells]	0.0	4	1	1	1
93508	1710	heat shock element-cont	[heat shock element-containing]	0.0	3	1	1	1
93509	1710	80% inhibition	[80% inhibition]	0.0	2	1	1	1
93510	1710	sensitive western blot assay	[sensitive Western blot assay]	0.0	4	1	1	1
93511	1710	express level of bcl-2	[expressing levels of Bcl-2]	0.0	4	1	1	1
93512	1710	Subcellular localization analysis	[Subcellular localization analysis]	0.0	3	1	1	1
93513	1710	human accessory cell	[human accessory cells]	0.0	3	1	1	1
93514	1710	cytokine receptors,	[cytokine receptors,]	0.0	2	1	1	1
93515	1710	cell cycle-dependent transcription	[cell cycle-dependent transcription]	0.0	3	1	1	1
93516	1710	other immunoglobulin chain gene	[other immunoglobulin chain genes]	0.0	4	1	1	1
93517	1710	sp1 cleavage during apoptosis	[SP1 cleavage during apoptosis]	0.0	4	1	1	1
93518	1710	potency synthetic glucocorticoid	[potency synthetic glucocorticoid]	0.0	3	1	1	1
93519	1710	activity of the gcr	[activity of the GCR]	0.0	4	1	1	1
93520	1710	protein repressor	[protein repressor]	0.0	2	1	1	1
93521	1710	anti-inflammatory sesquiterpene lactone	[anti-inflammatory sesquiterpene lactone]	0.0	3	1	1	1
93522	1710	complex class molecule on cell	[complex class molecules on cells]	0.0	5	1	1	1
93523	1710	cell line U 937	[cell line U 937]	0.0	4	1	1	1
93524	1710	subunit of pka	[subunit of PKA]	0.0	3	1	1	1
93525	1710	effect inhibition	[effects inhibition]	0.0	2	1	1	1
93526	1710	form of the ciita gene	[form of the CIITA gene]	0.0	5	1	1	1
93527	1710	mutant derivative of SIVmac239	[mutants derivative of SIVmac239]	0.0	4	1	1	1
93528	1710	effect on induction of nf-kappab	[effects on induction of NF-kappaB]	0.0	5	1	1	1
93529	1710	encode a protein protein	[encoding a protein protein]	0.0	4	1	1	1
93530	1710	interaction with the er	[interaction with the ER]	0.0	4	1	1	1
93531	1710	several methods, with eight pair	[several methods, with eight pairs]	0.0	5	1	1	1
93532	1710	link between differentiation arrest	[link between differentiation arrest]	0.0	4	1	1	1
93533	1710	organogenesis of secondary tissue	[organogenesis of secondary tissues]	0.0	4	1	1	1
93534	1710	expression of Egr	[expression of Egr]	0.0	3	1	1	1
93535	1710	TA1	[TA1]	0.0	1	1	1	1
93536	1710	retention of nuclear factor-kappaB	[retention of nuclear factor-kappaB]	0.0	4	1	1	1
93537	1710	erythrocyte-specific anhydrase	[erythrocyte-specific anhydrase]	0.0	2	1	1	1
93538	1710	lineage-specific factor	[lineage-specific factor]	0.0	2	1	1	1
93539	1710	successive stage of commitment	[successive stages of commitment]	0.0	4	1	1	1
93540	1710	correlation 1 alteration	[correlation 1 alterations]	0.0	3	1	1	1
93541	1710	approximately substnfkappab substSpl2 approximately substSp23	[approximately substNFkappaB substSpl2 approximately substSp23]	0.0	5	1	1	1
93542	1710	contain a binding site	[containing a binding site]	0.0	4	1	1	1
93543	1710	multiple isotype	[multiple isotypes]	0.0	2	1	1	1
93544	1710	related DNA bind specificity	[related DNA binding specificity]	0.0	4	1	1	1
93545	1710	increase in c-fo protein expression	[increases in c-Fos protein expression]	0.0	5	1	1	1
93546	1710	several type	[several types]	0.0	2	1	1	1
93547	1710	relation between density lipoprotein	[relation between density lipoprotein]	0.0	4	1	1	1
93548	1710	b lymphoma line	[B lymphoma line]	0.0	3	1	1	1
93549	1710	growth of myeloid leukemia cell	[growth of myeloid leukemia cells]	0.0	5	1	1	1
93550	1710	TAR	[TAR]	0.0	1	1	1	1
93551	1710	protein of the envelope membrane	[protein of the envelope membrane]	0.0	5	2	2	1
93552	1710	promoter region in the genome	[promoter region in the genome]	0.0	5	1	1	1
93553	1710	m-csf protein	[M-CSF protein]	0.0	2	1	1	1
93554	1710	redox stabilization	[redox stabilization]	0.0	2	1	1	1
93555	1710	hyperproduction	[hyperproduction]	0.0	1	1	1	1
93556	1710	allele-specific system	[allele-specific system]	0.0	2	1	1	1
93557	1710	binding to TCEd DNA	[binding to TCEd DNA]	0.0	4	1	1	1
93558	1710	together with the finding	[together with the findings]	0.0	4	1	1	1
93559	1710	two transcript isolation	[two transcripts isolation]	0.0	3	1	1	1
93560	1710	indicate heterogeneity within muscle	[indicating heterogeneity within muscle]	0.0	4	1	1	1
93561	1710	present in early infancy	[presenting in early infancy]	0.0	4	1	1	1
93562	1710	co-transfected IL-2 promoter	[co-transfected IL-2 promoter]	0.0	3	1	1	1
93563	1710	role in mitogen activation	[role in mitogen activation]	0.0	4	1	1	1
93564	1710	block translocation affect synthesis	[block translocation affecting synthesis]	0.0	4	1	1	1
93565	1710	human cell (dc)	[human cells (DC)]	0.0	3	1	1	1
93566	1710	Albuminemia indicator of platelet aggregation	[Albuminemia indicator of Platelet Aggregation]	0.0	5	1	1	1
93567	1710	fide p50/p65 heterodimer	[fide p50/p65 heterodimers]	0.0	3	1	1	1
93568	1710	interleukin IL2 production	[interleukin IL2 production]	0.0	3	1	1	1
93569	1710	thus, coupling of tcr-regulated ptk	[Thus, coupling of TCR-regulated PTKs]	0.0	5	1	1	1
93570	1710	pulse of tumor necrosis factor	[pulse of tumor necrosis factor]	0.0	5	1	1	1
93571	1710	regulation cytokine receptor expression by glucocorticoid	[Regulation cytokine receptor expression by glucocorticoids]	0.0	6	1	1	1
93572	1710	TCP	[TCP]	0.0	1	1	1	1
93573	1710	MIP-1 alpha protein (MNP) site	[MIP-1 alpha protein (MNP) site]	0.0	5	1	1	1
93574	1710	promoter (pp) repeat	[promoter (pp) repeat]	0.0	3	1	1	1
93575	1710	leukocyte from subject	[leukocytes from subjects]	0.0	3	1	1	1
93576	1710	Interestingly, residue	[Interestingly, residue]	0.0	2	1	1	1
93577	1710	redox status of protein	[redox status of proteins]	0.0	4	1	1	1
93578	1710	typical inflammation in RA	[typical inflammation in RA]	0.0	4	1	1	1
93579	1710	new complex with a mobility	[new complex with an mobility]	0.0	5	1	1	1
93580	1710	active mutant of pkc	[active mutant of PKC]	0.0	4	1	1	1
93581	1710	transgenic expression	[Transgenic expression]	0.0	2	1	1	1
93582	1710	ic50 value nmol/L) versus 9.5+/-0.3 nmol/L)	[IC50 values nmol/L) versus 9.5+/-0.3 nmol/L)]	0.0	6	1	1	1
93583	1710	lymphocyte of healthy person	[lymphocytes of healthy persons]	0.0	4	1	1	1
93584	1710	bat cd20-cat construct	[BAT CD20-CAT construct]	0.0	3	1	1	1
93585	1710	express the delta-opioid receptor	[expressing the delta-opioid receptor]	0.0	4	1	1	1
93586	1710	tryptophan photoproduct	[tryptophan photoproduct]	0.0	2	1	1	1
93587	1710	Minimal disease in acute myelogenous leukemia	[Minimal disease in acute myelogenous leukemia]	0.0	6	1	1	1
93588	1710	adhesion molecule-1 gene expression in cell	[adhesion molecule-1 gene expression in cells]	0.0	6	1	1	1
93589	1710	especially lymphoma with a large-cell component	[especially lymphomas with a large-cell component]	0.0	6	1	1	1
93590	1710	same transcription factor	[same transcription factor]	0.0	3	1	1	1
93591	1710	b manner	[B manner]	0.0	2	2	2	1
93592	1710	integration sites,	[integration sites,]	0.0	2	1	1	1
93593	1710	active woman	[active women]	0.0	2	1	1	1
93594	1710	47-kda	[47-kDa]	0.0	1	1	1	1
93595	1710	potent repressor	[potent repressor]	0.0	2	1	1	1
93596	1710	receptor hormone-binding domain binding	[receptor hormone-binding domain binding]	0.0	4	1	1	1
93597	1710	two RAR ligand	[two RAR ligands]	0.0	3	1	1	1
93598	1710	R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,	[R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,]	0.0	4	1	1	1
93599	1710	human glomerular mesangial cell	[human glomerular mesangial cells]	0.0	4	1	1	1
93600	1710	membrane-associated lymphotoxin on killer cell	[Membrane-associated lymphotoxin on killer cells]	0.0	5	1	1	1
93601	1710	Th1 development distinct from action	[Th1 development distinct from actions]	0.0	5	1	1	1
93602	1710	transactivation of a promoter construct	[transactivation of a promoter construct]	0.0	5	1	1	1
93603	1710	DNA breaks,	[DNA breaks,]	0.0	2	1	1	1
93604	1710	formation of the transactivate factor	[formation of the transactivating factor]	0.0	5	1	1	1
93605	1710	kinetic (high turnover) property	[kinetic (high turnover) properties]	0.0	4	1	1	1
93606	1710	IkappaB-alpha mrna transcript	[IkappaB-alpha mRNA transcripts]	0.0	3	1	1	1
93607	1710	platelet ca(2+)-atpase	[platelet Ca(2+)-ATPases]	0.0	2	1	1	1
93608	1710	immune state	[immune states]	0.0	2	1	1	1
93609	1710	Ser	[Ser]	0.0	1	1	1	1
93610	1710	immunosuppressive effect of SR	[immunosuppressive effect of SR]	0.0	4	1	1	1
93611	1710	cytomegalovirus immediate-early enhancer	[cytomegalovirus immediate-early enhancer]	0.0	3	1	1	1
93612	1710	transcriptional activity of promoter	[transcriptional activities of promoters]	0.0	4	1	1	1
93613	1710	information about the protein	[information about the proteins]	0.0	4	1	1	1
93614	1710	inhibition during the second A/R insult	[Inhibition during the second A/R insult]	0.0	6	1	1	1
93615	1710	loss of cp activity	[loss of Cp activity]	0.0	4	1	1	1
93616	1710	productive immunodeficiency virus type	[Productive immunodeficiency virus type]	0.0	4	1	1	1
93617	1710	description of a region responsive	[description of a region responsive]	0.0	5	1	1	1
93618	1710	mark a transformation effector site TES2	[marking a transformation effector site TES2]	0.0	6	1	1	1
93619	1710	non-hodgkin's lymphoma of type	[non-Hodgkin's lymphoma of type]	0.0	4	1	1	1
93620	1710	primary monocyte correlate	[primary monocytes correlating]	0.0	3	1	1	1
93621	1710	strong accumulation	[strong accumulation]	0.0	2	1	1	1
93622	1710	tyrosine phosphorylation to a extent, stat1	[Tyrosine phosphorylation to a extent, Stat1]	0.0	6	1	1	1
93623	1710	hiv infection of monocyte	[HIV infection of monocytes]	0.0	4	1	1	1
93624	1710	relevant promoter	[relevant promoter]	0.0	2	1	1	1
93625	1710	factor(s)	[factor(s).]	0.0	1	1	1	1
93626	1710	assembly of gene factor	[assembly of gene factor]	0.0	4	1	1	1
93627	1710	pathology such as disease	[pathologies such as disease]	0.0	4	1	1	1
93628	1710	high level of lucigenin-enhanced cl	[high levels of lucigenin-enhanced CL]	0.0	5	1	1	1
93629	1710	direct suppression of stat1 function	[Direct suppression of Stat1 function]	0.0	5	1	1	1
93630	1710	megakaryocyte-specific protein act as transcription factor	[megakaryocyte-specific proteins acting as transcription factors]	0.0	6	1	1	1
93631	1710	transduction into this hl-60r subclone	[transduction into this HL-60R subclone]	0.0	5	1	1	1
93632	1710	transporter	[transporter]	0.0	1	1	1	1
93633	1710	Functional analysis of sequence	[Functional analysis of sequences]	0.0	4	1	1	1
93634	1710	chromosome lp	[chromosome lp]	0.0	2	1	1	1
93635	1710	least in part dependent	[least in part dependent]	0.0	4	2	2	1
93636	1710	expression in response	[expression in response]	0.0	3	1	1	1
93637	1710	significant new insight	[significant new insights]	0.0	3	1	1	1
93638	1710	cellular sensitivity	[cellular sensitivity]	0.0	2	1	1	1
93639	1710	link between this two events.	[link between these two events.]	0.0	5	1	1	1
93640	1710	many important gene	[many important genes]	0.0	3	1	1	1
93641	1710	Northern (rna)	[Northern (RNA)]	0.0	2	1	1	1
93642	1710	isoproterenol ISO	[isoproterenol ISO]	0.0	2	1	1	1
93643	1710	suggest of functional importance	[suggesting of functional importance]	0.0	4	1	1	1
93644	1710	tyrosine kinase inhibition	[Tyrosine kinase inhibition]	0.0	3	1	1	1
93645	1710	subject (2.0	[subjects (2.0]	0.0	2	1	1	1
93646	1710	follow rearrangement involve band	[following rearrangements involving band]	0.0	4	1	1	1
93647	1710	patient with myelodysplastic syndrome	[patients with myelodysplastic syndromes]	0.0	4	1	1	1
93648	1710	discourse between the immune system	[discourse between the immune system]	0.0	5	1	1	1
93649	1710	blockade of prostaglandin	[blockade of prostaglandin]	0.0	3	1	1	1
93650	1710	consensus GRE	[consensus GRE]	0.0	2	1	1	1
93651	1710	subsequent translocation of stat3	[subsequent translocation of stat3]	0.0	4	2	2	1
93652	1710	involvement of cyclase in il-10 up-regulation	[Involvement of cyclase in IL-10 up-regulation]	0.0	6	1	1	1
93653	1710	number of hsv-specific clone	[number of HSV-specific clones]	0.0	4	1	1	1
93654	1710	effective therapy in the treatment	[effective therapy in the treatment]	0.0	5	1	1	1
93655	1710	form of cn kinase C transcription	[forms of CN kinase C transcription]	0.0	6	1	1	1
93656	1710	mobilization of only a fraction	[mobilization of only a fraction]	0.0	5	1	1	1
93657	1710	physiological trigger for the expression	[physiological trigger for the expression]	0.0	5	1	1	1
93658	1710	blood stem cell from leukemia	[blood stem cells from leukemia]	0.0	5	1	1	1
93659	1710	nf-kappab transcription in human cell	[NF-kappaB transcription in human cells]	0.0	5	1	1	1
93660	1710	elf-1 factor	[Elf-1 factor]	0.0	2	1	1	1
93661	1710	inhibitor kinase upstream	[inhibitors kinase upstream]	0.0	3	1	1	1
93662	1710	patient with anemia	[patients with anemia]	0.0	3	1	1	1
93663	1710	monocyte extract	[monocyte extracts]	0.0	2	1	1	1
93664	1710	E(gre) motif equally,	[E(gre) motifs equally,]	0.0	3	1	1	1
93665	1710	6 h from undetectable level	[6 h from undetectable levels]	0.0	5	1	1	1
93666	1710	few cell-specific steroid-regulated gene	[few cell-specific steroid-regulated genes]	0.0	4	1	1	1
93667	1710	CREB /atf-1 family	[CREB /ATF-1 family]	0.0	3	1	1	1
93668	1710	Specific translocation of [3H]calcitriol/VDR	[Specific translocation of [3H]calcitriol/VDR]	0.0	4	2	2	1
93669	1710	costimulation /anti-cd28 T lymphocyte with il-7	[Costimulation /anti-CD28 T lymphocytes with IL-7]	0.0	6	1	1	1
93670	1710	unde3r this circumstances,	[unde3r these circumstances,]	0.0	3	1	1	1
93671	1710	influx of ca2+	[influx of Ca2+]	0.0	3	1	1	1
93672	1710	24-hydroxylase mrna level	[24-hydroxylase mRNA levels]	0.0	3	2	2	1
93673	1710	transcription stat6 tyrosine phosphorylation	[transcription STAT6 tyrosine phosphorylation]	0.0	4	1	1	1
93674	1710	study in primate	[studies in primates]	0.0	3	1	1	1
93675	1710	property of the molecule in solution	[properties of the molecule in solution]	0.0	6	1	1	1
93676	1710	Ad2 gene	[Ad2 genes]	0.0	2	1	1	1
93677	1710	cell-specific stage-specific nuclear factor-DNA complex	[cell-specific stage-specific nuclear factor-DNA complexes]	0.0	5	1	1	1
93678	1710	marker for tcr gene	[markers for TCR genes]	0.0	4	1	1	1
93679	1710	evidence mediator during syphilis disease	[evidence mediators during syphilis disease]	0.0	5	1	1	1
93680	1710	4) clone	[4) clones]	0.0	2	1	1	1
93681	1710	result via activating region	[resulting via activating regions]	0.0	4	1	1	1
93682	1710	subgroup c	[subgroup C]	0.0	2	1	1	1
93683	1710	gata protein	[GATA proteins]	0.0	2	1	1	1
93684	1710	determine the rank order for corticosteroid	[determining the rank order for corticosteroids]	0.0	6	1	1	1
93685	1710	rrna encode gamma-globin delta-aminolevulinate synthase	[mRNAs encoding gamma-globin delta-aminolevulinate synthase]	0.0	5	1	1	1
93686	1710	pertussis toxin pathway	[pertussis toxin pathway]	0.0	3	1	1	1
93687	1710	mechanism underlie this response	[mechanism underlying this response]	0.0	4	1	1	1
93688	1710	heterogeneous population hematopoietic progenitor	[heterogeneous populations hematopoietic progenitors]	0.0	4	1	1	1
93689	1710	transcription analysis	[transcription analysis]	0.0	2	1	1	1
93690	1710	subgroup A	[subgroups A]	0.0	2	1	1	1
93691	1710	cortex function	[cortex function]	0.0	2	1	1	1
93692	1710	transfection of 2 line	[transfection of 2 lines]	0.0	4	1	1	1
93693	1710	activate transcription of gene	[activating transcription of genes]	0.0	4	1	1	1
93694	1710	heavy chain expression	[heavy chain expression]	0.0	3	1	1	1
93695	1710	human granzyme b expression	[human granzyme B expression]	0.0	4	1	1	1
93696	1710	copy of the AP-1 binding site	[copies of the AP-1 binding sites]	0.0	6	1	1	1
93697	1710	physiological substrate	[physiological substrates]	0.0	2	1	1	1
93698	1710	superaddition under condition	[superaddition under conditions]	0.0	3	1	1	1
93699	1710	il-9 tyrosine phosphorylation	[IL-9 tyrosine phosphorylation]	0.0	3	1	1	1
93700	1710	lineage- expression	[Lineage- expression]	0.0	2	1	1	1
93701	1710	extract of induced, Il-2	[extracts of induced, Il-2]	0.0	4	1	1	1
93702	1710	tnf-alpha protein comparable with level	[TNF-alpha protein comparable with levels]	0.0	5	1	1	1
93703	1710	one domain	[one domain]	0.0	2	1	1	1
93704	1710	frequency of il-12 th cell	[frequency of IL-12 Th cells]	0.0	5	1	1	1
93705	1710	human herpesvirus 6 strain gs	[human herpesvirus 6 strains GS]	0.0	5	1	1	1
93706	1710	10(-6) m rapid elevation	[10(-6) M rapid elevation]	0.0	4	1	1	1
93707	1710	hour of the membrane-bound enzyme	[hours of the membrane-bound enzyme]	0.0	5	1	1	1
93708	1710	develop from blood mononuclear precursor	[developing from blood mononuclear precursors]	0.0	5	1	1	1
93709	1710	expression level of AhR mrna	[expression levels of AhR mRNA]	0.0	5	1	1	1
93710	1710	TNF-alpha hiv-1 repeat	[TNF-alpha HIV-1 repeat]	0.0	3	1	1	1
93711	1710	trans-disulfide of thiamine	[trans-disulfide of thiamine]	0.0	3	1	1	1
93712	1710	block mab fibrinogen nf-kappa b activation	[Blocking mAbs fibrinogen NF-kappa B activation]	0.0	6	1	1	1
93713	1710	correct order	[correct order]	0.0	2	1	1	1
93714	1710	facilitate the collaboration of multiple protein	[facilitating the collaboration of multiple proteins]	0.0	6	1	1	1
93715	1710	TRH	[TRH]	0.0	1	1	1	1
93716	1710	granulopoiesis postnatally, typically die days.	[granulopoiesis postnatally, typically dying days.]	0.0	5	1	1	1
93717	1710	development of endometriosis	[development of endometriosis]	0.0	3	1	1	1
93718	1710	STAT activity	[STAT activity]	0.0	2	1	1	1
93719	1710	upstream nuclear factor-kappa b site	[upstream nuclear factor-kappa B site]	0.0	5	1	1	1
93720	1710	approximation	[approximation]	0.0	1	1	1	1
93721	1710	1,25-dihydroxyvitamin D3 a structurally distinct agent	[1,25-dihydroxyvitamin D3 a structurally distinct agent]	0.0	6	1	1	1
93722	1710	induction of MHC class	[induction of MHC class]	0.0	4	1	1	1
93723	1710	demonstration of cell growth	[Demonstration of cell growth]	0.0	4	1	1	1
93724	1710	(ltr) of hiv-1	[(LTR) of HIV-1]	0.0	3	1	1	1
93725	1710	leukemia virus enhancer core	[leukemia virus enhancer cores]	0.0	4	1	1	1
93726	1710	manifestation of the state	[manifestation of the state]	0.0	4	1	1	1
93727	1710	reduction in gm-csf mrna	[reduction in GM-CSF mRNA]	0.0	4	1	1	1
93728	1710	low level of IFN a	[low levels of IFN A]	0.0	5	1	1	1
93729	1710	role regulate the immune response	[role regulating the immune response]	0.0	5	1	1	1
93730	1710	nf-kappab regulation during ureteral obstruction	[NF-kappaB regulation during ureteral obstruction]	0.0	5	1	1	1
93731	1710	il-1 beta expression	[IL-1 beta expression]	0.0	3	1	1	1
93732	1710	keep strictly erythroid-specific property	[keeping strictly erythroid-specific properties]	0.0	4	1	1	1
93733	1710	activity of retinoic acid	[activities of retinoic acid]	0.0	4	1	1	1
93734	1710	13 control	[13 controls]	0.0	2	1	1	1
93735	1710	blood leucocyte of control subject	[blood leucocytes of control subjects]	0.0	5	1	1	1
93736	1710	growth fraction	[growth fraction]	0.0	2	1	1	1
93737	1710	novel, faster-migrating complex	[novel, faster-migrating complex]	0.0	3	1	1	1
93738	1710	biochemically distinct form of e2f	[biochemically distinct forms of E2F]	0.0	5	1	1	1
93739	1710	novel T negative element	[novel T negative element]	0.0	4	1	1	1
93740	1710	act on the prb protein	[acting on the pRB protein]	0.0	5	1	1	1
93741	1710	potential of the regulatory gene	[potential of the regulatory gene]	0.0	5	1	1	1
93742	1710	combination of retinoic acid	[combination of retinoic acid]	0.0	4	1	1	1
93743	1710	Jurkat T cell DNA	[Jurkat T cell DNA]	0.0	4	1	1	1
93744	1710	ifn-gamma receptor activation in CLL	[IFN-gamma receptor activation in CLL]	0.0	5	1	1	1
93745	1710	blood of healthy donor	[blood of healthy donors]	0.0	4	2	2	1
93746	1710	overexpression of beta-adrenergic receptor kinase peptide	[Overexpression of beta-adrenergic receptor kinase peptide]	0.0	6	1	1	1
93747	1710	type cell	[type cell]	0.0	2	1	1	1
93748	1710	bond rearrangement	[bond rearrangement]	0.0	2	1	1	1
93749	1710	patient 2.7)	[patients 2.7)]	0.0	2	1	1	1
93750	1710	knowledge concern	[knowledge concerning]	0.0	2	1	1	1
93751	1710	underlie endothelial cell activation	[underlying endothelial cell activation]	0.0	4	1	1	1
93752	1710	cd40-cd40	[CD40-CD40]	0.0	1	1	1	1
93753	1710	series of stimuli-specific pathway	[series of stimuli-specific pathways]	0.0	4	1	1	1
93754	1710	peroxisome receptor gamma	[peroxisome receptor gamma]	0.0	3	1	1	1
93755	1710	extract of jurkat cell	[extract of Jurkat cells]	0.0	4	1	1	1
93756	1710	almost the degree,	[almost the degree,]	0.0	3	1	1	1
93757	1710	term glucocorticoid treatment	[term glucocorticoid treatment]	0.0	3	1	1	1
93758	1710	Serum	[Serum]	0.0	1	1	1	1
93759	1710	Mole Cell. Biol. 8:5581-5587,	[Mol. Cell. Biol. 8:5581-5587,]	0.0	4	1	1	1
93760	1710	Biphasic control role	[Biphasic control role]	0.0	3	1	1	1
93761	1710	dose of parenteral corticosteroid	[doses of parenteral corticosteroid]	0.0	4	1	1	1
93762	1710	c-raf	[c-raf]	0.0	1	1	1	1
93763	1710	alpha-helice class ii MHC molecule	[alpha-helices class II MHC molecules]	0.0	5	1	1	1
93764	1710	hereditary hypercholesteremia of type	[hereditary hypercholesteremia of type]	0.0	4	1	1	1
93765	1710	thrombin generation by vascular muscle cell	[Thrombin generation by vascular muscle cells]	0.0	6	1	1	1
93766	1710	il-1beta from pbmc	[IL-1beta from PBMC]	0.0	3	1	1	1
93767	1710	immediate early cycle protein	[Immediate early cycle proteins]	0.0	4	1	1	1
93768	1710	divide cell	[dividing cells]	0.0	2	1	1	1
93769	1710	Intimate interaction	[Intimate interactions]	0.0	2	1	1	1
93770	1710	significant proliferation	[significant proliferation]	0.0	2	1	1	1
93771	1710	peak thrombin (pt)	[peak thrombin (PT)]	0.0	3	1	1	1
93772	1710	erythroid-specific cis-acting element include a gata-1	[erythroid-specific cis-acting elements including a GATA-1]	0.0	6	1	1	1
93773	1710	additional protein crossreactive	[additional proteins crossreactive]	0.0	3	1	1	1
93774	1710	encode a kb mrna	[encoding a kb mRNA]	0.0	4	1	1	1
93775	1710	apoptotic smooth muscle cell	[apoptotic smooth muscle cells]	0.0	4	1	1	1
93776	1710	influence human immunodeficiency virus replication	[influencing human immunodeficiency virus replication]	0.0	5	1	1	1
93777	1710	23 positive cells, respectively),	[23 positive cells, respectively),]	0.0	4	1	1	1
93778	1710	response in perennial allergic rhinitis	[Response in perennial allergic rhinitis]	0.0	5	1	1	1
93779	1710	three disease tuberculosis	[three diseases tuberculosis]	0.0	3	1	1	1
93780	1710	steroid hormone-resistant state	[steroid hormone-resistant state]	0.0	3	1	1	1
93781	1710	use tetanus toxoid hla-dr-restricted T lymphocyte	[Using tetanus toxoid HLA-DR-restricted T lymphocytes]	0.0	6	1	1	1
93782	1710	fragment of k protein	[fragment of K protein]	0.0	4	1	1	1
93783	1710	distinct set at different stage	[distinct sets at different stages]	0.0	5	1	1	1
93784	1710	picture in ischemia/reperfusion	[picture in ischemia/reperfusion]	0.0	3	1	1	1
93785	1710	differentiation potential of myeloid cell	[differentiation potential of myeloid cells]	0.0	5	1	1	1
93786	1710	glial cell in the system	[glial cells in the system]	0.0	5	1	1	1
93787	1710	follow treatment with all-tran acid atra	[following treatment with all-trans acid ATRA]	0.0	6	1	1	1
93788	1710	two nf-kappab site present	[two NF-kappaB sites present]	0.0	4	1	1	1
93789	1710	nf-kappab protein activity after particle exposure	[NF-kappaB protein activity after particle exposure]	0.0	6	1	1	1
93790	1710	potent effect in T cell	[potent effects in T cells]	0.0	5	1	1	1
93791	1710	repressive state of the gene	[repressive state of the gene]	0.0	5	1	1	1
93792	1710	state level of HLA-DRalpha	[state levels of HLA-DRalpha]	0.0	4	1	1	1
93793	1710	gp160 with cd4-igg	[gp160 with CD4-IgG]	0.0	3	1	1	1
93794	1710	cortivazol act in dex cell	[cortivazol acts in dex cells]	0.0	5	1	1	1
93795	1710	comparable amount	[comparable amounts]	0.0	2	1	1	1
93796	1710	regulation of adhesion molecule	[regulation of adhesion molecules]	0.0	4	1	1	1
93797	1710	regard to the allele	[regard to the allele]	0.0	4	1	1	1
93798	1710	LP individual	[LP individuals]	0.0	2	1	1	1
93799	1710	optimal induction	[optimal induction]	0.0	2	1	1	1
93800	1710	initial step in the transition	[initial step in the transition]	0.0	5	1	1	1
93801	1710	expression of IRF-1	[expression of IRF-1]	0.0	3	1	1	1
93802	1710	potential usefulness	[potential usefulness]	0.0	2	1	1	1
93803	1710	contrast, viral product	[contrast, viral products]	0.0	3	1	1	1
93804	1710	immunodeficiency disease XCID	[immunodeficiency disease XCID]	0.0	3	1	1	1
93805	1710	DM+, DO- T cell line	[DM+, DO- T cell line]	0.0	5	1	1	1
93806	1710	parasite survival strategy	[parasite survival strategies]	0.0	3	1	1	1
93807	1710	retinoic x receptor alpha	[retinoic X receptor alpha]	0.0	4	1	1	1
93808	1710	group),	[group),]	0.0	1	1	1	1
93809	1710	retinoblastoma susceptibility gene product	[retinoblastoma susceptibility gene product]	0.0	4	1	1	1
93810	1710	expression of antigen	[expression of antigens]	0.0	3	1	1	1
93811	1710	nos protein	[NOS protein]	0.0	2	1	1	1
93812	1710	e.g. interleukin-3 colony-stimumulatelany-stg factor	[e.g. interleukin-3 colony-stimulating factor]	0.0	4	1	1	1
93813	1710	concomitant effect	[concomitant effects]	0.0	2	1	1	1
93814	1710	affect several transcription factor	[affecting several transcription factors]	0.0	4	1	1	1
93815	1710	inhibition through induction	[inhibition through induction]	0.0	3	1	1	1
93816	1710	controls, peripheral blood cell	[controls, peripheral blood cell]	0.0	4	1	1	1
93817	1710	stable DCoH-HNF-1 alpha complex	[stable DCoH-HNF-1 alpha complex]	0.0	4	1	1	1
93818	1710	encode transcriptional transactivator	[encoding transcriptional transactivators]	0.0	3	1	1	1
93819	1710	suggest a specific role	[suggesting a specific role]	0.0	4	1	1	1
93820	1710	chemoattract at physiologically relevant concentrations.	[chemoattractants at physiologically relevant concentrations.]	0.0	5	1	1	1
93821	1710	single ubiquitous element	[single ubiquitous element]	0.0	3	1	1	1
93822	1710	target of alpha,25-dihydroxyvitamin D3	[targets of alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
93823	1710	link this two class	[linking these two classes]	0.0	4	1	1	1
93824	1710	constituent such as lps	[constituents such as LPS]	0.0	4	2	2	1
93825	1710	factor eklf activity	[factor EKLF activity]	0.0	3	1	1	1
93826	1710	membrane protein 1 of ebv	[membrane protein 1 of EBV]	0.0	5	1	1	1
93827	1710	lps factor-kappaB nf-kappab	[LPS factor-kappaB NF-kappaB]	0.0	3	1	1	1
93828	1710	renin -angiotensin	[renin -angiotensin]	0.0	2	1	1	1
93829	1710	hut-78 T	[Hut-78 T]	0.0	2	1	1	1
93830	1710	staining in the synovial lining	[staining in the synovial lining]	0.0	5	1	1	1
93831	1710	adult t-cell leukemia patient	[adult T-cell leukemia patients]	0.0	4	1	1	1
93832	1710	cell from cavity fluid	[cells from cavity fluids]	0.0	4	1	1	1
93833	1710	EBV Epstein-Barr region (EBER)	[EBV Epstein-Barr region (EBER)]	0.0	4	1	1	1
93834	1710	pathogenic process	[pathogenic processes]	0.0	2	1	1	1
93835	1710	use two approach	[using two approaches]	0.0	3	1	1	1
93836	1710	rhythm the inhibition	[rhythms the inhibition]	0.0	3	1	1	1
93837	1710	magnetic resonance spectroscopy	[magnetic resonance spectroscopy]	0.0	3	1	1	1
93838	1710	blast from patient with myeloid leukaemia	[blasts from patients with myeloid leukaemia]	0.0	6	1	1	1
93839	1710	level of creb protein	[level of CREB protein]	0.0	4	1	1	1
93840	1710	dissimilar oncogenicity of adenoviruse	[dissimilar oncogenicities of adenoviruses]	0.0	4	1	1	1
93841	1710	induction of the PML-RAR rrna	[induction of the PML-RAR mRNAs]	0.0	5	1	1	1
93842	1710	autoinduction	[autoinduction]	0.0	1	1	1	1
93843	1710	myd88 th1-developing	[MyD88 Th1-developing]	0.0	2	1	1	1
93844	1710	rapidly migrate b2 complex	[rapidly migrating B2 complex]	0.0	4	1	1	1
93845	1710	STAT1 nuclear import by delivery	[STAT1 nuclear import by delivery]	0.0	5	1	1	1
93846	1710	full-length il-1beta promoter	[full-length IL-1beta promoter]	0.0	3	1	1	1
93847	1710	infection interleukin-8 IL-8	[infection interleukin-8 IL-8]	0.0	3	1	1	1
93848	1710	mechanism of age-related lymphocyte dysfunction	[mechanisms of age-related lymphocyte dysfunction]	0.0	5	1	1	1
93849	1710	phorbol acetate nf-kappa b	[phorbol acetate NF-kappa B]	0.0	4	1	1	1
93850	1710	optimal concentration a inhibitor	[optimal concentration an inhibitor]	0.0	4	1	1	1
93851	1710	hormone-inducible trans-activate protein	[hormone-inducible trans-activating proteins]	0.0	3	1	1	1
93852	1710	inhibit generation of ldl putative molecule	[inhibiting generation of LDL putative molecule]	0.0	6	1	1	1
93853	1710	tnf production 5-fold	[TNF production 5-fold]	0.0	3	1	1	1
93854	1710	mip-1 alpha gene	[MIP-1 alpha gene]	0.0	3	1	1	1
93855	1710	kinetic of c-jun induction	[kinetics of c-jun induction]	0.0	4	1	1	1
93856	1710	level of interleukin 1 beta	[levels of interleukin 1 beta]	0.0	5	1	1	1
93857	1710	important b co-activator	[important B co-activator]	0.0	3	1	1	1
93858	1710	inhibition of b activity	[Inhibition of B activity]	0.0	4	1	1	1
93859	1710	rise to a proliferation	[rise to a proliferation]	0.0	4	1	1	1
93860	1710	preferential activity	[preferential activity]	0.0	2	1	1	1
93861	1710	patient with defect	[patients with defects]	0.0	3	1	1	1
93862	1710	three repeat element-1	[three repeats element-1]	0.0	3	1	1	1
93863	1710	uptake with chronic failure A-CRF	[uptake with chronic failure A-CRF]	0.0	5	1	1	1
93864	1710	interaction with receptor	[interaction with receptor]	0.0	3	1	1	1
93865	1710	use a heterologous promoter.	[using a heterologous promoter.]	0.0	4	1	1	1
93866	1710	disorders.	[disorders.]	0.0	1	1	1	1
93867	1710	multicopy basal enhancer motif	[multicopy basal enhancer motifs]	0.0	4	1	1	1
93868	1710	open reading frame ORF	[open reading frame ORF]	0.0	4	1	1	1
93869	1710	GM-CSF transcription	[GM-CSF transcription]	0.0	2	1	1	1
93870	1710	highly specific protein myeloperoxidase mpo	[highly specific proteins myeloperoxidase MPO]	0.0	5	1	1	1
93871	1710	sodium dodecyl sulfate-polyacrylamide	[sodium dodecyl sulfate-polyacrylamide]	0.0	3	2	2	1
93872	1710	trancriptional role in normal monocyte	[trancriptional roles in normal monocytes]	0.0	5	1	1	1
93873	1710	class major histocompatibility promoter	[class major histocompatibility promoters]	0.0	4	2	2	1
93874	1710	BCL-6 mutation evidence of hypermutation act	[BCL-6 mutations evidence of hypermutation acting]	0.0	6	1	1	1
93875	1710	efficient transcription initiation	[efficient transcription initiation]	0.0	3	1	1	1
93876	1710	involvement of stat5b	[involvement of STAT5b]	0.0	3	1	1	1
93877	1710	soluble antigen	[soluble antigen]	0.0	2	1	1	1
93878	1710	encode a chicken cytokine	[encoding a chicken cytokine]	0.0	4	1	1	1
93879	1710	particle by transmission electron microscopy em	[particles by transmission electron microscopy EM]	0.0	6	1	1	1
93880	1710	ethanol treatment in vitro	[ethanol treatment in vitro]	0.0	4	1	1	1
93881	1710	biologic function from proliferation	[biologic functions from proliferation]	0.0	4	1	1	1
93882	1710	T fashion	[T fashion]	0.0	2	1	1	1
93883	1710	immortalization tax mutant	[Immortalization Tax mutants]	0.0	3	1	1	1
93884	1710	maximal gene activation	[maximal gene activation]	0.0	3	1	1	1
93885	1710	motif-1	[motif-1]	0.0	1	1	1	1
93886	1710	signal for induction, PMA	[signals for induction, PMA]	0.0	4	1	1	1
93887	1710	Hungarian breast cancer patient	[Hungarian breast cancer patients]	0.0	4	1	1	1
93888	1710	oxidant-regulation of gene expression	[Oxidant-regulation of gene expression]	0.0	4	1	1	1
93889	1710	2.89 fmol/10(6) cell	[2.89 fmol/10(6) cells]	0.0	3	1	1	1
93890	1710	Positive regulation role of sites.	[Positive regulation role of sites.]	0.0	5	1	1	1
93891	1710	group A	[group A]	0.0	2	1	1	1
93892	1710	+/- ng/10(6) cells)	[+/- ng/10(6) cells)]	0.0	3	1	1	1
93893	1710	group C	[group C]	0.0	2	1	1	1
93894	1710	change in nf-il6beta expression	[changes in NF-IL6beta expression]	0.0	4	1	1	1
93895	1710	pu.1 DNA	[PU.1 DNA]	0.0	2	2	2	1
93896	1710	kappaB- Sp1 concatamer -295	[kappaB- Sp1 concatamers -295]	0.0	4	1	1	1
93897	1710	use synthetic ligand to acid receptor	[Using synthetic ligands to acid receptors]	0.0	6	1	1	1
93898	1710	group 1	[group 1]	0.0	2	1	1	1
93899	1710	role for PKCalpha	[role for PKCalpha]	0.0	3	1	1	1
93900	1710	evidence for a autosomal form	[evidence for an autosomal form]	0.0	5	1	1	1
93901	1710	form of suicide	[form of suicide]	0.0	3	1	1	1
93902	1710	egr-1 promoter-reporter construct	[EGR-1 promoter-reporter constructs]	0.0	3	1	1	1
93903	1710	effect on the lps synthesis	[effects on the LPS synthesis]	0.0	5	1	1	1
93904	1710	Ter cell from mouse	[Ter cells from mice]	0.0	4	1	1	1
93905	1710	mitogen for smooth muscle cell	[mitogen for smooth muscle cells]	0.0	5	1	1	1
93906	1710	specific RA receptor	[specific RA receptors]	0.0	3	1	1	1
93907	1710	control of insulin-gene activity	[control of insulin-gene activity]	0.0	4	1	1	1
93908	1710	vitro to macrophage mdm	[vitro to macrophages MDMs]	0.0	4	1	1	1
93909	1710	regulation of cd44 transcription	[regulation of CD44 transcription]	0.0	4	1	1	1
93910	1710	IL-10 signal transduction	[IL-10 signal transduction]	0.0	3	1	1	1
93911	1710	mapping with DNase i	[mapping with DNase I]	0.0	4	1	1	1
93912	1710	erythroid delta-aminolevulinate synthase	[erythroid delta-aminolevulinate synthase]	0.0	3	1	1	1
93913	1710	mbp release of il-8	[MBP release of IL-8]	0.0	4	1	1	1
93914	1710	include asthma	[including asthma]	0.0	2	1	1	1
93915	1710	myocardial infarction AMI	[myocardial infarction AMI]	0.0	3	1	1	1
93916	1710	chemically-reactive metabolite	[chemically-reactive metabolites]	0.0	2	1	1	1
93917	1710	progesterone monoclonal antibody mPRI	[progesterone monoclonal antibody mPRI]	0.0	4	1	1	1
93918	1710	fluorescence in-situ	[fluorescence in-situ]	0.0	2	1	1	1
93919	1710	general activator	[general activators]	0.0	2	1	1	1
93920	1710	Tec	[Tec]	0.0	1	1	1	1
93921	1710	clonogenetic calf serum efcs culture	[clonogenetic calf serum (FCS+) culture]	0.0	5	1	1	1
93922	1710	development in Hox11 mouse	[development in Hox11 mice]	0.0	4	1	1	1
93923	1710	selection marker in es cell	[selection marker in ES cells]	0.0	5	1	1	1
93924	1710	conjugation of ubiquitin to the precursor	[conjugation of ubiquitin to the precursor]	0.0	6	1	1	1
93925	1710	A6H mAb	[A6H mAb]	0.0	2	1	1	1
93926	1710	transcriptional activation of the terminal repeat	[transcriptional activation of the terminal repeat]	0.0	6	1	1	1
93927	1710	control mechanism in response	[control mechanisms in response]	0.0	4	1	1	1
93928	1710	CAT reporter gene construct	[CAT reporter gene constructs]	0.0	4	1	1	1
93929	1710	pcd41 sequence	[pCD41 sequence]	0.0	2	1	1	1
93930	1710	alteration responsible	[alterations responsible]	0.0	2	1	1	1
93931	1710	only individual	[only individuals]	0.0	2	1	1	1
93932	1710	cd20+	[CD20+]	0.0	1	1	1	1
93933	1710	identification of a component	[Identification of a component]	0.0	4	1	1	1
93934	1710	ebna-2 type	[EBNA-2 type]	0.0	2	1	1	1
93935	1710	promoter region of 1056 bp.	[promoter region of 1056 bp.]	0.0	5	1	1	1
93936	1710	Biochemical analysis by blotting of population	[Biochemical analysis by blotting of populations]	0.0	6	1	1	1
93937	1710	nf-at accumulation	[NF-AT accumulation]	0.0	2	1	1	1
93938	1710	monocyte-like (U937) cell	[monocyte-like (U937) cells]	0.0	3	1	1	1
93939	1710	MHC class transactivator CIITA	[MHC class transactivator CIITA]	0.0	4	2	2	1
93940	1710	80% treatment	[80% treatment]	0.0	2	1	1	1
93941	1710	concentration of immunodominant native peptide	[concentrations of immunodominant native peptide]	0.0	5	1	1	1
93942	1710	kda/65 kda	[kDa/65 kDa]	0.0	2	1	1	1
93943	1710	nuclear differentiation antigen	[nuclear differentiation antigen]	0.0	3	1	1	1
93944	1710	repressor ZEB	[repressor ZEB]	0.0	2	1	1	1
93945	1710	granulocyte/macrophage-colony stimulate factor	[granulocyte/macrophage-colony stimulating factor]	0.0	3	1	1	1
93946	1710	recipient of the drug.	[recipients of the drug.]	0.0	4	1	1	1
93947	1710	cd40l T lymphocyte	[CD40L T lymphocytes]	0.0	3	1	1	1
93948	1710	glucocorticoid responsiveness of human leukocyte HML	[glucocorticoid responsiveness of human leukocytes HML]	0.0	6	1	1	1
93949	1710	lymphocyte in active sle	[lymphocytes in active SLE]	0.0	4	1	1	1
93950	1710	human blood T lymphocyte PBL	[human blood T lymphocytes PBL]	0.0	5	1	1	1
93951	1710	r24 increase	[R24 increases]	0.0	2	1	1	1
93952	1710	recovery,	[recovery,]	0.0	1	1	1	1
93953	1710	recovery.	[recovery.]	0.0	1	1	1	1
93954	1710	11-base-pair DNA sequence motif	[11-base-pair DNA sequence motif]	0.0	4	1	1	1
93955	1710	production of cytokine in monocyte	[production of cytokines in monocytes]	0.0	5	1	1	1
93956	1710	variation in blood cell in individual	[variation in blood cells in individuals]	0.0	6	1	1	1
93957	1710	IkappaB alpha a inhibitor	[IkappaB alpha a inhibitor]	0.0	4	1	1	1
93958	1710	-replicative cycle	[-replicative cycle]	0.0	2	1	1	1
93959	1710	increase in nf-kappab2 p52	[increase in NF-kappaB2 p52]	0.0	4	1	1	1
93960	1710	case of leukemia aml	[cases of leukemia AML]	0.0	4	1	1	1
93961	1710	120-amino-acid n-terminal motif	[120-amino-acid N-terminal motif]	0.0	3	1	1	1
93962	1710	quantification of expression during differentiation	[quantification of expression during differentiation]	0.0	5	1	1	1
93963	1710	dependent adhesion umbilical vein cell	[dependent adhesion umbilical vein cells]	0.0	5	1	1	1
93964	1710	il-5 mechanism	[IL-5 mechanisms]	0.0	2	1	1	1
93965	1710	clinically significant class lymphoma plasmacytoid	[clinically significant class lymphoma plasmacytoid]	0.0	5	1	1	1
93966	1710	possible immunological variable	[possible immunological variable]	0.0	3	1	1	1
93967	1710	possible clinical use	[possible clinical use]	0.0	3	1	1	1
93968	1710	Ad12 E1A domain	[Ad12 E1A domains]	0.0	3	1	1	1
93969	1710	gene interleukin-2	[gene interleukin-2]	0.0	2	1	1	1
93970	1710	constitutive expression of CD20	[constitutive expression of CD20]	0.0	4	1	1	1
93971	1710	beta-globin yeast chromosome transgene	[beta-globin yeast chromosome transgene]	0.0	4	1	1	1
93972	1710	modes, like induction, superinfection	[modes, like induction, superinfection]	0.0	4	1	1	1
93973	1710	65-year-old woman	[65-year-old woman]	0.0	2	1	1	1
93974	1710	indicate a subtle effect.	[indicating a subtle effect.]	0.0	4	1	1	1
93975	1710	chi b complex	[chi B complexes]	0.0	3	1	1	1
93976	1710	first visit, within two week	[first visit, within two weeks]	0.0	5	1	1	1
93977	1710	only 10(-12) g/g	[only 10(-12) g/g]	0.0	3	1	1	1
93978	1710	insulin a glycolipid	[insulin a glycolipid]	0.0	3	1	1	1
93979	1710	10(-6) mol/L	[10(-6) mol/L]	0.0	2	1	1	1
93980	1710	group of 166 healthy female	[group of 166 healthy females]	0.0	5	1	1	1
93981	1710	PMA inducibility	[PMA inducibility]	0.0	2	1	1	1
93982	1710	enhancer with spacings.	[enhancers with spacings.]	0.0	3	1	1	1
93983	1710	alter weak, interaction to interactions.	[altering weak, interactions to interactions.]	0.0	5	1	1	1
93984	1710	b chemokine a inducer	[B chemokine a inducer]	0.0	4	1	1	1
93985	1710	mechanism of the tnf gene	[mechanisms of the TNF genes]	0.0	5	1	1	1
93986	1710	sp-b21	[SP-B21]	0.0	1	1	1	1
93987	1710	lysp100 domain	[LYSP100 domains]	0.0	2	1	1	1
93988	1710	different contribution in the expression	[different contribution in the expression]	0.0	5	1	1	1
93989	1710	block this element	[blocking these elements]	0.0	3	1	1	1
93990	1710	influence by influenza virus-exposed T cell	[Influence by influenza virus-exposed T cells]	0.0	6	1	1	1
93991	1710	endogenous repeat transcriptional activity	[endogenous repeat transcriptional activity]	0.0	4	1	1	1
93992	1710	suppress nervous system	[suppressing nervous system]	0.0	3	1	1	1
93993	1710	striking heterogeneity of development	[striking heterogeneity of development]	0.0	4	1	1	1
93994	1710	human MHC hla-dra class	[human MHC HLA-DRA class]	0.0	4	1	1	1
93995	1710	il-4 production in atopic th2 cell	[IL-4 production in atopic Th2 cells]	0.0	6	1	1	1
93996	1710	molecular protein sp	[molecular proteins SP]	0.0	3	1	1	1
93997	1710	clinical investigation.	[clinical investigation.]	0.0	2	1	1	1
93998	1710	activity at the time	[activity at the time]	0.0	4	1	1	1
93999	1710	lymphocyte of 24 healthy woman	[lymphocytes of 24 healthy women]	0.0	5	1	1	1
94000	1710	gh (except in patient	[GH (except in patient]	0.0	4	1	1	1
94001	1710	14 subject	[14 subjects]	0.0	2	1	1	1
94002	1710	repressor of shock gene	[repressor of shock genes]	0.0	4	1	1	1
94003	1710	normal epidermal keratinocyte	[normal epidermal keratinocytes]	0.0	3	1	1	1
94004	1710	v3 loop antibody antibody	[V3 loop antibody antibody]	0.0	4	1	1	1
94005	1710	THR beta	[THR beta]	0.0	2	1	1	1
94006	1710	particles, integration	[particles, integration]	0.0	2	1	1	1
94007	1710	complete resistance	[complete resistance]	0.0	2	1	1	1
94008	1710	kind of cell include macrophage	[kinds of cells including macrophages]	0.0	5	1	1	1
94009	1710	two hil-5 cell line	[two hIL-5 cell lines]	0.0	4	1	1	1
94010	1710	assess the risk of failure,	[assessing the risk of failure,]	0.0	5	1	1	1
94011	1710	IL-2- NK cell	[IL-2- NK cells]	0.0	3	1	1	1
94012	1710	class RB -defective line	[class RB -defective lines]	0.0	4	1	1	1
94013	1710	UPS	[UPS]	0.0	1	1	1	1
94014	1710	vcam-	[VCAM-]	0.0	1	1	1	1
94015	1710	make extract	[making extracts]	0.0	2	1	1	1
94016	1710	transcriptional sequence	[transcriptional sequences]	0.0	2	1	1	1
94017	1710	10(-7) m all-tran acid RA	[10(-7) M all-trans acid RA]	0.0	5	1	1	1
94018	1710	proliferation of b lymphocyte	[proliferation of B lymphocytes]	0.0	4	1	1	1
94019	1710	weak affinity	[weak affinity]	0.0	2	1	1	1
94020	1710	[molecular	[[Molecular]	0.0	1	1	1	1
94021	1710	lymphoid cell transcription factor	[lymphoid cell transcription factors]	0.0	4	1	1	1
94022	1710	ifn-gamma response	[IFN-gamma response]	0.0	2	1	1	1
94023	1710	IL-4 gamma 3	[IL-4 gamma 3]	0.0	3	1	1	1
94024	1710	platelet tether	[platelets tether]	0.0	2	1	1	1
94025	1710	fibroblast pge2	[fibroblast PGE2]	0.0	2	1	1	1
94026	1710	five clone member	[five clones members]	0.0	3	1	1	1
94027	1710	Jak1 -dependent signal	[Jak1 -dependent signals]	0.0	3	1	1	1
94028	1710	form of early-onset type diabete	[forms of early-onset type diabetes]	0.0	5	1	1	1
94029	1710	IL-3 proximal promoter	[IL-3 proximal promoter]	0.0	3	1	1	1
94030	1710	mechanism of action of glucocorticoid	[mechanisms of action of glucocorticoids]	0.0	5	1	1	1
94031	1710	hour 30 minute	[hr 30 min]	0.0	3	1	1	1
94032	1710	B1 /alpha b2 ratio	[B1 /alpha B2 ratio]	0.0	4	1	1	1
94033	1710	activity of SB	[activity of SB]	0.0	3	1	1	1
94034	1710	escape of human cytomegalovirus	[Escape of human cytomegalovirus]	0.0	4	1	1	1
94035	1710	encompass end	[encompassing ends]	0.0	2	2	2	1
94036	1710	such as histocompatibility (mhc) class	[such as histocompatibility (MHC) class]	0.0	5	1	1	1
94037	1710	region -73 to -16	[region -73 to -16]	0.0	4	1	1	1
94038	1710	mean values: 385	[mean values: 385]	0.0	3	1	1	1
94039	1710	two domain the domain	[two domains the domain]	0.0	4	1	1	1
94040	1710	carboxylesterase in monocytic cell	[carboxylesterase in monocytic cells]	0.0	4	1	1	1
94041	1710	70-kda protein corresponding	[70-kDa protein corresponding]	0.0	3	1	1	1
94042	1710	absence of alteration	[absence of alteration]	0.0	3	1	1	1
94043	1710	contain four repeat of 21 bp	[containing four repeats of 21 bp]	0.0	6	1	1	1
94044	1710	ldl putative trigger molecule	[LDL putative triggering molecule]	0.0	4	1	1	1
94045	1710	lymphotropic virus type htlv-1 tax	[lymphotropic virus type HTLV-1 Tax]	0.0	5	1	1	1
94046	1710	apparent frequency	[apparent frequency]	0.0	2	1	1	1
94047	1710	express c-myc	[expressing c-myc]	0.0	2	1	1	1
94048	1710	huvec by 56%	[HUVEC by 56%]	0.0	3	1	1	1
94049	1710	contrast, large amount	[contrast, large amounts]	0.0	3	1	1	1
94050	1710	state level of ifn-gamma mrna	[state levels of IFN-gamma mRNA]	0.0	5	1	1	1
94051	1710	glucocorticoid autoregulation	[glucocorticoid autoregulation]	0.0	2	1	1	1
94052	1710	M-CSF by MM-LDL	[M-CSF by MM-LDL]	0.0	3	1	1	1
94053	1710	interaction of extract	[Interaction of extracts]	0.0	3	1	1	1
94054	1710	b-cell component	[B-cell component]	0.0	2	1	1	1
94055	1710	high-affinity binding site in region	[high-affinity binding site in regions]	0.0	5	1	1	1
94056	1710	microm dexamethasone for h. treatment	[microM dexamethasone for h, treatment]	0.0	5	1	1	1
94057	1710	lymphocyte activation on transcription	[lymphocyte activation on transcription]	0.0	4	1	1	1
94058	1710	UTR	[UTR]	0.0	1	2	2	1
94059	1710	peroxisomal proliferator-activated receptor gamma expression	[peroxisomal proliferator-activated receptor gamma expression]	0.0	5	1	1	1
94060	1710	lead to variable anemic severity	[leading to variable anemic severity]	0.0	5	1	1	1
94061	1710	bcr1 type-pml/RAR	[bcr1 type-pml/RAR]	0.0	2	1	1	1
94062	1710	50000 Dalton	[50000 Dalton]	0.0	2	1	1	1
94063	1710	treatment with different schedule	[Treatment with different schedules]	0.0	4	1	1	1
94064	1710	polymorphism at residue	[polymorphism at residue]	0.0	3	2	2	1
94065	1710	11 kb	[11 kb]	0.0	2	1	1	1
94066	1710	simian immunodeficiency	[simian immunodeficiency]	0.0	2	1	1	1
94067	1710	replication in monocytic cell	[replication in monocytic cells]	0.0	4	1	1	1
94068	1710	individual enhancer sequence	[individual enhancer sequences]	0.0	3	1	1	1
94069	1710	lineage (day 21	[lineages (days 21]	0.0	3	1	1	1
94070	1710	UV-	[UV-]	0.0	1	1	1	1
94071	1710	pre-B lymphoblastic leukemia all	[pre-B lymphoblastic leukemia ALL]	0.0	4	1	1	1
94072	1710	[an overexpression of acid receptor alpha	[[An overexpression of acid receptor alpha]	0.0	6	1	1	1
94073	1710	hematopoiesis in vivo,	[hematopoiesis in vivo,]	0.0	3	1	1	1
94074	1710	myeloid-specific gene expression	[myeloid-specific gene expression]	0.0	3	1	1	1
94075	1710	mouse ectoderm development gene	[mouse ectoderm development gene]	0.0	4	1	1	1
94076	1710	transcription complex tfiid TAFII32	[transcription complex TFIID TAFII32]	0.0	4	1	1	1
94077	1710	vcam-1 in huvec	[VCAM-1 in HUVEC]	0.0	3	1	1	1
94078	1710	1.7 nm at degree	[1.7 nM at degrees]	0.0	4	1	1	1
94079	1710	NK cell-mediated clearance of cell	[NK cell-mediated clearance of cells]	0.0	5	1	1	1
94080	1710	detectable quantity	[detectable quantities]	0.0	2	1	1	1
94081	1710	immature ba/f3 cell	[immature Ba/F3 cells]	0.0	3	1	1	1
94082	1710	increase amount of recombinant nfatp	[increasing amounts of recombinant NFATp]	0.0	5	1	1	1
94083	1710	cloning of a homologue	[cloning of a homologue]	0.0	4	1	1	1
94084	1710	two domain LCD motif	[two domains LCD motifs]	0.0	4	1	1	1
94085	1710	important growth factor	[important growth factor]	0.0	3	1	1	1
94086	1710	cd25 promoter	[CD25 promoter]	0.0	2	1	1	1
94087	1710	zdevd-fmk a inhibitor	[zDEVD-fmk an inhibitor]	0.0	3	1	1	1
94088	1710	response upon in vitro tcr stimulation	[responses upon in vitro TCR stimulation]	0.0	6	1	1	1
94089	1710	igd+	[IgD+]	0.0	1	1	1	1
94090	1710	ebna2-dependent enhancer upstream	[EBNA2-dependent enhancer upstream]	0.0	3	1	1	1
94091	1710	concentration of HU below 250 microm	[concentrations of HU below 250 microM]	0.0	6	1	1	1
94092	1710	DQ cis-	[DQ cis-]	0.0	2	1	1	1
94093	1710	activity of NE	[activity of NE]	0.0	3	1	1	1
94094	1710	weight species of 24	[weight species of 24]	0.0	4	1	1	1
94095	1710	long repeat LTR region	[long repeat LTR region]	0.0	4	1	1	1
94096	1710	consider the strong regulatory effect	[Considering the strong regulatory effect]	0.0	5	1	1	1
94097	1710	understand the evolutionary event	[understanding the evolutionary events]	0.0	4	1	1	1
94098	1710	two form creb	[Two forms CREB]	0.0	3	1	1	1
94099	1710	activation transcription factor complex	[activation transcription factor complex]	0.0	4	1	1	1
94100	1710	nf-at complex with a oligonucleotide	[NF-AT complexes with an oligonucleotide]	0.0	5	1	1	1
94101	1710	level cd19 promoter expression	[level CD19 promoter expression]	0.0	4	1	1	1
94102	1710	correlation of level	[Correlations of levels]	0.0	3	1	1	1
94103	1710	atmospheric pollution	[atmospheric pollution]	0.0	2	1	1	1
94104	1710	clinical drug	[clinical drug]	0.0	2	1	1	1
94105	1710	shed form	[shed form]	0.0	2	1	1	1
94106	1710	hiv1 u937 cell	[HIV1 U937 cells]	0.0	3	1	1	1
94107	1710	malformation	[malformations]	0.0	1	1	1	1
94108	1710	early-lytic-cycle protein with homology to Bcl-2	[early-lytic-cycle protein with homology to Bcl-2]	0.0	6	1	1	1
94109	1710	dose of cerulein	[dose of cerulein]	0.0	3	1	1	1
94110	1710	advanced carcinoma	[advanced carcinoma]	0.0	2	1	1	1
94111	1710	low concentration of RA mol/L)	[Low concentrations of RA mol/L)]	0.0	5	1	1	1
94112	1710	phosphorylation in the cell	[phosphorylation in the cells]	0.0	4	1	1	1
94113	1710	8 a.m. receptor	[8 a.m. receptors]	0.0	3	1	1	1
94114	1710	human interleukin Il-2	[human Interleukin Il-2]	0.0	3	1	1	1
94115	1710	macrophage-depleted rat	[macrophage-depleted rats]	0.0	2	1	1	1
94116	1710	c-erba/tr-alpha in erythroblast	[c-erbA/TR-alpha in erythroblasts]	0.0	3	1	1	1
94117	1710	pregnant woman first, second	[pregnant women first, second]	0.0	4	1	1	1
94118	1710	nodular lymphocyte predominance subtype	[nodular lymphocyte predominance subtype]	0.0	4	1	1	1
94119	1710	domain homologous to the domain	[domain homologous to the domain]	0.0	5	1	1	1
94120	1710	part at the level	[part at the level]	0.0	4	1	1	1
94121	1710	range between 200-500	[ranging between 200-500]	0.0	3	1	1	1
94122	1710	E2A- leukemia factor protein	[E2A- leukemia factor proteins]	0.0	4	1	1	1
94123	1710	CD95L promoter sequence from -220	[CD95L promoter sequence from -220]	0.0	5	1	1	1
94124	1710	stimulation with interleukin-6 (il-6)	[stimulation with interleukin-6 (IL-6)]	0.0	4	1	1	1
94125	1710	important ebf	[important EBF]	0.0	2	1	1	1
94126	1710	cis-encoded DQ molecule	[cis-encoded DQ molecules]	0.0	3	1	1	1
94127	1710	microbicidal pathway	[microbicidal pathway]	0.0	2	1	1	1
94128	1710	two unknown cDNA sequence	[two unknown cDNA sequences]	0.0	4	1	1	1
94129	1710	illness involve inadequate response to stress	[illness involving inadequate responses to stress]	0.0	6	1	1	1
94130	1710	myeloid cell polymorphonuclear granulocyte pmn	[myeloid cells polymorphonuclear granulocytes PMN]	0.0	5	1	1	1
94131	1710	three category of factor	[three categories of factors]	0.0	4	1	1	1
94132	1710	rBPI21 a fragment lps expression	[rBPI21 a fragment LPS expression]	0.0	5	1	1	1
94133	1710	pHU-14 a probe include sequence hybridize	[pHU-14 a probe including sequences hybridizes]	0.0	6	1	1	1
94134	1710	consecutive series of case	[consecutive series of cases]	0.0	4	1	1	1
94135	1710	hiv-infected cell with monoclonal antibody	[HIV-infected cells with monoclonal antibody]	0.0	5	1	1	1
94136	1710	production of interleukin-2 il-2	[production of interleukin-2 IL-2]	0.0	4	1	1	1
94137	1710	cd3epsilon mouse	[CD3epsilon mice]	0.0	2	1	1	1
94138	1710	signal include hyperresponsiveness	[signaling including hyperresponsiveness]	0.0	3	1	1	1
94139	1710	potential open reading frame a	[potential open reading frames A]	0.0	5	1	1	1
94140	1710	igg+	[IgG+]	0.0	1	1	1	1
94141	1710	level of mnda	[levels of MNDA]	0.0	3	1	1	1
94142	1710	anti-STAT Abs	[anti-STAT Abs]	0.0	2	1	1	1
94143	1710	prior to activation.	[prior to activation.]	0.0	3	1	1	1
94144	1710	ubiquitous amp-responsive element	[ubiquitous AMP-responsive element]	0.0	3	1	1	1
94145	1710	titer anti-38,000-M(r) serum	[titer anti-38,000-M(r) serum]	0.0	3	1	1	1
94146	1710	effect of CyA all attributable	[effects of CyA all attributable]	0.0	5	1	1	1
94147	1710	activation of PKC/Ras-	[activation of PKC/Ras-]	0.0	3	1	1	1
94148	1710	(i) patient express er	[(i) patients express ER]	0.0	4	1	1	1
94149	1710	(spi-1)	[(spi-1)]	0.0	1	1	1	1
94150	1710	use a gcrbeta antibody by staining	[using a GCRbeta antibody by staining]	0.0	6	1	1	1
94151	1710	pseudohypoaldosteronism in form of inheritance	[Pseudohypoaldosteronism in forms of inheritance]	0.0	5	1	1	1
94152	1710	group of hmg box protein	[groups of HMG box proteins]	0.0	5	1	1	1
94153	1710	form of Ets-1	[form of Ets-1]	0.0	3	1	1	1
94154	1710	new group of protein	[new group of proteins]	0.0	4	1	1	1
94155	1710	differentiation of primary cell	[differentiation of primary cells]	0.0	4	1	1	1
94156	1710	case of syndrome dcs	[cases of syndrome DCS]	0.0	4	1	1	1
94157	1710	physical exercise follow phosphocreatine administration	[physical exercise following phosphocreatine administration]	0.0	5	1	1	1
94158	1710	proviral latency in monocytic cell	[proviral latency in monocytic cells]	0.0	5	1	1	1
94159	1710	11 obese subject	[11 obese subjects]	0.0	3	1	1	1
94160	1710	Genetic characterization of transactivation	[Genetic characterization of transactivation]	0.0	4	1	1	1
94161	1710	iggk	[IgGk]	0.0	1	1	1	1
94162	1710	T cell inhibitory activity	[T cell inhibitory activities]	0.0	4	1	1	1
94163	1710	glutamine synthetase	[glutamine synthetase]	0.0	2	2	2	1
94164	1710	JNK activation of AP-1	[JNK activation of AP-1]	0.0	4	1	1	1
94165	1710	(Renesto, p.,	[(Renesto, P.,]	0.0	2	1	1	1
94166	1710	level of hiv replication	[level of HIV replication]	0.0	4	2	2	1
94167	1710	prevent the release	[preventing the release]	0.0	3	1	1	1
94168	1710	natural ligands,	[natural ligands,]	0.0	2	1	1	1
94169	1710	multispecific response	[multispecific response]	0.0	2	1	1	1
94170	1710	regulatory event in the activation	[regulatory events in the activation]	0.0	5	1	1	1
94171	1710	OKA a inhibitor	[OKA a inhibitor]	0.0	3	1	1	1
94172	1710	igm+	[IgM+]	0.0	1	1	1	1
94173	1710	content for the symptom	[content for the symptoms]	0.0	4	1	1	1
94174	1710	activation of ca(2+) pathway alone	[Activation of Ca(2+) pathways alone]	0.0	5	1	1	1
94175	1710	difference between the patient (58.3	[difference between the patients (58.3]	0.0	5	1	1	1
94176	1710	true variant	[true variant]	0.0	2	1	1	1
94177	1710	feature of a immunodeficiency disease	[features of a immunodeficiency disease]	0.0	5	1	1	1
94178	1710	putative loci relevant to pel	[putative loci relevant to PEL]	0.0	5	1	1	1
94179	1710	receptor-effector-mechor-mechanisms for aldosterone	[receptor-effector-mechanisms for aldosterone]	0.0	3	1	1	1
94180	1710	antigen-presenting cell function	[antigen-presenting cell function]	0.0	3	1	1	1
94181	1710	obvious exception, and/or in cell	[obvious exception, and/or in cells]	0.0	5	1	1	1
94182	1710	subsequent inhibition	[subsequent inhibition]	0.0	2	1	1	1
94183	1710	icr27tk.3 cell contain receptor l753f	[ICR27TK.3 cells containing receptors L753F]	0.0	5	1	1	1
94184	1710	corticosteroid response	[corticosteroid responses]	0.0	2	1	1	1
94185	1710	(mean 37 years)	[(mean 37 years)]	0.0	3	1	1	1
94186	1710	platelet activator	[platelet activators]	0.0	2	1	1	1
94187	1710	relationship between the receptor level	[relationship between the receptor levels]	0.0	5	1	1	1
94188	1710	dose result on tissue oligonucleotide	[doses resulting on tissue oligonucleotide]	0.0	5	1	1	1
94189	1710	intracellular vitamin d binding protein	[intracellular vitamin D binding protein]	0.0	5	1	1	1
94190	1710	NFAT formation	[NFAT formation]	0.0	2	1	1	1
94191	1710	inflammatory mediator by epithelial cell	[inflammatory mediators by epithelial cells]	0.0	5	1	1	1
94192	1710	one means	[One means]	0.0	2	1	1	1
94193	1710	leukocyte by cortisol	[leukocytes by cortisol]	0.0	3	1	1	1
94194	1710	adenovirus major promoter	[adenovirus major promoter]	0.0	3	2	2	1
94195	1710	functional inhibition by dexamethasone	[functional inhibition by dexamethasone]	0.0	4	1	1	1
94196	1710	hd sample	[HD samples]	0.0	2	1	1	1
94197	1710	few cell types,	[few cell types,]	0.0	3	1	1	1
94198	1710	treatment of chronically hiv-infected pbmc	[Treatment of chronically HIV-infected PBMC]	0.0	5	1	1	1
94199	1710	tissue specificity of expression	[tissue specificity of expression]	0.0	4	1	1	1
94200	1710	suicide	[suicide]	0.0	1	1	1	1
94201	1710	stimulation with lectins	[stimulation with lectins]	0.0	3	1	1	1
94202	1710	inhibition of hiv-1 replication by combination	[Inhibition of HIV-1 replication by combination]	0.0	6	1	1	1
94203	1710	clinical side effect	[clinical side effects]	0.0	3	1	1	1
94204	1710	disease like bronchiti	[diseases like bronchitis]	0.0	3	1	1	1
94205	1710	kda form	[kDa form]	0.0	2	1	1	1
94206	1710	incubation from healthy individual	[incubation from healthy individuals]	0.0	4	1	1	1
94207	1710	thus exclude skewedness of x-inactivation	[thus excluding skewedness of X-inactivation]	0.0	5	1	1	1
94208	1710	isoforms, pax-5b	[isoforms, Pax-5b]	0.0	2	1	1	1
94209	1710	primary response in human	[primary responses in humans]	0.0	4	1	1	1
94210	1710	pseudohypoaldosteronism in eight family different form	[Pseudohypoaldosteronism in eight families: different forms]	0.0	6	1	1	1
94211	1710	effective indicator	[effective indicator]	0.0	2	1	1	1
94212	1710	function in the absence	[functions in the absence]	0.0	4	1	1	1
94213	1710	delivery vehicle for cytokine	[delivery vehicle for cytokines]	0.0	4	1	1	1
94214	1710	binding to a symmetry element	[binding to a symmetry element]	0.0	5	1	1	1
94215	1710	VDJ	[VDJ]	0.0	1	1	1	1
94216	1710	eiconsanoid a2 b4	[eiconsanoids A2 B4]	0.0	3	1	1	1
94217	1710	t-cell lymphoma with gcs	[T-cell lymphoma with GCs]	0.0	4	1	1	1
94218	1710	represent stage from precursor	[representing stages from precursors]	0.0	4	1	1	1
94219	1710	beta-adrenergic receptor kinase	[beta-adrenergic receptor kinase]	0.0	3	1	1	1
94220	1710	sequence similarity to SLP-76	[sequence similarity to SLP-76]	0.0	4	1	1	1
94221	1710	trace amount	[trace amounts]	0.0	2	1	1	1
94222	1710	relevant inhibitor in cell	[relevant inhibitor in cells]	0.0	4	1	1	1
94223	1710	such as the tax protein	[such as the Tax protein]	0.0	5	1	1	1
94224	1710	one abnormality,	[one abnormality,]	0.0	2	1	1	1
94225	1710	5-day macrophage	[5-day macrophages]	0.0	2	1	1	1
94226	1710	widespread expression	[widespread expression]	0.0	2	1	1	1
94227	1710	involvement in the signal	[involvement in the signaling]	0.0	4	1	1	1
94228	1710	decrease in the dna-binding activity	[decrease in the DNA-binding activity]	0.0	5	1	1	1
94229	1710	leukemia (apl) cell	[leukemia (APL) cells]	0.0	3	2	2	1
94230	1710	monoclonal cell antibody from a patient	[Monoclonal cell antibodies from a patient]	0.0	6	1	1	1
94231	1710	antitumour DNA	[antitumour DNA]	0.0	2	1	1	1
94232	1710	raji	[Raji]	0.0	1	1	1	1
94233	1710	induce the expression of nf-kappab	[inducing the expression of NF-kappaB]	0.0	5	1	1	1
94234	1710	transfection together with ap-1 reporter construct	[Transfection together with AP-1 reporter constructs]	0.0	6	1	1	1
94235	1710	reduction in the activation of ap-1	[reductions in the activation of AP-1]	0.0	6	1	1	1
94236	1710	rakfkqllq CTL	[RAKFKQLLQ CTL]	0.0	2	1	1	1
94237	1710	accordingly, blot with antibody specific	[Accordingly, blots with antibodies specific]	0.0	5	1	1	1
94238	1710	transient transfection of vcam-1 promoter construct	[Transient transfection of VCAM-1 promoter constructs]	0.0	6	1	1	1
94239	1710	cd23.	[CD23.]	0.0	1	1	1	1
94240	1710	Furthermore, blockade	[Furthermore, blockade]	0.0	2	1	1	1
94241	1710	several human leukemia cell line grow	[Several human leukemia cell lines growing]	0.0	6	1	1	1
94242	1710	IkappaB alpha a principal inhibitor	[IkappaB alpha a principal inhibitor]	0.0	5	1	1	1
94243	1710	type motif for formation	[type motif for formation]	0.0	4	1	1	1
94244	1710	site 4481 to 4982	[site 4481 to 4982]	0.0	4	1	1	1
94245	1710	t3-unresponsive jeg-3 cell	[T3-unresponsive JEG-3 cells]	0.0	3	1	1	1
94246	1710	collagen fibril	[collagen fibrils]	0.0	2	1	1	1
94247	1710	mcf13 murine leukemia virus	[MCF13 murine leukemia virus]	0.0	4	1	1	1
94248	1710	consequence downstream	[consequences downstream]	0.0	2	1	1	1
94249	1710	structure distinct from the structure	[structures distinct from the structures]	0.0	5	1	1	1
94250	1710	T fasl expression	[T FasL expression]	0.0	3	1	1	1
94251	1710	additional, rapamycin pathway	[additional, rapamycin pathways]	0.0	3	1	1	1
94252	1710	significantly inhibit the capacity	[significantly inhibiting the capacity]	0.0	4	1	1	1
94253	1710	highlight cancer related loci	[highlighting cancer related loci]	0.0	4	1	1	1
94254	1710	level of nf-atp capable	[levels of NF-ATp capable]	0.0	4	1	1	1
94255	1710	binding of ligand to receptor	[binding of ligands to receptors]	0.0	5	1	1	1
94256	1710	level of gene expression	[levels of gene expression]	0.0	4	1	1	1
94257	1710	acid RA maturation	[acid RA maturation]	0.0	3	1	1	1
94258	1710	il-2 target T	[IL-2 target T]	0.0	3	1	1	1
94259	1710	polyclonal stimulus in b-cell	[polyclonal stimuli in B-cells]	0.0	4	1	1	1
94260	1710	VII	[VII]	0.0	1	1	1	1
94261	1710	nuclear factor( binding	[nuclear factor(s) binding]	0.0	3	1	1	1
94262	1710	281 pmol/L; in normal pregnant woman	[281 pmol/L; in normal pregnant women]	0.0	6	1	1	1
94263	1710	increase peak in response	[increase peaking in response]	0.0	4	1	1	1
94264	1710	amount of recombinant nfatp	[amounts of recombinant NFATp]	0.0	4	1	1	1
94265	1710	differentiation of germinal center b cell	[differentiation of germinal center B cells]	0.0	6	1	1	1
94266	1710	different pattern of cytokine lymphokine	[different patterns of cytokine lymphokine]	0.0	5	1	1	1
94267	1710	upstream region UAS3	[upstream regions UAS3]	0.0	3	1	1	1
94268	1710	mycobacterium tuberculosis M. tuberculosis	[Mycobacterium tuberculosis M. tuberculosis]	0.0	4	1	1	1
94269	1710	pathophysiology of hypertension PIH	[pathophysiology of hypertension PIH]	0.0	4	1	1	1
94270	1710	epitope peptide-loaded cell	[epitope peptide-loaded cells]	0.0	3	1	1	1
94271	1710	t allele mrna	[t allele mRNA]	0.0	3	2	2	1
94272	1710	effect of leukotriene B4	[effect of leukotriene B4]	0.0	4	1	1	1
94273	1710	constitutive apoptosis in neutrophil	[constitutive apoptosis in neutrophils]	0.0	4	1	1	1
94274	1710	related c-c chemokine receptor-like gene	[related C-C chemokine receptor-like genes]	0.0	5	1	1	1
94275	1710	use DNA template	[using DNA templates]	0.0	3	1	1	1
94276	1710	liuwei dihuang pill	[liuwei dihuang pills]	0.0	3	1	1	1
94277	1710	protective role of BHRF1	[protective role of BHRF1]	0.0	4	1	1	1
94278	1710	precipitate Stat-3 from extract	[precipitating Stat-3 from extracts]	0.0	4	1	1	1
94279	1710	person with hypertension	[persons with hypertension]	0.0	3	1	1	1
94280	1710	effect of the camkiv	[effects of the CaMKIV]	0.0	4	1	1	1
94281	1710	CBF beta -myh11 positive,	[CBF beta -MYH11 positive,]	0.0	4	1	1	1
94282	1710	role in macrophage gene regulation	[role in macrophage gene regulation]	0.0	5	1	1	1
94283	1710	kinase cdk inhibitor p21(waf1/cip1)	[kinase cdk inhibitor p21(WAF1/CIP1)]	0.0	4	1	1	1
94284	1710	deletion of the dna-binding domain	[deletion of the DNA-binding domain]	0.0	5	1	1	1
94285	1710	phenotype, similar	[phenotype, similar]	0.0	2	1	1	1
94286	1710	production of the human p75tnf-r	[production of the human p75TNF-R]	0.0	5	1	1	1
94287	1710	datum on specific regulation	[data on specific regulation]	0.0	4	1	1	1
94288	1710	Ad12 E1A	[Ad12 E1A]	0.0	2	1	1	1
94289	1710	increase phospholipase c gamma	[increase phospholipase C gamma]	0.0	4	1	1	1
94290	1710	transformation of a cell common	[transformation of a cell common]	0.0	5	1	1	1
94291	1710	ssb reactivity	[SSB reactivity]	0.0	2	1	1	1
94292	1710	infection of Epstein-Barr virus ebv	[infection of Epstein-Barr virus EBV]	0.0	5	1	1	1
94293	1710	contain consensus binding site	[containing consensus binding sites]	0.0	4	1	1	1
94294	1710	supplement the culture with dose	[supplementing the cultures with doses]	0.0	5	1	1	1
94295	1710	tl20/12r sun lamp	[TL20/12RS sun lamps]	0.0	3	1	1	1
94296	1710	Vitamin e therapy acute ccl4	[Vitamin E therapy acute CCl4]	0.0	5	1	1	1
94297	1710	cd102	[CD102]	0.0	1	1	1	1
94298	1710	depressed,	[depressed,]	0.0	1	1	1	1
94299	1710	rar,	[RAR,]	0.0	1	1	1	1
94300	1710	most early cycle gene	[most early cycle genes]	0.0	4	1	1	1
94301	1710	upstream factor-kappa b NF-kappa b	[upstream factor-kappa B NF-kappa B]	0.0	5	1	1	1
94302	1710	overproduction of NFKB2 a mechanism	[Overproduction of NFKB2 a mechanism]	0.0	5	1	1	1
94303	1710	c-fo mrna level	[c-fos mRNA levels]	0.0	3	2	2	1
94304	1710	protein protein	[protein protein]	0.0	2	1	1	1
94305	1710	CD4 positive T cell line	[CD4 positive T cell lines]	0.0	5	1	1	1
94306	1710	key determinant of the activity	[key determinant of the activity]	0.0	5	1	1	1
94307	1710	submaximal exercise	[submaximal exercises]	0.0	2	1	1	1
94308	1710	BZLF1 -reactive component	[BZLF1 -reactive component]	0.0	3	1	1	1
94309	1710	receptor gr in lymphocyte	[receptors GR in lymphocytes]	0.0	4	1	1	1
94310	1710	/precursor	[/precursors]	0.0	1	1	1	1
94311	1710	retinoic enzyme aldehyde dehydrogenase	[retinoic enzyme aldehyde dehydrogenase]	0.0	4	1	1	1
94312	1710	engagement of the t-cell receptor	[Engagement of the T-cell receptor]	0.0	5	1	1	1
94313	1710	58 asthma child aged years.	[58 asthma children aged years.]	0.0	5	1	1	1
94314	1710	transfection of kinase-deficient mutant of IKKalpha	[Transfection of kinase-deficient mutants of IKKalpha]	0.0	6	1	1	1
94315	1710	sequence important for promoter activity,	[sequences important for promoter activity,]	0.0	5	1	1	1
94316	1710	consistent effect	[consistent effect]	0.0	2	1	1	1
94317	1710	aids -c group	[AIDS -C group]	0.0	3	1	1	1
94318	1710	sex reversal map kb from sox9	[sex reversal map kb from SOX9]	0.0	6	1	1	1
94319	1710	dimeric tnf receptor rhu tnfr:fc	[dimeric TNF receptor rhu TNFR:Fc]	0.0	5	1	1	1
94320	1710	cd56+ cd16+ killer cell	[CD56+ CD16+ killer cells]	0.0	4	1	1	1
94321	1710	activator protein dna-binding activity	[activator protein DNA-binding activity]	0.0	4	1	1	1
94322	1710	antibody in from carrier	[antibodies in from carriers]	0.0	4	1	1	1
94323	1710	domain of the precursor	[domain of the precursor]	0.0	4	1	1	1
94324	1710	pair of CD2 mab	[pairs of CD2 mAbs]	0.0	4	1	1	1
94325	1710	correlation between immune	[correlation between immune]	0.0	3	1	1	1
94326	1710	primitive myeloid progenitor cell	[primitive myeloid progenitor cells]	0.0	4	1	1	1
94327	1710	development of T	[development of T]	0.0	3	1	1	1
94328	1710	chromosome 11	[chromosome 11]	0.0	2	2	2	1
94329	1710	formation between protein	[formation between proteins]	0.0	3	1	1	1
94330	1710	loss of form	[loss of Form]	0.0	3	1	1	1
94331	1710	Recognition of NFATp/AP-1 element within gene	[Recognition of NFATp/AP-1 elements within genes]	0.0	6	1	1	1
94332	1710	expression plasmid for Sp1	[expression plasmids for Sp1]	0.0	4	1	1	1
94333	1710	eligible risk woman	[Eligible risk women]	0.0	3	1	1	1
94334	1710	rara	[RARA]	0.0	1	1	1	1
94335	1710	interfere with multiple event	[interfering with multiple events]	0.0	4	1	1	1
94336	1710	chromosome 21	[chromosome 21]	0.0	2	1	1	1
94337	1710	HeLa cell mrna	[HeLa cell mRNA]	0.0	3	1	1	1
94338	1710	sensitivity of monocyte to regulation	[sensitivity of monocytes to regulation]	0.0	5	1	1	1
94339	1710	METHODS: during a double-blind crossover study	[METHODS: During a double-blind crossover study]	0.0	6	1	1	1
94340	1710	(mhc) class ii-like molecule	[(MHC) class II-like molecule]	0.0	4	1	1	1
94341	1710	considerable datum relate ros activity	[considerable data relating ROS activity]	0.0	5	1	1	1
94342	1710	(il)-10 blocking factor pibf expression immuno-cytochemistry	[(IL)-10 blocking factor PIBF expression immuno-cytochemistry]	0.0	6	1	1	1
94343	1710	tf-h5r	[TF-h5R]	0.0	1	1	1	1
94344	1710	ap-1 DNA recognition	[AP-1 DNA recognition]	0.0	3	1	1	1
94345	1710	expression of Id3	[expression of Id3]	0.0	3	1	1	1
94346	1710	additional testing of a corresponding set	[additional testing of a corresponding set]	0.0	6	1	1	1
94347	1710	efficient lymphoblastoid cell outgrowth	[efficient lymphoblastoid cell outgrowth]	0.0	4	1	1	1
94348	1710	relevant role for NF-kappaB	[relevant role for NF-kappaB]	0.0	4	1	1	1
94349	1710	inhibition of IL-1	[inhibition of IL-1]	0.0	3	1	1	1
94350	1710	enhancer element activity	[enhancer element activities]	0.0	3	1	1	1
94351	1710	change follow treatment with 135(oh)2d3	[change following treatment with 1,25(OH)2D3]	0.0	5	1	1	1
94352	1710	regulation a comparative study with IL-4	[regulation a comparative study with IL-4]	0.0	6	1	1	1
94353	1710	il-10 receptor site	[IL-10 receptor sites]	0.0	3	1	1	1
94354	1710	immature normal myeloid cell	[immature normal myeloid cells]	0.0	4	1	1	1
94355	1710	gene in cell line	[genes in cell lines]	0.0	4	1	1	1
94356	1710	regard the class	[regarding the class]	0.0	3	1	1	1
94357	1710	activation of T cell (priming)	[activation of T cells (priming)]	0.0	5	1	1	1
94358	1710	TIMP-1 bl line	[TIMP-1 BL lines]	0.0	3	1	1	1
94359	1710	sensitivity of human monocyte	[sensitivity of human monocytes]	0.0	4	1	1	1
94360	1710	alternative to promoter	[alternatives to promoters]	0.0	3	1	1	1
94361	1710	5-lipoxygenase activity	[5-lipoxygenase activity]	0.0	2	1	1	1
94362	1710	virus-replicative lesion	[virus-replicative lesions]	0.0	2	1	1	1
94363	1710	retinoidal activity (agonist for acid receptor	[retinoidal activity (agonist for acid receptor]	0.0	6	1	1	1
94364	1710	expression lymphoid tissue	[expression lymphoid tissues]	0.0	3	1	1	1
94365	1710	patient with chronic disease (12:	[patients with chronic diseases (12:]	0.0	5	1	1	1
94366	1710	putative segment	[putative segments]	0.0	2	1	1	1
94367	1710	adenovirus early region ES	[adenovirus early region ES]	0.0	4	1	1	1
94368	1710	mobility group (hmg) protein	[mobility group (HMG) protein]	0.0	4	1	1	1
94369	1710	immunodeficiency virus type in cell	[immunodeficiency virus type in cells]	0.0	5	1	1	1
94370	1710	immediate gene under the control	[immediate genes under the control]	0.0	5	1	1	1
94371	1710	complex RFX	[complexes RFX]	0.0	2	1	1	1
94372	1710	finding of expression	[findings of expression]	0.0	3	1	1	1
94373	1710	(35 min) exercise	[(35 min) exercise]	0.0	3	1	1	1
94374	1710	b-lymphocyte cell	[B-lymphocyte cells]	0.0	2	1	1	1
94375	1710	p27(kip1 a protein	[p27(Kip1 an protein]	0.0	3	1	1	1
94376	1710	inflammatory disease such as dermatitis	[inflammatory diseases such as dermatitis]	0.0	5	1	1	1
94377	1710	negative sequence	[negative sequence]	0.0	2	3	3	1
94378	1710	(fasL)	[(fasL)]	0.0	1	1	1	1
94379	1710	functionally antagonize the IL-1 synthesis	[functionally antagonizing the IL-1 synthesis]	0.0	5	1	1	1
94380	1710	and/or expression	[and/or expression]	0.0	2	1	1	1
94381	1710	nuclear association	[nuclear association]	0.0	2	1	1	1
94382	1710	unique significance	[unique significance]	0.0	2	1	1	1
94383	1710	autosomal disorder	[autosomal disorder]	0.0	2	1	1	1
94384	1710	pathway of b activation	[pathway of B activation]	0.0	4	1	1	1
94385	1710	pluripotent hemopoietic progenitor to cell	[pluripotent hemopoietic progenitors to cells]	0.0	5	1	1	1
94386	1710	activation role of specific factor-DNA complex	[activation role of specific factor-DNA complexes]	0.0	6	1	1	1
94387	1710	also in individual for the purpose	[also in individuals for the purpose]	0.0	6	1	1	1
94388	1710	multiple somatic mutation	[multiple somatic mutations]	0.0	3	1	1	1
94389	1710	mechanism govern lineage	[mechanisms governing lineage]	0.0	3	1	1	1
94390	1710	enhancement HL 60 cell differentiated)	[enhancement HL 60 cells differentiated)]	0.0	5	1	1	1
94391	1710	amount costimulation	[amounts costimulation]	0.0	2	1	1	1
94392	1710	NF-kappa Bp65	[NF-kappa Bp65]	0.0	2	1	1	1
94393	1710	ciprofloxacin cipro	[ciprofloxacin cipro]	0.0	2	1	1	1
94394	1710	activation after ligation i	[Activation after ligation I]	0.0	4	1	1	1
94395	1710	pattern of functional response	[patterns of functional responses]	0.0	4	1	1	1
94396	1710	use of combination between ifi	[use of combinations between IFNs]	0.0	5	1	1	1
94397	1710	patient with inactive sle (0.2979	[patients with inactive SLE (0.2979]	0.0	5	1	1	1
94398	1710	center reaction	[center reaction]	0.0	2	1	1	1
94399	1710	intracellular oxygen species	[intracellular oxygen species]	0.0	3	1	1	1
94400	1710	pbmc with pertussis toxin	[PBMCs with pertussis toxin]	0.0	4	1	1	1
94401	1710	two cellular transcription factor	[two cellular transcription factors]	0.0	4	1	1	1
94402	1710	ald cell	[ALD cells]	0.0	2	1	1	1
94403	1710	repeat in T cell	[repeat in T cells]	0.0	4	1	1	1
94404	1710	29 amino acid	[29 amino acids]	0.0	3	1	1	1
94405	1710	datum on regulation of promoter	[data on regulation of promoters]	0.0	5	1	1	1
94406	1710	several role for hsp90	[Several roles for hsp90]	0.0	4	1	1	1
94407	1710	characterization of CD40 signal determinant	[Characterization of CD40 signaling determinants]	0.0	5	1	1	1
94408	1710	ad5e1a -express tumor	[Ad5E1A -expressing tumors]	0.0	3	1	1	1
94409	1710	use antigen peptide analog	[Using antigen peptide analogs]	0.0	4	1	1	1
94410	1710	6 to 15 year	[6 to 15 years]	0.0	4	1	1	1
94411	1710	DNA fragment of kb.	[DNA fragments of kb.]	0.0	4	1	1	1
94412	1710	+/- fmol/10(7) pbmc versus 4.43 1.38	[+/- fmol/10(7) PBMC vs 4.43 1.38]	0.0	6	1	1	1
94413	1710	activation of lymph node cell	[Activation of lymph node cells]	0.0	5	1	1	1
94414	1710	many hypothese concern the pathogenesis	[many hypotheses concerning the pathogenesis]	0.0	5	1	1	1
94415	1710	nm) of calyculin a	[nM) of calyculin A]	0.0	4	1	1	1
94416	1710	histone deacetylase subunit	[histone deacetylase subunit]	0.0	3	1	1	1
94417	1710	human carboxylesterase in cell	[human carboxylesterase in cells]	0.0	4	1	1	1
94418	1710	rapid testing of the effect	[rapid testing of the effects]	0.0	5	1	1	1
94419	1710	Nef protein,	[Nef protein,]	0.0	2	1	1	1
94420	1710	encode Ag 1	[encoding Ag 1]	0.0	3	1	1	1
94421	1710	21 control (21-50	[21 controls (21-50]	0.0	3	1	1	1
94422	1710	/STAT	[/STAT]	0.0	1	1	1	1
94423	1710	enzyme for (il)-2	[enzyme for (IL)-2]	0.0	3	1	1	1
94424	1710	lack of zebra staining	[lack of ZEBRA staining]	0.0	4	1	1	1
94425	1710	subject (bind capacity 3.3	[subjects (binding capacity 3.3]	0.0	4	1	1	1
94426	1710	beneficial effect of gdsp	[beneficial effect of GDSP]	0.0	4	1	1	1
94427	1710	cancer patients' lymphocyte	[cancer patients' lymphocytes]	0.0	3	1	1	1
94428	1710	demonstrate the immunosuppressive activity of tgf-beta	[demonstrating the immunosuppressive activity of TGF-beta]	0.0	6	1	1	1
94429	1710	demonstration of JAK phosphorylation	[demonstration of JAK phosphorylation]	0.0	4	1	1	1
94430	1710	outpatient visit, within week	[outpatient visit, within weeks]	0.0	4	1	1	1
94431	1710	rat splenocyte	[rat splenocyte]	0.0	2	1	1	1
94432	1710	gel supershift	[gel supershift]	0.0	2	1	1	1
94433	1710	protein tissue factor (tf)	[protein tissue factor (TF)]	0.0	4	1	1	1
94434	1710	aspect of IBR/F	[aspects of IBR/F]	0.0	3	1	1	1
94435	1710	M0/M1 cell	[M0/M1 cells]	0.0	2	1	1	1
94436	1710	various signal converge in pathway	[Various signals converging in pathways]	0.0	5	1	1	1
94437	1710	namely activator protein-1 nuclear factor nf-il6	[namely activator protein-1 nuclear factor NF-IL6]	0.0	6	1	1	1
94438	1710	ecori chromosome	[EcoRI chromosome]	0.0	2	1	1	1
94439	1710	transcription-activation element with characteristic	[transcription-activation element with characteristics]	0.0	4	1	1	1
94440	1710	related immunodeficiency virus	[related immunodeficiency virus]	0.0	3	1	1	1
94441	1710	multimerized region ii sequence element	[multimerized region II sequence elements]	0.0	5	1	1	1
94442	1710	distinct cofactor with the effector domain	[distinct cofactors with the effector domains]	0.0	6	1	1	1
94443	1710	interleukin-2 t-cell line	[interleukin-2 T-cell line]	0.0	3	1	1	1
94444	1710	construct of p85	[constructs of p85]	0.0	3	1	1	1
94445	1710	two-step model	[two-step model]	0.0	2	1	1	1
94446	1710	receptor in blood lymphocyte	[receptor in blood lymphocytes]	0.0	4	2	2	1
94447	1710	activin a-inducible antagonist	[activin A-inducible antagonist]	0.0	3	1	1	1
94448	1710	activation of transcription factor in neutrophil	[Activation of transcription factors in neutrophils]	0.0	6	1	1	1
94449	1710	activity okadaic	[activity okadaic]	0.0	2	1	1	1
94450	1710	possible explanation	[possible explanation]	0.0	2	1	1	1
94451	1710	eight transmembrane segment	[eight transmembrane segments]	0.0	3	1	1	1
94452	1710	manipulation of T cell immunity	[manipulation of T cell immunity]	0.0	5	1	1	1
94453	1710	cytokine modulating activity	[cytokine modulating activity]	0.0	3	1	1	1
94454	1710	accurate evaluation of the importance	[accurate evaluation of the importance]	0.0	5	1	1	1
94455	1710	share DNA binding specificity	[sharing DNA binding specificities]	0.0	4	1	1	1
94456	1710	gammadelta T cell	[gammadelta T cells]	0.0	3	1	1	1
94457	1710	use cell from rheumatoid arthritis patient	[Using cells from rheumatoid arthritis patients]	0.0	6	1	1	1
94458	1710	oxide guanine nucleotide exchange	[oxide guanine nucleotide exchange]	0.0	4	1	1	1
94459	1710	conferr DNA binding	[conferring DNA binding]	0.0	3	1	1	1
94460	1710	sub-unit of dna-protein kinase DNA-PK(CS)	[sub-unit of DNA-protein kinase DNA-PK(CS)]	0.0	5	1	1	1
94461	1710	field in molecular immunology	[field in molecular immunology]	0.0	4	1	1	1
94462	1710	transcriptional regulation of TNF	[transcriptional regulation of TNF]	0.0	4	1	1	1
94463	1710	localization after TNFalpha simulation	[localization after TNFalpha simulation]	0.0	4	1	1	1
94464	1710	cfp extract	[CFP extracts]	0.0	2	1	1	1
94465	1710	starting population	[starting population]	0.0	2	1	1	1
94466	1710	tissue-specific transcription factor bind	[tissue-specific transcription factor binding]	0.0	4	1	1	1
94467	1710	estrogen receptor expression	[estrogen receptor expression]	0.0	3	1	1	1
94468	1710	effect on a panel	[effects on a panel]	0.0	4	1	1	1
94469	1710	predictive protein-coding region	[predictive protein-coding region]	0.0	3	1	1	1
94470	1710	basophilia analysis	[basophilia analysis]	0.0	2	1	1	1
94471	1710	supercoiled, template	[supercoiled, templates,]	0.0	2	1	1	1
94472	1710	productive immunodeficiency virus type (hiv-1) infection	[Productive immunodeficiency virus type (HIV-1) infection]	0.0	6	1	1	1
94473	1710	major class chain promoter	[major class chain promoter]	0.0	4	1	1	1
94474	1710	coupling of ptk to signal pathway	[coupling of PTKs to signaling pathways]	0.0	6	1	1	1
94475	1710	underlie expression of cytokine	[underlying expression of cytokines]	0.0	4	1	1	1
94476	1710	patient (22%)	[patients (22%)]	0.0	2	1	1	1
94477	1710	pml gene product	[PML gene products]	0.0	3	1	1	1
94478	1710	induction of many gene	[induction of many genes]	0.0	4	1	1	1
94479	1710	same trans-acting factor	[same trans-acting factors]	0.0	3	1	1	1
94480	1710	angiotensin (ang) ii	[angiotensin (ANG) II]	0.0	3	1	1	1
94481	1710	mrna of protein	[mRNA of proteins]	0.0	3	1	1	1
94482	1710	CONCLUSIONS: leukocyte adhesion	[CONCLUSIONS: Leukocyte adhesion]	0.0	3	1	1	1
94483	1710	promoter of irf-2	[promoter of IRF-2]	0.0	3	1	1	1
94484	1710	immortalization of b-cell	[immortalization of B-cells]	0.0	3	1	1	1
94485	1710	t3, dysfunction hypophyseal	[T3, dysfunction hypophyseal]	0.0	3	1	1	1
94486	1710	most active nfat-like element	[most active NFAT-like elements]	0.0	4	1	1	1
94487	1710	trigger of CD40 signal pathway (s)	[triggering of CD40 signaling pathway (s)]	0.0	6	1	1	1
94488	1710	quiescent peripheral blood mononuclear cell	[quiescent peripheral blood mononuclear cells]	0.0	5	1	1	1
94489	1710	even the cell express high level	[even the cells expressing high levels]	0.0	6	1	1	1
94490	1710	110-kDa member	[110-kDa member]	0.0	2	1	1	1
94491	1710	c-Jun kinase JNK	[c-Jun kinase JNK]	0.0	3	1	1	1
94492	1710	context for activation by LEF-1	[context for activation by LEF-1]	0.0	5	1	1	1
94493	1710	repeat tax-responsive element-1	[repeats Tax-responsive element-1]	0.0	3	1	1	1
94494	1710	erythroid gene include alpha- globin	[erythroid genes including alpha- globin]	0.0	5	1	1	1
94495	1710	tight control.	[tight control.]	0.0	2	1	1	1
94496	1710	coincident with rante expression	[coincident with RANTES expression]	0.0	4	1	1	1
94497	1710	analysis of the EA-D promoter	[analysis of the EA-D promoter]	0.0	5	1	1	1
94498	1710	Ligand-dependent repression	[Ligand-dependent repression]	0.0	2	1	1	1
94499	1710	tcr beta gene	[TCR beta gene]	0.0	3	1	1	1
94500	1710	101 control	[101 controls]	0.0	2	1	1	1
94501	1710	co-repressor	[co-repressors]	0.0	1	1	1	1
94502	1710	such as budesonide	[such as budesonide]	0.0	3	1	1	1
94503	1710	immature (ccrf-cem) t-cell line	[immature (CCRF-CEM) T-cell lines]	0.0	4	1	1	1
94504	1710	receptor ERalpha	[receptors ERalpha]	0.0	2	1	1	1
94505	1710	feature of peripheral resistance to glucocorticoid	[features of peripheral resistance to glucocorticoids]	0.0	6	1	1	1
94506	1710	GATA-1 motif	[GATA-1 motifs]	0.0	2	1	1	1
94507	1710	basal-level activity	[basal-level activity]	0.0	2	1	1	1
94508	1710	interaction of transcription factor	[interaction of transcription factors]	0.0	4	1	1	1
94509	1710	base pair cis-acting element	[base pair cis-acting element]	0.0	4	1	1	1
94510	1710	1.8 kb promoter	[1.8 kb promoter]	0.0	3	1	1	1
94511	1710	rule"	[rule"]	0.0	1	1	1	1
94512	1710	human cd4+ t-cell line	[human CD4+ T-cell lines]	0.0	4	1	1	1
94513	1710	go t-cell	[Go T-cells]	0.0	2	1	1	1
94514	1710	(il)-2-receptor expression on the surface	[(IL)-2-receptor expression on the surface]	0.0	5	1	1	1
94515	1710	ROI in cell type	[ROIs in cell types]	0.0	4	1	1	1
94516	1710	only a few copy	[only a few copies]	0.0	4	1	1	1
94517	1710	proliferation of cell lineage	[proliferation of cell lineages]	0.0	4	1	1	1
94518	1710	-binding domain of the nucleoporin	[-binding domains of the nucleoporin]	0.0	5	1	1	1
94519	1710	NF-kappa b p65 -dependent activation	[NF-kappa B p65 -dependent activation]	0.0	5	1	1	1
94520	1710	promoter region -620	[promoter region -620]	0.0	3	1	1	1
94521	1710	androgen receptor gene humara	[androgen receptor gene HUMARA]	0.0	4	2	2	1
94522	1710	several class ii	[several class II]	0.0	3	1	1	1
94523	1710	cd16+	[CD16+]	0.0	1	1	1	1
94524	1710	bapta-am	[BAPTA-AM]	0.0	1	1	1	1
94525	1710	maintain expression	[maintaining expression]	0.0	2	1	1	1
94526	1710	alter weak, nonproductive interaction to interactions.	[altering weak, nonproductive interactions to interactions.]	0.0	6	1	1	1
94527	1710	chromosome 5.	[chromosome 5.]	0.0	2	1	1	1
94528	1710	p94 share homology with Stat1	[p94 share homology with Stat1]	0.0	5	1	1	1
94529	1710	patient with androgen insensitivity	[patient with androgen insensitivity]	0.0	4	1	1	1
94530	1710	retention of approximately 1600 VDR	[retention of approximately 1600 VDR]	0.0	5	1	1	1
94531	1710	dihydropyrimidine dehydrogenase DPD	[dihydropyrimidine dehydrogenase DPD]	0.0	3	1	1	1
94532	1710	cd15)	[CD15)]	0.0	1	1	1	1
94533	1710	explanation for toxicity	[explanation for toxicities]	0.0	3	1	1	1
94534	1710	cell permissiveness	[cell permissiveness]	0.0	2	1	1	1
94535	1710	thrombin receptor activation peptide	[Thrombin receptor activation peptide]	0.0	4	1	1	1
94536	1710	WEB	[WEB]	0.0	1	1	1	1
94537	1710	use t-lymphocyte from VZV human donor	[using T-lymphocytes from VZV human donors]	0.0	6	1	1	1
94538	1710	regulatory control.	[regulatory control.]	0.0	2	1	1	1
94539	1710	labelling	[labelling]	0.0	1	1	1	1
94540	1710	5 to 10% bovine serum	[5 to 10% bovine serum]	0.0	5	1	1	1
94541	1710	localization analysis in various cells,	[localization analysis in various cells,]	0.0	5	1	1	1
94542	1710	active principle	[active principle]	0.0	2	1	1	1
94543	1710	b -mediated gene expression	[B -mediated gene expression]	0.0	4	1	1	1
94544	1710	effector of lmp-1 signal	[effector of LMP-1 signaling]	0.0	4	1	1	1
94545	1710	prevent target cell uptake	[preventing target cell uptake]	0.0	4	1	1	1
94546	1710	ANG effect	[ANG effect]	0.0	2	1	1	1
94547	1710	anti- CD30 monoclonal antibody,	[anti- CD30 monoclonal antibody,]	0.0	4	1	1	1
94548	1710	Chinese hamster ovary cell	[Chinese hamster ovary cells]	0.0	4	1	1	1
94549	1710	disease include leukemia	[diseases including leukemia]	0.0	3	1	1	1
94550	1710	isoform of WT1	[isoforms of WT1]	0.0	3	1	1	1
94551	1710	CD28 response complex	[CD28 response complex]	0.0	3	1	1	1
94552	1710	nuclei of unstimulated pbl from donor	[Nuclei of unstimulated PBL from donors]	0.0	6	1	1	1
94553	1710	6 mAECA ec	[6 mAECA EC]	0.0	3	1	1	1
94554	1710	/cd40l	[/CD40L]	0.0	1	1	1	1
94555	1710	domain consist	[domain consisting]	0.0	2	1	1	1
94556	1710	implication of signal in myeloid cell	[implications of signals in myeloid cells]	0.0	6	1	1	1
94557	1710	inhibitory Ras construct	[inhibitory Ras construct]	0.0	3	1	1	1
94558	1710	mononuclear leukocyte in this patient	[mononuclear leukocytes in these patients]	0.0	5	1	1	1
94559	1710	activation of two form 90-kda stat3alpha	[activation of two forms 90-kDa STAT3alpha]	0.0	6	1	1	1
94560	1710	rna EBERs	[RNAs EBERs]	0.0	2	1	1	1
94561	1710	male with severe immunodeficiency xscid	[Males with severe immunodeficiency XSCID]	0.0	5	1	1	1
94562	1710	distinguishable gr bind abnormalities:	[distinguishable GR binding abnormalities:]	0.0	4	1	1	1
94563	1710	morphologic change	[morphologic changes]	0.0	2	1	1	1
94564	1710	six early protein	[six early proteins]	0.0	3	1	1	1
94565	1710	five dnase I site 5'hs1-5	[five DNase I sites 5'HS1-5]	0.0	5	1	1	1
94566	1710	binding present	[binding present]	0.0	2	1	1	1
94567	1710	specific probe for chromosome	[specific probes for chromosomes]	0.0	4	1	1	1
94568	1710	effect on slp-76 function	[effect on SLP-76 function]	0.0	4	1	1	1
94569	1710	activation, inflammation	[activation, inflammation]	0.0	2	1	1	1
94570	1710	girl with feature	[girl with features]	0.0	3	1	1	1
94571	1710	three site for c/ebp protein	[Three sites for C/EBP proteins]	0.0	5	1	1	1
94572	1710	independent sequence	[independent sequences]	0.0	2	1	1	1
94573	1710	body NB	[body NB]	0.0	2	1	1	1
94574	1710	level of Spi-B in cell	[levels of Spi-B in cells]	0.0	5	1	1	1
94575	1710	production of il-1rii	[production of IL-1RII]	0.0	3	1	1	1
94576	1710	EBV lesion	[EBV lesions]	0.0	2	1	1	1
94577	1710	microm dmdtc	[microM DMDTC]	0.0	2	2	2	1
94578	1710	gata element of the repeat	[GATA elements of the repeat]	0.0	5	1	1	1
94579	1710	signal isoform	[signaling isoform]	0.0	2	1	1	1
94580	1710	regulation of erythroid gene expression	[regulation of erythroid gene expression]	0.0	5	1	1	1
94581	1710	beta,19-epoxy-3-hydroxypregnan-20-one	[beta,19-epoxy-3-hydroxypregnan-20-one]	0.0	1	1	1	1
94582	1710	Fibroblast growth factor	[Fibroblast growth factors]	0.0	3	1	1	1
94583	1710	only g/g of total mrna	[only g/g of total mRNA]	0.0	5	1	1	1
94584	1710	extent, of nf-il6	[extent, of NF-IL6]	0.0	3	1	1	1
94585	1710	isolated case	[isolated cases]	0.0	2	1	1	1
94586	1710	(ii) chain	[(Ii) chains]	0.0	2	1	1	1
94587	1710	uninduced U937 cell	[uninduced U937 cells]	0.0	3	1	1	1
94588	1710	long terminal repeat (ltr)	[long terminal repeat (LTR)]	0.0	4	1	1	1
94589	1710	Jak tyrosine kinase human T	[Jak tyrosine kinases human T]	0.0	5	1	1	1
94590	1710	blood lymphocyte from young adults.	[blood lymphocytes from young adults.]	0.0	5	1	1	1
94591	1710	drive a ifn-gamma -inducible expression	[driving an IFN-gamma -inducible expression]	0.0	5	1	1	1
94592	1710	transcriptional activation of a nuclear factor	[transcriptional activation of a nuclear factor]	0.0	6	1	1	1
94593	1710	lps binding	[LPS binding]	0.0	2	1	1	1
94594	1710	differentiation of HL-60 leukemia cell	[differentiation of HL-60 leukemia cells]	0.0	5	1	1	1
94595	1710	various breakpoint	[various breakpoints]	0.0	2	1	1	1
94596	1710	transactivation during hhv-6(gs) infection	[transactivation during HHV-6(GS) infection]	0.0	4	1	1	1
94597	1710	ig gene class	[Ig gene class]	0.0	3	1	1	1
94598	1710	affinity for GRE site	[affinity for GRE sites]	0.0	4	1	1	1
94599	1710	role on gr transcriptional activation	[role on GR transcriptional activation]	0.0	5	1	1	1
94600	1710	gcr on mnl	[GCR on MNL]	0.0	3	1	1	1
94601	1710	Glucocorticoid receptor in lymphocyte	[Glucocorticoid receptors in lymphocytes]	0.0	4	1	1	1
94602	1710	activate the transcription factor factor	[activating the transcription factor factor]	0.0	5	1	1	1
94603	1710	promoter region ebv	[promoter regions EBV]	0.0	3	1	1	1
94604	1710	interaction of cell	[interaction of cells]	0.0	3	1	1	1
94605	1710	efficient interaction	[efficient interaction]	0.0	2	1	1	1
94606	1710	activate pml pathway	[activating PML pathways]	0.0	3	1	1	1
94607	1710	affinity of the drug	[affinity of the drugs]	0.0	4	1	1	1
94608	1710	Arg91	[Arg91]	0.0	1	1	1	1
94609	1710	suppressive effect of liposomal mpl	[suppressive effect of liposomal MPL]	0.0	5	1	1	1
94610	1710	deletion of the entire domain	[deletion of the entire domain]	0.0	5	1	1	1
94611	1710	use a negative form Max	[using a negative form Max]	0.0	5	1	1	1
94612	1710	cell-associated surface	[cell-associated surface]	0.0	2	1	1	1
94613	1710	signal tcr signal	[signal TCR signal]	0.0	3	1	1	1
94614	1710	prevent translocation	[preventing translocation]	0.0	2	2	2	1
94615	1710	glucocorticoid therapy in colitis	[glucocorticoid therapy in colitis]	0.0	4	1	1	1
94616	1710	precurser	[precursers]	0.0	1	1	1	1
94617	1710	first rdna	[first cDNAs]	0.0	2	1	1	1
94618	1710	region at position	[region at positions]	0.0	3	1	1	1
94619	1710	deletion of 346 C-terminal residue	[deletion of 346 C-terminal residues]	0.0	5	1	1	1
94620	1710	hormone acth stimulation test	[hormone ACTH stimulation tests]	0.0	4	1	1	1
94621	1710	appropriate regulation	[appropriate regulation]	0.0	2	1	1	1
94622	1710	repeat LTR nf-kappa b	[repeat LTR NF-kappa B]	0.0	4	1	1	1
94623	1710	Jurkat T cell cells/ml)	[Jurkat T cells cells/ml)]	0.0	4	1	1	1
94624	1710	age-related alteration	[age-related alterations]	0.0	2	1	1	1
94625	1710	decline in barrier function	[decline in barrier function]	0.0	4	1	1	1
94626	1710	theory of the histogenesis	[theories of the histogenesis]	0.0	4	1	1	1
94627	1710	more research	[more research]	0.0	2	1	1	1
94628	1710	perturbation	[perturbation]	0.0	1	1	1	1
94629	1710	class of transcription factor	[classes of transcription factors]	0.0	4	1	1	1
94630	1710	rapid turnover	[rapid turnover]	0.0	2	1	1	1
94631	1710	cell line lack Oct-2	[cell lines lacking Oct-2]	0.0	4	1	1	1
94632	1710	inhibitor of protein kinase activation	[inhibitor of protein kinase activation]	0.0	5	1	1	1
94633	1710	adherence-associated gene	[adherence-associated genes]	0.0	2	1	1	1
94634	1710	protein (ap-1) binding site	[protein (AP-1) binding site]	0.0	4	1	1	1
94635	1710	factor-1 receptor csf-1r	[factor-1 receptor CSF-1R]	0.0	3	1	1	1
94636	1710	contain repeat of amino acid	[containing repeats of amino acids]	0.0	5	1	1	1
94637	1710	cell inflammatory response to infection	[cell inflammatory responses to infection]	0.0	5	1	1	1
94638	1710	one gene, two transcript	[One gene, two transcripts]	0.0	4	1	1	1
94639	1710	metabolic status comparison with prognostic criteria]	[metabolic status comparison with prognostic criteria]]	0.0	6	1	1	1
94640	1710	HSB-2	[HSB-2]	0.0	1	1	1	1
94641	1710	cytochrome p-450 skf525a	[cytochrome P-450 SKF525a]	0.0	3	1	1	1
94642	1710	DNA control element	[DNA control elements]	0.0	3	1	1	1
94643	1710	leukostasis,	[leukostasis,]	0.0	1	1	1	1
94644	1710	endogenous ikappab kinase ikk activation	[endogenous IkappaB kinase IKK activation]	0.0	5	1	1	1
94645	1710	regression of fibrosarcomas	[regression of fibrosarcomas]	0.0	3	1	1	1
94646	1710	transduction mechanism	[transduction mechanism]	0.0	2	1	1	1
94647	1710	approach.	[approach.]	0.0	1	1	1	1
94648	1710	standard	[standard]	0.0	1	1	1	1
94649	1710	requirement for immunodeficiency virus entry	[requirement for immunodeficiency virus entry]	0.0	5	1	1	1
94650	1710	one line, re-expression	[one line, re-expression]	0.0	3	1	1	1
94651	1710	weight gain (14 +/-	[weight gain (14 +/-]	0.0	4	1	1	1
94652	1710	tumor necrosis factor alpha gene	[tumor necrosis factor alpha gene]	0.0	5	1	1	1
94653	1710	such as Epstein-Barr virus	[such as Epstein-Barr virus]	0.0	4	1	1	1
94654	1710	patient with malignant melanoma	[patients with malignant melanoma]	0.0	4	1	1	1
94655	1710	Biological marker of ovulation	[Biological markers of ovulation]	0.0	4	1	1	1
94656	1710	32Dcl3 cell express bcl-2	[32Dcl3 cells expressing Bcl-2]	0.0	4	1	1	1
94657	1710	cd40:	[CD40:]	0.0	1	1	1	1
94658	1710	endocrine cell type-specific formation	[endocrine cell type-specific formation]	0.0	4	1	1	1
94659	1710	octamer-DNA binding protein	[octamer-DNA binding proteins]	0.0	3	1	1	1
94660	1710	epo -dependent differentiation in erythroblast	[Epo -dependent differentiation in erythroblasts]	0.0	5	1	1	1
94661	1710	(1) ige production	[(1) IgE production]	0.0	3	1	1	1
94662	1710	cocultivation -express r59z activator cell	[cocultivation -expressing R59Z activator cells]	0.0	5	1	1	1
94663	1710	molecular chaperone hsp90	[molecular chaperone hsp90]	0.0	3	1	1	1
94664	1710	two distinct domain the ligand-binding domain	[two distinct domains the ligand-binding domain]	0.0	6	1	1	1
94665	1710	downstream binding factor	[downstream binding factor]	0.0	3	1	1	1
94666	1710	Tax1 expression of two transcription factor	[Tax1 expression of two transcription factors]	0.0	6	1	1	1
94667	1710	expression of a calcineurin	[Expression of a calcineurin]	0.0	4	1	1	1
94668	1710	specific glucocorticoid receptor blocker	[specific glucocorticoid receptor blocker]	0.0	4	1	1	1
94669	1710	role in the production	[role in the production]	0.0	4	1	1	1
94670	1710	affinity chromatography	[affinity chromatography]	0.0	2	1	1	1
94671	1710	characteristic of a 'silencer'	[characteristics of a 'silencer']	0.0	4	1	1	1
94672	1710	cell lineage as GATA-1	[cell lineages as GATA-1]	0.0	4	1	1	1
94673	1710	nuclear factor.kappa b	[nuclear factor.kappa B]	0.0	3	1	1	1
94674	1710	vector-mediated transduction	[vector-mediated transduction]	0.0	2	1	1	1
94675	1710	include pre-B leukemia	[including pre-B leukemia]	0.0	3	1	1	1
94676	1710	effect 1) inhibition	[effects 1) inhibition]	0.0	3	1	1	1
94677	1710	case of chronic leukemia	[cases of chronic leukemia]	0.0	4	1	1	1
94678	1710	endogenous murine protein,	[endogenous murine protein,]	0.0	3	1	1	1
94679	1710	transactivation domain of Stat5	[transactivation domains of Stat5]	0.0	4	1	1	1
94680	1710	seven unstable untreated patient	[seven unstable untreated patients]	0.0	4	1	1	1
94681	1710	results: in blood of pregnant woman	[RESULTS: In blood of pregnant women]	0.0	6	1	1	1
94682	1710	pathway for induction of cell death	[pathways for induction of cell death]	0.0	6	1	1	1
94683	1710	interaction between cellular protein	[interactions between cellular proteins]	0.0	4	1	1	1
94684	1710	use the LCK promoter	[using the LCK promoter]	0.0	4	1	1	1
94685	1710	consensus DNA	[consensus DNA]	0.0	2	1	1	1
94686	1710	subdominant cycle reactivity	[subdominant cycle reactivities]	0.0	3	1	1	1
94687	1710	ras in c5b-9 immunoprecipitate	[Ras in C5b-9 immunoprecipitates]	0.0	4	1	1	1
94688	1710	reading frame in the exon	[reading frame in the exon]	0.0	5	1	1	1
94689	1710	vivo inhibition	[vivo inhibition]	0.0	2	1	1	1
94690	1710	signal in precursor b cell	[signaling in precursor B cells]	0.0	5	1	1	1
94691	1710	complex translocations,	[complex translocations,]	0.0	2	1	1	1
94692	1710	GSH:oxidized gsh ratio	[GSH:oxidized GSH ratio]	0.0	3	1	1	1
94693	1710	5-aminolevulinate synthase promoter analysis	[5-aminolevulinate synthase promoter analysis]	0.0	4	1	1	1
94694	1710	gene in a erythropoietin manner	[genes in an erythropoietin manner]	0.0	5	1	1	1
94695	1710	(-139)long	[(-139)long]	0.0	1	1	1	1
94696	1710	mutation in the terminal repeat	[mutations in the terminal repeat]	0.0	5	1	1	1
94697	1710	activation in a cyclosporin a pathway	[Activation in a cyclosporin A pathway]	0.0	6	1	1	1
94698	1710	mature monocyte-derived m phi	[maturing monocyte-derived M phi]	0.0	4	1	1	1
94699	1710	transfectant of the porcine b-cell line	[transfectants of the porcine B-cell line]	0.0	6	1	1	1
94700	1710	T virus (htlv)-i	[T virus (HTLV)-I]	0.0	3	1	1	1
94701	1710	adenovirus gene therapy vector	[adenovirus gene therapy vectors]	0.0	4	1	1	1
94702	1710	variation in blood cell	[variation in blood cells]	0.0	4	1	1	1
94703	1710	such as generation	[such as generation]	0.0	3	1	1	1
94704	1710	rapidak accumulating, long-lasting tyrosine	[rapid, accumulating, long-lasting tyrosine]	0.0	4	1	1	1
94705	1710	understand the function during ontogeny	[understanding the function during ontogeny]	0.0	5	1	1	1
94706	1710	five major DNase-I site	[Five major DNase-I sites]	0.0	4	1	1	1
94707	1710	nf-kappab activation terminal repeat	[NF-kappaB activation terminal repeat]	0.0	4	1	1	1
94708	1710	il-10 pre-treatment	[IL-10 pre-treatment]	0.0	2	1	1	1
94709	1710	cd4+,	[CD4+,]	0.0	1	1	1	1
94710	1710	encode interleukin-2	[encoding interleukin-2]	0.0	2	1	1	1
94711	1710	nfat DNA	[NFAT DNA]	0.0	2	1	1	1
94712	1710	follow engagement (e.g. cell-to-cell contact).	[following engagement (e.g. cell-to-cell contact).]	0.0	5	1	1	1
94713	1710	separation from XIC/XIST	[separation from XIC/XIST]	0.0	3	1	1	1
94714	1710	55 kd, result from splicing	[55 kD, resulting from splicing]	0.0	5	1	1	1
94715	1710	human immunodeficiency virus type hiv- replication	[human immunodeficiency virus type HIV- replication]	0.0	6	1	1	1
94716	1710	phase of infection	[phase of infection]	0.0	3	1	1	1
94717	1710	protein human x box	[protein human X box]	0.0	4	1	1	1
94718	1710	negative form of CBP	[negative form of CBP]	0.0	4	1	1	1
94719	1710	breakpoint range	[breakpoints ranging]	0.0	2	1	1	1
94720	1710	beta-globin (hbb)-like gene	[beta-globin (HBB)-like genes]	0.0	3	1	1	1
94721	1710	pu.1 ggaa	[PU.1 GGAA]	0.0	2	1	1	1
94722	1710	repress Th1 development distinct from action	[repressing Th1 development distinct from actions]	0.0	6	1	1	1
94723	1710	hiv-1 repeat LTR transcription	[HIV-1 repeat LTR transcription]	0.0	4	1	1	1
94724	1710	modulation subsequent	[modulations subsequent]	0.0	2	1	1	1
94725	1710	20 control	[20 controls]	0.0	2	1	1	1
94726	1710	differentiation of progenitor to dendritic cell	[differentiation of progenitors to dendritic cells]	0.0	6	1	1	1
94727	1710	site for rela	[site for RelA]	0.0	3	1	1	1
94728	1710	bioactive m-csf protein	[bioactive M-CSF protein]	0.0	3	1	1	1
94729	1710	SCL protein level	[SCL protein levels]	0.0	3	2	2	1
94730	1710	undesirable activation	[undesirable activation]	0.0	2	1	1	1
94731	1710	NF-kappa b capacity	[NF-kappa B capacity]	0.0	3	1	1	1
94732	1710	coagulation activation	[coagulation activation]	0.0	2	1	1	1
94733	1710	sense orientation tata	[sense orientation tat/S]	0.0	3	1	1	1
94734	1710	sle (92.9%)	[SLE (92.9%)]	0.0	2	1	1	1
94735	1710	strength of T cell receptor	[Strength of T cell receptor]	0.0	5	1	1	1
94736	1710	cell a cellular component	[cells a cellular component]	0.0	4	1	1	1
94737	1710	methods, include annexin-V staining	[methods, including annexin-V staining]	0.0	4	1	1	1
94738	1710	macrophage form	[macrophage form]	0.0	2	1	1	1
94739	1710	(auc of +/- nmol	[(AUC of +/- nmol]	0.0	4	1	1	1
94740	1710	implication for the regulation of response	[implications for the regulation of responses]	0.0	6	1	1	1
94741	1710	mass of 80 kda.	[mass of 80 kDa.]	0.0	4	1	1	1
94742	1710	relative expression	[Relative expressions]	0.0	2	1	1	1
94743	1710	immunohistochemical staining with a panel	[immunohistochemical staining with a panel]	0.0	5	1	1	1
94744	1710	small deletion within beta-catenin	[small deletion within beta-catenin]	0.0	4	1	1	1
94745	1710	pyrolidine	[pyrolidine]	0.0	1	1	1	1
94746	1710	expression of the histocompatibility class	[expression of the histocompatibility class]	0.0	5	1	1	1
94747	1710	similar, activity	[similar, activity]	0.0	2	1	1	1
94748	1710	regulation during induction of monocytic differentiation	[Regulation during induction of monocytic differentiation]	0.0	6	1	1	1
94749	1710	tcr T	[TCR T]	0.0	2	1	1	1
94750	1710	Hunninghake, G. W. (1998) J.	[Hunninghake, G. W. (1998) J.]	0.0	5	1	1	1
94751	1710	induction of nuclear factor antibody	[Induction of nuclear factor antibodies]	0.0	5	1	1	1
94752	1710	family of receptors,	[family of receptors,]	0.0	3	1	1	1
94753	1710	potential target for therapy	[potential target for therapy]	0.0	4	1	1	1
94754	1710	generation of response	[generation of responses]	0.0	3	1	1	1
94755	1710	encode the hepatocyte nuclear factor HNF-1alpha	[encoding the hepatocyte nuclear factors HNF-1alpha]	0.0	6	1	1	1
94756	1710	beta ligand	[beta ligands]	0.0	2	1	1	1
94757	1710	HMG box protein	[HMG box proteins]	0.0	3	1	1	1
94758	1710	translocation oligonucleotide contain nf-kappab binding sequence	[translocation oligonucleotides containing NF-kappaB binding sequence]	0.0	6	1	1	1
94759	1710	IL-4 germline c	[IL-4 germline C]	0.0	3	1	1	1
94760	1710	form functional heterodimer	[forming functional heterodimers]	0.0	3	1	1	1
94761	1710	fetal organ culture	[fetal organ culture]	0.0	3	3	3	1
94762	1710	recombinant gp41 aa565-647 the domain	[recombinant gp41 aa565-647 the domain]	0.0	5	1	1	1
94763	1710	whole-cell method	[whole-cell method]	0.0	2	1	1	1
94764	1710	IL-4 fashion	[IL-4 fashion]	0.0	2	1	1	1
94765	1710	content of linear ebv DNA	[content of linear EBV DNA]	0.0	5	1	1	1
94766	1710	ineffective CD3 stimulation	[ineffective CD3 stimulation]	0.0	3	1	1	1
94767	1710	cytokine -production pattern	[cytokine -production patterns]	0.0	3	1	1	1
94768	1710	phosphotyrosine labeling	[phosphotyrosine labeling]	0.0	2	1	1	1
94769	1710	response to NF-kappa b activation	[response to NF-kappa B activation]	0.0	5	1	1	1
94770	1710	h with mAb	[h with mAb]	0.0	3	1	1	1
94771	1710	platelet activate factor as a ganglioside	[platelet activating factor as a gangliosides]	0.0	6	1	1	1
94772	1710	nf-kappa b subunit	[NF-kappa B subunits]	0.0	3	1	1	1
94773	1710	thus establish NF-kappaB	[thus establishing NF-kappaB]	0.0	3	1	1	1
94774	1710	hypolipidaemic proliferator	[hypolipidaemic proliferator]	0.0	2	1	1	1
94775	1710	status of knowledge	[status of knowledge]	0.0	3	1	1	1
94776	1710	event in human tumor	[events in human tumors]	0.0	4	1	1	1
94777	1710	several interaction	[Several interactions]	0.0	2	1	1	1
94778	1710	determinant of gene expression	[determinants of gene expression]	0.0	4	1	1	1
94779	1710	multiple stage	[multiple stages]	0.0	2	1	1	1
94780	1710	31834500), (range, 2594-3979)	[3183-4450), (range, 2594-3979)]	0.0	3	1	1	1
94781	1710	various stress agent like radiation exposure	[Various stress agents like radiation exposure]	0.0	6	1	1	1
94782	1710	C-terminal splice variant	[C-terminal splice variant]	0.0	3	1	1	1
94783	1710	etiology of palmar fibromatosis	[etiology of palmar fibromatosis]	0.0	4	1	1	1
94784	1710	effect on b-cll cell	[effects on B-CLL cells]	0.0	4	1	1	1
94785	1710	suppression of corticosterone	[suppression of corticosterone]	0.0	3	1	1	1
94786	1710	phosphatase-positive multinucleated giant cell from monocyte	[phosphatase-positive multinucleated giant cells from monocytes]	0.0	6	1	1	1
94787	1710	encode a mutant	[encoding a mutant]	0.0	3	1	1	1
94788	1710	background: tumor necrosis factor alpha	[BACKGROUND: Tumor necrosis factor alpha]	0.0	5	1	1	1
94789	1710	preexisting, T component	[preexisting, T component]	0.0	3	1	1	1
94790	1710	receptor gamma expression	[receptor gamma expression]	0.0	3	1	1	1
94791	1710	critical b gene	[critical B gene]	0.0	3	1	1	1
94792	1710	effect of chimeric gp130	[effect of chimeric gp130]	0.0	4	1	1	1
94793	1710	property for MHC class expression	[properties for MHC class expression]	0.0	5	1	1	1
94794	1710	considerable increase	[considerable increases]	0.0	2	1	1	1
94795	1710	glucocorticoid receptor messenger	[glucocorticoid receptor messenger]	0.0	3	1	1	1
94796	1710	constitute biological model for the marker	[constituting biological models for the markers]	0.0	6	1	1	1
94797	1710	il-8 by ECs	[IL-8 by ECs]	0.0	3	1	1	1
94798	1710	protease activation of b	[protease activation of B]	0.0	4	1	1	1
94799	1710	mobility shift ems analysis	[mobility shift EMS analyses]	0.0	4	1	1	1
94800	1710	network of interaction	[network of interactions]	0.0	3	1	1	1
94801	1710	stably associate	[stably associates]	0.0	2	1	1	1
94802	1710	multiple intracellular substrate	[multiple intracellular substrates]	0.0	3	1	1	1
94803	1710	class of receptor	[classes of receptors]	0.0	3	1	1	1
94804	1710	nonatopic control subject ige 112+/-28	[nonatopic control subjects IgE 112+/-28]	0.0	5	1	1	1
94805	1710	hormone deficiency	[hormone deficiency]	0.0	2	2	2	1
94806	1710	promoter activation via nf-kappa b	[promoter activation via NF-kappa B]	0.0	5	1	1	1
94807	1710	atf/ creb class	[ATF/ CREB class]	0.0	3	1	1	1
94808	1710	anti- immunodeficiency virus type	[anti- immunodeficiency virus type]	0.0	4	1	1	1
94809	1710	candidate gene for ags nuclear factor	[candidate genes for AGS nuclear factor]	0.0	6	1	1	1
94810	1710	nuclear factor of cell	[nuclear factor of cells]	0.0	4	1	1	1
94811	1710	tal1 transcription (affect	[TAL1 transcription (affecting]	0.0	3	1	1	1
94812	1710	component of memory	[components of memory]	0.0	3	1	1	1
94813	1710	various differentiation induction system	[various differentiation induction systems]	0.0	4	1	1	1
94814	1710	molecular weight of 50 kD	[molecular weight of 50 kD]	0.0	5	1	1	1
94815	1710	suggest extensive cross-talk	[suggesting extensive cross-talk]	0.0	3	1	1	1
94816	1710	modulation of receptor content	[modulation of receptor content]	0.0	4	1	1	1
94817	1710	fetal/neonatal t-cell activation	[fetal/neonatal T-cell activation]	0.0	3	1	1	1
94818	1710	RNA-positive	[RNA-positive]	0.0	1	1	1	1
94819	1710	translocation of NF-kappaB complex	[translocation of NF-kappaB complexes]	0.0	4	1	1	1
94820	1710	independent cloning from neuronal cell	[independent cloning from neuronal cells]	0.0	5	1	1	1
94821	1710	tail of the tnf-alpha	[tails of the TNF-alpha]	0.0	4	1	1	1
94822	1710	clone from the naive b cell	[clones from the naive B cells]	0.0	6	1	1	1
94823	1710	Functional study in extra-renal, cell	[Functional studies in extra-renal, cells]	0.0	5	1	1	1
94824	1710	Runt domain	[Runt domain]	0.0	2	1	1	1
94825	1710	expression of class major gene	[expression of class major genes]	0.0	5	1	1	1
94826	1710	enhancement of human immunodeficiency virus replication	[Enhancement of human immunodeficiency virus replication]	0.0	6	1	1	1
94827	1710	c/ebp activator nf-il-6	[C/EBP activator NF-IL-6]	0.0	3	1	1	1
94828	1710	activity in mouse	[activity in mice]	0.0	3	1	1	1
94829	1710	t-helper cell activation	[T-helper cell activation]	0.0	3	1	1	1
94830	1710	treat inflammation	[treating inflammation]	0.0	2	1	1	1
94831	1710	extensive granulopoiesis postnatally, typically die	[extensive granulopoiesis postnatally, typically dying]	0.0	5	1	1	1
94832	1710	model of cell line	[models of cell lines]	0.0	4	1	1	1
94833	1710	LTR alpha promoters,	[LTR alpha promoters,]	0.0	3	1	1	1
94834	1710	number of purine-rich stretch	[number of purine-rich stretches]	0.0	4	1	1	1
94835	1710	aneusomy with under-representation	[aneusomy with under-representation]	0.0	3	1	1	1
94836	1710	accumulation of cell	[accumulation of cells]	0.0	3	1	1	1
94837	1710	kD factor	[kD factor]	0.0	2	1	1	1
94838	1710	virus 40 enhancer	[virus 40 enhancer]	0.0	3	1	1	1
94839	1710	agreement on the pathogenesis of asthma	[agreement on the pathogenesis of asthma]	0.0	6	1	1	1
94840	1710	chimeric factor	[chimeric factors]	0.0	2	1	1	1
94841	1710	explain this collection	[explaining this collection]	0.0	3	1	1	1
94842	1710	fresh monocyte	[fresh monocytes]	0.0	2	1	1	1
94843	1710	cell cycle control of human cell	[cell cycle control of human cells]	0.0	6	1	1	1
94844	1710	hypotonic extract of T cell	[hypotonic extracts of T cells]	0.0	5	2	2	1
94845	1710	cell-dependent b cell immunopoiesis	[cell-dependent B cell immunopoiesis]	0.0	4	1	1	1
94846	1710	human genetic disorder	[human genetic disorder]	0.0	3	1	1	1
94847	1710	contain at least the transcription factor	[containing at least the transcription factor]	0.0	6	1	1	1
94848	1710	increase in il-2r alpha	[increase in IL-2R alpha]	0.0	4	1	1	1
94849	1710	pseudohypoaldosteronism in family form of inheritance	[Pseudohypoaldosteronism in families: forms of inheritance]	0.0	6	1	1	1
94850	1710	methionine codon	[methionine codons]	0.0	2	1	1	1
94851	1710	differentiation a experimental model	[differentiation a experimental model]	0.0	4	1	1	1
94852	1710	lipopolysaccharide expression	[lipopolysaccharide expression]	0.0	2	2	2	1
94853	1710	(12d:12l; light	[(12D:12L; lights]	0.0	2	1	1	1
94854	1710	mitogenic anti-cd2 antibody	[mitogenic anti-CD2 antibodies]	0.0	3	1	1	1
94855	1710	nf-kappab dna-binding complex	[NF-kappaB DNA-binding complex]	0.0	3	1	1	1
94856	1710	C-terminal homeodomain	[C-terminal homeodomain]	0.0	2	1	1	1
94857	1710	have a effect through tnf-alpha release	[having a effect through TNF-alpha release]	0.0	6	1	1	1
94858	1710	various mutant	[various mutants]	0.0	2	1	1	1
94859	1710	ut-7 epo	[UT-7 Epo]	0.0	2	1	1	1
94860	1710	(alpha)	[(alpha)]	0.0	1	1	1	1
94861	1710	use hbxag protein	[Using HBxAg protein]	0.0	3	1	1	1
94862	1710	macrophage-CSF in monocyte	[macrophage-CSF in monocytes]	0.0	3	1	1	1
94863	1710	modest increase in promoter strength	[modest increase in promoter strength]	0.0	5	1	1	1
94864	1710	renal insufficiency M-CRF	[renal insufficiency M-CRF]	0.0	3	1	1	1
94865	1710	specific chromosome translocation	[specific chromosome translocations]	0.0	3	1	1	1
94866	1710	physiological relevance	[physiological relevance]	0.0	2	3	3	1
94867	1710	express v-abl kinase activity	[expressing v-abl kinase activity]	0.0	4	1	1	1
94868	1710	nf-kappa b agent	[NF-kappa B agents]	0.0	3	1	1	1
94869	1710	human recessive disease xeroderma pigmentosum	[human recessive disease xeroderma pigmentosum]	0.0	5	1	1	1
94870	1710	molecular event coincide	[molecular events coinciding]	0.0	3	1	1	1
94871	1710	cell surface glycophorin	[cell surface glycophorin]	0.0	3	1	1	1
94872	1710	retinoblastoma control	[retinoblastoma control]	0.0	2	1	1	1
94873	1710	cobalt	[Cobalt]	0.0	1	1	1	1
94874	1710	adhesion molecule-1 cd106 on vein cell	[adhesion molecule-1 CD106 on vein cells]	0.0	6	1	1	1
94875	1710	dna-binding study evidence for formation	[DNA-binding studies evidence for formation]	0.0	5	1	1	1
94876	1710	ecd45ra+) T cell subset from donor	[(CD45RA+) T cell subsets from donors]	0.0	6	1	1	1
94877	1710	possible correlation with variable	[possible correlation with variables]	0.0	4	1	1	1
94878	1710	extracellular protein kinase	[extracellular protein kinase]	0.0	3	1	1	1
94879	1710	follow ptk activation	[following PTK activation]	0.0	3	1	1	1
94880	1710	wild-type acid receptor alpha	[wild-type acid receptor alpha]	0.0	4	1	1	1
94881	1710	identical nucleotide sequence	[identical nucleotide sequence]	0.0	3	1	1	1
94882	1710	nucleotide of the IL-2Rbeta promoter	[nucleotides of the IL-2Rbeta promoter]	0.0	5	1	1	1
94883	1710	nonmonocytic cell line	[nonmonocytic cell lines]	0.0	3	1	1	1
94884	1710	TNFR factor	[TNFR factors]	0.0	2	1	1	1
94885	1710	CD45-deficient variant	[CD45-deficient variants]	0.0	2	1	1	1
94886	1710	cellular factor-KB NF-kappa b	[cellular factor-KB NF-kappa B]	0.0	4	1	1	1
94887	1710	Fe2+	[Fe2+]	0.0	1	1	1	1
94888	1710	preexisting, T component nf-atp	[preexisting, T component NF-ATp]	0.0	4	1	1	1
94889	1710	Surprisingly, multimer of kappa 1-kappa	[Surprisingly, multimers of kappa 1-kappa]	0.0	5	1	1	1
94890	1710	differential assembly in T cell	[differential assembly in T cells]	0.0	5	1	1	1
94891	1710	underline the role during the process	[underlining the role during the process]	0.0	6	1	1	1
94892	1710	abnormality of adenosine monophosphate signal	[Abnormalities of adenosine monophosphate signaling]	0.0	5	1	1	1
94893	1710	hematopoietic stem cell hsc	[hematopoietic stem cells HSCs]	0.0	4	1	1	1
94894	1710	key mediator of interaction	[key mediators of interactions]	0.0	4	1	1	1
94895	1710	low to level	[low to levels]	0.0	3	1	1	1
94896	1710	individual of histocompatibility (mhc) haplotype	[individuals of histocompatibility (MHC) haplotypes]	0.0	5	1	1	1
94897	1710	stimulation of CD3	[stimulation of CD3]	0.0	3	1	1	1
94898	1710	parental cell line Jijoye	[parental cell line Jijoye]	0.0	4	1	1	1
94899	1710	new hypothesis	[new hypothesis]	0.0	2	1	1	1
94900	1710	genital tract of woman	[genital tracts of women]	0.0	4	1	1	1
94901	1710	residue of the cytoplasmic tail,	[residues of the cytoplasmic tail,]	0.0	5	1	1	1
94902	1710	transcriptional activity, DNA sequence specificity,	[transcriptional activity, DNA sequence specificity,]	0.0	5	1	1	1
94903	1710	pancreatic beta-cell function	[pancreatic beta-cell function]	0.0	3	1	1	1
94904	1710	cd8+), cd56+ cell	[CD8+), CD56+ cells]	0.0	3	1	1	1
94905	1710	malignant tumor material	[malignant tumor material]	0.0	3	1	1	1
94906	1710	hypothalamic level,	[hypothalamic level,]	0.0	2	1	1	1
94907	1710	indicate a requirement for additional interaction	[indicating a requirement for additional interactions]	0.0	6	1	1	1
94908	1710	tissue expression of the sclerosis gene	[Tissue expression of the sclerosis gene]	0.0	6	1	1	1
94909	1710	consist of healthy male	[consisting of healthy males]	0.0	4	1	1	1
94910	1710	promoter in cell of species	[promoters in cells of species]	0.0	5	1	1	1
94911	1710	XLA	[XLA]	0.0	1	1	1	1
94912	1710	constitutive binding of Sp1 in extract	[constitutive binding of Sp1 in extracts]	0.0	6	1	1	1
94913	1710	promyelocytic leukemia the variant	[promyelocytic leukemia the variant]	0.0	4	1	1	1
94914	1710	tcr receptor	[TCR receptors]	0.0	2	1	1	1
94915	1710	antigen-specific reactivity	[antigen-specific reactivities]	0.0	2	1	1	1
94916	1710	three prototype stress hormone	[three prototype stress hormones]	0.0	4	1	1	1
94917	1710	relevant NF-kappa b	[relevant NF-kappa B]	0.0	3	1	1	1
94918	1710	two homologue	[Two homologues]	0.0	2	1	1	1
94919	1710	induction of the replication cycle	[induction of the replication cycle]	0.0	5	1	1	1
94920	1710	mitogen-activated protein kinase tyrosine phosphatase	[mitogen-activated protein kinase tyrosine phosphatase]	0.0	5	1	1	1
94921	1710	retinoic enzyme aldehyde dehydrogenase Aldh1	[retinoic enzyme aldehyde dehydrogenase Aldh1]	0.0	5	1	1	1
94922	1710	tetrahydrocortisol mg/24h;	[tetrahydrocortisol mg/24h;]	0.0	2	1	1	1
94923	1710	manifestation of advanced infection	[manifestations of advanced infection]	0.0	4	1	1	1
94924	1710	antigen T cell-b cell interaction	[antigen T cell-B cell interactions]	0.0	5	1	1	1
94925	1710	72 P; in protein	[72 h; in protein]	0.0	4	1	1	1
94926	1710	ifn-alpha receptor	[IFN-alpha receptor]	0.0	2	1	1	1
94927	1710	large dose	[large doses]	0.0	2	1	1	1
94928	1710	stat1 immune-response gene	[Stat1 immune-response genes]	0.0	3	1	1	1
94929	1710	completely substitute	[completely substitutes]	0.0	2	1	1	1
94930	1710	biological response to the hormone,	[biological responses to the hormone,]	0.0	5	1	1	1
94931	1710	chloramphenicol acetyltransferase assay after cotransfection	[Chloramphenicol acetyltransferase assay after cotransfection]	0.0	5	1	1	1
94932	1710	p53 mechanism	[p53 mechanism]	0.0	2	1	1	1
94933	1710	RAR alpha expression	[RAR alpha expression]	0.0	3	1	1	1
94934	1710	graves' disease gd	[Graves' disease GD]	0.0	3	1	1	1
94935	1710	decline in blood histamine	[decline in blood histamine]	0.0	4	1	1	1
94936	1710	unique transcriptional mechanism	[unique transcriptional mechanism]	0.0	3	1	1	1
94937	1710	express ebna2 as fusion protein	[expressing EBNA2 as fusion protein]	0.0	5	1	1	1
94938	1710	p50 NF-kappa b	[p50 NF-kappa B]	0.0	3	1	1	1
94939	1710	vitro substrate for calcineurin	[vitro substrate for calcineurin]	0.0	4	1	1	1
94940	1710	zap-70 associate	[ZAP-70 associates]	0.0	2	1	1	1
94941	1710	Ca2+ induction of gene	[Ca2+ induction of genes]	0.0	4	1	1	1
94942	1710	src homology (sh2) domain	[src homology (SH2) domain]	0.0	4	1	1	1
94943	1710	transcription factor include AP-1	[transcription factors including AP-1]	0.0	4	1	1	1
94944	1710	two potential open reading frame	[two potential open reading frames]	0.0	5	1	1	1
94945	1710	cell type-specific activation of STAT3	[cell type-specific activation of STAT3]	0.0	5	1	1	1
94946	1710	variation during the cycle	[variations during the cycle]	0.0	4	1	1	1
94947	1710	other macrophage marker	[other macrophage markers]	0.0	3	1	1	1
94948	1710	PHA-stimulated T lymphocyte	[PHA-stimulated T lymphocytes]	0.0	3	1	1	1
94949	1710	insight into molecular event	[insights into molecular events]	0.0	4	1	1	1
94950	1710	vein cell CoCl2	[vein cells CoCl2]	0.0	3	1	1	1
94951	1710	abolish hat activity	[abolishing HAT activity]	0.0	3	1	1	1
94952	1710	egl from proliferative samples, activity	[eGLs from proliferative samples, activity]	0.0	5	1	1	1
94953	1710	Octamer factor	[Octamer factors]	0.0	2	1	1	1
94954	1710	tnf-alpha a PKC stimulus	[TNF-alpha a PKC stimulus]	0.0	4	1	1	1
94955	1710	isolation of lh-2	[isolation of LH-2]	0.0	3	1	1	1
94956	1710	pkc inhibitor ro	[PKC inhibitor Ro]	0.0	3	1	1	1
94957	1710	factor-kappa B	[factor-kappa B]	0.0	2	1	1	1
94958	1710	family kinase	[family kinase]	0.0	2	1	1	1
94959	1710	islet b	[islet B]	0.0	2	1	1	1
94960	1710	removal from the medium	[removal from the medium]	0.0	4	1	1	1
94961	1710	component of the vaginal floram	[component of the vaginal flora,]	0.0	5	1	1	1
94962	1710	less efficiently by H-8,	[less efficiently by H-8,]	0.0	4	1	1	1
94963	1710	only in the structure of domain	[only in the structures of domains]	0.0	6	1	1	1
94964	1710	differentiation include the CD34 promoter	[differentiation including the CD34 promoter]	0.0	5	1	1	1
94965	1710	marker for a region	[markers for an region]	0.0	4	1	1	1
94966	1710	promise	[promise]	0.0	1	1	1	1
94967	1710	t(12;15) translocation	[t(12;15) translocation]	0.0	2	1	1	1
94968	1710	one factor determine specific gene activation	[one factor determining specific gene activation]	0.0	6	1	1	1
94969	1710	dnase footprinting of the TNF-alpha promoter	[DNase footprinting of the TNF-alpha promoter]	0.0	6	1	1	1
94970	1710	human monoclonal antibody	[human monoclonal antibody]	0.0	3	1	1	1
94971	1710	two kind the steroid-MR complex	[two kinds the steroid-MR complex]	0.0	5	1	1	1
94972	1710	cellular transcriptional factor-KB	[cellular transcriptional factor-KB]	0.0	3	1	1	1
94973	1710	novel lysis substrate	[novel lysis substrate]	0.0	3	1	1	1
94974	1710	responsiveness in Philadelphia chromosome	[responsiveness in Philadelphia chromosome]	0.0	4	1	1	1
94975	1710	bp relative to the cap site	[bp relative to the cap site]	0.0	6	1	1	1
94976	1710	cdc10/ankyrin motif	[cdc10/ankyrin motif]	0.0	2	1	1	1
94977	1710	lymphoblastic leukemia t-all	[lymphoblastic leukemia T-ALL]	0.0	3	1	1	1
94978	1710	tal-1 transcription in line	[TAL-1 transcription in lines]	0.0	4	1	1	1
94979	1710	two distinct cell surface receptor	[two distinct cell surface receptors]	0.0	5	1	1	1
94980	1710	the/thf (0.24; n:	[THE/THF (0.24; N:]	0.0	3	1	1	1
94981	1710	correlation with variable such as stage	[correlation with variables such as stage]	0.0	6	1	1	1
94982	1710	RANTES factor	[RANTES Factor]	0.0	2	1	1	1
94983	1710	various aspect	[various aspects]	0.0	2	2	2	1
94984	1710	interleukin-10 il-10 production in monocyte	[interleukin-10 IL-10 production in monocytes]	0.0	5	1	1	1
94985	1710	ramification in T cell development	[ramifications in T cell development]	0.0	5	1	1	1
94986	1710	qp function,	[Qp function,]	0.0	2	1	1	1
94987	1710	heterotrans-activation of JAK1	[heterotrans-activation of JAK1]	0.0	3	1	1	1
94988	1710	3' utr	[3' UTR]	0.0	2	1	1	1
94989	1710	lytic cycle progeny virus expression	[lytic cycle progeny virus expression]	0.0	5	1	1	1
94990	1710	Latent membrane protein of Epstein-Barr virus	[Latent membrane protein of Epstein-Barr virus]	0.0	6	1	1	1
94991	1710	provide the activity.	[providing the activity.]	0.0	3	1	1	1
94992	1710	sialoglycoprotein of leukocyte	[sialoglycoprotein of leukocytes]	0.0	3	1	1	1
94993	1710	expression of nfat-family protein	[Expression of NFAT-family proteins]	0.0	4	1	1	1
94994	1710	type of response	[types of responses]	0.0	3	1	1	1
94995	1710	induction with appropriate inducers.	[induction with appropriate inducers.]	0.0	4	1	1	1
94996	1710	human myeloproliferative disorder	[human myeloproliferative disorders]	0.0	3	1	1	1
94997	1710	c/ebP-binding site	[C/EBP-binding site]	0.0	2	1	1	1
94998	1710	cell express high level	[cells expressing high levels]	0.0	4	1	1	1
94999	1710	target for signalling process	[targets for signalling processes]	0.0	4	1	1	1
95000	1710	496 stage I-II patient	[496 Stage I-II patients]	0.0	4	1	1	1
95001	1710	contrast, out of patient	[contrast, out of patients]	0.0	4	1	1	1
95002	1710	paf change	[PAF changes]	0.0	2	1	1	1
95003	1710	often converge in intracellular pathway	[often converging in intracellular pathways]	0.0	5	1	1	1
95004	1710	Clathrin	[Clathrin]	0.0	1	1	1	1
95005	1710	inhibitors, cyclosporin a CsA	[inhibitors, cyclosporin A CsA]	0.0	4	1	1	1
95006	1710	tax -independent mechanism	[Tax -independent mechanism]	0.0	3	1	1	1
95007	1710	involve calcium	[involving calcium]	0.0	2	1	1	1
95008	1710	correlation between ic5 of prednisolone	[correlation between IC50S of prednisolone]	0.0	5	1	1	1
95009	1710	down-regulation of icam-i	[down-regulation of ICAM-I]	0.0	3	1	1	1
95010	1710	transcription factor kB	[transcription factor kB]	0.0	3	1	1	1
95011	1710	increase in the localization	[increases in the localization]	0.0	4	1	1	1
95012	1710	murine cDNA encoding transcription	[murine cDNA encoding transcription]	0.0	4	1	1	1
95013	1710	b4-2	[B4-2]	0.0	1	1	1	1
95014	1710	oligodeoxynucleotides target gata-1 p45 nf-e2 protein	[oligodeoxynucleotides targeting GATA-1 p45 NF-E2 proteins]	0.0	6	1	1	1
95015	1710	loss of interleukin	[loss of interleukin]	0.0	3	1	1	1
95016	1710	difference in this related hematopoietic lineage	[differences in these related hematopoietic lineages]	0.0	6	1	1	1
95017	1710	CsA manner	[CsA manner]	0.0	2	2	2	1
95018	1710	intensity, by the gch	[intensity, by the GCH]	0.0	4	1	1	1
95019	1710	placebo administration	[placebo administration]	0.0	2	1	1	1
95020	1710	oxidoreductive regulation of factor	[Oxidoreductive regulation of factor]	0.0	4	1	1	1
95021	1710	cellular coactivator	[cellular coactivator]	0.0	2	1	1	1
95022	1710	stimulation with (il-6) a multipotential cytokine	[stimulation with (IL-6) an multipotential cytokine]	0.0	6	1	1	1
95023	1710	translocation of c-Rel /p65 heterodimer	[translocation of c-Rel /p65 heterodimers]	0.0	5	2	2	1
95024	1710	role of the IkKs	[role of the IKKs]	0.0	4	1	1	1
95025	1710	down-regulation of icam-1	[down-regulation of ICAM-1]	0.0	3	1	1	1
95026	1710	b7.1 b cell	[B7.1 B cells]	0.0	3	1	1	1
95027	1710	volunteer without psychiatric disorder	[volunteers without psychiatric disorders]	0.0	4	1	1	1
95028	1710	stat3alpha protein	[STAT3alpha proteins]	0.0	2	1	1	1
95029	1710	defective transcription	[Defective transcription]	0.0	2	1	1	1
95030	1710	oligonucleotide to the p65 subunit	[oligonucleotides to the p65 subunit]	0.0	5	1	1	1
95031	1710	physiopathologic role	[physiopathologic role]	0.0	2	1	1	1
95032	1710	heat-labile	[heat-labile]	0.0	1	1	1	1
95033	1710	interaction between c-Jun complex	[interaction between c-Jun complexes]	0.0	4	1	1	1
95034	1710	homology to Bcl-2	[homology to Bcl-2]	0.0	3	1	1	1
95035	1710	useful drug	[useful drug]	0.0	2	1	1	1
95036	1710	complementation analysis	[complementation analysis]	0.0	2	1	1	1
95037	1710	immunodeficiency virus contain linker substitution mutation	[immunodeficiency viruses containing linker substitution mutations]	0.0	6	1	1	1
95038	1710	messenger for the effect	[messenger for the effects]	0.0	4	1	1	1
95039	1710	t-cell leukemia virus htlv-i	[T-cell leukemia virus HTLV-I]	0.0	4	2	2	1
95040	1710	nf-kb-related factor	[NF-KB-related factors]	0.0	2	1	1	1
95041	1710	addition, DNA	[addition, DNA]	0.0	2	1	1	1
95042	1710	co-express the il-10r	[co-expressing the IL-10R]	0.0	3	1	1	1
95043	1710	however, a transactivator of element-containing promoter	[However, a transactivator of element-containing promoters]	0.0	6	1	1	1
95044	1710	proximal sequence element	[proximal sequence element]	0.0	3	1	1	1
95045	1710	correlation between lymphocyte infiltration	[correlation between lymphocyte infiltration]	0.0	4	1	1	1
95046	1710	tf antibody	[TF antibody]	0.0	2	1	1	1
95047	1710	[induction	[[Induction]	0.0	1	1	1	1
95048	1710	role in the proliferation	[role in the proliferation]	0.0	4	1	1	1
95049	1710	200 bp	[200 bp]	0.0	2	1	1	1
95050	1710	however, two x-inactivation pattern	[however, two X-inactivation patterns]	0.0	4	1	1	1
95051	1710	infection of immunodeficiency virus analysis LTR	[Infection of immunodeficiency viruses analyses LTR]	0.0	6	1	1	1
95052	1710	proximal CD25 promoter	[proximal CD25 promoter]	0.0	3	1	1	1
95053	1710	c-fo expression in b cell	[c-fos expression in B cells]	0.0	5	1	1	1
95054	1710	adhesion molecule include alpha	[adhesion molecules including alpha]	0.0	4	1	1	1
95055	1710	binding of 125i-labeled aldosterone	[Binding of 125I-labeled aldosterone]	0.0	4	1	1	1
95056	1710	three category cell-specific factor	[three categories cell-specific factors]	0.0	4	1	1	1
95057	1710	understanding of regulation of adhesion molecule	[understanding of regulation of adhesion molecules]	0.0	6	1	1	1
95058	1710	volunteers,	[volunteers,]	0.0	1	1	1	1
95059	1710	patient with chronic leukemia CLL	[patients with chronic leukemia CLL]	0.0	5	1	1	1
95060	1710	[3H] DHEA	[[3H] DHEA]	0.0	2	1	1	1
95061	1710	control (abdominal obese:	[controls (abdominal obese:]	0.0	3	1	1	1
95062	1710	treatment of blood T cell	[Treatment of blood T cells]	0.0	5	1	1	1
95063	1710	IL-2 cell antigen receptor induction	[IL-2 cell antigen receptor induction]	0.0	5	1	1	1
95064	1710	paracrine effect on expression	[paracrine effect on expression]	0.0	4	1	1	1
95065	1710	(3h)-thymidine incorporation	[(3H)-thymidine incorporation]	0.0	2	1	1	1
95066	1710	certain subject	[certain subjects]	0.0	2	1	1	1
95067	1710	(three individual	[(three individuals]	0.0	2	1	1	1
95068	1710	role in fasL up-regulation	[role in fasL up-regulation]	0.0	4	1	1	1
95069	1710	(hour 48) of the enzyme	[(hour 48) of the enzyme]	0.0	5	1	1	1
95070	1710	first cytokine gene	[first cytokine gene]	0.0	3	1	1	1
95071	1710	human MHC class gene transcription	[Human MHC class gene transcription]	0.0	5	1	1	1
95072	1710	g-csf dead cell at day	[G-CSF dead cells at day]	0.0	5	1	1	1
95073	1710	additional distinct transcription factor	[additional distinct transcription factors]	0.0	4	1	1	1
95074	1710	treatment of hcd57 cell	[Treatment of HCD57 cells]	0.0	4	1	1	1
95075	1710	hiv repeat transcription in hiv cell	[HIV repeat transcription in HIV cells]	0.0	6	1	1	1
95076	1710	human gata-4	[human GATA-4]	0.0	2	1	1	1
95077	1710	Effect of aldosterone	[Effects of aldosterone]	0.0	3	1	1	1
95078	1710	molecular mass,	[molecular mass,]	0.0	2	1	1	1
95079	1710	immediate-early protein ie1	[immediate-early protein IE1]	0.0	3	1	1	1
95080	1710	gene expression of cell growth-related gene	[gene expression of cell growth-related genes]	0.0	6	1	1	1
95081	1710	(kappa B)	[(kappa B)]	0.0	2	1	1	1
95082	1710	generation compound Canventol	[generation compound Canventol]	0.0	3	1	1	1
95083	1710	newly emerge family	[newly emerging family]	0.0	3	1	1	1
95084	1710	potencies, with ec50 value	[potencies, with EC50 values]	0.0	4	1	1	1
95085	1710	decrease in induction	[decrease in induction]	0.0	3	1	1	1
95086	1710	many species	[many species]	0.0	2	1	1	1
95087	1710	use in a variety	[use in a variety]	0.0	4	1	1	1
95088	1710	use adeno-associated virus	[using adeno-associated virus]	0.0	3	1	1	1
95089	1710	removal of 20 residue	[removal of 20 residues]	0.0	4	1	1	1
95090	1710	transactivation of cis element S	[transactivation of cis elements S]	0.0	5	1	1	1
95091	1710	follow lps stimulation in addition	[following LPS stimulation in addition]	0.0	5	1	1	1
95092	1710	gcr count	[GCR count]	0.0	2	1	1	1
95093	1710	combination of T cell stimulus	[combination of T cell stimuli]	0.0	5	1	1	1
95094	1710	several oncoprotein	[several oncoproteins]	0.0	2	1	1	1
95095	1710	respectively), indicate a rate of apoptosis	[respectively), indicating an rate of apoptosis]	0.0	6	1	1	1
95096	1710	malignant melanoma RCC	[malignant melanoma RCC]	0.0	3	1	1	1
95097	1710	loci on the arm	[loci on the arm]	0.0	4	1	1	1
95098	1710	effect in the T lymphocyte	[effect in the T lymphocytes]	0.0	5	1	1	1
95099	1710	mononuclear leukocyte from male	[mononuclear leukocytes from males]	0.0	4	1	1	1
95100	1710	expression of human MHC class gene	[expression of human MHC class genes]	0.0	6	1	1	1
95101	1710	factor colony-stimulating factor	[factor colony-stimulating factor]	0.0	3	1	1	1
95102	1710	aging change of receptor	[aging changes of receptor]	0.0	4	1	1	1
95103	1710	major factor for the expression	[major factor for the expression]	0.0	5	1	1	1
95104	1710	placebo-controlled crossover study	[placebo-controlled crossover study]	0.0	3	1	1	1
95105	1710	receptor complex in rabbit uterine	[receptor complexes in rabbit uterine]	0.0	5	1	1	1
95106	1710	expression of the lectin galectin-3	[expression of the lectin galectin-3]	0.0	5	1	1	1
95107	1710	specific domain sequence	[specific domain sequences]	0.0	3	1	1	1
95108	1710	effect generation	[effect generation]	0.0	2	1	1	1
95109	1710	mature normal myeloid cell	[mature normal myeloid cells]	0.0	4	1	1	1
95110	1710	alveoli, elevation	[alveoli, elevation]	0.0	2	1	1	1
95111	1710	tetraproline	[tetraproline]	0.0	1	1	1	1
95112	1710	erythroid development; addition to hpc	[erythroid development; addition to HPC]	0.0	5	1	1	1
95113	1710	peroxyl radical scavenging	[peroxyl radical scavenging]	0.0	3	1	1	1
95114	1710	first visit, within week	[first visit, within weeks]	0.0	4	1	1	1
95115	1710	stimulation, new kappa B-specific complex	[stimulation, new kappa B-specific complexes]	0.0	5	1	1	1
95116	1710	certain subset	[certain subsets]	0.0	2	1	1	1
95117	1710	N-terminal sequence homology	[N-terminal sequence homology]	0.0	3	1	1	1
95118	1710	stage-	[stage-]	0.0	1	1	1	1
95119	1710	hpp-cfc colony	[HPP-CFC colonies]	0.0	2	1	1	1
95120	1710	target gata-1 nf-e2 protein	[targeting GATA-1 NF-E2 proteins]	0.0	4	1	1	1
95121	1710	b -related protein	[B -related proteins]	0.0	3	1	1	1
95122	1710	numerous atypical feature	[numerous atypical features]	0.0	3	1	1	1
95123	1710	activation by modification of protein kinase	[activation by modification of protein kinases]	0.0	6	1	1	1
95124	1710	only in DC	[only in DC]	0.0	3	1	1	1
95125	1710	signal for optimal induction, PMA	[signals for optimal induction, PMA]	0.0	5	1	1	1
95126	1710	two cell in the system	[two cells in the system]	0.0	5	1	1	1
95127	1710	PPARbeta	[PPARbeta]	0.0	1	1	1	1
95128	1710	accumulation of the viral gag-pol mrna	[accumulation of the viral gag-pol mRNA]	0.0	6	1	1	1
95129	1710	such interaction	[such interactions]	0.0	2	1	1	1
95130	1710	8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	5	1	1	1
95131	1710	Rapid shuttling of NF-AT	[Rapid shuttling of NF-AT]	0.0	4	1	1	1
95132	1710	hiv-1 expression,	[HIV-1 expression,]	0.0	2	1	1	1
95133	1710	three genotype groups,	[three genotype groups,]	0.0	3	1	1	1
95134	1710	suggest a function of the c-erbA	[suggesting a function of the c-erbA]	0.0	6	1	1	1
95135	1710	stretch for the factor	[stretches for the factors]	0.0	4	1	1	1
95136	1710	tax deletion	[Tax deletion]	0.0	2	1	1	1
95137	1710	stress with oxygen formation	[stress with oxygen formation]	0.0	4	1	1	1
95138	1710	atra receptor (rar) gene	[ATRA receptor (RAR) gene]	0.0	4	1	1	1
95139	1710	intracellular concentration of Ca2+	[intracellular concentration of Ca2+]	0.0	4	1	1	1
95140	1710	possible approach to the immunotherapy	[possible approaches to the immunotherapy]	0.0	5	1	1	1
95141	1710	method in cell	[method in cells]	0.0	3	1	1	1
95142	1710	gm-csf production	[GM-CSF production]	0.0	2	1	1	1
95143	1710	inoculation (i.p.)	[inoculation (i.p.)]	0.0	2	1	1	1
95144	1710	degree, infiltration	[degree, infiltration]	0.0	2	1	1	1
95145	1710	isoform Pax-5	[isoform Pax-5]	0.0	2	1	1	1
95146	1710	cd27- b cell	[CD27- B cells]	0.0	3	1	1	1
95147	1710	IFN assembly	[IFN assembly]	0.0	2	1	1	1
95148	1710	micromol/L; genistein	[micromol/L; genistein]	0.0	2	1	1	1
95149	1710	frequent expression in placentae	[frequent expression in placentae]	0.0	4	1	1	1
95150	1710	lymphocyte death	[lymphocyte death]	0.0	2	2	2	1
95151	1710	prevention through selective displacement	[prevention through selective displacement]	0.0	4	1	1	1
95152	1710	include more vigorous tyrosine phosphorylation	[including more vigorous tyrosine phosphorylation]	0.0	5	1	1	1
95153	1710	lactosylceramide present	[lactosylceramide present]	0.0	2	1	1	1
95154	1710	support of this mutation	[support of this mutation]	0.0	4	1	1	1
95155	1710	inhibitor of map kinase platelet-activating factor	[Inhibitors of MAP kinase platelet-activating factor]	0.0	6	1	1	1
95156	1710	chemoattractant cytokine important	[chemoattractant cytokine important]	0.0	3	1	1	1
95157	1710	'octamer' sequence	['octamer' sequence]	0.0	2	1	1	1
95158	1710	complete elimination of suppression	[complete elimination of suppression]	0.0	4	1	1	1
95159	1710	include alpha- globin band	[including alpha- globin band]	0.0	4	1	1	1
95160	1710	CBFA2 locus	[CBFA2 locus]	0.0	2	1	1	1
95161	1710	however, more recent study	[However, more recent studies]	0.0	4	1	1	1
95162	1710	oral prednisolone	[oral prednisolone]	0.0	2	1	1	1
95163	1710	co-treatment of IL-4	[Co-treatment of IL-4]	0.0	3	1	1	1
95164	1710	series of hl-60 subclone	[series of HL-60 subclones]	0.0	4	1	1	1
95165	1710	parameters, such as glycosidase activity	[parameters, such as glycosidase activities]	0.0	5	1	1	1
95166	1710	expression in b lymphoblast	[expression in B lymphoblasts]	0.0	4	1	1	1
95167	1710	lymphocyte function	[lymphocyte function]	0.0	2	1	1	1
95168	1710	interleukin signal pathway	[interleukin signaling pathways]	0.0	3	1	1	1
95169	1710	different type of disease	[different types of disease]	0.0	4	1	1	1
95170	1710	uptake of NF-kappa b complex	[uptake of NF-kappa B complexes]	0.0	5	1	1	1
95171	1710	less than ng angiotensin i/l	[less than ng angiotensin I/L]	0.0	5	1	1	1
95172	1710	same electrophoretic mobility 120 kd)	[same electrophoretic mobility 120 kD)]	0.0	5	1	1	1
95173	1710	C. pneumoniae	[C. pneumoniae]	0.0	2	1	1	1
95174	1710	il2r	[IL2R]	0.0	1	1	1	1
95175	1710	view of a impaired plasticity	[view of an impaired plasticity]	0.0	5	1	1	1
95176	1710	hematopoietic cell molecule	[hematopoietic cell molecules]	0.0	3	1	1	1
95177	1710	interleukin receptor superfamily	[interleukin receptor superfamily]	0.0	3	1	1	1
95178	1710	avian retroviruse	[avian retroviruses]	0.0	2	1	1	1
95179	1710	adhesion the tethering factor	[Adhesion the tethering factor]	0.0	4	1	1	1
95180	1710	level of pu.1 Spi-1	[levels of PU.1 Spi-1]	0.0	4	1	1	1
95181	1710	region contain four repeat DR	[region containing four repeats DR]	0.0	5	1	1	1
95182	1710	glucocorticoid in leukemia	[glucocorticoids in leukemia]	0.0	3	1	1	1
95183	1710	Specific effect of dioxyvit	[Specific effect of dioxyvit]	0.0	4	1	1	1
95184	1710	lymphocyte in active sle (92.9%)	[lymphocytes in active SLE (92.9%)]	0.0	5	1	1	1
95185	1710	surface of macrophage	[surface of macrophages]	0.0	3	1	1	1
95186	1710	particular, class of protein	[particular, class of proteins]	0.0	4	1	1	1
95187	1710	par protein	[PAR proteins]	0.0	2	1	1	1
95188	1710	effect on cd34+ cell g-csf cell	[effects on CD34+ cells G-CSF cells]	0.0	6	1	1	1
95189	1710	different factor with affinity	[different factors with affinity]	0.0	4	1	1	1
95190	1710	rapid expansion now suitable	[rapid expansion now suitable]	0.0	4	1	1	1
95191	1710	several block	[several blocks]	0.0	2	1	1	1
95192	1710	t-cell-activating superantigen enterotoxin a sea	[T-cell-activating superantigen enterotoxin A SEA]	0.0	5	1	1	1
95193	1710	Fusion of murine T cell	[Fusion of murine T cells]	0.0	5	1	1	1
95194	1710	anti-p-selectin antibody phase-1 neutrophil adhesion	[anti-P-selectin antibodies phase-1 neutrophil adhesion]	0.0	5	1	1	1
95195	1710	overexpression of ikappab-alpha	[overexpression of IkappaB-alpha]	0.0	3	1	1	1
95196	1710	zeta-globin gene	[zeta-globin gene]	0.0	2	1	1	1
95197	1710	Interestingly, alteration in a 70-base-pair fragment	[Interestingly, alteration in a 70-base-pair fragment]	0.0	6	1	1	1
95198	1710	occur in patient suffer	[occurring in patients suffering]	0.0	4	1	1	1
95199	1710	migrating complex	[migrating complexes]	0.0	2	1	1	1
95200	1710	expression of the major class	[expression of the major class]	0.0	5	1	1	1
95201	1710	AP-2 cDNA	[AP-2 cDNA]	0.0	2	1	1	1
95202	1710	expression of triptolide degradation	[expression of triptolide degradation]	0.0	4	1	1	1
95203	1710	mouse with human cd3epsilon gene	[mice with human CD3epsilon gene]	0.0	5	1	1	1
95204	1710	replication of a virus	[replication of a virus]	0.0	4	1	1	1
95205	1710	differentiation to monocyte	[differentiation to monocytes]	0.0	3	1	1	1
95206	1710	suggest autoregulatory control	[suggesting autoregulatory control]	0.0	3	1	1	1
95207	1710	give inhibition	[giving inhibition]	0.0	2	1	1	1
95208	1710	49 patient	[49 patients]	0.0	2	1	1	1
95209	1710	6 to 24 hours.	[6 to 24 hours.]	0.0	4	1	1	1
95210	1710	Regulatory effect during lung injury	[Regulatory effects during lung injury]	0.0	5	1	1	1
95211	1710	gst-pi promoter	[GST-pi promoter]	0.0	2	1	1	1
95212	1710	abundance of a VDR	[abundance of a VDR]	0.0	4	1	1	1
95213	1710	several gene such as ip-10	[several genes such as IP-10]	0.0	5	1	1	1
95214	1710	HPC differentiation	[HPC differentiation]	0.0	2	1	1	1
95215	1710	acid lipase in differentiate monocyte	[acid lipase in differentiating monocytes]	0.0	5	1	1	1
95216	1710	biochemical signal lead	[biochemical signals leading]	0.0	3	1	1	1
95217	1710	effect of tcdd	[effect of TCDD]	0.0	3	1	1	1
95218	1710	patient with primary syndrome MDS	[patients with primary syndromes MDS]	0.0	5	1	1	1
95219	1710	option for hiv gene therapy	[option for HIV gene therapy]	0.0	5	1	1	1
95220	1710	p50/p105-NF-kappa b	[p50/p105-NF-kappa B]	0.0	2	1	1	1
95221	1710	only interleukin expression on the surface	[only interleukin expression on the surface]	0.0	6	1	1	1
95222	1710	antagonistic antibody	[antagonistic antibody]	0.0	2	1	1	1
95223	1710	leader protein	[leader protein]	0.0	2	1	1	1
95224	1710	Jak tyrosine kinase	[Jak tyrosine kinases]	0.0	3	1	1	1
95225	1710	consist of 32 healthy male	[consisting of 32 healthy males]	0.0	5	1	1	1
95226	1710	binding to the intracellular receptor	[binding to the intracellular receptor]	0.0	5	1	1	1
95227	1710	important role mediate neutrophil adhesion	[important role mediating neutrophil adhesion]	0.0	5	1	1	1
95228	1710	monocytic activity factor colony-stimulating factor	[monocytic activity factor colony-stimulating factor]	0.0	5	1	1	1
95229	1710	low multinuclearity	[low multinuclearity]	0.0	2	1	1	1
95230	1710	suppress b mobilization	[suppressing B mobilization]	0.0	3	1	1	1
95231	1710	4-fold increase	[4-fold increase]	0.0	2	2	2	1
95232	1710	cytoplasmic signal molecule	[cytoplasmic signaling molecules]	0.0	3	1	1	1
95233	1710	belong to subgroup	[belonging to subgroups]	0.0	3	1	1	1
95234	1710	induction of a labile factor	[induction of a labile factor]	0.0	5	1	1	1
95235	1710	receptor number during depression	[receptor numbers during depression]	0.0	4	1	1	1
95236	1710	Ig chain locus	[Ig chain locus]	0.0	3	1	1	1
95237	1710	cd3epsilon gene	[CD3epsilon gene]	0.0	2	1	1	1
95238	1710	increase in the percentage of cell	[increase in the percentage of cells]	0.0	6	1	1	1
95239	1710	adherence of red blood cell	[adherence of red blood cells]	0.0	5	1	1	1
95240	1710	low level of nf-kappa b	[low levels of NF-kappa B]	0.0	5	1	1	1
95241	1710	b domain zre-b	[B domain ZRE-B]	0.0	3	1	1	1
95242	1710	linear relationship	[linear relationship]	0.0	2	1	1	1
95243	1710	secretion of the proinflammatory lymphokine interleukin-1beta	[secretion of the proinflammatory lymphokine interleukin-1beta]	0.0	6	1	1	1
95244	1710	(atf) family	[(ATF) family]	0.0	2	1	1	1
95245	1710	function of activation	[functions of activation]	0.0	3	1	1	1
95246	1710	platelet/endothelial cell adhesion	[platelet/endothelial cell adhesion]	0.0	3	1	1	1
95247	1710	membrane protein 1 activation	[membrane protein 1 activation]	0.0	4	1	1	1
95248	1710	factor-dependent pkb/akt	[factor-dependent PKB/Akt]	0.0	2	1	1	1
95249	1710	eosinophil via the release	[eosinophils via the release]	0.0	4	1	1	1
95250	1710	two single mutation of R-276	[two single mutations of R-276]	0.0	5	1	1	1
95251	1710	role in C3a enhancement lps-	[role in C3a enhancement LPS-]	0.0	5	1	1	1
95252	1710	set of latent gene	[set of latent genes]	0.0	4	1	1	1
95253	1710	lack xist expression (xiste-), from female	[lacking XIST expression (XISTE-), from females]	0.0	6	1	1	1
95254	1710	role in normal beta-cell function	[role in normal beta-cell function]	0.0	5	1	1	1
95255	1710	preincubation of cell with endotoxin	[Preincubation of cells with endotoxin]	0.0	5	1	1	1
95256	1710	human endothelial cell HAEC	[human endothelial cells HAEC]	0.0	4	1	1	1
95257	1710	reduce the oxidant stress	[reducing the oxidant stress]	0.0	4	1	1	1
95258	1710	human development	[human development]	0.0	2	1	1	1
95259	1710	lymphoid tissue structure	[lymphoid tissue structure]	0.0	3	1	1	1
95260	1710	oncogene in glucocorticoid cell lysis	[oncogenes in glucocorticoid cell lysis]	0.0	5	1	1	1
95261	1710	expression of protein include c-myc	[expression of proteins including c-myc]	0.0	5	1	1	1
95262	1710	granulocyte factor granulocyte-macrophage factor proliferation	[granulocyte factor granulocyte-macrophage factor proliferation]	0.0	5	1	1	1
95263	1710	receive 5-fluorouracil as adjuvant chemotherapy	[receiving 5-fluorouracil as adjuvant chemotherapy]	0.0	5	1	1	1
95264	1710	ebna-2 -pu.1	[EBNA-2 -PU.1]	0.0	2	1	1	1
95265	1710	constitutive activation of nf-at1	[constitutive activation of NF-AT1]	0.0	4	1	1	1
95266	1710	(three individual from the group),	[(three individuals from the group),]	0.0	5	1	1	1
95267	1710	Furthermore, concentration below 250 microm	[Furthermore, concentrations below 250 microM]	0.0	5	1	1	1
95268	1710	ligand-induced homodimerization	[ligand-induced homodimerization]	0.0	2	1	1	1
95269	1710	specific protein substrates.	[specific protein substrates.]	0.0	3	1	1	1
95270	1710	fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	4	1	1	1
95271	1710	Xp.	[Xp.]	0.0	1	1	1	1
95272	1710	thus, cell	[Thus, cells]	0.0	2	1	1	1
95273	1710	mechanism with the cell cycle control	[mechanism with the cell cycle control]	0.0	6	1	1	1
95274	1710	transcription of the long repeat region	[transcription of the long repeat region]	0.0	6	1	1	1
95275	1710	evaluation of the respiratory epithelium	[Evaluation of the respiratory epithelium]	0.0	5	1	1	1
95276	1710	precursor by proviral insertion	[precursors by proviral insertion]	0.0	4	1	1	1
95277	1710	interleukin-2-	[interleukin-2-]	0.0	1	1	1	1
95278	1710	event detectable (Martin	[events detectable (Martin]	0.0	3	1	1	1
95279	1710	abnormality one	[Abnormalities one]	0.0	2	1	1	1
95280	1710	stimulation of CD40 on malignant melanoma	[Stimulation of CD40 on malignant melanomas]	0.0	6	1	1	1
95281	1710	subunit of relative mass	[subunits of relative mass]	0.0	4	1	1	1
95282	1710	four protein complex a factor	[four protein complexes a factor]	0.0	5	1	1	1
95283	1710	only in a reactivation	[only in a reactivation]	0.0	4	1	1	1
95284	1710	[differential value of receptor	[[Differential value of receptors]	0.0	4	1	1	1
95285	1710	myeloid leukemic cell line	[myeloid leukemic cell line]	0.0	4	1	1	1
95286	1710	protein factor (nf)-kb	[protein factor (NF)-kB]	0.0	3	1	1	1
95287	1710	expression of receptor from patient	[Expression of receptors from patients]	0.0	5	1	1	1
95288	1710	kind of hematopoietic cell	[kinds of hematopoietic cells]	0.0	4	1	1	1
95289	1710	signal protein such as CBL	[signaling proteins such as CBL]	0.0	5	1	1	1
95290	1710	active version	[active version]	0.0	2	2	2	1
95291	1710	suggest a target	[suggesting a target]	0.0	3	1	1	1
95292	1710	nearly complete loss	[nearly complete loss]	0.0	3	1	1	1
95293	1710	one factor nf-kappa b (position	[one factor NF-kappa B (positions]	0.0	5	1	1	1
95294	1710	hemopoietic progenitor to dendritic cell	[hemopoietic progenitors to dendritic cells]	0.0	5	1	1	1
95295	1710	alpha2 gene expression	[alpha2 gene expression]	0.0	3	1	1	1
95296	1710	powerful assembly	[powerful assemblies]	0.0	2	1	1	1
95297	1710	examination of the basal factor	[Examination of the basal factors]	0.0	5	1	1	1
95298	1710	Genetic evidence for a factor	[Genetic evidence for an factor]	0.0	5	1	1	1
95299	1710	monocyte tissue	[monocyte tissue]	0.0	2	1	1	1
95300	1710	signal event through association	[signaling events through association]	0.0	4	1	1	1
95301	1710	response to aldosterone	[response to aldosterone]	0.0	3	1	1	1
95302	1710	nongenomic	[nongenomic]	0.0	1	1	1	1
95303	1710	interleukin-4,	[interleukin-4,]	0.0	1	1	1	1
95304	1710	viral target,	[viral target,]	0.0	2	1	1	1
95305	1710	relative binding affinity the high	[relative binding affinities the highest]	0.0	5	1	1	1
95306	1710	c-mpl a receptor	[c-Mpl a receptor]	0.0	3	1	1	1
95307	1710	gene 4	[gene 4]	0.0	2	1	1	1
95308	1710	glucocorticoid at relevant concentration	[glucocorticoids at relevant concentrations]	0.0	4	1	1	1
95309	1710	expression plasmid encode region	[Expression plasmids encoding regions]	0.0	4	1	1	1
95310	1710	neurotoxin edn	[neurotoxin EDN]	0.0	2	1	1	1
95311	1710	invasion	[invasion]	0.0	1	1	1	1
95312	1710	treatment of human blood lymphocyte	[Treatment of human blood lymphocytes]	0.0	5	1	1	1
95313	1710	circulate human mononuclear leukocyte	[circulating human mononuclear leukocytes]	0.0	4	1	1	1
95314	1710	triamcinolone	[triamcinolone]	0.0	1	1	1	1
95315	1710	hydrophobic group	[hydrophobic group]	0.0	2	1	1	1
95316	1710	AP-1 independent transactivation	[AP-1 independent transactivation]	0.0	3	1	1	1
95317	1710	overproduction of NFKB2 lyt-10	[Overproduction of NFKB2 lyt-10]	0.0	4	1	1	1
95318	1710	killer cell by IL-2	[killer cells by IL-2]	0.0	4	1	1	1
95319	1710	cell reservoir	[cell reservoir]	0.0	2	1	1	1
95320	1710	generation of 12 family	[generations of 12 families]	0.0	4	1	1	1
95321	1710	b cell-encoded gene	[B cell-encoded genes]	0.0	3	1	1	1
95322	1710	several new, compound	[Several new, compounds]	0.0	3	1	1	1
95323	1710	encompass all	[encompassing all]	0.0	2	1	1	1
95324	1710	deletion of upstream NF-kappa b site	[deletion of upstream NF-kappa B site]	0.0	6	1	1	1
95325	1710	contrast, ap-1	[contrast, AP-1]	0.0	2	1	1	1
95326	1710	highlight putative novel cancer related loci	[highlighting putative novel cancer related loci]	0.0	6	1	1	1
95327	1710	blood mononuclear cell compartment	[blood mononuclear cell compartment]	0.0	4	1	1	1
95328	1710	several cell	[several cells]	0.0	2	1	1	1
95329	1710	two transcription factor pat	[two transcription factors pAT]	0.0	4	1	1	1
95330	1710	specific power	[specific power]	0.0	2	1	1	1
95331	1710	modulation of myelopoiesis	[modulation of myelopoiesis]	0.0	3	1	1	1
95332	1710	contain six cell cycle	[containing six cell cycle]	0.0	4	1	1	1
95333	1710	predictor for the further course	[predictor for the further course]	0.0	5	1	1	1
95334	1710	distal factor (NF)-AT proximal NF-AT	[distal factor (NF)-AT proximal NF-AT]	0.0	5	1	1	1
95335	1710	deviation in this immunological variable	[deviations in these immunological variables]	0.0	5	1	1	1
95336	1710	PTT shift	[PTT shifts]	0.0	2	1	1	1
95337	1710	stably express a rev protein	[stably expressing a Rev protein]	0.0	5	1	1	1
95338	1710	min),	[min),]	0.0	1	1	1	1
95339	1710	human cd3epsilon transgenic mouse line	[human CD3epsilon transgenic mouse lines]	0.0	5	1	1	1
95340	1710	ca(2+)-dependent signal-transduction pathway	[Ca(2+)-dependent signal-transduction pathway]	0.0	3	1	1	1
95341	1710	apical surface.	[apical surface.]	0.0	2	1	1	1
95342	1710	frequency,	[frequency,]	0.0	1	1	1	1
95343	1710	frequency.	[frequency.]	0.0	1	1	1	1
95344	1710	autologous thymic epithelial cell	[autologous thymic epithelial cells]	0.0	4	1	1	1
95345	1710	extensive granulopoiesis typically die	[extensive granulopoiesis typically dying]	0.0	4	1	1	1
95346	1710	BRLF-1 locus	[BRLF-1 locus]	0.0	2	1	1	1
95347	1710	rapamycin mutant	[rapamycin mutant]	0.0	2	1	1	1
95348	1710	tlr-dependent transcription of oxide synthase	[TLR-dependent transcription of oxide synthase]	0.0	5	1	1	1
95349	1710	such as psoriasis	[such as psoriasis]	0.0	3	1	1	1
95350	1710	stimulate blood cell	[stimulating blood cells]	0.0	3	1	1	1
95351	1710	extensive granulopoiesis die days.	[extensive granulopoiesis dying days.]	0.0	4	1	1	1
95352	1710	major challenge	[major challenge]	0.0	2	1	1	1
95353	1710	use reporter construct with multiple	[using reporter constructs with multiples]	0.0	5	1	1	1
95354	1710	il-12 target gene	[IL-12 target genes]	0.0	3	1	1	1
95355	1710	Jak 2 -stat signal pathway	[Jak 2 -STAT signaling pathway]	0.0	5	1	1	1
95356	1710	difference between Ramos b cell	[difference between Ramos B cells]	0.0	5	1	1	1
95357	1710	first analysis	[first analysis]	0.0	2	1	1	1
95358	1710	volunteer without disorder	[volunteers without disorders]	0.0	3	1	1	1
95359	1710	mesenchyme the organ develops,	[mesenchyme the organ develops,]	0.0	4	1	1	1
95360	1710	demonstrate a response.	[demonstrating a response.]	0.0	3	1	1	1
95361	1710	thyrotropin receptor	[thyrotropin receptor]	0.0	2	1	1	1
95362	1710	expose vein cell huvec to anoxia/reoxygenation	[Exposing vein cells HUVECs to anoxia/reoxygenation]	0.0	6	1	1	1
95363	1710	similar analysis	[Similar analysis]	0.0	2	1	1	1
95364	1710	(include muscle actin	[(including muscle actin]	0.0	3	1	1	1
95365	1710	kappa B-alpha( mad-3	[kappa B-alpha( MAD-3]	0.0	3	1	1	1
95366	1710	t-cell-restricted marker include CD2	[T-cell-restricted markers including CD2]	0.0	4	1	1	1
95367	1710	distinct protein- dependent complex	[distinct protein- dependent complexes]	0.0	4	1	1	1
95368	1710	NFAT -1-mediated gene expression	[NFAT -1-mediated gene expression]	0.0	4	1	1	1
95369	1710	total population t-cell killer population	[total populations T-cell killer populations]	0.0	5	1	1	1
95370	1710	carcinoma cell line N-Tera2	[carcinoma cell line N-Tera2]	0.0	4	1	1	1
95371	1710	reticulocyte of the same animal	[reticulocytes of the same animals]	0.0	5	1	1	1
95372	1710	study the link arrest	[studying the link arrest]	0.0	4	1	1	1
95373	1710	domain of human il-7r alpha	[domains of human IL-7R alpha]	0.0	5	1	1	1
95374	1710	genes, against promoter	[genes, against promoters]	0.0	3	1	1	1
95375	1710	ino synthase activity	[iNO synthase activity]	0.0	3	1	1	1
95376	1710	dependence in a human cell line	[Dependence in a human cell line]	0.0	6	1	1	1
95377	1710	hepatic injury with alpha-tocopherol	[hepatic injury with alpha-tocopherol]	0.0	4	1	1	1
95378	1710	peak at 24 h.	[peaks at 24 h,]	0.0	4	1	1	1
95379	1710	role influence expression	[role influencing expression]	0.0	3	1	1	1
95380	1710	abnormal feedback	[Abnormal feedback]	0.0	2	1	1	1
95381	1710	24 woman (11 first, second	[24 women (11 first, second]	0.0	5	1	1	1
95382	1710	block the translocation into the compartment	[blocking the translocation into the compartment]	0.0	6	1	1	1
95383	1710	coexpression a human tnf transgene	[coexpression a human TNF transgene]	0.0	5	1	1	1
95384	1710	(il)-2 gene expression	[(IL)-2 gene expression]	0.0	3	1	1	1
95385	1710	proto-oncogene belong	[proto-oncogene belonging]	0.0	2	1	1	1
95386	1710	cns-derived cell	[CNS-derived cells]	0.0	2	1	1	1
95387	1710	Culture of hl60 cell	[Culture of HL60 cells]	0.0	4	1	1	1
95388	1710	blockade of differentiation	[blockade of differentiation]	0.0	3	1	1	1
95389	1710	interleukin-1beta il-1beta in cells,	[interleukin-1beta IL-1beta in cells,]	0.0	4	1	1	1
95390	1710	intron, transcription factor	[intron, transcription factor]	0.0	3	1	1	1
95391	1710	signal pathway,	[signaling pathway,]	0.0	2	1	1	1
95392	1710	hiv-infected T lymphocyte	[HIV-infected T lymphocytes]	0.0	3	1	1	1
95393	1710	expression a murine member	[expression a murine member]	0.0	4	1	1	1
95394	1710	viral protein Epstein Barr	[viral proteins Epstein Barr]	0.0	4	1	1	1
95395	1710	Paternal expression	[Paternal expression]	0.0	2	1	1	1
95396	1710	possibility directly use cell line	[possibility directly using cell lines]	0.0	5	1	1	1
95397	1710	suggest highly selective	[suggesting highly selective]	0.0	3	1	1	1
95398	1710	IBD group	[IBD groups]	0.0	2	1	1	1
95399	1710	lck activation	[Lck activation]	0.0	2	1	1	1
95400	1710	pharmacologic blockade of endogenous nfat activity	[Pharmacologic blockade of endogenous NFAT activity]	0.0	6	1	1	1
95401	1710	involvement in the initial stage	[involvement in the initial stage]	0.0	5	1	1	1
95402	1710	granulocyte-monocyte colony activity	[granulocyte-monocyte colony activity]	0.0	3	1	1	1
95403	1710	positivity for the bcl-6 protein	[positivity for the BCL-6 protein]	0.0	5	1	1	1
95404	1710	family of transcriptional regulatory protein	[family of transcriptional regulatory proteins]	0.0	5	1	1	1
95405	1710	production by monocyte	[production by monocytes]	0.0	3	1	1	1
95406	1710	immunodeficiency virus-type	[immunodeficiency virus-type]	0.0	2	1	1	1
95407	1710	adolescent disorder	[adolescent disorder]	0.0	2	1	1	1
95408	1710	least two activity	[least two activities]	0.0	3	1	1	1
95409	1710	PPARgamma activation	[PPARgamma activation]	0.0	2	1	1	1
95410	1710	influence of the sequence	[influence of the sequences]	0.0	4	1	1	1
95411	1710	cocultivation of BZLF 1	[cocultivation of BZLF 1]	0.0	4	1	1	1
95412	1710	pu.1 pip site	[PU.1 Pip site]	0.0	3	1	1	1
95413	1710	useful system study the mechanism	[useful system studying the mechanisms]	0.0	5	1	1	1
95414	1710	include factor kappa b	[including factor kappa B]	0.0	4	1	1	1
95415	1710	cleavage of the terminus	[cleavage of the terminus]	0.0	4	1	1	1
95416	1710	exposure to hypoxia (0.02% o2)	[exposure to hypoxia (0.02% O2)]	0.0	5	1	1	1
95417	1710	contribution 1 gene product	[contribution 1 gene products]	0.0	4	1	1	1
95418	1710	Comparison to the PMA subline kg1a	[Comparison to the PMA subline KG1a]	0.0	6	1	1	1
95419	1710	human pulmonary macrophage PAM	[human pulmonary macrophages PAM]	0.0	4	1	1	1
95420	1710	intraductal component eic	[intraductal component EIC]	0.0	3	1	1	1
95421	1710	formation of a activity	[formation of a activity]	0.0	4	1	1	1
95422	1710	Nonradioactive quantification of glucocorticoid expression	[Nonradioactive quantification of glucocorticoid expression]	0.0	5	1	1	1
95423	1710	isomorph by gel analysis	[isomorphs by gel analysis]	0.0	4	1	1	1
95424	1710	gp extract	[gp extracts]	0.0	2	1	1	1
95425	1710	deletion of p16 alone	[deletion of p16 alone]	0.0	4	1	1	1
95426	1710	JCam/ Lck	[JCam/ Lck]	0.0	2	1	1	1
95427	1710	simian CMV	[simian CMV]	0.0	2	1	1	1
95428	1710	advanced failure A-CRF with insufficiency	[advanced failure A-CRF with insufficiency]	0.0	5	1	1	1
95429	1710	observation of down-regulation	[observation of down-regulation]	0.0	3	1	1	1
95430	1710	nf-kappab transactivation	[NF-kappaB transactivation]	0.0	2	1	1	1
95431	1710	case of B-cell chronic leukemia	[cases of B-cell chronic leukemia]	0.0	5	1	1	1
95432	1710	clinical resistance	[clinical resistance]	0.0	2	1	1	1
95433	1710	T cell protein	[T cell proteins]	0.0	3	2	2	1
95434	1710	complete loss of cp activity	[complete loss of Cp activity]	0.0	5	1	1	1
95435	1710	leukemia with promyelocytic feature	[leukemia with promyelocytic features]	0.0	4	1	1	1
95436	1710	level of 135(oh)2d3 receptor rna	[levels of 1,25(OH)2D3 receptor RNA]	0.0	5	1	1	1
95437	1710	reflect difference in sensitivity between tissues.	[reflecting differences in sensitivity between tissues.]	0.0	6	1	1	1
95438	1710	saphenous vein endothelial cell	[saphenous vein endothelial cells]	0.0	4	1	1	1
95439	1710	other anti-inflammatory drug nsaid	[other anti-inflammatory drugs NSAIDs]	0.0	4	1	1	1
95440	1710	scavenging of no	[scavenging of NO]	0.0	3	1	1	1
95441	1710	gene product htlv-1	[gene products HTLV-1]	0.0	3	1	1	1
95442	1710	whole-cell bind radioassay use [3H]-dexamethasone	[whole-cell binding radioassay using [3H]-dexamethasone]	0.0	5	1	1	1
95443	1710	fmol/million cells; p less than 0.01).	[fmol/million cells; P less than 0.01).]	0.0	6	1	1	1
95444	1710	c-Rel cell monolayer	[c-Rel cell monolayers]	0.0	3	1	1	1
95445	1710	difference between il-10	[difference between IL-10]	0.0	3	1	1	1
95446	1710	expression latent membrane protein lmp-1	[Expression latent membrane protein LMP-1]	0.0	5	1	1	1
95447	1710	mucosa-associated tissue malt	[mucosa-associated tissue MALT]	0.0	3	1	1	1
95448	1710	peripheral blood-derived monocyte pbm	[peripheral blood-derived monocytes PBM]	0.0	4	1	1	1
95449	1710	host defense, include phagocytosis	[host defense, including phagocytosis]	0.0	4	1	1	1
95450	1710	eukaryotic vector	[eukaryotic vectors]	0.0	2	1	1	1
95451	1710	vla-5	[VLA-5]	0.0	1	1	1	1
95452	1710	T cell specificity repertoire	[T cell specificity repertoire]	0.0	4	1	1	1
95453	1710	Epstein-Barr virus b-cell line	[Epstein-Barr virus B-cell lines]	0.0	4	1	1	1
95454	1710	cellular response to type	[cellular response to type]	0.0	4	1	1	1
95455	1710	target of cyclosporin a	[target of cyclosporin A]	0.0	4	1	1	1
95456	1710	heavy chain enhancer igh-enhancer	[heavy chain enhancer IgH-enhancer]	0.0	4	1	1	1
95457	1710	tpa element	[TPA elements]	0.0	2	1	1	1
95458	1710	ikk1	[IKK1]	0.0	1	1	1	1
95459	1710	constitutively significant level of proto-oncogent	[constitutively significant levels of proto-oncogenes]	0.0	5	1	1	1
95460	1710	amp-responsive element modulator CREM	[AMP-responsive element modulator CREM]	0.0	4	1	1	1
95461	1710	anti- tat single-chain antibody intrabody	[anti- Tat single-chain antibody intrabody]	0.0	5	1	1	1
95462	1710	ap-1 regulation	[AP-1 regulation]	0.0	2	1	1	1
95463	1710	regulator of several cytokine genes,	[regulators of several cytokine genes,]	0.0	5	1	1	1
95464	1710	four near-perfect direct repeat DR	[four near-perfect direct repeats DR]	0.0	5	1	1	1
95465	1710	lymphoid tissue lymphoma (19 of 45	[lymphoid tissue lymphoma (19 of 45]	0.0	6	1	1	1
95466	1710	a function	[A function]	0.0	2	2	2	1
95467	1710	gene product,	[gene product,]	0.0	2	1	1	1
95468	1710	proliferation of several type	[proliferation of several types]	0.0	4	1	1	1
95469	1710	treatment (day hpc	[treatment (day HPCs]	0.0	3	1	1	1
95470	1710	modulation of nuclear factor	[modulation of nuclear factors]	0.0	4	1	1	1
95471	1710	interaction between transcriptional coactivator	[interactions between transcriptional coactivators]	0.0	4	1	1	1
95472	1710	activation in hiv monocyte	[activation in HIV monocytes]	0.0	4	1	1	1
95473	1710	nucleus in	[nucleus in]	0.0	2	1	1	1
95474	1710	further setting of vascular pathology	[further settings of vascular pathology]	0.0	5	1	1	1
95475	1710	one b clone	[one B clone]	0.0	3	1	1	1
95476	1710	corresponding to residue	[corresponding to residues]	0.0	3	1	1	1
95477	1710	express gata-2	[expressing GATA-2]	0.0	2	1	1	1
95478	1710	light-chain enhancer e lambda	[light-chain enhancer E lambda]	0.0	4	1	1	1
95479	1710	166 female aged	[166 females aged]	0.0	3	1	1	1
95480	1710	Recognition	[Recognition]	0.0	1	3	3	1
95481	1710	cell contain gamma-globin	[cells containing gamma-globin]	0.0	3	1	1	1
95482	1710	process extend	[processes extending]	0.0	2	1	1	1
95483	1710	GH-N	[GH-N]	0.0	1	1	1	1
95484	1710	two antibody specific	[two antibodies specific]	0.0	3	1	1	1
95485	1710	inhibition of g0s2 expression	[inhibition of G0S2 expression]	0.0	4	1	1	1
95486	1710	sublects: Fifteen patient with sepsis	[SUBJECTS: Fifteen patients with sepsis]	0.0	5	1	1	1
95487	1710	IL-8 a potent factor for granulocyte	[IL-8 a potent factor for granulocytes]	0.0	6	1	1	1
95488	1710	c-terminal serine region of BSAP	[C-terminal serine region of BSAP]	0.0	5	1	1	1
95489	1710	a b ebv carrier	[A B EBV carriers]	0.0	4	1	1	1
95490	1710	helix-loop-helix" protein	[helix-loop-helix" proteins]	0.0	2	1	1	1
95491	1710	full activation by CIITA	[full activation by CIITA]	0.0	4	1	1	1
95492	1710	critical step for effect	[critical step for effects]	0.0	4	1	1	1
95493	1710	effect on a na+ channel	[effect on a Na+ channel]	0.0	5	1	1	1
95494	1710	megakaryocytic gene in a erythropoietin manner	[megakaryocytic genes in an erythropoietin manner]	0.0	6	1	1	1
95495	1710	precise mechanism lead to apoptosis	[precise mechanisms leading to apoptosis]	0.0	5	1	1	1
95496	1710	absence of disulfide bridge	[absence of disulfide bridges]	0.0	4	1	1	1
95497	1710	gene on different chromosomes.	[genes on different chromosomes.]	0.0	4	1	1	1
95498	1710	bank of 6 Philips	[bank of 6 Philips]	0.0	4	1	1	1
95499	1710	Philadelphia chronic myeloid leukemia	[Philadelphia chronic myeloid leukemia]	0.0	4	2	2	1
95500	1710	prevention of adherence	[prevention of adherence]	0.0	3	1	1	1
95501	1710	vitro reconstitution assay	[vitro reconstitution assay]	0.0	3	1	1	1
95502	1710	glucocorticoid receptor site	[glucocorticoid receptor sites]	0.0	3	1	1	1
95503	1710	incubation of cell ECs in hypoxia	[Incubation of cells ECs in hypoxia]	0.0	6	1	1	1
95504	1710	stimulus in neutrophil	[stimuli in neutrophils]	0.0	3	1	1	1
95505	1710	CstF-64	[CstF-64]	0.0	1	1	1	1
95506	1710	dna-binding complex in extract	[DNA-binding complexes in extracts]	0.0	4	1	1	1
95507	1710	N terminal	[N terminal]	0.0	2	1	1	1
95508	1710	histological feature in patient	[histological features in patients]	0.0	4	1	1	1
95509	1710	complex MHC	[complex MHC]	0.0	2	1	1	1
95510	1710	15.5 (p 0.05, p 0.01	[15.5 (P 0.05, P 0.01]	0.0	5	1	1	1
95511	1710	balance between oxidation of SMX	[balance between oxidation of SMX]	0.0	5	1	1	1
95512	1710	residual disease MRD of patient	[residual disease MRD of patients]	0.0	5	1	1	1
95513	1710	use bead with DNA	[Using beads with DNA]	0.0	4	1	1	1
95514	1710	develop central system	[developing central system]	0.0	3	1	1	1
95515	1710	various genetic defect	[various genetic defects]	0.0	3	1	1	1
95516	1710	pig donor in xenotransplantation	[pig donors in xenotransplantation]	0.0	4	1	1	1
95517	1710	create a proline carboxy terminus	[creating a proline carboxy terminus]	0.0	5	1	1	1
95518	1710	weak competitor in intact cell	[weak competitor in intact cells]	0.0	5	1	1	1
95519	1710	microm aldosterone	[microM aldosterone]	0.0	2	1	1	1
95520	1710	trans-gene expression in T cell	[trans-gene expression in T cells]	0.0	5	1	1	1
95521	1710	staining for Bcl-6 /cd20	[staining for Bcl-6 /CD20]	0.0	4	1	1	1
95522	1710	mumol cortisol to normal subject	[mumol cortisol to normal subjects]	0.0	5	1	1	1
95523	1710	immunoglobulin heavy-chain gene enhancer	[immunoglobulin heavy-chain gene enhancer]	0.0	4	1	1	1
95524	1710	presence of functional 135-(oh)2d3 receptors;	[presence of functional 1,25-(OH)2D3 receptors;]	0.0	5	1	1	1
95525	1710	immunogenicity of viral antigen	[immunogenicity of viral antigens]	0.0	4	1	1	1
95526	1710	factor otf2	[factor OTF2]	0.0	2	1	1	1
95527	1710	uncouple hs1 phosphorylation from nuclear factor	[Uncoupling HS1 phosphorylation from nuclear factor]	0.0	6	1	1	1
95528	1710	development; addition	[development; addition]	0.0	2	1	1	1
95529	1710	experimental system combine gene transfer	[experimental system combining gene transfer]	0.0	5	1	1	1
95530	1710	PMA ap-1	[PMA AP-1]	0.0	2	1	1	1
95531	1710	activation of this pathway	[activation of this pathway]	0.0	4	1	1	1
95532	1710	decidual transformation	[decidual transformation]	0.0	2	1	1	1
95533	1710	androgen on mature cell	[androgens on mature cells]	0.0	4	1	1	1
95534	1710	subject 2.89 fmol/10(6) cell	[subjects 2.89 fmol/10(6) cells]	0.0	4	1	1	1
95535	1710	expression in primary human monocyte	[expression in primary human monocytes]	0.0	5	1	1	1
95536	1710	novel specificity-conferring mechanism	[novel specificity-conferring mechanism]	0.0	3	1	1	1
95537	1710	mM d-ribose	[mM D-ribose]	0.0	2	1	1	1
95538	1710	Tax1 -inducible pathway	[Tax1 -inducible pathway]	0.0	3	1	1	1
95539	1710	813-bp open reading frame	[813-bp open reading frame]	0.0	4	1	1	1
95540	1710	selective appearance	[selective appearance]	0.0	2	1	1	1
95541	1710	concentration of HU	[concentrations of HU]	0.0	3	1	1	1
95542	1710	-sensitive induction in a20 b cell	[-sensitive induction in A20 B cells]	0.0	6	1	1	1
95543	1710	4,19-disubstituted derivative of doc	[4,19-disubstituted derivatives of DOC]	0.0	4	1	1	1
95544	1710	infectious clone of HTLV-II	[infectious clone of HTLV-II]	0.0	4	1	1	1
95545	1710	flow assay	[flow assays]	0.0	2	1	1	1
95546	1710	lead to repression	[leading to repression]	0.0	3	1	1	1
95547	1710	methods: pbmc from 8 patient	[METHODS: PBMCs from 8 patients]	0.0	5	1	1	1
95548	1710	1.16 units, p young	[1.16 units, P young]	0.0	4	1	1	1
95549	1710	nf-kappab /rel protein	[NF-kappaB /Rel proteins]	0.0	3	1	1	1
95550	1710	patient with primary ovarian carcinoma	[patients with primary ovarian carcinoma]	0.0	5	1	1	1
95551	1710	also in DNA synthesis	[also in DNA synthesis]	0.0	4	1	1	1
95552	1710	1alpha,25(OH)2-d5-previtamin D3 HF	[1alpha,25(OH)2-d5-previtamin D3 HF]	0.0	3	1	1	1
95553	1710	diffusible activity tag	[diffusible activity TAG]	0.0	3	1	1	1
95554	1710	homodimer.	[homodimer.]	0.0	1	1	1	1
95555	1710	function in hiv infection	[function in HIV infection]	0.0	4	1	1	1
95556	1710	six patient with asthma	[six patients with asthma]	0.0	4	1	1	1
95557	1710	basal transcription activity	[basal transcription activity]	0.0	3	1	1	1
95558	1710	however, in the presence a transactivator	[However, in the presence a transactivator]	0.0	6	1	1	1
95559	1710	Conclusions: growth inhibition	[CONCLUSIONS: growth inhibition]	0.0	3	1	1	1
95560	1710	day liver	[day liver]	0.0	2	1	1	1
95561	1710	rBPI21 a N-terminal fragment	[rBPI21 a N-terminal fragment]	0.0	4	1	1	1
95562	1710	viable erythroid cell	[viable erythroid cells]	0.0	3	1	1	1
95563	1710	region of the 5'-utr	[regions of the 5'-UTR]	0.0	4	1	1	1
95564	1710	dna-swap experiment	[DNA-swap experiments]	0.0	2	1	1	1
95565	1710	caprine arthritis-encephalitis	[caprine arthritis-encephalitis]	0.0	2	1	1	1
95566	1710	close relatedness with the reticulocyte-type 15-lipoxygenase	[close relatedness with the reticulocyte-type 15-lipoxygenase]	0.0	6	1	1	1
95567	1710	signal critical	[signal critical]	0.0	2	1	1	1
95568	1710	low level of trap fluoride-resistant- alpha-naphthyl-acetate-esterase	[low levels of TRAP fluoride-resistant- alpha-naphthyl-acetate-esterase]	0.0	6	1	1	1
95569	1710	angle of degree	[angle of degrees]	0.0	3	1	1	1
95570	1710	regions, dp1 -140 to -92 bp	[regions, DP1 -140 to -92 bp]	0.0	6	1	1	1
95571	1710	implantation site	[implantation sites]	0.0	2	1	1	1
95572	1710	inhibitory ikbalpha protein degradation	[inhibitory IkBalpha protein degradation]	0.0	4	1	1	1
95573	1710	residual pml/rar alpha cell	[residual PML/RAR alpha cells]	0.0	4	1	1	1
95574	1710	effect of aldosterone on electrolyte	[effects of aldosterone on electrolytes]	0.0	5	1	1	1
95575	1710	patient with insufficiency	[patients with insufficiency]	0.0	3	1	1	1
95576	1710	highlight novel loci relevant	[highlighting novel loci relevant]	0.0	4	1	1	1
95577	1710	include interleukin-1 il-1	[including interleukin-1 IL-1]	0.0	3	1	1	1
95578	1710	rna in cell-sorted monocyte	[RNA in cell-sorted monocytes]	0.0	4	1	1	1
95579	1710	number with occasional aggregate formation	[numbers with occasional aggregate formation]	0.0	5	1	1	1
95580	1710	treatment of neoplasm	[treatment of neoplasms]	0.0	3	1	1	1
95581	1710	Ubiquitin-mediated processing	[Ubiquitin-mediated processing]	0.0	2	1	1	1
95582	1710	result neutrophil-mediated tissue damage	[resulting neutrophil-mediated tissue damage]	0.0	4	1	1	1
95583	1710	1alpha,25(OH)2-d5-previtamin D3 JN	[1alpha,25(OH)2-d5-previtamin D3 JN]	0.0	3	1	1	1
95584	1710	experimentally B	[Experimentally B]	0.0	2	1	1	1
95585	1710	dilution cloning	[dilution cloning]	0.0	2	1	1	1
95586	1710	EBNA-2 -positive nuclear extract	[EBNA-2 -positive nuclear extracts]	0.0	4	1	1	1
95587	1710	major component in the extract	[major component in the extract]	0.0	5	1	1	1
95588	1710	ga-binding protein alpha gabp alpha	[GA-binding protein alpha GABP alpha]	0.0	5	1	1	1
95589	1710	inhibition through adenosine triphosphate atp	[inhibition through adenosine triphosphate ATP]	0.0	5	1	1	1
95590	1710	characterization of -regulatory element	[characterization of -regulatory elements]	0.0	4	1	1	1
95591	1710	CIITA cell	[CIITA cells]	0.0	2	1	1	1
95592	1710	4 kb downstream	[4 kb downstream]	0.0	3	1	1	1
95593	1710	contain deletion in the samples.	[containing deletions in the samples.]	0.0	5	1	1	1
95594	1710	fibrosarcoma histiocytoma	[fibrosarcoma histiocytoma]	0.0	2	1	1	1
95595	1710	concentration of NE	[concentration of NE]	0.0	3	1	1	1
95596	1710	NK cell-mediated clearance	[NK cell-mediated clearance]	0.0	3	1	1	1
95597	1710	regulation of m-csf expression	[Regulation of M-CSF expression]	0.0	4	1	1	1
95598	1710	proline-rich sequence in the region	[proline-rich sequence in the region]	0.0	5	1	1	1
95599	1710	transcriptional property for E2A- HLF	[transcriptional properties for E2A- HLF]	0.0	5	1	1	1
95600	1710	cellular catalyst thioredoxin trx	[cellular catalyst thioredoxin Trx]	0.0	4	1	1	1
95601	1710	obtain new probe	[obtaining new probes]	0.0	3	1	1	1
95602	1710	nf-kappab protein activity	[NF-kappaB protein activity]	0.0	3	1	1	1
95603	1710	IL-10 concentration	[IL-10 concentration]	0.0	2	1	1	1
95604	1710	yeast regulator Rpd3p	[yeast regulator Rpd3p]	0.0	3	1	1	1
95605	1710	introduction of gata-1 in mel cell	[introduction of GATA-1 in MEL cells]	0.0	6	1	1	1
95606	1710	results: in peripheral blood	[RESULTS: In peripheral blood]	0.0	4	1	1	1
95607	1710	differentiation to macrophage AMs	[differentiation to macrophages AMs]	0.0	4	1	1	1
95608	1710	p42/44 (erk) mapk activation	[p42/44 (ERK) MAPk activation]	0.0	4	1	1	1
95609	1710	expression of LSF	[expression of LSF]	0.0	3	1	1	1
95610	1710	MIP-1 alpha transcription	[MIP-1 alpha transcription]	0.0	3	1	1	1
95611	1710	form, stat3beta	[form, Stat3beta]	0.0	2	1	1	1
95612	1710	rapid growth	[rapid growth]	0.0	2	2	2	1
95613	1710	mrna species 2.7	[mRNA species 2.7]	0.0	3	1	1	1
95614	1710	gamma/delta T cell receptor	[gamma/delta T cell receptor]	0.0	4	1	1	1
95615	1710	monoclonal antibody recognition	[monoclonal antibody recognition]	0.0	3	1	1	1
95616	1710	adjacent site at position	[adjacent sites at positions]	0.0	4	1	1	1
95617	1710	determinant of the expression	[determinant of the expression]	0.0	4	1	1	1
95618	1710	pluripotent hemopoietic progenitor	[pluripotent hemopoietic progenitors]	0.0	3	1	1	1
95619	1710	DNase I mapping of DNA	[DNase I mapping of DNA]	0.0	5	1	1	1
95620	1710	nucleotide retain promoter activity	[nucleotides retaining promoter activity]	0.0	4	1	1	1
95621	1710	regions, dp1	[regions, DP1]	0.0	2	1	1	1
95622	1710	requirement in il-2 promoter activation	[requirement in IL-2 promoter activation]	0.0	5	1	1	1
95623	1710	addition, il-13	[addition, IL-13]	0.0	2	1	1	1
95624	1710	patient with ulcerative colitis (56.1	[patients with ulcerative colitis (56.1]	0.0	5	1	1	1
95625	1710	res.	[Res.]	0.0	1	1	1	1
95626	1710	level fluoride-resistant- alpha-naphthyl-acetate-esterase	[levels fluoride-resistant- alpha-naphthyl-acetate-esterase]	0.0	3	1	1	1
95627	1710	unexpectedly, expression of another immediate-early protein	[unexpectedly, expression of another immediate-early protein]	0.0	6	1	1	1
95628	1710	octamer-binding protein (s)	[octamer-binding protein (s)]	0.0	3	1	1	1
95629	1710	role in the domain	[role in the domain]	0.0	4	1	1	1
95630	1710	PGE2 formation by monocyte	[PGE2 formation by monocytes]	0.0	4	1	1	1
95631	1710	ester-inducible transcription	[ester-inducible transcription]	0.0	2	1	1	1
95632	1710	relative of IDDM subject	[relatives of IDDM subjects]	0.0	4	1	1	1
95633	1710	mononuclear cell reaction mcr grade	[mononuclear cell reaction MCR grade]	0.0	5	1	1	1
95634	1710	quantitative experiment	[Quantitative experiments]	0.0	2	1	1	1
95635	1710	region of target gene	[regions of target genes]	0.0	4	1	1	1
95636	1710	group of 166 female aged	[group of 166 females aged]	0.0	5	1	1	1
95637	1710	study, adolescent	[study, adolescents]	0.0	2	1	1	1
95638	1710	gene expression in T cell	[gene expression in T cells]	0.0	5	1	1	1
95639	1710	human genital herpes lesion	[human genital herpes lesions]	0.0	4	1	1	1
95640	1710	5' LCR region	[5' LCR region]	0.0	3	1	1	1
95641	1710	complex (mhc) class gene expression	[complex (MHC) class gene expression]	0.0	5	1	1	1
95642	1710	marker of prognosis,	[markers of prognosis,]	0.0	3	1	1	1
95643	1710	normal human pbl	[normal human PBL]	0.0	3	1	1	1
95644	1710	only after internalization from surface.	[only after internalization from surface.]	0.0	5	1	1	1
95645	1710	first transcription factor participate	[first transcription factor participating]	0.0	4	1	1	1
95646	1710	decrease in expression by cell	[decreases in expression by cells]	0.0	5	1	1	1
95647	1710	high level induction	[high level induction]	0.0	3	1	1	1
95648	1710	transfection of trans-dominant negative expression vector	[Transfection of trans-dominant negative expression vectors]	0.0	6	1	1	1
95649	1710	various adhesion molecule in cell	[various adhesion molecules in cells]	0.0	5	1	1	1
95650	1710	use a viral stock	[using a viral stock]	0.0	4	1	1	1
95651	1710	factor of T cell family	[factor of T cells family]	0.0	5	1	1	1
95652	1710	cytoplasmic/nuclear	[cytoplasmic/nuclear]	0.0	1	1	1	1
95653	1710	sexual differentiation	[sexual differentiation]	0.0	2	1	1	1
95654	1710	physiological processes, include cell growth	[physiological processes, including cell growth]	0.0	5	1	1	1
95655	1710	control reactvation from latency.	[controlling reactvation from latency.]	0.0	4	1	1	1
95656	1710	prolonged cyclic load	[prolonged cyclic load]	0.0	3	1	1	1
95657	1710	cd56.	[CD56.]	0.0	1	1	1	1
95658	1710	conflict result from research groups.	[conflicting results from research groups.]	0.0	5	1	1	1
95659	1710	motifs:	[motifs:]	0.0	1	1	1	1
95660	1710	patient with syndrome MDS	[patients with syndromes MDS]	0.0	4	1	1	1
95661	1710	lining,	[lining,]	0.0	1	1	1	1
95662	1710	factor kappab binding in t-lymphocyte	[factor kappaB binding in T-lymphocytes]	0.0	5	1	1	1
95663	1710	woman first, second	[women first, second]	0.0	3	1	1	1
95664	1710	structural element	[structural elements]	0.0	2	1	1	1
95665	1710	difference between EBNA-2 nuclear extract	[differences between EBNA-2 nuclear extracts]	0.0	5	1	1	1
95666	1710	distinct cell-specific coactivator	[distinct cell-specific coactivators]	0.0	3	1	1	1
95667	1710	erythroleukemia (mel) cell	[erythroleukemia (MEL) cells]	0.0	3	1	1	1
95668	1710	h follow lps addition	[h following LPS addition]	0.0	4	1	1	1
95669	1710	hpv type	[HPV type]	0.0	2	1	1	1
95670	1710	rna-protein	[RNA-protein]	0.0	1	1	1	1
95671	1710	nf-kappab transcription in monocytic cell	[NF-kappaB transcription in monocytic cells]	0.0	5	1	1	1
95672	1710	case with eosinophil abnormality	[case with eosinophil abnormalities]	0.0	4	1	1	1
95673	1710	association of cytoplasmic terminus ct	[association of cytoplasmic terminus CT]	0.0	5	1	1	1
95674	1710	activation-specific expression	[activation-specific expression]	0.0	2	1	1	1
95675	1710	activation of activator protein-1	[activation of activator protein-1]	0.0	4	1	1	1
95676	1710	apolar substitution 11 alpha-methyl, 11 alpha-fluoromethyl	[apolar substitutions 11 alpha-methyl, 11 alpha-fluoromethyl]	0.0	6	1	1	1
95677	1710	putative homolog of nrl	[putative homolog of NRL]	0.0	4	1	1	1
95678	1710	adipocyte differentiation through proliferator-activated receptor gamma	[adipocyte differentiation through proliferator-activated receptor gamma]	0.0	6	1	1	1
95679	1710	ras mutant,	[ras mutant,]	0.0	2	1	1	1
95680	1710	IL-4 receptor IL-4R	[IL-4 receptor IL-4R]	0.0	3	1	1	1
95681	1710	inhibitor of oxide synthase	[inhibitor of oxide synthase]	0.0	4	1	1	1
95682	1710	induction of c-jun by H2O2	[induction of c-jun by H2O2]	0.0	5	1	1	1
95683	1710	neomycin	[neomycin]	0.0	1	1	1	1
95684	1710	dihydropyrimidine dehydrogenase deficiency	[dihydropyrimidine dehydrogenase deficiency]	0.0	3	1	1	1
95685	1710	results: incubation	[RESULTS: Incubation]	0.0	2	1	1	1
95686	1710	suggest the need	[suggesting the need]	0.0	3	1	1	1
95687	1710	small substance such as formylpeptide	[small substances such as formylpeptides]	0.0	5	1	1	1
95688	1710	gene in leukaemia	[genes in leukaemia]	0.0	3	1	1	1
95689	1710	ms-5 cell	[MS-5 cells]	0.0	2	1	1	1
95690	1710	various immediate serum responsive gene	[various immediate serum responsive genes]	0.0	5	1	1	1
95691	1710	regulate the response by external stimuli.	[regulating the response by external stimuli.]	0.0	6	1	1	1
95692	1710	t-cell lymphoma with germinal center	[T-cell lymphoma with germinal centers]	0.0	5	1	1	1
95693	1710	mouse hepa-1	[mouse Hepa-1]	0.0	2	1	1	1
95694	1710	-luciferase construct	[-luciferase construct]	0.0	2	1	1	1
95695	1710	moreover, il-4 costimulation	[Moreover, IL-4 costimulation]	0.0	3	1	1	1
95696	1710	purpose of the study	[purpose of the study]	0.0	4	1	1	1
95697	1710	cytokine-stimulated cell	[cytokine-stimulated cells]	0.0	2	1	1	1
95698	1710	stimulation with a ceramide analog	[stimulation with a ceramide analog]	0.0	5	1	1	1
95699	1710	express the normal protein mds1/evi1	[expressing the normal protein MDS1/EVI1]	0.0	5	1	1	1
95700	1710	cd57+	[CD57+]	0.0	1	2	2	1
95701	1710	most sample	[most samples]	0.0	2	1	1	1
95702	1710	individual with primary infection	[individuals with primary infection]	0.0	4	1	1	1
95703	1710	mild-moderate renal insufficiency	[mild-moderate renal insufficiency]	0.0	3	1	1	1
95704	1710	lack antigen	[lacking antigens]	0.0	2	1	1	1
95705	1710	early growth response gene-1	[early growth response gene-1]	0.0	4	1	1	1
95706	1710	pharmacological concentration to &mgr;m)	[pharmacological concentrations to &mgr;M)]	0.0	4	1	1	1
95707	1710	stage of erythropoietic differentiation	[stages of erythropoietic differentiation]	0.0	4	1	1	1
95708	1710	day cells,	[day cells,]	0.0	2	1	1	1
95709	1710	pro- glutathione antioxidant	[pro- glutathione antioxidant]	0.0	3	1	1	1
95710	1710	ifngr1 small deletion	[IFNGR1 small deletions]	0.0	3	1	1	1
95711	1710	second, b-cell line	[second, B-cell line]	0.0	3	1	1	1
95712	1710	ten hiv-infected patient with receptor affinity	[Ten HIV-infected patients with receptor affinity]	0.0	6	1	1	1
95713	1710	center region of tonsil	[center region of tonsil]	0.0	4	1	1	1
95714	1710	chimeric receptor system	[chimeric receptor system]	0.0	3	1	1	1
95715	1710	random breast aspirate of woman	[random breast aspirates of women]	0.0	5	1	1	1
95716	1710	involvement of this molecule	[involvement of this molecule]	0.0	4	1	1	1
95717	1710	t-lymphocyte from VZV donor	[T-lymphocytes from VZV donors]	0.0	4	1	1	1
95718	1710	such as major histocompatibility (mhc) class	[such as major histocompatibility (MHC) class]	0.0	6	1	1	1
95719	1710	tissue factor tf the initiator	[tissue factor TF the initiator]	0.0	5	1	1	1
95720	1710	peripheral blood lymphocyte generation	[peripheral blood lymphocytes Generation]	0.0	4	1	1	1
95721	1710	carboxyl-terminal 15-amino acid sequence	[Carboxyl-terminal 15-amino acid sequence]	0.0	4	1	1	1
95722	1710	appropriate reporter gene	[appropriate reporter genes]	0.0	3	1	1	1
95723	1710	property of the compound	[properties of the compounds]	0.0	4	1	1	1
95724	1710	vitro culture system	[vitro culture system]	0.0	3	1	1	1
95725	1710	ICSBP a member	[ICSBP a member]	0.0	3	1	1	1
95726	1710	complex molecule	[complex molecules]	0.0	2	1	1	1
95727	1710	e.g. interleukin-3	[e.g. interleukin-3]	0.0	2	1	1	1
95728	1710	fresh epstein-barr virus	[fresh Epstein-Barr virus]	0.0	3	1	1	1
95729	1710	third region	[third region]	0.0	2	1	1	1
95730	1710	onset within min.	[onset within min.]	0.0	3	1	1	1
95731	1710	clinical application.	[clinical application.]	0.0	2	1	1	1
95732	1710	transcription of the immunoglobulin heavy-chain gene	[transcription of the immunoglobulin heavy-chain gene]	0.0	6	1	1	1
95733	1710	mu/l physiological limit	[mU/L physiological limit]	0.0	3	1	1	1
95734	1710	endogenous mechanism	[endogenous mechanisms]	0.0	2	1	1	1
95735	1710	intracellular concentration	[intracellular concentration]	0.0	2	2	2	1
95736	1710	blockade of nfat activity	[blockade of NFAT activity]	0.0	4	1	1	1
95737	1710	tata motif	[TATA motifs]	0.0	2	1	1	1
95738	1710	analysis of the 12 rdna	[analysis of the 12 cDNAs]	0.0	5	1	1	1
95739	1710	causal relationship between the events.	[causal relationship between the events.]	0.0	5	1	1	1
95740	1710	therapeutic approach by application	[therapeutic approach by application]	0.0	4	1	1	1
95741	1710	redox status in activity	[redox status in activity]	0.0	4	1	1	1
95742	1710	administration for one month	[Administration for one month]	0.0	4	1	1	1
95743	1710	complex with different class of receptor	[complexes with different classes of receptors]	0.0	6	1	1	1
95744	1710	112 patient with disorder	[112 patients with disorder]	0.0	4	1	1	1
95745	1710	uncouple activation-dependent hs1 phosphorylation from factor	[Uncoupling activation-dependent HS1 phosphorylation from factor]	0.0	6	1	1	1
95746	1710	thus, cell with the property	[Thus, cells with the properties]	0.0	5	1	1	1
95747	1710	lipid a	[lipid A]	0.0	2	1	1	1
95748	1710	[3H]dexamethasone (p 0.01)	[[3H]dexamethasone (P 0.01)]	0.0	3	1	1	1
95749	1710	last amino acid	[last amino acids]	0.0	3	1	1	1
95750	1710	immunodepletion	[Immunodepletion]	0.0	1	1	1	1
95751	1710	synthetic oligodeoxyribonucleotide contain a sp1-box	[synthetic oligodeoxyribonucleotide containing an SP1-box]	0.0	5	1	1	1
95752	1710	copy of imperfect repeat	[copies of imperfect repeats]	0.0	4	1	1	1
95753	1710	mix study from squirrel monkey lymphocyte	[mixing studies from squirrel monkey lymphocytes]	0.0	6	1	1	1
95754	1710	copy of the gc-box	[copies of the GC-box]	0.0	4	1	1	1
95755	1710	immunological parameter restoration	[immunological parameters restoration]	0.0	3	1	1	1
95756	1710	and/or expression of delta-	[and/or expression of delta-]	0.0	4	1	1	1
95757	1710	abnormality at the NF-AT site	[abnormalities at the NF-AT site]	0.0	5	1	1	1
95758	1710	induction of differentiation by immunodeficiency virus	[Induction of differentiation by immunodeficiency virus]	0.0	6	1	1	1
95759	1710	growth hormone hgh	[growth hormone hGH]	0.0	3	1	1	1
95760	1710	b cell-specific regulation	[B cell-specific regulation]	0.0	3	1	1	1
95761	1710	monocyte-specific promoter activity	[monocyte-specific promoter activity]	0.0	3	1	1	1
95762	1710	4-trifluoromethyl derivative	[4-trifluoromethyl derivatives]	0.0	2	1	1	1
95763	1710	mass proteins.	[masses proteins.]	0.0	2	1	1	1
95764	1710	mechanism control gene expression	[mechanism controlling gene expression]	0.0	4	1	1	1
95765	1710	reduction of peroxide level	[reduction of peroxide level]	0.0	4	1	1	1
95766	1710	preassociation in separate signalling complex	[Preassociation in separate signalling complexes]	0.0	5	1	1	1
95767	1710	lymphocyte of patient with arthritis RA	[Lymphocytes of patients with arthritis RA]	0.0	6	1	1	1
95768	1710	functional alteration	[functional alterations]	0.0	2	1	1	1
95769	1710	suggest new strategy for the detection	[suggesting new strategies for the detection]	0.0	6	1	1	1
95770	1710	genomic organisation exon of 132,	[genomic organisation exons of 132,]	0.0	5	1	1	1
95771	1710	exposure of certain cell type	[Exposure of certain cell types]	0.0	5	1	1	1
95772	1710	receptor mutant subclone	[Receptor mutant subclones]	0.0	3	1	1	1
95773	1710	thus implicate CAML as a intermediate	[thus implicating CAML as a intermediate]	0.0	6	1	1	1
95774	1710	surface igd	[surface IgD]	0.0	2	1	1	1
95775	1710	polymorphic, tandem repeat	[polymorphic, tandem repeats]	0.0	3	1	1	1
95776	1710	ELK-1 genes,	[ELK-1 genes,]	0.0	2	1	1	1
95777	1710	major disorder: lack of evidence	[major disorder: lack of evidence]	0.0	5	1	1	1
95778	1710	continuously grow myeloid cell line	[continuously growing myeloid cell line]	0.0	5	1	1	1
95779	1710	neoplasia er	[neoplasia ER]	0.0	2	1	1	1
95780	1710	Circadian rhythm of glucocorticoid receptor	[Circadian rhythm of glucocorticoid receptors]	0.0	5	1	1	1
95781	1710	pyrimidine element	[pyrimidine elements]	0.0	2	1	1	1
95782	1710	selection,	[selection,]	0.0	1	1	1	1
95783	1710	transcription factor in early differentiation	[transcription factors in early differentiation]	0.0	5	1	1	1
95784	1710	similar level of elf-2 transcript	[similar levels of elf-2 transcripts]	0.0	5	1	1	1
95785	1710	human (h) irak	[human (h) IRAK]	0.0	3	1	1	1
95786	1710	il-1beta protein	[IL-1beta protein]	0.0	2	3	3	1
95787	1710	class of compound	[classes of compounds]	0.0	3	1	1	1
95788	1710	wide range of effect related	[wide range of effects related]	0.0	5	1	1	1
95789	1710	second sse-like element	[second SSE-like element]	0.0	3	1	1	1
95790	1710	severe degree of deficiency	[severe degree of deficiency]	0.0	4	1	1	1
95791	1710	cell line contain Oct2	[cell lines containing Oct2]	0.0	4	1	1	1
95792	1710	lymphoblastic Jurkat T cell	[lymphoblastic Jurkat T cells]	0.0	4	1	1	1
95793	1710	negative mutant NFAT delta418	[negative mutant NFAT delta418]	0.0	4	1	1	1
95794	1710	heavy chain gene rearrangement	[heavy chain gene rearrangement]	0.0	4	1	1	1
95795	1710	optimal induction of bcl-2 expression	[optimal induction of bcl-2 expression]	0.0	5	1	1	1
95796	1710	property in common	[properties in common]	0.0	3	1	1	1
95797	1710	phenotypic drift from latency latency	[phenotypic drift from latency latency]	0.0	5	1	1	1
95798	1710	ehuaess) endothelial cell	[(HUAECs) endothelial cells]	0.0	3	1	1	1
95799	1710	passage cell in cytotoxic function	[passage cells in cytotoxic function]	0.0	5	1	1	1
95800	1710	regulation of response include pathway	[regulation of responses including pathways]	0.0	5	1	1	1
95801	1710	differentiate progeny	[differentiating progeny]	0.0	2	1	1	1
95802	1710	include ionizing radiation.	[including ionizing radiation.]	0.0	3	1	1	1
95803	1710	chymotryptic activity independent of age.	[chymotryptic activity independent of age.]	0.0	5	1	1	1
95804	1710	Xenogeneic	[Xenogeneic]	0.0	1	2	2	1
95805	1710	26s protease	[26S protease]	0.0	2	3	3	1
95806	1710	neighbor sequence within the element	[neighboring sequences within the element]	0.0	5	1	1	1
95807	1710	element between kb act	[elements between kb act]	0.0	4	1	1	1
95808	1710	matrix attachment region	[matrix attachment region]	0.0	3	1	1	1
95809	1710	ap1 reporter construct (ic50 nm),	[AP1 reporter constructs (IC50 nM),]	0.0	5	1	1	1
95810	1710	receptor-CD3	[receptor-CD3]	0.0	1	1	1	1
95811	1710	human lymphocyte from blood	[human lymphocytes from blood]	0.0	4	1	1	1
95812	1710	produce enhancement of non- lps uptake	[producing enhancement of non- LPS uptake]	0.0	6	1	1	1
95813	1710	interestingly, expression of cd95	[interestingly, expression of CD95]	0.0	4	1	1	1
95814	1710	then interleukin (il)-10 blocking factor expression	[then interleukin (IL)-10 blocking factor expression]	0.0	6	1	1	1
95815	1710	bryostatin 1 another activator	[bryostatin 1 another activator]	0.0	4	1	1	1
95816	1710	(l&h)	[(L&H)]	0.0	1	1	1	1
95817	1710	human haematopoietic line	[human haematopoietic lines]	0.0	3	1	1	1
95818	1710	day erythroid precursor	[day erythroid precursors]	0.0	3	1	1	1
95819	1710	autoimmune inflammatory disease	[autoimmune inflammatory disease]	0.0	3	1	1	1
95820	1710	abnormality of the organ	[abnormalities of the organs]	0.0	4	1	1	1
95821	1710	capacity of erythroid progenitor cell	[capacity of erythroid progenitor cells]	0.0	5	1	1	1
95822	1710	stimulus-dependent nf-at complex	[stimulus-dependent NF-AT complexes]	0.0	3	1	1	1
95823	1710	promoter/5'-flank	[promoter/5'-flank]	0.0	1	1	1	1
95824	1710	70-kda protein	[70-kDa protein]	0.0	2	1	1	1
95825	1710	size of kilodalton	[size of kilodaltons]	0.0	3	1	1	1
95826	1710	protein critical to differentiation in species	[proteins critical to differentiation in species]	0.0	6	1	1	1
95827	1710	lineage-dependent abrogation of gata-1 expression	[lineage-dependent abrogation of GATA-1 expression]	0.0	5	1	1	1
95828	1710	bp from the transcription site	[bp from the transcription site]	0.0	5	1	1	1
95829	1710	DNA in reticulocyte lysate	[DNA in reticulocyte lysates]	0.0	4	1	1	1
95830	1710	TNF-alpha localization in memory	[TNF-alpha localization in memory]	0.0	4	1	1	1
95831	1710	cytostasis	[cytostasis]	0.0	1	1	1	1
95832	1710	fraction contain the protein	[fractions containing the protein]	0.0	4	1	1	1
95833	1710	single class similar	[single class similar]	0.0	3	1	1	1
95834	1710	concentration of gc	[concentration of GC]	0.0	3	1	1	1
95835	1710	nfat activity by FK506	[NFAT activity by FK506]	0.0	4	1	1	1
95836	1710	tissue-specific transcriptional activation	[tissue-specific transcriptional activation]	0.0	3	1	1	1
95837	1710	ebv-immortalized b lymphoblast	[EBV-immortalized B lymphoblasts]	0.0	3	1	1	1
95838	1710	moreover, alteration cis-element	[Moreover, alteration cis-element]	0.0	3	1	1	1
95839	1710	increase in thf with the/thf	[increase in THF with THE/THF]	0.0	5	1	1	1
95840	1710	implication in regulation of germline transcription	[implications in regulation of germline transcription]	0.0	6	1	1	1
95841	1710	dramatic increase phospholipase c gamma	[dramatic increase phospholipase C gamma]	0.0	5	1	1	1
95842	1710	mammalian IL2 promoter	[mammalian IL2 promoters]	0.0	3	1	1	1
95843	1710	promyelocytic leukemia (apl): ii	[promyelocytic leukemia (APL): II]	0.0	4	1	1	1
95844	1710	-bsa-fitc by laser scanning microscopy	[-BSA-FITC by laser scanning microscopy]	0.0	5	1	1	1
95845	1710	constant surveillance	[constant surveillance]	0.0	2	1	1	1
95846	1710	prostaglandin pge2	[prostaglandin PGE2]	0.0	2	1	1	1
95847	1710	inhibition of NOS	[Inhibition of NOS]	0.0	3	1	1	1
95848	1710	activity of the IgH-luciferase construct	[activity of the IgH-luciferase construct]	0.0	5	1	1	1
95849	1710	efficacy as a inhibitor	[efficacy as an inhibitor]	0.0	4	1	1	1
95850	1710	mbcl6 gene	[mBCL6 gene]	0.0	2	1	1	1
95851	1710	c-fo p62c-fo	[c-fos p62c-fos]	0.0	2	1	1	1
95852	1710	ap-1 specificity	[AP-1 specificity]	0.0	2	1	1	1
95853	1710	N-terminal transcriptional activation domain	[N-terminal transcriptional activation domain]	0.0	4	1	1	1
95854	1710	mutant of the rev protein	[mutant of the Rev protein]	0.0	5	1	1	1
95855	1710	assembly of the ligand	[assembly of the ligands]	0.0	4	1	1	1
95856	1710	high grade astrocytomas	[high grade astrocytomas]	0.0	3	1	1	1
95857	1710	hiv terminal repeat (which	[HIV terminal repeat (which]	0.0	4	1	1	1
95858	1710	transcriptional difference	[Transcriptional differences]	0.0	2	1	1	1
95859	1710	series of study	[series of studies]	0.0	3	1	1	1
95860	1710	early divergence	[early divergence]	0.0	2	1	1	1
95861	1710	class ii expression,	[class II expression,]	0.0	3	1	1	1
95862	1710	allele of c-Raf-1 Raf	[allele of c-Raf-1 Raf]	0.0	4	1	1	1
95863	1710	b binding site	[B binding sites]	0.0	3	1	1	1
95864	1710	chicken IL2 promoter	[chicken IL2 promoter]	0.0	3	1	1	1
95865	1710	expression of Pax5 a paradigm	[expression of Pax5 a paradigm]	0.0	5	1	1	1
95866	1710	inflammatory c ytokine mrna level	[inflammatory c ytokine mRNA levels]	0.0	5	1	1	1
95867	1710	tubulointerstitial disease of kidney	[tubulointerstitial disease of kidney]	0.0	4	1	1	1
95868	1710	administration of gram metyrapone	[administration of g metyrapone]	0.0	4	1	1	1
95869	1710	3 h of stimulation	[3 h of stimulation]	0.0	4	1	1	1
95870	1710	respectively, corresponding to a -2 molecule	[respectively, corresponding to an -2 molecules]	0.0	6	1	1	1
95871	1710	expression of erythroid-specific gene in disorder	[Expression of erythroid-specific genes in disorders]	0.0	6	1	1	1
95872	1710	case of t-cell proliferation	[cases of T-cell proliferations]	0.0	4	1	1	1
95873	1710	diseases, include atherosclerosis	[diseases, including atherosclerosis]	0.0	3	1	1	1
95874	1710	only in the majority	[only in the majority]	0.0	4	1	1	1
95875	1710	after TNFalpha simulation	[after TNFalpha simulation]	0.0	3	1	1	1
95876	1710	-contain leukocyte protein tightly	[-containing leukocyte protein tightly]	0.0	4	1	1	1
95877	1710	similar box sry	[similar boxes SRY]	0.0	3	1	1	1
95878	1710	chloramphenicol acetyltransferase production by 75%	[chloramphenicol acetyltransferase production by 75%]	0.0	5	1	1	1
95879	1710	effect on c-fo induction	[effect on c-fos induction]	0.0	4	1	1	1
95880	1710	human il4 transcription	[human IL4 transcription]	0.0	3	1	1	1
95881	1710	presence of responsiveness to ifn-alpha	[presence of responsiveness to IFN-alpha]	0.0	5	1	1	1
95882	1710	Interleukin-2 promoter	[Interleukin-2 promoter]	0.0	2	1	1	1
95883	1710	most case	[most cases]	0.0	2	1	1	1
95884	1710	receptor present in cytosolic extract	[receptor present in cytosolic extracts]	0.0	5	1	1	1
95885	1710	IFN factor irf-1	[IFN factor IRF-1]	0.0	3	1	1	1
95886	1710	Burkitt' lymphoma cell lines, weak	[Burkitt's lymphoma cell lines, weak]	0.0	5	1	1	1
95887	1710	role in Stat5 gene expression	[role in Stat5 gene expression]	0.0	5	1	1	1
95888	1710	support property of stromal cell	[supporting properties of stromal cells]	0.0	5	1	1	1
95889	1710	nf-kappab activation of long repeat LTR	[NF-kappaB activation of long repeat LTR]	0.0	6	1	1	1
95890	1710	leukemia factor LIF	[leukemia factor LIF]	0.0	3	1	1	1
95891	1710	strong inducer	[strong inducer]	0.0	2	1	1	1
95892	1710	property of the receptor	[properties of the receptors]	0.0	4	1	1	1
95893	1710	anti- stat transducer	[anti- STAT transducers]	0.0	3	1	1	1
95894	1710	gene of the cluster	[genes of the cluster]	0.0	4	1	1	1
95895	1710	regulation of ebna expression	[regulation of EBNA expression]	0.0	4	1	1	1
95896	1710	human cell inflammatory response	[Human cell inflammatory responses]	0.0	4	1	1	1
95897	1710	contrast, stimulation a CD3 event	[contrast, stimulation a CD3 event]	0.0	5	1	1	1
95898	1710	presence of domain	[presence of domains]	0.0	3	1	1	1
95899	1710	dependence on octamer	[dependence on octamer]	0.0	3	1	1	1
95900	1710	cytokine granulocyte/macrophage colony-stimulating factor gm-csf	[cytokines granulocyte/macrophage colony-stimulating factor GM-CSF]	0.0	5	1	1	1
95901	1710	relevant stimulation,	[relevant stimulation,]	0.0	2	1	1	1
95902	1710	transcription of nuclear rna gene	[transcription of nuclear RNA genes]	0.0	5	1	1	1
95903	1710	use a dominant form	[using a dominant form]	0.0	4	1	1	1
95904	1710	transcription initiation assembly	[transcription initiation assembly]	0.0	3	1	1	1
95905	1710	bacterial transcription	[bacterial transcription]	0.0	2	1	1	1
95906	1710	benefit for eukaryote	[benefit for eukaryotes]	0.0	3	1	1	1
95907	1710	calcineurin manner	[calcineurin manner]	0.0	2	1	1	1
95908	1710	hemoglobin F	[hemoglobin F]	0.0	2	1	1	1
95909	1710	distinct subunit	[distinct subunits]	0.0	2	1	1	1
95910	1710	respectively, indicate a affinity	[respectively, indicating an affinity]	0.0	4	1	1	1
95911	1710	therapeutic drug for inflammatory disease	[therapeutic drugs for inflammatory diseases]	0.0	5	1	1	1
95912	1710	therefore part of the R- enhancer	[therefore part of the R- enhancer]	0.0	6	1	1	1
95913	1710	response to therapy in asthma.	[response to therapy in asthma.]	0.0	5	1	1	1
95914	1710	potent activator through induction	[potent activator through induction]	0.0	4	1	1	1
95915	1710	heavy-chain igh	[heavy-chain IgH]	0.0	2	1	1	1
95916	1710	mnda expression in monocyte	[MNDA expression in monocytes]	0.0	4	1	1	1
95917	1710	least sevenfold) of site	[least sevenfold) of site]	0.0	4	1	1	1
95918	1710	31747a-binding	[31747A-binding]	0.0	1	1	1	1
95919	1710	infiltrate hamster wound	[infiltrating hamster wounds]	0.0	3	1	1	1
95920	1710	Nuclear RB	[Nuclear RB]	0.0	2	1	1	1
95921	1710	kappa b reporter construct	[kappa B reporter constructs]	0.0	4	1	1	1
95922	1710	important role in the cascade	[important role in the cascade]	0.0	5	1	1	1
95923	1710	menstruation	[menstruations]	0.0	1	1	1	1
95924	1710	transcriptional control of activity	[transcriptional control of activity]	0.0	4	1	1	1
95925	1710	cytokine pleiotropy	[cytokine pleiotropy]	0.0	2	1	1	1
95926	1710	CD40 ligand+ hyper	[CD40 ligand+ hyper]	0.0	3	1	1	1
95927	1710	tcc ras	[TCC Ras]	0.0	2	1	1	1
95928	1710	immunity result	[immunity resulting]	0.0	2	1	1	1
95929	1710	viral strain	[viral strains]	0.0	2	1	1	1
95930	1710	promoter activity in cell	[promoter activity in cells]	0.0	4	1	1	1
95931	1710	contain five tandem repeat	[containing five tandem repeats]	0.0	4	1	1	1
95932	1710	cysteine-rich protein 3	[cysteine-rich protein 3]	0.0	3	1	1	1
95933	1710	mobility shift ems	[mobility shift EMS]	0.0	3	1	1	1
95934	1710	pkc activation nuclear factor	[PKC activation nuclear factor]	0.0	4	1	1	1
95935	1710	lesion in several aspect	[lesions in several aspects]	0.0	4	1	1	1
95936	1710	lack immunodominant antigen	[lacking immunodominant antigens]	0.0	3	1	1	1
95937	1710	detection of various signal protein	[Detection of various signaling proteins]	0.0	5	1	1	1
95938	1710	PBLs	[PBLs]	0.0	1	1	1	1
95939	1710	concentration of mp	[concentrations of MP]	0.0	3	1	1	1
95940	1710	catecholamine on IL-12	[catecholamine on IL-12]	0.0	3	1	1	1
95941	1710	significance for mechanism	[significance for mechanisms]	0.0	3	1	1	1
95942	1710	evidence for the involvement transcription factor	[evidence for the involvement transcription factor]	0.0	6	1	1	1
95943	1710	roughly in categories: induction	[roughly in categories: induction]	0.0	4	1	1	1
95944	1710	consistent effect on pdgf(b) mrna accumulation	[consistent effect on PDGF(B) mRNA accumulation]	0.0	6	1	1	1
95945	1710	human locus in cell	[human locus in cells]	0.0	4	1	1	1
95946	1710	factor-kappa b site	[factor-kappa B site]	0.0	3	1	1	1
95947	1710	underphosphorylated form	[underphosphorylated form]	0.0	2	2	2	1
95948	1710	identification of the target	[Identification of the target]	0.0	4	1	1	1
95949	1710	nucleus cells.	[nucleus cells.]	0.0	2	1	1	1
95950	1710	transcriptional activation of interleukin gene	[transcriptional activation of interleukin gene]	0.0	5	1	1	1
95951	1710	2 (il-2)	[2 (IL-2)]	0.0	2	1	1	1
95952	1710	three tandem zinc-finger sequence	[three tandem zinc-finger sequences]	0.0	4	1	1	1
95953	1710	sublining,	[sublining,]	0.0	1	1	1	1
95954	1710	domain-helix-loop-helix protein	[domain-helix-loop-helix protein]	0.0	2	1	1	1
95955	1710	screen system	[screening system]	0.0	2	1	1	1
95956	1710	pd-135,158	[PD-135,158]	0.0	1	1	1	1
95957	1710	produce a putative retrovirus	[producing a putative retrovirus]	0.0	4	1	1	1
95958	1710	myeloperoxidase activity	[myeloperoxidase activity]	0.0	2	1	1	1
95959	1710	interaction between two b coactivator	[interactions between two B coactivators]	0.0	5	1	1	1
95960	1710	autoantigen pbc.m2	[autoantigens PBC.M2]	0.0	2	1	1	1
95961	1710	cytokine dysregulation immunodeficiency virus type	[Cytokine dysregulation immunodeficiency virus type]	0.0	5	1	1	1
95962	1710	MHC antigen expression	[MHC antigen expression]	0.0	3	1	1	1
95963	1710	NFATp/AP-1 element	[NFATp/AP-1 elements]	0.0	2	1	1	1
95964	1710	ap-1 -binding site	[AP-1 -binding site]	0.0	3	1	1	1
95965	1710	(64 mv), normalize	[(64 mV), normalizing]	0.0	3	1	1	1
95966	1710	recombinant human il-2 rhil-2	[recombinant human IL-2 rhIL-2]	0.0	4	1	1	1
95967	1710	(10(-10) to 10(-7) mol/L)	[(10(-10) to 10(-7) mol/L)]	0.0	4	1	1	1
95968	1710	leucocyte in 22 woman	[leucocytes in 22 women]	0.0	4	1	1	1
95969	1710	tr alpha 1	[TR alpha 1]	0.0	3	1	1	1
95970	1710	anti- inhibition of cell proliferation	[anti- inhibition of cell proliferation]	0.0	5	1	1	1
95971	1710	human herpesvirus 6 strain	[human herpesvirus 6 strains]	0.0	4	1	1	1
95972	1710	factor granulocyte-macrophage colony-stimumulatelany-stg factor proliferation	[factor granulocyte-macrophage colony-stimulating factor proliferation]	0.0	5	1	1	1
95973	1710	subsequent cytosolic nf-kappa b accumulation	[subsequent cytosolic NF-kappa B accumulation]	0.0	5	1	1	1
95974	1710	cell with ifn-alpha	[cells with IFN-alpha]	0.0	3	1	1	1
95975	1710	Stat3 recruitment by distinct docking site	[Stat3 recruitment by distinct docking sites]	0.0	6	1	1	1
95976	1710	study of expression	[study of expression]	0.0	3	1	1	1
95977	1710	potential factor (NF)-kappaB binding site	[potential factor (NF)-kappaB binding sites]	0.0	5	1	1	1
95978	1710	additional bind site	[additional binding site]	0.0	3	2	2	1
95979	1710	however, subsequent analysis	[However, subsequent analysis]	0.0	3	1	1	1
95980	1710	increase hiv expression	[increasing HIV expression]	0.0	3	1	1	1
95981	1710	-phosphorylated	[-phosphorylated]	0.0	1	1	1	1
95982	1710	site in the enhancer	[sites in the enhancer]	0.0	4	1	1	1
95983	1710	indicate a down-regulatory effect.	[indicating a down-regulatory effect.]	0.0	4	1	1	1
95984	1710	lps factor nf-kappa b	[LPS factor NF-kappa B]	0.0	4	1	1	1
95985	1710	encode region	[encoding regions]	0.0	2	1	1	1
95986	1710	m, serum concentration during danazol therapy	[M, serum concentration during danazol therapy]	0.0	6	1	1	1
95987	1710	express the mutant allele	[expressing the mutant allele]	0.0	4	1	1	1
95988	1710	association between oncogene amplification	[association between oncogene amplification]	0.0	4	1	1	1
95989	1710	blood plasma triidothyronine	[blood plasma triidothyronine]	0.0	3	1	1	1
95990	1710	clinical application	[clinical applications]	0.0	2	1	1	1
95991	1710	LCR HS4	[LCR HS4]	0.0	2	1	1	1
95992	1710	Nuclear association	[Nuclear association]	0.0	2	1	1	1
95993	1710	activate protein-1 bind tpa element TRE	[Activating protein-1 binding TPA elements TRE]	0.0	6	1	1	1
95994	1710	expression of the il-2	[expression of the IL-2]	0.0	4	1	1	1
95995	1710	estrogen protein"	[estrogen protein"]	0.0	2	1	1	1
95996	1710	two group of hypercortisolemic patient	[two groups of hypercortisolemic patients]	0.0	5	1	1	1
95997	1710	Partial sequence	[Partial sequences]	0.0	2	1	1	1
95998	1710	contrast, dexamethasone a potent inhibitor	[contrast, dexamethasone a potent inhibitor]	0.0	5	1	1	1
95999	1710	human blood mononuclear precursor	[human blood mononuclear precursors]	0.0	4	1	1	1
96000	1710	i.e. neutrophilic granulocyte pmn	[i.e. neutrophilic granulocytes PMN]	0.0	4	1	1	1
96001	1710	nf-kappab heterodimer binding	[NF-kappaB heterodimer binding]	0.0	3	1	1	1
96002	1710	activation the viral gene promoter	[activation the viral gene promoter]	0.0	5	1	1	1
96003	1710	major physiological glucocorticoid cortisol	[major physiological glucocorticoid cortisol]	0.0	4	1	1	1
96004	1710	American Society	[American Society]	0.0	2	2	2	1
96005	1710	lymphocyte in 14 sle	[lymphocytes in 14 SLE]	0.0	4	1	1	1
96006	1710	correlation between the rate	[correlation between the rate]	0.0	4	1	1	1
96007	1710	implication for gene	[implications for genes]	0.0	3	1	1	1
96008	1710	extrauterine site	[extrauterine sites]	0.0	2	1	1	1
96009	1710	effect of lps antibody on uptake	[effects of LPS antibodies on uptake]	0.0	6	1	1	1
96010	1710	chemotactic mcp-1 adhesive property	[chemotactic MCP-1 adhesive properties]	0.0	4	1	1	1
96011	1710	15-mer AS oligonucleotide C-JUN as oligonucleotide	[15-mer AS oligonucleotides C-JUN AS oligonucleotides]	0.0	6	1	1	1
96012	1710	cortisol the number	[cortisol the number]	0.0	3	1	1	1
96013	1710	two female (mz) twin	[two female (MZ) twins]	0.0	4	1	1	1
96014	1710	e2f dna-binding protein	[E2F DNA-binding protein]	0.0	3	1	1	1
96015	1710	inhibition of phorbol differentiation by dexamethasone	[Inhibition of phorbol differentiation by dexamethasone]	0.0	6	1	1	1
96016	1710	lymphoid cell molt4	[lymphoid cells MOLT4]	0.0	3	1	1	1
96017	1710	concanavalin-a	[Concanavalin-A]	0.0	1	1	1	1
96018	1710	functional collaboration of protein	[functional collaboration of proteins]	0.0	4	1	1	1
96019	1710	factor A1	[factors A1]	0.0	2	1	1	1
96020	1710	lymphocyte by phytohaemagglutinin	[lymphocytes by phytohaemagglutinin]	0.0	3	1	1	1
96021	1710	transcription polymerase chain reaction (rt-pcr) assay	[transcription polymerase chain reaction (RT-PCR) assays]	0.0	6	1	1	1
96022	1710	identical proteins,	[identical proteins,]	0.0	2	1	1	1
96023	1710	strike insensitivity to the effect	[striking insensitivity to the effects]	0.0	5	1	1	1
96024	1710	early proliferative samples, activity	[early proliferative samples, activity]	0.0	4	1	1	1
96025	1710	viscosity	[viscosity]	0.0	1	2	2	1
96026	1710	CD40 /cd40l pathway	[CD40 /CD40L pathway]	0.0	3	1	1	1
96027	1710	hla class antigen processing by cell	[HLA class antigen processing by cells]	0.0	6	1	1	1
96028	1710	enhance inactivation to tnf-alpha receptor type	[enhancing inactivation to TNF-alpha receptor type]	0.0	6	1	1	1
96029	1710	t-cell effect with PGE2	[T-cell effects with PGE2]	0.0	4	1	1	1
96030	1710	IL-4 activation of stat5	[IL-4 activation of STAT5]	0.0	4	1	1	1
96031	1710	unstimulated human b cell	[unstimulated human B cells]	0.0	4	1	1	1
96032	1710	p26rex	[p26rex]	0.0	1	1	1	1
96033	1710	STAT1 import by noninvasive delivery	[STAT1 import by noninvasive delivery]	0.0	5	1	1	1
96034	1710	b-binding protein	[B-binding protein]	0.0	2	2	2	1
96035	1710	pathway dependent in lymphoid cell	[pathway dependent in lymphoid cells]	0.0	5	1	1	1
96036	1710	early-phase infection	[early-phase infection]	0.0	2	1	1	1
96037	1710	activity of the protein	[activity of the protein]	0.0	4	1	1	1
96038	1710	incubation with different dose	[incubation with different doses]	0.0	4	1	1	1
96039	1710	promoter follow transfection	[promoter following transfection]	0.0	3	1	1	1
96040	1710	activity a new potential antirheumatic	[activity a new potential antirheumatic]	0.0	5	1	1	1
96041	1710	age-associated impairment	[age-associated impairments]	0.0	2	1	1	1
96042	1710	promyelocytic leukemia (apl):	[promyelocytic leukemia (APL):]	0.0	3	1	1	1
96043	1710	labelling of DNA strand	[labelling of DNA strand]	0.0	4	1	1	1
96044	1710	intracellular oxidant stress	[intracellular oxidant stress]	0.0	3	1	1	1
96045	1710	express ebv	[expressing EBV]	0.0	2	1	1	1
96046	1710	leukocyte population in trimester human pregnancy	[Leukocyte populations in trimester human pregnancies]	0.0	6	1	1	1
96047	1710	stimulator of t-cell recognition	[stimulators of T-cell recognition]	0.0	4	1	1	1
96048	1710	crossreact protein in lymphocyte	[crossreacting proteins in lymphocytes]	0.0	4	1	1	1
96049	1710	mechanism by tax	[mechanism by Tax]	0.0	3	1	1	1
96050	1710	5'-cgaaaatttcc-3'	[5'-CGAAAATTTCC-3']	0.0	1	1	1	1
96051	1710	blood serum	[blood serum]	0.0	2	1	1	1
96052	1710	co-expression in nonlymphoid cell	[Co-expression in nonlymphoid cells]	0.0	4	1	1	1
96053	1710	RNA-dependent protein kinase pkr	[RNA-dependent protein kinase PKR]	0.0	4	2	2	1
96054	1710	role in the pathway	[role in the pathway]	0.0	4	1	1	1
96055	1710	mip-2	[MIP-2]	0.0	1	1	1	1
96056	1710	presence of Zn++ ion	[presence of Zn++ ions]	0.0	4	1	1	1
96057	1710	DNA triplex	[DNA triplex]	0.0	2	1	1	1
96058	1710	pathogenesis of bronchial asthma	[pathogenesis of bronchial asthma]	0.0	4	1	1	1
96059	1710	adjacent sp site	[adjacent Sp site]	0.0	3	1	1	1
96060	1710	NK cell-mediated cytotoxicity	[NK cell-mediated cytotoxicity]	0.0	3	1	1	1
96061	1710	suggest a regulatory molecule	[suggesting a regulatory molecule]	0.0	4	1	1	1
96062	1710	molecular analysis of immunodeficiency virus apoptosis	[Molecular analysis of immunodeficiency virus apoptosis]	0.0	6	1	1	1
96063	1710	Peroxisomal receptor gamma PPARgamma	[Peroxisomal receptor gamma PPARgamma]	0.0	4	1	1	1
96064	1710	secretion by lps	[secretion by LPS]	0.0	3	1	1	1
96065	1710	hepatitis b virus infection in African	[hepatitis B virus infection in Africans]	0.0	6	1	1	1
96066	1710	cis element especially S	[cis elements especially S]	0.0	4	1	1	1
96067	1710	untransformed receptor complex	[untransformed receptor complexes]	0.0	3	1	1	1
96068	1710	endogenous sp3 expression	[endogenous Sp3 expression]	0.0	3	1	1	1
96069	1710	production of interleukin 2	[production of interleukin 2]	0.0	4	1	1	1
96070	1710	two assays), a value	[two assays), a value]	0.0	4	1	1	1
96071	1710	Peripheral blood lymphocyte of both group	[Peripheral blood lymphocytes of both groups]	0.0	6	1	1	1
96072	1710	receptor on leucocyte	[receptors on leucocytes]	0.0	3	1	1	1
96073	1710	virus SV40	[virus SV40]	0.0	2	1	1	1
96074	1710	antiproliferative effect in T cell	[antiproliferative effects in T cells]	0.0	5	1	1	1
96075	1710	dibenzo-p-dioxin pcdd/pcdf	[dibenzo-p-dioxins PCDD/PCDF]	0.0	2	1	1	1
96076	1710	inhibition express a rev protein	[inhibition expressing a Rev protein]	0.0	5	1	1	1
96077	1710	binding specificity cd336	[binding specificity CD336]	0.0	3	1	1	1
96078	1710	several b cell line	[several B cell lines]	0.0	4	1	1	1
96079	1710	suggest a inducer	[suggesting a inducer]	0.0	3	1	1	1
96080	1710	schedule of calcitriol (five patient	[schedules of calcitriol (five patients]	0.0	5	1	1	1
96081	1710	transcription STAT1alpha	[transcription STAT1alpha]	0.0	2	1	1	1
96082	1710	lymphotropic virus type tax	[lymphotropic virus type Tax]	0.0	4	1	1	1
96083	1710	inhibition of cytokine expression	[inhibition of cytokine expression]	0.0	4	1	1	1
96084	1710	cis-acting cis-acting segment oriP	[cis-acting cis-acting segment oriP]	0.0	4	1	1	1
96085	1710	induction of factor kappa B/Rel activity	[Induction of factor kappa B/Rel activity]	0.0	6	1	1	1
96086	1710	1000 VDR by 24 P.	[1000 VDR by 24 h.]	0.0	5	1	1	1
96087	1710	role for abnormality	[role for abnormalities]	0.0	3	1	1	1
96088	1710	viability exclusion	[viability exclusion]	0.0	2	1	1	1
96089	1710	response to D3	[response to D3]	0.0	3	1	1	1
96090	1710	factor KB	[factor KB]	0.0	2	1	1	1
96091	1710	nf-kappa b in nuclear extract	[NF-kappa B in nuclear extracts]	0.0	5	1	1	1
96092	1710	three overlapping pcr product	[Three overlapping PCR products]	0.0	4	1	1	1
96093	1710	give rise	[giving rise]	0.0	2	1	1	1
96094	1710	latent, signal transducer	[latent, signal transducers]	0.0	3	1	1	1
96095	1710	role of Spi-1	[role of Spi-1]	0.0	3	1	1	1
96096	1710	identification of element within the region	[Identification of elements within the region]	0.0	6	1	1	1
96097	1710	trial with il-10	[trials with IL-10]	0.0	3	1	1	1
96098	1710	level in all other population	[levels in all other populations]	0.0	5	1	1	1
96099	1710	activators, include 15-deoxy-delta12,14-prostaglandin J2	[activators, including 15-deoxy-delta12,14-prostaglandin J2]	0.0	4	1	1	1
96100	1710	least a partial explanation	[least a partial explanation]	0.0	4	1	1	1
96101	1710	inducer of maturation in NB4	[inducer of maturation in NB4]	0.0	5	1	1	1
96102	1710	effect of compound	[effect of compounds]	0.0	3	1	1	1
96103	1710	(571 ng/ml) with the symptom score	[(571 ng/mL) with the symptom score]	0.0	6	1	1	1
96104	1710	combine protein	[combining proteins]	0.0	2	1	1	1
96105	1710	unique target of alpha,25-dihydroxyvitamin D3	[unique targets of alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
96106	1710	regulation of cell adhesion molecule	[regulation of cell adhesion molecules]	0.0	5	1	1	1
96107	1710	inhibitor of p38 map kinase	[inhibitor of p38 MAP kinase]	0.0	5	1	1	1
96108	1710	long gene silencing	[long-term gene silencing]	0.0	3	1	1	1
96109	1710	dose of vitamin D3	[dose of vitamin D3]	0.0	4	1	1	1
96110	1710	transactivator in the presence	[transactivator in the presence]	0.0	4	1	1	1
96111	1710	(5118), chronic ebv infection	[(5/18), chronic EBV infection]	0.0	4	1	1	1
96112	1710	suggest positive cooperativity in the response	[suggesting positive cooperativity in the response]	0.0	6	1	1	1
96113	1710	normal myeloid cell StatG	[normal myeloid cells StatG]	0.0	4	1	1	1
96114	1710	TCR phosphorylation of pp36-38	[TCR phosphorylation of pp36-38]	0.0	4	1	1	1
96115	1710	specific protein inhibitor	[specific protein inhibitor]	0.0	3	1	1	1
96116	1710	capacity of gamma-herpesvirus	[capacity of gamma-herpesvirus]	0.0	3	1	1	1
96117	1710	expression of the gene a enzyme	[Expression of the gene an enzyme]	0.0	6	1	1	1
96118	1710	cholesterol synthesis in hypercholesterolemia	[cholesterol synthesis in hypercholesterolemia]	0.0	4	1	1	1
96119	1710	interaction with thymic cell TEC	[interaction with thymic cells TEC]	0.0	5	1	1	1
96120	1710	-depleting	[-depleting]	0.0	1	1	1	1
96121	1710	related family of protein	[related family of proteins]	0.0	4	1	1	1
96122	1710	+/- 16 versus +/-	[+/- 16 versus +/-]	0.0	4	1	1	1
96123	1710	addition to time course	[addition to time course]	0.0	4	1	1	1
96124	1710	mechanism control p27kip1 gene expression,	[mechanisms controlling p27Kip1 gene expression,]	0.0	5	1	1	1
96125	1710	conformer of alphaIIbbeta3	[conformers of alphaIIbbeta3]	0.0	3	1	1	1
96126	1710	expression of ICAM-1	[expression of ICAM-1]	0.0	3	1	1	1
96127	1710	human mononuclear leukocyte of donor	[human mononuclear leukocytes of donors]	0.0	5	1	1	1
96128	1710	correlation with class expression	[correlation with class expression]	0.0	4	1	1	1
96129	1710	site of steroid action.	[site of steroid action.]	0.0	4	1	1	1
96130	1710	0.05, increase in the percentage	[0.05, increase in the percentage]	0.0	5	1	1	1
96131	1710	nf-kappa b chemokine IL-8	[NF-kappa B chemokine IL-8]	0.0	4	1	1	1
96132	1710	NF kappab activation	[NF kappaB activation]	0.0	3	1	1	1
96133	1710	45 kb	[45 kb]	0.0	2	1	1	1
96134	1710	amount of DNA	[amount of DNA]	0.0	3	1	1	1
96135	1710	GM-CSF tata box	[GM-CSF TATA box]	0.0	3	1	1	1
96136	1710	kinase-deficient mutant of NIK	[kinase-deficient mutant of NIK]	0.0	4	1	1	1
96137	1710	form in lymphoblastoid cell line	[form in lymphoblastoid cell lines]	0.0	5	1	1	1
96138	1710	il-4- gene expression in monocyte	[IL-4- gene expression in monocytes]	0.0	5	1	1	1
96139	1710	cell line of hematopoietic origin	[cell lines of hematopoietic origin]	0.0	5	1	1	1
96140	1710	identification as protein	[Identification as protein]	0.0	3	1	1	1
96141	1710	ISGF3 response	[ISGF3 response]	0.0	2	1	1	1
96142	1710	target of export complex	[targeting of export complexes]	0.0	4	1	1	1
96143	1710	potential TFIID binding site	[potential TFIID binding site]	0.0	4	1	1	1
96144	1710	baby rat kidney	[baby rat kidney]	0.0	3	1	1	1
96145	1710	kappa B-specific activity a report.	[kappa B-specific activity a report.]	0.0	5	1	1	1
96146	1710	signal 2 costimulatory signal	[signal 2 costimulatory signal]	0.0	4	1	1	1
96147	1710	same factor family	[same factor family]	0.0	3	1	1	1
96148	1710	target for SR	[target for SR]	0.0	3	1	1	1
96149	1710	mouse leukemia M1 cell	[mouse leukemia M1 cells]	0.0	4	1	1	1
96150	1710	prerequisite for activation	[prerequisite for activation]	0.0	3	1	1	1
96151	1710	immune gene	[immune genes]	0.0	2	1	1	1
96152	1710	lipocalin a member	[lipocalin a member]	0.0	3	1	1	1
96153	1710	general approach	[general approach]	0.0	2	1	1	1
96154	1710	two small rna gene	[two small RNA genes]	0.0	4	1	1	1
96155	1710	antibody from normal, healthy carrier	[antibodies from normal, healthy carriers]	0.0	5	1	1	1
96156	1710	alpha-herpesviruse	[alpha-herpesviruses]	0.0	1	1	1	1
96157	1710	interleukin-5 il-5 a factor	[interleukin-5 IL-5 a factor]	0.0	4	1	1	1
96158	1710	maximal induction h.	[maximal induction h,]	0.0	3	1	1	1
96159	1710	oct-binding factor 1	[Oct-binding factor 1]	0.0	3	1	1	1
96160	1710	concanavalin a	[concanavalin A]	0.0	2	1	1	1
96161	1710	expression of ah receptor mrna	[expression of Ah receptor mRNA]	0.0	5	1	1	1
96162	1710	rest normal lymphocyte from peripheral blood	[resting normal lymphocytes from peripheral blood]	0.0	6	1	1	1
96163	1710	presence in culture medium	[presence in culture medium]	0.0	4	1	1	1
96164	1710	principal ligand for CD28	[principal ligands for CD28]	0.0	4	1	1	1
96165	1710	frequency of this defect	[frequency of this defect]	0.0	4	1	1	1
96166	1710	sequenced,	[sequenced,]	0.0	1	1	1	1
96167	1710	Conclusions: substantial growth inhibition	[CONCLUSIONS: Substantial growth inhibition]	0.0	4	1	1	1
96168	1710	Class ii cell MHC class ii	[Class II cell MHC class II]	0.0	6	1	1	1
96169	1710	substantial proportion	[substantial proportion]	0.0	2	2	2	1
96170	1710	parenteral corticosteroid	[parenteral corticosteroid]	0.0	2	1	1	1
96171	1710	apparent molecular mass	[apparent molecular mass]	0.0	3	3	3	1
96172	1710	constitutive appearance	[Constitutive appearance]	0.0	2	1	1	1
96173	1710	binding of at least three complex	[binding of at least three complexes]	0.0	6	1	1	1
96174	1710	suggest the existence of difference	[suggesting the existence of differences]	0.0	5	1	1	1
96175	1710	large IL-4 region for enhancer activity	[large IL-4 regions for enhancer activity]	0.0	6	1	1	1
96176	1710	early b cell factor	[Early B cell factor]	0.0	4	1	1	1
96177	1710	topoisomerase in nuclear extract	[topoisomerases in nuclear extracts]	0.0	4	1	1	1
96178	1710	distal factor (NF)-AT AP-1/Octamer UPS	[distal factor (NF)-AT AP-1/Octamer UPS]	0.0	5	1	1	1
96179	1710	acid pa	[acid PA]	0.0	2	1	1	1
96180	1710	significant effect of glucocorticoid	[significant effects of glucocorticoids]	0.0	4	1	1	1
96181	1710	induce protein expression in tissue	[inducing protein expression in tissues]	0.0	5	1	1	1
96182	1710	p53-null cell	[p53-null cells]	0.0	2	1	1	1
96183	1710	ensue production	[ensuing production]	0.0	2	1	1	1
96184	1710	mammalian homeodomain protein	[mammalian homeodomain protein]	0.0	3	1	1	1
96185	1710	activator of viral promoter	[activator of viral promoters]	0.0	4	1	1	1
96186	1710	approach by application of drugs,	[approach by application of drugs,]	0.0	5	1	1	1
96187	1710	22 woman with syndrome	[22 women with syndrome]	0.0	4	1	1	1
96188	1710	subsequent determination	[subsequent determination]	0.0	2	1	1	1
96189	1710	tyrosine phosphoprotein of 38	[tyrosine phosphoproteins of 38]	0.0	4	1	1	1
96190	1710	follow t(1;19) translocation in acute leukemia	[following t(1;19) translocations in acute leukemias]	0.0	6	1	1	1
96191	1710	express level of cell surface molecules,	[expressing levels of cell surface molecules,]	0.0	6	1	1	1
96192	1710	such example	[such example]	0.0	2	1	1	1
96193	1710	inducible component within 30 minute	[inducible component within 30 min]	0.0	5	1	1	1
96194	1710	metabolite more polar	[metabolites more polar]	0.0	3	1	1	1
96195	1710	strong enhancer element essential	[strong enhancer element essential]	0.0	4	1	1	1
96196	1710	panning	[panning]	0.0	1	1	1	1
96197	1710	study on the IL-2 gene expression	[studies on the IL-2 gene expression]	0.0	6	1	1	1
96198	1710	finally, immunoblot analysis of extract	[Finally, immunoblot analysis of extracts]	0.0	5	1	1	1
96199	1710	fluid phase macromolecule uptake	[fluid phase macromolecule uptake]	0.0	4	1	1	1
96200	1710	radiotherapy in cell carcinoma	[radiotherapy in cell carcinomas]	0.0	4	1	1	1
96201	1710	second, b-cell line im-9	[second, B-cell line IM-9]	0.0	4	1	1	1
96202	1710	bp insertion result	[bp insertion resulting]	0.0	3	1	1	1
96203	1710	concordance of c-myb expression	[concordance of c-myb expression]	0.0	4	1	1	1
96204	1710	induction of factor antibody	[Induction of factor antibodies]	0.0	4	1	1	1
96205	1710	engagement of cytotoxicity program	[Engagement of cytotoxicity programs]	0.0	4	1	1	1
96206	1710	encompass a regulatory element NF-AT-1	[encompassing an regulatory element NF-AT-1]	0.0	5	1	1	1
96207	1710	one half	[one half]	0.0	2	1	1	1
96208	1710	10 fold decrease	[10 fold decrease]	0.0	3	1	1	1
96209	1710	translocation of the latter	[translocation of the latter]	0.0	4	1	1	1
96210	1710	role of bcl6	[role of BCL6]	0.0	3	1	1	1
96211	1710	effect on various organ	[effects on various organs]	0.0	4	1	1	1
96212	1710	encompass a important regulatory element	[encompassing an important regulatory element]	0.0	5	1	1	1
96213	1710	annexin V .0001	[annexin V .0001]	0.0	3	1	1	1
96214	1710	increase in mrna steady-state level	[increase in mRNA steady-state level]	0.0	5	1	1	1
96215	1710	look back at success in approach	[Looking back at successes in approaches]	0.0	6	1	1	1
96216	1710	reflect the presence	[reflecting the presence]	0.0	3	1	1	1
96217	1710	src homology 2	[src homology 2]	0.0	3	1	1	1
96218	1710	complex transcriptional regulation	[complex transcriptional regulation]	0.0	3	1	1	1
96219	1710	GR element level	[GR element level]	0.0	3	1	1	1
96220	1710	cytoplasmic nucleoporin	[cytoplasmic nucleoporin]	0.0	2	1	1	1
96221	1710	RAKFKQLLQ CTL precursor frequency	[RAKFKQLLQ CTL precursor frequencies]	0.0	4	1	1	1
96222	1710	35 +/-	[35 +/-]	0.0	2	1	1	1
96223	1710	cell in hypoxia po2	[cells in hypoxia PO2]	0.0	4	1	1	1
96224	1710	ara-c on neutral sphingomyelinase	[Ara-C on neutral sphingomyelinase]	0.0	4	1	1	1
96225	1710	sodium depletion	[sodium depletion]	0.0	2	1	1	1
96226	1710	b transcriptional promoter activity	[B transcriptional promoter activity]	0.0	4	1	1	1
96227	1710	increase in level	[increase in levels]	0.0	3	1	1	1
96228	1710	distinguished: 1) sign	[distinguished: 1) signs]	0.0	3	1	1	1
96229	1710	expressed; cell	[expressed; cells]	0.0	2	1	1	1
96230	1710	thus, competition between general transcriptional activator	[Thus, competition between general transcriptional activators]	0.0	6	1	1	1
96231	1710	expression by Gardnerella vaginalis	[expression by Gardnerella vaginalis]	0.0	4	1	1	1
96232	1710	receptor on leucocyte in patient	[receptors on leucocytes in patients]	0.0	5	1	1	1
96233	1710	use dexamethasone	[using dexamethasone]	0.0	2	1	1	1
96234	1710	block formation of the dimer	[blocking formation of the dimer]	0.0	5	1	1	1
96235	1710	several copy	[several copies]	0.0	2	1	1	1
96236	1710	CONCLUSION: cytomegalovirus gene product expression	[CONCLUSION: Cytomegalovirus gene products expression]	0.0	5	1	1	1
96237	1710	autologous cell line	[autologous cell lines]	0.0	3	1	1	1
96238	1710	t-cell tumor	[T-cell tumors]	0.0	2	1	1	1
96239	1710	region -119 to -88	[region -119 to -88]	0.0	4	1	1	1
96240	1710	important cellular mediator	[important cellular mediator]	0.0	3	1	1	1
96241	1710	repressor protein with different effect	[repressor proteins with different effects]	0.0	5	1	1	1
96242	1710	pc4 from the unfractionated extract	[PC4 from the unfractionated extract]	0.0	5	1	1	1
96243	1710	regulation of monocyte monokine synthesis	[regulation of monocyte monokine synthesis]	0.0	5	1	1	1
96244	1710	pathological situations,	[pathological situations,]	0.0	2	1	1	1
96245	1710	1 long repeat quasispecy	[1 long repeat quasispecies]	0.0	4	1	1	1
96246	1710	possible t-cell killer population	[possible T-cell killer populations]	0.0	4	1	1	1
96247	1710	cord lymphocyte c-fo	[cord lymphocyte c-fos]	0.0	3	1	1	1
96248	1710	administration of 1.5 gram metyrapone	[administration of 1.5 g metyrapone]	0.0	5	1	1	1
96249	1710	b lymphocyte in vitro.	[B lymphocytes in vitro.]	0.0	4	1	1	1
96250	1710	specific marker for acute leukemia	[specific marker for acute leukemia]	0.0	5	1	1	1
96251	1710	METHODS: malignant cell line	[METHODS: malignant cell lines]	0.0	4	1	1	1
96252	1710	first footprint	[first footprints]	0.0	2	1	1	1
96253	1710	four base pair substitution	[four base pair substitutions]	0.0	4	1	1	1
96254	1710	repeat activity in human T	[repeat activity in human T]	0.0	5	1	1	1
96255	1710	ca2+ dependent step	[Ca2+ dependent step]	0.0	3	1	1	1
96256	1710	constitutive MHC class gene expression	[constitutive MHC class gene expression]	0.0	5	1	1	1
96257	1710	case of twin	[case of twins]	0.0	3	1	1	1
96258	1710	factor at the site	[factors at the site]	0.0	4	1	1	1
96259	1710	translocation in a leukemia	[translocation in a leukemia]	0.0	4	1	1	1
96260	1710	gp130 cytoplasmic tail	[gp130 cytoplasmic tail]	0.0	3	1	1	1
96261	1710	expression of receptor rna	[expression of receptor RNA]	0.0	4	1	1	1
96262	1710	transfection of the rdna	[transfection of the cDNAs]	0.0	4	1	1	1
96263	1710	act independently	[acting independently]	0.0	2	1	1	1
96264	1710	thus, substitution	[Thus, substitutions]	0.0	2	1	1	1
96265	1710	study with isomerase inhibitor	[studies with isomerase inhibitors]	0.0	4	1	1	1
96266	1710	expression (irf) family transcription factor	[expression (IRF) family transcription factors]	0.0	5	1	1	1
96267	1710	four distinct binding site for protein	[four distinct binding sites for proteins]	0.0	6	1	1	1
96268	1710	percent of fragment	[percent of fragments]	0.0	3	1	1	1
96269	1710	antigenic stimulus	[antigenic stimulus]	0.0	2	1	1	1
96270	1710	differentiate agent retinoic acid	[differentiating agent retinoic acid]	0.0	4	1	1	1
96271	1710	two crossreact protein in lymphocyte	[two crossreacting proteins in lymphocytes]	0.0	5	1	1	1
96272	1710	VDRnuc	[VDRnuc]	0.0	1	1	1	1
96273	1710	M. tuberculosis infection	[M. tuberculosis infection]	0.0	3	1	1	1
96274	1710	biology,	[biology,]	0.0	1	1	1	1
96275	1710	inflammatory pathway in monocyte	[inflammatory pathways in monocytes]	0.0	4	1	1	1
96276	1710	malignant melanoma MMs	[malignant melanomas MMs]	0.0	3	1	1	1
96277	1710	inhibition of cd45	[inhibition of CD45]	0.0	3	1	1	1
96278	1710	regulation of interleukin in T lymphocyte	[regulation of interleukin in T lymphocytes]	0.0	6	1	1	1
96279	1710	consequence of the cellular content	[consequences of the cellular content]	0.0	5	1	1	1
96280	1710	ino synthase ino activity	[iNO synthase iNOS activity]	0.0	4	1	1	1
96281	1710	HL cell (granulocytic differentiated)	[HL cells (granulocytic differentiated)]	0.0	4	1	1	1
96282	1710	tsc2 gene expression in human tissue	[TSC2 gene expression in human tissues]	0.0	6	1	1	1
96283	1710	productive interaction of the transcription factor	[productive interactions of the transcription factors]	0.0	6	1	1	1
96284	1710	receptor partner	[receptor partners]	0.0	2	1	1	1
96285	1710	increase over subject	[increase over subjects]	0.0	3	1	1	1
96286	1710	production of interleukin-2	[production of interleukin-2]	0.0	3	1	1	1
96287	1710	several class promoter-specific DNA binding factor	[several class promoter-specific DNA binding factors]	0.0	6	1	1	1
96288	1710	kappa B/Rel activity lymphocyte by class	[kappa B/Rel activity lymphocytes by class]	0.0	6	1	1	1
96289	1710	involve rxr-alpha	[involving RXR-alpha]	0.0	2	1	1	1
96290	1710	mutant probe	[mutant probes]	0.0	2	1	1	1
96291	1710	sr-bp high	[SR-BP higher]	0.0	2	1	1	1
96292	1710	activity of erythrocyte nuclear protein	[activities of erythrocyte nuclear proteins]	0.0	5	1	1	1
96293	1710	mucosa-associated tissue lymphoma (19	[mucosa-associated tissue lymphoma (19]	0.0	4	1	1	1
96294	1710	vascular antiatherogenic mechanism	[vascular antiatherogenic mechanism]	0.0	3	1	1	1
96295	1710	growth factor-B pdgf-b proto-oncogene	[growth factor-B PDGF-B proto-oncogene]	0.0	4	1	1	1
96296	1710	erythrocyte-specific anhydrase ii caii	[erythrocyte-specific anhydrase II CAII]	0.0	4	1	1	1
96297	1710	regulation by a synovial microenvironment	[regulation by an synovial microenvironment]	0.0	5	1	1	1
96298	1710	interaction in patient	[interactions in patients]	0.0	3	1	1	1
96299	1710	p130 complex	[p130 complexes]	0.0	2	1	1	1
96300	1710	ro(ssa) precipitins, of ro(ssa) patient	[Ro(SSA) precipitins, of Ro(SSA) patients]	0.0	5	1	1	1
96301	1710	pulmonary alveolar macrophage	[pulmonary alveolar macrophages]	0.0	3	1	1	1
96302	1710	cluster of leukemia-specific translocation	[cluster of leukemia-specific translocations]	0.0	4	1	1	1
96303	1710	stationary-phase sigma	[stationary-phase sigma]	0.0	2	1	1	1
96304	1710	major subpopulation	[major subpopulation]	0.0	2	1	1	1
96305	1710	CD40 up-regulation of b7-1	[CD40 up-regulation of B7-1]	0.0	4	1	1	1
96306	1710	predominant one in population	[predominant one in populations]	0.0	4	1	1	1
96307	1710	syphilis disease	[syphilis disease]	0.0	2	1	1	1
96308	1710	beneficial profile,	[beneficial profile,]	0.0	2	1	1	1
96309	1710	stabilizer	[stabilizers]	0.0	1	1	1	1
96310	1710	non-dividing, pbl	[non-dividing, PBL]	0.0	2	1	1	1
96311	1710	uptake in leukocyte	[uptake in leukocytes]	0.0	3	1	1	1
96312	1710	antibody recognition	[antibody recognition]	0.0	2	1	1	1
96313	1710	b cell component	[B cell components]	0.0	3	1	1	1
96314	1710	human leukocyte of donor of sexes.	[human leukocytes of donors of sexes.]	0.0	6	1	1	1
96315	1710	effect than the response	[effects than the responses]	0.0	4	1	1	1
96316	1710	colony (>1 mm)	[colonies (>1 mm)]	0.0	3	1	1	1
96317	1710	significant effect on adrenal function	[significant effects on adrenal function]	0.0	5	1	1	1
96318	1710	ligand dil	[ligands DILs]	0.0	2	1	1	1
96319	1710	new variant translocation of (q27;q32)	[new variant translocation of (q27;q32)]	0.0	5	1	1	1
96320	1710	chronic lymphatic leukemia CLL	[chronic lymphatic leukemia CLL]	0.0	4	1	1	1
96321	1710	continuous nf-kappa b translocation result	[continuous NF-kappa B translocation results]	0.0	5	1	1	1
96322	1710	plasma cyst(e)ine	[plasma cyst(e)ine]	0.0	2	1	1	1
96323	1710	significance to aids patient	[significance to AIDS patients]	0.0	4	1	1	1
96324	1710	demonstrate coupling between sIg protein	[demonstrating coupling between sIg proteins]	0.0	5	1	1	1
96325	1710	underlie this role	[underlying this role]	0.0	3	1	1	1
96326	1710	lead to proliferation	[leading to proliferation]	0.0	3	1	1	1
96327	1710	indicate the importance	[indicating the importance]	0.0	3	1	1	1
96328	1710	type of disease	[types of disease]	0.0	3	1	1	1
96329	1710	thereby mark a transformation effector site	[thereby marking a transformation effector site]	0.0	6	1	1	1
96330	1710	HTLV-I long terminal repeat	[HTLV-I long terminal repeat]	0.0	4	1	1	1
96331	1710	transient expression assay with plasmid	[Transient expression assays with plasmids]	0.0	5	1	1	1
96332	1710	activate stat3 signal transducer	[activating STAT3 signal transducer]	0.0	4	1	1	1
96333	1710	site-directed mutagenesis of human HSs	[site-directed mutagenesis of human HSs]	0.0	5	1	1	1
96334	1710	activation in human cell	[activation in human cells]	0.0	4	1	1	1
96335	1710	moderate correlation	[moderate correlation]	0.0	2	1	1	1
96336	1710	site of g28-5	[site of G28-5]	0.0	3	1	1	1
96337	1710	produce a new retrovirus	[producing a new retrovirus]	0.0	4	1	1	1
96338	1710	evidence for a inducible pathway	[evidence for an inducible pathway]	0.0	5	1	1	1
96339	1710	disease (12:	[diseases (12:]	0.0	2	1	1	1
96340	1710	unsynchronized state	[unsynchronized state]	0.0	2	1	1	1
96341	1710	five DNA binding subunit	[five DNA binding subunits]	0.0	4	1	1	1
96342	1710	dominant IkappaBalpha construct	[dominant IkappaBalpha construct]	0.0	3	1	1	1
96343	1710	product such as lipopolysaccharide	[products such as lipopolysaccharide]	0.0	4	1	1	1
96344	1710	Finally, reactivation	[Finally, reactivation]	0.0	2	1	1	1
96345	1710	interaction between the kinase	[interaction between the kinase]	0.0	4	1	1	1
96346	1710	site -187	[site -187]	0.0	2	1	1	1
96347	1710	expression in mouse T cell	[expression in mouse T cells]	0.0	5	1	1	1
96348	1710	antigen-specific reactivity at least as high	[antigen-specific reactivities at least as high]	0.0	6	1	1	1
96349	1710	determine function in this cells.	[determining function in these cells.]	0.0	5	1	1	1
96350	1710	Ca2+ element obligatory	[Ca2+ element obligatory]	0.0	3	1	1	1
96351	1710	phosphatase inhibitor for protein phosphatase	[phosphatase inhibitors for protein phosphatase]	0.0	5	1	1	1
96352	1710	3-deazaadenosine a inhibitor	[3-deazaadenosine a inhibitor]	0.0	3	1	1	1
96353	1710	palindromic octamer sequence pos	[palindromic octamer sequence POS]	0.0	4	1	1	1
96354	1710	b- cell development	[B- cell development]	0.0	3	1	1	1
96355	1710	involve ros	[involving ROS]	0.0	2	1	1	1
96356	1710	abnormal nuclear morphology indicative	[abnormal nuclear morphology indicative]	0.0	4	1	1	1
96357	1710	monocyte binding to human cell	[monocyte binding to human cells]	0.0	5	1	1	1
96358	1710	few year	[few years]	0.0	2	1	1	1
96359	1710	cDNA end 5'-race analysis	[cDNA ends 5'-RACE analysis]	0.0	4	1	1	1
96360	1710	gh (except in obese patient	[GH (except in obese patient]	0.0	5	1	1	1
96361	1710	member of the family A-myb	[member of the family A-myb]	0.0	5	1	1	1
96362	1710	protein), a increase	[protein), a increase]	0.0	3	1	1	1
96363	1710	events; however, addition	[events; however, addition]	0.0	3	1	1	1
96364	1710	activator of NF-kappa b	[activators of NF-kappa B]	0.0	4	1	1	1
96365	1710	trans-act negative regulator	[trans-acting negative regulator]	0.0	3	1	1	1
96366	1710	monocyte activity of mcp-1 production	[monocyte activity of MCP-1 production]	0.0	5	1	1	1
96367	1710	suggest traffic	[suggesting traffic]	0.0	2	1	1	1
96368	1710	several chronic rheumatoid arthritis patient	[several chronic rheumatoid arthritis patients]	0.0	5	1	1	1
96369	1710	site at position bp	[site at position bp]	0.0	4	1	1	1
96370	1710	least three form	[least three forms]	0.0	3	1	1	1
96371	1710	immunophilin fkbp51	[immunophilin FKBP51]	0.0	2	1	1	1
96372	1710	differentiation induction system	[differentiation induction systems]	0.0	3	1	1	1
96373	1710	noncomedo variant	[noncomedo variant]	0.0	2	1	1	1
96374	1710	immunophilin fkbp54	[immunophilins FKBP54]	0.0	2	1	1	1
96375	1710	elucidation	[Elucidation]	0.0	1	3	3	1
96376	1710	human soluble tnf receptor	[human soluble TNF receptor]	0.0	4	1	1	1
96377	1710	tcc c5b-7 on target cell	[TCC C5b-7 on target cells]	0.0	5	1	1	1
96378	1710	hsp60 in vein cell	[Hsp60 in vein cells]	0.0	4	1	1	1
96379	1710	least 1 h	[least 1 h]	0.0	3	1	1	1
96380	1710	protect b cell	[protecting B cells]	0.0	3	1	1	1
96381	1710	nuclear extract upon translocation	[nuclear extracts upon translocation]	0.0	4	1	1	1
96382	1710	basis from translation start site	[bases from translation start site]	0.0	5	1	1	1
96383	1710	deletion of domain	[deletions of domain]	0.0	3	1	1	1
96384	1710	effect of phorbol acetate	[effect of phorbol acetate]	0.0	4	1	1	1
96385	1710	effect of therapy	[effect of therapy]	0.0	3	1	1	1
96386	1710	synthesis of the subunit	[synthesis of the subunit]	0.0	4	1	1	1
96387	1710	Xq13 region	[Xq13 region]	0.0	2	1	1	1
96388	1710	isoform of stat5	[isoforms of STAT5]	0.0	3	1	1	1
96389	1710	similar selective effect	[Similar selective effects]	0.0	3	1	1	1
96390	1710	lymphocyte in sle (92.9%)	[lymphocytes in SLE (92.9%)]	0.0	4	1	1	1
96391	1710	coincide with the release	[coinciding with the release]	0.0	4	1	1	1
96392	1710	murine splenic T cell	[murine splenic T cells]	0.0	4	1	1	1
96393	1710	sequential development of alteration	[Sequential development of alterations]	0.0	4	1	1	1
96394	1710	mobility-shift analysis of extract	[mobility-shift analysis of extracts]	0.0	4	1	1	1
96395	1710	however, mutation	[However, mutation]	0.0	2	2	2	1
96396	1710	consist of the intracellular domain	[consisting of the intracellular domain]	0.0	5	1	1	1
96397	1710	heterotetramer	[heterotetramer]	0.0	1	1	1	1
96398	1710	signal-transducing pathway	[signal-transducing pathway]	0.0	2	1	1	1
96399	1710	Tcf-1 knock-out mouse	[Tcf-1 knock-out mice]	0.0	3	1	1	1
96400	1710	approximately eightfold amount a member	[approximately eightfold amounts a member]	0.0	5	1	1	1
96401	1710	h versus 18	[h vs 18]	0.0	3	1	1	1
96402	1710	plasma bicarbonate	[plasma bicarbonates]	0.0	2	1	1	1
96403	1710	four patient f.r., m.m., P.	[four patients F.R., M.M., P.]	0.0	5	1	1	1
96404	1710	26 squamous cell carcinoma	[26 squamous cell carcinomas]	0.0	4	1	1	1
96405	1710	granulocyte-macrophage factor production	[granulocyte-macrophage factor production]	0.0	3	1	1	1
96406	1710	cell leukemia(atl)	[cell leukemia(ATL)]	0.0	2	1	1	1
96407	1710	component of a immune response	[component of a immune response]	0.0	5	1	1	1
96408	1710	gamma(c)-positive, alpha1 daudi cell	[gamma(c)-positive, alpha1 Daudi cells]	0.0	4	1	1	1
96409	1710	EBV mrna transcript	[EBV mRNA transcripts]	0.0	3	1	1	1
96410	1710	even low level expression	[even low level expression]	0.0	4	1	1	1
96411	1710	weight of 50000 Dalton	[weight of 50000 Dalton]	0.0	4	1	1	1
96412	1710	self renewal of erythroid progenitor	[Self renewal of erythroid progenitors]	0.0	5	1	1	1
96413	1710	hpa axis regulation	[HPA axis regulation]	0.0	3	1	1	1
96414	1710	hybridization pattern	[hybridization pattern]	0.0	2	1	1	1
96415	1710	patient suffer from telangiectasia	[patients suffering from telangiectasia]	0.0	4	1	1	1
96416	1710	carry mutation in the 5' part	[carrying mutations in the 5' part]	0.0	6	1	1	1
96417	1710	1, D3 receptor VDR	[1, D3 receptor VDR]	0.0	4	1	1	1
96418	1710	X1 dna-binding activity	[X1 DNA-binding activities]	0.0	3	1	1	1
96419	1710	nm23 protein on induction	[nm23 proteins on induction]	0.0	4	1	1	1
96420	1710	use of peptide bcr1/9	[use of peptides BCR1/9]	0.0	4	1	1	1
96421	1710	mimic	[mimics]	0.0	1	1	1	1
96422	1710	association proviral latency in certain cell	[Association proviral latency in certain cells]	0.0	6	1	1	1
96423	1710	protein other	[protein other]	0.0	2	1	1	1
96424	1710	jun b proto-oncogent	[jun B proto-oncogenes]	0.0	3	1	1	1
96425	1710	chronic inflammation in RA	[chronic inflammation in RA]	0.0	4	1	1	1
96426	1710	HeLa carcinoma cell	[HeLa carcinoma cells]	0.0	3	1	1	1
96427	1710	expression of gene in megakaryoblastic leukaemia	[Expression of genes in megakaryoblastic leukaemia]	0.0	6	1	1	1
96428	1710	excess of unlabeled ligand	[excess of unlabeled ligand]	0.0	4	1	1	1
96429	1710	two-dimensional electrophoretic analysis	[Two-dimensional electrophoretic analysis]	0.0	3	1	1	1
96430	1710	mechanism for loss of heterozygosity	[mechanism for loss of heterozygosity]	0.0	5	1	1	1
96431	1710	characterization of a gene	[Characterization of an gene]	0.0	4	1	1	1
96432	1710	sIgM	[sIgM]	0.0	1	1	1	1
96433	1710	factor kB	[factor kB]	0.0	2	1	1	1
96434	1710	Epstein-Barr virus EBV antigen 2	[Epstein-Barr virus EBV antigen 2]	0.0	5	1	1	1
96435	1710	gradual decline	[gradual decline]	0.0	2	1	1	1
96436	1710	methods: lymphocyte	[METHODS: Lymphocyte]	0.0	2	1	1	1
96437	1710	exogenous IL-6 prb	[exogenous IL-6 pRB]	0.0	3	1	1	1
96438	1710	study of the sequence	[studies of the sequence]	0.0	4	1	1	1
96439	1710	Aldh1 protein	[Aldh1 protein]	0.0	2	1	1	1
96440	1710	embryocarcinoma f9 cell	[embryocarcinoma F9 cells]	0.0	3	1	1	1
96441	1710	human glial astrocyte	[human glial astrocytes]	0.0	3	1	1	1
96442	1710	il-4 target gene	[IL-4 target genes]	0.0	3	1	1	1
96443	1710	synthesis of a peptide	[synthesis of a peptide]	0.0	4	1	1	1
96444	1710	control collagenase transcription	[controlling collagenase transcription]	0.0	3	1	1	1
96445	1710	influenza T cell	[influenza T cells]	0.0	3	1	1	1
96446	1710	lymphoid gene expression 3 promoter	[Lymphoid gene expression 3 promoter]	0.0	5	1	1	1
96447	1710	t-cell mitogenesis	[T-cell mitogenesis]	0.0	2	1	1	1
96448	1710	thrombin-activated platelet	[thrombin-activated platelets]	0.0	2	1	1	1
96449	1710	IL-12 heterodimer	[IL-12 heterodimer]	0.0	2	1	1	1
96450	1710	base difference	[base difference]	0.0	2	1	1	1
96451	1710	cytokine dysregulation human immunodeficiency virus type	[Cytokine dysregulation human immunodeficiency virus type]	0.0	6	1	1	1
96452	1710	nuclear expression of nf-kappab	[nuclear expression of NF-kappaB]	0.0	4	1	1	1
96453	1710	activation 1 expression	[Activation 1 expression]	0.0	3	1	1	1
96454	1710	ifn-gamma for hour	[IFN-gamma for hr]	0.0	3	1	1	1
96455	1710	mrna for IL-2	[mRNA for IL-2]	0.0	3	1	1	1
96456	1710	1.2-kb cDNA encoding full-length c/ebp-epsilon	[1.2-kb cDNA encoding full-length C/EBP-epsilon]	0.0	5	1	1	1
96457	1710	activation gene transcription	[Activation gene transcription]	0.0	3	1	1	1
96458	1710	level in normal T lymphocyte	[levels in normal T lymphocytes]	0.0	5	1	1	1
96459	1710	high level in monocytic	[higher levels in monocytic]	0.0	4	1	1	1
96460	1710	stat in T	[STATs in T]	0.0	3	1	1	1
96461	1710	independent activation domain	[independent activation domain]	0.0	3	1	1	1
96462	1710	possible involvement of this messenger	[possible involvement of these messengers]	0.0	5	1	1	1
96463	1710	specific context of protein	[specific context of proteins]	0.0	4	1	1	1
96464	1710	molecular mechanism of adherence	[Molecular mechanisms of adherence]	0.0	4	1	1	1
96465	1710	virus region	[virus region]	0.0	2	1	1	1
96466	1710	nuclear subvolumes:	[nuclear subvolumes:]	0.0	2	1	1	1
96467	1710	expression of ciita major surface protein	[expression of CIITA major surface proteins]	0.0	6	1	1	1
96468	1710	dna-binding activity of extract	[DNA-binding activity of extracts]	0.0	4	1	1	1
96469	1710	histiocytic u937 cell	[histiocytic U937 cells]	0.0	3	1	1	1
96470	1710	activation of nf-at1 in T cell	[activation of NF-AT1 in T cells]	0.0	6	1	1	1
96471	1710	only in cell of origin	[only in cells of origin]	0.0	5	1	1	1
96472	1710	peripheral adaptation in receptor number	[peripheral adaptation in receptor number]	0.0	5	1	1	1
96473	1710	cytokine gene expression in monocyte	[cytokine gene expression in monocytes]	0.0	5	1	1	1
96474	1710	inhibition during the A/R insult	[Inhibition during the A/R insult]	0.0	5	1	1	1
96475	1710	(common)	[(common)]	0.0	1	1	1	1
96476	1710	more precise definition	[more precise definition]	0.0	3	1	1	1
96477	1710	look back in new approach	[Looking back in newer approaches]	0.0	5	1	1	1
96478	1710	PKC activator	[PKC activator]	0.0	2	1	1	1
96479	1710	camp analogue dbcamp	[cAMP analogue dbcAMP]	0.0	3	1	1	1
96480	1710	er cell by immunocytochemistry;	[ER cells by immunocytochemistry;]	0.0	4	1	1	1
96481	1710	Differential localization	[Differential localization]	0.0	2	1	1	1
96482	1710	finding synergistic in tumorigenesis	[findings synergistic in tumorigenesis]	0.0	4	1	1	1
96483	1710	number endometrium	[numbers endometrium]	0.0	2	1	1	1
96484	1710	treatment of human T lymphocyte	[treatment of human T lymphocytes]	0.0	5	1	1	1
96485	1710	cis-acting enhancer motif	[cis-acting enhancer motif]	0.0	3	1	1	1
96486	1710	organ inflammation	[organ inflammation]	0.0	2	1	1	1
96487	1710	STAT5 site	[STAT5 site]	0.0	2	1	1	1
96488	1710	antiproliferative, function	[antiproliferative, functions]	0.0	2	1	1	1
96489	1710	tissue-specific transcriptional activator	[tissue-specific transcriptional activator]	0.0	3	1	1	1
96490	1710	inducible nitric oxide synthase	[inducible nitric oxide synthase]	0.0	4	1	1	1
96491	1710	phospholipase c gamma 1	[phospholipase C gamma 1]	0.0	4	1	1	1
96492	1710	glucocorticoid in thp 1 cell	[glucocorticoids in THP 1 cells]	0.0	5	1	1	1
96493	1710	dexamethasone on eosinophil apoptosis	[dexamethasone on eosinophil apoptosis]	0.0	4	1	1	1
96494	1710	255 nucleotide	[255 nucleotides]	0.0	2	1	1	1
96495	1710	IFN cytoprotection	[IFN cytoprotection]	0.0	2	1	1	1
96496	1710	largely due to inhibition of gene	[largely due to inhibition of genes]	0.0	6	1	1	1
96497	1710	include b lymphocyte	[including B lymphocytes]	0.0	3	1	1	1
96498	1710	high incidence of relapse	[high incidence of relapse]	0.0	4	1	1	1
96499	1710	investigations, use serum-free hl60 cell	[investigations, using serum-free HL60 cells]	0.0	5	1	1	1
96500	1710	normal virus-immortalized b cell	[normal virus-immortalized B cells]	0.0	4	1	1	1
96501	1710	measure venule pcv	[measuring venules PCVs]	0.0	3	1	1	1
96502	1710	exhibit activity RARalpha403	[exhibiting activity RARalpha403]	0.0	3	1	1	1
96503	1710	encode transcription factor	[encoding transcription factors]	0.0	3	1	1	1
96504	1710	underlie the initiation of fibrin deposition	[underlying the initiation of fibrin deposition]	0.0	6	1	1	1
96505	1710	V.Wendel-Hansen,	[V.Wendel-Hansen,]	0.0	1	1	1	1
96506	1710	notch complex	[Notch complex]	0.0	2	1	1	1
96507	1710	promising new avenue	[promising new avenue]	0.0	3	1	1	1
96508	1710	major histocompatibility complex	[major histocompatibility complex]	0.0	3	1	1	1
96509	1710	49 case of chronic leukemia	[49 cases of chronic leukemia]	0.0	5	1	1	1
96510	1710	several positive mechanism	[several positive mechanisms]	0.0	3	1	1	1
96511	1710	subdivide the subject	[subdividing the subjects]	0.0	3	1	1	1
96512	1710	results: after stimulation, il-5 production	[RESULTS: After stimulation, IL-5 production]	0.0	5	1	1	1
96513	1710	viral life cycle	[viral life cycle]	0.0	3	1	1	1
96514	1710	responsiveness of human leukocyte HML	[responsiveness of human leukocytes HML]	0.0	5	1	1	1
96515	1710	h of virus	[h of virus]	0.0	3	1	1	1
96516	1710	specific decrease	[specific decrease]	0.0	2	1	1	1
96517	1710	mcp-1 by RA	[MCP-1 by RA]	0.0	3	1	1	1
96518	1710	NK cell membrane	[NK cell membrane]	0.0	3	1	1	1
96519	1710	report in endothelial cell	[report in endothelial cells]	0.0	4	1	1	1
96520	1710	activity of tepoxalin a new potential	[activity of tepoxalin a new potential]	0.0	6	1	1	1
96521	1710	ppargamma differentiation-dependent receptor gamma ppargamma expression	[PPARgamma differentiation-dependent receptor gamma PPARgamma expression]	0.0	6	1	1	1
96522	1710	infection analysis	[Infection analyses]	0.0	2	1	1	1
96523	1710	active form partially substitute	[active form partially substitutes]	0.0	4	1	1	1
96524	1710	IL-10 effect	[IL-10 effect]	0.0	2	1	1	1
96525	1710	octamer site transcription	[octamer site transcription]	0.0	3	1	1	1
96526	1710	DNA helix,	[DNA helix,]	0.0	2	1	1	1
96527	1710	CsA T	[CsA T]	0.0	2	1	1	1
96528	1710	peripheral cell pbmc	[peripheral cells PBMC]	0.0	3	1	1	1
96529	1710	unique mechanism distinct	[unique mechanism distinct]	0.0	3	1	1	1
96530	1710	application of drugs,	[application of drugs,]	0.0	3	1	1	1
96531	1710	complex (MHC) class promoter	[complex (MHC) class promoters]	0.0	4	1	1	1
96532	1710	control antibody	[control antibody]	0.0	2	1	1	1
96533	1710	parasitic	[parasitic]	0.0	1	1	1	1
96534	1710	aldosterone effect	[aldosterone effects]	0.0	2	1	1	1
96535	1710	proliferation recent-onset iddm subject	[proliferation recent-onset IDDM subjects]	0.0	4	1	1	1
96536	1710	CaM-K	[CaM-K]	0.0	1	2	2	1
96537	1710	intp	[dNTPs]	0.0	1	1	1	1
96538	1710	long maintenance of proviral transcription	[long-term maintenance of proviral transcription]	0.0	5	1	1	1
96539	1710	300 bp of the 3'-region	[300 bp of the 3'-region]	0.0	5	1	1	1
96540	1710	LTB4 adhesive interaction	[LTB4 adhesive interactions]	0.0	3	1	1	1
96541	1710	rectal value	[rectal values]	0.0	2	1	1	1
96542	1710	antagonize the IL-1 synthesis	[antagonizing the IL-1 synthesis]	0.0	4	1	1	1
96543	1710	lead to induction	[leading to induction]	0.0	3	1	1	1
96544	1710	leukotriene B4 a potent mediator	[leukotriene B4 a potent mediator]	0.0	5	1	1	1
96545	1710	rearrangement of kappa gene	[rearrangement of kappa genes]	0.0	4	1	1	1
96546	1710	neural development	[neural development]	0.0	2	1	1	1
96547	1710	protein than T cell	[proteins than T cells]	0.0	4	1	1	1
96548	1710	partial domain	[partial domain]	0.0	2	1	1	1
96549	1710	phenotypic marker of different subpopulation	[phenotypic marker of different subpopulations]	0.0	5	1	1	1
96550	1710	development of lymphoblastic leukemia	[development of lymphoblastic leukemia]	0.0	4	1	1	1
96551	1710	persist lifelong, in the host, hiding	[persisting lifelong, in the host, hiding]	0.0	6	1	1	1
96552	1710	enhance transcription of several cellular gene	[enhancing transcription of several cellular genes]	0.0	6	1	1	1
96553	1710	protection employ extract from B	[protection employing extracts from B]	0.0	5	1	1	1
96554	1710	additional lymphoid-specific transcription factor	[additional lymphoid-specific transcription factor]	0.0	4	1	1	1
96555	1710	basAl, adhesion with 50% inhibition	[basal, adhesion with 50% inhibition]	0.0	5	1	1	1
96556	1710	important stage	[important stage]	0.0	2	1	1	1
96557	1710	importantly a NF-kappa b site	[importantly an NF-kappa B site]	0.0	5	1	1	1
96558	1710	cell complex formation	[cell complex formation]	0.0	3	1	1	1
96559	1710	diameter	[diameter]	0.0	1	2	2	1
96560	1710	CstF-64 to the site	[CstF-64 to the site]	0.0	4	1	1	1
96561	1710	GATA-1 protein level	[GATA-1 protein level]	0.0	3	1	1	1
96562	1710	nf.kappa	[NF.kappa]	0.0	1	3	3	1
96563	1710	iron complex	[iron complexes]	0.0	2	1	1	1
96564	1710	monocyte/neutrophil	[monocyte/neutrophil]	0.0	1	1	1	1
96565	1710	selectively along the erythroid pathway	[selectively along the erythroid pathway]	0.0	5	1	1	1
96566	1710	vigorous replication	[vigorous replication]	0.0	2	1	1	1
96567	1710	Burkitt' lymphoma rael cell	[Burkitt's lymphoma Rael cells]	0.0	4	1	1	1
96568	1710	b lymphocyte with h-89	[B lymphocytes with H-89]	0.0	4	1	1	1
96569	1710	cell/monocyte	[cell/monocyte]	0.0	1	1	1	1
96570	1710	exchange of peptide clip	[exchange of peptides CLIP]	0.0	4	1	1	1
96571	1710	cooperative action of the receptor	[cooperative action of the receptors]	0.0	5	1	1	1
96572	1710	element identical to the "octamer" motif	[element identical to the "octamer" motif]	0.0	6	1	1	1
96573	1710	CD28 abs	[CD28 Abs]	0.0	2	1	1	1
96574	1710	induction by macrophage factor in monocyte	[Induction by macrophage factor in monocytes]	0.0	6	1	1	1
96575	1710	cell type include cd8+	[cell types including CD8+]	0.0	4	1	1	1
96576	1710	activation of a plasmid	[activation of a plasmid]	0.0	4	1	1	1
96577	1710	Sp3ilday expression	[Sp3 expression]	0.0	2	1	1	1
96578	1710	function for phospholipase a2	[function for phospholipase A2]	0.0	4	1	1	1
96579	1710	interleukin-5 a selective eosinophil-activating factor	[interleukin-5 a selective eosinophil-activating factor]	0.0	5	1	1	1
96580	1710	PKC isotype	[PKC isotypes]	0.0	2	1	1	1
96581	1710	restoration of il-2 mrna	[restoration of IL-2 mRNA]	0.0	4	1	1	1
96582	1710	accurate picture,	[accurate picture,]	0.0	2	1	1	1
96583	1710	recent years, study	[recent years, studies]	0.0	3	1	1	1
96584	1710	suggest a divergence of the pathways.	[suggesting an divergence of the pathways.]	0.0	6	1	1	1
96585	1710	none of 33 pbmc specimen	[None of 33 PBMC specimens]	0.0	5	2	2	1
96586	1710	mode of oxidative stress	[modes of oxidative stress]	0.0	4	1	1	1
96587	1710	expression analysis in cell of origin	[expression analyses in cells of origin]	0.0	6	1	1	1
96588	1710	calcium gene induction	[Calcium gene induction]	0.0	3	1	1	1
96589	1710	(ayt)gataeatarr	[(A/T)GATA(A/G)]	0.0	1	1	1	1
96590	1710	-dependent cell adhesion of beta integrin	[-dependent cell adhesion of beta integrins]	0.0	6	1	1	1
96591	1710	molecular site	[molecular site]	0.0	2	1	1	1
96592	1710	protein mar-bp1	[protein MAR-BP1]	0.0	2	1	1	1
96593	1710	platelet to adherent monocyte	[platelets to adherent monocytes]	0.0	4	1	1	1
96594	1710	part of large sequence	[part of larger sequences]	0.0	4	1	1	1
96595	1710	target the membrane glycoprotein cd36	[targets the membrane glycoprotein CD36]	0.0	5	1	1	1
96596	1710	follow multiple administration	[following multiple administrations]	0.0	3	1	1	1
96597	1710	drug-free patient with disorder euthymic,	[drug-free patients with disorder euthymic,]	0.0	5	1	1	1
96598	1710	main approaches.	[main approaches.]	0.0	2	1	1	1
96599	1710	genomic IL-4 region	[genomic IL-4 regions]	0.0	3	1	1	1
96600	1710	parasitism	[parasitism]	0.0	1	1	1	1
96601	1710	direct target	[direct target]	0.0	2	1	1	1
96602	1710	intracellular biochemical event lead	[intracellular biochemical events leading]	0.0	4	1	1	1
96603	1710	high level of the dna-binding activity	[High levels of the DNA-binding activity]	0.0	6	1	1	1
96604	1710	gamma c expression	[gamma c expression]	0.0	3	1	1	1
96605	1710	Interleukin-6 production	[Interleukin-6 production]	0.0	2	1	1	1
96606	1710	direct interaction antagonism	[Direct interaction antagonism]	0.0	3	1	1	1
96607	1710	transcription of histocompatibility class ii gene	[transcription of histocompatibility class II genes]	0.0	6	1	1	1
96608	1710	fat level	[fat level]	0.0	2	1	1	1
96609	1710	control transcription factor	[control transcription factors]	0.0	3	1	1	1
96610	1710	two approach	[two approaches]	0.0	2	1	1	1
96611	1710	low the/thf alpha thf/thf	[low THE/THF alpha THF/THF]	0.0	4	1	1	1
96612	1710	one cause of persistent arthritis	[one cause of persistent arthritis]	0.0	5	2	2	1
96613	1710	labeling by immunofluorescence from normal tonsil	[labeling by immunofluorescence from normal tonsils]	0.0	6	1	1	1
96614	1710	two amino acid alteration within domain	[two amino acid alterations within domain]	0.0	6	1	1	1
96615	1710	gene encode component	[genes encoding components]	0.0	3	1	1	1
96616	1710	turn, assembly	[turn, assembly]	0.0	2	1	1	1
96617	1710	elevation of bronchoalveolar lavage cellularity	[elevation of bronchoalveolar lavage cellularity]	0.0	5	1	1	1
96618	1710	produce a induction within 1 hour	[producing a induction within 1 hour]	0.0	6	1	1	1
96619	1710	heat-labile serum	[heat-labile serum]	0.0	2	1	1	1
96620	1710	cell to DFX	[cells to DFX]	0.0	3	1	1	1
96621	1710	uninfected peripheral blood monocyte	[uninfected peripheral blood monocytes]	0.0	4	1	1	1
96622	1710	major histocompatibility complex MHC	[major histocompatibility complex MHC]	0.0	4	1	1	1
96623	1710	major complex molecule	[major complex molecules]	0.0	3	1	1	1
96624	1710	inactivate nucleotide substitution in the counterpart	[inactivating nucleotide substitutions in the counterpart]	0.0	6	1	1	1
96625	1710	Autocrine role	[Autocrine role]	0.0	2	1	1	1
96626	1710	calcitriol action	[calcitriol action]	0.0	2	1	1	1
96627	1710	Jakdstat inhibitory gene	[JAK/STAT inhibitory gene]	0.0	3	1	1	1
96628	1710	action of pc4	[action of PC4]	0.0	3	1	1	1
96629	1710	co-receptor molecule	[co-receptor molecule]	0.0	2	1	1	1
96630	1710	involvement in regulation	[involvement in regulation]	0.0	3	1	1	1
96631	1710	adult blood lymphocyte sample	[adult blood lymphocyte samples]	0.0	4	1	1	1
96632	1710	36 race- control subject	[36 race- control subjects]	0.0	4	1	1	1
96633	1710	identical dual signal requirement	[identical dual signal requirement]	0.0	4	1	1	1
96634	1710	determinant govern process of differentiation	[determinant governing processes of differentiation]	0.0	5	1	1	1
96635	1710	icr27tk.3 cell contain mutant receptor	[ICR27TK.3 cells containing mutant receptors]	0.0	5	1	1	1
96636	1710	binding of ICSAT to icss	[binding of ICSAT to ICSs]	0.0	5	1	1	1
96637	1710	induction of non-cytokine gene	[induction of non-cytokine genes]	0.0	4	1	1	1
96638	1710	appropriate redox status	[appropriate redox status]	0.0	3	1	1	1
96639	1710	enhancer of other gene	[enhancers of other genes]	0.0	4	1	1	1
96640	1710	alas-e	[ALAS-E]	0.0	1	1	1	1
96641	1710	similar effect in b cell	[similar effects in B cells]	0.0	5	1	1	1
96642	1710	three lac+clone out of transformant	[three Lac+clones out of transformants]	0.0	5	1	1	1
96643	1710	class molecule for antigenic peptide	[class molecules for antigenic peptides]	0.0	5	1	1	1
96644	1710	suggest activity	[suggesting activity]	0.0	2	1	1	1
96645	1710	Nm23H2 in b cell extract	[Nm23H2 in B cell extracts]	0.0	5	1	1	1
96646	1710	IL-2R(alpha)	[IL-2R(alpha)]	0.0	1	1	1	1
96647	1710	goals: (1)	[goals: (1)]	0.0	2	1	1	1
96648	1710	4 cases,	[4 cases,]	0.0	2	1	1	1
96649	1710	h from undetectable level	[h from undetectable levels]	0.0	4	1	1	1
96650	1710	induction a inhibitor	[Induction an inhibitor]	0.0	3	1	1	1
96651	1710	fivefold increase	[fivefold increase]	0.0	2	1	1	1
96652	1710	dexamethasone on the production of cytokine	[dexamethasone on the production of cytokines]	0.0	6	1	1	1
96653	1710	fold of the domain, interference	[folding of the domain, interference]	0.0	5	1	1	1
96654	1710	Itk a T tyrosine kinase	[Itk a T tyrosine kinase]	0.0	5	1	1	1
96655	1710	biphasic increase to huvec	[biphasic increase to HUVECs]	0.0	4	1	1	1
96656	1710	occur in response	[occurring in response]	0.0	3	1	1	1
96657	1710	addition, stimulation	[addition, stimulation]	0.0	2	1	1	1
96658	1710	expression of cytokine by T cell	[expression of cytokines by T cells]	0.0	6	1	1	1
96659	1710	affinity for complex	[affinity for complexes]	0.0	3	1	1	1
96660	1710	normal woman of childbearing	[normal women of childbearing]	0.0	4	1	1	1
96661	1710	gliotoxin activation of a form	[gliotoxin activation of an form]	0.0	5	1	1	1
96662	1710	novel regulatory role	[novel regulatory role]	0.0	3	1	1	1
96663	1710	amplification of each oncogene	[amplification of each oncogene]	0.0	4	1	1	1
96664	1710	characteristic of il-12 ril-12	[characteristics of IL-12 rIL-12]	0.0	4	1	1	1
96665	1710	two most active element	[two most active elements]	0.0	4	1	1	1
96666	1710	isotype.	[isotype.]	0.0	1	1	1	1
96667	1710	aspect of interaction between system	[aspects of interaction between systems]	0.0	5	1	1	1
96668	1710	cover the coding sequence of mrna	[covering the coding sequence of mRNA]	0.0	6	1	1	1
96669	1710	tissue-damaging granulocyte	[tissue-damaging granulocytes]	0.0	2	1	1	1
96670	1710	roi- pathway	[ROI- pathway]	0.0	2	1	1	1
96671	1710	picture weakness	[picture weakness]	0.0	2	1	1	1
96672	1710	association in NF-kappa b moiety latency	[Association in NF-kappa B moieties latency]	0.0	6	1	1	1
96673	1710	lymphocyte subset in leukocyte in aging.	[lymphocyte subsets in leukocytes in aging.]	0.0	6	1	1	1
96674	1710	rest t-cell	[resting T-cells]	0.0	2	1	1	1
96675	1710	calcitriol ethanol concentration 0.0001%	[calcitriol ethanol concentration 0.0001%]	0.0	4	1	1	1
96676	1710	immunologically important protein	[immunologically important proteins]	0.0	3	1	1	1
96677	1710	high proportion of double-positive cell	[high proportion of double-positive cells]	0.0	5	1	1	1
96678	1710	corresponding to sequence	[corresponding to sequences]	0.0	3	1	1	1
96679	1710	"death	["death]	0.0	1	1	1	1
96680	1710	factor irf-1	[factor IRF-1]	0.0	2	1	1	1
96681	1710	5 protein binding region	[5 protein binding regions]	0.0	4	1	1	1
96682	1710	contrast to kinase receptor	[contrast to kinase receptors]	0.0	4	1	1	1
96683	1710	direct scavenging property	[direct scavenging properties]	0.0	3	1	1	1
96684	1710	negative mutant pathway	[negative mutants pathway]	0.0	3	1	1	1
96685	1710	il-13r alpha1	[IL-13R alpha1]	0.0	2	1	1	1
96686	1710	description, to knowledge,	[description, to knowledge,]	0.0	3	1	1	1
96687	1710	affinity for this subunit.	[affinities for this subunit.]	0.0	4	1	1	1
96688	1710	cells)	[cells)]	0.0	1	1	1	1
96689	1710	immuno-cytochemistry	[immuno-cytochemistry]	0.0	1	1	1	1
96690	1710	immediate-early class	[immediate-early classes]	0.0	2	1	1	1
96691	1710	11 phosphoprotein along with others,	[11 phosphoproteins along with others,]	0.0	5	1	1	1
96692	1710	however, exposure of u-937 cell	[However, exposure of U-937 cells]	0.0	5	1	1	1
96693	1710	binding of several b transcription factor	[binding of several B transcription factors]	0.0	6	1	1	1
96694	1710	one "octamer" complex	[one "octamer" complex]	0.0	3	1	1	1
96695	1710	absence in lesion together	[absence in lesions together]	0.0	4	1	1	1
96696	1710	Differential induction (ifn)-inducible protein follow differentiation	[Differential induction (IFN)-inducible protein following differentiation]	0.0	6	1	1	1
96697	1710	appearance in the thymus	[appearance in the thymus]	0.0	4	1	1	1
96698	1710	mouse carry the irf-1 gene	[mice carrying the IRF-1 gene]	0.0	5	1	1	1
96699	1710	il-13r alpha1 expression	[IL-13R alpha1 expression]	0.0	3	1	1	1
96700	1710	(mean 37	[(mean 37]	0.0	2	1	1	1
96701	1710	ATL-16T extract	[ATL-16T extract]	0.0	2	1	1	1
96702	1710	vd receptor (vdr)	[VD receptor (VDR)]	0.0	3	1	1	1
96703	1710	clone reactive	[clone reactive]	0.0	2	1	1	1
96704	1710	gene expression in b cell	[gene expression in B cells]	0.0	5	1	1	1
96705	1710	minutes) to retinoic acid washed,	[minutes) to retinoic acid washed,]	0.0	5	1	1	1
96706	1710	Tenascin	[Tenascin]	0.0	1	1	1	1
96707	1710	production of 24,25-dihydroxy-vitamin D3	[production of 24,25-dihydroxy-vitamin D3]	0.0	4	1	1	1
96708	1710	distinct signal pathway lead	[distinct signaling pathways leading]	0.0	4	1	1	1
96709	1710	cytokine such as TNF	[cytokines such as TNF]	0.0	4	1	1	1
96710	1710	cell-death specification	[cell-death specification]	0.0	2	1	1	1
96711	1710	mechanism of transactivation by factor	[Mechanisms of transactivation by factor]	0.0	5	1	1	1
96712	1710	only the activity	[Only the activities]	0.0	3	1	1	1
96713	1710	addition a new complex	[addition a new complex]	0.0	4	1	1	1
96714	1710	formation of distinct dna-binding complex	[formation of distinct DNA-binding complexes]	0.0	5	1	1	1
96715	1710	primary T cell modulation	[primary T cells modulation]	0.0	4	1	1	1
96716	1710	putative ikappabalpha kinase	[putative IkappaBalpha kinase]	0.0	3	1	1	1
96717	1710	CCAAT/enhancer -binding protein	[CCAAT/enhancer -binding protein]	0.0	3	1	1	1
96718	1710	family with a mode	[families with an mode]	0.0	4	1	1	1
96719	1710	group of phenolic compound	[group of phenolic compounds]	0.0	4	1	1	1
96720	1710	treatment with TNF-alpha nuclear localization irrespective	[treatment with TNF-alpha nuclear localization irrespective]	0.0	6	1	1	1
96721	1710	inhibition expression	[inhibition expression]	0.0	2	1	1	1
96722	1710	related octamer-binding protein	[related octamer-binding protein]	0.0	3	1	1	1
96723	1710	only level of nf-kappa b	[only levels of NF-kappa B]	0.0	5	1	1	1
96724	1710	genetic approach	[genetic approach]	0.0	2	1	1	1
96725	1710	major histocompatibility class ii molecule	[major histocompatibility class II molecules]	0.0	5	1	1	1
96726	1710	regulate IL-2 gene expression	[regulating IL-2 gene expression]	0.0	4	1	1	1
96727	1710	link this important class	[linking these important classes]	0.0	4	1	1	1
96728	1710	specific gene expression 3 promoter	[specific gene expression 3 promoter]	0.0	5	1	1	1
96729	1710	result in the suppression	[resulting in the suppression]	0.0	4	1	1	1
96730	1710	Differential inhibition on bone protein-	[Differential inhibition on bone protein-]	0.0	5	1	1	1
96731	1710	myeloblastic leukemia cell	[myeloblastic leukemia cells]	0.0	3	1	1	1
96732	1710	anti-ERK signal-regulated kinase	[anti-ERK signal-regulated kinase]	0.0	3	1	1	1
96733	1710	1.4-kb tnf-alpha promoter	[1.4-kb TNF-alpha promoter]	0.0	3	1	1	1
96734	1710	mediator by epithelial cell	[mediators by epithelial cells]	0.0	4	1	1	1
96735	1710	potent inhibitor of cell	[potent inhibitor of cells]	0.0	4	1	1	1
96736	1710	DNase-I site HS	[DNase-I sites HS]	0.0	3	1	1	1
96737	1710	DNA bind domain of MyoD	[DNA binding domain of MyoD]	0.0	5	1	1	1
96738	1710	direct vascular mechanism	[direct vascular mechanism]	0.0	3	1	1	1
96739	1710	advance age	[advancing age]	0.0	2	1	1	1
96740	1710	presence of regulators/adapter	[presence of regulators/adapters]	0.0	3	1	1	1
96741	1710	apoptosis of endothelial cell	[apoptosis of endothelial cells]	0.0	4	1	1	1
96742	1710	gammac chain deficiency	[gammac chain deficiency]	0.0	3	1	1	1
96743	1710	carry copy	[carrying copies]	0.0	2	1	1	1
96744	1710	c-myc mrna expression high	[c-myc mRNA expression high]	0.0	4	1	1	1
96745	1710	identification during t-cell activation	[Identification during T-cell activation]	0.0	4	1	1	1
96746	1710	loss of a chromosome	[loss of a chromosome]	0.0	4	1	1	1
96747	1710	IL-7 a crucial factor	[IL-7 a crucial factor]	0.0	4	1	1	1
96748	1710	autoregulatory inhibitor of inflammation	[autoregulatory inhibitor of inflammation]	0.0	4	1	1	1
96749	1710	(mean 78	[(mean 78]	0.0	2	1	1	1
96750	1710	upregulation of a carboxylesterase	[upregulation of a carboxylesterase]	0.0	4	1	1	1
96751	1710	acute myeloid leukemia-M3	[acute myeloid leukemia-M3]	0.0	3	1	1	1
96752	1710	carry the ebna2 gene	[carrying the EBNA2 gene]	0.0	4	1	1	1
96753	1710	differential phosphorylation	[differential phosphorylation]	0.0	2	1	1	1
96754	1710	(18- to 35-year-old) female volunteer	[(18- to 35-year-old) female volunteers]	0.0	5	1	1	1
96755	1710	human leukocyte of healthy donor	[human leukocytes of healthy donors]	0.0	5	1	1	1
96756	1710	absence of viral	[absence of viral]	0.0	3	1	1	1
96757	1710	target of gc action	[targets of GC actions]	0.0	4	1	1	1
96758	1710	value of support,	[value of support,]	0.0	3	1	1	1
96759	1710	b-cell response in chronic hepatitis c	[B-cell response in chronic hepatitis C]	0.0	6	1	1	1
96760	1710	factor (ref.	[factor (ref.]	0.0	2	1	1	1
96761	1710	fashion in myelomonocytic cell	[fashion in myelomonocytic cells]	0.0	4	1	1	1
96762	1710	information on the event occur	[information on the events occurring]	0.0	5	1	1	1
96763	1710	tyrosine residue within the domain	[tyrosine residues within the domain]	0.0	5	1	1	1
96764	1710	have a ec50 of microM.	[having an EC50 of microM.]	0.0	5	1	1	1
96765	1710	similar role	[similar role]	0.0	2	1	1	1
96766	1710	however, a transactivator in the presence	[However, a transactivator in the presence]	0.0	6	1	1	1
96767	1710	ACH-2 T	[ACH-2 T]	0.0	2	1	1	1
96768	1710	type il-13	[types IL-13]	0.0	2	1	1	1
96769	1710	myelopathy/tropical paraparesis	[myelopathy/tropical paraparesis]	0.0	2	1	1	1
96770	1710	NFAT-1 mutant	[NFAT-1 mutant]	0.0	2	1	1	1
96771	1710	+/cd10-/cd5-	[+/CD10-/CD5-]	0.0	1	1	1	1
96772	1710	PEER	[PEER]	0.0	1	1	1	1
96773	1710	quantification by polymerase chain reaction	[Quantification by polymerase chain reaction]	0.0	5	1	1	1
96774	1710	early inflammatory event	[early inflammatory events]	0.0	3	1	1	1
96775	1710	contain c-rel-like protein	[containing c-Rel-like proteins]	0.0	3	1	1	1
96776	1710	IL-7 a factor for thymopoiesis	[IL-7 a factor for thymopoiesis]	0.0	5	1	1	1
96777	1710	dose of mg/d.	[dose of mg/d.]	0.0	3	1	1	1
96778	1710	two form diabete	[two forms diabetes]	0.0	3	1	1	1
96779	1710	activation of the nf-kappab kinase NIK	[activation of the NF-kappaB kinase NIK]	0.0	6	1	1	1
96780	1710	STAT1 activation	[STAT1 activation]	0.0	2	1	1	1
96781	1710	Cushing' disease within the range	[Cushing's disease within the range,]	0.0	5	1	1	1
96782	1710	deltadna-binding domain	[deltaDNA-binding domain]	0.0	2	1	1	1
96783	1710	two ls mutation	[two LS mutations]	0.0	3	1	1	1
96784	1710	constitute two model	[constituting two models]	0.0	3	1	1	1
96785	1710	type il-1r	[type IL-1R]	0.0	2	1	1	1
96786	1710	characteristic of hnf-1 alpha	[characteristics of HNF-1 alpha]	0.0	4	1	1	1
96787	1710	a.l.,	[A.L.,]	0.0	1	1	1	1
96788	1710	binding of 3h-dexamethasone	[Binding of 3H-dexamethasone]	0.0	3	1	1	1
96789	1710	combination with colony-stimulating factor G-CSF	[combination with colony-stimulating factor G-CSF]	0.0	5	1	1	1
96790	1710	alpha/beta interferon	[alpha/beta interferon]	0.0	2	1	1	1
96791	1710	CML protein	[CML proteins]	0.0	2	1	1	1
96792	1710	Janus tyrosine kinase-3	[Janus tyrosine kinase-3]	0.0	3	1	1	1
96793	1710	transcriptional control of insulin-gene activity	[transcriptional control of insulin-gene activity]	0.0	5	1	1	1
96794	1710	stimulation use 100 ng/ml	[stimulation using 100 ng/ml]	0.0	4	1	1	1
96795	1710	day establish pbmc culture in colony	[days establishing PBMC cultures in colonies]	0.0	6	1	1	1
96796	1710	triflusal animal	[triflusal animals]	0.0	2	1	1	1
96797	1710	myelopoiesis in vivo	[myelopoiesis in vivo]	0.0	3	1	1	1
96798	1710	ifn-stimulated gene	[IFN-stimulated gene]	0.0	2	1	1	1
96799	1710	roughly the level	[roughly the level]	0.0	3	1	1	1
96800	1710	transactivate function.	[transactivating function.]	0.0	2	1	1	1
96801	1710	subdominant latent cycle reactivity	[subdominant latent cycle reactivities]	0.0	4	1	1	1
96802	1710	only signal	[only signal]	0.0	2	1	1	1
96803	1710	effect on inflammatory response	[effect on inflammatory responses]	0.0	4	1	1	1
96804	1710	protein present in extract	[proteins present in extracts]	0.0	4	1	1	1
96805	1710	myeloid- transcription factor	[myeloid- transcription factor]	0.0	3	1	1	1
96806	1710	case of cd16	[case of CD16]	0.0	3	1	1	1
96807	1710	consequently lead to variable severity	[consequently leading to variable severity]	0.0	5	1	1	1
96808	1710	chemokine production	[chemokine production]	0.0	2	1	1	1
96809	1710	cells:	[cells:]	0.0	1	1	1	1
96810	1710	specific inhibitor of b activation	[specific inhibitors of B activation]	0.0	5	1	1	1
96811	1710	mrna I HTLV-I	[mRNA I HTLV-I]	0.0	3	1	1	1
96812	1710	novel effector	[novel effector]	0.0	2	1	1	1
96813	1710	adhesion molecule-1 in huvec	[adhesion molecule-1 in HUVECs]	0.0	4	1	1	1
96814	1710	dna-binding complex include Stat1 alpha	[DNA-binding complexes including Stat1 alpha]	0.0	5	1	1	1
96815	1710	hl-60 eosinophilic subline	[HL-60 eosinophilic sublines]	0.0	3	1	1	1
96816	1710	mechanism responsible for this expression,	[mechanisms responsible for this expression,]	0.0	5	1	1	1
96817	1710	use transcription-polymerase chain reaction	[using transcription-polymerase chain reaction]	0.0	4	1	1	1
96818	1710	transmembrane segment	[transmembrane segments]	0.0	2	1	1	1
96819	1710	kappa B/Rel activity	[kappa B/Rel activity]	0.0	3	1	1	1
96820	1710	nuclear factor-kappa beta in monocyte	[nuclear factor-kappa beta in monocytes]	0.0	5	1	1	1
96821	1710	immuno-deficiency virus	[immuno-deficiency virus]	0.0	2	1	1	1
96822	1710	activation of the hiv terminal repeat	[activation of the HIV terminal repeat]	0.0	6	1	1	1
96823	1710	four kind	[four kinds]	0.0	2	1	1	1
96824	1710	polymorphism of BRCA1	[polymorphism of BRCA1]	0.0	3	1	1	1
96825	1710	40 patient	[40 patients]	0.0	2	1	1	1
96826	1710	incubation of each of the TRs	[Incubation of each of the TRs]	0.0	6	1	1	1
96827	1710	uptake by PBMC of woman	[uptake by PBMC of women]	0.0	5	1	1	1
96828	1710	event lead to activation	[events leading to activation]	0.0	4	1	1	1
96829	1710	model by the antigen receptor	[model by the antigen receptor]	0.0	5	1	1	1
96830	1710	permutation	[permutation]	0.0	1	1	1	1
96831	1710	low activation of nf-kappab	[low activation of NF-kappaB]	0.0	4	2	2	1
96832	1710	principle of medicine chan'su	[principle of medicine chan'su]	0.0	4	1	1	1
96833	1710	phorbol myristate acetate PMA stimulation	[phorbol myristate acetate PMA stimulation]	0.0	5	1	1	1
96834	1710	DC in vitro.	[DC in vitro.]	0.0	3	1	1	1
96835	1710	suggest reliable surrogate	[suggesting reliable surrogates]	0.0	3	1	1	1
96836	1710	ebv -positive carcinoma tissue	[EBV -positive carcinoma tissues]	0.0	4	1	1	1
96837	1710	expression activator protein-1 factor	[expression activator protein-1 factor]	0.0	4	1	1	1
96838	1710	repression of muscle gene	[repression of muscle genes]	0.0	4	1	1	1
96839	1710	Tax1 expression	[Tax1 expression]	0.0	2	1	1	1
96840	1710	immunodeficiency virus 1 hiv-1 infection	[immunodeficiency virus 1 HIV-1 infection]	0.0	5	1	1	1
96841	1710	distinct specificity for kappa b motif	[distinct specificities for kappa B motifs]	0.0	6	1	1	1
96842	1710	case aml	[cases AML]	0.0	2	1	1	1
96843	1710	tpa -inducible factor octamer-associated protein	[TPA -inducible factor octamer-associated protein]	0.0	5	1	1	1
96844	1710	stimulation of promonocytic cells.	[stimulation of promonocytic cells.]	0.0	4	1	1	1
96845	1710	seventeen patient with primary syndrome	[seventeen patients with primary syndromes]	0.0	5	1	1	1
96846	1710	expression of a single gene ORF	[expression of a single gene ORF]	0.0	6	1	1	1
96847	1710	consist only of the domain icn	[consisting only of the domain ICN]	0.0	6	1	1	1
96848	1710	amino enhancer	[amino enhancer]	0.0	2	1	1	1
96849	1710	mutant of the Abelson virus	[mutants of the Abelson virus]	0.0	5	1	1	1
96850	1710	reduce platelet transfusion	[reducing platelet transfusion]	0.0	3	1	1	1
96851	1710	similar pattern of signal event	[similar pattern of signaling events]	0.0	5	1	1	1
96852	1710	response to G(Anh)MTetra induction	[response to G(Anh)MTetra induction]	0.0	4	1	1	1
96853	1710	cellular nuclear factor-KB NF-kappa b	[cellular nuclear factor-KB NF-kappa B]	0.0	5	1	1	1
96854	1710	level of in patient	[levels of in patients]	0.0	4	1	1	1
96855	1710	exposure to CD40L together	[exposure to CD40L together]	0.0	4	1	1	1
96856	1710	such as salicylate	[such as salicylates]	0.0	3	1	1	1
96857	1710	three bind site for factor	[three binding sites for factors]	0.0	5	1	1	1
96858	1710	negative pi3-k construct	[negative PI3-K constructs]	0.0	3	1	1	1
96859	1710	human tnf receptor rhu tnfr:fc	[human TNF receptor rhu TNFR:Fc]	0.0	5	1	1	1
96860	1710	IL-4 -inducible reporter	[IL-4 -inducible reporter]	0.0	3	1	1	1
96861	1710	peripheral blood DC	[peripheral blood DC]	0.0	3	1	1	1
96862	1710	significant variation in Lyonization	[significant variation in Lyonization]	0.0	4	1	1	1
96863	1710	structure/function analysis	[Structure/function analysis]	0.0	2	1	1	1
96864	1710	50 mcr young	[50, MCR younger]	0.0	3	1	1	1
96865	1710	further support a mechanism	[further supporting a mechanism]	0.0	4	1	1	1
96866	1710	stable retinobenzoic derivative	[stable retinobenzoic derivative]	0.0	3	1	1	1
96867	1710	subpopulation of cell	[subpopulation of cells]	0.0	3	1	1	1
96868	1710	tonsillar mononuclear cell with interleukin-4	[tonsillar mononuclear cells with interleukin-4]	0.0	5	1	1	1
96869	1710	site alone	[site alone]	0.0	2	1	1	1
96870	1710	clinical spectra	[clinical spectra]	0.0	2	1	1	1
96871	1710	killer NK	[killer NK]	0.0	2	1	1	1
96872	1710	normal gene	[normal gene]	0.0	2	1	1	1
96873	1710	formation of active binding heterodimers,	[formation of active binding heterodimers,]	0.0	5	1	1	1
96874	1710	translocation of b	[translocation of B]	0.0	3	2	2	1
96875	1710	immunodeficiency virus SIVmac251	[immunodeficiency virus SIVmac251]	0.0	3	1	1	1
96876	1710	relationship between the change in runner	[relationship between the changes in runner]	0.0	6	1	1	1
96877	1710	transcriptionally active form	[transcriptionally active form]	0.0	3	1	1	1
96878	1710	/threonine phosphatase	[/threonine phosphatases]	0.0	2	1	1	1
96879	1710	labeling by immunofluorescence from human tonsil	[labeling by immunofluorescence from human tonsils]	0.0	6	1	1	1
96880	1710	rhabdomyosarcoma 10, leiomyosarcoma	[rhabdomyosarcoma 10, leiomyosarcoma]	0.0	3	1	1	1
96881	1710	second complex resemble nuclear factor	[second complex resembling nuclear factor]	0.0	5	1	1	1
96882	1710	sequence within the negative element	[sequences within the negative element]	0.0	5	1	1	1
96883	1710	only low weight species	[only lower weight species]	0.0	4	1	1	1
96884	1710	feature occur in family	[feature occurring in families]	0.0	4	1	1	1
96885	1710	leukemia cell Nalm-6	[leukemia cells Nalm-6]	0.0	3	1	1	1
96886	1710	H-89	[H-89]	0.0	1	1	1	1
96887	1710	rabbit 15-lipoxygenase gene	[rabbit 15-lipoxygenase gene]	0.0	3	1	1	1
96888	1710	different effect in T cell	[different effects in T cells]	0.0	5	1	1	1
96889	1710	phenotype into peripheral blood lymphocyte	[phenotypes into peripheral blood lymphocytes]	0.0	5	1	1	1
96890	1710	inhibition of translocation	[inhibition of translocation]	0.0	3	1	1	1
96891	1710	mzf-1 regulatory function	[MZF-1 regulatory function]	0.0	3	1	1	1
96892	1710	reflect sequestration	[reflecting sequestration]	0.0	2	1	1	1
96893	1710	protein-dna complex of nf-kappa b	[Protein-DNA complexes of NF-kappa B]	0.0	5	1	1	1
96894	1710	acid regulatory motif	[acid regulatory motif]	0.0	3	1	1	1
96895	1710	direct role in fasL up-regulation	[direct role in fasL up-regulation]	0.0	5	1	1	1
96896	1710	underlie the initiation	[underlying the initiation]	0.0	3	1	1	1
96897	1710	cross-linking of tyrosine phosphorylation	[Cross-linking of tyrosine phosphorylation]	0.0	4	1	1	1
96898	1710	tetrameric complex	[tetrameric complexes]	0.0	2	1	1	1
96899	1710	erythroid factor eklf activity	[erythroid factor EKLF activity]	0.0	4	1	1	1
96900	1710	PMA T cell	[PMA T cells]	0.0	3	1	1	1
96901	1710	show degree of staining.	[showing degrees of staining.]	0.0	4	1	1	1
96902	1710	mouse lymphoma cell	[mouse lymphoma cells]	0.0	3	1	1	1
96903	1710	lymphocytic leukemia (cll) sample	[lymphocytic leukemia (CLL) samples]	0.0	4	1	1	1
96904	1710	human coactivator hbob1	[human coactivator hBob1]	0.0	3	1	1	1
96905	1710	H-8,	[H-8,]	0.0	1	1	1	1
96906	1710	oxygen intermediate after oxidative stress	[oxygen intermediates after oxidative stress]	0.0	5	1	1	1
96907	1710	CD45RA+	[CD45RA+]	0.0	1	1	1	1
96908	1710	vitro cell culture	[vitro cell culture]	0.0	3	1	1	1
96909	1710	amount of receptor in lymphocyte	[amount of receptors in lymphocytes]	0.0	5	1	1	1
96910	1710	up-regulation of lung icam-1	[up-regulation of lung ICAM-1]	0.0	4	2	2	1
96911	1710	interaction between protein kinase c	[Interaction between protein kinase C]	0.0	5	1	1	1
96912	1710	lymphocyte subset in mononuclear leukocyte	[lymphocyte subsets in mononuclear leukocytes]	0.0	5	1	1	1
96913	1710	subunits; genes, nfkb1 p105	[subunits; genes, NFKB1 p105]	0.0	4	1	1	1
96914	1710	BCL-6 mutation evidence of hypermutation	[BCL-6 mutations evidence of hypermutation]	0.0	5	1	1	1
96915	1710	pag phop gene	[pag phoP gene]	0.0	3	1	1	1
96916	1710	camp inducibility of repressor icer	[cAMP inducibility of repressor ICER]	0.0	5	1	1	1
96917	1710	concentration of mol/L	[concentrations of mol/L]	0.0	3	1	1	1
96918	1710	many environmental factors, in particular, cytokine	[Many environmental factors, in particular, cytokines]	0.0	6	1	1	1
96919	1710	U/ml, 6 h)	[U/ml, 6 h)]	0.0	3	1	1	1
96920	1710	T lymphocyte response in type	[T lymphocyte response in type]	0.0	5	1	1	1
96921	1710	significantly favorable clinical course	[significantly favorable clinical course]	0.0	4	1	1	1
96922	1710	cytogenetic clone	[cytogenetic clones]	0.0	2	1	1	1
96923	1710	sequence-binding complex contain STAT3	[sequence-binding complexes containing STAT3]	0.0	4	1	1	1
96924	1710	N-terminal domain amino acid	[N-terminal domain amino acids]	0.0	4	1	1	1
96925	1710	addition, lack of killer cell	[addition, lack of killer cells]	0.0	5	1	1	1
96926	1710	important morphogen a constituent	[important morphogen a constituent]	0.0	4	1	1	1
96927	1710	thus lead to production	[thus leading to production]	0.0	4	1	1	1
96928	1710	IL production	[IL production]	0.0	2	1	1	1
96929	1710	direct stimulation with cytokine	[direct stimulation with cytokines]	0.0	4	1	1	1
96930	1710	induce respiratory distress syndrome	[inducing respiratory distress syndrome]	0.0	4	1	1	1
96931	1710	camp protein kinase inhibitor h-89	[cAMP protein kinase inhibitor H-89]	0.0	5	1	1	1
96932	1710	event in the initiation	[event in the initiation]	0.0	4	1	1	1
96933	1710	SLP-76 two cell specific molecule	[SLP-76 two cell specific molecules]	0.0	5	1	1	1
96934	1710	contain 35s- tr alpha	[containing 35S- TR alpha]	0.0	4	1	1	1
96935	1710	follow cd16 cross-linking	[following CD16 cross-linking]	0.0	3	1	1	1
96936	1710	e2f expression	[E2F expression]	0.0	2	1	1	1
96937	1710	one in population of people	[one in populations of people]	0.0	5	1	1	1
96938	1710	down-regulation of c-fo	[down-regulation of c-fos]	0.0	3	1	1	1
96939	1710	infected virus carrier	[infected virus carriers]	0.0	3	1	1	1
96940	1710	latency in cell	[latency in cells]	0.0	3	1	1	1
96941	1710	lymphoid gene	[lymphoid gene]	0.0	2	1	1	1
96942	1710	gata-1 allele, consequently lead	[GATA-1 allele, consequently leading]	0.0	4	1	1	1
96943	1710	calcineurin to nfat	[calcineurin to NFAT]	0.0	3	1	1	1
96944	1710	association of the disease	[association of the disease]	0.0	4	1	1	1
96945	1710	virus type 1 htlv-1 tax	[virus type 1 HTLV-1 Tax]	0.0	5	1	1	1
96946	1710	lbf4- binding site	[LBF4- binding sites]	0.0	3	1	1	1
96947	1710	persistence of reactive CTL clone	[persistence of reactive CTL clones]	0.0	5	1	1	1
96948	1710	regulation by IFNs	[regulation by IFNs]	0.0	3	1	1	1
96949	1710	tpa transcription	[TPA transcription]	0.0	2	1	1	1
96950	1710	T lymphocyte of two sibling	[T lymphocytes of two siblings]	0.0	5	1	1	1
96951	1710	p38alpha MAPk	[p38alpha MAPk]	0.0	2	1	1	1
96952	1710	low affinity to glucocorticoid	[low affinity to glucocorticoids]	0.0	4	1	1	1
96953	1710	level)	[level)]	0.0	1	2	2	1
96954	1710	stem (es) cell	[stem (ES) cells]	0.0	3	1	1	1
96955	1710	sectioning	[sectioning]	0.0	1	1	1	1
96956	1710	45-nucleotide sequence regulatory element	[45-nucleotide sequence regulatory element]	0.0	4	1	1	1
96957	1710	participant in inflammation	[participant in inflammation]	0.0	3	1	1	1
96958	1710	ifn-gamma-induced class	[IFN-gamma-induced class]	0.0	2	1	1	1
96959	1710	topoisomerase in extract upon translocation	[topoisomerases in extracts upon translocation]	0.0	5	1	1	1
96960	1710	reactivity to the cycle epitope	[reactivities to the cycle epitopes]	0.0	5	1	1	1
96961	1710	several cycle	[several cycles]	0.0	2	1	1	1
96962	1710	one genes, loss	[one genes, loss]	0.0	3	1	1	1
96963	1710	kinase inhibitor staurosporine	[kinase inhibitors staurosporine]	0.0	3	1	1	1
96964	1710	AMP -dependent protein kinase	[AMP -dependent protein kinase]	0.0	4	1	1	1
96965	1710	major fashion	[major fashion]	0.0	2	1	1	1
96966	1710	role in hb-egf expression	[role in HB-EGF expression]	0.0	4	1	1	1
96967	1710	facilitate antibody	[facilitating antibody]	0.0	2	1	1	1
96968	1710	understanding of the immunosuppressive activity	[understanding of the immunosuppressive activity]	0.0	5	1	1	1
96969	1710	addition, technology	[addition, technology]	0.0	2	1	1	1
96970	1710	SPD in patient	[SPD in patients]	0.0	3	1	1	1
96971	1710	motheaten	[motheaten]	0.0	1	1	1	1
96972	1710	C5MJ2	[C5MJ2]	0.0	1	1	1	1
96973	1710	maturation pathway	[maturation pathway]	0.0	2	1	1	1
96974	1710	normal mammary gland	[normal mammary glands]	0.0	3	1	1	1
96975	1710	inhibition by dexamethasone	[inhibition by dexamethasone]	0.0	3	1	1	1
96976	1710	discrete polymorphism	[discrete polymorphisms]	0.0	2	1	1	1
96977	1710	suppression phenomenon	[suppression phenomenon]	0.0	2	1	1	1
96978	1710	aldosterone antagonist canrenone (140	[aldosterone antagonist canrenone (140]	0.0	4	1	1	1
96979	1710	treatment with a concentration a inhibitor	[Treatment with an concentration an inhibitor]	0.0	6	1	1	1
96980	1710	residual disease in acute leukemia	[residual disease in acute leukemia]	0.0	5	1	1	1
96981	1710	Initial dexamethasone	[Initial dexamethasone]	0.0	2	1	1	1
96982	1710	regulation potential role of physical interaction	[Regulation potential role of physical interactions]	0.0	6	1	1	1
96983	1710	0.4-fold	[0.4-fold]	0.0	1	1	1	1
96984	1710	nuclear factor-kappa beta enf-kappa	[nuclear factor-kappa beta (NF-kappa]	0.0	4	1	1	1
96985	1710	time-frame of action	[time-frame of action]	0.0	3	1	1	1
96986	1710	nuclear protein complex a ubiquitous factor	[nuclear protein complexes a ubiquitous factor]	0.0	6	1	1	1
96987	1710	acidic domain with sh2 domain-binding motif	[acidic domains with SH2 domain-binding motifs]	0.0	6	1	1	1
96988	1710	c-jun protooncogene	[c-jun protooncogene]	0.0	2	1	1	1
96989	1710	class of high-affinity binding site	[class of high-affinity binding sites]	0.0	5	1	1	1
96990	1710	unstimulated u1 cell	[unstimulated U1 cells]	0.0	3	1	1	1
96991	1710	interleukin-4 -responsive element	[interleukin-4 -responsive element]	0.0	3	1	1	1
96992	1710	tyrphostin a tyrosine kinase inhibitor	[tyrphostin a tyrosine kinase inhibitor]	0.0	5	1	1	1
96993	1710	differ from nonresponder	[differing from nonresponders]	0.0	3	1	1	1
96994	1710	collagenase transcription in cell	[collagenase transcription in cells]	0.0	4	1	1	1
96995	1710	include peripheral blood mononuclear cell	[including peripheral blood mononuclear cells]	0.0	5	1	1	1
96996	1710	1) PMA for h.	[1) PMA for h,]	0.0	4	1	1	1
96997	1710	ebna gene	[EBNA gene]	0.0	2	1	1	1
96998	1710	salt concentration mM edta	[salt concentrations mM EDTA]	0.0	4	1	1	1
96999	1710	proximal GHF-1/Pit-1 binding site	[proximal GHF-1/Pit-1 binding site]	0.0	4	1	1	1
97000	1710	receptor consist of the extracellular domain	[receptors consisting of the extracellular domain]	0.0	6	1	1	1
97001	1710	g/g of rna in monocyte	[g/g of RNA in monocytes]	0.0	5	1	1	1
97002	1710	age-related decrease in induction	[age-related decrease in induction]	0.0	4	1	1	1
97003	1710	Leu-7+ natural killer cell	[Leu-7+ natural killer cells]	0.0	4	1	1	1
97004	1710	homodimer with heterodimer follow time	[homodimers with heterodimers following time]	0.0	5	1	1	1
97005	1710	level beta il-1 beta	[levels beta IL-1 beta]	0.0	4	1	1	1
97006	1710	low gr number	[low GR number]	0.0	3	1	1	1
97007	1710	wild-type CD40	[wild-type CD40]	0.0	2	1	1	1
97008	1710	rna gene by RNA polymerase	[RNA genes by RNA polymerases]	0.0	5	1	1	1
97009	1710	factor-IL6 NF-IL6 binding site	[factor-IL6 NF-IL6 binding site]	0.0	4	1	1	1
97010	1710	tar activation	[TAR activation]	0.0	2	1	1	1
97011	1710	calcineurin docking	[calcineurin docking]	0.0	2	1	1	1
97012	1710	signal as il-1 in phagocyte	[signaling as IL-1 in phagocytes]	0.0	5	1	1	1
97013	1710	diseases)	[diseases).]	0.0	1	1	1	1
97014	1710	parallel the decline	[paralleling the decline]	0.0	3	1	1	1
97015	1710	activation of intracellular event	[activation of intracellular events]	0.0	4	1	1	1
97016	1710	31 woman	[31 women]	0.0	2	1	1	1
97017	1710	proliferation in response recent-onset iddm subject	[proliferation in response recent-onset IDDM subjects]	0.0	6	1	1	1
97018	1710	cell line bear dqa1*0201/dqb1*0201	[cell lines bearing DQA1*0201/DQB1*0201]	0.0	4	1	1	1
97019	1710	cellular production of mediator	[cellular production of mediators]	0.0	4	1	1	1
97020	1710	regulation by GC	[regulation by GC]	0.0	3	1	1	1
97021	1710	bind site-specific property for E2A- HLF	[binding site-specific properties for E2A- HLF]	0.0	6	1	1	1
97022	1710	hiv-1 laboratory	[HIV-1 laboratory]	0.0	2	1	1	1
97023	1710	airway T cell	[airway T cells]	0.0	3	2	2	1
97024	1710	hToll	[hToll]	0.0	1	1	1	1
97025	1710	inducible regulator of cellular gene	[inducible regulators of cellular genes]	0.0	5	1	1	1
97026	1710	nf-kappab translocation in pbmc	[NF-kappaB translocation in PBMCs]	0.0	4	1	1	1
97027	1710	electron examination	[electron examinations]	0.0	2	1	1	1
97028	1710	206 risk woman	[206 risk women]	0.0	3	1	1	1
97029	1710	abnormal nuclear morphology	[abnormal nuclear morphology]	0.0	3	1	1	1
97030	1710	such as adult distress syndrome	[such as adult distress syndrome]	0.0	5	1	1	1
97031	1710	composite octamer motif enhancer	[composite octamer motif enhancer]	0.0	4	1	1	1
97032	1710	b leukemia	[B leukemias]	0.0	2	1	1	1
97033	1710	negative role for gata-2	[negative role for GATA-2]	0.0	4	1	1	1
97034	1710	expression pattern during induction,	[expression patterns during induction,]	0.0	4	1	1	1
97035	1710	sequencing of the region	[Sequencing of the region]	0.0	4	1	1	1
97036	1710	antibody of significance.	[antibodies of significance.]	0.0	3	1	1	1
97037	1710	IL-6 gene expression	[IL-6 gene expression]	0.0	3	1	1	1
97038	1710	oligonucleotide contain binding site	[oligonucleotides containing binding sites]	0.0	4	1	1	1
97039	1710	intact leukocyte HML	[intact leukocytes HML]	0.0	3	1	1	1
97040	1710	approximately 1000 VDR	[approximately 1000 VDR]	0.0	3	1	1	1
97041	1710	distinct effect increase of total ca2+	[distinct effect increase of total Ca2+]	0.0	6	1	1	1
97042	1710	transcriptional induction by CD40 ligation	[transcriptional induction by CD40 ligation]	0.0	5	1	1	1
97043	1710	silent mutation in codon 10	[silent mutation in codon 10]	0.0	5	1	1	1
97044	1710	human cell line CEM	[human cell line CEM]	0.0	4	1	1	1
97045	1710	final determinant	[final determinants]	0.0	2	1	1	1
97046	1710	marginally in cell	[marginally in cells]	0.0	3	1	1	1
97047	1710	42 ovulation woman	[42 ovulation women]	0.0	3	1	1	1
97048	1710	patient before month after delivery	[patients before months after delivery]	0.0	5	1	1	1
97049	1710	128 bp of sequence	[128 bp of sequence]	0.0	4	1	1	1
97050	1710	apoptosis potential role	[apoptosis potential role]	0.0	3	1	1	1
97051	1710	airway cell from asthmatics	[airway cells from asthmatics]	0.0	4	1	1	1
97052	1710	dose ng/ml)	[dose ng/ml)]	0.0	2	1	1	1
97053	1710	local augmentative cis element	[local augmentative cis elements]	0.0	4	1	1	1
97054	1710	CMV gene product expression	[CMV gene product expression]	0.0	4	1	1	1
97055	1710	specificity-conferring mechanism for action	[specificity-conferring mechanism for action]	0.0	4	1	1	1
97056	1710	molecule in the activation	[molecule in the activation]	0.0	4	1	1	1
97057	1710	Raw 264.7 cell	[Raw 264.7 cells]	0.0	3	1	1	1
97058	1710	transcription stat5	[transcription STAT5]	0.0	2	1	1	1
97059	1710	insulin on receptor	[insulin on receptor]	0.0	3	1	1	1
97060	1710	transcription stat1	[transcription STAT1]	0.0	2	1	1	1
97061	1710	role integrate the short-lived signal	[role integrating the short-lived signal]	0.0	5	1	1	1
97062	1710	part via nf-kappab generation	[part via NF-kappaB generation]	0.0	4	1	1	1
97063	1710	drosophila Schneider 2 cell	[Drosophila Schneider 2 cells]	0.0	4	1	1	1
97064	1710	nf-kappa b the low activity	[NF-kappa B the low activity]	0.0	5	1	1	1
97065	1710	T cell from other individual	[T cells from other individuals]	0.0	5	1	1	1
97066	1710	stimulation of the CD3 /tcr pathway	[stimulation of the CD3 /TCR pathway]	0.0	6	1	1	1
97067	1710	normal binding	[normal binding]	0.0	2	1	1	1
97068	1710	family RA receptor rar	[families RA receptors RARs]	0.0	4	1	1	1
97069	1710	messenger rna	[messenger RNAs]	0.0	2	1	1	1
97070	1710	patient with ro(ssa) precipitins,	[patients with Ro(SSA) precipitins,]	0.0	4	1	1	1
97071	1710	p50 /p50 homodimer	[p50 /p50 homodimer]	0.0	3	1	1	1
97072	1710	dna-binding activity of transcription factor NFkappaB	[DNA-binding activities of transcription factors NFkappaB]	0.0	6	1	1	1
97073	1710	dna-binding species	[DNA-binding species]	0.0	2	1	1	1
97074	1710	cellular distribution	[cellular distribution]	0.0	2	2	2	1
97075	1710	role for tumor necrosis factor	[role for tumor necrosis factor]	0.0	5	1	1	1
97076	1710	cell repertoire	[cell repertoire]	0.0	2	1	1	1
97077	1710	five inhibitors, cyclosporin a	[five inhibitors, cyclosporin A]	0.0	4	1	1	1
97078	1710	breast-cancer sample	[breast-cancer samples]	0.0	2	1	1	1
97079	1710	nf-kappab binding activity,	[NF-kappaB binding activity,]	0.0	3	1	1	1
97080	1710	two events: the CsA translocation	[two events: the CsA translocation]	0.0	5	1	1	1
97081	1710	sequence homology with human gene	[sequence homology with human genes]	0.0	5	1	1	1
97082	1710	carry base substitution	[carrying base substitutions]	0.0	3	1	1	1
97083	1710	many tissue include cell	[many tissues including cells]	0.0	4	1	1	1
97084	1710	3 h in hl60 cell	[3 h in HL60 cells]	0.0	5	1	1	1
97085	1710	relationship between glucocorticoid receptor	[Relationship between glucocorticoid receptor]	0.0	4	1	1	1
97086	1710	receptor (gr) level in the hippocampus	[receptor (GR) levels in the hippocampus]	0.0	6	1	1	1
97087	1710	binding of interferon-gamma	[Binding of interferon-gamma]	0.0	3	1	1	1
97088	1710	c-erb b-2 expression.	[c-erb B-2 expression.]	0.0	3	1	1	1
97089	1710	cell line DH42	[cell line DH42]	0.0	3	1	1	1
97090	1710	highly homologous gene encode scm-1alpha	[highly homologous genes encoding SCM-1alpha]	0.0	5	1	1	1
97091	1710	pre-B acute lymphoblastic leukemia	[pre-B acute lymphoblastic leukemia]	0.0	4	1	1	1
97092	1710	factor-1 gene expression	[factor-1 gene expression]	0.0	3	1	1	1
97093	1710	demonstrate the immunosuppressive activity	[demonstrating the immunosuppressive activity]	0.0	4	1	1	1
97094	1710	contrast, tnfalpha level	[contrast, TNFalpha levels]	0.0	3	1	1	1
97095	1710	primer corresponding amino acid sequence	[primers corresponding amino acid sequences]	0.0	5	1	1	1
97096	1710	camp protein kinase c	[cAMP protein kinase C]	0.0	4	1	1	1
97097	1710	lead to the conversion	[leading to the conversion]	0.0	4	1	1	1
97098	1710	polar substitution	[polar substitutions]	0.0	2	1	1	1
97099	1710	IkappaBalpha construct	[IkappaBalpha construct]	0.0	2	1	1	1
97100	1710	use a panel of line	[using a panel of lines]	0.0	5	1	1	1
97101	1710	immunoglobulin heavy chain intronic enhancer	[immunoglobulin heavy chain intronic enhancer]	0.0	5	1	1	1
97102	1710	cd95,	[CD95,]	0.0	1	1	1	1
97103	1710	kd value at pH	[Kd value at pH]	0.0	4	1	1	1
97104	1710	hiv-1 accessory	[HIV-1 accessory]	0.0	2	1	1	1
97105	1710	activator protein-1 factor il-6 nf-il6	[activator protein-1 factor IL-6 NF-IL6]	0.0	5	1	1	1
97106	1710	different granule from neutrophil	[different granules from neutrophils]	0.0	4	1	1	1
97107	1710	c-Fos mutant	[c-Fos mutant]	0.0	2	1	1	1
97108	1710	alpha thf/thf n: ratios.	[alpha THF/THF N: ratios.]	0.0	4	1	1	1
97109	1710	extent, stat1	[extent, Stat1]	0.0	2	1	1	1
97110	1710	hla-dr11 restrict molecule	[HLA-DR11 restricting molecule]	0.0	3	1	1	1
97111	1710	evidence of proliferative activity	[evidence of proliferative activity]	0.0	4	1	1	1
97112	1710	MHC class gene-specific transcription activator	[MHC class gene-specific transcription activator]	0.0	5	1	1	1
97113	1710	Addition of compounds,	[Addition of compounds,]	0.0	3	1	1	1
97114	1710	site of active tuberculosis	[sites of active tuberculosis]	0.0	4	1	1	1
97115	1710	indicate different aetiology	[indicating different aetiologies]	0.0	3	1	1	1
97116	1710	subsequent monocyte adhesion	[subsequent monocyte adhesion]	0.0	3	2	2	1
97117	1710	light of work implicate zebra	[light of work implicating ZEBRA]	0.0	5	1	1	1
97118	1710	certain characteristic of b cell	[certain characteristics of B cells]	0.0	5	1	1	1
97119	1710	mechanism of fasl regulation	[mechanisms of FasL regulation]	0.0	4	1	1	1
97120	1710	Jeg-3 choriocarcinoma-induced immunosuppression	[Jeg-3 choriocarcinoma-induced immunosuppression]	0.0	3	1	1	1
97121	1710	biologic	[biologic]	0.0	1	1	1	1
97122	1710	amount of monocytic precursor	[amounts of monocytic precursors]	0.0	4	1	1	1
97123	1710	healthy subject yr)	[healthy subjects yr)]	0.0	3	1	1	1
97124	1710	novel, 320-kda species	[novel, 320-kDa species]	0.0	3	1	1	1
97125	1710	specific pattern of cytokine	[specific pattern of cytokines]	0.0	4	1	1	1
97126	1710	encode nf-x2	[encoding NF-X2]	0.0	2	1	1	1
97127	1710	addition of acid the physiologic product	[addition of acid the physiologic product]	0.0	6	1	1	1
97128	1710	transactivator for rante	[transactivator for RANTES]	0.0	3	1	1	1
97129	1710	near-perfect direct repeat DR of bp	[near-perfect direct repeats DR of bp]	0.0	6	1	1	1
97130	1710	lineage-determinetermining factor	[lineage-determining factors]	0.0	2	1	1	1
97131	1710	map kinase signal transduction	[MAP kinase signal transduction]	0.0	4	1	1	1
97132	1710	cerebral cortex in cord	[cerebral cortex in cord]	0.0	4	1	1	1
97133	1710	cellular/molecular event of inflammation	[cellular/molecular events of inflammation]	0.0	4	1	1	1
97134	1710	TNF/neuron	[TNF/neuron]	0.0	1	1	1	1
97135	1710	k44m	[K44M]	0.0	1	1	1	1
97136	1710	predominant kb id-3 transcript	[predominant kb Id-3 transcript]	0.0	4	1	1	1
97137	1710	(il)-10 blocking factor	[(IL)-10 blocking factor]	0.0	3	1	1	1
97138	1710	induction by factor in normal monocyte	[Induction by factor in normal monocytes]	0.0	6	1	1	1
97139	1710	approximation of the effect	[approximation of the effects]	0.0	4	1	1	1
97140	1710	icam-1 adhesivity toward leukocyte	[ICAM-1 adhesivity toward leukocytes]	0.0	4	1	1	1
97141	1710	phosphopeptide map	[phosphopeptide maps]	0.0	2	1	1	1
97142	1710	binding to a osteoblast-specific element	[binding to an osteoblast-specific element]	0.0	5	1	1	1
97143	1710	complete inhibition of histamine	[complete inhibition of histamine]	0.0	4	1	1	1
97144	1710	deltorphin activity	[deltorphin activity]	0.0	2	1	1	1
97145	1710	8% cell	[8% cells]	0.0	2	1	1	1
97146	1710	vaginal fluid	[vaginal fluid]	0.0	2	1	1	1
97147	1710	surfactant' effect on inflammatory cytokine production	[surfactant's effects on inflammatory cytokine production]	0.0	6	1	1	1
97148	1710	involve defective differentiation in karyotypic male	[involving defective differentiation in karyotypic males]	0.0	6	1	1	1
97149	1710	B-cell lymphocytic leukemia CLL	[B-cell lymphocytic leukemia CLL]	0.0	4	1	1	1
97150	1710	expression of cDNA clone in bacterium	[Expression of cDNA clones in bacteria]	0.0	6	1	1	1
97151	1710	induction of the cytokine	[induction of the cytokines]	0.0	4	1	1	1
97152	1710	IL-3 factor dna-binding complex	[IL-3 factor DNA-binding complexes]	0.0	4	1	1	1
97153	1710	dramatic reduction in response	[dramatic reduction in response]	0.0	4	1	1	1
97154	1710	(non t) effect of cya	[(non T) effects of CyA]	0.0	5	1	1	1
97155	1710	modes, like induction, lytic superinfection	[modes, like induction, lytic superinfection]	0.0	5	1	1	1
97156	1710	copyright press.	[Copyright Press.]	0.0	2	26	26	1
97157	1710	expression in human u937 cell	[Expression in human U937 cells]	0.0	5	1	1	1
97158	1710	interleukin-8 gene expression in cell	[interleukin-8 gene expression in cells]	0.0	5	1	1	1
97159	1710	regulator of hematopoletic differentiation	[regulators of hematopoletic differentiation]	0.0	4	1	1	1
97160	1710	terminal repeat nf-kappa b	[terminal repeat NF-kappa B]	0.0	4	1	1	1
97161	1710	various kind	[various kinds]	0.0	2	2	2	1
97162	1710	coactivator bob.1/obf.1	[coactivator BOB.1/OBF.1]	0.0	2	1	1	1
97163	1710	translocations,	[translocations,]	0.0	1	1	1	1
97164	1710	genome homologue of herpesviruse	[genome homologues of herpesviruses]	0.0	4	1	1	1
97165	1710	2-fold low affinity	[2-fold lower affinity]	0.0	3	1	1	1
97166	1710	I gene	[I genes]	0.0	2	1	1	1
97167	1710	IL-13 treatment	[IL-13 treatment]	0.0	2	1	1	1
97168	1710	encode hsv-2 cd4+ antigen	[encoding HSV-2 CD4+ antigens]	0.0	4	1	1	1
97169	1710	human cd4(+) T cell line	[human CD4(+) T cell lines]	0.0	5	1	1	1
97170	1710	strong ap-1 activity	[strong AP-1 activity]	0.0	3	1	1	1
97171	1710	factor 4681 to 4701	[Factors 4681 to 4701]	0.0	4	1	1	1
97172	1710	individual gata factor	[individual GATA factors]	0.0	3	1	1	1
97173	1710	release of calcium	[release of calcium]	0.0	3	2	2	1
97174	1710	status s-phase fraction	[status S-phase fraction]	0.0	3	1	1	1
97175	1710	course (p chi2	[course (P chi2]	0.0	3	1	1	1
97176	1710	multiple lytic antigen-specific reactivity	[multiple lytic antigen-specific reactivities]	0.0	4	1	1	1
97177	1710	generation of tumor necrosis factor-alpha	[Generation of tumor necrosis factor-alpha]	0.0	5	1	1	1
97178	1710	aml m4 without eosinophil	[AML M4 without eosinophils]	0.0	4	1	1	1
97179	1710	reactivation of gene expression	[reactivation of gene expression]	0.0	4	1	1	1
97180	1710	express cd40l	[expressing CD40L]	0.0	2	1	1	1
97181	1710	ability of c-ErbB	[ability of c-ErbB]	0.0	3	1	1	1
97182	1710	bind tpa element TRE	[binding TPA elements TRE]	0.0	4	1	1	1
97183	1710	suppression during infection	[suppression during infection]	0.0	3	1	1	1
97184	1710	initial phase	[initial phase]	0.0	2	1	1	1
97185	1710	single start site	[single start site]	0.0	3	1	1	1
97186	1710	important implication for the use	[important implications for the use]	0.0	5	1	1	1
97187	1710	mediators: study	[mediators: study]	0.0	2	1	1	1
97188	1710	predictive value of social support,	[predictive value of social support,]	0.0	5	1	1	1
97189	1710	autologous cell apc	[autologous cell APC]	0.0	3	1	1	1
97190	1710	nonspecific hyperplasia	[nonspecific hyperplasia]	0.0	2	1	1	1
97191	1710	radiation dose 10,	[radiation doses 10,]	0.0	3	1	1	1
97192	1710	however, three order potent than H	[however, three orders potent than H]	0.0	6	1	1	1
97193	1710	electrostatic interaction	[electrostatic interactions]	0.0	2	1	1	1
97194	1710	control expression of collagenase-1	[control expression of collagenase-1]	0.0	4	1	1	1
97195	1710	phase of replication.	[phase of replication.]	0.0	3	1	1	1
97196	1710	profile of sigma 1 receptor	[profile of sigma 1 receptors]	0.0	5	1	1	1
97197	1710	dna-binding characteristic of ef1	[DNA-binding characteristics of EF1]	0.0	4	1	1	1
97198	1710	neonatal distress syndrome NRDS	[neonatal distress syndrome NRDS]	0.0	4	1	1	1
97199	1710	therapy of leukemia patient	[therapy of leukemia patients]	0.0	4	1	1	1
97200	1710	granuloma formation at site	[granuloma formation at sites]	0.0	4	1	1	1
97201	1710	recent discovery factor kappa b	[recent discovery factor kappa B]	0.0	5	1	1	1
97202	1710	level of Bcl-x b cell	[levels of Bcl-x B cells]	0.0	5	1	1	1
97203	1710	level expression of this receptor	[level expression of these receptors]	0.0	5	1	1	1
97204	1710	il-5,	[IL-5,]	0.0	1	1	1	1
97205	1710	Similarly, Jurkat T cell line	[Similarly, Jurkat T cell lines]	0.0	5	1	1	1
97206	1710	il-3 expression	[IL-3 expression]	0.0	2	1	1	1
97207	1710	region at position between -95	[region at positions between -95]	0.0	5	1	1	1
97208	1710	cd33+, cd56+, cd16 leukemia	[CD33+, CD56+, CD16 leukemias]	0.0	4	1	1	1
97209	1710	disease of patient with leukemia	[disease of patients with leukemia]	0.0	5	1	1	1
97210	1710	molecular pathogenesis of APL	[molecular pathogenesis of APL]	0.0	4	1	1	1
97211	1710	variation in gene expression pattern	[variation in gene expression patterns]	0.0	5	1	1	1
97212	1710	different Jak tyrosine kinase T	[different Jak tyrosine kinases T]	0.0	5	1	1	1
97213	1710	suggest lack of (a) transcriptional factor	[suggesting lack of (a) transcriptional factor]	0.0	6	1	1	1
97214	1710	class of snrna gene	[classes of snRNA genes]	0.0	4	1	1	1
97215	1710	IL igm production	[IL IgM production]	0.0	3	1	1	1
97216	1710	bind to the PRE-I site	[binding to the PRE-I site]	0.0	5	1	1	1
97217	1710	constitute biological model	[constituting biological models]	0.0	3	1	1	1
97218	1710	chemical induction, lytic superinfection	[chemical induction, lytic superinfection]	0.0	4	1	1	1
97219	1710	chronic, severe,	[chronic, severe,]	0.0	2	1	1	1
97220	1710	endothelial monolayer in assay	[endothelial monolayers in assays]	0.0	4	1	1	1
97221	1710	interaction functional antagonism in erythroid cell	[interaction functional antagonism in erythroid cells]	0.0	6	1	1	1
97222	1710	negative mutant form	[negative mutant forms]	0.0	3	1	1	1
97223	1710	il-2a	[IL-2A]	0.0	1	1	1	1
97224	1710	il-2e	[IL-2E]	0.0	1	1	1	1
97225	1710	structure-based enhancement of potency	[structure-based enhancement of potency]	0.0	4	1	1	1
97226	1710	analysis of sensorgram with recombinant hugata-3	[analysis of sensorgrams with recombinant huGATA-3]	0.0	6	1	1	1
97227	1710	effect on signaling.	[effect on signaling.]	0.0	3	1	1	1
97228	1710	inhibit c epsilon transcription	[inhibiting C epsilon transcription]	0.0	4	1	1	1
97229	1710	(outer limits, one	[(outer limits, one]	0.0	3	1	1	1
97230	1710	strong RBP-Jkappa -binding site	[stronger RBP-Jkappa -binding site]	0.0	4	1	1	1
97231	1710	camp agent	[cAMP agents]	0.0	2	1	1	1
97232	1710	murine erythroleukemia	[murine erythroleukemia]	0.0	2	1	1	1
97233	1710	various activators,	[various activators,]	0.0	2	1	1	1
97234	1710	target organ	[target organ]	0.0	2	1	1	1
97235	1710	evidence of differentiation	[evidence of differentiation]	0.0	3	1	1	1
97236	1710	pharmacologic blockade	[Pharmacologic blockade]	0.0	2	1	1	1
97237	1710	effect on the minimal b29 promoter	[effect on the minimal B29 promoter]	0.0	6	1	1	1
97238	1710	distinct heteromeric complex with protein	[distinct heteromeric complexes with proteins]	0.0	5	1	1	1
97239	1710	(sap)	[(SAP)]	0.0	1	1	1	1
97240	1710	abnormal b cell development	[abnormal B cell development]	0.0	4	1	1	1
97241	1710	year of symbiotic, persistent relationship	[years of symbiotic, persistent relationship]	0.0	5	1	1	1
97242	1710	insight into event	[insights into events]	0.0	3	1	1	1
97243	1710	c-terminal residue	[C-terminal residues]	0.0	2	1	1	1
97244	1710	human b lymphoblast	[human B lymphoblasts]	0.0	3	1	1	1
97245	1710	common pharmacogenetic syndrome	[common pharmacogenetic syndrome]	0.0	3	1	1	1
97246	1710	effect on pre-B cell	[effects on pre-B cells]	0.0	4	1	1	1
97247	1710	potent signal for AP-1	[potent signal for AP-1]	0.0	4	1	1	1
97248	1710	two group of patient one	[two groups of patients one]	0.0	5	1	1	1
97249	1710	oligomerized motif	[oligomerized motif]	0.0	2	1	1	1
97250	1710	result displacement	[resulting displacement]	0.0	2	1	1	1
97251	1710	E2F-I bind protein, likely dpii,	[E2F-I binding protein, likely DP-I,]	0.0	5	1	1	1
97252	1710	il-18	[IL-18]	0.0	1	1	1	1
97253	1710	3 microm etoposide	[3 microM etoposide]	0.0	3	1	1	1
97254	1710	response of NF-kappaB	[response of NF-kappaB]	0.0	3	1	1	1
97255	1710	tumor cell 9	[Tumor cells 9]	0.0	3	1	1	1
97256	1710	P3HR-1 genome	[P3HR-1 genome]	0.0	2	1	1	1
97257	1710	chemokine family	[chemokine family]	0.0	2	1	1	1
97258	1710	vivo effect of glucocorticoid	[vivo effects of glucocorticoids]	0.0	4	1	1	1
97259	1710	common occurrence	[common occurrence]	0.0	2	1	1	1
97260	1710	cervical carcinoma	[cervical carcinoma]	0.0	2	1	1	1
97261	1710	tr TREp complex	[TR TREp complex]	0.0	3	1	1	1
97262	1710	dissociation constant kd for aldosterone	[dissociation constant Kd for aldosterone]	0.0	5	1	1	1
97263	1710	up-regulate gene expression via interaction	[up-regulate gene expression via interaction]	0.0	5	1	1	1
97264	1710	deaminase	[deaminase]	0.0	1	1	1	1
97265	1710	similar rhythm	[similar rhythm]	0.0	2	1	1	1
97266	1710	target to the side	[targeting to the side]	0.0	4	1	1	1
97267	1710	cis-acting element in the promoter	[cis-acting element in the promoter]	0.0	5	1	1	1
97268	1710	signal in blood mononuclear cell	[signalling in blood mononuclear cells]	0.0	5	1	1	1
97269	1710	high metastatic potential	[high metastatic potential]	0.0	3	1	1	1
97270	1710	lymphocyte-activating cytokine include the interferon	[lymphocyte-activating cytokines including the interferons]	0.0	5	1	1	1
97271	1710	bone cell	[bone cells]	0.0	2	1	1	1
97272	1710	hb24 expression	[HB24 expression]	0.0	2	1	1	1
97273	1710	putative zinc finger protein	[putative zinc finger protein]	0.0	4	1	1	1
97274	1710	unexpected functional redundancy	[unexpected functional redundancy.]	0.0	3	1	1	1
97275	1710	nuclei of the upper layer	[nuclei of the upper layer]	0.0	5	1	1	1
97276	1710	influenza virus-exposed T cell	[influenza virus-exposed T cells]	0.0	4	1	1	1
97277	1710	allergen-specific T cell	[Allergen-specific T cells]	0.0	3	1	1	1
97278	1710	aids-related neoplasm	[AIDS-related neoplasms]	0.0	2	1	1	1
97279	1710	AhR mrna level	[AhR mRNA level]	0.0	3	1	1	1
97280	1710	regulator for cell differentiation	[regulator for cell differentiation]	0.0	4	1	1	1
97281	1710	proliferate erythroid cell	[proliferating erythroid cells]	0.0	3	1	1	1
97282	1710	2 hour at degree c,	[2 hours at degrees C,]	0.0	5	1	1	1
97283	1710	concentration of soluble peptide	[concentrations of soluble peptide]	0.0	4	1	1	1
97284	1710	adhesion of cell umbilical vein cell	[adhesion of cells umbilical vein cells]	0.0	6	1	1	1
97285	1710	Epstein-Barr virus a oncogenic human herpesvirus	[Epstein-Barr virus an oncogenic human herpesvirus]	0.0	6	1	1	1
97286	1710	epithelial fashion	[epithelial fashion]	0.0	2	1	1	1
97287	1710	helenalin to a degree, 11alpha,13-dihydrohelenalin	[helenalin to a degree, 11alpha,13-dihydrohelenalin]	0.0	5	1	1	1
97288	1710	model for this disorder.	[model for this disorder.]	0.0	4	1	1	1
97289	1710	[induction of apoptosis	[[Induction of apoptosis]	0.0	3	1	1	1
97290	1710	binding of NFATp	[binding of NFATp]	0.0	3	1	1	1
97291	1710	aberrant expression	[aberrant expression]	0.0	2	2	2	1
97292	1710	merit in long in vivo study	[merit in long-term in vivo studies]	0.0	6	1	1	1
97293	1710	level of c-myb protein	[levels of c-Myb protein]	0.0	4	1	1	1
97294	1710	significance for different mechanism	[significance for different mechanisms]	0.0	4	1	1	1
97295	1710	domain of RFX5	[domain of RFX5]	0.0	3	1	1	1
97296	1710	exactly the phenomenon	[exactly the phenomenon]	0.0	3	1	1	1
97297	1710	active metabolite dihydroxyvitamin d3,	[active metabolite dihydroxyvitamin D3,]	0.0	4	1	1	1
97298	1710	endotoxin,	[endotoxin,]	0.0	1	1	1	1
97299	1710	results: gel-shift	[RESULTS: Gel-shift]	0.0	2	1	1	1
97300	1710	example.	[example.]	0.0	1	1	1	1
97301	1710	element-bind protein complex	[element-binding protein complexes]	0.0	3	1	1	1
97302	1710	patient with disorder MDD	[patients with disorder MDD]	0.0	4	1	1	1
97303	1710	produce hiv tat protein	[producing HIV Tat protein]	0.0	4	1	1	1
97304	1710	order of erythrocyte ghost membrane	[order of erythrocyte ghost membrane]	0.0	5	2	2	1
97305	1710	major region	[major region]	0.0	2	1	1	1
97306	1710	stimulation of Jurkat T cell	[stimulation of Jurkat T cells]	0.0	5	1	1	1
97307	1710	HeLa extract	[HeLa extracts]	0.0	2	1	1	1
97308	1710	epo -responsive cell type	[EPO -responsive cell type]	0.0	4	1	1	1
97309	1710	tcr nf-at	[TCR NF-AT]	0.0	2	1	1	1
97310	1710	Thrombopoietin TPO the primary regulator	[Thrombopoietin TPO the primary regulator]	0.0	5	1	1	1
97311	1710	capacity of Jun	[capacity of Jun]	0.0	3	1	1	1
97312	1710	system of WT1	[system of WT1]	0.0	3	1	1	1
97313	1710	alveoli, elevation of lavage cellularity	[alveoli, elevation of lavage cellularity]	0.0	5	1	1	1
97314	1710	II-deficient b	[II-deficient B]	0.0	2	1	1	1
97315	1710	involve interaction between transcriptional element	[involving interactions between transcriptional elements]	0.0	5	1	1	1
97316	1710	include nuclear factor	[including nuclear factor]	0.0	3	1	1	1
97317	1710	critical signal molecule	[critical signaling molecule]	0.0	3	1	1	1
97318	1710	decrease in il-2 -produce cell	[decrease in IL-2 -producing cells]	0.0	5	1	1	1
97319	1710	negatively with the proportion of cell	[negatively with the proportion of cells]	0.0	6	1	1	1
97320	1710	bipartite interleukin-4 IL-4	[bipartite interleukin-4 IL-4]	0.0	3	1	1	1
97321	1710	underlie the activity of Tat	[underlying the activity of Tat]	0.0	5	1	1	1
97322	1710	corresponding region of mzf-1	[corresponding region of MZF-1]	0.0	4	1	1	1
97323	1710	metabolite to protein	[metabolites to proteins]	0.0	3	1	1	1
97324	1710	D variant cell	[D variant cells]	0.0	3	1	1	1
97325	1710	use tetanus toxoid T lymphocyte	[Using tetanus toxoid T lymphocytes]	0.0	5	1	1	1
97326	1710	proportion of dp1	[proportion of DP1]	0.0	3	1	1	1
97327	1710	domain d1	[domain D1]	0.0	2	1	1	1
97328	1710	interference in activity	[interference in activities]	0.0	3	1	1	1
97329	1710	human adult globin (hbb)	[human adult globin (HBB)]	0.0	4	1	1	1
97330	1710	mechanism of inhibition of nuclear factor	[mechanisms of inhibition of nuclear factor]	0.0	6	1	1	1
97331	1710	CIITA mutant	[CIITA mutants]	0.0	2	1	1	1
97332	1710	heavy chain igh gene rearrangement	[heavy chain IgH gene rearrangement]	0.0	5	1	1	1
97333	1710	genetic marker of leukemia apl	[genetic markers of leukemias APLs]	0.0	5	1	1	1
97334	1710	succinimide-containing peptide show cross-reactivity	[succinimide-containing peptide showing cross-reactivity]	0.0	4	1	1	1
97335	1710	genomic effects,	[genomic effects,]	0.0	2	2	2	1
97336	1710	activator protein-1 binding activity; in fact,	[activator protein-1 binding activity; in fact,]	0.0	6	1	1	1
97337	1710	new findings.	[new findings.]	0.0	2	1	1	1
97338	1710	colony-stimulating factor colony-stimumulatelany-stg factor proliferation	[colony-stimulating factor colony-stimulating factor proliferation]	0.0	5	1	1	1
97339	1710	transcriptase -polymerase chain reaction RT-PCR	[transcriptase -polymerase chain reaction RT-PCR]	0.0	5	1	1	1
97340	1710	late b cell development	[late B cell development]	0.0	4	1	1	1
97341	1710	tsc2 expression	[TSC2 expression]	0.0	2	1	1	1
97342	1710	rodent cell in cooperation	[rodent cells in cooperation]	0.0	4	1	1	1
97343	1710	cytogenetic abnormality highlight loci relevant	[cytogenetic abnormalities highlighting loci relevant]	0.0	5	1	1	1
97344	1710	consistent alterations.	[consistent alterations.]	0.0	2	1	1	1
97345	1710	use specific decrease in the activity	[using specific decrease in the activity]	0.0	6	1	1	1
97346	1710	progesterone monoclonal antibody	[progesterone monoclonal antibody]	0.0	3	1	1	1
97347	1710	interleukin (il)-1 receptor	[interleukin (IL)-1 receptor]	0.0	3	1	1	1
97348	1710	only a inhibition	[only a inhibition]	0.0	3	1	1	1
97349	1710	overexpression of htafii105	[overexpression of hTAFII105]	0.0	3	1	1	1
97350	1710	detection of intracellular stat-1	[Detection of intracellular STAT-1]	0.0	4	1	1	1
97351	1710	marker for potential	[marker for potential]	0.0	3	1	1	1
97352	1710	increase in intracellular ca2+ concentration	[increase in intracellular Ca2+ concentration]	0.0	5	1	1	1
97353	1710	unicellular daughter cell culture	[unicellular daughter cell culture]	0.0	4	1	1	1
97354	1710	microm at pH	[microM at pH]	0.0	3	1	1	1
97355	1710	nearby site originate bp	[nearby sites originating bp]	0.0	4	1	1	1
97356	1710	amplicon (target)	[amplicon (target)]	0.0	2	1	1	1
97357	1710	method of study: lymphocyte	[METHOD OF STUDY: lymphocytes]	0.0	4	1	1	1
97358	1710	relatively short C terminus	[relatively short C terminus]	0.0	4	1	1	1
97359	1710	domain of factor	[domain of factor]	0.0	3	1	1	1
97360	1710	bind to receptor domain sequence	[binding to receptor domain sequences]	0.0	5	1	1	1
97361	1710	migration response	[migration response]	0.0	2	1	1	1
97362	1710	use with a mass	[using with a mass]	0.0	4	1	1	1
97363	1710	effect on primary human NK	[effects on primary human NK]	0.0	5	1	1	1
97364	1710	intracellular level of stat1	[intracellular levels of STAT1]	0.0	4	1	1	1
97365	1710	specific matrix process	[specific matrix processes]	0.0	3	1	1	1
97366	1710	prime in the absence	[priming in the absence]	0.0	4	1	1	1
97367	1710	IL-2mRNA synthesis	[IL-2mRNA synthesis]	0.0	2	2	2	1
97368	1710	human interleukin (il) gene	[human interleukin (IL) gene]	0.0	4	1	1	1
97369	1710	10(5)- amplification	[10(5)- amplification]	0.0	2	1	1	1
97370	1710	thus suggest a requirement for function	[thus suggesting a requirement for function]	0.0	6	1	1	1
97371	1710	human ciita coding sequence	[human CIITA coding sequence]	0.0	4	1	1	1
97372	1710	binding of traf2	[binding of TRAF2]	0.0	3	2	2	1
97373	1710	first bp of DNA	[first bp of DNA]	0.0	4	1	1	1
97374	1710	expression of myb,	[expression of myb,]	0.0	3	1	1	1
97375	1710	apparent resistance in major disorder	[apparent resistance in major disorder]	0.0	5	1	1	1
97376	1710	T cell in atopic patient	[T cells in atopic patients]	0.0	5	1	1	1
97377	1710	role of Egr-2 in T cell	[Role of Egr-2 in T cells]	0.0	6	1	1	1
97378	1710	band-shift assay	[band-shift assay]	0.0	2	1	1	1
97379	1710	cell-death	[cell-death]	0.0	1	1	1	1
97380	1710	quieiescent patient	[quieiescent patients]	0.0	2	1	1	1
97381	1710	activator tcf-1	[activator TCF-1]	0.0	2	1	1	1
97382	1710	peripheral blood from donor	[peripheral blood from donors]	0.0	4	1	1	1
97383	1710	indicate the factor	[indicating the factor]	0.0	3	1	1	1
97384	1710	basis of activation	[basis of activation]	0.0	3	1	1	1
97385	1710	specify the terminus	[specifying the terminus]	0.0	3	1	1	1
97386	1710	u937 monocytic cell	[U937 monocytic cells]	0.0	3	1	1	1
97387	1710	bear ZEBRA -responsive promoter	[bearing ZEBRA -responsive promoters]	0.0	4	1	1	1
97388	1710	approximately -500 bp	[approximately -500 bp]	0.0	3	1	1	1
97389	1710	mobility shift assay analysis of protein	[mobility shift assay analysis of proteins]	0.0	6	1	1	1
97390	1710	neutralize anti- csf-1r antibody	[neutralizing anti- CSF-1R antibodies]	0.0	4	1	1	1
97391	1710	human Chr	[human Chr]	0.0	2	1	1	1
97392	1710	formation stat5	[formation STAT5]	0.0	2	1	1	1
97393	1710	proteins, aml1a	[proteins, AML1a]	0.0	2	1	1	1
97394	1710	expression of lytic cycle gene	[expression of lytic cycle genes]	0.0	5	1	1	1
97395	1710	amino acid capable	[amino acids capable]	0.0	3	1	1	1
97396	1710	inflammatory injury	[inflammatory injury]	0.0	2	1	1	1
97397	1710	patient nine	[patient nine]	0.0	2	1	1	1
97398	1710	site, absent	[site, absent]	0.0	2	1	1	1
97399	1710	protein with distant homology	[protein with distant homology]	0.0	4	1	1	1
97400	1710	normal transendothelial migration response	[normal transendothelial migration response]	0.0	4	1	1	1
97401	1710	(scf)	[(SCF)]	0.0	1	1	1	1
97402	1710	bipartite human interleukin-4	[bipartite human interleukin-4]	0.0	3	1	1	1
97403	1710	lineage absent	[lineages absent]	0.0	2	1	1	1
97404	1710	activation translocation of a zeta isoform	[activation translocation of a zeta isoform]	0.0	6	1	1	1
97405	1710	critical role in differentiation	[critical roles in differentiation]	0.0	4	1	1	1
97406	1710	early treatment	[early treatment]	0.0	2	1	1	1
97407	1710	hemopoietic cell differentiation	[hemopoietic cell differentiation]	0.0	3	1	1	1
97408	1710	high frequency.	[high frequency.]	0.0	2	1	1	1
97409	1710	infiltrate primary melanoma	[infiltrating primary melanomas]	0.0	3	1	1	1
97410	1710	Bcl-x b cell	[Bcl-x B cells]	0.0	3	1	1	1
97411	1710	cold air degree c) twice/d,	[cold air degrees C) twice/d,]	0.0	5	1	1	1
97412	1710	seven half-site	[seven half-sites]	0.0	2	1	1	1
97413	1710	view a homodimer	[view a homodimer]	0.0	3	1	1	1
97414	1710	potent inducer of ifn-gamma gene expression	[potent inducers of IFN-gamma gene expression]	0.0	6	1	1	1
97415	1710	asthma child aged years.	[asthma children aged years.]	0.0	4	1	1	1
97416	1710	interaction of a transcriptional activator	[Interactions of a transcriptional activator]	0.0	5	1	1	1
97417	1710	interpretation a response	[interpretation a response]	0.0	3	1	1	1
97418	1710	8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[8, histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
97419	1710	aspect of tissue development	[aspects of tissue development]	0.0	4	1	1	1
97420	1710	(phenotype	[(phenotype]	0.0	1	1	1	1
97421	1710	pulmonary condition	[pulmonary conditions]	0.0	2	1	1	1
97422	1710	induction in (U937) cell	[induction in (U937) cells]	0.0	4	1	1	1
97423	1710	assay conditions-concentration nmol/l, incubation time	[assay conditions-concentration nmol/l, incubation time]	0.0	5	1	1	1
97424	1710	individual with inflammatory disease	[individuals with inflammatory disease]	0.0	4	1	1	1
97425	1710	interface	[interface]	0.0	1	1	1	1
97426	1710	bona th2 cell	[bona Th2 cells]	0.0	3	1	1	1
97427	1710	evidence for a additional factor	[evidence for an additional factor]	0.0	5	1	1	1
97428	1710	follicular cell in center	[follicular cells in centers]	0.0	4	1	1	1
97429	1710	ig class switch	[Ig class switching]	0.0	3	1	1	1
97430	1710	form of positive selection	[forms of positive selection]	0.0	4	1	1	1
97431	1710	nonmobilized blood mononuclear cell pbmc	[nonmobilized blood mononuclear cells PBMC]	0.0	5	1	1	1
97432	1710	clone of HTLV-II	[clone of HTLV-II]	0.0	3	1	1	1
97433	1710	present a hierarchical structure	[presenting a hierarchical structure]	0.0	4	1	1	1
97434	1710	gc -insensitive asthma	[GC -insensitive asthma]	0.0	3	1	1	1
97435	1710	functional expression of CD40	[functional expression of CD40]	0.0	4	1	1	1
97436	1710	2 lytic transcript	[2 lytic transcripts]	0.0	3	1	1	1
97437	1710	Syk protein skip	[Syk proteins SKIPs]	0.0	3	1	1	1
97438	1710	functional promoter region with respect	[functional promoter region with respect]	0.0	5	1	1	1
97439	1710	(scc)	[(SCC)]	0.0	1	1	1	1
97440	1710	stat1 with stat2	[STAT1 with STAT2]	0.0	3	1	1	1
97441	1710	lysozyme release	[lysozyme release]	0.0	2	1	1	1
97442	1710	analysis use Southern blot hybridisation	[analysis using Southern blot hybridisation]	0.0	5	1	1	1
97443	1710	action of alpha-lipoic acid	[action of alpha-lipoic acid]	0.0	4	1	1	1
97444	1710	sox9 coding	[SOX9 coding]	0.0	2	1	1	1
97445	1710	box in the mammalian gene	[boxes in the mammalian gene]	0.0	5	1	1	1
97446	1710	adult globin (hbb) promoter	[adult globin (HBB) promoter]	0.0	4	1	1	1
97447	1710	second AIDS retrovirus	[second AIDS retrovirus]	0.0	3	1	1	1
97448	1710	expression tumor	[expression tumors]	0.0	2	1	1	1
97449	1710	activity on the RA signalling pathway	[activities on the RA signalling pathway]	0.0	6	1	1	1
97450	1710	inhibitor of reverse transcriptase	[inhibitor of reverse transcriptase]	0.0	4	1	1	1
97451	1710	one class of protein	[one class of proteins]	0.0	4	1	1	1
97452	1710	aldosterone antagonist	[aldosterone antagonist]	0.0	2	1	1	1
97453	1710	change in this network	[Changes in this network]	0.0	4	1	1	1
97454	1710	activation of NF-AT reporter	[activation of NF-AT reporters]	0.0	4	1	1	1
97455	1710	stage i	[Stage I]	0.0	2	1	1	1
97456	1710	patient, transient reduction	[patient, transient reduction]	0.0	3	1	1	1
97457	1710	other cd3epsilon mouse line	[other CD3epsilon mouse lines]	0.0	4	1	1	1
97458	1710	ad region 1a gene	[Ad region 1A gene]	0.0	4	1	1	1
97459	1710	consider the effect of this element	[Considering the effect of this element]	0.0	6	1	1	1
97460	1710	cyclic element-binding protein	[cyclic element-binding protein]	0.0	3	1	1	1
97461	1710	Virol.	[Virol.]	0.0	1	1	1	1
97462	1710	state of unresponsiveness	[state of unresponsiveness]	0.0	3	1	1	1
97463	1710	include the sry (sex region	[including the SRY (sex region]	0.0	5	1	1	1
97464	1710	L- MPL rat	[L- MPL rats]	0.0	3	1	1	1
97465	1710	proper development	[proper development]	0.0	2	1	1	1
97466	1710	S6 kinase pp90rsk	[S6 kinase pp90rsk]	0.0	3	1	1	1
97467	1710	cell type-specific activation	[cell type-specific activation]	0.0	3	1	1	1
97468	1710	virus infections.	[virus infections.]	0.0	2	1	1	1
97469	1710	T lymphocyte clonotypes: implication	[T lymphocyte clonotypes: implications]	0.0	4	1	1	1
97470	1710	representate the spectrum of differentiation	[representating the spectrum of differentiation]	0.0	5	1	1	1
97471	1710	stage B	[stages B]	0.0	2	1	1	1
97472	1710	great stimulation	[great stimulation]	0.0	2	1	1	1
97473	1710	amino acid-rich	[amino acid-rich]	0.0	2	1	1	1
97474	1710	level in all haematopoietic population	[levels in all haematopoietic populations]	0.0	5	1	1	1
97475	1710	c/ebpalpha target	[C/EBPalpha target]	0.0	2	1	1	1
97476	1710	contrast, no effect	[contrast, no effect]	0.0	3	1	1	1
97477	1710	o-phenanthroline metal-ion chelator	[o-phenanthroline metal-ion chelator]	0.0	3	1	1	1
97478	1710	etiological relationship between the variants,	[etiological relationship between the variants,]	0.0	5	1	1	1
97479	1710	two distinct species,	[two distinct species,]	0.0	3	1	1	1
97480	1710	patient without complication	[patients without complications]	0.0	3	1	1	1
97481	1710	induce agents.	[inducing agents.]	0.0	2	1	1	1
97482	1710	Calphostin	[Calphostin]	0.0	1	1	1	1
97483	1710	cd8(+) cytotoxic T lymphocyte	[CD8(+) cytotoxic T lymphocytes]	0.0	4	1	1	1
97484	1710	homeobox gene distantly related	[homeobox gene distantly related]	0.0	4	1	1	1
97485	1710	model to DC differentiation	[model to DC differentiation]	0.0	4	1	1	1
97486	1710	activity of the origin	[activity of the origin]	0.0	4	1	1	1
97487	1710	ultimately result of the gssg deficiency	[ultimately results of the GSSG deficiency]	0.0	6	1	1	1
97488	1710	chronic lymphocytic leukemia B-CLL	[chronic lymphocytic leukemia B-CLL]	0.0	4	1	1	1
97489	1710	high replicative capacity NF-kappaB	[high replicative capacity NF-kappaB]	0.0	4	1	1	1
97490	1710	gamma(c)-positive, il-13r	[gamma(c)-positive, IL-13R]	0.0	2	1	1	1
97491	1710	splenic precursor cell	[splenic precursor cells]	0.0	3	1	1	1
97492	1710	blood of 7 patient	[blood of 7 patients]	0.0	4	1	1	1
97493	1710	4-year probability of relapse	[4-year probability of relapse]	0.0	4	1	1	1
97494	1710	binding of the receptor	[binding of the receptor]	0.0	4	2	2	1
97495	1710	chromosome 17p13.3	[chromosome 17p13.3]	0.0	2	1	1	1
97496	1710	use phorbol ester	[using phorbol ester]	0.0	3	1	1	1
97497	1710	fold.	[fold.]	0.0	1	1	1	1
97498	1710	kda protein in lymphocyte	[kDa protein in lymphocytes]	0.0	4	1	1	1
97499	1710	gold compound autg	[gold compound AuTG]	0.0	3	1	1	1
97500	1710	p80c-rel tyrosine phosphorylation	[p80c-rel tyrosine phosphorylation]	0.0	3	1	1	1
97501	1710	Dithiocarbamates DTC a diverse group	[Dithiocarbamates DTC a diverse group]	0.0	5	1	1	1
97502	1710	gene specific	[genes specific]	0.0	2	1	1	1
97503	1710	Platelet/endothelium	[Platelet/endothelium]	0.0	1	1	1	1
97504	1710	reactive oxygen -release	[Reactive oxygen -release]	0.0	3	1	1	1
97505	1710	copy of the p sequence	[copies of the P sequence]	0.0	5	1	1	1
97506	1710	Sp1 factor	[Sp1 factor]	0.0	2	1	1	1
97507	1710	chimaeric product	[chimaeric product]	0.0	2	1	1	1
97508	1710	previously unknown locus sil	[previously unknown locus SIL]	0.0	4	1	1	1
97509	1710	model, polymorphism	[model, polymorphisms]	0.0	2	1	1	1
97510	1710	gene encode cytoskeletal protein	[genes encoding cytoskeletal proteins]	0.0	4	1	1	1
97511	1710	level in keratoacanthomas kas	[levels in keratoacanthomas KAs]	0.0	4	1	1	1
97512	1710	oestrogen receptor analysis correlation	[Oestrogen receptor analysis correlation]	0.0	4	1	1	1
97513	1710	mostly of the NF-kappa B1 subunit	[mostly of the NF-kappa B1 subunit]	0.0	6	1	1	1
97514	1710	mnda cell differentiation antigen	[MNDA cell differentiation antigen]	0.0	4	1	1	1
97515	1710	quantitative reverse transcription-PCR assay	[quantitative reverse transcription-PCR assay]	0.0	4	1	1	1
97516	1710	il-1 beta mrna expression	[IL-1 beta mRNA expression]	0.0	4	1	1	1
97517	1710	level of mrna for protein-1	[levels of mRNA for protein-1]	0.0	5	1	1	1
97518	1710	mol/microgram rna	[mol/microgram RNA]	0.0	2	1	1	1
97519	1710	full range	[full range]	0.0	2	1	1	1
97520	1710	overall effect	[overall effect]	0.0	2	1	1	1
97521	1710	Oct-2 transactivation	[Oct-2 transactivation]	0.0	2	1	1	1
97522	1710	stringent systems,	[stringent systems,]	0.0	2	1	1	1
97523	1710	percutaneous angioplasty	[percutaneous angioplasty]	0.0	2	1	1	1
97524	1710	high gene	[higher gene]	0.0	2	1	1	1
97525	1710	region for CD4 dimerization	[region for CD4 dimerization]	0.0	4	1	1	1
97526	1710	75-kDa hematopoietic signal protein	[75-kDa hematopoietic signaling protein]	0.0	4	1	1	1
97527	1710	entry site IRES	[entry site IRES]	0.0	3	1	1	1
97528	1710	Epstein-Barr virus transformation	[Epstein-Barr virus transformation]	0.0	3	1	1	1
97529	1710	salicylic	[salicylic]	0.0	1	3	3	1
97530	1710	feature of discordant xenograft rejection	[feature of discordant xenograft rejection]	0.0	5	1	1	1
97531	1710	G-CSF colony formation	[G-CSF colony formation]	0.0	3	1	1	1
97532	1710	ten normal blood lymphocyte sample	[ten normal blood lymphocyte samples]	0.0	5	1	1	1
97533	1710	scavenging tnf- cell	[scavenging TNF- cells]	0.0	3	1	1	1
97534	1710	implication for gene expression	[implications for gene expression]	0.0	4	1	1	1
97535	1710	potential nf-kappa b binding sites)	[potential NF-kappa B binding sites)]	0.0	5	1	1	1
97536	1710	basis of gc insensitivity	[basis of GC insensitivity]	0.0	4	2	2	1
97537	1710	nuclear factor-mu regulator	[nuclear factor-mu regulator]	0.0	3	1	1	1
97538	1710	absence of other viral	[absence of other viral]	0.0	4	1	1	1
97539	1710	EBV antigen EBNA2 one	[EBV antigen EBNA2 one]	0.0	4	1	1	1
97540	1710	interaction with vein cell	[interaction with vein cells]	0.0	4	1	1	1
97541	1710	blot analysis of extract	[blot analysis of extracts]	0.0	4	1	1	1
97542	1710	6 gram	[6 g]	0.0	2	1	1	1
97543	1710	intracellular localization after TNFalpha simulation	[intracellular localization after TNFalpha simulation]	0.0	5	1	1	1
97544	1710	tumour necrosis factor-alpha in the supernatants.	[tumour necrosis factor-alpha in the supernatants.]	0.0	6	1	1	1
97545	1710	(2) search	[(2) search]	0.0	2	1	1	1
97546	1710	level of nf(kappa)b	[levels of NF(kappa)B]	0.0	3	1	1	1
97547	1710	ectopic expression Oct2	[ectopic expression Oct2]	0.0	3	1	1	1
97548	1710	employed,	[employed,]	0.0	1	1	1	1
97549	1710	additional gene segment	[Additional gene segments]	0.0	3	1	1	1
97550	1710	serine/threonine phosphatase okadaic acid	[serine/threonine phosphatases okadaic acid]	0.0	4	1	1	1
97551	1710	mode of basic regulation	[modes of basic regulation]	0.0	4	1	1	1
97552	1710	glucocorticoid in subject	[glucocorticoids in subjects]	0.0	3	1	1	1
97553	1710	bronchial asthma child aged	[bronchial asthma children aged]	0.0	4	1	1	1
97554	1710	lead to androgen insensitivity syndrome	[leading to androgen insensitivity syndrome]	0.0	5	1	1	1
97555	1710	course of disease	[course of diseases]	0.0	3	1	1	1
97556	1710	antibody in from healthy carrier	[antibodies in from healthy carriers]	0.0	5	1	1	1
97557	1710	amp-responsive element-binding protein	[AMP-responsive element-binding protein]	0.0	3	1	1	1
97558	1710	report of a physical interaction	[report of a physical interaction]	0.0	5	1	1	1
97559	1710	mechanism contribute	[mechanisms contributing]	0.0	2	1	1	1
97560	1710	-terminal amino	[-terminal amino]	0.0	2	1	1	1
97561	1710	cd14 gene	[CD14 gene]	0.0	2	1	1	1
97562	1710	replication-incompetent clone	[replication-incompetent clone]	0.0	2	1	1	1
97563	1710	heat-shock for hour at 42 degree	[Heat-shock for hours at 42 degrees]	0.0	6	1	1	1
97564	1710	prevalence in breast aspirate of woman	[Prevalence in breast aspirates of women]	0.0	6	1	1	1
97565	1710	production of hiv-1	[Production of HIV-1]	0.0	3	1	1	1
97566	1710	agent with activity	[agent with activity]	0.0	3	1	1	1
97567	1710	myeloid cell i.e. granulocyte	[myeloid cells i.e. granulocytes]	0.0	4	1	1	1
97568	1710	form, CBF beta	[form, CBF beta]	0.0	3	1	1	1
97569	1710	pre-B mb-1 gene	[pre-B mb-1 gene]	0.0	3	1	1	1
97570	1710	two x chromosome	[two X chromosomes]	0.0	3	1	1	1
97571	1710	transcription from early gene	[transcription from early genes]	0.0	4	1	1	1
97572	1710	pkc -dependent signal system	[PKC -dependent signaling systems]	0.0	4	1	1	1
97573	1710	somatic deletion of the allele	[somatic deletion of the allele]	0.0	5	1	1	1
97574	1710	nuclear factor include Sp1	[nuclear factors including Sp1]	0.0	4	1	1	1
97575	1710	starting point	[starting point]	0.0	2	1	1	1
97576	1710	early treatment 0 hpc with alpha-pml	[early treatment 0 HPCs with alpha-PML]	0.0	6	1	1	1
97577	1710	fluoride-resistant- alpha-naphthyl-acetate-esterase naf-r-nse	[fluoride-resistant- alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	3	1	1	1
97578	1710	site of interaction involve factor	[site of interactions involving factor]	0.0	5	1	1	1
97579	1710	splice product	[splice products]	0.0	2	1	1	1
97580	1710	NF-kappaB a regulator of response	[NF-kappaB a regulator of responses]	0.0	5	1	1	1
97581	1710	DNA-protein complex with nuclear extract	[DNA-protein complexes with nuclear extracts]	0.0	5	1	1	1
97582	1710	prominent isoforms.	[prominent isoforms.]	0.0	2	1	1	1
97583	1710	human endothelial cell ECs	[human endothelial cells ECs]	0.0	4	1	1	1
97584	1710	level in u937	[levels in U937]	0.0	3	1	1	1
97585	1710	inhibitory peptide of nf-kappab	[inhibitory peptide of NF-kappaB]	0.0	4	1	1	1
97586	1710	complex -restricted fashion	[complex -restricted fashion]	0.0	3	1	1	1
97587	1710	Chemical cross-linking	[Chemical cross-linking]	0.0	2	1	1	1
97588	1710	level of antibodies patient with mononucleosis	[levels of antibodies, patients with mononucleosis]	0.0	6	1	1	1
97589	1710	ongoing response	[ongoing response]	0.0	2	1	1	1
97590	1710	change of serine to alanine	[change of serine to alanine]	0.0	5	1	1	1
97591	1710	microE5/kappa motif	[microE5/kappa motif]	0.0	2	2	2	1
97592	1710	therefore a potential target	[therefore a potential target]	0.0	4	1	1	1
97593	1710	result in hyper-sensitivity	[resulting in hyper-sensitivity]	0.0	3	1	1	1
97594	1710	E2F-I bind protein, dpii,	[E2F-I binding protein, DP-I,]	0.0	4	1	1	1
97595	1710	gene transcription in tissue	[gene transcription in tissues]	0.0	4	1	1	1
97596	1710	stat1 other control transcription factor	[Stat1 other control transcription factors]	0.0	5	1	1	1
97597	1710	gene rearrangement event	[gene rearrangement events]	0.0	3	1	1	1
97598	1710	5 nm vd3 for h	[5 nM VD3 for h]	0.0	5	1	1	1
97599	1710	high titre antibody with specificity	[high titre antibodies with specificities]	0.0	5	1	1	1
97600	1710	influence of element	[influence of elements]	0.0	3	1	1	1
97601	1710	cellular homologue	[cellular homologues]	0.0	2	1	1	1
97602	1710	retinaldehyde dehydrogenase RALDH2	[retinaldehyde dehydrogenase RALDH2]	0.0	3	1	1	1
97603	1710	two stages: a chronic	[two stages: a chronic]	0.0	4	1	1	1
97604	1710	SLP-76 function	[SLP-76 function]	0.0	2	1	1	1
97605	1710	range for person	[range for persons]	0.0	3	1	1	1
97606	1710	activation, with phytohemagglutinin to CD3	[activation, with phytohemagglutinin to CD3]	0.0	5	1	1	1
97607	1710	muscle myosin chain Smmhc	[muscle myosin chain Smmhc]	0.0	4	1	1	1
97608	1710	human herpesvirus a predominantly T virus	[Human herpesvirus a predominantly T virus]	0.0	6	1	1	1
97609	1710	furthermore, ectopic expression of ebf	[Furthermore, ectopic expression of EBF]	0.0	5	1	1	1
97610	1710	ad group	[Ad groups]	0.0	2	1	1	1
97611	1710	subcellular compartmentalization	[subcellular compartmentalization]	0.0	2	1	1	1
97612	1710	factor kappab nfkappab program	[factor kappaB NFkappaB program]	0.0	4	1	1	1
97613	1710	stat protein in the generation	[Stat proteins in the generation]	0.0	5	1	1	1
97614	1710	disrupt regulatory domain	[disrupting regulatory domain]	0.0	3	1	1	1
97615	1710	separate heterocomplex	[separate heterocomplexes]	0.0	2	1	1	1
97616	1710	signal-regulated protein kinase erk	[signal-regulated protein kinase ERK]	0.0	4	1	1	1
97617	1710	However, BRL49653	[However, BRL49653]	0.0	2	1	1	1
97618	1710	two antitumour DNA topoisomerase inhibitor	[two antitumour DNA topoisomerase inhibitors]	0.0	5	1	1	1
97619	1710	bind power of receptor	[binding power of receptor]	0.0	4	1	1	1
97620	1710	add with RA m).	[adding with RA M).]	0.0	4	1	1	1
97621	1710	nfat-1 factor of t-cell	[NFAT-1 factor of T-cells]	0.0	4	1	1	1
97622	1710	IL-3 gene 5'	[IL-3 gene 5']	0.0	3	1	1	1
97623	1710	metabolism of steroid by normal	[metabolism of steroids by normal]	0.0	5	1	1	1
97624	1710	two different strain	[Two different strains]	0.0	3	1	1	1
97625	1710	OBF-1 a b coactivator	[OBF-1 a B coactivator]	0.0	4	1	1	1
97626	1710	protein bind to the ap-1	[proteins binding to the AP-1]	0.0	5	1	1	1
97627	1710	histogenetic subtype	[histogenetic subtypes]	0.0	2	1	1	1
97628	1710	ubiquitous nuclear component	[ubiquitous nuclear component]	0.0	3	1	1	1
97629	1710	Ets family protein	[Ets family protein]	0.0	3	1	1	1
97630	1710	pair silencer	[pair silencer]	0.0	2	1	1	1
97631	1710	regard to relevance	[regard to relevance]	0.0	3	1	1	1
97632	1710	inhibition of response	[inhibition of responses]	0.0	3	1	1	1
97633	1710	transcription tfiid TAFII32	[transcription TFIID TAFII32]	0.0	3	1	1	1
97634	1710	terminal repeat proviruse	[terminal repeat proviruses]	0.0	3	1	1	1
97635	1710	regulation switch	[regulation switching]	0.0	2	1	1	1
97636	1710	cloning murine	[Cloning murine]	0.0	2	1	1	1
97637	1710	Platelet/endothelial	[Platelet/endothelial]	0.0	1	1	1	1
97638	1710	protect cell	[protecting cells]	0.0	2	1	1	1
97639	1710	intracellular oxygen species generation	[intracellular oxygen species generation]	0.0	4	1	1	1
97640	1710	rest T	[resting T]	0.0	2	1	1	1
97641	1710	creb kinase	[CREB kinase]	0.0	2	1	1	1
97642	1710	(range, (range, 5.86-6.74) nm,	[(range, (range, 5.86-6.74) nM,]	0.0	4	1	1	1
97643	1710	anti-immunoglobulin	[anti-immunoglobulin]	0.0	1	1	1	1
97644	1710	absence in endometriotic lesion	[absence in endometriotic lesions]	0.0	4	1	1	1
97645	1710	sound basis	[sound basis]	0.0	2	1	1	1
97646	1710	prostaglandin e2 on cytokine production	[prostaglandin E2 on cytokine production]	0.0	5	1	1	1
97647	1710	(lytic) infection	[(lytic) infections]	0.0	2	1	1	1
97648	1710	rest b	[resting B]	0.0	2	1	1	1
97649	1710	distinct stimuli, tcr	[distinct stimuli, TCR]	0.0	3	1	1	1
97650	1710	overexpression of gamma-globin	[overexpression of gamma-globin]	0.0	3	1	1	1
97651	1710	protein kinase pathway PD	[protein kinase pathway PD]	0.0	4	1	1	1
97652	1710	different allele	[different alleles]	0.0	2	1	1	1
97653	1710	addition of fos	[addition of Fos]	0.0	3	1	1	1
97654	1710	inhibition of secretion by lps	[Inhibition of secretion by LPS]	0.0	5	1	1	1
97655	1710	contrast, oxidation with glucose oxidase	[contrast, oxidation with glucose oxidase]	0.0	5	1	1	1
97656	1710	experimental series: at normal subject	[experimental series: at normal subjects]	0.0	5	1	1	1
97657	1710	less intercellular adhesion molecule-1	[lesser intercellular adhesion molecule-1]	0.0	4	1	1	1
97658	1710	acid-binding protein	[acid-binding protein]	0.0	2	1	1	1
97659	1710	structure important in development	[structure important in development]	0.0	4	1	1	1
97660	1710	role in the gene expression	[role in the gene expression]	0.0	5	1	1	1
97661	1710	express socs-3	[expressing SOCS-3]	0.0	2	1	1	1
97662	1710	elderly donor	[elderly donors]	0.0	2	1	1	1
97663	1710	er region	[ER region]	0.0	2	1	1	1
97664	1710	2 pre-B leukemia all	[2 pre-B leukemia ALL]	0.0	4	1	1	1
97665	1710	further evidence to the notion	[further evidence to the notion]	0.0	5	1	1	1
97666	1710	migration of leukocyte to serum	[migration of leukocytes to serum]	0.0	5	1	1	1
97667	1710	transcriptional activator of hiv expression	[transcriptional activator of HIV expression]	0.0	5	1	1	1
97668	1710	transcription factor yb-1	[transcription factor YB-1]	0.0	3	1	1	1
97669	1710	expression of a gene ORF 50	[expression of a gene ORF 50]	0.0	6	1	1	1
97670	1710	follow rearrangement involve band 3q26	[following rearrangements involving band 3q26]	0.0	5	1	1	1
97671	1710	nuclear antigens, u1rnp	[nuclear antigens, U1RNP]	0.0	3	1	1	1
97672	1710	exhibit change	[exhibiting changes]	0.0	2	1	1	1
97673	1710	compartmentalization of this protein	[compartmentalization of these proteins]	0.0	4	1	1	1
97674	1710	expression of myf3	[expression of myf3]	0.0	3	1	1	1
97675	1710	tyrosine-phosphorylated factor treatment of human neutrophils.	[tyrosine-phosphorylated factor treatment of human neutrophils.]	0.0	6	1	1	1
97676	1710	partial proteolysis profile	[partial proteolysis profile]	0.0	3	1	1	1
97677	1710	underlie this anti-inflammatory capacity	[underlying this anti-inflammatory capacity]	0.0	4	1	1	1
97678	1710	acute leukemia evi1 fusion	[acute leukemia EVI1 fusions]	0.0	4	1	1	1
97679	1710	new insight into the protein-protein interaction	[new insights into the protein-protein interactions]	0.0	6	1	1	1
97680	1710	gr number with affinity	[GR number with affinity]	0.0	4	1	1	1
97681	1710	member especially the homolog c/ebp-beta	[members especially the homolog C/EBP-beta]	0.0	5	1	1	1
97682	1710	only the single mutation	[only the single mutations]	0.0	4	1	1	1
97683	1710	responsiveness to Ag	[responsiveness to Ag]	0.0	3	1	1	1
97684	1710	monoclonal cross-linking tyrosine phosphorylation	[monoclonal cross-linking tyrosine phosphorylation]	0.0	4	1	1	1
97685	1710	leukemia (pll)	[leukemias (PLL)]	0.0	2	1	1	1
97686	1710	Strikingly, costimulation	[Strikingly, costimulation]	0.0	2	1	1	1
97687	1710	transcriptional activator tcf-1 t-cell factor-1	[transcriptional activator TCF-1 T-Cell Factor-1]	0.0	5	1	1	1
97688	1710	control protein	[control protein]	0.0	2	1	1	1
97689	1710	time-dependent binding two antibody	[time-dependent binding two antibodies]	0.0	4	1	1	1
97690	1710	interferon protein	[interferon protein]	0.0	2	1	1	1
97691	1710	patient with early RA	[patients with early RA]	0.0	4	1	1	1
97692	1710	RAR x receptor RXR receptor	[RAR X receptor RXR receptors]	0.0	5	1	1	1
97693	1710	absence of il-13r alpha1	[absence of IL-13R alpha1]	0.0	4	1	1	1
97694	1710	b-lymphopoiesis on this transcription factor	[B-lymphopoiesis on this transcription factor]	0.0	5	1	1	1
97695	1710	subregion of the enhancer element	[subregions of the enhancer element]	0.0	5	1	1	1
97696	1710	Rho activity	[Rho activity]	0.0	2	1	1	1
97697	1710	Interferon factor 2 irf-2	[Interferon factor 2 IRF-2]	0.0	4	1	1	1
97698	1710	wild-type ecem) cell	[wild-type (CEM) cells]	0.0	3	1	1	1
97699	1710	stably overexpress pkc-zeta	[stably overexpressing PKC-zeta]	0.0	3	1	1	1
97700	1710	rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione (8)	[rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione (8)]	0.0	5	1	1	1
97701	1710	other transcription factor include nf- il-6	[other transcription factors including NF- IL-6]	0.0	6	1	1	1
97702	1710	four kind of il-4ralpha	[four kinds of IL-4Ralpha]	0.0	4	1	1	1
97703	1710	same size	[same size]	0.0	2	1	1	1
97704	1710	Ca2+ regulatory element	[Ca2+ regulatory element]	0.0	3	1	1	1
97705	1710	(EBER)	[(EBER)]	0.0	1	1	1	1
97706	1710	child at the step	[children at the step]	0.0	4	1	1	1
97707	1710	charybdotoxin-sensitive,	[Charybdotoxin-sensitive,]	0.0	1	1	1	1
97708	1710	abnormality of p16	[Abnormalities of p16]	0.0	3	1	1	1
97709	1710	PHA/	[PHA/]	0.0	1	2	2	1
97710	1710	function of human alveolar macrophage	[functions of human alveolar macrophages]	0.0	5	1	1	1
97711	1710	1 P; immediate) binding of heterodimer	[1 h; immediate) binding of heterodimers]	0.0	6	1	1	1
97712	1710	model of center maturation	[model of center maturation]	0.0	4	1	1	1
97713	1710	translocation of NF-kB	[translocation of NF-kB]	0.0	3	1	1	1
97714	1710	transient and/or expression	[transient and/or expression]	0.0	3	1	1	1
97715	1710	affinity for interleukin-6	[affinity for interleukin-6]	0.0	3	1	1	1
97716	1710	-dependent transcriptional activation of gene	[-dependent transcriptional activation of gene]	0.0	5	1	1	1
97717	1710	expression of pu.1 in cell	[Expression of PU.1 in cells]	0.0	5	1	1	1
97718	1710	difference in tcr affinity	[differences in TCR affinities]	0.0	4	1	1	1
97719	1710	mononuclear leukocyte from obese subject	[mononuclear leukocytes from obese subjects]	0.0	5	1	1	1
97720	1710	absent MHC class expression	[absent MHC class expression]	0.0	4	1	1	1
97721	1710	15-LO promoter region	[15-LO promoter region]	0.0	3	1	1	1
97722	1710	critical cis element	[critical cis elements]	0.0	3	1	1	1
97723	1710	situations,	[situations,]	0.0	1	1	1	1
97724	1710	rise in ca2+ concentration	[rise in Ca2+ concentration]	0.0	4	1	1	1
97725	1710	affinity of glucocorticoid-receptors	[affinity of glucocorticoid-receptors]	0.0	3	1	1	1
97726	1710	contain monovalent gold ion	[containing monovalent gold ion]	0.0	4	1	1	1
97727	1710	ligation on IL-2- NK cell	[Ligation on IL-2- NK cells]	0.0	5	1	1	1
97728	1710	precursor cell in mature cell	[precursor cells in mature cells]	0.0	5	1	1	1
97729	1710	A. Rosen,	[A. Rosen,]	0.0	2	1	1	1
97730	1710	alpha-hydroxyprogesterone	[alpha-hydroxyprogesterone]	0.0	1	1	1	1
97731	1710	subset of CLL	[subset of CLL]	0.0	3	1	1	1
97732	1710	strong activation on the dprl promoter	[strong activation on the dPRL promoter]	0.0	6	1	1	1
97733	1710	immunosuppressive factor in bovine colostrum	[immunosuppressive factor in bovine colostrum]	0.0	5	1	1	1
97734	1710	globin gene switch	[globin gene switching]	0.0	3	1	1	1
97735	1710	evidence for functional disomy	[evidence for functional disomy]	0.0	4	1	1	1
97736	1710	candidate for the atopy gene	[candidate for the atopy gene]	0.0	5	1	1	1
97737	1710	activation of multiple member	[activation of multiple members]	0.0	4	1	1	1
97738	1710	ap-1 concentration in lymphocyte	[AP-1 concentrations in lymphocytes]	0.0	4	1	1	1
97739	1710	oral administration of gram metyrapone	[oral administration of g metyrapone]	0.0	5	1	1	1
97740	1710	DNA fragment contain bp	[DNA fragment containing bp]	0.0	4	1	1	1
97741	1710	genistein at micromol/L	[genistein at micromol/L]	0.0	3	1	1	1
97742	1710	However, induction	[However, induction]	0.0	2	1	1	1
97743	1710	blot of extract	[blots of extracts]	0.0	3	1	1	1
97744	1710	antibody supershift assay	[antibody supershift assays]	0.0	3	1	1	1
97745	1710	fetal calf serum efcs culture	[fetal calf serum (FCS+) culture]	0.0	5	1	1	1
97746	1710	three pathway involve kinase c	[three pathways involving kinase C]	0.0	5	1	1	1
97747	1710	f.r., m.m., P. with bcr1/25	[F.R., M.M., P. with BCR1/25]	0.0	5	1	1	1
97748	1710	nfatc (predominant form	[NFATc (predominant form]	0.0	3	1	1	1
97749	1710	only significant effect on adrenal function	[only significant effects on adrenal function]	0.0	6	1	1	1
97750	1710	protein otf-2	[protein OTF-2]	0.0	2	1	1	1
97751	1710	corresponding binding	[corresponding binding]	0.0	2	1	1	1
97752	1710	cd14(+) cell	[CD14(+) cells]	0.0	2	1	1	1
97753	1710	four- to 10-fold amount	[four- to 10-fold amounts]	0.0	4	1	1	1
97754	1710	eventual recovery	[eventual recovery]	0.0	2	1	1	1
97755	1710	dose of specific peptide	[doses of specific peptide]	0.0	4	1	1	1
97756	1710	human CMV	[human CMV]	0.0	2	1	1	1
97757	1710	activator protein 1 ap-1	[activator protein 1 AP-1]	0.0	4	1	1	1
97758	1710	cross-linking by gp120-anti-gp120 immune complex	[cross-linking by gp120-anti-gp120 immune complexes]	0.0	5	1	1	1
97759	1710	transcriptional regulation of adhesion molecule-1	[transcriptional regulation of adhesion molecule-1]	0.0	5	1	1	1
97760	1710	intracellular inhibition	[intracellular inhibition]	0.0	2	1	1	1
97761	1710	Nuclear localization 1 complex	[Nuclear localization 1 complexes]	0.0	4	1	1	1
97762	1710	CF individual 7 (13%)	[CF individuals 7 (13%)]	0.0	4	1	1	1
97763	1710	host control in T cell	[Host control in T cells]	0.0	5	1	1	1
97764	1710	mechanism lead to hiv-1 replication	[mechanisms leading to HIV-1 replication]	0.0	5	1	1	1
97765	1710	homeodomain pouhd	[homeodomain POUHD]	0.0	2	1	1	1
97766	1710	cell subtype of lymphoma	[cell subtype of lymphoma]	0.0	4	1	1	1
97767	1710	use differential RNA display	[using differential RNA display]	0.0	4	1	1	1
97768	1710	dramatic increase phospholipase c 1	[dramatic increase phospholipase C 1]	0.0	5	1	1	1
97769	1710	positive effect on vcam-1 expression	[positive effect on VCAM-1 expression]	0.0	5	1	1	1
97770	1710	coordinate the activity of several element	[coordinating the activity of several elements]	0.0	6	1	1	1
97771	1710	follow treatment with all-tran retinoic acid	[following treatment with all-trans retinoic acid]	0.0	6	1	1	1
97772	1710	biopsy a lesion	[Biopsies an lesion]	0.0	3	1	1	1
97773	1710	use antibody against transcription factor	[using antibodies against transcription factors]	0.0	5	1	1	1
97774	1710	expression of interferon isotype	[expression of interferon isotypes]	0.0	4	1	1	1
97775	1710	double infection with two virion	[double infection with two virions]	0.0	5	1	1	1
97776	1710	prevent induction	[preventing induction]	0.0	2	1	1	1
97777	1710	g-seropositive donor	[G-seropositive donors]	0.0	2	1	1	1
97778	1710	hla dqb1*0201	[HLA DQB1*0201]	0.0	2	1	1	1
97779	1710	analysis of the region	[analysis of the region]	0.0	4	1	1	1
97780	1710	relation to major complex class	[relation to major complex classes]	0.0	5	1	1	1
97781	1710	quantitative analysis with isoform-specific antibody	[quantitative analysis with isoform-specific antibodies]	0.0	5	1	1	1
97782	1710	cytotoxic assay	[cytotoxic assays]	0.0	2	1	1	1
97783	1710	transcription of genes.	[transcription of genes.]	0.0	3	1	1	1
97784	1710	previously unrecognized mutation	[previously unrecognized mutation]	0.0	3	1	1	1
97785	1710	hmd similar	[HMDS similar]	0.0	2	1	1	1
97786	1710	2 receptor gamma chain	[2 receptor gamma chain]	0.0	4	1	1	1
97787	1710	lead to the binding	[leading to the binding]	0.0	4	1	1	1
97788	1710	clonality of blood cell	[clonality of blood cells]	0.0	4	1	1	1
97789	1710	suggest the presence of positive element	[suggesting the presence of positive elements]	0.0	6	1	1	1
97790	1710	607 amino acid	[607 amino acids]	0.0	3	1	1	1
97791	1710	antibody in	[antibodies in]	0.0	2	1	1	1
97792	1710	inhibition after withdrawal of il-2	[inhibition after withdrawal of IL-2]	0.0	5	1	1	1
97793	1710	respectively, prevent target cell uptake	[respectively, preventing target cell uptake]	0.0	5	1	1	1
97794	1710	analysis of monocyte	[Analysis of monocytes]	0.0	3	1	1	1
97795	1710	various breakpoint range from q13	[various breakpoints ranging from q13]	0.0	5	1	1	1
97796	1710	region, in rheumatoid	[region, in rheumatoid]	0.0	3	1	1	1
97797	1710	antibody kn	[antibody KN]	0.0	2	1	1	1
97798	1710	nuclear analysis	[nuclear analysis]	0.0	2	1	1	1
97799	1710	other early gene	[other early genes]	0.0	3	1	1	1
97800	1710	motif in the tcr-alpha enhancer	[motifs in the TCR-alpha enhancers]	0.0	5	1	1	1
97801	1710	of bind GM5	[of binding GM5]	0.0	3	1	1	1
97802	1710	AP1 regulator	[AP1 regulator]	0.0	2	1	1	1
97803	1710	il-2 production by means influence NFAT-1	[IL-2 production by means influencing NFAT-1]	0.0	6	1	1	1
97804	1710	expression of negative n17rac	[Expression of negative N17Rac]	0.0	4	1	1	1
97805	1710	human leukemia cell line u937	[human leukemia cell line U937]	0.0	5	1	1	1
97806	1710	cd11a+, cd13lo, cd15lo,	[CD11a+, CD13lo, CD15lo,]	0.0	3	1	1	1
97807	1710	down-regulation in hypercortisolemic patient	[down-regulation in hypercortisolemic patients]	0.0	4	1	1	1
97808	1710	anti-early antigen ea anti-viral antigen vca	[anti-early antigen EA anti-viral antigen VCA]	0.0	6	1	1	1
97809	1710	co-cultured bronchial cell	[co-cultured bronchial cells]	0.0	3	1	1	1
97810	1710	pair of CD2 mab capable	[pairs of CD2 mAbs capable]	0.0	5	1	1	1
97811	1710	provide one explanation	[providing one explanation]	0.0	3	1	1	1
97812	1710	putative regulator of myeloid differentiation	[putative regulator of myeloid differentiation]	0.0	5	1	1	1
97813	1710	Class histocompatibility	[Class histocompatibility]	0.0	2	1	1	1
97814	1710	rapidak measurement of CIF	[rapid, measurement of CIF]	0.0	4	1	1	1
97815	1710	response to u/ml interleukin-2 time	[response to U/ml interleukin-2 time]	0.0	5	1	1	1
97816	1710	weak T	[weaker T]	0.0	2	1	1	1
97817	1710	sensitive activate pathway	[sensitive activating pathway]	0.0	3	1	1	1
97818	1710	DNA topoisomerase ii inhibitor	[DNA topoisomerase II inhibitors]	0.0	4	1	1	1
97819	1710	contain a promoter,	[containing an promoter,]	0.0	3	1	1	1
97820	1710	novel b-cell-specific transcription factor	[novel B-cell-specific transcription factor]	0.0	4	1	1	1
97821	1710	approaches,	[approaches,]	0.0	1	1	1	1
97822	1710	effect in disease	[effects in diseases]	0.0	3	1	1	1
97823	1710	pre-B leukemia all	[pre-B leukemia ALL]	0.0	3	1	1	1
97824	1710	response to other stimuli,	[response to other stimuli,]	0.0	4	1	1	1
97825	1710	nf-kappab -contain extract	[NF-kappaB -containing extract]	0.0	3	1	1	1
97826	1710	6tg1.1 icr27tk.3	[6TG1.1 ICR27TK.3]	0.0	2	1	1	1
97827	1710	T cell receptor-beta gene rearrangement	[T cell receptor-beta gene rearrangements]	0.0	5	1	1	1
97828	1710	stimulation rest T lymphocyte	[stimulation resting T lymphocytes]	0.0	4	1	1	1
97829	1710	complexity due to difference	[complexity due to differences]	0.0	4	1	1	1
97830	1710	involve response	[involving responses]	0.0	2	1	1	1
97831	1710	factor determine specific gene activation	[factor determining specific gene activation]	0.0	5	1	1	1
97832	1710	regulation of proenkephalin by JunD	[regulation of proenkephalin by JunD]	0.0	5	1	1	1
97833	1710	R-276 to alanine	[R-276 to alanine]	0.0	3	1	1	1
97834	1710	percent of isolated fragment	[percent of isolated fragments]	0.0	4	1	1	1
97835	1710	polyacrylamide gel electrophoresis	[polyacrylamide gel electrophoresis]	0.0	3	2	2	1
97836	1710	lymphocytic system	[lymphocytic systems]	0.0	2	1	1	1
97837	1710	effect on mcp-1 expression	[effect on MCP-1 expression]	0.0	4	1	1	1
97838	1710	peripheral blood T lymphoblast	[peripheral blood T lymphoblasts]	0.0	4	2	2	1
97839	1710	Pterin	[Pterin]	0.0	1	1	1	1
97840	1710	expression in x ;autosome translocation	[expression in X ;autosome translocations]	0.0	5	1	1	1
97841	1710	interaction of steroid -receptor complex	[interaction of steroid -receptor complexes]	0.0	5	1	1	1
97842	1710	modulate intracellular calcium	[modulating intracellular calcium]	0.0	3	1	1	1
97843	1710	hl60 cell binding	[HL60 cell binding]	0.0	3	1	1	1
97844	1710	provide the immediate early transactivator bzlf1	[providing the immediate early transactivator BZLF1]	0.0	6	1	1	1
97845	1710	activity of protease	[activity of proteases]	0.0	3	1	1	1
97846	1710	unicellular-unilineage culture	[Unicellular-unilineage cultures]	0.0	2	1	1	1
97847	1710	balance between positive regulatory mechanism	[balance between positive regulatory mechanisms]	0.0	5	1	1	1
97848	1710	action CPRE at -49/41	[action CPRE at -49/-41,]	0.0	4	1	1	1
97849	1710	anoxia/reoxygenation-induced neutrophil adherence	[anoxia/reoxygenation-induced neutrophil adherence]	0.0	3	1	1	1
97850	1710	ng/ml endogenous tbp-1	[ng/ml endogenous TBP-1]	0.0	3	1	1	1
97851	1710	mutation in the DRE sequence	[mutations in the DRE sequence]	0.0	5	1	1	1
97852	1710	xy sex reversal	[XY sex reversal]	0.0	3	1	1	1
97853	1710	CD95L promoter sequence	[CD95L promoter sequence]	0.0	3	1	1	1
97854	1710	blastogenesis	[blastogenesis]	0.0	1	1	1	1
97855	1710	evaluate epithelium of normal with cf	[evaluating epithelium of normals with CF]	0.0	6	1	1	1
97856	1710	2 receptor expression	[2 receptor expression]	0.0	3	1	1	1
97857	1710	extent the kD factor	[extent the kD factor]	0.0	4	1	1	1
97858	1710	human squamous cell carcinoma	[human squamous cell carcinomas]	0.0	4	2	2	1
97859	1710	strong decrease in the translocation	[strong decrease in the translocation]	0.0	5	1	1	1
97860	1710	stat1 binding	[STAT1 binding]	0.0	2	1	1	1
97861	1710	one purpose	[One purpose]	0.0	2	1	1	1
97862	1710	murine immunoglobulin heavy-chain	[murine immunoglobulin heavy-chain]	0.0	3	1	1	1
97863	1710	receptor characteristic on monocyte	[receptor characteristics on monocytes]	0.0	4	1	1	1
97864	1710	distal nuclear factor (NF)-AT proximal NF-AT	[distal nuclear factor (NF)-AT proximal NF-AT]	0.0	6	1	1	1
97865	1710	cis-acting dominant negative regulatory effect	[cis-acting dominant negative regulatory effect]	0.0	5	1	1	1
97866	1710	alteration in signal transduction element	[alterations in signal transduction elements]	0.0	5	1	1	1
97867	1710	system CNS	[system CNS]	0.0	2	3	3	1
97868	1710	mean values:	[mean values:]	0.0	2	1	1	1
97869	1710	depletion of neutrophil	[depletion of neutrophils]	0.0	3	1	1	1
97870	1710	-C-C	[-C-C]	0.0	1	1	1	1
97871	1710	result from research groups.	[results from research groups.]	0.0	4	1	1	1
97872	1710	HIV infection	[HIV infection]	0.0	2	1	1	1
97873	1710	comparative mapping	[Comparative mapping]	0.0	2	1	1	1
97874	1710	b1/	[B1/]	0.0	1	1	1	1
97875	1710	genome homologue of other herpesviruse	[genome homologues of other herpesviruses]	0.0	5	1	1	1
97876	1710	cellular abnormality	[cellular abnormalities]	0.0	2	1	1	1
97877	1710	stimulation b	[Stimulation B]	0.0	2	1	1	1
97878	1710	association through the a 187	[association through the aa 187]	0.0	5	1	1	1
97879	1710	bhlh motif contiguous	[bHLH motif contiguous]	0.0	3	1	1	1
97880	1710	efficient binding	[efficient binding]	0.0	2	2	2	1
97881	1710	substSp23	[substSp23]	0.0	1	1	1	1
97882	1710	works? even with a therapy specific	[works? Even with a therapy specific]	0.0	6	1	1	1
97883	1710	ebv-negative B-lymphoma cell line	[EBV-negative B-lymphoma cell lines]	0.0	4	1	1	1
97884	1710	cell cycle analysis in T cell	[Cell cycle analysis in T cells]	0.0	6	1	1	1
97885	1710	/cell for type i	[/cell for type I]	0.0	4	1	1	1
97886	1710	radiometric assay	[radiometric assay]	0.0	2	1	1	1
97887	1710	receptor present in extract	[receptor present in extracts]	0.0	4	1	1	1
97888	1710	culture of rat pancrea	[cultures of rat pancreas]	0.0	4	1	1	1
97889	1710	fusion of the e2a gene	[fusion of the E2A genes]	0.0	5	1	1	1
97890	1710	transcriptional regulator of differentiation	[transcriptional regulator of differentiation]	0.0	4	1	1	1
97891	1710	high increase	[highest increase]	0.0	2	1	1	1
97892	1710	treatment of human peripheral blood lymphocyte	[Treatment of human peripheral blood lymphocytes]	0.0	6	1	1	1
97893	1710	positively regulatory function	[positively regulatory function]	0.0	3	1	1	1
97894	1710	impaired myelopoiesis	[Impaired myelopoiesis]	0.0	2	1	1	1
97895	1710	endoglycosidase h	[endoglycosidase H]	0.0	2	1	1	1
97896	1710	T cell activation factor	[T cell activation factor]	0.0	4	1	1	1
97897	1710	patient with idiopathic myelofibrosis	[patients with idiopathic myelofibrosis]	0.0	4	1	1	1
97898	1710	SLP-76 a Grb2-associated tyrosine protein	[SLP-76 a Grb2-associated tyrosine protein]	0.0	5	1	1	1
97899	1710	GC asthma	[GC asthma]	0.0	2	1	1	1
97900	1710	morphological analysis	[morphological analysis]	0.0	2	1	1	1
97901	1710	human intraspecy hybrid	[human intraspecies hybrids]	0.0	3	1	1	1
97902	1710	oxidative-stress sensor	[oxidative-stress sensor]	0.0	2	1	1	1
97903	1710	small apolar substitution alpha-methyl, 11 alpha-fluoromethyl	[Small apolar substitutions alpha-methyl, 11 alpha-fluoromethyl]	0.0	6	1	1	1
97904	1710	signal in human erythroid precursor	[signaling in human erythroid precursors]	0.0	5	1	1	1
97905	1710	anti- tnf-alpha inhibition	[anti- TNF-alpha inhibition]	0.0	3	1	1	1
97906	1710	binding of tax to element 1	[Binding of Tax to element 1]	0.0	6	1	1	1
97907	1710	contain il-6-responsive gene element	[containing IL-6-responsive gene elements]	0.0	4	1	1	1
97908	1710	alteration in cis-acting regulatory sequence	[alterations in cis-acting regulatory sequences]	0.0	5	1	1	1
97909	1710	percentage of molecule	[percentage of molecules]	0.0	3	1	1	1
97910	1710	activator of the il-2 gene	[activators of the IL-2 gene]	0.0	5	1	1	1
97911	1710	addition, il-2 factor	[addition, IL-2 factors]	0.0	3	1	1	1
97912	1710	distinct family of transcriptional factor	[distinct families of transcriptional factors]	0.0	5	1	1	1
97913	1710	purification of this early b-cell factor	[Purification of this early B-cell factor]	0.0	6	1	1	1
97914	1710	IL-4 T cell	[IL-4 T cells]	0.0	3	1	1	1
97915	1710	TNF-alpha translocation primarily of p50-p65	[TNF-alpha translocation primarily of p50-p65]	0.0	5	1	1	1
97916	1710	analysis of only signal molecule	[analysis of only signaling molecule]	0.0	5	1	1	1
97917	1710	conjunctiva of patient with vkc	[conjunctiva of patients with VKC]	0.0	5	1	1	1
97918	1710	eosinophilia such as asthma	[eosinophilia such as asthma]	0.0	4	1	1	1
97919	1710	noncycling b cell	[noncycling B cells]	0.0	3	1	1	1
97920	1710	23 cases,	[23 cases,]	0.0	2	1	1	1
97921	1710	observation on the regulation	[observations on the regulation]	0.0	4	1	1	1
97922	1710	similar kinetic of c-jun induction	[Similar kinetics of c-jun induction]	0.0	5	1	1	1
97923	1710	three lac+clone	[three Lac+clones]	0.0	2	1	1	1
97924	1710	BFU-E cell	[BFU-E cells]	0.0	2	1	1	1
97925	1710	consensus element consistent with gene expression	[consensus elements consistent with gene expression]	0.0	6	1	1	1
97926	1710	1 ng/ml endogenous tbp-1	[1 ng/ml endogenous TBP-1]	0.0	4	1	1	1
97927	1710	ebf mouse	[EBF mice]	0.0	2	1	1	1
97928	1710	nf-kappab -dependent in rheumatoid synovial tissue	[NF-kappaB -dependent in rheumatoid synovial tissue]	0.0	6	1	1	1
97929	1710	typical sedimentation coefficient	[typical sedimentation coefficient]	0.0	3	1	1	1
97930	1710	lineage (day	[lineages (days]	0.0	2	1	1	1
97931	1710	dichloromethylene diphosphonate	[dichloromethylene diphosphonate]	0.0	2	1	1	1
97932	1710	factor-kappa b nf-kappab tnf-alpha release	[factor-kappa B NF-kappaB TNF-alpha release]	0.0	5	1	1	1
97933	1710	unusual case of a woman	[unusual case of a woman]	0.0	5	1	1	1
97934	1710	CD30 a member	[CD30 a member]	0.0	3	1	1	1
97935	1710	basal induction of transcription	[basal induction of transcription]	0.0	4	1	1	1
97936	1710	expression integrin on neutrophil granulocyte	[expression integrins on neutrophil granulocytes]	0.0	5	1	1	1
97937	1710	b5a	[B5A]	0.0	1	1	1	1
97938	1710	gsh pool	[GSH pool]	0.0	2	1	1	1
97939	1710	group difference	[group differences]	0.0	2	1	1	1
97940	1710	target for early B-cell factor	[target for early B-cell factor]	0.0	5	1	1	1
97941	1710	stimulation of neutrophil with chemoattract fmlp	[Stimulation of neutrophils with chemoattractants FMLP]	0.0	6	1	1	1
97942	1710	different no synthase (nos) isoform	[different NO synthase (NOS) isoforms]	0.0	5	1	1	1
97943	1710	1.1 kb id-3l transcript	[1.1 kb Id-3L transcript]	0.0	4	1	1	1
97944	1710	transcription signal	[transcription signaling]	0.0	2	1	1	1
97945	1710	various breakpoint on chromosome 11	[various breakpoints on chromosome 11]	0.0	5	1	1	1
97946	1710	limit the duration	[limiting the duration]	0.0	3	1	1	1
97947	1710	resident tissue	[resident tissue]	0.0	2	1	1	1
97948	1710	result in activation of regulatory factor	[resulting in activation of regulatory factors]	0.0	6	1	1	1
97949	1710	site of transcription	[sites of transcription]	0.0	3	1	1	1
97950	1710	adipocyte differentiation through peroxisome receptor gamma	[adipocyte differentiation through peroxisome receptor gamma]	0.0	6	1	1	1
97951	1710	severe phenotypes.	[severe phenotypes.]	0.0	2	1	1	1
97952	1710	feature of a immunodeficiency disease XCID	[features of a immunodeficiency disease XCID]	0.0	6	1	1	1
97953	1710	upstream factor-kappa b	[upstream factor-kappa B]	0.0	3	1	1	1
97954	1710	predisposition for atopy	[predisposition for atopy]	0.0	3	1	1	1
97955	1710	carry b27 antigen	[carrying B27 antigen]	0.0	3	1	1	1
97956	1710	anti-mbp antibody	[anti-MBP antibody]	0.0	2	1	1	1
97957	1710	inhibition of no production by L-N-monomethyl-arginine	[Inhibition of NO production by L-N-monomethyl-arginine]	0.0	6	1	1	1
97958	1710	thyroid fragment	[thyroid fragments]	0.0	2	1	1	1
97959	1710	staining for estrogen receptor	[staining for estrogen receptors]	0.0	4	1	1	1
97960	1710	condition occur	[condition occurring]	0.0	2	1	1	1
97961	1710	class ii major gene	[class II major genes]	0.0	4	1	1	1
97962	1710	unique inhibitory role of NFAT1	[unique inhibitory role of NFAT1]	0.0	5	1	1	1
97963	1710	cyclooxygenase/5-lipoxygenase compound	[cyclooxygenase/5-lipoxygenase compound]	0.0	2	1	1	1
97964	1710	positive region PRRI	[positive regions PRRI]	0.0	3	1	1	1
97965	1710	extensive cell infiltration	[extensive cell infiltration]	0.0	3	1	1	1
97966	1710	subunit the b2 isoform	[subunit the B2 isoform]	0.0	4	1	1	1
97967	1710	however, three order potent	[however, three orders potent]	0.0	4	1	1	1
97968	1710	expression of the map phosphatase mkp-1	[Expression of the MAP phosphatase MKP-1]	0.0	6	1	1	1
97969	1710	ubiquitinylating enzyme	[ubiquitinylating enzymes]	0.0	2	1	1	1
97970	1710	role in tnf-alpha expression	[role in TNF-alpha expression]	0.0	4	1	1	1
97971	1710	modulation subsequent to	[modulations subsequent to]	0.0	3	1	1	1
97972	1710	gata-1 allele,	[GATA-1 allele,]	0.0	2	1	1	1
97973	1710	activator protein-1 factor il-6	[activator protein-1 factor IL-6]	0.0	4	1	1	1
97974	1710	cortisol feedback resistance	[cortisol feedback resistance]	0.0	3	1	1	1
97975	1710	class complex -negative cell line	[class complex -negative cell lines]	0.0	5	1	1	1
97976	1710	tissue transglutaminase	[tissue transglutaminase]	0.0	2	1	1	1
97977	1710	kilobase (kb)	[kilobase (kb)]	0.0	2	1	1	1
97978	1710	residual gr	[residual GR]	0.0	2	1	1	1
97979	1710	additional DNA segment	[additional DNA segments]	0.0	3	1	1	1
97980	1710	however, recent study	[However, recent studies]	0.0	3	1	1	1
97981	1710	activation in lipopolysaccharide u937 cell	[Activation in lipopolysaccharide U937 cells]	0.0	5	1	1	1
97982	1710	expression of responsiveness	[expression of responsiveness]	0.0	3	1	1	1
97983	1710	role of the molecular chaperone hsp90	[roles of the molecular chaperone hsp90]	0.0	6	1	1	1
97984	1710	antituberculous immune response	[antituberculous immune response]	0.0	3	1	1	1
97985	1710	macrophage by bacterial lipopolysaccharide	[macrophages by bacterial lipopolysaccharide]	0.0	4	1	1	1
97986	1710	approximately 1 P; binding of heterodimer	[approximately 1 h; binding of heterodimers]	0.0	6	1	1	1
97987	1710	interleukin-3 (il-3)-	[interleukin-3 (IL-3)-]	0.0	2	1	1	1
97988	1710	healthy volunteer without psychiatric disorder	[healthy volunteers without psychiatric disorders]	0.0	5	1	1	1
97989	1710	suggest direct control	[suggesting direct control]	0.0	3	1	1	1
97990	1710	HHV-6 (gs) cDNA clone pcd41	[HHV-6 (GS) cDNA clone pCD41]	0.0	5	1	1	1
97991	1710	use of staining	[use of staining]	0.0	3	1	1	1
97992	1710	lucigenin-enhanced cl	[lucigenin-enhanced CL]	0.0	2	1	1	1
97993	1710	lead to stress-dependent activation	[leading to stress-dependent activation]	0.0	4	1	1	1
97994	1710	tax-responsive element tre1 necessary	[Tax-responsive element TRE1 necessary]	0.0	4	1	1	1
97995	1710	ikappab cytoplasmic inhibitor	[IkappaB cytoplasmic inhibitors]	0.0	3	1	1	1
97996	1710	activation by N-terminal deletion	[activation by N-terminal deletions]	0.0	4	1	1	1
97997	1710	age-related decline in chymotryptic activity	[age-related decline in chymotryptic activity]	0.0	5	1	1	1
97998	1710	form of nuclear factor	[forms of nuclear factor]	0.0	4	1	1	1
97999	1710	specific type of myeloid leukemia	[specific type of myeloid leukemia]	0.0	5	1	1	1
98000	1710	family of nf-at factor	[family of NF-AT factors]	0.0	4	1	1	1
98001	1710	major class transactivator	[major class transactivator]	0.0	3	1	1	1
98002	1710	patient with myeloid leukemia AML	[patients with myeloid leukemia AML]	0.0	5	1	1	1
98003	1710	concentration in the presence	[concentration in the presence]	0.0	4	1	1	1
98004	1710	contain nuclear factor kappab complex	[containing nuclear factor kappaB complexes]	0.0	5	1	1	1
98005	1710	use deoxyribonuclease	[using deoxyribonuclease]	0.0	2	1	1	1
98006	1710	promoter manner;	[promoter manner;]	0.0	2	1	1	1
98007	1710	advantage of pbsct	[advantages of PBSCT]	0.0	3	1	1	1
98008	1710	human leucocyte in 12 woman	[human leucocytes in 12 women]	0.0	5	1	1	1
98009	1710	dna-binding study evidence for complex formation	[DNA-binding studies evidence for complex formation]	0.0	6	1	1	1
98010	1710	involve the sphingomyelinase of the membrane	[involving the sphingomyelinase of the membrane]	0.0	6	1	1	1
98011	1710	Finally, chromosomal localization	[Finally, chromosomal localization]	0.0	3	1	1	1
98012	1710	dual action of retinoic acid blockade	[Dual action of retinoic acid blockade]	0.0	6	1	1	1
98013	1710	assembly of multiple protein	[assembly of multiple proteins]	0.0	4	1	1	1
98014	1710	fibrosarcoma malignant histiocytoma	[fibrosarcoma malignant histiocytoma]	0.0	3	1	1	1
98015	1710	few depressed subject down-regulated Bmax	[fewer depressed subjects down-regulated Bmax]	0.0	5	1	1	1
98016	1710	level of 5s rrna	[levels of 5S rRNA]	0.0	4	1	1	1
98017	1710	expression of CD3	[expression of CD3]	0.0	3	1	1	1
98018	1710	expression of CD2	[expression of CD2]	0.0	3	1	1	1
98019	1710	major cytoplasmic inhibitor	[major cytoplasmic inhibitor]	0.0	3	1	1	1
98020	1710	4-fold increase in adherence	[4-fold increase in adherence]	0.0	4	1	1	1
98021	1710	expression of CD4	[expression of CD4]	0.0	3	1	1	1
98022	1710	dt-40 b cell	[DT-40 B cells]	0.0	3	1	1	1
98023	1710	hamster ovary cell express human alphaiibbeta3	[hamster ovary cells expressing human alphaIIbbeta3]	0.0	6	1	1	1
98024	1710	chi b complex formation	[chi B complex formation]	0.0	4	1	1	1
98025	1710	macrophage migration inhibitory related protein	[Macrophage migration inhibitory related protein]	0.0	5	1	1	1
98026	1710	morphologically distinct subset with translocation	[morphologically distinct subsets with translocation]	0.0	5	1	1	1
98027	1710	study with mutant	[studies with mutants]	0.0	3	1	1	1
98028	1710	tissue lymphoma (19 of 45	[tissue lymphoma (19 of 45]	0.0	5	1	1	1
98029	1710	blood lymphocytes,	[blood lymphocytes,]	0.0	2	1	1	1
98030	1710	chromosomal translocation result	[Chromosomal translocation resulting]	0.0	3	1	1	1
98031	1710	C5a stimulation of blood monocyte	[C5a stimulation of blood monocytes]	0.0	5	1	1	1
98032	1710	tetrahydrocortisol 13.3 mg/24h;	[tetrahydrocortisol 13.3 mg/24h;]	0.0	3	1	1	1
98033	1710	first trimester human pregnancy	[first trimester human pregnancies]	0.0	4	1	1	1
98034	1710	protein localization	[protein localization]	0.0	2	1	1	1
98035	1710	mechanism in atl-derived cell line	[mechanism in ATL-derived cell lines]	0.0	5	1	1	1
98036	1710	woman 10 second	[women 10 second]	0.0	3	1	1	1
98037	1710	activity of the gland	[activity of the glands]	0.0	4	1	1	1
98038	1710	nf-kappab (level of p50	[NF-kappaB (levels of p50]	0.0	4	1	1	1
98039	1710	nevertheless, relatively high, concentration	[Nevertheless, relatively high, concentrations]	0.0	4	1	1	1
98040	1710	nfat-1 nuclear factor	[NFAT-1 nuclear factor]	0.0	3	1	1	1
98041	1710	6 year	[6 years]	0.0	2	1	1	1
98042	1710	specific lysis	[specific lysis]	0.0	2	1	1	1
98043	1710	induction in t-cell transfectant	[Induction in T-cell transfectants]	0.0	4	1	1	1
98044	1710	interaction with cell TEC	[interaction with cells TEC]	0.0	4	1	1	1
98045	1710	interstitial collagenase a metalloproteinase	[Interstitial collagenase a metalloproteinase]	0.0	4	1	1	1
98046	1710	tyrosine residue stat3	[tyrosine residues Stat3]	0.0	3	1	1	1
98047	1710	effect on promoter occupation	[effect on promoter occupation]	0.0	4	1	1	1
98048	1710	regulation of receptor in mononuclear cell	[Regulation of receptors in mononuclear cells]	0.0	6	1	1	1
98049	1710	sensitive monitoring of residual disease	[sensitive monitoring of residual disease]	0.0	5	1	1	1
98050	1710	protein species	[protein species]	0.0	2	1	1	1
98051	1710	member of the NFAT factor	[members of the NFAT factor]	0.0	5	1	1	1
98052	1710	adhesion molecule expression in human venous	[adhesion molecule expression in human venous]	0.0	6	1	1	1
98053	1710	treatment with microm dexamethasone	[treatment with microM dexamethasone]	0.0	4	1	1	1
98054	1710	two inhibitor kinase upstream of ERK1/2	[two inhibitors kinase upstream of ERK1/2]	0.0	6	1	1	1
98055	1710	activation in CD4 T cell	[activation in CD4 T cells]	0.0	5	1	1	1
98056	1710	oxidoreductive regulation	[Oxidoreductive regulation]	0.0	2	1	1	1
98057	1710	increase in the ikappabalpha level	[increase in the IkappaBalpha levels]	0.0	5	1	1	1
98058	1710	biological effect of isoflavone	[biological effects of isoflavones]	0.0	4	1	1	1
98059	1710	factor-kappaB -dependent induction evidence	[factor-kappaB -dependent induction evidence]	0.0	4	1	1	1
98060	1710	mutation lbf4- binding site	[Mutations LBF4- binding sites]	0.0	4	1	1	1
98061	1710	requirement for event	[requirement for events]	0.0	3	1	1	1
98062	1710	intact mononuclear leukocyte HML	[intact mononuclear leukocytes HML]	0.0	4	1	1	1
98063	1710	rna polymerase gene expression	[RNA polymerase gene expression]	0.0	4	1	1	1
98064	1710	exchange of invariant chain-derived peptide	[exchange of invariant chain-derived peptides]	0.0	5	1	1	1
98065	1710	hybridize	[hybridizes]	0.0	1	1	1	1
98066	1710	major immediate-early protein	[major immediate-early protein]	0.0	3	1	1	1
98067	1710	repressive effect of GRalpha	[repressive effects of GRalpha]	0.0	4	1	1	1
98068	1710	analysis of regulatory gene expression	[analysis of regulatory gene expression]	0.0	5	1	1	1
98069	1710	thin-layer chromatography	[thin-layer chromatography]	0.0	2	1	1	1
98070	1710	block the translocation of NF-kappa b	[blocking the translocation of NF-kappa B]	0.0	6	1	1	1
98071	1710	3 h with mAb l243	[3 h with mAb L243]	0.0	5	1	1	1
98072	1710	aa2	[AA2]	0.0	1	1	1	1
98073	1710	serine kinase target	[serine kinase target]	0.0	3	1	1	1
98074	1710	neutralize anti- il-6 antibody	[neutralizing anti- IL-6 antibody]	0.0	4	1	1	1
98075	1710	UAS1 binding site	[UAS1 binding sites]	0.0	3	1	1	1
98076	1710	blood NK cell genistein	[blood NK cells genistein]	0.0	4	1	1	1
98077	1710	dependence on disease	[dependence on disease]	0.0	3	1	1	1
98078	1710	cytosine at position binding	[cytosine at position binding]	0.0	4	1	1	1
98079	1710	dimer of calcineurin a	[dimer of calcineurin A]	0.0	4	1	1	1
98080	1710	functionally important b co-activator	[functionally important B co-activator]	0.0	4	1	1	1
98081	1710	transcript for osteoprotegerin ligand OPGL	[Transcripts for osteoprotegerin ligand OPGL]	0.0	5	1	1	1
98082	1710	age young than years,	[age younger than years,]	0.0	4	1	1	1
98083	1710	Eighteen hirsute patient	[Eighteen hirsute patients]	0.0	3	1	1	1
98084	1710	antigen staining	[antigen staining]	0.0	2	1	1	1
98085	1710	iodide staining	[iodide staining]	0.0	2	1	1	1
98086	1710	T. pallidum lipoprotein Tpp47	[T. pallidum lipoproteins Tpp47]	0.0	4	1	1	1
98087	1710	granular Sudan b	[granular Sudan B]	0.0	3	1	1	1
98088	1710	one sp1 cleavage	[one SP1 cleavage]	0.0	3	1	1	1
98089	1710	18 protein	[18 proteins]	0.0	2	1	1	1
98090	1710	normal peripheral blood T cell	[normal peripheral blood T cells]	0.0	5	1	1	1
98091	1710	IL-3 factor dna-binding complex in eosinophil	[IL-3 factor DNA-binding complexes in eosinophils]	0.0	6	1	1	1
98092	1710	rather a process unique to stimulus	[rather a process unique to stimuli]	0.0	6	1	1	1
98093	1710	class compounds,	[class compounds,]	0.0	2	1	1	1
98094	1710	low failure rate	[low failure rate]	0.0	3	1	1	1
98095	1710	evidence for disomy	[evidence for disomy]	0.0	3	1	1	1
98096	1710	TCL1 oncogene on chromosome	[TCL1 oncogene on chromosome]	0.0	4	1	1	1
98097	1710	rapid apoptosis	[rapid apoptosis]	0.0	2	1	1	1
98098	1710	human diploid fibroblast	[human diploid fibroblasts]	0.0	3	1	1	1
98099	1710	appearance of a nuclear factor	[appearance of an nuclear factor]	0.0	5	1	1	1
98100	1710	10 hiv-infected patient	[10 HIV-infected patients]	0.0	3	1	1	1
98101	1710	lymphoma plasmacytoid	[lymphoma plasmacytoid]	0.0	2	1	1	1
98102	1710	contrast, tg receptor	[contrast, TG receptors]	0.0	3	1	1	1
98103	1710	overt hypo hyper thyroidism	[overt hypo hyper thyroidism]	0.0	4	1	1	1
98104	1710	t-cell protein	[T-cell protein]	0.0	2	2	2	1
98105	1710	human ebv include tumorigenesis.	[human EBV including tumorigenesis.]	0.0	4	1	1	1
98106	1710	hiv-1 nf-kb probe	[HIV-1 NF-kB probe]	0.0	3	1	1	1
98107	1710	significant twofold increase	[significant twofold increase]	0.0	3	1	1	1
98108	1710	other SR patient	[other SR patients]	0.0	3	1	1	1
98109	1710	(1) inactivate substitution	[(1) inactivating substitutions]	0.0	3	1	1	1
98110	1710	population of immature cell	[population of immature cells]	0.0	4	1	1	1
98111	1710	adhesion of u937 cell to ec	[adhesion of U937 cells to EC]	0.0	6	1	1	1
98112	1710	basal blood cell	[Basal blood cell]	0.0	3	1	1	1
98113	1710	cytokine -modulate activity a potential	[Cytokine -modulating activity a potential]	0.0	5	1	1	1
98114	1710	element necessary alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Elements necessary alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	5	1	1	1
98115	1710	add	[adding]	0.0	1	1	1	1
98116	1710	three Japanese child	[three Japanese children]	0.0	3	1	1	1
98117	1710	heterozygous mutation	[heterozygous mutation]	0.0	2	1	1	1
98118	1710	specific transcription factor complex	[specific transcription factor complexes]	0.0	4	1	1	1
98119	1710	modification of multiple protein kinase	[modification of multiple protein kinases]	0.0	5	1	1	1
98120	1710	part, through signal transduction pathway	[part, through signal transduction pathways]	0.0	5	1	1	1
98121	1710	binding protein CsA	[binding proteins CsA]	0.0	3	1	1	1
98122	1710	transactivate activity of the GCR	[transactivating activity of the GCR]	0.0	5	1	1	1
98123	1710	factor-kappaB inhibitor IkappaB-alphaS32/36A	[factor-kappaB inhibitor IkappaB-alphaS32/36A]	0.0	3	1	1	1
98124	1710	subunits, p50	[subunits, p50]	0.0	2	2	2	1
98125	1710	concentration of two ald	[concentrations of two ALD]	0.0	4	1	1	1
98126	1710	heterogeneous pattern at the level	[heterogeneous pattern at the level]	0.0	5	1	1	1
98127	1710	immunodeficiency virus type 1 hiv- replication	[immunodeficiency virus type 1 HIV- replication]	0.0	6	1	1	1
98128	1710	binding of ifn-gamma to eosinophil	[binding of IFN-gamma to eosinophils]	0.0	5	1	1	1
98129	1710	early growth response-1 gene	[early growth response-1 gene]	0.0	4	1	1	1
98130	1710	-CD8	[-CD8]	0.0	1	1	1	1
98131	1710	24-hydroxylated metabolite polar	[24-hydroxylated metabolites polar]	0.0	3	1	1	1
98132	1710	20 copy	[20 copies]	0.0	2	1	1	1
98133	1710	kappa dna-binding activity a report.	[kappa DNA-binding activity a report.]	0.0	5	1	1	1
98134	1710	most likely identical proteins, differ	[most likely identical proteins, differing]	0.0	5	1	1	1
98135	1710	utilize such vector	[utilizing such vectors]	0.0	3	1	1	1
98136	1710	expression of the different isoform	[expression of the different isoforms]	0.0	5	1	1	1
98137	1710	monolayer of umbilical vein cell	[monolayers of umbilical vein cells]	0.0	5	1	1	1
98138	1710	autosomal sex reversal map 130 kb	[autosomal sex reversal map 130 kb]	0.0	6	1	1	1
98139	1710	downregulation in a plasmacytoma	[downregulation in a plasmacytoma]	0.0	4	1	1	1
98140	1710	kilobasis of 5'-upstream sequence	[kilobases of 5'-upstream sequence]	0.0	4	1	1	1
98141	1710	tyrosine -phosphorylated stat1 protein	[tyrosine -phosphorylated stat1 proteins]	0.0	4	1	1	1
98142	1710	hypothesis, expression	[hypothesis, expression]	0.0	2	1	1	1
98143	1710	aids Epstein-Barr virus	[AIDS Epstein-Barr virus]	0.0	3	1	1	1
98144	1710	stimulation with ligand	[stimulation with ligand]	0.0	3	1	1	1
98145	1710	reactive oxygen intermediate after stress	[reactive oxygen intermediates after stress]	0.0	5	1	1	1
98146	1710	hormonal metabolic status after conservative surgery	[Hormonal metabolic status after conservative surgery]	0.0	6	1	1	1
98147	1710	isre	[ISRE]	0.0	1	1	1	1
98148	1710	Ran GTP -dependent association	[Ran GTP -dependent association]	0.0	4	1	1	1
98149	1710	synergy between tal1	[synergy between TAL1]	0.0	3	1	1	1
98150	1710	specific marker for leukemia	[specific marker for leukemia]	0.0	4	1	1	1
98151	1710	AIR-1 locus function	[AIR-1 locus function]	0.0	3	1	1	1
98152	1710	nfat factor	[NFAT factor]	0.0	2	1	1	1
98153	1710	glucocorticoid on endogenous peripheral function	[glucocorticoids on endogenous peripheral function]	0.0	5	1	1	1
98154	1710	pathway with sensitivity to Bcl-2	[pathways with sensitivity to Bcl-2]	0.0	5	1	1	1
98155	1710	namely, the double-positive (dp) CD4	[namely, the double-positive (DP) CD4]	0.0	5	1	1	1
98156	1710	rat muscle cell vsmc	[rat muscle cells VSMCs]	0.0	4	1	1	1
98157	1710	dna-binding activity of NF-kappa b	[DNA-binding activity of NF-kappa B]	0.0	5	1	1	1
98158	1710	12 normal woman age.	[12 normal women age.]	0.0	4	1	1	1
98159	1710	Intratracheal instillation of IL-6	[Intratracheal instillation of IL-6]	0.0	4	1	1	1
98160	1710	potential role of IL-1 beta	[potential role of IL-1 beta]	0.0	5	1	1	1
98161	1710	trigger of effector function	[triggering of effector function]	0.0	4	1	1	1
98162	1710	CONCLUSION: cytomegalovirus immediate gene product expression	[CONCLUSION: Cytomegalovirus immediate gene products expression]	0.0	6	1	1	1
98163	1710	ng/mL), interleukin-3	[ng/mL), interleukin-3]	0.0	2	1	1	1
98164	1710	enhancement transactivate protein tax	[enhancement transactivating protein Tax]	0.0	4	1	1	1
98165	1710	clone CIITA allele	[clone CIITA alleles]	0.0	3	1	1	1
98166	1710	epithelial cell response to infection	[epithelial cell responses to infection]	0.0	5	1	1	1
98167	1710	B-cell gene expression	[B-cell gene expression]	0.0	3	1	1	1
98168	1710	inhibition on bone morphogenetic protein-	[inhibition on bone morphogenetic protein-]	0.0	5	1	1	1
98169	1710	cytoplasmic 105k precursor	[cytoplasmic 105K precursor]	0.0	3	1	1	1
98170	1710	differentiation to macrophage	[differentiation to macrophages]	0.0	3	1	1	1
98171	1710	level only 2 17	[levels only 2 17]	0.0	4	1	1	1
98172	1710	formation of mitogen-inducible complex	[formation of mitogen-inducible complexes]	0.0	4	1	1	1
98173	1710	mrna pAT 133	[mRNA pAT 133]	0.0	3	1	1	1
98174	1710	(il)-1 beta	[(IL)-1 beta]	0.0	2	1	1	1
98175	1710	inhibition by anti- VCAM-1 antibody 1g11	[Inhibition by anti- VCAM-1 antibody 1G11]	0.0	6	1	1	1
98176	1710	signal function	[signaling functions]	0.0	2	1	1	1
98177	1710	2 expression in t-cell acute leukemia	[2 expression in T-cell acute leukemia]	0.0	6	1	1	1
98178	1710	strong increase in urinary thf	[strong increase in urinary THF]	0.0	5	1	1	1
98179	1710	IL3 gene	[IL3 gene]	0.0	2	1	1	1
98180	1710	determine factor	[determining factor]	0.0	2	1	1	1
98181	1710	fk506 consistent with the hypothesis	[FK506 consistent with the hypothesis]	0.0	5	1	1	1
98182	1710	acid response element	[acid response element]	0.0	3	1	1	1
98183	1710	regulate human apoptosis	[regulating human apoptosis]	0.0	3	1	1	1
98184	1710	1 alpha,25-(OH)2D3 analog	[1 alpha,25-(OH)2D3 analogs]	0.0	3	1	1	1
98185	1710	350 case of acute leukemia	[350 cases of acute leukemia]	0.0	5	1	1	1
98186	1710	vivo substrate	[vivo substrate]	0.0	2	1	1	1
98187	1710	erythroid mrna level	[erythroid mRNA level]	0.0	3	1	1	1
98188	1710	assay conditions-concentration of the ligand	[assay conditions-concentration of the ligand]	0.0	5	1	1	1
98189	1710	normal mature b lymphocyte	[normal mature B lymphocytes]	0.0	4	1	1	1
98190	1710	age-associated decline in T cell	[age-associated decline in T cells]	0.0	5	1	1	1
98191	1710	absence alpha1	[absence alpha1]	0.0	2	1	1	1
98192	1710	pcr-based technique	[PCR-based techniques]	0.0	2	1	1	1
98193	1710	several th2 cytokine	[several Th2 cytokines]	0.0	3	1	1	1
98194	1710	patient with micrograms/day for 7 day	[patients with micrograms/day for 7 days)]	0.0	6	1	1	1
98195	1710	EBNA-2 -responsive lmp-1 promoter	[EBNA-2 -responsive LMP-1 promoter]	0.0	4	1	1	1
98196	1710	phosphorylation of Jak kinase	[phosphorylation of Jak kinases]	0.0	4	1	1	1
98197	1710	accompanying gssg deficiency	[accompanying GSSG deficiency]	0.0	3	1	1	1
98198	1710	elimination of cell	[elimination of cells]	0.0	3	1	1	1
98199	1710	viral activity	[viral activities]	0.0	2	1	1	1
98200	1710	leukocyte in endometrium	[leukocytes in endometrium]	0.0	3	1	1	1
98201	1710	b agent	[B agents]	0.0	2	1	1	1
98202	1710	block induction	[blocking induction]	0.0	2	1	1	1
98203	1710	functional domain for receptor coupling	[functional domain for receptor coupling]	0.0	5	1	1	1
98204	1710	strong tyrosine phosphorylation	[strong tyrosine phosphorylation]	0.0	3	1	1	1
98205	1710	soluble form	[soluble forms]	0.0	2	1	1	1
98206	1710	lineage in leukemia hl-60 cell	[lineage in leukemia HL-60 cells]	0.0	5	1	1	1
98207	1710	have g3 tumor with margin	[having G3 tumors with margins]	0.0	5	1	1	1
98208	1710	expression of gene in monocyte	[expression of genes in monocytes]	0.0	5	1	1	1
98209	1710	several gene in cell	[several genes in cells]	0.0	4	1	1	1
98210	1710	stimulation of the tcr	[stimulation of the TCR]	0.0	4	1	1	1
98211	1710	receptor/ characteristic	[receptor/s characteristics]	0.0	2	1	1	1
98212	1710	control proliferation	[controlling proliferation]	0.0	2	1	1	1
98213	1710	use concentration of native peptide ligand	[using concentrations of native peptide ligand]	0.0	6	1	1	1
98214	1710	deletion of the Y box	[deletion of the Y box]	0.0	5	1	1	1
98215	1710	amp	[amp]	0.0	1	1	1	1
98216	1710	number of GCR-beta cell	[number of GCR-beta cells]	0.0	4	1	1	1
98217	1710	bank tl20/12r sun lamp	[bank TL20/12RS sun lamps]	0.0	4	1	1	1
98218	1710	anorexic patient aged 16-27 years,	[anorexic patients aged 16-27 years,]	0.0	5	1	1	1
98219	1710	such as failure during sepsis	[such as failure during sepsis]	0.0	5	1	1	1
98220	1710	comprehensive analysis of tissues,	[comprehensive analysis of tissues,]	0.0	4	1	1	1
98221	1710	rank induction	[RANK induction]	0.0	2	1	1	1
98222	1710	CCACC site	[CCACC site]	0.0	2	1	1	1
98223	1710	gene amplification	[gene amplification]	0.0	2	1	1	1
98224	1710	cd34(+) stem/progenitor cell	[CD34(+) stem/progenitor cells]	0.0	3	1	1	1
98225	1710	mab clb-cd28/1	[mAb CLB-CD28/1]	0.0	2	1	1	1
98226	1710	polyadenylated rna	[polyadenylated RNA]	0.0	2	1	1	1
98227	1710	other mitogen-inducible transcription factor	[other mitogen-inducible transcription factors]	0.0	4	1	1	1
98228	1710	specific proteasome inhibitor z-lll-h	[specific proteasome inhibitor Z-LLL-H]	0.0	4	1	1	1
98229	1710	EBV protein transactivator	[EBV protein transactivator]	0.0	3	1	1	1
98230	1710	high concentration of 125d3	[higher concentrations of 1,25D3]	0.0	4	1	1	1
98231	1710	myelogenous leukemia CML cell	[myelogenous leukemia CML cells]	0.0	4	1	1	1
98232	1710	relationship between receptor level	[relationship between receptor levels]	0.0	4	1	1	1
98233	1710	two paf receptor antagonist	[two PAF receptor antagonists]	0.0	4	1	1	1
98234	1710	ape	[apes]	0.0	1	5	5	1
98235	1710	message-destabilizing element	[message-destabilizing elements]	0.0	2	1	1	1
98236	1710	G0S2 a member	[G0S2 a member]	0.0	3	1	1	1
98237	1710	role in the cytokine activation	[role in the cytokine activation]	0.0	5	1	1	1
98238	1710	sequence element DRE to +240	[sequence element DRE to +240]	0.0	5	1	1	1
98239	1710	gc at concentration	[GC at concentrations]	0.0	3	1	1	1
98240	1710	activity of NFkappaB	[activities of NFkappaB]	0.0	3	1	1	1
98241	1710	fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
98242	1710	coordinate induction of this genes.	[coordinate induction of these genes.]	0.0	5	1	1	1
98243	1710	CRF patient 6.04 fmol/10(6) cell	[CRF patients 6.04 fmol/10(6) cells]	0.0	5	1	1	1
98244	1710	characterization of the gene encode LBR	[Characterization of the gene encoding LBR]	0.0	6	1	1	1
98245	1710	dense lymphocyte infiltration a role	[dense lymphocyte infiltration a role]	0.0	5	1	1	1
98246	1710	regulation of nuclear t3r	[regulation of nuclear T3R]	0.0	4	1	1	1
98247	1710	c3a	[C3a]	0.0	1	1	1	1
98248	1710	replicate as a result	[replicating as a result]	0.0	4	1	1	1
98249	1710	characterization of end	[Characterization of end]	0.0	3	1	1	1
98250	1710	combine gene transfer	[combining gene transfer]	0.0	3	1	1	1
98251	1710	moreover, TNF-alpha hiv-1 repeat LTR transcription	[Moreover, TNF-alpha HIV-1 repeat LTR transcription]	0.0	6	1	1	1
98252	1710	normal migration response	[normal migration response]	0.0	3	1	1	1
98253	1710	Complementary DNA encode a tfiid protein	[Complementary DNA encoding a TFIID protein]	0.0	6	1	1	1
98254	1710	possible variable	[possible variable]	0.0	2	1	1	1
98255	1710	Differential induction (ifn)-inducible protein differentiation	[Differential induction (IFN)-inducible protein differentiation]	0.0	5	1	1	1
98256	1710	molecular analysis of immunodeficiency virus	[Molecular analysis of immunodeficiency virus]	0.0	5	1	1	1
98257	1710	suggest a distinct role	[suggesting a distinct role]	0.0	4	1	1	1
98258	1710	mutation of the gamma chain gene	[mutation of the gamma chain gene]	0.0	6	1	1	1
98259	1710	signal for initiation.	[signals for initiation.]	0.0	3	1	1	1
98260	1710	pattern of tissue specificity of expression	[patterns of tissue specificity of expression]	0.0	6	1	1	1
98261	1710	three copy of repeat	[three copies of repeats]	0.0	4	1	1	1
98262	1710	Stable expression of tax	[Stable expression of Tax]	0.0	4	1	1	1
98263	1710	cellular equivalent c-myb	[cellular equivalent c-myb]	0.0	3	1	1	1
98264	1710	leukemia 1- respectively,	[leukemia 1- respectively,]	0.0	3	1	1	1
98265	1710	aspect of effects.	[aspects of effects.]	0.0	3	1	1	1
98266	1710	evidence for change by tcdd	[evidence for changes by TCDD]	0.0	5	1	1	1
98267	1710	hcmv in tumorigenesis	[HCMV in tumorigenesis]	0.0	3	1	1	1
98268	1710	g0/g1 switch gene g0s gene	[G0/G1 switch genes G0S genes]	0.0	5	1	1	1
98269	1710	10 ng/ml	[10 ng/ml]	0.0	2	1	1	1
98270	1710	dna-binding hmg box closely related	[DNA-binding HMG box closely related]	0.0	5	1	1	1
98271	1710	hepatocyte in cultures.	[hepatocytes in cultures.]	0.0	3	1	1	1
98272	1710	fourfold high 12-lipoxygenase activity	[fourfold higher 12-lipoxygenase activity]	0.0	4	1	1	1
98273	1710	asa	[ASA]	0.0	1	1	1	1
98274	1710	mode after administration	[mode after administration]	0.0	3	1	1	1
98275	1710	Locus control	[Locus control]	0.0	2	1	1	1
98276	1710	activation of STAT3 by interferon-gamma	[activation of STAT3 by interferon-gamma]	0.0	5	1	1	1
98277	1710	nfatp a dna-binding protein	[NFATp a DNA-binding protein]	0.0	4	1	1	1
98278	1710	acid protein	[acid protein]	0.0	2	1	1	1
98279	1710	induction of il-5 mrna	[Induction of IL-5 mRNA]	0.0	4	1	1	1
98280	1710	organisation exon of 132, 112	[organisation exons of 132, 112]	0.0	5	1	1	1
98281	1710	expression of DNA	[Expression of DNA]	0.0	3	1	1	1
98282	1710	asn	[Asn]	0.0	1	1	1	1
98283	1710	stimulatory mab BW	[stimulatory mAb BW]	0.0	3	1	1	1
98284	1710	mediate directly the release	[mediating directly the release]	0.0	4	1	1	1
98285	1710	factor (NF)-AT AP-1/Octamer UPS	[factor (NF)-AT AP-1/Octamer UPS]	0.0	4	1	1	1
98286	1710	ap-1 by CD28	[AP-1 by CD28]	0.0	3	1	1	1
98287	1710	acid,	[acid,]	0.0	1	1	1	1
98288	1710	New World primate nwp	[New World primate NWP]	0.0	4	1	1	1
98289	1710	expression of the Epstein-Barr virus EBV	[Expression of the Epstein-Barr virus EBV]	0.0	6	1	1	1
98290	1710	further, complete activation	[Further, complete activation]	0.0	3	1	1	1
98291	1710	virus with sp1 site	[virus with Sp1 sites]	0.0	4	1	1	1
98292	1710	acid-	[acid-]	0.0	1	1	1	1
98293	1710	viable mature cell a phenotype	[viable mature cells a phenotype]	0.0	5	1	1	1
98294	1710	two distinct activity on T cell	[two distinct activities on T cells]	0.0	6	1	1	1
98295	1710	pre-b-cell	[pre-B-cell]	0.0	1	1	1	1
98296	1710	Ile50 pbmc	[Ile50 PBMC]	0.0	2	1	1	1
98297	1710	tyrosine within the amino-terminal region	[tyrosine within the amino-terminal region]	0.0	5	1	1	1
98298	1710	other pathophysiological condition	[other pathophysiological conditions]	0.0	3	1	1	1
98299	1710	cellular systems,	[cellular systems,]	0.0	2	1	1	1
98300	1710	factor bind not 4681	[Factors binding nt 4681]	0.0	4	1	1	1
98301	1710	basal factor interact	[basal factors interacting]	0.0	3	1	1	1
98302	1710	t-cell leukemia ATL	[T-cell leukemia ATL]	0.0	3	1	1	1
98303	1710	cells, nuclear factor	[cells, nuclear factors]	0.0	3	1	1	1
98304	1710	regulation of cell adhesion molecule-1	[regulation of cell adhesion molecule-1]	0.0	5	1	1	1
98305	1710	vdre -binding protein	[VDRE -binding protein]	0.0	3	1	1	1
98306	1710	D3 135(oh)2d3 receptor VDR	[D3 1,25(OH)2D3 receptor VDR]	0.0	4	1	1	1
98307	1710	Granulocyte-macrophage factor gm-csf	[Granulocyte-macrophage factor GM-CSF]	0.0	3	1	1	1
98308	1710	b lymphocyte culture	[B lymphocyte cultures]	0.0	3	1	1	1
98309	1710	low proliferative activity,	[low proliferative activity,]	0.0	3	1	1	1
98310	1710	5'-Rapid amplification	[5'-Rapid amplification]	0.0	2	1	1	1
98311	1710	Negative regulation of human interleukin gene	[Negative regulation of human interleukin gene]	0.0	6	1	1	1
98312	1710	transcript the major coat protein	[Transcripts the major coat protein]	0.0	5	1	1	1
98313	1710	25 h (viability	[25 h (viability]	0.0	3	1	1	1
98314	1710	oxidoreductive pathway for the activity	[oxidoreductive pathway for the activity]	0.0	5	1	1	1
98315	1710	rela p65 subunit	[RelA p65 subunit]	0.0	3	2	2	1
98316	1710	7.0 kb	[7.0 kb]	0.0	2	1	1	1
98317	1710	involvement by a recurrent translocation	[involvement by a recurrent translocation]	0.0	5	1	1	1
98318	1710	cross-competition mobility shift assay	[cross-competition mobility shift assays]	0.0	4	1	1	1
98319	1710	epithelial cell response	[epithelial cell responses]	0.0	3	1	1	1
98320	1710	Eed homeotic gene expression	[Eed homeotic gene expression]	0.0	4	1	1	1
98321	1710	inactive allele in cell line	[inactive alleles in cell lines]	0.0	5	1	1	1
98322	1710	IL-6 downregulation	[IL-6 downregulation]	0.0	2	1	1	1
98323	1710	cell nuclear differentiation antigen	[cell nuclear differentiation antigen]	0.0	4	1	1	1
98324	1710	d-associated	[D-associated]	0.0	1	1	1	1
98325	1710	Epstein-Barr virus cp promoter	[Epstein-Barr virus Cp promoter]	0.0	4	1	1	1
98326	1710	adrenal gland,y	[adrenal gland,]	0.0	2	1	1	1
98327	1710	control of apoptosis in thymoma cell	[control of apoptosis in thymoma cells]	0.0	6	1	1	1
98328	1710	use stat5 binding site	[using STAT5 binding site]	0.0	4	1	1	1
98329	1710	rna,	[RNA,]	0.0	1	1	1	1
98330	1710	wide range of effect	[wide range of effects]	0.0	4	1	1	1
98331	1710	uracil-DNA	[uracil-DNA]	0.0	1	2	2	1
98332	1710	accumulation of c-fo messenger rna (mrna)	[accumulation of c-fos messenger RNA (mRNA)]	0.0	6	1	1	1
98333	1710	7 mol/L	[7 mol/L]	0.0	2	1	1	1
98334	1710	absence of region	[absence of regions]	0.0	3	1	1	1
98335	1710	oncology group study	[oncology group study]	0.0	3	1	1	1
98336	1710	affinity il-2 receptor	[affinity IL-2 receptors]	0.0	3	1	1	1
98337	1710	rheumatoid fluid monocyte /macrophage	[rheumatoid fluid monocytes /macrophages]	0.0	4	1	1	1
98338	1710	BHA a phenolic, antioxidant	[BHA a phenolic, antioxidant]	0.0	4	1	1	1
98339	1710	microgram fluticasone propionate nasal spray	[micrograms fluticasone propionate nasal spray]	0.0	5	1	1	1
98340	1710	Recently, group	[Recently, groups]	0.0	2	1	1	1
98341	1710	29% decrease	[29% decrease]	0.0	2	1	1	1
98342	1710	(hsf2)	[(HSF2)]	0.0	1	1	1	1
98343	1710	Simon observations).	[Simon observations).]	0.0	2	1	1	1
98344	1710	sequester bhlh target in heterodimer	[sequestering bHLH targets in heterodimers]	0.0	5	1	1	1
98345	1710	nm alpha,25-dihydroxyvitamin D3	[nM alpha,25-dihydroxyvitamin D3]	0.0	3	1	1	1
98346	1710	only -73 bp	[only -73 bp]	0.0	3	1	1	1
98347	1710	negative modulator (1-231)-mediated nf-kappab activation	[negative modulator (1-231)-mediated NF-kappaB activation]	0.0	5	1	1	1
98348	1710	T cell with phorbol ester	[T cells with phorbol esters]	0.0	5	1	1	1
98349	1710	five protein p52	[Five proteins p52]	0.0	3	1	1	1
98350	1710	circularization	[Circularization]	0.0	1	1	1	1
98351	1710	localization of Nef	[localization of Nef]	0.0	3	1	1	1
98352	1710	peptide rrkykqii	[peptide RRKYKQII]	0.0	2	1	1	1
98353	1710	mrna display reverse transcriptase pcr ddpcr	[mRNA display reverse transcriptase PCR DDPCR]	0.0	6	1	1	1
98354	1710	amide-containing amino acid	[amide-containing amino acids]	0.0	3	1	1	1
98355	1710	SIT in jurkat cell	[SIT in Jurkat cells]	0.0	4	1	1	1
98356	1710	infection of Epstein-Barr virus b cell	[infection of Epstein-Barr virus B cells]	0.0	6	1	1	1
98357	1710	males,	[males,]	0.0	1	1	1	1
98358	1710	blood mononuclear cell of three	[blood mononuclear cells of three]	0.0	5	1	1	1
98359	1710	production type 1	[production type 1]	0.0	3	1	1	1
98360	1710	human myeloid cells.	[human myeloid cells.]	0.0	3	1	1	1
98361	1710	SCL locus	[SCL locus]	0.0	2	1	1	1
98362	1710	numerous gene fall	[numerous genes falling]	0.0	3	1	1	1
98363	1710	site mutation of this gata site	[site mutation of these GATA sites]	0.0	6	1	1	1
98364	1710	gene include interleukin-2 IL-2	[genes including interleukin-2 IL-2]	0.0	4	1	1	1
98365	1710	ig chain enhancer	[Ig chain enhancer]	0.0	3	3	3	1
98366	1710	immature T cell in	[immature T cells in]	0.0	4	1	1	1
98367	1710	C3a enhancement lps-	[C3a enhancement LPS-]	0.0	3	1	1	1
98368	1710	generation of receptor	[generation of receptors]	0.0	3	1	1	1
98369	1710	ifn-alpha signal	[IFN-alpha signaling]	0.0	2	1	1	1
98370	1710	second A/R challenge	[second A/R challenge]	0.0	3	1	1	1
98371	1710	include ifn-gamma	[including IFN-gamma]	0.0	2	1	1	1
98372	1710	control reactvation	[controlling reactvation]	0.0	2	1	1	1
98373	1710	cell line Mono Mac	[cell line Mono Mac]	0.0	4	2	2	1
98374	1710	activate hiv-1	[activating HIV-1]	0.0	2	1	1	1
98375	1710	cell adhesive	[cell adhesive]	0.0	2	1	1	1
98376	1710	nf- cle0 gamma	[NF- CLE0 gamma]	0.0	3	1	1	1
98377	1710	receptor alpha ligand WY	[receptor alpha ligand WY]	0.0	4	1	1	1
98378	1710	factor from 10(-12) to m elevation	[factor from 10(-12) to M elevation]	0.0	6	1	1	1
98379	1710	calcium potency as vd	[calcium potency as VD]	0.0	4	1	1	1
98380	1710	sensitive chronic leukemia patient	[sensitive chronic leukemia patients]	0.0	4	1	1	1
98381	1710	cell mimick cell growth	[cells mimicking cell growth]	0.0	4	1	1	1
98382	1710	nm, respectively, in monocyte	[nM, respectively, in monocytes]	0.0	4	1	1	1
98383	1710	blood with PGG-Glucan	[blood with PGG-Glucan]	0.0	3	1	1	1
98384	1710	suppressor protein	[suppressor proteins]	0.0	2	1	1	1
98385	1710	Jak tyrosine kinase T	[Jak tyrosine kinases T]	0.0	4	1	1	1
98386	1710	active ingredient	[active ingredients]	0.0	2	1	1	1
98387	1710	protein possibly, responsive	[proteins possibly, responsive]	0.0	3	1	1	1
98388	1710	orally)	[orally)]	0.0	1	1	1	1
98389	1710	calcium mobilization a component	[calcium mobilization an component]	0.0	4	1	1	1
98390	1710	database	[databases]	0.0	1	1	1	1
98391	1710	change in protein tyrosine phosphorylation	[changes in protein tyrosine phosphorylation]	0.0	5	1	1	1
98392	1710	comedo versus noncomedo	[comedo versus noncomedo]	0.0	3	1	1	1
98393	1710	implications, in particular, in relation	[implications, in particular, in relation]	0.0	5	1	1	1
98394	1710	p65 phosphorylation	[p65 phosphorylation]	0.0	2	1	1	1
98395	1710	sp1 cleavage product.	[SP1 cleavage product.]	0.0	3	1	1	1
98396	1710	maintain the level	[maintaining the level]	0.0	3	1	1	1
98397	1710	suggest a bioinactivation mechanism	[suggesting an bioinactivation mechanism]	0.0	4	1	1	1
98398	1710	potential inhibitor	[potential inhibitor]	0.0	2	1	1	1
98399	1710	i.e., defect	[i.e., defects]	0.0	2	1	1	1
98400	1710	mineralocorticoid (primary	[mineralocorticoids (primary]	0.0	2	1	1	1
98401	1710	IL-4 -secret	[IL-4 -secreting]	0.0	2	1	1	1
98402	1710	endogenous thyroid hormone	[endogenous thyroid hormone]	0.0	3	1	1	1
98403	1710	express a series of GM-CSFRalpha mutant	[expressing a series of GM-CSFRalpha mutants]	0.0	6	1	1	1
98404	1710	quantity of a number of metabolite	[quantities of a number of metabolites]	0.0	6	1	1	1
98405	1710	cytolytic machinery	[cytolytic machinery]	0.0	2	1	1	1
98406	1710	exposure to shear	[exposure to shear]	0.0	3	1	1	1
98407	1710	promoter function of the 5' region	[Promoter function of the 5' region]	0.0	6	1	1	1
98408	1710	stage-specific expression	[stage-specific expression]	0.0	2	3	3	1
98409	1710	uptake with chronic failure	[uptake with chronic failure]	0.0	4	1	1	1
98410	1710	(sh)2	[(SH)2]	0.0	1	1	1	1
98411	1710	high responsiveness	[higher responsiveness]	0.0	2	1	1	1
98412	1710	deletion by cloning	[deletion by cloning]	0.0	3	1	1	1
98413	1710	abovesaid	[abovesaid]	0.0	1	1	1	1
98414	1710	include inhibition	[including inhibition]	0.0	2	1	1	1
98415	1710	acute myeloid blast use virus	[acute myeloid blasts using virus]	0.0	5	1	1	1
98416	1710	pharmacologic control of expression	[Pharmacologic control of expression]	0.0	4	1	1	1
98417	1710	occurrence in a subset	[occurrence in a subset]	0.0	4	1	1	1
98418	1710	set with residue kinetic analysis	[sets with residues Kinetic analysis]	0.0	5	1	1	1
98419	1710	human ifngr1 deletion	[human IFNGR1 deletions]	0.0	3	1	1	1
98420	1710	/drip	[/DRIP]	0.0	1	1	1	1
98421	1710	such step	[such steps]	0.0	2	1	1	1
98422	1710	breakpoint 11 range to q23	[breakpoints 11 ranging to q23]	0.0	5	1	1	1
98423	1710	incomplete androgen insensitivity	[incomplete androgen insensitivity]	0.0	3	1	1	1
98424	1710	result hybrids.	[resulting hybrids.]	0.0	2	1	1	1
98425	1710	Southern blot hybridisation	[Southern blot hybridisation]	0.0	3	1	1	1
98426	1710	tyrosine phosphorylation in htlv-i(+) t-cell line	[tyrosine phosphorylation in HTLV-I(+) T-cell lines]	0.0	6	1	1	1
98427	1710	extract from B	[extracts from B]	0.0	3	1	1	1
98428	1710	transactivation type tax protein	[Transactivation type Tax proteins]	0.0	4	1	1	1
98429	1710	potent factor for granulocyte	[potent factor for granulocytes]	0.0	4	1	1	1
98430	1710	genomic probe	[genomic probes]	0.0	2	1	1	1
98431	1710	adenovirus,	[adenovirus,]	0.0	1	1	1	1
98432	1710	blood mononuclear cell from seventeen patient	[blood mononuclear cells from seventeen patients]	0.0	6	1	1	1
98433	1710	TNF interleukin-1	[TNF interleukin-1]	0.0	2	1	1	1
98434	1710	mutant receptor	[mutant receptors]	0.0	2	1	1	1
98435	1710	bcc	[BCCs]	0.0	1	1	1	1
98436	1710	TNF promoter GGGGCTGTCCC	[TNF promoter GGGGCTGTCCC]	0.0	3	1	1	1
98437	1710	aldosterone on sodium in patient	[aldosterone on sodium in patients]	0.0	5	1	1	1
98438	1710	transcription factor Egr-1	[transcription factor Egr-1]	0.0	3	2	2	1
98439	1710	least sevenfold)	[least sevenfold)]	0.0	2	1	1	1
98440	1710	factor (NF)-kappaB binding site	[factor (NF)-kappaB binding sites]	0.0	4	1	1	1
98441	1710	myeloid differentiation a novel experimental model	[myeloid differentiation a novel experimental model]	0.0	6	1	1	1
98442	1710	ability -express fibroblastic human cell	[abilities -expressing fibroblastic human cells]	0.0	5	1	1	1
98443	1710	one abnormality, the majority	[one abnormality, the majority]	0.0	4	1	1	1
98444	1710	triepoxide with potent immunosuppressive property	[triepoxide with potent immunosuppressive properties]	0.0	5	1	1	1
98445	1710	year: 4.1 versus 14.1	[year: 4.1 versus 14.1]	0.0	4	1	1	1
98446	1710	antigen capsid antigen vca	[antigen capsid antigen VCA]	0.0	4	1	1	1
98447	1710	ca2+ response to h2o2	[Ca2+ responses to H2O2]	0.0	4	1	1	1
98448	1710	target in the development	[target in the development]	0.0	4	1	1	1
98449	1710	analysis of erythroblast	[Analysis of erythroblasts]	0.0	3	1	1	1
98450	1710	therapy the number of patient	[therapy the number of patients]	0.0	5	1	1	1
98451	1710	show a 5- increase	[showing a 5- increase]	0.0	4	1	1	1
98452	1710	factor bind not 4681 to 4701	[Factors binding nt 4681 to 4701]	0.0	6	1	1	1
98453	1710	U1 culture	[U1 cultures]	0.0	2	1	1	1
98454	1710	overexpression of inactive mutant	[overexpression of inactive mutants]	0.0	4	1	1	1
98455	1710	event for T cell proliferation	[event for T cell proliferation]	0.0	5	1	1	1
98456	1710	vaginal host	[vaginal host]	0.0	2	1	1	1
98457	1710	constitutive expression in primary monocyte	[constitutive expression in primary monocytes]	0.0	5	1	1	1
98458	1710	indicate due to a factor	[indicating due to a factor]	0.0	5	1	1	1
98459	1710	high malignancy human melanoma	[high malignancy human melanomas]	0.0	4	1	1	1
98460	1710	contribution of ebv	[contribution of EBV]	0.0	3	1	1	1
98461	1710	few tumor cell	[few tumor cells]	0.0	3	1	1	1
98462	1710	site of chromosomal damage	[site of chromosomal damage]	0.0	4	1	1	1
98463	1710	previous datum from fibroblast	[previous data from fibroblasts]	0.0	4	1	1	1
98464	1710	release of chemotactic cytokine	[release of chemotactic cytokines]	0.0	4	1	1	1
98465	1710	level of chromosome translocation	[level of chromosome translocations]	0.0	4	1	1	1
98466	1710	25 cell carcinoma	[25 cell carcinomas]	0.0	3	1	1	1
98467	1710	stimulation of relb translocation by CD40	[stimulation of RelB translocation by CD40]	0.0	6	1	1	1
98468	1710	myeloid patient	[myeloid patients]	0.0	2	1	1	1
98469	1710	IP-10 promoter region	[IP-10 promoter region]	0.0	3	1	1	1
98470	1710	expression in human jurkat-t cell	[expression in human Jurkat-T cells]	0.0	5	1	1	1
98471	1710	subunits; genes, nfkb1 nfkb2 rela(p65)	[subunits; genes, NFKB1 NFKB2 RelA(p65)]	0.0	5	1	1	1
98472	1710	remodeling of tissue rich	[remodeling of tissues rich]	0.0	4	1	1	1
98473	1710	contrast, engagement by class MHC/superantigen	[contrast, engagement by class MHC/superantigen]	0.0	5	1	1	1
98474	1710	domain with eight transmembrane segment	[domain with eight transmembrane segments]	0.0	5	1	1	1
98475	1710	rapid activation of NF-kappa b	[rapid activation of NF-kappa B]	0.0	5	1	1	1
98476	1710	receptor binding in peripheral leucocyte	[receptor binding in peripheral leucocytes]	0.0	5	1	1	1
98477	1710	differential expression of the class isotype	[differential expression of the class isotypes]	0.0	6	1	1	1
98478	1710	response by a LTR	[response by a LTR]	0.0	4	1	1	1
98479	1710	variety of tissues,	[variety of tissues,]	0.0	3	1	1	1
98480	1710	human triiodothyronine plasma clearance rate	[human triiodothyronine plasma clearance rates]	0.0	5	1	1	1
98481	1710	stimulation with gc at concentration	[Stimulation with GC at concentrations]	0.0	5	1	1	1
98482	1710	clonal b cell line	[clonal B cell lines]	0.0	4	1	1	1
98483	1710	PB1 element	[PB1 element]	0.0	2	1	1	1
98484	1710	process affect transcription factor	[process affecting transcription factors]	0.0	4	1	1	1
98485	1710	gene result	[gene resulting]	0.0	2	1	1	1
98486	1710	NF-kappaB activation mechanism	[NF-kappaB activation mechanism]	0.0	3	1	1	1
98487	1710	factor as a stimulus, ganglioside	[factor as a stimulus, gangliosides]	0.0	5	1	1	1
98488	1710	suggest a common target for protein	[suggesting a common target for proteins]	0.0	6	1	1	1
98489	1710	numerous growth factor	[numerous growth factors]	0.0	3	1	1	1
98490	1710	second translocation adjacent	[second translocation adjacent]	0.0	3	1	1	1
98491	1710	differentiate myeloid cell	[differentiating myeloid cells]	0.0	3	1	1	1
98492	1710	expression of inhibitor b alpha	[expression of inhibitor B alpha]	0.0	5	1	1	1
98493	1710	gene regulatory molecule	[gene regulatory molecules]	0.0	3	1	1	1
98494	1710	CD3-stimulated peripheral T lymphocyte	[CD3-stimulated peripheral T lymphocytes]	0.0	4	1	1	1
98495	1710	highlight putative novel loci relevant	[highlighting putative novel loci relevant]	0.0	5	1	1	1
98496	1710	catalyze the step in the generation	[catalyzing the step in the generation]	0.0	6	1	1	1
98497	1710	selenium inhibition	[Selenium inhibition]	0.0	2	1	1	1
98498	1710	mediator of inflammation	[mediators of inflammation]	0.0	3	1	1	1
98499	1710	interferon (ifn) factor	[interferon (IFN) factors]	0.0	3	1	1	1
98500	1710	(sh2)	[(SH2)]	0.0	1	2	2	1
98501	1710	control cells, class	[control cells, class]	0.0	3	1	1	1
98502	1710	leiomyosarcoma liposarcoma 5).	[leiomyosarcoma liposarcoma 5).]	0.0	3	1	1	1
98503	1710	cytokine interleukin-8	[cytokine interleukin-8]	0.0	2	1	1	1
98504	1710	endothelial activation a direct mechanism	[endothelial activation A direct mechanism]	0.0	5	1	1	1
98505	1710	cytokine interleukin-7	[cytokine interleukin-7]	0.0	2	1	1	1
98506	1710	ets-like factor present	[ETS-like factors present]	0.0	3	1	1	1
98507	1710	target sequence of c-jun	[target sequence of c-jun]	0.0	4	1	1	1
98508	1710	transcription from gene	[transcription from genes]	0.0	3	1	1	1
98509	1710	molecule of SIT	[molecule of SIT]	0.0	3	1	1	1
98510	1710	bko	[BKO]	0.0	1	1	1	1
98511	1710	other hla-b8-restricted epitope	[other HLA-B8-restricted epitopes]	0.0	3	1	1	1
98512	1710	express (tcr) region beta-chain family	[expressing (TCR) region beta-chain families]	0.0	5	1	1	1
98513	1710	activation of regulatory protein	[activation of regulatory proteins]	0.0	4	1	1	1
98514	1710	il-2r pathway	[IL-2R pathway]	0.0	2	1	1	1
98515	1710	precursor cell line 32dcl3	[precursor cell line 32Dcl3]	0.0	4	1	1	1
98516	1710	gtp p21ras	[GTP p21ras]	0.0	2	1	1	1
98517	1710	use human cell	[using human cells]	0.0	3	1	1	1
98518	1710	rheumatoid synovial T cell	[rheumatoid synovial T cells]	0.0	4	1	1	1
98519	1710	ras effector molecule	[Ras effector molecules]	0.0	3	1	1	1
98520	1710	treatment of 10	[Treatment of 10]	0.0	3	1	1	1
98521	1710	dominant T lymphocyte response in type	[Dominant T lymphocyte response in type]	0.0	6	1	1	1
98522	1710	essential mediator	[essential mediator]	0.0	2	1	1	1
98523	1710	invariant peptide	[invariant peptides]	0.0	2	1	1	1
98524	1710	induction during a immune response,	[induction during an immune response,]	0.0	5	1	1	1
98525	1710	C3a enhancement	[C3a enhancement]	0.0	2	1	1	1
98526	1710	d10	[D10]	0.0	1	1	1	1
98527	1710	venous blood from healthy donor	[venous blood from healthy donors]	0.0	5	1	1	1
98528	1710	weight variant in human monocyte	[weight variant in human monocytes]	0.0	5	1	1	1
98529	1710	6tg1.1 cell before steroid treatment	[6TG1.1 cells before steroid treatment]	0.0	5	1	1	1
98530	1710	response to stimulus vitamin D3	[response to stimuli vitamin D3]	0.0	5	1	1	1
98531	1710	gene association with eosinophil	[genes association with eosinophils]	0.0	4	1	1	1
98532	1710	bp)	[bp)]	0.0	1	1	1	1
98533	1710	correction for TNF polymorphism	[correction for TNF polymorphisms]	0.0	4	1	1	1
98534	1710	activity in transfection	[activity in transfections]	0.0	3	1	1	1
98535	1710	human t-cell acute lymphoblastic leukemia	[human T-cell acute lymphoblastic leukemia]	0.0	5	1	1	1
98536	1710	site for transcription factor ap1	[sites for transcription factors AP1]	0.0	5	1	1	1
98537	1710	quantification lack of correspondence	[Quantification lack of correspondence]	0.0	4	1	1	1
98538	1710	heterozygosity rate	[heterozygosity rate]	0.0	2	1	1	1
98539	1710	associate signal molecule	[associates signaling molecules]	0.0	3	1	1	1
98540	1710	costimulatory signal to pbl	[costimulatory signals to PBL]	0.0	4	1	1	1
98541	1710	low-potency agonist, have a ec50	[low-potency agonist, having an EC50]	0.0	5	1	1	1
98542	1710	5-aminolevulinate synthase	[5-aminolevulinate synthase]	0.0	2	1	1	1
98543	1710	p50 subunit in EMSAs	[p50 subunits in EMSAs]	0.0	4	1	1	1
98544	1710	human immunodeficiency virus hiv persistence	[human immunodeficiency virus HIV persistence]	0.0	5	2	2	1
98545	1710	C; analysis	[C; analysis]	0.0	2	1	1	1
98546	1710	treatment with desferrioxamine	[treatment with desferrioxamine]	0.0	3	1	1	1
98547	1710	gene contain element	[genes containing elements]	0.0	3	1	1	1
98548	1710	recycling	[recycling]	0.0	1	1	1	1
98549	1710	bpv	[BPV]	0.0	1	1	1	1
98550	1710	high level of inactive p50 homodimer	[high levels of inactive p50 homodimer]	0.0	6	1	1	1
98551	1710	variety of function	[variety of functions]	0.0	3	1	1	1
98552	1710	cd3+/cd4+ T cell nearby to	[CD3+/CD4+ T cells nearby to]	0.0	5	1	1	1
98553	1710	formation of DNA-protein complex	[formation of DNA-protein complexes]	0.0	4	1	1	1
98554	1710	+/cd3+	[+/CD3+]	0.0	1	1	1	1
98555	1710	NF-kappa b pathway of hiv activation	[NF-kappa B pathways of HIV activation]	0.0	6	1	1	1
98556	1710	SMX itself,	[SMX itself,]	0.0	2	1	1	1
98557	1710	arrest this immune response	[arresting this immune response]	0.0	4	1	1	1
98558	1710	early-lytic-cycle protein with homology	[early-lytic-cycle protein with homology]	0.0	4	1	1	1
98559	1710	follow ligand engagement	[following ligand engagement]	0.0	3	1	1	1
98560	1710	copy of the cyclophilin gene	[copies of the cyclophilin gene]	0.0	5	1	1	1
98561	1710	ald T	[ALD T]	0.0	2	1	1	1
98562	1710	membrane cd14 mcd14	[membrane CD14 mCD14]	0.0	3	1	1	1
98563	1710	role in IL-7 proliferation	[role in IL-7 proliferation]	0.0	4	1	1	1
98564	1710	substantial kappa b-binding activity	[substantial kappa B-binding activity]	0.0	4	1	1	1
98565	1710	leukemia (pml)	[leukemia (PML)]	0.0	2	1	1	1
98566	1710	means of separate transduction pathway	[means of separate transduction pathways]	0.0	5	1	1	1
98567	1710	exogenous expression of the isoform	[exogenous expression of the isoforms]	0.0	5	1	1	1
98568	1710	mutual association	[Mutual association]	0.0	2	1	1	1
98569	1710	recognition T lymphocyte clonotypes: implication	[recognition T lymphocyte clonotypes: implications]	0.0	5	1	1	1
98570	1710	brl	[BRL]	0.0	1	1	1	1
98571	1710	importance of lesion	[importance of lesions]	0.0	3	1	1	1
98572	1710	removal of ml-9	[removal of ML-9]	0.0	3	1	1	1
98573	1710	lymphoma-derived hybridoma pc60	[lymphoma-derived hybridoma PC60]	0.0	3	1	1	1
98574	1710	temperature-induced down-regulation of the glucocorticoid receptor	[Temperature-induced down-regulation of the glucocorticoid receptor]	0.0	6	1	1	1
98575	1710	results: concentration	[RESULTS: concentrations]	0.0	2	1	1	1
98576	1710	archetypal t-cell gene	[archetypal T-cell gene]	0.0	3	1	1	1
98577	1710	induction by binding of platelet	[Induction by binding of platelets]	0.0	5	1	1	1
98578	1710	sensitivity to other, non-cross-resisting agent	[sensitivity to other, non-cross-resisting agents]	0.0	5	1	1	1
98579	1710	supershif the complex	[supershifting the complexes]	0.0	3	1	1	1
98580	1710	carry defect	[carrying defect]	0.0	2	1	1	1
98581	1710	expression of interleukin-2 il-2	[expression of interleukin-2 IL-2]	0.0	4	1	1	1
98582	1710	competitive enzyme-linked assay ELISA	[competitive enzyme-linked assay ELISA]	0.0	4	1	1	1
98583	1710	event in early signalling	[event in early signalling]	0.0	4	1	1	1
98584	1710	steady-state level in level	[steady-state levels in levels]	0.0	4	1	1	1
98585	1710	CCAAT/enhancer-binding protein-beta C/EBP-beta binding site	[CCAAT/enhancer-binding protein-beta C/EBP-beta binding site]	0.0	5	1	1	1
98586	1710	little effect on a na+ channel	[little effect on a Na+ channel]	0.0	6	1	1	1
98587	1710	factor 3 beta hnf3 beta	[factor 3 beta HNF3 beta]	0.0	5	1	1	1
98588	1710	expression alpha (tnf-alpha) il-6 rrna	[expression alpha (TNF-alpha) IL-6 mRNAs]	0.0	5	1	1	1
98589	1710	treatment with a variety	[treatment with a variety]	0.0	4	1	1	1
98590	1710	ligand-induced homodimerization of chimeric surface receptor	[ligand-induced homodimerization of chimeric surface receptors]	0.0	6	1	1	1
98591	1710	blot hybridisation	[blot hybridisation]	0.0	2	1	1	1
98592	1710	nuclei of pbl from different donor	[Nuclei of PBL from different donors]	0.0	6	1	1	1
98593	1710	dominant gsk-3beta	[dominant GSK-3beta]	0.0	2	1	1	1
98594	1710	mapping purposes,	[mapping purposes,]	0.0	2	1	1	1
98595	1710	high concentration of wild type peptide	[higher concentrations of wild type peptides]	0.0	6	1	1	1
98596	1710	normal pbmc	[normal PBMC]	0.0	2	1	1	1
98597	1710	monocytic differentiation pathway	[monocytic differentiation pathways]	0.0	3	1	1	1
98598	1710	level in the pathogenesis	[levels in the pathogenesis]	0.0	4	1	1	1
98599	1710	cells, include erythroid precursor	[cells, including erythroid precursors]	0.0	4	1	1	1
98600	1710	allele in early b-lymphoid progenitor	[alleles in early B-lymphoid progenitors]	0.0	5	1	1	1
98601	1710	basis of indirect observations,	[basis of indirect observations,]	0.0	4	1	1	1
98602	1710	addition activate stat3	[addition activating STAT3]	0.0	3	1	1	1
98603	1710	degradation of c-fo	[degradation of c-Fos]	0.0	3	1	1	1
98604	1710	daily resistant	[daily resistant]	0.0	2	1	1	1
98605	1710	threonine domain	[threonine domain]	0.0	2	1	1	1
98606	1710	anti-Class monoclonal antibody	[anti-Class monoclonal antibodies]	0.0	3	1	1	1
98607	1710	center GC formation in the ILFs	[center GC formation in the ILFs]	0.0	6	1	1	1
98608	1710	interleukin-9 receptor	[interleukin-9 receptor]	0.0	2	1	1	1
98609	1710	pml/rar-alpha peptide by APL patient	[pml/RAR-alpha peptides by APL patients]	0.0	5	1	1	1
98610	1710	however, continuous treatment with subcytotoxic concentration	[However, continuous treatments with subcytotoxic concentrations]	0.0	6	1	1	1
98611	1710	activator of factor	[activators of factors]	0.0	3	1	1	1
98612	1710	v-atpase b subunit amplification	[V-ATPase B subunit amplification]	0.0	4	1	1	1
98613	1710	factor 10	[factor 10]	0.0	2	1	1	1
98614	1710	namely activator protein-1 factor	[namely activator protein-1 factor]	0.0	4	1	1	1
98615	1710	potentially novel protein (around kda	[potentially novel proteins (around kDa]	0.0	5	1	1	1
98616	1710	rhythm of receptor in human leukocyte	[rhythm of receptors in human leukocytes]	0.0	6	1	1	1
98617	1710	bun	[BUN]	0.0	1	1	1	1
98618	1710	contain mutation	[containing mutations]	0.0	2	2	2	1
98619	1710	footprint cell	[footprinting cells]	0.0	2	1	1	1
98620	1710	step in cd8+ t-cell activation	[steps in CD8+ T-cell activation]	0.0	5	1	1	1
98621	1710	convert extracellular signal into biochemical event	[converting extracellular signals into biochemical events]	0.0	6	1	1	1
98622	1710	include zebra activity	[including ZEBRA activity]	0.0	3	1	1	1
98623	1710	contain vp16 in a hsv-1 background	[containing VP16 in an HSV-1 background]	0.0	6	1	1	1
98624	1710	depressed patient with disorder	[depressed patients with disorder]	0.0	4	1	1	1
98625	1710	molecule by cell	[molecules by cells]	0.0	3	1	1	1
98626	1710	30%, overexpression	[30%, overexpression]	0.0	2	1	1	1
98627	1710	corresponding in size	[corresponding in size]	0.0	3	1	1	1
98628	1710	extract from this cell	[extracts from these cells]	0.0	4	1	1	1
98629	1710	primarily from the degradation	[primarily from the degradation]	0.0	4	1	1	1
98630	1710	mental illness	[mental illness]	0.0	2	1	1	1
98631	1710	concentration effect of phosphate supplementation	[concentration effect of phosphate supplementation]	0.0	5	1	1	1
98632	1710	hla molecule	[HLA molecule]	0.0	2	1	1	1
98633	1710	epitope peptide-loaded dendritic cell	[epitope peptide-loaded dendritic cells]	0.0	4	1	1	1
98634	1710	human T cell leukemia virus-1	[human T cell leukemia virus-1]	0.0	5	1	1	1
98635	1710	level of immunoglobulin heavy-chain mrna	[levels of immunoglobulin heavy-chain mRNA]	0.0	5	1	1	1
98636	1710	T cell proliferation in mid-late g1	[T cell proliferation in mid-late G1]	0.0	6	1	1	1
98637	1710	mutant Stat3	[mutant Stat3]	0.0	2	1	1	1
98638	1710	study with prolyl isomerase inhibitor	[studies with prolyl isomerase inhibitors]	0.0	5	1	1	1
98639	1710	anti- TNF-alpha hiv-1 long terminal repeat	[anti- TNF-alpha HIV-1 long terminal repeat]	0.0	6	1	1	1
98640	1710	HT-29	[HT-29]	0.0	1	1	1	1
98641	1710	cellular status	[cellular status]	0.0	2	1	1	1
98642	1710	other neotropical primate	[other neotropical primates]	0.0	3	1	1	1
98643	1710	attention in biology	[attention in biology]	0.0	3	1	1	1
98644	1710	present a similarity to a initiator	[presenting a similarity to an initiator]	0.0	6	1	1	1
98645	1710	testing of a set of peptide	[testing of a set of peptides]	0.0	6	1	1	1
98646	1710	strong production of interleukin	[strong production of interleukin]	0.0	4	1	1	1
98647	1710	role in host defense	[role in host defense]	0.0	4	1	1	1
98648	1710	lineage-specific activation by interferon-gamma in neutrophil	[Lineage-specific activation by interferon-gamma in neutrophils]	0.0	6	1	1	1
98649	1710	potential value alter pathologic immune response	[potential value altering pathologic immune responses]	0.0	6	1	1	1
98650	1710	transcription of this carboxylesterase gene	[transcription of this carboxylesterase gene]	0.0	5	1	1	1
98651	1710	lymphocyte of the blood	[lymphocytes of the blood]	0.0	4	1	1	1
98652	1710	prime by cytokine from signal to	[priming by cytokines from signal to]	0.0	6	1	1	1
98653	1710	DEX isoproterenol	[DEX isoproterenol]	0.0	2	1	1	1
98654	1710	type lymphocyte syndrome-associated factor	[type lymphocyte syndrome-associated factor]	0.0	4	1	1	1
98655	1710	great proportion of cd4+	[greater proportion of CD4+]	0.0	4	1	1	1
98656	1710	human T cell leukemia virus-i	[Human T cell leukemia virus-I]	0.0	5	1	1	1
98657	1710	aldosterone binding at a weight	[aldosterone binding at a weight]	0.0	5	1	1	1
98658	1710	phosphatidylethanolamine	[phosphatidylethanolamine]	0.0	1	1	1	1
98659	1710	normal, carrier	[normal, carriers]	0.0	2	1	1	1
98660	1710	antiviral action	[antiviral action]	0.0	2	1	1	1
98661	1710	predictor for the course	[predictor for the course]	0.0	4	1	1	1
98662	1710	membrane protein related	[membrane protein related]	0.0	3	1	1	1
98663	1710	immune response in T cell	[immune response in T cells]	0.0	5	1	1	1
98664	1710	leucocyte in patient with yang-deficiency	[leucocytes in patients with Yang-deficiency]	0.0	5	1	1	1
98665	1710	Interleukin-10 like IL-4	[Interleukin-10 like IL-4]	0.0	3	1	1	1
98666	1710	genotype tt	[genotype tt]	0.0	2	1	1	1
98667	1710	block translocation	[block translocation]	0.0	2	1	1	1
98668	1710	demonstrate a inhibitory process	[demonstrating an inhibitory process]	0.0	4	1	1	1
98669	1710	highlight loci relevant	[highlighting loci relevant]	0.0	3	1	1	1
98670	1710	human immune deficiency virus type hiv-1	[human immune deficiency virus type HIV-1]	0.0	6	1	1	1
98671	1710	210 respectively,	[210 respectively,]	0.0	2	1	1	1
98672	1710	hiv person	[HIV persons]	0.0	2	1	1	1
98673	1710	maturity-onset diabete	[maturity-onset diabetes]	0.0	2	1	1	1
98674	1710	entire mr	[entire MR]	0.0	2	1	1	1
98675	1710	response to TG	[response to TG]	0.0	3	1	1	1
98676	1710	J.M.Hardwick, j.virol.63:3040-3050,	[J.M.Hardwick, J.Virol.63:3040-3050,]	0.0	2	1	1	1
98677	1710	-binding (creb) protein	[-binding (CREB) protein]	0.0	3	1	1	1
98678	1710	reticuloendotheliosis virus long repeat element	[Reticuloendotheliosis virus long repeat elements]	0.0	5	1	1	1
98679	1710	intact gp130 tail	[intact gp130 tail]	0.0	3	1	1	1
98680	1710	component of glucocorticoid-induced cell death	[component of glucocorticoid-induced cell death]	0.0	5	1	1	1
98681	1710	surface plasmon resonance approach	[surface plasmon resonance approach]	0.0	4	1	1	1
98682	1710	selective ability	[selective ability]	0.0	2	1	1	1
98683	1710	domain d1 of CD4	[domain D1 of CD4]	0.0	4	1	1	1
98684	1710	glucocorticoid receptor l753f	[glucocorticoid receptors L753F]	0.0	3	1	1	1
98685	1710	ldl-receptor gene transcription in lymphocyte	[LDL-receptor gene transcription in lymphocytes]	0.0	5	1	1	1
98686	1710	factor-kappaB translocation human monocyte	[factor-kappaB translocation human monocytes]	0.0	4	1	1	1
98687	1710	outcome of syndrome	[outcome of syndromes]	0.0	3	1	1	1
98688	1710	role regulate stat serine phosphorylation	[role regulating STAT serine phosphorylation]	0.0	5	1	1	1
98689	1710	transcript of PEBP2 alpha a	[transcripts of PEBP2 alpha A]	0.0	5	1	1	1
98690	1710	almost all cytokine	[almost all cytokines]	0.0	3	1	1	1
98691	1710	mechanism underlie the translocation	[mechanisms underlying the translocation]	0.0	4	1	1	1
98692	1710	mammary epithelial cell grow	[mammary epithelial cells growing]	0.0	4	1	1	1
98693	1710	susceptibility,	[susceptibility,]	0.0	1	1	1	1
98694	1710	methov of human vein cell	[METHODS of human vein cells]	0.0	5	1	1	1
98695	1710	cytoplasmic ikappabalpha level	[cytoplasmic IkappaBalpha levels]	0.0	3	1	1	1
98696	1710	complexity of the dtc activity	[complexity of the DTCs activities]	0.0	5	1	1	1
98697	1710	regulation of lysosomal acid lipase	[regulation of lysosomal acid lipase]	0.0	5	1	1	1
98698	1710	addition the product	[addition the product]	0.0	3	1	1	1
98699	1710	degree of infiltration	[degree of infiltration]	0.0	3	1	1	1
98700	1710	differentiation promonocytic cell	[Differentiation promonocytic cells]	0.0	3	1	1	1
98701	1710	contain sequence	[containing sequences]	0.0	2	1	1	1
98702	1710	two distinct type	[two distinct types]	0.0	3	1	1	1
98703	1710	il13r	[IL13R]	0.0	1	1	1	1
98704	1710	prb -null clone	[pRB -null clones]	0.0	3	1	1	1
98705	1710	important modulator	[important modulator]	0.0	2	1	1	1
98706	1710	Effect by peripheral blood mononuclear cell	[Effects by peripheral blood mononuclear cells]	0.0	6	1	1	1
98707	1710	role in the cell cycle	[role in the cell cycle]	0.0	5	1	1	1
98708	1710	positive leukemia	[positive leukemia]	0.0	2	1	1	1
98709	1710	center b cell differentiation	[center B cell differentiation]	0.0	4	1	1	1
98710	1710	constitutive presence of factor	[constitutive presence of factors]	0.0	4	1	1	1
98711	1710	two general activator RelA	[two general activators RelA]	0.0	4	1	1	1
98712	1710	compared, suggest selective	[compared, suggesting selective]	0.0	3	1	1	1
98713	1710	human Chr centromere	[human Chr centromere]	0.0	3	1	1	1
98714	1710	hsv infection	[HSV infection]	0.0	2	1	1	1
98715	1710	involvement in the assembly	[involvement in the assembly]	0.0	4	1	1	1
98716	1710	sequence downstream from the start site	[sequences downstream from the start site]	0.0	6	1	1	1
98717	1710	difference between Ramos	[difference between Ramos]	0.0	3	1	1	1
98718	1710	analysis of tissues,	[analysis of tissues,]	0.0	3	1	1	1
98719	1710	new facet	[new facet]	0.0	2	1	1	1
98720	1710	differentiation of cd4+ cell	[differentiation of CD4+ cells]	0.0	4	1	1	1
98721	1710	bind efficiency	[binding efficiency]	0.0	2	1	1	1
98722	1710	protein kinase c downstream	[protein kinase C downstream]	0.0	4	1	1	1
98723	1710	NK-chi b	[NK-chi B]	0.0	2	1	1	1
98724	1710	domain of bsap	[domain of BSAP]	0.0	3	1	1	1
98725	1710	phosphorylations.	[phosphorylations.]	0.0	1	1	1	1
98726	1710	infiltrate cd4-bearing T cell	[infiltrating CD4-bearing T cells]	0.0	4	1	1	1
98727	1710	proliferation (71%) recent-onset iddm subject 8	[proliferation (71%) recent-onset IDDM subjects 8]	0.0	6	1	1	1
98728	1710	factor with property indistinguishable	[factor with properties indistinguishable]	0.0	4	1	1	1
98729	1710	antigen ea anti-viral capsid antigen	[antigen EA anti-viral capsid antigen]	0.0	5	1	1	1
98730	1710	cd14-transfected hamster ovary fibroblast	[CD14-transfected hamster ovary fibroblasts]	0.0	4	1	1	1
98731	1710	critical element in the polarization	[critical element in the polarization]	0.0	5	1	1	1
98732	1710	lipopolysaccharide-activated blood	[lipopolysaccharide-activated blood]	0.0	2	1	1	1
98733	1710	cav	[CAV]	0.0	1	2	2	1
98734	1710	presence of mab anti-CD40	[presence of mAb anti-CD40]	0.0	4	1	1	1
98735	1710	effect in the presence	[effect in the presence]	0.0	4	1	1	1
98736	1710	Nuclear 3,5,3'-triiodothyronine receptor t3r	[Nuclear 3,5,3'-triiodothyronine receptors T3R]	0.0	4	1	1	1
98737	1710	b cell line BL-2	[B cell line BL-2]	0.0	4	1	1	1
98738	1710	o-phenanthroline OP metal-ion chelator	[o-phenanthroline OP metal-ion chelator]	0.0	4	1	1	1
98739	1710	C. pneumoniae-mediated activation	[C. pneumoniae-mediated activation]	0.0	3	1	1	1
98740	1710	analysis of the sequence upstream	[Analysis of the sequence upstream]	0.0	5	1	1	1
98741	1710	efficiently arrest differentiation	[efficiently arresting differentiation]	0.0	3	1	1	1
98742	1710	nonpeptidyl small molecule	[nonpeptidyl small molecule]	0.0	3	1	1	1
98743	1710	mg flutamide	[mg flutamide]	0.0	2	1	1	1
98744	1710	implicate the N-terminal domain	[implicating the N-terminal domain]	0.0	4	1	1	1
98745	1710	important ramification	[important ramifications]	0.0	2	1	1	1
98746	1710	hypoxia po2	[hypoxia PO2]	0.0	2	1	1	1
98747	1710	Jurkat T cell cho-cd80	[Jurkat T cells CHO-CD80]	0.0	4	1	1	1
98748	1710	other EBV-associated, latent epitope	[other EBV-associated, latent epitopes]	0.0	4	1	1	1
98749	1710	active mutant of Toll	[active mutant of Toll]	0.0	4	1	1	1
98750	1710	aminothiol compound	[aminothiol compound]	0.0	2	2	2	1
98751	1710	monoblastoid cell line	[monoblastoid cell line]	0.0	3	1	1	1
98752	1710	stimulation of quiescent b lymphocyte	[stimulation of quiescent B lymphocytes]	0.0	5	1	1	1
98753	1710	regulator of T cell homeostasis	[regulator of T cell homeostasis]	0.0	5	1	1	1
98754	1710	fast mechanism	[fast mechanism]	0.0	2	1	1	1
98755	1710	Genetic characterization binding of tax	[Genetic characterization Binding of Tax]	0.0	5	1	1	1
98756	1710	571 base pair	[571 base pairs]	0.0	3	1	1	1
98757	1710	progesterone on blood lymphocyte	[progesterone on blood lymphocytes]	0.0	4	1	1	1
98758	1710	inhibitor in monocyte	[inhibitors in monocytes]	0.0	3	1	1	1
98759	1710	rightward transcript	[rightward transcripts]	0.0	2	1	1	1
98760	1710	blastogenesis of blood lymphocyte generation	[blastogenesis of blood lymphocytes Generation]	0.0	5	1	1	1
98761	1710	great ap-1 activity of nuclear protein	[greater AP-1 activity of nuclear proteins]	0.0	6	1	1	1
98762	1710	underlie this rapid effect	[underlying these rapid effects]	0.0	4	1	1	1
98763	1710	characterization of the mechanism	[Characterization of the mechanisms]	0.0	4	1	1	1
98764	1710	roll	[rolling]	0.0	1	1	1	1
98765	1710	factor csf-1	[factor CSF-1]	0.0	2	1	1	1
98766	1710	removal of the JNK phosphorylation site	[removal of the JNK phosphorylation sites]	0.0	6	1	1	1
98767	1710	stimulation by CD2	[stimulation by CD2]	0.0	3	1	1	1
98768	1710	nik in cell	[NIK in cells]	0.0	3	1	1	1
98769	1710	transcription of the 1beta	[transcription of the 1beta]	0.0	4	1	1	1
98770	1710	study of factor/DNA interaction	[study of factor/DNA interactions]	0.0	4	1	1	1
98771	1710	platelet cell adhesion molecule	[platelet cell adhesion molecules]	0.0	4	1	1	1
98772	1710	leukemic cell whatever	[leukemic cells whatever]	0.0	3	1	1	1
98773	1710	additional b enhancer element	[additional B enhancer elements]	0.0	4	1	1	1
98774	1710	expression of serum responsive gene	[expression of serum responsive genes]	0.0	5	1	1	1
98775	1710	b cell recognize DNA	[B cells recognizing DNA]	0.0	4	1	1	1
98776	1710	mutant adenovirus ad5 with DNA sequence	[Mutants adenovirus Ad5 with DNA sequences]	0.0	6	1	1	1
98777	1710	Y chromosome sequence	[Y chromosome sequences]	0.0	3	1	1	1
98778	1710	follicular lymphoma (25	[follicular lymphoma (25]	0.0	3	1	1	1
98779	1710	significant influence	[significant influence]	0.0	2	2	2	1
98780	1710	patient with secondary hyperparathyroidism	[patients with secondary hyperparathyroidism]	0.0	4	1	1	1
98781	1710	adulthood,	[adulthood,]	0.0	1	1	1	1
98782	1710	other mutation	[other mutations]	0.0	2	1	1	1
98783	1710	two activity transactivation	[two activities transactivation]	0.0	3	1	1	1
98784	1710	means of the axis	[means of the axis]	0.0	4	1	1	1
98785	1710	apc for vzv peptide	[APC for VZV peptides]	0.0	4	1	1	1
98786	1710	such as surface expression	[such as surface expression]	0.0	4	1	1	1
98787	1710	protein critical in species	[proteins critical in species]	0.0	4	1	1	1
98788	1710	persistent replication in monocyte	[persistent replication in monocytes]	0.0	4	1	1	1
98789	1710	sample of 80	[samples of 80]	0.0	3	1	1	1
98790	1710	fluid from RCC explant	[fluid from RCC explants]	0.0	4	1	1	1
98791	1710	HIV-LTR-kappaB site	[HIV-LTR-kappaB site]	0.0	2	1	1	1
98792	1710	zeta 2 globin promoter activity	[zeta 2 globin promoter activity]	0.0	5	1	1	1
98793	1710	furthermore, CD28 -dependent elevation	[Furthermore, CD28 -dependent elevation]	0.0	4	1	1	1
98794	1710	number of cancer	[number of cancers]	0.0	3	1	1	1
98795	1710	base exchange by polymorphism SSCP	[base exchanges by polymorphism SSCP]	0.0	5	1	1	1
98796	1710	corticosteroid bronchial asthma	[corticosteroid bronchial asthma]	0.0	3	1	1	1
98797	1710	spinal muscular atrophy a adult-onset form	[spinal muscular atrophy an adult-onset form]	0.0	6	1	1	1
98798	1710	diploid state	[diploid state]	0.0	2	1	1	1
98799	1710	majority of the case	[majority of the cases]	0.0	4	1	1	1
98800	1710	B-cell chronic leukemia B-CLL	[B-cell chronic leukemia B-CLL]	0.0	4	1	1	1
98801	1710	gtp-bound ras in c5b-9 immunoprecipitate	[GTP-bound Ras in C5b-9 immunoprecipitates]	0.0	5	1	1	1
98802	1710	protein kinase mapk activation	[protein kinase MAPK activation]	0.0	4	1	1	1
98803	1710	phorbol ester -responsive motif	[phorbol ester -responsive motifs]	0.0	4	1	1	1
98804	1710	heteromeric complex	[heteromeric complexes]	0.0	2	1	1	1
98805	1710	10% human serum	[10% human serum]	0.0	3	1	1	1
98806	1710	characterization the factor relationship	[Characterization the factor relationship]	0.0	4	1	1	1
98807	1710	alpha-helice each with a proportion	[alpha-helices each with a proportion]	0.0	5	1	1	1
98808	1710	range [1-3 ppt tcdd	[range [1-3 ppt TCDD]	0.0	4	1	1	1
98809	1710	study use human endothelial cell	[studies using human endothelial cells]	0.0	5	1	1	1
98810	1710	expression of receptor on alveolar lymphocyte	[Expression of receptors on alveolar lymphocytes]	0.0	6	1	1	1
98811	1710	proliferative potential 47.10 cell	[proliferative potential 47.10 cells]	0.0	4	1	1	1
98812	1710	long lymphoblastoid cell outgrowth	[long-term lymphoblastoid cell outgrowth]	0.0	4	1	1	1
98813	1710	specify cell type	[specifying cell types]	0.0	3	1	1	1
98814	1710	hcd57 cell with SCF	[HCD57 cells with SCF]	0.0	4	1	1	1
98815	1710	tyrosine phosphorylation of key protein	[tyrosine phosphorylation of key proteins]	0.0	5	1	1	1
98816	1710	downstream activation of a tata-less promoter	[Downstream activation of a TATA-less promoter]	0.0	6	1	1	1
98817	1710	importance of nfat	[importance of NFAT]	0.0	3	1	1	1
98818	1710	imply a positive role	[implying a positive role]	0.0	4	1	1	1
98819	1710	strong transcriptional activation	[strong transcriptional activation]	0.0	3	1	1	1
98820	1710	epitope for mAb j393	[epitopes for mAb J393]	0.0	4	1	1	1
98821	1710	different set of gene	[different set of genes]	0.0	4	1	1	1
98822	1710	component of the il-4r	[component of the IL-4R]	0.0	4	1	1	1
98823	1710	human t-cell immune response	[human T-cell immune responses]	0.0	4	1	1	1
98824	1710	form of early-onset type	[forms of early-onset type]	0.0	4	1	1	1
98825	1710	e.)	[E.)]	0.0	1	1	1	1
98826	1710	b-lymphopoiesis	[B-lymphopoiesis]	0.0	1	1	1	1
98827	1710	binding site of factor	[binding sites of factors]	0.0	4	1	1	1
98828	1710	conformation polymorphism analysis	[conformation polymorphism analysis]	0.0	3	1	1	1
98829	1710	human cd34+ hpc	[human CD34+ HPC]	0.0	3	1	1	1
98830	1710	initiate event in monocyte	[initiating events in monocytes]	0.0	4	1	1	1
98831	1710	production of interleukin factor	[production of interleukin factor]	0.0	4	1	1	1
98832	1710	same domain	[same domain]	0.0	2	1	1	1
98833	1710	enhancement 1 replication in monocyte	[Enhancement 1 replication in monocytes]	0.0	5	1	1	1
98834	1710	transfection assay in IARC cell	[transfection assays in IARC cells]	0.0	5	1	1	1
98835	1710	herpes simplex vaccine	[herpes simplex vaccines]	0.0	3	1	1	1
98836	1710	g-csf 8% cell at day 6;	[G-CSF 8% cells at day 6;]	0.0	6	1	1	1
98837	1710	lead to proteolysis	[leading to proteolysis]	0.0	3	1	1	1
98838	1710	GR in MNL	[GR in MNL]	0.0	3	1	1	1
98839	1710	adenovirus infection of cell	[adenovirus infection of cells]	0.0	4	1	1	1
98840	1710	ap1 -dependent reporter construct	[AP1 -dependent reporter constructs]	0.0	4	1	1	1
98841	1710	disulfide of bmt	[disulfide of BMT]	0.0	3	1	1	1
98842	1710	inhibitor of cell	[inhibitor of cells]	0.0	3	1	1	1
98843	1710	rel-related domain	[Rel-related domain]	0.0	2	1	1	1
98844	1710	interaction between multiple positive regulatory element	[interactions between multiple positive regulatory elements]	0.0	6	1	1	1
98845	1710	transient pseudo-hypoaldosteronism follow resection level	[Transient pseudo-hypoaldosteronism following resection level]	0.0	5	1	1	1
98846	1710	amino acid in the end	[amino acids in the end]	0.0	5	1	1	1
98847	1710	prevent cell surface expression	[preventing cell surface expression]	0.0	4	1	1	1
98848	1710	cloning from olfactory cell	[cloning from olfactory cells]	0.0	4	1	1	1
98849	1710	stimulation of neutrophil interleukin-8 production	[Stimulation of neutrophil interleukin-8 production]	0.0	5	1	1	1
98850	1710	extract of u937 cell	[extracts of U937 cells]	0.0	4	1	1	1
98851	1710	basAl, adhesion with inhibition at mM.	[basal, adhesion with inhibition at mM.]	0.0	6	1	1	1
98852	1710	little effect on pdgf(b) mrna accumulation	[little effect on PDGF(B) mRNA accumulation]	0.0	6	1	1	1
98853	1710	downregulation of p27(kip1)	[downregulation of p27(Kip1)]	0.0	3	1	1	1
98854	1710	oxidant-induced nf-kappa b activation	[oxidant-induced NF-kappa B activation]	0.0	4	1	1	1
98855	1710	mechanism of neutrophil adherence	[mechanisms of neutrophil adherence]	0.0	4	1	1	1
98856	1710	ets family protein	[Ets family proteins]	0.0	3	1	1	1
98857	1710	il-12 th cell	[IL-12 Th cells]	0.0	3	1	1	1
98858	1710	DNA binding ability	[DNA binding ability]	0.0	3	1	1	1
98859	1710	distinct cellular transcription factor	[distinct cellular transcription factors]	0.0	4	1	1	1
98860	1710	direct analysis of sensorgram	[Direct analysis of sensorgrams]	0.0	4	1	1	1
98861	1710	p65( rela )/p50 heterodimer	[p65( RelA )/p50 heterodimers]	0.0	4	1	1	1
98862	1710	co-infection of T cell	[Co-infection of T cells]	0.0	4	1	1	1
98863	1710	positive action on cytokine	[positive actions on cytokines]	0.0	4	1	1	1
98864	1710	specific pattern of expression	[specific pattern of expression]	0.0	4	1	1	1
98865	1710	production of amount	[production of amounts]	0.0	3	1	1	1
98866	1710	activity of this element	[activity of this element]	0.0	4	1	1	1
98867	1710	e3'	[E3']	0.0	1	2	2	1
98868	1710	hematopoietic erythroleukemia cell	[hematopoietic erythroleukemia cells]	0.0	3	1	1	1
98869	1710	involve proliferation	[involving proliferation]	0.0	2	1	1	1
98870	1710	transient expression of p16	[Transient expression of p16]	0.0	4	1	1	1
98871	1710	gamma induction pathway	[gamma induction pathway]	0.0	3	1	1	1
98872	1710	ATL-1k	[ATL-1k]	0.0	1	1	1	1
98873	1710	-ggaa-	[-GGAA-]	0.0	1	1	1	1
98874	1710	course of bacterial infection	[course of bacterial infections]	0.0	4	2	2	1
98875	1710	impact binding to b cell	[impact binding to B cells]	0.0	5	1	1	1
98876	1710	response to t-cell virus type	[response to T-cell virus type]	0.0	5	1	1	1
98877	1710	malignant histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[malignant histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
98878	1710	b7-transfected CHO cell	[B7-transfected CHO cells]	0.0	3	1	1	1
98879	1710	typical G receptor	[typical G receptor]	0.0	3	1	1	1
98880	1710	sites/cell respectively, statistically significant	[sites/cell respectively, statistically significant]	0.0	4	1	1	1
98881	1710	precursor of DC in culture.	[precursors of DC in culture.]	0.0	5	1	1	1
98882	1710	therapeutic index	[therapeutic index]	0.0	2	1	1	1
98883	1710	CD40-specific single-chain Fv	[CD40-specific single-chain Fv]	0.0	3	1	1	1
98884	1710	nucleoprotein extract show activity	[nucleoprotein extracts showing activity]	0.0	4	1	1	1
98885	1710	anti- TNF-alpha hiv-1 repeat LTR transcription	[anti- TNF-alpha HIV-1 repeat LTR transcription]	0.0	6	1	1	1
98886	1710	subject young	[subjects younger]	0.0	2	1	1	1
98887	1710	human yeast artificial chromosome transgene	[human yeast artificial chromosome transgene]	0.0	5	1	1	1
98888	1710	cellular transcriptional factor-KB result	[cellular transcriptional factor-KB resulting]	0.0	4	1	1	1
98889	1710	patient relative	[patient relative]	0.0	2	1	1	1
98890	1710	c-Jun amino-terminal kinase	[c-Jun amino-terminal kinase]	0.0	3	1	1	1
98891	1710	first bp upstream	[first bp upstream]	0.0	3	1	1	1
98892	1710	different creb mutant	[different CREB mutants]	0.0	3	1	1	1
98893	1710	vimentin increase	[vimentin increase]	0.0	2	1	1	1
98894	1710	eight pair	[eight pairs]	0.0	2	1	1	1
98895	1710	competitive silencing	[competitive silencing]	0.0	2	2	2	1
98896	1710	signal transduction study	[signal transduction studies]	0.0	3	1	1	1
98897	1710	viral regulatory protein	[viral regulatory proteins]	0.0	3	1	1	1
98898	1710	nf-(kappa)b	[NF-(kappa)B]	0.0	1	1	1	1
98899	1710	murine cell line RAW	[murine cell line RAW]	0.0	4	1	1	1
98900	1710	isoform of JNK	[isoforms of JNK]	0.0	3	1	1	1
98901	1710	regulate factor-kappa b activation	[regulating factor-kappa B activation]	0.0	4	1	1	1
98902	1710	cd8+ t-cell activation	[CD8+ T-cell activation]	0.0	3	1	1	1
98903	1710	tumor-eradicate CTL	[tumor-eradicating CTL]	0.0	2	1	1	1
98904	1710	upstream regulatory sequence similar	[upstream regulatory sequences similar]	0.0	4	1	1	1
98905	1710	understanding of effect	[understanding of effects]	0.0	3	1	1	1
98906	1710	chronic reaction	[chronic reaction]	0.0	2	1	1	1
98907	1710	epipodophyllotoxin etoposide	[epipodophyllotoxin etoposide]	0.0	2	1	1	1
98908	1710	major difficulty	[major difficulty]	0.0	2	1	1	1
98909	1710	second alteration,	[second alteration,]	0.0	2	1	1	1
98910	1710	distinct normalize effect	[distinct normalizing effect]	0.0	3	1	1	1
98911	1710	clinical syndrome include infectious disease	[clinical syndromes including infectious diseases]	0.0	5	1	1	1
98912	1710	T cell receptor tcr signal	[T cell receptor TCR signaling]	0.0	5	1	1	1
98913	1710	mixture with heparin-like gag	[mixture with heparin-like GAGs]	0.0	4	1	1	1
98914	1710	cue	[cues]	0.0	1	1	1	1
98915	1710	product of monocyte	[products of monocytes]	0.0	3	1	1	1
98916	1710	use the ifn-gamma-activated sequence related oligonucleotide	[using the IFN-gamma-activated sequence related oligonucleotides]	0.0	6	1	1	1
98917	1710	addition, expression	[addition, expression]	0.0	2	2	2	1
98918	1710	component in the progression	[component in the progression]	0.0	4	1	1	1
98919	1710	T cell lymphotropic virus type	[T cell lymphotropic virus type]	0.0	5	2	2	1
98920	1710	phosphorylation of member	[phosphorylation of members]	0.0	3	1	1	1
98921	1710	treatment with acid RA	[treatment with acid RA]	0.0	4	1	1	1
98922	1710	species of ubiquitin -protein ligase	[species of ubiquitin -protein ligase]	0.0	5	1	1	1
98923	1710	NFAT promoter by Tpl-2	[NFAT promoter by Tpl-2]	0.0	4	1	1	1
98924	1710	pd-c hydrogenation	[Pd-C hydrogenation]	0.0	2	1	1	1
98925	1710	however, exposure to 135-(oh)2d3	[However, exposure to 1,25-(OH)2D3]	0.0	4	1	1	1
98926	1710	untreated acid cell	[untreated acid cells]	0.0	3	1	1	1
98927	1710	single serine	[single serine]	0.0	2	1	1	1
98928	1710	c/ebpalpha target gene	[C/EBPalpha target genes]	0.0	3	1	1	1
98929	1710	approximately 1.8 kb	[approximately 1.8 kb]	0.0	3	1	1	1
98930	1710	IFN regulate	[IFN regulating]	0.0	2	1	1	1
98931	1710	many investigator	[many investigators]	0.0	2	1	1	1
98932	1710	thyroid disease: coregulation with parameter	[thyroid disease: coregulation with parameters]	0.0	5	1	1	1
98933	1710	pancrea development	[pancreas development]	0.0	2	1	1	1
98934	1710	biochemical marker in group	[biochemical marker in groups]	0.0	4	1	1	1
98935	1710	protein antigen	[protein antigen]	0.0	2	2	2	1
98936	1710	cell progenitor	[cell progenitors]	0.0	2	1	1	1
98937	1710	R24 increase	[R24 increase]	0.0	2	1	1	1
98938	1710	role in IL-4 gene control	[role in IL-4 gene control]	0.0	5	1	1	1
98939	1710	e.g. between status	[e.g. between status]	0.0	3	1	1	1
98940	1710	monocyte with phorbol-13-acetate for h	[monocytes with phorbol-13-acetate for h]	0.0	5	1	1	1
98941	1710	/mn2+	[/Mn2+]	0.0	1	1	1	1
98942	1710	Peripheral lymphocyte from healthy woman	[Peripheral lymphocytes from healthy women]	0.0	5	1	1	1
98943	1710	impaired activation of factor	[impaired activation of factors]	0.0	4	1	1	1
98944	1710	comparative sequence analysis between show	[Comparative sequence analysis between shows]	0.0	5	1	1	1
98945	1710	novel dyad sequence	[novel dyad sequence]	0.0	3	1	1	1
98946	1710	kb-like sequence	[kB-like sequence]	0.0	2	1	1	1
98947	1710	factor the other	[factor the other]	0.0	3	1	1	1
98948	1710	multiple event	[multiple events]	0.0	2	1	1	1
98949	1710	relatively high, pharmacological concentration to &mgr;m)	[relatively high, pharmacological concentrations to &mgr;M)]	0.0	6	1	1	1
98950	1710	nuclear factor (nfat) group	[nuclear factor (NFAT) group]	0.0	4	1	1	1
98951	1710	ebv immortalization	[EBV immortalization]	0.0	2	1	1	1
98952	1710	protein with a mass	[protein with an mass]	0.0	4	1	1	1
98953	1710	immunogens,	[immunogens,]	0.0	1	1	1	1
98954	1710	consecutive ms patient	[consecutive MS patients]	0.0	3	1	1	1
98955	1710	ca2+ store	[Ca2+ stores]	0.0	2	1	1	1
98956	1710	hamartoma	[hamartoma]	0.0	1	1	1	1
98957	1710	paf receptor antagonist	[PAF receptor antagonists]	0.0	3	1	1	1
98958	1710	(cdiia) mrna	[(CDIIa) mRNA]	0.0	2	1	1	1
98959	1710	Tat b	[Tat B]	0.0	2	1	1	1
98960	1710	include growth factor	[including growth factors]	0.0	3	1	1	1
98961	1710	costimulation-induced protein kinase activation	[costimulation-induced protein kinase activation]	0.0	4	1	1	1
98962	1710	3'-most site	[3'-most site]	0.0	2	1	1	1
98963	1710	splicing of rna transcript	[splicing of RNA transcripts]	0.0	4	1	1	1
98964	1710	signal event for proliferation	[signaling events for proliferation]	0.0	4	1	1	1
98965	1710	contain the -148 region	[containing the -148 region]	0.0	4	1	1	1
98966	1710	include domain for DNA	[including domains for DNA]	0.0	4	1	1	1
98967	1710	mapk kinase-1	[MAPK kinase-1]	0.0	2	2	2	1
98968	1710	inhibition of migration rate	[inhibition of migration rate]	0.0	4	1	1	1
98969	1710	probe, extract	[probe, extracts]	0.0	2	1	1	1
98970	1710	Oct-2 contain pouhd	[Oct-2 containing POUHD]	0.0	3	1	1	1
98971	1710	silencing of the cis-linked CAT gene	[silencing of the cis-linked CAT gene]	0.0	6	1	1	1
98972	1710	Bcl-6 expression heterogeneity of t-cell	[Bcl-6 expression heterogeneity of T-cells]	0.0	5	1	1	1
98973	1710	dominant version of TRAF6	[dominant version of TRAF6]	0.0	4	1	1	1
98974	1710	(MHC) class ii promoter	[(MHC) class II promoters]	0.0	4	1	1	1
98975	1710	Philadelphia leukemia cell line	[Philadelphia leukemia cell line]	0.0	4	1	1	1
98976	1710	superoxide dismutase Mn-SOD	[superoxide dismutase Mn-SOD]	0.0	3	1	1	1
98977	1710	acid receptor alpha403 heterodimer	[acid receptor alpha403 heterodimers]	0.0	4	1	1	1
98978	1710	drug in APL patient	[drug in APL patients]	0.0	4	1	1	1
98979	1710	protein phosphatase type	[protein phosphatase type]	0.0	3	1	1	1
98980	1710	type of hybrid	[types of hybrids]	0.0	3	1	1	1
98981	1710	analysis of the cDNA genomic clone	[analysis of the cDNA genomic clones]	0.0	6	1	1	1
98982	1710	increase in well-differentiated th1 cell	[increase in well-differentiated Th1 cells]	0.0	5	1	1	1
98983	1710	Interfollicular bcl-6 +/cd3+ cell	[Interfollicular Bcl-6 +/CD3+ cells]	0.0	4	1	1	1
98984	1710	consistency	[consistency]	0.0	1	1	1	1
98985	1710	pag activation (phenotype phopc	[pag activation (phenotype PhoPc]	0.0	4	1	1	1
98986	1710	translocation factor lymphocyte	[translocation factor lymphocytes]	0.0	3	1	1	1
98987	1710	intracellular vitamin d receptor	[intracellular vitamin D receptor]	0.0	4	2	2	1
98988	1710	ss reticulocyte	[SS reticulocytes]	0.0	2	2	2	1
98989	1710	10 individual as normal control	[10 individuals as normal control]	0.0	5	1	1	1
98990	1710	presentation by autologous cell	[presentation by autologous cell]	0.0	4	1	1	1
98991	1710	enzymatic means use deoxyribonuclease	[enzymatic means using deoxyribonuclease]	0.0	4	1	1	1
98992	1710	plc gamma overexpression	[PLC gamma overexpression]	0.0	3	1	1	1
98993	1710	expression a T factor	[expression a T factor]	0.0	4	1	1	1
98994	1710	chain (igh) gene expression	[chain (IgH) gene expression]	0.0	4	1	1	1
98995	1710	interleukin survival of pro-B lymphocyte	[interleukin survival of pro-B lymphocytes]	0.0	5	1	1	1
98996	1710	different requirement for efficient binding,	[different requirements for efficient binding,]	0.0	5	1	1	1
98997	1710	include leukaemia CML	[including leukaemia CML]	0.0	3	2	2	1
98998	1710	ubiquitous contaminant	[ubiquitous contaminant]	0.0	2	1	1	1
98999	1710	mechanism underlie cell activation by serum	[mechanisms underlying cell activation by serum]	0.0	6	1	1	1
99000	1710	one plasma cell line,	[one plasma cell line,]	0.0	4	1	1	1
99001	1710	family acid receptor rar	[families acid receptors RARs]	0.0	4	1	1	1
99002	1710	group of dna-binding protein	[group of DNA-binding proteins]	0.0	4	1	1	1
99003	1710	only low level of hiv-1 expression	[only low levels of HIV-1 expression]	0.0	6	1	1	1
99004	1710	direct substrate in cells.	[direct substrates in cells.]	0.0	4	1	1	1
99005	1710	chemokine (thus Duffy Antigen Receptor	[chemokines (thus Duffy Antigen Receptor]	0.0	5	1	1	1
99006	1710	relatively few cell-specific gene	[relatively few cell-specific genes]	0.0	4	1	1	1
99007	1710	neutralize abs	[neutralizing Abs]	0.0	2	2	2	1
99008	1710	fluticasone propionate in patient	[fluticasone propionate in patients]	0.0	4	1	1	1
99009	1710	transcription bear ZEBRA -responsive promoter	[transcription bearing ZEBRA -responsive promoters]	0.0	5	1	1	1
99010	1710	type of lymphoblast	[types of lymphoblasts]	0.0	3	1	1	1
99011	1710	transfection analysis with target plasmid	[transfection analysis with target plasmids]	0.0	5	1	1	1
99012	1710	C epsilon gas	[C epsilon GAS]	0.0	3	1	1	1
99013	1710	relative decrease	[relative decrease]	0.0	2	1	1	1
99014	1710	B-cell commitment	[B-cell commitment]	0.0	2	1	1	1
99015	1710	TCL1 locus on chromosome	[TCL1 locus on chromosome]	0.0	4	1	1	1
99016	1710	Epstein-Barr virus ebv a oncogenic herpesvirus	[Epstein-Barr virus EBV an oncogenic herpesvirus]	0.0	6	1	1	1
99017	1710	low ki-67 values.	[low Ki-67 values.]	0.0	3	1	1	1
99018	1710	rapid non-genomic effect on electrolyte movement	[rapid non-genomic effects on electrolyte movements]	0.0	6	1	1	1
99019	1710	hemopoi-etic cell mthc	[hemopoi-etic cells MTHC]	0.0	3	1	1	1
99020	1710	bryostatin (10 nm), another activator	[bryostatin (10 nM), another activator]	0.0	5	1	1	1
99021	1710	asthma]	[asthma]]	0.0	1	1	1	1
99022	1710	production of mature double-positive population	[production of mature double-positive populations]	0.0	5	1	1	1
99023	1710	similar rise	[similar rise]	0.0	2	1	1	1
99024	1710	effect of type	[effects of types]	0.0	3	1	1	1
99025	1710	factor kappab binding to DNA	[factor kappaB binding to DNA]	0.0	5	1	1	1
99026	1710	glucocorticoid receptor in runner	[glucocorticoid receptor in runner]	0.0	4	1	1	1
99027	1710	subtle alteration in sequence	[subtle alterations in sequences]	0.0	4	1	1	1
99028	1710	mg bolus)	[mg bolus)]	0.0	2	1	1	1
99029	1710	lead to a lack	[leading to a lack]	0.0	4	1	1	1
99030	1710	tar-deleted mutant	[TAR-deleted mutants]	0.0	2	1	1	1
99031	1710	group c, adenovirus serotype	[Group C, adenovirus serotype]	0.0	4	1	1	1
99032	1710	mechanism similar	[mechanisms similar]	0.0	2	1	1	1
99033	1710	CD4 cell number	[CD4 cell number]	0.0	3	1	1	1
99034	1710	clonality analysis study	[Clonality analysis study]	0.0	3	1	1	1
99035	1710	77 nucleotide	[77 nucleotides]	0.0	2	1	1	1
99036	1710	t-cell trans-activator	[T-cell trans-activator]	0.0	2	1	1	1
99037	1710	important functional site between position	[important functional site between positions]	0.0	5	1	1	1
99038	1710	period of incubation	[periods of incubation]	0.0	3	1	1	1
99039	1710	show a increase of AhR mrna	[showing a increase of AhR mRNA]	0.0	6	1	1	1
99040	1710	rbp binding site	[RBP binding site]	0.0	3	1	1	1
99041	1710	normal counterpart to lymphocytic leukemia	[normal counterpart to lymphocytic leukemias]	0.0	5	1	1	1
99042	1710	garlic compound, s-allyl cysteine	[garlic compound, S-allyl cysteine]	0.0	4	1	1	1
99043	1710	cell-type expression of several genes.	[cell-type expression of several genes.]	0.0	5	1	1	1
99044	1710	Oct-1 member	[Oct-1 members]	0.0	2	1	1	1
99045	1710	progeny of progenitor	[progeny of progenitors]	0.0	3	1	1	1
99046	1710	twelve cord blood	[twelve cord blood]	0.0	3	1	1	1
99047	1710	cell from human monocyte	[cells from human monocytes]	0.0	4	1	1	1
99048	1710	human elk-1	[human elk-1]	0.0	2	1	1	1
99049	1710	change in receptor in lymphocyte	[changes in receptors in lymphocytes]	0.0	5	1	1	1
99050	1710	receptor in mononuclear leukocyte in patient	[receptors in mononuclear leukocytes in patients]	0.0	6	1	1	1
99051	1710	novel, complex	[novel, complex]	0.0	2	1	1	1
99052	1710	accord to stage	[according to stage]	0.0	3	1	1	1
99053	1710	variant of the Jurkat t-cell line	[variants of the Jurkat T-cell line]	0.0	6	1	1	1
99054	1710	near-perfect direct repeat of 21 bp	[near-perfect direct repeats of 21 bp]	0.0	6	1	1	1
99055	1710	mpl homodimerization	[Mpl homodimerization]	0.0	2	1	1	1
99056	1710	years) hypertensive versus years) subject	[years) hypertensives vs years) subjects]	0.0	5	1	1	1
99057	1710	allow translocation of NF-kappa b	[allowing translocation of NF-kappa B]	0.0	5	1	1	1
99058	1710	therefore a EB1 element	[therefore an EB1 element]	0.0	4	1	1	1
99059	1710	two such form of the protein	[two such forms of the protein]	0.0	6	1	1	1
99060	1710	suggest control mechanism	[suggesting control mechanisms]	0.0	3	1	1	1
99061	1710	bind datum	[binding data,]	0.0	2	1	1	1
99062	1710	intracellular formation of oxygen intermediate	[intracellular formation of oxygen intermediates]	0.0	5	1	1	1
99063	1710	level of transcription activation	[level of transcription activation]	0.0	4	1	1	1
99064	1710	production of reactive metabolite	[production of reactive metabolites]	0.0	4	1	1	1
99065	1710	df,	[df,]	0.0	1	2	2	1
99066	1710	NFATp/c	[NFATp/c]	0.0	1	1	1	1
99067	1710	nonselfness	[nonselfness]	0.0	1	1	1	1
99068	1710	high thymidine	[higher thymidine]	0.0	2	1	1	1
99069	1710	further insight into the mechanism	[further insight into the mechanisms]	0.0	5	1	1	1
99070	1710	nsaid family member	[NSAID family members]	0.0	3	1	1	1
99071	1710	(high turnover) property	[(high turnover) properties]	0.0	3	1	1	1
99072	1710	mobility on 5-20% sucrose gradients,	[mobility on 5-20% sucrose gradients,]	0.0	5	1	1	1
99073	1710	t-cell activation by dithiocarbamate	[T-cell activation by dithiocarbamates]	0.0	4	1	1	1
99074	1710	regulation of this gene,	[regulation of this gene,]	0.0	4	1	1	1
99075	1710	include distinct domain	[including distinct domains]	0.0	3	1	1	1
99076	1710	8% cell at day 6;	[8% cells at day 6;]	0.0	5	1	1	1
99077	1710	weight of approximately 50 kD	[weight of approximately 50 kD]	0.0	5	1	1	1
99078	1710	glucocorticoid receptor of blood leukocyte	[glucocorticoid receptors of blood leukocytes]	0.0	5	1	1	1
99079	1710	well-known consequence of gsh depletion	[well-known consequences of GSH depletion]	0.0	5	1	1	1
99080	1710	serine phosphorylation site	[serine phosphorylation site]	0.0	3	1	1	1
99081	1710	10 microm sodium orthovanadate NaOV	[10 microM sodium orthovanadate NaOV]	0.0	5	1	1	1
99082	1710	dep	[DEPs]	0.0	1	1	1	1
99083	1710	express p45	[expressing p45]	0.0	2	1	1	1
99084	1710	induction by ultra-violet irradiation	[induction by UV irradiation]	0.0	4	1	1	1
99085	1710	ap-1 transcription factor by PGN	[AP-1 transcription factors by PGN]	0.0	5	1	1	1
99086	1710	receptor for calcitriol	[receptors for calcitriol]	0.0	3	1	1	1
99087	1710	microm etoposide	[microM etoposide]	0.0	2	1	1	1
99088	1710	foreign body	[foreign body]	0.0	2	1	1	1
99089	1710	chicken immature erythrocyte protein	[chicken immature erythrocyte proteins]	0.0	4	1	1	1
99090	1710	herpesvirus saimiry associate lck activation	[herpesvirus saimiri associates Lck activation]	0.0	5	1	1	1
99091	1710	degradation a role in senescence	[degradation A role in senescence]	0.0	5	1	1	1
99092	1710	13 human thyroid fragment	[13 human thyroid fragments]	0.0	4	1	1	1
99093	1710	mmp9 activity,	[MMP9 activity,]	0.0	2	1	1	1
99094	1710	novel taf of kda	[novel TAF of kDa]	0.0	4	1	1	1
99095	1710	reconstitution in jcam1 cell	[Reconstitution in JCaM1 cells]	0.0	4	1	1	1
99096	1710	benzene contaminate	[benzene contaminating]	0.0	2	1	1	1
99097	1710	c/ebpepsilon mrna level	[C/EBPepsilon mRNA levels]	0.0	3	1	1	1
99098	1710	factor-kappaB NF-kappaB binding site	[factor-kappaB NF-kappaB binding site]	0.0	4	1	1	1
99099	1710	induce monocyte differentiation	[inducing monocyte differentiation]	0.0	3	1	1	1
99100	1710	ligand signal	[ligand signal]	0.0	2	1	1	1
99101	1710	(i) patient er	[(i) patients ER]	0.0	3	1	1	1
99102	1710	allow rapid activation	[allowing rapid activation]	0.0	3	1	1	1
99103	1710	z responsiveness,	[Z responsiveness,]	0.0	2	1	1	1
99104	1710	critical role convert signal	[critical role converting signals]	0.0	4	1	1	1
99105	1710	use in the cyto-differentiaterentiating treatment	[use in the cyto-differentiating treatment]	0.0	5	1	1	1
99106	1710	similar level of htr beta	[Similar levels of hTR beta]	0.0	5	1	1	1
99107	1710	interleukin-10 inhibition	[interleukin-10 inhibition]	0.0	2	1	1	1
99108	1710	target of drug development	[target of drug development]	0.0	4	1	1	1
99109	1710	defective onset	[defective onset]	0.0	2	1	1	1
99110	1710	portion of Oct2	[portion of Oct2]	0.0	3	1	1	1
99111	1710	alteration in the activity	[alterations in the activity]	0.0	4	1	1	1
99112	1710	hmg-coa	[HMG-CoA]	0.0	1	1	1	1
99113	1710	progenitor (EML)	[progenitor (EML)]	0.0	2	1	1	1
99114	1710	propagation of the tat mutant	[propagation of the tat mutants]	0.0	5	1	1	1
99115	1710	Thus, lps activation of monocytic cell	[Thus, LPS activation of monocytic cells]	0.0	6	1	1	1
99116	1710	express form of the protein	[expressing forms of the protein]	0.0	5	1	1	1
99117	1710	rpmi	[RPMI]	0.0	1	1	1	1
99118	1710	circulate leukocyte into extravascular tissue	[circulating leukocytes into extravascular tissues]	0.0	5	1	1	1
99119	1710	component of the mechanism	[component of the mechanism]	0.0	4	1	1	1
99120	1710	suggest strategy	[suggesting strategies]	0.0	2	1	1	1
99121	1710	chromosome 11p15	[chromosomes 11p15]	0.0	2	1	1	1
99122	1710	concept a subtype of hd	[concept an subtype of HD]	0.0	5	1	1	1
99123	1710	offersugg a aspect of down-regulation	[offersuggesting a aspect of down-regulation]	0.0	5	1	1	1
99124	1710	level in leukemic cell	[levels in leukemic cells]	0.0	4	1	1	1
99125	1710	change of serine	[change of serine]	0.0	3	1	1	1
99126	1710	produce a putative human retrovirus	[producing a putative human retrovirus]	0.0	5	1	1	1
99127	1710	(hiv-1) replication	[(HIV-1) replication]	0.0	2	1	1	1
99128	1710	occur at minute (phase	[occurring at minutes (phase]	0.0	4	1	1	1
99129	1710	therefore a element in the polarization	[therefore a element in the polarization]	0.0	6	1	1	1
99130	1710	combination of T cell activation signal	[combinations of T cell activation signals]	0.0	6	1	1	1
99131	1710	viral gene promoter	[viral gene promoter]	0.0	3	1	1	1
99132	1710	nine woman with recurrent abortion	[nine women with recurrent abortion]	0.0	5	1	1	1
99133	1710	h (and up to 250-fold	[h (and up to 250-fold]	0.0	5	1	1	1
99134	1710	i.e., factor	[i.e., factor]	0.0	2	1	1	1
99135	1710	histocompatibility complex (mhc) class molecule	[histocompatibility complex (MHC) class molecules]	0.0	5	1	1	1
99136	1710	two IL-1alpha kappab-like site -1065	[two IL-1alpha kappaB-like sites -1,065]	0.0	5	1	1	1
99137	1710	erythroleukemia cell line in vivo	[erythroleukemia cell lines in vivo]	0.0	5	1	1	1
99138	1710	proportion 0.01-5%)	[proportion 0.01-5%)]	0.0	2	1	1	1
99139	1710	individual with aging syndrome	[individuals with aging syndromes]	0.0	4	1	1	1
99140	1710	Cox analysis for patient	[Cox analysis for patients]	0.0	4	1	1	1
99141	1710	high millileter	[high ml]	0.0	2	1	1	1
99142	1710	5' noncode region	[5' noncoding region]	0.0	3	1	1	1
99143	1710	finding a characteristic	[findings a characteristic]	0.0	3	1	1	1
99144	1710	expression of tumor necrosis gene	[expression of tumor necrosis genes]	0.0	5	1	1	1
99145	1710	early transactivator	[early transactivator]	0.0	2	1	1	1
99146	1710	expression of viral latent gene	[expression of viral latent genes]	0.0	5	1	1	1
99147	1710	pathway as the way	[pathway as the way]	0.0	4	1	1	1
99148	1710	human interferon regulatory factor 2	[Human interferon regulatory factor 2]	0.0	5	1	1	1
99149	1710	instillation of IL-6 into normal rat	[instillation of IL-6 into normal rats]	0.0	6	1	1	1
99150	1710	ino expression in cell	[iNOS expression in cells]	0.0	4	1	1	1
99151	1710	n-terminal sequencing	[N-Terminal sequencing]	0.0	2	1	1	1
99152	1710	infection with two virion	[infection with two virions]	0.0	4	1	1	1
99153	1710	potent activator of hiv expression	[potent activator of HIV expression]	0.0	5	1	1	1
99154	1710	carcinoma patient	[carcinoma patients]	0.0	2	1	1	1
99155	1710	breast cancer mortality	[breast cancer mortality]	0.0	3	1	1	1
99156	1710	main pacemaker of GR	[main pacemaker of GR]	0.0	4	1	1	1
99157	1710	contrasting effect	[contrasting effects]	0.0	2	1	1	1
99158	1710	reporter construct contain region	[reporter constructs containing regions]	0.0	4	1	1	1
99159	1710	prime with nm RA	[Priming with nM RA]	0.0	4	1	1	1
99160	1710	contain c-mim	[containing c-mim]	0.0	2	1	1	1
99161	1710	binding of nuclear protein (s)	[binding of nuclear protein (s)]	0.0	5	1	1	1
99162	1710	number of prediction	[number of predictions]	0.0	3	1	1	1
99163	1710	significant association	[significant association]	0.0	2	2	2	1
99164	1710	accompany up-regulation	[accompanying up-regulation]	0.0	2	1	1	1
99165	1710	use the retinoic acid receptor alpha	[Using the retinoic acid receptor alpha]	0.0	6	1	1	1
99166	1710	CTL control	[CTL control]	0.0	2	1	1	1
99167	1710	fos/cun-contain nf-at	[Fos/Jun-containing NF-AT]	0.0	2	1	1	1
99168	1710	high concentrations.	[high concentrations.]	0.0	2	1	1	1
99169	1710	thyroid hormone-	[thyroid hormone-]	0.0	2	1	1	1
99170	1710	typical features.	[typical features.]	0.0	2	1	1	1
99171	1710	doc	[DOC]	0.0	1	1	1	1
99172	1710	relevance of this observations.	[relevance of these observations.]	0.0	4	1	1	1
99173	1710	expression of erythroid-specific gene in leukaemia	[Expression of erythroid-specific genes in leukaemia]	0.0	6	1	1	1
99174	1710	possible T	[possible T]	0.0	2	1	1	1
99175	1710	15 amino acid in the end	[15 amino acids in the end]	0.0	6	1	1	1
99176	1710	dot	[dots]	0.0	1	1	1	1
99177	1710	dox	[DOX]	0.0	1	1	1	1
99178	1710	related, cell	[related, cells]	0.0	2	1	1	1
99179	1710	mapk kinase 1	[MAPK kinase 1]	0.0	3	1	1	1
99180	1710	include plasma cells,	[including plasma cells,]	0.0	3	1	1	1
99181	1710	association with tnfr factor	[association with TNFR factors]	0.0	4	1	1	1
99182	1710	pattern of cytokine lymphokine	[patterns of cytokine lymphokine]	0.0	4	1	1	1
99183	1710	immunogenicity of antigen	[immunogenicity of antigens]	0.0	3	1	1	1
99184	1710	contrast to endometrial cell	[contrast to endometrial cells]	0.0	4	1	1	1
99185	1710	c-Rel/ p65	[c-Rel/ p65]	0.0	2	1	1	1
99186	1710	striking contrast	[striking contrast]	0.0	2	1	1	1
99187	1710	several casein kinase site (37	[several casein kinase sites (37]	0.0	5	1	1	1
99188	1710	dph	[DPH]	0.0	1	1	1	1
99189	1710	trend for some of the biomarker	[trends for some of the biomarkers]	0.0	6	1	1	1
99190	1710	expression tumor originate	[expression tumors originating]	0.0	3	1	1	1
99191	1710	transcription tfiid	[transcription TFIID]	0.0	2	1	1	1
99192	1710	level for icam-1	[levels for ICAM-1]	0.0	3	1	1	1
99193	1710	mutant kappa B	[mutant kappa B]	0.0	3	1	1	1
99194	1710	binding of the basic protein	[binding of the basic protein]	0.0	5	1	1	1
99195	1710	1,25 alpha-Dihydroxicholecalciferol	[1,25 alpha-Dihydroxicholecalciferol]	0.0	2	1	1	1
99196	1710	transcription by IL-10	[transcription by IL-10]	0.0	3	1	1	1
99197	1710	c-fo mrna expression in cord	[c-fos mRNA expression in cord]	0.0	5	1	1	1
99198	1710	test: corticosteroid receptor regulation	[test: corticosteroid receptors regulation]	0.0	4	1	1	1
99199	1710	TF cofactor	[TF cofactor]	0.0	2	1	1	1
99200	1710	apparently healthy volunteer man	[apparently healthy volunteers men]	0.0	4	1	1	1
99201	1710	substrate for shp1 in cells.	[substrates for SHP1 in cells.]	0.0	5	1	1	1
99202	1710	response of neonatal T lymphocyte	[response of neonatal T lymphocytes]	0.0	5	1	1	1
99203	1710	factor of T cell nfat-1	[factor of T cells NFAT-1]	0.0	5	1	1	1
99204	1710	activation of c-rel/ p65 heterodimer	[activation of c-Rel/ p65 heterodimers]	0.0	5	1	1	1
99205	1710	cell of hemopoietic lineage	[cells of hemopoietic lineages]	0.0	4	1	1	1
99206	1710	metabolism, disposition of SMX	[metabolism, disposition of SMX]	0.0	4	1	1	1
99207	1710	ltr-cat reporter	[LTR-CAT reporter]	0.0	2	1	1	1
99208	1710	prime by cytokine	[priming by cytokines]	0.0	3	1	1	1
99209	1710	gr -dependent transcription from GRE	[GR -dependent transcription from GRE]	0.0	5	1	1	1
99210	1710	intracellular protein lead	[intracellular proteins leading]	0.0	3	1	1	1
99211	1710	activation of nf-kappa b element	[activation of NF-kappa B elements]	0.0	5	1	1	1
99212	1710	interleukin-2-gene expression in T lymphocyte	[interleukin-2-gene expression in T lymphocytes]	0.0	5	1	1	1
99213	1710	human line u937 in fibroblast	[human lines U937 in fibroblasts]	0.0	5	1	1	1
99214	1710	activation of a HIV reporter	[activation of an HIV reporter]	0.0	5	1	1	1
99215	1710	CD28 with PMA	[CD28 with PMA]	0.0	3	1	1	1
99216	1710	Liuwei Dihuang Pills LDP	[Liuwei Dihuang Pills LDP]	0.0	4	1	1	1
99217	1710	ebv b-cell	[EBV B-cell]	0.0	2	1	1	1
99218	1710	firm arrest, spreading,	[firm arrest, spreading,]	0.0	3	1	1	1
99219	1710	express target fibroblast	[expressing target fibroblasts]	0.0	3	1	1	1
99220	1710	suppressive effect on immune function	[suppressive effect on immune functions]	0.0	5	1	1	1
99221	1710	line of evidence	[lines of evidence]	0.0	3	3	3	1
99222	1710	response through inverse effect	[responses through inverse effects]	0.0	4	1	1	1
99223	1710	affinity consistent	[affinity consistent]	0.0	2	1	1	1
99224	1710	heterodimerizerizerizerizerizerizerizerizerizerize	[heterodimerizing]	0.0	1	1	1	1
99225	1710	increase-ratio (post/pre ratio) after mitogen stimulation	[increase-ratios (post/pre ratio) after mitogen stimulation]	0.0	6	1	1	1
99226	1710	contrast, injection cd4+ t-cell deletion	[contrast, injections CD4+ T-cell deletion]	0.0	5	1	1	1
99227	1710	(auc)	[(AUC)]	0.0	1	1	1	1
99228	1710	slightly high content of gcr	[slightly higher content of GCR]	0.0	5	1	1	1
99229	1710	heterotrimeric g	[heterotrimeric G]	0.0	2	1	1	1
99230	1710	inasmuch presumably through opening	[Inasmuch presumably through opening]	0.0	4	1	1	1
99231	1710	cross-link on the THP-1 cell line	[Cross-linking on the THP-1 cell line]	0.0	6	1	1	1
99232	1710	tool assess the risk	[tool assessing the risk]	0.0	4	1	1	1
99233	1710	use early hematopoietic progenitor cell	[using early hematopoietic progenitor cells]	0.0	5	1	1	1
99234	1710	interaction with umbilical vein cell	[interaction with umbilical vein cells]	0.0	5	1	1	1
99235	1710	also effect	[also effects]	0.0	2	2	2	1
99236	1710	common event in agonist-induced signalling	[common event in agonist-induced signalling]	0.0	5	1	1	1
99237	1710	protein translation	[protein translation]	0.0	2	1	1	1
99238	1710	involve differentiation	[involving differentiation]	0.0	2	1	1	1
99239	1710	Study into the effect	[Studies into the effect]	0.0	4	1	1	1
99240	1710	regulation in differentiation	[regulation in differentiation]	0.0	3	1	1	1
99241	1710	PLZF	[PLZF]	0.0	1	1	1	1
99242	1710	anti-HLA-DR monoclonal antibody	[anti-HLA-DR monoclonal antibody]	0.0	3	1	1	1
99243	1710	increase success in the treatment	[Increasing success in the treatment]	0.0	5	1	1	1
99244	1710	more extensive deletion of sequence	[More extensive deletion of sequences]	0.0	5	1	1	1
99245	1710	interleukin IL-2 gene through interference	[interleukin IL-2 gene through interference]	0.0	5	1	1	1
99246	1710	new retrovirus	[new retrovirus]	0.0	2	1	1	1
99247	1710	a20 b cell	[A20 B cells]	0.0	3	1	1	1
99248	1710	differentiation cell by etoposide	[Differentiation cells by etoposide]	0.0	4	1	1	1
99249	1710	donor of sexes.	[donors of sexes.]	0.0	3	1	1	1
99250	1710	development of product	[development of products]	0.0	3	1	1	1
99251	1710	regulate expression in u937 cell	[regulating expression in U937 cells]	0.0	5	1	1	1
99252	1710	patient before RAI	[patients before RAI]	0.0	3	1	1	1
99253	1710	hydroxyanisole	[hydroxyanisole]	0.0	1	1	1	1
99254	1710	human mediator of the response	[human mediator of the response]	0.0	5	1	1	1
99255	1710	kappab-dependent	[kappaB-dependent]	0.0	1	1	1	1
99256	1710	steady-state fluorescence anisotropy dph	[steady-state fluorescence anisotropy DPH]	0.0	4	1	1	1
99257	1710	biopsy from patient	[biopsies from patients]	0.0	3	1	1	1
99258	1710	such as tumor necrosis factor alpha	[such as tumor necrosis factor alpha]	0.0	6	1	1	1
99259	1710	activation from a remote position	[activation from a remote position]	0.0	5	1	1	1
99260	1710	specificity mutant	[specificity mutants]	0.0	2	1	1	1
99261	1710	several target gene	[several target genes]	0.0	3	1	1	1
99262	1710	apoptosis induce apoptosis	[apoptosis inducing apoptosis]	0.0	3	1	1	1
99263	1710	cell with marker	[cells with marker]	0.0	3	1	1	1
99264	1710	methyl xanthine derivative	[methyl xanthine derivative]	0.0	3	1	1	1
99265	1710	interaction of the two transcription factor	[interactions of the two transcription factors]	0.0	6	1	1	1
99266	1710	different model accounting	[different models accounting]	0.0	3	1	1	1
99267	1710	action of concentration	[action of concentration]	0.0	3	1	1	1
99268	1710	three distinct multi-protein complex RFX	[three distinct multi-protein complexes RFX]	0.0	5	1	1	1
99269	1710	modification on target tissue	[modifications on target tissues]	0.0	4	1	1	1
99270	1710	icr27tk.3 leukemic T cell	[ICR27TK.3 leukemic T cells]	0.0	4	1	1	1
99271	1710	migration through huvec monolayer	[migration through HUVEC monolayers]	0.0	4	1	1	1
99272	1710	contrast, two drug	[contrast, two drugs]	0.0	3	1	1	1
99273	1710	cytokine-induced human immunodeficiency virus type	[cytokine-induced human immunodeficiency virus type]	0.0	5	1	1	1
99274	1710	erythroid ALAS gene	[erythroid ALAS gene]	0.0	3	1	1	1
99275	1710	(atf)	[(ATF)]	0.0	1	1	1	1
99276	1710	pattern of x inactivation	[pattern of X inactivation]	0.0	4	1	1	1
99277	1710	several molecular aspect	[several molecular aspects]	0.0	3	1	1	1
99278	1710	same property in response	[same properties in response]	0.0	4	1	1	1
99279	1710	concentration of cortivazol	[concentrations of cortivazol]	0.0	3	1	1	1
99280	1710	express nef	[expressing Nefs]	0.0	2	1	1	1
99281	1710	nonactivated, b cell	[nonactivated, B cells]	0.0	3	1	1	1
99282	1710	include a function of gh	[including a function of GH]	0.0	5	1	1	1
99283	1710	CCACC/Sp1 family	[CCACC/Sp1 family]	0.0	2	1	1	1
99284	1710	most active element	[most active elements]	0.0	3	1	1	1
99285	1710	treatment with wild-type mutant form	[Treatment with wild-type mutant forms]	0.0	5	1	1	1
99286	1710	TNF/neuron growth	[TNF/neuron growth]	0.0	2	1	1	1
99287	1710	proliferation of leukemic cell	[proliferation of leukemic cells]	0.0	4	1	1	1
99288	1710	microm of C-JUN as oligonucleotide	[microM of C-JUN AS oligonucleotides]	0.0	5	1	1	1
99289	1710	range from 25 kD to kd,	[ranging from 25 kD to kD,]	0.0	6	1	1	1
99290	1710	i ifi IFN-alpha/beta	[I IFNs IFN-alpha/beta]	0.0	3	1	1	1
99291	1710	class ii molecule on cell	[class II molecules on cells]	0.0	5	1	1	1
99292	1710	nonpeptidyl molecule 247464	[nonpeptidyl molecule 247464]	0.0	3	1	1	1
99293	1710	antibody monoclonal antibody mab	[antibodies monoclonal antibodies mAbs]	0.0	4	1	1	1
99294	1710	expression p45 nf-e2 mrna in granurocyte	[expression P45 NF-E2 mRNA in granurocytes]	0.0	6	1	1	1
99295	1710	expression a activator	[expression an activator]	0.0	3	1	1	1
99296	1710	multinucleated cell from monocyte	[multinucleated cells from monocytes]	0.0	4	1	1	1
99297	1710	target of signal	[target of signals]	0.0	3	1	1	1
99298	1710	females),	[females),]	0.0	1	1	1	1
99299	1710	normal comparison group	[normal comparison group]	0.0	3	1	1	1
99300	1710	role mediate immune response	[roles mediating immune responses]	0.0	4	1	1	1
99301	1710	role in proliferation	[roles in proliferation]	0.0	3	1	1	1
99302	1710	CCAAT/enhancer-binding protein	[CCAAT/enhancer-binding protein]	0.0	2	1	1	1
99303	1710	mapping in the ape	[mapping in the apes]	0.0	4	1	1	1
99304	1710	membrane of ghost	[membrane of ghosts]	0.0	3	1	1	1
99305	1710	one other gene	[one other gene]	0.0	3	1	1	1
99306	1710	m.w. of 60000	[m.w. of 60,000]	0.0	3	1	1	1
99307	1710	corresponding specific binding at kd-value	[corresponding specific binding at Kd-values]	0.0	5	1	1	1
99308	1710	depend on immediate environment.	[depending on immediate environment.]	0.0	4	1	1	1
99309	1710	rhesus monkey macrophage	[rhesus monkey macrophages]	0.0	3	1	1	1
99310	1710	late result	[later result]	0.0	2	1	1	1
99311	1710	moreover, supernatant	[Moreover, supernatants]	0.0	2	1	1	1
99312	1710	signal pathway result in the induction	[signaling pathways resulting in the induction]	0.0	6	1	1	1
99313	1710	two CCAAT sequence for transcription factor	[two CCAAT sequences for transcription factors]	0.0	6	1	1	1
99314	1710	patient with leukemia APL	[patients with leukemia APL]	0.0	4	1	1	1
99315	1710	latent, transformation-associated gene	[latent, transformation-associated genes]	0.0	3	1	1	1
99316	1710	peroxisomal proliferator-activated receptor gamma ppargamma expression	[peroxisomal proliferator-activated receptor gamma PPARgamma expression]	0.0	6	1	1	1
99317	1710	relationship between the finding	[relationship between the findings]	0.0	4	1	1	1
99318	1710	amino acid human tramp	[amino acid human TRAMP]	0.0	4	1	1	1
99319	1710	(5118), chronic ebv infection ebv reactivation	[(5/18), chronic EBV infection EBV reactivation]	0.0	6	1	1	1
99320	1710	immunoglobulin heavy chain enhancer igh-enhancer	[immunoglobulin heavy chain enhancer IgH-enhancer]	0.0	5	1	1	1
99321	1710	suppressive property	[suppressive properties]	0.0	2	1	1	1
99322	1710	contrast, overexpression of constitutive activation	[contrast, overexpression of constitutive activation]	0.0	5	1	1	1
99323	1710	low extent.	[lower extent.]	0.0	2	1	1	1
99324	1710	binding of plasma factor vii/viia	[Binding of plasma Factor VII/VIIa]	0.0	5	1	1	1
99325	1710	role of acid.	[role of acid.]	0.0	3	1	1	1
99326	1710	clone extract	[clone extracts]	0.0	2	1	1	1
99327	1710	patient with leukemia AML	[patients with leukemia AML]	0.0	4	1	1	1
99328	1710	AP-1/Octamer UPS	[AP-1/Octamer UPS]	0.0	2	1	1	1
99329	1710	heterozygosity on chromosome	[heterozygosity on chromosome]	0.0	3	1	1	1
99330	1710	mismatch cleavage	[mismatch cleavage]	0.0	2	1	1	1
99331	1710	effect include change in gene expression,	[effects including changes in gene expression,]	0.0	6	1	1	1
99332	1710	combinatorial activation of gene	[combinatorial activation of genes]	0.0	4	1	1	1
99333	1710	component of outgrowth	[component of outgrowth]	0.0	3	1	1	1
99334	1710	endothelial cell with endotoxin	[endothelial cells with endotoxin]	0.0	4	1	1	1
99335	1710	secret el4 cell	[secreting El4 cells]	0.0	3	1	1	1
99336	1710	cellular kinase ikappab kinase alpha	[cellular kinases IkappaB kinase alpha]	0.0	5	1	1	1
99337	1710	exposure dyn/cm2) haec	[exposure dyn/cm2) HAEC]	0.0	3	1	1	1
99338	1710	IL-4 transcription factor	[IL-4 transcription factor]	0.0	3	1	1	1
99339	1710	X2 NF-X2	[X2 NF-X2]	0.0	2	1	1	1
99340	1710	tumor necrosis factor-alpha 10 U/ml,	[tumor necrosis factor-alpha 10 U/ml,]	0.0	5	1	1	1
99341	1710	bead with DNA	[beads with DNA]	0.0	3	1	1	1
99342	1710	Nuclear factor kappa B	[Nuclear Factor kappa B]	0.0	4	1	1	1
99343	1710	methyl prednisolone mg/day) for days.	[methyl prednisolone mg/day) for days.]	0.0	5	1	1	1
99344	1710	eb1	[EB1]	0.0	1	1	1	1
99345	1710	circulate granulocyte	[circulating granulocytes]	0.0	2	1	1	1
99346	1710	potential amphipatic protein segment	[potential amphipatic protein segments]	0.0	4	1	1	1
99347	1710	condition of response	[conditions of response]	0.0	3	1	1	1
99348	1710	two amino acid alteration	[two amino acid alterations]	0.0	4	1	1	1
99349	1710	overexpression of ikk protein transcription,	[Overexpression of IKK protein transcription,]	0.0	5	1	1	1
99350	1710	target the viral protein	[targeting the viral protein]	0.0	4	1	1	1
99351	1710	-adherent	[-adherent]	0.0	1	1	1	1
99352	1710	mechanism of the response	[mechanisms of the response]	0.0	4	1	1	1
99353	1710	inversion of antigen responsiveness	[inversion of antigen responsiveness]	0.0	4	1	1	1
99354	1710	basic method	[basic methods]	0.0	2	1	1	1
99355	1710	2-kb downstream	[2-kb downstream]	0.0	2	1	1	1
99356	1710	however, order of magnitude less potent	[however, orders of magnitude less potent]	0.0	6	1	1	1
99357	1710	region 5'	[region 5']	0.0	2	1	1	1
99358	1710	[3H]dexamethasone binding site on HML	[[3H]dexamethasone binding sites on HML]	0.0	5	1	1	1
99359	1710	inhibitor of p38alpha mapk	[inhibitors of p38alpha MAPk]	0.0	4	1	1	1
99360	1710	abnormal morphology indicative	[abnormal morphology indicative]	0.0	3	1	1	1
99361	1710	proliferation in response (71%) iddm subject	[proliferation in response (71%) IDDM subjects]	0.0	6	1	1	1
99362	1710	stat6 -deficient mouse	[STAT6 -deficient mice]	0.0	3	1	1	1
99363	1710	increase in free ca2+ concentration	[increase in free Ca2+ concentration]	0.0	5	1	1	1
99364	1710	adhesion of dimethyl sulfoxide	[adhesion of dimethyl sulfoxide]	0.0	4	1	1	1
99365	1710	actin filament	[actin filaments]	0.0	2	1	1	1
99366	1710	11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	3	1	1	1
99367	1710	Kasumi-1	[Kasumi-1]	0.0	1	1	1	1
99368	1710	higher-molecular-weight species (of 110	[Higher-molecular-weight species (of 110]	0.0	4	1	1	1
99369	1710	hpb-all	[HPB-ALL]	0.0	1	1	1	1
99370	1710	promoter/enhancer-luciferase	[promoter/enhancer-luciferase]	0.0	1	1	1	1
99371	1710	ecp	[ECP]	0.0	1	2	2	1
99372	1710	whole-cell method in cell	[whole-cell method in cells]	0.0	4	1	1	1
99373	1710	immunocytogenetic study use antibody	[immunocytogenetic studies using antibodies]	0.0	4	1	1	1
99374	1710	support from the patient' physician	[support from the patient's physician]	0.0	5	1	1	1
99375	1710	proenkephalin mrna	[proenkephalin mRNA]	0.0	2	1	1	1
99376	1710	pyruvate kinase promoter	[pyruvate kinase promoter]	0.0	3	1	1	1
99377	1710	domain of the pp56(lck) molecule	[domains of the pp56(lck) molecule]	0.0	5	1	1	1
99378	1710	two contacts,	[two contacts,]	0.0	2	1	1	1
99379	1710	vivo evidence	[vivo evidence]	0.0	2	2	2	1
99380	1710	edn	[EDN]	0.0	1	1	1	1
99381	1710	processing system	[processing system]	0.0	2	1	1	1
99382	1710	ifngr1 frameshift deletion	[IFNGR1 frameshift deletions]	0.0	3	1	1	1
99383	1710	tandem dinucleotide repeat	[tandem dinucleotide repeats]	0.0	3	1	1	1
99384	1710	lymphoid-specific enhancer element	[lymphoid-specific enhancer element]	0.0	3	1	1	1
99385	1710	interaction of ags	[interaction of Ags]	0.0	3	1	1	1
99386	1710	b gene blk	[B gene blk]	0.0	3	1	1	1
99387	1710	distinct complementation group	[distinct complementation groups]	0.0	3	1	1	1
99388	1710	transcription factor with affinity	[transcription factor with affinity]	0.0	4	1	1	1
99389	1710	treatment with okadaic acid a inhibitor	[Treatment with okadaic acid an inhibitor]	0.0	6	1	1	1
99390	1710	eg,	[eg,]	0.0	1	1	1	1
99391	1710	phosphorylation of the protein.	[phosphorylation of the protein.]	0.0	4	1	1	1
99392	1710	indirect, alteration	[indirect, alteration]	0.0	2	1	1	1
99393	1710	hand, activation	[hand, activation]	0.0	2	1	1	1
99394	1710	monoblastic cell	[monoblastic cells]	0.0	2	1	1	1
99395	1710	major cell	[major cells]	0.0	2	1	1	1
99396	1710	means regulate cytokine T cell response	[means regulating cytokine T cell responses]	0.0	6	1	1	1
99397	1710	target structure of the cd8(+)-t-cell response	[Target structures of the CD8(+)-T-cell response]	0.0	6	1	1	1
99398	1710	site of genes, loss	[site of genes, loss]	0.0	4	1	1	1
99399	1710	globin element	[globin element]	0.0	2	1	1	1
99400	1710	NH2 terminus of receptor-1	[NH2 terminus of receptor-1]	0.0	4	1	1	1
99401	1710	short arm of human chromosome	[short arm of human chromosome]	0.0	5	1	1	1
99402	1710	wide variety include interferon	[wide variety including interferons]	0.0	4	1	1	1
99403	1710	express exogenous gata-2	[expressing exogenous GATA-2]	0.0	3	1	1	1
99404	1710	10 hiv-infected patient with low affinity	[10 HIV-infected patients with low affinity]	0.0	6	1	1	1
99405	1710	majority of human tissue	[majority of human tissues]	0.0	4	1	1	1
99406	1710	NTF interaction with DNA element	[NTF interactions with DNA elements]	0.0	5	1	1	1
99407	1710	amino- domain	[amino- domains]	0.0	2	1	1	1
99408	1710	three IL-2 cell line	[three IL-2 cell lines]	0.0	4	1	1	1
99409	1710	direct evidence for the involvement	[direct evidence for the involvement]	0.0	5	1	1	1
99410	1710	min) exercise ppe	[min) exercise PPE]	0.0	3	1	1	1
99411	1710	bcl-6 mrna expression,	[BCL-6 MRNA expression,]	0.0	3	1	1	1
99412	1710	I type ii interferon	[I type II interferons]	0.0	4	1	1	1
99413	1710	factor nf-il6 (position -153	[factor NF-IL6 (positions -153]	0.0	4	1	1	1
99414	1710	consequence of the differentiation.	[consequence of the differentiation.]	0.0	4	1	1	1
99415	1710	specific binding of protein (s)	[specific binding of protein (s)]	0.0	5	1	1	1
99416	1710	tyrosine phosphorylation the stat-1alpha	[tyrosine phosphorylation the STAT-1alpha]	0.0	4	1	1	1
99417	1710	undetectable level in platelet	[undetectable levels in platelets]	0.0	4	1	1	1
99418	1710	derepression	[derepression]	0.0	1	1	1	1
99419	1710	stimulation of ap-1 binding activity	[stimulation of AP-1 binding activity]	0.0	5	1	1	1
99420	1710	PMA factor PIF	[PMA factor PIF]	0.0	3	1	1	1
99421	1710	belong by a negative mutant	[belonging by a negative mutant]	0.0	5	1	1	1
99422	1710	16HBE cell	[16HBE cells]	0.0	2	1	1	1
99423	1710	activation by stimulus in human neutrophil	[Activation by stimuli in human neutrophils]	0.0	6	1	1	1
99424	1710	oligodeoxyribonucleotide	[oligodeoxyribonucleotide]	0.0	1	1	1	1
99425	1710	hormone bind domain variant	[hormone binding domain variants]	0.0	4	1	1	1
99426	1710	hierarchical structure similar	[hierarchical structure similar]	0.0	3	1	1	1
99427	1710	negative regulation at the level	[negative regulation at the level]	0.0	5	1	1	1
99428	1710	cd36 -specific antibody okm5	[CD36 -specific antibody OKM5]	0.0	4	1	1	1
99429	1710	effect a component	[effects an component]	0.0	3	1	1	1
99430	1710	common abnormality in neoplasia	[common abnormalities in neoplasia]	0.0	4	1	1	1
99431	1710	24 woman second	[24 women second]	0.0	3	1	1	1
99432	1710	Th1-dominated inflammation in RA	[Th1-dominated inflammation in RA]	0.0	4	1	1	1
99433	1710	estrogen receptor in sle	[estrogen receptor in SLE]	0.0	4	1	1	1
99434	1710	promoter activity of CXCR4	[promoter activity of CXCR4]	0.0	4	2	2	1
99435	1710	analysis of human immunodeficiency virus apoptosis	[analysis of human immunodeficiency virus apoptosis]	0.0	6	1	1	1
99436	1710	lymphocyte predominance hd nlphd	[lymphocyte predominance HD NLPHD]	0.0	4	1	1	1
99437	1710	generation of ldl putative trigger molecule	[generation of LDL putative triggering molecule]	0.0	6	1	1	1
99438	1710	inverse relation to complex class	[inverse relation to complex classes]	0.0	5	1	1	1
99439	1710	weak, interaction	[weak, interactions]	0.0	2	1	1	1
99440	1710	PMNL	[PMNL]	0.0	1	1	1	1
99441	1710	pan gamma/delta antibody	[pan gamma/delta antibody]	0.0	3	1	1	1
99442	1710	increase awareness of necrosis of bone	[increasing awareness of necrosis of bone]	0.0	6	1	1	1
99443	1710	10(-12) g/g of mrna in lymphocyte	[10(-12) g/g of mRNA in lymphocytes]	0.0	6	1	1	1
99444	1710	multiple inactivate substitution	[multiple inactivating substitutions]	0.0	3	1	1	1
99445	1710	level U2	[levels U2]	0.0	2	1	1	1
99446	1710	also in maintenance	[also in maintenance]	0.0	3	1	1	1
99447	1710	homozygous stat6 mouse	[homozygous STAT6 mice]	0.0	3	1	1	1
99448	1710	beta-(1,3)-linked glucose homopolymer	[beta-(1,3)-linked glucose homopolymer]	0.0	3	1	1	1
99449	1710	phagocyte MNP	[phagocytes MNP]	0.0	2	1	1	1
99450	1710	therapy of tumor	[therapy of tumors]	0.0	3	1	1	1
99451	1710	selective dna-binding activity	[Selective DNA-binding activity]	0.0	3	1	1	1
99452	1710	strong staining for nf-kappabp65 than patient	[stronger staining for NF-kappaBp65 than patients]	0.0	6	1	1	1
99453	1710	motif characteristic of a family	[motif characteristic of a family]	0.0	5	1	1	1
99454	1710	increase body	[increasing body]	0.0	2	1	1	1
99455	1710	pmol/L).	[pmol/L).]	0.0	1	1	1	1
99456	1710	T-helper 0	[T-helper 0]	0.0	2	1	1	1
99457	1710	isoflavone metabolite	[isoflavone metabolites]	0.0	2	1	1	1
99458	1710	potent activator of many promoter	[potent activator of many promoters]	0.0	5	1	1	1
99459	1710	1/oct	[1/Oct]	0.0	1	1	1	1
99460	1710	ca2+-mediated activation	[Ca2+-mediated activation]	0.0	2	1	1	1
99461	1710	interaction with cell-specific coactivator	[interactions with cell-specific coactivators]	0.0	4	1	1	1
99462	1710	activate effect of pa	[activating effect of PA]	0.0	4	1	1	1
99463	1710	31 kda	[31 kDa]	0.0	2	1	1	1
99464	1710	A a tyrosine kinase inhibitor	[A a tyrosine kinase inhibitor]	0.0	5	1	1	1
99465	1710	critical mechanism in the system	[critical mechanism in the system]	0.0	5	1	1	1
99466	1710	group type	[group type]	0.0	2	1	1	1
99467	1710	b1 transcript	[B1 transcript]	0.0	2	1	1	1
99468	1710	process unique	[process unique]	0.0	2	1	1	1
99469	1710	contrast, ligand activation	[contrast, ligand activation]	0.0	3	1	1	1
99470	1710	cytokine of cell death	[cytokines of cell death]	0.0	4	1	1	1
99471	1710	nucleotide identity	[nucleotide identity]	0.0	2	1	1	1
99472	1710	marker of osteoclast vitronectin receptor VR	[markers of osteoclasts vitronectin receptor VR]	0.0	6	1	1	1
99473	1710	g2,	[G2,]	0.0	1	1	1	1
99474	1710	two cis-acting regulatory elements,	[two cis-acting regulatory elements,]	0.0	4	1	1	1
99475	1710	signal function similar in cell	[signaling functions similar in cells]	0.0	5	1	1	1
99476	1710	use systems, such as cell-free extract	[using systems, such as cell-free extracts]	0.0	6	1	1	1
99477	1710	presence of a domain	[presence of an domain]	0.0	4	1	1	1
99478	1710	vitro cortisol inhibition	[vitro cortisol inhibition]	0.0	3	1	1	1
99479	1710	addition of E220K ubiquitinylation of c-Jun	[addition of E220K ubiquitinylation of c-Jun]	0.0	6	1	1	1
99480	1710	blot analysis on human tissue	[blot analysis on human tissues]	0.0	5	1	1	1
99481	1710	b serum	[B serum]	0.0	2	1	1	1
99482	1710	selection of lymphocyte	[selection of lymphocytes]	0.0	3	1	1	1
99483	1710	class ii-like molecule	[class II-like molecule]	0.0	3	1	1	1
99484	1710	response with bacterium	[response with bacteria]	0.0	3	1	1	1
99485	1710	single acid response element	[single acid response element]	0.0	4	1	1	1
99486	1710	induction of neutrophil binding	[induction of neutrophil binding]	0.0	4	1	1	1
99487	1710	multiple regulatory sites.	[multiple regulatory sites.]	0.0	3	1	1	1
99488	1710	two dose	[two doses]	0.0	2	1	1	1
99489	1710	epf	[E2Fs]	0.0	1	1	1	1
99490	1710	beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	4	1	1	1
99491	1710	wide range of mutation	[wide range of mutations]	0.0	4	1	1	1
99492	1710	double time of about 25 h	[doubling times of about 25 h]	0.0	6	1	1	1
99493	1710	stress include thiol deprivation	[stress including thiol deprivation]	0.0	4	1	1	1
99494	1710	experimental basis	[experimental basis]	0.0	2	1	1	1
99495	1710	cloning of a cDNA	[cloning of a cDNA]	0.0	4	1	1	1
99496	1710	ca2+ step	[Ca2+ step]	0.0	2	1	1	1
99497	1710	contain repeat of bp	[containing repeats of bp]	0.0	4	1	1	1
99498	1710	il-2 protein	[IL-2 protein]	0.0	2	1	1	1
99499	1710	profile of sigma receptor	[profile of sigma receptors]	0.0	4	1	1	1
99500	1710	two activator	[two activators]	0.0	2	1	1	1
99501	1710	include psoriasis	[including psoriasis]	0.0	2	1	1	1
99502	1710	pp pp1	[PPs PP1/PP2A]	0.0	2	1	1	1
99503	1710	interleukin-2 signal	[interleukin-2 signaling]	0.0	2	1	1	1
99504	1710	important role regulate signal	[important role regulating signaling]	0.0	4	1	1	1
99505	1710	young (18- healthy female volunteer	[young (18- healthy female volunteers]	0.0	5	1	1	1
99506	1710	cell ECs in hypoxia po2	[cells ECs in hypoxia PO2]	0.0	5	1	1	1
99507	1710	expression of gr isoform	[expression of GR isoforms]	0.0	4	1	1	1
99508	1710	interaction with multiple partners,	[interaction with multiple partners,]	0.0	4	1	1	1
99509	1710	era	[era]	0.0	1	1	1	1
99510	1710	erk2 a element	[erk2 a element]	0.0	3	1	1	1
99511	1710	class major histocompatibility cell line	[class major histocompatibility cell lines]	0.0	5	1	1	1
99512	1710	loss of interleukin (il-6) receptor	[loss of interleukin (IL-6) receptor]	0.0	5	1	1	1
99513	1710	chicken NF-M transcription	[Chicken NF-M transcription]	0.0	3	1	1	1
99514	1710	site in the TNF-alpha promoter (kappa	[sites in the TNF-alpha promoter (kappa]	0.0	6	1	1	1
99515	1710	method of lymphocyte from woman	[METHOD OF lymphocytes from women]	0.0	5	1	1	1
99516	1710	other activity	[other activities]	0.0	2	1	1	1
99517	1710	function of mzf-2	[function of MZF-2]	0.0	3	1	1	1
99518	1710	positive regulator of nf-kappab	[positive regulator of NF-kappaB]	0.0	4	1	1	1
99519	1710	blot analysis use anti-ERK kinase antibody	[blot analysis using anti-ERK kinase antibodies]	0.0	6	1	1	1
99520	1710	factor kappa b site	[factor kappa B site]	0.0	4	1	1	1
99521	1710	interaction of eed	[interaction of Eed]	0.0	3	1	1	1
99522	1710	cell of lymphocytic system	[cells of lymphocytic systems]	0.0	4	1	1	1
99523	1710	cell fate development	[cell fate development]	0.0	3	1	1	1
99524	1710	interleukin il-2 synthesis	[interleukin IL-2 synthesis]	0.0	3	1	1	1
99525	1710	human nucleolin	[human nucleolin]	0.0	2	1	1	1
99526	1710	erythrocyte protein	[erythrocyte proteins]	0.0	2	1	1	1
99527	1710	disease xeroderma pigmentosum	[disease xeroderma pigmentosum]	0.0	3	1	1	1
99528	1710	patient with normal receptor affinity	[patients with normal receptor affinity]	0.0	5	1	1	1
99529	1710	esc	[Esc]	0.0	1	1	1	1
99530	1710	transient pseudohypoaldosteronism in renal disease	[Transient pseudohypoaldosteronism in renal disease]	0.0	5	1	1	1
99531	1710	cell express receptor	[cells expressing receptors]	0.0	3	1	1	1
99532	1710	show essential	[showing essential]	0.0	2	1	1	1
99533	1710	different hil-5 cell line	[different hIL-5 cell lines]	0.0	4	1	1	1
99534	1710	phorbol ester ionomycin activation	[phorbol ester ionomycin activation]	0.0	4	1	1	1
99535	1710	e production	[E production]	0.0	2	1	1	1
99536	1710	cytokine -modulate activity of tepoxalin	[Cytokine -modulating activity of tepoxalin]	0.0	5	1	1	1
99537	1710	level of heat stable alkaline phosphatase	[levels of heat stable alkaline phosphatase]	0.0	6	1	1	1
99538	1710	important alteration	[important alterations]	0.0	2	1	1	1
99539	1710	position -78 to +16	[positions -78 to +16]	0.0	4	1	1	1
99540	1710	alter the redox status in macrophage	[altering the redox status in macrophages]	0.0	6	1	1	1
99541	1710	counterpart to leukemia	[counterpart to leukemias]	0.0	3	1	1	1
99542	1710	light of use as agent	[light of use as agents]	0.0	5	1	1	1
99543	1710	kit225 cell	[Kit225 cells]	0.0	2	1	1	1
99544	1710	lymphoid tumor	[lymphoid tumors]	0.0	2	1	1	1
99545	1710	METHOD: two	[METHOD: Two]	0.0	2	1	1	1
99546	1710	bovine pulmonary artery cell	[bovine pulmonary artery cells]	0.0	4	1	1	1
99547	1710	negative form of IKK alpha	[negative forms of IKK alpha]	0.0	5	1	1	1
99548	1710	switch gear	[Switching gears]	0.0	2	1	1	1
99549	1710	surface tr75	[surface TR75]	0.0	2	1	1	1
99550	1710	level in Cushing' disease	[level in Cushing's disease]	0.0	4	1	1	1
99551	1710	accurate initiation of transcription	[accurate initiation of transcription]	0.0	4	1	1	1
99552	1710	novel hiv-1 isolate	[novel HIV-1 isolate]	0.0	3	1	1	1
99553	1710	trafficking	[trafficking]	0.0	1	1	1	1
99554	1710	nfatx isoform	[NFATx isoforms]	0.0	2	1	1	1
99555	1710	start 0/1	[starting 0/1]	0.0	2	1	1	1
99556	1710	1 expression in monocytic cell	[1 expression in monocytic cells]	0.0	5	1	1	1
99557	1710	related member share DNA binding specificity	[related members sharing DNA binding specificities]	0.0	6	1	1	1
99558	1710	dominant mode of transmission	[dominant mode of transmission]	0.0	4	2	2	1
99559	1710	ldl-receptor gene transcription	[LDL-receptor gene transcription]	0.0	3	1	1	1
99560	1710	two functionally different activation domain	[two functionally different activation domains]	0.0	5	1	1	1
99561	1710	12-myristate -13- acetate	[12-myristate -13- acetate]	0.0	3	1	1	1
99562	1710	contain follicular DC	[containing follicular DC]	0.0	3	1	1	1
99563	1710	progenitor burst-form units-erythroid	[progenitors burst-forming units-erythroid]	0.0	3	1	1	1
99564	1710	18 case for tsc2 mutation	[18 cases for TSC2 mutations]	0.0	5	1	1	1
99565	1710	use peripheral blood mononuclear cell	[Using peripheral blood mononuclear cells]	0.0	5	1	1	1
99566	1710	cyclosporin tumor necrosis factor	[cyclosporin tumor necrosis factor]	0.0	4	1	1	1
99567	1710	6 menstruate woman	[6 menstruating women]	0.0	3	1	1	1
99568	1710	hsp60 in vein endothelial cell	[Hsp60 in vein endothelial cells]	0.0	5	1	1	1
99569	1710	goal of ongoing study	[goal of ongoing study]	0.0	4	1	1	1
99570	1710	immunodeficiency virus transcription in cell	[immunodeficiency virus transcription in cells]	0.0	5	1	1	1
99571	1710	interaction of ebv	[interaction of EBV]	0.0	3	1	1	1
99572	1710	stimulation of blood platelet	[Stimulation of blood platelets]	0.0	4	1	1	1
99573	1710	large, cell	[large, cells]	0.0	2	1	1	1
99574	1710	vivo models,	[vivo models,]	0.0	2	1	1	1
99575	1710	shock HS	[shock HS]	0.0	2	1	1	1
99576	1710	x-linked spinal muscular atrophy	[X-linked spinal muscular atrophy]	0.0	4	1	1	1
99577	1710	PHA-activated peripheral cell	[PHA-activated peripheral cells]	0.0	3	1	1	1
99578	1710	encode for lymphokine	[encoding for lymphokines]	0.0	3	1	1	1
99579	1710	role protein in cyclic AMP inhibition	[Role protein in cyclic AMP inhibition]	0.0	6	1	1	1
99580	1710	ebv infection most	[EBV infection most]	0.0	3	1	1	1
99581	1710	low balance	[lower balance]	0.0	2	1	1	1
99582	1710	STAT binding sequence present	[STAT binding sequences present]	0.0	4	1	1	1
99583	1710	many inflammatory disorder	[many inflammatory disorders]	0.0	3	1	1	1
99584	1710	ppargamma proliferator-activated receptor gamma expression	[PPARgamma proliferator-activated receptor gamma expression]	0.0	5	1	1	1
99585	1710	346 residue	[346 residues]	0.0	2	1	1	1
99586	1710	25-fold less a-myb rna	[25-fold less A-myb RNA]	0.0	4	1	1	1
99587	1710	emcv ires fragment	[EMCV IRES fragments]	0.0	3	1	1	1
99588	1710	productive interaction	[productive interactions]	0.0	2	1	1	1
99589	1710	expression to tissue	[expression to tissues]	0.0	3	1	1	1
99590	1710	high efficacy	[high efficacy]	0.0	2	1	1	1
99591	1710	loosely cell with neurite process	[loosely cells with neurite processes]	0.0	5	1	1	1
99592	1710	b mrna	[B mRNA]	0.0	2	1	1	1
99593	1710	pcr analysis from individual with infection	[PCR analysis from individuals with infection]	0.0	6	1	1	1
99594	1710	extract upon translocation of VDR	[extracts upon translocation of VDR]	0.0	5	1	1	1
99595	1710	high ligand binding	[high ligand binding]	0.0	3	1	1	1
99596	1710	promote the NK clearance of cell	[promoting the NK clearance of cells]	0.0	6	1	1	1
99597	1710	individual response to the early protein	[individual responses to the early proteins]	0.0	6	1	1	1
99598	1710	stimulation of tonsillar mononuclear cell	[Stimulation of tonsillar mononuclear cells]	0.0	5	1	1	1
99599	1710	rare zone cell	[rare zone cells]	0.0	3	1	1	1
99600	1710	b-alpha level	[B-alpha levels]	0.0	2	1	1	1
99601	1710	ccaac	[CCAAC]	0.0	1	1	1	1
99602	1710	individual between 20-50%	[individuals between 20-50%]	0.0	3	1	1	1
99603	1710	ccaag	[CCAAG]	0.0	1	1	1	1
99604	1710	reverse effect	[reverse effects]	0.0	2	1	1	1
99605	1710	DNA region specify affinity	[DNA region specifying affinity]	0.0	4	1	1	1
99606	1710	LTR revertant	[LTR revertants]	0.0	2	1	1	1
99607	1710	use x-chromosome inactivation	[using X-chromosome inactivation]	0.0	3	1	1	1
99608	1710	regulatory factor-kappa beta enf-kappa	[regulatory factor-kappa beta (NF-kappa]	0.0	4	1	1	1
99609	1710	blood pressure monitor	[blood pressure monitor]	0.0	3	1	1	1
99610	1710	apparent size of kilodalton	[apparent size of kilodaltons]	0.0	4	1	1	1
99611	1710	substantial decrease in response	[substantial decrease in response]	0.0	4	1	1	1
99612	1710	level of c-erbB2 amplification	[levels of c-erbB2 amplification]	0.0	4	1	1	1
99613	1710	cis-act regulatory element	[cis-acting regulatory elements]	0.0	3	1	1	1
99614	1710	5 m D3	[5 M D3]	0.0	3	1	1	1
99615	1710	precursor of DC	[precursors of DC]	0.0	3	1	1	1
99616	1710	b activation in human monocyte	[B activation in human monocytes]	0.0	5	1	1	1
99617	1710	spontaneous lymphocyte proliferation in healthy control	[spontaneous lymphocyte proliferation in healthy controls]	0.0	6	1	1	1
99618	1710	arthritis example, osteoarthritis	[arthritis example, osteoarthritis]	0.0	3	1	1	1
99619	1710	sensitive activate pathway distinct	[sensitive activating pathway distinct]	0.0	4	1	1	1
99620	1710	withdrawal of the antithyroid	[withdrawal of the antithyroid]	0.0	4	1	1	1
99621	1710	alone in combination	[alone in combination]	0.0	3	1	1	1
99622	1710	absence of alpha,25-(OH)2D3	[absence of alpha,25-(OH)2D3]	0.0	3	1	1	1
99623	1710	recombinant dimeric tnf receptor	[recombinant dimeric TNF receptor]	0.0	4	1	1	1
99624	1710	anti-infective activity	[anti-infective activity]	0.0	2	1	1	1
99625	1710	membrane protein of the envelope	[membrane protein of the envelope]	0.0	5	1	1	1
99626	1710	site of constitutive DNA-protein interaction	[site of constitutive DNA-protein interactions]	0.0	5	1	1	1
99627	1710	glucocorticoid synthesis	[glucocorticoid synthesis]	0.0	2	1	1	1
99628	1710	interconversion	[interconversion]	0.0	1	1	1	1
99629	1710	(stat) family	[(STAT) family]	0.0	2	1	1	1
99630	1710	nfaT-containing complex devoid	[NFAT-containing complexes devoid]	0.0	3	1	1	1
99631	1710	upregulation of colony-stimulating factor receptor	[Upregulation of colony-stimulating factor receptors]	0.0	5	1	1	1
99632	1710	action of steroid hormone	[action of steroid hormones]	0.0	4	1	1	1
99633	1710	such as distress syndrome ards	[such as distress syndrome ARDS]	0.0	5	1	1	1
99634	1710	reservoir for viral production	[reservoir for viral production]	0.0	4	1	1	1
99635	1710	haemoglobin production	[haemoglobin production]	0.0	2	3	3	1
99636	1710	aldosterone receptor outside the phase	[aldosterone receptors outside the phase]	0.0	5	1	1	1
99637	1710	expose umbilical vein endothelial cell	[Exposing umbilical vein endothelial cells]	0.0	5	1	1	1
99638	1710	ifn-gamma -independent manner	[IFN-gamma -independent manner]	0.0	3	1	1	1
99639	1710	golgi processing	[Golgi processing]	0.0	2	1	1	1
99640	1710	various breakpoint 11 range to q23	[various breakpoints 11 ranging to q23]	0.0	6	1	1	1
99641	1710	micrograms/kg).	[micrograms/kg).]	0.0	1	1	1	1
99642	1710	translocation of this member of NF-AT	[translocation of these members of NF-AT]	0.0	6	1	1	1
99643	1710	beta h1-globin	[beta h1-globin]	0.0	2	1	1	1
99644	1710	purified, blood T cell	[purified, blood T cells]	0.0	4	1	1	1
99645	1710	kind include ionizing radiation.	[kinds including ionizing radiation.]	0.0	4	1	1	1
99646	1710	expression of bcl-6 protein in skin	[Expression of bcl-6 protein in skin]	0.0	6	1	1	1
99647	1710	four binding site for protein	[four binding sites for proteins]	0.0	5	1	1	1
99648	1710	level b4	[levels B4]	0.0	2	1	1	1
99649	1710	essential component of promoter activity	[essential component of promoter activity]	0.0	5	1	1	1
99650	1710	immunodeficiency virus infection (5/24)	[immunodeficiency virus infection (5/24)]	0.0	4	1	1	1
99651	1710	suggest a pivotal role of RXR	[suggesting a pivotal role of RXR]	0.0	6	1	1	1
99652	1710	two kappa b site	[two kappa B sites]	0.0	4	1	1	1
99653	1710	young (18- volunteer	[young (18- volunteers]	0.0	3	1	1	1
99654	1710	soluble product from RCC explant	[soluble products from RCC explants]	0.0	5	1	1	1
99655	1710	early receptor binding study	[earlier receptor binding studies]	0.0	4	1	1	1
99656	1710	possibly a platelet function	[possibly a platelet function]	0.0	4	1	1	1
99657	1710	thyroid hormone receptor protein	[thyroid hormone receptor protein]	0.0	4	1	1	1
99658	1710	fab fragment	[Fab fragment]	0.0	2	1	1	1
99659	1710	soluble mediators,	[soluble mediators,]	0.0	2	1	1	1
99660	1710	RA target	[RA target]	0.0	2	1	1	1
99661	1710	peripheral mononuclear leukocyte of patient	[peripheral mononuclear leukocytes of patients]	0.0	5	2	2	1
99662	1710	fab	[Fab]	0.0	1	1	1	1
99663	1710	hpr cDNA	[hPR cDNA]	0.0	2	1	1	1
99664	1710	CTLA-4 inhibition of event	[CTLA-4 inhibition of events]	0.0	4	1	1	1
99665	1710	fac	[FACS]	0.0	1	1	1	1
99666	1710	deletion variant of tlr2	[deletion variants of TLR2]	0.0	4	1	1	1
99667	1710	active form of cn	[active forms of CN]	0.0	4	1	1	1
99668	1710	continuously grow leukemic cell line	[continuously growing leukemic cell line]	0.0	5	1	1	1
99669	1710	il-6 by blood mononuclear cell pbmc	[IL-6 by blood mononuclear cells PBMC]	0.0	6	1	1	1
99670	1710	contain copy of nf-kappa b site	[containing copies of NF-kappa B site]	0.0	6	1	1	1
99671	1710	chimaeric product of PML-RAR alpha	[chimaeric product of PML-RAR alpha]	0.0	5	1	1	1
99672	1710	control the early step	[controlling the early steps]	0.0	4	1	1	1
99673	1710	DNase-I site	[DNase-I sites]	0.0	2	1	1	1
99674	1710	biological model of a situation	[biological models of an situation]	0.0	5	1	1	1
99675	1710	T cell-specific tyrosine kinase	[T cell-specific tyrosine kinase]	0.0	4	1	1	1
99676	1710	monocyte binding to cell	[monocyte binding to cells]	0.0	4	1	1	1
99677	1710	n-Acetyl-L-cysteine a antioxidant,	[n-Acetyl-L-cysteine a antioxidant,]	0.0	3	1	1	1
99678	1710	rank order of potency	[rank order of potency]	0.0	4	1	1	1
99679	1710	fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	5	1	1	1
99680	1710	PB1 protein complex	[PB1 protein complex]	0.0	3	1	1	1
99681	1710	Caspase-3 activation result	[Caspase-3 activation resulting]	0.0	3	1	1	1
99682	1710	two potential Sp1 binding site	[two potential Sp1 binding sites]	0.0	5	1	1	1
99683	1710	map kinase pd98059	[MAP kinase PD98059]	0.0	3	1	1	1
99684	1710	potent inducer of monocytic differentiation	[potent inducer of monocytic differentiation]	0.0	5	1	1	1
99685	1710	contain sequence from glucocorticoid -repressible gene	[containing sequences from glucocorticoid -repressible genes]	0.0	6	1	1	1
99686	1710	activation of the repeat type 1	[activation of the repeat type 1]	0.0	6	1	1	1
99687	1710	more extensive footprint than the globin	[more extensive footprints than the globin]	0.0	6	1	1	1
99688	1710	Paternal expression of WT1 in fibroblast	[Paternal expression of WT1 in fibroblasts]	0.0	6	1	1	1
99689	1710	further incubation	[further incubation]	0.0	2	1	1	1
99690	1710	sequela in adult patient	[sequela in adult patients]	0.0	4	1	1	1
99691	1710	reduction of DNA binding capacity	[reduction of DNA binding capacity]	0.0	5	1	1	1
99692	1710	patient with mense	[patients with menses]	0.0	3	1	1	1
99693	1710	gata element of the long repeat	[GATA elements of the long repeat]	0.0	6	1	1	1
99694	1710	effect on transcriptional factor	[effects on transcriptional factors]	0.0	4	1	1	1
99695	1710	alpha chain gamma chain	[alpha chain gamma chain]	0.0	4	1	1	1
99696	1710	normal thymus	[normal thymus]	0.0	2	1	1	1
99697	1710	2 different line	[2 different lines]	0.0	3	1	1	1
99698	1710	cytokine mrna expression,	[cytokine mRNA expression,]	0.0	3	1	1	1
99699	1710	dominance	[dominance]	0.0	1	1	1	1
99700	1710	phorbol-13-acetate tpa for h	[phorbol-13-acetate TPA for h]	0.0	4	1	1	1
99701	1710	course chi2	[course chi2]	0.0	2	1	1	1
99702	1710	include tumor necrosis factor-alpha	[including tumor necrosis factor-alpha]	0.0	4	1	1	1
99703	1710	band range from 25 kD	[bands ranging from 25 kD]	0.0	5	1	1	1
99704	1710	interaction between cell-specific transcriptional coactivator	[interactions between cell-specific transcriptional coactivators]	0.0	5	1	1	1
99705	1710	regulator i	[regulator I]	0.0	2	1	1	1
99706	1710	development of treatment	[development of treatments]	0.0	3	1	1	1
99707	1710	sex steroid regulation	[Sex steroid regulation]	0.0	3	1	1	1
99708	1710	topographical region	[topographical regions]	0.0	2	1	1	1
99709	1710	gene activation culminate	[gene activation culminating]	0.0	3	1	1	1
99710	1710	human a promoter region (-36	[humans a promoter region (-36]	0.0	5	1	1	1
99711	1710	previously, a nuclear factor	[Previously, a nuclear factor]	0.0	4	1	1	1
99712	1710	state level of tnf mrna	[state levels of TNF mRNA]	0.0	5	1	1	1
99713	1710	trigger of the ag receptor	[triggering of the Ag receptor]	0.0	5	1	1	1
99714	1710	24 healthy volunteer	[24 healthy volunteers]	0.0	3	1	1	1
99715	1710	hiv infection of U937 monocytic cell	[HIV infection of U937 monocytic cells]	0.0	6	1	1	1
99716	1710	gene therapy protocol for cf	[gene therapy protocols for CF]	0.0	5	1	1	1
99717	1710	abnormality gene in recurrent malignant astrocytomas	[Abnormalities genes in recurrent malignant astrocytomas]	0.0	6	1	1	1
99718	1710	papillomavirus	[papillomavirus]	0.0	1	1	1	1
99719	1710	regulatory pathway during activation	[regulatory pathways during activation]	0.0	4	1	1	1
99720	1710	functional activation by beta-phorbol 12-myristate	[functional activation by beta-phorbol 12-myristate]	0.0	5	1	1	1
99721	1710	key inducer	[key inducer]	0.0	2	1	1	1
99722	1710	implication for therapy of tumor	[implications for therapy of tumors]	0.0	5	1	1	1
99723	1710	(44-55 years) hypertensive	[(44-55 years) hypertensives]	0.0	3	1	1	1
99724	1710	wd-40 repeat	[WD-40 repeats]	0.0	2	1	1	1
99725	1710	il-4 il-7 signal pathway	[IL-4 IL-7 signaling pathways]	0.0	4	1	1	1
99726	1710	rel-related DNA	[rel-related DNA]	0.0	2	1	1	1
99727	1710	primary sjogren' syndrome (ss)	[primary Sjogren's syndrome (SS)]	0.0	4	1	1	1
99728	1710	human cell response to amebic infection	[Human cell responses to amebic infection]	0.0	6	1	1	1
99729	1710	chicken NF-M	[Chicken NF-M]	0.0	2	1	1	1
99730	1710	rearrangement of at least one	[Rearrangement of at least one]	0.0	5	1	1	1
99731	1710	fgf	[FGFs]	0.0	1	1	1	1
99732	1710	increase within 1 h	[increase within 1 h]	0.0	4	1	1	1
99733	1710	Potent attenuation of live-hiv-1	[Potent attenuation of live-HIV-1]	0.0	4	1	1	1
99734	1710	nmol/l, incubation time 2 h	[nmol/l, incubation time 2 h]	0.0	5	1	1	1
99735	1710	acid atra washed,	[acid ATRA washed,]	0.0	3	1	1	1
99736	1710	critical event in the process	[critical event in the process]	0.0	5	1	1	1
99737	1710	n-acetylcysteine nac	[N-acetylcysteine NAC]	0.0	2	1	1	1
99738	1710	glucocorticoid therapy in leukocyte	[glucocorticoid therapy in leukocytes]	0.0	4	1	1	1
99739	1710	cluster of residue	[cluster of residues]	0.0	3	1	1	1
99740	1710	model for human apl	[model for human APL]	0.0	4	1	1	1
99741	1710	polychlorinated dibenzo-p-dioxin pcdd/pcdf	[polychlorinated dibenzo-p-dioxins PCDD/PCDF]	0.0	3	1	1	1
99742	1710	two virion	[two virions]	0.0	2	1	1	1
99743	1710	human blood burst-forming unit-erythroid bfu-e	[human blood burst-forming unit-erythroid BFU-E]	0.0	5	1	1	1
99744	1710	further evidence important in transformation	[further evidence important in transformation]	0.0	5	1	1	1
99745	1710	human il-5 receptor	[human IL-5 receptor]	0.0	3	1	1	1
99746	1710	continuous cell line	[continuous cell line]	0.0	3	1	1	1
99747	1710	four nf-kappa b binding site	[four NF-kappa B binding sites]	0.0	5	1	1	1
99748	1710	incubation of mbp-	[incubation of MBP-]	0.0	3	1	1	1
99749	1710	cooperative effect of B7	[cooperative effect of B7]	0.0	4	1	1	1
99750	1710	rat tissue	[rat tissues]	0.0	2	1	1	1
99751	1710	h.,	[H.,]	0.0	1	1	1	1
99752	1710	low level of response	[low levels of response]	0.0	4	1	1	1
99753	1710	activation of human zeta	[activation of human zeta]	0.0	4	1	1	1
99754	1710	protective effect of sp	[protective effect of SP]	0.0	4	1	1	1
99755	1710	caspase substrate	[caspase substrate]	0.0	2	1	1	1
99756	1710	h+-atpase	[H+-ATPase]	0.0	1	1	1	1
99757	1710	germline transcription	[germline transcription]	0.0	2	3	3	1
99758	1710	ROI fluorochrome dcfh	[ROI fluorochrome DCFH-DA]	0.0	3	1	1	1
99759	1710	African African population	[African African populations]	0.0	3	1	1	1
99760	1710	sites/cell respectively, p less	[sites/cell respectively, P less]	0.0	4	1	1	1
99761	1710	encode transactivator	[encoding transactivators]	0.0	2	1	1	1
99762	1710	form, Stat3alpha	[form, Stat3alpha]	0.0	2	1	1	1
99763	1710	epo signal for differentiation	[EPO signal for differentiation]	0.0	4	1	1	1
99764	1710	exact etiology of sclerosis	[exact etiology of sclerosis]	0.0	4	1	1	1
99765	1710	factor tcf-1 alpha	[factor TCF-1 alpha]	0.0	3	1	1	1
99766	1710	cytokine stimulate growth	[cytokine stimulating growth]	0.0	3	1	1	1
99767	1710	interaction antagonism in cell	[interaction antagonism in cells]	0.0	4	1	1	1
99768	1710	concanavalin-a cona	[Concanavalin-A ConA]	0.0	2	1	1	1
99769	1710	multiple X1 box-specific activity	[multiple X1 box-specific activities]	0.0	4	1	1	1
99770	1710	NFAT-1 protein complex	[NFAT-1 protein complexes]	0.0	3	1	1	1
99771	1710	dna-binding activity consist	[DNA-binding activity consisting]	0.0	3	1	1	1
99772	1710	distinct immediate regulator	[distinct immediate regulators]	0.0	3	1	1	1
99773	1710	biochemical property	[biochemical properties]	0.0	2	1	1	1
99774	1710	such clone	[such clones]	0.0	2	1	1	1
99775	1710	expression pattern of the bcl-6 protein	[expression pattern of the BCL-6 protein]	0.0	6	1	1	1
99776	1710	results: neutrophil adhesion	[RESULTS: Neutrophil adhesion]	0.0	3	1	1	1
99777	1710	initial regulatory point	[initial regulatory point]	0.0	3	1	1	1
99778	1710	certain individual of particular (mhc) haplotype	[certain individuals of particular (MHC) haplotypes]	0.0	6	1	1	1
99779	1710	motif potentially important	[motifs potentially important]	0.0	3	1	1	1
99780	1710	response element TCE	[response element TCE]	0.0	3	1	1	1
99781	1710	nuclear antigen EBNA	[nuclear antigen EBNA]	0.0	3	2	2	1
99782	1710	pfp9a20 contain -73 bp	[PFP9a20 containing -73 bp]	0.0	4	1	1	1
99783	1710	substantial growth inhibition	[Substantial growth inhibition]	0.0	3	1	1	1
99784	1710	CRE reporter plasmid	[CRE reporter plasmid]	0.0	3	1	1	1
99785	1710	entry site rna-protein interaction	[entry site RNA-protein interactions]	0.0	4	1	1	1
99786	1710	stable clone of two line	[stable clones of two lines]	0.0	5	1	1	1
99787	1710	diffusible activity capable of activation	[diffusible activity capable of activation]	0.0	5	1	1	1
99788	1710	activity of plasma il-1	[activity of plasma IL-1]	0.0	4	1	1	1
99789	1710	acute hepatic injury with alpha-tocopherol	[acute hepatic injury with alpha-tocopherol]	0.0	5	1	1	1
99790	1710	epidemiologic feature with ebv	[epidemiologic features with EBV]	0.0	4	1	1	1
99791	1710	c-fo immunoreactivity	[c-Fos immunoreactivity]	0.0	2	1	1	1
99792	1710	neutrophil transendothelial migration	[neutrophil transendothelial migration]	0.0	3	1	1	1
99793	1710	megakaryocyte-specific nuclear protein	[megakaryocyte-specific nuclear proteins]	0.0	3	1	1	1
99794	1710	circulate lymphocyte thyroidism	[circulating lymphocytes thyroidism]	0.0	3	1	1	1
99795	1710	sensitive (ic50	[sensitive (IC50]	0.0	2	1	1	1
99796	1710	stat5 from erythropoietin erythroid cell	[STAT5 from erythropoietin erythroid cells]	0.0	5	1	1	1
99797	1710	activation in response to pathogenic signal	[activation in response to pathogenic signals]	0.0	6	1	1	1
99798	1710	functional hiv tat protein	[functional HIV Tat protein]	0.0	4	1	1	1
99799	1710	alpha-tocopheryl succinate	[alpha-tocopheryl succinate]	0.0	2	1	1	1
99800	1710	variable examined: serum calcitriol	[variables examined: serum calcitriol]	0.0	4	1	1	1
99801	1710	cytoplasmic factor	[cytoplasmic factor]	0.0	2	1	1	1
99802	1710	EBNA-2 cell	[EBNA-2 cells]	0.0	2	1	1	1
99803	1710	vmax of monocyte mitochondrial	[Vmax of monocyte mitochondrial]	0.0	4	1	1	1
99804	1710	130 base pair	[130 base pairs]	0.0	3	1	1	1
99805	1710	other LCR HSs	[other LCR HSs]	0.0	3	1	1	1
99806	1710	major role in activation	[major role in activation]	0.0	4	1	1	1
99807	1710	behaviour of Albuminemia indicator	[behaviour of Albuminemia indicator]	0.0	4	1	1	1
99808	1710	novel specificity-conferring mechanism for action	[novel specificity-conferring mechanism for action]	0.0	5	1	1	1
99809	1710	alpha-globin G 5' region	[alpha-globin G 5' region]	0.0	4	1	1	1
99810	1710	concentration of steroid	[concentrations of steroid]	0.0	3	1	1	1
99811	1710	h2b	[H2B]	0.0	1	1	1	1
99812	1710	m all-tran acid RA	[M all-trans acid RA]	0.0	4	1	1	1
99813	1710	formation of two complex	[formation of two complexes]	0.0	4	1	1	1
99814	1710	one cDNA clone	[One cDNA clone]	0.0	3	1	1	1
99815	1710	low-level expression of stat binding factor	[low-level expression of STAT binding factors]	0.0	6	1	1	1
99816	1710	viral structural protein expression	[viral structural protein expression]	0.0	4	1	1	1
99817	1710	salt loss lead to hyponatremia	[salt loss leading to hyponatremia]	0.0	5	1	1	1
99818	1710	subset of b	[subset of B]	0.0	3	1	1	1
99819	1710	soluble, mab j393	[soluble, mAb J393]	0.0	3	1	1	1
99820	1710	HLA DR	[HLA DR]	0.0	2	1	1	1
99821	1710	vdrnrar- vdre formation	[VDR-RXR- VDRE formation]	0.0	3	1	1	1
99822	1710	allow rapid testing	[allowing rapid testing]	0.0	3	1	1	1
99823	1710	thyroid hormone element	[thyroid hormone element]	0.0	3	1	1	1
99824	1710	different activation domain at the N	[different activation domains at the N]	0.0	6	1	1	1
99825	1710	obstructive disease	[obstructive disease]	0.0	2	1	1	1
99826	1710	z-lll-h transcriptional activity	[Z-LLL-H transcriptional activity]	0.0	3	1	1	1
99827	1710	ML-1 human leukemia cell	[ML-1 human leukemia cells]	0.0	4	1	1	1
99828	1710	antibody against c-fos.	[antibody against c-fos.]	0.0	3	1	1	1
99829	1710	immature class heterodimer	[immature class heterodimers]	0.0	3	1	1	1
99830	1710	dual-specific map kinase phosphatase	[dual-specific MAP kinase phosphatases]	0.0	4	1	1	1
99831	1710	similarity among lipopolysaccharide (lps)-	[similarities among lipopolysaccharide (LPS)-]	0.0	4	1	1	1
99832	1710	IL-2 transcriptional regulator c-fo	[IL-2 transcriptional regulators c-fos]	0.0	4	1	1	1
99833	1710	B-cell transformation	[B-cell transformation]	0.0	2	1	1	1
99834	1710	stage- manner	[stage- manner]	0.0	2	1	1	1
99835	1710	major component of the activity	[major component of the activity]	0.0	5	1	1	1
99836	1710	glucocorticoid tested, methylprednisolone	[glucocorticoids tested, methylprednisolone]	0.0	3	1	1	1
99837	1710	proteolysis-resistant inhibitor of nf-kappab	[proteolysis-resistant inhibitor of NF-kappaB]	0.0	4	1	1	1
99838	1710	10 polymorphism to condition	[10 polymorphism to conditions]	0.0	4	1	1	1
99839	1710	radical scavenging	[radical scavenging]	0.0	2	1	1	1
99840	1710	b-lymphocyte cell use separation	[B-lymphocyte cells using separation]	0.0	4	1	1	1
99841	1710	stem-loop stability encoding protein	[stem-loop stability encoding proteins]	0.0	4	1	1	1
99842	1710	immature lymphoid t-cell proliferation	[immature lymphoid T-cell proliferations]	0.0	4	1	1	1
99843	1710	site of constitutive interaction	[site of constitutive interactions]	0.0	4	1	1	1
99844	1710	different class	[different classes]	0.0	2	1	1	1
99845	1710	apc fibroblast	[APCs fibroblasts]	0.0	2	1	1	1
99846	1710	group dissociation	[groups dissociation]	0.0	2	1	1	1
99847	1710	competition between transcriptional activator	[competition between transcriptional activators]	0.0	4	1	1	1
99848	1710	expression of a novel factor	[expression of a novel factor]	0.0	5	1	1	1
99849	1710	446 bp	[446 bp]	0.0	2	1	1	1
99850	1710	more accurately, amount	[more accurately, amounts]	0.0	3	1	1	1
99851	1710	vitro, viral nuclear antigen EBNAs	[vitro, viral nuclear antigens EBNAs]	0.0	5	1	1	1
99852	1710	kill target	[killing targets]	0.0	2	1	1	1
99853	1710	stimulation on immunogenic human melanoma	[Stimulation on immunogenic human melanomas]	0.0	5	1	1	1
99854	1710	interleukin 2 gene expression	[interleukin 2 gene expression]	0.0	4	1	1	1
99855	1710	human factor-1 receptor	[human factor-1 receptor]	0.0	3	1	1	1
99856	1710	cell (3-5%)	[cells (3-5%)]	0.0	2	1	1	1
99857	1710	long terminal repeat promoter region	[long terminal repeat promoter region]	0.0	5	1	1	1
99858	1710	phenolic, chain-breaking antioxidant	[phenolic, chain-breaking antioxidants]	0.0	3	1	1	1
99859	1710	point mutation in tax	[point mutations in Tax]	0.0	4	1	1	1
99860	1710	origin for maintenance	[origin for maintenance]	0.0	3	1	1	1
99861	1710	many HSV CD4 T cell	[many HSV CD4 T cells]	0.0	5	1	1	1
99862	1710	disposition	[disposition]	0.0	1	1	1	1
99863	1710	bind avidity	[binding avidity]	0.0	2	1	1	1
99864	1710	(12.2+/-1.6	[(12.2+/-1.6]	0.0	1	1	1	1
99865	1710	dna-transfected u-937 cell	[DNA-transfected U-937 cells]	0.0	3	1	1	1
99866	1710	E-box consensus motif CAGATG	[E-box consensus motifs CAGATG]	0.0	4	1	1	1
99867	1710	il-2 DNA enhancer element nf-at	[IL-2 DNA enhancer elements NF-AT]	0.0	5	1	1	1
99868	1710	number of glucocorticoid receptor GCR	[number of glucocorticoid receptors GCR]	0.0	5	1	1	1
99869	1710	combination of splicing	[combination of splicing]	0.0	3	1	1	1
99870	1710	follicle with gc formation	[follicles with GC formation]	0.0	4	1	1	1
99871	1710	analysis in the presence	[analysis in the presence]	0.0	4	1	1	1
99872	1710	terminal repeat transactivation	[terminal repeat transactivation]	0.0	3	1	1	1
99873	1710	mechanism in bronchial cell	[mechanisms in bronchial cells]	0.0	4	1	1	1
99874	1710	role of the IL-13Ralpha1 chain	[role of the IL-13Ralpha1 chain]	0.0	5	1	1	1
99875	1710	follow engagement	[following engagement]	0.0	2	1	1	1
99876	1710	mnda expression in maturing granulocyte	[MNDA expression in maturing granulocytes]	0.0	5	1	1	1
99877	1710	ubiquitous cyclic amp-responsive element	[ubiquitous cyclic AMP-responsive element]	0.0	4	1	1	1
99878	1710	NF-kappa B/Rel family	[NF-kappa B/Rel family]	0.0	3	1	1	1
99879	1710	regulation of interleukin IL-2 gene	[regulation of interleukin IL-2 gene]	0.0	5	1	1	1
99880	1710	ebv type 1	[EBV type 1]	0.0	3	1	1	1
99881	1710	tax -dependent correlation	[Tax -dependent correlation]	0.0	3	1	1	1
99882	1710	log-fold more glucocorticoid	[log-fold more glucocorticoids]	0.0	3	1	1	1
99883	1710	Rb inactivation,	[Rb inactivation,]	0.0	2	1	1	1
99884	1710	prevalence in a group	[prevalence in a group]	0.0	4	1	1	1
99885	1710	acid alpha-lipoic acid	[acid alpha-lipoic acid]	0.0	3	1	1	1
99886	1710	29.9% cd3+ cell	[29.9% CD3+ cells]	0.0	3	1	1	1
99887	1710	transcription factor such as Fos	[transcription factors such as Fos]	0.0	5	1	1	1
99888	1710	reverse transcription-polymerase chain reaction pcr	[reverse transcription-polymerase chain reaction PCR]	0.0	5	1	1	1
99889	1710	72-kDa immediate-early protein	[72-kDa immediate-early protein]	0.0	3	1	1	1
99890	1710	level of hiv-1 replication	[level of HIV-1 replication]	0.0	4	1	1	1
99891	1710	PPARgamma ligand	[PPARgamma ligand]	0.0	2	1	1	1
99892	1710	reduce the yield	[reducing the yields]	0.0	3	1	1	1
99893	1710	definitive colony	[definitive colonies]	0.0	2	1	1	1
99894	1710	element tre-1	[element TRE-1]	0.0	2	1	1	1
99895	1710	Maximal inhibition	[Maximal inhibition]	0.0	2	2	2	1
99896	1710	kinetic (high turnover)	[kinetic (high turnover)]	0.0	3	1	1	1
99897	1710	blood lymphocyte sample	[blood lymphocyte samples]	0.0	3	1	1	1
99898	1710	inclusion of 1 microm RU	[inclusion of 1 microM RU]	0.0	5	1	1	1
99899	1710	MRD -positive MRD	[MRD -positive MRD]	0.0	3	1	1	1
99900	1710	cause of T cell apoptosis	[cause of T cell apoptosis]	0.0	5	1	1	1
99901	1710	hla-dq response	[HLA-DQ response]	0.0	2	1	1	1
99902	1710	(except in one obese patient	[(except in one obese patient]	0.0	5	1	1	1
99903	1710	responsiveness of mononuclear leukocyte	[responsiveness of mononuclear leukocytes]	0.0	4	1	1	1
99904	1710	significant correlation with her-2/neu expression	[significant correlation with HER-2/neu expression]	0.0	5	1	1	1
99905	1710	own gas DNA binding pattern	[own GAS DNA binding patterns]	0.0	5	1	1	1
99906	1710	(pebp2/cbf)	[(PEBP2/CBF)]	0.0	1	1	1	1
99907	1710	anorexic patient	[anorexic patients]	0.0	2	1	1	1
99908	1710	hyperabsorption of calcium	[hyperabsorption of calcium]	0.0	3	1	1	1
99909	1710	clonal expansion) (by stimulation lead	[clonal expansion) (by stimulation leading]	0.0	5	1	1	1
99910	1710	mechanism lead to apoptosis	[mechanisms leading to apoptosis]	0.0	4	1	1	1
99911	1710	tyrosine phosphorylation of kda protein	[tyrosine phosphorylation of kDa proteins]	0.0	5	1	1	1
99912	1710	role in vertebrate t-cell-specific regulation	[role in vertebrate T-cell-specific regulation]	0.0	5	1	1	1
99913	1710	form.	[form.]	0.0	1	1	1	1
99914	1710	powerful inducer	[powerful inducer]	0.0	2	1	1	1
99915	1710	filaria-induced pathology LP	[filaria-induced pathology LP]	0.0	3	1	1	1
99916	1710	valid technique	[valid technique]	0.0	2	1	1	1
99917	1710	encode the lectin-type ldl receptor	[encoding the lectin-type LDL receptor]	0.0	5	1	1	1
99918	1710	expression of a viral immediate-early protein	[expression of a viral immediate-early protein]	0.0	6	1	1	1
99919	1710	ctl-mediated immunity against tumor	[CTL-mediated immunity against tumors]	0.0	4	1	1	1
99920	1710	reactivity to a progesterone antibody	[Reactivity to a progesterone antibody]	0.0	5	1	1	1
99921	1710	specific recovery of beta-galactosidase	[specific recovery of beta-galactosidase]	0.0	4	1	1	1
99922	1710	intracellular binding protein	[intracellular binding proteins]	0.0	3	1	1	1
99923	1710	equivalent increase	[equivalent increase]	0.0	2	2	2	1
99924	1710	alpha 4 beta in T cell	[alpha 4 beta in T cells]	0.0	6	1	1	1
99925	1710	expression protein	[Expression protein]	0.0	2	1	1	1
99926	1710	receptor for mip-1alpha	[receptor for MIP-1alpha]	0.0	3	1	1	1
99927	1710	worker with a pcdd/pcdf -body burden	[workers with a PCDD/PCDF -body burden]	0.0	6	1	1	1
99928	1710	similar circadian rhythm	[similar circadian rhythm]	0.0	3	1	1	1
99929	1710	difficulty obtain monocyte	[difficulty obtaining monocytes]	0.0	3	1	1	1
99930	1710	limited stimulation	[limited stimulation]	0.0	2	1	1	1
99931	1710	wild-type gr gene	[wild-type GR gene]	0.0	3	1	1	1
99932	1710	response to concanavalin-a cona	[response to Concanavalin-A ConA]	0.0	4	1	1	1
99933	1710	transcription pathway in asthma	[transcription pathway in asthma]	0.0	4	1	1	1
99934	1710	TRAIL tnf-related apoptosis -induce ligand	[TRAIL TNF-related apoptosis -inducing ligand]	0.0	5	1	1	1
99935	1710	heterogeneous pattern	[heterogeneous pattern]	0.0	2	1	1	1
99936	1710	positive feedback loop	[positive feedback loop]	0.0	3	1	1	1
99937	1710	responsiveness of HML	[responsiveness of HML]	0.0	3	1	1	1
99938	1710	specificity for repression	[specificity for repression]	0.0	3	1	1	1
99939	1710	Rb binding site	[Rb binding sites]	0.0	3	1	1	1
99940	1710	most example of IDC	[most examples of IDC]	0.0	4	1	1	1
99941	1710	insulin response	[insulin response]	0.0	2	1	1	1
99942	1710	DNA variation 2418delA in tumor	[DNA variations 2418delA in tumor]	0.0	5	1	1	1
99943	1710	time per day for 12	[times per day for 12]	0.0	5	1	1	1
99944	1710	decline in the capacity	[decline in the capacities]	0.0	4	1	1	1
99945	1710	syk kinase	[Syk kinases]	0.0	2	1	1	1
99946	1710	autosomal disease xeroderma pigmentosum XP	[autosomal disease xeroderma pigmentosum XP]	0.0	5	1	1	1
99947	1710	support the notion	[supporting the notion]	0.0	3	1	1	1
99948	1710	apc during response	[APC during responses]	0.0	3	1	1	1
99949	1710	b-cell response in intrahepatic lymphoid follicle	[B-cell response in intrahepatic lymphoid follicles]	0.0	6	1	1	1
99950	1710	process unique to stimulus	[process unique to stimuli]	0.0	4	1	1	1
99951	1710	resistance of b-cell line	[resistance of B-cell lines]	0.0	4	1	1	1
99952	1710	dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin	[doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.0	3	1	1	1
99953	1710	steroid to receptor	[steroids to receptors]	0.0	3	1	1	1
99954	1710	genomic phage clone	[genomic phage clones]	0.0	3	1	1	1
99955	1710	Dehydroepiandrosterone	[Dehydroepiandrosterone]	0.0	1	1	1	1
99956	1710	Class endothelial cell MHC class ii	[Class endothelial cell MHC class II]	0.0	6	1	1	1
99957	1710	activation from monocyte	[activation from monocytes]	0.0	3	1	1	1
99958	1710	effect in T cell line	[effects in T cell lines]	0.0	5	1	1	1
99959	1710	transcription follow engagement (e.g. cell-to-cell	[transcription following engagement (e.g. cell-to-cell]	0.0	5	1	1	1
99960	1710	evaluation of cohort of patient	[Evaluation of cohorts of patients]	0.0	5	1	1	1
99961	1710	little effect on the binding	[little effect on the binding]	0.0	5	1	1	1
99962	1710	gap	[gaps]	0.0	1	1	1	1
99963	1710	Functional testosterone receptor	[Functional testosterone receptors]	0.0	3	1	1	1
99964	1710	CAV isolate	[CAV isolates]	0.0	2	1	1	1
99965	1710	patient with affinity to glucocorticoid AIDS-GR	[patients with affinity to glucocorticoids AIDS-GR]	0.0	6	1	1	1
99966	1710	localisation of factor	[localisation of factors]	0.0	3	1	1	1
99967	1710	protein truncation	[protein truncation]	0.0	2	2	2	1
99968	1710	interaction between elf-1	[interactions between Elf-1]	0.0	3	1	1	1
99969	1710	intact nf-kappab binding sequence	[intact NF-kappaB binding sequences]	0.0	4	1	1	1
99970	1710	megakaryocyte growth	[megakaryocyte growth]	0.0	2	1	1	1
99971	1710	encompass a proline rich sequence	[encompassing a proline rich sequence]	0.0	5	1	1	1
99972	1710	infection analysis of mutation	[Infection analyses of mutations]	0.0	4	1	1	1
99973	1710	diethylstilbestrol tamoxifen	[diethylstilbestrol tamoxifen]	0.0	2	1	1	1
99974	1710	hER	[hER]	0.0	1	1	1	1
99975	1710	characterization of two lymphoma cell line	[characterization of two lymphoma cell lines]	0.0	6	1	1	1
99976	1710	signal signal	[signal signal]	0.0	2	1	1	1
99977	1710	express complex (mhc) class gene	[expressing complex (MHC) class genes]	0.0	5	1	1	1
99978	1710	chromatin in vitro	[chromatin in vitro]	0.0	3	1	1	1
99979	1710	acute hepatitis	[acute hepatitis]	0.0	2	1	1	1
99980	1710	IFN-gamma locus	[IFN-gamma locus]	0.0	2	1	1	1
99981	1710	calcium-mobilize receptor	[calcium-mobilizing receptors]	0.0	2	1	1	1
99982	1710	cluster of activator protein-2	[cluster of activator protein-2]	0.0	4	1	1	1
99983	1710	high affinity ligand-binding	[high affinity ligand-binding]	0.0	3	1	1	1
99984	1710	contain the CAII erba-binding site	[containing the CAII erbA-binding site]	0.0	5	1	1	1
99985	1710	opposite effect on this signal	[opposite effects on these signals]	0.0	5	1	1	1
99986	1710	receptor on endothelial cell	[receptors on endothelial cells]	0.0	4	1	1	1
99987	1710	human gene cluster	[human gene cluster]	0.0	3	1	1	1
99988	1710	PL/IM antibody	[PL/IM antibody]	0.0	2	1	1	1
99989	1710	force	[force]	0.0	1	1	1	1
99990	1710	implicate this kinase	[implicating these kinases]	0.0	3	1	1	1
99991	1710	autoimmune disease biliary cirrhosis	[autoimmune disease biliary cirrhosis]	0.0	4	1	1	1
99992	1710	Differential localization of p50	[Differential localization of p50]	0.0	4	1	1	1
99993	1710	endothelial cell huvec	[endothelial cells HUVECs]	0.0	3	1	1	1
99994	1710	least in part, for induction	[least in part, for induction]	0.0	5	1	1	1
99995	1710	analysis of possible T	[analysis of possible T]	0.0	4	1	1	1
99996	1710	interleukin-4 IL-4 on function	[interleukin-4 IL-4 on functions]	0.0	4	1	1	1
99997	1710	functional specificity	[functional specificity]	0.0	2	1	1	1
99998	1710	signals, include cytokine	[signals, including cytokines]	0.0	3	1	1	1
99999	1710	also to the eukaryotic transcription factor	[also to the eukaryotic transcription factors]	0.0	6	1	1	1
100000	1710	phagocytosis of pseudomonas aeruginosa by macrophage	[phagocytosis of Pseudomonas aeruginosa by macrophages]	0.0	6	1	1	1
100001	1710	t-cell tolerance induction	[T-cell tolerance induction]	0.0	3	1	1	1
100002	1710	substrate in cell	[substrates in cells]	0.0	3	1	1	1
100003	1710	cell complex	[cell complexes]	0.0	2	1	1	1
100004	1710	-201 region	[-201 region]	0.0	2	1	1	1
100005	1710	myeloid blast use adeno-associated virus	[myeloid blasts using adeno-associated virus]	0.0	5	1	1	1
100006	1710	additional month	[additional months]	0.0	2	1	1	1
100007	1710	follow platelet activation	[following platelet activation]	0.0	3	1	1	1
100008	1710	polyclonal anti- tf antibody	[polyclonal anti- TF antibody]	0.0	4	1	1	1
100009	1710	gh3	[GH3]	0.0	1	1	1	1
100010	1710	lead to modulation from cell	[leading to modulation from cells]	0.0	5	1	1	1
100011	1710	specific cooperation	[specific cooperation]	0.0	2	1	1	1
100012	1710	Gene for a tissue-specific activator	[Gene for a tissue-specific activator]	0.0	5	1	1	1
100013	1710	granulomatous disease tuberculosis	[granulomatous diseases tuberculosis]	0.0	3	1	1	1
100014	1710	Nuclear factor-kappa b activity	[Nuclear factor-kappa B activity]	0.0	4	1	1	1
100015	1710	include the t-cell antigen receptor	[including the T-cell antigen receptor]	0.0	5	1	1	1
100016	1710	i+/	[I+/]	0.0	1	1	1	1
100017	1710	unexpectedly, expression of another protein BRLF1	[unexpectedly, expression of another protein BRLF1]	0.0	6	1	1	1
100018	1710	involve transcription factor	[involving transcription factors]	0.0	3	1	1	1
100019	1710	Japanese child with hormone deficiency	[Japanese children with hormone deficiency]	0.0	5	1	1	1
100020	1710	regulatory element the N element	[regulatory element the N element]	0.0	5	1	1	1
100021	1710	receptor blocker	[receptor blocker]	0.0	2	1	1	1
100022	1710	splicing (R) rna	[splicing (R) RNA]	0.0	3	1	1	1
100023	1710	CLL sample	[CLL samples]	0.0	2	1	1	1
100024	1710	granulocyte colony-stimulating factor granulocyte-macrophage factor proliferation	[granulocyte colony-stimulating factor granulocyte-macrophage factor proliferation]	0.0	6	1	1	1
100025	1710	expression of inhibitor kappa b alpha	[expression of inhibitor kappa B alpha]	0.0	6	1	1	1
100026	1710	functionally active factor	[functionally active factor]	0.0	3	1	1	1
100027	1710	retention of inactive factor-kappaB	[retention of inactive factor-kappaB]	0.0	4	1	1	1
100028	1710	reporter expression	[reporter expression]	0.0	2	1	1	1
100029	1710	hl-60 leukemia cell line	[HL-60 leukemia cell line]	0.0	4	1	1	1
100030	1710	heparin-binding epidermal growth growth factor	[heparin-binding epidermal growth growth factor]	0.0	5	1	1	1
100031	1710	pma-differentiated cell	[PMA-differentiated cells]	0.0	2	1	1	1
100032	1710	malignant histiocytoma rhabdomyosarcoma	[malignant histiocytoma rhabdomyosarcoma]	0.0	3	1	1	1
100033	1710	evidence of low proliferative activity	[evidence of low proliferative activity]	0.0	5	1	1	1
100034	1710	production in peripheral blood monocyte	[production in peripheral blood monocytes]	0.0	5	1	1	1
100035	1710	RA sensitivity of hematopoietic cell	[RA sensitivity of hematopoietic cells]	0.0	5	1	1	1
100036	1710	circulate human leukocyte of donor	[circulating human leukocytes of donors]	0.0	5	1	1	1
100037	1710	gene response	[gene responses]	0.0	2	1	1	1
100038	1710	elevation of free calcium concentration	[elevation of free calcium concentrations]	0.0	5	1	1	1
100039	1710	epsilon mrna	[epsilon mRNA]	0.0	2	1	1	1
100040	1710	factor enf)-kappa b activation	[factor (NF)-kappa B activation]	0.0	4	1	1	1
100041	1710	death effector protease caspase-1 -like	[death effector proteases caspase-1 -like]	0.0	5	1	1	1
100042	1710	possibly organ	[possibly organs]	0.0	2	1	1	1
100043	1710	span portion	[spanning portions]	0.0	2	1	1	1
100044	1710	highly sensitive screen assay	[highly sensitive screening assay]	0.0	4	1	1	1
100045	1710	lymphokine deficiency	[lymphokine deficiency]	0.0	2	2	2	1
100046	1710	long repeat sequence diversity	[long repeat sequence diversity]	0.0	4	1	1	1
100047	1710	vacuolar h(+)-atpase v-atpase	[vacuolar H(+)-ATPase V-ATPase]	0.0	3	1	1	1
100048	1710	depletion A1 from nuclear extract	[depletion A1 from nuclear extracts]	0.0	5	1	1	1
100049	1710	icam-1 endothelial adhesivity	[ICAM-1 endothelial adhesivity]	0.0	3	1	1	1
100050	1710	negative outcome.	[negative outcome.]	0.0	2	1	1	1
100051	1710	up-regulation via nf-at	[up-regulation via NF-AT]	0.0	3	1	1	1
100052	1710	pre-B gene	[pre-B genes]	0.0	2	1	1	1
100053	1710	good predictor	[good predictor]	0.0	2	1	1	1
100054	1710	expression of lineage cell	[expression of lineage cells]	0.0	4	1	1	1
100055	1710	level of heat alkaline phosphatase	[levels of heat alkaline phosphatase]	0.0	5	1	1	1
100056	1710	precisely similarity among lipopolysaccharide (lps)-	[precisely similarities among lipopolysaccharide (LPS)-]	0.0	5	1	1	1
100057	1710	individual response to the protein BZLF1	[individual responses to the proteins BZLF1]	0.0	6	1	1	1
100058	1710	patient with leukemia CLL	[patients with leukemia CLL]	0.0	4	1	1	1
100059	1710	environmental antigen	[environmental antigens]	0.0	2	1	1	1
100060	1710	specific receptor consist	[specific receptor consisting]	0.0	3	1	1	1
100061	1710	apoptosis of mononucleated cell	[apoptosis of mononucleated cells]	0.0	4	1	1	1
100062	1710	(amino acid)	[(amino acid)]	0.0	2	1	1	1
100063	1710	activity of NF kappa b	[activity of NF kappa B]	0.0	5	1	1	1
100064	1710	chimeric type ii/type	[chimeric type II/type]	0.0	3	1	1	1
100065	1710	regulatory mechanism control gene expression	[regulatory mechanism controlling gene expression]	0.0	5	1	1	1
100066	1710	Src family	[Src family]	0.0	2	1	1	1
100067	1710	effect in naive b cell	[effects in naive B cells]	0.0	5	1	1	1
100068	1710	tpa b cell	[TPA B cells]	0.0	3	1	1	1
100069	1710	patient with outcome.	[patients with outcome.]	0.0	3	1	1	1
100070	1710	CD40 -cd40 ligand	[CD40 -CD40 ligand]	0.0	3	1	1	1
100071	1710	status after conservative surgery	[status after conservative surgery]	0.0	4	1	1	1
100072	1710	stimulatory effect.	[stimulatory effect.]	0.0	2	1	1	1
100073	1710	antiinflammatory, antiallergic, activity	[antiinflammatory, antiallergic, activities]	0.0	3	1	1	1
100074	1710	deficiency-heat syndrome dhs	[deficiency-heat syndrome DHS]	0.0	3	1	1	1
100075	1710	protection against a signal	[protection against an signal]	0.0	4	1	1	1
100076	1710	gld	[gld]	0.0	1	1	1	1
100077	1710	spatial alignment of this element	[spatial alignment of these elements]	0.0	5	1	1	1
100078	1710	side effect of CsA	[side effects of CsA]	0.0	4	1	1	1
100079	1710	type with bcl6 rearrangement	[type with BCL6 rearrangement]	0.0	4	1	1	1
100080	1710	study signal in primary precursor	[studies signaling in primary precursors]	0.0	5	1	1	1
100081	1710	t-cell-expressed cytokine	[T-cell-expressed cytokines]	0.0	2	1	1	1
100082	1710	topographical distribution	[topographical distributions]	0.0	2	1	1	1
100083	1710	efficient DRA expression	[efficient DRA expression]	0.0	3	1	1	1
100084	1710	activation of human zeta role	[activation of human zeta role]	0.0	5	1	1	1
100085	1710	action of acid	[action of acid]	0.0	3	1	1	1
100086	1710	poor separation of granule	[poor separation of granules]	0.0	4	1	1	1
100087	1710	significant amount costimulation	[significant amounts costimulation]	0.0	3	1	1	1
100088	1710	cd33+, cd16	[CD33+, CD16]	0.0	2	1	1	1
100089	1710	patient with graves' disease gd	[patients with Graves' disease GD]	0.0	5	1	1	1
100090	1710	epstein-barr virus DNA	[Epstein-Barr virus DNA]	0.0	3	1	1	1
100091	1710	Electrophoretic mobility gel shift	[Electrophoretic mobility gel shift]	0.0	4	1	1	1
100092	1710	apparently healthy volunteer	[apparently healthy volunteers]	0.0	3	1	1	1
100093	1710	use experimental approach	[using experimental approaches]	0.0	3	1	1	1
100094	1710	memory CTL	[memory CTLs]	0.0	2	1	1	1
100095	1710	rssb	[rSSB]	0.0	1	1	1	1
100096	1710	bind activity of erythrocyte protein	[binding activities of erythrocyte proteins]	0.0	5	1	1	1
100097	1710	induction of nuclear factor monoclonal antibody	[Induction of nuclear factor monoclonal antibodies]	0.0	6	1	1	1
100098	1710	eosinophilia in IHES	[eosinophilia in IHES]	0.0	3	1	1	1
100099	1710	t-cell leukemia cell	[T-cell leukemia cells]	0.0	3	1	1	1
100100	1710	uptake in pbmc	[uptake in PBMC]	0.0	3	1	1	1
100101	1710	undifferentiated stromal cell	[undifferentiated stromal cells]	0.0	3	1	1	1
100102	1710	region contain direct repeat	[region containing direct repeats]	0.0	4	1	1	1
100103	1710	preferential presentation dqa1*0501/dqb1*0201	[Preferential presentation DQA1*0501/DQB1*0201]	0.0	3	1	1	1
100104	1710	same mobility kd)	[same mobility kD)]	0.0	3	1	1	1
100105	1710	progenitor cell in tg epsilon26 mouse	[progenitor cells in tg epsilon26 mice]	0.0	6	1	1	1
100106	1710	receptor ebi1	[receptor EBI1]	0.0	2	1	1	1
100107	1710	rearrangement of gene	[rearrangement of genes]	0.0	3	1	1	1
100108	1710	specific, activation	[specific, activation]	0.0	2	1	1	1
100109	1710	one cellular event	[one cellular event]	0.0	3	1	1	1
100110	1710	-contain member	[-containing member]	0.0	2	1	1	1
100111	1710	nuclei of cell	[nuclei of cells]	0.0	3	1	1	1
100112	1710	dexamethasone in serum-free medium	[dexamethasone in serum-free medium]	0.0	4	1	1	1
100113	1710	extensive deletion of sequence upstream	[extensive deletion of sequences upstream]	0.0	5	1	1	1
100114	1710	induction of neuroblastoma differentiation	[induction of neuroblastoma differentiation]	0.0	4	1	1	1
100115	1710	time-dependent binding two monoclonal antibody	[time-dependent binding two monoclonal antibodies]	0.0	5	1	1	1
100116	1710	many inflammatory cytokine gene	[many inflammatory cytokine genes]	0.0	4	1	1	1
100117	1710	[ca2+]i of T cell	[[Ca2+]i of T cells]	0.0	4	1	1	1
100118	1710	1 (ap-1)	[1 (AP-1)]	0.0	2	1	1	1
100119	1710	bronchial asthma]	[bronchial asthma]]	0.0	2	1	1	1
100120	1710	suppression of nf-kappa b activation	[suppression of NF-kappa B activation]	0.0	5	1	1	1
100121	1710	depressed subject down-regulated Bmax after DEX	[depressed subjects down-regulated Bmax after DEX]	0.0	6	1	1	1
100122	1710	ifi IFN-alpha/beta in addition to IL-12	[IFNs IFN-alpha/beta in addition to IL-12]	0.0	6	1	1	1
100123	1710	acid lipase lal expression	[acid lipase LAL expression]	0.0	4	1	1	1
100124	1710	tarsal biopsy from patient with vkc	[tarsal biopsies from patients with VKC]	0.0	6	1	1	1
100125	1710	especially the homolog c/ebp-beta	[especially the homolog C/EBP-beta]	0.0	4	1	1	1
100126	1710	resistance in mouse lymphoma cell	[resistance in mouse lymphoma cells]	0.0	5	1	1	1
100127	1710	mechanism a study	[mechanisms a study]	0.0	3	1	1	1
100128	1710	cross-reactivity	[cross-reactivity]	0.0	1	1	1	1
100129	1710	human acute leukemia cell line	[human acute leukemia cell line]	0.0	5	1	1	1
100130	1710	RBP to this site	[RBP to this site]	0.0	4	1	1	1
100131	1710	mouse MHC class ii	[mouse MHC class II]	0.0	4	1	1	1
100132	1710	increase a increase	[increase an increase]	0.0	3	1	1	1
100133	1710	Dexamethasone a synthetic glucocorticoid hormone	[Dexamethasone a synthetic glucocorticoid hormone]	0.0	5	1	1	1
100134	1710	globin gene switching?	[globin gene switching?]	0.0	3	1	1	1
100135	1710	gene silencing activity	[gene silencing activity]	0.0	3	1	1	1
100136	1710	receptor count	[receptor count]	0.0	2	1	1	1
100137	1710	(IL)-12	[(IL)-12]	0.0	1	1	1	1
100138	1710	more profound depression	[more profound depression]	0.0	3	1	1	1
100139	1710	include stem cell	[including stem cells]	0.0	3	1	1	1
100140	1710	involve stage of commitment	[involving stages of commitment]	0.0	4	1	1	1
100141	1710	basis define the characteristic	[basis defining the characteristics]	0.0	4	1	1	1
100142	1710	low the/thf alpha thf/thf ratios.	[low THE/THF alpha THF/THF ratios.]	0.0	5	1	1	1
100143	1710	p65 mrna (75	[p65 mRNA (75]	0.0	3	1	1	1
100144	1710	periphery,	[periphery,]	0.0	1	1	1	1
100145	1710	il-4 transcription	[IL-4 transcription]	0.0	2	1	1	1
100146	1710	blast sensitivity	[Blast sensitivity]	0.0	2	1	1	1
100147	1710	4E-BP1	[4E-BP1]	0.0	1	1	1	1
100148	1710	periphery.	[periphery.]	0.0	1	1	1	1
100149	1710	regulation in primary human NK cell	[regulation in primary human NK cells]	0.0	6	1	1	1
100150	1710	range between 200-500 nm.	[ranging between 200-500 nM.]	0.0	4	1	1	1
100151	1710	cooperation of two transcription factor	[cooperation of two transcription factors]	0.0	5	1	1	1
100152	1710	T negative regulation	[T negative regulation]	0.0	3	1	1	1
100153	1710	prognostic character in abortion	[prognostic character in abortion]	0.0	4	1	1	1
100154	1710	T lymphocyte-specific transcription factor	[T lymphocyte-specific transcription factor]	0.0	4	1	1	1
100155	1710	V beta t-cell receptor	[V beta T-cell receptors]	0.0	4	1	1	1
100156	1710	cycle reactivity undetectable	[cycle reactivities undetectable]	0.0	3	1	1	1
100157	1710	system-derived (n-oct) protein	[system-derived (N-Oct) proteins]	0.0	3	1	1	1
100158	1710	imply a role for camp	[implying a role for cAMP]	0.0	5	1	1	1
100159	1710	503-amino-acid-long protein	[503-amino-acid-long protein]	0.0	2	1	1	1
100160	1710	conditions, delta	[conditions, delta]	0.0	2	1	1	1
100161	1710	stimulation with mbp	[stimulation with MBP]	0.0	3	1	1	1
100162	1710	epidermal growth factor-like growth factor	[epidermal growth factor-like growth factor]	0.0	5	1	1	1
100163	1710	comparison with protein	[comparison with proteins]	0.0	3	1	1	1
100164	1710	human 15-lipoxygenase gene promoter	[Human 15-lipoxygenase gene promoter]	0.0	4	1	1	1
100165	1710	notably phospholipase c gamma	[notably phospholipase C gamma]	0.0	4	1	1	1
100166	1710	five DNase-I site HS	[Five DNase-I sites HS]	0.0	4	1	1	1
100167	1710	interferon-alpha IFN alpha	[interferon-alpha IFN alpha]	0.0	3	1	1	1
100168	1710	comprise domain	[comprising domains]	0.0	2	1	1	1
100169	1710	gp120-anti-gp120 immune complex	[gp120-anti-gp120 immune complexes]	0.0	3	1	1	1
100170	1710	lymphokine interleukin-1	[lymphokine interleukin-1]	0.0	2	1	1	1
100171	1710	land structure distinct from the structure	[LANDs structures distinct from the structures]	0.0	6	1	1	1
100172	1710	role of CaM-K	[role of CaM-K]	0.0	3	1	1	1
100173	1710	induction of CD38 in leukemia cell	[Induction of CD38 in leukemia cells]	0.0	6	1	1	1
100174	1710	octamer sequence pos	[octamer sequence POS]	0.0	3	1	1	1
100175	1710	increase expression	[increasing expression]	0.0	2	1	1	1
100176	1710	powerful ptpase inhibitor	[powerful PTPase inhibitor]	0.0	3	1	1	1
100177	1710	region of the mouse gene	[region of the mouse gene]	0.0	5	1	1	1
100178	1710	apparent remission.	[apparent remission.]	0.0	2	1	1	1
100179	1710	prevent activation of T cell	[preventing activation of T cells]	0.0	5	1	1	1
100180	1710	cases, include aml	[cases, including AML]	0.0	3	1	1	1
100181	1710	mediate diverse response	[mediating diverse responses]	0.0	3	1	1	1
100182	1710	T cell with antigen	[T cells with antigen]	0.0	4	1	1	1
100183	1710	interact proteins: RXR	[interacting proteins: RXR]	0.0	3	1	1	1
100184	1710	Genetic variation	[Genetic variation]	0.0	2	1	1	1
100185	1710	double time of h (viability	[doubling times of h (viability]	0.0	5	1	1	1
100186	1710	heparan	[heparan]	0.0	1	1	1	1
100187	1710	Antisera	[Antisera]	0.0	1	1	1	1
100188	1710	insensitivity to the effect of tnf	[insensitivity to the effects of TNF]	0.0	6	1	1	1
100189	1710	cell of T lineage	[cells of T lineage]	0.0	4	1	1	1
100190	1710	substrate for shp1 in intact cells.	[substrates for SHP1 in intact cells.]	0.0	6	1	1	1
100191	1710	platelet patient with bipolar disorder	[platelets patients with bipolar disorder]	0.0	5	1	1	1
100192	1710	pulp of the spleen	[pulp of the spleen]	0.0	4	1	1	1
100193	1710	encode the form	[encoding the form]	0.0	3	1	1	1
100194	1710	de novo radiation-induced translocation	[de novo radiation-induced translocations]	0.0	4	1	1	1
100195	1710	C/EBPdelta	[C/EBPdelta]	0.0	1	1	1	1
100196	1710	advance in understanding	[advances in understanding]	0.0	3	1	1	1
100197	1710	regulatory role for GATA-1	[regulatory role for GATA-1]	0.0	4	1	1	1
100198	1710	increase time	[increasing time]	0.0	2	1	1	1
100199	1710	treatment with growth factor	[treatment with growth factors]	0.0	4	1	1	1
100200	1710	repression direct inhibition of NFATp/AP-1 formation	[repression direct inhibition of NFATp/AP-1 formation]	0.0	6	1	1	1
100201	1710	overexpression in blood cell	[overexpression in blood cells]	0.0	4	1	1	1
100202	1710	blood T cell proliferation	[blood T cell proliferation]	0.0	4	1	1	1
100203	1710	latent ebv genome	[latent EBV genome]	0.0	3	1	1	1
100204	1710	two domain the ligand-binding domain	[two domains the ligand-binding domain]	0.0	5	1	1	1
100205	1710	evidence for the local modulation	[evidence for the local modulation]	0.0	5	1	1	1
100206	1710	contain the ubiquitous transcription factor	[containing the ubiquitous transcription factor]	0.0	5	1	1	1
100207	1710	interferon-inducible fashion	[interferon-inducible fashion]	0.0	2	1	1	1
100208	1710	nuclear factor-IL6 binding site	[nuclear factor-IL6 binding site]	0.0	4	1	1	1
100209	1710	protein dimerization domain of HLF factor	[protein dimerization domain of HLF factor]	0.0	6	1	1	1
100210	1710	Clinical deterioration immunodeficiency virus type hiv-1	[Clinical deterioration immunodeficiency virus type HIV-1]	0.0	6	1	1	1
100211	1710	ether	[ether]	0.0	1	1	1	1
100212	1710	apc function	[APC function]	0.0	2	1	1	1
100213	1710	hhv-8 +/ebv- pel in the case	[HHV-8 +/EBV- PEL in the case]	0.0	6	1	1	1
100214	1710	promoter occupancy	[promoter occupancy]	0.0	2	1	1	1
100215	1710	activity of cyclin/cdk kinase complex	[activity of cyclin/cdks kinase complexes]	0.0	5	1	1	1
100216	1710	lack xist expression	[lacking XIST expression]	0.0	3	1	1	1
100217	1710	BCL-6 mrna	[BCL-6 mRNA]	0.0	2	1	1	1
100218	1710	moreover, follow incubation	[Moreover, following incubation]	0.0	3	1	1	1
100219	1710	C3/5 clone	[C3/5 clone]	0.0	2	1	1	1
100220	1710	emergence of this protein	[emergence of these proteins]	0.0	4	1	1	1
100221	1710	jcam1 cell by Syk	[JCaM1 cells by Syk]	0.0	4	1	1	1
100222	1710	direct percutaneous transluminal angioplasty PTCA	[direct percutaneous transluminal angioplasty PTCA]	0.0	5	1	1	1
100223	1710	course 0.05, chi2 test).	[course 0.05, chi2 test).]	0.0	4	1	1	1
100224	1710	reduction due to fluticasone propionate	[reduction due to fluticasone propionate]	0.0	5	1	1	1
100225	1710	postnatally, die	[postnatally, dying]	0.0	2	1	1	1
100226	1710	kinase inhibitor p21(waf1/cip1)	[kinase inhibitor p21(WAF1/CIP1)]	0.0	3	1	1	1
100227	1710	nervous tissue	[nervous tissues]	0.0	2	1	1	1
100228	1710	inhibitor p21(waf1/cip1)	[inhibitor p21(WAF1/CIP1)]	0.0	2	1	1	1
100229	1710	antitumor immune	[antitumor immune]	0.0	2	1	1	1
100230	1710	expression of c-rel /p50	[expression of c-Rel /p50]	0.0	4	1	1	1
100231	1710	nuclear nf-kappab in mononuclear cell	[nuclear NF-kappaB in mononuclear cells]	0.0	5	1	1	1
100232	1710	consequence, to the activity	[consequence, to the activity]	0.0	4	1	1	1
100233	1710	accord to pbmc sensitivity	[according to PBMC sensitivity]	0.0	4	1	1	1
100234	1710	peroxisome receptor activator	[Peroxisome receptor activators]	0.0	3	1	1	1
100235	1710	event of T cell activation	[events of T cell activation]	0.0	5	1	1	1
100236	1710	[3H] pyrilamine binding	[[3H] pyrilamine binding]	0.0	3	1	1	1
100237	1710	Costimulatory signals,	[Costimulatory signals,]	0.0	2	1	1	1
100238	1710	antigen-driven expansion) (by stimulation lead	[antigen-driven expansion) (by stimulation leading]	0.0	5	1	1	1
100239	1710	disease with pml/rar alpha	[disease with PML/RAR alpha]	0.0	4	1	1	1
100240	1710	Ii-expressing t-cell line	[Ii-expressing T-cell line]	0.0	3	1	1	1
100241	1710	sedimenting at 8.3s	[sedimenting at 8.3S]	0.0	3	1	1	1
100242	1710	p-glycoprotein	[P-glycoprotein]	0.0	1	1	1	1
100243	1710	regulation in human monocytic cell line	[regulation in human monocytic cell lines]	0.0	6	1	1	1
100244	1710	emphasize the antiatherosclerotic potential of antioxidant	[emphasizing the antiatherosclerotic potential of antioxidants]	0.0	6	1	1	1
100245	1710	stain by a procedure	[staining by an procedure]	0.0	4	1	1	1
100246	1710	activity of the receptor promoter	[activity of the receptor promoter]	0.0	5	1	1	1
100247	1710	serum-contain colony	[serum-containing colonies]	0.0	2	1	1	1
100248	1710	N9 cell line	[N9 cell line]	0.0	3	1	1	1
100249	1710	receptor ar/tr2/ar	[receptor AR/TR2/AR]	0.0	2	1	1	1
100250	1710	capacity, mobility on sucrose gradients,	[capacity, mobility on sucrose gradients,]	0.0	5	1	1	1
100251	1710	chloramphenicol acetyltransferase CAT assay	[Chloramphenicol acetyltransferase CAT assay]	0.0	4	1	1	1
100252	1710	(p less than p	[(P less than P]	0.0	4	1	1	1
100253	1710	type human immunodeficiency virus	[type human immunodeficiency virus]	0.0	4	1	1	1
100254	1710	b cell surface molecule	[B cell surface molecule]	0.0	4	1	1	1
100255	1710	phosphorylation pattern	[phosphorylation pattern]	0.0	2	1	1	1
100256	1710	same body	[same bodies]	0.0	2	1	1	1
100257	1710	vsmc express c-myc	[VSMCs expressing c-myc]	0.0	3	1	1	1
100258	1710	anoxia/reoxygenation-induced adherence to endothelial cell	[anoxia/reoxygenation-induced adherence to endothelial cells]	0.0	5	1	1	1
100259	1710	produce stimulation	[producing stimulation]	0.0	2	1	1	1
100260	1710	steroid region	[steroid region]	0.0	2	1	1	1
100261	1710	increase in CD4 thymocyte	[increase in CD4 thymocytes]	0.0	4	1	1	1
100262	1710	correlation between tyrosine phosphorylation	[correlation between tyrosine phosphorylation]	0.0	4	1	1	1
100263	1710	can metabolism	[Ca metabolism]	0.0	2	1	1	1
100264	1710	actual activity	[actual activity]	0.0	2	1	1	1
100265	1710	tnf-alpha expression	[TNF-alpha expression]	0.0	2	1	1	1
100266	1710	hat	[HAT]	0.0	1	1	1	1
100267	1710	ligand, start at minute	[ligand, starting at min]	0.0	4	1	1	1
100268	1710	regulating protein fos	[regulating proteins Fos]	0.0	3	1	1	1
100269	1710	patient suggest great	[patient suggesting greater]	0.0	3	1	1	1
100270	1710	preliminary evidence	[preliminary evidence]	0.0	2	1	1	1
100271	1710	major subpopulation the (dp) CD4	[major subpopulation the (DP) CD4]	0.0	5	1	1	1
100272	1710	hbb	[HBB]	0.0	1	1	1	1
100273	1710	mitogen activation of peripheral T lymphocyte	[Mitogen activation of peripheral T lymphocytes]	0.0	6	2	2	1
100274	1710	periodontal tissue damage	[periodontal tissue damage]	0.0	3	1	1	1
100275	1710	5 region e1a	[5 regions E1A]	0.0	3	1	1	1
100276	1710	pathogenesis of chronic lymphocytic leukemia	[pathogenesis of chronic lymphocytic leukemia]	0.0	5	1	1	1
100277	1710	differentiation in culture	[differentiation in culture]	0.0	3	1	1	1
100278	1710	embryonic zeta globin promoter	[embryonic zeta globin promoter]	0.0	4	1	1	1
100279	1710	kda nf-kappa b protein	[kDa NF-kappa B protein]	0.0	4	1	1	1
100280	1710	suppress central system	[suppressing central system]	0.0	3	1	1	1
100281	1710	agonistic anti- CD30 antibody	[agonistic anti- CD30 antibodies]	0.0	4	1	1	1
100282	1710	event in oncogenic transformation	[event in oncogenic transformation]	0.0	4	1	1	1
100283	1710	role of caspase 3-like protease	[role of caspase 3-like proteases]	0.0	5	1	1	1
100284	1710	cysteine region LIM domain	[cysteine regions LIM domains]	0.0	4	1	1	1
100285	1710	very little activation	[very little activation]	0.0	3	1	1	1
100286	1710	hcl	[HCl]	0.0	1	1	1	1
100287	1710	hamster ovary cell express recombinant alphaiibbeta3	[hamster ovary cells expressing recombinant alphaIIbbeta3]	0.0	6	1	1	1
100288	1710	immunoglobulin region promoter	[immunoglobulin region promoters]	0.0	3	1	1	1
100289	1710	qr -specific inhibitor	[QR -specific inhibitor]	0.0	3	1	1	1
100290	1710	intact pu.1 site	[intact PU.1 site]	0.0	3	1	1	1
100291	1710	tnf-alpha icam-1 transcription	[TNF-alpha ICAM-1 transcription]	0.0	3	1	1	1
100292	1710	gata-associated site CACCC	[GATA-associated sites CACCC]	0.0	3	1	1	1
100293	1710	colony-form unit monocyte	[colony-forming unit monocyte]	0.0	3	1	1	1
100294	1710	appearance of a novel	[appearance of a novel]	0.0	4	1	1	1
100295	1710	ATLL patient	[ATLL patients]	0.0	2	1	1	1
100296	1710	NF-kB T	[NF-kB T]	0.0	2	1	1	1
100297	1710	weak phosphorylation of stat3	[weak phosphorylation of STAT3]	0.0	4	1	1	1
100298	1710	patient from five family	[patients from five families]	0.0	4	1	1	1
100299	1710	ratio-dependent increase	[ratio-dependent increase]	0.0	2	1	1	1
100300	1710	mimick clonal cell growth	[mimicking clonal cell growth]	0.0	4	1	1	1
100301	1710	stat family	[STAT family]	0.0	2	1	1	1
100302	1710	aim/cd69	[AIM/CD69]	0.0	1	1	1	1
100303	1710	ifn-alpha/beta-induced transcription isgf3	[IFN-alpha/beta-induced transcription ISGF3]	0.0	3	1	1	1
100304	1710	T helper cell mrna	[T helper cell mRNA]	0.0	4	1	1	1
100305	1710	defect in production of factor	[defects in production of factor]	0.0	5	1	1	1
100306	1710	remission of the state in mouse	[remissions of the state in mice]	0.0	6	1	1	1
100307	1710	hdn	[HDN]	0.0	1	1	1	1
100308	1710	key step in the shaping	[key step in the shaping]	0.0	5	1	1	1
100309	1710	specific stage	[specific stage]	0.0	2	1	1	1
100310	1710	IKAROS/LYF-1 transcription	[IKAROS/LYF-1 transcription]	0.0	2	1	1	1
100311	1710	left region	[left region]	0.0	2	1	1	1
100312	1710	interaction of extract from cell line	[Interaction of extracts from cell lines]	0.0	6	1	1	1
100313	1710	p50/rela(p65) complex	[p50/RelA(p65) complexes]	0.0	2	1	1	1
100314	1710	two population of effector cell	[two populations of effector cells]	0.0	5	1	1	1
100315	1710	few instances.	[few instances.]	0.0	2	1	1	1
100316	1710	mrna expression of il-1beta	[mRNA expression of IL-1beta]	0.0	4	1	1	1
100317	1710	insulin tolerance test	[insulin tolerance test]	0.0	3	1	1	1
100318	1710	blood lymphocyte of asthma patient	[blood lymphocytes of asthma patients]	0.0	5	1	1	1
100319	1710	visit,	[visit,]	0.0	1	1	1	1
100320	1710	kappa b-binding activity in extract	[kappa B-binding activity in extracts]	0.0	5	1	1	1
100321	1710	level of other transcription factor	[level of other transcription factors]	0.0	5	1	1	1
100322	1710	min) nf-kappa b	[min) NF-kappa B]	0.0	3	1	1	1
100323	1710	distinct pathways: Lyn	[distinct pathways: Lyn]	0.0	3	1	1	1
100324	1710	expression of PML gene	[Expression of PML gene]	0.0	4	1	1	1
100325	1710	prolyl	[prolyl]	0.0	1	1	1	1
100326	1710	response to a set	[response to a set]	0.0	4	1	1	1
100327	1710	increase in plap activity	[increase in PLAP activity]	0.0	4	1	1	1
100328	1710	patient before month	[patients before months]	0.0	3	1	1	1
100329	1710	er content from 27 SLE patient	[ER content from 27 SLE patients]	0.0	6	1	1	1
100330	1710	primitive erythroid cell in mouse	[primitive erythroid cells in mice]	0.0	5	1	1	1
100331	1710	mnp site	[MNP site]	0.0	2	1	1	1
100332	1710	regulate the expression during the response	[regulating the expression during the response]	0.0	6	1	1	1
100333	1710	mutagenesis of this element	[mutagenesis of these elements]	0.0	4	1	1	1
100334	1710	hgf	[HGFs]	0.0	1	1	1	1
100335	1710	activation of MAPK	[activation of MAPK]	0.0	3	2	2	1
100336	1710	mitogen-inducible dna-binding complex	[mitogen-inducible DNA-binding complexes]	0.0	3	1	1	1
100337	1710	hgh	[hGH]	0.0	1	1	1	1
100338	1710	mediate the pharmacological effect	[mediating the pharmacological effect]	0.0	4	1	1	1
100339	1710	signal from T cell	[signals from T cells]	0.0	4	1	1	1
100340	1710	factor critical directly to hiv-1 replication	[factors critical directly to HIV-1 replication]	0.0	6	1	1	1
100341	1710	hgr	[hGRs]	0.0	1	1	1	1
100342	1710	convert ligand-receptor interaction at the membrane	[converting ligand-receptor interactions at the membrane]	0.0	6	1	1	1
100343	1710	Blood,	[Blood,]	0.0	1	1	1	1
100344	1710	sp-1 element within the LTR	[Sp-1 elements within the LTR]	0.0	5	1	1	1
100345	1710	MHC class gene activation	[MHC class gene activation]	0.0	4	1	1	1
100346	1710	primary human cell in culture	[primary human cells in cultures]	0.0	5	1	1	1
100347	1710	CD40 cell (26%)	[CD40 cells (26%)]	0.0	3	1	1	1
100348	1710	biological marker	[biological marker]	0.0	2	1	1	1
100349	1710	activation of select b gene	[activation of select B genes]	0.0	5	1	1	1
100350	1710	inducible, T cell-specific enhancer	[inducible, T cell-specific enhancers]	0.0	4	1	1	1
100351	1710	drip coactivator binding	[DRIP coactivator binding]	0.0	3	1	1	1
100352	1710	(range):	[(range):]	0.0	1	1	1	1
100353	1710	anti- tat single-chain antibody	[anti- Tat single-chain antibody]	0.0	4	1	1	1
100354	1710	IL-3 factor two complex	[IL-3 factor two complexes]	0.0	4	1	1	1
100355	1710	MRD -/lt)	[MRD -/LT)]	0.0	2	1	1	1
100356	1710	nfat-binding element	[NFAT-binding elements]	0.0	2	1	1	1
100357	1710	pdgf(b) mrna accumulation	[PDGF(B) mRNA accumulation]	0.0	3	1	1	1
100358	1710	partial independence	[partial independence]	0.0	2	1	1	1
100359	1710	(consist of subunit	[(consisting of subunits]	0.0	3	1	1	1
100360	1710	nuclear localization by techniques: blot	[nuclear localization by techniques: blot]	0.0	5	1	1	1
100361	1710	follow engagement cell-to-cell	[following engagement cell-to-cell]	0.0	3	1	1	1
100362	1710	use this cDNA	[Using this cDNA]	0.0	3	1	1	1
100363	1710	brain development due to prenatal challenge	[brain development due to prenatal challenge]	0.0	6	1	1	1
100364	1710	common regulatory element	[common regulatory element]	0.0	3	1	1	1
100365	1710	physiologic relevance of no regulation	[physiologic relevance of NO regulation]	0.0	5	1	1	1
100366	1710	yyabu	[YY-Bu]	0.0	1	1	1	1
100367	1710	recruiting histone deacetylase complex	[recruiting histone deacetylase complexes]	0.0	4	1	1	1
100368	1710	contain near-perfect repeat of 21 bp	[containing near-perfect repeats of 21 bp]	0.0	6	1	1	1
100369	1710	pathway essential for this stage	[pathways essential for this stage]	0.0	5	1	1	1
100370	1710	two latent epitope	[two latent epitopes]	0.0	3	1	1	1
100371	1710	potential of antioxidant	[potential of antioxidants]	0.0	3	1	1	1
100372	1710	potential role of interaction	[potential role of interactions]	0.0	4	1	1	1
100373	1710	126 amino acid of bob.1/obf.1	[126 amino acids of BOB.1/OBF.1]	0.0	5	1	1	1
100374	1710	human blood monocyte Mo	[Human blood monocytes Mo]	0.0	4	1	1	1
100375	1710	Differential induction differentiation of a monocyte	[Differential induction differentiation of a monocyte]	0.0	6	1	1	1
100376	1710	lmp-2a loci	[LMP-2A loci]	0.0	2	1	1	1
100377	1710	beta ifn-beta	[beta IFN-beta]	0.0	2	1	1	1
100378	1710	normal Ter erythroid cell	[normal Ter erythroid cells]	0.0	4	1	1	1
100379	1710	immunity result in inflammatory response	[immunity resulting in inflammatory response]	0.0	5	1	1	1
100380	1710	inhibition of the gene transcription	[inhibition of the gene transcription]	0.0	5	1	1	1
100381	1710	anti-early antigen anti-viral antigen vca	[anti-early antigen anti-viral antigen VCA]	0.0	5	1	1	1
100382	1710	reflect sequestration of the tax protein	[reflecting sequestration of the Tax protein]	0.0	6	1	1	1
100383	1710	lmp-1 signal	[LMP-1 signaling]	0.0	2	1	1	1
100384	1710	cysteine-rich antigen segment resistant	[cysteine-rich antigen segments resistant]	0.0	4	1	1	1
100385	1710	binding of a polypeptide	[binding of a polypeptide]	0.0	4	1	1	1
100386	1710	key role b cell maturation	[key role B cell maturation]	0.0	5	1	1	1
100387	1710	antagonism of the action	[antagonism of the action]	0.0	4	1	1	1
100388	1710	transactivate activity	[transactivating activity]	0.0	2	2	2	1
100389	1710	component of the il13r	[components of the IL13R]	0.0	4	1	1	1
100390	1710	event in steroid-treated cells.	[events in steroid-treated cells.]	0.0	4	1	1	1
100391	1710	two chromatographic step	[two chromatographic steps]	0.0	3	1	1	1
100392	1710	cell possible enhancement of dna-binding	[cells possible enhancement of DNA-binding]	0.0	5	1	1	1
100393	1710	valuable tool	[valuable tools]	0.0	2	1	1	1
100394	1710	superaddition	[superaddition]	0.0	1	1	1	1
100395	1710	functional redundancy in coactivator	[functional redundancy in coactivators]	0.0	4	1	1	1
100396	1710	four method	[Four methods]	0.0	2	1	1	1
100397	1710	activity of plasma in runner	[activity of plasma in runner]	0.0	5	1	1	1
100398	1710	(mhc) class ii gene	[(MHC) class II genes]	0.0	4	4	4	1
100399	1710	marker include CD2	[markers including CD2]	0.0	3	1	1	1
100400	1710	hematopoietic-specific transcription factor complex	[hematopoietic-specific transcription factor complex]	0.0	4	1	1	1
100401	1710	anti-TNF antibody	[anti-TNF antibody]	0.0	2	1	1	1
100402	1710	ifn-alpha /beta T cell clone	[IFN-alpha /beta T cell clones]	0.0	5	1	1	1
100403	1710	include adhesion-dependent pathway	[including adhesion-dependent pathways]	0.0	3	1	1	1
100404	1710	multifactor negative regulation	[Multifactor negative regulation]	0.0	3	1	1	1
100405	1710	less tyrosine stat5b	[less tyrosine STAT5B]	0.0	3	1	1	1
100406	1710	ng/ml il-8	[ng/ml IL-8]	0.0	2	2	2	1
100407	1710	autoimmune disease primary cirrhosis	[autoimmune disease primary cirrhosis]	0.0	4	1	1	1
100408	1710	furthermore, multimerized region sequence element	[Furthermore, multimerized region sequence elements]	0.0	5	1	1	1
100409	1710	stable clone of B-cell line	[stable clones of B-cell lines]	0.0	5	1	1	1
100410	1710	gr gene	[GR gene]	0.0	2	1	1	1
100411	1710	b activation in T cell	[B activation in T cells]	0.0	5	1	1	1
100412	1710	marker of icenko- cushingd' syndrome	[markers of Icenko- Cushing's syndrome]	0.0	5	1	1	1
100413	1710	domain of the cytoplasmic tail	[domains of the cytoplasmic tail]	0.0	5	1	1	1
100414	1710	expression of CD30	[Expression of CD30]	0.0	3	1	1	1
100415	1710	(7/8 patient	[(7/8 patients]	0.0	2	1	1	1
100416	1710	bipartite human interleukin-4 receptor	[bipartite human interleukin-4 receptor]	0.0	4	1	1	1
100417	1710	overexpression in b cell	[Overexpression in B cells]	0.0	4	1	1	1
100418	1710	model of adenovirus 5 infection	[model of adenovirus 5 infection]	0.0	5	1	1	1
100419	1710	hcmv a betaherpesvirus	[HCMV a betaherpesvirus]	0.0	3	1	1	1
100420	1710	human granulocyte-macrophage CSF	[human granulocyte-macrophage CSF]	0.0	3	1	1	1
100421	1710	primary nuclear transcription factor	[primary nuclear transcription factors]	0.0	4	1	1	1
100422	1710	important insight into role	[important insights into role]	0.0	4	1	1	1
100423	1710	derivative of doc	[derivatives of DOC]	0.0	3	1	1	1
100424	1710	addition of interleukin-2	[addition of interleukin-2]	0.0	3	1	1	1
100425	1710	expression of CD40	[expression of CD40]	0.0	3	1	1	1
100426	1710	shift in prb weight	[shift in pRB weight]	0.0	4	1	1	1
100427	1710	immunocytochemical evaluation	[immunocytochemical evaluation]	0.0	2	1	1	1
100428	1710	band range to kd, result	[bands ranging to kD, resulting]	0.0	5	1	1	1
100429	1710	acute myelogenous leukemia 1-	[acute myelogenous leukemia 1-]	0.0	4	1	1	1
100430	1710	mutant of the IL-1 signal	[mutants of the IL-1 signaling]	0.0	5	1	1	1
100431	1710	blood polymorphonuclear cell pmnc	[blood polymorphonuclear cells PMNCs]	0.0	4	1	1	1
100432	1710	datum along with finding	[data, along with findings]	0.0	4	1	1	1
100433	1710	radiotherapy in squamous cell carcinoma	[radiotherapy in squamous cell carcinomas]	0.0	5	1	1	1
100434	1710	attribute the lack	[attributing the lack]	0.0	3	1	1	1
100435	1710	number (mnl)	[number (MNL)]	0.0	2	1	1	1
100436	1710	ciita promoter suppression cell hybrid	[CIITA promoter suppression cell hybrids]	0.0	5	1	1	1
100437	1710	binding to response element	[binding to response element]	0.0	4	1	1	1
100438	1710	control of infection	[control of infection]	0.0	3	1	1	1
100439	1710	preferential coupling	[preferential coupling]	0.0	2	1	1	1
100440	1710	Jurkat in the regulation	[Jurkat in the regulation]	0.0	4	1	1	1
100441	1710	much high concentration of other antioxidant	[Much higher concentrations of other antioxidants]	0.0	6	1	1	1
100442	1710	ap-2 transcription factor	[AP-2 transcription factor]	0.0	3	1	1	1
100443	1710	palindromic site	[palindromic site]	0.0	2	1	1	1
100444	1710	U937 line	[U937 line]	0.0	2	1	1	1
100445	1710	herpesvirus saimiry HVS reading frame	[herpesvirus saimiri HVS reading frame]	0.0	5	1	1	1
100446	1710	hes-1 transcript	[HES-1 transcripts]	0.0	2	1	1	1
100447	1710	neutrophil gene expression	[neutrophil gene expression]	0.0	3	1	1	1
100448	1710	support a role	[supporting a role]	0.0	3	1	1	1
100449	1710	inhibition of Smad6	[inhibition of Smad6]	0.0	3	1	1	1
100450	1710	inflammatory-type	[inflammatory-type]	0.0	1	1	1	1
100451	1710	Functional expression of the il-2ralpha	[Functional expression of the IL-2Ralpha]	0.0	5	1	1	1
100452	1710	result from 9 healthy volunteer	[results from 9 healthy volunteers]	0.0	5	1	1	1
100453	1710	hsi	[HSI]	0.0	1	1	1	1
100454	1710	parent cell line	[parent cell line]	0.0	3	1	1	1
100455	1710	PYBF -binding site	[PYBF -binding site]	0.0	3	1	1	1
100456	1710	core recognition	[core recognition]	0.0	2	1	1	1
100457	1710	ebv b	[EBV B]	0.0	2	1	1	1
100458	1710	sequence in the regulatory element	[sequence in the regulatory element]	0.0	5	1	1	1
100459	1710	CEM-ICR lymphoblast	[CEM-ICR lymphoblasts]	0.0	2	1	1	1
100460	1710	short-term incubation	[short-term incubation]	0.0	2	1	1	1
100461	1710	mouse development in system	[mouse development in system]	0.0	4	1	1	1
100462	1710	ebv T	[EBV T]	0.0	2	1	1	1
100463	1710	blockade of nf-kappab activity	[blockade of NF-kappaB activity]	0.0	4	1	1	1
100464	1710	cd34+thy-1+ cb subset	[CD34+Thy-1+ CB subset]	0.0	3	1	1	1
100465	1710	nuclear depletion of transcription factor	[nuclear depletion of transcription factors]	0.0	5	1	1	1
100466	1710	hth	[HTH]	0.0	1	1	1	1
100467	1710	level of proenkephalin mrna	[levels of proenkephalin mRNA]	0.0	4	1	1	1
100468	1710	h of exposure	[h of exposure]	0.0	3	1	1	1
100469	1710	X1 box-specific dna-binding activity	[X1 box-specific DNA-binding activities]	0.0	4	1	1	1
100470	1710	ii-positive b	[II-positive B]	0.0	2	1	1	1
100471	1710	A.Rajadhyaksha,	[A.Rajadhyaksha,]	0.0	1	1	1	1
100472	1710	transient increase in g0s2 mrna	[transient increase in G0S2 mRNA]	0.0	5	1	1	1
100473	1710	(prd) ii	[(PRD) II]	0.0	2	1	1	1
100474	1710	partial resistance	[partial resistance]	0.0	2	1	1	1
100475	1710	comparable functional effect	[comparable functional effects]	0.0	3	1	1	1
100476	1710	translocation of nfat factor lymphocyte	[translocation of NFAT factor lymphocytes]	0.0	5	1	1	1
100477	1710	intracellular adhesion molecule	[intracellular adhesion molecule]	0.0	3	1	1	1
100478	1710	potent transcription activator of gene	[potent transcription activator of genes]	0.0	5	1	1	1
100479	1710	cd20/b1 antigen	[CD20/B1 antigen]	0.0	2	1	1	1
100480	1710	negative mutant form of component	[negative mutant forms of components]	0.0	5	1	1	1
100481	1710	T cell protein tcf-1	[T cell protein TCF-1]	0.0	4	1	1	1
100482	1710	cells, respectively),	[cells, respectively),]	0.0	2	1	1	1
100483	1710	fiberoptic bronchoscopy	[fiberoptic bronchoscopy]	0.0	2	1	1	1
100484	1710	VitD3 response reporter construct	[VitD3 response reporter construct]	0.0	4	1	1	1
100485	1710	protein bind in a manner	[proteins binding in a manner]	0.0	5	1	1	1
100486	1710	alpha-Tocopheryl	[alpha-Tocopheryl]	0.0	1	1	1	1
100487	1710	transcription by 80-90%	[transcription by 80-90%]	0.0	3	1	1	1
100488	1710	(hpa) axis functioning	[(HPA) axis functioning]	0.0	3	1	1	1
100489	1710	take change into account.	[taking changes into account.]	0.0	4	1	1	1
100490	1710	gamma(c) chain	[gamma(c) chain]	0.0	2	1	1	1
100491	1710	9s receptor complex in cytosol	[9S receptor complexes in cytosol]	0.0	5	1	1	1
100492	1710	apparent dissociation constant kd	[apparent dissociation constant Kd]	0.0	4	1	1	1
100493	1710	only site	[only site]	0.0	2	1	1	1
100494	1710	myeloid cytokine	[myeloid cytokines]	0.0	2	1	1	1
100495	1710	uv-induced cyp1a1 gene expression	[UV-induced CYP1A1 gene expression]	0.0	4	1	1	1
100496	1710	immunoprecipitated Jak	[immunoprecipitated Jak]	0.0	2	1	1	1
100497	1710	management of asthma	[management of asthma]	0.0	3	1	1	1
100498	1710	rare form of t-cell leukemia	[rare form of T-cell leukemias]	0.0	5	1	1	1
100499	1710	glucocorticoid responsiveness of leukocyte HML	[glucocorticoid responsiveness of leukocytes HML]	0.0	5	1	1	1
100500	1710	response to (il)-4 stimulation	[response to (IL)-4 stimulation]	0.0	4	1	1	1
100501	1710	generate a humoral immune response	[generating an humoral immune response]	0.0	5	1	1	1
100502	1710	11 abdominal subject	[11 abdominal subjects]	0.0	3	1	1	1
100503	1710	competition between transcriptional activator RelA	[competition between transcriptional activators RelA]	0.0	5	1	1	1
100504	1710	regulation at the level	[regulation at the level]	0.0	4	1	1	1
100505	1710	similar upregulation	[similar upregulation]	0.0	2	1	1	1
100506	1710	machinery during human differentiation	[machinery during human differentiation]	0.0	4	1	1	1
100507	1710	the/thf alpha thf/thf (0.35;	[THE/THF alpha THF/THF (0.35;]	0.0	4	1	1	1
100508	1710	translocation of NF-kappaB subunit	[translocation of NF-kappaB subunits]	0.0	4	1	1	1
100509	1710	kda stat5b protein	[kDa STAT5B protein]	0.0	3	1	1	1
100510	1710	suppression to the corneal endothelium	[Suppression to the corneal endothelium]	0.0	5	1	1	1
100511	1710	interleukin-3 il-3 gene	[interleukin-3 IL-3 gene]	0.0	3	1	1	1
100512	1710	nmol/L; daidzein	[nmol/L; daidzein]	0.0	2	1	1	1
100513	1710	putative receptor	[putative receptors]	0.0	2	1	1	1
100514	1710	surgery),	[surgery),]	0.0	1	1	1	1
100515	1710	Eleven patient with ulcerative colitis	[Eleven patients with ulcerative colitis]	0.0	5	1	1	1
100516	1710	efficient binding,	[efficient binding,]	0.0	2	1	1	1
100517	1710	ala asp amino	[Ala Asp amino]	0.0	3	1	1	1
100518	1710	extensive analysis for the specificity	[extensive analyses for the specificity]	0.0	5	1	1	1
100519	1710	three-dimensional nuclear resonance 3d-nmr spectroscopy	[three-dimensional nuclear resonance 3D-NMR spectroscopy]	0.0	5	1	1	1
100520	1710	dependence for the response	[Dependence for the response]	0.0	4	1	1	1
100521	1710	nevertheless, relatively high, concentration to &mgr;m)	[Nevertheless, relatively high, concentrations to &mgr;M)]	0.0	6	1	1	1
100522	1710	monocyte adhesion in vein cell HUVECs	[monocyte adhesion in vein cells HUVECs]	0.0	6	1	1	1
100523	1710	weight 13000	[weight 13,000]	0.0	2	1	1	1
100524	1710	transfection of a b lymphoma line	[transfection of a B lymphoma line]	0.0	6	1	1	1
100525	1710	small change	[smaller changes]	0.0	2	1	1	1
100526	1710	t(15;	[t(15;]	0.0	1	1	1	1
100527	1710	number of related receptor	[number of related receptors]	0.0	4	1	1	1
100528	1710	fusion follow t(1;19) chromosomal translocation	[fusion following t(1;19) chromosomal translocations]	0.0	5	1	1	1
100529	1710	level 1 beta il-1 beta	[levels 1 beta IL-1 beta]	0.0	5	1	1	1
100530	1710	utilization in the stimulation	[utilization in the stimulation]	0.0	4	1	1	1
100531	1710	ligand CD80	[ligand CD80]	0.0	2	1	1	1
100532	1710	role for a Raf kinase	[role for a Raf kinase]	0.0	5	1	1	1
100533	1710	hsf-1 activity	[HSF-1 activity]	0.0	2	1	1	1
100534	1710	two potential reading frame orf	[two potential reading frames ORFs]	0.0	5	1	1	1
100535	1710	prime from signal to	[priming from signal to]	0.0	4	1	1	1
100536	1710	recombinant thyroid hormone receptor	[recombinant thyroid hormone receptors]	0.0	4	1	1	1
100537	1710	proliferate human epstein-barr virus b lymphocyte	[proliferating human Epstein-Barr virus B lymphocytes]	0.0	6	1	1	1
100538	1710	class similar	[class similar]	0.0	2	1	1	1
100539	1710	structural domain include distinct domain	[structural domains including distinct domains]	0.0	5	1	1	1
100540	1710	272 97 receptor	[272 97 receptors]	0.0	3	1	1	1
100541	1710	migration rate of polymorphonuclear leukocyte	[migration rate of polymorphonuclear leukocytes]	0.0	5	1	1	1
100542	1710	beta-methyl analog	[beta-methyl analog]	0.0	2	1	1	1
100543	1710	monocyte maturation/differentiation	[monocyte maturation/differentiation]	0.0	2	1	1	1
100544	1710	various lineages.	[various lineages.]	0.0	2	1	1	1
100545	1710	action of nf-kappa b	[action of NF-kappa B]	0.0	4	1	1	1
100546	1710	primary culture of thymic cell	[primary cultures of thymic cells]	0.0	5	1	1	1
100547	1710	constituent of the factor kappab	[constituents of the factor kappaB]	0.0	5	1	1	1
100548	1710	succinimide intermediate	[succinimide intermediates]	0.0	2	1	1	1
100549	1710	cd15 Lewis X	[CD15 Lewis X]	0.0	3	1	1	1
100550	1710	corresponding specific binding to plasma membrane	[corresponding specific binding to plasma membranes]	0.0	6	1	1	1
100551	1710	differential diagnostic purpose	[differential diagnostic purposes]	0.0	3	1	1	1
100552	1710	delineate the role	[delineating the roles]	0.0	3	1	1	1
100553	1710	contrast, cdk4	[contrast, cdk4]	0.0	2	1	1	1
100554	1710	grow in the stage	[growing in the stages]	0.0	4	1	1	1
100555	1710	treatment with TNF-alpha localization irrespective	[treatment with TNF-alpha localization irrespective]	0.0	5	1	1	1
100556	1710	amelioration	[Amelioration]	0.0	1	1	1	1
100557	1710	year period	[year period]	0.0	2	1	1	1
100558	1710	6 h from basal level	[6 h from basal levels]	0.0	5	1	1	1
100559	1710	Stepwise deletion	[Stepwise deletions]	0.0	2	1	1	1
100560	1710	inhibition of Tat -mediated activation	[inhibition of Tat -mediated activation]	0.0	5	1	1	1
100561	1710	absence of t-cell- transcription factor tcf-1	[Absence of T-cell- transcription factors TCF-1]	0.0	6	1	1	1
100562	1710	Epstein-Barr virus antigen component	[Epstein-Barr virus antigen component]	0.0	4	1	1	1
100563	1710	c-fo mrna expression a analysis	[c-fos mRNA expression an analysis]	0.0	5	1	1	1
100564	1710	IgE by IL-4	[IgE by IL-4]	0.0	3	1	1	1
100565	1710	microm diacylglycerol	[microM diacylglycerol]	0.0	2	1	1	1
100566	1710	involve interaction between transcriptional regulatory element	[involving interactions between transcriptional regulatory elements]	0.0	6	1	1	1
100567	1710	level of nf-atp	[levels of NF-ATp]	0.0	3	1	1	1
100568	1710	elucidation of il-5 mechanism	[Elucidation of IL-5 mechanisms]	0.0	4	1	1	1
100569	1710	protein-coupled transcription	[protein-coupled transcription]	0.0	2	1	1	1
100570	1710	Differential inhibition on bone morphogenetic protein-	[Differential inhibition on bone morphogenetic protein-]	0.0	6	1	1	1
100571	1710	plasmid contain length	[plasmids containing lengths]	0.0	3	1	1	1
100572	1710	encode amino acid residue	[encoding amino acid residues]	0.0	4	1	1	1
100573	1710	inversion with tcr alpha/beta loci	[inversions with TCR alpha/beta loci]	0.0	5	1	1	1
100574	1710	promoter-CAT	[promoter-CAT]	0.0	1	1	1	1
100575	1710	whole blood from healthy donor	[whole blood from healthy donors]	0.0	5	1	1	1
100576	1710	gc receptor gcr	[GC receptor GCR]	0.0	3	1	1	1
100577	1710	crucial signal for the biogenesis	[crucial signals for the biogenesis]	0.0	5	1	1	1
100578	1710	molecular link	[molecular link]	0.0	2	1	1	1
100579	1710	Glucocorticoid -resistance	[Glucocorticoid -resistance]	0.0	2	1	1	1
100580	1710	action of sex steroid hormone	[actions of sex steroid hormones]	0.0	5	1	1	1
100581	1710	individual with lymphatic pathology LP	[individuals with lymphatic pathology LP]	0.0	5	1	1	1
100582	1710	translocation to the nucleus.	[translocation to the nucleus.]	0.0	4	1	1	1
100583	1710	chloramphenicol acetyltransferase production in the fragment	[chloramphenicol acetyltransferase production in the fragment]	0.0	6	1	1	1
100584	1710	particular importance in the system	[particular importance in the system]	0.0	5	1	1	1
100585	1710	tpa element TRE	[TPA elements TRE]	0.0	3	1	1	1
100586	1710	events; addition of TNF-alpha	[events; addition of TNF-alpha]	0.0	4	1	1	1
100587	1710	NLS disruption of the nuclear import	[NLS disruption of the nuclear import]	0.0	6	1	1	1
100588	1710	action of the positive element	[actions of the positive elements]	0.0	5	1	1	1
100589	1710	ic5	[IC50S]	0.0	1	1	1	1
100590	1710	crossover study	[crossover study]	0.0	2	1	1	1
100591	1710	bronchial epithelial cell BEAS-2B	[bronchial epithelial cells BEAS-2B]	0.0	4	1	1	1
100592	1710	MEKK1	[MEKK1]	0.0	1	1	1	1
100593	1710	bp -128	[bp -128]	0.0	2	1	1	1
100594	1710	sequence of erythroid-specific gene	[sequences of erythroid-specific genes]	0.0	4	1	1	1
100595	1710	VCAM-1 surface expression	[VCAM-1 surface expression]	0.0	3	1	1	1
100596	1710	histocompatibility class DRA promoter occupancy	[histocompatibility class DRA promoter occupancy]	0.0	5	1	1	1
100597	1710	cytochrome p-450 skf525a vcam-1 induction	[cytochrome P-450 SKF525a VCAM-1 induction]	0.0	5	1	1	1
100598	1710	constitutive phosphorylation of Jak3 STAT3	[Constitutive phosphorylation of Jak3 STAT3]	0.0	5	1	1	1
100599	1710	overlapping CD40L	[overlapping CD40L]	0.0	2	1	1	1
100600	1710	induction (ifn)-inducible protein differentiation	[induction (IFN)-inducible protein differentiation]	0.0	4	1	1	1
100601	1710	id1	[Id1]	0.0	1	1	1	1
100602	1710	hsv-1 background	[HSV-1 background]	0.0	2	1	1	1
100603	1710	prolonged degradation of ikappab-alpha of nf-kappab	[prolonged degradation of IkappaB-alpha of NF-kappaB]	0.0	6	1	1	1
100604	1710	31-55 months).	[31-55 months).]	0.0	2	1	1	1
100605	1710	whole cell to m/l calcitriol	[whole cells to M/l calcitriol]	0.0	5	1	1	1
100606	1710	follow stimulation of line	[following stimulation of lines]	0.0	4	1	1	1
100607	1710	STAT3alpha on serine 727	[STAT3alpha on serine 727]	0.0	4	1	1	1
100608	1710	approach for disease	[approach for disease]	0.0	3	1	1	1
100609	1710	alkaline phosphatase plap	[alkaline phosphatase PLAP]	0.0	3	1	1	1
100610	1710	inhibition of activation signal	[Inhibition of activation signalling]	0.0	4	1	1	1
100611	1710	involve immune	[involving immune]	0.0	2	1	1	1
100612	1710	ie1	[IE1]	0.0	1	1	1	1
100613	1710	molecular heterogeneity	[molecular heterogeneity]	0.0	2	1	1	1
100614	1710	low bone mineral density	[low bone mineral density]	0.0	4	1	1	1
100615	1710	distinct interference of RU 486	[distinct interference of RU 486]	0.0	5	1	1	1
100616	1710	potential nuclear factor (NF)-kappaB binding site	[potential nuclear factor (NF)-kappaB binding sites]	0.0	6	1	1	1
100617	1710	inactivation inconsistent with the usual mechanism	[inactivation inconsistent with the usual mechanism]	0.0	6	1	1	1
100618	1710	idc	[IDCs]	0.0	1	1	1	1
100619	1710	characterization of lymphoma cell line CRO-AP/3	[characterization of lymphoma cell lines CRO-AP/3]	0.0	6	1	1	1
100620	1710	growth, differentiation, death,	[growth, differentiation, death,]	0.0	3	1	1	1
100621	1710	mechanism govern the proliferative response	[mechanism governing the proliferative response]	0.0	5	1	1	1
100622	1710	whole-cell radioassay use [3H]-dexamethasone	[whole-cell radioassay using [3H]-dexamethasone]	0.0	4	1	1	1
100623	1710	double-label electron microscopy on intact cell	[double-labeling electron microscopy on intact cells]	0.0	6	1	1	1
100624	1710	human tr beta 1 mrna level	[Human TR beta 1 mRNA levels]	0.0	6	1	1	1
100625	1710	suggest a role for G(Anh)MTetra	[suggesting a role for G(Anh)MTetra]	0.0	5	1	1	1
100626	1710	role for egr-1	[role for egr-1]	0.0	3	1	1	1
100627	1710	adhesion hl-60 leukemia cell	[adhesion HL-60 leukemia cells]	0.0	4	1	1	1
100628	1710	rule	[rules]	0.0	1	1	1	1
100629	1710	infection interleukin-8 IL-8 gene transcription	[infection interleukin-8 IL-8 gene transcription]	0.0	5	1	1	1
100630	1710	controversies,	[controversies,]	0.0	1	1	1	1
100631	1710	b lymphocytes.	[B lymphocytes.]	0.0	2	1	1	1
100632	1710	inhibition by interleukin-6 of the class	[inhibition by interleukin-6 of the class]	0.0	6	1	1	1
100633	1710	rare semen sample	[rare semen sample]	0.0	3	1	1	1
100634	1710	ec HUVEC	[EC HUVEC]	0.0	2	1	1	1
100635	1710	B/rel in the IL-4	[B/rel in the IL-4]	0.0	4	1	1	1
100636	1710	extensive deletion of sequence	[extensive deletion of sequences]	0.0	4	1	1	1
100637	1710	2 pre-B leukemia	[2 pre-B leukemia]	0.0	3	1	1	1
100638	1710	contrast, mild oxidation	[contrast, mild oxidation]	0.0	3	1	1	1
100639	1710	stress with reactive oxygen formation	[stress with reactive oxygen formation]	0.0	5	1	1	1
100640	1710	rat air pouch	[rat air pouch]	0.0	3	1	1	1
100641	1710	repression of the human gene	[repression of the human gene]	0.0	5	1	1	1
100642	1710	burst.	[burst.]	0.0	1	1	1	1
100643	1710	patient, reduction of aldosterone receptor	[patient, reduction of aldosterone receptors]	0.0	5	1	1	1
100644	1710	B2 subunit	[B2 subunit]	0.0	2	1	1	1
100645	1710	several animal model	[several animal models]	0.0	3	1	1	1
100646	1710	cell lack endogenous functional receptor.	[cells lacking endogenous functional receptor.]	0.0	5	1	1	1
100647	1710	gene responsible	[gene responsible]	0.0	2	1	1	1
100648	1710	active event in the thyrocyte	[active events in the thyrocyte]	0.0	5	1	1	1
100649	1710	fresh case of b leukemia	[fresh cases of B leukemias]	0.0	5	1	1	1
100650	1710	increase during exposure to tpa	[increasing during exposure to TPA]	0.0	5	1	1	1
100651	1710	nf-kappa b activity in om-10.1	[NF-kappa B activity in OM-10.1]	0.0	5	1	1	1
100652	1710	important determinant for MLV activity	[important determinants for MLV activity]	0.0	5	1	1	1
100653	1710	hang drop-mediated transfer into thymus lobe	[Hanging drop-mediated transfer into thymus lobes]	0.0	6	1	1	1
100654	1710	lps- induction	[LPS- induction]	0.0	2	1	1	1
100655	1710	il4 promoter transcription	[IL4 promoter transcription]	0.0	3	1	1	1
100656	1710	phenomenon of apoptosis	[phenomenon of apoptosis]	0.0	3	1	1	1
100657	1710	contain constitutive nf-kappa b	[containing constitutive NF-kappa B]	0.0	4	1	1	1
100658	1710	b DNA binding protein	[B DNA binding proteins]	0.0	4	2	2	1
100659	1710	pkc inhibitors, pentoxifylline PTX	[PKC inhibitors, pentoxifylline PTX]	0.0	4	1	1	1
100660	1710	pgn activation	[PGN activation]	0.0	2	1	1	1
100661	1710	possible consequence of the content	[possible consequences of the content]	0.0	5	1	1	1
100662	1710	stimulation by superantigen	[stimulation by superantigens]	0.0	3	1	1	1
100663	1710	encode initiation factor	[encoding initiation factors]	0.0	3	1	1	1
100664	1710	low cd4+ cell count 0.05)	[low CD4+ cell counts 0.05)]	0.0	5	1	1	1
100665	1710	intact e(gre) motif mediate activation	[intact E(gre) motifs mediating activation]	0.0	5	1	1	1
100666	1710	effect of v3-bh10	[effect of V3-BH10]	0.0	3	1	1	1
100667	1710	histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	5	1	1	1
100668	1710	cyclophilin ligand	[cyclophilin ligand]	0.0	2	1	1	1
100669	1710	combination nf-kappa b	[combination NF-kappa B]	0.0	3	1	1	1
100670	1710	iia	[IIa]	0.0	1	2	2	1
100671	1710	IL-3 granulocyte-macrophage colony-stimumulatelany-stg factor two complex	[IL-3 granulocyte-macrophage colony-stimulating factor two complexes]	0.0	6	1	1	1
100672	1710	iib	[IIb]	0.0	1	1	1	1
100673	1710	mental illness involve response	[mental illness involving responses]	0.0	4	1	1	1
100674	1710	polyposis gene family	[polyposis gene family]	0.0	3	1	1	1
100675	1710	datum along with observation	[data along with observations]	0.0	4	1	1	1
100676	1710	domain stem cell factor	[domain stem cell factor]	0.0	4	1	1	1
100677	1710	transfection experiments, overexpression of type	[transfection experiments, overexpression of type]	0.0	5	1	1	1
100678	1710	k.0	[kd,]	0.0	1	2	2	1
100679	1710	il2	[IL2s]	0.0	1	1	1	1
100680	1710	simple activation	[Simple activation]	0.0	2	1	1	1
100681	1710	granulocyte-macrophage colony-stimumulatelany-stg factor promoter	[granulocyte-macrophage colony-stimulating factor promoters]	0.0	4	1	1	1
100682	1710	CD28 responsive element cd28re	[CD28 responsive element CD28RE]	0.0	4	1	1	1
100683	1710	rna polymerase transcription factor	[RNA polymerase transcription factor]	0.0	4	1	1	1
100684	1710	also rapid non-genomic effect	[also rapid non-genomic effects]	0.0	4	1	1	1
100685	1710	I -182	[I -182]	0.0	2	1	1	1
100686	1710	number of individual gene	[number of individual genes]	0.0	4	1	1	1
100687	1710	fibrosarcoma 8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[fibrosarcoma 8, histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
100688	1710	human factor-1 receptor csf-1r	[human factor-1 receptor CSF-1R]	0.0	4	1	1	1
100689	1710	nonfinger region	[nonfinger region]	0.0	2	1	1	1
100690	1710	cell-specific binding of protein,	[cell-specific binding of protein,]	0.0	4	1	1	1
100691	1710	signalling molecule	[signalling molecules]	0.0	2	1	1	1
100692	1710	factor-kappa beta in human monocyte	[factor-kappa beta in human monocytes]	0.0	5	1	1	1
100693	1710	old individual	[older individuals]	0.0	2	1	1	1
100694	1710	attendant symptom	[attendant symptoms]	0.0	2	1	1	1
100695	1710	activation in a t-cell line	[Activation in a T-cell line]	0.0	5	1	1	1
100696	1710	such as endotoxin	[such as endotoxin]	0.0	3	1	1	1
100697	1710	DNA domain of Ets-1	[DNA domain of Ets-1]	0.0	4	1	1	1
100698	1710	number of ut-7 cell	[number of UT-7 cells]	0.0	4	1	1	1
100699	1710	inverse relation to histocompatibility complex class	[inverse relation to histocompatibility complex classes]	0.0	6	1	1	1
100700	1710	Exploration at the level	[Exploration at the level]	0.0	4	1	1	1
100701	1710	factor of T	[factor of T]	0.0	3	1	1	1
100702	1710	multiple activity of acid	[multiple activities of acid]	0.0	4	1	1	1
100703	1710	Tax1 a potent activator	[Tax1 a potent activator]	0.0	4	1	1	1
100704	1710	other activity downstream of ZEBRA	[other activities downstream of ZEBRA]	0.0	5	1	1	1
100705	1710	CD43/leukosialin pathway	[CD43/leukosialin pathway]	0.0	2	1	1	1
100706	1710	cold shock pathway	[cold shock pathways]	0.0	3	1	1	1
100707	1710	proliferation, generation	[proliferation, generation]	0.0	2	1	1	1
100708	1710	example glucocorticoid receptor hGR	[example glucocorticoid receptors hGR]	0.0	4	1	1	1
100709	1710	antigen psa	[antigen PSA]	0.0	2	1	1	1
100710	1710	enhancer in erythroid cell	[enhancer in erythroid cells]	0.0	4	1	1	1
100711	1710	absence of marker	[absence of markers]	0.0	3	1	1	1
100712	1710	rich sequence within the stretch	[rich sequence within the stretch]	0.0	5	1	1	1
100713	1710	4 cases, include aml	[4 cases, including AML]	0.0	4	1	1	1
100714	1710	int	[INT]	0.0	1	1	1	1
100715	1710	calcium -signal transduction	[calcium -signal transduction]	0.0	3	1	1	1
100716	1710	cyclin-dependent-kinase-	[cyclin-dependent-kinase-]	0.0	1	1	1	1
100717	1710	NF-kappa b motif	[NF-kappa B motif]	0.0	3	1	1	1
100718	1710	start 0/1 of cultivation	[starting 0/1 of cultivation]	0.0	4	1	1	1
100719	1710	subsequent rolling, adhesion, of leukocyte	[subsequent rolling, adhesion, of leukocytes]	0.0	5	1	1	1
100720	1710	young person	[young persons]	0.0	2	1	1	1
100721	1710	novel b cell-specific coactivator	[novel B cell-specific coactivator]	0.0	4	1	1	1
100722	1710	IL-4STAT	[IL-4STAT]	0.0	1	1	1	1
100723	1710	individual with filaria-induced pathology	[individuals with filaria-induced pathology]	0.0	4	1	1	1
100724	1710	dna-binding activity of interleukin-10 stat molecule	[DNA-binding activity of interleukin-10 STAT molecules]	0.0	6	1	1	1
100725	1710	establish a relation	[establishing an relation]	0.0	3	1	1	1
100726	1710	various promoter element	[various promoter elements]	0.0	3	1	1	1
100727	1710	T cell cytokine	[T cell cytokine]	0.0	3	1	1	1
100728	1710	DNase-I hypersensitive site HS	[DNase-I hypersensitive sites HS]	0.0	4	1	1	1
100729	1710	latent gene promoter	[latent gene promoter]	0.0	3	1	1	1
100730	1710	two SR patient	[two SR patients]	0.0	3	1	1	1
100731	1710	two monozygotic (mz) twin	[two monozygotic (MZ) twins]	0.0	4	1	1	1
100732	1710	CAGATG	[CAGATG]	0.0	1	1	1	1
100733	1710	occur at minute 1)	[occurring at minutes 1)]	0.0	4	1	1	1
100734	1710	bind traz	[binding TRAFs]	0.0	2	1	1	1
100735	1710	oxygen species serve	[oxygen species serving]	0.0	3	1	1	1
100736	1710	E220K ubiquitinylation of c-Jun	[E220K ubiquitinylation of c-Jun]	0.0	4	1	1	1
100737	1710	cytopathic effect in hiv-infected T cell	[cytopathic effects in HIV-infected T cells]	0.0	6	1	1	1
100738	1710	intracellular stat-1	[intracellular STAT-1]	0.0	2	1	1	1
100739	1710	regulation of il-1beta expression	[regulation of IL-1beta expression]	0.0	4	1	1	1
100740	1710	mutation in the purine region	[mutations in the purine region]	0.0	5	1	1	1
100741	1710	responsiveness in Philadelphia chromosome leukemia	[responsiveness in Philadelphia chromosome leukemia]	0.0	5	1	1	1
100742	1710	high concentration of other antioxidant	[higher concentrations of other antioxidants]	0.0	5	1	1	1
100743	1710	Biologic effect on NK	[Biologic effects on NK]	0.0	4	1	1	1
100744	1710	second E2F-I bind protein,	[second E2F-I binding protein,]	0.0	4	1	1	1
100745	1710	nb4 myeloid leukemia	[NB4 myeloid leukemia]	0.0	3	1	1	1
100746	1710	JNK c-Jun kinase	[JNK c-Jun kinase]	0.0	3	1	1	1
100747	1710	control:	[control:]	0.0	1	1	1	1
100748	1710	phosphorylation in b cell	[phosphorylation in B cells]	0.0	4	1	1	1
100749	1710	variant translocation in promyelocytic leukaemia	[variant translocation in promyelocytic leukaemia]	0.0	5	1	1	1
100750	1710	nf-kappab -dependent activation 1 repeat	[NF-kappaB -dependent activation 1 repeat]	0.0	5	1	1	1
100751	1710	intestinal cell response to amebic infection	[intestinal cell responses to amebic infection]	0.0	6	1	1	1
100752	1710	especially with marker of high rate	[especially with markers of high rate]	0.0	6	1	1	1
100753	1710	nonproductive interaction at the x box	[nonproductive interactions at the X boxes]	0.0	6	1	1	1
100754	1710	total of chronic, severe,	[total of chronic, severe,]	0.0	4	1	1	1
100755	1710	only interleukin expression	[only interleukin expression]	0.0	3	1	1	1
100756	1710	1, D3 135(oh)2d3 receptor	[1, D3 1,25(OH)2D3 receptor]	0.0	4	1	1	1
100757	1710	15.5 (p 0.05, p	[15.5 (P 0.05, P]	0.0	4	1	1	1
100758	1710	brief introduction	[brief introduction]	0.0	2	1	1	1
100759	1710	cathepsin g alone	[cathepsin G alone]	0.0	3	1	1	1
100760	1710	association of hla-dq allele	[association of HLA-DQ alleles]	0.0	4	1	1	1
100761	1710	CCAAT/enhancer bind	[CCAAT/enhancer binding]	0.0	2	1	1	1
100762	1710	also improve the definition of endpoint	[also improving the definitions of endpoints]	0.0	6	1	1	1
100763	1710	common intracellular signal pathway	[Common intracellular signaling pathways]	0.0	4	1	1	1
100764	1710	biologic,	[biologic,]	0.0	1	1	1	1
100765	1710	receptor alpha PPARalpha ligand WY	[receptor alpha PPARalpha ligand WY]	0.0	5	1	1	1
100766	1710	clonality in tissue	[clonality in tissue]	0.0	3	1	1	1
100767	1710	binding of cortisol	[binding of cortisol]	0.0	3	1	1	1
100768	1710	studies, rat lung	[studies, rat lungs]	0.0	3	1	1	1
100769	1710	TNF-alpha hiv-1 long repeat	[TNF-alpha HIV-1 long repeat]	0.0	4	1	1	1
100770	1710	monocytes/macrophages in human lesion	[monocytes/macrophages in human lesions]	0.0	4	1	1	1
100771	1710	LIM-only protein gene	[LIM-only protein gene]	0.0	3	1	1	1
100772	1710	woman old	[women older]	0.0	2	1	1	1
100773	1710	lead to transendothelial migration	[leading to transendothelial migration]	0.0	4	1	1	1
100774	1710	treatment of leukemia cell with 12-o-tetradecanoylphorbol-13-acetate	[treatment of leukemia cells with 12-O-tetradecanoylphorbol-13-acetate]	0.0	6	1	1	1
100775	1710	dephosphorylation of T cell activation	[Dephosphorylation of T cell activation]	0.0	5	1	1	1
100776	1710	factor NF-AT AP-1/Octamer UPS	[factor NF-AT AP-1/Octamer UPS]	0.0	4	1	1	1
100777	1710	cell surface molecules,	[cell surface molecules,]	0.0	3	2	2	1
100778	1710	four specific NF-kappaB complex	[four specific NF-kappaB complexes]	0.0	4	1	1	1
100779	1710	GATA-1 gene silent in progenitor	[GATA-1 gene silent in progenitors]	0.0	5	1	1	1
100780	1710	evidence mediator	[evidence mediators]	0.0	2	1	1	1
100781	1710	minute exposure	[minutes exposure]	0.0	2	1	1	1
100782	1710	chloram-phenicol	[chloram-phenicol]	0.0	1	1	1	1
100783	1710	enolase	[enolase]	0.0	1	1	1	1
100784	1710	regulate map kinase in the cytosol	[regulating MAP kinases in the cytosol]	0.0	6	1	1	1
100785	1710	target structure the 72-kilodalton major protein	[Target structures the 72-kilodalton major protein]	0.0	6	1	1	1
100786	1710	OVTAL	[OVTAL]	0.0	1	1	1	1
100787	1710	express a polyclonal pattern	[expressing a polyclonal pattern]	0.0	4	1	1	1
100788	1710	molecular event occur	[molecular events occurring]	0.0	3	1	1	1
100789	1710	drive a ifn-gamma expression of ciita	[driving an IFN-gamma expression of CIITA]	0.0	6	1	1	1
100790	1710	abundant cell	[abundant cells]	0.0	2	1	1	1
100791	1710	acid-alpha receptor RAR alpha	[acid-alpha receptor RAR alpha]	0.0	4	1	1	1
100792	1710	m-tat/epo cell	[M-TAT/EPO cells]	0.0	2	1	1	1
100793	1710	corticosteroid action	[corticosteroid action]	0.0	2	1	1	1
100794	1710	classical protein kinase C isoenzyme	[classical protein kinase C isoenzymes]	0.0	5	1	1	1
100795	1710	hormone gene promoter	[hormone gene promoter]	0.0	3	1	1	1
100796	1710	immunodeficiency virus hiv in cell	[immunodeficiency virus HIV in cells]	0.0	5	1	1	1
100797	1710	23 case of lymphoma	[23 cases of lymphoma]	0.0	4	1	1	1
100798	1710	il-2r alpha protein	[IL-2R alpha protein]	0.0	3	1	1	1
100799	1710	export of mrna	[export of mRNA]	0.0	3	1	1	1
100800	1710	il-1alpha by HTLV-I	[IL-1alpha by HTLV-I]	0.0	3	1	1	1
100801	1710	functionally interfere	[functionally interfering]	0.0	2	1	1	1
100802	1710	glutathione-s-transferase pi	[glutathione-S-transferase pi]	0.0	2	1	1	1
100803	1710	produce a divergence in cytokine profile	[producing a divergence in cytokine profiles]	0.0	6	1	1	1
100804	1710	affinity of this kda factor	[affinity of this kDa factor]	0.0	5	1	1	1
100805	1710	Furthermore, acid receptor	[Furthermore, acid receptor]	0.0	3	1	1	1
100806	1710	atopic b cell	[atopic B cells]	0.0	3	1	1	1
100807	1710	resistance to antidepressant of hypercortisolemia	[resistance to antidepressants of hypercortisolemia]	0.0	5	1	1	1
100808	1710	early erythroid progenitor	[early erythroid progenitors]	0.0	3	1	1	1
100809	1710	exercise in human	[exercise in humans]	0.0	3	1	1	1
100810	1710	myelomonocytic differentiation aml-m2	[myelomonocytic differentiation AML-M2]	0.0	3	1	1	1
100811	1710	IgE synthesis	[IgE synthesis]	0.0	2	1	1	1
100812	1710	encode a putative regulator	[encoding a putative regulator]	0.0	4	1	1	1
100813	1710	role for a SP1/Egr-1 binding site	[roles for an SP1/Egr-1 binding site]	0.0	6	1	1	1
100814	1710	MPD 71 (82%)	[MPD 71 (82%)]	0.0	3	1	1	1
100815	1710	immune challenge	[immune challenge]	0.0	2	1	1	1
100816	1710	high relative affinity (at sevenfold)	[higher relative affinity (at sevenfold)]	0.0	5	1	1	1
100817	1710	d-dependent	[D-dependent]	0.0	1	1	1	1
100818	1710	highlight novel loci	[highlighting novel loci]	0.0	3	1	1	1
100819	1710	ribonucleoprotein k	[ribonucleoprotein K]	0.0	2	1	1	1
100820	1710	(range, 4.27 (range,	[(range, 4.27 (range,]	0.0	3	1	1	1
100821	1710	adjacent terminal repeat region	[adjacent terminal repeat region]	0.0	4	1	1	1
100822	1710	way accounting	[way accounting]	0.0	2	1	1	1
100823	1710	contain amino acid side chain	[containing amino acid side chains]	0.0	5	1	1	1
100824	1710	GM-CSF peripheral blood polymorphonuclear leukocyte	[GM-CSF peripheral blood polymorphonuclear leukocytes]	0.0	5	1	1	1
100825	1710	concomitant presence	[concomitant presence]	0.0	2	1	1	1
100826	1710	select subordinate gene	[select subordinate genes]	0.0	3	1	1	1
100827	1710	t(17;19) lymphoblastic leukemia chimera	[t(17;19) lymphoblastic leukemia chimera]	0.0	4	1	1	1
100828	1710	deactivation	[Deactivation]	0.0	1	2	2	1
100829	1710	contribution in the expression	[contribution in the expression]	0.0	4	1	1	1
100830	1710	contrast IL-12 IFN gene	[contrasting IL-12 IFN genes]	0.0	4	1	1	1
100831	1710	several putative binding sequence	[several putative binding sequences]	0.0	4	1	1	1
100832	1710	artery-SCID chimera for 1 wk	[artery-SCID chimeras for 1 wk]	0.0	5	1	1	1
100833	1710	pld lipid	[PLD lipids]	0.0	2	1	1	1
100834	1710	expression of megakaryocytic gene	[expression of megakaryocytic genes]	0.0	4	1	1	1
100835	1710	intracytoplasmic tnfalpha level	[intracytoplasmic TNFalpha levels]	0.0	3	1	1	1
100836	1710	transcription factor activation in killer cell	[Transcription factor activation in killer cells]	0.0	6	1	1	1
100837	1710	c-fos/c-jun promoter element	[c-fos/c-jun promoter elements]	0.0	3	1	1	1
100838	1710	two NFATp -binding site	[Two NFATp -binding sites]	0.0	4	1	1	1
100839	1710	include cell distribution	[including cell distribution]	0.0	3	1	1	1
100840	1710	three mutant	[Three mutants]	0.0	2	1	1	1
100841	1710	pituitary hormone deficiency	[pituitary hormone deficiency]	0.0	3	2	2	1
100842	1710	oxidant acid mm)	[oxidant acid mM)]	0.0	3	1	1	1
100843	1710	genistein another tyrosine kinase inhibitor	[genistein another tyrosine kinase inhibitor]	0.0	5	1	1	1
100844	1710	analysis of mnda in tissue section	[analysis of MNDA in tissue sections]	0.0	6	1	1	1
100845	1710	leukocyte protein a adaptor protein	[leukocyte protein a adaptor protein]	0.0	5	1	1	1
100846	1710	four Epo-dependent cell line	[four Epo-dependent cell lines]	0.0	4	1	1	1
100847	1710	express complex (mhc) class ii gene	[expressing complex (MHC) class II genes]	0.0	6	1	1	1
100848	1710	tyrosine phosphorylation of substrate in cell	[tyrosine phosphorylation of substrates in cells]	0.0	6	1	1	1
100849	1710	regulation of processes,	[regulation of processes,]	0.0	3	1	1	1
100850	1710	activate the transcription factor nfat	[activating the transcription factor NFAT]	0.0	5	1	1	1
100851	1710	immediate early serum gene	[immediate early serum genes]	0.0	4	1	1	1
100852	1710	vitamin d3-responsive element in promoter	[vitamin D3-responsive element in promoter]	0.0	5	1	1	1
100853	1710	use a g-csfr mutant	[Using a G-CSFR mutant]	0.0	4	1	1	1
100854	1710	fibromyalgia fms	[fibromyalgia FMS]	0.0	2	1	1	1
100855	1710	well-known and/or anti-inflammatory cytokine	[well-known and/or anti-inflammatory cytokine]	0.0	4	1	1	1
100856	1710	enhancement of the activity	[enhancement of the activity]	0.0	4	1	1	1
100857	1710	residue SFLLRNP	[residues SFLLRNP]	0.0	2	1	1	1
100858	1710	inhibition of interferon	[Inhibition of interferon]	0.0	3	1	1	1
100859	1710	active binding heterodimers,	[active binding heterodimers,]	0.0	3	1	1	1
100860	1710	Positive regulation of gene expression	[Positive regulation of gene expression]	0.0	5	1	1	1
100861	1710	interleukin granulocyte-macrophage colony-stimulating factor	[interleukin granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
100862	1710	normal monocyte with phorbol-13-acetate tpa	[normal monocytes with phorbol-13-acetate TPA]	0.0	5	1	1	1
100863	1710	bicycle ergometer) level	[bicycle ergometer) levels]	0.0	3	1	1	1
100864	1710	inhibition of interferon (ifn)-gamma	[inhibition of interferon (IFN)-gamma]	0.0	4	1	1	1
100865	1710	exposure to 10 nm 2,3,377-tc	[exposure to 10 nM 2,3,7,8-TCDD]	0.0	5	1	1	1
100866	1710	thymocyte with cell TEC	[thymocytes with cells TEC]	0.0	4	1	1	1
100867	1710	member the human homolog c/ebp-beta	[members the human homolog C/EBP-beta]	0.0	5	1	1	1
100868	1710	induction follow cd19 cross-linking	[induction following CD19 cross-linking]	0.0	4	1	1	1
100869	1710	crp1 c/ebp-epsilon	[CRP1 C/EBP-epsilon]	0.0	2	1	1	1
100870	1710	T cell receptor gamma tcrg	[T cell receptor gamma TCRG]	0.0	5	1	1	1
100871	1710	four genomic probe	[four genomic probes]	0.0	3	1	1	1
100872	1710	plausibility	[plausibility]	0.0	1	1	1	1
100873	1710	sla-dq antigen induction	[SLA-DQ antigen induction]	0.0	3	1	1	1
100874	1710	constituent of cytokine receptor	[constituent of cytokine receptors]	0.0	4	1	1	1
100875	1710	susceptibility to killer lysis	[susceptibility to killer lysis]	0.0	4	1	1	1
100876	1710	neuroendocrine cell characteristic	[neuroendocrine cell characteristics]	0.0	3	1	1	1
100877	1710	blood lymphocyte in patient	[blood lymphocytes in patients]	0.0	4	1	1	1
100878	1710	result of trial with il-10	[results of trials with IL-10]	0.0	5	1	1	1
100879	1710	Eleven patient	[Eleven patients]	0.0	2	1	1	1
100880	1710	efficient expression of this r-pk promoter	[efficient expression of this R-PK promoter]	0.0	6	1	1	1
100881	1710	full activation of nf-at	[full activation of NF-AT]	0.0	4	1	1	1
100882	1710	effect on event	[effect on event]	0.0	3	1	1	1
100883	1710	M1-CAT	[M1-CAT]	0.0	1	1	1	1
100884	1710	relationship to MS	[relationship to MS]	0.0	3	1	1	1
100885	1710	MRD -positive soon relapsed.	[MRD -positive soon relapsed.]	0.0	4	1	1	1
100886	1710	identification of a lim-hox gene hlh-2	[Identification of a LIM-Hox gene hLH-2]	0.0	6	1	1	1
100887	1710	microm concentration,	[microM concentration,]	0.0	2	1	1	1
100888	1710	selective activation of STAT1alpha	[Selective activation of STAT1alpha]	0.0	4	1	1	1
100889	1710	about the event	[about the events]	0.0	3	1	1	1
100890	1710	Safety	[Safety]	0.0	1	1	1	1
100891	1710	cooh-terminal region of il-2r beta	[COOH-terminal region of IL-2R beta]	0.0	5	1	1	1
100892	1710	results, extract	[results, extracts]	0.0	2	1	1	1
100893	1710	protein kinase c-depleted cell	[protein kinase C-depleted cells]	0.0	4	1	1	1
100894	1710	3 h- pgg-glucan	[3 H- PGG-Glucan]	0.0	3	1	1	1
100895	1710	human nuclear differentiation antigen	[human nuclear differentiation antigen]	0.0	4	1	1	1
100896	1710	erythroid environment, experiment	[erythroid environment, experiments]	0.0	3	1	1	1
100897	1710	present with hilar adenopathy	[presenting with hilar adenopathy]	0.0	4	1	1	1
100898	1710	study signal	[studies signaling]	0.0	2	1	1	1
100899	1710	element alpha,25-dihydroxyvitamin D3	[Elements alpha,25-dihydroxyvitamin D3]	0.0	3	1	1	1
100900	1710	beta cd49d/cd29 costimulation of T cell	[beta CD49d/CD29 costimulation of T cells]	0.0	6	1	1	1
100901	1710	androgen resistance	[androgen resistance]	0.0	2	1	1	1
100902	1710	release of factor	[release of factors]	0.0	3	1	1	1
100903	1710	reflect the level	[reflecting the levels]	0.0	3	1	1	1
100904	1710	infection ad5	[infection Ad5]	0.0	2	1	1	1
100905	1710	(35 min) exercise at 70%	[(35 min) exercise at 70%]	0.0	5	1	1	1
100906	1710	gene control apoptosis	[genes controlling apoptosis]	0.0	3	1	1	1
100907	1710	require specific signal	[requiring specific signals]	0.0	3	1	1	1
100908	1710	moreover, TNF-alpha hiv-1 terminal repeat transcription	[Moreover, TNF-alpha HIV-1 terminal repeat transcription]	0.0	6	1	1	1
100909	1710	receptor in patient with lupus nephritis	[receptor in patients with lupus nephritis]	0.0	6	1	1	1
100910	1710	recognition by cytotoxic T lymphocyte	[recognition by cytotoxic T lymphocytes]	0.0	5	1	1	1
100911	1710	regulate aggregation	[regulating aggregation]	0.0	2	1	1	1
100912	1710	tal1 express tal1	[TAL1 expressing TAL1]	0.0	3	1	1	1
100913	1710	receptor on blood t-lymphocyte	[receptors on blood T-lymphocytes]	0.0	4	1	1	1
100914	1710	several levels,	[several levels,]	0.0	2	1	1	1
100915	1710	presence of two kind	[presence of two kinds]	0.0	4	1	1	1
100916	1710	target for a screen of individual	[targets for a screening of individuals]	0.0	6	1	1	1
100917	1710	human immunodeficiency virus in cell	[human immunodeficiency virus in cells]	0.0	5	1	1	1
100918	1710	C5a stimulation of human blood monocyte	[C5a stimulation of human blood monocytes]	0.0	6	1	1	1
100919	1710	promoter element for transcription	[promoter elements for transcription]	0.0	4	1	1	1
100920	1710	area of tissue insult	[areas of tissue insult]	0.0	4	1	1	1
100921	1710	blood monocyte from hiv-seronegative donor	[blood monocytes from HIV-seronegative donors]	0.0	5	1	1	1
100922	1710	high promoter activity	[higher promoter activity]	0.0	3	1	1	1
100923	1710	-contain leukocyte protein of kD slp-76	[-containing leukocyte protein of kD SLP-76]	0.0	6	1	1	1
100924	1710	study on heterogeneous population	[studies on heterogeneous populations]	0.0	4	1	1	1
100925	1710	two sequence-specific dna-binding protein	[two sequence-specific DNA-binding proteins]	0.0	4	1	1	1
100926	1710	T cell mitogenesis	[T cell mitogenesis]	0.0	3	1	1	1
100927	1710	skewedness of x-inactivation	[skewedness of X-inactivation]	0.0	3	1	1	1
100928	1710	NFAT factor	[NFAT factor]	0.0	2	1	1	1
100929	1710	BL cell contain low level	[BL cells containing low levels]	0.0	5	1	1	1
100930	1710	nuclear RelB	[nuclear RelB]	0.0	2	1	1	1
100931	1710	six group A-F	[six groups A-F]	0.0	3	1	1	1
100932	1710	increase by 2 P.	[increase by 2 h.]	0.0	4	1	1	1
100933	1710	kDa	[kDa]	0.0	1	1	1	1
100934	1710	bivalent mab j393	[bivalent mAb J393]	0.0	3	1	1	1
100935	1710	gp120 astrocyte	[gp120 astrocytes]	0.0	2	1	1	1
100936	1710	development of malignancy role	[development of malignancies roles]	0.0	4	1	1	1
100937	1710	primary b cell by ebv	[primary B cells by EBV]	0.0	5	1	1	1
100938	1710	tnf cell line	[TNF cell lines]	0.0	3	1	1	1
100939	1710	glycogen synthase kinase-3	[glycogen synthase kinase-3]	0.0	3	1	1	1
100940	1710	amount of the 3.5 kb transcript	[amounts of the 3.5 kb transcript]	0.0	6	1	1	1
100941	1710	SCL mrna	[SCL mRNA]	0.0	2	1	1	1
100942	1710	insulin on glucocorticoid receptor	[insulin on glucocorticoid receptor]	0.0	4	1	1	1
100943	1710	element-regulated reporter gene	[element-regulated reporter gene]	0.0	3	1	1	1
100944	1710	effect of N-acetyl-L-cysteine	[effects of N-acetyl-L-cysteine]	0.0	3	1	1	1
100945	1710	"dominant-negative," form	["dominant-negative," form]	0.0	2	1	1	1
100946	1710	pha stimulation	[PHA stimulation]	0.0	2	1	1	1
100947	1710	role in the up-regulation	[role in the up-regulation]	0.0	4	1	1	1
100948	1710	potent activator htlv-1 transcription	[potent activator HTLV-1 transcription]	0.0	4	1	1	1
100949	1710	v3 loop antibody	[V3 loop antibody]	0.0	3	1	1	1
100950	1710	intronic DHS	[intronic DHS]	0.0	2	1	1	1
100951	1710	high capacity of cell in	[high capacity of cells in]	0.0	5	1	1	1
100952	1710	cd11a+, cd13lo, cd15lo, cd34+/-, hla-dr	[CD11a+, CD13lo, CD15lo, CD34+/-, HLA-DR]	0.0	5	1	1	1
100953	1710	Group A	[Group A]	0.0	2	1	1	1
100954	1710	binding site for factor	[binding sites for factors]	0.0	4	1	1	1
100955	1710	Group C	[Group C]	0.0	2	1	1	1
100956	1710	mutation in exon 7	[mutation in exon 7]	0.0	4	1	1	1
100957	1710	rapid response,	[rapid response,]	0.0	2	1	1	1
100958	1710	blood T lymphocyte PBL	[blood T lymphocytes PBL]	0.0	4	1	1	1
100959	1710	only increase in ea-d promoter activity	[only increases in EA-D promoter activity]	0.0	6	1	1	1
100960	1710	17% cell	[17% cells]	0.0	2	1	1	1
100961	1710	thymocyte from transgenic mouse	[thymocytes from transgenic mice]	0.0	4	1	1	1
100962	1710	nuclear protein-binding activity	[nuclear protein-binding activities]	0.0	3	1	1	1
100963	1710	domain of the androgen receptor	[domains of the androgen receptor]	0.0	5	1	1	1
100964	1710	interleukin gene in T cell	[interleukin gene in T cells]	0.0	5	1	1	1
100965	1710	two NF-kappa b activity	[two NF-kappa B activities]	0.0	4	1	1	1
100966	1710	lps translocation in cho/ cd14 cell	[LPS translocation in CHO/ CD14 cells]	0.0	6	1	1	1
100967	1710	human t-cell fk506	[human T-cell FK506]	0.0	3	1	1	1
100968	1710	x-scid patient	[X-SCID patients]	0.0	2	1	1	1
100969	1710	type of H-RS cell line	[types of H-RS cell lines]	0.0	5	1	1	1
100970	1710	pkc alpha to the fraction	[PKC alpha to the fraction]	0.0	5	1	1	1
100971	1710	deacetylase	[deacetylase]	0.0	1	1	1	1
100972	1710	transcription at the level	[transcription at the level]	0.0	4	1	1	1
100973	1710	cyclooxygenase/5-lipoxygenase compound currently under investigation.	[cyclooxygenase/5-lipoxygenase compound currently under investigation.]	0.0	5	1	1	1
100974	1710	lymphoid follicle ILF formation	[lymphoid follicle ILF formation]	0.0	4	1	1	1
100975	1710	cytokine profile of peripheral blood cell	[Cytokine profiles of peripheral blood cells]	0.0	6	1	1	1
100976	1710	peripheral leucocyte in 13 man	[peripheral leucocytes in 13 men]	0.0	5	1	1	1
100977	1710	level of a factor(	[levels of a factor(s)]	0.0	4	1	1	1
100978	1710	function other than histone acetylation	[functions other than histone acetylation]	0.0	5	1	1	1
100979	1710	-binding domain of the cytoplasmic nucleoporin	[-binding domains of the cytoplasmic nucleoporin]	0.0	6	1	1	1
100980	1710	interaction tax transactivator	[Interaction tax transactivator]	0.0	3	1	1	1
100981	1710	Janus kinase jak3 activity	[Janus kinase JAK3 activity]	0.0	4	1	1	1
100982	1710	dose nf-kappa b p65 mrna accumulation	[doses NF-kappa B p65 mRNA accumulation]	0.0	6	1	1	1
100983	1710	novel dimer	[novel dimer]	0.0	2	1	1	1
100984	1710	c ytokine mrna level	[c ytokine mRNA levels]	0.0	4	1	1	1
100985	1710	degree for h	[degrees for h]	0.0	3	1	1	1
100986	1710	Effect of the antisense myb expression	[Effects of the antisense myb expression]	0.0	6	1	1	1
100987	1710	1 gene transcription during induction	[1 gene transcription during induction]	0.0	5	1	1	1
100988	1710	pluripotent progenitor to cell	[pluripotent progenitors to cells]	0.0	4	1	1	1
100989	1710	preferential activation	[preferential activation]	0.0	2	1	1	1
100990	1710	impaired insulin secretion	[impaired insulin secretion]	0.0	3	1	1	1
100991	1710	epitope on the CD4 coreceptor	[epitopes on the CD4 coreceptor]	0.0	5	1	1	1
100992	1710	E3 regulation	[E3 regulation]	0.0	2	1	1	1
100993	1710	DNA topoisomerase inhibitor	[DNA topoisomerase inhibitors]	0.0	3	1	1	1
100994	1710	(NFAT)	[(NFAT)]	0.0	1	1	1	1
100995	1710	transcriptional element promoter,	[transcriptional elements promoter,]	0.0	3	1	1	1
100996	1710	ltb4 stimulation	[LTB4 stimulation]	0.0	2	1	1	1
100997	1710	transcriptional regulator of several cytokine genes,	[transcriptional regulators of several cytokine genes,]	0.0	6	1	1	1
100998	1710	stable yeast cell	[stable yeast cells]	0.0	3	1	1	1
100999	1710	understanding of the process	[understanding of the process]	0.0	4	1	1	1
101000	1710	IL-2 proliferation,	[IL-2 proliferation,]	0.0	2	1	1	1
101001	1710	1.5 microM.	[1.5 microM.]	0.0	2	1	1	1
101002	1710	modulate gene expression	[modulating gene expression]	0.0	3	1	1	1
101003	1710	activation of leukocyte by stimulus	[Activation of leukocytes by stimuli]	0.0	5	1	1	1
101004	1710	infiltrate into different pathologic process	[infiltrating into different pathologic processes]	0.0	5	1	1	1
101005	1710	antagonism between VitD3	[antagonism between VitD3]	0.0	3	1	1	1
101006	1710	tamoxifen tam	[tamoxifen TAM]	0.0	2	1	1	1
101007	1710	effector cd4+ T	[effector CD4+ T]	0.0	3	1	1	1
101008	1710	simultaneous exposure to CD40L	[simultaneous exposure to CD40L]	0.0	4	1	1	1
101009	1710	PMA alpha activation	[PMA alpha activation]	0.0	3	1	1	1
101010	1710	cell infiltration score	[cell infiltration score]	0.0	3	1	1	1
101011	1710	binding of viral peptide	[Binding of viral peptide]	0.0	4	1	1	1
101012	1710	high level of exogenous bcl-2	[high levels of exogenous Bcl-2]	0.0	5	1	1	1
101013	1710	high affinity for dna-binding	[higher affinity for DNA-binding]	0.0	4	1	1	1
101014	1710	up-regulation I gene	[up-regulation I genes]	0.0	3	1	1	1
101015	1710	level of SRF binding	[level of SRF binding]	0.0	4	1	1	1
101016	1710	coronary angioplasty PTCA	[coronary angioplasty PTCA]	0.0	3	1	1	1
101017	1710	eklf allele	[EKLF alleles]	0.0	2	1	1	1
101018	1710	stimulation by IFN	[stimulation by IFN]	0.0	3	1	1	1
101019	1710	initial point in the response	[initial point in the response]	0.0	5	1	1	1
101020	1710	control entry	[controlling entry]	0.0	2	1	1	1
101021	1710	gr in blood leukocyte in runner	[GR in blood leukocytes in runner]	0.0	6	1	1	1
101022	1710	Oct2 transactivation	[Oct2 transactivation]	0.0	2	1	1	1
101023	1710	8 nmol	[8 nmol]	0.0	2	1	1	1
101024	1710	expression of the four isoform	[expression of the four isoforms]	0.0	5	1	1	1
101025	1710	immunoregulatory property	[immunoregulatory properties]	0.0	2	1	1	1
101026	1710	5'-noncoding	[5'-noncoding]	0.0	1	1	1	1
101027	1710	expression of SCL mrna	[expression of SCL mRNA]	0.0	4	1	1	1
101028	1710	translocation breakpoint in three patient	[Translocation breakpoints in three patients]	0.0	5	1	1	1
101029	1710	opposite effect on this two signal	[opposite effects on these two signals]	0.0	6	1	1	1
101030	1710	binding of tcf-1 alpha	[binding of TCF-1 alpha]	0.0	4	1	1	1
101031	1710	Soluble tumor	[Soluble tumor]	0.0	2	1	1	1
101032	1710	two inhibitor of serine/threonine phosphatase -1	[two inhibitors of serine/threonine phosphatases -1]	0.0	6	1	1	1
101033	1710	change in glucocorticoid receptor in lymphocyte	[changes in glucocorticoid receptors in lymphocytes]	0.0	6	1	1	1
101034	1710	allergen-specific T	[Allergen-specific T]	0.0	2	1	1	1
101035	1710	prior to complete arrest	[prior to complete arrest]	0.0	4	1	1	1
101036	1710	serotonin reuptake inhibitor	[serotonin reuptake inhibitors]	0.0	3	1	1	1
101037	1710	hsf2 activity	[HSF2 activity]	0.0	2	1	1	1
101038	1710	strict guideline	[strict guidelines]	0.0	2	1	1	1
101039	1710	non-Hodgkin' lymphoma cell	[non-Hodgkin's lymphoma cells]	0.0	3	1	1	1
101040	1710	have the high amount	[having the highest amounts]	0.0	4	1	1	1
101041	1710	expression of CD4 a marker	[expression of CD4 a marker]	0.0	5	1	1	1
101042	1710	delivery of peptide	[delivery of peptide]	0.0	3	1	1	1
101043	1710	peak expiratory flow pef	[peak expiratory flow PEF]	0.0	4	1	1	1
101044	1710	normal cytoplasmic level	[normal cytoplasmic levels]	0.0	3	1	1	1
101045	1710	effect on hiv-1 production	[effect on HIV-1 production]	0.0	4	1	1	1
101046	1710	prior to activation	[prior to activation]	0.0	3	1	1	1
101047	1710	putative mammalian gene	[putative mammalian gene]	0.0	3	1	1	1
101048	1710	kinetic (high	[kinetic (high]	0.0	2	1	1	1
101049	1710	internalization of antigen	[internalization of antigen]	0.0	3	1	1	1
101050	1710	species in the transduction mechanism.	[species in the transduction mechanism.]	0.0	5	1	1	1
101051	1710	control of steroid-regulated apoptosis	[control of steroid-regulated apoptosis]	0.0	4	1	1	1
101052	1710	kappa b-responsive gene	[kappa B-responsive genes]	0.0	3	1	1	1
101053	1710	characterization of the activity of cyclosporine	[characterization of the activity of cyclosporine]	0.0	6	1	1	1
101054	1710	proteins; type	[proteins; type]	0.0	2	1	1	1
101055	1710	jnk	[JNKs]	0.0	1	1	1	1
101056	1710	mutation cbp	[mutation CBP]	0.0	2	1	1	1
101057	1710	factor include two sp1	[factors including two Sp1]	0.0	4	1	1	1
101058	1710	monocytic expression of cd14	[monocytic expression of CD14]	0.0	4	1	1	1
101059	1710	simultaneous study of clonality	[simultaneous study of clonality]	0.0	4	1	1	1
101060	1710	activation of the transcription factor mef2c	[Activation of the transcription factor MEF2C]	0.0	6	1	1	1
101061	1710	other MHC class ligand	[other MHC class ligands]	0.0	4	1	1	1
101062	1710	anti- tumor necrosis factor	[anti- tumor necrosis factor]	0.0	4	1	1	1
101063	1710	B-cell stimulation	[B-cell stimulation]	0.0	2	1	1	1
101064	1710	however, simultaneous incubation	[However, simultaneous incubation]	0.0	3	1	1	1
101065	1710	human CD80 cho-cd80	[human CD80 CHO-CD80]	0.0	3	1	1	1
101066	1710	amplify expression	[amplifying expression]	0.0	2	1	1	1
101067	1710	variety include adhesion	[variety including adhesion]	0.0	3	1	1	1
101068	1710	class ii complex gene	[class II complex genes]	0.0	4	1	1	1
101069	1710	monocyte cell death	[monocyte cell death]	0.0	3	1	1	1
101070	1710	mechanism of the early	[mechanism of the early]	0.0	4	1	1	1
101071	1710	control person	[control persons]	0.0	2	1	1	1
101072	1710	action in leukemia cell	[actions in leukemia cells]	0.0	4	1	1	1
101073	1710	selection of strategy	[selection of strategies]	0.0	3	1	1	1
101074	1710	mouse Th2 clone	[mouse Th2 clone]	0.0	3	1	1	1
101075	1710	c/ebp beta in inflammation	[C/EBP beta in inflammation]	0.0	4	1	1	1
101076	1710	pseudohypoaldosteronism in renal disease with reduction	[pseudohypoaldosteronism in renal disease with reduction]	0.0	6	1	1	1
101077	1710	more substitution 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[more substitutions 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	6	1	1	1
101078	1710	terminus ct	[terminus CT]	0.0	2	1	1	1
101079	1710	blood cell from acute patient	[blood cells from acute patients]	0.0	5	1	1	1
101080	1710	other process	[other processes]	0.0	2	1	1	1
101081	1710	phenolic, lipid-soluble, chain-breaking antioxidant hydroxyanisole	[phenolic, lipid-soluble, chain-breaking antioxidants hydroxyanisole]	0.0	5	1	1	1
101082	1710	neoplastic disorder in woman	[neoplastic disorders in women]	0.0	4	1	1	1
101083	1710	cd14- phosphorylation- event	[CD14- phosphorylation- event]	0.0	3	1	1	1
101084	1710	commitment to death.	[commitment to death.]	0.0	3	1	1	1
101085	1710	study the binding of SR 31747a	[studying the binding of SR 31747A]	0.0	6	1	1	1
101086	1710	receptor on b cell	[receptor on B cells]	0.0	4	1	1	1
101087	1710	repeat of bp with 12-bp insert	[repeats of bp with 12-bp insert]	0.0	6	1	1	1
101088	1710	level in human monocyte	[levels in human monocytes]	0.0	4	1	1	1
101089	1710	whereas, in the presence	[whereas, in the presence]	0.0	4	1	1	1
101090	1710	blot analysis of polyadenylated rna	[blot analysis of polyadenylated RNA]	0.0	5	1	1	1
101091	1710	PMA alpha activation in jurkat t-cell	[PMA alpha activation in Jurkat T-cells]	0.0	6	1	1	1
101092	1710	tcr-regulated ptk	[TCR-regulated PTKs]	0.0	2	1	1	1
101093	1710	multiple DNA-protein complex	[multiple DNA-protein complexes]	0.0	3	1	1	1
101094	1710	ic50 value for dexamethasone (3.4+/-0.3	[IC50 values for dexamethasone (3.4+/-0.3]	0.0	5	1	1	1
101095	1710	alpha,25-dihydroxyvitamin D3 receptor	[alpha,25-dihydroxyvitamin D3 receptor]	0.0	3	1	1	1
101096	1710	t-cell gene include interleukin-2 IL-2	[T-cell genes including interleukin-2 IL-2]	0.0	5	1	1	1
101097	1710	equivalent gos19	[equivalent GOS19]	0.0	2	1	1	1
101098	1710	viral maintenance	[viral maintenance]	0.0	2	1	1	1
101099	1710	secretion of protein-1	[secretion of protein-1]	0.0	3	1	1	1
101100	1710	BZLF1 -reactive component of clonotype	[BZLF1 -reactive component of clonotypes]	0.0	5	1	1	1
101101	1710	infarction patient	[infarction patients]	0.0	2	1	1	1
101102	1710	three distinct element	[three distinct elements]	0.0	3	1	1	1
101103	1710	b lymphocyte line	[B lymphocyte lines]	0.0	3	1	1	1
101104	1710	ec e-selectin	[EC E-selectin]	0.0	2	1	1	1
101105	1710	western blot analysis use anti-ERK antibody	[Western blot analysis using anti-ERK antibodies]	0.0	6	1	1	1
101106	1710	apparent expression of a form	[apparent expression of a form]	0.0	5	1	1	1
101107	1710	wild-type u937 cell	[wild-type U937 cells]	0.0	3	1	1	1
101108	1710	more glucocorticoid for a degree	[more glucocorticoids for an degree]	0.0	5	1	1	1
101109	1710	octamer site manner	[octamer site manner]	0.0	3	1	1	1
101110	1710	one cellular event to cell	[one cellular event to cells]	0.0	5	1	1	1
101111	1710	form of TRAF2	[form of TRAF2]	0.0	3	1	1	1
101112	1710	weak induction	[weak induction]	0.0	2	1	1	1
101113	1710	effect of mutant	[effects of mutants]	0.0	3	1	1	1
101114	1710	enable T cell a response	[enabling T cells a response]	0.0	5	1	1	1
101115	1710	trigger CR1	[triggering CR1]	0.0	2	2	2	1
101116	1710	YLPA	[YLPA]	0.0	1	1	1	1
101117	1710	pattern of chromosome 1 abnormality	[patterns of chromosome 1 abnormalities]	0.0	5	1	1	1
101118	1710	(il-6) a immunoregulatory cytokine	[(IL-6) an immunoregulatory cytokine]	0.0	4	1	1	1
101119	1710	major infectious disease tuberculosis	[major infectious diseases tuberculosis]	0.0	4	1	1	1
101120	1710	cd4(-)	[CD4(-)]	0.0	1	1	1	1
101121	1710	MOPC promoter	[MOPC promoter]	0.0	2	1	1	1
101122	1710	C196 T	[C196 T]	0.0	2	1	1	1
101123	1710	up-regulated fasL mrna in HeLa cell	[up-regulated fasL mRNA in HeLa cells]	0.0	6	1	1	1
101124	1710	stimulate blood cell hla b8+	[stimulating blood cells HLA B8+]	0.0	5	1	1	1
101125	1710	patient with myelopathy/tropical spastic paraparesis	[patient with myelopathy/tropical spastic paraparesis]	0.0	5	1	1	1
101126	1710	cell of myelogenous leukemia patient	[cells of myelogenous leukemia patients]	0.0	5	1	1	1
101127	1710	calcium-independent anti-cd28 ab	[calcium-independent anti-CD28 Ab]	0.0	3	1	1	1
101128	1710	il-4 stat	[IL-4 STAT]	0.0	2	1	1	1
101129	1710	k562 cell undergo differentiation	[K562 cells undergoing differentiation]	0.0	4	1	1	1
101130	1710	suggest a receptor model	[suggesting a receptor model]	0.0	4	1	1	1
101131	1710	typically die by 8 days.	[typically dying by 8 days.]	0.0	5	1	1	1
101132	1710	native long terminal repeat	[native long terminal repeat]	0.0	4	1	1	1
101133	1710	means of two transduction pathway	[means of two transduction pathways]	0.0	5	1	1	1
101134	1710	signal from the epor	[signaling from the EpoR]	0.0	4	1	1	1
101135	1710	localization 1 complex	[localization 1 complexes]	0.0	3	1	1	1
101136	1710	correction of vitamin d deficiency	[correction of vitamin D deficiency]	0.0	5	1	1	1
101137	1710	latter signal	[latter signals]	0.0	2	1	1	1
101138	1710	0.2-kb region	[0.2-kb region]	0.0	2	1	1	1
101139	1710	Thrombopoietin the primary physiological regulator	[Thrombopoietin the primary physiological regulator]	0.0	5	1	1	1
101140	1710	10, leiomyosarcoma liposarcoma	[10, leiomyosarcoma liposarcoma]	0.0	3	1	1	1
101141	1710	treatment of nuclear extract	[treatment of nuclear extracts]	0.0	4	1	1	1
101142	1710	rebound,	[rebound,]	0.0	1	1	1	1
101143	1710	donor rar-alpha cd4(+) t-cell clone	[donor RAR-alpha CD4(+) T-cell clones]	0.0	5	1	1	1
101144	1710	localization signal present	[localization signal present]	0.0	3	1	1	1
101145	1710	undetectable b activity, p65 complex	[undetectable B activity, p65 complexes]	0.0	5	1	1	1
101146	1710	nf-kappab activation of hiv-1 repeat LTR	[NF-kappaB activation of HIV-1 repeat LTR]	0.0	6	1	1	1
101147	1710	coordinate downregulation of globin	[coordinate downregulation of globin]	0.0	4	1	1	1
101148	1710	NF-kappaB -dependent activation	[NF-kappaB -dependent activation]	0.0	3	1	1	1
101149	1710	effect on hepatocyte	[effect on hepatocytes]	0.0	3	1	1	1
101150	1710	virus region nucleotide number	[virus region nucleotide numbers]	0.0	4	1	1	1
101151	1710	factor act on megakaryocytopoiesis	[factor acting on megakaryocytopoiesis]	0.0	4	1	1	1
101152	1710	other serine /threonine kinase	[other serine /threonine kinases]	0.0	4	1	1	1
101153	1710	p50 homodimers.	[p50 homodimers.]	0.0	2	1	1	1
101154	1710	association of isgf3	[association of ISGF3]	0.0	3	1	1	1
101155	1710	stimulation a CD3 event	[stimulation a CD3 event]	0.0	4	1	1	1
101156	1710	positive autoregulation in cell	[positive autoregulation in cells]	0.0	4	1	1	1
101157	1710	use a recombinant adenovirus	[using a recombinant adenovirus]	0.0	4	1	1	1
101158	1710	various rheumatic disease	[various rheumatic diseases]	0.0	3	1	1	1
101159	1710	hiv -1 expression	[HIV -1 expression]	0.0	3	1	1	1
101160	1710	unstable asthmatic patient	[unstable asthmatic patients]	0.0	3	1	1	1
101161	1710	HLA-DQ trans-acting factor	[HLA-DQ trans-acting factor]	0.0	3	1	1	1
101162	1710	lymphoid cell type	[lymphoid cell types]	0.0	3	1	1	1
101163	1710	powerful inhibitor	[powerful inhibitors]	0.0	2	1	1	1
101164	1710	adp-	[ADP-]	0.0	1	1	1	1
101165	1710	il-8 messenger rna	[IL-8 messenger RNA]	0.0	3	1	1	1
101166	1710	47-bp sequence	[47-bp sequence]	0.0	2	1	1	1
101167	1710	transmembrane activator	[transmembrane activator]	0.0	2	1	1	1
101168	1710	regulatory,	[regulatory,]	0.0	1	1	1	1
101169	1710	adhesion umbilical vein endothelial cell	[adhesion umbilical vein endothelial cells]	0.0	5	1	1	1
101170	1710	Furthermore, recruitment of EKLF	[Furthermore, recruitment of EKLF]	0.0	4	1	1	1
101171	1710	airway hyperresponsiveness	[airway hyperresponsiveness]	0.0	2	1	1	1
101172	1710	large amount early	[large amounts early]	0.0	3	1	1	1
101173	1710	mediate il-6 gene expression role	[mediating IL-6 gene expression role]	0.0	5	1	1	1
101174	1710	breast/ovarian	[breast/ovarian]	0.0	1	1	1	1
101175	1710	cleavage of transcription factor by caspase	[Cleavage of transcription factor by caspases]	0.0	6	1	1	1
101176	1710	NK function under oxidative condition	[NK functions under oxidative conditions]	0.0	5	1	1	1
101177	1710	isolation of a rel-related cDNA	[Isolation of a rel-related cDNA]	0.0	5	1	1	1
101178	1710	natural variant with sp1 site	[natural variant with Sp1 sites]	0.0	5	1	1	1
101179	1710	wide variety of stimuli,	[wide variety of stimuli,]	0.0	4	1	1	1
101180	1710	variant translocation molecular characterization	[variant translocation molecular characterization]	0.0	4	1	1	1
101181	1710	cell from rhesus macaque	[cells from rhesus macaques]	0.0	4	1	1	1
101182	1710	i monoclonal antibody	[I monoclonal antibody]	0.0	3	1	1	1
101183	1710	m 1	[M 1]	0.0	2	1	1	1
101184	1710	filarial antigen t-cell	[filarial antigen T-cells]	0.0	3	1	1	1
101185	1710	inhibition of approximately 90%.	[inhibition of approximately 90%.]	0.0	4	1	1	1
101186	1710	presence of IFN activity	[presence of IFN activity]	0.0	4	1	1	1
101187	1710	second positive element	[second positive element]	0.0	3	1	1	1
101188	1710	consequence follow alteration	[consequences following alterations]	0.0	3	1	1	1
101189	1710	hiv-1 from cell	[HIV-1 from cells]	0.0	3	1	1	1
101190	1710	intestinal receptor	[intestinal receptor]	0.0	2	2	2	1
101191	1710	activity colony-stimumulatelany-stg factor	[activity colony-stimulating factor]	0.0	3	1	1	1
101192	1710	m-tat/scf cell	[M-TAT/SCF cells]	0.0	2	1	1	1
101193	1710	other class b cell line	[other class B cell lines]	0.0	5	1	1	1
101194	1710	nfil3/e4bp4 nuclear factor	[NFIL3/E4BP4 nuclear factor]	0.0	3	1	1	1
101195	1710	valuable model	[valuable model]	0.0	2	1	1	1
101196	1710	copy upstream	[copies upstream]	0.0	2	1	1	1
101197	1710	transfection technique,	[transfection technique,]	0.0	2	1	1	1
101198	1710	cd34+thy-1+ cell	[CD34+Thy-1+ cells]	0.0	2	2	2	1
101199	1710	summary, receptor determination a clue	[summary, receptor determination a clue]	0.0	5	1	1	1
101200	1710	glucocorticoid function	[glucocorticoid function]	0.0	2	1	1	1
101201	1710	differentiation a novel experimental model	[differentiation a novel experimental model]	0.0	5	1	1	1
101202	1710	identification of gene	[identification of genes]	0.0	3	1	1	1
101203	1710	consent,	[consent,]	0.0	1	1	1	1
101204	1710	stimulate factor g-csf	[stimulating factor G-CSF]	0.0	3	1	1	1
101205	1710	morphology adherent cell with neurite process	[morphology adherent cells with neurite processes]	0.0	6	1	1	1
101206	1710	protein from cell	[proteins from cells]	0.0	3	1	1	1
101207	1710	SLP-76 leukocyte protein of 76 kda)	[SLP-76 leukocyte protein of 76 kDa)]	0.0	6	1	1	1
101208	1710	blast cell M7	[blast cells M7]	0.0	3	1	1	1
101209	1710	dependency of fetal b-lymphopoiesis	[dependency of fetal B-lymphopoiesis]	0.0	4	1	1	1
101210	1710	provide one explanation important.	[providing one explanation important.]	0.0	4	1	1	1
101211	1710	isolation of a alternative transcript	[isolation of an alternative transcript]	0.0	5	1	1	1
101212	1710	fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
101213	1710	fresh cell whatever stage	[fresh cells whatever stage]	0.0	4	1	1	1
101214	1710	J.M.Hardwick, 1990).	[J.M.Hardwick, 1990).]	0.0	2	1	1	1
101215	1710	blood cell HPFH	[blood cells HPFH]	0.0	3	1	1	1
101216	1710	only by a enzyme-linked immunosorbent assay	[only by an enzyme-linked immunosorbent assay]	0.0	6	1	1	1
101217	1710	study of disorder	[study of disorders]	0.0	3	1	1	1
101218	1710	(scf) receptor	[(SCF) receptor]	0.0	2	1	1	1
101219	1710	target by the zinc-finger transcription factor	[targets by the zinc-finger transcription factor]	0.0	6	1	1	1
101220	1710	Val50	[Val50]	0.0	1	1	1	1
101221	1710	considerable sequence identity	[considerable sequence identity]	0.0	3	1	1	1
101222	1710	creb mutant with this system	[CREB mutants with this system]	0.0	5	1	1	1
101223	1710	20 min), c-jun,	[20 min), c-jun,]	0.0	3	1	1	1
101224	1710	suggest essential for DNA binding	[suggesting essential for DNA binding]	0.0	5	1	1	1
101225	1710	involvement of jak1	[involvement of JAK1]	0.0	3	1	1	1
101226	1710	contain two cysteine region LIM domain	[containing two cysteine regions LIM domains]	0.0	6	1	1	1
101227	1710	(e.g. cell-to-cell contact).	[(e.g. cell-to-cell contact).]	0.0	3	1	1	1
101228	1710	preservation	[preservation]	0.0	1	1	1	1
101229	1710	relationship to nephrotoxicity	[relationship to nephrotoxicity]	0.0	3	1	1	1
101230	1710	component of the 26s protease	[component of the 26S protease]	0.0	5	1	1	1
101231	1710	primary restriction element	[primary restriction elements]	0.0	3	1	1	1
101232	1710	deletion -533 basis	[deletion -533 bases]	0.0	3	1	1	1
101233	1710	autosomal dominant disorder	[autosomal dominant disorder]	0.0	3	1	1	1
101234	1710	dna- receptor formation	[DNA- receptor formation]	0.0	3	1	1	1
101235	1710	receptor in this patient	[receptor in these patients]	0.0	4	1	1	1
101236	1710	kas	[KAs]	0.0	1	1	1	1
101237	1710	time-dependent binding of pac-1	[time-dependent binding of PAC-1]	0.0	4	1	1	1
101238	1710	severe forms, granulocyte	[severe forms, granulocytes]	0.0	3	1	1	1
101239	1710	purely enhancer-dependent effect	[purely enhancer-dependent effect]	0.0	3	1	1	1
101240	1710	leukaemia gene	[leukaemia gene]	0.0	2	1	1	1
101241	1710	receptor signal transduction	[receptor signal transduction]	0.0	3	1	1	1
101242	1710	equal, unequal expression in three,	[equal, unequal expression in three,]	0.0	5	1	1	1
101243	1710	kd)	[kD)]	0.0	1	1	1	1
101244	1710	kd,	[kD,]	0.0	1	1	1	1
101245	1710	proportion of promoter	[proportion of promoters]	0.0	3	1	1	1
101246	1710	amino-acid protein p13mtcp1	[amino-acid protein p13MTCP1]	0.0	3	1	1	1
101247	1710	physiological upper limit	[physiological upper limit]	0.0	3	1	1	1
101248	1710	normal pulmonary alveolar macrophage	[Normal pulmonary alveolar macrophages]	0.0	4	1	1	1
101249	1710	enhancement of potency	[enhancement of potency]	0.0	3	1	1	1
101250	1710	interleukin-1beta in cells,	[interleukin-1beta in cells,]	0.0	3	1	1	1
101251	1710	grade malignant astrocytomas	[grade malignant astrocytomas]	0.0	3	1	1	1
101252	1710	activation of the enhancer	[Activation of the enhancer]	0.0	4	1	1	1
101253	1710	expression of another viral immediate-early protein	[expression of another viral immediate-early protein]	0.0	6	1	1	1
101254	1710	library of compound	[library of compounds]	0.0	3	1	1	1
101255	1710	16 abnormality by metaphase analysis	[16 abnormalities by metaphase analysis]	0.0	5	1	1	1
101256	1710	activation of phosphatidylinositol 3-kinase pi3-kinase translocation	[activation of phosphatidylinositol 3-kinase PI3-kinase translocation]	0.0	6	1	1	1
101257	1710	major DNase-I site	[major DNase-I sites]	0.0	3	1	1	1
101258	1710	costimulation of cell	[Costimulation of cells]	0.0	3	1	1	1
101259	1710	induction induction	[Induction induction]	0.0	2	1	1	1
101260	1710	protein with homology to Bcl-2	[protein with homology to Bcl-2]	0.0	5	1	1	1
101261	1710	30 minute (phase 1)	[30 minutes (phase 1)]	0.0	4	1	1	1
101262	1710	variable severity	[variable severity]	0.0	2	1	1	1
101263	1710	[change in level	[[Changes in levels]	0.0	3	1	1	1
101264	1710	10(-12) g/g of mrna	[10(-12) g/g of mRNA]	0.0	4	1	1	1
101265	1710	gata-1 binding activity	[GATA-1 binding activity]	0.0	3	1	1	1
101266	1710	SCL/tal-1,	[SCL/tal-1,]	0.0	1	1	1	1
101267	1710	addition of anti- antibody	[addition of anti- antibody]	0.0	4	1	1	1
101268	1710	il-2r alpha expression,	[IL-2R alpha expression,]	0.0	3	1	1	1
101269	1710	transduction/ transcription	[transduction/ transcription]	0.0	2	1	1	1
101270	1710	4 beta-phorbol 13-acetate	[4 beta-phorbol 13-acetate]	0.0	3	1	1	1
101271	1710	-MCP	[-MCP]	0.0	1	2	2	1
101272	1710	simultaneously; non-dividing, pbl	[simultaneously; non-dividing, PBL]	0.0	3	1	1	1
101273	1710	ets member	[Ets members]	0.0	2	1	1	1
101274	1710	element the chain enhancer	[element the chain enhancer]	0.0	4	1	1	1
101275	1710	killer (nk) cell line	[killer (NK) cell line]	0.0	4	1	1	1
101276	1710	additional 20 h	[additional 20 h]	0.0	3	1	1	1
101277	1710	western blot analysis of mouse tissue	[Western blot analysis of mouse tissues]	0.0	6	1	1	1
101278	1710	combination with ca2+ ionophore	[combination with Ca2+ ionophores]	0.0	4	1	1	1
101279	1710	genetic characterization	[genetic characterization]	0.0	2	1	1	1
101280	1710	32 nm tpa	[32 nM TPA]	0.0	3	1	1	1
101281	1710	extend 2738 nucleotide	[extending 2,738 nucleotides]	0.0	3	1	1	1
101282	1710	bp of 5'-flanking sequence	[bp of 5'-flanking sequences]	0.0	4	1	1	1
101283	1710	homologous mechanism	[homologous mechanism]	0.0	2	1	1	1
101284	1710	least six subregion	[least six subregions]	0.0	3	1	1	1
101285	1710	key	[key]	0.0	1	1	1	1
101286	1710	prototypic class promoter	[prototypic class promoter]	0.0	3	1	1	1
101287	1710	distribution of the cell	[distribution of the cells]	0.0	4	1	1	1
101288	1710	least sevenfold) 3.	[least sevenfold) 3.]	0.0	3	1	1	1
101289	1710	formation of the transactivate complex, factor	[formation of the transactivating complex, factor]	0.0	6	1	1	1
101290	1710	activity include SP-1	[activity including SP-1]	0.0	3	1	1	1
101291	1710	interaction between Tax	[interaction between Tax]	0.0	3	1	1	1
101292	1710	activation of nuclear transcriptional factor	[activation of nuclear transcriptional factors]	0.0	5	1	1	1
101293	1710	isolation of a promoter	[Isolation of a promoter]	0.0	4	1	1	1
101294	1710	-Stat	[-Stat]	0.0	1	1	1	1
101295	1710	b cell-specific co-activator of A-MYB	[B cell-specific co-activator of A-MYB]	0.0	5	1	1	1
101296	1710	monocyte adhesion in vein endothelial cell	[monocyte adhesion in vein endothelial cells]	0.0	6	1	1	1
101297	1710	number of receptor in patient	[number of receptors in patients]	0.0	5	1	1	1
101298	1710	thereby provide a additional mechanism	[thereby providing an additional mechanism]	0.0	5	1	1	1
101299	1710	tumor-suppressor gene expression	[tumor-suppressor gene expression]	0.0	3	1	1	1
101300	1710	suggest a property of inducible gene	[suggesting a property of inducible genes]	0.0	6	1	1	1
101301	1710	heavy chain enhancer	[heavy chain enhancer]	0.0	3	1	1	1
101302	1710	action of 1,25-dihydroxyvitamin D3	[actions of 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
101303	1710	two mode	[two modes]	0.0	2	1	1	1
101304	1710	coculture,n induce	[coculture, induce]	0.0	2	1	1	1
101305	1710	response to aldosterone in leukocyte	[response to aldosterone in leukocytes]	0.0	5	1	1	1
101306	1710	primary leukemic T cell	[primary leukemic T cells]	0.0	4	1	1	1
101307	1710	alveolar rat	[alveolar rats]	0.0	2	1	1	1
101308	1710	unstimulated tnf- cell	[unstimulated TNF- cells]	0.0	3	1	1	1
101309	1710	regard the role	[regarding the role]	0.0	3	1	1	1
101310	1710	Rat-1 fibroblast transformation,	[Rat-1 fibroblast transformation,]	0.0	3	1	1	1
101311	1710	case with tmd	[cases with TMD]	0.0	3	1	1	1
101312	1710	fibrosarcoma 8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrosarcoma 8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
101313	1710	maximum level	[maximum levels]	0.0	2	1	1	1
101314	1710	specific domain sequence contain phosphotyrosine	[specific domain sequences containing phosphotyrosine]	0.0	5	1	1	1
101315	1710	induction, superinfection	[induction, superinfection]	0.0	2	1	1	1
101316	1710	distinguish this atra case	[distinguishing these ATRA cases]	0.0	4	1	1	1
101317	1710	topoisomerase in extract	[topoisomerases in extracts]	0.0	3	1	1	1
101318	1710	most cases, a heterodimer consist	[most cases, a heterodimer consisting]	0.0	5	1	1	1
101319	1710	reversible differentiation of leukemia u937 cell	[Reversible differentiation of leukemia U937 cells]	0.0	6	1	1	1
101320	1710	appear in some case	[appearing in some cases]	0.0	4	1	1	1
101321	1710	version vp16	[version VP16]	0.0	2	1	1	1
101322	1710	HLF consensus	[HLF consensus]	0.0	2	1	1	1
101323	1710	m-1	[M-1]	0.0	1	1	1	1
101324	1710	oxygen intermediate -release of monocyte	[oxygen intermediate -release of monocytes]	0.0	5	1	1	1
101325	1710	T cell-specific regulation of transcription	[T cell-specific regulation of transcription]	0.0	5	1	1	1
101326	1710	differentiation, with c-jun expression good	[differentiation, with c-jun expression best]	0.0	5	1	1	1
101327	1710	receptor saturate	[receptor saturating]	0.0	2	1	1	1
101328	1710	full differentiation response	[full differentiation response]	0.0	3	1	1	1
101329	1710	induction of TNF alpha mrna	[induction of TNF alpha mRNA]	0.0	5	1	1	1
101330	1710	transcription factor with function	[transcription factor with functions]	0.0	4	1	1	1
101331	1710	use a protein kinase inhibitor	[using a protein kinase inhibitor]	0.0	5	1	1	1
101332	1710	other hla-b8-restricted latent epitope	[other HLA-B8-restricted latent epitopes]	0.0	4	1	1	1
101333	1710	exon sequence	[exon sequence]	0.0	2	1	1	1
101334	1710	unilineage differentiation in liquid culture	[unilineage differentiation in liquid culture]	0.0	5	1	1	1
101335	1710	fibrosarcoma malignant fibrous histiocytoma	[fibrosarcoma malignant fibrous histiocytoma]	0.0	4	1	1	1
101336	1710	regulation a study	[regulation a study]	0.0	3	1	1	1
101337	1710	expose vein cell to anoxia/reoxygenation a/r	[Exposing vein cells to anoxia/reoxygenation A/R]	0.0	6	1	1	1
101338	1710	disease (12: four	[diseases (12: four]	0.0	3	1	1	1
101339	1710	IRF-1 gamma site	[IRF-1 gamma site]	0.0	3	1	1	1
101340	1710	10% xenogeneic serum	[10% xenogeneic serum]	0.0	3	1	1	1
101341	1710	erythropoietin erythroid cell	[erythropoietin erythroid cells]	0.0	3	1	1	1
101342	1710	expression b-cell maturation arrest	[expression B-cell maturation arrest]	0.0	4	1	1	1
101343	1710	effect of linear loop peptide	[effect of linear loop peptides]	0.0	5	1	1	1
101344	1710	increase the number	[increase the number]	0.0	3	1	1	1
101345	1710	cell in the host	[cells in the host]	0.0	4	1	1	1
101346	1710	interference of complex binding	[interference of complex binding]	0.0	4	1	1	1
101347	1710	platelet-activate factor from 10(-12)	[platelet-activating factor from 10(-12)]	0.0	4	1	1	1
101348	1710	interleukin-2 sequence	[interleukin-2 sequence]	0.0	2	1	1	1
101349	1710	membrane ca2+ chelator	[membrane Ca2+ chelator]	0.0	3	1	1	1
101350	1710	differentiate in response	[differentiating in response]	0.0	3	1	1	1
101351	1710	intracellular sequestration of class heterodimer	[intracellular sequestration of class heterodimers]	0.0	5	1	1	1
101352	1710	selective inhibitor of mek1	[selective inhibitor of MEK1]	0.0	4	1	1	1
101353	1710	exposure to ionize radiation	[exposure to ionizing radiation]	0.0	4	1	1	1
101354	1710	h of incubation ultra-violet irradiation.	[h of incubation UV irradiation.]	0.0	5	1	1	1
101355	1710	regulatory protein for the replication	[regulatory protein for the replication]	0.0	5	1	1	1
101356	1710	17 sr patient	[17 SR patients]	0.0	3	1	1	1
101357	1710	endothelial cell pivotal	[endothelial cells pivotal]	0.0	3	1	1	1
101358	1710	sequence motif in subunit	[sequence motif in subunit]	0.0	4	1	1	1
101359	1710	Glucocorticoid receptor on human peripheral mononuclear	[Glucocorticoid receptors on human peripheral mononuclear]	0.0	6	1	1	1
101360	1710	anti-c/ebpdelta nf-il6beta	[anti-C/EBPdelta NF-IL6beta]	0.0	2	1	1	1
101361	1710	nuclear uptake	[nuclear uptake]	0.0	2	1	1	1
101362	1710	contain kappab site in a promoter	[containing kappaB sites in a promoter]	0.0	6	1	1	1
101363	1710	(ie62) protein	[(IE62) protein]	0.0	2	1	1	1
101364	1710	myelomonocytic lineage gene	[myelomonocytic lineage gene]	0.0	3	1	1	1
101365	1710	express wild-type CD40	[expressing wild-type CD40]	0.0	3	1	1	1
101366	1710	primarily at stage	[primarily at stages]	0.0	3	1	1	1
101367	1710	more intense T	[more intense T]	0.0	3	1	1	1
101368	1710	novel alternative mechanism	[novel alternative mechanism]	0.0	3	1	1	1
101369	1710	trypsin digestion receptor	[trypsin digestion receptor]	0.0	3	1	1	1
101370	1710	model for differentiation	[model for differentiation]	0.0	3	1	1	1
101371	1710	mrna expression of fatty protein	[mRNA expression of fatty protein]	0.0	5	1	1	1
101372	1710	CsA transcription	[CsA transcription]	0.0	2	1	1	1
101373	1710	repeat in T lymphocyte	[repeat in T lymphocytes]	0.0	4	1	1	1
101374	1710	genome of HTLV-I	[genome of HTLV-I]	0.0	3	1	1	1
101375	1710	culminate in activation	[culminating in activation]	0.0	3	1	1	1
101376	1710	+/- 0.92 fmol/10(7) pbmc fmol/10(7)	[+/- 0.92 fmol/10(7) PBMC fmol/10(7)]	0.0	5	1	1	1
101377	1710	express level of exogenous bcl-2	[expressing levels of exogenous Bcl-2]	0.0	5	1	1	1
101378	1710	predominant b species in cell	[predominant B species in cells]	0.0	5	1	1	1
101379	1710	expression in gene-modified T cell	[expression in gene-modified T cells]	0.0	5	1	1	1
101380	1710	genetic marker of promyelocytic leukemia	[genetic markers of promyelocytic leukemias]	0.0	5	1	1	1
101381	1710	hyperparathyroidism to failure	[hyperparathyroidism to failure]	0.0	3	1	1	1
101382	1710	m32	[M32]	0.0	1	1	1	1
101383	1710	several binding sequence for transcription factor	[several binding sequences for transcription factors]	0.0	6	1	1	1
101384	1710	three, rare DNA variation	[three, rare DNA variations]	0.0	4	1	1	1
101385	1710	association with each stat5 isomer	[association with each STAT5 isomer]	0.0	5	1	1	1
101386	1710	effect all attributable	[effects all attributable]	0.0	3	1	1	1
101387	1710	antiapoptotic molecule a1/bfl-1	[antiapoptotic molecule A1/Bfl-1]	0.0	3	1	1	1
101388	1710	activation of interleukin 2 gene	[activation of interleukin 2 gene]	0.0	5	1	1	1
101389	1710	bp -301	[bp -301]	0.0	2	1	1	1
101390	1710	IL-1beta promoter,	[IL-1beta promoter,]	0.0	2	1	1	1
101391	1710	effect on JNK activity	[effects on JNK activity]	0.0	4	1	1	1
101392	1710	other mature population	[other mature populations]	0.0	3	1	1	1
101393	1710	m41	[M41]	0.0	1	1	1	1
101394	1710	major human class gene	[major human class genes]	0.0	4	1	1	1
101395	1710	m47	[M47]	0.0	1	1	1	1
101396	1710	unique, high potency glucocorticoid	[unique, high potency glucocorticoid]	0.0	4	1	1	1
101397	1710	IL-2 translocation	[IL-2 translocation]	0.0	2	1	1	1
101398	1710	I receptor type receptor	[I receptors Type receptors]	0.0	4	1	1	1
101399	1710	curcumin microM)	[curcumin microM)]	0.0	2	1	1	1
101400	1710	result in phosphorylation of protein	[resulting in phosphorylation of proteins]	0.0	5	1	1	1
101401	1710	cycle promoter	[cycle promoters]	0.0	2	1	1	1
101402	1710	treatment for allergic disease	[treatments for allergic diseases]	0.0	4	1	1	1
101403	1710	specific protein complex	[specific protein complex]	0.0	3	1	1	1
101404	1710	bhrf1 protein with distant homology	[BHRF1 protein with distant homology]	0.0	5	1	1	1
101405	1710	two atf1 isoform consistent	[two ATF1 isoforms consistent]	0.0	4	1	1	1
101406	1710	Jak -stat signal pathway	[Jak -STAT signaling pathway]	0.0	4	1	1	1
101407	1710	nitroblue tetrazolium	[nitroblue tetrazolium]	0.0	2	1	1	1
101408	1710	minimal disease of patient with leukemia	[minimal disease of patients with leukemia]	0.0	6	1	1	1
101409	1710	dnase hypersensitivity extend to -300bp	[DNase hypersensitivity extending to -300bp]	0.0	5	1	1	1
101410	1710	abundant expression of pkc-alpha	[abundant expression of PKC-alpha]	0.0	4	1	1	1
101411	1710	ligand stimulation.	[ligand stimulation.]	0.0	2	1	1	1
101412	1710	diamide (reversible)	[diamide (reversible)]	0.0	2	1	1	1
101413	1710	block NF-kappaB	[Blocking NF-kappaB]	0.0	2	1	1	1
101414	1710	difference in the regulation of expression	[differences in the regulation of expression]	0.0	6	1	1	1
101415	1710	8, histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma	[8, histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
101416	1710	interaction between lymphoid cell	[interaction between lymphoid cells]	0.0	4	1	1	1
101417	1710	sequence element DRE	[sequence element DRE]	0.0	3	1	1	1
101418	1710	replicative pathway	[replicative pathway]	0.0	2	1	1	1
101419	1710	NF-kappa b-like transcription	[NF-kappa B-like transcription]	0.0	3	1	1	1
101420	1710	activator of many viral promoter	[activator of many viral promoters]	0.0	5	1	1	1
101421	1710	peptide in the reticulum immunize cell	[peptides in the reticulum immunizing cells]	0.0	6	1	1	1
101422	1710	L&H cell in NLPHD	[L&H cells in NLPHD]	0.0	4	1	1	1
101423	1710	effect in hiv infection	[effects in HIV infection]	0.0	4	1	1	1
101424	1710	protein truncation test ptt	[protein truncation test PTT]	0.0	4	2	2	1
101425	1710	interaction between coactivator	[interactions between coactivators]	0.0	3	1	1	1
101426	1710	thus, substitution within the domain	[Thus, substitutions within the domain]	0.0	5	1	1	1
101427	1710	block formation	[blocking formation]	0.0	2	1	1	1
101428	1710	pathology such as failure	[pathologies such as failure]	0.0	4	1	1	1
101429	1710	transactivation the type lymphocyte syndrome-associated factor	[Transactivation the type lymphocyte syndrome-associated factor]	0.0	6	1	1	1
101430	1710	migration of monocyte in response	[migration of monocytes in response]	0.0	5	1	1	1
101431	1710	ets-1,	[Ets-1,]	0.0	1	1	1	1
101432	1710	increase stat1	[increase STAT1]	0.0	2	1	1	1
101433	1710	fraction of dlcl cases,	[fraction of DLCL cases,]	0.0	4	1	1	1
101434	1710	genotype groups,	[genotype groups,]	0.0	2	1	1	1
101435	1710	malignant fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[malignant fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
101436	1710	independence from growth stimulus	[independence from growth stimuli]	0.0	4	1	1	1
101437	1710	CD2 -based	[CD2 -based]	0.0	2	1	1	1
101438	1710	proliferation reduction mechanism	[proliferation reduction mechanism]	0.0	3	1	1	1
101439	1710	hereditary disorder	[hereditary disorder]	0.0	2	1	1	1
101440	1710	nuclear translocation nuclear factor lymphocyte	[nuclear translocation nuclear factor lymphocytes]	0.0	5	1	1	1
101441	1710	1.3 kilobasis	[1.3 kilobases]	0.0	2	1	1	1
101442	1710	differentiation-inducing therapy	[differentiation-inducing therapy]	0.0	2	1	1	1
101443	1710	thus establish the cross-specy effectiveness	[thus establishing the cross-species effectiveness]	0.0	5	1	1	1
101444	1710	over one month	[over one month]	0.0	3	1	1	1
101445	1710	min) of c-jun transcript	[min) of c-jun transcripts]	0.0	4	1	1	1
101446	1710	class ii complex promoter	[class II complex promoters]	0.0	4	1	1	1
101447	1710	expression of tcl1 mrna	[expression of TCL1 mRNA]	0.0	4	1	1	1
101448	1710	reactivity to ssb rssb	[reactivity to SSB rSSB]	0.0	4	1	1	1
101449	1710	ag-3	[Ag-3]	0.0	1	1	1	1
101450	1710	IL-12 receptor	[IL-12 receptor]	0.0	2	1	1	1
101451	1710	expression of the platelet gpiib gene	[expression of the platelet GPIIb gene]	0.0	6	1	1	1
101452	1710	induction expression	[Induction expression]	0.0	2	1	1	1
101453	1710	development of a adaptive system	[development of an adaptive system]	0.0	5	1	1	1
101454	1710	MCM action.	[MCM action.]	0.0	2	1	1	1
101455	1710	treatment of human erythrocyte	[Treatment of human erythrocytes]	0.0	4	1	1	1
101456	1710	different amount	[Different amounts]	0.0	2	1	1	1
101457	1710	determinant of T cell differentiation	[determinants of T cell differentiation]	0.0	5	1	1	1
101458	1710	T cell expression of interleukin	[T cell expression of interleukin]	0.0	5	1	1	1
101459	1710	7.03 (range, (range,	[7.03 (range, (range,]	0.0	3	1	1	1
101460	1710	rdna with identity to gene product	[cDNAs with identity to gene products]	0.0	6	1	1	1
101461	1710	Glucocorticoid receptor on mononuclear change	[Glucocorticoid receptors on mononuclear changes]	0.0	5	1	1	1
101462	1710	lbp nmol/l) subject	[LBP nmol/l) subjects]	0.0	3	1	1	1
101463	1710	interaction of tax1	[interaction of Tax1]	0.0	3	1	1	1
101464	1710	region of human thymus lobule	[regions of human thymus lobules]	0.0	5	1	1	1
101465	1710	receptor binding in mononuclear leukocyte	[receptor binding in mononuclear leukocytes]	0.0	5	1	1	1
101466	1710	optimal il-4 promoter activity	[optimal IL-4 promoter activity]	0.0	4	1	1	1
101467	1710	correlation between this inhibition	[correlation between this inhibition]	0.0	4	1	1	1
101468	1710	FAB aml	[FAB AML]	0.0	2	1	1	1
101469	1710	immunodeficiency virus (hiv)-1 terminal repeat	[immunodeficiency virus (HIV)-1 terminal repeat]	0.0	5	1	1	1
101470	1710	expression along the erythroid pathway	[expression along the erythroid pathway]	0.0	5	1	1	1
101471	1710	germinal center region	[germinal center region]	0.0	3	1	1	1
101472	1710	downstream of a CpG island	[downstream of a CpG island]	0.0	5	1	1	1
101473	1710	subset of cd8+ T cell	[subset of CD8+ T cells]	0.0	5	1	1	1
101474	1710	consist of male	[consisting of males]	0.0	3	1	1	1
101475	1710	b cell leukemia (bcp-all) cell	[B cell leukemia (BCP-ALL) cells]	0.0	5	1	1	1
101476	1710	cortisol in hml	[cortisol in HML]	0.0	3	1	1	1
101477	1710	7.03 (range, 4.27 (range,	[7.03 (range, 4.27 (range,]	0.0	4	1	1	1
101478	1710	single-residue substitution	[single-residue substitution]	0.0	2	1	1	1
101479	1710	polyomavirus transcription factor	[polyomavirus transcription factor]	0.0	3	1	1	1
101480	1710	dna-binding domain lack sequence similarity	[DNA-binding domain lacking sequence similarity]	0.0	5	1	1	1
101481	1710	little effect on the promoter	[little effect on the promoter]	0.0	5	1	1	1
101482	1710	mrna level in human lipopolysaccharide	[mRNA levels in human lipopolysaccharide]	0.0	5	1	1	1
101483	1710	response element ngre	[response element nGRE]	0.0	3	1	1	1
101484	1710	full cell cycle	[full cell cycle]	0.0	3	1	1	1
101485	1710	complex interplay	[complex interplay]	0.0	2	3	3	1
101486	1710	stimulation of ppargamma	[Stimulation of PPARgamma]	0.0	3	1	1	1
101487	1710	two protein of kD	[two proteins of kD]	0.0	4	1	1	1
101488	1710	lymphycryptoviruss	[lymphycryptoviruses]	0.0	1	1	1	1
101489	1710	dmso solvent/media control	[DMSO solvent/media control]	0.0	3	1	1	1
101490	1710	factor such as ap-1	[factors such as AP-1]	0.0	4	1	1	1
101491	1710	degenerate primer	[degenerate primers]	0.0	2	1	1	1
101492	1710	tumor necrosis factor receptor-1	[Tumor necrosis factor receptor-1]	0.0	4	1	1	1
101493	1710	antibody CRE	[Antibodies CRE]	0.0	2	1	1	1
101494	1710	predominant BLS complementation group	[predominant BLS complementation group]	0.0	4	1	1	1
101495	1710	small-bowel resection in patient	[Small-bowel resection in patients]	0.0	4	1	1	1
101496	1710	sex reversal map	[sex reversal map]	0.0	3	1	1	1
101497	1710	efficient transcriptional activation	[efficient transcriptional activation]	0.0	3	1	1	1
101498	1710	non- lps uptake	[non- LPS uptake]	0.0	3	1	1	1
101499	1710	other.	[other.]	0.0	1	2	2	1
101500	1710	clone DEG5	[clone DEG5]	0.0	2	1	1	1
101501	1710	stat1 function	[Stat1 function]	0.0	2	1	1	1
101502	1710	3-o-methyl-d-glucose transport in human leukocyte	[3-O-methyl-D-glucose transport in human leukocyte]	0.0	5	1	1	1
101503	1710	pharmacological (high turnover) property	[pharmacological (high turnover) properties]	0.0	4	1	1	1
101504	1710	molecular probe study signal transduction	[molecular probes studying signal transduction]	0.0	5	1	1	1
101505	1710	basis for this synergism,	[basis for this synergism,]	0.0	4	1	1	1
101506	1710	molecular mechanism of anoxia/reoxygenation-induced adherence	[Molecular mechanisms of anoxia/reoxygenation-induced adherence]	0.0	5	1	1	1
101507	1710	atra expression	[ATRA expression]	0.0	2	1	1	1
101508	1710	examination of the factor	[Examination of the factors]	0.0	4	1	1	1
101509	1710	activation of form	[activation of forms]	0.0	3	1	1	1
101510	1710	regulate the machinery	[regulating the machinery]	0.0	3	1	1	1
101511	1710	chromosome band rhombotin	[chromosome bands rhombotin]	0.0	3	1	1	1
101512	1710	DNA mobility shift	[DNA mobility shift]	0.0	3	1	1	1
101513	1710	relevance of this finding	[relevance of this finding]	0.0	4	1	1	1
101514	1710	effect of th2 cytokine	[effect of Th2 cytokines]	0.0	4	1	1	1
101515	1710	Consequently, inhibition	[Consequently, inhibition]	0.0	2	1	1	1
101516	1710	protein- tyrosine phosphatase	[protein- tyrosine phosphatase]	0.0	3	1	1	1
101517	1710	tar mechanism	[TAR mechanism]	0.0	2	1	1	1
101518	1710	band p11.23 to p12.3	[bands p11.23 to p12.3]	0.0	4	1	1	1
101519	1710	generation of lymphocyte against peptide	[generation of lymphocytes against peptides]	0.0	5	1	1	1
101520	1710	contrast, inhibition of magnitude	[contrast, inhibition of magnitude]	0.0	4	1	1	1
101521	1710	il-2 promoter repression	[IL-2 promoter repression]	0.0	3	1	1	1
101522	1710	contain the element NREs	[containing the elements NREs]	0.0	4	1	1	1
101523	1710	tetrameric DCoH-HNF-1 alpha complex	[tetrameric DCoH-HNF-1 alpha complex]	0.0	4	1	1	1
101524	1710	nfatc mrna	[NFATc mRNA]	0.0	2	1	1	1
101525	1710	activation antigen cd69	[activation antigen CD69]	0.0	3	1	1	1
101526	1710	lak lysis of control	[LAK lysis of control]	0.0	4	1	1	1
101527	1710	expression construct	[expression constructs]	0.0	2	2	2	1
101528	1710	transduce signal to the nucleus	[transducing signals to the nucleus]	0.0	5	1	1	1
101529	1710	(chi2=6.25, 1 df,	[(chi2=6.25, 1 df,]	0.0	3	1	1	1
101530	1710	rapid progress	[rapid progress]	0.0	2	1	1	1
101531	1710	govern the proliferative response	[governing the proliferative response]	0.0	4	1	1	1
101532	1710	chronic immune-mediated inflammation	[chronic immune-mediated inflammation]	0.0	3	1	1	1
101533	1710	low basal activity	[low basal activity]	0.0	3	1	1	1
101534	1710	type receptor gcii	[type receptor GCII]	0.0	3	1	1	1
101535	1710	complex, nuclear factor	[complex, nuclear factor]	0.0	3	1	1	1
101536	1710	cell culture of peripheral monocyte	[cell cultures of peripheral monocytes]	0.0	5	1	1	1
101537	1710	homologue activation of immunity	[homologue activation of immunity]	0.0	4	1	1	1
101538	1710	treatment with hematopoietic growth factor	[treatment with hematopoietic growth factors]	0.0	5	1	1	1
101539	1710	early t-cell activation	[early T-cell activation]	0.0	3	1	1	1
101540	1710	feature of differentiation	[features of differentiation]	0.0	3	1	1	1
101541	1710	low the/thf (0.24; n:	[low THE/THF (0.24; N:]	0.0	4	1	1	1
101542	1710	CD4 promoter transactivation	[CD4 promoter transactivation]	0.0	3	1	1	1
101543	1710	halflife of minute	[halflife of min]	0.0	3	1	1	1
101544	1710	(consist	[(consisting]	0.0	1	1	1	1
101545	1710	repeat of the immunodeficiency virus	[repeat of the immunodeficiency virus]	0.0	5	1	1	1
101546	1710	possible latency	[possible latency]	0.0	2	1	1	1
101547	1710	tissue-specific control of insulin-gene activity	[tissue-specific control of insulin-gene activity]	0.0	5	1	1	1
101548	1710	non-cytotoxic dose of autg	[non-cytotoxic doses of AuTG]	0.0	4	1	1	1
101549	1710	HBxAg -specific polypeptide	[HBxAg -specific polypeptides]	0.0	3	1	1	1
101550	1710	effect on complex	[effects on complexes]	0.0	3	1	1	1
101551	1710	wide variety of signal	[wide variety of signals]	0.0	4	1	1	1
101552	1710	-erythroid	[-erythroid]	0.0	1	1	1	1
101553	1710	unique target of alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3	[unique targets of alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3]	0.0	6	1	1	1
101554	1710	ribonucleoproteins	[ribonucleoproteins]	0.0	1	1	1	1
101555	1710	concordance of endogenous c-myb expression	[concordance of endogenous c-myb expression]	0.0	5	1	1	1
101556	1710	use mutagenesis	[Using mutagenesis]	0.0	2	1	1	1
101557	1710	constitutional loss of allele	[constitutional losses of allele]	0.0	4	1	1	1
101558	1710	member of the TNFR family	[member of the TNFR family]	0.0	5	1	1	1
101559	1710	B29 beta-chain	[B29 beta-chain]	0.0	2	1	1	1
101560	1710	lack of (a) factor	[lack of (a) factor]	0.0	4	1	1	1
101561	1710	binding of type	[Binding of type]	0.0	3	1	1	1
101562	1710	PB1 nuclear protein-binding complex	[PB1 nuclear protein-binding complex]	0.0	4	1	1	1
101563	1710	classification of ivs1-10t-->c as a polymorphism	[Classification of IVS1-10T-->C as a polymorphism]	0.0	6	1	1	1
101564	1710	pha normal blood lymphocyte	[PHA normal blood lymphocytes]	0.0	4	1	1	1
101565	1710	double- mouse	[double- mice]	0.0	2	1	1	1
101566	1710	murine counterpart of AML1	[murine counterpart of AML1]	0.0	4	1	1	1
101567	1710	lcr	[LCRs]	0.0	1	1	1	1
101568	1710	tcr-beta	[TcR-beta]	0.0	1	1	1	1
101569	1710	parallel, level	[parallel, levels]	0.0	2	1	1	1
101570	1710	minutes) to all-tran acid atra washed,	[minutes) to all-trans acid ATRA washed,]	0.0	6	1	1	1
101571	1710	distinct factor with mobilities,	[distinct factors with mobilities,]	0.0	4	1	1	1
101572	1710	interaction between hemopoietic stem cell	[interactions between hemopoietic stem cells]	0.0	5	1	1	1
101573	1710	endogenous il-1ra production	[endogenous IL-1ra production]	0.0	3	1	1	1
101574	1710	fibrous histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma	[fibrous histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
101575	1710	adenovirus gene	[adenovirus gene]	0.0	2	1	1	1
101576	1710	respect to the other protein,	[respect to the other protein,]	0.0	5	1	1	1
101577	1710	g-csf 8% cell at day g-csf	[G-CSF 8% cells at day G-CSF]	0.0	6	1	1	1
101578	1710	direct percutaneous transluminal angioplasty	[direct percutaneous transluminal angioplasty]	0.0	4	1	1	1
101579	1710	surface of cell ECs	[surface of cells ECs]	0.0	4	1	1	1
101580	1710	good model for study	[good model for studies]	0.0	4	1	1	1
101581	1710	look in new approach	[Looking in newer approaches]	0.0	4	1	1	1
101582	1710	myeloid (nk) cell	[myeloid (NK) cells]	0.0	3	1	1	1
101583	1710	B-cell chronic leukemia CLL	[B-cell chronic leukemia CLL]	0.0	4	1	1	1
101584	1710	three essential element	[three essential elements]	0.0	3	1	1	1
101585	1710	A6H antibody	[A6H antibody]	0.0	2	1	1	1
101586	1710	migration related protein	[migration related protein]	0.0	3	1	1	1
101587	1710	zinc-finger gene	[zinc-finger genes]	0.0	2	1	1	1
101588	1710	adult differentiation	[adult differentiation]	0.0	2	1	1	1
101589	1710	form of selection antigen-driven clonal expansion)	[forms of selection antigen-driven clonal expansion)]	0.0	6	1	1	1
101590	1710	interleukin-2 receptor-gamma	[interleukin-2 receptor-gamma]	0.0	2	1	1	1
101591	1710	initial point	[initial point]	0.0	2	1	1	1
101592	1710	marker of PMA differentiation;	[markers of PMA differentiation;]	0.0	4	1	1	1
101593	1710	viral enhancer by nf-kappab	[viral enhancer by NF-kappaB]	0.0	4	1	1	1
101594	1710	whole peripheral blood from donor	[whole peripheral blood from donors]	0.0	5	1	1	1
101595	1710	secondary hyperparathyroidism to chronic failure	[secondary hyperparathyroidism to chronic failure]	0.0	5	1	1	1
101596	1710	high, pharmacological concentration	[high, pharmacological concentrations]	0.0	3	1	1	1
101597	1710	aids-related effusion lymphoma pel	[AIDS-related effusion lymphoma PEL]	0.0	4	1	1	1
101598	1710	mode of action after administration	[mode of action after administration]	0.0	5	1	1	1
101599	1710	CCGAAACTGAAAAGG	[CCGAAACTGAAAAGG]	0.0	1	1	1	1
101600	1710	distinct subset with translocation t(10;11)	[distinct subsets with translocation t(10;11)]	0.0	5	1	1	1
101601	1710	corresponding to the C-terminal domain	[corresponding to the C-terminal domain]	0.0	5	1	1	1
101602	1710	rearrangement in the different great ape	[rearrangements in the different great apes]	0.0	6	1	1	1
101603	1710	activation of CD4 T lymphocyte	[Activation of CD4 T lymphocytes]	0.0	5	1	1	1
101604	1710	human immune deficiency virus type	[human immune deficiency virus type]	0.0	5	1	1	1
101605	1710	use two cell line	[using two cell lines]	0.0	4	1	1	1
101606	1710	acute leukemia APL the variant	[acute leukemia APL the variant]	0.0	5	1	1	1
101607	1710	class MHC Ag	[class MHC Ag]	0.0	3	1	1	1
101608	1710	Ii invariant chain	[Ii invariant chain]	0.0	3	1	1	1
101609	1710	viral transactivator BZLF1 Z	[viral transactivators BZLF1 Z]	0.0	4	1	1	1
101610	1710	mediate il-4- gene expression	[mediating IL-4- gene expression]	0.0	4	1	1	1
101611	1710	small epithelium	[small epithelium]	0.0	2	1	1	1
101612	1710	prolonged pressure-stretch load	[prolonged pressure-stretching load]	0.0	3	1	1	1
101613	1710	nm tpa	[nM TPA]	0.0	2	1	1	1
101614	1710	elective termination of uterine pregnancy	[elective termination of uterine pregnancy]	0.0	5	1	1	1
101615	1710	low bone density	[low bone density]	0.0	3	1	1	1
101616	1710	(il)-2-receptor expression	[(IL)-2-receptor expression]	0.0	2	1	1	1
101617	1710	effect of e3330 a quinone derivative	[effect of E3330 a quinone derivative]	0.0	6	1	1	1
101618	1710	treatment of u1 cell with r-h-tbp-1	[Treatment of U1 cells with r-h-TBP-1]	0.0	6	1	1	1
101619	1710	immunogenicity of viral protein epitope	[immunogenicity of viral protein epitopes]	0.0	5	1	1	1
101620	1710	thus, competition between two activator RelA	[Thus, competition between two activators RelA]	0.0	6	1	1	1
101621	1710	endocrine lineage use antisera	[endocrine lineages using antisera]	0.0	4	1	1	1
101622	1710	decrease in interleukin 2	[decrease in interleukin 2]	0.0	4	1	1	1
101623	1710	transcription of gene include IL-2	[transcription of genes including IL-2]	0.0	5	1	1	1
101624	1710	blastogenesis of human peripheral blood lymphocyte	[blastogenesis of human peripheral blood lymphocytes]	0.0	6	1	1	1
101625	1710	difference between the mechanism	[differences between the mechanism]	0.0	4	1	1	1
101626	1710	usual mechanism	[usual mechanism]	0.0	2	1	1	1
101627	1710	goals:	[goals:]	0.0	1	1	1	1
101628	1710	effect on lymphocyte inhibition	[effects on lymphocytes inhibition]	0.0	4	1	1	1
101629	1710	functional state in patient	[functional state in patients]	0.0	4	1	1	1
101630	1710	vivo modulation by fluticasone propionate	[vivo modulation by fluticasone propionate]	0.0	5	1	1	1
101631	1710	four patient with micrograms/day for day	[four patients with micrograms/day for days)]	0.0	6	1	1	1
101632	1710	patient proband	[patient proband]	0.0	2	1	1	1
101633	1710	lie	[lying]	0.0	1	1	1	1
101634	1710	human T lymphotropic virus-i infection	[Human T lymphotropic virus-I infection]	0.0	5	1	1	1
101635	1710	maximum value in etoposide cell	[maximum value in etoposide cells]	0.0	5	1	1	1
101636	1710	whole-cell competitive binding assay	[whole-cell competitive binding assay]	0.0	4	1	1	1
101637	1710	chemotactic adhesive property of endothelial cell	[chemotactic adhesive properties of endothelial cells]	0.0	6	1	1	1
101638	1710	full response	[full response]	0.0	2	1	1	1
101639	1710	mechanism of neutrophil-endothelial cell adhesion	[mechanisms of neutrophil-endothelial cell adhesion]	0.0	5	1	1	1
101640	1710	polymerase chain reaction in pbmc	[polymerase chain reaction in PBMC]	0.0	5	1	1	1
101641	1710	adnexal region	[adnexal region]	0.0	2	1	1	1
101642	1710	regulator of cell development	[regulators of cell development]	0.0	4	1	1	1
101643	1710	adenomatous polyposis gene family	[adenomatous polyposis gene family]	0.0	4	1	1	1
101644	1710	understanding of effect on lymphocyte	[understanding of effects on lymphocytes]	0.0	5	1	1	1
101645	1710	T cell cDNA library	[T cell cDNA library]	0.0	4	1	1	1
101646	1710	(66 microg/100 millileter	[(66 microg/100 ml]	0.0	3	1	1	1
101647	1710	cell-type transcription factor	[cell-type transcription factor]	0.0	3	1	1	1
101648	1710	mM.	[mM.]	0.0	1	1	1	1
101649	1710	interaction between product	[interactions between products]	0.0	3	1	1	1
101650	1710	recent functional analysis	[recent functional analysis]	0.0	3	1	1	1
101651	1710	expense of reactivities.	[expense of reactivities.]	0.0	3	1	1	1
101652	1710	compounds' potency	[compounds' potency]	0.0	2	1	1	1
101653	1710	specific induction of AhR	[specific induction of AhR]	0.0	4	1	1	1
101654	1710	involve the 14q32.1 region	[involving the 14q32.1 regions]	0.0	4	1	1	1
101655	1710	one hundred primary breast cancer sample	[One hundred primary breast cancer samples]	0.0	6	1	1	1
101656	1710	TUNEL assay	[TUNEL assay]	0.0	2	1	1	1
101657	1710	dendritic assay	[dendritic assay]	0.0	2	1	1	1
101658	1710	transcription factor related	[transcription factor related]	0.0	3	1	1	1
101659	1710	cross point between regulate signal pathway	[cross points between regulating signaling pathways]	0.0	6	1	1	1
101660	1710	tolerance of mouse for tcf-1	[tolerance of mice for TCF-1]	0.0	5	1	1	1
101661	1710	cells, accumulation	[cells, accumulation]	0.0	2	1	1	1
101662	1710	mutant mrna without exon	[mutant mRNA without exon]	0.0	4	1	1	1
101663	1710	contrast, product	[contrast, products]	0.0	2	1	1	1
101664	1710	distinct family of transcription factor	[distinct families of transcription factors]	0.0	5	1	1	1
101665	1710	affinity between ligand	[affinity between ligand]	0.0	3	1	1	1
101666	1710	surface receptor on subpopulation	[surface receptors on subpopulations]	0.0	4	1	1	1
101667	1710	opposite effect on RA differentiation	[opposite effects on RA differentiation]	0.0	5	1	1	1
101668	1710	stimulate the release	[stimulating the release]	0.0	3	1	1	1
101669	1710	addition to the protein	[addition to the proteins]	0.0	4	1	1	1
101670	1710	hematopoetic cell line	[hematopoetic cell lines]	0.0	3	1	1	1
101671	1710	transgenic mouse with a defect	[Transgenic mice with a defect]	0.0	5	1	1	1
101672	1710	hematopoietic cell-specific pattern	[hematopoietic cell-specific pattern]	0.0	3	1	1	1
101673	1710	CD3 mab	[CD3 mAbs]	0.0	2	1	1	1
101674	1710	concentration in myocardial infarction	[concentration in myocardial infarction]	0.0	4	1	1	1
101675	1710	such as 12-o-tetradecanoyl-phorbol-13 acetate	[such as 12-O-tetradecanoyl-phorbol-13 acetate]	0.0	4	1	1	1
101676	1710	health impact	[health impact]	0.0	2	1	1	1
101677	1710	T cell (priming)	[T cells (priming)]	0.0	3	1	1	1
101678	1710	alteration in factor-kappa b moiety	[alterations in factor-kappa B moieties]	0.0	5	1	1	1
101679	1710	cluster bind consensus site	[cluster binding consensus sites]	0.0	4	1	1	1
101680	1710	retrievable macrophage	[retrievable macrophages]	0.0	2	1	1	1
101681	1710	specific binding of protein	[specific binding of protein]	0.0	4	1	1	1
101682	1710	class ii -negative cell line	[class II -negative cell lines]	0.0	5	1	1	1
101683	1710	normal adult blood lymphocyte sample	[normal adult blood lymphocyte samples]	0.0	5	1	1	1
101684	1710	Tat-activated, interferon gene	[Tat-activated, interferon gene]	0.0	3	1	1	1
101685	1710	isotype of protein kinase C PKC	[isotypes of protein kinase C PKC]	0.0	6	1	1	1
101686	1710	glucocorticoid binding rhythm	[glucocorticoid binding rhythms]	0.0	3	1	1	1
101687	1710	inducer of prl gene expression	[inducer of PRL gene expression]	0.0	5	1	1	1
101688	1710	receptor activation	[receptor activation]	0.0	2	1	1	1
101689	1710	cell-type-specific transactivation	[Cell-type-specific transactivation]	0.0	2	1	1	1
101690	1710	change of protein	[changes of proteins]	0.0	3	1	1	1
101691	1710	angioimmunoblastic t-cell lymphoma with hyperplastic center	[angioimmunoblastic T-cell lymphoma with hyperplastic centers]	0.0	6	1	1	1
101692	1710	regulatory sequence (affect expression	[regulatory sequences (affecting expression]	0.0	4	1	1	1
101693	1710	molecular mimicry involve class CTL	[molecular mimicry involving class CTLs]	0.0	5	1	1	1
101694	1710	downstream interactor (s)	[downstream interactor (s)]	0.0	3	1	1	1
101695	1710	(il-9r)	[(IL-9R)]	0.0	1	1	1	1
101696	1710	hiv-1 repeat promoter	[HIV-1 repeat promoter]	0.0	3	1	1	1
101697	1710	reliability	[reliability]	0.0	1	1	1	1
101698	1710	various reverse effect	[various reverse effects]	0.0	3	1	1	1
101699	1710	vitro cortisol	[vitro cortisol]	0.0	2	1	1	1
101700	1710	resistance of naive T cell	[resistance of naive T cells]	0.0	5	1	1	1
101701	1710	enzyme-linked assay procedure use zebra protein	[enzyme-linked assay procedure using ZEBRA protein]	0.0	6	1	1	1
101702	1710	glucocorticoid responsiveness of leukocyte	[glucocorticoid responsiveness of leukocytes]	0.0	4	1	1	1
101703	1710	characterization of early b-cell factor	[characterization of early B-cell factor]	0.0	5	1	1	1
101704	1710	icam-1 molecule	[ICAM-1 molecules]	0.0	2	1	1	1
101705	1710	&mgr;m)	[&mgr;M)]	0.0	1	1	1	1
101706	1710	extract from hypoxic ECs	[extracts from hypoxic ECs]	0.0	4	1	1	1
101707	1710	il-10 (10	[IL-10 (10]	0.0	2	1	1	1
101708	1710	sedimentation coefficient of 3.7 s	[sedimentation coefficient of 3.7 S]	0.0	5	1	1	1
101709	1710	type-II EBS	[type-II EBS]	0.0	2	1	1	1
101710	1710	palindromic sequence in each	[palindromic sequences in each]	0.0	4	1	1	1
101711	1710	bioactivation to metabolite	[Bioactivation to metabolites]	0.0	3	1	1	1
101712	1710	gene after kind	[genes after kinds]	0.0	3	1	1	1
101713	1710	small number hematopoietic progenitor cell	[small number hematopoietic progenitor cells]	0.0	5	1	1	1
101714	1710	icr27tk.3 cell contain receptor	[ICR27TK.3 cells containing receptors]	0.0	4	1	1	1
101715	1710	tested, methylprednisolone	[tested, methylprednisolone]	0.0	2	1	1	1
101716	1710	complex encompass the cd28re	[complexes encompassing the CD28RE]	0.0	4	1	1	1
101717	1710	tumor cell growth	[tumor cell growth]	0.0	3	1	1	1
101718	1710	ebv binding on b cell	[EBV binding on B cells]	0.0	5	1	1	1
101719	1710	influence on vaginal physiology	[influence on vaginal physiology]	0.0	4	1	1	1
101720	1710	responsiveness to factor kappa b	[responsiveness to factor kappa B]	0.0	5	1	1	1
101721	1710	cross-linking of tyrosine phosphorylation of Tyk2	[Cross-linking of tyrosine phosphorylation of Tyk2]	0.0	6	1	1	1
101722	1710	infection genome-positive b cell	[infection genome-positive B cells]	0.0	4	1	1	1
101723	1710	effect on potential signal pathway	[effects on potential signaling pathways]	0.0	5	1	1	1
101724	1710	p50 homodimer with heterodimer	[p50 homodimers with heterodimers]	0.0	4	1	1	1
101725	1710	mutation of abolish hat activity	[mutation of abolishing HAT activity]	0.0	5	1	1	1
101726	1710	approximately substSp23	[approximately substSp23]	0.0	2	1	1	1
101727	1710	socs-3 expression in response	[SOCS-3 expression in response]	0.0	4	1	1	1
101728	1710	proliferation of the T cell	[proliferation of the T cells]	0.0	5	1	1	1
101729	1710	novel agent with activity	[novel agent with activity]	0.0	4	1	1	1
101730	1710	icam-1 -dependent endothelial adhesivity	[ICAM-1 -dependent endothelial adhesivity]	0.0	4	1	1	1
101731	1710	dominant inheritance	[dominant inheritance]	0.0	2	1	1	1
101732	1710	elevation in calcium	[elevation in calcium]	0.0	3	1	1	1
101733	1710	hcmv DNA	[HCMV DNA]	0.0	2	1	1	1
101734	1710	cell-specific fashion	[cell-specific fashion]	0.0	2	1	1	1
101735	1710	lrr	[LRR]	0.0	1	1	1	1
101736	1710	toxic effect	[toxic effects]	0.0	2	1	1	1
101737	1710	nongenomic mechanism for immunosuppression: inhibition	[nongenomic mechanism for immunosuppression: inhibition]	0.0	5	1	1	1
101738	1710	stage development,	[stage, development,]	0.0	2	1	1	1
101739	1710	expression of the IkappaBalpha	[expression of the IkappaBalpha]	0.0	4	1	1	1
101740	1710	antiserum (identical to kda	[antiserum (identical to kDa]	0.0	4	1	1	1
101741	1710	slight augmentation in some experiments).	[slight augmentation in some experiments).]	0.0	5	1	1	1
101742	1710	cell infiltration around the airways,	[cell infiltration around the airways,]	0.0	5	1	1	1
101743	1710	promote the generation of plasma cell	[promoting the generation of plasma cells]	0.0	6	1	1	1
101744	1710	decline in cortisol level	[decline in cortisol levels]	0.0	4	1	1	1
101745	1710	uptake of 135(oh)2d3 in pbmc	[uptake of 1,25(OH)2D3 in PBMC]	0.0	5	1	1	1
101746	1710	effect on virus expression	[effect on virus expression]	0.0	4	1	1	1
101747	1710	woman (11 first, second	[women (11 first, second]	0.0	4	1	1	1
101748	1710	blood mononuclear cell hla b8+	[blood mononuclear cells HLA B8+]	0.0	5	1	1	1
101749	1710	history of disease	[history of disease.]	0.0	3	1	1	1
101750	1710	negative respond element NREs	[negative responding elements NREs]	0.0	4	1	1	1
101751	1710	thiobarbituric acid-reactive substance	[thiobarbituric acid-reactive substances]	0.0	3	1	1	1
101752	1710	CL response	[CL responses]	0.0	2	1	1	1
101753	1710	nuclear stimulation of factor kappa b	[nuclear stimulation of factor kappa B]	0.0	6	1	1	1
101754	1710	activity factor	[activity factor]	0.0	2	1	1	1
101755	1710	interleukin-2 expression a natural gene	[interleukin-2 expression a natural gene]	0.0	5	1	1	1
101756	1710	early wk to 12 mo)	[early wk to 12 mo)]	0.0	5	1	1	1
101757	1710	polyadenylylation site	[polyadenylylation sites]	0.0	2	1	1	1
101758	1710	cell in germinal center	[cells in germinal centers]	0.0	4	1	1	1
101759	1710	dose-dependence study	[Dose-dependence studies]	0.0	2	1	1	1
101760	1710	presence base pair upstream	[presence base pairs upstream]	0.0	4	1	1	1
101761	1710	pre-incubation of extract	[pre-incubation of extracts]	0.0	3	1	1	1
101762	1710	expression from two REV ltr	[expression from two REV LTRs]	0.0	5	1	1	1
101763	1710	inhibitor of map kinase pd98059	[Inhibitors of MAP kinase PD98059]	0.0	5	1	1	1
101764	1710	b4-2 DNA	[B4-2 DNA]	0.0	2	1	1	1
101765	1710	subunits; genes, nfkb1	[subunits; genes, NFKB1]	0.0	3	1	1	1
101766	1710	none of the leukemia	[None of the leukemias]	0.0	4	1	1	1
101767	1710	in-vitro cleavage by recombinant caspase cpp32	[In-vitro cleavage by recombinant caspase CPP32]	0.0	6	1	1	1
101768	1710	value in untreated patient	[values in untreated patients]	0.0	4	1	1	1
101769	1710	Jeg-3 choriocarcinoma-induced immunosuppression downregulation of interleukin-2	[Jeg-3 choriocarcinoma-induced immunosuppression downregulation of interleukin-2]	0.0	6	1	1	1
101770	1710	overrepresentation of clinically aggressive type	[overrepresentation of clinically aggressive types]	0.0	5	1	1	1
101771	1710	effect on factor-kappaB regulation	[effects on factor-kappaB regulation]	0.0	4	1	1	1
101772	1710	phosphorylation prb	[phosphorylation pRb]	0.0	2	1	1	1
101773	1710	gsh glutathione ratio	[GSH glutathione ratio]	0.0	3	1	1	1
101774	1710	stage-specific protein	[stage-specific protein]	0.0	2	1	1	1
101775	1710	tyrosine -phosphorylated stat1 protein kda protein	[tyrosine -phosphorylated stat1 proteins kDa proteins]	0.0	6	1	1	1
101776	1710	MEK1 mutant	[MEK1 mutants]	0.0	2	1	1	1
101777	1710	distinct cytokine expression pattern	[distinct cytokine expression patterns]	0.0	4	1	1	1
101778	1710	fcr -dependent activation	[FcR -dependent activation]	0.0	3	1	1	1
101779	1710	coupling of ptk	[coupling of PTKs]	0.0	3	1	1	1
101780	1710	use sulfate as the footprinting agent	[using sulfate as the footprinting agent]	0.0	6	1	1	1
101781	1710	abundance in a variety	[abundance in a variety]	0.0	4	1	1	1
101782	1710	end of thromboxane receptor gene	[end of thromboxane receptor gene]	0.0	5	1	1	1
101783	1710	blastic transformation in leukemia	[blastic transformation in leukemia]	0.0	4	1	1	1
101784	1710	manage setting of vascular pathology	[managing settings of vascular pathology]	0.0	5	1	1	1
101785	1710	clone of B-cell line	[clones of B-cell lines]	0.0	4	1	1	1
101786	1710	differentiation, respiratory burst	[differentiation, respiratory burst]	0.0	3	1	1	1
101787	1710	gh in patient	[GH in patient]	0.0	3	1	1	1
101788	1710	weight of 39000.	[weight of 39,000.]	0.0	3	1	1	1
101789	1710	RANTES factor RFLAT-1	[RANTES Factor RFLAT-1]	0.0	3	1	1	1
101790	1710	activation of lytic viral promoter	[activation of lytic viral promoters]	0.0	5	1	1	1
101791	1710	effect increase of ca2+	[effect increase of Ca2+]	0.0	4	1	1	1
101792	1710	negligible dna-binding activity	[negligible DNA-binding activity]	0.0	3	1	1	1
101793	1710	and/or fetal	[and/or fetal]	0.0	2	1	1	1
101794	1710	kda/65 kda (p50/p65) heterodimer	[kDa/65 kDa (p50/p65) heterodimer]	0.0	4	1	1	1
101795	1710	rrna encode gamma-globin erythroid delta-aminolevulinate synthase	[mRNAs encoding gamma-globin erythroid delta-aminolevulinate synthase]	0.0	6	1	1	1
101796	1710	-specific (as) phosphorothioate oligonucleotide	[-specific (AS) phosphorothioate oligonucleotides]	0.0	4	1	1	1
101797	1710	reduction of suppressive nfat1 activity	[reduction of suppressive NFAT1 activity]	0.0	5	1	1	1
101798	1710	lineage switch from the eosinophil	[lineage switching from the eosinophil]	0.0	5	1	1	1
101799	1710	human tumor cell line	[human tumor cell lines]	0.0	4	1	1	1
101800	1710	subject (62-97 yr)	[subjects (62-97 yr)]	0.0	3	1	1	1
101801	1710	role induction of tnf-alpha	[role induction of TNF-alpha]	0.0	4	1	1	1
101802	1710	cellular proliferation of antigen-activated T cell	[cellular proliferation of antigen-activated T cells]	0.0	6	1	1	1
101803	1710	histocompatibility surface protein	[histocompatibility surface proteins]	0.0	3	1	1	1
101804	1710	motif-rich protein	[motif-rich proteins]	0.0	2	1	1	1
101805	1710	ets binding motif TTCC	[ETS binding motifs TTCC]	0.0	4	1	1	1
101806	1710	lyt	[Lyt]	0.0	1	1	1	1
101807	1710	region to the exon,	[region to the exon,]	0.0	4	1	1	1
101808	1710	axillary lymph node involvement	[axillary lymph node involvement]	0.0	4	1	1	1
101809	1710	acceleration	[acceleration]	0.0	1	1	1	1
101810	1710	enhancement HL cell differentiated)	[enhancement HL cells differentiated)]	0.0	4	1	1	1
101811	1710	cognate interaction of b cell	[cognate interaction of B cells]	0.0	5	1	1	1
101812	1710	marker of rate	[markers of rate]	0.0	3	1	1	1
101813	1710	monoclonal antibody phosphatidylinositol 3-kinase	[monoclonal antibody phosphatidylinositol 3-kinase]	0.0	4	1	1	1
101814	1710	therapeutic use as /hypereosinophilic agent	[therapeutic use as /hypereosinophilic agents]	0.0	5	1	1	1
101815	1710	alpha sialyltransferase isozyme	[alpha sialyltransferase isozyme]	0.0	3	1	1	1
101816	1710	nucleoside diphosphate kinase	[nucleoside diphosphate kinase]	0.0	3	1	1	1
101817	1710	Ig chain enhancer	[Ig chain enhancer]	0.0	3	1	1	1
101818	1710	complete dependence	[complete dependence]	0.0	2	1	1	1
101819	1710	cis-acting dominant regulatory effect	[cis-acting dominant regulatory effect]	0.0	4	1	1	1
101820	1710	variant er form	[variant ER forms]	0.0	3	1	1	1
101821	1710	target of CsA	[target of CsA]	0.0	3	1	1	1
101822	1710	rate of grade before radiotherapy	[rate of grades before radiotherapy]	0.0	5	1	1	1
101823	1710	normal human eosinophil	[normal human eosinophils]	0.0	3	1	1	1
101824	1710	regulation of interleukin gene	[regulation of interleukin gene]	0.0	4	1	1	1
101825	1710	ifn-gamma tyrosine phosphorylation	[IFN-gamma tyrosine phosphorylation]	0.0	3	1	1	1
101826	1710	free cortisol excretion in FMS	[free cortisol excretion in FMS]	0.0	5	1	1	1
101827	1710	enhancer in	[enhancer in]	0.0	2	1	1	1
101828	1710	involvement in igm production	[Involvement in IgM production]	0.0	4	1	1	1
101829	1710	follow a initial genotype screen	[Following an initial genotype screening]	0.0	5	1	1	1
101830	1710	acute transfection under control of virus	[Acute transfection under control of virus]	0.0	6	1	1	1
101831	1710	prognostic criteria]	[prognostic criteria]]	0.0	2	1	1	1
101832	1710	Th2 lineage relative	[Th2 lineage relative]	0.0	3	1	1	1
101833	1710	effect on pattern of calcium metabolism	[effect on patterns of calcium metabolism]	0.0	6	1	1	1
101834	1710	g/g of total rna	[g/g of total RNA]	0.0	4	1	1	1
101835	1710	requirement for tcr coengagement	[requirement for TCR coengagement]	0.0	4	1	1	1
101836	1710	cluster of conserved, residue	[cluster of conserved, residues]	0.0	4	1	1	1
101837	1710	SCL expression proliferate cell	[SCL expression proliferating cells]	0.0	4	1	1	1
101838	1710	determinant for MLV transcriptional activity	[determinants for MLV transcriptional activity]	0.0	5	1	1	1
101839	1710	bacterial lipopolysaccharide-induced transcription	[bacterial lipopolysaccharide-induced transcription]	0.0	3	1	1	1
101840	1710	binding of multi-protein complex RFX	[binding of multi-protein complexes RFX]	0.0	5	1	1	1
101841	1710	sh3-interacting	[SH3-interacting]	0.0	1	1	1	1
101842	1710	interleukin-5 il-5 a selective factor	[interleukin-5 IL-5 a selective factor]	0.0	5	1	1	1
101843	1710	use vary conditions, three complex	[Using varying conditions, three complexes]	0.0	5	1	1	1
101844	1710	permit the release of nf-kappab	[permitting the release of NF-kappaB]	0.0	5	1	1	1
101845	1710	specific binding site, result	[specific binding site, resulting]	0.0	4	1	1	1
101846	1710	gene transcription, protein synthesis in cell	[gene transcription, protein synthesis in cells]	0.0	6	1	1	1
101847	1710	use ligand to retinoic acid receptor	[Using ligands to retinoic acid receptors]	0.0	6	1	1	1
101848	1710	zoster	[zoster]	0.0	1	1	1	1
101849	1710	form of selection clonal expansion)	[forms of selection clonal expansion)]	0.0	5	1	1	1
101850	1710	methov with platelet-activate factor	[METHODS with platelet-activating factor]	0.0	4	1	1	1
101851	1710	cd8+cd56+/cd57+	[CD8+CD56+/CD57+]	0.0	1	1	1	1
101852	1710	processes, for example,	[processes, for example,]	0.0	3	1	1	1
101853	1710	expression of a single gene	[expression of a single gene]	0.0	5	1	1	1
101854	1710	5'-upstream sequence	[5'-upstream sequence]	0.0	2	1	1	1
101855	1710	human cell in hypoxia po2	[human cells in hypoxia PO2]	0.0	5	1	1	1
101856	1710	level of ikappabalpha degradation	[level of IkappaBalpha degradation]	0.0	4	1	1	1
101857	1710	further enhancement	[further enhancement]	0.0	2	1	1	1
101858	1710	9,11-dihydro derivative	[9,11-dihydro derivative]	0.0	2	1	1	1
101859	1710	transactivate domain	[transactivating domain]	0.0	2	1	1	1
101860	1710	AP-1/ CRE site	[AP-1/ CRE site]	0.0	3	1	1	1
101861	1710	dependence in a hematopoietic cell line	[Dependence in a hematopoietic cell line]	0.0	6	1	1	1
101862	1710	patient with acute leukaemia AML	[patients with acute leukaemia AML]	0.0	5	1	1	1
101863	1710	perhaps through a effect	[perhaps through an effect]	0.0	4	1	1	1
101864	1710	tissue factor the principal initiator	[tissue factor the principal initiator]	0.0	5	1	1	1
101865	1710	expression of RAG-1	[expression of RAG-1]	0.0	3	1	1	1
101866	1710	triiodothyronine leukocyte receptor kinetic	[triiodothyronine leukocyte receptor kinetics]	0.0	4	1	1	1
101867	1710	positive selection clonal expansion)	[positive selection clonal expansion)]	0.0	4	1	1	1
101868	1710	expression pattern in cell	[expression patterns in cells]	0.0	4	1	1	1
101869	1710	different zinc finger protein	[different zinc finger proteins]	0.0	4	1	1	1
101870	1710	response during infection	[responses during infection]	0.0	3	1	1	1
101871	1710	number of (positive) predictions.	[number of (positive) predictions.]	0.0	4	1	1	1
101872	1710	thus contribute	[thus contributing]	0.0	2	1	1	1
101873	1710	one mechanism lead	[one mechanism leading]	0.0	3	1	1	1
101874	1710	coincubation of tr alpha	[coincubation of TR alpha]	0.0	4	1	1	1
101875	1710	alter the redox status	[altering the redox status]	0.0	4	1	1	1
101876	1710	retinoic element-containing promoter	[retinoic element-containing promoters]	0.0	3	1	1	1
101877	1710	amount additionally, costimulation	[amounts additionally, costimulation]	0.0	3	1	1	1
101878	1710	implication for some role	[implications for some roles]	0.0	4	1	1	1
101879	1710	nonpeptidyl small molecule 247464 capable	[nonpeptidyl small molecule 247464 capable]	0.0	5	1	1	1
101880	1710	TCR delta enhancer	[TCR delta enhancer]	0.0	3	1	1	1
101881	1710	domain of the intestinal receptor	[domain of the intestinal receptor]	0.0	5	1	1	1
101882	1710	level of regulatory protein	[levels of regulatory proteins]	0.0	4	1	1	1
101883	1710	also other cytokine	[also other cytokines]	0.0	3	1	1	1
101884	1710	sideroblast with ring sideroblast	[sideroblasts with ring sideroblasts]	0.0	4	1	1	1
101885	1710	maz	[MAZ]	0.0	1	1	1	1
101886	1710	GM-CSF promoter region	[GM-CSF promoter region]	0.0	3	1	1	1
101887	1710	notion substrate for shp1	[notion substrates for SHP1]	0.0	4	1	1	1
101888	1710	examine overall change	[examining overall changes]	0.0	3	1	1	1
101889	1710	devd-cho	[DEVD-CHO]	0.0	1	1	1	1
101890	1710	clinical importance for counseling.	[clinical importance for counseling.]	0.0	4	1	1	1
101891	1710	mutation in a patient with scid	[Mutation in a patient with SCID]	0.0	6	1	1	1
101892	1710	relationship with centers.	[relationship with centers.]	0.0	3	1	1	1
101893	1710	such as nerve growth factor	[such as nerve growth factor]	0.0	5	1	1	1
101894	1710	appearance of a inducible factor	[appearance of an inducible factor]	0.0	5	1	1	1
101895	1710	bovine papilloma virus	[bovine papilloma virus]	0.0	3	1	1	1
101896	1710	accelerate the degradation	[accelerating the degradation]	0.0	3	1	1	1
101897	1710	glucocorticoid receptor to therapy	[glucocorticoid receptor to therapy]	0.0	4	1	1	1
101898	1710	tamoxifen Tx a antagonist	[tamoxifen Tx an antagonist]	0.0	4	1	1	1
101899	1710	presence in the atherosclerotic plaque	[presence in the atherosclerotic plaques]	0.0	5	1	1	1
101900	1710	two pkc inhibitors, pentoxifylline PTX	[two PKC inhibitors, pentoxifylline PTX]	0.0	5	1	1	1
101901	1710	two other EBV-associated, latent epitope	[two other EBV-associated, latent epitopes]	0.0	5	1	1	1
101902	1710	one-hybrid assay in yeast	[One-hybrid assays in yeast]	0.0	4	1	1	1
101903	1710	constitutive interaction involve nuclear factor	[constitutive interactions involving nuclear factor]	0.0	5	1	1	1
101904	1710	tissue cell	[tissue cells]	0.0	2	1	1	1
101905	1710	cooperative binding of the sh2 domain	[cooperative binding of the SH2 domains]	0.0	6	1	1	1
101906	1710	blood group	[blood group]	0.0	2	2	2	1
101907	1710	readout	[readout]	0.0	1	1	1	1
101908	1710	nf-kappa b the basal activity	[NF-kappa B the basal activity]	0.0	5	1	1	1
101909	1710	other targets,	[other targets,]	0.0	2	1	1	1
101910	1710	tcr-induced il-2 production	[TCR-induced IL-2 production]	0.0	3	1	1	1
101911	1710	level of the messenger rna	[levels of the messenger RNAs]	0.0	5	1	1	1
101912	1710	hematopoietic precurser	[hematopoietic precursers]	0.0	2	1	1	1
101913	1710	CoCl2 cellular signal	[CoCl2 cellular signals]	0.0	3	1	1	1
101914	1710	association proviral latency	[Association proviral latency]	0.0	3	1	1	1
101915	1710	inhibition in pbmc	[inhibition in PBMC]	0.0	3	1	1	1
101916	1710	hormonal control	[hormonal control]	0.0	2	1	1	1
101917	1710	kilometer tnf receptor expression	[kd TNF receptor expression]	0.0	4	1	1	1
101918	1710	(range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564	[(range, 4484-5643),]	0.0	2	1	1	1
101919	1710	normal blood lymphocyte with cysteamine	[normal blood lymphocytes with cysteamine]	0.0	5	1	1	1
101920	1710	clinical course chi2 test).	[clinical course chi2 test).]	0.0	4	1	1	1
101921	1710	distinct change	[distinct changes]	0.0	2	1	1	1
101922	1710	EBV-associated, hla-b8-restricted epitope	[EBV-associated, HLA-B8-restricted epitopes]	0.0	3	1	1	1
101923	1710	1 receptor in human leukocyte	[1 receptors in human leukocytes]	0.0	5	1	1	1
101924	1710	phorbol 12-myristate 13-acetate hiv-1 replication	[phorbol 12-myristate 13-acetate HIV-1 replication]	0.0	5	1	1	1
101925	1710	notable difference	[notable differences]	0.0	2	1	1	1
101926	1710	contrast to the type,	[contrast to the type,]	0.0	4	1	1	1
101927	1710	1 overexpression	[1 overexpression]	0.0	2	1	1	1
101928	1710	early-phase	[early-phase]	0.0	1	1	1	1
101929	1710	reservoir of hiv	[reservoirs of HIV]	0.0	3	1	1	1
101930	1710	inflammatory disease include asthma	[inflammatory diseases including asthma]	0.0	4	1	1	1
101931	1710	rest secretion	[resting secretion]	0.0	2	1	1	1
101932	1710	normal thyroid tissue	[normal thyroid tissue]	0.0	3	1	1	1
101933	1710	constitutive activation of a reporter	[constitutive activation of a reporter]	0.0	5	1	1	1
101934	1710	basis for the notion	[basis for the notion]	0.0	4	1	1	1
101935	1710	135-(oh)2d3 receptor	[1,25-(OH)2D3 receptor]	0.0	2	1	1	1
101936	1710	-nf-y	[-NF-Y]	0.0	1	1	1	1
101937	1710	patient (age 25-79) with sepsis	[patients (age 25-79) with sepsis]	0.0	5	1	1	1
101938	1710	introduction of a phosphoserine mimetic	[introduction of a phosphoserine mimetic]	0.0	5	1	1	1
101939	1710	potent regulator of stat6	[potent regulator of STAT6]	0.0	4	1	1	1
101940	1710	GRE site	[GRE sites]	0.0	2	1	1	1
101941	1710	growth factor such as 12-o-tetradecanoylphorbol-13-acetate	[growth factors such as 12-O-tetradecanoylphorbol-13-acetate]	0.0	5	1	1	1
101942	1710	terminal repeat ltr	[terminal repeats LTRs]	0.0	3	1	1	1
101943	1710	Potent attenuation	[Potent attenuation]	0.0	2	1	1	1
101944	1710	two isoform to IL-2-	[two isoforms to IL-2-]	0.0	4	1	1	1
101945	1710	bb genotype	[Bb genotype]	0.0	2	2	2	1
101946	1710	role in T cell costimulation	[role in T cell costimulation]	0.0	5	1	1	1
101947	1710	CTL against epitope	[CTLs against epitopes]	0.0	3	1	1	1
101948	1710	350 kb of DNA	[350 kb of DNA]	0.0	4	1	1	1
101949	1710	result in suppression	[resulting in suppression]	0.0	3	1	1	1
101950	1710	97 (18- volunteer	[97 (18- volunteers]	0.0	3	1	1	1
101951	1710	negative form of aml1 AML1a	[negative form of AML1 AML1a]	0.0	5	1	1	1
101952	1710	even more striking downregulation	[even more striking downregulation]	0.0	4	1	1	1
101953	1710	cd95 fas /apo-1	[CD95 Fas /Apo-1]	0.0	3	1	1	1
101954	1710	evidence link behavior of stat pathway	[evidence linking behavior of STAT pathways]	0.0	6	1	1	1
101955	1710	region between basis	[region between bases]	0.0	3	1	1	1
101956	1710	36-kDa transcription factor	[36-kDa transcription factor]	0.0	3	1	1	1
101957	1710	minute 2).	[minutes 2).]	0.0	2	1	1	1
101958	1710	occur after reoxygenation	[occurring after reoxygenation]	0.0	3	1	1	1
101959	1710	reinfusion	[reinfusion]	0.0	1	2	2	1
101960	1710	seasonal variation	[seasonal variation]	0.0	2	1	1	1
101961	1710	depressive disorder in adolescent	[depressive disorder in adolescents]	0.0	4	1	1	1
101962	1710	iron availability	[iron availability]	0.0	2	1	1	1
101963	1710	compelling link	[compelling links]	0.0	2	1	1	1
101964	1710	detrimental effect	[detrimental effect]	0.0	2	1	1	1
101965	1710	a protein with a mass	[aa protein with a mass]	0.0	5	1	1	1
101966	1710	selective chemical modification	[selective chemical modification]	0.0	3	1	1	1
101967	1710	role in the cyclosporin induction	[role in the cyclosporin induction]	0.0	5	1	1	1
101968	1710	three ATL cell line	[Three ATL cell lines]	0.0	4	1	1	1
101969	1710	detection of disease in a patient	[Detection of disease in a patient]	0.0	6	1	1	1
101970	1710	transcription factor of the family	[transcription factors of the family]	0.0	5	1	1	1
101971	1710	isoquinoline	[isoquinoline]	0.0	1	1	1	1
101972	1710	ten hiv-infected patient with affinity	[Ten HIV-infected patients with affinity]	0.0	5	1	1	1
101973	1710	fusion follow t(1;19) translocation	[fusion following t(1;19) translocations]	0.0	4	1	1	1
101974	1710	eight form of inheritance	[eight forms of inheritance]	0.0	4	1	1	1
101975	1710	target of Dex	[target of Dex]	0.0	3	1	1	1
101976	1710	contribution to rheumatoid arthritis	[contribution to rheumatoid arthritis]	0.0	4	1	1	1
101977	1710	seven non-pregnant woman	[seven non-pregnant women]	0.0	3	1	1	1
101978	1710	accompany aging.	[accompanying aging.]	0.0	2	1	1	1
101979	1710	acid (ra) resistance	[acid (RA) resistance]	0.0	3	1	1	1
101980	1710	s protease	[S proteases]	0.0	2	1	1	1
101981	1710	level in erythrocyte	[levels in erythrocytes]	0.0	3	1	1	1
101982	1710	compensate for difference	[compensating for differences]	0.0	3	1	1	1
101983	1710	12l:12d light regime, peak value	[12L:12D light regime, peak values]	0.0	5	1	1	1
101984	1710	cell adhesion to ec in response	[cell adhesion to EC in response]	0.0	6	1	1	1
101985	1710	G point mutation	[G point mutation]	0.0	3	1	1	1
101986	1710	human intestinal epithelial cell response	[Human intestinal epithelial cell responses]	0.0	5	1	1	1
101987	1710	thymocyte from thy-tax mouse	[thymocytes from Thy-tax mice]	0.0	4	1	1	1
101988	1710	group type ii MHC cid	[group type II MHC CID]	0.0	5	1	1	1
101989	1710	number of stretch	[number of stretches]	0.0	3	1	1	1
101990	1710	case of acute myelogenous leukaemia	[cases of acute myelogenous leukaemia]	0.0	5	1	1	1
101991	1710	mm,	[mM,]	0.0	1	1	1	1
101992	1710	terminal repeat in T cell	[terminal repeat in T cells]	0.0	5	1	1	1
101993	1710	rac-1 signal pathway	[Rac-1 signaling pathways]	0.0	3	1	1	1
101994	1710	early event detectable	[earliest events detectable]	0.0	3	1	1	1
101995	1710	mutant leukemic cell	[mutant leukemic cells]	0.0	3	1	1	1
101996	1710	series:	[series:]	0.0	1	1	1	1
101997	1710	nm23 function	[nm23 function]	0.0	2	1	1	1
101998	1710	Furthermore, loss	[Furthermore, loss]	0.0	2	1	1	1
101999	1710	contain orf2	[containing ORF2]	0.0	2	1	1	1
102000	1710	TCR Vbeta promoter	[TCR Vbeta promoter]	0.0	3	1	1	1
102001	1710	region important, through interaction	[regions important, through interaction]	0.0	4	1	1	1
102002	1710	Ala618	[Ala618]	0.0	1	1	1	1
102003	1710	different virologic subtype	[different virologic subtypes]	0.0	3	1	1	1
102004	1710	T cell by tcr engagement	[T cells by TCR engagement]	0.0	5	1	1	1
102005	1710	CD14 translocation	[CD14 translocation]	0.0	2	1	1	1
102006	1710	allow	[allowing]	0.0	1	1	1	1
102007	1710	mouse bone marrow	[mouse bone marrow]	0.0	3	1	1	1
102008	1710	uncouple in a T cell.	[Uncoupling in an T cell.]	0.0	5	1	1	1
102009	1710	induce CAT activity by 3.2-fold, costimulation	[inducing CAT activity by 3.2-fold, costimulation]	0.0	6	1	1	1
102010	1710	cell receptor-CD3	[cell receptor-CD3]	0.0	2	1	1	1
102011	1710	unique latency	[unique latency]	0.0	2	1	1	1
102012	1710	mo)	[mo)]	0.0	1	1	1	1
102013	1710	activation of kappa b-driven gene	[activation of kappa B-driven genes]	0.0	5	1	1	1
102014	1710	(1) part of the effect	[(1) part of the effect]	0.0	5	1	1	1
102015	1710	lymphotropic virus type 1 htlv-1	[lymphotropic virus type 1 HTLV-1]	0.0	5	1	1	1
102016	1710	mo.	[mo.]	0.0	1	1	1	1
102017	1710	mmp	[MMPs]	0.0	1	1	1	1
102018	1710	origin of ebv replication	[origin of EBV replication]	0.0	4	1	1	1
102019	1710	DNase hypersensitive site	[DNase hypersensitive sites]	0.0	3	1	1	1
102020	1710	acute pancreatitis in the rat	[acute pancreatitis in the rat]	0.0	5	1	1	1
102021	1710	gene' start site	[gene's start site]	0.0	3	1	1	1
102022	1710	number of bcl-6	[number of Bcl-6]	0.0	3	1	1	1
102023	1710	action of acid on hematopoiesis blockade	[action of acid on hematopoiesis blockade]	0.0	6	1	1	1
102024	1710	p95vav alone	[p95vav alone]	0.0	2	1	1	1
102025	1710	change in phosphorylation follow cell stimulation.	[changes in phosphorylation following cell stimulation.]	0.0	6	1	1	1
102026	1710	early lytic transcript	[early lytic transcripts]	0.0	3	1	1	1
102027	1710	genesis of chronic leukemia	[genesis of chronic leukemia]	0.0	4	1	1	1
102028	1710	ig ligand	[Ig ligand]	0.0	2	1	1	1
102029	1710	decrease nf-kappab heterodimer binding	[decrease NF-kappaB heterodimer binding]	0.0	4	1	1	1
102030	1710	comparable sensitivity against all type	[comparable sensitivity against all types]	0.0	5	1	1	1
102031	1710	respond to the factor	[responding to the factor]	0.0	4	1	1	1
102032	1710	weak complex	[weak complex]	0.0	2	1	1	1
102033	1710	proliferation in spleen cell	[proliferation in spleen cells]	0.0	4	1	1	1
102034	1710	ikappab alpha in cell	[IkappaB alpha in cells]	0.0	4	1	1	1
102035	1710	age]	[age]]	0.0	1	1	1	1
102036	1710	regulate hematopoietic differentiation	[regulating hematopoietic differentiation]	0.0	3	1	1	1
102037	1710	regulate t-cell gene expression	[regulating T-cell gene expression]	0.0	4	1	1	1
102038	1710	membrane-associated lymphotoxin	[Membrane-associated lymphotoxin]	0.0	2	1	1	1
102039	1710	potential phosphoprotein of unknown function.	[potential phosphoprotein of unknown function.]	0.0	5	1	1	1
102040	1710	transcription factor of importance	[transcription factors of importance]	0.0	4	1	1	1
102041	1710	lipophilic substance	[lipophilic substances]	0.0	2	1	1	1
102042	1710	mobility of 80 kda	[mobility of 80 kDa]	0.0	4	1	1	1
102043	1710	mechanism for alteration	[mechanism for alteration]	0.0	3	1	1	1
102044	1710	mpo	[MPO]	0.0	1	1	1	1
102045	1710	deoxyribonucleic acid (dna) protein exhibit change	[deoxyribonucleic acid (DNA) proteins exhibiting changes]	0.0	6	1	1	1
102046	1710	possible enhancement of dna-binding	[possible enhancement of DNA-binding]	0.0	4	1	1	1
102047	1710	vascular cell adhesion molecule surface expression	[vascular cell adhesion molecule surface expression]	0.0	6	1	1	1
102048	1710	activation by sp-a dose	[Activation by SP-A doses]	0.0	4	1	1	1
102049	1710	class chain promoter	[class chain promoter]	0.0	3	1	1	1
102050	1710	Immunol jul;27(7):1830]	[Immunol Jul;27(7):1830]]	0.0	2	1	1	1
102051	1710	EBNA-2 cell line	[EBNA-2 cell lines]	0.0	3	1	1	1
102052	1710	interleukin-2 il-2 promoter	[interleukin-2 IL-2 promoter]	0.0	3	1	1	1
102053	1710	T cell with ionomycin	[T cells with ionomycin]	0.0	4	1	1	1
102054	1710	NF kappab activation in glia	[NF kappaB activation in glia]	0.0	5	1	1	1
102055	1710	expression within limits.	[expression within limits.]	0.0	3	1	1	1
102056	1710	many factors, in cytokine	[Many factors, in cytokines]	0.0	4	1	1	1
102057	1710	c-Jun -contain	[c-Jun -containing]	0.0	2	1	1	1
102058	1710	co-express gata	[co-expressing GATA]	0.0	2	1	1	1
102059	1710	Ramos b	[Ramos B]	0.0	2	1	1	1
102060	1710	100% inhibition of binding	[100% inhibition of binding]	0.0	4	1	1	1
102061	1710	functional factor kB element	[functional factor kB elements]	0.0	4	1	1	1
102062	1710	regulatory factor in monocyte	[regulatory factors in monocytes]	0.0	4	1	1	1
102063	1710	lung icam-1	[lung ICAM-1]	0.0	2	2	2	1
102064	1710	formation of the B1 complex	[formation of the B1 complex]	0.0	5	1	1	1
102065	1710	mrp	[MRP]	0.0	1	1	1	1
102066	1710	anti-D reagent	[anti-D reagents]	0.0	2	1	1	1
102067	1710	nucleotide mutation	[nucleotide mutations]	0.0	2	1	1	1
102068	1710	acute lymphoblastic leukemia cell	[acute lymphoblastic leukemia cells]	0.0	4	1	1	1
102069	1710	soluble transglycosylase of Escherichia coli	[soluble transglycosylase of Escherichia coli]	0.0	5	1	1	1
102070	1710	internal promoter	[internal promoter]	0.0	2	1	1	1
102071	1710	first cytokine gene mapped.	[first cytokine gene mapped.]	0.0	4	1	1	1
102072	1710	CNS disease state	[CNS disease states]	0.0	3	1	1	1
102073	1710	include a response	[including a response]	0.0	3	1	1	1
102074	1710	line of mouse display erythroid-specific expression	[lines of mice displaying erythroid-specific expression]	0.0	6	1	1	1
102075	1710	(nf-at)	[(NF-AT)]	0.0	1	1	1	1
102076	1710	23 to 40% positive cells, respectively),	[23 to 40% positive cells, respectively),]	0.0	6	1	1	1
102077	1710	potential kda ca(2+)-atpase target	[potential kDa Ca(2+)-ATPase target]	0.0	4	1	1	1
102078	1710	healthy woman (controls)	[healthy women (controls)]	0.0	3	1	1	1
102079	1710	control subject ige 112+/-28	[control subjects IgE 112+/-28]	0.0	4	1	1	1
102080	1710	Jak -STAT 1 pathway	[Jak -STAT 1 pathway]	0.0	4	1	1	1
102081	1710	cd86 cho-cd86	[CD86 CHO-CD86]	0.0	2	1	1	1
102082	1710	transient increase peak between h.	[transient increase peaking between h,]	0.0	5	1	1	1
102083	1710	least two factor	[least two factors]	0.0	3	1	1	1
102084	1710	expression of p16 in human lymphocyte	[expression of p16 in human lymphocytes]	0.0	6	1	1	1
102085	1710	overexpression of mutant of Raf-1	[overexpression of mutants of Raf-1]	0.0	5	1	1	1
102086	1710	four late histone h2a-2 gene	[four late histone H2A-2 genes]	0.0	5	1	1	1
102087	1710	alter the redox state.	[altering the redox state.]	0.0	4	1	1	1
102088	1710	thigh lesion	[thigh lesions]	0.0	2	1	1	1
102089	1710	presence of alpha-helice each	[presence of alpha-helices each]	0.0	4	1	1	1
102090	1710	amount of creb protein	[amounts of CREB protein]	0.0	4	1	1	1
102091	1710	dna-mobility shift	[DNA-mobility shift]	0.0	2	1	1	1
102092	1710	x consensus element	[X consensus element]	0.0	3	1	1	1
102093	1710	hour of cross-linking.	[hours of cross-linking.]	0.0	3	1	1	1
102094	1710	aspect include presentation, response	[aspects including presentation, response]	0.0	4	1	1	1
102095	1710	patient with chronic failure	[patients with chronic failure]	0.0	4	1	1	1
102096	1710	gata-1 expression in progenitor	[GATA-1 expression in progenitors]	0.0	4	1	1	1
102097	1710	2) biochemical sign of hypothyroidism	[2) biochemical signs of hypothyroidism]	0.0	5	1	1	1
102098	1710	variety of immune cell	[variety of immune cells]	0.0	4	1	1	1
102099	1710	contain four near-perfect repeat DR	[containing four near-perfect repeats DR]	0.0	5	1	1	1
102100	1710	contain nf-atp	[containing NF-ATp]	0.0	2	1	1	1
102101	1710	microenvironment-directed, two-step	[microenvironment-directed, two-step]	0.0	2	1	1	1
102102	1710	pathogenesis in t-cell leukemia	[pathogenesis in T-cell leukemia]	0.0	4	1	1	1
102103	1710	RESULTS: the number of receptor	[RESULTS: The number of receptors]	0.0	5	1	1	1
102104	1710	variety of response	[variety of responses]	0.0	3	1	1	1
102105	1710	interaction site	[interaction site]	0.0	2	1	1	1
102106	1710	vd response element	[VD response element]	0.0	3	1	1	1
102107	1710	nuclear factor ms-2	[nuclear factor MS-2]	0.0	3	1	1	1
102108	1710	E1A sensitization to apoptosis	[E1A sensitization to apoptosis]	0.0	4	1	1	1
102109	1710	use site-directed mutagenesis	[Using site-directed mutagenesis]	0.0	3	1	1	1
102110	1710	physiological glucocorticoid	[physiological glucocorticoid]	0.0	2	1	1	1
102111	1710	pathway distinct from translocation	[pathway distinct from translocation]	0.0	4	1	1	1
102112	1710	up pnu156804	[UP PNU156804]	0.0	2	1	1	1
102113	1710	nitric oxide a autoregulatory feedback inhibitor	[nitric oxide an autoregulatory feedback inhibitor]	0.0	6	1	1	1
102114	1710	case of t-cell lymphoma	[cases of T-cell lymphoma]	0.0	4	1	1	1
102115	1710	granule from human neutrophil	[granules from human neutrophils]	0.0	4	1	1	1
102116	1710	downregulation of interleukin-2	[downregulation of interleukin-2]	0.0	3	1	1	1
102117	1710	lead to stat-1 activation	[leading to STAT-1 activation]	0.0	4	1	1	1
102118	1710	protein kinase/c-Jun NH2-terminal kinase	[protein kinase/c-Jun NH2-terminal kinases]	0.0	4	1	1	1
102119	1710	glucocorticoid type ii receptor gcii	[glucocorticoid type II receptor GCII]	0.0	5	1	1	1
102120	1710	contain the human gamma ECS	[containing the human gamma ECS]	0.0	5	1	1	1
102121	1710	95-kDa protein	[95-kDa protein]	0.0	2	1	1	1
102122	1710	adhesion molecule induction	[adhesion molecule induction]	0.0	3	1	1	1
102123	1710	sites/cell), kd value	[sites/cell), Kd values]	0.0	3	1	1	1
102124	1710	expression pattern from the virus,	[expression patterns from the virus,]	0.0	5	1	1	1
102125	1710	effect on promoter activity	[effect on promoter activity]	0.0	4	1	1	1
102126	1710	peptide represent the NH2 terminus	[peptide representing the NH2 terminus]	0.0	5	1	1	1
102127	1710	offersugg a aspect	[offersuggesting a aspect]	0.0	3	1	1	1
102128	1710	specific antagonist	[specific antagonists]	0.0	2	1	1	1
102129	1710	adaptor addition	[adaptors addition]	0.0	2	1	1	1
102130	1710	state of a Th1 cell	[state of a Th1 cell]	0.0	5	1	1	1
102131	1710	mutational analysis of the CD19 promoter	[mutational analysis of the CD19 promoter]	0.0	6	1	1	1
102132	1710	activity of tepoxalin a potential	[activity of tepoxalin a potential]	0.0	5	1	1	1
102133	1710	human tsp -chloramphenicol acetyltransferase construct	[human TSP -chloramphenicol acetyltransferase constructs]	0.0	5	1	1	1
102134	1710	suggest a property of gene	[suggesting a property of genes]	0.0	5	1	1	1
102135	1710	role in IL-2 t-cell transformation	[role in IL-2 T-cell transformation]	0.0	5	1	1	1
102136	1710	cooperative interaction between b transcriptional coactivator	[cooperative interactions between B transcriptional coactivators]	0.0	6	1	1	1
102137	1710	improve the definition at the level.	[improving the definitions at the level.]	0.0	6	1	1	1
102138	1710	experiment involve proviral clone	[experiments involving proviral clones]	0.0	4	1	1	1
102139	1710	difference among the three group	[difference among the three groups]	0.0	5	1	1	1
102140	1710	expression in skin	[Expression in skin]	0.0	3	1	1	1
102141	1710	blood assay	[blood assays]	0.0	2	1	1	1
102142	1710	acute megakaryoblastic leukemia	[Acute megakaryoblastic leukemia]	0.0	3	1	1	1
102143	1710	4 transcription	[4 transcription]	0.0	2	1	1	1
102144	1710	factor almost completely,	[factor almost completely,]	0.0	3	1	1	1
102145	1710	cytogenetic change present	[cytogenetic change present]	0.0	3	1	1	1
102146	1710	signal signal alone without signal 1	[signal signal alone without signal 1]	0.0	6	1	1	1
102147	1710	b- cell stage	[B- cell stages]	0.0	3	1	1	1
102148	1710	u-937 promonocytic cell	[U-937 promonocytic cells]	0.0	3	1	1	1
102149	1710	homozygous a	[homozygous A]	0.0	2	1	1	1
102150	1710	model of differentiation	[model of differentiation]	0.0	3	1	1	1
102151	1710	mutant of type	[Mutants of type]	0.0	3	1	1	1
102152	1710	massive enhancement HL 60 cell	[massive enhancement HL 60 cells]	0.0	5	1	1	1
102153	1710	staining for c/ebp beta	[staining for C/EBP beta]	0.0	4	1	1	1
102154	1710	negative inhibitor	[negative inhibitor]	0.0	2	2	2	1
102155	1710	lineage-specific activation	[Lineage-specific activation]	0.0	2	1	1	1
102156	1710	major increase	[major increase]	0.0	2	1	1	1
102157	1710	much good transactivator	[much better transactivator]	0.0	3	1	1	1
102158	1710	residual disease in acute myelogenous leukemia	[residual disease in acute myelogenous leukemia]	0.0	6	1	1	1
102159	1710	however, in contrast to the endotoxin,	[However, in contrast to the endotoxin,]	0.0	6	1	1	1
102160	1710	ouabain resistant,	[ouabain resistant,]	0.0	2	1	1	1
102161	1710	end of NFATx1	[end of NFATx1]	0.0	3	1	1	1
102162	1710	12 ad patient	[12 AD patients]	0.0	3	1	1	1
102163	1710	bind the "octamer" binding protein	[binding the "octamer" binding proteins]	0.0	5	1	1	1
102164	1710	However, BAL content	[However, BAL content]	0.0	3	1	1	1
102165	1710	reactive oxygen intermediate -release	[Reactive oxygen intermediate -release]	0.0	4	1	1	1
102166	1710	change of the thymocyte	[changes of the thymocyte]	0.0	4	1	1	1
102167	1710	x-ray-treated carcinoma cell line	[X-ray-treated carcinoma cell line]	0.0	4	1	1	1
102168	1710	signal pathway use a combination	[signaling pathways using a combination]	0.0	5	1	1	1
102169	1710	implication for the treatment of asthma	[implications for the treatment of asthma]	0.0	6	1	1	1
102170	1710	chemotherapy follow atra therapy	[chemotherapy following ATRA therapy]	0.0	4	1	1	1
102171	1710	measure blood plasma triidothyronine	[measuring blood plasma triidothyronine]	0.0	4	1	1	1
102172	1710	mechanisms, such as the one	[mechanisms, such as the one]	0.0	5	1	1	1
102173	1710	retain either	[retaining either]	0.0	2	1	1	1
102174	1710	undefined role	[undefined role]	0.0	2	1	1	1
102175	1710	(10-fold expansion) occur	[(10-fold expansion) occurring]	0.0	3	1	1	1
102176	1710	aids -c group 0.8	[AIDS -C group 0.8]	0.0	4	1	1	1
102177	1710	"stem cell" disorder	["stem cell" disorders]	0.0	3	1	1	1
102178	1710	physiologically, level of nuclear of p50	[physiologically, levels of nuclear of p50]	0.0	6	1	1	1
102179	1710	gene encode primary granule protein	[genes encoding primary granule proteins]	0.0	5	1	1	1
102180	1710	tcr-regulated nuclear factor	[TCR-regulated nuclear factor]	0.0	3	1	1	1
102181	1710	1 replication in monocyte	[1 replication in monocytes]	0.0	4	1	1	1
102182	1710	preferential suppression	[preferential suppression]	0.0	2	1	1	1
102183	1710	blast crisis	[blast crisis]	0.0	2	1	1	1
102184	1710	major disorder MDD in adolescent	[Major disorder MDD in adolescents]	0.0	5	1	1	1
102185	1710	growth inhibition without evidence of differentiation	[growth inhibition without evidence of differentiation]	0.0	6	1	1	1
102186	1710	effect on proteasomal degradation	[effect on proteasomal degradation]	0.0	4	1	1	1
102187	1710	progression of malignancy	[progression of malignancies]	0.0	3	2	2	1
102188	1710	function of iNO	[function of iNO]	0.0	3	1	1	1
102189	1710	synthase NOS	[synthase NOS]	0.0	2	1	1	1
102190	1710	twelve amino acid peptide	[Twelve amino acid peptides]	0.0	4	1	1	1
102191	1710	expression of laz3/bcl6 in center	[Expression of LAZ3/BCL6 in center]	0.0	5	1	1	1
102192	1710	physiologically relevant inhibitor in cell	[physiologically relevant inhibitor in cells]	0.0	5	1	1	1
102193	1710	combination of different promoter	[combinations of different promoters]	0.0	4	1	1	1
102194	1710	-contain leukocyte protein of kD	[-containing leukocyte protein of kD]	0.0	5	1	1	1
102195	1710	region responsible for the activity	[region responsible for the activity]	0.0	5	1	1	1
102196	1710	metabolite include benzoquinone BQ	[metabolites including benzoquinone BQ]	0.0	4	1	1	1
102197	1710	support variable	[support variable]	0.0	2	1	1	1
102198	1710	encode oct-binding factor	[encoding Oct-binding factor]	0.0	3	1	1	1
102199	1710	n-acetyl-L-cysteine NAC	[n-acetyl-L-cysteine NAC]	0.0	2	1	1	1
102200	1710	CD28 complex cd28rc	[CD28 complex CD28RC]	0.0	3	1	1	1
102201	1710	complete tolerance for human tcf-1	[complete tolerance for human TCF-1]	0.0	5	1	1	1
102202	1710	total rna in monocyte	[total RNA in monocytes]	0.0	4	1	1	1
102203	1710	interleukin-12 a key signal	[interleukin-12 a key signal]	0.0	4	1	1	1
102204	1710	use of antibody	[use of antibodies]	0.0	3	1	1	1
102205	1710	vitro degradation	[vitro degradation]	0.0	2	1	1	1
102206	1710	group type ii	[group type II]	0.0	3	1	1	1
102207	1710	formation of the nuclear factor	[formation of the nuclear factor]	0.0	5	1	1	1
102208	1710	potential target for drug therapy	[potential target for drug therapy]	0.0	5	1	1	1
102209	1710	certain individual of complex (mhc) haplotype	[certain individuals of complex (MHC) haplotypes]	0.0	6	1	1	1
102210	1710	step in other cell systems.	[step in other cell systems.]	0.0	5	1	1	1
102211	1710	cd1+relb+ cell DC	[CD1+relB+ cells DC]	0.0	3	1	1	1
102212	1710	aspect of the signalling network	[aspects of the signalling network]	0.0	5	1	1	1
102213	1710	MHC class gene factor	[MHC class gene factor]	0.0	4	1	1	1
102214	1710	various breakpoint on chromosome range	[various breakpoints on chromosome ranging]	0.0	5	1	1	1
102215	1710	cell of CLL patient	[cells of CLL patients]	0.0	4	1	1	1
102216	1710	nab	[NaB]	0.0	1	1	1	1
102217	1710	c-fo mrna level in monocyte	[c-fos mRNA levels in monocytes]	0.0	5	1	1	1
102218	1710	include granuloma formation	[including granuloma formation]	0.0	3	1	1	1
102219	1710	human bcl6 (hbcl6) cDNA	[human BCL6 (hBCL6) cDNA]	0.0	4	1	1	1
102220	1710	B29 promoter in absence.	[B29 promoter in absence.]	0.0	4	1	1	1
102221	1710	region of the cytoplasmic domain	[region of the cytoplasmic domain]	0.0	5	1	1	1
102222	1710	(srf)	[(SRF)]	0.0	1	1	1	1
102223	1710	such cofactor	[such cofactor]	0.0	2	1	1	1
102224	1710	increase physical exercise	[increasing physical exercise]	0.0	3	1	1	1
102225	1710	G3AG4AG3	[G3AG4AG3]	0.0	1	1	1	1
102226	1710	epithelial (h292) cell-line dexamethasone basal	[epithelial (H292) cell-line dexamethasone basal]	0.0	5	1	1	1
102227	1710	myeloid-associated growth factor	[myeloid-associated growth factor]	0.0	3	1	1	1
102228	1710	cd4+ t-cell deletion	[CD4+ T-cell deletion]	0.0	3	1	1	1
102229	1710	nbt	[NBT]	0.0	1	1	1	1
102230	1710	blood mononuclear leukocyte of patient	[blood mononuclear leukocytes of patients]	0.0	5	1	1	1
102231	1710	downstream nf-kappab activation of repeat	[downstream NF-kappaB activation of repeat]	0.0	5	1	1	1
102232	1710	major cis element	[major cis elements]	0.0	3	1	1	1
102233	1710	role for ceramide release	[role for ceramide release]	0.0	4	1	1	1
102234	1710	Epstein-Barr nuclear antigen EBNA	[Epstein-Barr nuclear antigen EBNA]	0.0	4	1	1	1
102235	1710	represent endocrine lineage use antisera	[representing endocrine lineages using antisera]	0.0	5	1	1	1
102236	1710	role in proliferation of cell	[roles in proliferation of cells]	0.0	5	1	1	1
102237	1710	acute leukemia the microgranular variant	[acute leukemia the microgranular variant]	0.0	5	1	1	1
102238	1710	40-bp region	[40-bp region]	0.0	2	1	1	1
102239	1710	detection of other signal protein	[Detection of other signaling proteins]	0.0	5	1	1	1
102240	1710	surface ag receptor	[surface Ag receptor]	0.0	3	1	1	1
102241	1710	treatment of T	[Treatment of T]	0.0	3	1	1	1
102242	1710	Jak -stat 1 signal pathway	[Jak -STAT 1 signaling pathway]	0.0	5	1	1	1
102243	1710	receptor in leukocyte in subject	[receptors in leukocytes in subjects]	0.0	5	1	1	1
102244	1710	other nonselective RAR ligand	[other nonselective RAR ligands]	0.0	4	1	1	1
102245	1710	various estrogen	[various estrogens]	0.0	2	1	1	1
102246	1710	overt homology to the BH1 domain	[overt homology to the BH1 domains]	0.0	6	1	1	1
102247	1710	analysis with recombinant hugata-3	[analysis with recombinant huGATA-3]	0.0	4	1	1	1
102248	1710	namely activator protein-1 factor il-6	[namely activator protein-1 factor IL-6]	0.0	5	1	1	1
102249	1710	naive neonatal T lymphocyte	[naive neonatal T lymphocytes]	0.0	4	1	1	1
102250	1710	promoter in monocytic cell	[promoters in monocytic cells]	0.0	4	1	1	1
102251	1710	induction of interferon protein follow differentiation	[induction of interferon protein following differentiation]	0.0	6	1	1	1
102252	1710	affinity aldosterone binding	[affinity aldosterone binding]	0.0	3	1	1	1
102253	1710	monomeric form	[monomeric form]	0.0	2	1	1	1
102254	1710	patient p	[patients P]	0.0	2	1	1	1
102255	1710	correlation between bind affinity	[correlation between binding affinity]	0.0	4	1	1	1
102256	1710	rule with the surface domain	[rules with the surface domain]	0.0	5	1	1	1
102257	1710	even with a therapy specific	[Even with a therapy specific]	0.0	5	1	1	1
102258	1710	induction of GR mrna	[induction of GR mRNA]	0.0	4	1	1	1
102259	1710	recognizable association	[recognizable association]	0.0	2	1	1	1
102260	1710	immunohistochemical analysis of mononuclear	[immunohistochemical analysis of mononuclear]	0.0	4	1	1	1
102261	1710	dermatomyositis/polymyositis	[dermatomyositis/polymyositis]	0.0	1	1	1	1
102262	1710	Cytokine	[Cytokine]	0.0	1	1	1	1
102263	1710	expression of rna	[expression of RNA]	0.0	3	1	1	1
102264	1710	presence of stimulation	[presence of stimulation]	0.0	3	1	1	1
102265	1710	least one relative;	[least one relative;]	0.0	3	1	1	1
102266	1710	stimulation of activity,	[stimulation of activity,]	0.0	3	1	1	1
102267	1710	anti- ptf beta antibody	[anti- PTF beta antibodies]	0.0	4	1	1	1
102268	1710	human cell-based assay	[human cell-based assay]	0.0	3	1	1	1
102269	1710	selective activity of interleukin-10 stat molecule	[Selective activity of interleukin-10 STAT molecules]	0.0	6	1	1	1
102270	1710	activity of the proteasome	[activity of the proteasome]	0.0	4	1	1	1
102271	1710	apoptosis effector	[apoptosis effector]	0.0	2	1	1	1
102272	1710	vitro with transcriptional activity	[vitro with transcriptional activity]	0.0	4	1	1	1
102273	1710	expression on the surface	[expression on the surface]	0.0	4	1	1	1
102274	1710	intracellular signalling molecule	[intracellular signalling molecules]	0.0	3	1	1	1
102275	1710	generation of ldl putative molecule	[generation of LDL putative molecule]	0.0	5	1	1	1
102276	1710	analysis of p40	[analyses of p40]	0.0	3	1	1	1
102277	1710	trypsin digestion of antiandrogen	[trypsin digestion of antiandrogen]	0.0	4	1	1	1
102278	1710	E1A -positive sarcoma cell	[E1A -positive sarcoma cells]	0.0	4	1	1	1
102279	1710	vitro production	[vitro production]	0.0	2	1	1	1
102280	1710	member of the NF-kappa B family	[members of the NF-kappa B family]	0.0	6	2	2	1
102281	1710	significant difference between EBNA-2 extract	[significant differences between EBNA-2 extracts]	0.0	5	1	1	1
102282	1710	cotransfection in sense orientation tata	[cotransfection in sense orientation tat/S]	0.0	5	1	1	1
102283	1710	b -binding element	[B -binding elements]	0.0	3	1	1	1
102284	1710	protein c/ebp alpha	[protein C/EBP alpha]	0.0	3	1	1	1
102285	1710	different pattern of response	[different patterns of responses]	0.0	4	1	1	1
102286	1710	also terminal	[also terminals]	0.0	2	1	1	1
102287	1710	number of receptor on leukocyte	[number of receptors on leukocytes]	0.0	5	1	1	1
102288	1710	murine macrophage protein	[Murine macrophage protein]	0.0	3	1	1	1
102289	1710	sucrose gradient fraction	[sucrose gradient fractions]	0.0	3	1	1	1
102290	1710	long isoform in T cell	[long isoforms in T cells]	0.0	5	1	1	1
102291	1710	CD3 /il-2	[CD3 /IL-2]	0.0	2	1	1	1
102292	1710	tyrosine phosphorylation of several protein	[tyrosine phosphorylation of several proteins]	0.0	5	1	1	1
102293	1710	ig isotype switch	[Ig isotype switching]	0.0	3	1	1	1
102294	1710	underlie phenomena.	[underlying phenomena.]	0.0	2	1	1	1
102295	1710	involve sexual differentiation in male	[involving sexual differentiation in males]	0.0	5	1	1	1
102296	1710	necessity for alignment	[necessity for alignment]	0.0	3	1	1	1
102297	1710	partitioning	[Partitioning]	0.0	1	1	1	1
102298	1710	morphology aml	[morphology AML]	0.0	2	1	1	1
102299	1710	lipoarabinomannan of mycobacterium tuberculosis	[lipoarabinomannan of Mycobacterium tuberculosis]	0.0	4	1	1	1
102300	1710	kind the steroid-MR complex	[kinds the steroid-MR complex]	0.0	4	1	1	1
102301	1710	m-crf:	[M-CRF:]	0.0	1	1	1	1
102302	1710	EA-D BMRF1	[EA-D BMRF1]	0.0	2	1	1	1
102303	1710	PILOT	[PILOT]	0.0	1	1	1	1
102304	1710	activation, block	[activation, blocks]	0.0	2	1	1	1
102305	1710	localization signal (89	[localization signal (89]	0.0	3	1	1	1
102306	1710	sequence (-7.0 kb)	[sequence (-7.0 kb)]	0.0	3	1	1	1
102307	1710	response with macrophage activation	[response with macrophage activation]	0.0	4	1	1	1
102308	1710	cyclic load	[cyclic load]	0.0	2	1	1	1
102309	1710	epidemiologic feature	[epidemiologic features]	0.0	2	1	1	1
102310	1710	Uneven x inactivation	[Uneven X inactivation]	0.0	3	1	1	1
102311	1710	models,	[models,]	0.0	1	1	1	1
102312	1710	models.	[models.]	0.0	1	1	1	1
102313	1710	p.,	[P.,]	0.0	1	1	1	1
102314	1710	induction, superinfection with ebv	[induction, superinfection with EBV]	0.0	4	1	1	1
102315	1710	therefore action of sex steroid hormone	[therefore actions of sex steroid hormones]	0.0	6	1	1	1
102316	1710	molecular mass 50000 (50k)	[molecular mass 50,000 (50K)]	0.0	4	1	1	1
102317	1710	carboxyl-terminal amino acid (aa)	[carboxyl-terminal amino acids (aa)]	0.0	4	1	1	1
102318	1710	RXR alpha in differentiation	[RXR alpha in differentiation]	0.0	4	1	1	1
102319	1710	24-hour incubation	[24-hour incubation]	0.0	2	1	1	1
102320	1710	transient membrane hyperpolarization	[transient membrane hyperpolarization]	0.0	3	1	1	1
102321	1710	frequent emergence of resistant variant	[frequent emergence of resistant variants]	0.0	5	1	1	1
102322	1710	standard treatment of attack	[standard treatment of attacks]	0.0	4	1	1	1
102323	1710	h for culture	[h for cultures]	0.0	3	1	1	1
102324	1710	bind to specific intracellular domain sequence	[binding to specific intracellular domain sequences]	0.0	6	1	1	1
102325	1710	2000 mu/l insulin	[2,000 mU/L insulin]	0.0	3	1	1	1
102326	1710	dex cell	[dex cells]	0.0	2	1	1	1
102327	1710	combination of this two transcription factor	[combinations of these two transcription factors]	0.0	6	1	1	1
102328	1710	induction in promyelocytic leukemia cell	[Induction in promyelocytic leukemia cells]	0.0	5	1	1	1
102329	1710	induction 1 (egr-1) gene expression	[induction 1 (EGR-1) gene expression]	0.0	5	1	1	1
102330	1710	activation in monocyte	[activation in monocytes]	0.0	3	1	1	1
102331	1710	new donor rar-alpha cd4(+) t-cell clone	[new donor RAR-alpha CD4(+) T-cell clones]	0.0	6	1	1	1
102332	1710	expression of CTCF	[expression of CTCF]	0.0	3	1	1	1
102333	1710	endothelia	[endothelia]	0.0	1	1	1	1
102334	1710	D3 on myelopoiesis	[D3 on myelopoiesis]	0.0	3	1	1	1
102335	1710	(6,7-3h) estradiol 3h-e2	[(6,7-3H) estradiol 3H-E2]	0.0	3	1	1	1
102336	1710	change to motifs, site alpha	[changes to motifs, site alpha]	0.0	5	1	1	1
102337	1710	activation of interleukin-1beta in cells,	[activation of interleukin-1beta in cells,]	0.0	5	1	1	1
102338	1710	other protein in platelet	[other proteins in platelets]	0.0	4	1	1	1
102339	1710	induction of 24-hydroxylase mrna level	[induction of 24-hydroxylase mRNA levels]	0.0	5	1	1	1
102340	1710	hydrogen peroxide at microM,	[hydrogen peroxide at microM,]	0.0	4	1	1	1
102341	1710	nls	[NLS]	0.0	1	1	1	1
102342	1710	supernatant from RCC explant	[supernatants from RCC explants]	0.0	4	1	1	1
102343	1710	patient less than ng angiotensin i/l	[Patients less than ng angiotensin I/L]	0.0	6	1	1	1
102344	1710	OCTA enhancer activity	[OCTA enhancer activity]	0.0	3	1	1	1
102345	1710	consensus sequences,	[consensus sequences,]	0.0	2	1	1	1
102346	1710	impairment in T cell	[impairments in T cells]	0.0	4	1	1	1
102347	1710	chloramphenicol acetyl-transferase	[chloramphenicol acetyl-transferase]	0.0	2	1	1	1
102348	1710	govern lineage	[governing lineage]	0.0	2	1	1	1
102349	1710	inhibition occur at a dose	[inhibition occurring at a dose]	0.0	5	1	1	1
102350	1710	similar pattern of tissue specificity	[similar patterns of tissue specificity]	0.0	5	1	1	1
102351	1710	inactivation in fibroblast	[inactivation in fibroblasts]	0.0	3	1	1	1
102352	1710	protein crucial to embryogenesis	[proteins crucial to embryogenesis]	0.0	4	1	1	1
102353	1710	transcriptional effect on the hiv-1 promoter	[transcriptional effects on the HIV-1 promoters]	0.0	6	1	1	1
102354	1710	12-0-tetradecanoyl phorbol-13-acetate	[12-0-tetradecanoyl phorbol-13-acetate]	0.0	2	1	1	1
102355	1710	lipopolysaccharide induction in cell	[lipopolysaccharide induction in cells]	0.0	4	1	1	1
102356	1710	AML1/CBF	[AML1/CBF]	0.0	1	1	1	1
102357	1710	imaging	[imaging]	0.0	1	1	1	1
102358	1710	p21	[p21]	0.0	1	1	1	1
102359	1710	finding synergistic in mouse	[findings synergistic in mice]	0.0	4	1	1	1
102360	1710	3610 (range, 2594-3979)	[3610 (range, 2594-3979)]	0.0	3	1	1	1
102361	1710	response in perennial rhinitis	[Response in perennial rhinitis]	0.0	4	1	1	1
102362	1710	dpii,	[DP-I,]	0.0	1	1	1	1
102363	1710	lavage t-lymphocyte from patient	[Lavage T-lymphocytes from patients]	0.0	4	1	1	1
102364	1710	immunophenotype of idc	[immunophenotype of IDCs]	0.0	3	1	1	1
102365	1710	different promoters, anf-e2 promoter	[different promoters, aNF-E2 promoter]	0.0	4	1	1	1
102366	1710	framework signal in phagocyte	[framework signaling in phagocytes]	0.0	4	1	1	1
102367	1710	ED50 cortisol concentration	[ED50 cortisol concentration]	0.0	3	1	1	1
102368	1710	enzyme for interleukin (il)-2	[enzyme for interleukin (IL)-2]	0.0	4	1	1	1
102369	1710	unresponsive cell	[unresponsive cells]	0.0	2	1	1	1
102370	1710	ectopic expression of a transcription factor	[ectopic expression of a transcription factor]	0.0	6	1	1	1
102371	1710	counteract 5' DNA sequence	[counteracting 5' DNA sequences]	0.0	4	1	1	1
102372	1710	increase recognition	[increasing recognition]	0.0	2	1	1	1
102373	1710	three, DNA variation 2418delA in tumor	[three, DNA variations 2418delA in tumor]	0.0	6	1	1	1
102374	1710	host erythrocyte	[host erythrocytes]	0.0	2	1	1	1
102375	1710	specific action on expression	[specific actions on expression]	0.0	4	1	1	1
102376	1710	p35	[p35]	0.0	1	1	1	1
102377	1710	potential in hiv-1 -infected patient	[potential in HIV-1 -infected patients]	0.0	5	1	1	1
102378	1710	various markers,	[various markers,]	0.0	2	1	1	1
102379	1710	mesenchymal cell include fibroblast	[mesenchymal cells including fibroblasts]	0.0	4	1	1	1
102380	1710	include DHEA sulfate	[including DHEA sulfate]	0.0	3	1	1	1
102381	1710	expansion) occur between day 7	[expansion) occurring between day 7]	0.0	5	1	1	1
102382	1710	HeLa,	[HeLa,]	0.0	1	1	1	1
102383	1710	npc	[NPC]	0.0	1	1	1	1
102384	1710	p4)	[P4)]	0.0	1	1	1	1
102385	1710	reverse primer	[reverse primer]	0.0	2	1	1	1
102386	1710	epithelial icam-1	[epithelial ICAM-1]	0.0	2	1	1	1
102387	1710	high proliferative potential 47.10 cell	[high proliferative potential 47.10 cells]	0.0	5	1	1	1
102388	1710	facet to understanding of biology	[facet to understanding of biology]	0.0	5	1	1	1
102389	1710	complex with the gata site	[complex with the GATA site]	0.0	5	1	1	1
102390	1710	effect for zk157202	[effect for ZK157202]	0.0	3	1	1	1
102391	1710	lac operon	[lac operon]	0.0	2	1	1	1
102392	1710	IFN a	[IFN A]	0.0	2	1	1	1
102393	1710	3-o-methyl-d glucose	[3-O-methyl-D glucose]	0.0	2	1	1	1
102394	1710	protein related to Stat1	[protein related to Stat1]	0.0	4	1	1	1
102395	1710	consequent formation of binding heterodimers,	[consequent formation of binding heterodimers,]	0.0	5	1	1	1
102396	1710	interferon factor gene	[interferon factor gene]	0.0	3	1	1	1
102397	1710	replication isolate	[replication isolate]	0.0	2	1	1	1
102398	1710	2.3-kb tcr delta transcript	[2.3-kb TcR delta transcript]	0.0	4	1	1	1
102399	1710	dna-binding specificity mutant	[DNA-binding specificity mutants]	0.0	3	1	1	1
102400	1710	receptor on non-T cell	[receptors on non-T cells]	0.0	4	2	2	1
102401	1710	concurrent enhancement of non- lps uptake	[concurrent enhancement of non- LPS uptake]	0.0	6	1	1	1
102402	1710	p57	[p57]	0.0	1	1	1	1
102403	1710	apolar substitution alpha-methyl, 11 alpha-fluoromethyl	[apolar substitutions alpha-methyl, 11 alpha-fluoromethyl]	0.0	5	1	1	1
102404	1710	rate of transmission	[rate of transmission]	0.0	3	1	1	1
102405	1710	gradually accumulating, long-lasting tyrosine	[gradually accumulating, long-lasting tyrosine]	0.0	4	1	1	1
102406	1710	STP-A11	[STP-A11]	0.0	1	1	1	1
102407	1710	two cytokine systems,	[two cytokine systems,]	0.0	3	1	1	1
102408	1710	identification of inhibitor of b activation	[Identification of inhibitors of B activation]	0.0	6	1	1	1
102409	1710	rest normal lymphocyte	[resting normal lymphocytes]	0.0	3	1	1	1
102410	1710	maintain survival	[maintaining survival]	0.0	2	1	1	1
102411	1710	use nuclear extract from human eosinophil	[using nuclear extracts from human eosinophils]	0.0	6	1	1	1
102412	1710	novel IL-2 inhibitor	[novel IL-2 inhibitors]	0.0	3	1	1	1
102413	1710	expression of rar	[expression of RARs]	0.0	3	1	1	1
102414	1710	human saphenous vein endothelial cell	[human saphenous vein endothelial cells]	0.0	5	1	1	1
102415	1710	immunoglobulin chain gene rearrangement	[immunoglobulin chain gene rearrangement]	0.0	4	1	1	1
102416	1710	colour fish analysis use specific probe	[colour FISH analysis using specific probes]	0.0	6	1	1	1
102417	1710	erythroid-specific footprint	[erythroid-specific footprint]	0.0	2	1	1	1
102418	1710	zebra z(s186a)	[ZEBRA Z(S186A)]	0.0	2	1	1	1
102419	1710	gene (nf)-kappab pathway	[genes (NF)-kappaB pathway]	0.0	3	1	1	1
102420	1710	malfunction of the glucocorticoid response	[malfunction of the glucocorticoid response]	0.0	5	1	1	1
102421	1710	short region -73	[short region -73]	0.0	3	1	1	1
102422	1710	slightly on epidermal basal cell	[slightly on epidermal basal cells]	0.0	5	1	1	1
102423	1710	role of cyclic AMP response protein	[Role of cyclic AMP response protein]	0.0	6	1	1	1
102424	1710	prognostic indicator of progression	[prognostic indicator of progression]	0.0	4	1	1	1
102425	1710	only the addition	[only the addition]	0.0	3	1	1	1
102426	1710	immunodeficiency virus monocyte	[immunodeficiency virus monocytes]	0.0	3	1	1	1
102427	1710	binding site for testosterone	[Binding sites for testosterone]	0.0	4	1	1	1
102428	1710	involvement (tnfr)-associated factor	[involvement (TNFR)-associated factors]	0.0	3	1	1	1
102429	1710	more permanent th2 phenotype	[more permanent Th2 phenotype]	0.0	4	1	1	1
102430	1710	endocrine lineage	[endocrine lineages]	0.0	2	1	1	1
102431	1710	position in the reciprocal product	[position in the reciprocal products]	0.0	5	1	1	1
102432	1710	receptor binding specificity	[receptor binding specificity]	0.0	3	1	1	1
102433	1710	Intimate interaction between multipotential stem cell	[Intimate interactions between multipotential stem cells]	0.0	6	1	1	1
102434	1710	2 micrograms/day for day	[2 micrograms/day for days)]	0.0	4	1	1	1
102435	1710	Throger 102	[Thr 102]	0.0	2	1	1	1
102436	1710	hiv-1 therapy	[HIV-1 therapy]	0.0	2	1	1	1
102437	1710	activator phorbol	[activator phorbol]	0.0	2	1	1	1
102438	1710	activation-dependent expression of important protein	[activation-dependent expression of important proteins]	0.0	5	1	1	1
102439	1710	oct-2 gene	[Oct-2 gene]	0.0	2	1	1	1
102440	1710	antigenic region	[antigenic region]	0.0	2	1	1	1
102441	1710	involvement of a transcription factor	[Involvement of an transcription factor]	0.0	5	1	1	1
102442	1710	2 pre-B lymphoblastic leukemia all	[2 pre-B lymphoblastic leukemia ALL]	0.0	5	1	1	1
102443	1710	express nuclear protein	[expressed, nuclear protein]	0.0	3	1	1	1
102444	1710	retinoid include acid	[Retinoids including acid]	0.0	3	1	1	1
102445	1710	blood cell in individual	[blood cells in individuals]	0.0	4	1	1	1
102446	1710	[corrected]	[[corrected]]	0.0	1	1	1	1
102447	1710	La(SSB) T cell	[La(SSB) T cells]	0.0	3	1	1	1
102448	1710	impaired activation of the transcription factor	[impaired activation of the transcription factor]	0.0	6	1	1	1
102449	1710	other ATL cell line	[other ATL cell lines]	0.0	4	1	1	1
102450	1710	transcriptional enhancer of gene	[transcriptional enhancers of genes]	0.0	4	1	1	1
102451	1710	t(15;17) leukemia APL	[t(15;17) leukemia APL]	0.0	3	1	1	1
102452	1710	(1) multiple inactivate nucleotide substitution	[(1) multiple inactivating nucleotide substitutions]	0.0	5	1	1	1
102453	1710	CD8 contribution	[CD8 contribution]	0.0	2	1	1	1
102454	1710	multiple positive regulatory element	[multiple positive regulatory elements]	0.0	4	1	1	1
102455	1710	nonresponsive progenitor	[nonresponsive progenitors]	0.0	2	1	1	1
102456	1710	plasma IFN alpha	[plasma IFN alpha]	0.0	3	1	1	1
102457	1710	alone	[alone;]	0.0	1	1	1	1
102458	1710	concentration of mumol/L,	[concentration of mumol/L,]	0.0	3	1	1	1
102459	1710	function of cbp/p300 other	[functions of CBP/p300 other]	0.0	4	1	1	1
102460	1710	multiple somatic mutation a proto-oncogene encoding	[multiple somatic mutations a proto-oncogene encoding]	0.0	6	1	1	1
102461	1710	T cell leukemia/lymphoma	[T cell leukemia/lymphoma]	0.0	3	1	1	1
102462	1710	woman with PIH	[women with PIH]	0.0	3	1	1	1
102463	1710	level of p50 homodimer	[levels of p50 homodimer]	0.0	4	1	1	1
102464	1710	cause resistance	[causing resistance]	0.0	2	1	1	1
102465	1710	combination of all-tran acid RA	[combination of all-trans acid RA]	0.0	5	2	2	1
102466	1710	overexpression of receptor kinase	[Overexpression of receptor kinase]	0.0	4	1	1	1
102467	1710	thioctic acid	[thioctic acid]	0.0	2	1	1	1
102468	1710	binding of erythroid nuclear protein	[Binding of erythroid nuclear proteins]	0.0	5	1	1	1
102469	1710	macrophage in atherosclerotic lesion	[macrophages in atherosclerotic lesions]	0.0	4	1	1	1
102470	1710	three different form	[three different forms]	0.0	3	1	1	1
102471	1710	double time of 25 h (viability	[doubling times of 25 h (viability]	0.0	6	1	1	1
102472	1710	cellular redox state.	[cellular redox state.]	0.0	3	1	1	1
102473	1710	cell carcinoma SCC	[cell carcinomas SCCs]	0.0	3	1	1	1
102474	1710	CRE -cat plasmide	[CRE -CAT plasmide]	0.0	3	1	1	1
102475	1710	partitioning into red blood cell	[Partitioning into red blood cells]	0.0	5	1	1	1
102476	1710	amount of iron result	[amount of iron resulting]	0.0	4	1	1	1
102477	1710	recently, mononuclear leukocyte	[recently, mononuclear leukocytes]	0.0	3	1	1	1
102478	1710	regulation expression	[regulation expression]	0.0	2	1	1	1
102479	1710	early induction	[early induction]	0.0	2	1	1	1
102480	1710	25-dihydroxyvitamin D3	[25-dihydroxyvitamin D3]	0.0	2	1	1	1
102481	1710	region contain repeat of bp	[region containing repeats of bp]	0.0	5	1	1	1
102482	1710	vivo interaction	[vivo interaction]	0.0	2	1	1	1
102483	1710	differentiation of k562 leukemia cell	[differentiation of K562 leukemia cells]	0.0	5	1	1	1
102484	1710	receptor for Dihydroxyvitamin D3	[receptors for Dihydroxyvitamin D3]	0.0	4	1	1	1
102485	1710	aberrant er form in tumour	[aberrant ER forms in tumours]	0.0	5	1	1	1
102486	1710	change present	[change present]	0.0	2	1	1	1
102487	1710	77 +/- 16 versus +/-	[77 +/- 16 versus +/-]	0.0	5	1	1	1
102488	1710	lymphoid factor in vivo	[lymphoid factor in vivo]	0.0	4	1	1	1
102489	1710	genomic footprint	[genomic footprint]	0.0	2	1	1	1
102490	1710	fundamental cellular processes,	[fundamental cellular processes,]	0.0	3	1	1	1
102491	1710	different cytosolic protein	[different cytosolic protein]	0.0	3	1	1	1
102492	1710	other primate	[other primates]	0.0	2	1	1	1
102493	1710	NF-Y subunit expression	[NF-Y subunit expression]	0.0	3	1	1	1
102494	1710	Retroviral transduction of RA receptor	[Retroviral transduction of RA receptor]	0.0	5	1	1	1
102495	1710	alkaline phosphatase activity	[alkaline phosphatase activity]	0.0	3	1	1	1
102496	1710	block a target	[blocking a target]	0.0	3	1	1	1
102497	1710	gm-csf hgm-csf	[GM-CSF hGM-CSF]	0.0	2	1	1	1
102498	1710	domain with eight segment	[domain with eight segments]	0.0	4	1	1	1
102499	1710	rhinitis.	[rhinitis.]	0.0	1	1	1	1
102500	1710	two gene c-fo	[two genes c-fos]	0.0	3	1	1	1
102501	1710	interaction with the DNA	[interaction with the DNA]	0.0	4	1	1	1
102502	1710	bacterial transcription of tumor necrosis factor-alpha	[bacterial transcription of tumor necrosis factor-alpha]	0.0	6	1	1	1
102503	1710	3 to 4 hour	[3 to 4 hours]	0.0	4	1	1	1
102504	1710	subunit CBF alpha	[subunit CBF alpha]	0.0	3	1	1	1
102505	1710	prevent the late phase of reaction	[preventing the late phase of reaction]	0.0	6	1	1	1
102506	1710	(egf) receptor	[(EGF) receptor]	0.0	2	1	1	1
102507	1710	linker substitution (LS) mutation	[linker substitution (LS) mutations]	0.0	4	1	1	1
102508	1710	growth of phagocyte	[growth of phagocytes]	0.0	3	1	1	1
102509	1710	IL2 transcription	[IL2 transcription]	0.0	2	1	1	1
102510	1710	characterization determinant	[Characterization determinants]	0.0	2	1	1	1
102511	1710	first evidence for a mechanism	[first evidence for a mechanism]	0.0	5	1	1	1
102512	1710	contain heterologous enhancer/promoters	[containing heterologous enhancer/promoters]	0.0	3	1	1	1
102513	1710	human-peripheral-blood T	[human-peripheral-blood T]	0.0	2	1	1	1
102514	1710	mass of 35 kda	[mass of 35 kDa]	0.0	4	1	1	1
102515	1710	culture of T cell	[cultures of T cells]	0.0	4	1	1	1
102516	1710	abundant expression of erythroid transcription factor	[Abundant expression of erythroid transcription factor]	0.0	6	1	1	1
102517	1710	mg/kg iv bolus dose	[mg/kg IV bolus doses]	0.0	4	1	1	1
102518	1710	residual disease in patient	[residual disease in patients]	0.0	4	1	1	1
102519	1710	suggest responsible for stimulation	[suggesting responsible for stimulation]	0.0	4	1	1	1
102520	1710	one t-cell clone	[one T-cell clone]	0.0	3	1	1	1
102521	1710	shift from multipotent/erythroid/monocytic	[shift from multipotent/erythroid/monocytic]	0.0	3	1	1	1
102522	1710	potent apc during response	[potent APC during responses]	0.0	4	1	1	1
102523	1710	IL-4 tyrosine phosphorylation	[IL-4 tyrosine phosphorylation]	0.0	3	1	1	1
102524	1710	other characteristic of monocytic differentiation	[other characteristics of monocytic differentiation]	0.0	5	1	1	1
102525	1710	than rest b cell	[than resting B cells]	0.0	4	1	1	1
102526	1710	assembly with a family	[assembly with a family]	0.0	4	1	1	1
102527	1710	transfectant with the CIITA construct	[transfectants with the CIITA constructs]	0.0	5	1	1	1
102528	1710	pigment in the rhizome	[pigment in the rhizome]	0.0	4	1	1	1
102529	1710	only factor present in extract	[only factor present in extracts]	0.0	5	1	1	1
102530	1710	rodent mutant cell chotsh1-1	[rodent mutant cells CHOtsH1-1]	0.0	4	1	1	1
102531	1710	contain a enhancer-like element	[containing a enhancer-like element]	0.0	4	1	1	1
102532	1710	four near-perfect repeat DR	[four near-perfect repeats DR]	0.0	4	1	1	1
102533	1710	human neuroblastoma cell line	[human neuroblastoma cell lines]	0.0	4	1	1	1
102534	1710	16HBE bronchial epithelial cell	[16HBE bronchial epithelial cells]	0.0	4	1	1	1
102535	1710	fetal globin expression	[fetal globin expression]	0.0	3	1	1	1
102536	1710	(nf-e2)	[(NF-E2)]	0.0	1	1	1	1
102537	1710	two viral gene	[two viral genes]	0.0	3	1	1	1
102538	1710	study of the defect(s)	[study of the defect(s)]	0.0	4	1	1	1
102539	1710	gene such as IL-8	[genes such as IL-8]	0.0	4	1	1	1
102540	1710	dnase I site 5'hs1-5	[DNase I sites 5'HS1-5]	0.0	4	1	1	1
102541	1710	region of the same genes,	[regions of the same genes,]	0.0	5	1	1	1
102542	1710	present datum along with finding	[present data, along with findings]	0.0	5	1	1	1
102543	1710	alternatively, through antagonism of the action	[alternatively, through antagonism of the action]	0.0	6	1	1	1
102544	1710	characteristic of ef1 at abundance	[characteristics of EF1 at abundance]	0.0	5	1	1	1
102545	1710	require glucocorticoid	[requiring glucocorticoids]	0.0	2	1	1	1
102546	1710	fragment contain sequence	[fragments containing sequences]	0.0	3	1	1	1
102547	1710	signal in monocytic cell	[signaling in monocytic cells]	0.0	4	1	1	1
102548	1710	GC -resistance	[GC -resistance]	0.0	2	1	1	1
102549	1710	treatment of serum-grown hl60 cell	[treatment of serum-grown HL60 cells]	0.0	5	1	1	1
102550	1710	uptake with failure	[uptake with failure]	0.0	3	1	1	1
102551	1710	il-2 receptor component	[IL-2 receptor components]	0.0	3	1	1	1
102552	1710	block of respective gene	[block of respective genes]	0.0	4	1	1	1
102553	1710	study of the activity	[Study of the activities]	0.0	4	1	1	1
102554	1710	apoptosis of T. T cell	[apoptosis of T. T cells]	0.0	5	1	1	1
102555	1710	co-expression of p65 (rel a)	[Co-expression of p65 (Rel A)]	0.0	5	1	1	1
102556	1710	erythroid cell lineage	[erythroid cell lineages]	0.0	3	1	1	1
102557	1710	many similarity	[many similarities]	0.0	2	1	1	1
102558	1710	negative pi3-k construct comprise domain	[negative PI3-K constructs comprising domains]	0.0	5	1	1	1
102559	1710	activation of thymocyte after infection	[Activation of thymocytes after infection]	0.0	5	1	1	1
102560	1710	existence of a loop	[existence of a loop]	0.0	4	1	1	1
102561	1710	increase understanding	[increasing understanding]	0.0	2	1	1	1
102562	1710	age-related decrease in il-2 production	[Age-related decreases in IL-2 production]	0.0	5	1	1	1
102563	1710	improvement in protein excretion	[Improvement in protein excretion]	0.0	4	1	1	1
102564	1710	inhibition of sequence-specific protein	[Inhibition of sequence-specific proteins]	0.0	4	1	1	1
102565	1710	interaction between PML	[interaction between PML]	0.0	3	1	1	1
102566	1710	T cell-specific regulatory element nre	[T cell-specific regulatory element NRE]	0.0	5	1	1	1
102567	1710	exclusive binding a element	[exclusive binding an element]	0.0	4	1	1	1
102568	1710	molecular basis of the induction	[molecular basis of the induction]	0.0	5	1	1	1
102569	1710	pkc -dependent linkage	[PKC -dependent linkage]	0.0	3	1	1	1
102570	1710	E1C3 cell	[E1C3 cells]	0.0	2	1	1	1
102571	1710	I kappa b molecule	[I kappa B molecules]	0.0	4	1	1	1
102572	1710	hypothesis, 4-h	[hypothesis, 4-h]	0.0	2	1	1	1
102573	1710	DU528	[DU528]	0.0	1	1	1	1
102574	1710	specific member	[specific members]	0.0	2	3	3	1
102575	1710	PMA ap-1 activation	[PMA AP-1 activation]	0.0	3	1	1	1
102576	1710	steroid hormone anti-sera	[steroid hormone anti-sera]	0.0	3	1	1	1
102577	1710	degradation of cytoplasmic inhibitor	[degradation of cytoplasmic inhibitors]	0.0	4	1	1	1
102578	1710	concomitant loss of transactivation,	[concomitant loss of transactivation,]	0.0	4	1	1	1
102579	1710	early gene egr-1	[early gene egr-1]	0.0	3	1	1	1
102580	1710	lack xist expression from female	[lacking XIST expression from females]	0.0	5	1	1	1
102581	1710	Rex mrna complex	[Rex mRNA complexes]	0.0	3	1	1	1
102582	1710	regulate granulocyte apoptosis	[regulating granulocyte apoptosis]	0.0	3	1	1	1
102583	1710	possible enhancement transactivate protein tax	[possible enhancement transactivating protein Tax]	0.0	5	1	1	1
102584	1710	one type-specific clone reactive	[one type-specific clone reactive]	0.0	4	1	1	1
102585	1710	moreover, mobility shift assay	[Moreover, mobility shift assays]	0.0	4	1	1	1
102586	1710	localization contain factor kappab complex	[localization containing factor kappaB complexes]	0.0	5	1	1	1
102587	1710	activation-induced change in set	[activation-induced changes in set]	0.0	4	1	1	1
102588	1710	over-ride determinant	[over-riding determinant]	0.0	2	1	1	1
102589	1710	notion multifactorial, involve alteration	[notion multifactorial, involving alterations]	0.0	4	1	1	1
102590	1710	regulate the response to activation	[regulating the response to activation]	0.0	5	1	1	1
102591	1710	analysis by hybridization	[analysis by hybridization]	0.0	3	1	1	1
102592	1710	patient with lymphoma	[patient with lymphoma]	0.0	3	1	1	1
102593	1710	lipopolysaccharide induction of gene	[lipopolysaccharide induction of genes]	0.0	4	1	1	1
102594	1710	5-Aminolevulinate	[5-Aminolevulinate]	0.0	1	1	1	1
102595	1710	stat5a /stat5b heterodimerization	[STAT5A /STAT5B heterodimerization]	0.0	3	1	1	1
102596	1710	odd	[odds]	0.0	1	1	1	1
102597	1710	distal nuclear factor (NF)-AT NF-AT	[distal nuclear factor (NF)-AT NF-AT]	0.0	5	1	1	1
102598	1710	bcr/abl mrna level	[bcr/abl mRNA levels]	0.0	3	1	1	1
102599	1710	resemble a dbd adjacent	[resembling a DBD adjacent]	0.0	4	1	1	1
102600	1710	T cell membrane expression	[T cell membrane expression]	0.0	4	1	1	1
102601	1710	different domain include distinct domain	[different domains including distinct domains]	0.0	5	1	1	1
102602	1710	various disease (12:	[various diseases (12:]	0.0	3	1	1	1
102603	1710	substantial molar amount of tata-binding protein	[substantial molar amounts of TATA-binding protein]	0.0	6	1	1	1
102604	1710	coactivator Bob1 hbob1	[coactivator Bob1 hBob1]	0.0	3	1	1	1
102605	1710	early messenger generation	[early messenger generation]	0.0	3	1	1	1
102606	1710	short-term response	[short-term responses]	0.0	2	1	1	1
102607	1710	32 healthy male	[32 healthy males]	0.0	3	1	1	1
102608	1710	chronic response	[chronic response]	0.0	2	1	1	1
102609	1710	pathogenic signal	[pathogenic signals]	0.0	2	1	1	1
102610	1710	(karyopherin)-alpha	[(karyopherin)-alpha]	0.0	1	1	1	1
102611	1710	10 woman (controls)	[10 women (controls)]	0.0	3	1	1	1
102612	1710	antiserum to 50 kda	[antiserum to 50 kDa]	0.0	4	1	1	1
102613	1710	severe condition	[severe conditions]	0.0	2	1	1	1
102614	1710	AIDS patient	[AIDS patients]	0.0	2	1	1	1
102615	1710	participate quantitatively to beta-globin switch	[participating quantitatively to beta-globin switch]	0.0	5	1	1	1
102616	1710	tcp (200	[TCP (200]	0.0	2	1	1	1
102617	1710	camp -dependent regulation effect	[cAMP -dependent regulation effects]	0.0	4	1	1	1
102618	1710	monocyte/neutrophil elastase inhibitor	[monocyte/neutrophil elastase inhibitor]	0.0	3	1	1	1
102619	1710	anomalous activation	[anomalous activation]	0.0	2	1	1	1
102620	1710	peak.	[peak.]	0.0	1	1	1	1
102621	1710	interaction on the level	[interactions on the level]	0.0	4	1	1	1
102622	1710	common mechanism for gene transcription	[common mechanisms for gene transcription]	0.0	5	1	1	1
102623	1710	CALM yac	[CALM YACS]	0.0	2	1	1	1
102624	1710	involve successive stage	[involving successive stages]	0.0	3	1	1	1
102625	1710	alter pathologic immune response	[altering pathologic immune responses]	0.0	4	1	1	1
102626	1710	induction of fasl	[induction of FasL]	0.0	3	1	1	1
102627	1710	functional expression on melanoma	[functional expression on melanomas]	0.0	4	1	1	1
102628	1710	thymocyte with thymic cell	[thymocytes with thymic cells]	0.0	4	1	1	1
102629	1710	dna-binding domain from GAL4 activator	[DNA-binding domain from GAL4 activators]	0.0	5	1	1	1
102630	1710	32 healthy person	[32 healthy persons]	0.0	3	1	1	1
102631	1710	subdominant epitope	[subdominant epitopes]	0.0	2	1	1	1
102632	1710	N-terminal hydrophilic domain	[N-terminal hydrophilic domain]	0.0	3	1	1	1
102633	1710	/calmodulin	[/calmodulin]	0.0	1	1	1	1
102634	1710	B-cell leukemia (b-cll) cell	[B-cell leukemia (B-CLL) cells]	0.0	4	1	1	1
102635	1710	signal-regulated kinase ERK in monocyte	[signal-regulated kinase ERK in monocytes]	0.0	5	1	1	1
102636	1710	structural requirement for transcriptional activation	[structural requirements for transcriptional activation]	0.0	5	1	1	1
102637	1710	histocompatibility immune deficiency type MHC cid	[histocompatibility immune deficiency type MHC CID]	0.0	6	1	1	1
102638	1710	induction of p105 processing	[induction of p105 processing]	0.0	4	1	1	1
102639	1710	transcription of the human gene cluster	[Transcription of the human gene cluster]	0.0	6	1	1	1
102640	1710	low level of receptor	[lower levels of receptors]	0.0	4	1	1	1
102641	1710	epstein-barr virus -negative b lymphocyte	[Epstein-Barr virus -negative B lymphocytes]	0.0	5	1	1	1
102642	1710	ii-negative lymphocyte syndrome	[II-negative lymphocyte syndrome]	0.0	3	1	1	1
102643	1710	t-cell line JPX-9	[T-cell line JPX-9]	0.0	3	1	1	1
102644	1710	impairment of ap-1 activation	[impairments of AP-1 activation]	0.0	4	1	1	1
102645	1710	different experimental approach	[different experimental approaches]	0.0	3	1	1	1
102646	1710	only molecule	[only molecule]	0.0	2	1	1	1
102647	1710	inducibility of expression	[inducibility of expression]	0.0	3	1	1	1
102648	1710	well-defined entity	[well-defined entity]	0.0	2	1	1	1
102649	1710	NK cell for hour	[NK cells for hr]	0.0	4	1	1	1
102650	1710	similarity with the oncogene product	[similarity with the oncogene product]	0.0	5	1	1	1
102651	1710	use 100 ng/ml	[using 100 ng/ml]	0.0	3	1	1	1
102652	1710	also no correlation	[Also no correlations]	0.0	3	1	1	1
102653	1710	IFN-alpha responsiveness in Philadelphia chromosome	[IFN-alpha responsiveness in Philadelphia chromosome]	0.0	5	1	1	1
102654	1710	release of activity	[release of activities]	0.0	3	1	1	1
102655	1710	analysis of normal tissues,	[analysis of normal tissues,]	0.0	4	1	1	1
102656	1710	expression of tumor necrosis factor	[expression of tumor necrosis factor]	0.0	5	1	1	1
102657	1710	CD40 induction in b cell	[CD40 induction in B cells]	0.0	5	1	1	1
102658	1710	th1-type response	[Th1-type responses]	0.0	2	1	1	1
102659	1710	mechanism control the competence	[mechanisms controlling the competence]	0.0	4	1	1	1
102660	1710	use of the gr	[use of the GR]	0.0	4	1	1	1
102661	1710	human housekeeping alas precursor	[human housekeeping ALAS precursor]	0.0	4	1	1	1
102662	1710	peak value (8:00)	[peak values (8:00)]	0.0	3	1	1	1
102663	1710	transcriptional activation the latent gene promoter	[transcriptional activation the latent gene promoter]	0.0	6	1	1	1
102664	1710	TGF-beta modulation	[TGF-beta modulation]	0.0	2	1	1	1
102665	1710	search for loss	[search for losses]	0.0	3	1	1	1
102666	1710	positive regulatory role for GATA-1	[positive regulatory role for GATA-1]	0.0	5	1	1	1
102667	1710	trigger by the l243 significantly (p	[Triggering by the L243 significantly (P]	0.0	6	1	1	1
102668	1710	specific signal event	[specific signaling events]	0.0	3	1	1	1
102669	1710	mean number	[mean number]	0.0	2	2	2	1
102670	1710	histological feature	[histological features]	0.0	2	1	1	1
102671	1710	om10.1 cell	[OM10.1 cells]	0.0	2	2	2	1
102672	1710	complex formation between protein	[complex formation between proteins]	0.0	4	1	1	1
102673	1710	recombinant tumor necrosis	[recombinant tumor necrosis]	0.0	3	1	1	1
102674	1710	low level in a population	[low level in a population]	0.0	5	1	1	1
102675	1710	expression of the transcriptional activity	[expression of the transcriptional activity]	0.0	5	1	1	1
102676	1710	increase in concentration	[increases in concentrations]	0.0	3	1	1	1
102677	1710	prevent the tyrosine phosphorylation of STAT1	[preventing the tyrosine phosphorylation of STAT1]	0.0	6	1	1	1
102678	1710	hsv-1 replication	[HSV-1 replication]	0.0	2	1	1	1
102679	1710	phenolic, lipid-soluble, antioxidant	[phenolic, lipid-soluble, antioxidant]	0.0	3	1	1	1
102680	1710	her-2/neu overexpression +/-	[HER-2/neu overexpression +/-]	0.0	3	1	1	1
102681	1710	activation by phagocytic stimulus in neutrophils.	[Activation by phagocytic stimuli in neutrophils.]	0.0	6	1	1	1
102682	1710	myeloid precursor into myelomonocytic cell	[myeloid precursors into myelomonocytic cells]	0.0	5	1	1	1
102683	1710	vulva	[vulva]	0.0	1	1	1	1
102684	1710	tyrosine include y292	[tyrosines including Y292]	0.0	3	1	1	1
102685	1710	DQA1*0501	[DQA1*0501]	0.0	1	1	1	1
102686	1710	immediate early (ie62) protein	[immediate early (IE62) protein]	0.0	4	1	1	1
102687	1710	patient (range from 11.1 to 174))	[patients (ranging from 11.1 to 17.4),]	0.0	6	1	1	1
102688	1710	class of body	[class of bodies]	0.0	3	1	1	1
102689	1710	PKC activator,	[PKC activator,]	0.0	2	1	1	1
102690	1710	marker of osteoclast vitronectin receptor	[markers of osteoclasts vitronectin receptor]	0.0	5	1	1	1
102691	1710	functional program	[functional programs]	0.0	2	1	1	1
102692	1710	ligation of the full-length receptor	[ligation of the full-length receptor]	0.0	5	1	1	1
102693	1710	strand nick in DNA,	[strand nicks in DNA,]	0.0	4	1	1	1
102694	1710	constitutive activation of factor	[constitutive activation of factor]	0.0	4	1	1	1
102695	1710	enhancement of il-2 mrna expression	[enhancement of IL-2 mRNA expression]	0.0	5	1	1	1
102696	1710	complex (mhc) class ii molecule	[complex (MHC) class II molecules]	0.0	5	1	1	1
102697	1710	feedback sensitivity at level	[feedback sensitivity at levels]	0.0	4	1	1	1
102698	1710	kinase C PKC	[kinase C PKC]	0.0	3	1	1	1
102699	1710	element necessary alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[Elements necessary alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	0.0	6	1	1	1
102700	1710	form of type 2 diabete	[forms of type 2 diabetes]	0.0	5	1	1	1
102701	1710	nf-kappab (level	[NF-kappaB (levels]	0.0	2	1	1	1
102702	1710	acidosis	[acidosis]	0.0	1	1	1	1
102703	1710	suggest effective in the compensatory phase	[suggesting effective in the compensatory phase]	0.0	6	1	1	1
102704	1710	increase in mad3 protein	[increase in MAD3 protein]	0.0	4	1	1	1
102705	1710	definitive progenitor	[definitive progenitors]	0.0	2	1	1	1
102706	1710	glucocorticoid receptor functionality	[glucocorticoid receptor functionality]	0.0	3	1	1	1
102707	1710	analysis of beta-cell	[analyses of beta-cells]	0.0	3	1	1	1
102708	1710	ubiquitous cellular transcription factor	[ubiquitous cellular transcription factors]	0.0	4	1	1	1
102709	1710	molecular weight of about 32, 36	[molecular weights of about 32, 36]	0.0	6	1	1	1
102710	1710	cell to lipopolysaccharide lps	[cells to lipopolysaccharide LPS]	0.0	4	1	1	1
102711	1710	role in myeloid lineage development	[role in myeloid lineage development]	0.0	5	1	1	1
102712	1710	different ad group	[different Ad groups]	0.0	3	1	1	1
102713	1710	addition, pretreatment	[addition, pretreatment]	0.0	2	1	1	1
102714	1710	T lymphocyte erratum	[T lymphocytes erratum]	0.0	3	1	1	1
102715	1710	nuclear exclusion	[nuclear exclusion]	0.0	2	1	1	1
102716	1710	difference between this ltr	[differences between these LTRs]	0.0	4	1	1	1
102717	1710	matrix protein fibronectin	[matrix protein fibronectin]	0.0	3	1	1	1
102718	1710	novel T regulatory element nre	[novel T regulatory element NRE]	0.0	5	1	1	1
102719	1710	isoquinoline derivative H7	[isoquinoline derivative H7]	0.0	3	1	1	1
102720	1710	up-regulation of high-affinity dehydroepiandrosterone binding activity	[Up-regulation of high-affinity dehydroepiandrosterone binding activity]	0.0	6	1	1	1
102721	1710	pRb	[pRb]	0.0	1	1	1	1
102722	1710	individual with pathology	[individuals with pathology]	0.0	3	1	1	1
102723	1710	juxtapose promoter	[juxtaposing promoters]	0.0	2	1	1	1
102724	1710	specific down-regulation	[specific down-regulation]	0.0	2	1	1	1
102725	1710	fluticasone propionate for weeks.	[fluticasone propionate for weeks.]	0.0	4	1	1	1
102726	1710	cytotoxic T lymphocyte response in type	[cytotoxic T lymphocyte response in type]	0.0	6	1	1	1
102727	1710	Interleukin-2 gene expression	[Interleukin-2 gene expression]	0.0	3	1	1	1
102728	1710	tam for EBS	[TAM for EBS]	0.0	3	1	1	1
102729	1710	enhancer tc-ii NF-kappa b	[enhancer TC-II NF-kappa B]	0.0	4	1	1	1
102730	1710	role of IKK1	[Role of IKK1]	0.0	3	1	1	1
102731	1710	(nk) activity	[(NK) activity]	0.0	2	1	1	1
102732	1710	involvement in oxidant-induced nf-kappa b activation	[Involvement in oxidant-induced NF-kappa B activation]	0.0	6	1	1	1
102733	1710	analysis use blot hybridisation	[analysis using blot hybridisation]	0.0	4	1	1	1
102734	1710	T enhancer of murine	[T enhancers of murine]	0.0	4	1	1	1
102735	1710	expression of gene through interaction	[expression of genes through interaction]	0.0	5	1	1	1
102736	1710	nature Arg91 one	[nature Arg91 one]	0.0	3	1	1	1
102737	1710	gp160 for h at degree	[gp160 for h at degrees]	0.0	5	1	1	1
102738	1710	activation of early growth response	[Activation of early growth response]	0.0	5	1	1	1
102739	1710	tyrosine phosphorylation of the STATs	[tyrosine phosphorylation of the STATs]	0.0	5	1	1	1
102740	1710	miss the -417 region	[missing the -417 region]	0.0	4	1	1	1
102741	1710	ori	[ori]	0.0	1	1	1	1
102742	1710	heterozygous loss-of-function mutation	[heterozygous loss-of-function mutation]	0.0	3	1	1	1
102743	1710	locus LCR	[locus LCR]	0.0	2	1	1	1
102744	1710	replication defect	[replication defects]	0.0	2	1	1	1
102745	1710	mobility of complex	[mobility of complexes]	0.0	3	1	1	1
102746	1710	requisite ligand	[requisite ligands]	0.0	2	1	1	1
102747	1710	intraperitoneal injection of blood cell	[intraperitoneal injection of blood cells]	0.0	5	1	1	1
102748	1710	several family member	[several family members]	0.0	3	1	1	1
102749	1710	fast-migrate protein-DNA complex	[fast-migrating protein-DNA complexes]	0.0	3	1	1	1
102750	1710	phosphorylation proteins; in	[phosphorylation proteins; in]	0.0	3	1	1	1
102751	1710	activation of transcriptional regulatory factor	[activation of transcriptional regulatory factors]	0.0	5	1	1	1
102752	1710	CEM cell clone	[CEM cell clone]	0.0	3	1	1	1
102753	1710	p27rex /p21rex	[p27rex /p21rex]	0.0	2	1	1	1
102754	1710	cell carcinoma RCC	[cell carcinoma RCC]	0.0	3	2	2	1
102755	1710	expression a member	[expression a member]	0.0	3	1	1	1
102756	1710	other specific factor	[other specific factors]	0.0	3	1	1	1
102757	1710	induction in T lymphocytic cell	[induction in T lymphocytic cells]	0.0	5	1	1	1
102758	1710	prl (hprl) gene	[PRL (hPRL) gene]	0.0	3	1	1	1
102759	1710	related hepatocyte factor HNF-1alpha	[related hepatocyte factors HNF-1alpha]	0.0	4	1	1	1
102760	1710	13 sex-and healthy subject	[13 sex-and healthy subjects]	0.0	4	1	1	1
102761	1710	interplay of ubiquitous protein	[interplay of ubiquitous proteins]	0.0	4	1	1	1
102762	1710	-nfat	[-NFAT]	0.0	1	1	1	1
102763	1710	fasL up-regulation in lpr/lpr	[fasL up-regulation in lpr/lpr]	0.0	4	1	1	1
102764	1710	result of infection with virion	[result of infection with virions]	0.0	5	1	1	1
102765	1710	(3.4+/-0.3	[(3.4+/-0.3]	0.0	1	1	1	1
102766	1710	antibody against subunit of protein	[antibodies against subunits of proteins]	0.0	5	1	1	1
102767	1710	gene encode granule protein	[genes encoding granule proteins]	0.0	4	1	1	1
102768	1710	mutation of Ikaros	[Mutation of Ikaros]	0.0	3	1	1	1
102769	1710	d oligonucleotide	[ds oligonucleotides]	0.0	2	1	1	1
102770	1710	particular major (mhc) haplotype	[particular major (MHC) haplotypes]	0.0	4	1	1	1
102771	1710	transcription follow ligand engagement cell-to-cell	[transcription following ligand engagement cell-to-cell]	0.0	5	1	1	1
102772	1710	coexpression of negative ras	[Coexpression of negative Ras]	0.0	4	1	1	1
102773	1710	mouse t-lymphocyte (ctl) library	[mouse T-lymphocyte (CTL) library]	0.0	4	1	1	1
102774	1710	cytokine by monocyte	[cytokines by monocytes]	0.0	3	1	1	1
102775	1710	increase use	[increasing use]	0.0	2	1	1	1
102776	1710	hematopoietic cytokine interleukin-2	[hematopoietic cytokine interleukin-2]	0.0	3	1	1	1
102777	1710	express trx	[expressing Trx]	0.0	2	1	1	1
102778	1710	role define the pattern	[role defining the pattern]	0.0	4	1	1	1
102779	1710	functional cooperation in transactivation	[functional cooperation in transactivation]	0.0	4	1	1	1
102780	1710	mature cells).	[mature cells).]	0.0	2	1	1	1
102781	1710	transcriptional competence	[transcriptional competence]	0.0	2	1	1	1
102782	1710	restoration of differentiation	[Restoration of differentiation]	0.0	3	1	1	1
102783	1710	[differential value of D3 calcitriol determination	[[Differential value of D3 calcitriol determination]	0.0	6	1	1	1
102784	1710	effect by G. vaginalis	[effect by G. vaginalis]	0.0	4	1	1	1
102785	1710	rest normal human lymphocyte from blood	[resting normal human lymphocytes from blood]	0.0	6	1	1	1
102786	1710	elastase inhibitor peptide gdsp	[elastase inhibitor peptide GDSP]	0.0	4	1	1	1
102787	1710	calcium activation	[Calcium activation]	0.0	2	1	1	1
102788	1710	expiratory	[expiratory]	0.0	1	1	1	1
102789	1710	enzyme cathepsin b	[enzymes cathepsin B]	0.0	3	1	1	1
102790	1710	regulatory factor critical to hiv-1 replication	[regulatory factors critical to HIV-1 replication]	0.0	6	1	1	1
102791	1710	affinity for a sterol regulatory sequence	[affinity for a sterol regulatory sequence]	0.0	6	1	1	1
102792	1710	three distinct form of (free) e2f	[three distinct forms of (free) E2F]	0.0	6	1	1	1
102793	1710	expression of pax-5 isoform	[expression of Pax-5 isoforms]	0.0	4	1	1	1
102794	1710	constitutively produce p40 with ebv	[constitutively producing p40 with EBV]	0.0	5	1	1	1
102795	1710	regulation by the NF-kappaB subunit	[regulation by the NF-kappaB subunits]	0.0	5	1	1	1
102796	1710	presence of factor in PBL	[presence of factors in PBL]	0.0	5	1	1	1
102797	1710	transcriptional activity in IL-4 T cell	[transcriptional activities in IL-4 T cells]	0.0	6	1	1	1
102798	1710	change in the redox status	[changes in the redox status]	0.0	5	1	1	1
102799	1710	jak3 /stat5a/b	[JAK3 /STAT5a/b]	0.0	2	1	1	1
102800	1710	integrin gene expression	[integrin gene expression]	0.0	3	1	1	1
102801	1710	physical property	[physical properties]	0.0	2	1	1	1
102802	1710	encode the beta subunit of Pebp2	[encoding the beta subunit of Pebp2]	0.0	6	1	1	1
102803	1710	200 mu/l physiological limit	[200 mU/L physiological limit]	0.0	4	1	1	1
102804	1710	contain linker substitution mutation	[containing linker substitution mutations]	0.0	4	1	1	1
102805	1710	early gene of cytomegalovirus	[early genes of cytomegalovirus]	0.0	4	1	1	1
102806	1710	replacement in vitro by incubation	[replacement in vitro by incubation]	0.0	5	1	1	1
102807	1710	nevertheless, high, pharmacological concentration to &mgr;m)	[Nevertheless, high, pharmacological concentrations to &mgr;M)]	0.0	6	1	1	1
102808	1710	nuclear export factor of T cell	[nuclear export factor of T cells]	0.0	6	1	1	1
102809	1710	phase of viral infection	[phase of viral infection]	0.0	4	1	1	1
102810	1710	cell-dependent b cell maturation	[cell-dependent B cell maturation]	0.0	4	1	1	1
102811	1710	differentiation of u-937 promonocytic cell	[Differentiation of U-937 promonocytic cells]	0.0	5	1	1	1
102812	1710	acetylation of erythroid Kruppel-like factor activity	[Acetylation of erythroid Kruppel-like factor activity]	0.0	6	1	1	1
102813	1710	activation of MHC class promoter	[Activation of MHC class promoters]	0.0	5	1	1	1
102814	1710	use a radioligand assay analysis	[using a radioligand assay analysis]	0.0	5	1	1	1
102815	1710	association of cytoplasmic terminus	[association of cytoplasmic terminus]	0.0	4	1	1	1
102816	1710	human homolog of crp1	[human homolog of CRP1]	0.0	4	1	1	1
102817	1710	cyclic amp-responsive element	[cyclic AMP-responsive element]	0.0	3	1	1	1
102818	1710	binding I interferon ifn-alpha/beta	[Binding I interferon IFN-alpha/beta]	0.0	4	1	1	1
102819	1710	effect of il-13 on NK	[effects of IL-13 on NK]	0.0	5	1	1	1
102820	1710	related effector mechanism in disorder	[related effector mechanism in disorders]	0.0	5	1	1	1
102821	1710	binding of lifer	[binding of livers]	0.0	3	1	1	1
102822	1710	cyclic-AMP -responsive element	[cyclic-AMP -responsive element]	0.0	3	1	1	1
102823	1710	total cellular pkc activity	[Total cellular PKC activity]	0.0	4	1	1	1
102824	1710	approximately the transactivation ability as otf-2	[approximately the transactivation ability as OTF-2]	0.0	6	1	1	1
102825	1710	specific interferon isotype	[specific interferon isotypes]	0.0	3	1	1	1
102826	1710	identify malignancy melanoma	[identifying malignancy melanomas]	0.0	3	1	1	1
102827	1710	CAII erba-binding site	[CAII erbA-binding site]	0.0	3	1	1	1
102828	1710	cellular event in plaque development	[cellular event in plaque development]	0.0	5	1	1	1
102829	1710	loss of 1p36	[loss of 1p36]	0.0	3	1	1	1
102830	1710	map kinase p38	[MAP kinase p38]	0.0	3	1	1	1
102831	1710	structure lead	[structure leading]	0.0	2	1	1	1
102832	1710	expression of SERCA	[expressions of SERCA]	0.0	3	1	1	1
102833	1710	estrogen receptor breast cancer cell line	[Estrogen receptor breast cancer cell lines]	0.0	6	1	1	1
102834	1710	occur in mononuclear cell	[occurring in mononuclear cells]	0.0	4	1	1	1
102835	1710	mutant pathway	[mutants pathway]	0.0	2	1	1	1
102836	1710	stimulation by protein phosphatase	[Stimulation by protein phosphatase]	0.0	4	1	1	1
102837	1710	functional deficiency virus type	[functional deficiency virus type]	0.0	4	1	1	1
102838	1710	inhibitor rapamycin	[inhibitors rapamycin]	0.0	2	1	1	1
102839	1710	differentiation-dependent proliferator-activated receptor gamma ppargamma	[differentiation-dependent proliferator-activated receptor gamma PPARgamma]	0.0	5	1	1	1
102840	1710	ets-1-containg complex	[Ets-1-containing complex]	0.0	2	1	1	1
102841	1710	gp91phox gene	[gp91phox gene]	0.0	2	1	1	1
102842	1710	zip site	[ZIP site]	0.0	2	1	1	1
102843	1710	lymphocyte predominance hodgkin' disease	[lymphocyte predominance Hodgkin's disease]	0.0	4	1	1	1
102844	1710	growth in medium.	[growth in medium.]	0.0	3	1	1	1
102845	1710	ga-binding protein factor	[GA-binding protein factors]	0.0	3	1	1	1
102846	1710	(day culture	[(day culture)]	0.0	2	1	1	1
102847	1710	15 patient with graves' disease	[15 patients with Graves' disease]	0.0	5	1	1	1
102848	1710	erythroid cell-specific stage-specific factor-DNA complex	[erythroid cell-specific stage-specific factor-DNA complexes]	0.0	5	1	1	1
102849	1710	mononuclear leukocyte of donor	[mononuclear leukocytes of donors]	0.0	4	1	1	1
102850	1710	erythroblast coexpress the v-erbA oncoprotein	[erythroblasts coexpressing the v-erbA oncoprotein]	0.0	5	1	1	1
102851	1710	cytoplasmic store	[cytoplasmic stores]	0.0	2	1	1	1
102852	1710	fl5.12	[FL5.12]	0.0	1	1	1	1
102853	1710	homology to a putative protein	[homology to a putative protein]	0.0	5	1	1	1
102854	1710	control group binding sites/cell;	[control group binding sites/cell;]	0.0	4	1	1	1
102855	1710	govern lineage switch to monocytic lineage	[governing lineage switching to monocytic lineages]	0.0	6	1	1	1
102856	1710	phenotype in viral replication	[phenotype in viral replication]	0.0	4	1	1	1
102857	1710	synovial fluid monocyte /macrophage	[synovial fluid monocytes /macrophages]	0.0	4	1	1	1
102858	1710	include up-regulation	[including up-regulation]	0.0	2	1	1	1
102859	1710	base pair mutation	[base pair mutation]	0.0	3	1	1	1
102860	1710	stimulate peripheral blood mononuclear cell	[stimulating peripheral blood mononuclear cells]	0.0	5	1	1	1
102861	1710	study in mononuclear leukocyte	[studies in mononuclear leukocytes]	0.0	4	1	1	1
102862	1710	failure A-CRF with mild-moderate insufficiency	[failure A-CRF with mild-moderate insufficiency]	0.0	5	1	1	1
102863	1710	then (il)-10 blocking factor pibf expression	[then (IL)-10 blocking factor PIBF expression]	0.0	6	1	1	1
102864	1710	pb1	[PB1]	0.0	1	1	1	1
102865	1710	role control level	[role controlling levels]	0.0	3	1	1	1
102866	1710	immunodeficiency virus type LTR	[immunodeficiency virus type LTR]	0.0	4	1	1	1
102867	1710	ags with tcr	[Ags with TCR]	0.0	3	1	1	1
102868	1710	aitl	[AITL]	0.0	1	1	1	1
102869	1710	endothelial protein such as soluble e-selectin	[endothelial proteins such as soluble E-selectin]	0.0	6	1	1	1
102870	1710	pah	[PAHs]	0.0	1	1	1	1
102871	1710	major regulatory function	[major regulatory functions]	0.0	3	1	1	1
102872	1710	pak	[PAK]	0.0	1	1	1	1
102873	1710	cytokine genes,	[cytokine genes,]	0.0	2	1	1	1
102874	1710	mature form of tf	[mature forms of TF]	0.0	4	1	1	1
102875	1710	await further elucidation.	[awaiting further elucidation.]	0.0	3	1	1	1
102876	1710	thyroid antibody production	[thyroid antibody production]	0.0	3	1	1	1
102877	1710	number of small mutation	[number of small mutations]	0.0	4	1	1	1
102878	1710	pat	[pAT]	0.0	1	1	1	1
102879	1710	b binding protein	[B binding proteins]	0.0	3	1	1	1
102880	1710	immunophilin-drug complex	[immunophilin-drug complexes]	0.0	2	1	1	1
102881	1710	two transcription factor TCF-1	[two transcription factors TCF-1]	0.0	4	1	1	1
102882	1710	IFN stimulus response	[IFN stimulus response]	0.0	3	1	1	1
102883	1710	form of virus latency	[forms of virus latency]	0.0	4	1	1	1
102884	1710	mechanism a novel type	[mechanisms a novel type]	0.0	4	1	1	1
102885	1710	role in AMP inhibition	[Role in AMP inhibition]	0.0	4	1	1	1
102886	1710	(hmg) protein	[(HMG) protein]	0.0	2	1	1	1
102887	1710	therefore a potential target under condition	[therefore a potential target under conditions]	0.0	6	1	1	1
102888	1710	dupuytren' disease	[Dupuytren's disease]	0.0	2	1	1	1
102889	1710	important activity	[important activity]	0.0	2	1	1	1
102890	1710	direct genetic target	[direct genetic target]	0.0	3	1	1	1
102891	1710	pbr	[PBR]	0.0	1	1	1	1
102892	1710	effect of a beta	[effects of A beta]	0.0	4	1	1	1
102893	1710	only CsA component	[only CsA component]	0.0	3	1	1	1
102894	1710	STAT1 import by delivery	[STAT1 import by delivery]	0.0	4	1	1	1
102895	1710	cell in culture, lead	[cells in culture, leading]	0.0	4	1	1	1
102896	1710	succinimide-containing peptide show weak cross-reactivity	[succinimide-containing peptide showing weak cross-reactivity]	0.0	5	1	1	1
102897	1710	transcription in T lymphocyte	[transcription in T lymphocytes]	0.0	4	1	1	1
102898	1710	regulatory activity of 20-methyl analogue	[regulatory activities of 20-methyl analogues]	0.0	5	1	1	1
102899	1710	Ireland,	[Ireland,]	0.0	1	1	1	1
102900	1710	multiple isotype of protein kinase C	[multiple isotypes of protein kinase C]	0.0	6	1	1	1
102901	1710	cytokine in bronchial cell	[cytokines in bronchial cells]	0.0	4	1	1	1
102902	1710	case of myeloid leukemia aml	[cases of myeloid leukemia AML]	0.0	5	1	1	1
102903	1710	namely, the (dp) CD4 cd8(+) CD3	[namely, the (DP) CD4 CD8(+) CD3]	0.0	6	1	1	1
102904	1710	formulation of methylprednisolone	[formulation of methylprednisolone]	0.0	3	1	1	1
102905	1710	focus of attention	[focus of attention]	0.0	3	1	1	1
102906	1710	(NF)-kappaB binding site	[(NF)-kappaB binding sites]	0.0	3	1	1	1
102907	1710	potential c/ebP-binding site	[potential C/EBP-binding site]	0.0	3	1	1	1
102908	1710	steroid-resistant subject	[steroid-resistant subjects]	0.0	2	1	1	1
102909	1710	expression of a ras mutant,	[expression of a ras mutant,]	0.0	5	1	1	1
102910	1710	sds-stable class alphabeta dimer	[SDS-stable class alphabeta dimers]	0.0	4	1	1	1
102911	1710	cellular incorporation of 3h-thymidine	[cellular incorporation of 3H-thymidine]	0.0	4	1	1	1
102912	1710	simultaneous activation of two messenger	[simultaneous activation of two messengers]	0.0	5	1	1	1
102913	1710	inducible promoter contain element	[inducible promoter containing elements]	0.0	4	1	1	1
102914	1710	region encompass a proline sequence	[region encompassing a proline sequence]	0.0	5	1	1	1
102915	1710	biphasic kinetic	[biphasic kinetics]	0.0	2	1	1	1
102916	1710	single class of site	[single class of sites]	0.0	4	1	1	1
102917	1710	(pt) of 154	[(PT) of 154]	0.0	3	1	1	1
102918	1710	localization of I(kappa)B(alpha)	[localization of I(kappa)B(alpha)]	0.0	3	1	1	1
102919	1710	overlapping mechanism of action,	[overlapping mechanisms of action,]	0.0	4	1	1	1
102920	1710	pef	[PEF]	0.0	1	1	1	1
102921	1710	threonine residue at position	[threonine residue at position]	0.0	4	1	1	1
102922	1710	alpha-helice with a high proportion	[alpha-helices with a high proportion]	0.0	5	1	1	1
102923	1710	IL-8 family	[IL-8 family]	0.0	2	1	1	1
102924	1710	cis-element responsible for the regulation	[cis-elements responsible for the regulation]	0.0	5	1	1	1
102925	1710	require ROI production in monocytic cell	[requiring ROI production in monocytic cells]	0.0	6	1	1	1
102926	1710	interleukin 3 survival	[interleukin 3 survival]	0.0	3	1	1	1
102927	1710	time of observation	[time of observation]	0.0	3	1	1	1
102928	1710	pfa	[/Fas]	0.0	1	1	1	1
102929	1710	transcript isolation of a alternative transcript	[transcripts isolation of an alternative transcript]	0.0	6	1	1	1
102930	1710	include the surface of cell	[including the surface of cells]	0.0	5	1	1	1
102931	1710	ph,	[pH,]	0.0	1	1	1	1
102932	1710	month of age,	[months of age,]	0.0	3	1	1	1
102933	1710	pfu	[pfu]	0.0	1	1	1	1
102934	1710	analyze the mechanism	[analyzing the mechanism]	0.0	3	1	1	1
102935	1710	insight into the function of e2a-hlf	[insight into the function of E2A-HLF]	0.0	6	1	1	1
102936	1710	stimulation of b-2 cell	[stimulation of B-2 cells]	0.0	4	1	1	1
102937	1710	MHC class ii transactivator	[MHC class II transactivator]	0.0	4	2	2	1
102938	1710	methods: pbmc from patient	[METHODS: PBMCs from patients]	0.0	4	1	1	1
102939	1710	flank region extend from bp	[flanking regions extending from bp]	0.0	5	1	1	1
102940	1710	domain) protein	[domain) proteins]	0.0	2	1	1	1
102941	1710	translocation of c-Rel heterodimer	[translocation of c-Rel heterodimers]	0.0	4	1	1	1
102942	1710	reactivity to ssb	[reactivity to SSB]	0.0	3	1	1	1
102943	1710	CD30 with a anti- CD30 antibody,	[CD30 with an anti- CD30 antibody,]	0.0	6	1	1	1
102944	1710	activation of mitogen-inducible transcription factor	[activation of mitogen-inducible transcription factors]	0.0	5	1	1	1
102945	1710	isolation of nuclei	[isolation of nuclei]	0.0	3	1	1	1
102946	1710	basal redox equilibrium tend	[basal redox equilibrium tending]	0.0	4	1	1	1
102947	1710	vein cell monolayer for hour	[vein cell monolayers for hours]	0.0	5	1	1	1
102948	1710	emission of a probe	[emission of a probe]	0.0	4	1	1	1
102949	1710	association with the hil-4r alpha	[association with the hIL-4R alpha]	0.0	5	1	1	1
102950	1710	molecular mechanism signal	[molecular mechanisms signaling]	0.0	3	1	1	1
102951	1710	novel mz twin pair	[novel MZ twin pair]	0.0	4	1	1	1
102952	1710	examination use murine Th1 th2 clone	[examination using murine Th1 Th2 clones]	0.0	6	1	1	1
102953	1710	196, p	[196, p]	0.0	2	1	1	1
102954	1710	specific monoclonal antibody	[specific monoclonal antibody]	0.0	3	1	1	1
102955	1710	leukocyte glucocorticoid	[leukocyte glucocorticoid]	0.0	2	1	1	1
102956	1710	detectable activation of pp70s6k	[detectable activation of pp70S6K]	0.0	4	1	1	1
102957	1710	interrelationship in platelet function	[interrelationship in platelet function]	0.0	4	1	1	1
102958	1710	pif	[PIF]	0.0	1	1	1	1
102959	1710	blood cell proliferation from six patient	[blood cell proliferation from six patients]	0.0	6	1	1	1
102960	1710	markers, include p53	[markers, including p53]	0.0	3	1	1	1
102961	1710	antisense rxr-alpha sequence	[antisense RXR-alpha sequences]	0.0	3	1	1	1
102962	1710	exogenous gata-2	[exogenous GATA-2]	0.0	2	1	1	1
102963	1710	costimulation with fibrinogen	[costimulation with fibrinogen]	0.0	3	1	1	1
102964	1710	particular, cytokine	[particular, cytokines]	0.0	2	1	1	1
102965	1710	cell line of and/or fetal	[cell line of and/or fetal]	0.0	5	1	1	1
102966	1710	culture of cell TEC	[cultures of cells TEC]	0.0	4	1	1	1
102967	1710	require signal for initiation.	[requiring signals for initiation.]	0.0	4	1	1	1
102968	1710	complex protein CREB	[complexes protein CREB]	0.0	3	1	1	1
102969	1710	rest platelet	[resting platelets]	0.0	2	1	1	1
102970	1710	proapoptotic member	[proapoptotic members]	0.0	2	1	1	1
102971	1710	association of SCL	[association of SCL]	0.0	3	1	1	1
102972	1710	evolutionary conservation.	[evolutionary conservation.]	0.0	2	1	1	1
102973	1710	human monocyte use tf antibody	[human monocytes using TF antibody]	0.0	5	1	1	1
102974	1710	presence of kind	[presence of kinds]	0.0	3	1	1	1
102975	1710	exposure of human cell HAEC	[exposure of human cells HAEC]	0.0	5	1	1	1
102976	1710	Grb2 mutant	[Grb2 mutant]	0.0	2	1	1	1
102977	1710	1000 VDR	[1000 VDR]	0.0	2	1	1	1
102978	1710	regulator of cytokine receptor genes,	[regulators of cytokine receptor genes,]	0.0	5	1	1	1
102979	1710	lead to migration	[leading to migration]	0.0	3	1	1	1
102980	1710	syndrome MDS in advanced stage	[syndromes MDS in advanced stage]	0.0	5	1	1	1
102981	1710	hence the resumption	[hence the resumption]	0.0	3	1	1	1
102982	1710	pkb	[PKB]	0.0	1	1	1	1
102983	1710	thymocyte development after efficient inhibition	[thymocyte development after efficient inhibition]	0.0	5	1	1	1
102984	1710	Epstein-Barr virus immediate-early protein	[Epstein-Barr virus immediate-early protein]	0.0	4	1	1	1
102985	1710	vitamin receptor VDR	[vitamin receptor VDR]	0.0	3	1	1	1
102986	1710	raf-1 mek1 expression	[Raf-1 MEK1 expression]	0.0	3	1	1	1
102987	1710	membrane antigen lmp	[membrane antigens LMP]	0.0	3	1	1	1
102988	1710	repression genes.	[repression genes.]	0.0	2	1	1	1
102989	1710	substitution 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[substitutions 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	4	1	1	1
102990	1710	1-long terminal repeat hiv-1-ltr	[1-long terminal repeat HIV-1-LTR]	0.0	4	1	1	1
102991	1710	nf-kappab activation by interleukin-1beta	[NF-kappaB activation by interleukin-1beta]	0.0	4	1	1	1
102992	1710	black woman	[black women]	0.0	2	1	1	1
102993	1710	population of /precursor	[populations of /precursors]	0.0	3	1	1	1
102994	1710	several regulatory region	[several regulatory regions]	0.0	3	1	1	1
102995	1710	alter immunoregulatory signal transduction	[altering immunoregulatory signal transduction]	0.0	4	1	1	1
102996	1710	translocation of nuclear factor kappab	[translocation of nuclear factor kappaB]	0.0	5	1	1	1
102997	1710	one subunit in particular,	[one subunit in particular,]	0.0	4	1	1	1
102998	1710	DNA sequence CTG-motif	[DNA sequence CTG-motif]	0.0	3	1	1	1
102999	1710	CTL hplc peptide fraction	[CTL HPLC peptide fraction]	0.0	4	1	1	1
103000	1710	KOX 25	[KOX 25]	0.0	2	1	1	1
103001	1710	po2	[PO2]	0.0	1	1	1	1
103002	1710	three point mutation	[three point mutations]	0.0	3	1	1	1
103003	1710	cell of leukemia patient	[cells of leukemia patients]	0.0	4	1	1	1
103004	1710	expression of the c/ebp protein LIP	[expression of the C/EBP protein LIP]	0.0	6	1	1	1
103005	1710	HeLa phenotype	[HeLa phenotype]	0.0	2	1	1	1
103006	1710	other factor present	[Other factors present]	0.0	3	1	1	1
103007	1710	expression of the receptor isoform	[expression of the receptor isoforms]	0.0	5	1	1	1
103008	1710	concentration of antioxidant --including ascorbic acid	[concentrations of antioxidants --including ascorbic acid]	0.0	6	1	1	1
103009	1710	annexin V (p	[annexin V (P]	0.0	3	1	1	1
103010	1710	significant decrease in the switch	[significant decrease in the switch]	0.0	5	1	1	1
103011	1710	state level ifn-gamma	[state levels IFN-gamma]	0.0	3	1	1	1
103012	1710	novel molecule this group	[novel molecule this group]	0.0	4	1	1	1
103013	1710	il-4 signal pathway	[IL-4 signaling pathways]	0.0	3	1	1	1
103014	1710	human genomic DNA clone	[human genomic DNA clones]	0.0	4	1	1	1
103015	1710	poz/zinc-finger	[POZ/zinc-finger]	0.0	1	1	1	1
103016	1710	various mode of basic regulation	[Various modes of basic regulation]	0.0	5	1	1	1
103017	1710	regulator of platelet function	[regulator of platelet function]	0.0	4	1	1	1
103018	1710	location of t-helper-cell epitope	[location of T-helper-cell epitopes]	0.0	4	1	1	1
103019	1710	subunits; five genes, nfkb1	[subunits; five genes, NFKB1]	0.0	4	1	1	1
103020	1710	version of 430-444	[version of 430-444]	0.0	3	1	1	1
103021	1710	receptor-mediated effect	[receptor-mediated effects]	0.0	2	1	1	1
103022	1710	interaction with nuclear protein	[interaction with nuclear proteins]	0.0	4	1	1	1
103023	1710	adenoviral serotype	[adenoviral serotypes]	0.0	2	2	2	1
103024	1710	b -like factor	[B -like factor]	0.0	3	1	1	1
103025	1710	ligation of CD28 with CD80	[ligation of CD28 with CD80]	0.0	5	1	1	1
103026	1710	hGR level between patient	[hGR levels between patients]	0.0	4	1	1	1
103027	1710	Epstein-Barr virus oncogene	[Epstein-Barr virus oncogene]	0.0	3	1	1	1
103028	1710	immunoregulatory effect of cyclosporin a	[immunoregulatory effects of cyclosporin A]	0.0	5	1	1	1
103029	1710	evidence the CsA -sensitive component	[evidence the CsA -sensitive component]	0.0	5	1	1	1
103030	1710	concentration of >10(-14) mol/L	[concentrations of >10(-14) mol/L]	0.0	4	1	1	1
103031	1710	activity of 20-methyl analogue	[activities of 20-methyl analogues]	0.0	4	1	1	1
103032	1710	tcr profile	[TCR profile]	0.0	2	1	1	1
103033	1710	factor-kappa B NF-kappaB family	[factor-kappa B NF-kappaB family]	0.0	4	1	1	1
103034	1710	portion of the e2a protein	[portions of the E2A protein]	0.0	5	1	1	1
103035	1710	immature t-cell proliferation	[immature T-cell proliferations]	0.0	3	1	1	1
103036	1710	germ-line brca2 mutation	[germ-line BRCA2 mutations]	0.0	3	1	1	1
103037	1710	detectable abnormality in neoplasia	[detectable abnormalities in neoplasia]	0.0	4	1	1	1
103038	1710	extracellular signal-regulated kinase in monocyte	[extracellular signal-regulated kinase in monocytes]	0.0	5	1	1	1
103039	1710	implicate specific sequence	[implicating specific sequences]	0.0	3	1	1	1
103040	1710	distinct "octamer" complex	[distinct "octamer" complex]	0.0	3	1	1	1
103041	1710	activation by bufalin	[activation by bufalin]	0.0	3	1	1	1
103042	1710	receptor il-1r superfamily	[receptor IL-1R superfamily]	0.0	3	1	1	1
103043	1710	macrophage tissue	[macrophage tissue]	0.0	2	1	1	1
103044	1710	inositoltrisphosphate generation corresponding specific binding	[inositoltrisphosphate generation corresponding specific binding]	0.0	5	1	1	1
103045	1710	status change in child	[status changes in children]	0.0	4	1	1	1
103046	1710	function of stat1 protein	[function of Stat1 proteins]	0.0	4	1	1	1
103047	1710	element in a enhancer	[element in a enhancer]	0.0	4	1	1	1
103048	1710	lymphocyte by glucocorticoid	[lymphocytes by glucocorticoids]	0.0	3	1	1	1
103049	1710	Beres	[Beres]	0.0	1	1	1	1
103050	1710	crux of activation	[crux of activation]	0.0	3	1	1	1
103051	1710	expression of tip	[Expression of Tip]	0.0	3	1	1	1
103052	1710	bind radioassay use [3H]-dexamethasone	[binding radioassay using [3H]-dexamethasone]	0.0	4	1	1	1
103053	1710	two difference	[two differences]	0.0	2	1	1	1
103054	1710	AP-1 recognition sequence	[AP-1 recognition sequence]	0.0	3	1	1	1
103055	1710	genomic sterol regulatory element SRE	[genomic sterol regulatory element SRE]	0.0	5	1	1	1
103056	1710	superinduction of c-jun	[superinduction of c-jun]	0.0	3	1	1	1
103057	1710	include some non-Ashkenazi group	[including some non-Ashkenazi groups]	0.0	4	1	1	1
103058	1710	disorders: xeroderma	[disorders: xeroderma]	0.0	2	1	1	1
103059	1710	nf-at transactivate pathway	[NF-AT transactivating pathways]	0.0	3	1	1	1
103060	1710	faster-migrating NF kappa b species	[faster-migrating NF kappa B species]	0.0	5	1	1	1
103061	1710	arm of human chromosome	[arm of human chromosome]	0.0	4	1	1	1
103062	1710	atpase	[ATPase]	0.0	1	1	1	1
103063	1710	study of border	[study of borders]	0.0	3	1	1	1
103064	1710	significant variation	[significant variation]	0.0	2	1	1	1
103065	1710	event downstream	[events downstream]	0.0	2	1	1	1
103066	1710	resistance apoptosis in vitro	[Resistance apoptosis in vitro]	0.0	4	1	1	1
103067	1710	feedback of the hypothalamic-pituitary-adrenal axis	[feedback of the hypothalamic-pituitary-adrenal axis]	0.0	5	1	1	1
103068	1710	increase in 5-day m phi uptake	[increases in 5-day M phi uptake]	0.0	6	1	1	1
103069	1710	incubation for day result	[incubation for days, resulting]	0.0	4	1	1	1
103070	1710	plasmacytoma b	[plasmacytoma B]	0.0	2	1	1	1
103071	1710	expression of the stimulatory g protein	[Expression of the stimulatory G protein]	0.0	6	1	1	1
103072	1710	inflammatory response,	[inflammatory response,]	0.0	2	1	1	1
103073	1710	mechanism contribute to response	[mechanisms contributing to response]	0.0	4	1	1	1
103074	1710	contain gold ion HAuCl3	[containing gold ion HAuCl3]	0.0	4	1	1	1
103075	1710	spinal muscular atrophy a form	[spinal muscular atrophy an form]	0.0	5	1	1	1
103076	1710	pse	[PSE]	0.0	1	1	1	1
103077	1710	minimal promoter (-62	[minimal promoter (-62]	0.0	3	1	1	1
103078	1710	dse site within the leader	[DSE sites within the leader]	0.0	5	1	1	1
103079	1710	dna-binding characteristic	[DNA-binding characteristics]	0.0	2	1	1	1
103080	1710	contain a core 5'-ggaa-3'	[containing a core 5'-GGAA-3']	0.0	4	1	1	1
103081	1710	minimal element	[minimal element]	0.0	2	1	1	1
103082	1710	t-cell-specific activator tcf-1	[T-cell-specific activator TCF-1]	0.0	3	1	1	1
103083	1710	contrast to the anti-inflammatory mediator	[contrast to the anti-inflammatory mediators]	0.0	5	1	1	1
103084	1710	GM-CSF gene activation	[GM-CSF gene activation]	0.0	3	1	1	1
103085	1710	diffusible activity capable	[diffusible activity capable]	0.0	3	1	1	1
103086	1710	dissociation from inhibitor	[dissociation from inhibitor]	0.0	3	1	1	1
103087	1710	protein kinase B	[Protein kinase B]	0.0	3	1	1	1
103088	1710	pathogenesis arthritis.	[pathogenesis arthritis.]	0.0	2	1	1	1
103089	1710	different REV ltr	[different REV LTRs]	0.0	3	1	1	1
103090	1710	autosomal sex reversal map kb	[autosomal sex reversal map kb]	0.0	5	1	1	1
103091	1710	ldl-receptor	[LDL-receptor]	0.0	1	1	1	1
103092	1710	antiinflammatory mechanism	[antiinflammatory mechanisms]	0.0	2	1	1	1
103093	1710	ref-1 from monocyte	[REF-1 from monocytes]	0.0	3	1	1	1
103094	1710	dominant nf-il6 mutant	[dominant NF-IL6 mutant]	0.0	3	1	1	1
103095	1710	polymorphonuclear neutrophilic granulocyte	[polymorphonuclear neutrophilic granulocytes]	0.0	3	1	1	1
103096	1710	exposure to 137c gamma ray	[exposure to 137Cs gamma rays]	0.0	5	1	1	1
103097	1710	ptx	[PTX]	0.0	1	1	1	1
103098	1710	regulation of t3r	[regulation of T3R]	0.0	3	1	1	1
103099	1710	influence of estradiol	[Influence of estradiol]	0.0	3	1	1	1
103100	1710	T-helper 0 th0	[T-helper 0 Th0]	0.0	3	1	1	1
103101	1710	puc	[pUC]	0.0	1	1	1	1
103102	1710	protein kinase b	[Protein kinase B]	0.0	3	1	1	1
103103	1710	system a grow cell line	[systems a growing cell line]	0.0	5	1	1	1
103104	1710	effect of e1a expression	[effect of E1A expression]	0.0	4	1	1	1
103105	1710	other component of the network	[other components of the network]	0.0	5	1	1	1
103106	1710	D3 calcitriol	[D3 calcitriol]	0.0	2	1	1	1
103107	1710	binding to the dna.	[binding to the DNA.]	0.0	4	1	1	1
103108	1710	ifn-gamma element	[IFN-gamma element]	0.0	2	1	1	1
103109	1710	number in blood lymphocyte	[numbers in blood lymphocytes]	0.0	4	1	1	1
103110	1710	calcium ionophore in Jurkat T cell	[calcium ionophore in Jurkat T cells]	0.0	6	1	1	1
103111	1710	complex protein network	[complex protein network]	0.0	3	1	1	1
103112	1710	select nf-kappa b gene	[select NF-kappa B genes]	0.0	4	1	1	1
103113	1710	protein kinase 1	[protein kinase 1]	0.0	3	1	1	1
103114	1710	single transcription factor	[single transcription factor]	0.0	3	1	1	1
103115	1710	three DNA clone	[Three DNA clones]	0.0	3	1	1	1
103116	1710	active binding heterodimers, at times.	[active binding heterodimers, at times.]	0.0	5	1	1	1
103117	1710	new complex c	[new complex c]	0.0	3	1	1	1
103118	1710	four different icss	[four different ICSs]	0.0	3	1	1	1
103119	1710	cytokine production deficiency	[cytokine production deficiency]	0.0	3	1	1	1
103120	1710	preparation of otf-1	[preparation of OTF-1]	0.0	3	1	1	1
103121	1710	degree of cell contamination	[degree of cell contamination]	0.0	4	2	2	1
103122	1710	immune-modulating effect	[immune-modulating effects]	0.0	2	1	1	1
103123	1710	assembly c5b-7	[Assembly C5b-7]	0.0	2	1	1	1
103124	1710	er level in leukocyte	[ER level in leukocytes]	0.0	4	1	1	1
103125	1710	indicate a role for protooncogene	[indicating a role for protooncogenes]	0.0	5	1	1	1
103126	1710	receptor gr of human leukocyte	[receptor GR of human leukocytes]	0.0	5	1	1	1
103127	1710	latent, viral gene	[latent, viral genes]	0.0	3	1	1	1
103128	1710	differentiation to alveolar macrophage	[differentiation to alveolar macrophages]	0.0	4	1	1	1
103129	1710	inhibitor of the phosphatidylinositol 3-kinase	[inhibitors of the phosphatidylinositol 3-kinase]	0.0	5	1	1	1
103130	1710	hpc colony-forming cell	[HPCs colony-forming cells]	0.0	3	1	1	1
103131	1710	induction by a variety	[induction by a variety]	0.0	4	1	1	1
103132	1710	activation of human blood T cell	[activation of human blood T cells]	0.0	6	1	1	1
103133	1710	interferon-inducible element	[interferon-inducible element]	0.0	2	1	1	1
103134	1710	analysis in tnf-alpha T lymphocyte	[Analyses in TNF-alpha T lymphocytes]	0.0	5	1	1	1
103135	1710	mechanism regulate apoptosis	[mechanisms regulating apoptosis]	0.0	3	1	1	1
103136	1710	lt gene induction	[LT gene induction]	0.0	3	1	1	1
103137	1710	ets transcription factor Fli-1	[Ets transcription factor Fli-1]	0.0	4	1	1	1
103138	1710	two il-4 signal pathway	[two IL-4 signaling pathways]	0.0	4	1	1	1
103139	1710	time of h	[times of h]	0.0	3	1	1	1
103140	1710	ca2+ response	[Ca2+ responses]	0.0	2	1	1	1
103141	1710	woman with dupuytren' disease	[women with Dupuytren's disease]	0.0	4	1	1	1
103142	1710	patient with major depressive disorder	[patients with major depressive disorder]	0.0	5	1	1	1
103143	1710	use standard technique	[using standard techniques]	0.0	3	1	1	1
103144	1710	site-specific property	[site-specific properties]	0.0	2	1	1	1
103145	1710	factor like nf-il6	[factors like NF-IL6]	0.0	3	1	1	1
103146	1710	tal1 activation	[TAL1 activation]	0.0	2	1	1	1
103147	1710	then the high expression	[then the high expression]	0.0	4	1	1	1
103148	1710	myelomonocytic cell line om-10.1	[myelomonocytic cell line OM-10.1]	0.0	4	1	1	1
103149	1710	approximate map region	[approximate map regions]	0.0	3	1	1	1
103150	1710	lymphocytic infiltrate	[lymphocytic infiltrates]	0.0	2	1	1	1
103151	1710	mechanism involve other steroid hormone	[mechanisms involving other steroid hormones]	0.0	5	1	1	1
103152	1710	dna-swap	[DNA-swap]	0.0	1	1	1	1
103153	1710	two groups, sr	[two groups, SR]	0.0	3	1	1	1
103154	1710	develop thymocyte a form	[developing thymocytes a form]	0.0	4	1	1	1
103155	1710	t-cell proliferation with t(x;14) translocation	[T-cell proliferations with t(X;14) translocations]	0.0	5	1	1	1
103156	1710	patient with major disorder MDD	[patients with major disorder MDD]	0.0	5	1	1	1
103157	1710	isolation of cell	[Isolation of cells]	0.0	3	1	1	1
103158	1710	eosinophil life-prolonging effect	[eosinophil life-prolonging effects]	0.0	3	1	1	1
103159	1710	IL-12 up-regulation	[IL-12 up-regulation]	0.0	2	1	1	1
103160	1710	-326 region	[-326 region]	0.0	2	1	1	1
103161	1710	low calcemic effect	[lower calcemic effects]	0.0	3	1	1	1
103162	1710	T pathway	[T pathway]	0.0	2	1	1	1
103163	1710	phosphorylate nfatp	[phosphorylating NFATp]	0.0	2	1	1	1
103164	1710	number of gr (mnl)	[number of GR (MNL)]	0.0	4	1	1	1
103165	1710	cd19 /vav/phosphatidylinositol-3	[CD19 /Vav/phosphatidylinositol-3]	0.0	2	1	1	1
103166	1710	prolonged infection	[prolonged infection]	0.0	2	1	1	1
103167	1710	activity gene element	[activity gene elements]	0.0	3	1	1	1
103168	1710	rate of migration	[rate of migration]	0.0	3	1	1	1
103169	1710	vitro, antigen	[vitro, antigens]	0.0	2	1	1	1
103170	1710	distal nf-kappa b motif	[distal NF-kappa B motif]	0.0	4	1	1	1
103171	1710	IL-13 activation	[IL-13 activation]	0.0	2	1	1	1
103172	1710	activation of factor-kappaB by lipopolysaccharide	[Activation of factor-kappaB by lipopolysaccharide]	0.0	5	1	1	1
103173	1710	interaction with other component	[interaction with other components]	0.0	4	1	1	1
103174	1710	activity of MCM gene promoter	[activities of MCM gene promoters]	0.0	5	1	1	1
103175	1710	role of glucocorticoid receptor/ characteristic	[role of glucocorticoid receptor/s characteristics]	0.0	5	1	1	1
103176	1710	hydroxylase	[hydroxylase]	0.0	1	1	1	1
103177	1710	role as a mechanism	[role as a mechanism]	0.0	4	1	1	1
103178	1710	CIITA overexpression in cell	[CIITA overexpression in cells]	0.0	4	1	1	1
103179	1710	astrocytomas /glioblastomas	[astrocytomas /glioblastomas]	0.0	2	1	1	1
103180	1710	signal with CD40 ligand activation	[Signaling with CD40 ligand activation]	0.0	5	1	1	1
103181	1710	posttranslational activation via release	[posttranslational activation via release]	0.0	4	1	1	1
103182	1710	tolerance induction	[tolerance induction]	0.0	2	1	1	1
103183	1710	fasl promoter activity	[FasL promoter activity]	0.0	3	1	1	1
103184	1710	g-csf 8% dead cell g-csf	[G-CSF 8% dead cells G-CSF]	0.0	5	1	1	1
103185	1710	diapedesis of leukocyte	[diapedesis of leukocytes]	0.0	3	1	1	1
103186	1710	major histocompatibility fashion	[major histocompatibility fashion]	0.0	3	1	1	1
103187	1710	target cell for IL-5	[target cells for IL-5]	0.0	4	1	1	1
103188	1710	transcription factor for maximal expression	[transcription factor for maximal expression]	0.0	5	1	1	1
103189	1710	element ionophore a23187	[element ionophore A23187]	0.0	3	1	1	1
103190	1710	existence of a copy	[existence of a copies]	0.0	4	1	1	1
103191	1710	peripheral lymphocyte from the two	[peripheral lymphocytes from the two]	0.0	5	1	1	1
103192	1710	cause of growth arrest.	[cause of growth arrest.]	0.0	4	1	1	1
103193	1710	host interaction	[host interaction]	0.0	2	1	1	1
103194	1710	blood leukocyte from carrier	[blood leukocytes from carriers]	0.0	4	1	1	1
103195	1710	inhibition by the matrix protein tenascin	[Inhibition by the matrix protein tenascin]	0.0	6	1	1	1
103196	1710	infection of b-lymphocyte	[Infection of B-lymphocytes]	0.0	3	1	1	1
103197	1710	fuse cell	[fusing cells]	0.0	2	1	1	1
103198	1710	factor-kappa b dna-binding activity	[factor-kappa B DNA-binding activity]	0.0	4	1	1	1
103199	1710	absence of t-cell- transcription factor	[Absence of T-cell- transcription factors]	0.0	5	1	1	1
103200	1710	dominant ikappab	[dominant IkappaB]	0.0	2	1	1	1
103201	1710	degradation of peptide	[degradation of peptide]	0.0	3	1	1	1
103202	1710	course (p	[course (P]	0.0	2	1	1	1
103203	1710	tpa factor octamer-associated protein	[TPA factor octamer-associated protein]	0.0	4	1	1	1
103204	1710	transmembrane mechanism in T lymphocyte	[transmembrane mechanism in T lymphocytes]	0.0	5	1	1	1
103205	1710	allele-specific expression of wt1	[allele-specific expression of WT1]	0.0	4	1	1	1
103206	1710	patient with primary myelodysplastic syndrome	[patients with primary myelodysplastic syndromes]	0.0	5	1	1	1
103207	1710	overexpression of camp inhibition	[overexpression of cAMP inhibition]	0.0	4	1	1	1
103208	1710	implication for specificity of the enhancer	[implications for specificity of the enhancer]	0.0	6	1	1	1
103209	1710	aldosterone,	[aldosterone,]	0.0	1	1	1	1
103210	1710	stimulation, two kappa complex	[stimulation, two kappa complexes]	0.0	4	1	1	1
103211	1710	abundant activity of extract	[abundant activity of extracts]	0.0	4	1	1	1
103212	1710	effect on differentiation of k562 cell	[effects on differentiation of K562 cells]	0.0	6	1	1	1
103213	1710	various breakpoint range	[various breakpoints ranging]	0.0	3	1	1	1
103214	1710	45 residue	[45 residues]	0.0	2	1	1	1
103215	1710	rapidak effect	[rapid, effects]	0.0	2	1	1	1
103216	1710	only the association GATA binding site	[only the association GATA binding sites]	0.0	6	1	1	1
103217	1710	catalytic subunit of protein kinase	[catalytic subunit of protein kinase]	0.0	5	1	1	1
103218	1710	83% increase	[83% increase]	0.0	2	1	1	1
103219	1710	downmodulation of transcription factor	[downmodulation of transcription factors]	0.0	4	1	1	1
103220	1710	plasmid replication	[plasmid replication]	0.0	2	1	1	1
103221	1710	turn due to deregulation	[turn due to deregulation]	0.0	4	1	1	1
103222	1710	combination of this transcription factor	[combinations of these transcription factors]	0.0	5	1	1	1
103223	1710	immediate dephosphorylation at phosphoserine residue	[immediate dephosphorylation at phosphoserine residues]	0.0	5	1	1	1
103224	1710	induction of growth response	[induction of growth response]	0.0	4	1	1	1
103225	1710	carry status.	[carrying status.]	0.0	2	1	1	1
103226	1710	overrepresentation of aggressive histologic type	[overrepresentation of aggressive histologic types]	0.0	5	1	1	1
103227	1710	use in treatment	[use in treatment]	0.0	3	1	1	1
103228	1710	Owen	[Owen]	0.0	1	1	1	1
103229	1710	three- to eight-fold enhancement	[three- to eight-fold enhancement]	0.0	4	1	1	1
103230	1710	deletion in blood (PB) granulocyte	[deletions in blood (PB) granulocytes]	0.0	5	1	1	1
103231	1710	gamma-chain	[gamma-chain]	0.0	1	1	1	1
103232	1710	BOX1 motif	[BOX1 motif]	0.0	2	2	2	1
103233	1710	activation of the jun	[activation of the jun]	0.0	4	1	1	1
103234	1710	similar concentration	[similar concentrations]	0.0	2	1	1	1
103235	1710	especially low density lipoprotein	[especially low density lipoprotein]	0.0	4	1	1	1
103236	1710	alteration of a serine	[Alteration of a serine]	0.0	4	1	1	1
103237	1710	high constitutive expression	[high constitutive expression]	0.0	3	1	1	1
103238	1710	mutagenesis of a site	[mutagenesis of an site]	0.0	4	1	1	1
103239	1710	herpesvirus 6 strain gs	[herpesvirus 6 strains GS]	0.0	4	1	1	1
103240	1710	2.5- reduction	[2.5- reduction]	0.0	2	1	1	1
103241	1710	use a nfatp antibody	[using a NFATp antibody]	0.0	4	1	1	1
103242	1710	regulate the machinery in pro-B cell	[regulating the machinery in pro-B cells]	0.0	6	1	1	1
103243	1710	cis-acting motif	[cis-acting motifs]	0.0	2	1	1	1
103244	1710	tissue homogenate	[tissue homogenates]	0.0	2	1	1	1
103245	1710	variation in cytokine promoter region	[variation in cytokine promoter regions]	0.0	5	1	1	1
103246	1710	15 microm	[15 microM]	0.0	2	1	1	1
103247	1710	encode ebf	[encoding EBF]	0.0	2	1	1	1
103248	1710	five member MYC	[Five members MYC]	0.0	3	1	1	1
103249	1710	properties unlike oncoprotein	[properties, unlike oncoproteins]	0.0	3	1	1	1
103250	1710	animal model of autoimmunity,	[animal models of autoimmunity,]	0.0	4	1	1	1
103251	1710	transcriptional element in the tsp	[transcriptional elements in the TSP]	0.0	5	1	1	1
103252	1710	secretion of ig	[secretion of Ig]	0.0	3	1	1	1
103253	1710	granulocyte/ macrophage colony-stimumulatelany-stg factor	[granulocyte/ macrophage colony-stimulating factor]	0.0	4	1	1	1
103254	1710	acting responses.	[acting responses.]	0.0	2	1	1	1
103255	1710	circumstances, Calphostin C	[circumstances, Calphostin C]	0.0	3	1	1	1
103256	1710	xist locus	[XIST locus]	0.0	2	1	1	1
103257	1710	intracellular receptor for fk506	[intracellular receptors for FK506]	0.0	4	1	1	1
103258	1710	retroviral	[retroviral]	0.0	1	1	1	1
103259	1710	allele of c-Raf-1	[allele of c-Raf-1]	0.0	3	1	1	1
103260	1710	hiv long repeat transcription	[HIV long repeat transcription]	0.0	4	1	1	1
103261	1710	th cell line	[Th cell lines]	0.0	3	1	1	1
103262	1710	localize the time-frame of action	[localizing the time-frame of action]	0.0	5	1	1	1
103263	1710	transcription involvement of a set	[transcription involvement of a set]	0.0	5	1	1	1
103264	1710	expression vector of ras	[expression vectors of ras]	0.0	4	1	1	1
103265	1710	direct interaction with nfatp	[direct interaction with NFATp]	0.0	4	1	1	1
103266	1710	underlie the biological activity	[underlying the biological activity]	0.0	4	1	1	1
103267	1710	min) exercise	[min) exercise]	0.0	2	1	1	1
103268	1710	basis of severe infection	[basis of severe infections]	0.0	4	1	1	1
103269	1710	previously, a inducible enhancer between nucleotide	[Previously, an inducible enhancer between nucleotides]	0.0	6	1	1	1
103270	1710	hepor transcription activity	[hEpoR transcription activity]	0.0	3	1	1	1
103271	1710	whole peripheral blood from healthy donor	[whole peripheral blood from healthy donors]	0.0	6	1	1	1
103272	1710	thus, ligation	[Thus, ligation]	0.0	2	1	1	1
103273	1710	promoter region upstream	[promoter region upstream]	0.0	3	1	1	1
103274	1710	high level of b1 encoding transcript	[higher levels of B1 encoding transcripts]	0.0	6	1	1	1
103275	1710	glucocorticoid receptor characteristic on leukocyte	[glucocorticoid receptor characteristics on leukocytes]	0.0	5	1	1	1
103276	1710	moreover, nf-atp mouse old than week	[Moreover, NF-ATp mice older than weeks]	0.0	6	1	1	1
103277	1710	Gardnerella	[Gardnerella]	0.0	1	1	1	1
103278	1710	potent presenter	[potent presenters]	0.0	2	1	1	1
103279	1710	status comparison with criteria]	[status comparison with criteria]]	0.0	4	1	1	1
103280	1710	"pure"	["pure"]	0.0	1	1	1	1
103281	1710	lead to expression of gene	[leading to expression of genes]	0.0	5	1	1	1
103282	1710	protein kinase (sapk)/jun n-terminal kinase	[protein kinase (SAPK)/Jun N-terminal kinase]	0.0	5	1	1	1
103283	1710	proliferator-activated receptor gamma a transcription factor	[proliferator-activated receptor gamma a transcription factor]	0.0	6	1	1	1
103284	1710	position -306 relative	[positions -306 relative]	0.0	3	1	1	1
103285	1710	several new function	[Several new functions]	0.0	3	1	1	1
103286	1710	small potential phosphoprotein of function.	[small potential phosphoprotein of function.]	0.0	5	1	1	1
103287	1710	production in precursors, blood monocyte	[production in precursors, blood monocytes]	0.0	5	1	1	1
103288	1710	purpose in view.	[purposes in view.]	0.0	3	1	1	1
103289	1710	dual action of retinoic acid	[Dual action of retinoic acid]	0.0	5	1	1	1
103290	1710	20 exposures.	[20 exposures.]	0.0	2	1	1	1
103291	1710	early effect	[early effects]	0.0	2	1	1	1
103292	1710	two region in the domain	[two regions in the domain]	0.0	5	1	1	1
103293	1710	t-cell line 6tg1.1	[T-cell line 6TG1.1]	0.0	3	1	1	1
103294	1710	implication for the role	[implications for the role]	0.0	4	1	1	1
103295	1710	il-2r alpha tac	[IL-2R alpha Tac]	0.0	3	1	1	1
103296	1710	hormonal regulation	[hormonal regulation]	0.0	2	1	1	1
103297	1710	different approach	[different approaches]	0.0	2	1	1	1
103298	1710	tract-binding protein	[tract-binding protein]	0.0	2	1	1	1
103299	1710	20- affinity	[20- affinity]	0.0	2	1	1	1
103300	1710	T lymphocytic lineage	[T lymphocytic lineage]	0.0	3	1	1	1
103301	1710	multinucleated cell	[multinucleated cells]	0.0	2	1	1	1
103302	1710	peptide residue contact tcr	[peptide residues contacting TCR]	0.0	4	1	1	1
103303	1710	continuous myeloid cell line	[continuous myeloid cell line]	0.0	4	1	1	1
103304	1710	various breakpoint 11 range	[various breakpoints 11 ranging]	0.0	4	1	1	1
103305	1710	however, use ATL-16T extract	[However, using ATL-16T extract]	0.0	4	1	1	1
103306	1710	expression of cycle gene include brlf1	[expression of cycle genes including BRLF1]	0.0	6	1	1	1
103307	1710	include chronic leukaemia CML	[including chronic leukaemia CML]	0.0	4	2	2	1
103308	1710	preferential presentation in comparison	[Preferential presentation in comparison]	0.0	4	1	1	1
103309	1710	42 gene	[42 genes]	0.0	2	1	1	1
103310	1710	3.16 mg/24h; n:	[3.16 mg/24h; N:]	0.0	3	1	1	1
103311	1710	molecular mechanism of functional synergy	[molecular mechanisms of functional synergy]	0.0	5	1	1	1
103312	1710	NFAT translocation	[NFAT translocation]	0.0	2	1	1	1
103313	1710	monocyte correlate	[monocytes correlating]	0.0	2	1	1	1
103314	1710	initiator of coagulation	[initiator of coagulation]	0.0	3	1	1	1
103315	1710	activator of the long repeat	[activator of the long repeat]	0.0	5	1	1	1
103316	1710	differentiation of progenitor to cell	[differentiation of progenitors to cells]	0.0	5	1	1	1
103317	1710	factor bind to the tced	[factors binding to the TCEd]	0.0	5	1	1	1
103318	1710	drosophila Schneider cell	[Drosophila Schneider cells]	0.0	3	1	1	1
103319	1710	nm in controls; p than 0.01).	[nM in controls; P than 0.01).]	0.0	6	1	1	1
103320	1710	analysis of mononuclear	[analysis of mononuclear]	0.0	3	1	1	1
103321	1710	extensive evaluation	[extensive evaluation]	0.0	2	1	1	1
103322	1710	persistent group c infection	[persistent group C infection]	0.0	4	2	2	1
103323	1710	patient present with hilar adenopathy	[patients presenting with hilar adenopathy]	0.0	5	1	1	1
103324	1710	association of alteration proviral latency	[Association of alterations proviral latency]	0.0	5	1	1	1
103325	1710	turnover rate,	[turnover rate,]	0.0	2	1	1	1
103326	1710	pregnant woman first, 10 second	[pregnant women first, 10 second]	0.0	5	1	1	1
103327	1710	MKK activity	[MKK activity]	0.0	2	1	1	1
103328	1710	disease in acute myelogenous leukemia	[disease in acute myelogenous leukemia]	0.0	5	1	1	1
103329	1710	interferon-induced transcription factor	[interferon-induced transcription factor]	0.0	3	1	1	1
103330	1710	role of e2f-1 in differentiation	[role of E2F-1 in differentiation]	0.0	5	1	1	1
103331	1710	variant.	[variant.]	0.0	1	1	1	1
103332	1710	antibody against CD40	[antibody against CD40]	0.0	3	1	1	1
103333	1710	r-htbp-1 with rhu tnfr:fc	[r-hTBP-1 with rhu TNFR:Fc]	0.0	4	1	1	1
103334	1710	1,25-(oh)2 D3 in monocyte	[1,25-(OH)2 D3 in monocytes]	0.0	4	1	1	1
103335	1710	thymus environment	[thymus environment]	0.0	2	1	1	1
103336	1710	key role in the action	[key role in the actions]	0.0	5	1	1	1
103337	1710	activation of 3 -stat5a pathway	[Activation of 3 -STAT5a pathway]	0.0	5	1	1	1
103338	1710	hepatocyte factor HNF-1alpha	[hepatocyte factors HNF-1alpha]	0.0	3	1	1	1
103339	1710	high (p<.001) in untreated euthymic patient	[higher (P<.001) in untreated euthymic patients]	0.0	6	1	1	1
103340	1710	antigen production	[antigen production]	0.0	2	1	1	1
103341	1710	step in the study	[step in the study]	0.0	4	1	1	1
103342	1710	direct mechanism of a component	[direct mechanism of a component]	0.0	5	1	1	1
103343	1710	execution	[execution]	0.0	1	1	1	1
103344	1710	efficient promoter in cell of species	[efficient promoters in cells of species]	0.0	6	1	1	1
103345	1710	subgroup c strain	[subgroup C strain]	0.0	3	1	1	1
103346	1710	variance results.	[variance results.]	0.0	2	1	1	1
103347	1710	ca2+ in the tubule	[Ca2+ in the tubules]	0.0	4	1	1	1
103348	1710	(1) multiple substitution	[(1) multiple substitutions]	0.0	3	1	1	1
103349	1710	prerequisite step	[prerequisite step]	0.0	2	1	1	1
103350	1710	three disparate stimulus-	[three disparate stimulus-]	0.0	3	1	1	1
103351	1710	high level of a binding activity	[high levels of a binding activity]	0.0	6	1	1	1
103352	1710	adhesion to ec	[adhesion to EC]	0.0	3	1	1	1
103353	1710	T lymphocyte-specific enhancer element	[T lymphocyte-specific enhancer element]	0.0	4	1	1	1
103354	1710	early event in erythroid maturation	[early events in erythroid maturation]	0.0	5	1	1	1
103355	1710	inhibitor of nf-kappab ikappab-alphas32/36a	[inhibitor of NF-kappaB IkappaB-alphaS32/36A]	0.0	4	1	1	1
103356	1710	human immunodeficiency virus terminal	[human immunodeficiency virus terminal]	0.0	4	1	1	1
103357	1710	reactivity to alpha,25(OH)2D3	[reactivity to alpha,25(OH)2D3]	0.0	3	1	1	1
103358	1710	anti- CD28 antibody	[anti- CD28 antibody]	0.0	3	1	1	1
103359	1710	22% probability recur	[22% probability recurring]	0.0	3	1	1	1
103360	1710	phospholipase C gamma	[phospholipase C gamma]	0.0	3	2	2	1
103361	1710	two response element ISRE	[Two response elements ISRE]	0.0	4	1	1	1
103362	1710	3 kb upstream	[3 kb upstream]	0.0	3	1	1	1
103363	1710	run-on transcription assay	[run-on transcription assays]	0.0	3	1	1	1
103364	1710	natural variant	[natural variant]	0.0	2	1	1	1
103365	1710	respect to expansion	[respect to expansion]	0.0	3	1	1	1
103366	1710	woman with cancer	[woman with cancer]	0.0	3	1	1	1
103367	1710	hla-dr- a form of leukemia	[HLA-DR- a form of leukemia]	0.0	5	1	1	1
103368	1710	spread on cell	[spreading on cells]	0.0	3	1	1	1
103369	1710	receptor GCR on peripheral leucocyte	[receptors GCR on peripheral leucocytes]	0.0	5	1	1	1
103370	1710	rather marker	[rather markers]	0.0	2	1	1	1
103371	1710	exposure of cell to lipopolysaccharide	[Exposure of cells to lipopolysaccharide]	0.0	5	1	1	1
103372	1710	x-y element	[X-Y elements]	0.0	2	1	1	1
103373	1710	inhibitor of protein phosphatase	[inhibitor of protein phosphatases]	0.0	4	1	1	1
103374	1710	role for NF-AT	[role for NF-AT]	0.0	3	1	1	1
103375	1710	thus, competition between general activator	[Thus, competition between general activators]	0.0	5	1	1	1
103376	1710	clinical course 0.05, chi2	[clinical course 0.05, chi2]	0.0	4	1	1	1
103377	1710	[effect	[[Effect]	0.0	1	2	2	1
103378	1710	strong active promoter	[strong active promoter]	0.0	3	1	1	1
103379	1710	negative regulation of the promoter	[negative regulation of the promoter]	0.0	5	1	1	1
103380	1710	translocation nuclear factor	[translocation nuclear factor]	0.0	3	2	2	1
103381	1710	b/rel activity	[B/Rel activity]	0.0	2	1	1	1
103382	1710	correlation tcrzeta	[Correlations TCRzeta]	0.0	2	1	1	1
103383	1710	CD40 signal component	[CD40 signaling components]	0.0	3	1	1	1
103384	1710	replication of Epstein-Barr virus	[replication of Epstein-Barr virus]	0.0	4	1	1	1
103385	1710	significant rapid increase	[significant rapid increase]	0.0	3	1	1	1
103386	1710	lead to gc resistance	[leading to GC resistance]	0.0	4	1	1	1
103387	1710	absence of CD28 MoAb	[absence of CD28 MoAb]	0.0	4	1	1	1
103388	1710	production of type 2 cytokine	[production of type 2 cytokines]	0.0	5	1	1	1
103389	1710	major histocompatibility class immunodeficiency	[major histocompatibility class immunodeficiency]	0.0	4	1	1	1
103390	1710	study, corticosteroid type	[study, corticosteroid Type]	0.0	3	1	1	1
103391	1710	characteristic binding profile	[characteristic binding profile]	0.0	3	1	1	1
103392	1710	gp160 activation	[gp160 activation]	0.0	2	1	1	1
103393	1710	make use of the gr	[making use of the GR]	0.0	5	1	1	1
103394	1710	factor specific to hematopoietic cell	[factor specific to hematopoietic cells]	0.0	5	1	1	1
103395	1710	transcription factor from family	[transcription factors from families]	0.0	4	1	1	1
103396	1710	separate cis-acting regulatory element	[separate cis-acting regulatory elements]	0.0	4	1	1	1
103397	1710	subsequent apoptosis	[subsequent apoptosis]	0.0	2	1	1	1
103398	1710	546-nucleotide reading frame ORF	[546-nucleotide reading frame ORF]	0.0	4	1	1	1
103399	1710	blast from patient with leukaemia AML	[blasts from patients with leukaemia AML]	0.0	6	1	1	1
103400	1710	common origin	[common origin]	0.0	2	1	1	1
103401	1710	tyrosine phosphorylation of substrate in	[tyrosine phosphorylation of substrates in]	0.0	5	1	1	1
103402	1710	namely the immunoglobulin chain enhancer	[namely the immunoglobulin chain enhancer]	0.0	5	1	1	1
103403	1710	reach a peak at minute	[reaching a peak at min]	0.0	5	1	1	1
103404	1710	male with x-linked immunodeficiency	[Males with X-linked immunodeficiency]	0.0	4	1	1	1
103405	1710	action of cytotoxic protein	[action of cytotoxic proteins]	0.0	4	1	1	1
103406	1710	involve the arm of human chromosome	[involving the arm of human chromosome]	0.0	6	1	1	1
103407	1710	vddr-ii	[VDDR-II]	0.0	1	1	1	1
103408	1710	absorptive patient	[absorptive patients]	0.0	2	1	1	1
103409	1710	expression in HeLa cell	[expression in HeLa cells]	0.0	4	1	1	1
103410	1710	pro-interleukin 1beta gene	[pro-interleukin 1beta gene]	0.0	3	1	1	1
103411	1710	immunodeficiency virus type 1 repeat	[immunodeficiency virus type 1 repeats]	0.0	5	1	1	1
103412	1710	populations, include some non-Ashkenazi group	[populations, including some non-Ashkenazi groups]	0.0	5	1	1	1
103413	1710	signal response	[signalling response]	0.0	2	1	1	1
103414	1710	number of site	[number of sites]	0.0	3	1	1	1
103415	1710	variety of malignancy	[variety of malignancies]	0.0	3	1	1	1
103416	1710	however, simultaneous incubation with dexamethasone	[However, simultaneous incubation with dexamethasone]	0.0	5	1	1	1
103417	1710	Also, mol/L)	[Also, mol/L)]	0.0	2	1	1	1
103418	1710	transcription of certain mediator	[transcription of certain mediators]	0.0	4	1	1	1
103419	1710	encode endothelial adhesion molecule	[encoding endothelial adhesion molecules]	0.0	4	1	1	1
103420	1710	stimulation of mononuclear cell with interleukin-4	[Stimulation of mononuclear cells with interleukin-4]	0.0	6	1	1	1
103421	1710	presence of 1	[presence of 1]	0.0	3	1	1	1
103422	1710	same site specificity	[same site specificity]	0.0	3	1	1	1
103423	1710	expression of kappa gene	[expression of kappa genes]	0.0	4	1	1	1
103424	1710	bovine serum-contain medium	[bovine serum-containing medium]	0.0	3	1	1	1
103425	1710	high-resolution, gel electrophoresis system	[high-resolution, gel electrophoresis system]	0.0	4	1	1	1
103426	1710	great inhibition	[greater inhibition]	0.0	2	1	1	1
103427	1710	BZ1 monoclonal antibody	[BZ1 monoclonal antibody]	0.0	3	1	1	1
103428	1710	induction of gene product	[induction of gene products]	0.0	4	1	1	1
103429	1710	many report	[many reports]	0.0	2	1	1	1
103430	1710	suggest a functional interaction	[suggesting a functional interaction]	0.0	4	1	1	1
103431	1710	protein in the regulation	[proteins in the regulation]	0.0	4	1	1	1
103432	1710	clonal expansion) (by abortive stimulation	[clonal expansion) (by abortive stimulation]	0.0	5	1	1	1
103433	1710	complex with extract from Jurkat cell	[complexes with extracts from Jurkat cells]	0.0	6	1	1	1
103434	1710	epitope outside this region	[epitopes outside this region]	0.0	4	1	1	1
103435	1710	cd11b/cd18 expression	[CD11b/CD18 expression]	0.0	2	2	2	1
103436	1710	h before il-4 stimulation	[h before IL-4 stimulation]	0.0	4	1	1	1
103437	1710	stimulation of junb transcription	[stimulation of junB transcription]	0.0	4	1	1	1
103438	1710	ebv protein expression	[EBV protein expression]	0.0	3	1	1	1
103439	1710	asparagine (succinimide) residue	[asparagine (succinimide) residue]	0.0	3	1	1	1
103440	1710	angioimmunoblastic t-cell lymphoma AITL	[angioimmunoblastic T-cell lymphoma AITL]	0.0	4	1	1	1
103441	1710	woman with non-hodgkin' lymphoma	[woman with non-Hodgkin's lymphoma]	0.0	4	1	1	1
103442	1710	transactivate protein	[transactivating protein]	0.0	2	1	1	1
103443	1710	isolation of cell from peripheral blood	[Isolation of cells from peripheral blood]	0.0	6	1	1	1
103444	1710	region beta chain V beta	[region beta chain V beta]	0.0	5	1	1	1
103445	1710	Comparison human mouse genomic sequence	[Comparison human mouse genomic sequences]	0.0	5	1	1	1
103446	1710	susceptibility to this lysis	[susceptibility to this lysis]	0.0	4	1	1	1
103447	1710	number of protein via interaction	[number of proteins via interaction]	0.0	5	1	1	1
103448	1710	functional t1/2 of 4 hour	[functional t1/2 of 4 hr]	0.0	5	1	1	1
103449	1710	triplex formation	[Triplex formation]	0.0	2	1	1	1
103450	1710	receptor factor in the signal mechanism	[receptor factors in the signaling mechanisms]	0.0	6	1	1	1
103451	1710	form of arthritis example, osteoarthritis	[forms of arthritis example, osteoarthritis]	0.0	5	1	1	1
103452	1710	Abelson virus	[Abelson virus]	0.0	2	1	1	1
103453	1710	potential homologue of cyclosporin a	[potential homologues of cyclosporin A]	0.0	5	1	1	1
103454	1710	tissue-specific expression of class gene	[tissue-specific expression of class genes]	0.0	5	1	1	1
103455	1710	cell divisions,	[cell divisions,]	0.0	2	1	1	1
103456	1710	cell to apoptosis	[cells to apoptosis]	0.0	3	2	2	1
103457	1710	cortisol the number of glucocorticoid receptor	[cortisol the number of glucocorticoid receptors]	0.0	6	1	1	1
103458	1710	regulator of human granulocyte apoptosis	[regulator of human granulocyte apoptosis]	0.0	5	1	1	1
103459	1710	weak competitor	[weak competitor]	0.0	2	1	1	1
103460	1710	molecular weight of kda	[molecular weight of kDa]	0.0	4	1	1	1
103461	1710	extracellular kinase erk pathway	[extracellular kinase Erk pathway]	0.0	4	1	1	1
103462	1710	second weak complex	[second weak complex]	0.0	3	1	1	1
103463	1710	pp56(lck) mutant lack the entire domain	[pp56(lck) mutants lacking the entire domain]	0.0	6	1	1	1
103464	1710	cn inhibition in leukocyte	[CN inhibition in leukocytes]	0.0	4	1	1	1
103465	1710	potential target in state	[potential target in states]	0.0	4	1	1	1
103466	1710	production of (tnf)-alpha	[production of (TNF)-alpha]	0.0	3	1	1	1
103467	1710	binding of peptide	[Binding of peptide]	0.0	3	1	1	1
103468	1710	pathway dependent	[pathway dependent]	0.0	2	1	1	1
103469	1710	suggest cooperativity	[suggesting cooperativity]	0.0	2	1	1	1
103470	1710	possibilities, such as distribution	[possibilities, such as distribution]	0.0	4	1	1	1
103471	1710	blood of allergic patient	[blood of allergic patients]	0.0	4	1	1	1
103472	1710	t-cell expression	[T-cell expression]	0.0	2	1	1	1
103473	1710	multifunctional target	[multifunctional target]	0.0	2	1	1	1
103474	1710	sense orientation	[sense orientation]	0.0	2	1	1	1
103475	1710	case of lymphocytic leukemia CLL	[cases of lymphocytic leukemia CLL]	0.0	5	1	1	1
103476	1710	t3 receptor nt3r	[T3 receptor NT3R]	0.0	3	1	1	1
103477	1710	minority	[minority]	0.0	1	4	4	1
103478	1710	regulation in normal blood T cell	[regulation in normal blood T cells]	0.0	6	1	1	1
103479	1710	mechanism for cytokine	[mechanism for cytokine]	0.0	3	1	1	1
103480	1710	hybridization signal in interphase	[hybridization signals in interphase]	0.0	4	1	1	1
103481	1710	late phase of reaction	[late phase of reaction]	0.0	4	1	1	1
103482	1710	chicken erythrocyte factor kda)	[chicken erythrocyte factor kDa)]	0.0	4	1	1	1
103483	1710	however, a transactivator	[However, a transactivator]	0.0	3	1	1	1
103484	1710	role of various element	[role of various elements]	0.0	4	1	1	1
103485	1710	RA enhancer of RA gene	[RA enhancers of RA genes]	0.0	5	1	1	1
103486	1710	nuclear factor (nf)-il6	[nuclear factor (NF)-IL6]	0.0	3	1	1	1
103487	1710	nuclear volume,	[nuclear volume,]	0.0	2	1	1	1
103488	1710	study of leukocyte in endometrium	[studies of leukocytes in endometrium]	0.0	5	1	1	1
103489	1710	type ii interleukin-1	[type II interleukin-1]	0.0	3	1	1	1
103490	1710	dna-binding specificity for kappa b motif	[DNA-binding specificities for kappa B motifs]	0.0	6	1	1	1
103491	1710	gene in the beta-globin locus	[genes in the beta-globin locus]	0.0	5	1	1	1
103492	1710	transactivation of gene	[transactivation of genes]	0.0	3	1	1	1
103493	1710	fragment extend nucleotide 5'	[fragment extending nucleotides 5']	0.0	4	1	1	1
103494	1710	activation of different Jak tyrosine kinase	[activation of different Jak tyrosine kinases]	0.0	6	1	1	1
103495	1710	motif in the cd3-epsilon	[motifs in the CD3-epsilon]	0.0	4	1	1	1
103496	1710	regulation of human epsilon germline transcription	[Regulation of human epsilon germline transcription]	0.0	6	1	1	1
103497	1710	requirement in the system	[requirement in the system]	0.0	4	1	1	1
103498	1710	gabp binding	[GABP binding]	0.0	2	1	1	1
103499	1710	Epstein-Barr virus EBV antigen EBNA-2	[Epstein-Barr virus EBV antigen EBNA-2]	0.0	5	1	1	1
103500	1710	class ii histocompatibility cell line	[class II histocompatibility cell lines]	0.0	5	1	1	1
103501	1710	however, high millileter at P;	[However, high ml at h;]	0.0	5	1	1	1
103502	1710	exact role of this protein	[exact role of these proteins]	0.0	5	1	1	1
103503	1710	week after termination	[weeks after termination]	0.0	3	1	1	1
103504	1710	lymphocyte of healthy woman second	[lymphocytes of healthy women second]	0.0	5	1	1	1
103505	1710	preincubation of endothelial cell with endotoxin	[Preincubation of endothelial cells with endotoxin]	0.0	6	1	1	1
103506	1710	fine azurophilic granularity	[fine azurophilic granularity]	0.0	3	1	1	1
103507	1710	apparent effect	[apparent effect]	0.0	2	2	2	1
103508	1710	activation-dependent events: the CsA translocation	[activation-dependent events: the CsA translocation]	0.0	5	1	1	1
103509	1710	tested: dephosphorylation of factor	[tested: dephosphorylation of factor]	0.0	4	1	1	1
103510	1710	25 basal cell carcinoma bcc	[25 basal cell carcinomas BCCs]	0.0	5	1	1	1
103511	1710	relationship of b activation	[relationship of B activation]	0.0	4	1	1	1
103512	1710	internal peptide	[internal peptides]	0.0	2	1	1	1
103513	1710	cell cycle activation program	[cell cycle activation program]	0.0	4	1	1	1
103514	1710	RNA partition	[RNA partition]	0.0	2	1	1	1
103515	1710	differential expression in tissue	[differential expression in tissues]	0.0	4	1	1	1
103516	1710	normal induction	[normal induction]	0.0	2	1	1	1
103517	1710	antagonist of activin growth arrest	[antagonist of activin growth arrest]	0.0	5	1	1	1
103518	1710	reaction velocity	[reaction velocity]	0.0	2	1	1	1
103519	1710	ig kappa b	[Ig kappa B]	0.0	3	1	1	1
103520	1710	raz	[RAZ]	0.0	1	1	1	1
103521	1710	autocrine growth	[autocrine growth]	0.0	2	1	1	1
103522	1710	contain -73 bp	[containing -73 bp]	0.0	3	1	1	1
103523	1710	c-rel/p50 heterodimer	[c-Rel/p50 heterodimers]	0.0	2	1	1	1
103524	1710	naive Mono Mac cell	[naive Mono Mac cells]	0.0	4	1	1	1
103525	1710	increase glutathione disulfide level	[increasing glutathione disulfide levels]	0.0	4	1	1	1
103526	1710	Jun/Fos heterodimer	[Jun/Fos heterodimers]	0.0	2	1	1	1
103527	1710	plasma prednisolone	[plasma prednisolone]	0.0	2	1	1	1
103528	1710	transient cotransfection of tat cDNA together	[Transient cotransfection of tat cDNA together]	0.0	6	1	1	1
103529	1710	stati DNA binding element	[STATI DNA binding elements]	0.0	4	1	1	1
103530	1710	Drosophila cell	[Drosophila cells]	0.0	2	1	1	1
103531	1710	important morphogen a normal constituent	[important morphogen a normal constituent]	0.0	5	1	1	1
103532	1710	Functional antagonism between vitamin D3	[Functional antagonism between vitamin D3]	0.0	5	1	1	1
103533	1710	pmol/l; 0.5-2.5).	[pmol/l; 0.5-2.5).]	0.0	2	1	1	1
103534	1710	comprise the lac repressor	[comprising the lac repressor]	0.0	4	1	1	1
103535	1710	NFAT domain	[NFAT domain]	0.0	2	1	1	1
103536	1710	five clone	[five clones]	0.0	2	1	1	1
103537	1710	thiol/disulfide	[thiol/disulfide]	0.0	1	1	1	1
103538	1710	several p85 allele	[several p85 alleles]	0.0	3	1	1	1
103539	1710	multiple aspect	[multiple aspects]	0.0	2	1	1	1
103540	1710	GAL4 activator	[GAL4 activators]	0.0	2	1	1	1
103541	1710	activation response element in hiv-2	[activation response element in HIV-2]	0.0	5	1	1	1
103542	1710	interaction with pu.1	[interaction with PU.1]	0.0	3	1	1	1
103543	1710	PMA/ionomycin inducible factor	[PMA/ionomycin inducible factors]	0.0	3	1	1	1
103544	1710	atl cell	[ATL cells]	0.0	2	1	1	1
103545	1710	correlation with the quantitative sba	[correlation with the quantitative SBA]	0.0	5	1	1	1
103546	1710	two polypeptide of kD	[two polypeptides of kD]	0.0	4	1	1	1
103547	1710	marker of growth rate	[marker of growth rate]	0.0	4	1	1	1
103548	1710	T allele in lymphocyte	[T allele in lymphocytes]	0.0	4	1	1	1
103549	1710	overexpress hsf2-beta	[overexpressing HSF2-beta]	0.0	2	1	1	1
103550	1710	cis inactivation of material	[cis inactivation of material]	0.0	4	1	1	1
103551	1710	expression of cytokine in monocytes/macrophages	[expression of cytokines in monocytes/macrophages]	0.0	5	1	1	1
103552	1710	calcium-dependent, cyclosporin-sensitive, posttranslational modification	[calcium-dependent, cyclosporin-sensitive, posttranslational modification]	0.0	4	1	1	1
103553	1710	encode fas	[encoding Fas]	0.0	2	1	1	1
103554	1710	severe dermatitis patient	[severe dermatitis patients]	0.0	3	1	1	1
103555	1710	result phosphorylation of c-Jun	[resulting phosphorylation of c-Jun]	0.0	4	1	1	1
103556	1710	ref	[refs]	0.0	1	1	1	1
103557	1710	role in monocytic differentiation	[roles in monocytic differentiation]	0.0	4	1	1	1
103558	1710	role in t-cell biology	[role in T-cell biology]	0.0	4	2	2	1
103559	1710	upregulation of protein expression	[upregulation of protein expression]	0.0	4	1	1	1
103560	1710	expression of the interfere	[expression of the interfering]	0.0	4	1	1	1
103561	1710	human t-cell leukemia T cell	[human T-cell leukemia T cells]	0.0	5	1	1	1
103562	1710	sFv	[sFv]	0.0	1	1	1	1
103563	1710	sites/cell respectively, with the low gcr	[sites/cell respectively, with the lowest GCR]	0.0	6	1	1	1
103564	1710	impaired fetal thymocyte development	[Impaired fetal thymocyte development]	0.0	4	1	1	1
103565	1710	two-dimensional gel analysis	[two-dimensional gel analysis]	0.0	3	1	1	1
103566	1710	induction of NFAT in cell	[induction of NFAT in cells]	0.0	5	1	1	1
103567	1710	intermediate step	[intermediate step]	0.0	2	1	1	1
103568	1710	lymphocyte from FDC cluster	[lymphocytes from FDC clusters]	0.0	4	1	1	1
103569	1710	charybdotoxin-sensitive, ca(2+) membrane potential change	[Charybdotoxin-sensitive, Ca(2+) membrane potential changes]	0.0	5	1	1	1
103570	1710	complex common to all cell type	[complexes common to all cell types]	0.0	6	1	1	1
103571	1710	binding interaction between CIITA	[binding interactions between CIITA]	0.0	4	1	1	1
103572	1710	measure incorporation	[measuring incorporation]	0.0	2	1	1	1
103573	1710	kv1.3 component	[Kv1.3 components]	0.0	2	1	1	1
103574	1710	element the N element	[element the N element]	0.0	4	1	1	1
103575	1710	corresponding increase	[corresponding increase]	0.0	2	1	1	1
103576	1710	thus establish a relation MHC	[thus establishing an relation MHC]	0.0	5	1	1	1
103577	1710	activation by c-Myb /et	[activation by c-Myb /Ets]	0.0	4	1	1	1
103578	1710	G-200	[G-200]	0.0	1	1	1	1
103579	1710	part dependent on stress	[part dependent on stress]	0.0	4	1	1	1
103580	1710	exchange of invariant peptide clip	[exchange of invariant peptides CLIP]	0.0	5	1	1	1
103581	1710	short c-terminal peptide of isoform	[shorter C-terminal peptide of isoform]	0.0	5	1	1	1
103582	1710	ic50 in the micromolar	[IC50s in the micromolar]	0.0	4	1	1	1
103583	1710	periphery	[periphery]	0.0	1	1	1	1
103584	1710	activation of the terminal repeat type	[activation of the terminal repeat type]	0.0	6	1	1	1
103585	1710	suggest a physiologically relevant functional interaction	[suggesting a physiologically relevant functional interaction]	0.0	6	1	1	1
103586	1710	thus, localization	[Thus, localization]	0.0	2	1	1	1
103587	1710	limbic-hippocampal type ii receptor	[limbic-hippocampal type II receptor]	0.0	4	1	1	1
103588	1710	complex (mhc) class antigen	[complex (MHC) class antigens]	0.0	4	2	2	1
103589	1710	vitro cleavage	[vitro cleavage]	0.0	2	1	1	1
103590	1710	several IL-6 kappa kappa b motif	[several IL-6 kappa kappa B motifs]	0.0	6	1	1	1
103591	1710	exposure of endothelial cell HAEC	[exposure of endothelial cells HAEC]	0.0	5	1	1	1
103592	1710	expression with Epstein-Barr virus	[expression with Epstein-Barr virus]	0.0	4	1	1	1
103593	1710	cytokine-induced hiv-1	[cytokine-induced HIV-1]	0.0	2	1	1	1
103594	1710	addition, level of expression	[addition, level of expression]	0.0	4	1	1	1
103595	1710	use the coiled-coil region	[Using the coiled-coil region]	0.0	4	1	1	1
103596	1710	express dq0302	[expressing DQ0302]	0.0	2	1	1	1
103597	1710	il-3 pro-B cell after il-3 withdrawal	[IL-3 pro-B cells after IL-3 withdrawal]	0.0	6	1	1	1
103598	1710	nuclear factor-kappaB translocation in lipopolysaccharide	[nuclear factor-kappaB translocation in lipopolysaccharide]	0.0	5	1	1	1
103599	1710	current understanding with particular emphasis	[current understanding with particular emphasis]	0.0	5	1	1	1
103600	1710	important mechanism of insensitivity	[important mechanism of insensitivity]	0.0	4	1	1	1
103601	1710	different modes, like induction, superinfection	[Different modes, like induction, superinfection]	0.0	5	1	1	1
103602	1710	suppression of stat1 function	[suppression of Stat1 function]	0.0	4	1	1	1
103603	1710	human gata3 zinc finger	[human GATA3 zinc fingers]	0.0	4	1	1	1
103604	1710	such sequence	[such sequences]	0.0	2	1	1	1
103605	1710	success in the treatment	[success in the treatment]	0.0	4	1	1	1
103606	1710	metabolism of methylprednisolone mp	[metabolism of methylprednisolone MP]	0.0	4	1	1	1
103607	1710	disable mutation	[disabling mutations]	0.0	2	1	1	1
103608	1710	rapamycin mutant of p70(s6k)	[rapamycin mutant of p70(s6k)]	0.0	4	1	1	1
103609	1710	association of alteration latency	[Association of alterations latency]	0.0	4	1	1	1
103610	1710	interleukin il-3	[interleukin IL-3]	0.0	2	1	1	1
103611	1710	partial differentiation	[partial differentiation]	0.0	2	1	1	1
103612	1710	reflect cytoplasmic sequestration	[reflecting cytoplasmic sequestration]	0.0	3	1	1	1
103613	1710	monocyte peptide-1	[monocyte peptide-1]	0.0	2	1	1	1
103614	1710	system a cell line	[systems a cell line]	0.0	4	1	1	1
103615	1710	potential therapeutic drug for disease	[potential therapeutic drugs for diseases]	0.0	5	1	1	1
103616	1710	terminal region	[terminal region]	0.0	2	1	1	1
103617	1710	ultra-violet response	[UV responses]	0.0	2	1	1	1
103618	1710	administration of the cytokine interleukin-2	[Administration of the cytokine interleukin-2]	0.0	5	1	1	1
103619	1710	Comparison to varicella-zoster virus peptide	[Comparison to varicella-zoster virus peptides]	0.0	5	1	1	1
103620	1710	two protein of 52	[two proteins of 52]	0.0	4	1	1	1
103621	1710	however, treatment of hl-60 cell	[However, treatment of HL-60 cells]	0.0	5	1	1	1
103622	1710	incubation for several day result	[incubation for several days, resulting]	0.0	5	1	1	1
103623	1710	class MHC molecule	[class MHC molecules]	0.0	3	1	1	1
103624	1710	human interleukin-9 receptor	[human interleukin-9 receptor]	0.0	3	1	1	1
103625	1710	expression of obf-1	[expression of OBF-1]	0.0	3	1	1	1
103626	1710	Tat element	[Tat element]	0.0	2	2	2	1
103627	1710	nf-kappab activation repeat in T cell	[NF-kappaB activation repeat in T cells]	0.0	6	1	1	1
103628	1710	pyrimidine element 5'-pyctttg-3' present	[pyrimidine elements 5'-PyCTTTG-3' present]	0.0	4	1	1	1
103629	1710	il-12 action,	[IL-12 action,]	0.0	2	1	1	1
103630	1710	chromosomal translocation in myeloproliferative disorder	[chromosomal translocations in myeloproliferative disorders]	0.0	5	1	1	1
103631	1710	1a9-m cell express bcl2	[1A9-M cells expressing BCL2]	0.0	4	1	1	1
103632	1710	introduction of exogenous gata-1	[introduction of exogenous GATA-1]	0.0	4	1	1	1
103633	1710	elderly woman	[elderly women]	0.0	2	1	1	1
103634	1710	function of cell belong	[function of cells belonging]	0.0	4	1	1	1
103635	1710	possibility important	[possibility important]	0.0	2	1	1	1
103636	1710	neoplastic disorder in heterozygous woman	[neoplastic disorders in heterozygous women]	0.0	5	1	1	1
103637	1710	major depressive disorder in adolescent	[Major depressive disorder in adolescents]	0.0	5	1	1	1
103638	1710	induction of immediate gene	[induction of immediate genes]	0.0	4	1	1	1
103639	1710	distal il-2 enhancer	[distal IL-2 enhancer]	0.0	3	1	1	1
103640	1710	additional mechanism	[additional mechanism]	0.0	2	1	1	1
103641	1710	add with RA	[adding with RA]	0.0	3	1	1	1
103642	1710	major aspect of effects.	[major aspects of effects.]	0.0	4	1	1	1
103643	1710	individual with filaria-induced pathology LP	[individuals with filaria-induced pathology LP]	0.0	5	1	1	1
103644	1710	sv40 promoter	[SV40 promoter]	0.0	2	1	1	1
103645	1710	t/nk-cell phenotype	[T/NK-cell phenotype]	0.0	2	1	1	1
103646	1710	down-regulation of surface marker	[down-regulation of surface markers]	0.0	4	1	1	1
103647	1710	further setting	[further settings]	0.0	2	1	1	1
103648	1710	protein with a molecular mass	[protein with an molecular mass]	0.0	5	1	1	1
103649	1710	analysis of lysate by antiphosphotyrosine immunoblotting	[Analysis of lysates by antiphosphotyrosine immunoblotting]	0.0	6	1	1	1
103650	1710	basal plasma	[basal plasma]	0.0	2	1	1	1
103651	1710	main regulatory pathway	[main regulatory pathways]	0.0	3	1	1	1
103652	1710	different band	[different bands]	0.0	2	1	1	1
103653	1710	signal mediator in cell	[signaling mediators in cells]	0.0	4	1	1	1
103654	1710	increase in sensitivity to inhibitor	[increase in sensitivity to inhibitors]	0.0	5	1	1	1
103655	1710	downstream activation by modification	[downstream activation by modification]	0.0	4	1	1	1
103656	1710	component of antigen-specific memory	[components of antigen-specific memory]	0.0	4	1	1	1
103657	1710	capacity of c3a	[capacity of C3a]	0.0	3	1	1	1
103658	1710	splicing of exon	[splicing of exon]	0.0	3	1	1	1
103659	1710	chloramphenicol acetyltransferase production	[chloramphenicol acetyltransferase production]	0.0	3	1	1	1
103660	1710	viable mature definitive erythroid cell	[viable mature definitive erythroid cells]	0.0	5	1	1	1
103661	1710	other myeloid-cell-specific gene	[other myeloid-cell-specific genes]	0.0	3	1	1	1
103662	1710	prostate cancer lncap cell	[prostate cancer LNCaP cells]	0.0	4	1	1	1
103663	1710	Percoll gradient	[Percoll gradients]	0.0	2	1	1	1
103664	1710	rapid mitotic rate	[rapid mitotic rate]	0.0	3	1	1	1
103665	1710	hour pulse-treatment with 3 microm etoposide	[hour pulse-treatment with 3 microM etoposide]	0.0	6	1	1	1
103666	1710	nuclear localization of the 135eoh)2d3 receptor	[nuclear localization of the 1,25(OH)2D3 receptor]	0.0	6	1	1	1
103667	1710	molecular mechanism of cell adhesion	[Molecular mechanisms of cell adhesion]	0.0	5	1	1	1
103668	1710	aberrant activation of ap-1	[aberrant activation of AP-1]	0.0	4	1	1	1
103669	1710	tenfold increase	[tenfold increase]	0.0	2	1	1	1
103670	1710	type of target cell.	[types of target cell.]	0.0	4	1	1	1
103671	1710	other leukocyte	[other leukocytes]	0.0	2	1	1	1
103672	1710	such as ap-1 of nf-kappa b	[such as AP-1 of NF-kappa B]	0.0	6	1	1	1
103673	1710	class major cell line	[class major cell lines]	0.0	4	1	1	1
103674	1710	monocyte by type	[monocytes by type]	0.0	3	1	1	1
103675	1710	one signal PMA	[one signal PMA]	0.0	3	1	1	1
103676	1710	CD4 transcription	[CD4 transcription]	0.0	2	1	1	1
103677	1710	5'-ttgtcccgtggacaaatgtcc-3'	[5'-TTGTCCcgtGGACAAaTGTCC-3']	0.0	1	1	1	1
103678	1710	necrosis of bone	[necrosis of bone]	0.0	3	1	1	1
103679	1710	study: Peripheral lymphocyte	[STUDY: Peripheral lymphocytes]	0.0	3	1	1	1
103680	1710	immuno-deficiency virus hiv	[immuno-deficiency virus HIV]	0.0	3	1	1	1
103681	1710	transcription factor activation from patient	[Transcription factor activation from patients]	0.0	5	1	1	1
103682	1710	first report of NFAT	[first report of NFAT]	0.0	4	1	1	1
103683	1710	repression of human immunodeficiency virus type	[Repression of human immunodeficiency virus type]	0.0	6	1	1	1
103684	1710	receptor on T lymphocyte	[receptors on T lymphocytes]	0.0	4	1	1	1
103685	1710	region include the Sp1 element	[region including the Sp1 element]	0.0	5	1	1	1
103686	1710	level of hiv-1	[levels of HIV-1]	0.0	3	1	1	1
103687	1710	staining in 14.6 +/-	[staining in 14.6 +/-]	0.0	4	1	1	1
103688	1710	kind of il-4ralpha carry Val	[kinds of IL-4Ralpha carrying Val]	0.0	5	1	1	1
103689	1710	co-cultured blood monocyte	[co-cultured blood monocytes]	0.0	3	1	1	1
103690	1710	two-fold increase	[two-fold increase]	0.0	2	1	1	1
103691	1710	expression with late kinetic	[expression with late kinetics]	0.0	4	1	1	1
103692	1710	primitive progenitor proliferation	[primitive progenitor proliferation]	0.0	3	1	1	1
103693	1710	signal with soluble CD40 ligand activation	[Signaling with soluble CD40 ligand activation]	0.0	6	1	1	1
103694	1710	however, removal of pc4	[however, removal of PC4]	0.0	4	1	1	1
103695	1710	proximal bind element p0	[proximal binding element P0]	0.0	4	1	1	1
103696	1710	transfection of EBNA-LP	[Transfection of EBNA-LP]	0.0	3	1	1	1
103697	1710	rta	[Rta]	0.0	1	1	1	1
103698	1710	patient rarely express er	[patients rarely express ER]	0.0	4	1	1	1
103699	1710	correlation, with a be value	[correlation, with an r value]	0.0	5	1	1	1
103700	1710	target the molecule	[targeting the molecule]	0.0	3	1	1	1
103701	1710	recombinant caspase cpp32	[recombinant caspase CPP32]	0.0	3	1	1	1
103702	1710	marker of prognosis, include estrogen	[markers of prognosis, including estrogen]	0.0	5	1	1	1
103703	1710	agonist of endothelial cell	[agonist of endothelial cells]	0.0	4	1	1	1
103704	1710	adhesion to p-selectin the tethering factor	[Adhesion to P-selectin the tethering factor]	0.0	6	1	1	1
103705	1710	three clone	[Three clones]	0.0	2	1	1	1
103706	1710	new system combine gene transfer	[new system combining gene transfer]	0.0	5	1	1	1
103707	1710	number in late secretory phase	[numbers in late secretory phase]	0.0	5	1	1	1
103708	1710	gene expression in peripheral lymphocyte	[gene expression in peripheral lymphocytes]	0.0	5	1	1	1
103709	1710	human monkey glucocorticoid receptor	[human monkey glucocorticoid receptors]	0.0	4	1	1	1
103710	1710	tg receptor on non-T	[TG receptors on non-T]	0.0	4	1	1	1
103711	1710	bacterial lipoprotein	[bacterial lipoproteins]	0.0	2	1	1	1
103712	1710	complete resistance against anti-fa antibody	[complete resistance against anti-Fas antibody]	0.0	5	1	1	1
103713	1710	(bcg)	[(BCG)]	0.0	1	1	1	1
103714	1710	mobilization of calcium	[mobilization of calcium]	0.0	3	1	1	1
103715	1710	patient with nontuberculous condition	[patients with nontuberculous conditions]	0.0	4	1	1	1
103716	1710	functionally critical cis element	[functionally critical cis elements]	0.0	4	1	1	1
103717	1710	accumulation of mrna I HTLV-I	[accumulation of mRNA I HTLV-I]	0.0	5	1	1	1
103718	1710	aortic endothelial cell HAEC	[aortic endothelial cells HAEC]	0.0	4	1	1	1
103719	1710	E220K ubiquitinylation suggest a role	[E220K ubiquitinylation suggesting a role]	0.0	5	1	1	1
103720	1710	GCR-beta cell in blood	[GCR-beta cells in blood]	0.0	4	1	1	1
103721	1710	affinity with the negative correlation	[affinity with the negative correlation]	0.0	5	1	1	1
103722	1710	oncogenic ets transcription factor	[oncogenic Ets transcription factor]	0.0	4	1	1	1
103723	1710	mm) of acute ethanol treatment	[mM) of acute ethanol treatment]	0.0	5	1	1	1
103724	1710	SLP-76 a tyrosine -phosphorylated protein	[SLP-76 a tyrosine -phosphorylated protein]	0.0	5	1	1	1
103725	1710	effect of protein kinase c inhibitor	[effects of protein kinase C inhibitors]	0.0	6	1	1	1
103726	1710	autosomal disease	[autosomal disease]	0.0	2	1	1	1
103727	1710	regulation of interleukin IL3	[regulation of interleukin IL3]	0.0	4	1	1	1
103728	1710	n-acetyl-L-cysteine a potent thiol antioxidant	[n-acetyl-L-cysteine a potent thiol antioxidant]	0.0	5	1	1	1
103729	1710	decrease in expression of spi-1	[decrease in expression of Spi-1]	0.0	5	1	1	1
103730	1710	Ser551 to Throger	[Ser551 to Thr]	0.0	3	1	1	1
103731	1710	increase in icam-1 mrna	[increases in ICAM-1 mRNA]	0.0	4	1	1	1
103732	1710	e2a protein expression	[E2A protein expression]	0.0	3	1	1	1
103733	1710	level for macrophage chemotactic protein-1	[levels for macrophage chemotactic protein-1]	0.0	5	1	1	1
103734	1710	micromol/L to 7.30	[micromol/L to 7.30]	0.0	3	1	1	1
103735	1710	protocol of immunotherapy	[protocols of immunotherapy]	0.0	3	1	1	1
103736	1710	ach molecular clone	[ACH molecular clone]	0.0	3	1	1	1
103737	1710	signals, include exogenous cytokine	[signals, including exogenous cytokines]	0.0	4	1	1	1
103738	1710	progression of type include leukaemia	[progression of types including leukaemia]	0.0	5	2	2	1
103739	1710	inhibition in human t-cell line	[Inhibition in human T-cell lines]	0.0	5	1	1	1
103740	1710	rabbit reticulocyte	[rabbit reticulocyte]	0.0	2	1	1	1
103741	1710	putative target sequence	[putative targeting sequence]	0.0	3	1	1	1
103742	1710	augmentation in some individual experiments).	[augmentation in some individual experiments).]	0.0	5	1	1	1
103743	1710	role for CaMKIV/Gr	[role for CaMKIV/Gr]	0.0	3	1	1	1
103744	1710	ces-2 neuron-specific mediator	[CES-2 neuron-specific mediator]	0.0	3	1	1	1
103745	1710	laminar flow	[laminar flow]	0.0	2	1	1	1
103746	1710	fresh epstein-barr virus -negative b lymphocyte	[fresh Epstein-Barr virus -negative B lymphocytes]	0.0	6	1	1	1
103747	1710	stimulation of the t-cell antigen receptor-CD3	[Stimulation of the T-cell antigen receptor-CD3]	0.0	6	1	1	1
103748	1710	factor bind to site 4681	[Factors binding to site 4681]	0.0	5	1	1	1
103749	1710	require ROI production	[requiring ROI production]	0.0	3	1	1	1
103750	1710	NF-kappa b pathway	[NF-kappa B pathways]	0.0	3	1	1	1
103751	1710	factor bind to the AP-1 element	[factors binding to the AP-1 element]	0.0	6	1	1	1
103752	1710	concentration of receptor in spleen	[concentration of receptors in spleen]	0.0	5	1	1	1
103753	1710	kappa element	[kappa element]	0.0	2	3	3	1
103754	1710	globin cis-element	[globin cis-elements]	0.0	2	1	1	1
103755	1710	adult hematopoietic cell factor	[adult hematopoietic cells factor]	0.0	4	1	1	1
103756	1710	inhibit activation of factor-kappaB	[inhibiting activation of factor-kappaB]	0.0	4	1	1	1
103757	1710	simple culture condition	[simple culture conditions]	0.0	3	1	1	1
103758	1710	six week	[Six weeks]	0.0	2	2	2	1
103759	1710	C. activation of cell	[C. activation of cells]	0.0	4	1	1	1
103760	1710	antiinflammatory activity potent	[antiinflammatory activity potent]	0.0	3	1	1	1
103761	1710	decrease in translocation	[decrease in translocation]	0.0	3	1	1	1
103762	1710	same degree,	[same degree,]	0.0	2	1	1	1
103763	1710	patient in long	[patients in long-term]	0.0	3	1	1	1
103764	1710	moderate number with aggregate formation	[moderate numbers with aggregate formation]	0.0	5	1	1	1
103765	1710	similar rhythm of hepatic gr	[similar rhythm of hepatic GR]	0.0	5	1	1	1
103766	1710	pathway dependent by 5-lox	[pathway dependent by 5-LOX]	0.0	4	1	1	1
103767	1710	potency of one class	[potency of one class]	0.0	4	1	1	1
103768	1710	derivative chromosome	[derivative chromosome]	0.0	2	1	1	1
103769	1710	transactivation by Tat in cell	[transactivation by Tat in cells]	0.0	5	1	1	1
103770	1710	aspect of T cell biology	[aspects of T cell biology]	0.0	5	1	1	1
103771	1710	suggest effective	[suggesting effective]	0.0	2	1	1	1
103772	1710	20 copy of the cyclophilin gene	[20 copies of the cyclophilin gene]	0.0	6	1	1	1
103773	1710	distinct histopathological entity	[distinct histopathological entity]	0.0	3	1	1	1
103774	1710	c-terminal 13	[C-terminal 13]	0.0	2	1	1	1
103775	1710	SML cytosol	[SML cytosol]	0.0	2	2	2	1
103776	1710	bipotential myelomonoblastic cell population capable	[bipotential myelomonoblastic cell population capable]	0.0	5	1	1	1
103777	1710	inhibition of dna-binding protein	[Inhibition of DNA-binding proteins]	0.0	4	1	1	1
103778	1710	LT-293	[LT-293]	0.0	1	1	1	1
103779	1710	biopsy from patient with vkc	[biopsies from patients with VKC]	0.0	5	1	1	1
103780	1710	nuclear transcription factor bind	[nuclear transcription factors binding]	0.0	4	1	1	1
103781	1710	combination hormonal protocol	[combination hormonal protocols]	0.0	3	1	1	1
103782	1710	Intratracheal instillation	[Intratracheal instillation]	0.0	2	1	1	1
103783	1710	exposure together	[exposure together]	0.0	2	1	1	1
103784	1710	kinase NIK	[kinase NIK]	0.0	2	1	1	1
103785	1710	pbc.m2	[PBC.M2]	0.0	1	1	1	1
103786	1710	underlie cell activation by serum	[underlying cell activation by serum]	0.0	5	1	1	1
103787	1710	novel cancer related loci	[novel cancer related loci]	0.0	4	1	1	1
103788	1710	c-fm protooncogene	[c-fms protooncogene]	0.0	2	1	1	1
103789	1710	interferon-gamma-induced binding factor	[interferon-gamma-induced binding factor]	0.0	3	1	1	1
103790	1710	response to the immediate protein BZLF1	[responses to the immediate proteins BZLF1]	0.0	6	1	1	1
103791	1710	peptide corresponding	[peptide corresponding]	0.0	2	2	2	1
103792	1710	presence of er form	[presence of ER forms]	0.0	4	1	1	1
103793	1710	explanation for the effect	[explanation for the effects]	0.0	4	1	1	1
103794	1710	dna-binding protein protein	[DNA-binding protein protein]	0.0	3	1	1	1
103795	1710	preincubation with il-1 beta mrna level	[Preincubation with IL-1 beta mRNA levels]	0.0	6	1	1	1
103796	1710	expression of pcd/dcoh	[expression of PCD/DCoH]	0.0	3	1	1	1
103797	1710	result in selective activation of factor	[resulting in selective activation of factors]	0.0	6	1	1	1
103798	1710	moderate grade	[moderate grades]	0.0	2	1	1	1
103799	1710	8, malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[8, malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
103800	1710	chemotactic protein-1 mcp-1	[chemotactic protein-1 MCP-1]	0.0	3	1	1	1
103801	1710	direct information	[direct information]	0.0	2	1	1	1
103802	1710	unactivated T cell from donor	[unactivated T cells from donors]	0.0	5	1	1	1
103803	1710	strong increase the normal number	[strong increase the normal number]	0.0	5	1	1	1
103804	1710	keratoconjunctivitis a allergic disease	[keratoconjunctivitis an allergic disease.]	0.0	4	1	1	1
103805	1710	function during early-phase infection	[function during early-phase infection]	0.0	4	1	1	1
103806	1710	bear dqa1*0201 in comparison	[bearing DQA1*0201 in comparison]	0.0	4	1	1	1
103807	1710	bp il-2	[bp IL-2]	0.0	2	1	1	1
103808	1710	high expression level characteristic	[high expression level characteristic]	0.0	4	1	1	1
103809	1710	sequence from the extreme c-terminus	[sequences from the extreme C-terminus]	0.0	5	1	1	1
103810	1710	peptide represent acid sequence	[peptides representing acid sequences]	0.0	4	1	1	1
103811	1710	stage of erythropoiesis	[stages of erythropoiesis]	0.0	3	1	1	1
103812	1710	EBNA2 positive cell extract	[EBNA2 positive cell extracts]	0.0	4	1	1	1
103813	1710	efficient precursor of DC in culture.	[efficient precursors of DC in culture.]	0.0	6	1	1	1
103814	1710	structure of the gata3 gene	[Structure of the GATA3 gene]	0.0	5	1	1	1
103815	1710	CTLA-4 -mediated inhibition of event	[CTLA-4 -Mediated inhibition of events]	0.0	5	1	1	1
103816	1710	(1) inactivate substitution in the counterpart	[(1) inactivating substitutions in the counterpart]	0.0	6	1	1	1
103817	1710	allergen-specific population in patient	[allergen-specific populations in patients]	0.0	4	1	1	1
103818	1710	ttca sequence	[TTCA sequence]	0.0	2	1	1	1
103819	1710	Internal labeling with [35s]methionine	[Internal labeling with [35S]methionine]	0.0	4	1	1	1
103820	1710	retinoic acid similar	[retinoic acid similar]	0.0	3	1	1	1
103821	1710	inhibition of no production	[Inhibition of NO production]	0.0	4	1	1	1
103822	1710	b enhancer	[B enhancer]	0.0	2	1	1	1
103823	1710	sba	[SBA]	0.0	1	1	1	1
103824	1710	cell with marker Neo(r)	[cells with marker Neo(r)]	0.0	4	1	1	1
103825	1710	various serum responsive gene	[various serum responsive genes]	0.0	4	1	1	1
103826	1710	one cause of inflammatory arthritis	[one cause of inflammatory arthritis]	0.0	5	2	2	1
103827	1710	restoration of content lymphocyte	[restoration of content lymphocytes]	0.0	4	1	1	1
103828	1710	consequence of pf treatment	[consequences of PF treatment]	0.0	4	1	1	1
103829	1710	day result	[days, resulting]	0.0	2	1	1	1
103830	1710	serum amyloid A	[Serum amyloid A]	0.0	3	1	1	1
103831	1710	common intracellular signal pathway in neutrophil	[Common intracellular signaling pathways in neutrophils]	0.0	6	1	1	1
103832	1710	sensitive screen assay	[sensitive screening assay]	0.0	3	1	1	1
103833	1710	inducible oxide synthase	[inducible oxide synthase]	0.0	3	1	1	1
103834	1710	expression of the NF-kappaB /rel family	[expression of the NF-kappaB /Rel family]	0.0	6	1	1	1
103835	1710	short DNA sequence	[short DNA sequence]	0.0	3	1	1	1
103836	1710	mature human myeloid cell granulocyte	[mature human myeloid cells granulocytes]	0.0	5	1	1	1
103837	1710	blr1 core promoter	[blr1 core promoter]	0.0	3	1	1	1
103838	1710	lymphatic pathology	[lymphatic pathology]	0.0	2	1	1	1
103839	1710	association of alteration	[Association of alterations]	0.0	3	1	1	1
103840	1710	level of htr beta mrna level	[levels of hTR beta mRNA levels]	0.0	6	1	1	1
103841	1710	Effect by blood mononuclear cell	[Effects by blood mononuclear cells]	0.0	5	1	1	1
103842	1710	homology to a protein	[homology to a protein]	0.0	4	1	1	1
103843	1710	molecular weight of k.0	[molecular weight of kd,]	0.0	4	1	1	1
103844	1710	synergistic transactivation	[Synergistic transactivation]	0.0	2	2	2	1
103845	1710	recent-onset iddm subject 8	[recent-onset IDDM subjects 8]	0.0	4	1	1	1
103846	1710	enhancer of interferon (ifn)-inducible genes.	[enhancers of interferon (IFN)-inducible genes.]	0.0	5	1	1	1
103847	1710	dense granule	[dense granules]	0.0	2	1	1	1
103848	1710	adhesive ICAM-1 property of cell	[adhesive ICAM-1 properties of cells]	0.0	5	1	1	1
103849	1710	adhesion of Mo to cell	[adhesion of Mo to cells]	0.0	5	1	1	1
103850	1710	major mrna transcript	[major mRNA transcript]	0.0	3	1	1	1
103851	1710	polymerase chain reaction pcr assay	[polymerase chain reaction PCR assay]	0.0	5	1	1	1
103852	1710	constituent of the nuclear factor kappab	[constituents of the nuclear factor kappaB]	0.0	6	1	1	1
103853	1710	factor bind to the -90/-79 sequence	[factors binding to the -90/-79 sequence]	0.0	6	1	1	1
103854	1710	phagocyte human glomerular mesangial cell	[phagocytes human glomerular mesangial cells]	0.0	5	1	1	1
103855	1710	case of deficiency-heat syndrome	[cases of deficiency-heat syndrome]	0.0	4	1	1	1
103856	1710	line Jurkat	[line Jurkat]	0.0	2	1	1	1
103857	1710	demonstration of absent	[demonstration of absent]	0.0	3	1	1	1
103858	1710	novel element within the region	[novel elements within the region]	0.0	5	1	1	1
103859	1710	nuclear component within 30 minute	[nuclear component within 30 min]	0.0	5	1	1	1
103860	1710	calcineurin kappab reporter activity	[calcineurin kappaB reporter activity]	0.0	4	1	1	1
103861	1710	(15;17)	[(15;17)]	0.0	1	1	1	1
103862	1710	nitric oxide a pathway	[nitric oxide a pathway]	0.0	4	1	1	1
103863	1710	furthermore, region	[Furthermore, region]	0.0	2	1	1	1
103864	1710	surfactant Survanta	[surfactant Survanta]	0.0	2	1	1	1
103865	1710	ca2+ ion	[Ca2+ ions]	0.0	2	1	1	1
103866	1710	single transcriptional start site	[single transcriptional start site]	0.0	4	1	1	1
103867	1710	chain switch	[chain switch]	0.0	2	1	1	1
103868	1710	sh-	[Sh-]	0.0	1	1	1	1
103869	1710	phenotypic analysis of NF-AT mouse	[phenotypic analysis of NF-AT mice]	0.0	5	1	1	1
103870	1710	development, maturation,	[development, maturation,]	0.0	2	1	1	1
103871	1710	significant role in hiv-1 activation	[significant role in HIV-1 activation]	0.0	5	1	1	1
103872	1710	very strong association	[very strong association]	0.0	3	1	1	1
103873	1710	tax protein a transactivator	[Tax protein a transactivator]	0.0	4	1	1	1
103874	1710	lytic antigen-specific reactivity at level high	[lytic antigen-specific reactivities at levels high]	0.0	6	1	1	1
103875	1710	binding in lymphocyte	[binding in lymphocytes]	0.0	3	3	3	1
103876	1710	cell include peripheral cell	[cells including peripheral cells]	0.0	4	1	1	1
103877	1710	3-O-MG	[3-O-MG]	0.0	1	1	1	1
103878	1710	activation of a element cd28re	[activation of an element CD28RE]	0.0	5	1	1	1
103879	1710	increase evidence mediator	[increasing evidence mediators]	0.0	3	1	1	1
103880	1710	such phagocyte system	[such phagocyte system]	0.0	3	1	1	1
103881	1710	amount of il-8 costimulation with anti-CD3	[amounts of IL-8 costimulation with anti-CD3]	0.0	6	1	1	1
103882	1710	tissue rich in collagen	[tissues rich in collagen]	0.0	4	1	1	1
103883	1710	ppargamma proliferator-activated receptor gamma ppargamma expression	[PPARgamma proliferator-activated receptor gamma PPARgamma expression]	0.0	6	1	1	1
103884	1710	gene activity of nf-kappa b	[gene activity of NF-kappa B]	0.0	5	1	1	1
103885	1710	site of action	[site of action]	0.0	3	1	1	1
103886	1710	early cycle protein	[early cycle proteins]	0.0	3	1	1	1
103887	1710	Tcf-dependent transcription	[Tcf-dependent transcription]	0.0	2	1	1	1
103888	1710	activation 2 globin promoter	[activation 2 globin promoter]	0.0	4	1	1	1
103889	1710	element probe	[element probe]	0.0	2	1	1	1
103890	1710	mechanism in the system	[mechanism in the system]	0.0	4	1	1	1
103891	1710	novel elastase inhibitor guamerin-derived peptide	[novel elastase inhibitor guamerin-derived peptide]	0.0	5	1	1	1
103892	1710	hour of 135(oh)2d3 treatment	[hours of 1,25(OH)2D3 treatment]	0.0	4	1	1	1
103893	1710	transcription complex contain different protein	[transcription complexes containing different proteins]	0.0	5	1	1	1
103894	1710	independent mode	[independent modes]	0.0	2	1	1	1
103895	1710	two nonselective RAR ligand	[two nonselective RAR ligands]	0.0	4	1	1	1
103896	1710	vitro exposure to level	[vitro exposure to levels]	0.0	4	1	1	1
103897	1710	decrease in il-2 production	[decreases in IL-2 production]	0.0	4	1	1	1
103898	1710	relationship between the two events.	[relationship between the two events.]	0.0	5	1	1	1
103899	1710	course mg	[course mg]	0.0	2	1	1	1
103900	1710	class histocompatibility gene transcription	[class histocompatibility gene transcription]	0.0	4	1	1	1
103901	1710	cloning of a protein,	[cloning of a protein,]	0.0	4	1	1	1
103902	1710	nucleotide identity with a core	[nucleotide identity with a core]	0.0	5	1	1	1
103903	1710	indicator of platelet aggregation	[indicator of Platelet Aggregation]	0.0	4	1	1	1
103904	1710	CEM-ICR leukemic lymphoblast	[CEM-ICR leukemic lymphoblasts]	0.0	3	1	1	1
103905	1710	BP1 binding site.	[BP1 binding site.]	0.0	3	1	1	1
103906	1710	culture of pbmc	[cultures of PBMC]	0.0	3	1	1	1
103907	1710	receptor level in vitro.	[receptor level in vitro.]	0.0	4	1	1	1
103908	1710	t/natural killer	[T/natural killer]	0.0	2	1	1	1
103909	1710	regulation of m-csf expression by M-CSF	[Regulation of M-CSF expression by M-CSF]	0.0	6	1	1	1
103910	1710	transactivation in Drosophila Schneider cell	[transactivation in Drosophila Schneider cells]	0.0	5	1	1	1
103911	1710	(gs)p41	[(GS)P41]	0.0	1	1	1	1
103912	1710	acute leukemia 1- evi1 fusion respectively,	[acute leukemia 1- EVI1 fusions respectively,]	0.0	6	1	1	1
103913	1710	factor (nf)-kappab activation	[factor (NF)-kappaB activation]	0.0	3	1	1	1
103914	1710	helix-loop-helix-zipper protein	[helix-loop-helix-zipper proteins]	0.0	2	1	1	1
103915	1710	x-chromosomes	[X-chromosomes]	0.0	1	1	1	1
103916	1710	contrast, T cell with level	[contrast, T cells with levels]	0.0	5	1	1	1
103917	1710	expression cell	[Expression cells]	0.0	2	1	1	1
103918	1710	use cell line lack er peptide	[using cell lines lacking ER peptides]	0.0	6	1	1	1
103919	1710	few minute	[few minutes]	0.0	2	1	1	1
103920	1710	primary cell PBMC	[primary cells PBMC]	0.0	3	2	2	1
103921	1710	only at residue	[only at residue]	0.0	3	1	1	1
103922	1710	however, disruption	[However, disruption]	0.0	2	1	1	1
103923	1710	S.Benn,	[S.Benn,]	0.0	1	1	1	1
103924	1710	five protein	[Five proteins]	0.0	2	1	1	1
103925	1710	protein by Epstein-Barr virus mutant	[proteins by Epstein-Barr virus mutants]	0.0	5	1	1	1
103926	1710	contain four near-perfect repeat of bp	[containing four near-perfect repeats of bp]	0.0	6	1	1	1
103927	1710	normal constituent	[normal constituent]	0.0	2	1	1	1
103928	1710	growth of mammalian cell	[growth of mammalian cells]	0.0	4	1	1	1
103929	1710	component of the lymphoid tissue	[components of the lymphoid tissues]	0.0	5	1	1	1
103930	1710	CCAAT element	[CCAAT element]	0.0	2	1	1	1
103931	1710	fos gene expression in human monocyte	[fos gene expression in human monocytes]	0.0	6	1	1	1
103932	1710	shear flow	[shear flow]	0.0	2	3	3	1
103933	1710	mds1- evi1	[MDS1- EVI1]	0.0	2	1	1	1
103934	1710	putative activation domain	[putative activation domain]	0.0	3	1	1	1
103935	1710	comparison to DQA1*0501	[comparison to DQA1*0501]	0.0	3	1	1	1
103936	1710	c-myc oncogene	[c-myc oncogene]	0.0	2	2	2	1
103937	1710	soluble mediators, include growth factor	[soluble mediators, including growth factors]	0.0	5	1	1	1
103938	1710	association with RBP-Jkappa	[association with RBP-Jkappa]	0.0	3	1	1	1
103939	1710	Peptidoglycan PGN	[Peptidoglycan PGN]	0.0	2	1	1	1
103940	1710	mmol/l); hyperkalemia	[mmol/l); hyperkalemia]	0.0	2	1	1	1
103941	1710	gliotoxin -inhibitable activation	[gliotoxin -inhibitable activation]	0.0	3	1	1	1
103942	1710	acid at dose	[acid at doses]	0.0	3	1	1	1
103943	1710	infiltration of T lymphocyte	[infiltration of T lymphocytes]	0.0	4	1	1	1
103944	1710	reside within RelB	[residing within RelB]	0.0	3	1	1	1
103945	1710	b-related moiety	[B-related moieties]	0.0	2	1	1	1
103946	1710	h2a-2	[H2A-2]	0.0	1	1	1	1
103947	1710	repeat LTR region	[repeat LTR region]	0.0	3	1	1	1
103948	1710	event in the pathogenesis	[event in the pathogenesis]	0.0	4	1	1	1
103949	1710	endocrine beta-cell	[endocrine beta-cells]	0.0	2	1	1	1
103950	1710	susceptibility to infection [see comments]	[susceptibility to infection [see comments]]	0.0	5	1	1	1
103951	1710	er level in cell	[ER levels in cell]	0.0	4	1	1	1
103952	1710	gene of cytomegalovirus	[genes of cytomegalovirus]	0.0	3	1	1	1
103953	1710	interaction with the machinery.	[interaction with the machinery.]	0.0	4	1	1	1
103954	1710	mutant adenovirus ad5	[Mutants adenovirus Ad5]	0.0	3	1	1	1
103955	1710	influence on the positive selection	[influence on the positive selection]	0.0	5	1	1	1
103956	1710	son	[son]	0.0	1	1	1	1
103957	1710	stat5 target gene	[STAT5 target genes]	0.0	3	1	1	1
103958	1710	tight linkage between marker	[tight linkage between markers]	0.0	4	1	1	1
103959	1710	expression of a constitutively active form	[expression of a constitutively active form]	0.0	6	1	1	1
103960	1710	expression of c-erba/tr-alpha in erythroblast	[expression of c-erbA/TR-alpha in erythroblasts]	0.0	5	1	1	1
103961	1710	12-o-tetradecanoylphorbol induction of factor-kappaB NF-kappaB activity	[12-O-tetradecanoylphorbol induction of factor-kappaB NF-kappaB activity]	0.0	6	1	1	1
103962	1710	biologically distinct subset	[biologically distinct subsets]	0.0	3	1	1	1
103963	1710	inhibition of complement	[Inhibition of complement]	0.0	3	1	1	1
103964	1710	serum-supplemented cultures.	[serum-supplemented cultures.]	0.0	2	1	1	1
103965	1710	simultaneous activation of pair	[simultaneous activation of pairs]	0.0	4	1	1	1
103966	1710	particularly in the function	[particularly in the function]	0.0	4	1	1	1
103967	1710	continue for 24 P.	[continuing for 24 h.]	0.0	4	1	1	1
103968	1710	use anti-Class ii antibody	[using anti-Class II antibodies]	0.0	4	1	1	1
103969	1710	marker of high mitotic rate	[markers of high mitotic rate]	0.0	5	1	1	1
103970	1710	inverse relation to major histocompatibility class	[inverse relation to major histocompatibility classes]	0.0	6	1	1	1
103971	1710	contribute to response to glucocorticoid therapy	[contributing to response to glucocorticoid therapy]	0.0	6	1	1	1
103972	1710	activation of the long repeat type	[activation of the long repeat type]	0.0	6	1	1	1
103973	1710	determination of hiv-1 burden	[determination of HIV-1 burden]	0.0	4	1	1	1
103974	1710	manage further setting of pathology	[managing further settings of pathology]	0.0	5	1	1	1
103975	1710	NF-kappaB/Rel family	[NF-kappaB/Rel family]	0.0	2	1	1	1
103976	1710	medication	[medications]	0.0	1	1	1	1
103977	1710	set of nuclear factor	[set of nuclear factor]	0.0	4	1	1	1
103978	1710	vcam-1 adhesion molecule-1 ICAM-1 promoter	[VCAM-1 adhesion molecule-1 ICAM-1 promoters]	0.0	5	1	1	1
103979	1710	tnf-alpha in macrophage-depleted rat	[TNF-alpha in macrophage-depleted rats]	0.0	4	1	1	1
103980	1710	contrast, LPS binding	[contrast, LPS binding]	0.0	3	1	1	1
103981	1710	sensitive monitoring of disease	[sensitive monitoring of disease]	0.0	4	1	1	1
103982	1710	potent signal	[potent signal]	0.0	2	1	1	1
103983	1710	region within the sequence	[region within the sequences]	0.0	4	1	1	1
103984	1710	production of oxidant	[production of oxidants]	0.0	3	1	1	1
103985	1710	g1 cyclin D2	[G1 cyclins D2]	0.0	3	1	1	1
103986	1710	T lymphocyte resistant	[T lymphocytes resistant]	0.0	3	1	1	1
103987	1710	acid -responsive element-containing promoter	[acid -responsive element-containing promoters]	0.0	4	1	1	1
103988	1710	synchronization	[synchronization]	0.0	1	1	1	1
103989	1710	key role of erythropoietin Epo	[key role of erythropoietin Epo]	0.0	5	1	1	1
103990	1710	monoclonal antibody specific for the conformer	[monoclonal antibodies specific for the conformers]	0.0	6	1	1	1
103991	1710	major complex class I molecule	[major complex class I molecules]	0.0	5	1	1	1
103992	1710	new evidence for a relationship	[new evidence for a relationship]	0.0	5	1	1	1
103993	1710	human gene encode a member	[human gene encoding a member]	0.0	5	1	1	1
103994	1710	up-regulation of fas ligand	[up-regulation of Fas ligand]	0.0	4	1	1	1
103995	1710	functional implication	[functional implications]	0.0	2	1	1	1
103996	1710	intragenic deletion the homolog	[Intragenic deletions the homolog]	0.0	4	1	1	1
103997	1710	only a partial domain	[only a partial domain]	0.0	4	1	1	1
103998	1710	receptor concentration before glucocorticoid therapy	[receptor concentrations before glucocorticoid therapy]	0.0	5	1	1	1
103999	1710	leucocyte with this chemokine	[leucocytes with this chemokine]	0.0	4	1	1	1
104000	1710	information from receptor	[information from receptors]	0.0	3	1	1	1
104001	1710	interaction with cytokine	[interactions with cytokines]	0.0	3	1	1	1
104002	1710	human pulmonary alveolar macrophage PAM	[human pulmonary alveolar macrophages PAM]	0.0	5	1	1	1
104003	1710	alpha,25-dihydroxyvitamin D3 in normal lymphocyte	[alpha,25-dihydroxyvitamin D3 in normal lymphocytes]	0.0	5	1	1	1
104004	1710	awareness of necrosis	[awareness of necrosis]	0.0	3	1	1	1
104005	1710	4.2 kilobasis	[4.2 kilobases]	0.0	2	1	1	1
104006	1710	microbial pathogen such as lipopolysaccharide	[microbial pathogens such as lipopolysaccharide]	0.0	5	1	1	1
104007	1710	solubilization	[Solubilization]	0.0	1	1	1	1
104008	1710	independent T cell receptor	[independent T cell receptor]	0.0	4	1	1	1
104009	1710	effect on il-2-alpha receptor expression	[effects on IL-2-alpha receptor expression]	0.0	5	1	1	1
104010	1710	signalling system	[signalling systems]	0.0	2	1	1	1
104011	1710	assembly of protein	[assembly of proteins]	0.0	3	1	1	1
104012	1710	protein in platelet activation	[proteins in platelet activation]	0.0	4	1	1	1
104013	1710	combination of this DNA element	[combinations of these DNA elements]	0.0	5	1	1	1
104014	1710	lack of level in cell	[lack of levels in cells]	0.0	5	1	1	1
104015	1710	Tcf-1 transcription role	[Tcf-1 transcription role]	0.0	3	1	1	1
104016	1710	sun	[sun]	0.0	1	1	1	1
104017	1710	base pair long region	[base pair long region]	0.0	4	1	1	1
104018	1710	maintenance of nf-kappa b	[maintenance of NF-kappa B]	0.0	4	1	1	1
104019	1710	lipoarabinomannan from the mycobacterial cell wall,	[lipoarabinomannan from the mycobacterial cell wall,]	0.0	6	1	1	1
104020	1710	major histocompatibility class ii gene	[major histocompatibility class II genes]	0.0	5	1	1	1
104021	1710	autoregulatory sequence	[autoregulatory sequences]	0.0	2	1	1	1
104022	1710	effect in	[effects in]	0.0	2	1	1	1
104023	1710	emergence of variant	[emergence of variants]	0.0	3	1	1	1
104024	1710	menopausal type diabete	[menopausal type diabetes]	0.0	3	2	2	1
104025	1710	include cholera toxin	[including cholera toxin]	0.0	3	1	1	1
104026	1710	fmol/mg protein of estrogen receptor (mean	[fmol/mg protein of estrogen receptor (mean]	0.0	6	1	1	1
104027	1710	ligation of a inhibitory receptor	[ligation of a inhibitory receptor]	0.0	5	1	1	1
104028	1710	t-cell inhibitory effect	[T-cell inhibitory effects]	0.0	3	1	1	1
104029	1710	dominant negative function	[dominant negative functions]	0.0	3	1	1	1
104030	1710	CD43/leukosialin the major sialoglycoprotein	[CD43/leukosialin the major sialoglycoprotein]	0.0	4	1	1	1
104031	1710	vitro effect on the concentration	[vitro effects on the concentrations]	0.0	5	1	1	1
104032	1710	STAT nuclear factor	[STAT nuclear factors]	0.0	3	1	1	1
104033	1710	correlation of hiv-1 transcriptional induction	[correlation of HIV-1 transcriptional induction]	0.0	5	1	1	1
104034	1710	model dissect the event	[model dissecting the events]	0.0	4	1	1	1
104035	1710	exercise at 70%	[exercises at 70%]	0.0	3	1	1	1
104036	1710	symbol	[symbol]	0.0	1	1	1	1
104037	1710	inhibition of anti-cd3 antibody t-cell proliferation	[Inhibition of anti-CD3 antibody T-cell proliferation]	0.0	6	1	1	1
104038	1710	stat protein capable	[STAT proteins capable]	0.0	3	1	1	1
104039	1710	patient with untreated RA	[patients with untreated RA]	0.0	4	1	1	1
104040	1710	(nk) cell	[(NK) cells]	0.0	2	1	1	1
104041	1710	separation of the granule from neutrophil	[separation of the granules from neutrophils]	0.0	6	1	1	1
104042	1710	stimulation defect	[stimulation defects]	0.0	2	1	1	1
104043	1710	sodium n-butyrate	[sodium n-butyrate]	0.0	2	1	1	1
104044	1710	durable inhibition	[durable inhibition]	0.0	2	1	1	1
104045	1710	activation by NF-kappaB	[activation by NF-kappaB]	0.0	3	1	1	1
104046	1710	transcription factor signal transducer	[transcription factor signal transducer]	0.0	4	1	1	1
104047	1710	two protein of 75	[Two proteins of 75]	0.0	4	1	1	1
104048	1710	human peripheral blood burst-forming unit-erythroid	[human peripheral blood burst-forming unit-erythroid]	0.0	5	1	1	1
104049	1710	furthermore, extract	[Furthermore, extracts]	0.0	2	1	1	1
104050	1710	substance such as bacterial formylpeptide lps	[substances such as bacterial formylpeptides LPS]	0.0	6	1	1	1
104051	1710	inhibitory step	[inhibitory steps]	0.0	2	1	1	1
104052	1710	bending	[bending]	0.0	1	1	1	1
104053	1710	four NF-kappa b recognition site	[four NF-kappa B recognition sites]	0.0	5	1	1	1
104054	1710	alpha CD3	[alpha CD3]	0.0	2	1	1	1
104055	1710	NH2 regulatory, domain	[NH2 regulatory, domain]	0.0	3	1	1	1
104056	1710	adherence-associated early gene	[adherence-associated early genes]	0.0	3	1	1	1
104057	1710	marrow-derived progenitor cell	[marrow-derived progenitor cells]	0.0	3	1	1	1
104058	1710	factor of T cell NF-MATp35	[factor of T cells NF-MATp35]	0.0	5	1	1	1
104059	1710	gc-r bmax in pbmc	[GC-R Bmax in PBMC]	0.0	4	1	1	1
104060	1710	deterioration human immunodeficiency virus type 1	[deterioration human immunodeficiency virus type 1]	0.0	6	1	1	1
104061	1710	consensus nf-kappa b oligonucleotide	[consensus NF-kappa B oligonucleotide]	0.0	4	1	1	1
104062	1710	regard to the release	[regarding to the release]	0.0	4	1	1	1
104063	1710	complement-dependent lps uptake	[complement-dependent LPS uptake]	0.0	3	1	1	1
104064	1710	cd86 b7-2 ligand for CD28	[CD86 B7-2 ligands for CD28]	0.0	5	1	1	1
104065	1710	U3 region domain	[U3 region domain]	0.0	3	1	1	1
104066	1710	kb 5'-flanking region	[kb 5'-flanking region]	0.0	3	1	1	1
104067	1710	trigger on T cell	[triggering on T cell]	0.0	4	1	1	1
104068	1710	IL-2 production,	[IL-2 production,]	0.0	2	1	1	1
104069	1710	expression in specimen	[expression in specimens]	0.0	3	1	1	1
104070	1710	CRE binding protein	[CRE binding protein]	0.0	3	1	1	1
104071	1710	stat pathway	[STAT pathways]	0.0	2	1	1	1
104072	1710	significant homology to a protein	[significant homology to a protein]	0.0	5	1	1	1
104073	1710	activity 100-fold low	[activity 100-fold lower]	0.0	3	1	1	1
104074	1710	specific receptor blocker RU43044	[specific receptor blocker RU43044]	0.0	4	1	1	1
104075	1710	structure important	[structure important]	0.0	2	1	1	1
104076	1710	nonspecific follicular hyperplasia fh	[nonspecific follicular hyperplasia FH]	0.0	4	1	1	1
104077	1710	kappab transcription in a manner	[kappaB transcription in a manner]	0.0	5	1	1	1
104078	1710	significant production	[significant production]	0.0	2	1	1	1
104079	1710	B-lymphoma cell line BJAB	[B-lymphoma cell lines BJAB]	0.0	4	1	1	1
104080	1710	production of 24,25-dihydroxy-vitamin D3 a response	[production of 24,25-dihydroxy-vitamin D3 a response]	0.0	6	1	1	1
104081	1710	local adjacent cis element	[local adjacent cis elements]	0.0	4	1	1	1
104082	1710	other dibenzo-p-dioxin	[other dibenzo-p-dioxins]	0.0	2	1	1	1
104083	1710	clone of two B-cell line	[clones of two B-cell lines]	0.0	5	1	1	1
104084	1710	promising new avenue of therapy	[promising new avenue of therapy]	0.0	5	1	1	1
104085	1710	clonal t-cell population	[clonal T-cell population]	0.0	3	1	1	1
104086	1710	murine B29 promoter	[murine B29 promoter]	0.0	3	1	1	1
104087	1710	mechanism restrict hiv-1 gene expression	[mechanism restricting HIV-1 gene expression]	0.0	5	1	1	1
104088	1710	cd36 cell	[CD36 cells]	0.0	2	1	1	1
104089	1710	point mutation in the Pit-1 gene	[point mutations in the Pit-1 gene]	0.0	6	1	1	1
104090	1710	expression of STAT regulatory factor	[expression of STAT regulatory factor]	0.0	5	1	1	1
104091	1710	material in the work,	[MATERIALS In the work,]	0.0	4	1	1	1
104092	1710	conditions, delta cam-ai	[conditions, delta CaM-AI]	0.0	3	1	1	1
104093	1710	dose of autg (>10 microm	[doses of AuTG (>10 microM]	0.0	5	1	1	1
104094	1710	v-abl mutant	[v-Abl mutant]	0.0	2	1	1	1
104095	1710	preexisting form of factor	[preexisting forms of factor]	0.0	4	1	1	1
104096	1710	edge: tcr stimulation	[edge: TCR stimulation]	0.0	3	1	1	1
104097	1710	c-jun response gene	[c-jun response gene]	0.0	3	1	1	1
104098	1710	adult level	[adult levels]	0.0	2	1	1	1
104099	1710	effect of active mutant	[effects of active mutants]	0.0	4	1	1	1
104100	1710	follow exposure of intact human platelet	[following exposure of intact human platelets]	0.0	6	1	1	1
104101	1710	coimmunoadsorption of the stat protein	[coimmunoadsorption of the STAT protein]	0.0	5	1	1	1
104102	1710	cloning of the cDNA encoding	[Cloning of the cDNA encoding]	0.0	5	1	1	1
104103	1710	addition of compound	[addition of compounds]	0.0	3	1	1	1
104104	1710	DNA present	[DNA present]	0.0	2	1	1	1
104105	1710	yeast two-hybrid system,	[yeast two-hybrid system,]	0.0	3	1	1	1
104106	1710	nf-at gene	[NF-AT genes]	0.0	2	1	1	1
104107	1710	work, employ sequential deletion	[work, employing sequential deletions]	0.0	4	1	1	1
104108	1710	hbv gene expression	[HBV gene expression]	0.0	3	1	1	1
104109	1710	t-lymphocyte culture	[T-lymphocytes culture]	0.0	2	1	1	1
104110	1710	indicate importance	[indicating importance]	0.0	2	1	1	1
104111	1710	increase in calcium	[increase in calcium]	0.0	3	1	1	1
104112	1710	high-affinity surface receptor for igg	[high-affinity surface receptor for IgG]	0.0	5	1	1	1
104113	1710	ligand-induced membrane hyperpolarization	[ligand-induced membrane hyperpolarization]	0.0	3	1	1	1
104114	1710	inhibition ic50	[inhibition IC50]	0.0	2	1	1	1
104115	1710	salt condition	[salt conditions]	0.0	2	1	1	1
104116	1710	activator of hiv-1 gene	[activator of HIV-1 gene]	0.0	4	1	1	1
104117	1710	mip-1alpha-r mrna	[MIP-1alpha-R mRNA]	0.0	2	1	1	1
104118	1710	gr in peripheral leukocyte	[GR in peripheral leukocytes]	0.0	4	1	1	1
104119	1710	all-tran acid ATRA	[all-trans acid ATRA]	0.0	3	2	2	1
104120	1710	pkc isoenzyme include pkc-zeta	[PKC isoenzymes including PKC-zeta]	0.0	4	1	1	1
104121	1710	atf1 isoform consistent	[ATF1 isoforms consistent]	0.0	3	1	1	1
104122	1710	adhesion in tnf-treated vein endothelial cell	[adhesion in TNF-treated vein endothelial cells]	0.0	6	1	1	1
104123	1710	essential positive regulatory element	[essential positive regulatory element]	0.0	4	1	1	1
104124	1710	cleavage during B-cell apoptosis	[Cleavage during B-cell apoptosis]	0.0	4	1	1	1
104125	1710	route on nuclear signalling	[routes on nuclear signalling]	0.0	4	1	1	1
104126	1710	cd34+thy-1+ subset	[CD34+Thy-1+ subset]	0.0	2	1	1	1
104127	1710	down-regulation in hypercortisolemic patient suffer	[down-regulation in hypercortisolemic patients suffering]	0.0	5	1	1	1
104128	1710	tac	[Tac]	0.0	1	1	1	1
104129	1710	inducer of the factor.	[inducers of the factor.]	0.0	4	1	1	1
104130	1710	mature myeloid cell neutrophilic granulocyte	[mature myeloid cells neutrophilic granulocytes]	0.0	5	1	1	1
104131	1710	even a increase	[Even a increase]	0.0	3	1	1	1
104132	1710	il-4 of transfectant	[IL-4 of transfectants]	0.0	3	1	1	1
104133	1710	test the effect of novel strategy	[testing the effects of novel strategies]	0.0	6	1	1	1
104134	1710	assembly of cis element	[assemblies of cis elements]	0.0	4	1	1	1
104135	1710	previous study use oligonucleotide	[Previous studies using oligonucleotides]	0.0	4	1	1	1
104136	1710	lymphocyte model	[lymphocyte models]	0.0	2	1	1	1
104137	1710	two kappa complex	[two kappa complexes]	0.0	3	1	1	1
104138	1710	disulfide tds	[disulfide TDS]	0.0	2	1	1	1
104139	1710	molecule of this group SIT	[molecule of this group SIT]	0.0	5	1	1	1
104140	1710	gata-1 to site	[GATA-1 to sites]	0.0	3	1	1	1
104141	1710	incubation for day	[incubation for days,]	0.0	3	1	1	1
104142	1710	culminate in cell profibrotic growth factor	[culminating in cells profibrotic growth factors]	0.0	6	1	1	1
104143	1710	protein excretion	[protein excretion]	0.0	2	1	1	1
104144	1710	RT-PCR approach	[RT-PCR approach]	0.0	2	1	1	1
104145	1710	Eicosanoids before mastectomy	[Eicosanoids before mastectomy]	0.0	3	1	1	1
104146	1710	initiate il-4-induced tyrosine phosphorylation	[initiating IL-4-induced tyrosine phosphorylation]	0.0	4	1	1	1
104147	1710	49 case of B-cell leukemia CLL	[49 cases of B-cell leukemia CLL]	0.0	6	1	1	1
104148	1710	two schedule of calcitriol	[two schedules of calcitriol]	0.0	4	1	1	1
104149	1710	binding site for protein	[binding sites for proteins]	0.0	4	1	1	1
104150	1710	contain vp16 of hsv-2	[containing VP16 of HSV-2]	0.0	4	1	1	1
104151	1710	initial fate	[initial fate]	0.0	2	1	1	1
104152	1710	target for p21ras	[target for p21ras]	0.0	3	1	1	1
104153	1710	complex class ii molecule	[complex class II molecules]	0.0	4	1	1	1
104154	1710	TAL1 expression by cell	[TAL1 expression by cells]	0.0	4	1	1	1
104155	1710	300 bp	[300 bp]	0.0	2	1	1	1
104156	1710	number (mnl) of 10 patient	[number (MNL) of 10 patients]	0.0	5	1	1	1
104157	1710	other chain gene	[other chain genes]	0.0	3	1	1	1
104158	1710	indicate a critical involvement of Itk	[indicating a critical involvement of Itk]	0.0	6	1	1	1
104159	1710	permeabilized cell	[permeabilized cells]	0.0	2	1	1	1
104160	1710	depletion A1 from extract	[depletion A1 from extracts]	0.0	4	1	1	1
104161	1710	interaction with component	[interaction with components]	0.0	3	1	1	1
104162	1710	form heterodimer with other hormone receptor	[forming heterodimers with other hormone receptors]	0.0	6	1	1	1
104163	1710	50% concentration of mp value	[50% concentrations of MP values]	0.0	5	1	1	1
104164	1710	constituent of the prototypic factor kappab	[constituents of the prototypic factor kappaB]	0.0	6	1	1	1
104165	1710	mutants, iexc29	[mutants, IEXC29S]	0.0	2	1	1	1
104166	1710	cytotoxic effector	[cytotoxic effector]	0.0	2	1	1	1
104167	1710	cd56 in leukemic blast	[CD56 in leukemic blasts]	0.0	4	1	1	1
104168	1710	structural homology	[structural homologies]	0.0	2	1	1	1
104169	1710	transcription, suggest important	[transcription, suggesting important]	0.0	3	1	1	1
104170	1710	transactivation potential of bsap pax-5	[transactivation potential of BSAP Pax-5]	0.0	5	1	1	1
104171	1710	CCAAT/enhancer-binding protein-beta binding site	[CCAAT/enhancer-binding protein-beta binding site]	0.0	4	1	1	1
104172	1710	minimal promoter activity	[minimal promoter activity]	0.0	3	1	1	1
104173	1710	transactivation potential of bsap pax-2	[transactivation potential of BSAP Pax-2]	0.0	5	1	1	1
104174	1710	RAR x receptor nuclear receptor	[RAR X receptor nuclear receptors]	0.0	5	1	1	1
104175	1710	heterozygous DNA variation in tumor	[heterozygous DNA variations in tumor]	0.0	5	1	1	1
104176	1710	however, latent, viral gene	[However, latent, viral genes]	0.0	4	1	1	1
104177	1710	hsp60 in umbilical vein endothelial cell	[Hsp60 in umbilical vein endothelial cells]	0.0	6	1	1	1
104178	1710	cell as	[cells as]	0.0	2	1	1	1
104179	1710	seven volunteers.	[seven volunteers.]	0.0	2	1	1	1
104180	1710	interaction between Ets	[interactions between Ets]	0.0	3	1	1	1
104181	1710	definition of the characteristic	[definition of the characteristics]	0.0	4	1	1	1
104182	1710	3' regulatory sequence	[3' regulatory sequences]	0.0	3	1	1	1
104183	1710	interleukin-2 IL2	[interleukin-2 IL2]	0.0	2	1	1	1
104184	1710	differentiation of lineage	[differentiation of lineages]	0.0	3	1	1	1
104185	1710	interferon factor (irf) family	[interferon factor (IRF) family]	0.0	4	1	1	1
104186	1710	nuclear factor-kappaB regulation	[nuclear factor-kappaB regulation]	0.0	3	1	1	1
104187	1710	potential use in a variety	[potential use in a variety]	0.0	5	1	1	1
104188	1710	binding of protein (s)	[binding of protein (s)]	0.0	4	1	1	1
104189	1710	thf	[THF]	0.0	1	1	1	1
104190	1710	DNA of the 15-lox gene	[DNA of the 15-lox gene]	0.0	5	1	1	1
104191	1710	only low level of nf-kappa b	[only low levels of NF-kappa B]	0.0	6	1	1	1
104192	1710	Dexamethasone Dex a glucocorticoid hormone	[Dexamethasone Dex a glucocorticoid hormone]	0.0	5	1	1	1
104193	1710	immune system target stem cell	[immune system targets stem cells]	0.0	5	1	1	1
104194	1710	methyl prednisolone mg/day) for 10 days.	[methyl prednisolone mg/day) for 10 days.]	0.0	6	1	1	1
104195	1710	signal-regulated kinase in human monocyte	[signal-regulated kinase in human monocytes]	0.0	5	1	1	1
104196	1710	element in the maturation pathway	[elements in the maturation pathway]	0.0	5	1	1	1
104197	1710	allogeneic endothelial cell	[allogeneic endothelial cells]	0.0	3	1	1	1
104198	1710	namely, the double-positive (dp) CD4 thymocyte	[namely, the double-positive (DP) CD4 thymocytes]	0.0	6	1	1	1
104199	1710	mediators,	[mediators,]	0.0	1	1	1	1
104200	1710	mediators.	[mediators.]	0.0	1	1	1	1
104201	1710	uptake by alternative phagocyte	[uptake by alternative phagocytes]	0.0	4	1	1	1
104202	1710	new avenue of therapy	[new avenue of therapy]	0.0	4	1	1	1
104203	1710	discrepancy in the coding region	[discrepancies in the coding region]	0.0	5	1	1	1
104204	1710	ap-2- like consensus sequence	[AP-2- like consensus sequences]	0.0	4	1	1	1
104205	1710	effect on hiv-1 replication	[effect on HIV-1 replication]	0.0	4	1	1	1
104206	1710	tic	[t(3;21),]	0.0	1	1	1	1
104207	1710	inhibitor of proliferation	[inhibitor of proliferation]	0.0	3	1	1	1
104208	1710	include sequence	[including sequences]	0.0	2	1	1	1
104209	1710	membrane protein -driven activation	[membrane protein -driven activation]	0.0	4	1	1	1
104210	1710	length cDNA	[length cDNA]	0.0	2	1	1	1
104211	1710	mediators:	[mediators:]	0.0	1	1	1	1
104212	1710	DNA marker in the gene	[DNA markers in the genes]	0.0	5	1	1	1
104213	1710	deletion of sequence upstream of cp	[deletion of sequences upstream of Cp]	0.0	6	1	1	1
104214	1710	CsA treatment of Raji B	[CsA treatment of Raji B]	0.0	5	1	1	1
104215	1710	long repeat type 1	[long repeat type 1]	0.0	4	1	1	1
104216	1710	levels: 3	[levels: 3]	0.0	2	1	1	1
104217	1710	DQB promoter	[DQB promoter]	0.0	2	1	1	1
104218	1710	increase in the activity (nf)-kappab	[increase in the activity (NF)-kappaB]	0.0	5	1	1	1
104219	1710	overlapping binding site	[overlapping binding sites]	0.0	3	1	1	1
104220	1710	harbor mutation within two C/EBP site	[harboring mutations within two C/EBP sites]	0.0	6	1	1	1
104221	1710	(27.7 nmol/l)	[(27.7 nmol/l)]	0.0	2	1	1	1
104222	1710	nuclei from monocyte	[nuclei from monocytes]	0.0	3	1	1	1
104223	1710	stimulation of the ea-d promoter	[stimulation of the EA-D promoter]	0.0	5	1	1	1
104224	1710	tyrosine phosphorylation of proteins,	[tyrosine phosphorylation of proteins,]	0.0	4	1	1	1
104225	1710	variable predict NK activity	[variable predicting NK activity]	0.0	4	1	1	1
104226	1710	group type MHC cid	[group type MHC CID]	0.0	4	1	1	1
104227	1710	blood lymphocyte bronchial asthma BA	[blood lymphocytes bronchial asthma BA]	0.0	5	1	1	1
104228	1710	factors, in particular, proinflammatory cytokine	[factors, in particular, proinflammatory cytokines]	0.0	5	1	1	1
104229	1710	v-j	[V-J]	0.0	1	1	1	1
104230	1710	problem for patient	[problem for patients]	0.0	3	1	1	1
104231	1710	various gene product from other virus	[Various gene products from other viruses]	0.0	6	1	1	1
104232	1710	role in the stimulation	[role in the stimulation]	0.0	4	1	1	1
104233	1710	dexamethasone to artery-SCID chimera	[dexamethasone to artery-SCID chimeras]	0.0	4	1	1	1
104234	1710	cortisol aids	[cortisol AIDS]	0.0	2	1	1	1
104235	1710	clinically relevant compound	[clinically relevant compounds]	0.0	3	1	1	1
104236	1710	-nonproduce	[-nonproducing]	0.0	1	1	1	1
104237	1710	microM, h),	[microM, h),]	0.0	2	1	1	1
104238	1710	c-fo with anti-CD3 stimulation	[c-fos with anti-CD3 stimulation]	0.0	4	1	1	1
104239	1710	interferon-gamma in blood lymphocyte	[interferon-gamma in blood lymphocytes]	0.0	4	1	1	1
104240	1710	different strain of hhv-6	[different strains of HHV-6]	0.0	4	1	1	1
104241	1710	26 patient	[26 patients]	0.0	2	1	1	1
104242	1710	tlc	[TLC]	0.0	1	1	1	1
104243	1710	involve interaction between multiple transcriptional element	[involving interactions between multiple transcriptional elements]	0.0	6	1	1	1
104244	1710	expression of nf-kappa b T cell	[expression of NF-kappa B T cells]	0.0	6	1	1	1
104245	1710	kappa b-related sequence element	[kappa B-related sequence elements]	0.0	4	1	1	1
104246	1710	induce stat3 tyrosine phosphorylation	[inducing STAT3 tyrosine phosphorylation]	0.0	4	1	1	1
104247	1710	E2F -contain complex	[E2F -containing complexes]	0.0	3	1	1	1
104248	1710	tnf produce cell line	[TNF producing cell lines]	0.0	4	1	1	1
104249	1710	three-dimensional magnetic resonance spectroscopy	[three-dimensional magnetic resonance spectroscopy]	0.0	4	1	1	1
104250	1710	Potential site for transcription factor	[Potential sites for transcription factors]	0.0	5	1	1	1
104251	1710	and,	[and,]	0.0	1	1	1	1
104252	1710	hmg box transcription	[HMG box transcription]	0.0	3	1	1	1
104253	1710	follow discontinuation of drug	[Following discontinuation of drugs]	0.0	4	1	1	1
104254	1710	stimulation of il-2	[stimulation of IL-2]	0.0	3	1	1	1
104255	1710	vitro reporter gene function	[vitro reporter gene function]	0.0	4	1	1	1
104256	1710	negative er-: mda-mb-231	[negative ER-: MDA-MB-231]	0.0	3	1	1	1
104257	1710	activation with PMA	[activation with PMA]	0.0	3	1	1	1
104258	1710	prediction of benefit	[prediction of benefit]	0.0	3	1	1	1
104259	1710	to:	[to:]	0.0	1	1	1	1
104260	1710	effect in u937 cell	[effect in U937 cells]	0.0	4	1	1	1
104261	1710	presence 30 base pair upstream	[presence 30 base pairs upstream]	0.0	5	1	1	1
104262	1710	proliferation index as a marker	[Proliferation index as a marker]	0.0	5	1	1	1
104263	1710	marker,	[marker,]	0.0	1	1	1	1
104264	1710	lung cell type	[lung cell types]	0.0	3	1	1	1
104265	1710	additional staining with a panel	[additional staining with a panel]	0.0	5	1	1	1
104266	1710	anae	[ANAE]	0.0	1	1	1	1
104267	1710	intrinsic kinase activity	[intrinsic kinase activity]	0.0	3	1	1	1
104268	1710	two distinct stages:	[two distinct stages:]	0.0	3	1	1	1
104269	1710	uptake with primary hyperparathyroidism	[uptake with primary hyperparathyroidism]	0.0	4	1	1	1
104270	1710	lead to modulation from monocytic cell	[leading to modulation from monocytic cells]	0.0	6	1	1	1
104271	1710	cytoplasm with fine azurophilic granularity	[cytoplasm with fine azurophilic granularity]	0.0	5	1	1	1
104272	1710	metabolism, disposition	[metabolism, disposition]	0.0	2	1	1	1
104273	1710	interleukin 2 gene by glucocorticoid	[interleukin 2 gene by glucocorticoids]	0.0	5	1	1	1
104274	1710	activation by various cellular stimulus	[Activation by various cellular stimuli]	0.0	5	1	1	1
104275	1710	express cell in contrast	[expressing cells in contrast]	0.0	4	1	1	1
104276	1710	efficient delivery vehicle	[efficient delivery vehicle]	0.0	3	1	1	1
104277	1710	helix-loop-helix (bhlh) protein e2a	[helix-loop-helix (bHLH) protein E2A]	0.0	4	1	1	1
104278	1710	human interleukin-4 IL-4 receptor	[human interleukin-4 IL-4 receptor]	0.0	4	1	1	1
104279	1710	relevance of no regulation	[relevance of NO regulation]	0.0	4	1	1	1
104280	1710	specific uptake with primary hyperparathyroidism	[specific uptake with primary hyperparathyroidism]	0.0	5	1	1	1
104281	1710	regulation of hemoglobin switch	[regulation of hemoglobin switching]	0.0	4	1	1	1
104282	1710	Interestingly, alteration	[Interestingly, alteration]	0.0	2	1	1	1
104283	1710	signal signal alone without signal	[signal signal alone without signal]	0.0	5	1	1	1
104284	1710	Cp the promoter	[Cp the promoter]	0.0	3	1	1	1
104285	1710	special focus on study	[special focus on studies]	0.0	4	1	1	1
104286	1710	activation c-fos/c-jun ap-1	[activation c-Fos/c-Jun AP-1]	0.0	3	1	1	1
104287	1710	tow	[tow]	0.0	1	1	1	1
104288	1710	presence in the plaque of artery	[presence in the plaques of arteries]	0.0	6	1	1	1
104289	1710	class ii RB line	[class II RB lines]	0.0	4	1	1	1
104290	1710	express the variable region beta chain	[expressing the variable region beta chain]	0.0	6	1	1	1
104291	1710	mononuclear leukocyte HML	[mononuclear leukocytes HML]	0.0	3	3	3	1
104292	1710	effect at 10 nm	[effect at 10 nM]	0.0	4	1	1	1
104293	1710	patient (range	[patients (ranging]	0.0	2	1	1	1
104294	1710	include binding site	[including binding sites]	0.0	3	1	1	1
104295	1710	high level of type EBS	[higher levels of type EBS]	0.0	5	1	1	1
104296	1710	initiator specify the unique terminus	[initiator specifying the unique terminus]	0.0	5	1	1	1
104297	1710	experiment.	[experiment.]	0.0	1	1	1	1
104298	1710	x receptor alpha	[X receptor alpha]	0.0	3	1	1	1
104299	1710	stimulation of conventional b-2 cell	[stimulation of conventional B-2 cells]	0.0	5	1	1	1
104300	1710	binding at different level	[binding at different levels]	0.0	4	1	1	1
104301	1710	effect on NK	[effects on NK]	0.0	3	1	1	1
104302	1710	differentiation response with combination	[differentiation response with combinations]	0.0	4	1	1	1
104303	1710	five human tonsil	[five human tonsils]	0.0	3	1	1	1
104304	1710	experiment,	[experiment,]	0.0	1	1	1	1
104305	1710	cause degradation	[causing degradation]	0.0	2	1	1	1
104306	1710	inhibition of activation of transcription factor	[Inhibition of activation of transcription factor]	0.0	6	1	1	1
104307	1710	impaired cortisol binding to receptor	[Impaired cortisol binding to receptors]	0.0	5	1	1	1
104308	1710	evidence a target	[evidence a target]	0.0	3	1	1	1
104309	1710	Ca2+ isoform in macrophage	[Ca2+ isoforms in macrophages]	0.0	4	1	1	1
104310	1710	export nuclear factor	[export nuclear factor]	0.0	3	1	1	1
104311	1710	contrast, a negative mutant	[contrast, a negative mutant]	0.0	4	1	1	1
104312	1710	characteristic of this pathway	[characteristics of this pathway]	0.0	4	2	2	1
104313	1710	HLA-Cw*0702 system	[HLA-Cw*0702 system]	0.0	2	1	1	1
104314	1710	immunodeficiency virus (hiv)-1 replication	[immunodeficiency virus (HIV)-1 replication]	0.0	4	1	1	1
104315	1710	detection in cell	[Detection in cells]	0.0	3	1	1	1
104316	1710	LMP1 ct a 333	[LMP1 CT aa 333]	0.0	4	1	1	1
104317	1710	transwell	[transwell]	0.0	1	1	1	1
104318	1710	tt4	[TT4]	0.0	1	1	1	1
104319	1710	prostatic cell	[prostatic cells]	0.0	2	1	1	1
104320	1710	leukemia B-CLL	[leukemia B-CLL]	0.0	2	1	1	1
104321	1710	fresh leukemic cell whatever	[fresh leukemic cells whatever]	0.0	4	1	1	1
104322	1710	DNA methyltransferase	[DNA methyltransferase]	0.0	2	1	1	1
104323	1710	regulate cell fate decision	[regulating cell fate decisions]	0.0	4	1	1	1
104324	1710	affinity kd for dexamethasone	[affinity Kd for dexamethasone]	0.0	4	1	1	1
104325	1710	nfkb2 p100 rela(p65)	[NFKB2 p100 RelA(p65)]	0.0	3	1	1	1
104326	1710	CF individual 7 of 52	[CF individuals 7 of 52]	0.0	5	1	1	1
104327	1710	depletion of Sp1 A1	[depletion of Sp1 A1]	0.0	4	1	1	1
104328	1710	molecular characterization of the variant allele	[Molecular characterization of the variant allele]	0.0	6	1	1	1
104329	1710	T cell LAT	[T cells LAT]	0.0	3	1	1	1
104330	1710	possible mechanism underlie endothelial cell activation	[possible mechanisms underlying endothelial cell activation]	0.0	6	1	1	1
104331	1710	N-Acetylcysteine	[N-Acetylcysteine]	0.0	1	1	1	1
104332	1710	action in human t- lymphocyte	[action in human T- lymphocytes]	0.0	5	1	1	1
104333	1710	novel transcription factor BSAP	[novel transcription factor BSAP]	0.0	4	1	1	1
104334	1710	association dissociation rate	[association dissociation rates]	0.0	3	1	1	1
104335	1710	pathogenesis of vernal keratoconjunctivitis	[pathogenesis of vernal keratoconjunctivitis]	0.0	4	1	1	1
104336	1710	access of the sterol- VDR complex	[access of the sterol- VDR complex]	0.0	6	1	1	1
104337	1710	activation of p50/c-Rel in thymocyte	[activation of p50/c-Rel in thymocytes]	0.0	5	1	1	1
104338	1710	amount of e2 from E1	[amounts of E2 from E1]	0.0	5	1	1	1
104339	1710	apoptosis in lymphocyte	[apoptosis in lymphocytes]	0.0	3	1	1	1
104340	1710	dodecyl	[dodecyl]	0.0	1	1	1	1
104341	1710	context-dependent activation	[context-dependent activation]	0.0	2	1	1	1
104342	1710	cluster in the 5'-regulatory region	[clustering in the 5'-regulatory region]	0.0	5	1	1	1
104343	1710	ttk	[ttk]	0.0	1	1	1	1
104344	1710	IL-1/tumor necrosis factor-responsive element	[IL-1/tumor necrosis factor-responsive element]	0.0	4	1	1	1
104345	1710	human hamster ovary fibroblast	[human hamster ovary fibroblasts]	0.0	4	1	1	1
104346	1710	two hiv-1 cell line	[Two HIV-1 cell lines]	0.0	4	1	1	1
104347	1710	ca2+ in the tubules:	[Ca2+ in the tubules:]	0.0	4	1	1	1
104348	1710	urinary free cortisol the number	[urinary free cortisol the number]	0.0	5	1	1	1
104349	1710	LTR gene expression	[LTR gene expression]	0.0	3	1	1	1
104350	1710	ligand-induced, docking site	[ligand-induced, docking sites]	0.0	3	1	1	1
104351	1710	dominant negative mutant pathway include myd88	[dominant negative mutants pathway including MyD88]	0.0	6	1	1	1
104352	1710	anti-38,000-M(r)	[anti-38,000-M(r)]	0.0	1	1	1	1
104353	1710	Comparing the regulation	[Comparing the regulation]	0.0	3	1	1	1
104354	1710	signal for induction,	[signals for induction,]	0.0	3	1	1	1
104355	1710	addition, N-acetyl-L-cysteine a antioxidant,	[addition, N-acetyl-L-cysteine a antioxidant,]	0.0	4	1	1	1
104356	1710	related kinase inhibitor	[related kinase inhibitor]	0.0	3	1	1	1
104357	1710	inflammatory syndrome	[inflammatory syndrome]	0.0	2	1	1	1
104358	1710	selection maintain variation	[selection maintaining variation]	0.0	3	1	1	1
104359	1710	spectrometry study	[spectrometry studies]	0.0	2	1	1	1
104360	1710	type ii-like cell	[type II-like cells]	0.0	3	1	1	1
104361	1710	b promoter activity	[B promoter activity]	0.0	3	1	1	1
104362	1710	activity by apc	[activity by APCs]	0.0	3	1	1	1
104363	1710	version of pi 3-kinase	[versions of PI 3-kinase]	0.0	4	1	1	1
104364	1710	cell level in animal	[cell level in animals]	0.0	4	1	1	1
104365	1710	lps factor-kappaB	[LPS factor-kappaB]	0.0	2	1	1	1
104366	1710	Precise regulation	[Precise regulation]	0.0	2	1	1	1
104367	1710	pnf-kappa	[pNF-kappa]	0.0	1	1	1	1
104368	1710	multiple complex with nuclear extract	[multiple complexes with nuclear extracts]	0.0	5	1	1	1
104369	1710	synthesis of long isoform	[synthesis of long isoforms]	0.0	4	1	1	1
104370	1710	cell with number	[cells with numbers]	0.0	3	1	1	1
104371	1710	4,19-disubstituted derivative	[4,19-disubstituted derivatives]	0.0	2	1	1	1
104372	1710	transcription/translation of this cDNA	[transcription/translation of this cDNA]	0.0	4	1	1	1
104373	1710	T cell-specific component	[T cell-specific component]	0.0	3	1	1	1
104374	1710	insensitivity in prostate cancer	[insensitivity in prostate cancer]	0.0	4	1	1	1
104375	1710	control of simian virus	[control of simian virus]	0.0	4	1	1	1
104376	1710	TCF/LEF	[TCF/LEF]	0.0	1	1	1	1
104377	1710	ROI-dependent NF-kappaB transcription of cytokine	[ROI-dependent NF-kappaB transcription of cytokines]	0.0	5	1	1	1
104378	1710	nuclear factor-KB NF-kappa b	[nuclear factor-KB NF-kappa B]	0.0	4	1	1	1
104379	1710	principal epo cell type	[principal EPO cell type]	0.0	4	1	1	1
104380	1710	hiv repeat LTR	[HIV repeat LTR]	0.0	3	1	1	1
104381	1710	four repeat DR of bp	[four repeats DR of bp]	0.0	5	1	1	1
104382	1710	subunit of this factor	[subunits of these factors]	0.0	4	1	1	1
104383	1710	cell BEAS-2B	[cells BEAS-2B]	0.0	2	1	1	1
104384	1710	alignment of site	[alignment of sites]	0.0	3	1	1	1
104385	1710	concentration of compound	[concentrations of compound]	0.0	3	1	1	1
104386	1710	sex-matched healthy control	[sex-matched healthy controls]	0.0	3	1	1	1
104387	1710	signal pathway with sensitivity to Bcl-2	[signaling pathways with sensitivity to Bcl-2]	0.0	6	1	1	1
104388	1710	(90%) patient	[(90%) patients]	0.0	2	1	1	1
104389	1710	blood leukocyte content of receptor GCR	[blood leukocyte content of receptors GCR]	0.0	6	1	1	1
104390	1710	immunity against many pathogen	[immunity against many pathogens]	0.0	4	1	1	1
104391	1710	suggest a mechanism for the effect.	[suggesting a mechanism for the effect.]	0.0	6	1	1	1
104392	1710	copy binding site	[copies binding sites]	0.0	3	1	1	1
104393	1710	peroxyl scavenging in unstimulated tnf- cell	[peroxyl scavenging in unstimulated TNF- cells]	0.0	6	1	1	1
104394	1710	pkc responsiveness	[PKC responsiveness]	0.0	2	1	1	1
104395	1710	TRAF2 mutant.	[TRAF2 mutant.]	0.0	2	1	1	1
104396	1710	thus, replication	[Thus, replication]	0.0	2	1	1	1
104397	1710	c-Jun at NH(2)-termini	[c-Jun at NH(2)-termini]	0.0	3	1	1	1
104398	1710	actual transcription	[actual transcription]	0.0	2	1	1	1
104399	1710	signal pathway result	[signaling pathways resulting]	0.0	3	1	1	1
104400	1710	such mediator	[such mediators]	0.0	2	1	1	1
104401	1710	lysosomal acid lipase LAL	[lysosomal acid lipase LAL]	0.0	4	1	1	1
104402	1710	accumulation of high concentration	[accumulation of high concentrations]	0.0	4	1	1	1
104403	1710	SCC cell line	[SCC cell line]	0.0	3	1	1	1
104404	1710	many disorder	[many disorders]	0.0	2	1	1	1
104405	1710	various gene product from virus	[Various gene products from viruses]	0.0	5	1	1	1
104406	1710	85 volunteer	[85 volunteers]	0.0	2	1	1	1
104407	1710	expression of a negative mutant	[expression of a negative mutant]	0.0	5	1	1	1
104408	1710	functional effect on b-cll cell	[functional effects on B-CLL cells]	0.0	5	1	1	1
104409	1710	immunodeficiency virus in monocytic cell	[immunodeficiency virus in monocytic cells]	0.0	5	1	1	1
104410	1710	form of translocations.	[form of translocations.]	0.0	3	1	1	1
104411	1710	phenomenon of resistance	[phenomenon of resistance]	0.0	3	1	1	1
104412	1710	interface in ectopic tissue	[interface in ectopic tissue]	0.0	4	1	1	1
104413	1710	regulate transcription of collagenase-1	[regulating transcription of collagenase-1]	0.0	4	1	1	1
104414	1710	membrane perturbation the possibility	[membrane perturbation the possibility]	0.0	4	1	1	1
104415	1710	role in cyclic AMP inhibition	[Role in cyclic AMP inhibition]	0.0	5	1	1	1
104416	1710	aspect of calcium	[aspects of calcium]	0.0	3	1	1	1
104417	1710	function of the infiltrate	[function of the infiltrate]	0.0	4	1	1	1
104418	1710	effect of IL-4 on cell	[effects of IL-4 on cells]	0.0	5	1	1	1
104419	1710	methods, with pair	[methods, with pairs]	0.0	3	1	1	1
104420	1710	repeat number	[repeat number]	0.0	2	1	1	1
104421	1710	two early gene c-fo	[two early genes c-fos]	0.0	4	1	1	1
104422	1710	observation on Tcf-1 knock-out mouse	[observations on Tcf-1 knock-out mice]	0.0	5	1	1	1
104423	1710	immunodeficiency virus type 1 tat	[immunodeficiency virus type 1 Tat]	0.0	5	1	1	1
104424	1710	interleukin-5 il-5	[interleukin-5 IL-5]	0.0	2	1	1	1
104425	1710	cytokines, include ifn-gamma	[cytokines, including IFN-gamma]	0.0	3	1	1	1
104426	1710	separate gene on chromosomes.	[separate genes on chromosomes.]	0.0	4	1	1	1
104427	1710	exhibit plasmacytoid differentiation	[exhibiting plasmacytoid differentiation]	0.0	3	1	1	1
104428	1710	GC b cell	[GC B cells]	0.0	3	1	1	1
104429	1710	expression of a NF-kappa b complex	[expression of a NF-kappa B complex]	0.0	6	1	1	1
104430	1710	binding of a fetal protein	[binding of a fetal protein]	0.0	5	1	1	1
104431	1710	N-terminal 86 amino acid	[N-terminal 86 amino acids]	0.0	4	1	1	1
104432	1710	map kinase kinase-3 MKK3	[MAP kinase kinase-3 MKK3]	0.0	4	1	1	1
104433	1710	aspect of Rel /nf-kappa b activity	[aspects of Rel /NF-kappa B activity]	0.0	6	1	1	1
104434	1710	IL-4 promoter 10-fold	[IL-4 promoter 10-fold]	0.0	3	1	1	1
104435	1710	IRF-1 promoter	[IRF-1 promoter]	0.0	2	1	1	1
104436	1710	synergism between distinct element during activation	[Synergism between distinct elements during activation]	0.0	6	1	1	1
104437	1710	great ap-1 -binding activity	[greater AP-1 -binding activity]	0.0	4	1	1	1
104438	1710	cell-specific pattern of mnda expression	[cell-specific pattern of MNDA expression]	0.0	5	1	1	1
104439	1710	two class of dex clone	[two classes of dex clones]	0.0	5	1	1	1
104440	1710	negative form of aml1	[negative form of AML1]	0.0	4	1	1	1
104441	1710	implication of a novel mutation	[implications of a novel mutation]	0.0	5	1	1	1
104442	1710	potential NFAT element in promoter	[potential NFAT elements in promoters]	0.0	5	1	1	1
104443	1710	determine the regulation in other lineage	[determining the regulation in other lineages]	0.0	6	1	1	1
104444	1710	Specific complex formation	[Specific complex formation]	0.0	3	1	1	1
104445	1710	cytokine receptor genes,	[cytokine receptor genes,]	0.0	3	1	1	1
104446	1710	generation by (mnc)	[generation by (MNC)]	0.0	3	1	1	1
104447	1710	direct result	[direct result]	0.0	2	1	1	1
104448	1710	endothelial activation a antiatherogenic mechanism	[endothelial activation A antiatherogenic mechanism]	0.0	5	1	1	1
104449	1710	include precursor	[including precursors]	0.0	2	1	1	1
104450	1710	area of dnase hypersensitivity extend	[area of DNase hypersensitivity extending]	0.0	5	1	1	1
104451	1710	corticosteroid produce 50% inhibition	[corticosteroid producing 50% inhibition]	0.0	4	1	1	1
104452	1710	less than 4% cells;	[less than 4% cells;]	0.0	4	1	1	1
104453	1710	role in adipocytes.	[role in adipocytes.]	0.0	3	1	1	1
104454	1710	familial cancer case	[familial cancer cases]	0.0	3	1	1	1
104455	1710	hl60 to hormone	[HL60 to hormone]	0.0	3	1	1	1
104456	1710	drive the expression	[driving the expression]	0.0	3	1	1	1
104457	1710	cell susceptibility to lysis by lymphocyte	[cell susceptibility to lysis by lymphocytes]	0.0	6	1	1	1
104458	1710	tend toward oxidation	[tending toward oxidation]	0.0	3	1	1	1
104459	1710	lineage cell p45 mrna	[lineage cells p45 mRNA]	0.0	4	1	1	1
104460	1710	12.5-kb upstream	[12.5-kb upstream]	0.0	2	1	1	1
104461	1710	expression of enzyme,	[expression of enzyme,]	0.0	3	1	1	1
104462	1710	association of Nmi with Stat5	[association of Nmi with Stat5]	0.0	5	1	1	1
104463	1710	use in combination with antiretroviral compound	[use in combination with antiretroviral compounds]	0.0	6	1	1	1
104464	1710	cell in lineage	[cells in lineage]	0.0	3	1	1	1
104465	1710	first report in cell	[first report in cells]	0.0	4	1	1	1
104466	1710	different isoform of CBF beta	[different isoforms of CBF beta]	0.0	5	1	1	1
104467	1710	factor in this context.	[factor in this context.]	0.0	4	1	1	1
104468	1710	bp of c-fe 5'-flanking sequence	[bp of c-fes 5'-flanking sequences]	0.0	5	1	1	1
104469	1710	median year gail risk	[median year Gail risk]	0.0	4	1	1	1
104470	1710	molecular function	[molecular function]	0.0	2	1	1	1
104471	1710	molecular mechanism regulate this response	[molecular mechanisms regulating this response]	0.0	5	1	1	1
104472	1710	run-off	[run-off]	0.0	1	1	1	1
104473	1710	protein lead	[proteins leading]	0.0	2	1	1	1
104474	1710	molecule such as CD28	[molecules such as CD28]	0.0	4	1	1	1
104475	1710	pre- value	[pre- values]	0.0	2	1	1	1
104476	1710	multifactorial, involve alteration	[multifactorial, involving alterations]	0.0	3	1	1	1
104477	1710	event in the inflammatory process	[event in the inflammatory process]	0.0	5	1	1	1
104478	1710	fascinating field	[fascinating field]	0.0	2	1	1	1
104479	1710	level of a specific binding activity	[levels of a specific binding activity]	0.0	6	1	1	1
104480	1710	cell EC	[cells EC]	0.0	2	1	1	1
104481	1710	different cell include peripheral cell	[different cells including peripheral cells]	0.0	5	1	1	1
104482	1710	il-12 signaling,	[IL-12 signaling,]	0.0	2	1	1	1
104483	1710	e2f function	[E2F function]	0.0	2	1	1	1
104484	1710	dnase chromatin site	[DNase chromatin site]	0.0	3	1	1	1
104485	1710	key role in cell development	[key role in cell development]	0.0	5	1	1	1
104486	1710	value in patient with disorder	[values in patients with disorder]	0.0	5	1	1	1
104487	1710	element homologous	[elements homologous]	0.0	2	1	1	1
104488	1710	role for hsp90	[roles for hsp90]	0.0	3	1	1	1
104489	1710	ppargamma in atherosclerosis	[PPARgamma in atherosclerosis]	0.0	3	1	1	1
104490	1710	transcriptional activity in RAW cell	[transcriptional activity in RAW cells]	0.0	5	1	1	1
104491	1710	t-all cell line	[T-ALL cell lines]	0.0	3	1	1	1
104492	1710	human equivalent	[human equivalent]	0.0	2	1	1	1
104493	1710	early RA	[early RA]	0.0	2	1	1	1
104494	1710	embryonic expression of musculin	[embryonic expression of musculin]	0.0	4	1	1	1
104495	1710	accumulation of the unspliced gag-pol mrna	[accumulation of the unspliced gag-pol mRNA]	0.0	6	1	1	1
104496	1710	(18 year of age),	[(18 years of age),]	0.0	4	1	1	1
104497	1710	(bcr)-	[(BCR)-]	0.0	1	1	1	1
104498	1710	surface expression by TNF	[surface expression by TNF]	0.0	4	1	1	1
104499	1710	induction of the c-fo gene	[induction of the c-fos gene]	0.0	5	1	1	1
104500	1710	directly repress Th1 development distinct	[directly repressing Th1 development distinct]	0.0	5	1	1	1
104501	1710	expansion of the number suitable	[expansion of the number suitable]	0.0	5	1	1	1
104502	1710	mutagenesis of binding site	[mutagenesis of binding sites]	0.0	4	1	1	1
104503	1710	effect of novel strategy	[effects of novel strategies]	0.0	4	1	1	1
104504	1710	glucocorticoid-receptors in failure patient	[glucocorticoid-receptors in failure patients]	0.0	4	1	1	1
104505	1710	monocyte pdgf(b) mrna	[monocyte PDGF(B) mRNA]	0.0	3	1	1	1
104506	1710	3' xpb helicase activity.	[3' XPB helicase activity.]	0.0	4	1	1	1
104507	1710	structural requirement for activation	[structural requirements for activation]	0.0	4	1	1	1
104508	1710	cell-free processing system	[cell-free processing system]	0.0	3	1	1	1
104509	1710	minor kb id-3l transcript	[minor kb Id-3L transcript]	0.0	4	1	1	1
104510	1710	mechanism cause the haploinsufficiency	[mechanism causing the haploinsufficiency]	0.0	4	1	1	1
104511	1710	exposure time	[exposure time]	0.0	2	1	1	1
104512	1710	(30 minutes) to acid	[(30 minutes) to acid]	0.0	4	1	1	1
104513	1710	transient transcriptional upregulation	[transient transcriptional upregulation]	0.0	3	1	1	1
104514	1710	regulation haec vcam-1 expression	[Regulation HAEC VCAM-1 expression]	0.0	4	1	1	1
104515	1710	transcription of chromatin structure	[transcription of chromatin structure]	0.0	4	1	1	1
104516	1710	Glucocorticoid gc resistance	[Glucocorticoid GC resistance]	0.0	3	1	1	1
104517	1710	PKC alpha	[PKC alpha]	0.0	2	1	1	1
104518	1710	CTL cross-priming	[CTL cross-priming]	0.0	2	1	1	1
104519	1710	paralysis	[paralysis]	0.0	1	1	1	1
104520	1710	chemotactic migration rate of leukocyte	[chemotactic migration rate of leukocytes]	0.0	5	1	1	1
104521	1710	tissues, gr	[tissues, GR]	0.0	2	1	1	1
104522	1710	peroxisome receptor alpha	[peroxisome receptor alpha]	0.0	3	1	1	1
104523	1710	level of protease	[levels of proteases]	0.0	3	1	1	1
104524	1710	two Sp1 binding site gc box	[two Sp1 binding sites GC box]	0.0	6	1	1	1
104525	1710	6 hours.	[6 hours.]	0.0	2	1	1	1
104526	1710	NF-IL-6 motif	[NF-IL-6 motifs]	0.0	2	1	1	1
104527	1710	grade of lymphocyte	[grades of lymphocytes]	0.0	3	1	1	1
104528	1710	Oct2-isoform expression in b cell	[Oct2-isoform expression in B cells]	0.0	5	1	1	1
104529	1710	alpha,25-dihydroxycholecalciferol dhcc	[alpha,25-dihydroxycholecalciferol DHCC]	0.0	2	1	1	1
104530	1710	inhibition of activation signal in t-cell	[Inhibition of activation signalling in T-cells]	0.0	6	1	1	1
104531	1710	human T helper clone	[human T helper clones]	0.0	4	1	1	1
104532	1710	cd11b promoter activity.	[CD11b promoter activity.]	0.0	3	1	1	1
104533	1710	easily accessible cell model	[easily accessible cell model]	0.0	4	1	1	1
104534	1710	-bsa-fitc by confocal laser scanning microscopy	[-BSA-FITC by confocal laser scanning microscopy]	0.0	6	1	1	1
104535	1710	N-terminal acidic domain with sh2 motif	[N-terminal acidic domains with SH2 motifs]	0.0	6	1	1	1
104536	1710	inhibitor of NFAT transcription	[inhibitors of NFAT transcription]	0.0	4	1	1	1
104537	1710	CD40 receptor	[CD40 receptor]	0.0	2	1	1	1
104538	1710	transcription of histocompatibility class gene	[transcription of histocompatibility class genes]	0.0	5	1	1	1
104539	1710	CD2/CD4-positive, subtype	[CD2/CD4-positive, subtype]	0.0	2	1	1	1
104540	1710	Electrophoretic mobility shift ems analysis	[Electrophoretic mobility shift EMS analyses]	0.0	5	1	1	1
104541	1710	dominant form of Ras	[dominant form of Ras]	0.0	4	1	1	1
104542	1710	addition, reach the effect	[addition, reaching the effect]	0.0	4	1	1	1
104543	1710	thp-1 a human cell line	[THP-1 a human cell line]	0.0	5	1	1	1
104544	1710	macrophage-colony-stimulating factor	[Macrophage-colony-stimulating factor]	0.0	2	1	1	1
104545	1710	biological model	[biological models]	0.0	2	1	1	1
104546	1710	maximal binding capacity	[maximal binding capacity]	0.0	3	1	1	1
104547	1710	erythropoietic culture analysis	[erythropoietic cultures analysis]	0.0	3	1	1	1
104548	1710	ring sideroblast rar	[ring sideroblasts RARS]	0.0	3	1	1	1
104549	1710	up-regulate gene expression hiv-1 long repeat	[up-regulate gene expression HIV-1 long repeats]	0.0	6	1	1	1
104550	1710	level of receptor mr in leucocyte	[levels of receptor MR in leucocytes]	0.0	6	1	1	1
104551	1710	monocytic thp 1 cell	[monocytic THP 1 cells]	0.0	4	1	1	1
104552	1710	major putative site	[major putative site]	0.0	3	1	1	1
104553	1710	healthy woman first, 10 second	[healthy women first, 10 second]	0.0	5	1	1	1
104554	1710	vitamin element	[vitamin element]	0.0	2	1	1	1
104555	1710	genomic organisation exon	[genomic organisation exons]	0.0	3	1	1	1
104556	1710	set of word oligopeptide	[set of words oligopeptides]	0.0	4	1	1	1
104557	1710	various organs,	[various organs,]	0.0	2	1	1	1
104558	1710	alteration in glucocorticoid receptor binding	[alterations in glucocorticoid receptor binding]	0.0	5	1	1	1
104559	1710	d response	[D response]	0.0	2	1	1	1
104560	1710	increase of protein complex	[increases of protein complexes]	0.0	4	1	1	1
104561	1710	modulation of corticosensitivity in TNFalpha-	[modulation of corticosensitivity in TNFalpha-]	0.0	5	1	1	1
104562	1710	receptor in vitro	[receptor in vitro]	0.0	3	1	1	1
104563	1710	establish pbmc culture	[establishing PBMC cultures]	0.0	3	1	1	1
104564	1710	flow-induced haec vcam-1 expression	[flow-induced HAEC VCAM-1 expression]	0.0	4	1	1	1
104565	1710	CD8 cell surface	[CD8 cell surface]	0.0	3	1	1	1
104566	1710	nf-kappab activation of terminal repeat	[NF-kappaB activation of terminal repeat]	0.0	5	1	1	1
104567	1710	novel 5' octamer sequence	[novel 5' octamer sequence]	0.0	4	1	1	1
104568	1710	also effect on transmembrane electrolyte movement	[also effects on transmembrane electrolyte movements]	0.0	6	2	2	1
104569	1710	hypercalciuria condition	[hypercalciuria condition]	0.0	2	1	1	1
104570	1710	/precursor grow	[/precursors growing]	0.0	2	1	1	1
104571	1710	developmental specificity	[developmental specificity]	0.0	2	1	1	1
104572	1710	tumour burden,	[tumour burden,]	0.0	2	1	1	1
104573	1710	cytoplasmic side	[cytoplasmic side]	0.0	2	1	1	1
104574	1710	assay in tissue tumor	[assay in tissue tumors]	0.0	4	1	1	1
104575	1710	mediate responsiveness to signal	[mediating responsiveness to signals]	0.0	4	1	1	1
104576	1710	system hpa	[system HPA]	0.0	2	1	1	1
104577	1710	suppress infiltration	[suppressing infiltration]	0.0	2	1	1	1
104578	1710	fetal cell line k562	[fetal cell line K562]	0.0	4	1	1	1
104579	1710	characteristic of IkappaB-alphaS32/36A	[characteristics of IkappaB-alphaS32/36A]	0.0	3	1	1	1
104580	1710	pkr activity	[PKR activity]	0.0	2	1	1	1
104581	1710	cytokine secretion profile	[cytokine secretion profiles]	0.0	3	1	1	1
104582	1710	young adult before dst mg).	[young adults before DST mg).]	0.0	5	1	1	1
104583	1710	direct the cytolytic action	[directing the cytolytic action]	0.0	4	1	1	1
104584	1710	up-	[up-]	0.0	1	1	1	1
104585	1710	main target of signal	[main target of signals]	0.0	4	1	1	1
104586	1710	combination of phytohemagglutinin	[combination of phytohemagglutinin]	0.0	3	1	1	1
104587	1710	endogenous receptor	[endogenous receptors]	0.0	2	1	1	1
104588	1710	cellular content of h+-atpase	[cellular content of H+-ATPase]	0.0	4	1	1	1
104589	1710	action of NK cell	[action of NK cells]	0.0	4	1	1	1
104590	1710	high-proliferative potential colony-forming cell	[high-proliferative potential colony-forming cells]	0.0	4	1	1	1
104591	1710	unknown step	[unknown step]	0.0	2	1	1	1
104592	1710	incubation of whole blood with PGG-Glucan	[Incubation of whole blood with PGG-Glucan]	0.0	6	1	1	1
104593	1710	t-cell killer	[T-cell killer]	0.0	2	1	1	1
104594	1710	differentiation of monocyte cell line	[differentiation of monocyte cell lines]	0.0	5	1	1	1
104595	1710	matrix protein tenascin	[matrix protein tenascin]	0.0	3	1	1	1
104596	1710	monocytic thp-1 cell at doses.	[monocytic THP-1 cells at doses.]	0.0	5	1	1	1
104597	1710	homolog Escherichia coli stress	[homolog Escherichia coli stress]	0.0	4	1	1	1
104598	1710	cell to environmental condition	[cells to environmental conditions]	0.0	4	1	1	1
104599	1710	LCL T cell blast	[LCL T cell blasts]	0.0	4	1	1	1
104600	1710	important genetic determinant	[important genetic determinants]	0.0	3	1	1	1
104601	1710	protein isgf3 gamma	[protein ISGF3 gamma]	0.0	3	1	1	1
104602	1710	nm, in monocyte	[nM, in monocytes]	0.0	3	1	1	1
104603	1710	sse-like element	[SSE-like element]	0.0	2	1	1	1
104604	1710	ligand WY 14643	[ligand WY 14,643]	0.0	3	1	1	1
104605	1710	deletion of self-reactive T cell	[deletion of self-reactive T cells]	0.0	5	1	1	1
104606	1710	plethora	[plethora]	0.0	1	1	1	1
104607	1710	different cell-specific pathway	[different cell-specific pathways]	0.0	3	1	1	1
104608	1710	Comparison of the combination	[Comparison of the combinations]	0.0	4	1	1	1
104609	1710	autoregulatory control of gata-1 transcription	[autoregulatory control of GATA-1 transcription]	0.0	5	1	1	1
104610	1710	expression in adenovirus cell	[expression in adenovirus cells]	0.0	4	1	1	1
104611	1710	panel of line	[panel of lines]	0.0	3	1	1	1
104612	1710	(3-5 day	[(3-5 days)]	0.0	2	1	1	1
104613	1710	(il-10)	[(IL-10)]	0.0	1	1	1	1
104614	1710	CIF block	[CIF blocks]	0.0	2	1	1	1
104615	1710	human il-2 rhil-2	[human IL-2 rhIL-2]	0.0	3	1	1	1
104616	1710	hybrid promoter by tnf-alpha	[hybrid promoters by TNF-alpha]	0.0	4	1	1	1
104617	1710	strong trans-activation domain tad-a	[strong trans-activation domain TAD-A]	0.0	4	1	1	1
104618	1710	induction of immediate-early gene	[induction of immediate-early genes]	0.0	4	1	1	1
104619	1710	cytokine neutrophil chemoattractant	[cytokine neutrophil chemoattractant]	0.0	3	1	1	1
104620	1710	insight into inflammation	[insights into inflammation]	0.0	3	1	1	1
104621	1710	basAl, adhesion with inhibition	[basal, adhesion with inhibition]	0.0	4	1	1	1
104622	1710	symptom of aging	[symptoms of aging]	0.0	3	1	1	1
104623	1710	two transactivator BZLF1 Z	[two transactivators BZLF1 Z]	0.0	4	1	1	1
104624	1710	inhibitor of ifn-gamma induction	[inhibitor of IFN-gamma induction]	0.0	4	1	1	1
104625	1710	t-lymphotrophic virus type HTLV-I	[T-lymphotrophic virus type HTLV-I]	0.0	4	1	1	1
104626	1710	homologue activation of adaptive immunity	[homologue activation of adaptive immunity]	0.0	5	1	1	1
104627	1710	cell type-specific subunit	[cell type-specific subunit]	0.0	3	1	1	1
104628	1710	level of the transcriptional factor	[levels of the transcriptional factor]	0.0	5	1	1	1
104629	1710	dominant negative mutant of the IL-1	[dominant negative mutants of the IL-1]	0.0	6	1	1	1
104630	1710	circulate mononuclear leukocyte	[circulating mononuclear leukocytes]	0.0	3	1	1	1
104631	1710	consider receptor study	[considering receptor studies]	0.0	3	1	1	1
104632	1710	protein/activating	[protein/activating]	0.0	1	1	1	1
104633	1710	4) mutation	[4) mutation]	0.0	2	1	1	1
104634	1710	rrna encode receptor	[mRNAs encoding receptors]	0.0	3	1	1	1
104635	1710	autoregulatory pathway	[autoregulatory pathway]	0.0	2	2	2	1
104636	1710	maturation of a promyelocytic cell line	[maturation of a promyelocytic cell line]	0.0	6	1	1	1
104637	1710	permit the release	[permitting the release]	0.0	3	1	1	1
104638	1710	utr	[UTR]	0.0	1	1	1	1
104639	1710	isotype class	[isotype class]	0.0	2	1	1	1
104640	1710	(RNA) blot	[(RNA) blots]	0.0	2	1	1	1
104641	1710	stage of thymocyte development	[stage of thymocyte development]	0.0	4	1	1	1
104642	1710	accurate model for human apl	[accurate model for human APL]	0.0	5	1	1	1
104643	1710	coagulopathy	[coagulopathy]	0.0	1	1	1	1
104644	1710	tissue malt lymphoma	[tissue MALT lymphoma]	0.0	3	1	1	1
104645	1710	promoter with DNA motif	[promoters with DNA motifs]	0.0	4	1	1	1
104646	1710	cytoplasmic sequestration	[cytoplasmic sequestration]	0.0	2	1	1	1
104647	1710	spatial distribution evidence	[spatial distribution evidence]	0.0	3	1	1	1
104648	1710	unique raralpha	[unique RARalpha]	0.0	2	1	1	1
104649	1710	high level of steroid hormone	[high levels of steroid hormones]	0.0	5	1	1	1
104650	1710	receptor alpha ligand WY 14643	[receptor alpha ligand WY 14,643]	0.0	5	1	1	1
104651	1710	undefined role of this motif	[undefined role of these motifs]	0.0	5	1	1	1
104652	1710	uvb	[UVB]	0.0	1	1	1	1
104653	1710	effect of adrenocortical activity	[effects of adrenocortical activity]	0.0	4	2	2	1
104654	1710	NFAT-1 bind	[NFAT-1 binding]	0.0	2	1	1	1
104655	1710	T-lymphoid	[T-lymphoid]	0.0	1	1	1	1
104656	1710	AML1 gene on chromosome	[AML1 gene on chromosome]	0.0	4	1	1	1
104657	1710	timp-1 antibody	[TIMP-1 antibodies]	0.0	2	1	1	1
104658	1710	expression a activator of transcription	[expression an activator of transcription]	0.0	5	1	1	1
104659	1710	hallmark of b differentiation	[hallmarks of B differentiation]	0.0	4	1	1	1
104660	1710	correlation with variable	[correlation with variables]	0.0	3	1	1	1
104661	1710	use a assay with (6,7-3h) estradiol	[using a assay with (6,7-3H) estradiol]	0.0	6	1	1	1
104662	1710	tal-15' region	[tal-15' region]	0.0	2	1	1	1
104663	1710	apparent bind affinity	[apparent binding affinity]	0.0	3	1	1	1
104664	1710	immunologic crossreactivity	[immunologic crossreactivity]	0.0	2	1	1	1
104665	1710	Spi-1/PU.1-family	[Spi-1/PU.1-family]	0.0	1	1	1	1
104666	1710	pretreatment of "semimature"	[Pretreatment of "semimature"]	0.0	3	1	1	1
104667	1710	impact of factor binding	[impact of factor binding]	0.0	4	1	1	1
104668	1710	good correlation with the sba	[good correlation with the SBA]	0.0	5	1	1	1
104669	1710	HIV regulatory region	[HIV regulatory region]	0.0	3	1	1	1
104670	1710	signal lead to cellular activation	[signals leading to cellular activation]	0.0	5	1	1	1
104671	1710	activation after ligation of histocompatibility class	[Activation after ligation of histocompatibility class]	0.0	6	1	1	1
104672	1710	system pyramidal cell	[system pyramidal cells]	0.0	3	1	1	1
104673	1710	woman with climacteric syndrome	[women with climacteric syndrome]	0.0	4	1	1	1
104674	1710	evidence of a immune-endocrine interplay	[evidence of an immune-endocrine interplay]	0.0	5	1	1	1
104675	1710	8, malignant fibrous histiocytoma	[8, malignant fibrous histiocytoma]	0.0	4	1	1	1
104676	1710	major histocompatibility complex way	[major histocompatibility complex way]	0.0	4	1	1	1
104677	1710	homologous member the homolog c/ebp-beta	[homologous members the homolog C/EBP-beta]	0.0	5	1	1	1
104678	1710	fos/jun	[Fos/Jun]	0.0	1	1	1	1
104679	1710	construct of RAR alpha	[construct of RAR alpha]	0.0	4	1	1	1
104680	1710	dnase hypersensitivity extend	[DNase hypersensitivity extending]	0.0	3	1	1	1
104681	1710	c3/5	[C3/5]	0.0	1	1	1	1
104682	1710	aspect of microarchitecture	[aspects of microarchitecture]	0.0	3	1	1	1
104683	1710	use tnf-alpha-activity antibody	[Using TNF-alpha-activity antibodies]	0.0	3	1	1	1
104684	1710	distinct form of active transcription factor	[distinct forms of active transcription factor]	0.0	6	1	1	1
104685	1710	cell-specific expression of transcription factor	[Cell-specific expression of transcription factors]	0.0	5	1	1	1
104686	1710	kd-restricted epitope	[Kd-restricted epitope]	0.0	2	1	1	1
104687	1710	visit, within week of discharge.	[visit, within weeks of discharge.]	0.0	5	1	1	1
104688	1710	whole peripheral blood	[whole peripheral blood]	0.0	3	1	1	1
104689	1710	apoptosis in lymphoblastoid t-cell-line-expressing CD4 receptor	[apoptosis in lymphoblastoid T-cell-line-expressing CD4 receptors]	0.0	6	1	1	1
104690	1710	treatment with two schedule	[Treatment with two schedules]	0.0	4	1	1	1
104691	1710	heavy chain gene in cell	[heavy chain genes in cells]	0.0	5	1	1	1
104692	1710	cis-act element	[cis-acting elements]	0.0	2	1	1	1
104693	1710	processing by NF-kappaB protein	[processing by NF-kappaB proteins]	0.0	4	1	1	1
104694	1710	dominant molecule	[dominant molecule]	0.0	2	1	1	1
104695	1710	phosphatidic signalling	[phosphatidic signalling]	0.0	2	1	1	1
104696	1710	other dinucleotide trinucleotide repeat	[other dinucleotide trinucleotide repeats]	0.0	4	1	1	1
104697	1710	octamer-DNA binding protein distinct	[octamer-DNA binding proteins distinct]	0.0	4	1	1	1
104698	1710	addition to properties	[addition to properties,]	0.0	3	1	1	1
104699	1710	anti-cd28 mab induction	[anti-CD28 mAb induction]	0.0	3	1	1	1
104700	1710	transcriptional activity through element	[transcriptional activity through elements]	0.0	4	1	1	1
104701	1710	scd8	[sCD8]	0.0	1	1	1	1
104702	1710	scd4	[sCD4]	0.0	1	1	1	1
104703	1710	effect on il-2 induction	[effect on IL-2 induction]	0.0	4	1	1	1
104704	1710	cytokine -dependent cell line	[cytokine -dependent cell line]	0.0	4	1	1	1
104705	1710	nf-kappab activation of repeat	[NF-kappaB activation of repeat]	0.0	4	1	1	1
104706	1710	anti-atherogenic effect	[anti-atherogenic effect]	0.0	2	1	1	1
104707	1710	substantial quantity of a number	[substantial quantities of a number]	0.0	5	1	1	1
104708	1710	abrogate	[abrogates]	0.0	1	1	1	1
104709	1710	considerable datum available	[considerable data available]	0.0	3	1	1	1
104710	1710	nucleotide number	[nucleotide numbers]	0.0	2	1	1	1
104711	1710	long repeat promoter region	[long repeat promoter region]	0.0	4	1	1	1
104712	1710	interpretation the target	[interpretation the target]	0.0	3	1	1	1
104713	1710	effect of dexamethasone dm	[effect of dexamethasone DM]	0.0	4	1	1	1
104714	1710	oligonucleotide to c-fo	[oligonucleotides to c-fos]	0.0	3	1	1	1
104715	1710	induction monocytic differentiation	[Induction monocytic differentiation]	0.0	3	1	1	1
104716	1710	regulation of the octamer motif	[regulation of the octamer motif]	0.0	5	1	1	1
104717	1710	synovium	[synovium]	0.0	1	1	1	1
104718	1710	(il-2)r	[(IL-2)R]	0.0	1	1	1	1
104719	1710	patient with ovary syndrome	[patients with ovary syndrome]	0.0	4	1	1	1
104720	1710	activity in tumour	[activity in tumours]	0.0	3	1	1	1
104721	1710	effect on NF-kappaB gene expression	[effect on NF-kappaB gene expression]	0.0	5	1	1	1
104722	1710	dihydro derivative	[dihydro derivatives]	0.0	2	1	1	1
104723	1710	transcription factor in h-rs cell	[transcription factor in H-RS cells]	0.0	5	1	1	1
104724	1710	affinity to glucocorticoid AIDS-C	[affinity to glucocorticoids AIDS-C]	0.0	4	1	1	1
104725	1710	differentiation of skw cell	[differentiation of SKW cells]	0.0	4	1	1	1
104726	1710	Effect modulation	[Effects modulation]	0.0	2	1	1	1
104727	1710	CF individual	[CF individuals]	0.0	2	1	1	1
104728	1710	600 nm,	[600 nM,]	0.0	2	1	1	1
104729	1710	member of the protein	[members of the proteins]	0.0	4	1	1	1
104730	1710	clonal cytogenetic change present	[clonal cytogenetic change present]	0.0	4	1	1	1
104731	1710	dissociation signal	[Dissociation signaling]	0.0	2	1	1	1
104732	1710	gene in mononuclear cell	[genes in mononuclear cells]	0.0	4	1	1	1
104733	1710	primary myelodysplastic syndrome in stage	[primary myelodysplastic syndromes in stage]	0.0	5	1	1	1
104734	1710	detection of antibody	[detection of antibodies]	0.0	3	1	1	1
104735	1710	c-reactive protein	[C-reactive protein]	0.0	2	1	1	1
104736	1710	transcription factor tata-binding protein	[transcription factors TATA-binding protein]	0.0	4	1	1	1
104737	1710	activation of response gene	[activation of response genes]	0.0	4	1	1	1
104738	1710	sex-determine gene	[sex-determining gene]	0.0	2	1	1	1
104739	1710	activation of two second messenger	[activation of two second messengers]	0.0	5	1	1	1
104740	1710	information about role	[information about roles]	0.0	3	1	1	1
104741	1710	steroid-resistant asthmatic subject	[steroid-resistant asthmatic subjects]	0.0	3	1	1	1
104742	1710	hydrophobic domain with eight segment	[hydrophobic domain with eight segments]	0.0	5	1	1	1
104743	1710	length of the 5' sequence	[lengths of the 5' sequence]	0.0	5	1	1	1
104744	1710	palindromic sequence in the element	[palindromic sequence in the element]	0.0	5	1	1	1
104745	1710	tcr alpha/beta loci	[TCR alpha/beta loci]	0.0	3	1	1	1
104746	1710	dissociation constant of glucocorticoid receptor	[dissociation constant of glucocorticoid receptor]	0.0	5	4	4	1
104747	1710	essential site	[essential site]	0.0	2	1	1	1
104748	1710	follow glucocorticoid treatment	[Following glucocorticoid treatment]	0.0	3	1	1	1
104749	1710	activator of transcription protein	[activator of transcription proteins]	0.0	4	1	1	1
104750	1710	critical tool for monitoring	[critical tools for monitoring]	0.0	4	1	1	1
104751	1710	effect on response	[effect on responses]	0.0	3	1	1	1
104752	1710	mechanism of t-lymphocyte anergy in	[mechanisms of T-lymphocyte anergy in]	0.0	5	1	1	1
104753	1710	growth factor-like growth factor HB-EGF	[growth factor-like growth factor HB-EGF]	0.0	5	1	1	1
104754	1710	regulation of ifn-gamma production	[regulation of IFN-gamma production]	0.0	4	1	1	1
104755	1710	factor (m-csf) receptor	[factor (M-CSF) receptor]	0.0	3	1	1	1
104756	1710	extract from jurkat cell	[extracts from Jurkat cells]	0.0	4	1	1	1
104757	1710	Conclusions: NK cell membrane-bound lt signal	[CONCLUSIONS: NK cell membrane-bound LT signals]	0.0	6	1	1	1
104758	1710	level of oxidative stress	[levels of oxidative stress]	0.0	4	2	2	1
104759	1710	antigen-specific T cell clone	[antigen-specific T cell clones]	0.0	4	1	1	1
104760	1710	multiple signals, include cytokine	[multiple signals, including cytokines]	0.0	4	1	1	1
104761	1710	direct, receptor-mediated effect of androgen	[direct, receptor-mediated effects of androgens]	0.0	5	1	1	1
104762	1710	use immunomagnetic separation	[using immunomagnetic separation]	0.0	3	1	1	1
104763	1710	involve expression of the response gene	[involving expression of the response genes]	0.0	6	1	1	1
104764	1710	extension	[extension]	0.0	1	1	1	1
104765	1710	use water phorbol ester	[using water phorbol esters]	0.0	4	1	1	1
104766	1710	B-cell transformation in some neoplasia	[B-cell transformation in some neoplasias]	0.0	5	1	1	1
104767	1710	identification of a interaction between calcineurin	[Identification of a interaction between calcineurin]	0.0	6	1	1	1
104768	1710	class of site	[class of sites]	0.0	3	1	1	1
104769	1710	correlation between the transcriptional	[correlation between the transcriptional]	0.0	4	1	1	1
104770	1710	CD3 /tcr pathway	[CD3 /TCR pathway]	0.0	3	1	1	1
104771	1710	role in AMP inhibition of transcription	[Role in AMP inhibition of transcription]	0.0	6	1	1	1
104772	1710	keratoconjunctivitis vkc	[keratoconjunctivitis VKC]	0.0	2	1	1	1
104773	1710	Stat3EE a mutant	[Stat3EE a mutant]	0.0	3	1	1	1
104774	1710	etv6-	[ETV6-]	0.0	1	1	1	1
104775	1710	atra-induced differentiation	[ATRA-induced differentiation]	0.0	2	1	1	1
104776	1710	135-(oh)2d3 induction of degradation.	[1,25-(OH)2D3 induction of degradation.]	0.0	4	1	1	1
104777	1710	repeat LTR sequence diversity	[repeat LTR sequence diversity]	0.0	4	1	1	1
104778	1710	molecular lesion	[molecular lesion]	0.0	2	1	1	1
104779	1710	study the binding	[studying the binding]	0.0	3	1	1	1
104780	1710	form of Stat1alpha	[forms of Stat1alpha]	0.0	3	1	1	1
104781	1710	normal lymphocyte from peripheral blood	[normal lymphocytes from peripheral blood]	0.0	5	1	1	1
104782	1710	span 45 kb of DNA	[spanning 45 kb of DNA]	0.0	5	1	1	1
104783	1710	three rflp	[Three RFLPs]	0.0	2	1	1	1
104784	1710	vdr	[VDRs]	0.0	1	1	1	1
104785	1710	compensatory phase of sepsis	[compensatory phase of sepsis]	0.0	4	2	2	1
104786	1710	mode of helix-loop-helix regulation	[modes of helix-loop-helix regulation]	0.0	4	1	1	1
104787	1710	similar activation	[similar activation]	0.0	2	1	1	1
104788	1710	cytokine-induced abnormality	[cytokine-induced abnormalities]	0.0	2	1	1	1
104789	1710	effect of IL-11	[effects of IL-11]	0.0	3	1	1	1
104790	1710	simultaneous immunocytogenetic study use antibody	[simultaneous immunocytogenetic studies using antibodies]	0.0	5	1	1	1
104791	1710	generation of oxygen species	[generation of oxygen species]	0.0	4	1	1	1
104792	1710	disorder in heterozygous woman	[disorders in heterozygous women]	0.0	4	1	1	1
104793	1710	use culture	[using cultures]	0.0	2	1	1	1
104794	1710	diverse subpopulation	[diverse subpopulations]	0.0	2	1	1	1
104795	1710	basic (bhlh) transcription factor	[basic (bHLH) transcription factors]	0.0	4	1	1	1
104796	1710	involve interaction	[involving interactions]	0.0	2	1	1	1
104797	1710	activation of glucocorticoid binding	[activation of glucocorticoid binding]	0.0	4	1	1	1
104798	1710	activation of the cytokine	[activation of the cytokines]	0.0	4	1	1	1
104799	1710	gain in signal	[gain in signal]	0.0	3	1	1	1
104800	1710	distinct inhibitory receptor	[distinct inhibitory receptor]	0.0	3	1	1	1
104801	1710	specify the terminus of pp52 mrna	[specifying the terminus of pp52 mRNA]	0.0	6	1	1	1
104802	1710	family, like the (proto)oncogenes	[family, like the (proto)oncogenes]	0.0	4	1	1	1
104803	1710	interferon-gamma production	[interferon-gamma production]	0.0	2	1	1	1
104804	1710	Effect modulation of function of protein	[Effects modulation of functions of proteins]	0.0	6	1	1	1
104805	1710	base pair substitution	[base pair substitutions]	0.0	3	1	1	1
104806	1710	tnf to phorbol myristate acetate	[TNF to phorbol myristate acetate]	0.0	5	1	1	1
104807	1710	immunocytochemistry;	[immunocytochemistry;]	0.0	1	1	1	1
104808	1710	suppression by CsA	[suppression by CsA]	0.0	3	1	1	1
104809	1710	two molecules, nfatp	[Two molecules, NFATp]	0.0	3	1	1	1
104810	1710	scl)	[SCL)]	0.0	1	1	1	1
104811	1710	terminal repeat type 1	[terminal repeat type 1]	0.0	4	1	1	1
104812	1710	cell from primate with resistance	[cells from primates with resistance]	0.0	5	1	1	1
104813	1710	adhesion with 50% inhibition at mM.	[adhesion with 50% inhibition at mM.]	0.0	6	1	1	1
104814	1710	fourth, extensive purification by cycle	[Fourth, extensive purification by cycles]	0.0	5	1	1	1
104815	1710	beta cap	[beta cap]	0.0	2	1	1	1
104816	1710	il-1 nf-kappa b	[IL-1 NF-kappa B]	0.0	3	1	1	1
104817	1710	Furthermore, concentration microm	[Furthermore, concentrations microM]	0.0	3	1	1	1
104818	1710	combination of disable mutation	[combinations of disabling mutations]	0.0	4	1	1	1
104819	1710	domain include domain	[domains including domains]	0.0	3	1	1	1
104820	1710	direct correlation between plasma cortisol	[direct correlation between plasma cortisol]	0.0	5	1	1	1
104821	1710	heavy chain (igh) gene expression	[heavy chain (IgH) gene expression]	0.0	5	1	1	1
104822	1710	docking site within individual cytokine receptor	[docking sites within individual cytokine receptors]	0.0	6	1	1	1
104823	1710	modulation by adenoviral transfer	[modulation by adenoviral transfer]	0.0	4	1	1	1
104824	1710	in-situ labelling of DNA strand	[in-situ labelling of DNA strand]	0.0	5	1	1	1
104825	1710	2 pre-B acute leukemia	[2 pre-B acute leukemia]	0.0	4	1	1	1
104826	1710	hhv-6 orf	[HHV-6 ORFs]	0.0	2	1	1	1
104827	1710	myelomonocytic cell gene	[myelomonocytic cell genes]	0.0	3	1	1	1
104828	1710	activator of PKB/Akt	[activator of PKB/Akt]	0.0	3	1	1	1
104829	1710	methods: Eleven patient	[METHODS: Eleven patients]	0.0	3	1	1	1
104830	1710	other parameters,	[Other parameters,]	0.0	2	1	1	1
104831	1710	binding site the transcription factor	[binding sites the transcription factor]	0.0	5	1	1	1
104832	1710	-rich domain	[-rich domain]	0.0	2	1	1	1
104833	1710	factor kappab nf-kappab kinase	[factor kappaB NF-kappaB kinase]	0.0	4	1	1	1
104834	1710	dihydropyrimidine dehydrogenase DPD the enzyme	[dihydropyrimidine dehydrogenase DPD the enzyme]	0.0	5	1	1	1
104835	1710	peptide onto class molecule	[peptides onto class molecules]	0.0	4	1	1	1
104836	1710	reveal a functional redundancy	[revealing an functional redundancy.]	0.0	4	1	1	1
104837	1710	transcription of the terminal repeat LTR	[transcription of the terminal repeats LTR]	0.0	6	1	1	1
104838	1710	weight 13000 to 24000	[weight 13,000 to 24,000]	0.0	4	1	1	1
104839	1710	region contain near-perfect repeat DR	[region containing near-perfect repeats DR]	0.0	5	1	1	1
104840	1710	three transcription initiation site	[three transcription initiation sites]	0.0	4	1	1	1
104841	1710	hematopoietic-specific transcript	[hematopoietic-specific transcript]	0.0	2	1	1	1
104842	1710	extract from ml-1 cell	[extracts from ML-1 cells]	0.0	4	1	1	1
104843	1710	one cytokine	[one cytokine]	0.0	2	2	2	1
104844	1710	use display rt-pcr	[using display RT-PCR]	0.0	3	1	1	1
104845	1710	different aetiology for this disorders.	[different aetiologies for these disorders.]	0.0	5	1	1	1
104846	1710	s-100	[S-100]	0.0	1	1	1	1
104847	1710	production by effector cell	[production by effector cells]	0.0	4	1	1	1
104848	1710	arthritis synovial tissue	[arthritis synovial tissue]	0.0	3	1	1	1
104849	1710	Intriguingly, surface	[Intriguingly, surface]	0.0	2	1	1	1
104850	1710	contain direct repeat of bp	[containing direct repeats of bp]	0.0	5	1	1	1
104851	1710	rapid desensitization	[rapid desensitization]	0.0	2	1	1	1
104852	1710	molecular regulation of cytokine gene expression	[Molecular regulation of cytokine gene expression]	0.0	6	1	1	1
104853	1710	include atherosclerosis	[including atherosclerosis]	0.0	2	1	1	1
104854	1710	end a site	[end a site]	0.0	3	1	1	1
104855	1710	LYSP100 dot	[LYSP100 dots]	0.0	2	1	1	1
104856	1710	anti-estrogen therapy on serum immunoglobulin	[anti-estrogen therapy on serum immunoglobulin]	0.0	5	1	1	1
104857	1710	tissue examined, breast	[tissues examined, breast]	0.0	3	1	1	1
104858	1710	effectiveness from delivery	[effectiveness from delivery]	0.0	3	1	1	1
104859	1710	gliadin peptide -hla class	[gliadin peptide -HLA class]	0.0	4	1	1	1
104860	1710	blockade of endogenous nfat activity	[blockade of endogenous NFAT activity]	0.0	5	1	1	1
104861	1710	deletion of a amino- (940-984) region	[Deletions of a amino- (940-984) region]	0.0	6	1	1	1
104862	1710	nf-kappab -dependent in rheumatoid tissue	[NF-kappaB -dependent in rheumatoid tissue]	0.0	5	1	1	1
104863	1710	two EBV-associated, hla-b8-restricted latent epitope	[two EBV-associated, HLA-B8-restricted latent epitopes]	0.0	5	1	1	1
104864	1710	Myc-associated zinc finger protein	[Myc-associated zinc finger protein]	0.0	4	1	1	1
104865	1710	effector T	[effector T]	0.0	2	3	3	1
104866	1710	study use oligonucleotide	[studies using oligonucleotides]	0.0	3	1	1	1
104867	1710	and/or stage-specific expression of delta-	[and/or stage-specific expression of delta-]	0.0	5	1	1	1
104868	1710	motif important	[motifs important]	0.0	2	1	1	1
104869	1710	encode scm-1alpha	[encoding SCM-1alpha]	0.0	2	1	1	1
104870	1710	complex change	[complex change]	0.0	2	1	1	1
104871	1710	related acid receptor	[related acid receptor]	0.0	3	1	1	1
104872	1710	result of infection	[result of infection]	0.0	3	1	1	1
104873	1710	striking heterogeneity	[striking heterogeneity]	0.0	2	1	1	1
104874	1710	novel 9-bp motif with homology	[novel 9-bp motifs with homology]	0.0	5	1	1	1
104875	1710	70z/3 sequence	[70Z/3 sequences]	0.0	2	1	1	1
104876	1710	x-y	[X-Y]	0.0	1	1	1	1
104877	1710	mechanism for dioxin-mediated alteration	[mechanism for dioxin-mediated alteration]	0.0	4	1	1	1
104878	1710	activator of many gene	[activator of many genes]	0.0	4	1	1	1
104879	1710	express t-cell line	[expressing T-cell lines]	0.0	3	1	1	1
104880	1710	several region include CBF	[several regions including CBF]	0.0	4	1	1	1
104881	1710	induction by tumor necrosis factor	[induction by tumor necrosis factor]	0.0	5	1	1	1
104882	1710	gene agent	[gene agents]	0.0	2	1	1	1
104883	1710	intron in cells,	[intron in cells,]	0.0	3	1	1	1
104884	1710	sclerosis ms	[sclerosis MS]	0.0	2	1	1	1
104885	1710	structural similarity with the oncogene product	[structural similarity with the oncogene product]	0.0	6	1	1	1
104886	1710	DNA sequence upstream	[DNA sequence upstream]	0.0	3	1	1	1
104887	1710	contrast, level ap-1	[contrast, levels AP-1]	0.0	3	1	1	1
104888	1710	x1-	[X1-]	0.0	1	1	1	1
104889	1710	specific marker for b-1 cell	[specific marker for B-1 cells]	0.0	5	1	1	1
104890	1710	binding result	[binding results]	0.0	2	1	1	1
104891	1710	DNA receptor	[DNA receptors]	0.0	2	1	1	1
104892	1710	adherence/contact of ss RBC	[adherence/contact of SS RBC]	0.0	4	1	1	1
104893	1710	transcriptional activate effect	[transcriptional activating effects]	0.0	3	1	1	1
104894	1710	viable definitive erythroid cell	[viable definitive erythroid cells]	0.0	4	1	1	1
104895	1710	residue at the COOH terminus	[residues at the COOH terminus]	0.0	5	1	1	1
104896	1710	non-hodgkin lymphoma exhibit differentiation	[non-Hodgkin lymphomas exhibiting differentiation]	0.0	4	1	1	1
104897	1710	aml1-related transcription factor	[AML1-related transcription factor]	0.0	3	1	1	1
104898	1710	stable clone	[stable clones]	0.0	2	1	1	1
104899	1710	functional diversification	[functional diversification]	0.0	2	1	1	1
104900	1710	involve a interaction	[involving a interaction]	0.0	3	1	1	1
104901	1710	5-fold affinity	[5-fold affinity]	0.0	2	1	1	1
104902	1710	minimal activation of c-fo expression	[minimal activation of c-fos expression]	0.0	5	1	1	1
104903	1710	HLA Class dependency	[HLA Class dependency]	0.0	3	1	1	1
104904	1710	il-4-induced tyrosine phosphorylation of substrate	[IL-4-induced tyrosine phosphorylation of substrates]	0.0	5	1	1	1
104905	1710	NE of atp-depleted platelet	[NE of ATP-depleted platelets]	0.0	4	1	1	1
104906	1710	Erythroid-specific rrna	[Erythroid-specific mRNAs]	0.0	2	1	1	1
104907	1710	blood substrate	[blood substrates]	0.0	2	1	1	1
104908	1710	colonic carcinoma cell line	[colonic carcinoma cell line]	0.0	4	1	1	1
104909	1710	implication of signal in cell	[implications of signals in cells]	0.0	5	1	1	1
104910	1710	differential display	[differential display]	0.0	2	1	1	1
104911	1710	control of NF-kappa b activation	[control of NF-kappa B activation]	0.0	5	1	1	1
104912	1710	modification of free sulfhydryl group	[modification of free sulfhydryl groups]	0.0	5	1	1	1
104913	1710	dramatic loss of cell production	[dramatic loss of cell production]	0.0	5	1	1	1
104914	1710	heterozygosity in DNA	[heterozygosity in DNA]	0.0	3	1	1	1
104915	1710	modulate the differentiation-dependent transcription	[modulating the differentiation-dependent transcription]	0.0	4	1	1	1
104916	1710	Janus cell line	[Janus cell line]	0.0	3	1	1	1
104917	1710	viability trypan exclusion	[viability trypan exclusion]	0.0	3	1	1	1
104918	1710	0.23 p than 0.001)	[0.23, P than 0.001)]	0.0	4	1	1	1
104919	1710	effective treatment for asthma	[effective treatment for asthma]	0.0	4	1	1	1
104920	1710	response along the erythroid	[response along the erythroid]	0.0	4	1	1	1
104921	1710	activate element	[activating elements]	0.0	2	1	1	1
104922	1710	microgram/day for 1 month	[microgram/day for 1 month]	0.0	4	1	1	1
104923	1710	trans activation in T cell	[trans activation in T cells]	0.0	5	1	1	1
104924	1710	activation of hematopoietic gene	[activation of hematopoietic genes]	0.0	4	1	1	1
104925	1710	proximal c-jun promoter element	[proximal c-jun promoter element]	0.0	4	1	1	1
104926	1710	regulation role of protein kinase c	[Regulation role of protein kinase C]	0.0	6	1	1	1
104927	1710	regulate a b cell-specific gene blk	[regulating a B cell-specific gene blk]	0.0	6	1	1	1
104928	1710	166 female	[166 females]	0.0	2	1	1	1
104929	1710	mating	[mating]	0.0	1	1	1	1
104930	1710	binding of pac-1 5.5-fold	[binding of PAC-1 5.5-fold]	0.0	4	1	1	1
104931	1710	signal pathway regulate gene expression	[signaling pathway regulating gene expression]	0.0	5	1	1	1
104932	1710	multiple tyrosine kinase	[multiple tyrosine kinases]	0.0	3	1	1	1
104933	1710	AP-1 content	[AP-1 contents]	0.0	2	1	1	1
104934	1710	response to stimulus product	[response to stimuli products]	0.0	4	1	1	1
104935	1710	role protein in AMP inhibition	[Role protein in AMP inhibition]	0.0	5	1	1	1
104936	1710	expression of the p50	[expression of the p50]	0.0	4	1	1	1
104937	1710	expression of the AMP response	[Expression of the AMP response]	0.0	5	1	1	1
104938	1710	e(2) murine monocytic line,	[E(2) murine monocytic line,]	0.0	4	1	1	1
104939	1710	(NF)-AT	[(NF)-AT]	0.0	1	1	1	1
104940	1710	recruitment of dna-binding activity	[recruitment of DNA-binding activity]	0.0	4	1	1	1
104941	1710	characteristic plasmalemmal localization	[characteristic plasmalemmal localization]	0.0	3	1	1	1
104942	1710	mol/L for 13-cis RA	[mol/L for 13-cis RA]	0.0	4	1	1	1
104943	1710	resident tissue fibroblast	[resident tissue fibroblasts]	0.0	3	1	1	1
104944	1710	small apolar substitution	[Small apolar substitutions]	0.0	3	1	1	1
104945	1710	deterioration immunodeficiency virus type hiv-1	[deterioration immunodeficiency virus type HIV-1]	0.0	5	1	1	1
104946	1710	level of constitutive virus expression	[levels of constitutive virus expression]	0.0	5	1	1	1
104947	1710	lineage- specific expression	[Lineage- specific expression]	0.0	3	1	1	1
104948	1710	promote mm cell growth	[promoting MM cell growth]	0.0	4	1	1	1
104949	1710	human interferon beta IFN-beta element	[human interferon beta IFN-beta element]	0.0	5	1	1	1
104950	1710	activity of the FasL reporter	[activity of the FasL reporter]	0.0	5	1	1	1
104951	1710	separate pathway	[separate pathways]	0.0	2	1	1	1
104952	1710	total of severe, asthmatic patient	[total of severe, asthmatic patients]	0.0	5	1	1	1
104953	1710	early viral protein and/or	[early viral proteins and/or]	0.0	4	1	1	1
104954	1710	human epithelial cell response	[Human epithelial cell responses]	0.0	4	1	1	1
104955	1710	anti-cd8 mab	[anti-CD8 mAb]	0.0	2	1	1	1
104956	1710	role for the Epstein-Barr virus antigen	[Role for the Epstein-Barr virus antigen]	0.0	6	1	1	1
104957	1710	subsequent replacement in vitro	[subsequent replacement in vitro]	0.0	4	1	1	1
104958	1710	viable mature definitive cell	[viable mature definitive cells]	0.0	4	1	1	1
104959	1710	cell of T lymphocytic lineage	[cells of T lymphocytic lineage]	0.0	5	1	1	1
104960	1710	gel electrophoresis system	[gel electrophoresis system]	0.0	3	1	1	1
104961	1710	b alpha embryonic fibroblast	[B alpha embryonic fibroblasts]	0.0	4	1	1	1
104962	1710	other proliferator receptor	[Other proliferator receptor]	0.0	3	1	1	1
104963	1710	mouse lymph	[mouse lymph]	0.0	2	1	1	1
104964	1710	delta 5' region	[delta 5' regions]	0.0	3	1	1	1
104965	1710	nf-kappab in cell	[NF-kappaB in cells]	0.0	3	1	1	1
104966	1710	five severe dermatitis patient	[five severe dermatitis patients]	0.0	4	1	1	1
104967	1710	5- increase in the level	[5- increase in the level]	0.0	5	1	1	1
104968	1710	general role in differentiation	[general role in differentiation]	0.0	4	1	1	1
104969	1710	nuclear CaM kinase	[nuclear CaM kinase]	0.0	3	1	1	1
104970	1710	IL-2 deprivation-induced apoptosis	[IL-2 deprivation-induced apoptosis]	0.0	3	1	1	1
104971	1710	77 +/- versus +/-	[77 +/- versus +/-]	0.0	4	1	1	1
104972	1710	response to the two protein BZLF1	[responses to the two proteins BZLF1]	0.0	6	1	1	1
104973	1710	environmental cycle	[environmental cycle]	0.0	2	1	1	1
104974	1710	Functional role of the transcription factor	[Functional roles of the transcription factor]	0.0	6	1	1	1
104975	1710	Addition to the thymocyte culture	[Addition to the thymocyte cultures]	0.0	5	1	1	1
104976	1710	methov of umbilical vein endothelial cell	[METHODS of umbilical vein endothelial cells]	0.0	6	1	1	1
104977	1710	/Stat	[/Stat]	0.0	1	1	1	1
104978	1710	glucocorticoid by virtue	[glucocorticoids by virtue]	0.0	3	1	1	1
104979	1710	response in prostate cancer lncap cell	[responses in prostate cancer LNCaP cells]	0.0	6	1	1	1
104980	1710	integratory messenger	[integratory messenger]	0.0	2	1	1	1
104981	1710	Gallo,	[Gallo,]	0.0	1	1	1	1
104982	1710	host cell differentiation	[host cell differentiation]	0.0	3	1	1	1
104983	1710	ar-5	[Ar-5]	0.0	1	1	1	1
104984	1710	cytokine -production	[cytokine -production]	0.0	2	1	1	1
104985	1710	intermediate T	[intermediate T]	0.0	2	1	1	1
104986	1710	il-2 target	[IL-2 target]	0.0	2	1	1	1
104987	1710	response result tissue damage	[response resulting tissue damage]	0.0	4	1	1	1
104988	1710	activator of promoter	[activator of promoters]	0.0	3	1	1	1
104989	1710	mononucleosis patient	[mononucleosis patients]	0.0	2	1	1	1
104990	1710	/CD57	[/CD57]	0.0	1	1	1	1
104991	1710	Fifteen patient (age 25-79)	[Fifteen patients (age 25-79)]	0.0	4	1	1	1
104992	1710	major complex (mhc) class molecule	[major complex (MHC) class molecules]	0.0	5	1	1	1
104993	1710	map kinases/extracellular signal	[MAP kinases/extracellular signal]	0.0	3	1	1	1
104994	1710	dissection of a range	[dissection of a range]	0.0	4	1	1	1
104995	1710	mesenchymal cell	[mesenchymal cells]	0.0	2	1	1	1
104996	1710	dissociation constant for binding	[dissociation constants for binding]	0.0	4	1	1	1
104997	1710	heterodimer of p50	[heterodimer of p50]	0.0	3	1	1	1
104998	1710	t(17;19) acute leukemia chimera	[t(17;19) acute leukemia chimera]	0.0	4	1	1	1
104999	1710	human globin gene	[human globin genes]	0.0	3	1	1	1
105000	1710	exogenous c-erba/tr-alpha	[exogenous c-erbA/TR-alpha]	0.0	2	1	1	1
105001	1710	DNA affinity of pouhd	[DNA affinity of POUHD]	0.0	4	1	1	1
105002	1710	nuclear localization of p50	[nuclear localization of p50]	0.0	4	1	1	1
105003	1710	t-cell translocation to chromosome	[T-cell translocations to chromosomes]	0.0	4	1	1	1
105004	1710	Burkitt' lymphoma receptor blr1	[Burkitt's lymphoma receptor BLR1]	0.0	4	1	1	1
105005	1710	gas-binding protein	[GAS-binding proteins]	0.0	2	1	1	1
105006	1710	lysis by lymphocyte	[lysis by lymphocytes]	0.0	3	1	1	1
105007	1710	interleukin -12	[interleukin -12]	0.0	2	1	1	1
105008	1710	region important, respectively, to immunoglobulin promoter	[regions important, respectively, to immunoglobulin promoters]	0.0	6	1	1	1
105009	1710	significant increase from patient	[significant increase from patients]	0.0	4	1	1	1
105010	1710	two homologous gene	[two homologous genes]	0.0	3	1	1	1
105011	1710	ciita inducibility	[CIITA inducibility]	0.0	2	1	1	1
105012	1710	hormonal dysregulation	[hormonal dysregulation]	0.0	2	1	1	1
105013	1710	finding highly synergistic	[findings highly synergistic]	0.0	3	1	1	1
105014	1710	function of this regulatory element	[function of this regulatory element]	0.0	5	1	1	1
105015	1710	stimulation by ligation	[Stimulation by ligation]	0.0	3	1	1	1
105016	1710	origin for episomal maintenance	[origin for episomal maintenance]	0.0	4	1	1	1
105017	1710	lack a signal transducer	[lack a signal transducer]	0.0	4	1	1	1
105018	1710	genome carry the cDNA	[genome carrying the cDNA]	0.0	4	1	1	1
105019	1710	human immunodeficiency virus type cell	[human immunodeficiency virus type cells]	0.0	5	1	1	1
105020	1710	amplify expression of own receptor	[amplifying expression of own receptor]	0.0	5	1	1	1
105021	1710	increase notably phospholipase c gamma	[increase notably phospholipase C gamma]	0.0	5	1	1	1
105022	1710	mp treatment	[MP treatments]	0.0	2	1	1	1
105023	1710	cues,	[cues,]	0.0	1	1	1	1
105024	1710	segment with sequence homology	[segment with sequence homology]	0.0	4	1	1	1
105025	1710	glucocorticoid receptor gr of leukocyte	[glucocorticoid receptor GR of leukocytes]	0.0	5	1	1	1
105026	1710	(range, 4-.11), 6.18 (range, 5.86-6.74) nm,	[(range, 4-5.13), 6.18 (range, 5.86-6.74) nM,]	0.0	6	1	1	1
105027	1710	calcium dephosphorylation	[calcium dephosphorylation]	0.0	2	1	1	1
105028	1710	opposite phenotype	[opposite phenotypes]	0.0	2	1	1	1
105029	1710	five lymph node with hyperplasia	[five lymph nodes with hyperplasia]	0.0	5	1	1	1
105030	1710	mutagenesis of HSs	[mutagenesis of HSs]	0.0	3	1	1	1
105031	1710	export of viral mrna	[export of viral mRNA]	0.0	4	1	1	1
105032	1710	ca2+ mobilization,	[Ca2+ mobilization,]	0.0	2	1	1	1
105033	1710	mechanism of IL-5	[mechanisms of IL-5]	0.0	3	1	1	1
105034	1710	dnase I hypersensitive site 5'hs1-5	[DNase I hypersensitive sites 5'HS1-5]	0.0	5	1	1	1
105035	1710	NF kappa b2	[NF kappa B2]	0.0	3	1	1	1
105036	1710	NF kappa b1	[NF kappa B1]	0.0	3	1	1	1
105037	1710	receptor for lipoprotein	[receptor for lipoprotein]	0.0	3	1	1	1
105038	1710	Burkitt' lymphoma b cell line	[Burkitt's lymphoma B cell lines]	0.0	5	1	1	1
105039	1710	rpose control	[RpoS control]	0.0	2	1	1	1
105040	1710	ige isotype	[IgE isotype]	0.0	2	2	2	1
105041	1710	12-o-tetradecanoylphorbol 13-acetate induction	[12-O-tetradecanoylphorbol 13-acetate induction]	0.0	3	1	1	1
105042	1710	3'- end	[3'- ends]	0.0	2	1	1	1
105043	1710	IFN-alpha responsiveness chronic myelogenous leukemia	[IFN-alpha responsiveness chronic myelogenous leukemia]	0.0	5	1	1	1
105044	1710	transfection study use VCAM-1 promoter construct	[transfection studies using VCAM-1 promoter constructs]	0.0	6	1	1	1
105045	1710	immediate protein BZLF1	[immediate proteins BZLF1]	0.0	3	1	1	1
105046	1710	effectively by steroid include DHEA sulfate	[effectively by steroids including DHEA sulfate]	0.0	6	1	1	1
105047	1710	cell-cycle-regulated phosphorylation	[cell-cycle-regulated phosphorylation]	0.0	2	1	1	1
105048	1710	p300/cbp-type transcriptional coactivator	[p300/CBP-type transcriptional coactivators]	0.0	3	1	1	1
105049	1710	alternative nf-kappab element	[alternative NF-kappaB elements]	0.0	3	1	1	1
105050	1710	lymphotoxin-beta	[lymphotoxin-beta]	0.0	1	1	1	1
105051	1710	elevation of cyclic AMP	[elevation of cyclic AMP]	0.0	4	1	1	1
105052	1710	heat-shock for hour	[Heat-shock for hours]	0.0	3	1	1	1
105053	1710	clonal deletion	[clonal deletion]	0.0	2	1	1	1
105054	1710	t (15;17)	[t (15;17)]	0.0	2	1	1	1
105055	1710	region in PFP9a20	[region in PFP9a20]	0.0	3	1	1	1
105056	1710	airway obstruction	[airways obstruction]	0.0	2	1	1	1
105057	1710	suggest genotypic marker	[suggesting genotypic markers]	0.0	3	1	1	1
105058	1710	rise in calcium	[rise in calcium]	0.0	3	1	1	1
105059	1710	expression for glucocorticoid receptor	[expression for glucocorticoid receptor]	0.0	4	1	1	1
105060	1710	hiv-1 terminal repeat promoter	[HIV-1 terminal repeat promoter]	0.0	4	1	1	1
105061	1710	ecem)	[(CEM)]	0.0	1	1	1	1
105062	1710	permanent control of the process	[permanent control of the processes]	0.0	5	1	1	1
105063	1710	two other DNA fragment	[two other DNA fragments]	0.0	4	1	1	1
105064	1710	expression of fasL	[expression of fasL]	0.0	3	1	1	1
105065	1710	lipopolysaccharide viral production	[lipopolysaccharide viral production]	0.0	3	1	1	1
105066	1710	immunosuppressive activity low	[immunosuppressive activity lower]	0.0	3	1	1	1
105067	1710	develop therapeutic strategy	[developing therapeutic strategies]	0.0	3	1	1	1
105068	1710	overexpression in myeloid cell lines,	[overexpression in myeloid cell lines,]	0.0	5	1	1	1
105069	1710	role of oxygen intermediate ROI	[role of oxygen intermediates ROIs]	0.0	5	1	1	1
105070	1710	erythroblastic permanent cell line	[erythroblastic permanent cell lines]	0.0	4	1	1	1
105071	1710	interleukin-5 il-5 a eosinophil-activating factor	[interleukin-5 IL-5 a eosinophil-activating factor]	0.0	5	1	1	1
105072	1710	induction in lymphocyte	[Induction in lymphocytes]	0.0	3	1	1	1
105073	1710	stress disorder	[stress disorder]	0.0	2	1	1	1
105074	1710	t-cell-line-expressing wild-type CD4 receptor	[T-cell-line-expressing wild-type CD4 receptors]	0.0	4	1	1	1
105075	1710	adhesion molecule-1 gene expression	[adhesion molecule-1 gene expression]	0.0	4	1	1	1
105076	1710	cell development in the mouse thymus	[cell development in the mouse thymus]	0.0	6	1	1	1
105077	1710	level of all nf-kappa b	[levels of all NF-kappa B]	0.0	5	1	1	1
105078	1710	two different pathway	[two different pathways]	0.0	3	1	1	1
105079	1710	gold compound aurothioglucose AuTG	[gold compounds aurothioglucose AuTG]	0.0	4	1	1	1
105080	1710	stable transfection into b cell	[stable transfection into B cells]	0.0	5	1	1	1
105081	1710	weight gain (14 +/- (pre)	[weight gain (14 +/- (pre)]	0.0	5	1	1	1
105082	1710	major lineage	[major lineages]	0.0	2	1	1	1
105083	1710	requirement provide explanation important.	[requirement providing explanation important.]	0.0	4	1	1	1
105084	1710	obtain informative probe specific	[obtaining informative probes specific]	0.0	4	1	1	1
105085	1710	alteration in isozyme activity	[alterations in isozyme activity]	0.0	4	1	1	1
105086	1710	four genes,	[four genes,]	0.0	2	1	1	1
105087	1710	different form include lymphoblastic leukemia	[different forms including lymphoblastic leukemia]	0.0	5	1	1	1
105088	1710	nf-kappa b activation with inducer	[NF-kappa B activation with inducers]	0.0	5	1	1	1
105089	1710	potentially result	[potentially resulting]	0.0	2	1	1	1
105090	1710	include the phosphatase calcineurin	[including the phosphatase calcineurin]	0.0	4	1	1	1
105091	1710	range of leukemia	[range of leukemias]	0.0	3	1	1	1
105092	1710	b activation in monocyte	[B activation in monocytes]	0.0	4	1	1	1
105093	1710	htlv-i infection per se	[HTLV-I infection per se]	0.0	4	1	1	1
105094	1710	element tre1 necessary for transactivation	[element TRE1 necessary for transactivation]	0.0	5	1	1	1
105095	1710	apparently inactive form	[apparently inactive form]	0.0	3	1	1	1
105096	1710	kilobasis (kb)	[kilobases (kb)]	0.0	2	1	1	1
105097	1710	sf-2	[SF-2]	0.0	1	1	1	1
105098	1710	several class DNA binding factor	[several class DNA binding factors]	0.0	5	1	1	1
105099	1710	order potent than H	[orders potent than H]	0.0	4	1	1	1
105100	1710	manipulate response	[manipulating responses]	0.0	2	1	1	1
105101	1710	tonsillar t- lymphocyte	[tonsillar T- lymphocytes]	0.0	3	2	2	1
105102	1710	value in the treatment	[value in the treatment]	0.0	4	1	1	1
105103	1710	half-life in hl-60 cell	[half-life in HL-60 cells]	0.0	4	1	1	1
105104	1710	IL-2 prl protein in Nb2	[IL-2 PRL proteins in Nb2]	0.0	5	1	1	1
105105	1710	JunD pc-fo	[JunD /c-Fos]	0.0	2	1	1	1
105106	1710	dependent adhesion vein endothelial cell	[dependent adhesion vein endothelial cells]	0.0	5	1	1	1
105107	1710	strict guideline related	[strict guidelines related]	0.0	3	1	1	1
105108	1710	binding method	[binding method]	0.0	2	1	1	1
105109	1710	machinery during differentiation	[machinery during differentiation]	0.0	3	1	1	1
105110	1710	radioassay with [3h]-dexamethasone	[radioassay with [3H]-dexamethasone]	0.0	3	1	1	1
105111	1710	pterin	[pterin]	0.0	1	1	1	1
105112	1710	E2 to E1	[E2 to E1]	0.0	3	1	1	1
105113	1710	ca. reduction	[ca. reduction]	0.0	2	1	1	1
105114	1710	differentiation in erythroblast	[differentiation in erythroblasts]	0.0	3	1	1	1
105115	1710	consist of the NF-kappa b heterodimer	[consisting of the NF-kappa B heterodimer]	0.0	6	1	1	1
105116	1710	one clone reactive	[one clone reactive]	0.0	3	1	1	1
105117	1710	chronic low back pain	[chronic low back pain]	0.0	4	1	1	1
105118	1710	labeling by immunofluorescence	[labeling by immunofluorescence]	0.0	3	1	1	1
105119	1710	10 patient with low receptor affinity	[10 patients with low receptor affinity]	0.0	6	1	1	1
105120	1710	qp function	[Qp function]	0.0	2	1	1	1
105121	1710	sv40 early promoter	[SV40 early promoters]	0.0	3	1	1	1
105122	1710	melanoma than in cell line	[melanomas than in cell lines]	0.0	5	1	1	1
105123	1710	new, member family.	[new, member family.]	0.0	3	1	1	1
105124	1710	marker of mitotic rate	[markers of mitotic rate]	0.0	4	1	1	1
105125	1710	u937 cell to lps	[U937 cells to LPS]	0.0	4	1	1	1
105126	1710	human immunodeficiency virus patient	[human immunodeficiency virus patients]	0.0	4	1	1	1
105127	1710	silent mutation in codon	[silent mutation in codon]	0.0	4	1	1	1
105128	1710	Intercellular adhesion molecule	[Intercellular adhesion molecule]	0.0	3	1	1	1
105129	1710	binding of er	[Binding of ER]	0.0	3	1	1	1
105130	1710	546-nucleotide open reading frame	[546-nucleotide open reading frame]	0.0	4	1	1	1
105131	1710	activation of a promoter	[activation of a promoter]	0.0	4	1	1	1
105132	1710	IL-1alpha kappab-like site	[IL-1alpha kappaB-like sites]	0.0	3	1	1	1
105133	1710	slp-76 function,	[SLP-76 function,]	0.0	2	1	1	1
105134	1710	multiple biologic activity of acid	[multiple biologic activities of acid]	0.0	5	1	1	1
105135	1710	other process essential to a response	[other processes essential to an response]	0.0	6	1	1	1
105136	1710	suggest a relevant functional interaction	[suggesting a relevant functional interaction]	0.0	5	1	1	1
105137	1710	the/thf alpha thf/thf n:	[THE/THF alpha THF/THF N:]	0.0	4	1	1	1
105138	1710	significant activity	[significant activity]	0.0	2	1	1	1
105139	1710	-p100	[-p100]	0.0	1	1	1	1
105140	1710	mutant b	[mutant B]	0.0	2	1	1	1
105141	1710	detectable activation during tpa-	[detectable activation during TPA-]	0.0	4	1	1	1
105142	1710	pattern dominant	[pattern dominant]	0.0	2	1	1	1
105143	1710	H5sub304 infection	[H5sub304 infection]	0.0	2	1	1	1
105144	1710	promoter function of the region	[Promoter function of the region]	0.0	5	1	1	1
105145	1710	suppression of wp activity	[suppression of Wp activity]	0.0	4	1	1	1
105146	1710	inhibition of no synthase	[Inhibition of NO synthase]	0.0	4	1	1	1
105147	1710	mutant T	[mutant T]	0.0	2	1	1	1
105148	1710	tpa hl-60 cell differentiation	[TPA HL-60 cell differentiation]	0.0	4	1	1	1
105149	1710	primitive environment	[primitive environment]	0.0	2	1	1	1
105150	1710	maximally effective dose mol/L).	[maximally effective dose mol/L).]	0.0	4	1	1	1
105151	1710	apc peptide	[APC peptides]	0.0	2	1	1	1
105152	1710	characterization of nf(p) the factor	[Characterization of NF(P) the factor]	0.0	5	1	1	1
105153	1710	Degenerate primer	[Degenerate primers]	0.0	2	1	1	1
105154	1710	method in mononuclear cell	[method in mononuclear cells]	0.0	4	1	1	1
105155	1710	(hIL-5)	[(hIL-5)]	0.0	1	1	1	1
105156	1710	bcl-6 +/cd3+	[Bcl-6 +/CD3+]	0.0	2	1	1	1
105157	1710	lymphoid-specific nuclear factor	[lymphoid-specific nuclear factor]	0.0	3	1	1	1
105158	1710	paf receptor transcript leukocyte-type	[PAF receptor transcript leukocyte-type]	0.0	4	1	1	1
105159	1710	metabolite 1,25 dihydroxyvitamin d3,	[metabolite 1,25 dihydroxyvitamin D3,]	0.0	4	1	1	1
105160	1710	ifn-gamma receptor chain	[IFN-gamma receptor chain]	0.0	3	1	1	1
105161	1710	many part of the program	[many parts of the program]	0.0	5	1	1	1
105162	1710	kinetic in cell	[kinetics in cells]	0.0	3	1	1	1
105163	1710	activate gene	[activating genes]	0.0	2	1	1	1
105164	1710	recognition of glycoconjugate	[recognition of glycoconjugates]	0.0	3	1	1	1
105165	1710	normal c-myb	[normal c-myb]	0.0	2	1	1	1
105166	1710	nf-kappab activation 1 long terminal repeat	[NF-kappaB activation 1 long terminal repeat]	0.0	6	1	1	1
105167	1710	approximately eightfold low amount	[approximately eightfold lower amounts]	0.0	4	1	1	1
105168	1710	combination of p49(100)	[combination of p49(100)]	0.0	3	1	1	1
105169	1710	addition, assay of pbmc	[addition, assay of PBMC]	0.0	4	2	2	1
105170	1710	NF-kappa Bp65 Rel A	[NF-kappa Bp65 Rel A]	0.0	4	1	1	1
105171	1710	principal protein of the lineage	[principal protein of the lineage]	0.0	5	1	1	1
105172	1710	interaction between multipotential stem cell	[interactions between multipotential stem cells]	0.0	5	1	1	1
105173	1710	emergence of CTL against epitope	[emergence of CTLs against epitopes]	0.0	5	1	1	1
105174	1710	vascular cell adhesion molecule vcam-1 nac	[vascular cell adhesion molecule VCAM-1 NAC]	0.0	6	1	1	1
105175	1710	induction of CD38	[Induction of CD38]	0.0	3	1	1	1
105176	1710	expression of host transcription factor	[expression of host transcription factors]	0.0	5	1	1	1
105177	1710	weight dextran sulfate hmd	[weight dextran sulfate HMDS]	0.0	4	1	1	1
105178	1710	investigation as a potential therapy	[investigation as a potential therapy]	0.0	5	1	1	1
105179	1710	differentiation-dependent peroxisomal proliferator-activated receptor gamma expression	[differentiation-dependent peroxisomal proliferator-activated receptor gamma expression]	0.0	6	1	1	1
105180	1710	metabolite tetrahydrocortisol	[metabolite tetrahydrocortisol]	0.0	2	1	1	1
105181	1710	complex in IM-9 nuclear extract	[complex in IM-9 nuclear extracts]	0.0	5	1	1	1
105182	1710	addition, treatment	[addition, treatment]	0.0	2	1	1	1
105183	1710	antiserum against aml-1 protein	[antiserum against AML-1 proteins]	0.0	4	1	1	1
105184	1710	only in tissue	[only in tissues]	0.0	3	1	1	1
105185	1710	mechanism accounting	[mechanisms accounting]	0.0	2	1	1	1
105186	1710	role of retinoic acid	[role of retinoic acid]	0.0	4	1	1	1
105187	1710	potent 15-mer AS oligonucleotide	[potent 15-mer AS oligonucleotides]	0.0	4	1	1	1
105188	1710	postinduction repression	[postinduction repression]	0.0	2	1	1	1
105189	1710	pressure-stretch strain	[pressure-stretching strain]	0.0	2	1	1	1
105190	1710	rt-pcr analysis of rna	[RT-PCR analysis of RNA]	0.0	4	1	1	1
105191	1710	LTR in siv	[LTR in SIVs]	0.0	3	1	1	1
105192	1710	hiv transcription factor	[HIV transcription factors]	0.0	3	1	1	1
105193	1710	heterokaryon system	[heterokaryon system]	0.0	2	1	1	1
105194	1710	response in single cases.	[response in single cases.]	0.0	4	1	1	1
105195	1710	transcription factor IL-4 Stat	[transcription factor IL-4 Stat]	0.0	4	1	1	1
105196	1710	low expression in patient	[low expression in patients]	0.0	4	1	1	1
105197	1710	specific negative regulation	[specific negative regulation]	0.0	3	1	1	1
105198	1710	repressor element	[repressor element]	0.0	2	1	1	1
105199	1710	functional state of cortex	[functional state of cortex]	0.0	4	1	1	1
105200	1710	secretion of pge2	[secretion of PGE2]	0.0	3	1	1	1
105201	1710	mouse with a lymphocyte-specific defect	[mice with a lymphocyte-specific defect]	0.0	5	1	1	1
105202	1710	transcriptional properties unlike other nuclear oncoprotein	[transcriptional properties, unlike other nuclear oncoproteins]	0.0	6	1	1	1
105203	1710	implicate cyclophilin b	[implicating cyclophilin B]	0.0	3	1	1	1
105204	1710	result of recombination	[result of recombination]	0.0	3	1	1	1
105205	1710	breast carcinoma cell line	[breast carcinoma cell line]	0.0	4	1	1	1
105206	1710	LYSP100 nuclear dot	[LYSP100 nuclear dots]	0.0	3	1	1	1
105207	1710	il-2 binding	[IL-2 binding]	0.0	2	3	3	1
105208	1710	alpha-naphthyl-acetate-esterase	[alpha-naphthyl-acetate-esterase]	0.0	1	1	1	1
105209	1710	Epstein-Barr virus ebv replication	[Epstein-Barr virus EBV replication]	0.0	4	1	1	1
105210	1710	heteromeric complex with other nuclear protein	[heteromeric complexes with other nuclear proteins]	0.0	6	1	1	1
105211	1710	p45 nf-e2 mrna in granurocyte	[P45 NF-E2 mRNA in granurocytes]	0.0	5	1	1	1
105212	1710	ecto-5'-nucleotidase	[ecto-5'-nucleotidase]	0.0	1	1	1	1
105213	1710	receptor binding in blood lymphocyte	[receptor binding in blood lymphocytes]	0.0	5	1	1	1
105214	1710	action blockade	[action blockade]	0.0	2	1	1	1
105215	1710	include alpha	[including alpha]	0.0	2	1	1	1
105216	1710	proto-enhancer element	[proto-enhancer element]	0.0	2	1	1	1
105217	1710	level of class determinant	[levels of class determinants]	0.0	4	1	1	1
105218	1710	other cells, include precursor	[other cells, including precursors]	0.0	4	1	1	1
105219	1710	wk to mo) untreated RA	[wk to mo) untreated RA]	0.0	5	1	1	1
105220	1710	development in chronic myeloproliferative disorder	[development in chronic myeloproliferative disorders]	0.0	5	1	1	1
105221	1710	several intracellular substrate	[several intracellular substrates]	0.0	3	1	1	1
105222	1710	65 woman	[65 women]	0.0	2	1	1	1
105223	1710	co-operative interaction	[co-operative interactions]	0.0	2	1	1	1
105224	1710	mcr grade	[MCR grade]	0.0	2	1	1	1
105225	1710	transfection of negative expression vector	[Transfection of negative expression vectors]	0.0	5	1	1	1
105226	1710	increase in the lysopc content	[increase in the lysoPC content]	0.0	5	1	1	1
105227	1710	certain (tcr) region beta-chain family	[certain (TCR) region beta-chain families]	0.0	5	1	1	1
105228	1710	osteoclast-like cell from human monocyte	[osteoclast-like cells from human monocytes]	0.0	5	1	1	1
105229	1710	vary concentration	[varying concentrations]	0.0	2	1	1	1
105230	1710	stem-loop stability	[stem-loop stability]	0.0	2	1	1	1
105231	1710	interleukin 16 promoter	[interleukin 16 promoter]	0.0	3	1	1	1
105232	1710	interaction with molecular partners,	[interaction with molecular partners,]	0.0	4	1	1	1
105233	1710	mobilization of a fraction	[mobilization of a fraction]	0.0	4	1	1	1
105234	1710	nuclear, acid (dna) bind protein	[nuclear, acid (DNA) binding proteins]	0.0	5	1	1	1
105235	1710	domain for peptidyl substrate	[domain for peptidyl substrates]	0.0	4	1	1	1
105236	1710	sequence within the so-called AU-rich element	[sequences within the so-called AU-rich elements]	0.0	6	1	1	1
105237	1710	predictive clue assess responsiveness	[predictive clue assessing responsiveness]	0.0	4	1	1	1
105238	1710	messenger in c-fo induction	[messengers in c-Fos induction]	0.0	4	1	1	1
105239	1710	glucocorticoid receptor on lymphocyte	[glucocorticoid receptors on lymphocytes]	0.0	4	1	1	1
105240	1710	epsilon BP protein	[epsilon BP protein]	0.0	3	1	1	1
105241	1710	constitutively active form kinase C transcription	[constitutively active forms kinase C transcription]	0.0	6	1	1	1
105242	1710	low weight stat5 isoform	[lower weight STAT5 isoforms]	0.0	4	1	1	1
105243	1710	N-terminal amino acid of Elf-1	[N-terminal amino acids of Elf-1]	0.0	5	1	1	1
105244	1710	IL-2 -independent activation in T cell	[IL-2 -independent activation in T cells]	0.0	6	1	1	1
105245	1710	express a pattern of cytokine	[expressing a pattern of cytokines]	0.0	5	1	1	1
105246	1710	karyotypic study on blood lymphocyte culture	[karyotypic studies on blood lymphocyte cultures]	0.0	6	1	1	1
105247	1710	potent chemotactic factor	[potent chemotactic factor]	0.0	3	1	1	1
105248	1710	overlapping cosmid encode ciita	[overlapping cosmids encoding CIITA]	0.0	4	1	1	1
105249	1710	signal transduction molecule in pbmc	[signal transduction molecules in PBMC]	0.0	5	1	1	1
105250	1710	basis of the translocation	[basis of the translocation]	0.0	4	1	1	1
105251	1710	fc gammaR1 gene	[Fc gammaR1 gene]	0.0	3	1	1	1
105252	1710	expression at 4 hours)	[expression at 4 hours)]	0.0	4	1	1	1
105253	1710	lack JAK3	[lacking JAK3]	0.0	2	1	1	1
105254	1710	protein Id-3	[protein Id-3]	0.0	2	1	1	1
105255	1710	recruitment phosphorylation	[recruitment phosphorylation]	0.0	2	1	1	1
105256	1710	induction of interferon 10 follow differentiation	[induction of interferon 10 following differentiation]	0.0	6	1	1	1
105257	1710	risk of failure,	[risk of failure,]	0.0	3	1	1	1
105258	1710	transducing	[transducing]	0.0	1	1	1	1
105259	1710	differentiation of the c-jun	[differentiation of the c-jun]	0.0	4	1	1	1
105260	1710	selective lysis	[selective lysis]	0.0	2	2	2	1
105261	1710	sequence in a region	[sequences in a region]	0.0	4	1	1	1
105262	1710	CEM human cell clone	[CEM human cell clone]	0.0	4	1	1	1
105263	1710	(il)-2 in vitro.	[(IL)-2 in vitro.]	0.0	3	1	1	1
105264	1710	monocyte-like u-937 cell culture	[monocyte-like U-937 cell cultures]	0.0	4	1	1	1
105265	1710	cell-type-specific transactivation I tax	[Cell-type-specific transactivation I tax]	0.0	4	1	1	1
105266	1710	use neuroblastoma cell line	[Using neuroblastoma cell lines]	0.0	4	1	1	1
105267	1710	block transcript degradation	[blocking transcript degradation]	0.0	3	1	1	1
105268	1710	2 gene	[2 gene]	0.0	2	1	1	1
105269	1710	regard the effect of pentoxifylline	[regarding the effects of pentoxifylline]	0.0	5	1	1	1
105270	1710	kb of the sequence	[kb of the sequence]	0.0	4	1	1	1
105271	1710	compound on il-1beta promoter activity	[compounds on IL-1beta promoter activity]	0.0	5	1	1	1
105272	1710	postnatally, die days.	[postnatally, dying days.]	0.0	3	1	1	1
105273	1710	use c-c chemokine in cell	[using C-C chemokines in cells]	0.0	5	1	1	1
105274	1710	NFAT-1 site enhancer	[NFAT-1 site enhancer]	0.0	3	1	1	1
105275	1710	elucidation of the nature	[Elucidation of the nature]	0.0	4	1	1	1
105276	1710	use decrease in the dna-binding activity	[using decrease in the DNA-binding activity]	0.0	6	1	1	1
105277	1710	mean level	[mean level]	0.0	2	1	1	1
105278	1710	induction of differentiation of hel	[induction of differentiation of HEL]	0.0	5	1	1	1
105279	1710	108 amino acid residue	[108 amino acid residues]	0.0	4	1	1	1
105280	1710	clinical test of receptor	[clinical test of receptors]	0.0	4	1	1	1
105281	1710	complex in unstimulated cell	[complex in unstimulated cells]	0.0	4	1	1	1
105282	1710	effect on ikappab kinase activation	[effect on IkappaB kinase activation]	0.0	5	1	1	1
105283	1710	aml m2 with eosinophilia	[AML M2 with eosinophilia]	0.0	4	1	1	1
105284	1710	response of lymphocyte involve proliferation	[responses of lymphocytes involving proliferation]	0.0	5	1	1	1
105285	1710	induction via activation of factor-kappaB	[Induction via activation of factor-kappaB]	0.0	5	1	1	1
105286	1710	Ikaros transcription factor	[Ikaros transcription factors]	0.0	3	1	1	1
105287	1710	consequently lead	[consequently leading]	0.0	2	1	1	1
105288	1710	progressive lung disease	[progressive lung disease]	0.0	3	1	1	1
105289	1710	homologue activation	[homologue activation]	0.0	2	1	1	1
105290	1710	transcription, thereby amplify expression	[transcription, thereby amplifying expression]	0.0	4	1	1	1
105291	1710	convert extracellular signal	[converting extracellular signals]	0.0	3	1	1	1
105292	1710	activation of human monocyte factor-kappaB	[activation of human monocyte factor-kappaB]	0.0	5	1	1	1
105293	1710	follow rearrangement	[following rearrangements]	0.0	2	1	1	1
105294	1710	value of D3 determination in lymphocyte	[value of D3 determination in lymphocytes]	0.0	6	1	1	1
105295	1710	abnormal biomarker between the risk	[abnormal biomarkers between the risk]	0.0	5	1	1	1
105296	1710	ifn-alpha-stimulated gene	[IFN-alpha-stimulated genes]	0.0	2	1	1	1
105297	1710	several myeloid leukemia cell line	[Several myeloid leukemia cell lines]	0.0	5	1	1	1
105298	1710	transfection of HEK 293 cell	[transfection of HEK 293 cells]	0.0	5	1	1	1
105299	1710	dose of prednisone	[doses of prednisone]	0.0	3	1	1	1
105300	1710	typical (ie, aitl	[typical (ie, AITL]	0.0	3	1	1	1
105301	1710	Antisense phosphorothioate oligonucleotide	[Antisense phosphorothioate oligonucleotides]	0.0	3	1	1	1
105302	1710	agent acid RA	[agent acid RA]	0.0	3	1	1	1
105303	1710	blood concentration	[blood concentrations]	0.0	2	1	1	1
105304	1710	2-day incubation	[2-day incubation]	0.0	2	1	1	1
105305	1710	two factor kB regulatory element	[two factor kB regulatory elements]	0.0	5	1	1	1
105306	1710	13 sex-and age-matched subject	[13 sex-and age-matched subjects]	0.0	4	1	1	1
105307	1710	g3 tumor with margin	[G3 tumors with margins]	0.0	4	1	1	1
105308	1710	month of flutamide	[months of flutamide]	0.0	3	1	1	1
105309	1710	involvement of protein kinase	[Involvement of protein kinases]	0.0	4	1	1	1
105310	1710	phosphorylation STAT3	[phosphorylation STAT3]	0.0	2	1	1	1
105311	1710	P; immediate) binding	[h; immediate) binding]	0.0	3	1	1	1
105312	1710	play a important costimulatory role	[playing an important costimulatory role]	0.0	5	1	1	1
105313	1710	pseudohypoaldosteronism in obstructive renal disease	[pseudohypoaldosteronism in obstructive renal disease]	0.0	5	1	1	1
105314	1710	inhibitory kappa b alpha	[inhibitory kappa B alpha]	0.0	4	1	1	1
105315	1710	cellular parameters, such as glycosidase activity	[cellular parameters, such as glycosidase activities]	0.0	6	1	1	1
105316	1710	infection with immunodeficiency virus	[infection with immunodeficiency virus]	0.0	4	1	1	1
105317	1710	various other condition of importance.	[various other conditions of importance.]	0.0	5	1	1	1
105318	1710	visit, within week	[visit, within weeks]	0.0	3	1	1	1
105319	1710	growth phase-dependent resistance	[growth phase-dependent resistance]	0.0	3	1	1	1
105320	1710	preferential gas DNA binding pattern	[preferential GAS DNA binding patterns]	0.0	5	1	1	1
105321	1710	Oct-1 octamer sequence atgcaaat	[Oct-1 octamer sequence ATGCAAAT]	0.0	4	1	1	1
105322	1710	means modulate sensitivity	[means modulating sensitivity]	0.0	3	1	1	1
105323	1710	er variant	[ER variants]	0.0	2	2	2	1
105324	1710	potent pkc inhibitor ro	[potent PKC inhibitor Ro]	0.0	4	1	1	1
105325	1710	epo signal	[EPO signal]	0.0	2	1	1	1
105326	1710	erythroid cell of the lineage	[erythroid cells of the lineage]	0.0	5	1	1	1
105327	1710	epithelial necrosis	[epithelial necrosis]	0.0	2	1	1	1
105328	1710	inhibition by a dominant-negative form	[Inhibition by a dominant-negative form]	0.0	5	1	1	1
105329	1710	x receptor -vitamin	[X receptor -vitamin]	0.0	3	1	1	1
105330	1710	abundant activity of B-cell extract	[abundant activity of B-cell extracts]	0.0	5	1	1	1
105331	1710	change in ig synthesis	[changes in Ig synthesis]	0.0	4	1	1	1
105332	1710	b lymphocyte from mouse	[B lymphocytes from mice]	0.0	4	1	1	1
105333	1710	males, 1.13	[males, 1.13]	0.0	2	1	1	1
105334	1710	kilobase pair	[kilobase pairs]	0.0	2	1	1	1
105335	1710	course (p 0.05, chi2 test).	[course (P 0.05, chi2 test).]	0.0	5	1	1	1
105336	1710	regulation by AMP	[regulation by AMP]	0.0	3	1	1	1
105337	1710	use RNA display DD	[using RNA display DD]	0.0	4	1	1	1
105338	1710	nuclear factor kB element	[nuclear factor kB elements]	0.0	4	1	1	1
105339	1710	dominant neoplastic clone	[dominant neoplastic clone]	0.0	3	1	1	1
105340	1710	il-4 costimulation with il-2	[IL-4 costimulation with IL-2]	0.0	4	1	1	1
105341	1710	counterpart to chronic lymphocytic leukemia	[counterpart to chronic lymphocytic leukemias]	0.0	5	1	1	1
105342	1710	expression of TCRzeta signal element	[expression of TCRzeta signaling elements]	0.0	5	1	1	1
105343	1710	leukemia all	[leukemia ALL]	0.0	2	3	3	1
105344	1710	immunodeficiency virus type 1 cell	[immunodeficiency virus type 1 cells]	0.0	5	1	1	1
105345	1710	competition between two general activator RelA	[competition between two general activators RelA]	0.0	6	1	1	1
105346	1710	mutant of the IL-1	[mutants of the IL-1]	0.0	4	1	1	1
105347	1710	il-10 of cytokine release	[IL-10 of cytokine release]	0.0	4	1	1	1
105348	1710	stimulation, kappa complex	[stimulation, kappa complexes]	0.0	3	1	1	1
105349	1710	further dissection	[Further dissection]	0.0	2	1	1	1
105350	1710	target fibroblast	[target fibroblasts]	0.0	2	1	1	1
105351	1710	pathogenesis of pel	[pathogenesis of PEL]	0.0	3	1	1	1
105352	1710	increase in calcium ion	[increase in calcium ions]	0.0	4	1	1	1
105353	1710	control group (300	[control group (300]	0.0	3	1	1	1
105354	1710	lacz reporter	[lacZ reporter]	0.0	2	1	1	1
105355	1710	pattern of expression in b cell	[pattern of expression in B cells]	0.0	6	1	1	1
105356	1710	two distinct family RA receptor	[two distinct families RA receptors]	0.0	5	1	1	1
105357	1710	activation/repression	[activation/repression]	0.0	1	1	1	1
105358	1710	Comparison sequence	[Comparison sequences]	0.0	2	1	1	1
105359	1710	CD34+/CD38(2+)	[CD34+/CD38(2+)]	0.0	1	1	1	1
105360	1710	heterodimer formation	[heterodimer formation]	0.0	2	2	2	1
105361	1710	subvolumes:	[subvolumes:]	0.0	1	1	1	1
105362	1710	Study on daughter cell culture	[Studies on daughter cell culture]	0.0	5	1	1	1
105363	1710	leukemia CML cell	[leukemia CML cells]	0.0	3	1	1	1
105364	1710	ebv genome lymphoid cell line	[EBV genome lymphoid cell lines]	0.0	5	1	1	1
105365	1710	large b-cell lymphoma	[large B-cell lymphomas]	0.0	3	1	1	1
105366	1710	microgram/day for month	[microgram/day for month]	0.0	3	1	1	1
105367	1710	sporadic report	[sporadic reports]	0.0	2	1	1	1
105368	1710	lysate from CD19 cell	[Lysates from CD19 cells]	0.0	4	1	1	1
105369	1710	glucocorticoid receptor gcR in lymphocyte	[glucocorticoid receptors gcR in lymphocytes]	0.0	5	1	1	1
105370	1710	basal enhancer motif	[basal enhancer motifs]	0.0	3	1	1	1
105371	1710	early treatment (day 0 hpc	[early treatment (day 0 HPCs]	0.0	5	1	1	1
105372	1710	moreover, a marker of early event	[moreover, a marker of early events]	0.0	6	1	1	1
105373	1710	association of phosphoinositide 3-kinase	[association of phosphoinositide 3-kinase]	0.0	4	1	1	1
105374	1710	leukocyte protein of 76	[leukocyte protein of 76]	0.0	4	1	1	1
105375	1710	novel approach to intervention.	[novel approach to intervention.]	0.0	4	1	1	1
105376	1710	sp-a treatment	[SP-A treatment]	0.0	2	1	1	1
105377	1710	CPRE GGACTACAG	[CPRE GGACTACAG]	0.0	2	1	1	1
105378	1710	high-affinity binding site for inhibitor	[high-affinity binding site for inhibitor]	0.0	5	1	1	1
105379	1710	result from blot	[Results from blot]	0.0	3	1	1	1
105380	1710	10% fetal bovine serum	[10% fetal bovine serum]	0.0	4	1	1	1
105381	1710	small dose	[small doses]	0.0	2	2	2	1
105382	1710	close relationship	[close relationship]	0.0	2	1	1	1
105383	1710	signal role	[signaling role]	0.0	2	1	1	1
105384	1710	cis-acting genetic cis-acting segment	[cis-acting genetic cis-acting segment]	0.0	4	1	1	1
105385	1710	activation of the C gamma gene	[activation of the C gamma gene]	0.0	6	1	1	1
105386	1710	model of apoptosis	[models of apoptosis]	0.0	3	1	1	1
105387	1710	regulatory factor critical	[regulatory factors critical]	0.0	3	1	1	1
105388	1710	epse)-binding transcription	[(PSE)-binding transcription]	0.0	2	1	1	1
105389	1710	Geha	[Geha]	0.0	1	1	1	1
105390	1710	heterologous viral domain	[heterologous viral domain]	0.0	3	1	1	1
105391	1710	functional il-12	[functional IL-12]	0.0	2	1	1	1
105392	1710	multiple, dna-binding protein	[multiple, DNA-binding proteins]	0.0	3	1	1	1
105393	1710	human cell partner	[human cell partner]	0.0	3	1	1	1
105394	1710	b cell function deficient	[B cell functions deficient]	0.0	4	1	1	1
105395	1710	potential open reading frame orf a	[potential open reading frames ORFs A]	0.0	6	1	1	1
105396	1710	cytokine production by PBMC	[cytokine production by PBMC]	0.0	4	1	1	1
105397	1710	use the charcoal binding assay	[using the charcoal binding assay]	0.0	5	1	1	1
105398	1710	exogenous c-erba/tr-alpha in erythroblast	[exogenous c-erbA/TR-alpha in erythroblasts]	0.0	4	1	1	1
105399	1710	closely mimick into tissue	[closely mimicking into tissues]	0.0	4	1	1	1
105400	1710	analysis of the form of factor	[Analysis of the forms of factor]	0.0	6	1	1	1
105401	1710	transient expression of the transcription factor	[transient expression of the transcription factor]	0.0	6	1	1	1
105402	1710	play a role in the response	[playing an role in the response]	0.0	6	1	1	1
105403	1710	extremely low level of expression	[extremely low levels of expression]	0.0	5	1	1	1
105404	1710	pmn chemotaxis in a dose-dependent manner	[PMNs chemotaxis in a dose-dependent manner]	0.0	6	1	1	1
105405	1710	IL-2 growth in human T cell	[IL-2 growth in human T cells]	0.0	6	1	1	1
105406	1710	significantly into phosphatidylethanolamine	[significantly into phosphatidylethanolamine]	0.0	3	1	1	1
105407	1710	basis for the critical interaction	[basis for the critical interaction]	0.0	5	1	1	1
105408	1710	positive cells)	[positive cells)]	0.0	2	1	1	1
105409	1710	concentration as high	[concentration as high]	0.0	3	1	1	1
105410	1710	interleukin-2 IL-2 receptor beta-chain	[interleukin-2 IL-2 receptor beta-chain]	0.0	4	1	1	1
105411	1710	relationship a approach.	[Relationship a approach.]	0.0	3	1	1	1
105412	1710	development of sideroblast	[development of sideroblasts]	0.0	3	1	1	1
105413	1710	inverse relation to class	[inverse relation to classes]	0.0	4	1	1	1
105414	1710	expression of jun	[expression of jun]	0.0	3	1	1	1
105415	1710	several mouse	[several mice]	0.0	2	1	1	1
105416	1710	primary role in leukemogenesis	[primary role in leukemogenesis]	0.0	4	1	1	1
105417	1710	neutralize anti-TNF-alpha antibody	[neutralizing anti-TNF-alpha antibodies]	0.0	3	1	1	1
105418	1710	regulation of the factor	[Regulation of the factor]	0.0	4	1	1	1
105419	1710	-like activity in cell	[-like activity in cells]	0.0	4	1	1	1
105420	1710	subregions, nre gamma	[subregions, NRE gamma]	0.0	3	1	1	1
105421	1710	value explore signal pathway	[value exploring signaling pathways]	0.0	4	1	1	1
105422	1710	least two domain	[least two domains]	0.0	3	1	1	1
105423	1710	form of arthritis	[forms of arthritis]	0.0	3	1	1	1
105424	1710	region 255 nucleotide	[region 255 nucleotides]	0.0	3	1	1	1
105425	1710	diagnosis of relapse	[diagnosis of relapse]	0.0	3	1	1	1
105426	1710	binding of SR	[binding of SR]	0.0	3	1	1	1
105427	1710	9 amino acid domain	[9 amino acid domain]	0.0	4	1	1	1
105428	1710	Differential induction of interferon differentiation	[Differential induction of interferon differentiation]	0.0	5	1	1	1
105429	1710	CREB /atf	[CREB /ATF]	0.0	2	1	1	1
105430	1710	potential nfat element	[potential NFAT elements]	0.0	3	1	1	1
105431	1710	expression of cellular promoter	[expression of cellular promoters]	0.0	4	1	1	1
105432	1710	requirement for oxygen species generation	[requirement for oxygen species generation]	0.0	5	1	1	1
105433	1710	class ii restriction element	[class II restriction element]	0.0	4	1	1	1
105434	1710	Recombinant tumor necrosis factor	[Recombinant tumor necrosis factor]	0.0	4	1	1	1
105435	1710	correlation between receptor positivity	[correlation between receptor positivity]	0.0	4	1	1	1
105436	1710	interaction between the gata site	[Interactions between the GATA site]	0.0	5	1	1	1
105437	1710	monocyte protein-1 mcp-1 secretion	[monocyte protein-1 MCP-1 secretion]	0.0	4	1	1	1
105438	1710	ldl MM-LDL	[LDL MM-LDL]	0.0	2	1	1	1
105439	1710	binding of RA	[binding of RA]	0.0	3	1	1	1
105440	1710	globular, structure morphologically distinct	[globular, structures morphologically distinct]	0.0	4	1	1	1
105441	1710	il-8 by neutrophil	[IL-8 by neutrophils]	0.0	3	1	1	1
105442	1710	transcript monocyte chemoattractant protein mcp-1	[transcripts monocyte chemoattractant protein MCP-1]	0.0	5	1	1	1
105443	1710	B lineage	[B lineages]	0.0	2	1	1	1
105444	1710	notion direct substrate for shp1	[notion direct substrates for SHP1]	0.0	5	1	1	1
105445	1710	base pair of DNA	[base pairs of DNA]	0.0	4	1	1	1
105446	1710	myelodysplastic syndrome MDS	[myelodysplastic syndromes MDS]	0.0	3	1	1	1
105447	1710	cell ig	[cell Ig]	0.0	2	1	1	1
105448	1710	value explore stress-induced signal pathway	[value exploring stress-induced signaling pathways]	0.0	5	1	1	1
105449	1710	tnfr factor TRAFs	[TNFR factors TRAFs]	0.0	3	1	1	1
105450	1710	transcript encode gp350/220	[Transcripts encoding gp350/220]	0.0	3	1	1	1
105451	1710	information about role in the process	[information about roles in the processes]	0.0	6	1	1	1
105452	1710	control level of cell death	[controlling levels of cell death]	0.0	5	1	1	1
105453	1710	four protein	[four proteins]	0.0	2	1	1	1
105454	1710	novel 5'	[novel 5']	0.0	2	1	1	1
105455	1710	cytomegalovirus immediate gene	[Cytomegalovirus immediate genes]	0.0	3	1	1	1
105456	1710	potent competitor	[potent competitor]	0.0	2	1	1	1
105457	1710	monocytic cell to lipopolysaccharide	[monocytic cells to lipopolysaccharide]	0.0	4	1	1	1
105458	1710	simultaneous addition of microm pdtc	[simultaneous addition of microM PDTC]	0.0	5	1	1	1
105459	1710	several casein kinase ii site	[several casein kinase II sites]	0.0	5	1	1	1
105460	1710	region contain four direct repeat	[region containing four direct repeats]	0.0	5	1	1	1
105461	1710	contrast to lymphocyte	[contrast to lymphocytes]	0.0	3	1	1	1
105462	1710	TNF alpha U/ml),	[TNF alpha U/ml),]	0.0	3	1	1	1
105463	1710	inhibitory effect on degradation	[inhibitory effect on degradation]	0.0	4	1	1	1
105464	1710	leukocyte monocyte	[leukocytes monocytes]	0.0	2	1	1	1
105465	1710	protein differ at amino termini	[proteins differing at amino termini]	0.0	5	1	1	1
105466	1710	Comparison of group 1 human sequence	[Comparison of group 1 human sequences]	0.0	6	1	1	1
105467	1710	two major cell	[two major cells]	0.0	3	1	1	1
105468	1710	g1 protein p27(kip1)	[G1 proteins p27(Kip1)]	0.0	3	1	1	1
105469	1710	(partial)	[(partial)]	0.0	1	1	1	1
105470	1710	active DNA replication	[active DNA replication]	0.0	3	1	1	1
105471	1710	very low apparent dissociation constant	[very low apparent dissociation constant]	0.0	5	1	1	1
105472	1710	activator protein-1 gene activation	[activator protein-1 gene activation]	0.0	4	1	1	1
105473	1710	potentiate activity	[potentiating activity]	0.0	2	1	1	1
105474	1710	follow tnf-alpha-	[following TNF-alpha-]	0.0	2	1	1	1
105475	1710	t3r mbc of lymphocyte	[T3R MBC of lymphocytes]	0.0	4	1	1	1
105476	1710	Immunol Jul 15;153(2):910]	[Immunol Jul 15;153(2):910]]	0.0	3	1	1	1
105477	1710	L. pneumophila rpose	[L. pneumophila RpoS]	0.0	3	1	1	1
105478	1710	examine the effect	[examining the effects]	0.0	3	1	1	1
105479	1710	Germ	[Germ]	0.0	1	1	1	1
105480	1710	tcrzeta level (p	[TCRzeta levels (P]	0.0	3	1	1	1
105481	1710	various effect	[various effects]	0.0	2	1	1	1
105482	1710	response of myeloid cell	[response of myeloid cells]	0.0	4	1	1	1
105483	1710	mediate tnf-alpha release	[mediating TNF-alpha release]	0.0	3	1	1	1
105484	1710	human LCR HSs	[human LCR HSs]	0.0	3	1	1	1
105485	1710	inhibit endothelial expression	[inhibiting endothelial expression]	0.0	3	1	1	1
105486	1710	mol/L phorbol	[mol/L phorbol]	0.0	2	1	1	1
105487	1710	use a sensitive screen assay	[Using a sensitive screening assay]	0.0	5	1	1	1
105488	1710	various allele	[various alleles]	0.0	2	1	1	1
105489	1710	substitute for tpa	[substitute for TPA]	0.0	3	1	1	1
105490	1710	one hour pulse-treatment with microm etoposide	[One hour pulse-treatment with microM etoposide]	0.0	6	1	1	1
105491	1710	degree of inflammation	[degree of inflammation]	0.0	3	1	1	1
105492	1710	mutation by gene truncation	[mutations by gene truncation]	0.0	4	1	1	1
105493	1710	second exon,	[second exon,]	0.0	2	1	1	1
105494	1710	salient difference	[salient difference]	0.0	2	1	1	1
105495	1710	difference between EBNA-2 -negative extract	[differences between EBNA-2 -negative extracts]	0.0	5	1	1	1
105496	1710	case of g	[case of G]	0.0	3	1	1	1
105497	1710	course of cytotoxicity	[course of cytotoxicity]	0.0	3	1	1	1
105498	1710	internal deletion	[internal deletion]	0.0	2	2	2	1
105499	1710	hox11	[HOX11]	0.0	1	1	1	1
105500	1710	mispair event	[mispairing events]	0.0	2	1	1	1
105501	1710	pb-697	[PB-697]	0.0	1	1	1	1
105502	1710	t-lymphocyte cell line s-lb1	[T-lymphocyte cell line S-LB1]	0.0	4	1	1	1
105503	1710	cell by hydrogen peroxide	[cells by hydrogen peroxide]	0.0	4	1	1	1
105504	1710	signal in T lymphocytes.	[signaling in T lymphocytes.]	0.0	4	1	1	1
105505	1710	regulation of the ferritin gene	[regulation of the ferritin gene]	0.0	5	1	1	1
105506	1710	mouse genomic sequence	[mouse genomic sequences]	0.0	3	1	1	1
105507	1710	functional il-2r	[functional IL-2r]	0.0	2	1	1	1
105508	1710	peak between h.	[peaking between h,]	0.0	3	1	1	1
105509	1710	murine stem (es) cell	[murine stem (ES) cells]	0.0	4	1	1	1
105510	1710	efficient activation	[efficient activation]	0.0	2	1	1	1
105511	1710	obese subject	[obese subjects]	0.0	2	2	2	1
105512	1710	Effect of il-10	[Effects of IL-10]	0.0	3	1	1	1
105513	1710	promoter motif on IFNalpha- gene	[promoter motifs on IFNalpha- genes]	0.0	5	1	1	1
105514	1710	gy result in expression	[Gy results in expression]	0.0	4	1	1	1
105515	1710	accurately, amount of a size variant	[accurately, amounts of a size variant]	0.0	6	1	1	1
105516	1710	region (position	[region (positions]	0.0	2	1	1	1
105517	1710	weak activation	[weak activation]	0.0	2	1	1	1
105518	1710	b- development	[B- development]	0.0	2	1	1	1
105519	1710	incorporation of 3h-thymidine	[incorporation of 3H-thymidine]	0.0	3	1	1	1
105520	1710	protein binding property	[protein binding properties]	0.0	3	1	1	1
105521	1710	B-cell leukemia B-CLL	[B-cell leukemia B-CLL]	0.0	3	1	1	1
105522	1710	proliferative effect	[proliferative effect]	0.0	2	2	2	1
105523	1710	localization in PBL	[localization in PBL]	0.0	3	1	1	1
105524	1710	30 minute of reoxygenation	[30 minutes of reoxygenation]	0.0	4	1	1	1
105525	1710	40 years,	[40 years,]	0.0	2	1	1	1
105526	1710	DNA target sequence as heterodimer	[DNA target sequences as heterodimers]	0.0	5	1	1	1
105527	1710	expression of pilot a transcription factor	[Expression of PILOT a transcription factor]	0.0	6	1	1	1
105528	1710	expression of mapkk-1	[Expression of MAPKK-1]	0.0	3	1	1	1
105529	1710	outcome of diverse clinical syndrome	[outcome of diverse clinical syndromes]	0.0	5	1	1	1
105530	1710	low the/thf n:	[low THE/THF N:]	0.0	3	1	1	1
105531	1710	ROI -nf-kappa b	[ROI -NF-kappa B]	0.0	3	1	1	1
105532	1710	cell of sensitive leukemia patient	[cells of sensitive leukemia patients]	0.0	5	1	1	1
105533	1710	cell-specific activator	[cell-specific activator]	0.0	2	1	1	1
105534	1710	NH2-terminal amino acid of bob.1/obf.1	[NH2-terminal amino acids of BOB.1/OBF.1]	0.0	5	1	1	1
105535	1710	function among protein	[function among proteins]	0.0	3	1	1	1
105536	1710	c-fo promoter fc3	[c-fos promoter FC3]	0.0	3	1	1	1
105537	1710	novel apoptosis-mediating	[novel apoptosis-mediating]	0.0	2	1	1	1
105538	1710	specific uptake in pbmc	[specific uptake in PBMC]	0.0	4	1	1	1
105539	1710	normal myeloid cell granulocyte	[normal myeloid cells granulocytes]	0.0	4	1	1	1
105540	1710	stimulation with ionomycin	[stimulation with ionomycin]	0.0	3	1	1	1
105541	1710	RESULTS: secretion	[RESULTS: Secretion]	0.0	2	1	1	1
105542	1710	mononuclear leukocyte of ad patient	[mononuclear leukocytes of AD patients]	0.0	5	1	1	1
105543	1710	xpa	[XPA]	0.0	1	1	1	1
105544	1710	affect level	[affecting levels]	0.0	2	1	1	1
105545	1710	key mechanism increase il-2 transcription	[key mechanism increasing IL-2 transcription]	0.0	5	1	1	1
105546	1710	leukocyte-endothelium	[leukocyte-endothelium]	0.0	1	1	1	1
105547	1710	development of gd	[development of GD]	0.0	3	1	1	1
105548	1710	have the high amount of precursor	[having the highest amounts of precursors]	0.0	6	1	1	1
105549	1710	cell highly resistant	[cells highly resistant]	0.0	3	1	1	1
105550	1710	leukocyte protein of kD	[leukocyte protein of kD]	0.0	4	1	1	1
105551	1710	1 lmp-1	[1 LMP-1]	0.0	2	1	1	1
105552	1710	nonphlogistic phagocytosis	[nonphlogistic phagocytosis]	0.0	2	1	1	1
105553	1710	capacity of hiv	[capacity of HIV]	0.0	3	1	1	1
105554	1710	appearance of this transcription factor	[appearance of this transcription factor]	0.0	5	1	1	1
105555	1710	intact il-2 promoter	[intact IL-2 promoter]	0.0	3	1	1	1
105556	1710	response include phytohemagglutinin pha	[response including phytohemagglutinin PHA]	0.0	4	1	1	1
105557	1710	RB sense, oligonucleotide	[RB sense, oligonucleotide]	0.0	3	1	1	1
105558	1710	ards	[ARDS]	0.0	1	1	1	1
105559	1710	human interleukin IL-2 gene	[human interleukin IL-2 gene]	0.0	4	1	1	1
105560	1710	sex,	[sex,]	0.0	1	1	1	1
105561	1710	t-helper lymphocyte (th2) phenotype	[T-helper lymphocyte (Th2) phenotype]	0.0	4	1	1	1
105562	1710	steroid-regulated expression	[steroid-regulated expression]	0.0	2	1	1	1
105563	1710	phorbol myristate acetate stimulation	[phorbol myristate acetate stimulation]	0.0	4	1	1	1
105564	1710	hGR level in ibd patient	[hGR levels in IBD patients]	0.0	5	1	1	1
105565	1710	evidence for the suppression of TNF	[evidence for the suppression of TNF]	0.0	6	1	1	1
105566	1710	namely activator protein-1 factor nf-il6	[namely activator protein-1 factor NF-IL6]	0.0	5	1	1	1
105567	1710	effective site	[effective site]	0.0	2	1	1	1
105568	1710	significance of the expression	[significance of the expression]	0.0	4	1	1	1
105569	1710	displacement of 17beta-(3H) estradiol (cb50)	[displacement of 17beta-(3H) estradiol (CB50)]	0.0	5	1	1	1
105570	1710	activity of cyclin/cdk complex	[activity of cyclin/cdks complexes]	0.0	4	1	1	1
105571	1710	lead to stat1 activation	[leading to STAT1 activation]	0.0	4	1	1	1
105572	1710	kappa b a mediator	[kappa B a mediator]	0.0	4	1	1	1
105573	1710	histocompatibility complex (mhc) haplotype	[histocompatibility complex (MHC) haplotypes]	0.0	4	1	1	1
105574	1710	inhibition for the period,	[inhibition for the period,]	0.0	4	1	1	1
105575	1710	(hlh) protein	[(HLH) proteins]	0.0	2	1	1	1
105576	1710	P; binding of p50.p65 heterodimer	[h; binding of p50.p65 heterodimers]	0.0	5	1	1	1
105577	1710	alternative treatment approach for asthma	[alternative treatment approaches for asthma]	0.0	5	1	1	1
105578	1710	role in repression genes.	[role in repression genes.]	0.0	4	1	1	1
105579	1710	IL-2 cell antigen receptor induction phosphorylation	[IL-2 cell antigen receptor induction phosphorylation]	0.0	6	1	1	1
105580	1710	system of primary culture	[system of primary cultures]	0.0	4	1	1	1
105581	1710	two activity i.e. transactivation	[two activities i.e. transactivation]	0.0	4	1	1	1
105582	1710	approximately 42 gene HZF	[approximately 42 genes HZF]	0.0	4	1	1	1
105583	1710	one class compounds,	[one class compounds,]	0.0	3	1	1	1
105584	1710	iron complex with pdtc	[iron complexes with PDTC]	0.0	4	1	1	1
105585	1710	glucocorticoid receptor in asthma	[glucocorticoid receptor in asthma]	0.0	4	1	1	1
105586	1710	affinity ligand-binding	[affinity ligand-binding]	0.0	2	1	1	1
105587	1710	mcd14 uptake	[mCD14 uptake]	0.0	2	1	1	1
105588	1710	addition to b lymphocyte culture	[addition to B lymphocyte cultures]	0.0	5	1	1	1
105589	1710	2 il-2 synthesis	[2 IL-2 synthesis]	0.0	3	1	1	1
105590	1710	blood of healthy subject	[blood of healthy subjects]	0.0	4	1	1	1
105591	1710	spite of association with p50	[spite of association with p50]	0.0	5	1	1	1
105592	1710	surveillance of liver function	[surveillance of liver function]	0.0	4	1	1	1
105593	1710	value of D3 determination	[value of D3 determination]	0.0	4	1	1	1
105594	1710	exogenous ttg	[exogenous tTG]	0.0	2	1	1	1
105595	1710	multiple binding site for sp1	[multiple binding sites for Sp1]	0.0	5	1	1	1
105596	1710	consequence of hypercortisolism	[consequences of hypercortisolism]	0.0	3	1	1	1
105597	1710	event lead to stat1 activation	[events leading to STAT1 activation]	0.0	5	1	1	1
105598	1710	sensitivity to NK cell	[sensitivity to NK cells]	0.0	4	1	1	1
105599	1710	clone from the b cell	[clones from the B cells]	0.0	5	1	1	1
105600	1710	oxide synthase -mRNA level	[oxide synthase -mRNA level]	0.0	4	1	1	1
105601	1710	two distinct tyrosine-phosphorylated docking site	[two distinct tyrosine-phosphorylated docking sites]	0.0	5	1	1	1
105602	1710	reduction of IkappaBalpha	[reduction of IkappaBalpha]	0.0	3	1	1	1
105603	1710	exist isoform	[existing isoform]	0.0	2	1	1	1
105604	1710	expression level in cell line	[expression levels in cell lines]	0.0	5	1	1	1
105605	1710	mcp-1 expression in monocyte	[MCP-1 expression in monocytes]	0.0	4	1	1	1
105606	1710	encode a member	[encoding a member]	0.0	3	1	1	1
105607	1710	immune activation pathway	[immune activation pathways]	0.0	3	1	1	1
105608	1710	Leu-7+ killer cell (p less	[Leu-7+ killer cells (P less]	0.0	5	1	1	1
105609	1710	NFAT/AP-1	[NFAT/AP-1]	0.0	1	1	1	1
105610	1710	rel family protein	[Rel family proteins]	0.0	3	1	1	1
105611	1710	t-cell leukemia virus type I HTLV-I	[T-cell leukemia virus type I HTLV-I]	0.0	6	2	2	1
105612	1710	-267 construct	[-267 construct]	0.0	2	1	1	1
105613	1710	ability of nf-kappa b subunit	[abilities of NF-kappa B subunits]	0.0	5	1	1	1
105614	1710	long a subject	[long a subject]	0.0	3	1	1	1
105615	1710	chronic leukemia (cll) sample	[chronic leukemia (CLL) samples]	0.0	4	1	1	1
105616	1710	abnormality highlight loci	[abnormalities highlighting loci]	0.0	3	1	1	1
105617	1710	latency of HTLV-I	[latency of HTLV-I]	0.0	3	1	1	1
105618	1710	vein cell HUVECs	[vein cells HUVECs]	0.0	3	2	2	1
105619	1710	clinical significance of the expression	[clinical significance of the expression]	0.0	5	1	1	1
105620	1710	treatment of inflammatory disease	[treatment of inflammatory diseases]	0.0	4	1	1	1
105621	1710	arm,	[arm,]	0.0	1	1	1	1
105622	1710	fascinating new field in immunology	[fascinating new field in immunology]	0.0	5	1	1	1
105623	1710	several chemoattract at concentrations.	[several chemoattractants at concentrations.]	0.0	4	1	1	1
105624	1710	protein/drug	[protein/drug]	0.0	1	1	1	1
105625	1710	modulation of il-1 beta	[Modulation of IL-1 beta]	0.0	4	1	1	1
105626	1710	step-wise increase physical exercise	[step-wise increasing physical exercise]	0.0	4	1	1	1
105627	1710	low dissociation	[lower dissociation]	0.0	2	1	1	1
105628	1710	expression of the fas -regulatory gene	[expression of the Fas -regulatory gene]	0.0	6	1	1	1
105629	1710	mass,	[mass,]	0.0	1	1	1	1
105630	1710	quantitative thin-layer chromatography tlc	[Quantitative thin-layer chromatography TLC]	0.0	4	1	1	1
105631	1710	nuclear factor nf-il6 (position -153	[nuclear factor NF-IL6 (positions -153]	0.0	5	1	1	1
105632	1710	ii-peptide	[II-peptide]	0.0	1	1	1	1
105633	1710	immunofluorescence study on thymic population	[Immunofluorescence studies on thymic populations]	0.0	5	1	1	1
105634	1710	prototype stress	[prototype stress]	0.0	2	1	1	1
105635	1710	transcript of kilobasis	[transcript of kilobases]	0.0	3	1	1	1
105636	1710	transcript a osteoclast differentiation factor	[Transcripts an osteoclast differentiation factor]	0.0	5	1	1	1
105637	1710	group c infection	[group C infection]	0.0	3	2	2	1
105638	1710	extent, intercellular adhesion molecule-1	[extent, intercellular adhesion molecule-1]	0.0	4	1	1	1
105639	1710	effect phorbol	[effect phorbol]	0.0	2	1	1	1
105640	1710	type adenovirus in t-lymphocyte	[type adenovirus in T-lymphocytes]	0.0	4	1	1	1
105641	1710	important event in signalling	[important event in signalling]	0.0	4	1	1	1
105642	1710	particular complex (mhc) haplotype	[particular complex (MHC) haplotypes]	0.0	4	1	1	1
105643	1710	distal nuclear factor (NF)-AT AP-1/Octamer	[distal nuclear factor (NF)-AT AP-1/Octamer]	0.0	5	1	1	1
105644	1710	clonality in individual,	[clonality in individual,]	0.0	3	1	1	1
105645	1710	element propagate the inactive state,	[elements propagating the inactive state,]	0.0	5	1	1	1
105646	1710	o-phenanthroline on the induction of apoptosis	[o-phenanthroline on the induction of apoptosis]	0.0	6	1	1	1
105647	1710	six ebv-encoded nuclear antigen	[six EBV-encoded nuclear antigens]	0.0	4	1	1	1
105648	1710	expression of mammalian mcm5	[expression of mammalian MCM5]	0.0	4	1	1	1
105649	1710	bone mineralization	[bone mineralization]	0.0	2	1	1	1
105650	1710	-priming stage of differentiation,	[-priming stage of differentiation,]	0.0	4	1	1	1
105651	1710	structure lead to accessibility	[structure leading to accessibility]	0.0	4	1	1	1
105652	1710	effect on the production	[effect on the production]	0.0	4	1	1	1
105653	1710	DNA bind activity kbf1/p50	[DNA binding activity KBF1/p50]	0.0	4	1	1	1
105654	1710	other cd3epsilon transgenic mouse line	[other CD3epsilon transgenic mouse lines]	0.0	5	1	1	1
105655	1710	xpb XPD gene	[XPB XPD gene]	0.0	3	1	1	1
105656	1710	blastogenesis of peripheral blood lymphocyte generation	[blastogenesis of peripheral blood lymphocytes Generation]	0.0	6	1	1	1
105657	1710	significant amount of il-8 additionally, costimulation	[significant amounts of IL-8 additionally, costimulation]	0.0	6	1	1	1
105658	1710	precursor,	[precursor,]	0.0	1	1	1	1
105659	1710	evidence important in malignant transformation	[evidence important in malignant transformation]	0.0	5	1	1	1
105660	1710	require signal	[requiring signals]	0.0	2	1	1	1
105661	1710	class factor-induced gene	[class factor-induced genes]	0.0	3	1	1	1
105662	1710	direct binding to the dna.	[direct binding to the DNA.]	0.0	5	1	1	1
105663	1710	level nf-at complex	[levels NF-AT complexes]	0.0	3	1	1	1
105664	1710	disorder involve differentiation in male	[disorders involving differentiation in males]	0.0	5	1	1	1
105665	1710	flank region extend	[flanking regions extending]	0.0	3	1	1	1
105666	1710	mechanism (s) responsible	[mechanism (s) responsible]	0.0	3	1	1	1
105667	1710	hiv protein nf-kappa b	[HIV protein NF-kappa B]	0.0	4	1	1	1
105668	1710	human monocyte factor-kappaB	[human monocyte factor-kappaB]	0.0	3	1	1	1
105669	1710	variable phosphorylation of stat3	[variable phosphorylation of STAT3]	0.0	4	1	1	1
105670	1710	phorbol ester phorbol	[phorbol ester phorbol]	0.0	3	1	1	1
105671	1710	methods: eosinophil	[METHODS: eosinophils]	0.0	2	1	1	1
105672	1710	plasmid with mutation	[plasmids with mutations]	0.0	3	1	1	1
105673	1710	beta,19-epoxypregn-5-ene-4,20-dione	[beta,19-epoxypregn-5-ene-4,20-dione]	0.0	1	1	1	1
105674	1710	interaction between binding site	[interactions between binding sites]	0.0	4	1	1	1
105675	1710	polyomavirus transcription	[polyomavirus transcription]	0.0	2	1	1	1
105676	1710	t- acute chronic leukemia	[T- acute chronic leukemias]	0.0	4	1	1	1
105677	1710	lymphoid cell include peripheral cell	[lymphoid cells including peripheral cells]	0.0	5	1	1	1
105678	1710	cell line bear dqa1*0201	[cell lines bearing DQA1*0201]	0.0	4	1	1	1
105679	1710	messenger in c-fo	[messengers in c-Fos]	0.0	3	1	1	1
105680	1710	common immunophilin binding protein	[common immunophilin binding protein]	0.0	4	1	1	1
105681	1710	two gata3 zinc finger	[two GATA3 zinc fingers]	0.0	4	1	1	1
105682	1710	intrapulmonary instillation	[intrapulmonary instillation]	0.0	2	1	1	1
105683	1710	BZLF1 component of clonotype	[BZLF1 component of clonotypes]	0.0	4	1	1	1
105684	1710	extensive granulopoiesis typically die by 8	[extensive granulopoiesis typically dying by 8]	0.0	6	1	1	1
105685	1710	comparison with prognostic factor	[comparison with prognostic factors]	0.0	4	1	1	1
105686	1710	function of ZEBRA	[functions of ZEBRA]	0.0	3	1	1	1
105687	1710	T cell cd8+cd56+/cd57+	[T cells CD8+CD56+/CD57+]	0.0	3	1	1	1
105688	1710	increase in promoter strength relative	[increase in promoter strength relative]	0.0	5	1	1	1
105689	1710	PMA (iono, ic50	[PMA (Iono, IC50]	0.0	3	1	1	1
105690	1710	involve activation of two form stat3alpha	[involving activation of two forms STAT3alpha]	0.0	6	1	1	1
105691	1710	well-studied molecule	[well-studied molecules]	0.0	2	1	1	1
105692	1710	glucocorticoid at dose	[glucocorticoids at doses]	0.0	3	1	1	1
105693	1710	pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	3	1	1	1
105694	1710	early development of lineage	[early development of lineages]	0.0	4	1	1	1
105695	1710	expression through interaction	[expression through interaction]	0.0	3	1	1	1
105696	1710	difference in the system	[differences in the system]	0.0	4	1	1	1
105697	1710	activity of CREB	[activity of CREB]	0.0	3	1	1	1
105698	1710	antibodies patient	[antibodies, patients]	0.0	2	1	1	1
105699	1710	acidic sphingomyelinase of the membrane	[acidic sphingomyelinase of the membrane]	0.0	5	1	1	1
105700	1710	favorable clinical course (p chi2	[favorable clinical course (P chi2]	0.0	5	1	1	1
105701	1710	group of disorder involve differentiation	[group of disorders involving differentiation]	0.0	5	1	1	1
105702	1710	recognition of a nuclear localization sequence	[recognition of a nuclear localization sequence]	0.0	6	1	1	1
105703	1710	respectively, j393/ cd43	[respectively, J393/ CD43]	0.0	3	1	1	1
105704	1710	regulate the expression of cytokine gene	[regulating the expression of cytokine genes]	0.0	6	1	1	1
105705	1710	patient with dermatitis ad	[patients with dermatitis AD]	0.0	4	1	1	1
105706	1710	include 3 aml with immature morphology	[including 3 AML with immature morphology]	0.0	6	1	1	1
105707	1710	domain from GAL4 activator capable	[domain from GAL4 activators capable]	0.0	5	1	1	1
105708	1710	inhibition of il-8 expression	[inhibition of IL-8 expression]	0.0	4	1	1	1
105709	1710	nuclearity, cover the surface days.	[nuclearity, covering the surface days.]	0.0	5	1	1	1
105710	1710	molecule, such as CD80	[molecule, such as CD80]	0.0	4	1	1	1
105711	1710	interaction of nuclear extract	[Interaction of nuclear extracts]	0.0	4	1	1	1
105712	1710	expression in precursor by insertion	[expression in precursors by insertion]	0.0	5	1	1	1
105713	1710	induction of early gene	[induction of early genes]	0.0	4	1	1	1
105714	1710	protein (around 35 kda	[proteins (around 35 kDa]	0.0	4	1	1	1
105715	1710	dose-dependent stimulation synthesis.	[dose-dependent stimulation synthesis.]	0.0	3	1	1	1
105716	1710	low il-2 production	[low IL-2 production]	0.0	3	1	1	1
105717	1710	era in biomedical research	[era in biomedical research]	0.0	4	1	1	1
105718	1710	high level of cell adhesion molecule	[high levels of cell adhesion molecule]	0.0	6	1	1	1
105719	1710	recombinant gp41 the domain	[recombinant gp41 the domain]	0.0	4	1	1	1
105720	1710	region for the induction	[region for the induction]	0.0	4	1	1	1
105721	1710	stress-activated kinase pathway	[stress-activated kinase pathway]	0.0	3	1	1	1
105722	1710	adenosine monophosphate camp accumulation	[adenosine monophosphate cAMP accumulation]	0.0	4	1	1	1
105723	1710	heat labile activity	[heat labile activity]	0.0	3	1	1	1
105724	1710	seven woman	[seven women]	0.0	2	1	1	1
105725	1710	role for tax induction	[role for Tax induction]	0.0	4	1	1	1
105726	1710	part of a symmetry element	[part of a symmetry element]	0.0	5	1	1	1
105727	1710	viral antigen staining	[viral antigen staining]	0.0	3	1	1	1
105728	1710	minimal residual disease MRD of patient	[minimal residual disease MRD of patients]	0.0	6	1	1	1
105729	1710	Thr729	[Thr729]	0.0	1	1	1	1
105730	1710	polyomavirus protein 2/core-binding factor pebp2/cbf	[polyomavirus protein 2/core-binding factor PEBP2/CBF]	0.0	5	1	1	1
105731	1710	macrophage maturation, expression	[macrophage maturation, expression]	0.0	3	1	1	1
105732	1710	entire cytoplasmic pool	[entire cytoplasmic pool]	0.0	3	1	1	1
105733	1710	activation globin promoter functional role	[activation globin promoter functional role]	0.0	5	1	1	1
105734	1710	granulocyte-macrophage factor promoter in T cell	[granulocyte-macrophage factor promoters in T cells]	0.0	6	1	1	1
105735	1710	differential binding of factor	[differential binding of factors]	0.0	4	1	1	1
105736	1710	sem body mass index	[SEM body mass index]	0.0	4	1	1	1
105737	1710	distinct activity on T cell	[distinct activities on T cells]	0.0	5	1	1	1
105738	1710	suppression continue	[suppression continuing]	0.0	2	1	1	1
105739	1710	reticulocyte of the animal	[reticulocytes of the animals]	0.0	4	1	1	1
105740	1710	immunodeficiency x-scid	[immunodeficiency X-SCID]	0.0	2	1	1	1
105741	1710	injury with alpha-tocopherol	[injury with alpha-tocopherol]	0.0	3	1	1	1
105742	1710	disruption of a sequence motif box1	[disruption of a sequence motif box1]	0.0	6	1	1	1
105743	1710	rational strategy manipulate pathological response	[rational strategies manipulating pathological responses]	0.0	5	1	1	1
105744	1710	use condition	[Using conditions]	0.0	2	1	1	1
105745	1710	box of the domain	[box of the domain]	0.0	4	1	1	1
105746	1710	3) content of t3, 4) dysfunction	[3) content of T3, 4) dysfunction]	0.0	6	1	1	1
105747	1710	monocyte with il-1beta	[monocytes with IL-1beta]	0.0	3	1	1	1
105748	1710	x ;autosome translocation	[X ;autosome translocations]	0.0	3	1	1	1
105749	1710	c/ebp proximal	[C/EBP proximal]	0.0	2	1	1	1
105750	1710	c-jun by oligonucleotide	[c-jun by oligonucleotides]	0.0	3	1	1	1
105751	1710	positivity 0.05).	[positivity 0.05).]	0.0	2	1	1	1
105752	1710	tal1 transcription (affect expression	[TAL1 transcription (affecting expression]	0.0	4	1	1	1
105753	1710	yield of protein	[yields of proteins]	0.0	3	1	1	1
105754	1710	set of cell hybrid	[sets of cell hybrids]	0.0	4	1	1	1
105755	1710	nuclear p50	[nuclear p50]	0.0	2	1	1	1
105756	1710	two nuclear factor kB NF-kB element	[two nuclear factor kB NF-kB elements]	0.0	6	1	1	1
105757	1710	postanoxic huvec	[postanoxic HUVECs]	0.0	2	1	1	1
105758	1710	part, for induction	[part, for induction]	0.0	3	1	1	1
105759	1710	circulate immune complex	[circulating immune complexes]	0.0	3	1	1	1
105760	1710	insulin pi 3-kinase activation	[insulin PI 3-kinase activation]	0.0	4	1	1	1
105761	1710	b -like factor evidence	[B -like factor evidence]	0.0	4	1	1	1
105762	1710	therefore likely: correct fold	[therefore likely: correct folding]	0.0	4	1	1	1
105763	1710	cell reaction histologic grade	[cell reaction histologic grade]	0.0	4	1	1	1
105764	1710	mononuclear (mnc)	[mononuclear (MNC)]	0.0	2	1	1	1
105765	1710	immediate (ie62) protein vzv	[immediate (IE62) protein VZV]	0.0	4	1	1	1
105766	1710	IL-13 a cytokine similar	[IL-13 a cytokine similar]	0.0	4	1	1	1
105767	1710	staining in +/- 3.7%	[staining in +/- 3.7%]	0.0	4	1	1	1
105768	1710	pyrimidine (and fura	[pyrimidine (and FUra]	0.0	3	1	1	1
105769	1710	9-bp motif with homology	[9-bp motifs with homology]	0.0	4	1	1	1
105770	1710	dephosphorylation of prb of p130 form	[dephosphorylation of pRb of p130 Form]	0.0	6	1	1	1
105771	1710	S-adenosylhomocysteine	[S-adenosylhomocysteine]	0.0	1	1	1	1
105772	1710	tandem ap1 binding site with symmetry	[tandem AP1 binding sites with symmetry]	0.0	6	1	1	1
105773	1710	lmp promoter fragment	[LMP promoter fragments]	0.0	3	1	1	1
105774	1710	effect on nip repression	[effects on NIP repression]	0.0	4	1	1	1
105775	1710	319ll-r	[319LL-RS]	0.0	1	1	1	1
105776	1710	sea cause	[SEA cause]	0.0	2	1	1	1
105777	1710	immunological cross-linking	[immunological cross-linking]	0.0	2	1	1	1
105778	1710	influence of age on the production	[Influence of age on the production]	0.0	6	1	1	1
105779	1710	action of atra	[actions of ATRA]	0.0	3	1	1	1
105780	1710	t-cell-specific transcriptional activator tcf-1	[T-cell-specific transcriptional activator TCF-1]	0.0	4	1	1	1
105781	1710	familiess	[families,]	0.0	1	1	1	1
105782	1710	expression of the map	[Expression of the MAP]	0.0	4	1	1	1
105783	1710	unique function among herpesviral protein	[unique function among herpesviral proteins]	0.0	5	1	1	1
105784	1710	CD28 ab	[CD28 Ab]	0.0	2	1	1	1
105785	1710	early marker of differentiation	[early markers of differentiation]	0.0	4	1	1	1
105786	1710	IL-8 a factor for granulocyte	[IL-8 a factor for granulocytes]	0.0	5	1	1	1
105787	1710	-200 bp	[-200 bp]	0.0	2	1	1	1
105788	1710	binding site per cell)	[binding sites per cell)]	0.0	4	1	1	1
105789	1710	use deletion mutant in transfection assays,	[Using deletion mutants in transfection assays,]	0.0	6	1	1	1
105790	1710	estrogen e(2)	[estrogen E(2)]	0.0	2	1	1	1
105791	1710	transcription bear ZEBRA promoter	[transcription bearing ZEBRA promoters]	0.0	4	1	1	1
105792	1710	adult human bone marrow	[adult human bone marrow]	0.0	4	1	1	1
105793	1710	human blood NK cell	[human blood NK cells]	0.0	4	1	1	1
105794	1710	urinary cortisol excretion before treatment	[urinary cortisol excretion before treatment]	0.0	5	1	1	1
105795	1710	Sp1 family	[Sp1 families]	0.0	2	1	1	1
105796	1710	cortical thymocyte undergo selection	[cortical thymocytes undergoing selection]	0.0	4	1	1	1
105797	1710	disease four with rheumatoid arthritis	[diseases four with rheumatoid arthritis]	0.0	5	1	1	1
105798	1710	48 hour time	[48 hours time]	0.0	3	2	2	1
105799	1710	also in long maintenance of transcription	[also in long-term maintenance of transcription]	0.0	6	1	1	1
105800	1710	deletion of CIITA	[deletions of CIITA]	0.0	3	1	1	1
105801	1710	expression in monocytes/macrophages	[expression in monocytes/macrophages]	0.0	3	1	1	1
105802	1710	treatment of er- cell with E2	[treatment of ER- cells with E2]	0.0	6	1	1	1
105803	1710	oct2-isoform	[Oct2-isoform]	0.0	1	1	1	1
105804	1710	cytokine similar	[cytokine similar]	0.0	2	1	1	1
105805	1710	viral rna splicing pattern	[viral RNA splicing patterns]	0.0	4	1	1	1
105806	1710	other cell sensitive	[other cells sensitive]	0.0	3	1	1	1
105807	1710	result from extensive splicing	[resulting from extensive splicing]	0.0	4	1	1	1
105808	1710	ic50 of nm	[IC50s of nM]	0.0	3	1	1	1
105809	1710	NFAT activation,	[NFAT activation,]	0.0	2	1	1	1
105810	1710	interleukin-4 element in cell	[interleukin-4 element in cells]	0.0	4	1	1	1
105811	1710	important functional site	[important functional site]	0.0	3	1	1	1
105812	1710	cyto-differentiating effect on acute leukemia cell	[cyto-differentiating effects on acute leukemia cells]	0.0	6	1	1	1
105813	1710	Kruppel-like factor eklf	[Kruppel-like factor EKLF]	0.0	3	1	1	1
105814	1710	requirement for human immunodeficiency virus	[requirement for human immunodeficiency virus]	0.0	5	1	1	1
105815	1710	0.5 -2 molecule	[0.5 -2 molecules]	0.0	3	1	1	1
105816	1710	105-kDa protein p105	[105-kDa protein p105]	0.0	3	1	1	1
105817	1710	(cr) subject	[(CR) subjects]	0.0	2	1	1	1
105818	1710	anoxia/reoxygenation-induced tolerance with respect	[Anoxia/reoxygenation-induced tolerance with respect]	0.0	4	1	1	1
105819	1710	site of disease	[site of disease]	0.0	3	1	1	1
105820	1710	involvement in induction	[Involvement in induction]	0.0	3	1	1	1
105821	1710	cytokine gamma-ifn	[cytokine gamma-IFN]	0.0	2	1	1	1
105822	1710	lymphoid cell with interleukin-1beta	[lymphoid cells with interleukin-1beta]	0.0	4	1	1	1
105823	1710	evaluation of large cohort	[Evaluation of large cohorts]	0.0	4	1	1	1
105824	1710	antigen-driven expansion) (by abortive stimulation	[antigen-driven expansion) (by abortive stimulation]	0.0	5	1	1	1
105825	1710	four nucleotide	[four nucleotides]	0.0	2	1	1	1
105826	1710	expression a putative transcription factor	[Expression a putative transcription factor]	0.0	5	1	1	1
105827	1710	contain direct repeat DR of bp	[containing direct repeats DR of bp]	0.0	6	1	1	1
105828	1710	generate level of cl	[generating levels of CL]	0.0	4	1	1	1
105829	1710	platelet membrane vesicle	[platelet membrane vesicles]	0.0	3	1	1	1
105830	1710	t-cell -specific gene	[T-cell -specific gene]	0.0	3	1	1	1
105831	1710	underlying molecular mechanism for effect	[underlying molecular mechanism for effects]	0.0	5	1	1	1
105832	1710	h in hl60 cell	[h in HL60 cells]	0.0	4	1	1	1
105833	1710	effect on number of receptor	[effects on number of receptors]	0.0	5	1	1	1
105834	1710	centers.	[centers.]	0.0	1	1	1	1
105835	1710	recognition of a localization sequence	[recognition of a localization sequence]	0.0	5	1	1	1
105836	1710	receptor present on leukocyte cell membrane	[Receptors present on leukocyte cell membranes]	0.0	6	1	1	1
105837	1710	incubation of endothelial cell with oleate	[Incubation of endothelial cells with oleate]	0.0	6	1	1	1
105838	1710	involve steroid hormone	[involving steroid hormones]	0.0	3	1	1	1
105839	1710	evidence for activity	[Evidence for activity]	0.0	3	1	1	1
105840	1710	epithelial signal transducer	[epithelial signal transducer]	0.0	3	1	1	1
105841	1710	interleukin-1 signal mediator	[interleukin-1 signaling mediators]	0.0	3	1	1	1
105842	1710	rare hereditary disorder present	[rare hereditary disorder presenting]	0.0	4	1	1	1
105843	1710	perhaps in transformation in some neoplasia	[perhaps in transformation in some neoplasias]	0.0	6	1	1	1
105844	1710	second hypersensitive site	[second hypersensitive site]	0.0	3	1	1	1
105845	1710	basement membrane immunoreactivity	[Basement membrane immunoreactivity]	0.0	3	1	1	1
105846	1710	active ras mutant,	[active ras mutant,]	0.0	3	1	1	1
105847	1710	all-tran retinoic acid RA treatment	[all-trans retinoic acid RA treatment]	0.0	5	1	1	1
105848	1710	bovine ganglioside	[bovine gangliosides]	0.0	2	1	1	1
105849	1710	similarly in alveolar macrophage	[similarly in alveolar macrophages]	0.0	4	1	1	1
105850	1710	indicate difference in transactivation	[indicating differences in transactivation]	0.0	4	1	1	1
105851	1710	yr)	[yr)]	0.0	1	1	1	1
105852	1710	xscid, x-chromosome inactivation	[XSCID, X-chromosome inactivation]	0.0	3	1	1	1
105853	1710	important cell membrane constituent	[important cell membrane constituents]	0.0	4	1	1	1
105854	1710	accumulation of unspliced mrna	[accumulation of unspliced mRNA]	0.0	4	1	1	1
105855	1710	nfatp formation	[NFATp formation]	0.0	2	1	1	1
105856	1710	expression of interferon isotype from individual	[expression of interferon isotypes from individuals]	0.0	6	1	1	1
105857	1710	cooperative activity of factor	[cooperative activity of factors]	0.0	4	1	1	1
105858	1710	regulate stage	[regulating stages]	0.0	2	1	1	1
105859	1710	vivo from the protease	[vivo from the protease]	0.0	4	1	1	1
105860	1710	estimate of the detection rate	[estimate of the detection rate]	0.0	5	1	1	1
105861	1710	mouse deficient	[mice deficient]	0.0	2	1	1	1
105862	1710	huvec with thrombin	[HUVEC with thrombin]	0.0	3	1	1	1
105863	1710	subunit ikappabalpha	[subunit IkappaBalpha]	0.0	2	1	1	1
105864	1710	cytosolic extract of cell	[cytosolic extracts of cells]	0.0	4	1	1	1
105865	1710	tsg101 deletion in rna transcript	[TSG101 deletions in RNA transcripts]	0.0	5	1	1	1
105866	1710	patient with RA	[patients with RA]	0.0	3	1	1	1
105867	1710	steady-state immunoglobulin heavy-chain mrna	[steady-state immunoglobulin heavy-chain mRNA]	0.0	4	1	1	1
105868	1710	list of molecule	[list of molecules]	0.0	3	1	1	1
105869	1710	inhibitor of acidic sphingomyelinase	[inhibitor of acidic sphingomyelinase]	0.0	4	1	1	1
105870	1710	period of time.	[periods of time.]	0.0	3	1	1	1
105871	1710	increase in phosphotyrosine labeling of proteins.	[increases in phosphotyrosine labeling of proteins.]	0.0	6	1	1	1
105872	1710	exposure together with il-4	[exposure together with IL-4]	0.0	4	1	1	1
105873	1710	development of DC	[development of DC]	0.0	3	1	1	1
105874	1710	characteristic of child with variant	[characteristic of children with variants]	0.0	5	1	1	1
105875	1710	coping strategy,	[coping strategy,]	0.0	2	1	1	1
105876	1710	overexpression a constitutive version of c-Raf	[Overexpression a constitutive version of c-Raf]	0.0	6	1	1	1
105877	1710	element distinct	[elements distinct]	0.0	2	1	1	1
105878	1710	TNF-alpha hiv activation	[TNF-alpha HIV activation]	0.0	3	1	1	1
105879	1710	concurrent enhancement of lps uptake	[concurrent enhancement of LPS uptake]	0.0	5	1	1	1
105880	1710	first time HBxAg	[first time HBxAg]	0.0	3	1	1	1
105881	1710	factor namely,	[factors namely,]	0.0	2	1	1	1
105882	1710	role in several animal model	[role in several animal models]	0.0	5	1	1	1
105883	1710	lymphoblastoid phenotype	[lymphoblastoid phenotype]	0.0	2	1	1	1
105884	1710	alteration in receptor gr	[alterations in receptor GR]	0.0	4	1	1	1
105885	1710	central mediator	[central mediator]	0.0	2	1	1	1
105886	1710	mature monocyte/macrophage-like cell	[mature monocyte/macrophage-like cells]	0.0	3	1	1	1
105887	1710	erythroid-specific cis-acting element	[erythroid-specific cis-acting elements]	0.0	3	1	1	1
105888	1710	rearrangement of the tal1 gene	[rearrangements of the TAL1 gene]	0.0	5	1	1	1
105889	1710	specimen of lymph node	[specimens of lymph nodes]	0.0	4	1	1	1
105890	1710	acute leukemia gene AML1	[acute leukemia gene AML1]	0.0	4	1	1	1
105891	1710	different forms: the mutant p53	[different forms: the mutant p53]	0.0	5	1	1	1
105892	1710	T cell costimulatory molecule	[T cell costimulatory molecule]	0.0	4	1	1	1
105893	1710	-148 region	[-148 region]	0.0	2	1	1	1
105894	1710	only individual of particular (mhc) haplotype	[only individuals of particular (MHC) haplotypes]	0.0	6	1	1	1
105895	1710	availability of proteasome inhibitor	[availability of proteasome inhibitors]	0.0	4	1	1	1
105896	1710	malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
105897	1710	apparent lack	[apparent lack]	0.0	2	1	1	1
105898	1710	Interestingly, coincubation of tr alpha	[Interestingly, coincubation of TR alpha]	0.0	5	1	1	1
105899	1710	display difference in activity	[displaying differences in activity]	0.0	4	1	1	1
105900	1710	element of gene	[elements of genes]	0.0	3	1	1	1
105901	1710	weak stress	[weak stress]	0.0	2	1	1	1
105902	1710	presence of oestrogen progesterone receptor	[presence of oestrogen progesterone receptors]	0.0	5	1	1	1
105903	1710	dosage of lipopolysaccharide	[dosages of lipopolysaccharides]	0.0	3	1	1	1
105904	1710	suppression of t-cell proliferation	[suppression of T-cell proliferation]	0.0	4	1	1	1
105905	1710	relative affinity (at sevenfold)	[relative affinity (at sevenfold)]	0.0	4	1	1	1
105906	1710	endodermal origin	[endodermal origin]	0.0	2	1	1	1
105907	1710	(cre) binding site	[(CRE) binding sites]	0.0	3	1	1	1
105908	1710	p27(kip1) transcript	[p27(KIP1) transcript]	0.0	2	1	1	1
105909	1710	information about the mechanism	[information about the mechanisms]	0.0	4	1	1	1
105910	1710	prominent E2F activity	[prominent E2F activity]	0.0	3	1	1	1
105911	1710	/nerve	[/nerve]	0.0	1	1	1	1
105912	1710	rapid increase in GRE binding	[rapid increase in GRE binding]	0.0	5	1	1	1
105913	1710	well-established risk factor	[well-established risk factor]	0.0	3	1	1	1
105914	1710	subclone of a bone	[subclone of a bone]	0.0	4	1	1	1
105915	1710	heterogeneous group	[heterogeneous group]	0.0	2	2	2	1
105916	1710	blastogenesis of peripheral blood lymphocyte	[blastogenesis of peripheral blood lymphocytes]	0.0	5	1	1	1
105917	1710	biological form of vitamin D3	[biological form of vitamin D3]	0.0	5	1	1	1
105918	1710	express the protein mds1/evi1	[expressing the protein MDS1/EVI1]	0.0	4	1	1	1
105919	1710	difference in transcription efficiency	[differences in transcription efficiencies]	0.0	4	1	1	1
105920	1710	precursor cell line hl60	[precursor cell lines HL60]	0.0	4	1	1	1
105921	1710	entry of cell	[entry of cells]	0.0	3	1	1	1
105922	1710	erythropoietic culture molecular analysis	[erythropoietic cultures molecular analysis]	0.0	4	1	1	1
105923	1710	tat intracellular antibody	[Tat intracellular antibody]	0.0	3	1	1	1
105924	1710	eight different form of inheritance	[eight different forms of inheritance]	0.0	5	1	1	1
105925	1710	functionally distinct receptor	[functionally distinct receptors]	0.0	3	1	1	1
105926	1710	1 trans-activator	[1 trans-activator]	0.0	2	1	1	1
105927	1710	alpha-methyl, alpha-fluoromethyl	[alpha-methyl, alpha-fluoromethyl]	0.0	2	1	1	1
105928	1710	circulate human leukocyte of healthy donor	[circulating human leukocytes of healthy donors]	0.0	6	1	1	1
105929	1710	multiple substrate	[multiple substrates]	0.0	2	1	1	1
105930	1710	effector plasmid	[effector plasmid]	0.0	2	1	1	1
105931	1710	artery-SCID chimera for wk	[artery-SCID chimeras for wk]	0.0	4	1	1	1
105932	1710	yy1	[YY1]	0.0	1	1	1	1
105933	1710	cyclosporin mechanism	[cyclosporin mechanism]	0.0	2	1	1	1
105934	1710	essential mediator generate mechanism	[essential mediator generating mechanisms]	0.0	4	1	1	1
105935	1710	transcriptional control of gene	[transcriptional control of genes]	0.0	4	1	1	1
105936	1710	factor binding motif	[factor binding motifs]	0.0	3	1	1	1
105937	1710	difference in the specificity	[differences in the specificity]	0.0	4	1	1	1
105938	1710	allergen-specific cd4+ T cell clone	[allergen-specific CD4+ T cell clones]	0.0	5	1	1	1
105939	1710	course 20 mg	[course 20 mg]	0.0	3	1	1	1
105940	1710	cytokine upon treatment	[cytokines upon treatment]	0.0	3	1	1	1
105941	1710	recurrent abnormality highlight novel loci	[recurrent abnormalities highlighting novel loci]	0.0	5	1	1	1
105942	1710	pathway operate downstream	[pathways operating downstream]	0.0	3	1	1	1
105943	1710	erythroid development of m-tat cell	[erythroid development of M-TAT cells]	0.0	5	1	1	1
105944	1710	IL-4 gene,	[IL-4 gene,]	0.0	2	1	1	1
105945	1710	protein (s) from lam-	[protein (s) from LAM-]	0.0	4	1	1	1
105946	1710	proil-1 beta requirement	[proIL-1 beta requirement]	0.0	3	1	1	1
105947	1710	activator protein-1 activation	[activator protein-1 activation]	0.0	3	1	1	1
105948	1710	tbp -contain complex	[TBP -containing complex]	0.0	3	1	1	1
105949	1710	use systems,	[using systems,]	0.0	2	1	1	1
105950	1710	combination of phorbol-12-myristate acetate	[combination of phorbol-12-myristate acetate]	0.0	4	1	1	1
105951	1710	characterization of tumor necrosis factor-alpha element	[characterization of tumor necrosis factor-alpha elements]	0.0	6	1	1	1
105952	1710	induction of immunodeficiency virus type	[Induction of immunodeficiency virus type]	0.0	5	1	1	1
105953	1710	addition between naive T cell	[addition between naive T cells]	0.0	5	1	1	1
105954	1710	'default' state.	['default' state.]	0.0	2	1	1	1
105955	1710	potential in skin cancer	[potential in skin cancer]	0.0	4	1	1	1
105956	1710	rna polymerase transcription in cell	[RNA polymerase transcription in cells]	0.0	5	1	1	1
105957	1710	accumulation of the 47-kd glycoprotein	[accumulation of the 47-kD glycoprotein]	0.0	5	1	1	1
105958	1710	two inhibitor of NFAT -1-mediated transcription	[two inhibitors of NFAT -1-mediated transcription]	0.0	6	1	1	1
105959	1710	expression of gm-csf	[expression of GM-CSF]	0.0	3	1	1	1
105960	1710	expression from normal individual	[expression from normal individuals]	0.0	4	1	1	1
105961	1710	activity for pmn	[activity for PMNs]	0.0	3	1	1	1
105962	1710	only in the expression	[only in the expression]	0.0	4	1	1	1
105963	1710	two type il-13	[two types IL-13]	0.0	3	1	1	1
105964	1710	involvement of /threonine protein phosphorylation	[involvement of /threonine protein phosphorylation]	0.0	5	1	1	1
105965	1710	octamer motif enhancer	[octamer motif enhancer]	0.0	3	1	1	1
105966	1710	cyclic adenosine monophosphate signal	[cyclic adenosine monophosphate signaling]	0.0	4	1	1	1
105967	1710	4 non-hodgkin' lymphoma	[4 non-Hodgkin's lymphoma]	0.0	3	1	1	1
105968	1710	function of transcriptional activation	[functions of transcriptional activation]	0.0	4	1	1	1
105969	1710	element between MEL cell	[element between MEL cells]	0.0	4	1	1	1
105970	1710	salicylate derivative	[salicylate derivatives]	0.0	2	1	1	1
105971	1710	expression of the rar-alpha in erythroblast	[Expression of the RAR-alpha in erythroblasts]	0.0	6	1	1	1
105972	1710	expression of tax1 antigen	[expression of tax1 antigens]	0.0	4	1	1	1
105973	1710	leukemic transformation	[leukemic transformation]	0.0	2	1	1	1
105974	1710	human T cell-specific	[human T cell-specific]	0.0	3	1	1	1
105975	1710	tal-1 expression in cell	[tal-1 expression in cells]	0.0	4	1	1	1
105976	1710	mean type EBS level	[mean type EBS levels]	0.0	4	1	1	1
105977	1710	protein Ets-1	[protein Ets-1]	0.0	2	1	1	1
105978	1710	b cell by ebv	[B cells by EBV]	0.0	4	1	1	1
105979	1710	cellular event to cell ECs	[cellular event to cells ECs]	0.0	5	1	1	1
105980	1710	cell within atherosclerotic plaque	[cells within atherosclerotic plaques]	0.0	4	1	1	1
105981	1710	role for this region	[role for this region]	0.0	4	1	1	1
105982	1710	enzyme activities,	[enzyme activities,]	0.0	2	1	1	1
105983	1710	particular value explore signal pathway	[particular value exploring signaling pathways]	0.0	5	1	1	1
105984	1710	protein eventually lead	[proteins eventually leading]	0.0	3	1	1	1
105985	1710	blotting Northern (rna) blotting assay	[blotting Northern (RNA) blotting assays]	0.0	5	1	1	1
105986	1710	polymorphic dinucleotide repeat	[polymorphic dinucleotide repeat]	0.0	3	1	1	1
105987	1710	tyrosine phosphorylation of intracellular protein	[tyrosine phosphorylation of intracellular proteins]	0.0	5	1	1	1
105988	1710	8.9+/-1.2 nmol/L)	[8.9+/-1.2 nmol/L)]	0.0	2	1	1	1
105989	1710	(bko)	[(BKO)]	0.0	1	1	1	1
105990	1710	mechanical type	[mechanical types]	0.0	2	1	1	1
105991	1710	early stage of b-lymphocyte development	[early stages of B-lymphocyte development]	0.0	5	1	1	1
105992	1710	B-specific binding factor	[B-specific binding factors]	0.0	3	1	1	1
105993	1710	coproporphyrinogen	[coproporphyrinogen]	0.0	1	1	1	1
105994	1710	use TAP-deficient cell line	[using TAP-deficient cell lines]	0.0	4	1	1	1
105995	1710	(p chi2 test),	[(P chi2 test),]	0.0	3	1	1	1
105996	1710	transduction/	[transduction/]	0.0	1	1	1	1
105997	1710	gm-csf-responsive cell line	[GM-CSF-responsive cell lines]	0.0	3	1	1	1
105998	1710	four copy	[four copies]	0.0	2	1	1	1
105999	1710	cell line use co-transfection assay	[cell lines using co-transfection assays]	0.0	5	1	1	1
106000	1710	beta-like globin gene delta	[beta-like globin genes delta]	0.0	4	1	1	1
106001	1710	CREB/ATF-1/CREM	[CREB/ATF-1/CREM]	0.0	1	1	1	1
106002	1710	D3 on can metabolism	[D3 on Ca metabolism]	0.0	4	1	1	1
106003	1710	inactive, complex	[inactive, complex]	0.0	2	1	1	1
106004	1710	lack cell	[lacking cells]	0.0	2	1	1	1
106005	1710	effect on the replication	[effects on the replication]	0.0	4	1	1	1
106006	1710	important primary mechanism	[important primary mechanism]	0.0	3	1	1	1
106007	1710	expression of Aldh1	[expression of Aldh1]	0.0	3	1	1	1
106008	1710	induction by phorbol ester	[induction by phorbol esters]	0.0	4	1	1	1
106009	1710	Zta up-regulation	[Zta up-regulation]	0.0	2	1	1	1
106010	1710	e(gre) motif	[E(gre) motifs]	0.0	2	1	1	1
106011	1710	3,5,3'-triiodothyronine receptor circulate lymphocyte in hyper-	[3,5,3'-triiodothyronine receptors circulating lymphocytes in hyper-]	0.0	6	1	1	1
106012	1710	5' region of kb	[5' region of kb]	0.0	4	1	1	1
106013	1710	normal T cell a component	[normal T cells a component]	0.0	5	1	1	1
106014	1710	DNA cDNA	[DNA cDNA]	0.0	2	1	1	1
106015	1710	formation of DNase site	[formation of DNase sites]	0.0	4	1	1	1
106016	1710	whole-blood cell culture	[whole-blood cell cultures]	0.0	3	1	1	1
106017	1710	30 minute (phase	[30 minutes (phase]	0.0	3	1	1	1
106018	1710	udg promoter sequence	[UDG promoter sequences]	0.0	3	1	1	1
106019	1710	patient receive therapy for disease	[patients receiving therapy for diseases]	0.0	5	1	1	1
106020	1710	b cell activator protein BSAP	[B cell activator protein BSAP]	0.0	5	1	1	1
106021	1710	tissue pattern	[tissue pattern]	0.0	2	1	1	1
106022	1710	glucocorticoid receptor gr binding	[glucocorticoid receptor GR binding]	0.0	4	1	1	1
106023	1710	Comparison of the different combination	[Comparison of the different combinations]	0.0	5	1	1	1
106024	1710	leukocyte pmn adhesion	[leukocyte PMN adhesion]	0.0	3	1	1	1
106025	1710	mnda cell between level	[MNDA cells between levels]	0.0	4	1	1	1
106026	1710	particle exposure	[particle exposure]	0.0	2	1	1	1
106027	1710	monocytic cell maturation	[monocytic cell maturation]	0.0	3	1	1	1
106028	1710	express the tax protein	[expressing the Tax protein]	0.0	4	1	1	1
106029	1710	vitro-differentiated embryonic stem cell	[vitro-differentiated embryonic stem cells]	0.0	4	1	1	1
106030	1710	loss of tgf-beta -mediated growth inhibition	[loss of TGF-beta -mediated growth inhibition]	0.0	6	1	1	1
106031	1710	defect in t-cell activation	[defects in T-cell activation]	0.0	4	1	1	1
106032	1710	use synthetic peptide	[using synthetic peptides]	0.0	3	1	1	1
106033	1710	twofold increase from patient	[twofold increase from patients]	0.0	4	1	1	1
106034	1710	immunoglobulin chain gene cluster	[immunoglobulin chain gene cluster]	0.0	4	1	1	1
106035	1710	wild-type hiv in blood lymphocyte	[wild-type HIV in blood lymphocytes]	0.0	5	1	1	1
106036	1710	microvascular ec bone marrow ec	[microvascular EC bone marrow EC]	0.0	5	1	1	1
106037	1710	lesion with age	[lesions with age]	0.0	3	1	1	1
106038	1710	(iono,	[(Iono,]	0.0	1	1	1	1
106039	1710	serine alanine substitution	[serine alanine substitution]	0.0	3	1	1	1
106040	1710	anti-early antigen ea antigen	[anti-early antigen EA antigen]	0.0	4	1	1	1
106041	1710	suggest up-regulation	[suggesting up-regulation]	0.0	2	1	1	1
106042	1710	adhesion with monocyte	[adhesions with monocytes]	0.0	3	1	1	1
106043	1710	murine TNF promoter	[murine TNF promoter]	0.0	3	1	1	1
106044	1710	l132	[L132]	0.0	1	1	1	1
106045	1710	work from laboratory	[work from laboratories]	0.0	3	1	1	1
106046	1710	namely, copy	[namely, copies]	0.0	2	1	1	1
106047	1710	patient with ad	[Patients with AD]	0.0	3	1	1	1
106048	1710	control for the proteins.	[control for the proteins.]	0.0	4	1	1	1
106049	1710	hour at 42 degree	[hours at 42 degrees]	0.0	4	1	1	1
106050	1710	1.16 units, p	[1.16 units, P]	0.0	3	1	1	1
106051	1710	u-937 monocyte-like cell	[U-937 monocyte-like cells]	0.0	3	1	1	1
106052	1710	erythropoietin epo granulocyte/macrophage colony stimulate factor	[Erythropoietin Epo granulocyte/macrophage colony stimulating factor]	0.0	6	1	1	1
106053	1710	regions, BR3	[regions, BR3]	0.0	2	1	1	1
106054	1710	antiallergic, activity	[antiallergic, activities]	0.0	2	1	1	1
106055	1710	binding to plasma membrane of HML	[Binding to plasma membranes of HML]	0.0	6	1	1	1
106056	1710	subsequent glucocorticoid replacement	[subsequent glucocorticoid replacement]	0.0	3	1	1	1
106057	1710	two nuclear factor kB regulatory element	[two nuclear factor kB regulatory elements]	0.0	6	1	1	1
106058	1710	tcr signal function	[TCR signaling function]	0.0	3	1	1	1
106059	1710	5-day human macrophage	[5-day human macrophages]	0.0	3	1	1	1
106060	1710	three membrane protein lmp1	[three membrane proteins LMP1]	0.0	4	1	1	1
106061	1710	high extent	[higher extent]	0.0	2	1	1	1
106062	1710	search Ag for amphipatic protein segment	[searching Ag for amphipatic protein segments]	0.0	6	1	1	1
106063	1710	persistent hiv infection of U937 cell	[Persistent HIV infection of U937 cells]	0.0	6	1	1	1
106064	1710	helix-loop-helix regulation	[helix-loop-helix regulation]	0.0	2	1	1	1
106065	1710	mechanism underlie immunosenescence	[mechanisms underlying immunosenescence]	0.0	3	1	1	1
106066	1710	several line of transgenic mouse	[several lines of transgenic mice]	0.0	5	1	1	1
106067	1710	require a a	[requiring an A]	0.0	3	1	1	1
106068	1710	cDNA encode factor (nf)-il6	[cDNA encoding factor (NF)-IL6]	0.0	4	1	1	1
106069	1710	absence for day	[absence for days]	0.0	3	1	1	1
106070	1710	mutant TNFRI	[mutant TNFRI]	0.0	2	1	1	1
106071	1710	allergen-specific T cell in patient	[Allergen-specific T cells in patients]	0.0	5	1	1	1
106072	1710	sensitive transcription factor	[sensitive transcription factor]	0.0	3	1	1	1
106073	1710	autosomal form of inheritance	[autosomal form of inheritance]	0.0	4	1	1	1
106074	1710	such rev protein	[such Rev proteins]	0.0	3	1	1	1
106075	1710	state of nonresponsiveness	[state of nonresponsiveness]	0.0	3	1	1	1
106076	1710	mutation in site	[mutations in sites]	0.0	3	1	1	1
106077	1710	response through effect	[responses through effects]	0.0	3	1	1	1
106078	1710	alpha-dihydroxycholecalciferol	[alpha-dihydroxycholecalciferol]	0.0	1	1	1	1
106079	1710	cortisol response.	[cortisol response.]	0.0	2	1	1	1
106080	1710	NF-IL6 anti-c/ebpdelta	[NF-IL6 anti-C/EBPdelta]	0.0	2	1	1	1
106081	1710	low layer	[lower layers]	0.0	2	1	1	1
106082	1710	endothelial activation a direct antiatherogenic mechanism	[endothelial activation A direct antiatherogenic mechanism]	0.0	6	1	1	1
106083	1710	il-3 pro-B cell	[IL-3 pro-B cells]	0.0	3	1	1	1
106084	1710	important subunit,	[important subunit,]	0.0	2	1	1	1
106085	1710	expression of a viral gene ORF	[expression of a viral gene ORF]	0.0	6	1	1	1
106086	1710	distinct domain the domain	[distinct domains the domain]	0.0	4	1	1	1
106087	1710	optimal transcription involvement	[optimal transcription involvement]	0.0	3	1	1	1
106088	1710	indicate dependent on protein synthesis.	[indicating dependent on protein synthesis.]	0.0	5	1	1	1
106089	1710	certain region	[certain regions]	0.0	2	1	1	1
106090	1710	ctll-2 beta-casein	[CTLL-2 beta-casein]	0.0	2	1	1	1
106091	1710	glucocorticoid receptor constant in lymphocyte	[glucocorticoid receptors constant in lymphocytes]	0.0	5	1	1	1
106092	1710	allelic variant	[allelic variants]	0.0	2	1	1	1
106093	1710	promoter in cell of various species	[promoters in cells of various species]	0.0	6	1	1	1
106094	1710	HTLV-I T	[HTLV-I T]	0.0	2	1	1	1
106095	1710	even at dose high	[even at doses high]	0.0	4	1	1	1
106096	1710	factor in human macrophage	[factors in human macrophages]	0.0	4	1	1	1
106097	1710	simultaneously; (3) pbl	[simultaneously; (3) PBL]	0.0	3	1	1	1
106098	1710	interferon gamma stimulation	[interferon gamma stimulation]	0.0	3	1	1	1
106099	1710	hepatocyte factor-1 alpha hnf-1 alpha	[Hepatocyte factor-1 alpha HNF-1 alpha]	0.0	5	1	1	1
106100	1710	perhaps by regulation	[perhaps by regulation]	0.0	3	1	1	1
106101	1710	similar degree of inhibition	[similar degree of inhibition]	0.0	4	1	1	1
106102	1710	activator capable	[activator capable]	0.0	2	1	1	1
106103	1710	capability of T cell pre-treatment	[capabilities of T cells pre-treatment]	0.0	5	1	1	1
106104	1710	variation of glucocorticoid in healthy subject	[Variation of glucocorticoids in healthy subjects]	0.0	6	1	1	1
106105	1710	blot analysis on tissue	[blot analysis on tissues]	0.0	4	1	1	1
106106	1710	action on th2-specific cytokine	[actions on Th2-specific cytokines]	0.0	4	1	1	1
106107	1710	cell culture from 7	[cell cultures from 7]	0.0	4	1	1	1
106108	1710	endogenous ceramide release in apoptosis	[endogenous ceramide release in apoptosis]	0.0	5	1	1	1
106109	1710	half of the case	[half of the cases]	0.0	4	1	1	1
106110	1710	cross-linking of cell surface CD4	[cross-linking of cell surface CD4]	0.0	5	1	1	1
106111	1710	inhibition by forskolin	[inhibition by forskolin]	0.0	3	2	2	1
106112	1710	hiv-1 harbor mutation within C/EBP site	[HIV-1 harboring mutations within C/EBP sites]	0.0	6	1	1	1
106113	1710	allow translocation of the latter	[allowing translocation of the latter]	0.0	5	1	1	1
106114	1710	survival of pro-B lymphocyte	[survival of pro-B lymphocytes]	0.0	4	1	1	1
106115	1710	display reverse	[display reverse]	0.0	2	1	1	1
106116	1710	use a specific antibody	[using a specific antibody]	0.0	4	1	1	1
106117	1710	repressive effect on IL-2 expression	[repressive effect on IL-2 expression]	0.0	5	1	1	1
106118	1710	expression of immediate serum responsive gene	[expression of immediate serum responsive genes]	0.0	6	1	1	1
106119	1710	monoblastic leukemia cell line u937	[monoblastic leukemia cell line U937]	0.0	5	1	1	1
106120	1710	receptor affinity to glucocorticoid AIDS-C	[receptor affinity to glucocorticoids AIDS-C]	0.0	5	1	1	1
106121	1710	expression of receptor of differentiation	[expression of receptors of differentiation]	0.0	5	1	1	1
106122	1710	hypermutation act	[hypermutation acting]	0.0	2	1	1	1
106123	1710	acid on hematopoiesis	[acid on hematopoiesis]	0.0	3	1	1	1
106124	1710	kb of the upstream sequence	[kb of the upstream sequence]	0.0	5	1	1	1
106125	1710	time course in induction	[time course in induction]	0.0	4	1	1	1
106126	1710	regulation of immune gene	[regulation of immune genes]	0.0	4	1	1	1
106127	1710	effect on the sodium	[effects on the sodium]	0.0	4	1	1	1
106128	1710	phospholipase c 1	[phospholipase C 1]	0.0	3	1	1	1
106129	1710	immunosuppressive cytokine tgf-beta	[immunosuppressive cytokine TGF-beta]	0.0	3	1	1	1
106130	1710	step in the import process	[step in the import process]	0.0	5	1	1	1
106131	1710	points), body mass	[points), body mass]	0.0	3	1	1	1
106132	1710	Glucocorticoid receptor on leukocyte	[Glucocorticoid receptors on leukocytes]	0.0	4	2	2	1
106133	1710	cell to bacterial lipopolysaccharide lps	[cells to bacterial lipopolysaccharide LPS]	0.0	5	1	1	1
106134	1710	dominant form of binding partner,	[dominant form of binding partner,]	0.0	5	1	1	1
106135	1710	tnf-treated umbilical vein cell	[TNF-treated umbilical vein cells]	0.0	4	1	1	1
106136	1710	evidence for a effect	[evidence for an effect]	0.0	4	1	1	1
106137	1710	high concentration of antigen	[high concentration of antigen]	0.0	4	1	1	1
106138	1710	regulation of glucocorticoid receptor effect	[Regulation of glucocorticoid receptors effects]	0.0	5	1	1	1
106139	1710	g0/g1 state	[G0/G1 state]	0.0	2	2	2	1
106140	1710	immunosuppressant action	[immunosuppressant action]	0.0	2	1	1	1
106141	1710	binding of lipoprotein ox ldl	[binding of lipoprotein Ox LDL]	0.0	5	1	1	1
106142	1710	domain of the type	[domain of the type]	0.0	4	1	1	1
106143	1710	portion of the extracellular domain	[portion of the extracellular domain]	0.0	5	1	1	1
106144	1710	mrna of gata-binding protein	[mRNA of GATA-binding proteins]	0.0	4	1	1	1
106145	1710	as many as 27 child	[As many as 27 children]	0.0	5	1	1	1
106146	1710	Glucocorticoid inhibition	[Glucocorticoid inhibition]	0.0	2	1	1	1
106147	1710	FVA cell extract	[FVA cell extracts]	0.0	3	1	1	1
106148	1710	molecular genetic characterization	[Molecular genetic characterization]	0.0	3	1	1	1
106149	1710	patient with the disease cirrhosis	[patients with the disease cirrhosis]	0.0	5	1	1	1
106150	1710	phenotypic marker of subpopulation	[phenotypic marker of subpopulations]	0.0	4	1	1	1
106151	1710	direct the expression of immunoglobulin gene	[directing the expression of immunoglobulin genes]	0.0	6	1	1	1
106152	1710	tissue fibroblast	[tissue fibroblasts]	0.0	2	1	1	1
106153	1710	oral administration of 276 mumol cortisol	[Oral administration of 276 mumol cortisol]	0.0	6	1	1	1
106154	1710	Prostaglandin e2 induction	[Prostaglandin E2 induction]	0.0	3	1	1	1
106155	1710	steroid state in nwp	[steroid state in NWP]	0.0	4	1	1	1
106156	1710	master switch	[master switch]	0.0	2	1	1	1
106157	1710	sequence (start at 532, 710,	[sequences (starting at 532, 710,]	0.0	5	1	1	1
106158	1710	regulation of the I	[regulation of the I]	0.0	4	1	1	1
106159	1710	form of the protein.	[form of the protein.]	0.0	4	1	1	1
106160	1710	herpes virus	[herpes virus]	0.0	2	1	1	1
106161	1710	cotransfection with a mutant	[Cotransfection with a mutant]	0.0	4	1	1	1
106162	1710	interleukin-4 il-4 on cell	[interleukin-4 IL-4 on cells]	0.0	4	1	1	1
106163	1710	level of b	[levels of B]	0.0	3	1	1	1
106164	1710	downstream T enhancer element	[downstream T enhancer element]	0.0	4	1	1	1
106165	1710	failure,	[failure,]	0.0	1	1	1	1
106166	1710	relatedness with the reticulocyte-type 15-lipoxygenase	[relatedness with the reticulocyte-type 15-lipoxygenase]	0.0	5	1	1	1
106167	1710	40 late promoter	[40 late promoter]	0.0	3	1	1	1
106168	1710	inhibition with antibody	[Inhibition with antibodies]	0.0	3	1	1	1
106169	1710	t-cell leukemia virus type 1 htlv-1	[T-cell leukemia virus type 1 HTLV-1]	0.0	6	2	2	1
106170	1710	malignant lymphoma	[malignant lymphomas]	0.0	2	1	1	1
106171	1710	cell in response to granulocyte-macrophage	[cells in response to granulocyte-macrophage]	0.0	5	1	1	1
106172	1710	other T control region	[other T control regions]	0.0	4	1	1	1
106173	1710	expose vein endothelial cell huvec	[Exposing vein endothelial cells HUVECs]	0.0	5	1	1	1
106174	1710	growth factor HGF	[growth factor HGF]	0.0	3	1	1	1
106175	1710	G76 L128G	[G76 L128G]	0.0	2	1	1	1
106176	1710	underlie this activity	[underlying this activity]	0.0	3	1	1	1
106177	1710	characterization of a complex	[characterization of a complex]	0.0	4	1	1	1
106178	1710	one mechanism of transformation	[one mechanism of transformation]	0.0	4	1	1	1
106179	1710	42 degree for h	[42 degrees for h]	0.0	4	1	1	1
106180	1710	stromal	[stromal]	0.0	1	1	1	1
106181	1710	involvement of gsk-3beta	[involvement of GSK-3beta]	0.0	3	1	1	1
106182	1710	elicit stress	[eliciting stress]	0.0	2	1	1	1
106183	1710	hla peptide rakfkqllq	[HLA peptide RAKFKQLLQ]	0.0	3	1	1	1
106184	1710	bone protein-	[bone protein-]	0.0	2	1	1	1
106185	1710	lps uptake by monocyte	[LPS uptake by monocytes]	0.0	4	1	1	1
106186	1710	56-kDa protein	[56-kDa protein]	0.0	2	1	1	1
106187	1710	day with dimethylsulfoxide dmso	[days) with dimethylsulfoxide DMSO]	0.0	4	1	1	1
106188	1710	135eoh)2d3 receptor protein	[1,25(OH)2D3 receptor protein]	0.0	3	1	1	1
106189	1710	week after termination of treatment,	[weeks after termination of treatment,]	0.0	5	1	1	1
106190	1710	parental mpc11 cell	[parental MPC11 cells]	0.0	3	1	1	1
106191	1710	effect of Toremifene	[effect of Toremifene]	0.0	3	1	1	1
106192	1710	axis activation	[axis activation]	0.0	2	1	1	1
106193	1710	DNA bend	[DNA bend]	0.0	2	1	1	1
106194	1710	anti-viral capsid antigen vca	[anti-viral capsid antigen VCA]	0.0	4	1	1	1
106195	1710	human DNA clone contain the region	[human DNA clones containing the region]	0.0	6	1	1	1
106196	1710	beta myh11	[beta MYH11]	0.0	2	1	1	1
106197	1710	distinct property	[distinct properties]	0.0	2	1	1	1
106198	1710	nuclear nf-kappab (level	[nuclear NF-kappaB (levels]	0.0	3	1	1	1
106199	1710	2 hours.	[2 hours.]	0.0	2	1	1	1
106200	1710	primary lymphocyte model	[primary lymphocyte models]	0.0	3	1	1	1
106201	1710	molecular mechanism of differentiation	[molecular mechanisms of differentiation]	0.0	4	1	1	1
106202	1710	certain hemopoietic growth factor	[certain hemopoietic growth factors]	0.0	4	1	1	1
106203	1710	(66 millileter at P;	[(66 ml at h;]	0.0	4	1	1	1
106204	1710	growth of blast cell	[growth of blast cells]	0.0	4	2	2	1
106205	1710	vitamin World primate cell	[vitamin World primate cells]	0.0	4	1	1	1
106206	1710	hla-dr11 restrict	[HLA-DR11 restricting]	0.0	2	1	1	1
106207	1710	change of binding	[changes of binding]	0.0	3	1	1	1
106208	1710	class RB -defective tumor line	[class RB -defective tumor lines]	0.0	5	1	1	1
106209	1710	VDR /rxr binding	[VDR /RXR binding]	0.0	3	1	1	1
106210	1710	development of a system	[development of an system]	0.0	4	1	1	1
106211	1710	IL-8 family interferon-gamma	[IL-8 family interferon-gamma]	0.0	3	1	1	1
106212	1710	principal inhibitor of nf-kappab	[principal inhibitor of NF-kappaB]	0.0	4	1	1	1
106213	1710	autoregulation in cell	[autoregulation in cells]	0.0	3	1	1	1
106214	1710	htlv-i-negative t-cell line	[HTLV-I-negative T-cell lines]	0.0	3	1	1	1
106215	1710	activation of NF-kappa b by stimulus	[Activation of NF-kappa B by stimuli]	0.0	6	1	1	1
106216	1710	MHC class antigen processing	[MHC class antigen processing]	0.0	4	1	1	1
106217	1710	inhibition by overexpression	[Inhibition by overexpression]	0.0	3	1	1	1
106218	1710	cell express e2a-hlf	[cells expressing E2A-HLF]	0.0	3	1	1	1
106219	1710	lps-stimulated tnf production	[LPS-stimulated TNF production]	0.0	3	1	1	1
106220	1710	human MHC class ii gene transcription	[Human MHC class II gene transcription]	0.0	6	1	1	1
106221	1710	congenital absence	[congenital absence]	0.0	2	1	1	1
106222	1710	include hydroxyanisole bha tetrahydropapaveroline	[including hydroxyanisole BHA tetrahydropapaveroline]	0.0	4	1	1	1
106223	1710	target of vector to the progeny	[targeting of vectors to the progeny]	0.0	6	1	1	1
106224	1710	c-Jun expression in plasma cell	[c-Jun expression in plasma cells]	0.0	5	1	1	1
106225	1710	include immunodeficiency virus hiv gene	[including immunodeficiency virus HIV genes]	0.0	5	1	1	1
106226	1710	immunodeficiency virus type-2 gene expression enhancer	[immunodeficiency virus type-2 gene expression enhancers]	0.0	6	1	1	1
106227	1710	stabilize one	[stabilizing one]	0.0	2	1	1	1
106228	1710	class t-cell line	[class T-cell lines]	0.0	3	1	1	1
106229	1710	mouse l929 cells,	[mouse L929 cells,]	0.0	3	1	1	1
106230	1710	DLCL the form of NHL	[DLCL the form of NHL]	0.0	5	1	1	1
106231	1710	abnormally plasma cysteine level	[abnormally plasma cysteine levels]	0.0	4	1	1	1
106232	1710	NF-kappa b gene expression	[NF-kappa B gene expression]	0.0	4	2	2	1
106233	1710	localize to hsv lesion	[localizing to HSV lesions]	0.0	4	1	1	1
106234	1710	uninduced myelomonocytic cell line	[uninduced myelomonocytic cell lines]	0.0	4	1	1	1
106235	1710	mc903	[MC903]	0.0	1	1	1	1
106236	1710	inhibition replication in vitro	[Inhibition replication in vitro]	0.0	4	1	1	1
106237	1710	interleukin-3 colony-stimumulatelany-stg factor	[interleukin-3 colony-stimulating factor]	0.0	3	1	1	1
106238	1710	differentiation of primary cd34+ progenitor cell	[differentiation of primary CD34+ progenitor cells]	0.0	6	1	1	1
106239	1710	have a region	[having a region]	0.0	3	1	1	1
106240	1710	blood to the phenotype	[blood to the phenotype]	0.0	4	1	1	1
106241	1710	RA -resistant subclone	[RA -resistant subclone]	0.0	3	1	1	1
106242	1710	expression of p16	[expression of p16]	0.0	3	1	1	1
106243	1710	only a amount of p65	[only a amount of P65]	0.0	5	2	2	1
106244	1710	serine residue Ser5	[serine residue Ser5]	0.0	3	1	1	1
106245	1710	interleukin-6 expression in monocyte	[interleukin-6 expression in monocytes]	0.0	4	1	1	1
106246	1710	amount of cbp	[amounts of CBP]	0.0	3	1	1	1
106247	1710	activation by beta-phorbol 13-acetate	[activation by beta-phorbol 13-acetate]	0.0	4	1	1	1
106248	1710	SLP-76 two cell molecule	[SLP-76 two cell molecules]	0.0	4	1	1	1
106249	1710	thiobarbituric substance	[thiobarbituric substances]	0.0	2	1	1	1
106250	1710	maintenance of transformation.	[maintenance of transformation.]	0.0	3	1	1	1
106251	1710	region of mouse Chr	[region of mouse Chr]	0.0	4	1	1	1
106252	1710	activity of interleukin-10 stat molecule	[activity of interleukin-10 STAT molecules]	0.0	5	1	1	1
106253	1710	packaging of particles, integration	[Packaging of particles, integration]	0.0	4	1	1	1
106254	1710	prominent defect	[prominent defects]	0.0	2	1	1	1
106255	1710	lymphocyte syndrome BLS	[lymphocyte syndrome BLS]	0.0	3	1	1	1
106256	1710	peptide-pulsed cell line	[peptide-pulsed cell lines]	0.0	3	1	1	1
106257	1710	significance in carcinogenesis	[significance in carcinogenesis]	0.0	3	1	1	1
106258	1710	protein stat6	[protein Stat6]	0.0	2	1	1	1
106259	1710	inductive signal for AP-1	[inductive signal for AP-1]	0.0	4	1	1	1
106260	1710	complex with nf-kappa b	[complexes with NF-kappa B]	0.0	4	1	1	1
106261	1710	area responsive	[area responsive]	0.0	2	1	1	1
106262	1710	important role for tnf-alpha secretion	[important role for TNF-alpha secretion]	0.0	5	1	1	1
106263	1710	characteristic among factor	[characteristic among factors]	0.0	3	1	1	1
106264	1710	transcriptional effect on IL-2 expression	[transcriptional effect on IL-2 expression]	0.0	5	1	1	1
106265	1710	degradation in T cell a role	[degradation in T cells A role]	0.0	6	1	1	1
106266	1710	compounds' anti-inflammatory potency	[compounds' anti-inflammatory potency]	0.0	3	1	1	1
106267	1710	LMP-1 effect	[LMP-1 effects]	0.0	2	1	1	1
106268	1710	growth factor beta1	[growth factor beta1]	0.0	3	1	1	1
106269	1710	cell than asthmatics	[cells than asthmatics]	0.0	3	1	1	1
106270	1710	other antioxidant --including acid	[other antioxidants --including acid]	0.0	4	1	1	1
106271	1710	multinucleated giant cell from monocyte	[multinucleated giant cells from monocytes]	0.0	5	1	1	1
106272	1710	eicosanoid synthesis	[eicosanoid synthesis]	0.0	2	1	1	1
106273	1710	human adult hematopoiesis	[human adult hematopoiesis]	0.0	3	1	1	1
106274	1710	role negatively regulate e2f	[role negatively regulating E2F]	0.0	4	1	1	1
106275	1710	-inducible ifn-gamma transcription	[-inducible IFN-gamma transcription]	0.0	3	1	1	1
106276	1710	bind activity of nf-kb	[binding activity of NF-kB]	0.0	4	1	1	1
106277	1710	intracellular tyrosine phosphatase	[intracellular tyrosine phosphatase]	0.0	3	1	1	1
106278	1710	expression of the beta-galactoside-binding lectin	[expression of the beta-galactoside-binding lectin]	0.0	5	1	1	1
106279	1710	correlate with ability	[correlating with ability]	0.0	3	1	1	1
106280	1710	phosphoprotein effect	[phosphoproteins effects]	0.0	2	1	1	1
106281	1710	generate high level	[generating high levels]	0.0	3	1	1	1
106282	1710	partial monosomy of loci	[partial monosomy of loci]	0.0	4	1	1	1
106283	1710	human myeloma cell line	[human myeloma cell lines]	0.0	4	3	3	1
106284	1710	Addition during the 4 h	[Addition during the 4 h]	0.0	5	1	1	1
106285	1710	e2f DNA binding	[E2F DNA binding]	0.0	3	1	1	1
106286	1710	nine binding site for a factor	[nine binding sites for a factor]	0.0	6	1	1	1
106287	1710	contain oligonucleotide probe	[containing oligonucleotide probes]	0.0	3	1	1	1
106288	1710	marker as Ki-67 staining grade).	[markers as Ki-67 staining grade).]	0.0	5	1	1	1
106289	1710	significant thiol decrease,	[significant thiol decrease,]	0.0	3	1	1	1
106290	1710	T cell NF-MATp35	[T cells NF-MATp35]	0.0	3	1	1	1
106291	1710	NF-kappaB a key transcriptional regulator	[NF-kappaB a key transcriptional regulator]	0.0	5	1	1	1
106292	1710	recognition by T lymphocyte CTL	[recognition by T lymphocytes CTL]	0.0	5	1	1	1
106293	1710	tcr locus	[TCR locus]	0.0	2	1	1	1
106294	1710	exact cellular mechanism	[exact cellular mechanisms]	0.0	3	1	1	1
106295	1710	clone of herpesvirus-6	[clones of herpesvirus-6]	0.0	3	1	1	1
106296	1710	Ca2+/calmodulin-regulated,	[Ca2+/calmodulin-regulated,]	0.0	1	1	1	1
106297	1710	splicing mechanism	[splicing mechanism]	0.0	2	2	2	1
106298	1710	distinct family retinoic acid receptor	[distinct families retinoic acid receptors]	0.0	5	1	1	1
106299	1710	kappa activity a preliminary report.	[kappa activity a preliminary report.]	0.0	5	1	1	1
106300	1710	reciprocal product	[reciprocal products]	0.0	2	1	1	1
106301	1710	ifn-alpha-activated protein	[IFN-alpha-activated proteins]	0.0	2	1	1	1
106302	1710	DNA region specify high affinity	[DNA region specifying high affinity]	0.0	5	1	1	1
106303	1710	join BSLF2	[joining BSLF2]	0.0	2	1	1	1
106304	1710	association with drug-induced toxicity	[association with drug-induced toxicity]	0.0	4	1	1	1
106305	1710	throughput screen of microbial broth	[throughput screening of microbial broths]	0.0	5	1	1	1
106306	1710	regulator of myeloid differentiation	[regulator of myeloid differentiation]	0.0	4	1	1	1
106307	1710	effect inhibition of growth depletion	[effects inhibition of growth depletion]	0.0	5	1	1	1
106308	1710	two form of proteins, aml1a	[two forms of proteins, AML1a]	0.0	5	1	1	1
106309	1710	1 (egr-1)	[1 (EGR-1)]	0.0	2	1	1	1
106310	1710	focus understand th1/th2 development	[focus understanding Th1/Th2 development]	0.0	4	1	1	1
106311	1710	central regulator of differentiation	[central regulator of differentiation]	0.0	4	1	1	1
106312	1710	antigen to T cell line	[antigen to T cell lines]	0.0	5	1	1	1
106313	1710	enzyme luciferase	[enzyme luciferase]	0.0	2	1	1	1
106314	1710	mouse leukemia	[mouse leukemia]	0.0	2	1	1	1
106315	1710	enhancer-blocking element	[enhancer-blocking element]	0.0	2	1	1	1
106316	1710	ifngr1 small deletion hotspot	[IFNGR1 small deletion hotspot]	0.0	4	1	1	1
106317	1710	induction of taxi jurkat	[Induction of TaxI Jurkat]	0.0	4	1	1	1
106318	1710	sensitivity for detection of antibody	[sensitivity for detection of antibodies]	0.0	5	1	1	1
106319	1710	pou-specific domain POUs	[POU-specific domain POUs]	0.0	3	1	1	1
106320	1710	thus provide a basis	[thus providing a basis]	0.0	4	1	1	1
106321	1710	mediate shear- cytokine-induced ec-mn adhesion	[mediating shear- cytokine-induced EC-Mn adhesion]	0.0	5	1	1	1
106322	1710	effect through tnf-alpha release	[effect through TNF-alpha release]	0.0	4	1	1	1
106323	1710	aldosterone receptor mechanism at the level	[aldosterone receptors mechanism at the level]	0.0	6	1	1	1
106324	1710	site NF kappa	[site NF kappa]	0.0	3	1	1	1
106325	1710	human soluble tnf receptor rhu tnfr:fc	[human soluble TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
106326	1710	other b cell membrane protein	[other B cell membrane proteins]	0.0	5	1	1	1
106327	1710	impaired activation of factor ap-1	[impaired activation of factors AP-1]	0.0	5	1	1	1
106328	1710	cell gssg	[cell GSSG]	0.0	2	1	1	1
106329	1710	pentadecamer peptide	[pentadecamer peptides]	0.0	2	1	1	1
106330	1710	helper-inducer (memory) T cell	[helper-inducer (memory) T cells]	0.0	4	1	1	1
106331	1710	(from hour of the membrane-bound enzyme	[(from hours of the membrane-bound enzyme]	0.0	6	1	1	1
106332	1710	class alphabeta dimer	[class alphabeta dimers]	0.0	3	1	1	1
106333	1710	mrna half-life	[mRNA half-life]	0.0	2	1	1	1
106334	1710	part, by the induction	[part, by the induction]	0.0	4	1	1	1
106335	1710	activator function	[activator functions]	0.0	2	1	1	1
106336	1710	beta-phorbol	[beta-phorbol]	0.0	1	2	2	1
106337	1710	vitro tcr stimulation	[vitro TCR stimulation]	0.0	3	1	1	1
106338	1710	activate protein-1 tpa responsive element TRE	[Activating protein-1 TPA responsive elements TRE]	0.0	6	1	1	1
106339	1710	thf with low the/thf	[THF with low THE/THF]	0.0	4	1	1	1
106340	1710	level in all population	[levels in all populations]	0.0	4	1	1	1
106341	1710	two novel inhibitor of NFAT transcription	[two novel inhibitors of NFAT transcription]	0.0	6	1	1	1
106342	1710	center reaction,	[center reaction,]	0.0	2	1	1	1
106343	1710	anthropometric,	[anthropometric,]	0.0	1	1	1	1
106344	1710	inhibition of migration	[inhibition of migration]	0.0	3	1	1	1
106345	1710	beta subunit of Pebp2	[beta subunit of Pebp2]	0.0	4	1	1	1
106346	1710	transgene reduction	[transgene reduction]	0.0	2	1	1	1
106347	1710	patient than in person	[patients than in persons]	0.0	4	1	1	1
106348	1710	thp-1-hgh	[THP-1-hGH]	0.0	1	1	1	1
106349	1710	contrast to the effect	[contrast to the effect]	0.0	4	1	1	1
106350	1710	therapy in peripheral mononuclear leukocyte	[therapy in peripheral mononuclear leukocytes]	0.0	5	1	1	1
106351	1710	fkbp mrna	[FKBP mRNA]	0.0	2	1	1	1
106352	1710	growth of this cells.	[growth of these cells.]	0.0	4	1	1	1
106353	1710	objective: activation	[OBJECTIVE: Activation]	0.0	2	1	1	1
106354	1710	volume,	[volume,]	0.0	1	1	1	1
106355	1710	tsh receptor cDNA probe	[TSH receptor cDNA probe]	0.0	4	1	1	1
106356	1710	activity of analogue of dihydroxyvitamin D3	[activities of analogues of dihydroxyvitamin D3]	0.0	6	1	1	1
106357	1710	late G1 phase	[late G1 phases]	0.0	3	1	1	1
106358	1710	gene product from other virus htlv-1	[gene products from other viruses HTLV-1]	0.0	6	1	1	1
106359	1710	prolonged strain	[prolonged strain]	0.0	2	1	1	1
106360	1710	x chromosome inactivation	[X chromosome inactivation]	0.0	3	2	2	1
106361	1710	bone marrow cell of patient	[bone marrow cells of patients]	0.0	5	1	1	1
106362	1710	buthionine sulfoximine bso (an inhibitor	[buthionine sulfoximine BSO (an inhibitor]	0.0	5	1	1	1
106363	1710	common element in the promoter	[common element in the promoter]	0.0	5	1	1	1
106364	1710	relatively little nfat activity	[relatively little NFAT activity]	0.0	4	1	1	1
106365	1710	gene product from other virus	[gene products from other viruses]	0.0	5	1	1	1
106366	1710	expression of aml1/mds1/evi1 block differentiation	[expression of AML1/MDS1/EVI1 blocks differentiation]	0.0	5	1	1	1
106367	1710	predominantly in cell	[predominantly in cells]	0.0	3	1	1	1
106368	1710	ratio of pebp2 isoform	[ratio of PEBP2 isoforms]	0.0	4	1	1	1
106369	1710	clearly illustrate a target.	[clearly illustrating a target.]	0.0	4	1	1	1
106370	1710	distinct heteromeric complex with other protein	[distinct heteromeric complexes with other proteins]	0.0	6	1	1	1
106371	1710	effect of as2o3	[effects of As2O3]	0.0	3	1	1	1
106372	1710	thyroglobulin tg	[thyroglobulin TG]	0.0	2	1	1	1
106373	1710	related domain protein pax-1	[related domain protein Pax-1]	0.0	4	1	1	1
106374	1710	incubation from individual for day	[incubation from individuals for days,]	0.0	5	1	1	1
106375	1710	giant cell	[giant cells]	0.0	2	1	1	1
106376	1710	new insight into the slow rate	[new insights into the slow rate]	0.0	6	1	1	1
106377	1710	specificity for c-maf	[specificity for c-Maf]	0.0	3	1	1	1
106378	1710	Schreiber	[Schreiber]	0.0	1	1	1	1
106379	1710	analysis of the property	[Analysis of the properties]	0.0	4	1	1	1
106380	1710	c-fo in T lymphoid	[c-Fos in T lymphoid]	0.0	4	1	1	1
106381	1710	cell with pyrrolidine dithiocarbamate	[cells with pyrrolidine dithiocarbamate]	0.0	4	1	1	1
106382	1710	20- to 50-fold affinity	[20- to 50-fold affinity]	0.0	4	1	1	1
106383	1710	mutation in the repeat LTR	[mutations in the repeat LTR]	0.0	5	1	1	1
106384	1710	Syk protein	[Syk proteins]	0.0	2	1	1	1
106385	1710	mechanism of anoxia/reoxygenation-induced adherence	[mechanisms of anoxia/reoxygenation-induced adherence]	0.0	4	1	1	1
106386	1710	acid-response element	[acid-response element]	0.0	2	1	1	1
106387	1710	summary, receptor determination in patient	[summary, receptor determination in patients]	0.0	5	1	1	1
106388	1710	steroid receptors,	[steroid receptors,]	0.0	2	1	1	1
106389	1710	expiratory volume fev1	[expiratory volume FEV1]	0.0	3	1	1	1
106390	1710	novel mechanism control E2F activity	[novel mechanism controlling E2F activity]	0.0	5	1	1	1
106391	1710	quantification during differentiation of human cell	[quantification during differentiation of human cells]	0.0	6	1	1	1
106392	1710	pleiotropic effect include change	[pleiotropic effects including changes]	0.0	4	1	1	1
106393	1710	modulate the expression of cytokine	[modulating the expression of cytokines]	0.0	5	1	1	1
106394	1710	oestrogen receptor analysis	[Oestrogen receptor analysis]	0.0	3	1	1	1
106395	1710	catalytically similar proteins, cyclophilin	[catalytically similar proteins, cyclophilin]	0.0	4	1	1	1
106396	1710	mol/L) in combination with RA	[mol/L) in combination with RA]	0.0	5	1	1	1
106397	1710	transfection of u937 cell with sense	[transfection of U937 cells with sense]	0.0	6	1	1	1
106398	1710	pmol/L (p	[pmol/L (P]	0.0	2	1	1	1
106399	1710	breast tumor lymphocyte of peptide corresponding	[breast tumor lymphocytes of peptides corresponding]	0.0	6	1	1	1
106400	1710	antioxidant activate pathway	[antioxidant activating pathway]	0.0	3	1	1	1
106401	1710	addition of ref-1	[addition of REF-1]	0.0	3	1	1	1
106402	1710	functional cooperation between p50b	[functional cooperation between p50B]	0.0	4	1	1	1
106403	1710	high efficacy in child	[high efficacy in children]	0.0	4	1	1	1
106404	1710	cytokine in macrophage	[cytokines in macrophages]	0.0	3	1	1	1
106405	1710	nonlymphoid tissue	[nonlymphoid tissues]	0.0	2	1	1	1
106406	1710	l243	[L243]	0.0	1	1	1	1
106407	1710	peak thrombin	[peak thrombin]	0.0	2	1	1	1
106408	1710	il-1 signal lead	[IL-1 signaling leading]	0.0	3	1	1	1
106409	1710	change in ebv latency	[changes in EBV latency]	0.0	4	1	1	1
106410	1710	domain of transcription factor	[domains of transcription factors]	0.0	4	1	1	1
106411	1710	long terminal repeat in macrophages/ monocyte	[long terminal repeat in macrophages/ monocytes]	0.0	6	1	1	1
106412	1710	factor binding to the interleukin-4 element	[factor binding to the interleukin-4 element]	0.0	6	1	1	1
106413	1710	significant correlation between plasma cortisol	[significant correlation between plasma cortisol]	0.0	5	1	1	1
106414	1710	result in the selective lysis	[resulting in the selective lysis]	0.0	5	1	1	1
106415	1710	carboxy-terminal regulatory domain	[carboxy-terminal regulatory domain]	0.0	3	1	1	1
106416	1710	epithelial stat1	[epithelial Stat1]	0.0	2	1	1	1
106417	1710	56-kDa protein of abundance	[56-kDa protein of abundance]	0.0	4	1	1	1
106418	1710	significant insight into the interaction	[significant insights into the interactions]	0.0	5	1	1	1
106419	1710	two signal cascade in T lymphocyte	[two signal cascades in T lymphocytes]	0.0	6	1	1	1
106420	1710	classical thyroid hormone response element	[classical thyroid hormone response element]	0.0	5	1	1	1
106421	1710	reduction, underline a proliferation reduction mechanism	[reduction, underlining a proliferation reduction mechanism]	0.0	6	1	1	1
106422	1710	receptor concentration before therapy in leukocyte	[receptor concentrations before therapy in leukocytes]	0.0	6	1	1	1
106423	1710	detection system	[detection system]	0.0	2	1	1	1
106424	1710	follow neutrophil stimulation with agonist	[Following neutrophil stimulation with agonists]	0.0	5	1	1	1
106425	1710	drug resistant marker Neo(r)	[drug resistant marker Neo(r)]	0.0	4	1	1	1
106426	1710	sodium deoxycholate	[sodium deoxycholate]	0.0	2	1	1	1
106427	1710	disorders: xeroderma pigmentosum	[disorders: xeroderma pigmentosum]	0.0	3	1	1	1
106428	1710	healthy T cell	[healthy T cells]	0.0	3	1	1	1
106429	1710	patient with allergic rhinitis	[patients with allergic rhinitis]	0.0	4	1	1	1
106430	1710	most black	[most blacks]	0.0	2	1	1	1
106431	1710	(endothelial) accessory cells,	[(endothelial) accessory cells,]	0.0	3	1	1	1
106432	1710	activity of NF-kappaB	[activity of NF-kappaB]	0.0	3	1	1	1
106433	1710	Slight difference with difference	[Slight differences with differences]	0.0	4	1	1	1
106434	1710	brca1 change	[BRCA1 change]	0.0	2	1	1	1
106435	1710	hsf3 dna-binding activity	[HSF3 DNA-binding activity]	0.0	3	2	2	1
106436	1710	mediate cell survival	[mediating cell survival]	0.0	3	1	1	1
106437	1710	nonleukemogenic virus	[nonleukemogenic virus]	0.0	2	1	1	1
106438	1710	bind to site b	[binding to site B]	0.0	4	1	1	1
106439	1710	severe 5-fluorouracil toxicity secondary	[Severe 5-fluorouracil toxicity secondary]	0.0	4	1	1	1
106440	1710	nonpeptidyl molecule capable	[nonpeptidyl molecule capable]	0.0	3	1	1	1
106441	1710	nf-kappa b species in cell	[NF-kappa B species in cells]	0.0	5	1	1	1
106442	1710	select gene	[select genes]	0.0	2	1	1	1
106443	1710	physical exercise to maximal	[physical exercise to maximal]	0.0	4	1	1	1
106444	1710	unfractionated blood mononuclear cell	[unfractionated blood mononuclear cells]	0.0	4	1	1	1
106445	1710	cell in the presence	[cells in the presence]	0.0	4	1	1	1
106446	1710	bind to site C	[binding to site C]	0.0	4	1	1	1
106447	1710	encompass a element NF-AT-1	[encompassing an element NF-AT-1]	0.0	4	1	1	1
106448	1710	subject (bind capacity	[subjects (binding capacity]	0.0	3	1	1	1
106449	1710	suggest a link between pathway	[suggesting a link between pathways]	0.0	5	1	1	1
106450	1710	Pd-C	[Pd-C]	0.0	1	1	1	1
106451	1710	15% calf serum fcs	[15% calf serum FCS]	0.0	4	1	1	1
106452	1710	retain promoter activity in erythroleukemia cell	[retaining promoter activity in erythroleukemia cells]	0.0	6	1	1	1
106453	1710	Specific calcitropic effect	[Specific calcitropic effect]	0.0	3	1	1	1
106454	1710	(ref. 1)	[(ref. 1)]	0.0	2	1	1	1
106455	1710	counteract regulatory DNA sequence	[counteracting regulatory DNA sequences]	0.0	4	1	1	1
106456	1710	IFN-alpha responsiveness chronic leukemia	[IFN-alpha responsiveness chronic leukemia]	0.0	4	1	1	1
106457	1710	nonspecific reactive follicular hyperplasia	[nonspecific reactive follicular hyperplasia]	0.0	4	1	1	1
106458	1710	pivotal role transduce signal	[pivotal role transducing signals]	0.0	4	1	1	1
106459	1710	pathologic condition	[pathologic conditions]	0.0	2	1	1	1
106460	1710	n-terminal motif	[N-terminal motif]	0.0	2	1	1	1
106461	1710	receptor regulation	[receptor regulation]	0.0	2	1	1	1
106462	1710	anti-cd3 T cell	[anti-CD3 T cells]	0.0	3	1	1	1
106463	1710	PPARgamma activation in phagocyte	[PPARgamma activation in phagocytes]	0.0	4	1	1	1
106464	1710	bind site for Sp1	[binding site for Sp1]	0.0	4	1	1	1
106465	1710	molecular mass of 84 kda	[molecular mass of 84 kDa]	0.0	5	1	1	1
106466	1710	atra growth inhibition	[ATRA growth inhibition]	0.0	3	1	1	1
106467	1710	two positive regulatory region	[two positive regulatory regions]	0.0	4	1	1	1
106468	1710	and/or leukocyte adhesion molecule	[and/or leukocyte adhesion molecules]	0.0	4	1	1	1
106469	1710	specific gene (E box) sequence	[specific gene (E box) sequences]	0.0	5	1	1	1
106470	1710	requirement in this system.	[requirement in this system.]	0.0	4	1	1	1
106471	1710	Cepsilon gene	[Cepsilon gene]	0.0	2	1	1	1
106472	1710	level in all mature population	[levels in all mature populations]	0.0	5	1	1	1
106473	1710	binding to -rich region	[binding to -rich regions]	0.0	4	1	1	1
106474	1710	25- to 30-fold increase	[25- to 30-fold increase]	0.0	4	1	1	1
106475	1710	erythropoietin induction of hemoglobin synthesis	[Erythropoietin induction of hemoglobin synthesis]	0.0	5	1	1	1
106476	1710	nondivide macrophage	[Nondividing macrophages]	0.0	2	1	1	1
106477	1710	syk kinases-interact	[Syk kinases-interacting]	0.0	2	1	1	1
106478	1710	treatment with all-tran retinoic acid	[treatment with all-trans retinoic acid]	0.0	5	1	1	1
106479	1710	interaction of PML	[interaction of PML]	0.0	3	1	1	1
106480	1710	(th2) cell	[(Th2) cells]	0.0	2	2	2	1
106481	1710	considerable biologic,	[considerable biologic,]	0.0	2	1	1	1
106482	1710	IFN regulate factor-1 gene expression	[IFN regulating factor-1 gene expression]	0.0	5	1	1	1
106483	1710	immunohistological staining	[immunohistological staining]	0.0	2	1	1	1
106484	1710	8, histiocytoma rhabdomyosarcoma leiomyosarcoma	[8, histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	4	1	1	1
106485	1710	gene network	[gene networks]	0.0	2	1	1	1
106486	1710	(gammac)	[(gammac)]	0.0	1	1	1	1
106487	1710	destabilization	[destabilization]	0.0	1	1	1	1
106488	1710	level of c-jun gene transcription	[levels of c-jun gene transcription]	0.0	5	1	1	1
106489	1710	approximately the transactivation ability	[approximately the transactivation ability]	0.0	4	1	1	1
106490	1710	segregate the human Chr	[segregating the human Chr]	0.0	4	1	1	1
106491	1710	affect the NF-kappa b element	[affecting the NF-kappa B element]	0.0	5	1	1	1
106492	1710	effect on cytokine synthesis	[effect on cytokine synthesis]	0.0	4	1	1	1
106493	1710	ten blood lymphocyte sample	[ten blood lymphocyte samples]	0.0	4	1	1	1
106494	1710	t- acute chronic leukemia arise	[T- acute chronic leukemias arising]	0.0	5	1	1	1
106495	1710	generation of molecule in the process	[generation of molecule in the process]	0.0	6	1	1	1
106496	1710	only g/g of mrna in lymphocyte	[only g/g of mRNA in lymphocytes]	0.0	6	1	1	1
106497	1710	receptor isoform in lymphocyte	[receptor isoforms in lymphocytes]	0.0	4	1	1	1
106498	1710	bear on this transformation	[bearing on this transformation]	0.0	4	1	1	1
106499	1710	uncouple of tyrosine kinase	[Uncoupling of tyrosine kinases]	0.0	4	1	1	1
106500	1710	functional role of factor-DNA complex	[functional role of factor-DNA complexes]	0.0	5	1	1	1
106501	1710	clinical glucocorticoid resistance in asthma	[clinical glucocorticoid resistance in asthma]	0.0	5	1	1	1
106502	1710	subset-restricted expression	[subset-restricted expression]	0.0	2	1	1	1
106503	1710	two element (igh) enhancer	[two elements (IgH) enhancer]	0.0	4	1	1	1
106504	1710	land globular, structure morphologically distinct	[LANDs globular, structures morphologically distinct]	0.0	5	1	1	1
106505	1710	new strategy for the detection	[new strategies for the detection]	0.0	5	1	1	1
106506	1710	2.0 nm less than 0.01).	[2.0 nM less than 0.01).]	0.0	5	1	1	1
106507	1710	enf)-kappa b binding activity	[(NF)-kappa B binding activities]	0.0	4	1	1	1
106508	1710	group of athlete	[group of athletes]	0.0	3	1	1	1
106509	1710	directly interact transcription factor	[directly interacting transcription factors]	0.0	4	1	1	1
106510	1710	regulation by DNA sequence motif	[regulation by DNA sequence motifs]	0.0	5	1	1	1
106511	1710	intrinsic transcriptional activation motif	[intrinsic transcriptional activation motifs]	0.0	4	1	1	1
106512	1710	suggest a role process.	[suggesting a role process.]	0.0	4	1	1	1
106513	1710	great amount of the kb transcript	[greater amounts of the kb transcript]	0.0	6	1	1	1
106514	1710	cd4+cd45ro+ T	[CD4+CD45RO+ T]	0.0	2	1	1	1
106515	1710	expression of genes, in particular	[expression of genes, in particular]	0.0	5	1	1	1
106516	1710	ig class	[Ig class]	0.0	2	1	1	1
106517	1710	microm cadmium chloride	[microM cadmium chloride]	0.0	3	1	1	1
106518	1710	morphological differentiation in cell	[morphological differentiation in cells]	0.0	4	1	1	1
106519	1710	participate to beta-globin switch	[participating to beta-globin switch]	0.0	4	1	1	1
106520	1710	use binding peptide	[using binding peptides]	0.0	3	1	1	1
106521	1710	synthetic E6 motif	[synthetic E6 motif]	0.0	3	1	1	1
106522	1710	region of the CD11b promoter	[region of the CD11b promoter]	0.0	5	1	1	1
106523	1710	high number of gcrbeta cell	[higher number of GCRbeta cells]	0.0	5	1	1	1
106524	1710	non-hodgkin' lymphoma arnhl	[non-Hodgkin's lymphoma ARNHL]	0.0	3	1	1	1
106525	1710	late promoter erratum	[late promoter erratum]	0.0	3	1	1	1
106526	1710	understanding of the action	[understanding of the action]	0.0	4	1	1	1
106527	1710	difference in nucleic acid sequence	[differences in nucleic acid sequence]	0.0	5	1	1	1
106528	1710	c-erbA activation	[c-erbA activation]	0.0	2	1	1	1
106529	1710	caspase-3 -like cpp32/yama/apopain	[caspase-3 -like CPP32/Yama/apopain]	0.0	3	1	1	1
106530	1710	differentiation of hemopoietic progenitor to cell	[differentiation of hemopoietic progenitors to cells]	0.0	6	1	1	1
106531	1710	CR individual	[CR individuals]	0.0	2	1	1	1
106532	1710	common property	[common property]	0.0	2	1	1	1
106533	1710	protein interaction necessary	[protein interactions necessary]	0.0	3	1	1	1
106534	1710	follow viral binding to monocyte	[following viral binding to monocytes]	0.0	5	1	1	1
106535	1710	m-csf expression by M-CSF	[M-CSF expression by M-CSF]	0.0	4	1	1	1
106536	1710	enhancer contain the mua	[enhancer containing the muA]	0.0	4	1	1	1
106537	1710	phenotypic study of leukocyte in endometrium	[Phenotypic studies of leukocytes in endometrium]	0.0	6	1	1	1
106538	1710	T substitution at nucleotide	[T substitution at nucleotide]	0.0	4	1	1	1
106539	1710	pebp2 isoform regulate the level	[PEBP2 isoforms regulating the levels]	0.0	5	1	1	1
106540	1710	b cell centroblast	[B cells centroblasts]	0.0	3	1	1	1
106541	1710	elevation of gamma-globin expression	[elevation of gamma-globin expression]	0.0	4	1	1	1
106542	1710	evidence for involvement in transcription	[evidence for involvement in transcription]	0.0	5	1	1	1
106543	1710	p50/NF-kappa b homodimer	[p50/NF-kappa B homodimers]	0.0	3	1	1	1
106544	1710	none of this region	[none of these regions]	0.0	4	1	1	1
106545	1710	putative receptor for fk506	[putative receptors for FK506]	0.0	4	1	1	1
106546	1710	antigen response	[antigen responses]	0.0	2	1	1	1
106547	1710	involve stage	[involving stages]	0.0	2	1	1	1
106548	1710	target for down-regulation	[target for down-regulation]	0.0	3	1	1	1
106549	1710	tyrosine -protein kinase inhibitor	[tyrosine -protein kinase inhibitor]	0.0	4	1	1	1
106550	1710	aspect of nongenomic effects.	[aspects of nongenomic effects.]	0.0	4	1	1	1
106551	1710	treatment of childhood	[treatment of childhood]	0.0	3	1	1	1
106552	1710	Thapsigargin a inhibitor of ca(2+)-atpase	[Thapsigargin an inhibitor of Ca(2+)-ATPase]	0.0	5	1	1	1
106553	1710	mediate the dysfunction	[mediating the dysfunction]	0.0	3	1	1	1
106554	1710	latent complex	[latent complexes]	0.0	2	1	1	1
106555	1710	male sibling	[male siblings]	0.0	2	1	1	1
106556	1710	series include response	[series including response]	0.0	3	1	1	1
106557	1710	return to baseline after P.	[returning to baseline after h.]	0.0	5	1	1	1
106558	1710	rheumatic disease (12:	[rheumatic diseases (12:]	0.0	3	1	1	1
106559	1710	analysis by mammalian cell transfection	[analysis by mammalian cell transfection]	0.0	5	1	1	1
106560	1710	pwm lymphocyte culture	[PWM lymphocyte cultures]	0.0	3	1	1	1
106561	1710	variant of the il-4r alpha-chain gene	[variants of the IL-4R alpha-chain gene]	0.0	6	1	1	1
106562	1710	3'-azido-3'-deoxythymidine	[3'-azido-3'-deoxythymidine]	0.0	1	1	1	1
106563	1710	mutant mek1s218/222a	[mutant MEK1S218/222A]	0.0	2	1	1	1
106564	1710	IFN activity equivalent iu/ml.	[IFN activity equivalent IU/mL.]	0.0	4	1	1	1
106565	1710	two potent 15-mer AS oligonucleotide	[two potent 15-mer AS oligonucleotides]	0.0	5	1	1	1
106566	1710	role for thiol	[role for thiols]	0.0	3	1	1	1
106567	1710	vitro protein-DNA	[vitro protein-DNA]	0.0	2	1	1	1
106568	1710	protein),	[protein),]	0.0	1	1	1	1
106569	1710	t-cell leukemia virus type-i htlv-i	[T-cell leukemia virus type-I HTLV-I]	0.0	5	1	1	1
106570	1710	density of binding site	[density of binding sites]	0.0	4	1	1	1
106571	1710	divergence of the two pathways.	[divergence of the two pathways.]	0.0	5	1	1	1
106572	1710	stimulation of this kinase	[stimulation of this kinase]	0.0	4	1	1	1
106573	1710	t-helper cell cytokine IL-2	[T-helper cell cytokines IL-2]	0.0	4	1	1	1
106574	1710	relative affinity of transcriptional element	[Relative affinities of transcriptional elements]	0.0	5	1	1	1
106575	1710	arteritis-SCID chimera	[arteritis-SCID chimeras]	0.0	2	1	1	1
106576	1710	induction of b/rel nuclear activity	[induction of B/Rel nuclear activity]	0.0	5	1	1	1
106577	1710	Interestingly, reexpression	[Interestingly, reexpression]	0.0	2	1	1	1
106578	1710	msr protein	[MSR protein]	0.0	2	1	1	1
106579	1710	simultaneous study use antibody	[simultaneous studies using antibodies]	0.0	4	1	1	1
106580	1710	activation by stimulus in human neutrophils.	[Activation by stimuli in human neutrophils.]	0.0	6	1	1	1
106581	1710	distal nuclear factor AP-1/Octamer	[distal nuclear factor AP-1/Octamer]	0.0	4	1	1	1
106582	1710	moreover, anti- TNF-alpha hiv-1 repeat transcription	[Moreover, anti- TNF-alpha HIV-1 repeat transcription]	0.0	6	1	1	1
106583	1710	PML-RAR rrna	[PML-RAR mRNAs]	0.0	2	1	1	1
106584	1710	acid phosphatase giant cell	[acid phosphatase giant cells]	0.0	4	1	1	1
106585	1710	dna-binding protein j kappa	[DNA-binding protein J kappa]	0.0	4	1	1	1
106586	1710	amino-terminal portion	[amino-terminal portion]	0.0	2	3	3	1
106587	1710	ligation of the chimeric receptor	[ligation of the chimeric receptor]	0.0	5	1	1	1
106588	1710	immune system target lymphocyte stem cell	[immune system targets lymphocyte stem cells]	0.0	6	1	1	1
106589	1710	illness involve response to stress	[illness involving responses to stress]	0.0	5	1	1	1
106590	1710	parameter tsh-r	[parameters TSH-R]	0.0	2	1	1	1
106591	1710	leukemia evi1 fusion	[leukemia EVI1 fusions]	0.0	3	1	1	1
106592	1710	infection of b-lymphocyte by Epstein-Barr virus	[Infection of B-lymphocytes by Epstein-Barr virus]	0.0	6	1	1	1
106593	1710	N-acetyl-L-cysteine a well-characterized, antioxidant	[N-acetyl-L-cysteine a well-characterized, antioxidant]	0.0	4	1	1	1
106594	1710	first rdna HZF	[first cDNAs HZF]	0.0	3	1	1	1
106595	1710	addition, assay	[addition, assay]	0.0	2	2	2	1
106596	1710	order: MRD -/lt patient	[order: MRD -/LT patients]	0.0	4	1	1	1
106597	1710	several human cell line	[several human cell lines]	0.0	4	1	1	1
106598	1710	variant with four sp1 site	[variant with four Sp1 sites]	0.0	5	1	1	1
106599	1710	day with dimethylsulfoxide	[days) with dimethylsulfoxide]	0.0	3	1	1	1
106600	1710	location of the HSV-2 gene	[locations of the HSV-2 genes]	0.0	5	1	1	1
106601	1710	region important, for recruitment through interaction	[regions important, for recruitment through interaction]	0.0	6	1	1	1
106602	1710	unique feature membrane	[unique features membranes]	0.0	3	1	1	1
106603	1710	immortalization by Epstein-Barr virus EBV	[immortalization by Epstein-Barr virus EBV]	0.0	5	1	1	1
106604	1710	nfat transcriptional activation	[NFAT transcriptional activation]	0.0	3	1	1	1
106605	1710	long period before development	[long period before development]	0.0	4	1	1	1
106606	1710	route on signalling	[routes on signalling]	0.0	3	1	1	1
106607	1710	mode of basic helix-loop-helix regulation	[modes of basic helix-loop-helix regulation]	0.0	5	1	1	1
106608	1710	suppression by protease inhibitor	[suppression by protease inhibitors]	0.0	4	1	1	1
106609	1710	strong positive regulatory effect	[strong positive regulatory effect]	0.0	4	1	1	1
106610	1710	myeloid-cell-specific expression of the c-fe gene	[myeloid-cell-specific expression of the c-fes gene]	0.0	6	1	1	1
106611	1710	use pd-98059 inhibitor kinase upstream	[using PD-98059 inhibitors kinase upstream]	0.0	5	1	1	1
106612	1710	Representative environmental estrogenic compound	[Representative environmental estrogenic compounds]	0.0	4	1	1	1
106613	1710	80% follow treatment	[80% following treatment]	0.0	3	1	1	1
106614	1710	HLF dna-binding domain	[HLF DNA-binding domain]	0.0	3	1	1	1
106615	1710	transcriptional factor-KB	[transcriptional factor-KB]	0.0	2	1	1	1
106616	1710	expression of one	[expression of one]	0.0	3	1	1	1
106617	1710	multiple functional element	[multiple functional elements]	0.0	3	1	1	1
106618	1710	change in the form of translocations.	[changes in the form of translocations.]	0.0	6	1	1	1
106619	1710	lack fresh cell	[lacking fresh cells]	0.0	3	1	1	1
106620	1710	deletion of TSG101 the human homolog	[deletions of TSG101 the human homolog]	0.0	6	1	1	1
106621	1710	breakpoint of transcript deletion	[breakpoints of transcript deletions]	0.0	4	1	1	1
106622	1710	response to h	[response to h]	0.0	3	1	1	1
106623	1710	ester-inducible transcription factor	[ester-inducible transcription factor]	0.0	3	1	1	1
106624	1710	chronically hiv-1 cell line	[chronically HIV-1 cell lines]	0.0	4	1	1	1
106625	1710	b-directed transcription	[B-directed transcription]	0.0	2	1	1	1
106626	1710	pi3-k inhibitor	[PI3-K inhibitor]	0.0	2	1	1	1
106627	1710	expression in a b cell line	[expression in a B cell line]	0.0	6	1	1	1
106628	1710	output	[output]	0.0	1	1	1	1
106629	1710	stable binding of specific factor	[stable binding of specific factors]	0.0	5	1	1	1
106630	1710	group of related disorder	[group of related disorders]	0.0	4	1	1	1
106631	1710	T leukemia virus type htlv-1	[T leukemia virus type HTLV-1]	0.0	5	1	1	1
106632	1710	peak after minute exposure to RA	[peaking after minutes exposure to RA]	0.0	6	1	1	1
106633	1710	estrogen bind assay	[estrogen binding assay]	0.0	3	1	1	1
106634	1710	lymphoblastoid cell line stimulation	[lymphoblastoid cell line stimulation]	0.0	4	1	1	1
106635	1710	respectively, corresponding	[respectively, corresponding]	0.0	2	1	1	1
106636	1710	elucidation of il-5 regulatory mechanism	[Elucidation of IL-5 regulatory mechanisms]	0.0	5	1	1	1
106637	1710	contain transcription factor in differentiation	[containing transcription factors in differentiation]	0.0	5	1	1	1
106638	1710	consist of cyclophosphamide	[consisting of cyclophosphamide]	0.0	3	1	1	1
106639	1710	activity a transcriptional activator	[activity a transcriptional activator]	0.0	4	1	1	1
106640	1710	p50 DNA binding	[p50 DNA binding]	0.0	3	1	1	1
106641	1710	1,25 alpha-dihydroxycholecalciferol	[1,25 alpha-dihydroxycholecalciferol]	0.0	2	1	1	1
106642	1710	lead from cell	[leading from cells]	0.0	3	1	1	1
106643	1710	subject in patient with ss	[subjects in patients with SS]	0.0	5	1	1	1
106644	1710	gene expression in th cell	[gene expression in TH cells]	0.0	5	1	1	1
106645	1710	mediate apoptosis	[mediating apoptosis]	0.0	2	1	1	1
106646	1710	four different isoform	[four different isoforms]	0.0	3	2	2	1
106647	1710	generation of diversity	[generation of diversity]	0.0	3	1	1	1
106648	1710	transmembrane electrolyte movement	[transmembrane electrolyte movements]	0.0	3	2	2	1
106649	1710	stimulation, b	[stimulation, B]	0.0	2	1	1	1
106650	1710	50% displacement of 17beta-(3H) estradiol	[50% displacement of 17beta-(3H) estradiol]	0.0	5	1	1	1
106651	1710	b-cell lymphoma especially lymphoma	[B-cell lymphomas especially lymphomas]	0.0	4	1	1	1
106652	1710	significant change in 17beta-HSD iv	[significant change in 17beta-HSD IV]	0.0	5	1	1	1
106653	1710	vitro migration circulate t-cell	[vitro migration circulating T-cells]	0.0	4	1	1	1
106654	1710	study with Bcl-6 staining	[study with Bcl-6 staining]	0.0	4	1	1	1
106655	1710	gc -dependent enhancement	[GC -dependent enhancement]	0.0	3	1	1	1
106656	1710	recognition of self ligand by class	[recognition of self, ligands by class]	0.0	6	1	1	1
106657	1710	degree dephosphorylation of factor	[degree dephosphorylation of factor]	0.0	4	1	1	1
106658	1710	protein from monocytic cell	[proteins from monocytic cells]	0.0	4	1	1	1
106659	1710	disruption of assembly	[disruption of assembly]	0.0	3	1	1	1
106660	1710	il-9ralpha other	[IL-9Ralpha other]	0.0	2	1	1	1
106661	1710	defense system	[defense system]	0.0	2	1	1	1
106662	1710	lymphocyte of pregnant woman second	[lymphocytes of pregnant women second]	0.0	5	1	1	1
106663	1710	variations.	[variations.]	0.0	1	1	1	1
106664	1710	binding of pac-1 antibody specific	[binding of PAC-1 antibodies specific]	0.0	5	1	1	1
106665	1710	control population	[control populations]	0.0	2	1	1	1
106666	1710	activity of protein kbf1/p50	[activity of proteins KBF1/p50]	0.0	4	1	1	1
106667	1710	Sjogren' syndromee	[Sjogren's syndrome.]	0.0	2	1	1	1
106668	1710	protein tyrosine phosphatase inhibitor	[protein tyrosine phosphatase inhibitors]	0.0	4	1	1	1
106669	1710	alteration in function	[alterations in function]	0.0	3	1	1	1
106670	1710	inhibitor of replication	[inhibitor of replication]	0.0	3	1	1	1
106671	1710	counseling	[counseling]	0.0	1	1	1	1
106672	1710	transduction of RA receptor	[transduction of RA receptor]	0.0	4	1	1	1
106673	1710	protein 7	[protein 7]	0.0	2	1	1	1
106674	1710	protein 1	[protein 1]	0.0	2	1	1	1
106675	1710	megakaryocyte-specific nuclear protein act	[megakaryocyte-specific nuclear proteins acting]	0.0	4	1	1	1
106676	1710	IkappaBalpha a physiological inhibitor	[IkappaBalpha a physiological inhibitor]	0.0	4	1	1	1
106677	1710	protein 3	[protein 3]	0.0	2	1	1	1
106678	1710	effect o.,	[effects on,]	0.0	2	1	1	1
106679	1710	oligopeptide in all proteins.	[oligopeptides in all proteins.]	0.0	4	1	1	1
106680	1710	high, concentration to 10 &mgr;m)	[high, concentrations to 10 &mgr;M)]	0.0	5	1	1	1
106681	1710	er associate in a manner	[ER associate in a manner]	0.0	5	1	1	1
106682	1710	same cell cycle	[same cell cycle]	0.0	3	1	1	1
106683	1710	total lack	[total lack]	0.0	2	1	1	1
106684	1710	chimeric receptor consist of the domain	[chimeric receptors consisting of the domain]	0.0	6	1	1	1
106685	1710	and/or megakaryocytic lineage	[and/or megakaryocytic lineages]	0.0	3	1	1	1
106686	1710	of lap as much	[of LAP as much]	0.0	4	1	1	1
106687	1710	mammalian response include the activation	[mammalian responses including the activation]	0.0	5	1	1	1
106688	1710	FL monocytic progenitor	[FL monocytic progenitors]	0.0	3	1	1	1
106689	1710	CONCLUSION: cytomegalovirus immediate gene product	[CONCLUSION: Cytomegalovirus immediate gene products]	0.0	5	1	1	1
106690	1710	induction in leukemia cell	[Induction in leukemia cells]	0.0	4	1	1	1
106691	1710	cell in vessel	[cells in vessel]	0.0	3	1	1	1
106692	1710	polyclonal activator phorbol ester	[polyclonal activator phorbol ester]	0.0	4	1	1	1
106693	1710	cell of promyelocytic leukemia	[cells of promyelocytic leukemia]	0.0	4	1	1	1
106694	1710	contrast, rt-pcr analysis	[contrast, RT-PCR analysis]	0.0	3	1	1	1
106695	1710	tf-h5r alpha	[TF-h5R alpha]	0.0	2	1	1	1
106696	1710	b binding site at position	[B binding sites at positions]	0.0	5	1	1	1
106697	1710	cell grow	[cells growing]	0.0	2	1	1	1
106698	1710	soluble dimeric tnf receptor rhu tnfr:fc	[soluble dimeric TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
106699	1710	tcr/cd3 -signaling defect	[TCR/CD3 -signaling defect]	0.0	3	1	1	1
106700	1710	low activity,	[low activity,]	0.0	2	1	1	1
106701	1710	estrogen type	[estrogen type]	0.0	2	1	1	1
106702	1710	(approximately 1-5 nm)	[(approximately 1-5 nM)]	0.0	3	1	1	1
106703	1710	distinct pattern of growth	[distinct patterns of growth]	0.0	4	1	1	1
106704	1710	T leukemia virus type	[T leukemia virus type]	0.0	4	1	1	1
106705	1710	58 asthma child	[58 asthma children]	0.0	3	1	1	1
106706	1710	cDNA fusion protein	[cDNA fusion protein]	0.0	3	1	1	1
106707	1710	eight patient in long	[Eight patients in long-term]	0.0	4	1	1	1
106708	1710	ligand-binding domain, interference	[ligand-binding domain, interference]	0.0	3	1	1	1
106709	1710	comparison to HLA dqa1*0201/dqb1*0201	[comparison to HLA DQA1*0201/DQB1*0201]	0.0	4	1	1	1
106710	1710	transcriptional activation by deletion of CIITA	[transcriptional activation by deletions of CIITA]	0.0	6	1	1	1
106711	1710	only by a immunosorbent assay ELISA	[only by an immunosorbent assay ELISA]	0.0	6	1	1	1
106712	1710	gene such as ICAM-1	[genes such as ICAM-1]	0.0	4	1	1	1
106713	1710	toxic shock syndrome toxin-1	[toxic shock syndrome toxin-1]	0.0	4	1	1	1
106714	1710	follow ligand engagement cell-to-cell contact).	[following ligand engagement cell-to-cell contact).]	0.0	5	1	1	1
106715	1710	facilitate the assembly of protein	[facilitating the assembly of proteins]	0.0	5	1	1	1
106716	1710	level of the signal molecule	[levels of the signaling molecules]	0.0	5	1	1	1
106717	1710	p65 NF-kappa b component	[p65 NF-kappa B components]	0.0	4	1	1	1
106718	1710	receptor dor1	[receptor DOR1]	0.0	2	1	1	1
106719	1710	domain a flexible linker	[domain a flexible linker]	0.0	4	1	1	1
106720	1710	composite	[composite]	0.0	1	1	1	1
106721	1710	Ca2+ element	[Ca2+ element]	0.0	2	1	1	1
106722	1710	C a exchange base pair	[C A exchange base pairs]	0.0	5	1	1	1
106723	1710	Zebra promoter	[Zebra promoter]	0.0	2	1	1	1
106724	1710	8 woman	[8 women]	0.0	2	1	1	1
106725	1710	leukemia 1- evi1 fusion respectively,	[leukemia 1- EVI1 fusions respectively,]	0.0	5	1	1	1
106726	1710	induction type ii interferon	[Induction type II interferons]	0.0	4	1	1	1
106727	1710	GATA-1 factor binding motif	[GATA-1 factor binding motifs]	0.0	4	1	1	1
106728	1710	malaria [see	[malaria [see]	0.0	2	1	1	1
106729	1710	depletion of transcription factor	[depletion of transcription factors]	0.0	4	1	1	1
106730	1710	NF-kappa B1 precursor	[NF-kappa B1 precursor]	0.0	3	1	1	1
106731	1710	most likely interpretation	[most likely interpretation]	0.0	3	1	1	1
106732	1710	dimeric form	[dimeric form]	0.0	2	1	1	1
106733	1710	contrast, stimulus	[contrast, stimuli]	0.0	2	1	1	1
106734	1710	inhibition of cd45 evidence	[inhibition of CD45 evidence]	0.0	4	1	1	1
106735	1710	CD2 mab capable	[CD2 mAbs capable]	0.0	3	1	1	1
106736	1710	two nuclear factor nf-il6 (position	[Two nuclear factor NF-IL6 (positions]	0.0	5	1	1	1
106737	1710	blood mononuclear cell from individual	[blood mononuclear cells from individuals]	0.0	5	1	1	1
106738	1710	trigger by CD40 ligand	[triggering by CD40 ligands]	0.0	4	1	1	1
106739	1710	mcp-1 production	[MCP-1 production]	0.0	2	3	3	1
106740	1710	product of genes,	[products of genes,]	0.0	3	1	1	1
106741	1710	redox homeostasis	[redox homeostasis]	0.0	2	1	1	1
106742	1710	NH2-terminal amino acid	[NH2-terminal amino acids]	0.0	3	1	1	1
106743	1710	specific adhesion molecule	[specific adhesion molecules]	0.0	3	1	1	1
106744	1710	activation of lt	[activation of LT]	0.0	3	1	1	1
106745	1710	/nfat	[/NFAT]	0.0	1	2	2	1
106746	1710	binding to four different icss	[binding to four different ICSs]	0.0	5	1	1	1
106747	1710	selective regulator	[selective regulator]	0.0	2	1	1	1
106748	1710	long mechanism	[long-term mechanisms]	0.0	2	1	1	1
106749	1710	effect of 17 beta- estradiol	[effect of 17 beta- estradiol]	0.0	5	1	1	1
106750	1710	change of protein-binding activity	[changes of protein-binding activities]	0.0	4	1	1	1
106751	1710	accounting for the haploinsufficiency	[accounting for the haploinsufficiency]	0.0	4	1	1	1
106752	1710	various lesion with advance age	[various lesions with advancing age]	0.0	5	1	1	1
106753	1710	corticosensitivity in TNFalpha-	[corticosensitivity in TNFalpha-]	0.0	3	1	1	1
106754	1710	protein kinase c--responsive element	[protein kinase C--responsive elements]	0.0	4	1	1	1
106755	1710	large amount of rna	[Large amounts of RNA]	0.0	4	1	1	1
106756	1710	different pkc isotype	[different PKC isotypes]	0.0	3	1	1	1
106757	1710	patient leucocyte	[patient's leucocytes]	0.0	2	1	1	1
106758	1710	gp nuclear extract	[gp nuclear extracts]	0.0	3	1	1	1
106759	1710	weak competitor of GcR	[weak competitor of GcR]	0.0	4	1	1	1
106760	1710	pml/rar alpha mrna -contain cell	[PML/RAR alpha mRNA -containing cells]	0.0	5	1	1	1
106761	1710	myeloma (mm) cell	[myeloma (MM) cells]	0.0	3	1	1	1
106762	1710	epo cell line	[EPO cell lines]	0.0	3	1	1	1
106763	1710	kD activator nf-kappab subunit	[kD activator NF-kappaB subunit]	0.0	4	1	1	1
106764	1710	constitutive protein/dna interaction erratum	[Constitutive protein/DNA interactions erratum]	0.0	4	1	1	1
106765	1710	particular lysosomal serine protease	[particular lysosomal serine proteases]	0.0	4	1	1	1
106766	1710	cysteine oncogene	[cysteine oncogenes]	0.0	2	1	1	1
106767	1710	expression of a novel mutation	[expression of a novel mutation]	0.0	5	1	1	1
106768	1710	brief overview	[brief overview]	0.0	2	1	1	1
106769	1710	binding of Sp1 in nuclear extract	[binding of Sp1 in nuclear extracts]	0.0	6	1	1	1
106770	1710	alpha-chain on blood monocyte	[alpha-chain on blood monocytes]	0.0	4	1	1	1
106771	1710	nf-kappab activation proteasome inhibitor	[NF-kappaB activation proteasome inhibitor]	0.0	4	1	1	1
106772	1710	assay with wild-type form	[assays with wild-type forms]	0.0	4	1	1	1
106773	1710	occur mutation	[occurring mutation]	0.0	2	1	1	1
106774	1710	lineage switch to lineage	[lineage switching to lineages]	0.0	4	1	1	1
106775	1710	Germ line	[Germ line]	0.0	2	1	1	1
106776	1710	reverse transcription-PCR assay	[reverse transcription-PCR assay]	0.0	3	1	1	1
106777	1710	dyn/cm2)	[dyn/cm2)]	0.0	1	1	1	1
106778	1710	EBV promoter bmrf1	[EBV promoter BMRF1]	0.0	3	1	1	1
106779	1710	express a transdominant rev protein	[expressing a transdominant Rev protein]	0.0	5	1	1	1
106780	1710	cause of level of receptor	[cause of levels of receptors]	0.0	5	1	1	1
106781	1710	cell model	[cell model]	0.0	2	1	1	1
106782	1710	infarction AMI	[infarction AMI]	0.0	2	1	1	1
106783	1710	lps activation of the factor	[LPS activation of the factor]	0.0	5	1	1	1
106784	1710	importance of deamidation	[importance of deamidation]	0.0	3	1	1	1
106785	1710	amount of e2f	[amount of E2F]	0.0	3	1	1	1
106786	1710	excess of unlabelled testosterone	[excess of unlabelled testosterone]	0.0	4	1	1	1
106787	1710	eosinophil granule major basic protein	[eosinophil granule major basic protein]	0.0	5	2	2	1
106788	1710	cell localization	[Cell localization]	0.0	2	1	1	1
106789	1710	120-kDa protein	[120-kDa protein]	0.0	2	1	1	1
106790	1710	encode immunologically relevant protein	[encoding immunologically relevant proteins]	0.0	4	1	1	1
106791	1710	analysis of a series	[Analysis of a series]	0.0	4	1	1	1
106792	1710	uninduced virus	[Uninduced virus]	0.0	2	1	1	1
106793	1710	16-hour incubation with oleate	[16-hour incubation with oleate]	0.0	4	1	1	1
106794	1710	use 125i-labeled c-c chemokine in cell	[using 125I-labeled C-C chemokines in cells]	0.0	6	1	1	1
106795	1710	gene-nonexpress	[gene-nonexpressing]	0.0	1	1	1	1
106796	1710	also in long maintenance	[also in long-term maintenance]	0.0	4	1	1	1
106797	1710	ubiquitous ap-1 factor	[ubiquitous AP-1 factors]	0.0	3	1	1	1
106798	1710	formation in T cell	[formation in T cells]	0.0	4	1	1	1
106799	1710	sox9 allele	[SOX9 alleles]	0.0	2	1	1	1
106800	1710	mouse ino gene	[mouse iNOS gene]	0.0	3	1	1	1
106801	1710	hundred basis	[hundred bases]	0.0	2	1	1	1
106802	1710	(type ii)	[(type II)]	0.0	2	1	1	1
106803	1710	24-hydroxylase message	[24-hydroxylase message]	0.0	2	1	1	1
106804	1710	accompany the turnover the I	[Accompanying the turnover the I]	0.0	5	1	1	1
106805	1710	normal human myeloid cell granulocyte	[normal human myeloid cells granulocytes]	0.0	5	1	1	1
106806	1710	thymocyte compartment	[thymocyte compartment]	0.0	2	1	1	1
106807	1710	SS Oct-1	[SS Oct-1]	0.0	2	1	1	1
106808	1710	association of alteration latency in cell	[Association of alterations latency in cells]	0.0	6	1	1	1
106809	1710	pattern of transmission	[pattern of transmission]	0.0	3	1	1	1
106810	1710	cyclosporin -sensitive dnase i-hypersensitive site	[cyclosporin -sensitive DNase I-hypersensitive site]	0.0	5	1	1	1
106811	1710	demonstration immunologic crossreactivity	[Demonstration immunologic crossreactivity]	0.0	3	1	1	1
106812	1710	gtpase rac-1	[GTPase Rac-1]	0.0	2	1	1	1
106813	1710	particular form	[particular form]	0.0	2	1	1	1
106814	1710	hemopoietic lineage	[hemopoietic lineages]	0.0	2	1	1	1
106815	1710	Indeed, secretion of the lymphokine interleukin-1beta	[Indeed, secretion of the lymphokine interleukin-1beta]	0.0	6	1	1	1
106816	1710	immunity result in response	[immunity resulting in response]	0.0	4	1	1	1
106817	1710	intrahepatic lymphoid follicle formation	[Intrahepatic lymphoid follicle formation]	0.0	4	1	1	1
106818	1710	mineralocorticoid receptor mr status	[mineralocorticoid receptor MR status]	0.0	4	1	1	1
106819	1710	requirement for efficient binding,	[requirements for efficient binding,]	0.0	4	1	1	1
106820	1710	modification of a cofactor	[modification of a cofactor]	0.0	4	1	1	1
106821	1710	gene expression promoter	[gene expression promoter]	0.0	3	1	1	1
106822	1710	cellular signal	[cellular signal]	0.0	2	1	1	1
106823	1710	tissue inhibitor of (timp)-1	[tissue inhibitor of (TIMP)-1]	0.0	4	1	1	1
106824	1710	24 volunteer without psychiatric disorder	[24 volunteers without psychiatric disorders]	0.0	5	1	1	1
106825	1710	maturation of lineage	[maturation of lineages]	0.0	3	1	1	1
106826	1710	protein direct the expression	[proteins directing the expression]	0.0	4	1	1	1
106827	1710	case of Arnhl	[cases of ARNHL]	0.0	3	1	1	1
106828	1710	sevenfold) 3.	[sevenfold) 3.]	0.0	2	1	1	1
106829	1710	peak thrombin (pt) of 154	[peak thrombin (PT) of 154]	0.0	5	1	1	1
106830	1710	key element for the regulation	[key element for the regulation]	0.0	5	1	1	1
106831	1710	interestingly, that events,	[Interestingly, those events,]	0.0	3	1	1	1
106832	1710	mechanism in monocytic cell line	[mechanisms in monocytic cell lines]	0.0	5	1	1	1
106833	1710	mammary tumor	[mammary tumors]	0.0	2	1	1	1
106834	1710	potential target the membrane glycoprotein cd36	[potential targets the membrane glycoprotein CD36]	0.0	6	1	1	1
106835	1710	disease (55.3%	[disease (55.3%]	0.0	2	1	1	1
106836	1710	kappa b-dependent	[kappa B-dependent]	0.0	2	1	1	1
106837	1710	reactive follicular hyperplasia fh	[reactive follicular hyperplasia FH]	0.0	4	1	1	1
106838	1710	specific promoter activity	[specific promoter activity]	0.0	3	1	1	1
106839	1710	T cell from certain subject	[T cells from certain subjects]	0.0	5	1	1	1
106840	1710	transformation of Philadelphia myeloid leukemia	[transformation of Philadelphia myeloid leukemia]	0.0	5	1	1	1
106841	1710	opposite effect on this apoptotic signal	[opposite effects on these apoptotic signals]	0.0	6	1	1	1
106842	1710	characteristic marker	[characteristic markers]	0.0	2	1	1	1
106843	1710	clinical syndrome include disease	[clinical syndromes including diseases]	0.0	4	1	1	1
106844	1710	point estimation	[point estimation]	0.0	2	1	1	1
106845	1710	mm cell line	[MM cell lines]	0.0	3	1	1	1
106846	1710	efficient induction	[efficient induction]	0.0	2	1	1	1
106847	1710	ab fragment	[Ab fragment]	0.0	2	1	1	1
106848	1710	recruitment of cell	[recruitment of cells]	0.0	3	1	1	1
106849	1710	bhrf1 a Epstein-Barr virus	[BHRF1 an Epstein-Barr virus]	0.0	4	1	1	1
106850	1710	instance of instability	[instance of instability]	0.0	3	1	1	1
106851	1710	rel a binding site	[Rel A binding site]	0.0	4	1	1	1
106852	1710	receptor-associated factor	[receptor-associated factors]	0.0	2	1	1	1
106853	1710	interleukin colony-stimulating factor	[interleukin colony-stimulating factor]	0.0	3	1	1	1
106854	1710	blood lymphocyte PBL generation	[blood lymphocytes PBL Generation]	0.0	4	1	1	1
106855	1710	provide functional evidence for the presence	[providing functional evidence for the presence]	0.0	6	1	1	1
106856	1710	differentiation of precursor	[differentiation of precursors]	0.0	3	1	1	1
106857	1710	eventual activation of carcinogen	[eventual activation of carcinogens]	0.0	4	1	1	1
106858	1710	mammalian histone deacetylase	[mammalian histone deacetylase]	0.0	3	1	1	1
106859	1710	air degree c) twice/d,	[air degrees C) twice/d,]	0.0	4	1	1	1
106860	1710	study signal in erythroid precursor	[studies signaling in erythroid precursors]	0.0	5	1	1	1
106861	1710	inclusion of this LTR	[Inclusion of this LTR]	0.0	4	1	1	1
106862	1710	isoform of the amp-responsive element modulator	[isoforms of the AMP-responsive element modulator]	0.0	6	1	1	1
106863	1710	third tyrosine	[third tyrosine]	0.0	2	1	1	1
106864	1710	c-Rel protein	[c-Rel protein]	0.0	2	1	1	1
106865	1710	monocyte il-1 receptor antagonist	[monocyte IL-1 receptor antagonist]	0.0	4	1	1	1
106866	1710	4 hour at pH	[4 hr at pH]	0.0	4	1	1	1
106867	1710	moderate form of immunodeficiency	[moderate form of immunodeficiency]	0.0	4	1	1	1
106868	1710	observation inactive	[observation inactive]	0.0	2	1	1	1
106869	1710	stage I-II patient	[Stage I-II patients]	0.0	3	1	1	1
106870	1710	steroid ligands.	[steroid ligands.]	0.0	2	1	1	1
106871	1710	mature normal human myeloid cell	[mature normal human myeloid cells]	0.0	5	1	1	1
106872	1710	monosomy of loci on chromosome	[monosomy of loci on chromosome]	0.0	5	1	1	1
106873	1710	Polymyxin	[Polymyxin]	0.0	1	1	1	1
106874	1710	activation nf-kappa b in ML-1a	[activation NF-kappa B in ML-1a]	0.0	5	1	1	1
106875	1710	promise for the immunotherapy	[promise for the immunotherapy]	0.0	4	1	1	1
106876	1710	existence of a locus	[existence of a locus]	0.0	4	1	1	1
106877	1710	overexpression of a v14rho construct	[Overexpression of a V14Rho construct]	0.0	5	1	1	1
106878	1710	recognition of the peptide bond	[recognition of the peptide bond]	0.0	5	1	1	1
106879	1710	t3 microgram	[T3 micrograms]	0.0	2	1	1	1
106880	1710	transcript in pre-B line	[transcripts in pre-B lines]	0.0	4	1	1	1
106881	1710	match	[match]	0.0	1	1	1	1
106882	1710	10 lymphoma	[10 lymphoma]	0.0	2	1	1	1
106883	1710	genetic marker of acute leukemia	[genetic markers of acute leukemias]	0.0	5	1	1	1
106884	1710	extend from -500 promoter region	[extending from -500 promoter regions]	0.0	5	1	1	1
106885	1710	regulator of the promoter activity	[regulators of the promoter activity]	0.0	5	1	1	1
106886	1710	pebp2 alpha a	[PEBP2 alpha A]	0.0	3	1	1	1
106887	1710	hplc peptide	[HPLC peptide]	0.0	2	1	1	1
106888	1710	sequence in the negative element	[sequence in the negative element]	0.0	5	1	1	1
106889	1710	potential activity	[potential activity]	0.0	2	1	1	1
106890	1710	steroid-resistant bronchial subject	[steroid-resistant bronchial subjects]	0.0	3	1	1	1
106891	1710	5 u/ml interleukin-2 time	[5 U/ml interleukin-2 time]	0.0	4	1	1	1
106892	1710	least four host protein	[least four host proteins]	0.0	4	1	1	1
106893	1710	tpa increase	[TPA increases]	0.0	2	1	1	1
106894	1710	ref52	[REF52]	0.0	1	1	1	1
106895	1710	blockade of primitive progenitor proliferation	[blockade of primitive progenitor proliferation]	0.0	5	1	1	1
106896	1710	divergent effect	[divergent effects]	0.0	2	2	2	1
106897	1710	threefold to 12-lipoxygenase activity	[threefold to 12-lipoxygenase activity]	0.0	4	1	1	1
106898	1710	use of RA	[use of RA]	0.0	3	1	1	1
106899	1710	mapping of sry	[mapping of SRY]	0.0	3	1	1	1
106900	1710	signal from patient with thalassaemia	[signalling from patients with thalassaemia]	0.0	5	1	1	1
106901	1710	analysis by blotting of fetal population	[analysis by blotting of fetal populations]	0.0	6	1	1	1
106902	1710	s multicatalytic protease	[S multicatalytic proteases]	0.0	3	1	1	1
106903	1710	express cell in the 3' sequence	[expressing cells in the 3' sequences]	0.0	6	1	1	1
106904	1710	sequence from glucocorticoid -repressible gene	[sequences from glucocorticoid -repressible genes]	0.0	5	1	1	1
106905	1710	adenovirus ad infection	[adenovirus Ad infection]	0.0	3	1	1	1
106906	1710	overexpression in Saos cell	[Overexpression in Saos cells]	0.0	4	1	1	1
106907	1710	condition of immune glomerulopathy	[conditions of immune glomerulopathy]	0.0	4	1	1	1
106908	1710	more than 900 x-chromosomes	[more than 900 X-chromosomes]	0.0	4	1	1	1
106909	1710	measurement of the activity after transfection	[Measurement of the activity after transfection]	0.0	6	1	1	1
106910	1710	resumption	[resumption]	0.0	1	1	1	1
106911	1710	IFN regulate factor-1 irf-1 gene expression	[IFN regulating factor-1 IRF-1 gene expression]	0.0	6	1	1	1
106912	1710	secretion of low amount	[secretion of low amounts]	0.0	4	1	1	1
106913	1710	Intracellular deletion variant	[Intracellular deletion variants]	0.0	3	1	1	1
106914	1710	currently under clinical investigation	[currently under clinical investigation]	0.0	4	1	1	1
106915	1710	follow lps stimulation in monocyte	[following LPS stimulation in monocytes]	0.0	5	1	1	1
106916	1710	palindrome 5'-ttgtcccgtggacaaatgtcc-3'	[palindromes 5'-TTGTCCcgtGGACAAaTGTCC-3']	0.0	2	1	1	1
106917	1710	contrast, dexamethasone a inhibitor	[contrast, dexamethasone a inhibitor]	0.0	4	1	1	1
106918	1710	lysis by lymphocyte CL	[lysis by lymphocytes CLs]	0.0	4	1	1	1
106919	1710	hla-dq -specific response	[HLA-DQ -specific response]	0.0	3	1	1	1
106920	1710	hormonal status after conservative surgery comparison	[Hormonal status after conservative surgery comparison]	0.0	6	1	1	1
106921	1710	cosmid encode ciita	[cosmids encoding CIITA]	0.0	3	1	1	1
106922	1710	molecule in the process	[molecule in the process]	0.0	4	1	1	1
106923	1710	physiologically, level of nuclear	[physiologically, levels of nuclear]	0.0	4	1	1	1
106924	1710	ikb alpha phosphorylation /degradation	[IkB alpha phosphorylation /degradation]	0.0	4	1	1	1
106925	1710	activator a member	[activator a member]	0.0	3	1	1	1
106926	1710	serious problem	[serious problem]	0.0	2	1	1	1
106927	1710	expression of tal-1 protein during hematopoiesis	[Expression of tal-1 proteins during hematopoiesis]	0.0	6	1	1	1
106928	1710	express form of the human protein	[expressing forms of the human protein]	0.0	6	1	1	1
106929	1710	inducible nf-at complex with a oligonucleotide	[inducible NF-AT complexes with an oligonucleotide]	0.0	6	1	1	1
106930	1710	leukocyte population in trimester pregnancy	[Leukocyte populations in trimester pregnancies]	0.0	5	1	1	1
106931	1710	apolar substitution alpha-methyl, alpha-fluoromethyl	[apolar substitutions alpha-methyl, alpha-fluoromethyl]	0.0	4	1	1	1
106932	1710	repeat of a pair sequence	[repeats of a pair sequence]	0.0	5	1	1	1
106933	1710	such as monocyte	[such as monocytes]	0.0	3	1	1	1
106934	1710	include Stat1 alpha	[including Stat1 alpha]	0.0	3	1	1	1
106935	1710	mediate growth inhibition during differentiation	[mediating growth inhibition during differentiation]	0.0	5	1	1	1
106936	1710	myelodysplastic syndrome in stage	[myelodysplastic syndromes in stage]	0.0	4	1	1	1
106937	1710	necrosis factor-alpha	[necrosis factor-alpha]	0.0	2	1	1	1
106938	1710	migration of 48-hr t-cell	[migration of 48-hr T-cells]	0.0	4	1	1	1
106939	1710	marker for lymphoid cell	[marker for lymphoid cells]	0.0	4	1	1	1
106940	1710	kinase ERK1/2	[kinase ERK1/2]	0.0	2	1	1	1
106941	1710	extract of pma-differentiated u937 cell	[extracts of PMA-differentiated U937 cells]	0.0	5	1	1	1
106942	1710	10 differentiation of a monocyte	[10 differentiation of a monocyte]	0.0	5	1	1	1
106943	1710	increase phospholipase c 1	[increase phospholipase C 1]	0.0	4	1	1	1
106944	1710	express the receptor dor1	[expressing the receptor DOR1]	0.0	4	1	1	1
106945	1710	one target of this positive/negative regulation	[one target of this positive/negative regulation]	0.0	6	1	1	1
106946	1710	primarily a feature of the rna	[primarily a feature of the RNA]	0.0	6	1	1	1
106947	1710	Gene for a tissue-specific transcriptional activator	[Gene for a tissue-specific transcriptional activator]	0.0	6	1	1	1
106948	1710	c-fo protein level	[c-Fos protein levels]	0.0	3	1	1	1
106949	1710	analysis factor	[analysis factor]	0.0	2	1	1	1
106950	1710	role for erythroid cell development	[role for erythroid cell development]	0.0	5	1	1	1
106951	1710	T cell with BW	[T cells with BW]	0.0	4	1	1	1
106952	1710	delicate balance between mechanism	[delicate balance between mechanisms]	0.0	4	1	1	1
106953	1710	element microb	[element microB]	0.0	2	1	1	1
106954	1710	NK cytolytic proliferative activity	[NK cytolytic proliferative activities]	0.0	4	1	1	1
106955	1710	homologous member the human homolog	[homologous members the human homolog]	0.0	5	1	1	1
106956	1710	mrna at level	[mRNA at levels]	0.0	3	1	1	1
106957	1710	effect increase of total ca2+	[effect increase of total Ca2+]	0.0	5	1	1	1
106958	1710	id3 cell cycle	[Id3 cell cycle]	0.0	3	1	1	1
106959	1710	cellular defense system	[cellular defense system]	0.0	3	1	1	1
106960	1710	promote ige synthesis	[promoting IgE synthesis]	0.0	3	1	1	1
106961	1710	factor from 10(-12)	[factor from 10(-12)]	0.0	3	1	1	1
106962	1710	use rabbit anti-c/ebp-epsilon antibody	[using rabbit anti-C/EBP-epsilon antibodies]	0.0	4	1	1	1
106963	1710	NF-kappa b kappa b	[NF-kappa B kappa B]	0.0	4	1	1	1
106964	1710	receptor in the induction	[receptors in the induction]	0.0	4	1	1	1
106965	1710	virtually all gene	[virtually all genes]	0.0	3	1	1	1
106966	1710	great reduction of cell proliferation	[greater reduction of cell proliferation]	0.0	5	1	1	1
106967	1710	signal pathway with differential sensitivity	[signaling pathways with differential sensitivity]	0.0	5	1	1	1
106968	1710	biodisposal of all-tran acid	[biodisposal of all-trans acid]	0.0	4	1	1	1
106969	1710	cd15lo,	[CD15lo,]	0.0	1	1	1	1
106970	1710	November	[Nov]	0.0	1	1	1	1
106971	1710	activation of a promoter by Oct-2	[activation of a promoter by Oct-2]	0.0	6	1	1	1
106972	1710	response to activators,	[response to activators,]	0.0	3	1	1	1
106973	1710	BamHI-Q promoter	[BamHI-Q promoter]	0.0	2	1	1	1
106974	1710	I-Ek	[I-Ek]	0.0	1	1	1	1
106975	1710	adenocarcinoma reactive human-mouse monoclonal antibody	[adenocarcinoma reactive human-mouse monoclonal antibody]	0.0	5	1	1	1
106976	1710	biodisposal of acid	[biodisposal of acid]	0.0	3	1	1	1
106977	1710	subpopulations,	[subpopulations,]	0.0	1	1	1	1
106978	1710	feb;72(2):1709]	[Feb;72(2):1709]]	0.0	1	1	1	1
106979	1710	alas precursor protein	[ALAS precursor protein]	0.0	3	1	1	1
106980	1710	long double time, saturation density	[longer doubling time, saturation density]	0.0	5	1	1	1
106981	1710	thrombin generation by vsmc express c-myc	[thrombin generation by VSMCs expressing c-myc]	0.0	6	1	1	1
106982	1710	mouse mammary	[mouse mammary]	0.0	2	1	1	1
106983	1710	relate the two nuclear nf-at complex	[relating the two nuclear NF-AT complexes]	0.0	6	1	1	1
106984	1710	dissociation (Kd)	[dissociation (Kd)]	0.0	2	1	1	1
106985	1710	I-II	[I-II]	0.0	1	1	1	1
106986	1710	10 individual for the purpose	[10 individuals for the purpose]	0.0	5	1	1	1
106987	1710	other oestrogen target organ	[other oestrogen target organs]	0.0	4	1	1	1
106988	1710	increase in irf-1 gene expression	[increase in IRF-1 gene expression]	0.0	5	1	1	1
106989	1710	multiple mutation a encoding	[multiple mutations a encoding]	0.0	4	1	1	1
106990	1710	protein to the silencer	[proteins to the silencer]	0.0	4	1	1	1
106991	1710	allele of the gene	[allele of the genes]	0.0	4	1	1	1
106992	1710	two reading frame orf a	[two reading frames ORFs A]	0.0	5	1	1	1
106993	1710	time as a antigen	[time as an antigen]	0.0	4	1	1	1
106994	1710	simultaneous analysis of gene	[Simultaneous analysis of genes]	0.0	4	1	1	1
106995	1710	child with variant	[children with variants]	0.0	3	1	1	1
106996	1710	mammalian runt product in hematopoiesis	[mammalian runt products in hematopoiesis]	0.0	5	1	1	1
106997	1710	change the proportion of fatty acid	[changing the proportions of fatty acids]	0.0	6	1	1	1
106998	1710	J Biol Chem Jun	[J Biol Chem Jun]	0.0	4	1	1	1
106999	1710	low level of trap	[low levels of TRAP]	0.0	4	1	1	1
107000	1710	chain-break antioxidant	[chain-breaking antioxidant]	0.0	2	1	1	1
107001	1710	18-hydroxy-corticosterone 18-oh-b level in woman	[18-hydroxy-corticosterone 18-OH-B levels in women]	0.0	5	1	1	1
107002	1710	induction of interleukin-1 receptor synthesis	[induction of interleukin-1 receptor synthesis]	0.0	5	1	1	1
107003	1710	block antibody	[blocking antibody]	0.0	2	1	1	1
107004	1710	fasL up-regulation	[fasL up-regulation]	0.0	2	1	1	1
107005	1710	signalling during lymphocyte activation	[signalling during lymphocyte activation]	0.0	4	1	1	1
107006	1710	inducible PB1 protein complex	[inducible PB1 protein complex]	0.0	4	1	1	1
107007	1710	expression of th2 cytokine	[expression of Th2 cytokines]	0.0	4	1	1	1
107008	1710	volunteer with essential hypertension.	[volunteers with essential hypertension.]	0.0	4	1	1	1
107009	1710	[3H]1 alpha,25-dihydroxyvitamin D3 135eoh)2d3	[[3H]1 alpha,25-dihydroxyvitamin D3 1,25(OH)2D3]	0.0	4	1	1	1
107010	1710	effect upon Bcl-2	[effect upon Bcl-2]	0.0	3	1	1	1
107011	1710	functional promoter region -620	[functional promoter region -620]	0.0	4	1	1	1
107012	1710	(5118), ebv infection ebv reactivation	[(5/18), EBV infection EBV reactivation]	0.0	5	1	1	1
107013	1710	dramatic loss	[dramatic loss]	0.0	2	1	1	1
107014	1710	cl assay	[CL assays]	0.0	2	1	1	1
107015	1710	level of RelA	[levels of RelA]	0.0	3	1	1	1
107016	1710	biomarker abnormality	[biomarker abnormalities]	0.0	2	1	1	1
107017	1710	cortisol the number of receptor	[cortisol the number of receptors]	0.0	5	1	1	1
107018	1710	high tissue-specific expression	[high tissue-specific expression]	0.0	3	1	1	1
107019	1710	low dose ng/ml)	[low dose ng/ml)]	0.0	3	1	1	1
107020	1710	patient with a population	[patient with a population]	0.0	4	1	1	1
107021	1710	extend from approximately -500 to +50bp	[extending from approximately -500 to +50bp]	0.0	6	1	1	1
107022	1710	however, high (66 millileter at P;	[However, high (66 ml at h;]	0.0	6	1	1	1
107023	1710	event in lymphoid tumor	[events in lymphoid tumors]	0.0	4	1	1	1
107024	1710	effect in hiv-infected human T cell	[effects in HIV-infected human T cells]	0.0	6	1	1	1
107025	1710	ifn-gamma mechanism	[IFN-gamma mechanism]	0.0	2	1	1	1
107026	1710	protein expression of several signal molecule	[protein expression of several signaling molecules]	0.0	6	1	1	1
107027	1710	cyclic AMP element	[Cyclic AMP element]	0.0	3	1	1	1
107028	1710	terminal repeat activity in T	[terminal repeat activity in T]	0.0	5	1	1	1
107029	1710	cDNA fusion	[cDNA fusion]	0.0	2	1	1	1
107030	1710	phosphorylation of STAT3alpha on serine	[phosphorylation of STAT3alpha on serine]	0.0	5	1	1	1
107031	1710	49 healthy aged subject	[49 healthy aged subjects]	0.0	4	1	1	1
107032	1710	differentiation of definitive cell	[differentiation of definitive cells]	0.0	4	1	1	1
107033	1710	cell assay with 3h-dex	[cell assay with 3H-Dex]	0.0	4	1	1	1
107034	1710	other signal protein	[other signaling proteins]	0.0	3	1	1	1
107035	1710	upregulation of binding	[upregulation of binding]	0.0	3	1	1	1
107036	1710	biphasic increase in pdgf(b) mrna	[biphasic increase in PDGF(B) mRNA]	0.0	5	1	1	1
107037	1710	developmental stage homogeneity	[developmental stage homogeneity]	0.0	3	1	1	1
107038	1710	however, stimulation of b-cell	[However, stimulation of B-cells]	0.0	4	1	1	1
107039	1710	hl60 cell differentiation	[HL60 cell differentiation]	0.0	3	1	1	1
107040	1710	tyrosyl phosphorylation	[tyrosyl phosphorylation]	0.0	2	1	1	1
107041	1710	pattern of signal for two chemoattract	[patterns of signaling for two chemoattractants]	0.0	6	1	1	1
107042	1710	inhibition activity.	[inhibition activity.]	0.0	2	1	1	1
107043	1710	pfu/animal, on day	[pfu/animal, on days]	0.0	3	1	1	1
107044	1710	alpha thf/thf (0.35;	[alpha THF/THF (0.35;]	0.0	3	1	1	1
107045	1710	unique profilin-like fashion.	[unique profilin-like fashion.]	0.0	3	1	1	1
107046	1710	Cbf alpha 2 subunit	[Cbf alpha 2 subunit]	0.0	4	1	1	1
107047	1710	T cell from human blood	[T cells from human blood]	0.0	5	1	1	1
107048	1710	history of genetic disorder	[history of genetic disorders]	0.0	4	1	1	1
107049	1710	maximum (3h)-thymidine incorporation	[maximum (3H)-thymidine incorporation]	0.0	3	1	1	1
107050	1710	apoptosis in contrast	[apoptosis in contrast]	0.0	3	1	1	1
107051	1710	multiple TcR delta transcript	[Multiple TcR delta transcripts]	0.0	4	1	1	1
107052	1710	other gene tnf-alpha	[other genes TNF-alpha]	0.0	3	1	1	1
107053	1710	primary breast tumor	[primary breast tumors]	0.0	3	1	1	1
107054	1710	microgram fluticasone propionate spray	[micrograms fluticasone propionate spray]	0.0	4	1	1	1
107055	1710	CD4 il-2 production	[CD4 IL-2 production]	0.0	3	1	1	1
107056	1710	kappa light	[kappa light]	0.0	2	2	2	1
107057	1710	only one case with a reaction	[only one case with a reaction]	0.0	6	1	1	1
107058	1710	Albuminemia platelet factor indicator	[Albuminemia Platelet Factor indicator]	0.0	4	1	1	1
107059	1710	prevent expression	[preventing expression]	0.0	2	1	1	1
107060	1710	conjunction with interferon gamma stimulation	[conjunction with interferon gamma stimulation]	0.0	5	1	1	1
107061	1710	elam-1 of elam-1 (ic50	[ELAM-1 of ELAM-1 (IC50]	0.0	4	1	1	1
107062	1710	genital herpes simplex virus	[genital herpes simplex virus]	0.0	4	1	1	1
107063	1710	dephosphorylation of prb of form	[dephosphorylation of pRb of Form]	0.0	5	1	1	1
107064	1710	myeloid patient aml (10	[myeloid patients AML (10]	0.0	4	1	1	1
107065	1710	activation of a factor of element	[activation of a factor of element]	0.0	6	1	1	1
107066	1710	activation of two form	[activation of two forms]	0.0	4	1	1	1
107067	1710	ad 2/5 primer	[Ad 2/5 primers]	0.0	3	1	1	1
107068	1710	effect on huvec adhesion molecule	[effects on HUVEC adhesion molecules]	0.0	5	1	1	1
107069	1710	low level of hiv-1 expression	[low levels of HIV-1 expression]	0.0	5	1	1	1
107070	1710	apparent seasonal variation	[apparent seasonal variation]	0.0	3	1	1	1
107071	1710	protein in nasal lymphoma	[proteins in nasal lymphoma]	0.0	4	1	1	1
107072	1710	expression of the cd95 ligand	[Expression of the CD95 ligand]	0.0	5	1	1	1
107073	1710	species of NFATc	[species of NFATc]	0.0	3	1	1	1
107074	1710	surface expression of lt-alpha1beta2	[surface expression of LT-alpha1beta2]	0.0	4	1	1	1
107075	1710	role of microtubule	[role of microtubules]	0.0	3	1	1	1
107076	1710	211 +/- nmol	[211 +/- nmol]	0.0	3	1	1	1
107077	1710	different domain include domain	[different domains including domains]	0.0	4	1	1	1
107078	1710	effect in hiv-infected T cell	[effects in HIV-infected T cells]	0.0	5	1	1	1
107079	1710	enhancer between nucleotide	[enhancer between nucleotides]	0.0	3	1	1	1
107080	1710	putative cancer related loci	[putative cancer related loci]	0.0	4	1	1	1
107081	1710	ebv transcription factor	[EBV transcription factors]	0.0	3	1	1	1
107082	1710	nuclear affinity for T3	[nuclear affinity for T3]	0.0	4	1	1	1
107083	1710	bowel disease colitis	[bowel diseases colitis]	0.0	3	1	1	1
107084	1710	mitogen tnf-alpha	[mitogen TNF-alpha]	0.0	2	1	1	1
107085	1710	relation to approach	[relation to approaches]	0.0	3	1	1	1
107086	1710	convertase	[convertase]	0.0	1	1	1	1
107087	1710	immunocytogenetic study	[immunocytogenetic studies]	0.0	2	1	1	1
107088	1710	alone, provide evidence	[alone, providing evidence]	0.0	3	1	1	1
107089	1710	distinct adhesion molecule	[distinct adhesion molecules]	0.0	3	1	1	1
107090	1710	2.0 0.8 nm than 0.01).	[2.0 0.8 nM than 0.01).]	0.0	5	1	1	1
107091	1710	virtue of the nature	[virtue of the nature]	0.0	4	1	1	1
107092	1710	infiltrate of several disease	[infiltrates of several diseases]	0.0	4	1	1	1
107093	1710	cross-linking result	[cross-linking results]	0.0	2	1	1	1
107094	1710	cellular homeostatic switch	[cellular homeostatic switch]	0.0	3	1	1	1
107095	1710	I-TE	[I-TE]	0.0	1	1	1	1
107096	1710	d-type	[D-type]	0.0	1	1	1	1
107097	1710	phenotype in replication	[phenotype in replication]	0.0	3	1	1	1
107098	1710	transcription regulation.	[transcription regulation.]	0.0	2	1	1	1
107099	1710	interaction include the retinoblastoma protein	[interactions including the retinoblastoma protein]	0.0	5	1	1	1
107100	1710	induce characteristic	[inducing characteristics]	0.0	2	1	1	1
107101	1710	30 days.	[30 days.]	0.0	2	1	1	1
107102	1710	same calcium potency as vd	[same calcium potency as VD]	0.0	5	1	1	1
107103	1710	selective phosphatase inhibitor for protein phosphatase	[Selective phosphatase inhibitors for protein phosphatase]	0.0	6	1	1	1
107104	1710	airway cell of -insensitive asthma	[airway cells of -insensitive asthma]	0.0	5	1	1	1
107105	1710	anti-viral capsid antigen	[anti-viral capsid antigen]	0.0	3	1	1	1
107106	1710	effect of cyclosporine	[effect of cyclosporine]	0.0	3	1	1	1
107107	1710	sedimentation coefficient	[sedimentation coefficient]	0.0	2	1	1	1
107108	1710	il-8 messenger rna mrna	[IL-8 messenger RNA mRNA]	0.0	4	1	1	1
107109	1710	intracellular signalling event	[intracellular signalling event]	0.0	3	1	1	1
107110	1710	Lin- bone marrow progenitor cell	[Lin- bone marrow progenitor cells]	0.0	5	1	1	1
107111	1710	indicate functional importance	[indicating functional importance]	0.0	3	1	1	1
107112	1710	subsequent adhesion in umbilical vein cell	[subsequent adhesion in umbilical vein cells]	0.0	6	1	1	1
107113	1710	requirement for pc4 usa-derived component	[requirement for PC4 USA-derived component]	0.0	5	1	1	1
107114	1710	different systems,	[different systems,]	0.0	2	1	1	1
107115	1710	ligand-induced homodimerization of surface receptor consist	[ligand-induced homodimerization of surface receptors consisting]	0.0	6	1	1	1
107116	1710	comparable formation	[comparable formation]	0.0	2	1	1	1
107117	1710	chimeric fusion protein	[chimeric fusion protein]	0.0	3	1	1	1
107118	1710	aldosterone binding indicate the absence	[aldosterone binding indicating the absence]	0.0	5	1	1	1
107119	1710	hematopoietic progenitor with no erythropoietic potential	[hematopoietic progenitors with no erythropoietic potential]	0.0	6	1	1	1
107120	1710	two sh2 domain	[two SH2 domains]	0.0	3	2	2	1
107121	1710	target malignancy	[targeting malignancies]	0.0	2	1	1	1
107122	1710	cd37 b lymphocyte	[CD37 B lymphocytes]	0.0	3	1	1	1
107123	1710	different site	[different sites]	0.0	2	1	1	1
107124	1710	constitutive sla-dr	[constitutive SLA-DR]	0.0	2	1	1	1
107125	1710	a for G point mutation	[A for G point mutation]	0.0	5	1	1	1
107126	1710	mutation in DNA rna sample	[mutations in DNA RNA samples]	0.0	5	1	1	1
107127	1710	distal nf-kappab	[distal NF-kappaB]	0.0	2	1	1	1
107128	1710	interaction at 2% concentration	[interaction at 2% concentration]	0.0	4	1	1	1
107129	1710	oncogenic event	[oncogenic events]	0.0	2	1	1	1
107130	1710	fibrinous matrix	[fibrinous matrix]	0.0	2	1	1	1
107131	1710	prior to treatment with PAO	[prior to treatment with PAO]	0.0	5	1	1	1
107132	1710	encode the beta subunit	[encoding the beta subunit]	0.0	4	1	1	1
107133	1710	replacement suggest a additional structural role	[Replacement suggesting an additional structural role]	0.0	6	1	1	1
107134	1710	component in the development	[component in the development]	0.0	4	1	1	1
107135	1710	application of two drugs, one	[application of two drugs, one]	0.0	5	1	1	1
107136	1710	Importantly, enhancement	[Importantly, enhancement]	0.0	2	1	1	1
107137	1710	restrict expression to that lymphocyte	[restricting expression to those lymphocytes]	0.0	5	1	1	1
107138	1710	specific enhancer in assay	[specific enhancer in assays]	0.0	4	1	1	1
107139	1710	reaction of allergic asthma	[reaction of allergic asthma]	0.0	4	1	1	1
107140	1710	However, retroviral transduction develop T cell	[However, retroviral transduction developing T cells]	0.0	6	1	1	1
107141	1710	splicing (R) pre-messenger rna	[splicing (R) pre-messenger RNA]	0.0	4	1	1	1
107142	1710	coexpression of pathology	[coexpression of pathology]	0.0	3	1	1	1
107143	1710	facilitate the functional collaboration of protein	[facilitating the functional collaboration of proteins]	0.0	6	1	1	1
107144	1710	radical production/oxidative stress	[radical production/oxidative stress]	0.0	3	1	1	1
107145	1710	translocation of the latent transcription factor	[translocation of the latent transcription factor]	0.0	6	1	1	1
107146	1710	R-PK DNA fragment extend	[R-PK DNA fragment extending]	0.0	4	1	1	1
107147	1710	other pathway lead	[other pathways leading]	0.0	3	1	1	1
107148	1710	shift in the distribution	[shifts in the distribution]	0.0	4	1	1	1
107149	1710	nuclear translocation factor of T	[nuclear translocation factor of T]	0.0	5	1	1	1
107150	1710	transcriptional activation of the promoter	[transcriptional activation of the promoter]	0.0	5	1	1	1
107151	1710	lead to anemic severity	[leading to anemic severity]	0.0	4	1	1	1
107152	1710	mc38 colon adenocarcinoma	[MC38 colon adenocarcinoma]	0.0	3	1	1	1
107153	1710	plasma membrane from human leukocyte	[plasma membranes from human leukocytes]	0.0	5	1	1	1
107154	1710	cell death in cell	[cell death in cells]	0.0	4	1	1	1
107155	1710	displacement of a E-box-binding repressor implication	[Displacement of an E-box-binding repressor implications]	0.0	6	1	1	1
107156	1710	PKC -independent stimulus	[PKC -independent stimulus]	0.0	3	1	1	1
107157	1710	aldosterone to mineralocorticoid receptor	[aldosterone to mineralocorticoid receptors]	0.0	4	1	1	1
107158	1710	differentiation of HEL cell	[differentiation of HEL cells]	0.0	4	2	2	1
107159	1710	inducible nuclear component after activation	[inducible nuclear component after activation]	0.0	5	1	1	1
107160	1710	weight adaptor protein	[weight adaptor proteins]	0.0	3	1	1	1
107161	1710	CD14 5'	[CD14 5']	0.0	2	1	1	1
107162	1710	hemoglobin F staining	[hemoglobin F staining]	0.0	3	1	1	1
107163	1710	surround sequence	[surrounding sequences]	0.0	2	1	1	1
107164	1710	12-o-tetradecanoylphorbol 13-acetate induction of factor-kappaB activity	[12-O-tetradecanoylphorbol 13-acetate induction of factor-kappaB activity]	0.0	6	1	1	1
107165	1710	activator of 5'hs3	[activator of 5'HS3]	0.0	3	1	1	1
107166	1710	T cell a component	[T cells a component]	0.0	4	1	1	1
107167	1710	human killer cell by IL-2	[human killer cells by IL-2]	0.0	5	1	1	1
107168	1710	inhibitory effect in bone protein-2-	[inhibitory effects in bone protein-2-]	0.0	5	1	1	1
107169	1710	messenger pathway	[messenger pathway]	0.0	2	1	1	1
107170	1710	p50 protein level	[p50 protein levels]	0.0	3	1	1	1
107171	1710	use site-directed mutagenesis of HSs	[Using site-directed mutagenesis of HSs]	0.0	5	1	1	1
107172	1710	heterodimerizerizerizerizerizerizerizerizerizerize in solution.	[heterodimerizing in solution.]	0.0	3	1	1	1
107173	1710	multiple lytic antigen-specific reactivity as high	[multiple lytic antigen-specific reactivities as high]	0.0	6	1	1	1
107174	1710	(il)-2 promoter activity	[(IL)-2 promoter activity]	0.0	3	1	1	1
107175	1710	increase in acth in response	[increase in ACTH in response]	0.0	5	1	1	1
107176	1710	variety of pathway	[variety of pathways]	0.0	3	1	1	1
107177	1710	aml with myelomonocytic differentiation	[AML with myelomonocytic differentiation]	0.0	4	1	1	1
107178	1710	indicate independent of NFATc	[indicating independent of NFATc]	0.0	4	1	1	1
107179	1710	expansion of T cell	[expansion of T cells]	0.0	4	1	1	1
107180	1710	two trans-acting regulatory gene	[two trans-acting regulatory genes]	0.0	4	1	1	1
107181	1710	T cell during selection	[T cells during selection]	0.0	4	1	1	1
107182	1710	function of USA	[function of USA]	0.0	3	1	1	1
107183	1710	transcriptional activation of latency.	[transcriptional activation of latency.]	0.0	4	1	1	1
107184	1710	HTLV-I lymphocyte line	[HTLV-I lymphocyte line]	0.0	3	1	1	1
107185	1710	direct interaction of hematopoietic transcription factor	[Direct interaction of hematopoietic transcription factors]	0.0	6	1	1	1
107186	1710	include tumor necrosis factor alpha-induced	[including tumor necrosis factor alpha-induced]	0.0	5	1	1	1
107187	1710	determinant in protein antigen	[determinants in protein antigens]	0.0	4	1	1	1
107188	1710	two antisense rna probe	[two antisense RNA probes]	0.0	4	1	1	1
107189	1710	antigen vca	[antigen VCA]	0.0	2	1	1	1
107190	1710	sh-group in the domain	[SH-groups in the domain]	0.0	4	1	1	1
107191	1710	domain contain tandem repeat	[domain containing tandem repeats]	0.0	4	1	1	1
107192	1710	t-cell accumulation	[T-cell accumulation]	0.0	2	1	1	1
107193	1710	patient with receptor status	[patient with receptor status]	0.0	4	1	1	1
107194	1710	diverse cell types,	[diverse cell types,]	0.0	3	1	1	1
107195	1710	coordinate activation of hsf	[coordinate activation of HSF]	0.0	4	1	1	1
107196	1710	3'-azido-3'-deoxythymidine a inhibitor	[3'-azido-3'-deoxythymidine an inhibitor]	0.0	3	1	1	1
107197	1710	patient by rt-pcr	[patient by RT-PCR]	0.0	3	1	1	1
107198	1710	consistent feature	[consistent feature]	0.0	2	1	1	1
107199	1710	(five patient	[(five patients]	0.0	2	1	1	1
107200	1710	fc epsilon	[Fc epsilon]	0.0	2	1	1	1
107201	1710	various hematopoietic cell	[various hematopoietic cells]	0.0	3	1	1	1
107202	1710	ubiquitin -protein ligase	[ubiquitin -protein ligase]	0.0	3	1	1	1
107203	1710	effect during acute lung injury	[effects during acute lung injury]	0.0	5	1	1	1
107204	1710	Spi-1 transcript at temperature	[Spi-1 transcripts at temperature]	0.0	4	1	1	1
107205	1710	inhibition in ctll-2 cell	[inhibition in CTLL-2 cells]	0.0	4	1	1	1
107206	1710	IL-4 gene control	[IL-4 gene control]	0.0	3	1	1	1
107207	1710	lack the kb promoter	[lacking the kb promoter]	0.0	4	1	1	1
107208	1710	rapid posttranslational activation	[rapid posttranslational activation]	0.0	3	1	1	1
107209	1710	activation ap-1 transcription factor by PGN	[activation AP-1 transcription factors by PGN]	0.0	6	1	1	1
107210	1710	immunodeficiency virus hiv-1 repeat	[immunodeficiency virus HIV-1 repeat]	0.0	4	1	1	1
107211	1710	severe preeclampsia	[severe preeclampsia]	0.0	2	1	1	1
107212	1710	region with cofactor	[regions with cofactors]	0.0	3	1	1	1
107213	1710	lmp1 signal transduction	[LMP1 signal transduction]	0.0	3	1	1	1
107214	1710	cd86 b7-2 principal ligand for CD28	[CD86 B7-2 principal ligands for CD28]	0.0	6	1	1	1
107215	1710	approximately substnfkappab substSpl2	[approximately substNFkappaB substSpl2]	0.0	3	1	1	1
107216	1710	monocyte on endothelium	[monocytes on endothelium]	0.0	3	1	1	1
107217	1710	novel APL cell line	[novel APL cell line]	0.0	4	1	1	1
107218	1710	novel cancer related loci relevant	[novel cancer related loci relevant]	0.0	5	1	1	1
107219	1710	role in state	[role in states]	0.0	3	1	1	1
107220	1710	corticotropin release hormone gene	[corticotropin releasing hormone gene]	0.0	4	1	1	1
107221	1710	adenylyl	[adenylyl]	0.0	1	1	1	1
107222	1710	beta-actin mrna	[beta-actin mRNA]	0.0	2	1	1	1
107223	1710	gene under the control	[genes under the control]	0.0	4	1	1	1
107224	1710	contrast, engagement	[contrast, engagement]	0.0	2	1	1	1
107225	1710	transiently express LMP1 in a range	[transiently expressing LMP1 in a range]	0.0	6	1	1	1
107226	1710	tnf-alpha secretion by lps	[TNF-alpha secretion by LPS]	0.0	4	1	1	1
107227	1710	genome cell	[genome cell]	0.0	2	1	1	1
107228	1710	region of Stat3	[regions of Stat3]	0.0	3	1	1	1
107229	1710	region of Stat6	[region of Stat6]	0.0	3	1	1	1
107230	1710	model of adenovirus	[model of adenovirus]	0.0	3	1	1	1
107231	1710	electron-dense structure distinct	[electron-dense structures distinct]	0.0	3	1	1	1
107232	1710	therefore as a determinant	[therefore as a determinant]	0.0	4	1	1	1
107233	1710	activation a direct mechanism	[activation A direct mechanism]	0.0	4	1	1	1
107234	1710	encode a protein x box	[encoding a protein X box]	0.0	5	1	1	1
107235	1710	high 4-year probability	[higher 4-year probability]	0.0	3	1	1	1
107236	1710	expression of MHC class ii gene	[expression of MHC class II genes]	0.0	6	1	1	1
107237	1710	80.2 (p	[80.2 (P]	0.0	2	1	1	1
107238	1710	expression c-jun	[expression c-jun]	0.0	2	1	1	1
107239	1710	bp crh promoter fragment	[bp CRH promoter fragment]	0.0	4	1	1	1
107240	1710	hml with hypertension	[HML with hypertension]	0.0	3	1	1	1
107241	1710	heterogeneous group of disorder	[heterogeneous group of disorders]	0.0	4	1	1	1
107242	1710	subtype of acid receptor	[subtypes of acid receptors]	0.0	4	1	1	1
107243	1710	ebv-positive npc cell line	[EBV-positive NPC cell lines]	0.0	4	1	1	1
107244	1710	v14rho construct incapable	[V14Rho construct incapable]	0.0	3	1	1	1
107245	1710	certain t-cell (tcr) region beta-chain family	[certain T-cell (TCR) region beta-chain families]	0.0	6	1	1	1
107246	1710	cell-cycle-regulated phosphorylation of Id3	[cell-cycle-regulated phosphorylation of Id3]	0.0	4	1	1	1
107247	1710	normal cord blood	[normal cord blood]	0.0	3	1	1	1
107248	1710	coculture assay system	[coculture assay system]	0.0	3	1	1	1
107249	1710	basic regulation	[basic regulation]	0.0	2	1	1	1
107250	1710	immediate-early t-cell gene	[immediate-early T-cell genes]	0.0	3	1	1	1
107251	1710	implication for some physiological role	[implications for some physiological roles]	0.0	5	1	1	1
107252	1710	active transcription	[active transcription]	0.0	2	1	1	1
107253	1710	translocation of active nf-kappa b	[translocation of active NF-kappa B]	0.0	5	1	1	1
107254	1710	transcription of hiv-1	[transcription of HIV-1]	0.0	3	1	1	1
107255	1710	strong repressor	[strong repressors]	0.0	2	1	1	1
107256	1710	suggest surrogate	[suggesting surrogates]	0.0	2	1	1	1
107257	1710	however, microg/100 millileter	[However, microg/100 ml]	0.0	3	1	1	1
107258	1710	sequence within site b	[sequence within site B]	0.0	4	1	1	1
107259	1710	functional antagonism in cell	[functional antagonism in cells]	0.0	4	1	1	1
107260	1710	low number of predictions.	[low number of predictions.]	0.0	4	1	1	1
107261	1710	weight of 32, 36 to 42,	[weights of 32, 36 to 42,]	0.0	6	1	1	1
107262	1710	effect on ap-1 -binding activity	[effect on AP-1 -binding activity]	0.0	5	1	1	1
107263	1710	treatment of normal peripheral blood lymphocyte	[Treatment of normal peripheral blood lymphocytes]	0.0	6	1	1	1
107264	1710	interferon factor-1 irf-1 gene	[interferon factor-1 IRF-1 gene]	0.0	4	1	1	1
107265	1710	T cell malignancy	[T cell malignancies]	0.0	3	1	1	1
107266	1710	almost to the control level	[almost to the control level]	0.0	5	1	1	1
107267	1710	nfatc protein	[NFATc protein]	0.0	2	1	1	1
107268	1710	Rapid shuttling	[Rapid shuttling]	0.0	2	1	1	1
107269	1710	distinct subtype	[distinct subtypes]	0.0	2	1	1	1
107270	1710	detection of other intracellular signal protein	[Detection of other intracellular signaling proteins]	0.0	6	1	1	1
107271	1710	include acute lymphoblastic leukemia	[including acute lymphoblastic leukemia]	0.0	4	1	1	1
107272	1710	alloimmune	[alloimmune]	0.0	1	1	1	1
107273	1710	affect the activity of the proteasome	[affecting the activity of the proteasome]	0.0	6	1	1	1
107274	1710	express recombinant alphaiibbeta3	[expressing recombinant alphaIIbbeta3]	0.0	3	1	1	1
107275	1710	presence of a TATA element	[presence of a TATA element]	0.0	5	1	1	1
107276	1710	factor macrophage colony-stimulating factor	[factor macrophage colony-stimulating factor]	0.0	4	1	1	1
107277	1710	low content of t3, dysfunction	[low content of T3, dysfunction]	0.0	5	1	1	1
107278	1710	nuclear export nfat nuclear factor	[nuclear export NFAT nuclear factor]	0.0	5	1	1	1
107279	1710	ISGF3 alpha the component	[ISGF3 alpha the component]	0.0	4	1	1	1
107280	1710	memory cell	[memory cells]	0.0	2	1	1	1
107281	1710	gm-csf enhancer	[GM-CSF enhancers]	0.0	2	1	1	1
107282	1710	transcriptional activation of promoter	[transcriptional activation of promoters]	0.0	4	1	1	1
107283	1710	most abundant protein.	[most abundant protein.]	0.0	3	1	1	1
107284	1710	spectra	[spectra]	0.0	1	1	1	1
107285	1710	(0.8 fmol/10(7) cell	[(0.8 fmol/10(7) cells]	0.0	3	1	1	1
107286	1710	include immuno-modulatory effect	[including immuno-modulatory effects]	0.0	3	1	1	1
107287	1710	generation of unrelated family	[generations of unrelated families]	0.0	4	1	1	1
107288	1710	Differential regulation in human cell line	[Differential regulation in human cell lines]	0.0	6	1	1	1
107289	1710	domain include distinct domain	[domains including distinct domains]	0.0	4	1	1	1
107290	1710	mechanism in rheumatoid synovium	[mechanisms in rheumatoid synovium]	0.0	4	1	1	1
107291	1710	cell types, include T lymphocyte	[cell types, including T lymphocytes]	0.0	5	1	1	1
107292	1710	hydrocortisone (F)	[hydrocortisone (F)]	0.0	2	1	1	1
107293	1710	vdrnrar-	[VDR-RXR-]	0.0	1	1	1	1
107294	1710	c-terminus of NF-kappa b p65	[C-terminus of NF-kappa B p65]	0.0	5	1	1	1
107295	1710	inhibitory action of nm23 protein	[Inhibitory action of nm23 proteins]	0.0	5	1	1	1
107296	1710	encode sequence	[encoding sequences]	0.0	2	1	1	1
107297	1710	binding of transactivation factor	[binding of transactivation factor]	0.0	4	1	1	1
107298	1710	role in z responsiveness,	[role in Z responsiveness,]	0.0	4	1	1	1
107299	1710	expression analysis	[expression analyses]	0.0	2	1	1	1
107300	1710	genital herpes simplex virus hsv	[genital herpes simplex virus HSV]	0.0	5	1	1	1
107301	1710	expression comments]	[expression comments]]	0.0	2	1	1	1
107302	1710	susceptibility of this cell	[susceptibility of these cells]	0.0	4	1	1	1
107303	1710	Class endothelial cell MHC class	[Class endothelial cell MHC class]	0.0	5	1	1	1
107304	1710	molecular mimicry between gliadin peptide	[molecular mimicry between gliadin peptides]	0.0	5	1	1	1
107305	1710	hiv reverse transcription	[HIV reverse transcription]	0.0	3	1	1	1
107306	1710	field gel	[field gel]	0.0	2	1	1	1
107307	1710	novel tip-associated protein	[novel Tip-associated protein]	0.0	3	1	1	1
107308	1710	potent AS oligonucleotide C-JUN as oligonucleotide	[potent AS oligonucleotides C-JUN AS oligonucleotides]	0.0	6	1	1	1
107309	1710	icam-1 adhesivity toward polymorphonuclear leukocyte	[ICAM-1 adhesivity toward polymorphonuclear leukocytes]	0.0	5	1	1	1
107310	1710	opposite (stimulatory effect	[opposite (stimulatory effects]	0.0	3	1	1	1
107311	1710	po-b dna-binding	[PO-B DNA-binding]	0.0	2	1	1	1
107312	1710	(12-25 repeats).	[(12-25 repeats).]	0.0	2	1	1	1
107313	1710	migration of filarial antigen t-cell	[migration of filarial antigen T-cells]	0.0	5	1	1	1
107314	1710	subtypes,	[subtypes,]	0.0	1	1	1	1
107315	1710	human gene locus	[human gene locus]	0.0	3	1	1	1
107316	1710	DNA template contain copy	[DNA templates containing copies]	0.0	4	1	1	1
107317	1710	subtypes.	[subtypes.]	0.0	1	1	1	1
107318	1710	DNA binding protein complex	[DNA binding protein complexes]	0.0	4	1	1	1
107319	1710	sequence similarity to NFATp -binding site	[sequence similarity to NFATp -binding sites]	0.0	6	1	1	1
107320	1710	adrenocorticotropic hormone acth	[adrenocorticotropic hormone ACTH]	0.0	3	1	1	1
107321	1710	gdsp a novel elastase inhibitor	[GDSP a novel elastase inhibitor]	0.0	5	1	1	1
107322	1710	molecular background	[molecular background]	0.0	2	1	1	1
107323	1710	id family of protein	[Id family of proteins]	0.0	4	1	1	1
107324	1710	perspective to the molecular interaction	[perspective to the molecular interactions]	0.0	5	1	1	1
107325	1710	nuclear protein repressor element	[nuclear protein repressor element]	0.0	4	1	1	1
107326	1710	inhibitory effect a novel quinone derivative	[Inhibitory effect a novel quinone derivative]	0.0	6	1	1	1
107327	1710	promoter in b lymphocyte	[promoters in B lymphocytes]	0.0	4	1	1	1
107328	1710	depletion of Sp1	[depletion of Sp1]	0.0	3	1	1	1
107329	1710	increase in the bind activity	[increase in the binding activity]	0.0	5	1	1	1
107330	1710	primary hyperparathyroidism php	[primary hyperparathyroidism PHP]	0.0	3	1	1	1
107331	1710	expression of 135(oh)2d3 receptor on lymphocyte	[Expression of 1,25(OH)2D3 receptors on lymphocytes]	0.0	6	1	1	1
107332	1710	ubiquitin-activating enzyme	[ubiquitin-activating enzyme]	0.0	2	1	1	1
107333	1710	regulate multiple stage of cell development	[regulating multiple stages of cell development]	0.0	6	1	1	1
107334	1710	intraductal component	[intraductal component]	0.0	2	1	1	1
107335	1710	use immunostaining	[using immunostaining]	0.0	2	1	1	1
107336	1710	response to the immediate early protein	[responses to the immediate early proteins]	0.0	6	1	1	1
107337	1710	level of g0s2 mrna	[levels of G0S2 mRNA]	0.0	4	1	1	1
107338	1710	anthracycline cell	[anthracycline cells]	0.0	2	1	1	1
107339	1710	signal to a heterologous domain	[signal to a heterologous domain]	0.0	5	1	1	1
107340	1710	3 other autoantigen	[3 other autoantigens]	0.0	3	1	1	1
107341	1710	include organ	[including organs]	0.0	2	1	1	1
107342	1710	implication for disorder	[implications for disorders]	0.0	3	1	1	1
107343	1710	functional ebf -binding site	[functional EBF -binding sites]	0.0	4	1	1	1
107344	1710	physiologic plausibility	[physiologic plausibility]	0.0	2	1	1	1
107345	1710	expression of the NF-YA subunit	[expression of the NF-YA subunit]	0.0	5	1	1	1
107346	1710	group cid cell	[group CID cells]	0.0	3	1	1	1
107347	1710	protein in the T cell clone	[protein in the T cell clones]	0.0	6	1	1	1
107348	1710	mitogenic agent	[mitogenic agents]	0.0	2	1	1	1
107349	1710	topoisomerase drug	[topoisomerase drugs]	0.0	2	1	1	1
107350	1710	migration of 48-hr antigen t-cell	[migration of 48-hr antigen T-cells]	0.0	5	1	1	1
107351	1710	il-1beta in cell	[IL-1beta in cells]	0.0	3	1	1	1
107352	1710	specific uptake with failure A-CRF	[specific uptake with failure A-CRF]	0.0	5	1	1	1
107353	1710	different stage of commitment	[different stages of commitment]	0.0	4	1	1	1
107354	1710	proteins, differ in degree	[proteins, differing in degree]	0.0	4	1	1	1
107355	1710	bimodal pattern	[bimodal pattern]	0.0	2	1	1	1
107356	1710	inhibition of transcriptional regulatory protein	[inhibition of transcriptional regulatory proteins]	0.0	5	1	1	1
107357	1710	extensive granulopoiesis postnatally, die by 8	[extensive granulopoiesis postnatally, dying by 8]	0.0	6	1	1	1
107358	1710	demonstrate the activity	[demonstrating the activity]	0.0	3	1	1	1
107359	1710	tcf-2 alpha	[TCF-2 alpha]	0.0	2	1	1	1
107360	1710	b cell factor	[B cell factor]	0.0	3	1	1	1
107361	1710	ongoing protein	[ongoing protein]	0.0	2	1	1	1
107362	1710	C/EBP family member	[C/EBP family member]	0.0	3	1	1	1
107363	1710	transcription of gene include gm-csf	[transcription of genes including GM-CSF]	0.0	5	1	1	1
107364	1710	activator protein-1 nuclear factor il-6	[activator protein-1 nuclear factor IL-6]	0.0	5	1	1	1
107365	1710	resting extract	[Resting extracts]	0.0	2	1	1	1
107366	1710	prevalence in breast aspirate	[Prevalence in breast aspirates]	0.0	4	1	1	1
107367	1710	(bind capacity 3.3	[(binding capacity 3.3]	0.0	3	1	1	1
107368	1710	monocytes:	[monocytes:]	0.0	1	1	1	1
107369	1710	Ter cell from transgenic mouse	[Ter cells from transgenic mice]	0.0	5	1	1	1
107370	1710	dose-related increase in tal1 mrna	[dose-related increase in TAL1 mRNA]	0.0	5	1	1	1
107371	1710	role binding motif by mutagenesis	[roles binding motifs by mutagenesis]	0.0	5	1	1	1
107372	1710	cell reaction	[cell reaction]	0.0	2	1	1	1
107373	1710	cell ECs in hypoxia	[cells ECs in hypoxia]	0.0	4	1	1	1
107374	1710	analysis use a viral stock	[analysis using a viral stock]	0.0	5	1	1	1
107375	1710	skip	[SKIPs]	0.0	1	1	1	1
107376	1710	activation of replication	[activation of replication]	0.0	3	1	1	1
107377	1710	basic leucine zipper (bzip)	[basic leucine zipper (bZIP)]	0.0	4	1	1	1
107378	1710	recur	[recurring]	0.0	1	1	1	1
107379	1710	nf-kappab response	[NF-kappaB response]	0.0	2	1	1	1
107380	1710	old) from individual	[old) from individuals]	0.0	3	1	1	1
107381	1710	lymphocytic leukaemias	[lymphocytic leukaemias]	0.0	2	1	1	1
107382	1710	function for different pkc isotype	[functions for different PKC isotypes]	0.0	5	1	1	1
107383	1710	use a novel assay	[Using a novel assay]	0.0	4	1	1	1
107384	1710	MNC nuclear extract	[MNC nuclear extracts]	0.0	3	1	1	1
107385	1710	tnf myristate acetate PMA	[TNF myristate acetate PMA]	0.0	4	1	1	1
107386	1710	most effective therapy	[most effective therapy]	0.0	3	1	1	1
107387	1710	bacterial response element	[bacterial response elements]	0.0	3	1	1	1
107388	1710	use of two promoter	[use of two promoters]	0.0	4	1	1	1
107389	1710	GM-CSF tata box bp	[GM-CSF TATA box bp]	0.0	4	1	1	1
107390	1710	expression of the rar-alpha	[Expression of the RAR-alpha]	0.0	4	1	1	1
107391	1710	coactivator cbp	[coactivator CBP]	0.0	2	1	1	1
107392	1710	two single mutation	[two single mutations]	0.0	3	1	1	1
107393	1710	activation in pma-treated fibroblast	[activation in PMA-treated fibroblasts]	0.0	4	1	1	1
107394	1710	role control hematopoietic gene transcription	[role controlling hematopoietic gene transcription]	0.0	5	1	1	1
107395	1710	pathogenesis of lymphocytic leukemia CLL	[pathogenesis of lymphocytic leukemia CLL]	0.0	5	1	1	1
107396	1710	response gene expression	[response gene expression]	0.0	3	1	1	1
107397	1710	cytokine interleukin-8 il-8	[cytokine interleukin-8 IL-8]	0.0	3	1	1	1
107398	1710	anti- il-6 monoclonal antibody MoAb	[anti- IL-6 monoclonal antibody MoAb]	0.0	5	1	1	1
107399	1710	e2f-1 level	[E2F-1 levels]	0.0	2	1	1	1
107400	1710	-null	[-null]	0.0	1	1	1	1
107401	1710	BamHI-A region	[BamHI-A region]	0.0	2	1	1	1
107402	1710	factor lbf2 to lbf7	[factors LBF2 to LBF7]	0.0	4	1	1	1
107403	1710	ets binding site EBS	[Ets binding sites EBS]	0.0	4	1	1	1
107404	1710	function in pre-B cell	[function in pre-B cells]	0.0	4	1	1	1
107405	1710	l540	[L540]	0.0	1	1	1	1
107406	1710	calf efcs culture	[calf (FCS+) culture]	0.0	3	1	1	1
107407	1710	zeta- luciferase	[zeta- luciferase]	0.0	2	1	1	1
107408	1710	40-50% decrease in ap-1	[40-50% decrease in AP-1]	0.0	4	1	1	1
107409	1710	basophilia in leukaemia analysis	[basophilia in leukaemia analysis]	0.0	4	1	1	1
107410	1710	contain factor kappab NFkappaB complex	[containing factor kappaB NFkappaB complexes]	0.0	5	1	1	1
107411	1710	cd44 mrna expression	[CD44 mRNA expression]	0.0	3	1	1	1
107412	1710	two protein in normal human lymphocyte	[two proteins in normal human lymphocytes]	0.0	6	1	1	1
107413	1710	use antisense oligonucleotide	[using antisense oligonucleotides]	0.0	3	1	1	1
107414	1710	sample of 80 21/10(3)	[samples of 80 21/10(3)]	0.0	4	1	1	1
107415	1710	erythroleukemic cell line	[erythroleukemic cell lines]	0.0	3	1	1	1
107416	1710	nf-kappa b gene expression	[NF-kappa B gene expression]	0.0	4	1	1	1
107417	1710	apparent association of hla-dr3	[apparent association of HLA-DR3]	0.0	4	1	1	1
107418	1710	induction upon stimulation	[induction upon stimulation]	0.0	3	1	1	1
107419	1710	functionally express receptor mutant	[functionally expressing receptor mutants]	0.0	4	1	1	1
107420	1710	potential hpp- cell	[potential HPP- cells]	0.0	3	1	1	1
107421	1710	13-kb c-fe locus	[13-kb c-fes locus]	0.0	3	1	1	1
107422	1710	role mediate	[role mediating]	0.0	2	1	1	1
107423	1710	thrombin -generate capacity secondary	[thrombin -generating capacity secondary]	0.0	4	1	1	1
107424	1710	mature myeloid cell granulocyte pmn	[mature myeloid cells granulocytes PMN]	0.0	5	1	1	1
107425	1710	upper limit of er content	[upper limit of ER content]	0.0	5	1	1	1
107426	1710	also element	[also elements]	0.0	2	1	1	1
107427	1710	proliferation in response to stimulation	[proliferation in response to stimulation]	0.0	5	1	1	1
107428	1710	affect naive th cell	[affecting naive Th cells]	0.0	4	1	1	1
107429	1710	shp2-interacting adaptor protein a disulfide-linked dimer	[SHP2-interacting adaptor protein a disulfide-linked dimer]	0.0	6	1	1	1
107430	1710	prior modification	[prior modification]	0.0	2	1	1	1
107431	1710	dibutyrate/calcium	[dibutyrate/calcium]	0.0	1	1	1	1
107432	1710	zap-70- signal pathway	[zap-70- signaling pathways]	0.0	3	1	1	1
107433	1710	treatment with high-dose RA	[treatment with high-dose RA]	0.0	4	1	1	1
107434	1710	inhibition by combination of a inhibitor	[Inhibition by combination of a inhibitor]	0.0	6	1	1	1
107435	1710	genital tract with bv	[genital tracts with BV]	0.0	4	1	1	1
107436	1710	cell use a adenovirus	[cells using a adenovirus]	0.0	4	1	1	1
107437	1710	patient with depressive disorder MDD	[patients with depressive disorder MDD]	0.0	5	1	1	1
107438	1710	cell-surface isoform	[cell-surface isoforms]	0.0	2	1	1	1
107439	1710	leukocyte in patient with hypertension	[leukocytes in patients with hypertension]	0.0	5	1	1	1
107440	1710	incubation of jurkat cell	[incubation of Jurkat cells]	0.0	4	1	1	1
107441	1710	accord to affinities.	[according to affinities.]	0.0	3	1	1	1
107442	1710	kinetic relative	[kinetics relative]	0.0	2	1	1	1
107443	1710	Differential responsiveness	[Differential responsiveness]	0.0	2	1	1	1
107444	1710	center of organ	[center of organs]	0.0	3	1	1	1
107445	1710	compound 4-octylphenol	[compound 4-octylphenol]	0.0	2	1	1	1
107446	1710	thus, deregulation	[Thus, deregulation]	0.0	2	1	1	1
107447	1710	and/or post-translational modification	[and/or post-translational modification]	0.0	3	2	2	1
107448	1710	resistance in major depressive disorder	[resistance in major depressive disorder]	0.0	5	2	2	1
107449	1710	-biotin peroxidase detection system	[-biotin peroxidase detection system]	0.0	4	1	1	1
107450	1710	[3h]aldosterone mbp-hbd	[[3H]aldosterone MBP-HBD]	0.0	2	1	1	1
107451	1710	maintain the basal level	[maintaining the basal level]	0.0	4	1	1	1
107452	1710	uptake with renal failure A-CRF	[uptake with renal failure A-CRF]	0.0	5	1	1	1
107453	1710	contain the potent vp16 transactivation domain	[containing the potent VP16 transactivation domains]	0.0	6	1	1	1
107454	1710	activation of myeloid-cell-specific gene	[activation of myeloid-cell-specific genes]	0.0	4	1	1	1
107455	1710	deficiency syndrome the hot	[deficiency syndromes the hot]	0.0	4	1	1	1
107456	1710	unidentified factor(	[unidentified factor(s)]	0.0	2	1	1	1
107457	1710	pea1 AP1	[PEA1 AP1]	0.0	2	1	1	1
107458	1710	degradation in the process	[degradation in the process]	0.0	4	1	1	1
107459	1710	12 follicular hyperplasia fh	[12 follicular hyperplasia FH]	0.0	4	1	1	1
107460	1710	characterization signal determinant	[Characterization signaling determinants]	0.0	3	1	1	1
107461	1710	exposure to 10 nm	[exposure to 10 nM]	0.0	4	1	1	1
107462	1710	protein latency	[Protein latency]	0.0	2	1	1	1
107463	1710	increase the probability	[increasing the probability]	0.0	3	1	1	1
107464	1710	20 additional residue	[20 additional residues]	0.0	3	1	1	1
107465	1710	terminus of the ar	[terminus of the AR]	0.0	4	1	1	1
107466	1710	kinase such as Syk	[kinases such as Syk]	0.0	4	1	1	1
107467	1710	thus, tal1 activation	[Thus, TAL1 activation]	0.0	3	1	1	1
107468	1710	reactivity to a progesterone receptor-specific antibody	[Reactivity to a progesterone receptor-specific antibody]	0.0	6	1	1	1
107469	1710	Intranuclear delivery of functional nf-kappab	[Intranuclear delivery of functional NF-kappaB]	0.0	5	1	1	1
107470	1710	renewal	[renewal]	0.0	1	1	1	1
107471	1710	glucocorticoid type	[glucocorticoid type]	0.0	2	1	1	1
107472	1710	severe embryonic development abnormality	[severe embryonic development abnormalities]	0.0	4	1	1	1
107473	1710	prostaglandin I2 PGI2 a regulator	[prostaglandin I2 PGI2 a regulator]	0.0	5	1	1	1
107474	1710	human osteosarcoma cell	[human osteosarcoma cells]	0.0	3	1	1	1
107475	1710	first evidence for the requirement	[first evidence for the requirement]	0.0	5	1	1	1
107476	1710	contain zinc finger through and,	[containing zinc fingers through and,]	0.0	5	1	1	1
107477	1710	mediator in disease	[mediators in diseases]	0.0	3	1	1	1
107478	1710	antagonism in cell	[antagonism in cells]	0.0	3	1	1	1
107479	1710	peripheral venous blood	[peripheral venous blood]	0.0	3	1	1	1
107480	1710	subunit of nf-at	[subunit of NF-AT]	0.0	3	1	1	1
107481	1710	protein from IARC 301	[proteins from IARC 301]	0.0	4	1	1	1
107482	1710	constitutive basal phosphorylation STAT3	[Constitutive basal phosphorylation STAT3]	0.0	4	1	1	1
107483	1710	form of transcription factor	[forms of transcription factor]	0.0	4	1	1	1
107484	1710	effect of cortisol level	[effects of cortisol level]	0.0	4	1	1	1
107485	1710	two response element	[Two response elements]	0.0	3	1	1	1
107486	1710	protein include Cbl	[proteins including Cbl]	0.0	3	1	1	1
107487	1710	sharp contrast,	[sharp contrast,]	0.0	2	1	1	1
107488	1710	mass-spectrometric analysis	[mass-spectrometric analysis]	0.0	2	1	1	1
107489	1710	receptor on human leukocyte	[receptors on human leukocytes]	0.0	4	1	1	1
107490	1710	therapy of hiv-1 infection	[therapy of HIV-1 infection]	0.0	4	1	1	1
107491	1710	Bmax after DEX	[Bmax after DEX]	0.0	3	1	1	1
107492	1710	requirement in activation	[requirement in activation]	0.0	3	1	1	1
107493	1710	immunofluorescence study of monocyte	[Immunofluorescence studies of monocytes]	0.0	4	1	1	1
107494	1710	24r,25 (oh)2d3	[24R,25 (OH)2D3]	0.0	2	1	1	1
107495	1710	type a family	[Type a family]	0.0	3	1	1	1
107496	1710	mechanism of gp91phox gene expression	[mechanism of gp91phox gene expression]	0.0	5	1	1	1
107497	1710	vitro tyrosine	[vitro tyrosine]	0.0	2	1	1	1
107498	1710	patient with x-linked ricket	[patients with X-linked rickets]	0.0	4	1	1	1
107499	1710	xp/ cs entity	[XP/ CS entity]	0.0	3	1	1	1
107500	1710	bioavailability from cell	[bioavailability from cells]	0.0	3	1	1	1
107501	1710	inducible nuclear component within minute	[inducible nuclear component within min]	0.0	5	1	1	1
107502	1710	resistance in depressive disorder	[resistance in depressive disorder]	0.0	4	2	2	1
107503	1710	synthesis of the nuclear subunit	[synthesis of the nuclear subunit]	0.0	5	1	1	1
107504	1710	however, nuclear target	[However, nuclear targets]	0.0	3	1	1	1
107505	1710	g0s2 expression	[G0S2 expression]	0.0	2	1	1	1
107506	1710	site in the cytosol	[sites in the cytosol]	0.0	4	1	1	1
107507	1710	p100 inhibition	[p100 inhibition]	0.0	2	1	1	1
107508	1710	complex with b subunit	[complex with B subunit]	0.0	4	1	1	1
107509	1710	colony-stimumulatelany-stg factor proliferation	[colony-stimulating factor proliferation]	0.0	3	1	1	1
107510	1710	signal result	[signal resulting]	0.0	2	1	1	1
107511	1710	status of the cell	[status of the cells]	0.0	4	1	1	1
107512	1710	major active component	[major active component]	0.0	3	1	1	1
107513	1710	epsilon BP	[epsilon BP]	0.0	2	1	1	1
107514	1710	also a effector	[also an effector]	0.0	3	1	1	1
107515	1710	mv), normalize after delivery	[mV), normalizing after delivery]	0.0	4	1	1	1
107516	1710	increase in tnf-alpha mrna	[increase in TNF-alpha mRNA]	0.0	4	1	1	1
107517	1710	scheme for asthma pathogenesis	[scheme for asthma pathogenesis]	0.0	4	1	1	1
107518	1710	domain of il-2r beta	[domains of IL-2R beta]	0.0	4	1	1	1
107519	1710	concern the signal	[concerning the signals]	0.0	3	1	1	1
107520	1710	basal activity a transcriptional activator	[basal activity a transcriptional activator]	0.0	5	1	1	1
107521	1710	G1/S phase control	[G1/S phase control]	0.0	3	1	1	1
107522	1710	major complex fashion	[major complex fashion]	0.0	3	1	1	1
107523	1710	6 h from level	[6 h from levels]	0.0	4	1	1	1
107524	1710	bhrf1 early-lytic-cycle protein with distant homology	[BHRF1 early-lytic-cycle protein with distant homology]	0.0	6	1	1	1
107525	1710	polypryrimidine-binding factor pybf	[polypryrimidine-binding factor PYBF]	0.0	3	1	1	1
107526	1710	only the kD protein	[only the kD protein]	0.0	4	1	1	1
107527	1710	specific nfatp antibody	[specific NFATp antibody]	0.0	3	1	1	1
107528	1710	selectivity for aldosterone over cortisol	[selectivity for aldosterone over cortisol]	0.0	5	2	2	1
107529	1710	several marker of poor prognosis,	[several markers of poor prognosis,]	0.0	5	1	1	1
107530	1710	(iii) activation of factor kappa b	[(iii) activation of factor kappa B]	0.0	6	1	1	1
107531	1710	strategy for the detection	[strategies for the detection]	0.0	4	1	1	1
107532	1710	vein cell HUVEC CoCl2	[vein cells HUVEC CoCl2]	0.0	4	1	1	1
107533	1710	factor (ref. 1)	[factor (ref. 1)]	0.0	3	1	1	1
107534	1710	inducible transcriptional regulator of cellular gene	[inducible transcriptional regulators of cellular genes]	0.0	6	1	1	1
107535	1710	several other b gene	[several other B genes]	0.0	4	1	1	1
107536	1710	dead cell g-csf	[dead cells G-CSF]	0.0	3	1	1	1
107537	1710	activity in cell type	[activity in cell types]	0.0	4	1	1	1
107538	1710	thrombin receptor agonist peptide trp	[thrombin receptor agonist peptide TRP]	0.0	5	1	1	1
107539	1710	induction requirement in T cell	[Induction requirements in T cells]	0.0	5	1	1	1
107540	1710	neutrophil stimulus	[neutrophil stimuli]	0.0	2	1	1	1
107541	1710	various chronic rheumatic disease (12:	[various chronic rheumatic diseases (12:]	0.0	5	1	1	1
107542	1710	61 pmol/L; in woman	[61 pmol/L; in women]	0.0	4	1	1	1
107543	1710	CD48 NF-kappa b site	[CD48 NF-kappa B site]	0.0	4	1	1	1
107544	1710	elf-2	[elf-2]	0.0	1	1	1	1
107545	1710	extract from human k562 cell	[extracts from human K562 cells]	0.0	5	1	1	1
107546	1710	molecular mechanism of IL-5	[molecular mechanisms of IL-5]	0.0	4	1	1	1
107547	1710	action of cytokine tnf	[action of cytokines TNF]	0.0	4	1	1	1
107548	1710	polysomy	[polysomy]	0.0	1	1	1	1
107549	1710	therapeutic approach to the immunotherapy	[therapeutic approaches to the immunotherapy]	0.0	5	1	1	1
107550	1710	silencer of homeotic gene	[silencer of homeotic genes]	0.0	4	1	1	1
107551	1710	polymorphic, tandem repeat CAG	[polymorphic, tandem repeats CAG]	0.0	4	1	1	1
107552	1710	mrna (75 versus 150 minutes).	[mRNA (75 vs 150 minutes).]	0.0	5	1	1	1
107553	1710	presence of Lymphotoxin-alpha	[presence of Lymphotoxin-alpha]	0.0	3	1	1	1
107554	1710	characteristic of YJ cell	[characteristics of YJ cells]	0.0	4	1	1	1
107555	1710	renal failure CRF	[renal failure CRF]	0.0	3	1	1	1
107556	1710	ligation with CD80	[ligation with CD80]	0.0	3	1	1	1
107557	1710	major histocompatibility (mhc) class molecule	[major histocompatibility (MHC) class molecules]	0.0	5	1	1	1
107558	1710	export nfat	[export NFAT]	0.0	2	1	1	1
107559	1710	5' DNA sequence	[5' DNA sequences]	0.0	3	1	1	1
107560	1710	promoter of cytokine interleukin	[promoters of cytokines interleukin]	0.0	4	1	1	1
107561	1710	cis-activation of promoter 1b	[cis-activation of promoter 1b]	0.0	4	1	1	1
107562	1710	mutation in the bp region	[mutations in the bp region]	0.0	5	1	1	1
107563	1710	previously, a inducible enhancer	[Previously, an inducible enhancer]	0.0	4	1	1	1
107564	1710	nf-kappa b in human lesion	[NF-kappa B in human lesions]	0.0	5	1	1	1
107565	1710	human il-5 gene transcription	[human IL-5 gene transcription]	0.0	4	1	1	1
107566	1710	context of bl cell	[context of BL cells]	0.0	4	1	1	1
107567	1710	pure p21ras	[pure p21ras]	0.0	2	1	1	1
107568	1710	il-2 -dependent cell transformation	[IL-2 -dependent cell transformation]	0.0	4	1	1	1
107569	1710	human TAFII	[Human TAFII]	0.0	2	1	1	1
107570	1710	content of b transcription factor	[contents of B transcription factors]	0.0	5	1	1	1
107571	1710	/Fas ligand	[/Fas ligand]	0.0	2	1	1	1
107572	1710	three gata element of hiv-1 repeat	[three GATA elements of HIV-1 repeat]	0.0	6	1	1	1
107573	1710	bypass T cell receptor signal	[bypassing T cell receptor signaling]	0.0	5	1	1	1
107574	1710	monocytic thp-1 cell at relevant doses.	[monocytic THP-1 cells at relevant doses.]	0.0	6	1	1	1
107575	1710	gene transfection	[gene transfection]	0.0	2	1	1	1
107576	1710	alter other pathway	[altering other pathways]	0.0	3	1	1	1
107577	1710	parallel the normal decline	[paralleling the normal decline]	0.0	4	1	1	1
107578	1710	ibr/f	[IBR/F]	0.0	1	1	1	1
107579	1710	activity of extract	[activity of extracts]	0.0	3	1	1	1
107580	1710	distinct, subtype	[distinct, subtype]	0.0	2	1	1	1
107581	1710	high expression of c-fo	[high expression of c-fos]	0.0	4	1	1	1
107582	1710	blood lymphocyte chronic leukemia	[blood lymphocytes chronic leukemia]	0.0	4	1	1	1
107583	1710	Subunit a integral component	[Subunit an integral component]	0.0	4	1	1	1
107584	1710	monocytic hl60 cell	[monocytic HL60 cells]	0.0	3	1	1	1
107585	1710	Epstein-Barr virus infection of b cell	[Epstein-Barr virus infection of B cells]	0.0	6	1	1	1
107586	1710	naturally occur breakdown product	[naturally occurring breakdown product]	0.0	4	1	1	1
107587	1710	disruption of motifs: the activation domain	[disruptions of motifs: the activation domain]	0.0	6	1	1	1
107588	1710	acid decarboxylase	[acid decarboxylase]	0.0	2	2	2	1
107589	1710	potential sequence	[potential sequences]	0.0	2	1	1	1
107590	1710	actively divide positive cell	[actively dividing positive cells]	0.0	4	1	1	1
107591	1710	contrast to b cell	[contrast to B cells]	0.0	4	1	1	1
107592	1710	bind site in a b-cell line	[binding site in a B-cell line]	0.0	6	1	1	1
107593	1710	mediate neutrophil adhesion	[mediating neutrophil adhesion]	0.0	3	1	1	1
107594	1710	protein of daltons.	[protein of daltons.]	0.0	3	1	1	1
107595	1710	potentiation of nonphlogistic clearance	[potentiation of nonphlogistic clearance]	0.0	4	1	1	1
107596	1710	endocrine lineage use polyclonal antisera	[endocrine lineages using polyclonal antisera]	0.0	5	1	1	1
107597	1710	transcription-polymerase chain reaction pcr	[transcription-polymerase chain reaction PCR]	0.0	4	1	1	1
107598	1710	include thiol deprivation	[including thiol deprivation]	0.0	3	1	1	1
107599	1710	domain in interleukin -9-mediate cell proliferation	[domains in interleukin -9-mediated cell proliferation]	0.0	6	1	1	1
107600	1710	organs,	[organs,]	0.0	1	1	1	1
107601	1710	follow stimulate factor treatment	[following stimulating factor treatment]	0.0	4	1	1	1
107602	1710	bcl-2 to CD3	[BCL-2 to CD3]	0.0	3	1	1	1
107603	1710	factor not 4681 to 4701	[Factors nt 4681 to 4701]	0.0	5	1	1	1
107604	1710	also constitutive activity	[also constitutive activity]	0.0	3	1	1	1
107605	1710	dominant mutant of the IL-1	[dominant mutants of the IL-1]	0.0	5	1	1	1
107606	1710	selective function	[selective functions]	0.0	2	1	1	1
107607	1710	multiple functionally critical cis element	[multiple functionally critical cis elements]	0.0	5	1	1	1
107608	1710	addition to mAb-stimulated T cell	[addition to mAb-stimulated T cells]	0.0	5	1	1	1
107609	1710	cloning of TCF-1	[cloning of TCF-1]	0.0	3	1	1	1
107610	1710	specific binding to a receptor	[specific binding to a receptor]	0.0	5	1	1	1
107611	1710	ar antibody	[AR antibodies]	0.0	2	2	2	1
107612	1710	gp160 for h	[gp160 for h]	0.0	3	1	1	1
107613	1710	applicability, allow testing of the effect	[applicability, allowing testing of the effects]	0.0	6	1	1	1
107614	1710	BRCA1 function,	[BRCA1 function,]	0.0	2	1	1	1
107615	1710	mediator of light	[mediators of light]	0.0	3	1	1	1
107616	1710	express human CD40	[expressing human CD40]	0.0	3	1	1	1
107617	1710	gm-csf receptor beta subunit	[GM-CSF receptor beta subunit]	0.0	4	1	1	1
107618	1710	population of progenitor /precursor grow	[populations of progenitors /precursors growing]	0.0	5	1	1	1
107619	1710	variable include plasma hormone	[variables, including plasma hormone]	0.0	4	1	1	1
107620	1710	valine gtt	[valine GTT]	0.0	2	1	1	1
107621	1710	high, thus establish a relation MHC	[high, thus establishing an relation MHC]	0.0	6	1	1	1
107622	1710	kappa b dna-binding	[kappa B DNA-binding]	0.0	3	1	1	1
107623	1710	pkc isoform in human macrophage	[PKC isoforms in human macrophages]	0.0	5	1	1	1
107624	1710	support the expression	[supporting the expression]	0.0	3	1	1	1
107625	1710	start at minute	[starting at min]	0.0	3	1	1	1
107626	1710	DNase-I hypersensitive site	[DNase-I hypersensitive sites]	0.0	3	1	1	1
107627	1710	active sle (92.9%)	[active SLE (92.9%)]	0.0	3	1	1	1
107628	1710	human myeloid u-937 cell	[human myeloid U-937 cells]	0.0	4	1	1	1
107629	1710	kb id-3l transcript	[kb Id-3L transcript]	0.0	3	1	1	1
107630	1710	Positive autoregulation	[Positive autoregulation]	0.0	2	1	1	1
107631	1710	stimulation major basic protein	[Stimulation major basic protein]	0.0	4	1	1	1
107632	1710	control subject ige	[control subjects IgE]	0.0	3	1	1	1
107633	1710	antioxidants, n-acetylcysteine nac	[antioxidants, N-acetylcysteine NAC]	0.0	3	1	1	1
107634	1710	Notch1/TAN-1 receptor	[Notch1/TAN-1 receptor]	0.0	2	1	1	1
107635	1710	hour in icrf-193 cell	[hour in ICRF-193 cells]	0.0	4	1	1	1
107636	1710	pts; fluticasone: pts)	[pts; fluticasone: pts)]	0.0	3	1	1	1
107637	1710	Interestingly, alteration in a fragment	[Interestingly, alteration in a fragment]	0.0	5	1	1	1
107638	1710	extend from -392 bp	[extending from -392 bp]	0.0	4	1	1	1
107639	1710	cell of cardiac transplant recipient	[cells of cardiac transplant recipients]	0.0	5	1	1	1
107640	1710	glucocorticoid binding circadian rhythm of adrenocorticotropin	[glucocorticoid binding circadian rhythms of adrenocorticotropin]	0.0	6	1	1	1
107641	1710	overall amino acid homology	[overall amino acid homology]	0.0	4	1	1	1
107642	1710	mp of 5 ng/ml	[MP of 5 ng/ml]	0.0	4	1	1	1
107643	1710	sequence-specific small molecule	[Sequence-specific small molecules]	0.0	3	1	1	1
107644	1710	inhibitor kappa b	[inhibitor kappa B]	0.0	3	1	1	1
107645	1710	low level of trap alpha-naphthyl-acetate-esterase	[low levels of TRAP alpha-naphthyl-acetate-esterase]	0.0	5	1	1	1
107646	1710	GATA-3 bind to the gata site	[GATA-3 binding to the GATA site]	0.0	6	1	1	1
107647	1710	peptide selection more selective	[peptide selection more selective]	0.0	4	1	1	1
107648	1710	increase in the steady-state level	[increase in the steady-state level]	0.0	5	1	1	1
107649	1710	position effect	[Position effect]	0.0	2	1	1	1
107650	1710	pfu of Ad5 /animal,	[pfu of Ad5 /animal,]	0.0	4	1	1	1
107651	1710	express human CD80	[expressing human CD80]	0.0	3	1	1	1
107652	1710	fetal hemoglobin HbF	[fetal hemoglobin HbF]	0.0	3	1	1	1
107653	1710	Effect of oxidative stress	[Effects of oxidative stress]	0.0	4	1	1	1
107654	1710	Functional b-cell response	[Functional B-cell response]	0.0	3	1	1	1
107655	1710	mutation ap3-l site	[mutation AP3-L site]	0.0	3	1	1	1
107656	1710	tcr delta gene expression	[TcR delta gene expression]	0.0	4	1	1	1
107657	1710	(j774) cell line	[(J774) cell lines]	0.0	3	1	1	1
107658	1710	fragment in yeast	[fragments in yeast]	0.0	3	1	1	1
107659	1710	alpha,25-dihydroxyvitamin D3 monocytic differentiation	[alpha,25-dihydroxyvitamin D3 monocytic differentiation]	0.0	4	1	1	1
107660	1710	role regulate the expression	[role regulating the expression]	0.0	4	2	2	1
107661	1710	induction of fra-1 follow engagement	[Induction of fra-1 following engagement]	0.0	5	1	1	1
107662	1710	modulation of cell phenotype	[modulation of cell phenotype]	0.0	4	1	1	1
107663	1710	human erythroid	[human erythroid]	0.0	2	1	1	1
107664	1710	repressor of translation initiation	[repressors of translation initiation]	0.0	4	2	2	1
107665	1710	induction by t-cell leukemia virus type	[Induction by T-cell leukemia virus type]	0.0	6	1	1	1
107666	1710	-21/-1	[-21/-12,]	0.0	1	1	1	1
107667	1710	Nuclear 3,5,3'-triiodothyronine receptor circulate lymphocyte	[Nuclear 3,5,3'-triiodothyronine receptors circulating lymphocytes]	0.0	5	1	1	1
107668	1710	difference in NDP kinase expression	[difference in NDP kinase expression]	0.0	5	1	1	1
107669	1710	activation of interactions.	[activation of interactions.]	0.0	3	1	1	1
107670	1710	negative molecule	[negative molecule]	0.0	2	1	1	1
107671	1710	overexpression a protein phosphatase	[overexpression a protein phosphatase]	0.0	4	1	1	1
107672	1710	binding of this factor	[Binding of these factors]	0.0	4	1	1	1
107673	1710	Raf-1 kinase activity	[Raf-1 kinase activity]	0.0	3	1	1	1
107674	1710	two major protein-binding site	[Two major protein-binding sites]	0.0	4	1	1	1
107675	1710	rate of constitutive apoptosis	[rate of constitutive apoptosis]	0.0	4	1	1	1
107676	1710	succinimide-containing peptide	[succinimide-containing peptide]	0.0	2	1	1	1
107677	1710	mobility shift assay complex	[mobility shift assay complexes]	0.0	4	1	1	1
107678	1710	antigen-driven expansion)	[antigen-driven expansion)]	0.0	2	1	1	1
107679	1710	ligand-induced homodimerization of surface receptor	[ligand-induced homodimerization of surface receptors]	0.0	5	1	1	1
107680	1710	well-known immunological consequence	[well-known immunological consequences]	0.0	3	1	1	1
107681	1710	disease expression	[disease expression]	0.0	2	1	1	1
107682	1710	ifn- gamma	[IFN- gamma]	0.0	2	1	1	1
107683	1710	copy of the PRDII domain	[copies of the PRDII domain]	0.0	5	1	1	1
107684	1710	depend on the combination	[depending on the combination]	0.0	4	1	1	1
107685	1710	conformational change in p21ras	[conformational change in p21ras]	0.0	4	1	1	1
107686	1710	thapsigargin ca2+	[thapsigargin Ca2+]	0.0	2	1	1	1
107687	1710	oxidative condition	[oxidative conditions]	0.0	2	1	1	1
107688	1710	nonstructural trans-acting regulatory gene	[nonstructural trans-acting regulatory genes]	0.0	4	1	1	1
107689	1710	tar sequence	[TAR sequence]	0.0	2	1	1	1
107690	1710	induce expression from viral cycle promoter	[inducing expression from viral cycle promoters]	0.0	6	1	1	1
107691	1710	endemic bl	[endemic BL]	0.0	2	1	1	1
107692	1710	removal of the site	[removal of the site]	0.0	4	1	1	1
107693	1710	protein products, p27rex	[protein products, p27rex]	0.0	3	1	1	1
107694	1710	Central system cell	[Central system cells]	0.0	3	1	1	1
107695	1710	soluble transglycosylase	[soluble transglycosylase]	0.0	2	1	1	1
107696	1710	complex adaptor function	[complex adaptor function]	0.0	3	1	1	1
107697	1710	involvement of adenylate cyclase	[Involvement of adenylate cyclase]	0.0	4	1	1	1
107698	1710	transduction mechanism.	[transduction mechanism.]	0.0	2	1	1	1
107699	1710	alpha a -gene product	[alpha A -gene product]	0.0	4	1	1	1
107700	1710	suggest a effect at the level.	[suggesting a effect at the level.]	0.0	6	1	1	1
107701	1710	subsequent loss of function	[subsequent loss of function]	0.0	4	1	1	1
107702	1710	two protein tyrosine kinase module	[two protein tyrosine kinase modules]	0.0	5	1	1	1
107703	1710	diffuse b cell lymphoma	[diffuse B cell lymphomas]	0.0	4	1	1	1
107704	1710	retinoic acid metabolism	[retinoic acid metabolism]	0.0	3	1	1	1
107705	1710	single protein bzlf1	[single protein BZLF1]	0.0	3	1	1	1
107706	1710	half of the hbx protein	[half of the HBx protein]	0.0	5	1	1	1
107707	1710	oxidant acid hocl 1 mm)	[oxidant acid HOCl 1 mM)]	0.0	5	1	1	1
107708	1710	reactivation of x-chromosome material	[reactivation of X-chromosome material]	0.0	4	1	1	1
107709	1710	primary carcinoma	[primary carcinoma]	0.0	2	1	1	1
107710	1710	contain 128 bp of sequence	[containing 128 bp of sequence]	0.0	5	1	1	1
107711	1710	cell harc	[cells HAECs]	0.0	2	1	1	1
107712	1710	eosinophil-associated granule protein	[eosinophil-associated granule proteins]	0.0	3	1	1	1
107713	1710	mbp gene transcription	[MBP gene transcription]	0.0	3	1	1	1
107714	1710	human counterpart.	[human counterpart.]	0.0	2	1	1	1
107715	1710	hormone for h	[hormone for h]	0.0	3	1	1	1
107716	1710	molecular basis of the translocation	[molecular basis of the translocation]	0.0	5	1	1	1
107717	1710	nuclear t3 binding capacity	[nuclear T3 binding capacity]	0.0	4	1	1	1
107718	1710	unit monocyte	[unit monocyte]	0.0	2	1	1	1
107719	1710	early expression of BZLF-1	[early expression of BZLF-1]	0.0	4	1	1	1
107720	1710	severe atopic dermatitis patient	[severe atopic dermatitis patients]	0.0	4	1	1	1
107721	1710	calcineurin a type	[calcineurin a type]	0.0	3	1	1	1
107722	1710	implication for condition	[implications for conditions]	0.0	3	1	1	1
107723	1710	percentage of t-cell leukemia	[percentage of T-cell leukemias]	0.0	4	1	1	1
107724	1710	likely other components.	[likely other components.]	0.0	3	1	1	1
107725	1710	response region,	[response region,]	0.0	2	1	1	1
107726	1710	MAPk kinase	[MAPk kinase]	0.0	2	1	1	1
107727	1710	effect on hiv expression	[effects on HIV expression]	0.0	4	1	1	1
107728	1710	mef2c activation	[MEF2C activation]	0.0	2	1	1	1
107729	1710	mouse il-10r	[mouse IL-10R]	0.0	2	1	1	1
107730	1710	involve ca2+	[involving Ca2+]	0.0	2	1	1	1
107731	1710	molecular framework signal as il-1	[molecular framework signaling as IL-1]	0.0	5	1	1	1
107732	1710	majority of adult tissue	[majority of adult tissues]	0.0	4	1	1	1
107733	1710	binding to DNA	[binding to DNA]	0.0	3	1	1	1
107734	1710	close gene	[close genes]	0.0	2	1	1	1
107735	1710	transform property	[transforming properties]	0.0	2	1	1	1
107736	1710	effect on the trans-activation	[effect on the trans-activation]	0.0	4	1	1	1
107737	1710	function similar to il-6r	[functions similar to IL-6R]	0.0	4	1	1	1
107738	1710	strength signal	[Strength signaling]	0.0	2	1	1	1
107739	1710	tradd mutant	[TRADD mutant]	0.0	2	1	1	1
107740	1710	several problem	[several problems]	0.0	2	1	1	1
107741	1710	activation of Stat1alpha	[activation of Stat1alpha]	0.0	3	1	1	1
107742	1710	il-4 b cell	[IL-4 B cells]	0.0	3	1	1	1
107743	1710	class of growth	[class of growth]	0.0	3	1	1	1
107744	1710	phase protein in response	[phase proteins in response]	0.0	4	1	1	1
107745	1710	E-box-dependent reporter	[E-box-dependent reporter]	0.0	2	1	1	1
107746	1710	department of lymphocyte	[Department of lymphocytes]	0.0	3	1	1	1
107747	1710	factor control vascular-specific expression	[factors controlling vascular-specific expression]	0.0	4	1	1	1
107748	1710	slot	[slot]	0.0	1	1	1	1
107749	1710	non-malignant lymph node	[non-malignant lymph nodes]	0.0	3	1	1	1
107750	1710	formation of active tetrameric complex	[formation of active tetrameric complexes]	0.0	5	1	1	1
107751	1710	cyto-differentiating potential	[cyto-differentiating potential]	0.0	2	1	1	1
107752	1710	characterization of HZF	[characterization of HZF]	0.0	3	1	1	1
107753	1710	activation of the transcriptional factor	[activation of the transcriptional factor]	0.0	5	1	1	1
107754	1710	diversification of a number	[diversification of a number]	0.0	4	1	1	1
107755	1710	Effect on les-induced transcription factor ap-1	[Effects on LPS-induced transcription factors AP-1]	0.0	6	1	1	1
107756	1710	cell-permeable peptide	[cell-permeable peptide]	0.0	2	1	1	1
107757	1710	retinoic acid receptor pml-rar	[retinoic acid receptor PML-RAR]	0.0	4	1	1	1
107758	1710	truly uncommon phenomenon	[truly uncommon phenomenon]	0.0	3	1	1	1
107759	1710	Ireland	[Ireland]	0.0	1	1	1	1
107760	1710	response to corticotropin-releasing hormone	[response to corticotropin-releasing hormone]	0.0	4	1	1	1
107761	1710	(day hpc	[(day HPCs]	0.0	2	1	1	1
107762	1710	clone with ltr contain b element	[clones with LTRs containing B elements]	0.0	6	1	1	1
107763	1710	adherence of monocyte	[adherence of monocytes]	0.0	3	1	1	1
107764	1710	evidence for a sensitive pathway	[evidence for an sensitive pathway]	0.0	5	1	1	1
107765	1710	cytokine namely, by il-2	[cytokines namely, by IL-2]	0.0	4	1	1	1
107766	1710	identification of gene hypermethylation	[identification of gene hypermethylation]	0.0	4	1	1	1
107767	1710	DNA bind basic domain	[DNA binding basic domain]	0.0	4	1	1	1
107768	1710	regulate lymphocyte homeostasis	[regulating lymphocyte homeostasis]	0.0	3	1	1	1
107769	1710	antisense phosphorothioate oligodeoxynucleotides	[antisense phosphorothioate oligodeoxynucleotides]	0.0	3	1	1	1
107770	1710	result on cell line	[results on cell lines]	0.0	4	1	1	1
107771	1710	potent transcriptional repressor icer	[potent transcriptional repressor ICER]	0.0	4	1	1	1
107772	1710	alpha,25-dihydroxyvitamin D3 differentiation	[alpha,25-dihydroxyvitamin D3 differentiation]	0.0	3	1	1	1
107773	1710	three category of factor cell-specific factor	[three categories of factors cell-specific factors]	0.0	6	1	1	1
107774	1710	growth stimulus	[growth stimuli]	0.0	2	1	1	1
107775	1710	autocrine regulatory mechanism for cytokine	[autocrine regulatory mechanism for cytokine]	0.0	5	1	1	1
107776	1710	cell dexamethasone binding assay	[cell dexamethasone binding assay]	0.0	4	1	1	1
107777	1710	least six isomorph	[least six isomorphs]	0.0	3	1	1	1
107778	1710	trigger of complement receptor CR1	[triggering of complement receptors CR1]	0.0	5	2	2	1
107779	1710	presence 13-acetate	[presence 13-acetate]	0.0	2	1	1	1
107780	1710	gel analysis	[gel analysis]	0.0	2	1	1	1
107781	1710	Finapres	[Finapres]	0.0	1	1	1	1
107782	1710	reduction in gene activation	[reduction in gene activation]	0.0	4	1	1	1
107783	1710	cycle gene	[cycle genes]	0.0	2	3	3	1
107784	1710	selective activation of transcriptional factor	[selective activation of transcriptional factors]	0.0	5	1	1	1
107785	1710	group of individual	[group of individuals]	0.0	3	1	1	1
107786	1710	/TRAF2	[/TRAF2]	0.0	1	1	1	1
107787	1710	molecular weight 13000	[molecular weight 13,000]	0.0	3	1	1	1
107788	1710	chromosomal localization use fluorescence	[chromosomal localization using fluorescence]	0.0	4	1	1	1
107789	1710	phase of friend erythroleukemia	[phase of Friend erythroleukemia]	0.0	4	1	1	1
107790	1710	possible mechanism of estradiol acting	[possible mechanisms of estradiol acting]	0.0	5	1	1	1
107791	1710	DNA-protein complex formation	[DNA-protein complex formation]	0.0	3	1	1	1
107792	1710	IFN a IFNA	[IFN A IFNA]	0.0	3	1	1	1
107793	1710	proteasome degradation a role in senescence	[proteasome degradation A role in senescence]	0.0	6	1	1	1
107794	1710	-3alpha	[-3alpha]	0.0	1	1	1	1
107795	1710	MEDLINE search	[MEDLINE search]	0.0	2	1	1	1
107796	1710	separable gene inhibitory response	[separable gene inhibitory responses]	0.0	4	1	1	1
107797	1710	endometrium during the menstrual cycle	[endometrium during the menstrual cycle]	0.0	5	1	1	1
107798	1710	chronic leukemia CML cell	[chronic leukemia CML cells]	0.0	4	1	1	1
107799	1710	level of hiv rna	[levels of HIV RNA]	0.0	4	1	1	1
107800	1710	Furthermore, function	[Furthermore, functions]	0.0	2	1	1	1
107801	1710	human peripheral blood NK cell	[human peripheral blood NK cells]	0.0	5	1	1	1
107802	1710	determinant process of normal differentiation	[determinant processes of normal differentiation]	0.0	5	1	1	1
107803	1710	concern the pathogenesis	[concerning the pathogenesis]	0.0	3	1	1	1
107804	1710	four cell gene	[four cell genes]	0.0	3	1	1	1
107805	1710	approximately substnfkappab substSp23	[approximately substNFkappaB substSp23]	0.0	3	1	1	1
107806	1710	erp -related transcript	[ERP -related transcripts]	0.0	3	1	1	1
107807	1710	varicella-zoster virus peptide in vitro	[varicella-zoster virus peptides in vitro]	0.0	5	1	1	1
107808	1710	intima beneath ec	[intima beneath EC]	0.0	3	1	1	1
107809	1710	cytosolic nf-kappa b accumulation ready	[cytosolic NF-kappa B accumulation ready]	0.0	5	1	1	1
107810	1710	factor-kappaB transcription factor	[factor-kappaB transcription factors]	0.0	3	1	1	1
107811	1710	activation of the isoform	[activation of the isoforms]	0.0	4	1	1	1
107812	1710	inhibition in monocytic cell	[inhibition in monocytic cells]	0.0	4	1	1	1
107813	1710	16-bp AMP response element	[16-bp AMP response element]	0.0	4	1	1	1
107814	1710	addition of nfkb2	[addition of NFKB2]	0.0	3	1	1	1
107815	1710	differential b -mediated gene expression	[differential B -mediated gene expression]	0.0	5	1	1	1
107816	1710	42 month (range, months).	[42 months (range, months).]	0.0	4	1	1	1
107817	1710	tyrosine kinase activity,	[tyrosine kinase activity,]	0.0	3	1	1	1
107818	1710	change of nuclear protein-binding activity	[changes of nuclear protein-binding activities]	0.0	5	1	1	1
107819	1710	stress lead to migration	[stress leading to migration]	0.0	4	1	1	1
107820	1710	two-dimensional analysis	[Two-dimensional analysis]	0.0	2	1	1	1
107821	1710	JAK3 type ii	[JAK3 Type II]	0.0	3	1	1	1
107822	1710	rapid induction of collagenase-1 transcription	[rapid induction of collagenase-1 transcription]	0.0	5	1	1	1
107823	1710	induction of transcriptional activation	[induction of transcriptional activation]	0.0	4	1	1	1
107824	1710	expression of bhrf1 in a line	[expression of BHRF1 in a line]	0.0	6	1	1	1
107825	1710	ring chromosome	[ring chromosome]	0.0	2	1	1	1
107826	1710	regulator of b gene expression	[regulator of B gene expression]	0.0	5	1	1	1
107827	1710	initiation of inflammation	[initiation of inflammation]	0.0	3	1	1	1
107828	1710	underlying suppression	[underlying suppression]	0.0	2	1	1	1
107829	1710	contrast, CAT gene expression	[contrast, CAT gene expression]	0.0	4	1	1	1
107830	1710	rapid rate epithelia	[rapid rate epithelia]	0.0	3	1	1	1
107831	1710	kd nmol/L) nmol/L)	[Kd nmol/L) nmol/L)]	0.0	3	1	1	1
107832	1710	stage of myeloid commitment	[stages of myeloid commitment]	0.0	4	1	1	1
107833	1710	enhancer-dependent effect of cytokine	[enhancer-dependent effect of cytokines]	0.0	4	1	1	1
107834	1710	5 u/ml	[5 U/mL]	0.0	2	1	1	1
107835	1710	rapid modulation	[rapid modulation]	0.0	2	1	1	1
107836	1710	additional residue	[additional residues]	0.0	2	1	1	1
107837	1710	incubation of extract NE	[incubation of extracts NE]	0.0	4	1	1	1
107838	1710	factor activation	[factor activation]	0.0	2	2	2	1
107839	1710	mouse spleen development	[mouse spleen development]	0.0	3	1	1	1
107840	1710	ca2+-mediated activation of Rap1 in platelet	[Ca2+-mediated activation of Rap1 in platelets]	0.0	6	1	1	1
107841	1710	functional role of this factor	[functional roles of these factor]	0.0	5	1	1	1
107842	1710	thus, competition between two activator	[Thus, competition between two activators]	0.0	5	1	1	1
107843	1710	protective role	[protective role]	0.0	2	1	1	1
107844	1710	expression of adult globin gene	[expression of adult globin genes]	0.0	5	1	1	1
107845	1710	migration ChtM of leukocyte to serum	[migration ChtM of leukocytes to serum]	0.0	6	1	1	1
107846	1710	cord T	[cord T]	0.0	2	1	1	1
107847	1710	virus latent	[virus latent]	0.0	2	1	1	1
107848	1710	isoform, nfatc.beta	[isoform, NFATc.beta]	0.0	2	1	1	1
107849	1710	different pattern secretion.	[different patterns secretion.]	0.0	3	1	1	1
107850	1710	Furthermore, introduction	[Furthermore, introduction]	0.0	2	1	1	1
107851	1710	precise congruence	[precise congruence]	0.0	2	1	1	1
107852	1710	stress-induced signal pathway	[stress-induced signaling pathways]	0.0	3	1	1	1
107853	1710	human interleukin gene by glucocorticoid	[human interleukin gene by glucocorticoids]	0.0	5	1	1	1
107854	1710	pdtc pathway	[PDTC pathways]	0.0	2	1	1	1
107855	1710	bovine artery	[bovine artery]	0.0	2	1	1	1
107856	1710	direct bear	[direct bearing]	0.0	2	1	1	1
107857	1710	TCR phosphorylation	[TCR phosphorylation]	0.0	2	1	1	1
107858	1710	stimulation of pml expression	[stimulation of PML expression]	0.0	4	1	1	1
107859	1710	overexpression of IL-1 kinase	[overexpression of IL-1 kinase]	0.0	4	1	1	1
107860	1710	suppression of one	[suppression of one]	0.0	3	1	1	1
107861	1710	indirect, role: alteration	[indirect, role: alteration]	0.0	3	1	1	1
107862	1710	ebv binding to cd21	[EBV binding to CD21]	0.0	4	1	1	1
107863	1710	immediate early regulator	[immediate early regulators]	0.0	3	1	1	1
107864	1710	reaction of asthma	[reaction of asthma]	0.0	3	1	1	1
107865	1710	role of cyclic AMP response	[Role of cyclic AMP response]	0.0	5	1	1	1
107866	1710	protein with a partial domain	[proteins with a partial domain]	0.0	5	1	1	1
107867	1710	molecular evidence	[molecular evidence]	0.0	2	1	1	1
107868	1710	incubation,	[incubation,]	0.0	1	1	1	1
107869	1710	generation of NFAT complex	[generation of NFAT complexes]	0.0	4	1	1	1
107870	1710	multiple effect	[multiple effects]	0.0	2	3	3	1
107871	1710	protein j kappa	[protein J kappa]	0.0	3	1	1	1
107872	1710	only in the presence	[only in the presence]	0.0	4	1	1	1
107873	1710	first, cd45 antibody	[First, CD45 antibodies]	0.0	3	1	1	1
107874	1710	major histocompatibility complex immune deficiency	[major histocompatibility complex immune deficiency]	0.0	5	1	1	1
107875	1710	CD30 antibody,	[CD30 antibody,]	0.0	2	1	1	1
107876	1710	strand hGR rdna	[strand hGR cDNAs]	0.0	3	1	1	1
107877	1710	export of unspliced mrna	[export of unspliced mRNA]	0.0	4	1	1	1
107878	1710	Monoclonal	[Monoclonal]	0.0	1	1	1	1
107879	1710	Interferon-alpha induction	[Interferon-alpha induction]	0.0	2	1	1	1
107880	1710	close, inverse correlation	[close, inverse correlation]	0.0	3	1	1	1
107881	1710	tartrate-resistant acid phosphatase	[tartrate-resistant acid phosphatase]	0.0	3	1	1	1
107882	1710	multiple effect on cytokine production	[multiple effects on cytokine production]	0.0	5	1	1	1
107883	1710	half-life (t1/2)	[Half-life (t1/2)]	0.0	2	1	1	1
107884	1710	cell carcinoma patient	[cell carcinoma patients]	0.0	3	1	1	1
107885	1710	endogenous fasL mrna	[endogenous fasL mRNA]	0.0	3	1	1	1
107886	1710	segment to p element	[segment to P elements]	0.0	4	1	1	1
107887	1710	transcriptional response include pathway	[transcriptional responses including pathways]	0.0	4	1	1	1
107888	1710	peptide gdsp	[peptide GDSP]	0.0	2	1	1	1
107889	1710	down-regulation of mcp-1 expression	[down-regulation of MCP-1 expression]	0.0	4	1	1	1
107890	1710	smad	[Smad]	0.0	1	1	1	1
107891	1710	renin (869 pg/ml;	[renin (869 pg/ml;]	0.0	3	1	1	1
107892	1710	domain with sh2 domain-binding motif	[domains with SH2 domain-binding motifs]	0.0	5	1	1	1
107893	1710	effect on the induction phase	[effect on the induction phase]	0.0	5	1	1	1
107894	1710	processes, include cell growth	[processes, including cell growth]	0.0	4	1	1	1
107895	1710	deletion of residue	[deletion of residues]	0.0	3	1	1	1
107896	1710	class of structure	[class of structures]	0.0	3	1	1	1
107897	1710	growth factor receptor EGFR	[growth factor receptor EGFR]	0.0	4	1	1	1
107898	1710	DNA-protein complex with extract	[DNA-protein complexes with extracts]	0.0	4	1	1	1
107899	1710	mouse 70z/3 cell	[mouse 70Z/3 cells]	0.0	3	1	1	1
107900	1710	adenoviral technique block nf-kappab	[adenoviral technique blocking NF-kappaB]	0.0	4	1	1	1
107901	1710	thymus-dependent humoral immune response	[thymus-dependent humoral immune responses]	0.0	4	1	1	1
107902	1710	effect on TNFalpha release	[effects on TNFalpha release]	0.0	4	1	1	1
107903	1710	mineralocorticoid receptor status	[mineralocorticoid receptor status]	0.0	3	1	1	1
107904	1710	remarkable change	[remarkable changes]	0.0	2	1	1	1
107905	1710	2 retinoid -dependent marker	[2 retinoid -dependent markers]	0.0	4	1	1	1
107906	1710	viral survivalepromot protein Epstein Barr	[viral survival-promoting proteins Epstein Barr]	0.0	5	1	1	1
107907	1710	expression of cytoskeleton	[expression of cytoskeleton]	0.0	3	1	1	1
107908	1710	latter nuclear factor	[latter nuclear factor]	0.0	3	1	1	1
107909	1710	significance,	[significance,]	0.0	1	1	1	1
107910	1710	central component	[central components]	0.0	2	1	1	1
107911	1710	transcription 6 tyrosine phosphorylation	[transcription 6 tyrosine phosphorylation]	0.0	4	1	1	1
107912	1710	unidentified factor( binding	[unidentified factor(s) binding]	0.0	3	1	1	1
107913	1710	fibroblast b	[fibroblast B]	0.0	2	1	1	1
107914	1710	labeling by immunofluorescence from five tonsil	[labeling by immunofluorescence from five tonsils]	0.0	6	1	1	1
107915	1710	nf-kappa b accumulation	[NF-kappa B accumulation]	0.0	3	1	1	1
107916	1710	presence of serum	[presence of serum]	0.0	3	1	1	1
107917	1710	T cell responsive	[T cells responsive]	0.0	3	1	1	1
107918	1710	cell priming culture	[cell priming cultures]	0.0	3	1	1	1
107919	1710	complete tolerance	[complete tolerance]	0.0	2	1	1	1
107920	1710	high proportion of low responder	[higher proportions of low responders]	0.0	5	1	1	1
107921	1710	individual response to the protein	[individual responses to the proteins]	0.0	5	1	1	1
107922	1710	genomic transcription	[genomic transcription]	0.0	2	1	1	1
107923	1710	one other nfat-sensitive gene	[one other NFAT-sensitive gene]	0.0	4	1	1	1
107924	1710	concentration of native peptide ligand	[concentrations of native peptide ligand]	0.0	5	1	1	1
107925	1710	hiv-1 disease	[HIV-1 disease]	0.0	2	1	1	1
107926	1710	contact between blood lymphocyte	[contact between blood lymphocytes]	0.0	4	1	1	1
107927	1710	signal pathway with sensitivity	[signaling pathways with sensitivity]	0.0	4	1	1	1
107928	1710	pts; fluticasone: 2.4 pts)	[pts; fluticasone: 2.4 pts)]	0.0	4	1	1	1
107929	1710	discernible effect	[discernible effect]	0.0	2	1	1	1
107930	1710	b-cell proliferation of protein	[B-cell proliferation of proteins]	0.0	4	1	1	1
107931	1710	increase exercise	[increasing exercise]	0.0	2	1	1	1
107932	1710	hydrophobic c-terminal tail	[hydrophobic C-terminal tail]	0.0	3	1	1	1
107933	1710	expression of gene in primary cell	[expression of genes in primary cells]	0.0	6	1	1	1
107934	1710	inhibition in b cell	[inhibition in B cells]	0.0	4	1	1	1
107935	1710	expansion of the Th2 lineage	[expansion of the Th2 lineage]	0.0	5	1	1	1
107936	1710	region of nf-kappab p65	[region of NF-kappaB p65]	0.0	4	1	1	1
107937	1710	6 hours' exposure	[6 hours' exposure]	0.0	3	1	1	1
107938	1710	reconstitution in jcam1 cell by Syk	[Reconstitution in JCaM1 cells by Syk]	0.0	6	1	1	1
107939	1710	cd11b antigen in cell	[CD11b antigen in cells]	0.0	4	1	1	1
107940	1710	extend bp	[extending bp]	0.0	2	1	1	1
107941	1710	Indeed, addition	[Indeed, addition]	0.0	2	1	1	1
107942	1710	complex, gpiiia	[complex, GPIIIa]	0.0	2	1	1	1
107943	1710	binding of IL-2	[binding of IL-2]	0.0	3	1	1	1
107944	1710	effect of monochloramine	[effects of monochloramine]	0.0	3	1	1	1
107945	1710	presence of recombinant il-10	[presence of recombinant IL-10]	0.0	4	1	1	1
107946	1710	monoclonal cell antibody maeca	[monoclonal cell antibodies mAECA]	0.0	4	1	1	1
107947	1710	Addition of the sequence	[Addition of the sequence]	0.0	4	1	1	1
107948	1710	calcium -dependent gene induction	[Calcium -dependent gene induction]	0.0	4	1	1	1
107949	1710	contrast, somatic cell fusion	[contrast, somatic cell fusion]	0.0	4	1	1	1
107950	1710	role of protein	[role of proteins]	0.0	3	1	1	1
107951	1710	monocyte production of cytokine	[monocyte production of cytokines]	0.0	4	1	1	1
107952	1710	healthy smoker	[healthy smokers]	0.0	2	1	1	1
107953	1710	envelope inner membrane	[envelope inner membrane]	0.0	3	2	2	1
107954	1710	resolution through two step	[Resolution through two steps]	0.0	4	1	1	1
107955	1710	factor nf-at (ref. 1)	[factor NF-AT (ref. 1)]	0.0	4	1	1	1
107956	1710	Jurkat T cell line deficient	[Jurkat T cell lines deficient]	0.0	5	1	1	1
107957	1710	distinct intracellular signal pathway	[distinct intracellular signaling pathways]	0.0	4	1	1	1
107958	1710	motif by fide p50/p65 heterodimer	[motif by fide p50/p65 heterodimers]	0.0	5	1	1	1
107959	1710	eight different form	[eight different forms]	0.0	3	1	1	1
107960	1710	human jurkat mouse el-4 cell	[human Jurkat mouse EL-4 cells]	0.0	5	1	1	1
107961	1710	contrast to lps effects, ap-1	[contrast to LPS effects, AP-1]	0.0	5	1	1	1
107962	1710	long term treatment	[long term treatment]	0.0	3	1	1	1
107963	1710	cross-linking tyrosine phosphorylation of Itk	[cross-linking tyrosine phosphorylation of Itk]	0.0	5	1	1	1
107964	1710	nf-kappab -binding activity	[NF-kappaB -binding activity]	0.0	3	1	1	1
107965	1710	cytokine -modulate	[Cytokine -modulating]	0.0	2	1	1	1
107966	1710	stimulation by dose of specific peptide	[Stimulation by doses of specific peptide]	0.0	6	1	1	1
107967	1710	expression during the response	[expression during the response]	0.0	4	1	1	1
107968	1710	only the exon	[only the exon]	0.0	3	1	1	1
107969	1710	far-upstream alpha-globin enhancer	[far-upstream alpha-globin enhancer]	0.0	3	1	1	1
107970	1710	binding interaction	[binding interactions]	0.0	2	1	1	1
107971	1710	smooth muscle myosin chain	[smooth muscle myosin chain]	0.0	4	1	1	1
107972	1710	transform ability	[transforming abilities]	0.0	2	1	1	1
107973	1710	role for calcitriol	[role for calcitriol]	0.0	3	1	1	1
107974	1710	regulatory property of leukemia factor HLF	[regulatory properties of leukemia factor HLF]	0.0	6	1	1	1
107975	1710	viral latency.	[viral latency.]	0.0	2	1	1	1
107976	1710	distal factor (NF)-AT	[distal factor (NF)-AT]	0.0	3	1	1	1
107977	1710	generation of cytotoxic lymphocyte	[generation of cytotoxic lymphocytes]	0.0	4	1	1	1
107978	1710	subpopulation t-	[subpopulations T-]	0.0	2	1	1	1
107979	1710	restrictive anorexia nervosa	[restrictive anorexia nervosa]	0.0	3	1	1	1
107980	1710	TGACGTCA	[TGACGTCA]	0.0	1	1	1	1
107981	1710	stimulation on melanoma	[Stimulation on melanomas]	0.0	3	1	1	1
107982	1710	Chronic leukemia	[Chronic leukemia]	0.0	2	1	1	1
107983	1710	glucocorticoid receptor (gr) level	[glucocorticoid receptor (GR) levels]	0.0	4	1	1	1
107984	1710	induce the nuclear expression of nf-kappab	[inducing the nuclear expression of NF-kappaB]	0.0	6	1	1	1
107985	1710	precursor of kda	[precursor of kDa]	0.0	3	1	1	1
107986	1710	phosphorylation of the retinoblastoma family	[phosphorylation of the retinoblastoma family]	0.0	5	1	1	1
107987	1710	role of physical interaction	[role of physical interactions]	0.0	4	1	1	1
107988	1710	dephosphorylated form	[dephosphorylated form]	0.0	2	2	2	1
107989	1710	cellular stress agent	[cellular stress agents]	0.0	3	1	1	1
107990	1710	Ca2+ channel	[Ca2+ channel]	0.0	2	1	1	1
107991	1710	use approach	[using approaches]	0.0	2	1	1	1
107992	1710	ng/ml of phorbol ester	[ng/ml of phorbol ester]	0.0	4	1	1	1
107993	1710	mediator in human cell	[mediators in human cells]	0.0	4	1	1	1
107994	1710	3 member	[3 members]	0.0	2	1	1	1
107995	1710	rise to a long proliferation	[rise to a long proliferation]	0.0	5	1	1	1
107996	1710	patient' physician	[patient's physician]	0.0	2	1	1	1
107997	1710	dna-binding structure	[DNA-binding structure]	0.0	2	1	1	1
107998	1710	lac repressor	[lac repressor]	0.0	2	1	1	1
107999	1710	favorable course 0.05, chi2 test).	[favorable course 0.05, chi2 test).]	0.0	5	1	1	1
108000	1710	Furthermore, retinoic acid receptor	[Furthermore, retinoic acid receptor]	0.0	4	1	1	1
108001	1710	protein family, homologous	[protein family, homologous]	0.0	3	1	1	1
108002	1710	mumol cortisol to subject	[mumol cortisol to subjects]	0.0	4	1	1	1
108003	1710	(30 minutes) to retinoic acid	[(30 minutes) to retinoic acid]	0.0	5	1	1	1
108004	1710	terminal segment	[terminal segment]	0.0	2	1	1	1
108005	1710	CD3 phosphorylation	[CD3 phosphorylation]	0.0	2	1	1	1
108006	1710	8.9+/-1.2 nmol/L) for cortisol	[8.9+/-1.2 nmol/L) for cortisol]	0.0	4	1	1	1
108007	1710	presence of protein	[presence of proteins]	0.0	3	1	1	1
108008	1710	early promoter	[early promoter]	0.0	2	1	1	1
108009	1710	3,5,3'-triiodothyronine receptor t3r circulate human lymphocyte	[3,5,3'-triiodothyronine receptors T3R circulating human lymphocytes]	0.0	6	1	1	1
108010	1710	c-fo (99+/-15	[c-fos (99+/-15]	0.0	2	1	1	1
108011	1710	level of tnf mrna expression	[level of TNF mRNA expression]	0.0	5	1	1	1
108012	1710	transluminal angioplasty	[transluminal angioplasty]	0.0	2	1	1	1
108013	1710	increase in plasma cortisol level	[increase in plasma cortisol levels]	0.0	5	1	1	1
108014	1710	carboxy-terminal region	[carboxy-terminal regions]	0.0	2	1	1	1
108015	1710	two potential reading frame	[two potential reading frames]	0.0	4	1	1	1
108016	1710	herpes tegument protein	[herpes tegument proteins]	0.0	3	1	1	1
108017	1710	CD40 immunogenic MMs	[CD40 immunogenic MMs]	0.0	3	1	1	1
108018	1710	factors, in proinflammatory cytokine	[factors, in proinflammatory cytokines]	0.0	4	1	1	1
108019	1710	e2f dna-binding activity	[E2F DNA-binding activities]	0.0	3	1	1	1
108020	1710	retinoid X receptor RXR activation	[Retinoid X receptor RXR activation]	0.0	5	1	1	1
108021	1710	mcp-1 content	[MCP-1 content]	0.0	2	1	1	1
108022	1710	nf-kappa b of some, gene	[NF-kappa B of some, genes]	0.0	5	1	1	1
108023	1710	analyze the effect	[analyzing the effects]	0.0	3	1	1	1
108024	1710	class nonexpress cell	[class nonexpressing cells]	0.0	3	1	1	1
108025	1710	IL-2 promoter factor NF-AT	[IL-2 promoter factor NF-AT]	0.0	4	1	1	1
108026	1710	functional Ikaros transcription factor	[functional Ikaros transcription factors]	0.0	4	1	1	1
108027	1710	skin tumor	[skin tumor]	0.0	2	1	1	1
108028	1710	(hour 48) of the membrane-bound enzyme	[(hour 48) of the membrane-bound enzyme]	0.0	6	1	1	1
108029	1710	interaction of the NF-kappa b complex	[interactions of the NF-kappa B complex]	0.0	6	1	1	1
108030	1710	distinct effect on two marker	[distinct effects on two markers]	0.0	5	1	1	1
108031	1710	lipid-soluble, chain-break antioxidant	[lipid-soluble, chain-breaking antioxidant]	0.0	3	1	1	1
108032	1710	also in the presence	[also in the presence]	0.0	4	1	1	1
108033	1710	(facs-isolated) subset	[(FACS-isolated) subsets]	0.0	2	1	1	1
108034	1710	map kinase-specific phosphatase	[MAP kinase-specific phosphatase]	0.0	3	1	1	1
108035	1710	type domain	[type domain]	0.0	2	1	1	1
108036	1710	binding of lipoprotein	[binding of lipoprotein]	0.0	3	1	1	1
108037	1710	whole peripheral venous blood	[whole peripheral venous blood]	0.0	4	1	1	1
108038	1710	12 sclerosis	[12 sclerosis]	0.0	2	1	1	1
108039	1710	population of /precursor grow	[populations of /precursors growing]	0.0	4	1	1	1
108040	1710	reflect the c-terminal domain	[reflecting the C-terminal domain]	0.0	4	1	1	1
108041	1710	superantigen enterotoxin a	[superantigen enterotoxin A]	0.0	3	1	1	1
108042	1710	response of transcription factor	[response of transcription factor]	0.0	4	1	1	1
108043	1710	derivative,	[derivative,]	0.0	1	1	1	1
108044	1710	labelling of DNA strand breaks.	[labelling of DNA strand breaks.]	0.0	5	1	1	1
108045	1710	However, examination in this T cell	[However, examination in these T cells]	0.0	6	1	1	1
108046	1710	region of the 5' flank	[region of the 5' flank]	0.0	5	1	1	1
108047	1710	Electrophoretic mobility shift analysis utilize oligonucleotide	[Electrophoretic mobility shift analyses utilizing oligonucleotides]	0.0	6	1	1	1
108048	1710	range of b cell	[range of B cells]	0.0	4	1	1	1
108049	1710	investigation of the event	[investigation of the events]	0.0	4	1	1	1
108050	1710	nuclear protein -408	[nuclear proteins -408]	0.0	3	1	1	1
108051	1710	monitoring of minimal residual disease	[monitoring of minimal residual disease]	0.0	5	1	1	1
108052	1710	member of this family, aml-1b	[member of this family, AML-1B]	0.0	5	1	1	1
108053	1710	critical effector of gata-1 signal	[critical effector of GATA-1 signals]	0.0	5	1	1	1
108054	1710	binding of glucocorticoid receptor	[binding of glucocorticoid receptor]	0.0	4	1	1	1
108055	1710	vitamin a derivative	[vitamin A derivative]	0.0	3	1	1	1
108056	1710	virtually complete inhibition	[virtually complete inhibition]	0.0	3	1	1	1
108057	1710	differentiation of normal cell	[differentiation of normal cells]	0.0	4	1	1	1
108058	1710	CD28 costimulation,	[CD28 costimulation,]	0.0	2	1	1	1
108059	1710	young human	[young humans]	0.0	2	1	1	1
108060	1710	DNA site	[DNA site]	0.0	2	1	1	1
108061	1710	cytoplasm in cell	[cytoplasm in cells]	0.0	3	1	1	1
108062	1710	activation of viral promoter	[activation of viral promoters]	0.0	4	1	1	1
108063	1710	constitutive nf kappa b	[constitutive NF kappa B]	0.0	4	1	1	1
108064	1710	protective ctl-mediated immunity	[protective CTL-mediated immunity]	0.0	3	1	1	1
108065	1710	P-like complex	[P-like complexes]	0.0	2	1	1	1
108066	1710	administration of gram metyrapone met	[administration of g metyrapone MET]	0.0	5	1	1	1
108067	1710	integrin ligation with antibody	[integrin ligation with antibodies]	0.0	4	1	1	1
108068	1710	other factor lbf2	[other factors LBF2]	0.0	3	1	1	1
108069	1710	co-stimulation of microglia with concentration	[Co-stimulation of microglia with concentrations]	0.0	5	1	1	1
108070	1710	highly conserved, protein	[highly conserved, protein]	0.0	3	1	1	1
108071	1710	gata regulatory element	[GATA regulatory elements]	0.0	3	1	1	1
108072	1710	leukemia virus transcription	[leukemia virus transcription]	0.0	3	1	1	1
108073	1710	differentiation of monocytoid leukemia cell line	[differentiation of monocytoid leukemia cell lines]	0.0	6	1	1	1
108074	1710	inducible enhancer in cell	[inducible enhancer in cells]	0.0	4	1	1	1
108075	1710	15% calf serum	[15% calf serum]	0.0	3	1	1	1
108076	1710	class promoter-specific DNA binding factor	[class promoter-specific DNA binding factors]	0.0	5	1	1	1
108077	1710	2 log-fold glucocorticoid	[2 log-fold glucocorticoids]	0.0	3	1	1	1
108078	1710	sixteen anorexic patient aged years, (range	[Sixteen anorexic patients aged years, (ranging]	0.0	6	1	1	1
108079	1710	superantigen enterotoxin b	[superantigen enterotoxin B]	0.0	3	1	1	1
108080	1710	heavy-chain igh locus	[heavy-chain IgH locus]	0.0	3	1	1	1
108081	1710	activity ap-1	[activity AP-1]	0.0	2	2	2	1
108082	1710	one pathway	[one pathway]	0.0	2	1	1	1
108083	1710	few regulatory protein	[few regulatory proteins]	0.0	3	1	1	1
108084	1710	development of lymphoid tissue	[Development of lymphoid tissues]	0.0	4	1	1	1
108085	1710	expression of this construct	[expression of these constructs]	0.0	4	1	1	1
108086	1710	Epstein-Barr virus ebv a human herpesvirus	[Epstein-Barr virus EBV an human herpesvirus]	0.0	6	1	1	1
108087	1710	percutaneous transluminal coronary angioplasty	[percutaneous transluminal coronary angioplasty]	0.0	4	1	1	1
108088	1710	use pure p21ras	[using pure p21ras]	0.0	3	1	1	1
108089	1710	doxepin-sensitive h1-histamine receptor	[doxepin-sensitive H1-histamine receptors]	0.0	3	1	1	1
108090	1710	dendritic process	[dendritic processes]	0.0	2	1	1	1
108091	1710	clinicopathological aspect include presentation, response	[clinicopathological aspects including presentation, response]	0.0	5	1	1	1
108092	1710	beta 1 ligand	[beta 1 ligands]	0.0	3	1	1	1
108093	1710	interestingly, early treatment 0 hpc	[Interestingly, early treatment 0 HPCs]	0.0	5	1	1	1
108094	1710	T lymphocyte a target	[T lymphocytes a target]	0.0	4	1	1	1
108095	1710	formal demonstration	[formal demonstration]	0.0	2	1	1	1
108096	1710	human erythroid cell in culture	[human erythroid cells in cultures]	0.0	5	1	1	1
108097	1710	phage clone	[phage clones]	0.0	2	1	1	1
108098	1710	cell-specific difference in activation	[Cell-specific differences in activation]	0.0	4	1	1	1
108099	1710	express LMP1 from a active promoter	[expressing LMP1 from a active promoter]	0.0	6	1	1	1
108100	1710	potential in the treatment of asthma	[potential in the treatment of asthma]	0.0	6	1	1	1
108101	1710	proteolysis of specific substrate	[proteolysis of specific substrates]	0.0	4	1	1	1
108102	1710	fresh pbmc from individual	[fresh PBMC from individuals]	0.0	4	1	1	1
108103	1710	number in years) hypertensive	[number in years) hypertensives]	0.0	4	1	1	1
108104	1710	awareness	[awareness]	0.0	1	1	1	1
108105	1710	34-fold high	[34-fold higher]	0.0	2	1	1	1
108106	1710	good prototype	[good prototype]	0.0	2	1	1	1
108107	1710	immunogenetic basis of infection	[immunogenetic basis of infections]	0.0	4	1	1	1
108108	1710	putative NFAT-1 site	[putative NFAT-1 site]	0.0	3	1	1	1
108109	1710	identification of oriP	[identification of oriP]	0.0	3	1	1	1
108110	1710	suggest a negative effect	[suggesting a negative effect]	0.0	4	1	1	1
108111	1710	distress syndrome NRDS	[distress syndrome NRDS]	0.0	3	1	1	1
108112	1710	expression of a transcription factor Oct-2	[expression of a transcription factor Oct-2]	0.0	6	1	1	1
108113	1710	sequence homology of this element	[sequence homology of this element]	0.0	5	1	1	1
108114	1710	T cell leukemia virus type I	[T cell leukemia virus type I]	0.0	6	1	1	1
108115	1710	response to pma/a23187	[response to PMA/A23187]	0.0	3	1	1	1
108116	1710	back pain a pain	[back pain a pain]	0.0	4	1	1	1
108117	1710	IFN increase in rar(alpha) level	[IFN increase in RAR(alpha) levels]	0.0	5	1	1	1
108118	1710	especially the human homolog c/ebp-beta	[especially the human homolog C/EBP-beta]	0.0	5	1	1	1
108119	1710	effect in b cell	[effects in B cells]	0.0	4	1	1	1
108120	1710	Yang	[Yang]	0.0	1	1	1	1
108121	1710	most cases, a heterodimer	[most cases, a heterodimer]	0.0	4	1	1	1
108122	1710	severity of sign	[severity of signs]	0.0	3	1	1	1
108123	1710	margins:	[margins:]	0.0	1	1	1	1
108124	1710	chromosome region	[chromosome region]	0.0	2	1	1	1
108125	1710	two domains, a	[two domains, A]	0.0	3	1	1	1
108126	1710	affinity of dexamethasone	[affinity of dexamethasone]	0.0	3	1	1	1
108127	1710	pattern of regulatory element	[pattern of regulatory elements]	0.0	4	1	1	1
108128	1710	effect il-1r gene expression	[effects IL-1R gene expression]	0.0	4	1	1	1
108129	1710	sufficient TRs	[sufficient TRs]	0.0	2	1	1	1
108130	1710	effect of radiation therapy	[effects of radiation therapy]	0.0	4	1	1	1
108131	1710	increase in il-2r alpha transcript	[increase in IL-2R alpha transcripts]	0.0	5	1	1	1
108132	1710	stat complex in primary T	[STAT complexes in primary T]	0.0	5	1	1	1
108133	1710	rapidak protein appearance	[rapid, protein appearance]	0.0	3	1	1	1
108134	1710	gcr number	[GCR number]	0.0	2	1	1	1
108135	1710	cd86 two ligand	[CD86 two ligands]	0.0	3	1	1	1
108136	1710	active protein	[active protein]	0.0	2	2	2	1
108137	1710	NFAT- p0 formation	[NFAT- P0 formation]	0.0	3	1	1	1
108138	1710	novel cytokine	[novel cytokine]	0.0	2	1	1	1
108139	1710	analysis from a variety of tissue	[analysis from a variety of tissues]	0.0	6	1	1	1
108140	1710	neutrophil-endothelial cell adhesion	[neutrophil-endothelial cell adhesion]	0.0	3	1	1	1
108141	1710	hiv long terminal repeat activation	[HIV long terminal repeat activation]	0.0	5	1	1	1
108142	1710	toll-like receptor-2 htlr2	[Toll-like receptor-2 hTLR2]	0.0	3	1	1	1
108143	1710	erythroid progeny	[erythroid progeny]	0.0	2	1	1	1
108144	1710	steroid-regulated expression of a gene	[steroid-regulated expression of an gene]	0.0	5	1	1	1
108145	1710	New drug pnu156804	[New drug PNU156804]	0.0	3	1	1	1
108146	1710	7.1 nm	[7.1 nM]	0.0	2	1	1	1
108147	1710	sensitivity against all type	[sensitivity against all types]	0.0	4	1	1	1
108148	1710	NF-kappa b /ap-1	[NF-kappa B /AP-1]	0.0	3	1	1	1
108149	1710	use a mitogenically incompetent g-csfr mutant	[Using a mitogenically incompetent G-CSFR mutant]	0.0	6	1	1	1
108150	1710	protein in lymphoma	[proteins in lymphoma]	0.0	3	1	1	1
108151	1710	clonogenesis	[clonogenesis]	0.0	1	1	1	1
108152	1710	GATA-1 gene though virtually silent	[GATA-1 gene though virtually silent]	0.0	5	1	1	1
108153	1710	cell line U937	[cell line U937]	0.0	3	1	1	1
108154	1710	intracellular calcium level,	[intracellular calcium level,]	0.0	3	1	1	1
108155	1710	relative proportion of acid	[relative proportions of acids]	0.0	4	1	1	1
108156	1710	resection margin	[resection margins]	0.0	2	1	1	1
108157	1710	monocyte factor-kappaB	[monocyte factor-kappaB]	0.0	2	1	1	1
108158	1710	cell carcinoma bcc	[cell carcinomas BCCs]	0.0	3	1	1	1
108159	1710	monkey glucocorticoid receptor	[monkey glucocorticoid receptors]	0.0	3	1	1	1
108160	1710	mediator in human disease	[mediators in human diseases]	0.0	4	1	1	1
108161	1710	several nervous tissue	[several nervous tissues]	0.0	3	1	1	1
108162	1710	constitutive localization of NFAT4	[constitutive localization of NFAT4]	0.0	4	1	1	1
108163	1710	alpha 4 beta ligation alone	[alpha 4 beta ligation alone]	0.0	5	1	1	1
108164	1710	silencing of gamma-globin expression	[silencing of gamma-globin expression]	0.0	4	1	1	1
108165	1710	down-regulation of many cell-specific gene	[down-regulation of many cell-specific genes]	0.0	5	1	1	1
108166	1710	perforin-expressing lymphocyte	[perforin-expressing lymphocytes]	0.0	2	1	1	1
108167	1710	45 residue of the tail,	[45 residues of the tail,]	0.0	5	1	1	1
108168	1710	age-related reduction in the activation	[age-related reductions in the activation]	0.0	5	1	1	1
108169	1710	first step-wise	[first step-wise]	0.0	2	1	1	1
108170	1710	pzvh14	[pZVH14]	0.0	1	1	1	1
108171	1710	effect on hemoglobinization	[effect on hemoglobinization]	0.0	3	1	1	1
108172	1710	immediate-early antigen	[immediate-early antigen]	0.0	2	1	1	1
108173	1710	3-carboranyl-substituted compound	[3-carboranyl-substituted compounds]	0.0	2	1	1	1
108174	1710	preferential activation of p50/c-Rel	[preferential activation of p50/c-Rel]	0.0	4	1	1	1
108175	1710	healthy child	[healthy children]	0.0	2	1	1	1
108176	1710	33 repetitive stretch	[33 repetitive stretch]	0.0	3	1	1	1
108177	1710	blood eosinophil	[blood eosinophils]	0.0	2	1	1	1
108178	1710	viral protein adenovirus e1b-19 kda	[viral proteins adenovirus E1B-19 kDa]	0.0	5	1	1	1
108179	1710	cell gene like globin	[cell genes like globin]	0.0	4	1	1	1
108180	1710	ic50 for the group	[IC50s for the group]	0.0	4	1	1	1
108181	1710	lipoprotein ox ldl	[lipoprotein Ox LDL]	0.0	3	1	1	1
108182	1710	cell-cycle gene activation	[cell-cycle gene activation]	0.0	3	1	1	1
108183	1710	one interpretation	[One interpretation]	0.0	2	1	1	1
108184	1710	two activation-dependent events: the CsA translocation	[two activation-dependent events: the CsA translocation]	0.0	6	1	1	1
108185	1710	inflammatory mechanism in cell	[inflammatory mechanisms in cells]	0.0	4	1	1	1
108186	1710	soluble beta-(1,3)-linked glucose homopolymer	[soluble beta-(1,3)-linked glucose homopolymer]	0.0	4	1	1	1
108187	1710	20 kda.	[20 kDa.]	0.0	2	1	1	1
108188	1710	type 5 adenovirus	[type 5 adenovirus]	0.0	3	1	1	1
108189	1710	potential phosphoprotein	[potential phosphoprotein]	0.0	2	1	1	1
108190	1710	gene related to sex differentiation	[genes related to sex differentiation]	0.0	5	1	1	1
108191	1710	blood of subject	[blood of subjects]	0.0	3	1	1	1
108192	1710	putative regulator	[putative regulator]	0.0	2	1	1	1
108193	1710	carry genetic defect	[carrying genetic defect]	0.0	3	1	1	1
108194	1710	major histocompatibility immune deficiency	[major histocompatibility immune deficiency]	0.0	4	1	1	1
108195	1710	therapy for systemic disease	[therapy for systemic diseases]	0.0	4	1	1	1
108196	1710	C/EBP-epsilon sense	[C/EBP-epsilon sense]	0.0	2	1	1	1
108197	1710	nf-kappabp65 than patient	[NF-kappaBp65 than patients]	0.0	3	1	1	1
108198	1710	healthy control in vitro.	[healthy controls in vitro.]	0.0	4	1	1	1
108199	1710	employed, incorporate antigen	[employed, incorporating antigens]	0.0	3	1	1	1
108200	1710	Epstein-Barr virus oncogene lmp1	[Epstein-Barr virus oncogene LMP1]	0.0	4	1	1	1
108201	1710	role in the physiology	[role in the physiology]	0.0	4	1	1	1
108202	1710	common structure during deamidation	[common structure during deamidation]	0.0	4	1	1	1
108203	1710	effect in patient	[effect in patients]	0.0	3	1	1	1
108204	1710	involve pkc activation	[involving PKC activation]	0.0	3	1	1	1
108205	1710	T lymphocyte growth factor	[T lymphocyte growth factor]	0.0	4	1	1	1
108206	1710	basal -value	[basal -values]	0.0	2	1	1	1
108207	1710	immediate response	[immediate response]	0.0	2	1	1	1
108208	1710	factor-kappaB nf-kappab transcription factor	[factor-kappaB NF-kappaB transcription factors]	0.0	4	1	1	1
108209	1710	major infectious disease	[major infectious diseases]	0.0	3	1	1	1
108210	1710	use TGF elisa	[using TGF ELISAs]	0.0	3	1	1	1
108211	1710	tcr alpha/beta	[TCR alpha/beta]	0.0	2	1	1	1
108212	1710	reveal a selective role	[revealing a selective role]	0.0	4	1	1	1
108213	1710	role for hmg-i(y)	[role for HMG-I(Y)]	0.0	3	1	1	1
108214	1710	two goals: (1)	[two goals: (1)]	0.0	3	1	1	1
108215	1710	dose of 1r25-dihydroxy vitamin D3	[dose of 1,25-dihydroxy vitamin D3]	0.0	5	1	1	1
108216	1710	action of cortisol	[action of cortisol]	0.0	3	1	1	1
108217	1710	monocyte to cell	[monocytes to cells]	0.0	3	1	1	1
108218	1710	bamhi h, r,	[BamHI Z, R,]	0.0	3	1	1	1
108219	1710	multiple stage B	[multiple stages B]	0.0	3	1	1	1
108220	1710	putative disorder	[putative disorder]	0.0	2	1	1	1
108221	1710	Minimal disease with pml/rar alpha	[Minimal disease with PML/RAR alpha]	0.0	5	1	1	1
108222	1710	polyclonal granulocyte	[polyclonal granulocytes]	0.0	2	1	1	1
108223	1710	17 out of 23 t-cell determinant	[17 out of 23 T-cell determinants]	0.0	6	1	1	1
108224	1710	level of the il-12r beta1 subunit	[levels of the IL-12R beta1 subunit]	0.0	6	1	1	1
108225	1710	Duffy chemokine	[Duffy chemokine]	0.0	2	1	1	1
108226	1710	LEF-1 HMG-88	[LEF-1 HMG-88]	0.0	2	1	1	1
108227	1710	red cell progenitor	[red cell progenitors]	0.0	3	1	1	1
108228	1710	human gene therapy protocol utilize vector	[human gene therapy protocols utilizing vectors]	0.0	6	1	1	1
108229	1710	ige germline gene	[IgE germline gene]	0.0	3	1	1	1
108230	1710	HRF factor	[HRF factor]	0.0	2	1	1	1
108231	1710	incubation medium.	[incubation medium.]	0.0	2	1	1	1
108232	1710	upstream cryptic splice site	[upstream cryptic splice site]	0.0	4	1	1	1
108233	1710	40 major promoter erratum	[40 major promoter erratum]	0.0	4	1	1	1
108234	1710	(24 hour earlier) exposure	[(24 hours earlier) exposure]	0.0	4	1	1	1
108235	1710	production of cytokine in vitro	[production of cytokines in vitro]	0.0	5	1	1	1
108236	1710	receptor (gr)-defective clone icr-27	[receptor (GR)-defective clone ICR-27]	0.0	4	1	1	1
108237	1710	region of CD40	[region of CD40]	0.0	3	1	1	1
108238	1710	50 65 kda polypeptide	[50 65 kDa polypeptides]	0.0	4	1	1	1
108239	1710	5'-pyctttg-3'	[5'-PyCTTTG-3']	0.0	1	1	1	1
108240	1710	overcome block to provirus establishment	[overcoming blocks to provirus establishment]	0.0	5	1	1	1
108241	1710	(IL)-2	[(IL)-2]	0.0	1	1	1	1
108242	1710	(IL)-4	[(IL)-4]	0.0	1	1	1	1
108243	1710	presence progesterone receptor	[presence progesterone receptors]	0.0	3	1	1	1
108244	1710	Gene for a transcriptional activator ebf	[Gene for a transcriptional activator EBF]	0.0	6	1	1	1
108245	1710	block a potential target in culture	[blocking a potential target in cultures]	0.0	6	1	1	1
108246	1710	human leukocyte to serum	[human leukocytes to serum]	0.0	4	1	1	1
108247	1710	histochemical staining	[histochemical staining]	0.0	2	1	1	1
108248	1710	Furthermore, LMP1 cell size	[Furthermore, LMP1 cell size]	0.0	4	1	1	1
108249	1710	tuberculosis,	[tuberculosis,]	0.0	1	1	1	1
108250	1710	transient pseudohypoaldosteronism with reduction	[Transient pseudohypoaldosteronism with reduction]	0.0	4	1	1	1
108251	1710	1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin D3	[1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin D3]	0.0	2	1	1	1
108252	1710	complex (mhc) class ii antigen	[complex (MHC) class II antigens]	0.0	5	2	2	1
108253	1710	young (mean 37	[young (mean 37]	0.0	3	1	1	1
108254	1710	erythroleukemia (mel) cell to differentiation.	[erythroleukemia (MEL) cells to differentiation.]	0.0	5	1	1	1
108255	1710	expression on malignant melanoma	[expression on malignant melanomas]	0.0	4	1	1	1
108256	1710	matrix process	[matrix processes]	0.0	2	1	1	1
108257	1710	splenic t-lymphocyte culture in condition	[splenic T-lymphocytes culture in conditions]	0.0	5	1	1	1
108258	1710	adenovirus ad5 infection	[adenovirus Ad5 infection]	0.0	3	1	1	1
108259	1710	primary source	[primary source]	0.0	2	1	1	1
108260	1710	c-terminal peptide nf-atc /b	[C-terminal peptide NF-ATc /B]	0.0	4	1	1	1
108261	1710	alpha-chloromethyl	[alpha-chloromethyl]	0.0	1	1	1	1
108262	1710	heterodimerizerizerizerizerizerizerizerizerizerize with thr	[heterodimerizing with THR]	0.0	3	1	1	1
108263	1710	6 week after termination	[6 weeks after termination]	0.0	4	1	1	1
108264	1710	chaperoning protein to cellular organelle	[chaperoning proteins to cellular organelles]	0.0	5	1	1	1
108265	1710	DNase site in the region	[DNase sites in the regions]	0.0	5	1	1	1
108266	1710	possible role of the ap-1	[possible role of the AP-1]	0.0	5	1	1	1
108267	1710	HLA-A3 system	[HLA-A3 system]	0.0	2	1	1	1
108268	1710	addition of E220K ubiquitinylation	[addition of E220K ubiquitinylation]	0.0	4	1	1	1
108269	1710	length sp1 /DNA complex	[length SP1 /DNA complex]	0.0	4	1	1	1
108270	1710	5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation	[5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation]	0.0	6	1	1	1
108271	1710	t(17;19) translocation in acute leukemia	[t(17;19) translocation in acute leukemias]	0.0	5	1	1	1
108272	1710	availability of the metabolic substrate	[availability of the metabolic substrates]	0.0	5	1	1	1
108273	1710	ap-1-binding motif	[AP-1-binding motif]	0.0	2	1	1	1
108274	1710	5' sequence of the gene	[5' sequence of the gene]	0.0	5	1	1	1
108275	1710	human blood burst-forming unit-erythroid	[human blood burst-forming unit-erythroid]	0.0	4	1	1	1
108276	1710	mechanism for loss	[mechanism for loss]	0.0	3	1	1	1
108277	1710	120 h	[120 h]	0.0	2	1	1	1
108278	1710	lps translocation of NF-kappa b	[LPS translocation of NF-kappa B]	0.0	5	1	1	1
108279	1710	up-regulated fasL mrna	[up-regulated fasL mRNA]	0.0	3	1	1	1
108280	1710	fresh case	[fresh cases]	0.0	2	1	1	1
108281	1710	make extract from myelo- cell	[making extracts from myelo- cells]	0.0	5	1	1	1
108282	1710	addition of mM aminoguanidine	[addition of mM aminoguanidine]	0.0	4	1	1	1
108283	1710	impairment in the translocation	[Impairments in the translocation]	0.0	4	1	1	1
108284	1710	collectively, transcriptional factor necessary	[Collectively, transcriptional factor necessary]	0.0	4	1	1	1
108285	1710	CstF-64 to the proximal site	[CstF-64 to the proximal site]	0.0	5	1	1	1
108286	1710	importance of species	[importance of species]	0.0	3	1	1	1
108287	1710	excess of testosterone	[excess of testosterone]	0.0	3	1	1	1
108288	1710	alpha-tocopherol alpha-tcp	[alpha-tocopherol alpha-tcp]	0.0	2	1	1	1
108289	1710	necessity for spatial alignment	[necessity for spatial alignment]	0.0	4	1	1	1
108290	1710	category of factor factor	[categories of factors factors]	0.0	4	1	1	1
108291	1710	great migration through huvec monolayer	[greater migration through HUVEC monolayers]	0.0	5	1	1	1
108292	1710	cell during experimental anemia	[cells during experimental anemia]	0.0	4	1	1	1
108293	1710	iron storage, regulation	[iron storage, regulation]	0.0	3	1	1	1
108294	1710	existence of a trans-active locus	[existence of a trans-active locus]	0.0	5	1	1	1
108295	1710	peripheral circulation	[peripheral circulation]	0.0	2	1	1	1
108296	1710	human homeobox gene distantly related	[human homeobox gene distantly related]	0.0	5	1	1	1
108297	1710	activity of effector pathway	[activity of effector pathways]	0.0	4	1	1	1
108298	1710	jurkat T leukemia cell	[Jurkat T leukemia cells]	0.0	4	2	2	1
108299	1710	antioxidant such as pyrrolidine dithiocarbamate	[antioxidants such as pyrrolidine dithiocarbamate]	0.0	5	1	1	1
108300	1710	family of activator	[family of activators]	0.0	3	1	1	1
108301	1710	kb fasl promoter	[kb FasL promoter]	0.0	3	1	1	1
108302	1710	inhibition of specific protein	[inhibition of specific proteins]	0.0	4	1	1	1
108303	1710	cleavage of bcl-2	[cleavage of bcl-2]	0.0	3	1	1	1
108304	1710	inhibition of il-12r beta expression	[inhibition of IL-12R beta expression]	0.0	5	1	1	1
108305	1710	preincubation of cell in u-937	[Preincubation of cells in U-937]	0.0	5	1	1	1
108306	1710	inhibition of constitutive activation	[inhibition of constitutive activation]	0.0	4	1	1	1
108307	1710	negative mutant ikk1 k44m	[negative mutant IKK1 K44M]	0.0	4	1	1	1
108308	1710	requirement for spacing	[requirement for spacing]	0.0	3	1	1	1
108309	1710	upstream region in Jurkat	[upstream region in Jurkat]	0.0	4	1	1	1
108310	1710	Finally, addition	[Finally, addition]	0.0	2	1	1	1
108311	1710	monoclonal antibody against CD40	[monoclonal antibody against CD40]	0.0	4	1	1	1
108312	1710	pkc-zeta isoform	[PKC-zeta isoforms]	0.0	2	1	1	1
108313	1710	change in il-1	[changes in IL-1]	0.0	3	1	1	1
108314	1710	v-atpase subunit	[V-ATPase subunits]	0.0	2	1	1	1
108315	1710	type of skin	[types of skin]	0.0	3	1	1	1
108316	1710	role a gene	[role a gene]	0.0	3	1	1	1
108317	1710	CR3 abs	[CR3 Abs]	0.0	2	1	1	1
108318	1710	study of affinity	[study of affinity]	0.0	3	1	1	1
108319	1710	hypermethylation	[Hypermethylation]	0.0	1	2	2	1
108320	1710	monocyte-macrophage surface antigen	[monocyte-macrophage surface antigen]	0.0	3	1	1	1
108321	1710	stage homogeneity of cell	[stage homogeneity of cells]	0.0	4	1	1	1
108322	1710	other pre-B gene	[other pre-B genes]	0.0	3	1	1	1
108323	1710	single bipartite acid response element	[single bipartite acid response element]	0.0	5	1	1	1
108324	1710	inhibitor of cellular proliferation	[inhibitor of cellular proliferation]	0.0	4	1	1	1
108325	1710	several sequence tag	[several sequence tags]	0.0	3	1	1	1
108326	1710	contain the flank region	[containing the flanking region]	0.0	4	1	1	1
108327	1710	abnormality in human neoplasia	[abnormalities in human neoplasia]	0.0	4	1	1	1
108328	1710	framework signal as il-1	[framework signaling as IL-1]	0.0	4	1	1	1
108329	1710	t-cell via CD2 adhesion molecule	[T-cells via CD2 adhesion molecules]	0.0	5	1	1	1
108330	1710	strong effect on the expression	[strong effect on the expression]	0.0	5	1	1	1
108331	1710	acid 9cisra	[acid 9cisRA]	0.0	2	1	1	1
108332	1710	importance of virus-replicative lesion	[importance of virus-replicative lesions]	0.0	4	1	1	1
108333	1710	efficient tg presentation	[efficient TG presentation]	0.0	3	1	1	1
108334	1710	contain hhv-6(gs) genomic fragment	[containing HHV-6(GS) genomic fragments]	0.0	4	1	1	1
108335	1710	value of social support,	[value of social support,]	0.0	4	1	1	1
108336	1710	immunogenic protein in lymphoma	[immunogenic proteins in lymphoma]	0.0	4	1	1	1
108337	1710	change in nature	[change in nature]	0.0	3	1	1	1
108338	1710	oestrogen concentration	[oestrogen concentration]	0.0	2	1	1	1
108339	1710	nuclear nf-kb expression	[nuclear NF-KB expression]	0.0	3	1	1	1
108340	1710	intercellular adhesion molecule-1 expression	[intercellular adhesion molecule-1 expression]	0.0	4	1	1	1
108341	1710	effect of monocyte adhesion	[effects of monocyte adhesion]	0.0	4	1	1	1
108342	1710	these marker	[theses markers]	0.0	2	1	1	1
108343	1710	hybridization datum	[hybridization data]	0.0	2	1	1	1
108344	1710	C-terminal part	[C-terminal part]	0.0	2	1	1	1
108345	1710	Strikingly, deletion	[Strikingly, deletion]	0.0	2	1	1	1
108346	1710	novel tre	[novel TRE]	0.0	2	1	1	1
108347	1710	expression of p45 lineage cell	[expression of p45 lineage cells]	0.0	5	1	1	1
108348	1710	effect on hiv reverse transcription	[effect on HIV reverse transcription]	0.0	5	1	1	1
108349	1710	pharmacodynamic response	[pharmacodynamic responses]	0.0	2	1	1	1
108350	1710	conjugation to the precursor	[conjugation to the precursor]	0.0	4	1	1	1
108351	1710	variety of cells, include precursor	[variety of cells, including precursors]	0.0	5	1	1	1
108352	1710	expression of crh	[expression of CRH]	0.0	3	1	1	1
108353	1710	Effect on les-induced transcription factor	[Effects on LPS-induced transcription factors]	0.0	5	1	1	1
108354	1710	identification of novel element	[Identification of novel elements]	0.0	4	1	1	1
108355	1710	TNFR family	[TNFR family]	0.0	2	1	1	1
108356	1710	role in signal	[role in signaling]	0.0	3	1	1	1
108357	1710	three candidate gene for ags factor	[three candidate genes for AGS factor]	0.0	6	1	1	1
108358	1710	dominant clone	[dominant clone]	0.0	2	1	1	1
108359	1710	ag receptor in T	[Ag receptors in T]	0.0	4	1	1	1
108360	1710	activation of the delta-globin gene promoter	[Activation of the delta-globin gene promoter]	0.0	6	1	1	1
108361	1710	GATA-2 mrna	[GATA-2 mRNA]	0.0	2	1	1	1
108362	1710	diffusible activity tag capable	[diffusible activity TAG capable]	0.0	4	1	1	1
108363	1710	inhibition of tnf-alpha secretion	[Inhibition of TNF-alpha secretion]	0.0	4	1	1	1
108364	1710	cyclosporin-sensitive protein	[cyclosporin-sensitive protein]	0.0	2	1	1	1
108365	1710	result in the induction of NF-kappaB	[resulting in the induction of NF-kappaB]	0.0	6	1	1	1
108366	1710	radiometric assay use FUra	[radiometric assay using FUra]	0.0	4	1	1	1
108367	1710	red blood cell to cell	[red blood cells to cells]	0.0	5	1	1	1
108368	1710	human baf170	[human BAF170]	0.0	2	1	1	1
108369	1710	receptor determination in patient	[receptor determination in patients]	0.0	4	1	1	1
108370	1710	il-1 convert enzyme caspase-3 -like	[IL-1 converting enzyme caspase-3 -like]	0.0	5	1	1	1
108371	1710	myb rna expression.	[myb RNA expression.]	0.0	3	1	1	1
108372	1710	ppb for benzene	[PPB for benzene]	0.0	3	1	1	1
108373	1710	level of AP-1	[levels of AP-1]	0.0	3	1	1	1
108374	1710	NK/ T	[NK/ T]	0.0	2	1	1	1
108375	1710	interfere mutant rxr	[interfering mutant RXRs]	0.0	3	1	1	1
108376	1710	protein-1alpha mip-1alpha	[protein-1alpha MIP-1alpha]	0.0	2	1	1	1
108377	1710	rapid rate	[rapid rate]	0.0	2	1	1	1
108378	1710	late onset menarche	[late onset menarche]	0.0	3	1	1	1
108379	1710	PKC response	[PKC responses]	0.0	2	2	2	1
108380	1710	deficiency syndrome	[deficiency syndromes]	0.0	2	1	1	1
108381	1710	ap1 transcriptional complex	[AP1 transcriptional complex]	0.0	3	1	1	1
108382	1710	group c, adenovirus serotype ad5	[Group C, adenovirus serotype Ad5]	0.0	5	1	1	1
108383	1710	t-cell activation signal	[T-cell activation signals]	0.0	3	1	1	1
108384	1710	exclusively lymphoma	[exclusively lymphomas]	0.0	2	1	1	1
108385	1710	alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	2	1	1	1
108386	1710	large cohort	[large cohorts]	0.0	2	1	1	1
108387	1710	NF-E1 ref	[NF-E1 refs]	0.0	2	1	1	1
108388	1710	pathogenesis of x-scid	[pathogenesis of X-SCID]	0.0	3	1	1	1
108389	1710	trigger into phenotypic changes,	[triggering into phenotypic changes,]	0.0	4	1	1	1
108390	1710	generation of chi b complex	[generation of chi B complexes]	0.0	5	1	1	1
108391	1710	bone marrow cell from mouse	[bone marrow cells from mice]	0.0	5	1	1	1
108392	1710	2.3 kb.	[2.3 kb.]	0.0	2	1	1	1
108393	1710	monoclonal integration to the genome	[monoclonal integration to the genome]	0.0	5	1	1	1
108394	1710	study use a form	[studies using a form]	0.0	4	1	1	1
108395	1710	interaction between all-tran RA	[interactions between all-trans RA]	0.0	4	1	1	1
108396	1710	anti- CD30 monoclonal antibody	[anti- CD30 monoclonal antibodies]	0.0	4	1	1	1
108397	1710	range to 10(-6) M.	[ranging to 10(-6) M.]	0.0	4	1	1	1
108398	1710	emergence of clone	[emergence of clones]	0.0	3	1	1	1
108399	1710	host control by the nuclear factor	[Host control by the nuclear factor]	0.0	6	1	1	1
108400	1710	alpha CD3 ab	[alpha CD3 Ab]	0.0	3	1	1	1
108401	1710	human recombinant alphaiibbeta3	[human recombinant alphaIIbbeta3]	0.0	3	1	1	1
108402	1710	highly efficient class processing	[highly efficient class processing]	0.0	4	1	1	1
108403	1710	two immediate gene c-fo	[two immediate genes c-fos]	0.0	4	1	1	1
108404	1710	PhoQ	[PhoQ]	0.0	1	1	1	1
108405	1710	Arre-2 binding activity	[ARRE-2 binding activity]	0.0	3	1	1	1
108406	1710	effect of gamma-ifn	[effects of gamma-IFN]	0.0	3	1	1	1
108407	1710	sp1 binding element	[Sp1 binding elements]	0.0	3	1	1	1
108408	1710	low level constitutively,	[low levels constitutively,]	0.0	3	1	1	1
108409	1710	low pkc activity	[low PKC activity]	0.0	3	1	1	1
108410	1710	activity of JNK kinase-related kinase	[activity of JNK kinase-related kinase]	0.0	5	1	1	1
108411	1710	response to alteration	[response to alterations]	0.0	3	1	1	1
108412	1710	erythroid-specific site	[erythroid-specific site]	0.0	2	1	1	1
108413	1710	myeloid leukemia gene	[myeloid leukemia gene]	0.0	3	1	1	1
108414	1710	CsA -sensitive translocation	[CsA -sensitive translocation]	0.0	3	1	1	1
108415	1710	cysteine -contain t-cell determinant	[cysteine -containing T-cell determinants]	0.0	4	1	1	1
108416	1710	distinct level	[distinct level]	0.0	2	1	1	1
108417	1710	contain glucocorticoid receptor	[containing glucocorticoid receptors]	0.0	3	1	1	1
108418	1710	Tax1 expression of other transcription factor	[Tax1 expression of other transcription factors]	0.0	6	1	1	1
108419	1710	E1A -positive cell	[E1A -positive cells]	0.0	3	1	1	1
108420	1710	functional localization signal present	[functional localization signal present]	0.0	4	1	1	1
108421	1710	/nm23	[/nm23]	0.0	1	1	1	1
108422	1710	5.5 kb	[5.5 kb]	0.0	2	1	1	1
108423	1710	separation of latency	[separation of latency]	0.0	3	1	1	1
108424	1710	single-stranded conformational polymorphism	[single-stranded conformational polymorphism]	0.0	3	1	1	1
108425	1710	cause of level	[cause of levels]	0.0	3	1	1	1
108426	1710	activation-dependent expression of many protein	[activation-dependent expression of many proteins]	0.0	5	1	1	1
108427	1710	binding of distinct complex	[binding of distinct complexes]	0.0	4	1	1	1
108428	1710	analysis of the domain	[Analysis of the domain]	0.0	4	1	1	1
108429	1710	immunodeficiency virus type 1 factor	[immunodeficiency virus type 1 factor]	0.0	5	1	1	1
108430	1710	x-linked spinal atrophy a form	[X-linked spinal atrophy an form]	0.0	5	1	1	1
108431	1710	breast cancer development.	[breast cancer development.]	0.0	3	1	1	1
108432	1710	3'-untranslated region polymorphism	[3'-untranslated region polymorphisms]	0.0	3	1	1	1
108433	1710	I kappa b -alpha pool	[I kappa B -alpha pool]	0.0	5	1	1	1
108434	1710	/elf-1	[/Elf-1]	0.0	1	2	2	1
108435	1710	healthy control obese: 31.90	[healthy controls obese: 31.90]	0.0	4	1	1	1
108436	1710	Saimiri STP	[Saimiri STP]	0.0	2	1	1	1
108437	1710	precursor cell in lymphoid cell	[precursor cells in lymphoid cells]	0.0	5	1	1	1
108438	1710	natural DNA response	[natural DNA response]	0.0	3	1	1	1
108439	1710	kidney disease	[kidney diseases]	0.0	2	1	1	1
108440	1710	family member in development	[family members in development]	0.0	4	1	1	1
108441	1710	especially the homolog	[especially the homolog]	0.0	3	1	1	1
108442	1710	[differential diagnostic value of D3 determination	[[Differential diagnostic value of D3 determination]	0.0	6	1	1	1
108443	1710	early g1 cell cycle function	[early G1 cell cycle function]	0.0	5	1	1	1
108444	1710	proto-oncogent in leukemia	[proto-oncogenes in leukemia]	0.0	3	1	1	1
108445	1710	low ratio of glutathione	[lower ratio of glutathione]	0.0	4	1	1	1
108446	1710	manner at the stage	[manner at the stage]	0.0	4	1	1	1
108447	1710	PGG-Glucan a soluble beta-(1,6)-branched glucose homopolymer	[PGG-Glucan a soluble beta-(1,6)-branched glucose homopolymer]	0.0	6	1	1	1
108448	1710	transcriptional activator tcf-1	[transcriptional activator TCF-1]	0.0	3	1	1	1
108449	1710	tf activation occur in cell	[TF activation occurring in cells]	0.0	5	1	1	1
108450	1710	occupancy of the immunodeficiency virus type	[occupancy of the immunodeficiency virus type]	0.0	6	1	1	1
108451	1710	degree of similarity	[degree of similarity]	0.0	3	1	1	1
108452	1710	retinoic acid atra	[retinoic acid ATRA]	0.0	3	4	4	1
108453	1710	mutation between -93	[mutations between -93]	0.0	3	1	1	1
108454	1710	original ddpcr protocol	[original DDPCR protocol]	0.0	3	1	1	1
108455	1710	Epstein-Barr virus nuclear antigen EBNA-2	[Epstein-Barr virus nuclear antigen EBNA-2]	0.0	5	1	1	1
108456	1710	corresponding to mrna species	[corresponding to mRNA species]	0.0	4	1	1	1
108457	1710	il-4 -inducible transcription factor	[IL-4 -inducible transcription factor]	0.0	4	1	1	1
108458	1710	activation agent	[activation agents]	0.0	2	1	1	1
108459	1710	level in myeloid cell	[levels in myeloid cells]	0.0	4	1	1	1
108460	1710	C5a calcium mobilization	[C5a calcium mobilization]	0.0	3	1	1	1
108461	1710	recombinant chloramphenicol acetyltransferase	[recombinant chloramphenicol acetyltransferase]	0.0	3	1	1	1
108462	1710	target for manipulation	[targets for manipulation]	0.0	3	1	1	1
108463	1710	most tissue	[most tissues]	0.0	2	1	1	1
108464	1710	drug-induced toxicity	[drug-induced toxicity]	0.0	2	1	1	1
108465	1710	interleukin-1 beta convert enzyme	[interleukin-1 beta converting enzyme]	0.0	4	1	1	1
108466	1710	thyroid status	[thyroid status]	0.0	2	1	1	1
108467	1710	information about the regulation	[information about the regulation]	0.0	4	1	1	1
108468	1710	position in the product	[position in the products]	0.0	4	1	1	1
108469	1710	expression of monocytic gene tnf-alpha	[expression of monocytic genes TNF-alpha]	0.0	5	1	1	1
108470	1710	require only the addition of tfiid	[requiring only the addition of TFIID]	0.0	6	1	1	1
108471	1710	complex contain stat4	[complexes containing STAT4]	0.0	3	1	1	1
108472	1710	cd4+ helper T	[CD4+ helper T]	0.0	3	1	1	1
108473	1710	homeodomain of Pbx1	[homeodomain of Pbx1]	0.0	3	1	1	1
108474	1710	transactivation experiment	[transactivation experiments]	0.0	2	1	1	1
108475	1710	glucocorticoid-induced apoptosis of cell	[Glucocorticoid-induced apoptosis of cells]	0.0	4	1	1	1
108476	1710	hypertensive patient of age]	[hypertensive patients of age]]	0.0	4	1	1	1
108477	1710	roughly the same level	[roughly the same level]	0.0	4	1	1	1
108478	1710	vivo response,	[vivo response,]	0.0	2	1	1	1
108479	1710	component of isgf3	[component of ISGF3]	0.0	3	1	1	1
108480	1710	0.25-2.0 gy	[0.25-2.0 Gy]	0.0	2	1	1	1
108481	1710	cytokine-induced cell adhesion molecule-1 expression	[cytokine-induced cell adhesion molecule-1 expression]	0.0	5	1	1	1
108482	1710	regulate sensitivity	[regulating sensitivity]	0.0	2	1	1	1
108483	1710	precipitate Stat-3	[precipitating Stat-3]	0.0	2	1	1	1
108484	1710	hour of the addition	[hr of the addition]	0.0	4	2	2	1
108485	1710	p24 antigen release	[p24 antigen release]	0.0	3	1	1	1
108486	1710	il-2r alpha promoter	[IL-2R alpha promoter]	0.0	3	1	1	1
108487	1710	cell adhesion molecule vcam	[cell adhesion molecule VCAM]	0.0	4	1	1	1
108488	1710	rhesus monkey for a comparative study	[rhesus monkeys for a comparative study]	0.0	6	1	1	1
108489	1710	adoptive transfer	[adoptive transfer]	0.0	2	3	3	1
108490	1710	signal in leukemic cell	[signals in leukemic cells]	0.0	4	1	1	1
108491	1710	1 year: 4.1	[1 year: 4.1]	0.0	3	1	1	1
108492	1710	bind to a receptor	[binding to an receptor]	0.0	4	1	1	1
108493	1710	important regulator of cell development	[important regulators of cell development]	0.0	5	1	1	1
108494	1710	disproportionate occurrence	[disproportionate occurrence]	0.0	2	1	1	1
108495	1710	g-csf dead cell g-csf	[G-CSF dead cells G-CSF]	0.0	4	1	1	1
108496	1710	1 interferon	[1 interferon]	0.0	2	1	1	1
108497	1710	collinear triplex	[collinear triplex]	0.0	2	1	1	1
108498	1710	LTR -based vector	[LTR -based vectors]	0.0	3	1	1	1
108499	1710	leucine domain	[leucine domains]	0.0	2	1	1	1
108500	1710	alternative element	[alternative elements]	0.0	2	1	1	1
108501	1710	gene class ii transactivator	[gene class II transactivator]	0.0	4	1	1	1
108502	1710	such as bcl-xl expression	[such as Bcl-XL expression]	0.0	4	1	1	1
108503	1710	cytokine interleukin-2 IL-2	[cytokine interleukin-2 IL-2]	0.0	3	1	1	1
108504	1710	strong transactivator in T cell	[strong transactivator in T cells]	0.0	5	1	1	1
108505	1710	glucocorticoid replacement in vitro	[glucocorticoid replacement in vitro]	0.0	4	1	1	1
108506	1710	structural comparison of the promoter	[structural comparison of the promoters]	0.0	5	1	1	1
108507	1710	nuclear factor kB NF-kB regulatory element	[nuclear factor kB NF-kB regulatory elements]	0.0	6	1	1	1
108508	1710	factor gene promoter	[factor gene promoter]	0.0	3	1	1	1
108509	1710	specific hrbc antibody production	[specific HRBC antibody production]	0.0	4	1	1	1
108510	1710	use c-c chemokine	[using C-C chemokines]	0.0	3	1	1	1
108511	1710	expression of gamma-ifn gene monocyte	[Expression of gamma-IFN genes monocytes]	0.0	5	1	1	1
108512	1710	5 human blood cell	[5 human blood cells]	0.0	4	1	1	1
108513	1710	inflammatory event	[inflammatory events]	0.0	2	1	1	1
108514	1710	high, pharmacological concentration to &mgr;m)	[high, pharmacological concentrations to &mgr;M)]	0.0	5	1	1	1
108515	1710	nf-at nuclear factor of T cell	[NF-AT nuclear factor of T cells]	0.0	6	1	1	1
108516	1710	abnormality gene in recurrent astrocytomas	[Abnormalities genes in recurrent astrocytomas]	0.0	5	1	1	1
108517	1710	factor such as NF-kappa b	[factors such as NF-kappa B]	0.0	5	1	1	1
108518	1710	kappa b-binding protein	[kappa B-binding protein]	0.0	3	1	1	1
108519	1710	il-1 nfkappab activity	[IL-1 NFkappaB activity]	0.0	3	1	1	1
108520	1710	phosphatase-positive giant cell	[phosphatase-positive giant cells]	0.0	3	1	1	1
108521	1710	putative binding sequence	[putative binding sequences]	0.0	3	1	1	1
108522	1710	time course of neutrophil adhesion	[time course of neutrophil adhesion]	0.0	5	1	1	1
108523	1710	nitrogen intermediate	[nitrogen intermediates]	0.0	2	1	1	1
108524	1710	thp-1 cell for cell activation	[THP-1 cells for cell activation]	0.0	5	1	1	1
108525	1710	constitutive basal phosphorylation	[Constitutive basal phosphorylation]	0.0	3	1	1	1
108526	1710	class switch recombination	[class switch recombination]	0.0	3	1	1	1
108527	1710	Vitamin e therapy ccl4	[Vitamin E therapy CCl4]	0.0	4	1	1	1
108528	1710	proliferative response to u/ml interleukin-2	[proliferative response to U/ml interleukin-2]	0.0	5	1	1	1
108529	1710	mechanism of action of S9a	[mechanism of action of S9a]	0.0	5	1	1	1
108530	1710	receptor coupling	[receptor coupling]	0.0	2	1	1	1
108531	1710	5-10% difference	[5-10% difference]	0.0	2	1	1	1
108532	1710	TNF in MVEC	[TNF in MVEC]	0.0	3	1	1	1
108533	1710	other human cd3epsilon mouse line	[other human CD3epsilon mouse lines]	0.0	5	1	1	1
108534	1710	pml protein degradation	[PML protein degradation]	0.0	3	1	1	1
108535	1710	flank the CALM region	[flanking the CALM region]	0.0	4	1	1	1
108536	1710	tumor necrosis factor-alpha adhesion molecule expression	[tumor necrosis factor-alpha adhesion molecule expression]	0.0	6	1	1	1
108537	1710	phosphorylation state of substrates.	[phosphorylation state of substrates.]	0.0	4	1	1	1
108538	1710	second family of protein	[second family of proteins]	0.0	4	1	1	1
108539	1710	encode the hepatocyte factor	[encoding the hepatocyte factors]	0.0	4	1	1	1
108540	1710	Nuclear translocation of nf-kappa b	[Nuclear translocation of NF-kappa B]	0.0	5	1	1	1
108541	1710	beta-phorbol 12-myristate 13-acetate addition of dm	[beta-phorbol 12-myristate 13-acetate addition of DM]	0.0	6	1	1	1
108542	1710	amplify th2 cell differentiation	[amplifying Th2 cell differentiation]	0.0	4	1	1	1
108543	1710	one class of helix-loop-helix protein	[one class of helix-loop-helix proteins]	0.0	5	1	1	1
108544	1710	incubation of human endothelial cell ECs	[Incubation of human endothelial cells ECs]	0.0	6	1	1	1
108545	1710	transcriptional control of expression	[transcriptional control of expression]	0.0	4	1	1	1
108546	1710	T cell transcription factor gata-3	[T cell transcription factor GATA-3]	0.0	5	1	1	1
108547	1710	Sp1 binding site gc box	[Sp1 binding sites GC box]	0.0	5	1	1	1
108548	1710	1-2 peak at h.	[1-2 peaks at h,]	0.0	4	1	1	1
108549	1710	strategy for therapy	[strategy for therapy]	0.0	3	1	1	1
108550	1710	Fli-1 transcription	[Fli-1 transcription]	0.0	2	1	1	1
108551	1710	modification such as phosphorylation,	[modification such as phosphorylation,]	0.0	4	1	1	1
108552	1710	domain with sh2 domain-binding phosphotyrosine-based motif	[domains with SH2 domain-binding phosphotyrosine-based motifs]	0.0	6	1	1	1
108553	1710	patient with severe anorexia nervosa	[patients with severe anorexia nervosa]	0.0	5	1	1	1
108554	1710	however, (66 millileter at 10:00 P;	[However, (66 ml at 10:00 h;]	0.0	6	1	1	1
108555	1710	65 kda polypeptide	[65 kDa polypeptides]	0.0	3	1	1	1
108556	1710	ligand activation of c-Kit	[ligand activation of c-Kit]	0.0	4	1	1	1
108557	1710	EBNA -dependent enhancer	[EBNA -dependent enhancer]	0.0	3	3	3	1
108558	1710	dysregulation of rara	[dysregulation of RARA]	0.0	3	1	1	1
108559	1710	(apl) cell line	[(APL) cell line]	0.0	3	1	1	1
108560	1710	mononucleated cell	[mononucleated cells]	0.0	2	1	1	1
108561	1710	SH2/SH3	[SH2/SH3]	0.0	1	1	1	1
108562	1710	normal binding activity in extract	[normal binding activities in extracts]	0.0	5	1	1	1
108563	1710	Liuwei Dihuang Pills	[Liuwei Dihuang Pills]	0.0	3	1	1	1
108564	1710	tr beta mrna level in lymphocyte	[TR beta mRNA levels in lymphocytes]	0.0	6	1	1	1
108565	1710	RNA transcript	[RNA transcript]	0.0	2	1	1	1
108566	1710	DNA clone contain hhv-6(gs) genomic fragment	[DNA clones containing HHV-6(GS) genomic fragments]	0.0	6	1	1	1
108567	1710	PTF beta	[PTF beta]	0.0	2	1	1	1
108568	1710	histocompatibility (mhc) haplotype	[histocompatibility (MHC) haplotypes]	0.0	3	1	1	1
108569	1710	camp elevate	[cAMP elevating]	0.0	2	1	1	1
108570	1710	peptidyl-prolyl amide bond	[peptidyl-prolyl amide bond]	0.0	3	1	1	1
108571	1710	anti- tat single-chain intracellular antibody	[anti- Tat single-chain intracellular antibody]	0.0	5	1	1	1
108572	1710	general	[general]	0.0	1	1	1	1
108573	1710	negative regulatory role	[negative regulatory role]	0.0	3	1	1	1
108574	1710	cell of transplant recipient	[cells of transplant recipients]	0.0	4	1	1	1
108575	1710	inducer of sialoadhesin expression	[inducer of sialoadhesin expression]	0.0	4	1	1	1
108576	1710	use protein	[using proteins]	0.0	2	1	1	1
108577	1710	hypothese concern the pathogenesis of endometriosis	[hypotheses concerning the pathogenesis of endometriosis]	0.0	6	1	1	1
108578	1710	increase from patient	[increase from patients]	0.0	3	1	1	1
108579	1710	concentration of Ca2+	[concentration of Ca2+]	0.0	3	1	1	1
108580	1710	alveolar macrophage protein	[alveolar macrophage proteins]	0.0	3	1	1	1
108581	1710	efficient class processing	[efficient class processing]	0.0	3	1	1	1
108582	1710	transfection in thymocyte	[transfections in thymocytes]	0.0	3	1	1	1
108583	1710	sinus	[sinus]	0.0	1	1	1	1
108584	1710	contribution of hhv-8	[contribution of HHV-8]	0.0	3	1	1	1
108585	1710	two immediate-early transactivator BZLF1 Z	[two immediate-early transactivators BZLF1 Z]	0.0	5	1	1	1
108586	1710	(brk)	[(BRK)]	0.0	1	1	1	1
108587	1710	domain contain five tandem repeat	[domain containing five tandem repeats]	0.0	5	1	1	1
108588	1710	human alas isozyme	[human ALAS isozyme]	0.0	3	1	1	1
108589	1710	T lymphocyte proliferation	[T lymphocyte proliferation]	0.0	3	1	1	1
108590	1710	acid signalling	[acid signalling]	0.0	2	1	1	1
108591	1710	molecular mechanism underlie expression	[Molecular mechanisms underlying expression]	0.0	4	1	1	1
108592	1710	recombinant tumor necrosis factor	[recombinant tumor necrosis factor]	0.0	4	1	1	1
108593	1710	'constitutive' nf-kappa b	['constitutive' NF-kappa B]	0.0	3	1	1	1
108594	1710	DNA electrophoresis	[DNA electrophoresis]	0.0	2	1	1	1
108595	1710	such differentiation block	[Such differentiation block]	0.0	3	1	1	1
108596	1710	transcription of pro-inflammatory mediator	[transcription of pro-inflammatory mediators]	0.0	4	1	1	1
108597	1710	up-regulation of rp1 mrna	[up-regulation of RP1 mRNA]	0.0	4	1	1	1
108598	1710	factor-kappaB NF-kappaB activity	[factor-kappaB NF-kappaB activity]	0.0	3	1	1	1
108599	1710	nuclear factor kappab system	[nuclear factor kappaB system]	0.0	4	1	1	1
108600	1710	-repressible gene	[-repressible genes]	0.0	2	1	1	1
108601	1710	STAT1 import by delivery of peptide	[STAT1 import by delivery of peptide]	0.0	6	1	1	1
108602	1710	membrane protein 1 LMP1 homolog	[membrane protein 1 LMP1 homologs]	0.0	5	1	1	1
108603	1710	KG1 cell	[KG1 cells]	0.0	2	1	1	1
108604	1710	monoclonal integration	[monoclonal integration]	0.0	2	1	1	1
108605	1710	binding to this oligonucleotide	[binding to this oligonucleotide]	0.0	4	1	1	1
108606	1710	also a target	[also a target]	0.0	3	1	1	1
108607	1710	reach the effect	[reaching the effect]	0.0	3	1	1	1
108608	1710	blockade of the complex	[Blockade of the complexes]	0.0	4	1	1	1
108609	1710	(include zebra activity	[(including ZEBRA activity]	0.0	3	1	1	1
108610	1710	new region	[new regions]	0.0	2	1	1	1
108611	1710	receptor in apoptosis	[receptor in apoptosis]	0.0	3	1	1	1
108612	1710	jun1	[jun1]	0.0	1	1	1	1
108613	1710	eight untrained male volunteer	[Eight untrained male volunteers]	0.0	4	1	1	1
108614	1710	pseudo-hypoaldosteronism normal level of aldosterone receptor	[pseudo-hypoaldosteronism normal level of aldosterone receptors]	0.0	6	1	1	1
108615	1710	effect on cd14 gene expression	[effects on CD14 gene expression]	0.0	5	1	1	1
108616	1710	orientation in this promoter region	[orientation in this promoter region]	0.0	5	1	1	1
108617	1710	immunodeficiency virus hiv entry	[immunodeficiency virus HIV entry]	0.0	4	1	1	1
108618	1710	additional unknown factor for activity	[additional unknown factors for activity]	0.0	5	1	1	1
108619	1710	use as agent	[use as agents]	0.0	3	1	1	1
108620	1710	protein in Genbank	[proteins in Genbank]	0.0	3	1	1	1
108621	1710	plaque formation.	[plaque formation.]	0.0	2	1	1	1
108622	1710	corresponding binding at kd-value of nm	[corresponding binding at Kd-values of nM]	0.0	6	1	1	1
108623	1710	protein binding region br	[protein binding regions BRs]	0.0	4	1	1	1
108624	1710	function of Ras	[functions of Ras]	0.0	3	1	1	1
108625	1710	activation via T cell receptor	[Activation via T cell receptor]	0.0	5	1	1	1
108626	1710	1 mM edta	[1 mM EDTA]	0.0	3	1	1	1
108627	1710	cases, a regulator	[cases, a regulator]	0.0	3	1	1	1
108628	1710	differential effect on complex	[differential effects on complexes]	0.0	4	1	1	1
108629	1710	abundant production	[abundant production]	0.0	2	1	1	1
108630	1710	use c-jun (as) phosphorothioate oligonucleotide	[using c-jun (AS) phosphorothioate oligonucleotides]	0.0	5	1	1	1
108631	1710	development of inflammation	[development of inflammation]	0.0	3	1	1	1
108632	1710	express wild-type tdag51	[expressing wild-type TDAG51]	0.0	3	1	1	1
108633	1710	transfection overexpression of type ikk1	[transfection overexpression of type IKK1]	0.0	5	1	1	1
108634	1710	activity complex in response	[activity complex in response]	0.0	4	1	1	1
108635	1710	(inhibitory) effect on differentiation	[(inhibitory) effects on differentiation]	0.0	4	1	1	1
108636	1710	regimen of kidney-tonifying	[regimen of kidney-tonifying]	0.0	3	1	1	1
108637	1710	early production 2	[early production 2]	0.0	3	1	1	1
108638	1710	localize cis-element responsible	[localizing cis-elements responsible]	0.0	3	1	1	1
108639	1710	cells/ml)	[cells/ml)]	0.0	1	1	1	1
108640	1710	hiv-1 NF-kappaB site	[HIV-1 NF-kappaB site]	0.0	3	1	1	1
108641	1710	regulation of tissue-specific promoter	[regulation of tissue-specific promoters]	0.0	4	1	1	1
108642	1710	lps stimulation of monocyte	[LPS stimulation of monocytes]	0.0	4	1	1	1
108643	1710	gene in anti-CD3-activated T lymphocyte	[genes in anti-CD3-activated T lymphocytes]	0.0	5	1	1	1
108644	1710	rapid apoptosis of T. T cell	[rapid apoptosis of T. T cells]	0.0	6	1	1	1
108645	1710	sequence from exon	[sequences from exons]	0.0	3	1	1	1
108646	1710	proof of clonality	[proof of clonality]	0.0	3	1	1	1
108647	1710	monochloramine nh2cl	[monochloramine NH2Cl]	0.0	2	1	1	1
108648	1710	leukemia particularly the microgranular variant	[leukemia particularly the microgranular variant]	0.0	5	1	1	1
108649	1710	phosphatidylinositol 3-kinase pi 3-kinase activity	[phosphatidylinositol 3-kinase PI 3-kinase activity]	0.0	5	1	1	1
108650	1710	CD15 engagement by antibody	[CD15 engagement by antibody]	0.0	4	1	1	1
108651	1710	Staurosporine a inhibitor of PKC	[Staurosporine a inhibitor of PKC]	0.0	5	1	1	1
108652	1710	latent membrane protein LMP1 homolog	[latent membrane protein LMP1 homologs]	0.0	5	1	1	1
108653	1710	presence of phorbol 13-acetate	[presence of phorbol 13-acetate]	0.0	4	1	1	1
108654	1710	include presentation, response with all-tran acid	[including presentation, response with all-trans acid]	0.0	6	1	1	1
108655	1710	possible importance	[possible importance]	0.0	2	1	1	1
108656	1710	function of SCL	[function of SCL]	0.0	3	1	1	1
108657	1710	-cd3	[-CD3]	0.0	1	1	1	1
108658	1710	-STAT5A	[-STAT5A]	0.0	1	1	1	1
108659	1710	-STAT5B	[-STAT5B]	0.0	1	1	1	1
108660	1710	thereby provide a firm structural basis	[thereby providing a firm structural basis]	0.0	6	1	1	1
108661	1710	protein other than Rb	[protein other than Rb]	0.0	4	1	1	1
108662	1710	modulator of LMP1 nf-kappab activation	[modulator of LMP1 NF-kappaB activation]	0.0	5	1	1	1
108663	1710	weak up-regulation	[weak up-regulation]	0.0	2	1	1	1
108664	1710	isoform expression pattern	[isoform expression patterns]	0.0	3	1	1	1
108665	1710	upstream of the IL-4 gene	[upstream of the IL-4 gene]	0.0	5	1	1	1
108666	1710	two 40mer oligonucleotide	[Two 40mer oligonucleotides]	0.0	3	1	1	1
108667	1710	however, latent, transformation-associated gene	[However, latent, transformation-associated genes]	0.0	4	1	1	1
108668	1710	short c-terminal peptide nf-atc /b	[shorter C-terminal peptide NF-ATc /B]	0.0	5	1	1	1
108669	1710	function divide lymphocyte	[function dividing lymphocytes]	0.0	3	1	1	1
108670	1710	marker of acute leukemia	[markers of acute leukemias]	0.0	4	1	1	1
108671	1710	absence of the receptor	[absence of the receptor]	0.0	4	1	1	1
108672	1710	treatment approach	[treatment approaches]	0.0	2	1	1	1
108673	1710	7 MRD -positive relapsed.	[7 MRD -positive relapsed.]	0.0	4	1	1	1
108674	1710	p50/p65 Rel a heterodimeric form	[p50/p65 Rel A heterodimeric form]	0.0	5	1	1	1
108675	1710	pcr injection	[PCr injection]	0.0	2	1	1	1
108676	1710	modest inhibitor	[modest inhibitors]	0.0	2	1	1	1
108677	1710	rs cell the membrane protein LMP1	[RS cells the membrane protein LMP1]	0.0	6	1	1	1
108678	1710	sr-bp high than for pentazocine	[SR-BP higher than for pentazocine]	0.0	5	1	1	1
108679	1710	hiv-infected pbmc	[HIV-infected PBMC]	0.0	2	1	1	1
108680	1710	ligation of histocompatibility class i	[ligation of histocompatibility class I]	0.0	5	1	1	1
108681	1710	pattern of viral latency	[pattern of viral latency]	0.0	4	1	1	1
108682	1710	rank order for corticosteroid	[rank order for corticosteroids]	0.0	4	1	1	1
108683	1710	set a series of response	[setting a series of responses]	0.0	5	1	1	1
108684	1710	aspect of the isolation	[aspect of the isolation]	0.0	4	1	1	1
108685	1710	IL-13 receptor complex on monocyte	[IL-13 receptor complex on monocytes]	0.0	5	1	1	1
108686	1710	clone C3/5, CD3(+), CD4(+), CD8(-)	[clone C3/5, CD3(+), CD4(+), CD8(-)]	0.0	5	1	1	1
108687	1710	cyclosporine at concentration	[cyclosporine at concentrations]	0.0	3	1	1	1
108688	1710	(Kd) nmol/l)	[(Kd) nmol/l)]	0.0	2	1	1	1
108689	1710	hydrocortisone (F) of concentration mol/L)	[hydrocortisone (F) of concentration mol/L)]	0.0	5	1	1	1
108690	1710	receptor to DNA in asthma	[receptor to DNA in asthma]	0.0	5	1	1	1
108691	1710	two inhibitor of MEK1	[two inhibitors of MEK1]	0.0	4	1	1	1
108692	1710	CMPD1 translocation case	[CMPD1 translocation cases]	0.0	3	1	1	1
108693	1710	Concern tumor-infiltrating lymphocyte	[Concerning tumor-infiltrating lymphocytes]	0.0	3	1	1	1
108694	1710	physiologic concentration of DEX	[physiologic concentrations of DEX]	0.0	4	1	1	1
108695	1710	signal in JAK3 immunodeficiency lymphocyte	[Signaling in JAK3 immunodeficiency lymphocytes]	0.0	5	1	1	1
108696	1710	alpha production by okadaic acid	[alpha production by okadaic acid]	0.0	5	1	1	1
108697	1710	number of cytosolic glucocorticoid receptor	[number of cytosolic glucocorticoid receptors]	0.0	5	1	1	1
108698	1710	T cell leukemia virus-1 htlv-1	[T cell leukemia virus-1 HTLV-1]	0.0	5	1	1	1
108699	1710	anti- c5b-9 immunoprecipitate	[anti- C5b-9 immunoprecipitates]	0.0	3	1	1	1
108700	1710	differential expression of set	[differential expression of sets]	0.0	4	1	1	1
108701	1710	transform protein t-cell leukemia virus type	[transforming protein T-cell leukemia virus type]	0.0	6	1	1	1
108702	1710	level of transcriptionally inactive p50 homodimer	[levels of transcriptionally inactive p50 homodimer]	0.0	6	1	1	1
108703	1710	low glycoprotein iib	[low glycoprotein IIb]	0.0	3	1	1	1
108704	1710	faithful expression	[faithful expression]	0.0	2	1	1	1
108705	1710	lymphocyte of woman (11	[lymphocytes of women (11]	0.0	4	1	1	1
108706	1710	etoposide dexamethasone-induced apoptosis	[etoposide dexamethasone-induced apoptosis]	0.0	3	1	1	1
108707	1710	binding of tg	[binding of TG]	0.0	3	1	1	1
108708	1710	sequence with base substitution	[sequence with base substitution]	0.0	4	1	1	1
108709	1710	colony-stimulating factor factor	[colony-stimulating factor factor]	0.0	3	1	1	1
108710	1710	immunogold electron microscopy	[immunogold electron microscopy]	0.0	3	1	1	1
108711	1710	synthetase (oas) gene expression	[synthetase (OAS) gene expression]	0.0	4	1	1	1
108712	1710	over-expression of b gene	[over-expression of B genes]	0.0	4	1	1	1
108713	1710	approach statistical significance	[approaching statistical significance]	0.0	3	1	1	1
108714	1710	heterogeneity of intrafollicular t-cell	[heterogeneity of intrafollicular T-cells]	0.0	4	1	1	1
108715	1710	endocrine cell lineage	[endocrine cell lineages]	0.0	3	1	1	1
108716	1710	-ck1	[-CK1]	0.0	1	1	1	1
108717	1710	new probe specific	[new probes specific]	0.0	3	1	1	1
108718	1710	functional factor kB regulatory element	[functional factor kB regulatory elements]	0.0	5	1	1	1
108719	1710	innate response in drosophila	[innate response in Drosophila]	0.0	4	1	1	1
108720	1710	over-expression of this protein by transfection	[over-expression of this protein by transfection]	0.0	6	1	1	1
108721	1710	expression of the (igh) gene	[expression of the (IgH) gene]	0.0	5	1	1	1
108722	1710	yeast colonies, four	[yeast colonies, four]	0.0	3	1	1	1
108723	1710	gata-associated site	[GATA-associated sites]	0.0	2	1	1	1
108724	1710	soot	[soot]	0.0	1	1	1	1
108725	1710	activation of blood T cell	[activation of blood T cells]	0.0	5	1	1	1
108726	1710	element between kb act in concert	[elements between kb act in concert]	0.0	6	1	1	1
108727	1710	continuous nf-kappa b p50/p65 translocation result	[continuous NF-kappa B p50/p65 translocation results]	0.0	6	1	1	1
108728	1710	conjunctival biopsy	[conjunctival biopsies]	0.0	2	1	1	1
108729	1710	jun1 tumor element	[jun1 tumor element]	0.0	3	1	1	1
108730	1710	U937 histiocytic lymphoma cell	[U937 histiocytic lymphoma cells]	0.0	4	1	1	1
108731	1710	latent, gene	[latent, genes]	0.0	2	1	1	1
108732	1710	analysis of monocytic thp-1 cell	[analysis of monocytic THP-1 cells]	0.0	5	1	1	1
108733	1710	1 receptor il-1r superfamily	[1 receptor IL-1R superfamily]	0.0	4	1	1	1
108734	1710	beta 2-integrin gene	[beta 2-integrin genes]	0.0	3	1	1	1
108735	1710	suggest the presence of several element	[suggesting the presence of several elements]	0.0	6	1	1	1
108736	1710	homology to motif	[homology to motifs]	0.0	3	1	1	1
108737	1710	leukemia-derived cell line	[leukemia-derived cell lines]	0.0	3	1	1	1
108738	1710	raf-1 phosphorylate	[Raf-1 phosphorylates]	0.0	2	1	1	1
108739	1710	(m/z)	[(m/z)]	0.0	1	1	1	1
108740	1710	leukaemic transformation	[leukaemic transformation]	0.0	2	1	1	1
108741	1710	e.g. interleukin-3 factor	[e.g. interleukin-3 factor]	0.0	3	1	1	1
108742	1710	interleukin-4, tumor	[interleukin-4, tumor]	0.0	2	1	1	1
108743	1710	135(oh)2d3 receptor on blood t-lymphocyte	[1,25(OH)2D3 receptors on blood T-lymphocytes]	0.0	5	1	1	1
108744	1710	kappab reporter activity	[kappaB reporter activity]	0.0	3	1	1	1
108745	1710	Positive induction	[Positive induction]	0.0	2	1	1	1
108746	1710	presence of the nuclear form	[presence of the nuclear form]	0.0	5	1	1	1
108747	1710	basophilia in acute promyelocytic leukaemia analysis	[basophilia in acute promyelocytic leukaemia analysis]	0.0	6	1	1	1
108748	1710	ap-1 activity of protein	[AP-1 activity of proteins]	0.0	4	1	1	1
108749	1710	abnormal apoptosis progression	[Abnormal apoptosis progression]	0.0	3	1	1	1
108750	1710	hiv type 1 infection	[HIV type 1 infection]	0.0	4	1	1	1
108751	1710	92-kda protein in monocyte	[92-kDa protein in monocytes]	0.0	4	1	1	1
108752	1710	human umbilical vein cell monolayer	[human umbilical vein cell monolayers]	0.0	5	1	1	1
108753	1710	novel substoichiometric taf of kda	[novel substoichiometric TAF of kDa]	0.0	5	1	1	1
108754	1710	determine the steady-state fluorescence anisotropy	[determining the steady-state fluorescence anisotropy]	0.0	5	1	1	1
108755	1710	corresponding to a 10(5)- amplification	[corresponding to a 10(5)- amplification]	0.0	5	1	1	1
108756	1710	Previously, transcription	[Previously, transcription]	0.0	2	1	1	1
108757	1710	interaction of VDR	[interaction of VDR]	0.0	3	1	1	1
108758	1710	clearly cells, respectively),	[clearly cells, respectively),]	0.0	3	1	1	1
108759	1710	b4 LTB4	[B4 LTB4]	0.0	2	1	1	1
108760	1710	effect of liposomal mpl	[effect of liposomal MPL]	0.0	4	1	1	1
108761	1710	regulate different function in this cells.	[regulating different functions in these cells.]	0.0	6	1	1	1
108762	1710	surrogate tg receptor on t) cell	[surrogate TG receptors on T) cells]	0.0	6	1	1	1
108763	1710	presence of virus	[presence of virus]	0.0	3	1	1	1
108764	1710	cytokine for b function	[cytokine for B function]	0.0	4	1	1	1
108765	1710	modulate perforin gene expression	[modulating perforin gene expression]	0.0	4	1	1	1
108766	1710	Study in culture	[Studies in culture]	0.0	3	1	1	1
108767	1710	day in human serum	[days in human serum]	0.0	4	1	1	1
108768	1710	study group	[study group]	0.0	2	1	1	1
108769	1710	enhance the safety phenotype	[enhancing the safety phenotype]	0.0	4	1	1	1
108770	1710	breast cancer cytotoxicity facilitate antibody	[breast cancer cytotoxicity facilitating antibody]	0.0	5	1	1	1
108771	1710	ifn-gamma stat1	[IFN-gamma STAT1]	0.0	2	1	1	1
108772	1710	ebv binding on human b cell	[EBV binding on human B cells]	0.0	6	1	1	1
108773	1710	peptide Arg-Gly-Asp	[peptide Arg-Gly-Asp]	0.0	2	1	1	1
108774	1710	cck(b) receptor antagonist	[CCK(B) receptor antagonist]	0.0	3	1	1	1
108775	1710	viral isolate of individual	[viral isolates of individuals]	0.0	4	1	1	1
108776	1710	unrecognized property	[unrecognized property]	0.0	2	1	1	1
108777	1710	granule mediate inflammatory response	[granules mediating inflammatory responses]	0.0	4	1	1	1
108778	1710	specific gene expression in lymphocyte	[specific gene expression in lymphocytes]	0.0	5	1	1	1
108779	1710	overexpress Bcl-2	[overexpressing Bcl-2]	0.0	2	1	1	1
108780	1710	case of immature lymphoid t-cell proliferation	[cases of immature lymphoid T-cell proliferations]	0.0	6	1	1	1
108781	1710	provide a structural basis	[providing a structural basis]	0.0	4	1	1	1
108782	1710	c-jun promoter fragment	[c-jun promoter fragments]	0.0	3	1	1	1
108783	1710	expression in gingival fibroblast	[expression in gingival fibroblasts]	0.0	4	1	1	1
108784	1710	analysis of 5' deletion construct	[analysis of 5' deletion constructs]	0.0	5	1	1	1
108785	1710	evidence for a mechanism for transcription	[evidence for an mechanism for transcription]	0.0	6	1	1	1
108786	1710	complex in Jurkat T cell	[complexes in Jurkat T cells]	0.0	5	1	1	1
108787	1710	large amount of the protein	[large amounts of the protein]	0.0	5	1	1	1
108788	1710	include a regulatory function	[including a regulatory function]	0.0	4	1	1	1
108789	1710	reading frame brlf1	[reading frame BRLF1]	0.0	3	1	1	1
108790	1710	factor with different mobilities,	[factors with different mobilities,]	0.0	4	1	1	1
108791	1710	powerful cyto-differentiating effect	[powerful cyto-differentiating effects]	0.0	3	1	1	1
108792	1710	change in tr expression	[changes in TR expression]	0.0	4	1	1	1
108793	1710	negative growth signal	[negative growth signals]	0.0	3	1	1	1
108794	1710	activation of b transcription factor	[activation of B transcription factors]	0.0	5	1	1	1
108795	1710	development of eosinophilic inflammation	[development of eosinophilic inflammation]	0.0	4	1	1	1
108796	1710	a at the position	[A at the position]	0.0	4	1	1	1
108797	1710	stat4 inducible protein	[Stat4 inducible proteins]	0.0	3	1	1	1
108798	1710	productive (lytic)	[productive (lytic)]	0.0	2	1	1	1
108799	1710	transactivation of multiple cis element	[transactivation of multiple cis elements]	0.0	5	1	1	1
108800	1710	type ii lymphocyte syndrome-associated factor	[type II lymphocyte syndrome-associated factor]	0.0	5	1	1	1
108801	1710	eight family form	[eight families: forms]	0.0	3	1	1	1
108802	1710	about 2-fold low affinity	[about 2-fold lower affinity]	0.0	4	1	1	1
108803	1710	approximately 80% follow treatment	[approximately 80% following treatment]	0.0	4	1	1	1
108804	1710	covalent modification of free sulfhydryl group	[covalent modification of free sulfhydryl groups]	0.0	6	1	1	1
108805	1710	(571 236 ng/ml)	[(571 236 ng/mL)]	0.0	3	1	1	1
108806	1710	immunosuppressive agent cyclosporin	[immunosuppressive agent cyclosporin]	0.0	3	1	1	1
108807	1710	T cell binding site	[T cells binding site]	0.0	4	1	1	1
108808	1710	role of a intronic sequence	[role of a intronic sequence]	0.0	5	1	1	1
108809	1710	regulation of 4e-bp1 during cell differentiation	[regulation of 4E-BP1 during cell differentiation]	0.0	6	1	1	1
108810	1710	activation follow binding to monocyte	[activation following binding to monocytes]	0.0	5	1	1	1
108811	1710	use VCAM-1 promoter construct	[using VCAM-1 promoter constructs]	0.0	4	1	1	1
108812	1710	involvement in the transformation	[involvement in the transformation]	0.0	4	1	1	1
108813	1710	silencing of the CAT gene	[silencing of the CAT gene]	0.0	5	1	1	1
108814	1710	identification of inhibitor	[Identification of inhibitors]	0.0	3	1	1	1
108815	1710	activation globin promoter	[activation globin promoter]	0.0	3	1	1	1
108816	1710	mediate aspect	[mediating aspects]	0.0	2	1	1	1
108817	1710	-e2f	[-E2F]	0.0	1	1	1	1
108818	1710	expression of another protein BRLF1	[expression of another protein BRLF1]	0.0	5	1	1	1
108819	1710	calcineurin-nuclear factor	[calcineurin-nuclear factors]	0.0	2	1	1	1
108820	1710	DNA control	[DNA control]	0.0	2	1	1	1
108821	1710	deletion of the arm	[deletion of the arm]	0.0	4	1	1	1
108822	1710	hiv-1 repeat transcription in monocyte	[HIV-1 repeat transcription in monocytes]	0.0	5	1	1	1
108823	1710	specify affinity for GRE site	[specifying affinity for GRE sites]	0.0	5	1	1	1
108824	1710	anti-immunoglobulin-treated b cell	[anti-immunoglobulin-treated B cells]	0.0	3	1	1	1
108825	1710	1 alpha,25-dihydroxyvitamin D3 monocytic differentiation	[1 alpha,25-dihydroxyvitamin D3 monocytic differentiation]	0.0	5	1	1	1
108826	1710	schedule (five patient	[schedules (five patients]	0.0	3	1	1	1
108827	1710	blood cell development	[blood cell development]	0.0	3	1	1	1
108828	1710	phosphorylation of the jak3	[phosphorylation of the Jak3]	0.0	4	1	1	1
108829	1710	delivery vehicle	[delivery vehicle]	0.0	2	1	1	1
108830	1710	genesis	[genesis]	0.0	1	2	2	1
108831	1710	interferon (ifn)-inducible	[interferon (IFN)-inducible]	0.0	2	1	1	1
108832	1710	two t-cell-specific transcription factor	[two T-cell-specific transcription factors]	0.0	4	1	1	1
108833	1710	-crh	[-CRH]	0.0	1	1	1	1
108834	1710	prevent the expression	[preventing the expression]	0.0	3	1	1	1
108835	1710	two strain	[Two strains]	0.0	2	1	1	1
108836	1710	several protein of mass	[several proteins of mass]	0.0	4	1	1	1
108837	1710	human umbilical arterial endothelial cell	[human umbilical arterial endothelial cells]	0.0	5	1	1	1
108838	1710	proliferator-activated receptor gamma ppargamma expression	[proliferator-activated receptor gamma PPARgamma expression]	0.0	5	1	1	1
108839	1710	human group c	[human group C]	0.0	3	1	1	1
108840	1710	h stimulation with concanavalin	[h stimulation with concanavalin]	0.0	4	1	1	1
108841	1710	granulocyte macrophage-colony stimulate factor	[granulocyte macrophage-colony stimulating factor]	0.0	4	1	1	1
108842	1710	bp promoter fragment	[bp promoter fragment]	0.0	3	1	1	1
108843	1710	long repeat site	[long repeat sites]	0.0	3	1	1	1
108844	1710	multiple reactivity as high	[multiple reactivities as high]	0.0	4	1	1	1
108845	1710	malaria research	[malaria research]	0.0	2	1	1	1
108846	1710	four tissue-specific histone h2a-2 gene	[four tissue-specific histone H2A-2 genes]	0.0	5	1	1	1
108847	1710	macrophage-competent derivative	[macrophage-competent derivative]	0.0	2	1	1	1
108848	1710	cell microg/ml)/mn2+ (50 microM)	[Cells microg/ml)/Mn2+ (50 microM)]	0.0	4	1	1	1
108849	1710	cell in the nervous system	[cells in the nervous system]	0.0	5	1	1	1
108850	1710	mrna to 50	[mRNA to 50]	0.0	3	1	1	1
108851	1710	cell in liquid culture	[cells in liquid cultures]	0.0	4	1	1	1
108852	1710	study signal transduction	[studying signal transduction]	0.0	3	1	1	1
108853	1710	tobacco smoke exposure	[Tobacco smoke exposure]	0.0	3	1	1	1
108854	1710	significance of glucocorticoid receptor determination	[significance of glucocorticoid receptor determination]	0.0	5	1	1	1
108855	1710	several hematopoietic gene	[several hematopoietic genes]	0.0	3	1	1	1
108856	1710	proliferation to apoptosis,	[proliferation to apoptosis,]	0.0	3	1	1	1
108857	1710	expression of c-fo protein	[Expression of c-fos proteins]	0.0	4	1	1	1
108858	1710	blood pressure measurement	[blood pressure measurements]	0.0	3	1	1	1
108859	1710	SLP-76 sh2 domain	[SLP-76 SH2 domain]	0.0	3	1	1	1
108860	1710	mechanism of hiv-1 gene regulation	[mechanism of HIV-1 gene regulation]	0.0	5	1	1	1
108861	1710	characterization of a second element	[characterization of a second element]	0.0	5	1	1	1
108862	1710	treatment modality for lupus erythematosus	[treatment modality for lupus erythematosus]	0.0	5	1	1	1
108863	1710	relevant concentration in vitro,	[relevant concentrations in vitro,]	0.0	4	1	1	1
108864	1710	ubiquitous protein neg-2 binding	[ubiquitous protein Neg-2 binding]	0.0	4	1	1	1
108865	1710	virus multiplication	[virus multiplication]	0.0	2	1	1	1
108866	1710	ach clone of htlv-1	[ACH clone of HTLV-1]	0.0	4	1	1	1
108867	1710	octamer motif ATGCAAAT	[octamer motif ATGCAAAT]	0.0	3	1	1	1
108868	1710	affinity of this receptor	[affinity of these receptors]	0.0	4	1	1	1
108869	1710	intracellular peroxide level	[intracellular peroxide level]	0.0	3	1	1	1
108870	1710	effect on vWf	[effect on vWf]	0.0	3	1	1	1
108871	1710	pma-mediated induction of collagenase-1 transcription	[PMA-mediated induction of collagenase-1 transcription]	0.0	5	1	1	1
108872	1710	Chignard, M. (1993) Blood	[Chignard, M. (1993) Blood]	0.0	4	1	1	1
108873	1710	micromolar concentration of dexamethasone	[micromolar concentrations of dexamethasone]	0.0	4	1	1	1
108874	1710	molecule on normal human lung fibroblast	[molecule on normal human lung fibroblasts]	0.0	6	1	1	1
108875	1710	systems, fragmentation	[systems, fragmentation]	0.0	2	1	1	1
108876	1710	killer cell line	[killer cell line]	0.0	3	1	1	1
108877	1710	allele allele ratio	[allele allele ratio]	0.0	3	1	1	1
108878	1710	Nuclear extract from human T lymphocyte	[Nuclear extracts from human T lymphocytes]	0.0	6	1	1	1
108879	1710	GM-CSF proliferation of mo7e cell	[GM-CSF proliferation of MO7e cells]	0.0	5	1	1	1
108880	1710	unidentified factor present	[unidentified factors present]	0.0	3	1	1	1
108881	1710	active mutant	[active mutant]	0.0	2	3	3	1
108882	1710	certain response through inverse effect	[certain responses through inverse effects]	0.0	5	1	1	1
108883	1710	determinant distinct from that traz	[determinants distinct from those TRAFs]	0.0	5	1	1	1
108884	1710	response to the hormone,	[responses to the hormone,]	0.0	4	1	1	1
108885	1710	former factor	[former factor]	0.0	2	1	1	1
108886	1710	overexpression in adult blood cell	[overexpression in adult blood cells]	0.0	5	1	1	1
108887	1710	supershift experiment use abs	[supershift experiments using Abs]	0.0	4	1	1	1
108888	1710	infiltrate of disease	[infiltrates of diseases]	0.0	3	1	1	1
108889	1710	effect in the patient	[effect in the patients]	0.0	4	1	1	1
108890	1710	mg/24h; n:	[mg/24h; N:]	0.0	2	1	1	1
108891	1710	novel taf	[novel TAF]	0.0	2	1	1	1
108892	1710	il-10 on lipopolysaccharide	[IL-10 on lipopolysaccharide]	0.0	3	1	1	1
108893	1710	toxic metabolite to protein	[toxic metabolites to proteins]	0.0	4	1	1	1
108894	1710	antigen ea anti-viral antigen vca	[antigen EA anti-viral antigen VCA]	0.0	5	1	1	1
108895	1710	2000 mu/l concentration insulin	[2,000 mU/L concentration insulin]	0.0	4	1	1	1
108896	1710	detailed histogenetic characterization	[Detailed histogenetic characterization]	0.0	3	1	1	1
108897	1710	human tissue breast	[human tissues breast]	0.0	3	1	1	1
108898	1710	polymorphic dinucleotide trinucleotide repeat	[polymorphic dinucleotide trinucleotide repeats]	0.0	4	1	1	1
108899	1710	involvement of dendritic cell FDC	[involvement of dendritic cells FDC]	0.0	5	1	1	1
108900	1710	reporter gene luciferase	[reporter gene luciferase]	0.0	3	1	1	1
108901	1710	difference between EBNA-2 extract	[differences between EBNA-2 extracts]	0.0	4	1	1	1
108902	1710	N-terminal fragment lps expression	[N-terminal fragment LPS expression]	0.0	4	1	1	1
108903	1710	model of a opposite situation	[models of an opposite situation]	0.0	5	1	1	1
108904	1710	bind the regulatory element	[binding the regulatory element]	0.0	4	1	1	1
108905	1710	mediator of th1-type response	[mediators of Th1-type responses]	0.0	4	1	1	1
108906	1710	adherence to cell	[adherence to cells]	0.0	3	1	1	1
108907	1710	translocation of [3H]calcitriol/VDR	[translocation of [3H]calcitriol/VDR]	0.0	3	2	2	1
108908	1710	replicate pseudoautosomal segment	[replicating pseudoautosomal segment]	0.0	3	1	1	1
108909	1710	224 ng/mL,	[224 ng/mL,]	0.0	2	1	1	1
108910	1710	several regulator	[several regulators]	0.0	2	1	1	1
108911	1710	monocyte use tf antibody	[monocytes using TF antibody]	0.0	4	1	1	1
108912	1710	il-6 synthesis	[IL-6 synthesis]	0.0	2	1	1	1
108913	1710	Prostaglandin E2 up-regulate	[Prostaglandin E2 Up-regulates]	0.0	3	1	1	1
108914	1710	pathway of the process	[pathway of the process]	0.0	4	1	1	1
108915	1710	cell with the property	[cells with the properties]	0.0	4	1	1	1
108916	1710	mobility shift assay with probe	[Mobility shift assays with probes]	0.0	5	1	1	1
108917	1710	(il1-ra)	[(IL1-RA)]	0.0	1	1	1	1
108918	1710	Differential induction of interferon protein differentiation	[Differential induction of interferon protein differentiation]	0.0	6	1	1	1
108919	1710	reactivity to the lytic cycle epitope	[reactivities to the lytic cycle epitopes]	0.0	6	1	1	1
108920	1710	Stable expression a homeobox gene	[Stable expression a homeobox gene]	0.0	5	1	1	1
108921	1710	c-jun phosphorylation	[c-Jun phosphorylation]	0.0	2	1	1	1
108922	1710	adult erythroid differentiation	[adult erythroid differentiation]	0.0	3	1	1	1
108923	1710	appear after the induction	[appearing after the induction]	0.0	4	1	1	1
108924	1710	further emphasize the potential of antioxidant	[further emphasizing the potential of antioxidants]	0.0	6	1	1	1
108925	1710	inhibit the activity of factor	[inhibiting the activity of factor]	0.0	5	1	1	1
108926	1710	activity a autophosphorylation site y518	[activity an autophosphorylation site Y518]	0.0	5	1	1	1
108927	1710	pair upstream sequence	[pair upstream sequence]	0.0	3	1	1	1
108928	1710	interaction between immunoglobulin-like transcript-2/leukocyte ig-like receptor	[Interaction between immunoglobulin-like transcript-2/leukocyte Ig-like receptor]	0.0	6	1	1	1
108929	1710	peripheral blood lymphocyte in patient	[peripheral blood lymphocytes in patients]	0.0	5	1	1	1
108930	1710	two mutant with point mutation	[two mutants with point mutations]	0.0	5	1	1	1
108931	1710	immunodeficiency virus patient	[immunodeficiency virus patients]	0.0	3	1	1	1
108932	1710	alteration in a fragment	[alteration in a fragment]	0.0	4	1	1	1
108933	1710	respectively, the lack	[respectively, the lack]	0.0	3	1	1	1
108934	1710	affinity for T3	[affinity for T3]	0.0	3	1	1	1
108935	1710	notably phospholipase c 1	[notably phospholipase C 1]	0.0	4	1	1	1
108936	1710	cd4+ T cell with lfa-3	[CD4+ T cells with LFA-3]	0.0	5	1	1	1
108937	1710	autologous peripheral blood stem cell transplantation	[Autologous peripheral blood stem cell transplantation]	0.0	6	1	1	1
108938	1710	basic-helix-loop-helix motif characteristic	[basic-helix-loop-helix motif characteristic]	0.0	3	1	1	1
108939	1710	differentiation induction system of cell	[differentiation induction systems of cells]	0.0	5	1	1	1
108940	1710	variation of glucocorticoid in subject	[Variation of glucocorticoids in subjects]	0.0	5	1	1	1
108941	1710	slowly migrate complex	[slowly migrating complex]	0.0	3	1	1	1
108942	1710	unregulated expression of myb,	[unregulated expression of myb,]	0.0	4	1	1	1
108943	1710	pyrrole-imidazole	[pyrrole-imidazole]	0.0	1	1	1	1
108944	1710	monocytic cell transcriptional induction	[Monocytic cell transcriptional induction]	0.0	4	1	1	1
108945	1710	human tr beta mrna level	[Human TR beta mRNA levels]	0.0	5	1	1	1
108946	1710	mediator of immunotoxicity	[mediator of immunotoxicity]	0.0	3	1	1	1
108947	1710	nfat-	[NFAT-]	0.0	1	1	1	1
108948	1710	direct ebna-2 -pu.1	[direct EBNA-2 -PU.1]	0.0	3	1	1	1
108949	1710	parenteral corticosteroid methyl prednisolone 120	[parenteral corticosteroid methyl prednisolone 120]	0.0	5	1	1	1
108950	1710	own group	[own group]	0.0	2	1	1	1
108951	1710	obscure, line	[obscure, lines]	0.0	2	1	1	1
108952	1710	stimulation with (il-6)	[stimulation with (IL-6)]	0.0	3	1	1	1
108953	1710	activation of extracellular kinase	[activation of extracellular kinases]	0.0	4	1	1	1
108954	1710	promoter (pp) repeat U1	[promoter (pp) repeat U1]	0.0	4	1	1	1
108955	1710	liposarcoma	[liposarcoma]	0.0	1	1	1	1
108956	1710	virus, implicate sequence	[virus, implicating sequences]	0.0	3	1	1	1
108957	1710	(inactivated)	[(inactivated)]	0.0	1	1	1	1
108958	1710	(paf)-	[(PAF)-]	0.0	1	1	1	1
108959	1710	pyrrole-imidazole polyamide	[pyrrole-imidazole polyamides]	0.0	2	1	1	1
108960	1710	requirement for activity,	[requirement for activity,]	0.0	3	1	1	1
108961	1710	c-fos/c-jun promoter element in T cell	[c-fos/c-jun promoter elements in T cells]	0.0	6	1	1	1
108962	1710	9 adult before dst mg).	[9 adults before DST mg).]	0.0	5	1	1	1
108963	1710	CAAX site	[CAAX site]	0.0	2	1	1	1
108964	1710	zinc finger of the c2h2-type	[zinc fingers of the C2H2-type]	0.0	5	1	1	1
108965	1710	sophisticated strategy persist lifelong,	[sophisticated strategy persisting lifelong,]	0.0	4	1	1	1
108966	1710	development in the thymus	[development in the thymus]	0.0	4	1	1	1
108967	1710	diethyl	[diethyl]	0.0	1	1	1	1
108968	1710	Vitamin d3-	[Vitamin D3-]	0.0	2	1	1	1
108969	1710	il-9 epo	[IL-9 Epo]	0.0	2	1	1	1
108970	1710	310 binding sites/nucleus	[310 binding sites/nucleus]	0.0	3	1	1	1
108971	1710	ikappabalpha constitutive expression	[IkappaBalpha constitutive expression]	0.0	3	1	1	1
108972	1710	big T allele	[big T allele]	0.0	3	1	1	1
108973	1710	protein with a dna-binding domain	[proteins with a DNA-binding domain]	0.0	5	1	1	1
108974	1710	require the activation	[requiring the activation]	0.0	3	1	1	1
108975	1710	most characteristic feature	[most characteristic features]	0.0	3	1	1	1
108976	1710	critical b cell-specific gene	[critical B cell-specific gene]	0.0	4	1	1	1
108977	1710	downregulation implication	[downregulation implications]	0.0	2	1	1	1
108978	1710	cooperation between the hsv-1-activated factor icp0	[cooperation between the HSV-1-activated factor ICP0]	0.0	6	1	1	1
108979	1710	macrophage protein-2 mip-2	[macrophage protein-2 MIP-2]	0.0	3	1	1	1
108980	1710	axis activation during critical illness	[axis activation during critical illness]	0.0	5	1	1	1
108981	1710	a gene	[A gene]	0.0	2	1	1	1
108982	1710	tal1 in tumorigenesis	[TAL1 in tumorigenesis]	0.0	3	1	1	1
108983	1710	expression of fas	[expression of Fas]	0.0	3	1	1	1
108984	1710	immune responses,	[immune responses,]	0.0	2	1	1	1
108985	1710	DNA binding activity of extract	[DNA binding activity of extracts]	0.0	5	1	1	1
108986	1710	T cell p55/p75	[T cells p55/p75]	0.0	3	1	1	1
108987	1710	rapid decrease	[rapid decrease]	0.0	2	2	2	1
108988	1710	mouse 70z/3	[mouse 70Z/3]	0.0	2	1	1	1
108989	1710	rna transcriptional activity	[RNA transcriptional activity]	0.0	3	1	1	1
108990	1710	relation to major class	[relation to major classes]	0.0	4	1	1	1
108991	1710	factor to the region	[factor to the region]	0.0	4	1	1	1
108992	1710	relation to features: implications.	[relations to features: implications.]	0.0	4	1	1	1
108993	1710	tandem Ap1 site	[tandem Ap1 sites]	0.0	3	1	1	1
108994	1710	dominant susceptibility	[dominant susceptibility]	0.0	2	2	2	1
108995	1710	affinity of heterodimeric NFKB2	[affinity of heterodimeric NFKB2]	0.0	4	1	1	1
108996	1710	wild-type human ecem) cell	[wild-type human (CEM) cells]	0.0	4	1	1	1
108997	1710	(estrogen	[(estrogen]	0.0	1	1	1	1
108998	1710	molecular target for SR	[molecular target for SR]	0.0	4	1	1	1
108999	1710	Specific docking site within cytokine receptor	[Specific docking sites within cytokine receptors]	0.0	6	1	1	1
109000	1710	pkc NF-kappa b inhibitors, pentoxifylline	[PKC NF-kappa B inhibitors, pentoxifylline]	0.0	5	1	1	1
109001	1710	1-beta	[1-beta]	0.0	1	1	1	1
109002	1710	high dose of parenteral corticosteroid	[high doses of parenteral corticosteroid]	0.0	5	1	1	1
109003	1710	tumor-suppressor	[tumor-suppressor]	0.0	1	1	1	1
109004	1710	region of the IL-2R alpha gene	[regions of the IL-2R alpha gene]	0.0	6	1	1	1
109005	1710	gene encode CD11a	[genes encoding CD11a]	0.0	3	1	1	1
109006	1710	suggest a carboxy-terminal domain	[suggesting a carboxy-terminal domain]	0.0	4	1	1	1
109007	1710	immunohistochemical study of lymphocyte	[Immunohistochemical study of lymphocytes]	0.0	4	1	1	1
109008	1710	stimulus include anti-CD3	[stimuli including anti-CD3]	0.0	3	1	1	1
109009	1710	antioxidant activate pathway distinct	[antioxidant activating pathway distinct]	0.0	4	1	1	1
109010	1710	0.9 (1.1-4.4) fmol/10(7) cell	[0.9 (1.1-4.4) fmol/10(7) cells]	0.0	4	3	3	1
109011	1710	trans-disulfide disulfide tds	[trans-disulfide disulfide TDS]	0.0	3	1	1	1
109012	1710	exposure to signals,	[exposure to signals,]	0.0	3	1	1	1
109013	1710	authors' laboratory	[authors' laboratory]	0.0	2	1	1	1
109014	1710	reduction in the activation	[reductions in the activation]	0.0	4	1	1	1
109015	1710	host event	[host events]	0.0	2	1	1	1
109016	1710	signal-transducing receptor	[signal-transducing receptor]	0.0	2	1	1	1
109017	1710	IL-6 -responsive gene	[IL-6 -responsive genes]	0.0	3	1	1	1
109018	1710	dysfunction.	[dysfunction.]	0.0	1	1	1	1
109019	1710	only in cooperation	[only in cooperation]	0.0	3	1	1	1
109020	1710	region of calcineurin	[region of calcineurin]	0.0	3	1	1	1
109021	1710	significant inactivation of the x inconsistent	[significant inactivation of the X inconsistent]	0.0	6	1	1	1
109022	1710	t-lymphocyte culture in normal condition	[T-lymphocytes culture in normal conditions]	0.0	5	1	1	1
109023	1710	direct contribution of ebv	[direct contribution of EBV]	0.0	4	1	1	1
109024	1710	peroxide level	[peroxide level]	0.0	2	1	1	1
109025	1710	multiple polypeptide range	[multiple polypeptides ranging]	0.0	3	1	1	1
109026	1710	requirement for pc4 component	[requirement for PC4 component]	0.0	4	1	1	1
109027	1710	low level expression of this receptor	[low level expression of these receptors]	0.0	6	1	1	1
109028	1710	90 min)	[90 min)]	0.0	2	1	1	1
109029	1710	10-fold 4 to 5 day	[10-fold 4 to 5 days]	0.0	5	1	1	1
109030	1710	patient with (6 wk RA	[patients with (6 wk RA]	0.0	5	1	1	1
109031	1710	fate decision of progenitor	[fate decisions of progenitors]	0.0	4	1	1	1
109032	1710	induction of t-cell gene	[induction of T-cell genes]	0.0	4	1	1	1
109033	1710	density lipoprotein response in endothelial cell	[density lipoprotein responses in endothelial cells]	0.0	6	1	1	1
109034	1710	lectin-type ldl receptor olr1	[lectin-type LDL receptor OLR1]	0.0	4	1	1	1
109035	1710	allele Raf	[allele Raf]	0.0	2	1	1	1
109036	1710	protein synthesis-independent appearance	[protein synthesis-independent appearance]	0.0	3	1	1	1
109037	1710	fixative-sensitive a epitope	[fixative-sensitive a epitope]	0.0	3	1	1	1
109038	1710	25(OH)D3	[25(OH)D3]	0.0	1	1	1	1
109039	1710	contain ebf -binding site	[containing EBF -binding sites]	0.0	4	1	1	1
109040	1710	dexamethasone (ic50 nm,	[dexamethasone (IC50 nM,]	0.0	3	1	1	1
109041	1710	Class ii endothelial cell MHC class	[Class II endothelial cell MHC class]	0.0	6	1	1	1
109042	1710	domain in -9-mediate cell proliferation	[domains in -9-mediated cell proliferation]	0.0	5	1	1	1
109043	1710	activation of reporter gene	[activation of reporter genes]	0.0	4	1	1	1
109044	1710	basis for the action	[basis for the actions]	0.0	4	1	1	1
109045	1710	about 2-fold affinity	[about 2-fold affinity]	0.0	3	1	1	1
109046	1710	interestingly, early treatment hpc	[Interestingly, early treatment HPCs]	0.0	4	1	1	1
109047	1710	homologous peptide	[homologous peptide]	0.0	2	1	1	1
109048	1710	namely the chain enhancer	[namely the chain enhancer]	0.0	4	1	1	1
109049	1710	World primate nwp	[World primate NWP]	0.0	3	1	1	1
109050	1710	exhibit change in phosphorylation	[exhibiting changes in phosphorylation]	0.0	4	1	1	1
109051	1710	therapeutic approach against aids	[therapeutic approach against AIDS]	0.0	4	1	1	1
109052	1710	nuclear rna gene	[nuclear RNA genes]	0.0	3	2	2	1
109053	1710	12 menopausal woman	[12 menopausal women]	0.0	3	1	1	1
109054	1710	synthesis of protein,	[synthesis of protein,]	0.0	3	1	1	1
109055	1710	homeobox gene related	[homeobox gene related]	0.0	3	1	1	1
109056	1710	group of rdna	[group of cDNAs]	0.0	3	1	1	1
109057	1710	footprint erythroid cell	[footprinting erythroid cells]	0.0	3	1	1	1
109058	1710	contain the gamma chain	[containing the gamma chain]	0.0	4	1	1	1
109059	1710	Janus kinase tyrosine kinase	[Janus kinase tyrosine kinase]	0.0	4	1	1	1
109060	1710	gram-negative bacterial endotoxin Escherichia coli lps	[gram-negative bacterial endotoxin Escherichia coli LPS]	0.0	6	1	1	1
109061	1710	modest increase relative	[modest increase relative]	0.0	3	1	1	1
109062	1710	derivative 16	[derivative 16]	0.0	2	1	1	1
109063	1710	alpha enhancer	[alpha enhancer]	0.0	2	1	1	1
109064	1710	relevance for this model.	[relevance for this model.]	0.0	4	1	1	1
109065	1710	human immunodeficiency virus type 1 factor	[Human immunodeficiency virus type 1 factor]	0.0	6	1	1	1
109066	1710	il-2r beta gene	[IL-2R beta gene]	0.0	3	1	1	1
109067	1710	interleukin gene enhancer	[interleukin gene enhancer]	0.0	3	1	1	1
109068	1710	factor-IL6 motif	[factor-IL6 motifs]	0.0	2	1	1	1
109069	1710	18 breast cancer patient	[18 breast cancer patients]	0.0	4	1	1	1
109070	1710	accord to results,	[According to results,]	0.0	3	1	1	1
109071	1710	t-cell leukemia T cell	[T-cell leukemia T cells]	0.0	4	1	1	1
109072	1710	endogenous virus isolate	[endogenous virus isolates]	0.0	3	1	1	1
109073	1710	Concomitant downregulation	[Concomitant downregulation]	0.0	2	1	1	1
109074	1710	also in 10 healthy individual	[also in 10 healthy individuals]	0.0	5	1	1	1
109075	1710	haematological remission CHR	[haematological remission CHR]	0.0	3	2	2	1
109076	1710	contrast, LPS binding of factor-kappaB/Rel	[contrast, LPS binding of factor-kappaB/Rel]	0.0	5	1	1	1
109077	1710	cis-acting regulatory effect	[cis-acting regulatory effect]	0.0	3	1	1	1
109078	1710	coactivation by OCA-B definition of region	[Coactivation by OCA-B definition of regions]	0.0	6	1	1	1
109079	1710	less degree, 11alpha,13-dihydrohelenalin	[lesser degree, 11alpha,13-dihydrohelenalin]	0.0	3	1	1	1
109080	1710	only individual of complex (mhc) haplotype	[only individuals of complex (MHC) haplotypes]	0.0	6	1	1	1
109081	1710	dithiothreitol	[dithiothreitol]	0.0	1	1	1	1
109082	1710	level of steroid receptor	[level of steroid receptors]	0.0	4	2	2	1
109083	1710	member of the gata-binding protein	[members of the GATA-binding proteins]	0.0	5	1	1	1
109084	1710	B1 complex	[B1 complex]	0.0	2	1	1	1
109085	1710	peptide VP16	[peptide VP16]	0.0	2	1	1	1
109086	1710	subsequently respond ifn-alpha	[subsequently responding IFN-alpha]	0.0	3	1	1	1
109087	1710	microm 1-beta-d-arabinofuranosylcytosine	[microM 1-beta-D-arabinofuranosylcytosine]	0.0	2	1	1	1
109088	1710	comparison no synthase ino gene	[comparison NO synthase iNOS genes]	0.0	5	1	1	1
109089	1710	absence of mrna	[absence of mRNA]	0.0	3	1	1	1
109090	1710	link arrest	[link arrest]	0.0	2	1	1	1
109091	1710	cell-surface isoform of cd43	[cell-surface isoforms of CD43]	0.0	4	1	1	1
109092	1710	overlapping cosmid encode human ciita	[overlapping cosmids encoding human CIITA]	0.0	5	1	1	1
109093	1710	current state	[current state]	0.0	2	1	1	1
109094	1710	Comparing the regulation gene	[Comparing the regulation genes]	0.0	4	1	1	1
109095	1710	patient with rheumatic disease (12:	[patients with rheumatic diseases (12:]	0.0	5	1	1	1
109096	1710	compartments.	[compartments.]	0.0	1	1	1	1
109097	1710	age-associated impairment of ap-1	[age-associated impairments of AP-1]	0.0	4	1	1	1
109098	1710	affinity b	[affinity B]	0.0	2	1	1	1
109099	1710	demonstration of the dependence	[Demonstration of the dependence]	0.0	4	1	1	1
109100	1710	relevant protein	[relevant proteins]	0.0	2	1	1	1
109101	1710	protein kinase c isoform	[protein kinase C isoforms]	0.0	4	1	1	1
109102	1710	cell-specific interaction	[cell-specific interaction]	0.0	2	1	1	1
109103	1710	(atf-1)	[(ATF-1)]	0.0	1	1	1	1
109104	1710	antipeptide antibody	[antipeptide antibodies]	0.0	2	1	1	1
109105	1710	transfection of mutant	[Transfection of mutants]	0.0	3	1	1	1
109106	1710	induction in a line	[Induction in a line]	0.0	4	1	1	1
109107	1710	budesonide bud	[budesonide BUD]	0.0	2	1	1	1
109108	1710	low level expression	[low level expression]	0.0	3	1	1	1
109109	1710	role of pebp2	[role of PEBP2]	0.0	3	1	1	1
109110	1710	differential effect in bone protein-2-	[differential effects in bone protein-2-]	0.0	5	1	1	1
109111	1710	new human retrovirus	[new human retrovirus]	0.0	3	1	1	1
109112	1710	yy-1 yyabu	[YY-1 YY-Bu]	0.0	2	1	1	1
109113	1710	factor (s) from blood monocyte	[factor (s) from blood monocytes]	0.0	5	1	1	1
109114	1710	maximum stimulation	[maximum stimulation]	0.0	2	1	1	1
109115	1710	selective blockade of differentiation	[selective blockade of differentiation]	0.0	4	1	1	1
109116	1710	one function of tax	[one function of Tax]	0.0	4	1	1	1
109117	1710	70% sequence similarity	[70% sequence similarity]	0.0	3	1	1	1
109118	1710	alpha- globin chain	[alpha- globin chains]	0.0	3	1	1	1
109119	1710	wild-type form	[wild-type forms]	0.0	2	1	1	1
109120	1710	none to on epidermal cell	[none to on epidermal cells]	0.0	5	1	1	1
109121	1710	long repeat of this retrovirus	[long repeat of this retrovirus]	0.0	5	1	1	1
109122	1710	novel ets-related transcription factor	[novel Ets-related transcription factor]	0.0	4	2	2	1
109123	1710	abnormality of retinoblastoma protein	[Abnormalities of retinoblastoma protein]	0.0	4	1	1	1
109124	1710	multiple distinct family	[multiple distinct families]	0.0	3	1	1	1
109125	1710	then the expression	[then the expression]	0.0	3	1	1	1
109126	1710	establishment of branchpoint	[establishment of branchpoints]	0.0	3	1	1	1
109127	1710	region contain the hmg box	[region containing the HMG box]	0.0	5	1	1	1
109128	1710	level of il-2 production	[levels of IL-2 production]	0.0	4	1	1	1
109129	1710	ig-secreting	[Ig-secreting]	0.0	1	1	1	1
109130	1710	abnormality, the majority	[abnormality, the majority]	0.0	3	1	1	1
109131	1710	nutritionally relevant concentration	[nutritionally relevant concentrations]	0.0	3	1	1	1
109132	1710	affinity of element for respective factor	[affinities of elements for respective factor]	0.0	6	1	1	1
109133	1710	alter immune response	[altering immune responses]	0.0	3	1	1	1
109134	1710	evidence to previous observation	[evidence to previous observations]	0.0	4	1	1	1
109135	1710	method of Peripheral lymphocyte	[METHOD OF Peripheral lymphocytes]	0.0	4	1	1	1
109136	1710	overexpression the product	[Overexpression the product]	0.0	3	1	1	1
109137	1710	proximal bind element	[proximal binding element]	0.0	3	1	1	1
109138	1710	CD40 ligand expression	[CD40 ligand expression]	0.0	3	1	1	1
109139	1710	combination of factor	[combinations of factors]	0.0	3	1	1	1
109140	1710	major putative downstream site	[major putative downstream site]	0.0	4	1	1	1
109141	1710	hd sample nlphd	[HD samples NLPHD]	0.0	3	1	1	1
109142	1710	clue for predisposition for atopy	[clue for predisposition for atopy]	0.0	5	1	1	1
109143	1710	interleukin-6 gene	[interleukin-6 gene]	0.0	2	1	1	1
109144	1710	spxx	[SPXX]	0.0	1	1	1	1
109145	1710	Bob-1	[Bob-1]	0.0	1	1	1	1
109146	1710	granulopoiesis postnatally, die days.	[granulopoiesis postnatally, dying days.]	0.0	4	1	1	1
109147	1710	detectable nfatc protein in extract	[detectable NFATc protein in extracts]	0.0	5	1	1	1
109148	1710	evidence a target for immunosuppression	[evidence a target for immunosuppression]	0.0	5	1	1	1
109149	1710	frequent cause	[frequent cause]	0.0	2	1	1	1
109150	1710	also no partial correlation	[Also no partial correlations]	0.0	4	1	1	1
109151	1710	stat6 mouse	[STAT6 mice]	0.0	2	1	1	1
109152	1710	role in the manifestation	[role in the manifestations]	0.0	4	1	1	1
109153	1710	treatment of blood lymphocyte	[Treatment of blood lymphocytes]	0.0	4	1	1	1
109154	1710	continuous treatment with subcytotoxic concentration	[continuous treatments with subcytotoxic concentrations]	0.0	5	1	1	1
109155	1710	/p130	[/p130]	0.0	1	1	1	1
109156	1710	defect in transduction	[defect in transduction]	0.0	3	1	1	1
109157	1710	detailed analysis of the 12 rdna	[Detailed analysis of the 12 cDNAs]	0.0	6	1	1	1
109158	1710	human t-cell type	[human T-cell types]	0.0	3	1	1	1
109159	1710	toxic side effect	[toxic side effects]	0.0	3	1	1	1
109160	1710	1.3-1.5 kb	[1.3-1.5 kb]	0.0	2	1	1	1
109161	1710	Rel similarity region	[Rel similarity region]	0.0	3	1	1	1
109162	1710	E1a- ad vector	[E1a- Ad vectors]	0.0	3	1	1	1
109163	1710	control with respect use a assay	[controls with respect using a assay]	0.0	6	1	1	1
109164	1710	pretreatment with 10(-7) m dexamethasone	[pretreatment with 10(-7) M dexamethasone]	0.0	5	1	1	1
109165	1710	chromosome breakpoint in leukemia	[chromosome breakpoints in leukemias]	0.0	4	1	1	1
109166	1710	link between change	[link between changes]	0.0	3	1	1	1
109167	1710	(delta383)	[(delta383)]	0.0	1	1	1	1
109168	1710	pseudohypoaldosteronism in different form of inheritance	[Pseudohypoaldosteronism in different forms of inheritance]	0.0	6	1	1	1
109169	1710	significant decline in chymotryptic activity	[significant decline in chymotryptic activity]	0.0	5	1	1	1
109170	1710	synergy between the pkc stimulator	[synergy between the PKC stimulator]	0.0	5	1	1	1
109171	1710	activation with VDR	[activation with VDR]	0.0	3	1	1	1
109172	1710	similar pattern of factor binding	[similar pattern of factor binding]	0.0	5	1	1	1
109173	1710	sertraline response in disorder MDD	[sertraline response in disorder MDD]	0.0	5	1	1	1
109174	1710	function of c-Rel	[function of c-Rel]	0.0	3	1	1	1
109175	1710	expression of endogenous cytokine gene	[expression of endogenous cytokine genes]	0.0	5	1	1	1
109176	1710	gene encode gamma-globin deaminase	[genes encoding gamma-globin deaminase]	0.0	4	1	1	1
109177	1710	HeLa cell extract	[HeLa cell extracts]	0.0	3	1	1	1
109178	1710	Differential induction of interferon 10 differentiation	[Differential induction of interferon 10 differentiation]	0.0	6	1	1	1
109179	1710	pg/ml,	[pg/ml,]	0.0	1	1	1	1
109180	1710	EBNA-LP alone	[EBNA-LP alone]	0.0	2	1	1	1
109181	1710	expose umbilical vein cell to anoxia/reoxygenation	[Exposing umbilical vein cells to anoxia/reoxygenation]	0.0	6	1	1	1
109182	1710	5'-upstream	[5'-upstream]	0.0	1	1	1	1
109183	1710	D3 calcitriol determination in lymphocyte	[D3 calcitriol determination in lymphocytes]	0.0	5	1	1	1
109184	1710	camp element	[cAMP element]	0.0	2	1	1	1
109185	1710	region of potential in a segment	[Regions of potential in a segment]	0.0	6	1	1	1
109186	1710	untreated euthymic patient with disorder	[untreated euthymic patients with disorder]	0.0	5	1	1	1
109187	1710	effect on cytokine production	[effects on cytokine production]	0.0	4	1	1	1
109188	1710	HLA-DR3 positive	[HLA-DR3 positive]	0.0	2	1	1	1
109189	1710	dose of t3 (10(-10)	[dose of T3 (10(-10)]	0.0	4	1	1	1
109190	1710	patient with depressive disorder	[patients with depressive disorder]	0.0	4	1	1	1
109191	1710	purine-rich binding site	[purine-rich binding sites]	0.0	3	1	1	1
109192	1710	range of cell types,	[range of cell types,]	0.0	4	1	1	1
109193	1710	Epstein-Barr virus binding	[Epstein-Barr virus binding]	0.0	3	1	1	1
109194	1710	isoform-specific antibody	[isoform-specific antibodies]	0.0	2	1	1	1
109195	1710	serum responsive element SRE	[serum responsive element SRE]	0.0	4	1	1	1
109196	1710	block a therapeutic target	[blocking a therapeutic target]	0.0	4	1	1	1
109197	1710	hmg domain	[HMG domain]	0.0	2	3	3	1
109198	1710	moreover, TNF-alpha hiv-1 long repeat	[Moreover, TNF-alpha HIV-1 long repeat]	0.0	5	1	1	1
109199	1710	etoposide microM)	[etoposide microM)]	0.0	2	1	1	1
109200	1710	active maintenance of NFAT	[active maintenance of NFAT]	0.0	4	1	1	1
109201	1710	downstream beta-like globin gene	[downstream beta-like globin genes]	0.0	4	1	1	1
109202	1710	huvec surface	[HUVEC surface]	0.0	2	1	1	1
109203	1710	alternative model	[alternative model]	0.0	2	1	1	1
109204	1710	presence of multiple binding site	[presence of multiple binding sites]	0.0	5	1	1	1
109205	1710	neonatal than T cell	[neonatal than T cells]	0.0	4	1	1	1
109206	1710	thus activate transcription factor	[thus activating transcription factors]	0.0	4	1	1	1
109207	1710	complementarity	[complementarity]	0.0	1	1	1	1
109208	1710	means of transduction pathway	[means of transduction pathways]	0.0	4	1	1	1
109209	1710	assay nf-atp	[assays NF-ATp]	0.0	2	1	1	1
109210	1710	T lymphotropic	[T lymphotropic]	0.0	2	1	1	1
109211	1710	b p65 mutant	[B p65 mutants]	0.0	3	1	1	1
109212	1710	level of ifn-gamma	[levels of IFN-gamma]	0.0	3	1	1	1
109213	1710	several stimulus elicit stress	[several stimuli eliciting stress]	0.0	4	1	1	1
109214	1710	smad2 phosphorylation	[Smad2 phosphorylation]	0.0	2	1	1	1
109215	1710	20- increase	[20- increase]	0.0	2	1	1	1
109216	1710	implication in aids pathogenesis	[implications in AIDS pathogenesis]	0.0	4	1	1	1
109217	1710	IL-12 induction	[IL-12 induction]	0.0	2	1	1	1
109218	1710	growth factor requirement	[growth factor requirement]	0.0	3	1	1	1
109219	1710	Furthermore, concentration of HU microm	[Furthermore, concentrations of HU microM]	0.0	5	1	1	1
109220	1710	methods: pbmc	[METHODS: PBMCs]	0.0	2	1	1	1
109221	1710	ro(ssa) patient lack la(ssb) precipitin	[Ro(SSA) patients lacking La(SSB) precipitins]	0.0	5	1	1	1
109222	1710	(71%) recent-onset iddm subject	[(71%) recent-onset IDDM subjects]	0.0	4	1	1	1
109223	1710	underlie the expression	[underlying the expression]	0.0	3	1	1	1
109224	1710	mouse erythroleukemia	[mouse erythroleukemia]	0.0	2	1	1	1
109225	1710	cell grow in culture.	[cells growing in culture.]	0.0	4	1	1	1
109226	1710	parathyroid hormone-related protein promoter	[parathyroid hormone-related protein promoter]	0.0	4	1	1	1
109227	1710	deletion the homolog	[deletions the homolog]	0.0	3	1	1	1
109228	1710	acute attack of bowel disease	[acute attacks of bowel disease]	0.0	5	1	1	1
109229	1710	cis-activation of tal-1 promoter	[cis-activation of tal-1 promoter]	0.0	4	1	1	1
109230	1710	apoptosis in hiv-infected cell	[apoptosis in HIV-infected cells]	0.0	4	1	1	1
109231	1710	production of interleukin 1beta	[production of interleukin 1beta]	0.0	4	1	1	1
109232	1710	-130 ap-1-like site -187	[-130 AP-1-like site -187]	0.0	4	1	1	1
109233	1710	function of alveolar macrophage	[functions of alveolar macrophages]	0.0	4	1	1	1
109234	1710	two transactivator BZLF1	[two transactivators BZLF1]	0.0	3	1	1	1
109235	1710	cellular immunity result in response	[cellular immunity resulting in response]	0.0	5	1	1	1
109236	1710	expression in u937 cell	[Expression in U937 cells]	0.0	4	1	1	1
109237	1710	gata-1 expression in pure progenitor	[GATA-1 expression in pure progenitors]	0.0	5	1	1	1
109238	1710	additional unknown factor	[additional unknown factors]	0.0	3	1	1	1
109239	1710	domain e	[domain E]	0.0	2	1	1	1
109240	1710	extensive footprint than the fetal globin	[extensive footprints than the fetal globin]	0.0	6	1	1	1
109241	1710	Effect of oxidative stress lead	[Effects of oxidative stress leading]	0.0	5	1	1	1
109242	1710	cell on reporter gene	[cells on reporter genes]	0.0	4	1	1	1
109243	1710	receptor promoter	[receptor promoter]	0.0	2	1	1	1
109244	1710	complex way	[complex way]	0.0	2	1	1	1
109245	1710	regulate important aspect	[regulating important aspects]	0.0	3	1	1	1
109246	1710	gliotoxin activation	[gliotoxin activation]	0.0	2	1	1	1
109247	1710	IL igm production by SKW cell	[IL IgM production by SKW cells]	0.0	6	1	1	1
109248	1710	activation by sp-a dose low	[Activation by SP-A doses low]	0.0	5	1	1	1
109249	1710	concomitant modification	[concomitant modifications]	0.0	2	1	1	1
109250	1710	Internal labeling with anti-igm	[Internal labeling with anti-IgM]	0.0	4	1	1	1
109251	1710	lymphocyte depletion	[lymphocyte depletion]	0.0	2	1	1	1
109252	1710	literature describe the activation	[literature describing the activation]	0.0	4	1	1	1
109253	1710	transcription complex NF-AT	[transcription complex NF-AT]	0.0	3	1	1	1
109254	1710	HT-2	[HT-2]	0.0	1	1	1	1
109255	1710	evidence for a variation	[evidence for a variation]	0.0	4	1	1	1
109256	1710	criteria, extremely unbalanced inactivation	[criteria, extremely unbalanced inactivation]	0.0	4	1	1	1
109257	1710	role of runt product	[role of runt products]	0.0	4	1	1	1
109258	1710	CsA T cell factor	[CsA T cell factors]	0.0	4	1	1	1
109259	1710	binding of tax to element	[Binding of Tax to element]	0.0	5	1	1	1
109260	1710	clone pgd41	[clone pGD41]	0.0	2	1	1	1
109261	1710	mechanism in leukemic cell	[mechanism in leukemic cells]	0.0	4	1	1	1
109262	1710	creb isoform with dna-binding specificity	[CREB isoforms with DNA-binding specificities]	0.0	5	1	1	1
109263	1710	class lymphoma plasmacytoid	[class lymphoma plasmacytoid]	0.0	3	1	1	1
109264	1710	hour at pH	[hr at pH]	0.0	3	1	1	1
109265	1710	french-american-british myeloid leukemia-M3	[French-American-British myeloid leukemia-M3]	0.0	3	1	1	1
109266	1710	repressor by helix-loop-helix protein	[repressor by helix-loop-helix proteins]	0.0	4	1	1	1
109267	1710	involvement of NF-chi b in induction	[Involvement of NF-chi B in induction]	0.0	6	1	1	1
109268	1710	insight on the origin	[insight on the origin]	0.0	4	1	1	1
109269	1710	evidence for formation	[evidence for formation]	0.0	3	1	1	1
109270	1710	whole-cell binding assay	[whole-cell binding assay]	0.0	3	1	1	1
109271	1710	nuclear appearance of NF-kappaB	[nuclear appearance of NF-kappaB]	0.0	4	1	1	1
109272	1710	primary adult cell	[primary adult cells]	0.0	3	1	1	1
109273	1710	induce expression in 244b lymphoblastoid cell	[inducing expression in 244B lymphoblastoid cells]	0.0	6	1	1	1
109274	1710	major target for p21ras	[major target for p21ras]	0.0	4	1	1	1
109275	1710	I gamma ECS	[I gamma ECS]	0.0	3	1	1	1
109276	1710	association through the a	[association through the aa]	0.0	4	1	1	1
109277	1710	murine promyelocytic leukemia	[murine promyelocytic leukemia]	0.0	3	1	1	1
109278	1710	factor bind to one	[factor binding to one]	0.0	4	1	1	1
109279	1710	rate epithelia	[rate epithelia]	0.0	2	1	1	1
109280	1710	results, nuclear extract	[results, nuclear extracts]	0.0	3	1	1	1
109281	1710	many effect of lipopolysaccharide	[Many effects of lipopolysaccharide]	0.0	4	1	1	1
109282	1710	repopulate	[repopulating]	0.0	1	1	1	1
109283	1710	basis for the transcriptional regulation	[basis for the transcriptional regulation]	0.0	5	1	1	1
109284	1710	bcl-6 lesion	[BCL-6 lesions]	0.0	2	1	1	1
109285	1710	cycle of ebv infection	[cycle of EBV infection]	0.0	4	1	1	1
109286	1710	increase in tal1 mrna	[increase in TAL1 mRNA]	0.0	4	1	1	1
109287	1710	mutant of Ras	[mutants of Ras]	0.0	3	1	1	1
109288	1710	CD1+relB+DC	[CD1+relB+DC]	0.0	1	1	1	1
109289	1710	jy25	[JY25]	0.0	1	1	1	1
109290	1710	antigen, lectin	[antigen, lectin]	0.0	2	1	1	1
109291	1710	alpha beta 1 ligation	[alpha beta 1 ligation]	0.0	4	1	1	1
109292	1710	possibility inactive	[possibility inactive]	0.0	2	1	1	1
109293	1710	NF-kappaB/NFAT protein	[NF-kappaB/NFAT proteins]	0.0	2	1	1	1
109294	1710	total population killer population	[total populations killer populations]	0.0	4	1	1	1
109295	1710	imperfect repeat	[imperfect repeats]	0.0	2	1	1	1
109296	1710	activation of the repeat	[activation of the repeat]	0.0	4	1	1	1
109297	1710	differentiation of promyelomonocytic hl-60 cell	[differentiation of promyelomonocytic HL-60 cells]	0.0	5	1	1	1
109298	1710	encompass the fusion region	[encompassing the fusion region]	0.0	4	1	1	1
109299	1710	adolescent major depressive disorder	[adolescent major depressive disorder]	0.0	4	1	1	1
109300	1710	several cell line of origin	[Several cell lines of origin]	0.0	5	1	1	1
109301	1710	alter the gene	[altering the gene]	0.0	3	1	1	1
109302	1710	-223 basis	[-223 bases]	0.0	2	1	1	1
109303	1710	rac1 gtpase	[Rac1 GTPases]	0.0	2	1	1	1
109304	1710	hormonal metabolic status comparison with criteria]	[Hormonal metabolic status comparison with criteria]]	0.0	6	1	1	1
109305	1710	10(5)- amplification of cell	[10(5)- amplification of cells]	0.0	4	1	1	1
109306	1710	defective gene type	[defective genes type]	0.0	3	1	1	1
109307	1710	expression of gcr	[expression of gcRs]	0.0	3	1	1	1
109308	1710	gross rearrangement	[gross rearrangements]	0.0	2	1	1	1
109309	1710	intima	[intima]	0.0	1	1	1	1
109310	1710	antiinflammatory property in endothelial cell	[antiinflammatory properties in endothelial cells]	0.0	5	1	1	1
109311	1710	hs-40 motif	[HS-40 motifs]	0.0	2	1	1	1
109312	1710	beta-like globin gene kilobasis	[beta-like globin genes kilobases]	0.0	4	1	1	1
109313	1710	lipopolysaccharide factor	[lipopolysaccharide factor]	0.0	2	1	1	1
109314	1710	suggest Oct-1	[suggesting Oct-1]	0.0	2	1	1	1
109315	1710	cell expression	[Cell expression]	0.0	2	1	1	1
109316	1710	result in phosphorylation of numerous substrate	[resulting in phosphorylation of numerous substrates]	0.0	6	1	1	1
109317	1710	Comparison of primary sensitization	[Comparison of primary sensitization]	0.0	4	1	1	1
109318	1710	HTLV-1 transformation of cell	[HTLV-1 transformation of cells]	0.0	4	1	1	1
109319	1710	distinct DNA binding specificity	[distinct DNA binding specificities]	0.0	4	1	1	1
109320	1710	basis of nf-kappab dna-binding activity	[basis of NF-kappaB DNA-binding activity]	0.0	5	1	1	1
109321	1710	reticuloendotheliosis virus terminal repeat element	[Reticuloendotheliosis virus terminal repeat elements]	0.0	5	1	1	1
109322	1710	SCL 5'	[SCL 5']	0.0	2	1	1	1
109323	1710	scheme	[scheme]	0.0	1	1	1	1
109324	1710	also in the eventual activation	[also in the eventual activation]	0.0	5	1	1	1
109325	1710	rapid activator	[rapid activator]	0.0	2	1	1	1
109326	1710	92 base pair of 5'-flanking DNA	[92 base pairs of 5'-flanking DNA]	0.0	6	1	1	1
109327	1710	water soluble phorbol ester	[water soluble phorbol esters]	0.0	4	1	1	1
109328	1710	similar inverse change	[similar inverse changes]	0.0	3	1	1	1
109329	1710	inhibition of 62%	[inhibition of 62%]	0.0	3	1	1	1
109330	1710	physiologic molecular switch	[physiologic molecular switch]	0.0	3	1	1	1
109331	1710	RpoN mutant	[RpoN mutant]	0.0	2	1	1	1
109332	1710	coagulation protease	[coagulation protease]	0.0	2	2	2	1
109333	1710	asthma patient both	[asthma patients both]	0.0	3	1	1	1
109334	1710	translocation of NF-kappa b-related transcription factor	[translocation of NF-kappa B-related transcription factors]	0.0	6	1	1	1
109335	1710	dead cell at day g-csf	[dead cells at day G-CSF]	0.0	5	1	1	1
109336	1710	activation of the sensitive transcription factor	[activation of the sensitive transcription factor]	0.0	6	1	1	1
109337	1710	overexpression a active version	[Overexpression a active version]	0.0	4	1	1	1
109338	1710	Potential site	[Potential sites]	0.0	2	1	1	1
109339	1710	enhancer in the gene	[enhancer in the gene]	0.0	4	1	1	1
109340	1710	link between cellular production	[link between cellular production]	0.0	4	1	1	1
109341	1710	initiation mrna	[initiation mRNA]	0.0	2	1	1	1
109342	1710	HB-EGF mrna	[HB-EGF mRNA]	0.0	2	1	1	1
109343	1710	METHODS: seventeen case of Arnhl	[METHODS: Seventeen cases of ARNHL]	0.0	5	1	1	1
109344	1710	calf serum fcs on the binding	[calf serum FCS on the binding]	0.0	6	1	1	1
109345	1710	dna-binding of Stat 5b	[DNA-binding of Stat 5b]	0.0	4	1	1	1
109346	1710	latent membrane protein -driven activation	[latent membrane protein -driven activation]	0.0	5	1	1	1
109347	1710	cDNA genomic clone	[cDNA genomic clones]	0.0	3	1	1	1
109348	1710	gtp-binding	[GTP-binding]	0.0	1	1	1	1
109349	1710	U-937 human cell	[U-937 human cells]	0.0	3	1	1	1
109350	1710	placebo treatment period	[placebo treatment period]	0.0	3	1	1	1
109351	1710	tcc -inducible signal	[TCC -inducible signaling]	0.0	3	1	1	1
109352	1710	cyclic-AMP element binding factor	[cyclic-AMP element binding factor]	0.0	4	1	1	1
109353	1710	suppress two pathway essential	[suppressing two pathways essential]	0.0	4	1	1	1
109354	1710	identical motif	[identical motif]	0.0	2	1	1	1
109355	1710	induction during b-cell activation	[Induction during B-cell activation]	0.0	4	1	1	1
109356	1710	receptor in spleen	[receptors in spleen]	0.0	3	1	1	1
109357	1710	four host protein	[four host proteins]	0.0	3	1	1	1
109358	1710	p65 component	[p65 components]	0.0	2	1	1	1
109359	1710	only 10(-12) g/g of total mrna	[only 10(-12) g/g of total mRNA]	0.0	6	1	1	1
109360	1710	human T cell leukemia/lymphoma	[human T cell leukemia/lymphoma]	0.0	4	1	1	1
109361	1710	activation of gene product	[activation of gene products]	0.0	4	1	1	1
109362	1710	rest umbilical vein endothelial cell	[resting umbilical vein endothelial cells]	0.0	5	1	1	1
109363	1710	primary effusion lymphoma pel	[primary effusion lymphoma PEL]	0.0	4	1	1	1
109364	1710	competitive silencing of the promoter	[competitive silencing of the promoter]	0.0	5	1	1	1
109365	1710	factor specific to cell	[factor specific to cells]	0.0	4	1	1	1
109366	1710	feature occur	[feature occurring]	0.0	2	1	1	1
109367	1710	hypothesis responsible	[hypothesis responsible]	0.0	2	1	1	1
109368	1710	extracellular kinase in human monocyte	[extracellular kinase in human monocytes]	0.0	5	1	1	1
109369	1710	additional isoform of NFATx	[additional isoforms of NFATx]	0.0	4	1	1	1
109370	1710	important part achieve ebv activation	[important part achieving EBV activation]	0.0	5	1	1	1
109371	1710	antigen-specific reactivity as high	[antigen-specific reactivities as high]	0.0	4	1	1	1
109372	1710	transactivate activity of the gcr	[transactivating activity of the GCR]	0.0	5	1	1	1
109373	1710	include gamma-globin	[including gamma-globin]	0.0	2	1	1	1
109374	1710	two SH2 domain	[two SH2 domains]	0.0	3	1	1	1
109375	1710	1 alteration	[1 alterations]	0.0	2	1	1	1
109376	1710	latent form.	[latent form.]	0.0	2	1	1	1
109377	1710	activation of the cyclic-AMP element	[activation of the cyclic-AMP element]	0.0	5	1	1	1
109378	1710	maintenance during latency	[maintenance during latency]	0.0	3	1	1	1
109379	1710	downregulation of BCL-6 mrna	[downregulation of BCL-6 mRNA]	0.0	4	1	1	1
109380	1710	contain the sh3-sh2-sh3 motif	[containing the SH3-SH2-SH3 motif]	0.0	4	1	1	1
109381	1710	thrombin generation by muscle cell	[Thrombin generation by muscle cells]	0.0	5	1	1	1
109382	1710	rel a	[Rel A]	0.0	2	1	1	1
109383	1710	the/thf alpha thf/thf n: ratios.	[THE/THF alpha THF/THF N: ratios.]	0.0	5	1	1	1
109384	1710	spatial distribution of immunoglobulin gene	[spatial distribution of immunoglobulin genes]	0.0	5	1	1	1
109385	1710	interplay of positive element	[interplay of positive elements]	0.0	4	1	1	1
109386	1710	accord to results, however, entities.	[According to results, however, entities.]	0.0	5	1	1	1
109387	1710	mouse resistant to dosage of lipopolysaccharide	[mice resistant to dosages of lipopolysaccharides]	0.0	6	1	1	1
109388	1710	direct assay	[Direct assays]	0.0	2	1	1	1
109389	1710	-9-mediate	[-9-mediated]	0.0	1	1	1	1
109390	1710	packaging into chromatin	[packaging into chromatin]	0.0	3	1	1	1
109391	1710	signal signal alone	[signal signal alone]	0.0	3	1	1	1
109392	1710	persistence over a period.	[persistence over a period.]	0.0	4	1	1	1
109393	1710	vitamin D3 metabolite	[vitamin D3 metabolite]	0.0	3	1	1	1
109394	1710	gene Ie of cytomegalovirus	[genes IE of cytomegalovirus]	0.0	4	1	1	1
109395	1710	hbv infection	[HBV infection]	0.0	2	1	1	1
109396	1710	two family retinoic acid receptor	[two families retinoic acid receptors]	0.0	5	1	1	1
109397	1710	activation role of factor-DNA complex	[activation role of factor-DNA complexes]	0.0	5	1	1	1
109398	1710	Genetic mapping study	[Genetic mapping studies]	0.0	3	1	1	1
109399	1710	jak1 to il-2r beta	[JAK1 to IL-2R beta]	0.0	4	1	1	1
109400	1710	Phosphoamino	[Phosphoamino]	0.0	1	1	1	1
109401	1710	il-10 pre-treatment on Teflon	[IL-10 pre-treatment on Teflon]	0.0	4	1	1	1
109402	1710	prognostic features: implications.	[prognostic features: implications.]	0.0	3	1	1	1
109403	1710	hence, phosphorylation	[Hence, phosphorylation]	0.0	2	1	1	1
109404	1710	inhibit ige synthesis	[inhibiting IgE synthesis]	0.0	3	1	1	1
109405	1710	disease-activated macrophage	[disease-activated macrophages]	0.0	2	1	1	1
109406	1710	anergic cd4+ T cell	[anergic CD4+ T cells]	0.0	4	1	1	1
109407	1710	lymphocyte tropism	[lymphocyte tropisms]	0.0	2	1	1	1
109408	1710	prolonged, dayus- glucocorticoid therapy	[prolonged, day, glucocorticoid therapy]	0.0	4	1	1	1
109409	1710	release of the chemokine	[release of the chemokines]	0.0	4	1	1	1
109410	1710	icam-1 adhesivity	[ICAM-1 adhesivity]	0.0	2	1	1	1
109411	1710	parameter of pancreatitis	[parameters of pancreatitis]	0.0	3	1	1	1
109412	1710	depend on the combination of factor	[depending on the combination of factors]	0.0	6	1	1	1
109413	1710	enhancement of immunodeficiency virus	[Enhancement of immunodeficiency virus]	0.0	4	1	1	1
109414	1710	HL60R	[HL60R]	0.0	1	1	1	1
109415	1710	immunophilin binding protein	[immunophilin binding protein]	0.0	3	1	1	1
109416	1710	three MHC class ii gene	[three MHC class II genes]	0.0	5	1	1	1
109417	1710	apoptosis in CD4 receptor	[apoptosis in CD4 receptors]	0.0	4	1	1	1
109418	1710	anti-class i antibody mab	[anti-class I antibody mAb]	0.0	4	1	1	1
109419	1710	protein- tre -DNA interaction	[protein- TRE -DNA interactions]	0.0	4	1	1	1
109420	1710	TSHR peptide	[TSHR peptides]	0.0	2	1	1	1
109421	1710	calcium ion	[calcium ions]	0.0	2	1	1	1
109422	1710	expression of the class isotype	[expression of the class isotypes]	0.0	5	1	1	1
109423	1710	interface in tissue	[interface in tissue]	0.0	3	1	1	1
109424	1710	ciita promoter suppression in MHC class	[CIITA promoter suppression in MHC class]	0.0	6	1	1	1
109425	1710	gata-4 hgata-4	[GATA-4 hGATA-4]	0.0	2	1	1	1
109426	1710	resting state	[resting state]	0.0	2	1	1	1
109427	1710	13 healthy subject	[13 healthy subjects]	0.0	3	1	1	1
109428	1710	activation by this form of DeltaE	[activation by this form of DeltaE]	0.0	6	1	1	1
109429	1710	translocation of this receptor,	[translocation of this receptor,]	0.0	4	1	1	1
109430	1710	TRAFs	[TRAFs]	0.0	1	1	1	1
109431	1710	viral antigen EBNAs	[viral antigen EBNAs]	0.0	3	2	2	1
109432	1710	putative novel loci relevant	[putative novel loci relevant]	0.0	4	1	1	1
109433	1710	reconstitution of a system	[Reconstitution of a system]	0.0	4	1	1	1
109434	1710	atypical feature	[atypical features]	0.0	2	1	1	1
109435	1710	analysis of signal molecule	[analysis of signaling molecule]	0.0	4	1	1	1
109436	1710	macrophages/ monocyte	[macrophages/ monocytes]	0.0	2	1	1	1
109437	1710	Alternate immune system target	[Alternate immune system targets]	0.0	4	1	1	1
109438	1710	biochemically distinct form	[biochemically distinct forms]	0.0	3	1	1	1
109439	1710	corresponding leukocyte	[corresponding leukocytes]	0.0	2	1	1	1
109440	1710	stat3 signal	[STAT3 signaling]	0.0	2	1	1	1
109441	1710	mechanism of interaction in hypertension	[mechanisms of interactions in hypertension]	0.0	5	1	1	1
109442	1710	novel binding activity	[novel binding activity]	0.0	3	1	1	1
109443	1710	antibody 60b	[antibody 60b]	0.0	2	1	1	1
109444	1710	human platelet to thrombin	[human platelets to thrombin]	0.0	4	1	1	1
109445	1710	good linear correlation,	[good linear correlation,]	0.0	3	1	1	1
109446	1710	sequence within the AU-rich element AREs	[sequences within the AU-rich elements AREs]	0.0	6	1	1	1
109447	1710	Vitamin e therapy of injury	[Vitamin E therapy of injury]	0.0	5	1	1	1
109448	1710	addition of acid pa the product	[addition of acid PA the product]	0.0	6	1	1	1
109449	1710	unique 5' terminus	[unique 5' terminus]	0.0	3	1	1	1
109450	1710	basis of assay	[basis of assays]	0.0	3	1	1	1
109451	1710	Elsevier	[Elsevier]	0.0	1	1	1	1
109452	1710	form of proteins, aml1a	[forms of proteins, AML1a]	0.0	4	1	1	1
109453	1710	fos content	[Fos content]	0.0	2	1	1	1
109454	1710	novel E2F sequence	[novel E2F sequence]	0.0	3	1	1	1
109455	1710	Functional characterization	[Functional characterization]	0.0	2	3	3	1
109456	1710	80% treatment with MCM	[80% treatment with MCM]	0.0	4	1	1	1
109457	1710	E2 alone	[E2 alone]	0.0	2	1	1	1
109458	1710	nb4 leukemia	[NB4 leukemia]	0.0	2	1	1	1
109459	1710	mutation rna sample	[mutations RNA samples]	0.0	3	1	1	1
109460	1710	zebra staining	[ZEBRA staining]	0.0	2	1	1	1
109461	1710	lipopolysaccharide (lps)-	[lipopolysaccharide (LPS)-]	0.0	2	1	1	1
109462	1710	therefore a candidate	[Therefore a candidate]	0.0	3	1	1	1
109463	1710	i.e. polymorphonuclear granulocyte pmn	[i.e. polymorphonuclear granulocytes PMN]	0.0	4	1	1	1
109464	1710	centre b cell	[centre B cell]	0.0	3	1	1	1
109465	1710	IP-10 mrna inducibility	[IP-10 mRNA inducibility]	0.0	3	1	1	1
109466	1710	indicate a important determinant	[indicating an important determinant]	0.0	4	1	1	1
109467	1710	exposure to IL-4 gamma	[exposure to IL-4 gamma]	0.0	4	1	1	1
109468	1710	range of gammac mutation	[range of gammac mutations]	0.0	4	1	1	1
109469	1710	lps enhancement	[LPS enhancement]	0.0	2	1	1	1
109470	1710	T cell line ach-2,	[T cell line ACH-2,]	0.0	4	1	1	1
109471	1710	interleukin (il) gene	[interleukin (IL) gene]	0.0	3	1	1	1
109472	1710	incubation of cell ECs	[Incubation of cells ECs]	0.0	4	1	1	1
109473	1710	development of neoplasm	[development of neoplasms]	0.0	3	1	1	1
109474	1710	many cytokine gene include tnf	[many cytokine genes including TNF]	0.0	5	1	1	1
109475	1710	unique activator,	[unique activator,]	0.0	2	1	1	1
109476	1710	BZLF1 protein	[BZLF1 protein]	0.0	2	1	1	1
109477	1710	poz/zinc-finger protein	[POZ/zinc-finger protein]	0.0	2	1	1	1
109478	1710	mAECA to human ec	[mAECA to human EC]	0.0	4	1	1	1
109479	1710	promoter region of megakaryocytic-specific gene	[promoter regions of megakaryocytic-specific genes]	0.0	5	1	1	1
109480	1710	leucocyte in man	[leucocytes in men]	0.0	3	1	1	1
109481	1710	PGG-Glucan a beta-(1,3)-linked glucose homopolymer	[PGG-Glucan a beta-(1,3)-linked glucose homopolymer]	0.0	5	1	1	1
109482	1710	prolonged period in cell	[prolonged periods in cells]	0.0	4	1	1	1
109483	1710	genetic analysis LTR	[genetic analyses LTR]	0.0	3	1	1	1
109484	1710	stat activation	[STAT activation]	0.0	2	1	1	1
109485	1710	clear correlation to response.	[clear correlation to response.]	0.0	4	1	1	1
109486	1710	recurrent cytogenetic abnormality	[recurrent cytogenetic abnormalities]	0.0	3	1	1	1
109487	1710	phosphatidylinositol 3-kinase inhibitor	[phosphatidylinositol 3-kinase inhibitor]	0.0	3	1	1	1
109488	1710	response to IL-13 by monocyte	[responses to IL-13 by monocytes]	0.0	5	1	1	1
109489	1710	cyclooxygenase/5-lipoxygenase anti-inflammatory compound	[cyclooxygenase/5-lipoxygenase anti-inflammatory compound]	0.0	3	1	1	1
109490	1710	hormonal dysregulation of (hpa) axis	[hormonal dysregulation of (HPA) axis]	0.0	5	1	1	1
109491	1710	differential hybridization analysis	[differential hybridization analysis]	0.0	3	1	1	1
109492	1710	Succinate	[Succinate]	0.0	1	1	1	1
109493	1710	acid modulation	[acid modulation]	0.0	2	1	1	1
109494	1710	Drosophila Toll hToll	[Drosophila Toll hToll]	0.0	3	1	1	1
109495	1710	indirect link between this events.	[indirect link between these events.]	0.0	5	1	1	1
109496	1710	powerful tool	[powerful tool]	0.0	2	1	1	1
109497	1710	involve the short arm of chromosome	[involving the short arm of chromosome]	0.0	6	1	1	1
109498	1710	statg in immature myeloid cell	[StatG in immature myeloid cells]	0.0	5	1	1	1
109499	1710	target of t-cell in iddm	[target of T-cells in IDDM]	0.0	5	1	1	1
109500	1710	two form 90-kda stat3alpha	[two forms 90-kDa STAT3alpha]	0.0	4	1	1	1
109501	1710	target the protein	[targeting the protein]	0.0	3	1	1	1
109502	1710	bryostatin another activator	[bryostatin another activator]	0.0	3	1	1	1
109503	1710	dysregulation of monocytic nuclear factor-kappa b	[Dysregulation of monocytic nuclear factor-kappa B]	0.0	6	1	1	1
109504	1710	epo cell type	[EPO cell type]	0.0	3	1	1	1
109505	1710	EBNA2 synthesis of mrna	[EBNA2 synthesis of mRNA]	0.0	4	1	1	1
109506	1710	Peripheral blood cell glucocorticoid receptor	[Peripheral blood cell glucocorticoid receptors]	0.0	5	1	1	1
109507	1710	potential interaction	[potential interactions]	0.0	2	1	1	1
109508	1710	alpha 4 beta ligand	[alpha 4 beta ligands]	0.0	4	1	1	1
109509	1710	transactivation function,	[transactivation function,]	0.0	2	1	1	1
109510	1710	specific isozyme activity	[specific isozyme activity]	0.0	3	1	1	1
109511	1710	alpha-like	[alpha-like]	0.0	1	1	1	1
109512	1710	leukocyte in asthmatic subject	[leukocytes in asthmatic subjects]	0.0	4	1	1	1
109513	1710	ap-1 motif	[AP-1 motif]	0.0	2	1	1	1
109514	1710	gata factor expression	[GATA factor expression]	0.0	3	1	1	1
109515	1710	blood mononuclear cell by C3a	[blood mononuclear cells by C3a]	0.0	5	1	1	1
109516	1710	then interleukin (il)-10 blocking factor	[then interleukin (IL)-10 blocking factor]	0.0	5	1	1	1
109517	1710	PMA t-cell line	[PMA T-cell lines]	0.0	3	1	1	1
109518	1710	LT-kappa b construct	[LT-kappa B construct]	0.0	3	1	1	1
109519	1710	(1) multiple substitution in the counterpart	[(1) multiple substitutions in the counterpart]	0.0	6	1	1	1
109520	1710	ikk-gamma	[IKK-gamma]	0.0	1	1	1	1
109521	1710	anti-lambda	[anti-lambda]	0.0	1	1	1	1
109522	1710	coordination between Sp1 with factor	[coordination between Sp1 with factors]	0.0	5	1	1	1
109523	1710	mouse l929	[mouse L929]	0.0	2	1	1	1
109524	1710	level of interleukin beta	[levels of interleukin beta]	0.0	4	1	1	1
109525	1710	co-stimulation with concentration of a beta	[Co-stimulation with concentrations of A beta]	0.0	6	1	1	1
109526	1710	pg/mL,	[pg/mL,]	0.0	1	1	1	1
109527	1710	negative event	[negative events]	0.0	2	1	1	1
109528	1710	variation in Lyonization in blood cell	[variation in Lyonization in blood cells]	0.0	6	1	1	1
109529	1710	t1/2 of 4 hour	[t1/2 of 4 hr]	0.0	4	1	1	1
109530	1710	49 healthy subject yr)	[49 healthy subjects yr)]	0.0	4	1	1	1
109531	1710	injection of human blood cell	[injection of human blood cells]	0.0	5	1	1	1
109532	1710	myeloid leukaemia AML	[myeloid leukaemia AML]	0.0	3	1	1	1
109533	1710	follow expression in NIH 3t3 cell	[following expression in NIH 3T3 cells]	0.0	6	1	1	1
109534	1710	response by 50%.	[response by 50%.]	0.0	3	1	1	1
109535	1710	androgen receptor (ar) locus	[androgen receptor (AR) locus]	0.0	4	1	1	1
109536	1710	regulation of IkappaBalpha	[regulation of IkappaBalpha]	0.0	3	1	1	1
109537	1710	epsilon-globin gene	[epsilon-globin gene]	0.0	2	1	1	1
109538	1710	activity of kinase	[activities of kinases]	0.0	3	1	1	1
109539	1710	high concentration of antioxidant	[higher concentrations of antioxidants]	0.0	4	1	1	1
109540	1710	gal4 activation domain	[GAL4 activation domain]	0.0	3	1	1	1
109541	1710	several marker include CD2	[several markers including CD2]	0.0	4	1	1	1
109542	1710	sra1	[SRA1]	0.0	1	1	1	1
109543	1710	selective agonist WY	[selective agonist WY]	0.0	3	1	1	1
109544	1710	ifn-alpha treatment	[IFN-alpha treatment]	0.0	2	1	1	1
109545	1710	major glucocorticoid	[major glucocorticoid]	0.0	2	1	1	1
109546	1710	contribution to pel growth	[contribution to PEL growth]	0.0	4	1	1	1
109547	1710	parathyroid hormone-related protein	[parathyroid hormone-related protein]	0.0	3	1	1	1
109548	1710	dn thymocyte	[DN thymocytes]	0.0	2	1	1	1
109549	1710	function in the assay system	[function in the assay system]	0.0	5	1	1	1
109550	1710	il-2-induced NK cytolytic activity	[IL-2-induced NK cytolytic activities]	0.0	4	1	1	1
109551	1710	binding to the cytoplasmic domain	[binding to the cytoplasmic domain]	0.0	5	1	1	1
109552	1710	partial dna-binding domain	[partial DNA-binding domain]	0.0	3	1	1	1
109553	1710	otherwise nonpermissive u-937 cell culture	[otherwise nonpermissive U-937 cell cultures]	0.0	5	1	1	1
109554	1710	cytogenetic abnormality highlight loci	[cytogenetic abnormalities highlighting loci]	0.0	4	1	1	1
109555	1710	component of a antituberculous response	[component of a antituberculous response]	0.0	5	1	1	1
109556	1710	four repeat of 21 bp	[four repeats of 21 bp]	0.0	5	1	1	1
109557	1710	other regulatory site	[other regulatory sites]	0.0	3	1	1	1
109558	1710	phase-dependent resistance to stress	[phase-dependent resistance to stress]	0.0	4	1	1	1
109559	1710	protein kinase mapk signal pathway	[protein kinase MAPK signaling pathway]	0.0	5	2	2	1
109560	1710	factor from THP-1	[factor from THP-1]	0.0	3	1	1	1
109561	1710	protein oct-1	[protein Oct-1]	0.0	2	1	1	1
109562	1710	effect on agonist-induced cell adhesion	[effects on agonist-induced cell adhesion]	0.0	5	1	1	1
109563	1710	cross point between signal pathway	[cross points between signaling pathways]	0.0	5	1	1	1
109564	1710	other aspect	[other aspects]	0.0	2	1	1	1
109565	1710	stimulation of lymphocyte proliferation	[Stimulation of lymphocyte proliferation]	0.0	4	1	1	1
109566	1710	migration of S6	[migration of S6]	0.0	3	1	1	1
109567	1710	hsp70 mrna	[HSP70 mRNA]	0.0	2	1	1	1
109568	1710	potency glucocorticoid	[potency glucocorticoid]	0.0	2	1	1	1
109569	1710	mAb enhancement	[mAb enhancement]	0.0	2	1	1	1
109570	1710	VDR gene	[VDR gene]	0.0	2	1	1	1
109571	1710	repeat (ltr)	[repeat (LTR)]	0.0	2	1	1	1
109572	1710	generate positive mechanism	[generating positive mechanisms]	0.0	3	1	1	1
109573	1710	activation of pair	[activation of pairs]	0.0	3	1	1	1
109574	1710	particular serine protease such as elastase	[particular serine proteases such as elastase]	0.0	6	1	1	1
109575	1710	Bcl-6 staining	[Bcl-6 staining]	0.0	2	1	1	1
109576	1710	x-chromosome methylation pattern	[X-chromosome methylation patterns]	0.0	3	1	1	1
109577	1710	two main activity of glucocorticoid transactivation	[two main activities of glucocorticoids transactivation]	0.0	6	1	1	1
109578	1710	aberrancy in the signal pathway	[aberrancies in the signaling pathways]	0.0	5	1	1	1
109579	1710	sixteen patient aged 16-27 years,	[Sixteen patients aged 16-27 years,]	0.0	5	1	1	1
109580	1710	unrestricted expression of gene	[unrestricted expression of genes]	0.0	4	1	1	1
109581	1710	release of mediator	[release of mediators]	0.0	3	1	1	1
109582	1710	lipophilic substance such as formylpeptide lps	[lipophilic substances such as formylpeptides LPS]	0.0	6	1	1	1
109583	1710	condition during host cell differentiation	[conditions during host cell differentiation]	0.0	5	1	1	1
109584	1710	srf/	[SRF/]	0.0	1	1	1	1
109585	1710	peptide recognition	[peptide recognition]	0.0	2	1	1	1
109586	1710	neuronal nos	[neuronal NOS]	0.0	2	1	1	1
109587	1710	human dimeric tnf receptor rhu tnfr:fc	[human dimeric TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
109588	1710	cd34(+) hematopoietic progenitor cell	[CD34(+) hematopoietic progenitor cells]	0.0	4	1	1	1
109589	1710	promoter region span position -78	[promoter region spanning positions -78]	0.0	5	1	1	1
109590	1710	dexamethasone stimulation	[dexamethasone stimulation]	0.0	2	1	1	1
109591	1710	sre-	[SRE-]	0.0	1	1	1	1
109592	1710	affinity for glucocorticosteroids	[affinity for glucocorticosteroids]	0.0	3	1	1	1
109593	1710	mouse chromosome 3	[mouse chromosome 3]	0.0	3	1	1	1
109594	1710	3.16 mg/24h; n: 2.7+/-2.0)	[3.16 mg/24h; N: 2.7+/-2.0)]	0.0	4	1	1	1
109595	1710	reduction in tnf promoter activity	[reduction in TNF promoter activity]	0.0	5	1	1	1
109596	1710	unique viral latency	[unique viral latency]	0.0	3	1	1	1
109597	1710	retinoic acid treatment in leukemia	[retinoic acid treatment in leukemia]	0.0	5	1	1	1
109598	1710	major (MHC) class ii promoter	[major (MHC) class II promoters]	0.0	5	1	1	1
109599	1710	blood mononuclear cell use dexamethasone	[blood mononuclear cells using dexamethasone]	0.0	5	1	1	1
109600	1710	Specific calcitropic effect of dioxyvit	[Specific calcitropic effect of dioxyvit]	0.0	5	1	1	1
109601	1710	transfection of line	[transfection of lines]	0.0	3	1	1	1
109602	1710	inhibition signal in human t-cell	[Inhibition signalling in human T-cells]	0.0	5	1	1	1
109603	1710	derive	[deriving]	0.0	1	1	1	1
109604	1710	region of the IL-1beta promoter,	[region of the IL-1beta promoter,]	0.0	5	1	1	1
109605	1710	regulator for the induction	[regulator for the induction]	0.0	4	1	1	1
109606	1710	vincristine-selected, multidrug resistance	[vincristine-selected, multidrug resistance]	0.0	3	1	1	1
109607	1710	studies, interferon-gamma piec clone	[studies, interferon-gamma PIEC clones]	0.0	4	1	1	1
109608	1710	gene dorsal	[gene dorsal]	0.0	2	1	1	1
109609	1710	wild-type grf40	[wild-type Grf40]	0.0	2	1	1	1
109610	1710	activator of the proliferation	[activator of the proliferation]	0.0	4	1	1	1
109611	1710	membrane protein gene promoter-binding protein	[membrane protein gene promoter-binding proteins]	0.0	5	1	1	1
109612	1710	NK-kappa b transcription	[NK-kappa B transcription]	0.0	3	1	1	1
109613	1710	myb:maf complex	[Myb:Maf complexes]	0.0	2	1	1	1
109614	1710	viability, erythroid	[viability, erythroid]	0.0	2	1	1	1
109615	1710	p-selectin through ligand	[P-selectin through ligands]	0.0	3	1	1	1
109616	1710	octamer-DNA	[octamer-DNA]	0.0	1	1	1	1
109617	1710	cd4+/cd45ro T cell	[CD4+/CD45RO T cells]	0.0	3	1	1	1
109618	1710	fraction of the pool	[fraction of the pool]	0.0	4	1	1	1
109619	1710	gc-box binding activity	[GC-box binding activity]	0.0	3	1	1	1
109620	1710	T disease	[T diseases]	0.0	2	1	1	1
109621	1710	principal cytoplasmic inhibitor	[principal cytoplasmic inhibitor]	0.0	3	1	1	1
109622	1710	fmol/10(7) cell in controls).	[fmol/10(7) cells in controls).]	0.0	4	1	1	1
109623	1710	various signal often converge in pathway	[Various signals often converging in pathways]	0.0	6	1	1	1
109624	1710	latent cycle reactivity though undetectable	[latent cycle reactivities though undetectable]	0.0	5	1	1	1
109625	1710	non-rheumatoid arthritis	[non-rheumatoid arthritis]	0.0	2	1	1	1
109626	1710	expression of IL-2 transcriptional regulator	[expression of IL-2 transcriptional regulators]	0.0	5	1	1	1
109627	1710	recovery from bacterial lysate	[recovery from bacterial lysates]	0.0	4	1	1	1
109628	1710	novel mar-binding protein	[novel MAR-binding protein]	0.0	3	1	1	1
109629	1710	principal IL-2 component	[principal IL-2 component]	0.0	3	1	1	1
109630	1710	further analysis of coactivator requirement	[Further analysis of coactivator requirements]	0.0	5	1	1	1
109631	1710	low-affinity receptor	[low-affinity receptor]	0.0	2	1	1	1
109632	1710	terminal sequence	[terminal sequences]	0.0	2	1	1	1
109633	1710	initiation at site	[initiation at sites]	0.0	3	1	1	1
109634	1710	repeat lrr domain	[repeat LRR domain]	0.0	3	1	1	1
109635	1710	defective recruitment	[defective recruitment]	0.0	2	1	1	1
109636	1710	multipotent /monocytic hpc growth	[multipotent /monocytic HPC growth]	0.0	4	1	1	1
109637	1710	none to on basal cell	[none to on basal cells]	0.0	5	1	1	1
109638	1710	rcgcrygcgy consensus	[RCGCRYGCGY consensus]	0.0	2	1	1	1
109639	1710	t-cell leukemia line	[T-cell leukemia line]	0.0	3	1	1	1
109640	1710	transcription of the proenkephalin gene	[transcription of the proenkephalin gene]	0.0	5	1	1	1
109641	1710	include pre-B acute leukemia	[including pre-B acute leukemia]	0.0	4	1	1	1
109642	1710	moderate level only 2 17	[moderate levels only 2 17]	0.0	5	1	1	1
109643	1710	upstream of the transcription start site	[upstream of the transcription start site]	0.0	6	1	1	1
109644	1710	ppargamma peroxisomal receptor gamma ppargamma expression	[PPARgamma peroxisomal receptor gamma PPARgamma expression]	0.0	6	1	1	1
109645	1710	cell line at degree	[cell line at degrees]	0.0	4	1	1	1
109646	1710	expression at mRNA level	[expression at mRNA level]	0.0	4	1	1	1
109647	1710	influence on the production of Fos	[Influence on the production of Fos]	0.0	6	1	1	1
109648	1710	two component	[two components]	0.0	2	1	1	1
109649	1710	porcine b-cell	[porcine B-cell]	0.0	2	2	2	1
109650	1710	distinct promoter promoter	[distinct promoters promoter]	0.0	3	1	1	1
109651	1710	codon site	[codon site]	0.0	2	1	1	1
109652	1710	Paternal expression of WT1	[Paternal expression of WT1]	0.0	4	1	1	1
109653	1710	pbmc with anti-cd2 mab	[PBMC with anti-CD2 mAb]	0.0	4	1	1	1
109654	1710	approach by application	[approach by application]	0.0	3	1	1	1
109655	1710	comparative analysis factor of T cell	[Comparative analysis factor of T cells]	0.0	6	1	1	1
109656	1710	typical inducer of differentiation	[typical inducer of differentiation]	0.0	4	1	1	1
109657	1710	mapping of the repression domain	[Mapping of the repression domain]	0.0	5	1	1	1
109658	1710	patient groups,	[patient groups,]	0.0	2	1	1	1
109659	1710	element necessary alpha,25-dihydroxyvitamin D3	[Elements necessary alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
109660	1710	significant il-2	[significant IL-2]	0.0	2	1	1	1
109661	1710	several function of Ras	[Several functions of Ras]	0.0	4	1	1	1
109662	1710	previous study in leukocyte	[previous studies in leukocytes]	0.0	4	1	1	1
109663	1710	domain of CD4	[domain of CD4]	0.0	3	1	1	1
109664	1710	linker substitution (LS) mutation between -201	[linker substitution (LS) mutations between -201]	0.0	6	1	1	1
109665	1710	characteristic of b cell	[characteristics of B cells]	0.0	4	1	1	1
109666	1710	deletion of all element	[Deletion of all elements]	0.0	4	1	1	1
109667	1710	antibody to BZLF1	[antibody to BZLF1]	0.0	3	1	1	1
109668	1710	induction of stat protein	[induction of STAT proteins]	0.0	4	1	1	1
109669	1710	different tissue	[different tissues]	0.0	2	1	1	1
109670	1710	peroxisome proliferator receptor ppar	[peroxisome proliferator receptor PPAR]	0.0	4	1	1	1
109671	1710	induce tal-1 protein expression	[inducing tal-1 protein expression]	0.0	4	1	1	1
109672	1710	AP-1 transcriptional activity	[AP-1 transcriptional activity]	0.0	3	1	1	1
109673	1710	addition to the isoform Pax-5	[addition to the isoform Pax-5]	0.0	5	1	1	1
109674	1710	human erythroid cell	[human erythroid cells]	0.0	3	1	1	1
109675	1710	binding of [3h]aldosterone	[binding of [3H]aldosterone]	0.0	3	1	1	1
109676	1710	interleukin-7 receptor	[interleukin-7 receptor]	0.0	2	1	1	1
109677	1710	pih group binding sites/cell)	[PIH group binding sites/cell)]	0.0	4	1	1	1
109678	1710	summary, glucocorticoid receptor determination	[summary, glucocorticoid receptor determination]	0.0	4	1	1	1
109679	1710	viral latency in the tumour cell	[viral latency in the tumour cells]	0.0	6	1	1	1
109680	1710	cell-initiated inflammation	[cell-initiated inflammation]	0.0	2	1	1	1
109681	1710	role of darc	[roles of DARC]	0.0	3	1	1	1
109682	1710	CONCLUSION: cytomegalovirus gene product	[CONCLUSION: Cytomegalovirus gene products]	0.0	4	1	1	1
109683	1710	4 beta 1 in T cell	[4 beta 1 in T cells]	0.0	6	1	1	1
109684	1710	expression/repression	[expression/repression]	0.0	1	1	1	1
109685	1710	antibody specific for thyroglobulin	[antibody specific for thyroglobulin]	0.0	4	1	1	1
109686	1710	restriction element	[restriction elements]	0.0	2	1	1	1
109687	1710	PML gene in hematopoiesis	[PML gene in hematopoiesis]	0.0	4	1	1	1
109688	1710	number of enhancer	[number of enhancers]	0.0	3	1	1	1
109689	1710	receptor kd of nmol/L	[receptor Kd of nmol/L]	0.0	4	1	1	1
109690	1710	hla class molecule distal	[HLA class molecules distal]	0.0	4	1	1	1
109691	1710	affinity Ka for T3	[affinity Ka for T3]	0.0	4	1	1	1
109692	1710	expression of adherence-associated gene	[expression of adherence-associated genes]	0.0	4	1	1	1
109693	1710	different pattern of cytokine secretion.	[different patterns of cytokine secretion.]	0.0	5	1	1	1
109694	1710	antigen antigen vca	[antigen antigen VCA]	0.0	3	1	1	1
109695	1710	competitive model	[competitive model]	0.0	2	1	1	1
109696	1710	DQ cis- dimer	[DQ cis- dimer]	0.0	3	1	1	1
109697	1710	three candidate gene factor hnf3 beta	[three candidate genes factor HNF3 beta]	0.0	6	1	1	1
109698	1710	thereby contribute to the expression	[thereby contributing to the expression]	0.0	5	1	1	1
109699	1710	increase in ap-1	[increase in AP-1]	0.0	3	1	1	1
109700	1710	promonocytic U937 cell line	[promonocytic U937 cell line]	0.0	4	1	1	1
109701	1710	domain of the phoq protein	[domain of the PhoQ protein]	0.0	5	1	1	1
109702	1710	however, secretion	[However, secretion]	0.0	2	1	1	1
109703	1710	stress on activity	[stress on activities]	0.0	3	1	1	1
109704	1710	resistant icr27tk.3	[resistant ICR27TK.3]	0.0	2	1	1	1
109705	1710	one molecule present	[one molecule present]	0.0	3	1	1	1
109706	1710	h peak at h.	[h peaks at h,]	0.0	4	1	1	1
109707	1710	result from 9 volunteer	[results from 9 volunteers]	0.0	4	1	1	1
109708	1710	suggest a common target	[suggesting a common target]	0.0	4	1	1	1
109709	1710	b epstein-barr	[B Epstein-Barr]	0.0	2	1	1	1
109710	1710	require log-fold more glucocorticoid	[requiring log-fold more glucocorticoids]	0.0	4	1	1	1
109711	1710	creb kinase in T cell	[CREB kinase in T cells]	0.0	5	1	1	1
109712	1710	nuclear magnetic resonance spectroscopy	[nuclear magnetic resonance spectroscopy]	0.0	4	1	1	1
109713	1710	pbmc resistance to GC	[PBMC resistance to GC]	0.0	4	1	1	1
109714	1710	expression of nuclear factor kappab activation	[expression of nuclear factor kappaB activation]	0.0	6	1	1	1
109715	1710	different level of hsf2-alpha	[different levels of HSF2-alpha]	0.0	4	1	1	1
109716	1710	NF-kappaB/Rel transcription	[NF-kappaB/Rel transcription]	0.0	2	1	1	1
109717	1710	inactivation of IkappaBbeta	[Inactivation of IkappaBbeta]	0.0	3	1	1	1
109718	1710	immunosuppressive activity 100-fold low	[immunosuppressive activity 100-fold lower]	0.0	4	1	1	1
109719	1710	favorable activity profile	[favorable activity profile]	0.0	3	1	1	1
109720	1710	affinity low	[affinity lower]	0.0	2	1	1	1
109721	1710	inhibitor of tyrosine kinase	[inhibitor of tyrosine kinase]	0.0	4	1	1	1
109722	1710	transcription factor family MNP family	[transcription factor family MNP family]	0.0	5	1	1	1
109723	1710	activated, addition	[activated, addition]	0.0	2	1	1	1
109724	1710	iron staining	[iron staining]	0.0	2	1	1	1
109725	1710	study responsiveness	[studying responsiveness]	0.0	2	1	1	1
109726	1710	role for the protein kinase	[role for the protein kinase]	0.0	5	1	1	1
109727	1710	two alpha-helice of class I	[two alpha-helices of class I]	0.0	5	1	1	1
109728	1710	Interestingly, evidence	[Interestingly, evidence]	0.0	2	1	1	1
109729	1710	activation of growth response	[Activation of growth response]	0.0	4	1	1	1
109730	1710	(creb)	[(CREB)]	0.0	1	1	1	1
109731	1710	eosinophil from patient with eosinophilia	[eosinophils from patients with eosinophilia]	0.0	5	1	1	1
109732	1710	potential hpp- 47.10 cell	[potential HPP- 47.10 cells]	0.0	4	1	1	1
109733	1710	counterpart to human lymphocytic leukemia	[counterpart to human lymphocytic leukemias]	0.0	5	1	1	1
109734	1710	hybrids.	[hybrids.]	0.0	1	1	1	1
109735	1710	undifferentiated DC in skin	[undifferentiated DC in skin]	0.0	4	1	1	1
109736	1710	hybrids,	[hybrids,]	0.0	1	1	1	1
109737	1710	effector mechanism in different disorder	[effector mechanism in different disorders]	0.0	5	1	1	1
109738	1710	induce differentiation in Mono Mac cell	[inducing differentiation in Mono Mac cells]	0.0	6	1	1	1
109739	1710	tax in CTLL-2	[Tax in CTLL-2]	0.0	3	1	1	1
109740	1710	rele family	[rel family]	0.0	2	1	1	1
109741	1710	form of testing	[form of testing]	0.0	3	1	1	1
109742	1710	level of i(kappa)b(alpha)	[levels of I(kappa)B(alpha)]	0.0	3	1	1	1
109743	1710	4.27 (range, 6.18 (range, 5.86-6.74) nm,	[4.27 (range, 6.18 (range, 5.86-6.74) nM,]	0.0	6	1	1	1
109744	1710	57 substitution	[57 substitution]	0.0	2	1	1	1
109745	1710	proximal mouse Chr	[proximal mouse Chr]	0.0	3	1	1	1
109746	1710	fetal organ	[fetal organ]	0.0	2	1	1	1
109747	1710	pax-5 transcription	[PAX-5 transcription]	0.0	2	1	1	1
109748	1710	transcription of hiv provirus	[transcription of HIV provirus]	0.0	4	1	1	1
109749	1710	ROI-dependent NF-kappaB transcription	[ROI-dependent NF-kappaB transcription]	0.0	3	1	1	1
109750	1710	inducible camp repressor	[inducible cAMP repressor]	0.0	3	1	1	1
109751	1710	population possible t-cell killer population	[populations possible T-cell killer populations]	0.0	5	1	1	1
109752	1710	localization of kox zinc finger gene	[localization of KOX zinc finger genes]	0.0	6	1	1	1
109753	1710	ciita -deficient cell line	[CIITA -deficient cell line]	0.0	4	1	1	1
109754	1710	complex with protein	[complexes with proteins]	0.0	3	1	1	1
109755	1710	10-fold reduction	[10-fold reduction]	0.0	2	1	1	1
109756	1710	resonance	[resonance]	0.0	1	1	1	1
109757	1710	single c-myb binding site	[single c-Myb binding site]	0.0	4	1	1	1
109758	1710	remix	[Remixing]	0.0	1	1	1	1
109759	1710	il-3 /gm-csf	[IL-3 /GM-CSF]	0.0	2	1	1	1
109760	1710	immunoreceptor inhibition motif.	[immunoreceptor inhibition motif.]	0.0	3	1	1	1
109761	1710	lps gene induction	[LPS gene induction]	0.0	3	1	1	1
109762	1710	form of type	[forms of type]	0.0	3	1	1	1
109763	1710	grade (p less than 0.0001)	[grade (P less than 0.0001),]	0.0	5	1	1	1
109764	1710	ligand-induced receptor heterodimerization	[ligand-induced receptor heterodimerization]	0.0	3	1	1	1
109765	1710	appear in some case of leukemia	[appearing in some cases of leukemia]	0.0	6	1	1	1
109766	1710	important regulatory DNA element	[important regulatory DNA element]	0.0	4	1	1	1
109767	1710	stat1 alpha only in NK cell	[STAT1 alpha only in NK cells]	0.0	6	1	1	1
109768	1710	kappa light-chain gene	[kappa light-chain genes]	0.0	3	1	1	1
109769	1710	datum demonstrate a consequence	[data demonstrating a consequence]	0.0	4	1	1	1
109770	1710	syndrome involve the pancrea	[syndrome involving the pancreas]	0.0	4	1	1	1
109771	1710	expression of ap1 reporter construct (ic50	[expression of AP1 reporter constructs (IC50]	0.0	6	1	1	1
109772	1710	incubation of the cell	[incubation of the cells]	0.0	4	1	1	1
109773	1710	use a -assembly system	[using a -assembly system]	0.0	4	1	1	1
109774	1710	clone member	[clones members]	0.0	2	1	1	1
109775	1710	19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione	[19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione]	0.0	1	1	1	1
109776	1710	fibronectin receptor mrna	[fibronectin receptor mRNA]	0.0	3	1	1	1
109777	1710	cotransfection of a constitutively active form	[Cotransfection of a constitutively active form]	0.0	6	1	1	1
109778	1710	NFATp/AP-1 formation	[NFATp/AP-1 formation]	0.0	2	1	1	1
109779	1710	maturation, GPA	[maturation, GPA]	0.0	2	1	1	1
109780	1710	characterization of a isoform	[Characterization of a isoform]	0.0	4	1	1	1
109781	1710	phosphatase-positive osteoclast-like cell from human monocyte	[phosphatase-positive osteoclast-like cells from human monocytes]	0.0	6	1	1	1
109782	1710	induction upon mitogenic stimulation	[induction upon mitogenic stimulation]	0.0	4	1	1	1
109783	1710	mechanism underlie the activity	[mechanisms underlying the activity]	0.0	4	1	1	1
109784	1710	role for the form	[roles for the forms]	0.0	4	1	1	1
109785	1710	injury with alpha-tocopherol a radical scavenger	[injury with alpha-tocopherol a radical scavenger]	0.0	6	1	1	1
109786	1710	erythroid cell-specific factor-DNA complex	[erythroid cell-specific factor-DNA complexes]	0.0	4	1	1	1
109787	1710	glucocorticoid in disease include leukemia	[glucocorticoids in diseases including leukemia]	0.0	5	1	1	1
109788	1710	nuclear translocation of this receptor,	[nuclear translocation of this receptor,]	0.0	5	1	1	1
109789	1710	ehuaess) cell	[(HUAECs) cells]	0.0	2	1	1	1
109790	1710	activators, include J2	[activators, including J2]	0.0	3	1	1	1
109791	1710	control region DCR	[control region DCR]	0.0	3	1	1	1
109792	1710	albeit to level	[albeit to levels]	0.0	3	1	1	1
109793	1710	anti-cd40 antibody	[anti-CD40 antibody]	0.0	2	2	2	1
109794	1710	presence of human il-10	[presence of human IL-10]	0.0	4	1	1	1
109795	1710	kb promoter	[kb promoter]	0.0	2	1	1	1
109796	1710	type cell line	[type cell line]	0.0	3	1	1	1
109797	1710	difference in the number (6500+/-1001	[differences in the number (6500+/-1001]	0.0	5	1	1	1
109798	1710	triplet of deoxyguanosine residue	[triplet of deoxyguanosine residues]	0.0	4	1	1	1
109799	1710	stress disorder.	[stress disorder.]	0.0	2	1	1	1
109800	1710	assay ligand binding affinity	[assaying ligand binding affinities]	0.0	4	1	1	1
109801	1710	isomorph	[isomorphs]	0.0	1	1	1	1
109802	1710	cDNA encoding human c/ebp-epsilon	[cDNA encoding human C/EBP-epsilon]	0.0	4	1	1	1
109803	1710	element at -65,	[element at -65,]	0.0	3	1	1	1
109804	1710	multipotent/erythroid/monocytic to differentiation program	[multipotent/erythroid/monocytic to differentiation program]	0.0	4	1	1	1
109805	1710	Additionally, activation	[Additionally, activation]	0.0	2	1	1	1
109806	1710	tf promotor	[TF promotor]	0.0	2	1	1	1
109807	1710	androgen binding site in mononuclear leukocyte	[Androgen binding sites in mononuclear leukocytes]	0.0	6	1	1	1
109808	1710	Differential contribution	[Differential contribution]	0.0	2	1	1	1
109809	1710	involve distinct transcription factor family	[involving distinct transcription factor families]	0.0	5	1	1	1
109810	1710	hormone gch	[hormones GCH]	0.0	2	1	1	1
109811	1710	encode EBNA	[encoding EBNA]	0.0	2	1	1	1
109812	1710	approach in favour	[approach in favour]	0.0	3	1	1	1
109813	1710	dose of dexamethasone	[doses of dexamethasone]	0.0	3	1	1	1
109814	1710	level in normal b	[levels in normal B]	0.0	4	1	1	1
109815	1710	blotting of NK cell	[blotting of NK cell]	0.0	4	1	1	1
109816	1710	type include myeloid leukaemia	[types including myeloid leukaemia]	0.0	4	2	2	1
109817	1710	expression in MHC class ii -cell	[expression in MHC class II -cells]	0.0	6	1	1	1
109818	1710	cellular production of such mediator	[cellular production of such mediators]	0.0	5	1	1	1
109819	1710	aldosterone nmol/l)	[aldosterone nmol/l)]	0.0	2	1	1	1
109820	1710	identify a disorder	[identifying a disorder]	0.0	3	1	1	1
109821	1710	notably bacterial product such as lipopolysaccharide	[notably bacterial products such as lipopolysaccharide]	0.0	6	1	1	1
109822	1710	incubation of cell for 72 hour	[Incubation of cells for 72 hours]	0.0	6	1	1	1
109823	1710	binding monoclonal antibody	[binding monoclonal antibodies]	0.0	3	1	1	1
109824	1710	activate effect on gene expression	[activating effect on gene expression]	0.0	5	1	1	1
109825	1710	multipotent /erythroid hpc growth	[multipotent /erythroid HPC growth]	0.0	4	1	1	1
109826	1710	hemopoietic cell in G0	[hemopoietic cells in G0]	0.0	4	1	1	1
109827	1710	use reverse-transcription pcr display	[Using reverse-transcription PCR display]	0.0	4	1	1	1
109828	1710	hcmv infection	[HCMV infection]	0.0	2	1	1	1
109829	1710	constitutive transcriptional enhancement	[constitutive transcriptional enhancement]	0.0	3	1	1	1
109830	1710	induction kappa B/Rel nuclear activity	[Induction kappa B/Rel nuclear activity]	0.0	5	1	1	1
109831	1710	clinically aggressive type	[clinically aggressive types]	0.0	3	1	1	1
109832	1710	type of cancer include leukaemia	[types of cancers including leukaemia]	0.0	5	2	2	1
109833	1710	promoter motif	[promoter motifs]	0.0	2	1	1	1
109834	1710	novel protein Bik	[novel protein Bik]	0.0	3	1	1	1
109835	1710	potential role of promoter sequence	[potential role of promoter sequences]	0.0	5	1	1	1
109836	1710	distinct subtype of hodgkin' disease	[distinct subtypes of Hodgkin's disease]	0.0	5	1	1	1
109837	1710	CCAAT sequence	[CCAAT sequences]	0.0	2	1	1	1
109838	1710	grow in the stage of development.	[growing in the stages of development.]	0.0	6	1	1	1
109839	1710	therapy with captopril on gluco-	[therapy with captopril on gluco-]	0.0	5	1	1	1
109840	1710	last 4 h	[last 4 h]	0.0	3	1	1	1
109841	1710	analog with substitution	[Analogs with substitutions]	0.0	3	1	1	1
109842	1710	other disease subject	[other disease subjects]	0.0	3	1	1	1
109843	1710	stress with reactive oxygen intermediate formation	[stress with reactive oxygen intermediate formation]	0.0	6	1	1	1
109844	1710	stat1 protein start 0/1	[STAT1 protein starting 0/1]	0.0	4	1	1	1
109845	1710	nature Arg91	[nature Arg91]	0.0	2	1	1	1
109846	1710	raralpha exhibit activity RARalpha403	[RARalpha exhibiting activity RARalpha403]	0.0	4	1	1	1
109847	1710	son of the sister	[son of the sister]	0.0	4	1	1	1
109848	1710	polypeptide of unknown function	[polypeptide of unknown function]	0.0	4	1	1	1
109849	1710	lack E1A	[lacking E1A]	0.0	2	1	1	1
109850	1710	even the cell	[even the cells]	0.0	3	1	1	1
109851	1710	ets-related regulator	[ets-related regulators]	0.0	2	1	1	1
109852	1710	pair of anti- CD2 mab	[pairs of anti- CD2 mAbs]	0.0	5	1	1	1
109853	1710	discrete stage	[discrete stages]	0.0	2	1	1	1
109854	1710	region PRRI	[regions PRRI]	0.0	2	1	1	1
109855	1710	t-cell translocation to human chromosome	[T-cell translocations to human chromosomes]	0.0	5	1	1	1
109856	1710	poor induction of a response	[poor induction of a response]	0.0	5	1	1	1
109857	1710	increase the rate	[increasing the rate]	0.0	3	1	1	1
109858	1710	CD40 MMs	[CD40 MMs]	0.0	2	1	1	1
109859	1710	confirmation of the significance of zinc	[Confirmation of the significance of zinc]	0.0	6	1	1	1
109860	1710	evidence proteins,	[evidence proteins,]	0.0	2	1	1	1
109861	1710	factor Kappa-B NF-kappa b	[factor Kappa-B NF-kappa B]	0.0	4	1	1	1
109862	1710	vitro level	[vitro levels]	0.0	2	1	1	1
109863	1710	rdna transcription	[rDNA transcription]	0.0	2	1	1	1
109864	1710	il-10 up-regulation in monocyte	[IL-10 up-regulation in monocytes]	0.0	4	1	1	1
109865	1710	well-documented phenomenon	[well-documented phenomenon]	0.0	2	1	1	1
109866	1710	level of endogenous protease	[levels of endogenous proteases]	0.0	4	1	1	1
109867	1710	response to the early protein BZLF1	[responses to the early proteins BZLF1]	0.0	6	1	1	1
109868	1710	lymphoid tissue malt lymphoma (19	[lymphoid tissue MALT lymphoma (19]	0.0	5	1	1	1
109869	1710	hla-dr-restricted T	[HLA-DR-restricted T]	0.0	2	1	1	1
109870	1710	cancer related loci relevant to pel	[cancer related loci relevant to PEL]	0.0	6	1	1	1
109871	1710	multiple activating agents.	[multiple activating agents.]	0.0	3	1	1	1
109872	1710	addition contribute	[addition contributing]	0.0	2	1	1	1
109873	1710	16HBE epithelial cell	[16HBE epithelial cells]	0.0	3	1	1	1
109874	1710	cell line of the patient	[cell lines of the patient]	0.0	5	1	1	1
109875	1710	maturation of erythrocyte	[maturation of erythrocytes]	0.0	3	1	1	1
109876	1710	three cell line u-937	[three cell lines U-937]	0.0	4	1	1	1
109877	1710	suggest a dominant negative effect	[suggesting a dominant negative effect]	0.0	5	1	1	1
109878	1710	infection of immunodeficiency virus genetic analysis	[Infection of immunodeficiency viruses genetic analyses]	0.0	6	1	1	1
109879	1710	regulation of gtp -cyclohydrolase	[regulation of GTP -cyclohydrolase]	0.0	4	1	1	1
109880	1710	survivalepromot protein adenovirus e1b-19 kda	[survival-promoting proteins adenovirus E1B-19 kDa]	0.0	5	1	1	1
109881	1710	gata-3 factor	[GATA-3 factors]	0.0	2	1	1	1
109882	1710	4 beta in T cell	[4 beta in T cells]	0.0	5	1	1	1
109883	1710	DNA binding activity of NF-kappa b	[DNA binding activity of NF-kappa B]	0.0	6	1	1	1
109884	1710	281 61 pmol/L; in normal woman	[281 61 pmol/L; in normal women]	0.0	6	1	1	1
109885	1710	index of a pattern	[index of an pattern]	0.0	4	1	1	1
109886	1710	binding site, result in the interference	[binding site, resulting in the interference]	0.0	6	1	1	1
109887	1710	number of receptor ro	[number of receptors Ro]	0.0	4	1	1	1
109888	1710	t(15;17) acute promyelocytic leukemia	[t(15;17) acute promyelocytic leukemia]	0.0	4	1	1	1
109889	1710	long activation of human t-lymphocyte	[long-term activation of human T-lymphocytes]	0.0	5	1	1	1
109890	1710	factor activator protein-1	[factor activator protein-1]	0.0	3	1	1	1
109891	1710	condition for expression	[conditions for expression]	0.0	3	1	1	1
109892	1710	significantly change the proportion	[significantly changing the proportions]	0.0	4	1	1	1
109893	1710	mouse plasmacytoma	[mouse plasmacytoma]	0.0	2	1	1	1
109894	1710	10 micromol/L for hours, oleate	[10 micromol/L for hours, oleate]	0.0	5	1	1	1
109895	1710	trans class	[trans class]	0.0	2	1	1	1
109896	1710	evidence for a recessive form	[evidence for an recessive form]	0.0	5	1	1	1
109897	1710	follow adherence of monocyte	[following adherence of monocytes]	0.0	4	1	1	1
109898	1710	Ca2+ mobilization dependent expression	[Ca2+ mobilization dependent expression]	0.0	4	1	1	1
109899	1710	only after incubation	[only after incubation]	0.0	3	1	1	1
109900	1710	use transactivation transrepression model	[using transactivation transrepression models]	0.0	4	1	1	1
109901	1710	overexpression of p95vav alone	[overexpression of p95vav alone]	0.0	4	1	1	1
109902	1710	II-positive	[II-positive]	0.0	1	1	1	1
109903	1710	tcp microM, h),	[TCP microM, h),]	0.0	3	1	1	1
109904	1710	positive action	[positive actions]	0.0	2	1	1	1
109905	1710	considerable change in chemical nature	[considerable change in chemical nature]	0.0	5	1	1	1
109906	1710	support a role for transactivation	[supporting a role for transactivation]	0.0	5	1	1	1
109907	1710	one-hybrid assay nf-atp	[One-hybrid assays NF-ATp]	0.0	3	1	1	1
109908	1710	even after the culture	[even after the culture]	0.0	4	1	1	1
109909	1710	patient in remission	[patients in remission]	0.0	3	1	1	1
109910	1710	virus-negative T	[virus-negative T]	0.0	2	1	1	1
109911	1710	identity with the I gamma	[identity with the I gamma]	0.0	5	1	1	1
109912	1710	dependent adhesion vein cell	[dependent adhesion vein cells]	0.0	4	1	1	1
109913	1710	gtp-bound ras in ras immunoprecipitate	[GTP-bound Ras in Ras immunoprecipitates]	0.0	5	1	1	1
109914	1710	DNA change	[DNA change]	0.0	2	1	1	1
109915	1710	activity of Oct-2	[activity of Oct-2]	0.0	3	3	3	1
109916	1710	dissection of the event	[dissection of the events]	0.0	4	1	1	1
109917	1710	gene GR6	[gene GR6]	0.0	2	1	1	1
109918	1710	-express fibroblastic human cell	[-expressing fibroblastic human cells]	0.0	4	1	1	1
109919	1710	immunoprecipitation of BKO	[Immunoprecipitation of BKO]	0.0	3	1	1	1
109920	1710	level of gr	[levels of GR]	0.0	3	1	1	1
109921	1710	site at position -50	[sites at positions -50]	0.0	4	1	1	1
109922	1710	other motif-rich protein	[other motif-rich proteins]	0.0	3	1	1	1
109923	1710	AP-1 pma-mediated transactivation	[AP-1 PMA-mediated transactivation]	0.0	3	1	1	1
109924	1710	chromatin reorganization	[chromatin reorganization]	0.0	2	1	1	1
109925	1710	transcriptional regulation of the fas promoter	[transcriptional regulation of the Fas promoter]	0.0	6	1	1	1
109926	1710	chronic lymphocytic leukaemia	[chronic lymphocytic leukaemia]	0.0	3	1	1	1
109927	1710	presence of responsiveness	[presence of responsiveness]	0.0	3	1	1	1
109928	1710	sscp	[SSCP]	0.0	1	1	1	1
109929	1710	hyperparathyroidism to chronic failure	[hyperparathyroidism to chronic failure]	0.0	4	1	1	1
109930	1710	binding of the rel-related protein	[binding of the Rel-related proteins]	0.0	5	1	1	1
109931	1710	pg/ml versus 11.5+/-7.1 pg/mL,	[pg/mL vs 11.5+/-7.1 pg/mL,]	0.0	4	1	1	1
109932	1710	subdominant latent cycle reactivity to epitope	[subdominant latent cycle reactivities to epitopes]	0.0	6	1	1	1
109933	1710	nfat1 activity	[NFAT1 activity]	0.0	2	1	1	1
109934	1710	stimulation of dnd39 cell with il-4	[Stimulation of DND39 cells with IL-4]	0.0	6	1	1	1
109935	1710	approximately 10-fold 4 day	[approximately 10-fold 4 days]	0.0	4	1	1	1
109936	1710	direct the tissue-specific expression	[directing the tissue-specific expression]	0.0	4	1	1	1
109937	1710	non-significant trend	[non-significant trend]	0.0	2	1	1	1
109938	1710	number of receptor gr	[number of receptors GR]	0.0	4	1	1	1
109939	1710	native-Western analysis of beta-cell	[native-Western analyses of beta-cells]	0.0	4	1	1	1
109940	1710	il-2 promoter-enhancer	[IL-2 promoter-enhancer]	0.0	2	1	1	1
109941	1710	expression gene in monocyte	[expression genes in monocytes]	0.0	4	1	1	1
109942	1710	unique pml/ raralpha	[unique PML/ RARalpha]	0.0	3	1	1	1
109943	1710	mild-moderate insufficiency	[mild-moderate insufficiency]	0.0	2	1	1	1
109944	1710	lymphoblastic t-cell line	[lymphoblastic T-cell line]	0.0	3	1	1	1
109945	1710	mrna in cell	[mRNA in cells]	0.0	3	1	1	1
109946	1710	patient with eosinophilia	[patients with eosinophilia]	0.0	3	1	1	1
109947	1710	collaboration of protein	[collaboration of proteins]	0.0	3	1	1	1
109948	1710	earlier)	[earlier)]	0.0	1	1	1	1
109949	1710	(il)-2 gene induction	[(IL)-2 gene induction]	0.0	3	1	1	1
109950	1710	nm, bmax +/- 29.8	[nM, Bmax +/- 29.8]	0.0	4	1	1	1
109951	1710	temperature-sensitive mutant	[temperature-sensitive mutants]	0.0	2	1	1	1
109952	1710	factor Kappa-B	[factor Kappa-B]	0.0	2	1	1	1
109953	1710	bu/ml)	[BU/mL)]	0.0	1	1	1	1
109954	1710	undifferentiated carcinoma	[undifferentiated carcinomas]	0.0	2	1	1	1
109955	1710	sensitivity to vincristine	[sensitivity to vincristine]	0.0	3	1	1	1
109956	1710	bzlf1 transcript	[BZLF1 transcripts]	0.0	2	1	1	1
109957	1710	Zap70	[Zap70]	0.0	1	1	1	1
109958	1710	overexpression in cell lines,	[overexpression in cell lines,]	0.0	4	1	1	1
109959	1710	use a nfatp polyclonal antibody	[using a NFATp polyclonal antibody]	0.0	5	1	1	1
109960	1710	tax-responsive element necessary for transactivation	[Tax-responsive element necessary for transactivation]	0.0	5	1	1	1
109961	1710	obtain probe specific	[obtaining probes specific]	0.0	3	1	1	1
109962	1710	mAb L243	[mAb L243]	0.0	2	1	1	1
109963	1710	regulatory mobility group	[regulatory mobility group]	0.0	3	1	1	1
109964	1710	antiinflammatory mechanism of gc	[antiinflammatory mechanisms of GC]	0.0	4	1	1	1
109965	1710	undergo ptca	[undergoing PTCA]	0.0	2	1	1	1
109966	1710	Willebrand	[Willebrand]	0.0	1	1	1	1
109967	1710	AACAAAG motif	[AACAAAG motif]	0.0	2	1	1	1
109968	1710	erk and/or p38	[ERK and/or p38]	0.0	3	1	1	1
109969	1710	cysteine cys gsh	[cysteine CYS GSH]	0.0	3	1	1	1
109970	1710	utility for a definition	[utility for a definition]	0.0	4	1	1	1
109971	1710	Jeg-3 immunosuppression downregulation	[Jeg-3 immunosuppression downregulation]	0.0	3	1	1	1
109972	1710	7.03 (range, (range, 4-.11),	[7.03 (range, (range, 4-5.13),]	0.0	4	1	1	1
109973	1710	hypo hyper thyroidism	[hypo hyper thyroidism]	0.0	3	1	1	1
109974	1710	oncogenic effect in T cell	[oncogenic effect in T cells]	0.0	5	1	1	1
109975	1710	one region	[one region]	0.0	2	1	1	1
109976	1710	several weight transmembrane adaptor protein	[several weight transmembrane adaptor proteins]	0.0	5	1	1	1
109977	1710	minimal disease MRD of patient	[minimal disease MRD of patients]	0.0	5	1	1	1
109978	1710	major positive role	[major positive role]	0.0	3	1	1	1
109979	1710	similar reduction	[similar reduction]	0.0	2	1	1	1
109980	1710	phosphatidylinositol-3,4,5-trisphosphate concentration in monocytic cell	[phosphatidylinositol-3,4,5-trisphosphate concentration in monocytic cells]	0.0	5	1	1	1
109981	1710	promoter (termed UAS1	[promoter (termed UAS1]	0.0	3	1	1	1
109982	1710	contain titre antibody with specificity	[containing titre antibodies with specificities]	0.0	5	1	1	1
109983	1710	recent literature	[recent literature]	0.0	2	1	1	1
109984	1710	IL-2 proliferative growth	[IL-2 proliferative growth]	0.0	3	1	1	1
109985	1710	introduction of mutation	[introduction of mutations]	0.0	3	1	1	1
109986	1710	loss of tnf-alpha synthesis	[loss of TNF-alpha synthesis]	0.0	4	1	1	1
109987	1710	properties unlike other oncoprotein	[properties, unlike other oncoproteins]	0.0	4	1	1	1
109988	1710	colony-stimulating factor granulocyte-macrophage colony-stimumulatelany-stg factor	[colony-stimulating factor granulocyte-macrophage colony-stimulating factor]	0.0	5	1	1	1
109989	1710	NFAT1 (nfatp)	[NFAT1 (NFATp)]	0.0	2	1	1	1
109990	1710	GGGGGCTTTCCC	[GGGGGCTTTCCC]	0.0	1	1	1	1
109991	1710	also in 10 individual	[also in 10 individuals]	0.0	4	1	1	1
109992	1710	amino acid rich	[amino acids rich]	0.0	3	1	1	1
109993	1710	outcome of clinical syndrome	[outcome of clinical syndromes]	0.0	4	1	1	1
109994	1710	unicellular-unilineage culture analysis	[Unicellular-unilineage cultures analysis]	0.0	3	1	1	1
109995	1710	subject in the stage	[subjects in the stage]	0.0	4	1	1	1
109996	1710	induction of fra-1 engagement of CD40	[Induction of fra-1 engagement of CD40]	0.0	6	1	1	1
109997	1710	elastase inhibitor synthetic peptide gdsp	[elastase inhibitor synthetic peptide GDSP]	0.0	5	1	1	1
109998	1710	NF-kappa b consensus sequence	[NF-kappa B consensus sequence]	0.0	4	1	1	1
109999	1710	putative stem cell	[putative stem cells]	0.0	3	1	1	1
110000	1710	such as downregulation of complex molecule	[such as downregulation of complex molecules]	0.0	6	1	1	1
110001	1710	include a heterodimer from t-cell extract	[including a heterodimer from T-cell extracts]	0.0	6	1	1	1
110002	1710	previously undefined role	[previously undefined role]	0.0	3	1	1	1
110003	1710	stlv-i	[STLV-I]	0.0	1	1	1	1
110004	1710	result in divergent expression of gene	[resulting in divergent expression of genes]	0.0	6	1	1	1
110005	1710	screen assay of the dna-	[screening assay of the DNA-]	0.0	5	1	1	1
110006	1710	direct activation with PMA	[Direct activation with PMA]	0.0	4	1	1	1
110007	1710	compare the FISH result	[comparing the FISH results]	0.0	4	1	1	1
110008	1710	A/R insult	[A/R insult]	0.0	2	1	1	1
110009	1710	downregulation of p27(kip1	[downregulation of p27(Kip1]	0.0	3	1	1	1
110010	1710	order of magnitude potent	[orders of magnitude potent]	0.0	4	1	1	1
110011	1710	14 nonatopic control subject ige	[14 nonatopic control subjects IgE]	0.0	5	1	1	1
110012	1710	mg/24h; n: 2.7+/-2.0)	[mg/24h; N: 2.7+/-2.0)]	0.0	3	1	1	1
110013	1710	material mdhm	[material MDHM]	0.0	2	1	1	1
110014	1710	link between system	[link between systems]	0.0	3	1	1	1
110015	1710	binding in unactivated nuclear extract	[binding in unactivated nuclear extracts]	0.0	5	1	1	1
110016	1710	vitro colony formation assay	[vitro colony formation assays]	0.0	4	1	1	1
110017	1710	expression of p50 homodimer	[expression of p50 homodimer]	0.0	4	1	1	1
110018	1710	regulation of immunodeficiency virus type hiv-1	[regulation of immunodeficiency virus type HIV-1]	0.0	6	1	1	1
110019	1710	gammaRI	[gammaRI]	0.0	1	1	1	1
110020	1710	proximal site NF kappa	[proximal site NF kappa]	0.0	4	1	1	1
110021	1710	T cell with concentration	[T cells with concentrations]	0.0	4	1	1	1
110022	1710	versatile homeostatic switch	[versatile homeostatic switch]	0.0	3	1	1	1
110023	1710	contain the domain stem cell factor	[containing the domain stem cell factor]	0.0	6	1	1	1
110024	1710	beta-amyloid	[beta-amyloid]	0.0	1	1	1	1
110025	1710	FY*B coding sequence	[FY*B coding sequence]	0.0	3	1	1	1
110026	1710	affinity Ka	[affinity Ka]	0.0	2	1	1	1
110027	1710	antigen-presenting cell with receptor	[antigen-presenting cells with receptors]	0.0	4	1	1	1
110028	1710	amount of p50	[amounts of p50]	0.0	3	1	1	1
110029	1710	capacity of the component	[capacity of the component]	0.0	4	1	1	1
110030	1710	reflect the unique c-terminal domain	[reflecting the unique C-terminal domain]	0.0	5	1	1	1
110031	1710	interleukin-3 granulocyte-macrophage colony-stimulating factor	[interleukin-3 granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
110032	1710	influence immunodeficiency virus replication in monocyte	[influencing immunodeficiency virus replication in monocytes]	0.0	6	1	1	1
110033	1710	contain the protein Sp1	[containing the protein Sp1]	0.0	4	1	1	1
110034	1710	rest peripheral blood monocyte	[resting peripheral blood monocytes]	0.0	4	1	1	1
110035	1710	member factor	[members factors]	0.0	2	1	1	1
110036	1710	hl-60 to cell	[HL-60 to cells]	0.0	3	1	1	1
110037	1710	optimization of culture conditions, type	[optimization of culture conditions, type]	0.0	5	1	1	1
110038	1710	wild-type -resistant ecem) cell	[wild-type -resistant (CEM) cells]	0.0	4	1	1	1
110039	1710	light on the biochemical mechanism	[light on the biochemical mechanisms]	0.0	5	1	1	1
110040	1710	+55 region nucleotide number	[+55 region nucleotide numbers]	0.0	4	1	1	1
110041	1710	show only weak cross-reactivity	[showing only weak cross-reactivity]	0.0	4	1	1	1
110042	1710	subunit a dp65	[subunits an dp65]	0.0	3	1	1	1
110043	1710	cooperate transcription factor	[cooperating transcription factors]	0.0	3	1	1	1
110044	1710	event of T cell proliferation	[events of T cell proliferation]	0.0	5	1	1	1
110045	1710	potent cytokine tgf-beta	[potent cytokine TGF-beta]	0.0	3	1	1	1
110046	1710	suggest deleterious in preinjured lung	[suggesting deleterious in preinjured lungs]	0.0	5	1	1	1
110047	1710	binding to icss	[binding to ICSs]	0.0	3	1	1	1
110048	1710	two reading frame of hhv-6	[two reading frames of HHV-6]	0.0	5	1	1	1
110049	1710	sequence include kb	[sequence including kb]	0.0	3	1	1	1
110050	1710	cell by superantigen	[cells by superantigens]	0.0	3	1	1	1
110051	1710	time of basophilia	[time of basophilia]	0.0	3	1	1	1
110052	1710	tlr by lipoprotein	[TLRs by lipoproteins]	0.0	3	1	1	1
110053	1710	Finally, reactivation of tumor-suppressor gene expression	[Finally, reactivation of tumor-suppressor gene expression]	0.0	6	1	1	1
110054	1710	46,xx	[46,XX]	0.0	1	1	1	1
110055	1710	Bcl-6 expression in reactive hyperplasia	[Bcl-6 expression in reactive hyperplasia]	0.0	5	1	1	1
110056	1710	unique deleterious mechanism related	[unique deleterious mechanism related]	0.0	4	1	1	1
110057	1710	fundamental processes,	[fundamental processes,]	0.0	2	1	1	1
110058	1710	Chignard, M. Blood 82,	[Chignard, M. Blood 82,]	0.0	4	1	1	1
110059	1710	development in myeloproliferative disorder	[development in myeloproliferative disorders]	0.0	4	1	1	1
110060	1710	u-937 cell culture	[U-937 cell cultures]	0.0	3	1	1	1
110061	1710	blood lymphocyte from human	[blood lymphocytes from humans]	0.0	4	1	1	1
110062	1710	t- leukemia	[T- leukemias]	0.0	2	1	1	1
110063	1710	low level in T lymphocyte	[lower levels in T lymphocytes]	0.0	5	1	1	1
110064	1710	furthermore, ectopic expression in HeLa cell	[Furthermore, ectopic expression in HeLa cells]	0.0	6	1	1	1
110065	1710	exclude skewedness of random x-inactivation	[excluding skewedness of random X-inactivation]	0.0	5	1	1	1
110066	1710	polyclonal activation	[polyclonal activation]	0.0	2	1	1	1
110067	1710	after crosslinking LMP1 chimera	[after crosslinking LMP1 chimera]	0.0	4	1	1	1
110068	1710	role in inducible expression	[role in inducible expression]	0.0	4	1	1	1
110069	1710	interleukin-12 expression with Epstein-Barr virus	[Interleukin-12 expression with Epstein-Barr virus]	0.0	5	1	1	1
110070	1710	DNA clone contain the 5' region	[DNA clones containing the 5' region]	0.0	6	1	1	1
110071	1710	antibody against subunit	[antibodies against subunits]	0.0	3	1	1	1
110072	1710	back	[back]	0.0	1	2	2	1
110073	1710	indexing term immunology	[indexing terms immunology]	0.0	3	1	1	1
110074	1710	suggest a role in repression	[suggesting a role in repression]	0.0	5	1	1	1
110075	1710	alpha thf/thf n:	[alpha THF/THF N:]	0.0	3	1	1	1
110076	1710	tpa activation	[TPA activation]	0.0	2	1	1	1
110077	1710	effect of pyrrolidine dithiocarbamate	[effect of pyrrolidine dithiocarbamate]	0.0	4	1	1	1
110078	1710	Interferon factor	[Interferon factor]	0.0	2	1	1	1
110079	1710	treatment with different schedule of calcitriol	[Treatment with different schedules of calcitriol]	0.0	6	1	1	1
110080	1710	time (12-24 h)	[times (12-24 h)]	0.0	3	1	1	1
110081	1710	interaction between two coactivator	[interactions between two coactivators]	0.0	4	1	1	1
110082	1710	specific cytokine by il-2	[specific cytokines by IL-2]	0.0	4	1	1	1
110083	1710	neotropical primate with resistance	[neotropical primates with resistance]	0.0	4	1	1	1
110084	1710	activity of the silencer	[activity of the silencer]	0.0	4	1	1	1
110085	1710	young subject type receptor	[young subjects Type receptors]	0.0	4	1	1	1
110086	1710	identification of disease	[identification of disease]	0.0	3	1	1	1
110087	1710	redox control	[redox control]	0.0	2	1	1	1
110088	1710	cell of acute promyelocytic leukemia	[cells of acute promyelocytic leukemia]	0.0	5	1	1	1
110089	1710	immunodeficiency virus-type hiv-1	[immunodeficiency virus-type HIV-1]	0.0	3	1	1	1
110090	1710	oxygen intermediate ROI after stress	[oxygen intermediates ROI after stress]	0.0	5	1	1	1
110091	1710	role ensure the differentiation	[role ensuring the differentiation]	0.0	4	1	1	1
110092	1710	Effect of mitogenic agent	[Effects of mitogenic agents]	0.0	4	1	1	1
110093	1710	second messenger system	[second messenger systems]	0.0	3	1	1	1
110094	1710	(nf)-kappab pathway	[(NF)-kappaB pathway]	0.0	2	1	1	1
110095	1710	range from 1 mmol/L.	[ranging from 1 mmol/L.]	0.0	4	1	1	1
110096	1710	similarly, a mutant	[Similarly, a mutant]	0.0	3	1	1	1
110097	1710	IL-2 release	[IL-2 release]	0.0	2	1	1	1
110098	1710	few virus-exposed cell	[Fewer virus-exposed cells]	0.0	3	1	1	1
110099	1710	provide explanation	[providing explanation]	0.0	2	1	1	1
110100	1710	measurement with a mode	[measurement with a mode]	0.0	4	1	1	1
110101	1710	level rest b	[levels resting B]	0.0	3	1	1	1
110102	1710	receptor beta in airway cell	[receptor beta in airway cells]	0.0	5	1	1	1
110103	1710	involvement of egr-1 /rela synergy	[Involvement of Egr-1 /RelA synergy]	0.0	5	1	1	1
110104	1710	ndp kinase	[NDP kinase]	0.0	2	1	1	1
110105	1710	synovial fluid monocyte	[synovial fluid monocytes]	0.0	3	1	1	1
110106	1710	population of progenitor /precursor	[populations of progenitors /precursors]	0.0	4	1	1	1
110107	1710	expression protein ip-10	[Expression protein IP-10]	0.0	3	1	1	1
110108	1710	(atf) family CREB	[(ATF) family CREB]	0.0	3	1	1	1
110109	1710	manic)	[manic)]	0.0	1	1	1	1
110110	1710	sensitive (ic50 ng/ml)	[sensitive (IC50 ng/mL)]	0.0	3	1	1	1
110111	1710	level in cell type	[levels in cell types]	0.0	4	1	1	1
110112	1710	further 16-hour incubation microg/mL lps	[further 16-hour incubation microg/mL LPS]	0.0	5	1	1	1
110113	1710	kappa -binding	[kappa -binding]	0.0	2	1	1	1
110114	1710	x gene in patient	[X gene in patients]	0.0	4	1	1	1
110115	1710	thiol-containing antioxidant	[thiol-containing antioxidant]	0.0	2	1	1	1
110116	1710	formation of ap1 complex in monocyte	[formation of AP1 complex in monocytes]	0.0	6	1	1	1
110117	1710	activation of pair of jak kinase	[activation of pairs of JAK kinases]	0.0	6	1	1	1
110118	1710	childhood T	[childhood T]	0.0	2	1	1	1
110119	1710	program underlie differentiation	[program underlying differentiation]	0.0	3	1	1	1
110120	1710	inverse relation between parameter	[inverse relation between parameters]	0.0	4	1	1	1
110121	1710	enhancement of germline cepsilon transcription	[enhancement of germline Cepsilon transcription]	0.0	5	1	1	1
110122	1710	recruitment cooperate transcription factor	[recruitment cooperating transcription factors]	0.0	4	1	1	1
110123	1710	human leukocyte MNL	[human leukocytes MNL]	0.0	3	1	1	1
110124	1710	stromal cell-mediated tcell rescue	[stromal cell-mediated Tcell rescue]	0.0	4	1	1	1
110125	1710	neonatal response	[neonatal response]	0.0	2	1	1	1
110126	1710	occlusion a major cause	[occlusion a major cause]	0.0	4	1	1	1
110127	1710	stress fiber formation	[stress fiber formation]	0.0	3	1	1	1
110128	1710	childhood b	[childhood B]	0.0	2	1	1	1
110129	1710	essential intermediate step	[essential intermediate step]	0.0	3	1	1	1
110130	1710	directly, provide functional evidence	[directly, providing functional evidence]	0.0	4	1	1	1
110131	1710	process involve stage of commitment	[process involving stages of commitment]	0.0	5	1	1	1
110132	1710	preinjured lung	[preinjured lungs]	0.0	2	1	1	1
110133	1710	common property of gene	[common property of genes]	0.0	4	1	1	1
110134	1710	ras transformation of human b lymphoblast	[Ras transformation of human B lymphoblasts]	0.0	6	1	1	1
110135	1710	member of this family MYC	[members of this family MYC]	0.0	5	1	1	1
110136	1710	o-phenanthroline OP on the induction	[o-phenanthroline OP on the induction]	0.0	5	1	1	1
110137	1710	activation of program	[activation of programs]	0.0	3	1	1	1
110138	1710	such as cell size increase	[such as cell size increase]	0.0	5	1	1	1
110139	1710	only low affinity	[only low affinity]	0.0	3	1	1	1
110140	1710	difference in transcription	[differences in transcription]	0.0	3	1	1	1
110141	1710	3' site fp4-3'	[3' site FP4-3']	0.0	3	1	1	1
110142	1710	3bp2 overexpression	[3BP2 overexpression]	0.0	2	1	1	1
110143	1710	T cell inhibitory activity present	[T cell inhibitory activities present]	0.0	5	1	1	1
110144	1710	use pbmc	[using PBMCs]	0.0	2	1	1	1
110145	1710	two discrete cell-surface isoform	[two discrete cell-surface isoforms]	0.0	4	1	1	1
110146	1710	interferon beta promoter	[interferon beta promoter]	0.0	3	1	1	1
110147	1710	clinically distinct stages:	[clinically distinct stages:]	0.0	3	1	1	1
110148	1710	effect in comparison with drug	[effect in comparison with drug]	0.0	5	1	1	1
110149	1710	subsequent monocyte adhesion in vein cell	[subsequent monocyte adhesion in vein cells]	0.0	6	1	1	1
110150	1710	activity on the modulation	[activities on the modulation]	0.0	4	1	1	1
110151	1710	distinguished: biochemical sign of hypothyroidism	[distinguished: biochemical signs of hypothyroidism]	0.0	5	1	1	1
110152	1710	function of CIITA	[functions of CIITA]	0.0	3	1	1	1
110153	1710	human tonsillar cell	[human tonsillar cells]	0.0	3	1	1	1
110154	1710	contrast to subject	[contrast to subjects]	0.0	3	1	1	1
110155	1710	zipper DNA	[zipper DNA]	0.0	2	1	1	1
110156	1710	leucocyte recruitment across vascular endothelium	[leucocyte recruitment across vascular endothelium]	0.0	5	1	1	1
110157	1710	stimulus, ganglioside	[stimulus, gangliosides]	0.0	2	1	1	1
110158	1710	mimicry in autoimmune disease	[mimicry in autoimmune disease]	0.0	4	1	1	1
110159	1710	significantly low concentration	[significantly lower concentration]	0.0	3	1	1	1
110160	1710	cell whatever stage	[cells whatever stage]	0.0	3	1	1	1
110161	1710	recent years, study of regulation	[recent years, studies of regulation]	0.0	5	1	1	1
110162	1710	only the association of CCACC/Sp1	[only the association of CCACC/Sp1]	0.0	5	1	1	1
110163	1710	role in different cell type	[roles in different cell types]	0.0	5	1	1	1
110164	1710	regulator of growth of hematopoietic cell	[regulators of growth of hematopoietic cells]	0.0	6	1	1	1
110165	1710	deletion of the upstream portion	[deletion of the upstream portion]	0.0	5	1	1	1
110166	1710	pos protein	[POS protein]	0.0	2	1	1	1
110167	1710	actively divide immature cell	[actively dividing immature cells]	0.0	4	1	1	1
110168	1710	additional size heterogeneity	[Additional size heterogeneity]	0.0	3	1	1	1
110169	1710	large b cell lymphoma	[large B cell lymphomas]	0.0	4	1	1	1
110170	1710	glucocorticoid receptor without change	[glucocorticoid receptors without changes]	0.0	4	1	1	1
110171	1710	present in infancy with salt loss	[presenting in infancy with salt loss]	0.0	6	1	1	1
110172	1710	erythroid Kruppel-like factor activity	[erythroid Kruppel-like factor activity]	0.0	4	1	1	1
110173	1710	cell adhesion molecule-1 pecam-1 phosphorylation	[cell adhesion molecule-1 PECAM-1 phosphorylation]	0.0	5	1	1	1
110174	1710	thp 1 cell	[THP 1 cells]	0.0	3	1	1	1
110175	1710	co-localization	[co-localization]	0.0	1	1	1	1
110176	1710	role of acid (ra)	[role of acid (RA)]	0.0	4	1	1	1
110177	1710	transduce distal signal	[transducing distal signals]	0.0	3	1	1	1
110178	1710	distinct apoptosis signal pathway with sensitivity	[distinct apoptosis signaling pathways with sensitivity]	0.0	6	1	1	1
110179	1710	bank	[bank]	0.0	1	1	1	1
110180	1710	stimulus in b-cell	[stimuli in B-cells]	0.0	3	1	1	1
110181	1710	inducible component within minute	[inducible component within min]	0.0	4	1	1	1
110182	1710	long terminal repeat hiv-1-ltr	[long terminal repeat HIV-1-LTR]	0.0	4	1	1	1
110183	1710	inhibition by IFN	[inhibition by IFN]	0.0	3	1	1	1
110184	1710	specific gene expression promoter	[specific gene expression promoter]	0.0	4	1	1	1
110185	1710	gene HZF	[genes HZF]	0.0	2	1	1	1
110186	1710	contribute to inadequate response	[contributing to inadequate response]	0.0	4	1	1	1
110187	1710	acid moiety	[acid moiety]	0.0	2	1	1	1
110188	1710	proximal site,	[proximal site,]	0.0	2	1	1	1
110189	1710	mantle zone;	[mantle zone;]	0.0	2	1	1	1
110190	1710	overexpression a constitutive active version	[Overexpression a constitutive active version]	0.0	5	1	1	1
110191	1710	function of macrophage	[functions of macrophages]	0.0	3	1	1	1
110192	1710	false prediction	[false predictions]	0.0	2	1	1	1
110193	1710	steel factor stimulation,	[Steel factor stimulation,]	0.0	3	1	1	1
110194	1710	cd28re complex	[CD28RE complex]	0.0	2	1	1	1
110195	1710	NF-kappaB like site	[NF-kappaB like site]	0.0	3	1	1	1
110196	1710	stimulation of phagocytosis	[stimulation of phagocytosis]	0.0	3	1	1	1
110197	1710	transduce a raralpha exhibit activity	[transducing a RARalpha exhibiting activity]	0.0	5	1	1	1
110198	1710	'constitutive'	['constitutive']	0.0	1	1	1	1
110199	1710	suggest deleterious	[suggesting deleterious]	0.0	2	1	1	1
110200	1710	translocation of b/c-rel protein	[translocation of B/c-Rel proteins]	0.0	4	1	1	1
110201	1710	myristic acetate	[myristic acetate]	0.0	2	1	1	1
110202	1710	competition analysis with transcription factor	[competition analysis with transcription factor]	0.0	5	1	1	1
110203	1710	substrate for kinase	[substrate for kinase]	0.0	3	1	1	1
110204	1710	cd4+ T cell clone	[CD4+ T cell clones]	0.0	4	1	1	1
110205	1710	suppression of nf-kappab activation by fluid	[Suppression of NF-kappaB activation by fluid]	0.0	6	1	1	1
110206	1710	heat shock transcription factor hsf	[heat shock transcription factor HSF]	0.0	5	1	1	1
110207	1710	cox-2 protein expression	[COX-2 protein expression]	0.0	3	1	1	1
110208	1710	neonatal distress syndrome	[neonatal distress syndrome]	0.0	3	1	1	1
110209	1710	Northern analysis of mrna	[Northern analysis of mRNA]	0.0	4	1	1	1
110210	1710	therefore a strategy	[therefore an strategy]	0.0	3	1	1	1
110211	1710	mechanism for transcription	[mechanism for transcription]	0.0	3	1	1	1
110212	1710	cell highly resistant to apoptosis	[cells highly resistant to apoptosis]	0.0	5	1	1	1
110213	1710	Recombinant human tumor necrosis factor	[Recombinant human tumor necrosis factor]	0.0	5	1	1	1
110214	1710	transcriptional factor-KB NF-kappa b result	[transcriptional factor-KB NF-kappa B resulting]	0.0	5	1	1	1
110215	1710	interaction implication	[Interaction implications]	0.0	2	1	1	1
110216	1710	total of 37 severe,	[total of 37 severe,]	0.0	4	1	1	1
110217	1710	include tyrosine phosphorylation	[including tyrosine phosphorylation]	0.0	3	1	1	1
110218	1710	complex resemble factor	[complex resembling factor]	0.0	3	1	1	1
110219	1710	effect on GATA-1	[effects on GATA-1]	0.0	3	1	1	1
110220	1710	coordination of the response	[Coordination of the response]	0.0	4	1	1	1
110221	1710	inhibitor of MEK1	[inhibitors of MEK1]	0.0	3	1	1	1
110222	1710	early samples, cytotoxic activity	[early samples, cytotoxic activity]	0.0	4	1	1	1
110223	1710	abnormal clearance	[abnormal clearance]	0.0	2	1	1	1
110224	1710	1, D3 135(oh)2d3	[1, D3 1,25(OH)2D3]	0.0	3	1	1	1
110225	1710	two structurally unique raralpha	[two structurally unique RARalpha]	0.0	4	1	1	1
110226	1710	apc (e.g. fibroblast	[APCs (e.g. fibroblasts]	0.0	3	1	1	1
110227	1710	cellular mechanism contribute	[Cellular mechanisms contributing]	0.0	3	1	1	1
110228	1710	ribosomal entry site IRES	[ribosomal entry site IRES]	0.0	4	1	1	1
110229	1710	amplification of cDNA end analysis	[amplification of cDNA ends analysis]	0.0	5	1	1	1
110230	1710	nuclear marker for b-1 cell	[nuclear marker for B-1 cells]	0.0	5	1	1	1
110231	1710	transcriptional element of t-cell gene	[transcriptional elements of T-cell genes]	0.0	5	1	1	1
110232	1710	different b inducer	[different B inducers]	0.0	3	1	1	1
110233	1710	age-matched subject	[age-matched subjects]	0.0	2	1	1	1
110234	1710	40-fold activity	[40-fold activity]	0.0	2	1	1	1
110235	1710	stimulation of phosphatidylinositol turnover	[stimulation of phosphatidylinositol turnover]	0.0	4	1	1	1
110236	1710	RAR gamma tgase	[RAR gamma TGase]	0.0	3	1	1	1
110237	1710	two phenotype	[Two phenotypes]	0.0	2	1	1	1
110238	1710	135(oh)2d3 degradation	[1,25(OH)2D3 degradation]	0.0	2	1	1	1
110239	1710	conventional equi-effective doses.	[conventional equi-effective doses.]	0.0	3	1	1	1
110240	1710	malignant lymphoma, diffuse, cell" type	[malignant lymphoma, diffuse, cell" type]	0.0	5	1	1	1
110241	1710	other adaptor addition	[other adaptors addition]	0.0	3	1	1	1
110242	1710	critical involvement of Itk	[critical involvement of Itk]	0.0	4	1	1	1
110243	1710	vasoactive factor	[vasoactive factors]	0.0	2	1	1	1
110244	1710	kappa manner	[kappa manner]	0.0	2	1	1	1
110245	1710	primary tool	[primary tool]	0.0	2	1	1	1
110246	1710	monocyte cytokine	[monocyte cytokine]	0.0	2	1	1	1
110247	1710	level of gene activity	[levels of gene activity]	0.0	4	1	1	1
110248	1710	binding to a novel element	[Binding to a novel element]	0.0	5	1	1	1
110249	1710	t- leukemia arise in case	[T- leukemias arising in cases]	0.0	5	1	1	1
110250	1710	subset of myocyte	[subset of myocytes]	0.0	3	1	1	1
110251	1710	copy of consensus nf-kappa b site	[copies of consensus NF-kappa B site]	0.0	6	1	1	1
110252	1710	first atg	[first ATG]	0.0	2	1	1	1
110253	1710	cell activation by lipoprotein	[Cell activation by lipoproteins]	0.0	4	1	1	1
110254	1710	marker for diagnosis	[marker for diagnosis]	0.0	3	1	1	1
110255	1710	event in the transduction	[event in the transduction]	0.0	4	1	1	1
110256	1710	bash	[BASH]	0.0	1	1	1	1
110257	1710	monoallelic of patient	[monoallelic of patients]	0.0	3	1	1	1
110258	1710	paraparesis/ htlv-i myelopathy	[paraparesis/ HTLV-I myelopathy]	0.0	3	1	1	1
110259	1710	overcome several block	[overcoming several blocks]	0.0	3	1	1	1
110260	1710	monosaccharide glycan	[monosaccharide glycans]	0.0	2	1	1	1
110261	1710	synergistic proinflammatory effect of stress	[Synergistic proinflammatory effects of stress]	0.0	5	1	1	1
110262	1710	activity of B-cell nuclear extract	[activity of B-cell nuclear extracts]	0.0	5	1	1	1
110263	1710	support to report	[support to reports]	0.0	3	1	1	1
110264	1710	differentiation of 32dcl3 cell	[differentiation of 32Dcl3 cells]	0.0	4	1	1	1
110265	1710	lack capability	[lacking capability]	0.0	2	1	1	1
110266	1710	affect the activity independent	[affecting the activity independent]	0.0	4	1	1	1
110267	1710	lysis gene	[lysis genes]	0.0	2	1	1	1
110268	1710	dna-dependent atpase	[DNA-dependent ATPase]	0.0	2	1	1	1
110269	1710	significant variation in blood cell	[significant variation in blood cells]	0.0	5	1	1	1
110270	1710	distribution of lineage-associated cytokine receptor	[distribution of lineage-associated cytokine receptors]	0.0	5	1	1	1
110271	1710	marmoset t-lymphocyte	[marmoset T-lymphocyte]	0.0	2	1	1	1
110272	1710	modification of target tissue	[modifications of target tissues]	0.0	4	1	1	1
110273	1710	immunodeficiency virus type hiv-1 infection	[immunodeficiency virus type HIV-1 infection]	0.0	5	1	1	1
110274	1710	Vitamin e therapy of ccl4 injury	[Vitamin E therapy of CCl4 injury]	0.0	6	1	1	1
110275	1710	control of il-4 expression	[control of IL-4 expression]	0.0	4	1	1	1
110276	1710	calcitriol receptor	[calcitriol receptors]	0.0	2	1	1	1
110277	1710	mediator of neuroendocrine-immune regulatory interaction	[mediators of neuroendocrine-immune regulatory interactions]	0.0	5	1	1	1
110278	1710	activation 2 globin promoter functional role	[activation 2 globin promoter functional role]	0.0	6	1	1	1
110279	1710	adult erythroid cell haec system	[adult erythroid cell hAEC system]	0.0	5	1	1	1
110280	1710	fibrosarcoma 8, malignant histiocytoma rhabdomyosarcoma	[fibrosarcoma 8, malignant histiocytoma rhabdomyosarcoma]	0.0	5	1	1	1
110281	1710	translocation of RelB	[translocation of RelB]	0.0	3	1	1	1
110282	1710	agent cyclosporin A CsA	[agent cyclosporin A CsA]	0.0	4	1	1	1
110283	1710	underlie this capacity	[underlying this capacity]	0.0	3	1	1	1
110284	1710	CD4 subpopulation	[CD4 subpopulations]	0.0	2	1	1	1
110285	1710	block a target in culture	[blocking a target in cultures]	0.0	5	1	1	1
110286	1710	such unique activation	[such unique activation]	0.0	3	1	1	1
110287	1710	heterodimer follow time	[heterodimers following time]	0.0	3	1	1	1
110288	1710	two man aged	[two men aged]	0.0	3	1	1	1
110289	1710	regard, cytokine lps	[regard, cytokines LPS]	0.0	3	1	1	1
110290	1710	regulation of this related zinc-finger	[regulation of these related zinc-finger]	0.0	5	1	1	1
110291	1710	multiple, distinct protein	[multiple, distinct proteins]	0.0	3	1	1	1
110292	1710	membrane-proximal sequence motif box1	[membrane-proximal sequence motif box1]	0.0	4	1	1	1
110293	1710	moreover, the factor present in extract	[Moreover, the factor present in extracts]	0.0	6	1	1	1
110294	1710	importance of endogenous nfat	[importance of endogenous NFAT]	0.0	4	1	1	1
110295	1710	L128G	[L128G]	0.0	1	1	1	1
110296	1710	domain of E2A	[domains of E2A]	0.0	3	1	1	1
110297	1710	treatment of monocyte with phorbol-13-acetate	[Treatment of monocytes with phorbol-13-acetate]	0.0	5	1	1	1
110298	1710	inhibitory effect of DEX	[inhibitory effects of DEX]	0.0	4	1	1	1
110299	1710	monosaccharide	[monosaccharide]	0.0	1	1	1	1
110300	1710	region of 16	[region of 16]	0.0	3	1	1	1
110301	1710	primary rest T	[Primary resting T]	0.0	3	1	1	1
110302	1710	length variation	[length variation]	0.0	2	1	1	1
110303	1710	core of the promoter	[core of the promoter]	0.0	4	1	1	1
110304	1710	E-box-binding repressor	[E-box-binding repressor]	0.0	2	1	1	1
110305	1710	Interleukin-5 signal	[Interleukin-5 signaling]	0.0	2	1	1	1
110306	1710	other characteristic of differentiation	[other characteristics of differentiation]	0.0	4	1	1	1
110307	1710	binding activity on the hand,	[binding activities on the hand,]	0.0	5	1	1	1
110308	1710	corresponding to the pml	[corresponding to the pml]	0.0	4	1	1	1
110309	1710	analysis of gene-targeted mouse	[analysis of gene-targeted mice]	0.0	4	1	1	1
110310	1710	induction in endothelial cell	[induction in endothelial cells]	0.0	4	1	1	1
110311	1710	CD40 ligation growth inhibition in mm	[CD40 ligation growth inhibition in MM]	0.0	6	1	1	1
110312	1710	early stage cell	[early stage cells]	0.0	3	1	1	1
110313	1710	bioactivation of sulphamethoxazole to metabolite	[Bioactivation of sulphamethoxazole to metabolites]	0.0	5	1	1	1
110314	1710	hematopoietic growth factor HGF	[hematopoietic growth factor HGF]	0.0	4	1	1	1
110315	1710	downstream activation of a promoter	[Downstream activation of a promoter]	0.0	5	1	1	1
110316	1710	preincubation of HUVEC	[preincubation of HUVEC]	0.0	3	1	1	1
110317	1710	interaction between the stage selector element	[Interaction between the stage selector element]	0.0	6	1	1	1
110318	1710	effect on the b29 promoter	[effect on the B29 promoter]	0.0	5	1	1	1
110319	1710	FN il-1beta protein production	[FN IL-1beta protein production]	0.0	4	1	1	1
110320	1710	t-cell leukemia virus type tax	[T-cell leukemia virus type Tax]	0.0	5	1	1	1
110321	1710	4 h at degree	[4 h at degrees]	0.0	4	1	1	1
110322	1710	lymphocyte syndrome ebls) patients.	[Lymphocyte Syndrome (BLS) patients.]	0.0	4	1	1	1
110323	1710	action of the element	[actions of the elements]	0.0	4	1	1	1
110324	1710	CCAAT/enhancer-binding protein (c/ebp) family member	[CCAAT/enhancer-binding protein (C/EBP) family member]	0.0	5	1	1	1
110325	1710	cellular transduction mutant	[cellular transduction mutant]	0.0	3	1	1	1
110326	1710	b /rel subunit	[B /Rel subunits]	0.0	3	2	2	1
110327	1710	glucocorticoid drug	[glucocorticoid drugs]	0.0	2	1	1	1
110328	1710	quantitation of beta	[Quantitation of beta]	0.0	3	1	1	1
110329	1710	Chignard, M.	[Chignard, M.]	0.0	2	1	1	1
110330	1710	myeloid cell granulocyte pmn	[myeloid cells granulocytes PMN]	0.0	4	1	1	1
110331	1710	receptor in myeloid cell	[receptors in myeloid cells]	0.0	4	1	1	1
110332	1710	transient upregulation of a carboxylesterase	[transient upregulation of a carboxylesterase]	0.0	5	1	1	1
110333	1710	trifluoromethylketone inhibitor	[trifluoromethylketone inhibitors]	0.0	2	1	1	1
110334	1710	gene expression in glial cell	[gene expression in glial cells]	0.0	5	1	1	1
110335	1710	cell cycle s	[cell cycle S]	0.0	3	1	1	1
110336	1710	Effect of ara-c on sphingomyelinase	[Effects of Ara-C on sphingomyelinase]	0.0	5	1	1	1
110337	1710	(19 nlphd	[(19 NLPHD]	0.0	2	1	1	1
110338	1710	analysis in HUVECs	[analysis in HUVECs]	0.0	3	1	1	1
110339	1710	other hyperplasias	[other hyperplasias]	0.0	2	1	1	1
110340	1710	i.e.,	[i.e.,]	0.0	1	1	1	1
110341	1710	target binding	[target binding]	0.0	2	1	1	1
110342	1710	factor-kappa B/Rel induction	[factor-kappa B/Rel induction]	0.0	3	1	1	1
110343	1710	antibody to Fos protein	[antibodies to Fos proteins]	0.0	4	1	1	1
110344	1710	possible clinical relevance	[possible clinical relevance]	0.0	3	1	1	1
110345	1710	4-fold increase a increase	[4-fold increase an increase]	0.0	4	1	1	1
110346	1710	eosinophil-activating factor	[eosinophil-activating factor]	0.0	2	1	1	1
110347	1710	85 kda	[85 kDa]	0.0	2	1	1	1
110348	1710	activation of ebv	[activation of EBV]	0.0	3	1	1	1
110349	1710	addition, N-acetyl-L-cysteine a potent antioxidant,	[addition, N-acetyl-L-cysteine a potent antioxidant,]	0.0	5	1	1	1
110350	1710	-specific protein	[-specific protein]	0.0	2	1	1	1
110351	1710	hiv tat protein	[HIV Tat protein]	0.0	3	1	1	1
110352	1710	resistance to disease	[resistance to diseases]	0.0	3	1	1	1
110353	1710	gata site at -59/-54,	[GATA site at -59/-54,]	0.0	4	1	1	1
110354	1710	2.5 microg/g tissue	[2.5 microg/g tissue]	0.0	3	1	1	1
110355	1710	loop,	[loop,]	0.0	1	1	1	1
110356	1710	Oct-2 tester strain	[Oct-2 tester strain]	0.0	3	2	2	1
110357	1710	region of all gene	[regions of all genes]	0.0	4	1	1	1
110358	1710	normal cell type	[normal cell types]	0.0	3	1	1	1
110359	1710	lymphoid-enhancer binding	[lymphoid-enhancer binding]	0.0	2	1	1	1
110360	1710	t(17;19) leukemia chimera	[t(17;19) leukemia chimera]	0.0	3	1	1	1
110361	1710	herpesvirus hhv-6 strain gs	[herpesvirus HHV-6 strains GS]	0.0	4	1	1	1
110362	1710	h from undetectable basal level	[h from undetectable basal levels]	0.0	5	1	1	1
110363	1710	expression of the ebv receptor	[expression of the EBV receptor]	0.0	5	1	1	1
110364	1710	serum as a source of antibody	[serum as a source of antibodies]	0.0	6	1	1	1
110365	1710	detectable e1a sequence	[detectable E1a sequences]	0.0	3	1	1	1
110366	1710	0.7 kb	[0.7 kb]	0.0	2	1	1	1
110367	1710	high efficacy in treatment	[high efficacy in treatment]	0.0	4	1	1	1
110368	1710	pregnant woman (11	[pregnant women (11]	0.0	3	1	1	1
110369	1710	yeast sterol isomerase	[yeast sterol isomerase]	0.0	3	1	1	1
110370	1710	translocation,	[translocation,]	0.0	1	1	1	1
110371	1710	aberrancy in transcriptional protein	[aberrancies in transcriptional proteins]	0.0	4	1	1	1
110372	1710	fas ligand interaction	[Fas ligand interaction]	0.0	3	1	1	1
110373	1710	growth-factor-dependent myeloid cell line	[growth-factor-dependent myeloid cell line]	0.0	4	1	1	1
110374	1710	Thrombopoietin the physiological regulator	[Thrombopoietin the physiological regulator]	0.0	4	1	1	1
110375	1710	recent datum	[recent data]	0.0	2	1	1	1
110376	1710	anti-igm-induced B-cell apoptosis	[anti-IgM-induced B-cell apoptosis]	0.0	3	1	1	1
110377	1710	progenitor cell differentiation	[progenitor cell differentiation]	0.0	3	1	1	1
110378	1710	discordant expression of a mutation	[discordant expression of a mutation]	0.0	5	1	1	1
110379	1710	n-formyl-methionyl-leucyl-phenylalanine cytokine granulocyte/macrophage colony-stimulating factor	[N-formyl-methionyl-leucyl-phenylalanine cytokines granulocyte/macrophage colony-stimulating factor]	0.0	5	1	1	1
110380	1710	unidentified proximal position	[unidentified proximal position]	0.0	3	1	1	1
110381	1710	-hla	[-HLA]	0.0	1	1	1	1
110382	1710	nfil3	[Nfil3]	0.0	1	1	1	1
110383	1710	affinity nm	[affinity nM]	0.0	2	1	1	1
110384	1710	difference in the phosphorylation	[differences in the phosphorylation]	0.0	4	1	1	1
110385	1710	HMG box	[HMG box]	0.0	2	1	1	1
110386	1710	(6 wk to mo) RA	[(6 wk to mo) RA]	0.0	5	1	1	1
110387	1710	csf-1r antibody	[CSF-1R antibodies]	0.0	2	1	1	1
110388	1710	target of this regulation	[target of this regulation]	0.0	4	1	1	1
110389	1710	173% increase in camp	[173% increase in cAMP]	0.0	4	1	1	1
110390	1710	synergistic effect of stress	[Synergistic effects of stress]	0.0	4	1	1	1
110391	1710	h in quiescent cell	[h in quiescent cells]	0.0	4	1	1	1
110392	1710	T-helper th0 2 subset	[T-helper Th0 2 subset]	0.0	4	1	1	1
110393	1710	even striking downregulation	[even striking downregulation]	0.0	3	1	1	1
110394	1710	affinity purification	[affinity purification]	0.0	2	2	2	1
110395	1710	presence il-4	[presence IL-4]	0.0	2	1	1	1
110396	1710	infection of human intestine	[infection of human intestine]	0.0	4	1	1	1
110397	1710	leucocyte recruitment	[leucocyte recruitment]	0.0	2	1	1	1
110398	1710	sublethal level	[sublethal levels]	0.0	2	1	1	1
110399	1710	sample of all FAB type	[samples of all FAB types]	0.0	5	1	1	1
110400	1710	element in the p2 promoter	[element in the P2 promoter]	0.0	5	1	1	1
110401	1710	limited requirement for il-2	[limited requirement for IL-2]	0.0	4	1	1	1
110402	1710	DNA from patient	[DNA from patients]	0.0	3	1	1	1
110403	1710	first limitation to antiviral effect	[first limitation to antiviral effects]	0.0	5	1	1	1
110404	1710	groups, 17 sr	[groups, 17 SR]	0.0	3	1	1	1
110405	1710	interruption of a locus	[interruption of a locus]	0.0	4	1	1	1
110406	1710	(99+/-15	[(99+/-15]	0.0	1	1	1	1
110407	1710	HLA-DMA	[HLA-DMA]	0.0	1	1	1	1
110408	1710	significantly (p<.001) in untreated patient	[significantly (P<.001) in untreated patients]	0.0	5	1	1	1
110409	1710	acute ccl4	[acute CCl4]	0.0	2	1	1	1
110410	1710	mitogen T	[mitogen T]	0.0	2	1	1	1
110411	1710	contrast to human lymphocyte	[contrast to human lymphocytes]	0.0	4	1	1	1
110412	1710	encode a transcriptional regulator	[encoding a transcriptional regulator]	0.0	4	1	1	1
110413	1710	increase in factor kappab	[increase in factor kappaB]	0.0	4	1	1	1
110414	1710	promoter by octamer-binding transcription factor	[promoters by octamer-binding transcription factors]	0.0	5	1	1	1
110415	1710	human h(+)-atpase	[human H(+)-ATPase]	0.0	2	1	1	1
110416	1710	stress-activated protein kinase/c-Jun kinase	[stress-activated protein kinase/c-Jun kinases]	0.0	4	1	1	1
110417	1710	specific uptake of 135(oh)2d3	[specific uptake of 1,25(OH)2D3]	0.0	4	1	1	1
110418	1710	ifngr1 frameshift small deletion	[IFNGR1 frameshift small deletions]	0.0	4	1	1	1
110419	1710	suppression of proliferation	[suppression of proliferation]	0.0	3	1	1	1
110420	1710	methyl prednisolone 120	[methyl prednisolone 120]	0.0	3	1	1	1
110421	1710	active form of calcineurin substitute	[active form of calcineurin substitutes]	0.0	5	1	1	1
110422	1710	reporter chloramphenicol acetyltransferase plasmid	[reporter chloramphenicol acetyltransferase plasmids]	0.0	4	1	1	1
110423	1710	lymphoma model	[lymphoma model]	0.0	2	1	1	1
110424	1710	Ets transcription factor	[Ets transcription factor]	0.0	3	1	1	1
110425	1710	E2F activation	[E2F activation]	0.0	2	1	1	1
110426	1710	blood lymphocyte PBL from young human	[blood lymphocytes PBL from young humans]	0.0	6	1	1	1
110427	1710	main feature	[main feature]	0.0	2	1	1	1
110428	1710	mbcl6	[mBCL6]	0.0	1	1	1	1
110429	1710	modulator (1-231)-mediated	[modulator (1-231)-mediated]	0.0	2	1	1	1
110430	1710	motifs, site alpha	[motifs, site alpha]	0.0	3	1	1	1
110431	1710	ubiquitous transcription factor nf-y	[ubiquitous transcription factor NF-Y]	0.0	4	1	1	1
110432	1710	IL-2 apoptosis	[IL-2 apoptosis]	0.0	2	1	1	1
110433	1710	tonsillar gc b cell	[tonsillar GC B cells]	0.0	4	1	1	1
110434	1710	rodent thermosensitive mutant cell	[rodent thermosensitive mutant cells]	0.0	4	1	1	1
110435	1710	phosphatidylethanolamine at concentration range	[phosphatidylethanolamine at concentrations ranging]	0.0	4	1	1	1
110436	1710	underlie the development	[underlying the development]	0.0	3	1	1	1
110437	1710	consequence follow such alteration	[consequences following such alterations]	0.0	4	1	1	1
110438	1710	antigenic response toward immunity	[antigenic response toward immunity]	0.0	4	1	1	1
110439	1710	0.95 kb id-3 transcript	[0.95 kb Id-3 transcript]	0.0	4	1	1	1
110440	1710	EBNA2 specific antibody	[EBNA2 specific antibodies]	0.0	3	1	1	1
110441	1710	e2f-1 binding protein	[E2F-1 binding protein]	0.0	3	1	1	1
110442	1710	alpha-like globin gene	[alpha-like globin genes]	0.0	3	1	1	1
110443	1710	HLA-DR3	[HLA-DR3]	0.0	1	1	1	1
110444	1710	mediator include hemodynamic instability	[mediators including hemodynamic instability]	0.0	4	1	1	1
110445	1710	anti- ap-1 activity in cell	[anti- AP-1 activity in cells]	0.0	5	1	1	1
110446	1710	kinase-specific phosphatase	[kinase-specific phosphatase]	0.0	2	1	1	1
110447	1710	PML alpha expression in normal cell	[PML alpha expression in normal cells]	0.0	6	1	1	1
110448	1710	cv3988	[CV3988]	0.0	1	1	1	1
110449	1710	loss of proliferative potential	[loss of proliferative potential]	0.0	4	1	1	1
110450	1710	affinity (Kd) in 15 term	[affinity (Kd) in 15 term]	0.0	5	1	1	1
110451	1710	distal interleukin (il-2) enhancer	[distal interleukin (IL-2) enhancer]	0.0	4	1	1	1
110452	1710	influence nf-at	[influencing NF-AT]	0.0	2	1	1	1
110453	1710	histiocytoma rhabdomyosarcoma	[histiocytoma rhabdomyosarcoma]	0.0	2	1	1	1
110454	1710	-sized artery	[-sized arteries]	0.0	2	1	1	1
110455	1710	aggregate formation	[aggregate formation]	0.0	2	1	1	1
110456	1710	element ionophore	[element ionophore]	0.0	2	1	1	1
110457	1710	number of glucocorticoid receptor gcr	[number of glucocorticoid receptors GCR]	0.0	5	1	1	1
110458	1710	Nuclear b activity	[Nuclear B activity]	0.0	3	1	1	1
110459	1710	important inhibitor of inflammation	[important inhibitor of inflammation]	0.0	4	1	1	1
110460	1710	adhesion of monocyte to p-selectin	[Adhesion of monocytes to P-selectin]	0.0	5	1	1	1
110461	1710	amount of the cytokine	[amounts of the cytokines]	0.0	4	1	1	1
110462	1710	characteristic chronic (auto)immune inflammation	[characteristic chronic (auto)immune inflammation]	0.0	4	1	1	1
110463	1710	only at residue 57	[only at residue 57]	0.0	4	1	1	1
110464	1710	saturation	[saturation]	0.0	1	1	1	1
110465	1710	role of receptor/ characteristic	[role of receptor/s characteristics]	0.0	4	1	1	1
110466	1710	isolate belong	[isolates belonging]	0.0	2	1	1	1
110467	1710	human gene hbd	[human gene HBD]	0.0	3	1	1	1
110468	1710	P. falciparum	[P. falciparum]	0.0	2	1	1	1
110469	1710	element modulator CREM	[element modulator CREM]	0.0	3	1	1	1
110470	1710	activity in T cell line	[activity in T cell lines]	0.0	5	1	1	1
110471	1710	special focus	[special focus]	0.0	2	1	1	1
110472	1710	number of glucocorticoid receptor gcR	[number of glucocorticoid receptors gcR]	0.0	5	1	1	1
110473	1710	calcium ca2+ ionophore	[calcium Ca2+ ionophore]	0.0	3	1	1	1
110474	1710	occasionally in mantle cell lymphoma	[occasionally in mantle cell lymphoma]	0.0	5	1	1	1
110475	1710	molecular study on population	[molecular studies on populations]	0.0	4	1	1	1
110476	1710	mutant NFAT delta418	[mutant NFAT delta418]	0.0	3	1	1	1
110477	1710	ap1 transcriptional complex in monocyte	[AP1 transcriptional complex in monocytes]	0.0	5	1	1	1
110478	1710	time point,	[time point,]	0.0	2	1	1	1
110479	1710	prototype stress hormone	[prototype stress hormones]	0.0	3	1	1	1
110480	1710	epithelial tumor ag	[epithelial tumor Ag]	0.0	3	1	1	1
110481	1710	role protect injury	[role protecting injury]	0.0	3	1	1	1
110482	1710	various species include lymphoid cell	[various species including lymphoid cells]	0.0	5	1	1	1
110483	1710	colony-stimulating factor m-csf	[colony-stimulating factor M-CSF]	0.0	3	1	1	1
110484	1710	(mhc) haplotype	[(MHC) haplotypes]	0.0	2	1	1	1
110485	1710	specific inhibitor of serine/threonine phosphatase	[specific inhibitors of serine/threonine phosphatases]	0.0	5	1	1	1
110486	1710	temperature (26 degree c)	[temperature (26 degrees C)]	0.0	4	1	1	1
110487	1710	just like counterpart.	[just like counterpart.]	0.0	3	1	1	1
110488	1710	identical proteins, differ in degree	[identical proteins, differing in degree]	0.0	5	1	1	1
110489	1710	extend from -392	[extending from -392]	0.0	3	1	1	1
110490	1710	control of NF-kappa b	[control of NF-kappa B]	0.0	4	1	1	1
110491	1710	sub.	[Sub.]	0.0	1	1	1	1
110492	1710	(dys)regulation	[(dys)regulation]	0.0	1	1	1	1
110493	1710	other b -binding element	[other B -binding elements]	0.0	4	1	1	1
110494	1710	membrane-proximal proline-rich sequence motif	[membrane-proximal proline-rich sequence motif]	0.0	4	1	1	1
110495	1710	Indeed, transfection	[Indeed, transfection]	0.0	2	1	1	1
110496	1710	hypertension mr -status	[hypertension MR -status]	0.0	3	1	1	1
110497	1710	molecular mechanism for complex effect	[molecular mechanism for complex effects]	0.0	5	1	1	1
110498	1710	contrast, three cell line	[contrast, three cell lines]	0.0	4	1	1	1
110499	1710	phyto- hemagglutinin	[phyto- hemagglutinin]	0.0	2	1	1	1
110500	1710	IL-6 prb	[IL-6 pRB]	0.0	2	1	1	1
110501	1710	affinity to glucocorticoid AIDS-GR	[affinity to glucocorticoids AIDS-GR]	0.0	4	1	1	1
110502	1710	clone from the germinal centre	[clones from the germinal centre]	0.0	5	1	1	1
110503	1710	transcription of several gene include IL-2	[transcription of several genes including IL-2]	0.0	6	1	1	1
110504	1710	insight into the rate	[insights into the rate]	0.0	4	1	1	1
110505	1710	increase in il-2 transcription	[increase in IL-2 transcription]	0.0	4	1	1	1
110506	1710	ifn-gamma to human eosinophil	[IFN-gamma to human eosinophils]	0.0	4	1	1	1
110507	1710	yeast polypeptide	[yeast polypeptides]	0.0	2	1	1	1
110508	1710	10 micromol/L) dose-dependently	[10 micromol/L) dose-dependently]	0.0	3	1	1	1
110509	1710	rapid up-regulation	[rapid up-regulation]	0.0	2	1	1	1
110510	1710	streptoavidin	[streptoavidin]	0.0	1	1	1	1
110511	1710	receptor l753f	[receptors L753F]	0.0	2	1	1	1
110512	1710	analysis with antibody	[analysis with antibodies]	0.0	3	1	1	1
110513	1710	b cell in vitro	[B cells in vitro]	0.0	4	1	1	1
110514	1710	distinct interference	[distinct interference]	0.0	2	1	1	1
110515	1710	signal due to anti-ig stimulation	[Signaling due to anti-Ig stimulation]	0.0	5	1	1	1
110516	1710	tat single-chain antibody	[Tat single-chain antibody]	0.0	3	1	1	1
110517	1710	identical deletions.	[identical deletions.]	0.0	2	1	1	1
110518	1710	NFKB family member	[NFKB family members]	0.0	3	1	1	1
110519	1710	native envelope glycoprotein of hiv-1	[native envelope glycoproteins of HIV-1]	0.0	5	1	1	1
110520	1710	introduce a splice site	[introducing a splice site]	0.0	4	1	1	1
110521	1710	negative effector on activity	[negative effector on activity]	0.0	4	1	1	1
110522	1710	CD40 ligation on mm	[CD40 ligation on MM]	0.0	4	1	1	1
110523	1710	stat3 signal transducer	[STAT3 signal transducer]	0.0	3	1	1	1
110524	1710	consist of p50 nfkappab1	[consisting of p50 NFkappaB1]	0.0	4	1	1	1
110525	1710	marker of other, polymorphism	[marker(s) of other, polymorphisms]	0.0	4	1	1	1
110526	1710	centre b	[centre B]	0.0	2	1	1	1
110527	1710	thereby allow translocation of NF-kappa b	[thereby allowing translocation of NF-kappa B]	0.0	6	1	1	1
110528	1710	mediate adhesion during inflammation	[mediating adhesion during inflammation]	0.0	4	1	1	1
110529	1710	Akv MLV	[Akv MLV]	0.0	2	1	1	1
110530	1710	m-csf gene in primary syndrome	[M-CSF genes in primary syndromes]	0.0	5	1	1	1
110531	1710	il-4 signaling,	[IL-4 signaling,]	0.0	2	1	1	1
110532	1710	binding of tax	[Binding of Tax]	0.0	3	1	1	1
110533	1710	contribution of herpes simplex virus type	[contribution of herpes simplex virus type]	0.0	6	1	1	1
110534	1710	Specific translocation	[Specific translocation]	0.0	2	2	2	1
110535	1710	pseudo-hypoaldosteronism follow resection of the ileum	[pseudo-hypoaldosteronism following resection of the ileum]	0.0	6	1	1	1
110536	1710	variety of cell lineage	[variety of cell lineages]	0.0	4	1	1	1
110537	1710	molecular study on heterogeneous population	[molecular studies on heterogeneous populations]	0.0	5	1	1	1
110538	1710	[differential value of D3 determination	[[Differential value of D3 determination]	0.0	5	1	1	1
110539	1710	encode interleukin-2 IL2 a cytokine	[encoding interleukin-2 IL2 a cytokine]	0.0	5	1	1	1
110540	1710	unusual transcription element	[unusual transcription element]	0.0	3	1	1	1
110541	1710	variant translocation of t(3;14) (q27;q32)	[variant translocation of t(3;14) (q27;q32)]	0.0	5	1	1	1
110542	1710	progeny virus	[progeny virus]	0.0	2	1	1	1
110543	1710	several b gene	[several B genes]	0.0	3	1	1	1
110544	1710	three day establish pbmc culture (1.5	[Three days establishing PBMC cultures (1.5]	0.0	6	1	1	1
110545	1710	thalassemia patient with HbF production	[thalassemia patient with HbF production]	0.0	5	1	1	1
110546	1710	dermal microvessel cell hdmec	[dermal microvessel cells HDMEC]	0.0	4	1	1	1
110547	1710	effect on this two apoptotic signal	[effects on these two apoptotic signals]	0.0	6	1	1	1
110548	1710	response to the protein BZLF1	[responses to the proteins BZLF1]	0.0	5	1	1	1
110549	1710	J Immunol Jul	[J Immunol Jul]	0.0	3	1	1	1
110550	1710	63% nucleotide identity	[63% nucleotide identity]	0.0	3	1	1	1
110551	1710	g-csf dead cell at day 6;	[G-CSF dead cells at day 6;]	0.0	6	1	1	1
110552	1710	fivefold decrease in growth	[fivefold decrease in growth]	0.0	4	1	1	1
110553	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation]	0.0	4	1	1	1
110554	1710	rabbit uterine	[rabbit uterine]	0.0	2	1	1	1
110555	1710	mediate cell death	[mediating cell death]	0.0	3	1	1	1
110556	1710	ebv disease pathogenesis	[EBV disease pathogenesis]	0.0	3	1	1	1
110557	1710	transient cotransfection in sense orientation	[Transient cotransfection in sense orientation]	0.0	5	1	1	1
110558	1710	NF-ATc.alpha mrna	[NF-ATc.alpha mRNA]	0.0	2	1	1	1
110559	1710	GATA-1 gene virtually silent	[GATA-1 gene virtually silent]	0.0	4	1	1	1
110560	1710	protein of the cascade	[proteins of the cascade]	0.0	4	1	1	1
110561	1710	major disease	[major diseases]	0.0	2	1	1	1
110562	1710	METHODS: during a crossover study	[METHODS: During a crossover study]	0.0	5	1	1	1
110563	1710	histocompatibility class ii gene expression	[histocompatibility class II gene expression]	0.0	5	1	1	1
110564	1710	therapy as specific	[therapy as specific]	0.0	3	1	1	1
110565	1710	MHC class molecule in cell	[MHC class molecules in cells]	0.0	5	1	1	1
110566	1710	subsequent cloning	[Subsequent cloning]	0.0	2	1	1	1
110567	1710	gene in neutrophil	[genes in neutrophils]	0.0	3	1	1	1
110568	1710	various enzyme inhibitor	[various enzyme inhibitors]	0.0	3	1	1	1
110569	1710	bcl-6 in B-cell development	[BCL-6 in B-cell development]	0.0	4	1	1	1
110570	1710	cascade within the few minute	[cascade within the few minutes]	0.0	5	1	1	1
110571	1710	ovulation woman	[ovulation women]	0.0	2	1	1	1
110572	1710	mechanistic consequence follow alteration	[mechanistic consequences following alterations]	0.0	4	1	1	1
110573	1710	dopamine responsiveness	[dopamine responsiveness]	0.0	2	1	1	1
110574	1710	turnover rate	[turnover rate]	0.0	2	1	1	1
110575	1710	il-1 receptor nf-kappab	[IL-1 receptor NF-kappaB]	0.0	3	1	1	1
110576	1710	polymorphism within the VDR 3'-utr	[polymorphisms within the VDR 3'-UTR]	0.0	5	1	1	1
110577	1710	peptide length	[peptide lengths]	0.0	2	1	1	1
110578	1710	persistent accumulation	[persistent accumulation]	0.0	2	2	2	1
110579	1710	keep property through the immortalization	[keeping properties through the immortalization]	0.0	5	1	1	1
110580	1710	killer (nk) cell activity	[killer (NK) cell activity]	0.0	4	3	3	1
110581	1710	exposure to shear dyn/cm2)	[exposure to shear dyn/cm2)]	0.0	4	1	1	1
110582	1710	two splice product	[two splice products]	0.0	3	1	1	1
110583	1710	lipocalin from human	[lipocalin from humans]	0.0	3	1	1	1
110584	1710	furthermore, activation-dependent tyrosine phosphorylation	[Furthermore, activation-dependent tyrosine phosphorylation]	0.0	4	1	1	1
110585	1710	expression in leukocyte	[expression in leukocytes]	0.0	3	1	1	1
110586	1710	include anti- zebra activity	[including anti- ZEBRA activity]	0.0	4	1	1	1
110587	1710	adjacent site at position -50	[adjacent sites at positions -50]	0.0	5	1	1	1
110588	1710	role of polyamine	[role of polyamines]	0.0	3	1	1	1
110589	1710	methov of vein cell	[METHODS of vein cells]	0.0	4	1	1	1
110590	1710	expression of a rapamycin mutant	[Expression of a rapamycin mutant]	0.0	5	1	1	1
110591	1710	nf-kappab activation of hiv-1 terminal repeat	[NF-kappaB activation of HIV-1 terminal repeat]	0.0	6	1	1	1
110592	1710	Ag may,	[Ag may,]	0.0	2	1	1	1
110593	1710	normal human keratinocyte	[normal human keratinocytes]	0.0	3	1	1	1
110594	1710	female steroid hormone estrogen	[female steroid hormones estrogen]	0.0	4	1	1	1
110595	1710	encompass nucleotide	[encompassing nucleotides]	0.0	2	1	1	1
110596	1710	requirement for binding,	[requirements for binding,]	0.0	3	1	1	1
110597	1710	trend toward staining	[trend toward staining]	0.0	3	1	1	1
110598	1710	adherent cell with long neurite process	[adherent cells with long neurite processes]	0.0	6	1	1	1
110599	1710	potent activity of tgf-beta	[potent activity of TGF-beta]	0.0	4	1	1	1
110600	1710	differentiation-dependent mechanism	[differentiation-dependent mechanisms]	0.0	2	1	1	1
110601	1710	spite of this signalling,	[spite of this signalling,]	0.0	4	1	1	1
110602	1710	number of nitroblue tetrazolium cell	[number of nitroblue tetrazolium cells]	0.0	5	1	1	1
110603	1710	look.	[look.]	0.0	1	1	1	1
110604	1710	cell type-specific tfiid subunit related	[cell type-specific TFIID subunit related]	0.0	5	1	1	1
110605	1710	contrast, in Th1 clone	[contrast, in Th1 clones]	0.0	4	1	1	1
110606	1710	excellent paradigm	[excellent paradigm]	0.0	2	1	1	1
110607	1710	widespread extinction of cell-encoded gene	[widespread extinction of cell-encoded genes]	0.0	5	1	1	1
110608	1710	use the PL/IM antibody	[using the PL/IM antibody]	0.0	4	1	1	1
110609	1710	pattern of signal for chemoattract	[patterns of signaling for chemoattractants]	0.0	5	1	1	1
110610	1710	unique, high potency	[unique, high potency]	0.0	3	1	1	1
110611	1710	priming of monocyte	[Priming of monocytes]	0.0	3	1	1	1
110612	1710	step-wise increase exercise to maximal	[step-wise increasing exercise to maximal]	0.0	5	1	1	1
110613	1710	potential bzlf	[potential BZLF]	0.0	2	1	1	1
110614	1710	activation gene expression	[activation gene expression]	0.0	3	1	1	1
110615	1710	range of effect related	[range of effects related]	0.0	4	1	1	1
110616	1710	biogenesis of organ	[biogenesis of organs]	0.0	3	1	1	1
110617	1710	antioxidant n-acetyl-l-cysteine	[antioxidant N-acetyl-L-cysteine]	0.0	2	1	1	1
110618	1710	binding two monoclonal antibody specific	[binding two monoclonal antibodies specific]	0.0	5	1	1	1
110619	1710	nitrogen release	[nitrogen release]	0.0	2	1	1	1
110620	1710	tyrosine phosphorylation of 92-kda protein	[tyrosine phosphorylation of 92-kDa protein]	0.0	5	1	1	1
110621	1710	tool for monitoring of disease	[tools for monitoring of disease]	0.0	5	1	1	1
110622	1710	immunotherapeutic target	[immunotherapeutic targets]	0.0	2	1	1	1
110623	1710	lack of full activation	[Lack of full activation]	0.0	4	1	1	1
110624	1710	EB1 -binding site	[EB1 -binding site]	0.0	3	1	1	1
110625	1710	hexasaccharide	[hexasaccharide]	0.0	1	1	1	1
110626	1710	activation of creb /atf	[activation of CREB /ATF]	0.0	4	1	1	1
110627	1710	hiv plasmid	[HIV plasmid]	0.0	2	1	1	1
110628	1710	model of leukemic cell line	[models of leukemic cell lines]	0.0	5	1	1	1
110629	1710	non-permissive chromatin structure	[non-permissive chromatin structure]	0.0	3	1	1	1
110630	1710	trigger necrosis factor-alpha in cell	[Triggering necrosis factor-alpha in cells]	0.0	5	1	1	1
110631	1710	tre dr+2	[TRE DR+2]	0.0	2	1	1	1
110632	1710	camp activity	[cAMP activity]	0.0	2	1	1	1
110633	1710	also (p 0.025) low	[also (P 0.025) lower]	0.0	4	1	1	1
110634	1710	large trial	[large trial]	0.0	2	1	1	1
110635	1710	protein in development	[proteins in development]	0.0	3	1	1	1
110636	1710	follow bilateral adrenalectomy	[following bilateral adrenalectomy]	0.0	3	1	1	1
110637	1710	early event in maturation	[early events in maturation]	0.0	4	1	1	1
110638	1710	sequence within the repetitive stretch	[sequence within the repetitive stretch]	0.0	5	1	1	1
110639	1710	Kinetic study	[Kinetic studies]	0.0	2	1	1	1
110640	1710	induction between 1	[induction between 1]	0.0	3	1	1	1
110641	1710	only in a context of protein	[only in a context of proteins]	0.0	6	1	1	1
110642	1710	affect the metabolism	[affecting the metabolism]	0.0	3	1	1	1
110643	1710	provide evidence for the presence	[providing evidence for the presence]	0.0	5	1	1	1
110644	1710	ets-1, pu.1	[Ets-1, PU.1]	0.0	2	1	1	1
110645	1710	sequence-binding	[sequence-binding]	0.0	1	2	2	1
110646	1710	c-erbA in erythropoiesis	[c-erbA in erythropoiesis]	0.0	3	1	1	1
110647	1710	caenorhabditis elegan cell	[Caenorhabditis elegans cell]	0.0	3	1	1	1
110648	1710	receive glucocorticoid therapy	[receiving glucocorticoid therapy]	0.0	3	1	1	1
110649	1710	49 case of chronic lymphocytic leukemia	[49 cases of chronic lymphocytic leukemia]	0.0	6	1	1	1
110650	1710	tfiiib molecule	[TFIIIB molecules]	0.0	2	1	1	1
110651	1710	Circadian rhythm of receptor	[Circadian rhythm of receptors]	0.0	4	1	1	1
110652	1710	genomic organisation exon 112	[genomic organisation exons 112]	0.0	4	1	1	1
110653	1710	receptor concentration in leukocyte MNL	[receptor concentrations in leukocytes MNL]	0.0	5	1	1	1
110654	1710	immature b-cell line	[immature B-cell line]	0.0	3	1	1	1
110655	1710	transfection system	[transfection system]	0.0	2	1	1	1
110656	1710	ikb alpha	[IkB alpha]	0.0	2	1	1	1
110657	1710	elucidation of il-5 -specific mechanism	[Elucidation of IL-5 -specific mechanisms]	0.0	5	1	1	1
110658	1710	interrupt locus	[interrupting locus]	0.0	2	1	1	1
110659	1710	supt	[SupT]	0.0	1	1	1	1
110660	1710	patient vs. the period	[patients vs. the period]	0.0	4	1	1	1
110661	1710	factor establish mnda expression	[factors establishing MNDA expression]	0.0	4	1	1	1
110662	1710	-ii;	[-II;]	0.0	1	1	1	1
110663	1710	induce promoter-dependent reporter construct	[inducing promoter-dependent reporter constructs]	0.0	4	1	1	1
110664	1710	number in phase eutopic endometrium	[numbers in phase eutopic endometrium]	0.0	5	1	1	1
110665	1710	reliable indicator of ca2+ load	[reliable indicators of Ca2+ load]	0.0	5	1	1	1
110666	1710	mrna use a nonradioactive assay	[mRNA using a nonradioactive assay]	0.0	5	1	1	1
110667	1710	evidence at proximal element p0	[Evidence at proximal element P0]	0.0	5	1	1	1
110668	1710	cushingd' syndrome type	[Cushing's syndrome Type]	0.0	3	1	1	1
110669	1710	CEM c7 cell	[CEM C7 cells]	0.0	3	1	1	1
110670	1710	activity of ap-1/tpa responsive element	[activity of AP-1/TPA responsive elements]	0.0	5	1	1	1
110671	1710	frequency of cd16 cell	[frequency of CD16 cells]	0.0	4	1	1	1
110672	1710	Bfl-1	[Bfl-1]	0.0	1	1	1	1
110673	1710	positive cell line Jijoye	[positive cell line Jijoye]	0.0	4	1	1	1
110674	1710	deletion of T cell	[deletion of T cells]	0.0	4	1	1	1
110675	1710	amino-terminal dna-binding domain	[amino-terminal DNA-binding domain]	0.0	3	1	1	1
110676	1710	ige (p	[IgE (p]	0.0	2	1	1	1
110677	1710	500-bp human il-5 gene segment	[500-bp human IL-5 gene segment]	0.0	5	1	1	1
110678	1710	[3h] dexamethasone binding	[[3H] dexamethasone binding]	0.0	3	1	1	1
110679	1710	unexpected variability in the expression	[unexpected variability in the expression]	0.0	5	1	1	1
110680	1710	contain sequence from glucocorticoid gene	[containing sequences from glucocorticoid genes]	0.0	5	1	1	1
110681	1710	steroid therapy	[steroid therapy]	0.0	2	1	1	1
110682	1710	inhibition by a alkaloid in cell	[inhibition by an alkaloid in cells]	0.0	6	1	1	1
110683	1710	expression of interferon factor gene	[expression of interferon factor gene]	0.0	5	1	1	1
110684	1710	keratoconjunctivitis vkc a allergic disease	[keratoconjunctivitis VKC an allergic disease.]	0.0	5	1	1	1
110685	1710	regulator of erythroid cell development	[regulators of erythroid cell development]	0.0	5	1	1	1
110686	1710	embryonic cell	[embryonic cells]	0.0	2	1	1	1
110687	1710	monocyte chemotactic peptide-1	[monocyte chemotactic peptide-1]	0.0	3	1	1	1
110688	1710	IL-2 inducibility	[IL-2 inducibility]	0.0	2	1	1	1
110689	1710	fmol/mg protein).	[fmol/mg protein).]	0.0	2	1	1	1
110690	1710	marker in breast cancer	[marker in breast cancer]	0.0	4	1	1	1
110691	1710	pre-Talpha	[pre-Talpha]	0.0	1	1	1	1
110692	1710	contain gene by the factor	[containing genes by the factor]	0.0	5	1	1	1
110693	1710	upregulation of interleukin colony-stimulating factor receptor	[Upregulation of interleukin colony-stimulating factor receptors]	0.0	6	1	1	1
110694	1710	p 0.01).	[P 0.01).]	0.0	2	1	1	1
110695	1710	creb- factor	[CREB- factors]	0.0	2	1	1	1
110696	1710	exercise on bicycle ergometer) level	[exercise on bicycle ergometer) levels]	0.0	5	1	1	1
110697	1710	allele loss on chromosome 20q	[allele loss on chromosome 20q]	0.0	5	1	1	1
110698	1710	other ets-like factor present	[Other ETS-like factors present]	0.0	4	1	1	1
110699	1710	bipartite retinoic acid response element	[bipartite retinoic acid response element]	0.0	5	1	1	1
110700	1710	would in the absence	[d in the absence]	0.0	4	1	1	1
110701	1710	immunodeficiency virus SIVmac251 in vitro.	[immunodeficiency virus SIVmac251 in vitro.]	0.0	5	1	1	1
110702	1710	constitutive expression of stat binding factor	[constitutive expression of STAT binding factors]	0.0	6	1	1	1
110703	1710	internalization from apical surface.	[internalization from apical surface.]	0.0	4	1	1	1
110704	1710	inhibit vdrnrar- vdre formation	[inhibiting VDR-RXR- VDRE formation]	0.0	4	1	1	1
110705	1710	induce apoptosis in cell	[inducing apoptosis in cells]	0.0	4	1	1	1
110706	1710	anaerobic threshold	[Anaerobic threshold]	0.0	2	1	1	1
110707	1710	defective retroviruse	[defective retroviruses]	0.0	2	1	1	1
110708	1710	pair (bp) fragment	[pair (bp) fragment]	0.0	3	1	1	1
110709	1710	13 patient with inactive sle	[13 patients with inactive SLE]	0.0	5	1	1	1
110710	1710	Novel aldosterone receptor specificity-conferring mechanism	[Novel aldosterone receptors specificity-conferring mechanism]	0.0	5	1	1	1
110711	1710	messenger up-regulation	[messenger up-regulation]	0.0	2	1	1	1
110712	1710	decrease in nf-kappab dna-binding activity	[decrease in NF-kappaB DNA-binding activity]	0.0	5	1	1	1
110713	1710	lymphotoxin-beta receptor	[lymphotoxin-beta receptor]	0.0	2	1	1	1
110714	1710	JAK kinase family	[JAK kinase family]	0.0	3	1	1	1
110715	1710	pge2 bind to receptor	[PGE2 bind to receptors]	0.0	4	1	1	1
110716	1710	m 9-cis RA	[M 9-cis RA]	0.0	3	1	1	1
110717	1710	kda heat shock protein hsp70	[kDa heat shock protein Hsp70]	0.0	5	1	1	1
110718	1710	suggest largely responsible	[suggesting largely responsible]	0.0	3	1	1	1
110719	1710	neutralize il-6 antibody MoAb	[neutralizing IL-6 antibody MoAb]	0.0	4	1	1	1
110720	1710	recognize antigen	[recognizing antigens]	0.0	2	1	1	1
110721	1710	child under term treatment	[children under term treatment]	0.0	4	1	1	1
110722	1710	common gamma-chain	[common gamma-chain]	0.0	2	1	1	1
110723	1710	four patient with micrograms/day	[four patients with micrograms/day]	0.0	4	1	1	1
110724	1710	lineage switch to monocytic lineage	[lineage switching to monocytic lineages]	0.0	5	1	1	1
110725	1710	key determinant of recognition	[key determinant of recognition]	0.0	4	1	1	1
110726	1710	pathway of adhesion molecule	[pathway of adhesion molecules]	0.0	4	1	1	1
110727	1710	constitutive nuclear localization	[constitutive nuclear localization]	0.0	3	3	3	1
110728	1710	317 amino acid	[317 amino acids]	0.0	3	1	1	1
110729	1710	genomic alteration of the locus.	[genomic alteration of the locus.]	0.0	5	1	1	1
110730	1710	retinoblastoma control element	[retinoblastoma control element]	0.0	3	1	1	1
110731	1710	sequence from the start site	[sequences from the start site]	0.0	5	1	1	1
110732	1710	notch-1 on apoptosis	[notch-1 on apoptosis]	0.0	3	1	1	1
110733	1710	specification	[specification]	0.0	1	1	1	1
110734	1710	domain act together	[domains acting together]	0.0	3	1	1	1
110735	1710	detailed understanding of the regulation	[detailed understanding of the regulation]	0.0	5	1	1	1
110736	1710	alteration of the microb site	[alteration of the microB site]	0.0	5	1	1	1
110737	1710	chronic disease (12:	[chronic diseases (12:]	0.0	3	1	1	1
110738	1710	induction of icam-1 role	[induction of ICAM-1 role]	0.0	4	1	1	1
110739	1710	identity with the tfiid protein	[identity with the TFIID protein]	0.0	5	1	1	1
110740	1710	pu.1 transcription	[PU.1 transcription]	0.0	2	1	1	1
110741	1710	ikaros-null thymocyte	[Ikaros-null thymocytes]	0.0	2	1	1	1
110742	1710	OM-10.1 promyelocytic model	[OM-10.1 promyelocytic model]	0.0	3	1	1	1
110743	1710	killer (nk) cell lineage	[killer (NK) cell lineage]	0.0	4	1	1	1
110744	1710	number with alteration in affinity	[numbers with alteration in affinity]	0.0	5	1	1	1
110745	1710	return by min.	[returning by min.]	0.0	3	1	1	1
110746	1710	photic cycle	[photic cycle]	0.0	2	1	1	1
110747	1710	follow direct pkc activation	[following direct PKC activation]	0.0	4	1	1	1
110748	1710	phenotype than the myeloblast	[phenotype than the myeloblasts]	0.0	4	1	1	1
110749	1710	signalsome,	[signalsome,]	0.0	1	1	1	1
110750	1710	enhancer in transient assay	[enhancer in transient assays]	0.0	4	1	1	1
110751	1710	powerful assembly of element	[powerful assemblies of elements]	0.0	4	1	1	1
110752	1710	level t-cell receptor (tcr)-zeta	[levels T-cell receptor (TCR)-zeta]	0.0	4	1	1	1
110753	1710	optimal function	[optimal function]	0.0	2	1	1	1
110754	1710	cox-2 expression	[COX-2 expression]	0.0	2	1	1	1
110755	1710	control value	[control value]	0.0	2	1	1	1
110756	1710	synergy between tal1 in tumorigenesis	[synergy between TAL1 in tumorigenesis]	0.0	5	1	1	1
110757	1710	autofluoresence	[autofluoresence]	0.0	1	1	1	1
110758	1710	presence of a positive-acting element	[presence of a positive-acting element]	0.0	5	1	1	1
110759	1710	array of nf-kappab/ntat ets binding site	[arrays of NF-kappaB/NFAT Ets binding sites]	0.0	6	1	1	1
110760	1710	Furthermore, expression in the absence	[Furthermore, expression in the absence]	0.0	5	1	1	1
110761	1710	lox-1 gene hgmw-approved symbol olr1	[LOX-1 gene HGMW-approved symbol OLR1]	0.0	5	1	1	1
110762	1710	primarily at early stage	[primarily at early stages]	0.0	4	1	1	1
110763	1710	30-fold high	[30-fold higher]	0.0	2	1	1	1
110764	1710	BP1 binding site	[BP1 binding site]	0.0	3	1	1	1
110765	1710	cut edge: dominant effect	[Cutting edge: dominant effect]	0.0	4	1	1	1
110766	1710	level of cytokine gene expression	[levels of cytokine gene expression]	0.0	5	1	1	1
110767	1710	several methods, with pair	[several methods, with pairs]	0.0	4	1	1	1
110768	1710	effectively by steroid	[effectively by steroids]	0.0	3	1	1	1
110769	1710	gld T	[gld T]	0.0	2	1	1	1
110770	1710	c-myc vsmc-myc	[c-myc VSMC-myc]	0.0	2	1	1	1
110771	1710	macrophage tissue factor	[macrophage tissue factor]	0.0	3	1	1	1
110772	1710	activation by interferon-gamma	[activation by interferon-gamma]	0.0	3	1	1	1
110773	1710	tegument protein ie62	[tegument protein IE62]	0.0	3	1	1	1
110774	1710	activity of wild-type protein	[activity of wild-type proteins]	0.0	4	1	1	1
110775	1710	reduction of transcription	[reduction of transcription]	0.0	3	1	1	1
110776	1710	mrna in rest lymphocyte	[mRNA in resting lymphocytes]	0.0	4	1	1	1
110777	1710	cell at levels,	[cells at levels,]	0.0	3	1	1	1
110778	1710	germline brca1 mutation	[germline BRCA1 mutation]	0.0	3	1	1	1
110779	1710	normal constituent in adult blood	[normal constituent in adult blood]	0.0	5	1	1	1
110780	1710	clonal development in myeloproliferative disorder	[clonal development in myeloproliferative disorders]	0.0	5	1	1	1
110781	1710	binding capacity nmax	[binding capacity Nmax]	0.0	3	1	1	1
110782	1710	(6 wk untreated RA	[(6 wk untreated RA]	0.0	4	1	1	1
110783	1710	interleukin Il-2	[Interleukin Il-2]	0.0	2	1	1	1
110784	1710	nuclear export nfat	[nuclear export NFAT]	0.0	3	1	1	1
110785	1710	myeloblast-derived lambda gt11 library	[myeloblast-derived lambda gt11 library]	0.0	4	1	1	1
110786	1710	involvement in il-10 up-regulation in monocyte	[Involvement in IL-10 up-regulation in monocytes]	0.0	6	1	1	1
110787	1710	necessary cofactor	[necessary cofactor]	0.0	2	1	1	1
110788	1710	2000 mu/l pharmacological concentration	[2,000 mU/L pharmacological concentration]	0.0	4	1	1	1
110789	1710	change in acth concentration	[changes in ACTH concentrations]	0.0	4	1	1	1
110790	1710	transcriptional activity of the LTR	[transcriptional activity of the LTR]	0.0	5	1	1	1
110791	1710	overlapping effect	[overlapping effects]	0.0	2	1	1	1
110792	1710	blood lymphocyte PBL of both group	[blood lymphocytes PBL of both groups]	0.0	6	1	1	1
110793	1710	interleukin (il) production	[interleukin (IL) production]	0.0	3	1	1	1
110794	1710	tlr-dependent transcription of nitric oxide synthase	[TLR-dependent transcription of nitric oxide synthase]	0.0	6	1	1	1
110795	1710	CTLA-4 -mediated inhibition	[CTLA-4 -Mediated inhibition]	0.0	3	1	1	1
110796	1710	important molecular site	[important molecular site]	0.0	3	1	1	1
110797	1710	expression of this r-pk promoter	[expression of this R-PK promoter]	0.0	5	1	1	1
110798	1710	tumor-derived product	[Tumor-derived products]	0.0	2	1	1	1
110799	1710	Ca2+ pkc isoform in monocyte	[Ca2+ PKC isoforms in monocytes]	0.0	5	1	1	1
110800	1710	factor of cell	[factor of cells]	0.0	3	1	1	1
110801	1710	elderly (mean	[elderly (mean]	0.0	2	1	1	1
110802	1710	powerful cyto-differentiating effect on leukemia cell	[powerful cyto-differentiating effects on leukemia cells]	0.0	6	1	1	1
110803	1710	communication	[communications]	0.0	1	1	1	1
110804	1710	concentration inhibit ige synthesis (10(-10) mol/L)	[concentrations inhibiting IgE synthesis (10(-10) mol/L)]	0.0	6	1	1	1
110805	1710	expression of leukocyte adhesion molecule	[expression of leukocyte adhesion molecules]	0.0	5	1	1	1
110806	1710	j(2) Wyeth 14643	[J(2) Wyeth 14643]	0.0	3	1	1	1
110807	1710	activate protein-1 tpa element TRE	[Activating protein-1 TPA elements TRE]	0.0	5	1	1	1
110808	1710	biogenesis	[biogenesis]	0.0	1	1	1	1
110809	1710	factor tafii32	[factor TAFII32]	0.0	2	1	1	1
110810	1710	adhesive property via a NF-kappaB mechanism	[adhesive properties via an NF-kappaB mechanism]	0.0	6	1	1	1
110811	1710	human t-cell line 6tg1.1	[human T-cell line 6TG1.1]	0.0	4	1	1	1
110812	1710	generation of 12 unrelated family	[generations of 12 unrelated families]	0.0	5	1	1	1
110813	1710	mouse lack T cell	[mice lacking T cells]	0.0	4	1	1	1
110814	1710	domain of CD40	[domain of CD40]	0.0	3	1	1	1
110815	1710	eight family different form	[eight families: different forms]	0.0	4	1	1	1
110816	1710	monocytoid differentiation	[monocytoid differentiation]	0.0	2	1	1	1
110817	1710	activation-dependent, T transacting factor	[activation-dependent, T transacting factors]	0.0	4	1	1	1
110818	1710	1,25-dihydroxyvitamin D3 (1325(oh)2d3)	[1,25-dihydroxyvitamin D3 (1,25(OH)2D3)]	0.0	3	1	1	1
110819	1710	cytokine in monocytes/macrophages via cd14	[cytokines in monocytes/macrophages via CD14]	0.0	5	1	1	1
110820	1710	F mutant of Syk	[F mutant of Syk]	0.0	4	1	1	1
110821	1710	express different level	[expressing different levels]	0.0	3	1	1	1
110822	1710	correlation to response.	[correlation to response.]	0.0	3	1	1	1
110823	1710	peripheral blood lymphocyte sample	[peripheral blood lymphocyte samples]	0.0	4	1	1	1
110824	1710	domain of CD30	[domain of CD30]	0.0	3	1	1	1
110825	1710	result of ability	[result of abilities]	0.0	3	1	1	1
110826	1710	significant amount costimulation with anti-CD3	[significant amounts costimulation with anti-CD3]	0.0	5	1	1	1
110827	1710	5 of cases, include case	[5 of cases, including case]	0.0	5	1	1	1
110828	1710	activation of e2f	[activation of E2F]	0.0	3	1	1	1
110829	1710	stimulus such as h2o2	[stimuli such as H2O2]	0.0	4	1	1	1
110830	1710	loosely adherent cell	[loosely adherent cells]	0.0	3	1	1	1
110831	1710	various other signal protein	[various other signaling proteins]	0.0	4	1	1	1
110832	1710	first day	[first day]	0.0	2	1	1	1
110833	1710	however, long period	[However, longer periods]	0.0	3	1	1	1
110834	1710	specifically accumulation of the mrna	[specifically accumulation of the mRNA]	0.0	5	1	1	1
110835	1710	age-associated decline in the induction	[age-associated decline in the induction]	0.0	5	1	1	1
110836	1710	function in addition	[function in addition]	0.0	3	1	1	1
110837	1710	regard to potential relevance	[regard to potential relevance]	0.0	4	1	1	1
110838	1710	uncouple in a slP-76-deficient T cell.	[Uncoupling in an SLP-76-deficient T cell.]	0.0	6	1	1	1
110839	1710	spleen lymphocytic cell	[spleen lymphocytic cell]	0.0	3	1	1	1
110840	1710	expression on human melanoma	[expression on human melanomas]	0.0	4	1	1	1
110841	1710	gene expression via receptor binding	[gene expression via receptor binding]	0.0	5	1	1	1
110842	1710	acute leukemia respectively,	[acute leukemia respectively,]	0.0	3	1	1	1
110843	1710	closely related hematopoietic lineage	[closely related hematopoietic lineages]	0.0	4	1	1	1
110844	1710	virus type I gene expression	[virus type I gene expression]	0.0	5	1	1	1
110845	1710	hemopoietic cell in g0	[hemopoietic cells in G0]	0.0	4	1	1	1
110846	1710	structural analysis of the 12 rdna	[structural analysis of the 12 cDNAs]	0.0	6	1	1	1
110847	1710	camp concentration	[cAMP concentrations]	0.0	2	1	1	1
110848	1710	importantly, testing of a set	[Importantly, testing of a set]	0.0	5	1	1	1
110849	1710	phosphatidylinositol 3-kinase activity	[phosphatidylinositol 3-kinase activity]	0.0	3	1	1	1
110850	1710	interleukin promoter activity	[interleukin promoter activity]	0.0	3	1	1	1
110851	1710	use polyclonal tf antibody	[using polyclonal TF antibody]	0.0	4	1	1	1
110852	1710	the/thf alpha thf/thf	[THE/THF alpha THF/THF]	0.0	3	1	1	1
110853	1710	element act of each control expression	[elements acting of each control expression]	0.0	6	1	1	1
110854	1710	more common pharmacogenetic syndrome	[more common pharmacogenetic syndrome]	0.0	4	1	1	1
110855	1710	blot analysis of poly(A) rna	[blot analysis of poly(A) RNA]	0.0	5	1	1	1
110856	1710	statistical evaluation	[statistical evaluation]	0.0	2	1	1	1
110857	1710	follow neutrophil stimulation tumor necrosis factor-alpha	[Following neutrophil stimulation tumor necrosis factor-alpha]	0.0	6	1	1	1
110858	1710	great migration through unstimulated huvec monolayer	[greater migration through unstimulated HUVEC monolayers]	0.0	6	1	1	1
110859	1710	fourth g76:gpltplpv aes1/2	[fourth G76:GPLTPLPV AES1/2]	0.0	3	1	1	1
110860	1710	0.016 microg/ml in PMA u1 cell	[0.016 microg/ml in PMA U1 cells]	0.0	6	1	1	1
110861	1710	protein Bik	[protein Bik]	0.0	2	1	1	1
110862	1710	express LMP1 from a strong promoter	[expressing LMP1 from a strong promoter]	0.0	6	1	1	1
110863	1710	cell type to lipopolysaccharide	[cell types to lipopolysaccharide]	0.0	4	1	1	1
110864	1710	ALY lef-1 -interact protein	[ALY LEF-1 -interacting protein]	0.0	4	1	1	1
110865	1710	tyrosine-phosphorylated docking site	[tyrosine-phosphorylated docking sites]	0.0	3	1	1	1
110866	1710	p85 allele	[p85 alleles]	0.0	2	1	1	1
110867	1710	ifn-gamma -dependent mechanism	[IFN-gamma -dependent mechanism]	0.0	3	1	1	1
110868	1710	complex phenomenon await elucidation.	[complex phenomenon awaiting elucidation.]	0.0	4	1	1	1
110869	1710	tr2 orphan receptor response element	[TR2 orphan receptor response element]	0.0	5	1	1	1
110870	1710	number of colony	[number of colonies]	0.0	3	1	1	1
110871	1710	activity towards hl-60 cell	[activity towards HL-60 cells]	0.0	4	1	1	1
110872	1710	trypsin fragment	[trypsin fragments]	0.0	2	1	1	1
110873	1710	estrogen receptor in peripheral leucocyte	[estrogen receptors in peripheral leucocytes]	0.0	5	1	1	1
110874	1710	form of aml1 AML1a	[form of AML1 AML1a]	0.0	4	1	1	1
110875	1710	good health	[good health]	0.0	2	1	1	1
110876	1710	10-60 mM	[10-60 mM]	0.0	2	1	1	1
110877	1710	major minor transcription start site	[major minor transcription start site]	0.0	5	1	1	1
110878	1710	hog-1 mapk	[HOG-1 MAPk]	0.0	2	1	1	1
110879	1710	vary potential	[varying potential]	0.0	2	1	1	1
110880	1710	regulator in this cell types.	[regulator in these cell types.]	0.0	5	1	1	1
110881	1710	robust Janus kinase jak3 activity	[robust Janus kinase JAK3 activity]	0.0	5	1	1	1
110882	1710	potential regulation	[potential regulation]	0.0	2	1	1	1
110883	1710	patient receive 5-fluorouracil	[patient receiving 5-fluorouracil]	0.0	3	1	1	1
110884	1710	Reed-Sternberg (rs) cell	[Reed-Sternberg (RS) cells]	0.0	3	1	1	1
110885	1710	blockade of hl-60 differentiation	[blockade of HL-60 differentiation]	0.0	4	1	1	1
110886	1710	depend on the repression of Nur77	[depending on the repression of Nur77]	0.0	6	1	1	1
110887	1710	cell PBMC	[cells PBMC]	0.0	2	3	3	1
110888	1710	involvement of a saf-like transcription factor	[Involvement of an SAF-like transcription factor]	0.0	6	1	1	1
110889	1710	regulatory region of b gene	[regulatory regions of B genes]	0.0	5	1	1	1
110890	1710	four isoform of wt1	[four isoforms of WT1]	0.0	4	1	1	1
110891	1710	gh production	[GH production]	0.0	2	1	1	1
110892	1710	antigen in e1a	[antigen in E1A]	0.0	3	1	1	1
110893	1710	atf/cre	[ATF/CRE]	0.0	1	1	1	1
110894	1710	(2.5 points), body mass	[(2.5 points), body mass]	0.0	4	1	1	1
110895	1710	igm-secreting cell	[IgM-secreting cells]	0.0	2	1	1	1
110896	1710	region of THR beta	[region of THR beta]	0.0	4	1	1	1
110897	1710	P56lck pathway of CD2 signal	[p56lck pathway of CD2 signaling]	0.0	5	1	1	1
110898	1710	potent activator of promoter	[potent activator of promoters]	0.0	4	1	1	1
110899	1710	57- protein	[57- proteins]	0.0	2	1	1	1
110900	1710	promoter of the gene	[promoters of the genes]	0.0	4	1	1	1
110901	1710	fundamental aspect	[fundamental aspects]	0.0	2	1	1	1
110902	1710	monocyte-specific expression	[monocyte-specific expression]	0.0	2	1	1	1
110903	1710	hiv-1 long repeat reporter gene activity	[HIV-1 long repeat reporter gene activity]	0.0	6	1	1	1
110904	1710	active form substitute	[active form substitutes]	0.0	3	1	1	1
110905	1710	human ICAM-1 promoter	[human ICAM-1 promoter]	0.0	3	1	1	1
110906	1710	transcriptional activation of the provirus	[transcriptional activation of the provirus]	0.0	5	1	1	1
110907	1710	multiple cellular factor	[multiple cellular factors]	0.0	3	1	1	1
110908	1710	cross-talk between stat5	[cross-talk between STAT5]	0.0	3	1	1	1
110909	1710	identify agents,	[identifying agents,]	0.0	2	1	1	1
110910	1710	nine pax gene	[nine Pax genes]	0.0	3	1	1	1
110911	1710	large panel	[large panel]	0.0	2	1	1	1
110912	1710	Southern blot analysis of DNA	[Southern blot analysis of DNA]	0.0	5	1	1	1
110913	1710	distinct, novel inhibitor	[distinct, novel inhibitors]	0.0	3	1	1	1
110914	1710	alzheimer' disease	[Alzheimer's disease]	0.0	2	1	1	1
110915	1710	significantly large extent	[significantly larger extent]	0.0	3	1	1	1
110916	1710	cd40l reactive T cell	[CD40L reactive T cells]	0.0	4	1	1	1
110917	1710	active tetrameric complex	[active tetrameric complexes]	0.0	3	1	1	1
110918	1710	CD30 with a CD30 -specific antibody,	[CD30 with an CD30 -specific antibody,]	0.0	6	1	1	1
110919	1710	component eic	[component EIC]	0.0	2	1	1	1
110920	1710	follow long expression of tax	[following long-term expression of Tax]	0.0	5	1	1	1
110921	1710	lineage gene	[lineage gene]	0.0	2	1	1	1
110922	1710	assay conditions-concentration	[assay conditions-concentration]	0.0	2	1	1	1
110923	1710	different variant of syndrome	[different variants of syndrome]	0.0	4	1	1	1
110924	1710	3 day of adherence	[3 days of adherence]	0.0	4	1	1	1
110925	1710	regulation elf-1	[Regulation Elf-1]	0.0	2	1	1	1
110926	1710	identify MNDA	[identifying MNDA]	0.0	2	1	1	1
110927	1710	potential of lipid soluble antioxidant	[potential of lipid soluble antioxidants]	0.0	5	1	1	1
110928	1710	nuclear translocation of factor-kappaB	[nuclear translocation of factor-kappaB]	0.0	4	1	1	1
110929	1710	effect on IRF-1	[effect on IRF-1]	0.0	3	1	1	1
110930	1710	ar loci on the arm,	[AR loci on the arm,]	0.0	5	1	1	1
110931	1710	assessment of the role	[assessment of the roles]	0.0	4	1	1	1
110932	1710	fourth g76:gpltplpv	[fourth G76:GPLTPLPV]	0.0	2	1	1	1
110933	1710	serine phosphorylation site in STAT3alpha	[serine phosphorylation site in STAT3alpha]	0.0	5	1	1	1
110934	1710	variety of other cells,	[variety of other cells,]	0.0	4	1	1	1
110935	1710	survival of interleukin-3	[survival of interleukin-3]	0.0	3	1	1	1
110936	1710	regulator of signal transduction	[regulators of signal transduction]	0.0	4	1	1	1
110937	1710	Animal	[Animal]	0.0	1	1	1	1
110938	1710	tpa microM)	[TPA microM)]	0.0	2	1	1	1
110939	1710	normal pulmonary macrophage PAM	[Normal pulmonary macrophages PAM]	0.0	4	1	1	1
110940	1710	hydrochlorothiazide	[Hydrochlorothiazide]	0.0	1	1	1	1
110941	1710	MHC class gene regulatory factor	[MHC class gene regulatory factor]	0.0	5	1	1	1
110942	1710	t-cell mitogens,	[T-cell mitogens,]	0.0	2	1	1	1
110943	1710	inhibition of processing by NF-kappaB protein	[Inhibition of processing by NF-kappaB proteins]	0.0	6	1	1	1
110944	1710	molecule(s)	[molecule(s)]	0.0	1	1	1	1
110945	1710	t-cell translocation to chromosome 11p15	[T-cell translocations to chromosomes 11p15]	0.0	5	1	1	1
110946	1710	cell adhesion molecule-1 pecam-1	[cell adhesion molecule-1 PECAM-1]	0.0	4	1	1	1
110947	1710	CD3 -dependent event	[CD3 -dependent event]	0.0	3	1	1	1
110948	1710	protein content of NF-kappaB subunit	[protein content of NF-kappaB subunit]	0.0	5	1	1	1
110949	1710	leukotriene B4 LTB4	[leukotriene B4 LTB4]	0.0	3	1	1	1
110950	1710	demonstration of interaction	[demonstration of interactions]	0.0	3	1	1	1
110951	1710	GM-CSF in pmn	[GM-CSF in PMN]	0.0	3	1	1	1
110952	1710	factor role	[factor role]	0.0	2	1	1	1
110953	1710	affinity p49	[affinity p49]	0.0	2	1	1	1
110954	1710	level of cytokine	[levels of cytokines]	0.0	3	1	1	1
110955	1710	negative response element	[negative response element]	0.0	3	1	1	1
110956	1710	ratio of 10%.	[ratio of 10%.]	0.0	3	1	1	1
110957	1710	ligation of major class	[ligation of major class]	0.0	4	1	1	1
110958	1710	enzyme e1	[enzyme E1]	0.0	2	1	1	1
110959	1710	100 u/ml	[100 U/ml]	0.0	2	1	1	1
110960	1710	separable gene response	[separable gene responses]	0.0	3	1	1	1
110961	1710	transcription factor Oct1	[transcription factors Oct1]	0.0	3	1	1	1
110962	1710	large isoform, oct2ab	[large isoform, Oct2ab]	0.0	3	1	1	1
110963	1710	region of kb	[region of kb]	0.0	3	1	1	1
110964	1710	extend from -500	[extending from -500]	0.0	3	1	1	1
110965	1710	great than 10 microm	[greater than 10 microM]	0.0	4	1	1	1
110966	1710	possible existence	[possible existence]	0.0	2	1	1	1
110967	1710	bind to the promoter	[binding to the promoter]	0.0	4	1	1	1
110968	1710	bear tumor for a few week	[bearing tumor for a few weeks]	0.0	6	1	1	1
110969	1710	effect on lymphocyte inhibition depletion	[effects on lymphocytes inhibition depletion]	0.0	5	1	1	1
110970	1710	culture, lead to adhesion	[culture, leading to adhesion]	0.0	4	1	1	1
110971	1710	number in secretory phase endometrium	[numbers in secretory phase endometrium]	0.0	5	1	1	1
110972	1710	potency of class compounds,	[potency of class compounds,]	0.0	4	1	1	1
110973	1710	type used,	[type used,]	0.0	2	1	1	1
110974	1710	human IL-3 promoter	[human IL-3 promoter]	0.0	3	1	1	1
110975	1710	study of B-cell development	[study of B-cell development]	0.0	4	1	1	1
110976	1710	first study of expression	[first study of expression]	0.0	4	1	1	1
110977	1710	R- enhancer	[R- enhancer]	0.0	2	1	1	1
110978	1710	nuclear expression of NF-kappaB/Rel family	[nuclear expression of NF-kappaB/Rel family]	0.0	5	1	1	1
110979	1710	human platelet lysate	[human platelet lysates]	0.0	3	1	1	1
110980	1710	amount early	[amounts early]	0.0	2	1	1	1
110981	1710	cytokine human interleukin	[cytokines human interleukin]	0.0	3	1	1	1
110982	1710	dominant disorder	[dominant disorder]	0.0	2	1	1	1
110983	1710	cytokine -modulate activity	[Cytokine -modulating activity]	0.0	3	1	1	1
110984	1710	expression of another immediate-early protein	[expression of another immediate-early protein]	0.0	5	1	1	1
110985	1710	cell viability.	[cell viability.]	0.0	2	1	1	1
110986	1710	essential factor	[essential factor]	0.0	2	1	1	1
110987	1710	distal factor AP-1/Octamer	[distal factor AP-1/Octamer]	0.0	3	1	1	1
110988	1710	study use a negative form	[studies using a negative form]	0.0	5	1	1	1
110989	1710	hiv-1 LTR vector	[HIV-1 LTR vectors]	0.0	3	1	1	1
110990	1710	bind affinity of quercetin	[binding affinity of quercetin]	0.0	4	1	1	1
110991	1710	two ccaat box	[two CCAAT boxes]	0.0	3	1	1	1
110992	1710	decrease in host destruction	[decrease in host destruction]	0.0	4	1	1	1
110993	1710	type of leukemia blast cell	[types of leukemia blast cells]	0.0	5	1	1	1
110994	1710	typical pattern	[typical pattern]	0.0	2	1	1	1
110995	1710	presence of 25(oh)d3 lymphocyte	[presence of 25(OH)D3 lymphocytes]	0.0	4	1	1	1
110996	1710	p39c-jun expression	[p39c-jun expression]	0.0	2	1	1	1
110997	1710	interleukin-10 production	[interleukin-10 production]	0.0	2	1	1	1
110998	1710	radioiodine	[radioiodine]	0.0	1	1	1	1
110999	1710	aspect of lymphoid tissue development	[aspects of lymphoid tissue development]	0.0	5	1	1	1
111000	1710	result from down-regulation	[resulting from down-regulation]	0.0	3	1	1	1
111001	1710	4 control donor	[4 control donors]	0.0	3	1	1	1
111002	1710	conventional doses.	[conventional doses.]	0.0	2	1	1	1
111003	1710	possible mechanism of transformation	[possible mechanism of transformation]	0.0	4	1	1	1
111004	1710	contain a beta-galactosidase gene	[containing a beta-galactosidase gene]	0.0	4	1	1	1
111005	1710	novel, species	[novel, species]	0.0	2	1	1	1
111006	1710	IL-2 receptor stimulation	[IL-2 receptor stimulation]	0.0	3	1	1	1
111007	1710	group of U937 promonocytic cell	[groups of U937 promonocytic cells]	0.0	5	1	1	1
111008	1710	phosphatidylethanolamine at concentration	[phosphatidylethanolamine at concentrations]	0.0	3	1	1	1
111009	1710	rel-related cDNA	[rel-related cDNA]	0.0	2	1	1	1
111010	1710	short term culture	[short term culture]	0.0	3	1	1	1
111011	1710	3.7 kilobasis	[3.7 kilobases]	0.0	2	1	1	1
111012	1710	absence only pu.1	[absence only PU.1]	0.0	3	1	1	1
111013	1710	disparate fate	[disparate fates]	0.0	2	1	1	1
111014	1710	KV channel	[KV channels]	0.0	2	1	1	1
111015	1710	expression of il-1alpha by HTLV-I	[Expression of IL-1alpha by HTLV-I]	0.0	5	1	1	1
111016	1710	rdna the catalytic sub-unit	[cDNAs the catalytic sub-unit]	0.0	4	1	1	1
111017	1710	transfection of deletional vcam-1 promoter construct	[transfection of deletional VCAM-1 promoter constructs]	0.0	6	1	1	1
111018	1710	kinase cdk inhibitor	[kinase cdk inhibitor]	0.0	3	1	1	1
111019	1710	identify MNDA as a gene	[identifying MNDA as a gene]	0.0	5	1	1	1
111020	1710	activation of the p46 isoform	[activation of the p46 isoforms]	0.0	5	1	1	1
111021	1710	acute adrenal failure	[acute adrenal failure]	0.0	3	1	1	1
111022	1710	investigations,	[investigations,]	0.0	1	1	1	1
111023	1710	135eoh)2d3 uptake	[1,25(OH)2D3 uptake]	0.0	2	1	1	1
111024	1710	potent immunosuppressive activity at concentration low	[potent immunosuppressive activity at concentrations lower]	0.0	6	1	1	1
111025	1710	1beta,25-dihydroxyvitamin D3 HL	[1beta,25-dihydroxyvitamin D3 HL]	0.0	3	1	1	1
111026	1710	short- effect	[short- effects]	0.0	2	1	1	1
111027	1710	resemble nuclear factor of T cell	[resembling nuclear factor of T cells]	0.0	6	1	1	1
111028	1710	leukemia-specific t(15;17) translocation	[leukemia-specific t(15;17) translocation]	0.0	3	1	1	1
111029	1710	number of cellular response	[number of cellular responses]	0.0	4	1	1	1
111030	1710	IL-3 colony-stimumulatelany-stg factor complex	[IL-3 colony-stimulating factor complexes]	0.0	4	1	1	1
111031	1710	FcepsilonRIIb receptor in monocyte	[FcepsilonRIIb receptor in monocytes]	0.0	4	1	1	1
111032	1710	Bcl-6 expression in follicular hyperplasia	[Bcl-6 expression in follicular hyperplasia]	0.0	5	1	1	1
111033	1710	multiple transcript	[multiple transcripts]	0.0	2	1	1	1
111034	1710	Differential induction (ifn)-inducible protein 10 differentiation	[Differential induction (IFN)-inducible protein 10 differentiation]	0.0	6	1	1	1
111035	1710	tyrosine phosphorylation of multiple intracellular substrate	[tyrosine phosphorylation of multiple intracellular substrates]	0.0	6	1	1	1
111036	1710	clinical consequence	[clinical consequences]	0.0	2	1	1	1
111037	1710	2 transactivation	[2 transactivation]	0.0	2	1	1	1
111038	1710	glucocorticoid-sensitive 6tg1.1 cell	[glucocorticoid-sensitive 6TG1.1 cells]	0.0	3	1	1	1
111039	1710	recombinant tnf receptor rhu tnfr:fc	[recombinant TNF receptor rhu TNFR:Fc]	0.0	5	1	1	1
111040	1710	activity low than cyclosporin a	[activity lower than cyclosporin A]	0.0	5	1	1	1
111041	1710	functional implication of a mutation	[functional implications of a mutation]	0.0	5	1	1	1
111042	1710	functional activation by beta-phorbol 13-acetate	[functional activation by beta-phorbol 13-acetate]	0.0	5	1	1	1
111043	1710	contrast to the beta- gene	[contrast to the beta- gene]	0.0	5	1	1	1
111044	1710	up-regulation of cd14 expression	[up-regulation of CD14 expression]	0.0	4	1	1	1
111045	1710	constitutive nuclear form	[constitutive nuclear form]	0.0	3	1	1	1
111046	1710	malignant fibrous histiocytoma rhabdomyosarcoma	[malignant fibrous histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
111047	1710	arm of human chromosome 11	[arm of human chromosome 11]	0.0	5	1	1	1
111048	1710	mpl concentration	[MPL concentrations]	0.0	2	1	1	1
111049	1710	report.	[report.]	0.0	1	2	2	1
111050	1710	immunomodulatory property	[immunomodulatory properties]	0.0	2	1	1	1
111051	1710	interferon family	[interferon family]	0.0	2	1	1	1
111052	1710	effect of Ara-C	[effects of Ara-C]	0.0	3	1	1	1
111053	1710	minute posttreatment)	[minutes posttreatment)]	0.0	2	1	1	1
111054	1710	alteration in a XY female	[alteration in an XY female]	0.0	5	1	1	1
111055	1710	differentiation in cell line	[differentiation in cell lines]	0.0	4	1	1	1
111056	1710	proinflammatory effect	[proinflammatory effects]	0.0	2	1	1	1
111057	1710	blood cell ss RBC	[blood cells SS RBC]	0.0	4	1	1	1
111058	1710	activation of other transcription factor	[activation of other transcription factors]	0.0	5	1	1	1
111059	1710	dysregulation accompany aging	[dysregulation accompanying aging]	0.0	3	1	1	1
111060	1710	spread on endothelial cell	[spreading on endothelial cells]	0.0	4	1	1	1
111061	1710	effect of a anti-inflammatory drug	[effects of a anti-inflammatory drug]	0.0	5	1	1	1
111062	1710	cocultivation of BZLF	[cocultivation of BZLF]	0.0	3	1	1	1
111063	1710	significance for this patient population	[significance for this patient population]	0.0	5	1	1	1
111064	1710	full maturation	[full maturation]	0.0	2	1	1	1
111065	1710	immunodeficiency virus expression	[immunodeficiency virus expression]	0.0	3	1	1	1
111066	1710	bmlf1 protein	[BMLF1 proteins]	0.0	2	1	1	1
111067	1710	mobilization of the granule	[mobilization of the granules]	0.0	4	1	1	1
111068	1710	tax -dependent correlation between expression	[Tax -dependent correlation between expression]	0.0	5	1	1	1
111069	1710	phorbol dibutyrate/calcium ionophore a23187 combination	[phorbol dibutyrate/calcium ionophore A23187 combination]	0.0	5	1	1	1
111070	1710	-contain leukocyte protein tightly than Grb2	[-containing leukocyte protein tightly than Grb2]	0.0	6	1	1	1
111071	1710	even in response	[even in response]	0.0	3	1	1	1
111072	1710	70-base-pair fragment	[70-base-pair fragment]	0.0	2	1	1	1
111073	1710	addition of tgf-beta	[addition of TGF-beta]	0.0	3	1	1	1
111074	1710	Interleukin-1 beta	[Interleukin-1 beta]	0.0	2	1	1	1
111075	1710	signal transduction pathway in monocyte	[Signal transduction pathways in monocytes]	0.0	5	1	1	1
111076	1710	1-5 nm)	[1-5 nM)]	0.0	2	1	1	1
111077	1710	CD4 lymphocyte cytotoxicity	[CD4 lymphocyte cytotoxicity]	0.0	3	1	1	1
111078	1710	developmental regulation in b cell	[developmental regulation in B cells]	0.0	5	1	1	1
111079	1710	parallel, level of transcript	[parallel, levels of transcripts]	0.0	4	1	1	1
111080	1710	level of nfat activity	[levels of NFAT activities]	0.0	4	1	1	1
111081	1710	1.16 arbitrary units, p young	[1.16 arbitrary units, P young]	0.0	5	1	1	1
111082	1710	211 +/-	[211 +/-]	0.0	2	1	1	1
111083	1710	single open reading frame	[single open reading frame]	0.0	4	1	1	1
111084	1710	include stat5a	[including STAT5a]	0.0	2	1	1	1
111085	1710	ineffective dose of vitamin D3	[ineffective dose of vitamin D3]	0.0	5	1	1	1
111086	1710	even after hour	[even after hr]	0.0	3	1	1	1
111087	1710	transition of Epstein-Barr virus ebv	[transition of Epstein-Barr virus EBV]	0.0	5	1	1	1
111088	1710	regulation of c-fos/c-jun	[regulation of c-fos/c-jun]	0.0	3	1	1	1
111089	1710	polyclonal activator phytohemagglutinin	[polyclonal activator phytohemagglutinin]	0.0	3	1	1	1
111090	1710	exclusive binding of nf-atp	[exclusive binding of NF-ATp]	0.0	4	1	1	1
111091	1710	underlie cell activation by xenogeneic serum	[underlying cell activation by xenogeneic serum]	0.0	6	1	1	1
111092	1710	particular histocompatibility complex (mhc) haplotype	[particular histocompatibility complex (MHC) haplotypes]	0.0	5	1	1	1
111093	1710	six flavonoid on IkappaB kinase	[six flavonoids on IkappaB kinase]	0.0	5	1	1	1
111094	1710	only in lymphoid tissue	[only in lymphoid tissues]	0.0	4	1	1	1
111095	1710	induction of IL-6 transcription	[induction of IL-6 transcription]	0.0	4	1	1	1
111096	1710	compete for binding	[competing for binding]	0.0	3	1	1	1
111097	1710	sp-a dose	[SP-A doses]	0.0	2	1	1	1
111098	1710	activation lymphocyte	[Activation lymphocytes]	0.0	2	1	1	1
111099	1710	study indicate a role	[studies indicating a role]	0.0	4	1	1	1
111100	1710	ecotropic insertion site in leukemia	[ecotropic insertion site in leukemia]	0.0	5	1	1	1
111101	1710	general transcription tfiid TAFII32	[general transcription TFIID TAFII32]	0.0	4	1	1	1
111102	1710	least one clone reactive	[least one clone reactive]	0.0	4	1	1	1
111103	1710	herpesvirus 8	[herpesvirus 8]	0.0	2	1	1	1
111104	1710	lectin-type ldl receptor	[lectin-type LDL receptor]	0.0	3	1	1	1
111105	1710	contain the promoter-binding protein	[containing the promoter-binding protein]	0.0	4	1	1	1
111106	1710	T cell with low concentration	[T cells with low concentrations]	0.0	5	1	1	1
111107	1710	infection genome-positive b cell by herpesvirus	[infection genome-positive B cells by herpesvirus]	0.0	6	1	1	1
111108	1710	hiv-1 repeat site	[HIV-1 repeat sites]	0.0	3	1	1	1
111109	1710	cell TEC	[cells TEC]	0.0	2	3	3	1
111110	1710	potential signal pathway involve expression	[potential signaling pathways involving expression]	0.0	5	1	1	1
111111	1710	leishmania-infected cell	[leishmania-infected cells]	0.0	2	1	1	1
111112	1710	positive activator	[positive activator]	0.0	2	1	1	1
111113	1710	ifn-gamma-activated sequence-binding complex contain STAT3	[IFN-gamma-activated sequence-binding complexes containing STAT3]	0.0	5	1	1	1
111114	1710	tyrosine-containing stat	[tyrosine-containing STAT]	0.0	2	1	1	1
111115	1710	activation of the creb/atf	[activation of the CREB/ATF]	0.0	4	1	1	1
111116	1710	only activity of B-cell extract	[only activity of B-cell extracts]	0.0	5	1	1	1
111117	1710	population t-cell killer T/NK population	[populations T-cell killer T/NK populations]	0.0	5	1	1	1
111118	1710	contain one b element	[containing one B elements]	0.0	4	1	1	1
111119	1710	ap-1 activation pathway	[AP-1 activation pathway]	0.0	3	1	1	1
111120	1710	transcription factor for expression	[transcription factor for expression]	0.0	4	1	1	1
111121	1710	colony-stimulating factor G-CSF	[colony-stimulating factor G-CSF]	0.0	3	2	2	1
111122	1710	domain POUs a linker	[domain POUs a linker]	0.0	4	1	1	1
111123	1710	m dm	[M DM]	0.0	2	2	2	1
111124	1710	independent T cell receptor element	[independent T cell receptor elements]	0.0	5	1	1	1
111125	1710	role in platelet activation	[role in platelet activation]	0.0	4	1	1	1
111126	1710	reactive oxygen species in disease	[Reactive oxygen species in diseases]	0.0	5	1	1	1
111127	1710	yeast reporter	[yeast reporter]	0.0	2	1	1	1
111128	1710	b-lymphocyte precursor cell	[B-lymphocyte precursor cells]	0.0	3	1	1	1
111129	1710	group of hypercortisolemic patient	[groups of hypercortisolemic patients]	0.0	4	1	1	1
111130	1710	utilization of alternative signal transduction pathway	[utilization of alternative signal transduction pathways]	0.0	6	1	1	1
111131	1710	(iii) activation	[(iii) activation]	0.0	2	1	1	1
111132	1710	stimulation with material mdhm	[stimulation with material MDHM]	0.0	4	1	1	1
111133	1710	T cell nfat-1	[T cells NFAT-1]	0.0	3	1	1	1
111134	1710	isoform of CBF beta	[isoforms of CBF beta]	0.0	4	1	1	1
111135	1710	analysis of il-10 receptor expression	[analysis of IL-10 receptor expression]	0.0	5	1	1	1
111136	1710	first limitation to effect	[first limitation to effects]	0.0	4	1	1	1
111137	1710	consequence for cell effector function	[consequences for cell effector function]	0.0	5	1	1	1
111138	1710	rate and/or	[rate and/or]	0.0	2	1	1	1
111139	1710	two form of the protein	[two forms of the protein]	0.0	5	1	1	1
111140	1710	dependent adhesion human vein cell	[dependent adhesion human vein cells]	0.0	5	1	1	1
111141	1710	deficient ability in response	[deficient ability in response]	0.0	4	1	1	1
111142	1710	clinical resistance in asthma	[clinical resistance in asthma]	0.0	4	1	1	1
111143	1710	human leukemic ecem) cell	[human leukemic (CEM) cells]	0.0	4	1	1	1
111144	1710	encode for a 41-kDa protein	[encoding for a 41-kDa protein]	0.0	5	1	1	1
111145	1710	two pathways:	[two pathways:]	0.0	2	1	1	1
111146	1710	lytic reactivity high	[lytic reactivities high]	0.0	3	1	1	1
111147	1710	immunofluorescence study on population carry transgene	[Immunofluorescence studies on populations carrying transgenes]	0.0	6	1	1	1
111148	1710	deletion hotspot	[deletion hotspot]	0.0	2	1	1	1
111149	1710	bp of -flanking sequence	[bp of -flanking sequence]	0.0	4	1	1	1
111150	1710	mutually exclusive interaction	[Mutually exclusive interaction]	0.0	3	1	1	1
111151	1710	immunoglobulin light-chain	[immunoglobulin light-chain]	0.0	2	1	1	1
111152	1710	superinduction transcripts.	[superinduction transcripts.]	0.0	2	1	1	1
111153	1710	involve response to stress	[involving responses to stress]	0.0	4	1	1	1
111154	1710	normal cell from cavity fluid	[normal cells from cavity fluids]	0.0	5	1	1	1
111155	1710	fourteen percent of fragment	[Fourteen percent of fragments]	0.0	4	1	1	1
111156	1710	level of Pan protein	[levels of Pan proteins]	0.0	4	1	1	1
111157	1710	factor-kappa b activation in ec	[factor-kappa B activation in EC]	0.0	5	1	1	1
111158	1710	signal lead to Egr-1 induction	[signals leading to Egr-1 induction]	0.0	5	1	1	1
111159	1710	b cell from apoptosis.	[B cells from apoptosis.]	0.0	4	1	1	1
111160	1710	DEX mg	[DEX mg]	0.0	2	1	1	1
111161	1710	ovarian cancer case	[ovarian cancer cases]	0.0	3	1	1	1
111162	1710	proximal 45 residue of the tail,	[proximal 45 residues of the tail,]	0.0	6	1	1	1
111163	1710	swap	[swap]	0.0	1	1	1	1
111164	1710	nuclear factor irf-1 interferon factor	[nuclear factor IRF-1 interferon factor]	0.0	5	1	1	1
111165	1710	type of promoter	[type of promoter]	0.0	3	1	1	1
111166	1710	polyomavirus enhancer-binding protein 2/core-binding factor	[polyomavirus enhancer-binding protein 2/core-binding factor]	0.0	5	1	1	1
111167	1710	liver library	[liver library]	0.0	2	1	1	1
111168	1710	hypothalamus of rat	[hypothalamus of rats]	0.0	3	1	1	1
111169	1710	potential therapeutic value	[potential therapeutic value]	0.0	3	1	1	1
111170	1710	five DNase-I hypersensitive site	[Five DNase-I hypersensitive sites]	0.0	4	1	1	1
111171	1710	adhesion molecule on the surface	[adhesion molecules on the surface]	0.0	5	1	1	1
111172	1710	30 base pair upstream	[30 base pairs upstream]	0.0	4	1	1	1
111173	1710	glucocorticoid insensitivity with expression	[glucocorticoid insensitivity with expression]	0.0	4	1	1	1
111174	1710	GR -responsive element level	[GR -responsive element level]	0.0	4	1	1	1
111175	1710	activity of alpha-galactosidase a	[activity of alpha-galactosidase A]	0.0	4	1	1	1
111176	1710	combination pu.1	[combination PU.1]	0.0	2	1	1	1
111177	1710	natural photic cycle	[natural photic cycle]	0.0	3	1	1	1
111178	1710	addition of magnitude.	[addition of magnitude.]	0.0	3	1	1	1
111179	1710	existence of pax-5 transcript	[existence of Pax-5 transcripts]	0.0	4	1	1	1
111180	1710	co-infection	[Co-infection]	0.0	1	1	1	1
111181	1710	significant insight into the protein-protein interaction	[significant insights into the protein-protein interactions]	0.0	6	1	1	1
111182	1710	induction of synthesis by 135(oh)2d3	[Induction of synthesis by 1,25(OH)2D3]	0.0	5	1	1	1
111183	1710	occur in distinct family	[occurring in distinct families]	0.0	4	1	1	1
111184	1710	extend base pair	[extending base pairs]	0.0	3	1	1	1
111185	1710	block cellular uptake	[blocking cellular uptake]	0.0	3	1	1	1
111186	1710	expression of a hiv-1 long repeat	[expression of a HIV-1 long repeat]	0.0	6	1	1	1
111187	1710	induction in blood monocyte	[Induction in blood monocytes]	0.0	4	1	1	1
111188	1710	roll of monocyte	[rolling of monocytes]	0.0	3	1	1	1
111189	1710	genomic response to D3	[genomic response to D3]	0.0	4	1	1	1
111190	1710	protein of 82	[proteins of 82]	0.0	3	1	1	1
111191	1710	sex reversal map more than kb	[sex reversal map more than kb]	0.0	6	1	1	1
111192	1710	role for alteration	[roles for alterations]	0.0	3	1	1	1
111193	1710	intracellular messenger induction	[intracellular messengers induction]	0.0	3	1	1	1
111194	1710	hydrophobic domain with putative transmembrane segment	[hydrophobic domain with putative transmembrane segments]	0.0	6	1	1	1
111195	1710	ig heavy chain enhancer	[Ig heavy chain enhancer]	0.0	4	3	3	1
111196	1710	nuclear component within minute	[nuclear component within min]	0.0	4	1	1	1
111197	1710	addition, ligation	[addition, ligation]	0.0	2	1	1	1
111198	1710	novel protein from matrix preparation	[novel protein from matrix preparations]	0.0	5	1	1	1
111199	1710	hpp- cell	[HPP- cells]	0.0	2	1	1	1
111200	1710	macrophage-competent derivative of SIVmac239	[macrophage-competent derivative of SIVmac239]	0.0	4	1	1	1
111201	1710	antiserum to kda	[antiserum to kDa]	0.0	3	1	1	1
111202	1710	EBNA-2 -negative extract	[EBNA-2 -negative extracts]	0.0	3	1	1	1
111203	1710	protein x box	[protein X box]	0.0	3	1	1	1
111204	1710	different isoform of WT1	[different isoforms of WT1]	0.0	4	1	1	1
111205	1710	probably due to difference in route	[probably due to differences in route]	0.0	6	1	1	1
111206	1710	expression of the Ca2+ isoform	[expression of the Ca2+ isoforms]	0.0	5	1	1	1
111207	1710	expression of this regulator	[expression of these regulators]	0.0	4	1	1	1
111208	1710	macrophage chemotactic protein-1	[macrophage chemotactic protein-1]	0.0	3	1	1	1
111209	1710	family of interactive protein	[family of interactive proteins]	0.0	4	1	1	1
111210	1710	binding site for a nuclear factor	[binding sites for a nuclear factor]	0.0	6	1	1	1
111211	1710	augment antitumor immunity	[augmenting antitumor immunity]	0.0	3	1	1	1
111212	1710	interaction with the ptf	[interaction with the PTF]	0.0	4	1	1	1
111213	1710	effect with low dose	[effects with low doses]	0.0	4	1	1	1
111214	1710	range of proinflammatory cytokine	[range of proinflammatory cytokines]	0.0	4	1	1	1
111215	1710	glucocorticoid cortisol	[glucocorticoid cortisol]	0.0	2	1	1	1
111216	1710	regulation of c-jun	[regulation of c-jun]	0.0	3	1	1	1
111217	1710	protein DNA	[protein DNA]	0.0	2	1	1	1
111218	1710	lipid-soluble, chain-breaking antioxidant	[lipid-soluble, chain-breaking antioxidants]	0.0	3	1	1	1
111219	1710	umbilical vein cell HUVEC CoCl2	[umbilical vein cells HUVEC CoCl2]	0.0	5	1	1	1
111220	1710	nuclear factor-kappaB translocation monocyte	[nuclear factor-kappaB translocation monocytes]	0.0	4	1	1	1
111221	1710	induction of c-jun	[induction of c-jun]	0.0	3	1	1	1
111222	1710	normal blood donor	[normal blood donor]	0.0	3	1	1	1
111223	1710	nuclear factor (ref.	[nuclear factor (ref.]	0.0	3	1	1	1
111224	1710	vis-a-vis hormone status	[vis-a-vis hormone status]	0.0	3	1	1	1
111225	1710	many application	[many applications]	0.0	2	1	1	1
111226	1710	EBV-associated, hla-b8-restricted latent epitope	[EBV-associated, HLA-B8-restricted latent epitopes]	0.0	4	1	1	1
111227	1710	role in the molecular process	[role in the molecular processes]	0.0	5	1	1	1
111228	1710	Okadaic acid a inhibitor	[Okadaic acid an inhibitor]	0.0	4	1	1	1
111229	1710	herpesvirus-6	[herpesvirus-6]	0.0	1	1	1	1
111230	1710	stretch of amino acid rich	[stretch of amino acids rich]	0.0	5	1	1	1
111231	1710	Sp-deficient drosophila Schneider cell	[Sp-deficient Drosophila Schneider cells]	0.0	4	1	1	1
111232	1710	low value	[lower values]	0.0	2	1	1	1
111233	1710	NF-kappa b component	[NF-kappa B components]	0.0	3	1	1	1
111234	1710	partial receptor occupancy	[partial receptor occupancy]	0.0	3	1	1	1
111235	1710	unicellular-unilineage culture molecular analysis	[Unicellular-unilineage cultures molecular analysis]	0.0	4	1	1	1
111236	1710	enhancer element responsible	[enhancer elements responsible]	0.0	3	1	1	1
111237	1710	express c-myc with a area	[expressing c-myc with an area]	0.0	5	1	1	1
111238	1710	dual colour fish analysis use probe	[dual colour FISH analysis using probes]	0.0	6	1	1	1
111239	1710	killer (nk) cell with cell	[killer (NK) cells with cells]	0.0	5	1	1	1
111240	1710	single reading frame in frame	[single reading frame in frame]	0.0	5	1	1	1
111241	1710	activation after infection by EBV	[Activation after infection by EBV]	0.0	5	1	1	1
111242	1710	wild-type nfat1	[wild-type NFAT1]	0.0	2	1	1	1
111243	1710	noticeable adhesion	[noticeable adhesion]	0.0	2	1	1	1
111244	1710	cause secretion	[causing secretion]	0.0	2	2	2	1
111245	1710	il-1 nf-kappa b gene transcription	[IL-1 NF-kappa B gene transcription]	0.0	5	1	1	1
111246	1710	cell by cell wall derivative	[cells by cell wall derivatives]	0.0	5	1	1	1
111247	1710	evidence the CsA component limit signal	[evidence the CsA component limiting signaling]	0.0	6	1	1	1
111248	1710	proximal tsp	[proximal TSP]	0.0	2	1	1	1
111249	1710	Jurkat CD4	[Jurkat CD4]	0.0	2	1	1	1
111250	1710	Effect lead	[Effects leading]	0.0	2	1	1	1
111251	1710	reporter mouse	[reporter mice]	0.0	2	1	1	1
111252	1710	pool of NF-kappaB /IkappaBalpha	[pool of NF-kappaB /IkappaBalpha]	0.0	4	1	1	1
111253	1710	patient with this disease	[patients with this disease]	0.0	4	1	1	1
111254	1710	site in vitro.	[sites in vitro.]	0.0	3	1	1	1
111255	1710	part achieve efficient ebv activation	[part achieving efficient EBV activation]	0.0	5	1	1	1
111256	1710	1 aml m4 with atypical eosinophil	[1 AML M4 with atypical eosinophils]	0.0	6	1	1	1
111257	1710	inhibition of rela function	[inhibition of RelA function]	0.0	4	1	1	1
111258	1710	ah receptor deficient cell line	[Ah receptor deficient cell lines]	0.0	5	1	1	1
111259	1710	comprise individual domain	[comprising individual domains]	0.0	3	1	1	1
111260	1710	prerequisite for a level	[prerequisite for a level]	0.0	4	1	1	1
111261	1710	minutes) to all-tran acid washed,	[minutes) to all-trans acid washed,]	0.0	5	1	1	1
111262	1710	putative intracellular receptor	[putative intracellular receptors]	0.0	3	1	1	1
111263	1710	increase in urinary thf	[increase in urinary THF]	0.0	4	1	1	1
111264	1710	biologic action	[biologic actions]	0.0	2	2	2	1
111265	1710	inhibition of apoptosis after withdrawal	[inhibition of apoptosis after withdrawal]	0.0	5	1	1	1
111266	1710	LCK promoter	[LCK promoter]	0.0	2	1	1	1
111267	1710	contain little ng of total rna.	[containing little ng of total RNA.]	0.0	6	1	1	1
111268	1710	120 h. spleen	[120 h, spleen]	0.0	3	1	1	1
111269	1710	activity of a nuclear factor	[activity of an nuclear factor]	0.0	5	1	1	1
111270	1710	individual of complex (mhc) haplotype	[individuals of complex (MHC) haplotypes]	0.0	5	1	1	1
111271	1710	role in antigen receptor signal	[role in antigen receptor signaling]	0.0	5	1	1	1
111272	1710	action of this molecule	[actions of these molecules]	0.0	4	1	1	1
111273	1710	NF-kappaB complex with extract	[NF-kappaB complex with extract]	0.0	4	1	1	1
111274	1710	suggest a role of Ras	[suggesting a role of Ras]	0.0	5	1	1	1
111275	1710	acid lipase lal	[acid lipase LAL]	0.0	3	1	1	1
111276	1710	assessment of IL production	[assessment of IL production]	0.0	4	1	1	1
111277	1710	early precursor of human	[early precursors of humans]	0.0	4	1	1	1
111278	1710	Burkitt' lymphoma b cell line dnd39	[Burkitt's lymphoma B cell lines DND39]	0.0	6	1	1	1
111279	1710	glutathione -s-transferase gst	[glutathione -S-transferase GST]	0.0	3	1	1	1
111280	1710	Comparison of retinoic acid	[Comparison of retinoic acid]	0.0	4	1	1	1
111281	1710	form of calcineurin partially substitute	[form of calcineurin partially substitutes]	0.0	5	1	1	1
111282	1710	differentiation- expression	[differentiation- expression]	0.0	2	1	1	1
111283	1710	n-acetyl	[N-acetyl]	0.0	1	1	1	1
111284	1710	three stimulus-	[three stimulus-]	0.0	2	1	1	1
111285	1710	blood of woman	[blood of women]	0.0	3	1	1	1
111286	1710	alteration of order	[Alteration of order]	0.0	3	1	1	1
111287	1710	autosomal pattern	[autosomal pattern]	0.0	2	1	1	1
111288	1710	early mrna expression	[early mRNA expression]	0.0	3	1	1	1
111289	1710	stat4 protein	[Stat4 proteins]	0.0	2	1	1	1
111290	1710	HSV DNA	[HSV DNA]	0.0	2	1	1	1
111291	1710	constitutive MHC class mrna expression	[constitutive MHC class mRNA expression]	0.0	5	1	1	1
111292	1710	down-regulation of erythroid cell-specific gene	[down-regulation of erythroid cell-specific genes]	0.0	5	1	1	1
111293	1710	gene type ii	[genes type II]	0.0	3	1	1	1
111294	1710	endogenous ceramide release	[endogenous ceramide release]	0.0	3	1	1	1
111295	1710	intestinal cell inflammatory response	[intestinal cell inflammatory responses]	0.0	4	1	1	1
111296	1710	two pathway of synthesis	[Two pathways of synthesis]	0.0	4	1	1	1
111297	1710	h at a concentration	[h at a concentration]	0.0	4	1	1	1
111298	1710	induction of nuclear factor-kappaB	[induction of nuclear factor-kappaB]	0.0	4	1	1	1
111299	1710	inhibition of Smad6 on bone protein-	[inhibition of Smad6 on bone protein-]	0.0	6	1	1	1
111300	1710	major challenge for immunology	[major challenge for immunology]	0.0	4	1	1	1
111301	1710	macrophage protein-1	[macrophage protein-1]	0.0	2	1	1	1
111302	1710	oncogenic effect	[oncogenic effect]	0.0	2	1	1	1
111303	1710	oxygen radical scavenger enzyme	[oxygen radical scavenger enzymes]	0.0	4	1	1	1
111304	1710	hsc/ hpc proliferation	[HSC/ HPC proliferation]	0.0	3	1	1	1
111305	1710	METHOD: color flow cytometry analysis	[METHOD: color flow cytometry analysis]	0.0	5	1	1	1
111306	1710	indicate a target	[indicating a target]	0.0	3	1	1	1
111307	1710	drug sodium salicylate	[drugs sodium salicylate]	0.0	3	1	1	1
111308	1710	response in	[response in]	0.0	2	1	1	1
111309	1710	c-myb in lineage-specific expression	[c-Myb in lineage-specific expression]	0.0	4	1	1	1
111310	1710	two nonsteroidal drug	[two nonsteroidal drugs]	0.0	3	1	1	1
111311	1710	certain cellular processes,	[certain cellular processes,]	0.0	3	1	1	1
111312	1710	level of steady-state immunoglobulin heavy-chain mrna	[levels of steady-state immunoglobulin heavy-chain mRNA]	0.0	6	1	1	1
111313	1710	leukocyte from woman	[leukocytes from women]	0.0	3	1	1	1
111314	1710	AMP response element site	[AMP response element site]	0.0	4	1	1	1
111315	1710	chromatin manner	[chromatin manner]	0.0	2	2	2	1
111316	1710	immunotherapy of cancer.	[immunotherapy of cancer.]	0.0	3	1	1	1
111317	1710	aCT-1-activating region	[ACT-1-activating region]	0.0	2	1	1	1
111318	1710	two nonoverlapping epitope	[two nonoverlapping epitopes]	0.0	3	1	1	1
111319	1710	bear	[bearing]	0.0	1	1	1	1
111320	1710	response to injury	[response to injury]	0.0	3	1	1	1
111321	1710	fluticasone propionate in bronchial mucosa	[fluticasone propionate in bronchial mucosa]	0.0	5	1	1	1
111322	1710	production of IL-5	[production of IL-5]	0.0	3	1	1	1
111323	1710	regulator of the lineage-specific transcription factor	[regulators of the lineage-specific transcription factor]	0.0	6	1	1	1
111324	1710	protein of 52	[proteins of 52]	0.0	3	1	1	1
111325	1710	nuclear protein to the silencer	[nuclear proteins to the silencer]	0.0	5	1	1	1
111326	1710	blood leukocyte of patient	[blood leukocytes of patients]	0.0	4	1	1	1
111327	1710	quantification during differentiation of cell	[quantification during differentiation of cells]	0.0	5	1	1	1
111328	1710	three series: at normal subject	[three series: at normal subjects]	0.0	5	1	1	1
111329	1710	Interestingly, treatment	[Interestingly, treatment]	0.0	2	1	1	1
111330	1710	abnormal receptor	[abnormal receptors]	0.0	2	1	1	1
111331	1710	vcam regulation	[VCAM regulation]	0.0	2	1	1	1
111332	1710	inhibitor through association	[inhibitors through association]	0.0	3	1	1	1
111333	1710	blotting analysis	[blotting analysis]	0.0	2	2	2	1
111334	1710	repeat of 38 glutamine residue	[repeat of 38 glutamine residues]	0.0	5	1	1	1
111335	1710	primary erythroid cell in culture	[primary erythroid cells in cultures]	0.0	5	1	1	1
111336	1710	transient outgrowth	[transient outgrowth]	0.0	2	1	1	1
111337	1710	reside in granule	[residing in granules]	0.0	3	1	1	1
111338	1710	transactivation domain present	[transactivation domain present]	0.0	3	1	1	1
111339	1710	use the sequence related oligonucleotide	[using the sequence related oligonucleotides]	0.0	5	1	1	1
111340	1710	basic helix-loop-helix regulation	[basic helix-loop-helix regulation]	0.0	3	1	1	1
111341	1710	osm gene	[OSM gene]	0.0	2	1	1	1
111342	1710	primary defect in ricket	[primary defect in rickets]	0.0	4	1	1	1
111343	1710	(pou[s]) domain	[(POU[S]) domain]	0.0	2	1	1	1
111344	1710	potentially dysfunctional T cell	[potentially dysfunctional T cells]	0.0	4	1	1	1
111345	1710	nuclear antigen EBNAs	[nuclear antigen EBNAs]	0.0	3	2	2	1
111346	1710	use serological technique	[using serological techniques]	0.0	3	1	1	1
111347	1710	Curcumin	[Curcumin]	0.0	1	1	1	1
111348	1710	-like activity	[-like activity]	0.0	2	1	1	1
111349	1710	protein of 75	[proteins of 75]	0.0	3	1	1	1
111350	1710	induction RAR(alpha)	[induction RAR(alpha)]	0.0	2	1	1	1
111351	1710	rapid mode of action	[rapid mode of action]	0.0	4	1	1	1
111352	1710	significant anti activity	[significant anti activity]	0.0	3	1	1	1
111353	1710	immune pathway result	[immune pathways resulting]	0.0	3	1	1	1
111354	1710	analysis with C-terminal antibody	[analysis with C-terminal antibodies]	0.0	4	1	1	1
111355	1710	B-cell specificity of the enhancer	[B-cell specificity of the enhancer]	0.0	5	1	1	1
111356	1710	element of the tnf gene	[elements of the TNF gene]	0.0	5	1	1	1
111357	1710	myeloid cell differentiation antigen MNDA	[myeloid cell differentiation antigen MNDA]	0.0	5	2	2	1
111358	1710	possible killer T/NK population	[possible killer T/NK populations]	0.0	4	1	1	1
111359	1710	role of Sp1urday transcription factor	[role of Sp1- transcription factors]	0.0	5	1	1	1
111360	1710	signal alone without signal	[signal alone without signal]	0.0	4	1	1	1
111361	1710	surround mesenchyme	[surrounding mesenchyme]	0.0	2	1	1	1
111362	1710	profile of p16	[profile of p16]	0.0	3	1	1	1
111363	1710	differentiation in most cell line	[differentiation in most cell lines]	0.0	5	1	1	1
111364	1710	possible relationship between the change	[Possible relationship between the changes]	0.0	5	1	1	1
111365	1710	suggest sufficient	[suggesting sufficient]	0.0	2	1	1	1
111366	1710	sodium molybdate	[sodium molybdate]	0.0	2	1	1	1
111367	1710	up-modulation	[up-modulation]	0.0	1	1	1	1
111368	1710	level of il-2 in T cell	[levels of IL-2 in T cells]	0.0	6	1	1	1
111369	1710	gene transcription activation	[gene transcription activation]	0.0	3	1	1	1
111370	1710	21 control	[21 controls]	0.0	2	1	1	1
111371	1710	different defect	[different defects]	0.0	2	1	1	1
111372	1710	blood lymphocyte lymphocytic leukemia	[blood lymphocytes lymphocytic leukemia]	0.0	4	1	1	1
111373	1710	rna polymerase iii-dependent gene	[RNA polymerase III-dependent genes]	0.0	4	1	1	1
111374	1710	regulation of hematopoietic progenitor	[regulation of hematopoietic progenitors]	0.0	4	1	1	1
111375	1710	dexamethasone: potential regulation	[dexamethasone: potential regulation]	0.0	3	1	1	1
111376	1710	interaction with nfatp	[interaction with NFATp]	0.0	3	1	1	1
111377	1710	wk RA	[wk RA]	0.0	2	1	1	1
111378	1710	differentiation of human blood monocyte	[differentiation of human blood monocytes]	0.0	5	1	1	1
111379	1710	pAT 591/EGR2	[pAT 591/EGR2]	0.0	2	1	1	1
111380	1710	kinase inhibitor active on pkc,	[kinase inhibitor active on PKC,]	0.0	5	1	1	1
111381	1710	keep strictly erythroid-specific property in vitro	[keeping strictly erythroid-specific properties in vitro]	0.0	6	1	1	1
111382	1710	bp EBNA2 region	[bp EBNA2 region]	0.0	3	1	1	1
111383	1710	extent than jak1	[extent than JAK1]	0.0	3	1	1	1
111384	1710	show degree	[showing degrees]	0.0	2	1	1	1
111385	1710	glutathione-s-transferase pi use method	[glutathione-S-transferase pi using methods]	0.0	4	1	1	1
111386	1710	role modulate function	[role modulating function]	0.0	3	1	1	1
111387	1710	complex from monocytic cell	[complex from monocytic cells]	0.0	4	1	1	1
111388	1710	pathway to the nucleus	[pathway to the nucleus]	0.0	4	1	1	1
111389	1710	selenium inhibition of transcription factor	[Selenium inhibition of transcription factor]	0.0	5	1	1	1
111390	1710	b cell adaptor	[B cell adaptor]	0.0	3	1	1	1
111391	1710	bending of DNA	[bending of DNA]	0.0	3	1	1	1
111392	1710	amino acid identity	[amino acid identity]	0.0	3	1	1	1
111393	1710	coronary plaque	[coronary plaques]	0.0	2	1	1	1
111394	1710	long term therapy with atd	[long term therapy with ATD]	0.0	5	1	1	1
111395	1710	NK function under physiologic condition	[NK functions under physiologic conditions]	0.0	5	1	1	1
111396	1710	degree of staining.	[degrees of staining.]	0.0	3	1	1	1
111397	1710	kappa b-binding complex with RelB	[kappa B-binding complexes with RelB]	0.0	5	1	1	1
111398	1710	land globular, electron-dense structure morphologically distinct	[LANDs globular, electron-dense structures morphologically distinct]	0.0	6	1	1	1
111399	1710	tcr delta mrna	[TcR delta mRNA]	0.0	3	1	1	1
111400	1710	preincubation lipopolysaccharide	[Preincubation lipopolysaccharide]	0.0	2	1	1	1
111401	1710	platelet 15 nmol	[platelets 15 nmol]	0.0	3	1	1	1
111402	1710	ap-1 from cell	[AP-1 from cells]	0.0	3	1	1	1
111403	1710	complex with this element,	[complex with this element,]	0.0	4	1	1	1
111404	1710	squamous cell carcinoma SCC	[squamous cell carcinomas SCCs]	0.0	4	1	1	1
111405	1710	Albuminemia platelet factor iv	[Albuminemia Platelet Factor IV]	0.0	4	1	1	1
111406	1710	family different form	[families: different forms]	0.0	3	1	1	1
111407	1710	developmental control of gene	[developmental control of genes]	0.0	4	1	1	1
111408	1710	lymphokine deficiency in this patient	[lymphokine deficiency in this patient]	0.0	5	1	1	1
111409	1710	possible involvement in disease	[possible involvement in diseases]	0.0	4	1	1	1
111410	1710	total patient	[total patients]	0.0	2	1	1	1
111411	1710	sixteen patient (range from 11.1	[Sixteen patients (ranging from 11.1]	0.0	5	1	1	1
111412	1710	transcription factor during lineage commitment	[transcription factors during lineage commitment]	0.0	5	1	1	1
111413	1710	cocktail colony-stimumulatelany-stg factor	[cocktail colony-stimulating factor]	0.0	3	1	1	1
111414	1710	damage to the gene	[Damage to the genes]	0.0	4	1	1	1
111415	1710	subject of intense study.	[subject of intense study.]	0.0	4	1	1	1
111416	1710	marker of subpopulation t-	[marker of subpopulations T-]	0.0	4	1	1	1
111417	1710	defect in the oct-1 protein	[defect in the Oct-1 protein]	0.0	5	1	1	1
111418	1710	cases, a heterodimer consist	[cases, a heterodimer consisting]	0.0	4	1	1	1
111419	1710	hiv-1 transcriptional activation	[HIV-1 transcriptional activation]	0.0	3	1	1	1
111420	1710	proximal pebp2/cbf site	[proximal PEBP2/CBF site]	0.0	3	1	1	1
111421	1710	activator protein-1 nuclear factor nf-il6	[activator protein-1 nuclear factor NF-IL6]	0.0	5	1	1	1
111422	1710	leukotriene b4 generation by neutrophil pmn	[leukotriene B4 generation by neutrophils PMN]	0.0	6	1	1	1
111423	1710	phosphate-supplemented patient (58.3	[phosphate-supplemented patients (58.3]	0.0	3	1	1	1
111424	1710	leiomyosarcoma liposarcoma	[leiomyosarcoma liposarcoma]	0.0	2	1	1	1
111425	1710	paf receptor antagonist WEB 2086	[PAF receptor antagonists WEB 2086]	0.0	5	1	1	1
111426	1710	activation in progenitor	[Activation in progenitors]	0.0	3	1	1	1
111427	1710	cellular stimulus	[cellular stimuli]	0.0	2	2	2	1
111428	1710	form of the CD4 cytoplasmic tail	[forms of the CD4 cytoplasmic tail]	0.0	6	1	1	1
111429	1710	survival of thymocyte	[survival of thymocytes]	0.0	3	1	1	1
111430	1710	interleukin-1 receptor	[interleukin-1 receptor]	0.0	2	1	1	1
111431	1710	distinct protein complex a factor	[distinct protein complexes a factor]	0.0	5	1	1	1
111432	1710	variable phosphorylation	[variable phosphorylation]	0.0	2	1	1	1
111433	1710	RA vitd3 pathway	[RA VitD3 pathways]	0.0	3	1	1	1
111434	1710	specific signal pathway	[specific signaling pathways]	0.0	3	1	1	1
111435	1710	sites/cell respectively, significant	[sites/cell respectively, significant]	0.0	3	1	1	1
111436	1710	about 30% large b-cell lymphoma	[about 30% large B-cell lymphomas]	0.0	5	1	1	1
111437	1710	antagonist to FN action,	[antagonist to FN action,]	0.0	4	1	1	1
111438	1710	transcription from reporter	[transcription from reporters]	0.0	3	1	1	1
111439	1710	vitro, viral nuclear antigen	[vitro, viral nuclear antigens]	0.0	4	1	1	1
111440	1710	expression in blood lymphocyte pbl	[expression in blood lymphocytes PBLs]	0.0	5	1	1	1
111441	1710	1,25-dihydroxyvitamin D3 protein	[1,25-dihydroxyvitamin D3 protein]	0.0	3	1	1	1
111442	1710	use cross-linking	[Using cross-linking]	0.0	2	1	1	1
111443	1710	prior to arrest	[prior to arrest]	0.0	3	1	1	1
111444	1710	involve gene transfection	[involving gene transfection]	0.0	3	1	1	1
111445	1710	95% decrease	[95% decrease]	0.0	2	1	1	1
111446	1710	bend	[bend]	0.0	1	1	1	1
111447	1710	(rt) assay	[(RT) assay]	0.0	2	1	1	1
111448	1710	Ets binding site EBS	[Ets binding site EBS]	0.0	4	1	1	1
111449	1710	intragenic deletion	[Intragenic deletions]	0.0	2	1	1	1
111450	1710	mutant of hiv-1	[mutants of HIV-1]	0.0	3	1	1	1
111451	1710	correlation between the degree	[correlation between the degree]	0.0	4	1	1	1
111452	1710	characteristic.	[characteristic.]	0.0	1	1	1	1
111453	1710	revert to a state,	[reverting to a state,]	0.0	4	1	1	1
111454	1710	cell-permeable camp analogue	[cell-permeable cAMP analogue]	0.0	3	1	1	1
111455	1710	patient with myeloproliferative disease	[patients with myeloproliferative diseases]	0.0	4	1	1	1
111456	1710	disappointing result of clinical trial	[disappointing results of clinical trials]	0.0	5	1	1	1
111457	1710	binding of gata-1 to site	[binding of GATA-1 to sites]	0.0	5	1	1	1
111458	1710	receptor chain	[receptor chains]	0.0	2	1	1	1
111459	1710	Appraisal of therapeutic index of antioxidant	[Appraisal of therapeutic index of antioxidants]	0.0	6	1	1	1
111460	1710	experience toxicity secondary to FUra chemotherapy	[experiencing toxicity secondary to FUra chemotherapy]	0.0	6	1	1	1
111461	1710	contribution of product	[contribution of products]	0.0	3	1	1	1
111462	1710	study of candidate genes.	[study of candidate genes.]	0.0	4	1	1	1
111463	1710	show only cross-reactivity at concentration	[showing only cross-reactivity at concentrations]	0.0	5	1	1	1
111464	1710	anatomy	[anatomy]	0.0	1	1	1	1
111465	1710	gh/prl- produce	[GH/PRL- producing]	0.0	2	1	1	1
111466	1710	function of Oct2	[function of Oct2]	0.0	3	1	1	1
111467	1710	55 kD tnf receptor	[55 kD TNF receptor]	0.0	4	1	1	1
111468	1710	two class transcriptional mutant cell line	[two class transcriptional mutant cell lines]	0.0	6	1	1	1
111469	1710	protein with distant homology to Bcl-2	[protein with distant homology to Bcl-2]	0.0	6	1	1	1
111470	1710	NF-ATc.alpha	[NF-ATc.alpha]	0.0	1	1	1	1
111471	1710	disorder: lack	[disorder: lack]	0.0	2	1	1	1
111472	1710	Vietnam	[Vietnam]	0.0	1	1	1	1
111473	1710	major protein ie1	[major protein IE1]	0.0	3	1	1	1
111474	1710	clinical resistance in chronic asthma	[clinical resistance in chronic asthma]	0.0	5	1	1	1
111475	1710	receptor -negative status	[receptor -negative status]	0.0	3	1	1	1
111476	1710	expression of the genes,	[expression of the genes,]	0.0	4	1	1	1
111477	1710	fetal calf efcs culture	[fetal calf (FCS+) culture]	0.0	4	1	1	1
111478	1710	several line of CEM cell	[several lines of CEM cells]	0.0	5	1	1	1
111479	1710	sera of ebv individual	[sera of EBV individuals]	0.0	4	1	1	1
111480	1710	percent of gamma/delta tcr+ pregnancy lymphocyte	[percent of gamma/delta TCR+ pregnancy lymphocytes]	0.0	6	1	1	1
111481	1710	analysis of e2f dna-binding activity	[analysis of E2F DNA-binding activities]	0.0	5	1	1	1
111482	1710	expression of negative mutant	[expression of negative mutants]	0.0	4	1	1	1
111483	1710	new family	[new family]	0.0	2	2	2	1
111484	1710	murine erythroleukemias	[murine erythroleukemias]	0.0	2	1	1	1
111485	1710	critical illness	[critical illness]	0.0	2	1	1	1
111486	1710	identification of novel regulatory element	[Identification of novel regulatory elements]	0.0	5	1	1	1
111487	1710	mutant glucocorticoid receptor	[mutant glucocorticoid receptors]	0.0	3	1	1	1
111488	1710	inflammatory cell infiltration with necrosis	[inflammatory cell infiltration with necrosis]	0.0	5	1	1	1
111489	1710	pre-existing, cytosolic component	[pre-existing, cytosolic component]	0.0	3	1	1	1
111490	1710	leukocyte subset	[leukocyte subsets]	0.0	2	1	1	1
111491	1710	also, the size	[also, the size]	0.0	3	1	1	1
111492	1710	comparing,	[comparing,]	0.0	1	1	1	1
111493	1710	near-perfect repeat of bp	[near-perfect repeats of bp]	0.0	4	1	1	1
111494	1710	morphology indicative of dysplasia	[morphology indicative of dysplasia]	0.0	4	1	1	1
111495	1710	mv), normalize	[mV), normalizing]	0.0	2	1	1	1
111496	1710	suggest a role of RXR	[suggesting a role of RXR]	0.0	5	1	1	1
111497	1710	corticosteroid asthma	[corticosteroid asthma]	0.0	2	1	1	1
111498	1710	particular, one class	[particular, one class]	0.0	3	1	1	1
111499	1710	stimulus in Jurkat T cell	[stimuli in Jurkat T cells]	0.0	5	1	1	1
111500	1710	translocation of Rap1	[translocation of Rap1]	0.0	3	1	1	1
111501	1710	granulocyte factor factor	[granulocyte factor factor]	0.0	3	1	1	1
111502	1710	b-cell-specific transcription of gene	[B-cell-specific transcription of genes]	0.0	4	1	1	1
111503	1710	evidence in human T lymphocyte	[Evidence in human T lymphocytes]	0.0	5	1	1	1
111504	1710	factor STAT-1	[factor STAT-1]	0.0	2	1	1	1
111505	1710	signals, PMA	[signals, PMA]	0.0	2	1	1	1
111506	1710	t-cell extract consist	[T-cell extracts consisting]	0.0	3	1	1	1
111507	1710	feasibility of this approach	[feasibility of this approach]	0.0	4	1	1	1
111508	1710	transiently express LMP1 from a promoter	[transiently expressing LMP1 from a promoter]	0.0	6	1	1	1
111509	1710	(35 min) submaximal physical exercise ppe	[(35 min) submaximal physical exercise PPE]	0.0	6	1	1	1
111510	1710	contribute to the understanding	[contributing to the understanding]	0.0	4	1	1	1
111511	1710	HIV protease cleavage site	[HIV protease cleavage site]	0.0	4	1	1	1
111512	1710	unique morphologic feature	[unique morphologic features]	0.0	3	1	1	1
111513	1710	correlation between genomic footprinting datum	[correlation between genomic footprinting data]	0.0	5	1	1	1
111514	1710	impairment in human T cell	[impairments in human T cells]	0.0	5	1	1	1
111515	1710	31834500), 3610 (range,	[3183-4450), 3610 (range,]	0.0	3	1	1	1
111516	1710	regulating	[regulating]	0.0	1	1	1	1
111517	1710	th1/th2 differentiation	[Th1/Th2 differentiation]	0.0	2	1	1	1
111518	1710	ic50 value versus 3.1+/-0.2 nmol/L) nmol/L)	[IC50 values versus 3.1+/-0.2 nmol/L) nmol/L)]	0.0	6	1	1	1
111519	1710	up-regulation in T lymphocyte	[Up-regulation in T lymphocytes]	0.0	4	1	1	1
111520	1710	human g0/g1 switch gene	[human G0/G1 switch gene]	0.0	4	1	1	1
111521	1710	cd8+ t-cell	[CD8+ T-cells]	0.0	2	1	1	1
111522	1710	furthermore, prolonged degradation	[Furthermore, prolonged degradation]	0.0	3	1	1	1
111523	1710	chromosomal breakpoint	[chromosomal breakpoint]	0.0	2	1	1	1
111524	1710	min) physical exercise ppe at 70%	[min) physical exercise PPE at 70%]	0.0	6	1	1	1
111525	1710	inhibition by overexpression CD40 up-regulation	[Inhibition by overexpression CD40 up-regulation]	0.0	5	1	1	1
111526	1710	constitutive nuclear translocation of this member	[constitutive nuclear translocation of these members]	0.0	6	1	1	1
111527	1710	about 0.8 microm	[about 0.8 microM]	0.0	3	1	1	1
111528	1710	subsequent maintenance of NFAT	[subsequent maintenance of NFAT]	0.0	4	1	1	1
111529	1710	primary effusion lymphoma	[primary effusion lymphoma]	0.0	3	1	1	1
111530	1710	b cell coactivator	[B cell coactivator]	0.0	3	1	1	1
111531	1710	express a series in wt19 cell	[expressing a series in WT19 cells]	0.0	6	1	1	1
111532	1710	specific recovery from lysate	[specific recovery from lysates]	0.0	4	1	1	1
111533	1710	Novel membrane receptor for aldosterone	[Novel membrane receptors for aldosterone]	0.0	5	1	1	1
111534	1710	(18- healthy female volunteer	[(18- healthy female volunteers]	0.0	4	1	1	1
111535	1710	core binding motif	[core binding motif]	0.0	3	1	1	1
111536	1710	hormone crh	[hormone CRH]	0.0	2	1	1	1
111537	1710	cytokine -secret	[cytokine -secreting]	0.0	2	1	1	1
111538	1710	electromobility shift assay nf-kappa b	[electromobility shift assays NF-kappa B]	0.0	5	1	1	1
111539	1710	essentially complete inhibition	[essentially complete inhibition]	0.0	3	1	1	1
111540	1710	12 mo)	[12 mo)]	0.0	2	1	1	1
111541	1710	great activation of erk2 kinase	[greater activation of ERK2 kinase]	0.0	5	1	1	1
111542	1710	nfat binding activity	[NFAT binding activity]	0.0	3	1	1	1
111543	1710	expression of dominant mapkk-1	[Expression of dominant MAPKK-1]	0.0	4	1	1	1
111544	1710	c-type lectin leukocyte receptor	[C-type lectin leukocyte receptor]	0.0	4	1	1	1
111545	1710	common use as /hypereosinophilic agent	[common use as /hypereosinophilic agents]	0.0	5	1	1	1
111546	1710	subtype of pel	[subtypes of PEL]	0.0	3	1	1	1
111547	1710	peak expiratory flow after prednisolone	[peak expiratory flow after prednisolone]	0.0	5	1	1	1
111548	1710	acid treatment in leukemia	[acid treatment in leukemia]	0.0	4	1	1	1
111549	1710	volunteer by polymerase chain reaction	[volunteers by polymerase chain reaction]	0.0	5	1	1	1
111550	1710	carboxy-terminal amino acid	[carboxy-terminal amino acids]	0.0	3	1	1	1
111551	1710	sensitive monitoring of minimal disease	[sensitive monitoring of minimal disease]	0.0	5	1	1	1
111552	1710	lipophilic substance such as formylpeptide	[lipophilic substances such as formylpeptides]	0.0	5	1	1	1
111553	1710	fraction contain the promoter-binding protein	[fractions containing the promoter-binding protein]	0.0	5	1	1	1
111554	1710	five target	[five targets]	0.0	2	1	1	1
111555	1710	adenocarcinoma monoclonal antibody ing-1	[adenocarcinoma monoclonal antibody ING-1]	0.0	4	1	1	1
111556	1710	beta-phorbol 12-myristate	[beta-phorbol 12-myristate]	0.0	2	1	1	1
111557	1710	myb-transformed cell mthc	[myb-transformed cells MTHC]	0.0	3	1	1	1
111558	1710	important role regulate the response	[important role regulating the response]	0.0	5	1	1	1
111559	1710	region amino acid 286-551	[region amino acids 286-551]	0.0	4	1	1	1
111560	1710	assay with form of EBF	[assays with forms of EBF]	0.0	5	1	1	1
111561	1710	span the nucleotide from position	[spanning the nucleotides from positions]	0.0	5	1	1	1
111562	1710	signal mediator	[signaling mediators]	0.0	2	1	1	1
111563	1710	sp1 activity in the liver culture	[SP1 activity in the liver cultures]	0.0	6	1	1	1
111564	1710	class transactivator CIITA mrna expression	[class transactivator CIITA mRNA expression]	0.0	5	1	1	1
111565	1710	interaction between tbp	[interactions between TBP]	0.0	3	1	1	1
111566	1710	deregulation of calcineurin	[deregulation of calcineurin]	0.0	3	1	1	1
111567	1710	form of membrane-bound DeltaE	[form of membrane-bound DeltaE]	0.0	4	1	1	1
111568	1710	release expression of il-8	[release expression of IL-8]	0.0	4	1	1	1
111569	1710	interaction between tax	[interaction between Tax]	0.0	3	1	1	1
111570	1710	HL cell	[HL cells]	0.0	2	1	1	1
111571	1710	overexpression of ikk complex protein transcription,	[Overexpression of IKK complex protein transcription,]	0.0	6	1	1	1
111572	1710	T function for TCF-1	[T function for TCF-1]	0.0	4	1	1	1
111573	1710	look back at success	[Looking back at successes]	0.0	4	1	1	1
111574	1710	such as helenalin	[such as helenalin]	0.0	3	1	1	1
111575	1710	function of cbp/p300 than histone acetylation	[functions of CBP/p300 than histone acetylation]	0.0	6	1	1	1
111576	1710	S. typhimurium survival	[S. typhimurium survival]	0.0	3	1	1	1
111577	1710	several lymphoid cell line	[several lymphoid cell lines]	0.0	4	1	1	1
111578	1710	polymerase chain method	[polymerase chain method]	0.0	3	1	1	1
111579	1710	expression of tax protein	[Expression of Tax protein]	0.0	4	1	1	1
111580	1710	capacity of cell in	[capacity of cells in]	0.0	4	1	1	1
111581	1710	different levels, include suppression	[different levels, including suppression]	0.0	4	1	1	1
111582	1710	phorbol cell	[phorbol cells]	0.0	2	1	1	1
111583	1710	development of chronic inflammation	[development of chronic inflammation]	0.0	4	1	1	1
111584	1710	contain sh2 domain	[containing SH2 domain]	0.0	3	1	1	1
111585	1710	different schedule (five patient	[different schedules (five patients]	0.0	4	1	1	1
111586	1710	nfat nuclear translocation	[NFAT nuclear translocation]	0.0	3	1	1	1
111587	1710	maximal stimulation	[maximal stimulation]	0.0	2	2	2	1
111588	1710	costimulation with CD3	[costimulation with CD3]	0.0	3	1	1	1
111589	1710	t-cell-leukemia virus type 1	[T-cell-leukemia virus type 1]	0.0	4	1	1	1
111590	1710	compelling evidence for a sequence	[compelling evidence for a sequence]	0.0	5	1	1	1
111591	1710	CREB two isoform	[CREB two isoforms]	0.0	3	1	1	1
111592	1710	engagement by natural ligands,	[engagement by natural ligands,]	0.0	4	1	1	1
111593	1710	binding of superantigen	[Binding of superantigens]	0.0	3	1	1	1
111594	1710	reduction of CAT activity	[reduction of CAT activity]	0.0	4	1	1	1
111595	1710	subsequent accumulation of c-rel	[subsequent accumulation of c-Rel]	0.0	4	1	1	1
111596	1710	amount of rna	[amounts of RNA]	0.0	3	1	1	1
111597	1710	interaction with distinct b coactivator	[interactions with distinct B coactivators]	0.0	5	1	1	1
111598	1710	receptor on the surface	[receptors on the surface]	0.0	4	1	1	1
111599	1710	clinically relevant form	[clinically relevant form]	0.0	3	1	1	1
111600	1710	nuclear factor (NF)-AT AP-1/Octamer	[nuclear factor (NF)-AT AP-1/Octamer]	0.0	4	1	1	1
111601	1710	activation of gata-1	[activation of GATA-1]	0.0	3	1	1	1
111602	1710	gene product from virus htlv-1	[gene products from viruses HTLV-1]	0.0	5	1	1	1
111603	1710	three protein binding sequence	[three protein binding sequences]	0.0	4	1	1	1
111604	1710	suppressive effect of dexamethasone	[suppressive effect of dexamethasone]	0.0	4	1	1	1
111605	1710	transendothelial migration response	[transendothelial migration response]	0.0	3	1	1	1
111606	1710	biopsy from seven patient	[biopsies from seven patients]	0.0	4	1	1	1
111607	1710	tcc assembly	[TCC assembly]	0.0	2	1	1	1
111608	1710	time-dependent differentiation	[time-dependent differentiation]	0.0	2	1	1	1
111609	1710	n-terminal sequencing amino acid	[N-Terminal sequencing amino acids]	0.0	4	1	1	1
111610	1710	two class ii mutant cell line	[two class II mutant cell lines]	0.0	6	1	1	1
111611	1710	marginal level	[marginal levels]	0.0	2	1	1	1
111612	1710	cell lines, protein of weight	[cell lines, proteins of weight]	0.0	5	1	1	1
111613	1710	b co-activator of A-MYB	[B co-activator of A-MYB]	0.0	4	1	1	1
111614	1710	monitoring of residual disease	[monitoring of residual disease]	0.0	4	1	1	1
111615	1710	presence of p65	[presence of p65]	0.0	3	1	1	1
111616	1710	effect on IL-2 promoter activity	[effects on IL-2 promoter activity]	0.0	5	1	1	1
111617	1710	separation due to mechanism	[separation due to mechanisms]	0.0	4	1	1	1
111618	1710	contain amino terminal insert	[containing amino terminal insert]	0.0	4	1	1	1
111619	1710	surface expression of the receptor	[surface expression of the receptor]	0.0	5	1	1	1
111620	1710	cell in center	[cells in centers]	0.0	3	1	1	1
111621	1710	predictive value of support,	[predictive value of support,]	0.0	4	1	1	1
111622	1710	C-terminal hmg box	[C-terminal HMG box]	0.0	3	1	1	1
111623	1710	various type include leukaemia CML	[various types including leukaemia CML]	0.0	5	2	2	1
111624	1710	replacement dose	[replacement dose]	0.0	2	1	1	1
111625	1710	production precursors,	[production precursors,]	0.0	2	1	1	1
111626	1710	trans-acting activator function	[trans-acting activator function]	0.0	3	1	1	1
111627	1710	nucleolin expression	[nucleolin expression]	0.0	2	1	1	1
111628	1710	HBxAg stimulation	[HBxAg stimulation]	0.0	2	1	1	1
111629	1710	thymocyte from mouse	[thymocytes from mice]	0.0	3	1	1	1
111630	1710	recombinant p21ras	[recombinant p21ras]	0.0	2	1	1	1
111631	1710	pre-treatment of cd4+ T cell	[pre-treatment of CD4+ T cells]	0.0	5	1	1	1
111632	1710	latent to viral infection	[latent to viral infection]	0.0	4	1	1	1
111633	1710	71 receptor	[71 receptors]	0.0	2	1	1	1
111634	1710	Jurkat t-cells.	[Jurkat T-cells.]	0.0	2	1	1	1
111635	1710	vector contain wild-type kappab site	[vectors containing wild-type kappaB sites]	0.0	5	1	1	1
111636	1710	er form in Oestrogen-dependent tumour	[ER forms in Oestrogen-dependent tumours]	0.0	5	1	1	1
111637	1710	functional capability of T cell	[functional capabilities of T cells]	0.0	5	1	1	1
111638	1710	molecular effect VDR	[molecular effects VDR]	0.0	3	1	1	1
111639	1710	undergo	[undergoing]	0.0	1	1	1	1
111640	1710	major (mhc) class ii antigen	[major (MHC) class II antigens]	0.0	5	3	3	1
111641	1710	M.Feldman,	[M.Feldman,]	0.0	1	1	1	1
111642	1710	one possible mechanism of transformation	[one possible mechanism of transformation]	0.0	5	1	1	1
111643	1710	disease in leukemia	[disease in leukemia]	0.0	3	1	1	1
111644	1710	basis for the interplay	[basis for the interplay]	0.0	4	1	1	1
111645	1710	fluorogenic peptide assay	[fluorogenic peptide assays]	0.0	3	1	1	1
111646	1710	transactivator of retinoic element-containing promoter	[transactivator of retinoic element-containing promoters]	0.0	5	1	1	1
111647	1710	HL60 cell line	[HL60 cell line]	0.0	3	1	1	1
111648	1710	activity of NK cell	[activity of NK cells]	0.0	4	1	1	1
111649	1710	bare lymphocyte syndrome-associated transactivator	[bare lymphocyte syndrome-associated transactivators]	0.0	4	1	1	1
111650	1710	evidence of regulation	[evidence of regulation]	0.0	3	1	1	1
111651	1710	p38 map	[p38 MAP]	0.0	2	1	1	1
111652	1710	multiple mutation cluster a proto-oncogene encoding	[multiple mutations clustering a proto-oncogene encoding]	0.0	6	1	1	1
111653	1710	activation of caspase -1	[activation of caspase -1]	0.0	4	1	1	1
111654	1710	t-cell receptor alpha-	[T-cell receptor alpha-]	0.0	3	1	1	1
111655	1710	fc gammaRI	[Fc gammaRI]	0.0	2	1	1	1
111656	1710	encode a major component	[encoding a major component]	0.0	4	1	1	1
111657	1710	cellular protein bind	[cellular proteins binding]	0.0	3	1	1	1
111658	1710	rakfkqllq CTL precursor frequency	[RAKFKQLLQ CTL precursor frequency]	0.0	4	1	1	1
111659	1710	approach to therapeutic intervention.	[approach to therapeutic intervention.]	0.0	4	1	1	1
111660	1710	transcriptional activity of a factor	[transcriptional activity of an factor]	0.0	5	1	1	1
111661	1710	signal pathway operate downstream	[signaling pathways operating downstream]	0.0	4	1	1	1
111662	1710	kappab -dependent activity	[kappaB -dependent activity]	0.0	3	1	1	1
111663	1710	3 h of incubation	[3 h of incubation]	0.0	4	1	1	1
111664	1710	differential rescue	[differential rescue]	0.0	2	1	1	1
111665	1710	50 kda/65 kda	[50 kDa/65 kDa]	0.0	3	1	1	1
111666	1710	strategy for the detection of disease	[strategies for the detection of disease.]	0.0	6	1	1	1
111667	1710	cell permissiveness to replication	[cell permissiveness to replication]	0.0	4	1	1	1
111668	1710	heteromeric complex with other protein	[heteromeric complexes with other proteins]	0.0	5	1	1	1
111669	1710	presence of a intact domain	[presence of an intact domain]	0.0	5	1	1	1
111670	1710	importance in the system	[importance in the system]	0.0	4	1	1	1
111671	1710	cell il-5	[cell IL-5]	0.0	2	1	1	1
111672	1710	uninfected blood monocyte	[uninfected blood monocytes]	0.0	3	1	1	1
111673	1710	gammac promoter	[gammac promoter]	0.0	2	1	1	1
111674	1710	several clinically relevant compound	[Several clinically relevant compounds]	0.0	4	1	1	1
111675	1710	tumor er concentration	[tumor ER concentration]	0.0	3	1	1	1
111676	1710	CIITA mrna	[CIITA mRNA]	0.0	2	1	1	1
111677	1710	proteins, cyclophilin	[proteins, cyclophilin]	0.0	2	1	1	1
111678	1710	element il-4re	[element IL-4RE]	0.0	2	1	1	1
111679	1710	cloning of the Epstein-Barr virus	[Cloning of the Epstein-Barr virus]	0.0	5	1	1	1
111680	1710	expression of kappa b-binding activity	[expression of kappa B-binding activity]	0.0	5	1	1	1
111681	1710	protein-protein interaction with component	[protein-protein interaction with components]	0.0	4	1	1	1
111682	1710	(tnfr)-associated factor	[(TNFR)-associated factors]	0.0	2	1	1	1
111683	1710	kD mobility)	[kD mobility)]	0.0	2	1	1	1
111684	1710	specifically regulate map kinase	[specifically regulating MAP kinases]	0.0	4	1	1	1
111685	1710	silencer extend from -392	[silencer extending from -392]	0.0	4	1	1	1
111686	1710	region regulatory element	[region regulatory elements]	0.0	3	1	1	1
111687	1710	inducer of collagenase expression	[inducers of collagenase expression]	0.0	4	1	1	1
111688	1710	NFAT gene expression	[NFAT gene expression]	0.0	3	1	1	1
111689	1710	indicate a relationship between the events.	[indicating a relationship between the events.]	0.0	6	1	1	1
111690	1710	various serum gene	[various serum genes]	0.0	3	1	1	1
111691	1710	amino acid of p95vav	[amino acids of p95vav]	0.0	4	1	1	1
111692	1710	more frequent use	[More frequent use]	0.0	3	1	1	1
111693	1710	processivity	[processivity]	0.0	1	1	1	1
111694	1710	il-6 antibody MoAb	[IL-6 antibody MoAb]	0.0	3	1	1	1
111695	1710	use anti- ptf beta antibody	[using anti- PTF beta antibodies]	0.0	5	1	1	1
111696	1710	APL cell with ifn-gamma	[APL cells with IFN-gamma]	0.0	4	1	1	1
111697	1710	reversible differentiation	[Reversible differentiation]	0.0	2	1	1	1
111698	1710	trifluoromethylketone inhibitor of phospholipase a2	[trifluoromethylketone inhibitors of phospholipase A2]	0.0	5	1	1	1
111699	1710	response in hiv cell	[response in HIV cells]	0.0	4	1	1	1
111700	1710	regulatory element act somewhat independently	[regulatory elements acting somewhat independently]	0.0	5	1	1	1
111701	1710	er regulatory region	[ER regulatory region]	0.0	3	1	1	1
111702	1710	large (12-25 repeats).	[large (12-25 repeats).]	0.0	3	1	1	1
111703	1710	presence of structural element	[presence of structural elements]	0.0	4	1	1	1
111704	1710	active nf-kappa b complex	[active NF-kappa B complex]	0.0	4	1	1	1
111705	1710	relatively high, concentration	[relatively high, concentrations]	0.0	3	1	1	1
111706	1710	expression of gene in acute leukaemia	[Expression of genes in acute leukaemia]	0.0	6	1	1	1
111707	1710	thymidine kinase promoter	[thymidine kinase promoter]	0.0	3	1	1	1
111708	1710	encode immediate-early transactivator	[encoding immediate-early transactivators]	0.0	3	1	1	1
111709	1710	delta-aminolevulinate synthase	[delta-aminolevulinate synthase]	0.0	2	1	1	1
111710	1710	(sffv)	[(SFFV)]	0.0	1	1	1	1
111711	1710	dementia	[dementia]	0.0	1	1	1	1
111712	1710	different transcriptional activity	[different transcriptional activities]	0.0	3	1	1	1
111713	1710	signal in b-lymphocyte precursor	[signal in B-lymphocyte precursors]	0.0	4	1	1	1
111714	1710	response toward Th1	[response toward Th1]	0.0	3	1	1	1
111715	1710	myeloid leukemia m2-type cell line	[myeloid leukemia M2-type cell line]	0.0	5	1	1	1
111716	1710	important site between position	[important site between positions]	0.0	4	1	1	1
111717	1710	[molecular mechanism	[[Molecular mechanism]	0.0	2	2	2	1
111718	1710	intraspecy hybrid the coordinate suppression	[intraspecies hybrids the coordinate suppression]	0.0	5	1	1	1
111719	1710	CD4 promoter activation	[CD4 promoter activation]	0.0	3	1	1	1
111720	1710	comprise the GM-CSF promoter element	[comprising the GM-CSF promoter element]	0.0	5	1	1	1
111721	1710	polymorphonuclear granulocyte	[polymorphonuclear granulocytes]	0.0	2	1	1	1
111722	1710	glucocorticoid type ii	[glucocorticoid type II]	0.0	3	1	1	1
111723	1710	element response element	[element Response Element]	0.0	3	1	1	1
111724	1710	effect on the inducibility	[effect on the inducibility]	0.0	4	1	1	1
111725	1710	8.3 kilobasis	[8.3 kilobases]	0.0	2	1	1	1
111726	1710	granulocyte/macrophage colony	[granulocyte/macrophage colony]	0.0	2	1	1	1
111727	1710	kappa b-like motif at position	[kappa B-like motifs at positions]	0.0	5	1	1	1
111728	1710	stimulation of production	[stimulation of production]	0.0	3	1	1	1
111729	1710	(hdac)	[(HDAC)]	0.0	1	1	1	1
111730	1710	-ltr	[-LTR]	0.0	1	1	1	1
111731	1710	genome-positive b cell by herpesvirus	[genome-positive B cells by herpesvirus]	0.0	5	1	1	1
111732	1710	value of the polyamine pattern	[value of the polyamine patterns]	0.0	5	1	1	1
111733	1710	c-Myb /et	[c-Myb /Ets]	0.0	2	1	1	1
111734	1710	resolution through step	[Resolution through steps]	0.0	3	1	1	1
111735	1710	condition occur in patient suffer	[condition occurring in patients suffering]	0.0	5	1	1	1
111736	1710	bcl-x(l) expression	[Bcl-x(L) expression]	0.0	2	1	1	1
111737	1710	dna-probe	[DNA-probe]	0.0	1	1	1	1
111738	1710	p50-p65 complex from cytoplasmic pools,	[p50-p65 complex from cytoplasmic pools,]	0.0	5	1	1	1
111739	1710	direct molecular effect	[direct molecular effects]	0.0	3	1	1	1
111740	1710	phagocyte function	[phagocyte functions]	0.0	2	1	1	1
111741	1710	binding to receptor protein	[binding to receptor proteins]	0.0	4	1	1	1
111742	1710	effect of pnu156804	[effect of PNU156804]	0.0	3	1	1	1
111743	1710	remedy	[remedies]	0.0	1	1	1	1
111744	1710	coactivate nf-kappab	[coactivating NF-kappaB]	0.0	2	1	1	1
111745	1710	amount of tcr	[amount of TcR]	0.0	3	1	1	1
111746	1710	fasl protein	[FasL protein]	0.0	2	1	1	1
111747	1710	phosphatase-positive osteoclast-like giant cell	[phosphatase-positive osteoclast-like giant cells]	0.0	4	1	1	1
111748	1710	very mild down-regulation	[very mild down-regulation]	0.0	3	1	1	1
111749	1710	down-regulate the immune response	[down-regulating the immune response]	0.0	4	1	1	1
111750	1710	-luc	[-luc]	0.0	1	1	1	1
111751	1710	role initiate that response.	[role initiating that response.]	0.0	4	1	1	1
111752	1710	potentiate interleukin-3 il-3 commitment lineage.	[potentiating interleukin-3 IL-3 commitment lineage.]	0.0	5	1	1	1
111753	1710	transfection of fos -cat construct	[transfection of fos -CAT constructs]	0.0	5	1	1	1
111754	1710	major complex (mhc) class antigen	[major complex (MHC) class antigens]	0.0	5	2	2	1
111755	1710	Epstein-Barr virus the agent	[Epstein-Barr virus the agent]	0.0	4	1	1	1
111756	1710	euthymic patient with bipolar disorder	[euthymic patients with bipolar disorder]	0.0	5	1	1	1
111757	1710	bioactivation of sulphamethoxazole SMX to metabolite	[Bioactivation of sulphamethoxazole SMX to metabolites]	0.0	6	1	1	1
111758	1710	T lymphocyte cell line library	[T lymphocyte cell line libraries]	0.0	5	1	1	1
111759	1710	gene expression follow CD3	[gene expression following CD3]	0.0	4	1	1	1
111760	1710	activation of b element	[activation of B elements]	0.0	4	1	1	1
111761	1710	new function such as downregulation	[new functions such as downregulation]	0.0	5	1	1	1
111762	1710	limited activation of NF-kappa b	[limited activation of NF-kappa B]	0.0	5	1	1	1
111763	1710	factor role in up-regulation	[factor role in up-regulation]	0.0	4	1	1	1
111764	1710	candidate study the effect	[candidate studying the effects]	0.0	4	1	1	1
111765	1710	co-express Spi-1	[co-expressing Spi-1]	0.0	2	1	1	1
111766	1710	factor in the generation	[factor in the generation]	0.0	4	1	1	1
111767	1710	depend on the repression	[depending on the repression]	0.0	4	1	1	1
111768	1710	83-kDa stat3beta	[83-kDa STAT3beta]	0.0	2	1	1	1
111769	1710	kappa b alpha mad3	[kappa B alpha MAD3]	0.0	4	1	1	1
111770	1710	ikappab kinase ikk signalsome activation	[IkappaB kinase IKK signalsome activation]	0.0	5	1	1	1
111771	1710	binding in nuclear extract	[binding in nuclear extracts]	0.0	4	1	1	1
111772	1710	diffuse cell lymphoma	[diffuse cell lymphoma]	0.0	3	1	1	1
111773	1710	infection by adenoviruse	[infection by adenoviruses]	0.0	3	1	1	1
111774	1710	incubation of endothelial cell ECs	[Incubation of endothelial cells ECs]	0.0	5	1	1	1
111775	1710	interleukin differentiation	[Interleukin differentiation]	0.0	2	1	1	1
111776	1710	proteolysis of the terminus	[proteolysis of the terminus]	0.0	4	1	1	1
111777	1710	normal mesothelial cell	[normal mesothelial cells]	0.0	3	1	1	1
111778	1710	clinical strains.	[clinical strains.]	0.0	2	1	1	1
111779	1710	type phenotype	[type phenotypes]	0.0	2	1	1	1
111780	1710	mutagenesis of nf-kappa b motif	[mutagenesis of NF-kappa B motif]	0.0	5	1	1	1
111781	1710	hyperadhesivity of huvec	[hyperadhesivity of HUVECs]	0.0	3	1	1	1
111782	1710	follow the addition	[following the addition]	0.0	3	1	1	1
111783	1710	unstimulated pbl from donor	[unstimulated PBL from donors]	0.0	4	1	1	1
111784	1710	nonphlogistic clearance of apoptotic leukocyte	[nonphlogistic clearance of apoptotic leukocytes]	0.0	5	1	1	1
111785	1710	potent regulator of monocyte/macrophage function	[potent regulator of monocyte/macrophage function]	0.0	5	1	1	1
111786	1710	ineffectiveness as antagonist	[ineffectiveness as antagonists]	0.0	3	2	2	1
111787	1710	reduce catalyst thioredoxin trx	[reducing catalyst thioredoxin Trx]	0.0	4	1	1	1
111788	1710	Recent development	[Recent development]	0.0	2	1	1	1
111789	1710	compartmentalization	[compartmentalization]	0.0	1	1	1	1
111790	1710	event of ZAP-70 such as activation	[events of ZAP-70 such as activation]	0.0	6	1	1	1
111791	1710	tal1 gene rearrangement	[TAL1 gene rearrangement]	0.0	3	1	1	1
111792	1710	effect on lymphocyte inhibition of growth	[effects on lymphocytes inhibition of growth]	0.0	6	1	1	1
111793	1710	splicing of the tsc2 gene	[splicing of the TSC2 gene]	0.0	5	1	1	1
111794	1710	human leukaemia cell	[human leukaemia cells]	0.0	3	1	1	1
111795	1710	13 thyroid fragment	[13 thyroid fragments]	0.0	3	1	1	1
111796	1710	West Africa.	[West Africa.]	0.0	2	1	1	1
111797	1710	apoptosis by GC	[apoptosis by GC]	0.0	3	2	2	1
111798	1710	multifunctional target for protein	[multifunctional target for proteins]	0.0	4	1	1	1
111799	1710	cortisol-dependent BA patient	[cortisol-dependent BA patients]	0.0	3	1	1	1
111800	1710	oxide synthetase activity	[oxide synthetase activity]	0.0	3	1	1	1
111801	1710	TRAF association	[TRAF association]	0.0	2	1	1	1
111802	1710	gene in astrocytomas	[genes in astrocytomas]	0.0	3	1	1	1
111803	1710	neutrophilic differentiation	[neutrophilic differentiation]	0.0	2	1	1	1
111804	1710	apparently identical signal pathways,	[apparently identical signaling pathways,]	0.0	4	1	1	1
111805	1710	transient stimulation with a cocktail	[Transient stimulation with a cocktail]	0.0	5	1	1	1
111806	1710	transmembrane potential	[transmembrane potential]	0.0	2	1	1	1
111807	1710	p27kip1 gene from genomic DNA	[p27Kip1 gene from genomic DNA]	0.0	5	1	1	1
111808	1710	presence of a codon site	[presence of a codon site]	0.0	5	1	1	1
111809	1710	particular major complex (mhc) haplotype	[particular major complex (MHC) haplotypes]	0.0	5	1	1	1
111810	1710	-motif	[-motif]	0.0	1	1	1	1
111811	1710	rt-pcr product	[RT-PCR product]	0.0	2	1	1	1
111812	1710	c-sis/pdgb promoter element necessary	[c-sis/PDGF-B promoter element necessary]	0.0	4	1	1	1
111813	1710	induction by CD40 ligation	[induction by CD40 ligation]	0.0	4	1	1	1
111814	1710	utilize oligonucleotide	[utilizing oligonucleotides]	0.0	2	1	1	1
111815	1710	mammalian gene sry	[mammalian gene Sry]	0.0	3	1	1	1
111816	1710	sodium loss	[sodium losses]	0.0	2	1	1	1
111817	1710	fos to the complex	[Fos to the complex]	0.0	4	1	1	1
111818	1710	protein of molecular weight	[proteins of molecular weights]	0.0	4	1	1	1
111819	1710	possible role of ERK in proliferation	[Possible roles of ERK in proliferation]	0.0	6	1	1	1
111820	1710	role of platelet	[role of platelets]	0.0	3	1	1	1
111821	1710	epitope for mAb	[epitopes for mAb]	0.0	3	1	1	1
111822	1710	mol/L for b cell	[mol/L for B cells]	0.0	4	1	1	1
111823	1710	clinical course (p 0.05, chi2	[clinical course (P 0.05, chi2]	0.0	5	1	1	1
111824	1710	understanding of the activity of heparin	[understanding of the activity of heparin]	0.0	6	1	1	1
111825	1710	mutation ap-1(iii)/	[mutation AP-1(III)/]	0.0	2	1	1	1
111826	1710	lavage cell tuberculosis patient	[lavage cells tuberculosis patients]	0.0	4	1	1	1
111827	1710	production of factor kappab binding	[production of factor kappaB binding]	0.0	5	1	1	1
111828	1710	patient with polycystic ovary syndrome	[patients with polycystic ovary syndrome]	0.0	5	1	1	1
111829	1710	peripheral blood volunteer	[peripheral blood volunteers]	0.0	3	1	1	1
111830	1710	amount of the coactivator cbp	[amounts of the coactivator CBP]	0.0	5	1	1	1
111831	1710	ERK1/2 activation	[ERK1/2 activation]	0.0	2	1	1	1
111832	1710	interaction with the RAR alpha -LBD	[interactions with the RAR alpha -LBD]	0.0	6	1	1	1
111833	1710	govern proliferation	[governing proliferation]	0.0	2	1	1	1
111834	1710	adhesion with inhibition	[adhesion with inhibition]	0.0	3	1	1	1
111835	1710	double oligomer representative	[double oligomers representative]	0.0	3	1	1	1
111836	1710	expression establish a relation	[expression establishing an relation]	0.0	4	1	1	1
111837	1710	include lymphoblastic leukemia	[including lymphoblastic leukemia]	0.0	3	1	1	1
111838	1710	marker of poor prognosis,	[markers of poor prognosis,]	0.0	4	1	1	1
111839	1710	similar (inhibitory) effect	[similar (inhibitory) effects]	0.0	3	1	1	1
111840	1710	inhibition by DN	[inhibition by DN]	0.0	3	1	1	1
111841	1710	incubation microg/mL lps	[incubation microg/mL LPS]	0.0	3	1	1	1
111842	1710	glucocorticoid for a equivalent degree	[glucocorticoids for an equivalent degree]	0.0	5	1	1	1
111843	1710	DMSO differentiation	[DMSO differentiation]	0.0	2	1	1	1
111844	1710	contrast to tyrosine kinase receptor	[contrast to tyrosine kinase receptors]	0.0	5	1	1	1
111845	1710	mobility shift assay with various probe	[Mobility shift assays with various probes]	0.0	6	1	1	1
111846	1710	suggest of importance	[suggesting of importance]	0.0	3	1	1	1
111847	1710	ebv nuclear antigen	[EBV nuclear antigen]	0.0	3	1	1	1
111848	1710	other individual	[other individuals]	0.0	2	1	1	1
111849	1710	nucleotide within the human IL-4 promoter	[nucleotides within the human IL-4 promoter]	0.0	6	1	1	1
111850	1710	yet, the molecule	[Yet, the molecules]	0.0	3	1	1	1
111851	1710	LTR expression	[LTR expression]	0.0	2	1	1	1
111852	1710	inflammation in animal model	[inflammation in animal models]	0.0	4	1	1	1
111853	1710	ig enhancer	[Ig enhancer]	0.0	2	1	1	1
111854	1710	correlation between ngal expression	[correlation between NGAL expression]	0.0	4	1	1	1
111855	1710	produce infectious progeny	[producing infectious progeny]	0.0	3	1	1	1
111856	1710	same differentiation response	[same differentiation response]	0.0	3	1	1	1
111857	1710	isoform of the estrogen receptor	[isoforms of the estrogen receptor]	0.0	5	1	1	1
111858	1710	compounds, such as l-cystine	[compounds, such as L-cystine]	0.0	4	1	1	1
111859	1710	multiplicity	[multiplicity]	0.0	1	1	1	1
111860	1710	IL-5 t-cell line	[IL-5 T-cell line]	0.0	3	1	1	1
111861	1710	other inhibitor include pervanadate	[other inhibitors including pervanadate]	0.0	4	1	1	1
111862	1710	promising tool	[promising tool]	0.0	2	1	1	1
111863	1710	leukemia involve the arm	[leukemia involving the arm]	0.0	4	1	1	1
111864	1710	translocation of the heterodimer nf-kappa b	[translocation of the heterodimer NF-kappa B]	0.0	6	1	1	1
111865	1710	[age-related change in lymphocyte of person	[[Age-related changes in lymphocytes of persons]	0.0	6	1	1	1
111866	1710	subpopulation the double-positive (dp) CD4	[subpopulation the double-positive (DP) CD4]	0.0	5	1	1	1
111867	1710	peptide ANG ii	[peptide ANG II]	0.0	3	1	1	1
111868	1710	cell possible enhancement transactivate protein tax	[cells possible enhancement transactivating protein Tax]	0.0	6	1	1	1
111869	1710	cloning of the DNA	[cloning of the DNA]	0.0	4	1	1	1
111870	1710	expansion) (by stimulation	[expansion) (by stimulation]	0.0	3	1	1	1
111871	1710	treatment with mutant form	[Treatment with mutant forms]	0.0	4	1	1	1
111872	1710	2 bipotent myeloid progenitor cell	[2 bipotent myeloid progenitor cells]	0.0	5	1	1	1
111873	1710	total nonsmok asthmatic patient	[total nonsmoking asthmatic patients]	0.0	4	1	1	1
111874	1710	distinct domain the ligand-binding domain	[distinct domains the ligand-binding domain]	0.0	5	1	1	1
111875	1710	function in T lymphocyte	[functions in T lymphocytes]	0.0	4	1	1	1
111876	1710	Cbf alpha subunit CBF alpha	[Cbf alpha subunit CBF alpha]	0.0	5	1	1	1
111877	1710	complex system	[complex system]	0.0	2	1	1	1
111878	1710	phosphorothioate oligodeoxynucleotides complementary	[phosphorothioate oligodeoxynucleotides complementary]	0.0	3	1	1	1
111879	1710	mechanism with the class gene	[mechanism with the class genes]	0.0	5	1	1	1
111880	1710	optimal function of oct-1 /oca-b	[optimal function of Oct-1 /OCA-B]	0.0	5	1	1	1
111881	1710	activation in T cell progenitor	[activation in T cell progenitors]	0.0	5	1	1	1
111882	1710	cells, use a specific antibody	[cells, using a specific antibody]	0.0	5	1	1	1
111883	1710	criteria]	[criteria]]	0.0	1	1	1	1
111884	1710	exogenous growth	[exogenous growth]	0.0	2	1	1	1
111885	1710	subset include fcepsilonriib	[subset including FcepsilonRIIb]	0.0	3	1	1	1
111886	1710	criteria.	[criteria.]	0.0	1	1	1	1
111887	1710	regulation of immunoglobulin gene expression	[regulation of immunoglobulin gene expression]	0.0	5	1	1	1
111888	1710	region on the LMP promoter	[region on the LMP promoter]	0.0	5	1	1	1
111889	1710	inhibit expression of adhesion molecule	[inhibiting expression of adhesion molecules]	0.0	5	1	1	1
111890	1710	instead, signal transduction	[Instead, signal transduction]	0.0	3	1	1	1
111891	1710	mononuclear leukocyte of healthy male	[mononuclear leukocytes of healthy males]	0.0	5	1	1	1
111892	1710	murine IL-2 element	[murine IL-2 element]	0.0	3	1	1	1
111893	1710	HLA-DR3 with no association of hla-dr3	[HLA-DR3 with no association of HLA-DR3]	0.0	6	1	1	1
111894	1710	many patient with sjogren' syndrome (ss)	[Many patients with Sjogren's syndrome (SS)]	0.0	6	1	1	1
111895	1710	synthesis in material	[synthesis in material]	0.0	3	1	1	1
111896	1710	pro-interleukin-1beta gene	[pro-interleukin-1beta gene]	0.0	2	1	1	1
111897	1710	T lymphocyte by aspirin drug	[T lymphocytes by aspirin drugs]	0.0	5	1	1	1
111898	1710	site in the beta-globin loci	[sites in the beta-globin loci]	0.0	5	1	1	1
111899	1710	loop region	[loop regions]	0.0	2	1	1	1
111900	1710	inhibitor of the production of (tnf)-alpha	[inhibitors of the production of (TNF)-alpha]	0.0	6	1	1	1
111901	1710	role in vcam-1 expression	[role in VCAM-1 expression]	0.0	4	1	1	1
111902	1710	urinary cortisol excretion in FMS	[Urinary cortisol excretion in FMS]	0.0	5	1	1	1
111903	1710	activation of human cell	[Activation of human cells]	0.0	4	1	1	1
111904	1710	neutrophil migration during inflammation	[neutrophil migration during inflammation]	0.0	4	1	1	1
111905	1710	iddm subject 8	[IDDM subjects 8]	0.0	3	1	1	1
111906	1710	zipper DNA binding motif	[zipper DNA binding motif]	0.0	4	1	1	1
111907	1710	demonstrate the potent immunosuppressive activity	[demonstrating the potent immunosuppressive activity]	0.0	5	1	1	1
111908	1710	Albuminemia platelet factor	[Albuminemia Platelet Factor]	0.0	3	1	1	1
111909	1710	complex contain 35s- tr alpha	[complexes containing 35S- TR alpha]	0.0	5	1	1	1
111910	1710	protein conjugation	[protein conjugation]	0.0	2	1	1	1
111911	1710	modulation of cd23	[modulation of CD23]	0.0	3	1	1	1
111912	1710	development (with respect	[development (with respect]	0.0	3	1	1	1
111913	1710	respect to inhibition	[respect to inhibition]	0.0	3	1	1	1
111914	1710	tnf-treated umbilical vein cell HUVECs	[TNF-treated umbilical vein cells HUVECs]	0.0	5	1	1	1
111915	1710	majority of T cell	[majority of T cells]	0.0	4	1	1	1
111916	1710	normal gene expression in glial cell	[normal gene expression in glial cells]	0.0	6	1	1	1
111917	1710	contain as a enhancer	[containing as an enhancer]	0.0	4	1	1	1
111918	1710	individual.	[individual.]	0.0	1	1	1	1
111919	1710	individual,	[individual,]	0.0	1	1	1	1
111920	1710	microg/ml in PMA u1 cell respectively.	[microg/ml in PMA U1 cells respectively.]	0.0	6	1	1	1
111921	1710	DNA polymerase inhibitor acid	[DNA polymerase inhibitor acid]	0.0	4	1	1	1
111922	1710	expression of tax function	[expression of Tax function]	0.0	4	1	1	1
111923	1710	addition in u-937 cell	[addition in U-937 cells]	0.0	4	1	1	1
111924	1710	degradation in lipopolysaccharide monocytic cell	[degradation in lipopolysaccharide monocytic cells]	0.0	5	1	1	1
111925	1710	level relevant to disease	[levels relevant to disease]	0.0	4	1	1	1
111926	1710	homologous lps	[homologous LPS]	0.0	2	1	1	1
111927	1710	SML lymphocyte	[SML lymphocytes]	0.0	2	1	1	1
111928	1710	formation of the dimer b subunit	[formation of the dimer B subunits]	0.0	6	1	1	1
111929	1710	component of a response	[component of a response]	0.0	4	1	1	1
111930	1710	wild-type -resistant leukemic ecem) cell	[wild-type -resistant leukemic (CEM) cells]	0.0	5	1	1	1
111931	1710	mechanism of anoxia/reoxygenation-induced neutrophil adherence	[mechanisms of anoxia/reoxygenation-induced neutrophil adherence]	0.0	5	1	1	1
111932	1710	Exploration	[Exploration]	0.0	1	1	1	1
111933	1710	rela -i	[RelA -I]	0.0	2	1	1	1
111934	1710	human immunodeficiency virus entry into cell	[human immunodeficiency virus entry into cells]	0.0	6	1	1	1
111935	1710	80.2 15.5 (p 0.05, p	[80.2 15.5 (P 0.05, P]	0.0	5	1	1	1
111936	1710	factor into a promoter	[factor into a promoter]	0.0	4	1	1	1
111937	1710	linkage between marker	[linkage between markers]	0.0	3	1	1	1
111938	1710	I interferon to receptor	[I interferon to receptors]	0.0	4	1	1	1
111939	1710	putatively non-cross-resisting agent	[putatively non-cross-resisting agents]	0.0	3	1	1	1
111940	1710	comparing, in cases, constitutive DNA	[comparing, in cases, constitutive DNA]	0.0	5	1	1	1
111941	1710	alcohol-induced regulation of nuclear factor-kappa beta	[Alcohol-induced regulation of nuclear factor-kappa beta]	0.0	6	1	1	1
111942	1710	HMG i/y	[HMG I/Y]	0.0	2	1	1	1
111943	1710	trophoblast cell	[trophoblast cells]	0.0	2	1	1	1
111944	1710	cell cycle- control	[cell cycle- controlling]	0.0	3	1	1	1
111945	1710	other family member	[other family members]	0.0	3	1	1	1
111946	1710	1.5 nm	[1.5 nM]	0.0	2	1	1	1
111947	1710	th protein	[TH protein]	0.0	2	1	1	1
111948	1710	rest lymphocyte from peripheral blood	[resting lymphocytes from peripheral blood]	0.0	5	1	1	1
111949	1710	stringency of viral latency	[stringency of viral latency]	0.0	4	1	1	1
111950	1710	level of 6%	[level of 6%]	0.0	3	1	1	1
111951	1710	Differential regulation a study	[Differential regulation a study]	0.0	4	1	1	1
111952	1710	band range to 55 kd,	[bands ranging to 55 kD,]	0.0	5	1	1	1
111953	1710	suppress activation of STAT6	[suppressing activation of STAT6]	0.0	4	1	1	1
111954	1710	involve activation of form stat3alpha	[involving activation of forms STAT3alpha]	0.0	5	1	1	1
111955	1710	exon, result	[exon, resulting]	0.0	2	1	1	1
111956	1710	Sp1-binding site	[Sp1-binding site]	0.0	2	1	1	1
111957	1710	late time point P;	[later time points h;]	0.0	4	1	1	1
111958	1710	TCEd T cell element	[TCEd T cell element]	0.0	4	1	1	1
111959	1710	factor-kappa b tnf-alpha release	[factor-kappa B TNF-alpha release]	0.0	4	1	1	1
111960	1710	dose of budesonide	[doses of budesonide]	0.0	3	1	1	1
111961	1710	stimulation with phytohaemagglutinin pha	[stimulation with phytohaemagglutinin PHA]	0.0	4	1	1	1
111962	1710	36 to 48 h	[36 to 48 h]	0.0	4	1	1	1
111963	1710	autocrine regulatory mechanism	[autocrine regulatory mechanism]	0.0	3	1	1	1
111964	1710	reduction of nfat1 activity	[reduction of NFAT1 activity]	0.0	4	1	1	1
111965	1710	low level of viral transcription transcription	[Low levels of viral transcription transcription]	0.0	6	1	1	1
111966	1710	cosmid probe	[Cosmid probe]	0.0	2	1	1	1
111967	1710	hence, integration	[Hence, integration]	0.0	2	1	1	1
111968	1710	correlation between hyperthermia	[correlation between hyperthermia]	0.0	3	1	1	1
111969	1710	translocation of protein kinase	[translocation of protein kinase]	0.0	4	1	1	1
111970	1710	factor.kappa	[factor.kappa]	0.0	1	1	1	1
111971	1710	positive autoregulation of gr expression	[positive autoregulation of GR expression]	0.0	5	1	1	1
111972	1710	butyrate esterase staining	[butyrate esterase staining]	0.0	3	1	1	1
111973	1710	response to the protein	[responses to the proteins]	0.0	4	1	1	1
111974	1710	mutant of Toll	[mutant of Toll]	0.0	3	1	1	1
111975	1710	derivate	[derivates,]	0.0	1	1	1	1
111976	1710	expression in uninduced cell	[expression in uninduced cells]	0.0	4	1	1	1
111977	1710	level of transcription transcription	[levels of transcription transcription]	0.0	4	1	1	1
111978	1710	nuclear factor specific	[nuclear factor specific]	0.0	3	2	2	1
111979	1710	region of mAb	[regions of mAb]	0.0	3	1	1	1
111980	1710	interleukin 4 gene	[interleukin 4 gene]	0.0	3	1	1	1
111981	1710	common step,	[common step,]	0.0	2	1	1	1
111982	1710	complete sequence	[complete sequence]	0.0	2	1	1	1
111983	1710	virtually all cell-specific gene	[virtually all cell-specific genes]	0.0	4	1	1	1
111984	1710	group of patient suffer	[groups of patients suffering]	0.0	4	1	1	1
111985	1710	bzlf1 transactivator protein in oral leukoplakia	[BZLF1 transactivator protein in oral leukoplakia]	0.0	6	1	1	1
111986	1710	cytogenetic study	[Cytogenetic studies]	0.0	2	1	1	1
111987	1710	chain gene in cell	[chain genes in cells]	0.0	4	1	1	1
111988	1710	variety include interferon	[variety including interferons]	0.0	3	1	1	1
111989	1710	t-cell gene during thymocyte ontogeny	[T-cell genes during thymocyte ontogeny]	0.0	5	1	1	1
111990	1710	normal subject (bind capacity	[normal subjects (binding capacity]	0.0	4	1	1	1
111991	1710	xeroderma pigmentosum group	[xeroderma pigmentosum groups]	0.0	3	1	1	1
111992	1710	control the phosphorylation state	[controlling the phosphorylation state]	0.0	4	1	1	1
111993	1710	main co-activator for the expression	[main co-activator for the expression]	0.0	5	1	1	1
111994	1710	hiv-1 -infected patient	[HIV-1 -infected patients]	0.0	3	1	1	1
111995	1710	anaphylaxis	[anaphylaxis]	0.0	1	1	1	1
111996	1710	progression of type include leukaemia CML	[progression of types including leukaemia CML]	0.0	6	2	2	1
111997	1710	(control	[(control]	0.0	1	1	1	1
111998	1710	common intermediate structure	[common intermediate structure]	0.0	3	1	1	1
111999	1710	study on population	[studies on populations]	0.0	3	1	1	1
112000	1710	form of the receptor	[form of the receptor]	0.0	4	1	1	1
112001	1710	presence of 5'hs2	[presence of 5'HS2]	0.0	3	1	1	1
112002	1710	type ii receptor in ovulation woman	[Type II receptors in ovulation women]	0.0	6	1	1	1
112003	1710	cd15lo, cd34+/-, hla-dr cd16	[CD15lo, CD34+/-, HLA-DR CD16]	0.0	4	1	1	1
112004	1710	B2 site,	[B2 site,]	0.0	2	1	1	1
112005	1710	anti-SSB	[anti-SSB]	0.0	1	1	1	1
112006	1710	enhancer activation in monocyte	[enhancer activation in monocytes]	0.0	4	1	1	1
112007	1710	mnp-1 expression	[MNP-1 expression]	0.0	2	1	1	1
112008	1710	d.baltimore,	[D.Baltimore,]	0.0	1	1	1	1
112009	1710	also by the result displacement	[also by the resulting displacement]	0.0	5	1	1	1
112010	1710	high, concentration	[high, concentrations]	0.0	2	1	1	1
112011	1710	considerable proportion	[considerable proportion]	0.0	2	1	1	1
112012	1710	induction without inflammatory cytokine production	[Induction without inflammatory cytokine production]	0.0	5	1	1	1
112013	1710	alpha 4	[alpha 4]	0.0	2	1	1	1
112014	1710	establish pbmc culture in serum-contain colony	[establishing PBMC cultures in serum-containing colonies]	0.0	6	1	1	1
112015	1710	show essential for the RA effect	[showing essential for the RA effect]	0.0	6	1	1	1
112016	1710	65 kda p65 polypeptide	[65 kDa p65 polypeptides]	0.0	4	1	1	1
112017	1710	grow myeloid cell line	[growing myeloid cell line]	0.0	4	1	1	1
112018	1710	novel RAR -selective antagonist	[novel RAR -selective antagonist]	0.0	4	1	1	1
112019	1710	cover the complete 491-amino-acid sequence	[covering the complete 491-amino-acid sequence]	0.0	5	1	1	1
112020	1710	helix-loop-helix motif	[helix-loop-helix motifs]	0.0	2	1	1	1
112021	1710	two nf-kappa b binding sites)	[two NF-kappa B binding sites)]	0.0	5	1	1	1
112022	1710	production of major cytokine	[production of major cytokines]	0.0	4	1	1	1
112023	1710	stimulation of cd4+ t-cell clone	[Stimulation of CD4+ T-cell clones]	0.0	5	1	1	1
112024	1710	extreme phenotype	[extreme phenotypes]	0.0	2	1	1	1
112025	1710	chronic inflammatory disorder a problem	[chronic inflammatory disorders a problem]	0.0	5	1	1	1
112026	1710	anti- inhibition	[anti- inhibition]	0.0	2	1	1	1
112027	1710	include JAK2	[including JAK2]	0.0	2	1	1	1
112028	1710	property regard phosphorylation	[properties regarding phosphorylation]	0.0	3	1	1	1
112029	1710	cells, use a antibody	[cells, using a antibody]	0.0	4	1	1	1
112030	1710	include JAK1	[including JAK1]	0.0	2	1	1	1
112031	1710	significant correlation between high infiltration	[significant correlation between high infiltration]	0.0	5	1	1	1
112032	1710	stat binding	[STAT binding]	0.0	2	1	1	1
112033	1710	stimulation of alpha production	[stimulation of alpha production]	0.0	4	1	1	1
112034	1710	produce the transcriptional regulating protein	[producing the transcriptional regulating proteins]	0.0	5	1	1	1
112035	1710	leukocyte recruitment to lesion	[leukocyte recruitment to lesions]	0.0	4	1	1	1
112036	1710	coordination of the response to injury	[Coordination of the response to injury]	0.0	6	1	1	1
112037	1710	generate the diversity	[generating the diversity]	0.0	3	1	1	1
112038	1710	stomach cancer cell line	[stomach cancer cell line]	0.0	4	1	1	1
112039	1710	alteration cis-element	[alteration cis-element]	0.0	2	1	1	1
112040	1710	hiv replication in phagocyte	[HIV replication in phagocytes]	0.0	4	1	1	1
112041	1710	rdna encoding protein	[cDNAs encoding proteins]	0.0	3	1	1	1
112042	1710	immunodeficiency virus type-1 transcription	[immunodeficiency virus type-1 transcription]	0.0	4	1	1	1
112043	1710	nf-kappa b mrna	[NF-kappa B mRNA]	0.0	3	1	1	1
112044	1710	amplify cellular event lead	[amplifying cellular events leading]	0.0	4	1	1	1
112045	1710	other primate with glucocorticoid resistance	[other primates with glucocorticoid resistance]	0.0	5	1	1	1
112046	1710	many inducible gene	[many inducible genes]	0.0	3	1	1	1
112047	1710	uptake with advanced failure A-CRF	[uptake with advanced failure A-CRF]	0.0	5	1	1	1
112048	1710	GM-CSFRalpha mutant	[GM-CSFRalpha mutants]	0.0	2	1	1	1
112049	1710	proportion of (palmitic acid	[proportions of (palmitic acids]	0.0	4	1	1	1
112050	1710	repeat gene activity	[repeat gene activity]	0.0	3	1	1	1
112051	1710	ESb-L T	[ESb-L T]	0.0	2	1	1	1
112052	1710	cellular processes, for example,	[cellular processes, for example,]	0.0	4	1	1	1
112053	1710	discovery in T cell malignancy	[discovery in T cell malignancies]	0.0	5	1	1	1
112054	1710	Kmone value of microm	[Km value of microM]	0.0	4	1	1	1
112055	1710	peak of basal activity	[peaks of basal activity]	0.0	4	1	1	1
112056	1710	eosinophil with il-5	[eosinophils with IL-5]	0.0	3	1	1	1
112057	1710	regulate localization	[regulating localization]	0.0	2	1	1	1
112058	1710	TCL1 oncogene activation	[TCL1 oncogene activation]	0.0	3	1	1	1
112059	1710	induction of fra-1 engagement	[Induction of fra-1 engagement]	0.0	4	1	1	1
112060	1710	use retinoid with receptor binding specificity	[Using retinoids with receptor binding specificity]	0.0	6	1	1	1
112061	1710	originate bp	[originating bp]	0.0	2	1	1	1
112062	1710	complex network	[complex network]	0.0	2	1	1	1
112063	1710	molecular mechanism of neutrophil adherence	[Molecular mechanisms of neutrophil adherence]	0.0	5	1	1	1
112064	1710	effect on function in vitro	[effect on functions in vitro]	0.0	5	1	1	1
112065	1710	require the addition of tfiid	[requiring the addition of TFIID]	0.0	5	1	1	1
112066	1710	nuclear calcium/calmodulin-dependent protein kinase	[nuclear calcium/calmodulin-dependent protein kinase]	0.0	4	1	1	1
112067	1710	effect on this sites.	[effects on these sites.]	0.0	4	1	1	1
112068	1710	activation of e2f transcription	[Activation of E2F transcription]	0.0	4	1	1	1
112069	1710	cytokine on IL-2 apoptosis	[cytokines on IL-2 apoptosis]	0.0	4	1	1	1
112070	1710	serine-phenylalanine "SFS" domain	[serine-phenylalanine "SFS" domain]	0.0	3	1	1	1
112071	1710	alpha-lipoate	[alpha-lipoate]	0.0	1	1	1	1
112072	1710	act of each other, control expression	[acting of each other, control expression]	0.0	6	1	1	1
112073	1710	basis of infection	[basis of infections]	0.0	3	1	1	1
112074	1710	stain lymphocyte	[staining lymphocytes]	0.0	2	1	1	1
112075	1710	human T cell with concentration	[human T cells with concentrations]	0.0	5	1	1	1
112076	1710	vitamin d receptor VDRnuc	[vitamin D receptor VDRnuc]	0.0	4	1	1	1
112077	1710	oxidant hypochlorous acid hocl mm)	[oxidant hypochlorous acid HOCl mM)]	0.0	5	1	1	1
112078	1710	kill by cytolytic lymphocyte	[killing by cytolytic lymphocytes]	0.0	4	1	1	1
112079	1710	cis-acting control element	[cis-acting control elements]	0.0	3	1	1	1
112080	1710	positive margin (31% at years).	[positive margins (31% at years).]	0.0	5	1	1	1
112081	1710	low level of constitutive hiv production	[low levels of constitutive HIV production]	0.0	6	1	1	1
112082	1710	[effect of the regimen on change	[[Effect of the regimen on changes]	0.0	6	1	1	1
112083	1710	oncostatin m	[oncostatin M]	0.0	2	1	1	1
112084	1710	whole-cell assay with [3H]dexamethasone	[whole-cell assay with [3H]dexamethasone]	0.0	4	1	1	1
112085	1710	g1 checkpoint	[G1 checkpoint]	0.0	2	1	1	1
112086	1710	selective expression of a receptor component	[Selective expression of an receptor component]	0.0	6	1	1	1
112087	1710	occurrence of region 1a reiteration mutant	[occurrence of region 1A reiteration mutants]	0.0	6	1	1	1
112088	1710	two protein nf-kappa b (consist	[two proteins NF-kappa B (consisting]	0.0	5	1	1	1
112089	1710	hl-60r subclone	[HL-60R subclone]	0.0	2	1	1	1
112090	1710	process involve stage	[process involving stages]	0.0	3	1	1	1
112091	1710	prime from cellular signal	[priming from cellular signal]	0.0	4	1	1	1
112092	1710	level of dp	[levels of DP]	0.0	3	1	1	1
112093	1710	chemotactic migration ChtM	[chemotactic migration ChtM]	0.0	3	1	1	1
112094	1710	production of colony-stimulating factor	[production of colony-stimulating factor]	0.0	4	1	1	1
112095	1710	lead to oxidative activation	[leading to oxidative activation]	0.0	4	1	1	1
112096	1710	position 10182 of exon	[position 10182 of exon]	0.0	4	1	1	1
112097	1710	ebv DNA molecule	[EBV DNA molecule]	0.0	3	1	1	1
112098	1710	oncogenic gene	[oncogenic genes]	0.0	2	1	1	1
112099	1710	level of er	[levels of ER]	0.0	3	1	1	1
112100	1710	somatic hypermutation act	[somatic hypermutation acting]	0.0	3	1	1	1
112101	1710	two control element	[two control elements]	0.0	3	1	1	1
112102	1710	CVZ -resistant cell	[CVZ -resistant cells]	0.0	3	1	1	1
112103	1710	resolution of disease	[resolution of diseases]	0.0	3	1	1	1
112104	1710	zinc-finger protein	[zinc-finger proteins]	0.0	2	1	1	1
112105	1710	ability in response	[ability in response]	0.0	3	1	1	1
112106	1710	oriP the origin	[oriP the origin]	0.0	3	1	1	1
112107	1710	karyotypic study	[karyotypic studies]	0.0	2	1	1	1
112108	1710	establish the cross-specy effectiveness	[establishing the cross-species effectiveness]	0.0	4	1	1	1
112109	1710	induction 1 infection	[Induction 1 infection]	0.0	3	1	1	1
112110	1710	pmol/L	[pmol/L]	0.0	1	1	1	1
112111	1710	TRAIL tnf-related apoptosis ligand a dil	[TRAIL TNF-related apoptosis ligand a DIL]	0.0	6	1	1	1
112112	1710	65-kd protein	[65-kD protein]	0.0	2	1	1	1
112113	1710	mu/l insulin in the incubation medium.	[mU/L insulin in the incubation medium.]	0.0	6	1	1	1
112114	1710	exposure of T lymphocyte	[Exposure of T lymphocytes]	0.0	4	1	1	1
112115	1710	evidence for direct coupling	[evidence for direct coupling]	0.0	4	1	1	1
112116	1710	specificity of htlv-1 tax	[specificity of HTLV-1 Tax]	0.0	4	1	1	1
112117	1710	adenovirus 12 cell	[adenovirus 12 cells]	0.0	3	1	1	1
112118	1710	show weak cross-reactivity at concentration	[showing weak cross-reactivity at concentrations]	0.0	5	1	1	1
112119	1710	include 3 aml with morphology	[including 3 AML with morphology]	0.0	5	1	1	1
112120	1710	indicate responsible	[indicating responsible]	0.0	2	1	1	1
112121	1710	level of cu	[levels of Cu]	0.0	3	1	1	1
112122	1710	pmol/l	[pmol/l]	0.0	1	1	1	1
112123	1710	genome evolution	[genome evolution]	0.0	2	1	1	1
112124	1710	level of cl	[levels of CL]	0.0	3	1	1	1
112125	1710	tyrosine -phosphorylated motif	[tyrosine -phosphorylated motifs]	0.0	3	1	1	1
112126	1710	IFN-gamma promoter	[IFN-gamma promoter]	0.0	2	1	1	1
112127	1710	23 to 40% clearly cells, respectively),	[23 to 40% clearly cells, respectively),]	0.0	6	1	1	1
112128	1710	lymphocyte of person with hypertension	[lymphocytes of persons with hypertension]	0.0	5	1	1	1
112129	1710	presence of mab	[presence of mAb]	0.0	3	1	1	1
112130	1710	RU 38486	[RU 38486]	0.0	2	1	1	1
112131	1710	develop nervous system	[developing nervous system]	0.0	3	1	1	1
112132	1710	affinity between patient	[affinity between patients]	0.0	3	1	1	1
112133	1710	lead to hyponatremia	[leading to hyponatremia]	0.0	3	1	1	1
112134	1710	MHC -diverse population	[MHC -diverse population]	0.0	3	1	1	1
112135	1710	analysis of V region promoter	[analyses of V region promoters]	0.0	5	1	1	1
112136	1710	fusion follow translocation	[fusion following translocations]	0.0	3	1	1	1
112137	1710	syndrome in advanced stage	[syndromes in advanced stage]	0.0	4	1	1	1
112138	1710	other isomerase inhibitor	[other isomerase inhibitors]	0.0	3	1	1	1
112139	1710	receptor gr expression	[receptor GR expression]	0.0	3	1	1	1
112140	1710	gamma 3	[gamma 3]	0.0	2	1	1	1
112141	1710	gamma 1	[gamma 1]	0.0	2	1	1	1
112142	1710	activate factor g-csf signal transduction pathway	[activating factor G-CSF signal transduction pathways]	0.0	6	1	1	1
112143	1710	activation in a -resistant pathway	[Activation in A -resistant pathway]	0.0	5	1	1	1
112144	1710	other epithelial tumor ag	[other epithelial tumor Ag]	0.0	4	1	1	1
112145	1710	class MHC gene	[class MHC genes]	0.0	3	1	1	1
112146	1710	effect on cytotoxicity	[effect on cytotoxicity]	0.0	3	1	1	1
112147	1710	intracellular signal include hyperresponsiveness	[intracellular signaling including hyperresponsiveness]	0.0	4	1	1	1
112148	1710	vernal keratoconjunctivitis vkc	[vernal keratoconjunctivitis VKC]	0.0	3	1	1	1
112149	1710	Addition to U1 cell	[Addition to U1 cells]	0.0	4	1	1	1
112150	1710	FK506 pathway	[FK506 pathway]	0.0	2	1	1	1
112151	1710	e2a-pbx1	[E2a-Pbx1]	0.0	1	1	1	1
112152	1710	observation on the distinct regulation	[observations on the distinct regulation]	0.0	5	1	1	1
112153	1710	Southern blot analysis of human DNA	[Southern blot analysis of human DNA]	0.0	6	1	1	1
112154	1710	transcription (stat)1	[transcription (Stat)1]	0.0	2	1	1	1
112155	1710	complex protein	[complexes protein]	0.0	2	1	1	1
112156	1710	E1A oncogene induction of susceptibility kill	[E1A oncogene induction of susceptibility killing]	0.0	6	1	1	1
112157	1710	reiteration	[reiteration]	0.0	1	1	1	1
112158	1710	interaction between positive element	[interactions between positive elements]	0.0	4	1	1	1
112159	1710	transcript of 2 kilobasis	[transcript of 2 kilobases]	0.0	4	1	1	1
112160	1710	long-lasting stimulatory effect	[long-lasting stimulatory effect]	0.0	3	1	1	1
112161	1710	condition of cell stimulation	[conditions of cell stimulation]	0.0	4	1	1	1
112162	1710	normal woman of childbearing age.	[normal women of childbearing age.]	0.0	5	1	1	1
112163	1710	dominant effector on dna-binding activity	[dominant effector on DNA-binding activity]	0.0	5	1	1	1
112164	1710	estrogen receptor tumor status	[estrogen receptor tumor status]	0.0	4	1	1	1
112165	1710	prediction into question	[prediction into question]	0.0	3	1	1	1
112166	1710	CD8+CD28null T	[CD8+CD28null T]	0.0	2	1	1	1
112167	1710	encode oct-binding factor a protein	[encoding Oct-binding factor a protein]	0.0	5	1	1	1
112168	1710	ic50 value nmol/L) nmol/L)	[IC50 values nmol/L) nmol/L)]	0.0	4	1	1	1
112169	1710	MHC class inducibility	[MHC class inducibility]	0.0	3	1	1	1
112170	1710	contain a octamer motif	[containing an octamer motif]	0.0	4	1	1	1
112171	1710	enhancer-mediated activation	[enhancer-mediated activation]	0.0	2	1	1	1
112172	1710	R.Cheynier, M.Feldman, P.S.Sarin,	[R.Cheynier, M.Feldman, P.S.Sarin,]	0.0	3	1	1	1
112173	1710	persistent accumulation of RelB	[persistent accumulation of RelB]	0.0	4	2	2	1
112174	1710	regulate protein as polyclonal stimulus	[regulating proteins as polyclonal stimuli]	0.0	5	1	1	1
112175	1710	ca2+ concentration from the pool	[Ca2+ concentration from the pool]	0.0	5	1	1	1
112176	1710	correlation between ic5	[correlation between IC50S]	0.0	3	1	1	1
112177	1710	activity profile than UP	[activity profile than UP]	0.0	4	1	1	1
112178	1710	induction of Mn sod	[Induction of Mn SOD]	0.0	4	1	1	1
112179	1710	further consideration	[further consideration]	0.0	2	1	1	1
112180	1710	time course to monolayer	[time course to monolayers]	0.0	4	1	1	1
112181	1710	current state include the phenomenon	[current state including the phenomenon]	0.0	5	1	1	1
112182	1710	mechanism for persistent cytokine	[mechanism for persistent cytokine]	0.0	4	1	1	1
112183	1710	hiv type protease activation	[HIV type protease activation]	0.0	4	1	1	1
112184	1710	27 kD	[27 kD]	0.0	2	1	1	1
112185	1710	TGTGGTCA	[TGTGGTCA]	0.0	1	1	1	1
112186	1710	compensatory response	[compensatory response]	0.0	2	1	1	1
112187	1710	relevance of this increase	[relevance of this increase]	0.0	4	1	1	1
112188	1710	region of the IL-1alpha promoter	[regions of the IL-1alpha promoter]	0.0	5	1	1	1
112189	1710	reversible differentiation a inhibitor	[Reversible differentiation an inhibitor]	0.0	4	1	1	1
112190	1710	activity follow PMA	[activity following PMA]	0.0	3	1	1	1
112191	1710	indicate a affinity of sr-bp 50-fold	[indicating an affinity of SR-BP 50-fold]	0.0	6	1	1	1
112192	1710	gm-csf receptor beta	[GM-CSF receptor beta]	0.0	3	1	1	1
112193	1710	ciita b-cell-specific promoter suppression	[CIITA B-cell-specific promoter suppression]	0.0	4	1	1	1
112194	1710	binding to cell line	[Binding to cell lines]	0.0	4	1	1	1
112195	1710	activation by 4 beta-phorbol	[activation by 4 beta-phorbol]	0.0	4	1	1	1
112196	1710	MHC class transcription activator	[MHC class transcription activator]	0.0	4	1	1	1
112197	1710	even with the messenger response	[even with the messenger response]	0.0	5	1	1	1
112198	1710	receptor concentration in mononuclear leukocyte MNL	[receptor concentrations in mononuclear leukocytes MNL]	0.0	6	1	1	1
112199	1710	b in monocyte	[B in monocytes]	0.0	3	1	1	1
112200	1710	interaction between RFX5	[interaction between RFX5]	0.0	3	1	1	1
112201	1710	signal for transformation through carboxyl-terminal tail	[signals for transformation through carboxyl-terminal tail]	0.0	6	1	1	1
112202	1710	loss in activity.	[loss in activity.]	0.0	3	1	1	1
112203	1710	further requirement	[further requirement]	0.0	2	1	1	1
112204	1710	promoter specific	[promoter specific]	0.0	2	1	1	1
112205	1710	nf-kappa b luciferase construct	[NF-kappa B luciferase constructs]	0.0	4	1	1	1
112206	1710	Potent inhibition in monocytic cell	[Potent inhibition in monocytic cells]	0.0	5	1	1	1
112207	1710	unique mechanism related	[unique mechanism related]	0.0	3	1	1	1
112208	1710	contain mutant receptor l753f	[containing mutant receptors L753F]	0.0	4	1	1	1
112209	1710	glucocorticoid therapy in patient	[glucocorticoid therapy in patients]	0.0	4	1	1	1
112210	1710	183 +/-	[183 +/-]	0.0	2	1	1	1
112211	1710	promote the NK cell-mediated clearance	[promoting the NK cell-mediated clearance]	0.0	5	1	1	1
112212	1710	Finally, mutation	[Finally, mutations]	0.0	2	1	1	1
112213	1710	bhrf1 a Epstein-Barr virus ebv	[BHRF1 an Epstein-Barr virus EBV]	0.0	5	1	1	1
112214	1710	previous observation on the regulation	[previous observations on the regulation]	0.0	5	1	1	1
112215	1710	true IL-12 developmental stage	[true IL-12 developmental stage]	0.0	4	1	1	1
112216	1710	non-steroidal drug nsaid	[non-steroidal drugs NSAIDs]	0.0	3	1	1	1
112217	1710	binding of p50	[binding of p50]	0.0	3	1	1	1
112218	1710	factor with antigenic property	[factor with antigenic properties]	0.0	4	1	1	1
112219	1710	(e.g. cell-to-cell	[(e.g. cell-to-cell]	0.0	2	1	1	1
112220	1710	deletion of the response element	[Deletion of the response elements]	0.0	5	1	1	1
112221	1710	Raf-1 kinase activity maximum	[Raf-1 kinase activity maximum]	0.0	4	1	1	1
112222	1710	apoptosis by cytokine	[apoptosis by cytokines]	0.0	3	1	1	1
112223	1710	stat-1 phosphorylation	[STAT-1 phosphorylation]	0.0	2	1	1	1
112224	1710	important implication in regulation	[important implications in regulation]	0.0	4	1	1	1
112225	1710	extract from zymosan cell	[extracts from zymosan cells]	0.0	4	1	1	1
112226	1710	latency in certain cell	[latency in certain cells]	0.0	4	1	1	1
112227	1710	property of leukemia factor HLF	[properties of leukemia factor HLF]	0.0	5	1	1	1
112228	1710	p16 in human lymphocyte	[p16 in human lymphocytes]	0.0	4	1	1	1
112229	1710	reduction with bha treatment	[reduction with BHA treatment]	0.0	4	1	1	1
112230	1710	role for the factor	[role for the factor]	0.0	4	1	1	1
112231	1710	increase in mad3 mrna	[increase in MAD3 mRNA]	0.0	4	1	1	1
112232	1710	candidate gene hepatic factor beta	[candidate genes hepatic factor beta]	0.0	5	1	1	1
112233	1710	activate transcription from class complex promoter	[activating transcription from class complex promoters]	0.0	6	1	1	1
112234	1710	biochemical intervention	[biochemical intervention]	0.0	2	1	1	1
112235	1710	syncytia formation	[syncytia formation]	0.0	2	1	1	1
112236	1710	Jurkat cells, expression	[Jurkat cells, expression]	0.0	3	1	1	1
112237	1710	cyclic adenosine monophosphate accumulation	[cyclic adenosine monophosphate accumulation]	0.0	4	1	1	1
112238	1710	synergistic activation via nf-kappa b	[synergistic activation via NF-kappa B]	0.0	5	1	1	1
112239	1710	cytokine-produce-pduce-pduce-prine-prine-prine-pri effector cell	[cytokine-producing effector cells]	0.0	3	1	1	1
112240	1710	stimulation with lipopolysaccharide	[stimulation with lipopolysaccharide]	0.0	3	1	1	1
112241	1710	insensitivity of endothelium	[insensitivity of endothelium]	0.0	3	1	1	1
112242	1710	peripheral blood lymphocyte leukemia	[peripheral blood lymphocytes leukemia]	0.0	4	1	1	1
112243	1710	highly basic region	[highly basic region]	0.0	3	1	1	1
112244	1710	2-phase neutrophil adhesion response	[2-phase neutrophil adhesion response]	0.0	4	1	1	1
112245	1710	0.5 h	[0.5 h]	0.0	2	1	1	1
112246	1710	function of NF-kappa b	[Function of NF-kappa B]	0.0	4	1	1	1
112247	1710	differentiation of cells.	[differentiation of cells.]	0.0	3	1	1	1
112248	1710	differentiation of cells,	[differentiation of cells,]	0.0	3	1	1	1
112249	1710	include RA synovitis	[including RA synovitis]	0.0	3	1	1	1
112250	1710	ebf homologous sequence	[EBF homologous sequences]	0.0	3	1	1	1
112251	1710	5-bromo-2'-deoxyuridine incorporation	[5-bromo-2'-deoxyuridine incorporation]	0.0	2	1	1	1
112252	1710	binding of p75	[binding of p75]	0.0	3	1	1	1
112253	1710	loss of 32p	[loss of 32P]	0.0	3	1	1	1
112254	1710	IL-8 a chemotactic factor for granulocyte	[IL-8 a chemotactic factor for granulocytes]	0.0	6	1	1	1
112255	1710	low abundance in a variety	[low abundance in a variety]	0.0	5	1	1	1
112256	1710	make extract from monocytic cell	[making extracts from monocytic cells]	0.0	5	1	1	1
112257	1710	m nacl	[M NaCl]	0.0	2	1	1	1
112258	1710	induction of this signal	[induction of these signals]	0.0	4	1	1	1
112259	1710	EBV nuclear antigen EBNA2	[EBV nuclear antigen EBNA2]	0.0	4	1	1	1
112260	1710	b regulation	[B regulation]	0.0	2	1	1	1
112261	1710	early gene Ie	[early genes IE]	0.0	3	1	1	1
112262	1710	role in b-cell differentiation	[role in B-cell differentiation]	0.0	4	1	1	1
112263	1710	amino acid peptide	[amino acid peptides]	0.0	3	1	1	1
112264	1710	corresponding to protein of native weight	[corresponding to proteins of native weights]	0.0	6	1	1	1
112265	1710	GAL4 activator capable	[GAL4 activators capable]	0.0	3	1	1	1
112266	1710	leukocyte MNL in this patient	[leukocytes MNL in these patients]	0.0	5	1	1	1
112267	1710	hl-60egr-1	[HL-60Egr-1]	0.0	1	1	1	1
112268	1710	cytokine signal cascade	[cytokine signaling cascade]	0.0	3	1	1	1
112269	1710	33 case of lymphoid t-cell proliferation	[33 cases of lymphoid T-cell proliferations]	0.0	6	1	1	1
112270	1710	precise role	[precise role]	0.0	2	3	3	1
112271	1710	only weight species	[only weight species]	0.0	3	1	1	1
112272	1710	pathologic, result	[pathologic, resulting]	0.0	2	1	1	1
112273	1710	amplify event lead	[amplifying events leading]	0.0	3	1	1	1
112274	1710	NFAT-1 -dependent gene expression	[NFAT-1 -dependent gene expression]	0.0	4	1	1	1
112275	1710	consequence of differentiation	[consequence of differentiation]	0.0	3	1	1	1
112276	1710	CD30 -specific monoclonal antibody,	[CD30 -specific monoclonal antibody,]	0.0	4	1	1	1
112277	1710	consequently lead to anemic severity	[consequently leading to anemic severity]	0.0	5	1	1	1
112278	1710	Differential expression during differentiation	[Differential expression during differentiation]	0.0	4	1	1	1
112279	1710	level of component	[levels of components]	0.0	3	1	1	1
112280	1710	regulate this inflammatory response	[regulating this inflammatory response]	0.0	4	1	1	1
112281	1710	DNA bind capability	[DNA binding capability]	0.0	3	1	1	1
112282	1710	light chain kinase	[light chain kinase]	0.0	3	1	1	1
112283	1710	promoter for suppressive activity	[promoter for suppressive activity]	0.0	4	1	1	1
112284	1710	receptor domain in agonist	[receptor domain in agonist]	0.0	4	1	1	1
112285	1710	etiological relationship	[etiological relationship]	0.0	2	1	1	1
112286	1710	percentage of lymphoblastic leukemia	[percentage of lymphoblastic leukemias]	0.0	4	1	1	1
112287	1710	tf antigen	[TF antigen]	0.0	2	1	1	1
112288	1710	i.stefanescu, D.V.Ablashi,	[I.Stefanescu, D.V.Ablashi,]	0.0	2	1	1	1
112289	1710	HIV terminal	[HIV terminal]	0.0	2	1	1	1
112290	1710	surface markers, intracytoplasmic content	[surface markers, intracytoplasmic content]	0.0	4	1	1	1
112291	1710	initiate tyrosine phosphorylation of substrate	[initiating tyrosine phosphorylation of substrates]	0.0	5	1	1	1
112292	1710	relevant role activate transcription	[relevant role activating transcription]	0.0	4	1	1	1
112293	1710	stat3 serine kinase	[STAT3 serine kinase]	0.0	3	1	1	1
112294	1710	eig)-secreting cell pwm lymphocyte culture	[(Ig)-secreting cells PWM lymphocyte cultures]	0.0	5	1	1	1
112295	1710	possible linkage of er codon	[possible linkage of ER codon]	0.0	5	1	1	1
112296	1710	human papillomaviruse	[human papillomaviruses]	0.0	2	1	1	1
112297	1710	correlation of hiv-1 induction	[correlation of HIV-1 induction]	0.0	4	1	1	1
112298	1710	probe study intracellular signal transduction	[probes studying intracellular signal transduction]	0.0	5	1	1	1
112299	1710	2-fold increase	[2-fold increase]	0.0	2	3	3	1
112300	1710	Ciprofibrate a hypolipidaemic proliferator	[Ciprofibrate an hypolipidaemic proliferator]	0.0	4	1	1	1
112301	1710	cofactor in the development	[cofactor in the development]	0.0	4	1	1	1
112302	1710	expression for the gata-binding protein	[Expression for the GATA-binding proteins]	0.0	5	1	1	1
112303	1710	number of the CAG	[number of the CAGs]	0.0	4	1	1	1
112304	1710	system in vertebrate	[system in vertebrates]	0.0	3	1	1	1
112305	1710	AIDS retrovirus	[AIDS retrovirus]	0.0	2	1	1	1
112306	1710	direct transluminal angioplasty	[direct transluminal angioplasty]	0.0	3	1	1	1
112307	1710	human cell pbmc	[human cells PBMC]	0.0	3	1	1	1
112308	1710	selection along the differentiation	[Selection along the differentiation]	0.0	4	1	1	1
112309	1710	status change in child with asthma	[status changes in children with asthma]	0.0	6	1	1	1
112310	1710	occurrence of proliferations.	[occurrence of proliferations.]	0.0	3	1	1	1
112311	1710	haploinsufficiency	[haploinsufficiency]	0.0	1	3	3	1
112312	1710	killer cell T lymphocyte function	[killer cell T lymphocyte functions]	0.0	5	1	1	1
112313	1710	dyn/cm2) for h.	[dyn/cm2) for h,]	0.0	3	1	1	1
112314	1710	gh (except in one patient	[GH (except in one patient]	0.0	5	1	1	1
112315	1710	overexpression of the gene in cell	[overexpression of the gene in cells]	0.0	6	1	1	1
112316	1710	human papillomavirus-	[human papillomavirus-]	0.0	2	1	1	1
112317	1710	Finally, localization	[Finally, localization]	0.0	2	1	1	1
112318	1710	dinucleotide trinucleotide repeat	[dinucleotide trinucleotide repeats]	0.0	3	1	1	1
112319	1710	diterpene triepoxide	[diterpene triepoxide]	0.0	2	1	1	1
112320	1710	switch the cell	[Switching the cells]	0.0	3	1	1	1
112321	1710	lysosomal acid lipase in monocyte	[lysosomal acid lipase in monocytes]	0.0	5	1	1	1
112322	1710	encephalomyocarditis virus emcv	[encephalomyocarditis virus EMCV]	0.0	3	1	1	1
112323	1710	activity of the Bcl-2 family	[activity of the Bcl-2 family]	0.0	5	1	1	1
112324	1710	human gene enhancer	[human gene enhancer]	0.0	3	1	1	1
112325	1710	CD40 molecule at the state	[CD40 molecules at the state]	0.0	5	1	1	1
112326	1710	distinct family RA receptor	[distinct families RA receptors]	0.0	4	1	1	1
112327	1710	transform protein from the retrovirus	[transforming protein from the retrovirus]	0.0	5	1	1	1
112328	1710	human immunodeficiency virus type progeny	[human immunodeficiency virus type progeny]	0.0	5	1	1	1
112329	1710	dramatic decrease in expression	[dramatic decreases in expression]	0.0	4	1	1	1
112330	1710	normal increase in acth	[normal increase in ACTH]	0.0	4	1	1	1
112331	1710	central issue	[central issue]	0.0	2	1	1	1
112332	1710	such cross-talking	[such cross-talking]	0.0	2	1	1	1
112333	1710	beta-hydroxysteroid dehydrogenase	[beta-hydroxysteroid dehydrogenase]	0.0	2	2	2	1
112334	1710	t-lymphocyte anergy	[T-lymphocyte anergy]	0.0	2	1	1	1
112335	1710	2.3 fmol/million cells; p	[2.3 fmol/million cells; P]	0.0	4	1	1	1
112336	1710	classification of carcinoma IDC	[classification of carcinoma IDC]	0.0	4	1	1	1
112337	1710	activation response of thymocyte	[activation responses of thymocytes]	0.0	4	1	1	1
112338	1710	case of B-cell leukaemias	[cases of B-cell leukaemias]	0.0	4	1	1	1
112339	1710	1988 family	[1988, families]	0.0	2	1	1	1
112340	1710	exposure of rwleu-4 cell	[Exposure of RWLeu-4 cells]	0.0	4	2	2	1
112341	1710	human dermal microvessel cell MVEC	[human dermal microvessel cells MVEC]	0.0	5	1	1	1
112342	1710	leukemic entity	[leukemic entity]	0.0	2	1	1	1
112343	1710	protein tpa b cell	[protein TPA B cells]	0.0	4	1	1	1
112344	1710	enhancement replication in monocyte by 1,25-dihydroxycholecalciferol	[Enhancement replication in monocytes by 1,25-dihydroxycholecalciferol]	0.0	6	1	1	1
112345	1710	lack in G1 phase	[lack in G1 phases]	0.0	4	1	1	1
112346	1710	repression through the novel cooperation	[Repression through the novel cooperation]	0.0	5	1	1	1
112347	1710	proximal domain	[proximal domains]	0.0	2	1	1	1
112348	1710	least one clone	[least one clone]	0.0	3	1	1	1
112349	1710	anti- CD28 together	[anti- CD28 together]	0.0	3	1	1	1
112350	1710	squelching of transcription.	[squelching of transcription.]	0.0	3	1	1	1
112351	1710	LMP start site	[LMP start site]	0.0	3	1	1	1
112352	1710	works? even with a therapy	[works? Even with a therapy]	0.0	5	1	1	1
112353	1710	direct effect a effect	[direct effect an effect]	0.0	4	1	1	1
112354	1710	specific modulation	[specific modulation]	0.0	2	1	1	1
112355	1710	fc gamma RIC promoter sequence	[Fc gamma RIC promoter sequences]	0.0	5	1	1	1
112356	1710	n: 0.92+/-0.42)	[N: 0.92+/-0.42)]	0.0	2	1	1	1
112357	1710	LPS binding	[LPS binding]	0.0	2	1	1	1
112358	1710	use a hybridization assay	[using a hybridization assay]	0.0	4	1	1	1
112359	1710	PGE2 formation	[PGE2 formation]	0.0	2	1	1	1
112360	1710	2-4-fold increase	[2-4-fold increase]	0.0	2	1	1	1
112361	1710	anti- tat intracellular antibody	[anti- Tat intracellular antibody]	0.0	4	1	1	1
112362	1710	new avenue	[new avenue]	0.0	2	1	1	1
112363	1710	nuclear Site IV	[nuclear Site IV]	0.0	3	1	1	1
112364	1710	suggest a role for cell development	[suggesting a role for cell development]	0.0	6	1	1	1
112365	1710	prolyl cis-tran isomerase activity	[prolyl cis-trans isomerase activities]	0.0	4	1	1	1
112366	1710	additional signal	[additional signal]	0.0	2	1	1	1
112367	1710	maximal inhibition of 62% 5%	[maximal inhibition of 62% 5%]	0.0	5	1	1	1
112368	1710	extent, ebv antigen 2	[extent, EBV antigen 2]	0.0	4	1	1	1
112369	1710	CD4 subset	[CD4 subset]	0.0	2	1	1	1
112370	1710	th1/th2 development	[Th1/Th2 development]	0.0	2	1	1	1
112371	1710	express osteoclast marker	[expressing osteoclast markers]	0.0	3	1	1	1
112372	1710	subset include fcepsilonriib 15-lipoxygenase	[subset including FcepsilonRIIb 15-lipoxygenase]	0.0	4	1	1	1
112373	1710	tetrahydrocortisone mg/24h;	[tetrahydrocortisone mg/24h;]	0.0	2	1	1	1
112374	1710	respond to salt supplementation	[responding to salt supplementation]	0.0	4	1	1	1
112375	1710	human class gene	[human class genes]	0.0	3	1	1	1
112376	1710	50% inhibition of migration	[50% inhibition of migration]	0.0	4	1	1	1
112377	1710	Antigen	[Antigen]	0.0	1	1	1	1
112378	1710	cyclin/cdk kinase	[cyclin/cdks kinase]	0.0	2	1	1	1
112379	1710	cell line co-express gata	[cell lines co-expressing GATA]	0.0	4	1	1	1
112380	1710	exchangeable ca2+ in the tubules:	[exchangeable Ca2+ in the tubules:]	0.0	5	1	1	1
112381	1710	interaction of factor of T cell	[interaction of factor of T cells]	0.0	6	1	1	1
112382	1710	interleukin-2 receptor-alpha	[interleukin-2 receptor-alpha]	0.0	2	1	1	1
112383	1710	evasion mechanism	[evasion mechanisms]	0.0	2	1	1	1
112384	1710	tolerance of exercise	[tolerance of exercise]	0.0	3	1	1	1
112385	1710	erythroid-specific chromatin structure	[erythroid-specific chromatin structure]	0.0	3	1	1	1
112386	1710	partitioning of SMX -nhoh	[Partitioning of SMX -NHOH]	0.0	4	1	1	1
112387	1710	total population of CD4	[total populations of CD4]	0.0	4	1	1	1
112388	1710	rna analysis	[RNA analysis]	0.0	2	1	1	1
112389	1710	incubation of RU	[incubation of RU]	0.0	3	1	1	1
112390	1710	participation of the upstream element	[participation of the upstream element]	0.0	5	1	1	1
112391	1710	loss of phorbol monocytic differentiation	[loss of phorbol monocytic differentiation]	0.0	5	1	1	1
112392	1710	activation of this genes.	[activation of these genes.]	0.0	4	1	1	1
112393	1710	element within the enhancer	[elements within the enhancer]	0.0	4	1	1	1
112394	1710	BLIN-1 cell	[BLIN-1 cells]	0.0	2	1	1	1
112395	1710	indicator for control	[indicator for control]	0.0	3	1	1	1
112396	1710	map phosphatase mkp-1	[MAP phosphatase MKP-1]	0.0	3	1	1	1
112397	1710	pituitary adrenocorticotropic hormone release	[pituitary adrenocorticotropic hormone release]	0.0	4	1	1	1
112398	1710	rdna encode subunit	[cDNAs encoding subunits]	0.0	3	1	1	1
112399	1710	number with type diabete	[number with type diabetes]	0.0	4	1	1	1
112400	1710	level of type ii EBS	[levels of type II EBS]	0.0	5	1	1	1
112401	1710	linkage polymorphism to condition	[linkage polymorphism to conditions]	0.0	4	1	1	1
112402	1710	-polymerase	[-polymerase]	0.0	1	4	4	1
112403	1710	stimulation with all-tran retinoic acid	[stimulation with all-trans retinoic acid]	0.0	5	1	1	1
112404	1710	inhibit the binding	[inhibiting the binding]	0.0	3	1	1	1
112405	1710	cortisol inhibition	[cortisol inhibition]	0.0	2	1	1	1
112406	1710	infiltration of tumor tissue	[infiltration of tumor tissue]	0.0	4	1	1	1
112407	1710	reconstitution of function	[reconstitution of functions]	0.0	3	1	1	1
112408	1710	tnfrp55 function	[TNFRp55 function]	0.0	2	1	1	1
112409	1710	contrast, synthesis	[contrast, synthesis]	0.0	2	1	1	1
112410	1710	apoptosis in lymphoblastoid CD4 receptor	[apoptosis in lymphoblastoid CD4 receptors]	0.0	5	1	1	1
112411	1710	independence of electrolyte	[independence of electrolytes]	0.0	3	1	1	1
112412	1710	lps a b inducer	[LPS a B inducer]	0.0	4	1	1	1
112413	1710	gc production express sialoadhesin	[GC production express sialoadhesin]	0.0	4	1	1	1
112414	1710	prior to arrest in G1,	[prior to arrest in G1,]	0.0	5	1	1	1
112415	1710	constitutive hiv-enhancer activity concomitant	[constitutive HIV-enhancer activity concomitant]	0.0	4	1	1	1
112416	1710	encode the Epstein-Barr virus dutpase	[encoding the Epstein-Barr virus dUTPase]	0.0	5	1	1	1
112417	1710	modulate agent,	[modulating agent,]	0.0	2	1	1	1
112418	1710	model for the function	[model for the function]	0.0	4	1	1	1
112419	1710	bcl6+/cd3+/cd20-/cd57-	[Bcl6+/CD3+/CD20-/CD57-]	0.0	1	1	1	1
112420	1710	receptor content by 3-o-methyl-d-glucose transport	[receptor content by 3-O-methyl-D-glucose transport]	0.0	5	1	1	1
112421	1710	41 small exon span 45 kb	[41 small exons spanning 45 kb]	0.0	6	1	1	1
112422	1710	ar present	[AR present]	0.0	2	1	1	1
112423	1710	NF-kappa b translocation step	[NF-kappa B translocation step]	0.0	4	1	1	1
112424	1710	viral nuclear antigen	[viral nuclear antigen]	0.0	3	2	2	1
112425	1710	manner by element	[manner by elements]	0.0	3	1	1	1
112426	1710	el4 overexpress (h) irak	[EL4 overexpressing (h) IRAK]	0.0	4	1	1	1
112427	1710	comprise the October	[comprising the Oct]	0.0	3	1	1	1
112428	1710	role for nno	[role for nNOS]	0.0	3	1	1	1
112429	1710	lymphokine interferon-gamma	[lymphokine interferon-gamma]	0.0	2	1	1	1
112430	1710	acute transfection under control	[Acute transfection under control]	0.0	4	1	1	1
112431	1710	structure contain a (pou[s]) domain	[structure containing a (POU[S]) domain]	0.0	5	1	1	1
112432	1710	certain mnda cell	[certain MNDA cells]	0.0	3	1	1	1
112433	1710	certain mnda positive cell	[certain MNDA positive cells]	0.0	4	1	1	1
112434	1710	Cbl-b a homologue	[Cbl-b a homologue]	0.0	3	1	1	1
112435	1710	mark a second transformation effector site	[marking a second transformation effector site]	0.0	6	1	1	1
112436	1710	member of repressor protein	[members of repressor proteins]	0.0	4	1	1	1
112437	1710	non-dividing, normal pbl	[non-dividing, normal PBL]	0.0	3	1	1	1
112438	1710	1 carboxyl-terminal peptide	[1 carboxyl-terminal peptide]	0.0	3	1	1	1
112439	1710	low weight transmembrane adaptor protein	[low weight transmembrane adaptor proteins]	0.0	5	1	1	1
112440	1710	major class molecule on cell	[major class molecules on cells]	0.0	5	1	1	1
112441	1710	BRCA1 allele	[BRCA1 allele]	0.0	2	1	1	1
112442	1710	marker of hl-60 myelomonocytic differentiation	[marker of HL-60 myelomonocytic differentiation]	0.0	5	1	1	1
112443	1710	ptf a complex	[PTF a complex]	0.0	3	1	1	1
112444	1710	patient years)	[patients years)]	0.0	2	1	1	1
112445	1710	type include leukaemia	[types including leukaemia]	0.0	3	2	2	1
112446	1710	preclude the selective lysis	[precluding the selective lysis]	0.0	4	1	1	1
112447	1710	two pathway essential	[two pathways essential]	0.0	3	1	1	1
112448	1710	maintain a load throughout ebv persistence	[maintaining a load throughout EBV persistence]	0.0	6	1	1	1
112449	1710	localization in accessory cell	[localization in accessory cells]	0.0	4	1	1	1
112450	1710	T beta 5	[T beta 5]	0.0	3	1	1	1
112451	1710	alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3	[alpha,25-dihydroxyvitamin D3 alpha,25(OH)2D3]	0.0	3	1	1	1
112452	1710	palindromic thyroid hormone element	[palindromic thyroid hormone element]	0.0	4	1	1	1
112453	1710	immunodeficiency virus contain heterologous enhancer/promoters	[immunodeficiency viruses containing heterologous enhancer/promoters]	0.0	5	1	1	1
112454	1710	retinoid differentiation pathway	[retinoid differentiation pathway]	0.0	3	1	1	1
112455	1710	four NF-kappa b binding site	[four NF-kappa B binding sites]	0.0	5	1	1	1
112456	1710	human neutrophil granulocyte	[human neutrophil granulocytes]	0.0	3	1	1	1
112457	1710	23% blood histamine response	[23% blood histamine response]	0.0	4	1	1	1
112458	1710	Glucocorticoid receptor concentration	[Glucocorticoid receptor concentrations]	0.0	3	1	1	1
112459	1710	tax induction of c-rel expression	[Tax induction of c-Rel expression]	0.0	5	1	1	1
112460	1710	form lack the primary binding site	[forms lacking the primary binding site]	0.0	6	1	1	1
112461	1710	protein ip-10	[protein IP-10]	0.0	2	1	1	1
112462	1710	stain by a procedure avidin-biotin complex	[staining by an procedure avidin-biotin complex]	0.0	6	1	1	1
112463	1710	leukocyte of healthy donor of sexes.	[leukocytes of healthy donors of sexes.]	0.0	6	1	1	1
112464	1710	mitogenic agent upon action	[mitogenic agents upon action]	0.0	4	1	1	1
112465	1710	difference in binding affinity	[differences in binding affinities]	0.0	4	1	1	1
112466	1710	elucidate the background	[elucidating the background]	0.0	3	1	1	1
112467	1710	mediators, include various growth factor	[mediators, including various growth factors]	0.0	5	1	1	1
112468	1710	functional studies, interferon-gamma	[functional studies, interferon-gamma]	0.0	3	1	1	1
112469	1710	mammalian protein	[mammalian protein]	0.0	2	1	1	1
112470	1710	blood burst-forming	[blood burst-forming]	0.0	2	1	1	1
112471	1710	include AP-1 NF-kappaB	[including AP-1 NF-kappaB]	0.0	3	1	1	1
112472	1710	factor with property common	[factors with properties common]	0.0	4	1	1	1
112473	1710	skewing of x inactivation result	[skewing of X inactivation resulting]	0.0	5	1	1	1
112474	1710	affect growth	[affecting growth]	0.0	2	1	1	1
112475	1710	expand family	[expanding family]	0.0	2	1	1	1
112476	1710	basis of composition	[basis of composition]	0.0	3	1	1	1
112477	1710	decrease in zeta-chain	[decrease in zeta-chain]	0.0	3	1	1	1
112478	1710	two antitumour DNA topoisomerase ii inhibitor	[two antitumour DNA topoisomerase II inhibitors]	0.0	6	1	1	1
112479	1710	however a cofactor	[However a cofactor]	0.0	3	1	1	1
112480	1710	hiv-1 enhancer 80-	[HIV-1 enhancer 80-]	0.0	3	1	1	1
112481	1710	repeat of the "instability" motif attta	[repeats of the "instability" motif ATTTA]	0.0	6	1	1	1
112482	1710	increase in cell proliferation	[increase in cell proliferation]	0.0	4	1	1	1
112483	1710	two distinct activity	[two distinct activities]	0.0	3	1	1	1
112484	1710	first minute	[first minutes]	0.0	2	1	1	1
112485	1710	induction protein differentiation of a monocyte	[induction protein differentiation of a monocyte]	0.0	6	1	1	1
112486	1710	cultured cell	[cultured cells]	0.0	2	1	1	1
112487	1710	respect to b cell	[respect to B cells]	0.0	4	1	1	1
112488	1710	activation of Zap	[activation of Zap]	0.0	3	1	1	1
112489	1710	anti- v3 loop antibody	[anti- V3 loop antibody]	0.0	4	1	1	1
112490	1710	class ii dimer	[class II dimers]	0.0	3	1	1	1
112491	1710	RA receptor RAR alpha	[RA receptor RAR alpha]	0.0	4	1	1	1
112492	1710	cyclosporin b	[cyclosporin B]	0.0	2	1	1	1
112493	1710	contain regulatory sequence from -repressible gene	[containing regulatory sequences from -repressible genes]	0.0	6	1	1	1
112494	1710	low-mobility complex	[low-mobility complexes]	0.0	2	1	1	1
112495	1710	reduction in kappa L chain	[reduction in kappa L chain]	0.0	5	1	1	1
112496	1710	partial explanation for the effect	[partial explanation for the effects]	0.0	5	1	1	1
112497	1710	breast cancer cytotoxicity	[breast cancer cytotoxicity]	0.0	3	1	1	1
112498	1710	value of 1,25-dihydroxyvitamin D3 determination	[value of 1,25-dihydroxyvitamin D3 determination]	0.0	5	1	1	1
112499	1710	immunize mouse	[immunizing mice]	0.0	2	1	1	1
112500	1710	level of receptor in leucocyte	[levels of receptor in leucocytes]	0.0	5	1	1	1
112501	1710	il-6 antibody	[IL-6 antibody]	0.0	2	1	1	1
112502	1710	12 nonspecific reactive follicular hyperplasia	[12 nonspecific reactive follicular hyperplasia]	0.0	5	1	1	1
112503	1710	factor (irf) family	[factor (IRF) family]	0.0	3	1	1	1
112504	1710	remission in patient with promyelocytic leukemia	[remission in patients with promyelocytic leukemia]	0.0	6	1	1	1
112505	1710	occasional GC	[occasional GC]	0.0	2	1	1	1
112506	1710	new, compound	[new, compounds]	0.0	2	1	1	1
112507	1710	repetitive stretch	[repetitive stretch]	0.0	2	1	1	1
112508	1710	effect on apoptosis	[effects on apoptosis]	0.0	3	1	1	1
112509	1710	twenty-two patient	[Twenty-two patients]	0.0	2	1	1	1
112510	1710	interestingly, a activator	[Interestingly, a activator]	0.0	3	1	1	1
112511	1710	expression in a variety	[expression in a variety]	0.0	4	1	1	1
112512	1710	bacterial lps a b inducer	[bacterial LPS a B inducer]	0.0	5	1	1	1
112513	1710	T cell leukemia/lymphoma t-all	[T cell leukemia/lymphoma T-ALL]	0.0	4	1	1	1
112514	1710	cis-active sequence	[cis-active sequences]	0.0	2	1	1	1
112515	1710	revert	[reverting]	0.0	1	1	1	1
112516	1710	motif-rich protein include the product	[motif-rich proteins including the products]	0.0	5	1	1	1
112517	1710	gonadotropin-releasing	[Gonadotropin-releasing]	0.0	1	1	1	1
112518	1710	active mapkk-1	[active MAPKK-1]	0.0	2	1	1	1
112519	1710	expression of the human class isotype	[expression of the human class isotypes]	0.0	6	1	1	1
112520	1710	activation expression by Gardnerella vaginalis	[Activation expression by Gardnerella vaginalis]	0.0	5	1	1	1
112521	1710	contain high titre antibody	[containing high titre antibodies]	0.0	4	1	1	1
112522	1710	nongenomic in vitro effect	[nongenomic in vitro effects]	0.0	4	1	1	1
112523	1710	il-9 gene expression	[IL-9 gene expression]	0.0	3	1	1	1
112524	1710	treatment of cell with ifn-gamma	[treatment of cells with IFN-gamma]	0.0	5	1	1	1
112525	1710	glucocorticoid-mediated potentiation	[glucocorticoid-mediated potentiation]	0.0	2	1	1	1
112526	1710	acid receptor alpha by mutagenesis	[acid receptor alpha by mutagenesis]	0.0	5	1	1	1
112527	1710	2.0 0.8 nm in controls; p	[2.0 0.8 nM in controls; P]	0.0	6	1	1	1
112528	1710	property of effect	[properties of effects]	0.0	3	1	1	1
112529	1710	screen for signal defect	[screening for signaling defects]	0.0	4	1	1	1
112530	1710	ifn-alpha binding	[IFN-alpha binding]	0.0	2	1	1	1
112531	1710	multiple somatic mutation a encoding	[multiple somatic mutations a encoding]	0.0	5	1	1	1
112532	1710	simultaneous incubation of RU with dexamethasone	[simultaneous incubation of RU with dexamethasone]	0.0	6	1	1	1
112533	1710	Conclusions: Intestinal cell	[CONCLUSIONS: Intestinal cells]	0.0	3	1	1	1
112534	1710	effect together with PGE2	[effects together with PGE2]	0.0	4	1	1	1
112535	1710	likely dpii,	[likely DP-I,]	0.0	2	1	1	1
112536	1710	CD18 antibody	[CD18 antibody]	0.0	2	1	1	1
112537	1710	mechanism of the inhibitory effect	[mechanism of the inhibitory effect]	0.0	5	1	1	1
112538	1710	expression of the nucleoside diphosphate kinase	[Expression of the nucleoside diphosphate kinase]	0.0	6	1	1	1
112539	1710	bind tpa element	[binding TPA elements]	0.0	3	1	1	1
112540	1710	aldosterone from mononuclear leukocyte	[aldosterone from mononuclear leukocytes]	0.0	4	1	1	1
112541	1710	Furthermore, expression of level	[Furthermore, expression of levels]	0.0	4	1	1	1
112542	1710	Thapsigargin a inhibitor	[Thapsigargin an inhibitor]	0.0	3	1	1	1
112543	1710	stat3 ab	[STAT3 Ab]	0.0	2	1	1	1
112544	1710	gh in subset	[GH in subsets]	0.0	3	1	1	1
112545	1710	extensive sequence homology	[extensive sequence homology]	0.0	3	1	1	1
112546	1710	nf-kappab system	[NF-kappaB system]	0.0	2	1	1	1
112547	1710	putative disorder at this level.	[putative disorder at this level.]	0.0	5	1	1	1
112548	1710	EB1 element J.M.Hardwick, j.virol.63:3040-3050,	[EB1 element J.M.Hardwick, J.Virol.63:3040-3050,]	0.0	4	1	1	1
112549	1710	erythroid culture	[erythroid cultures]	0.0	2	1	1	1
112550	1710	two difference between the mechanism	[two differences between the mechanism]	0.0	5	1	1	1
112551	1710	study 1,25-dihydroxyvitamin D3	[studying 1,25-dihydroxyvitamin D3]	0.0	3	1	1	1
112552	1710	burst-forming unit	[burst-forming units]	0.0	2	1	1	1
112553	1710	immature DC	[immature DC]	0.0	2	1	1	1
112554	1710	relationship between the change	[relationship between the changes]	0.0	4	1	1	1
112555	1710	cell in AITL	[cells in AITL]	0.0	3	1	1	1
112556	1710	(18- to 35-year-old) volunteer	[(18- to 35-year-old) volunteers]	0.0	4	1	1	1
112557	1710	elucidate the molecular mechanism govern lineage	[elucidating the molecular mechanisms governing lineage]	0.0	6	1	1	1
112558	1710	differentiation control	[differentiation control]	0.0	2	1	1	1
112559	1710	important regulatory element NF-AT-1	[important regulatory element NF-AT-1]	0.0	4	1	1	1
112560	1710	cell in bone marrow	[cells in bone marrow]	0.0	4	1	1	1
112561	1710	genital herpes simplex virus type	[genital herpes simplex virus type]	0.0	5	1	1	1
112562	1710	Erythropoietin Epo	[Erythropoietin Epo]	0.0	2	1	1	1
112563	1710	nonspecific follicular hyperplasia	[nonspecific follicular hyperplasia]	0.0	3	1	1	1
112564	1710	double labeling	[double labeling]	0.0	2	1	1	1
112565	1710	CRE motif	[CRE motifs]	0.0	2	1	1	1
112566	1710	binding assay with extract from cell	[binding assays with extracts from cells]	0.0	6	1	1	1
112567	1710	include cell growth	[including cell growth]	0.0	3	1	1	1
112568	1710	0 hours,	[0 hours,]	0.0	2	1	1	1
112569	1710	difference between the phosphate-supplemented patient	[difference between the phosphate-supplemented patients]	0.0	5	1	1	1
112570	1710	level of the factor	[levels of the factor]	0.0	4	1	1	1
112571	1710	several cytokine in vitro	[several cytokines in vitro]	0.0	4	1	1	1
112572	1710	transcriptionally regulatory region	[transcriptionally regulatory regions]	0.0	3	1	1	1
112573	1710	similar inhibition of NFAT gene expression	[Similar inhibition of NFAT gene expression]	0.0	6	1	1	1
112574	1710	new marker	[new markers]	0.0	2	1	1	1
112575	1710	hotspot for human ifngr1 deletion	[hotspot for human IFNGR1 deletions]	0.0	5	1	1	1
112576	1710	ig-like	[Ig-like]	0.0	1	1	1	1
112577	1710	SCID-HU- int mouse	[SCID-HU- INT mice]	0.0	3	1	1	1
112578	1710	none to slightly on cell	[none to slightly on cells]	0.0	5	1	1	1
112579	1710	tcl1 protein expression	[TCL1 protein expression]	0.0	3	1	1	1
112580	1710	il-2 teceptor	[IL-2 teceptor]	0.0	2	1	1	1
112581	1710	cis- element	[cis- elements]	0.0	2	1	1	1
112582	1710	hypercortisolemia	[hypercortisolemia]	0.0	1	1	1	1
112583	1710	DNA-protein complex specific	[DNA-protein complexes specific]	0.0	3	1	1	1
112584	1710	CONCLUSIONS: ECs	[CONCLUSIONS: ECs]	0.0	2	1	1	1
112585	1710	profibrotic growth factor	[profibrotic growth factors]	0.0	3	1	1	1
112586	1710	T cell to CD28 activation	[T cells to CD28 activation]	0.0	5	1	1	1
112587	1710	elderly years) subject	[elderly years) subjects]	0.0	3	1	1	1
112588	1710	express human trx	[expressing human Trx]	0.0	3	1	1	1
112589	1710	interleukin-6 gene by interferon-gamma	[interleukin-6 gene by interferon-gamma]	0.0	4	1	1	1
112590	1710	growth factor fgf	[growth factors FGFs]	0.0	3	1	1	1
112591	1710	implication for the use of combination	[implications for the use of combinations]	0.0	6	1	1	1
112592	1710	promoter of the ifn-regulated gene	[promoters of the IFN-regulated genes]	0.0	5	1	1	1
112593	1710	c-jun of ras	[c-jun of ras]	0.0	3	1	1	1
112594	1710	cell clone express different level	[cell clones expressing different levels]	0.0	5	1	1	1
112595	1710	pts; fluticasone:	[pts; fluticasone:]	0.0	2	1	1	1
112596	1710	b-cell oncogene	[B-cell oncogene]	0.0	2	1	1	1
112597	1710	DRE 1 sequence	[DRE 1 sequence]	0.0	3	2	2	1
112598	1710	binding to the receptor.	[binding to the receptor.]	0.0	4	1	1	1
112599	1710	mechanism for the constitutive activation	[mechanism for the constitutive activation]	0.0	5	1	1	1
112600	1710	myeloid-cell-specific gene in cell type	[myeloid-cell-specific genes in cell types]	0.0	5	1	1	1
112601	1710	N-terminal phosphorylation	[N-terminal phosphorylation]	0.0	2	1	1	1
112602	1710	air degree c) twice/d, min/exposure,	[air degrees C) twice/d, min/exposure,]	0.0	5	1	1	1
112603	1710	class of LTR size variant	[classes of LTR size variants]	0.0	5	1	1	1
112604	1710	design future strategy	[designing future strategies]	0.0	3	1	1	1
112605	1710	histocompatibility (mhc) class ii molecule	[histocompatibility (MHC) class II molecules]	0.0	5	1	1	1
112606	1710	optimal augmentation	[optimal augmentation]	0.0	2	1	1	1
112607	1710	ap-1 consensus oligonucleotide	[AP-1 consensus oligonucleotides]	0.0	3	1	1	1
112608	1710	5-LOX enzyme	[5-LOX enzyme]	0.0	2	1	1	1
112609	1710	originate approximately 204 bp	[originating approximately 204 bp]	0.0	4	1	1	1
112610	1710	phosphorylation of Bcl-2	[phosphorylation of Bcl-2]	0.0	3	1	1	1
112611	1710	m-csf gene in syndrome	[M-CSF genes in syndromes]	0.0	4	1	1	1
112612	1710	adult T lymphocyte	[adult T lymphocytes]	0.0	3	1	1	1
112613	1710	final step	[final step]	0.0	2	1	1	1
112614	1710	T negative regulatory element	[T negative regulatory element]	0.0	4	1	1	1
112615	1710	shuttling transcription	[shuttling transcription]	0.0	2	1	1	1
112616	1710	immunosuppressant binding protein	[immunosuppressant binding protein]	0.0	3	1	1	1
112617	1710	binding by peripheral lymphocyte receptor	[Binding by peripheral lymphocyte receptors]	0.0	5	1	1	1
112618	1710	low level of lipopolysaccharide	[low levels of lipopolysaccharide]	0.0	4	1	1	1
112619	1710	regulation positive effect of ap-1 protein	[regulation positive effects of AP-1 proteins]	0.0	6	1	1	1
112620	1710	Furthermore, timp-1	[Furthermore, TIMP-1]	0.0	2	1	1	1
112621	1710	target of autoreactive t-cell	[target of autoreactive T-cells]	0.0	4	1	1	1
112622	1710	proximal functional promoter region	[proximal functional promoter region]	0.0	4	1	1	1
112623	1710	unilineage erythropoietic differentiation in culture	[unilineage erythropoietic differentiation in culture]	0.0	5	1	1	1
112624	1710	major protein mbp	[major protein MBP]	0.0	3	1	1	1
112625	1710	subline cell of tissue	[sublining cells of tissue]	0.0	4	1	1	1
112626	1710	potent mediator of gene expression	[potent mediator of gene expression]	0.0	5	1	1	1
112627	1710	visualization of nf-kappa b protein	[visualization of NF-kappa B proteins]	0.0	5	1	1	1
112628	1710	role of the signalsome protein	[role of the signalsome proteins]	0.0	5	1	1	1
112629	1710	expression of cd69 reporter gene construct	[expression of CD69 reporter gene constructs]	0.0	6	1	1	1
112630	1710	interrelation	[Interrelations]	0.0	1	1	1	1
112631	1710	divalent gold ion HAuCl3	[divalent gold ion HAuCl3]	0.0	4	1	1	1
112632	1710	blood cell of woman	[blood cells of women]	0.0	4	1	1	1
112633	1710	blood sample of young female	[blood samples of young females]	0.0	5	1	1	1
112634	1710	Epstein-Barr virus with gastric carcinoma	[Epstein-Barr virus with gastric carcinoma]	0.0	5	1	1	1
112635	1710	three alpha-helice Val10-Gln22	[three alpha-helices Val10-Gln22]	0.0	3	1	1	1
112636	1710	animal model of xenotransplantation	[animal models of xenotransplantation]	0.0	4	1	1	1
112637	1710	12 hyperplasia	[12 hyperplasia]	0.0	2	1	1	1
112638	1710	mol/microgram rna corresponding to a molecule	[mol/microgram RNA corresponding to an molecules]	0.0	6	1	1	1
112639	1710	role element-binding protein in AMP inhibition	[Role element-binding protein in AMP inhibition]	0.0	6	1	1	1
112640	1710	T cell-receptor-induced	[T cell-receptor-induced]	0.0	2	1	1	1
112641	1710	signal converge	[signals converging]	0.0	2	1	1	1
112642	1710	central role in t-cell-specific regulation	[central role in T-cell-specific regulation]	0.0	5	1	1	1
112643	1710	activity in IL-4 -positive T cell	[activities in IL-4 -positive T cells]	0.0	6	1	1	1
112644	1710	160 N-terminal amino acid	[160 N-terminal amino acids]	0.0	4	1	1	1
112645	1710	involvement of transcription factor yb-1	[Involvement of transcription factor YB-1]	0.0	5	1	1	1
112646	1710	migration of double oligomer	[migration of double oligomers]	0.0	4	1	1	1
112647	1710	ebv antibody	[EBV antibody]	0.0	2	1	1	1
112648	1710	more extensive deletion of sequence upstream	[More extensive deletion of sequences upstream]	0.0	6	1	1	1
112649	1710	use extract from normal eosinophil	[using extracts from normal eosinophils]	0.0	5	1	1	1
112650	1710	inactivity of the x	[inactivity of the X]	0.0	4	1	1	1
112651	1710	anti-DNA	[anti-DNA]	0.0	1	1	1	1
112652	1710	hiv-tf1 by phosphatase	[HIV-TF1 by phosphatase]	0.0	3	1	1	1
112653	1710	cell cycle control of hematopoietic cell	[cell cycle control of hematopoietic cells]	0.0	6	1	1	1
112654	1710	granulopoiesis postnatally, die	[granulopoiesis postnatally, dying]	0.0	3	1	1	1
112655	1710	NK clearance of Ad-infected cell	[NK clearance of Ad-infected cells]	0.0	5	1	1	1
112656	1710	protein lmp1	[protein LMP1]	0.0	2	1	1	1
112657	1710	various element	[various elements]	0.0	2	1	1	1
112658	1710	kappa complex	[kappa complexes]	0.0	2	1	1	1
112659	1710	enhance effect	[enhancing effect]	0.0	2	2	2	1
112660	1710	mature CD4 subset	[mature CD4 subset]	0.0	3	1	1	1
112661	1710	elk-1 point toward defect	[Elk-1 pointing toward defects]	0.0	4	1	1	1
112662	1710	octamer- binding	[octamer- binding]	0.0	2	1	1	1
112663	1710	use the sequence gas related oligonucleotide	[using the sequence GAS related oligonucleotides]	0.0	6	1	1	1
112664	1710	long double time,	[longer doubling time,]	0.0	3	1	1	1
112665	1710	c-kit/epo-r	[c-Kit/Epo-R]	0.0	1	1	1	1
112666	1710	nuclear factor irf-1	[nuclear factor IRF-1]	0.0	3	1	1	1
112667	1710	heterodimer to the nucleus	[heterodimer to the nucleus]	0.0	4	1	1	1
112668	1710	testosterone receptor	[testosterone receptors]	0.0	2	1	1	1
112669	1710	IL-10 inhibition of ICAM-1 mrna	[IL-10 inhibition of ICAM-1 mRNA]	0.0	5	1	1	1
112670	1710	complex common to each	[complexes common to each]	0.0	4	1	1	1
112671	1710	calcium -dependent dephosphorylation	[calcium -dependent dephosphorylation]	0.0	3	1	1	1
112672	1710	other autoantigen pbc.m2	[other autoantigens PBC.M2]	0.0	3	1	1	1
112673	1710	peptide in the er	[peptides in the ER]	0.0	4	1	1	1
112674	1710	significantly low concentration (21.7	[significantly lower concentration (21.7]	0.0	4	1	1	1
112675	1710	change in lymphocyte of healthy person	[changes in lymphocytes of healthy persons]	0.0	6	1	1	1
112676	1710	therapy in patient with colitis	[therapy in patients with colitis]	0.0	5	1	1	1
112677	1710	2.0 nm in controls; p	[2.0 nM in controls; P]	0.0	5	1	1	1
112678	1710	mechanism of antiandrogen action conformational change	[Mechanism of antiandrogen action conformational changes]	0.0	6	1	1	1
112679	1710	hyper- thyroid patient	[hyper- thyroid patients]	0.0	3	1	1	1
112680	1710	Furthermore, replacement of the gamma(c) domain	[Furthermore, replacement of the gamma(c) domain]	0.0	6	1	1	1
112681	1710	Hashimoto' goiter	[Hashimoto's goiter]	0.0	2	1	1	1
112682	1710	potential reading frame orf	[potential reading frames ORFs]	0.0	4	1	1	1
112683	1710	phosphorylation of erk-2	[phosphorylation of ERK-2]	0.0	3	1	1	1
112684	1710	(range, 5.66-10) 4.27 (range,	[(range, 5.66-10), 4.27 (range,]	0.0	4	1	1	1
112685	1710	ad 2/5 E1a-specific primer	[Ad 2/5 E1a-specific primers]	0.0	4	1	1	1
112686	1710	1 vcam-1 nac	[1 VCAM-1 NAC]	0.0	3	1	1	1
112687	1710	patient with chronic failure CRF	[patients with chronic failure CRF]	0.0	5	1	1	1
112688	1710	core histone	[core histones]	0.0	2	1	1	1
112689	1710	3-kinase activation	[3-kinase activation]	0.0	2	1	1	1
112690	1710	cytokine T cell response	[cytokine T cell responses]	0.0	4	1	1	1
112691	1710	12.1 respectively), indicate a rate	[12.1 respectively), indicating an rate]	0.0	5	1	1	1
112692	1710	A.Rickinson,	[A.Rickinson,]	0.0	1	1	1	1
112693	1710	control hiv replication in T cell	[controlling HIV replication in T cells]	0.0	6	1	1	1
112694	1710	cd36 antibody okm5	[CD36 antibody OKM5]	0.0	3	1	1	1
112695	1710	major complex class ii molecule	[major complex class II molecules]	0.0	5	1	1	1
112696	1710	T cell-deficient mouse	[T cell-deficient mice]	0.0	3	1	1	1
112697	1710	normal myelomonocytic cell	[normal myelomonocytic cells]	0.0	3	1	1	1
112698	1710	four classical NFkappaB site	[four classical NFkappaB sites]	0.0	4	1	1	1
112699	1710	Jurkat T cell library	[Jurkat T cell library]	0.0	4	1	1	1
112700	1710	Ter cell express T antigen	[Ter cells expressing T antigen]	0.0	5	1	1	1
112701	1710	phagocyte upon stimulation	[phagocytes upon stimulation]	0.0	3	1	1	1
112702	1710	fundamental role in reaction	[fundamental role in reactions]	0.0	4	1	1	1
112703	1710	high correlation	[high correlation]	0.0	2	1	1	1
112704	1710	influence expression of the class isotype	[influencing expression of the class isotypes]	0.0	6	1	1	1
112705	1710	factor not 4681	[Factors nt 4681]	0.0	3	1	1	1
112706	1710	marrow-derived cell line	[marrow-derived cell line]	0.0	3	1	1	1
112707	1710	base order-dependent stem-loop potential	[base order-dependent stem-loop potential]	0.0	4	1	1	1
112708	1710	postnatally, typically die	[postnatally, typically dying]	0.0	3	1	1	1
112709	1710	stimulation mono Mac with lipopolysaccharide lps	[Stimulation Mono Mac with lipopolysaccharide LPS]	0.0	6	1	1	1
112710	1710	nuclear positivity for the bcl-6 protein	[nuclear positivity for the BCL-6 protein]	0.0	6	1	1	1
112711	1710	even to the agent	[even to the agents]	0.0	4	1	1	1
112712	1710	direct effect VDR	[direct effects VDR]	0.0	3	1	1	1
112713	1710	follow t(1;19) translocation in leukemia	[following t(1;19) translocations in leukemias]	0.0	5	1	1	1
112714	1710	patient with restrictive anorexia nervosa	[patients with restrictive anorexia nervosa]	0.0	5	1	1	1
112715	1710	low-density lipoprotein modulation	[low-density lipoprotein modulation]	0.0	3	1	1	1
112716	1710	inhibition of Ca2+ redistribution	[inhibition of Ca2+ redistribution]	0.0	4	1	1	1
112717	1710	antiviral,	[antiviral,]	0.0	1	1	1	1
112718	1710	a2 b4	[A2 B4]	0.0	2	1	1	1
112719	1710	nuclear extract NE	[nuclear extracts NE]	0.0	3	1	1	1
112720	1710	least four NF-kappaB complex	[least four NF-kappaB complexes]	0.0	4	1	1	1
112721	1710	concentration of tetracycline	[concentrations of tetracyclines]	0.0	3	1	1	1
112722	1710	35s- tr alpha 1	[35S- TR alpha 1]	0.0	4	1	1	1
112723	1710	human myeloid cell i.e. granulocyte	[human myeloid cells i.e. granulocytes]	0.0	5	1	1	1
112724	1710	activation a vascular mechanism	[activation A vascular mechanism]	0.0	4	1	1	1
112725	1710	population possible killer population	[populations possible killer populations]	0.0	4	1	1	1
112726	1710	dominant pi3-k construct comprise domain	[dominant PI3-K constructs comprising domains]	0.0	5	1	1	1
112727	1710	high affinity receptor VDR	[High affinity receptors VDR]	0.0	4	1	1	1
112728	1710	ig alpha	[Ig alpha]	0.0	2	1	1	1
112729	1710	rheumatoid T cell	[rheumatoid T cells]	0.0	3	1	1	1
112730	1710	matrix metalloproteinase-9	[matrix metalloproteinase-9]	0.0	2	1	1	1
112731	1710	functional disomy of sequence	[functional disomy of sequences]	0.0	4	1	1	1
112732	1710	glucocorticoid binding rhythm of adrenocorticotropin	[glucocorticoid binding rhythms of adrenocorticotropin]	0.0	5	1	1	1
112733	1710	induction of susceptibility	[induction of susceptibility]	0.0	3	1	1	1
112734	1710	BRCA1 mutation	[BRCA1 mutations]	0.0	2	1	1	1
112735	1710	c-fo transcript	[c-fos transcripts]	0.0	2	1	1	1
112736	1710	reveal a role for traf6	[revealing a role for TRAF6]	0.0	5	1	1	1
112737	1710	nuclear export factor	[nuclear export factor]	0.0	3	1	1	1
112738	1710	factor-kappaB inhibitor	[factor-kappaB inhibitor]	0.0	2	1	1	1
112739	1710	regulate cytokine production	[regulating cytokine production]	0.0	3	1	1	1
112740	1710	sex (1.35 m	[sexes (1.35 M]	0.0	3	1	1	1
112741	1710	dissociation of nf kappa b	[Dissociation of NF kappa B]	0.0	5	1	1	1
112742	1710	kox zinc finger gene	[KOX zinc finger genes]	0.0	4	1	1	1
112743	1710	murine macrophage-like cell line	[murine macrophage-like cell line]	0.0	4	1	1	1
112744	1710	activate protein-1 ap-1 tpa responsive element	[Activating protein-1 AP-1 TPA responsive elements]	0.0	6	1	1	1
112745	1710	also a consequence	[also a consequence]	0.0	3	1	1	1
112746	1710	novel experimental model	[novel experimental model]	0.0	3	1	1	1
112747	1710	tissue histiocyte	[tissue histiocytes]	0.0	2	1	1	1
112748	1710	alu sequence	[Alu sequences]	0.0	2	1	1	1
112749	1710	other ATL cell line TL-OmI	[other ATL cell lines TL-OmI]	0.0	5	1	1	1
112750	1710	facilitate the functional collaboration	[facilitating the functional collaboration]	0.0	4	1	1	1
112751	1710	underlie selective expression	[underlying selective expression]	0.0	3	1	1	1
112752	1710	b cell precursor leukemia	[B cell precursor leukemias]	0.0	4	1	1	1
112753	1710	regulate integrin gene expression	[regulating integrin gene expression]	0.0	4	1	1	1
112754	1710	1-5 nm) of calyculin a	[1-5 nM) of calyculin A]	0.0	5	1	1	1
112755	1710	biol	[Biol]	0.0	1	1	1	1
112756	1710	ligand WY	[ligand WY]	0.0	2	1	1	1
112757	1710	therapy of acute leukemia patient	[therapy of acute leukemia patients]	0.0	5	1	1	1
112758	1710	major signal	[major signal]	0.0	2	1	1	1
112759	1710	factor from the patient'	[factors from the patient's]	0.0	4	1	1	1
112760	1710	binding site for STAT6	[binding sites for STAT6]	0.0	4	1	1	1
112761	1710	interaction of hematopoietic transcription factor pu.1	[interaction of hematopoietic transcription factors PU.1]	0.0	6	1	1	1
112762	1710	synteny of location	[synteny of location]	0.0	3	1	1	1
112763	1710	1 signal	[1 signaling]	0.0	2	1	1	1
112764	1710	selective NK cell-mediated clearance	[selective NK cell-mediated clearance]	0.0	4	1	1	1
112765	1710	diverse clonotype	[diverse clonotypes]	0.0	2	1	1	1
112766	1710	many genetic change in the form	[many genetic changes in the form]	0.0	6	1	1	1
112767	1710	single ubiquitous amp-responsive element	[single ubiquitous AMP-responsive element]	0.0	4	1	1	1
112768	1710	b1 encoding transcript	[B1 encoding transcripts]	0.0	3	1	1	1
112769	1710	adult bronchiti	[adult bronchitis]	0.0	2	1	1	1
112770	1710	new element	[new element]	0.0	2	1	1	1
112771	1710	adaptation in glucocorticoid receptor number	[adaptation in glucocorticoid receptor number]	0.0	5	1	1	1
112772	1710	erythropoietin epo stem cell factor	[erythropoietin Epo stem cell factor]	0.0	5	1	1	1
112773	1710	one band	[one band]	0.0	2	1	1	1
112774	1710	apparent alteration of the locus.	[apparent alteration of the locus.]	0.0	5	1	1	1
112775	1710	additional immunohistochemical staining	[additional immunohistochemical staining]	0.0	3	1	1	1
112776	1710	distal factor NF-AT AP-1/Octamer UPS	[distal factor NF-AT AP-1/Octamer UPS]	0.0	5	1	1	1
112777	1710	percentage of Hodgkin cell	[percentage of Hodgkin cells]	0.0	4	1	1	1
112778	1710	positive domain i-binding factor-1	[positive domain I-binding factor-1]	0.0	4	2	2	1
112779	1710	reduction,	[reduction,]	0.0	1	1	1	1
112780	1710	2 terminal repeat	[2 terminal repeat]	0.0	3	1	1	1
112781	1710	stimulation on human melanoma	[Stimulation on human melanomas]	0.0	4	1	1	1
112782	1710	consideration as tumor ag in cancer	[consideration as tumor Ag in cancers]	0.0	6	1	1	1
112783	1710	number circulate neutrophil	[numbers circulating neutrophils]	0.0	3	1	1	1
112784	1710	ventilation in vitro.	[ventilation in vitro.]	0.0	3	1	1	1
112785	1710	T regulatory element	[T regulatory element]	0.0	3	1	1	1
112786	1710	indicate a regulatory function	[indicating a regulatory function]	0.0	4	1	1	1
112787	1710	capsid antigen staining with bz1 reactivity	[capsid antigen staining with BZ1 reactivity]	0.0	6	1	1	1
112788	1710	factor to 10(-6) m rapid elevation	[factor to 10(-6) M rapid elevation]	0.0	6	1	1	1
112789	1710	Molt-4 cell	[Molt-4 cells]	0.0	2	1	1	1
112790	1710	morphogen a constituent	[morphogen a constituent]	0.0	3	1	1	1
112791	1710	progression of e1a-immortalized cell	[progression of E1A-immortalized cells]	0.0	4	1	1	1
112792	1710	include the ability	[including the ability]	0.0	3	1	1	1
112793	1710	proto-oncogene in the context	[proto-oncogene in the context]	0.0	4	1	1	1
112794	1710	weight of nfatp	[weight of NFATp]	0.0	3	2	2	1
112795	1710	cooperation between Spi-1	[cooperation between Spi-1]	0.0	3	1	1	1
112796	1710	distinct, novel inhibitor of NFAT transcription	[distinct, novel inhibitors of NFAT transcription]	0.0	6	1	1	1
112797	1710	interleukin (il),1 beta	[interleukin (IL),1 beta]	0.0	3	1	1	1
112798	1710	htoll activation of protein kinase/c-Jun kinase	[hToll activation of protein kinase/c-Jun kinases]	0.0	6	1	1	1
112799	1710	1,25-dihydroxy-vitamin	[1,25-dihydroxy-vitamin]	0.0	1	1	1	1
112800	1710	ebv -positive b-lymphoblastoid cell line	[EBV -positive B-lymphoblastoid cell lines]	0.0	5	1	1	1
112801	1710	cellular abnormality in immune regulation	[cellular abnormalities in immune regulation]	0.0	5	1	1	1
112802	1710	functional anti-tumor immunity	[functional anti-tumor immunity]	0.0	3	1	1	1
112803	1710	IM-9 nuclear extract	[IM-9 nuclear extracts]	0.0	3	1	1	1
112804	1710	expression of pilot	[Expression of PILOT]	0.0	3	1	1	1
112805	1710	presence of creb isoform	[presence of CREB isoforms]	0.0	4	1	1	1
112806	1710	97 young (18- female volunteer	[97 young (18- female volunteers]	0.0	5	1	1	1
112807	1710	crh synthesis	[CRH synthesis]	0.0	2	1	1	1
112808	1710	5 copy	[5 copies]	0.0	2	1	1	1
112809	1710	incubation of each	[Incubation of each]	0.0	3	1	1	1
112810	1710	augmentation in some experiments).	[augmentation in some experiments).]	0.0	4	1	1	1
112811	1710	inhibition of cytotoxicity	[inhibition of cytotoxicity]	0.0	3	1	1	1
112812	1710	granulocyte- macrophage colony-stimumulatelany-stg factor	[granulocyte- macrophage colony-stimulating factor]	0.0	4	1	1	1
112813	1710	Kruppel-like zinc-finger motif	[Kruppel-like zinc-finger motif]	0.0	3	1	1	1
112814	1710	results: Nuclear factor	[RESULTS: Nuclear factor]	0.0	3	1	1	1
112815	1710	tgf-beta in cell	[TGF-beta in cells]	0.0	3	1	1	1
112816	1710	high affinity aldosterone	[High affinity aldosterone]	0.0	3	1	1	1
112817	1710	granulopoiesis die	[granulopoiesis dying]	0.0	2	1	1	1
112818	1710	lead into the cell cycle	[leading into the cell cycle]	0.0	5	1	1	1
112819	1710	vitro macrophage MDMac	[vitro macrophages MDMac]	0.0	3	1	1	1
112820	1710	pharmacologic control	[Pharmacologic control]	0.0	2	1	1	1
112821	1710	leukemia (pml) gene	[leukemia (PML) gene]	0.0	3	1	1	1
112822	1710	tumor necrosis factor a cytokine	[tumor necrosis factor a cytokine]	0.0	5	1	1	1
112823	1710	study of protein	[study of proteins]	0.0	3	1	1	1
112824	1710	normal increase	[normal increase]	0.0	2	1	1	1
112825	1710	6, rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma	[6, rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
112826	1710	matrix metalloproteinase 9 factor	[matrix metalloproteinase 9 factor]	0.0	4	1	1	1
112827	1710	human antibody	[human antibody]	0.0	2	1	1	1
112828	1710	nm, bmax 183 +/-	[nM, Bmax 183 +/-]	0.0	4	1	1	1
112829	1710	factor (nf)-il6	[factor (NF)-IL6]	0.0	2	1	1	1
112830	1710	role in ige synthesis	[role in IgE synthesis]	0.0	4	1	1	1
112831	1710	mass for tbp7	[mass for TBP7]	0.0	3	1	1	1
112832	1710	activation of early response gene	[activation of early response genes]	0.0	5	1	1	1
112833	1710	bind affinity of Oct-1	[binding affinity of Oct-1]	0.0	4	1	1	1
112834	1710	recognition molecule	[recognition molecule]	0.0	2	1	1	1
112835	1710	developmental stage- specific regulation	[developmental stage- specific regulation]	0.0	4	1	1	1
112836	1710	signal transducing pathway lead	[signal transducing pathways leading]	0.0	4	1	1	1
112837	1710	contribution of two product	[contribution of two products]	0.0	4	1	1	1
112838	1710	Conversely, inhibition	[Conversely, inhibition]	0.0	2	1	1	1
112839	1710	transcriptional protein in eukaryote	[transcriptional proteins in eukaryotes]	0.0	4	1	1	1
112840	1710	pbmc culture	[PBMC cultures]	0.0	2	1	1	1
112841	1710	anti inflammatory activity	[anti inflammatory activity]	0.0	3	1	1	1
112842	1710	rat vascular smooth muscle cell	[rat vascular smooth muscle cells]	0.0	5	1	1	1
112843	1710	decrease in membrane structural order	[decrease in membrane structural order]	0.0	5	1	1	1
112844	1710	TCL1 oncogene activation from a case	[TCL1 oncogene activation from a case]	0.0	6	1	1	1
112845	1710	morphological change consistent	[morphological changes consistent]	0.0	3	1	1	1
112846	1710	Jak1 -express counterpart	[Jak1 -expressing counterpart]	0.0	3	1	1	1
112847	1710	97 (18- healthy volunteer	[97 (18- healthy volunteers]	0.0	4	1	1	1
112848	1710	mechanism involve steroid hormone	[mechanisms involving steroid hormones]	0.0	4	1	1	1
112849	1710	1,2-bis(o-aminophenoxy)-ethane-n,n,n',n'-tetraacetic	[1,2-bis(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic]	0.0	1	1	1	1
112850	1710	change in a silencer	[changes in a silencer]	0.0	4	1	1	1
112851	1710	immunosuppressive and/or anti-inflammatory cytokine	[immunosuppressive and/or anti-inflammatory cytokine]	0.0	4	1	1	1
112852	1710	contain sense antisense rxr-alpha sequence	[containing sense antisense RXR-alpha sequences]	0.0	5	1	1	1
112853	1710	metabolite to bodily protein	[metabolites to bodily proteins]	0.0	4	1	1	1
112854	1710	mechanims.	[mechanims.]	0.0	1	1	1	1
112855	1710	functional receptor-effector system	[functional receptor-effector system]	0.0	3	1	1	1
112856	1710	expression of this proteinase	[expression of this proteinase]	0.0	4	1	1	1
112857	1710	mechanims:	[mechanims:]	0.0	1	1	1	1
112858	1710	pp90rsk activity	[pp90rsk activity]	0.0	2	1	1	1
112859	1710	case of acute leukemia aml	[cases of acute leukemia AML]	0.0	5	1	1	1
112860	1710	transcriptional element for factor	[transcriptional elements for factor]	0.0	4	1	1	1
112861	1710	Effect of glucocorticoid in patient	[Effects of glucocorticoids in patients]	0.0	5	1	1	1
112862	1710	tumor like KS	[tumors like KS]	0.0	3	1	1	1
112863	1710	triiodothyronine plasma clearance rate	[triiodothyronine plasma clearance rates]	0.0	4	1	1	1
112864	1710	body burden of 2,3,7,8-tetrachlorodibenzo-p-dioxin	[body burdens of 2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.0	4	1	1	1
112865	1710	cooperation with CIITA	[cooperation with CIITA]	0.0	3	1	1	1
112866	1710	beta-estradiol on NK activity	[beta-estradiol on NK activity]	0.0	4	1	1	1
112867	1710	Martin,	[Martin,]	0.0	1	1	1	1
112868	1710	motif important for transcription,	[motifs important for transcription,]	0.0	4	1	1	1
112869	1710	pharmacological concentration of RA	[pharmacological concentrations of RA]	0.0	4	1	1	1
112870	1710	cell October factor	[cell Oct factors]	0.0	3	1	1	1
112871	1710	inducible ubiquitous component	[inducible ubiquitous component]	0.0	3	1	1	1
112872	1710	unit ac unit	[unit AC unit]	0.0	3	1	1	1
112873	1710	characterization of blood t-lymphocyte	[Characterization of blood T-lymphocytes]	0.0	4	1	1	1
112874	1710	-stat5a	[-STAT5a]	0.0	1	1	1	1
112875	1710	interaction between overlapping binding site	[interactions between overlapping binding sites]	0.0	5	1	1	1
112876	1710	microh	[microH]	0.0	1	1	1	1
112877	1710	prolactin-induced transcription factor	[prolactin-induced transcription factor]	0.0	3	1	1	1
112878	1710	difference th1	[differences Th1]	0.0	2	1	1	1
112879	1710	stimulus such as hyperosmotic shock	[stimuli such as hyperosmotic shock]	0.0	5	1	1	1
112880	1710	same type	[same type]	0.0	2	1	1	1
112881	1710	rest (G0) T cell	[resting (G0) T cells]	0.0	4	1	1	1
112882	1710	naturally occur mutation (-175 t-c)	[naturally occurring mutation (-175 T-C)]	0.0	5	1	1	1
112883	1710	definition of this pathway	[definition of this pathway]	0.0	4	1	1	1
112884	1710	epithelial layer	[epithelial layers]	0.0	2	1	1	1
112885	1710	deletion of a amino- terminal region	[Deletions of a amino- terminal region]	0.0	6	1	1	1
112886	1710	ML-1 leukemia cell	[ML-1 leukemia cells]	0.0	3	1	1	1
112887	1710	different pathologic process	[different pathologic processes]	0.0	3	1	1	1
112888	1710	herbimycin A pathway	[herbimycin A pathway]	0.0	3	1	1	1
112889	1710	fusion follow chromosomal translocation	[fusion following chromosomal translocations]	0.0	4	1	1	1
112890	1710	dose on tissue oligonucleotide	[doses on tissue oligonucleotide]	0.0	4	1	1	1
112891	1710	use vector	[using vectors]	0.0	2	1	1	1
112892	1710	indicate a relationship	[indicating a relationship]	0.0	3	1	1	1
112893	1710	heterodimer with the mutant	[heterodimers with the mutant]	0.0	4	1	1	1
112894	1710	regulation of shear	[Regulation of shear]	0.0	3	1	1	1
112895	1710	extent than c-fo	[extent than c-fos]	0.0	3	1	1	1
112896	1710	U1 cellular proliferation	[U1 cellular proliferation]	0.0	3	1	1	1
112897	1710	microB	[microB]	0.0	1	1	1	1
112898	1710	surfactant' suppressive effect	[surfactant's suppressive effects]	0.0	3	1	1	1
112899	1710	class molecule for peptide	[class molecules for peptides]	0.0	4	1	1	1
112900	1710	basAl, adhesion	[basal, adhesion]	0.0	2	1	1	1
112901	1710	gene inactivation study	[Gene inactivation studies]	0.0	3	1	1	1
112902	1710	follow activation in the presence	[following activation in the presence]	0.0	5	1	1	1
112903	1710	cysteine t-cell determinant	[cysteine T-cell determinants]	0.0	3	1	1	1
112904	1710	level of e1a protein	[levels of E1A proteins]	0.0	4	1	1	1
112905	1710	human leukemia cell line thp-1	[human leukemia cell line THP-1]	0.0	5	2	2	1
112906	1710	more accurately, equal amount	[more accurately, equal amounts]	0.0	4	1	1	1
112907	1710	integrate the short-lived signal	[integrating the short-lived signal]	0.0	4	1	1	1
112908	1710	large case-control study of population	[large case-control studies of populations]	0.0	5	1	1	1
112909	1710	upregulation of 12-lipoxygenase activity	[upregulation of 12-lipoxygenase activity]	0.0	4	1	1	1
112910	1710	low potential	[low potential]	0.0	2	1	1	1
112911	1710	distinct tyrosine-phosphorylated docking site	[distinct tyrosine-phosphorylated docking sites]	0.0	4	1	1	1
112912	1710	degenerative paraparesis	[degenerative paraparesis]	0.0	2	1	1	1
112913	1710	crosslinking study	[crosslinking studies]	0.0	2	1	1	1
112914	1710	CsA -sensitive component limit signal	[CsA -sensitive component limiting signaling]	0.0	5	1	1	1
112915	1710	capacity NF-kappaB	[capacity NF-kappaB]	0.0	2	1	1	1
112916	1710	protein regulate gene transcription	[proteins regulating gene transcription]	0.0	4	1	1	1
112917	1710	kappab-like	[kappaB-like]	0.0	1	1	1	1
112918	1710	follow expression in cos-1 cell	[following expression in COS-1 cells]	0.0	5	1	1	1
112919	1710	precursor isgf3 alpha	[precursors ISGF3 alpha]	0.0	3	1	1	1
112920	1710	well-defined phenotypic change	[well-defined phenotypic changes]	0.0	3	1	1	1
112921	1710	isoform, oct2ab	[isoform, Oct2ab]	0.0	2	1	1	1
112922	1710	use of the dnase	[use of the DNase]	0.0	4	1	1	1
112923	1710	efficient expression	[efficient expression]	0.0	2	1	1	1
112924	1710	evidence for involvement	[evidence for involvement]	0.0	3	2	2	1
112925	1710	other agents.	[other agents.]	0.0	2	1	1	1
112926	1710	lymphoid-derived disease	[lymphoid-derived diseases]	0.0	2	1	1	1
112927	1710	multidish	[multidishes]	0.0	1	1	1	1
112928	1710	radiation dose 20	[radiation dose 20]	0.0	3	1	1	1
112929	1710	AGATAA	[AGATAA]	0.0	1	1	1	1
112930	1710	secret il-2	[secreting IL-2]	0.0	2	1	1	1
112931	1710	stimulation experiment	[Stimulation experiments]	0.0	2	1	1	1
112932	1710	biological impact	[biological impact]	0.0	2	1	1	1
112933	1710	feasible manipulation of growth	[feasible manipulation of growth]	0.0	4	1	1	1
112934	1710	pattern of kappab -binding activity	[pattern of kappaB -binding activity]	0.0	5	1	1	1
112935	1710	classical metaphase analysis	[classical metaphase analysis]	0.0	3	1	1	1
112936	1710	gene class transactivator ciita	[gene class transactivator CIITA]	0.0	4	1	1	1
112937	1710	mobility shift assay use	[mobility shift assay using]	0.0	4	1	1	1
112938	1710	effect either on the minimal promoter	[effect either on the minimal promoter]	0.0	6	1	1	1
112939	1710	encode the lymphocyte homing	[encoding the lymphocyte homing]	0.0	4	1	1	1
112940	1710	b species in lymphocytic cell	[B species in lymphocytic cells]	0.0	5	1	1	1
112941	1710	death ligand TNF	[death ligands TNF]	0.0	3	1	1	1
112942	1710	relatively high specificity	[relatively high specificity]	0.0	3	1	1	1
112943	1710	antibodies patient with mononucleosis	[antibodies, patients with mononucleosis]	0.0	4	1	1	1
112944	1710	transcription-activation element	[transcription-activation element]	0.0	2	1	1	1
112945	1710	cellular tip-associated protein	[cellular Tip-associated protein]	0.0	3	1	1	1
112946	1710	range.	[range.]	0.0	1	1	1	1
112947	1710	VDR target gene	[VDR target gene]	0.0	3	1	1	1
112948	1710	affinity to,	[affinity to,]	0.0	2	1	1	1
112949	1710	plc gamma expression	[PLC gamma expression]	0.0	3	1	1	1
112950	1710	pa phosphohydrolase	[PA phosphohydrolase]	0.0	2	1	1	1
112951	1710	cell reaction mcr grade	[cell reaction MCR grade]	0.0	4	1	1	1
112952	1710	N-terminal c-jun kinase	[N-terminal c-Jun kinase]	0.0	3	1	1	1
112953	1710	macrophage migration protein	[Macrophage migration protein]	0.0	3	1	1	1
112954	1710	generation of genomic diversity	[generation of genomic diversity]	0.0	4	1	1	1
112955	1710	myeloid precursor cell line	[myeloid precursor cell lines]	0.0	4	1	1	1
112956	1710	growth transformation of normal b-cell	[Growth transformation of normal B-cells]	0.0	5	1	1	1
112957	1710	mature human b lymphocyte	[mature human B lymphocytes]	0.0	4	1	1	1
112958	1710	contain four copy	[containing four copies]	0.0	3	1	1	1
112959	1710	bear tumor	[bearing tumor]	0.0	2	1	1	1
112960	1710	year (2/73)	[years (2/73)]	0.0	2	1	1	1
112961	1710	nausea	[nausea]	0.0	1	1	1	1
112962	1710	one example	[One example]	0.0	2	1	1	1
112963	1710	b cell-specific transcriptional coactivator	[B cell-specific transcriptional coactivators]	0.0	4	2	2	1
112964	1710	effect in T cell representative	[effects in T cells representative]	0.0	5	1	1	1
112965	1710	product of pathogen such as lipopolysaccharide	[products of pathogens such as lipopolysaccharide]	0.0	6	1	1	1
112966	1710	time between infection	[time between infection]	0.0	3	1	1	1
112967	1710	coupling to interleukin-2 receptor-gamma	[coupling to interleukin-2 receptor-gamma]	0.0	4	1	1	1
112968	1710	(1) the appearance	[(1) the appearance]	0.0	3	1	1	1
112969	1710	antigen segment resistant to cleavage	[antigen segments resistant to cleavage]	0.0	5	1	1	1
112970	1710	multiple creb isoform	[multiple CREB isoforms]	0.0	3	1	1	1
112971	1710	region encompass a sequence	[region encompassing a sequence]	0.0	4	1	1	1
112972	1710	cell from 24%	[cells from 24%]	0.0	3	1	1	1
112973	1710	interferon-gamma-induced adhesion molecule-1 gene transcription	[interferon-gamma-induced adhesion molecule-1 gene transcription]	0.0	5	1	1	1
112974	1710	Differential induction of interferon (ifn)-inducible protein	[Differential induction of interferon (IFN)-inducible protein]	0.0	6	1	1	1
112975	1710	level of serum 135eoh)2d3	[levels of serum 1,25(OH)2D3]	0.0	4	1	1	1
112976	1710	htlv-i tumor in mouse	[HTLV-I tumors in mice]	0.0	4	1	1	1
112977	1710	increase peak between h.	[increase peaking between h,]	0.0	4	1	1	1
112978	1710	acid insertion present	[acid insertion present]	0.0	3	1	1	1
112979	1710	class II-specific transcription factor	[class II-specific transcription factors]	0.0	4	1	1	1
112980	1710	addition of tnf-alpha antibody	[addition of TNF-alpha antibody]	0.0	4	1	1	1
112981	1710	parallel activation of c-Jun	[parallel activation of c-Jun]	0.0	4	1	1	1
112982	1710	increase in response to hypoglycemia	[increase in response to hypoglycemia]	0.0	5	1	1	1
112983	1710	nf-atc /b	[NF-ATc /B]	0.0	2	1	1	1
112984	1710	ccaat/enhancer binding protein gene	[CCAAT/enhancer binding protein gene]	0.0	4	1	1	1
112985	1710	hiv mrna	[HIV mRNA]	0.0	2	2	2	1
112986	1710	four dihydro derivative	[four dihydro derivatives]	0.0	3	1	1	1
112987	1710	class complex cell line	[class complex cell lines]	0.0	4	1	1	1
112988	1710	human platelet-activating factor receptor gene	[human platelet-activating factor receptor gene]	0.0	5	1	1	1
112989	1710	globin developmental program	[globin developmental program]	0.0	3	1	1	1
112990	1710	Nuclear factor-kappa b activity a report.	[Nuclear factor-kappa B activity a report.]	0.0	6	1	1	1
112991	1710	concentration (10(-9)-10(-7)	[concentration (10(-9)-10(-7)]	0.0	2	1	1	1
112992	1710	effect of pokeweed mitogen pwm	[effects of pokeweed mitogen PWM]	0.0	5	1	1	1
112993	1710	adaptor addition to p300/cbp	[adaptors addition to p300/CBP]	0.0	4	1	1	1
112994	1710	involvement of Jak kinase signal	[involvement of Jak kinases signaling]	0.0	5	1	1	1
112995	1710	cellular activator of hiv-1 gene	[cellular activator of HIV-1 gene]	0.0	5	1	1	1
112996	1710	bear ZEBRA promoter	[bearing ZEBRA promoters]	0.0	3	1	1	1
112997	1710	potential clinical relevance	[potential clinical relevance]	0.0	3	1	1	1
112998	1710	mechanism of adherence	[mechanisms of adherence]	0.0	3	1	1	1
112999	1710	decrease of activation-induced p65/	[decrease of activation-induced p65/]	0.0	4	1	1	1
113000	1710	dual effect inhibition of growth depletion	[dual effects inhibition of growth depletion]	0.0	6	1	1	1
113001	1710	clonality of eosinophil	[Clonality of eosinophils]	0.0	3	1	1	1
113002	1710	novel human homeobox gene related	[novel human homeobox gene related]	0.0	5	1	1	1
113003	1710	directly to the epithelium	[directly to the epithelium]	0.0	4	1	1	1
113004	1710	transactivation of the tcr-regulated factor	[transactivation of the TCR-regulated factor]	0.0	5	1	1	1
113005	1710	p65 subunit of factor	[p65 subunit of factor]	0.0	4	1	1	1
113006	1710	activity of three transcription factor	[activities of three transcription factors]	0.0	5	1	1	1
113007	1710	transcriptional regulator of response	[transcriptional regulator of responses]	0.0	4	1	1	1
113008	1710	reduction of the cortisol excretion	[reduction of the cortisol excretion]	0.0	5	1	1	1
113009	1710	express cell surface glycophorin a	[expressing cell surface glycophorin A]	0.0	5	1	1	1
113010	1710	MEK1 -interfer mutant	[MEK1 -interfering mutants]	0.0	3	1	1	1
113011	1710	c-myb 5' sequence	[c-myb 5' sequence]	0.0	3	1	1	1
113012	1710	result phosphorylation	[resulting phosphorylation]	0.0	2	1	1	1
113013	1710	absence of sh-group	[absence of SH-groups]	0.0	3	1	1	1
113014	1710	palindrome tgcgcatgcgca	[palindrome TGCGCATGCGCA]	0.0	2	1	1	1
113015	1710	twice/d, 30 min/exposure,	[twice/d, 30 min/exposure,]	0.0	3	1	1	1
113016	1710	polyether alcohol polymer detergent	[polyether alcohol polymer detergent]	0.0	4	1	1	1
113017	1710	-phosphorylated lat	[-phosphorylated LAT]	0.0	2	1	1	1
113018	1710	receptor positivity	[receptor positivity]	0.0	2	1	1	1
113019	1710	cause of maternal morbidity	[cause of maternal morbidity]	0.0	4	1	1	1
113020	1710	activation of NF-kappa b by interleukin	[Activation of NF-kappa B by interleukin]	0.0	6	1	1	1
113021	1710	anti-ERK	[anti-ERK]	0.0	1	1	1	1
113022	1710	encompass a important element	[encompassing an important element]	0.0	4	1	1	1
113023	1710	protein kinase/c-Jun	[protein kinase/c-Jun]	0.0	2	1	1	1
113024	1710	moreover, cd3+ T cell	[Moreover, CD3+ T cells]	0.0	4	1	1	1
113025	1710	vascular-cell adhesion molecule-1	[vascular-cell adhesion molecule-1]	0.0	3	1	1	1
113026	1710	T element nre	[T element NRE]	0.0	3	1	1	1
113027	1710	clinical responsiveness 0.01).	[clinical responsiveness 0.01).]	0.0	3	1	1	1
113028	1710	indolocarbazole	[indolocarbazoles]	0.0	1	1	1	1
113029	1710	factor specific to adult cell	[factor specific to adult cells]	0.0	5	1	1	1
113030	1710	differentiation into dendritic cell	[differentiation into dendritic cells]	0.0	4	1	1	1
113031	1710	bq dead cell	[BQ dead cells]	0.0	3	1	1	1
113032	1710	transcriptional activate proteins,	[transcriptional activating proteins,]	0.0	3	1	1	1
113033	1710	spectrum bind transcriptional property	[spectrum binding transcriptional properties]	0.0	4	1	1	1
113034	1710	fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
113035	1710	independent methods,	[independent methods,]	0.0	2	1	1	1
113036	1710	effect of 9-cis-ra	[effect of 9-cis-RA]	0.0	3	1	1	1
113037	1710	polyomavirus reactivations.	[polyomavirus reactivations.]	0.0	2	1	1	1
113038	1710	muscle cell	[muscle cells]	0.0	2	6	6	1
113039	1710	zinc-binding potential transcription factor	[zinc-binding potential transcription factor]	0.0	4	1	1	1
113040	1710	absence of a additional signal	[absence of an additional signal]	0.0	5	1	1	1
113041	1710	human platelet-activating factor receptor	[human platelet-activating factor receptor]	0.0	4	1	1	1
113042	1710	matrix metalloproteinase 1	[matrix metalloproteinases 1]	0.0	3	1	1	1
113043	1710	explain how	[explaining how]	0.0	2	1	1	1
113044	1710	embryonic/fetal hematopoiesis	[embryonic/fetal hematopoiesis]	0.0	2	1	1	1
113045	1710	Stat1,	[Stat1,]	0.0	1	1	1	1
113046	1710	low-level activation of lt	[low-level activation of LT]	0.0	4	1	1	1
113047	1710	mediator by bronchial epithelial cell	[mediators by bronchial epithelial cells]	0.0	5	1	1	1
113048	1710	total of combination of promoter	[total of combinations of promoters]	0.0	5	1	1	1
113049	1710	inducible camp	[inducible cAMP]	0.0	2	1	1	1
113050	1710	Epo-dependent cell line	[Epo-dependent cell lines]	0.0	3	1	1	1
113051	1710	hamster ovary (cho)-dr	[hamster ovary (CHO)-DR]	0.0	3	1	1	1
113052	1710	form of notch1	[forms of NOTCH1]	0.0	3	1	1	1
113053	1710	vitamin ricket type	[vitamin rickets type]	0.0	3	1	1	1
113054	1710	human epsilon	[human epsilon]	0.0	2	1	1	1
113055	1710	estrogen lymphoblastoid	[estrogen lymphoblastoid]	0.0	2	1	1	1
113056	1710	immunocytochemical method	[immunocytochemical methods]	0.0	2	1	1	1
113057	1710	case of preincubation microM),	[case of preincubation microM),]	0.0	4	1	1	1
113058	1710	pyrimidine -rich element present	[pyrimidine -rich elements present]	0.0	4	1	1	1
113059	1710	il-13 gene expression	[IL-13 gene expression]	0.0	3	1	1	1
113060	1710	modulation by transfer	[modulation by transfer]	0.0	3	1	1	1
113061	1710	region nucleotide number 5'-gttaaggttcgtaggtcatgga-3'	[region nucleotide numbers 5'-GTTAAGGTTCGTAGGTCATGGA-3']	0.0	4	1	1	1
113062	1710	change to alanine	[change to alanine]	0.0	3	1	1	1
113063	1710	45-nucleotide sequence downstream regulatory element	[45-nucleotide sequence downstream regulatory element]	0.0	5	1	1	1
113064	1710	lead to hiv replication	[leading to HIV replication]	0.0	4	1	1	1
113065	1710	site at position	[sites at positions]	0.0	3	1	1	1
113066	1710	differentiate in unilineage culture	[differentiating in unilineage cultures]	0.0	4	1	1	1
113067	1710	minute (phase 2)	[minutes (phase 2)]	0.0	3	1	1	1
113068	1710	one transcription factor bsap	[one transcription factor BSAP]	0.0	4	1	1	1
113069	1710	IL-12 up-regulation of irf-1	[IL-12 up-regulation of IRF-1]	0.0	4	1	1	1
113070	1710	bone lesion	[bone lesions]	0.0	2	1	1	1
113071	1710	variant of a vitamin cell line	[variants of a vitamin cell line]	0.0	6	1	1	1
113072	1710	METHODS: transfectant	[METHODS: transfectants]	0.0	2	1	1	1
113073	1710	vivo effect of formulation	[vivo effect of formulation]	0.0	4	1	1	1
113074	1710	clearly positive cells, respectively),	[clearly positive cells, respectively),]	0.0	4	1	1	1
113075	1710	distinguished: sign of hypothyroidism	[distinguished: signs of hypothyroidism]	0.0	4	1	1	1
113076	1710	blot of t-cell lysate	[blots of T-cell lysates]	0.0	4	1	1	1
113077	1710	/stat5b	[/STAT5B]	0.0	1	1	1	1
113078	1710	cell-specific factor contain c-rel-like protein	[cell-specific factor containing c-Rel-like proteins]	0.0	5	1	1	1
113079	1710	normal kidney tissue	[normal kidney tissue]	0.0	3	1	1	1
113080	1710	pmol/L; in normal pregnant woman	[pmol/L; in normal pregnant women]	0.0	5	1	1	1
113081	1710	significance for patient with c-erbB2 amplification	[significance for patients with c-erbB2 amplifications]	0.0	6	1	1	1
113082	1710	number of gcrbeta -immunoreactive cell	[number of GCRbeta -immunoreactive cells]	0.0	5	1	1	1
113083	1710	tcrzeta level 0.001)	[TCRzeta levels 0.001)]	0.0	3	1	1	1
113084	1710	degradation of inhibitory peptide	[degradation of inhibitory peptide]	0.0	4	1	1	1
113085	1710	gender-specific difference in the system	[gender-specific differences in the system]	0.0	5	1	1	1
113086	1710	Hemin	[Hemin]	0.0	1	2	2	1
113087	1710	thus suggest a requirement	[thus suggesting a requirement]	0.0	4	1	1	1
113088	1710	hGATA-3 expression	[hGATA-3 expression]	0.0	2	1	1	1
113089	1710	mutant with point mutation in tax	[mutants with point mutations in Tax]	0.0	6	1	1	1
113090	1710	transcription factor pebp2	[transcription factor PEBP2]	0.0	3	1	1	1
113091	1710	time of monocyte	[time of monocytes]	0.0	3	1	1	1
113092	1710	vitro-translated pu.1	[vitro-translated PU.1]	0.0	2	1	1	1
113093	1710	effect of As2O3	[effects of As2O3]	0.0	3	1	1	1
113094	1710	immediate gene of cytomegalovirus CMV	[immediate genes of cytomegalovirus CMV]	0.0	5	1	1	1
113095	1710	gene, suppressor	[gene, suppressor]	0.0	2	1	1	1
113096	1710	CsA -sensitive stage	[CsA -sensitive stage]	0.0	3	1	1	1
113097	1710	signal 2 costimulatory signal alone	[signal 2 costimulatory signal alone]	0.0	5	1	1	1
113098	1710	CD28 of neonatal T lymphocyte	[CD28 of neonatal T lymphocytes]	0.0	5	1	1	1
113099	1710	extra-renal, nonepithelial cell	[extra-renal, nonepithelial cells]	0.0	3	1	1	1
113100	1710	chain gene rearrangement	[chain gene rearrangement]	0.0	3	1	1	1
113101	1710	production of cell	[production of cells]	0.0	3	1	1	1
113102	1710	three isoforms.	[three isoforms.]	0.0	2	1	1	1
113103	1710	eight synthetic peptide	[eight synthetic peptides]	0.0	3	1	1	1
113104	1710	role in tissue damage	[role in tissue damage]	0.0	4	1	1	1
113105	1710	multinucleated giant cell	[multinucleated giant cells]	0.0	3	1	1	1
113106	1710	different binding specificity	[different binding specificity]	0.0	3	1	1	1
113107	1710	RCC explant RCC	[RCC explants RCC]	0.0	3	1	1	1
113108	1710	inverse correlation between receptor positivity	[inverse correlation between receptor positivity]	0.0	5	1	1	1
113109	1710	relative mass 50000 (50k)	[relative mass 50,000 (50K)]	0.0	4	1	1	1
113110	1710	minimal EBNA-2 lmp-1 promoter	[minimal EBNA-2 LMP-1 promoter]	0.0	4	1	1	1
113111	1710	dual cyclooxygenase/5-lipoxygenase anti-inflammatory compound	[dual cyclooxygenase/5-lipoxygenase anti-inflammatory compound]	0.0	4	1	1	1
113112	1710	more than kb from sox9	[more than kb from SOX9]	0.0	5	1	1	1
113113	1710	contrast, cell fusion between clone	[contrast, cell fusion between clone]	0.0	5	1	1	1
113114	1710	include chemotherapy drug	[including chemotherapy drugs]	0.0	3	1	1	1
113115	1710	characteristic (auto)immune inflammation	[characteristic (auto)immune inflammation]	0.0	3	1	1	1
113116	1710	immunodeficiency virus-1 tat protein	[immunodeficiency virus-1 Tat protein]	0.0	4	1	1	1
113117	1710	genomic sterol element	[genomic sterol element]	0.0	3	1	1	1
113118	1710	p38alpha protein kinase	[p38alpha protein kinase]	0.0	3	1	1	1
113119	1710	minimal beta-casein stat5 element	[minimal beta-casein STAT5 element]	0.0	4	1	1	1
113120	1710	mitogenic combination include CD28 signaling.	[mitogenic combination including CD28 signaling.]	0.0	5	1	1	1
113121	1710	17% barely positive cell	[17% barely positive cells]	0.0	4	1	1	1
113122	1710	Glucocorticoid apoptosis of leukemic cell	[Glucocorticoid apoptosis of leukemic cells]	0.0	5	1	1	1
113123	1710	index subject' leukocyte	[index subject's leukocytes]	0.0	3	1	1	1
113124	1710	lack the three binding site	[lacking the three binding sites]	0.0	5	1	1	1
113125	1710	HLF domain	[HLF domain]	0.0	2	1	1	1
113126	1710	cell regard to the release	[cells regarding to the release]	0.0	5	1	1	1
113127	1710	ovary syndrome pco	[ovary syndrome PCOS]	0.0	3	1	1	1
113128	1710	involvement in human disease	[involvement in human diseases]	0.0	4	1	1	1
113129	1710	such as hyaluronic acid	[such as hyaluronic acid]	0.0	4	1	1	1
113130	1710	cellular SRF	[cellular SRF]	0.0	2	1	1	1
113131	1710	cd38(-) cell differentiate	[CD38(-) cells differentiating]	0.0	3	1	1	1
113132	1710	125 amino acid	[125 amino acids]	0.0	3	1	1	1
113133	1710	two protein products,	[two protein products,]	0.0	3	1	1	1
113134	1710	resistance apoptosis	[Resistance apoptosis]	0.0	2	1	1	1
113135	1710	2 0.5 u/ml	[2 0.5 U/mL]	0.0	3	1	1	1
113136	1710	p65 translocation	[p65 translocation]	0.0	2	1	1	1
113137	1710	follow t(1;19) chromosomal translocation	[following t(1;19) chromosomal translocations]	0.0	4	1	1	1
113138	1710	encompass this hypersensitive site 4481	[encompassing this hypersensitive site 4481]	0.0	5	1	1	1
113139	1710	oxidative suppression	[oxidative suppression]	0.0	2	1	1	1
113140	1710	pco patient	[PCOS patients]	0.0	2	1	1	1
113141	1710	mononuclear leukocyte of male	[mononuclear leukocytes of males]	0.0	4	1	1	1
113142	1710	action of mineralocorticoid	[actions of mineralocorticoids]	0.0	3	1	1	1
113143	1710	tyrosine -phosphorylated stat1 protein 91	[tyrosine -phosphorylated stat1 proteins 91]	0.0	5	1	1	1
113144	1710	define crucial signal	[defining crucial signals]	0.0	3	1	1	1
113145	1710	three stimuli, stimulus-	[three stimuli, stimulus-]	0.0	3	1	1	1
113146	1710	IL-12 IFN -alpha-inducible gene	[IL-12 IFN -alpha-inducible genes]	0.0	4	1	1	1
113147	1710	potential regulator for cell differentiation	[potential regulator for cell differentiation]	0.0	5	1	1	1
113148	1710	cycle reactivity to epitope undetectable	[cycle reactivities to epitopes undetectable]	0.0	5	1	1	1
113149	1710	response of peripheral blood cell	[responses of peripheral blood cells]	0.0	5	1	1	1
113150	1710	stimulation of mononuclear cell	[Stimulation of mononuclear cells]	0.0	4	1	1	1
113151	1710	stat transducer of transcription) 6	[STAT transducers of transcription) 6]	0.0	5	1	1	1
113152	1710	determinant of recognition	[determinant of recognition]	0.0	3	1	1	1
113153	1710	activity of T3SO4	[activity of T3SO4]	0.0	3	1	1	1
113154	1710	amino-terminal cysteine-rich domain	[amino-terminal cysteine-rich domain]	0.0	3	1	1	1
113155	1710	only the mutant allele	[only the mutant allele]	0.0	4	1	1	1
113156	1710	ecem) cell	[(CEM) cells]	0.0	2	1	1	1
113157	1710	sarco(endo)plasmic reticulum ser	[sarco(endo)plasmic reticulum SER]	0.0	3	1	1	1
113158	1710	dnase hypersensitive site-forming element	[DNase hypersensitive site-forming element]	0.0	4	1	1	1
113159	1710	beta 1 cd49d/cd29 costimulation	[beta 1 CD49d/CD29 costimulation]	0.0	4	1	1	1
113160	1710	tnf-alpha level	[TNF-alpha level]	0.0	2	1	1	1
113161	1710	nf-kappab activation 1 long repeat	[NF-kappaB activation 1 long repeat]	0.0	5	1	1	1
113162	1710	activation of nuclear factor ap-1	[activation of nuclear factors AP-1]	0.0	5	1	1	1
113163	1710	consequence of ebv infection	[consequences of EBV infection]	0.0	4	1	1	1
113164	1710	corticosteroid receptor in leukocyte	[corticosteroid receptors in leukocytes]	0.0	4	1	1	1
113165	1710	50% inhibition of lymphocyte proliferation	[50% inhibition of lymphocyte proliferation]	0.0	5	1	1	1
113166	1710	resistance to therapy	[Resistance to therapy]	0.0	3	1	1	1
113167	1710	most dramatic effect	[most dramatic effects]	0.0	3	1	1	1
113168	1710	stone-forming condition	[stone-forming condition]	0.0	2	1	1	1
113169	1710	<0.5 micromol/L	[<0.5 micromol/L]	0.0	2	1	1	1
113170	1710	sixteen patient aged years,	[Sixteen patients aged years,]	0.0	4	1	1	1
113171	1710	case with a negative reaction	[case with a negative reaction]	0.0	5	1	1	1
113172	1710	putative erythroid-specific cis-acting element	[putative erythroid-specific cis-acting elements]	0.0	4	1	1	1
113173	1710	transcription c-fo	[transcription c-fos]	0.0	2	1	1	1
113174	1710	bp capable	[bp capable]	0.0	2	1	1	1
113175	1710	ubiquitous, inducible component	[ubiquitous, inducible component]	0.0	3	1	1	1
113176	1710	(h) irak	[(h) IRAK]	0.0	2	1	1	1
113177	1710	effect on NFAT	[effects on NFAT]	0.0	3	1	1	1
113178	1710	produce inhibition	[producing inhibition]	0.0	2	1	1	1
113179	1710	one parent with receptor binding	[one parent with receptor binding]	0.0	5	1	1	1
113180	1710	describe the activation of other gene	[describing the activation of other genes]	0.0	6	1	1	1
113181	1710	basis for the pathogenesis	[basis for the pathogenesis]	0.0	4	1	1	1
113182	1710	of GM5	[of GM5]	0.0	2	1	1	1
113183	1710	gene for differentiation	[genes for differentiation]	0.0	3	1	1	1
113184	1710	g/g of mrna	[g/g of mRNA]	0.0	3	1	1	1
113185	1710	leukocyte-specific component	[leukocyte-specific component]	0.0	2	1	1	1
113186	1710	immunological disease	[immunological diseases]	0.0	2	1	1	1
113187	1710	cd56+ lymphocyte (egls)	[CD56+ lymphocytes (eGLs)]	0.0	3	1	1	1
113188	1710	positive cis element	[positive cis elements]	0.0	3	1	1	1
113189	1710	novel ets-related protein	[novel Ets-related protein]	0.0	3	1	1	1
113190	1710	latent protein via interaction	[latent proteins via interaction]	0.0	4	1	1	1
113191	1710	receptor for il-12	[receptors for IL-12]	0.0	3	1	1	1
113192	1710	primary mechanism of insensitivity	[primary mechanism of insensitivity]	0.0	4	1	1	1
113193	1710	[32P]orthophosphate	[[32P]orthophosphate]	0.0	1	1	1	1
113194	1710	ubiquitinylation of transcription factor	[Ubiquitinylation of transcription factors]	0.0	4	1	1	1
113195	1710	htoll activation of stress-activated protein kinase/c-Jun	[hToll activation of stress-activated protein kinase/c-Jun]	0.0	6	1	1	1
113196	1710	gene, aml1/eto (mtg8)	[gene, AML1/ETO (MTG8)]	0.0	3	1	1	1
113197	1710	two AS oligonucleotide C-JUN as oligonucleotide	[two AS oligonucleotides C-JUN AS oligonucleotides]	0.0	6	1	1	1
113198	1710	control of the NF-kappaB/Rel pathway	[control of the NF-kappaB/Rel pathway]	0.0	5	1	1	1
113199	1710	severe anaphylaxis	[severe anaphylaxis]	0.0	2	1	1	1
113200	1710	tnfalpha phosphorylation	[TNFalpha phosphorylation]	0.0	2	1	1	1
113201	1710	inducer of drip coactivator binding	[inducers of DRIP coactivator binding]	0.0	5	1	1	1
113202	1710	mrna bp	[mRNA bp]	0.0	2	1	1	1
113203	1710	cellular mechanism of il-5 synthesis	[Cellular mechanisms of IL-5 synthesis]	0.0	5	1	1	1
113204	1710	CD28 ligand CD80	[CD28 ligands CD80]	0.0	3	1	1	1
113205	1710	e1a activities,	[E1A activities,]	0.0	2	1	1	1
113206	1710	BA patient on hormone therapy	[BA patients on hormone therapy]	0.0	5	1	1	1
113207	1710	chloramphenicol acetyl-transferase assay	[chloramphenicol acetyl-transferase assay]	0.0	3	1	1	1
113208	1710	suppressive nfat1 activity	[suppressive NFAT1 activity]	0.0	3	1	1	1
113209	1710	cell adhesion molecule vcam-1 nac	[cell adhesion molecule VCAM-1 NAC]	0.0	5	1	1	1
113210	1710	pu.1 from nuclear extract	[PU.1 from nuclear extracts]	0.0	4	1	1	1
113211	1710	tartrate-resistant acid phosphatase giant cell	[tartrate-resistant acid phosphatase giant cells]	0.0	5	1	1	1
113212	1710	nevertheless, relatively high, concentration of RA	[Nevertheless, relatively high, concentrations of RA]	0.0	6	1	1	1
113213	1710	biochemical sign of primary hypothyroidism	[biochemical signs of primary hypothyroidism]	0.0	5	1	1	1
113214	1710	encode component of signal transduction	[encoding components of signal transduction]	0.0	5	1	1	1
113215	1710	gene reporter in dt-40 b cell	[gene reporters in DT-40 B cells]	0.0	6	1	1	1
113216	1710	carboxy- terminal	[carboxy- terminal]	0.0	2	1	1	1
113217	1710	(activated) prb block	[(activated) pRB blocks]	0.0	3	1	1	1
113218	1710	35 kilobasis	[35 kilobases]	0.0	2	1	1	1
113219	1710	JAK3 pathway	[JAK3 pathways]	0.0	2	1	1	1
113220	1710	treatment of hypertension	[treatment of hypertension]	0.0	3	1	1	1
113221	1710	cellular metabolism, disposition	[cellular metabolism, disposition]	0.0	3	1	1	1
113222	1710	downstream of p21ras	[downstream of p21ras]	0.0	3	1	1	1
113223	1710	il-3 expression to normal	[IL-3 expression to normal]	0.0	4	1	1	1
113224	1710	depletion from nuclear extract	[depletion from nuclear extracts]	0.0	4	1	1	1
113225	1710	human myeloid cell neutrophilic granulocyte	[human myeloid cells neutrophilic granulocytes]	0.0	5	1	1	1
113226	1710	ar-cre	[AR-CRE]	0.0	1	1	1	1
113227	1710	composition in myeloid cell granulocyte	[composition in myeloid cells granulocytes]	0.0	5	1	1	1
113228	1710	cotransfection analysis	[cotransfection analysis]	0.0	2	1	1	1
113229	1710	transfer of such preparation	[transfer of such preparations]	0.0	4	1	1	1
113230	1710	inverse relation to major complex class	[inverse relation to major complex classes]	0.0	6	1	1	1
113231	1710	il-8 mrna	[IL-8 mRNA]	0.0	2	1	1	1
113232	1710	key participant	[key participants]	0.0	2	1	1	1
113233	1710	dihydrochloride	[dihydrochloride]	0.0	1	1	1	1
113234	1710	new nomenclature	[new nomenclature]	0.0	2	1	1	1
113235	1710	peroxyl scavenging	[peroxyl scavenging]	0.0	2	1	1	1
113236	1710	two signal pathway operate	[two signaling pathways operating]	0.0	4	1	1	1
113237	1710	low normal range	[lower normal range]	0.0	3	1	1	1
113238	1710	atherosclerotic disease	[atherosclerotic disease]	0.0	2	1	1	1
113239	1710	matrix interaction	[matrix interactions]	0.0	2	1	1	1
113240	1710	Rel /nf-kappa b activity	[Rel /NF-kappa B activity]	0.0	4	1	1	1
113241	1710	activation of -stat5a pathway	[Activation of -STAT5a pathway]	0.0	4	1	1	1
113242	1710	cfu-il6	[CFU-IL6]	0.0	1	1	1	1
113243	1710	fos gene expression by the factor	[fos gene expression by the factor]	0.0	6	1	1	1
113244	1710	induction of several cytokine	[induction of several cytokine]	0.0	4	1	1	1
113245	1710	tnf-alpha degradation of IkappaB alpha	[TNF-alpha degradation of IkappaB alpha]	0.0	5	1	1	1
113246	1710	cell adhesion molecule-1 in cell	[cell adhesion molecule-1 in cells]	0.0	5	1	1	1
113247	1710	antigen receptor response	[antigen receptor response]	0.0	3	1	1	1
113248	1710	insensitivity to the effect	[insensitivity to the effects]	0.0	4	1	1	1
113249	1710	nuclear factor AP-1/Octamer	[nuclear factor AP-1/Octamer]	0.0	3	1	1	1
113250	1710	transcription stat pathway	[transcription STAT pathway]	0.0	3	1	1	1
113251	1710	CD95 ligand	[CD95 ligand]	0.0	2	1	1	1
113252	1710	above markers,	[above markers,]	0.0	2	1	1	1
113253	1710	Oct2ab isoform	[Oct2ab isoforms]	0.0	2	1	1	1
113254	1710	mapping of probe	[mapping of probes]	0.0	3	1	1	1
113255	1710	opposite effect on differentiation	[opposite effects on differentiation]	0.0	4	1	1	1
113256	1710	Thus, NF-kappa B	[Thus, NF-kappa B]	0.0	3	1	1	1
113257	1710	rheumatoid arthritis five	[rheumatoid arthritis five]	0.0	3	1	1	1
113258	1710	support a mechanism	[supporting a mechanism]	0.0	3	1	1	1
113259	1710	h (and	[h (and]	0.0	2	1	1	1
113260	1710	human genomic sterol element SRE	[human genomic sterol element SRE]	0.0	5	1	1	1
113261	1710	antigen capsid antigen	[antigen capsid antigen]	0.0	3	1	1	1
113262	1710	particular dexamethasone	[particular dexamethasone]	0.0	2	1	1	1
113263	1710	nuclear factor 3 beta	[nuclear factor 3 beta]	0.0	4	1	1	1
113264	1710	TH -dependent effect	[TH -dependent effect]	0.0	3	1	1	1
113265	1710	phosphoprotein along with others,	[phosphoproteins along with others,]	0.0	4	1	1	1
113266	1710	Nuclear factor of t-cell	[Nuclear factor of T-cells]	0.0	4	1	1	1
113267	1710	bind tpa responsive element	[binding TPA responsive elements]	0.0	4	1	1	1
113268	1710	anti- ap-1 -binding activity	[anti- AP-1 -binding activity]	0.0	4	1	1	1
113269	1710	three site for cellular factor	[three sites for cellular factors]	0.0	5	1	1	1
113270	1710	phase of interleukin-2 il-2 growth	[phase of interleukin-2 IL-2 growth]	0.0	5	1	1	1
113271	1710	NF-kappa b transcriptional activation	[NF-kappa B transcriptional activation]	0.0	4	1	1	1
113272	1710	dominant negative n17rac	[dominant negative N17Rac]	0.0	3	1	1	1
113273	1710	histamine receptor subtype	[histamine receptor subtypes]	0.0	3	1	1	1
113274	1710	anti-CD3/anti-CD28	[anti-CD3/anti-CD28]	0.0	1	1	1	1
113275	1710	different transcription initiation site	[different transcription initiation sites]	0.0	4	1	1	1
113276	1710	one minor transcription start site	[One minor transcription start site]	0.0	5	1	1	1
113277	1710	role of ascorbate in the activation	[Role of ascorbate in the activation]	0.0	6	1	1	1
113278	1710	gata-1 expression differentiate progenitor	[GATA-1 expression differentiating progenitors]	0.0	4	1	1	1
113279	1710	processing b1/ p105	[processing B1/ p105]	0.0	3	1	1	1
113280	1710	rna display	[RNA display]	0.0	2	1	1	1
113281	1710	regulation by apoptosis-linked gene 4	[Regulation by apoptosis-linked gene 4]	0.0	5	1	1	1
113282	1710	region of the protein.	[regions of the protein.]	0.0	4	1	1	1
113283	1710	Jun family	[Jun families]	0.0	2	1	1	1
113284	1710	functional deficiency virus type 1 hiv-1	[functional deficiency virus type 1 HIV-1]	0.0	6	1	1	1
113285	1710	42 zinc finger protein	[42 zinc finger proteins]	0.0	4	1	1	1
113286	1710	appearance in cd4+ lymphocyte	[appearance in CD4+ lymphocytes]	0.0	4	1	1	1
113287	1710	only marginally in cell	[only marginally in cells]	0.0	4	1	1	1
113288	1710	phorbol 12-myristate differentiation	[phorbol 12-myristate differentiation]	0.0	3	1	1	1
113289	1710	single injection of blood cell	[single injection of blood cells]	0.0	5	1	1	1
113290	1710	adoptive transfer of preparation	[adoptive transfer of preparations]	0.0	4	1	1	1
113291	1710	endotoxemia	[endotoxemia]	0.0	1	1	1	1
113292	1710	aggtcatgacct	[AGGTCATGACCT]	0.0	1	1	1	1
113293	1710	provide evidence of a interplay	[providing evidence of an interplay]	0.0	5	1	1	1
113294	1710	mesothelial cell	[mesothelial cells]	0.0	2	1	1	1
113295	1710	leukocyte in obesity.	[leukocyte in obesity.]	0.0	3	1	1	1
113296	1710	site of pulmonary tuberculosis	[sites of pulmonary tuberculosis]	0.0	4	1	1	1
113297	1710	inhibitor of K+ channel	[inhibitor of K+ channels]	0.0	4	1	1	1
113298	1710	purine box 1	[purine box 1]	0.0	3	1	1	1
113299	1710	CsA associate with intracellular binding protein	[CsA associate with intracellular binding proteins]	0.0	6	1	1	1
113300	1710	change in T cell transmembrane signal	[changes in T cell transmembrane signaling]	0.0	6	1	1	1
113301	1710	include aml with morphology aml	[including AML with morphology AML]	0.0	5	1	1	1
113302	1710	localize to -2 lesion	[localizing to -2 lesions]	0.0	4	1	1	1
113303	1710	[35s]methionine	[[35S]methionine]	0.0	1	1	1	1
113304	1710	use virus	[using virus]	0.0	2	1	1	1
113305	1710	chain igh gene rearrangement	[chain IgH gene rearrangement]	0.0	4	1	1	1
113306	1710	anti-ig response element	[anti-Ig response elements]	0.0	3	1	1	1
113307	1710	overexpression of receptor kinase carboxyl-terminal peptide	[Overexpression of receptor kinase carboxyl-terminal peptide]	0.0	6	1	1	1
113308	1710	concentration as low	[concentration as low]	0.0	3	1	1	1
113309	1710	involve activation of two form	[involving activation of two forms]	0.0	5	1	1	1
113310	1710	human mononulear leukocyte	[human mononulear leukocytes]	0.0	3	1	1	1
113311	1710	DNA segment with enhancer activity	[DNA segments with enhancer activity]	0.0	5	1	1	1
113312	1710	differentiation of m2-type blast cell	[differentiation of M2-type blast cells]	0.0	5	1	1	1
113313	1710	extend from bp	[extending from bp]	0.0	3	1	1	1
113314	1710	family RA receptor	[families RA receptors]	0.0	3	1	1	1
113315	1710	role in the inducible transcription	[role in the inducible transcription]	0.0	5	1	1	1
113316	1710	consist of residue 122	[consisting of residues 122]	0.0	4	1	1	1
113317	1710	unequal paternal expression in three,	[unequal paternal expression in three,]	0.0	5	1	1	1
113318	1710	cytosolic extract from k562 cell	[cytosolic extracts from K562 cells]	0.0	5	1	1	1
113319	1710	exudate	[exudate]	0.0	1	1	1	1
113320	1710	comparison to cell	[comparison to cells]	0.0	3	1	1	1
113321	1710	Ad5 E1A cell line	[Ad5 E1A cell lines]	0.0	4	1	1	1
113322	1710	AMP -responsive element -dependent activation	[AMP -responsive element -dependent activation]	0.0	5	1	1	1
113323	1710	Chinese hamster ovary (cho)-dr	[Chinese hamster ovary (CHO)-DR]	0.0	4	1	1	1
113324	1710	involvement in t-cell virus type	[Involvement in T-cell virus type]	0.0	5	1	1	1
113325	1710	sensitization of human T cell	[sensitization of human T cells]	0.0	5	1	1	1
113326	1710	cyclic AMP element activation	[Cyclic AMP element activation]	0.0	4	1	1	1
113327	1710	gr -dependent activation of GRE	[GR -dependent activation of GRE]	0.0	5	1	1	1
113328	1710	sites/cell significant from the control group	[sites/cell significant from the control group]	0.0	6	1	1	1
113329	1710	Dramatic stimulation	[Dramatic stimulation]	0.0	2	1	1	1
113330	1710	analysis by western blotting	[analysis by Western blotting]	0.0	4	1	1	1
113331	1710	activation in this T cell	[activation in these T cells]	0.0	5	1	1	1
113332	1710	inhibition of transcription factor	[Inhibition of transcription factors]	0.0	4	1	1	1
113333	1710	determinant of the lymphoid-specific expression	[determinant of the lymphoid-specific expression]	0.0	5	1	1	1
113334	1710	postvaccine response use monocyte in 69%	[postvaccine responses using monocytes in 69%]	0.0	6	1	1	1
113335	1710	induction in cell	[induction in cells]	0.0	3	1	1	1
113336	1710	response to mineralocorticoid	[response to mineralocorticoids]	0.0	3	1	1	1
113337	1710	gene transcriptional activity	[gene transcriptional activity]	0.0	3	1	1	1
113338	1710	lps enhancer	[LPS enhancer]	0.0	2	1	1	1
113339	1710	eventually lead	[eventually leading]	0.0	2	1	1	1
113340	1710	combination of antibody	[combination of antibodies]	0.0	3	1	1	1
113341	1710	such proliferations.	[such proliferations.]	0.0	2	1	1	1
113342	1710	heterotrimeric protein	[heterotrimeric proteins]	0.0	2	1	1	1
113343	1710	signal transduction pathway in normal monocyte	[Signal transduction pathways in normal monocytes]	0.0	6	1	1	1
113344	1710	MHC class induction	[MHC class induction]	0.0	3	1	1	1
113345	1710	different transcription factor in monocyte	[different transcription factors in monocytes]	0.0	5	1	1	1
113346	1710	overexpress hIRAK a constitutive activation	[overexpressing hIRAK a constitutive activation]	0.0	5	1	1	1
113347	1710	pkc NF-kappa b inhibitors, pentoxifylline PTX	[PKC NF-kappa B inhibitors, pentoxifylline PTX]	0.0	6	1	1	1
113348	1710	pluripotent activator of inflammation	[pluripotent activator of inflammation]	0.0	4	1	1	1
113349	1710	T lymphocyte with function	[T lymphocytes with functions]	0.0	4	1	1	1
113350	1710	bipotent myeloid progenitor cell	[bipotent myeloid progenitor cells]	0.0	4	1	1	1
113351	1710	activation 1 expression by Gardnerella vaginalis	[Activation 1 expression by Gardnerella vaginalis]	0.0	6	1	1	1
113352	1710	monocytes/macrophages via cd14	[monocytes/macrophages via CD14]	0.0	3	1	1	1
113353	1710	replacement of the DQB x2-box	[replacement of the DQB X2-box]	0.0	5	1	1	1
113354	1710	localization sequence NLS	[localization sequence NLS]	0.0	3	1	1	1
113355	1710	Concomitant downregulation implication	[Concomitant downregulation implications]	0.0	3	1	1	1
113356	1710	response by lymphocyte factor	[response by lymphocyte factors]	0.0	4	1	1	1
113357	1710	human melanoma study	[human melanoma study]	0.0	3	1	1	1
113358	1710	induction of CD8 antigen	[Induction of CD8 antigen]	0.0	4	1	1	1
113359	1710	activation of PKC subfamily	[activation of PKC subfamilies]	0.0	4	1	1	1
113360	1710	induction kappa B/Rel activity antibody	[Induction kappa B/Rel activity antibodies]	0.0	5	1	1	1
113361	1710	T regulatory element nre	[T regulatory element NRE]	0.0	4	1	1	1
113362	1710	tfiid subunit related to htafii130	[TFIID subunit related to hTAFII130]	0.0	5	1	1	1
113363	1710	inhibition of adenylyl cyclase	[Inhibition of adenylyl cyclase]	0.0	4	1	1	1
113364	1710	two footprint	[two footprints]	0.0	2	1	1	1
113365	1710	encompass a sequence	[encompassing a sequence]	0.0	3	1	1	1
113366	1710	e-selectin by tumor necrosis factor-alpha	[E-selectin by tumor necrosis factor-alpha]	0.0	5	1	1	1
113367	1710	[3H]dexamethasone binding site	[[3H]dexamethasone binding sites]	0.0	3	1	1	1
113368	1710	c-cerba/thyroid hormone	[c-cerbA/thyroid hormone]	0.0	2	1	1	1
113369	1710	vitamin D3 metabolite 1,25-dihydroxycholecalciferol	[vitamin D3 metabolite 1,25-dihydroxycholecalciferol]	0.0	4	1	1	1
113370	1710	only tool	[only tool]	0.0	2	1	1	1
113371	1710	stat1 signal	[STAT1 signaling]	0.0	2	1	1	1
113372	1710	status of knowledge the role	[status of knowledge the roles]	0.0	5	1	1	1
113373	1710	T cell during aging	[T cells during aging]	0.0	4	1	1	1
113374	1710	pool of oligonucleotide	[pool of oligonucleotides]	0.0	3	1	1	1
113375	1710	define the operational characteristic	[defining the operational characteristics]	0.0	4	1	1	1
113376	1710	important role in state	[important role in states]	0.0	4	1	1	1
113377	1710	epo mechanism	[Epo mechanisms]	0.0	2	1	1	1
113378	1710	b species in most cell	[B species in most cells]	0.0	5	1	1	1
113379	1710	interferon-gamma ifn-gamma in peripheral blood lymphocyte	[interferon-gamma IFN-gamma in peripheral blood lymphocytes]	0.0	6	1	1	1
113380	1710	viremia	[viremia]	0.0	1	1	1	1
113381	1710	herpesvirus strain gs	[herpesvirus strains GS]	0.0	3	1	1	1
113382	1710	tissue factor expression by cell	[Tissue factor expression by cells]	0.0	5	1	1	1
113383	1710	1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin	[1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin]	0.0	1	1	1	1
113384	1710	interaction receptor-associated factor	[interaction receptor-associated factors]	0.0	3	1	1	1
113385	1710	tissue infiltration	[tissue infiltration]	0.0	2	1	1	1
113386	1710	ec expression	[EC expression]	0.0	2	1	1	1
113387	1710	switch during stage of infection	[switching during stages of infection]	0.0	5	1	1	1
113388	1710	apoptosis of human cd34+ progenitor cell	[apoptosis of human CD34+ progenitor cells]	0.0	6	1	1	1
113389	1710	(position -153 to -145	[(positions -153 to -145]	0.0	4	1	1	1
113390	1710	Affinity-driven peptide selection more selective	[Affinity-driven peptide selection more selective]	0.0	5	1	1	1
113391	1710	venule	[venules]	0.0	1	1	1	1
113392	1710	transcription of the repeat	[transcription of the repeats]	0.0	4	1	1	1
113393	1710	T negative regulatory element nre	[T negative regulatory element NRE]	0.0	5	1	1	1
113394	1710	keep	[keeping]	0.0	1	1	1	1
113395	1710	similarly in normal alveolar macrophage	[similarly in normal alveolar macrophages]	0.0	5	1	1	1
113396	1710	Sp1 bind	[Sp1 binding]	0.0	2	1	1	1
113397	1710	blood mononuclear cell from subject	[blood mononuclear cells from subjects]	0.0	5	1	1	1
113398	1710	her-2/neu overexpression +/- 11.0%).	[HER-2/neu overexpression +/- 11.0%).]	0.0	4	1	1	1
113399	1710	signal pathway normally responsible	[signaling pathways normally responsible]	0.0	4	1	1	1
113400	1710	induction P-4501A1 CYP1A1 activity	[Induction P-4501A1 CYP1A1 activity]	0.0	4	1	1	1
113401	1710	ligation of complex class	[ligation of complex class]	0.0	4	1	1	1
113402	1710	use probe for chromosome	[using probes for chromosomes]	0.0	4	1	1	1
113403	1710	cp a region from -429	[Cp a region from -429]	0.0	5	1	1	1
113404	1710	site-directed mutation	[site-directed mutations]	0.0	2	1	1	1
113405	1710	study responsiveness to transactivator BZLF1 Z	[studying responsiveness to transactivators BZLF1 Z]	0.0	6	1	1	1
113406	1710	burst in U937 cell	[burst in U937 cells]	0.0	4	1	1	1
113407	1710	patient aged years, (range from 11.1	[patients aged years, (ranging from 11.1]	0.0	6	1	1	1
113408	1710	t-cell leukemia T-PLL a rare form	[T-cell leukemia T-PLL a rare form]	0.0	6	1	1	1
113409	1710	coculture cellular assay system	[coculture cellular assay system]	0.0	4	1	1	1
113410	1710	possibility of cis inactivation	[possibility of cis inactivation]	0.0	4	1	1	1
113411	1710	only CsA -sensitive component	[only CsA -sensitive component]	0.0	4	1	1	1
113412	1710	potentially result in phosphorylation	[potentially resulting in phosphorylation]	0.0	4	1	1	1
113413	1710	response to various activators,	[response to various activators,]	0.0	4	1	1	1
113414	1710	putative NF-kappa b binding site	[putative NF-kappa B binding sites]	0.0	5	1	1	1
113415	1710	vitro phosphorylation	[vitro phosphorylation]	0.0	2	1	1	1
113416	1710	63-kda	[63-kDa]	0.0	1	1	1	1
113417	1710	effector include the tyrosine protein kinase	[effectors including the tyrosine protein kinase]	0.0	6	1	1	1
113418	1710	growth signal pathway	[growth signaling pathway]	0.0	3	1	1	1
113419	1710	human cd3-cd16+	[Human CD3-CD16+]	0.0	2	1	1	1
113420	1710	ifn-beta promoter transcription	[IFN-beta promoter transcription]	0.0	3	1	1	1
113421	1710	il-2 production by means	[IL-2 production by means]	0.0	4	1	1	1
113422	1710	5 of 6 cases,	[5 of 6 cases,]	0.0	4	1	1	1
113423	1710	mediator generate only positive mechanism	[mediator generating only positive mechanisms]	0.0	5	1	1	1
113424	1710	antiviral, activity	[antiviral, activities]	0.0	2	1	1	1
113425	1710	ro(ssa) precipitins,	[Ro(SSA) precipitins,]	0.0	2	1	1	1
113426	1710	candidate gene nuclear factor	[candidate genes nuclear factor]	0.0	4	1	1	1
113427	1710	z-lll-h activity	[Z-LLL-H activity]	0.0	2	1	1	1
113428	1710	total 25(oh)d3 uptake	[total 25(OH)D3 uptake]	0.0	3	1	1	1
113429	1710	genomic action	[genomic actions]	0.0	2	1	1	1
113430	1710	intervene region	[intervening regions]	0.0	2	1	1	1
113431	1710	Nuclear extract of cd15 cell	[Nuclear extracts of CD15 cells]	0.0	5	1	1	1
113432	1710	anti-proliferative effect on T cell	[anti-proliferative effects on T cells]	0.0	5	1	1	1
113433	1710	elicit remission of the preleukemic state	[eliciting remissions of the preleukemic state]	0.0	6	1	1	1
113434	1710	low molecular weight species of 24	[lower molecular weight species of 24]	0.0	6	1	1	1
113435	1710	Surprisingly, overexpression of GRbeta	[Surprisingly, overexpression of GRbeta]	0.0	4	1	1	1
113436	1710	transactivator of viral gene expression.	[transactivators of viral gene expression.]	0.0	5	1	1	1
113437	1710	inhibit the transcription	[inhibiting the transcription]	0.0	3	1	1	1
113438	1710	differentiation a model	[differentiation a model]	0.0	3	1	1	1
113439	1710	ten patient with normal affinity	[Ten patients with normal affinity]	0.0	5	1	1	1
113440	1710	primary syndrome MDS	[primary syndromes MDS]	0.0	3	1	1	1
113441	1710	aspect of interaction	[aspects of interaction]	0.0	3	1	1	1
113442	1710	induction by hemin increases,	[Induction by hemin increases,]	0.0	4	1	1	1
113443	1710	14 ppb	[14 PPB]	0.0	2	1	1	1
113444	1710	normal primitive progenitor cell	[normal primitive progenitor cells]	0.0	4	1	1	1
113445	1710	complex include Stat1 alpha	[complexes including Stat1 alpha]	0.0	4	1	1	1
113446	1710	most permanent cell line	[most permanent cell lines]	0.0	4	1	1	1
113447	1710	protein mar-bp1 from matrix preparation	[protein MAR-BP1 from matrix preparations]	0.0	5	1	1	1
113448	1710	human rel family protein	[human Rel family proteins]	0.0	4	1	1	1
113449	1710	susceptibility to killer cell	[Susceptibility to killer cells]	0.0	4	1	1	1
113450	1710	implication regard the clinical use	[implications regarding the clinical use]	0.0	5	1	1	1
113451	1710	immunosuppressive drug cyclosporin	[immunosuppressive drugs cyclosporin]	0.0	3	2	2	1
113452	1710	overall increase	[overall increase]	0.0	2	1	1	1
113453	1710	translocation of cytosolic c-rel/ p65 heterodimer	[translocation of cytosolic c-Rel/ p65 heterodimers]	0.0	6	1	1	1
113454	1710	well-standardized criteria, unbalanced inactivation	[well-standardized criteria, unbalanced inactivation]	0.0	4	1	1	1
113455	1710	expression of the cd95 ligand cd95l	[Expression of the CD95 ligand CD95L]	0.0	6	1	1	1
113456	1710	human blood cell hrbc	[human blood cells HRBC]	0.0	4	1	1	1
113457	1710	have a long-distance effect	[having a long-distance effect]	0.0	4	1	1	1
113458	1710	Epstein-Barr nuclear antigen expression	[Epstein-Barr nuclear antigen expression]	0.0	4	1	1	1
113459	1710	IL-6 kappa b-related kappa b motif	[IL-6 kappa B-related kappa B motifs]	0.0	6	1	1	1
113460	1710	NFAT-1 bind motif	[NFAT-1 binding motif]	0.0	3	1	1	1
113461	1710	il-12 phosphorylation	[IL-12 phosphorylation]	0.0	2	1	1	1
113462	1710	interleukin-10 production in human monocyte	[interleukin-10 production in human monocytes]	0.0	5	1	1	1
113463	1710	action law.	[action law.]	0.0	2	1	1	1
113464	1710	in-vitro-stimulated normal cord blood	[in-vitro-stimulated normal cord blood]	0.0	4	1	1	1
113465	1710	activation of lineage	[activation of lineages]	0.0	3	1	1	1
113466	1710	factor of t-cell (nfat) site	[factors of T-cell (NFAT) sites]	0.0	5	1	1	1
113467	1710	first step-wise increase exercise	[first step-wise increasing exercise]	0.0	4	1	1	1
113468	1710	CD30 ligand	[CD30 ligand]	0.0	2	1	1	1
113469	1710	thus permit the release	[thus permitting the release]	0.0	4	1	1	1
113470	1710	screen method	[screening methods]	0.0	2	1	1	1
113471	1710	factor in DNA damage	[factor in DNA damage]	0.0	4	1	1	1
113472	1710	pbmc on Teflon	[PBMC on Teflon]	0.0	3	1	1	1
113473	1710	nf-kappa b /rel binding motif	[NF-kappa B /Rel binding motif]	0.0	5	1	1	1
113474	1710	ca2+-mediated activation in human platelet	[Ca2+-mediated activation in human platelets]	0.0	5	1	1	1
113475	1710	region include the enhancer	[regions including the enhancer]	0.0	4	1	1	1
113476	1710	encompass a important element NF-AT-1	[encompassing an important element NF-AT-1]	0.0	5	1	1	1
113477	1710	exposure of cell to adverse condition	[Exposure of cells to adverse conditions]	0.0	6	1	1	1
113478	1710	two Duffy antigen Fya	[two Duffy antigens Fya]	0.0	4	1	1	1
113479	1710	involvement in human lymphotropic virus type	[Involvement in human lymphotropic virus type]	0.0	6	1	1	1
113480	1710	suggest local proliferation.	[suggesting local proliferation.]	0.0	3	1	1	1
113481	1710	T cell leukemia(atl) cell	[T cell leukemia(ATL) cells]	0.0	4	1	1	1
113482	1710	immunodeficiency virus 1	[immunodeficiency virus 1]	0.0	3	1	1	1
113483	1710	analysis of gene in progenitor cell	[Analysis of genes in progenitor cells]	0.0	6	1	1	1
113484	1710	study of leukocyte	[studies of leukocytes]	0.0	3	1	1	1
113485	1710	role signal	[roles signaling]	0.0	2	1	1	1
113486	1710	dendritic cell in s.c. lymph nodes;	[dendritic cells in s.c. lymph nodes;]	0.0	6	1	1	1
113487	1710	integrin-containing adhesion	[integrin-containing adhesions]	0.0	2	1	1	1
113488	1710	cell at day 6; g-csf	[cells at day 6; G-CSF]	0.0	5	1	1	1
113489	1710	tnf T	[TNF T]	0.0	2	1	1	1
113490	1710	expression of a single viral gene	[expression of a single viral gene]	0.0	6	1	1	1
113491	1710	widespread use	[widespread use]	0.0	2	1	1	1
113492	1710	main activity of glucocorticoid transactivation	[main activities of glucocorticoids transactivation]	0.0	5	1	1	1
113493	1710	combination of hla-dq haplotype	[combinations of HLA-DQ haplotypes]	0.0	4	1	1	1
113494	1710	cut edge: tcr stimulation	[Cutting edge: TCR stimulation]	0.0	4	1	1	1
113495	1710	predominant synthesis	[predominant synthesis]	0.0	2	1	1	1
113496	1710	promote plaque formation.	[promoting plaque formation.]	0.0	3	1	1	1
113497	1710	events; addition	[events; addition]	0.0	2	1	1	1
113498	1710	main cellular source	[main cellular source]	0.0	3	1	1	1
113499	1710	splenic T cell in vitro	[splenic T cells in vitro]	0.0	5	1	1	1
113500	1710	expression to immunodeficiency virus type	[expression to immunodeficiency virus type]	0.0	5	1	1	1
113501	1710	inhibitor in pbmc from patient	[inhibitor in PBMC from patients]	0.0	5	1	1	1
113502	1710	interaction with cbp/p300	[interaction with CBP/p300]	0.0	3	1	1	1
113503	1710	consensus ap-1 tre motif	[consensus AP-1 TRE motifs]	0.0	4	1	1	1
113504	1710	NK cell-derived granule	[NK cell-derived granules]	0.0	3	1	1	1
113505	1710	th2-type lymphokine	[Th2-type lymphokines]	0.0	2	1	1	1
113506	1710	novel function of stat1 protein	[novel function of Stat1 proteins]	0.0	5	1	1	1
113507	1710	(igh) enhancer	[(IgH) enhancer]	0.0	2	1	1	1
113508	1710	dependency	[dependency]	0.0	1	1	1	1
113509	1710	lower	[lowering]	0.0	1	1	1	1
113510	1710	hiv long repeat activation	[HIV long repeat activation]	0.0	4	1	1	1
113511	1710	alteration of NF kappa b	[alterations of NF kappa B]	0.0	5	1	1	1
113512	1710	sequence analysis of different cDNA clone	[Sequence analysis of different cDNA clones]	0.0	6	1	1	1
113513	1710	T cell deficient	[T cells deficient]	0.0	3	1	1	1
113514	1710	sensitivity against all three type	[sensitivity against all three types]	0.0	5	1	1	1
113515	1710	little direct evidence	[little direct evidence]	0.0	3	1	1	1
113516	1710	normal blood cell	[normal blood cells]	0.0	3	1	1	1
113517	1710	rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	4	1	1	1
113518	1710	property for a androgen receptor	[properties for a androgen receptor]	0.0	5	1	1	1
113519	1710	prior to the onset	[prior to the onset]	0.0	4	1	1	1
113520	1710	MHC transcript	[MHC transcripts]	0.0	2	1	1	1
113521	1710	zona glomerulosa	[zona glomerulosa]	0.0	2	1	1	1
113522	1710	such as cell adhesion molecule-1 vcam-1	[such as cell adhesion molecule-1 VCAM-1]	0.0	6	1	1	1
113523	1710	use a semiquantitative hybridization assay	[using a semiquantitative hybridization assay]	0.0	5	1	1	1
113524	1710	analysis of poly(A) rna	[analysis of poly(A) RNA]	0.0	4	1	1	1
113525	1710	97 (18- to 35-year-old) volunteer	[97 (18- to 35-year-old) volunteers]	0.0	5	1	1	1
113526	1710	-red	[-red]	0.0	1	1	1	1
113527	1710	complex class gene	[complex class genes]	0.0	3	1	1	1
113528	1710	calf serum efcs culture	[calf serum (FCS+) culture]	0.0	4	1	1	1
113529	1710	pan-1 respectively),	[Pan-1 respectively),]	0.0	2	1	1	1
113530	1710	corresponding 3- increase	[corresponding 3- increase]	0.0	3	1	1	1
113531	1710	human immunodeficiency virus apoptosis	[human immunodeficiency virus apoptosis]	0.0	4	1	1	1
113532	1710	also for several region	[also for several regions]	0.0	4	1	1	1
113533	1710	gtp motif	[GTP motif]	0.0	2	1	1	1
113534	1710	bactericidal/permeability-increasing protein bpi	[bactericidal/permeability-increasing protein BPI]	0.0	3	1	1	1
113535	1710	leukaemia cell carry the translocation t(17;19)	[leukaemia cells carrying the translocation t(17;19)]	0.0	6	1	1	1
113536	1710	transactivation response	[transactivation response]	0.0	2	1	1	1
113537	1710	mg/dl)	[mg/dl)]	0.0	1	1	1	1
113538	1710	bone marrow infiltration	[bone marrow infiltration]	0.0	3	1	1	1
113539	1710	transactivation response element	[transactivation response element]	0.0	3	1	1	1
113540	1710	autologous blood stem cell transplantation	[Autologous blood stem cell transplantation]	0.0	5	1	1	1
113541	1710	occur in allelic family	[occurring in allelic families]	0.0	4	1	1	1
113542	1710	immediate regulator	[immediate regulators]	0.0	2	1	1	1
113543	1710	high level of expression	[high levels of expression]	0.0	4	1	1	1
113544	1710	factor for nk/lgl cell	[factors for NK/LGL cells]	0.0	4	1	1	1
113545	1710	advanced chronic failure A-CRF	[advanced chronic failure A-CRF]	0.0	4	1	1	1
113546	1710	cytokine include the interferon	[cytokines including the interferons]	0.0	4	1	1	1
113547	1710	presumably through opening of Ca(2+)-stimulated K+	[presumably through opening of Ca(2+)-stimulated K+]	0.0	6	1	1	1
113548	1710	100-500 microm	[100-500 microM]	0.0	2	1	1	1
113549	1710	employ the motif	[employing the motif]	0.0	3	1	1	1
113550	1710	point mutant of zebra	[point mutant of ZEBRA]	0.0	4	1	1	1
113551	1710	hypothesis due	[hypothesis due]	0.0	2	1	1	1
113552	1710	recurrent feature of hla-dq evolution	[recurrent feature of HLA-DQ evolution]	0.0	5	1	1	1
113553	1710	viral gag-pol mrna	[viral gag-pol mRNA]	0.0	3	1	1	1
113554	1710	expression of a trans-dominant form	[expression of a trans-dominant form]	0.0	5	1	1	1
113555	1710	GC with a border	[GC with an border]	0.0	4	1	1	1
113556	1710	FL hpc	[FL HPCs]	0.0	2	1	1	1
113557	1710	lymphoid-specific immunoglobulin mu	[lymphoid-specific immunoglobulin mu]	0.0	3	1	1	1
113558	1710	affinity of quercetin	[affinity of quercetin]	0.0	3	1	1	1
113559	1710	cell cycle-associated gene in cell	[cell cycle-associated genes in cells]	0.0	5	1	1	1
113560	1710	6- stimulation of LTR transcription	[6- stimulation of LTR transcription]	0.0	5	1	1	1
113561	1710	transcription factor SP1	[transcription factor SP1]	0.0	3	1	1	1
113562	1710	gingivalis	[gingivalis]	0.0	1	1	1	1
113563	1710	twofold increase from asthmatic patient	[twofold increase from asthmatic patients]	0.0	5	1	1	1
113564	1710	tcp (200 microM, h),	[TCP (200 microM, h),]	0.0	4	1	1	1
113565	1710	emergence of LTR revertant	[emergence of LTR revertants]	0.0	4	1	1	1
113566	1710	hyperglycemia	[hyperglycemia]	0.0	1	1	1	1
113567	1710	prodigiosin family	[prodigiosin family]	0.0	2	1	1	1
113568	1710	moreover, transient transfection	[Moreover, transient transfection]	0.0	3	1	1	1
113569	1710	basis for activation	[basis for activation]	0.0	3	1	1	1
113570	1710	inhibition by acetylsalicylate	[inhibition by acetylsalicylate]	0.0	3	1	1	1
113571	1710	il-13-induced regulatory factor	[IL-13-induced regulatory factors]	0.0	3	1	1	1
113572	1710	only activation	[only activation]	0.0	2	1	1	1
113573	1710	chain class	[chain class]	0.0	2	1	1	1
113574	1710	bhrf1 protein with homology to Bcl-2	[BHRF1 protein with homology to Bcl-2]	0.0	6	1	1	1
113575	1710	next to lymphocyte infiltration	[next to lymphocyte infiltration]	0.0	4	1	1	1
113576	1710	thus for monocyte infiltration	[thus for monocyte infiltration]	0.0	4	1	1	1
113577	1710	doses,	[doses,]	0.0	1	1	1	1
113578	1710	control of the process	[control of the processes]	0.0	4	1	1	1
113579	1710	nine cDNA clone	[nine cDNA clones]	0.0	3	1	1	1
113580	1710	adhesion human umbilical vein cell	[adhesion human umbilical vein cells]	0.0	5	1	1	1
113581	1710	additional formation in the presence	[additional formation in the presence]	0.0	5	1	1	1
113582	1710	typical chronic inflammation	[typical chronic inflammation]	0.0	3	1	1	1
113583	1710	inhibition of factor kappab activation	[Inhibition of factor kappaB activation]	0.0	5	1	1	1
113584	1710	vacuolar h+-atpase v-atpase	[vacuolar H+-ATPase V-ATPase]	0.0	3	1	1	1
113585	1710	ion of similar masses;	[ions of similar masses;]	0.0	4	1	1	1
113586	1710	effect of monocyte	[effects of monocytes]	0.0	3	1	1	1
113587	1710	binding of type I interferon	[Binding of type I interferon]	0.0	5	1	1	1
113588	1710	present a similarity	[presenting a similarity]	0.0	3	1	1	1
113589	1710	fibrosarcoma 8, malignant fibrous histiocytoma	[fibrosarcoma 8, malignant fibrous histiocytoma]	0.0	5	1	1	1
113590	1710	c-c chemokine in cell	[C-C chemokines in cells]	0.0	4	1	1	1
113591	1710	abnormality of p16 gene	[Abnormalities of p16 genes]	0.0	4	1	1	1
113592	1710	anti-HLA-DR antibody	[anti-HLA-DR antibody]	0.0	2	1	1	1
113593	1710	encode transactivator in EBV T cell	[encoding transactivators in EBV T cells]	0.0	6	1	1	1
113594	1710	expression in t-cell lymphoblastic leukemia	[expression in T-cell lymphoblastic leukemia]	0.0	5	1	1	1
113595	1710	polymorphism at codon	[polymorphism at codon]	0.0	3	1	1	1
113596	1710	adhesion of RA synovial cell	[adhesion of RA synovial cells]	0.0	5	1	1	1
113597	1710	comparable decrease	[comparable decrease]	0.0	2	1	1	1
113598	1710	response to activation,	[response to activation,]	0.0	3	1	1	1
113599	1710	effect on early gene expression	[effect on early gene expression]	0.0	5	1	1	1
113600	1710	western blot with antibody	[Western blots with antibodies]	0.0	4	1	1	1
113601	1710	tuberculosis df, p=.01)	[tuberculosis df, P=.01)]	0.0	3	1	1	1
113602	1710	Unexpectedly, stimulation	[Unexpectedly, stimulation]	0.0	2	1	1	1
113603	1710	role in igh gene expression	[role in IgH gene expression]	0.0	5	1	1	1
113604	1710	addition, two	[addition, two]	0.0	2	1	1	1
113605	1710	understanding of the impact	[understanding of the impact]	0.0	4	1	1	1
113606	1710	protein of nf-kappa b	[protein of NF-kappa B]	0.0	4	1	1	1
113607	1710	accompany the rapid turnover	[Accompanying the rapid turnover]	0.0	4	1	1	1
113608	1710	experimental conditions.	[experimental conditions.]	0.0	2	1	1	1
113609	1710	dominant form of Stat1alpha	[Dominant forms of Stat1alpha]	0.0	4	1	1	1
113610	1710	Namalwa b	[Namalwa B]	0.0	2	1	1	1
113611	1710	ifn-gamma colony-stimulating factor cytoplasmic mrna	[IFN-gamma colony-stimulating factor cytoplasmic mRNA]	0.0	5	1	1	1
113612	1710	negative creb	[negative CREB]	0.0	2	1	1	1
113613	1710	cyclooxygenase/5-lipoxygenase compound under investigation.	[cyclooxygenase/5-lipoxygenase compound under investigation.]	0.0	4	1	1	1
113614	1710	regulation of certain processes,	[regulation of certain processes,]	0.0	4	1	1	1
113615	1710	exogenous addition	[Exogenous addition]	0.0	2	1	1	1
113616	1710	phase of b development	[phase of B development]	0.0	4	1	1	1
113617	1710	lps treatment of RAW cell	[LPS treatment of RAW cells]	0.0	5	1	1	1
113618	1710	case of acute leukaemia	[cases of acute leukaemia]	0.0	4	1	1	1
113619	1710	thus a target in inflammatory state	[thus a target in inflammatory states]	0.0	6	1	1	1
113620	1710	position of the hil-5 promoter	[positions of the hIL-5 promoter]	0.0	5	1	1	1
113621	1710	however, disruption of a sequence motif	[However, disruption of a sequence motif]	0.0	6	1	1	1
113622	1710	hgm-csf cell proliferation	[hGM-CSF cell proliferation]	0.0	3	1	1	1
113623	1710	stimulation antibody mab phosphatidylinositol 3-kinase	[Stimulation antibody mAb phosphatidylinositol 3-kinase]	0.0	5	1	1	1
113624	1710	cell cycling	[cell cycling]	0.0	2	1	1	1
113625	1710	75-kDa cytokine	[75-kDa cytokine]	0.0	2	1	1	1
113626	1710	a10 antigen incidence	[A10 antigen incidence]	0.0	3	1	1	1
113627	1710	french-american-british leukemia-M3	[French-American-British leukemia-M3]	0.0	2	1	1	1
113628	1710	maturation of T cell	[maturation of T cells]	0.0	4	1	1	1
113629	1710	assay with [3H]dexamethasone	[assay with [3H]dexamethasone]	0.0	3	1	1	1
113630	1710	stage involve modification and/or translocation	[stage involving modification and/or translocation]	0.0	5	1	1	1
113631	1710	fluid from RCC explant RCC	[fluid from RCC explants RCC]	0.0	5	1	1	1
113632	1710	immunogenic malignant melanoma	[immunogenic malignant melanomas]	0.0	3	1	1	1
113633	1710	gene encode granule protein ecp	[genes encoding granule proteins ECP]	0.0	5	1	1	1
113634	1710	component of the b transcription factor	[component of the B transcription factor]	0.0	6	1	1	1
113635	1710	immunomodulating properties	[immunomodulating properties,]	0.0	2	1	1	1
113636	1710	non-steroidal anti-inflammatory drug	[non-steroidal anti-inflammatory drugs]	0.0	3	1	1	1
113637	1710	DNA binding pea1	[DNA binding PEA1]	0.0	3	1	1	1
113638	1710	expression of elam-1 p	[expression of ELAM-1 P]	0.0	4	1	1	1
113639	1710	affinity of transcriptional element for factor	[affinities of transcriptional elements for factor]	0.0	6	1	1	1
113640	1710	schedule (five patient with microgram/day	[schedules (five patients with microgram/day]	0.0	5	1	1	1
113641	1710	activation by lipopolysaccharide in mononuclear leukocyte	[Activation by lipopolysaccharide in mononuclear leukocytes]	0.0	6	1	1	1
113642	1710	incubation of RU 486	[incubation of RU 486]	0.0	4	1	1	1
113643	1710	adrenal failure	[adrenal failure]	0.0	2	1	1	1
113644	1710	polypeptide subunit	[polypeptide subunits]	0.0	2	1	1	1
113645	1710	putative ets binding site EBS	[putative Ets binding sites EBS]	0.0	5	1	1	1
113646	1710	proto-oncogene response in pbmo cell	[proto-oncogene responses in PBMo cells]	0.0	5	1	1	1
113647	1710	protein and/or DNA	[proteins and/or DNA]	0.0	3	1	1	1
113648	1710	aggressive histologic type	[aggressive histologic types]	0.0	3	1	1	1
113649	1710	effective inhibition of nf-at activation	[effective inhibition of NF-AT activation]	0.0	5	1	1	1
113650	1710	activation C	[activation C]	0.0	2	1	1	1
113651	1710	overexpression of negative form	[Overexpression of negative forms]	0.0	4	1	1	1
113652	1710	constitutive, low-level expression of type	[constitutive, low-level expression of type]	0.0	5	1	1	1
113653	1710	demonstrate a population by DNA staining	[demonstrating a population by DNA staining]	0.0	6	1	1	1
113654	1710	stimulation by mbp	[stimulation by MBP]	0.0	3	1	1	1
113655	1710	identical proteins, differ	[identical proteins, differing]	0.0	3	1	1	1
113656	1710	nuclear factor-kappaB activity	[nuclear factor-kappaB activity]	0.0	3	1	1	1
113657	1710	GM-CSF blood polymorphonuclear leukocyte	[GM-CSF blood polymorphonuclear leukocytes]	0.0	4	1	1	1
113658	1710	Glucocorticoid receptor on human mononuclear change	[Glucocorticoid receptors on human mononuclear changes]	0.0	6	1	1	1
113659	1710	spxx motif	[SPXX motifs]	0.0	2	1	1	1
113660	1710	middle-aged (44-55 years) hypertensive	[middle-aged (44-55 years) hypertensives]	0.0	4	1	1	1
113661	1710	infection interleukin-8 gene transcription	[infection interleukin-8 gene transcription]	0.0	4	1	1	1
113662	1710	early development of multiple lineage	[early development of multiple lineages]	0.0	5	1	1	1
113663	1710	low relative binding affinity	[low relative binding affinities]	0.0	4	1	1	1
113664	1710	only cross-reactivity	[only cross-reactivity]	0.0	2	1	1	1
113665	1710	list of cytokine	[list of cytokines]	0.0	3	1	1	1
113666	1710	involvement in induction of IL-6 transcription	[Involvement in induction of IL-6 transcription]	0.0	6	1	1	1
113667	1710	gene ORF 50	[gene ORF 50]	0.0	3	1	1	1
113668	1710	staining in the lining	[staining in the lining]	0.0	4	1	1	1
113669	1710	ebv in vivo	[EBV in vivo]	0.0	3	1	1	1
113670	1710	nf-kappab -dependent gene expression	[NF-kappaB -dependent gene expression]	0.0	4	1	1	1
113671	1710	little alteration	[little alteration]	0.0	2	1	1	1
113672	1710	effect Ca2+	[effects Ca2+]	0.0	2	1	1	1
113673	1710	protein pml/rar alpha present	[protein pml/RAR alpha present]	0.0	4	1	1	1
113674	1710	such as adhesion molecule-1 icam-1	[such as adhesion molecule-1 ICAM-1]	0.0	5	1	1	1
113675	1710	puc 1.77	[pUC 1.77]	0.0	2	1	1	1
113676	1710	transcription-independent surface expression	[transcription-independent surface expression]	0.0	3	2	2	1
113677	1710	80.2 (p less than p	[80.2 (P less than P]	0.0	5	1	1	1
113678	1710	formation of two stat complex	[formation of two STAT complexes]	0.0	5	1	1	1
113679	1710	[effect of the regimen of kidney-tonifying	[[Effect of the regimen of kidney-tonifying]	0.0	6	1	1	1
113680	1710	rate of grade	[rate of grades]	0.0	3	1	1	1
113681	1710	risk: mononuclear cell reaction grade	[risk: mononuclear cell reaction grade]	0.0	5	1	1	1
113682	1710	anti-MHC class ii	[anti-MHC class II]	0.0	3	1	1	1
113683	1710	two gata-associated site	[two GATA-associated sites]	0.0	3	1	1	1
113684	1710	dominant neurocutaneous disorder	[dominant neurocutaneous disorder]	0.0	3	1	1	1
113685	1710	indicate a aspect	[indicating an aspect]	0.0	3	1	1	1
113686	1710	presentation dqa1*0501/dqb1*0201	[presentation DQA1*0501/DQB1*0201]	0.0	2	1	1	1
113687	1710	interaction with beta-catenin	[interaction with beta-catenin]	0.0	3	1	1	1
113688	1710	addition of heterodimeric nfkb2	[addition of heterodimeric NFKB2]	0.0	4	1	1	1
113689	1710	identification of Bcd a proto-oncogene	[Identification of Bcd a proto-oncogene]	0.0	5	1	1	1
113690	1710	thus establish the effectiveness	[thus establishing the effectiveness]	0.0	4	1	1	1
113691	1710	peculiarity	[peculiarities]	0.0	1	1	1	1
113692	1710	transcription of the proto-oncogent c-fo	[transcription of the proto-oncogenes c-fos]	0.0	5	1	1	1
113693	1710	comparable level in tissues.	[comparable levels in tissues.]	0.0	4	1	1	1
113694	1710	contrast, introduction	[contrast, introduction]	0.0	2	1	1	1
113695	1710	G.Klein,	[G.Klein,]	0.0	1	1	1	1
113696	1710	transcription factor SCL	[transcription factor SCL]	0.0	3	1	1	1
113697	1710	patient with cell carcinoma RCC	[patients with cell carcinomas RCCs]	0.0	5	2	2	1
113698	1710	stimulation of jurkat T cell	[stimulation of Jurkat T cells]	0.0	5	1	1	1
113699	1710	t-cell protein complex	[T-cell protein complex]	0.0	3	1	1	1
113700	1710	also with motif-rich protein	[also with motif-rich proteins]	0.0	4	1	1	1
113701	1710	Japan, cepharanthine	[Japan, cepharanthine]	0.0	2	1	1	1
113702	1710	polymorphic dinucleotide	[polymorphic dinucleotide]	0.0	2	1	1	1
113703	1710	potent activity low	[potent activity lower]	0.0	3	1	1	1
113704	1710	mammalian nuclear rna (snrna) gene	[mammalian nuclear RNA (snRNA) genes]	0.0	5	1	1	1
113705	1710	agreement with this finding,	[agreement with this finding,]	0.0	4	1	1	1
113706	1710	pathogenesis of immunodeficiency	[pathogenesis of immunodeficiency]	0.0	3	1	1	1
113707	1710	favor action	[favoring actions]	0.0	2	1	1	1
113708	1710	z-lll-h -insensitive transcriptional activity	[Z-LLL-H -insensitive transcriptional activity]	0.0	4	1	1	1
113709	1710	activity factor 1 colony-stimulating factor	[activity factor 1 colony-stimulating factor]	0.0	5	1	1	1
113710	1710	form of mature t-cell leukemia	[form of mature T-cell leukemias]	0.0	5	1	1	1
113711	1710	cell susceptibility	[cell susceptibility]	0.0	2	1	1	1
113712	1710	49 fresh case	[49 fresh cases]	0.0	3	1	1	1
113713	1710	fold of the ligand-binding domain, interference	[folding of the ligand-binding domain, interference]	0.0	6	1	1	1
113714	1710	poor separation	[poor separation]	0.0	2	1	1	1
113715	1710	double-label electron microscopy on cell	[double-labeling electron microscopy on cells]	0.0	5	1	1	1
113716	1710	expression of major complex surface protein	[expression of major complex surface proteins]	0.0	6	1	1	1
113717	1710	unique set of gene	[unique set of genes]	0.0	4	1	1	1
113718	1710	13-kilobase-pair (kb) c-fe transgene	[13-kilobase-pair (kb) c-fes transgene]	0.0	4	1	1	1
113719	1710	ability of thp-1 cell	[ability of THP-1 cells]	0.0	4	1	1	1
113720	1710	hypermutation of ig gene	[hypermutation of Ig genes]	0.0	4	1	1	1
113721	1710	patient with significant defect	[patients with significant defects]	0.0	4	1	1	1
113722	1710	many gene include the enhancer	[many genes including the enhancer]	0.0	5	1	1	1
113723	1710	lymphocytic lymphoma	[lymphocytic lymphoma]	0.0	2	1	1	1
113724	1710	multiple factor binding motif	[multiple factor binding motifs]	0.0	4	1	1	1
113725	1710	vitro, underline the central role	[vitro, underlining the central role]	0.0	5	1	1	1
113726	1710	z-lll-h -insensitive activity	[Z-LLL-H -insensitive activity]	0.0	3	1	1	1
113727	1710	icam-1 endothelial adhesivity toward leukocyte	[ICAM-1 endothelial adhesivity toward leukocytes]	0.0	5	1	1	1
113728	1710	result from the activity	[resulting from the activity]	0.0	4	1	1	1
113729	1710	regulator of the immune response	[regulators of the immune response]	0.0	5	1	1	1
113730	1710	Peripheral blood lymphocyte from ss patient	[Peripheral blood lymphocytes from SS patients]	0.0	6	1	1	1
113731	1710	different pathway upstream	[different pathways upstream]	0.0	3	1	1	1
113732	1710	microsomal membrane from leukocyte	[microsomal membranes from leukocytes]	0.0	4	1	1	1
113733	1710	mammalian cell transfection	[mammalian cell transfection]	0.0	3	1	1	1
113734	1710	induction by hydrogen peroxide	[induction by hydrogen peroxide]	0.0	4	1	1	1
113735	1710	other cell gene	[other cell genes]	0.0	3	1	1	1
113736	1710	gata-2 binding element	[GATA-2 binding element]	0.0	3	1	1	1
113737	1710	healthy aged person	[healthy aged persons]	0.0	3	1	1	1
113738	1710	progression of astrocytomas	[progression of astrocytomas]	0.0	3	1	1	1
113739	1710	free stress	[free stress]	0.0	2	1	1	1
113740	1710	underlie il-2 blockade	[underlying IL-2 blockade]	0.0	3	1	1	1
113741	1710	event in plaque development	[event in plaque development]	0.0	4	1	1	1
113742	1710	microgram/ml	[microgram/ml]	0.0	1	1	1	1
113743	1710	ligand cd40l	[ligand CD40L]	0.0	2	1	1	1
113744	1710	abundant protein of 75 kD	[abundant proteins of 75 kD]	0.0	5	1	1	1
113745	1710	gene characteristic for cell	[genes characteristic for cells]	0.0	4	1	1	1
113746	1710	accurate model for apl	[accurate model for APL]	0.0	4	1	1	1
113747	1710	different il-4 promoter construct	[different IL-4 promoter constructs]	0.0	4	1	1	1
113748	1710	dose p50 on tissue oligonucleotide	[doses p50 on tissue oligonucleotide]	0.0	5	1	1	1
113749	1710	Effect of stress on signal transduction	[Effects of stress on signal transduction]	0.0	6	1	1	1
113750	1710	decrease in the synthesis	[decrease in the synthesis]	0.0	4	1	1	1
113751	1710	antigen segment resistant	[antigen segments resistant]	0.0	3	1	1	1
113752	1710	further definition	[Further definition]	0.0	2	1	1	1
113753	1710	il-10 receptor activation	[IL-10 receptor activation]	0.0	3	1	1	1
113754	1710	loss of allele	[losses of allele]	0.0	3	1	1	1
113755	1710	exposure of human aortic cell HAEC	[exposure of human aortic cells HAEC]	0.0	6	1	1	1
113756	1710	hormonal status comparison with prognostic criteria]	[Hormonal status comparison with prognostic criteria]]	0.0	6	1	1	1
113757	1710	recruitment of kruppel-like factor	[recruitment of Kruppel-like factor]	0.0	4	1	1	1
113758	1710	24,25-dihydroxyvitamin D3 on can metabolism	[24,25-dihydroxyvitamin D3 on Ca metabolism]	0.0	5	1	1	1
113759	1710	immune response to hbx-antigen	[Immune response to HBx-antigen]	0.0	4	1	1	1
113760	1710	proteolysis-resistant nuclear factor-kappaB inhibitor	[proteolysis-resistant nuclear factor-kappaB inhibitor]	0.0	4	1	1	1
113761	1710	related antiapoptotic molecule	[related antiapoptotic molecule]	0.0	3	1	1	1
113762	1710	apoptotic pathway in T lymphocyte	[apoptotic pathways in T lymphocytes]	0.0	5	1	1	1
113763	1710	former substance	[former substances]	0.0	2	1	1	1
113764	1710	suggest a role for the residue	[suggesting a role for the residues]	0.0	6	1	1	1
113765	1710	several laboratory	[several laboratories]	0.0	2	1	1	1
113766	1710	related condition	[related condition]	0.0	2	1	1	1
113767	1710	expression of the human c-fe gene	[expression of the human c-fes gene]	0.0	6	1	1	1
113768	1710	level by a promoter	[level by a promoter]	0.0	4	1	1	1
113769	1710	express PML/RARalpha	[expressing PML/RARalpha]	0.0	2	1	1	1
113770	1710	certain cell of origin	[certain cells of origin]	0.0	4	1	1	1
113771	1710	level of nf-kappa b1 encoding transcript	[levels of NF-kappa B1 encoding transcripts]	0.0	6	1	1	1
113772	1710	high affinity (at sevenfold) 3.	[higher affinity (at sevenfold) 3.]	0.0	5	1	1	1
113773	1710	sle (0.9356	[SLE (0.9356]	0.0	2	1	1	1
113774	1710	distinguishable gr abnormalities:	[distinguishable GR abnormalities:]	0.0	3	1	1	1
113775	1710	polyA site	[polyA site]	0.0	2	2	2	1
113776	1710	young (18-	[young (18-]	0.0	2	1	1	1
113777	1710	endothelial activation the expression	[endothelial activation the expression]	0.0	4	1	1	1
113778	1710	high microg/100 millileter	[high microg/100 ml]	0.0	3	1	1	1
113779	1710	hpfh syndrome	[HPFH syndrome]	0.0	2	1	1	1
113780	1710	type of reactivity:	[types of reactivity:]	0.0	3	1	1	1
113781	1710	potential significance	[potential significance]	0.0	2	1	1	1
113782	1710	parameter of the low protein	[parameters of the low proteins]	0.0	5	1	1	1
113783	1710	such specificity,	[such specificity,]	0.0	2	1	1	1
113784	1710	ten peripheral blood lymphocyte sample	[ten peripheral blood lymphocyte samples]	0.0	5	1	1	1
113785	1710	intracellular mediator	[intracellular mediator]	0.0	2	1	1	1
113786	1710	30% rt-pcr product	[30% RT-PCR product]	0.0	3	1	1	1
113787	1710	fetal -specific protein	[fetal -specific protein]	0.0	3	1	1	1
113788	1710	hormone action	[hormone action]	0.0	2	1	1	1
113789	1710	erythroblast from human bone marrow	[erythroblasts from human bone marrow]	0.0	5	1	1	1
113790	1710	normal macrophage PAM	[Normal macrophages PAM]	0.0	3	1	1	1
113791	1710	number of tetrazolium cell	[number of tetrazolium cells]	0.0	4	1	1	1
113792	1710	high molecular weight form	[higher molecular weight forms]	0.0	4	1	1	1
113793	1710	degradation in hiv-1 cell	[degradation in HIV-1 cells]	0.0	4	1	1	1
113794	1710	case of leukaemias	[cases of leukaemias]	0.0	3	1	1	1
113795	1710	physiological target cell	[physiological target cells]	0.0	3	1	1	1
113796	1710	regulation by the ets transcription factor	[Regulation by the Ets transcription factor]	0.0	6	1	1	1
113797	1710	removal of interdomain b	[removal of interdomain B]	0.0	4	1	1	1
113798	1710	various set	[various sets]	0.0	2	1	1	1
113799	1710	cell-cell interaction	[cell-cell interactions]	0.0	2	1	1	1
113800	1710	two segment	[two segments]	0.0	2	1	1	1
113801	1710	signal 2 alone	[signal 2 alone]	0.0	3	1	1	1
113802	1710	bcl-6 syn-1 phenotype	[BCL-6 syn-1 phenotype]	0.0	3	1	1	1
113803	1710	activation of CD4 T cell	[Activation of CD4 T cells]	0.0	5	1	1	1
113804	1710	simultaneous stimulation	[simultaneous stimulation]	0.0	2	1	1	1
113805	1710	constitutive interferon-gamma receptor expression	[constitutive interferon-gamma receptor expression]	0.0	4	1	1	1
113806	1710	signal upon treatment with desferrioxamine	[signalling upon treatment with desferrioxamine]	0.0	5	1	1	1
113807	1710	syndrome after resection	[syndrome after resection]	0.0	3	1	1	1
113808	1710	significant level of Spi-B	[significant levels of Spi-B]	0.0	4	1	1	1
113809	1710	inhibit the production	[inhibiting the production]	0.0	3	1	1	1
113810	1710	4.3 nmol/l,	[4.3 nmol/L,]	0.0	2	1	1	1
113811	1710	p40 induction	[p40 induction]	0.0	2	1	1	1
113812	1710	four transcription factor	[four transcription factors]	0.0	3	1	1	1
113813	1710	il-4 of gene	[IL-4 of genes]	0.0	3	1	1	1
113814	1710	Oct-2 function element.	[Oct-2 function element.]	0.0	3	1	1	1
113815	1710	infection in individual	[infection in individuals]	0.0	3	1	1	1
113816	1710	scm-1-producer T	[SCM-1-producer T]	0.0	2	1	1	1
113817	1710	interleukin-2 receptor alpha gene	[interleukin-2 receptor alpha gene]	0.0	4	1	1	1
113818	1710	encode the cell-type transcription factor gata-1	[encoding the cell-type transcription factor GATA-1]	0.0	6	1	1	1
113819	1710	receptor surface	[receptor surface]	0.0	2	1	1	1
113820	1710	viral protein BRLF1	[viral protein BRLF1]	0.0	3	1	1	1
113821	1710	lesional tissue	[lesional tissue]	0.0	2	1	1	1
113822	1710	tat- immunodeficiency virus	[Tat- immunodeficiency viruses]	0.0	3	1	1	1
113823	1710	IL-8 mrna	[IL-8 mRNA]	0.0	2	2	2	1
113824	1710	platelet-activating factor receptor gene	[platelet-activating factor receptor gene]	0.0	4	1	1	1
113825	1710	analysis of the induction	[analyses of the induction]	0.0	4	1	1	1
113826	1710	more recently circulate	[more recently circulating]	0.0	3	2	2	1
113827	1710	mechanism as the result	[mechanisms as the result]	0.0	4	1	1	1
113828	1710	number of gene IL-1beta	[number of genes IL-1beta]	0.0	4	1	1	1
113829	1710	provide a mechanism for therapeutic effect	[providing an mechanism for therapeutic effects]	0.0	6	1	1	1
113830	1710	TNFRp55 mouse	[TNFRp55 mice]	0.0	2	1	1	1
113831	1710	member of early gene	[members of early genes]	0.0	4	1	1	1
113832	1710	B-cell leukemia CLL	[B-cell leukemia CLL]	0.0	3	1	1	1
113833	1710	zeta globin promoter activity	[zeta globin promoter activity]	0.0	4	1	1	1
113834	1710	role in inflammatory state	[role in inflammatory states]	0.0	4	1	1	1
113835	1710	prostaglandin I2 PGI2	[prostaglandin I2 PGI2]	0.0	3	1	1	1
113836	1710	decrease in the localization	[decreases in the localization]	0.0	4	1	1	1
113837	1710	gro-alpha	[GRO-alpha]	0.0	1	1	1	1
113838	1710	interleukin (il)-10 blocking factor expression immuno-cytochemistry	[interleukin (IL)-10 blocking factor expression immuno-cytochemistry]	0.0	6	1	1	1
113839	1710	cell ganglioside	[cell gangliosides]	0.0	2	1	1	1
113840	1710	lymphocyte of acute leukemia patient	[lymphocytes of acute leukemia patients]	0.0	5	1	1	1
113841	1710	Intrafollicular	[Intrafollicular]	0.0	1	1	1	1
113842	1710	eight patient in long years)	[Eight patients in long-term years)]	0.0	5	1	1	1
113843	1710	level of hiv-1 LTR transcription	[levels of HIV-1 LTR transcription]	0.0	5	1	1	1
113844	1710	effect on Rel A	[effect on Rel A]	0.0	4	1	1	1
113845	1710	I (p55) (p75)	[I (p55) (p75)]	0.0	3	1	1	1
113846	1710	regulation of low shear	[Regulation of low shear]	0.0	4	1	1	1
113847	1710	other antigen (include muscle actin	[other antigens (including muscle actin]	0.0	5	1	1	1
113848	1710	emphasize the potential of antioxidant	[emphasizing the potential of antioxidants]	0.0	5	1	1	1
113849	1710	10 individual as control	[10 individuals as control]	0.0	4	1	1	1
113850	1710	prototype class gene	[prototype class gene]	0.0	3	1	1	1
113851	1710	activation of two messenger	[activation of two messengers]	0.0	4	1	1	1
113852	1710	distinct cofactor in concert	[distinct cofactors in concert]	0.0	4	1	1	1
113853	1710	use of 9-mer peptide	[use of 9-mer peptides]	0.0	4	1	1	1
113854	1710	HTLV-I T cell line	[HTLV-I T cell lines]	0.0	4	1	1	1
113855	1710	combination with granulocyte colony-stimulating factor	[combination with granulocyte colony-stimulating factor]	0.0	5	1	1	1
113856	1710	aldosterone from leukocyte	[aldosterone from leukocytes]	0.0	3	1	1	1
113857	1710	Finally, virus stock	[Finally, virus stocks]	0.0	3	1	1	1
113858	1710	immunogenic tumor	[immunogenic tumors]	0.0	2	1	1	1
113859	1710	inflammatory stimulus bacterial product	[inflammatory stimuli bacterial products]	0.0	4	1	1	1
113860	1710	pediatric patient	[pediatric patients]	0.0	2	1	1	1
113861	1710	repair/transcription factor	[repair/transcription factor]	0.0	2	1	1	1
113862	1710	appropriate alignment	[appropriate alignment]	0.0	2	1	1	1
113863	1710	Bcl-2 expression by Aiolos	[Bcl-2 expression by Aiolos]	0.0	4	1	1	1
113864	1710	distribution of gene	[distribution of genes]	0.0	3	1	1	1
113865	1710	expression latent membrane protein	[Expression latent membrane protein]	0.0	4	1	1	1
113866	1710	herpesvirus Saimiri STP	[herpesvirus Saimiri STP]	0.0	3	1	1	1
113867	1710	context of site	[context of site]	0.0	3	1	1	1
113868	1710	express Gal/ER	[expressing Gal/ER]	0.0	2	1	1	1
113869	1710	only at level	[only at levels]	0.0	3	1	1	1
113870	1710	granulocyte/macrophage-colony factor gm-csf	[granulocyte/macrophage-colony factor GM-CSF]	0.0	3	1	1	1
113871	1710	/calmodulin-dependent	[/calmodulin-dependent]	0.0	1	1	1	1
113872	1710	glucocorticoid receptor hgr	[glucocorticoid receptors hGRs]	0.0	3	1	1	1
113873	1710	high millileter at 10:00 P;	[high ml at 10:00 h;]	0.0	5	1	1	1
113874	1710	extent fra-1	[extent Fra-1]	0.0	2	1	1	1
113875	1710	potency of class	[potency of class]	0.0	3	1	1	1
113876	1710	variety of signals,	[variety of signals,]	0.0	3	1	1	1
113877	1710	gene movement within that topographical region	[gene movements within those topographical regions]	0.0	6	1	1	1
113878	1710	NFATp kda	[NFATp kDa]	0.0	2	1	1	1
113879	1710	nuclear expression of factor kappab nf-kappab	[nuclear expression of factor kappaB NF-kappaB]	0.0	6	1	1	1
113880	1710	t(17;19) translocation in lymphoblastic leukemia	[t(17;19) translocation in lymphoblastic leukemias]	0.0	5	1	1	1
113881	1710	dominant interference activity	[dominant interference activity]	0.0	3	1	1	1
113882	1710	decrease of agonist	[decrease of agonist]	0.0	3	1	1	1
113883	1710	matrix proteins,	[matrix proteins,]	0.0	2	1	1	1
113884	1710	bipartite human interleukin-4 IL-4	[bipartite human interleukin-4 IL-4]	0.0	4	1	1	1
113885	1710	effect result from activation	[effect resulting from activation]	0.0	4	1	1	1
113886	1710	activation-induced change in one set	[activation-induced changes in one set]	0.0	5	1	1	1
113887	1710	site in the TNF-alpha promoter	[sites in the TNF-alpha promoter]	0.0	5	1	1	1
113888	1710	have the amount	[having the amounts]	0.0	3	1	1	1
113889	1710	human ino promoter	[human iNOS promoter]	0.0	3	1	1	1
113890	1710	NF-kappaB suppression	[NF-kappaB suppression]	0.0	2	1	1	1
113891	1710	(mhc) class ii gene expression	[(MHC) class II gene expression]	0.0	5	1	1	1
113892	1710	system combine gene transfer	[system combining gene transfer]	0.0	4	1	1	1
113893	1710	p65 p50	[p65 p50]	0.0	2	1	1	1
113894	1710	15N resonance	[15N resonance]	0.0	2	1	1	1
113895	1710	use retinoid with binding specificity	[Using retinoids with binding specificity]	0.0	5	1	1	1
113896	1710	datum available	[data available]	0.0	2	1	1	1
113897	1710	cell-specific factor such as Oct-2A	[cell-specific factors such as Oct-2A]	0.0	5	1	1	1
113898	1710	least two nonoverlapping epitope	[least two nonoverlapping epitopes]	0.0	4	1	1	1
113899	1710	three order potent than H 1285	[three orders potent than H 1285]	0.0	6	1	1	1
113900	1710	70z/3-derived pre-b-cell line	[70Z/3-derived pre-B-cell lines]	0.0	3	1	1	1
113901	1710	human monocyte pdgf(b) mrna	[human monocyte PDGF(B) mRNA]	0.0	4	1	1	1
113902	1710	relevance for gastroenterology	[relevance for gastroenterology]	0.0	3	1	1	1
113903	1710	fasl reporter construct	[FasL reporter constructs]	0.0	3	1	1	1
113904	1710	human adult blood	[human adult blood]	0.0	3	1	1	1
113905	1710	zinc sulfate	[zinc sulfate]	0.0	2	1	1	1
113906	1710	focus-form murine erythroleukemias	[focus-forming murine erythroleukemias]	0.0	3	1	1	1
113907	1710	development of immunosuppressive agent	[development of immunosuppressive agents]	0.0	4	1	1	1
113908	1710	(nf)-il6	[(NF)-IL6]	0.0	1	1	1	1
113909	1710	lipopolysaccharide production of cytokine	[lipopolysaccharide production of cytokines]	0.0	4	1	1	1
113910	1710	unique mechanism fundamentally related	[unique mechanism fundamentally related]	0.0	4	1	1	1
113911	1710	DNA binding pea1 AP1	[DNA binding PEA1 AP1]	0.0	4	1	1	1
113912	1710	frequency, distribution,	[frequency, distribution,]	0.0	2	1	1	1
113913	1710	factor of the NFAT family	[factors of the NFAT family]	0.0	5	1	1	1
113914	1710	monocyte cytotoxicity against cell line	[monocyte cytotoxicity against cell lines]	0.0	5	1	1	1
113915	1710	interferon-alpha production	[interferon-alpha production]	0.0	2	1	1	1
113916	1710	single transcription start site	[single transcription start site]	0.0	4	1	1	1
113917	1710	oct2 isoform	[Oct2 isoforms]	0.0	2	1	1	1
113918	1710	chronic back pain	[chronic back pain]	0.0	3	1	1	1
113919	1710	regulate the apoptotic machinery	[regulating the apoptotic machinery]	0.0	4	1	1	1
113920	1710	basal activity of promoter	[basal activity of promoters]	0.0	4	1	1	1
113921	1710	oct-binding factor 1 obf-1	[Oct-binding factor 1 OBF-1]	0.0	4	1	1	1
113922	1710	nuclear staining in +/- 3.7%	[nuclear staining in +/- 3.7%]	0.0	5	1	1	1
113923	1710	NF-kappa b )/rel	[NF-kappa B )/Rel]	0.0	3	1	1	1
113924	1710	inactivation of the igh 3' enhancer	[inactivation of the IgH 3' enhancer]	0.0	6	1	1	1
113925	1710	binary fate decision	[binary fate decisions]	0.0	3	1	1	1
113926	1710	ten in-vitro-stimulated peripheral blood lymphocyte sample	[ten in-vitro-stimulated peripheral blood lymphocyte samples]	0.0	6	1	1	1
113927	1710	express tdag51	[expressing TDAG51]	0.0	2	1	1	1
113928	1710	mediate immune response	[mediating immune responses]	0.0	3	1	1	1
113929	1710	evidence for in vivo interaction	[evidence for in vivo interaction]	0.0	5	1	1	1
113930	1710	inhibitor of extracellular protein kinase	[inhibitor of extracellular protein kinase]	0.0	5	1	1	1
113931	1710	effect of glucocorticoid on interleukin -12	[effects of glucocorticoids on interleukin -12]	0.0	6	1	1	1
113932	1710	number of receptor for il-12	[number of receptors for IL-12]	0.0	5	1	1	1
113933	1710	average value	[average values]	0.0	2	1	1	1
113934	1710	Ras construct	[Ras construct]	0.0	2	1	1	1
113935	1710	efficiency of the enhancer	[efficiency of the enhancers]	0.0	4	1	1	1
113936	1710	copy of the consensus sequence	[copies of the consensus sequence]	0.0	5	1	1	1
113937	1710	bacterial product	[bacterial products]	0.0	2	1	1	1
113938	1710	three major disease	[three major diseases]	0.0	3	1	1	1
113939	1710	hd case	[HD cases]	0.0	2	1	1	1
113940	1710	designation myeloid/NK leukemia	[designation myeloid/NK leukemia]	0.0	3	1	1	1
113941	1710	lineage restriction	[lineage restriction]	0.0	2	1	1	1
113942	1710	protein, likely dpii,	[protein, likely DP-I,]	0.0	3	1	1	1
113943	1710	stimulation by dose	[Stimulation by doses]	0.0	3	1	1	1
113944	1710	selectively in extract of cell	[selectively in extracts of cells]	0.0	5	1	1	1
113945	1710	t-cell functional region	[T-cell functional regions]	0.0	3	1	1	1
113946	1710	RB expression	[RB expression]	0.0	2	1	1	1
113947	1710	AP-1 family member c-fos	[AP-1 family members c-Fos]	0.0	4	1	1	1
113948	1710	htoll activation	[hToll activation]	0.0	2	1	1	1
113949	1710	active renin (869	[active renin (869]	0.0	3	1	1	1
113950	1710	core binding factor-	[core binding factor-]	0.0	3	1	1	1
113951	1710	ap-1 activate gst-pi promoter	[AP-1 activating GST-pi promoter]	0.0	4	1	1	1
113952	1710	two highly homologous gene	[two highly homologous genes]	0.0	4	1	1	1
113953	1710	motif in the gene enhancer	[motifs in the gene enhancer]	0.0	5	1	1	1
113954	1710	activate transcription from class ii promoter	[activating transcription from class II promoters]	0.0	6	1	1	1
113955	1710	distinct subgroups, protein	[distinct subgroups, proteins]	0.0	3	1	1	1
113956	1710	dual effect 1) inhibition	[dual effects 1) inhibition]	0.0	4	1	1	1
113957	1710	18 unrelated case	[18 unrelated cases]	0.0	3	1	1	1
113958	1710	signal in human precursor	[signaling in human precursors]	0.0	4	1	1	1
113959	1710	mutant form of the CD4 tail	[mutant forms of the CD4 tail]	0.0	6	1	1	1
113960	1710	slight expression	[slight expression]	0.0	2	1	1	1
113961	1710	regulation by a microenvironment	[regulation by an microenvironment]	0.0	4	1	1	1
113962	1710	addition, seek support	[addition, seeking support]	0.0	3	1	1	1
113963	1710	(17 subject	[(17 subjects]	0.0	2	1	1	1
113964	1710	181 amino acid	[181 amino acids]	0.0	3	1	1	1
113965	1710	thyroid tissue of euthyroid patient	[thyroid tissue of euthyroid patients]	0.0	5	1	1	1
113966	1710	course (p chi2 test).	[course (P chi2 test).]	0.0	4	1	1	1
113967	1710	organisation exon 112	[organisation exons 112]	0.0	3	1	1	1
113968	1710	exposure to the low level	[exposure to the lowest level]	0.0	5	1	1	1
113969	1710	small population	[small population]	0.0	2	2	2	1
113970	1710	c-Rel /p65 heterodimer	[c-Rel /p65 heterodimers]	0.0	3	3	3	1
113971	1710	10(7.0) pfu	[10(7.0) pfu]	0.0	2	1	1	1
113972	1710	raf-1 in Jurkat T cell	[Raf-1 in Jurkat T cells]	0.0	5	1	1	1
113973	1710	recombinant tnf receptor	[recombinant TNF receptor]	0.0	3	1	1	1
113974	1710	control of il-2 promoter activity	[control of IL-2 promoter activity]	0.0	5	1	1	1
113975	1710	leukemia to combination chemotherapy	[leukemia to combination chemotherapy]	0.0	4	1	1	1
113976	1710	unique region contain repeat	[unique region containing repeats]	0.0	4	1	1	1
113977	1710	change in cytosolic ca2+	[changes in cytosolic Ca2+]	0.0	4	1	1	1
113978	1710	rapidly inducible activator	[rapidly inducible activator]	0.0	3	1	1	1
113979	1710	gr in mononuclear leukocyte	[GR in mononuclear leukocytes]	0.0	4	1	1	1
113980	1710	include tnf-alpha	[including TNF-alpha]	0.0	2	1	1	1
113981	1710	region of tcf-1	[region of TCF-1]	0.0	3	1	1	1
113982	1710	overexpression in U937 cell	[overexpression in U937 cells]	0.0	4	1	1	1
113983	1710	R-PK DNA fragment	[R-PK DNA fragment]	0.0	3	1	1	1
113984	1710	reach a peak at min.	[reaching a peak at min.]	0.0	5	1	1	1
113985	1710	bacterial human blood	[bacterial human blood]	0.0	3	1	1	1
113986	1710	peripheral human mononuclear leukocyte	[peripheral human mononuclear leukocytes]	0.0	4	1	1	1
113987	1710	binary fate decision of progenitor	[binary fate decisions of progenitors]	0.0	5	1	1	1
113988	1710	sucrose density	[sucrose density]	0.0	2	1	1	1
113989	1710	cd4+ macrophage	[CD4+ macrophages]	0.0	2	1	1	1
113990	1710	baby rat kidney (brk) cell	[baby rat kidney (BRK) cells]	0.0	5	1	1	1
113991	1710	host defense gene	[host defense genes]	0.0	3	1	1	1
113992	1710	33 pbmc specimen	[33 PBMC specimens]	0.0	3	2	2	1
113993	1710	cd4+cd45ro-	[CD4+CD45RO-]	0.0	1	1	1	1
113994	1710	opposite glucocorticoid receptor changes,	[opposite glucocorticoid receptor changes,]	0.0	4	1	1	1
113995	1710	cd4+cd45ro+	[CD4+CD45RO+]	0.0	1	1	1	1
113996	1710	g76:gpltplpv aes1/2 (128-135)	[G76:GPLTPLPV AES1/2 (128-135)]	0.0	3	1	1	1
113997	1710	more increase	[more increase]	0.0	2	1	1	1
113998	1710	beta ifn-beta promoter	[beta IFN-beta promoter]	0.0	3	1	1	1
113999	1710	81 bp EBNA2 responsive region	[81 bp EBNA2 responsive region]	0.0	5	1	1	1
114000	1710	immune senescence.	[immune senescence.]	0.0	2	1	1	1
114001	1710	homozygote	[Homozygotes]	0.0	1	1	1	1
114002	1710	cell respond	[cells responding]	0.0	2	1	1	1
114003	1710	long cell proliferation	[long-term cell proliferation]	0.0	3	1	1	1
114004	1710	enable activation	[enabling activation]	0.0	2	1	1	1
114005	1710	Gail risk	[Gail risk]	0.0	2	1	1	1
114006	1710	impdh type gene expression	[IMPDH type gene expression]	0.0	4	1	1	1
114007	1710	use endothelial cell	[using endothelial cells]	0.0	3	1	1	1
114008	1710	more than kb	[more than kb]	0.0	3	1	1	1
114009	1710	normal tonsil	[normal tonsils]	0.0	2	1	1	1
114010	1710	antigen t-cell	[antigen T-cells]	0.0	2	1	1	1
114011	1710	4922 (range, 3413 (range,	[4922 (range, 3413 (range,]	0.0	4	1	1	1
114012	1710	z(s186a)	[Z(S186A)]	0.0	1	1	1	1
114013	1710	change the proportion	[changing the proportions]	0.0	3	1	1	1
114014	1710	abundant protein hmg-1	[abundant protein HMG-1]	0.0	3	1	1	1
114015	1710	several neoplasm	[several neoplasms]	0.0	2	1	1	1
114016	1710	activation of the interleukin gene enhancer	[activation of the interleukin gene enhancer]	0.0	6	1	1	1
114017	1710	level of IFN a IFNA constitutively,	[levels of IFN A IFNA constitutively,]	0.0	6	1	1	1
114018	1710	least some member	[least some members]	0.0	3	1	1	1
114019	1710	activation in neutrophil	[activation in neutrophils]	0.0	3	1	1	1
114020	1710	effect on blood cell response	[effects on blood cell responses]	0.0	5	1	1	1
114021	1710	three candidate gene nuclear factor beta	[three candidate genes nuclear factor beta]	0.0	6	1	1	1
114022	1710	il-2-r alpha	[IL-2-R alpha]	0.0	2	1	1	1
114023	1710	regulation in several cell line	[regulation in several cell lines]	0.0	5	1	1	1
114024	1710	IFN-alpha responsiveness positive chronic leukemia	[IFN-alpha responsiveness positive chronic leukemia]	0.0	5	1	1	1
114025	1710	role influence differential expression	[role influencing differential expression]	0.0	4	1	1	1
114026	1710	important role in response	[important roles in responses]	0.0	4	1	1	1
114027	1710	extend from -643	[extending from -643]	0.0	3	1	1	1
114028	1710	two cosmid encode human ciita	[two cosmids encoding human CIITA]	0.0	5	1	1	1
114029	1710	death ligand	[death ligands]	0.0	2	1	1	1
114030	1710	double-blind crossover study	[double-blind crossover study]	0.0	3	1	1	1
114031	1710	nonepithelial mineralocorticoid receptor	[nonepithelial mineralocorticoid receptors]	0.0	3	1	1	1
114032	1710	modification toward reduction with bha treatment	[modification toward reduction with BHA treatment]	0.0	6	1	1	1
114033	1710	background,	[background,]	0.0	1	1	1	1
114034	1710	DNA synthesis.	[DNA synthesis.]	0.0	2	1	1	1
114035	1710	steel factor proliferation	[Steel factor proliferation]	0.0	3	1	1	1
114036	1710	adrenocorticotropic	[adrenocorticotropic]	0.0	1	1	1	1
114037	1710	adrenocorticotropin	[adrenocorticotropin]	0.0	1	1	1	1
114038	1710	signal 2 alone without signal	[signal 2 alone without signal]	0.0	5	1	1	1
114039	1710	rapid change in the adhesion	[rapid changes in the adhesion]	0.0	5	1	1	1
114040	1710	mrna expression,	[mRNA expression,]	0.0	2	1	1	1
114041	1710	ifn-gamma colony-stimulating factor mrna	[IFN-gamma colony-stimulating factor mRNA]	0.0	4	1	1	1
114042	1710	photoaffinity	[Photoaffinity]	0.0	1	1	1	1
114043	1710	h up to 250-fold	[h up to 250-fold]	0.0	4	1	1	1
114044	1710	regard the use of lipid-lowering agent	[regarding the use of lipid-lowering agents]	0.0	6	1	1	1
114045	1710	basophilia analysis of the cell origin	[basophilia analysis of the cell origin]	0.0	6	1	1	1
114046	1710	induction jurkat carry the taxi gene	[Induction Jurkat carrying the TaxI gene]	0.0	6	1	1	1
114047	1710	induction of the cytokine il-6	[induction of the cytokines IL-6]	0.0	5	1	1	1
114048	1710	Epstein-Barr virus immediate-early antigen	[Epstein-Barr virus immediate-early antigen]	0.0	4	1	1	1
114049	1710	predominant factor bind	[predominant factor binding]	0.0	3	1	1	1
114050	1710	mutate the binding site	[mutating the binding site]	0.0	4	1	1	1
114051	1710	only nf-kappa b heteromer	[only NF-kappa B heteromers]	0.0	4	1	1	1
114052	1710	interferon-gamma ifn-gamma in blood lymphocyte	[interferon-gamma IFN-gamma in blood lymphocytes]	0.0	5	1	1	1
114053	1710	molecule of nfatp	[molecules of NFATp]	0.0	3	1	1	1
114054	1710	role of Jun oncogene family member	[role of Jun oncogene family members]	0.0	6	1	1	1
114055	1710	target structure for t-lymphocyte	[target structure for T-lymphocytes]	0.0	4	1	1	1
114056	1710	two piece of datum	[Two pieces of data]	0.0	4	1	1	1
114057	1710	lead to cellular activation	[leading to cellular activation]	0.0	4	1	1	1
114058	1710	T cell from (mean	[T cells from (mean]	0.0	4	1	1	1
114059	1710	identification of a lim-hox gene	[Identification of a LIM-Hox gene]	0.0	5	1	1	1
114060	1710	four mutant	[four mutants]	0.0	2	1	1	1
114061	1710	genomic DNA for irf-2 gene	[genomic DNA for IRF-2 gene]	0.0	5	1	1	1
114062	1710	166 healthy female aged years,	[166 healthy females aged years,]	0.0	5	1	1	1
114063	1710	promoter bp repeat	[promoter bp repeat]	0.0	3	1	1	1
114064	1710	surprisingly, however, removal	[Surprisingly, however, removal]	0.0	3	1	1	1
114065	1710	T cell representative	[T cells representative]	0.0	3	1	1	1
114066	1710	effect of isoflavone	[effects of isoflavones]	0.0	3	1	1	1
114067	1710	mzf-1 binding site	[MZF-1 binding sites]	0.0	3	1	1	1
114068	1710	eventual activation	[eventual activation]	0.0	2	1	1	1
114069	1710	potential role of e2f-1	[potential role of E2F-1]	0.0	4	1	1	1
114070	1710	leucocyte PMNL	[leucocytes PMNL]	0.0	2	1	1	1
114071	1710	interleukin-12 p40 transcript	[interleukin-12 p40 transcript]	0.0	3	1	1	1
114072	1710	presentation by HLA DQ2 heterodimer vary	[presentation by HLA DQ2 heterodimers varying]	0.0	6	1	1	1
114073	1710	promoter at Site I	[promoter at Site I]	0.0	4	1	1	1
114074	1710	Comparison as inducer	[Comparison as inducers]	0.0	3	1	1	1
114075	1710	tnf T cell	[TNF T cells]	0.0	3	1	1	1
114076	1710	deletion construct contain bp	[Deletion constructs containing bp]	0.0	4	1	1	1
114077	1710	context for activation	[context for activation]	0.0	3	1	1	1
114078	1710	low activation of binding	[lower activation of binding]	0.0	4	1	1	1
114079	1710	considerably high proportion	[Considerably higher proportions]	0.0	3	1	1	1
114080	1710	ets-1 protein.	[Ets-1 protein.]	0.0	2	1	1	1
114081	1710	monocyte-macrophage colony stimulate factor	[monocyte-macrophage colony stimulating factor]	0.0	4	1	1	1
114082	1710	basis of the weight,	[basis of the weight,]	0.0	4	1	1	1
114083	1710	cytotoxic T lymphocyte CTL response	[cytotoxic T lymphocyte CTL response]	0.0	5	1	1	1
114084	1710	I receptor in leukocyte	[I receptors in leukocytes]	0.0	4	1	1	1
114085	1710	lymphoid specific gene expression	[Lymphoid specific gene expression]	0.0	4	1	1	1
114086	1710	C3a enhancement of il-6 production	[C3a enhancement of IL-6 production]	0.0	5	1	1	1
114087	1710	T cell responsiveness	[T cell responsiveness]	0.0	3	1	1	1
114088	1710	study in nonepithelial cell	[studies in nonepithelial cells]	0.0	4	1	1	1
114089	1710	murine T cell in vitro	[murine T cells in vitro]	0.0	5	1	1	1
114090	1710	kb act in concert	[kb act in concert]	0.0	4	1	1	1
114091	1710	stage of erythroid differentiation	[stages of erythroid differentiation]	0.0	4	1	1	1
114092	1710	11 phosphoprotein with activity	[11 phosphoproteins with activity]	0.0	4	1	1	1
114093	1710	premature termination	[premature termination]	0.0	2	1	1	1
114094	1710	similar maximal increase	[similar maximal increases]	0.0	3	1	1	1
114095	1710	stimulation mono Mac with lipopolysaccharide	[Stimulation Mono Mac with lipopolysaccharide]	0.0	5	1	1	1
114096	1710	synthetic peptide in subunit vaccine	[synthetic peptides in subunit vaccines]	0.0	5	1	1	1
114097	1710	erythroid leukemia cell	[erythroid leukemia cells]	0.0	3	2	2	1
114098	1710	Rapid tyrosine phosphorylation of protein	[Rapid tyrosine phosphorylation of proteins]	0.0	5	1	1	1
114099	1710	internal entry site IRES	[internal entry site IRES]	0.0	4	1	1	1
114100	1710	evolution of the ape	[evolution of the apes]	0.0	4	1	1	1
114101	1710	Functional specificity	[Functional specificity]	0.0	2	1	1	1
114102	1710	generate level	[generating levels]	0.0	2	1	1	1
114103	1710	characterization of the human gene	[Characterization of the human gene]	0.0	5	1	1	1
114104	1710	t-cell clone reactive with gc	[T-cell clones reactive with gC]	0.0	5	1	1	1
114105	1710	possibility use cell line	[possibility using cell lines]	0.0	4	1	1	1
114106	1710	independent regulatory module	[independent regulatory module]	0.0	3	1	1	1
114107	1710	encode the acid-synthesizing enzyme aldehyde dehydrogenase	[encoding the acid-synthesizing enzyme aldehyde dehydrogenase]	0.0	6	1	1	1
114108	1710	early divergence of the pathways.	[early divergence of the pathways.]	0.0	5	1	1	1
114109	1710	expansion) (by abortive stimulation lead	[expansion) (by abortive stimulation leading]	0.0	5	1	1	1
114110	1710	protease cleavage	[protease cleavage]	0.0	2	1	1	1
114111	1710	amino acid of p105	[amino acids of p105]	0.0	4	1	1	1
114112	1710	analysis use a stock	[analysis using a stock]	0.0	4	1	1	1
114113	1710	RESULTS: administration	[RESULTS: Administration]	0.0	2	1	1	1
114114	1710	parasite-induced change	[parasite-induced changes]	0.0	2	1	1	1
114115	1710	messenger induction	[messengers induction]	0.0	2	1	1	1
114116	1710	presence of exon	[presence of exons]	0.0	3	1	1	1
114117	1710	active cbl mutant	[active Cbl mutant]	0.0	3	1	1	1
114118	1710	overexpression of AML1b	[overexpression of AML1b]	0.0	3	1	1	1
114119	1710	other unidentified factor present	[Other unidentified factors present]	0.0	4	1	1	1
114120	1710	il-2 therapy,	[IL-2 therapy,]	0.0	2	1	1	1
114121	1710	receptors, induction	[receptors, induction]	0.0	2	1	1	1
114122	1710	corresponding to protein of weight	[corresponding to proteins of weights]	0.0	5	1	1	1
114123	1710	Ki-67 staining grade).	[Ki-67 staining grade).]	0.0	3	1	1	1
114124	1710	mouse tissue include organ	[mouse tissues including organs]	0.0	4	1	1	1
114125	1710	detection of various other signal protein	[Detection of various other signaling proteins]	0.0	6	1	1	1
114126	1710	tat responsiveness	[Tat responsiveness]	0.0	2	1	1	1
114127	1710	thus, ebv binding to receptor	[Thus, EBV binding to receptor]	0.0	5	1	1	1
114128	1710	regulation of alpha-like globin promoter	[regulation of alpha-like globin promoters]	0.0	5	1	1	1
114129	1710	VCAM-1 surface	[VCAM-1 surface]	0.0	2	1	1	1
114130	1710	include the poz motif	[including the POZ motif]	0.0	4	1	1	1
114131	1710	influence on the selection	[influence on the selection]	0.0	4	1	1	1
114132	1710	transcriptional regulation of promoter	[transcriptional regulation of promoters]	0.0	4	1	1	1
114133	1710	induction by colony-stimumulatelany-stg factor in monocyte	[Induction by colony-stimulating factor in monocytes]	0.0	6	1	1	1
114134	1710	extracellular signal-regulated protein kinase	[extracellular signal-regulated protein kinase]	0.0	4	1	1	1
114135	1710	development of pathology such as failure	[development of pathologies such as failure]	0.0	6	1	1	1
114136	1710	binding site for nuclear factor	[binding sites for nuclear factors]	0.0	5	1	1	1
114137	1710	primary b-lymphocyte by Epstein-Barr virus	[primary B-lymphocytes by Epstein-Barr virus]	0.0	5	1	1	1
114138	1710	basAl, adhesion at mM.	[basal, adhesion at mM.]	0.0	4	1	1	1
114139	1710	type of cross-talk	[type of cross-talk]	0.0	3	1	1	1
114140	1710	expression during monocyte regulation	[expression during monocyte regulation]	0.0	4	1	1	1
114141	1710	monoclonal integration to the genome cell	[monoclonal integration to the genome cell]	0.0	6	1	1	1
114142	1710	tax-responsive element	[Tax-responsive element]	0.0	2	1	1	1
114143	1710	upstream sequence similar	[upstream sequences similar]	0.0	3	1	1	1
114144	1710	hematopoietic lineage commitment role	[Hematopoietic lineage commitment role]	0.0	4	1	1	1
114145	1710	immunodeficiency virus sivsmmpbj14	[immunodeficiency virus SIVsmmPBj14]	0.0	3	1	1	1
114146	1710	Ets transcription	[Ets transcription]	0.0	2	1	1	1
114147	1710	potency of one class compounds,	[potency of one class compounds,]	0.0	5	1	1	1
114148	1710	chimeric egf-gp130 receptor	[chimeric EGF-gp130 receptor]	0.0	3	1	1	1
114149	1710	nuclear nf-kappab in human cell	[nuclear NF-kappaB in human cells]	0.0	5	1	1	1
114150	1710	related factor Spi-B	[related factor Spi-B]	0.0	3	1	1	1
114151	1710	first case	[first case]	0.0	2	1	1	1
114152	1710	ets1 transactivation	[ETS1 transactivation]	0.0	2	1	1	1
114153	1710	lps factor	[LPS factor]	0.0	2	1	1	1
114154	1710	alternative pathway	[alternative pathway]	0.0	2	1	1	1
114155	1710	myelomonocytic differentiation include aml	[myelomonocytic differentiation including AML]	0.0	4	1	1	1
114156	1710	NF-kappa b dna-binding activity	[NF-kappa B DNA-binding activities]	0.0	4	1	1	1
114157	1710	glucocorticoid-mediated transrepression	[glucocorticoid-mediated transrepression]	0.0	2	1	1	1
114158	1710	p young	[P young]	0.0	2	1	1	1
114159	1710	presumably through opening of K+	[presumably through opening of K+]	0.0	5	1	1	1
114160	1710	human coactivator Bob1	[human coactivator Bob1]	0.0	3	1	1	1
114161	1710	region contain consensus binding site	[region containing consensus binding sites]	0.0	5	1	1	1
114162	1710	isomorph of p56	[isomorphs of p56]	0.0	3	1	1	1
114163	1710	active principle of Chinese medicine	[active principle of Chinese medicine]	0.0	5	1	1	1
114164	1710	nuclear inhibition of activation of NF-kappaB	[nuclear inhibition of activation of NF-kappaB]	0.0	6	1	1	1
114165	1710	selective deletion	[selective deletion]	0.0	2	1	1	1
114166	1710	antioxidant include hydroxyanisole tetrahydropapaveroline thp	[antioxidants including hydroxyanisole tetrahydropapaveroline THP]	0.0	5	1	1	1
114167	1710	dual effect 1) inhibition depletion	[dual effects 1) inhibition depletion]	0.0	5	1	1	1
114168	1710	expression of thrombospondin tsp	[expression of thrombospondin TSP]	0.0	4	1	1	1
114169	1710	30 minute at degree	[30 min at degrees]	0.0	4	1	1	1
114170	1710	(p<.001) in euthymic patient	[(P<.001) in euthymic patients]	0.0	4	1	1	1
114171	1710	TNFRp75	[TNFRp75]	0.0	1	1	1	1
114172	1710	17-isoaldosterone	[17-isoaldosterone]	0.0	1	1	1	1
114173	1710	g 5' region	[G 5' region]	0.0	3	1	1	1
114174	1710	cluster analysis of nfat element	[cluster analysis of NFAT elements]	0.0	5	1	1	1
114175	1710	Fos-B expression	[Fos-B expression]	0.0	2	1	1	1
114176	1710	activation of a second protein	[Activation of a second protein]	0.0	5	1	1	1
114177	1710	formation of tetrameric complex	[formation of tetrameric complexes]	0.0	4	1	1	1
114178	1710	-tcr	[-TCR]	0.0	1	1	1	1
114179	1710	one cause of arthritis	[one cause of arthritis]	0.0	4	2	2	1
114180	1710	kinase nik	[kinase NIK]	0.0	2	1	1	1
114181	1710	tnf-treated vein endothelial cell	[TNF-treated vein endothelial cells]	0.0	4	1	1	1
114182	1710	surfactant' effect on cytokine production	[surfactant's effects on cytokine production]	0.0	5	1	1	1
114183	1710	affinity receptor VDR for 1,25-dihydroxycholecalciferol calcitriol	[affinity receptors VDR for 1,25-dihydroxycholecalciferol calcitriol]	0.0	6	1	1	1
114184	1710	potent regulator in vitro.	[potent regulator in vitro.]	0.0	4	1	1	1
114185	1710	t- acute leukemia	[T- acute leukemias]	0.0	3	1	1	1
114186	1710	primary defect in hypophosphatemic ricket	[primary defect in hypophosphatemic rickets]	0.0	5	1	1	1
114187	1710	product such as lipopolysaccharide lps	[products such as lipopolysaccharide LPS]	0.0	5	1	1	1
114188	1710	constitutive expression of factor-1 receptor csf-1r	[Constitutive expression of factor-1 receptor CSF-1R]	0.0	6	1	1	1
114189	1710	twin discordant for Fabry disease	[twins discordant for Fabry disease]	0.0	5	1	1	1
114190	1710	immune response in rheumatoid arthritis	[immune response in rheumatoid arthritis]	0.0	5	1	1	1
114191	1710	cell growth in vitro,	[cell growth in vitro,]	0.0	4	1	1	1
114192	1710	ea-d promoter	[EA-D promoter]	0.0	2	1	1	1
114193	1710	mediator leukotriene b4 LTB4	[mediator leukotriene B4 LTB4]	0.0	4	1	1	1
114194	1710	high level of stat1	[higher levels of STAT1]	0.0	4	1	1	1
114195	1710	new system	[new system]	0.0	2	1	1	1
114196	1710	take	[taking]	0.0	1	1	1	1
114197	1710	element necessary for transactivation by tax	[element necessary for transactivation by Tax]	0.0	6	1	1	1
114198	1710	phosphorothioate oligonucleotide to the p50 subunit	[phosphorothioate oligonucleotides to the p50 subunits]	0.0	6	1	1	1
114199	1710	various human line	[various human lines]	0.0	3	1	1	1
114200	1710	modulate sensitivity	[modulating sensitivity]	0.0	2	1	1	1
114201	1710	secretion in response	[secretion in response]	0.0	3	1	1	1
114202	1710	critical proximal step	[critical proximal step]	0.0	3	1	1	1
114203	1710	outpatient visit,	[outpatient visit,]	0.0	2	1	1	1
114204	1710	follow stimulate factor treatment of neutrophils.	[following stimulating factor treatment of neutrophils.]	0.0	6	1	1	1
114205	1710	96 antigenic peptide	[96 antigenic peptides]	0.0	3	1	1	1
114206	1710	create a carboxy terminus	[creating a carboxy terminus]	0.0	4	1	1	1
114207	1710	jurkat lymphoblastoid cell	[Jurkat lymphoblastoid cells]	0.0	3	1	1	1
114208	1710	linkage cell development	[linkage cell development]	0.0	3	1	1	1
114209	1710	form of cn	[forms of CN]	0.0	3	1	1	1
114210	1710	active inhibitory process	[active inhibitory process]	0.0	3	1	1	1
114211	1710	defect in tnf production	[defect in TNF production]	0.0	4	1	1	1
114212	1710	bone-sparing effect of estrogen	[bone-sparing effect of estrogen]	0.0	4	1	1	1
114213	1710	RBP-Jkappa binding site	[RBP-Jkappa binding site]	0.0	3	1	1	1
114214	1710	sequence within the so-called element	[sequences within the so-called elements]	0.0	5	1	1	1
114215	1710	contain pouhd	[containing POUHD]	0.0	2	1	1	1
114216	1710	Potential role of a downstream sequence	[Potential role of a downstream sequence]	0.0	6	1	1	1
114217	1710	highly hydrophobic, polypeptide of function	[highly hydrophobic, polypeptide of function]	0.0	5	1	1	1
114218	1710	anchor residue	[anchor residues]	0.0	2	1	1	1
114219	1710	molecular basis for the expression	[molecular basis for the expression]	0.0	5	1	1	1
114220	1710	contrast with tnf-alpha	[contrast with TNF-alpha]	0.0	3	1	1	1
114221	1710	Rh(D) cell	[Rh(D) cells]	0.0	2	1	1	1
114222	1710	HL-60 promyelocytic leukemia cell	[HL-60 promyelocytic leukemia cells]	0.0	4	1	1	1
114223	1710	role in transformation	[role in transformation]	0.0	3	1	1	1
114224	1710	specific RA receptor rar	[specific RA receptors RARs]	0.0	4	1	1	1
114225	1710	active, gtp-bound form	[active, GTP-bound form]	0.0	3	1	1	1
114226	1710	proteasome degradation a role	[proteasome degradation A role]	0.0	4	1	1	1
114227	1710	association with CD28	[association with CD28]	0.0	3	1	1	1
114228	1710	cosignaling	[cosignaling]	0.0	1	1	1	1
114229	1710	+/- 0.92 fmol/10(7) pbmc fmol/10(7) pbmc	[+/- 0.92 fmol/10(7) PBMC fmol/10(7) PBMC]	0.0	6	1	1	1
114230	1710	combination 25(oh)2d3	[combination 25(OH)2D3]	0.0	2	1	1	1
114231	1710	lymphoid-specific transcription complex	[lymphoid-specific transcription complex]	0.0	3	1	1	1
114232	1710	cell at day 6;	[cells at day 6;]	0.0	4	1	1	1
114233	1710	cytoplasm with azurophilic granularity	[cytoplasm with azurophilic granularity]	0.0	4	1	1	1
114234	1710	hsp gene expression	[HSP gene expression]	0.0	3	1	1	1
114235	1710	leukemic blast use virus	[leukemic blasts using virus]	0.0	4	1	1	1
114236	1710	interaction with p300/cbp-type coactivator	[interaction with p300/CBP-type coactivators]	0.0	4	1	1	1
114237	1710	activation of monocyte nuclear factor-kappaB	[activation of monocyte nuclear factor-kappaB]	0.0	5	1	1	1
114238	1710	two week	[two weeks]	0.0	2	1	1	1
114239	1710	certain area	[certain areas]	0.0	2	1	1	1
114240	1710	correlation between induction	[correlation between induction]	0.0	3	1	1	1
114241	1710	phospholipase a2 in signal transduction	[phospholipase A2 in signal transduction]	0.0	5	1	1	1
114242	1710	target in b-cell development	[target in B-cell development]	0.0	4	1	1	1
114243	1710	differentiation to the granulocytic lineage	[differentiation to the granulocytic lineage]	0.0	5	1	1	1
114244	1710	endogenous nfat activity	[endogenous NFAT activity]	0.0	3	1	1	1
114245	1710	tat-	[Tat-]	0.0	1	1	1	1
114246	1710	low level of xenobiotic response	[low levels of xenobiotic response]	0.0	5	1	1	1
114247	1710	FMS group	[FMS group]	0.0	2	1	1	1
114248	1710	complete sequence on 10	[complete sequence on 10]	0.0	4	1	1	1
114249	1710	monocytic differentiation of U937 lymphoma cell	[monocytic differentiation of U937 lymphoma cells]	0.0	6	1	1	1
114250	1710	molecular detail of hormone action	[molecular details of hormone action]	0.0	5	1	1	1
114251	1710	form of IKK alpha	[forms of IKK alpha]	0.0	4	1	1	1
114252	1710	splicing site	[splicing sites]	0.0	2	1	1	1
114253	1710	fas cd95/apo-1	[Fas CD95/APO-1]	0.0	2	1	1	1
114254	1710	proliferator-activated receptor	[proliferator-activated receptor]	0.0	2	1	1	1
114255	1710	Differentiation-associated expression	[Differentiation-associated expression]	0.0	2	1	1	1
114256	1710	subject heterozygotic	[subjects heterozygotic]	0.0	2	1	1	1
114257	1710	anti-early antigen ea antigen vca	[anti-early antigen EA antigen VCA]	0.0	5	1	1	1
114258	1710	include the identification	[including the identification]	0.0	3	1	1	1
114259	1710	very strong association between amplification	[very strong association between amplification]	0.0	5	1	1	1
114260	1710	target of drug	[target of drugs]	0.0	3	1	1	1
114261	1710	il-4r alpha-chain gene	[IL-4R alpha-chain gene]	0.0	3	1	1	1
114262	1710	single mutation of R-276	[single mutations of R-276]	0.0	4	1	1	1
114263	1710	inhibitory effect in bone morphogenetic protein-2-	[inhibitory effects in bone morphogenetic protein-2-]	0.0	6	1	1	1
114264	1710	additional hcss	[additional HCSs]	0.0	2	1	1	1
114265	1710	position of exon 5	[position of exon 5]	0.0	4	1	1	1
114266	1710	insight into the role	[insight into the role]	0.0	4	1	1	1
114267	1710	novel homeobox gene HB9	[novel homeobox gene HB9]	0.0	4	1	1	1
114268	1710	Nuclear 3,5,3'-triiodothyronine receptor t3r circulate lymphocyte	[Nuclear 3,5,3'-triiodothyronine receptors T3R circulating lymphocytes]	0.0	6	1	1	1
114269	1710	removal from the essential USA fraction	[removal from the essential USA fraction]	0.0	6	1	1	1
114270	1710	activation of several genes.	[activation of several genes.]	0.0	4	1	1	1
114271	1710	role in FL hematopoiesis	[role in FL hematopoiesis]	0.0	4	1	1	1
114272	1710	difference between receptor	[differences between receptors]	0.0	3	1	1	1
114273	1710	distribution receptor	[distribution receptors]	0.0	2	1	1	1
114274	1710	task	[tasks]	0.0	1	1	1	1
114275	1710	regulation of transcriptional response	[regulation of transcriptional responses]	0.0	4	1	1	1
114276	1710	late differentiation	[later differentiation]	0.0	2	1	1	1
114277	1710	monoallelic (3 of patient	[monoallelic (3 of patients]	0.0	4	1	1	1
114278	1710	dramatic increase to 15-fold)	[dramatic increase to 15-fold)]	0.0	4	1	1	1
114279	1710	two C/EBP site	[two C/EBP sites]	0.0	3	1	1	1
114280	1710	salt supplementation	[salt supplementation]	0.0	2	1	1	1
114281	1710	immunoglobulin chain igh	[immunoglobulin chain IgH]	0.0	3	1	1	1
114282	1710	factor factor	[factor factor]	0.0	2	1	1	1
114283	1710	small increase in ea-d promoter activity	[small increases in EA-D promoter activity]	0.0	6	1	1	1
114284	1710	lymphoid tissue malt lymphoma	[lymphoid tissue MALT lymphoma]	0.0	4	1	1	1
114285	1710	D3 receptor in peripheral cell	[D3 receptors in peripheral cells]	0.0	5	1	1	1
114286	1710	reporter construct in mrl-lpr/lpr	[reporter constructs in MRL-lpr/lpr]	0.0	4	1	1	1
114287	1710	activate protein (ap-1) binding site	[activating protein (AP-1) binding site]	0.0	5	1	1	1
114288	1710	interleukin (il)-2-receptor expression	[interleukin (IL)-2-receptor expression]	0.0	3	1	1	1
114289	1710	-236 sequence	[-236 sequence]	0.0	2	2	2	1
114290	1710	acute leukemia 1-	[acute leukemia 1-]	0.0	3	1	1	1
114291	1710	enhancer-like characteristic	[enhancer-like characteristics]	0.0	2	1	1	1
114292	1710	tsh response	[TSH response]	0.0	2	1	1	1
114293	1710	suggest a consequence of immunological memory	[suggesting an consequence of immunological memory]	0.0	6	1	1	1
114294	1710	Polymorphic nucleotide	[Polymorphic nucleotides]	0.0	2	1	1	1
114295	1710	hyperdemarcation of membrane	[hyperdemarcation of membranes]	0.0	3	1	1	1
114296	1710	agonist, have a ec50	[agonist, having an EC50]	0.0	4	1	1	1
114297	1710	average, level	[average, levels]	0.0	2	1	1	1
114298	1710	PGG-Glucan a beta-(1,6)-branched glucose homopolymer	[PGG-Glucan a beta-(1,6)-branched glucose homopolymer]	0.0	5	1	1	1
114299	1710	CD40 agonist	[CD40 agonist]	0.0	2	1	1	1
114300	1710	cho-dr staphylococcal enterotoxin a	[CHO-DR staphylococcal enterotoxin A]	0.0	4	1	1	1
114301	1710	nervous system pyramidal cell	[nervous system pyramidal cells]	0.0	4	1	1	1
114302	1710	antigen to T cell receptor	[antigen to T cell receptors]	0.0	5	1	1	1
114303	1710	evidence for a coupling of jak3	[evidence for a coupling of JAK3]	0.0	6	1	1	1
114304	1710	single reading frame	[single reading frame]	0.0	3	1	1	1
114305	1710	protooncogene in the stress response	[protooncogenes in the stress response]	0.0	5	1	1	1
114306	1710	acute leukaemia AML	[acute leukaemia AML]	0.0	3	1	1	1
114307	1710	indirect, role: alteration of the sequence	[indirect, role: alteration of the sequence]	0.0	6	1	1	1
114308	1710	Conversely, rs cell the membrane protein	[Conversely, RS cells the membrane protein]	0.0	6	1	1	1
114309	1710	short antigenic region	[short antigenic region]	0.0	3	1	1	1
114310	1710	NF-kappa b heterodimer p50/rela	[NF-kappa B heterodimer p50/RelA]	0.0	4	1	1	1
114311	1710	domain receptor alpha subunit	[domain receptor alpha subunit]	0.0	4	1	1	1
114312	1710	ikappab-alpha in endothelial cell	[IkappaB-alpha in endothelial cells]	0.0	4	1	1	1
114313	1710	effect of hemin	[effects of hemin]	0.0	3	1	1	1
114314	1710	involvement in stage	[involvement in stages]	0.0	3	1	1	1
114315	1710	new cyclooxygenase/5-lipoxygenase compound under investigation.	[new cyclooxygenase/5-lipoxygenase compound under investigation.]	0.0	5	1	1	1
114316	1710	lineage maturation.	[lineage maturation.]	0.0	2	1	1	1
114317	1710	transiently cell line	[transiently cell lines]	0.0	3	1	1	1
114318	1710	one hundred six breast cancer sample	[One hundred six breast cancer samples]	0.0	6	1	1	1
114319	1710	low dose dexamethasone	[Low dose dexamethasone]	0.0	3	1	1	1
114320	1710	further addition of E220K ubiquitinylation	[Further addition of E220K ubiquitinylation]	0.0	5	1	1	1
114321	1710	tpa erk2	[TPA ERK2]	0.0	2	1	1	1
114322	1710	cytotoxic T lymphocyte clonotypes: implication	[cytotoxic T lymphocyte clonotypes: implications]	0.0	5	1	1	1
114323	1710	expression bzlf1 transactivator protein	[expression BZLF1 transactivator protein]	0.0	4	1	1	1
114324	1710	D3 in normal human monocyte	[D3 in normal human monocytes]	0.0	5	1	1	1
114325	1710	-130 site -187	[-130 site -187]	0.0	3	1	1	1
114326	1710	use hiv terminal repeat -cat construct	[using HIV terminal repeat -CAT constructs]	0.0	6	1	1	1
114327	1710	acute phase of infection	[acute phase of infection]	0.0	4	1	1	1
114328	1710	repeat LTR of hiv-1	[repeat LTR of HIV-1]	0.0	4	3	3	1
114329	1710	cytokine production from peripheral T cell	[cytokine production from peripheral T cells]	0.0	6	1	1	1
114330	1710	Differential inhibition	[Differential inhibition]	0.0	2	1	1	1
114331	1710	biosynthesis of tumor necrosis factor-alpha	[Biosynthesis of tumor necrosis factor-alpha]	0.0	5	1	1	1
114332	1710	membrane express SR-BP	[membranes expressing SR-BP]	0.0	3	1	1	1
114333	1710	contain the respond element NREs	[containing the responding elements NREs]	0.0	5	1	1	1
114334	1710	(inhibitory) effect on RA-independent differentiation	[(inhibitory) effects on RA-independent differentiation]	0.0	5	1	1	1
114335	1710	(88.6+/-11.5 pg/ml	[(88.6+/-11.5 pg/mL]	0.0	2	1	1	1
114336	1710	METHODS: cell line	[METHODS: cell lines]	0.0	3	1	1	1
114337	1710	suppression of c-jun	[Suppression of c-jun]	0.0	3	1	1	1
114338	1710	mediator of tgf-beta1 signal	[mediator of TGF-beta1 signaling]	0.0	4	1	1	1
114339	1710	divergent effect of hemin	[divergent effects of hemin]	0.0	4	1	1	1
114340	1710	footprint than the globin	[footprints than the globin]	0.0	4	1	1	1
114341	1710	six week after RAI therapy	[Six weeks after RAI therapy]	0.0	5	1	1	1
114342	1710	rescue MHC thymocyte	[rescuing MHC thymocytes]	0.0	3	1	1	1
114343	1710	biological function among protein	[biological function among proteins]	0.0	4	1	1	1
114344	1710	binding of three multi-protein complex RFX	[binding of three multi-protein complexes RFX]	0.0	6	1	1	1
114345	1710	set of peptide	[set of peptides]	0.0	3	1	1	1
114346	1710	add ttg	[adding tTG]	0.0	2	1	1	1
114347	1710	octamer element 5'-atgcaaag-3'	[octamer element 5'-ATGCAAAG-3']	0.0	3	1	1	1
114348	1710	tyrosine phosphorylation on contact	[tyrosine phosphorylation on contact]	0.0	4	1	1	1
114349	1710	activation in human T cell	[activation in human T cells]	0.0	5	1	1	1
114350	1710	cell microg/ml)/mn2+ microM) for h	[Cells microg/ml)/Mn2+ microM) for h]	0.0	5	1	1	1
114351	1710	immunodeficiency virus transmission	[immunodeficiency virus transmission]	0.0	3	1	1	1
114352	1710	cell extract from acute lymphoblastic leukemia	[cell extracts from acute lymphoblastic leukemia]	0.0	6	1	1	1
114353	1710	reuptake	[reuptake]	0.0	1	1	1	1
114354	1710	induction by CD28 stimulation	[Induction by CD28 stimulation]	0.0	4	1	1	1
114355	1710	subgroup A Ad12	[subgroups A Ad12]	0.0	3	1	1	1
114356	1710	fluorescence anisotropy of diphenylhexatriene dph	[fluorescence anisotropy of diphenylhexatriene DPH]	0.0	5	1	1	1
114357	1710	only in t-pll tumour	[only in T-PLL tumours]	0.0	4	1	1	1
114358	1710	two group one	[two groups one]	0.0	3	1	1	1
114359	1710	molecule CD28	[molecule CD28]	0.0	2	1	1	1
114360	1710	IDCs	[IDCs]	0.0	1	1	1	1
114361	1710	involve a silencer	[involving a silencer]	0.0	3	1	1	1
114362	1710	ebv promoter	[EBV promoters]	0.0	2	1	1	1
114363	1710	NF-kappaB component	[NF-kappaB components]	0.0	2	1	1	1
114364	1710	diverse tcr beta clonotype	[diverse TCR beta clonotypes]	0.0	4	1	1	1
114365	1710	respectively, reflect the high level	[respectively, reflecting the high levels]	0.0	5	1	1	1
114366	1710	response toward humoral immunity	[response toward humoral immunity]	0.0	4	1	1	1
114367	1710	anti-p-selectin antibody antibody	[anti-P-selectin antibodies antibodies]	0.0	3	1	1	1
114368	1710	induction of mrna level	[induction of mRNA levels]	0.0	4	1	1	1
114369	1710	subcytotoxic concentration of etoposide microM)	[subcytotoxic concentrations of etoposide microM)]	0.0	5	1	1	1
114370	1710	stage homogeneity of progenitor/precursor cell grow	[stage homogeneity of progenitor/precursor cells growing]	0.0	6	1	1	1
114371	1710	form of tf	[forms of TF]	0.0	3	1	1	1
114372	1710	woman with multifocal cancer	[woman with multifocal cancer]	0.0	4	1	1	1
114373	1710	viral antigen use T cell	[viral antigens using T cells]	0.0	5	1	1	1
114374	1710	patient with c-erbB2 amplification	[patients with c-erbB2 amplifications]	0.0	4	1	1	1
114375	1710	two interferon-stimulated response element	[Two interferon-stimulated response elements]	0.0	4	1	1	1
114376	1710	knock-out"	[knock-out"]	0.0	1	1	1	1
114377	1710	transcriptional protein distinct	[transcriptional proteins distinct]	0.0	3	1	1	1
114378	1710	ferritin heavy-chain gene	[ferritin heavy-chain gene]	0.0	3	1	1	1
114379	1710	support the relevance	[supporting the relevance]	0.0	3	1	1	1
114380	1710	pathologic immune response	[pathologic immune responses]	0.0	3	1	1	1
114381	1710	(0/3)	[(0/3)]	0.0	1	1	1	1
114382	1710	susceptibility of the organism	[susceptibility of the organism]	0.0	4	1	1	1
114383	1710	E. histolytica infection	[E. histolytica infection]	0.0	3	1	1	1
114384	1710	tool for the investigation	[tool for the investigation]	0.0	4	1	1	1
114385	1710	red cell production	[red cell production]	0.0	3	1	1	1
114386	1710	genetic analysis of mutation	[genetic analyses of mutations]	0.0	4	1	1	1
114387	1710	mediate il-6 gene expression	[mediating IL-6 gene expression]	0.0	4	1	1	1
114388	1710	T cell in complex	[T cells in complexes]	0.0	4	1	1	1
114389	1710	dual effect of lps antibody	[Dual effects of LPS antibodies]	0.0	5	1	1	1
114390	1710	methods: pbmc from patient with asthma	[METHODS: PBMCs from patients with asthma]	0.0	6	1	1	1
114391	1710	functional importance in the expression	[functional importance in the expression]	0.0	5	1	1	1
114392	1710	egl from endometrium	[eGLs from endometrium]	0.0	3	1	1	1
114393	1710	T cell from elderly (mean	[T cells from elderly (mean]	0.0	5	1	1	1
114394	1710	c-jun/c-fo heterodimer	[c-Jun/c-Fos heterodimers]	0.0	2	1	1	1
114395	1710	effect on malignant lymphocyte inhibition	[effects on malignant lymphocytes inhibition]	0.0	5	1	1	1
114396	1710	antibody mab phosphatidylinositol 3-kinase	[antibody mAb phosphatidylinositol 3-kinase]	0.0	4	1	1	1
114397	1710	2.5- to 3-fold reduction	[2.5- to 3-fold reduction]	0.0	4	1	1	1
114398	1710	growth rate in Jurkat cell	[growth rate in Jurkat cells]	0.0	5	1	1	1
114399	1710	regulation during induction of differentiation	[Regulation during induction of differentiation]	0.0	5	1	1	1
114400	1710	immediate-early gene product	[immediate-early gene product]	0.0	3	1	1	1
114401	1710	two signal for optimal induction,	[two signals for optimal induction,]	0.0	5	1	1	1
114402	1710	(940-984) region of the hbd fragment	[(940-984) region of the HBD fragment]	0.0	6	1	1	1
114403	1710	activity in tissue	[activity in tissue]	0.0	3	1	1	1
114404	1710	tnf-alpha promoter element	[TNF-alpha promoter element]	0.0	3	1	1	1
114405	1710	incorporation in the reaction	[incorporation in the reaction]	0.0	4	1	1	1
114406	1710	obtain informative probe	[obtaining informative probes]	0.0	3	1	1	1
114407	1710	lps cell adhesiveness	[LPS cell adhesiveness]	0.0	3	1	1	1
114408	1710	decline by human T cell	[decline by human T cells]	0.0	5	1	1	1
114409	1710	1 signal molecule	[1 signaling molecule]	0.0	3	1	1	1
114410	1710	6-h increase	[6-h increase]	0.0	2	2	2	1
114411	1710	Translational initiation	[Translational initiation]	0.0	2	1	1	1
114412	1710	specific glucocorticoid binding rhythm	[specific glucocorticoid binding rhythms]	0.0	4	1	1	1
114413	1710	PMA il-5 production	[PMA IL-5 production]	0.0	3	1	1	1
114414	1710	dose of ifn-gamma	[doses of IFN-gamma]	0.0	3	1	1	1
114415	1710	rdna encode kruppel-type zinc finger domain	[cDNAs encoding Kruppel-type zinc finger domains]	0.0	6	1	1	1
114416	1710	context of I-Ek	[context of I-Ek]	0.0	3	1	1	1
114417	1710	59.5 kilometer	[59.5 kd]	0.0	2	1	1	1
114418	1710	enzymatic activation	[enzymatic activation]	0.0	2	2	2	1
114419	1710	1.1 0.4 10(-18) mol/microgram rna	[1.1 0.4 10(-18) mol/microgram RNA]	0.0	5	1	1	1
114420	1710	Seminoma	[Seminoma]	0.0	1	1	1	1
114421	1710	target of retroviral vector	[targeting of retroviral vectors]	0.0	4	1	1	1
114422	1710	distinct effect increase	[distinct effect increase]	0.0	3	1	1	1
114423	1710	critical element within this region,	[critical elements within this region,]	0.0	5	1	1	1
114424	1710	SCID-HU-INT	[SCID-HU-INT]	0.0	1	1	1	1
114425	1710	novel activity	[novel activity]	0.0	2	1	1	1
114426	1710	defect in replication	[defect in replication]	0.0	3	1	1	1
114427	1710	protein dimerization domain	[protein dimerization domain]	0.0	3	1	1	1
114428	1710	fura toxicity secondary	[FUra toxicity secondary]	0.0	3	1	1	1
114429	1710	terminal repeat in macrophages/ monocyte	[terminal repeat in macrophages/ monocytes]	0.0	5	1	1	1
114430	1710	(mpro)	[(MPRO)]	0.0	1	1	1	1
114431	1710	defective transport along the pathway	[defective transport along the pathway]	0.0	5	1	1	1
114432	1710	bp65	[Bp65]	0.0	1	1	1	1
114433	1710	activate factor signal transduction pathway	[activating factor signal transduction pathways]	0.0	5	1	1	1
114434	1710	susceptibility kill by cytolytic lymphocyte	[susceptibility killing by cytolytic lymphocytes]	0.0	5	1	1	1
114435	1710	radiosensitivity.	[radiosensitivity.]	0.0	1	1	1	1
114436	1710	reactive disulfide	[reactive disulfide]	0.0	2	1	1	1
114437	1710	Intranuclear delivery of nf-kappab	[Intranuclear delivery of NF-kappaB]	0.0	4	1	1	1
114438	1710	inhibitory function in T lymphocyte	[inhibitory functions in T lymphocytes]	0.0	5	1	1	1
114439	1710	other ankyrin protein	[other ankyrin proteins]	0.0	3	1	1	1
114440	1710	age-matched healthy subject	[age-matched healthy subjects]	0.0	3	1	1	1
114441	1710	cell adhesion molecule-1 phosphorylation	[cell adhesion molecule-1 phosphorylation]	0.0	4	1	1	1
114442	1710	basis of the synergistic induction	[basis of the synergistic induction]	0.0	5	1	1	1
114443	1710	pattern of some enzyme activities,	[patterns of some enzyme activities,]	0.0	5	1	1	1
114444	1710	differential assembly	[differential assembly]	0.0	2	1	1	1
114445	1710	domain of the interaction the domain	[domains of the interaction the domain]	0.0	6	1	1	1
114446	1710	a 187	[aa 187]	0.0	2	1	1	1
114447	1710	platelet-activating factor receptor pafr	[platelet-activating factor receptor PAFR]	0.0	4	1	1	1
114448	1710	study a further series of patient	[studying a further series of patients]	0.0	6	1	1	1
114449	1710	increase in the infectivity	[increase in the infectivity]	0.0	4	1	1	1
114450	1710	functional consequence,	[functional consequence,]	0.0	2	1	1	1
114451	1710	lytic replication cycle	[lytic replication cycle]	0.0	3	1	1	1
114452	1710	counteract 5' negative DNA sequence	[counteracting 5' negative DNA sequences]	0.0	5	1	1	1
114453	1710	repression of globin genes.	[repression of globin genes.]	0.0	4	1	1	1
114454	1710	tyrosine 492/493	[tyrosines 492/493]	0.0	2	1	1	1
114455	1710	stress with oxygen intermediate formation	[stress with oxygen intermediate formation]	0.0	5	1	1	1
114456	1710	dyn/cm2) for h. haec	[dyn/cm2) for h, HAEC]	0.0	4	1	1	1
114457	1710	same picture of pseudohypoaldosteronism	[same picture of pseudohypoaldosteronism]	0.0	4	1	1	1
114458	1710	use a oligonucleotide probe	[using an oligonucleotide probe]	0.0	4	1	1	1
114459	1710	hepor gene expression	[hEpoR gene expression]	0.0	3	1	1	1
114460	1710	hml with essential hypertension	[HML with essential hypertension]	0.0	4	1	1	1
114461	1710	-3 tyrosine phosphorylation	[-3 tyrosine phosphorylation]	0.0	3	1	1	1
114462	1710	normal human pulmonary macrophage PAM	[Normal human pulmonary macrophages PAM]	0.0	5	1	1	1
114463	1710	8, malignant histiocytoma rhabdomyosarcoma	[8, malignant histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
114464	1710	function such as downregulation of molecule	[functions such as downregulation of molecules]	0.0	6	1	1	1
114465	1710	activity of gene	[activity of genes]	0.0	3	1	1	1
114466	1710	develop from peripheral blood mononuclear precursor	[developing from peripheral blood mononuclear precursors]	0.0	6	1	1	1
114467	1710	express major histocompatibility (mhc) class gene	[expressing major histocompatibility (MHC) class genes]	0.0	6	1	1	1
114468	1710	infection of primary b-lymphocyte	[Infection of primary B-lymphocytes]	0.0	4	1	1	1
114469	1710	epithelial level of stat1	[epithelial levels of Stat1]	0.0	4	1	1	1
114470	1710	cross-talking	[cross-talking]	0.0	1	1	1	1
114471	1710	extent, in cell	[extent, in cells]	0.0	3	1	1	1
114472	1710	distinct effect of b7 costimulation	[distinct effects of B7 costimulation]	0.0	5	1	1	1
114473	1710	peak value 0400	[peak values 0400]	0.0	3	1	1	1
114474	1710	x inactivation analysis	[X inactivation analysis]	0.0	3	1	1	1
114475	1710	regulation of retroviruse	[regulation of retroviruses]	0.0	3	1	1	1
114476	1710	egr1 protein	[EGR1 protein]	0.0	2	1	1	1
114477	1710	many more genetic change	[many more genetic changes]	0.0	4	1	1	1
114478	1710	interfere with event along the pathway	[interfering with events along the pathways]	0.0	6	1	1	1
114479	1710	possible difference in the mechanism(s)	[Possible differences in the mechanism(s)]	0.0	5	1	1	1
114480	1710	background: Polyaromatic hydrocarbons	[BACKGROUND: Polyaromatic hydrocarbons]	0.0	3	1	1	1
114481	1710	good candidate study the effect	[good candidate studying the effects]	0.0	5	1	1	1
114482	1710	follow treatment with retinoic acid atra	[following treatment with retinoic acid ATRA]	0.0	6	1	1	1
114483	1710	il-8 by hypoxic ECs	[IL-8 by hypoxic ECs]	0.0	4	1	1	1
114484	1710	dose-dependent stimulation	[dose-dependent stimulation]	0.0	2	1	1	1
114485	1710	capacity (184	[capacity (184]	0.0	2	1	1	1
114486	1710	CD28 of human T lymphocyte	[CD28 of human T lymphocytes]	0.0	5	1	1	1
114487	1710	glucocorticoid receptor in aged runner	[glucocorticoid receptor in aged runner]	0.0	5	1	1	1
114488	1710	significant age-related decline in activity	[significant age-related decline in activity]	0.0	5	1	1	1
114489	1710	differentiation of k562 cell a model	[differentiation of K562 cells a model]	0.0	6	1	1	1
114490	1710	steroid antagonist ru-486	[steroid antagonist RU-486]	0.0	3	1	1	1
114491	1710	pbgd rrna	[PBGD mRNAs]	0.0	2	1	1	1
114492	1710	(il)-10 blocking factor pibf expression	[(IL)-10 blocking factor PIBF expression]	0.0	5	1	1	1
114493	1710	activation of smad protein	[activation of Smad proteins]	0.0	4	1	1	1
114494	1710	+/- nM;	[+/- nM;]	0.0	2	1	1	1
114495	1710	component of a signal pathway	[component of an signaling pathway]	0.0	5	1	1	1
114496	1710	integration of htlv-1 provirus	[integration of HTLV-1 provirus]	0.0	4	1	1	1
114497	1710	peroxisome receptor (pparalpha) transcription factor	[peroxisome receptor (PPARalpha) transcription factor]	0.0	5	1	1	1
114498	1710	occur in multiple family	[occurring in multiple families]	0.0	4	1	1	1
114499	1710	follow differentiation of a monocyte	[following differentiation of a monocyte]	0.0	5	1	1	1
114500	1710	human interleukin-4 receptor	[human interleukin-4 receptor]	0.0	3	1	1	1
114501	1710	corticosteroid receptor a possible marker	[Corticosteroid receptors a possible marker]	0.0	5	1	1	1
114502	1710	activity colony-stimumulatelany-stg factor colony-stimulating factor	[activity colony-stimulating factor colony-stimulating factor]	0.0	5	1	1	1
114503	1710	role in hiv-1 transcriptional activation	[role in HIV-1 transcriptional activation]	0.0	5	1	1	1
114504	1710	distinct molecules, nfatp	[distinct molecules, NFATp]	0.0	3	1	1	1
114505	1710	nucleotide of a sequence	[nucleotide of a sequence]	0.0	4	1	1	1
114506	1710	follow phosphocreatine administration	[following phosphocreatine administration]	0.0	3	1	1	1
114507	1710	organization of a vertebrate gene	[organization of a vertebrate gene]	0.0	5	1	1	1
114508	1710	TGGAAATTCC	[TGGAAATTCC]	0.0	1	1	1	1
114509	1710	Btk gene	[Btk gene]	0.0	2	1	1	1
114510	1710	condition for transfection	[conditions for transfection]	0.0	3	1	1	1
114511	1710	information regard the class	[information regarding the class]	0.0	4	1	1	1
114512	1710	require glucocorticoid for a equivalent degree	[requiring glucocorticoids for an equivalent degree]	0.0	6	1	1	1
114513	1710	addition, this decrease	[addition, this decrease]	0.0	3	1	1	1
114514	1710	more efficient tg presentation	[more efficient TG presentation]	0.0	4	1	1	1
114515	1710	subdominant latent cycle reactivity rarely undetectable	[subdominant latent cycle reactivities rarely undetectable]	0.0	6	1	1	1
114516	1710	significant decrease in membrane order	[significant decrease in membrane order]	0.0	5	1	1	1
114517	1710	protein structure	[protein structure]	0.0	2	1	1	1
114518	1710	-stat 1	[-STAT 1]	0.0	2	1	1	1
114519	1710	various disorder in heterozygous woman	[various disorders in heterozygous women]	0.0	5	1	1	1
114520	1710	serpentine receptor	[serpentine receptors]	0.0	2	1	1	1
114521	1710	chimeric e2a-	[chimeric E2A-]	0.0	2	1	1	1
114522	1710	synthetic glucocorticoid hormone	[synthetic glucocorticoid hormone]	0.0	3	1	1	1
114523	1710	dimerization of a homeodomain protein	[dimerization of a homeodomain protein]	0.0	5	1	1	1
114524	1710	il-2r alpha transcript	[IL-2R alpha transcripts]	0.0	3	1	1	1
114525	1710	regulation of receptor in cell effect	[Regulation of receptors in cells effects]	0.0	6	1	1	1
114526	1710	Positive regulator of the transcription factor	[Positive regulators of the transcription factor]	0.0	6	1	1	1
114527	1710	responsiveness positive leukemia	[responsiveness positive leukemia]	0.0	3	1	1	1
114528	1710	myeloid leukemia aml	[myeloid leukemia AML]	0.0	3	2	2	1
114529	1710	power of receptor	[power of receptor]	0.0	3	1	1	1
114530	1710	level of tax expression	[levels of tax expression]	0.0	4	1	1	1
114531	1710	cd14-transfected Chinese hamster ovary fibroblast	[CD14-transfected Chinese hamster ovary fibroblasts]	0.0	5	1	1	1
114532	1710	tyrosine phosphorylation of key cellular protein	[tyrosine phosphorylation of key cellular proteins]	0.0	6	1	1	1
114533	1710	seen, migration	[seen, migration]	0.0	2	1	1	1
114534	1710	remarkable heterogeneity	[remarkable heterogeneity]	0.0	2	1	1	1
114535	1710	oligo stimulation	[oligo stimulation]	0.0	2	1	1	1
114536	1710	basophilia molecular analysis	[basophilia molecular analysis]	0.0	3	1	1	1
114537	1710	membrane result	[membrane resulting]	0.0	2	1	1	1
114538	1710	express PhoQ	[expressing PhoQ]	0.0	2	1	1	1
114539	1710	additional expression	[additional expression]	0.0	2	1	1	1
114540	1710	intracellular localization of NFkappaB	[intracellular localization of NFkappaB]	0.0	4	1	1	1
114541	1710	exposure to sulfoxide	[exposure to sulfoxide]	0.0	3	1	1	1
114542	1710	(memory) T cell	[(memory) T cells]	0.0	3	1	1	1
114543	1710	ligand-induced activation	[ligand-induced activation]	0.0	2	1	1	1
114544	1710	such as elastase	[such as elastase]	0.0	3	1	1	1
114545	1710	Epstein-Barr virus a gamma-herpesvirus	[Epstein-Barr virus a gamma-herpesvirus]	0.0	4	1	1	1
114546	1710	pseudohypoaldosteronism in different form	[Pseudohypoaldosteronism in different forms]	0.0	4	1	1	1
114547	1710	phorbol ester production of O2-	[phorbol ester production of O2-]	0.0	5	1	1	1
114548	1710	viral pattern similar	[viral pattern similar]	0.0	3	1	1	1
114549	1710	less than p	[less than P]	0.0	3	1	1	1
114550	1710	inhibition of cox-2 protein expression	[inhibition of COX-2 protein expression]	0.0	5	1	1	1
114551	1710	expose human vein endothelial cell	[Exposing human vein endothelial cells]	0.0	5	1	1	1
114552	1710	antioxidant pathway distinct	[antioxidant pathway distinct]	0.0	3	1	1	1
114553	1710	vein cell huvec	[vein cells HUVECs]	0.0	3	2	2	1
114554	1710	manage further setting	[managing further settings]	0.0	3	1	1	1
114555	1710	pathway lead to modulation	[pathway leading to modulation]	0.0	4	1	1	1
114556	1710	include vigorous tyrosine phosphorylation of jak3	[including vigorous tyrosine phosphorylation of JAK3]	0.0	6	1	1	1
114557	1710	locus sil interrupt locus	[locus SIL interrupting locus]	0.0	4	1	1	1
114558	1710	neu rat mammary carcinoma	[neu rat mammary carcinomas]	0.0	4	1	1	1
114559	1710	alter the status in response	[altering the status in response]	0.0	5	1	1	1
114560	1710	patient with hbv infection	[patients with HBV infection]	0.0	4	1	1	1
114561	1710	fate of two transcription factor	[fate of two transcription factors]	0.0	5	1	1	1
114562	1710	DQB x2-box	[DQB X2-box]	0.0	2	1	1	1
114563	1710	insight in the event	[insights in the events]	0.0	4	1	1	1
114564	1710	many disorder a challenging problem	[many disorders a challenging problem]	0.0	5	1	1	1
114565	1710	one other "octamer" complex	[one other "octamer" complex]	0.0	4	1	1	1
114566	1710	early treatment 0 hpc	[early treatment 0 HPCs]	0.0	4	1	1	1
114567	1710	studies, cell of the line	[studies, cells of the line]	0.0	5	1	1	1
114568	1710	class ii T cell line	[class II T cell line]	0.0	5	1	1	1
114569	1710	T cell the ability	[T cells the ability]	0.0	4	1	1	1
114570	1710	analysis of cis-linked regulatory sequence	[analysis of cis-linked regulatory sequences]	0.0	5	1	1	1
114571	1710	actions, include effect in vivo	[actions, including effects in vivo]	0.0	5	1	1	1
114572	1710	biologic activity of retinoic acid	[biologic activities of retinoic acid]	0.0	5	1	1	1
114573	1710	regulation in cells,	[regulation in cells,]	0.0	3	1	1	1
114574	1710	normal erythroid development; addition	[normal erythroid development; addition]	0.0	4	1	1	1
114575	1710	PLB-985	[PLB-985]	0.0	1	1	1	1
114576	1710	cytokine-induced function	[cytokine-induced functions]	0.0	2	1	1	1
114577	1710	MHC ii	[MHC II]	0.0	2	1	1	1
114578	1710	mature human T lymphocyte erratum	[mature human T lymphocytes erratum]	0.0	5	1	1	1
114579	1710	kd of nm.	[Kd of nM.]	0.0	3	1	1	1
114580	1710	hematopoietic stage	[hematopoietic stages]	0.0	2	1	1	1
114581	1710	g-csf cell at day g-csf	[G-CSF cells at day G-CSF]	0.0	5	1	1	1
114582	1710	subtraction potential difference	[subtraction potential difference]	0.0	3	1	1	1
114583	1710	concentration effect	[concentration effect]	0.0	2	1	1	1
114584	1710	thigh lesion of patient	[thigh lesions of patients]	0.0	4	1	1	1
114585	1710	nuclear protein capable	[nuclear proteins capable]	0.0	3	1	1	1
114586	1710	biological role in the control	[biological roles in the control]	0.0	5	1	1	1
114587	1710	chemical probe	[chemical probe]	0.0	2	1	1	1
114588	1710	mechanism underlie this effect	[mechanisms underlying these effects]	0.0	4	1	1	1
114589	1710	woman with neutrophilia	[women with neutrophilia]	0.0	3	1	1	1
114590	1710	event along the signal pathway	[events along the signaling pathways]	0.0	5	1	1	1
114591	1710	interferon beta element	[interferon beta element]	0.0	3	1	1	1
114592	1710	mesothelial cell from cavity fluid	[mesothelial cells from cavity fluids]	0.0	5	1	1	1
114593	1710	region of the CD11c promoter	[regions of the CD11c promoter]	0.0	5	1	1	1
114594	1710	exogenous gene in lymphoid cell	[exogenous genes in lymphoid cells]	0.0	5	1	1	1
114595	1710	woman with chronic mpd	[women with chronic MPDs]	0.0	4	1	1	1
114596	1710	2 healthy subject in patient	[2 healthy subjects in patients]	0.0	5	1	1	1
114597	1710	regulator of monocyte differentiation	[regulators of monocyte differentiation]	0.0	4	1	1	1
114598	1710	two pathway of interleukin-5 synthesis	[Two pathways of interleukin-5 synthesis]	0.0	5	1	1	1
114599	1710	mitogen for muscle cell	[mitogen for muscle cells]	0.0	4	1	1	1
114600	1710	association between amplification	[association between amplification]	0.0	3	1	1	1
114601	1710	man aged	[men aged]	0.0	2	1	1	1
114602	1710	include hematopoietic cell	[including hematopoietic cells]	0.0	3	1	1	1
114603	1710	differentiation of k562 cell with downregulation	[differentiation of K562 cells with downregulation]	0.0	6	1	1	1
114604	1710	TAFII 105	[TAFII 105]	0.0	2	1	1	1
114605	1710	activity of alpha-methyl-1 alpha,25-(OH)2D3	[activity of alpha-methyl-1 alpha,25-(OH)2D3]	0.0	4	1	1	1
114606	1710	haematopoietic tumour	[haematopoietic tumours]	0.0	2	1	1	1
114607	1710	parameter restoration	[parameters restoration]	0.0	2	1	1	1
114608	1710	prominent increase	[prominent increase]	0.0	2	2	2	1
114609	1710	PMA/PHA	[PMA/PHA]	0.0	1	1	1	1
114610	1710	protein creb	[protein CREB]	0.0	2	1	1	1
114611	1710	treatment of the immature b-cell line	[Treatment of the immature B-cell line]	0.0	6	1	1	1
114612	1710	serine alanine	[serine alanine]	0.0	2	1	1	1
114613	1710	suggest the actual target	[suggesting the actual target]	0.0	4	1	1	1
114614	1710	adenovirus late promoter	[adenovirus late promoter]	0.0	3	2	2	1
114615	1710	trigger by the l243 (p	[Triggering by the L243 (P]	0.0	5	1	1	1
114616	1710	interleukin IL-4 promoter	[interleukin IL-4 promoter]	0.0	3	1	1	1
114617	1710	bhlh-pas partner	[bHLH-PAS partner]	0.0	2	1	1	1
114618	1710	octamer -75	[octamer -75]	0.0	2	1	1	1
114619	1710	Epstein-Barr lymphoblastoid cell line	[Epstein-Barr lymphoblastoid cell lines]	0.0	4	1	1	1
114620	1710	subtle modification in sequence	[subtle modifications in sequences]	0.0	4	1	1	1
114621	1710	nf-at protein expression	[NF-AT protein expression]	0.0	3	1	1	1
114622	1710	abnormal behavior	[abnormal behavior]	0.0	2	1	1	1
114623	1710	region of major class molecule	[regions of major class molecules]	0.0	5	1	1	1
114624	1710	native terminal repeat	[native terminal repeat]	0.0	3	1	1	1
114625	1710	gene by the factor	[genes by the factor]	0.0	4	1	1	1
114626	1710	active maintenance	[active maintenance]	0.0	2	1	1	1
114627	1710	possible candidate compound	[possible candidate compounds]	0.0	3	1	1	1
114628	1710	response humoral immunity	[responses humoral immunity]	0.0	3	1	1	1
114629	1710	useful marker of cortisol receptor	[useful marker of cortisol receptor]	0.0	5	1	1	1
114630	1710	immediate serum responsive gene	[immediate serum responsive genes]	0.0	4	1	1	1
114631	1710	convergence of costimulatory signal	[Convergence of costimulatory signals]	0.0	4	1	1	1
114632	1710	efficiency in ad	[efficiency in AD]	0.0	3	1	1	1
114633	1710	allele in early progenitor	[alleles in early progenitors]	0.0	4	1	1	1
114634	1710	binding to the domain of CD30	[binding to the domain of CD30]	0.0	6	1	1	1
114635	1710	concomitant activation	[concomitant activation]	0.0	2	2	2	1
114636	1710	receptor binding to regulatory region	[receptor binding to regulatory regions]	0.0	5	1	1	1
114637	1710	in-vitro-stimulated blood lymphocyte sample	[in-vitro-stimulated blood lymphocyte samples]	0.0	4	1	1	1
114638	1710	develop strategy	[developing strategies]	0.0	2	1	1	1
114639	1710	plasma corticosterone level	[plasma corticosterone levels]	0.0	3	1	1	1
114640	1710	include cd8+	[including CD8+]	0.0	2	1	1	1
114641	1710	induce expression of socs-1	[inducing expression of SOCS-1]	0.0	4	1	1	1
114642	1710	study the molecular mechanism responsible	[studying the molecular mechanisms responsible]	0.0	5	1	1	1
114643	1710	encompass of this tyrosine residue stat3	[encompassing of these tyrosine residues Stat3]	0.0	6	1	1	1
114644	1710	effect on immunodeficiency virus replication	[effects on immunodeficiency virus replication]	0.0	5	1	1	1
114645	1710	appropriate region beta chain	[appropriate region beta chain]	0.0	4	1	1	1
114646	1710	lymph node of adult mouse	[lymph nodes of adult mice]	0.0	5	1	1	1
114647	1710	Thus, IL-2	[Thus, IL-2]	0.0	2	1	1	1
114648	1710	minute at degree	[min at degrees]	0.0	3	1	1	1
114649	1710	follow stimulation with proinflammatory agonist	[Following stimulation with proinflammatory agonists]	0.0	5	1	1	1
114650	1710	abnormality gene	[Abnormalities genes]	0.0	2	1	1	1
114651	1710	early gene in cell	[early genes in cells]	0.0	4	1	1	1
114652	1710	(cd33, cd13, cd15) (cd56) antigen	[(CD33, CD13, CD15) (CD56) antigens]	0.0	5	1	1	1
114653	1710	line, re-expression	[line, re-expression]	0.0	2	1	1	1
114654	1710	aspect of signal transduction	[aspect of signal transduction]	0.0	4	1	1	1
114655	1710	profound impact	[profound impact]	0.0	2	1	1	1
114656	1710	expression during monocyte	[expression during monocyte]	0.0	3	1	1	1
114657	1710	T cell activator protein-1 ap-1	[T cells activator protein-1 AP-1]	0.0	5	1	1	1
114658	1710	domain with putative segment	[domain with putative segments]	0.0	4	1	1	1
114659	1710	suggest overlapping mechanism	[suggesting overlapping mechanisms]	0.0	3	1	1	1
114660	1710	transcription factor nf-kappab one	[transcription factor NF-kappaB one]	0.0	4	1	1	1
114661	1710	dna-binding subunit of molecular mass	[DNA-binding subunits of molecular mass]	0.0	5	1	1	1
114662	1710	transition to plasma cell	[transition to plasma cell]	0.0	4	1	1	1
114663	1710	diabete mellitus	[diabetes mellitus]	0.0	2	3	3	1
114664	1710	myeloid leukemia m2-type	[myeloid leukemia M2-type]	0.0	3	1	1	1
114665	1710	IL-5 (hIL-5) promoter	[IL-5 (hIL-5) promoter]	0.0	3	1	1	1
114666	1710	synergistic effect of mechanical stress	[Synergistic effects of mechanical stress]	0.0	5	1	1	1
114667	1710	CsA associate with binding protein CsA	[CsA associate with binding proteins CsA]	0.0	6	1	1	1
114668	1710	reactivation of memory CTL	[reactivation of memory CTLs]	0.0	4	1	1	1
114669	1710	follow translocation	[following translocations]	0.0	2	1	1	1
114670	1710	amount of a size variant	[amounts of a size variant]	0.0	5	1	1	1
114671	1710	amino-acid protein	[amino-acid protein]	0.0	2	1	1	1
114672	1710	CD40 ligand+	[CD40 ligand+]	0.0	2	1	1	1
114673	1710	pmlrar alpha	[PMLRAR alpha]	0.0	2	1	1	1
114674	1710	IL-2 -inducible component	[IL-2 -inducible component]	0.0	3	1	1	1
114675	1710	sensitivity to mpl	[sensitivity to MPL]	0.0	3	1	1	1
114676	1710	inhibitor of mapk kinase 1	[inhibitor of MAPK kinase 1]	0.0	5	1	1	1
114677	1710	possible influence	[possible influence]	0.0	2	1	1	1
114678	1710	rapid up-regulation in T cell	[rapid up-regulation in T cells]	0.0	5	1	1	1
114679	1710	recombinant chloramphenicol acetyltransferase plasmid	[recombinant chloramphenicol acetyltransferase plasmids]	0.0	4	1	1	1
114680	1710	deletion of the normal allele	[deletion of the normal allele]	0.0	5	1	1	1
114681	1710	two subgroups, protein	[two subgroups, proteins]	0.0	3	1	1	1
114682	1710	regulate different function	[regulating different functions]	0.0	3	1	1	1
114683	1710	shutdown of cellular synthesis	[shutdown of cellular synthesis]	0.0	4	1	1	1
114684	1710	lack sequence similarity to transcription factor	[lacking sequence similarity to transcription factors]	0.0	6	1	1	1
114685	1710	regulation of commitment to plasma cell	[Regulation of commitment to plasma cells]	0.0	6	1	1	1
114686	1710	play a important role	[playing an important role]	0.0	4	1	1	1
114687	1710	primary b lymphocyte from mouse	[primary B lymphocytes from mice]	0.0	5	1	1	1
114688	1710	inhibition by interleukin-6	[inhibition by interleukin-6]	0.0	3	1	1	1
114689	1710	umbilical vein cell huvec	[umbilical vein cells HUVECs]	0.0	4	2	2	1
114690	1710	involve interaction between multiple element	[involving interactions between multiple elements]	0.0	5	1	1	1
114691	1710	B-cell lymphocytic leukemia cell	[B-cell lymphocytic leukemia cells]	0.0	4	1	1	1
114692	1710	experimental approach	[experimental approaches]	0.0	2	1	1	1
114693	1710	forms, granulocyte	[forms, granulocytes]	0.0	2	1	1	1
114694	1710	shear flow condition	[shear flow conditions]	0.0	3	1	1	1
114695	1710	effect of stress on activity	[effects of stress on activities]	0.0	5	1	1	1
114696	1710	cell line with potential	[cell lines with potential]	0.0	4	1	1	1
114697	1710	primary hemopoietic cell	[primary hemopoietic cells]	0.0	3	2	2	1
114698	1710	three E2F activity	[Three E2F activities]	0.0	3	1	1	1
114699	1710	related progesterone	[related progesterone]	0.0	2	1	1	1
114700	1710	inhibition of rat splenocyte proliferation	[Inhibition of rat splenocyte proliferation]	0.0	5	1	1	1
114701	1710	b29 gene	[B29 gene]	0.0	2	1	1	1
114702	1710	switch in hematopoietic development	[switching in hematopoietic development]	0.0	4	1	1	1
114703	1710	interleukin 2 T	[interleukin 2 T]	0.0	3	1	1	1
114704	1710	part achieve ebv activation	[part achieving EBV activation]	0.0	4	1	1	1
114705	1710	apoptotic lymphocyte	[apoptotic lymphocytes]	0.0	2	2	2	1
114706	1710	only case	[only case]	0.0	2	1	1	1
114707	1710	lysis of the cell	[lysis of the cells]	0.0	4	1	1	1
114708	1710	TCL1 oncogene activation in T cell	[TCL1 oncogene activation in T cells]	0.0	6	1	1	1
114709	1710	receptor per cell in patient	[receptors per cell in patients]	0.0	5	1	1	1
114710	1710	background: acid RA	[BACKGROUND: acid RA]	0.0	3	1	1	1
114711	1710	effect on binding	[effect on binding]	0.0	3	1	1	1
114712	1710	molecule of mrna present	[molecule of mRNA present]	0.0	4	1	1	1
114713	1710	disease in patient	[disease in patients]	0.0	3	1	1	1
114714	1710	feature with this datum	[features with these data.]	0.0	4	1	1	1
114715	1710	distinct action	[distinct action]	0.0	2	1	1	1
114716	1710	young (18- healthy volunteer	[young (18- healthy volunteers]	0.0	4	1	1	1
114717	1710	41 exon span 45 kb	[41 exons spanning 45 kb]	0.0	5	1	1	1
114718	1710	more striking downregulation	[more striking downregulation]	0.0	3	1	1	1
114719	1710	binding sites/cell;	[binding sites/cell;]	0.0	2	1	1	1
114720	1710	Staurosporine PKC inhibitor pentoxifylline	[Staurosporine PKC inhibitor pentoxifylline]	0.0	4	1	1	1
114721	1710	c-11 analog	[C-11 analogs]	0.0	2	1	1	1
114722	1710	persistent loss	[persistent loss]	0.0	2	1	1	1
114723	1710	resistance to certain disease	[resistance to certain diseases]	0.0	4	1	1	1
114724	1710	il-2 alpha expression	[IL-2 alpha expression]	0.0	3	1	1	1
114725	1710	criteria, include cell distribution	[criteria, including cell distribution]	0.0	4	1	1	1
114726	1710	HCMV version,	[HCMV version,]	0.0	2	1	1	1
114727	1710	different form include leukemia	[different forms including leukemia]	0.0	4	1	1	1
114728	1710	enzyme catalyze the step	[enzyme catalyzing the step]	0.0	4	1	1	1
114729	1710	double-immunogold labeling	[double-immunogold labeling]	0.0	2	1	1	1
114730	1710	binding sites/cell)	[binding sites/cell)]	0.0	2	1	1	1
114731	1710	t-cell effect of DEX	[T-cell effects of DEX]	0.0	4	1	1	1
114732	1710	nf-kappab heterodimer	[NF-kappaB heterodimers]	0.0	2	1	1	1
114733	1710	beta activation	[beta activation]	0.0	2	1	1	1
114734	1710	Egr-1 binding site	[Egr-1 binding site]	0.0	3	1	1	1
114735	1710	number of patient respond	[number of patients responding]	0.0	4	1	1	1
114736	1710	tumor control	[tumor control]	0.0	2	1	1	1
114737	1710	include cd14	[including CD14]	0.0	2	1	1	1
114738	1710	IL-12 receptor IL-12R	[IL-12 receptor IL-12R]	0.0	3	1	1	1
114739	1710	Jakdstat gene socs-1	[JAK/STAT gene SOCS-1]	0.0	3	1	1	1
114740	1710	MHC class ii -cell	[MHC class II -cells]	0.0	4	1	1	1
114741	1710	primary fms patient	[primary FMS patients]	0.0	3	1	1	1
114742	1710	activation of Wp,	[activation of Wp,]	0.0	3	1	1	1
114743	1710	tissue include hematopoietic cell	[tissues including hematopoietic cells]	0.0	4	1	1	1
114744	1710	inhibition of 62% 5%	[inhibition of 62% 5%]	0.0	4	1	1	1
114745	1710	role for glycogen synthase kinase-3	[role for glycogen synthase kinase-3]	0.0	5	1	1	1
114746	1710	increment	[increment]	0.0	1	1	1	1
114747	1710	two ebv transactivator	[two EBV transactivators]	0.0	3	1	1	1
114748	1710	selection along the monocytic differentiation	[Selection along the monocytic differentiation]	0.0	5	1	1	1
114749	1710	m-1)	[M-1)]	0.0	1	1	1	1
114750	1710	two element within the region	[two elements within the region]	0.0	5	1	1	1
114751	1710	nuclei from human monocyte	[nuclei from human monocytes]	0.0	4	1	1	1
114752	1710	extend from -870	[extending from -870]	0.0	3	1	1	1
114753	1710	poor response to glucocorticoid therapy	[poor response to glucocorticoid therapy]	0.0	5	1	1	1
114754	1710	receptor on cell	[receptors on cells]	0.0	3	1	1	1
114755	1710	two crucial element	[two crucial elements]	0.0	3	1	1	1
114756	1710	exposure to the level	[exposure to the level]	0.0	4	1	1	1
114757	1710	dendritic cell in center	[dendritic cells in centers]	0.0	4	1	1	1
114758	1710	il-4 stat stat6	[IL-4 STAT STAT6]	0.0	3	1	1	1
114759	1710	suggest the target of the silencing.	[suggesting the target of the silencing.]	0.0	6	1	1	1
114760	1710	deletion of the exon	[deletion of the exons]	0.0	4	1	1	1
114761	1710	encode b-binding-proteins	[encoding B-binding-proteins]	0.0	2	1	1	1
114762	1710	kill	[killing]	0.0	1	1	1	1
114763	1710	approximately 2 log-fold glucocorticoid	[approximately 2 log-fold glucocorticoids]	0.0	4	1	1	1
114764	1710	inverse change in nf-il6beta expression	[inverse changes in NF-IL6beta expression]	0.0	5	1	1	1
114765	1710	class major -negative cell line	[class major -negative cell lines]	0.0	5	1	1	1
114766	1710	short-term incubation of this cell	[short-term incubation of these cells]	0.0	5	1	1	1
114767	1710	pathogenic infections.	[pathogenic infections.]	0.0	2	1	1	1
114768	1710	(il) production by effector cell	[(IL) production by effector cells]	0.0	5	1	1	1
114769	1710	mechanism underlie differentiation	[mechanisms underlying differentiation]	0.0	3	1	1	1
114770	1710	activator protein-1 site	[activator protein-1 site]	0.0	3	1	1	1
114771	1710	beta-adrenoreceptor antagonist	[beta-adrenoreceptor antagonist]	0.0	2	1	1	1
114772	1710	hematopoietic cell line UT-7	[hematopoietic cell line UT-7]	0.0	4	1	1	1
114773	1710	time-dependent, activation of stat1 protein	[time-dependent, activation of STAT1 protein]	0.0	5	1	1	1
114774	1710	box)	[box)]	0.0	1	1	1	1
114775	1710	transcription in murine lymphocyte	[transcription in murine lymphocytes]	0.0	4	1	1	1
114776	1710	treatment with 10 micrograms/mL etoposide	[Treatment with 10 micrograms/mL etoposide]	0.0	5	1	1	1
114777	1710	CD38 expression in hematopoietic cell	[CD38 expression in hematopoietic cells]	0.0	5	1	1	1
114778	1710	activation of Egr-1 gene	[activation of Egr-1 gene]	0.0	4	1	1	1
114779	1710	two distinct lipopolysaccharide	[two distinct lipopolysaccharide]	0.0	3	1	1	1
114780	1710	chemoattractant cytokine	[chemoattractant cytokine]	0.0	2	1	1	1
114781	1710	cd68- cell	[CD68- cells]	0.0	2	1	1	1
114782	1710	heat placental alkaline phosphatase	[heat placental alkaline phosphatase]	0.0	4	1	1	1
114783	1710	analysis of the sedimentation peak	[analysis of the sedimentation peak]	0.0	5	1	1	1
114784	1710	describe the activation of hematopoietic gene	[describing the activation of hematopoietic genes]	0.0	6	1	1	1
114785	1710	high amount of precursor	[highest amounts of precursors]	0.0	4	1	1	1
114786	1710	1) sign of primary hypothyroidism	[1) signs of primary hypothyroidism]	0.0	5	1	1	1
114787	1710	cyclophilin b-binding-proteins use the yeast system	[cyclophilin B-binding-proteins using the yeast system]	0.0	6	1	1	1
114788	1710	peroxisome proliferator-activated receptor gamma	[peroxisome proliferator-activated receptor gamma]	0.0	4	1	1	1
114789	1710	previous month	[previous months]	0.0	2	1	1	1
114790	1710	monocyte binding to human endothelial cell	[monocyte binding to human endothelial cells]	0.0	6	1	1	1
114791	1710	role for nuclear protooncogene	[role for nuclear protooncogenes]	0.0	4	1	1	1
114792	1710	fold increase in number	[fold increase in number]	0.0	4	1	1	1
114793	1710	include the tyrosine phosphorylation of Cgamma1	[including the tyrosine phosphorylation of Cgamma1]	0.0	6	1	1	1
114794	1710	human major histocompatibility complex	[human major histocompatibility complex]	0.0	4	1	1	1
114795	1710	transcription/repair deficiency	[transcription/repair deficiency]	0.0	2	1	1	1
114796	1710	target of t-cell	[target of T-cells]	0.0	3	1	1	1
114797	1710	Comparison mouse genomic sequence	[Comparison mouse genomic sequences]	0.0	4	1	1	1
114798	1710	various biochemical lesion with age	[various biochemical lesions with age]	0.0	5	1	1	1
114799	1710	macrophage transcription	[macrophage transcription]	0.0	2	2	2	1
114800	1710	form of resistance	[form of resistance]	0.0	3	1	1	1
114801	1710	activation through stimulation	[activation through stimulation]	0.0	3	1	1	1
114802	1710	mouse gene SRG3	[mouse gene SRG3]	0.0	3	1	1	1
114803	1710	interaction of rank factor	[interaction of RANK factors]	0.0	4	1	1	1
114804	1710	prognosis of the patient	[prognosis of the patient]	0.0	4	1	1	1
114805	1710	P/I induction	[P/I induction]	0.0	2	1	1	1
114806	1710	inhibition of secretion	[Inhibition of secretion]	0.0	3	1	1	1
114807	1710	pattern of tal-1 expression	[pattern of tal-1 expression]	0.0	4	1	1	1
114808	1710	viral fusion/entry process	[viral fusion/entry process]	0.0	3	1	1	1
114809	1710	nm epidermal growth factor	[nM epidermal growth factor]	0.0	4	1	1	1
114810	1710	Karyotypic detection of 16 abnormality	[Karyotypic detection of 16 abnormalities]	0.0	5	1	1	1
114811	1710	corticosteroid produce inhibition ic50	[corticosteroid producing inhibition IC50]	0.0	4	1	1	1
114812	1710	autosomal form in familiess	[autosomal form in families,]	0.0	4	1	1	1
114813	1710	concert with vesicle	[concert with vesicles]	0.0	3	1	1	1
114814	1710	Dicarba-closo-dodecaboranes	[Dicarba-closo-dodecaboranes]	0.0	1	1	1	1
114815	1710	HTC cell	[HTC cells]	0.0	2	1	1	1
114816	1710	structure of Oct-2a	[structure of Oct-2a]	0.0	3	1	1	1
114817	1710	simultaneous incubation of RU 486	[simultaneous incubation of RU 486]	0.0	5	1	1	1
114818	1710	(dp) CD4 cd8(+) CD3	[(DP) CD4 CD8(+) CD3]	0.0	4	1	1	1
114819	1710	converge in common intracellular pathway	[converging in common intracellular pathways]	0.0	5	1	1	1
114820	1710	peripheral human T lymphocyte	[peripheral human T lymphocytes]	0.0	4	1	1	1
114821	1710	ifn-gamma cell	[IFN-gamma cells]	0.0	2	1	1	1
114822	1710	complement complex	[complement complexes]	0.0	2	1	1	1
114823	1710	number include phorbol 13-acetate	[number including phorbol 13-acetate]	0.0	4	1	1	1
114824	1710	less important role	[less important role]	0.0	3	1	1	1
114825	1710	analysis of cyclosporin mutant in yeast	[analysis of cyclosporin mutants in yeast]	0.0	6	1	1	1
114826	1710	interleukin 2 gene through interference	[interleukin 2 gene through interference]	0.0	5	1	1	1
114827	1710	Staurosporine a nonspecific inhibitor	[Staurosporine a nonspecific inhibitor]	0.0	4	1	1	1
114828	1710	member of this multigene family, gata-3	[member of this multigene family, GATA-3]	0.0	6	1	1	1
114829	1710	induction of vcam-1 E-selectin surface expression	[Induction of VCAM-1 E-selectin surface expression]	0.0	6	1	1	1
114830	1710	suppression by fluid from cell carcinoma	[Suppression by fluid from cell carcinomas]	0.0	6	1	1	1
114831	1710	Also, mol/L) in combination with RA	[Also, mol/L) in combination with RA]	0.0	6	1	1	1
114832	1710	immediate-early (<2 gene expression	[immediate-early (<2 gene expression]	0.0	4	1	1	1
114833	1710	mouse mpc11	[mouse MPC11]	0.0	2	1	1	1
114834	1710	molecular study on population progenitor	[molecular studies on populations progenitors]	0.0	5	1	1	1
114835	1710	several immuno-pathological condition	[several immuno-pathological conditions]	0.0	3	1	1	1
114836	1710	position -82 to -91	[positions -82 to -91]	0.0	4	1	1	1
114837	1710	virus peptide by dendritic cell	[virus peptides by dendritic cells]	0.0	5	1	1	1
114838	1710	action on expression of adhesion molecule	[actions on expression of adhesion molecules]	0.0	6	1	1	1
114839	1710	pattern of signal transduction	[patterns of signal transduction]	0.0	4	1	1	1
114840	1710	overlap the gas motif	[overlapping the GAS motif]	0.0	4	1	1	1
114841	1710	position relative	[positions relative]	0.0	2	1	1	1
114842	1710	number of binding site with alteration	[numbers of binding sites with alteration]	0.0	6	1	1	1
114843	1710	intermediate event	[intermediate event]	0.0	2	1	1	1
114844	1710	type of antioxidant molecule	[types of antioxidant molecules]	0.0	4	1	1	1
114845	1710	okadaic acid phosphatase	[okadaic acid phosphatases]	0.0	3	1	1	1
114846	1710	pocket protein-	[pocket protein-]	0.0	2	1	1	1
114847	1710	cell in blood	[cells in blood]	0.0	3	1	1	1
114848	1710	Hsp60 T cell with cell	[Hsp60 T cells with cells]	0.0	5	1	1	1
114849	1710	leukocyte from obese subject	[leukocytes from obese subjects]	0.0	4	1	1	1
114850	1710	binding of factor in	[binding of factors in]	0.0	4	1	1	1
114851	1710	one element identical	[one element identical]	0.0	3	1	1	1
114852	1710	Interleukin-2 IL-2 promoter	[Interleukin-2 IL-2 promoter]	0.0	3	1	1	1
114853	1710	synergistic action a gata site	[synergistic action a GATA site]	0.0	5	1	1	1
114854	1710	multimer of enhancer sequence	[multimers of enhancer sequences]	0.0	4	1	1	1
114855	1710	24 h. induce CAT activity	[24 h, inducing CAT activity]	0.0	5	1	1	1
114856	1710	human immunodeficiency virus hiv-1 infection	[human immunodeficiency virus HIV-1 infection]	0.0	5	1	1	1
114857	1710	T cell express MHC class	[T cells expressing MHC class]	0.0	5	1	1	1
114858	1710	increase in tetrahydrocortisone	[increase in tetrahydrocortisone]	0.0	3	1	1	1
114859	1710	apparent mass of kD.	[apparent mass of kD.]	0.0	4	1	1	1
114860	1710	timp-1 upregulation	[TIMP-1 upregulation]	0.0	2	1	1	1
114861	1710	involve the recognition	[involving the recognition]	0.0	3	1	1	1
114862	1710	binding heterodimers,	[binding heterodimers,]	0.0	2	1	1	1
114863	1710	other EBV-associated, hla-b8-restricted epitope	[other EBV-associated, HLA-B8-restricted epitopes]	0.0	4	1	1	1
114864	1710	endogenous c-myb expression	[endogenous c-myb expression]	0.0	3	1	1	1
114865	1710	active renin	[active renin]	0.0	2	1	1	1
114866	1710	nuclear mobilization	[nuclear mobilization]	0.0	2	1	1	1
114867	1710	NF-kappaB promoter in macrophage	[NF-kappaB promoter in macrophages]	0.0	4	1	1	1
114868	1710	dysregulation of factor-kappa b	[Dysregulation of factor-kappa B]	0.0	4	1	1	1
114869	1710	loci on the short arm	[loci on the short arm]	0.0	5	1	1	1
114870	1710	NF-AT mouse	[NF-AT mice]	0.0	2	1	1	1
114871	1710	addition of 50-500 microm pdtc	[addition of 50-500 microM PDTC]	0.0	5	1	1	1
114872	1710	natural cell wall breakdown product	[natural cell wall breakdown product]	0.0	5	1	1	1
114873	1710	stress such as cytokine	[stress such as cytokines]	0.0	4	1	1	1
114874	1710	vivo to a region	[vivo to a region]	0.0	4	1	1	1
114875	1710	distinct DNA binding subunit	[distinct DNA binding subunits]	0.0	4	1	1	1
114876	1710	arthritis, binding in T cell	[arthritis, binding in T cells]	0.0	5	1	1	1
114877	1710	theoretical pathway	[theoretical pathway]	0.0	2	1	1	1
114878	1710	neurocutaneous disorder	[neurocutaneous disorder]	0.0	2	1	1	1
114879	1710	interaction between multipotential hemopoietic stem cell	[interactions between multipotential hemopoietic stem cells]	0.0	6	1	1	1
114880	1710	three category	[three categories]	0.0	2	1	1	1
114881	1710	adhesion in tnf-treated human vein cell	[adhesion in TNF-treated human vein cells]	0.0	6	1	1	1
114882	1710	gene in human neutrophil	[genes in human neutrophils]	0.0	4	1	1	1
114883	1710	la(ssb) precipitin	[La(SSB) precipitins]	0.0	2	1	1	1
114884	1710	STAT protein in murine T cell	[STAT proteins in murine T cells]	0.0	6	1	1	1
114885	1710	heterodimeric HLA-DQ molecule	[heterodimeric HLA-DQ molecules]	0.0	3	1	1	1
114886	1710	cd38(-) cell	[CD38(-) cells]	0.0	2	1	1	1
114887	1710	10 bp for binding.	[10 bp for binding.]	0.0	4	1	1	1
114888	1710	class ii histocompatibility gene transcription	[class II histocompatibility gene transcription]	0.0	5	1	1	1
114889	1710	express major complex (mhc) class gene	[expressing major complex (MHC) class genes]	0.0	6	1	1	1
114890	1710	activation of transcription to a element	[Activation of transcription to a element]	0.0	6	1	1	1
114891	1710	restriction element for gliadin peptide	[restriction elements for gliadin peptides]	0.0	5	1	1	1
114892	1710	intestinal epithelial cell response to infection	[intestinal epithelial cell responses to infection]	0.0	6	1	1	1
114893	1710	lac+clone out of 1 transformant	[Lac+clones out of 1 transformants]	0.0	5	1	1	1
114894	1710	cyclin-dependent kinase inhibitor	[cyclin-dependent kinase inhibitor]	0.0	3	1	1	1
114895	1710	NFAT formation in cell types.	[NFAT formation in cell types.]	0.0	5	1	1	1
114896	1710	(25 mm)	[(25 mM)]	0.0	2	1	1	1
114897	1710	encode proinflammatory cytokine	[encoding proinflammatory cytokines]	0.0	3	1	1	1
114898	1710	monocyte to macrophage nuclear protein	[monocytes to macrophage nuclear proteins]	0.0	5	1	1	1
114899	1710	interaction of NF-kappa b	[interaction of NF-kappa B]	0.0	4	1	1	1
114900	1710	phosphatidylinositol-3,4,5-trisphosphate concentration in human cell	[phosphatidylinositol-3,4,5-trisphosphate concentration in human cells]	0.0	5	1	1	1
114901	1710	constitutive expression from individual	[Constitutive expression from individuals]	0.0	4	1	1	1
114902	1710	regulatory sequence within the element	[regulatory sequences within the elements]	0.0	5	1	1	1
114903	1710	relapse of disease	[relapse of disease]	0.0	3	1	1	1
114904	1710	intron of tnf-alpha	[intron of TNF-alpha]	0.0	3	1	1	1
114905	1710	only small increase	[only small increases]	0.0	3	1	1	1
114906	1710	transcription/translation	[transcription/translation]	0.0	1	1	1	1
114907	1710	immediate 5' region	[immediate 5' region]	0.0	3	1	1	1
114908	1710	useful drug for the treatment	[useful drug for the treatment]	0.0	5	1	1	1
114909	1710	t-lymphocyte from individual with filarial disease	[T-lymphocytes from individuals with filarial disease]	0.0	6	1	1	1
114910	1710	intermediate phenotype,	[intermediate phenotype,]	0.0	2	1	1	1
114911	1710	Jagged1 a ligand	[Jagged1 a ligand]	0.0	3	1	1	1
114912	1710	limit element	[limiting element]	0.0	2	1	1	1
114913	1710	cyclophosphamide CMF	[cyclophosphamide CMF]	0.0	2	1	1	1
114914	1710	region important, to immunoglobulin promoter	[regions important, to immunoglobulin promoters]	0.0	5	1	1	1
114915	1710	oxide no	[oxide NO]	0.0	2	3	3	1
114916	1710	Ile50Val variant	[Ile50Val variant]	0.0	2	1	1	1
114917	1710	female cell	[female cells]	0.0	2	1	1	1
114918	1710	variation of glucocorticoid	[Variation of glucocorticoids]	0.0	3	1	1	1
114919	1710	role in dysregulation	[role in dysregulation]	0.0	3	1	1	1
114920	1710	short arm of chromosome 11	[short arm of chromosome 11]	0.0	5	1	1	1
114921	1710	recent clinical initiative	[recent clinical initiative]	0.0	3	1	1	1
114922	1710	functionally distinct isoform	[functionally distinct isoforms]	0.0	3	1	1	1
114923	1710	R-PK DNA fragment relative	[R-PK DNA fragment relative]	0.0	4	1	1	1
114924	1710	efficient interaction with slp-76	[efficient interaction with SLP-76]	0.0	4	1	1	1
114925	1710	host-cell transcription	[host-cell transcription]	0.0	2	1	1	1
114926	1710	potential of the lytic gene	[potential of the lytic gene]	0.0	5	1	1	1
114927	1710	glucocorticoid receptor gcR	[glucocorticoid receptors gcR]	0.0	3	1	1	1
114928	1710	electrolyte movement	[electrolyte movements]	0.0	2	2	2	1
114929	1710	reduction of ikappab-alpha of nf-kappab	[reduction of IkappaB-alpha of NF-kappaB]	0.0	5	1	1	1
114930	1710	complex MHC way	[complex MHC way]	0.0	3	1	1	1
114931	1710	maximal increase	[maximal increases]	0.0	2	1	1	1
114932	1710	zdevd-fmk	[zDEVD-fmk]	0.0	1	1	1	1
114933	1710	cellular production	[cellular production]	0.0	2	1	1	1
114934	1710	role in fibroblast	[role in fibroblasts]	0.0	3	1	1	1
114935	1710	clinical behavior	[clinical behavior]	0.0	2	1	1	1
114936	1710	cell reporter	[cell reporter]	0.0	2	1	1	1
114937	1710	patient with campomelic dysplasia	[patients with campomelic dysplasia]	0.0	4	1	1	1
114938	1710	differentiation of th cell	[differentiation of Th cells]	0.0	4	1	1	1
114939	1710	progesterone receptor cDNA probe	[progesterone receptor cDNA probe]	0.0	4	1	1	1
114940	1710	response (myd) gene	[response (MyD) genes]	0.0	3	1	1	1
114941	1710	diversification of ig gene	[diversification of Ig genes]	0.0	4	1	1	1
114942	1710	activity i.e. transactivation	[activities i.e. transactivation]	0.0	3	1	1	1
114943	1710	nf-kappab recruitment	[NF-kappaB recruitment]	0.0	2	1	1	1
114944	1710	rbp-jkappa	[RBP-Jkappa]	0.0	1	1	1	1
114945	1710	lineage requirement for expression	[lineage requirements for expression]	0.0	4	1	1	1
114946	1710	nf-kappa b p50/p65 translocation result	[NF-kappa B p50/p65 translocation results]	0.0	5	1	1	1
114947	1710	phorbol signal	[phorbol signal]	0.0	2	1	1	1
114948	1710	delicate balance	[delicate balance]	0.0	2	1	1	1
114949	1710	Escherichia coli lps micrograms/kg).	[Escherichia coli LPS micrograms/kg).]	0.0	4	1	1	1
114950	1710	coupling of jak3	[coupling of JAK3]	0.0	3	1	1	1
114951	1710	Nuclear level	[Nuclear levels]	0.0	2	1	1	1
114952	1710	effect of activator protein	[effects of activator proteins]	0.0	4	1	1	1
114953	1710	inhibition of migration of t-cell	[inhibition of migration of T-cells]	0.0	5	1	1	1
114954	1710	il-6 monoclonal antibody MoAb	[IL-6 monoclonal antibody MoAb]	0.0	4	1	1	1
114955	1710	low level of otf-2	[low levels of OTF-2]	0.0	4	1	1	1
114956	1710	icam-i gene	[ICAM-I gene]	0.0	2	1	1	1
114957	1710	(nf-e2) transcription	[(NF-E2) transcription]	0.0	2	1	1	1
114958	1710	subcytotoxic concentration	[subcytotoxic concentrations]	0.0	2	1	1	1
114959	1710	pu.1 -interaction partner	[PU.1 -interaction partner]	0.0	3	1	1	1
114960	1710	vkc for the presence	[VKC for the presence]	0.0	4	1	1	1
114961	1710	proximity at position	[proximity at position]	0.0	3	1	1	1
114962	1710	intact carboxyl-terminal segment on cd36	[intact carboxyl-terminal segment on CD36]	0.0	5	1	1	1
114963	1710	type estrogenic receptor in ovulation woman	[Type estrogenic receptors in ovulation women]	0.0	6	1	1	1
114964	1710	SLP-76 sh2 domain leukocyte protein	[SLP-76 SH2 domain leukocyte protein]	0.0	5	1	1	1
114965	1710	expression protein a stat1alpha gene	[Expression protein a STAT1alpha gene]	0.0	5	1	1	1
114966	1710	methylprednisolone in man.	[methylprednisolone in man.]	0.0	3	1	1	1
114967	1710	role in normal monocyte	[roles in normal monocytes]	0.0	4	1	1	1
114968	1710	transcriptional enhancer of interferon (ifn)-inducible	[transcriptional enhancers of interferon (IFN)-inducible]	0.0	5	1	1	1
114969	1710	25 cell carcinoma bcc use immunohistochemistry	[25 cell carcinomas BCCs using immunohistochemistry]	0.0	6	1	1	1
114970	1710	induce acute respiratory distress syndrome	[inducing acute respiratory distress syndrome]	0.0	5	1	1	1
114971	1710	dtc activity	[DTCs activities]	0.0	2	1	1	1
114972	1710	mobility along with the inability	[mobilities along with the inability]	0.0	5	1	1	1
114973	1710	cepharanthine on hiv-1 repeat LTR	[cepharanthine on HIV-1 repeat LTR]	0.0	5	1	1	1
114974	1710	and/or compound	[and/or compound]	0.0	2	1	1	1
114975	1710	ick-1	[ICK-1]	0.0	1	1	1	1
114976	1710	membrane hyperpolarization	[membrane hyperpolarization]	0.0	2	1	1	1
114977	1710	(ds) phosphorothioate oligonucleotide	[(ds) phosphorothioate oligonucleotides]	0.0	3	1	1	1
114978	1710	class negative T cell line	[class negative T cell line]	0.0	5	1	1	1
114979	1710	basis of the mitogenic effect	[basis of the mitogenic effect]	0.0	5	1	1	1
114980	1710	form of egr-1 protein	[forms of EGR-1 protein]	0.0	4	1	1	1
114981	1710	1,25-Dihydroxy	[1,25-Dihydroxy]	0.0	1	1	1	1
114982	1710	notably bacterial product	[notably bacterial products]	0.0	3	1	1	1
114983	1710	AP-1 type complex	[AP-1 type complexes]	0.0	3	1	1	1
114984	1710	potent enzyme inhibitor	[potent enzyme inhibitor]	0.0	3	1	1	1
114985	1710	domain of the interaction	[domains of the interaction]	0.0	4	1	1	1
114986	1710	interleukin-1beta mrna transcription rate	[interleukin-1beta mRNA transcription rate]	0.0	4	1	1	1
114987	1710	rna activity	[RNA activity]	0.0	2	1	1	1
114988	1710	phorbolester	[phorbolester]	0.0	1	1	1	1
114989	1710	change such as cell size increase	[changes such as cell size increase]	0.0	6	1	1	1
114990	1710	disease include asthma	[diseases including asthma]	0.0	3	1	1	1
114991	1710	MDHM elevation	[MDHM elevation]	0.0	2	1	1	1
114992	1710	aberrancy in the signal pathway important	[aberrancies in the signaling pathways important]	0.0	6	1	1	1
114993	1710	model of cd34+ hpc	[model of CD34+ HPC]	0.0	4	1	1	1
114994	1710	dosage	[dosages]	0.0	1	1	1	1
114995	1710	apparent resistance in depressive disorder	[apparent resistance in depressive disorder]	0.0	5	1	1	1
114996	1710	Epstein-Barr virus mutant	[Epstein-Barr virus mutants]	0.0	3	1	1	1
114997	1710	hypothesis of receptor-mediated effect	[hypothesis of receptor-mediated effects]	0.0	4	1	1	1
114998	1710	200 mu/l limit	[200 mU/L limit]	0.0	3	1	1	1
114999	1710	however, (66 microg/100 millileter	[However, (66 microg/100 ml]	0.0	4	1	1	1
115000	1710	induction of the pro-myelocytic leukaemia gene	[Induction of the pro-myelocytic leukaemia gene]	0.0	6	1	1	1
115001	1710	level of gene regulation,	[level of gene regulation,]	0.0	4	1	1	1
115002	1710	appearance of egr1 protein	[appearance of EGR1 protein]	0.0	4	1	1	1
115003	1710	differential inhibitory effect in bone protein-2-	[differential inhibitory effects in bone protein-2-]	0.0	6	1	1	1
115004	1710	cognate octamer motif	[cognate octamer motif]	0.0	3	1	1	1
115005	1710	f(ab')2 fragment	[F(ab')2 fragments]	0.0	2	1	1	1
115006	1710	Jurkat induction	[Jurkat induction]	0.0	2	1	1	1
115007	1710	dna-binding property of leukemia factor	[DNA-binding properties of leukemia factor]	0.0	5	1	1	1
115008	1710	contain the element	[containing the elements]	0.0	3	1	1	1
115009	1710	activator stat	[activators STATs]	0.0	2	1	1	1
115010	1710	bb-94	[BB-94]	0.0	1	1	1	1
115011	1710	vitro, six antigen EBNAs	[vitro, six antigens EBNAs]	0.0	4	1	1	1
115012	1710	evidence for lck/fyn-	[evidence for Lck/Fyn-]	0.0	3	1	1	1
115013	1710	combination of panning	[combination of panning]	0.0	3	1	1	1
115014	1710	ten volunteer	[ten volunteers]	0.0	2	1	1	1
115015	1710	il-2 concentration	[IL-2 concentration]	0.0	2	1	1	1
115016	1710	fresh cell stage	[fresh cells stage]	0.0	3	1	1	1
115017	1710	Surprisingly, expression of bhrf1	[Surprisingly, expression of BHRF1]	0.0	4	1	1	1
115018	1710	strong affinity	[strong affinity]	0.0	2	1	1	1
115019	1710	t(17;19) (q22;p13) translocation	[t(17;19) (q22;p13) translocation]	0.0	3	1	1	1
115020	1710	eventuate	[eventuating]	0.0	1	1	1	1
115021	1710	little information about the regulation	[little information about the regulation]	0.0	5	1	1	1
115022	1710	29 minor salivary gland biopsy	[29 minor salivary gland biopsies]	0.0	5	1	1	1
115023	1710	structural analysis of the rdna HZF	[structural analysis of the cDNAs HZF]	0.0	6	1	1	1
115024	1710	dna-binding activity include SP-1	[DNA-binding activity including SP-1]	0.0	4	1	1	1
115025	1710	novel loci relevant to pel	[novel loci relevant to PEL]	0.0	5	1	1	1
115026	1710	RA sensitivity of precursor cell	[RA sensitivity of precursor cells]	0.0	5	1	1	1
115027	1710	22-bp sequence	[22-bp sequence]	0.0	2	1	1	1
115028	1710	line of mouse display expression	[lines of mice displaying expression]	0.0	5	1	1	1
115029	1710	other DNA fragment pzvb10	[other DNA fragments pZVB10]	0.0	4	1	1	1
115030	1710	only side effect	[only side effects]	0.0	3	1	1	1
115031	1710	gr upregulation	[GR upregulation]	0.0	2	1	1	1
115032	1710	900 amino acid	[900 amino acids]	0.0	3	1	1	1
115033	1710	hiv LTR construct	[HIV LTR constructs]	0.0	3	1	1	1
115034	1710	distinct pattern of chromosome abnormality	[Distinct patterns of chromosome abnormalities]	0.0	5	1	1	1
115035	1710	subsequent monocytic cell adhesion	[subsequent monocytic cell adhesion]	0.0	4	1	1	1
115036	1710	transfection of different line	[transfection of different lines]	0.0	4	1	1	1
115037	1710	age-related reduction in nf-at complex	[age-related reductions in NF-AT complexes]	0.0	5	1	1	1
115038	1710	mediate dopamine responsiveness	[mediating dopamine responsiveness]	0.0	3	1	1	1
115039	1710	224 ng/mL, respectively).	[224 ng/mL, respectively).]	0.0	3	1	1	1
115040	1710	il-1ra mrna expression	[IL-1ra mRNA expression]	0.0	3	1	1	1
115041	1710	transcriptional activator property in cell	[transcriptional activator properties in cells]	0.0	5	1	1	1
115042	1710	e2f -contain dna-binding complex	[E2F -containing DNA-binding complexes]	0.0	4	1	1	1
115043	1710	intricate arrangement	[intricate arrangement]	0.0	2	1	1	1
115044	1710	Study of the function	[Studies of the function]	0.0	4	1	1	1
115045	1710	prevention through displacement	[prevention through displacement]	0.0	3	1	1	1
115046	1710	count the percentage	[counting the percentage]	0.0	3	1	1	1
115047	1710	analog of alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Analogs of alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	5	1	1	1
115048	1710	binding in unactivated extract	[binding in unactivated extracts]	0.0	4	1	1	1
115049	1710	two t-cell line	[two T-cell lines]	0.0	3	1	1	1
115050	1710	factor cell line u1	[factor cell line U1]	0.0	4	1	1	1
115051	1710	ebv-mediated immortalization	[EBV-mediated immortalization]	0.0	2	1	1	1
115052	1710	certain rearrangement	[certain rearrangements]	0.0	2	1	1	1
115053	1710	upstream NF-kappa b site	[upstream NF-kappa B site]	0.0	4	1	1	1
115054	1710	activation independent	[activation independent]	0.0	2	1	1	1
115055	1710	proliferation capacity	[proliferation capacity]	0.0	2	1	1	1
115056	1710	subunit to region	[subunits to regions]	0.0	3	1	1	1
115057	1710	fetal (gamma)	[fetal (gamma)]	0.0	2	1	1	1
115058	1710	CLL disease	[CLL disease]	0.0	2	1	1	1
115059	1710	response in the presence	[response in the presence]	0.0	4	1	1	1
115060	1710	find hlh-2 expression	[finding hLH-2 expression]	0.0	3	1	1	1
115061	1710	interaction of thymocyte with thymic cell	[interaction of thymocytes with thymic cells]	0.0	6	1	1	1
115062	1710	role in cell development	[role in cell development]	0.0	4	1	1	1
115063	1710	cell at g2, increase	[cells at G2, increase]	0.0	4	1	1	1
115064	1710	multiple member of the protein	[multiple members of the proteins]	0.0	5	1	1	1
115065	1710	extracellular matrix protein fibronectin	[extracellular matrix protein fibronectin]	0.0	4	1	1	1
115066	1710	metastasis without metastasis	[metastasis without metastasis]	0.0	3	1	1	1
115067	1710	analysis from a variety	[analysis from a variety]	0.0	4	1	1	1
115068	1710	parath	[parath]	0.0	1	1	1	1
115069	1710	mechanism-based toxicity	[mechanism-based toxicities]	0.0	2	1	1	1
115070	1710	NF-E2/AP1 motif together	[NF-E2/AP1 motifs together]	0.0	3	1	1	1
115071	1710	significance of zinc	[significance of zinc]	0.0	3	1	1	1
115072	1710	recognition of the fusion region	[recognition of the fusion region]	0.0	5	1	1	1
115073	1710	response to all analog	[response to all analogs]	0.0	4	1	1	1
115074	1710	clinical significance in patient	[clinical significance in patients]	0.0	4	1	1	1
115075	1710	importantly, testing	[Importantly, testing]	0.0	2	1	1	1
115076	1710	decline in the induction	[decline in the induction]	0.0	4	1	1	1
115077	1710	require the addition	[requiring the addition]	0.0	3	1	1	1
115078	1710	one express a pattern	[one expressing a pattern]	0.0	4	1	1	1
115079	1710	secret il-2 after stimulation	[secreting IL-2 after stimulation]	0.0	4	1	1	1
115080	1710	incubation for hour	[Incubation for hours]	0.0	3	1	1	1
115081	1710	inhibition of K+ channel	[inhibition of K+ channels]	0.0	4	1	1	1
115082	1710	il-12r beta subunit	[IL-12R beta subunit]	0.0	3	1	1	1
115083	1710	low number of positive prediction	[lower number of positive predictions]	0.0	5	1	1	1
115084	1710	affinity of nf-kappa b	[affinity of NF-kappa B]	0.0	4	1	1	1
115085	1710	CD28 up-regulation of re/ap	[CD28 up-regulation of RE/AP]	0.0	4	1	1	1
115086	1710	nm 1 alpha,25-dihydroxyvitamin D3	[nM 1 alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
115087	1710	activation by the map kinase p38	[Activation by the MAP kinase p38]	0.0	6	1	1	1
115088	1710	class II-deficient immunodeficiency	[class II-deficient immunodeficiency]	0.0	3	1	1	1
115089	1710	ic50 value for dexamethasone	[IC50 values for dexamethasone]	0.0	4	1	1	1
115090	1710	require direct interaction	[requiring direct interaction]	0.0	3	1	1	1
115091	1710	costimulation due to stabilization	[costimulation due to stabilization]	0.0	4	1	1	1
115092	1710	antigen-activated human T cell	[antigen-activated human T cells]	0.0	4	1	1	1
115093	1710	length wild-type form	[length wild-type form]	0.0	3	1	1	1
115094	1710	bind protein hxbp-1	[binding protein hXBP-1]	0.0	3	1	1	1
115095	1710	sh-group	[SH-groups]	0.0	1	1	1	1
115096	1710	T cell type pathway	[T cell Type pathway]	0.0	4	1	1	1
115097	1710	less work	[less work]	0.0	2	1	1	1
115098	1710	one cofactor BOB.1/OBF.1	[One cofactor BOB.1/OBF.1]	0.0	3	1	1	1
115099	1710	weight species	[weight species]	0.0	2	1	1	1
115100	1710	receptor complexes:	[receptor complexes:]	0.0	2	1	1	1
115101	1710	contrast to a study,	[contrast to a study,]	0.0	4	2	2	1
115102	1710	ostensible stimulation	[ostensible stimulation]	0.0	2	1	1	1
115103	1710	problem use this clonality analysis method	[problem using these clonality analysis methods]	0.0	6	1	1	1
115104	1710	production of such important mediator	[production of such important mediators]	0.0	5	1	1	1
115105	1710	kappa b-alpha proteolysis by site-specific, phosphorylation	[kappa B-alpha proteolysis by site-specific, phosphorylation]	0.0	6	1	1	1
115106	1710	two type of reactivity:	[two types of reactivity:]	0.0	4	1	1	1
115107	1710	Clinical deterioration in infection	[Clinical deterioration in infection]	0.0	4	1	1	1
115108	1710	basis of observations,	[basis of observations,]	0.0	3	1	1	1
115109	1710	many puzzle	[many puzzles]	0.0	2	1	1	1
115110	1710	gata-3 activity	[GATA-3 activity]	0.0	2	1	1	1
115111	1710	regulate the distribution monocyte-binding receptor	[regulating the distribution monocyte-binding receptors]	0.0	5	1	1	1
115112	1710	10(5)- to 10(6)-fold amplification	[10(5)- to 10(6)-fold amplification]	0.0	4	1	1	1
115113	1710	DQ 2,7	[DQ 2,7]	0.0	2	1	1	1
115114	1710	cellular gene activation in monocyte	[cellular gene activation in monocytes]	0.0	5	1	1	1
115115	1710	granulopoiesis die days.	[granulopoiesis dying days.]	0.0	3	1	1	1
115116	1710	alpha-stimulated tyrosine	[alpha-stimulated tyrosine]	0.0	2	1	1	1
115117	1710	crossreactive recognition of viral, self ligand	[Crossreactive recognition of viral, self, ligands]	0.0	6	1	1	1
115118	1710	level relevant	[levels relevant]	0.0	2	1	1	1
115119	1710	contain the SRF	[containing the SRF]	0.0	3	1	1	1
115120	1710	level of constitutive hepor expression	[levels of constitutive hEpoR expression]	0.0	5	1	1	1
115121	1710	modulation in cell such as monocyte	[modulation in cells such as monocytes]	0.0	6	1	1	1
115122	1710	AML1 with BSAP	[AML1 with BSAP]	0.0	3	1	1	1
115123	1710	stimulation on immunogenic malignant melanoma	[Stimulation on immunogenic malignant melanomas]	0.0	5	1	1	1
115124	1710	remission in patient	[remission in patients]	0.0	3	1	1	1
115125	1710	p50/p65 Rel a form	[p50/p65 Rel A form]	0.0	4	1	1	1
115126	1710	reduce kv1.3 component current	[reducing Kv1.3 components current]	0.0	4	1	1	1
115127	1710	mutation cluster in the 5'-regulatory region	[mutations clustering in the 5'-regulatory region]	0.0	6	1	1	1
115128	1710	multiple element within this region,	[multiple elements within this region,]	0.0	5	1	1	1
115129	1710	80.2 (p less than p 0.01	[80.2 (P less than P 0.01]	0.0	6	1	1	1
115130	1710	expression of the transcription factor Oct2	[expression of the transcription factor Oct2]	0.0	6	1	1	1
115131	1710	XP symptom	[XP symptoms]	0.0	2	1	1	1
115132	1710	protein coding exon	[protein coding exons]	0.0	3	1	1	1
115133	1710	SSI/CIS	[SSI/CIS]	0.0	1	1	1	1
115134	1710	cd14 activation of transcription factor creb/atf	[CD14 activation of transcription factors CREB/ATF]	0.0	6	1	1	1
115135	1710	appearance of a factor bind	[appearance of an factor binding]	0.0	5	1	1	1
115136	1710	jy25 cell	[JY25 cells]	0.0	2	1	1	1
115137	1710	Random migration	[Random migration]	0.0	2	1	1	1
115138	1710	10,11-dihydroxyaporphine	[10,11-dihydroxyaporphine]	0.0	1	1	1	1
115139	1710	cis-acting negative regulatory effect	[cis-acting negative regulatory effect]	0.0	4	1	1	1
115140	1710	analysis of mutation in lymphoid cell	[analyses of mutations in lymphoid cells]	0.0	6	1	1	1
115141	1710	proximal functional promoter region -620	[proximal functional promoter region -620]	0.0	5	1	1	1
115142	1710	activation of peripheral blood T lymphoblast	[activation of peripheral blood T lymphoblasts]	0.0	6	1	1	1
115143	1710	include CBF	[including CBF]	0.0	2	1	1	1
115144	1710	clinical implication	[clinical implications]	0.0	2	1	1	1
115145	1710	role of bsap pax-5	[role of BSAP Pax-5]	0.0	4	1	1	1
115146	1710	bhlh gene expression	[bHLH gene expression]	0.0	3	1	1	1
115147	1710	e1a- adenovirus (ad) type	[E1a- adenovirus (Ad) type]	0.0	4	1	1	1
115148	1710	icr27tk.3 cell contain glucocorticoid receptor	[ICR27TK.3 cells containing glucocorticoid receptors]	0.0	5	1	1	1
115149	1710	property regard phosphorylation in response	[properties regarding phosphorylation in response]	0.0	5	1	1	1
115150	1710	ad of camp activity	[AD of cAMP activity]	0.0	4	1	1	1
115151	1710	enhancer inactivity	[enhancer inactivity]	0.0	2	1	1	1
115152	1710	FK506.FKBP12	[FK506.FKBP12]	0.0	1	1	1	1
115153	1710	129 breast cancer	[129 breast cancers]	0.0	3	1	1	1
115154	1710	responsiveness in vitro	[responsiveness in vitro]	0.0	3	1	1	1
115155	1710	AM580 a derivative of retinoic acid	[AM580 a derivative of retinoic acid]	0.0	6	1	1	1
115156	1710	bacterial actin motility	[bacterial actin motility]	0.0	3	1	1	1
115157	1710	lymphocyte predominance subtype	[lymphocyte predominance subtype]	0.0	3	1	1	1
115158	1710	labeling of PML	[labeling of PML]	0.0	3	1	1	1
115159	1710	tissue use the LCK promoter	[tissues using the LCK promoter]	0.0	5	1	1	1
115160	1710	immunosuppressive compound in vitro.	[immunosuppressive compound in vitro.]	0.0	4	1	1	1
115161	1710	plasma factor	[plasma Factor]	0.0	2	1	1	1
115162	1710	average of nucleotide change	[average of nucleotide changes]	0.0	4	1	1	1
115163	1710	interferon gamma a potent activator	[interferon gamma a potent activator]	0.0	5	1	1	1
115164	1710	XISTE- ring chromosome	[XISTE- ring chromosomes]	0.0	3	1	1	1
115165	1710	Ap2 binding	[Ap2 binding]	0.0	2	1	1	1
115166	1710	alpha,25-OH)2D3	[alpha,25-OH)2D3]	0.0	1	1	1	1
115167	1710	group of chemical	[group of chemicals]	0.0	3	1	1	1
115168	1710	encode a transcriptional regulator of differentiation	[encoding a transcriptional regulator of differentiation]	0.0	6	1	1	1
115169	1710	peripheral blood-derived monocyte	[peripheral blood-derived monocytes]	0.0	3	1	1	1
115170	1710	moreover, TNF-alpha hiv-1 long repeat transcription	[Moreover, TNF-alpha HIV-1 long repeat transcription]	0.0	6	1	1	1
115171	1710	mtbe induction	[MTBE induction]	0.0	2	1	1	1
115172	1710	p50 on tissue oligonucleotide	[p50 on tissue oligonucleotide]	0.0	4	1	1	1
115173	1710	quantitation of beta triiodothyronine receptor mrna	[Quantitation of beta triiodothyronine receptor mRNA]	0.0	6	1	1	1
115174	1710	relation to prognostic features: implications.	[relations to prognostic features: implications.]	0.0	5	1	1	1
115175	1710	T lymphocyte against epitope	[T lymphocytes against epitopes]	0.0	4	1	1	1
115176	1710	monocyte with ifn-beta	[monocytes with IFN-beta]	0.0	3	1	1	1
115177	1710	abundant activity of nuclear extract	[abundant activity of nuclear extracts]	0.0	5	1	1	1
115178	1710	marker of osteoclast	[markers of osteoclasts]	0.0	3	1	1	1
115179	1710	1 alpha	[1 alpha]	0.0	2	1	1	1
115180	1710	minimal inhibition	[minimal inhibition]	0.0	2	1	1	1
115181	1710	promoter with	[promoters with]	0.0	2	1	1	1
115182	1710	5637 cell line	[5637 cell line]	0.0	3	1	1	1
115183	1710	potent vp16 viral transactivation domain	[potent VP16 viral transactivation domains]	0.0	5	1	1	1
115184	1710	phase s	[phase S]	0.0	2	1	1	1
115185	1710	factor-mu regulator	[factor-mu regulator]	0.0	2	1	1	1
115186	1710	homology between this two gene	[homologies between these two genes]	0.0	5	1	1	1
115187	1710	X inactivation analysis in a female	[X inactivation analysis in a female]	0.0	6	1	1	1
115188	1710	cd4+ cell count 0.05)	[CD4+ cell counts 0.05)]	0.0	4	1	1	1
115189	1710	treatment of diseases,	[treatment of diseases,]	0.0	3	1	1	1
115190	1710	presence of a control element	[presence of a control element]	0.0	5	1	1	1
115191	1710	2 -stat	[2 -STAT]	0.0	2	1	1	1
115192	1710	promyelocytic hl60 cell	[promyelocytic HL60 cells]	0.0	3	1	1	1
115193	1710	region between -201	[regions between -201]	0.0	3	1	1	1
115194	1710	response T cell line	[responses T cell lines]	0.0	4	1	1	1
115195	1710	Paternal expression in human fibroblast	[Paternal expression in human fibroblasts]	0.0	5	1	1	1
115196	1710	synergistic action of atra	[synergistic actions of ATRA]	0.0	4	1	1	1
115197	1710	many environmental factors, in proinflammatory cytokine	[Many environmental factors, in proinflammatory cytokines]	0.0	6	1	1	1
115198	1710	0.05, p 0.01	[0.05, P 0.01]	0.0	3	1	1	1
115199	1710	interaction between cell-specific coactivator	[interactions between cell-specific coactivators]	0.0	4	1	1	1
115200	1710	NKL cell line	[NKL cell line]	0.0	3	1	1	1
115201	1710	represent tumor defense	[representing tumor defense]	0.0	3	1	1	1
115202	1710	large region nucleotide	[large region nucleotides]	0.0	3	1	1	1
115203	1710	40-kd tax protein	[40-kd Tax protein]	0.0	3	1	1	1
115204	1710	skin cancer	[skin cancer]	0.0	2	3	3	1
115205	1710	induction of the promoter	[induction of the promoter]	0.0	4	1	1	1
115206	1710	problem of the interaction	[problem of the interactions]	0.0	4	1	1	1
115207	1710	NK cell development	[NK cell development]	0.0	3	1	1	1
115208	1710	suggest independent of p23	[suggesting independent of p23]	0.0	4	1	1	1
115209	1710	potent presenter of antigen	[potent presenters of antigen]	0.0	4	1	1	1
115210	1710	regulation of T lymphocyte development	[regulation of T lymphocyte development]	0.0	5	1	1	1
115211	1710	independent cloning	[independent cloning]	0.0	2	1	1	1
115212	1710	second E2F-I bind protein, dpii,	[second E2F-I binding protein, DP-I,]	0.0	5	1	1	1
115213	1710	lymphoid gene expression	[Lymphoid gene expression]	0.0	3	1	1	1
115214	1710	human gene within the nucleus	[human genes within the nucleus]	0.0	5	1	1	1
115215	1710	b cell in the thymus	[B cells in the thymus]	0.0	5	1	1	1
115216	1710	STAT1 import in T lymphocyte	[STAT1 import in T lymphocytes]	0.0	5	1	1	1
115217	1710	drift from latency latency iii	[drift from latency latency III]	0.0	5	1	1	1
115218	1710	astrocyte from mouse	[astrocytes from mice]	0.0	3	1	1	1
115219	1710	time course analysis	[time course analysis]	0.0	3	1	1	1
115220	1710	base pair cis-acting regulatory element	[base pair cis-acting regulatory element]	0.0	5	1	1	1
115221	1710	role of p70(s6k) in, il-2	[role of p70(s6k) in, IL-2]	0.0	5	1	1	1
115222	1710	interaction with RXR	[interaction with RXR]	0.0	3	1	1	1
115223	1710	control in Epstein-Barr virus	[control in Epstein-Barr virus]	0.0	4	1	1	1
115224	1710	expression of early gene	[expression of early genes]	0.0	4	1	1	1
115225	1710	transgenic mouse display expression	[transgenic mice displaying expression]	0.0	4	1	1	1
115226	1710	induction expression in monocytic cell	[Induction expression in monocytic cells]	0.0	5	1	1	1
115227	1710	30 to 600 minute	[30 to 600 minutes]	0.0	4	1	1	1
115228	1710	type peptide	[type peptides]	0.0	2	1	1	1
115229	1710	characteristic pattern	[characteristic pattern]	0.0	2	1	1	1
115230	1710	artificially constructed, 60-kda precursor	[artificially constructed, 60-kDa precursor]	0.0	4	1	1	1
115231	1710	(starting	[(starting]	0.0	1	1	1	1
115232	1710	other inflammatory disease	[other inflammatory diseases]	0.0	3	1	1	1
115233	1710	short treatment	[short treatment]	0.0	2	1	1	1
115234	1710	proportion of double-positive cell	[proportion of double-positive cells]	0.0	4	1	1	1
115235	1710	purpose: influence	[PURPOSE: influences]	0.0	2	1	1	1
115236	1710	induction include enhancement	[induction including enhancement]	0.0	3	1	1	1
115237	1710	aml-1 protein in assay	[AML-1 proteins in assays]	0.0	4	1	1	1
115238	1710	lack in this u937-derived clone	[lack in these U937-derived clones]	0.0	5	1	1	1
115239	1710	transcription of the tnf-alpha gene	[transcription of the TNF-alpha gene]	0.0	5	1	1	1
115240	1710	leukotriene B4 a proinflammatory mediator	[leukotriene B4 a proinflammatory mediator]	0.0	5	1	1	1
115241	1710	However, inhibition	[However, inhibition]	0.0	2	1	1	1
115242	1710	2 translocations,	[2 translocations,]	0.0	2	1	1	1
115243	1710	affinity of NF-kappa b	[affinity of NF-kappa B]	0.0	4	1	1	1
115244	1710	1 tax -responsive element 1	[1 Tax -responsive element 1]	0.0	5	1	1	1
115245	1710	spacing between the CRE	[spacing between the CRE]	0.0	4	1	1	1
115246	1710	potential in pml-rar -contain cell	[potential in PML-RAR -containing cells]	0.0	5	1	1	1
115247	1710	use ubiquitinylating enzyme	[using ubiquitinylating enzymes]	0.0	3	1	1	1
115248	1710	West African population	[West African populations]	0.0	3	1	1	1
115249	1710	structure with domain for activation	[structure with domains for activation]	0.0	5	1	1	1
115250	1710	encode subunit	[encoding subunits]	0.0	2	1	1	1
115251	1710	SLP-76 leukocyte protein kda)	[SLP-76 leukocyte protein kDa)]	0.0	4	1	1	1
115252	1710	"pure" early progenitor	["pure" early progenitors]	0.0	3	1	1	1
115253	1710	fluticasone propionate fp for weeks.	[fluticasone propionate FP for weeks.]	0.0	5	1	1	1
115254	1710	variation in lighting	[variations in lighting]	0.0	3	1	1	1
115255	1710	oxidoreductive regulation of factor kappa b	[Oxidoreductive regulation of factor kappa B]	0.0	6	1	1	1
115256	1710	four patient with 2 micrograms/day	[four patients with 2 micrograms/day]	0.0	5	1	1	1
115257	1710	binding factor in the promoter	[binding factors in the promoter]	0.0	5	1	1	1
115258	1710	transcriptional regulation of interleukin gene	[transcriptional regulation of interleukin gene]	0.0	5	1	1	1
115259	1710	concomitant elevation	[concomitant elevations]	0.0	2	1	1	1
115260	1710	relation to receptor function	[relation to receptor function]	0.0	4	1	1	1
115261	1710	status change	[status changes]	0.0	2	1	1	1
115262	1710	other nuclear hormone receptor	[other nuclear hormone receptors]	0.0	4	1	1	1
115263	1710	potential delta	[potential delta]	0.0	2	1	1	1
115264	1710	maintain a viral load	[maintaining a viral load]	0.0	4	1	1	1
115265	1710	hypermutation in lymphoma	[hypermutation in lymphoma]	0.0	3	1	1	1
115266	1710	region -73	[region -73]	0.0	2	1	1	1
115267	1710	protein kinase hematopoietic tyrosine phosphatase	[protein kinase hematopoietic tyrosine phosphatase]	0.0	5	1	1	1
115268	1710	many effect of lipopolysaccharide lps	[Many effects of lipopolysaccharide LPS]	0.0	5	1	1	1
115269	1710	domain of the p85 subunit	[domains of the p85 subunit]	0.0	5	1	1	1
115270	1710	replication deficient	[replication deficient]	0.0	2	1	1	1
115271	1710	region in the CD4 promoter	[regions in the CD4 promoter]	0.0	5	1	1	1
115272	1710	primate siv infection	[primate SIV infection]	0.0	3	1	1	1
115273	1710	uptake with advanced renal failure	[uptake with advanced renal failure]	0.0	5	1	1	1
115274	1710	BRCA1 mrna	[BRCA1 mRNA]	0.0	2	1	1	1
115275	1710	human cord T	[human cord T]	0.0	3	1	1	1
115276	1710	response to level equivalent	[response to levels equivalent]	0.0	4	1	1	1
115277	1710	N9 murine cell line	[N9 murine cell line]	0.0	4	1	1	1
115278	1710	platelet-activate factor to m rapid elevation	[platelet-activating factor to M rapid elevation]	0.0	6	1	1	1
115279	1710	putative suppressor gene nm23-h1	[putative suppressor genes nm23-H1]	0.0	4	1	1	1
115280	1710	regulatory role for gata-2	[regulatory role for GATA-2]	0.0	4	1	1	1
115281	1710	kd-value of nm	[Kd-values of nM]	0.0	3	1	1	1
115282	1710	isolation for 42 zinc finger protein	[Isolation for 42 zinc finger proteins]	0.0	6	1	1	1
115283	1710	phosphorylation of linker protein	[phosphorylation of linker proteins]	0.0	4	1	1	1
115284	1710	affinity in mnc	[affinity in MNC]	0.0	3	1	1	1
115285	1710	short course	[short course]	0.0	2	1	1	1
115286	1710	rest human lymphocyte from blood	[resting human lymphocytes from blood]	0.0	5	1	1	1
115287	1710	D 4816 to 4851	[D 4816 to 4851]	0.0	4	1	1	1
115288	1710	consensus response element	[consensus response elements]	0.0	3	1	1	1
115289	1710	such defect in t-cell activation	[such defects in T-cell activation]	0.0	5	1	1	1
115290	1710	drug-free patient with bipolar disorder	[drug-free patients with bipolar disorder]	0.0	5	1	1	1
115291	1710	breast tumor lymphocyte	[breast tumor lymphocytes]	0.0	3	1	1	1
115292	1710	Ca2+ regulatory element obligatory	[Ca2+ regulatory element obligatory]	0.0	4	1	1	1
115293	1710	2 expression in t-cell lymphoblastic leukemia	[2 expression in T-cell lymphoblastic leukemia]	0.0	6	1	1	1
115294	1710	digoxigenin-labeled DNA probe	[digoxigenin-labeled DNA probe]	0.0	3	1	1	1
115295	1710	tumor ag in cancer	[tumor Ag in cancers]	0.0	4	1	1	1
115296	1710	pathway as the simple way	[pathway as the simplest way]	0.0	5	1	1	1
115297	1710	acute disease	[acute disease]	0.0	2	1	1	1
115298	1710	mechanism of antiandrogen action change	[Mechanism of antiandrogen action changes]	0.0	5	1	1	1
115299	1710	fibrosarcoma 8, histiocytoma rhabdomyosarcoma	[fibrosarcoma 8, histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
115300	1710	antigens, u1rnp	[antigens, U1RNP]	0.0	2	1	1	1
115301	1710	fmol/million cells; p 0.01)	[fmol/million cells; P 0.01)]	0.0	4	1	1	1
115302	1710	use a run-on assay	[Using a run-on assay]	0.0	4	1	1	1
115303	1710	tax-transformed fibroblast	[Tax-transformed fibroblasts]	0.0	2	1	1	1
115304	1710	step elucidate the function	[step elucidating the function]	0.0	4	1	1	1
115305	1710	herpesvirus strain	[herpesvirus strains]	0.0	2	1	1	1
115306	1710	susceptibility to cerebral malaria	[susceptibility to cerebral malaria]	0.0	4	1	1	1
115307	1710	hematopoietic-specific dnase I site	[hematopoietic-specific DNase I site]	0.0	4	1	1	1
115308	1710	responsive element ionophore a23187	[responsive element ionophore A23187]	0.0	4	1	1	1
115309	1710	virus-immortalized human b cell	[virus-immortalized human B cells]	0.0	4	1	1	1
115310	1710	(pparalpha)	[(PPARalpha)]	0.0	1	1	1	1
115311	1710	rest (ccrf-cem) t-cell line	[resting (CCRF-CEM) T-cell lines]	0.0	4	1	1	1
115312	1710	patient subsequently respond ifn-alpha	[patients subsequently responding IFN-alpha]	0.0	4	1	1	1
115313	1710	adhesion of monocytoid u937 cell	[Adhesion of monocytoid U937 cells]	0.0	5	1	1	1
115314	1710	123 staining	[123 staining]	0.0	2	1	1	1
115315	1710	probe, nuclear extract	[probe, nuclear extracts]	0.0	3	1	1	1
115316	1710	polyclonal etiology	[polyclonal etiology]	0.0	2	1	1	1
115317	1710	(cho)	[(CHO)]	0.0	1	2	2	1
115318	1710	category of factor	[categories of factors]	0.0	3	1	1	1
115319	1710	express the CD4 receptor	[expressing the CD4 receptor]	0.0	4	1	1	1
115320	1710	introduction to lineage commitment	[introduction to lineage commitment]	0.0	4	1	1	1
115321	1710	transcription site	[transcription site]	0.0	2	1	1	1
115322	1710	kinetic upon il-2	[kinetics upon IL-2]	0.0	3	1	1	1
115323	1710	extracellular-regulated kinase	[Extracellular-regulated kinase]	0.0	2	1	1	1
115324	1710	elective termination	[elective termination]	0.0	2	1	1	1
115325	1710	identify novel agents,	[identifying novel agents,]	0.0	3	1	1	1
115326	1710	significantly high (p<.001) in euthymic patient	[significantly higher (P<.001) in euthymic patients]	0.0	6	1	1	1
115327	1710	differentiation/retrodifferentiation	[differentiation/retrodifferentiation]	0.0	1	1	1	1
115328	1710	two cysteine region LIM domain	[two cysteine regions LIM domains]	0.0	5	1	1	1
115329	1710	Effect of overexpression	[Effects of overexpression]	0.0	3	1	1	1
115330	1710	strong association between oncogene amplification	[strong association between oncogene amplification]	0.0	5	1	1	1
115331	1710	namely the zymogen plasma factor	[namely the zymogen plasma factors]	0.0	5	1	1	1
115332	1710	protein of native molecular weight	[proteins of native molecular weights]	0.0	5	1	1	1
115333	1710	mouse tis11	[mouse TIS11]	0.0	2	1	1	1
115334	1710	synthase gene in response	[synthase genes in response]	0.0	4	1	1	1
115335	1710	nuclear T cell	[nuclear T cells]	0.0	3	1	1	1
115336	1710	response to glycoprotein b	[responses to glycoprotein B]	0.0	4	1	1	1
115337	1710	plasmid contain 151 bp	[Plasmids containing 151 bp]	0.0	4	1	1	1
115338	1710	cytokine mrna expression in monocyte	[cytokine mRNA expression in monocytes]	0.0	5	1	1	1
115339	1710	bp lps response element	[bp LPS Response Element]	0.0	4	1	1	1
115340	1710	AMP signal pathway	[AMP signaling pathway]	0.0	3	1	1	1
115341	1710	molecular mechanism of anoxia/reoxygenation-induced neutrophil adherence	[Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence]	0.0	6	1	1	1
115342	1710	negative effect on the hiv-1 promoter	[negative effects on the HIV-1 promoters]	0.0	6	1	1	1
115343	1710	impact of platelet-activate factor	[impact of platelet-activating factor]	0.0	4	1	1	1
115344	1710	proliferative samples, activity	[proliferative samples, activity]	0.0	3	1	1	1
115345	1710	ninety-seven percent	[Ninety-seven percent]	0.0	2	1	1	1
115346	1710	specific gene activation	[specific gene activation]	0.0	3	1	1	1
115347	1710	differential modification	[differential modification]	0.0	2	1	1	1
115348	1710	monocyte peptide-1 a chemokine important	[monocyte peptide-1 a chemokine important]	0.0	5	1	1	1
115349	1710	myelopoiesis due to pml/raralpha expression	[myelopoiesis due to PML/RARalpha expression]	0.0	5	1	1	1
115350	1710	frequent hypermutation in follicular lymphoma	[frequent hypermutation in follicular lymphoma]	0.0	5	1	1	1
115351	1710	Erythropoietin the primary regulator	[Erythropoietin the primary regulator]	0.0	4	1	1	1
115352	1710	h in HL60	[h in HL60]	0.0	3	1	1	1
115353	1710	T cell product	[T cell products]	0.0	3	1	1	1
115354	1710	Alzheimer's	[Alzheimer's]	0.0	1	1	1	1
115355	1710	instillation of IL-6 alone into rat	[instillation of IL-6 alone into rats]	0.0	6	1	1	1
115356	1710	target for this hormone	[targets for this hormone]	0.0	4	1	1	1
115357	1710	csf-1 2M-1 cell	[CSF-1 2M-1 cells]	0.0	3	1	1	1
115358	1710	three candidate gene factor 3 beta	[three candidate genes factor 3 beta]	0.0	6	1	1	1
115359	1710	positive-acting factor	[positive-acting factor]	0.0	2	1	1	1
115360	1710	two 9-bp motif	[two 9-bp motifs]	0.0	3	1	1	1
115361	1710	such as the receptor alpha-chain gene	[such as the receptor alpha-chain gene]	0.0	6	1	1	1
115362	1710	occur in response to signal transduction	[occurring in response to signal transduction]	0.0	6	1	1	1
115363	1710	prolactin gene transcription	[prolactin gene transcription]	0.0	3	1	1	1
115364	1710	EBV gene product	[EBV gene products]	0.0	3	1	1	1
115365	1710	concentration of mp of ng/ml	[concentrations of MP of ng/ml]	0.0	5	1	1	1
115366	1710	increase exercise to maximal	[increasing exercise to maximal]	0.0	4	1	1	1
115367	1710	particular role	[particular role]	0.0	2	1	1	1
115368	1710	kappab nf-kappab	[kappaB NF-kappaB]	0.0	2	1	1	1
115369	1710	aging process	[aging process]	0.0	2	1	1	1
115370	1710	(except in one patient	[(except in one patient]	0.0	4	1	1	1
115371	1710	jr-st	[JR-St]	0.0	1	1	1	1
115372	1710	tal-1 expression in hematopoietic cell	[tal-1 expression in hematopoietic cells]	0.0	5	1	1	1
115373	1710	expression in vivo	[expression in vivo]	0.0	3	1	1	1
115374	1710	endogenous gc production	[endogenous GC production]	0.0	3	1	1	1
115375	1710	trigger of hla class antigen (p	[Triggering of HLA class antigens (P]	0.0	6	1	1	1
115376	1710	snrna gene	[snRNA genes]	0.0	2	1	1	1
115377	1710	bind calcineurin, a phosphatase	[binding calcineurin, a phosphatase]	0.0	4	1	1	1
115378	1710	use cd45- variant	[Using CD45- variants]	0.0	3	1	1	1
115379	1710	BHA a antioxidant	[BHA a antioxidant]	0.0	3	1	1	1
115380	1710	treatment of umbilical vein cell monolayer	[Treatment of umbilical vein cell monolayers]	0.0	6	1	1	1
115381	1710	major histocompatibility class transactivator	[major histocompatibility class transactivator]	0.0	4	1	1	1
115382	1710	gene expression of several gene	[gene expression of several genes]	0.0	5	1	1	1
115383	1710	tat single-chain antibody intrabody	[Tat single-chain antibody intrabody]	0.0	4	1	1	1
115384	1710	(20 ng/ml)	[(20 ng/ml)]	0.0	2	1	1	1
115385	1710	excess of mineralocorticoid	[excess of mineralocorticoids]	0.0	3	1	1	1
115386	1710	cd3-cd16+ killer cell	[CD3-CD16+ killer cells]	0.0	3	1	1	1
115387	1710	mutant line	[mutant line]	0.0	2	1	1	1
115388	1710	two functional factor kB element	[two functional factor kB elements]	0.0	5	1	1	1
115389	1710	return to baseline	[returning to baseline]	0.0	3	1	1	1
115390	1710	activation of distinct factor	[activation of distinct factors]	0.0	4	1	1	1
115391	1710	evaluate respiratory epithelium of normal	[evaluating respiratory epithelium of normals]	0.0	5	1	1	1
115392	1710	level of cell surface mu chain	[levels of cell surface mu chain]	0.0	6	1	1	1
115393	1710	Appraisal of potential index	[Appraisal of potential index]	0.0	4	1	1	1
115394	1710	thyroid hormone responsiveness	[thyroid hormone responsiveness]	0.0	3	1	1	1
115395	1710	sh2 association with CD28	[SH2 association with CD28]	0.0	4	1	1	1
115396	1710	E-box-binding repressor by protein	[E-box-binding repressor by proteins]	0.0	4	1	1	1
115397	1710	significant increase from asthmatic patient	[significant increase from asthmatic patients]	0.0	5	1	1	1
115398	1710	cell to adverse condition	[cells to adverse conditions]	0.0	4	1	1	1
115399	1710	direct analysis	[Direct analysis]	0.0	2	2	2	1
115400	1710	uninduced extract,	[uninduced extract,]	0.0	2	1	1	1
115401	1710	low sp1 activity	[low SP1 activity]	0.0	3	1	1	1
115402	1710	pd-c hydrogenation of 3,21-diacetoxy-5	[Pd-C hydrogenation of 3,21-diacetoxy-5]	0.0	4	1	1	1
115403	1710	region important, respectively,	[regions important, respectively,]	0.0	3	1	1	1
115404	1710	cellular fraction	[cellular fractions]	0.0	2	1	1	1
115405	1710	leukocyte of healthy donor	[leukocytes of healthy donors]	0.0	4	1	1	1
115406	1710	hiv long repeat activity	[HIV long repeat activity]	0.0	4	1	1	1
115407	1710	prevent apoptosis of cell	[preventing apoptosis of cells]	0.0	4	1	1	1
115408	1710	human mineralocorticoid receptor domain	[human mineralocorticoid receptor domain]	0.0	4	1	1	1
115409	1710	overexpression of ZEBRA,	[Overexpression of ZEBRA,]	0.0	3	1	1	1
115410	1710	time point P;	[time points h;]	0.0	3	1	1	1
115411	1710	glycemic control	[glycemic control]	0.0	2	1	1	1
115412	1710	Flow cell sorting of bone marrow	[Flow cell sorting of bone marrow]	0.0	6	1	1	1
115413	1710	possible killer population in the bm	[possible killer populations in the BM]	0.0	6	1	1	1
115414	1710	t4 FT4	[T4 FT4]	0.0	2	1	1	1
115415	1710	Differential nuclear localization	[Differential nuclear localization]	0.0	3	1	1	1
115416	1710	partial responsiveness	[partial responsiveness]	0.0	2	1	1	1
115417	1710	development of new agent	[development of new agents]	0.0	4	1	1	1
115418	1710	isoforms, a form, stat3beta	[isoforms, a form, Stat3beta]	0.0	4	1	1	1
115419	1710	homodimerization of chimeric surface receptor	[homodimerization of chimeric surface receptors]	0.0	5	1	1	1
115420	1710	calcitropic effect of dioxyvit	[calcitropic effect of dioxyvit]	0.0	4	1	1	1
115421	1710	interaction implication for NF-kappa b	[Interaction implications for NF-kappa B]	0.0	5	1	1	1
115422	1710	(gc) b-cell	[(GC) B-cells]	0.0	2	1	1	1
115423	1710	interleukin-2 a cytokine facilitate progression	[interleukin-2 a cytokine facilitating progression]	0.0	5	1	1	1
115424	1710	surprisingly high capacity NF-kappaB	[surprisingly high capacity NF-kappaB]	0.0	4	1	1	1
115425	1710	Dexamethasone a hormone	[Dexamethasone a hormone]	0.0	3	1	1	1
115426	1710	mip-1alpha expression	[MIP-1alpha expression]	0.0	2	1	1	1
115427	1710	p50 DNA	[p50 DNA]	0.0	2	3	3	1
115428	1710	J.M.Hardwick,	[J.M.Hardwick,]	0.0	1	1	1	1
115429	1710	HLA Class ii	[HLA Class II]	0.0	3	1	1	1
115430	1710	kinase ERK in human monocyte	[kinase ERK in human monocytes]	0.0	5	1	1	1
115431	1710	tend	[tending]	0.0	1	1	1	1
115432	1710	/beta-induced tyrosine phosphorylation	[/beta-induced tyrosine phosphorylation]	0.0	3	1	1	1
115433	1710	delineate the role in condition	[delineating the roles in conditions]	0.0	5	1	1	1
115434	1710	anti-ERK antibody	[anti-ERK antibodies]	0.0	2	1	1	1
115435	1710	2 subunit	[2 subunit]	0.0	2	1	1	1
115436	1710	subunit of mass (50k)	[subunits of mass (50K)]	0.0	4	1	1	1
115437	1710	htlv-i retroviruse	[HTLV-I retroviruses]	0.0	2	1	1	1
115438	1710	inducer of NF-kappaB	[inducer of NF-kappaB]	0.0	3	1	1	1
115439	1710	reporter gata-1/lacz	[reporter GATA-1/lacZ]	0.0	2	1	1	1
115440	1710	analysis factor of T cell	[analysis factor of T cells]	0.0	5	1	1	1
115441	1710	induction by hiv type infection	[Induction by HIV type infection]	0.0	5	1	1	1
115442	1710	rare DNA variation	[rare DNA variations]	0.0	3	1	1	1
115443	1710	spatial distribution of human gene	[spatial distribution of human genes]	0.0	5	1	1	1
115444	1710	bursal b	[bursal B]	0.0	2	1	1	1
115445	1710	lack fresh antigen-presenting cell	[lacking fresh antigen-presenting cells]	0.0	4	1	1	1
115446	1710	Rel transcription	[Rel transcription]	0.0	2	1	1	1
115447	1710	diversification of a number of protein	[diversification of a number of proteins]	0.0	6	1	1	1
115448	1710	physiological concentration mol/L)	[physiological concentration mol/L)]	0.0	3	1	1	1
115449	1710	metabolite more polar than 135(oh)2d3	[metabolites more polar than 1,25(OH)2D3]	0.0	5	1	1	1
115450	1710	anti-cd3/ PMA T cell	[anti-CD3/ PMA T cells]	0.0	4	1	1	1
115451	1710	ef1 activity in cell	[EF1 activity in cells]	0.0	4	1	1	1
115452	1710	-regulatory	[-regulatory]	0.0	1	1	1	1
115453	1710	manipulation of interaction	[manipulation of interactions]	0.0	3	1	1	1
115454	1710	lytic reactivity as high	[lytic reactivities as high]	0.0	4	1	1	1
115455	1710	deletion alone of p16	[deletion alone of p16]	0.0	4	1	1	1
115456	1710	clear difference	[clear difference]	0.0	2	1	1	1
115457	1710	three form of (free) e2f	[three forms of (free) E2F]	0.0	5	1	1	1
115458	1710	unidentified ets-like factor present	[unidentified ETS-like factors present]	0.0	4	1	1	1
115459	1710	isolate of 17 individual	[isolates of 17 individuals]	0.0	4	1	1	1
115460	1710	level of nf-kappab activity	[level of NF-kappaB activity]	0.0	4	1	1	1
115461	1710	syncytium-forming capacity of cell	[syncytium-forming capacity of cells]	0.0	4	1	1	1
115462	1710	only in subset	[only in subsets]	0.0	3	1	1	1
115463	1710	3/4 b-cell	[3/4 B-cell]	0.0	2	2	2	1
115464	1710	effect of mpl in comparison	[effect of MPL in comparison]	0.0	5	1	1	1
115465	1710	aetiology of endometriosis	[aetiology of endometriosis]	0.0	3	1	1	1
115466	1710	multiple substrate in cell	[multiple substrates in cells]	0.0	4	1	1	1
115467	1710	extra-renal, cell	[extra-renal, cells]	0.0	2	1	1	1
115468	1710	Deoxycorticosterone	[Deoxycorticosterone]	0.0	1	1	1	1
115469	1710	langerhan	[Langerhans]	0.0	1	1	1	1
115470	1710	microtubule mediate	[Microtubules mediate]	0.0	2	1	1	1
115471	1710	circulate leukocyte of healthy donor	[circulating leukocytes of healthy donors]	0.0	5	1	1	1
115472	1710	heavy chain class switch recombination	[heavy chain class switch recombination]	0.0	5	1	1	1
115473	1710	several cytokine receptor genes,	[several cytokine receptor genes,]	0.0	4	1	1	1
115474	1710	result, ca2+ signal	[result, Ca2+ signaling]	0.0	3	1	1	1
115475	1710	lymphoma, cell" type	[lymphoma, cell" type]	0.0	3	1	1	1
115476	1710	coordination of the immune response	[Coordination of the immune response]	0.0	5	1	1	1
115477	1710	two nuclear protein nf-kappa b	[two nuclear proteins NF-kappa B]	0.0	5	1	1	1
115478	1710	total lack signal transducer	[total lack signal transducer]	0.0	4	1	1	1
115479	1710	nt3r value	[NT3R values]	0.0	2	1	1	1
115480	1710	high relative affinity	[higher relative affinity]	0.0	3	1	1	1
115481	1710	risk control	[risk controls]	0.0	2	1	1	1
115482	1710	such as ap-1 activator protein-1	[such as AP-1 activator protein-1]	0.0	5	1	1	1
115483	1710	mild-moderate renal insufficiency M-CRF	[mild-moderate renal insufficiency M-CRF]	0.0	4	1	1	1
115484	1710	80.2 15.5 (p less than p	[80.2 15.5 (P less than P]	0.0	6	1	1	1
115485	1710	fragment length	[fragment length]	0.0	2	1	1	1
115486	1710	value in etoposide cell	[value in etoposide cells]	0.0	4	1	1	1
115487	1710	analysis by western blotting of population	[analysis by Western blotting of populations]	0.0	6	1	1	1
115488	1710	apoptosis in T cell	[apoptosis in T cells]	0.0	4	1	1	1
115489	1710	cover the sequence of pp65 individual	[covering the sequence of pp65 individuals]	0.0	6	1	1	1
115490	1710	intrafollicular t-cell	[intrafollicular T-cells]	0.0	2	1	1	1
115491	1710	CEM-ICR lymphoblast a clone	[CEM-ICR lymphoblasts a clone]	0.0	4	1	1	1
115492	1710	nf-at in eosinophil	[NF-AT in eosinophils]	0.0	3	1	1	1
115493	1710	study in human immunodeficiency virus patient	[studies in human immunodeficiency virus patients]	0.0	6	1	1	1
115494	1710	classic hd	[classic HD]	0.0	2	1	1	1
115495	1710	immunoglobulin chain constant region	[immunoglobulin chain constant region]	0.0	4	1	1	1
115496	1710	p53 -conjugating ligase	[p53 -conjugating ligase]	0.0	3	1	1	1
115497	1710	progenitor of lineage	[progenitors of lineages]	0.0	3	1	1	1
115498	1710	test activity	[Testing activity]	0.0	2	1	1	1
115499	1710	nuclear binding site	[nuclear binding sites]	0.0	3	1	1	1
115500	1710	activation with pha	[activation with PHA]	0.0	3	1	1	1
115501	1710	archetypal t-cell -specific gene	[archetypal T-cell -specific gene]	0.0	4	1	1	1
115502	1710	inducer in T cell	[inducers in T cells]	0.0	4	1	1	1
115503	1710	receptor for leukocyte chemoattract	[Receptors for leukocyte chemoattractants]	0.0	4	1	1	1
115504	1710	BHRF1 against apoptosis	[BHRF1 against apoptosis]	0.0	3	1	1	1
115505	1710	50-kda protein nfkb1(p50)	[50-kDa protein NFKB1(p50)]	0.0	3	1	1	1
115506	1710	relevance of endogenous no regulation	[relevance of endogenous NO regulation]	0.0	5	1	1	1
115507	1710	mcd14 uptake of homologous lps	[mCD14 uptake of homologous LPS]	0.0	5	1	1	1
115508	1710	corresponding to a molecule per cell.	[corresponding to an molecules per cell.]	0.0	6	1	1	1
115509	1710	Nuclear extract from T lymphocyte	[Nuclear extracts from T lymphocytes]	0.0	5	1	1	1
115510	1710	University	[University]	0.0	1	1	1	1
115511	1710	STAT5 by IL-4	[STAT5 by IL-4]	0.0	3	1	1	1
115512	1710	use micrograms/ml	[using micrograms/ml]	0.0	2	1	1	1
115513	1710	amount of available iron	[amount of available iron]	0.0	4	1	1	1
115514	1710	different virologic subtype of pel	[different virologic subtypes of PEL]	0.0	5	1	1	1
115515	1710	activity of a number	[activity of a number]	0.0	4	1	1	1
115516	1710	effect monocyte tnf-alpha production	[effect monocyte TNF-alpha production]	0.0	4	1	1	1
115517	1710	enterotoxin a	[enterotoxin A]	0.0	2	1	1	1
115518	1710	enterotoxin b	[enterotoxin B]	0.0	2	1	1	1
115519	1710	present with severe immunodeficiency	[presenting with severe immunodeficiency]	0.0	4	1	1	1
115520	1710	receptor clone icr-27	[receptor clone ICR-27]	0.0	3	1	1	1
115521	1710	human b cell by ebv	[human B cells by EBV]	0.0	5	1	1	1
115522	1710	cell line m-tat	[cell line M-TAT]	0.0	3	1	1	1
115523	1710	exhibit a defect	[exhibiting a defect]	0.0	3	1	1	1
115524	1710	TCL1 gene sequence,	[TCL1 gene sequence,]	0.0	3	1	1	1
115525	1710	rectal minus value	[rectal minus values]	0.0	3	1	1	1
115526	1710	corresponding within a domain	[corresponding within a domain]	0.0	4	1	1	1
115527	1710	association between Ikaros	[associations between Ikaros]	0.0	3	1	1	1
115528	1710	Kenney,	[Kenney,]	0.0	1	1	1	1
115529	1710	schedule	[schedules]	0.0	1	1	1	1
115530	1710	t-cell-specific transcription factor TCF-1	[T-cell-specific transcription factors TCF-1]	0.0	4	1	1	1
115531	1710	factor-1 irf-1 gene	[factor-1 IRF-1 gene]	0.0	3	1	1	1
115532	1710	circulate cortisol	[circulating cortisol]	0.0	2	1	1	1
115533	1710	other b	[other B]	0.0	2	1	1	1
115534	1710	mechanism of steroid action	[mechanisms of steroid action]	0.0	4	1	1	1
115535	1710	GPIIb the subunit	[GPIIb the subunit]	0.0	3	1	1	1
115536	1710	ra-induced down-modulation of hpc growth	[RA-induced down-modulation of HPC growth]	0.0	5	1	1	1
115537	1710	unequal expression	[unequal expression]	0.0	2	1	1	1
115538	1710	simultaneous binding of October protein	[simultaneous binding of Oct proteins]	0.0	5	1	1	1
115539	1710	response toward cytokine stimulation	[response toward cytokine stimulation]	0.0	4	1	1	1
115540	1710	6, rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[6, rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	5	1	1	1
115541	1710	part of the genetic program	[parts of the genetic program]	0.0	5	1	1	1
115542	1710	cloning of gata-4 hgata-4	[cloning of GATA-4 hGATA-4]	0.0	4	1	1	1
115543	1710	various intracellular signal protein	[various intracellular signaling proteins]	0.0	4	1	1	1
115544	1710	molecular-biologic aspect	[Molecular-biologic aspects]	0.0	2	1	1	1
115545	1710	migration of gc cell	[migration of GC cells]	0.0	4	1	1	1
115546	1710	inflammatory fluid sf	[inflammatory fluids SFs]	0.0	3	1	1	1
115547	1710	only from patient	[only from patients]	0.0	3	1	1	1
115548	1710	simultaneous addition	[simultaneous addition]	0.0	2	1	1	1
115549	1710	Slight difference in the sequence	[Slight differences in the sequence]	0.0	5	1	1	1
115550	1710	fmol/microgram	[fmol/micrograms]	0.0	1	2	2	1
115551	1710	even with the second messenger response	[even with the second messenger response]	0.0	6	1	1	1
115552	1710	signal via IL-2	[Signaling via IL-2]	0.0	3	1	1	1
115553	1710	translocation factor of T	[translocation factor of T]	0.0	4	1	1	1
115554	1710	expression of transdominant rev protein	[expression of transdominant Rev protein]	0.0	5	1	1	1
115555	1710	gene such as embryonic fibroblast	[genes such as embryonic fibroblasts]	0.0	5	1	1	1
115556	1710	leukocyte in human endometrium	[leukocytes in human endometrium]	0.0	4	1	1	1
115557	1710	lytic transglycosylase of Escherichia coli	[lytic transglycosylase of Escherichia coli]	0.0	5	1	1	1
115558	1710	role in the balance	[role in the balance]	0.0	4	1	1	1
115559	1710	Functional study use endothelial cell	[Functional studies using endothelial cells]	0.0	5	1	1	1
115560	1710	association with event of inflammation	[association with events of inflammation]	0.0	5	1	1	1
115561	1710	finding of association	[findings of associations]	0.0	3	1	1	1
115562	1710	enhancer with two domains, a	[enhancer with two domains, A]	0.0	5	1	1	1
115563	1710	prevent the phase of allergic reaction	[preventing the phase of allergic reaction]	0.0	6	1	1	1
115564	1710	select aberration in the pathway	[select aberrations in the pathway]	0.0	5	1	1	1
115565	1710	early disease	[early disease]	0.0	2	2	2	1
115566	1710	alternative splicing in nfatx isoform	[alternative splicing in NFATx isoforms]	0.0	5	1	1	1
115567	1710	express the nef gene	[expressing the nef gene]	0.0	4	1	1	1
115568	1710	support a model	[supporting a model]	0.0	3	1	1	1
115569	1710	express alphaiibbeta3	[expressing alphaIIbbeta3]	0.0	2	1	1	1
115570	1710	inhibition of NFAT -1-mediated gene expression	[inhibition of NFAT -1-mediated gene expression]	0.0	6	1	1	1
115571	1710	Th1 response	[Th1 responses]	0.0	2	1	1	1
115572	1710	two pkc inhibitors, pentoxifylline	[two PKC inhibitors, pentoxifylline]	0.0	4	1	1	1
115573	1710	polychlorinated dibenzo-p-dioxin	[polychlorinated dibenzo-p-dioxins]	0.0	2	1	1	1
115574	1710	status in breast cancer patient comparison	[status in breast cancer patients comparison]	0.0	6	1	1	1
115575	1710	developmental gene expression	[developmental gene expression]	0.0	3	1	1	1
115576	1710	tyrosine kinase inhibition whereas inhibition	[Tyrosine kinase inhibition whereas inhibition]	0.0	5	1	1	1
115577	1710	heavy-chain gene expression	[heavy-chain gene expression]	0.0	3	1	1	1
115578	1710	far-Western blot	[far-Western blot]	0.0	2	1	1	1
115579	1710	pkc- dependent activation	[PKC- dependent activation]	0.0	3	1	1	1
115580	1710	60% reduction	[60% reduction]	0.0	2	1	1	1
115581	1710	unknown locus sil	[unknown locus SIL]	0.0	3	1	1	1
115582	1710	expression of erythroid transcription factor	[expression of erythroid transcription factor]	0.0	5	1	1	1
115583	1710	two h follow lps addition	[Two h following LPS addition]	0.0	5	1	1	1
115584	1710	mononuclear leukocyte hml	[mononuclear leukocytes HML]	0.0	3	1	1	1
115585	1710	effect of g-csf	[effects of G-CSF]	0.0	3	1	1	1
115586	1710	normal type er	[normal type ER]	0.0	3	1	1	1
115587	1710	response to foreign antigens.	[responses to foreign antigens.]	0.0	4	1	1	1
115588	1710	hSIE-oligonucleotide	[hSIE-oligonucleotide]	0.0	1	1	1	1
115589	1710	bioinactivation	[bioinactivation]	0.0	1	1	1	1
115590	1710	vital importance	[vital importance]	0.0	2	1	1	1
115591	1710	p105 precursor,	[p105 precursor,]	0.0	2	1	1	1
115592	1710	x-chromosome-specific element propagate the state,	[X-chromosome-specific elements propagating the state,]	0.0	5	1	1	1
115593	1710	powerful activator	[powerful activators]	0.0	2	1	1	1
115594	1710	peripheral adaptation	[peripheral adaptation]	0.0	2	1	1	1
115595	1710	select the specific oligonucleotide sequence	[selecting the specific oligonucleotide sequence]	0.0	5	1	1	1
115596	1710	pattern of signal	[patterns of signaling]	0.0	3	1	1	1
115597	1710	Northern (RNA) blot of mouse tissue	[Northern (RNA) blots of mouse tissues]	0.0	6	1	1	1
115598	1710	activation by phagocytic stimulus	[Activation by phagocytic stimuli]	0.0	4	1	1	1
115599	1710	CsA component	[CsA component]	0.0	2	1	1	1
115600	1710	glucocorticoid-sensitive leukemic t-cell line	[glucocorticoid-sensitive leukemic T-cell line]	0.0	4	1	1	1
115601	1710	two abundant protein of 75	[Two abundant proteins of 75]	0.0	5	1	1	1
115602	1710	structural comparison no synthase gene	[structural comparison NO synthase genes]	0.0	5	1	1	1
115603	1710	adult beta-globin expression during ontogeny	[adult beta-globin expression during ontogeny]	0.0	5	1	1	1
115604	1710	erythrocyte Duffy protein	[erythrocyte Duffy protein]	0.0	3	1	1	1
115605	1710	immunoglobulin (igh) gene	[immunoglobulin (IgH) gene]	0.0	3	1	1	1
115606	1710	differential activity of Bcl-2	[differential activity of Bcl-2]	0.0	4	1	1	1
115607	1710	somatic deletion	[somatic deletion]	0.0	2	1	1	1
115608	1710	distinct allelic family	[distinct allelic families]	0.0	3	1	1	1
115609	1710	clonality analysis simultaneous study	[Clonality analysis simultaneous study]	0.0	4	1	1	1
115610	1710	use oligonucleotide probe	[using oligonucleotide probes]	0.0	3	1	1	1
115611	1710	several cell include monocyte	[several cells including monocytes]	0.0	4	1	1	1
115612	1710	use cycloheximide	[using cycloheximide]	0.0	2	1	1	1
115613	1710	strictly erythroid-specific property	[strictly erythroid-specific properties]	0.0	3	1	1	1
115614	1710	mrna level for il-13r	[mRNA levels for IL-13R]	0.0	4	1	1	1
115615	1710	effect of AuTG	[effect of AuTG]	0.0	3	1	1	1
115616	1710	action of stimulus	[action of stimuli]	0.0	3	1	1	1
115617	1710	epor gene	[EpoR gene]	0.0	2	1	1	1
115618	1710	multifactorial,	[multifactorial,]	0.0	1	1	1	1
115619	1710	role -sensitive induction of tnf-alpha	[role -sensitive induction of TNF-alpha]	0.0	5	1	1	1
115620	1710	vitro, nuclear antigen EBNAs	[vitro, nuclear antigens EBNAs]	0.0	4	1	1	1
115621	1710	edema	[edema]	0.0	1	1	1	1
115622	1710	expression gene in mouse	[expression gene in mice]	0.0	4	1	1	1
115623	1710	inhibitory effect of hydrocortisone	[inhibitory effect of hydrocortisone]	0.0	4	1	1	1
115624	1710	112 drug-free patient with disorder	[112 drug-free patients with disorder]	0.0	5	1	1	1
115625	1710	1 colony-stimulating factor	[1 colony-stimulating factor]	0.0	3	1	1	1
115626	1710	DNA contain consensus c/ebp site	[DNA containing consensus C/EBP sites]	0.0	5	1	1	1
115627	1710	virus-infected human T cell	[virus-infected human T cells]	0.0	4	1	1	1
115628	1710	one gene, two transcript isolation	[One gene, two transcripts isolation]	0.0	5	1	1	1
115629	1710	T lymphotropic virus	[T lymphotropic virus]	0.0	3	1	1	1
115630	1710	memory (cd45ro+)	[memory (CD45RO+)]	0.0	2	1	1	1
115631	1710	namely the heavy chain enhancer	[namely the heavy chain enhancer]	0.0	5	1	1	1
115632	1710	selective activation of signal cascade	[selective activation of signaling cascades]	0.0	5	1	1	1
115633	1710	major site for E2F	[major site for E2F]	0.0	4	1	1	1
115634	1710	membrane protein of ebv	[membrane protein of EBV]	0.0	4	1	1	1
115635	1710	dose (more than mol/L)	[dose (more than mol/L)]	0.0	4	1	1	1
115636	1710	present a strong similarity	[presenting a strong similarity]	0.0	4	1	1	1
115637	1710	residual disease with pml/rar alpha	[residual disease with PML/RAR alpha]	0.0	5	1	1	1
115638	1710	include case	[including case]	0.0	2	1	1	1
115639	1710	T cell by hiv-1	[T cells by HIV-1]	0.0	4	1	1	1
115640	1710	mitogen-inducible complex	[mitogen-inducible complexes]	0.0	2	1	1	1
115641	1710	survival-promoting protein	[survival-promoting proteins]	0.0	2	1	1	1
115642	1710	E2F activity a cell cycle checkpoint	[E2F activity a cell cycle checkpoint]	0.0	6	1	1	1
115643	1710	environmental factors, in particular, proinflammatory cytokine	[environmental factors, in particular, proinflammatory cytokines]	0.0	6	1	1	1
115644	1710	genomic sterol element SRE	[genomic sterol element SRE]	0.0	4	1	1	1
115645	1710	growth-	[growth-]	0.0	1	1	1	1
115646	1710	epitope peptide-loaded cell dc	[epitope peptide-loaded cells DCs]	0.0	4	1	1	1
115647	1710	contact).	[contact).]	0.0	1	1	1	1
115648	1710	functional characterization of b-cell factor	[functional characterization of B-cell factor]	0.0	5	1	1	1
115649	1710	breast cancer in Hungary.	[breast cancer in Hungary.]	0.0	4	1	1	1
115650	1710	breast cancer in Hungary,	[breast cancer in Hungary,]	0.0	4	1	1	1
115651	1710	involve the acidic sphingomyelinase	[involving the acidic sphingomyelinase]	0.0	4	1	1	1
115652	1710	NF-AT signal transduction event	[NF-AT signal transduction events]	0.0	4	1	1	1
115653	1710	nineteen ltr	[nineteen LTRs]	0.0	2	1	1	1
115654	1710	use a thymic lymphoma-derived hybridoma	[using a thymic lymphoma-derived hybridoma]	0.0	5	1	1	1
115655	1710	stat5b in primary human precursor	[STAT5B in primary human precursors]	0.0	5	1	1	1
115656	1710	antigen-specific cd4+ t-cell line	[antigen-specific CD4+ T-cell lines]	0.0	4	1	1	1
115657	1710	core sequence cttgg	[core sequence CTTGG]	0.0	3	1	1	1
115658	1710	three agent endotoxin	[Three agents endotoxin]	0.0	3	1	1	1
115659	1710	binding of plasma factor	[Binding of plasma Factor]	0.0	4	1	1	1
115660	1710	umbilical cord T	[umbilical cord T]	0.0	3	1	1	1
115661	1710	functional region coding	[functional regions coding]	0.0	3	1	1	1
115662	1710	t-cell nuclear extract consist	[T-cell nuclear extracts consisting]	0.0	4	1	1	1
115663	1710	regulation of certain response	[regulation of certain responses]	0.0	4	1	1	1
115664	1710	activation protein/activation transcription factor family	[activation protein/activation transcription factor family]	0.0	5	1	1	1
115665	1710	cell from elderly donor	[cells from elderly donors]	0.0	4	1	1	1
115666	1710	nfatp polyclonal antibody	[NFATp polyclonal antibody]	0.0	3	1	1	1
115667	1710	interference with the nf-kappab activation	[interference with the NF-kappaB activation]	0.0	5	1	1	1
115668	1710	basic growth factor	[basic growth factor]	0.0	3	1	1	1
115669	1710	add b protein	[Adding B protein]	0.0	3	1	1	1
115670	1710	infection of target cell	[Infection of target cells]	0.0	4	1	1	1
115671	1710	uncouple hs1 phosphorylation from factor	[Uncoupling HS1 phosphorylation from factor]	0.0	5	1	1	1
115672	1710	share a DNA bind motif	[sharing a DNA binding motif]	0.0	5	1	1	1
115673	1710	control role	[control role]	0.0	2	1	1	1
115674	1710	great variety	[great variety]	0.0	2	1	1	1
115675	1710	modulate the transcription	[modulating the transcription]	0.0	3	1	1	1
115676	1710	nonglucocorticoid steroid	[nonglucocorticoid steroids]	0.0	2	1	1	1
115677	1710	cellular event lead	[cellular events leading]	0.0	3	1	1	1
115678	1710	complex (mhc) haplotype	[complex (MHC) haplotypes]	0.0	3	1	1	1
115679	1710	T cell surface	[T cell surface]	0.0	3	1	1	1
115680	1710	airway instillation	[airway instillation]	0.0	2	1	1	1
115681	1710	component lead	[component leading]	0.0	2	1	1	1
115682	1710	composition of transcription factor	[composition of transcription factor]	0.0	4	1	1	1
115683	1710	cell type specificity for nfat-1	[Cell type specificity for NFAT-1]	0.0	5	1	1	1
115684	1710	clone of human herpesvirus-6	[clones of human herpesvirus-6]	0.0	4	1	1	1
115685	1710	inhibitor b alpha evidence	[inhibitor B alpha evidence]	0.0	4	1	1	1
115686	1710	prime nb4 cell	[prime NB4 cells]	0.0	3	1	1	1
115687	1710	ileal	[ileal]	0.0	1	1	1	1
115688	1710	variety include muscle	[variety including muscle]	0.0	3	1	1	1
115689	1710	plasma clearance	[plasma clearance]	0.0	2	1	1	1
115690	1710	human T cell responsive	[human T cells responsive]	0.0	4	1	1	1
115691	1710	cell enhancement	[cells enhancement]	0.0	2	1	1	1
115692	1710	preosteoclast phenotype	[preosteoclast phenotype]	0.0	2	1	1	1
115693	1710	apoptosis inhibition after treatment	[Apoptosis inhibition after treatment]	0.0	4	1	1	1
115694	1710	phosphorothioate oligodeoxynucleotides	[phosphorothioate oligodeoxynucleotides]	0.0	2	1	1	1
115695	1710	accumulation of concentration	[accumulation of concentrations]	0.0	3	1	1	1
115696	1710	role of oxygen species	[role of oxygen species]	0.0	4	1	1	1
115697	1710	possible dysregulation of (hpa) axis	[possible dysregulation of (HPA) axis]	0.0	5	1	1	1
115698	1710	platelet from euthymic	[platelets from euthymic]	0.0	3	1	1	1
115699	1710	nf-kappa b factor-kappa b	[NF-kappa B factor-kappa B]	0.0	4	1	1	1
115700	1710	tissue-specific activation	[tissue-specific activation]	0.0	2	1	1	1
115701	1710	monoblastic cell THP-1	[monoblastic cells THP-1]	0.0	3	1	1	1
115702	1710	two subunit of molecular mass	[two subunits of molecular mass]	0.0	5	1	1	1
115703	1710	second messenger in b cell	[second messengers in B cells]	0.0	5	1	1	1
115704	1710	previous study pertain to LPS	[previous studies pertaining to LPS]	0.0	5	1	1	1
115705	1710	factor for thymopoiesis	[factor for thymopoiesis]	0.0	3	1	1	1
115706	1710	approach to the immunotherapy	[approaches to the immunotherapy]	0.0	4	1	1	1
115707	1710	peptide selection	[peptide selection]	0.0	2	1	1	1
115708	1710	(a) of 125d3 variant	[(A) of 1,25D3 variants]	0.0	4	1	1	1
115709	1710	phosphorylation of subunit IkappaB	[phosphorylation of subunit IkappaB]	0.0	4	1	1	1
115710	1710	two potential reading frame a	[two potential reading frames A]	0.0	5	1	1	1
115711	1710	addition, over-expression	[addition, over-expression]	0.0	2	1	1	1
115712	1710	lymphocytic transformation	[lymphocytic transformation]	0.0	2	1	1	1
115713	1710	nm23.h1	[NM23.H1]	0.0	1	1	1	1
115714	1710	cyclin kinase activity	[cyclin kinase activity]	0.0	3	1	1	1
115715	1710	analysis of the modulation	[Analysis of the modulation]	0.0	4	1	1	1
115716	1710	antibody against various markers,	[antibodies against various markers,]	0.0	4	1	1	1
115717	1710	two independent assays),	[two independent assays),]	0.0	3	1	1	1
115718	1710	blast differentiation	[blast differentiation]	0.0	2	1	1	1
115719	1710	novel lymphoma cell line	[novel lymphoma cell lines]	0.0	4	1	1	1
115720	1710	specificities, the reactivity	[specificities, the reactivities]	0.0	3	1	1	1
115721	1710	twelve in-vitro-stimulated cord blood	[twelve in-vitro-stimulated cord blood]	0.0	4	1	1	1
115722	1710	vaginal floram	[vaginal flora,]	0.0	2	1	1	1
115723	1710	inhibit synthesis to the form	[inhibiting synthesis to the form]	0.0	5	1	1	1
115724	1710	fibrosis sputum	[fibrosis sputum]	0.0	2	1	1	1
115725	1710	(approximately inhibition	[(approximately inhibition]	0.0	2	1	1	1
115726	1710	different condition of cell stimulation	[different conditions of cell stimulation]	0.0	5	1	1	1
115727	1710	partial depletion	[partial depletion]	0.0	2	1	1	1
115728	1710	change in phosphorylation	[changes in phosphorylation]	0.0	3	1	1	1
115729	1710	derivative of retinoic acid	[derivative of retinoic acid]	0.0	4	1	1	1
115730	1710	direct coronary angioplasty PTCA	[direct coronary angioplasty PTCA]	0.0	4	1	1	1
115731	1710	HSV CD4 T cell	[HSV CD4 T cells]	0.0	4	1	1	1
115732	1710	context of protein	[context of proteins]	0.0	3	1	1	1
115733	1710	marker of acute promyelocytic leukemia	[markers of acute promyelocytic leukemias]	0.0	5	1	1	1
115734	1710	level than ZEBRA	[levels than ZEBRA]	0.0	3	1	1	1
115735	1710	virtually all cd34(+) bone marrow cell	[virtually all CD34(+) bone marrow cells]	0.0	6	1	1	1
115736	1710	inhibition replication by a novel combination	[Inhibition replication by a novel combination]	0.0	6	1	1	1
115737	1710	onset menarche	[onset menarche]	0.0	2	1	1	1
115738	1710	long repeat type	[long repeat type]	0.0	3	1	1	1
115739	1710	pou(s) domain	[POU(S) domains]	0.0	2	1	1	1
115740	1710	depend on the kappa b motif	[depending on the kappa B motifs]	0.0	6	1	1	1
115741	1710	component of the t-cell receptor	[component of the T-cell receptor]	0.0	5	1	1	1
115742	1710	sequence requirement within a element	[sequence requirements within a element]	0.0	5	1	1	1
115743	1710	extend from -500 to +50bp	[extending from -500 to +50bp]	0.0	5	1	1	1
115744	1710	cycle reactivity	[cycle reactivities]	0.0	2	1	1	1
115745	1710	prevalence in breast aspirate at risk	[Prevalence in breast aspirates at risk]	0.0	6	1	1	1
115746	1710	Effect on transcription factor activation	[Effects on transcription factor activation]	0.0	5	1	1	1
115747	1710	contain 446 bp	[containing 446 bp]	0.0	3	1	1	1
115748	1710	distinct binding site for nuclear protein	[distinct binding sites for nuclear proteins]	0.0	6	1	1	1
115749	1710	induce CAT activity fibrinogen	[inducing CAT activity fibrinogen]	0.0	4	1	1	1
115750	1710	involvement in the response	[involvement in the response]	0.0	4	1	1	1
115751	1710	RA change	[RA changes]	0.0	2	1	1	1
115752	1710	18 case of tsc	[18 cases of TSC]	0.0	4	1	1	1
115753	1710	physiological concentration with a onset	[physiological concentrations with an onset]	0.0	5	2	2	1
115754	1710	transfection of expression vector	[Transfection of expression vectors]	0.0	4	1	1	1
115755	1710	signal for the biogenesis of organ	[signals for the biogenesis of organs]	0.0	6	1	1	1
115756	1710	nuclei from normal monocyte	[nuclei from normal monocytes]	0.0	4	1	1	1
115757	1710	4 T cell line	[4 T cell lines]	0.0	4	1	1	1
115758	1710	M.Nugeyre,	[M.Nugeyre,]	0.0	1	1	1	1
115759	1710	several site originate bp	[several sites originating bp]	0.0	4	1	1	1
115760	1710	24 h of stimulation	[24 h of stimulation]	0.0	4	1	1	1
115761	1710	trend of biology study	[trend of biology study]	0.0	4	1	1	1
115762	1710	T lymphocyte development,	[T lymphocyte development,]	0.0	3	1	1	1
115763	1710	th2-	[Th2-]	0.0	1	1	1	1
115764	1710	site beta	[site beta]	0.0	2	1	1	1
115765	1710	three series:	[three series:]	0.0	2	1	1	1
115766	1710	factor T cell	[factor T cells]	0.0	3	1	1	1
115767	1710	six other unidentified factor	[six other unidentified factors]	0.0	4	1	1	1
115768	1710	complex class molecule	[complex class molecules]	0.0	3	1	1	1
115769	1710	deletion of a amino-	[Deletions of a amino-]	0.0	4	1	1	1
115770	1710	other T cell line CEM	[other T cell lines CEM]	0.0	5	1	1	1
115771	1710	negative function in the absence	[negative functions in the absence]	0.0	5	1	1	1
115772	1710	myelomonocytic differentiation include secondary aml	[myelomonocytic differentiation including secondary AML]	0.0	5	1	1	1
115773	1710	IL-2 cell consist	[IL-2 cells consisting]	0.0	3	1	1	1
115774	1710	I-III	[I-III]	0.0	1	1	1	1
115775	1710	increase in gene expression	[increase in gene expression]	0.0	4	1	1	1
115776	1710	eosinophil granule protein mbp	[eosinophil granule protein MBP]	0.0	4	2	2	1
115777	1710	lack the gene encode EBNA	[lacking the gene encoding EBNA]	0.0	5	1	1	1
115778	1710	1, 25-dihydroxyvitamin D3 receptor VDR	[1, 25-dihydroxyvitamin D3 receptor VDR]	0.0	5	1	1	1
115779	1710	Effect differentiation of k562 cell	[Effects differentiation of K562 cells]	0.0	5	1	1	1
115780	1710	myeloblastic ml-1 cell	[myeloblastic ML-1 cell]	0.0	3	1	1	1
115781	1710	kda stat5 protein	[kDa STAT5 proteins]	0.0	3	1	1	1
115782	1710	native form	[native forms]	0.0	2	1	1	1
115783	1710	primary case of leukaemia	[primary cases of leukaemia]	0.0	4	1	1	1
115784	1710	fork head domain	[fork head domain]	0.0	3	1	1	1
115785	1710	phase-2	[phase-2]	0.0	1	1	1	1
115786	1710	virus peptide by cell	[virus peptides by cells]	0.0	4	1	1	1
115787	1710	bear the promoter region	[bearing the promoter regions]	0.0	4	1	1	1
115788	1710	lipoarabinomannan LAM	[lipoarabinomannan LAM]	0.0	2	1	1	1
115789	1710	other parameters, such as glycosidase activity	[Other parameters, such as glycosidase activities]	0.0	6	1	1	1
115790	1710	interaction with other factor	[interaction with other factors]	0.0	4	1	1	1
115791	1710	discovery identical	[discovery identical]	0.0	2	1	1	1
115792	1710	characterization of the cd36 gene promoter	[characterization of the CD36 gene promoter]	0.0	6	1	1	1
115793	1710	distinct mechanism for n-acetylcysteine inhibition	[Distinct mechanisms for N-acetylcysteine inhibition]	0.0	5	1	1	1
115794	1710	activate transcription from class histocompatibility promoter	[activating transcription from class histocompatibility promoters]	0.0	6	1	1	1
115795	1710	addition to ets1 transactivation	[addition to ETS1 transactivation]	0.0	4	1	1	1
115796	1710	use digestion by trypsin	[using digestion by trypsin]	0.0	4	1	1	1
115797	1710	clinical factor	[clinical factors]	0.0	2	1	1	1
115798	1710	apoplexic patient with lesion	[apoplexic patients with lesions]	0.0	4	1	1	1
115799	1710	treatment of a leukemia cell line	[Treatment of a leukemia cell line]	0.0	6	1	1	1
115800	1710	overproduction of NFKB2	[Overproduction of NFKB2]	0.0	3	1	1	1
115801	1710	contribution of tnf myristate acetate	[contributions of TNF myristate acetate]	0.0	5	1	1	1
115802	1710	acute infarction AMI	[acute infarction AMI]	0.0	3	1	1	1
115803	1710	role in the quiescence	[role in the quiescence]	0.0	4	1	1	1
115804	1710	other nonsteroidal drug nsaid	[other nonsteroidal drugs NSAIDs]	0.0	4	1	1	1
115805	1710	dexamethasone dm	[dexamethasone DM]	0.0	2	1	1	1
115806	1710	apoptosis in monocyte role	[apoptosis in monocytes role]	0.0	4	1	1	1
115807	1710	cyclic pressure-stretch strain	[cyclic pressure-stretching strain]	0.0	3	1	1	1
115808	1710	similar mutation	[similar mutations]	0.0	2	1	1	1
115809	1710	structure with separable domain	[structure with separable domains]	0.0	4	1	1	1
115810	1710	viable blood cell	[viable blood cells]	0.0	3	1	1	1
115811	1710	low apparent dissociation constant kd	[low apparent dissociation constant Kd]	0.0	5	1	1	1
115812	1710	reflect a shift	[reflecting a shift]	0.0	3	1	1	1
115813	1710	ebna2 mrna	[EBNA2 mRNA]	0.0	2	1	1	1
115814	1710	catalyze the exchange	[catalyzing the exchange]	0.0	3	1	1	1
115815	1710	rac1 gtpase enzyme	[Rac1 GTPases enzymes]	0.0	3	1	1	1
115816	1710	reactive oxygen species generation	[reactive oxygen species generation]	0.0	4	1	1	1
115817	1710	number in late phase	[numbers in late phase]	0.0	4	1	1	1
115818	1710	suppressor of adhesion molecule expression	[suppressor of adhesion molecule expression]	0.0	5	1	1	1
115819	1710	13.3 mg/24h;	[13.3 mg/24h;]	0.0	2	1	1	1
115820	1710	potential of sequence	[potential of sequences]	0.0	3	1	1	1
115821	1710	16 promoter	[16 promoter]	0.0	2	1	1	1
115822	1710	isolation of gelatinase granule	[Isolation of gelatinase granules]	0.0	4	1	1	1
115823	1710	mechanism of hiv inhibition	[mechanism of HIV inhibition]	0.0	4	1	1	1
115824	1710	other enhancer element	[other enhancer elements]	0.0	3	1	1	1
115825	1710	superantigen staphylococcal enterotoxin a sea	[superantigen staphylococcal enterotoxin A SEA]	0.0	5	1	1	1
115826	1710	impaired cortisol binding to glucocorticoid receptor	[Impaired cortisol binding to glucocorticoid receptors]	0.0	6	1	1	1
115827	1710	marker for leukemia	[marker for leukemia]	0.0	3	1	1	1
115828	1710	localization of rela	[localization of RelA]	0.0	3	1	1	1
115829	1710	small apolar substitution 11 alpha-methyl, alpha-fluoromethyl	[Small apolar substitutions 11 alpha-methyl, alpha-fluoromethyl]	0.0	6	1	1	1
115830	1710	major histocompatibility complex class immunodeficiency	[major histocompatibility complex class immunodeficiency]	0.0	5	1	1	1
115831	1710	cluster analysis	[cluster analysis]	0.0	2	1	1	1
115832	1710	lead to disruption	[leading to disruption]	0.0	3	1	1	1
115833	1710	cause T cell activation	[causing T cell activation]	0.0	4	1	1	1
115834	1710	transcriptional regulation of interleukin IL-2 gene	[transcriptional regulation of interleukin IL-2 gene]	0.0	6	1	1	1
115835	1710	accumulation of neutrophil	[accumulation of neutrophils]	0.0	3	1	1	1
115836	1710	encode the histone deacetylase subunit hd1	[encoding the histone deacetylase subunit HD1]	0.0	6	1	1	1
115837	1710	differentiation of a monocyte	[differentiation of a monocyte]	0.0	4	1	1	1
115838	1710	nf-kappa b -mediated gene expression	[NF-kappa B -mediated gene expression]	0.0	5	1	1	1
115839	1710	require interaction	[requiring interaction]	0.0	2	1	1	1
115840	1710	use constituent such as lps	[using constituents such as LPS]	0.0	5	1	1	1
115841	1710	control hiv replication because of ability	[controlling HIV replication because of ability]	0.0	6	1	1	1
115842	1710	hormone-inducible protein in transient transfection	[hormone-inducible proteins in transient transfection]	0.0	5	1	1	1
115843	1710	multiple mutation cluster a encoding	[multiple mutations clustering a encoding]	0.0	5	1	1	1
115844	1710	RA 27%).	[RA 27%).]	0.0	2	1	1	1
115845	1710	adhesion molecule-1 on vein endothelial cell	[adhesion molecule-1 on vein endothelial cells]	0.0	6	1	1	1
115846	1710	cover the surface days.	[covering the surface days.]	0.0	4	1	1	1
115847	1710	size of 65 kilodalton	[size of 65 kilodaltons]	0.0	4	1	1	1
115848	1710	other transcription factor of importance	[other transcription factors of importance]	0.0	5	1	1	1
115849	1710	activity of glucocorticoid receptor	[activity of glucocorticoid receptors]	0.0	4	1	1	1
115850	1710	mutation a proto-oncogene encoding	[mutations a proto-oncogene encoding]	0.0	4	1	1	1
115851	1710	modification responsible for the defect	[modifications responsible for the defect]	0.0	5	1	1	1
115852	1710	feature of transformation	[feature of transformation]	0.0	3	1	1	1
115853	1710	cd8(+) CD3	[CD8(+) CD3]	0.0	2	1	1	1
115854	1710	two binding protein kD	[two binding proteins kD]	0.0	4	1	1	1
115855	1710	MIP1 alpha protein a transcription factor	[MIP1 alpha protein a transcription factor]	0.0	6	1	1	1
115856	1710	reliable surrogate	[reliable surrogates]	0.0	2	1	1	1
115857	1710	chromatinized episome	[chromatinized episome]	0.0	2	1	1	1
115858	1710	amplification of cDNA end 5'-race analysis	[amplification of cDNA ends 5'-RACE analysis]	0.0	6	1	1	1
115859	1710	different dose DEX	[different doses DEX]	0.0	3	1	1	1
115860	1710	potent inducer in all	[potent inducer in all]	0.0	4	1	1	1
115861	1710	link between immune system	[link between immune systems]	0.0	4	1	1	1
115862	1710	transcription of major class gene	[transcription of major class genes]	0.0	5	1	1	1
115863	1710	monocyte adhesion in vein cell	[monocyte adhesion in vein cells]	0.0	5	1	1	1
115864	1710	role regulate the capacity	[role regulating the capacity]	0.0	4	1	1	1
115865	1710	tumor necrosis factor production	[tumor necrosis factor production]	0.0	4	1	1	1
115866	1710	chicken erythrocyte factor mass, kda)	[chicken erythrocyte factor mass, kDa)]	0.0	5	1	1	1
115867	1710	activation of b cell in vitro	[activation of B cells in vitro]	0.0	6	1	1	1
115868	1710	cd45 antibody	[CD45 antibodies]	0.0	2	1	1	1
115869	1710	72 bp	[72 bp]	0.0	2	1	1	1
115870	1710	HT-2 cell	[HT-2 cells]	0.0	2	1	1	1
115871	1710	magnitude of ROI	[magnitude of ROI]	0.0	3	1	1	1
115872	1710	rapidly tyrosine-phosphorylated stimulate factor treatment	[rapidly tyrosine-phosphorylated stimulating factor treatment]	0.0	5	1	1	1
115873	1710	underlie the initiation at site	[underlying the initiation at sites]	0.0	5	1	1	1
115874	1710	nuclear factor in human macrophage	[nuclear factors in human macrophages]	0.0	5	1	1	1
115875	1710	transendothelial migration of hl-60 cell	[transendothelial migration of HL-60 cells]	0.0	5	2	2	1
115876	1710	definition of clinical endpoint	[definitions of clinical endpoints]	0.0	4	1	1	1
115877	1710	possible mechanism for alteration	[possible mechanism for alteration]	0.0	4	1	1	1
115878	1710	subsequent adhesion in vein endothelial cell	[subsequent adhesion in vein endothelial cells]	0.0	6	1	1	1
115879	1710	mcd14 uptake of lps	[mCD14 uptake of LPS]	0.0	4	1	1	1
115880	1710	accumulation result in the reexpression	[accumulation resulting in the reexpression]	0.0	5	1	1	1
115881	1710	cell-to-cell contact).	[cell-to-cell contact).]	0.0	2	1	1	1
115882	1710	accumulation of lesion	[accumulation of lesions]	0.0	3	1	1	1
115883	1710	mouse T cell blast	[mouse T cell blasts]	0.0	4	1	1	1
115884	1710	variety of early response gene	[variety of early response genes]	0.0	5	1	1	1
115885	1710	translocation of nuclear factor	[translocation of nuclear factor]	0.0	4	1	1	1
115886	1710	(aids)	[(AIDS)]	0.0	1	1	1	1
115887	1710	cell growth-related gene	[cell growth-related genes]	0.0	3	1	1	1
115888	1710	T virus	[T virus]	0.0	2	1	1	1
115889	1710	epo -independent,	[EPO -independent,]	0.0	2	1	1	1
115890	1710	monocyte from (fh) subject	[monocytes from (FH) subjects]	0.0	4	1	1	1
115891	1710	cell culminate	[cells culminating]	0.0	2	1	1	1
115892	1710	basal expression of c-fo	[basal expression of c-fos]	0.0	4	1	1	1
115893	1710	same calcium potency	[same calcium potency]	0.0	3	1	1	1
115894	1710	murine antibody	[murine antibody]	0.0	2	1	1	1
115895	1710	ifn-gamma responsiveness on a promoter	[IFN-gamma responsiveness on a promoter]	0.0	5	1	1	1
115896	1710	tuberous sclerosis gene	[tuberous sclerosis gene]	0.0	3	1	1	1
115897	1710	only low relative binding affinity	[only low relative binding affinities]	0.0	5	1	1	1
115898	1710	level of three transcription factor	[level of three transcription factors]	0.0	5	1	1	1
115899	1710	span the nucleotide in front	[spanning the nucleotides in front]	0.0	5	1	1	1
115900	1710	b surface	[B surface]	0.0	2	1	1	1
115901	1710	Biologic effect of il-13 on NK	[Biologic effects of IL-13 on NK]	0.0	6	1	1	1
115902	1710	cell of all patient	[cells of all patients]	0.0	4	1	1	1
115903	1710	pfp9a20 contain bp	[PFP9a20 containing bp]	0.0	3	1	1	1
115904	1710	early regulation of TNF	[early regulation of TNF]	0.0	4	1	1	1
115905	1710	NF-kappa b /kbf1	[NF-kappa B /KBF1]	0.0	3	1	1	1
115906	1710	very early stage	[very early stage]	0.0	3	1	1	1
115907	1710	function than histone acetylation	[functions than histone acetylation]	0.0	4	1	1	1
115908	1710	filaria-induced pathology	[filaria-induced pathology]	0.0	2	1	1	1
115909	1710	micromol/(mg protein. min),	[micromol/(mg protein. min),]	0.0	3	1	1	1
115910	1710	potent inducer of collagenase expression	[potent inducers of collagenase expression]	0.0	5	1	1	1
115911	1710	ic50 value for dexamethasone nmol/L) nmol/L)	[IC50 values for dexamethasone nmol/L) nmol/L)]	0.0	6	1	1	1
115912	1710	Initial signal	[Initial signaling]	0.0	2	1	1	1
115913	1710	9s untransformed glucocorticoid receptor complex	[9S untransformed glucocorticoid receptor complexes]	0.0	5	1	1	1
115914	1710	millileter at P;	[ml at h;]	0.0	3	1	1	1
115915	1710	T helper cell cytokine production	[T helper cell cytokine production]	0.0	5	1	1	1
115916	1710	lethal dosage	[lethal dosages]	0.0	2	1	1	1
115917	1710	individual with infection	[individuals with infection]	0.0	3	1	1	1
115918	1710	response to fatty acid	[response to fatty acids]	0.0	4	1	1	1
115919	1710	PMA il-2 transcription	[PMA IL-2 transcription]	0.0	3	1	1	1
115920	1710	consequence for the function of Oct-2a	[consequences for the function of Oct-2a]	0.0	6	1	1	1
115921	1710	mu/l (physiological testing concentration),	[mU/L (physiological testing concentration),]	0.0	4	1	1	1
115922	1710	cell of patient with sepsis	[cells of patients with sepsis]	0.0	5	1	1	1
115923	1710	metalloproteinase inhibitor	[metalloproteinase inhibitor]	0.0	2	1	1	1
115924	1710	interleukin-1beta gene transcription	[interleukin-1beta gene transcription]	0.0	3	1	1	1
115925	1710	aspect of tcr response	[aspects of TCR responses]	0.0	4	1	1	1
115926	1710	factor cbf1/rbp-jkappa	[factor CBF1/RBP-Jkappa]	0.0	2	1	1	1
115927	1710	construct express a lacz reporter gene	[constructs expressing a lacZ reporter gene]	0.0	6	1	1	1
115928	1710	defective onset of the phase	[defective onset of the phase]	0.0	5	1	1	1
115929	1710	conclusion, due to the lack	[conclusion, due to the lack]	0.0	5	1	1	1
115930	1710	cleavage product of approximately 68 kda	[cleavage products of approximately 68 kDa]	0.0	6	1	1	1
115931	1710	immunological implication	[immunological implications]	0.0	2	1	1	1
115932	1710	cooperation between the cellular factor icp0	[cooperation between the cellular factor ICP0]	0.0	6	1	1	1
115933	1710	insight into the function in development	[insight into the function in development]	0.0	6	1	1	1
115934	1710	direct coronary angioplasty	[direct coronary angioplasty]	0.0	3	1	1	1
115935	1710	pbmc of patient with asthma	[PBMCs of patients with asthma]	0.0	5	1	1	1
115936	1710	multiple, biochemically distinct protein	[multiple, biochemically distinct proteins]	0.0	4	1	1	1
115937	1710	lymphoid-specific protein tcf-2 alpha	[lymphoid-specific protein TCF-2 alpha]	0.0	4	1	1	1
115938	1710	GR precursor	[GR precursor]	0.0	2	1	1	1
115939	1710	probably compete	[probably competing]	0.0	2	1	1	1
115940	1710	factor factor proliferation of cd34+ cell	[factor factor proliferation of CD34+ cells]	0.0	6	1	1	1
115941	1710	cell glutathione	[cell glutathione]	0.0	2	1	1	1
115942	1710	six male volunteer	[six male volunteers]	0.0	3	1	1	1
115943	1710	CD3 tcr	[CD3 TCR]	0.0	2	1	1	1
115944	1710	represent T lymphocyte (ctl) epitope	[representing T lymphocyte (CTL) epitopes]	0.0	5	1	1	1
115945	1710	cyclic element modulator CREM	[cyclic element modulator CREM]	0.0	4	1	1	1
115946	1710	hiv-1 repeat by Tat	[HIV-1 repeat by Tat]	0.0	4	1	1	1
115947	1710	triiodothyronine receptor mrna	[triiodothyronine receptor mRNA]	0.0	3	1	1	1
115948	1710	hla class constitutive expression	[HLA class constitutive expression]	0.0	4	1	1	1
115949	1710	woman with secondary neutrophilia	[women with secondary neutrophilia]	0.0	4	1	1	1
115950	1710	fusion transcript with insertion site	[fusion transcripts with insertion site]	0.0	5	1	1	1
115951	1710	vzv donor	[VZV donors]	0.0	2	1	1	1
115952	1710	anorexic patient aged 16-27 years, (range	[anorexic patients aged 16-27 years, (ranging]	0.0	6	1	1	1
115953	1710	involve sequence	[involving sequences]	0.0	2	1	1	1
115954	1710	about 30% b-cell lymphoma	[about 30% B-cell lymphomas]	0.0	4	1	1	1
115955	1710	unusual case	[unusual case]	0.0	2	1	1	1
115956	1710	stimulation of the neutrophil	[stimulation of the neutrophil]	0.0	4	1	1	1
115957	1710	type response	[type responses]	0.0	2	1	1	1
115958	1710	difference (tcr) gene rearrangement	[differences (TcR) gene rearrangement]	0.0	4	1	1	1
115959	1710	sectioning of 6 micrometer	[sectioning of 6 micrometer]	0.0	4	1	1	1
115960	1710	search for constitutional loss	[search for constitutional losses]	0.0	4	1	1	1
115961	1710	stimulation of human blood mononuclear cell	[Stimulation of human blood mononuclear cells]	0.0	6	1	1	1
115962	1710	Finally, reactivation of gene expression	[Finally, reactivation of gene expression]	0.0	5	1	1	1
115963	1710	stable transfectant variant	[stable transfectant variants]	0.0	3	1	1	1
115964	1710	patient lack precipitin	[patients lacking precipitins]	0.0	3	1	1	1
115965	1710	only in conjunction	[only in conjunction]	0.0	3	1	1	1
115966	1710	morphology indicative of granulocytic dysplasia	[morphology indicative of granulocytic dysplasia]	0.0	5	1	1	1
115967	1710	gcrbeta cell in bal blood	[GCRbeta cells in BAL blood]	0.0	5	1	1	1
115968	1710	p50/nf-kappa b inhibition	[p50/NF-kappa B inhibition]	0.0	3	1	1	1
115969	1710	full maturation of erythrocyte	[full maturation of erythrocytes]	0.0	4	1	1	1
115970	1710	effect of CaM-K	[effect of CaM-K]	0.0	3	1	1	1
115971	1710	hormonal status after surgery comparison	[Hormonal status after surgery comparison]	0.0	5	1	1	1
115972	1710	ifn-alpha in normal T cell	[IFN-alpha in normal T cells]	0.0	5	1	1	1
115973	1710	subsequently, increase expression	[Subsequently, increasing expression]	0.0	3	1	1	1
115974	1710	breakdown product of peptidoglycan	[breakdown product of peptidoglycan]	0.0	4	1	1	1
115975	1710	1 ng/ml	[1 ng/ml]	0.0	2	1	1	1
115976	1710	mp plasma concentration	[MP plasma concentrations]	0.0	3	1	1	1
115977	1710	patient with primary breast cancer	[patients with primary breast cancer]	0.0	5	1	1	1
115978	1710	CD28 signal cascade	[CD28 signaling cascade]	0.0	3	1	1	1
115979	1710	cyclosporin a ecsa)	[cyclosporin A (CsA)]	0.0	3	1	1	1
115980	1710	function of Ras such as downregulation	[functions of Ras such as downregulation]	0.0	6	1	1	1
115981	1710	relevant inhibitor in intact cell	[relevant inhibitor in intact cells]	0.0	5	1	1	1
115982	1710	receptor intracellular domain sequence	[receptor intracellular domain sequences]	0.0	4	1	1	1
115983	1710	leukocyte population in first trimester pregnancy	[Leukocyte populations in first trimester pregnancies]	0.0	6	1	1	1
115984	1710	monocyte adhesion to tumor necrosis factor-alpha	[monocyte adhesion to tumor necrosis factor-alpha]	0.0	6	1	1	1
115985	1710	activity NFkappaB	[activities NFkappaB]	0.0	2	1	1	1
115986	1710	relation to prognosis	[relation to prognosis]	0.0	3	1	1	1
115987	1710	tax sequence	[tax sequences]	0.0	2	1	1	1
115988	1710	same,	[same,]	0.0	1	1	1	1
115989	1710	excisional biopsy	[excisional biopsy]	0.0	2	1	1	1
115990	1710	factor include stat5	[factors including Stat5]	0.0	3	1	1	1
115991	1710	different b /rel subunit	[different B /Rel subunits]	0.0	4	1	1	1
115992	1710	contrast, inhibition beta	[contrast, inhibition beta]	0.0	3	1	1	1
115993	1710	hiv transcript	[HIV transcripts]	0.0	2	1	1	1
115994	1710	formation by nuclear extract	[formation by nuclear extracts]	0.0	4	1	1	1
115995	1710	long repeat ltr	[long repeats LTRs]	0.0	3	1	1	1
115996	1710	adhesion human vein endothelial cell	[adhesion human vein endothelial cells]	0.0	5	1	1	1
115997	1710	comprehensive analysis	[comprehensive analysis]	0.0	2	1	1	1
115998	1710	pml -dependent pathway	[PML -dependent pathways]	0.0	3	1	1	1
115999	1710	alpha-Dihydroxicholecalciferol	[alpha-Dihydroxicholecalciferol]	0.0	1	1	1	1
116000	1710	CD38 expression in cell	[CD38 expression in cells]	0.0	4	1	1	1
116001	1710	hypo-acetylation	[hypo-acetylation]	0.0	1	1	1	1
116002	1710	hormone inhibition of tumor cell cytostasis	[hormone inhibition of tumor cell cytostasis]	0.0	6	1	1	1
116003	1710	use magnetic bead	[Using magnetic beads]	0.0	3	1	1	1
116004	1710	only after internalization from apical surface.	[only after internalization from apical surface.]	0.0	6	1	1	1
116005	1710	multiple molecular partners,	[multiple molecular partners,]	0.0	3	1	1	1
116006	1710	pha peripheral blood lymphocyte pbl	[PHA peripheral blood lymphocytes PBL]	0.0	5	1	1	1
116007	1710	"SFS" domain	["SFS" domain]	0.0	2	1	1	1
116008	1710	comprise domain of the p85 subunit	[comprising domains of the p85 subunit]	0.0	6	1	1	1
116009	1710	absence of ascorbate	[absence of ascorbate]	0.0	3	1	1	1
116010	1710	rearrangement of kappa light-chain gene	[rearrangement of kappa light-chain genes]	0.0	5	1	1	1
116011	1710	member of the apoptotic cascade	[members of the apoptotic cascade]	0.0	5	1	1	1
116012	1710	role for Sp1	[role for Sp1]	0.0	3	1	1	1
116013	1710	feature of senescent T cell	[feature of senescent T cells]	0.0	5	1	1	1
116014	1710	hiv-1 long repeat LTR transcription	[HIV-1 long repeat LTR transcription]	0.0	5	1	1	1
116015	1710	consist of function	[consisting of functions]	0.0	3	1	1	1
116016	1710	human C gamma gene	[human C gamma gene]	0.0	4	2	2	1
116017	1710	extent in control cell	[extents in control cells]	0.0	4	1	1	1
116018	1710	TACI activation	[TACI activation]	0.0	2	1	1	1
116019	1710	restrict expression	[restricting expression]	0.0	2	1	1	1
116020	1710	functional heterodimer	[functional heterodimers]	0.0	2	1	1	1
116021	1710	additional protein factor	[additional protein factors]	0.0	3	1	1	1
116022	1710	specificity of transcriptional regulator	[specificity of transcriptional regulators]	0.0	4	1	1	1
116023	1710	resemble factor	[resembling factor]	0.0	2	1	1	1
116024	1710	72 P;	[72 h;]	0.0	2	1	1	1
116025	1710	part, to the modulation	[part, to the modulation]	0.0	4	1	1	1
116026	1710	important pathway	[important pathway]	0.0	2	1	1	1
116027	1710	nfkb2 p52 induction	[NFKB2 p52 induction]	0.0	3	1	1	1
116028	1710	lead in this cells.	[leading in these cells.]	0.0	4	1	1	1
116029	1710	factor treatment of neutrophils.	[factor treatment of neutrophils.]	0.0	4	1	1	1
116030	1710	oxidative stress on signal transduction	[oxidative stress on signal transduction]	0.0	5	1	1	1
116031	1710	myeloid-specific zinc finger protein	[myeloid-specific zinc finger protein]	0.0	4	1	1	1
116032	1710	human pre-B-cell line	[human pre-B-cell lines]	0.0	3	1	1	1
116033	1710	element restrict expression	[elements restricting expression]	0.0	3	1	1	1
116034	1710	158 base pair	[158 base pairs]	0.0	3	1	1	1
116035	1710	deletion (940-984) region	[Deletions (940-984) region]	0.0	3	1	1	1
116036	1710	use of stabilizer	[use of stabilizers]	0.0	3	1	1	1
116037	1710	such as asthma	[such as asthma]	0.0	3	1	1	1
116038	1710	dominant molecule of pkc-zeta	[dominant molecule of PKC-zeta]	0.0	4	1	1	1
116039	1710	interaction with PKC	[interaction with PKC]	0.0	3	1	1	1
116040	1710	NF-kappa b homodimer	[NF-kappa B homodimer]	0.0	3	1	1	1
116041	1710	two b DNA binding site	[two B DNA binding sites]	0.0	5	1	1	1
116042	1710	serum androgen	[serum androgens]	0.0	2	2	2	1
116043	1710	sp site in bja-b cell	[Sp site in BJA-B cells]	0.0	5	1	1	1
116044	1710	activity in	[activities in]	0.0	2	1	1	1
116045	1710	cohort of patient with disease	[cohorts of patients with diseases]	0.0	5	1	1	1
116046	1710	single base pair mutation	[single base pair mutation]	0.0	4	1	1	1
116047	1710	synthesis of ROI	[synthesis of ROI]	0.0	3	1	1	1
116048	1710	tg epsilon26 mouse	[tg epsilon26 mice]	0.0	3	1	1	1
116049	1710	g/g of mrna in rest lymphocyte	[g/g of mRNA in resting lymphocytes]	0.0	6	1	1	1
116050	1710	50% effective dose	[50% effective dose]	0.0	3	1	1	1
116051	1710	major protein-binding site within the element	[major protein-binding sites within the element]	0.0	6	1	1	1
116052	1710	activation of environmental carcinogen	[activation of environmental carcinogens]	0.0	4	1	1	1
116053	1710	trans-activating effect	[trans-activating effects]	0.0	2	1	1	1
116054	1710	c/ebpepsilon gene	[C/EBPepsilon gene]	0.0	2	1	1	1
116055	1710	-ig/ebp-1	[-Ig/EBP-1]	0.0	1	1	1	1
116056	1710	sequence from -417 to -207	[sequences from -417 to -207]	0.0	5	1	1	1
116057	1710	hiv-1 pathogenesis	[HIV-1 pathogenesis]	0.0	2	1	1	1
116058	1710	follow stimulation, lymphocyte activation	[following stimulation, lymphocyte activation]	0.0	4	1	1	1
116059	1710	stimulation by ligation of CD40 ag	[Stimulation by ligation of CD40 Ag]	0.0	6	1	1	1
116060	1710	icp27	[ICP27]	0.0	1	1	1	1
116061	1710	region of histocompatibility class molecule	[regions of histocompatibility class molecules]	0.0	5	1	1	1
116062	1710	Jurkat in the regulation of c-fo	[Jurkat in the regulation of c-fos]	0.0	6	1	1	1
116063	1710	PU.1 /elf-1 site	[PU.1 /Elf-1 site]	0.0	3	2	2	1
116064	1710	furthermore, prolonged degradation of ikappab-alpha	[Furthermore, prolonged degradation of IkappaB-alpha]	0.0	5	1	1	1
116065	1710	measure the contribution	[measuring the contribution]	0.0	3	1	1	1
116066	1710	human thrombospondin gene	[human thrombospondin gene]	0.0	3	1	1	1
116067	1710	new exon	[new exon]	0.0	2	1	1	1
116068	1710	cell line bms2.4	[cell line BMS2.4]	0.0	3	1	1	1
116069	1710	c6.1b/mtcp1 A1 transcript	[c6.1B/MTCP1 A1 transcript]	0.0	3	1	1	1
116070	1710	log-fold glucocorticoid for a degree	[log-fold glucocorticoids for an degree]	0.0	5	1	1	1
116071	1710	monocytic gene	[monocytic genes]	0.0	2	1	1	1
116072	1710	lead to tnf-alpha production	[leading to TNF-alpha production]	0.0	4	1	1	1
116073	1710	tumor with ki-67 values.	[tumors with Ki-67 values.]	0.0	4	1	1	1
116074	1710	skewedness of random x-inactivation	[skewedness of random X-inactivation]	0.0	4	1	1	1
116075	1710	population of effector cell	[populations of effector cells]	0.0	4	1	1	1
116076	1710	subset with translocation	[subsets with translocation]	0.0	3	1	1	1
116077	1710	keep property in vitro	[keeping properties in vitro]	0.0	4	1	1	1
116078	1710	level of hydrogen peroxide	[level of hydrogen peroxide]	0.0	4	1	1	1
116079	1710	f.r., m.m., P.	[F.R., M.M., P.]	0.0	3	1	1	1
116080	1710	306 +/-	[306 +/-]	0.0	2	1	1	1
116081	1710	ap-1/tpa element	[AP-1/TPA elements]	0.0	2	1	1	1
116082	1710	structure similar	[structure similar]	0.0	2	1	1	1
116083	1710	6.04 2.35 fmol/10(6) cell	[6.04 2.35 fmol/10(6) cells]	0.0	4	1	1	1
116084	1710	inflammation include interleukin-1	[inflammation including interleukin-1]	0.0	3	1	1	1
116085	1710	neuropeptide enkephalin	[neuropeptide enkephalin]	0.0	2	1	1	1
116086	1710	human melanoma MMs	[human melanomas MMs]	0.0	3	1	1	1
116087	1710	role switch during stage	[Role switching during stages]	0.0	4	1	1	1
116088	1710	human MHC class ii gene	[human MHC class II genes]	0.0	5	1	1	1
116089	1710	recombinant ghf-1	[recombinant GHF-1]	0.0	2	1	1	1
116090	1710	interaction between positive regulatory element	[interactions between positive regulatory elements]	0.0	5	1	1	1
116091	1710	2 transcription	[2 transcription]	0.0	2	1	1	1
116092	1710	proximal arm	[proximal arm]	0.0	2	1	1	1
116093	1710	zinc-binding transcription factor	[zinc-binding transcription factor]	0.0	3	1	1	1
116094	1710	role in viral gene expression	[role in viral gene expression]	0.0	5	1	1	1
116095	1710	human osteosarcoma	[human osteosarcoma]	0.0	2	1	1	1
116096	1710	E2F-I bind	[E2F-I binding]	0.0	2	1	1	1
116097	1710	contain a novel element	[containing a novel element]	0.0	4	1	1	1
116098	1710	100-500 microm OP	[100-500 microM OP]	0.0	3	1	1	1
116099	1710	degree in immunity	[degree in immunity]	0.0	3	1	1	1
116100	1710	deletional mutagenesis analysis	[deletional mutagenesis analyses]	0.0	3	1	1	1
116101	1710	N17-mutated dominant-negative Ras construct	[N17-mutated dominant-negative Ras construct]	0.0	4	1	1	1
116102	1710	phosphatase-positive cell	[phosphatase-positive cells]	0.0	2	1	1	1
116103	1710	controls, blood cell	[controls, blood cell]	0.0	3	1	1	1
116104	1710	use pd-98059 two inhibitor of MEK1	[using PD-98059 two inhibitors of MEK1]	0.0	6	1	1	1
116105	1710	progeny in vitro,	[progeny in vitro,]	0.0	3	1	1	1
116106	1710	only a degree	[only a degree]	0.0	3	1	1	1
116107	1710	proliferation reduction	[proliferation reduction]	0.0	2	1	1	1
116108	1710	lineage-dependent abrogation	[lineage-dependent abrogation]	0.0	2	1	1	1
116109	1710	nuclear factor-kappaB NFkappaB in memory	[nuclear factor-kappaB NFkappaB in memory]	0.0	5	1	1	1
116110	1710	interleukin-2 receptor beta-chain promoter	[interleukin-2 receptor beta-chain promoter]	0.0	4	1	1	1
116111	1710	human genomic DNA	[human genomic DNA]	0.0	3	1	1	1
116112	1710	b-cell-specific ciita	[B-cell-specific CIITA]	0.0	2	1	1	1
116113	1710	hormone therapy	[hormone therapy]	0.0	2	1	1	1
116114	1710	contain near-perfect direct repeat DR	[containing near-perfect direct repeats DR]	0.0	5	1	1	1
116115	1710	transfection of HEK cell	[transfection of HEK cells]	0.0	4	1	1	1
116116	1710	lack Rel	[lacking Rel]	0.0	2	1	1	1
116117	1710	include various growth factor	[including various growth factors]	0.0	4	1	1	1
116118	1710	acetylation of erythroid factor eklf activity	[Acetylation of erythroid factor EKLF activity]	0.0	6	1	1	1
116119	1710	hypophyseal	[hypophyseal]	0.0	1	1	1	1
116120	1710	even dose of ionizing radiation	[even doses of ionizing radiation]	0.0	5	1	1	1
116121	1710	multiple nf-atc isoform with individual property	[Multiple NF-ATc isoforms with individual properties]	0.0	6	1	1	1
116122	1710	class of oncogene	[class of oncogenes]	0.0	3	1	1	1
116123	1710	IFNgamma- gene expression	[IFNgamma- gene expression]	0.0	3	1	1	1
116124	1710	test:	[test:]	0.0	1	1	1	1
116125	1710	nucleotide binding	[nucleotide binding]	0.0	2	1	1	1
116126	1710	participation of STAT4	[participation of STAT4]	0.0	3	1	1	1
116127	1710	stimulation of human cd4+ t-cell clone	[Stimulation of human CD4+ T-cell clones]	0.0	6	1	1	1
116128	1710	CsA component limit signal	[CsA component limiting signaling]	0.0	4	1	1	1
116129	1710	interference of RU with dexamethasone	[interference of RU with dexamethasone]	0.0	5	1	1	1
116130	1710	50 kD polypeptide	[50 kD polypeptide]	0.0	3	1	1	1
116131	1710	major protein of 52 kD	[major protein of 52 kD]	0.0	5	1	1	1
116132	1710	vertebrate homolog of Zfh-1	[vertebrate homolog of Zfh-1]	0.0	4	1	1	1
116133	1710	peripheral cd56+ cd16+ killer cell	[peripheral CD56+ CD16+ killer cells]	0.0	5	1	1	1
116134	1710	bronchial subject	[bronchial subjects]	0.0	2	1	1	1
116135	1710	binding of specific factor in	[binding of specific factors in]	0.0	5	1	1	1
116136	1710	interaction NF-kappaB/NFAT protein	[interactions NF-kappaB/NFAT proteins]	0.0	3	1	1	1
116137	1710	12 woman age.	[12 women age.]	0.0	3	1	1	1
116138	1710	antigen, t-cell signal	[antigen, T-cell signals]	0.0	3	1	1	1
116139	1710	CRF patient fmol/10(6) cell	[CRF patients fmol/10(6) cells]	0.0	4	1	1	1
116140	1710	observation of stress-induced down-regulation	[observation of stress-induced down-regulation]	0.0	4	1	1	1
116141	1710	pattern of response	[patterns of responses]	0.0	3	1	1	1
116142	1710	concentration of the ligand, start	[concentrations of the ligand, starting]	0.0	5	1	1	1
116143	1710	OM-10.1	[OM-10.1]	0.0	1	1	1	1
116144	1710	colony-forming unit cfu-il6 in C/EBPalpha mouse	[colony-forming units CFU-IL6 in C/EBPalpha mice]	0.0	6	1	1	1
116145	1710	abnormal expression of Aldh1	[abnormal expression of Aldh1]	0.0	4	1	1	1
116146	1710	cytotoxicity of antisense phosphorothioate oligodeoxynucleotides	[cytotoxicity of antisense phosphorothioate oligodeoxynucleotides]	0.0	5	1	1	1
116147	1710	alpha-naphthyl-acetate-esterase naf-r-nse	[alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	2	1	1	1
116148	1710	trans-act dominant regulator	[trans-acting dominant regulator]	0.0	3	1	1	1
116149	1710	use enhancer	[using enhancers]	0.0	2	1	1	1
116150	1710	binding of [3H]dexamethasone (p 0.01)	[binding of [3H]dexamethasone (P 0.01)]	0.0	5	1	1	1
116151	1710	bind except for pu.1/spi-1	[binding except for PU.1/Spi-1]	0.0	4	1	1	1
116152	1710	nuclearity, cover the entire surface	[nuclearity, covering the entire surface]	0.0	5	1	1	1
116153	1710	important effect on T cell function	[important effects on T cell function]	0.0	6	1	1	1
116154	1710	aml1 AML1a	[AML1 AML1a]	0.0	2	1	1	1
116155	1710	frequent absence of marker	[frequent absence of markers]	0.0	4	1	1	1
116156	1710	relevance of this event	[relevance of these events]	0.0	4	1	1	1
116157	1710	two positive region	[two positive regions]	0.0	3	1	1	1
116158	1710	property of prolactin	[properties of prolactin]	0.0	3	1	1	1
116159	1710	pleural effusion from patient	[Pleural effusions from patients]	0.0	4	1	1	1
116160	1710	Academic press.	[Academic Press.]	0.0	2	16	16	1
116161	1710	receptor related to tnfr-1	[receptor related to TNFR-1]	0.0	4	1	1	1
116162	1710	correlation of tcrzeta level	[Correlations of TCRzeta levels]	0.0	4	1	1	1
116163	1710	promoter precede the exon	[promoter preceding the exon]	0.0	4	1	1	1
116164	1710	dominant negative allele	[dominant negative allele]	0.0	3	1	1	1
116165	1710	activity in specific cell type	[activity in specific cell types]	0.0	5	1	1	1
116166	1710	class ii cell	[class II cells]	0.0	3	1	1	1
116167	1710	pha normal human blood lymphocyte	[PHA normal human blood lymphocytes]	0.0	5	1	1	1
116168	1710	presence receptor-positive lymphocyte	[presence receptor-positive lymphocytes]	0.0	3	1	1	1
116169	1710	(clc)	[(CLC)]	0.0	1	1	1	1
116170	1710	high level in u937	[high levels in U937]	0.0	4	1	1	1
116171	1710	acute leukemic blast	[acute leukemic blasts]	0.0	3	1	1	1
116172	1710	j element	[J element]	0.0	2	1	1	1
116173	1710	cell adhesion of beta 1 integrin	[cell adhesion of beta 1 integrins]	0.0	6	1	1	1
116174	1710	six patient from family	[six patients from families]	0.0	4	1	1	1
116175	1710	expression of tal1 allele	[expression of TAL1 alleles]	0.0	4	1	1	1
116176	1710	peptide assay	[peptide assays]	0.0	2	1	1	1
116177	1710	5-fluorouracil FUra	[5-fluorouracil FUra]	0.0	2	1	1	1
116178	1710	DNA encode a tfiid protein	[DNA encoding a TFIID protein]	0.0	5	1	1	1
116179	1710	lymphocyte of pregnant woman (11	[lymphocytes of pregnant women (11]	0.0	5	1	1	1
116180	1710	characterization of hb24 expression	[Characterization of HB24 expression]	0.0	4	1	1	1
116181	1710	role of p70(s6k) 3-kinase activation	[role of p70(s6k) 3-kinase activation]	0.0	5	1	1	1
116182	1710	efficient hiv-1 transcription	[efficient HIV-1 transcription]	0.0	3	1	1	1
116183	1710	nonsmok patient with reversible airway obstruction	[nonsmoking patients with reversible airways obstruction]	0.0	6	1	1	1
116184	1710	also a receptor	[also a receptor]	0.0	3	1	1	1
116185	1710	the/thf (0.24; alpha thf/thf	[THE/THF (0.24; alpha THF/THF]	0.0	4	1	1	1
116186	1710	transcriptional activation of a reporter	[transcriptional activation of a reporter]	0.0	5	1	1	1
116187	1710	-mediated cell adhesion	[-mediated cell adhesion]	0.0	3	1	1	1
116188	1710	calcium-stimulated, cyclosporin a	[calcium-stimulated, cyclosporin A]	0.0	3	1	1	1
116189	1710	general agreement on the pathogenesis	[general agreement on the pathogenesis]	0.0	5	1	1	1
116190	1710	specific effector cell	[specific effector cells]	0.0	3	1	1	1
116191	1710	clinical response	[clinical response]	0.0	2	1	1	1
116192	1710	highly potent inhibitor	[highly potent inhibitor]	0.0	3	1	1	1
116193	1710	TRAIL apoptosis ligand	[TRAIL apoptosis ligand]	0.0	3	1	1	1
116194	1710	competition between two general transcriptional activator	[competition between two general transcriptional activators]	0.0	6	1	1	1
116195	1710	separation on percoll gradient	[separation on Percoll gradients]	0.0	4	1	1	1
116196	1710	response of blood cell pbmc	[responses of blood cells PBMC]	0.0	5	1	1	1
116197	1710	spectrum of progenitor cell	[spectrum of progenitor cells]	0.0	4	1	1	1
116198	1710	nucleus of dendritic cell	[nucleus of dendritic cells]	0.0	4	1	1	1
116199	1710	differentiation in normal cell	[differentiation in normal cells]	0.0	4	1	1	1
116200	1710	nuclear factor with mobilities,	[nuclear factors with mobilities,]	0.0	4	1	1	1
116201	1710	e2f-4 profile	[E2F-4 profile]	0.0	2	1	1	1
116202	1710	presence of oestrogen er	[presence of oestrogen ER]	0.0	4	1	1	1
116203	1710	cell reporter gene expression	[cell reporter gene expression]	0.0	4	1	1	1
116204	1710	high retinoidal activity	[High retinoidal activity]	0.0	3	1	1	1
116205	1710	evidence proteins, differ	[evidence proteins, differing]	0.0	3	1	1	1
116206	1710	detection in a patient	[Detection in a patient]	0.0	4	1	1	1
116207	1710	functional role in igh gene expression	[functional role in IgH gene expression]	0.0	6	1	1	1
116208	1710	mononuclear phagocyte by leukemia factor	[mononuclear phagocytes by leukemia factor]	0.0	5	1	1	1
116209	1710	lipopolysaccharide-induced expression	[lipopolysaccharide-induced expression]	0.0	2	1	1	1
116210	1710	human peripheral mononuclear	[human peripheral mononuclear]	0.0	3	1	1	1
116211	1710	activator protein-1 factor	[activator protein-1 factor]	0.0	3	1	1	1
116212	1710	morphological differentiation in epidermal cell	[morphological differentiation in epidermal cells]	0.0	5	1	1	1
116213	1710	such as interleukin (il)-2	[such as interleukin (IL)-2]	0.0	4	1	1	1
116214	1710	microsome in term culture	[microsomes in term culture]	0.0	4	1	1	1
116215	1710	thymoma cell	[thymoma cells]	0.0	2	1	1	1
116216	1710	binding of kda protein	[binding of kDa proteins]	0.0	4	1	1	1
116217	1710	CoCl2 cellular signal direct expression	[CoCl2 cellular signals directing expression]	0.0	5	1	1	1
116218	1710	population of CD4	[populations of CD4]	0.0	3	1	1	1
116219	1710	antiserum (identical to 50 kda	[antiserum (identical to 50 kDa]	0.0	5	1	1	1
116220	1710	kappa B-specific activity	[kappa B-specific activity]	0.0	3	1	1	1
116221	1710	putative transcription factor SCL	[putative transcription factor SCL]	0.0	4	1	1	1
116222	1710	general observation of down-regulation	[general observation of down-regulation]	0.0	4	1	1	1
116223	1710	megakaryoblastic leukemia aml-m7	[megakaryoblastic leukemia AML-M7]	0.0	3	1	1	1
116224	1710	enzyme 17beta-hydroxysteroid	[enzyme 17beta-hydroxysteroid]	0.0	2	1	1	1
116225	1710	culture-adapted tax-transformed fibroblast	[culture-adapted Tax-transformed fibroblasts]	0.0	3	1	1	1
116226	1710	leukemia-specific acid receptor	[leukemia-specific acid receptor]	0.0	3	1	1	1
116227	1710	other member of the TNFR superfamily	[other members of the TNFR superfamily]	0.0	6	1	1	1
116228	1710	Positive regulation role of multiple sites.	[Positive regulation role of multiple sites.]	0.0	6	1	1	1
116229	1710	two distinct transcription factor family	[two distinct transcription factor families]	0.0	5	1	1	1
116230	1710	two novel 9-bp motif (-90/-82	[two novel 9-bp motifs (-90/-82]	0.0	5	1	1	1
116231	1710	classic gcr	[classic GCR]	0.0	2	1	1	1
116232	1710	dominant mutant of Ras	[dominant mutants of Ras]	0.0	4	1	1	1
116233	1710	regulatory pathway of the cell systems.	[regulatory pathways of the cell systems.]	0.0	6	1	1	1
116234	1710	model of latent adenovirus	[model of latent adenovirus]	0.0	4	1	1	1
116235	1710	new ets-1-containg complex	[new Ets-1-containing complex]	0.0	3	1	1	1
116236	1710	element AREs	[elements AREs]	0.0	2	1	1	1
116237	1710	important IL-2 cis-regulatory element	[important IL-2 cis-regulatory elements]	0.0	4	1	1	1
116238	1710	peripheral b	[peripheral B]	0.0	2	2	2	1
116239	1710	individual as control	[individuals as control]	0.0	3	1	1	1
116240	1710	same clinical picture	[same clinical picture]	0.0	3	1	1	1
116241	1710	control cell release	[controlling cell release]	0.0	3	1	1	1
116242	1710	synergistic increase	[synergistic increase]	0.0	2	2	2	1
116243	1710	pma-treated fibroblast	[PMA-treated fibroblasts]	0.0	2	1	1	1
116244	1710	specificity of the complex	[specificity of the complex]	0.0	4	1	1	1
116245	1710	datum on the pharmacokinetics	[data on the pharmacokinetics]	0.0	4	1	1	1
116246	1710	contacts,	[contacts,]	0.0	1	1	1	1
116247	1710	decrease in the translocation	[decrease in the translocation]	0.0	4	1	1	1
116248	1710	three additional isoform	[three additional isoforms]	0.0	3	1	1	1
116249	1710	neutralize TNF alpha antibody	[neutralizing TNF alpha antibody]	0.0	4	1	1	1
116250	1710	100-fold further increase	[100-fold further increase]	0.0	3	1	1	1
116251	1710	treatment of infection	[treatment of infection]	0.0	3	1	1	1
116252	1710	persistence of macrophage despite paralysis	[persistence of macrophages despite paralysis]	0.0	5	1	1	1
116253	1710	role for this gene	[role for this gene]	0.0	4	1	1	1
116254	1710	atopic dermatitis patient	[atopic dermatitis patients]	0.0	3	1	1	1
116255	1710	putative human retrovirus	[putative human retrovirus]	0.0	3	1	1	1
116256	1710	study of the hiv-1 LTR	[studies of the HIV-1 LTR]	0.0	5	1	1	1
116257	1710	9s glucocorticoid receptor complex	[9S glucocorticoid receptor complexes]	0.0	4	1	1	1
116258	1710	binding of h- pgg-glucan	[binding of H- PGG-Glucan]	0.0	4	1	1	1
116259	1710	SH3-deleted Grf40 mutant	[SH3-deleted Grf40 mutant]	0.0	3	1	1	1
116260	1710	mediator of the inflammatory response	[mediator of the inflammatory response]	0.0	5	1	1	1
116261	1710	nodular sclerosis	[nodular sclerosis]	0.0	2	1	1	1
116262	1710	kda p65	[kDa p65]	0.0	2	1	1	1
116263	1710	follow cellular activation	[following cellular activation]	0.0	3	1	1	1
116264	1710	steroid-MR complex	[steroid-MR complex]	0.0	2	1	1	1
116265	1710	identify a human disorder	[identifying a human disorder]	0.0	4	1	1	1
116266	1710	relevant concentrations;	[relevant concentrations;]	0.0	2	1	1	1
116267	1710	clonal rearrangement	[clonal rearrangement]	0.0	2	1	1	1
116268	1710	relation between density lipoprotein HDL	[relation between density lipoprotein HDL]	0.0	5	1	1	1
116269	1710	series of 5'-truncation	[series of 5'-truncations]	0.0	3	1	1	1
116270	1710	transactivation by tax	[transactivation by Tax]	0.0	3	1	1	1
116271	1710	rapid non-genomic action	[rapid non-genomic actions]	0.0	3	1	1	1
116272	1710	29 asthma patient	[29 asthma patients]	0.0	3	1	1	1
116273	1710	cis-acting cis-acting segment	[cis-acting cis-acting segment]	0.0	3	1	1	1
116274	1710	dose mm)	[dose mM)]	0.0	2	1	1	1
116275	1710	cryptic epitope for mAb	[cryptic epitopes for mAb]	0.0	4	1	1	1
116276	1710	important inhibitor of vascular inflammation	[important inhibitor of vascular inflammation]	0.0	5	1	1	1
116277	1710	EBNA2 cis-acting element	[EBNA2 cis-acting element]	0.0	3	1	1	1
116278	1710	latency latency	[latency latency]	0.0	2	1	1	1
116279	1710	IgG immune model	[IgG immune model]	0.0	3	1	1	1
116280	1710	specific uptake with renal failure	[specific uptake with renal failure]	0.0	5	1	1	1
116281	1710	basis distinguish carrier	[basis distinguishing carriers]	0.0	3	1	1	1
116282	1710	induction protein 10 differentiation	[induction protein 10 differentiation]	0.0	4	1	1	1
116283	1710	use bacterial constituent such as lps	[using bacterial constituents such as LPS]	0.0	6	1	1	1
116284	1710	vitamin d-dependent ricket type	[vitamin D-dependent rickets type]	0.0	4	1	1	1
116285	1710	thrombin (auc of +/-	[thrombin (AUC of +/-]	0.0	4	1	1	1
116286	1710	suppress shock	[suppressing shock]	0.0	2	1	1	1
116287	1710	herpesvirus biology	[herpesvirus biology]	0.0	2	1	1	1
116288	1710	specific action	[specific actions]	0.0	2	1	1	1
116289	1710	subsequent monocyte arrest	[subsequent monocyte arrest]	0.0	3	1	1	1
116290	1710	include the retinoblastoma protein Rb	[including the retinoblastoma protein Rb]	0.0	5	1	1	1
116291	1710	12 normal woman of childbearing	[12 normal women of childbearing]	0.0	5	1	1	1
116292	1710	type interferon IFN	[type interferon IFN]	0.0	3	1	1	1
116293	1710	hypoxia po2 14-18 Torr,	[hypoxia PO2 14-18 Torr,]	0.0	4	1	1	1
116294	1710	expression of the g protein G(S)alpha	[Expression of the G protein G(S)alpha]	0.0	6	1	1	1
116295	1710	lymphocyte from peripheral blood	[lymphocytes from peripheral blood]	0.0	4	1	1	1
116296	1710	mechanism for the effect.	[mechanism for the effect.]	0.0	4	1	1	1
116297	1710	glomerular mesangial cell	[glomerular mesangial cells]	0.0	3	1	1	1
116298	1710	potentiate activity on the threshold	[potentiating activity on the threshold]	0.0	5	1	1	1
116299	1710	follow chromosomal translocation in acute leukemia	[following chromosomal translocations in acute leukemias]	0.0	6	1	1	1
116300	1710	change resemble b cell activation	[changes resembling B cell activation]	0.0	5	1	1	1
116301	1710	lt-293 CAT activity	[LT-293 CAT activity]	0.0	3	1	1	1
116302	1710	cover the coding sequence	[covering the coding sequence]	0.0	4	1	1	1
116303	1710	signalling network	[signalling network]	0.0	2	1	1	1
116304	1710	predominant androgen	[predominant androgen]	0.0	2	1	1	1
116305	1710	inhibitor of map kinase	[Inhibitors of MAP kinase]	0.0	4	1	1	1
116306	1710	immunodeficiency virus replication in phagocyte	[immunodeficiency virus replication in phagocytes]	0.0	5	1	1	1
116307	1710	cell death by tissue inhibitor	[cell death by tissue inhibitor]	0.0	5	1	1	1
116308	1710	acute myeloid patient	[acute myeloid patients]	0.0	3	1	1	1
116309	1710	member share similar DNA binding specificity	[members sharing similar DNA binding specificities]	0.0	6	1	1	1
116310	1710	expression of mutant form	[expression of mutant forms]	0.0	4	1	1	1
116311	1710	titre antibody	[titre antibodies]	0.0	2	1	1	1
116312	1710	competence of a subfamily	[competence of a subfamily]	0.0	4	1	1	1
116313	1710	disease of kidney under condition	[disease of kidney under conditions]	0.0	5	1	1	1
116314	1710	cell turnover	[cell turnover]	0.0	2	1	1	1
116315	1710	bp hEpoR promoter	[bp hEpoR promoter]	0.0	3	1	1	1
116316	1710	nuclear form of NF-AT	[nuclear form of NF-AT]	0.0	4	1	1	1
116317	1710	study cytokine regulation of hiv-1	[studying cytokine regulation of HIV-1]	0.0	5	1	1	1
116318	1710	estrogen receptor content of blood lymphocyte	[Estrogen receptor content of blood lymphocytes]	0.0	6	1	1	1
116319	1710	stimulation complex	[Stimulation complex]	0.0	2	1	1	1
116320	1710	constitutive expression of nf-kappab	[constitutive expression of NF-kappaB]	0.0	4	1	1	1
116321	1710	5 would	[5 d]	0.0	2	1	1	1
116322	1710	incubation from individual in IL-2	[incubation from individuals in IL-2]	0.0	5	1	1	1
116323	1710	hiv type transcription in cell-free assay	[HIV type transcription in cell-free assays]	0.0	6	1	1	1
116324	1710	use the pkc inhibitor 31-8425	[using the PKC inhibitor 31-8425]	0.0	5	1	1	1
116325	1710	only cell with nef gene	[only cells with nef genes]	0.0	5	1	1	1
116326	1710	regulation of the translational machinery	[regulation of the translational machinery]	0.0	5	1	1	1
116327	1710	incidence with cytomegalovirus CMV	[incidence with cytomegalovirus CMV]	0.0	4	1	1	1
116328	1710	role in the igh enhancer	[role in the IgH enhancer]	0.0	5	1	1	1
116329	1710	unique functional fashion.	[unique functional fashion.]	0.0	3	1	1	1
116330	1710	adhesion of monocyte the tethering factor	[Adhesion of monocytes the tethering factor]	0.0	6	1	1	1
116331	1710	transcriptional activation the gene promoter	[transcriptional activation the gene promoter]	0.0	5	1	1	1
116332	1710	rest vein endothelial cell HUVEC	[resting vein endothelial cells HUVEC]	0.0	5	1	1	1
116333	1710	contrast to activation	[contrast to activation]	0.0	3	1	1	1
116334	1710	v-erbA oncogene action	[v-erbA oncogene action]	0.0	3	1	1	1
116335	1710	express t-cell (tcr) region beta-chain family	[expressing T-cell (TCR) region beta-chain families]	0.0	6	1	1	1
116336	1710	participation of separate cis-acting element	[participation of separate cis-acting elements]	0.0	5	1	1	1
116337	1710	resting pbl	[resting PBL]	0.0	2	1	1	1
116338	1710	statg in human myeloid cell	[StatG in human myeloid cells]	0.0	5	1	1	1
116339	1710	cdc2 gene	[cdc2 gene]	0.0	2	1	1	1
116340	1710	recent-onset iddm subject	[recent-onset IDDM subjects]	0.0	3	1	1	1
116341	1710	antiatherogenic mechanism	[antiatherogenic mechanism]	0.0	2	1	1	1
116342	1710	relative affinity to,	[relative affinity to,]	0.0	3	1	1	1
116343	1710	hiv-2 tat	[HIV-2 tat]	0.0	2	1	1	1
116344	1710	southwestern renaturation experiment	[Southwestern renaturation experiments]	0.0	3	1	1	1
116345	1710	region of several human sequence	[regions of several human sequences]	0.0	5	1	1	1
116346	1710	process essential to a response	[processes essential to an response]	0.0	5	1	1	1
116347	1710	different research groups.	[different research groups.]	0.0	3	1	1	1
116348	1710	cytokine in th cell	[cytokines in Th cells]	0.0	4	1	1	1
116349	1710	pkc stimulator	[PKC stimulator]	0.0	2	1	1	1
116350	1710	link between pathway	[link between pathways]	0.0	3	1	1	1
116351	1710	purine-rich stretch with multiple site	[purine-rich stretches with multiple sites]	0.0	5	1	1	1
116352	1710	IFNgamma ip-10 mrna	[IFNgamma IP-10 mRNA]	0.0	3	1	1	1
116353	1710	ebv-transformed 244b lymphoblastoid cell	[EBV-transformed 244B lymphoblastoid cells]	0.0	4	1	1	1
116354	1710	role of tissue damage	[role of tissue damage]	0.0	4	1	1	1
116355	1710	nonactive fragment in yeast	[nonactive fragments in yeast]	0.0	4	1	1	1
116356	1710	first detailed analysis	[first detailed analysis]	0.0	3	1	1	1
116357	1710	STAT1 activation during monocyte	[STAT1 activation during monocyte]	0.0	4	1	1	1
116358	1710	chimeric ebna2 gene	[chimeric EBNA2 gene]	0.0	3	1	1	1
116359	1710	eukaryotic protein	[eukaryotic proteins]	0.0	2	1	1	1
116360	1710	fraction follow platelet activation	[fraction following platelet activation]	0.0	4	1	1	1
116361	1710	oligomer representative	[oligomers representative]	0.0	2	1	1	1
116362	1710	number of T lymphocyte	[numbers of T lymphocytes]	0.0	4	1	1	1
116363	1710	elevation of AMP	[elevation of AMP]	0.0	3	1	1	1
116364	1710	include the ca2+ protein kinase	[including the Ca2+ protein kinase]	0.0	5	1	1	1
116365	1710	transfectant variant	[transfectant variants]	0.0	2	1	1	1
116366	1710	tumor necrosis factor-alpha inhibitor	[tumor necrosis factor-alpha inhibitor]	0.0	4	1	1	1
116367	1710	series of parental hl-60 subclone	[series of parental HL-60 subclones]	0.0	5	1	1	1
116368	1710	moreover, the only factor present	[Moreover, the only factor present]	0.0	5	1	1	1
116369	1710	component lead to activation	[component leading to activation]	0.0	4	1	1	1
116370	1710	heat stable alkaline phosphatase	[heat stable alkaline phosphatase]	0.0	4	1	1	1
116371	1710	immune effect	[immune effects]	0.0	2	1	1	1
116372	1710	expression in the liver	[expression in the liver]	0.0	4	1	1	1
116373	1710	cell of the hematopoietic system.	[cells of the hematopoietic system.]	0.0	5	1	1	1
116374	1710	mutation in the noncode region	[mutations in the noncoding region]	0.0	5	1	1	1
116375	1710	nuclear mobilization of a fraction	[nuclear mobilization of a fraction]	0.0	5	1	1	1
116376	1710	role for Notch-1	[role for Notch-1]	0.0	3	1	1	1
116377	1710	reexpression of MHC class gene	[reexpression of MHC class genes]	0.0	5	1	1	1
116378	1710	NFAT-1 region	[NFAT-1 region]	0.0	2	1	1	1
116379	1710	results, Azeptin	[results, Azeptin]	0.0	2	1	1	1
116380	1710	binding of Sp1 in extract	[binding of Sp1 in extracts]	0.0	5	1	1	1
116381	1710	two activity of glucocorticoid transactivation	[two activities of glucocorticoids transactivation]	0.0	5	1	1	1
116382	1710	CMV early gene product expression	[CMV early gene product expression]	0.0	5	1	1	1
116383	1710	intact segment	[intact segment]	0.0	2	1	1	1
116384	1710	cytokine production from human T cell	[cytokine production from human T cells]	0.0	6	1	1	1
116385	1710	gene of human cytomegalovirus	[genes of human cytomegalovirus]	0.0	4	1	1	1
116386	1710	cytokine receptor gamma chain	[cytokine receptor gamma chain]	0.0	4	1	1	1
116387	1710	characterization of novel lymphoma cell line	[characterization of novel lymphoma cell lines]	0.0	6	1	1	1
116388	1710	defect in t-cell signal molecule	[defects in T-cell signaling molecules]	0.0	5	1	1	1
116389	1710	infection of human phagocyte	[infection of human phagocytes]	0.0	4	1	1	1
116390	1710	underlying mechanism for effect	[underlying mechanism for effects]	0.0	4	1	1	1
116391	1710	dextran	[dextran]	0.0	1	2	2	1
116392	1710	monocyte-macrophage lineage	[monocyte-macrophage lineage]	0.0	2	1	1	1
116393	1710	35 day	[35 days]	0.0	2	1	1	1
116394	1710	regulation in myelomonocytic cell line	[regulation in myelomonocytic cell lines]	0.0	5	1	1	1
116395	1710	three cytosin	[three cytosins]	0.0	2	1	1	1
116396	1710	high concentration of immunodominant peptide	[high concentrations of immunodominant peptide]	0.0	5	1	1	1
116397	1710	Cgamma1	[Cgamma1]	0.0	1	1	1	1
116398	1710	tnf-alpha contain medium	[TNF-alpha containing medium]	0.0	3	1	1	1
116399	1710	interactor	[interactor]	0.0	1	1	1	1
116400	1710	alter nonproductive interaction	[altering nonproductive interactions]	0.0	3	1	1	1
116401	1710	5-fluorouracil toxicity secondary	[5-fluorouracil toxicity secondary]	0.0	3	1	1	1
116402	1710	transcription factor participate quantitatively	[transcription factor participating quantitatively]	0.0	4	1	1	1
116403	1710	dst mg).	[DST mg).]	0.0	2	1	1	1
116404	1710	cell reporter plasmid	[cells reporter plasmids]	0.0	3	1	1	1
116405	1710	rodent mutant cell in-leucyl-tRNA synthetase	[rodent mutant cells in-leucyl-tRNA synthetase]	0.0	5	1	1	1
116406	1710	treatment with schedule	[Treatment with schedules]	0.0	3	1	1	1
116407	1710	polyclonal b lymphocyte	[polyclonal B lymphocytes]	0.0	3	1	1	1
116408	1710	IL-10 c-fo expression	[IL-10 c-fos expression]	0.0	3	1	1	1
116409	1710	61 pmol/L; in normal pregnant woman	[61 pmol/L; in normal pregnant women]	0.0	6	1	1	1
116410	1710	use the sequence gas oligonucleotide	[using the sequence GAS oligonucleotides]	0.0	5	1	1	1
116411	1710	dna-binding regulatory property	[DNA-binding regulatory properties]	0.0	3	1	1	1
116412	1710	antigen, t-cell	[antigen, T-cell]	0.0	2	1	1	1
116413	1710	DU528 a line	[DU528 a line]	0.0	3	1	1	1
116414	1710	encode protein in the ap-1 complex	[encoding proteins in the AP-1 complex]	0.0	6	1	1	1
116415	1710	soluble fas ligand	[soluble Fas ligand]	0.0	3	1	1	1
116416	1710	overexpression CN a Ca2+/calmodulin-dependent protein phosphatase	[overexpression CN a Ca2+/calmodulin-dependent protein phosphatase]	0.0	6	1	1	1
116417	1710	d oligonucleotide in a manner.	[ds oligonucleotides in a manner.]	0.0	5	1	1	1
116418	1710	underlying etiology	[underlying etiology]	0.0	2	1	1	1
116419	1710	activity in haematopoietic tumour	[activity in haematopoietic tumours]	0.0	4	1	1	1
116420	1710	change in cell glutathione	[changes in cell glutathione]	0.0	4	1	1	1
116421	1710	ssb T	[SSB T]	0.0	2	1	1	1
116422	1710	catalytic activation in T cell	[catalytic activation in T cells]	0.0	5	1	1	1
116423	1710	transcriptional inhibition of gene	[transcriptional inhibition of genes]	0.0	4	1	1	1
116424	1710	induce distress syndrome	[inducing distress syndrome]	0.0	3	1	1	1
116425	1710	stable divergence	[stable divergence]	0.0	2	1	1	1
116426	1710	monocytic cell a component	[monocytic cells a component]	0.0	4	1	1	1
116427	1710	mass (50k)	[mass (50K)]	0.0	2	1	1	1
116428	1710	potential pathway for tissue damage	[potential pathways for tissue damage]	0.0	5	1	1	1
116429	1710	effect of beta- estradiol	[effect of beta- estradiol]	0.0	4	1	1	1
116430	1710	antigen ea antigen vca	[antigen EA antigen VCA]	0.0	4	1	1	1
116431	1710	factor of T cell site	[factor of T cell sites]	0.0	5	1	1	1
116432	1710	interaction occur	[interactions occurring]	0.0	2	1	1	1
116433	1710	form include leukemia	[forms including leukemia]	0.0	3	1	1	1
116434	1710	b epsilon	[B epsilon]	0.0	2	1	1	1
116435	1710	two abundant protein	[Two abundant proteins]	0.0	3	1	1	1
116436	1710	mutagenesis in the upstream portion	[mutagenesis in the upstream portion]	0.0	5	1	1	1
116437	1710	uninfected line	[uninfected line]	0.0	2	1	1	1
116438	1710	signal for two chemoattract	[signaling for two chemoattractants]	0.0	4	1	1	1
116439	1710	separate exon	[separate exons]	0.0	2	1	1	1
116440	1710	gamma-ifn DNA binding activity	[gamma-IFN DNA binding activity]	0.0	4	1	1	1
116441	1710	ifn-gamma -inducible expression	[IFN-gamma -inducible expression]	0.0	3	1	1	1
116442	1710	difference (p 0.02)	[difference (P 0.02)]	0.0	3	1	1	1
116443	1710	role for SCL	[role for SCL]	0.0	3	1	1	1
116444	1710	T protein	[T protein]	0.0	2	1	1	1
116445	1710	h-7 used.	[H-7 used.]	0.0	2	1	1	1
116446	1710	region nucleotide	[region nucleotides]	0.0	2	1	1	1
116447	1710	little effect to the ap-1 site	[little effect to the AP-1 site]	0.0	6	1	1	1
116448	1710	embryonic expression a murine member	[embryonic expression a murine member]	0.0	5	1	1	1
116449	1710	nuclear inhibition of transcriptional activation	[nuclear inhibition of transcriptional activation]	0.0	5	1	1	1
116450	1710	fourth g76:gpltplpv (128-135)	[fourth G76:GPLTPLPV (128-135)]	0.0	3	1	1	1
116451	1710	inosine-5'-monophosphate dehydrogenase type	[inosine-5'-monophosphate dehydrogenase type]	0.0	3	1	1	1
116452	1710	human epo cell line	[human EPO cell lines]	0.0	4	1	1	1
116453	1710	human embryonic kidney cell	[human embryonic kidney cells]	0.0	4	1	1	1
116454	1710	role for traf6	[role for TRAF6]	0.0	3	1	1	1
116455	1710	several signal protein	[Several signaling proteins]	0.0	3	1	1	1
116456	1710	cell line of the lineage	[cell lines of the lineage]	0.0	5	1	1	1
116457	1710	gene within the nucleus	[genes within the nucleus]	0.0	4	1	1	1
116458	1710	bhrf1 in mcfffas cell	[BHRF1 in MCF-Fas cells]	0.0	4	1	1	1
116459	1710	control of the locus	[control of the locus]	0.0	4	1	1	1
116460	1710	seven case with tmd	[seven cases with TMD]	0.0	4	1	1	1
116461	1710	direct exposure	[Direct exposure]	0.0	2	2	2	1
116462	1710	135(oh)2d3 receptor in cell	[1,25(OH)2D3 receptors in cells]	0.0	4	1	1	1
116463	1710	affinity sites;	[affinity sites;]	0.0	2	1	1	1
116464	1710	presence of 135-(oh)2d3 receptors; 2)	[presence of 1,25-(OH)2D3 receptors; 2)]	0.0	5	1	1	1
116465	1710	Vignoli, E.Ramazzotti, M.C.Re, G.Visani,	[Vignoli, E.Ramazzotti, M.C.Re, G.Visani,]	0.0	4	1	1	1
116466	1710	first evidence of a role	[first evidence of a role]	0.0	5	1	1	1
116467	1710	number of stretch with site	[number of stretches with sites]	0.0	5	1	1	1
116468	1710	understand the role of p38	[understanding the role of p38]	0.0	5	1	1	1
116469	1710	rel-a translocation	[Rel-A translocation]	0.0	2	1	1	1
116470	1710	effective dose of nm	[effective dose of nM]	0.0	4	1	1	1
116471	1710	ar loci	[AR loci]	0.0	2	1	1	1
116472	1710	early, stage of differentiation	[early, stages of differentiation]	0.0	4	1	1	1
116473	1710	modular structure	[modular structure]	0.0	2	1	1	1
116474	1710	unstimulated peripheral b cell	[unstimulated peripheral B cells]	0.0	4	1	1	1
116475	1710	il-4 in cell	[IL-4 in cells]	0.0	3	1	1	1
116476	1710	FK-506 CsA enzyme	[FK-506 CsA enzyme]	0.0	3	1	1	1
116477	1710	binding to glucocorticoid response element	[binding to glucocorticoid response element]	0.0	5	1	1	1
116478	1710	tandem repeat of the SNE	[tandem repeats of the SNE]	0.0	5	1	1	1
116479	1710	specificities, suggest a role	[specificities, suggesting a role]	0.0	4	1	1	1
116480	1710	basophilia in promyelocytic leukaemia	[basophilia in promyelocytic leukaemia]	0.0	4	1	1	1
116481	1710	repressor by protein	[repressor by proteins]	0.0	3	1	1	1
116482	1710	normal messenger system	[normal messenger systems]	0.0	3	1	1	1
116483	1710	mechanism for progesterone-mediated immunosuppression: inhibition	[mechanism for progesterone-mediated immunosuppression: inhibition]	0.0	5	1	1	1
116484	1710	contrast to recent result	[contrast to recent results]	0.0	4	1	1	1
116485	1710	transcriptionally active heterodimer	[transcriptionally active heterodimers]	0.0	3	1	1	1
116486	1710	histogenetic subtype of hodgkin' disease	[histogenetic subtypes of Hodgkin's disease]	0.0	5	1	1	1
116487	1710	either on the promoter	[either on the promoter]	0.0	4	1	1	1
116488	1710	return to level by 30 min.	[returning to levels by 30 min.]	0.0	6	1	1	1
116489	1710	deletion of p16 of p16	[deletion of p16 of p16]	0.0	5	1	1	1
116490	1710	important mediator of the response	[important mediator of the response]	0.0	5	1	1	1
116491	1710	lymphocytic leukemia CLL	[lymphocytic leukemia CLL]	0.0	3	3	3	1
116492	1710	high expression of this protein	[high expression of these proteins]	0.0	5	1	1	1
116493	1710	T cell by R24	[T cells by R24]	0.0	4	1	1	1
116494	1710	(non t) effect	[(non T) effects]	0.0	3	1	1	1
116495	1710	J delta K	[J delta K]	0.0	3	1	1	1
116496	1710	acid fragment	[acid fragment]	0.0	2	1	1	1
116497	1710	nuclear factor-kappa B/Rel induction	[nuclear factor-kappa B/Rel induction]	0.0	4	1	1	1
116498	1710	differ in degree	[differing in degree]	0.0	3	1	1	1
116499	1710	CD28 -dependent effect	[CD28 -dependent effects]	0.0	3	1	1	1
116500	1710	mechanism contribute to inadequate response	[mechanisms contributing to inadequate response]	0.0	5	1	1	1
116501	1710	free-radical scavenging property	[free-radical scavenging properties]	0.0	3	1	1	1
116502	1710	effect of leukemia inhibitory factor	[effects of leukemia inhibitory factor]	0.0	5	1	1	1
116503	1710	electrophoretic mobility (approximately 120 kd)	[electrophoretic mobility (approximately 120 kD)]	0.0	5	1	1	1
116504	1710	predominance of homodimer	[predominance of homodimers]	0.0	3	1	1	1
116505	1710	patient with active sle	[patients with active SLE]	0.0	4	1	1	1
116506	1710	ATL-16T nuclear extract	[ATL-16T nuclear extract]	0.0	3	1	1	1
116507	1710	neutralize mab	[Neutralizing mAbs]	0.0	2	1	1	1
116508	1710	contain this domain	[containing these domains]	0.0	3	1	1	1
116509	1710	activation of viral replication	[activation of viral replication]	0.0	4	1	1	1
116510	1710	granule mediate early response	[granules mediating early responses]	0.0	4	1	1	1
116511	1710	JAK-1 hela cell	[JAK-1 HeLa cells]	0.0	3	1	1	1
116512	1710	decrease in the switch	[decrease in the switch]	0.0	4	1	1	1
116513	1710	permanent growth	[permanent growth]	0.0	2	1	1	1
116514	1710	okt8+ T	[OKT8+ T]	0.0	2	1	1	1
116515	1710	nf-kappab by pha	[NF-kappaB by PHA]	0.0	3	1	1	1
116516	1710	switch from fetal (gamma)	[switch from fetal (gamma)]	0.0	4	1	1	1
116517	1710	multiple mutation cluster	[multiple mutations clustering]	0.0	3	1	1	1
116518	1710	factor colony-stimumulatelany-stg factor proliferation	[factor colony-stimulating factor proliferation]	0.0	4	1	1	1
116519	1710	signal mediator in human endothelial cell	[signaling mediators in human endothelial cells]	0.0	6	1	1	1
116520	1710	beta-phenyl	[beta-phenyl]	0.0	1	1	1	1
116521	1710	endogenous gc production sialoadhesin	[endogenous GC production sialoadhesin]	0.0	4	1	1	1
116522	1710	inhibit the binding of factor	[inhibiting the binding of factors]	0.0	5	1	1	1
116523	1710	use the potent pkc inhibitor	[using the potent PKC inhibitor]	0.0	5	1	1	1
116524	1710	extracellular concentration of cysteine	[extracellular concentrations of cysteine]	0.0	4	1	1	1
116525	1710	potent inducer of monocyte differentiation	[potent inducers of monocyte differentiation]	0.0	5	1	1	1
116526	1710	alternative splicing pre-mrna	[Alternative splicing pre-mRNA]	0.0	3	1	1	1
116527	1710	lineage follow 3-day exposure	[lineage following 3-day exposures]	0.0	4	1	1	1
116528	1710	retrovirus-like particle	[retrovirus-like particles]	0.0	2	1	1	1
116529	1710	oppose macrophage differentiation	[opposing macrophage differentiation]	0.0	3	1	1	1
116530	1710	long terminal repeat transcriptional activity	[long terminal repeat transcriptional activity]	0.0	5	1	1	1
116531	1710	(c/ebp)	[(C/EBP)]	0.0	1	1	1	1
116532	1710	gene in malignant astrocytomas	[genes in malignant astrocytomas]	0.0	4	1	1	1
116533	1710	long effect with dose	[long-term effects with doses]	0.0	4	1	1	1
116534	1710	include cell from normal individual	[including cells from normal individuals]	0.0	5	1	1	1
116535	1710	human T cell a component	[human T cells a component]	0.0	5	1	1	1
116536	1710	cd34+ cell g-csf 8% cell	[CD34+ cells G-CSF 8% cells]	0.0	5	1	1	1
116537	1710	human homolog c/ebp-beta	[human homolog C/EBP-beta]	0.0	3	1	1	1
116538	1710	more glucocorticoid for a equivalent degree	[more glucocorticoids for an equivalent degree]	0.0	6	1	1	1
116539	1710	cockayne' syndrome	[Cockayne's syndrome]	0.0	2	1	1	1
116540	1710	system study the molecular mechanism	[system studying the molecular mechanisms]	0.0	5	1	1	1
116541	1710	support the transfection datum	[supporting the transfection data.]	0.0	4	1	1	1
116542	1710	HLA-DQ3.2 molecule	[HLA-DQ3.2 molecule]	0.0	2	1	1	1
116543	1710	suggest operational as	[suggesting operational as]	0.0	3	1	1	1
116544	1710	ARH77	[ARH77]	0.0	1	1	1	1
116545	1710	six protein	[six proteins]	0.0	2	1	1	1
116546	1710	insulin mrna	[insulin mRNA]	0.0	2	1	1	1
116547	1710	darc gene	[DARC gene]	0.0	2	1	1	1
116548	1710	functional importance of the region promoter.	[functional importance of the region promoter.]	0.0	6	1	1	1
116549	1710	Extrarenal receptor-effector-mechor-mechanisms for aldosterone the sequence	[Extrarenal receptor-effector-mechanisms for aldosterone the sequence]	0.0	6	1	1	1
116550	1710	about 1.5-1.6 time of the control	[about 1.5-1.6 times of the controls]	0.0	6	1	1	1
116551	1710	cell from ATL patient	[cells from ATL patients]	0.0	4	3	3	1
116552	1710	circulate mononuclear leukocyte of donor	[circulating mononuclear leukocytes of donors]	0.0	5	1	1	1
116553	1710	androgen on immunocompetent cell	[androgens on immunocompetent cells]	0.0	4	1	1	1
116554	1710	thymocyte apoptosis,	[thymocyte apoptosis,]	0.0	2	1	1	1
116555	1710	GR dna-binding domain	[GR DNA-binding domain]	0.0	3	1	1	1
116556	1710	belong by a transdominant mutant	[belonging by a transdominant mutant]	0.0	5	1	1	1
116557	1710	behaviour of Albuminemia	[behaviour of Albuminemia]	0.0	3	1	1	1
116558	1710	factor- element	[factor- elements]	0.0	2	1	1	1
116559	1710	role of BSAP	[role of BSAP]	0.0	3	1	1	1
116560	1710	expression of full-length cDNA clone	[Expression of full-length cDNA clones]	0.0	5	1	1	1
116561	1710	several new steroid	[Several new steroids]	0.0	3	1	1	1
116562	1710	minute of addition	[min of addition]	0.0	3	1	1	1
116563	1710	major cell in the system	[major cells in the system]	0.0	5	1	1	1
116564	1710	chronic inflammatory disorder	[chronic inflammatory disorders]	0.0	3	1	1	1
116565	1710	role of 5-hydroxyeicosatetraenoic acid	[role of 5-hydroxyeicosatetraenoic acid]	0.0	4	1	1	1
116566	1710	representate the spectrum	[representating the spectrum]	0.0	3	1	1	1
116567	1710	Threonine	[Threonine]	0.0	1	1	1	1
116568	1710	only case with a reaction	[only case with a reaction]	0.0	5	1	1	1
116569	1710	highlight putative cancer related loci relevant	[highlighting putative cancer related loci relevant]	0.0	6	1	1	1
116570	1710	assembly of terminal complement complex	[Assembly of terminal complement complexes]	0.0	5	1	1	1
116571	1710	b nuclear translocation	[B nuclear translocation]	0.0	3	1	1	1
116572	1710	hematopoietic stem	[hematopoietic stem]	0.0	2	1	1	1
116573	1710	reveal expression	[revealing expression]	0.0	2	1	1	1
116574	1710	major mechanism for loss	[major mechanism for loss]	0.0	4	1	1	1
116575	1710	study indicate a determinant	[studies indicating an determinant]	0.0	4	1	1	1
116576	1710	hiv-1 tat inhibitor	[HIV-1 Tat inhibitor]	0.0	3	1	1	1
116577	1710	protein in transfection	[proteins in transfection]	0.0	3	1	1	1
116578	1710	repression by ZEB	[repression by ZEB]	0.0	3	1	1	1
116579	1710	membrane-proximal region of il-2r beta	[membrane-proximal region of IL-2R beta]	0.0	5	1	1	1
116580	1710	IL-4 activation of Stat6	[IL-4 activation of Stat6]	0.0	4	1	1	1
116581	1710	hsp60 in human vein cell huvec	[Hsp60 in human vein cells HUVECs]	0.0	6	1	1	1
116582	1710	various mechanism	[various mechanisms]	0.0	2	1	1	1
116583	1710	rapid dominance of pathway	[rapid dominance of pathway]	0.0	4	1	1	1
116584	1710	10(2) cell	[10(2) cells]	0.0	2	1	1	1
116585	1710	beta- globin	[beta- globin]	0.0	2	1	1	1
116586	1710	h stimulation	[h stimulation]	0.0	2	1	1	1
116587	1710	detection of stat-1 by flow cytometry	[Detection of STAT-1 by flow cytometry]	0.0	6	1	1	1
116588	1710	simultaneous immunocytogenetic study	[simultaneous immunocytogenetic studies]	0.0	3	1	1	1
116589	1710	variant FAB aml -m3v	[variant FAB AML -M3v]	0.0	4	1	1	1
116590	1710	cytoplasmic inhibitor of nf-kappab	[cytoplasmic inhibitor of NF-kappaB]	0.0	4	1	1	1
116591	1710	colony-stimumulatelany-stg factor in normal monocyte	[colony-stimulating factor in normal monocytes]	0.0	5	1	1	1
116592	1710	coexpression of a tnf transgene pathology	[coexpression of a TNF transgene pathology]	0.0	6	1	1	1
116593	1710	margin (31% at years).	[margins (31% at years).]	0.0	4	1	1	1
116594	1710	assay of alpha-galactosidase	[assay of alpha-galactosidase]	0.0	3	1	1	1
116595	1710	vacuolar h(+)-atpase	[vacuolar H(+)-ATPase]	0.0	2	1	1	1
116596	1710	aberrancy in regulatory protein	[aberrancies in regulatory proteins]	0.0	4	1	1	1
116597	1710	expression of adhesion molecule-1 icam-1	[expression of adhesion molecule-1 ICAM-1]	0.0	5	1	1	1
116598	1710	5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	6	1	1	1
116599	1710	enhancer upstream of cp	[enhancer upstream of Cp]	0.0	4	1	1	1
116600	1710	corticosteroid cushingd' syndrome	[corticosteroids Cushing's syndrome]	0.0	3	1	1	1
116601	1710	effective dose of t3	[effective dose of T3]	0.0	4	1	1	1
116602	1710	(gh3) cell	[(GH3) cells]	0.0	2	1	1	1
116603	1710	expression of downstream gene	[expression of downstream genes]	0.0	4	1	1	1
116604	1710	patient of various age]	[patients of various age]]	0.0	4	1	1	1
116605	1710	induce differentiation in the absence	[inducing differentiation in the absence]	0.0	5	1	1	1
116606	1710	decrease in clonal growth	[decrease in clonal growth]	0.0	4	1	1	1
116607	1710	transcription factor oct-2a	[transcription factor oct-2A]	0.0	3	1	1	1
116608	1710	nuclear export nuclear factor	[nuclear export nuclear factor]	0.0	4	1	1	1
116609	1710	(3) non-dividing, normal pbl	[(3) non-dividing, normal PBL]	0.0	4	1	1	1
116610	1710	Class ii antigen	[Class II antigen]	0.0	3	1	1	1
116611	1710	microM) of zinc sulfate	[microM) of zinc sulfate]	0.0	4	1	1	1
116612	1710	delta-opioid receptor dor1	[delta-opioid receptor DOR1]	0.0	3	1	1	1
116613	1710	target cell lysis	[target cell lysis]	0.0	3	1	1	1
116614	1710	T cell into subpopulation	[T cells into subpopulations]	0.0	4	1	1	1
116615	1710	down-regulation of many gene	[down-regulation of many genes]	0.0	4	1	1	1
116616	1710	Differential expression of CTCF	[Differential expression of CTCF]	0.0	4	1	1	1
116617	1710	lymphocyte receptor in anorexia nervosa	[lymphocyte receptors in anorexia nervosa]	0.0	5	1	1	1
116618	1710	purine -rich region	[purine -rich region]	0.0	3	1	1	1
116619	1710	role in biology	[role in biology]	0.0	3	2	2	1
116620	1710	evidence of reversion	[evidence of reversion]	0.0	3	1	1	1
116621	1710	cmpd1	[CMPD1]	0.0	1	1	1	1
116622	1710	T cell in tax-expressing	[T cells in Tax-expressing]	0.0	4	1	1	1
116623	1710	anhydrase a gene	[anhydrase a gene]	0.0	3	1	1	1
116624	1710	functional cp a region	[functional Cp a region]	0.0	4	1	1	1
116625	1710	fragment acid	[fragment acids]	0.0	2	1	1	1
116626	1710	thus, a target site	[Thus, a target site]	0.0	4	1	1	1
116627	1710	integrin -ligand interaction	[integrin -ligand interactions]	0.0	3	1	1	1
116628	1710	regulate multiple stage	[regulating multiple stages]	0.0	3	1	1	1
116629	1710	reticulum er	[reticulum ER]	0.0	2	1	1	1
116630	1710	IKK1	[IKK1]	0.0	1	1	1	1
116631	1710	combat	[combat]	0.0	1	1	1	1
116632	1710	pbmc resistance in 21 CRF patient	[PBMC resistance in 21 CRF patients]	0.0	6	1	1	1
116633	1710	combination with RA	[combination with RA]	0.0	3	1	1	1
116634	1710	ICAM-1 steady-state mrna	[ICAM-1 steady-state mRNA]	0.0	3	1	1	1
116635	1710	resolution through two chromatographic step	[Resolution through two chromatographic steps]	0.0	5	1	1	1
116636	1710	oxygen -release	[oxygen -release]	0.0	2	1	1	1
116637	1710	proliferation nk-like cell line	[proliferation NK-like cell line]	0.0	4	1	1	1
116638	1710	potent inductive signal	[potent inductive signal]	0.0	3	1	1	1
116639	1710	B cell-specific nuclear factor	[B cell-specific nuclear factor]	0.0	4	1	1	1
116640	1710	12-day liver	[12-day liver]	0.0	2	1	1	1
116641	1710	level of nuclear nf kappa b	[levels of nuclear NF kappa B]	0.0	6	1	1	1
116642	1710	(71%) iddm subject 8	[(71%) IDDM subjects 8]	0.0	4	1	1	1
116643	1710	rate and/or extent	[rate and/or extent]	0.0	3	1	1	1
116644	1710	pel cell line	[PEL cell lines]	0.0	3	1	1	1
116645	1710	part of the erk activation	[part of the ERK activation]	0.0	5	1	1	1
116646	1710	form of NF-AT	[form of NF-AT]	0.0	3	1	1	1
116647	1710	number in human peripheral leucocyte	[number in human peripheral leucocytes]	0.0	5	2	2	1
116648	1710	progenitor/precursor cell grow	[progenitor/precursor cells growing]	0.0	3	1	1	1
116649	1710	key cellular protein	[key cellular proteins]	0.0	3	1	1	1
116650	1710	underlie the nuclear translocation	[underlying the nuclear translocation]	0.0	4	1	1	1
116651	1710	P. with bcr1/25 a pml/ rar-alpha	[P. with BCR1/25 a pml/ RAR-alpha]	0.0	6	1	1	1
116652	1710	dose of anti-CD3	[dose of anti-CD3]	0.0	3	1	1	1
116653	1710	determination of GH	[determination of GH]	0.0	3	1	1	1
116654	1710	use early progenitor cell HPC	[using early progenitor cells HPC]	0.0	5	1	1	1
116655	1710	appear in myeloblast cell	[appearing in myeloblast cells]	0.0	4	1	1	1
116656	1710	level in level	[levels in levels]	0.0	3	1	1	1
116657	1710	breakdown of IkappaBbeta	[breakdown of IkappaBbeta]	0.0	3	1	1	1
116658	1710	result in gene expression	[resulting in gene expression]	0.0	4	1	1	1
116659	1710	include plasma hormone	[including plasma hormone]	0.0	3	1	1	1
116660	1710	minimal e2re	[minimal E2RE]	0.0	2	1	1	1
116661	1710	glucocorticoid in lymphoblastic leukemia	[glucocorticoids in lymphoblastic leukemia]	0.0	4	1	1	1
116662	1710	cell by treponema pallidum	[cells by Treponema pallidum]	0.0	4	1	1	1
116663	1710	pathway for activation	[pathway for activation]	0.0	3	1	1	1
116664	1710	mechanism underlie the initiation	[mechanism underlying the initiation]	0.0	4	1	1	1
116665	1710	transcriptase polymerase chain reaction analysis	[transcriptase polymerase chain reaction analysis]	0.0	5	1	1	1
116666	1710	activation of the map kinase	[activation of the MAP kinases]	0.0	5	1	1	1
116667	1710	distinct mechanism for n-acetylcysteine inhibition e-selectin	[Distinct mechanisms for N-acetylcysteine inhibition E-selectin]	0.0	6	1	1	1
116668	1710	gata-1 signal	[GATA-1 signals]	0.0	2	1	1	1
116669	1710	CD28 costimulation pathway	[CD28 costimulation pathway]	0.0	3	1	1	1
116670	1710	discordance	[discordance]	0.0	1	1	1	1
116671	1710	suggest a interaction between c-Jun complex	[suggesting a interaction between c-Jun complexes]	0.0	6	1	1	1
116672	1710	immediate-early major tegument protein	[immediate-early major tegument protein]	0.0	4	1	1	1
116673	1710	trans-act regulator	[trans-acting regulator]	0.0	2	1	1	1
116674	1710	immunization express ad5e1a	[immunization expressing Ad5E1A]	0.0	3	1	1	1
116675	1710	include the sry (sex	[including the SRY (sex]	0.0	4	1	1	1
116676	1710	age distribution	[age distribution]	0.0	2	1	1	1
116677	1710	mouse thymus cDNA expression	[mouse thymus cDNA expression]	0.0	4	1	1	1
116678	1710	fusions.	[fusions.]	0.0	1	1	1	1
116679	1710	Negative regulation expression	[Negative regulation expression]	0.0	3	1	1	1
116680	1710	prevent induction of several cytokine	[preventing induction of several cytokine]	0.0	5	1	1	1
116681	1710	GM-CSF receptor beta	[GM-CSF receptor beta]	0.0	3	1	1	1
116682	1710	TH positive effect	[TH positive effect]	0.0	3	1	1	1
116683	1710	adult cell factor pybf	[adult cells factor PYBF]	0.0	4	1	1	1
116684	1710	gene transcription during induction	[gene transcription during induction]	0.0	4	1	1	1
116685	1710	significance in cutaneous carcinogenesis	[significance in cutaneous carcinogenesis]	0.0	4	1	1	1
116686	1710	chemotactic factor for granulocyte	[chemotactic factor for granulocytes]	0.0	4	1	1	1
116687	1710	induction of immediate early response gene	[Induction of immediate early response genes]	0.0	6	1	1	1
116688	1710	hsv/vzv recombinant	[HSV/VZV recombinants]	0.0	2	1	1	1
116689	1710	quality support from a spouse	[quality support from a spouse]	0.0	5	1	1	1
116690	1710	steady state ep<0.05)	[steady state (P<0.05)]	0.0	3	1	1	1
116691	1710	degree of suppression (or lack	[degree of suppression (or lack]	0.0	5	1	1	1
116692	1710	malignant fibrous histiocytoma 6, rhabdomyosarcoma	[malignant fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
116693	1710	parental ut-7 cell	[parental UT-7 cells]	0.0	3	1	1	1
116694	1710	clonality analysis study of clonality	[Clonality analysis study of clonality]	0.0	5	1	1	1
116695	1710	structural characterization	[Structural characterization]	0.0	2	1	1	1
116696	1710	circadian variation in lighting	[circadian variations in lighting]	0.0	4	1	1	1
116697	1710	pathway molecule analysis	[pathway molecule analysis]	0.0	3	1	1	1
116698	1710	tk-3	[TK-3]	0.0	1	1	1	1
116699	1710	study a series	[studying a series]	0.0	3	1	1	1
116700	1710	systemic disorder	[systemic disorder]	0.0	2	1	1	1
116701	1710	less degree,	[lesser degree,]	0.0	2	1	1	1
116702	1710	15.5 (p less than p 0.01	[15.5 (P less than P 0.01]	0.0	6	1	1	1
116703	1710	multiple cytokine deficiency	[multiple cytokine deficiency]	0.0	3	1	1	1
116704	1710	interferon regulatory factor-1	[interferon regulatory factor-1]	0.0	3	1	1	1
116705	1710	bind consensus site	[binding consensus sites]	0.0	3	1	1	1
116706	1710	protein 1 (ap-1) binding site	[protein 1 (AP-1) binding site]	0.0	5	1	1	1
116707	1710	make extract from cell	[making extracts from cells]	0.0	4	1	1	1
116708	1710	role direct the action	[role directing the action]	0.0	4	1	1	1
116709	1710	colitis (56.1 51.6	[colitis (56.1 51.6]	0.0	3	1	1	1
116710	1710	interferon ifn-alpha/beta	[interferons IFN-alpha/beta]	0.0	2	1	1	1
116711	1710	level of basal transcription	[levels of basal transcription]	0.0	4	1	1	1
116712	1710	protein kinase protein kinase a	[protein kinase protein kinase A]	0.0	5	1	1	1
116713	1710	dominant rac	[dominant Rac]	0.0	2	1	1	1
116714	1710	depend on the particular combination	[depending on the particular combination]	0.0	5	1	1	1
116715	1710	other kinase receptor	[other kinase receptors]	0.0	3	1	1	1
116716	1710	suggest a direct effect	[suggesting a direct effect]	0.0	4	1	1	1
116717	1710	X inactivation	[X inactivation]	0.0	2	1	1	1
116718	1710	other compartments.	[other compartments.]	0.0	2	1	1	1
116719	1710	expression in a class ii+	[Expression in a class II+]	0.0	5	1	1	1
116720	1710	induction of hiv repeat transcription	[induction of HIV repeat transcription]	0.0	5	1	1	1
116721	1710	rela -overexpress	[RelA -overexpressing]	0.0	2	1	1	1
116722	1710	dominant ras	[dominant Ras]	0.0	2	1	1	1
116723	1710	PU.1 a member	[PU.1 a member]	0.0	3	1	1	1
116724	1710	great than microm at pH	[greater than microM at pH]	0.0	5	1	1	1
116725	1710	1 alpha,25-dihydroxyvitamin D3 (vitd3)-induced differentiation	[1 alpha,25-dihydroxyvitamin D3 (VitD3)-induced differentiation]	0.0	5	1	1	1
116726	1710	coexpress the v-erbA oncoprotein	[coexpressing the v-erbA oncoprotein]	0.0	4	1	1	1
116727	1710	respect to dissociation constant capacity,	[respect to dissociation constant capacity,]	0.0	5	1	1	1
116728	1710	activity of nuclear extract	[activity of nuclear extracts]	0.0	4	1	1	1
116729	1710	human fetal globin expression	[human fetal globin expression]	0.0	4	1	1	1
116730	1710	Nonradioactive quantification during differentiation of cell	[Nonradioactive quantification during differentiation of cells]	0.0	6	1	1	1
116731	1710	human pulmonary alveolar macrophage	[human pulmonary alveolar macrophages]	0.0	4	1	1	1
116732	1710	wild-type b	[wild-type B]	0.0	2	1	1	1
116733	1710	deficiency virus type 1 hiv-1	[deficiency virus type 1 HIV-1]	0.0	5	1	1	1
116734	1710	gata element of the terminal repeat	[GATA elements of the terminal repeat]	0.0	6	1	1	1
116735	1710	recent investigations,	[recent investigations,]	0.0	2	1	1	1
116736	1710	repeat ltr	[repeats LTRs]	0.0	2	1	1	1
116737	1710	level of c-Jun	[levels of c-Jun]	0.0	3	1	1	1
116738	1710	production in blood monocyte PBM	[production in blood monocytes PBM]	0.0	5	1	1	1
116739	1710	inactive p50 homodimer	[inactive p50 homodimer]	0.0	3	2	2	1
116740	1710	il-13 regulation	[IL-13 regulation]	0.0	2	1	1	1
116741	1710	co-express gata -1	[co-expressing GATA -1]	0.0	3	1	1	1
116742	1710	aspect of down-regulation of inflammation	[aspect of down-regulation of inflammation]	0.0	5	1	1	1
116743	1710	phenotypic marker of osteoclast	[phenotypic markers of osteoclasts]	0.0	4	1	1	1
116744	1710	extract from human T lymphocyte	[extracts from human T lymphocytes]	0.0	5	1	1	1
116745	1710	importance for the absorption	[importance for the absorption]	0.0	4	1	1	1
116746	1710	light regime,	[light regime,]	0.0	2	1	1	1
116747	1710	(hmg-coa)	[(HMG-CoA)]	0.0	1	1	1	1
116748	1710	anti-inflammatory cytokine lps	[anti-inflammatory cytokines LPS]	0.0	3	1	1	1
116749	1710	patency disorder	[patency disorders]	0.0	2	1	1	1
116750	1710	receptor GRE binding	[receptor GRE binding]	0.0	3	1	1	1
116751	1710	different subtype of pel	[different subtypes of PEL]	0.0	4	1	1	1
116752	1710	inhibition of b activity.	[inhibition of B activity.]	0.0	4	1	1	1
116753	1710	dominant effect on the activity	[dominant effect on the activity]	0.0	5	1	1	1
116754	1710	obese:	[obese:]	0.0	1	1	1	1
116755	1710	site for phosphorylation	[sites for phosphorylation]	0.0	3	1	1	1
116756	1710	dephosphorylation of factor	[dephosphorylation of factor]	0.0	3	1	1	1
116757	1710	similar increase in c-fo (99+/-15	[similar increases in c-fos (99+/-15]	0.0	5	1	1	1
116758	1710	frequent expression in human placentae	[frequent expression in human placentae]	0.0	5	1	1	1
116759	1710	low transcription enhancement	[lower transcription enhancement]	0.0	3	1	1	1
116760	1710	growth-regulated expression	[growth-regulated expression]	0.0	2	1	1	1
116761	1710	region of the promoter element	[regions of the promoter elements]	0.0	5	1	1	1
116762	1710	virus type 1 htlv-1	[virus type 1 HTLV-1]	0.0	4	1	1	1
116763	1710	site for E2F	[site for E2F]	0.0	3	1	1	1
116764	1710	e1a-region Ad5E1A234-243	[E1A-region Ad5E1A234-243]	0.0	2	1	1	1
116765	1710	etiology of sclerosis	[etiology of sclerosis]	0.0	3	1	1	1
116766	1710	sertraline response in disorder	[sertraline response in disorder]	0.0	4	1	1	1
116767	1710	specific complex with the gata site	[specific complex with the GATA site]	0.0	6	1	1	1
116768	1710	regulatory cascade	[regulatory cascade]	0.0	2	1	1	1
116769	1710	double time of 25 h	[doubling times of 25 h]	0.0	5	1	1	1
116770	1710	activator of transcription stat6	[activator of transcription Stat6]	0.0	4	1	1	1
116771	1710	T cell domain	[T cell domain]	0.0	3	1	1	1
116772	1710	factor icp0	[factor ICP0]	0.0	2	1	1	1
116773	1710	two site within the regulatory element	[Two sites within the regulatory element]	0.0	6	1	1	1
116774	1710	efficient propagation	[efficient propagation]	0.0	2	1	1	1
116775	1710	case with m7	[cases with M7]	0.0	3	1	1	1
116776	1710	methallothionein	[methallothionein]	0.0	1	1	1	1
116777	1710	gc production sialoadhesin	[GC production sialoadhesin]	0.0	3	1	1	1
116778	1710	-negative status	[-negative status]	0.0	2	1	1	1
116779	1710	T lymphocyte with pge2	[T lymphocytes with PGE2]	0.0	4	1	1	1
116780	1710	suboptimal activation	[suboptimal activation]	0.0	2	1	1	1
116781	1710	deficiency in precursor cell in cell	[deficiencies in precursor cells in cells]	0.0	6	1	1	1
116782	1710	list of regulatory molecule	[list of regulatory molecules]	0.0	4	1	1	1
116783	1710	vector.	[vector.]	0.0	1	1	1	1
116784	1710	potent t-cell-specific enhancer	[potent T-cell-specific enhancer]	0.0	3	1	1	1
116785	1710	p53 pathway (s)	[p53 pathway (s)]	0.0	3	1	1	1
116786	1710	progesterone receptor-specific antibody	[progesterone receptor-specific antibody]	0.0	3	1	1	1
116787	1710	correct fold of the domain, interference	[correct folding of the domain, interference]	0.0	6	1	1	1
116788	1710	erythroid precursor by insertion	[erythroid precursors by insertion]	0.0	4	1	1	1
116789	1710	h from basal level	[h from basal levels]	0.0	4	1	1	1
116790	1710	persist lifelong, usually asymptomatically	[persisting lifelong, usually asymptomatically]	0.0	4	1	1	1
116791	1710	link between ebv	[link between EBV]	0.0	3	1	1	1
116792	1710	replication primary isolate	[replication primary isolate]	0.0	3	1	1	1
116793	1710	mediator of neuroendocrine-immune interaction	[mediators of neuroendocrine-immune interactions]	0.0	4	1	1	1
116794	1710	provide a firm basis for mimicry	[providing a firm basis for mimicry]	0.0	6	1	1	1
116795	1710	patient with corticosteroid asthma	[patients with corticosteroid asthma]	0.0	4	1	1	1
116796	1710	cytokine-induced abnormality in the capability	[cytokine-induced abnormalities in the capability]	0.0	5	1	1	1
116797	1710	transcription factor upstream factor	[transcription factor upstream factor]	0.0	4	1	1	1
116798	1710	unrecognized mechanism regulate sensitivity	[unrecognized mechanism regulating sensitivity]	0.0	4	1	1	1
116799	1710	biopsy from patient with severe vkc	[biopsies from patients with severe VKC]	0.0	6	1	1	1
116800	1710	characterization binding of tax	[characterization Binding of Tax]	0.0	4	1	1	1
116801	1710	chronic myelogenous leukemia cell	[chronic myelogenous leukemia cells]	0.0	4	1	1	1
116802	1710	myd88 gene	[MyD88 gene]	0.0	2	1	1	1
116803	1710	Epstein-Barr antigen expression	[Epstein-Barr antigen expression]	0.0	3	1	1	1
116804	1710	immunodeficiency virus type hiv-1 factor Nef	[immunodeficiency virus type HIV-1 factor Nef]	0.0	6	1	1	1
116805	1710	overexpression of hematopoietic protein- tyrosine phosphatase	[Overexpression of hematopoietic protein- tyrosine phosphatase]	0.0	6	1	1	1
116806	1710	activation-dependent events:	[activation-dependent events:]	0.0	2	1	1	1
116807	1710	steroid receptor drug such as raloxifene	[steroid receptor drugs such as Raloxifene]	0.0	6	1	1	1
116808	1710	extinction of several cell-encoded gene	[extinction of several cell-encoded genes]	0.0	5	1	1	1
116809	1710	b/c-rel protein	[B/c-Rel proteins]	0.0	2	1	1	1
116810	1710	controls).	[controls).]	0.0	1	1	1	1
116811	1710	low ratio	[lower ratio]	0.0	2	1	1	1
116812	1710	smx -nhoh	[SMX -NHOH]	0.0	2	1	1	1
116813	1710	13 patient	[13 patients]	0.0	2	2	2	1
116814	1710	25 h for culture (viability	[25 h for cultures (viability]	0.0	5	1	1	1
116815	1710	inducible oxide synthase gene	[inducible oxide synthase gene]	0.0	4	1	1	1
116816	1710	hemin-treated k562 cell undergo differentiation	[hemin-treated K562 cells undergoing differentiation]	0.0	5	1	1	1
116817	1710	106-kDa component	[106-kDa component]	0.0	2	1	1	1
116818	1710	vitro E-box-dependent reporter gene function	[vitro E-box-dependent reporter gene function]	0.0	5	1	1	1
116819	1710	transluminal coronary angioplasty	[transluminal coronary angioplasty]	0.0	3	1	1	1
116820	1710	5 of 6 evaluable cases,	[5 of 6 evaluable cases,]	0.0	5	1	1	1
116821	1710	Jak1 -express counterpart 1d4	[Jak1 -expressing counterpart 1D4]	0.0	4	1	1	1
116822	1710	terminal differentiation of cell	[terminal differentiation of cells]	0.0	4	1	1	1
116823	1710	cd56+, cd16- NK precursor cell	[CD56+, CD16- NK precursor cells]	0.0	5	1	1	1
116824	1710	case (0.2 microM),	[case (0.2 microM),]	0.0	3	1	1	1
116825	1710	region promoter.	[region promoter.]	0.0	2	1	1	1
116826	1710	activate the transcription factor nf-at	[activating the transcription factors NF-AT]	0.0	5	1	1	1
116827	1710	modulator of gene expression	[modulator of gene expression]	0.0	4	1	1	1
116828	1710	membrane receptor for aldosterone in lymphocyte	[membrane receptors for aldosterone in lymphocytes]	0.0	6	1	1	1
116829	1710	DEX mg orally)	[DEX mg orally)]	0.0	3	1	1	1
116830	1710	determine gene activation	[determining gene activation]	0.0	3	1	1	1
116831	1710	lipopolysaccharide in leukocyte	[lipopolysaccharide in leukocytes]	0.0	3	1	1	1
116832	1710	synthesis of galectin-3	[synthesis of galectin-3]	0.0	3	1	1	1
116833	1710	interferon regulatory factor 2	[interferon regulatory factor 2]	0.0	4	1	1	1
116834	1710	antigen anti-viral capsid antigen vca	[antigen anti-viral capsid antigen VCA]	0.0	5	1	1	1
116835	1710	impdh type gene	[IMPDH type gene]	0.0	3	1	1	1
116836	1710	vivo DMS footprinting	[vivo DMS footprinting]	0.0	3	1	1	1
116837	1710	analysis of regulatory sequence	[analysis of regulatory sequences]	0.0	4	1	1	1
116838	1710	minimal region responsible	[minimal region responsible]	0.0	3	1	1	1
116839	1710	receptor/ gr characteristic	[receptor/s GR characteristics]	0.0	3	1	1	1
116840	1710	various mode	[Various modes]	0.0	2	1	1	1
116841	1710	class heterodimer	[class heterodimers]	0.0	2	1	1	1
116842	1710	factor kappa B site	[factor kappa B site]	0.0	4	1	1	1
116843	1710	information available on the response	[information available on the response]	0.0	5	1	1	1
116844	1710	control of globin gene	[control of globin genes]	0.0	4	1	1	1
116845	1710	up-regulation of il-2	[up-regulation of IL-2]	0.0	3	1	1	1
116846	1710	adenosine triphosphate atp	[adenosine triphosphate ATP]	0.0	3	1	1	1
116847	1710	PMA in combination	[PMA in combination]	0.0	3	1	1	1
116848	1710	assay in monocyte	[assays in monocyte]	0.0	3	1	1	1
116849	1710	difference in redox sensitivity,	[differences in redox sensitivity,]	0.0	4	1	1	1
116850	1710	b lymphocyte from the blood	[B lymphocytes from the blood]	0.0	5	1	1	1
116851	1710	6 day in serum	[6 days in serum]	0.0	4	1	1	1
116852	1710	Messenger RNA mrna level receptor	[Messenger RNA mRNA levels receptor]	0.0	5	1	1	1
116853	1710	nuclear expression of NF-kappaB	[nuclear expression of NF-kappaB]	0.0	4	1	1	1
116854	1710	limitation to antiviral effect	[limitation to antiviral effects]	0.0	4	1	1	1
116855	1710	multimerized region sequence element	[multimerized region sequence elements]	0.0	4	1	1	1
116856	1710	murine macrophage protein 1 alpha	[Murine macrophage protein 1 alpha]	0.0	5	1	1	1
116857	1710	previously, a nuclear factor irf-1	[Previously, a nuclear factor IRF-1]	0.0	5	1	1	1
116858	1710	probably through cell cycle activity	[probably through cell cycle activity]	0.0	5	1	1	1
116859	1710	moreover, TCR	[Moreover, TCR]	0.0	2	1	1	1
116860	1710	carry a LMP1 gene	[carrying an LMP1 gene]	0.0	4	1	1	1
116861	1710	regulation of responses,	[regulation of responses,]	0.0	3	1	1	1
116862	1710	factor KB NF-KB	[factor KB NF-KB]	0.0	3	1	1	1
116863	1710	bind to the ap-1	[binding to the AP-1]	0.0	4	1	1	1
116864	1710	IkappaBalpha a inhibitor	[IkappaBalpha a inhibitor]	0.0	3	1	1	1
116865	1710	(il)-4 stimulation	[(IL)-4 stimulation]	0.0	2	1	1	1
116866	1710	IL-3 granulocyte-macrophage colony-stimumulatelany-stg factor	[IL-3 granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
116867	1710	acute onset within min.	[acute onset within min.]	0.0	4	1	1	1
116868	1710	selective ligand	[selective ligands]	0.0	2	1	1	1
116869	1710	c-Rel heterodimer	[c-Rel heterodimers]	0.0	2	1	1	1
116870	1710	e2f -contain	[E2F -containing]	0.0	2	1	1	1
116871	1710	estrogen lymphoblastoid cell line	[estrogen lymphoblastoid cell lines]	0.0	4	1	1	1
116872	1710	Lymphoid	[Lymphoid]	0.0	1	1	1	1
116873	1710	socs-1 gene expression	[SOCS-1 gene expression]	0.0	3	1	1	1
116874	1710	lymphoma, large cell" type	[lymphoma, large cell" type]	0.0	4	1	1	1
116875	1710	fluticasone propionate for 2 weeks.	[fluticasone propionate for 2 weeks.]	0.0	5	1	1	1
116876	1710	effect at nm	[effect at nM]	0.0	3	1	1	1
116877	1710	human vein cell HUVEC CoCl2	[human vein cells HUVEC CoCl2]	0.0	5	1	1	1
116878	1710	major complex (mhc) haplotype	[major complex (MHC) haplotypes]	0.0	4	1	1	1
116879	1710	activation transactivate function	[activation transactivating functions]	0.0	3	1	1	1
116880	1710	family retinoic acid receptor	[families retinoic acid receptors]	0.0	4	1	1	1
116881	1710	kappab reporter assay	[kappaB reporter assays]	0.0	3	1	1	1
116882	1710	phenotype of female	[phenotype of females]	0.0	3	1	1	1
116883	1710	matrix glycoprotein FN	[matrix glycoprotein FN]	0.0	3	1	1	1
116884	1710	thus, differentiation	[Thus, differentiation]	0.0	2	1	1	1
116885	1710	map kinase signal	[MAP kinase signal]	0.0	3	1	1	1
116886	1710	carboxyl portion	[carboxyl portion]	0.0	2	1	1	1
116887	1710	E2A- leukemia factor HLF protein	[E2A- leukemia factor HLF proteins]	0.0	5	1	1	1
116888	1710	class histocompatibility gene DPA	[class histocompatibility gene DPA]	0.0	4	1	1	1
116889	1710	effect of glucocorticoid on human interleukin	[effects of glucocorticoids on human interleukin]	0.0	6	1	1	1
116890	1710	retinoic acid-alpha receptor	[retinoic acid-alpha receptor]	0.0	3	1	1	1
116891	1710	cytokine -modulate activity a potential antirheumatic	[Cytokine -modulating activity a potential antirheumatic]	0.0	6	1	1	1
116892	1710	occur at minute (phase after reoxygenation	[occurring at minutes (phase after reoxygenation]	0.0	6	1	1	1
116893	1710	-regulatory element	[-regulatory elements]	0.0	2	1	1	1
116894	1710	mechanism of IL-5 signal	[mechanisms of IL-5 signaling]	0.0	4	1	1	1
116895	1710	subsequent active maintenance	[subsequent active maintenance]	0.0	3	1	1	1
116896	1710	BHA a lipid-soluble, chain-break antioxidant	[BHA a lipid-soluble, chain-breaking antioxidant]	0.0	5	1	1	1
116897	1710	analog of alpha,25-dihydroxyvitamin D3 with substitution	[Analogs of alpha,25-dihydroxyvitamin D3 with substitutions]	0.0	6	1	1	1
116898	1710	TcR delta transcript derive	[TcR delta transcripts deriving]	0.0	4	1	1	1
116899	1710	T cell response include il-2	[T cell responses including IL-2]	0.0	5	1	1	1
116900	1710	pHU-14 a probe include sequence	[pHU-14 a probe including sequences]	0.0	5	1	1	1
116901	1710	Sp 1-binding site	[Sp 1-binding sites]	0.0	3	1	1	1
116902	1710	hydroxyurea in k562 cell	[hydroxyurea in K562 cells]	0.0	4	1	1	1
116903	1710	regulatory element act independently	[regulatory elements acting independently]	0.0	4	1	1	1
116904	1710	only individual of histocompatibility (mhc) haplotype	[only individuals of histocompatibility (MHC) haplotypes]	0.0	6	1	1	1
116905	1710	possibly reflect difference in glucocorticoid sensitivity	[possibly reflecting differences in glucocorticoid sensitivity]	0.0	6	1	1	1
116906	1710	contain the respond element	[containing the responding elements]	0.0	4	1	1	1
116907	1710	coli tester	[coli tester]	0.0	2	1	1	1
116908	1710	expression of a tal1 allele	[expression of a TAL1 allele]	0.0	5	1	1	1
116909	1710	neutrophil respectively.	[neutrophils respectively.]	0.0	2	1	1	1
116910	1710	mutagenesis of one	[mutagenesis of one]	0.0	3	1	1	1
116911	1710	only low binding affinity the high	[only low binding affinities the highest]	0.0	6	1	1	1
116912	1710	amplify expression of high-affinity receptor	[amplifying expression of high-affinity receptor]	0.0	5	1	1	1
116913	1710	pathway of interleukin-5 synthesis	[pathways of interleukin-5 synthesis]	0.0	4	1	1	1
116914	1710	translocation of the p50	[translocation of the p50]	0.0	4	1	1	1
116915	1710	648 bp capable	[648 bp capable]	0.0	3	1	1	1
116916	1710	status in breast cancer patient	[status in breast cancer patients]	0.0	5	1	1	1
116917	1710	basal activity of the hiv enhancer	[basal activity of the HIV enhancer]	0.0	6	1	1	1
116918	1710	decline to the level	[decline to the level]	0.0	4	1	1	1
116919	1710	encode adhesion molecule	[encoding adhesion molecules]	0.0	3	1	1	1
116920	1710	diterpene triepoxide with potent property	[diterpene triepoxide with potent properties]	0.0	5	1	1	1
116921	1710	receptor changes,	[receptor changes,]	0.0	2	1	1	1
116922	1710	proteic inhibitor the IkB	[proteic inhibitor the IkB]	0.0	4	1	1	1
116923	1710	human retrovirus	[human retrovirus]	0.0	2	1	1	1
116924	1710	emergence of resistant variant	[emergence of resistant variants]	0.0	4	1	1	1
116925	1710	cell growth in myelogenous leukemia	[cell growth in myelogenous leukemia]	0.0	5	1	1	1
116926	1710	metastatic capacity of cell in	[metastatic capacity of cells in]	0.0	5	1	1	1
116927	1710	migration inhibitory related protein	[migration inhibitory related protein]	0.0	4	1	1	1
116928	1710	transactivation potential	[transactivation potential]	0.0	2	2	2	1
116929	1710	tal1 protein	[TAL1 protein]	0.0	2	1	1	1
116930	1710	cell assay of a transcription factor	[cell assay of a transcription factor]	0.0	6	1	1	1
116931	1710	lack of involvement	[lack of involvement]	0.0	3	1	1	1
116932	1710	tegument protein by CD4 T cell	[tegument proteins by CD4 T cells]	0.0	6	1	1	1
116933	1710	1 P; binding of p50.p65 heterodimer	[1 h; binding of p50.p65 heterodimers]	0.0	6	1	1	1
116934	1710	evaluable cases,	[evaluable cases,]	0.0	2	1	1	1
116935	1710	er content from SLE patient	[ER content from SLE patients]	0.0	5	1	1	1
116936	1710	binding site for factor-kappaB NF-kappaB	[binding site for factor-kappaB NF-kappaB]	0.0	5	1	1	1
116937	1710	activity of regulatory protein	[activity of regulatory proteins]	0.0	4	1	1	1
116938	1710	differentiation with the differentiation	[differentiation with the differentiation]	0.0	4	1	1	1
116939	1710	undetectable level in u937 cell	[undetectable levels in U937 cells]	0.0	5	1	1	1
116940	1710	1-(5-chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride a inhibitor	[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride an inhibitor]	0.0	4	1	1	1
116941	1710	critical molecule	[critical molecule]	0.0	2	1	1	1
116942	1710	fibroblastic human cell	[fibroblastic human cells]	0.0	3	1	1	1
116943	1710	cellular response to cues,	[cellular responses to cues,]	0.0	4	1	1	1
116944	1710	binding I interferon ifn-alpha/beta to receptor	[Binding I interferon IFN-alpha/beta to receptors]	0.0	6	1	1	1
116945	1710	ILFs	[ILFs]	0.0	1	1	1	1
116946	1710	lymphocyte cytosolic protein	[lymphocyte cytosolic protein]	0.0	3	1	1	1
116947	1710	activator of factor responsible	[activators of factors responsible]	0.0	4	1	1	1
116948	1710	link between differentiation	[link between differentiation]	0.0	3	1	1	1
116949	1710	cover the surface by 15 days.	[covering the surface by 15 days.]	0.0	6	1	1	1
116950	1710	813-bp reading frame ORF	[813-bp reading frame ORF]	0.0	4	1	1	1
116951	1710	Lung instillation of tnf-alpha	[Lung instillation of TNF-alpha]	0.0	4	1	1	1
116952	1710	lymphoid organs.	[lymphoid organs.]	0.0	2	1	1	1
116953	1710	role within signal transduction cascade	[role within signal transduction cascades]	0.0	5	1	1	1
116954	1710	kinase n-terminal kinase	[kinase N-terminal kinase]	0.0	3	1	1	1
116955	1710	August,	[August,]	0.0	1	1	1	1
116956	1710	reduction in expression	[reduction in expression]	0.0	3	1	1	1
116957	1710	Fibroblast growth factor-1	[Fibroblast growth factor-1]	0.0	3	1	1	1
116958	1710	the/thf 1.87+/-0.36) alpha thf/thf (0.35;	[THE/THF 1.87+/-0.36) alpha THF/THF (0.35;]	0.0	5	1	1	1
116959	1710	human T lymphocyte with	[human T lymphocytes with]	0.0	4	1	1	1
116960	1710	U/ml, il-10 tnf-alpha release	[U/ml, IL-10 TNF-alpha release]	0.0	4	1	1	1
116961	1710	hsp60 in human vein cell	[Hsp60 in human vein cells]	0.0	5	1	1	1
116962	1710	exchangeable ca2+ in the dense tubules:	[exchangeable Ca2+ in the dense tubules:]	0.0	6	1	1	1
116963	1710	transactivator such as the tax protein	[transactivators such as the Tax protein]	0.0	6	1	1	1
116964	1710	regulation of class switch	[regulation of class switching]	0.0	4	1	1	1
116965	1710	ec50 of microM.	[EC50 of microM.]	0.0	3	1	1	1
116966	1710	vivo differentiation therapy	[vivo differentiation therapy]	0.0	3	1	1	1
116967	1710	lymphoid component of the tissue	[lymphoid components of the tissues]	0.0	5	1	1	1
116968	1710	role for PKC	[role for PKC]	0.0	3	1	1	1
116969	1710	camp-responsive element binding protein creb	[cAMP-responsive element binding protein CREB]	0.0	5	1	1	1
116970	1710	formation of two mitogen-inducible complex	[formation of two mitogen-inducible complexes]	0.0	5	1	1	1
116971	1710	modulation subsequent in vivo therapy	[modulations subsequent in vivo therapy]	0.0	5	1	1	1
116972	1710	calcineurin expression	[calcineurin expression]	0.0	2	1	1	1
116973	1710	17% positive cell	[17% positive cells]	0.0	3	1	1	1
116974	1710	drug-free patient with disorder	[drug-free patients with disorder]	0.0	4	1	1	1
116975	1710	cell-type bacterial lps	[cell-type bacterial LPS]	0.0	3	1	1	1
116976	1710	transcriptional activation of interleukin 2 gene	[transcriptional activation of interleukin 2 gene]	0.0	6	1	1	1
116977	1710	A-MYB in B	[A-MYB in B]	0.0	3	1	1	1
116978	1710	Prostaglandin E2 up-regulate hiv-1 terminal	[Prostaglandin E2 Up-regulates HIV-1 terminal]	0.0	5	1	1	1
116979	1710	allergic disease include asthma	[allergic diseases including asthma]	0.0	4	1	1	1
116980	1710	signal step	[signaling steps]	0.0	2	1	1	1
116981	1710	inhibition by acetylsalicylate aspirin	[inhibition by acetylsalicylate aspirin]	0.0	4	1	1	1
116982	1710	exclude skewedness	[excluding skewedness]	0.0	2	1	1	1
116983	1710	RA-resistant hematopoietic cell	[RA-resistant hematopoietic cells]	0.0	3	1	1	1
116984	1710	class MHC/superantigen	[class MHC/superantigen]	0.0	2	1	1	1
116985	1710	viral transcription factor	[viral transcription factor]	0.0	3	1	1	1
116986	1710	herbimycin A	[herbimycin A]	0.0	2	2	2	1
116987	1710	shutdown of macromolecular synthesis	[shutdown of macromolecular synthesis]	0.0	4	1	1	1
116988	1710	actin -based motility	[actin -based motility]	0.0	3	1	1	1
116989	1710	cellular susceptibility kill	[cellular susceptibility killing]	0.0	3	1	1	1
116990	1710	retinoid differentiation therapy	[Retinoid differentiation therapy]	0.0	3	1	1	1
116991	1710	-traf2	[-TRAF2]	0.0	1	1	1	1
116992	1710	permeability	[permeability]	0.0	1	1	1	1
116993	1710	important morphogen in development,	[important morphogen in development,]	0.0	4	1	1	1
116994	1710	variables.	[variables.]	0.0	1	1	1	1
116995	1710	luciferase encoding	[luciferase encoding]	0.0	2	1	1	1
116996	1710	male subject	[male subjects]	0.0	2	1	1	1
116997	1710	binding by receptor	[binding by receptors]	0.0	3	1	1	1
116998	1710	distinct DNA binding affinity	[distinct DNA binding affinities]	0.0	4	1	1	1
116999	1710	antisera in immunoprecipitation assay	[antisera in immunoprecipitation assays]	0.0	4	1	1	1
117000	1710	bone morphogenetic protein-2-	[bone morphogenetic protein-2-]	0.0	3	1	1	1
117001	1710	cyclic AMP production	[cyclic AMP production]	0.0	3	1	1	1
117002	1710	trigger signal pathway	[triggering signaling pathways]	0.0	3	1	1	1
117003	1710	active negative process	[active negative process]	0.0	3	1	1	1
117004	1710	pretreatment with m dexamethasone	[pretreatment with M dexamethasone]	0.0	4	1	1	1
117005	1710	level of g(s)alpha expression	[levels of G(S)alpha expression]	0.0	4	1	1	1
117006	1710	arterial ehuaess) cell	[arterial (HUAECs) cells]	0.0	3	1	1	1
117007	1710	severe degree	[severe degree]	0.0	2	1	1	1
117008	1710	kinase target in T lymphocyte	[kinase target in T lymphocytes]	0.0	5	1	1	1
117009	1710	distinct role of the chaperone hsp90	[Distinct roles of the chaperone hsp90]	0.0	6	1	1	1
117010	1710	inhibitor of erk	[inhibitor of ERK]	0.0	3	1	1	1
117011	1710	sequence important	[sequences important]	0.0	2	1	1	1
117012	1710	number 135eoh)2d3 receptor	[number 1,25(OH)2D3 receptors]	0.0	3	1	1	1
117013	1710	cellular protein bind to tre-1	[cellular proteins binding to TRE-1]	0.0	5	1	1	1
117014	1710	therefore a candidate study the effect	[Therefore a candidate studying the effects]	0.0	6	1	1	1
117015	1710	patient with class II-deficient immunodeficiency	[patients with class II-deficient immunodeficiency]	0.0	5	1	1	1
117016	1710	various STAT isoform	[various STAT isoforms]	0.0	3	1	1	1
117017	1710	continuous nuclear expression	[continuous nuclear expression]	0.0	3	1	1	1
117018	1710	regulation of the IL-2 promoter	[regulation of the IL-2 promoter]	0.0	5	1	1	1
117019	1710	CD20 monoclonal antibody	[CD20 monoclonal antibody]	0.0	3	1	1	1
117020	1710	regulator of human peripheral blood T	[regulators of human peripheral blood T]	0.0	6	1	1	1
117021	1710	arsenic trioxide As2O3	[arsenic trioxide As2O3]	0.0	3	1	1	1
117022	1710	self-perpetuation of immunodeficiency virus transcription	[self-perpetuation of immunodeficiency virus transcription]	0.0	5	1	1	1
117023	1710	immortalize potential	[immortalizing potential]	0.0	2	1	1	1
117024	1710	subject fmol/10(6) cell	[subjects fmol/10(6) cells]	0.0	3	1	1	1
117025	1710	specific abs ligand	[specific Abs ligand]	0.0	3	1	1	1
117026	1710	prolyl cis-tran	[prolyl cis-trans]	0.0	2	1	1	1
117027	1710	mrna synthesis for c-rel	[mRNA synthesis for c-rel]	0.0	4	1	1	1
117028	1710	CD4 dimerization	[CD4 dimerization]	0.0	2	1	1	1
117029	1710	Functional study use human cell	[Functional studies using human cells]	0.0	5	1	1	1
117030	1710	factor include nfat	[factors including NFAT]	0.0	3	1	1	1
117031	1710	effect in hela cell	[effects in HeLa cells]	0.0	4	1	1	1
117032	1710	subpopulation of granule	[subpopulation of granules]	0.0	3	1	1	1
117033	1710	gene truncation	[gene truncation]	0.0	2	1	1	1
117034	1710	interleukin IL3	[interleukin IL3]	0.0	2	1	1	1
117035	1710	inactivate substitution in the human counterpart	[inactivating substitutions in the human counterpart]	0.0	6	1	1	1
117036	1710	several rheumatoid arthritis patient	[several rheumatoid arthritis patients]	0.0	4	1	1	1
117037	1710	corticosteroid produce inhibition	[corticosteroid producing inhibition]	0.0	3	1	1	1
117038	1710	capacity of the progenitor cell	[capacity of the progenitor cells]	0.0	5	1	1	1
117039	1710	derivative e box	[derivative E box]	0.0	3	1	1	1
117040	1710	contrast, stimulation	[contrast, stimulation]	0.0	2	1	1	1
117041	1710	PL/IM monoclonal antibody	[PL/IM monoclonal antibody]	0.0	3	1	1	1
117042	1710	export factor	[export factor]	0.0	2	1	1	1
117043	1710	concentration microm	[concentrations microM]	0.0	2	1	1	1
117044	1710	[differential value of 1,25-dihydroxyvitamin D3 determination	[[Differential value of 1,25-dihydroxyvitamin D3 determination]	0.0	6	1	1	1
117045	1710	signal on c-Jun	[signal on c-Jun]	0.0	3	1	1	1
117046	1710	diethylstilbestrol tamoxifen tam quercetin	[diethylstilbestrol tamoxifen TAM quercetin]	0.0	4	1	1	1
117047	1710	centromere probe for chromosome	[centromere probes for chromosomes]	0.0	4	1	1	1
117048	1710	namely, the (dp) CD4	[namely, the (DP) CD4]	0.0	4	1	1	1
117049	1710	activator phorbol ester	[activator phorbol ester]	0.0	3	1	1	1
117050	1710	I kappa b-alpha mad-3	[I kappa B-alpha MAD-3]	0.0	4	1	1	1
117051	1710	bhrf1 protein	[BHRF1 protein]	0.0	2	1	1	1
117052	1710	NF-kappa b activation minimal	[NF-kappa B activation minimal]	0.0	4	1	1	1
117053	1710	interleukin ILs	[interleukins ILs]	0.0	2	1	1	1
117054	1710	mutation in the context	[Mutation in the context]	0.0	4	1	1	1
117055	1710	pp56(lck) mutant lack the domain	[pp56(lck) mutants lacking the domain]	0.0	5	1	1	1
117056	1710	study responsiveness to immediate-early viral transactivator	[studying responsiveness to immediate-early viral transactivators]	0.0	6	1	1	1
117057	1710	efficient hormonal control	[efficient hormonal control]	0.0	3	1	1	1
117058	1710	ldl MM-LDL cell	[LDL MM-LDL cells]	0.0	3	1	1	1
117059	1710	leukocyte MNL from obese subject	[leukocytes MNL from obese subjects]	0.0	5	1	1	1
117060	1710	level comparable	[levels comparable]	0.0	2	1	1	1
117061	1710	50% inhibitory concentration	[50% inhibitory concentrations]	0.0	3	2	2	1
117062	1710	addition, component	[addition, components]	0.0	2	1	1	1
117063	1710	cellular pkc enzymatic activity	[cellular PKC enzymatic activity]	0.0	4	1	1	1
117064	1710	leukocyte antigen	[leukocyte antigen]	0.0	2	1	1	1
117065	1710	activation in EL4 cell	[activation in EL4 cells]	0.0	4	1	1	1
117066	1710	receptor/CD3 complex	[receptor/CD3 complex]	0.0	2	1	1	1
117067	1710	stage of the differentiation,	[stage of the differentiation,]	0.0	4	1	1	1
117068	1710	eosinophlic inflammation	[eosinophlic inflammation]	0.0	2	1	1	1
117069	1710	lead to hyponatremia despite level	[leading to hyponatremia despite levels]	0.0	5	1	1	1
117070	1710	breakdown product	[breakdown product]	0.0	2	1	1	1
117071	1710	transcriptional mechanism involve factor	[transcriptional mechanism involving factor]	0.0	4	1	1	1
117072	1710	chemokine superfamily of cytokine	[chemokine superfamily of cytokines]	0.0	4	1	1	1
117073	1710	plasma avp	[plasma AVP]	0.0	2	1	1	1
117074	1710	prognostic indicator of clinical progression	[prognostic indicator of clinical progression]	0.0	5	1	1	1
117075	1710	antigen-driven clonal expansion)	[antigen-driven clonal expansion)]	0.0	3	1	1	1
117076	1710	TAFII	[TAFII]	0.0	1	1	1	1
117077	1710	fibroblast reveal a unexpected redundancy	[fibroblasts revealing an unexpected redundancy.]	0.0	5	1	1	1
117078	1710	co-cultured bronchial epithelial cell	[co-cultured bronchial epithelial cells]	0.0	4	1	1	1
117079	1710	PEBP2/CBF site	[PEBP2/CBF site]	0.0	2	1	1	1
117080	1710	rBPI21 a fragment	[rBPI21 a fragment]	0.0	3	1	1	1
117081	1710	fifty retinoid	[fifty retinoids]	0.0	2	1	1	1
117082	1710	thaz, in the case	[that, in the case]	0.0	4	1	1	1
117083	1710	contribution to another function	[contribution to another function]	0.0	4	1	1	1
117084	1710	immunodeficiency virus type (hiv-1) infection	[immunodeficiency virus type (HIV-1) infection]	0.0	5	1	1	1
117085	1710	protein nuclear complex	[protein nuclear complexes]	0.0	3	1	1	1
117086	1710	asymptomatic phase	[asymptomatic phase]	0.0	2	1	1	1
117087	1710	competitive binding assay	[competitive binding assay]	0.0	3	1	1	1
117088	1710	La(SSB) specific T cell	[La(SSB) specific T cells]	0.0	4	1	1	1
117089	1710	peripheral blood monocyte to macrophage	[peripheral blood monocytes to macrophages]	0.0	5	1	1	1
117090	1710	indicate a direct target	[indicating a direct target]	0.0	4	1	1	1
117091	1710	similar analysis from a variety	[Similar analysis from a variety]	0.0	5	1	1	1
117092	1710	pathogenic retrovirus	[pathogenic retrovirus]	0.0	2	1	1	1
117093	1710	Octamer factor Oct-1 member	[Octamer factors Oct-1 members]	0.0	4	1	1	1
117094	1710	band range to kd,	[bands ranging to kD,]	0.0	4	1	1	1
117095	1710	patient with lymphocyte syndrome	[patients with lymphocyte syndrome]	0.0	4	1	1	1
117096	1710	main source	[main source]	0.0	2	1	1	1
117097	1710	study on heterogeneous population progenitor	[studies on heterogeneous populations progenitors]	0.0	5	1	1	1
117098	1710	long terminal repeat in T cell	[long terminal repeat in T cells]	0.0	6	1	1	1
117099	1710	normal thymocytes.	[normal thymocytes.]	0.0	2	1	1	1
117100	1710	represent stage of differentiation	[representing stages of differentiation]	0.0	4	1	1	1
117101	1710	leukemia respectively,	[leukemia respectively,]	0.0	2	1	1	1
117102	1710	overexpression in the risk woman	[overexpression in the risk women]	0.0	5	1	1	1
117103	1710	number mutant progenitor cell	[number mutant progenitor cells]	0.0	4	1	1	1
117104	1710	mouse with a defect	[mice with a defect]	0.0	4	1	1	1
117105	1710	Differential presentation by HLA DQ2 heterodimer	[Differential presentation by HLA DQ2 heterodimers]	0.0	6	1	1	1
117106	1710	mobilization of factor kappa b	[mobilization of factor kappa B]	0.0	5	1	1	1
117107	1710	induction of taxi in a line	[Induction of TaxI in a line]	0.0	6	1	1	1
117108	1710	autoregulation of receptor expression in t-	[autoregulation of receptor expression in T-]	0.0	6	1	1	1
117109	1710	affinity fc receptor	[affinity Fc receptor]	0.0	3	1	1	1
117110	1710	Class ii histocompatibility (class ii) gene	[Class II histocompatibility (class II) genes]	0.0	6	1	1	1
117111	1710	effect on the replication of hiv-1	[effects on the replication of HIV-1]	0.0	6	1	1	1
117112	1710	u-937 cell with 12-o-tetradecanoylphorbol-13-acetate	[U-937 cells with 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
117113	1710	spectrum bind site-specific property	[spectrum binding site-specific properties]	0.0	4	1	1	1
117114	1710	depletion of Sp1 from nuclear extract	[depletion of Sp1 from nuclear extracts]	0.0	6	1	1	1
117115	1710	type include leukaemia CML	[types including leukaemia CML]	0.0	4	2	2	1
117116	1710	use this antagonist RXR agonist	[Using this antagonist RXR agonist]	0.0	5	1	1	1
117117	1710	expression of raf-1	[Expression of Raf-1]	0.0	3	1	1	1
117118	1710	scm-1 promoter activity	[SCM-1 promoter activity]	0.0	3	1	1	1
117119	1710	NF-kappa b from a form	[NF-kappa B from a form]	0.0	5	1	1	1
117120	1710	vitamin d-responsive element	[vitamin D-responsive element]	0.0	3	1	1	1
117121	1710	antisense,	[antisense,]	0.0	1	1	1	1
117122	1710	patient 8.98 +/-	[patients 8.98 +/-]	0.0	3	1	1	1
117123	1710	control from the individuals,	[controls from the individuals,]	0.0	4	1	1	1
117124	1710	underlie endothelial cell activation by serum	[underlying endothelial cell activation by serum]	0.0	6	1	1	1
117125	1710	inhibitor of hiv-1 replication	[inhibitor of HIV-1 replication]	0.0	4	1	1	1
117126	1710	cell culture of elderly individual	[cell cultures of elderly individuals]	0.0	5	1	1	1
117127	1710	block induction of il-2	[blocking induction of IL-2]	0.0	4	1	1	1
117128	1710	likely, Stat4	[likely, Stat4]	0.0	2	1	1	1
117129	1710	host, hiding	[host, hiding]	0.0	2	1	1	1
117130	1710	il-4r alpha-chain il-4ralpha	[IL-4R alpha-chain IL-4Ralpha]	0.0	3	1	1	1
117131	1710	component of AP-1	[component of AP-1]	0.0	3	1	1	1
117132	1710	cell extract from leukemia all	[cell extracts from leukemia ALL]	0.0	5	1	1	1
117133	1710	condition of importance.	[conditions of importance.]	0.0	3	1	1	1
117134	1710	J delta 1	[J delta 1]	0.0	3	1	1	1
117135	1710	contain regulatory sequence from glucocorticoid gene	[containing regulatory sequences from glucocorticoid genes]	0.0	6	1	1	1
117136	1710	tolerance with respect	[tolerance with respect]	0.0	3	1	1	1
117137	1710	chronic ebv infection ebv reactivation	[chronic EBV infection EBV reactivation]	0.0	5	1	1	1
117138	1710	OFT-1	[OFT-1]	0.0	1	1	1	1
117139	1710	novel 17-bp serum response factor	[novel 17-bp serum response factor]	0.0	5	1	1	1
117140	1710	primary cd34(+) cell	[primary CD34(+) cells]	0.0	3	1	1	1
117141	1710	region nucleotide number	[region nucleotide numbers]	0.0	3	1	1	1
117142	1710	methyl prednisolone 120 for days.	[methyl prednisolone 120 for days.]	0.0	5	1	1	1
117143	1710	regulation of the human globin gene	[regulation of the human globin genes]	0.0	6	1	1	1
117144	1710	metabolic status after surgery	[metabolic status after surgery]	0.0	4	1	1	1
117145	1710	transcription factor effect	[Transcription factor effects]	0.0	3	1	1	1
117146	1710	low expression of NF-kappa b	[low expression of NF-kappa B]	0.0	5	1	1	1
117147	1710	Natural variant analysis of promoter	[Natural variants analysis of promoters]	0.0	5	1	1	1
117148	1710	24 of the null	[24 of the null]	0.0	4	1	1	1
117149	1710	observation, with the fact	[observation, with the fact]	0.0	4	1	1	1
117150	1710	signal-regulated protein kinase	[signal-regulated protein kinase]	0.0	3	1	1	1
117151	1710	CD4 cd8(-) CD3	[CD4 CD8(-) CD3]	0.0	3	1	1	1
117152	1710	infection in cd4+ T lymphocyte	[infection in CD4+ T lymphocytes]	0.0	5	1	1	1
117153	1710	agent of infectious mononucleosis	[agent of infectious mononucleosis]	0.0	4	1	1	1
117154	1710	mu/l pharmacological concentration insulin	[mU/L pharmacological concentration insulin]	0.0	4	1	1	1
117155	1710	molar amount of tata-binding protein	[molar amounts of TATA-binding protein]	0.0	5	1	1	1
117156	1710	year of symbiotic, relationship	[years of symbiotic, relationship]	0.0	4	1	1	1
117157	1710	activation of primary human t-lymphocyte	[Activation of primary human T-lymphocytes]	0.0	5	1	1	1
117158	1710	kinase erk	[kinase Erk]	0.0	2	1	1	1
117159	1710	65 patient	[65 patients]	0.0	2	1	1	1
117160	1710	membrane sensor kinase	[membrane sensor kinase]	0.0	3	1	1	1
117161	1710	ligation of major complex class	[ligation of major complex class]	0.0	5	1	1	1
117162	1710	signal in cell	[signals in cells]	0.0	3	1	1	1
117163	1710	activity of B-cell extract	[activity of B-cell extracts]	0.0	4	1	1	1
117164	1710	modulation of function	[modulation of functions]	0.0	3	1	1	1
117165	1710	factor of prognosis	[factors of prognosis]	0.0	3	1	1	1
117166	1710	biallelic mode	[biallelic mode]	0.0	2	1	1	1
117167	1710	condition such as cancer	[conditions such as cancer]	0.0	4	1	1	1
117168	1710	alpha,25-dihydroxyvitamin D3 in lymphocyte	[alpha,25-dihydroxyvitamin D3 in lymphocytes]	0.0	4	1	1	1
117169	1710	kappa b kappa	[kappa B kappa]	0.0	3	1	1	1
117170	1710	Finally, localization use fluorescence	[Finally, localization using fluorescence]	0.0	4	1	1	1
117171	1710	gene in acute leukaemia	[genes in acute leukaemia]	0.0	4	1	1	1
117172	1710	primary transcription factor	[primary transcription factors]	0.0	3	1	1	1
117173	1710	increase half-life from 24 min.	[increasing half-life from 24 min.]	0.0	5	1	1	1
117174	1710	results: incubation of blood	[RESULTS: Incubation of blood]	0.0	4	1	1	1
117175	1710	Messenger RNA level for the factor	[Messenger RNA levels for the factor]	0.0	6	1	1	1
117176	1710	aspirin drug	[aspirin drugs]	0.0	2	1	1	1
117177	1710	potent site induce the expansion	[potent site inducing the expansion]	0.0	5	1	1	1
117178	1710	mrna stabilization event	[mRNA stabilization events]	0.0	3	1	1	1
117179	1710	SH2 domain-contain	[SH2 domain-containing]	0.0	2	1	1	1
117180	1710	analysis for the bind specificity	[analyses for the binding specificity]	0.0	5	1	1	1
117181	1710	possibility of rapid analysis	[possibility of rapid analysis]	0.0	4	1	1	1
117182	1710	differentiation response to retinoid	[differentiation response to retinoids]	0.0	4	1	1	1
117183	1710	low level of this protein	[low levels of this protein]	0.0	5	1	1	1
117184	1710	CREB/ATF family factors.	[CREB/ATF family factors.]	0.0	3	1	1	1
117185	1710	binding to the receptor	[binding to the receptor]	0.0	4	1	1	1
117186	1710	14 patient with sle	[14 patients with SLE]	0.0	4	1	1	1
117187	1710	anoxia/reoxygenation-induced adherence	[anoxia/reoxygenation-induced adherence]	0.0	2	1	1	1
117188	1710	main pacemaker	[main pacemaker]	0.0	2	1	1	1
117189	1710	similar kinetic	[Similar kinetics]	0.0	2	1	1	1
117190	1710	mAb 9.3	[mAb 9.3]	0.0	2	1	1	1
117191	1710	reassembly	[reassembly]	0.0	1	1	1	1
117192	1710	interaction between ets	[interaction between Ets]	0.0	3	1	1	1
117193	1710	development of primary culture of megakaryocyte	[development of primary cultures of megakaryocytes]	0.0	6	1	1	1
117194	1710	lipoprotein modulation	[lipoprotein modulation]	0.0	2	1	1	1
117195	1710	Escherichia coli lac operator	[Escherichia coli lac operator]	0.0	4	1	1	1
117196	1710	mAb-stimulated T cell	[mAb-stimulated T cells]	0.0	3	1	1	1
117197	1710	suggest a carboxy-terminal regulatory domain	[suggesting a carboxy-terminal regulatory domain]	0.0	5	1	1	1
117198	1710	NF-kappaB transcription of inflammatory cytokine	[NF-kappaB transcription of inflammatory cytokines]	0.0	5	1	1	1
117199	1710	gram metyrapone	[g metyrapone]	0.0	2	1	1	1
117200	1710	protective mechanism	[protective mechanism]	0.0	2	1	1	1
117201	1710	consequently, one function of tax	[Consequently, one function of Tax]	0.0	5	1	1	1
117202	1710	lytic reactivity at level as high	[lytic reactivities at levels as high]	0.0	6	1	1	1
117203	1710	insulin-stimulated triglyceride accumulation	[insulin-stimulated triglyceride accumulation]	0.0	3	1	1	1
117204	1710	bfu-e response	[BFU-E response]	0.0	2	1	1	1
117205	1710	tcc with ifn-gamma level	[TCC with IFN-gamma levels]	0.0	4	1	1	1
117206	1710	BZLF1 mRNA	[BZLF1 mRNA]	0.0	2	1	1	1
117207	1710	develop from human peripheral blood precursor	[developing from human peripheral blood precursors]	0.0	6	1	1	1
117208	1710	accumulation of nuclear c-rel	[accumulation of nuclear c-Rel]	0.0	4	1	1	1
117209	1710	contribution of the regulatory domain	[contribution of the regulatory domains]	0.0	5	1	1	1
117210	1710	inhibition of rna polymerase transcription	[Inhibition of RNA polymerase transcription]	0.0	5	1	1	1
117211	1710	contrast, negative rac	[contrast, negative Rac]	0.0	3	1	1	1
117212	1710	+/- versus +/-	[+/- versus +/-]	0.0	3	1	1	1
117213	1710	expression of the gr isoform	[expression of the GR isoforms]	0.0	5	1	1	1
117214	1710	chromosome constitution of hybrid	[chromosome constitution of hybrids]	0.0	4	1	1	1
117215	1710	mechanism control cd19 gene expression	[mechanisms controlling CD19 gene expression]	0.0	5	1	1	1
117216	1710	(range	[(ranging]	0.0	1	1	1	1
117217	1710	number of cell line	[number of cell lines]	0.0	4	1	1	1
117218	1710	context of replication,	[context of replication,]	0.0	3	1	1	1
117219	1710	heparin-binding protein crucial	[heparin-binding proteins crucial]	0.0	3	1	1	1
117220	1710	overexpression of ikk protein stimulus-mediated transcription,	[Overexpression of IKK protein stimulus-mediated transcription,]	0.0	6	1	1	1
117221	1710	effect of lipopolysaccharide	[effects of lipopolysaccharide]	0.0	3	1	1	1
117222	1710	tandem ap1 site	[tandem AP1 sites]	0.0	3	1	1	1
117223	1710	amount of the cytokine upon treatment	[amounts of the cytokines upon treatment]	0.0	6	1	1	1
117224	1710	regulatory point in the response	[regulatory point in the response]	0.0	5	1	1	1
117225	1710	association with atopic disorder	[association with atopic disorders]	0.0	4	1	1	1
117226	1710	t3, 4) dysfunction hypophyseal	[T3, 4) dysfunction hypophyseal]	0.0	4	1	1	1
117227	1710	oxidant generation	[oxidant generation]	0.0	2	1	1	1
117228	1710	asthma patient 70%	[asthma patients 70%]	0.0	3	1	1	1
117229	1710	Z transactivator	[Z transactivator]	0.0	2	1	1	1
117230	1710	lineage in myeloblastic leukemia hl-60 cell	[lineage in myeloblastic leukemia HL-60 cells]	0.0	6	1	1	1
117231	1710	mature mitochondrial form	[mature mitochondrial forms]	0.0	3	1	1	1
117232	1710	translocation of p50/p65	[translocation of p50/p65]	0.0	3	1	1	1
117233	1710	follow lps addition to cell	[following LPS addition to cells]	0.0	5	1	1	1
117234	1710	electrophoretic analysis	[electrophoretic analysis]	0.0	2	1	1	1
117235	1710	monitor the expression pattern	[monitoring the expression pattern]	0.0	4	2	2	1
117236	1710	level of nuclear nf-atp capable	[levels of nuclear NF-ATp capable]	0.0	5	1	1	1
117237	1710	activation of the transcription factor nf-kb	[activation of the transcription factor NF-kB]	0.0	6	1	1	1
117238	1710	DMSO treatment,	[DMSO treatment,]	0.0	2	1	1	1
117239	1710	12 follicular hyperplasia	[12 follicular hyperplasia]	0.0	3	1	1	1
117240	1710	absence of phorbol ester	[absence of phorbol ester]	0.0	4	1	1	1
117241	1710	vein endothelial cell CoCl2	[vein endothelial cells CoCl2]	0.0	4	1	1	1
117242	1710	use a probe corresponding	[using an probe corresponding]	0.0	4	1	1	1
117243	1710	five positive clone member	[five positive clones members]	0.0	4	1	1	1
117244	1710	cytokine-stimulated human umbilical vein cell	[cytokine-stimulated human umbilical vein cells]	0.0	5	1	1	1
117245	1710	m; controls:	[M; controls:]	0.0	2	1	1	1
117246	1710	Immunoelectron	[Immunoelectron]	0.0	1	1	1	1
117247	1710	furthermore, nuclear extract	[Furthermore, nuclear extracts]	0.0	3	1	1	1
117248	1710	protein kinase erk	[protein kinase ERK]	0.0	3	1	1	1
117249	1710	fusion protein flexi-12 delivery	[fusion protein Flexi-12 delivery]	0.0	4	1	1	1
117250	1710	Syk kinases-interacting protein	[Syk kinases-interacting proteins]	0.0	3	1	1	1
117251	1710	1 out control	[1 out controls]	0.0	3	1	1	1
117252	1710	binding to IFNgamma	[binding to IFNgamma]	0.0	3	1	1	1
117253	1710	certain cell type to lipopolysaccharide	[certain cell types to lipopolysaccharide]	0.0	5	1	1	1
117254	1710	compete with MNP-2	[competing with MNP-2]	0.0	3	1	1	1
117255	1710	cell cytolytic	[cell cytolytic]	0.0	2	1	1	1
117256	1710	hepatocyte damage	[hepatocyte damage]	0.0	2	1	1	1
117257	1710	tandem cysteine	[tandem cysteine]	0.0	2	1	1	1
117258	1710	c-kit receptor	[c-kit receptors]	0.0	2	1	1	1
117259	1710	further series	[further series]	0.0	2	1	1	1
117260	1710	related receptor	[related receptors]	0.0	2	1	1	1
117261	1710	indicate a endocrine aspect	[indicating an endocrine aspect]	0.0	4	1	1	1
117262	1710	active prolactin	[active prolactin]	0.0	2	1	1	1
117263	1710	leukocyte adhesion to endothelium	[leukocyte adhesion to endothelium]	0.0	4	1	1	1
117264	1710	nf-kappa b binding proteins,	[NF-kappa B binding proteins,]	0.0	4	1	1	1
117265	1710	anti-cd3epsilon mab	[anti-CD3epsilon mAb]	0.0	2	1	1	1
117266	1710	involve clone with ltr	[involving clones with LTRs]	0.0	4	1	1	1
117267	1710	reduction of tnf-alpha	[reduction of TNF-alpha]	0.0	3	1	1	1
117268	1710	antiatherogenic mechanism of a component	[antiatherogenic mechanism of a component]	0.0	5	1	1	1
117269	1710	consensus b oligonucleotide	[consensus B oligonucleotide]	0.0	3	1	1	1
117270	1710	(egr-1)	[(EGR-1)]	0.0	1	1	1	1
117271	1710	prognostic marker	[prognostic marker]	0.0	2	1	1	1
117272	1710	ebv carcinoma tissue	[EBV carcinoma tissues]	0.0	3	1	1	1
117273	1710	demonstration of a role	[demonstration of a role]	0.0	4	1	1	1
117274	1710	pharmacological concentration of RA to &mgr;m)	[pharmacological concentrations of RA to &mgr;M)]	0.0	6	1	1	1
117275	1710	antibody in sera	[Antibodies in sera]	0.0	3	1	1	1
117276	1710	protease activation within T lymphoid cell	[protease activation within T lymphoid cells]	0.0	6	1	1	1
117277	1710	synthetic oligodeoxyribonudleotides	[synthetic oligodeoxyribonucleotides]	0.0	2	1	1	1
117278	1710	kidney failure	[kidney failure]	0.0	2	1	1	1
117279	1710	interleukin (il) production by effector cell	[interleukin (IL) production by effector cells]	0.0	6	1	1	1
117280	1710	aldosterone on intralymphocytic sodium	[aldosterone on intralymphocytic sodium]	0.0	4	1	1	1
117281	1710	factor Spi-B	[factor Spi-B]	0.0	2	1	1	1
117282	1710	acute leukemia the variant	[acute leukemia the variant]	0.0	4	1	1	1
117283	1710	hypotetraploid	[hypotetraploid]	0.0	1	1	1	1
117284	1710	concentration low as nm	[concentration low as nM]	0.0	4	1	1	1
117285	1710	increase in LAL expression	[increase in LAL expression]	0.0	4	1	1	1
117286	1710	addition to cell	[addition to cells]	0.0	3	1	1	1
117287	1710	Appraisal of potential therapeutic index	[Appraisal of potential therapeutic index]	0.0	5	1	1	1
117288	1710	contrast, overexpression of activation	[contrast, overexpression of activation]	0.0	4	1	1	1
117289	1710	porcine aortic endothelial cell	[Porcine aortic endothelial cells]	0.0	4	1	1	1
117290	1710	structural complementarity	[structural complementarity]	0.0	2	1	1	1
117291	1710	spite of activity	[spite of activity]	0.0	3	1	1	1
117292	1710	woman with mpd	[women with MPDs]	0.0	3	1	1	1
117293	1710	T mouse	[T mice]	0.0	2	1	1	1
117294	1710	DC in vivo	[DC in vivo]	0.0	3	1	1	1
117295	1710	hhv-6(gs) genomic fragment	[HHV-6(GS) genomic fragments]	0.0	3	1	1	1
117296	1710	stimulation of calcium influx	[stimulation of calcium influx]	0.0	4	1	1	1
117297	1710	involvement of nfatp	[involvement of NFATp]	0.0	3	1	1	1
117298	1710	T cell NFATp	[T cells NFATp]	0.0	3	2	2	1
117299	1710	functional clone	[functional clone]	0.0	2	1	1	1
117300	1710	effect of this cytokine	[effect of this cytokine]	0.0	4	1	1	1
117301	1710	gene by NFATx1	[genes by NFATx1]	0.0	3	1	1	1
117302	1710	number of neutrophilic cell	[numbers of neutrophilic cells]	0.0	4	1	1	1
117303	1710	level of inflammatory cytokine	[levels of inflammatory cytokines]	0.0	4	1	1	1
117304	1710	squelching of CBP	[squelching of CBP]	0.0	3	1	1	1
117305	1710	fate of hl-60 cell	[fates of HL-60 cells]	0.0	4	1	1	1
117306	1710	t-cell cytokine	[T-cell cytokine]	0.0	2	1	1	1
117307	1710	basis for anergy induction	[basis for anergy induction]	0.0	4	1	1	1
117308	1710	role binding motif of HS-40	[roles binding motifs of HS-40]	0.0	5	1	1	1
117309	1710	eosinophilia in a patient	[eosinophilia in a patient]	0.0	4	1	1	1
117310	1710	p27kip1 gene expression,	[p27Kip1 gene expression,]	0.0	3	1	1	1
117311	1710	several generation of family	[several generations of families]	0.0	4	1	1	1
117312	1710	-resistant ecem) cell	[-resistant (CEM) cells]	0.0	3	1	1	1
117313	1710	include effect in vivo	[including effects in vivo]	0.0	4	1	1	1
117314	1710	regulation in NK cell	[regulation in NK cells]	0.0	4	1	1	1
117315	1710	sensitive transcription factor nf-kappab	[sensitive transcription factor NF-kappaB]	0.0	4	1	1	1
117316	1710	gene expression in Epstein-Barr virus ebv	[gene expression in Epstein-Barr virus EBV]	0.0	6	1	1	1
117317	1710	inhibition through adenosine triphosphate	[inhibition through adenosine triphosphate]	0.0	4	1	1	1
117318	1710	addition of pu.1	[addition of PU.1]	0.0	3	1	1	1
117319	1710	transcriptional properties	[transcriptional properties,]	0.0	2	1	1	1
117320	1710	92 base pair bp of DNA	[92 base pairs bp of DNA]	0.0	6	1	1	1
117321	1710	calcium immediate-early gene induction	[Calcium immediate-early gene induction]	0.0	4	1	1	1
117322	1710	nonlymphocytic leukemia	[nonlymphocytic leukemias]	0.0	2	1	1	1
117323	1710	effect on adhesiveness of cell	[effect on adhesiveness of cells]	0.0	5	1	1	1
117324	1710	adaptive system in vertebrate	[adaptive system in vertebrates]	0.0	4	1	1	1
117325	1710	cerulein-induced pancreatitis	[cerulein-induced pancreatitis]	0.0	2	1	1	1
117326	1710	bcl6 rearrangement	[BCL6 rearrangement]	0.0	2	1	1	1
117327	1710	more change	[more changes]	0.0	2	1	1	1
117328	1710	investigate the role in progesterone immunomodulation	[investigating the role in progesterone immunomodulation]	0.0	6	1	1	1
117329	1710	biological principle	[biological principle]	0.0	2	1	1	1
117330	1710	rapid testing	[rapid testing]	0.0	2	1	1	1
117331	1710	inhibition of b mobilization	[inhibition of B mobilization]	0.0	4	1	1	1
117332	1710	other's actions,	[other's actions,]	0.0	2	1	1	1
117333	1710	near-perfect direct repeat DR	[near-perfect direct repeats DR]	0.0	4	1	1	1
117334	1710	however, high millileter at 10:00 P;	[However, high ml at 10:00 h;]	0.0	6	1	1	1
117335	1710	growth factor (tgf)-beta1 responsiveness	[growth factor (TGF)-beta1 responsiveness]	0.0	4	1	1	1
117336	1710	only a complex	[only a complex]	0.0	3	1	1	1
117337	1710	GATA binding site AGATAA	[GATA binding site AGATAA]	0.0	4	1	1	1
117338	1710	nf-kappab subunit plb-985	[NF-kappaB subunits PLB-985]	0.0	3	1	1	1
117339	1710	similar change	[similar changes]	0.0	2	1	1	1
117340	1710	line, tg	[line, tg]	0.0	2	1	1	1
117341	1710	high, concentration of RA	[high, concentrations of RA]	0.0	4	1	1	1
117342	1710	cell line at 42 degree	[cell line at 42 degrees]	0.0	5	1	1	1
117343	1710	form of retinoblastoma protein	[form of retinoblastoma protein]	0.0	4	1	1	1
117344	1710	immunodeficiency xscid	[immunodeficiency XSCID]	0.0	2	2	2	1
117345	1710	induction of bcl-x(l) expression	[Induction of Bcl-x(L) expression]	0.0	4	1	1	1
117346	1710	lymphoid-specific transcription factor nf-microb	[lymphoid-specific transcription factor NF-microB]	0.0	4	1	1	1
117347	1710	twenty man	[Twenty men]	0.0	2	1	1	1
117348	1710	HLA/peptide complex	[HLA/peptide complex]	0.0	2	1	1	1
117349	1710	g0/g1 switch gene g0s2	[G0/G1 switch gene G0S2]	0.0	4	1	1	1
117350	1710	cell cycle regulator by lmp-1	[cell cycle regulators by LMP-1]	0.0	5	1	1	1
117351	1710	T cell modulation	[T cells modulation]	0.0	3	1	1	1
117352	1710	different modes,	[Different modes,]	0.0	2	1	1	1
117353	1710	3-deazaadenosine a potent inhibitor	[3-deazaadenosine a potent inhibitor]	0.0	4	1	1	1
117354	1710	gata-3 gene	[GATA-3 gene]	0.0	2	1	1	1
117355	1710	metabolite by induction	[metabolite by induction]	0.0	3	1	1	1
117356	1710	DNA-protein complex with the gata site	[DNA-protein complex with the GATA site]	0.0	6	1	1	1
117357	1710	form of type diabete diabete	[forms of type diabetes diabetes]	0.0	5	1	1	1
117358	1710	benefit for high eukaryote	[benefit for higher eukaryotes]	0.0	4	1	1	1
117359	1710	eotaxin gene expression and/or	[eotaxin gene expression and/or]	0.0	4	1	1	1
117360	1710	hydrocortisone (F) of concentration	[hydrocortisone (F) of concentration]	0.0	4	1	1	1
117361	1710	expression of the CD4 gene	[expression of the CD4 gene]	0.0	5	1	1	1
117362	1710	atopic b	[atopic B]	0.0	2	1	1	1
117363	1710	t-cell leukemia a form	[T-cell leukemia a form]	0.0	4	1	1	1
117364	1710	inducers, such as hemin	[inducers, such as hemin]	0.0	4	1	1	1
117365	1710	enhancer upstream to the gene	[enhancer upstream to the gene]	0.0	5	1	1	1
117366	1710	short form, stat3beta	[short form, Stat3beta]	0.0	3	1	1	1
117367	1710	evidence for change	[evidence for changes]	0.0	3	1	1	1
117368	1710	GATA-1 a transcription factor	[GATA-1 an transcription factor]	0.0	4	1	1	1
117369	1710	thereof) to gliadin	[thereof) to gliadins]	0.0	3	1	1	1
117370	1710	use specific decrease	[using specific decrease]	0.0	3	1	1	1
117371	1710	rest umbilical vein cell HUVEC	[resting umbilical vein cells HUVEC]	0.0	5	1	1	1
117372	1710	cooperation between the factor	[cooperation between the factor]	0.0	4	1	1	1
117373	1710	cytoplasmic	[cytoplasmic]	0.0	1	1	1	1
117374	1710	domain (egf) receptor	[domain (EGF) receptor]	0.0	3	1	1	1
117375	1710	importance of oxidative species	[importance of oxidative species]	0.0	4	1	1	1
117376	1710	characteristic of recombinant il-12	[characteristics of recombinant IL-12]	0.0	4	1	1	1
117377	1710	evidence for the involvement in stage	[evidence for the involvement in stages]	0.0	6	1	1	1
117378	1710	sequence of this motif	[sequence of these motifs]	0.0	4	1	1	1
117379	1710	level of beta-	[levels of beta-]	0.0	3	1	1	1
117380	1710	tissue cell such as fibroblast	[tissue cells such as fibroblasts]	0.0	5	1	1	1
117381	1710	nm23-h1	[nm23-H1]	0.0	1	1	1	1
117382	1710	Thus, lps activation	[Thus, LPS activation]	0.0	3	1	1	1
117383	1710	pseudohypoaldosteronism in eight family form	[Pseudohypoaldosteronism in eight families: forms]	0.0	5	1	1	1
117384	1710	immune modulation	[immune modulation]	0.0	2	1	1	1
117385	1710	synthesize this cytokine	[synthesizing this cytokine]	0.0	3	1	1	1
117386	1710	titer igg autoantibody	[titer IgG autoantibodies]	0.0	3	1	1	1
117387	1710	isolated T cell	[isolated T cells]	0.0	3	1	1	1
117388	1710	expression of a constitutively active calcineurin	[Expression of a constitutively active calcineurin]	0.0	6	1	1	1
117389	1710	non-rheumatoid arthritis, binding	[non-rheumatoid arthritis, binding]	0.0	3	1	1	1
117390	1710	glucocorticoid response element ngre	[glucocorticoid response element nGRE]	0.0	4	1	1	1
117391	1710	mutate to a isoleucine	[mutating to an isoleucine]	0.0	4	1	1	1
117392	1710	dnase footprinting use increase amount	[DNase footprinting using increasing amounts]	0.0	5	1	1	1
117393	1710	region in the promoter	[regions in the promoter]	0.0	4	1	1	1
117394	1710	maximal inhibition in b cell	[maximal inhibition in B cells]	0.0	5	1	1	1
117395	1710	two cleavage product of kda	[two cleavage products of kDa]	0.0	5	1	1	1
117396	1710	level pcna	[level PCNA]	0.0	2	1	1	1
117397	1710	contribution of BRCA1 mutation	[contribution of BRCA1 mutations]	0.0	4	1	1	1
117398	1710	general observation	[general observation]	0.0	2	1	1	1
117399	1710	sp140 mrna	[Sp140 mRNA]	0.0	2	2	2	1
117400	1710	five member	[Five members]	0.0	2	1	1	1
117401	1710	different type of leukemia blast cell	[Different types of leukemia blast cells]	0.0	6	1	1	1
117402	1710	role in regulation of cd44 transcription	[Role in regulation of CD44 transcription]	0.0	6	1	1	1
117403	1710	clarification	[clarification]	0.0	1	1	1	1
117404	1710	exclusive bind selectivity for aldosterone	[exclusive binding selectivity for aldosterone]	0.0	5	1	1	1
117405	1710	binding site for cytoplasmic inhibitor	[binding site for cytoplasmic inhibitor]	0.0	5	1	1	1
117406	1710	consequence of gsh depletion	[consequences of GSH depletion]	0.0	4	1	1	1
117407	1710	monocyte binding to endothelial cell harc	[monocyte binding to endothelial cells HAECs]	0.0	6	1	1	1
117408	1710	pathway control vh-to-dhjh recombination	[pathway controlling VH-to-DHJH recombination]	0.0	4	1	1	1
117409	1710	facilitate the assembly	[facilitating the assembly]	0.0	3	1	1	1
117410	1710	cell APC	[cells APC]	0.0	2	1	1	1
117411	1710	CD40 ligation by CD40L l-cell	[CD40 ligation by CD40L L-cells]	0.0	5	1	1	1
117412	1710	c5b-7 at min,	[C5b-7 at min,]	0.0	3	1	1	1
117413	1710	response include stat6 phosphorylation	[responses including STAT6 phosphorylation]	0.0	4	1	1	1
117414	1710	structural protein expression	[structural protein expression]	0.0	3	1	1	1
117415	1710	antagonist ru486	[antagonist RU486]	0.0	2	1	1	1
117416	1710	element dna-probe	[element DNA-probe]	0.0	2	1	1	1
117417	1710	include fcepsilonriib 15-lipoxygenase	[including FcepsilonRIIb 15-lipoxygenase]	0.0	3	1	1	1
117418	1710	immune response through inverse effect	[immune responses through inverse effects]	0.0	5	1	1	1
117419	1710	protein kinase (erk)-dependent	[protein kinase (ERK)-dependent]	0.0	3	1	1	1
117420	1710	cytokine tgf-beta 2	[cytokine TGF-beta 2]	0.0	3	1	1	1
117421	1710	constitutive activity concomitant to a inhibition	[constitutive activity concomitant to an inhibition]	0.0	6	1	1	1
117422	1710	same functional domain	[same functional domain]	0.0	3	1	1	1
117423	1710	characterization of cis element	[characterization of cis elements]	0.0	4	1	1	1
117424	1710	second exon, result	[second exon, resulting]	0.0	3	1	1	1
117425	1710	sequence of effect	[sequence of effects]	0.0	3	1	1	1
117426	1710	lymphocyte from woman	[lymphocytes from women]	0.0	3	1	1	1
117427	1710	factor to m elevation	[factor to M elevation]	0.0	4	1	1	1
117428	1710	cyclic pressure-stretch load	[cyclic pressure-stretching load]	0.0	3	1	1	1
117429	1710	untreated u937 cell	[untreated U937 cells]	0.0	3	2	2	1
117430	1710	monocytic differentiation cell	[monocytic differentiation cells]	0.0	3	1	1	1
117431	1710	number of eig)-secreting cell	[number of (Ig)-secreting cells]	0.0	4	1	1	1
117432	1710	STAT1 factor	[STAT1 factor]	0.0	2	1	1	1
117433	1710	10, leiomyosarcoma	[10, leiomyosarcoma]	0.0	2	1	1	1
117434	1710	5 early region	[5 early regions]	0.0	3	1	1	1
117435	1710	Clinical efficacy	[Clinical efficacy]	0.0	2	1	1	1
117436	1710	apoptotic event in cells.	[apoptotic events in cells.]	0.0	4	1	1	1
117437	1710	addition between T cell	[addition between T cells]	0.0	4	1	1	1
117438	1710	growth factor during a response	[growth factor during a response]	0.0	5	1	1	1
117439	1710	factor kB NF-kB regulatory element	[factor kB NF-kB regulatory elements]	0.0	5	1	1	1
117440	1710	progenitor express Gal/ER	[progenitors expressing Gal/ER]	0.0	3	1	1	1
117441	1710	lead despite high level	[leading despite high levels]	0.0	4	1	1	1
117442	1710	major class DRA promoter occupancy	[major class DRA promoter occupancy]	0.0	5	1	1	1
117443	1710	ytokine	[ytokine]	0.0	1	1	1	1
117444	1710	(U937) cell line	[(U937) cell lines]	0.0	3	1	1	1
117445	1710	biological stimulus	[biological stimuli]	0.0	2	1	1	1
117446	1710	regulation of c-jun expression during differentiation	[regulation of c-jun expression during differentiation]	0.0	6	1	1	1
117447	1710	fk506 -binding protein	[FK506 -binding protein]	0.0	3	1	1	1
117448	1710	C terminal section	[C terminal section]	0.0	3	1	1	1
117449	1710	kinetic in T upon il-2	[kinetics in T upon IL-2]	0.0	5	1	1	1
117450	1710	extremely low level of hiv-1 expression	[extremely low levels of HIV-1 expression]	0.0	6	1	1	1
117451	1710	include the induction	[including the induction]	0.0	3	1	1	1
117452	1710	units,	[units,]	0.0	1	1	1	1
117453	1710	such as cyclosporin a	[such as cyclosporin A]	0.0	4	2	2	1
117454	1710	marker of differentiation, burst	[marker of differentiation, burst]	0.0	4	1	1	1
117455	1710	powerful pathway	[powerful pathway]	0.0	2	1	1	1
117456	1710	basis of the induction	[basis of the induction]	0.0	4	1	1	1
117457	1710	viral particles, integration	[viral particles, integration]	0.0	3	1	1	1
117458	1710	blk promoter activity	[blk promoter activity]	0.0	3	1	1	1
117459	1710	parallel the decline in cortisol level	[paralleling the decline in cortisol levels]	0.0	6	1	1	1
117460	1710	expression of perforin	[expression of perforin]	0.0	3	1	1	1
117461	1710	increase in susceptibility of monocyte	[increase in susceptibility of monocytes]	0.0	5	1	1	1
117462	1710	disruption of potential motifs:	[disruptions of potential motifs:]	0.0	4	1	1	1
117463	1710	tissue-specific region	[tissue-specific region]	0.0	2	1	1	1
117464	1710	inhibitory role of NFAT1	[inhibitory role of NFAT1]	0.0	4	1	1	1
117465	1710	decrease in the nuclear translocation	[decrease in the nuclear translocation]	0.0	5	1	1	1
117466	1710	tax the protein	[Tax the protein]	0.0	3	1	1	1
117467	1710	immunoregulation	[immunoregulation]	0.0	1	1	1	1
117468	1710	factor-kappa b binding	[factor-kappa B binding]	0.0	3	1	1	1
117469	1710	e1a sequence	[E1a sequences]	0.0	2	1	1	1
117470	1710	vivo through a growth-transforme infection	[vivo through a growth-transforming infection]	0.0	5	1	1	1
117471	1710	mapping to chromosome band	[mapping to chromosome bands]	0.0	4	1	1	1
117472	1710	transcriptional activation of the repeat type	[transcriptional activation of the repeat type]	0.0	6	1	1	1
117473	1710	cell release	[cell release]	0.0	2	1	1	1
117474	1710	novel human gene	[novel human gene]	0.0	3	1	1	1
117475	1710	normal number of mineralocorticoid receptor	[normal number of mineralocorticoid receptors]	0.0	5	1	1	1
117476	1710	decrease in antiproliferative response	[decrease in antiproliferative response]	0.0	4	1	1	1
117477	1710	activate protein-1 tpa responsive element	[Activating protein-1 TPA responsive elements]	0.0	5	1	1	1
117478	1710	(b) of variants,	[(B) of variants,]	0.0	3	1	1	1
117479	1710	(pt) nmol/L.	[(PT) nmol/L.]	0.0	2	1	1	1
117480	1710	significant increase in th1 cell	[significant increase in Th1 cells]	0.0	5	1	1	1
117481	1710	MHC ii transcript	[MHC II transcripts]	0.0	3	1	1	1
117482	1710	immunogenicity of antigen in vitro	[immunogenicity of antigens in vitro]	0.0	5	1	1	1
117483	1710	state of viral latency	[state of viral latency]	0.0	4	1	1	1
117484	1710	implicate cis-active sequence in the control	[implicating cis-active sequences in the control]	0.0	6	1	1	1
117485	1710	affinity purification of protein	[affinity purification of proteins]	0.0	4	1	1	1
117486	1710	relatively high, pharmacological concentration	[relatively high, pharmacological concentrations]	0.0	4	1	1	1
117487	1710	critical role induction	[critical role induction]	0.0	3	1	1	1
117488	1710	induction of a response	[induction of a response]	0.0	4	1	1	1
117489	1710	form of non-rheumatoid arthritis	[forms of non-rheumatoid arthritis]	0.0	4	1	1	1
117490	1710	bone metastase	[bone metastases]	0.0	2	1	1	1
117491	1710	normal decline	[normal decline]	0.0	2	1	1	1
117492	1710	case correlate	[case correlating]	0.0	2	1	1	1
117493	1710	local cis element	[local cis elements]	0.0	3	1	1	1
117494	1710	target for therapy	[target for therapy]	0.0	3	1	1	1
117495	1710	unrelated n-acetylcysteine	[unrelated N-acetylcysteine]	0.0	2	1	1	1
117496	1710	RA binding affinities;	[RA binding affinities;]	0.0	3	1	1	1
117497	1710	induce respiratory distress syndrome ARDS	[inducing respiratory distress syndrome ARDS]	0.0	5	1	1	1
117498	1710	constitutive overexpression of the gene	[Constitutive overexpression of the gene]	0.0	5	1	1	1
117499	1710	HTLV-I gene	[HTLV-I genes]	0.0	2	1	1	1
117500	1710	furthermore, 1,25-dihydroxyvitamin D3	[Furthermore, 1,25-dihydroxyvitamin D3]	0.0	3	1	1	1
117501	1710	effect of pnu156804 in vitro	[effect of PNU156804 in vitro]	0.0	5	1	1	1
117502	1710	high-mobility group	[high-mobility group]	0.0	2	1	1	1
117503	1710	hormone on cell proliferation	[hormone on cell proliferation]	0.0	4	1	1	1
117504	1710	receptor-mediated response.	[receptor-mediated response.]	0.0	2	1	1	1
117505	1710	expression through AMP production	[expression through AMP production]	0.0	4	1	1	1
117506	1710	role for acid during maturation	[role for acid during maturation]	0.0	5	1	1	1
117507	1710	mechanism in ATL cell line	[mechanism in ATL cell lines]	0.0	5	1	1	1
117508	1710	include sp1 binding protein	[including Sp1 binding proteins]	0.0	4	1	1	1
117509	1710	factor (NF)-kappaB consensus sequence	[factor (NF)-kappaB consensus sequence]	0.0	4	1	1	1
117510	1710	putative NF-kappa b recognition site	[putative NF-kappa B recognition sites]	0.0	5	1	1	1
117511	1710	differentiation-related antigen	[differentiation-related antigens]	0.0	2	1	1	1
117512	1710	role in senescence	[role in senescence]	0.0	3	1	1	1
117513	1710	complex with the ebf -binding site	[complexes with the EBF -binding site]	0.0	6	1	1	1
117514	1710	human granzyme b	[human granzyme B]	0.0	3	1	1	1
117515	1710	suppress tyrosine phosphorylation	[suppressing tyrosine phosphorylation]	0.0	3	1	1	1
117516	1710	resemble nuclear factor	[resembling nuclear factor]	0.0	3	1	1	1
117517	1710	differentiation implication of signal	[differentiation implications of signals]	0.0	4	1	1	1
117518	1710	ras oncogene transformation of b lymphoblast	[Ras oncogene transformation of B lymphoblasts]	0.0	6	1	1	1
117519	1710	/precursor grow in the stage	[/precursors growing in the stages]	0.0	5	1	1	1
117520	1710	3.5 fmol/10(6)	[3.5 fmol/10(6)]	0.0	2	1	1	1
117521	1710	peptide selection of a NFAT inhibitor	[peptide selection of an NFAT inhibitor]	0.0	6	1	1	1
117522	1710	cloning of gene by display	[Cloning of genes by display]	0.0	5	1	1	1
117523	1710	quinone	[quinone]	0.0	1	1	1	1
117524	1710	lavage (bal) cell	[lavage (BAL) cells]	0.0	3	1	1	1
117525	1710	increase with a similar increase	[increase with a similar increase]	0.0	5	1	1	1
117526	1710	partial variable monosomy of loci	[partial variable monosomy of loci]	0.0	5	1	1	1
117527	1710	cd15 a monocyte counter-receptor for selectin	[CD15 a monocyte counter-receptor for selectins]	0.0	6	1	1	1
117528	1710	functional selection	[functional selection]	0.0	2	1	1	1
117529	1710	abrogate kappab gene expression	[abrogates kappaB gene expression]	0.0	4	1	1	1
117530	1710	stage-specific expression of mnda	[stage-specific expression of MNDA]	0.0	4	1	1	1
117531	1710	factor kappa b nf-kappab	[factor kappa B NF-kappaB]	0.0	4	1	1	1
117532	1710	glycerophospholipid,	[glycerophospholipid,]	0.0	1	1	1	1
117533	1710	express kinase activity	[expressing kinase activity]	0.0	3	1	1	1
117534	1710	sectioning of micrometer	[sectioning of micrometer]	0.0	3	1	1	1
117535	1710	healthy individual as control	[healthy individuals as control]	0.0	4	1	1	1
117536	1710	stable binding of factor in	[stable binding of factors in]	0.0	5	1	1	1
117537	1710	level of il-2 concentration	[level of IL-2 concentration]	0.0	4	1	1	1
117538	1710	fresh epstein-barr virus b lymphocyte	[fresh Epstein-Barr virus B lymphocytes]	0.0	5	1	1	1
117539	1710	hl-60 myelomonocytic differentiation	[HL-60 myelomonocytic differentiation]	0.0	3	1	1	1
117540	1710	various signal often converge	[Various signals often converging]	0.0	4	1	1	1
117541	1710	CTLA-4 inhibition of early event	[CTLA-4 inhibition of early events]	0.0	5	1	1	1
117542	1710	upstream region (position	[upstream region (positions]	0.0	3	1	1	1
117543	1710	coordinate reduction	[coordinate reductions]	0.0	2	1	1	1
117544	1710	CD3 activation	[CD3 activation]	0.0	2	1	1	1
117545	1710	marker of nearby polymorphism	[marker(s) of nearby polymorphisms]	0.0	4	1	1	1
117546	1710	NFAT-1 gene expression	[NFAT-1 gene expression]	0.0	3	1	1	1
117547	1710	hsf of NFkappaB	[HSF of NFkappaB]	0.0	3	1	1	1
117548	1710	major glial cell	[major glial cells]	0.0	3	1	1	1
117549	1710	ppar activator j(2)	[PPAR activators J(2)]	0.0	3	1	1	1
117550	1710	ptk zap-70	[PTK ZAP-70]	0.0	2	1	1	1
117551	1710	element active in basophil	[element active in basophils]	0.0	4	1	1	1
117552	1710	sequence within the element AREs	[sequences within the elements AREs]	0.0	5	1	1	1
117553	1710	transcription ap-1	[transcription AP-1]	0.0	2	1	1	1
117554	1710	tat-binding protein	[Tat-binding protein]	0.0	2	1	1	1
117555	1710	expression of cell cycle-associated gene	[expression of cell cycle-associated genes]	0.0	5	1	1	1
117556	1710	RAI therapy the number	[RAI therapy the number]	0.0	4	1	1	1
117557	1710	level in 2 of tissue	[levels in 2 of tissues]	0.0	5	1	1	1
117558	1710	cell cycle regulation.	[cell cycle regulation.]	0.0	3	1	1	1
117559	1710	chimeric receptor consist	[chimeric receptors consisting]	0.0	3	1	1	1
117560	1710	level constitutively,	[levels constitutively,]	0.0	2	1	1	1
117561	1710	nfat dna-binding	[NFAT DNA-binding]	0.0	2	1	1	1
117562	1710	permissiveness	[Permissiveness]	0.0	1	1	1	1
117563	1710	threonine residue with tnf factor	[threonine residue with TNF factor]	0.0	5	1	1	1
117564	1710	nf-kappab activation.	[NF-kappaB activation.]	0.0	2	1	1	1
117565	1710	acute leukemia 1- evi1 fusion	[acute leukemia 1- EVI1 fusions]	0.0	5	1	1	1
117566	1710	4 hour at neutral pH	[4 hr at neutral pH]	0.0	5	1	1	1
117567	1710	function similar in cell	[functions similar in cells]	0.0	4	1	1	1
117568	1710	phosphorylation of tal1 protein	[phosphorylation of TAL1 protein]	0.0	4	1	1	1
117569	1710	related immunoglobulin g igg fc receptor	[related immunoglobulin G IgG Fc receptors]	0.0	6	1	1	1
117570	1710	growth factor-B promoter	[growth factor-B promoter]	0.0	3	1	1	1
117571	1710	age, sex,	[age, sex,]	0.0	2	1	1	1
117572	1710	also to the dna-binding transcription factor	[also to the DNA-binding transcription factors]	0.0	6	1	1	1
117573	1710	(m-csf)	[(M-CSF)]	0.0	1	2	2	1
117574	1710	trigger necrosis factor-alpha in monocytic cell	[Triggering necrosis factor-alpha in monocytic cells]	0.0	6	1	1	1
117575	1710	expression in b cell line	[expression in B cell lines]	0.0	5	1	1	1
117576	1710	role in light-regulated rhythm	[role in light-regulated rhythms]	0.0	4	1	1	1
117577	1710	distinct histogenetic subtype	[distinct histogenetic subtypes]	0.0	3	1	1	1
117578	1710	resistance to hiv infection,	[resistance to HIV infection,]	0.0	4	1	1	1
117579	1710	significant negative correlation between ic5	[significant negative correlation between IC50S]	0.0	5	1	1	1
117580	1710	distinct complexess	[distinct complexes,]	0.0	2	1	1	1
117581	1710	accumulation of gag/pol	[accumulation of gag/pol]	0.0	3	1	1	1
117582	1710	down-regulation of protein ebna2-ebna6 in lymphoma	[Down-regulation of proteins EBNA2-EBNA6 in lymphoma]	0.0	6	1	1	1
117583	1710	locus control region in	[locus control region in]	0.0	4	1	1	1
117584	1710	peripheral jurkat T cell	[peripheral Jurkat T cells]	0.0	4	1	1	1
117585	1710	capacity of the mutant	[capacities of the mutants]	0.0	4	1	1	1
117586	1710	mainly aromatic residue	[mainly aromatic residues]	0.0	3	1	1	1
117587	1710	application of drugs, one	[application of drugs, one]	0.0	4	1	1	1
117588	1710	atheogenic lipoprotein	[atheogenic lipoprotein]	0.0	2	1	1	1
117589	1710	-contain receptor related	[-containing receptor related]	0.0	3	1	1	1
117590	1710	mediuhd small adherent colony	[medium, small adherent colonies]	0.0	4	1	1	1
117591	1710	immature dn thymocyte	[immature DN thymocytes]	0.0	3	1	1	1
117592	1710	high value in depressed patient	[higher values in depressed patients]	0.0	5	1	1	1
117593	1710	evidence for a coupling	[evidence for a coupling]	0.0	4	1	1	1
117594	1710	mutational study of the sequence	[Mutational studies of the sequence]	0.0	5	1	1	1
117595	1710	10 year gail risk	[10 year Gail risk]	0.0	4	1	1	1
117596	1710	abnormality in disorder	[abnormality in disorders]	0.0	3	1	1	1
117597	1710	adjacent ets binding motif	[adjacent ETS binding motifs]	0.0	4	1	1	1
117598	1710	abnormal pattern of kappa activity	[abnormal pattern of kappa activity]	0.0	5	1	1	1
117599	1710	similar downregulation	[Similar downregulation]	0.0	2	1	1	1
117600	1710	integration into chromatin	[integration into chromatin]	0.0	3	1	1	1
117601	1710	evidence a major target	[evidence a major target]	0.0	4	1	1	1
117602	1710	follow treatment with acid	[following treatment with acid]	0.0	4	1	1	1
117603	1710	probe of BCL6	[probe of BCL6]	0.0	3	1	1	1
117604	1710	strain of hiv-1	[strains of HIV-1]	0.0	3	1	1	1
117605	1710	vsmc express c-myc vsmc-myc	[VSMCs expressing c-myc VSMC-myc]	0.0	4	1	1	1
117606	1710	double-positive (dp) CD4 thymocyte	[double-positive (DP) CD4 thymocytes]	0.0	4	1	1	1
117607	1710	CD4 promoter transactivation by herpesvirus	[CD4 promoter transactivation by herpesvirus]	0.0	5	1	1	1
117608	1710	intracellular tail	[intracellular tail]	0.0	2	1	1	1
117609	1710	human epsilon-globin-encoding gene [Cao	[human epsilon-globin-encoding gene [Cao]	0.0	4	1	1	1
117610	1710	58 asthma child aged	[58 asthma children aged]	0.0	4	1	1	1
117611	1710	gut-associated organ	[gut-associated organ]	0.0	2	1	1	1
117612	1710	severe hyperaldosteronism	[severe hyperaldosteronism]	0.0	2	1	1	1
117613	1710	hour at degree	[hours at degrees]	0.0	3	1	1	1
117614	1710	nuclear rna(snrna)-encoding	[nuclear RNA(snRNA)-encoding]	0.0	2	1	1	1
117615	1710	-150 ap-1 binding site	[-150 AP-1 binding site]	0.0	4	1	1	1
117616	1710	interval during the treatment,	[intervals during the treatment,]	0.0	4	1	1	1
117617	1710	pha human peripheral blood lymphocyte	[PHA human peripheral blood lymphocytes]	0.0	5	1	1	1
117618	1710	form of ebv DNA	[form of EBV DNA]	0.0	4	1	1	1
117619	1710	er in leucocyte	[ER in leucocytes]	0.0	3	1	1	1
117620	1710	cd3+ cell (2.2% of cd3+	[CD3+ cells (2.2% of CD3+]	0.0	5	1	1	1
117621	1710	interestingly, expression of cd95 fas /apo-1	[interestingly, expression of CD95 Fas /Apo-1]	0.0	6	1	1	1
117622	1710	cell transcriptional induction	[cell transcriptional induction]	0.0	3	1	1	1
117623	1710	recent analysis by Miyatake	[recent analysis by Miyatake]	0.0	4	1	1	1
117624	1710	tandem array range	[tandem arrays ranging]	0.0	3	1	1	1
117625	1710	immunogenicity of protein epitope in	[immunogenicity of protein epitopes in]	0.0	5	1	1	1
117626	1710	10(-6) mol/L for hydrocortisone	[10(-6) mol/L for hydrocortisone]	0.0	4	1	1	1
117627	1710	abrogation of tolerance	[abrogation of tolerance]	0.0	3	1	1	1
117628	1710	two distinct docking site	[two distinct docking sites]	0.0	4	1	1	1
117629	1710	activate subunit	[activating subunit]	0.0	2	1	1	1
117630	1710	phase CML patient	[phase CML patients]	0.0	3	1	1	1
117631	1710	male breast cancer case	[male breast cancer cases]	0.0	4	1	1	1
117632	1710	polypyrimidine protein	[polypyrimidine protein]	0.0	2	1	1	1
117633	1710	dose dexamethasone	[dose dexamethasone]	0.0	2	1	1	1
117634	1710	domain of the Thy-1 promoter	[domains of the Thy-1 promoter]	0.0	5	1	1	1
117635	1710	bsap-binding site	[BSAP-binding site]	0.0	2	1	1	1
117636	1710	estrogen receptor level in patient	[estrogen receptor levels in patients]	0.0	5	2	2	1
117637	1710	T cell anergy	[T cell anergy]	0.0	3	1	1	1
117638	1710	zinc finger motif	[zinc finger motifs]	0.0	3	1	1	1
117639	1710	signal lead to activation	[signals leading to activation]	0.0	4	1	1	1
117640	1710	progression of various type of cancer	[progression of various types of cancers]	0.0	6	2	2	1
117641	1710	formation ifn-gamma-activated sequence-binding complex	[formation IFN-gamma-activated sequence-binding complexes]	0.0	4	1	1	1
117642	1710	treatment, at regular interval	[treatment, at regular intervals]	0.0	4	1	1	1
117643	1710	yac flank the CALM region	[YACs flanking the CALM region]	0.0	5	1	1	1
117644	1710	human element hSIE	[human element hSIE]	0.0	3	1	1	1
117645	1710	gene effect	[gene effects]	0.0	2	1	1	1
117646	1710	weight of about 32, 36	[weights of about 32, 36]	0.0	5	1	1	1
117647	1710	binding of [3H]1 alpha,25-dihydroxyvitamin D3	[Binding of [3H]1 alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
117648	1710	transactivate factor	[transactivating factor]	0.0	2	1	1	1
117649	1710	activate granulocyte-colony-stimulating factor signal transduction pathway	[activating granulocyte-colony-stimulating factor signal transduction pathways]	0.0	6	1	1	1
117650	1710	collagenase expression in macrophage	[collagenase expression in macrophages]	0.0	4	1	1	1
117651	1710	high, pharmacological concentration of RA	[high, pharmacological concentrations of RA]	0.0	5	1	1	1
117652	1710	18 subject	[18 subjects]	0.0	2	1	1	1
117653	1710	use rabbit antibody	[using rabbit antibodies]	0.0	3	1	1	1
117654	1710	least three category factor	[least three categories factors]	0.0	4	1	1	1
117655	1710	number of peripheral blood leukocyte	[number of peripheral blood leukocytes]	0.0	5	1	1	1
117656	1710	application of two drugs,	[application of two drugs,]	0.0	4	1	1	1
117657	1710	keep erythroid-specific property	[keeping erythroid-specific properties]	0.0	3	1	1	1
117658	1710	basic potential phosphoprotein of function.	[basic potential phosphoprotein of function.]	0.0	5	1	1	1
117659	1710	environmental condition	[environmental conditions]	0.0	2	1	1	1
117660	1710	T cell with mitogen	[T cells with mitogens]	0.0	4	1	1	1
117661	1710	such as bacterial formylpeptide	[such as bacterial formylpeptides]	0.0	4	1	1	1
117662	1710	lineage-specific transcription factor such as gata-1	[lineage-specific transcription factors such as GATA-1]	0.0	6	1	1	1
117663	1710	microdeletion in the arm	[microdeletion in the arm]	0.0	4	1	1	1
117664	1710	little mrna	[little mRNA]	0.0	2	1	1	1
117665	1710	respond efficiently	[responding efficiently]	0.0	2	1	1	1
117666	1710	nevertheless, high, pharmacological concentration	[Nevertheless, high, pharmacological concentrations]	0.0	4	1	1	1
117667	1710	competitor of GcR	[competitor of GcR]	0.0	3	1	1	1
117668	1710	protein kinase in interleukin-1 cell	[protein kinases in interleukin-1 cells]	0.0	5	1	1	1
117669	1710	region UAS3 -1168	[regions UAS3 -1168]	0.0	3	1	1	1
117670	1710	chloramphenicol acetyltransferase CAT production by 75%	[chloramphenicol acetyltransferase CAT production by 75%]	0.0	6	1	1	1
117671	1710	casein kinase site (37	[casein kinase sites (37]	0.0	4	1	1	1
117672	1710	pp56(lck) mutant	[pp56(lck) mutants]	0.0	2	1	1	1
117673	1710	hypercalcemia of granulomato	[hypercalcemia of granulomatoses]	0.0	3	2	2	1
117674	1710	specificity of acid oxygenation	[specificity of acid oxygenation]	0.0	4	1	1	1
117675	1710	beta-globin locus in cell	[beta-globin locus in cells]	0.0	4	1	1	1
117676	1710	g protein G(S)alpha	[G protein G(S)alpha]	0.0	3	1	1	1
117677	1710	protein-DNA complex with similar mobility	[protein-DNA complexes with similar mobilities]	0.0	5	1	1	1
117678	1710	transformation of cell line	[transformation of cell lines]	0.0	4	1	1	1
117679	1710	actinomycin d pulse	[actinomycin D pulse]	0.0	3	1	1	1
117680	1710	origin of various neoplastic disorder	[origin of various neoplastic disorders]	0.0	5	1	1	1
117681	1710	sporadic androgen insensitivity syndrome	[sporadic androgen insensitivity syndrome]	0.0	4	1	1	1
117682	1710	phosphotyrosine phosphatase activity	[phosphotyrosine phosphatase activity]	0.0	3	1	1	1
117683	1710	tissue outside the pituitary	[tissues outside the pituitary]	0.0	4	1	1	1
117684	1710	transactivate region	[transactivating regions]	0.0	2	1	1	1
117685	1710	nmol/L) for cortisol	[nmol/L) for cortisol]	0.0	3	1	1	1
117686	1710	silencing of expression	[silencing of expression]	0.0	3	1	1	1
117687	1710	response to ultra-violet irradiation	[responses to UV irradiation]	0.0	4	1	1	1
117688	1710	positive control	[positive control]	0.0	2	1	1	1
117689	1710	short arm of Chr	[short arm of Chr]	0.0	4	1	1	1
117690	1710	fuse each of the factor	[fusing each of the factors]	0.0	5	1	1	1
117691	1710	constitutive activation tax protein	[Constitutive activation tax protein]	0.0	4	1	1	1
117692	1710	promoter of the B29 gene	[promoter of the B29 gene]	0.0	5	1	1	1
117693	1710	HLP-1	[HLP-1]	0.0	1	1	1	1
117694	1710	patient receive therapy	[patients receiving therapy]	0.0	3	1	1	1
117695	1710	gold compound especially aurothioglucose AuTG	[gold compounds especially aurothioglucose AuTG]	0.0	5	1	1	1
117696	1710	(five patient with microgram/day	[(five patients with microgram/day]	0.0	4	1	1	1
117697	1710	t-cell gene alpha tcr	[T-cell gene alpha TCR]	0.0	4	1	1	1
117698	1710	binding of three distinct complex RFX	[binding of three distinct complexes RFX]	0.0	6	1	1	1
117699	1710	three NF-ATc isoform	[three NF-ATc isoforms]	0.0	3	1	1	1
117700	1710	immature, multipotent eml cell	[immature, multipotent EML cells]	0.0	4	1	1	1
117701	1710	role for protooncogene	[role for protooncogenes]	0.0	3	1	1	1
117702	1710	treatment with a optimal concentration	[Treatment with an optimal concentration]	0.0	5	1	1	1
117703	1710	over-expression by transfection	[over-expression by transfection]	0.0	3	1	1	1
117704	1710	significant insight	[significant insights]	0.0	2	1	1	1
117705	1710	only in the expression of myb,	[only in the expression of myb,]	0.0	6	1	1	1
117706	1710	Erk2 activation	[Erk2 activation]	0.0	2	1	1	1
117707	1710	normal affinity to glucocorticoid AIDS-C	[normal affinity to glucocorticoids AIDS-C]	0.0	5	1	1	1
117708	1710	use version	[using versions]	0.0	2	1	1	1
117709	1710	unactivated extract	[unactivated extracts]	0.0	2	1	1	1
117710	1710	differential lineage requirement	[differential lineage requirements]	0.0	3	1	1	1
117711	1710	Rev M10	[Rev M10]	0.0	2	1	1	1
117712	1710	selection of lac+clone	[selection of Lac+clones]	0.0	3	1	1	1
117713	1710	mutation in the brca2	[mutations in the BRCA2]	0.0	4	1	1	1
117714	1710	tyrosine phosphorylation of multiple protein	[tyrosine phosphorylation of multiple proteins]	0.0	5	1	1	1
117715	1710	th1- gene expression	[Th1- gene expression]	0.0	3	1	1	1
117716	1710	clinical course (p chi2	[clinical course (P chi2]	0.0	4	1	1	1
117717	1710	only the mutation	[only the mutations]	0.0	3	1	1	1
117718	1710	lead to NF-kappaB translocation	[leading to NF-kappaB translocation]	0.0	4	1	1	1
117719	1710	absence transcription factor	[Absence transcription factors]	0.0	3	1	1	1
117720	1710	pattern of variation in expression	[patterns of variation in expression]	0.0	5	1	1	1
117721	1710	gammac promoter activity	[gammac promoter activity]	0.0	3	1	1	1
117722	1710	protein necessary for entry	[proteins necessary for entry]	0.0	4	1	1	1
117723	1710	body burdens.	[body burdens.]	0.0	2	1	1	1
117724	1710	high level in human monocyte	[highest levels in human monocytes]	0.0	5	1	1	1
117725	1710	b-cell proliferation of early protein	[B-cell proliferation of early proteins]	0.0	5	1	1	1
117726	1710	92-kda protein	[92-kDa protein]	0.0	2	1	1	1
117727	1710	diurnal rhythm	[diurnal rhythm]	0.0	2	2	2	1
117728	1710	factor in oxidant-induced nf-kappab activation	[factor in oxidant-induced NF-kappaB activation]	0.0	5	1	1	1
117729	1710	is, in part,	[is, in part,]	0.0	3	1	1	1
117730	1710	il-6 gene transcription	[IL-6 gene transcription]	0.0	3	1	1	1
117731	1710	requirement provide one explanation important.	[requirement providing one explanation important.]	0.0	5	1	1	1
117732	1710	sequence motif box1	[sequence motif box1]	0.0	3	1	1	1
117733	1710	transcriptional activation of lytic promoter	[transcriptional activation of lytic promoters]	0.0	5	1	1	1
117734	1710	transcription of the element	[transcription of the element]	0.0	4	1	1	1
117735	1710	t-cell-mediated immunity	[T-cell-mediated immunity]	0.0	2	1	1	1
117736	1710	microm pyrrolidine dithiocarbamate	[microM pyrrolidine dithiocarbamate]	0.0	3	1	1	1
117737	1710	E-box consensus motif	[E-box consensus motifs]	0.0	3	1	1	1
117738	1710	bhlh homo hetero dimer complex formation	[bHLH homo hetero dimer complex formation]	0.0	6	1	1	1
117739	1710	distinct regulatory element act independently	[distinct regulatory elements acting independently]	0.0	5	1	1	1
117740	1710	suggest a consequence of memory	[suggesting an consequence of memory]	0.0	5	1	1	1
117741	1710	age-related decline in il-2 production	[age-related decline in IL-2 production]	0.0	5	1	1	1
117742	1710	interleukin-3 il-3 granulocyte-macrophage colony-stimulating factor	[interleukin-3 IL-3 granulocyte-macrophage colony-stimulating factor]	0.0	5	1	1	1
117743	1710	total percentage CD4	[total percentage CD4]	0.0	3	1	1	1
117744	1710	1 P; binding of heterodimer	[1 h; binding of heterodimers]	0.0	5	1	1	1
117745	1710	small rna (snrna) gene	[small RNA (snRNA) genes]	0.0	4	1	1	1
117746	1710	class RB line	[class RB lines]	0.0	3	1	1	1
117747	1710	h- pgg-glucan	[H- PGG-Glucan]	0.0	2	1	1	1
117748	1710	reverse approach	[reverse approach]	0.0	2	1	1	1
117749	1710	retroviral transduction	[retroviral transduction]	0.0	2	1	1	1
117750	1710	mutually exclusive binding	[mutually exclusive binding]	0.0	3	1	1	1
117751	1710	transcription factor interferon factor	[transcription factor interferon factor]	0.0	4	1	1	1
117752	1710	tissue-specific expression in cell	[tissue-specific expression in cells]	0.0	4	1	1	1
117753	1710	Effect of glucocorticoid on peripheral function	[Effects of glucocorticoids on peripheral function]	0.0	6	1	1	1
117754	1710	[change	[[Changes]	0.0	1	4	4	1
117755	1710	feedback inhibitor of vascular inflammation	[feedback inhibitor of vascular inflammation]	0.0	5	1	1	1
117756	1710	fcs(-)-culture condition	[FCS(-)-culture conditions]	0.0	2	1	1	1
117757	1710	radical scavenging in unstimulated tnf- cell	[radical scavenging in unstimulated TNF- cells]	0.0	6	1	1	1
117758	1710	degradation of the inhibitor IkappaBalpha	[degradation of the inhibitor IkappaBalpha]	0.0	5	1	1	1
117759	1710	-resistance	[-resistance]	0.0	1	1	1	1
117760	1710	infiltrate into pathologic process	[infiltrating into pathologic processes]	0.0	4	1	1	1
117761	1710	lymphocyte OVTAL	[lymphocyte OVTAL]	0.0	2	1	1	1
117762	1710	21 bp with 12-bp insert	[21 bp with 12-bp insert]	0.0	5	1	1	1
117763	1710	skewedness	[skewedness]	0.0	1	1	1	1
117764	1710	human T leukemia virus type	[Human T leukemia virus type]	0.0	5	1	1	1
117765	1710	breast tumour	[breast tumours]	0.0	2	1	1	1
117766	1710	chromosome (Chr)	[Chromosome (Chr)]	0.0	2	1	1	1
117767	1710	cd45 on NF-kappa b	[CD45 on NF-kappa B]	0.0	4	1	1	1
117768	1710	a20 b	[A20 B]	0.0	2	1	1	1
117769	1710	evidence of switch recombination to epsilon	[evidence of switch recombination to epsilon]	0.0	6	1	1	1
117770	1710	alpha-globin G	[alpha-globin G]	0.0	2	1	1	1
117771	1710	three major MHC class gene	[three major MHC class genes]	0.0	5	1	1	1
117772	1710	promoter UAS1	[promoter UAS1]	0.0	2	1	1	1
117773	1710	efficacy of the drug	[efficacy of the drug]	0.0	4	1	1	1
117774	1710	nuclear translocation to activation	[nuclear translocation to activation]	0.0	4	1	1	1
117775	1710	contribute to inadequate response to therapy	[contributing to inadequate response to therapy]	0.0	6	1	1	1
117776	1710	comparative analysis of nfat	[Comparative analysis of NFAT]	0.0	4	1	1	1
117777	1710	calcium/calmodulin-dependent protein kinase ii	[calcium/calmodulin-dependent protein kinase II]	0.0	4	1	1	1
117778	1710	only significant systemic effect	[only significant systemic effects]	0.0	4	1	1	1
117779	1710	inducer il-1 beta	[inducer IL-1 beta]	0.0	3	1	1	1
117780	1710	evidence jak1 beta	[evidence JAK1 beta]	0.0	3	1	1	1
117781	1710	ifn-gamma level in the absence	[IFN-gamma levels in the absence]	0.0	5	1	1	1
117782	1710	decrease in LTR transcriptional activity	[decreases in LTR transcriptional activity]	0.0	5	1	1	1
117783	1710	discrimination of ca2+ signal	[discrimination of Ca2+ signals]	0.0	4	1	1	1
117784	1710	Ca(2+) -dependent factor	[Ca(2+) -dependent factor]	0.0	3	1	1	1
117785	1710	other protein family member	[other protein family members]	0.0	4	1	1	1
117786	1710	p-selectin-specific antibody	[P-selectin-specific antibodies]	0.0	2	1	1	1
117787	1710	nuclear extract consist	[nuclear extracts consisting]	0.0	3	1	1	1
117788	1710	taci activator	[TACI activator]	0.0	2	1	1	1
117789	1710	sp1 virus	[Sp1 virus]	0.0	2	1	1	1
117790	1710	ebv include tumorigenesis.	[EBV including tumorigenesis.]	0.0	3	1	1	1
117791	1710	moderate decrease	[moderate decreases]	0.0	2	1	1	1
117792	1710	temporal consequence	[temporal consequence]	0.0	2	1	1	1
117793	1710	excessive lyonization of cell	[excessive lyonization of cells]	0.0	4	1	1	1
117794	1710	thymocyte with autologous epithelial cell	[thymocytes with autologous epithelial cells]	0.0	5	1	1	1
117795	1710	i.e., factor receptor mrna	[i.e., factor receptor mRNA]	0.0	4	1	1	1
117796	1710	egl from samples, cytotoxic activity	[eGLs from samples, cytotoxic activity]	0.0	5	1	1	1
117797	1710	site within this promoter region	[sites within this promoter region]	0.0	5	1	1	1
117798	1710	novel immunosuppressive factor	[novel immunosuppressive factor]	0.0	3	1	1	1
117799	1710	nine woman	[nine women]	0.0	2	1	1	1
117800	1710	different kinases,	[different kinases,]	0.0	2	1	1	1
117801	1710	kRAB-containing zinc finger gene	[KRAB-containing zinc finger genes]	0.0	4	1	1	1
117802	1710	significantly early stage	[significantly earlier stages]	0.0	3	1	1	1
117803	1710	(mnl) of patient with pco	[(MNL) of patients with PCOS]	0.0	5	1	1	1
117804	1710	eosinophil granule basic protein	[eosinophil granule basic protein]	0.0	4	2	2	1
117805	1710	result from volunteer	[results from volunteers]	0.0	3	1	1	1
117806	1710	atp-depleted platelet	[ATP-depleted platelets]	0.0	2	1	1	1
117807	1710	sequence element epse)-binding transcription factor	[sequence element (PSE)-binding transcription factor]	0.0	5	1	1	1
117808	1710	Nonradioactive quantification	[Nonradioactive quantification]	0.0	2	1	1	1
117809	1710	lysopc to micromol/L) dose-dependently	[lysoPC to micromol/L) dose-dependently]	0.0	4	1	1	1
117810	1710	iddm subject	[IDDM subjects]	0.0	2	1	1	1
117811	1710	influence of age	[Influence of age]	0.0	3	1	1	1
117812	1710	10(-7) m all-tran retinoic acid	[10(-7) M all-trans retinoic acid]	0.0	5	1	1	1
117813	1710	dexamethasone suppressibility of mitogen-stimulated incorporation	[dexamethasone suppressibility of mitogen-stimulated incorporation]	0.0	5	1	1	1
117814	1710	response to stimulus bacterial product	[response to stimuli bacterial products]	0.0	5	1	1	1
117815	1710	use mobility shift assay EMSA	[Using mobility shift assays EMSA]	0.0	5	1	1	1
117816	1710	blood lymphocyte in sclerosis	[blood lymphocytes in sclerosis]	0.0	4	1	1	1
117817	1710	transcriptionally active tetrameric complex	[transcriptionally active tetrameric complexes]	0.0	4	1	1	1
117818	1710	recombinant gp41 the extracellular domain	[recombinant gp41 the extracellular domain]	0.0	5	1	1	1
117819	1710	6-fold high (KD	[6-fold higher (KD]	0.0	3	1	1	1
117820	1710	inhibitory effect of e3330	[Inhibitory effect of E3330]	0.0	4	1	1	1
117821	1710	erythroid-specific property in vitro	[erythroid-specific properties in vitro]	0.0	4	1	1	1
117822	1710	contain two copy	[containing two copies]	0.0	3	1	1	1
117823	1710	human sterol regulatory element	[human sterol regulatory element]	0.0	4	1	1	1
117824	1710	Differential regulation of proto-oncogent	[Differential regulation of proto-oncogenes]	0.0	4	1	1	1
117825	1710	ap-1 binding site -152	[AP-1 binding site -152]	0.0	4	1	1	1
117826	1710	different class of receptor	[different classes of receptors]	0.0	4	1	1	1
117827	1710	reinfection	[reinfection]	0.0	1	1	1	1
117828	1710	inhibition of IL-1 beta	[inhibition of IL-1 beta]	0.0	4	1	1	1
117829	1710	High concentration of a beta	[Higher concentrations of A beta]	0.0	5	1	1	1
117830	1710	STAT heterodimer	[STAT heterodimers]	0.0	2	1	1	1
117831	1710	promoter of certain growth-	[promoters of certain growth-]	0.0	4	1	1	1
117832	1710	transcription factor a central regulator	[transcription factor a central regulator]	0.0	5	1	1	1
117833	1710	transcription start site region	[transcription start site region]	0.0	4	1	1	1
117834	1710	chromatin structure lead	[chromatin structure leading]	0.0	3	1	1	1
117835	1710	pseudohypoaldosteronism with reduction of aldosterone receptor	[pseudohypoaldosteronism with reduction of aldosterone receptors]	0.0	6	1	1	1
117836	1710	Functional association	[Functional association]	0.0	2	1	1	1
117837	1710	translocation of nuclear factor-kappaB	[translocation of nuclear factor-kappaB]	0.0	4	1	1	1
117838	1710	nuclear translocation a member	[nuclear translocation a member]	0.0	4	1	1	1
117839	1710	microvascular ec	[microvascular EC]	0.0	2	1	1	1
117840	1710	main pathway involve kinase c	[main pathways involving kinase C]	0.0	5	1	1	1
117841	1710	cell contain lck	[cells containing Lck]	0.0	3	1	1	1
117842	1710	morphologically distinct subset	[morphologically distinct subsets]	0.0	3	2	2	1
117843	1710	potent enhancer	[potent enhancer]	0.0	2	1	1	1
117844	1710	hd of the population,	[HD of the population,]	0.0	4	1	1	1
117845	1710	use the puc probe specific	[using the pUC probes specific]	0.0	5	1	1	1
117846	1710	CIITA hybrid	[CIITA hybrids]	0.0	2	1	1	1
117847	1710	bone mip-1 alpha /gos19	[bone MIP-1 alpha /GOS19]	0.0	4	1	1	1
117848	1710	blood a phenomenon	[blood a phenomenon]	0.0	3	1	1	1
117849	1710	IL-10 release of il-1beta	[IL-10 release of IL-1beta]	0.0	4	1	1	1
117850	1710	require only the addition	[requiring only the addition]	0.0	4	1	1	1
117851	1710	hd of the population.	[HD of the population.]	0.0	4	1	1	1
117852	1710	neutralize abs to fibroblast growth factor	[neutralizing Abs to fibroblast growth factor]	0.0	6	1	1	1
117853	1710	extend from -392 bp relative	[extending from -392 bp relative]	0.0	5	1	1	1
117854	1710	certain makaume mtbe	[certain makeup, MTBE]	0.0	3	1	1	1
117855	1710	molecular understanding of effect	[molecular understanding of effects]	0.0	4	1	1	1
117856	1710	immunogenic human malignant melanoma	[immunogenic human malignant melanomas]	0.0	4	1	1	1
117857	1710	percentage of macrophage	[percentage of macrophages]	0.0	3	1	1	1
117858	1710	Nuclear accumulation	[Nuclear accumulation]	0.0	2	1	1	1
117859	1710	site of action of HePTP	[site of action of HePTP]	0.0	5	1	1	1
117860	1710	mM n-acetylcysteine	[mM N-acetylcysteine]	0.0	2	1	1	1
117861	1710	DNA affinity precipitation assay	[DNA affinity precipitation assay]	0.0	4	1	1	1
117862	1710	patient F.R.	[patients F.R.]	0.0	2	1	1	1
117863	1710	diagnosis, counseling,	[diagnosis, counseling,]	0.0	2	1	1	1
117864	1710	similar level 1 mrna level	[Similar levels 1 mRNA levels]	0.0	5	1	1	1
117865	1710	protein of the family	[proteins of the family]	0.0	4	1	1	1
117866	1710	plasma level	[plasma levels]	0.0	2	1	1	1
117867	1710	action between a element	[action between an element]	0.0	4	1	1	1
117868	1710	stimulus lipopolysaccharide	[stimulus lipopolysaccharide]	0.0	2	1	1	1
117869	1710	intron in pre-monocytic cells,	[intron in pre-monocytic cells,]	0.0	4	1	1	1
117870	1710	drive a ifn-gamma expression	[driving an IFN-gamma expression]	0.0	4	1	1	1
117871	1710	patient subsequently respond to therapy	[patients subsequently responding to therapy]	0.0	5	1	1	1
117872	1710	gene in megakaryoblastic disorder	[genes in megakaryoblastic disorders]	0.0	4	1	1	1
117873	1710	matrix metalloproteinase include mmp-9	[matrix metalloproteinases including MMP-9]	0.0	4	1	1	1
117874	1710	ifn-gamma -responsive gene	[IFN-gamma -responsive genes]	0.0	3	1	1	1
117875	1710	interleukin-3 granulocyte-macrophage colony-stimulating factor gm-csf	[interleukin-3 granulocyte-macrophage colony-stimulating factor GM-CSF]	0.0	5	1	1	1
117876	1710	relative difference	[relative differences]	0.0	2	1	1	1
117877	1710	progression of case	[progression of case]	0.0	3	1	1	1
117878	1710	low weight adaptor protein	[low weight adaptor proteins]	0.0	4	1	1	1
117879	1710	multipotential progenitor cell	[multipotential progenitor cells]	0.0	3	1	1	1
117880	1710	expression include member	[expression including members]	0.0	3	1	1	1
117881	1710	(18- to 35-year-old)	[(18- to 35-year-old)]	0.0	3	1	1	1
117882	1710	tissue type; level of expression	[tissue type; levels of expression]	0.0	5	1	1	1
117883	1710	activity for timp-1	[activity for TIMP-1]	0.0	3	1	1	1
117884	1710	interaction between AML1	[interactions between AML1]	0.0	3	1	1	1
117885	1710	evidence in T lymphocyte during aging.	[Evidence in T lymphocytes during aging.]	0.0	6	1	1	1
117886	1710	PRE-I site	[PRE-I site]	0.0	2	1	1	1
117887	1710	other distinct "octamer" complex	[other distinct "octamer" complex]	0.0	4	1	1	1
117888	1710	synergism between two element	[Synergism between two elements]	0.0	4	1	1	1
117889	1710	labeling with [32P]orthophosphate	[labeling with [32P]orthophosphate]	0.0	3	1	1	1
117890	1710	differential dependency of b-lymphopoiesis	[differential dependency of B-lymphopoiesis]	0.0	4	1	1	1
117891	1710	contain the translocation	[containing the translocation]	0.0	3	1	1	1
117892	1710	tumor necrosis factor traf3	[tumor necrosis factor TRAF3]	0.0	4	1	1	1
117893	1710	washout period	[washout period]	0.0	2	1	1	1
117894	1710	site CACCC	[sites CACCC]	0.0	2	1	1	1
117895	1710	Nuclear appearance	[Nuclear appearance]	0.0	2	1	1	1
117896	1710	area responsive to il-1	[area responsive to IL-1]	0.0	4	1	1	1
117897	1710	increase by P.	[increase by h.]	0.0	3	1	1	1
117898	1710	regulatory function in	[regulatory functions in]	0.0	3	1	1	1
117899	1710	kd value of 50nm	[Kd value of 50nM]	0.0	4	1	1	1
117900	1710	multiple complex with extract	[multiple complexes with extracts]	0.0	4	1	1	1
117901	1710	tissue-specific gene expression	[tissue-specific gene expression]	0.0	3	1	1	1
117902	1710	characteristic of child	[characteristic of children]	0.0	3	1	1	1
117903	1710	four map kinase	[four MAP kinase]	0.0	3	1	1	1
117904	1710	signal converge in pathway	[signals converging in pathways]	0.0	4	1	1	1
117905	1710	second class molecule	[second class molecule]	0.0	3	1	1	1
117906	1710	promoter of growth-	[promoters of growth-]	0.0	3	1	1	1
117907	1710	blastogenesis of blood lymphocyte PBL generation	[blastogenesis of blood lymphocytes PBL Generation]	0.0	6	1	1	1
117908	1710	Peptidoglycan	[Peptidoglycan]	0.0	1	1	1	1
117909	1710	/CAT	[/CAT]	0.0	1	1	1	1
117910	1710	different form of disease	[different forms of disease.]	0.0	4	1	1	1
117911	1710	C-terminal 70z/3 sequence	[C-terminal 70Z/3 sequences]	0.0	3	1	1	1
117912	1710	simultaneous activation of second messenger	[simultaneous activation of second messengers]	0.0	5	1	1	1
117913	1710	anti-P selectin antibody	[anti-P selectin antibodies]	0.0	3	1	1	1
117914	1710	overexpression of wild-type grf40	[Overexpression of wild-type Grf40]	0.0	4	1	1	1
117915	1710	abnormality in the capability	[abnormalities in the capability]	0.0	4	1	1	1
117916	1710	281 pmol/L; in normal woman	[281 pmol/L; in normal women]	0.0	5	1	1	1
117917	1710	clonal change present	[clonal change present]	0.0	3	1	1	1
117918	1710	(TNF)alpha	[(TNF)alpha]	0.0	1	1	1	1
117919	1710	patient with cirrhosis	[patient with cirrhosis]	0.0	3	1	1	1
117920	1710	il-2 induction of ifn-gamma mrna	[IL-2 induction of IFN-gamma mRNA]	0.0	5	1	1	1
117921	1710	umbilical vein endothelial cell monolayer	[umbilical vein endothelial cell monolayers]	0.0	5	1	1	1
117922	1710	mp of ng/ml	[MP of ng/ml]	0.0	3	1	1	1
117923	1710	order of magnitude the concentration	[orders of magnitude the concentration]	0.0	5	1	1	1
117924	1710	chi2 test),	[chi2 test),]	0.0	2	1	1	1
117925	1710	interleukin-2 expression a endogenous gene	[interleukin-2 expression a endogenous gene]	0.0	5	1	1	1
117926	1710	chi2 test).	[chi2 test).]	0.0	2	1	1	1
117927	1710	9-mer peptide bcr1/9	[9-mer peptides BCR1/9]	0.0	3	1	1	1
117928	1710	follow translocation in leukemia	[following translocations in leukemias]	0.0	4	1	1	1
117929	1710	activation of human zeta globin gene	[activation of human zeta globin gene]	0.0	6	1	1	1
117930	1710	NFAT family member responsible	[NFAT family member responsible]	0.0	4	1	1	1
117931	1710	p45 nf-e2 expression in differentiation	[p45 NF-E2 expression in differentiation]	0.0	5	1	1	1
117932	1710	infiltrate genital herpes lesion	[infiltrating genital herpes lesions]	0.0	4	1	1	1
117933	1710	affect upon cytokine production	[affect upon cytokine production]	0.0	4	1	1	1
117934	1710	lymphocyte of woman second	[lymphocytes of women second]	0.0	4	1	1	1
117935	1710	uncommon phenomenon in woman	[uncommon phenomenon in women]	0.0	4	1	1	1
117936	1710	transcriptional activation domain,	[transcriptional activation domain,]	0.0	3	1	1	1
117937	1710	mobilization of factor-kappaB nf-kappab	[Mobilization of factor-kappaB NF-kappaB]	0.0	4	1	1	1
117938	1710	culminate in cell	[culminating in cells]	0.0	3	1	1	1
117939	1710	underlie effect	[underlying effects]	0.0	2	1	1	1
117940	1710	anoxia /reoxygenation	[anoxia /reoxygenation]	0.0	2	1	1	1
117941	1710	interaction between PTF gamma/PTF delta	[interactions between PTF gamma/PTF delta]	0.0	5	1	1	1
117942	1710	kox gene	[KOX genes]	0.0	2	1	1	1
117943	1710	key step	[key step]	0.0	2	1	1	1
117944	1710	alpha-methyl,	[alpha-methyl,]	0.0	1	1	1	1
117945	1710	long repeat quasispecy	[long repeat quasispecies]	0.0	3	1	1	1
117946	1710	pbmc of several patient	[PBMCs of several patients]	0.0	4	1	1	1
117947	1710	level of c-jun transcription	[levels of c-jun transcription]	0.0	4	1	1	1
117948	1710	-negative status s-phase fraction	[-negative status S-phase fraction]	0.0	4	1	1	1
117949	1710	progression of one case	[progression of one case]	0.0	4	1	1	1
117950	1710	IL-2Rbeta promoter	[IL-2Rbeta promoter]	0.0	2	1	1	1
117951	1710	cytotoxicity pattern involve the recognition	[cytotoxicity patterns involving the recognition]	0.0	5	1	1	1
117952	1710	promyelocytic leukemia patient	[promyelocytic leukemia patients]	0.0	3	2	2	1
117953	1710	CholecystokininB	[CholecystokininB]	0.0	1	1	1	1
117954	1710	long terminal repeat site	[long terminal repeat sites]	0.0	4	1	1	1
117955	1710	replication of type	[Replication of type]	0.0	3	1	1	1
117956	1710	interaction with prb 105	[interaction with pRb 105]	0.0	4	1	1	1
117957	1710	two cis-acting element of the factor	[Two cis-acting elements of the factor]	0.0	6	1	1	1
117958	1710	utilize x-chromosome inactivation	[utilizing X-chromosome inactivation]	0.0	3	1	1	1
117959	1710	ic5 of prednisolone	[IC50S of prednisolone]	0.0	3	1	1	1
117960	1710	peripheral blood lymphocyte from human	[peripheral blood lymphocytes from humans]	0.0	5	1	1	1
117961	1710	surgery), proliferation	[surgery), proliferation]	0.0	2	1	1	1
117962	1710	activity of SV40 early promoter	[activities of SV40 early promoter]	0.0	5	1	1	1
117963	1710	prevent the phase of reaction	[preventing the phase of reaction]	0.0	5	1	1	1
117964	1710	binding capacity +/- fmol	[binding capacity +/- fmol]	0.0	4	1	1	1
117965	1710	design therapeutic strategy	[designing therapeutic strategies]	0.0	3	1	1	1
117966	1710	effective biologic concentration	[effective biologic concentrations]	0.0	3	1	1	1
117967	1710	cotransfection in sense orientation together	[cotransfection in sense orientation together]	0.0	5	1	1	1
117968	1710	level of the component	[levels of the components]	0.0	4	1	1	1
117969	1710	other nfat-sensitive gene	[other NFAT-sensitive gene]	0.0	3	1	1	1
117970	1710	acid CD40 cytoplasmic signal determinant	[acid CD40 cytoplasmic signaling determinant]	0.0	5	1	1	1
117971	1710	-795 bp	[-795 bp]	0.0	2	1	1	1
117972	1710	cellular promoter of growth-	[cellular promoters of growth-]	0.0	4	1	1	1
117973	1710	ALF1 transcription of Akv MLV	[ALF1 transcription of Akv MLV]	0.0	5	1	1	1
117974	1710	low cytoplasmic level	[low cytoplasmic levels]	0.0	3	1	1	1
117975	1710	express the hpv type 16	[expressing the HPV type 16]	0.0	5	1	1	1
117976	1710	nuclear nf-kappab in human mononuclear cell	[nuclear NF-kappaB in human mononuclear cells]	0.0	6	1	1	1
117977	1710	disruption of potential functional motifs:	[disruptions of potential functional motifs:]	0.0	5	1	1	1
117978	1710	down-regulation of protein	[Down-regulation of proteins]	0.0	3	1	1	1
117979	1710	constitutive c-fo transcript level	[constitutive c-fos transcript levels]	0.0	4	1	1	1
117980	1710	many alteration	[many alterations]	0.0	2	1	1	1
117981	1710	role of the intestinal cell	[role of the intestinal cell]	0.0	5	1	1	1
117982	1710	Furthermore, recruitment	[Furthermore, recruitment]	0.0	2	1	1	1
117983	1710	highlight novel cancer related loci	[highlighting novel cancer related loci]	0.0	5	1	1	1
117984	1710	isolation of a candidate repressor/activator	[Isolation of a candidate repressor/activator]	0.0	5	1	1	1
117985	1710	pathogenesis of keratoconjunctivitis	[pathogenesis of keratoconjunctivitis]	0.0	3	1	1	1
117986	1710	uptake in pbmc with hyperparathyroidism	[uptake in PBMC with hyperparathyroidism]	0.0	5	1	1	1
117987	1710	report on nur77 mouse	[reports on nur77 mice]	0.0	4	1	1	1
117988	1710	cd14 antibody	[CD14 antibody]	0.0	2	1	1	1
117989	1710	thp-1 cell at doses.	[THP-1 cells at doses.]	0.0	4	1	1	1
117990	1710	smooth muscle myosin chain Smmhc	[smooth muscle myosin chain Smmhc]	0.0	5	1	1	1
117991	1710	significant quantity	[significant quantities]	0.0	2	1	1	1
117992	1710	cytokine receptor interleukin (il)-2	[cytokine receptors interleukin (IL)-2]	0.0	4	1	1	1
117993	1710	immune system in vertebrate	[immune system in vertebrates]	0.0	4	1	1	1
117994	1710	confirm findings.	[confirming findings.]	0.0	2	1	1	1
117995	1710	kappa 3/CRE site	[kappa 3/CRE site]	0.0	3	1	1	1
117996	1710	(Krox-20);	[(Krox-20);]	0.0	1	1	1	1
117997	1710	tcf-1 alpha mrna	[TCF-1 alpha mRNA]	0.0	3	1	1	1
117998	1710	p45 nf-e2 mrna in human granurocyte	[P45 NF-E2 mRNA in human granurocytes]	0.0	6	1	1	1
117999	1710	polymorphism SSCP	[polymorphism SSCP]	0.0	2	1	1	1
118000	1710	general biological principle	[general biological principle]	0.0	3	1	1	1
118001	1710	undetectable consolidation	[undetectable consolidation]	0.0	2	1	1	1
118002	1710	bp element	[bp elements]	0.0	2	1	1	1
118003	1710	activity low	[activity lower]	0.0	2	1	1	1
118004	1710	breakage join recombination event	[breakage joining recombination events]	0.0	4	1	1	1
118005	1710	optimal motif	[optimal motifs]	0.0	2	1	1	1
118006	1710	good transactivator	[better transactivator]	0.0	2	1	1	1
118007	1710	cell at day g-csf	[cells at day G-CSF]	0.0	4	1	1	1
118008	1710	effect on level of transcription	[effect on levels of transcription]	0.0	5	1	1	1
118009	1710	different pathway of the cell systems.	[different pathways of the cell systems.]	0.0	6	1	1	1
118010	1710	represent the NH2 terminus of receptor-1	[representing the NH2 terminus of receptor-1]	0.0	6	1	1	1
118011	1710	hiv terminal repeat activation	[HIV terminal repeat activation]	0.0	4	1	1	1
118012	1710	provide a basis for molecular mimicry	[providing a basis for molecular mimicry]	0.0	6	1	1	1
118013	1710	regulate the activation	[regulating the activation]	0.0	3	1	1	1
118014	1710	10(-8) g/g of rna	[10(-8) g/g of RNA]	0.0	4	1	1	1
118015	1710	IRF-1 pathway in T lymphocyte	[IRF-1 pathway in T lymphocytes]	0.0	5	1	1	1
118016	1710	suppression of th1 function	[suppression of TH1 functions]	0.0	4	1	1	1
118017	1710	regulation of NF-kappa b activation	[regulation of NF-kappa B activation]	0.0	5	1	1	1
118018	1710	induction for a set	[induction for a set]	0.0	4	1	1	1
118019	1710	also in hela cell	[also in HeLa cells]	0.0	4	1	1	1
118020	1710	heterodimeric receptor	[heterodimeric receptor]	0.0	2	1	1	1
118021	1710	protein interaction necessary for transcriptional regulation	[protein interactions necessary for transcriptional regulation]	0.0	6	1	1	1
118022	1710	[regulatory effect	[[Regulatory effect]	0.0	2	1	1	1
118023	1710	disease status.	[disease status.]	0.0	2	1	1	1
118024	1710	exposure of aortic cell HAEC	[exposure of aortic cells HAEC]	0.0	5	1	1	1
118025	1710	1,25 dihydroxyvitamin d3,	[1,25 dihydroxyvitamin D3,]	0.0	3	1	1	1
118026	1710	Ca2+ induction	[Ca2+ induction]	0.0	2	1	1	1
118027	1710	shp2-interacting adaptor protein a novel dimer	[SHP2-interacting adaptor protein a novel dimer]	0.0	6	1	1	1
118028	1710	v/v)	[v/v)]	0.0	1	1	1	1
118029	1710	protein ebna2-ebna6 in nasal lymphoma	[proteins EBNA2-EBNA6 in nasal lymphoma]	0.0	5	1	1	1
118030	1710	different truncation mutant	[different truncation mutants]	0.0	3	1	1	1
118031	1710	hnf3 beta	[HNF3 beta]	0.0	2	1	1	1
118032	1710	alcoholic extract	[Alcoholic extracts]	0.0	2	1	1	1
118033	1710	leukemia cell with 12-o-tetradecanoylphorbol-13-acetate	[leukemia cells with 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
118034	1710	primary activation	[primary activation]	0.0	2	1	1	1
118035	1710	patient with bipolar disorder euthymic,	[patients with bipolar disorder euthymic,]	0.0	5	1	1	1
118036	1710	short motif	[short motif]	0.0	2	1	1	1
118037	1710	protein result	[proteins resulting]	0.0	2	1	1	1
118038	1710	addition of anti- tnf-alpha antibody	[addition of anti- TNF-alpha antibody]	0.0	5	1	1	1
118039	1710	therapy,	[therapy,]	0.0	1	1	1	1
118040	1710	Functional characterization of novel IL-2 inhibitor	[Functional characterization of novel IL-2 inhibitors]	0.0	6	1	1	1
118041	1710	footprint between -183	[footprint between -183]	0.0	3	1	1	1
118042	1710	level in level of protein	[levels in levels of protein]	0.0	5	1	1	1
118043	1710	time of exposure	[times of exposure]	0.0	3	1	1	1
118044	1710	day fetal liver	[day fetal liver]	0.0	3	1	1	1
118045	1710	h of ifn-alpha treatment peak	[h of IFN-alpha treatment peaks]	0.0	5	1	1	1
118046	1710	min) physical exercise ppe	[min) physical exercise PPE]	0.0	4	1	1	1
118047	1710	concentration (nmax)	[concentration (Nmax)]	0.0	2	1	1	1
118048	1710	same extract	[same extracts]	0.0	2	1	1	1
118049	1710	stimulation complex signal pathway	[Stimulation complex signaling pathway]	0.0	4	1	1	1
118050	1710	model for lineage restriction	[model for lineage restriction]	0.0	4	1	1	1
118051	1710	class of cytosolic receptor	[classes of cytosolic receptors]	0.0	4	1	1	1
118052	1710	role in initiation	[role in initiation]	0.0	3	1	1	1
118053	1710	fact consistent	[fact consistent]	0.0	2	1	1	1
118054	1710	Tcf-1 transcription in T lymphocyte role	[Tcf-1 transcription in T lymphocytes role]	0.0	6	1	1	1
118055	1710	rather a process	[rather a process]	0.0	3	1	1	1
118056	1710	effector on dna-binding activity	[effector on DNA-binding activity]	0.0	4	1	1	1
118057	1710	restriction point	[restriction points]	0.0	2	1	1	1
118058	1710	(hs)/stress	[(HS)/stress]	0.0	1	1	1	1
118059	1710	anti-m-csf	[anti-M-CSF]	0.0	1	1	1	1
118060	1710	several IL-2 DNA binding activity	[several IL-2 DNA binding activities]	0.0	5	1	1	1
118061	1710	map region	[map regions]	0.0	2	1	1	1
118062	1710	leukocyte from 11 obese subject	[leukocytes from 11 obese subjects]	0.0	5	1	1	1
118063	1710	latency type	[latency type]	0.0	2	1	1	1
118064	1710	presence during the cell cycle	[presence during the cell cycles]	0.0	5	1	1	1
118065	1710	-inducible transcription	[-inducible transcription]	0.0	2	1	1	1
118066	1710	breakpoint on chromosome 11	[breakpoints on chromosome 11]	0.0	4	1	1	1
118067	1710	intense exercise follow phosphocreatine administration	[intense exercise following phosphocreatine administration]	0.0	5	1	1	1
118068	1710	ctll-2 i.e. beta-casein	[CTLL-2 i.e. beta-casein]	0.0	3	1	1	1
118069	1710	cellular adhesion of sulfoxide	[cellular adhesion of sulfoxide]	0.0	4	1	1	1
118070	1710	b-cell-specific footprint	[B-cell-specific footprint]	0.0	2	1	1	1
118071	1710	Jurkat T cell in the regulation	[Jurkat T cells in the regulation]	0.0	6	1	1	1
118072	1710	same cell lineage	[same cell lineages]	0.0	3	1	1	1
118073	1710	individual mutation of the DBF	[Individual mutation of the DBF]	0.0	5	1	1	1
118074	1710	b7.1 gene	[B7.1 gene]	0.0	2	2	2	1
118075	1710	inhibition I type ii interferon	[Inhibition I type II interferons]	0.0	5	1	1	1
118076	1710	follow microglial cell stimulation	[following microglial cell stimulation]	0.0	4	1	1	1
118077	1710	HU cell	[HU cells]	0.0	2	1	1	1
118078	1710	shift in the weight	[shift in the weight]	0.0	4	1	1	1
118079	1710	microsomal membrane from mononuclear leukocyte	[microsomal membranes from mononuclear leukocytes]	0.0	5	1	1	1
118080	1710	constitutive association domain	[constitutive association domain]	0.0	3	1	1	1
118081	1710	(range, 4-.11),	[(range, 4-5.13),]	0.0	2	1	1	1
118082	1710	differentiation of mpro promyelocyte	[differentiation of MPRO promyelocytes]	0.0	4	1	1	1
118083	1710	exposure of aortic cell	[exposure of aortic cells]	0.0	4	1	1	1
118084	1710	signal molecule capable	[signaling molecule capable]	0.0	3	1	1	1
118085	1710	x-ray-treated colonic carcinoma cell line	[X-ray-treated colonic carcinoma cell line]	0.0	5	1	1	1
118086	1710	7 erythroid precursor	[7 erythroid precursors]	0.0	3	1	1	1
118087	1710	T hut78	[T HUT78]	0.0	2	1	1	1
118088	1710	specific binding of 135(oh)2d3	[specific binding of 1,25(OH)2D3]	0.0	4	1	1	1
118089	1710	inhibition of activation of nf-kappab	[inhibition of activation of NF-kappaB]	0.0	5	1	1	1
118090	1710	gene inhibitory response	[gene inhibitory responses]	0.0	3	1	1	1
118091	1710	2 receptor beta chain	[2 receptor beta chain]	0.0	4	1	1	1
118092	1710	two immediate early gene	[two immediate early genes]	0.0	4	1	1	1
118093	1710	monocytic m-csf receptor promoter	[monocytic M-CSF receptor promoter]	0.0	4	1	1	1
118094	1710	activation of the nf-kappab kinase	[activation of the NF-kappaB kinase]	0.0	5	1	1	1
118095	1710	Furthermore, ethanol	[Furthermore, ethanol]	0.0	2	1	1	1
118096	1710	system, RA	[system, RA]	0.0	2	1	1	1
118097	1710	Retinoic acid treatment	[Retinoic acid treatment]	0.0	3	2	2	1
118098	1710	interferon-induced, RNA protein kinase	[interferon-induced, RNA protein kinase]	0.0	4	1	1	1
118099	1710	bind specifically to the ap-1	[binding specifically to the AP-1]	0.0	5	1	1	1
118100	1710	mutation in this region	[mutations in these regions]	0.0	4	1	1	1
118101	1710	mutant of this kinase	[mutants of these kinases]	0.0	4	1	1	1
118102	1710	distinct regulatory element act somewhat independently	[distinct regulatory elements acting somewhat independently]	0.0	6	1	1	1
118103	1710	also a potent inhibitor	[also a potent inhibitor]	0.0	4	1	1	1
118104	1710	appropriate variable region beta chain	[appropriate variable region beta chain]	0.0	5	1	1	1
118105	1710	role of IKK1 in lipopolysaccharide	[Role of IKK1 in lipopolysaccharide]	0.0	5	1	1	1
118106	1710	finding of association between Ikaros	[findings of associations between Ikaros]	0.0	5	1	1	1
118107	1710	gene on chromosomes.	[genes on chromosomes.]	0.0	3	1	1	1
118108	1710	differentiation-associated phenotype	[differentiation-associated phenotypes]	0.0	2	1	1	1
118109	1710	version of TRAF6	[version of TRAF6]	0.0	3	1	1	1
118110	1710	gene expression in endothelial cell	[gene expression in endothelial cells]	0.0	5	1	1	1
118111	1710	presence of a pathway	[presence of a pathway]	0.0	4	1	1	1
118112	1710	transient tranfection	[Transient tranfection]	0.0	2	1	1	1
118113	1710	flexi-12 delivery to myeloid leukemic blast	[Flexi-12 delivery to myeloid leukemic blasts]	0.0	6	1	1	1
118114	1710	inactivation of the x inconsistent	[inactivation of the X inconsistent]	0.0	5	1	1	1
118115	1710	self-antigen by DC	[self-antigen by DC]	0.0	3	1	1	1
118116	1710	il-6 mrna stability	[IL-6 mRNA stability]	0.0	3	1	1	1
118117	1710	control of latency	[control of latency]	0.0	3	1	1	1
118118	1710	simultaneously; (3) normal pbl	[simultaneously; (3) normal PBL]	0.0	4	1	1	1
118119	1710	PMA ionophore	[PMA ionophore]	0.0	2	1	1	1
118120	1710	hour time	[hours time]	0.0	2	2	2	1
118121	1710	interleukin (il-2)	[interleukin (IL-2)]	0.0	2	1	1	1
118122	1710	calcium -dependent gene product	[calcium -dependent gene product]	0.0	4	1	1	1
118123	1710	view of the efficiency	[view of the efficiency]	0.0	4	1	1	1
118124	1710	long arm of chromosome	[long arm of chromosome]	0.0	4	1	1	1
118125	1710	differentiation inducer 12-o-tetradecanoylphorbol 13-acetate	[differentiation inducers 12-O-tetradecanoylphorbol 13-acetate]	0.0	4	1	1	1
118126	1710	Jun kinase a mediator pathways.	[Jun kinase a mediator pathways.]	0.0	5	1	1	1
118127	1710	distinguished: biochemical sign	[distinguished: biochemical signs]	0.0	3	1	1	1
118128	1710	biopsy of hairy leukoplakia	[Biopsies of hairy leukoplakia]	0.0	4	1	1	1
118129	1710	EGR-1 transcription	[EGR-1 transcription]	0.0	2	1	1	1
118130	1710	transcription factor such as member	[transcription factors such as members]	0.0	5	1	1	1
118131	1710	level in tissues.	[levels in tissues.]	0.0	3	1	1	1
118132	1710	pha human blood lymphocyte	[PHA human blood lymphocytes]	0.0	4	1	1	1
118133	1710	event such as leukocyte migration	[events such as leukocyte migration]	0.0	5	1	1	1
118134	1710	14 sle (92.9%)	[14 SLE (92.9%)]	0.0	3	1	1	1
118135	1710	methallothionein (mtiia)	[methallothionein (MTIIa)]	0.0	2	1	1	1
118136	1710	leukotriene B4	[leukotriene B4]	0.0	2	1	1	1
118137	1710	neutrophil with FMLP	[neutrophil with FMLP]	0.0	3	1	1	1
118138	1710	constitutively active form partially substitute	[constitutively active form partially substitutes]	0.0	5	1	1	1
118139	1710	step of infection	[steps of infection]	0.0	3	1	1	1
118140	1710	structural order of ghost membrane	[structural order of ghost membrane]	0.0	5	2	2	1
118141	1710	abnormal morphology	[abnormal morphology]	0.0	2	1	1	1
118142	1710	lack most	[lacking most]	0.0	2	1	1	1
118143	1710	contain four repeat DR of bp	[containing four repeats DR of bp]	0.0	6	1	1	1
118144	1710	p53 paradox	[p53 paradox]	0.0	2	1	1	1
118145	1710	nonpeptidyl small molecule capable	[nonpeptidyl small molecule capable]	0.0	4	1	1	1
118146	1710	TAL1 expression by erythroid cell	[TAL1 expression by erythroid cells]	0.0	5	1	1	1
118147	1710	system a myeloid cell line	[systems a myeloid cell line]	0.0	5	1	1	1
118148	1710	human CD4 T	[human CD4 T]	0.0	3	1	1	1
118149	1710	correlation between level	[correlation between level]	0.0	3	1	1	1
118150	1710	immunodeficiency virus type protease	[immunodeficiency virus type protease]	0.0	4	1	1	1
118151	1710	virus enhancer tc-ii element	[virus enhancer TC-II element]	0.0	4	1	1	1
118152	1710	(or lmp-1	[(or LMP-1]	0.0	2	1	1	1
118153	1710	selective NK clearance	[selective NK clearance]	0.0	3	1	1	1
118154	1710	1beta,25-dihydroxyvitamin D3 the antagonist	[1beta,25-dihydroxyvitamin D3 the antagonist]	0.0	4	1	1	1
118155	1710	constitutive expression in vivo	[Constitutive expression in vivo]	0.0	4	1	1	1
118156	1710	icam-1 surface protein (also in cell	[ICAM-1 surface protein (also in cells]	0.0	6	1	1	1
118157	1710	result in inflammatory response	[resulting in inflammatory response]	0.0	4	1	1	1
118158	1710	Strikingly, deletion of 346 residue	[Strikingly, deletion of 346 residues]	0.0	5	1	1	1
118159	1710	structural protein	[structural proteins]	0.0	2	1	1	1
118160	1710	double-stranded RNA manner	[double-stranded RNA manner]	0.0	3	1	1	1
118161	1710	major signal cascade in T lymphocyte	[major signal cascades in T lymphocytes]	0.0	6	1	1	1
118162	1710	diapedesis through the blood vessel	[diapedesis through the blood vessel]	0.0	5	1	1	1
118163	1710	shared, component	[shared, component]	0.0	2	1	1	1
118164	1710	form of joint disease	[forms of joint disease.]	0.0	4	1	1	1
118165	1710	effects:	[effects:]	0.0	1	1	1	1
118166	1710	involve transcript initiation	[involving transcript initiation]	0.0	3	1	1	1
118167	1710	ar present in T cell	[AR present in T cells]	0.0	5	1	1	1
118168	1710	23 case of nasal lymphoma	[23 cases of nasal lymphoma]	0.0	5	1	1	1
118169	1710	EBNA2 synthesis	[EBNA2 synthesis]	0.0	2	1	1	1
118170	1710	JAK3 -deficient severe immunodeficiency lymphocyte	[JAK3 -deficient severe immunodeficiency lymphocytes]	0.0	5	1	1	1
118171	1710	METHODS: out of 22 case	[METHODS: out of 22 cases]	0.0	5	1	1	1
118172	1710	polymorphism to condition	[polymorphism to conditions]	0.0	3	1	1	1
118173	1710	Fifteen patient (age 25-79) with sepsis	[Fifteen patients (age 25-79) with sepsis]	0.0	6	1	1	1
118174	1710	proliferation (71%) recent-onset iddm subject	[proliferation (71%) recent-onset IDDM subjects]	0.0	5	1	1	1
118175	1710	50% dose	[50% dose]	0.0	2	1	1	1
118176	1710	transluminal coronary angioplasty PTCA	[transluminal coronary angioplasty PTCA]	0.0	4	1	1	1
118177	1710	displacement implication for B-cell specificity	[Displacement implications for B-cell specificity]	0.0	5	1	1	1
118178	1710	h. treatment of 6tg1.1 cell	[h, treatment of 6TG1.1 cells]	0.0	5	1	1	1
118179	1710	double-positive (dp) CD4 cd8(+) CD3	[double-positive (DP) CD4 CD8(+) CD3]	0.0	5	1	1	1
118180	1710	mapping of sry in the ape	[mapping of SRY in the apes]	0.0	6	1	1	1
118181	1710	gene in heterologous cell type	[genes in heterologous cell types]	0.0	5	1	1	1
118182	1710	activity of plzf-rar alpha	[activities of PLZF-RAR alpha]	0.0	4	1	1	1
118183	1710	cellular mechanism govern the response	[cellular mechanism governing the response]	0.0	5	1	1	1
118184	1710	specific nf-kappa b heteromer	[specific NF-kappa B heteromers]	0.0	4	1	1	1
118185	1710	expression of hGATA-3	[expression of hGATA-3]	0.0	3	1	1	1
118186	1710	expression of serum gene	[expression of serum genes]	0.0	4	1	1	1
118187	1710	1/oct coactivator	[1/Oct coactivator]	0.0	2	1	1	1
118188	1710	advanced failure A-CRF	[advanced failure A-CRF]	0.0	3	1	1	1
118189	1710	lack of prb	[lack of pRB]	0.0	3	1	1	1
118190	1710	bp of the cd44 promoter	[bp of the CD44 promoter]	0.0	5	1	1	1
118191	1710	activation of erk2 kinase	[activation of ERK2 kinase]	0.0	4	1	1	1
118192	1710	12-0-tetradecanoyl phorbol-13-acetate tpa	[12-0-tetradecanoyl phorbol-13-acetate TPA]	0.0	3	1	1	1
118193	1710	(g-csf) receptor	[(G-CSF) receptor]	0.0	2	1	1	1
118194	1710	encode fkbp	[encoding FKBP]	0.0	2	1	1	1
118195	1710	occur in T lymphocyte	[occurring in T lymphocytes]	0.0	4	1	1	1
118196	1710	activation in response induce agents.	[activation in response inducing agents.]	0.0	5	1	1	1
118197	1710	leucocyte in 13 man	[leucocytes in 13 men]	0.0	4	1	1	1
118198	1710	activity of this proteins.	[activity of these proteins.]	0.0	4	1	1	1
118199	1710	underlying mechanism for complex effect	[underlying mechanism for complex effects]	0.0	5	1	1	1
118200	1710	protein expression in lymphoid tissue	[protein expression in lymphoid tissues]	0.0	5	1	1	1
118201	1710	small exon	[small exons]	0.0	2	1	1	1
118202	1710	individual of histocompatibility complex (mhc) haplotype	[individuals of histocompatibility complex (MHC) haplotypes]	0.0	6	1	1	1
118203	1710	unmanipulated (b-2) lymphocyte	[unmanipulated (B-2) lymphocytes]	0.0	3	1	1	1
118204	1710	expression in vivo of Fos	[expression in vivo of Fos]	0.0	5	1	1	1
118205	1710	namely c-fo	[namely c-fos]	0.0	2	1	1	1
118206	1710	level in vitro.	[level in vitro.]	0.0	3	1	1	1
118207	1710	Diamide	[Diamide]	0.0	1	1	1	1
118208	1710	sequence similarity to the family	[sequence similarities to the family]	0.0	5	1	1	1
118209	1710	specific nf-kappab oligoprobe	[specific NF-kappaB oligoprobe]	0.0	3	1	1	1
118210	1710	Concern lymphocyte	[Concerning lymphocytes]	0.0	2	1	1	1
118211	1710	tamarin	[tamarin]	0.0	1	2	2	1
118212	1710	extinction of several gene	[extinction of several genes]	0.0	4	1	1	1
118213	1710	test activity in mouse	[Testing activity in mice]	0.0	4	1	1	1
118214	1710	positive correlation between VDR concentration	[positive correlation between VDR concentration]	0.0	5	1	1	1
118215	1710	function of a various type	[functions of a various type]	0.0	5	1	1	1
118216	1710	competence of T cell	[competence of T cells]	0.0	4	1	1	1
118217	1710	vascular cell adhesion molecule-1 vcam-1 expression	[vascular cell adhesion molecule-1 VCAM-1 expression]	0.0	6	1	1	1
118218	1710	adenocarcinoma chimeric monoclonal antibody	[adenocarcinoma chimeric monoclonal antibody]	0.0	4	1	1	1
118219	1710	experimental series:	[experimental series:]	0.0	2	1	1	1
118220	1710	independently of the condition	[independently of the conditions]	0.0	4	1	1	1
118221	1710	60% similar (46%	[60% similar (46%]	0.0	3	1	1	1
118222	1710	constitutive tax expression	[constitutive Tax expression]	0.0	3	1	1	1
118223	1710	lysosomal protein myeloperoxidase	[lysosomal proteins myeloperoxidase]	0.0	3	1	1	1
118224	1710	novel growth-factor-dependent cell line	[novel growth-factor-dependent cell line]	0.0	4	1	1	1
118225	1710	use lymphoblastoid cell line	[using lymphoblastoid cell lines]	0.0	4	1	1	1
118226	1710	glucocorticoid receptor GCR on leucocyte	[glucocorticoid receptors GCR on leucocytes]	0.0	5	1	1	1
118227	1710	receptor consist of the domain	[receptors consisting of the domain]	0.0	5	1	1	1
118228	1710	enhancer element responsible for the regulation	[enhancer elements responsible for the regulation]	0.0	6	1	1	1
118229	1710	other homology	[other homologies]	0.0	2	1	1	1
118230	1710	processing b1/	[processing B1/]	0.0	2	1	1	1
118231	1710	effect on the activity of ap-1	[effects on the activity of AP-1]	0.0	6	1	1	1
118232	1710	gtp-bound form of Rap1	[GTP-bound form of Rap1]	0.0	4	1	1	1
118233	1710	number of receptor in mononuclear leukocyte	[number of receptors in mononuclear leukocytes]	0.0	6	1	1	1
118234	1710	reduction in response	[reduction in response]	0.0	3	1	1	1
118235	1710	lymphoblastoid cell by ionizing radiation	[lymphoblastoid cells by ionizing radiation]	0.0	5	1	1	1
118236	1710	regulator in differentiation	[regulators in differentiation]	0.0	3	1	1	1
118237	1710	pregnant woman second	[pregnant women second]	0.0	3	1	1	1
118238	1710	protein phosphatase type 1	[protein phosphatase type 1]	0.0	4	1	1	1
118239	1710	endothelial cell activation with leukocyte adhesion	[endothelial cell activation with leukocyte adhesion]	0.0	6	1	1	1
118240	1710	study define signal	[studies defining signals]	0.0	3	1	1	1
118241	1710	105-kDa precursor	[105-kDa precursor]	0.0	2	1	1	1
118242	1710	influence on the activity	[influence on the activity]	0.0	4	1	1	1
118243	1710	increase during expression	[Increases during expression]	0.0	3	1	1	1
118244	1710	high, establish a inverse relation MHC	[high, establishing an inverse relation MHC]	0.0	6	1	1	1
118245	1710	regulator of granulocyte apoptosis	[regulator of granulocyte apoptosis]	0.0	4	1	1	1
118246	1710	two h	[Two h]	0.0	2	1	1	1
118247	1710	several site originate 204 bp	[several sites originating 204 bp]	0.0	5	1	1	1
118248	1710	age-associated decline	[age-associated decline]	0.0	2	1	1	1
118249	1710	region (position responsive	[region (positions responsive]	0.0	3	1	1	1
118250	1710	IL-2 response element	[IL-2 response element]	0.0	3	1	1	1
118251	1710	(64 mv), normalize after delivery	[(64 mV), normalizing after delivery]	0.0	5	1	1	1
118252	1710	suggest a effect on IL-2 expression	[suggesting a effect on IL-2 expression]	0.0	6	1	1	1
118253	1710	lipopolysaccharide signal	[lipopolysaccharide signaling]	0.0	2	1	1	1
118254	1710	own production,	[own production,]	0.0	2	1	1	1
118255	1710	cystine	[cystine]	0.0	1	1	1	1
118256	1710	region important,	[regions important,]	0.0	2	1	1	1
118257	1710	direct repressive effect	[direct repressive effect]	0.0	3	1	1	1
118258	1710	monocytic cell line bf24	[monocytic cell line BF24]	0.0	4	1	1	1
118259	1710	x-ray cell	[X-ray cells]	0.0	2	1	1	1
118260	1710	hypothalamus.	[hypothalamus.]	0.0	1	1	1	1
118261	1710	run-off assay	[run-off assays]	0.0	2	1	1	1
118262	1710	effect of the ctg-motif	[effect of the CTG-motif]	0.0	4	1	1	1
118263	1710	CD40 mm	[CD40 MM]	0.0	2	1	1	1
118264	1710	epidemiologic feature with human ebv	[epidemiologic features with human EBV]	0.0	5	1	1	1
118265	1710	pressure-stretch load	[pressure-stretching load]	0.0	2	1	1	1
118266	1710	adhesion in human vein endothelial cell	[adhesion in human vein endothelial cells]	0.0	6	1	1	1
118267	1710	difference between antiandrogen	[difference between antiandrogens]	0.0	3	1	1	1
118268	1710	rapid increase from steroid-sensitive patient	[rapid increase from steroid-sensitive patients]	0.0	5	1	1	1
118269	1710	transcription factor np-tcii	[transcription factor NP-TCII]	0.0	3	1	1	1
118270	1710	nf-kappa b signal	[NF-kappa B signaling]	0.0	3	1	1	1
118271	1710	pombe	[pombe]	0.0	1	1	1	1
118272	1710	sertraline response in depressive disorder	[sertraline response in depressive disorder]	0.0	5	1	1	1
118273	1710	antibody against markers,	[antibodies against markers,]	0.0	3	1	1	1
118274	1710	[Cao	[[Cao]	0.0	1	1	1	1
118275	1710	hsv-1-mediated induction	[HSV-1-mediated induction]	0.0	2	1	1	1
118276	1710	opposite receptor changes, respectively oppose	[opposite receptor changes, respectively opposing]	0.0	5	1	1	1
118277	1710	apparent dissociation constant of nm	[apparent dissociation constant of nM]	0.0	5	1	1	1
118278	1710	Bcl-6 staining in reactive hyperplasias	[Bcl-6 staining in reactive hyperplasias]	0.0	5	1	1	1
118279	1710	form of hiv-1 LTR	[forms of HIV-1 LTR]	0.0	4	1	1	1
118280	1710	stimulation, kappa B-specific complex	[stimulation, kappa B-specific complexes]	0.0	4	1	1	1
118281	1710	nf-atc isoform with property	[NF-ATc isoforms with properties]	0.0	4	1	1	1
118282	1710	biological effect of activity	[biological effects of activity]	0.0	4	2	2	1
118283	1710	T lymphocyte fas ligand transcription	[T lymphocytes Fas ligand transcription]	0.0	5	1	1	1
118284	1710	relative formation	[relative formation]	0.0	2	1	1	1
118285	1710	alpha-galactosidase a	[alpha-galactosidase A]	0.0	2	1	1	1
118286	1710	region between -108 element	[region between -108 elements]	0.0	4	1	1	1
118287	1710	chronological sequence	[chronological sequence]	0.0	2	1	1	1
118288	1710	even by a depletion	[even by a depletion]	0.0	4	1	1	1
118289	1710	mediator during syphilis disease	[mediators during syphilis disease]	0.0	4	1	1	1
118290	1710	25-dihydroxyvitamin D3 135(oh)2d3 receptor	[25-dihydroxyvitamin D3 1,25(OH)2D3 receptor]	0.0	4	1	1	1
118291	1710	filopodia formation	[filopodia formation]	0.0	2	1	1	1
118292	1710	oral treatment	[oral treatment]	0.0	2	1	1	1
118293	1710	functional analysis by cell transfection	[functional analysis by cell transfection]	0.0	5	1	1	1
118294	1710	fast growth rate	[faster growth rates]	0.0	3	1	1	1
118295	1710	antigen ea capsid antigen vca	[antigen EA capsid antigen VCA]	0.0	5	1	1	1
118296	1710	nfatp /ap-1-dna complex	[NFATp /AP-1-DNA complex]	0.0	3	1	1	1
118297	1710	bare lymphocyte syndrome ebls)	[Bare Lymphocyte Syndrome (BLS)]	0.0	4	1	1	1
118298	1710	consequence of the activation of pkc	[consequence of the activation of PKC]	0.0	6	1	1	1
118299	1710	-encoding gene	[-encoding genes]	0.0	2	1	1	1
118300	1710	120-kDa	[120-kDa]	0.0	1	1	1	1
118301	1710	previous demonstration of interaction	[previous demonstration of interactions]	0.0	4	1	1	1
118302	1710	kinase ikappab kinase alpha IKKalpha	[kinases IkappaB kinase alpha IKKalpha]	0.0	5	1	1	1
118303	1710	four variant	[Four variants]	0.0	2	1	1	1
118304	1710	corresponding to transcript	[corresponding to transcripts]	0.0	3	1	1	1
118305	1710	ability of E1A -express cell	[abilities of E1A -expressing cells]	0.0	5	1	1	1
118306	1710	ppargamma peroxisomal proliferator-activated receptor gamma expression	[PPARgamma peroxisomal proliferator-activated receptor gamma expression]	0.0	6	1	1	1
118307	1710	specific protein interaction necessary for regulation	[specific protein interactions necessary for regulation]	0.0	6	1	1	1
118308	1710	differentiation of progenitor to cell DC	[differentiation of progenitors to cells DC]	0.0	6	1	1	1
118309	1710	mixture of heparin gag	[mixture of heparin GAGs]	0.0	4	1	1	1
118310	1710	role mediate diverse response	[roles mediating diverse responses]	0.0	4	1	1	1
118311	1710	development of leukemia	[development of leukemia]	0.0	3	1	1	1
118312	1710	protein epitope	[protein epitopes]	0.0	2	1	1	1
118313	1710	10(-7) mol/L 9-cis RA hours)	[10(-7) mol/L 9-cis RA hours)]	0.0	5	1	1	1
118314	1710	serum immunoglobulin	[serum immunoglobulin]	0.0	2	1	1	1
118315	1710	t3 (10(-10)	[T3 (10(-10)]	0.0	2	1	1	1
118316	1710	estrogen receptor in keratoconjunctivitis	[Estrogen receptors in keratoconjunctivitis]	0.0	4	1	1	1
118317	1710	DNA bind activity of protein	[DNA binding activity of proteins]	0.0	5	1	1	1
118318	1710	feature characteristic include sensitivity to neuraminidase	[features characteristic including sensitivity to neuraminidase]	0.0	6	1	1	1
118319	1710	activate a reporter gene	[activating an reporter gene]	0.0	4	1	1	1
118320	1710	mycobacterial cell wall,	[mycobacterial cell wall,]	0.0	3	1	1	1
118321	1710	mediate the activity of the region	[mediating the activity of the region]	0.0	6	1	1	1
118322	1710	set of signal	[sets of signals]	0.0	3	1	1	1
118323	1710	variant of hl60 cell	[variants of HL60 cells]	0.0	4	1	1	1
118324	1710	Bcl-2 expression	[Bcl-2 expression]	0.0	2	2	2	1
118325	1710	primary stimulation in vitro,	[primary stimulations in vitro,]	0.0	4	1	1	1
118326	1710	fragment lps expression	[fragment LPS expression]	0.0	3	1	1	1
118327	1710	kind of gas -motif sequence	[kinds of GAS -motif sequences]	0.0	5	1	1	1
118328	1710	course (p 0.05, chi2	[course (P 0.05, chi2]	0.0	4	1	1	1
118329	1710	several binding sequence	[several binding sequences]	0.0	3	1	1	1
118330	1710	analysis of nuclear translocation	[Analyses of nuclear translocation]	0.0	4	1	1	1
118331	1710	90.8 dpm	[90.8 dpm]	0.0	2	1	1	1
118332	1710	structural domain include domain	[structural domains including domains]	0.0	4	1	1	1
118333	1710	metastatic potential in skin cancer	[metastatic potential in skin cancer]	0.0	5	1	1	1
118334	1710	adhesion at 20 mM.	[adhesion at 20 mM.]	0.0	4	1	1	1
118335	1710	human homeobox gene related	[human homeobox gene related]	0.0	4	1	1	1
118336	1710	Eleven patient with colitis	[Eleven patients with colitis]	0.0	4	1	1	1
118337	1710	evidence for a sequence	[evidence for a sequence]	0.0	4	1	1	1
118338	1710	variant of change	[variants of changes]	0.0	3	1	1	1
118339	1710	potent mitogen	[potent mitogen]	0.0	2	1	1	1
118340	1710	significantly more cortivazol	[significantly more cortivazol]	0.0	3	1	1	1
118341	1710	oligo against hepatitis b virus	[oligos against hepatitis B virus]	0.0	5	1	1	1
118342	1710	origin of disorder in woman	[origin of disorders in women]	0.0	5	1	1	1
118343	1710	4 beta cd49d/cd29 integrin costimulation	[4 beta CD49d/CD29 integrin costimulation]	0.0	5	1	1	1
118344	1710	stimulus bacterial product	[stimuli bacterial products]	0.0	3	1	1	1
118345	1710	confirm the role	[confirming the role]	0.0	3	1	1	1
118346	1710	signal transduction through IFN-gammaR	[signal transduction through IFN-gammaR]	0.0	4	1	1	1
118347	1710	undergo megakaryocytic differentiation	[undergoing megakaryocytic differentiation]	0.0	3	1	1	1
118348	1710	recruitment of NF-kappa b	[recruitment of NF-kappa B]	0.0	4	1	1	1
118349	1710	Epstein-Barr virus EBV antigen ebna-2	[Epstein-Barr virus EBV antigen EBNA-2]	0.0	5	1	1	1
118350	1710	substnfkappab substSpl2 substSp23	[substNFkappaB substSpl2 substSp23]	0.0	3	1	1	1
118351	1710	VCAM-1 mrna by TNF	[VCAM-1 mRNA by TNF]	0.0	4	1	1	1
118352	1710	underlie the diversification	[underlying the diversification]	0.0	3	1	1	1
118353	1710	tissue-specific control	[tissue-specific control]	0.0	2	1	1	1
118354	1710	potential role of PKC	[potential role of PKC]	0.0	4	1	1	1
118355	1710	such cofactor BOB.1/OBF.1	[such cofactor BOB.1/OBF.1]	0.0	3	1	1	1
118356	1710	use a peptide substrate	[using a peptide substrate]	0.0	4	1	1	1
118357	1710	beta-globin-expressing erythroid leukemia cell	[beta-globin-expressing erythroid leukemia cells]	0.0	4	1	1	1
118358	1710	pag product	[pag product]	0.0	2	1	1	1
118359	1710	signal in b lymphocyte from patient	[signaling in B lymphocytes from patients]	0.0	6	1	1	1
118360	1710	immunodeficiency virus type -infected cell	[immunodeficiency virus type -infected cells]	0.0	5	1	1	1
118361	1710	PML-RAR alpha	[PML-RAR alpha]	0.0	2	1	1	1
118362	1710	cyclic element modulator	[cyclic element modulator]	0.0	3	1	1	1
118363	1710	intracellular substrate in proliferate cell	[intracellular substrates in proliferating cells]	0.0	5	1	1	1
118364	1710	suggest phosphorylation activation	[suggesting phosphorylation activation]	0.0	3	1	1	1
118365	1710	specific hormone receptor	[specific hormone receptors]	0.0	3	1	1	1
118366	1710	[regulatory	[[Regulatory]	0.0	1	1	1	1
118367	1710	mechanism such as a effect	[mechanisms such as an effect]	0.0	5	1	1	1
118368	1710	probability recur locally by 5	[probability recurring locally by 5]	0.0	5	1	1	1
118369	1710	100% inhibition	[100% inhibition]	0.0	2	1	1	1
118370	1710	significantly high level	[significantly higher levels]	0.0	3	1	1	1
118371	1710	specific target for a comprehensive screen	[specific targets for a comprehensive screening]	0.0	6	1	1	1
118372	1710	block nuclear factor	[blocking nuclear factor]	0.0	3	1	1	1
118373	1710	set at different stage	[sets at different stages]	0.0	4	1	1	1
118374	1710	obtain monocyte	[obtaining monocytes]	0.0	2	1	1	1
118375	1710	specific polyclonal antisera	[specific polyclonal antisera]	0.0	3	1	1	1
118376	1710	leukemia cell line rwleu-4	[leukemia cell line RWLeu-4]	0.0	4	1	1	1
118377	1710	peripheral blood volunteer man	[peripheral blood volunteers men]	0.0	4	1	1	1
118378	1710	hemin heat shock	[hemin heat shock]	0.0	3	1	1	1
118379	1710	nonpeptidyl small molecule sb capable	[nonpeptidyl small molecule SB capable]	0.0	5	1	1	1
118380	1710	IFNgamma enhanceosome formation	[IFNgamma enhanceosome formation]	0.0	3	1	1	1
118381	1710	relationship between drug concentration	[relationship between drug concentrations]	0.0	4	1	1	1
118382	1710	presence of number	[presence of numbers]	0.0	3	1	1	1
118383	1710	epitope-labeled BKO	[epitope-labeled BKO]	0.0	2	1	1	1
118384	1710	such as embryonic fibroblast	[such as embryonic fibroblasts]	0.0	4	1	1	1
118385	1710	b luciferase construct	[B luciferase constructs]	0.0	3	1	1	1
118386	1710	high dose on tissue oligonucleotide	[High doses on tissue oligonucleotide]	0.0	5	1	1	1
118387	1710	role in inflammation,	[role in inflammation,]	0.0	3	1	1	1
118388	1710	enhancement by the t-cell leukemia virus	[enhancement by the T-cell leukemia virus]	0.0	6	1	1	1
118389	1710	activation of cholesterol synthesis	[activation of cholesterol synthesis]	0.0	4	1	1	1
118390	1710	level of expression for icam-1	[levels of expression for ICAM-1]	0.0	5	1	1	1
118391	1710	die by 8	[dying by 8]	0.0	3	1	1	1
118392	1710	element necessary 1 alpha,25-dihydroxyvitamin D3	[Elements necessary 1 alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
118393	1710	variability of response	[variability of response]	0.0	3	1	1	1
118394	1710	4- bp insertion	[4- bp insertion]	0.0	3	1	1	1
118395	1710	constructed, 60-kda precursor	[constructed, 60-kDa precursor]	0.0	3	1	1	1
118396	1710	footprint over the canonical elements,	[footprints over the canonical elements,]	0.0	5	1	1	1
118397	1710	amino-terminal cysteine-rich dna-binding domain	[amino-terminal cysteine-rich DNA-binding domain]	0.0	4	1	1	1
118398	1710	pair of high grade astrocytomas	[pairs of high grade astrocytomas]	0.0	5	1	1	1
118399	1710	e2a moiety	[E2a moiety]	0.0	2	1	1	1
118400	1710	stat 5a	[Stat 5a]	0.0	2	1	1	1
118401	1710	dose, route	[dose, route]	0.0	2	1	1	1
118402	1710	minimize energy study	[Minimizing energy studies]	0.0	3	1	1	1
118403	1710	transcript of the gene	[transcripts of the genes]	0.0	4	1	1	1
118404	1710	sequence with one base substitution	[sequence with one base substitution]	0.0	5	1	1	1
118405	1710	class ii trans- activator	[class II trans- activator]	0.0	4	1	1	1
118406	1710	treatment irrespective of the age	[treatment irrespective of the age]	0.0	5	1	1	1
118407	1710	rapid tyrosine phosphorylation of substrate	[rapid tyrosine phosphorylation of substrates]	0.0	5	1	1	1
118408	1710	more potent inducer	[more potent inducers]	0.0	3	1	1	1
118409	1710	disomy of sequence	[disomy of sequences]	0.0	3	1	1	1
118410	1710	cross-linking of MHC-I tyrosine phosphorylation	[Cross-linking of MHC-I tyrosine phosphorylation]	0.0	5	1	1	1
118411	1710	fkbp binding	[FKBP binding]	0.0	2	1	1	1
118412	1710	Krone	[Kr]	0.0	1	1	1	1
118413	1710	31 woman with thrombocytosis	[31 women with thrombocytosis]	0.0	4	1	1	1
118414	1710	immunodeficiency virus type a early protein	[immunodeficiency virus type an early protein]	0.0	6	1	1	1
118415	1710	enhancer core	[enhancer core]	0.0	2	1	1	1
118416	1710	gene expression during lymphocyte activation	[gene expression during lymphocyte activation]	0.0	5	1	1	1
118417	1710	cell in culture,	[cells in culture,]	0.0	3	1	1	1
118418	1710	excessive lyonization	[excessive lyonization]	0.0	2	1	1	1
118419	1710	cell in culture.	[cells in culture.]	0.0	3	1	1	1
118420	1710	factor in function of accessory cell	[factors in functions of accessory cells]	0.0	6	1	1	1
118421	1710	one in population	[one in populations]	0.0	3	1	1	1
118422	1710	determinant of darc	[determinants of DARC]	0.0	3	1	1	1
118423	1710	regulate aspect of hematopoiesis	[regulating aspects of hematopoiesis]	0.0	4	1	1	1
118424	1710	adult beta-globin/alpha-globin mrna	[adult beta-globin/alpha-globin mRNA]	0.0	3	1	1	1
118425	1710	corresponding to a 0.5 -2 molecule	[corresponding to an 0.5 -2 molecules]	0.0	6	1	1	1
118426	1710	hmg-i binding	[HMG-I binding]	0.0	2	1	1	1
118427	1710	multigene family,	[multigene family,]	0.0	2	1	1	1
118428	1710	retroviral counterpart	[retroviral counterpart]	0.0	2	1	1	1
118429	1710	such as interleukin-2	[such as interleukin-2]	0.0	3	1	1	1
118430	1710	stimulation with cho-dr staphylococcal enterotoxin a	[stimulation with CHO-DR staphylococcal enterotoxin A]	0.0	6	1	1	1
118431	1710	(cre)	[(CRE)]	0.0	1	1	1	1
118432	1710	rat fibroblast	[rat fibroblasts]	0.0	2	1	1	1
118433	1710	ikappabalpha kinase	[IkappaBalpha kinase]	0.0	2	1	1	1
118434	1710	however, inhibition of Tat activation	[however, inhibition of Tat activation]	0.0	5	1	1	1
118435	1710	target of calcineurin	[targets of calcineurin]	0.0	3	1	1	1
118436	1710	certain individual of histocompatibility (mhc) haplotype	[certain individuals of histocompatibility (MHC) haplotypes]	0.0	6	1	1	1
118437	1710	cotransfection of a active form	[Cotransfection of a active form]	0.0	5	1	1	1
118438	1710	tpa nuclear factor protein OAP40	[TPA nuclear factor protein OAP40]	0.0	5	1	1	1
118439	1710	antibody in gel supershift assay	[antibodies in gel supershift assays]	0.0	5	1	1	1
118440	1710	nfat motif	[NFAT motif]	0.0	2	1	1	1
118441	1710	tyrosine-phosphorylated DNA binding protein	[tyrosine-phosphorylated DNA binding protein]	0.0	4	1	1	1
118442	1710	poly(	[poly(]	0.0	1	1	1	1
118443	1710	c-fo ap-1	[c-fos AP-1]	0.0	2	1	1	1
118444	1710	p70(s6k) a response	[p70(s6k) a response]	0.0	3	1	1	1
118445	1710	endothelial cell use a adenovirus	[endothelial cells using a adenovirus]	0.0	5	1	1	1
118446	1710	mediator in human dermal cell	[mediators in human dermal cells]	0.0	5	1	1	1
118447	1710	activator of adenylate cyclase	[activator of adenylate cyclase]	0.0	4	1	1	1
118448	1710	exchange of chain-derived peptide	[exchange of chain-derived peptides]	0.0	4	1	1	1
118449	1710	hyperparathyroidism to chronic renal failure	[hyperparathyroidism to chronic renal failure]	0.0	5	1	1	1
118450	1710	more glucocorticoid receptor gr	[more glucocorticoid receptors GR]	0.0	4	1	1	1
118451	1710	receptor vitamin D3 receptor VDR	[receptors vitamin D3 receptors VDR]	0.0	5	1	1	1
118452	1710	alter pathway lead to tnf-alpha production	[altering pathways leading to TNF-alpha production]	0.0	6	1	1	1
118453	1710	IFNalpha- gene	[IFNalpha- genes]	0.0	2	1	1	1
118454	1710	receptor together	[receptor together]	0.0	2	1	1	1
118455	1710	dna-binding activity of complex	[DNA-binding activity of complexes]	0.0	4	1	1	1
118456	1710	oxidative stress-dependent activation	[oxidative stress-dependent activation]	0.0	3	1	1	1
118457	1710	predisposition to b cell neoplasia	[predisposition to B cell neoplasia]	0.0	5	1	1	1
118458	1710	er -eia	[ER -EIA]	0.0	2	1	1	1
118459	1710	immunodeficiency virus in cell	[immunodeficiency virus in cells]	0.0	4	1	1	1
118460	1710	CD40 ag	[CD40 Ag]	0.0	2	1	1	1
118461	1710	ifn-alpha in CML	[IFN-alpha in CML]	0.0	3	1	1	1
118462	1710	capability of T cell	[capabilities of T cells]	0.0	4	1	1	1
118463	1710	individual with the bb genotype	[individuals with the Bb genotype]	0.0	5	1	1	1
118464	1710	adjacent cis-acting regulatory elements,	[adjacent cis-acting regulatory elements,]	0.0	4	1	1	1
118465	1710	porcine endothelial cell PAEC	[Porcine endothelial cells PAEC]	0.0	4	1	1	1
118466	1710	differentiation in colony	[differentiation in colonies]	0.0	3	1	1	1
118467	1710	negative association	[negative association]	0.0	2	1	1	1
118468	1710	expression tissue	[expression tissues]	0.0	2	1	1	1
118469	1710	aldosterone binding at a molecular weight	[aldosterone binding at a molecular weight]	0.0	6	1	1	1
118470	1710	transcriptional regulation of lysosomal acid lipase	[Transcriptional regulation of lysosomal acid lipase]	0.0	6	1	1	1
118471	1710	aim of this work	[aims of this work]	0.0	4	1	1	1
118472	1710	nuclear translocation factor of T cell	[nuclear translocation factor of T cells]	0.0	6	1	1	1
118473	1710	transcription apparatus	[transcription apparatus]	0.0	2	1	1	1
118474	1710	hormonal form	[hormonal form]	0.0	2	1	1	1
118475	1710	role in the anti-diabetic action	[role in the anti-diabetic actions]	0.0	5	1	1	1
118476	1710	discovery nuclear factor kappa b	[discovery nuclear factor kappa B]	0.0	5	1	1	1
118477	1710	similar array	[Similar arrays]	0.0	2	1	1	1
118478	1710	Comparison of sensitization with response	[Comparison of sensitization with responses]	0.0	5	1	1	1
118479	1710	nanomolar concentration	[nanomolar concentrations]	0.0	2	1	1	1
118480	1710	anti-endothelial cell antibody from a patient	[anti-endothelial cell antibodies from a patient]	0.0	6	1	1	1
118481	1710	four novel, occur sequence variant	[four novel, occurring sequence variants]	0.0	5	1	1	1
118482	1710	putative additional transcription factor	[putative additional transcription factor]	0.0	4	1	1	1
118483	1710	transcription complex contain protein	[transcription complexes containing proteins]	0.0	4	1	1	1
118484	1710	bp with 12-bp insert	[bp with 12-bp insert]	0.0	4	1	1	1
118485	1710	growth factor beta	[growth factor beta]	0.0	3	1	1	1
118486	1710	inverse relation to histocompatibility class	[inverse relation to histocompatibility classes]	0.0	5	1	1	1
118487	1710	constitutive, expression	[constitutive, expression]	0.0	2	1	1	1
118488	1710	human a functional promoter region	[humans a functional promoter region]	0.0	5	1	1	1
118489	1710	exhibit dominant-negative activity RARalpha403	[exhibiting dominant-negative activity RARalpha403]	0.0	4	1	1	1
118490	1710	5'-end termini	[5'-end termini]	0.0	2	1	1	1
118491	1710	five amino-acid motif	[five amino-acid motif]	0.0	3	1	1	1
118492	1710	hemopoietic progenitor to cell	[hemopoietic progenitors to cells]	0.0	4	1	1	1
118493	1710	specific bind power	[specific binding power]	0.0	3	1	1	1
118494	1710	major class ii transactivator	[major class II transactivator]	0.0	4	1	1	1
118495	1710	conclusion: ciita construct	[CONCLUSION: CIITA constructs]	0.0	3	1	1	1
118496	1710	burkitt' lymphoma	[Burkitt's lymphoma]	0.0	2	1	1	1
118497	1710	special program	[special program]	0.0	2	1	1	1
118498	1710	lipoarabinomannan from the cell wall,	[lipoarabinomannan from the cell wall,]	0.0	5	1	1	1
118499	1710	use the ROI fluorochrome dcfh	[using the ROI fluorochrome DCFH-DA]	0.0	5	1	1	1
118500	1710	recombinant hbxag protein	[recombinant HBxAg protein]	0.0	3	1	1	1
118501	1710	cloning of gata-4	[cloning of GATA-4]	0.0	3	1	1	1
118502	1710	high degree	[high degree]	0.0	2	3	3	1
118503	1710	cd4-bearing T	[CD4-bearing T]	0.0	2	1	1	1
118504	1710	anti-sense oligonucleotide	[anti-sense oligonucleotides]	0.0	2	1	1	1
118505	1710	complex with class of receptor	[complexes with classes of receptors]	0.0	5	1	1	1
118506	1710	factor- coactivator	[factor- coactivator]	0.0	2	1	1	1
118507	1710	(high affinity,	[(high affinity,]	0.0	2	1	1	1
118508	1710	use this clonality analysis method	[using these clonality analysis methods]	0.0	5	1	1	1
118509	1710	multiple lytic reactivity at level high	[multiple lytic reactivities at levels high]	0.0	6	1	1	1
118510	1710	C-terminal module	[C-terminal module]	0.0	2	1	1	1
118511	1710	same mobility 120 kd)	[same mobility 120 kD)]	0.0	4	1	1	1
118512	1710	alu consensus sequence	[Alu consensus sequences]	0.0	3	1	1	1
118513	1710	contain part	[containing parts]	0.0	2	1	1	1
118514	1710	mononuclear leukocyte from person	[Mononuclear leukocytes from persons]	0.0	4	1	1	1
118515	1710	modification of the retinoblastoma gene product	[modification of the retinoblastoma gene product]	0.0	6	1	1	1
118516	1710	activate transcription from the terminal repeat	[activating transcription from the terminal repeat]	0.0	6	1	1	1
118517	1710	repeat of bp	[repeats of bp]	0.0	3	1	1	1
118518	1710	two cosmid	[two cosmids]	0.0	2	1	1	1
118519	1710	kd similar	[Kd similar]	0.0	2	1	1	1
118520	1710	protein binding site between -3110	[protein binding sites between -3110]	0.0	5	1	1	1
118521	1710	kappab manner	[kappaB manner]	0.0	2	1	1	1
118522	1710	increase in acth	[increase in ACTH]	0.0	3	1	1	1
118523	1710	germline cepsilon transcription switch	[germline Cepsilon transcription switching]	0.0	4	1	1	1
118524	1710	evaluate study individual	[evaluating study individuals]	0.0	3	1	1	1
118525	1710	range of mutation	[range of mutations]	0.0	3	1	1	1
118526	1710	CsA synthesis of a component	[CsA synthesis of a component]	0.0	5	1	1	1
118527	1710	enhancer tc-ii	[enhancer TC-II]	0.0	2	1	1	1
118528	1710	role in the lipopolysaccharide induction	[role in the lipopolysaccharide induction]	0.0	5	1	1	1
118529	1710	somatic hypermutation mechanism	[somatic hypermutation mechanism]	0.0	3	1	1	1
118530	1710	stimulus-induced kappab transcription	[stimulus-induced kappaB transcription]	0.0	3	1	1	1
118531	1710	oxidation to metabolite	[oxidation to metabolites]	0.0	3	1	1	1
118532	1710	number of genes, most	[number of genes, most]	0.0	4	1	1	1
118533	1710	stage-specific dna-binding protein	[stage-specific DNA-binding protein]	0.0	3	1	1	1
118534	1710	pwm mitogenesis	[PWM mitogenesis]	0.0	2	2	2	1
118535	1710	two dna-binding subunit of mass	[two DNA-binding subunits of mass]	0.0	5	1	1	1
118536	1710	mononuclear leukocyte of subject	[mononuclear leukocytes of subjects]	0.0	4	1	1	1
118537	1710	addition, transfection	[addition, transfection]	0.0	2	1	1	1
118538	1710	evidence for a activate pathway	[evidence for an activating pathway]	0.0	5	1	1	1
118539	1710	vcam-1 gene expression	[VCAM-1 gene expression]	0.0	3	1	1	1
118540	1710	risk for breast cancer	[risk for breast cancer]	0.0	4	2	2	1
118541	1710	Brief exposure	[Brief exposure]	0.0	2	1	1	1
118542	1710	healthy volunteer man	[healthy volunteers men]	0.0	3	1	1	1
118543	1710	study the binding 31747a	[studying the binding 31747A]	0.0	4	1	1	1
118544	1710	none of the regulatory site	[None of the regulatory sites]	0.0	5	1	1	1
118545	1710	patient with yang-deficiency	[patients with yang-deficiency]	0.0	3	2	2	1
118546	1710	multiple lineages,	[multiple lineages,]	0.0	2	1	1	1
118547	1710	low concentration inhibit ige synthesis (10(-10)	[Low concentrations inhibiting IgE synthesis (10(-10)]	0.0	6	1	1	1
118548	1710	thus imply a role for SCL	[thus implying a role for SCL]	0.0	6	1	1	1
118549	1710	cells; active factor	[cells; active factors]	0.0	3	1	1	1
118550	1710	different b subunit	[different B subunits]	0.0	3	1	1	1
118551	1710	C. activation of endothelial cell	[C. activation of endothelial cells]	0.0	5	1	1	1
118552	1710	antigenic peptide in the reticulum	[antigenic peptides in the reticulum]	0.0	5	1	1	1
118553	1710	phasing	[phasing]	0.0	1	1	1	1
118554	1710	receptor expression in T cell	[receptor expression in T cells]	0.0	5	1	1	1
118555	1710	/EBV	[/EBV]	0.0	1	1	1	1
118556	1710	fibrosarcoma histiocytoma rhabdomyosarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma]	0.0	3	1	1	1
118557	1710	glucocorticoid cell lysis	[glucocorticoid cell lysis]	0.0	3	1	1	1
118558	1710	significantly (p<.001) in patient	[significantly (P<.001) in patients]	0.0	4	1	1	1
118559	1710	kappa B-specific complex	[kappa B-specific complexes]	0.0	3	1	1	1
118560	1710	mutation in the domain	[mutations in the domains]	0.0	4	1	1	1
118561	1710	two alpha-helical domain	[two alpha-helical domains]	0.0	3	1	1	1
118562	1710	Addition of exogenous tnf	[Addition of exogenous TNF]	0.0	4	1	1	1
118563	1710	activate protein-1 ap-1 tpa element TRE	[Activating protein-1 AP-1 TPA elements TRE]	0.0	6	1	1	1
118564	1710	vitamin d-responsive reporter gene	[vitamin D-responsive reporter gene]	0.0	4	1	1	1
118565	1710	form of the erythroid	[forms of the erythroid]	0.0	4	1	1	1
118566	1710	efficient control of this promoter	[efficient control of this promoter]	0.0	5	1	1	1
118567	1710	mrna stability, suggest gamma-ifn inhibition	[mRNA stability, suggesting gamma-IFN inhibition]	0.0	5	1	1	1
118568	1710	normal cell line	[normal cell lines]	0.0	3	1	1	1
118569	1710	transfection in u937 cell	[transfection in U937 cells]	0.0	4	1	1	1
118570	1710	proliferator-activated receptor gamma expression	[proliferator-activated receptor gamma expression]	0.0	4	1	1	1
118571	1710	Suppressive effect of anti-inflammatory agent	[Suppressive effects of anti-inflammatory agents]	0.0	5	1	1	1
118572	1710	(also in human umbilical cell	[(also in human umbilical cells]	0.0	5	1	1	1
118573	1710	culture of epithelial cell TEC	[cultures of epithelial cells TEC]	0.0	5	1	1	1
118574	1710	partial chromosome	[partial chromosome]	0.0	2	1	1	1
118575	1710	dissociation (kd)	[dissociation (KD)]	0.0	2	1	1	1
118576	1710	ifngamma-driven,	[IFNgamma-driven,]	0.0	1	1	1	1
118577	1710	cellular defect(s)	[cellular defect(s)]	0.0	2	1	1	1
118578	1710	(1.2-3.3) fmol/10(7) cell	[(1.2-3.3) fmol/10(7) cells]	0.0	3	1	1	1
118579	1710	lymphocyte of sibling	[lymphocytes of siblings]	0.0	3	1	1	1
118580	1710	strong staining	[stronger staining]	0.0	2	1	1	1
118581	1710	il-1beta gene expression	[IL-1beta gene expression]	0.0	3	1	1	1
118582	1710	level) by pcr assay	[level) by PCR assay]	0.0	4	2	2	1
118583	1710	encounter of T cell	[encounter of T cells]	0.0	4	1	1	1
118584	1710	granulocyte macrophage-colony stimulate factor promoter	[granulocyte macrophage-colony stimulating factor promoter]	0.0	5	1	1	1
118585	1710	manage setting of pathology	[managing settings of pathology]	0.0	4	1	1	1
118586	1710	phosphorylation of Jak3 STAT3	[phosphorylation of Jak3 STAT3]	0.0	4	1	1	1
118587	1710	nf kappab in cells;	[NF kappaB in cells;]	0.0	4	1	1	1
118588	1710	gene therapy protocol	[gene therapy protocols]	0.0	3	1	1	1
118589	1710	immunodeficiency virus-1 enhancer	[immunodeficiency virus-1 enhancer]	0.0	3	1	1	1
118590	1710	IgE/allergen	[IgE/allergen]	0.0	1	1	1	1
118591	1710	(lmp)	[(LMP)]	0.0	1	1	1	1
118592	1710	3-fold CAT activity	[3-fold CAT activity]	0.0	3	1	1	1
118593	1710	tone	[tone]	0.0	1	1	1	1
118594	1710	ppargamma differentiation-dependent peroxisomal receptor gamma expression	[PPARgamma differentiation-dependent peroxisomal receptor gamma expression]	0.0	6	1	1	1
118595	1710	virus-exposed cell	[virus-exposed cells]	0.0	2	1	1	1
118596	1710	contain 72 bp	[containing 72 bp]	0.0	3	1	1	1
118597	1710	distinct nfkb2	[distinct NFKB2]	0.0	2	1	1	1
118598	1710	negative modulator	[negative modulator]	0.0	2	1	1	1
118599	1710	gammaherpesvirus	[gammaherpesvirus]	0.0	1	1	1	1
118600	1710	dominant form of aml1 AML1a	[dominant form of AML1 AML1a]	0.0	5	1	1	1
118601	1710	25 healthy woman	[25 healthy women]	0.0	3	1	1	1
118602	1710	extracellular protein kinase (erk)-dependent	[Extracellular protein kinase (ERK)-dependent]	0.0	4	1	1	1
118603	1710	two anti-inflammatory drug	[two anti-inflammatory drugs]	0.0	3	1	1	1
118604	1710	high-level il-4 production in th2 cell	[high-level IL-4 production in Th2 cells]	0.0	6	1	1	1
118605	1710	30 micrograms/kg).	[30 micrograms/kg).]	0.0	2	1	1	1
118606	1710	nucleotide within the IL-4 promoter	[nucleotides within the IL-4 promoter]	0.0	5	1	1	1
118607	1710	target cell uptake of lps	[target cell uptake of LPS]	0.0	5	1	1	1
118608	1710	cell with monoclonal antibody (mab)	[cells with monoclonal antibody (MAb)]	0.0	5	1	1	1
118609	1710	10 &mgr;m)	[10 &mgr;M)]	0.0	2	1	1	1
118610	1710	aes sequence	[AES sequence]	0.0	2	1	1	1
118611	1710	increase of gpx activity	[increase of GPX activity]	0.0	4	1	1	1
118612	1710	/EIC	[/EIC]	0.0	1	1	1	1
118613	1710	blood lymphocyte in hypertensive patient	[blood lymphocytes in hypertensive patients]	0.0	5	1	1	1
118614	1710	monocyte chemotactic peptide-1 a chemokine	[monocyte chemotactic peptide-1 a chemokine]	0.0	5	1	1	1
118615	1710	281 pmol/L;	[281 pmol/L;]	0.0	2	1	1	1
118616	1710	(1) substitution in the counterpart	[(1) substitutions in the counterpart]	0.0	5	1	1	1
118617	1710	"targets" eosinophil	["targets" eosinophils]	0.0	2	1	1	1
118618	1710	many gene in monocyte	[many genes in monocytes]	0.0	4	1	1	1
118619	1710	Chignard, M. Blood	[Chignard, M. Blood]	0.0	3	1	1	1
118620	1710	high-resolution mapping	[high-resolution mapping]	0.0	2	1	1	1
118621	1710	(il-6) receptor	[(IL-6) receptor]	0.0	2	1	1	1
118622	1710	1 element tre-1	[1 element TRE-1]	0.0	3	1	1	1
118623	1710	effect of BHA a antioxidant	[effects of BHA a antioxidant]	0.0	5	1	1	1
118624	1710	fascinating new field	[fascinating new field]	0.0	3	1	1	1
118625	1710	human T cell express MHC class	[human T cells expressing MHC class]	0.0	6	1	1	1
118626	1710	thrombin responsiveness	[thrombin responsiveness]	0.0	2	1	1	1
118627	1710	native mr	[native MR]	0.0	2	1	1	1
118628	1710	increase half-life from 24 to 45	[increasing half-life from 24 to 45]	0.0	6	1	1	1
118629	1710	site by resident	[sites by resident]	0.0	3	1	1	1
118630	1710	human rdna encode subunit	[Human cDNAs encoding subunits]	0.0	4	1	1	1
118631	1710	40 enhancer tc-ii	[40 enhancer TC-II]	0.0	3	1	1	1
118632	1710	6, rhabdomyosarcoma 10, leiomyosarcoma	[6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	4	1	1	1
118633	1710	ascorbate nac	[ascorbate NAC]	0.0	2	1	1	1
118634	1710	signal via cd27	[signaling via CD27]	0.0	3	1	1	1
118635	1710	addition to T cell	[addition to T cells]	0.0	4	1	1	1
118636	1710	one gene, transcript isolation	[One gene, transcripts isolation]	0.0	4	1	1	1
118637	1710	subsequent cell adhesion to endothelial cell	[subsequent cell adhesion to endothelial cells]	0.0	6	1	1	1
118638	1710	amount of hmg-i(y)	[amount of HMG-I(Y)]	0.0	3	1	1	1
118639	1710	evidence for a considerable interindividual variation	[evidence for a considerable interindividual variation]	0.0	6	1	1	1
118640	1710	two pml/ raralpha	[two PML/ RARalpha]	0.0	3	1	1	1
118641	1710	cck(b) receptor antagonist pd-135,158	[CCK(B) receptor antagonist PD-135,158]	0.0	4	1	1	1
118642	1710	gh in one patient	[GH in one patient]	0.0	4	1	1	1
118643	1710	occur breakdown product of peptidoglycan	[occurring breakdown product of peptidoglycan]	0.0	5	1	1	1
118644	1710	asthma patient with expiratory volume fev1	[asthma patients with expiratory volume FEV1]	0.0	6	1	1	1
118645	1710	potent monocyte cytokine	[potent monocyte cytokine]	0.0	3	1	1	1
118646	1710	nfat beta-galactosidase activity	[NFAT beta-galactosidase activity]	0.0	3	1	1	1
118647	1710	other ccgccc binding protein from cell	[other CCGCCC binding proteins from cells]	0.0	6	1	1	1
118648	1710	APL blast available	[APL blasts available]	0.0	3	1	1	1
118649	1710	least two dna-binding protein	[least two DNA-binding proteins]	0.0	4	1	1	1
118650	1710	factor for induction	[factors for induction]	0.0	3	1	1	1
118651	1710	involve sequence at 14q11	[involving sequences at 14q11]	0.0	4	1	1	1
118652	1710	removal of the amino acid	[removal of the amino acids]	0.0	5	1	1	1
118653	1710	intracellular-free calcium ion	[intracellular-free calcium ions]	0.0	3	1	1	1
118654	1710	6.5- induction	[6.5- induction]	0.0	2	1	1	1
118655	1710	method of lymphocyte from healthy woman	[METHOD OF lymphocytes from healthy women]	0.0	6	1	1	1
118656	1710	GATA-1 gene though silent	[GATA-1 gene though silent]	0.0	4	1	1	1
118657	1710	activation of chemoattractant receptor	[activation of chemoattractant receptors]	0.0	4	1	1	1
118658	1710	p62 complex	[p62 complex]	0.0	2	1	1	1
118659	1710	similar (46% identical)	[similar (46% identical)]	0.0	3	1	1	1
118660	1710	gene product from virus	[gene products from viruses]	0.0	4	1	1	1
118661	1710	deletion of ccaat box	[deletion of CCAAT boxes]	0.0	4	1	1	1
118662	1710	differentiative fate of this cell	[differentiative fate of these cells]	0.0	5	1	1	1
118663	1710	statistically-significant difference between each group	[statistically-significant differences between each group]	0.0	5	1	1	1
118664	1710	rt-pcr result	[RT-PCR resulting]	0.0	2	1	1	1
118665	1710	cytokine level	[cytokine levels]	0.0	2	1	1	1
118666	1710	1 alpha,25-(OH)2D3 cell	[1 alpha,25-(OH)2D3 cells]	0.0	3	1	1	1
118667	1710	component of the immunoreaction	[components of the immunoreaction]	0.0	4	1	1	1
118668	1710	abundant protein.	[abundant protein.]	0.0	2	1	1	1
118669	1710	(rare)	[(rare)]	0.0	1	1	1	1
118670	1710	understanding of the molecular pathway	[understanding of the molecular pathways]	0.0	5	1	1	1
118671	1710	variety of process	[variety of processes]	0.0	3	2	2	1
118672	1710	superaddition under such condition	[superaddition under such conditions]	0.0	4	1	1	1
118673	1710	autoregulation in 6tg1.1 cell	[autoregulation in 6TG1.1 cells]	0.0	4	1	1	1
118674	1710	difference in the response	[differences in the response]	0.0	4	1	1	1
118675	1710	diseases, include malignancy	[diseases, including malignancies]	0.0	3	1	1	1
118676	1710	N-WASP by IcsA	[N-WASP by IcsA]	0.0	3	1	1	1
118677	1710	cytosine	[cytosine]	0.0	1	1	1	1
118678	1710	NF-kappa B1 p50 subunit	[NF-kappa B1 p50 subunit]	0.0	4	1	1	1
118679	1710	more position	[more positions]	0.0	2	1	1	1
118680	1710	concern the possible role	[concerning the possible role]	0.0	4	1	1	1
118681	1710	IL-10 modulation	[IL-10 modulation]	0.0	2	1	1	1
118682	1710	three human class gene	[three human class genes]	0.0	4	1	1	1
118683	1710	hiv-1 LTR -based vector	[HIV-1 LTR -based vectors]	0.0	4	1	1	1
118684	1710	negative form of binding partner,	[negative form of binding partner,]	0.0	5	1	1	1
118685	1710	strong transcriptional activate effect	[strong transcriptional activating effects]	0.0	4	1	1	1
118686	1710	mineralocorticoid receptor on mononuclear leukocyte	[mineralocorticoid receptors on mononuclear leukocytes]	0.0	5	1	1	1
118687	1710	contrast to other kinase receptor	[contrast to other kinase receptors]	0.0	5	1	1	1
118688	1710	soft agar)	[soft agar)]	0.0	2	1	1	1
118689	1710	IkappaBalpha construct resistant	[IkappaBalpha construct resistant]	0.0	3	1	1	1
118690	1710	relation to therapeutic approach	[relation to therapeutic approaches]	0.0	4	1	1	1
118691	1710	oxide synthase gene	[oxide synthase gene]	0.0	3	1	1	1
118692	1710	il-6 monoclonal antibody	[IL-6 monoclonal antibody]	0.0	3	1	1	1
118693	1710	nucleotide substitution in the counterpart	[nucleotide substitutions in the counterpart]	0.0	5	1	1	1
118694	1710	permit rapid translocation	[permitting rapid translocation]	0.0	3	1	1	1
118695	1710	Stable transfection of u937 cell	[Stable transfection of U937 cells]	0.0	5	1	1	1
118696	1710	sensitive polymerase chain reaction pcr	[sensitive polymerase chain reaction PCR]	0.0	5	1	1	1
118697	1710	uncoupling of cell cycle arrest	[Uncoupling of cell cycle arrest]	0.0	5	1	1	1
118698	1710	two general transcriptional activator	[two general transcriptional activators]	0.0	4	1	1	1
118699	1710	10(-6) m elevation	[10(-6) M elevation]	0.0	3	1	1	1
118700	1710	possibly cells; a component	[possibly cells; a component]	0.0	4	1	1	1
118701	1710	6.5- induction of activity	[6.5- induction of activity]	0.0	4	1	1	1
118702	1710	responsiveness to il-4	[responsiveness to IL-4]	0.0	3	1	1	1
118703	1710	number of kinases,	[number of kinases,]	0.0	3	1	1	1
118704	1710	appearance of a phenotype	[appearance of a phenotype]	0.0	4	1	1	1
118705	1710	ubiquitous "octamer" binding protein	[ubiquitous "octamer" binding proteins]	0.0	4	1	1	1
118706	1710	calcium stimulation	[calcium stimulation]	0.0	2	1	1	1
118707	1710	repressor protein with repressive effect	[repressor proteins with repressive effects]	0.0	5	1	1	1
118708	1710	immunoadsorption	[immunoadsorption]	0.0	1	1	1	1
118709	1710	agent troglitazone	[agent troglitazone]	0.0	2	1	1	1
118710	1710	member of a class	[member of a class]	0.0	4	1	1	1
118711	1710	sclerosis complex TSC	[sclerosis complex TSC]	0.0	3	1	1	1
118712	1710	b-cell response in lymphoid follicle	[B-cell response in lymphoid follicles]	0.0	5	1	1	1
118713	1710	independence from exogenous growth stimulus	[independence from exogenous growth stimuli]	0.0	5	1	1	1
118714	1710	interferon-gamma site	[interferon-gamma site]	0.0	2	1	1	1
118715	1710	cell FDC	[cells FDC]	0.0	2	2	2	1
118716	1710	modulation of nf-kappab by transfer	[modulation of NF-kappaB by transfer]	0.0	5	1	1	1
118717	1710	Proinflammatory cytokine	[Proinflammatory cytokines]	0.0	2	1	1	1
118718	1710	binding approximately 5.5-fold	[binding approximately 5.5-fold]	0.0	3	1	1	1
118719	1710	gata-3 recombinant	[GATA-3 recombinant]	0.0	2	1	1	1
118720	1710	lesion with advance age	[lesions with advancing age]	0.0	4	1	1	1
118721	1710	T-helper subset	[T-helper subset]	0.0	2	1	1	1
118722	1710	direct suppression	[Direct suppression]	0.0	2	1	1	1
118723	1710	unspliced mrna I HTLV-I	[unspliced mRNA I HTLV-I]	0.0	4	1	1	1
118724	1710	activation by lipopolysaccharide	[Activation by lipopolysaccharide]	0.0	3	1	1	1
118725	1710	Cupric	[Cupric]	0.0	1	1	1	1
118726	1710	cd69 by leukocyte	[CD69 by leukocytes]	0.0	3	1	1	1
118727	1710	many promoter of the gene	[many promoters of the genes]	0.0	5	1	1	1
118728	1710	cell-specific histone h5	[cell-specific histone H5]	0.0	3	1	1	1
118729	1710	ebv antibody titre (13	[EBV antibody titres (13]	0.0	4	1	1	1
118730	1710	instance of the principle	[instance of the principle]	0.0	4	1	1	1
118731	1710	-p65 heterodimer	[-p65 heterodimers]	0.0	2	1	1	1
118732	1710	alpha-tocopherol a scavenger	[alpha-tocopherol a scavenger]	0.0	3	1	1	1
118733	1710	low binding affinity the high	[low binding affinities the highest]	0.0	5	1	1	1
118734	1710	ets-binding factor	[ets-binding factor]	0.0	2	1	1	1
118735	1710	disease x-linked agammaglobulinemia	[disease X-linked agammaglobulinemia]	0.0	3	1	1	1
118736	1710	erythrocytes.	[erythrocytes.]	0.0	1	1	1	1
118737	1710	contrast, at a early stage.	[contrast, at a early stage.]	0.0	5	1	1	1
118738	1710	reporter construct in T cell hybridoma	[reporter constructs in T cell hybridomas]	0.0	6	1	1	1
118739	1710	monocyte) cell	[monocyte) cells]	0.0	2	1	1	1
118740	1710	decay of the message	[decay of the message]	0.0	4	1	1	1
118741	1710	gut inflammatory response	[gut inflammatory response]	0.0	3	1	1	1
118742	1710	simple procedure.	[simple procedure.]	0.0	2	1	1	1
118743	1710	gene effect on class	[gene effects on class]	0.0	4	1	1	1
118744	1710	key role for colony formation	[key role for colony formation]	0.0	5	1	1	1
118745	1710	intron, further transcription factor	[intron, further transcription factor]	0.0	4	1	1	1
118746	1710	clone of hiv-1	[clones of HIV-1]	0.0	3	1	1	1
118747	1710	th1-type	[Th1-type]	0.0	1	1	1	1
118748	1710	relatively young (18- volunteer	[relatively young (18- volunteers]	0.0	4	1	1	1
118749	1710	binding to a class	[binding to a class]	0.0	4	1	1	1
118750	1710	activation upon interleukin-5 hil-5 stimulation	[activation upon interleukin-5 hIL-5 stimulation]	0.0	5	1	1	1
118751	1710	reporter luciferase	[Reporter luciferase]	0.0	2	1	1	1
118752	1710	nfil3 protein	[Nfil3 protein]	0.0	2	1	1	1
118753	1710	certain interaction	[Certain interactions]	0.0	2	1	1	1
118754	1710	consideration as tumor ag	[consideration as tumor Ag]	0.0	4	1	1	1
118755	1710	cd14 gene expression	[CD14 gene expression]	0.0	3	1	1	1
118756	1710	role in functionality	[roles in functionality]	0.0	3	1	1	1
118757	1710	proximity to mammalian homologue	[proximity to mammalian homologues]	0.0	4	1	1	1
118758	1710	hbsag stimulation, expression	[HBsAg stimulation, expression]	0.0	3	1	1	1
118759	1710	decline in activity	[decline in activity]	0.0	3	1	1	1
118760	1710	human matrix metalloproteinase	[human matrix metalloproteinase]	0.0	3	1	1	1
118761	1710	one possible variable	[one possible variable]	0.0	3	1	1	1
118762	1710	follow chromosomal translocation	[following chromosomal translocations]	0.0	3	1	1	1
118763	1710	outside of development	[outside of development]	0.0	3	1	1	1
118764	1710	diagnostic value of D3 determination	[diagnostic value of D3 determination]	0.0	5	1	1	1
118765	1710	signal pathway by virtue	[signalling pathway by virtue]	0.0	4	1	1	1
118766	1710	tpa-	[TPA-]	0.0	1	1	1	1
118767	1710	differentiation-dependent receptor gamma expression	[differentiation-dependent receptor gamma expression]	0.0	4	1	1	1
118768	1710	expression of recombinant ebf	[Expression of recombinant EBF]	0.0	4	1	1	1
118769	1710	on/off switch of lineage-restricted transactivator	[on/off switches of lineage-restricted transactivators]	0.0	5	1	1	1
118770	1710	lipid-soluble, chain-breaking antioxidant hydroxyanisole bha	[lipid-soluble, chain-breaking antioxidants hydroxyanisole BHA]	0.0	5	1	1	1
118771	1710	chemotactic mcp-1 adhesive property of cell	[chemotactic MCP-1 adhesive properties of cells]	0.0	6	1	1	1
118772	1710	c-Rel dimer	[c-Rel dimers]	0.0	2	1	1	1
118773	1710	prominent increase stat1	[prominent increase STAT1]	0.0	3	1	1	1
118774	1710	nf-kappab regulation of fibrosis	[NF-kappaB regulation of fibrosis]	0.0	4	1	1	1
118775	1710	expression occur in promyelocyte	[expression occurring in promyelocyte]	0.0	4	1	1	1
118776	1710	bone marrow myeloid	[bone marrow myeloid]	0.0	3	1	1	1
118777	1710	single viral gene	[single viral gene]	0.0	3	1	1	1
118778	1710	result in transactivation activity	[resulting in transactivation activity]	0.0	4	1	1	1
118779	1710	assay with (6,7-3h) estradiol	[assay with (6,7-3H) estradiol]	0.0	4	1	1	1
118780	1710	primary erythroid precursor	[primary erythroid precursors]	0.0	3	2	2	1
118781	1710	secretion by macrophage	[secretion by macrophages]	0.0	3	1	1	1
118782	1710	prevention by red cell	[prevention by red cells]	0.0	4	1	1	1
118783	1710	mineralocorticoid receptor /cell	[mineralocorticoid receptors /cell]	0.0	3	1	1	1
118784	1710	extensive granulopoiesis die	[extensive granulopoiesis dying]	0.0	3	1	1	1
118785	1710	antagonist ru38486	[antagonist RU38486]	0.0	2	1	1	1
118786	1710	cys gsh blood cell	[CYS GSH blood cells]	0.0	4	1	1	1
118787	1710	time of the control	[times of the controls]	0.0	4	1	1	1
118788	1710	non-B lymphoma	[non-B lymphomas]	0.0	2	1	1	1
118789	1710	graft infiltration	[graft infiltration]	0.0	2	1	1	1
118790	1710	contrast, E1A cell	[contrast, E1A cells]	0.0	3	1	1	1
118791	1710	Tat-binding protein	[Tat-binding protein]	0.0	2	1	1	1
118792	1710	effector t-cell	[effector T-cells]	0.0	2	1	1	1
118793	1710	functional region of the genes,	[functional regions of the genes,]	0.0	5	1	1	1
118794	1710	induction of interferon protein 10 differentiation	[induction of interferon protein 10 differentiation]	0.0	6	1	1	1
118795	1710	distinct, subtype of hd	[distinct, subtype of HD]	0.0	4	1	1	1
118796	1710	vitamin d3-responsive	[vitamin D3-responsive]	0.0	2	1	1	1
118797	1710	BCL-6 5'-noncoding region	[BCL-6 5'-noncoding region]	0.0	3	1	1	1
118798	1710	recent result on cell line	[recent results on cell lines]	0.0	5	1	1	1
118799	1710	3'-azido-3'-deoxythymidine AZT	[3'-azido-3'-deoxythymidine AZT]	0.0	2	1	1	1
118800	1710	other processes.	[other processes.]	0.0	2	1	1	1
118801	1710	contrast, rt-pcr analysis of rna	[contrast, RT-PCR analysis of RNA]	0.0	5	1	1	1
118802	1710	organogenesis of tissue	[organogenesis of tissues]	0.0	3	1	1	1
118803	1710	transcription of the long repeat LTR	[transcription of the long repeats LTR]	0.0	6	1	1	1
118804	1710	localization use fluorescence	[localization using fluorescence]	0.0	3	1	1	1
118805	1710	tnf-alpha inhibition	[TNF-alpha inhibition]	0.0	2	1	1	1
118806	1710	also rapidak effect	[also rapid, effects]	0.0	3	1	1	1
118807	1710	agonist than G28-5 IgG	[agonist than G28-5 IgG]	0.0	4	1	1	1
118808	1710	x gene sequence ii	[X gene sequence II]	0.0	4	1	1	1
118809	1710	pafr gene expression	[PAFR gene expression]	0.0	3	1	1	1
118810	1710	three, DNA variation 2418delA	[three, DNA variations 2418delA]	0.0	4	1	1	1
118811	1710	day establish pbmc culture	[days establishing PBMC cultures]	0.0	4	1	1	1
118812	1710	physiological regulator of platelet production	[physiological regulator of platelet production]	0.0	5	1	1	1
118813	1710	2.0 0.8 nm	[2.0 0.8 nM]	0.0	3	1	1	1
118814	1710	significant correlation between ic5	[significant correlation between IC50S]	0.0	4	1	1	1
118815	1710	phenomenon await elucidation.	[phenomenon awaiting elucidation.]	0.0	3	1	1	1
118816	1710	hormone suppression	[hormone suppression]	0.0	2	1	1	1
118817	1710	pressures; activation	[pressures; activation]	0.0	2	1	1	1
118818	1710	novel, abundant, Rb- e2f complex	[novel, abundant, Rb- E2F complex.]	0.0	5	1	1	1
118819	1710	also a bind site	[also a binding site]	0.0	4	1	1	1
118820	1710	transition from a proliferate	[transition from a proliferating]	0.0	4	1	1	1
118821	1710	two b inhibitor	[two B inhibitors]	0.0	3	1	1	1
118822	1710	patient' brother,	[patient's brother,]	0.0	2	1	1	1
118823	1710	use in the analysis	[use in the analysis]	0.0	4	1	1	1
118824	1710	enhance transcription of gene	[enhancing transcription of genes]	0.0	4	1	1	1
118825	1710	two potent inhibitor kinase upstream	[two potent inhibitors kinase upstream]	0.0	5	1	1	1
118826	1710	availability of the substrate	[availability of the substrates]	0.0	4	1	1	1
118827	1710	prominent factor,	[prominent factor,]	0.0	2	1	1	1
118828	1710	study the binding 31747a on membrane	[studying the binding 31747A on membranes]	0.0	6	1	1	1
118829	1710	M.M.Lightfoote,	[M.M.Lightfoote,]	0.0	1	1	1	1
118830	1710	finger/homeodomain	[finger/homeodomain]	0.0	1	1	1	1
118831	1710	develop from human blood precursor	[developing from human blood precursors]	0.0	5	1	1	1
118832	1710	long-distance runner	[long-distance runner]	0.0	2	4	4	1
118833	1710	antigen-driven clonal expansion) (by abortive stimulation	[antigen-driven clonal expansion) (by abortive stimulation]	0.0	6	1	1	1
118834	1710	genomic anonymous probe	[genomic anonymous probes]	0.0	3	1	1	1
118835	1710	two other EBV-associated, epitope	[two other EBV-associated, epitopes]	0.0	4	1	1	1
118836	1710	vitro study use p21ras	[vitro studies using p21ras]	0.0	4	1	1	1
118837	1710	guardian of t-cell homeostasis	[guardian of T-cell homeostasis]	0.0	4	1	1	1
118838	1710	report of a activity	[report of an activity]	0.0	4	1	1	1
118839	1710	manipulation of growth of mammalian cell	[manipulation of growth of mammalian cells]	0.0	6	1	1	1
118840	1710	distinct b-cell-specific cofactor in concert	[distinct B-cell-specific cofactors in concert]	0.0	5	1	1	1
118841	1710	luciferase encoding vector	[luciferase encoding vector]	0.0	3	1	1	1
118842	1710	vh-to-dhjh recombination	[VH-to-DHJH recombination]	0.0	2	1	1	1
118843	1710	two site around position	[two sites around positions]	0.0	4	1	1	1
118844	1710	281 pmol/L; in woman	[281 pmol/L; in women]	0.0	4	1	1	1
118845	1710	pparalpha activator	[PPARalpha activators]	0.0	2	1	1	1
118846	1710	oxygen uptake	[oxygen uptake]	0.0	2	1	1	1
118847	1710	IFP53 GAS site.	[IFP53 GAS site.]	0.0	3	1	1	1
118848	1710	amino acid alteration within domain	[amino acid alterations within domain]	0.0	5	1	1	1
118849	1710	creb/atf-1	[CREB/ATF-1]	0.0	1	1	1	1
118850	1710	moderate grade of c-fos-positive lymphocyte	[moderate grades of c-fos-positive lymphocytes]	0.0	5	1	1	1
118851	1710	PRL expression	[PRL expression]	0.0	2	1	1	1
118852	1710	lack of level	[lack of levels]	0.0	3	1	1	1
118853	1710	major histocompatibility complex class transactivator	[major histocompatibility complex class transactivator]	0.0	5	1	1	1
118854	1710	detailed structural analysis of the rdna	[Detailed structural analysis of the cDNAs]	0.0	6	1	1	1
118855	1710	nuclear content	[nuclear contents]	0.0	2	1	1	1
118856	1710	evidence for the modulation of myelopoiesis	[evidence for the modulation of myelopoiesis]	0.0	6	1	1	1
118857	1710	immunocytochemistry minute	[Immunocytochemistry minutes]	0.0	2	1	1	1
118858	1710	important regulatory DNA element present	[important regulatory DNA element present]	0.0	5	1	1	1
118859	1710	bone protein-2-	[bone protein-2-]	0.0	2	1	1	1
118860	1710	regulatory sequence within the so-called element	[regulatory sequences within the so-called elements]	0.0	6	1	1	1
118861	1710	comparison, nuclei	[comparison, nuclei]	0.0	2	1	1	1
118862	1710	parallel series of pathway	[parallel series of pathways]	0.0	4	1	1	1
118863	1710	57 substitution binding	[57 substitution binding]	0.0	3	1	1	1
118864	1710	part, for induction follow activation	[part, for induction following activation]	0.0	5	1	1	1
118865	1710	treatment, at interval	[treatment, at intervals]	0.0	3	1	1	1
118866	1710	induction during b-cell activation from apoptosis.	[Induction during B-cell activation from apoptosis.]	0.0	6	1	1	1
118867	1710	operational definition	[operational definition]	0.0	2	1	1	1
118868	1710	nfatc transcription	[NFATc transcription]	0.0	2	1	1	1
118869	1710	cell of leukemia APL	[cells of leukemia APL]	0.0	4	1	1	1
118870	1710	protein nf-kappa b (consist	[proteins NF-kappa B (consisting]	0.0	4	1	1	1
118871	1710	uniformly of origin,	[uniformly of origin,]	0.0	3	1	1	1
118872	1710	truncated, constructed, 60-kda precursor	[truncated, constructed, 60-kDa precursor]	0.0	4	1	1	1
118873	1710	Acquisition of heat shock factor	[Acquisition of heat shock factor]	0.0	5	1	1	1
118874	1710	analysis of pair of grade astrocytomas	[Analysis of pairs of grade astrocytomas]	0.0	6	1	1	1
118875	1710	activator of hiv expression	[activator of HIV expression]	0.0	4	1	1	1
118876	1710	different modes, like induction, lytic superinfection	[Different modes, like induction, lytic superinfection]	0.0	6	1	1	1
118877	1710	tetrazolium (nbt)-positive cell	[tetrazolium (NBT)-positive cells]	0.0	3	1	1	1
118878	1710	glucocorticoid peripheral function	[glucocorticoid peripheral function]	0.0	3	1	1	1
118879	1710	year) in the presence	[year) in the presence]	0.0	4	1	1	1
118880	1710	-response	[-response]	0.0	1	1	1	1
118881	1710	influx of calcium	[influx of calcium]	0.0	3	1	1	1
118882	1710	cellular protein j kappa	[cellular protein J kappa]	0.0	4	1	1	1
118883	1710	differentiation potential of cell	[differentiation potential of cells]	0.0	4	1	1	1
118884	1710	human DNA sequence upstream	[human DNA sequence upstream]	0.0	4	1	1	1
118885	1710	[3h]glycosaminoglycan	[[3H]glycosaminoglycan]	0.0	1	1	1	1
118886	1710	copy of the binding site	[copies of the binding site]	0.0	5	2	2	1
118887	1710	many erythroid cell-specific gene	[many erythroid cell-specific genes]	0.0	4	1	1	1
118888	1710	inducer of granulocytic maturation	[inducer of granulocytic maturation]	0.0	4	1	1	1
118889	1710	CoCl2 signal	[CoCl2 signals]	0.0	2	1	1	1
118890	1710	bypass the requirement	[bypassing the requirement]	0.0	3	1	1	1
118891	1710	"giant" platelet	["giant" platelets]	0.0	2	1	1	1
118892	1710	change in the adhesion	[changes in the adhesion]	0.0	4	1	1	1
118893	1710	BSAP Pax-5	[BSAP Pax-5]	0.0	2	1	1	1
118894	1710	u-937 k-562	[U-937 K-562]	0.0	2	1	1	1
118895	1710	mcr histologic grade	[MCR histologic grade]	0.0	3	1	1	1
118896	1710	most common abnormality	[most common abnormalities]	0.0	3	1	1	1
118897	1710	evidence at the level	[evidence at the level]	0.0	4	1	1	1
118898	1710	(octa)-nucleotide	[(OCTA)-nucleotide]	0.0	1	1	1	1
118899	1710	action of therapy	[action of therapy]	0.0	3	1	1	1
118900	1710	lymphoid specific gene expression 3 promoter	[Lymphoid specific gene expression 3 promoter]	0.0	6	1	1	1
118901	1710	involve sequence from the tcr locus	[involving sequences from the TCR locus]	0.0	6	1	1	1
118902	1710	form of the CD4 tail	[forms of the CD4 tail]	0.0	5	1	1	1
118903	1710	weak stimulatory effect	[weak stimulatory effects]	0.0	3	1	1	1
118904	1710	disease pathogenesis	[disease pathogenesis]	0.0	2	1	1	1
118905	1710	overrepresentation of histologic type	[overrepresentation of histologic types]	0.0	4	1	1	1
118906	1710	mande b	[mande B]	0.0	2	1	1	1
118907	1710	calcitriol receptor in hyperparathyroidism	[calcitriol receptors in hyperparathyroidism]	0.0	4	1	1	1
118908	1710	human a gene	[human A gene]	0.0	3	1	1	1
118909	1710	sustained reduction of ikappab-alpha	[sustained reduction of IkappaB-alpha]	0.0	4	1	1	1
118910	1710	-inducible neutrophil	[-inducible neutrophil]	0.0	2	1	1	1
118911	1710	cell surface mu/kappa	[cell surface mu/kappa]	0.0	3	1	1	1
118912	1710	specificities, suggest a key role	[specificities, suggesting a key role]	0.0	5	1	1	1
118913	1710	cell with a rate	[cells with a rate]	0.0	4	1	1	1
118914	1710	T cell NFAT family	[T cells NFAT family]	0.0	4	1	1	1
118915	1710	nf-atp mouse old	[NF-ATp mice older]	0.0	3	1	1	1
118916	1710	major recent developments,	[Major recent developments,]	0.0	3	1	1	1
118917	1710	overexpression of hIRAK	[Overexpression of hIRAK]	0.0	3	1	1	1
118918	1710	peroxisome proliferator receptor	[peroxisome proliferator receptor]	0.0	3	1	1	1
118919	1710	a6h molecule	[A6H molecule]	0.0	2	1	1	1
118920	1710	priming of the cell	[priming of the cells]	0.0	4	1	1	1
118921	1710	human cell model	[human cell model]	0.0	3	1	1	1
118922	1710	mutant -201/-184 NXS	[mutants -201/-184 NXS]	0.0	3	1	1	1
118923	1710	cycle reactivity though undetectable	[cycle reactivities though undetectable]	0.0	4	1	1	1
118924	1710	drug undecylprodigiosin	[drug undecylprodigiosin]	0.0	2	1	1	1
118925	1710	use concentration	[using concentrations]	0.0	2	1	1	1
118926	1710	only molecular weight species	[only molecular weight species]	0.0	4	1	1	1
118927	1710	b-binding-proteins use the yeast system	[B-binding-proteins using the yeast system]	0.0	5	1	1	1
118928	1710	inducible nuclear factor	[inducible nuclear factor]	0.0	3	1	1	1
118929	1710	class restriction element differ	[class restriction element differing]	0.0	4	1	1	1
118930	1710	nonstimulated b cell	[nonstimulated B cells]	0.0	3	1	1	1
118931	1710	FKHRL1	[FKHRL1]	0.0	1	1	1	1
118932	1710	matrix regulate gene expression	[matrix regulating gene expression]	0.0	4	1	1	1
118933	1710	ca(2+)-transport	[Ca(2+)-transport]	0.0	1	1	1	1
118934	1710	unique capacity	[unique capacity]	0.0	2	1	1	1
118935	1710	mutant of pkc	[mutant of PKC]	0.0	3	1	1	1
118936	1710	demonstrate a general consequence	[demonstrating a general consequence]	0.0	4	1	1	1
118937	1710	Jak3 kinase	[Jak3 kinase]	0.0	2	1	1	1
118938	1710	patient with sle (0.9356	[patients with SLE (0.9356]	0.0	4	1	1	1
118939	1710	addition (in the form	[addition (in the form]	0.0	4	1	1	1
118940	1710	amol gr mrna /microg rna,	[amol GR mRNA /microg RNA,]	0.0	5	1	1	1
118941	1710	ALF1 transcription	[ALF1 transcription]	0.0	2	1	1	1
118942	1710	morphology adherent cell	[morphology adherent cells]	0.0	3	1	1	1
118943	1710	gene (-276	[genes (-276]	0.0	2	1	1	1
118944	1710	critical site	[critical sites]	0.0	2	1	1	1
118945	1710	ifn-alpha cell	[IFN-alpha cells]	0.0	2	1	1	1
118946	1710	effect result	[effect resulting]	0.0	2	1	1	1
118947	1710	presence of specific antibody	[presence of specific antibodies]	0.0	4	1	1	1
118948	1710	1 out healthy control	[1 out healthy controls]	0.0	4	1	1	1
118949	1710	lytic cycle protein	[lytic cycle proteins]	0.0	3	1	1	1
118950	1710	manage setting	[managing settings]	0.0	2	1	1	1
118951	1710	enhanced, h	[enhanced, h]	0.0	2	1	1	1
118952	1710	aggregation of Ri-I	[aggregation of Ri-I]	0.0	3	1	1	1
118953	1710	lymphoma (19 of 45	[lymphoma (19 of 45]	0.0	4	1	1	1
118954	1710	imply a physiological role	[implying a physiological role]	0.0	4	1	1	1
118955	1710	secretion of macrophage protein-1alpha	[secretion of macrophage protein-1alpha]	0.0	4	1	1	1
118956	1710	mouse e2a gene	[mouse E2A gene]	0.0	3	1	1	1
118957	1710	part of the defense system	[part of the defense system]	0.0	5	1	1	1
118958	1710	region of p65	[region of p65]	0.0	3	1	1	1
118959	1710	transition from to state	[transition from to state]	0.0	4	1	1	1
118960	1710	er cell by immunocytochemistry; fmol/mg protein	[ER cells by immunocytochemistry; fmol/mg protein]	0.0	6	1	1	1
118961	1710	Kruppel-like factor activity by interaction	[Kruppel-like factor activity by interaction]	0.0	5	1	1	1
118962	1710	osteoclast-like giant cell from monocyte	[osteoclast-like giant cells from monocytes]	0.0	5	1	1	1
118963	1710	immunodeficiency virus persistence in monocyte /macrophage	[immunodeficiency virus persistence in monocytes /macrophages]	0.0	6	1	1	1
118964	1710	biol.	[Biol.]	0.0	1	1	1	1
118965	1710	tal-1 protein expression in tissue	[tal-1 protein expression in tissues]	0.0	5	1	1	1
118966	1710	oxidoreductive regulatory pathway	[oxidoreductive regulatory pathway]	0.0	3	1	1	1
118967	1710	gamma/delta T	[gamma/delta T]	0.0	2	1	1	1
118968	1710	polyposis eb1-like gene family	[polyposis EB1-like gene family]	0.0	4	1	1	1
118969	1710	two events:	[two events:]	0.0	2	1	1	1
118970	1710	certain level of nf-kappab activity	[certain level of NF-kappaB activity]	0.0	5	1	1	1
118971	1710	occur in distinct allelic family	[occurring in distinct allelic families]	0.0	5	1	1	1
118972	1710	3610 (range,	[3610 (range,]	0.0	2	1	1	1
118973	1710	primate cytomegalovirus	[primate cytomegalovirus]	0.0	2	1	1	1
118974	1710	formation sequence-binding complex	[formation sequence-binding complexes]	0.0	3	1	1	1
118975	1710	as little as 72 bp	[as little as 72 bp]	0.0	5	1	1	1
118976	1710	alpha/beta interferon gene expression.	[alpha/beta interferon gene expression.]	0.0	4	1	1	1
118977	1710	latent transcription	[latent transcription]	0.0	2	1	1	1
118978	1710	use with a molecular mass	[using with a molecular mass]	0.0	5	1	1	1
118979	1710	recognize double-stranded DNA	[recognizing double-stranded DNA]	0.0	3	1	1	1
118980	1710	(MHC) class promoter	[(MHC) class promoters]	0.0	3	1	1	1
118981	1710	loci on chromosome	[loci on chromosome]	0.0	3	1	1	1
118982	1710	regulator in t-cell activation	[regulator in T-cell activation]	0.0	4	1	1	1
118983	1710	regulatory property of hepatic leukemia factor	[regulatory properties of hepatic leukemia factor]	0.0	6	1	1	1
118984	1710	class ii promoter-specific DNA binding factor	[class II promoter-specific DNA binding factors]	0.0	6	1	1	1
118985	1710	decidual transformation of the stroma	[decidual transformation of the stroma]	0.0	5	1	1	1
118986	1710	four mrna isoform	[four mRNA isoforms]	0.0	3	1	1	1
118987	1710	fluorescence anisotropy	[fluorescence anisotropy]	0.0	2	1	1	1
118988	1710	healthy woman (11 10 second	[healthy women (11 10 second]	0.0	5	1	1	1
118989	1710	cell adhesion molecule 1 vcam-1 nac	[cell adhesion molecule 1 VCAM-1 NAC]	0.0	6	1	1	1
118990	1710	stimulation of factor kappa b	[stimulation of factor kappa B]	0.0	5	1	1	1
118991	1710	thiol in the IL-1RI complex	[thiols in the IL-1RI complex]	0.0	5	1	1	1
118992	1710	new principle	[new principle]	0.0	2	1	1	1
118993	1710	decrease in the camp response	[decrease in the cAMP response]	0.0	5	1	1	1
118994	1710	two main activity	[two main activities]	0.0	3	1	1	1
118995	1710	complex with sos1	[complex with SOS1]	0.0	3	1	1	1
118996	1710	fate of this primitive cell	[fate of these primitive cells]	0.0	5	1	1	1
118997	1710	CR1 of uninfected blood monocyte	[CR1 of uninfected blood monocytes]	0.0	5	1	1	1
118998	1710	moreover, TNF-alpha hiv-1 terminal repeat	[Moreover, TNF-alpha HIV-1 terminal repeat]	0.0	5	1	1	1
118999	1710	less stringent systems,	[less stringent systems,]	0.0	3	1	1	1
119000	1710	u937 in diploid fibroblast	[U937 in diploid fibroblasts]	0.0	4	1	1	1
119001	1710	nonpeptidyl molecule	[nonpeptidyl molecule]	0.0	2	1	1	1
119002	1710	gata-2/estrogen receptor chimera	[GATA-2/estrogen receptor chimera]	0.0	3	1	1	1
119003	1710	mutation of hat activity	[mutation of HAT activity]	0.0	4	1	1	1
119004	1710	mechanism of rante expression	[mechanisms of RANTES expression]	0.0	4	1	1	1
119005	1710	Comparison of acid	[Comparison of acid]	0.0	3	1	1	1
119006	1710	isolated fragment	[isolated fragments]	0.0	2	1	1	1
119007	1710	multifactor regulation	[Multifactor regulation]	0.0	2	1	1	1
119008	1710	protein truncation test	[protein truncation test]	0.0	3	2	2	1
119009	1710	receptor-effector system for vd3	[receptor-effector system for VD3]	0.0	4	1	1	1
119010	1710	affect inflammation	[affecting inflammation]	0.0	2	1	1	1
119011	1710	promonocytic cell by etoposide	[promonocytic cells by etoposide]	0.0	4	1	1	1
119012	1710	major complex -restricted fashion	[major complex -restricted fashion]	0.0	4	1	1	1
119013	1710	receptor in human peripheral leukocyte	[receptor in human peripheral leukocytes]	0.0	5	2	2	1
119014	1710	respiratory distress syndrome NRDS	[respiratory distress syndrome NRDS]	0.0	4	1	1	1
119015	1710	pattern use extract from brain	[pattern using extracts from brain]	0.0	5	1	1	1
119016	1710	secretion in response to infection	[secretion in response to infection]	0.0	5	1	1	1
119017	1710	function similar	[functions similar]	0.0	2	1	1	1
119018	1710	h for serum-supplemented culture (viability	[h for serum-supplemented cultures (viability]	0.0	5	1	1	1
119019	1710	extract form Arnicae flo	[extracts form Arnicae flos]	0.0	4	1	1	1
119020	1710	production of mediator of inflammation	[production of mediators of inflammation]	0.0	5	1	1	1
119021	1710	voltage-gated na+ channel	[voltage-gated Na+ channel]	0.0	3	1	1	1
119022	1710	replication of immunodeficiency virus hiv	[replication of immunodeficiency virus HIV]	0.0	5	1	1	1
119023	1710	model for study of gr	[model for studies of GR]	0.0	5	1	1	1
119024	1710	selection antigen-driven expansion)	[selection antigen-driven expansion)]	0.0	3	1	1	1
119025	1710	euthymic patient with disorder	[euthymic patients with disorder]	0.0	4	1	1	1
119026	1710	threshold level for gene induction	[threshold levels for gene induction]	0.0	5	1	1	1
119027	1710	activation of distinct stat5 protein	[activation of distinct STAT5 proteins]	0.0	5	1	1	1
119028	1710	p45 megakaryocytic lineage cell	[p45 megakaryocytic lineage cells]	0.0	4	1	1	1
119029	1710	low number in blood lymphocyte	[low numbers in blood lymphocytes]	0.0	5	1	1	1
119030	1710	1) inhibition	[1) inhibition]	0.0	2	1	1	1
119031	1710	role for ras upstream	[role for ras upstream]	0.0	4	1	1	1
119032	1710	quantification lack	[Quantification lack]	0.0	2	1	1	1
119033	1710	transcription of tumor necrosis factor-alpha	[transcription of tumor necrosis factor-alpha]	0.0	5	1	1	1
119034	1710	cell enhancement of dna-binding	[cells enhancement of DNA-binding]	0.0	4	1	1	1
119035	1710	Yet, IL-2	[Yet, IL-2]	0.0	2	1	1	1
119036	1710	specificity of human cd4+ t-cell clone	[specificities of human CD4+ T-cell clones]	0.0	6	1	1	1
119037	1710	10 transplant recipient	[10 transplant recipients]	0.0	3	1	1	1
119038	1710	nuclear localization signal (89	[nuclear localization signal (89]	0.0	4	1	1	1
119039	1710	mmp-9 a enzyme	[MMP-9 an enzyme]	0.0	3	1	1	1
119040	1710	N-terminal domain with sh2 phosphotyrosine-based motif	[N-terminal domains with SH2 phosphotyrosine-based motifs]	0.0	6	1	1	1
119041	1710	notion substrate	[notion substrates]	0.0	2	1	1	1
119042	1710	100 patient with breast cancer	[100 patients with breast cancer]	0.0	5	1	1	1
119043	1710	abnormal renal phosphate transport	[Abnormal renal phosphate transport]	0.0	4	1	1	1
119044	1710	adenosine monophosphate accumulation	[adenosine monophosphate accumulation]	0.0	3	1	1	1
119045	1710	inhibit nf-kappab translocation into the nucleus	[inhibiting NF-kappaB translocation into the nucleus]	0.0	6	1	1	1
119046	1710	subunit of cytokine receptor	[subunit of cytokine receptors]	0.0	4	1	1	1
119047	1710	various proliferate cell	[various proliferating cells]	0.0	3	1	1	1
119048	1710	cell antibody maeca	[cell antibodies mAECA]	0.0	3	1	1	1
119049	1710	differentiation in primary erythroblast	[differentiation in primary erythroblasts]	0.0	4	1	1	1
119050	1710	experimental system of culture	[experimental system of cultures]	0.0	4	1	1	1
119051	1710	lambda gt11 library	[lambda gt11 library]	0.0	3	1	1	1
119052	1710	B-lymphoma cell line	[B-lymphoma cell lines]	0.0	3	1	1	1
119053	1710	opposing signal	[opposing signals]	0.0	2	1	1	1
119054	1710	Thrombopoietin TPO	[Thrombopoietin TPO]	0.0	2	1	1	1
119055	1710	fusion plasmid	[fusion plasmids]	0.0	2	1	1	1
119056	1710	inhibition for gene	[inhibition for genes]	0.0	3	1	1	1
119057	1710	pi-3 kinase	[PI-3 kinase]	0.0	2	1	1	1
119058	1710	pathway include JAK2	[pathway including JAK2]	0.0	3	1	1	1
119059	1710	lead to separable gene inhibitory response	[leading to separable gene inhibitory responses]	0.0	6	1	1	1
119060	1710	very limited stimulation	[very limited stimulation]	0.0	3	1	1	1
119061	1710	identification of a human lim-hox gene	[Identification of a human LIM-Hox gene]	0.0	6	1	1	1
119062	1710	coregulation of activation.	[coregulation of activation.]	0.0	3	1	1	1
119063	1710	Seminoma in a woman	[Seminoma in a woman]	0.0	4	1	1	1
119064	1710	cytokine in T lymphocyte	[cytokines in T lymphocytes]	0.0	4	1	1	1
119065	1710	first demonstration of a interaction	[first demonstration of a interaction]	0.0	5	1	1	1
119066	1710	verprolin-homology region	[verprolin-homology region]	0.0	2	1	1	1
119067	1710	nuclear protein-	[nuclear protein-]	0.0	2	1	1	1
119068	1710	hormone,	[hormone,]	0.0	1	1	1	1
119069	1710	gene interleukin-2 a cytokine	[gene interleukin-2 a cytokine]	0.0	4	1	1	1
119070	1710	considerable significance	[considerable significance]	0.0	2	1	1	1
119071	1710	Jun kinase a mediator	[Jun kinase a mediator]	0.0	4	1	1	1
119072	1710	important inflammatory mediator	[important inflammatory mediators]	0.0	3	1	1	1
119073	1710	4 beta-phorbol 12-myristate 13-acetate	[4 beta-phorbol 12-myristate 13-acetate]	0.0	4	2	2	1
119074	1710	important new insight	[important new insights]	0.0	3	1	1	1
119075	1710	culminate in cell growth factor	[culminating in cells growth factors]	0.0	5	1	1	1
119076	1710	modify agent	[modifying agents]	0.0	2	1	1	1
119077	1710	signal pathway for T lymphocyte activation	[signaling pathways for T lymphocyte activation]	0.0	6	1	1	1
119078	1710	4 kilobasis	[4 kilobases]	0.0	2	1	1	1
119079	1710	use retinoid with binding specificity cd336	[Using retinoids with binding specificity CD336]	0.0	6	1	1	1
119080	1710	healthy subject in two patient	[healthy subjects in two patients]	0.0	5	1	1	1
119081	1710	ac cascade	[AC cascade]	0.0	2	1	1	1
119082	1710	lineage-specific activation by interferon-gamma	[Lineage-specific activation by interferon-gamma]	0.0	4	1	1	1
119083	1710	six novel octamer binding protein	[six novel octamer binding proteins]	0.0	5	1	1	1
119084	1710	CD3 antigen-	[CD3 antigen-]	0.0	2	1	1	1
119085	1710	t-cell determinant in the ag	[T-cell determinants in the Ag]	0.0	5	1	1	1
119086	1710	kinase include protein kinase c	[kinases including protein kinase C]	0.0	5	1	1	1
119087	1710	TNF polymorphism	[TNF polymorphisms]	0.0	2	1	1	1
119088	1710	retinoid signal	[retinoid signaling]	0.0	2	1	1	1
119089	1710	few protein	[few proteins]	0.0	2	1	1	1
119090	1710	b cell transformation assay	[B cell transformation assays]	0.0	4	1	1	1
119091	1710	helix-loop-helix (bhlh) transcription factor	[helix-loop-helix (bHLH) transcription factors]	0.0	4	1	1	1
119092	1710	nuclear triiodothyronine	[nuclear triiodothyronine]	0.0	2	1	1	1
119093	1710	(100 ng/ml)	[(100 ng/ml)]	0.0	2	1	1	1
119094	1710	blood cell glucocorticoid receptor	[blood cell glucocorticoid receptors]	0.0	4	1	1	1
119095	1710	VZV immune donor	[VZV immune donors]	0.0	3	1	1	1
119096	1710	role in acute leukemia	[role in acute leukemias]	0.0	4	1	1	1
119097	1710	role in the differentiation/maturation process	[role in the differentiation/maturation process]	0.0	5	1	1	1
119098	1710	nuclear extract consist of Mr	[nuclear extracts consisting of Mr]	0.0	5	1	1	1
119099	1710	set of somatic cell hybrid	[sets of somatic cell hybrids]	0.0	5	1	1	1
119100	1710	ebv producer	[EBV producer]	0.0	2	1	1	1
119101	1710	consistent feature of xenograft rejection	[consistent feature of xenograft rejection]	0.0	5	1	1	1
119102	1710	factor specific to cell factor	[factor specific to cells factor]	0.0	5	1	1	1
119103	1710	kda sterol	[kDa sterol]	0.0	2	1	1	1
119104	1710	differentiation of leukemia u937 cell	[differentiation of leukemia U937 cells]	0.0	5	1	1	1
119105	1710	peroxide human Wurzburg t-cell	[peroxide human Wurzburg T-cells]	0.0	4	1	1	1
119106	1710	important tissue-specific DNA element	[important tissue-specific DNA element]	0.0	4	1	1	1
119107	1710	il-1ra secretion	[IL-1ra secretion]	0.0	2	1	1	1
119108	1710	gene network by receptor protein	[gene networks by receptor proteins]	0.0	5	1	1	1
119109	1710	clonotype persistence,	[clonotype persistence,]	0.0	2	1	1	1
119110	1710	endogenous host transcription factor	[endogenous host transcription factors]	0.0	4	1	1	1
119111	1710	acute lung	[acute lung]	0.0	2	1	1	1
119112	1710	NF-kappa b-inducible gene	[NF-kappa B-inducible genes]	0.0	3	1	1	1
119113	1710	semiquantitative rt-pcr analysis of rna	[semiquantitative RT-PCR analysis of RNA]	0.0	5	1	1	1
119114	1710	stimuli, include tumor necrosis factor alpha	[stimuli, including tumor necrosis factor alpha]	0.0	6	1	1	1
119115	1710	androgen insensitive carcinoma cell line	[androgen insensitive carcinoma cell lines]	0.0	5	1	1	1
119116	1710	two tyrosine-phosphorylated docking site	[two tyrosine-phosphorylated docking sites]	0.0	4	1	1	1
119117	1710	response to human virus type	[response to human virus type]	0.0	5	1	1	1
119118	1710	deltorphin activity of the NF-AT/AP-1-binding site	[deltorphin activity of the NF-AT/AP-1-binding site]	0.0	6	1	1	1
119119	1710	response to a cocktail	[response to a cocktail]	0.0	4	1	1	1
119120	1710	Jun pfo	[Jun /Fos]	0.0	2	1	1	1
119121	1710	distinct N-terminal half	[distinct N-terminal half]	0.0	3	1	1	1
119122	1710	METHODS: eight cell line	[METHODS: Eight cell lines]	0.0	4	1	1	1
119123	1710	inhibition of pkc enzymatic activity	[inhibition of PKC enzymatic activity]	0.0	5	1	1	1
119124	1710	histocompatibility complex fashion	[histocompatibility complex fashion]	0.0	3	1	1	1
119125	1710	factor for cell differentiation	[factor for cell differentiation]	0.0	4	1	1	1
119126	1710	unexpected observation of expression of wt1	[unexpected observations of expression of WT1]	0.0	6	1	1	1
119127	1710	distribution, of this mutation	[distribution, of these mutations]	0.0	4	1	1	1
119128	1710	respond to a stimulus	[responding to an stimulus]	0.0	4	1	1	1
119129	1710	S.D.	[S.D.]	0.0	1	1	1	1
119130	1710	derivative of vd	[derivatives of VD]	0.0	3	1	1	1
119131	1710	complex in nuclear extract	[complexes in nuclear extracts]	0.0	4	1	1	1
119132	1710	Epstein-Barr virus cell	[Epstein-Barr virus cells]	0.0	3	1	1	1
119133	1710	herpesvirus saimiry reading frame	[herpesvirus saimiri reading frame]	0.0	4	1	1	1
119134	1710	squelching by the receptor	[squelching by the receptor]	0.0	4	1	1	1
119135	1710	rearrangement of one of this gene	[Rearrangement of one of these genes]	0.0	6	1	1	1
119136	1710	cytosin	[cytosins]	0.0	1	1	1	1
119137	1710	profile,	[profile,]	0.0	1	1	1	1
119138	1710	novel mechanism of inhibition of factor	[novel mechanisms of inhibition of factor]	0.0	6	1	1	1
119139	1710	principal dna-binding protein	[principal DNA-binding protein]	0.0	3	1	1	1
119140	1710	immunosuppressive activity at concentration	[immunosuppressive activity at concentrations]	0.0	4	1	1	1
119141	1710	single hmg box closely related	[single HMG box closely related]	0.0	5	1	1	1
119142	1710	leukotriene b4	[leukotriene B4]	0.0	2	1	1	1
119143	1710	-59/-54,	[-59/-54,]	0.0	1	1	1	1
119144	1710	several important gene	[several important genes]	0.0	3	1	1	1
119145	1710	apoptosis inhibition	[Apoptosis inhibition]	0.0	2	1	1	1
119146	1710	include IL-6	[including IL-6]	0.0	2	1	1	1
119147	1710	distinct effect increase of ca2+	[distinct effect increase of Ca2+]	0.0	5	1	1	1
119148	1710	breakdown in T lymphocyte	[breakdown in T lymphocytes]	0.0	4	1	1	1
119149	1710	bhlh homo-	[bHLH homo-]	0.0	2	1	1	1
119150	1710	10(-8) mol/L for 13-cis RA	[10(-8) mol/L for 13-cis RA]	0.0	5	1	1	1
119151	1710	corresponding set	[corresponding set]	0.0	2	1	1	1
119152	1710	translocation of STAT3	[translocation of STAT3]	0.0	3	1	1	1
119153	1710	basis by lipopolysaccharide	[basis by lipopolysaccharide]	0.0	3	1	1	1
119154	1710	17beta-(3H) estradiol (cb50)	[17beta-(3H) estradiol (CB50)]	0.0	3	1	1	1
119155	1710	transcriptional activity of a individual factor	[transcriptional activity of an individual factor]	0.0	6	1	1	1
119156	1710	nf-kappa b1 encoding transcript	[NF-kappa B1 encoding transcripts]	0.0	4	1	1	1
119157	1710	percentage CD4	[percentage CD4]	0.0	2	1	1	1
119158	1710	form of Rap1	[form of Rap1]	0.0	3	1	1	1
119159	1710	time of h for culture (viability	[times of h for cultures (viability]	0.0	6	1	1	1
119160	1710	effect at supratherapeutic concentration	[effect at supratherapeutic concentrations]	0.0	4	1	1	1
119161	1710	third region encompass a sequence	[third region encompassing a sequence]	0.0	5	1	1	1
119162	1710	fas -mediated killing	[Fas -mediated killing]	0.0	3	1	1	1
119163	1710	year of age),	[years of age),]	0.0	3	1	1	1
119164	1710	(memory) T	[(memory) T]	0.0	2	1	1	1
119165	1710	vp16 viral transactivation domain	[VP16 viral transactivation domains]	0.0	4	1	1	1
119166	1710	flexi-12 delivery to acute blast	[Flexi-12 delivery to acute blasts]	0.0	5	1	1	1
119167	1710	action a gata site CPRE	[action a GATA site CPRE]	0.0	5	1	1	1
119168	1710	gcrbeta cell	[GCRbeta cells]	0.0	2	1	1	1
119169	1710	/GC,	[/GC,]	0.0	1	1	1	1
119170	1710	modification responsible	[modifications responsible]	0.0	2	1	1	1
119171	1710	enzyme in the endocytic pathway	[enzymes in the endocytic pathway]	0.0	5	1	1	1
119172	1710	alteration responsible for the response	[alterations responsible for the response]	0.0	5	1	1	1
119173	1710	gene expression in human cell	[gene expression in human cells]	0.0	5	1	1	1
119174	1710	cleavage during anti-igm-induced B-cell apoptosis	[Cleavage during anti-IgM-induced B-cell apoptosis]	0.0	5	1	1	1
119175	1710	interferon (ifn)-inducible genes.	[interferon (IFN)-inducible genes.]	0.0	3	1	1	1
119176	1710	42 Kruppel-related zinc finger protein	[42 Kruppel-related zinc finger proteins]	0.0	5	1	1	1
119177	1710	target cell,	[target cell,]	0.0	2	1	1	1
119178	1710	human carotid artery	[human carotid artery]	0.0	3	1	1	1
119179	1710	parent molecule	[parent molecules]	0.0	2	1	1	1
119180	1710	target cell.	[target cell.]	0.0	2	1	1	1
119181	1710	bacterial endotoxin Escherichia coli lps	[bacterial endotoxin Escherichia coli LPS]	0.0	5	1	1	1
119182	1710	/Fas	[/Fas]	0.0	1	1	1	1
119183	1710	methyl prednisolone for days.	[methyl prednisolone for days.]	0.0	4	1	1	1
119184	1710	neutralize il-6 antibody	[neutralizing IL-6 antibody]	0.0	3	1	1	1
119185	1710	plasma cortisol receptor	[plasma cortisol receptors]	0.0	3	1	1	1
119186	1710	BHA a phenolic, lipid-soluble, antioxidant	[BHA a phenolic, lipid-soluble, antioxidant]	0.0	5	1	1	1
119187	1710	species include lymphoid cell	[species including lymphoid cells]	0.0	4	1	1	1
119188	1710	link between this events.	[link between these events.]	0.0	4	1	1	1
119189	1710	active principle of medicine	[active principle of medicine]	0.0	4	1	1	1
119190	1710	nuclear localization signal present	[nuclear localization signal present]	0.0	4	1	1	1
119191	1710	oxidative stress with oxygen intermediate formation	[Oxidative stress with oxygen intermediate formation]	0.0	6	1	1	1
119192	1710	erythroid alas mrna	[erythroid ALAS mRNA]	0.0	3	1	1	1
119193	1710	whole brain	[whole brain]	0.0	2	1	1	1
119194	1710	sensitivity between tissues.	[sensitivity between tissues.]	0.0	3	1	1	1
119195	1710	gain of a inhibitor	[gain of a inhibitor]	0.0	4	1	1	1
119196	1710	gene regulation of the h(+)-atpase v-atpase	[gene regulation of the H(+)-ATPase V-ATPase]	0.0	6	1	1	1
119197	1710	activator protein-1 nuclear factor il-6 nf-il6	[activator protein-1 nuclear factor IL-6 NF-IL6]	0.0	6	1	1	1
119198	1710	deplete neutrophil	[depleting neutrophils]	0.0	2	1	1	1
119199	1710	identification of minimal disease	[identification of minimal disease]	0.0	4	1	1	1
119200	1710	effect of tax activity	[effect of Tax activity]	0.0	4	1	1	1
119201	1710	determinant govern process	[determinant governing processes]	0.0	3	1	1	1
119202	1710	activation with VDR in the absence	[activation with VDR in the absence]	0.0	6	1	1	1
119203	1710	carbonic anhydrase ii	[carbonic anhydrase II]	0.0	3	1	1	1
119204	1710	tyrosine phosphorylation of signal protein	[tyrosine phosphorylation of signaling proteins]	0.0	5	1	1	1
119205	1710	blockade of t-cell activation	[Blockade of T-cell activation]	0.0	4	1	1	1
119206	1710	inoculation	[inoculation]	0.0	1	1	1	1
119207	1710	three MHC class gene	[three MHC class genes]	0.0	4	1	1	1
119208	1710	three copy	[three copies]	0.0	2	3	3	1
119209	1710	Hashimoto' thyroiditis	[Hashimoto's thyroiditis]	0.0	2	1	1	1
119210	1710	T function	[T function]	0.0	2	1	1	1
119211	1710	implications, in particular,	[implications, in particular,]	0.0	3	1	1	1
119212	1710	histone h2a-2 gene	[histone H2A-2 genes]	0.0	3	1	1	1
119213	1710	immunodeficient (scid-husint) mouse	[immunodeficient (SCID-HU-INT) mice]	0.0	3	1	1	1
119214	1710	control peptide corresponding	[Control peptides corresponding]	0.0	3	1	1	1
119215	1710	factor Ets1	[factor Ets1]	0.0	2	1	1	1
119216	1710	E1a- replication-deficient vector	[E1a- replication-deficient vector]	0.0	3	1	1	1
119217	1710	subunit of tfiid	[subunit of TFIID]	0.0	3	1	1	1
119218	1710	transformation of cell type	[transformation of cell types]	0.0	4	1	1	1
119219	1710	induction in peripheral blood monocyte	[Induction in peripheral blood monocytes]	0.0	5	1	1	1
119220	1710	position -82 gggaactacc	[positions -82 GGGAACTACC]	0.0	3	1	1	1
119221	1710	require 2 log-fold more glucocorticoid	[requiring 2 log-fold more glucocorticoids]	0.0	5	1	1	1
119222	1710	same arrangement of sequence	[same arrangement of sequences]	0.0	4	1	1	1
119223	1710	NFATp/AP-1 complex formation	[NFATp/AP-1 complex formation]	0.0	3	1	1	1
119224	1710	promoter (-62 to +54)	[promoter (-62 to +54)]	0.0	4	1	1	1
119225	1710	nonstructured promoter	[nonstructured promoters]	0.0	2	1	1	1
119226	1710	family of dna-binding protein	[family of DNA-binding proteins]	0.0	4	1	1	1
119227	1710	human cell harc	[human cells HAECs]	0.0	3	1	1	1
119228	1710	two nfat-binding element	[two NFAT-binding elements]	0.0	3	1	1	1
119229	1710	tnfrp75	[TNFRp75]	0.0	1	1	1	1
119230	1710	Src kinase inhibitor	[Src kinase inhibitor]	0.0	3	1	1	1
119231	1710	presence of epo	[presence of EPO]	0.0	3	1	1	1
119232	1710	1-type	[1-type]	0.0	1	1	1	1
119233	1710	hematopoietic cell factor	[hematopoietic cells factor]	0.0	3	1	1	1
119234	1710	transactivation ability as otf-2	[transactivation ability as OTF-2]	0.0	4	1	1	1
119235	1710	p75tnf-r in transgenic mouse	[p75TNF-R in transgenic mice]	0.0	4	1	1	1
119236	1710	human t-cell clone reactive	[Human T-cell clones reactive]	0.0	4	1	1	1
119237	1710	lack gamma(c)	[lacking gamma(c)]	0.0	2	2	2	1
119238	1710	peroxisomal receptor gamma	[peroxisomal receptor gamma]	0.0	3	1	1	1
119239	1710	cis-acting element gm-kappa b/gc-box	[cis-acting elements GM-kappa B/GC-box]	0.0	4	1	1	1
119240	1710	chronic immune response	[chronic immune response]	0.0	3	1	1	1
119241	1710	Drosophila sequence	[Drosophila sequences]	0.0	2	1	1	1
119242	1710	c-fo promoter sis-inducible element	[c-fos promoter sis-inducible element]	0.0	4	1	1	1
119243	1710	two ccgccc binding protein from cell	[two CCGCCC binding proteins from cells]	0.0	6	1	1	1
119244	1710	heterodimer with other hormone receptor	[heterodimers with other hormone receptors]	0.0	5	1	1	1
119245	1710	contain gene	[containing genes]	0.0	2	1	1	1
119246	1710	monocyte tf induction	[monocyte TF induction]	0.0	3	1	1	1
119247	1710	transport along the endocytic pathway	[transport along the endocytic pathway]	0.0	5	1	1	1
119248	1710	target in state	[target in states]	0.0	3	1	1	1
119249	1710	800-base pair promoter	[800-base pair promoter]	0.0	3	1	1	1
119250	1710	interleukin (il) 4	[interleukin (IL) 4]	0.0	3	1	1	1
119251	1710	proto-oncogent in acute leukemia	[proto-oncogenes in acute leukemia]	0.0	4	1	1	1
119252	1710	occur in patient	[occurring in patients]	0.0	3	1	1	1
119253	1710	Indeed, secretion	[Indeed, secretion]	0.0	2	1	1	1
119254	1710	depend on the microenvironment.	[depending on the microenvironment.]	0.0	4	1	1	1
119255	1710	pre-T cell in a ftoc	[pre-T cells in an FTOC]	0.0	5	1	1	1
119256	1710	GRE-dependent luciferase reporter	[GRE-dependent luciferase reporter]	0.0	3	1	1	1
119257	1710	also a site	[also a site]	0.0	3	1	1	1
119258	1710	expression of a CAT reporter gene	[expression of a CAT reporter gene]	0.0	6	1	1	1
119259	1710	male with immunodeficiency xscid	[Males with immunodeficiency XSCID]	0.0	4	1	1	1
119260	1710	il-6 during h of stimulation	[IL-6 during h of stimulation]	0.0	5	1	1	1
119261	1710	human colonic carcinoma cell line	[human colonic carcinoma cell line]	0.0	5	1	1	1
119262	1710	contain a (pou[s]) domain	[containing a (POU[S]) domain]	0.0	4	1	1	1
119263	1710	human immunodeficiency virus type expression	[human immunodeficiency virus type expression]	0.0	5	1	1	1
119264	1710	mineralocorticoid receptor in mononuclear leucocyte	[mineralocorticoid receptor in mononuclear leucocytes]	0.0	5	1	1	1
119265	1710	anti-ERK extracellular signal-regulated kinase antibody	[anti-ERK extracellular signal-regulated kinase antibodies]	0.0	5	1	1	1
119266	1710	apparent function	[apparent function]	0.0	2	1	1	1
119267	1710	sequence from -417	[sequences from -417]	0.0	3	1	1	1
119268	1710	th1 clone	[Th1 clones]	0.0	2	1	1	1
119269	1710	chromatin process	[chromatin process]	0.0	2	1	1	1
119270	1710	group C Ad5	[group C Ad5]	0.0	3	1	1	1
119271	1710	rat lung	[rat lung]	0.0	2	1	1	1
119272	1710	response in rhinitis	[Response in rhinitis]	0.0	3	1	1	1
119273	1710	major component,	[major component,]	0.0	2	1	1	1
119274	1710	role in the faithful expression	[role in the faithful expression]	0.0	5	1	1	1
119275	1710	nf-kappa b binding site	[NF-kappa B binding sites]	0.0	4	1	1	1
119276	1710	disease MRD of patient with leukemia	[disease MRD of patients with leukemia]	0.0	6	1	1	1
119277	1710	cytokine systems, il-2	[cytokine systems, IL-2]	0.0	3	1	1	1
119278	1710	clone of line	[clones of lines]	0.0	3	1	1	1
119279	1710	bronchoscopy	[bronchoscopy]	0.0	1	1	1	1
119280	1710	amount of detailed information	[amount of detailed information]	0.0	4	1	1	1
119281	1710	affinity of NFKB2 p49 rela(p65)	[affinity of NFKB2 p49 RelA(p65)]	0.0	5	1	1	1
119282	1710	rearrangement corresponding	[rearrangements corresponding]	0.0	2	1	1	1
119283	1710	cytoplasmic inhibitor in pbmc	[cytoplasmic inhibitor in PBMC]	0.0	4	1	1	1
119284	1710	novel adult erythroid cell system	[novel adult erythroid cell system]	0.0	5	1	1	1
119285	1710	such as icam1 in b lymphocyte	[such as ICAM1 in B lymphocytes]	0.0	6	1	1	1
119286	1710	Positive element	[Positive element]	0.0	2	1	1	1
119287	1710	main piece	[main pieces]	0.0	2	1	1	1
119288	1710	such mediator of inflammation	[such mediators of inflammation]	0.0	4	1	1	1
119289	1710	two pp56(lck) mutant lack the domain	[Two pp56(lck) mutants lacking the domain]	0.0	6	1	1	1
119290	1710	miss the region	[missing the region]	0.0	3	1	1	1
119291	1710	study variation	[studying variation]	0.0	2	1	1	1
119292	1710	synergistic action between a element	[synergistic action between an element]	0.0	5	1	1	1
119293	1710	level on the tal1 locus	[levels on the TAL1 locus]	0.0	5	1	1	1
119294	1710	CD38 expression in other cell	[CD38 expression in other cells]	0.0	5	1	1	1
119295	1710	two species,	[two species,]	0.0	2	1	1	1
119296	1710	role in signal integration	[role in signal integration]	0.0	4	1	1	1
119297	1710	gtp-bound ras	[GTP-bound Ras]	0.0	2	2	2	1
119298	1710	regulator of t-cell activation	[regulators of T-cell activation]	0.0	4	1	1	1
119299	1710	department	[Department]	0.0	1	1	1	1
119300	1710	abnormal behavior of stat pathway	[abnormal behavior of STAT pathways]	0.0	5	1	1	1
119301	1710	factor proximal NF-AT AP-1/Octamer UPS	[factor proximal NF-AT AP-1/Octamer UPS]	0.0	5	1	1	1
119302	1710	metabolite 2-hydroxy-4-trifluoromethylbenzoic acid	[metabolite 2-hydroxy-4-trifluoromethylbenzoic acid]	0.0	3	1	1	1
119303	1710	related cation like cobalt, nickel,	[related cations like cobalt, nickel,]	0.0	5	1	1	1
119304	1710	4.3 pts;	[4.3 pts;]	0.0	2	1	1	1
119305	1710	distinguished: sign	[distinguished: signs]	0.0	2	1	1	1
119306	1710	dexamethasone (6.7+/-0.5	[dexamethasone (6.7+/-0.5]	0.0	2	1	1	1
119307	1710	2.0-kb region	[2.0-kb region]	0.0	2	1	1	1
119308	1710	two ccgccc binding protein	[two CCGCCC binding proteins]	0.0	4	1	1	1
119309	1710	down-regulation in patient with sepsis	[down-regulation in patients with sepsis]	0.0	5	1	1	1
119310	1710	noticeable adhesion after h	[noticeable adhesion after h]	0.0	4	1	1	1
119311	1710	(lox)	[(lox)]	0.0	1	1	1	1
119312	1710	first 12 rdna	[first 12 cDNAs]	0.0	3	1	1	1
119313	1710	specific type of acute leukemia	[specific type of acute leukemia]	0.0	5	1	1	1
119314	1710	critical b gene blk	[critical B gene blk]	0.0	4	1	1	1
119315	1710	reactivity toward antisera	[reactivities toward antisera]	0.0	3	1	1	1
119316	1710	(9.36 nm in group	[(9.36 nM in group]	0.0	4	1	1	1
119317	1710	property (deficiency-cold),	[property (deficiency-cold),]	0.0	2	1	1	1
119318	1710	pb mononuclear cell population	[PB mononuclear cell populations]	0.0	4	1	1	1
119319	1710	Dexamethasone Dex	[Dexamethasone Dex]	0.0	2	1	1	1
119320	1710	progression of cell	[progression of cells]	0.0	3	1	1	1
119321	1710	mononuclear cell reaction	[mononuclear cell reaction]	0.0	3	1	1	1
119322	1710	traz in transformation	[TRAFs in transformation]	0.0	3	1	1	1
119323	1710	meeting	[meeting]	0.0	1	1	1	1
119324	1710	CD4 lymphocyte	[CD4 lymphocytes]	0.0	2	1	1	1
119325	1710	inducible oxide synthase -mRNA level	[inducible oxide synthase -mRNA level]	0.0	5	1	1	1
119326	1710	Bcl-6 expression in reactive follicular hyperplasia	[Bcl-6 expression in reactive follicular hyperplasia]	0.0	6	1	1	1
119327	1710	cd4+ cd8+ lymphocyte	[CD4+ CD8+ lymphocytes]	0.0	3	1	1	1
119328	1710	TNF nf-kappa b	[TNF NF-kappa B]	0.0	3	1	1	1
119329	1710	potent cytokine	[potent cytokine]	0.0	2	1	1	1
119330	1710	gamma-Interferon resistance	[gamma-Interferon resistance]	0.0	2	1	1	1
119331	1710	RARalpha /pml	[RARalpha /PML]	0.0	2	1	1	1
119332	1710	Epstein-Barr virus with carcinoma	[Epstein-Barr virus with carcinoma]	0.0	4	1	1	1
119333	1710	Reciprocally, inhibition by a peptide inhibitor	[Reciprocally, inhibition by a peptide inhibitor]	0.0	6	1	1	1
119334	1710	gata-factor presumably gata-1	[GATA-factor presumably GATA-1]	0.0	3	1	1	1
119335	1710	stat6 gene expression	[STAT6 gene expression]	0.0	3	1	1	1
119336	1710	evidence from system	[Evidence from systems]	0.0	3	1	1	1
119337	1710	colony activity by 135(oh)2d3	[colony activity by 1,25(OH)2D3]	0.0	4	1	1	1
119338	1710	multiple lineages, include b lymphocyte	[multiple lineages, including B lymphocytes]	0.0	5	1	1	1
119339	1710	therapy of disease	[therapy of diseases]	0.0	3	1	1	1
119340	1710	peripheral cell of patient	[peripheral cells of patients]	0.0	4	1	1	1
119341	1710	effect, state level	[effect, state levels]	0.0	3	1	1	1
119342	1710	40-fold stimulation	[40-fold stimulation]	0.0	2	1	1	1
119343	1710	macrovascular ec HUVEC	[macrovascular EC HUVEC]	0.0	3	1	1	1
119344	1710	mechanism of gc inhibition	[mechanism of GC inhibition]	0.0	4	1	1	1
119345	1710	transient activation of protein kinase	[transient activation of protein kinase]	0.0	5	1	1	1
119346	1710	mitochondrial protein	[mitochondrial protein]	0.0	2	1	1	1
119347	1710	level of this hormone.	[levels of this hormone.]	0.0	4	1	1	1
119348	1710	medium artery	[medium arteries]	0.0	2	1	1	1
119349	1710	new informative probe specific	[new informative probes specific]	0.0	4	1	1	1
119350	1710	hematopoietic ba/f3 cell	[hematopoietic Ba/F3 cells]	0.0	3	1	1	1
119351	1710	proximal element p0	[proximal element P0]	0.0	3	1	1	1
119352	1710	cytokine regulation of hiv-1	[cytokine regulation of HIV-1]	0.0	4	1	1	1
119353	1710	receptor in blood mononuclear cell	[receptors in blood mononuclear cells]	0.0	5	1	1	1
119354	1710	murine erythroblast	[murine erythroblasts]	0.0	2	1	1	1
119355	1710	immunoregulatory	[immunoregulatory]	0.0	1	1	1	1
119356	1710	pathway in transformation	[pathways in transformation]	0.0	3	1	1	1
119357	1710	specific tyrosine phosphorylation	[specific tyrosine phosphorylation]	0.0	3	1	1	1
119358	1710	namely activator protein-1 factor il-6 nf-il6	[namely activator protein-1 factor IL-6 NF-IL6]	0.0	6	1	1	1
119359	1710	c-11 of 1 alpha,25-(OH)2D3	[C-11 of 1 alpha,25-(OH)2D3]	0.0	4	1	1	1
119360	1710	selective modulation	[Selective modulation]	0.0	2	2	2	1
119361	1710	difference in this related lineage	[differences in these related lineages]	0.0	5	1	1	1
119362	1710	rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione	[rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione]	0.0	4	1	1	1
119363	1710	stimulation by eosinophil granule	[Stimulation by eosinophil granule]	0.0	4	1	1	1
119364	1710	24 volunteer	[24 volunteers]	0.0	2	1	1	1
119365	1710	+/- versus 35 +/-	[+/- versus 35 +/-]	0.0	4	1	1	1
119366	1710	supershift assay in DC	[supershift assay in DC]	0.0	4	1	1	1
119367	1710	woman (controls)	[women (controls)]	0.0	2	1	1	1
119368	1710	85-kDa phospholipase a2	[85-kDa phospholipase A2]	0.0	3	1	1	1
119369	1710	exercise follow phosphocreatine administration	[exercise following phosphocreatine administration]	0.0	4	1	1	1
119370	1710	CAGGTG	[CAGGTG]	0.0	1	1	1	1
119371	1710	influence own expression	[influencing own expression]	0.0	3	1	1	1
119372	1710	icam-1 surface protein in umbilical cell	[ICAM-1 surface protein in umbilical cells]	0.0	6	1	1	1
119373	1710	cd13lo, cd15lo,	[CD13lo, CD15lo,]	0.0	2	1	1	1
119374	1710	protein in lps monocyte	[protein in LPS monocytes]	0.0	4	1	1	1
119375	1710	directly, provide evidence for the presence	[directly, providing evidence for the presence]	0.0	6	1	1	1
119376	1710	lymphoid follicle ILF	[lymphoid follicle ILF]	0.0	3	1	1	1
119377	1710	link this two important class	[linking these two important classes]	0.0	5	1	1	1
119378	1710	gene cascade	[gene cascade]	0.0	2	1	1	1
119379	1710	factor gata-1	[factor GATA-1]	0.0	2	1	1	1
119380	1710	view of the factor-kappaB	[view of the factor-kappaB]	0.0	4	1	1	1
119381	1710	NTF interaction (both with DNA element	[NTF interactions (both with DNA elements]	0.0	6	1	1	1
119382	1710	tnf-treated vein endothelial cell HUVECs	[TNF-treated vein endothelial cells HUVECs]	0.0	5	1	1	1
119383	1710	exposure dyn/cm2) for h. haec	[exposure dyn/cm2) for h, HAEC]	0.0	5	1	1	1
119384	1710	vector for expression	[vector for expression]	0.0	3	1	1	1
119385	1710	ferredoxin	[ferredoxins]	0.0	1	1	1	1
119386	1710	serine protease factor	[serine protease factor]	0.0	3	1	1	1
119387	1710	receptor-triggered events,	[receptor-triggered events,]	0.0	2	1	1	1
119388	1710	AIDS retrovirus hiv-2	[AIDS retrovirus HIV-2]	0.0	3	1	1	1
119389	1710	study in extrarenal, non-epithelial cell	[studies in extrarenal, non-epithelial cells]	0.0	5	1	1	1
119390	1710	cleavage product of kda	[cleavage products of kDa]	0.0	4	1	1	1
119391	1710	generation of low isoform	[generation of lower isoforms]	0.0	4	1	1	1
119392	1710	antibody phase-1 neutrophil adhesion	[antibodies phase-1 neutrophil adhesion]	0.0	4	1	1	1
119393	1710	cytotoxicity pattern	[cytotoxicity patterns]	0.0	2	1	1	1
119394	1710	follow treatment with acid atra	[following treatment with acid ATRA]	0.0	5	1	1	1
119395	1710	SOCS/CIS/SSI family	[SOCS/CIS/SSI family]	0.0	2	1	1	1
119396	1710	factor control expression of PECAM-1	[factors controlling expression of PECAM-1]	0.0	5	1	1	1
119397	1710	cdr2-loop in domain d1	[CDR2-loop in domain D1]	0.0	4	1	1	1
119398	1710	stabilizer like beta	[stabilizers like beta]	0.0	3	1	1	1
119399	1710	IL-2 component	[IL-2 component]	0.0	2	1	1	1
119400	1710	property of ccr-4	[properties of CCR-4]	0.0	3	1	1	1
119401	1710	induce the action	[inducing the action]	0.0	3	1	1	1
119402	1710	Acad.	[Acad.]	0.0	1	1	1	1
119403	1710	methov of vein endothelial cell	[METHODS of vein endothelial cells]	0.0	5	1	1	1
119404	1710	genome positional homologue	[genome positional homologues]	0.0	3	1	1	1
119405	1710	stain by a immunohistochemical procedure	[staining by an immunohistochemical procedure]	0.0	5	1	1	1
119406	1710	T cell dependent	[T cells dependent]	0.0	3	1	1	1
119407	1710	T cell leukemia virus-i tax	[T cell leukemia virus-I Tax]	0.0	5	1	1	1
119408	1710	cyclic sequence	[cyclic sequence]	0.0	2	1	1	1
119409	1710	action on the induction	[actions on the induction]	0.0	4	1	1	1
119410	1710	demonstration of a specific interaction	[demonstration of a specific interaction]	0.0	5	1	1	1
119411	1710	dominant mutant of NIK	[Dominant mutants of NIK]	0.0	4	1	1	1
119412	1710	mechanism of interaction	[mechanisms of interactions]	0.0	3	1	1	1
119413	1710	patient with airway obstruction	[patients with airways obstruction]	0.0	4	1	1	1
119414	1710	stimulation by CBF alpha twofold	[stimulation by CBF alpha twofold]	0.0	5	1	1	1
119415	1710	approximately 350 kb	[approximately 350 kb]	0.0	3	1	1	1
119416	1710	case of lymphoma	[cases of lymphoma]	0.0	3	1	1	1
119417	1710	model for promoter switch	[model for promoter switching]	0.0	4	1	1	1
119418	1710	presence of ebv	[presence of EBV]	0.0	3	1	1	1
119419	1710	novel type of cross-talk	[novel type of cross-talk]	0.0	4	1	1	1
119420	1710	inhibition of c/ebp protein	[Inhibition of C/EBP proteins]	0.0	4	1	1	1
119421	1710	region of the alpha-globin gene	[region of the alpha-globin gene]	0.0	5	1	1	1
119422	1710	search for loss of allele	[search for losses of allele]	0.0	5	1	1	1
119423	1710	sesquiterpene lactone such as helenalin	[sesquiterpene lactones such as helenalin]	0.0	5	1	1	1
119424	1710	clinical perspective	[clinical perspectives]	0.0	2	1	1	1
119425	1710	furthermore, region sequence element	[Furthermore, region sequence elements]	0.0	4	1	1	1
119426	1710	same phenotype of nf-kappab activation	[same phenotype of NF-kappaB activation]	0.0	5	1	1	1
119427	1710	anti-allergy agent	[anti-allergy agent]	0.0	2	1	1	1
119428	1710	gene encode for myeloperoxidase	[genes encoding for myeloperoxidase]	0.0	4	1	1	1
119429	1710	dramatic effect on SIVmac replication	[dramatic effects on SIVmac replication]	0.0	5	1	1	1
119430	1710	receptor in leukocyte in patient	[receptors in leukocytes in patients]	0.0	5	1	1	1
119431	1710	cytokine interleukin il-10	[cytokine interleukin IL-10]	0.0	3	1	1	1
119432	1710	consist of p50/p65 heterodimer	[consisting of p50/p65 heterodimer]	0.0	4	1	1	1
119433	1710	expression of other gene tnf-alpha	[expression of other genes TNF-alpha]	0.0	5	1	1	1
119434	1710	heterodimeric p50/p65 complex	[heterodimeric p50/p65 complexes]	0.0	3	1	1	1
119435	1710	protein-1 binding activity	[protein-1 binding activity]	0.0	3	1	1	1
119436	1710	construction characterization	[Construction characterization]	0.0	2	1	1	1
119437	1710	report on IL-10 signal transduction	[report on IL-10 signal transduction]	0.0	5	1	1	1
119438	1710	ifn(alpha)	[IFN(alpha)]	0.0	1	1	1	1
119439	1710	induction with inducers.	[induction with inducers.]	0.0	3	1	1	1
119440	1710	lck expression	[Lck expression]	0.0	2	1	1	1
119441	1710	intense transcription	[intense transcription]	0.0	2	1	1	1
119442	1710	reduction of brdu incorporation	[reduction of BrdU incorporation]	0.0	4	1	1	1
119443	1710	antibody supershift assay in EMSA	[antibody supershift assays in EMSA]	0.0	5	1	1	1
119444	1710	dominant mutant pathway	[dominant mutants pathway]	0.0	3	1	1	1
119445	1710	purine box -291	[purine box -291]	0.0	3	1	1	1
119446	1710	respond in hepatitis b patient	[responding in hepatitis B patients]	0.0	5	1	1	1
119447	1710	human immuno-deficiency virus	[human immuno-deficiency virus]	0.0	3	1	1	1
119448	1710	terminal repeat promoter	[terminal repeat promoter]	0.0	3	1	1	1
119449	1710	apoptosis in human thymocyte	[apoptosis in human thymocytes]	0.0	4	1	1	1
119450	1710	initiation.	[initiation.]	0.0	1	1	1	1
119451	1710	most important inflammatory mediator	[most important inflammatory mediators]	0.0	4	1	1	1
119452	1710	relevance.	[relevance.]	0.0	1	1	1	1
119453	1710	thereby provide a mechanism	[thereby providing an mechanism]	0.0	4	1	1	1
119454	1710	first group	[first group]	0.0	2	1	1	1
119455	1710	mcr young	[MCR younger]	0.0	2	1	1	1
119456	1710	expansion) occur between day	[expansion) occurring between day]	0.0	4	1	1	1
119457	1710	region homologous	[regions homologous]	0.0	2	1	1	1
119458	1710	function in the phase	[function in the phase]	0.0	4	1	1	1
119459	1710	50 kda polypeptide	[50 kDa polypeptides]	0.0	3	1	1	1
119460	1710	nondivide macrophage from individual	[Nondividing macrophages from individuals]	0.0	4	1	1	1
119461	1710	-SLP-76	[-SLP-76]	0.0	1	1	1	1
119462	1710	regulation kappa b	[regulation kappa B]	0.0	3	1	1	1
119463	1710	gpx activity	[GPX activity]	0.0	2	1	1	1
119464	1710	rs cell the latent membrane protein	[RS cells the latent membrane protein]	0.0	6	1	1	1
119465	1710	repression of adult globin	[repression of adult globin]	0.0	4	1	1	1
119466	1710	excess of cysteine	[excess of cysteine]	0.0	3	1	1	1
119467	1710	Chinese prescription Liuwei Dihuang Pills	[Chinese prescription Liuwei Dihuang Pills]	0.0	5	1	1	1
119468	1710	unregulated expression	[unregulated expression]	0.0	2	1	1	1
119469	1710	cell cycle control of cell	[cell cycle control of cells]	0.0	5	1	1	1
119470	1710	physical proximity	[physical proximity]	0.0	2	1	1	1
119471	1710	need for activation requirement	[need for activation requirements]	0.0	4	1	1	1
119472	1710	stretch of c-terminus	[stretch of C-terminus]	0.0	3	1	1	1
119473	1710	expression of factor-1 receptor csf-1r	[expression of factor-1 receptor CSF-1R]	0.0	5	1	1	1
119474	1710	AP-1 the polypeptide product	[AP-1 the polypeptide product]	0.0	4	1	1	1
119475	1710	correlation between plasma cortisol	[correlation between plasma cortisol]	0.0	4	1	1	1
119476	1710	interleukin (il)-1	[interleukin (IL)-1]	0.0	2	1	1	1
119477	1710	interleukin (il)-5	[interleukin (IL)-5]	0.0	2	1	1	1
119478	1710	gene assay	[gene assays]	0.0	2	1	1	1
119479	1710	anorexic patient aged years,	[anorexic patients aged years,]	0.0	4	1	1	1
119480	1710	significant influence on the induction	[significant influence on the induction]	0.0	5	1	1	1
119481	1710	expression of EBNA	[expression of EBNA]	0.0	3	1	1	1
119482	1710	feature of biological variation	[features of biological variation]	0.0	4	1	1	1
119483	1710	(30 minutes) to retinoic acid washed,	[(30 minutes) to retinoic acid washed,]	0.0	6	1	1	1
119484	1710	blin-1 cell	[BLIN-1 cells]	0.0	2	1	1	1
119485	1710	signal for cellular activation	[signals for cellular activation]	0.0	4	1	1	1
119486	1710	epithelial cell apoptosis	[epithelial cell apoptosis]	0.0	3	1	1	1
119487	1710	two subunit of mass	[two subunits of mass]	0.0	4	1	1	1
119488	1710	low protein sp	[low proteins SP]	0.0	3	1	1	1
119489	1710	successful antituberculous response	[successful antituberculous response]	0.0	3	1	1	1
119490	1710	transcriptional sequence of gene	[transcriptional sequences of genes]	0.0	4	1	1	1
119491	1710	m phi uptake of "targets"	[M phi uptake of "targets"]	0.0	5	1	1	1
119492	1710	similarity with the one	[similarities with the one]	0.0	4	1	1	1
119493	1710	interaction between transcriptional element	[interactions between transcriptional elements]	0.0	4	1	1	1
119494	1710	role in cell signal	[role in cell signaling]	0.0	4	1	1	1
119495	1710	development of tumor like KS	[development of tumors like KS]	0.0	5	1	1	1
119496	1710	affinity of element	[affinities of elements]	0.0	3	1	1	1
119497	1710	linkage to xic/xist	[linkage to XIC/XIST]	0.0	3	1	1	1
119498	1710	49 case of lymphocytic leukemia	[49 cases of lymphocytic leukemia]	0.0	5	1	1	1
119499	1710	two to 4 h	[Two to 4 h]	0.0	4	1	1	1
119500	1710	dendritic cell differentiation	[dendritic cell differentiation]	0.0	3	1	1	1
119501	1710	recombinant fragment acid	[recombinant fragment acids]	0.0	3	1	1	1
119502	1710	1) biochemical sign	[1) biochemical signs]	0.0	3	1	1	1
119503	1710	lymphocyte-specific mb-1	[lymphocyte-specific mb-1]	0.0	2	1	1	1
119504	1710	3 factor with affinity	[3 factors with affinity]	0.0	4	1	1	1
119505	1710	also a factor	[also a factor]	0.0	3	1	1	1
119506	1710	NF-AT(Rel)	[NF-AT(Rel)]	0.0	1	1	1	1
119507	1710	related molecule a1/bfl-1	[related molecule A1/Bfl-1]	0.0	3	1	1	1
119508	1710	41 exon span kb	[41 exons spanning kb]	0.0	4	1	1	1
119509	1710	transient pseudo-hypoaldosteronism follow resection normal level	[Transient pseudo-hypoaldosteronism following resection normal level]	0.0	6	1	1	1
119510	1710	strong immunohistological staining	[stronger immunohistological staining]	0.0	3	1	1	1
119511	1710	dominance of one pathway	[dominance of one pathway]	0.0	4	1	1	1
119512	1710	defect in hypophosphatemic ricket	[defect in hypophosphatemic rickets]	0.0	4	1	1	1
119513	1710	loop involve hiv infection	[loop involving HIV infection]	0.0	4	1	1	1
119514	1710	hang transfer into thymus lobe	[Hanging transfer into thymus lobes]	0.0	5	1	1	1
119515	1710	Oct-2 mrna	[Oct-2 mRNA]	0.0	2	1	1	1
119516	1710	structurally unique pml/ raralpha	[structurally unique PML/ RARalpha]	0.0	4	1	1	1
119517	1710	normal tissue structure	[normal tissue structure]	0.0	3	1	1	1
119518	1710	human leukocyte antigen-B8	[human leukocyte antigen-B8]	0.0	3	1	1	1
119519	1710	JAK Janus kinase	[JAK Janus kinase]	0.0	3	1	1	1
119520	1710	transfer protein	[transfer protein]	0.0	2	1	1	1
119521	1710	pAT 225/EGR1	[pAT 225/EGR1]	0.0	2	1	1	1
119522	1710	active component in the extract	[active component in the extract]	0.0	5	1	1	1
119523	1710	cytogenetic examination	[Cytogenetic examination]	0.0	2	1	1	1
119524	1710	chronic inflammatory-type condition	[chronic inflammatory-type conditions]	0.0	3	1	1	1
119525	1710	lack of il-12 phosphorylation	[lack of IL-12 phosphorylation]	0.0	4	1	1	1
119526	1710	Y rearrangement	[Y rearrangements]	0.0	2	1	1	1
119527	1710	initiate t-cell activation	[initiating T-cell activation]	0.0	3	1	1	1
119528	1710	autoreactive T cell during selection	[autoreactive T cells during selection]	0.0	5	1	1	1
119529	1710	2.5-kilobase sequence	[2.5-kilobase sequence]	0.0	2	1	1	1
119530	1710	trna	[tRNA]	0.0	1	1	1	1
119531	1710	activity of the activator	[activities of the activators]	0.0	4	1	1	1
119532	1710	binding of e2a	[binding of E2A]	0.0	3	1	1	1
119533	1710	individual with certain makaume mtbe	[individuals with certain makeup, MTBE]	0.0	5	1	1	1
119534	1710	diisopropyl	[diisopropyl]	0.0	1	1	1	1
119535	1710	peak expiratory flow after oral prednisolone	[peak expiratory flow after oral prednisolone]	0.0	6	1	1	1
119536	1710	mediator of response,	[mediator of response,]	0.0	3	1	1	1
119537	1710	correlation (2.5 points), body mass	[correlation (2.5 points), body mass]	0.0	5	1	1	1
119538	1710	activation of element	[activation of element]	0.0	3	1	1	1
119539	1710	primary case	[primary cases]	0.0	2	1	1	1
119540	1710	dramatic reduction	[dramatic reduction]	0.0	2	2	2	1
119541	1710	variable monosomy of loci on chromosome	[variable monosomy of loci on chromosome]	0.0	6	1	1	1
119542	1710	modulation of calcium	[modulation of calcium]	0.0	3	1	1	1
119543	1710	membrane-associated elam-1	[membrane-associated ELAM-1]	0.0	2	1	1	1
119544	1710	monocyte tnf-alpha production	[monocyte TNF-alpha production]	0.0	3	1	1	1
119545	1710	possible intervention	[possible intervention]	0.0	2	1	1	1
119546	1710	human interleukin-6 gene	[human interleukin-6 gene]	0.0	3	1	1	1
119547	1710	human t-cell leukemia virus type-i	[human T-cell leukemia virus type-I]	0.0	5	1	1	1
119548	1710	interferon-gamma-induced factor binding	[Interferon-gamma-induced factor binding]	0.0	3	1	1	1
119549	1710	use in combination	[use in combination]	0.0	3	1	1	1
119550	1710	interaction between two b transcriptional coactivator	[interactions between two B transcriptional coactivators]	0.0	6	1	1	1
119551	1710	regulate the maintenance in some cell-type	[regulating the maintenance in some cell-types]	0.0	6	1	1	1
119552	1710	phenotypic drift	[phenotypic drift]	0.0	2	1	1	1
119553	1710	oxidant-regulation	[Oxidant-regulation]	0.0	1	1	1	1
119554	1710	cardiac transplantation	[cardiac transplantation]	0.0	2	1	1	1
119555	1710	defective il-2 gene transcription	[defective IL-2 gene transcription]	0.0	4	1	1	1
119556	1710	deletion model of event	[deletion model of events]	0.0	4	1	1	1
119557	1710	cell v-atpase	[cell V-ATPase]	0.0	2	1	1	1
119558	1710	86 woman	[86 women]	0.0	2	1	1	1
119559	1710	involvement by a translocation	[involvement by a translocation]	0.0	4	1	1	1
119560	1710	dimethyl mel cell	[dimethyl MEL cells]	0.0	3	1	1	1
119561	1710	human ah receptor	[human Ah receptor]	0.0	3	1	1	1
119562	1710	activation of macrophage by mechanical ventilation	[Activation of macrophages by mechanical ventilation]	0.0	6	1	1	1
119563	1710	effect a quinone derivative	[effect a quinone derivative]	0.0	4	1	1	1
119564	1710	genetic marker	[genetic markers]	0.0	2	2	2	1
119565	1710	nf-kappa b signal transduction	[NF-kappa B signal transduction]	0.0	4	1	1	1
119566	1710	specific factor in	[specific factors in]	0.0	3	1	1	1
119567	1710	stimulate interleukin-2	[stimulating interleukin-2]	0.0	2	1	1	1
119568	1710	include the pseudoautosomal region	[including the pseudoautosomal region]	0.0	4	1	1	1
119569	1710	diagnosis of the tumour	[diagnosis of the tumours]	0.0	4	1	1	1
119570	1710	I trans-activator	[I trans-activator]	0.0	2	1	1	1
119571	1710	u937 cell overexpress pkc-zeta	[U937 cells overexpressing PKC-zeta]	0.0	4	1	1	1
119572	1710	function of tax	[function of Tax]	0.0	3	1	1	1
119573	1710	biologic activity of acid RA	[biologic activities of acid RA]	0.0	5	1	1	1
119574	1710	glucocorticoid receptor/progesterone receptor	[glucocorticoid receptor/progesterone receptor]	0.0	3	1	1	1
119575	1710	involve inadequate response to stress	[involving inadequate responses to stress]	0.0	5	1	1	1
119576	1710	presence of D3 125d3	[presence of D3 1,25D3]	0.0	4	1	1	1
119577	1710	partial cn inhibition	[partial CN inhibition]	0.0	3	1	1	1
119578	1710	plasma aldosterone in woman	[Plasma aldosterone in women]	0.0	4	1	1	1
119579	1710	capacity of glucocorticoid receptor hGR	[capacity of glucocorticoid receptor hGR]	0.0	5	1	1	1
119580	1710	1.2-kb cDNA encoding	[1.2-kb cDNA encoding]	0.0	3	1	1	1
119581	1710	define signal	[defining signals]	0.0	2	1	1	1
119582	1710	use lysate	[using lysates]	0.0	2	1	1	1
119583	1710	er mcf-7	[ER MCF-7]	0.0	2	1	1	1
119584	1710	inducibility/cell type	[inducibility/cell type]	0.0	2	1	1	1
119585	1710	active pkc -alpha	[active PKC -alpha]	0.0	3	1	1	1
119586	1710	addition, aberrancy	[addition, aberrancies]	0.0	2	1	1	1
119587	1710	local immune response	[local immune response]	0.0	3	1	1	1
119588	1710	t-cell factor-1	[T-Cell Factor-1]	0.0	2	1	1	1
119589	1710	physical exercise in human	[physical exercise in humans]	0.0	4	1	1	1
119590	1710	c-myb in expression	[c-Myb in expression]	0.0	3	1	1	1
119591	1710	expression of p13mtcp1 tissue	[expression of p13MTCP1 tissues]	0.0	4	1	1	1
119592	1710	contrast, even at dose high	[contrast, even at doses high]	0.0	5	1	1	1
119593	1710	assembly in human T cell	[assembly in human T cells]	0.0	5	1	1	1
119594	1710	pretreatment of "semimature" macrophage	[Pretreatment of "semimature" macrophages]	0.0	4	1	1	1
119595	1710	member of this family, gata-3	[member of this family, GATA-3]	0.0	5	1	1	1
119596	1710	regulation role of b-cell-specific activator protein	[Regulation role of B-cell-specific activator protein]	0.0	6	1	1	1
119597	1710	breakpoint range from q13 to q23	[breakpoints ranging from q13 to q23]	0.0	6	1	1	1
119598	1710	early cell	[early cells]	0.0	2	1	1	1
119599	1710	ig receptor	[Ig receptor]	0.0	2	1	1	1
119600	1710	mature t-cell leukemia	[mature T-cell leukemias]	0.0	3	1	1	1
119601	1710	stimulation monoclonal antibody phosphatidylinositol 3-kinase	[Stimulation monoclonal antibody phosphatidylinositol 3-kinase]	0.0	5	1	1	1
119602	1710	cell type-specific increase	[cell type-specific increase]	0.0	3	1	1	1
119603	1710	suggest proliferation.	[suggesting proliferation.]	0.0	2	1	1	1
119604	1710	use pd-98059 two potent inhibitor	[using PD-98059 two potent inhibitors]	0.0	5	1	1	1
119605	1710	beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation of 3,21-diacetoxy-5	[beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation of 3,21-diacetoxy-5]	0.0	6	1	1	1
119606	1710	ebv transcription	[EBV transcription]	0.0	2	1	1	1
119607	1710	four amino acid difference Ser551	[four amino acid differences Ser551]	0.0	5	1	1	1
119608	1710	42.2% induction	[42.2% induction]	0.0	2	1	1	1
119609	1710	non-PRL-secreting endometrial cell	[non-PRL-secreting endometrial cells]	0.0	3	1	1	1
119610	1710	t-lymphocyte from individual with disease	[T-lymphocytes from individuals with disease]	0.0	5	1	1	1
119611	1710	human globin expression	[human globin expression]	0.0	3	1	1	1
119612	1710	affinity column fraction, 12-fold	[affinity column fraction, 12-fold]	0.0	4	1	1	1
119613	1710	specific antibody from carrier	[specific antibodies from carriers]	0.0	4	1	1	1
119614	1710	progenitor cell via retrovirus vector	[progenitor cells via retrovirus vectors]	0.0	5	1	1	1
119615	1710	target of positive regulatory signal	[target of positive regulatory signals]	0.0	5	1	1	1
119616	1710	human cell line, ut-7	[human cell line, UT-7]	0.0	4	1	1	1
119617	1710	month (range, 31-55 months).	[months (range, 31-55 months).]	0.0	4	1	1	1
119618	1710	+55 region	[+55 region]	0.0	2	1	1	1
119619	1710	cd3/cd4+ T cell	[CD3/CD4+ T cells]	0.0	3	1	1	1
119620	1710	role of Jak3	[role of Jak3]	0.0	3	1	1	1
119621	1710	PB1 protein-binding complex	[PB1 protein-binding complex]	0.0	3	1	1	1
119622	1710	adhesion in endothelial cell	[adhesion in endothelial cells]	0.0	4	1	1	1
119623	1710	CTL precursor	[CTL precursor]	0.0	2	1	1	1
119624	1710	regulatory serine	[regulatory serines]	0.0	2	1	1	1
119625	1710	reproductive event	[reproductive events]	0.0	2	1	1	1
119626	1710	factor kappab nf kappab	[factor kappaB NF kappaB]	0.0	4	1	1	1
119627	1710	microbiological antigen	[microbiological antigens]	0.0	2	1	1	1
119628	1710	three finding	[three findings]	0.0	2	1	1	1
119629	1710	Oct-1 in particular nf-atp	[Oct-1 in particular NF-ATp]	0.0	4	1	1	1
119630	1710	unique feature nuclear membrane	[unique features nuclear membranes]	0.0	4	1	1	1
119631	1710	patient with active sle (0.9356	[patients with active SLE (0.9356]	0.0	5	1	1	1
119632	1710	phosphorylation in the leukemic cell	[phosphorylation in the leukemic cells]	0.0	5	1	1	1
119633	1710	NLS peptide-mediated disruption	[NLS peptide-mediated disruption]	0.0	3	1	1	1
119634	1710	EBNA-2 -positive extract	[EBNA-2 -positive extracts]	0.0	3	1	1	1
119635	1710	role of Grb2-binding protein	[role of Grb2-binding proteins]	0.0	4	1	1	1
119636	1710	nucleotide -158 to -90	[nucleotides -158 to -90]	0.0	4	1	1	1
119637	1710	undergo the phagocytosis	[undergoing the phagocytosis]	0.0	3	1	1	1
119638	1710	myeloid leukemia cell with 12-o-tetradecanoylphorbol-13-acetate	[myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate]	0.0	5	1	1	1
119639	1710	expression from a promoter	[expression from an promoter]	0.0	4	1	1	1
119640	1710	patient present than for patient	[patients presenting than for patients]	0.0	5	1	1	1
119641	1710	active p50/rela(p65) heterodimer	[active p50/RelA(p65) heterodimers]	0.0	3	1	1	1
119642	1710	long activation of t-lymphocyte	[long-term activation of T-lymphocytes]	0.0	4	1	1	1
119643	1710	apparently the product	[apparently the products]	0.0	3	1	1	1
119644	1710	direct interaction of transcription factor pu.1	[Direct interaction of transcription factors PU.1]	0.0	6	1	1	1
119645	1710	40 mM d-ribose respectively.	[40 mM D-ribose respectively.]	0.0	4	1	1	1
119646	1710	ectopic fragment	[ectopic fragments]	0.0	2	1	1	1
119647	1710	human subject	[human subjects]	0.0	2	1	1	1
119648	1710	induction of activation-related genes.	[induction of activation-related genes.]	0.0	4	1	1	1
119649	1710	unresponsiveness of patient	[unresponsiveness of patients]	0.0	3	1	1	1
119650	1710	oligonucleotide corresponding to partial sequence	[oligonucleotides corresponding to partial sequences]	0.0	5	1	1	1
119651	1710	employed, incorporate multiple antigen	[employed, incorporating multiple antigens]	0.0	4	1	1	1
119652	1710	npc cell line in culture	[NPC cell lines in culture]	0.0	5	1	1	1
119653	1710	deltorphin transcriptional activity	[deltorphin transcriptional activity]	0.0	3	1	1	1
119654	1710	synthesis from mammary cancer patient	[synthesis from mammary cancer patients]	0.0	5	1	1	1
119655	1710	homeobox gene HB9	[homeobox gene HB9]	0.0	3	1	1	1
119656	1710	NF-kappaB a key regulator	[NF-kappaB a key regulator]	0.0	4	1	1	1
119657	1710	exhibit proliferative behavior	[exhibiting proliferative behavior]	0.0	3	1	1	1
119658	1710	thus suggest a early divergence	[thus suggesting an early divergence]	0.0	5	1	1	1
119659	1710	detailed information about the protein	[detailed information about the proteins]	0.0	5	1	1	1
119660	1710	human t-lymphotropic virus type	[human T-lymphotropic virus type]	0.0	4	1	1	1
119661	1710	impaired fetal thymocyte development after inhibition	[Impaired fetal thymocyte development after inhibition]	0.0	6	1	1	1
119662	1710	contain a site for Sp1	[containing a site for Sp1]	0.0	5	1	1	1
119663	1710	expression in Jurkat T cell	[expression in Jurkat T cells]	0.0	5	1	1	1
119664	1710	CD2 receptor modulation	[CD2 receptor modulation]	0.0	3	1	1	1
119665	1710	transform latent membrane protein-1	[transforming latent membrane protein-1]	0.0	4	1	1	1
119666	1710	unknown autoantigen	[unknown autoantigen]	0.0	2	1	1	1
119667	1710	pattern of contact	[pattern of contacts]	0.0	3	1	1	1
119668	1710	role of the anaphylatoxin	[role of the anaphylatoxins]	0.0	4	1	1	1
119669	1710	pr patient respectively.	[PR patients respectively.]	0.0	3	1	1	1
119670	1710	hiv by acid	[HIV by acid]	0.0	3	1	1	1
119671	1710	end of the tail	[end of the tail]	0.0	4	1	1	1
119672	1710	include presentation, response with acid atra	[including presentation, response with acid ATRA]	0.0	6	1	1	1
119673	1710	subsequent dissociation	[subsequent dissociation]	0.0	2	1	1	1
119674	1710	several clonal line	[several clonal lines]	0.0	3	1	1	1
119675	1710	Clathrin Assembly	[Clathrin Assembly]	0.0	2	1	1	1
119676	1710	terminal step of export	[terminal step of export]	0.0	4	1	1	1
119677	1710	nuclear factor kappa b activity	[nuclear factor kappa B activity]	0.0	5	1	1	1
119678	1710	blood neutrophil count	[blood neutrophil counts]	0.0	3	1	1	1
119679	1710	adenovirus early region 3	[adenovirus early region 3]	0.0	4	1	1	1
119680	1710	several feature characteristic include sensitivity	[several features characteristic including sensitivity]	0.0	5	1	1	1
119681	1710	complete burst	[complete burst]	0.0	2	1	1	1
119682	1710	form include acute leukemia	[forms including acute leukemia]	0.0	4	1	1	1
119683	1710	t3 maximal binding capacity	[T3 maximal binding capacity]	0.0	4	1	1	1
119684	1710	only case with a negative reaction	[only case with a negative reaction]	0.0	6	1	1	1
119685	1710	as many as 20 copy	[as many as 20 copies]	0.0	5	1	1	1
119686	1710	pou-specific (pou[s]) domain	[POU-specific (POU[S]) domain]	0.0	3	1	1	1
119687	1710	modification of lysine arginine residue	[modification of lysine arginine residues]	0.0	5	1	1	1
119688	1710	monocytic cell induction of collagenase	[Monocytic cell induction of collagenase]	0.0	5	1	1	1
119689	1710	class major complex promoter	[class major complex promoters]	0.0	4	1	1	1
119690	1710	extracellular concentration	[extracellular concentrations]	0.0	2	1	1	1
119691	1710	first report in endothelial cell	[first report in endothelial cells]	0.0	5	1	1	1
119692	1710	role in HLA-DRA gene expression	[role in HLA-DRA gene expression]	0.0	5	1	1	1
119693	1710	ngf-r	[NGF-R]	0.0	1	1	1	1
119694	1710	inactive, form	[inactive, form]	0.0	2	1	1	1
119695	1710	repressive organization	[repressive organization]	0.0	2	1	1	1
119696	1710	two allele in progenitor	[two alleles in progenitors]	0.0	4	1	1	1
119697	1710	factor kappa b in cell	[factor kappa B in cells]	0.0	5	1	1	1
119698	1710	receptor beta-chain	[receptor beta-chain]	0.0	2	1	1	1
119699	1710	BHA a chain-break antioxidant	[BHA a chain-breaking antioxidant]	0.0	4	1	1	1
119700	1710	human t-cell leukemia virus type 1	[Human T-cell leukemia virus type 1]	0.0	6	2	2	1
119701	1710	minimal promoter.	[minimal promoter.]	0.0	2	1	1	1
119702	1710	gr abnormalities:	[GR abnormalities:]	0.0	2	1	1	1
119703	1710	abnormality in myeloproliferative disorder	[abnormality in myeloproliferative disorders]	0.0	4	1	1	1
119704	1710	Biologic effect on primary NK	[Biologic effects on primary NK]	0.0	5	1	1	1
119705	1710	various condition of importance.	[various conditions of importance.]	0.0	4	1	1	1
119706	1710	reporter gene assay use luciferase construct	[reporter gene assays using luciferase constructs]	0.0	6	1	1	1
119707	1710	include hyperresponsiveness	[including hyperresponsiveness]	0.0	2	1	1	1
119708	1710	ikk enzymatic activity	[IKK enzymatic activity]	0.0	3	1	1	1
119709	1710	produce a induction of mrna	[producing a induction of mRNA]	0.0	5	1	1	1
119710	1710	induction between 1 h.	[induction between 1 h,]	0.0	4	1	1	1
119711	1710	beta-globin gene silencing	[beta-globin gene silencing]	0.0	3	1	1	1
119712	1710	target than current opinion	[target than current opinion]	0.0	4	1	1	1
119713	1710	moderate decrease in LTR activity	[moderate decreases in LTR activity]	0.0	5	1	1	1
119714	1710	interleukin expression on the surface	[interleukin expression on the surface]	0.0	5	1	1	1
119715	1710	transcriptional regulator of inflammatory response	[transcriptional regulator of inflammatory responses]	0.0	5	1	1	1
119716	1710	Comparison of group human sequence	[Comparison of group human sequences]	0.0	5	1	1	1
119717	1710	promyelocytic feature	[promyelocytic features]	0.0	2	1	1	1
119718	1710	cell with a mitotic rate	[cells with a mitotic rate]	0.0	5	1	1	1
119719	1710	NFAT1/ nfatp	[NFAT1/ NFATp]	0.0	2	1	1	1
119720	1710	serum-inducible element dna-probe	[serum-inducible element DNA-probe]	0.0	3	1	1	1
119721	1710	Peptidoglycan the cell wall component	[Peptidoglycan the cell wall component]	0.0	5	1	1	1
119722	1710	up-regulate the activity	[up-regulating the activity]	0.0	3	1	1	1
119723	1710	host destruction	[host destruction]	0.0	2	1	1	1
119724	1710	putative effect	[putative effects]	0.0	2	1	1	1
119725	1710	major histocompatibility class ii transactivator	[major histocompatibility class II transactivator]	0.0	5	1	1	1
119726	1710	human blood NK cell genistein	[human blood NK cells genistein]	0.0	5	1	1	1
119727	1710	cellular homologue of cyclosporin a	[cellular homologues of cyclosporin A]	0.0	5	1	1	1
119728	1710	examination of the patient' young brother,	[examination of the patient's younger brother,]	0.0	6	1	1	1
119729	1710	level of c-Rel	[levels of c-Rel]	0.0	3	1	1	1
119730	1710	description,	[description,]	0.0	1	1	1	1
119731	1710	kappa b-driven gene	[kappa B-driven genes]	0.0	3	1	1	1
119732	1710	use high concentration of peptide ligand	[using high concentrations of peptide ligand]	0.0	6	1	1	1
119733	1710	expression of the nuclear factor	[expression of the nuclear factors]	0.0	5	1	1	1
119734	1710	level in mature b-cell line	[levels in mature B-cell lines]	0.0	5	1	1	1
119735	1710	pattern suggest a specific role	[pattern suggesting a specific role]	0.0	5	1	1	1
119736	1710	rabbit antibody	[rabbit antibodies]	0.0	2	1	1	1
119737	1710	nucleotide exchange	[nucleotide exchange]	0.0	2	3	3	1
119738	1710	immediate period	[immediate period]	0.0	2	1	1	1
119739	1710	hiv-1 terminal repeat reporter gene activity	[HIV-1 terminal repeat reporter gene activity]	0.0	6	1	1	1
119740	1710	role of Stat4 in regulation	[role of Stat4 in regulation]	0.0	5	1	1	1
119741	1710	concentration of okadaic acid	[concentration of okadaic acid]	0.0	4	1	1	1
119742	1710	sequence identity between mouse	[sequence identity between mouse]	0.0	4	1	1	1
119743	1710	retain this region.	[retaining this region.]	0.0	3	1	1	1
119744	1710	drugs, one	[drugs, one]	0.0	2	1	1	1
119745	1710	NK cell-target	[NK cell-target]	0.0	2	1	1	1
119746	1710	insight into parasite survival strategy	[insights into parasite survival strategies]	0.0	5	1	1	1
119747	1710	light-regulated rhythm	[light-regulated rhythms]	0.0	2	1	1	1
119748	1710	contain bp of upstream sequence	[containing bp of upstream sequence]	0.0	5	1	1	1
119749	1710	poly(i)-poly(c)-induced IFN alpha production	[poly(I)-poly(C)-induced IFN alpha production]	0.0	4	1	1	1
119750	1710	role of AMP response protein	[Role of AMP response protein]	0.0	5	1	1	1
119751	1710	localization contain nuclear factor kappab complex	[localization containing nuclear factor kappaB complexes]	0.0	6	1	1	1
119752	1710	mid-age patient	[mid-age patients]	0.0	2	1	1	1
119753	1710	apoptotic death	[apoptotic death]	0.0	2	2	2	1
119754	1710	alter interaction to interactions.	[altering interactions to interactions.]	0.0	4	1	1	1
119755	1710	immunohistochemical evidence	[Immunohistochemical evidence]	0.0	2	1	1	1
119756	1710	epithelial cell malignancy	[epithelial cell malignancies]	0.0	3	1	1	1
119757	1710	8-fold increase	[8-fold increase]	0.0	2	1	1	1
119758	1710	interaction antagonism in erythroid cell	[interaction antagonism in erythroid cells]	0.0	5	1	1	1
119759	1710	NF-kappa b dimerization	[NF-kappa B dimerization]	0.0	3	1	1	1
119760	1710	factor to this element	[factors to these elements]	0.0	4	1	1	1
119761	1710	treatment modality	[treatment modality]	0.0	2	1	1	1
119762	1710	reach the effect at 10 nm	[reaching the effect at 10 nM]	0.0	6	1	1	1
119763	1710	Leger	[Leger]	0.0	1	1	1	1
119764	1710	action include member	[action including members]	0.0	3	1	1	1
119765	1710	principle search Ag	[principle searching Ag]	0.0	3	1	1	1
119766	1710	identification of two novel element	[Identification of two novel elements]	0.0	5	1	1	1
119767	1710	mutation at the Sp1-binding site	[mutation at the Sp1-binding site]	0.0	5	1	1	1
119768	1710	progression of case of CLL	[progression of case of CLL]	0.0	5	1	1	1
119769	1710	alpha thf/thf (0.35; n: ratios.	[alpha THF/THF (0.35; N: ratios.]	0.0	5	1	1	1
119770	1710	12-o-tetradecanoylphorbol-13-acetate tpa represses, gene expression	[12-O-tetradecanoylphorbol-13-acetate TPA represses, gene expression]	0.0	5	1	1	1
119771	1710	dna-binding protein bind protein	[DNA-binding protein binding protein]	0.0	4	1	1	1
119772	1710	contain as a enhancer four copy	[containing as an enhancer four copies]	0.0	6	1	1	1
119773	1710	hematolymphopoietrope	[hematolymphopoietrope]	0.0	1	1	1	1
119774	1710	hmg-i(y) expression	[HMG-I(Y) expression]	0.0	2	1	1	1
119775	1710	activation enhancer	[Activation enhancer]	0.0	2	1	1	1
119776	1710	usefulness of this cl assay	[usefulness of these CL assays]	0.0	5	1	1	1
119777	1710	gelatinase-associated lipocalin from human	[gelatinase-associated lipocalin from humans]	0.0	4	1	1	1
119778	1710	heterogeneous group of related disorder	[heterogeneous group of related disorders]	0.0	5	1	1	1
119779	1710	response, reach a maximum	[response, reaching a maximum]	0.0	4	1	1	1
119780	1710	ad5 infection	[Ad5 infection]	0.0	2	1	1	1
119781	1710	beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation	[beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation]	0.0	3	1	1	1
119782	1710	nonspecific inhibitor	[nonspecific inhibitor]	0.0	2	1	1	1
119783	1710	express antisense VDR mrna	[expressing antisense VDR mRNA]	0.0	4	1	1	1
119784	1710	Rel/NF-kappa b transcription	[Rel/NF-kappa B transcription]	0.0	3	1	1	1
119785	1710	mechanism via the leukocyte	[mechanisms via the leukocytes]	0.0	4	1	1	1
119786	1710	pkc inhibition with Bis	[PKC inhibition with Bis]	0.0	4	1	1	1
119787	1710	lack of cortisol inhibition	[lack of cortisol inhibition]	0.0	4	1	1	1
119788	1710	regulation of the locus	[Regulation of the locus]	0.0	4	1	1	1
119789	1710	significant increase from steroid-sensitive patient	[significant increase from steroid-sensitive patients]	0.0	5	1	1	1
119790	1710	inhibition of phorbol ester-induced differentiation	[Inhibition of phorbol ester-induced differentiation]	0.0	5	1	1	1
119791	1710	means colonize hosts.	[means colonizing hosts.]	0.0	3	1	1	1
119792	1710	action on il-2r alpha expression,	[action on IL-2R alpha expression,]	0.0	5	1	1	1
119793	1710	human fosb gene	[human FOSB gene]	0.0	3	1	1	1
119794	1710	use a promoter.	[using a promoter.]	0.0	3	1	1	1
119795	1710	N-terminal fragment	[N-terminal fragment]	0.0	2	1	1	1
119796	1710	encode a novel component	[encoding a novel component]	0.0	4	1	1	1
119797	1710	Instead, regulation	[Instead, regulation]	0.0	2	1	1	1
119798	1710	finding of hpa abnormality	[findings of HPA abnormalities]	0.0	4	1	1	1
119799	1710	tumour cell of lymphoma	[tumour cells of lymphoma]	0.0	4	1	1	1
119800	1710	development role for alteration	[development roles for alterations]	0.0	4	1	1	1
119801	1710	increase inflammatory infiltrate (p than 0.02).	[increasing inflammatory infiltrate (P than 0.02).]	0.0	6	1	1	1
119802	1710	substitution binding of a hsv-2 peptide	[substitution binding of an HSV-2 peptide]	0.0	6	1	1	1
119803	1710	Janus kinase /signal transducer	[Janus kinase /signal transducer]	0.0	4	1	1	1
119804	1710	range for age,	[range for age,]	0.0	3	1	1	1
119805	1710	angioimmunoblastic t-cell lymphoma with gcs	[angioimmunoblastic T-cell lymphoma with GCs]	0.0	5	1	1	1
119806	1710	1 repeat quasispecy	[1 repeat quasispecies]	0.0	3	1	1	1
119807	1710	cell cycle s phase	[cell cycle S phase]	0.0	4	1	1	1
119808	1710	induction of human immunodeficiency virus type	[Induction of human immunodeficiency virus type]	0.0	6	1	1	1
119809	1710	translocation of NF-ATp	[translocation of NF-ATp]	0.0	3	1	1	1
119810	1710	Epstein-Barr virus a human herpesvirus	[Epstein-Barr virus an human herpesvirus]	0.0	5	1	1	1
119811	1710	mu/l testing concentration),	[mU/L testing concentration),]	0.0	3	1	1	1
119812	1710	addition to Bcl-x	[addition to Bcl-x]	0.0	3	1	1	1
119813	1710	patient with arthritis RA	[patients with arthritis RA]	0.0	4	1	1	1
119814	1710	112 drug-free patient	[112 drug-free patients]	0.0	3	1	1	1
119815	1710	acid cell	[acid cells]	0.0	2	1	1	1
119816	1710	over-lapping	[over-lapping]	0.0	1	1	1	1
119817	1710	patient with dermatomyositis/polymyositis	[patients with dermatomyositis/polymyositis]	0.0	3	1	1	1
119818	1710	phosphorylation-	[phosphorylation-]	0.0	1	1	1	1
119819	1710	atra cd38+ cell	[ATRA CD38+ cells]	0.0	3	1	1	1
119820	1710	lineages, include b lymphocyte	[lineages, including B lymphocytes]	0.0	4	1	1	1
119821	1710	phosphorylation,	[phosphorylation,]	0.0	1	1	1	1
119822	1710	add with RA (10(-6)	[adding with RA (10(-6)]	0.0	4	1	1	1
119823	1710	delta 5' region extend	[delta 5' regions extending]	0.0	4	1	1	1
119824	1710	il-4r alpha-chain	[IL-4R alpha-chain]	0.0	2	1	1	1
119825	1710	-bsa-induced	[-BSA-induced]	0.0	1	1	1	1
119826	1710	prevalence of aneuploidy in breast aspirate	[Prevalence of aneuploidy in breast aspirates]	0.0	6	1	1	1
119827	1710	important implication for the regulation	[important implications for the regulation]	0.0	5	1	1	1
119828	1710	intralymphocytic sodium in patient	[intralymphocytic sodium in patients]	0.0	4	1	1	1
119829	1710	site of chromosome translocation	[sites of chromosome translocation]	0.0	4	1	1	1
119830	1710	receptor status in leukocyte	[receptor status in leukocytes]	0.0	4	1	1	1
119831	1710	use form	[using forms]	0.0	2	1	1	1
119832	1710	factor present in osteoblast extract	[factor present in osteoblast extracts]	0.0	5	1	1	1
119833	1710	tyrosine -phosphorylated p80c-rel	[tyrosine -phosphorylated p80c-rel]	0.0	3	1	1	1
119834	1710	common signal pathway in neutrophil	[Common signaling pathways in neutrophils]	0.0	5	1	1	1
119835	1710	factor of T cell activity	[factor of T cells activity]	0.0	5	1	1	1
119836	1710	(range, (range, (range, 5.86-6.74) nm,	[(range, (range, (range, 5.86-6.74) nM,]	0.0	5	1	1	1
119837	1710	level alpha-naphthyl-acetate-esterase naf-r-nse	[levels alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	3	1	1	1
119838	1710	viable mature erythroid cell a phenotype	[viable mature erythroid cells a phenotype]	0.0	6	1	1	1
119839	1710	crossreactive recognition of self ligand	[Crossreactive recognition of self, ligands]	0.0	5	1	1	1
119840	1710	least some response gene	[least some response genes]	0.0	4	1	1	1
119841	1710	etiology for palmar fibromatosis	[etiology for palmar fibromatosis]	0.0	4	1	1	1
119842	1710	activity of the immediate-early gene	[activity of the immediate-early genes]	0.0	5	1	1	1
119843	1710	analogous framework signal as il-1	[analogous framework signaling as IL-1]	0.0	5	1	1	1
119844	1710	ATF/CRE motif	[ATF/CRE motif]	0.0	2	1	1	1
119845	1710	correlation between affinity	[correlation between affinity]	0.0	3	1	1	1
119846	1710	thus, replication of the template	[Thus, replication of the template]	0.0	5	1	1	1
119847	1710	four sp1 site	[four Sp1 sites]	0.0	3	2	2	1
119848	1710	P; in addition, protein	[h; in addition, protein]	0.0	4	1	1	1
119849	1710	spleen with liposomal mpl	[spleen with liposomal MPL]	0.0	4	1	1	1
119850	1710	study in non-human primate	[studies in non-human primates]	0.0	4	1	1	1
119851	1710	induction E-selectin surface expression	[Induction E-selectin surface expression]	0.0	4	1	1	1
119852	1710	cell of promyelocytic leukemia APL	[cells of promyelocytic leukemia APL]	0.0	5	1	1	1
119853	1710	related simian immunodeficiency virus	[related simian immunodeficiency virus]	0.0	4	1	1	1
119854	1710	expression of own receptor	[expression of own receptor]	0.0	4	1	1	1
119855	1710	caprine arthritis-encephalitis virus repeat	[caprine arthritis-encephalitis virus repeat]	0.0	4	1	1	1
119856	1710	Peptidoglycan the major cell wall component	[Peptidoglycan the major cell wall component]	0.0	6	1	1	1
119857	1710	patient with t-cell leukemia t-all	[patients with T-cell leukemia T-ALL]	0.0	5	1	1	1
119858	1710	two schedule	[two schedules]	0.0	2	1	1	1
119859	1710	antiviral, function	[antiviral, functions]	0.0	2	1	1	1
119860	1710	direct antiatherogenic mechanism	[direct antiatherogenic mechanism]	0.0	3	1	1	1
119861	1710	28 lbp patient	[28 LBP patients]	0.0	3	1	1	1
119862	1710	interaction between zeta globin promoter	[interaction between zeta globin promoter]	0.0	5	1	1	1
119863	1710	target for v-erbA oncogene action	[target for v-erbA oncogene action]	0.0	5	1	1	1
119864	1710	erythropoietin epo protein kinase b	[erythropoietin EPO protein kinase B]	0.0	5	1	1	1
119865	1710	control of antigen responsiveness	[control of antigen responsiveness]	0.0	4	1	1	1
119866	1710	g-csf dead cell at day g-csf	[G-CSF dead cells at day G-CSF]	0.0	6	1	1	1
119867	1710	b cell by human herpesvirus	[B cells by human herpesvirus]	0.0	5	1	1	1
119868	1710	encode a putative transcriptional regulator	[encoding a putative transcriptional regulator]	0.0	5	1	1	1
119869	1710	intracellular domain sequence	[intracellular domain sequences]	0.0	3	1	1	1
119870	1710	certain NF-kappaB/Rel member c-rel	[certain NF-kappaB/Rel members c-Rel]	0.0	4	1	1	1
119871	1710	presence of a cooh-terminal domain	[presence of an COOH-terminal domain]	0.0	5	1	1	1
119872	1710	trans-cellular activation	[trans-cellular activation]	0.0	2	1	1	1
119873	1710	nfkb2 rela(p65)	[NFKB2 RelA(p65)]	0.0	2	1	1	1
119874	1710	lymphocyte of leukemia patient	[lymphocytes of leukemia patients]	0.0	4	1	1	1
119875	1710	JNK /sapk	[JNK /SAPK]	0.0	2	1	1	1
119876	1710	T transcription factor tcf-1	[T transcription factor TCF-1]	0.0	4	1	1	1
119877	1710	encode a receptor	[encoding a receptor]	0.0	3	1	1	1
119878	1710	cell growth in chronic leukemia	[cell growth in chronic leukemia]	0.0	5	1	1	1
119879	1710	self-perpetuated transcription	[self-perpetuated transcription]	0.0	2	1	1	1
119880	1710	chicken immature erythrocyte nuclear protein	[chicken immature erythrocyte nuclear proteins]	0.0	5	1	1	1
119881	1710	5-20% sucrose gradients,	[5-20% sucrose gradients,]	0.0	3	1	1	1
119882	1710	level of lipopolysaccharide lps	[levels of lipopolysaccharide LPS]	0.0	4	1	1	1
119883	1710	transcription transcription factor	[transcription transcription factors]	0.0	3	1	1	1
119884	1710	enzyme aldehyde dehydrogenase	[enzyme aldehyde dehydrogenase]	0.0	3	1	1	1
119885	1710	child-bearing-age woman	[child-bearing-age women]	0.0	2	2	2	1
119886	1710	positive cell line	[positive cell line]	0.0	3	1	1	1
119887	1710	latent hiv-1	[latent HIV-1]	0.0	2	1	1	1
119888	1710	tat single-chain intracellular antibody intrabody	[Tat single-chain intracellular antibody intrabody]	0.0	5	1	1	1
119889	1710	extreme conservation.	[extreme conservation.]	0.0	2	1	1	1
119890	1710	chaperoning protein	[chaperoning proteins]	0.0	2	1	1	1
119891	1710	normal human pulmonary alveolar macrophage	[Normal human pulmonary alveolar macrophages]	0.0	5	1	1	1
119892	1710	contribute to the expression of cd11b	[contributing to the expression of CD11b]	0.0	6	1	1	1
119893	1710	vitro footprinting	[vitro footprinting]	0.0	2	1	1	1
119894	1710	mutant form of the protein	[mutant forms of the protein]	0.0	5	1	1	1
119895	1710	candidate influence disease	[candidates influencing disease]	0.0	3	1	1	1
119896	1710	kappab phosphorothioate oligonucleotide	[kappaB phosphorothioate oligonucleotide]	0.0	3	1	1	1
119897	1710	ng/ml),	[ng/ml),]	0.0	1	1	1	1
119898	1710	cell-like b	[cell-like B]	0.0	2	1	1	1
119899	1710	complex with the electrophoretic mobility	[complex with the electrophoretic mobility]	0.0	5	1	1	1
119900	1710	parenteral corticosteroid methyl prednisolone	[parenteral corticosteroid methyl prednisolone]	0.0	4	1	1	1
119901	1710	platelet from untreated euthymic patient	[platelets from untreated euthymic patients]	0.0	5	1	1	1
119902	1710	interaction with tumor necrosis factor	[interaction with tumor necrosis factor]	0.0	5	1	1	1
119903	1710	mouse display expression	[mice displaying expression]	0.0	3	1	1	1
119904	1710	approach in all	[approaches in ALL]	0.0	3	1	1	1
119905	1710	diffuse large b-cell lymphoma	[diffuse large B-cell lymphomas]	0.0	4	1	1	1
119906	1710	stimulation rest T cell	[Stimulation resting T cells]	0.0	4	1	1	1
119907	1710	chronic rheumatic disease (12: four	[chronic rheumatic diseases (12: four]	0.0	5	1	1	1
119908	1710	several feature	[several features]	0.0	2	1	1	1
119909	1710	three cellular transcription factor creb/atf	[three cellular transcription factors CREB/ATF]	0.0	5	1	1	1
119910	1710	seven ebv tumour tissue	[seven EBV tumour tissues]	0.0	4	1	1	1
119911	1710	blood cell from patient cases)	[blood cells from patients cases)]	0.0	5	1	1	1
119912	1710	well-defined change	[well-defined changes]	0.0	2	1	1	1
119913	1710	receptor gr n-terminal domain	[receptor GR N-terminal domain]	0.0	4	1	1	1
119914	1710	alpha2 enhancer	[alpha2 enhancer]	0.0	2	1	1	1
119915	1710	pretreatment of "semimature" 5-day monocyte-derived macrophage	[Pretreatment of "semimature" 5-day monocyte-derived macrophages]	0.0	6	1	1	1
119916	1710	LBR a integral protein	[LBR an integral protein]	0.0	4	2	2	1
119917	1710	histogenetically distinct, subtype	[histogenetically distinct, subtype]	0.0	3	1	1	1
119918	1710	treatment with all-tran acid RA	[treatment with all-trans acid RA]	0.0	5	1	1	1
119919	1710	nonpeptidyl small molecule 247464	[nonpeptidyl small molecule 247464]	0.0	4	1	1	1
119920	1710	additional immunohistochemical staining with a panel	[additional immunohistochemical staining with a panel]	0.0	6	1	1	1
119921	1710	individual of major histocompatibility (mhc) haplotype	[individuals of major histocompatibility (MHC) haplotypes]	0.0	6	1	1	1
119922	1710	sse-like element in the region	[SSE-like element in the region]	0.0	5	1	1	1
119923	1710	form of Stat3	[form of Stat3]	0.0	3	2	2	1
119924	1710	expression in the nucleus	[Expression in the nucleus]	0.0	4	1	1	1
119925	1710	external stimuli.	[external stimuli.]	0.0	2	1	1	1
119926	1710	colony-stimumulatelany-stg factor colony-stimulating factor	[colony-stimulating factor colony-stimulating factor]	0.0	4	1	1	1
119927	1710	T negative regulation of transcription	[T negative regulation of transcription]	0.0	5	1	1	1
119928	1710	m 9-cis RA together	[M 9-cis RA together]	0.0	4	1	1	1
119929	1710	finally week after termination	[finally weeks after termination]	0.0	4	1	1	1
119930	1710	day precursor	[day precursors]	0.0	2	1	1	1
119931	1710	related divalent cation	[related divalent cations]	0.0	3	1	1	1
119932	1710	two alteration	[two alterations]	0.0	2	1	1	1
119933	1710	activity a activator	[activity a activator]	0.0	3	1	1	1
119934	1710	specific, activation of stat1 protein	[specific, activation of STAT1 protein]	0.0	5	1	1	1
119935	1710	stimulation in the presence of serum	[Stimulation in the presence of serum]	0.0	6	1	1	1
119936	1710	cover the entire surface days.	[covering the entire surface days.]	0.0	5	1	1	1
119937	1710	expression of dominant n17rac	[Expression of dominant N17Rac]	0.0	4	1	1	1
119938	1710	virus-infected t-cell	[virus-infected T-cells]	0.0	2	1	1	1
119939	1710	6 h peak	[6 h peaks]	0.0	3	1	1	1
119940	1710	possibly lymphoid organ	[possibly lymphoid organs]	0.0	3	1	1	1
119941	1710	primary cd8+ CTL response	[primary CD8+ CTL response]	0.0	4	1	1	1
119942	1710	failure rate (2.6%	[failure rate (2.6%]	0.0	3	1	1	1
119943	1710	ng/mL), interleukin-3 ng/mL),	[ng/mL), interleukin-3 ng/mL),]	0.0	3	1	1	1
119944	1710	susceptibility in large case-control study	[susceptibility in large case-control studies]	0.0	5	1	1	1
119945	1710	diameter, corresponding to a increase	[diameter, corresponding to a increase]	0.0	5	1	1	1
119946	1710	concentration below 250 microm	[concentrations below 250 microM]	0.0	4	1	1	1
119947	1710	proliferation of the unstimulated T cell	[proliferation of the unstimulated T cells]	0.0	6	1	1	1
119948	1710	peripheral leucocyte in patient	[peripheral leucocytes in patients]	0.0	4	1	1	1
119949	1710	human a promoter region	[humans a promoter region]	0.0	4	1	1	1
119950	1710	lead in U937 cell	[leading in U937 cells]	0.0	4	1	1	1
119951	1710	human toll-like receptor	[Human Toll-like receptor]	0.0	3	1	1	1
119952	1710	biol chem	[Biol Chem]	0.0	2	1	1	1
119953	1710	labeling with [35s]methionine	[labeling with [35S]methionine]	0.0	3	1	1	1
119954	1710	human lymphoblastic t-cell line	[human lymphoblastic T-cell line]	0.0	4	1	1	1
119955	1710	common finding the infiltration	[common finding the infiltration]	0.0	4	1	1	1
119956	1710	mass of 67 kilodalton	[mass of 67 kilodaltons]	0.0	4	1	1	1
119957	1710	sufficient number of functional receptor	[sufficient numbers of functional receptors]	0.0	5	1	1	1
119958	1710	cell by IFN NK cell	[cells by IFN NK cells]	0.0	5	1	1	1
119959	1710	mass of 41 kilodalton	[mass of 41 kilodaltons]	0.0	4	1	1	1
119960	1710	use amount	[using amounts]	0.0	2	1	1	1
119961	1710	3,5,3'-triiodothyronine receptor t3r	[3,5,3'-triiodothyronine receptors T3R]	0.0	3	1	1	1
119962	1710	total of comparison	[total of comparisons]	0.0	3	1	1	1
119963	1710	stage of the intrathymic maturation	[stages of the intrathymic maturation]	0.0	5	1	1	1
119964	1710	definition of region	[definition of regions]	0.0	3	1	1	1
119965	1710	flank DNA of the gene	[flanking DNA of the gene]	0.0	5	1	1	1
119966	1710	parental hl-60 subclone	[parental HL-60 subclones]	0.0	3	1	1	1
119967	1710	study of regimen	[studies of regimens]	0.0	3	1	1	1
119968	1710	rapidly migrate	[rapidly migrating]	0.0	2	1	1	1
119969	1710	fk506-sensitive pathway	[FK506-sensitive pathway]	0.0	2	1	1	1
119970	1710	week after subtotal thyroidectomy	[weeks after subtotal thyroidectomy]	0.0	4	1	1	1
119971	1710	leukotriene b4 LTB4 generation by neutrophil	[leukotriene B4 LTB4 generation by neutrophils]	0.0	6	1	1	1
119972	1710	release of nf-kappab/rel protein	[release of NF-kappaB/Rel proteins]	0.0	4	1	1	1
119973	1710	transcriptional hierarchy	[transcriptional hierarchy]	0.0	2	1	1	1
119974	1710	dose as high	[doses as high]	0.0	3	1	1	1
119975	1710	endogenous virus,	[endogenous virus,]	0.0	2	1	1	1
119976	1710	DR-nm23	[DR-nm23]	0.0	1	1	1	1
119977	1710	CD40 ligand cd40l	[CD40 ligand CD40L]	0.0	3	1	1	1
119978	1710	camp early repressor	[cAMP early repressor]	0.0	3	1	1	1
119979	1710	Intranuclear delivery	[Intranuclear delivery]	0.0	2	1	1	1
119980	1710	multiple activity of retinoic acid	[multiple activities of retinoic acid]	0.0	5	1	1	1
119981	1710	ubiquitin-carrier protein	[ubiquitin-carrier protein]	0.0	2	1	1	1
119982	1710	apparent affinity of the receptor	[apparent affinity of the receptor]	0.0	5	1	1	1
119983	1710	low stat6 activity	[low STAT6 activity]	0.0	3	1	1	1
119984	1710	10(-9) m/l calcitriol	[10(-9) M/l calcitriol]	0.0	3	1	1	1
119985	1710	effect than the rapid responses.	[effects than the rapid responses.]	0.0	5	1	1	1
119986	1710	tnf-treated vein cell HUVECs	[TNF-treated vein cells HUVECs]	0.0	4	1	1	1
119987	1710	heavy chain igh	[heavy chain IgH]	0.0	3	1	1	1
119988	1710	part to activity	[part to activity]	0.0	3	1	1	1
119989	1710	reporter construct contain	[reporter construct containing]	0.0	3	1	1	1
119990	1710	cell type-specific pattern	[cell type-specific pattern]	0.0	3	1	1	1
119991	1710	multigene family, gata-3	[multigene family, GATA-3]	0.0	3	1	1	1
119992	1710	basal level of expression	[basal level of expression]	0.0	4	1	1	1
119993	1710	treatment of promonocytic u1 cell	[Treatment of promonocytic U1 cells]	0.0	5	1	1	1
119994	1710	block KV channel	[blocking KV channels]	0.0	3	1	1	1
119995	1710	concentration of D3 receptor	[concentration of D3 receptors]	0.0	4	1	1	1
119996	1710	overexpression of GRbeta in Jurkat cell	[overexpression of GRbeta in Jurkat cells]	0.0	6	1	1	1
119997	1710	analysis of mutation	[analyses of mutations]	0.0	3	1	1	1
119998	1710	JNK phosphorylation site	[JNK phosphorylation sites]	0.0	3	1	1	1
119999	1710	Specific binding at different level	[Specific binding at different levels]	0.0	5	1	1	1
120000	1710	component of factor	[component of factor]	0.0	3	1	1	1
120001	1710	receptor mrna expression (p	[receptor mRNA expression (P]	0.0	4	1	1	1
120002	1710	human mammary cell grow	[human mammary cells growing]	0.0	4	1	1	1
120003	1710	resemble the G receptor	[resembling the G receptor]	0.0	4	1	1	1
120004	1710	prolong survival	[prolonging survival]	0.0	2	1	1	1
120005	1710	interaction between positive transcriptional regulatory element	[interactions between positive transcriptional regulatory elements]	0.0	6	1	1	1
120006	1710	day fetal hematopoietic liver	[day fetal hematopoietic liver]	0.0	4	1	1	1
120007	1710	factor (NF)-AT AP-1/Octamer	[factor (NF)-AT AP-1/Octamer]	0.0	3	1	1	1
120008	1710	relevance of the observation	[relevance of the observation]	0.0	4	1	1	1
120009	1710	site originate bp	[sites originating bp]	0.0	3	1	1	1
120010	1710	10(-7) m dexamethasone	[10(-7) M dexamethasone]	0.0	3	1	1	1
120011	1710	respect use a whole-cell assay	[respect using a whole-cell assay]	0.0	5	1	1	1
120012	1710	Surprisingly, overexpression in Jurkat cell	[Surprisingly, overexpression in Jurkat cells]	0.0	5	1	1	1
120013	1710	peripheral blood lymphocyte asthma BA	[peripheral blood lymphocytes asthma BA]	0.0	5	1	1	1
120014	1710	12 hyperplasia fh	[12 hyperplasia FH]	0.0	3	1	1	1
120015	1710	epithelial manner	[epithelial manner]	0.0	2	1	1	1
120016	1710	exposure of cell to condition	[Exposure of cells to conditions]	0.0	5	1	1	1
120017	1710	suggest detectable	[suggesting detectable]	0.0	2	1	1	1
120018	1710	molecular mass of kD.	[molecular mass of kD.]	0.0	4	1	1	1
120019	1710	mechanism for constitutive induction	[mechanism for constitutive induction]	0.0	4	1	1	1
120020	1710	analysis take age-related change	[analysis taking age-related changes]	0.0	4	1	1	1
120021	1710	mouse Ig enhancer	[mouse Ig enhancer]	0.0	3	1	1	1
120022	1710	interleukin-4 receptor	[interleukin-4 receptor]	0.0	2	1	1	1
120023	1710	response to a antigenic challenge	[response to an antigenic challenge]	0.0	5	1	1	1
120024	1710	NF-kappa b1 gene expression,	[NF-kappa B1 gene expression,]	0.0	4	1	1	1
120025	1710	inhibit the activity of transcription factor	[inhibiting the activity of transcription factors]	0.0	6	1	1	1
120026	1710	oxygen scavenger enzyme	[oxygen scavenger enzymes]	0.0	3	1	1	1
120027	1710	four domain of chromatin structure	[four domains of chromatin structure]	0.0	5	1	1	1
120028	1710	cellular electrolyte transport	[cellular electrolyte transport]	0.0	3	1	1	1
120029	1710	demonstrate the potent activity	[demonstrating the potent activity]	0.0	4	1	1	1
120030	1710	im-9 lymphocyte	[IM-9 lymphocytes]	0.0	2	1	1	1
120031	1710	encode the ap-1 protein	[encoding the AP-1 proteins]	0.0	4	1	1	1
120032	1710	pathway in T lymphocyte	[pathways in T lymphocytes]	0.0	4	1	1	1
120033	1710	center cell	[center cells]	0.0	2	1	1	1
120034	1710	therefore, activation	[Therefore, activation]	0.0	2	3	3	1
120035	1710	mn-dependent superoxide dismutase Mn-SOD	[Mn-dependent superoxide dismutase Mn-SOD]	0.0	4	1	1	1
120036	1710	317 base pair cis-acting element	[317 base pair cis-acting element]	0.0	5	1	1	1
120037	1710	intrahepatic follicle	[intrahepatic follicles]	0.0	2	1	1	1
120038	1710	normal peripheral blood lymphocyte sample	[normal peripheral blood lymphocyte samples]	0.0	5	1	1	1
120039	1710	calm	[CALM]	0.0	1	1	1	1
120040	1710	accord to exercise protocols: the step-wise	[according to exercise protocols: the step-wise]	0.0	6	1	1	1
120041	1710	new analogue of up	[new analogue of UP]	0.0	4	1	1	1
120042	1710	pronounced, of c-rel	[pronounced, of c-Rel]	0.0	3	1	1	1
120043	1710	regulation in b-cell line	[regulation in B-cell lines]	0.0	4	1	1	1
120044	1710	identical zinc-finger domain	[identical zinc-finger domains]	0.0	3	1	1	1
120045	1710	corticosteroid methyl prednisolone mg/day)	[corticosteroid methyl prednisolone mg/day)]	0.0	4	1	1	1
120046	1710	effect on this promoter	[effect on this promoter]	0.0	4	1	1	1
120047	1710	hematopoletic differentiation	[hematopoletic differentiation]	0.0	2	1	1	1
120048	1710	recombinant fragment lps E-selectin expression	[recombinant fragment LPS E-selectin expression]	0.0	5	1	1	1
120049	1710	patient er	[patients ER]	0.0	2	1	1	1
120050	1710	repression by the region	[repression by the region]	0.0	4	1	1	1
120051	1710	analysis by blotting of population	[analysis by blotting of populations]	0.0	5	1	1	1
120052	1710	rat vascular muscle cell vsmc	[rat vascular muscle cells VSMCs]	0.0	5	1	1	1
120053	1710	response region	[response region]	0.0	2	1	1	1
120054	1710	evaluation of tissue	[evaluation of tissues]	0.0	3	1	1	1
120055	1710	estrogen receptor in patient	[estrogen receptor in patients]	0.0	4	1	1	1
120056	1710	include Src homology	[including Src homology]	0.0	3	1	1	1
120057	1710	microtubular assembly	[microtubular assembly]	0.0	2	1	1	1
120058	1710	possible enhancement of dna-binding of e2f	[possible enhancement of DNA-binding of E2F]	0.0	6	1	1	1
120059	1710	further evidence important	[further evidence important]	0.0	3	1	1	1
120060	1710	effect of alpha-tocopherol on event	[effect of alpha-tocopherol on event]	0.0	5	1	1	1
120061	1710	anoxia/reoxygenation a/r	[anoxia/reoxygenation A/R]	0.0	2	1	1	1
120062	1710	umbilical arterial endothelial cell	[umbilical arterial endothelial cells]	0.0	4	1	1	1
120063	1710	expression of the alpha-chain	[Expression of the alpha-chain]	0.0	4	1	1	1
120064	1710	use NFATp- antibody	[using NFATp- antibodies]	0.0	3	1	1	1
120065	1710	potent transactivation	[potent transactivation]	0.0	2	1	1	1
120066	1710	activity of granulocyte-macrophage factor gm-csf	[activity of granulocyte-macrophage factor GM-CSF]	0.0	5	1	1	1
120067	1710	(gamma)	[(gamma)]	0.0	1	1	1	1
120068	1710	abnormal nf-kappa b activity	[Abnormal NF-kappa B activity]	0.0	4	1	1	1
120069	1710	pre-b-cell line	[pre-B-cell lines]	0.0	2	1	1	1
120070	1710	interaction of thymocyte with epithelial cell	[interaction of thymocytes with epithelial cells]	0.0	6	1	1	1
120071	1710	contain cysteine	[containing cysteine]	0.0	2	1	1	1
120072	1710	icam-1 cd11b/cd18	[ICAM-1 CD11b/CD18]	0.0	2	1	1	1
120073	1710	phorbol ester cell differentiation	[Phorbol ester cell differentiation]	0.0	4	1	1	1
120074	1710	ttca	[TTCA]	0.0	1	1	1	1
120075	1710	percentage of leukemia	[percentage of leukemias]	0.0	3	1	1	1
120076	1710	nos iNOS	[NOS iNOS]	0.0	2	1	1	1
120077	1710	competitive radioassay use [3H]-dexamethasone	[competitive radioassay using [3H]-dexamethasone]	0.0	4	1	1	1
120078	1710	high level of cl	[high levels of CL]	0.0	4	1	1	1
120079	1710	mobility of kda	[mobility of kDa]	0.0	3	1	1	1
120080	1710	clinical responsiveness to prednisolone 0.01).	[clinical responsiveness to prednisolone 0.01).]	0.0	5	1	1	1
120081	1710	pld activation under conditions.	[PLD activation under conditions.]	0.0	4	1	1	1
120082	1710	degree of conservation	[degree of conservation]	0.0	3	1	1	1
120083	1710	microM, 72 h),	[microM, 72 h),]	0.0	3	1	1	1
120084	1710	transient cotransfection of tat cDNA	[Transient cotransfection of tat cDNA]	0.0	5	1	1	1
120085	1710	less factor-kappa B/Rel induction	[lesser factor-kappa B/Rel induction]	0.0	4	1	1	1
120086	1710	modification and/or	[modification and/or]	0.0	2	1	1	1
120087	1710	anti-early antigen capsid antigen	[anti-early antigen capsid antigen]	0.0	4	1	1	1
120088	1710	insert sequence	[inserting sequences]	0.0	2	1	1	1
120089	1710	clearly a b-cell-specific transcription factor	[clearly a B-cell-specific transcription factor]	0.0	5	1	1	1
120090	1710	part, follow activation	[part, following activation]	0.0	3	1	1	1
120091	1710	induction in monocyte-like (U937) cell	[induction in monocyte-like (U937) cells]	0.0	5	1	1	1
120092	1710	failure of bob.1/obf.1	[failure of BOB.1/OBF.1]	0.0	3	1	1	1
120093	1710	pma-induced il-2	[PMA-induced IL-2]	0.0	2	1	1	1
120094	1710	(il-1ra)	[(IL-1ra)]	0.0	1	1	1	1
120095	1710	obligatory bacterium	[obligatory bacterium]	0.0	2	1	1	1
120096	1710	component of this system	[components of this system]	0.0	4	1	1	1
120097	1710	such as muscle contraction	[such as muscle contraction]	0.0	4	1	1	1
120098	1710	possible dysregulation	[possible dysregulation]	0.0	2	1	1	1
120099	1710	high level of mrna	[high levels of mRNA]	0.0	4	1	1	1
120100	1710	peripheral venous blood from healthy donor	[peripheral venous blood from healthy donors]	0.0	6	1	1	1
120101	1710	hiv-1 transactivator tat	[HIV-1 transactivator TAT]	0.0	3	1	1	1
120102	1710	ly294002 a inhibitor	[LY294002 a inhibitor]	0.0	3	1	1	1
120103	1710	AP-2 response element	[AP-2 response elements]	0.0	3	1	1	1
120104	1710	however, target	[However, targets]	0.0	2	1	1	1
120105	1710	human blood cell pbmc response	[human blood cell PBMC responses]	0.0	5	1	1	1
120106	1710	inhibitory effect on IL-2 promoter	[inhibitory effect on IL-2 promoter]	0.0	5	1	1	1
120107	1710	two b transcription factor	[two B transcription factors]	0.0	4	1	1	1
120108	1710	RB gene	[RB gene]	0.0	2	1	1	1
120109	1710	significant amount of il-8	[significant amounts of IL-8]	0.0	4	1	1	1
120110	1710	6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	4	1	1	1
120111	1710	element the ap-1 protein	[elements the AP-1 protein]	0.0	4	1	1	1
120112	1710	carboxy-terminal half	[carboxy-terminal half]	0.0	2	1	1	1
120113	1710	induction by phorbol ester PMA	[induction by phorbol esters PMA]	0.0	5	1	1	1
120114	1710	overlapping mechanism	[overlapping mechanisms]	0.0	2	1	1	1
120115	1710	level of tcf-1 alpha mrna	[levels of TCF-1 alpha mRNA]	0.0	5	1	1	1
120116	1710	isolation of a transcript encode	[isolation of an transcript encoding]	0.0	5	1	1	1
120117	1710	vitamin New World primate cell	[vitamin New World primate cells]	0.0	5	1	1	1
120118	1710	effect in a fashion.	[effects in an fashion.]	0.0	4	1	1	1
120119	1710	BCL-6 mutation evidence	[BCL-6 mutations evidence]	0.0	3	1	1	1
120120	1710	only, site	[only, site]	0.0	2	1	1	1
120121	1710	regulation in peripheral blood mononuclear cell	[Regulation in peripheral blood mononuclear cells]	0.0	6	1	1	1
120122	1710	mechanism of expression	[mechanism of expression]	0.0	3	1	1	1
120123	1710	T delta element	[T delta element]	0.0	3	1	1	1
120124	1710	TGF-beta signal pathway lead	[TGF-beta signaling pathway leading]	0.0	4	1	1	1
120125	1710	I type interferon	[I type interferons]	0.0	3	1	1	1
120126	1710	apparent variation in gr	[apparent variation in GR]	0.0	4	1	1	1
120127	1710	mrna (75 versus minutes).	[mRNA (75 vs minutes).]	0.0	4	1	1	1
120128	1710	1.3E2 cell line	[1.3E2 cell line]	0.0	3	1	1	1
120129	1710	tumor necrosis factor cytokine	[tumor necrosis factor cytokines]	0.0	4	1	1	1
120130	1710	single-cell level	[single-cell level]	0.0	2	1	1	1
120131	1710	CD30 degradation	[CD30 degradation]	0.0	2	1	1	1
120132	1710	self-renewing b-1 cell	[self-renewing B-1 cells]	0.0	3	1	1	1
120133	1710	unique biological function	[unique biological function]	0.0	3	1	1	1
120134	1710	important role in the production	[important role in the production]	0.0	5	1	1	1
120135	1710	antisera contain titre antibody	[antisera containing titre antibodies]	0.0	4	1	1	1
120136	1710	have molecular weight in the range	[having molecular weights in the range]	0.0	6	1	1	1
120137	1710	10(-7) m all-tran acid	[10(-7) M all-trans acid]	0.0	4	1	1	1
120138	1710	gamma(c) domain	[gamma(c) domain]	0.0	2	1	1	1
120139	1710	myeloid cell neutrophilic granulocyte pmn	[myeloid cells neutrophilic granulocytes PMN]	0.0	5	1	1	1
120140	1710	bipartite nuclear localization signal	[bipartite nuclear localization signal]	0.0	4	1	1	1
120141	1710	undifferentiated endometrial stromal cell	[undifferentiated endometrial stromal cells]	0.0	4	1	1	1
120142	1710	METHODS: ten atopic subject	[METHODS: Ten atopic subjects]	0.0	4	1	1	1
120143	1710	human class trans-activator	[human class trans-activator]	0.0	3	1	1	1
120144	1710	activity of the igh enhancer	[activity of the IgH enhancer]	0.0	5	1	1	1
120145	1710	MZF-1 regulation	[MZF-1 regulation]	0.0	2	1	1	1
120146	1710	thereby provide a mechanism for effect	[thereby providing an mechanism for effects]	0.0	6	1	1	1
120147	1710	undifferentiated SCC cell line	[undifferentiated SCC cell line]	0.0	4	1	1	1
120148	1710	two drugs,	[two drugs,]	0.0	2	1	1	1
120149	1710	severely defective phenotype.	[severely defective phenotype.]	0.0	3	1	1	1
120150	1710	unidentified factor lbf2	[unidentified factors LBF2]	0.0	3	1	1	1
120151	1710	p38 mapk inhibitor SK&F	[p38 MAPk inhibitor SK&F]	0.0	4	1	1	1
120152	1710	only a region	[Only a region]	0.0	3	1	1	1
120153	1710	wt19 cell	[WT19 cells]	0.0	2	1	1	1
120154	1710	family receptor level	[family receptor levels]	0.0	3	1	1	1
120155	1710	ng cell	[ng cells]	0.0	2	1	1	1
120156	1710	receptor status s-phase fraction	[receptor status S-phase fraction]	0.0	4	1	1	1
120157	1710	endothelial monolayer	[endothelial monolayers]	0.0	2	1	1	1
120158	1710	76 kD slp-76	[76 kD SLP-76]	0.0	3	1	1	1
120159	1710	transcription difference	[Transcription differences]	0.0	2	1	1	1
120160	1710	block in maturation	[block in maturation]	0.0	3	1	1	1
120161	1710	61 pmol/L; in pregnant woman	[61 pmol/L; in pregnant women]	0.0	5	1	1	1
120162	1710	brlf1 protein	[BRLF1 protein]	0.0	2	1	1	1
120163	1710	fluorescence anisotropy dph	[fluorescence anisotropy DPH]	0.0	3	1	1	1
120164	1710	stimulation il-2	[stimulation IL-2]	0.0	2	1	1	1
120165	1710	transcript contain deletion	[transcripts containing deletions]	0.0	3	1	1	1
120166	1710	one subunit the b2 isoform	[one subunit the B2 isoform]	0.0	5	1	1	1
120167	1710	four nuclear protein complex a factor	[four nuclear protein complexes a factor]	0.0	6	1	1	1
120168	1710	infection of tat- immunodeficiency virus	[Infection of Tat- immunodeficiency viruses]	0.0	5	1	1	1
120169	1710	factor from non-transformed	[factors from non-transformed]	0.0	3	1	1	1
120170	1710	contain high level	[containing high levels]	0.0	3	1	1	1
120171	1710	adenovirus type during many year	[adenovirus types during many years]	0.0	5	1	1	1
120172	1710	immunity of T/NK cell	[immunity of T/NK cells]	0.0	4	1	1	1
120173	1710	combination with colony-stimulating factor	[combination with colony-stimulating factor]	0.0	4	1	1	1
120174	1710	cd8int/-	[CD8int/-]	0.0	1	2	2	1
120175	1710	T cell express cd40l	[T cells expressing CD40L]	0.0	4	1	1	1
120176	1710	element of the interferon-gamma promoter	[element of the interferon-gamma promoter]	0.0	5	1	1	1
120177	1710	possible use for the treatment	[possible use for the treatment]	0.0	5	1	1	1
120178	1710	suggest a physical association	[suggesting a physical association]	0.0	4	1	1	1
120179	1710	fall into that category	[falling into those categories]	0.0	4	1	1	1
120180	1710	capacity of IL-4	[capacity of IL-4]	0.0	3	1	1	1
120181	1710	TFIID binding site	[TFIID binding site]	0.0	3	1	1	1
120182	1710	specific gene expression in monocyte	[specific gene expression in monocytes]	0.0	5	1	1	1
120183	1710	replication by phorbol ester	[replication by phorbol ester]	0.0	4	1	1	1
120184	1710	cytomegalovirus ul44 gene coding	[cytomegalovirus UL44 gene coding]	0.0	4	1	1	1
120185	1710	sixteen patient (range	[Sixteen patients (ranging]	0.0	3	1	1	1
120186	1710	use a dominant negative ikappabalpha	[using a dominant negative IkappaBalpha]	0.0	5	1	1	1
120187	1710	tax gene product I	[tax gene product I]	0.0	4	1	1	1
120188	1710	inhibitor of the protease	[inhibitor of the protease]	0.0	4	1	1	1
120189	1710	delimitation	[delimitation]	0.0	1	1	1	1
120190	1710	inducer of b activity	[inducers of B activity]	0.0	4	2	2	1
120191	1710	immortalization of b lymphocyte	[immortalization of B lymphocytes]	0.0	4	1	1	1
120192	1710	early wk to mo) RA	[early wk to mo) RA]	0.0	5	1	1	1
120193	1710	PGE2 activation effect	[PGE2 activation effect]	0.0	3	1	1	1
120194	1710	recognition by lymphocyte	[recognition by lymphocyte]	0.0	3	1	1	1
120195	1710	transient short-term expression	[Transient short-term expression]	0.0	3	1	1	1
120196	1710	contrast, several p85 allele	[contrast, several p85 alleles]	0.0	4	1	1	1
120197	1710	region of both isoform	[region of both isoforms]	0.0	4	1	1	1
120198	1710	promoter in T lymphocyte	[promoter in T lymphocytes]	0.0	4	1	1	1
120199	1710	property of the compound zk161422	[properties of the compounds ZK161422]	0.0	5	1	1	1
120200	1710	dna-binding complex in IM-9 extract	[DNA-binding complex in IM-9 extracts]	0.0	5	1	1	1
120201	1710	lat in detergent lysate	[LAT in detergent lysates]	0.0	4	1	1	1
120202	1710	induction of cytokine	[induction of cytokine]	0.0	3	1	1	1
120203	1710	mononuclear leucocyte recruitment	[mononuclear leucocyte recruitment]	0.0	3	1	1	1
120204	1710	domain of il-9ralpha other	[domains of IL-9Ralpha other]	0.0	4	1	1	1
120205	1710	killer lysis	[killer lysis]	0.0	2	1	1	1
120206	1710	co-stimulation occupancy	[Co-stimulation occupancy]	0.0	2	1	1	1
120207	1710	activation in that inducibility	[activation in that inducibility]	0.0	4	1	1	1
120208	1710	t1/2 of hour	[t1/2 of hr]	0.0	3	1	1	1
120209	1710	novel taf of 105 kda	[novel TAF of 105 kDa]	0.0	5	1	1	1
120210	1710	hierarchy of hnf	[hierarchy of HNFs]	0.0	3	1	1	1
120211	1710	mycoplasma high-molecular-weight material	[Mycoplasma high-molecular-weight material]	0.0	3	1	1	1
120212	1710	(ic50 381 ng/ml)	[(IC50 381 ng/mL)]	0.0	3	1	1	1
120213	1710	relationship between the activation	[relationship between the activation]	0.0	4	1	1	1
120214	1710	Differential regulation in human NK cell	[Differential regulation in human NK cells]	0.0	6	1	1	1
120215	1710	production of active oxygen species	[production of active oxygen species]	0.0	5	1	1	1
120216	1710	share similar DNA binding specificity	[sharing similar DNA binding specificities]	0.0	5	1	1	1
120217	1710	CD40L l-cell	[CD40L L-cells]	0.0	2	1	1	1
120218	1710	subject down-regulated Bmax	[subjects down-regulated Bmax]	0.0	3	1	1	1
120219	1710	organisation exon of 132,	[organisation exons of 132,]	0.0	4	1	1	1
120220	1710	form of calcineurin substitute	[form of calcineurin substitutes]	0.0	4	1	1	1
120221	1710	binding-protein	[binding-protein]	0.0	1	1	1	1
120222	1710	tight complex with different class	[tight complexes with different classes]	0.0	5	1	1	1
120223	1710	increase in the mrna level	[increase in the mRNA levels]	0.0	5	1	1	1
120224	1710	concentration of dep- pah	[concentrations of DEP- PAHs]	0.0	4	1	1	1
120225	1710	gp 160 nuclear extract	[gp 160 nuclear extracts]	0.0	4	1	1	1
120226	1710	transcriptional activation on the dprl promoter	[transcriptional activation on the dPRL promoter]	0.0	6	1	1	1
120227	1710	lytic transglycosylase	[lytic transglycosylase]	0.0	2	1	1	1
120228	1710	patient with major disorder	[patients with major disorder]	0.0	4	1	1	1
120229	1710	treatment of extract from this cell	[treatment of extracts from these cells]	0.0	6	1	1	1
120230	1710	low the/thf (0.24;	[low THE/THF (0.24;]	0.0	3	1	1	1
120231	1710	further setting of pathology	[further settings of pathology]	0.0	4	1	1	1
120232	1710	gata-1 DNA binding	[GATA-1 DNA binding]	0.0	3	1	1	1
120233	1710	practice,	[practice,]	0.0	1	1	1	1
120234	1710	lipopolysaccharide increase	[lipopolysaccharide increases]	0.0	2	1	1	1
120235	1710	activation of the nf-kappab -induce kinase	[activation of the NF-kappaB -inducing kinase]	0.0	6	1	1	1
120236	1710	significant implication	[significant implications]	0.0	2	1	1	1
120237	1710	distal factor (NF)-AT NF-AT AP-1/Octamer UPS	[distal factor (NF)-AT NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
120238	1710	differentiation of U937 lymphoma cell	[differentiation of U937 lymphoma cells]	0.0	5	1	1	1
120239	1710	T transcription factor interact	[T transcription factor interacting]	0.0	4	1	1	1
120240	1710	progression of type	[progression of types]	0.0	3	2	2	1
120241	1710	two polypeptide of 50 kD	[two polypeptides of 50 kD]	0.0	5	1	1	1
120242	1710	time-dependent, activation	[time-dependent, activation]	0.0	2	1	1	1
120243	1710	135(oh)2d3 modulation	[1,25(OH)2D3 modulation]	0.0	2	1	1	1
120244	1710	function in the late phase	[function in the late phase]	0.0	5	1	1	1
120245	1710	Sp1 protein in expression	[Sp1 proteins in expression]	0.0	4	1	1	1
120246	1710	cell-specific transcriptional activator	[cell-specific transcriptional activator]	0.0	3	1	1	1
120247	1710	Nonradioactive quantification during differentiation	[Nonradioactive quantification during differentiation]	0.0	4	1	1	1
120248	1710	level the controversy	[level the controversy]	0.0	3	1	1	1
120249	1710	Maximal accumulation messenger rna (mrna)	[Maximal accumulation messenger RNA (mRNA)]	0.0	5	1	1	1
120250	1710	enhancer with domains, a	[enhancer with domains, A]	0.0	4	1	1	1
120251	1710	homologue,	[homologue,]	0.0	1	1	1	1
120252	1710	context of upstream sequence	[context of upstream sequences]	0.0	4	1	1	1
120253	1710	nuclear t3 binding capacity MBC	[nuclear T3 binding capacity MBC]	0.0	5	1	1	1
120254	1710	protein responsive to DNA damage	[proteins responsive to DNA damage]	0.0	5	1	1	1
120255	1710	consist of Mr	[consisting of Mr]	0.0	3	1	1	1
120256	1710	60 subject	[60 subjects]	0.0	2	1	1	1
120257	1710	most T cell	[most T cells]	0.0	3	1	1	1
120258	1710	accumulation of b cell	[accumulation of B cells]	0.0	4	1	1	1
120259	1710	anti-igm stimulation	[anti-IgM stimulation]	0.0	2	1	1	1
120260	1710	distinct cellular transcription factor creb/atf	[distinct cellular transcription factors CREB/ATF]	0.0	5	1	1	1
120261	1710	lymphocyte from individual	[lymphocytes from individuals]	0.0	3	1	1	1
120262	1710	control (HIV) long repeat	[control (HIV) long repeat]	0.0	4	1	1	1
120263	1710	200 mu/l upper limit	[200 mU/L upper limit]	0.0	4	1	1	1
120264	1710	ets-1 function as a activator	[ets-1 functions as a activator]	0.0	5	1	1	1
120265	1710	expression of IRF-1 a activator	[expression of IRF-1 an activator]	0.0	5	1	1	1
120266	1710	immortalization of human b-cell	[immortalization of human B-cells]	0.0	4	1	1	1
120267	1710	dose-related increase	[dose-related increase]	0.0	2	1	1	1
120268	1710	-regulation	[-regulation]	0.0	1	2	2	1
120269	1710	Study into the effect during evidence	[Studies into the effect during evidence]	0.0	6	1	1	1
120270	1710	induction in a20 b cell	[induction in A20 B cells]	0.0	5	1	1	1
120271	1710	variety of cells.	[variety of cells.]	0.0	3	1	1	1
120272	1710	phi) for h	[phi) for h]	0.0	3	1	1	1
120273	1710	growth factor-B pdgf-b	[growth factor-B PDGF-B]	0.0	3	1	1	1
120274	1710	peripheral blood cell response	[peripheral blood cell responses]	0.0	4	1	1	1
120275	1710	(54%) clone	[(54%) clones]	0.0	2	1	1	1
120276	1710	subline cell	[sublining cells]	0.0	2	1	1	1
120277	1710	human colony-stimulating factor receptor	[human colony-stimulating factor receptor]	0.0	4	1	1	1
120278	1710	eosinophilias	[eosinophilias]	0.0	1	2	2	1
120279	1710	b alpha evidence	[B alpha evidence]	0.0	3	1	1	1
120280	1710	stress lead to transendothelial migration	[stress leading to transendothelial migration]	0.0	5	1	1	1
120281	1710	percent of sertraline responder	[percent of sertraline responders]	0.0	4	1	1	1
120282	1710	lack stat3	[lacking STAT3]	0.0	2	1	1	1
120283	1710	mechanism lead to the conversion	[mechanism leading to the conversion]	0.0	5	1	1	1
120284	1710	distinct binding site	[distinct binding sites]	0.0	3	1	1	1
120285	1710	hie level	[HIE levels]	0.0	2	1	1	1
120286	1710	angle	[angle]	0.0	1	1	1	1
120287	1710	secretion of monocyte protein-1 mcp-1	[secretion of monocyte protein-1 MCP-1]	0.0	5	1	1	1
120288	1710	il-1 convert enzyme	[IL-1 converting enzyme]	0.0	3	1	1	1
120289	1710	identification of a physical interaction	[Identification of a physical interaction]	0.0	5	1	1	1
120290	1710	c-fo by CD40	[c-fos by CD40]	0.0	3	1	1	1
120291	1710	patient (n	[Patients (n]	0.0	2	1	1	1
120292	1710	inhibitor of pp1	[inhibitors of PP1]	0.0	3	1	1	1
120293	1710	cloning from cell	[cloning from cells]	0.0	3	1	1	1
120294	1710	in-vitro-stimulated cord blood	[in-vitro-stimulated cord blood]	0.0	3	1	1	1
120295	1710	CD40 cross-link	[CD40 cross-linking]	0.0	2	1	1	1
120296	1710	Class cell MHC class gene activation	[Class cell MHC class gene activation]	0.0	6	1	1	1
120297	1710	different gene important to biology,	[different genes important to biology,]	0.0	5	1	1	1
120298	1710	rarely express er	[rarely express ER]	0.0	3	1	1	1
120299	1710	multiple sites.	[multiple sites.]	0.0	2	1	1	1
120300	1710	support replication	[supporting replication]	0.0	2	1	1	1
120301	1710	activation motif in both regions.	[activation motifs in both regions.]	0.0	5	1	1	1
120302	1710	g-csf 8% dead cell at day	[G-CSF 8% dead cells at day]	0.0	6	1	1	1
120303	1710	dual action	[Dual action]	0.0	2	1	1	1
120304	1710	J.Babin,	[J.Babin,]	0.0	1	1	1	1
120305	1710	inducible DNA binding	[inducible DNA binding]	0.0	3	1	1	1
120306	1710	depressive disorder patient	[depressive disorder patients]	0.0	3	1	1	1
120307	1710	proteolysis of alphaiibh	[proteolysis of alphaIIbH]	0.0	3	1	1	1
120308	1710	year of life,	[year of life,]	0.0	3	1	1	1
120309	1710	dominant effector	[dominant effector]	0.0	2	1	1	1
120310	1710	appropriate site	[appropriate site]	0.0	2	1	1	1
120311	1710	viral transcriptional pattern	[viral transcriptional pattern]	0.0	3	1	1	1
120312	1710	level, expression	[level, expression]	0.0	2	1	1	1
120313	1710	mechanism of androgen insensitivity	[mechanism of androgen insensitivity]	0.0	4	1	1	1
120314	1710	tgf-alpha production	[TGF-alpha production]	0.0	2	1	1	1
120315	1710	carboxy-terminal negative regulatory domain	[carboxy-terminal negative regulatory domain]	0.0	4	1	1	1
120316	1710	inhibitory factor.	[inhibitory factor.]	0.0	2	1	1	1
120317	1710	potent inhibitor kinase upstream	[potent inhibitors kinase upstream]	0.0	4	1	1	1
120318	1710	prolonged exercise	[prolonged exercises]	0.0	2	1	1	1
120319	1710	form of motor neuron disease,	[form of motor neuron disease,]	0.0	5	1	1	1
120320	1710	tyrosine hydroxylase gene	[tyrosine hydroxylase gene]	0.0	3	1	1	1
120321	1710	developmental stage homogeneity of cell grow	[developmental stage homogeneity of cells growing]	0.0	6	1	1	1
120322	1710	host immune mechanism select	[host immune mechanisms selecting]	0.0	4	1	1	1
120323	1710	use chloramphenicol acetyl-transferase assay	[using chloramphenicol acetyl-transferase assay]	0.0	4	1	1	1
120324	1710	mechanism control E2F activity	[mechanism controlling E2F activity]	0.0	4	1	1	1
120325	1710	Monoallelic expression of Pax5 a paradigm	[Monoallelic expression of Pax5 a paradigm]	0.0	6	1	1	1
120326	1710	CKII site	[CKII site]	0.0	2	1	1	1
120327	1710	corticotropin-releasing hormone crh	[corticotropin-releasing hormone CRH]	0.0	3	1	1	1
120328	1710	possibility the mechanism	[possibility the mechanism]	0.0	3	1	1	1
120329	1710	suppression of corticosterone in plasma	[suppression of corticosterone in plasma]	0.0	5	1	1	1
120330	1710	rhythm in glucocorticoid receptor	[rhythm in glucocorticoid receptor]	0.0	4	1	1	1
120331	1710	mechanism of cell adhesion	[mechanisms of cell adhesion]	0.0	4	1	1	1
120332	1710	il-2 in th1 cell	[IL-2 in Th1 cells]	0.0	4	1	1	1
120333	1710	marker in two group	[marker in two groups]	0.0	4	1	1	1
120334	1710	first description, to knowledge,	[first description, to knowledge,]	0.0	4	1	1	1
120335	1710	factor-kappa B/Rel nuclear activity	[factor-kappa B/Rel nuclear activity]	0.0	4	1	1	1
120336	1710	receptor of human leukocyte	[receptor of human leukocytes]	0.0	4	1	1	1
120337	1710	incubation of Jurkat T cell	[Incubation of Jurkat T cells]	0.0	5	1	1	1
120338	1710	25-dihydroxyvitamin D3 receptor VDR	[25-dihydroxyvitamin D3 receptor VDR]	0.0	4	1	1	1
120339	1710	paraffin-embedded tissue	[paraffin-embedded tissues]	0.0	2	1	1	1
120340	1710	one enigmatic aspect	[One enigmatic aspect]	0.0	3	1	1	1
120341	1710	pyrrolidine dtc	[pyrrolidine DTC]	0.0	2	1	1	1
120342	1710	mediate CD40 signal	[mediating CD40 signals]	0.0	3	1	1	1
120343	1710	lps into monocyte	[LPS into monocytes]	0.0	3	1	1	1
120344	1710	motif,	[motif,]	0.0	1	1	1	1
120345	1710	transcription of several hematopoietic gene	[transcription of several hematopoietic genes]	0.0	5	1	1	1
120346	1710	correlation between infiltration in blood	[correlation between infiltration in blood]	0.0	5	1	1	1
120347	1710	exposure to microorganism	[exposure to microorganisms]	0.0	3	1	1	1
120348	1710	icenko- cushingd'	[Icenko- Cushing's]	0.0	2	1	1	1
120349	1710	edge: effect	[edge: effect]	0.0	2	1	1	1
120350	1710	significant effect on level	[significant effect on levels]	0.0	4	1	1	1
120351	1710	stat4 binding	[STAT4 binding]	0.0	2	1	1	1
120352	1710	consolidate the switch to level	[consolidating the switch to levels]	0.0	5	1	1	1
120353	1710	lipopolysaccharide increase in the expression	[lipopolysaccharide increases in the expression]	0.0	5	1	1	1
120354	1710	prevention of the activation	[prevention of the activation]	0.0	4	1	1	1
120355	1710	Stable expression of hb24	[Stable expression of HB24]	0.0	4	1	1	1
120356	1710	cyclic protein	[cyclic protein]	0.0	2	1	1	1
120357	1710	free sulfhydryl group	[free sulfhydryl groups]	0.0	3	1	1	1
120358	1710	patient with chronic lymphocytic leukaemia	[patients with chronic lymphocytic leukaemia]	0.0	5	1	1	1
120359	1710	reinsertion	[Reinsertion]	0.0	1	1	1	1
120360	1710	define the pattern	[defining the pattern]	0.0	3	1	1	1
120361	1710	gene Ie of human cytomegalovirus	[genes IE of human cytomegalovirus]	0.0	5	1	1	1
120362	1710	background of the defect	[background of the defects]	0.0	4	1	1	1
120363	1710	cell enhancement of dna-binding of e2f	[cells enhancement of DNA-binding of E2F]	0.0	6	1	1	1
120364	1710	ori lyt element	[ori Lyt element]	0.0	3	1	1	1
120365	1710	Grb2-like adaptor molecule	[Grb2-like adaptor molecule]	0.0	3	1	1	1
120366	1710	structure-based enhancement	[structure-based enhancement]	0.0	2	1	1	1
120367	1710	t- chronic leukemia	[T- chronic leukemias]	0.0	3	1	1	1
120368	1710	tissue-specific activation of gene	[tissue-specific activation of genes]	0.0	4	1	1	1
120369	1710	alteration moiety	[alterations moieties]	0.0	2	1	1	1
120370	1710	double-positive population	[double-positive populations]	0.0	2	1	1	1
120371	1710	monocytic factor-kappa b by lipoprotein	[monocytic factor-kappa B by lipoprotein]	0.0	5	1	1	1
120372	1710	cell monolayer	[cell monolayers]	0.0	2	1	1	1
120373	1710	APL blast	[APL blasts]	0.0	2	1	1	1
120374	1710	element in the tsp	[elements in the TSP]	0.0	4	1	1	1
120375	1710	J2 in macrophage	[J2 in macrophages]	0.0	3	1	1	1
120376	1710	c-sis/pdgb promoter tax-responsive element	[c-sis/PDGF-B promoter Tax-responsive element]	0.0	4	1	1	1
120377	1710	Sudan black b	[Sudan black B]	0.0	3	1	1	1
120378	1710	cell with vanadate	[cells with vanadate]	0.0	3	1	1	1
120379	1710	early development in Hox11 mouse	[early development in Hox11 mice]	0.0	5	1	1	1
120380	1710	megakaryocyte-specific protein act	[megakaryocyte-specific proteins acting]	0.0	3	1	1	1
120381	1710	fos/cun-contain nf-at complex	[Fos/Jun-containing NF-AT complexes]	0.0	3	1	1	1
120382	1710	lymphoblastoid cell line skw6.4	[lymphoblastoid cell line SKW6.4]	0.0	4	1	1	1
120383	1710	activity with a kd	[activity with an Kd]	0.0	4	1	1	1
120384	1710	subsequent analysis of the ICAM-1 promoter	[Subsequent analysis of the ICAM-1 promoter]	0.0	6	1	1	1
120385	1710	development of hyperparathyroidism	[development of hyperparathyroidism]	0.0	3	1	1	1
120386	1710	-resistant variant of hl60 cell	[-resistant variants of HL60 cells]	0.0	5	1	1	1
120387	1710	particle rvlp	[particles RVLPs]	0.0	2	1	1	1
120388	1710	alterations,	[alterations,]	0.0	1	1	1	1
120389	1710	negative regulation of il-1beta expression	[negative regulation of IL-1beta expression]	0.0	5	1	1	1
120390	1710	5.6 kb	[5.6 kb]	0.0	2	1	1	1
120391	1710	contrast, enhancement	[contrast, enhancement]	0.0	2	1	1	1
120392	1710	expression of l-selectin integrin	[expression of L-selectin integrins]	0.0	4	1	1	1
120393	1710	presence progesterone receptor pr	[presence progesterone receptors PR]	0.0	4	1	1	1
120394	1710	cytokine systems,	[cytokine systems,]	0.0	2	1	1	1
120395	1710	(10(-10) mol/L) in combination	[(10(-10) mol/L) in combination]	0.0	4	1	1	1
120396	1710	biallelic of patient	[biallelic of patients]	0.0	3	1	1	1
120397	1710	estrone	[estrone]	0.0	1	1	1	1
120398	1710	care unit	[care unit]	0.0	2	1	1	1
120399	1710	other component of the body	[other components of the bodies]	0.0	5	1	1	1
120400	1710	detectable activation of ap-1	[detectable activation of AP-1]	0.0	4	1	1	1
120401	1710	cd5+	[CD5+]	0.0	1	1	1	1
120402	1710	Differential regulation in cell line	[Differential regulation in cell lines]	0.0	5	1	1	1
120403	1710	Huh7	[Huh7]	0.0	1	1	1	1
120404	1710	C.J.Hetherington, H.-M.Chen,	[C.J.Hetherington, H.-M.Chen,]	0.0	2	1	1	1
120405	1710	localization of the NF-AT family	[localization of the NF-AT family]	0.0	5	1	1	1
120406	1710	include pkc-zeta	[including PKC-zeta]	0.0	2	1	1	1
120407	1710	regulation of adhesion molecule-1 icam-1	[regulation of adhesion molecule-1 ICAM-1]	0.0	5	1	1	1
120408	1710	polya+ rna	[polyA+ RNA]	0.0	2	1	1	1
120409	1710	factor kB element	[factor kB elements]	0.0	3	1	1	1
120410	1710	cd35	[CD35]	0.0	1	2	2	1
120411	1710	cd41	[CD41]	0.0	1	1	1	1
120412	1710	IL-2 activation in T cell	[IL-2 activation in T cells]	0.0	5	1	1	1
120413	1710	minor salivary gland biopsy	[minor salivary gland biopsies]	0.0	4	1	1	1
120414	1710	stimulate factor treatment	[stimulating factor treatment]	0.0	3	1	1	1
120415	1710	mechanism involve NF-ATp	[mechanism involving NF-ATp]	0.0	3	1	1	1
120416	1710	random replacement	[random replacement]	0.0	2	1	1	1
120417	1710	expression of adhesion molecule for neutrophil	[expression of adhesion molecules for neutrophils]	0.0	6	1	1	1
120418	1710	interactive mechanism	[interactive mechanisms]	0.0	2	1	1	1
120419	1710	distinctive gene expression pattern	[Distinctive gene expression patterns]	0.0	4	1	1	1
120420	1710	phenotype yj	[phenotype YJ]	0.0	2	1	1	1
120421	1710	cyclosporin -sensitive dnase site	[cyclosporin -sensitive DNase site]	0.0	4	1	1	1
120422	1710	analysis of sequence	[analysis of sequences]	0.0	3	1	1	1
120423	1710	mechanism of transformation	[mechanism of transformation]	0.0	3	1	1	1
120424	1710	step in the processing,	[step in the processing,]	0.0	4	1	1	1
120425	1710	acute myeloid (aml) blast	[acute myeloid (AML) blasts]	0.0	4	1	1	1
120426	1710	Stat1alpha -DNA complex	[Stat1alpha -DNA complexes]	0.0	3	1	1	1
120427	1710	nuclear protein act as transcription factor	[nuclear proteins acting as transcription factors]	0.0	6	1	1	1
120428	1710	receptor in human cell	[receptors in human cells]	0.0	4	1	1	1
120429	1710	Epstein-Barr virus the causative agent	[Epstein-Barr virus the causative agent]	0.0	5	1	1	1
120430	1710	nfat regulatory element	[NFAT regulatory element]	0.0	3	1	1	1
120431	1710	include 1695 bp	[including 1695 bp]	0.0	3	1	1	1
120432	1710	persistent relationship	[persistent relationship]	0.0	2	1	1	1
120433	1710	resolution of cell extract through step	[Resolution of cell extract through steps]	0.0	6	1	1	1
120434	1710	distinct dna-binding specificity	[distinct DNA-binding specificities]	0.0	3	1	1	1
120435	1710	concentration of the unlabeled compound	[concentrations of the unlabeled compound]	0.0	5	1	1	1
120436	1710	multicomponent receptor model	[multicomponent receptor model]	0.0	3	1	1	1
120437	1710	human monocytic thp cell	[human monocytic THP cells]	0.0	4	1	1	1
120438	1710	cell cycle regulation	[cell cycle regulation]	0.0	3	1	1	1
120439	1710	lack xist DNA	[lacking XIST DNA]	0.0	3	1	1	1
120440	1710	factor of T cell nf-at	[factor of T cells NF-AT]	0.0	5	2	2	1
120441	1710	different cocktail	[Different cocktails]	0.0	2	1	1	1
120442	1710	two binding site on the gr	[two binding sites on the GR]	0.0	6	1	1	1
120443	1710	degree of transcription,	[degree of transcription,]	0.0	3	1	1	1
120444	1710	signal sequence	[signal sequences]	0.0	2	1	1	1
120445	1710	molecule in mtbe induction	[molecule in MTBE induction]	0.0	4	1	1	1
120446	1710	repression inhibition of NFATp/AP-1 complex formation	[repression inhibition of NFATp/AP-1 complex formation]	0.0	6	1	1	1
120447	1710	indicate a affinity of sr-bp	[indicating an affinity of SR-BP]	0.0	5	1	1	1
120448	1710	great amplification	[greater amplification]	0.0	2	1	1	1
120449	1710	induction of activity relative	[induction of activity relative]	0.0	4	1	1	1
120450	1710	development of agent	[development of agents]	0.0	3	1	1	1
120451	1710	gc group	[GC group]	0.0	2	3	3	1
120452	1710	evidence for cross-talk with the calcineurin-	[evidence for cross-talk with the calcineurin-]	0.0	6	1	1	1
120453	1710	beta- gene promoter	[beta- gene promoters]	0.0	3	1	1	1
120454	1710	inasmuch through opening of K+	[Inasmuch through opening of K+]	0.0	5	1	1	1
120455	1710	inositoltrisphosphate generation corresponding binding	[inositoltrisphosphate generation corresponding binding]	0.0	4	1	1	1
120456	1710	pterin carbinolamine	[pterin carbinolamine]	0.0	2	1	1	1
120457	1710	50% inhibition ic50	[50% inhibition IC50]	0.0	3	1	1	1
120458	1710	binding to stat5 target sequence	[Binding to STAT5 target sequences]	0.0	5	1	1	1
120459	1710	rapid activation independent	[rapid activation independent]	0.0	3	1	1	1
120460	1710	expression of transcription factor gene	[Expression of transcription factor genes]	0.0	5	1	1	1
120461	1710	differentiation of myeloid leukemia cell	[differentiation of myeloid leukemia cells]	0.0	5	1	1	1
120462	1710	presence of a repressor.	[presence of a repressor.]	0.0	4	1	1	1
120463	1710	bind ga-binding protein alpha	[binding GA-binding protein alpha]	0.0	4	1	1	1
120464	1710	state ep<0.05)	[state (P<0.05)]	0.0	2	1	1	1
120465	1710	hour after this challenge.	[hours after this challenge.]	0.0	4	1	1	1
120466	1710	high level in T cell	[high level in T cells]	0.0	5	1	1	1
120467	1710	unexplained, eosinophilia	[unexplained, eosinophilia]	0.0	2	1	1	1
120468	1710	Jak3 JH4 domain	[Jak3 JH4 domain]	0.0	3	1	1	1
120469	1710	(TWHf)	[(TWHf)]	0.0	1	1	1	1
120470	1710	expression pattern suggest a property	[expression patterns suggesting a property]	0.0	5	1	1	1
120471	1710	AMP response element CRE	[AMP response element CRE]	0.0	4	2	2	1
120472	1710	factor kappab activity	[factor kappaB activity]	0.0	3	1	1	1
120473	1710	gene through a transcription factor	[genes through a transcription factor]	0.0	5	1	1	1
120474	1710	blot analysis of various mouse tissue	[blot analysis of various mouse tissues]	0.0	6	1	1	1
120475	1710	unstable untreated patient	[unstable untreated patients]	0.0	3	1	1	1
120476	1710	eosinophil-specific gene encode granule protein	[eosinophil-specific genes encoding granule proteins]	0.0	5	1	1	1
120477	1710	approximately 42 different gene	[approximately 42 different genes]	0.0	4	1	1	1
120478	1710	phases.	[phases.]	0.0	1	1	1	1
120479	1710	least four different NF-kappaB complex	[least four different NF-kappaB complexes]	0.0	5	1	1	1
120480	1710	compartment to membrane	[compartment to membranes]	0.0	3	1	1	1
120481	1710	mouse strain with defect	[mouse strains with defects]	0.0	4	1	1	1
120482	1710	one patient with myelopathy/tropical paraparesis	[one patient with myelopathy/tropical paraparesis]	0.0	5	1	1	1
120483	1710	hsv-2 type-specific cd4+ antigen	[HSV-2 type-specific CD4+ antigens]	0.0	4	1	1	1
120484	1710	human monocyte binding	[Human monocyte binding]	0.0	3	1	1	1
120485	1710	Stat5 in platelet lysate	[Stat5 in platelet lysates]	0.0	4	1	1	1
120486	1710	platelet-activate factor to m elevation	[platelet-activating factor to M elevation]	0.0	5	1	1	1
120487	1710	factor of t-cell NFAT-1	[factor of T-cells NFAT-1]	0.0	4	1	1	1
120488	1710	contain four near-perfect direct repeat DR	[containing four near-perfect direct repeats DR]	0.0	6	1	1	1
120489	1710	beta-catenin localize	[beta-catenin localizes]	0.0	2	1	1	1
120490	1710	cyclic AMP -responsive element activation	[Cyclic AMP -responsive element activation]	0.0	5	1	1	1
120491	1710	stem/progenitor	[stem/progenitor]	0.0	1	1	1	1
120492	1710	convert extracellular signal into intracellular event	[converting extracellular signals into intracellular events]	0.0	6	1	1	1
120493	1710	nf-kappab2 p52	[NF-kappaB2 p52]	0.0	2	1	1	1
120494	1710	late kinetic a finding	[late kinetics a finding]	0.0	4	1	1	1
120495	1710	level of trap fluoride-resistant- alpha-naphthyl-acetate-esterase naf-r-nse	[levels of TRAP fluoride-resistant- alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	6	1	1	1
120496	1710	GR element	[GR element]	0.0	2	1	1	1
120497	1710	monoclonal anti-hsp antibody	[monoclonal anti-hsp antibody]	0.0	3	1	1	1
120498	1710	2000 mu/l concentration	[2,000 mU/L concentration]	0.0	3	1	1	1
120499	1710	sh2 phosphotyrosine-based motif	[SH2 phosphotyrosine-based motifs]	0.0	3	1	1	1
120500	1710	addition of M-CSF	[addition of M-CSF]	0.0	3	1	1	1
120501	1710	dna-protein kinase	[DNA-protein kinase]	0.0	2	1	1	1
120502	1710	small potential phosphoprotein	[small potential phosphoprotein]	0.0	3	1	1	1
120503	1710	pp1 tautomycin	[PP1 tautomycin]	0.0	2	1	1	1
120504	1710	agent of ehrlichiosis	[agent of ehrlichiosis]	0.0	3	1	1	1
120505	1710	[induction of apoptosis between physiology	[[Induction of apoptosis between physiology]	0.0	5	1	1	1
120506	1710	random breast aspirate	[random breast aspirates]	0.0	3	1	1	1
120507	1710	concentration of reactive metabolite	[concentrations of reactive metabolites]	0.0	4	1	1	1
120508	1710	type cytokine	[type cytokines]	0.0	2	1	1	1
120509	1710	cross-linking on synovial cell	[Cross-linking on synovial cells]	0.0	4	1	1	1
120510	1710	type include chronic leukaemia CML	[types including chronic leukaemia CML]	0.0	5	2	2	1
120511	1710	bimodal pattern of expression	[bimodal pattern of expression]	0.0	4	1	1	1
120512	1710	concentration of the immunodominant epitope	[concentrations of the immunodominant epitope]	0.0	5	1	1	1
120513	1710	dendritic cell from peripheral blood	[dendritic cells from peripheral blood]	0.0	5	1	1	1
120514	1710	potential use	[potential use]	0.0	2	2	2	1
120515	1710	mzf protein	[MZF protein]	0.0	2	1	1	1
120516	1710	major Sp1 binding site	[major Sp1 binding site]	0.0	4	1	1	1
120517	1710	expand family of cytokine	[expanding family of cytokines]	0.0	4	1	1	1
120518	1710	three ap-1 site	[three AP-1 sites]	0.0	3	1	1	1
120519	1710	monoclonal antibody bz1	[monoclonal antibody BZ1]	0.0	3	1	1	1
120520	1710	progression from asymptomatic infection	[progression from asymptomatic infection]	0.0	4	1	1	1
120521	1710	myeloid-specific factor	[myeloid-specific factor]	0.0	2	1	1	1
120522	1710	cell adhesion molecule by TNF	[cell adhesion molecules by TNF]	0.0	5	1	1	1
120523	1710	evidence a role	[evidencing a role]	0.0	3	1	1	1
120524	1710	protein (creb)	[protein (CREB)]	0.0	2	1	1	1
120525	1710	activity tag	[activity TAG]	0.0	2	1	1	1
120526	1710	region encompass a rich sequence	[region encompassing a rich sequence]	0.0	5	1	1	1
120527	1710	repeat promoter region	[repeat promoter region]	0.0	3	1	1	1
120528	1710	expression of the CAT gene	[expression of the CAT gene]	0.0	5	1	1	1
120529	1710	protein bcl-2	[proteins bcl-2]	0.0	2	1	1	1
120530	1710	GCR-beta -immunoreactive cell	[GCR-beta -immunoreactive cells]	0.0	3	1	1	1
120531	1710	CREB/activating transcription factor	[CREB/activating transcription factor]	0.0	3	1	1	1
120532	1710	pollution	[pollution]	0.0	1	1	1	1
120533	1710	62 (ie62) protein vzv	[62 (IE62) protein VZV]	0.0	4	1	1	1
120534	1710	thus result	[thus resulting]	0.0	2	1	1	1
120535	1710	regulation of the human fas promoter	[regulation of the human Fas promoter]	0.0	6	1	1	1
120536	1710	core sequence aggc	[core sequence AGGC]	0.0	3	1	1	1
120537	1710	binding to the tissue factor	[Binding to the tissue factor]	0.0	5	1	1	1
120538	1710	RNA manner	[RNA manner]	0.0	2	1	1	1
120539	1710	stimulus elicit stress	[stimuli eliciting stress]	0.0	3	1	1	1
120540	1710	expense of subdominant reactivities.	[expense of subdominant reactivities.]	0.0	4	1	1	1
120541	1710	b oligonucleotide	[B oligonucleotide]	0.0	2	1	1	1
120542	1710	one hundred breast cancer sample	[One hundred breast cancer samples]	0.0	5	1	1	1
120543	1710	selective agonist of cell	[selective agonist of cells]	0.0	4	1	1	1
120544	1710	germline TaqI	[germline TaqI]	0.0	2	1	1	1
120545	1710	membrane protein-1 lmp-1	[membrane protein-1 LMP-1]	0.0	3	1	1	1
120546	1710	p130 phosphorylation	[p130 phosphorylation]	0.0	2	1	1	1
120547	1710	receptor with the actin cytoskeleton	[receptors with the actin cytoskeleton]	0.0	5	1	1	1
120548	1710	group of absorptive patient	[group of absorptive patients]	0.0	4	1	1	1
120549	1710	normal thymus environment	[normal thymus environment]	0.0	3	1	1	1
120550	1710	endothelial cell ec	[endothelial cells EC]	0.0	3	1	1	1
120551	1710	heavy chain IgH	[heavy chain IgH]	0.0	3	1	1	1
120552	1710	c-terminal domain	[C-terminal domain]	0.0	2	1	1	1
120553	1710	element within the core	[elements within the core]	0.0	4	1	1	1
120554	1710	rel-related human cDNA	[rel-related human cDNA]	0.0	3	1	1	1
120555	1710	binding site in leukocyte	[binding sites in leukocytes]	0.0	4	1	1	1
120556	1710	fc receptor lead	[Fc receptors leading]	0.0	3	1	1	1
120557	1710	different emcv ires fragment	[different EMCV IRES fragments]	0.0	4	1	1	1
120558	1710	accord to serum cortisol level	[according to serum cortisol levels]	0.0	5	1	1	1
120559	1710	factor for maximal activity	[factors for maximal activity]	0.0	4	1	1	1
120560	1710	protein distinct from c-jun/ ap-1	[proteins distinct from c-jun/ AP-1]	0.0	5	1	1	1
120561	1710	7.03 (range, 4.27 (range, 4-.11),	[7.03 (range, 4.27 (range, 4-5.13),]	0.0	5	1	1	1
120562	1710	presence of common element	[presence of common elements]	0.0	4	1	1	1
120563	1710	study signal in precursor	[studies signaling in precursors]	0.0	4	1	1	1
120564	1710	control of gene network	[control of gene networks]	0.0	4	1	1	1
120565	1710	inhibition 1 replication in vitro	[Inhibition 1 replication in vitro]	0.0	5	1	1	1
120566	1710	single inoculation (i.p.)	[single inoculation (i.p.)]	0.0	3	1	1	1
120567	1710	treatment with two schedule of calcitriol	[Treatment with two schedules of calcitriol]	0.0	6	1	1	1
120568	1710	inhalation	[inhalation]	0.0	1	1	1	1
120569	1710	two early protein	[two early proteins]	0.0	3	1	1	1
120570	1710	component of the element	[component of the element]	0.0	4	1	1	1
120571	1710	15d-pgj(2)	[15d-PGJ(2)]	0.0	1	1	1	1
120572	1710	activation of STAT5	[Activation of STAT5]	0.0	3	1	1	1
120573	1710	oct-1 /oca-b	[Oct-1 /OCA-B]	0.0	2	1	1	1
120574	1710	effect on the ifn-responsive gene	[effects on the IFN-responsive genes]	0.0	5	1	1	1
120575	1710	eukaryotic rna polymerase	[eukaryotic RNA polymerase]	0.0	3	1	1	1
120576	1710	hiv-1 transactivation	[HIV-1 transactivation]	0.0	2	1	1	1
120577	1710	somatic mutation cluster a encoding	[somatic mutations clustering a encoding]	0.0	5	1	1	1
120578	1710	identification of fusion transcript	[identification of fusion transcripts]	0.0	4	1	1	1
120579	1710	gene Oct-2	[genes Oct-2]	0.0	2	1	1	1
120580	1710	complex in T cell	[complexes in T cells]	0.0	4	1	1	1
120581	1710	myelin protein (mbp)- T cell line	[myelin protein (MBP)- T cell lines]	0.0	6	1	1	1
120582	1710	increase with peak	[increase with peaks]	0.0	3	1	1	1
120583	1710	evaluation of the epithelium of normal	[Evaluation of the epithelium of normals]	0.0	6	1	1	1
120584	1710	cervical carcinoma HeLa	[cervical carcinoma HeLa]	0.0	3	1	1	1
120585	1710	fk506 a calcineurin inhibitor consistent	[FK506 a calcineurin inhibitor consistent]	0.0	5	1	1	1
120586	1710	dichroism	[dichroism]	0.0	1	1	1	1
120587	1710	Spi-B transcription	[Spi-B transcription]	0.0	2	1	1	1
120588	1710	C5a stimulation of peripheral blood monocyte	[C5a stimulation of peripheral blood monocytes]	0.0	6	1	1	1
120589	1710	hmd similar to lipopolysaccharide	[HMDS similar to lipopolysaccharide]	0.0	4	1	1	1
120590	1710	c-jun mapk	[c-jun MAPk]	0.0	2	1	1	1
120591	1710	response to single	[responses to single]	0.0	3	1	1	1
120592	1710	type of process	[types of processes]	0.0	3	1	1	1
120593	1710	2-yr period.	[2-yr period.]	0.0	2	1	1	1
120594	1710	hypotheses.	[hypotheses.]	0.0	1	1	1	1
120595	1710	finding in herpesvirus system	[findings in herpesvirus systems]	0.0	4	1	1	1
120596	1710	parath hormone	[parath hormone]	0.0	2	1	1	1
120597	1710	fragment of bactericidal/permeability-increasing protein	[fragment of bactericidal/permeability-increasing protein]	0.0	4	1	1	1
120598	1710	two integrin	[two integrins]	0.0	2	1	1	1
120599	1710	effect increase	[effect increase]	0.0	2	1	1	1
120600	1710	cross-competition assay	[Cross-competition assays]	0.0	2	1	1	1
120601	1710	regulation of interleukin 2 IL-2 gene	[regulation of interleukin 2 IL-2 gene]	0.0	6	1	1	1
120602	1710	cross point	[cross points]	0.0	2	1	1	1
120603	1710	synergism during activation	[Synergism during activation]	0.0	3	1	1	1
120604	1710	positively regulate signal pathway	[positively regulating signaling pathways]	0.0	4	1	1	1
120605	1710	bind to DNA	[binding to DNA]	0.0	3	1	1	1
120606	1710	response to injury.	[response to injury.]	0.0	3	1	1	1
120607	1710	degenerate oligonucleotide	[degenerate oligonucleotides]	0.0	2	1	1	1
120608	1710	defect in aspect	[defects in aspects]	0.0	3	1	1	1
120609	1710	finally, study a series of patient	[Finally, studying a series of patients]	0.0	6	1	1	1
120610	1710	PML/RARalpha cDNA	[PML/RARalpha cDNA]	0.0	2	1	1	1
120611	1710	activity of dihydropyrimidine dehydrogenase	[activity of dihydropyrimidine dehydrogenase]	0.0	4	1	1	1
120612	1710	terminal repeat of hiv-1	[terminal repeat of HIV-1]	0.0	4	3	3	1
120613	1710	inhibitor of protein phosphatase type 1	[inhibitors of protein phosphatase type 1]	0.0	6	1	1	1
120614	1710	sideroblast with ring sideroblast rar	[sideroblasts with ring sideroblasts RARS]	0.0	5	1	1	1
120615	1710	two nuclear rna	[two nuclear RNAs]	0.0	3	1	1	1
120616	1710	nf-kappab -contain	[NF-kappaB -containing]	0.0	2	1	1	1
120617	1710	dna-binding complex in human eosinophil	[DNA-binding complexes in human eosinophils]	0.0	5	1	1	1
120618	1710	signal in human t-cell	[signalling in human T-cells]	0.0	4	1	1	1
120619	1710	mcf-7	[MCF-7]	0.0	1	1	1	1
120620	1710	distinct regulatory element act	[distinct regulatory elements acting]	0.0	4	1	1	1
120621	1710	permanent virus transcription	[permanent virus transcription]	0.0	3	1	1	1
120622	1710	interaction with ligand	[interaction with ligand]	0.0	3	1	1	1
120623	1710	mrna study	[mRNA studies]	0.0	2	1	1	1
120624	1710	case of follicular cell lymphoma	[cases of follicular cell lymphomas]	0.0	5	1	1	1
120625	1710	regard to relevance for gastroenterology	[regard to relevance for gastroenterology]	0.0	5	1	1	1
120626	1710	lymphocytic infiltrate of gland	[lymphocytic infiltrates of glands]	0.0	4	1	1	1
120627	1710	weight gain +/- (pre)	[weight gain +/- (pre)]	0.0	4	1	1	1
120628	1710	expression independently	[expression independently]	0.0	2	1	1	1
120629	1710	control (4419	[controls (4419]	0.0	2	1	1	1
120630	1710	decrease in ap-1	[decrease in AP-1]	0.0	3	1	1	1
120631	1710	modulate the expression of differentiation antigen	[modulating the expression of differentiation antigens]	0.0	6	1	1	1
120632	1710	pathologic,	[pathologic,]	0.0	1	1	1	1
120633	1710	(1) substitution	[(1) substitutions]	0.0	2	1	1	1
120634	1710	nm23-h2 gene product	[nm23-H2 gene product]	0.0	3	1	1	1
120635	1710	naive helper T cell	[naive helper T cells]	0.0	4	1	1	1
120636	1710	two activity of glucocorticoid	[two activities of glucocorticoids]	0.0	4	1	1	1
120637	1710	elicit remission of the state	[eliciting remissions of the state]	0.0	5	1	1	1
120638	1710	Ha-ras	[Ha-ras]	0.0	1	1	1	1
120639	1710	other class promoter	[other class promoters]	0.0	3	1	1	1
120640	1710	activation JAK stat signal pathway	[activation JAK STAT signaling pathway]	0.0	5	1	1	1
120641	1710	detection of signal transduction molecule	[Detection of signal transduction molecules]	0.0	5	1	1	1
120642	1710	virus-negative T cell	[virus-negative T cells]	0.0	3	1	1	1
120643	1710	cDNA encode nuclear factor	[cDNA encoding nuclear factor]	0.0	4	1	1	1
120644	1710	wt1 expression	[WT1 expression]	0.0	2	1	1	1
120645	1710	Differential activation of stat5 protein	[Differential activation of STAT5 proteins]	0.0	5	1	1	1
120646	1710	other leukocyte adhesion molecule	[other leukocyte adhesion molecules]	0.0	4	1	1	1
120647	1710	(0.2-1.6) fmol/10(7) cell	[(0.2-1.6) fmol/10(7) cells]	0.0	3	1	1	1
120648	1710	pparalpha activator fenofibrate	[PPARalpha activators fenofibrate]	0.0	3	1	1	1
120649	1710	costimulation of u1 cell	[Costimulation of U1 cells]	0.0	4	1	1	1
120650	1710	circulate t-cell from individual	[Circulating T-cells from individuals]	0.0	4	1	1	1
120651	1710	two viral transactivator BZLF1 Z	[two viral transactivators BZLF1 Z]	0.0	5	1	1	1
120652	1710	yield of structural protein	[yields of structural proteins]	0.0	4	1	1	1
120653	1710	durable inhibition of hiv-1 replication	[durable inhibition of HIV-1 replication]	0.0	5	1	1	1
120654	1710	serum-free conditions.	[serum-free conditions.]	0.0	2	1	1	1
120655	1710	TCF-1 hybridoma	[TCF-1 hybridomas]	0.0	2	1	1	1
120656	1710	determine the regulation	[determining the regulation]	0.0	3	1	1	1
120657	1710	action on human cell (dc)	[action on human cells (DC)]	0.0	5	1	1	1
120658	1710	92-kda	[92-kDa]	0.0	1	1	1	1
120659	1710	FGF-1 stimulation	[FGF-1 stimulation]	0.0	2	1	1	1
120660	1710	stat4 -contain	[STAT4 -containing]	0.0	2	1	1	1
120661	1710	Tat a potent activator	[Tat a potent activator]	0.0	4	1	1	1
120662	1710	human cd34(+) cell	[human CD34(+) cells]	0.0	3	1	1	1
120663	1710	predominant one	[predominant one]	0.0	2	1	1	1
120664	1710	replication of type 1 immunodeficiency virus	[Replication of type 1 immunodeficiency viruses]	0.0	6	1	1	1
120665	1710	alpha-tocopherol tcp	[alpha-tocopherol TCP]	0.0	2	1	1	1
120666	1710	identification of key transcription factor	[identification of key transcription factors]	0.0	5	1	1	1
120667	1710	D3 125d3	[D3 1,25D3]	0.0	2	1	1	1
120668	1710	mechanism related	[mechanism related]	0.0	2	1	1	1
120669	1710	various isolate	[various isolates]	0.0	2	1	1	1
120670	1710	part of the region	[part of the region]	0.0	4	1	1	1
120671	1710	establishment of airway hyperresponsiveness	[establishment of airway hyperresponsiveness]	0.0	4	1	1	1
120672	1710	cell from cytoplasmic form	[cells from cytoplasmic form]	0.0	4	1	1	1
120673	1710	concentration of other antioxidant	[concentrations of other antioxidants]	0.0	4	1	1	1
120674	1710	upstream exonic splice site	[upstream exonic splice site]	0.0	4	1	1	1
120675	1710	mcf13	[MCF13]	0.0	1	1	1	1
120676	1710	T helper clone	[T helper clones]	0.0	3	1	1	1
120677	1710	transfection overexpression	[transfection overexpression]	0.0	2	1	1	1
120678	1710	immunization with adenovirus vector	[immunizations with adenovirus vectors]	0.0	4	1	1	1
120679	1710	potential clinical usefulness	[potential clinical usefulness]	0.0	3	1	1	1
120680	1710	potent inhibitor kinase upstream of ERK1/2	[potent inhibitors kinase upstream of ERK1/2]	0.0	6	1	1	1
120681	1710	association domain	[association domain]	0.0	2	1	1	1
120682	1710	1-2 h.	[1-2 h,]	0.0	2	1	1	1
120683	1710	p65 heterodimer	[P65 heterodimer]	0.0	2	1	1	1
120684	1710	estrogen response	[estrogen response]	0.0	2	1	1	1
120685	1710	high infiltration	[high infiltration]	0.0	2	1	1	1
120686	1710	expression of subunit regulation	[expression of subunit regulation]	0.0	4	1	1	1
120687	1710	allele in b-lymphoid progenitor	[alleles in B-lymphoid progenitors]	0.0	4	1	1	1
120688	1710	contrast, tyrosine-phosphorylated peptide	[contrast, tyrosine-phosphorylated peptides]	0.0	3	1	1	1
120689	1710	NLS disruption of the import	[NLS disruption of the import]	0.0	5	1	1	1
120690	1710	signal in myeloid cell	[signals in myeloid cells]	0.0	4	1	1	1
120691	1710	adhesion to p-selectin	[Adhesion to P-selectin]	0.0	3	1	1	1
120692	1710	apoptotic vascular muscle cell	[apoptotic vascular muscle cells]	0.0	4	1	1	1
120693	1710	gene transcription in sle patient	[gene transcription in SLE patients]	0.0	5	1	1	1
120694	1710	myeloid cells.	[myeloid cells.]	0.0	2	1	1	1
120695	1710	nf-kb factor	[NF-KB factor]	0.0	2	1	1	1
120696	1710	TSH-R	[TSH-R]	0.0	1	1	1	1
120697	1710	oxidoreductive pathway	[oxidoreductive pathway]	0.0	2	1	1	1
120698	1710	Albuminemia	[Albuminemia]	0.0	1	1	1	1
120699	1710	inducibility by HHV-6	[inducibility by HHV-6]	0.0	3	1	1	1
120700	1710	patient in (st;	[patients in (ST;]	0.0	3	1	1	1
120701	1710	translocation into the compartment	[translocation into the compartment]	0.0	4	1	1	1
120702	1710	coordinate activation effect on TNFalpha release	[coordinate activation effects on TNFalpha release]	0.0	6	1	1	1
120703	1710	two novel element	[two novel elements]	0.0	3	1	1	1
120704	1710	design strategy	[designing strategies]	0.0	2	1	1	1
120705	1710	cell such as monocyte	[cells such as monocytes]	0.0	4	1	1	1
120706	1710	activate transcription from class promoter	[activating transcription from class promoters]	0.0	5	1	1	1
120707	1710	macrophage marker	[macrophage markers]	0.0	2	1	1	1
120708	1710	discordance in mnda positive cell	[discordance in MNDA positive cells]	0.0	5	1	1	1
120709	1710	distinct ligand-induced, tyrosine-phosphorylated docking site	[distinct ligand-induced, tyrosine-phosphorylated docking sites]	0.0	5	1	1	1
120710	1710	eosinophil granule basic protein mbp	[eosinophil granule basic protein MBP]	0.0	5	2	2	1
120711	1710	individual with makaume mtbe	[individuals with makeup, MTBE]	0.0	4	1	1	1
120712	1710	serum condition	[serum conditions]	0.0	2	1	1	1
120713	1710	acid RA treatment in leukemia	[acid RA treatment in leukemia]	0.0	5	1	1	1
120714	1710	site of receptor gcr	[sites of receptor GCR]	0.0	4	1	1	1
120715	1710	33 case	[33 cases]	0.0	2	1	1	1
120716	1710	regulation of c-jun expression during induction	[Regulation of c-jun expression during induction]	0.0	6	1	1	1
120717	1710	binding motif of HS-40 by mutagenesis	[binding motifs of HS-40 by mutagenesis]	0.0	6	1	1	1
120718	1710	(lm-pcr)	[(LM-PCR)]	0.0	1	1	1	1
120719	1710	simultaneous activation	[simultaneous activation]	0.0	2	4	4	1
120720	1710	involvement of Itk	[involvement of Itk]	0.0	3	1	1	1
120721	1710	indicate a rate	[indicating an rate]	0.0	3	1	1	1
120722	1710	Differential presentation	[Differential presentation]	0.0	2	1	1	1
120723	1710	range of pathology	[range of pathologies]	0.0	3	1	1	1
120724	1710	cellular content of tfiih	[cellular content of TFIIH]	0.0	4	1	1	1
120725	1710	chemotherapeutic potential	[chemotherapeutic potential]	0.0	2	1	1	1
120726	1710	myeloid lineage absent	[myeloid lineages absent]	0.0	3	1	1	1
120727	1710	2.3-kb LCR enhancer activity	[2.3-kb LCR enhancer activity]	0.0	4	1	1	1
120728	1710	-2 lesion	[-2 lesions]	0.0	2	1	1	1
120729	1710	Wyeth	[Wyeth]	0.0	1	1	1	1
120730	1710	activity, suggest essential for DNA binding	[activity, suggesting essential for DNA binding]	0.0	6	1	1	1
120731	1710	cd8(+) T lymphocyte	[CD8(+) T lymphocytes]	0.0	3	1	1	1
120732	1710	years, study	[years, studies]	0.0	2	1	1	1
120733	1710	(caccc)	[(CACCC)]	0.0	1	1	1	1
120734	1710	Mr protein	[Mr protein]	0.0	2	1	1	1
120735	1710	leukemic cell include many	[leukemic cells including many]	0.0	4	1	1	1
120736	1710	t-cell virus type 1 htlv-1	[T-cell virus type 1 HTLV-1]	0.0	5	1	1	1
120737	1710	nonfunctional sequence motif	[nonfunctional sequence motifs]	0.0	3	1	1	1
120738	1710	target cell lysis,	[target cell lysis,]	0.0	3	1	1	1
120739	1710	9-bp motif	[9-bp motifs]	0.0	2	1	1	1
120740	1710	-reactive	[-reactive]	0.0	1	1	1	1
120741	1710	differentiation by calcitriol	[differentiation by calcitriol]	0.0	3	1	1	1
120742	1710	diffuse lymphoma with a component	[diffuse lymphomas with a component]	0.0	5	1	1	1
120743	1710	erba-binding	[erbA-binding]	0.0	1	1	1	1
120744	1710	blood cell from myeloid patient	[blood cells from myeloid patients]	0.0	5	1	1	1
120745	1710	selective DNA binding	[selective DNA binding]	0.0	3	1	1	1
120746	1710	different cellular activation	[different cellular activation]	0.0	3	1	1	1
120747	1710	treatment with concentration of etoposide microM)	[treatments with concentrations of etoposide microM)]	0.0	6	1	1	1
120748	1710	distinct portion	[distinct portions]	0.0	2	1	1	1
120749	1710	histocompatibility complex class I molecule	[histocompatibility complex class I molecules]	0.0	5	1	1	1
120750	1710	cause a bp truncation of mrna	[causing a bp truncation of mRNA]	0.0	6	1	1	1
120751	1710	p55/p75 early	[p55/p75 early]	0.0	2	1	1	1
120752	1710	increase in factor kappab nf-kappab	[increase in factor kappaB NF-kappaB]	0.0	5	1	1	1
120753	1710	removal from the USA fraction	[removal from the USA fraction]	0.0	5	1	1	1
120754	1710	develop central nervous system	[developing central nervous system]	0.0	4	1	1	1
120755	1710	lymphocyte-specific regulation	[lymphocyte-specific regulation]	0.0	2	1	1	1
120756	1710	-express human human cell	[-expressing human human cells]	0.0	4	1	1	1
120757	1710	translocation nuclear factor lymphocyte	[translocation nuclear factor lymphocytes]	0.0	4	1	1	1
120758	1710	woman of childbearing age.	[women of childbearing age.]	0.0	4	1	1	1
120759	1710	interaction between tissue fibroblast	[interactions between tissue fibroblasts]	0.0	4	1	1	1
120760	1710	a6h ligation	[A6H ligation]	0.0	2	1	1	1
120761	1710	only interleukin (il)-2-receptor expression	[only interleukin (IL)-2-receptor expression]	0.0	4	1	1	1
120762	1710	other human sequence	[other human sequences]	0.0	3	1	1	1
120763	1710	triangle uplngfr	[triangle upLNGFR]	0.0	2	1	1	1
120764	1710	effect on the hiv-1 promoter	[effects on the HIV-1 promoters]	0.0	5	1	1	1
120765	1710	aetiology for this disorders.	[aetiologies for these disorders.]	0.0	4	1	1	1
120766	1710	relevance of this findings,	[relevance of these findings,]	0.0	4	1	1	1
120767	1710	Epstein-Barr virus nuclear antigen ebna-2	[Epstein-Barr virus nuclear antigen EBNA-2]	0.0	5	1	1	1
120768	1710	hormonal status in breast cancer patient	[Hormonal status in breast cancer patients]	0.0	6	1	1	1
120769	1710	A-CRF with insufficiency	[A-CRF with insufficiency]	0.0	3	1	1	1
120770	1710	expression level of c-myc characteristic	[expression level of c-myc characteristic]	0.0	5	1	1	1
120771	1710	recognition in hla-dq response	[recognition in HLA-DQ response]	0.0	4	1	1	1
120772	1710	amount early e1b	[amounts early E1B]	0.0	3	1	1	1
120773	1710	overexpression of calcineurin CN	[overexpression of calcineurin CN]	0.0	4	1	1	1
120774	1710	cytokine production profile	[cytokine production profiles]	0.0	3	1	1	1
120775	1710	PMA/PHA cell	[PMA/PHA cells]	0.0	2	1	1	1
120776	1710	peptide vaccine	[peptide vaccines]	0.0	2	1	1	1
120777	1710	downstream region	[downstream region]	0.0	2	2	2	1
120778	1710	sensitivity to regulation	[sensitivity to regulation]	0.0	3	1	1	1
120779	1710	thymocyte-thymic cell interaction	[Thymocyte-thymic cell interaction]	0.0	3	1	1	1
120780	1710	direct interaction antagonism in erythroid cell	[Direct interaction antagonism in erythroid cells]	0.0	6	1	1	1
120781	1710	thymocyte ontogeny	[thymocyte ontogeny]	0.0	2	1	1	1
120782	1710	allele of the gene.	[allele of the gene.]	0.0	4	1	1	1
120783	1710	autologous bone marrow transplantation	[autologous bone marrow transplantation]	0.0	4	1	1	1
120784	1710	three protein factor	[three protein factors]	0.0	3	1	1	1
120785	1710	Prostaglandin E2 PGE2 a immunomodulatory molecule	[Prostaglandin E2 PGE2 a immunomodulatory molecule]	0.0	6	1	1	1
120786	1710	development; addition to hpc	[development; addition to HPC]	0.0	4	1	1	1
120787	1710	two different cellular system	[two different cellular systems]	0.0	4	1	1	1
120788	1710	(25%) other disease subject	[(25%) other disease subjects]	0.0	4	1	1	1
120789	1710	factor-kappaB translocation monocyte	[factor-kappaB translocation monocytes]	0.0	3	1	1	1
120790	1710	il-1 signal	[IL-1 signaling]	0.0	2	1	1	1
120791	1710	case-control study of disease	[case-control studies of diseases]	0.0	4	1	1	1
120792	1710	polyanionic glycosaminoglycan	[polyanionic glycosaminoglycan]	0.0	2	1	1	1
120793	1710	understand the mechanism of fasl regulation	[Understanding the mechanisms of FasL regulation]	0.0	6	1	1	1
120794	1710	maturation of lineage 21	[maturation of lineages 21]	0.0	4	1	1	1
120795	1710	difference 0.02)	[difference 0.02)]	0.0	2	1	1	1
120796	1710	rar/rxr heterodimer	[RAR/RXR heterodimer]	0.0	2	1	1	1
120797	1710	action in tonsillar t- lymphocyte	[action in tonsillar T- lymphocytes]	0.0	5	1	1	1
120798	1710	macrophage of smoker	[macrophages of smokers]	0.0	3	1	1	1
120799	1710	ii-negative b	[II-negative B]	0.0	2	1	1	1
120800	1710	only receptor occupancy	[Only receptor occupancy]	0.0	3	1	1	1
120801	1710	composition in human myeloid cell	[composition in human myeloid cells]	0.0	5	1	1	1
120802	1710	nuclear factor kappa B site	[nuclear factor kappa B site]	0.0	5	1	1	1
120803	1710	minutes) to all-tran retinoic acid	[minutes) to all-trans retinoic acid]	0.0	5	1	1	1
120804	1710	analysis of promoter	[analysis of promoters]	0.0	3	1	1	1
120805	1710	marker specific	[markers specific]	0.0	2	1	1	1
120806	1710	use the same dose of anti-CD3	[using the same dose of anti-CD3]	0.0	6	1	1	1
120807	1710	lineage-specific activation of STAT3 by interferon-gamma	[Lineage-specific activation of STAT3 by interferon-gamma]	0.0	6	1	1	1
120808	1710	regulate a b cell-specific gene	[regulating a B cell-specific gene]	0.0	5	1	1	1
120809	1710	(HIV) repeat LTR	[(HIV) repeat LTR]	0.0	3	1	1	1
120810	1710	target NFAT-1 gene expression	[targeting NFAT-1 gene expression]	0.0	4	1	1	1
120811	1710	outcome of diverse syndrome	[outcome of diverse syndromes]	0.0	4	1	1	1
120812	1710	unresponsiveness for activation	[Unresponsiveness for activation]	0.0	3	1	1	1
120813	1710	lcr/gamma-globin	[LCR/gamma-globin]	0.0	1	1	1	1
120814	1710	receptor saturate concentration	[receptor saturating concentration]	0.0	3	1	1	1
120815	1710	inducer of CD38 expression	[inducer of CD38 expression]	0.0	4	1	1	1
120816	1710	CD4 antibody	[CD4 antibodies]	0.0	2	1	1	1
120817	1710	set of word	[set of words]	0.0	3	1	1	1
120818	1710	4 to 5 day	[4 to 5 days]	0.0	4	1	1	1
120819	1710	adjuvant chemotherapy consist	[adjuvant chemotherapy consisting]	0.0	3	1	1	1
120820	1710	embryonic muscle lineage	[embryonic muscle lineage]	0.0	3	1	1	1
120821	1710	treatment of a cell line	[Treatment of a cell line]	0.0	5	1	1	1
120822	1710	level of IFN a IFNA	[levels of IFN A IFNA]	0.0	5	1	1	1
120823	1710	several cytokine genes,	[several cytokine genes,]	0.0	3	1	1	1
120824	1710	mutation of the genuine site	[Mutations of the genuine site]	0.0	5	1	1	1
120825	1710	include Syk	[including Syk]	0.0	2	1	1	1
120826	1710	stimulus product	[stimuli products]	0.0	2	1	1	1
120827	1710	malignant lymphoid cell	[malignant lymphoid cells]	0.0	3	1	1	1
120828	1710	region of il-2r beta asn240-leu335	[region of IL-2R beta Asn240-Leu335]	0.0	5	1	1	1
120829	1710	early gene Ie of cytomegalovirus	[early genes IE of cytomegalovirus]	0.0	5	1	1	1
120830	1710	category of hiv- hd	[categories of HIV- HD]	0.0	4	1	1	1
120831	1710	fra-1 follow engagement	[fra-1 following engagement]	0.0	3	1	1	1
120832	1710	basis of a lymphokine deficiency	[basis of a lymphokine deficiency]	0.0	5	1	1	1
120833	1710	whole-cell competitive radioassay	[whole-cell competitive radioassay]	0.0	3	1	1	1
120834	1710	NH(2)-terminal domain	[NH(2)-terminal domain]	0.0	2	1	1	1
120835	1710	research groups.	[research groups.]	0.0	2	1	1	1
120836	1710	use anti-ERK signal-regulated kinase antibody	[using anti-ERK signal-regulated kinase antibodies]	0.0	5	1	1	1
120837	1710	protein kinase C depletion	[Protein kinase C depletion]	0.0	4	1	1	1
120838	1710	inhibitory subunit IkappaB	[inhibitory subunit IkappaB]	0.0	3	1	1	1
120839	1710	signalsome protein	[signalsome proteins]	0.0	2	1	1	1
120840	1710	il-7r signal transduction	[IL-7R signal transduction]	0.0	3	1	1	1
120841	1710	factor bind to site not 4681	[Factors binding to site nt 4681]	0.0	6	1	1	1
120842	1710	normal peripheral blood DC	[normal peripheral blood DC]	0.0	4	1	1	1
120843	1710	tcl1 (at 14q32	[TCL1 (at 14q32]	0.0	3	1	1	1
120844	1710	Nuclear factor-kappaB activation in monocyte	[Nuclear factor-kappaB activation in monocytes]	0.0	5	1	1	1
120845	1710	oxidant hypochlorous acid	[oxidant hypochlorous acid]	0.0	3	1	1	1
120846	1710	massive enhancement HL cell	[massive enhancement HL cells]	0.0	4	1	1	1
120847	1710	inhibition 2-hydroxy-4-trifluoromethylbenzoic acid	[Inhibition 2-hydroxy-4-trifluoromethylbenzoic acid]	0.0	3	1	1	1
120848	1710	proteolytic activity.	[proteolytic activity.]	0.0	2	1	1	1
120849	1710	extinction of other gene	[extinction of other genes]	0.0	4	1	1	1
120850	1710	NF-kappaB binding sequence	[NF-kappaB binding sequence]	0.0	3	1	1	1
120851	1710	functional synergy between il-12	[functional synergy between IL-12]	0.0	4	1	1	1
120852	1710	two nfat-like element	[two NFAT-like elements]	0.0	3	1	1	1
120853	1710	activity of basic hlh protein	[activities of basic HLH proteins]	0.0	5	1	1	1
120854	1710	arthrogenic autoantigen	[arthrogenic autoantigen]	0.0	2	1	1	1
120855	1710	palindromic nf-kappa b probe	[palindromic NF-kappa B probe]	0.0	4	1	1	1
120856	1710	chemoattractant receptor	[chemoattractant receptors]	0.0	2	1	1	1
120857	1710	tal1 locus	[TAL1 locus]	0.0	2	1	1	1
120858	1710	sphingomyelinase of the endolysosomial membrane	[sphingomyelinase of the endolysosomial membrane]	0.0	5	1	1	1
120859	1710	group of mutant	[group of mutants]	0.0	3	1	1	1
120860	1710	ALG-4F	[ALG-4F]	0.0	1	1	1	1
120861	1710	15.5 (p	[15.5 (P]	0.0	2	1	1	1
120862	1710	cell shape	[cell shape]	0.0	2	1	1	1
120863	1710	staurosporine kinase	[staurosporine kinase]	0.0	2	1	1	1
120864	1710	CCAAT sequence for several transcription factor	[CCAAT sequences for several transcription factors]	0.0	6	1	1	1
120865	1710	transcriptional activator of many promoter	[transcriptional activator of many promoters]	0.0	5	1	1	1
120866	1710	additionally, virus reactivation	[Additionally, virus reactivation]	0.0	3	1	1	1
120867	1710	enhancerless construct	[enhancerless construct]	0.0	2	1	1	1
120868	1710	oct-binding factor obf-1	[Oct-binding factor OBF-1]	0.0	3	1	1	1
120869	1710	long repeat of hiv-1	[long repeat of HIV-1]	0.0	4	3	3	1
120870	1710	protection against nf-kappab action	[protection against NF-kappaB action]	0.0	4	1	1	1
120871	1710	5 u/ml interleukin-2	[5 U/ml interleukin-2]	0.0	3	1	1	1
120872	1710	gag/pol	[gag/pol]	0.0	1	1	1	1
120873	1710	serum ast/alt	[serum AST/ALT]	0.0	2	1	1	1
120874	1710	erythropoietin manner	[erythropoietin manner]	0.0	2	1	1	1
120875	1710	glucocorticoid-evoked cell death	[glucocorticoid-evoked cell death]	0.0	3	1	1	1
120876	1710	enzyme of catabolism	[enzyme of catabolism]	0.0	3	1	1	1
120877	1710	stimuli, include tumor necrosis factor	[stimuli, including tumor necrosis factor]	0.0	5	1	1	1
120878	1710	initial enzyme pyrimidine (and fura	[initial enzyme pyrimidine (and FUra]	0.0	5	1	1	1
120879	1710	different gene element	[different gene elements]	0.0	3	1	1	1
120880	1710	human myeloid cell differentiation antigen	[human myeloid cell differentiation antigen]	0.0	5	2	2	1
120881	1710	young adult before dst	[young adults before DST]	0.0	4	1	1	1
120882	1710	75-kDa hematopoietic cell-specific signal protein	[75-kDa hematopoietic cell-specific signaling protein]	0.0	5	1	1	1
120883	1710	peptide in the endoplasmic reticulum	[peptides in the endoplasmic reticulum]	0.0	5	1	1	1
120884	1710	T cell during thymic selection	[T cells during thymic selection]	0.0	5	1	1	1
120885	1710	phosphoryl	[phosphoryl]	0.0	1	1	1	1
120886	1710	clone 13 extract	[clone 13 extracts]	0.0	3	1	1	1
120887	1710	formation the kappa b complex	[formation the kappa B complex]	0.0	5	1	1	1
120888	1710	h of stimulation with mAb	[h of stimulation with mAb]	0.0	5	1	1	1
120889	1710	peripheral blood lymphocyte PBL generation	[peripheral blood lymphocytes PBL Generation]	0.0	5	1	1	1
120890	1710	total 135eoh)2d3 uptake	[total 1,25(OH)2D3 uptake]	0.0	3	1	1	1
120891	1710	role for c-Myc	[role for c-Myc]	0.0	3	1	1	1
120892	1710	computer program.	[computer program.]	0.0	2	1	1	1
120893	1710	large cell lymphoma	[large cell lymphoma]	0.0	3	1	1	1
120894	1710	deficiency in lymphoid precursor cell	[deficiencies in lymphoid precursor cells]	0.0	5	1	1	1
120895	1710	leukocyte MNL from abdominal subject	[leukocytes MNL from abdominal subjects]	0.0	5	1	1	1
120896	1710	demonstrate independent	[demonstrating independent]	0.0	2	1	1	1
120897	1710	induction 1 expression in cell	[Induction 1 expression in cells]	0.0	5	1	1	1
120898	1710	high potential for mutation expansion	[high potential for mutation expansion]	0.0	5	1	1	1
120899	1710	function in Burkitt' lymphoma cell	[function in Burkitt's lymphoma cells]	0.0	5	1	1	1
120900	1710	EBV-associated, epitope	[EBV-associated, epitopes]	0.0	2	1	1	1
120901	1710	gram-negative bacterial endotoxin	[gram-negative bacterial endotoxin]	0.0	3	1	1	1
120902	1710	-specific phage clone	[-specific phage clones]	0.0	3	1	1	1
120903	1710	enhancement activator protein-1 binding activity;	[enhancement activator protein-1 binding activity;]	0.0	5	1	1	1
120904	1710	transcriptional regulation of acid lipase	[Transcriptional regulation of acid lipase]	0.0	5	1	1	1
120905	1710	oestrogen receptor er analysis correlation	[Oestrogen receptor ER analysis correlation]	0.0	5	1	1	1
120906	1710	additional stimulation	[Additional stimulation]	0.0	2	1	1	1
120907	1710	soluble dimeric tnf receptor	[soluble dimeric TNF receptor]	0.0	4	1	1	1
120908	1710	involvement of NF-kappa b	[involvement of NF-kappa B]	0.0	4	1	1	1
120909	1710	t-pll conditions.	[T-PLL conditions.]	0.0	2	1	1	1
120910	1710	role of macrophage	[role of macrophages]	0.0	3	1	1	1
120911	1710	function of signal transduction	[function of signal transduction]	0.0	4	1	1	1
120912	1710	8421 2126 (pre)	[8421 2126 (pre)]	0.0	3	1	1	1
120913	1710	identity with swi3 protein	[identity with SWI3 protein]	0.0	4	1	1	1
120914	1710	ptk to signal pathway	[PTKs to signaling pathways]	0.0	4	1	1	1
120915	1710	response induce agents.	[response inducing agents.]	0.0	3	1	1	1
120916	1710	2 h of ifn-gamma treatment	[2 h of IFN-gamma treatment]	0.0	5	1	1	1
120917	1710	zap-70 autophosphorylation	[ZAP-70 autophosphorylation]	0.0	2	1	1	1
120918	1710	proliferate epstein-barr virus b lymphocyte	[proliferating Epstein-Barr virus B lymphocytes]	0.0	5	1	1	1
120919	1710	syndrome with hyperkalemia	[syndrome with hyperkalemia]	0.0	3	1	1	1
120920	1710	nitric oxide synthase gene	[nitric oxide synthase gene]	0.0	4	1	1	1
120921	1710	disease four	[diseases four]	0.0	2	1	1	1
120922	1710	site of glucocorticoid receptor	[sites of glucocorticoid receptor]	0.0	4	1	1	1
120923	1710	receptor characteristic on leukocyte	[receptor characteristics on leukocytes]	0.0	4	1	1	1
120924	1710	cd16 activation	[CD16 activation]	0.0	2	1	1	1
120925	1710	mechanism of latency	[mechanism of latency]	0.0	3	1	1	1
120926	1710	erythroid factor activity by interaction	[erythroid factor activity by interaction]	0.0	5	1	1	1
120927	1710	0.1%	[0.1%]	0.0	1	1	1	1
120928	1710	cd4+ lymphocyte at level,	[CD4+ lymphocytes at level,]	0.0	4	1	1	1
120929	1710	binding assay with nuclear extract	[binding assays with nuclear extracts]	0.0	5	1	1	1
120930	1710	localization outside	[localization outside]	0.0	2	1	1	1
120931	1710	cell extract from lymphoblastic leukemia all	[cell extracts from lymphoblastic leukemia ALL]	0.0	6	1	1	1
120932	1710	uas1 sequence	[UAS1 sequences]	0.0	2	1	1	1
120933	1710	antigenic specificity	[antigenic specificity]	0.0	2	2	2	1
120934	1710	activation by NF-kappa b /ap-1	[activation by NF-kappa B /AP-1]	0.0	5	1	1	1
120935	1710	expression of CD38 antigen in cell	[expression of CD38 antigen in cells]	0.0	6	1	1	1
120936	1710	role for the progesterone receptor	[role for the progesterone receptor]	0.0	5	1	1	1
120937	1710	induction of MNP-1	[induction of MNP-1]	0.0	3	1	1	1
120938	1710	antiviral protection	[antiviral protection]	0.0	2	1	1	1
120939	1710	colony-stimulating factor g-csf	[colony-stimulating factor G-CSF]	0.0	3	2	2	1
120940	1710	matrix metalloproteinase 9 mmp9	[matrix metalloproteinase 9 MMP9]	0.0	4	1	1	1
120941	1710	mouse genomic DNA clone	[mouse genomic DNA clones]	0.0	4	1	1	1
120942	1710	ribonucleoprotein k protein	[ribonucleoprotein K protein]	0.0	3	1	1	1
120943	1710	p-creb level	[P-CREB levels]	0.0	2	1	1	1
120944	1710	mediator in inflammatory disease	[mediators in inflammatory diseases]	0.0	4	1	1	1
120945	1710	involvement of Jak	[involvement of Jak]	0.0	3	1	1	1
120946	1710	common sh3-sh2-sh3 motif	[common SH3-SH2-SH3 motif]	0.0	3	1	1	1
120947	1710	unexpected observation	[unexpected observations]	0.0	2	1	1	1
120948	1710	mixture of ifn-gamma gag	[mixture of IFN-gamma GAGs]	0.0	4	1	1	1
120949	1710	+/- 0.49	[+/- 0.49]	0.0	2	1	1	1
120950	1710	minor protein of 82	[minor proteins of 82]	0.0	4	1	1	1
120951	1710	granule exocytosis	[granule exocytosis]	0.0	2	1	1	1
120952	1710	significantly (p 0.01) leukocyte adhesion	[significantly (P 0.01) leukocyte adhesion]	0.0	5	1	1	1
120953	1710	b cell signal	[B cell signaling]	0.0	3	1	1	1
120954	1710	immunohistochemical analysis	[immunohistochemical analysis]	0.0	2	1	1	1
120955	1710	several molecular weight adaptor protein	[several molecular weight adaptor proteins]	0.0	5	1	1	1
120956	1710	th2-type lymphocyte	[Th2-type lymphocytes]	0.0	2	1	1	1
120957	1710	early production of factor kappab binding	[early production of factor kappaB binding]	0.0	6	1	1	1
120958	1710	suggest a cooperative effect	[suggesting a cooperative effect]	0.0	4	1	1	1
120959	1710	testing of the effect	[testing of the effects]	0.0	4	1	1	1
120960	1710	include case without detectable calm	[including case without detectable CALM]	0.0	5	1	1	1
120961	1710	new mrna synthesis	[new mRNA synthesis]	0.0	3	1	1	1
120962	1710	GR number lymphocyte	[GR number lymphocytes]	0.0	3	1	1	1
120963	1710	thin-layer chromatography analysis	[thin-layer chromatography analyses]	0.0	3	1	1	1
120964	1710	especially the human homolog c/ebp-beta NF-IL6	[especially the human homolog C/EBP-beta NF-IL6]	0.0	6	1	1	1
120965	1710	nf-kappab subunit activation	[NF-kappaB subunit activation]	0.0	3	1	1	1
120966	1710	cellular activation follow binding	[cellular activation following binding]	0.0	4	1	1	1
120967	1710	slight increases.	[slight increases.]	0.0	2	1	1	1
120968	1710	TP1 promoter-reporter gene construct	[TP1 promoter-reporter gene constructs]	0.0	4	1	1	1
120969	1710	intestinal	[intestinal]	0.0	1	1	1	1
120970	1710	also IL-4 activation	[also IL-4 activation]	0.0	3	1	1	1
120971	1710	recovery of surface expression	[recovery of surface expression]	0.0	4	1	1	1
120972	1710	activity of JNK kinase	[activity of JNK kinase]	0.0	4	1	1	1
120973	1710	season,	[season,]	0.0	1	1	1	1
120974	1710	pro-apoptotic effect	[pro-apoptotic effects]	0.0	2	1	1	1
120975	1710	developments, include the identification of family	[developments, including the identification of families]	0.0	6	1	1	1
120976	1710	molecular basis for the interaction	[molecular basis for the interaction]	0.0	5	1	1	1
120977	1710	ap-1;	[AP-1;]	0.0	1	1	1	1
120978	1710	surround background,	[surrounding background,]	0.0	2	1	1	1
120979	1710	overexpression of alg-4 transcription	[Overexpression of ALG-4 transcription]	0.0	4	1	1	1
120980	1710	ap-2-	[AP-2-]	0.0	1	1	1	1
120981	1710	small, increase	[small, increase]	0.0	2	1	1	1
120982	1710	tnf to phorbol	[TNF to phorbol]	0.0	3	1	1	1
120983	1710	NADPH oxidase	[NADPH oxidase]	0.0	2	1	1	1
120984	1710	antigen (include muscle actin	[antigens (including muscle actin]	0.0	4	1	1	1
120985	1710	therapy for disease	[therapy for diseases]	0.0	3	1	1	1
120986	1710	binding by the z protein	[binding by the Z protein]	0.0	5	1	1	1
120987	1710	effect of cysteamine	[effect of cysteamine]	0.0	3	1	1	1
120988	1710	event other	[events other]	0.0	2	1	1	1
120989	1710	Thus, NF-kappa B a potent activator	[Thus, NF-kappa B a potent activator]	0.0	6	1	1	1
120990	1710	calcineurin 2B protein phosphatase	[calcineurin 2B protein phosphatase]	0.0	4	1	1	1
120991	1710	only after internalization of antigen	[only after internalization of antigen]	0.0	5	1	1	1
120992	1710	several human cell include monocyte	[several human cells including monocytes]	0.0	5	1	1	1
120993	1710	granulocyte factor granulocyte-macrophage colony-stimumulatelany-stg factor proliferation	[granulocyte factor granulocyte-macrophage colony-stimulating factor proliferation]	0.0	6	1	1	1
120994	1710	antitumour DNA topoisomerase inhibitor	[antitumour DNA topoisomerase inhibitors]	0.0	4	1	1	1
120995	1710	interferon beta ifn-beta	[interferon beta IFN-beta]	0.0	3	1	1	1
120996	1710	binding site for b-cell-specific activator protein	[binding sites for B-cell-specific activator protein]	0.0	6	1	1	1
120997	1710	mixture, associate	[mixture, associates]	0.0	2	1	1	1
120998	1710	rwleu-4 cell to vd3	[RWLeu-4 cells to VD3]	0.0	4	1	1	1
120999	1710	dual action of acid on hematopoiesis	[Dual action of acid on hematopoiesis]	0.0	6	1	1	1
121000	1710	and/or anti-inflammatory cytokine	[and/or anti-inflammatory cytokine]	0.0	3	1	1	1
121001	1710	13 healthy control	[13 healthy controls]	0.0	3	1	1	1
121002	1710	up-regulation of MHC class	[up-regulation of MHC class]	0.0	4	1	1	1
121003	1710	broth	[broths]	0.0	1	1	1	1
121004	1710	high affinity tnfrp75 molecule	[high affinity TNFRp75 molecules]	0.0	4	1	1	1
121005	1710	erythroid factor-DNA complex	[erythroid factor-DNA complexes]	0.0	3	1	1	1
121006	1710	quantitation triiodothyronine receptor mrna in tissue	[Quantitation triiodothyronine receptor mRNA in tissues]	0.0	6	1	1	1
121007	1710	ligation of fas by abs ligand	[Ligation of Fas by Abs ligand]	0.0	6	1	1	1
121008	1710	activity at concentration low	[activity at concentrations lower]	0.0	4	1	1	1
121009	1710	allele in cell line	[alleles in cell lines]	0.0	4	1	1	1
121010	1710	free calcium concentration ca2+ ]i	[free calcium concentration Ca2+ ]i]	0.0	5	1	1	1
121011	1710	immunodeficiency virus type hiv-2 like hiv-1	[immunodeficiency virus type HIV-2 like HIV-1]	0.0	6	1	1	1
121012	1710	region of CBP	[region of CBP]	0.0	3	1	1	1
121013	1710	generation of immunity	[generation of immunity]	0.0	3	1	1	1
121014	1710	transactivation region	[transactivation region]	0.0	2	1	1	1
121015	1710	essential regulatory element	[essential regulatory element]	0.0	3	1	1	1
121016	1710	Stat6 dna-binding activity	[Stat6 DNA-binding activity]	0.0	3	1	1	1
121017	1710	activation by modification	[activation by modification]	0.0	3	1	1	1
121018	1710	drosophila transcription factor	[Drosophila transcription factor]	0.0	3	1	1	1
121019	1710	erythroid-specific dnase site-forming element HSFE	[erythroid-specific DNase site-forming element HSFE]	0.0	5	1	1	1
121020	1710	however, overexpression	[However, overexpression]	0.0	2	1	1	1
121021	1710	(18- female volunteer	[(18- female volunteers]	0.0	3	1	1	1
121022	1710	probably due to interaction	[probably due to interactions]	0.0	4	1	1	1
121023	1710	works,	[works,]	0.0	1	1	1	1
121024	1710	role of the epithelial cell	[role of the epithelial cell]	0.0	5	1	1	1
121025	1710	several feature characteristic of a ganglioside	[several features characteristic of a ganglioside]	0.0	6	1	1	1
121026	1710	rare heterozygous DNA variation 2418delA	[rare heterozygous DNA variations 2418delA]	0.0	5	1	1	1
121027	1710	works?	[works?]	0.0	1	1	1	1
121028	1710	evidence key mediator during syphilis disease	[evidence key mediators during syphilis disease]	0.0	6	1	1	1
121029	1710	two oligonucleotide	[Two oligonucleotides]	0.0	2	1	1	1
121030	1710	cd3+ cell in pregnancy	[CD3+ cells in pregnancy]	0.0	4	1	1	1
121031	1710	six nuclear antigen EBNA	[six nuclear antigens EBNA]	0.0	4	1	1	1
121032	1710	lymphocyte infiltration a role	[lymphocyte infiltration a role]	0.0	4	1	1	1
121033	1710	-353 bp	[-353 bp]	0.0	2	1	1	1
121034	1710	suppress central nervous system	[suppressing central nervous system]	0.0	4	1	1	1
121035	1710	hb-egf mrna	[HB-EGF mRNA]	0.0	2	3	3	1
121036	1710	relationship between gr binding capacity	[relationship between GR binding capacity]	0.0	5	1	1	1
121037	1710	set of independent evidence	[sets of independent evidences]	0.0	4	1	1	1
121038	1710	determine the differentiation pathway	[determining the differentiation pathway]	0.0	4	1	1	1
121039	1710	immunoperoxidase	[immunoperoxidase]	0.0	1	1	1	1
121040	1710	biological model of a opposite situation	[biological models of an opposite situation]	0.0	6	1	1	1
121041	1710	transcriptional activation of NF-AT	[transcriptional activation of NF-AT]	0.0	4	1	1	1
121042	1710	hashimoto	[Hashimoto's]	0.0	1	1	1	1
121043	1710	argument for a origin	[arguments for a origin]	0.0	4	1	1	1
121044	1710	trans-disulfide of thiamine holo drug	[trans-disulfide of thiamine holo drug]	0.0	5	1	1	1
121045	1710	immunosuppressive drug pnu156804	[immunosuppressive drug PNU156804]	0.0	3	1	1	1
121046	1710	region UAS3 -1168 to -440	[regions UAS3 -1168 to -440]	0.0	5	1	1	1
121047	1710	tyrosine phosphorylation indicate a causal relationship	[tyrosine phosphorylation indicating a causal relationship]	0.0	6	1	1	1
121048	1710	factor of T cell -1	[factor of T cells -1]	0.0	5	1	1	1
121049	1710	antagonism in erythroid cell	[antagonism in erythroid cells]	0.0	4	1	1	1
121050	1710	effect on event to cell	[effect on event to cells]	0.0	5	1	1	1
121051	1710	part to difference	[part to differences]	0.0	3	1	1	1
121052	1710	exposure, animal species	[exposure, animal species]	0.0	3	1	1	1
121053	1710	co-ligation	[Co-ligation]	0.0	1	1	1	1
121054	1710	single promoter region	[single promoter region]	0.0	3	1	1	1
121055	1710	study use antisense oligonucleotide	[studies using antisense oligonucleotides]	0.0	4	1	1	1
121056	1710	E-selectin gene exhibit	[E-selectin gene exhibits]	0.0	3	1	1	1
121057	1710	reconstitution of Rb	[reconstitution of Rb]	0.0	3	1	1	1
121058	1710	c-Jun n-terminal kinase JNK	[c-Jun N-terminal kinase JNK]	0.0	4	1	1	1
121059	1710	Specific binding at level	[Specific binding at levels]	0.0	4	1	1	1
121060	1710	identification as protein lsp1	[Identification as protein LSP1]	0.0	4	1	1	1
121061	1710	gene expression of diverse receptor	[gene expression of diverse receptors]	0.0	5	1	1	1
121062	1710	new perspective	[new perspectives]	0.0	2	1	1	1
121063	1710	nuclear factor STAT-1	[nuclear factor STAT-1]	0.0	3	1	1	1
121064	1710	lead from monocytic cell	[leading from monocytic cells]	0.0	4	1	1	1
121065	1710	coexpression of ras	[Coexpression of Ras]	0.0	3	1	1	1
121066	1710	il-2 induction mrna	[IL-2 induction mRNA]	0.0	3	1	1	1
121067	1710	Tcf transcription	[Tcf transcription]	0.0	2	1	1	1
121068	1710	IL-4 -positive T cell	[IL-4 -positive T cells]	0.0	4	1	1	1
121069	1710	cd11b antigen	[CD11b antigen]	0.0	2	1	1	1
121070	1710	12-0-tetradecanoyl phorbol-13-acetate for 4-24 h	[12-0-tetradecanoyl phorbol-13-acetate for 4-24 h]	0.0	5	1	1	1
121071	1710	hormone in undernutrition	[hormones in undernutrition]	0.0	3	1	1	1
121072	1710	immunoglobulin heavy chain gene rearrangement	[immunoglobulin heavy chain gene rearrangement]	0.0	5	1	1	1
121073	1710	distinct multi-protein complex RFX	[distinct multi-protein complexes RFX]	0.0	4	1	1	1
121074	1710	high dose (more	[higher dose (more]	0.0	3	1	1	1
121075	1710	subunit of a transcription factor	[subunits of a transcription factor]	0.0	5	1	1	1
121076	1710	manner parallel	[manner parallel]	0.0	2	1	1	1
121077	1710	IL-12 NK cell	[IL-12 NK cells]	0.0	3	1	1	1
121078	1710	low passage strains.	[low passage strains.]	0.0	3	1	1	1
121079	1710	grade of c-fos-positive lymphocyte	[grades of c-fos-positive lymphocytes]	0.0	4	1	1	1
121080	1710	isopropylidine group	[isopropylidine group]	0.0	2	1	1	1
121081	1710	cysteine derivative	[cysteine derivatives]	0.0	2	1	1	1
121082	1710	very low-potency agonist,	[very low-potency agonist,]	0.0	3	1	1	1
121083	1710	expression namely activator protein-1 factor	[expression namely activator protein-1 factor]	0.0	5	1	1	1
121084	1710	mass kda	[mass kDa]	0.0	2	1	1	1
121085	1710	control of NFATx1 translocation	[Control of NFATx1 translocation]	0.0	4	1	1	1
121086	1710	[il-2]-dependent ht-2 line	[[IL-2]-dependent HT-2 line]	0.0	3	1	1	1
121087	1710	lymphoid factor otf2	[lymphoid factor OTF2]	0.0	3	1	1	1
121088	1710	281 61 pmol/L;	[281 61 pmol/L;]	0.0	3	1	1	1
121089	1710	land globular, structure	[LANDs globular, structures]	0.0	3	1	1	1
121090	1710	transcription of the adjacent repeat region	[transcription of the adjacent repeat region]	0.0	6	1	1	1
121091	1710	nfat translocation	[NFAT translocation]	0.0	2	1	1	1
121092	1710	expansion now suitable	[expansion now suitable]	0.0	3	1	1	1
121093	1710	translocation of member	[translocation of members]	0.0	3	1	1	1
121094	1710	glycoprotein hormone erythropoietin	[glycoprotein hormone erythropoietin]	0.0	3	1	1	1
121095	1710	generation of inflammatory condition	[generation of inflammatory conditions]	0.0	4	1	1	1
121096	1710	immune pathway	[immune pathways]	0.0	2	1	1	1
121097	1710	dc-t-cell syncytia	[DC-T-cell syncytia]	0.0	2	1	1	1
121098	1710	analysis of nfat factor	[analysis of NFAT factor]	0.0	4	1	1	1
121099	1710	colony-form unit monocyte cfu-m	[colony-forming unit monocyte CFU-M]	0.0	4	1	1	1
121100	1710	cell before steroid treatment	[cells before steroid treatment]	0.0	4	1	1	1
121101	1710	infiltrate (p	[infiltrate (P]	0.0	2	1	1	1
121102	1710	697 pmol/L (p	[697 pmol/L (P]	0.0	3	1	1	1
121103	1710	number of lymphocytic mineralocorticoid receptor	[number of lymphocytic mineralocorticoid receptors]	0.0	5	1	1	1
121104	1710	pcdd/pcdf -body burden	[PCDD/PCDF -body burden]	0.0	3	1	1	1
121105	1710	endogenous il-4 mrna	[endogenous IL-4 mRNA]	0.0	3	1	1	1
121106	1710	jurkat-tag T	[Jurkat-TAg T]	0.0	2	1	1	1
121107	1710	viral antigen in vitro	[viral antigens in vitro]	0.0	4	1	1	1
121108	1710	cd14+ human monocyte	[CD14+ human monocytes]	0.0	3	1	1	1
121109	1710	mip-1 alpha /gos19	[MIP-1 alpha /GOS19]	0.0	3	1	1	1
121110	1710	interleukin-5 a factor	[interleukin-5 a factor]	0.0	3	1	1	1
121111	1710	Sp1 binding	[Sp1 binding]	0.0	2	1	1	1
121112	1710	only factor present	[only factor present]	0.0	3	1	1	1
121113	1710	region include the region	[region including the region]	0.0	4	1	1	1
121114	1710	role for the AP-1 site	[role for the AP-1 sites]	0.0	5	1	1	1
121115	1710	C-terminal activating region	[C-terminal activating regions]	0.0	3	1	1	1
121116	1710	Ca2+/calmodulin-regulated, protein phosphatase	[Ca2+/calmodulin-regulated, protein phosphatase]	0.0	3	1	1	1
121117	1710	lymphocytic	[lymphocytic]	0.0	1	1	1	1
121118	1710	deficiency of the T cell	[deficiency of the T cells]	0.0	5	1	1	1
121119	1710	actions, include immuno-modulatory effect	[actions, including immuno-modulatory effects]	0.0	4	1	1	1
121120	1710	glucocorticoid receptor on leucocyte	[glucocorticoid receptors on leucocytes]	0.0	4	1	1	1
121121	1710	potential binding site for ms-2	[potential binding sites for MS-2]	0.0	5	1	1	1
121122	1710	addition to the cell	[addition to the cells]	0.0	4	1	1	1
121123	1710	cover the entire surface	[covering the entire surface]	0.0	4	1	1	1
121124	1710	ability of different b subunit	[abilities of different B subunits]	0.0	5	1	1	1
121125	1710	active region	[active region]	0.0	2	1	1	1
121126	1710	demonstration of a inhibition	[demonstration of a inhibition]	0.0	4	1	1	1
121127	1710	inhibitor protein ikappab-alpha	[inhibitor protein IkappaB-alpha]	0.0	3	1	1	1
121128	1710	half-life of mrna	[half-life of mRNA]	0.0	3	1	1	1
121129	1710	downstream in the induction	[downstream in the induction]	0.0	4	1	1	1
121130	1710	adenosine monophosphate signal	[adenosine monophosphate signaling]	0.0	3	1	1	1
121131	1710	gene regulation.	[gene regulation.]	0.0	2	1	1	1
121132	1710	expression of the complex	[expression of the complex]	0.0	4	1	1	1
121133	1710	extend from approximately -500 promoter region	[extending from approximately -500 promoter regions]	0.0	6	1	1	1
121134	1710	region between basis -107	[region between bases -107]	0.0	4	1	1	1
121135	1710	intact leukocyte	[intact leukocytes]	0.0	2	1	1	1
121136	1710	switch during G1-to- phase	[switch during G1-to-S phase]	0.0	4	1	1	1
121137	1710	contain cell cycle	[containing cell cycle]	0.0	3	1	1	1
121138	1710	labial salivary gland biopsy	[labial salivary gland biopsies]	0.0	4	1	1	1
121139	1710	U-937 promonocytic cell	[U-937 promonocytic cells]	0.0	3	1	1	1
121140	1710	ap-1 activity by gel-shift analysis	[AP-1 activity by gel-shift analysis]	0.0	5	1	1	1
121141	1710	three class gene	[three class genes]	0.0	3	1	1	1
121142	1710	RNA polymerase repeat	[RNA polymerase repeat]	0.0	3	1	1	1
121143	1710	accord to exercise protocols:	[according to exercise protocols:]	0.0	4	1	1	1
121144	1710	204 bp	[204 bp]	0.0	2	1	1	1
121145	1710	possibly evasion	[possibly evasion]	0.0	2	1	1	1
121146	1710	activity of serine /threonine phosphatase	[activity of serine /threonine phosphatases]	0.0	5	1	1	1
121147	1710	regulatory domain i-binding factor-1	[regulatory domain I-binding factor-1]	0.0	4	2	2	1
121148	1710	such as NF-kB	[such as NF-kB]	0.0	3	1	1	1
121149	1710	nodular lymphocyte predominance	[nodular lymphocyte predominance]	0.0	3	1	1	1
121150	1710	adhesive role,	[adhesive role,]	0.0	2	1	1	1
121151	1710	e(2) murine monocytic line, e(2)	[E(2) murine monocytic line, E(2)]	0.0	5	1	1	1
121152	1710	creb )/activating transcription factor-1	[CREB )/activating transcription factor-1]	0.0	4	1	1	1
121153	1710	most primitive cell	[most primitive cells]	0.0	3	1	1	1
121154	1710	similar behaviour	[similar behaviours]	0.0	2	1	1	1
121155	1710	use a promoter construct	[using a promoter construct]	0.0	4	1	1	1
121156	1710	fetal thymus	[fetal thymus]	0.0	2	1	1	1
121157	1710	mrna display analysis	[mRNA display analysis]	0.0	3	1	1	1
121158	1710	50% dose of nm	[50% dose of nM]	0.0	4	1	1	1
121159	1710	hd of the population	[HD of the population]	0.0	4	1	1	1
121160	1710	hiv- LTR	[HIV- LTR]	0.0	2	1	1	1
121161	1710	variant analysis	[variants analysis]	0.0	2	1	1	1
121162	1710	myeloblastic leukemia hl-60 cell	[myeloblastic leukemia HL-60 cells]	0.0	4	1	1	1
121163	1710	study of the anti-tumor immunity	[studies of the anti-tumor immunity]	0.0	5	1	1	1
121164	1710	B.pertussis	[B.pertussis]	0.0	1	1	1	1
121165	1710	transmission electron	[transmission electron]	0.0	2	1	1	1
121166	1710	means understand the role of p38	[means understanding the role of p38]	0.0	6	1	1	1
121167	1710	mutation in a patient	[Mutation in a patient]	0.0	4	1	1	1
121168	1710	carry ig variable chain sequence	[carrying Ig variable chain sequences]	0.0	5	1	1	1
121169	1710	hour at degree c,	[hours at degrees C,]	0.0	4	1	1	1
121170	1710	cotransfection of JAK3 into cos-7 cell	[Cotransfection of JAK3 into COS-7 cells]	0.0	6	1	1	1
121171	1710	activation of STAT factor	[activation of STAT factors]	0.0	4	1	1	1
121172	1710	addition to the distinct complexess	[addition to the distinct complexes,]	0.0	5	1	1	1
121173	1710	relation between parameter	[relation between parameters]	0.0	3	1	1	1
121174	1710	reporter-gene assay	[reporter-gene assays]	0.0	2	1	1	1
121175	1710	various level	[Various levels]	0.0	2	1	1	1
121176	1710	moreover, TNF-alpha hiv-1 repeat LTR	[Moreover, TNF-alpha HIV-1 repeat LTR]	0.0	5	1	1	1
121177	1710	selective proteasome inhibitor	[selective proteasome inhibitors]	0.0	3	1	1	1
121178	1710	major growth factor	[major growth factor]	0.0	3	1	1	1
121179	1710	regulation of 4e-bp1	[regulation of 4E-BP1]	0.0	3	1	1	1
121180	1710	friend erythroleukemia	[Friend erythroleukemia]	0.0	2	1	1	1
121181	1710	woman with non-hodgkin' lymphoma NHL	[woman with non-Hodgkin's lymphoma NHL]	0.0	5	1	1	1
121182	1710	kind carry Val at 50	[kinds carrying Val at 50]	0.0	5	1	1	1
121183	1710	transgenic bone marrow cell	[transgenic bone marrow cells]	0.0	4	1	1	1
121184	1710	two adjacent cis-acting elements,	[two adjacent cis-acting elements,]	0.0	4	1	1	1
121185	1710	novel agents,	[novel agents,]	0.0	2	1	1	1
121186	1710	adolescent depressive disorder MDD	[adolescent depressive disorder MDD]	0.0	4	1	1	1
121187	1710	HL cell differentiated)	[HL cells differentiated)]	0.0	3	1	1	1
121188	1710	epidermal growth growth factor HB-EGF	[epidermal growth growth factor HB-EGF]	0.0	5	1	1	1
121189	1710	involve factor (nfat) protein	[involving factor (NFAT) proteins]	0.0	4	1	1	1
121190	1710	reduction of translocation	[reduction of translocation]	0.0	3	1	1	1
121191	1710	signal activity	[signaling activities]	0.0	2	1	1	1
121192	1710	level of a binding activity	[levels of a binding activity]	0.0	5	1	1	1
121193	1710	twou	[two,]	0.0	1	1	1	1
121194	1710	20- affinity consistent	[20- affinity consistent]	0.0	3	1	1	1
121195	1710	binding of thrombin-stimulated platelet	[binding of thrombin-stimulated platelets]	0.0	4	1	1	1
121196	1710	lineage hl60	[lineage HL60]	0.0	2	1	1	1
121197	1710	ICAM-1 /beta integrin fashion	[ICAM-1 /beta integrin fashion]	0.0	4	1	1	1
121198	1710	insight into the interaction	[insights into the interactions]	0.0	4	1	1	1
121199	1710	expression of ciita histocompatibility surface protein	[expression of CIITA histocompatibility surface proteins]	0.0	6	1	1	1
121200	1710	only mM	[only mM]	0.0	2	1	1	1
121201	1710	cd56+, cd33+, cd16- counterpart cell	[CD56+, CD33+, CD16- counterpart cell]	0.0	5	1	1	1
121202	1710	persist lifelong, asymptomatically	[persisting lifelong, asymptomatically]	0.0	3	1	1	1
121203	1710	include benzoquinone BQ	[including benzoquinone BQ]	0.0	3	1	1	1
121204	1710	circumvention	[Circumvention]	0.0	1	1	1	1
121205	1710	viral cycle promoter	[viral cycle promoters]	0.0	3	1	1	1
121206	1710	3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	[3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic]	0.0	1	1	1	1
121207	1710	putative stem cell hsc	[putative stem cells HSCs]	0.0	4	1	1	1
121208	1710	stimulus mediate different aspect	[stimuli mediating different aspects]	0.0	4	1	1	1
121209	1710	expression of histocompatibility complex surface protein	[expression of histocompatibility complex surface proteins]	0.0	6	1	1	1
121210	1710	two cleavage product	[two cleavage products]	0.0	3	1	1	1
121211	1710	equivalent levels:	[equivalent levels:]	0.0	2	1	1	1
121212	1710	two fold increase	[two fold increase]	0.0	3	1	1	1
121213	1710	cell-type specific induction	[cell-type specific induction]	0.0	3	1	1	1
121214	1710	Ligand-dependent repression of the transcription factor	[Ligand-dependent repression of the transcription factor]	0.0	6	1	1	1
121215	1710	hematopoietic cell T cell	[hematopoietic cells T cells]	0.0	4	1	1	1
121216	1710	effect of ventilatory strategy	[effects of ventilatory strategies]	0.0	4	1	1	1
121217	1710	N.Ringertz, G.Klein,	[N.Ringertz, G.Klein,]	0.0	2	1	1	1
121218	1710	activity, suggest essential	[activity, suggesting essential]	0.0	3	1	1	1
121219	1710	erythroid-specific hypersensitive site	[erythroid-specific hypersensitive site]	0.0	3	1	1	1
121220	1710	TNF-alpha hiv-1 terminal repeat LTR	[TNF-alpha HIV-1 terminal repeat LTR]	0.0	5	1	1	1
121221	1710	ebna-2 -pu.1 interaction.	[EBNA-2 -PU.1 interaction.]	0.0	3	1	1	1
121222	1710	glucocorticoid receptor in human cell	[glucocorticoid receptors in human cells]	0.0	5	1	1	1
121223	1710	pmol/L; in normal woman	[pmol/L; in normal women]	0.0	4	1	1	1
121224	1710	include t-cell mitogens, cytokine	[including T-cell mitogens, cytokines]	0.0	4	1	1	1
121225	1710	U937 clone	[U937 clones]	0.0	2	1	1	1
121226	1710	anti- TNF-alpha hiv-1 long repeat transcription	[anti- TNF-alpha HIV-1 long repeat transcription]	0.0	6	1	1	1
121227	1710	rdna the sub-unit of dna-protein kinase	[cDNAs the sub-unit of DNA-protein kinase]	0.0	6	1	1	1
121228	1710	dominant effector on activity	[dominant effector on activity]	0.0	4	1	1	1
121229	1710	two factor kB NF-kB regulatory element	[two factor kB NF-kB regulatory elements]	0.0	6	1	1	1
121230	1710	study on endocrine culture	[studies on endocrine cultures]	0.0	4	1	1	1
121231	1710	immediate gene egr-1	[immediate gene egr-1]	0.0	3	1	1	1
121232	1710	CD40-activated b lymphocyte	[CD40-activated B lymphocytes]	0.0	3	2	2	1
121233	1710	untreated subject	[untreated subjects]	0.0	2	1	1	1
121234	1710	8, histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[8, histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
121235	1710	However, result of staining	[However, results of staining]	0.0	4	1	1	1
121236	1710	harbor a yeast chromosome transgene	[harboring a yeast chromosome transgene]	0.0	5	1	1	1
121237	1710	kit ligand	[kit ligand]	0.0	2	1	1	1
121238	1710	microvessel cell hdmec	[microvessel cells HDMEC]	0.0	3	1	1	1
121239	1710	kilobasis (kb) of irf-1 5'-flanking DNA	[kilobases (kb) of IRF-1 5'-flanking DNA]	0.0	6	1	1	1
121240	1710	viral growth	[viral growth]	0.0	2	2	2	1
121241	1710	human cell line HL	[human cell line HL]	0.0	4	1	1	1
121242	1710	tyrosine kinase enzymatic activity	[tyrosine kinase enzymatic activity]	0.0	4	1	1	1
121243	1710	normal peripheral blood cell	[normal peripheral blood cells]	0.0	4	1	1	1
121244	1710	frequent lesion	[frequent lesion]	0.0	2	1	1	1
121245	1710	therapy in asthma.	[therapy in asthma.]	0.0	3	1	1	1
121246	1710	uncouple activation-dependent hs1 phosphorylation	[Uncoupling activation-dependent HS1 phosphorylation]	0.0	4	1	1	1
121247	1710	104-bp promoter region	[104-bp promoter region]	0.0	3	1	1	1
121248	1710	prominent constitutive binding	[prominent constitutive binding]	0.0	3	1	1	1
121249	1710	years) hypertensive	[years) hypertensives]	0.0	2	1	1	1
121250	1710	3) content of t3, dysfunction hypophyseal	[3) content of T3, dysfunction hypophyseal]	0.0	6	1	1	1
121251	1710	exhibit growth rate	[exhibiting growth rates]	0.0	3	1	1	1
121252	1710	drift from latency latency	[drift from latency latency]	0.0	4	1	1	1
121253	1710	Spi-1 transcript	[Spi-1 transcripts]	0.0	2	1	1	1
121254	1710	similar enhancement	[similar enhancement]	0.0	2	1	1	1
121255	1710	multiple response to the hormone,	[multiple responses to the hormone,]	0.0	5	1	1	1
121256	1710	profile of tissue	[profile of tissue]	0.0	3	1	1	1
121257	1710	constitutively active form substitute	[constitutively active form substitutes]	0.0	4	1	1	1
121258	1710	coproporphyrinogen oxidase	[coproporphyrinogen oxidase]	0.0	2	1	1	1
121259	1710	mucosal biopsy	[mucosal biopsies]	0.0	2	1	1	1
121260	1710	multiple regulatory region	[multiple regulatory regions]	0.0	3	1	1	1
121261	1710	inducible transcriptional regulator	[inducible transcriptional regulators]	0.0	3	1	1	1
121262	1710	diagnostic tool	[diagnostic tools]	0.0	2	1	1	1
121263	1710	level equivalent	[levels equivalent]	0.0	2	1	1	1
121264	1710	addition, N-acetyl-L-cysteine NAC a antioxidant,	[addition, N-acetyl-L-cysteine NAC a antioxidant,]	0.0	5	1	1	1
121265	1710	contain little	[containing little]	0.0	2	1	1	1
121266	1710	level of CAT activity	[level of CAT activity]	0.0	4	1	1	1
121267	1710	unrestricted expression of latent gene	[unrestricted expression of latent genes]	0.0	5	1	1	1
121268	1710	dehydroepiandrosterone binding activity by dehydroepiandrosterone	[dehydroepiandrosterone binding activity by dehydroepiandrosterone]	0.0	5	1	1	1
121269	1710	hypercholesteremia of type	[hypercholesteremia of type]	0.0	3	1	1	1
121270	1710	overview of bcl-2	[overview of bcl-2]	0.0	3	1	1	1
121271	1710	role a member	[role a member]	0.0	3	1	1	1
121272	1710	presence -neutralize antibody	[presence -neutralizing antibodies]	0.0	3	1	1	1
121273	1710	kinase -signal	[kinase -signal]	0.0	2	1	1	1
121274	1710	dominant negative pi3-k construct	[dominant negative PI3-K constructs]	0.0	4	1	1	1
121275	1710	inverse relation MHC	[inverse relation MHC]	0.0	3	1	1	1
121276	1710	effect of hypercortisolaemia on number	[effects of hypercortisolaemia on number]	0.0	5	1	1	1
121277	1710	patient with acne	[patients with acne]	0.0	3	1	1	1
121278	1710	rhythm of plasma cortisol	[rhythm of plasma cortisol]	0.0	4	1	1	1
121279	1710	positive margin (31%	[positive margins (31%]	0.0	3	1	1	1
121280	1710	interferon isotype	[interferon isotypes]	0.0	2	1	1	1
121281	1710	g/g of total rna in monocyte	[g/g of total RNA in monocytes]	0.0	6	1	1	1
121282	1710	target for kinase pathway	[targets for kinase pathways]	0.0	4	1	1	1
121283	1710	b lymphocyte immunoglobulin production	[B lymphocyte immunoglobulin production]	0.0	4	1	1	1
121284	1710	lineage-specific activation of STAT3	[Lineage-specific activation of STAT3]	0.0	4	1	1	1
121285	1710	patient undergo ptca	[patients undergoing PTCA]	0.0	3	1	1	1
121286	1710	primary site	[primary site]	0.0	2	2	2	1
121287	1710	secondary increase	[secondary increase]	0.0	2	1	1	1
121288	1710	NK cell membrane-bound lt signal	[NK cell membrane-bound LT signals]	0.0	5	1	1	1
121289	1710	molecule present	[molecule present]	0.0	2	1	1	1
121290	1710	several protein species	[several protein species]	0.0	3	1	1	1
121291	1710	distribution of nf-at activity	[distribution of NF-AT activity]	0.0	4	1	1	1
121292	1710	synovial lymphocyte reactivity	[synovial lymphocyte reactivity]	0.0	3	1	1	1
121293	1710	effect on electrolyte movement	[effects on electrolyte movements]	0.0	4	2	2	1
121294	1710	tnf-alpha protein	[TNF-alpha protein]	0.0	2	1	1	1
121295	1710	T cell by antigen	[T cell by antigen]	0.0	4	1	1	1
121296	1710	non hiv lymph node	[non HIV lymph nodes]	0.0	4	1	1	1
121297	1710	regulatory element of t-cell gene	[regulatory elements of T-cell genes]	0.0	5	1	1	1
121298	1710	assay of alpha-galactosidase in blood leucocyte	[assay of alpha-galactosidase in blood leucocytes]	0.0	6	1	1	1
121299	1710	pha normal peripheral blood lymphocyte pbl	[PHA normal peripheral blood lymphocytes PBL]	0.0	6	1	1	1
121300	1710	activation of form stat3alpha	[activation of forms STAT3alpha]	0.0	4	1	1	1
121301	1710	modification of Sp1	[modification of Sp1]	0.0	3	1	1	1
121302	1710	retinoic acid on human hematopoiesis	[retinoic acid on human hematopoiesis]	0.0	5	1	1	1
121303	1710	major glucocorticoid cortisol	[major glucocorticoid cortisol]	0.0	3	1	1	1
121304	1710	repeat transcription	[repeat transcription]	0.0	2	1	1	1
121305	1710	response by this two mechanism	[responses by these two mechanisms]	0.0	5	1	1	1
121306	1710	characterization of this element	[characterization of this element]	0.0	4	1	1	1
121307	1710	Anti-Ehrlichia	[Anti-Ehrlichia]	0.0	1	1	1	1
121308	1710	binding of [3H]1 alpha,25-dihydroxyvitamin D3 135eoh)2d3	[Binding of [3H]1 alpha,25-dihydroxyvitamin D3 1,25(OH)2D3]	0.0	6	1	1	1
121309	1710	(rt-pcr)	[(RT-PCR)]	0.0	1	2	2	1
121310	1710	leukemia m2-type cell line	[leukemia M2-type cell line]	0.0	4	1	1	1
121311	1710	cepharanthine on hiv-1 repeat	[cepharanthine on HIV-1 repeat]	0.0	4	1	1	1
121312	1710	differentiation of myeloid cells.	[differentiation of myeloid cells.]	0.0	4	1	1	1
121313	1710	concentration of protein	[concentrations of proteins]	0.0	3	1	1	1
121314	1710	encode gamma-globin delta-aminolevulinate synthase	[encoding gamma-globin delta-aminolevulinate synthase]	0.0	4	1	1	1
121315	1710	component of recruitment of monocyte	[component of recruitment of monocytes]	0.0	5	1	1	1
121316	1710	garlic s-allyl cysteine	[garlic S-allyl cysteine]	0.0	3	1	1	1
121317	1710	stretch of proline	[stretches of prolines]	0.0	3	1	1	1
121318	1710	CRE TGACGTCA	[CRE TGACGTCA]	0.0	2	1	1	1
121319	1710	healthy leukocyte antigen-B8	[healthy leukocyte antigen-B8]	0.0	3	1	1	1
121320	1710	binding of RBP	[Binding of RBP]	0.0	3	1	1	1
121321	1710	ELAM-1 by TNF	[ELAM-1 by TNF]	0.0	3	1	1	1
121322	1710	maternal infection	[maternal infections]	0.0	2	1	1	1
121323	1710	synthesis of derivative of doc	[Synthesis of derivatives of DOC]	0.0	5	1	1	1
121324	1710	ultimate outcome of exposure	[ultimate outcome of exposure]	0.0	4	1	1	1
121325	1710	Vitamin e therapy of hepatic injury	[Vitamin E therapy of hepatic injury]	0.0	6	1	1	1
121326	1710	control the step signal cascade	[controlling the steps signaling cascade]	0.0	5	1	1	1
121327	1710	modulate intracellular calcium in muscle cell	[modulating intracellular calcium in muscle cells]	0.0	6	1	1	1
121328	1710	txa2	[TXA2]	0.0	1	1	1	1
121329	1710	t-all cell	[T-ALL cells]	0.0	2	1	1	1
121330	1710	/precursor grow in culture,	[/precursors growing in culture,]	0.0	4	1	1	1
121331	1710	novel antitumor antibiotic	[novel antitumor antibiotic]	0.0	3	1	1	1
121332	1710	redox status.	[redox status.]	0.0	2	1	1	1
121333	1710	substantial importance for genetic counseling.	[substantial importance for genetic counseling.]	0.0	5	1	1	1
121334	1710	lymph node cell	[lymph node cells]	0.0	3	1	1	1
121335	1710	course of oral prednisone	[course of oral prednisone]	0.0	4	1	1	1
121336	1710	activation of N-WASP	[Activation of N-WASP]	0.0	3	1	1	1
121337	1710	RAR alpha hrar alpha	[RAR alpha hRAR alpha]	0.0	4	1	1	1
121338	1710	patterning	[patterning]	0.0	1	1	1	1
121339	1710	effect on the transcription factor	[effects on the transcription factor]	0.0	5	1	1	1
121340	1710	C beta gene	[C beta gene]	0.0	3	1	1	1
121341	1710	Bcl-6 expression heterogeneity	[Bcl-6 expression heterogeneity]	0.0	3	1	1	1
121342	1710	enhanced, follow h of cd19 cross-linking	[enhanced, following h of CD19 cross-linking]	0.0	6	1	1	1
121343	1710	gene in human progenitor cell	[genes in human progenitor cells]	0.0	5	1	1	1
121344	1710	human T cell transcription factor	[Human T cell transcription factor]	0.0	5	1	1	1
121345	1710	perception	[perception]	0.0	1	1	1	1
121346	1710	decline by T cell	[decline by T cells]	0.0	4	1	1	1
121347	1710	precursor cell of the lineage	[precursor cells of the lineage]	0.0	5	1	1	1
121348	1710	11 index absorptive patient	[11 index absorptive patients]	0.0	4	1	1	1
121349	1710	element from bp	[element from bp]	0.0	3	1	1	1
121350	1710	tnf- cell	[TNF- cells]	0.0	2	1	1	1
121351	1710	human 5-aminolevulinate synthase promoter analysis	[Human 5-aminolevulinate synthase promoter analysis]	0.0	5	1	1	1
121352	1710	receptor count in leukocyte	[receptor count in leukocytes]	0.0	4	1	1	1
121353	1710	transcriptional activate effect of p65	[transcriptional activating effects of p65]	0.0	5	1	1	1
121354	1710	quantitative dnase footprinting use increase amount	[quantitative DNase footprinting using increasing amounts]	0.0	6	1	1	1
121355	1710	acid HOCl	[acid HOCl]	0.0	2	1	1	1
121356	1710	autoregulation by cytoplasmic inhibitor	[Autoregulation by cytoplasmic inhibitors]	0.0	4	1	1	1
121357	1710	role of the proteasome	[roles of the proteasome]	0.0	4	1	1	1
121358	1710	activity il-1 in long-distance runner	[activity IL-1 in long-distance runner]	0.0	5	1	1	1
121359	1710	respect to control	[respect to control]	0.0	3	1	1	1
121360	1710	subset of CLL 25%	[subset of CLL 25%]	0.0	4	1	1	1
121361	1710	5'-race	[5'-RACE]	0.0	1	1	1	1
121362	1710	gr mrna induction.	[GR mRNA induction.]	0.0	3	1	1	1
121363	1710	autostimulatory loop	[autostimulatory loop]	0.0	2	1	1	1
121364	1710	arthritis synovium	[arthritis synovium]	0.0	2	1	1	1
121365	1710	vary concentration (0-125 microM)	[varying concentrations (0-125 microM)]	0.0	4	1	1	1
121366	1710	tyrosine phosphorylation indicate a relationship	[tyrosine phosphorylation indicating a relationship]	0.0	5	1	1	1
121367	1710	region two regulatory element	[region two regulatory elements]	0.0	4	1	1	1
121368	1710	component of human nf-at	[component of human NF-AT]	0.0	4	1	1	1
121369	1710	protein extract from leukemia CML cell	[protein extracts from leukemia CML cells]	0.0	6	1	1	1
121370	1710	several group	[several groups]	0.0	2	1	1	1
121371	1710	ebv DNA replication	[EBV DNA replication]	0.0	3	1	1	1
121372	1710	sensitization of naive T cell	[sensitization of naive T cells]	0.0	5	1	1	1
121373	1710	cell culture of human monocyte	[cell cultures of human monocytes]	0.0	5	1	1	1
121374	1710	mutagenesis sp-1 element	[Mutagenesis Sp-1 elements]	0.0	3	1	1	1
121375	1710	low level in cell type	[low levels in cell types]	0.0	5	1	1	1
121376	1710	nuclear resonance 3d-nmr spectroscopy	[nuclear resonance 3D-NMR spectroscopy]	0.0	4	1	1	1
121377	1710	U1 promonocytic culture	[U1 promonocytic cultures]	0.0	3	1	1	1
121378	1710	IL-5 -nonproduce	[IL-5 -nonproducing]	0.0	2	1	1	1
121379	1710	unicellular-unilineage erythropoietic culture	[Unicellular-unilineage erythropoietic cultures]	0.0	3	1	1	1
121380	1710	ifi IFN-alpha/beta in addition	[IFNs IFN-alpha/beta in addition]	0.0	4	1	1	1
121381	1710	sub-unit of dna-protein kinase	[sub-unit of DNA-protein kinase]	0.0	4	1	1	1
121382	1710	probe, extract from unstimulated T	[probe, extracts from unstimulated T]	0.0	5	1	1	1
121383	1710	topoisomerase ii	[topoisomerase II]	0.0	2	1	1	1
121384	1710	more mature phenotype	[more mature phenotype]	0.0	3	1	1	1
121385	1710	target of alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3	[targets of alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3]	0.0	6	1	1	1
121386	1710	induction I gene expression by il-4	[induction I gene expression by IL-4]	0.0	6	1	1	1
121387	1710	transfection experiments.	[transfection experiments.]	0.0	2	1	1	1
121388	1710	extent than diethylstilbestrol	[extent than diethylstilbestrol]	0.0	3	1	1	1
121389	1710	mechanism lead to B-cell apoptosis	[mechanisms leading to B-cell apoptosis]	0.0	5	1	1	1
121390	1710	transfection experiments,	[transfection experiments,]	0.0	2	1	1	1
121391	1710	signal-regulated kinase erk pathway	[signal-regulated kinase Erk pathway]	0.0	4	1	1	1
121392	1710	mono Mac with lipopolysaccharide lps	[Mono Mac with lipopolysaccharide LPS]	0.0	5	1	1	1
121393	1710	poor induction	[poor induction]	0.0	2	1	1	1
121394	1710	h of ifn-gamma treatment	[h of IFN-gamma treatment]	0.0	4	1	1	1
121395	1710	acute lung inflammatory injury	[acute lung inflammatory injury]	0.0	4	1	1	1
121396	1710	mucosa-associated tissue lymphoma (19 of 45	[mucosa-associated tissue lymphoma (19 of 45]	0.0	6	1	1	1
121397	1710	tissue-specific component of signal transduction	[tissue-specific components of signal transduction]	0.0	5	1	1	1
121398	1710	noncoding	[noncoding]	0.0	1	1	1	1
121399	1710	pathogenesis of lymphocytic leukemia	[pathogenesis of lymphocytic leukemia]	0.0	4	1	1	1
121400	1710	clearly high translocation	[clearly higher translocation]	0.0	3	1	1	1
121401	1710	activity of calcineurin	[activity of calcineurin]	0.0	3	1	1	1
121402	1710	sex (1.35	[sexes (1.35]	0.0	2	1	1	1
121403	1710	rare in cell	[RAREs in cells]	0.0	3	1	1	1
121404	1710	factor kappa b a mediator	[factor kappa B a mediator]	0.0	5	1	1	1
121405	1710	role in il-4 induction	[role in IL-4 induction]	0.0	4	1	1	1
121406	1710	endosome	[endosomes]	0.0	1	1	1	1
121407	1710	ii breast cancer	[II breast cancer]	0.0	3	1	1	1
121408	1710	mg/24h; n: excretion,	[mg/24h; N: excretion,]	0.0	3	1	1	1
121409	1710	chronic rheumatoid arthritis patient	[chronic rheumatoid arthritis patients]	0.0	4	1	1	1
121410	1710	Specific receptor for Dihydroxyvitamin D3	[Specific receptors for Dihydroxyvitamin D3]	0.0	5	1	1	1
121411	1710	TNF-alpha hiv-1 terminal repeat LTR transcription	[TNF-alpha HIV-1 terminal repeat LTR transcription]	0.0	6	1	1	1
121412	1710	weight gain 8421 (pre)	[weight gain 8421 (pre)]	0.0	4	1	1	1
121413	1710	invariant peptide clip	[invariant peptides CLIP]	0.0	3	1	1	1
121414	1710	human IL-4 promoter 10-fold	[human IL-4 promoter 10-fold]	0.0	4	1	1	1
121415	1710	ascorbate AFR act	[ascorbate AFR acts]	0.0	3	1	1	1
121416	1710	addition of il-6	[addition of IL-6]	0.0	3	1	1	1
121417	1710	significant lung injury	[significant lung injury]	0.0	3	1	1	1
121418	1710	oxidant-rich airway secretion	[oxidant-rich airway secretions]	0.0	3	1	1	1
121419	1710	region contain four near-perfect repeat	[region containing four near-perfect repeats]	0.0	5	1	1	1
121420	1710	significant capacity	[significant capacity]	0.0	2	1	1	1
121421	1710	insight into role in maturation	[insights into role in maturation]	0.0	5	1	1	1
121422	1710	oxidant,	[oxidant,]	0.0	1	1	1	1
121423	1710	role in signal transduction	[role in signal transduction]	0.0	4	1	1	1
121424	1710	interaction of the transcription factor Sp1	[interactions of the transcription factors Sp1]	0.0	6	1	1	1
121425	1710	two long isoform	[two long isoforms]	0.0	3	2	2	1
121426	1710	transient induction	[transient induction]	0.0	2	1	1	1
121427	1710	sensitivity to inhibitor	[sensitivity to inhibitors]	0.0	3	1	1	1
121428	1710	expose human vein cell huvec	[Exposing human vein cells HUVECs]	0.0	5	1	1	1
121429	1710	response in drosophila	[response in Drosophila]	0.0	3	1	1	1
121430	1710	element specific	[elements specific]	0.0	2	1	1	1
121431	1710	importance on IL-6 macrophage-differentiation	[importance on IL-6 macrophage-differentiation]	0.0	4	1	1	1
121432	1710	effect of activity	[effects of activity]	0.0	3	2	2	1
121433	1710	great part	[greater part]	0.0	2	1	1	1
121434	1710	nuclear expression T cell	[nuclear expression T cells]	0.0	4	1	1	1
121435	1710	(p 0.01) leukocyte adhesion	[(P 0.01) leukocyte adhesion]	0.0	4	1	1	1
121436	1710	expression of the parameter	[expression of the parameters]	0.0	4	1	1	1
121437	1710	peripheral blood healthy volunteer man	[peripheral blood healthy volunteers men]	0.0	5	1	1	1
121438	1710	rel/nf-kappab protein	[Rel/NF-kappaB proteins]	0.0	2	1	1	1
121439	1710	mouse T lymphocyte	[mouse T lymphocytes]	0.0	3	1	1	1
121440	1710	retrovirus-like particle rvlp	[retrovirus-like particles RVLPs]	0.0	3	1	1	1
121441	1710	distinct promoter in monocytes/macrophages	[distinct promoters in monocytes/macrophages]	0.0	4	1	1	1
121442	1710	THP-1 phagocyte cell line	[THP-1 phagocyte cell line]	0.0	4	1	1	1
121443	1710	breast cancer patient aged 25-77.	[breast cancer patients aged 25-77.]	0.0	5	1	1	1
121444	1710	drug ald	[drugs ALD]	0.0	2	2	2	1
121445	1710	regimen on aging change	[regimen on aging changes]	0.0	4	1	1	1
121446	1710	(571 ng/ml) in plasma	[(571 ng/mL) in plasma]	0.0	4	1	1	1
121447	1710	blot with antibody specific	[blots with antibodies specific]	0.0	4	1	1	1
121448	1710	myeloid nuclear differentiation antigen MNDA	[myeloid nuclear differentiation antigen MNDA]	0.0	5	1	1	1
121449	1710	ikappab alpha in 6tg1.1 cell	[IkappaB alpha in 6TG1.1 cells]	0.0	5	1	1	1
121450	1710	cysteine lim-domain oncogene	[cysteine LIM-domain oncogenes]	0.0	3	1	1	1
121451	1710	evidence a direct result of activation	[evidence a direct result of activation]	0.0	6	1	1	1
121452	1710	various disease in Japan, cepharanthine	[various diseases in Japan, cepharanthine]	0.0	5	1	1	1
121453	1710	peripheral leukocyte of male	[peripheral leukocytes of males]	0.0	4	1	1	1
121454	1710	patient with advanced carcinoma	[patients with advanced carcinoma]	0.0	4	1	1	1
121455	1710	ability through NF-kappaB	[ability through NF-kappaB]	0.0	3	1	1	1
121456	1710	moreover, anti- TNF-alpha hiv-1 terminal repeat	[Moreover, anti- TNF-alpha HIV-1 terminal repeat]	0.0	6	1	1	1
121457	1710	patient with t-all	[patients with T-ALL]	0.0	3	1	1	1
121458	1710	pretreatment with monophosphate	[pretreatment with monophosphate]	0.0	3	1	1	1
121459	1710	abnormality in ability	[abnormality in ability]	0.0	3	1	1	1
121460	1710	attachment of monocyte	[attachment of monocytes]	0.0	3	1	1	1
121461	1710	myeloid-cell-specific c/ebp-epsilon transcription factor	[myeloid-cell-specific C/EBP-epsilon transcription factor]	0.0	4	1	1	1
121462	1710	brain involution	[brain involution]	0.0	2	2	2	1
121463	1710	dnase i-hypersensitive site	[DNase I-hypersensitive site]	0.0	3	1	1	1
121464	1710	low weight variant of stat5	[lower weight variants of STAT5]	0.0	5	1	1	1
121465	1710	genetic cis-acting	[genetic cis-acting]	0.0	2	1	1	1
121466	1710	rest blood T lymphocyte	[resting blood T lymphocytes]	0.0	4	1	1	1
121467	1710	site of oxidant production	[sites of oxidant production]	0.0	4	1	1	1
121468	1710	overt thyroidism	[overt thyroidism]	0.0	2	1	1	1
121469	1710	kd (affinity)	[Kd (affinity)]	0.0	2	1	1	1
121470	1710	antigen responsiveness	[antigen responsiveness]	0.0	2	2	2	1
121471	1710	overproduction of protein	[overproduction of proteins]	0.0	3	1	1	1
121472	1710	PMA /PHA	[PMA /PHA]	0.0	2	1	1	1
121473	1710	differentiation by stimulation	[differentiation by stimulation]	0.0	3	1	1	1
121474	1710	mrna in lymphocyte	[mRNA in lymphocytes]	0.0	3	1	1	1
121475	1710	glucocorticoid on function	[glucocorticoids on function]	0.0	3	1	1	1
121476	1710	size, indicative of dephosphorylation	[size, indicative of dephosphorylation]	0.0	4	1	1	1
121477	1710	young female	[young females]	0.0	2	1	1	1
121478	1710	inhibitor of p70(S6)-kinase rapamycin	[inhibitors of p70(S6)-kinase rapamycin]	0.0	4	1	1	1
121479	1710	recruiting histone deacetylase complex to promoter	[recruiting histone deacetylase complexes to promoters]	0.0	6	1	1	1
121480	1710	staging, infiltration	[staging, infiltration]	0.0	2	1	1	1
121481	1710	element in b-cell line	[element in B-cell lines]	0.0	4	1	1	1
121482	1710	clinical significance in 20 patient	[clinical significance in 20 patients]	0.0	5	1	1	1
121483	1710	use a infectious clone	[using an infectious clone]	0.0	4	1	1	1
121484	1710	fact, nf-kappa b activity	[fact, NF-kappa B activity]	0.0	4	1	1	1
121485	1710	rhythm of receptor in peripheral leukocyte	[rhythm of receptors in peripheral leukocytes]	0.0	6	1	1	1
121486	1710	hand, within the range.	[hand, within the range.]	0.0	4	1	1	1
121487	1710	two lipopolysaccharide	[two lipopolysaccharide]	0.0	2	1	1	1
121488	1710	three site in the TNF-alpha promoter	[three sites in the TNF-alpha promoter]	0.0	6	1	1	1
121489	1710	cis-linked sequence	[cis-linked sequences]	0.0	2	1	1	1
121490	1710	cell-like	[cell-like]	0.0	1	1	1	1
121491	1710	glutathione -s-transferase affinity-binding assay	[glutathione -S-transferase affinity-binding assay]	0.0	4	1	1	1
121492	1710	analysis of coactivator requirement	[analysis of coactivator requirements]	0.0	4	1	1	1
121493	1710	advance in transcriptional regulation	[advances in transcriptional regulation]	0.0	4	1	1	1
121494	1710	level of id2 mrna	[levels of Id2 mRNA]	0.0	4	1	1	1
121495	1710	3 copy binding site	[3 copies binding sites]	0.0	4	1	1	1
121496	1710	threshold level	[threshold levels]	0.0	2	1	1	1
121497	1710	suppression of factor kappa b	[Suppression of factor kappa B]	0.0	5	1	1	1
121498	1710	protein of weight	[proteins of weights]	0.0	3	1	1	1
121499	1710	urinary cortisol the number of receptor	[urinary cortisol the number of receptors]	0.0	6	1	1	1
121500	1710	inhibition of transendothelial migration	[inhibition of transendothelial migration]	0.0	4	1	1	1
121501	1710	involve defective differentiation	[involving defective differentiation]	0.0	3	1	1	1
121502	1710	early signal event in cell	[early signaling events in cells]	0.0	5	1	1	1
121503	1710	eightfold low amount	[eightfold lower amounts]	0.0	3	1	1	1
121504	1710	study in human monocyte	[studies in human monocytes]	0.0	4	1	1	1
121505	1710	approximately substnfkappab approximately substSp23	[approximately substNFkappaB approximately substSp23]	0.0	4	1	1	1
121506	1710	stimulation of interleukin-8 production basic protein	[Stimulation of interleukin-8 production basic protein]	0.0	6	1	1	1
121507	1710	various regulatory element	[various regulatory elements]	0.0	3	1	1	1
121508	1710	kinase activity in cell	[kinase activity in cells]	0.0	4	1	1	1
121509	1710	concurrent enhancement	[concurrent enhancement]	0.0	2	1	1	1
121510	1710	immune response to hiv-1	[immune response to HIV-1]	0.0	4	1	1	1
121511	1710	encode a protein x box protein	[encoding a protein X box protein]	0.0	6	1	1	1
121512	1710	proliferation, level	[proliferation, levels]	0.0	2	1	1	1
121513	1710	specific protein binding site	[specific protein binding sites]	0.0	4	1	1	1
121514	1710	induction by colony-stimumulatelany-stg factor	[Induction by colony-stimulating factor]	0.0	4	1	1	1
121515	1710	primary cd34+ progenitor cell HPC	[primary CD34+ progenitor cells HPC]	0.0	5	1	1	1
121516	1710	5 ng/ml sodium	[5 ng/ml sodium]	0.0	3	1	1	1
121517	1710	establish NF-kappaB as a factor	[establishing NF-kappaB as a factor]	0.0	5	1	1	1
121518	1710	natural gata element of the repeat	[natural GATA elements of the repeat]	0.0	6	1	1	1
121519	1710	promoter for t-cell-restricted marker	[promoters for T-cell-restricted markers]	0.0	4	1	1	1
121520	1710	heavy-chain igh enhancer	[heavy-chain IgH enhancer]	0.0	3	1	1	1
121521	1710	h(+)-atpase b2 subunit gene	[H(+)-ATPase B2 subunit gene]	0.0	4	1	1	1
121522	1710	receptor motif	[receptor motifs]	0.0	2	1	1	1
121523	1710	dna-binding study evidence	[DNA-binding studies evidence]	0.0	3	1	1	1
121524	1710	entire pool	[entire pool]	0.0	2	1	1	1
121525	1710	signal mechanism distinct	[signaling mechanisms distinct]	0.0	3	1	1	1
121526	1710	1 enhancer by nf-kappa b	[1 enhancer by NF-kappa B]	0.0	5	1	1	1
121527	1710	regulatory element (igh) enhancer	[regulatory elements (IgH) enhancer]	0.0	4	1	1	1
121528	1710	level of stress	[levels of stress]	0.0	3	2	2	1
121529	1710	rel/kappab	[Rel/kappaB]	0.0	1	1	1	1
121530	1710	only expression on the surface	[only expression on the surface]	0.0	5	1	1	1
121531	1710	IkappaB alpha regulation	[IkappaB alpha regulation]	0.0	3	1	1	1
121532	1710	nm vd3 for h	[nM VD3 for h]	0.0	4	1	1	1
121533	1710	interaction of a activator	[Interactions of a activator]	0.0	4	1	1	1
121534	1710	cis-acting negative effect	[cis-acting negative effect]	0.0	3	1	1	1
121535	1710	mainly on the role	[mainly on the role]	0.0	4	1	1	1
121536	1710	5' negative regulatory DNA sequence	[5' negative regulatory DNA sequences]	0.0	5	1	1	1
121537	1710	lymphocyte glucocorticoid receptor binding	[Lymphocyte glucocorticoid receptor binding]	0.0	4	1	1	1
121538	1710	two distinct form of transcription factor	[Two distinct forms of transcription factor]	0.0	6	1	1	1
121539	1710	exposure to signals, include exogenous cytokine	[exposure to signals, including exogenous cytokines]	0.0	6	1	1	1
121540	1710	acid on embryonic/fetal hematopoiesis	[acid on embryonic/fetal hematopoiesis]	0.0	4	1	1	1
121541	1710	addition, single-cell	[addition, single-cell]	0.0	2	1	1	1
121542	1710	tnf-alpha -dose	[TNF-alpha -dose]	0.0	2	1	1	1
121543	1710	cd4+ T cell line	[CD4+ T cell lines]	0.0	4	1	1	1
121544	1710	human t-lymphocyte via CD2	[human T-lymphocytes via CD2]	0.0	4	1	1	1
121545	1710	include Vav	[including Vav]	0.0	2	1	1	1
121546	1710	10(-8) to 10(-7) g/g of rna	[10(-8) to 10(-7) g/g of RNA]	0.0	6	1	1	1
121547	1710	very little detectable activation	[very little detectable activation]	0.0	4	1	1	1
121548	1710	expression of IkappaBalpha	[Expression of IkappaBalpha]	0.0	3	1	1	1
121549	1710	protein substrates.	[protein substrates.]	0.0	2	1	1	1
121550	1710	rest human vein cell	[resting human vein cells]	0.0	4	1	1	1
121551	1710	induction (egr-1) gene expression	[induction (EGR-1) gene expression]	0.0	4	1	1	1
121552	1710	dimerization of the receptor,	[dimerization of the receptor,]	0.0	4	1	1	1
121553	1710	zinc finger protein nf-e1	[zinc finger protein NF-E1]	0.0	4	1	1	1
121554	1710	histocompatibility (mhc) class ii antigen	[histocompatibility (MHC) class II antigens]	0.0	5	2	2	1
121555	1710	strong enhancer element	[strong enhancer element]	0.0	3	1	1	1
121556	1710	MLV regulation	[MLV regulation]	0.0	2	1	1	1
121557	1710	group of eukaryotic protein	[group of eukaryotic proteins]	0.0	4	1	1	1
121558	1710	HMG-88	[HMG-88]	0.0	1	1	1	1
121559	1710	adrenocorticotropic hormone release	[adrenocorticotropic hormone release]	0.0	3	1	1	1
121560	1710	fresh blood cell	[fresh blood cells]	0.0	3	1	1	1
121561	1710	variety of response gene	[variety of response genes]	0.0	4	1	1	1
121562	1710	human hla-dq class	[human HLA-DQ class]	0.0	3	1	1	1
121563	1710	Epstein-Barr virus transform protein LMP1	[Epstein-Barr virus transforming protein LMP1]	0.0	5	1	1	1
121564	1710	binding of the complex to CRE	[Binding of the complexes to CRE]	0.0	6	1	1	1
121565	1710	regulation of reaction	[regulation of reactions]	0.0	3	1	1	1
121566	1710	low t3	[low T3]	0.0	2	1	1	1
121567	1710	three organism	[three organisms]	0.0	2	1	1	1
121568	1710	autocrine effect	[autocrine effect]	0.0	2	1	1	1
121569	1710	u937 transfectant express VDR mrna	[U937 transfectants expressing VDR mRNA]	0.0	5	1	1	1
121570	1710	staining,	[staining,]	0.0	1	1	1	1
121571	1710	E1A induction of susceptibility kill	[E1A induction of susceptibility killing]	0.0	5	1	1	1
121572	1710	interaction in the env gene	[Interactions in the env gene]	0.0	5	1	1	1
121573	1710	19-bp site	[19-bp site]	0.0	2	1	1	1
121574	1710	staining;	[staining;]	0.0	1	1	1	1
121575	1710	target certain malignancy	[targeting certain malignancies]	0.0	3	1	1	1
121576	1710	demonstration by analysis	[Demonstration by analysis]	0.0	3	1	1	1
121577	1710	staining.	[staining.]	0.0	1	1	1	1
121578	1710	occur between day 7	[occurring between day 7]	0.0	4	1	1	1
121579	1710	Nonradioactive quantification of expression	[Nonradioactive quantification of expression]	0.0	4	1	1	1
121580	1710	ng/ml sodium	[ng/ml sodium]	0.0	2	1	1	1
121581	1710	late effect than the responses.	[later effects than the responses.]	0.0	5	1	1	1
121582	1710	herpesvirus saimiry associate	[herpesvirus saimiri associates]	0.0	3	1	1	1
121583	1710	treatment with bivalent mab j393	[Treatment with bivalent mAb J393]	0.0	5	1	1	1
121584	1710	nuclear depletion	[nuclear depletion]	0.0	2	1	1	1
121585	1710	Cross titration	[Cross titration]	0.0	2	1	1	1
121586	1710	retinoic acid on hematopoiesis	[retinoic acid on hematopoiesis]	0.0	4	1	1	1
121587	1710	IL-3 granulocyte-macrophage colony-stimumulatelany-stg factor dna-binding complex	[IL-3 granulocyte-macrophage colony-stimulating factor DNA-binding complexes]	0.0	6	1	1	1
121588	1710	arthritis synovial	[arthritis synovial]	0.0	2	1	1	1
121589	1710	junb transcription wave	[junB transcription waves]	0.0	3	1	1	1
121590	1710	B7-independent T cell costimulatory molecule	[B7-independent T cell costimulatory molecule]	0.0	5	1	1	1
121591	1710	activation in the nuclear extract	[activation in the nuclear extracts]	0.0	5	1	1	1
121592	1710	residual disease of patient	[residual disease of patients]	0.0	4	1	1	1
121593	1710	return to level by min.	[returning to levels by min.]	0.0	5	1	1	1
121594	1710	effect on the hiv-1 LTR	[effects on the HIV-1 LTR]	0.0	5	1	1	1
121595	1710	59 amino acid	[59 amino acids]	0.0	3	1	1	1
121596	1710	large number of gene	[large number of genes]	0.0	4	1	1	1
121597	1710	minimal virus expression	[minimal virus expression]	0.0	3	1	1	1
121598	1710	dose of peptide micrograms),	[doses of peptide micrograms),]	0.0	4	1	1	1
121599	1710	results: in blood	[RESULTS: In blood]	0.0	3	1	1	1
121600	1710	proliferative samples, activity from endometrium	[proliferative samples, activity from endometrium]	0.0	5	1	1	1
121601	1710	encode a transmembrane receptor	[encoding a transmembrane receptor]	0.0	4	1	1	1
121602	1710	stress dependent nf-kappab activation	[stress dependent NF-kappaB activation]	0.0	4	1	1	1
121603	1710	defect in a step	[defect in a step]	0.0	4	1	1	1
121604	1710	degree c) twice/d, min/exposure,	[degrees C) twice/d, min/exposure,]	0.0	4	1	1	1
121605	1710	IkappaBalpha cell	[IkappaBalpha cells]	0.0	2	1	1	1
121606	1710	tissue factor expression of monocyte	[Tissue factor expression of monocytes]	0.0	5	1	1	1
121607	1710	hilar adenopathy	[hilar adenopathy]	0.0	2	1	1	1
121608	1710	addition of human gm-csf	[addition of human GM-CSF]	0.0	4	1	1	1
121609	1710	pattern of intracellular signal	[patterns of intracellular signaling]	0.0	4	1	1	1
121610	1710	physiological receptor-mediated agonist	[physiological receptor-mediated agonists]	0.0	3	1	1	1
121611	1710	variety of activities,	[variety of activities,]	0.0	3	1	1	1
121612	1710	evidence at proximal bind element p0	[Evidence at proximal binding element P0]	0.0	6	1	1	1
121613	1710	major interest	[major interest]	0.0	2	1	1	1
121614	1710	cytokine mrna expression in human monocyte	[cytokine mRNA expression in human monocytes]	0.0	6	1	1	1
121615	1710	study, use cd34+	[study, using CD34+]	0.0	3	1	1	1
121616	1710	potential of the gene	[potential of the gene]	0.0	4	1	1	1
121617	1710	develop central system CNS	[developing central system CNS]	0.0	4	1	1	1
121618	1710	expression of the chemokine receptor	[Expression of the chemokine receptor]	0.0	5	1	1	1
121619	1710	dimerization region contain two repeat	[dimerization region containing two repeats]	0.0	5	1	1	1
121620	1710	excessive expression	[excessive expression]	0.0	2	1	1	1
121621	1710	particular, occur sequence variation	[particular, occurring sequence variation]	0.0	4	1	1	1
121622	1710	similar inhibitory effect on the expression	[similar inhibitory effects on the expression]	0.0	6	1	1	1
121623	1710	activation of growth response gene transcription	[Activation of growth response gene transcription]	0.0	6	1	1	1
121624	1710	gene hbd	[gene HBD]	0.0	2	1	1	1
121625	1710	MCM on proliferation	[MCM on proliferation]	0.0	3	1	1	1
121626	1710	gene expression.	[gene expression.]	0.0	2	1	1	1
121627	1710	concept the result	[concept the result]	0.0	3	1	1	1
121628	1710	other marker of prognosis,	[other markers of prognosis,]	0.0	4	1	1	1
121629	1710	protein repressor element	[protein repressor element]	0.0	3	1	1	1
121630	1710	understanding at this stage	[understanding at this stage]	0.0	4	1	1	1
121631	1710	kinetic of translocation	[Kinetics of translocation]	0.0	3	1	1	1
121632	1710	77 +/- versus 35 +/-	[77 +/- versus 35 +/-]	0.0	5	1	1	1
121633	1710	peak between 1-2 h.	[peaking between 1-2 h,]	0.0	4	1	1	1
121634	1710	amount costimulation with anti-CD3	[amounts costimulation with anti-CD3]	0.0	4	1	1	1
121635	1710	show activity	[showing activity]	0.0	2	1	1	1
121636	1710	normal c-myc allele	[normal c-myc allele]	0.0	3	2	2	1
121637	1710	normal peripheral blood pb	[normal peripheral blood PB]	0.0	4	1	1	1
121638	1710	suggest a modulator	[suggesting an modulator]	0.0	3	1	1	1
121639	1710	suppression of basophil cell return	[suppression of basophil cell return]	0.0	5	1	1	1
121640	1710	cotransfection together	[cotransfection together]	0.0	2	1	1	1
121641	1710	phosphatidic acid pa	[phosphatidic acid PA]	0.0	3	1	1	1
121642	1710	rapidak non-genomic effect on electrolyte movement	[rapid, non-genomic effects on electrolyte movements]	0.0	6	1	1	1
121643	1710	transcriptional regulation of c-jun expression	[Transcriptional regulation of c-jun expression]	0.0	5	1	1	1
121644	1710	recent observation on Tcf-1 mouse	[recent observations on Tcf-1 mice]	0.0	5	1	1	1
121645	1710	human cell line u1	[human cell line U1]	0.0	4	1	1	1
121646	1710	ratio to T cell	[ratio to T cells]	0.0	4	1	1	1
121647	1710	regulator of adipocyte differentiation	[regulator of adipocyte differentiation]	0.0	4	1	1	1
121648	1710	peripheral mononuclear	[peripheral mononuclear]	0.0	2	1	1	1
121649	1710	intrafollicular cd3+ T cell	[Intrafollicular CD3+ T cells]	0.0	4	1	1	1
121650	1710	unexpectedly, expression of another protein	[unexpectedly, expression of another protein]	0.0	5	1	1	1
121651	1710	human intestinal cell	[human intestinal cells]	0.0	3	1	1	1
121652	1710	blast from 18 patient with leukaemia	[blasts from 18 patients with leukaemia]	0.0	6	1	1	1
121653	1710	steroid binding assay SBA	[steroid binding assay SBA]	0.0	4	1	1	1
121654	1710	domain RXR contain a deletion	[domain RXR containing a deletion]	0.0	5	1	1	1
121655	1710	fourier transformation	[Fourier transformations]	0.0	2	1	1	1
121656	1710	NF-KB2	[NF-KB2]	0.0	1	1	1	1
121657	1710	(ct)19/(ca)16	[(CT)19/(CA)16]	0.0	1	1	1	1
121658	1710	granuloma formation	[granuloma formation]	0.0	2	1	1	1
121659	1710	expression of 135(oh)2d3 receptor from patient	[Expression of 1,25(OH)2D3 receptors from patients]	0.0	6	1	1	1
121660	1710	proximal nf-kappa b motif	[proximal NF-kappa B motif]	0.0	4	1	1	1
121661	1710	zap-70 responsiveness to expression	[ZAP-70 responsiveness to expression]	0.0	4	1	1	1
121662	1710	regulatory region include the enhancer	[regulatory regions including the enhancer]	0.0	5	1	1	1
121663	1710	virtually all erythroid gene	[virtually all erythroid genes]	0.0	4	1	1	1
121664	1710	codon polymorphic site	[codon polymorphic site]	0.0	3	1	1	1
121665	1710	place.	[place.]	0.0	1	1	1	1
121666	1710	microm OP for 2 hour	[microM OP for 2 hr,]	0.0	5	1	1	1
121667	1710	4 beta-phorbol 12-myristate 13-acetate addition	[4 beta-phorbol 12-myristate 13-acetate addition]	0.0	5	1	1	1
121668	1710	activation of human zeta functional role	[activation of human zeta functional role]	0.0	6	1	1	1
121669	1710	suggest a action	[suggesting a action]	0.0	3	1	1	1
121670	1710	role mediate neutrophil adhesion	[role mediating neutrophil adhesion]	0.0	4	1	1	1
121671	1710	(range, (range, 4-.11), (range, 5.86-6.74) nm,	[(range, (range, 4-5.13), (range, 5.86-6.74) nM,]	0.0	6	1	1	1
121672	1710	proportion of transcript	[proportion of transcripts]	0.0	3	1	1	1
121673	1710	gene include hiv	[genes including HIV]	0.0	3	1	1	1
121674	1710	over-expression of b -dependent gene	[over-expression of B -dependent genes]	0.0	5	1	1	1
121675	1710	proliferation of type	[proliferation of types]	0.0	3	1	1	1
121676	1710	n-Acetyl-L-cysteine NAC	[n-Acetyl-L-cysteine NAC]	0.0	2	1	1	1
121677	1710	six ebv-encoded antigen	[six EBV-encoded antigens]	0.0	3	1	1	1
121678	1710	a GPA	[A GPA]	0.0	2	1	1	1
121679	1710	amplicon (probe)	[amplicon (probe)]	0.0	2	1	1	1
121680	1710	factors, in cytokine	[factors, in cytokines]	0.0	3	1	1	1
121681	1710	IEF-1 a beta-cell complex	[IEF-1 a beta-cell complex]	0.0	4	1	1	1
121682	1710	O-side mAb	[O-side mAb]	0.0	2	1	1	1
121683	1710	small substance such as bacterial formylpeptide	[small substances such as bacterial formylpeptides]	0.0	6	1	1	1
121684	1710	myelin protein (mbp)-	[myelin protein (MBP)-]	0.0	3	1	1	1
121685	1710	vitro reporter gene function in	[vitro reporter gene function in]	0.0	5	1	1	1
121686	1710	class ii transactivator mrna expression	[class II transactivator mRNA expression]	0.0	5	1	1	1
121687	1710	T hiv-1 entry	[T HIV-1 entry]	0.0	3	1	1	1
121688	1710	el4 6.1 overexpress (h) irak	[EL4 6.1 overexpressing (h) IRAK]	0.0	5	1	1	1
121689	1710	ascorbate dha	[ascorbate DHA]	0.0	2	1	1	1
121690	1710	gr isoform on transrepression	[GR isoforms on transrepression]	0.0	4	1	1	1
121691	1710	spi-1 -DNA binding activity	[Spi-1 -DNA binding activity]	0.0	4	1	1	1
121692	1710	mechanism of h2 receptor desensitization	[mechanism of H2 receptor desensitization]	0.0	5	1	1	1
121693	1710	addition, JNK activation	[addition, JNK activation]	0.0	3	1	1	1
121694	1710	have a ec50	[having an EC50]	0.0	3	1	1	1
121695	1710	azurophilic granularity	[azurophilic granularity]	0.0	2	1	1	1
121696	1710	include vigorous tyrosine phosphorylation	[including vigorous tyrosine phosphorylation]	0.0	4	1	1	1
121697	1710	same nuclear body	[same nuclear bodies]	0.0	3	1	1	1
121698	1710	Stat3 recruitment	[Stat3 recruitment]	0.0	2	1	1	1
121699	1710	activity of eosinophil	[activity of eosinophils]	0.0	3	1	1	1
121700	1710	expression in normal T cell	[Expression in normal T cells]	0.0	5	1	1	1
121701	1710	leukaemia gene product	[leukaemia gene product]	0.0	3	1	1	1
121702	1710	stat (signal transducer of transcription)	[STAT (signal transducers of transcription)]	0.0	5	1	1	1
121703	1710	protein by ultra-violet cross-linking	[protein by UV cross-linking]	0.0	4	1	1	1
121704	1710	distinct transcription factor creb/atf	[distinct transcription factors CREB/ATF]	0.0	4	1	1	1
121705	1710	taf subunit	[TAF subunits]	0.0	2	1	1	1
121706	1710	N-acetyl-L-cysteine a well-characterized, thiol-containing antioxidant	[N-acetyl-L-cysteine a well-characterized, thiol-containing antioxidant]	0.0	5	1	1	1
121707	1710	1 df,	[1 df,]	0.0	2	1	1	1
121708	1710	monoclonal integration of htlv-1 provirus	[monoclonal integration of HTLV-1 provirus]	0.0	5	1	1	1
121709	1710	overexpression in blood cell HPFH	[overexpression in blood cells HPFH]	0.0	5	1	1	1
121710	1710	xeroderma pigmentosum	[xeroderma pigmentosum]	0.0	2	1	1	1
121711	1710	29 (10%) aml m4	[29 (10%) AML M4]	0.0	4	1	1	1
121712	1710	transcription factor a inhibitor	[transcription factors an inhibitor]	0.0	4	1	1	1
121713	1710	disorder result	[disorder resulting]	0.0	2	1	1	1
121714	1710	independent criteria, include tyrosine phosphorylation	[independent criteria, including tyrosine phosphorylation]	0.0	5	1	1	1
121715	1710	release a elongation block	[releasing an elongation block]	0.0	4	1	1	1
121716	1710	induction of oxygen intermediate ROI	[induction of oxygen intermediates ROI]	0.0	5	1	1	1
121717	1710	4922 (range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564 (range,	[4922 (range, 4484-5643), (range,]	0.0	4	1	1	1
121718	1710	kinase jak3	[kinase JAK3]	0.0	2	1	1	1
121719	1710	release il-8	[release IL-8]	0.0	2	1	1	1
121720	1710	manner in the microenvironment	[manner in the microenvironment]	0.0	4	1	1	1
121721	1710	different Kruppel-related zinc finger protein	[different Kruppel-related zinc finger proteins]	0.0	5	1	1	1
121722	1710	cause transformation	[causing transformation]	0.0	2	1	1	1
121723	1710	proteolysis of substrate	[proteolysis of substrates]	0.0	3	1	1	1
121724	1710	biochemical response	[biochemical response]	0.0	2	1	1	1
121725	1710	T cell-specific factor	[T cell-specific factor]	0.0	3	1	1	1
121726	1710	hematopoietic pattern of mnda expression	[hematopoietic pattern of MNDA expression]	0.0	5	1	1	1
121727	1710	T cell stimulation-induced expression	[T cell stimulation-induced expression]	0.0	4	1	1	1
121728	1710	contrast to most lps	[contrast to most LPS]	0.0	4	1	1	1
121729	1710	alpha,25-(OH)2D3 -responsive cell	[alpha,25-(OH)2D3 -responsive cells]	0.0	3	1	1	1
121730	1710	ligand pair	[ligand pair]	0.0	2	1	1	1
121731	1710	presence of several positive element	[presence of several positive elements]	0.0	5	1	1	1
121732	1710	diesel organic extract	[diesel organic extracts]	0.0	3	1	1	1
121733	1710	compound r24571	[compound R24571]	0.0	2	1	1	1
121734	1710	two T. pallidum lipoprotein	[two T. pallidum lipoproteins]	0.0	4	1	1	1
121735	1710	Duffy polymorphic antigen	[Duffy polymorphic antigens]	0.0	3	1	1	1
121736	1710	normal race- control subject	[normal race- control subjects]	0.0	4	1	1	1
121737	1710	contain the cytomegalovirus immediate-early enhancer	[containing the cytomegalovirus immediate-early enhancer]	0.0	5	1	1	1
121738	1710	uncontrolled replication	[Uncontrolled replication]	0.0	2	1	1	1
121739	1710	nuclear component of nf-at	[nuclear component of NF-AT]	0.0	4	1	1	1
121740	1710	regulatory property	[regulatory properties]	0.0	2	1	1	1
121741	1710	il-6 to cd40l b cell	[IL-6 to CD40L B cells]	0.0	5	1	1	1
121742	1710	phosphatidylinositol-3,4,5-trisphosphate concentration in cell	[phosphatidylinositol-3,4,5-trisphosphate concentration in cells]	0.0	4	1	1	1
121743	1710	non-polymorphic region	[non-polymorphic regions]	0.0	2	1	1	1
121744	1710	blood from transgenic	[blood from transgenic]	0.0	3	1	1	1
121745	1710	gene organization	[gene organization]	0.0	2	1	1	1
121746	1710	seven patient with asthma	[seven patients with asthma]	0.0	4	1	1	1
121747	1710	contain two repeat	[containing two repeats]	0.0	3	1	1	1
121748	1710	contribution of the isoform	[contribution of the isoforms]	0.0	4	1	1	1
121749	1710	inducibility of ifn-beta	[Inducibility of IFN-beta]	0.0	3	1	1	1
121750	1710	blood of healthy individual	[blood of healthy individuals]	0.0	4	1	1	1
121751	1710	(creb/atf) family	[(CREB/ATF) family]	0.0	2	1	1	1
121752	1710	xist locus x chromosome	[XIST locus X chromosomes]	0.0	4	1	1	1
121753	1710	affinity to 5%	[affinity to 5%]	0.0	3	1	1	1
121754	1710	activator of many viral gene	[activator of many viral genes]	0.0	5	1	1	1
121755	1710	accumulation of the transcript	[accumulation of the transcripts]	0.0	4	1	1	1
121756	1710	induction gene expression	[induction gene expression]	0.0	3	1	1	1
121757	1710	putative transcriptional regulator	[putative transcriptional regulator]	0.0	3	1	1	1
121758	1710	Jakdstat gene	[JAK/STAT gene]	0.0	2	1	1	1
121759	1710	human g-csfr mutant	[human G-CSFR mutant]	0.0	3	1	1	1
121760	1710	N-terminal domain a linker	[N-terminal domain a linker]	0.0	4	1	1	1
121761	1710	expression of the alpha-subunit	[expression of the alpha-subunit]	0.0	4	1	1	1
121762	1710	tcl1 oncogene	[TCL1 oncogene]	0.0	2	1	1	1
121763	1710	mutation event at a mutation site	[mutation events at a mutation site]	0.0	6	1	1	1
121764	1710	contain bp of sequence	[containing bp of sequence]	0.0	4	1	1	1
121765	1710	evidence for activity at bind element	[Evidence for activity at binding element]	0.0	6	1	1	1
121766	1710	chromosome pneumophila	[chromosome pneumophila]	0.0	2	1	1	1
121767	1710	cell size	[cell size]	0.0	2	1	1	1
121768	1710	signal across the membrane	[signal across the membrane]	0.0	4	1	1	1
121769	1710	cellular infiltration	[cellular infiltration]	0.0	2	1	1	1
121770	1710	concentration between nm	[concentrations between nM]	0.0	3	1	1	1
121771	1710	lymphocyte stem cell	[lymphocyte stem cells]	0.0	3	1	1	1
121772	1710	differentiation into cell	[differentiation into cells]	0.0	3	1	1	1
121773	1710	cellular content of vacuolar h+-atpase	[cellular content of vacuolar H+-ATPase]	0.0	5	1	1	1
121774	1710	cross-linking MHC-I	[Cross-linking MHC-I]	0.0	2	1	1	1
121775	1710	single point estimation of glucocorticoid receptor	[Single point estimation of glucocorticoid receptors]	0.0	6	1	1	1
121776	1710	expression construct in cell	[expression constructs in cells]	0.0	4	1	1	1
121777	1710	description of a new class	[description of a new class]	0.0	5	1	1	1
121778	1710	positioning NFAT for dephosphorylation	[positioning NFAT for dephosphorylation]	0.0	4	1	1	1
121779	1710	ultimately result	[ultimately results]	0.0	2	1	1	1
121780	1710	level of response activity	[levels of response activity]	0.0	4	1	1	1
121781	1710	high concentration of peptide ligand	[high concentrations of peptide ligand]	0.0	5	1	1	1
121782	1710	protein-1 mcp-1	[protein-1 MCP-1]	0.0	2	1	1	1
121783	1710	produce a divergence	[producing a divergence]	0.0	3	1	1	1
121784	1710	two-phase cell adhesion response	[two-phase cell adhesion response]	0.0	4	1	1	1
121785	1710	collagenase induction in cell	[collagenase induction in cells]	0.0	4	1	1	1
121786	1710	Mesnier, Leger	[Mesnier, Leger]	0.0	2	1	1	1
121787	1710	(range, 4.27 (range, (range, 5.86-6.74) nm,	[(range, 4.27 (range, (range, 5.86-6.74) nM,]	0.0	6	1	1	1
121788	1710	leukotriene B4 a lipid mediator	[leukotriene B4 a lipid mediator]	0.0	5	1	1	1
121789	1710	nf-kappa b species	[NF-kappa B species]	0.0	3	1	1	1
121790	1710	induction of activator protein (ap)-1	[Induction of activator protein (AP)-1]	0.0	5	1	1	1
121791	1710	transient disorder	[transient disorder]	0.0	2	3	3	1
121792	1710	nf-kappa b of gene	[NF-kappa B of genes]	0.0	4	1	1	1
121793	1710	up-regulation during cell maturation	[up-regulation during cell maturation]	0.0	4	1	1	1
121794	1710	leukemia (apl): ii	[leukemia (APL): II]	0.0	3	1	1	1
121795	1710	several type of cell line	[several types of cell lines]	0.0	5	1	1	1
121796	1710	lack a transcription factor	[lacking a transcription factor]	0.0	4	1	1	1
121797	1710	loss of red cell production	[loss of red cell production]	0.0	5	1	1	1
121798	1710	regulation in differentiation of erythroleukemic cell	[regulation in differentiation of erythroleukemic cells]	0.0	6	1	1	1
121799	1710	enhancement of il-2 secretion	[enhancement of IL-2 secretion]	0.0	4	1	1	1
121800	1710	erythrocyte-specific gene	[erythrocyte-specific genes]	0.0	2	1	1	1
121801	1710	presence of three bind site	[presence of three binding sites]	0.0	5	1	1	1
121802	1710	relationship between lmp-1 protein level	[relationship between LMP-1 protein levels]	0.0	5	1	1	1
121803	1710	action for OCA-B	[action for OCA-B]	0.0	3	1	1	1
121804	1710	T cell the cell	[T cells the cells]	0.0	4	1	1	1
121805	1710	band q26	[band q26]	0.0	2	1	1	1
121806	1710	5' clone	[5' clone]	0.0	2	1	1	1
121807	1710	strike similarity to binding site	[striking similarity to binding sites]	0.0	5	1	1	1
121808	1710	adjacent sequence from the c-terminus	[adjacent sequences from the C-terminus]	0.0	5	1	1	1
121809	1710	activity less	[activity less]	0.0	2	1	1	1
121810	1710	inhibitor protein	[inhibitor protein]	0.0	2	1	1	1
121811	1710	bhrf1 in ebv cell	[BHRF1 in EBV cells]	0.0	4	1	1	1
121812	1710	acid lipase LAL	[acid lipase LAL]	0.0	3	1	1	1
121813	1710	Nuclear expression	[Nuclear expression]	0.0	2	2	2	1
121814	1710	54-year-old woman with cancer	[54-year-old woman with cancer]	0.0	4	1	1	1
121815	1710	Prostaglandin E2 a pleiotropic immunomodulatory molecule	[Prostaglandin E2 a pleiotropic immunomodulatory molecule]	0.0	6	1	1	1
121816	1710	widespread inactivation	[widespread inactivation]	0.0	2	1	1	1
121817	1710	presence of a inhibitor	[presence of an inhibitor]	0.0	4	1	1	1
121818	1710	total population killer T/NK population	[total populations killer T/NK populations]	0.0	5	1	1	1
121819	1710	enhancer by nf-kappa b	[enhancer by NF-kappa B]	0.0	4	1	1	1
121820	1710	human lymphotrophic virus type-i tax gene	[Human lymphotrophic virus type-I tax gene]	0.0	6	1	1	1
121821	1710	retinoic acid response element	[retinoic acid response element]	0.0	4	1	1	1
121822	1710	t3, dysfunction	[T3, dysfunction]	0.0	2	1	1	1
121823	1710	part, to a block	[part, to a block]	0.0	4	1	1	1
121824	1710	mechanism for this difference	[mechanism for these differences]	0.0	4	1	1	1
121825	1710	action of the upstream element	[actions of the upstream elements]	0.0	5	1	1	1
121826	1710	target of antibody	[target of antibodies]	0.0	3	1	1	1
121827	1710	monocytes/macrophages in lesion	[monocytes/macrophages in lesions]	0.0	3	1	1	1
121828	1710	1,25-dihydroxyvitamin D3 in human monocyte	[1,25-dihydroxyvitamin D3 in human monocytes]	0.0	5	1	1	1
121829	1710	il-4 activation	[IL-4 activation]	0.0	2	1	1	1
121830	1710	bind activity less	[binding activity less]	0.0	3	1	1	1
121831	1710	expression of genes.	[expression of genes.]	0.0	3	1	1	1
121832	1710	respiration	[respiration]	0.0	1	1	1	1
121833	1710	almost complete tolerance for tcf-1	[almost complete tolerance for TCF-1]	0.0	5	1	1	1
121834	1710	SCM-1-producer T cell line	[SCM-1-producer T cell lines]	0.0	4	1	1	1
121835	1710	involvement of gsk-3beta in transcription	[involvement of GSK-3beta in transcription]	0.0	5	1	1	1
121836	1710	T cell sensitization	[T cell sensitization]	0.0	3	1	1	1
121837	1710	Maximal increase	[Maximal increase]	0.0	2	1	1	1
121838	1710	expression of genes,	[expression of genes,]	0.0	3	1	1	1
121839	1710	X1 box activity	[X1 box activities]	0.0	3	1	1	1
121840	1710	adjacent cis element	[adjacent cis elements]	0.0	3	1	1	1
121841	1710	infection of immunodeficiency virus analysis	[Infection of immunodeficiency viruses analyses]	0.0	5	1	1	1
121842	1710	cd69 gene,	[CD69 gene,]	0.0	2	1	1	1
121843	1710	redox sensitive transcription factor	[redox sensitive transcription factor]	0.0	4	1	1	1
121844	1710	evidence for a association	[evidence for an association]	0.0	4	1	1	1
121845	1710	exogenous promoter in cell	[exogenous promoter in cells]	0.0	4	1	1	1
121846	1710	Lysophosphatidylethanolamine	[Lysophosphatidylethanolamine]	0.0	1	1	1	1
121847	1710	description of a class	[description of a class]	0.0	4	1	1	1
121848	1710	megakaryoblastic transformation of Philadelphia leukemia	[megakaryoblastic transformation of Philadelphia leukemia]	0.0	5	1	1	1
121849	1710	high-level zeta globin promoter activity	[high-level zeta globin promoter activity]	0.0	5	1	1	1
121850	1710	mammalian cells,	[mammalian cells,]	0.0	2	1	1	1
121851	1710	bind to specific receptor domain sequence	[binding to specific receptor domain sequences]	0.0	6	1	1	1
121852	1710	infection with this virus.	[infection with this virus.]	0.0	4	1	1	1
121853	1710	h. treatment	[h, treatment]	0.0	2	1	1	1
121854	1710	less than p 0.01	[less than P 0.01]	0.0	4	1	1	1
121855	1710	insight into the function	[insight into the function]	0.0	4	1	1	1
121856	1710	alpha 4 beta 1 ligation	[alpha 4 beta 1 ligation]	0.0	5	1	1	1
121857	1710	response to serum	[response to serum]	0.0	3	1	1	1
121858	1710	cell cycle behavior	[cell cycle behavior]	0.0	3	1	1	1
121859	1710	imprint a permanent th2 phenotype	[imprinting a permanent Th2 phenotype]	0.0	5	1	1	1
121860	1710	NFATx1 of the residue	[NFATx1 of the residues]	0.0	4	1	1	1
121861	1710	Proximal signal	[Proximal signal]	0.0	2	1	1	1
121862	1710	suggest particularly deleterious in lung	[suggesting particularly deleterious in lungs]	0.0	5	1	1	1
121863	1710	monocytic differentiation of leukemic cell	[monocytic differentiation of leukemic cells]	0.0	5	1	1	1
121864	1710	human immunodeficiency virus type tat	[human immunodeficiency virus type Tat]	0.0	5	1	1	1
121865	1710	specific; bacterial lps	[specific; bacterial LPS]	0.0	3	1	1	1
121866	1710	only individual of (mhc) haplotype	[only individuals of (MHC) haplotypes]	0.0	5	1	1	1
121867	1710	stable transfectant	[stable transfectants]	0.0	2	1	1	1
121868	1710	substitution 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[substitutions 11 alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	5	1	1	1
121869	1710	power	[power]	0.0	1	1	1	1
121870	1710	expression within normal limits.	[expression within normal limits.]	0.0	4	1	1	1
121871	1710	hiv-1 in macrophage	[HIV-1 in macrophages]	0.0	3	1	1	1
121872	1710	use two different approach	[using two different approaches]	0.0	4	1	1	1
121873	1710	patient with overt thyroidism	[Patients with overt thyroidism]	0.0	4	1	1	1
121874	1710	Locus control region	[Locus control regions]	0.0	3	1	1	1
121875	1710	disorder in adolescent	[disorder in adolescents]	0.0	3	1	1	1
121876	1710	kappab -dependent reporter activity	[kappaB -dependent reporter activity]	0.0	4	1	1	1
121877	1710	event in early agonist-induced signalling	[event in early agonist-induced signalling]	0.0	5	1	1	1
121878	1710	membrane receptor a novel pathway	[Membrane receptors a novel pathway]	0.0	5	1	1	1
121879	1710	Enzymatic assay of alpha-galactosidase	[Enzymatic assay of alpha-galactosidase]	0.0	4	1	1	1
121880	1710	dissociation from transactivation	[dissociation from transactivation]	0.0	3	1	1	1
121881	1710	cleavage a regulator	[cleavage a regulator]	0.0	3	1	1	1
121882	1710	use increase amount	[using increasing amounts]	0.0	3	1	1	1
121883	1710	hindrance	[hindrance]	0.0	1	1	1	1
121884	1710	mutant of KBF1/p50	[mutant of KBF1/p50]	0.0	3	1	1	1
121885	1710	human dermal endothelial cell	[human dermal endothelial cells]	0.0	4	1	1	1
121886	1710	adenoviral e1a oncoprotein	[adenoviral E1A oncoprotein]	0.0	3	1	1	1
121887	1710	cell receptor/CD3	[cell receptor/CD3]	0.0	2	1	1	1
121888	1710	sle Disease activity	[SLE Disease Activity]	0.0	3	1	1	1
121889	1710	concentration of the drug.	[concentration of the drug.]	0.0	4	1	1	1
121890	1710	clonality.	[clonality.]	0.0	1	1	1	1
121891	1710	fluid from renal cell carcinoma	[fluid from renal cell carcinomas]	0.0	5	1	1	1
121892	1710	mrna of bp	[mRNA of bp]	0.0	3	1	1	1
121893	1710	low passage	[low passage]	0.0	2	1	1	1
121894	1710	induce CAT activity costimulation	[inducing CAT activity costimulation]	0.0	4	1	1	1
121895	1710	gr bind abnormalities:	[GR binding abnormalities:]	0.0	3	1	1	1
121896	1710	glucocorticoid receptor constant	[glucocorticoid receptors constant]	0.0	3	1	1	1
121897	1710	decline in chymotryptic activity	[decline in chymotryptic activity]	0.0	4	1	1	1
121898	1710	binding assay in patient	[binding assay in patients]	0.0	4	1	1	1
121899	1710	recombinant caspase	[recombinant caspase]	0.0	2	1	1	1
121900	1710	Grb2-associated tyrosine	[Grb2-associated tyrosine]	0.0	2	1	1	1
121901	1710	involvement of a set of factor	[involvement of a set of factor]	0.0	6	1	1	1
121902	1710	units/ml recombinant m-csf	[units/ml recombinant M-CSF]	0.0	3	1	1	1
121903	1710	treatment of leukemia cell	[treatment of leukemia cells]	0.0	4	1	1	1
121904	1710	gene in a manner	[genes in an manner]	0.0	4	1	1	1
121905	1710	most interestingly, expression	[Most interestingly, expression]	0.0	3	1	1	1
121906	1710	terminal repeat of this retrovirus	[terminal repeat of this retrovirus]	0.0	5	1	1	1
121907	1710	mechanism via the leukocyte pmn	[mechanisms via the leukocytes PMNs]	0.0	5	1	1	1
121908	1710	cellular parameters,	[cellular parameters,]	0.0	2	1	1	1
121909	1710	monocyte protein mcp-1	[monocyte protein MCP-1]	0.0	3	1	1	1
121910	1710	transient change	[transient changes]	0.0	2	1	1	1
121911	1710	produce a 50-fold induction within hour	[producing a 50-fold induction within hour]	0.0	6	1	1	1
121912	1710	such as nf-kappab for expression.	[such as NF-kappaB for expression.]	0.0	5	1	1	1
121913	1710	fibrosarcoma fibrous histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
121914	1710	response to fluticasone propionate in rhinitis	[Response to fluticasone propionate in rhinitis]	0.0	6	1	1	1
121915	1710	synthetic RAR ligand	[synthetic RAR ligands]	0.0	3	1	1	1
121916	1710	vitamin d3-responsive element vdre	[vitamin D3-responsive element VDRE]	0.0	4	1	1	1
121917	1710	Specific family	[Specific families]	0.0	2	1	1	1
121918	1710	profound implication in biomedical research	[profound implication in biomedical research]	0.0	5	1	1	1
121919	1710	calcium potency	[calcium potency]	0.0	2	1	1	1
121920	1710	few 47.10 cell	[few 47.10 cells]	0.0	3	1	1	1
121921	1710	E2F-I bind protein,	[E2F-I binding protein,]	0.0	3	1	1	1
121922	1710	have a excisional biopsy	[having an excisional biopsy]	0.0	4	1	1	1
121923	1710	extract lps	[extracts LPS]	0.0	2	1	1	1
121924	1710	nf-kappa b (position	[NF-kappa B (positions]	0.0	3	1	1	1
121925	1710	association of this variable	[associations of these variables]	0.0	4	1	1	1
121926	1710	certain case	[certain cases]	0.0	2	1	1	1
121927	1710	contain gene element	[containing gene elements]	0.0	3	1	1	1
121928	1710	region extend from bp	[regions extending from bp]	0.0	4	1	1	1
121929	1710	11 alpha-methyl,	[11 alpha-methyl,]	0.0	2	1	1	1
121930	1710	promoter in a b	[promoter in a B]	0.0	4	1	1	1
121931	1710	decrease of constitutive activation	[decrease of constitutive activation]	0.0	4	1	1	1
121932	1710	in-vitro cleavage by recombinant caspase	[In-vitro cleavage by recombinant caspase]	0.0	5	1	1	1
121933	1710	(2) search for loss	[(2) search for losses]	0.0	4	1	1	1
121934	1710	hiv-1 infection.	[HIV-1 infection.]	0.0	2	1	1	1
121935	1710	prognostic indicator for control	[prognostic indicator for control]	0.0	4	1	1	1
121936	1710	Oct-2 responsivity	[Oct-2 responsivity]	0.0	2	1	1	1
121937	1710	soluble lytic transglycosylase	[soluble lytic transglycosylase]	0.0	3	1	1	1
121938	1710	tal-1 protein	[tal-1 proteins]	0.0	2	1	1	1
121939	1710	response to signal event	[response to signaling events]	0.0	4	1	1	1
121940	1710	identification of suppressor protein	[Identification of suppressor proteins]	0.0	4	1	1	1
121941	1710	histocompatibility complex class ii gene	[histocompatibility complex class II genes]	0.0	5	1	1	1
121942	1710	human acute t-cell line	[human acute T-cell line]	0.0	4	1	1	1
121943	1710	pc4 from the nuclear extract	[PC4 from the nuclear extract]	0.0	5	1	1	1
121944	1710	also a inducer in all	[also a inducer in all]	0.0	5	1	1	1
121945	1710	gr by ligand	[GR by ligand]	0.0	3	1	1	1
121946	1710	three mode of stress	[three modes of stress]	0.0	4	1	1	1
121947	1710	region extend	[regions extending]	0.0	2	1	1	1
121948	1710	synthesis of hemoglobin	[synthesis of hemoglobin]	0.0	3	1	1	1
121949	1710	indicate defective	[indicating defective]	0.0	2	1	1	1
121950	1710	porcine interferon-gamma	[porcine interferon-gamma]	0.0	2	1	1	1
121951	1710	er-negative breast cancer cell line	[ER-negative breast cancer cell lines]	0.0	5	1	1	1
121952	1710	agents, doses, and/or schedule	[agents, doses, and/or schedules]	0.0	4	1	1	1
121953	1710	clone with response	[Clones with responses]	0.0	3	1	1	1
121954	1710	result in translocation into the nucleus	[resulting in translocation into the nucleus]	0.0	6	1	1	1
121955	1710	monitoring of minimal disease	[monitoring of minimal disease]	0.0	4	1	1	1
121956	1710	t-cell receptor (tcr) region beta-chain family	[T-cell receptor (TCR) region beta-chain families]	0.0	6	1	1	1
121957	1710	TNF alpha monoclonal antibody	[TNF alpha monoclonal antibody]	0.0	4	1	1	1
121958	1710	neutrophil migration	[neutrophil migration]	0.0	2	1	1	1
121959	1710	minute of addition of M-CSF	[min of addition of M-CSF]	0.0	5	1	1	1
121960	1710	osteopontin	[osteopontin]	0.0	1	1	1	1
121961	1710	fourfold decrease	[fourfold decrease]	0.0	2	1	1	1
121962	1710	0.5 molecule	[0.5 molecules]	0.0	2	1	1	1
121963	1710	Ser-32	[Ser-32]	0.0	1	1	1	1
121964	1710	c-Myb reporter construct	[c-Myb reporter constructs]	0.0	3	1	1	1
121965	1710	TCF-1 a T transcription factor	[TCF-1 a T transcription factor]	0.0	5	2	2	1
121966	1710	nuclear nf-kappa b complex	[nuclear NF-kappa B complex]	0.0	4	1	1	1
121967	1710	hydrophobic, polypeptide of unknown function	[hydrophobic, polypeptide of unknown function]	0.0	5	1	1	1
121968	1710	gene movement within that region	[gene movements within those regions]	0.0	5	1	1	1
121969	1710	indicate aetiology for this disorders.	[indicating aetiologies for these disorders.]	0.0	5	1	1	1
121970	1710	expression of class complex gene	[expression of class complex genes]	0.0	5	1	1	1
121971	1710	deficient ability	[deficient ability]	0.0	2	1	1	1
121972	1710	chromatin from T lymphocyte	[chromatin from T lymphocytes]	0.0	4	1	1	1
121973	1710	responsiveness 0.01).	[responsiveness 0.01).]	0.0	2	1	1	1
121974	1710	term therapy in the patient	[term therapy in the patients]	0.0	5	1	1	1
121975	1710	il-4r kinase jak-1	[IL-4R kinase JAK-1]	0.0	3	1	1	1
121976	1710	family of host transcription factor	[family of host transcription factors]	0.0	5	1	1	1
121977	1710	lung parenchyma	[lung parenchyma]	0.0	2	1	1	1
121978	1710	enlarge	[enlarging]	0.0	1	1	1	1
121979	1710	expression assay with plasmid contain part	[expression assays with plasmids containing parts]	0.0	6	1	1	1
121980	1710	cytokine modulating	[cytokine modulating]	0.0	2	1	1	1
121981	1710	CR1 of blood monocyte	[CR1 of blood monocytes]	0.0	4	1	1	1
121982	1710	delineate the role in other condition	[delineating the roles in other conditions]	0.0	6	1	1	1
121983	1710	region upstream to the exon,	[region upstream to the exon,]	0.0	5	1	1	1
121984	1710	42.2% induction of degradation.	[42.2% induction of degradation.]	0.0	4	1	1	1
121985	1710	permanently a challenge for immunology	[Permanently a challenge for immunology]	0.0	5	1	1	1
121986	1710	8% cell at day g-csf	[8% cells at day G-CSF]	0.0	5	1	1	1
121987	1710	mononuclear phagocyte/neutrophil series	[mononuclear phagocyte/neutrophil series]	0.0	3	1	1	1
121988	1710	stat3 signal transducer of transcription-3	[STAT3 signal transducer of transcription-3]	0.0	5	1	1	1
121989	1710	Calyculin a	[Calyculin A]	0.0	2	1	1	1
121990	1710	similar region of human sequence	[similar regions of human sequences]	0.0	5	1	1	1
121991	1710	molecular isoform	[molecular isoforms]	0.0	2	1	1	1
121992	1710	specific assay use FUra	[specific assay using FUra]	0.0	4	1	1	1
121993	1710	receptor in patient with syndrome	[receptors in patients with syndromes]	0.0	5	1	1	1
121994	1710	phorbol transcription factor ap1	[phorbol transcription factor AP1]	0.0	4	1	1	1
121995	1710	cortivazol act	[cortivazol acts]	0.0	2	1	1	1
121996	1710	alpha- estradiol	[alpha- estradiol]	0.0	2	1	1	1
121997	1710	16 hour	[16 hr]	0.0	2	1	1	1
121998	1710	major nonoverlapping epitope	[major nonoverlapping epitopes]	0.0	3	1	1	1
121999	1710	Eur J Immunol	[Eur J Immunol]	0.0	3	1	1	1
122000	1710	cell in the system	[cells in the system]	0.0	4	1	1	1
122001	1710	adhesion molecule-1 induction	[adhesion molecule-1 induction]	0.0	3	1	1	1
122002	1710	noticeable exception	[noticeable exception]	0.0	2	1	1	1
122003	1710	renal phosphate transport	[renal phosphate transport]	0.0	3	1	1	1
122004	1710	extend nucleotide 5'	[extending nucleotides 5']	0.0	3	1	1	1
122005	1710	mouse tissue include lymphatic organ	[mouse tissues including lymphatic organs]	0.0	5	1	1	1
122006	1710	human tnf receptor	[human TNF receptor]	0.0	3	1	1	1
122007	1710	deoxyguanosine residue	[deoxyguanosine residues]	0.0	2	1	1	1
122008	1710	cytokine modulation	[Cytokine modulation]	0.0	2	1	1	1
122009	1710	degradation of protein	[degradation of protein]	0.0	3	1	1	1
122010	1710	Wiley-Liss,	[Wiley-Liss,]	0.0	1	1	1	1
122011	1710	express a egr-1 transgene hl-60egr-1	[expressing an Egr-1 transgene HL-60Egr-1]	0.0	5	1	1	1
122012	1710	impact for erythroid cell development	[impact for erythroid cell development]	0.0	5	1	1	1
122013	1710	upregulate il-6 secretion	[upregulating IL-6 secretion]	0.0	3	1	1	1
122014	1710	(tnf) receptor family,	[(TNF) receptor family,]	0.0	3	1	1	1
122015	1710	various organ	[various organs]	0.0	2	1	1	1
122016	1710	activity of topoisomerase	[activity of topoisomerases]	0.0	3	1	1	1
122017	1710	application to the study	[application to the study]	0.0	4	1	1	1
122018	1710	inhibition of less magnitude	[inhibition of lesser magnitude]	0.0	4	1	1	1
122019	1710	early to 12 mo)	[early to 12 mo)]	0.0	4	1	1	1
122020	1710	hiv-hd express	[HIV-HD express]	0.0	2	1	1	1
122021	1710	availability of transcription factor protein	[availability of transcription factor proteins]	0.0	5	1	1	1
122022	1710	use a binding assay	[Using a binding assay]	0.0	4	1	1	1
122023	1710	initial proliferation of b lymphocyte	[initial proliferation of B lymphocytes]	0.0	5	1	1	1
122024	1710	use a hybridoma	[using a hybridoma]	0.0	3	1	1	1
122025	1710	effect on pattern	[effect on patterns]	0.0	3	1	1	1
122026	1710	vector encode a mutant	[vector encoding a mutant]	0.0	4	1	1	1
122027	1710	Zp induction	[Zp induction]	0.0	2	1	1	1
122028	1710	consensus site in the loci	[consensus sites in the loci]	0.0	5	1	1	1
122029	1710	maturation of monocyte	[maturation of monocytes]	0.0	3	1	1	1
122030	1710	similar mobility	[similar mobilities]	0.0	2	1	1	1
122031	1710	importance after influenza infection	[importance after influenza infection]	0.0	4	1	1	1
122032	1710	CD30 by this cell	[CD30 by these cells]	0.0	4	1	1	1
122033	1710	other follicular hyperplasias	[other follicular hyperplasias]	0.0	3	1	1	1
122034	1710	subunit of relative molecular mass	[subunits of relative molecular mass]	0.0	5	1	1	1
122035	1710	antigens.	[antigens.]	0.0	1	1	1	1
122036	1710	atherosclerotic plaque of artery	[atherosclerotic plaques of arteries]	0.0	4	1	1	1
122037	1710	(oct-1p)-binding	[(OCT-1p)-binding]	0.0	1	1	1	1
122038	1710	-chaperoned peptide	[-chaperoned peptides]	0.0	2	1	1	1
122039	1710	antigens,	[antigens,]	0.0	1	1	1	1
122040	1710	costimulation /anti-cd28 T lymphocyte	[Costimulation /anti-CD28 T lymphocytes]	0.0	4	1	1	1
122041	1710	cell counterpart	[cell counterparts]	0.0	2	1	1	1
122042	1710	expose human umbilical vein cell huvec	[Exposing human umbilical vein cells HUVECs]	0.0	6	1	1	1
122043	1710	phorbol myristate acetate stimulation p40	[phorbol myristate acetate stimulation p40]	0.0	5	1	1	1
122044	1710	oncogene c-myb	[oncogene c-myb]	0.0	2	1	1	1
122045	1710	transcription) 6	[transcription) 6]	0.0	2	1	1	1
122046	1710	cases, constitutive DNA	[cases, constitutive DNA]	0.0	3	1	1	1
122047	1710	amount of jun-b	[amounts of Jun-B]	0.0	3	1	1	1
122048	1710	fitc-dextran	[FITC-dextran]	0.0	1	1	1	1
122049	1710	human ikappab alpha	[human IkappaB alpha]	0.0	3	1	1	1
122050	1710	contain cis element	[containing cis elements]	0.0	3	1	1	1
122051	1710	obtain new informative probe	[obtaining new informative probes]	0.0	4	1	1	1
122052	1710	lymphocyte of healthy pregnant woman	[lymphocytes of healthy pregnant women]	0.0	5	1	1	1
122053	1710	hut-78	[Hut-78]	0.0	1	1	1	1
122054	1710	gene mie	[gene MIE]	0.0	2	1	1	1
122055	1710	12-o-tetradecanoylphorbol-13-acetate tpa differentiation	[12-O-tetradecanoylphorbol-13-acetate TPA differentiation]	0.0	3	1	1	1
122056	1710	mutant glucocorticoid receptor l753f	[mutant glucocorticoid receptors L753F]	0.0	4	1	1	1
122057	1710	-dependent transcriptional activation of 2 gene	[-dependent transcriptional activation of 2 gene]	0.0	6	1	1	1
122058	1710	less severe degree	[less severe degree]	0.0	3	1	1	1
122059	1710	mutation in this same gene	[mutation in this same gene]	0.0	5	1	1	1
122060	1710	transactivation by the ciita	[transactivation by the CIITA]	0.0	4	1	1	1
122061	1710	protein dimerization domain hepatic leukemic factor	[protein dimerization domain hepatic leukemic factor]	0.0	6	1	1	1
122062	1710	exposure of cell to environmental condition	[Exposure of cells to environmental conditions]	0.0	6	1	1	1
122063	1710	irf-1 5'-flanking DNA	[IRF-1 5'-flanking DNA]	0.0	3	1	1	1
122064	1710	several protein species of the family	[several protein species of the family]	0.0	6	1	1	1
122065	1710	subsequent month	[subsequent months]	0.0	2	1	1	1
122066	1710	mar-bp1 binding	[MAR-BP1 binding]	0.0	2	1	1	1
122067	1710	residue-long peptide fragment	[residue-long peptide fragments]	0.0	3	1	1	1
122068	1710	include peripheral cell	[including peripheral cells]	0.0	3	1	1	1
122069	1710	sequence of the Agamma-	[sequences of the Agamma-]	0.0	4	1	1	1
122070	1710	b -dependent luciferase construct	[B -dependent luciferase constructs]	0.0	4	1	1	1
122071	1710	DNA basic domain	[DNA basic domain]	0.0	3	1	1	1
122072	1710	tandem array	[tandem arrays]	0.0	2	1	1	1
122073	1710	monosomy of loci on chromosome 17p	[monosomy of loci on chromosome 17p]	0.0	6	1	1	1
122074	1710	regulation of murine retroviruse	[regulation of murine retroviruses]	0.0	4	1	1	1
122075	1710	one bind site	[one binding site]	0.0	3	1	1	1
122076	1710	block chromatin fragmentation	[blocking chromatin fragmentation]	0.0	3	1	1	1
122077	1710	microg/ml respectively.	[microg/ml respectively.]	0.0	2	1	1	1
122078	1710	kda precursor of p50	[kDa precursor of p50]	0.0	4	1	1	1
122079	1710	addition of tfiid	[addition of TFIID]	0.0	3	1	1	1
122080	1710	therefore fold of the domain, interference	[therefore folding of the domain, interference]	0.0	6	1	1	1
122081	1710	overproduction a mechanism	[Overproduction a mechanism]	0.0	3	1	1	1
122082	1710	panoply	[panoply]	0.0	1	1	1	1
122083	1710	encode the t-cell receptor	[encoding the T-cell receptor]	0.0	4	1	1	1
122084	1710	significant alteration	[significant alterations]	0.0	2	1	1	1
122085	1710	alteration in glucocorticoid receptor gr	[alterations in glucocorticoid receptor GR]	0.0	5	1	1	1
122086	1710	functional tissues,	[functional tissues,]	0.0	2	1	1	1
122087	1710	correlation with class ii expression	[correlation with class II expression]	0.0	5	1	1	1
122088	1710	class of event	[class of events]	0.0	3	1	1	1
122089	1710	cooh-terminal polypeptide	[COOH-terminal polypeptide]	0.0	2	1	1	1
122090	1710	partial nucleotide sequence	[partial nucleotide sequence]	0.0	3	1	1	1
122091	1710	min) physical exercise	[min) physical exercise]	0.0	3	1	1	1
122092	1710	part of role	[part of role]	0.0	3	1	1	1
122093	1710	such as h2o2 PMA	[such as H2O2 PMA]	0.0	4	1	1	1
122094	1710	none of the other putative site	[None of the other putative sites]	0.0	6	1	1	1
122095	1710	PBMC from two child	[PBMC from two children]	0.0	4	2	2	1
122096	1710	use the bcl6 (hbcl6) cDNA	[using the BCL6 (hBCL6) cDNA]	0.0	5	1	1	1
122097	1710	sex reversal	[sex reversal]	0.0	2	1	1	1
122098	1710	patient with ductal cancer	[patients with ductal cancers]	0.0	4	1	1	1
122099	1710	cause of inflammatory arthritis	[cause of inflammatory arthritis]	0.0	4	2	2	1
122100	1710	menstruate	[menstruating]	0.0	1	1	1	1
122101	1710	basis -107	[bases -107]	0.0	2	1	1	1
122102	1710	manifestation of cystic fibrosis	[manifestations of cystic fibrosis]	0.0	4	1	1	1
122103	1710	identification of a major regulatory element	[Identification of a major regulatory element]	0.0	6	1	1	1
122104	1710	treatment of monocyte with il-1beta	[treatment of monocytes with IL-1beta]	0.0	5	1	1	1
122105	1710	stimulate the expression	[stimulating the expression]	0.0	3	1	1	1
122106	1710	adhesion with 50% inhibition	[adhesion with 50% inhibition]	0.0	4	1	1	1
122107	1710	EBV nuclear antigen EBNA2 one	[EBV nuclear antigen EBNA2 one]	0.0	5	1	1	1
122108	1710	smear of product	[smear of products]	0.0	3	1	1	1
122109	1710	hepatic nuclear factor beta hnf3 beta	[hepatic nuclear factor beta HNF3 beta]	0.0	6	1	1	1
122110	1710	constitutive nf-kappa b in cell	[Constitutive NF-kappa B in cells]	0.0	5	1	1	1
122111	1710	genetic program underlie differentiation	[genetic program underlying differentiation]	0.0	4	1	1	1
122112	1710	drift	[drift]	0.0	1	1	1	1
122113	1710	extensive cell infiltration with necrosis	[extensive cell infiltration with necrosis]	0.0	5	1	1	1
122114	1710	functional response by this mechanism	[functional responses by these mechanisms]	0.0	5	1	1	1
122115	1710	important factor determine gene activation	[important factor determining gene activation]	0.0	5	1	1	1
122116	1710	tissue-specific transcriptional response	[tissue-specific transcriptional response]	0.0	3	1	1	1
122117	1710	role of the protein ikk-alpha	[role of the proteins IKK-alpha]	0.0	5	1	1	1
122118	1710	ap-1 (-186	[AP-1 (-186]	0.0	2	1	1	1
122119	1710	interleukin-1 beta promoter	[interleukin-1 beta promoter]	0.0	3	1	1	1
122120	1710	cell line Jijoye	[cell line Jijoye]	0.0	3	1	1	1
122121	1710	specific inhibitor of mapk kinase	[specific inhibitor of MAPK kinase]	0.0	5	1	1	1
122122	1710	addition, cotransfection	[addition, cotransfection]	0.0	2	1	1	1
122123	1710	inflammatory infiltrate (p	[inflammatory infiltrate (P]	0.0	3	1	1	1
122124	1710	novel coupling	[novel coupling]	0.0	2	1	1	1
122125	1710	infectious kinetic	[infectious kinetics]	0.0	2	1	1	1
122126	1710	switch for lineage specification	[switch for lineage specification]	0.0	4	1	1	1
122127	1710	germ-line c alpha1 gene	[germ-line C alpha1 gene]	0.0	4	1	1	1
122128	1710	p-selectin translocation of factor-kappa b	[P-selectin translocation of factor-kappa B]	0.0	5	1	1	1
122129	1710	cDNA clone in bacterium	[cDNA clones in bacteria]	0.0	4	1	1	1
122130	1710	positive staining for estrogen receptor	[positive staining for estrogen receptors]	0.0	5	1	1	1
122131	1710	transactivation of the cd25 promoter	[transactivation of the CD25 promoter]	0.0	5	1	1	1
122132	1710	sequence from gene	[sequences from genes]	0.0	3	1	1	1
122133	1710	relapse,	[relapse,]	0.0	1	1	1	1
122134	1710	distinct form of unbound (free) e2f	[distinct forms of unbound (free) E2F]	0.0	6	1	1	1
122135	1710	however, b	[However, B]	0.0	2	1	1	1
122136	1710	disrupt domain	[disrupting domain]	0.0	2	1	1	1
122137	1710	effect of ciprofloxacin	[effect of ciprofloxacin]	0.0	3	1	1	1
122138	1710	significant relatedness to a transcription factor	[significant relatedness to a transcription factor]	0.0	6	1	1	1
122139	1710	luciferase reporter gene activation	[luciferase reporter gene activation]	0.0	4	1	1	1
122140	1710	TCP succinate microM,	[TCP succinate microM,]	0.0	3	1	1	1
122141	1710	RB tumor line	[RB tumor lines]	0.0	3	1	1	1
122142	1710	three trimester),	[three trimester),]	0.0	2	1	1	1
122143	1710	erythropoietin-dependent progenitor	[erythropoietin-dependent progenitors]	0.0	2	1	1	1
122144	1710	several putative erythroid-specific cis-acting element	[several putative erythroid-specific cis-acting elements]	0.0	5	1	1	1
122145	1710	class histocompatibility gene hla-dra	[class histocompatibility gene HLA-DRA]	0.0	4	1	1	1
122146	1710	originate bp upstream	[originating bp upstream]	0.0	3	1	1	1
122147	1710	defect in nf-kappab activation	[defect in NF-kappaB activation]	0.0	4	1	1	1
122148	1710	spite of association	[spite of association]	0.0	3	1	1	1
122149	1710	addition of phosphatidic acid the product	[addition of phosphatidic acid the product]	0.0	6	1	1	1
122150	1710	stati DNA binding	[STATI DNA binding]	0.0	3	1	1	1
122151	1710	relative to the LMP start site	[relative to the LMP start site]	0.0	6	1	1	1
122152	1710	protein vp16	[protein VP16]	0.0	2	1	1	1
122153	1710	induction surface expression by TNF	[Induction surface expression by TNF]	0.0	5	1	1	1
122154	1710	mineralocorticoid receptor status in leukocyte	[mineralocorticoid receptor status in leukocytes]	0.0	5	1	1	1
122155	1710	exact site of action	[exact site of action]	0.0	4	1	1	1
122156	1710	myeloid progenitor cells,	[myeloid progenitor cells,]	0.0	3	1	1	1
122157	1710	Internal binding	[Internal binding]	0.0	2	1	1	1
122158	1710	selection of three lac+clone	[selection of three Lac+clones]	0.0	4	1	1	1
122159	1710	endocrine culture	[endocrine cultures]	0.0	2	1	1	1
122160	1710	effective signal	[effective signals]	0.0	2	1	1	1
122161	1710	activation the molecular weight variant	[activation the molecular weight variant]	0.0	5	1	1	1
122162	1710	IL-2 t-cell transformation	[IL-2 T-cell transformation]	0.0	3	1	1	1
122163	1710	last	[lasting]	0.0	1	1	1	1
122164	1710	elucidate the mechanism govern lineage switch	[elucidating the mechanisms governing lineage switching]	0.0	6	1	1	1
122165	1710	simple binding	[simple binding]	0.0	2	1	1	1
122166	1710	joint requirement for optimal function	[joint requirement for optimal function]	0.0	5	1	1	1
122167	1710	differ at residue	[differing at residue]	0.0	3	1	1	1
122168	1710	cellular nuclear factor-KB result	[cellular nuclear factor-KB resulting]	0.0	4	1	1	1
122169	1710	great increase in state level	[greater increase in state levels]	0.0	5	1	1	1
122170	1710	loss of binding activity	[loss of binding activity]	0.0	4	1	1	1
122171	1710	immunodeficiency virus variant	[immunodeficiency virus variant]	0.0	3	1	1	1
122172	1710	regulate alpha2 integrin gene expression	[regulating alpha2 integrin gene expression]	0.0	5	1	1	1
122173	1710	overexpression carboxyl-terminal peptide	[Overexpression carboxyl-terminal peptide]	0.0	3	1	1	1
122174	1710	membrane from yeast	[membranes from yeast]	0.0	3	1	1	1
122175	1710	receptor-receptor	[receptor-receptor]	0.0	1	1	1	1
122176	1710	domain (prd) ii binding protein	[domain (PRD) II binding proteins]	0.0	5	1	1	1
122177	1710	only weight species of 24	[only weight species of 24]	0.0	5	1	1	1
122178	1710	up to 30-fold	[up to 30-fold]	0.0	3	1	1	1
122179	1710	replacement of the two AP-1 site	[Replacement of the two AP-1 sites]	0.0	6	1	1	1
122180	1710	incubation of leukemia (b-cll) cell	[Incubation of leukemia (B-CLL) cells]	0.0	5	1	1	1
122181	1710	Ad5 /animal,	[Ad5 /animal,]	0.0	2	1	1	1
122182	1710	sensitization of cell	[sensitization of cells]	0.0	3	1	1	1
122183	1710	tax-responsive element-1	[Tax-responsive element-1]	0.0	2	1	1	1
122184	1710	proenkephalin gene	[proenkephalin gene]	0.0	2	1	1	1
122185	1710	level expression of mmtv	[level expression of MMTV]	0.0	4	1	1	1
122186	1710	saphenous vein cell	[saphenous vein cells]	0.0	3	1	1	1
122187	1710	erythroid specificity	[erythroid specificity]	0.0	2	1	1	1
122188	1710	nonrelated cell	[nonrelated cells]	0.0	2	1	1	1
122189	1710	element-binding protein CREB	[element-binding protein CREB]	0.0	3	1	1	1
122190	1710	germ-line c	[germ-line C]	0.0	2	1	1	1
122191	1710	regulation of the glucocorticoid receptor	[regulation of the glucocorticoid receptor]	0.0	5	1	1	1
122192	1710	avenue of therapy	[avenue of therapy]	0.0	3	1	1	1
122193	1710	tumor originate	[tumors originating]	0.0	2	1	1	1
122194	1710	overexpression of IRAK	[overexpression of IRAK]	0.0	3	1	1	1
122195	1710	apoptosis-mediating receptor	[apoptosis-mediating receptor]	0.0	2	1	1	1
122196	1710	activation of zeta	[activation of zeta]	0.0	3	1	1	1
122197	1710	result in production of interleukin-2	[resulting in production of interleukin-2]	0.0	5	1	1	1
122198	1710	optimal transcription in cell	[optimal transcription in cells]	0.0	4	1	1	1
122199	1710	activity of hnf1	[activity of HNF1]	0.0	3	1	1	1
122200	1710	endogenous gm-csf	[endogenous GM-CSF]	0.0	2	1	1	1
122201	1710	replication of type 1	[Replication of type 1]	0.0	4	1	1	1
122202	1710	approximately 3kb upstream	[approximately 3kb upstream]	0.0	3	1	1	1
122203	1710	cytokine generation	[cytokine generation]	0.0	2	1	1	1
122204	1710	event of the activation cascade	[events of the activation cascade]	0.0	5	1	1	1
122205	1710	diferuoylmethane	[diferuoylmethane]	0.0	1	1	1	1
122206	1710	vaginosis	[vaginosis]	0.0	1	1	1	1
122207	1710	recent therapeutic initiative	[recent therapeutic initiative]	0.0	3	1	1	1
122208	1710	antibody t-cell proliferation	[antibody T-cell proliferation]	0.0	3	1	1	1
122209	1710	level of the dna-binding activity	[levels of the DNA-binding activity]	0.0	5	1	1	1
122210	1710	resting t-cell extract	[Resting T-cell extracts]	0.0	3	1	1	1
122211	1710	human monocyte pbm	[human monocytes PBM]	0.0	3	1	1	1
122212	1710	binding of distinct multi-protein complex RFX	[binding of distinct multi-protein complexes RFX]	0.0	6	1	1	1
122213	1710	significant depression	[significant depression]	0.0	2	1	1	1
122214	1710	expression of specific interferon isotype	[expression of specific interferon isotypes]	0.0	5	1	1	1
122215	1710	much low level	[much lower levels]	0.0	3	1	1	1
122216	1710	elf-1 by binding	[Elf-1 by binding]	0.0	3	1	1	1
122217	1710	arrest differentiation	[arresting differentiation]	0.0	2	1	1	1
122218	1710	lead to apoptosis	[leading to apoptosis]	0.0	3	1	1	1
122219	1710	inflammatory effector gene product	[inflammatory effector gene products]	0.0	4	1	1	1
122220	1710	rhabdomyosarcoma leiomyosarcoma	[rhabdomyosarcoma leiomyosarcoma]	0.0	2	1	1	1
122221	1710	upregulation intercellular adhesion molecule-1 icam-1	[upregulation intercellular adhesion molecule-1 ICAM-1]	0.0	5	1	1	1
122222	1710	orf transactivator	[ORF transactivator]	0.0	2	1	1	1
122223	1710	use a nonradioactive assay	[using a nonradioactive assay]	0.0	4	1	1	1
122224	1710	field in immunology	[field in immunology]	0.0	3	1	1	1
122225	1710	migration inhibitory protein	[migration inhibitory protein]	0.0	3	1	1	1
122226	1710	Functional activation	[Functional activation]	0.0	2	2	2	1
122227	1710	number of retrievable macrophage	[number of retrievable macrophages]	0.0	4	1	1	1
122228	1710	other dibenzo-p-dioxin pcdd/pcdf	[other dibenzo-p-dioxins PCDD/PCDF]	0.0	3	1	1	1
122229	1710	previously, a factor irf-1	[Previously, a factor IRF-1]	0.0	4	1	1	1
122230	1710	infection of phagocyte with L. donovani	[infection of phagocytes with L. donovani]	0.0	6	1	1	1
122231	1710	one type	[one type]	0.0	2	1	1	1
122232	1710	initiate tyrosine phosphorylation of substrate in	[initiating tyrosine phosphorylation of substrates in]	0.0	6	1	1	1
122233	1710	time h)	[times h)]	0.0	2	1	1	1
122234	1710	t-helper-cell determinant	[T-helper-cell determinants]	0.0	2	1	1	1
122235	1710	involve activation of form of stat3	[involving activation of forms of STAT3]	0.0	6	1	1	1
122236	1710	level of vitamin d receptor	[levels of vitamin D receptor]	0.0	5	1	1	1
122237	1710	additional complex formation	[additional complex formation]	0.0	3	1	1	1
122238	1710	daily replacement dose	[daily replacement dose]	0.0	3	1	1	1
122239	1710	signal in lymphocyte	[signaling in lymphocytes]	0.0	3	1	1	1
122240	1710	various normal cell type	[various normal cell types]	0.0	4	1	1	1
122241	1710	fibrosarcoma malignant histiocytoma rhabdomyosarcoma	[fibrosarcoma malignant histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
122242	1710	novel lysis synthetic substrate	[novel lysis synthetic substrate]	0.0	4	1	1	1
122243	1710	survival of thymocyte in transgenic mouse	[survival of thymocytes in transgenic mice]	0.0	6	1	1	1
122244	1710	analysis of nuclear translocation of member	[Analyses of nuclear translocation of members]	0.0	6	1	1	1
122245	1710	membrane perturbation	[membrane perturbation]	0.0	2	1	1	1
122246	1710	effect of hypercortisolaemia	[effects of hypercortisolaemia]	0.0	3	1	1	1
122247	1710	relationship between A-myb	[relationship between A-myb]	0.0	3	1	1	1
122248	1710	diabetic complication	[diabetic complications]	0.0	2	1	1	1
122249	1710	Addition of r-htbp-1	[Addition of r-hTBP-1]	0.0	3	1	1	1
122250	1710	g-csf 8% cell at day	[G-CSF 8% cells at day]	0.0	5	1	1	1
122251	1710	reveal a role	[revealing a role]	0.0	3	1	1	1
122252	1710	control gene expression in cell	[controlling gene expression in cells]	0.0	5	1	1	1
122253	1710	change in ca2+	[changes in Ca2+]	0.0	3	1	1	1
122254	1710	stimulatory effect on hiv production	[stimulatory effects on HIV production]	0.0	5	1	1	1
122255	1710	probability recur by 5	[probability recurring by 5]	0.0	4	1	1	1
122256	1710	effect of glucocorticoid on interleukin	[effects of glucocorticoids on interleukin]	0.0	5	1	1	1
122257	1710	clone in myeloproliferative disorder	[clone in myeloproliferative disorders]	0.0	4	1	1	1
122258	1710	more polar substitution alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[more polar substitutions alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	6	1	1	1
122259	1710	design of combination protocol	[design of combination protocols]	0.0	4	1	1	1
122260	1710	transcriptase-polymerase chain reaction RT-PCR	[transcriptase-polymerase chain reaction RT-PCR]	0.0	4	1	1	1
122261	1710	value explore physical signal pathway	[value exploring physical signaling pathways]	0.0	5	1	1	1
122262	1710	specific trans-acting factor	[specific trans-acting factors]	0.0	3	1	1	1
122263	1710	promoter region span position	[promoter region spanning positions]	0.0	4	1	1	1
122264	1710	regulate transcription in cell	[regulating transcription in cells]	0.0	4	1	1	1
122265	1710	nitric oxide synthase -mRNA level	[nitric oxide synthase -mRNA level]	0.0	5	1	1	1
122266	1710	factor contain stat1	[factor containing STAT1]	0.0	3	1	1	1
122267	1710	lps ng/ml)	[LPS ng/ml)]	0.0	2	1	1	1
122268	1710	other unidentified ets-like factor	[Other unidentified ETS-like factors]	0.0	4	1	1	1
122269	1710	surfactant' suppressive effect on cytokine production	[surfactant's suppressive effects on cytokine production]	0.0	6	1	1	1
122270	1710	requirement during cell cycle entry	[requirement during cell cycle entry]	0.0	5	1	1	1
122271	1710	consequence in the use	[consequences in the use]	0.0	4	1	1	1
122272	1710	human immunodeficiency virus individual	[human immunodeficiency virus individuals]	0.0	4	1	1	1
122273	1710	osteosarcoma Saos-2	[osteosarcoma Saos-2]	0.0	2	1	1	1
122274	1710	olfactory cell	[olfactory cells]	0.0	2	1	1	1
122275	1710	trans-activator tax protein	[trans-activator Tax protein]	0.0	3	1	1	1
122276	1710	integrin cell adhesion of beta integrin	[integrin cell adhesion of beta integrins]	0.0	6	1	1	1
122277	1710	(3) evidence	[(3) evidence]	0.0	2	1	1	1
122278	1710	release of normal platelet	[release of normal platelets]	0.0	4	1	1	1
122279	1710	Fos-B	[Fos-B]	0.0	1	1	1	1
122280	1710	aspect of the induction	[aspects of the induction]	0.0	4	1	1	1
122281	1710	protein, nf-gm2	[protein, NF-GM2]	0.0	2	1	1	1
122282	1710	significant variable	[significant variable]	0.0	2	1	1	1
122283	1710	chem	[Chem]	0.0	1	1	1	1
122284	1710	stress than lipid peroxidation	[stress than lipid peroxidation]	0.0	4	1	1	1
122285	1710	adhesion molecule-1 icam-1 expression	[adhesion molecule-1 ICAM-1 expression]	0.0	4	1	1	1
122286	1710	nf-kappab activation long terminal repeat	[NF-kappaB activation long terminal repeat]	0.0	5	1	1	1
122287	1710	importance for counseling.	[importance for counseling.]	0.0	3	1	1	1
122288	1710	two distinct stages: a chronic	[two distinct stages: a chronic]	0.0	5	1	1	1
122289	1710	level of nuclear nf-kappa b complex	[levels of nuclear NF-kappa B complex]	0.0	6	1	1	1
122290	1710	extensive application.	[extensive application.]	0.0	2	1	1	1
122291	1710	4X NF-AT-Oct	[4X NF-AT-Oct]	0.0	2	1	1	1
122292	1710	expression of gene tnf-alpha	[expression of genes TNF-alpha]	0.0	4	1	1	1
122293	1710	cd4(+) t-cell clone	[CD4(+) T-cell clones]	0.0	3	1	1	1
122294	1710	CEM leukemic cell clone	[CEM leukemic cell clone]	0.0	4	1	1	1
122295	1710	ap-1 activity in 1e8 cell	[AP-1 activity in 1E8 cells]	0.0	5	1	1	1
122296	1710	regulation in several human cell line	[regulation in several human cell lines]	0.0	6	1	1	1
122297	1710	phosphatase-positive cell from human monocyte	[phosphatase-positive cells from human monocytes]	0.0	5	1	1	1
122298	1710	(88.6+/-11.5 pg/ml pg/mL,	[(88.6+/-11.5 pg/mL pg/mL,]	0.0	3	1	1	1
122299	1710	human volunteer	[human volunteer]	0.0	2	1	1	1
122300	1710	12-0-tetradecanoyl phorbol-13-acetate tpa for h	[12-0-tetradecanoyl phorbol-13-acetate TPA for h]	0.0	5	1	1	1
122301	1710	hypothalamic-pituitary-adrenal hpa system	[hypothalamic-pituitary-adrenal HPA system]	0.0	3	1	1	1
122302	1710	map kinase kinase-3	[MAP kinase kinase-3]	0.0	3	1	1	1
122303	1710	homolog of crp1 c/ebp-epsilon	[homolog of CRP1 C/EBP-epsilon]	0.0	4	1	1	1
122304	1710	aggressive type	[aggressive types]	0.0	2	1	1	1
122305	1710	novel fusion transcript	[novel fusion transcript]	0.0	3	1	1	1
122306	1710	kb downstream	[kb downstream]	0.0	2	1	1	1
122307	1710	NFAT -1-mediated transcription	[NFAT -1-mediated transcription]	0.0	3	1	1	1
122308	1710	B-lymphoblastoid cell line produce a retrovirus	[B-lymphoblastoid cell lines producing a retrovirus]	0.0	6	1	1	1
122309	1710	expression of subordinate gene	[expression of subordinate genes]	0.0	4	1	1	1
122310	1710	eightfold amount of nf-at	[eightfold amounts of NF-AT]	0.0	4	1	1	1
122311	1710	active form kinase C PKC transcription	[active forms kinase C PKC transcription]	0.0	6	1	1	1
122312	1710	activity at concentration	[activity at concentrations]	0.0	3	1	1	1
122313	1710	complex in cell	[complex in cells]	0.0	3	1	1	1
122314	1710	advantage of Jurkat cell	[advantage of Jurkat cells]	0.0	4	1	1	1
122315	1710	qp responsiveness	[Qp responsiveness]	0.0	2	1	1	1
122316	1710	transition of Epstein-Barr virus EBV	[transition of Epstein-Barr virus EBV]	0.0	5	1	1	1
122317	1710	addition, level	[addition, level]	0.0	2	1	1	1
122318	1710	specific receptor vitamin D3 receptor	[specific receptors vitamin D3 receptors]	0.0	5	1	1	1
122319	1710	contrast, cotransfection	[contrast, cotransfection]	0.0	2	1	1	1
122320	1710	mutation/deletion of downstream NF-kappa b site	[mutation/deletion of downstream NF-kappa B site]	0.0	6	1	1	1
122321	1710	gene transcription of mediator	[gene transcription of mediators]	0.0	4	1	1	1
122322	1710	two nuclear binding protein kD	[two nuclear binding proteins kD]	0.0	5	1	1	1
122323	1710	type ii/type I interleukin-1 receptor	[type II/type I interleukin-1 receptor]	0.0	5	1	1	1
122324	1710	abnormally low level t-cell receptor (tcr)-zeta	[abnormally low levels T-cell receptor (TCR)-zeta]	0.0	6	1	1	1
122325	1710	fraction of T cell	[fraction of T cells]	0.0	4	1	1	1
122326	1710	induction requirement	[Induction requirements]	0.0	2	1	1	1
122327	1710	CIITA mrna transcription	[CIITA mRNA transcription]	0.0	3	1	1	1
122328	1710	affinity binding for dexamethasone (apparent kd,	[affinity binding for dexamethasone (apparent Kd,]	0.0	6	1	1	1
122329	1710	normal blood T cell	[normal blood T cells]	0.0	4	1	1	1
122330	1710	transcriptional activity of class promoter	[transcriptional activity of class promoters]	0.0	5	1	1	1
122331	1710	activation of the tf gene	[activation of the TF gene]	0.0	5	1	1	1
122332	1710	costimulation via CD28	[costimulation via CD28]	0.0	3	1	1	1
122333	1710	T-helper 2 subset	[T-helper 2 subset]	0.0	3	1	1	1
122334	1710	cell specific gene	[cell specific genes]	0.0	3	1	1	1
122335	1710	amino acid of vp16	[amino acids of VP16]	0.0	4	1	1	1
122336	1710	expression of interferon factor	[expression of interferon factor]	0.0	4	1	1	1
122337	1710	effect with dose of flutamide	[effects with doses of flutamide]	0.0	5	1	1	1
122338	1710	basis of il-12 action,	[basis of IL-12 action,]	0.0	4	1	1	1
122339	1710	case of lymphoma NL	[cases of lymphoma NL]	0.0	4	1	1	1
122340	1710	phosphatidylinositol-3-kinase	[phosphatidylinositol-3-kinase]	0.0	1	1	1	1
122341	1710	CATGTGGC	[CATGTGGC]	0.0	1	1	1	1
122342	1710	brain structure critical	[brain structure critical]	0.0	3	1	1	1
122343	1710	lbf2	[LBF2]	0.0	1	1	1	1
122344	1710	additional work,	[Additional work,]	0.0	2	1	1	1
122345	1710	include phagocytosis	[including phagocytosis]	0.0	2	1	1	1
122346	1710	[effect of antihypertensive therapy	[[Effect of antihypertensive therapy]	0.0	4	1	1	1
122347	1710	gata-1 transcription factor gene	[GATA-1 transcription factor gene]	0.0	4	1	1	1
122348	1710	effect on the sodium-proton-antiport	[effects on the sodium-proton-antiport]	0.0	4	1	1	1
122349	1710	unrelated antioxidant agent pyrrolidine dithiocarbamate	[unrelated antioxidant agents pyrrolidine dithiocarbamate]	0.0	5	1	1	1
122350	1710	specific antibody in	[specific antibodies in]	0.0	3	1	1	1
122351	1710	simultaneously; normal pbl	[simultaneously; normal PBL]	0.0	3	1	1	1
122352	1710	myc-max	[Myc-Max]	0.0	1	1	1	1
122353	1710	600 nm, in monocyte	[600 nM, in monocytes]	0.0	4	1	1	1
122354	1710	patient with x-linked immunodeficiency X-SCID	[patients with X-linked immunodeficiency X-SCID]	0.0	5	1	1	1
122355	1710	particular, the interferon factor-1 gene	[particular, the interferon factor-1 gene]	0.0	5	1	1	1
122356	1710	brtal	[BRTAL]	0.0	1	1	1	1
122357	1710	receptor from patient with disease	[receptors from patients with diseases]	0.0	5	1	1	1
122358	1710	rt-pcr analysis from reticulocyte	[RT-PCR analysis from reticulocytes]	0.0	4	1	1	1
122359	1710	major (MHC) class promoter	[major (MHC) class promoters]	0.0	4	1	1	1
122360	1710	indicate a effect	[indicating an effect]	0.0	3	1	1	1
122361	1710	activator protein ap-1	[activator protein AP-1]	0.0	3	1	1	1
122362	1710	intensity of the response	[intensity of the response]	0.0	4	1	1	1
122363	1710	LCL T	[LCL T]	0.0	2	1	1	1
122364	1710	investigation of maturation	[investigation of maturation]	0.0	3	1	1	1
122365	1710	stable b cell line	[stable B cell lines]	0.0	4	1	1	1
122366	1710	availability of the substrate necessary	[availability of the substrates necessary]	0.0	5	1	1	1
122367	1710	one nfat-sensitive gene	[one NFAT-sensitive gene]	0.0	3	1	1	1
122368	1710	induction of erythroblast transformation	[induction of erythroblast transformation]	0.0	4	1	1	1
122369	1710	NF-kappa b -binding	[NF-kappa B -binding]	0.0	3	1	1	1
122370	1710	function in tissue culture cell	[functions in tissue culture cells]	0.0	5	1	1	1
122371	1710	rs cell the membrane protein	[RS cells the membrane protein]	0.0	5	1	1	1
122372	1710	regulation of immunodeficiency virus type expression	[regulation of immunodeficiency virus type expression]	0.0	6	1	1	1
122373	1710	suggest strategy for the detection	[suggesting strategies for the detection]	0.0	5	1	1	1
122374	1710	HIV infection of monocyte	[HIV infection of monocytes]	0.0	4	1	1	1
122375	1710	induce the nuclear expression	[inducing the nuclear expression]	0.0	4	1	1	1
122376	1710	son of the unaffected sister	[son of the unaffected sister]	0.0	5	1	1	1
122377	1710	aml case	[AML cases]	0.0	2	1	1	1
122378	1710	oxygen species ROS)	[oxygen species ROS)]	0.0	3	1	1	1
122379	1710	implicate this gene	[implicating this gene]	0.0	3	1	1	1
122380	1710	own study on pluripotent culture	[own studies on pluripotent cultures]	0.0	5	1	1	1
122381	1710	potent scavenger	[potent scavenger]	0.0	2	1	1	1
122382	1710	dnase i site	[DNase I site]	0.0	3	1	1	1
122383	1710	spatial distribution	[spatial distribution]	0.0	2	1	1	1
122384	1710	selective ligand for acid receptor	[selective ligands for acid receptors]	0.0	5	1	1	1
122385	1710	il-12 ril-12	[IL-12 rIL-12]	0.0	2	1	1	1
122386	1710	T expression by promoter site	[T expression by promoter sites]	0.0	5	1	1	1
122387	1710	85 normal volunteer	[85 normal volunteers]	0.0	3	1	1	1
122388	1710	mononuclear cell reaction grade	[mononuclear cell reaction grade]	0.0	4	1	1	1
122389	1710	human interleukin-5 stimulation	[human interleukin-5 stimulation]	0.0	3	1	1	1
122390	1710	in-vitro cleavage of sp1	[In-vitro cleavage of SP1]	0.0	4	1	1	1
122391	1710	certain growth condition	[certain growth conditions]	0.0	3	1	1	1
122392	1710	IL-3 factor complex in human eosinophil	[IL-3 factor complexes in human eosinophils]	0.0	6	1	1	1
122393	1710	result in phosphorylation of intracellular substrate	[resulting in phosphorylation of intracellular substrates]	0.0	6	1	1	1
122394	1710	terminal b-cell differentiation	[terminal B-cell differentiation]	0.0	3	2	2	1
122395	1710	response by only 50%.	[response by only 50%.]	0.0	4	1	1	1
122396	1710	understanding with particular emphasis	[understanding with particular emphasis]	0.0	4	1	1	1
122397	1710	tyrosine phosphorylation of molecule	[tyrosine phosphorylation of molecules]	0.0	4	1	1	1
122398	1710	number of tetrazolium (nbt)-positive cell	[number of tetrazolium (NBT)-positive cells]	0.0	5	1	1	1
122399	1710	Anti- La(SSB) T cell	[Anti- La(SSB) T cells]	0.0	4	1	1	1
122400	1710	access Epstein-Barr virus memory	[Accessing Epstein-Barr virus memory]	0.0	4	1	1	1
122401	1710	T cell-specific element nre	[T cell-specific element NRE]	0.0	4	1	1	1
122402	1710	site for LEF-1	[sites for LEF-1]	0.0	3	1	1	1
122403	1710	effect of strategy	[effects of strategies]	0.0	3	1	1	1
122404	1710	large tsg101	[Large TSG101]	0.0	2	1	1	1
122405	1710	day of adherence to plastic.	[days of adherence to plastic.]	0.0	5	1	1	1
122406	1710	killer population in the bm	[killer populations in the BM]	0.0	5	1	1	1
122407	1710	malfunction	[malfunction]	0.0	1	1	1	1
122408	1710	Novel aldosterone receptor mechanism	[Novel aldosterone receptors mechanism]	0.0	4	1	1	1
122409	1710	complex with nf-kappab -contain extract	[complex with NF-kappaB -containing extract]	0.0	5	1	1	1
122410	1710	whole venous blood from healthy donor	[whole venous blood from healthy donors]	0.0	6	1	1	1
122411	1710	physical interaction of AML1	[Physical interaction of AML1]	0.0	4	1	1	1
122412	1710	Nuclear translocation of c-rel/ p65 heterodimer	[Nuclear translocation of c-Rel/ p65 heterodimers]	0.0	6	1	1	1
122413	1710	dp2 bp	[DP2 bp]	0.0	2	1	1	1
122414	1710	normal amount	[normal amounts]	0.0	2	1	1	1
122415	1710	cell type-specific gene	[cell type-specific genes]	0.0	3	1	1	1
122416	1710	sequence between position	[sequence between position]	0.0	3	1	1	1
122417	1710	presence of expression	[presence of expression]	0.0	3	1	1	1
122418	1710	production by lavage cell	[production by lavage cells]	0.0	4	1	1	1
122419	1710	vp16 transactivation domain	[VP16 transactivation domains]	0.0	3	1	1	1
122420	1710	contrary, steroid hormone	[contrary, steroid hormones]	0.0	3	1	1	1
122421	1710	adhesion in human umbilical vein cell	[adhesion in human umbilical vein cells]	0.0	6	1	1	1
122422	1710	evidence for a factor	[evidence for an factor]	0.0	4	1	1	1
122423	1710	suppression constitutive sla-dr	[suppression constitutive SLA-DR]	0.0	3	1	1	1
122424	1710	camp -dependent protein kinase a	[cAMP -dependent protein kinase A]	0.0	5	1	1	1
122425	1710	mobility group (hmg) box	[mobility group (HMG) box]	0.0	4	1	1	1
122426	1710	transcription, amplify expression of own receptor	[transcription, amplifying expression of own receptor]	0.0	6	1	1	1
122427	1710	further incubation microg/mL lps	[further incubation microg/mL LPS]	0.0	4	1	1	1
122428	1710	labile inhibitory factor	[labile inhibitory factor]	0.0	3	1	1	1
122429	1710	display difference	[displaying differences]	0.0	2	1	1	1
122430	1710	25(oh)d3 transport	[25(OH)D3 transport]	0.0	2	1	1	1
122431	1710	map kinase kinase 2	[MAP kinase kinase 2]	0.0	4	1	1	1
122432	1710	interleukin a activator of the proliferation	[interleukin a activator of the proliferation]	0.0	6	1	1	1
122433	1710	tal-1 expression in human cell	[tal-1 expression in human cells]	0.0	5	1	1	1
122434	1710	Glucocorticosteroid receptor on leukocyte	[Glucocorticosteroid receptors on leukocytes]	0.0	4	1	1	1
122435	1710	human histocompatibility complex MHC	[human histocompatibility complex MHC]	0.0	4	1	1	1
122436	1710	camp analogue	[cAMP analogue]	0.0	2	1	1	1
122437	1710	different cDNA clone	[different cDNA clones]	0.0	3	1	1	1
122438	1710	of induce lap	[of inducing LAP]	0.0	3	1	1	1
122439	1710	DNA accessibility within the chromosomal copy	[DNA accessibility within the chromosomal copy]	0.0	6	1	1	1
122440	1710	similar cooperation	[similar cooperation]	0.0	2	1	1	1
122441	1710	ten adult peripheral blood lymphocyte sample	[ten adult peripheral blood lymphocyte samples]	0.0	6	1	1	1
122442	1710	specific constitutive binding	[specific constitutive binding]	0.0	3	1	1	1
122443	1710	thus, ligation with CD80	[Thus, ligation with CD80]	0.0	4	1	1	1
122444	1710	treatment of this cell	[Treatment of these cells]	0.0	4	1	1	1
122445	1710	understand the signal event	[understanding the signaling events]	0.0	4	1	1	1
122446	1710	sequence 125-135	[sequence 125-135]	0.0	2	1	1	1
122447	1710	dna-binding affinity and/or specificity	[DNA-binding affinity and/or specificity]	0.0	4	1	1	1
122448	1710	leukemic cell resistant	[leukemic cells resistant]	0.0	3	1	1	1
122449	1710	phorbol 12-myristate 13-acetate stimulation,	[phorbol 12-myristate 13-acetate stimulation,]	0.0	4	1	1	1
122450	1710	min) submaximal exercise ppe	[min) submaximal exercise PPE]	0.0	4	1	1	1
122451	1710	action between a sp-1 -like element	[action between an SP-1 -like element]	0.0	6	1	1	1
122452	1710	blood monocytes.	[blood monocytes.]	0.0	2	2	2	1
122453	1710	cys gsh peripheral blood cell	[CYS GSH peripheral blood cells]	0.0	5	1	1	1
122454	1710	physiological trigger	[physiological trigger]	0.0	2	1	1	1
122455	1710	bank of Philips	[bank of Philips]	0.0	3	1	1	1
122456	1710	expression of mrna for the protein	[Expression of mRNA for the proteins]	0.0	6	1	1	1
122457	1710	primarily in the uvb range	[primarily in the UVB range]	0.0	5	1	1	1
122458	1710	transfection under control of simian virus	[transfection under control of simian virus]	0.0	6	1	1	1
122459	1710	cathepsin g platelet	[cathepsin G platelets]	0.0	3	1	1	1
122460	1710	level of cell death	[levels of cell death]	0.0	4	1	1	1
122461	1710	advanced chronic renal failure	[advanced chronic renal failure]	0.0	4	1	1	1
122462	1710	protein (around kda	[proteins (around kDa]	0.0	3	1	1	1
122463	1710	activation of endogenous lt	[activation of endogenous LT]	0.0	4	1	1	1
122464	1710	immunosuppressive drug cyclosporine	[immunosuppressive drug cyclosporine]	0.0	3	1	1	1
122465	1710	positive-pressure ventilation	[Positive-pressure ventilation]	0.0	2	1	1	1
122466	1710	three small region	[Three smaller regions]	0.0	3	1	1	1
122467	1710	3.6 kb sequence	[3.6 kb sequence]	0.0	3	1	1	1
122468	1710	switch during initial stage	[switching during initial stages]	0.0	4	1	1	1
122469	1710	mechanism for n-acetylcysteine inhibition	[mechanisms for N-acetylcysteine inhibition]	0.0	4	1	1	1
122470	1710	PTF gamma/PTF delta	[PTF gamma/PTF delta]	0.0	3	1	1	1
122471	1710	intact USA	[intact USA]	0.0	2	1	1	1
122472	1710	sensitivity to potential regulation	[sensitivity to potential regulation]	0.0	4	1	1	1
122473	1710	different isoform of wt1	[different isoforms of WT1]	0.0	4	1	1	1
122474	1710	nuclei of different cell types.	[nuclei of different cell types.]	0.0	5	1	1	1
122475	1710	Stat binding to the domain	[Stat binding to the domain]	0.0	5	1	1	1
122476	1710	hl-60-c15 cell with gp91phox promoter construct	[HL-60-C15 cells with gp91phox promoter constructs]	0.0	6	1	1	1
122477	1710	proximal residue	[proximal residues]	0.0	2	1	1	1
122478	1710	reactivity high	[reactivities high]	0.0	2	1	1	1
122479	1710	tumor cell in case	[tumor cells in cases]	0.0	4	1	1	1
122480	1710	hsp60 in human umbilical vein cell	[Hsp60 in human umbilical vein cells]	0.0	6	1	1	1
122481	1710	blood leukocyte from human	[blood leukocytes from humans]	0.0	4	1	1	1
122482	1710	protease activation	[protease activation]	0.0	2	1	1	1
122483	1710	inactivation by the tax protein	[Inactivation by the tax protein]	0.0	5	1	1	1
122484	1710	underlying aberrancy in the induction	[underlying aberrancies in the induction]	0.0	5	1	1	1
122485	1710	plate flow chamber	[plate flow chamber]	0.0	3	1	1	1
122486	1710	ig gene class switch	[Ig gene class switch]	0.0	4	1	1	1
122487	1710	differentiation of hematopoietic precursor cell line	[differentiation of hematopoietic precursor cell lines]	0.0	6	1	1	1
122488	1710	Appraisal	[Appraisal]	0.0	1	1	1	1
122489	1710	two enhancer element	[two enhancer elements]	0.0	3	1	1	1
122490	1710	gene in a -dependent manner	[genes in an -dependent manner]	0.0	5	1	1	1
122491	1710	Minimal disease in myelogenous leukemia	[Minimal disease in myelogenous leukemia]	0.0	5	1	1	1
122492	1710	regulate function in this cells.	[regulating functions in these cells.]	0.0	5	1	1	1
122493	1710	stimulation of the myelomonocytic cell line	[Stimulation of the myelomonocytic cell line]	0.0	6	1	1	1
122494	1710	possibly cells;	[possibly cells;]	0.0	2	1	1	1
122495	1710	activation of monocyte factor-kappaB	[activation of monocyte factor-kappaB]	0.0	4	1	1	1
122496	1710	flank the base pair long region	[flanking the base pair long region]	0.0	6	1	1	1
122497	1710	positive clone member	[positive clones members]	0.0	3	1	1	1
122498	1710	effect on binding affinity.	[effect on binding affinity.]	0.0	4	1	1	1
122499	1710	increase from steroid-sensitive patient	[increase from steroid-sensitive patients]	0.0	4	1	1	1
122500	1710	9-cis acid 9-cis RA	[9-cis acid 9-cis RA]	0.0	4	1	1	1
122501	1710	renin (869	[renin (869]	0.0	2	1	1	1
122502	1710	interplay between stimulus	[interplay between stimuli]	0.0	3	1	1	1
122503	1710	main target of positive signal	[main target of positive signals]	0.0	5	1	1	1
122504	1710	express the epo receptor	[expressing the Epo receptor]	0.0	4	1	1	1
122505	1710	mycoplasma fermentans-derived material	[Mycoplasma fermentans-derived material]	0.0	3	1	1	1
122506	1710	however, cell line	[However, cell lines]	0.0	3	1	1	1
122507	1710	apoptotic T cell line	[apoptotic T cell line]	0.0	4	1	1	1
122508	1710	p49(100) DNA	[p49(100) DNA]	0.0	2	1	1	1
122509	1710	expression of t-cell gene	[expression of T-cell genes]	0.0	4	1	1	1
122510	1710	intermediate structure	[intermediate structure]	0.0	2	1	1	1
122511	1710	hiv-1 reactivation	[HIV-1 reactivation]	0.0	2	1	1	1
122512	1710	lytic life cycle	[lytic life cycle]	0.0	3	1	1	1
122513	1710	il-4 promoter construct	[IL-4 promoter constructs]	0.0	3	1	1	1
122514	1710	CD80 b7-1	[CD80 B7-1]	0.0	2	1	1	1
122515	1710	multivalent guanylhydrazone	[multivalent guanylhydrazone]	0.0	2	1	1	1
122516	1710	blood of three patient	[blood of three patients]	0.0	4	1	1	1
122517	1710	5-azacytidine re-expression	[5-azacytidine re-expression]	0.0	2	1	1	1
122518	1710	manifestation of lupus erythematosus	[manifestations of lupus erythematosus]	0.0	4	1	1	1
122519	1710	multiple polypeptide range from kda	[multiple polypeptides ranging from kDa]	0.0	5	1	1	1
122520	1710	interact transcription factor	[interacting transcription factors]	0.0	3	1	1	1
122521	1710	await elucidation.	[awaiting elucidation.]	0.0	2	1	1	1
122522	1710	viral transactivator BZLF1	[viral transactivators BZLF1]	0.0	3	1	1	1
122523	1710	increase in colony size	[increase in colony size]	0.0	4	1	1	1
122524	1710	staT-dependent response gene expression	[STAT-dependent response gene expression]	0.0	4	1	1	1
122525	1710	full-length protein	[full-length protein]	0.0	2	1	1	1
122526	1710	produce a induction	[producing a induction]	0.0	3	1	1	1
122527	1710	include antitumor activity	[including antitumor activities]	0.0	3	1	1	1
122528	1710	Cp the promoter for ebna expression	[Cp the promoter for EBNA expression]	0.0	6	1	1	1
122529	1710	renal carcinoma	[renal carcinoma]	0.0	2	1	1	1
122530	1710	ah receptor mrna	[Ah receptor mRNA]	0.0	3	1	1	1
122531	1710	metabolic cascade	[metabolic cascade]	0.0	2	1	1	1
122532	1710	electrophoretic mobility of kda	[electrophoretic mobility of kDa]	0.0	4	1	1	1
122533	1710	frequent hypermutation in lymphoma (25	[frequent hypermutation in lymphoma (25]	0.0	5	1	1	1
122534	1710	follow a genotype screen	[Following an genotype screening]	0.0	4	1	1	1
122535	1710	NF- chi b site	[NF- chi B site]	0.0	4	1	1	1
122536	1710	vddr-ii rh- VDR	[VDDR-II Rh- VDR]	0.0	3	1	1	1
122537	1710	potential value	[potential value]	0.0	2	1	1	1
122538	1710	light-chain enhancer	[light-chain enhancer]	0.0	2	1	1	1
122539	1710	LYSP100 nuclear domain	[LYSP100 nuclear domains]	0.0	3	1	1	1
122540	1710	term of replication.	[terms of replication.]	0.0	3	1	1	1
122541	1710	disease in leukemia with pml/rar alpha	[disease in leukemia with PML/RAR alpha]	0.0	6	1	1	1
122542	1710	reach a peak at 15 minute	[reaching a peak at 15 min]	0.0	6	1	1	1
122543	1710	treatment of normal blood lymphocyte	[Treatment of normal blood lymphocytes]	0.0	5	1	1	1
122544	1710	binding to macrophage	[binding to macrophages]	0.0	3	1	1	1
122545	1710	possible mechanism via the leukocyte	[possible mechanisms via the leukocytes]	0.0	5	1	1	1
122546	1710	addition of nac	[addition of NAC]	0.0	3	1	1	1
122547	1710	Octamer factor Oct-1	[Octamer factors Oct-1]	0.0	3	1	1	1
122548	1710	resistance to antidepressant	[resistance to antidepressants]	0.0	3	1	1	1
122549	1710	asm expression	[ASM expression]	0.0	2	2	2	1
122550	1710	stat3 of c-myc	[STAT3 of c-myc]	0.0	3	1	1	1
122551	1710	preeminent agent	[preeminent agents]	0.0	2	1	1	1
122552	1710	two healthy man aged	[two healthy men aged]	0.0	4	1	1	1
122553	1710	acute leukemia blast cell	[acute leukemia blast cells]	0.0	4	1	1	1
122554	1710	few cell-specific gene	[few cell-specific genes]	0.0	3	1	1	1
122555	1710	miss the nf-kappab	[missing the NF-kappaB]	0.0	3	1	1	1
122556	1710	expression from individual	[expression from individuals]	0.0	3	1	1	1
122557	1710	upstream activator	[upstream activator]	0.0	2	1	1	1
122558	1710	resemble b cell activation	[resembling B cell activation]	0.0	4	1	1	1
122559	1710	androgen receptor in leukocyte	[androgen receptors in leukocytes]	0.0	4	3	3	1
122560	1710	acid release	[acid release]	0.0	2	2	2	1
122561	1710	direct link	[direct link]	0.0	2	2	2	1
122562	1710	affinity for gata-1	[affinity for GATA-1]	0.0	3	1	1	1
122563	1710	effect of interleukin-11 during lung injury	[effects of interleukin-11 during lung injury]	0.0	6	1	1	1
122564	1710	expression of oestrogen receptor	[expression of oestrogen receptors]	0.0	4	1	1	1
122565	1710	basal phosphorylation usually, STAT3	[basal phosphorylation usually, STAT3]	0.0	4	1	1	1
122566	1710	measurable amount of the cytokine	[measurable amounts of the cytokines]	0.0	5	1	1	1
122567	1710	specific probe	[specific probes]	0.0	2	1	1	1
122568	1710	responsiveness of mononuclear leukocyte HML	[responsiveness of mononuclear leukocytes HML]	0.0	5	1	1	1
122569	1710	two different schedule (five patient	[two different schedules (five patients]	0.0	5	1	1	1
122570	1710	tonsil b lymphocyte	[tonsil B lymphocytes]	0.0	3	1	1	1
122571	1710	(p 0.01)	[(P 0.01)]	0.0	2	1	1	1
122572	1710	more 5' site	[more 5' site]	0.0	3	1	1	1
122573	1710	(p 0.001	[(P 0.001]	0.0	2	1	1	1
122574	1710	gene transcription in lymphoid tissue	[gene transcription in lymphoid tissues]	0.0	5	1	1	1
122575	1710	pebp2 isoform	[PEBP2 isoforms]	0.0	2	1	1	1
122576	1710	more polar substitution	[more polar substitutions]	0.0	3	1	1	1
122577	1710	tal-1 potential	[tal-1 potential]	0.0	2	1	1	1
122578	1710	three multi-protein complex RFX	[three multi-protein complexes RFX]	0.0	4	1	1	1
122579	1710	review of immune property	[review of immune properties]	0.0	4	1	1	1
122580	1710	blood cell compartment	[blood cell compartment]	0.0	3	1	1	1
122581	1710	role of CD40	[role of CD40]	0.0	3	1	1	1
122582	1710	1.6 nm	[1.6 nM]	0.0	2	1	1	1
122583	1710	suggest a additional structural role	[suggesting an additional structural role]	0.0	5	1	1	1
122584	1710	October protein	[Oct proteins]	0.0	2	1	1	1
122585	1710	active principle of medicine chan'su	[active principle of medicine chan'su]	0.0	5	1	1	1
122586	1710	clinical significance to aids patient	[clinical significance to AIDS patients]	0.0	5	1	1	1
122587	1710	divergent region	[divergent region]	0.0	2	1	1	1
122588	1710	short t1/2 accumulation	[short t1/2, accumulation]	0.0	3	1	1	1
122589	1710	human interleukin gene promoter	[human interleukin gene promoter]	0.0	4	1	1	1
122590	1710	atra -nonresponsive case	[ATRA -nonresponsive cases]	0.0	3	1	1	1
122591	1710	272 receptor /cell	[272 receptors /cell]	0.0	3	1	1	1
122592	1710	association in IL-2 IFNgamma signal	[association in IL-2 IFNgamma signaling]	0.0	5	1	1	1
122593	1710	factor family	[factor family]	0.0	2	1	1	1
122594	1710	aldosterone over cortisol	[aldosterone over cortisol]	0.0	3	2	2	1
122595	1710	double-label electron microscopy	[double-labeling electron microscopy]	0.0	3	1	1	1
122596	1710	nf-kappab -dependent activation repeat	[NF-kappaB -dependent activation repeat]	0.0	4	1	1	1
122597	1710	expression in receptor-negative erythroblast	[Expression in receptor-negative erythroblasts]	0.0	4	1	1	1
122598	1710	NF-kappaB control	[NF-kappaB control]	0.0	2	1	1	1
122599	1710	component of latent antigen-specific memory	[components of latent antigen-specific memory]	0.0	5	1	1	1
122600	1710	block of differentiation	[Block of differentiation]	0.0	3	1	1	1
122601	1710	great migration	[greater migration]	0.0	2	1	1	1
122602	1710	blood lymphocyte of a patient	[blood lymphocytes of an patient]	0.0	5	2	2	1
122603	1710	968 amino acid	[968 amino acids]	0.0	3	1	1	1
122604	1710	immunity against pathogen	[immunity against pathogens]	0.0	3	1	1	1
122605	1710	effect on activity	[effect on activities]	0.0	3	1	1	1
122606	1710	cytokine-stimulated umbilical vein endothelial cell	[cytokine-stimulated umbilical vein endothelial cells]	0.0	5	1	1	1
122607	1710	asthma child aged 1 years.	[asthma children aged 1 years.]	0.0	5	1	1	1
122608	1710	defect in gamma delta T cell	[defects in gamma delta T cells]	0.0	6	1	1	1
122609	1710	use pre-b-cell line	[using pre-B-cell lines]	0.0	3	1	1	1
122610	1710	estrogenic compound from plant source	[estrogenic compounds from plant sources]	0.0	5	1	1	1
122611	1710	unrelated case for tsc2 mutation	[unrelated cases for TSC2 mutations]	0.0	5	1	1	1
122612	1710	sign of remission	[sign of remission]	0.0	3	1	1	1
122613	1710	progenitor to dendritic cell	[progenitors to dendritic cells]	0.0	4	1	1	1
122614	1710	t-cell extract-DNA complex	[T-cell extract-DNA complexes]	0.0	3	1	1	1
122615	1710	carboxy-terminal domain contain cell cycle	[carboxy-terminal domain containing cell cycle]	0.0	5	1	1	1
122616	1710	immunosorbent assay procedure	[immunosorbent assay procedure]	0.0	3	1	1	1
122617	1710	abolish injury with alpha-tocopherol	[abolishing injury with alpha-tocopherol]	0.0	4	1	1	1
122618	1710	leukemia ml-1 cell	[leukemia ML-1 cells]	0.0	3	1	1	1
122619	1710	respond element NREs	[responding elements NREs]	0.0	3	1	1	1
122620	1710	little DNA fragmentation	[little DNA fragmentation]	0.0	3	1	1	1
122621	1710	response of cell culminate	[response of cells culminating]	0.0	4	1	1	1
122622	1710	il-2rbeta promoter activity	[IL-2Rbeta promoter activity]	0.0	3	2	2	1
122623	1710	cross-linking with 125i-labeled	[cross-linking with 125I-labeled]	0.0	3	1	1	1
122624	1710	nm RA cell	[nM RA cells]	0.0	3	1	1	1
122625	1710	activator protein-1 ap-1 nuclear factor	[activator protein-1 AP-1 nuclear factor]	0.0	5	1	1	1
122626	1710	great activity.	[greater activity.]	0.0	2	1	1	1
122627	1710	involvement in human virus type	[Involvement in human virus type]	0.0	5	1	1	1
122628	1710	three ATL cell line TL-OmI	[Three ATL cell lines TL-OmI]	0.0	5	1	1	1
122629	1710	monocyte to macrophage differentiation,	[monocyte to macrophage differentiation,]	0.0	4	1	1	1
122630	1710	Ig-mediated b-cell activation	[Ig-mediated B-cell activation]	0.0	3	1	1	1
122631	1710	gata element of hiv-1 terminal repeat	[GATA elements of HIV-1 terminal repeat]	0.0	6	1	1	1
122632	1710	Cooperation of binding site	[Cooperation of binding sites]	0.0	4	1	1	1
122633	1710	CD28 element present	[CD28 element present]	0.0	3	1	1	1
122634	1710	cell-type expression	[cell-type expression]	0.0	2	1	1	1
122635	1710	antibody elevation	[antibodies elevation]	0.0	2	1	1	1
122636	1710	ccaat box upstream	[CCAAT box upstream]	0.0	3	1	1	1
122637	1710	absence specific transcription factor tcf-1	[Absence specific transcription factors TCF-1]	0.0	5	1	1	1
122638	1710	indicate the capacity	[indicating the capacity]	0.0	3	1	1	1
122639	1710	expression of myb rna	[Expression of myb RNA]	0.0	4	1	1	1
122640	1710	cell surface receptor of kilometer	[cell surface receptors of kd]	0.0	5	1	1	1
122641	1710	CD20 e box	[CD20 E box]	0.0	3	1	1	1
122642	1710	lymphoblastic T	[lymphoblastic T]	0.0	2	1	1	1
122643	1710	cell-type specific expression	[cell-type specific expression]	0.0	3	1	1	1
122644	1710	rar-rxr heterodimer	[RAR-RXR heterodimers]	0.0	2	1	1	1
122645	1710	however, (66 microg/100 millileter at P;	[However, (66 microg/100 ml at h;]	0.0	6	1	1	1
122646	1710	element tre1	[element TRE1]	0.0	2	1	1	1
122647	1710	growth transformation of primary b-cell	[Growth transformation of primary B-cells]	0.0	5	1	1	1
122648	1710	non-transformed murine Th1 th2 clone	[non-transformed murine Th1 Th2 clones]	0.0	5	1	1	1
122649	1710	activity at concentration 100-fold low	[activity at concentrations 100-fold lower]	0.0	5	1	1	1
122650	1710	acid aggregation	[acid aggregation]	0.0	2	1	1	1
122651	1710	patient with lymphocytic leukaemia	[patients with lymphocytic leukaemia]	0.0	4	1	1	1
122652	1710	Latent membrane protein LMP1	[Latent membrane protein LMP1]	0.0	4	1	1	1
122653	1710	protein- dependent complex	[protein- dependent complexes]	0.0	3	1	1	1
122654	1710	Retinoic acid maturation	[Retinoic acid maturation]	0.0	3	1	1	1
122655	1710	new insight into the rate	[new insights into the rate]	0.0	5	1	1	1
122656	1710	oligonucleotide encode sequence	[oligonucleotides encoding sequences]	0.0	3	1	1	1
122657	1710	inhibition of immunodeficiency virus type	[Inhibition of immunodeficiency virus type]	0.0	5	2	2	1
122658	1710	IL-4 reporter	[IL-4 reporter]	0.0	2	1	1	1
122659	1710	Functional antagonism in the regulation	[Functional antagonism in the regulation]	0.0	5	1	1	1
122660	1710	departure of the response	[departure of the response]	0.0	4	1	1	1
122661	1710	involve hiv infection	[involving HIV infection]	0.0	3	1	1	1
122662	1710	glucocorticoid responsiveness of human leukocyte	[glucocorticoid responsiveness of human leukocytes]	0.0	5	1	1	1
122663	1710	identification as the cis element	[identification as the cis elements]	0.0	5	1	1	1
122664	1710	confirm the importance of nfat	[confirming the importance of NFAT]	0.0	5	1	1	1
122665	1710	ssb T cell	[SSB T cells]	0.0	3	1	1	1
122666	1710	serum element present	[serum element present]	0.0	3	1	1	1
122667	1710	MRD +/lt	[MRD +/LT]	0.0	2	1	1	1
122668	1710	keratinocyte pcd/dcoh	[keratinocyte PCD/DCoH]	0.0	2	1	1	1
122669	1710	nf-kappa b from Jurkat T cell	[NF-kappa B from Jurkat T cells]	0.0	6	1	1	1
122670	1710	phosphorylation usually, STAT3	[phosphorylation usually, STAT3]	0.0	3	1	1	1
122671	1710	disposition implication	[disposition implications]	0.0	2	1	1	1
122672	1710	modulation of PML expression	[modulation of PML expression]	0.0	4	1	1	1
122673	1710	lmp-1 signal in b cell	[LMP-1 signaling in B cells]	0.0	5	1	1	1
122674	1710	stimulation with retinoic acid RA	[stimulation with retinoic acid RA]	0.0	5	1	1	1
122675	1710	specific inflammatory pathology	[specific inflammatory pathologies]	0.0	3	1	1	1
122676	1710	capacity of receptor hGR	[capacity of receptor hGR]	0.0	4	1	1	1
122677	1710	contain repeat DR of 21 bp	[containing repeats DR of 21 bp]	0.0	6	1	1	1
122678	1710	treatment with hcl	[Treatment with HCl]	0.0	3	1	1	1
122679	1710	effect of this element	[effect of this element]	0.0	4	1	1	1
122680	1710	human factor promoter	[human factor promoter]	0.0	3	1	1	1
122681	1710	interleukin 2 a potent activator	[interleukin 2 a potent activator]	0.0	5	1	1	1
122682	1710	lymphoid cell resistance	[Lymphoid cell resistance]	0.0	3	1	1	1
122683	1710	half-maximal induction	[half-maximal induction]	0.0	2	1	1	1
122684	1710	include a heterodimer from extract	[including a heterodimer from extracts]	0.0	5	1	1	1
122685	1710	lymphocytic leukemia B-CLL	[lymphocytic leukemia B-CLL]	0.0	3	1	1	1
122686	1710	cinc	[CINC]	0.0	1	1	1	1
122687	1710	total leukocyte	[total leukocytes]	0.0	2	1	1	1
122688	1710	lymphoma of malignancy	[lymphomas of malignancy]	0.0	3	1	1	1
122689	1710	characterize NF-kappa b transcriptional activation	[characterizing NF-kappa B transcriptional activation]	0.0	5	1	1	1
122690	1710	annexin-V	[annexin-V]	0.0	1	1	1	1
122691	1710	analysis of cell line	[Analysis of cell lines]	0.0	4	1	1	1
122692	1710	receptor gamma a transcription factor	[receptor gamma a transcription factor]	0.0	5	1	1	1
122693	1710	cis,	[cis,]	0.0	1	1	1	1
122694	1710	mrna levels,	[mRNA levels,]	0.0	2	1	1	1
122695	1710	enigmatic aspect	[enigmatic aspect]	0.0	2	1	1	1
122696	1710	proinflammatory cytokine in human monocyte	[proinflammatory cytokines in human monocytes]	0.0	5	1	1	1
122697	1710	surveillance	[surveillance]	0.0	1	1	1	1
122698	1710	major mrna transcript of kilobasis	[major mRNA transcript of kilobases]	0.0	5	1	1	1
122699	1710	107 amino-acid protein	[107 amino-acid protein]	0.0	3	1	1	1
122700	1710	knowledge, of element	[knowledge, of elements]	0.0	3	1	1	1
122701	1710	various gene product htlv-1	[Various gene products HTLV-1]	0.0	4	1	1	1
122702	1710	so-called ankyrin repeat	[so-called ankyrin repeats]	0.0	3	1	1	1
122703	1710	lipopolysaccharide-induced transcription of tumor necrosis factor-alpha	[lipopolysaccharide-induced transcription of tumor necrosis factor-alpha]	0.0	6	1	1	1
122704	1710	human prostatic epithelial cell	[Human prostatic epithelial cells]	0.0	4	1	1	1
122705	1710	difference in phenotype, t-cell receptor	[differences in phenotype, T-cell receptor]	0.0	5	1	1	1
122706	1710	expression of E2a- Pbx1	[expression of E2a- Pbx1]	0.0	4	1	1	1
122707	1710	viable mature erythroid cell	[viable mature erythroid cells]	0.0	4	1	1	1
122708	1710	effect on cd34+ cell	[effects on CD34+ cells]	0.0	4	1	1	1
122709	1710	switch from (gamma)	[switch from (gamma)]	0.0	3	1	1	1
122710	1710	transcriptional element in the tsp promoter,	[transcriptional elements in the TSP promoter,]	0.0	6	1	1	1
122711	1710	GATA-1 factor	[GATA-1 factor]	0.0	2	1	1	1
122712	1710	adenovirus 2	[adenovirus 2]	0.0	2	1	1	1
122713	1710	H 1285	[H 1285]	0.0	2	1	1	1
122714	1710	hormonal state	[hormonal state]	0.0	2	1	1	1
122715	1710	Raji B	[Raji B]	0.0	2	1	1	1
122716	1710	most other antigen	[most other antigens]	0.0	3	1	1	1
122717	1710	two consensus sequences,	[Two consensus sequences,]	0.0	3	1	1	1
122718	1710	minute of induction.	[min of induction.]	0.0	3	1	1	1
122719	1710	b-binding-proteins use the yeast two-hybrid system	[B-binding-proteins using the yeast two-hybrid system]	0.0	6	1	1	1
122720	1710	tumor necrosis factor other cytokine	[tumor necrosis factor other cytokines]	0.0	5	1	1	1
122721	1710	patient with lymphocytic leukaemia CLL	[patients with lymphocytic leukaemia CLL]	0.0	5	1	1	1
122722	1710	intact form	[intact forms]	0.0	2	1	1	1
122723	1710	belong to the factor (nfat) family	[belonging to the factor (NFAT) family]	0.0	6	1	1	1
122724	1710	regulation during differentiation of myeloid cell	[regulation during differentiation of myeloid cells]	0.0	6	1	1	1
122725	1710	comparison subject	[comparison subjects]	0.0	2	2	2	1
122726	1710	additional testing	[additional testing]	0.0	2	1	1	1
122727	1710	follow expression of hox11	[following expression of HOX11]	0.0	4	1	1	1
122728	1710	c group; p	[C group; P]	0.0	3	1	1	1
122729	1710	contain divalent gold ion	[containing divalent gold ion]	0.0	4	1	1	1
122730	1710	early index	[early indices]	0.0	2	1	1	1
122731	1710	smase activity	[SMase activity]	0.0	2	1	1	1
122732	1710	endogenous level of the component	[endogenous levels of the components]	0.0	5	1	1	1
122733	1710	basal acetate	[basal acetate]	0.0	2	1	1	1
122734	1710	integration to the genome cell	[integration to the genome cell]	0.0	5	1	1	1
122735	1710	involve this receptor.	[involving this receptor.]	0.0	3	1	1	1
122736	1710	one hundred milligram	[One hundred milligram]	0.0	3	1	1	1
122737	1710	prime from signal	[priming from signal]	0.0	3	1	1	1
122738	1710	b-chronic leukemia (b-cll) cell	[B-chronic leukemia (B-CLL) cells]	0.0	4	1	1	1
122739	1710	genomic DNA sequence	[genomic DNA sequence]	0.0	3	1	1	1
122740	1710	gene tnf-alpha	[genes TNF-alpha]	0.0	2	1	1	1
122741	1710	EBNA enhancer	[EBNA enhancer]	0.0	2	3	3	1
122742	1710	aspect of hematopoiesis	[aspects of hematopoiesis]	0.0	3	1	1	1
122743	1710	ADT mm)	[ADT mM)]	0.0	2	1	1	1
122744	1710	result from alternative splicing	[resulting from alternative splicing]	0.0	4	1	1	1
122745	1710	globin gene in tissue	[globin genes in tissues]	0.0	4	1	1	1
122746	1710	several cellular protein	[several cellular proteins]	0.0	3	1	1	1
122747	1710	response to nm D3	[response to nM D3]	0.0	4	1	1	1
122748	1710	physiological marker	[physiological marker]	0.0	2	1	1	1
122749	1710	DNA binding of ap-1	[DNA binding of AP-1]	0.0	4	1	1	1
122750	1710	fmol/mg protein (mean of two assays),	[fmol/mg protein (mean of two assays),]	0.0	6	1	1	1
122751	1710	aspect of the involvement	[aspects of the involvement]	0.0	4	1	1	1
122752	1710	inhibit generation	[inhibiting generation]	0.0	2	1	1	1
122753	1710	binding of nf-kappab	[binding of NF-kappaB]	0.0	3	1	1	1
122754	1710	myeloid promyelocytic cell	[myeloid promyelocytic cells]	0.0	3	1	1	1
122755	1710	transcriptional activation of interleukin-1beta il-1beta	[transcriptional activation of interleukin-1beta IL-1beta]	0.0	5	1	1	1
122756	1710	transcriptional regulatory protein distinct	[transcriptional regulatory proteins distinct]	0.0	4	1	1	1
122757	1710	(but b-lymphoid line	[(but B-lymphoid lines]	0.0	3	1	1	1
122758	1710	simultaneous presence of kind	[simultaneous presence of kinds]	0.0	4	1	1	1
122759	1710	EBNA2 antibody	[EBNA2 antibodies]	0.0	2	1	1	1
122760	1710	blin-1	[BLIN-1]	0.0	1	1	1	1
122761	1710	severe skewing of x inactivation	[Severe skewing of X inactivation]	0.0	5	1	1	1
122762	1710	inhibition signal in t-cell	[Inhibition signalling in T-cells]	0.0	4	1	1	1
122763	1710	large tsg101 transcript deletion	[Large TSG101 transcript deletions]	0.0	4	1	1	1
122764	1710	study in leukocyte	[studies in leukocytes]	0.0	3	1	1	1
122765	1710	TCR-associated ptk	[TCR-associated PTK]	0.0	2	1	1	1
122766	1710	dominant-negative cdk4	[dominant-negative cdk4]	0.0	2	1	1	1
122767	1710	other phenotypic characteristic	[other phenotypic characteristics]	0.0	3	1	1	1
122768	1710	cofactor with the effector domain	[cofactors with the effector domains]	0.0	5	1	1	1
122769	1710	mitogenic combination of CD2	[mitogenic combination of CD2]	0.0	4	1	1	1
122770	1710	cyp1a1 gene expression in cell	[CYP1A1 gene expression in cells]	0.0	5	1	1	1
122771	1710	gene regulation of the h(+)-atpase	[gene regulation of the H(+)-ATPase]	0.0	5	1	1	1
122772	1710	identification of sequence	[Identification of sequences]	0.0	3	1	1	1
122773	1710	m-csf mrna	[M-CSF mRNA]	0.0	2	1	1	1
122774	1710	blotting use the PL/IM antibody	[blotting using the PL/IM antibody]	0.0	5	1	1	1
122775	1710	two set of evidence	[Two sets of evidences]	0.0	4	1	1	1
122776	1710	inhibition of NF-kappa b erratum	[inhibition of NF-kappa B erratum]	0.0	5	1	1	1
122777	1710	live-hiv-1	[live-HIV-1]	0.0	1	1	1	1
122778	1710	2-integrin	[2-integrin]	0.0	1	1	1	1
122779	1710	probe encompass a region	[probe encompassing a region]	0.0	4	1	1	1
122780	1710	cd28-responsive	[CD28-responsive]	0.0	1	1	1	1
122781	1710	patient with rheumatic disease four	[patients with rheumatic diseases four]	0.0	5	1	1	1
122782	1710	use sulfate	[using sulfate]	0.0	2	1	1	1
122783	1710	separate pathway of signal transduction	[separate pathways of signal transduction]	0.0	5	1	1	1
122784	1710	mutation in the kinase domain	[Mutation in the kinase domain]	0.0	5	1	1	1
122785	1710	Secondarily, heat shock	[Secondarily, heat shock]	0.0	3	1	1	1
122786	1710	transcription of inducible nitric oxide synthase	[transcription of inducible nitric oxide synthase]	0.0	6	1	1	1
122787	1710	LMP1 gene	[LMP1 gene]	0.0	2	1	1	1
122788	1710	response to atra	[response to ATRA]	0.0	3	1	1	1
122789	1710	EBV-associated, latent epitope	[EBV-associated, latent epitopes]	0.0	3	1	1	1
122790	1710	include strain	[including strain]	0.0	2	1	1	1
122791	1710	function in the epstein-barr virus	[functions in the Epstein-Barr virus]	0.0	5	1	1	1
122792	1710	involve band 3q26	[involving band 3q26]	0.0	3	1	1	1
122793	1710	ap-2 transcription	[AP-2 transcription]	0.0	2	1	1	1
122794	1710	o., alternatively, through antagonism	[or, alternatively, through antagonism]	0.0	4	1	1	1
122795	1710	il-13-induced factor in monocyte	[IL-13-induced factors in monocytes]	0.0	4	1	1	1
122796	1710	member especially the human homolog	[members especially the human homolog]	0.0	5	1	1	1
122797	1710	hEpoR	[hEpoR]	0.0	1	1	1	1
122798	1710	other component of bacterium	[other component of bacteria]	0.0	4	1	1	1
122799	1710	81 pentadecamer peptide	[81 pentadecamer peptides]	0.0	3	1	1	1
122800	1710	view of a plasticity	[view of an plasticity]	0.0	4	1	1	1
122801	1710	346 C-terminal residue	[346 C-terminal residues]	0.0	3	1	1	1
122802	1710	effect of cepharanthine gene expression	[effects of cepharanthine gene expression]	0.0	5	1	1	1
122803	1710	as tracer, mnl of obese subject	[as tracer, MNL of obese subjects]	0.0	6	1	1	1
122804	1710	adhere pmn	[adhering PMN]	0.0	2	1	1	1
122805	1710	binding on the DNA	[binding on the DNA]	0.0	4	1	1	1
122806	1710	affinity p49 rela(p65)	[affinity p49 RelA(p65)]	0.0	3	1	1	1
122807	1710	nf-kappab reporter gene expression	[NF-kappaB reporter gene expression]	0.0	4	1	1	1
122808	1710	drug pnu156804	[drug PNU156804]	0.0	2	1	1	1
122809	1710	activate gene expression	[activating gene expression]	0.0	3	1	1	1
122810	1710	the/thf n: alpha thf/thf	[THE/THF N: alpha THF/THF]	0.0	4	1	1	1
122811	1710	brain development due to challenge	[brain development due to challenge]	0.0	5	1	1	1
122812	1710	c-myc -like characteristic	[c-myc -like characteristics]	0.0	3	1	1	1
122813	1710	regions, dp1 -140 to -92	[regions, DP1 -140 to -92]	0.0	5	1	1	1
122814	1710	cd1a+ cell	[CD1a+ cells]	0.0	2	1	1	1
122815	1710	possible role of ERK	[Possible roles of ERK]	0.0	4	1	1	1
122816	1710	general coactivator requirement	[general coactivator requirements]	0.0	3	1	1	1
122817	1710	visit, within two week	[visit, within two weeks]	0.0	4	1	1	1
122818	1710	incubation of cell with monoclonal antibody	[Incubation of cells with monoclonal antibody]	0.0	6	1	1	1
122819	1710	direct analysis of sensorgram with hugata-3	[Direct analysis of sensorgrams with huGATA-3]	0.0	6	1	1	1
122820	1710	900 bp	[900 bp]	0.0	2	1	1	1
122821	1710	fev1 value	[FEV1 values]	0.0	2	1	1	1
122822	1710	signal pathway in cd34+ progenitor	[signaling pathways in CD34+ progenitor]	0.0	5	1	1	1
122823	1710	express high v-abl kinase activity	[expressing high v-abl kinase activity]	0.0	5	1	1	1
122824	1710	functional expression	[functional expression]	0.0	2	1	1	1
122825	1710	nuclear retention	[nuclear retention]	0.0	2	1	1	1
122826	1710	assay in yeast nf-atp	[assays in yeast NF-ATp]	0.0	4	1	1	1
122827	1710	role of I(kappa)B(alpha)	[role of I(kappa)B(alpha)]	0.0	3	1	1	1
122828	1710	tumor cell in gct	[Tumor cells in GCT]	0.0	4	1	1	1
122829	1710	high-affinity element hsie	[high-affinity element hSIE]	0.0	3	1	1	1
122830	1710	human TNF promoter	[human TNF promoter]	0.0	3	1	1	1
122831	1710	indicate a genetic target	[indicating a genetic target]	0.0	4	1	1	1
122832	1710	transcription factor include AP-1 NF-kappaB	[transcription factors including AP-1 NF-kappaB]	0.0	5	1	1	1
122833	1710	five- increase	[five- increase]	0.0	2	1	1	1
122834	1710	aldosterone receptor mechanism	[aldosterone receptors mechanism]	0.0	3	1	1	1
122835	1710	human umbilical venous	[human umbilical venous]	0.0	3	1	1	1
122836	1710	ie2 transactivation	[IE2 transactivation]	0.0	2	1	1	1
122837	1710	study intracellular signal transduction	[studying intracellular signal transduction]	0.0	4	1	1	1
122838	1710	c-rel /p50	[c-Rel /p50]	0.0	2	1	1	1
122839	1710	two form of active transcription factor	[Two forms of active transcription factor]	0.0	6	1	1	1
122840	1710	activation of the nf-kappab kinase activation	[activation of the NF-kappaB kinase activation]	0.0	6	1	1	1
122841	1710	tf gene transcription in monocyte	[TF gene transcription in monocytes]	0.0	5	1	1	1
122842	1710	antiapoptotic role	[antiapoptotic role]	0.0	2	1	1	1
122843	1710	lead to adhesion of cell	[leading to adhesion of cells]	0.0	5	1	1	1
122844	1710	functional role a member	[functional role a member]	0.0	4	1	1	1
122845	1710	variant cell	[variant cells]	0.0	2	1	1	1
122846	1710	lack in this clone	[lack in these clones]	0.0	4	1	1	1
122847	1710	histologic category	[histologic categories]	0.0	2	1	1	1
122848	1710	c-fo content	[c-Fos content]	0.0	2	1	1	1
122849	1710	htlv-i enhancer	[HTLV-I enhancer]	0.0	2	1	1	1
122850	1710	nf-kappab protein activity in beas-2b cell	[NF-kappaB protein activity in BEAS-2B cells]	0.0	6	1	1	1
122851	1710	monocyte/macrophage-like cell	[monocyte/macrophage-like cells]	0.0	2	1	1	1
122852	1710	immunologic (type ii)	[immunologic (type II)]	0.0	3	1	1	1
122853	1710	10-fold reduction in affinity	[10-fold reduction in affinity]	0.0	4	1	1	1
122854	1710	synthesis of 4,19-disubstituted derivative	[Synthesis of 4,19-disubstituted derivatives]	0.0	4	1	1	1
122855	1710	component of each element-binding complex	[components of each element-binding complexes]	0.0	5	1	1	1
122856	1710	extent, c-jun complex	[extent, c-Jun complexes]	0.0	3	1	1	1
122857	1710	cytokine -mRNA level	[cytokine -mRNA level]	0.0	3	1	1	1
122858	1710	two cysteine -rich region	[two cysteine -rich regions]	0.0	4	1	1	1
122859	1710	factor-IL6 NF-IL6	[factor-IL6 NF-IL6]	0.0	2	1	1	1
122860	1710	vitro with activity	[vitro with activity]	0.0	3	1	1	1
122861	1710	state regard the effect	[state regarding the effects]	0.0	4	1	1	1
122862	1710	removal encompass all of the domain	[removal encompassing all of the domain]	0.0	6	1	1	1
122863	1710	exposure of cell to bacterial lipopolysaccharide	[Exposure of cells to bacterial lipopolysaccharide]	0.0	6	1	1	1
122864	1710	transcriptional control in development	[transcriptional control in development]	0.0	4	1	1	1
122865	1710	very mild down-regulation in hypercortisolemic patient	[very mild down-regulation in hypercortisolemic patients]	0.0	6	1	1	1
122866	1710	events, include granuloma formation	[events, including granuloma formation]	0.0	4	1	1	1
122867	1710	human leucocyte in 22 woman	[human leucocytes in 22 women]	0.0	5	1	1	1
122868	1710	zebra -binding site	[ZEBRA -binding sites]	0.0	3	1	1	1
122869	1710	subtype i.e. hhv-8 +/ebv- pel	[subtypes i.e. HHV-8 +/EBV- PEL]	0.0	5	1	1	1
122870	1710	human leukocyte hml	[human leukocytes HML]	0.0	3	1	1	1
122871	1710	variety of extracellular signal	[variety of extracellular signals]	0.0	4	1	1	1
122872	1710	gene expression through inhibition	[gene expression through inhibition]	0.0	4	1	1	1
122873	1710	accumulation of the junb protein	[accumulation of the JunB protein]	0.0	5	1	1	1
122874	1710	polyoma	[polyoma]	0.0	1	1	1	1
122875	1710	viable mature definitive cell a phenotype	[viable mature definitive cells a phenotype]	0.0	6	1	1	1
122876	1710	NF-kappa b as transcriptional activator	[NF-kappa B as transcriptional activator]	0.0	5	1	1	1
122877	1710	low the/thf alpha thf/thf n:	[low THE/THF alpha THF/THF N:]	0.0	5	1	1	1
122878	1710	octamer- binding protein	[octamer- binding proteins]	0.0	3	1	1	1
122879	1710	hiv in blood lymphocyte	[HIV in blood lymphocytes]	0.0	4	1	1	1
122880	1710	phi) for 24 h	[phi) for 24 h]	0.0	4	1	1	1
122881	1710	expression of the regulatory element	[expression of the regulatory elements]	0.0	5	1	1	1
122882	1710	il-2 DNA	[IL-2 DNA]	0.0	2	1	1	1
122883	1710	protein kinase cell	[protein kinase cells]	0.0	3	1	1	1
122884	1710	cell type-specific expression	[cell type-specific expression]	0.0	3	1	1	1
122885	1710	PMA ionomycin synthesis	[PMA ionomycin synthesis]	0.0	3	1	1	1
122886	1710	subset of non-hodgkin lymphoma	[subset of non-Hodgkin lymphomas]	0.0	4	1	1	1
122887	1710	Jurkat leukaemic t-cell	[Jurkat leukaemic T-cells]	0.0	3	1	1	1
122888	1710	multiple kinase pathway	[multiple kinase pathways]	0.0	3	1	1	1
122889	1710	c2h2 zinc finger	[C2H2 zinc fingers]	0.0	3	1	1	1
122890	1710	signal by a wide variety	[Signaling by a wide variety]	0.0	5	1	1	1
122891	1710	(ifn)-inducible protein	[(IFN)-inducible protein]	0.0	2	1	1	1
122892	1710	molecule in promotion	[molecule in promotion]	0.0	3	1	1	1
122893	1710	prerequisite for expression	[prerequisite for expression]	0.0	3	1	1	1
122894	1710	addition of mab	[addition of mAb]	0.0	3	1	1	1
122895	1710	commitment to plasma cell	[commitment to plasma cells]	0.0	4	1	1	1
122896	1710	tcp microM,	[TCP microM,]	0.0	2	1	1	1
122897	1710	only the sequence	[only the sequences]	0.0	3	1	1	1
122898	1710	implication for the role of bcl6	[implications for the role of BCL6]	0.0	6	1	1	1
122899	1710	developmental processes.	[developmental processes.]	0.0	2	1	1	1
122900	1710	impaired response in leishmania-infected cell	[impaired responses in leishmania-infected cells]	0.0	5	1	1	1
122901	1710	cellular factor-KB result	[cellular factor-KB resulting]	0.0	3	1	1	1
122902	1710	regulation of function.	[regulation of function.]	0.0	3	1	1	1
122903	1710	phenotypic female year	[phenotypic female years]	0.0	3	1	1	1
122904	1710	also week	[also weeks]	0.0	2	1	1	1
122905	1710	correlate to the classification	[correlates to the classification]	0.0	4	1	1	1
122906	1710	expression of interleukin-3 il-3	[expression of interleukin-3 IL-3]	0.0	4	1	1	1
122907	1710	protein critical to differentiation	[proteins critical to differentiation]	0.0	4	1	1	1
122908	1710	down-regulation of a molecule,	[down-regulation of a molecule,]	0.0	4	1	1	1
122909	1710	male with immunodeficiency	[Males with immunodeficiency]	0.0	3	1	1	1
122910	1710	mouse resistant	[mice resistant]	0.0	2	1	1	1
122911	1710	cell-type specific; lps	[cell-type specific; LPS]	0.0	3	1	1	1
122912	1710	nuclear protein complex a factor	[nuclear protein complexes a factor]	0.0	5	1	1	1
122913	1710	mechanism of estradiol acting	[mechanisms of estradiol acting]	0.0	4	1	1	1
122914	1710	two protein nf-kappa b	[two proteins NF-kappa B]	0.0	4	1	1	1
122915	1710	distinct stage	[distinct stage]	0.0	2	2	2	1
122916	1710	day of adherence	[days of adherence]	0.0	3	1	1	1
122917	1710	include granulocyte-macrophage colony-stimulating factor	[including granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
122918	1710	phosphorylation of STAT3alpha	[phosphorylation of STAT3alpha]	0.0	3	1	1	1
122919	1710	pattern of expression of downstream, gene	[patterns of expression of downstream, genes]	0.0	6	1	1	1
122920	1710	functionally critical element	[functionally critical elements]	0.0	3	1	1	1
122921	1710	min) in untreated acid cell	[min) in untreated acid cells]	0.0	5	1	1	1
122922	1710	inhibitory effect with PGE2	[inhibitory effects with PGE2]	0.0	4	1	1	1
122923	1710	dysregulation human immunodeficiency virus type hiv-1	[dysregulation human immunodeficiency virus type HIV-1]	0.0	6	1	1	1
122924	1710	reporter gene triangle uplngfr	[reporter genes triangle upLNGFR]	0.0	4	1	1	1
122925	1710	mean gc-r bmax	[mean GC-R Bmax]	0.0	3	1	1	1
122926	1710	camp repressor	[cAMP repressor]	0.0	2	1	1	1
122927	1710	ng/ml) groups.	[ng/mL) groups.]	0.0	2	1	1	1
122928	1710	transcription factor site	[transcription factor sites]	0.0	3	1	1	1
122929	1710	islet encode jun-B the transcription protein	[islet encoding jun-B the transcription protein]	0.0	6	1	1	1
122930	1710	ap-1 family	[AP-1 family]	0.0	2	1	1	1
122931	1710	type of hematopoietic neoplasm	[types of hematopoietic neoplasms]	0.0	4	1	1	1
122932	1710	strong cyto-differentiating potential of am580	[strong cyto-differentiating potential of AM580]	0.0	5	1	1	1
122933	1710	transfer of preparation	[transfer of preparations]	0.0	3	1	1	1
122934	1710	thymic lymphoma-derived hybridoma pc60	[thymic lymphoma-derived hybridoma PC60]	0.0	4	1	1	1
122935	1710	number of potential sequence	[number of potential sequences]	0.0	4	1	1	1
122936	1710	extracellular matrix glycoprotein	[extracellular matrix glycoprotein]	0.0	3	1	1	1
122937	1710	transmembrane adaptor protein	[transmembrane adaptor protein]	0.0	3	1	1	1
122938	1710	role: alteration	[role: alteration]	0.0	2	1	1	1
122939	1710	stress on signal transduction	[stress on signal transduction]	0.0	4	1	1	1
122940	1710	signal for activation	[signals for activation]	0.0	3	1	1	1
122941	1710	presence excess	[presence excess]	0.0	2	1	1	1
122942	1710	autoregulation of the cascade	[autoregulation of the cascade]	0.0	4	1	1	1
122943	1710	granulocytic differentiation of mpro promyelocyte	[granulocytic differentiation of MPRO promyelocytes]	0.0	5	1	1	1
122944	1710	other pb cell population	[other PB cell populations]	0.0	4	1	1	1
122945	1710	synergy between IL-2	[synergy between IL-2]	0.0	3	1	1	1
122946	1710	several nearby site originate bp	[several nearby sites originating bp]	0.0	5	1	1	1
122947	1710	subsequent activation of Janus tyrosine kinase	[subsequent activation of Janus tyrosine kinase]	0.0	6	1	1	1
122948	1710	tandem zinc-finger sequence of the type	[tandem zinc-finger sequences of the type]	0.0	6	1	1	1
122949	1710	up-regulation of icam-i	[up-regulation of ICAM-I]	0.0	3	1	1	1
122950	1710	IL 6 differentiation	[IL 6 differentiation]	0.0	3	1	1	1
122951	1710	mouse pro-B	[mouse pro-B]	0.0	2	1	1	1
122952	1710	type of cross-talk between glucocorticoid	[type of cross-talk between glucocorticoids]	0.0	5	1	1	1
122953	1710	generation of infiltrate	[generation of infiltrate]	0.0	3	1	1	1
122954	1710	type of acute leukemia	[type of acute leukemia]	0.0	4	1	1	1
122955	1710	production of nuclear factor kappab binding	[production of nuclear factor kappaB binding]	0.0	6	1	1	1
122956	1710	evidence for genetic defect	[evidence for genetic defects]	0.0	4	1	1	1
122957	1710	analysis of cell	[Analysis of cells]	0.0	3	1	1	1
122958	1710	cell-type regulation	[cell-type regulation]	0.0	2	1	1	1
122959	1710	activation in HIV individual	[activation in HIV individuals]	0.0	4	1	1	1
122960	1710	overexpression in some myeloid cell line	[Overexpression in some myeloid cell lines]	0.0	6	1	1	1
122961	1710	migration ChtM	[migration ChtM]	0.0	2	1	1	1
122962	1710	protein of 31 kda	[protein of 31 kDa]	0.0	4	1	1	1
122963	1710	potentially result in phosphorylation of protein	[potentially resulting in phosphorylation of proteins]	0.0	6	1	1	1
122964	1710	cells, support hypothesis	[cells, supporting hypothesis]	0.0	3	1	1	1
122965	1710	normal receptor affinity	[normal receptor affinity]	0.0	3	1	1	1
122966	1710	single tr	[single TR]	0.0	2	1	1	1
122967	1710	transmembrane	[transmembrane]	0.0	1	1	1	1
122968	1710	distinct regulator	[distinct regulators]	0.0	2	1	1	1
122969	1710	implication for the role in development	[implications for the role in development]	0.0	6	1	1	1
122970	1710	counteract effect	[counteracting effect]	0.0	2	1	1	1
122971	1710	anti-CD3 activation	[anti-CD3 activation]	0.0	2	1	1	1
122972	1710	action on hiv-1 gene expression	[action on HIV-1 gene expression]	0.0	5	1	1	1
122973	1710	notion substrate in intact cells.	[notion substrates in intact cells.]	0.0	5	1	1	1
122974	1710	mineralocorticoid receptor domain binding	[mineralocorticoid receptor domain binding]	0.0	4	1	1	1
122975	1710	c-fm gene	[c-fms gene]	0.0	2	1	1	1
122976	1710	AMP protein kinase sub.	[AMP protein kinase Sub.]	0.0	4	1	1	1
122977	1710	area of dnase 1 hypersensitivity	[area of DNase 1 hypersensitivity]	0.0	5	1	1	1
122978	1710	airway epithelial cell after challenge	[airway epithelial cells after challenge]	0.0	5	1	1	1
122979	1710	cell microg/ml)/mn2+ microM)	[Cells microg/ml)/Mn2+ microM)]	0.0	3	1	1	1
122980	1710	activity independent of age.	[activity independent of age.]	0.0	4	1	1	1
122981	1710	effect on the cleft	[effect on the cleft]	0.0	4	1	1	1
122982	1710	activation of immunodeficiency virus type expression	[Activation of immunodeficiency virus type expression]	0.0	6	1	1	1
122983	1710	interaction between multiple transcriptional regulatory element	[interactions between multiple transcriptional regulatory elements]	0.0	6	1	1	1
122984	1710	addition, il-2 factor nf-kappa b	[addition, IL-2 factors NF-kappa B]	0.0	5	1	1	1
122985	1710	corresponding specific binding	[corresponding specific binding]	0.0	3	1	1	1
122986	1710	various signal protein	[various signaling proteins]	0.0	3	1	1	1
122987	1710	cell line lack er peptide	[cell lines lacking ER peptides]	0.0	5	1	1	1
122988	1710	constitutive expression of factor-1 receptor	[Constitutive expression of factor-1 receptor]	0.0	5	1	1	1
122989	1710	case of B-cell lymphocytic leukemia CLL	[cases of B-cell lymphocytic leukemia CLL]	0.0	6	1	1	1
122990	1710	activation of immunoglobulin gene	[activation of immunoglobulin genes]	0.0	4	1	1	1
122991	1710	hormone binding domain hbd	[hormone binding domain HBD]	0.0	4	1	1	1
122992	1710	constitutive nuclear expression	[constitutive nuclear expression]	0.0	3	2	2	1
122993	1710	level in u937 cell	[levels in U937 cells]	0.0	4	1	1	1
122994	1710	addition of oligonucleotide to c-fo	[addition of oligonucleotides to c-fos]	0.0	5	1	1	1
122995	1710	lymphocyte-activating cytokine	[lymphocyte-activating cytokines]	0.0	2	1	1	1
122996	1710	m rapid elevation	[M rapid elevation]	0.0	3	1	1	1
122997	1710	signal transduction capacity	[signal transduction capacity]	0.0	3	1	1	1
122998	1710	concentration of ald	[concentrations of ALD]	0.0	3	1	1	1
122999	1710	consistent pattern of variation	[consistent patterns of variation]	0.0	4	1	1	1
123000	1710	E-selectin surface expression by TNF	[E-selectin surface expression by TNF]	0.0	5	1	1	1
123001	1710	49 subject yr)	[49 subjects yr)]	0.0	3	1	1	1
123002	1710	undifferentiated cell epithelioma	[undifferentiated cell epitheliomas]	0.0	3	1	1	1
123003	1710	common consensus motif	[common consensus motif]	0.0	3	1	1	1
123004	1710	PBSCT	[PBSCT]	0.0	1	1	1	1
123005	1710	formation of the factor	[formation of the factor]	0.0	4	1	1	1
123006	1710	Addition of platelet to monocyte	[Addition of platelets to monocytes]	0.0	5	1	1	1
123007	1710	transcription start site)	[transcription start site)]	0.0	3	1	1	1
123008	1710	160 amino acid	[160 amino acids]	0.0	3	1	1	1
123009	1710	treatment of the mouse	[treatment of the mice]	0.0	4	1	1	1
123010	1710	ap-1 /nf-at	[AP-1 /NF-AT]	0.0	2	1	1	1
123011	1710	presentation in comparison	[presentation in comparison]	0.0	3	1	1	1
123012	1710	Comparison of group mouse genomic sequence	[Comparison of group mouse genomic sequences]	0.0	6	1	1	1
123013	1710	normal human lymphocyte from blood	[normal human lymphocytes from blood]	0.0	5	1	1	1
123014	1710	expression of MHC class	[expression of MHC class]	0.0	4	1	1	1
123015	1710	chaperoning protein to organelle	[chaperoning proteins to organelles]	0.0	4	1	1	1
123016	1710	extensive evaluation of tissue	[extensive evaluation of tissues]	0.0	4	1	1	1
123017	1710	(on average	[(on average]	0.0	2	1	1	1
123018	1710	several enhancer element	[several enhancer elements]	0.0	3	1	1	1
123019	1710	nonspecific stimulation,	[nonspecific stimulation,]	0.0	2	1	1	1
123020	1710	emergence of variant to combination	[emergence of variants to combinations]	0.0	5	1	1	1
123021	1710	strike similarity for ets-related protein	[striking similarity for ets-related proteins]	0.0	5	1	1	1
123022	1710	inhibition beta	[inhibition beta]	0.0	2	1	1	1
123023	1710	effect of loop peptide	[effect of loop peptides]	0.0	4	1	1	1
123024	1710	non-genomic effect of aldosterone	[Non-genomic effects of aldosterone]	0.0	4	1	1	1
123025	1710	failure of virus-exposed T cell	[failure of virus-exposed T cells]	0.0	5	1	1	1
123026	1710	type of effector cell	[types of effector cells]	0.0	4	1	1	1
123027	1710	defense system against stress	[defense system against stress]	0.0	4	1	1	1
123028	1710	mean dissociation constant	[mean dissociation constant]	0.0	3	1	1	1
123029	1710	PML/ RARalpha mouse	[PML/ RARalpha mice]	0.0	3	1	1	1
123030	1710	addition of lps	[addition of LPS]	0.0	3	1	1	1
123031	1710	region contain near-perfect repeat	[region containing near-perfect repeats]	0.0	4	1	1	1
123032	1710	adaptor molecules.	[adaptor molecules.]	0.0	2	1	1	1
123033	1710	9.5 hour	[9.5 hours]	0.0	2	1	1	1
123034	1710	similarity between the effect	[Similarities between the effects]	0.0	4	1	1	1
123035	1710	mutation in this gene	[mutation in this gene]	0.0	4	1	1	1
123036	1710	glucocorticoid resistance in chronic asthma	[glucocorticoid resistance in chronic asthma]	0.0	5	1	1	1
123037	1710	tl20/12r	[TL20/12RS]	0.0	1	1	1	1
123038	1710	dual color microscopy	[dual color microscopy]	0.0	3	1	1	1
123039	1710	addition of anti-AIM mab	[addition of anti-AIM mAb]	0.0	4	1	1	1
123040	1710	atypical eosinophil	[atypical eosinophils]	0.0	2	1	1	1
123041	1710	resistance to productive hiv infection,	[resistance to productive HIV infection,]	0.0	5	1	1	1
123042	1710	quality emotional support	[quality emotional support]	0.0	3	1	1	1
123043	1710	cytokine of 13 kda	[cytokine of 13 kDa]	0.0	4	1	1	1
123044	1710	effect on downstream signal event	[effect on downstream signaling events]	0.0	5	1	1	1
123045	1710	ttca sequence in cell	[TTCA sequence in cells]	0.0	4	1	1	1
123046	1710	maturation in NB4	[maturation in NB4]	0.0	3	1	1	1
123047	1710	molecule by antigen-presenting cell	[molecules by antigen-presenting cells]	0.0	4	1	1	1
123048	1710	lineage switch in development	[lineage switching in development]	0.0	4	1	1	1
123049	1710	putative novel loci	[putative novel loci]	0.0	3	1	1	1
123050	1710	NF-kappa b -independent activation	[NF-kappa B -independent activation]	0.0	4	1	1	1
123051	1710	normal late gene expression	[normal late gene expression]	0.0	4	1	1	1
123052	1710	range from kD to kd,	[ranging from kD to kD,]	0.0	5	1	1	1
123053	1710	breast cancer cell	[breast cancer cell]	0.0	3	2	2	1
123054	1710	49 case of lymphocytic leukemia CLL	[49 cases of lymphocytic leukemia CLL]	0.0	6	1	1	1
123055	1710	molecular mechanism of IL-5 signal	[molecular mechanisms of IL-5 signaling]	0.0	5	1	1	1
123056	1710	coupling to pathway	[Coupling to pathways]	0.0	3	1	1	1
123057	1710	1alpha,25(OH)2-d5-previtamin	[1alpha,25(OH)2-d5-previtamin]	0.0	1	1	1	1
123058	1710	activity of plasma	[activity of plasma]	0.0	3	1	1	1
123059	1710	eight simian cell line	[eight simian cell lines]	0.0	4	1	1	1
123060	1710	two other NFATp -binding site	[Two other NFATp -binding sites]	0.0	5	1	1	1
123061	1710	transcriptional factor necessary for expression	[transcriptional factor necessary for expression]	0.0	5	1	1	1
123062	1710	peroxisomal receptor gamma ppargamma	[peroxisomal receptor gamma PPARgamma]	0.0	4	1	1	1
123063	1710	receptor for the fc portion	[Receptors for the Fc portion]	0.0	5	1	1	1
123064	1710	expression of the lectin	[expression of the lectin]	0.0	4	1	1	1
123065	1710	tfiib	[TFIIB]	0.0	1	1	1	1
123066	1710	dominant mutant form	[dominant mutant forms]	0.0	3	1	1	1
123067	1710	definite coagulopathy	[definite coagulopathy]	0.0	2	1	1	1
123068	1710	beta-cell complex	[beta-cell complex]	0.0	2	1	1	1
123069	1710	alternative promoter Palpha	[alternative promoters Palpha]	0.0	3	1	1	1
123070	1710	heat-shock for hour at degree c,	[Heat-shock for hours at degrees C,]	0.0	6	1	1	1
123071	1710	follow a injection of phosphocreatine	[following an injection of phosphocreatine]	0.0	5	1	1	1
123072	1710	t-cell-leukemia virus type htlv-1	[T-cell-leukemia virus type HTLV-1]	0.0	4	1	1	1
123073	1710	gene expression of the adenovirus region	[gene expression of the adenovirus region]	0.0	6	1	1	1
123074	1710	-phoq	[-phoQ]	0.0	1	1	1	1
123075	1710	stable binding	[stable binding]	0.0	2	1	1	1
123076	1710	alter position	[altering position]	0.0	2	1	1	1
123077	1710	Ter positive cell from mouse	[Ter positive cells from mice]	0.0	5	1	1	1
123078	1710	il-13 gene	[IL-13 gene]	0.0	2	1	1	1
123079	1710	regulation of the fas promoter	[regulation of the Fas promoter]	0.0	5	1	1	1
123080	1710	E2F dna-binding complex	[E2F DNA-binding complexes]	0.0	3	1	1	1
123081	1710	binding of ifn-gamma	[binding of IFN-gamma]	0.0	3	1	1	1
123082	1710	include tumor necrosis factor alpha	[including tumor necrosis factor alpha]	0.0	5	1	1	1
123083	1710	spite however,	[spite however,]	0.0	2	1	1	1
123084	1710	good tolerance	[better tolerance]	0.0	2	1	1	1
123085	1710	lytic antigen-specific reactivity	[lytic antigen-specific reactivities]	0.0	3	1	1	1
123086	1710	inflammatory mechanism in bronchial cell	[inflammatory mechanisms in bronchial cells]	0.0	5	1	1	1
123087	1710	gene therapy protocol utilize such vector	[gene therapy protocols utilizing such vectors]	0.0	6	1	1	1
123088	1710	regulator of hsf2 activity	[regulator of HSF2 activity]	0.0	4	1	1	1
123089	1710	endogenous transcription factor	[endogenous transcription factors]	0.0	3	1	1	1
123090	1710	analysis of deletion construct	[analysis of deletion constructs]	0.0	4	1	1	1
123091	1710	recurrent cytogenetic abnormality highlight loci	[recurrent cytogenetic abnormalities highlighting loci]	0.0	5	1	1	1
123092	1710	h2o2 in lymphocyte	[H2O2 in lymphocytes]	0.0	3	1	1	1
123093	1710	secret il-2 at a low level	[secreting IL-2 at a low level]	0.0	6	1	1	1
123094	1710	two novel regulatory element	[two novel regulatory elements]	0.0	4	1	1	1
123095	1710	distinct species,	[distinct species,]	0.0	2	1	1	1
123096	1710	transcription factor factor-kappaB nfkappab	[transcription factor factor-kappaB NFkappaB]	0.0	4	1	1	1
123097	1710	anti- hiv-1 therapy	[anti- HIV-1 therapy]	0.0	3	1	1	1
123098	1710	Positive regulation	[Positive regulation]	0.0	2	4	4	1
123099	1710	cofactor for nf-kappab activation	[cofactor for NF-kappaB activation]	0.0	4	1	1	1
123100	1710	cjun	[cJun]	0.0	1	1	1	1
123101	1710	peripheral leucocyte in 22 woman	[peripheral leucocytes in 22 women]	0.0	5	1	1	1
123102	1710	pre-treatment of pbmc	[pre-treatment of PBMC]	0.0	3	1	1	1
123103	1710	cytoadhesin	[cytoadhesin]	0.0	1	1	1	1
123104	1710	twenty healthy man	[Twenty healthy men]	0.0	3	1	1	1
123105	1710	apparent high frequency	[apparent high frequency]	0.0	3	1	1	1
123106	1710	feature characteristic include sensitivity	[features characteristic including sensitivity]	0.0	4	1	1	1
123107	1710	transient-transfection experiment in carcinoma cell	[Transient-transfection experiments in carcinoma cells]	0.0	5	1	1	1
123108	1710	inhibition of growth depletion	[inhibition of growth depletion]	0.0	4	1	1	1
123109	1710	high 12-lipoxygenase activity	[higher 12-lipoxygenase activity]	0.0	3	1	1	1
123110	1710	independent methods, include annexin-V staining	[independent methods, including annexin-V staining]	0.0	5	1	1	1
123111	1710	DNA aneuploidy	[DNA aneuploidy]	0.0	2	1	1	1
123112	1710	region of IL2	[region of IL2]	0.0	3	1	1	1
123113	1710	many hypothese	[many hypotheses]	0.0	2	1	1	1
123114	1710	monocyte peptide-1 mcp-1	[monocyte peptide-1 MCP-1]	0.0	3	1	1	1
123115	1710	histocompatibility class gene DRA	[histocompatibility class gene DRA]	0.0	4	1	1	1
123116	1710	effect of lectins	[effect of lectins]	0.0	3	1	1	1
123117	1710	eiconsanoid a2 b4 ltb4	[eiconsanoids A2 B4 LTB4]	0.0	4	1	1	1
123118	1710	holo- TFIIA	[holo- TFIIA]	0.0	2	1	1	1
123119	1710	small substance such as formylpeptide lps	[small substances such as formylpeptides LPS]	0.0	6	1	1	1
123120	1710	include blood mononuclear cell	[including blood mononuclear cells]	0.0	4	1	1	1
123121	1710	major subunit	[major subunits]	0.0	2	1	1	1
123122	1710	protein phosphatase 2a	[protein phosphatase 2A]	0.0	3	1	1	1
123123	1710	anti-cd3/ ln cell	[anti-CD3/ LN cells]	0.0	3	1	1	1
123124	1710	-137 element	[-137 element]	0.0	2	1	1	1
123125	1710	Epstein-Barr virus antigen component ea-d	[Epstein-Barr virus antigen component EA-D]	0.0	5	1	1	1
123126	1710	access Epstein-Barr virus t-cell memory	[Accessing Epstein-Barr virus T-cell memory]	0.0	5	1	1	1
123127	1710	functional complex	[functional complexes]	0.0	2	1	1	1
123128	1710	receptor expression in t-	[receptor expression in T-]	0.0	4	1	1	1
123129	1710	h for culture (viability great	[h for cultures (viability greater]	0.0	5	1	1	1
123130	1710	mononuclear leukocyte of healthy donor	[mononuclear leukocytes of healthy donors]	0.0	5	1	1	1
123131	1710	human line u937	[human lines U937]	0.0	3	1	1	1
123132	1710	t-cell signal molecule	[T-cell signaling molecules]	0.0	3	1	1	1
123133	1710	progression of various type include leukaemia	[progression of various types including leukaemia]	0.0	6	2	2	1
123134	1710	monovalent gold ion	[monovalent gold ion]	0.0	3	1	1	1
123135	1710	class invariant chain promoter	[class invariant chain promoter]	0.0	4	1	1	1
123136	1710	activation of thp-1 cell	[Activation of THP-1 cells]	0.0	4	1	1	1
123137	1710	type of acute leukemia blast cell	[types of acute leukemia blast cells]	0.0	6	1	1	1
123138	1710	increase in the production	[increase in the production]	0.0	4	1	1	1
123139	1710	differential treatment	[differential treatment]	0.0	2	1	1	1
123140	1710	hypersensitivity response	[hypersensitivity response]	0.0	2	1	1	1
123141	1710	study alteration	[studying alterations]	0.0	2	1	1	1
123142	1710	nf-kappab p50/p65	[NF-kappaB p50/p65]	0.0	2	1	1	1
123143	1710	rest umbilical vein cell	[resting umbilical vein cells]	0.0	4	1	1	1
123144	1710	[regulation	[[Regulation]	0.0	1	2	2	1
123145	1710	case of B-cell chronic lymphocytic leukemia	[cases of B-cell chronic lymphocytic leukemia]	0.0	6	1	1	1
123146	1710	human il-5	[Human IL-5]	0.0	2	1	1	1
123147	1710	induction P-4501A1 CYP1A1 activity by ultra-violet	[Induction P-4501A1 CYP1A1 activity by UV]	0.0	6	1	1	1
123148	1710	migration on SDS-PAGE	[migration on SDS-PAGE]	0.0	3	1	1	1
123149	1710	vla-5 receptor	[VLA-5 receptor]	0.0	2	1	1	1
123150	1710	human zeta globin gene	[human zeta globin gene]	0.0	4	1	1	1
123151	1710	moreover, virus 40 enhancer activity	[Moreover, virus 40 enhancer activity]	0.0	5	1	1	1
123152	1710	full complement	[full complement]	0.0	2	1	1	1
123153	1710	DNA variation 2418delA	[DNA variations 2418delA]	0.0	3	1	1	1
123154	1710	cycloheximide anytime	[cycloheximide anytime]	0.0	2	1	1	1
123155	1710	transcriptional regulation by NFKB2	[transcriptional regulation by NFKB2]	0.0	4	1	1	1
123156	1710	cell specificity	[cell specificity]	0.0	2	1	1	1
123157	1710	49 patient with MPD	[49 patients with MPD]	0.0	4	1	1	1
123158	1710	transactivation of a reporter gene	[transactivation of a reporter gene]	0.0	5	1	1	1
123159	1710	Rat-1 fibroblast	[Rat-1 fibroblasts]	0.0	2	1	1	1
123160	1710	sequence of the cdc2 gene	[sequence of the cdc2 gene]	0.0	5	1	1	1
123161	1710	Differential induction protein 10 follow differentiation	[Differential induction protein 10 following differentiation]	0.0	6	1	1	1
123162	1710	vitamin d,	[vitamin D,]	0.0	2	1	1	1
123163	1710	common member	[common members]	0.0	2	1	1	1
123164	1710	distinctive eosinophil abnormality	[distinctive eosinophil abnormalities]	0.0	3	1	1	1
123165	1710	reporter gene transcription of Stat	[reporter gene transcription of Stat]	0.0	5	1	1	1
123166	1710	process in the lung	[processes in the lung]	0.0	4	1	1	1
123167	1710	predominant E2F complex	[predominant E2F complex]	0.0	3	1	1	1
123168	1710	BZLF-1 locus	[BZLF-1 locus]	0.0	2	1	1	1
123169	1710	sites/cell with the gcr	[sites/cell with the GCR]	0.0	4	1	1	1
123170	1710	constellation of malformation	[constellation of malformations]	0.0	3	1	1	1
123171	1710	environmental factors, in cytokine	[environmental factors, in cytokines]	0.0	4	1	1	1
123172	1710	large clonal population	[large clonal population]	0.0	3	1	1	1
123173	1710	novel protein (around kda	[novel proteins (around kDa]	0.0	4	1	1	1
123174	1710	polyclonal stimulus	[polyclonal stimuli]	0.0	2	1	1	1
123175	1710	analysis of the coding sequence	[analysis of the coding sequence]	0.0	5	1	1	1
123176	1710	druilkience pyrrolidine dithiocarbamate	[drug, pyrrolidine dithiocarbamate]	0.0	3	1	1	1
123177	1710	part through activation	[part through activation]	0.0	3	1	1	1
123178	1710	follow treatment with MCM	[following treatment with MCM]	0.0	4	1	1	1
123179	1710	24 pregnant woman (11	[24 pregnant women (11]	0.0	4	1	1	1
123180	1710	induction of il-1 receptor type	[induction of IL-1 receptor type]	0.0	5	1	1	1
123181	1710	expression pattern of bcl-6	[expression pattern of BCL-6]	0.0	4	2	2	1
123182	1710	class ii chain promoter	[class II chain promoter]	0.0	4	1	1	1
123183	1710	incorporation of 32p	[incorporation of 32P]	0.0	3	1	1	1
123184	1710	inhibitor of sr 31747a binding	[inhibitor of SR 31747A binding]	0.0	5	1	1	1
123185	1710	potent inhibitor of the production	[potent inhibitors of the production]	0.0	5	1	1	1
123186	1710	reduction of cell proliferation	[reduction of cell proliferation]	0.0	4	1	1	1
123187	1710	reduction of IL-12 production	[reduction of IL-12 production]	0.0	4	1	1	1
123188	1710	set of genes.	[sets of genes.]	0.0	3	1	1	1
123189	1710	primary requirement for immunodeficiency virus	[primary requirement for immunodeficiency virus]	0.0	5	1	1	1
123190	1710	B lymphoid cell	[B lymphoid cells]	0.0	3	1	1	1
123191	1710	constitutive level in cell type	[constitutive levels in cell types]	0.0	5	1	1	1
123192	1710	growth of this tax-transformed fibroblast	[growth of these Tax-transformed fibroblasts]	0.0	5	1	1	1
123193	1710	cytokine gene include tnf	[cytokine genes including TNF]	0.0	4	1	1	1
123194	1710	probe specific for the deletion	[probes specific for the deletion]	0.0	5	1	1	1
123195	1710	dominant IkappaBalpha construct resistant	[dominant IkappaBalpha construct resistant]	0.0	4	1	1	1
123196	1710	developmental specific manner	[developmental specific manner]	0.0	3	1	1	1
123197	1710	mutation t-c)	[mutation T-C)]	0.0	2	1	1	1
123198	1710	latent cycle reactivity rarely undetectable	[latent cycle reactivities rarely undetectable]	0.0	5	1	1	1
123199	1710	antibody antibody mab phase-1 neutrophil adhesion	[antibodies antibodies mAbs phase-1 neutrophil adhesion]	0.0	6	1	1	1
123200	1710	drug interaction affect the metabolism	[drug interactions affecting the metabolism]	0.0	5	1	1	1
123201	1710	tenacious, protease	[tenacious, protease]	0.0	2	1	1	1
123202	1710	normal monocyte activation	[normal monocyte activation]	0.0	3	1	1	1
123203	1710	arrest of T cell development	[arrest of T cell development]	0.0	5	1	1	1
123204	1710	generation of cd1+relb+ cell	[Generation of CD1+RelB+ cells]	0.0	4	1	1	1
123205	1710	phosphatidylinositol 3-kinase ptdin 3-kinase	[Phosphatidylinositol 3-kinase PtdIns 3-kinase]	0.0	4	1	1	1
123206	1710	negatively with the proportion	[negatively with the proportion]	0.0	4	1	1	1
123207	1710	unique set	[unique set]	0.0	2	1	1	1
123208	1710	genes, alpha a	[genes, alpha A]	0.0	3	1	1	1
123209	1710	correlation in the cell	[correlation in the cells]	0.0	4	1	1	1
123210	1710	trancriptional role in human monocyte	[trancriptional roles in human monocytes]	0.0	5	1	1	1
123211	1710	response involve activation of form	[response involving activation of forms]	0.0	5	1	1	1
123212	1710	il-1beta mrna level	[IL-1beta mRNA levels]	0.0	3	1	1	1
123213	1710	modulate the balance	[modulating the balance]	0.0	3	1	1	1
123214	1710	putative cis-acting element	[putative cis-acting elements]	0.0	3	1	1	1
123215	1710	early event.	[early event.]	0.0	2	1	1	1
123216	1710	thus implicate this region	[thus implicating this region]	0.0	4	1	1	1
123217	1710	particularly the variant FAB aml -m3v	[particularly the variant FAB AML -M3v]	0.0	6	1	1	1
123218	1710	separable domain	[separable domains]	0.0	2	1	1	1
123219	1710	serum responsive element present	[serum responsive element present]	0.0	4	1	1	1
123220	1710	hiv-1 mutation	[HIV-1 mutations]	0.0	2	1	1	1
123221	1710	presence of distinct complex	[presence of distinct complexes]	0.0	4	1	1	1
123222	1710	effect of N-acetyl-L-cysteine NAC	[effects of N-acetyl-L-cysteine NAC]	0.0	4	1	1	1
123223	1710	dominant negative effector on activity	[dominant negative effector on activity]	0.0	5	1	1	1
123224	1710	CF individual 7	[CF individuals 7]	0.0	3	1	1	1
123225	1710	membrane protein LAMPf	[membrane proteins LAMPf]	0.0	3	1	1	1
123226	1710	mechanism increase il-2 transcription	[mechanism increasing IL-2 transcription]	0.0	4	1	1	1
123227	1710	GC-rich 5' sequence	[GC-rich 5' sequence]	0.0	3	1	1	1
123228	1710	beta-glucan neutrophil	[beta-glucan neutrophils]	0.0	2	1	1	1
123229	1710	weight in the range	[weights in the range]	0.0	4	1	1	1
123230	1710	isotype of protein kinase C	[isotypes of protein kinase C]	0.0	5	1	1	1
123231	1710	mitogen-inducible transcription factor	[mitogen-inducible transcription factors]	0.0	3	1	1	1
123232	1710	response-1 gene expression	[response-1 gene expression]	0.0	3	1	1	1
123233	1710	mrna of clone	[mRNA of clone]	0.0	3	1	1	1
123234	1710	pHU-14 a probe hybridize close	[pHU-14 a probe hybridizes close]	0.0	5	1	1	1
123235	1710	relate the nf-at complex to NF-ATp	[relating the NF-AT complexes to NF-ATp]	0.0	6	1	1	1
123236	1710	mammalian response	[mammalian responses]	0.0	2	1	1	1
123237	1710	anti-ERK signal-regulated kinase antibody	[anti-ERK signal-regulated kinase antibodies]	0.0	4	1	1	1
123238	1710	mutation within C/EBP site	[mutations within C/EBP sites]	0.0	4	1	1	1
123239	1710	isolation of cell from blood	[Isolation of cells from blood]	0.0	5	1	1	1
123240	1710	study the the gene for differentiation	[studying the the genes for differentiation]	0.0	6	1	1	1
123241	1710	three infectious disease tuberculosis	[three infectious diseases tuberculosis]	0.0	4	1	1	1
123242	1710	internal standard consist	[internal standard consisting]	0.0	3	1	1	1
123243	1710	analysis for the specificity	[analyses for the specificity]	0.0	4	1	1	1
123244	1710	detail of the mechanism	[details of the mechanism]	0.0	4	1	1	1
123245	1710	epipodophyllotoxin	[epipodophyllotoxin]	0.0	1	1	1	1
123246	1710	grade (p 0.0001)	[grade (P 0.0001),]	0.0	3	1	1	1
123247	1710	STAT isoform	[STAT isoforms]	0.0	2	1	1	1
123248	1710	exclusive selectivity	[exclusive selectivity]	0.0	2	1	1	1
123249	1710	intraluminal administration	[intraluminal administration]	0.0	2	1	1	1
123250	1710	extent, ebv nuclear antigen	[extent, EBV nuclear antigen]	0.0	4	1	1	1
123251	1710	granulocyte DNA from patient	[Granulocyte DNA from patients]	0.0	4	1	1	1
123252	1710	two donor	[two donors]	0.0	2	1	1	1
123253	1710	inasmuch presumably through opening of K+	[Inasmuch presumably through opening of K+]	0.0	6	1	1	1
123254	1710	t3 maximal binding capacity MBC	[T3 maximal binding capacity MBC]	0.0	5	1	1	1
123255	1710	MEK1/MEK2 inhibitor	[MEK1/MEK2 inhibitor]	0.0	2	1	1	1
123256	1710	Recent evidence for a coupling	[Recent evidence for a coupling]	0.0	5	1	1	1
123257	1710	stimulate il-6 release	[stimulating IL-6 release]	0.0	3	1	1	1
123258	1710	lean	[lean]	0.0	1	1	1	1
123259	1710	major pathway	[major pathway]	0.0	2	1	1	1
123260	1710	proto-oncoprotein ets-1	[proto-oncoprotein ets-1]	0.0	2	1	1	1
123261	1710	analysis by cell transfection	[analysis by cell transfection]	0.0	4	1	1	1
123262	1710	3 to 4 month	[3 to 4 months]	0.0	4	1	1	1
123263	1710	implication for negative regulation	[implications for negative regulation]	0.0	4	1	1	1
123264	1710	coupling between cytokine receptor	[coupling between cytokine receptor]	0.0	4	1	1	1
123265	1710	provide further evidence to the notion	[providing further evidence to the notion]	0.0	6	1	1	1
123266	1710	more than one abnormality,	[more than one abnormality,]	0.0	4	1	1	1
123267	1710	receptor on mononuclear leukocyte MNL	[receptors on mononuclear leukocytes MNL]	0.0	5	1	1	1
123268	1710	Appraisal of index of antioxidant	[Appraisal of index of antioxidants]	0.0	5	1	1	1
123269	1710	correlation with the pmn chemotaxis	[correlation with the PMNs chemotaxis]	0.0	5	1	1	1
123270	1710	form creb	[forms CREB]	0.0	2	1	1	1
123271	1710	apoptosis of lymphocyte	[apoptosis of lymphocytes]	0.0	3	1	1	1
123272	1710	activation of nf-kappa b rna	[activation of NF-kappa B RNA]	0.0	5	1	1	1
123273	1710	modulation of immune responsiveness by il-10	[modulation of immune responsiveness by IL-10]	0.0	6	1	1	1
123274	1710	stimulation of U1 cells.	[stimulation of U1 cells.]	0.0	4	1	1	1
123275	1710	calcium -mobilize potency	[calcium -mobilizing potency]	0.0	3	1	1	1
123276	1710	cytokine in the lung	[cytokine in the lung]	0.0	4	1	1	1
123277	1710	isgf3 alpha	[ISGF3 alpha]	0.0	2	1	1	1
123278	1710	respond to hbsag	[responding to HBsAg]	0.0	3	1	1	1
123279	1710	pallidum	[pallidum]	0.0	1	1	1	1
123280	1710	dihydrofolate reductase	[dihydrofolate reductase]	0.0	2	1	1	1
123281	1710	bovine homologue	[bovine homologue]	0.0	2	1	1	1
123282	1710	analysis with isoform-specific C-terminal antibody	[analysis with isoform-specific C-terminal antibodies]	0.0	5	1	1	1
123283	1710	b -like factor in pmn	[B -like factor in PMN]	0.0	5	1	1	1
123284	1710	acid (ra)-induced differentiation	[acid (RA)-induced differentiation]	0.0	3	1	1	1
123285	1710	mab inhibits,	[mAbs inhibits,]	0.0	2	1	1	1
123286	1710	role activate transcription of gene	[role activating transcription of genes]	0.0	5	1	1	1
123287	1710	ckii	[CKII]	0.0	1	1	1	1
123288	1710	immunoglobulin heavy chain IgH	[immunoglobulin heavy chain IgH]	0.0	4	1	1	1
123289	1710	element in the murine immunoglobulin heavy-chain	[elements in the murine immunoglobulin heavy-chain]	0.0	6	1	1	1
123290	1710	response to phorbol	[response to phorbol]	0.0	3	2	2	1
123291	1710	IL-4 receptor subunit	[IL-4 receptor subunits]	0.0	3	1	1	1
123292	1710	expression of luciferase	[Expression of luciferase]	0.0	3	1	1	1
123293	1710	(dbf)	[(DBF)]	0.0	1	1	1	1
123294	1710	dilution analysis	[dilution analysis]	0.0	2	1	1	1
123295	1710	expression of PPARgamma	[Expression of PPARgamma]	0.0	3	1	1	1
123296	1710	abnormally high level	[abnormally high levels]	0.0	3	1	1	1
123297	1710	camp response element present	[cAMP response element present]	0.0	4	1	1	1
123298	1710	converge in common pathway	[converging in common pathways]	0.0	4	1	1	1
123299	1710	stable binding of nuclear factor	[stable binding of nuclear factors]	0.0	5	1	1	1
123300	1710	regulatory factor-kappa beta in monocyte	[regulatory factor-kappa beta in monocytes]	0.0	5	1	1	1
123301	1710	clinical progression from asymptomatic infection	[clinical progression from asymptomatic infection]	0.0	5	1	1	1
123302	1710	presumably reflect the c-terminal domain	[presumably reflecting the C-terminal domain]	0.0	5	1	1	1
123303	1710	human cell ECs	[human cells ECs]	0.0	3	1	1	1
123304	1710	have weight in the range kd.	[having weights in the range kd.]	0.0	6	1	1	1
123305	1710	syndrome (cushing	[syndrome (Cushing's]	0.0	2	1	1	1
123306	1710	interference in activity of gata-1	[interference in activities of GATA-1]	0.0	5	1	1	1
123307	1710	dominant mutant ikk1 k44m	[dominant mutant IKK1 K44M]	0.0	4	1	1	1
123308	1710	mnc lysate	[MNC lysates]	0.0	2	1	1	1
123309	1710	especially patient	[especially patients]	0.0	2	1	1	1
123310	1710	approximately 1 ng/ml tbp-1	[approximately 1 ng/ml TBP-1]	0.0	4	1	1	1
123311	1710	hour time culture for IL-8	[hours time culture for IL-8]	0.0	5	1	1	1
123312	1710	trough value between 2300	[trough values between 2300]	0.0	4	1	1	1
123313	1710	140-kDa sp140	[140-kDa Sp140]	0.0	2	1	1	1
123314	1710	follicular dendritic cell in center	[follicular dendritic cells in centers]	0.0	5	1	1	1
123315	1710	monoblast cell line	[monoblast cell line]	0.0	3	2	2	1
123316	1710	cell autonomous coregulation	[cell autonomous coregulation]	0.0	3	1	1	1
123317	1710	factor-mu negative regulator	[factor-mu negative regulator]	0.0	3	1	1	1
123318	1710	two promoter in monocytes/macrophages	[two promoters in monocytes/macrophages]	0.0	4	1	1	1
123319	1710	c-fos-two component of the transcription factor	[c-fos-two components of the transcription factor]	0.0	6	1	1	1
123320	1710	gene encode interleukin-2 IL2	[gene encoding interleukin-2 IL2]	0.0	4	1	1	1
123321	1710	bind C	[binding C]	0.0	2	1	1	1
123322	1710	degree of down-regulation	[degree of down-regulation]	0.0	3	1	1	1
123323	1710	cell cDNA	[cell cDNA]	0.0	2	1	1	1
123324	1710	the/thf n: 1.87+/-0.36) alpha thf/thf	[THE/THF N: 1.87+/-0.36) alpha THF/THF]	0.0	5	1	1	1
123325	1710	several myeloid-cell-specific gene	[several myeloid-cell-specific genes]	0.0	3	1	1	1
123326	1710	autosomal dominant mode	[autosomal dominant mode]	0.0	3	2	2	1
123327	1710	(i) patient	[(i) patients]	0.0	2	1	1	1
123328	1710	thymocyte with cell	[thymocytes with cells]	0.0	3	1	1	1
123329	1710	five dnase I site	[five DNase I sites]	0.0	4	1	1	1
123330	1710	therapeutic target in state	[therapeutic target in states]	0.0	4	1	1	1
123331	1710	involvement receptor factor	[involvement receptor factors]	0.0	3	1	1	1
123332	1710	350 case of myeloid leukemia	[350 cases of myeloid leukemia]	0.0	5	1	1	1
123333	1710	1056 bp.	[1056 bp.]	0.0	2	1	1	1
123334	1710	blood cell culture to 100%	[blood cell cultures to 100%]	0.0	5	1	1	1
123335	1710	rate limit	[rate limiting]	0.0	2	1	1	1
123336	1710	use c-jun antisense (as) phosphorothioate oligonucleotide	[using c-jun antisense (AS) phosphorothioate oligonucleotides]	0.0	6	1	1	1
123337	1710	virus in	[viruses in]	0.0	2	1	1	1
123338	1710	persistent hiv infection of monocyte	[persistent HIV infection of monocytes]	0.0	5	1	1	1
123339	1710	activation of Stat 5b	[Activation of Stat 5b]	0.0	4	1	1	1
123340	1710	point assay of glucocorticoid receptor	[point assay of glucocorticoid receptors]	0.0	5	1	1	1
123341	1710	activation double-stranded rna	[activation double-stranded RNA]	0.0	3	1	1	1
123342	1710	comparative mapping of sry	[Comparative mapping of SRY]	0.0	4	1	1	1
123343	1710	NF-kappa b -independent mechanism	[NF-kappa B -independent mechanisms]	0.0	4	1	1	1
123344	1710	cell expression of mammalian mcm5	[Cell expression of mammalian MCM5]	0.0	5	1	1	1
123345	1710	prostatic carcinoma cell line	[prostatic carcinoma cell lines]	0.0	4	1	1	1
123346	1710	induce growth factor-beta expression	[inducing growth factor-beta expression]	0.0	4	1	1	1
123347	1710	lack signal transducer	[lack signal transducer]	0.0	3	1	1	1
123348	1710	repression of cp	[repression of Cp]	0.0	3	1	1	1
123349	1710	element NF-AT-1	[element NF-AT-1]	0.0	2	1	1	1
123350	1710	use a radioassay with [3h]-dexamethasone	[using a radioassay with [3H]-dexamethasone]	0.0	5	1	1	1
123351	1710	68 kda	[68 kDa]	0.0	2	1	1	1
123352	1710	factor responsible for a delay	[factors responsible for a delay]	0.0	5	1	1	1
123353	1710	expression of several genes.	[expression of several genes.]	0.0	4	1	1	1
123354	1710	regulation after transfer	[Regulation after transfer]	0.0	3	1	1	1
123355	1710	induction by human immunodeficiency virus infection	[Induction by human immunodeficiency virus infection]	0.0	6	1	1	1
123356	1710	two protein in human lymphocyte	[two proteins in human lymphocytes]	0.0	5	1	1	1
123357	1710	novel T cell-specific negative element	[novel T cell-specific negative element]	0.0	5	1	1	1
123358	1710	regulate protein as stimulus in b-cell	[regulating proteins as stimuli in B-cells]	0.0	6	1	1	1
123359	1710	monocyte nuclear factor-kappaB	[monocyte nuclear factor-kappaB]	0.0	3	1	1	1
123360	1710	effective drug	[effective drug]	0.0	2	1	1	1
123361	1710	cell partner	[cell partner]	0.0	2	1	1	1
123362	1710	responsiveness myelogenous leukemia	[responsiveness myelogenous leukemia]	0.0	3	1	1	1
123363	1710	use a proteasome inhibitor	[using a proteasome inhibitor]	0.0	4	1	1	1
123364	1710	multiple exposure	[multiple exposures]	0.0	2	1	1	1
123365	1710	aetiology a common disorder,	[aetiology a common disorder,]	0.0	4	1	1	1
123366	1710	tcc with low ifn-gamma level	[TCC with low IFN-gamma levels]	0.0	5	1	1	1
123367	1710	80.2 15.5 (p	[80.2 15.5 (P]	0.0	3	1	1	1
123368	1710	cell g-csf	[cells G-CSF]	0.0	2	1	1	1
123369	1710	transcription factor kB NF-kappa b	[transcription factor kB NF-kappa B]	0.0	5	1	1	1
123370	1710	chain-breaking antioxidant hydroxyanisole	[chain-breaking antioxidants hydroxyanisole]	0.0	3	1	1	1
123371	1710	tyrosine phosphorylation of wild-type Itk	[tyrosine phosphorylation of wild-type Itk]	0.0	5	1	1	1
123372	1710	t-cell gene include interleukin-2	[T-cell genes including interleukin-2]	0.0	4	1	1	1
123373	1710	new retrovirus (es)	[new retrovirus (es)]	0.0	3	1	1	1
123374	1710	disorder a clinical problem	[disorders a clinical problem]	0.0	4	1	1	1
123375	1710	level of the activity of e2f	[levels of the activity of E2F]	0.0	6	1	1	1
123376	1710	signal for transformation through tail	[signals for transformation through tail]	0.0	5	1	1	1
123377	1710	shp2-interacting transmembrane adaptor protein	[SHP2-interacting transmembrane adaptor protein]	0.0	4	1	1	1
123378	1710	J.M.Hardwick, j.virol.64:313-321,	[J.M.Hardwick, J.Virol.64:313-321,]	0.0	2	1	1	1
123379	1710	Eckhard	[Eckhard]	0.0	1	1	1	1
123380	1710	study of the primate Y chromosome	[studies of the primate Y chromosomes]	0.0	6	1	1	1
123381	1710	megakaryoblastic leukaemia m7	[megakaryoblastic leukaemia M7]	0.0	3	1	1	1
123382	1710	merit relative	[merits relative]	0.0	2	1	1	1
123383	1710	female twin pair	[female twin pair]	0.0	3	1	1	1
123384	1710	NK cell by interleukin-2	[NK cells by interleukin-2]	0.0	4	1	1	1
123385	1710	JAKs	[JAKs]	0.0	1	1	1	1
123386	1710	join gene segment at a stage	[joining gene segments at an stage]	0.0	6	1	1	1
123387	1710	form of unbound (free) e2f	[forms of unbound (free) E2F]	0.0	5	1	1	1
123388	1710	factor present in Jurkat cell	[factors present in Jurkat cells]	0.0	5	1	1	1
123389	1710	granulocyte-colony stimulate factor treatment of neutrophils.	[granulocyte-colony stimulating factor treatment of neutrophils.]	0.0	6	1	1	1
123390	1710	class of abundant receptor	[classes of abundant receptors]	0.0	4	1	1	1
123391	1710	interaction between calcineurin	[interaction between calcineurin]	0.0	3	2	2	1
123392	1710	reactivity to recombinant ssb	[reactivity to recombinant SSB]	0.0	4	1	1	1
123393	1710	activation by CIITA	[activation by CIITA]	0.0	3	1	1	1
123394	1710	b- case	[B- cases]	0.0	2	1	1	1
123395	1710	tyk2 dephosphorylation	[Tyk2 dephosphorylation]	0.0	2	1	1	1
123396	1710	mitogen-inducible gene product related	[mitogen-inducible gene product related]	0.0	4	1	1	1
123397	1710	concentration of wild type peptide	[concentrations of wild type peptides]	0.0	5	1	1	1
123398	1710	cellular block	[cellular blocks]	0.0	2	1	1	1
123399	1710	more glucocorticoid receptor	[more glucocorticoid receptors]	0.0	3	1	1	1
123400	1710	traffic between the cytoplasm	[traffic between the cytoplasm]	0.0	4	1	1	1
123401	1710	corresponding to a 0.5 molecule	[corresponding to an 0.5 molecules]	0.0	5	1	1	1
123402	1710	inhibition beta of magnitude	[inhibition beta of magnitude]	0.0	4	1	1	1
123403	1710	therefore, chromosome band	[Therefore, chromosome bands]	0.0	3	1	1	1
123404	1710	cd86 two ligand for CD28	[CD86 two ligands for CD28]	0.0	5	1	1	1
123405	1710	represent the NH2 terminus	[representing the NH2 terminus]	0.0	4	1	1	1
123406	1710	CD21 promoter	[CD21 promoter]	0.0	2	1	1	1
123407	1710	liposarcoma 5).	[liposarcoma 5).]	0.0	2	1	1	1
123408	1710	mg bolus	[mg bolus]	0.0	2	1	1	1
123409	1710	several peak	[several peaks]	0.0	2	1	1	1
123410	1710	non-lymphoid, il-5 cell line	[non-lymphoid, IL-5 cell line]	0.0	4	1	1	1
123411	1710	protein of varicella-zoster virus	[protein of varicella-zoster virus]	0.0	4	1	1	1
123412	1710	etiology of fibromatosis	[etiology of fibromatosis]	0.0	3	1	1	1
123413	1710	glucocorticoid action in t- lymphocyte	[glucocorticoid action in T- lymphocytes]	0.0	5	1	1	1
123414	1710	head-down bed rest)	[head-down bed rest)]	0.0	3	1	1	1
123415	1710	several immune cell	[several immune cells]	0.0	3	1	1	1
123416	1710	manifestation of thalassemia	[manifestation of thalassemia]	0.0	3	1	1	1
123417	1710	hypercellularity	[hypercellularity]	0.0	1	1	1	1
123418	1710	two fold	[two fold]	0.0	2	1	1	1
123419	1710	x box binding	[X box binding]	0.0	3	1	1	1
123420	1710	inducer here	[inducers here]	0.0	2	1	1	1
123421	1710	hematopoietic transcription factor SCL	[hematopoietic transcription factor SCL]	0.0	4	1	1	1
123422	1710	EBV anti-Z Epstein-Barr activator antigen	[EBV anti-Z Epstein-Barr activator antigen]	0.0	5	1	1	1
123423	1710	mmol/l);	[mmol/l);]	0.0	1	1	1	1
123424	1710	dna-binding activity,	[DNA-binding activity,]	0.0	2	1	1	1
123425	1710	ras peptide	[RAS peptides]	0.0	2	1	1	1
123426	1710	sometimes at variance with the transfection	[sometimes at variance with the transfection]	0.0	6	1	1	1
123427	1710	encompass a region	[encompassing a region]	0.0	3	1	1	1
123428	1710	factor nf-at (ref.	[factor NF-AT (ref.]	0.0	3	1	1	1
123429	1710	factor proximal NF-AT AP-1/Octamer	[factor proximal NF-AT AP-1/Octamer]	0.0	4	1	1	1
123430	1710	12-myristate acetate differentiation	[12-myristate acetate differentiation]	0.0	3	1	1	1
123431	1710	SCL gene	[SCL gene]	0.0	2	1	1	1
123432	1710	conjunction with therapy	[conjunction with therapy]	0.0	3	1	1	1
123433	1710	adherence/contact to cell	[adherence/contact to cells]	0.0	3	1	1	1
123434	1710	distinct entities.	[distinct entities.]	0.0	2	1	1	1
123435	1710	GATA-1 gene silent	[GATA-1 gene silent]	0.0	3	1	1	1
123436	1710	activation of il-4 il-7 signal pathway	[activation of IL-4 IL-7 signaling pathways]	0.0	6	1	1	1
123437	1710	concentration of gm-csf mrna	[concentration of GM-CSF mRNA]	0.0	4	1	1	1
123438	1710	beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation of 3,21-diacetoxy-5	[beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation of 3,21-diacetoxy-5]	0.0	5	1	1	1
123439	1710	signal mechanism induce transcription	[signaling mechanisms inducing transcription]	0.0	4	1	1	1
123440	1710	sophisticated strategy persist lifelong, asymptomatically	[sophisticated strategy persisting lifelong, asymptomatically]	0.0	5	1	1	1
123441	1710	similar cd11b+ population	[similar CD11b+ populations]	0.0	3	1	1	1
123442	1710	dimer consist	[dimers consisting]	0.0	2	1	1	1
123443	1710	pathway with sensitivity	[pathways with sensitivity]	0.0	3	1	1	1
123444	1710	substantial T cell proliferation	[substantial T cell proliferation]	0.0	4	1	1	1
123445	1710	extract from this subclone	[extracts from these subclones]	0.0	4	1	1	1
123446	1710	75 kilometer tnf receptor	[75 kd TNF receptor]	0.0	4	1	1	1
123447	1710	EBNA-2 deletion mutant	[EBNA-2 deletion mutant]	0.0	3	1	1	1
123448	1710	pnu156804 in vitro	[PNU156804 in vitro]	0.0	3	1	1	1
123449	1710	ifn-gamma expression of ciita	[IFN-gamma expression of CIITA]	0.0	4	1	1	1
123450	1710	glucocorticoid on interleukin -12	[glucocorticoids on interleukin -12]	0.0	4	1	1	1
123451	1710	cyclin-like DNA repair enzyme	[cyclin-like DNA repair enzyme]	0.0	4	1	1	1
123452	1710	hiv-1 variant	[HIV-1 variant]	0.0	2	1	1	1
123453	1710	different nf-kappa b inducer	[different NF-kappa B inducers]	0.0	4	1	1	1
123454	1710	individual of (mhc) haplotype	[individuals of (MHC) haplotypes]	0.0	4	1	1	1
123455	1710	crucial event in the activation	[crucial events in the activation]	0.0	5	1	1	1
123456	1710	downstream site	[downstream site]	0.0	2	1	1	1
123457	1710	pregnant woman (11 second	[pregnant women (11 second]	0.0	4	1	1	1
123458	1710	LMP1 DNA	[LMP1 DNA]	0.0	2	1	1	1
123459	1710	(NF)-kappaB sequence	[(NF)-kappaB sequence]	0.0	2	1	1	1
123460	1710	CD40 immunogenic human MMs	[CD40 immunogenic human MMs]	0.0	4	1	1	1
123461	1710	use a infectious molecular clone	[using an infectious molecular clone]	0.0	5	1	1	1
123462	1710	very low, concentration	[very low, concentrations]	0.0	3	2	2	1
123463	1710	lymphatic leukemia	[lymphatic leukemia]	0.0	2	1	1	1
123464	1710	deletion of a amino- (729-766) region	[Deletions of a amino- (729-766) region]	0.0	6	1	1	1
123465	1710	killer (lak) cell	[killer (LAK) cells]	0.0	3	1	1	1
123466	1710	role for the N-terminal residue	[role for the N-terminal residues]	0.0	5	1	1	1
123467	1710	TGF -specific elisa	[TGF -specific ELISAs]	0.0	3	1	1	1
123468	1710	peptide in subunit vaccine	[peptides in subunit vaccines]	0.0	4	1	1	1
123469	1710	patient with systemic resistance	[patient with systemic resistance]	0.0	4	1	1	1
123470	1710	clinical manifestation of infection	[clinical manifestations of infection]	0.0	4	1	1	1
123471	1710	cn b	[CN B]	0.0	2	1	1	1
123472	1710	lymphocyte LGL	[lymphocytes LGL]	0.0	2	1	1	1
123473	1710	long neurite process	[long neurite processes]	0.0	3	1	1	1
123474	1710	retinoid X receptor RXR agonist-induced activation	[Retinoid X receptor RXR agonist-induced activation]	0.0	6	1	1	1
123475	1710	inducible binding	[inducible binding]	0.0	2	1	1	1
123476	1710	evidence for a form of inheritance	[evidence for an form of inheritance]	0.0	6	1	1	1
123477	1710	contribution gene product	[contribution gene products]	0.0	3	1	1	1
123478	1710	il-4 phosphorylation	[IL-4 phosphorylation]	0.0	2	1	1	1
123479	1710	stimulation of monocyte cell line	[stimulation of monocyte cell lines]	0.0	5	1	1	1
123480	1710	peptide ANG	[peptide ANG]	0.0	2	1	1	1
123481	1710	major complex class transactivator	[major complex class transactivator]	0.0	4	1	1	1
123482	1710	relation MHC	[relation MHC]	0.0	2	1	1	1
123483	1710	trigger into changes,	[triggering into changes,]	0.0	3	1	1	1
123484	1710	research in this area	[research in this area]	0.0	4	1	1	1
123485	1710	human blood lymphocyte PBL generation	[human blood lymphocytes PBL Generation]	0.0	5	1	1	1
123486	1710	transcription factor athat	[transcription factor athat]	0.0	3	1	1	1
123487	1710	tsp 1 element	[TSP 1 element]	0.0	3	1	1	1
123488	1710	concentration (10(-6)	[concentration (10(-6)]	0.0	2	1	1	1
123489	1710	T. pallidum lipoprotein	[T. pallidum lipoproteins]	0.0	3	1	1	1
123490	1710	cell from healthy subject	[cells from healthy subjects]	0.0	4	1	1	1
123491	1710	strategy manipulate response	[strategies manipulating responses]	0.0	3	1	1	1
123492	1710	role of erythropoietin Epo	[role of erythropoietin Epo]	0.0	4	1	1	1
123493	1710	potential in a segment	[potential in a segment]	0.0	4	1	1	1
123494	1710	method of lymphocyte	[METHOD OF lymphocytes]	0.0	3	1	1	1
123495	1710	assay for the determination	[assay for the determination]	0.0	4	1	1	1
123496	1710	IL-2 cell consist mainly	[IL-2 cells consisting mainly]	0.0	4	1	1	1
123497	1710	high-affinity element	[high-affinity element]	0.0	2	1	1	1
123498	1710	difference in enhancer	[Differences in enhancers]	0.0	3	1	1	1
123499	1710	proliferation of hpc	[proliferation of HPCs]	0.0	3	1	1	1
123500	1710	NF-kappa b translocation cell	[NF-kappa B translocation cells]	0.0	4	1	1	1
123501	1710	level of Spi-B mrna	[levels of Spi-B mRNA]	0.0	4	1	1	1
123502	1710	processing to the nfkb2 form, induction	[processing to the NFKB2 form, induction]	0.0	6	1	1	1
123503	1710	model of differentiation.	[model of differentiation.]	0.0	3	1	1	1
123504	1710	techniques: blot	[techniques: blot]	0.0	2	1	1	1
123505	1710	CRE site in region	[CRE sites in region]	0.0	4	1	1	1
123506	1710	induction kappa B/Rel nuclear activity antibody	[Induction kappa B/Rel nuclear activity antibodies]	0.0	6	1	1	1
123507	1710	receptor contain the domain	[receptor containing the domain]	0.0	4	1	1	1
123508	1710	persistent nuclear accumulation	[persistent nuclear accumulation]	0.0	3	2	2	1
123509	1710	oral administration of mumol cortisol	[Oral administration of mumol cortisol]	0.0	5	1	1	1
123510	1710	potential NFAT composite element	[potential NFAT composite elements]	0.0	4	1	1	1
123511	1710	estrogen manner	[estrogen manner]	0.0	2	1	1	1
123512	1710	result in phosphorylation of substrate	[resulting in phosphorylation of substrates]	0.0	5	1	1	1
123513	1710	lack of requirement	[lack of requirement]	0.0	3	1	1	1
123514	1710	human T helper (th) clone	[human T helper (Th) clones]	0.0	5	1	1	1
123515	1710	Rapid tyrosine phosphorylation	[Rapid tyrosine phosphorylation]	0.0	3	1	1	1
123516	1710	cell type-specific induction of collagenase	[cell type-specific induction of collagenase]	0.0	5	1	1	1
123517	1710	distinctive pattern	[distinctive pattern]	0.0	2	2	2	1
123518	1710	light chain enhancer	[light chain enhancers]	0.0	3	1	1	1
123519	1710	cell carcinoma in sample	[cell carcinomas in samples]	0.0	4	1	1	1
123520	1710	nine DNA fragment of kb.	[nine DNA fragments of kb.]	0.0	5	1	1	1
123521	1710	huvec nuclear protein	[HUVEC nuclear proteins]	0.0	3	1	1	1
123522	1710	catalyze the exchange of peptide	[catalyzing the exchange of peptides]	0.0	5	1	1	1
123523	1710	low surface	[low surface]	0.0	2	1	1	1
123524	1710	new cell-specific transcription factor	[new cell-specific transcription factor]	0.0	4	1	1	1
123525	1710	western blot analysis use antibody	[Western Blot analysis using antibodies]	0.0	5	1	1	1
123526	1710	importance of apoptosis	[importance of apoptosis]	0.0	3	1	1	1
123527	1710	modulate the activity	[modulating the activity]	0.0	3	1	1	1
123528	1710	widespread applicability, allow rapid testing	[widespread applicability, allowing rapid testing]	0.0	5	1	1	1
123529	1710	related factor	[related factor]	0.0	2	1	1	1
123530	1710	incubation with antigen cell	[incubation with antigen cells]	0.0	4	1	1	1
123531	1710	present with isolated hilar adenopathy	[presenting with isolated hilar adenopathy]	0.0	5	1	1	1
123532	1710	abundance of a functional VDR	[abundance of a functional VDR]	0.0	5	1	1	1
123533	1710	antigen-induced airway hyperresponsiveness	[antigen-induced airway hyperresponsiveness]	0.0	3	1	1	1
123534	1710	decrease to subsequent addition	[decrease to subsequent addition]	0.0	4	1	1	1
123535	1710	understanding of the consequence	[understanding of the consequences]	0.0	4	1	1	1
123536	1710	unit-granulocyte-macrophage progenitor cell	[unit-granulocyte-macrophage progenitor cells]	0.0	3	1	1	1
123537	1710	pluripotent islet culture	[pluripotent islet cultures]	0.0	3	1	1	1
123538	1710	extend to -177 bp relative	[extending to -177 bp relative]	0.0	5	1	1	1
123539	1710	motif in the enhancer	[motifs in the enhancers]	0.0	4	1	1	1
123540	1710	meta(d+) binding	[META(D+) binding]	0.0	2	1	1	1
123541	1710	expression of human pcd/dcoh	[expression of human PCD/DCoH]	0.0	4	1	1	1
123542	1710	class expression,	[class expression,]	0.0	2	1	1	1
123543	1710	protein (c/ebp)	[protein (C/EBP)]	0.0	2	1	1	1
123544	1710	anti-CD3-activated peripheral T lymphocyte	[anti-CD3-activated peripheral T lymphocytes]	0.0	4	1	1	1
123545	1710	emergence of mutant	[emergence of mutants]	0.0	3	1	1	1
123546	1710	300-bp core promoter	[300-bp core promoter]	0.0	3	1	1	1
123547	1710	demonstration in vivo	[demonstration in vivo]	0.0	3	1	1	1
123548	1710	anti-hapten ab fragment	[anti-hapten Ab fragment]	0.0	3	1	1	1
123549	1710	Epstein-Barr virus protein BZLF1	[Epstein-Barr virus protein BZLF1]	0.0	4	1	1	1
123550	1710	human bone marrow culture	[human bone marrow cultures]	0.0	4	1	1	1
123551	1710	sequence include 3 kb	[sequence including 3 kb]	0.0	4	1	1	1
123552	1710	child with fatal infection	[children with fatal infection]	0.0	4	2	2	1
123553	1710	T lymphoblastic	[T lymphoblastic]	0.0	2	1	1	1
123554	1710	interaction with distinct sequence-specific protein	[interaction with distinct sequence-specific proteins]	0.0	5	1	1	1
123555	1710	stat5 isoform	[STAT5 isoforms]	0.0	2	1	1	1
123556	1710	expression of many protein	[expression of many proteins]	0.0	4	1	1	1
123557	1710	specific regulation in T cell	[specific regulation in T cells]	0.0	5	1	1	1
123558	1710	change present in all case	[change present in all cases]	0.0	5	1	1	1
123559	1710	h1-antagonist	[H1-antagonists]	0.0	1	1	1	1
123560	1710	short-term (st;	[short-term (ST;]	0.0	2	1	1	1
123561	1710	cloning by AU-motif-directed display	[Cloning by AU-motif-directed display]	0.0	4	1	1	1
123562	1710	AU-rich element AREs	[AU-rich elements AREs]	0.0	3	1	1	1
123563	1710	ubiquitin carrier enzyme	[ubiquitin carrier enzymes]	0.0	3	1	1	1
123564	1710	element important for lymphoid-specific expression	[element important for lymphoid-specific expression]	0.0	5	1	1	1
123565	1710	decrease in helicase	[decrease in helicase]	0.0	3	1	1	1
123566	1710	sr 31747a binding	[SR 31747A binding]	0.0	3	1	1	1
123567	1710	sex differentiation	[sex differentiation]	0.0	2	1	1	1
123568	1710	ubiquitous component within minute	[ubiquitous component within min]	0.0	4	1	1	1
123569	1710	MHC thymocyte	[MHC thymocytes]	0.0	2	1	1	1
123570	1710	mechanism signal	[mechanisms signaling]	0.0	2	1	1	1
123571	1710	interleukin receptor il-1r superfamily	[interleukin receptor IL-1R superfamily]	0.0	4	1	1	1
123572	1710	peptide vaccine against tumor	[peptide vaccines against tumors]	0.0	4	1	1	1
123573	1710	large amount of information	[large amount of information]	0.0	4	1	1	1
123574	1710	inhibitor of signal pathway	[inhibitors of signaling pathways]	0.0	4	1	1	1
123575	1710	colony-stimumulatelany-stg factor macrophage colony-stimulating factor	[colony-stimulating factor macrophage colony-stimulating factor]	0.0	5	1	1	1
123576	1710	normal development; addition of RA	[normal development; addition of RA]	0.0	5	1	1	1
123577	1710	intracellular receptor belong	[intracellular receptor belonging]	0.0	3	1	1	1
123578	1710	kb of the 5' sequence	[kb of the 5' sequence]	0.0	5	1	1	1
123579	1710	surround the gene	[surrounding the genes]	0.0	3	1	1	1
123580	1710	contrast, lymphoblastoid cell line	[contrast, lymphoblastoid cell lines]	0.0	4	1	1	1
123581	1710	almost exclusive bind selectivity	[almost exclusive binding selectivity]	0.0	4	1	1	1
123582	1710	granulocyte factor colony-stimumulatelany-stg factor	[granulocyte factor colony-stimulating factor]	0.0	4	1	1	1
123583	1710	various chemokine	[various chemokines]	0.0	2	1	1	1
123584	1710	determine the efficiency	[determining the efficiency]	0.0	3	1	1	1
123585	1710	1 expression in monocytes: role	[1 expression in monocytes: role]	0.0	5	1	1	1
123586	1710	expression of gamma-interferon protein ip-10	[Expression of gamma-interferon protein IP-10]	0.0	5	1	1	1
123587	1710	immunoglobulin heavy chain igh enhancer	[immunoglobulin heavy chain IgH enhancer]	0.0	5	1	1	1
123588	1710	functional context	[functional context]	0.0	2	1	1	1
123589	1710	suggest a direct transcriptional effect	[suggesting a direct transcriptional effect]	0.0	5	1	1	1
123590	1710	24 h stimulation	[24 h stimulation]	0.0	3	1	1	1
123591	1710	fragment acid 1-180)	[fragment acids 1-180)]	0.0	3	1	1	1
123592	1710	appropriate switch region	[appropriate switch region]	0.0	3	1	1	1
123593	1710	polyclonal pattern by humara analysis	[polyclonal pattern by HUMARA analysis]	0.0	5	1	1	1
123594	1710	human bone marrow ec	[human bone marrow EC]	0.0	4	1	1	1
123595	1710	persistence over a 2-yr period.	[persistence over a 2-yr period.]	0.0	5	1	1	1
123596	1710	cytokine tumor necrosis factor	[cytokine tumor necrosis factor]	0.0	4	1	1	1
123597	1710	decrease the vmax	[decreasing the Vmax]	0.0	3	1	1	1
123598	1710	cooperativity in the estrogenic response	[cooperativity in the estrogenic response]	0.0	5	1	1	1
123599	1710	improve the definition	[improving the definitions]	0.0	3	1	1	1
123600	1710	component of signal transduction	[components of signal transduction]	0.0	4	1	1	1
123601	1710	dose of t3 mol/L).	[dose of T3 mol/L).]	0.0	4	1	1	1
123602	1710	simultaneous activation of messenger	[simultaneous activation of messengers]	0.0	4	1	1	1
123603	1710	period in patient	[period in patients]	0.0	3	1	1	1
123604	1710	assay in asthmatics	[assay in asthmatics]	0.0	3	1	1	1
123605	1710	protective cellular	[protective cellular]	0.0	2	1	1	1
123606	1710	specific marker for promyelocytic leukemia	[specific marker for promyelocytic leukemia]	0.0	5	1	1	1
123607	1710	presence in cis,	[presence in cis,]	0.0	3	1	1	1
123608	1710	various cell	[various cells]	0.0	2	1	1	1
123609	1710	separation by time	[separation by time]	0.0	3	1	1	1
123610	1710	single hmg box related	[single HMG box related]	0.0	4	1	1	1
123611	1710	different role in cell type	[different roles in cell types]	0.0	5	1	1	1
123612	1710	blood cell proliferation	[blood cell proliferation]	0.0	3	1	1	1
123613	1710	NF-kappa b in extract	[NF-kappa B in extracts]	0.0	4	1	1	1
123614	1710	asthma patient with expiratory volume 70%	[asthma patients with expiratory volume 70%]	0.0	6	1	1	1
123615	1710	affinity (Kd) in term	[affinity (Kd) in term]	0.0	4	1	1	1
123616	1710	substitution of Arg551	[substitution of Arg551]	0.0	3	1	1	1
123617	1710	regulation by second messenger	[Regulation by second messengers]	0.0	4	1	1	1
123618	1710	regulator factor-kappaB	[regulator factor-kappaB]	0.0	2	1	1	1
123619	1710	Comparison as inducer of monocytic differentiation	[Comparison as inducers of monocytic differentiation]	0.0	6	1	1	1
123620	1710	quantification lack of correspondence with variant	[Quantification lack of correspondence with variants]	0.0	6	1	1	1
123621	1710	homolog of chicken nf-m c/ebp-beta	[homolog of chicken NF-M C/EBP-beta]	0.0	5	1	1	1
123622	1710	adult cell polypryrimidine-binding factor pybf	[adult cells polypryrimidine-binding factor PYBF]	0.0	5	1	1	1
123623	1710	gamma(c)-positive,	[gamma(c)-positive,]	0.0	1	1	1	1
123624	1710	molecule include Syk	[molecules including Syk]	0.0	3	1	1	1
123625	1710	native terminal repeat proviruse	[native terminal repeat proviruses]	0.0	4	1	1	1
123626	1710	effect of hydrocortisone	[effect of hydrocortisone]	0.0	3	1	1	1
123627	1710	hla-dq evolution	[HLA-DQ evolution]	0.0	2	1	1	1
123628	1710	normal tgf-beta receptor profile	[normal TGF-beta receptor profile]	0.0	4	1	1	1
123629	1710	A-CRF with renal insufficiency M-CRF	[A-CRF with renal insufficiency M-CRF]	0.0	5	1	1	1
123630	1710	part dependent	[part dependent]	0.0	2	2	2	1
123631	1710	notably phospholipase c	[notably phospholipase C]	0.0	3	1	1	1
123632	1710	protein- e2f	[protein- E2F]	0.0	2	1	1	1
123633	1710	key functional role	[key functional role]	0.0	3	1	1	1
123634	1710	even after hour of treatment.	[even after hr of treatment.]	0.0	5	1	1	1
123635	1710	anti-cd3epsilon mab okt3	[anti-CD3epsilon mAb OKT3]	0.0	3	1	1	1
123636	1710	appropriate inducers.	[appropriate inducers.]	0.0	2	1	1	1
123637	1710	family acid receptor	[families acid receptors]	0.0	3	1	1	1
123638	1710	involvement in the regulation of transcription	[Involvement in the regulation of transcription]	0.0	6	1	1	1
123639	1710	only low level of expression	[only low levels of expression]	0.0	5	1	1	1
123640	1710	ap-2 activation	[AP-2 activation]	0.0	2	1	1	1
123641	1710	evidence for the first time	[evidence for the first time]	0.0	5	1	1	1
123642	1710	distinct receptor	[distinct receptors]	0.0	2	1	1	1
123643	1710	human immunodeficiency virus type factor Nef	[Human immunodeficiency virus type factor Nef]	0.0	6	1	1	1
123644	1710	concentration of 0.2 ng/ml	[concentration of 0.2 ng/ml]	0.0	4	1	1	1
123645	1710	necessarily include CD28 signaling.	[necessarily including CD28 signaling.]	0.0	4	1	1	1
123646	1710	experience	[experiences]	0.0	1	1	1	1
123647	1710	majority of cell-specific gene	[majority of cell-specific genes]	0.0	4	1	1	1
123648	1710	75-kDa signal protein	[75-kDa signaling protein]	0.0	3	1	1	1
123649	1710	survival rate of animal	[survival rate of animals]	0.0	4	1	1	1
123650	1710	determine the ultimate outcome	[determining the ultimate outcome]	0.0	4	1	1	1
123651	1710	regulation expression in monocytes: role	[regulation expression in monocytes: role]	0.0	5	1	1	1
123652	1710	IARC T cell	[IARC T cells]	0.0	3	1	1	1
123653	1710	investigation as a therapy	[investigation as a therapy]	0.0	4	1	1	1
123654	1710	IL2 enhancer region (segment	[IL2 enhancer region (segments]	0.0	4	1	1	1
123655	1710	cd14 -dependent activation	[CD14 -dependent activation]	0.0	3	1	1	1
123656	1710	activity of stat4 -contain complex	[activity of STAT4 -containing complexes]	0.0	5	1	1	1
123657	1710	variety kappa b alpha	[variety kappa B alpha]	0.0	4	1	1	1
123658	1710	increase in th1 cell	[increase in Th1 cells]	0.0	4	1	1	1
123659	1710	contain promoter element	[containing promoter element]	0.0	3	1	1	1
123660	1710	consequence as	[consequence as]	0.0	2	1	1	1
123661	1710	NF-kappaB a key regulator of response	[NF-kappaB a key regulator of responses]	0.0	6	1	1	1
123662	1710	zinc finger at the carboxyl-terminus	[zinc fingers at the carboxyl-terminus]	0.0	5	1	1	1
123663	1710	lymphocyte from healthy woman	[lymphocytes from healthy women]	0.0	4	1	1	1
123664	1710	increase in g0s2 mrna peak	[increase in G0S2 mRNA peaking]	0.0	5	1	1	1
123665	1710	mutate at the carboxyl end	[mutating at the carboxyl end]	0.0	5	1	1	1
123666	1710	proliferative deficiency	[proliferative deficiency]	0.0	2	1	1	1
123667	1710	relief	[Relief]	0.0	1	1	1	1
123668	1710	level for chemotactic protein-1 another member	[levels for chemotactic protein-1 another member]	0.0	6	1	1	1
123669	1710	use pd-98059 inhibitor of MEK1	[using PD-98059 inhibitors of MEK1]	0.0	5	1	1	1
123670	1710	hierarchical structure	[hierarchical structure]	0.0	2	1	1	1
123671	1710	join recombination event	[joining recombination events]	0.0	3	1	1	1
123672	1710	only a induction	[only a induction]	0.0	3	1	1	1
123673	1710	immunoglobulin heavy- chain gene	[immunoglobulin heavy- chain genes]	0.0	4	1	1	1
123674	1710	repeat of consecutive glutamine residue	[repeat of consecutive glutamine residues]	0.0	5	1	1	1
123675	1710	addition of rbpi21	[addition of rBPI21]	0.0	3	1	1	1
123676	1710	less extent, adhesion molecule-1	[lesser extent, adhesion molecule-1]	0.0	4	1	1	1
123677	1710	hyperproduction of interleukin	[hyperproduction of interleukin]	0.0	3	1	1	1
123678	1710	distinct element act somewhat independently	[distinct elements acting somewhat independently]	0.0	5	1	1	1
123679	1710	downregulation during differentiation	[downregulation during differentiation]	0.0	3	1	1	1
123680	1710	expression by T helper 1 cell	[expression by T helper 1 cells]	0.0	6	1	1	1
123681	1710	/Syk	[/Syk]	0.0	1	1	1	1
123682	1710	chemoattractant cytokine chemokine important	[chemoattractant cytokine chemokine important]	0.0	4	1	1	1
123683	1710	disease-susceptible rhesus macaque	[disease-susceptible rhesus macaques]	0.0	3	1	1	1
123684	1710	281 pmol/L; in pregnant woman	[281 pmol/L; in pregnant women]	0.0	5	1	1	1
123685	1710	interpretation a primary response	[interpretation a primary response]	0.0	4	1	1	1
123686	1710	octamer-binding transcription	[octamer-binding transcription]	0.0	2	1	1	1
123687	1710	proliferation iddm subject	[proliferation IDDM subjects]	0.0	3	1	1	1
123688	1710	temperature, beta 2-microglobulin	[temperature, beta 2-microglobulin]	0.0	3	1	1	1
123689	1710	invariant-chain	[invariant-chain]	0.0	1	1	1	1
123690	1710	lh-2	[LH-2]	0.0	1	1	1	1
123691	1710	two cDNA sequence Nov1	[two cDNA sequences Nov1]	0.0	4	1	1	1
123692	1710	inhibitory protein NIP	[inhibitory protein NIP]	0.0	3	1	1	1
123693	1710	protein complex a ubiquitous factor	[protein complexes a ubiquitous factor]	0.0	5	1	1	1
123694	1710	18 case	[18 cases]	0.0	2	1	1	1
123695	1710	isolate false-positive dest	[isolating false-positive DESTs]	0.0	3	1	1	1
123696	1710	DNA band-shift	[DNA band-shift]	0.0	2	1	1	1
123697	1710	use peptide assay	[using peptide assays]	0.0	3	1	1	1
123698	1710	fragment contain sequence from gene	[fragments containing sequences from genes]	0.0	5	1	1	1
123699	1710	tre-like camp response element	[TRE-like cAMP response elements]	0.0	4	1	1	1
123700	1710	elderly adult	[elderly adults]	0.0	2	1	1	1
123701	1710	non-polyadenylated rna	[non-polyadenylated RNAs]	0.0	2	1	1	1
123702	1710	expression on melanoma	[expression on melanomas]	0.0	3	1	1	1
123703	1710	however, latent,	[However, latent,]	0.0	2	1	1	1
123704	1710	use antibody mab	[using antibodies mAb]	0.0	3	2	2	1
123705	1710	group of response	[group of responses]	0.0	3	1	1	1
123706	1710	Janus kinase family	[Janus kinase family]	0.0	3	1	1	1
123707	1710	involvement of type	[involvement of Type]	0.0	3	1	1	1
123708	1710	200 microgram fluticasone propionate spray	[200 micrograms fluticasone propionate spray]	0.0	5	1	1	1
123709	1710	property indistinguishable	[properties indistinguishable]	0.0	2	1	1	1
123710	1710	minute of reoxygenation	[minutes of reoxygenation]	0.0	3	1	1	1
123711	1710	other systems,	[other systems,]	0.0	2	1	1	1
123712	1710	regulate gene expression in t-cell	[regulating gene expression in T-cells]	0.0	5	1	1	1
123713	1710	restimulation of th2 line	[restimulation of Th2 lines]	0.0	4	1	1	1
123714	1710	2000 mu/l pharmacological concentration insulin	[2,000 mU/L pharmacological concentration insulin]	0.0	5	1	1	1
123715	1710	chain expression	[chain expression]	0.0	2	1	1	1
123716	1710	prevention of translocation	[prevention of translocation]	0.0	3	1	1	1
123717	1710	analysis of 5'-flanking region	[analysis of 5'-flanking region]	0.0	4	1	1	1
123718	1710	region (position -69 to -220)	[region (positions -69 to -220)]	0.0	5	1	1	1
123719	1710	exposure to nm	[exposure to nM]	0.0	3	1	1	1
123720	1710	-605 motif	[-605 motif]	0.0	2	1	1	1
123721	1710	16 (50%) ica-positive relative	[16 (50%) ICA-positive relatives]	0.0	4	1	1	1
123722	1710	1 (hiv-1) therapy	[1 (HIV-1) therapy]	0.0	3	1	1	1
123723	1710	certain number	[certain number]	0.0	2	1	1	1
123724	1710	form substitute	[form substitutes]	0.0	2	1	1	1
123725	1710	role of b-cell-specific activator protein	[role of B-cell-specific activator protein]	0.0	5	1	1	1
123726	1710	signal through sigm	[signals through sIgM]	0.0	3	1	1	1
123727	1710	glucocorticoid in leukocyte	[glucocorticoids in leukocytes]	0.0	3	1	1	1
123728	1710	increase in steady state level	[increase in steady state levels]	0.0	5	1	1	1
123729	1710	excellent correlation	[excellent correlation]	0.0	2	1	1	1
123730	1710	-myh11 positive, 1	[-MYH11 positive, 1]	0.0	3	1	1	1
123731	1710	contribution to the phenotype	[contribution to the phenotype]	0.0	4	1	1	1
123732	1710	competition between two general activator	[competition between two general activators]	0.0	5	1	1	1
123733	1710	strike similarity	[striking similarity]	0.0	2	1	1	1
123734	1710	correlation of effector cell function	[correlation of effector cell function]	0.0	5	1	1	1
123735	1710	36 h in medium	[36 h in medium]	0.0	4	1	1	1
123736	1710	67-kDa precursor protein	[67-kDa precursor protein]	0.0	3	1	1	1
123737	1710	various database	[various databases]	0.0	2	1	1	1
123738	1710	receptor ppar	[receptor PPAR]	0.0	2	1	1	1
123739	1710	span 45 kb	[spanning 45 kb]	0.0	3	1	1	1
123740	1710	high concentration of antioxidant --including acid	[higher concentrations of antioxidants --including acid]	0.0	6	1	1	1
123741	1710	theoretical possibility	[theoretical possibility]	0.0	2	1	1	1
123742	1710	case-control study of major disease	[case-control studies of major diseases]	0.0	5	1	1	1
123743	1710	TRAF aggregation	[TRAF aggregation]	0.0	2	1	1	1
123744	1710	two distinct pathway of synthesis	[Two distinct pathways of synthesis]	0.0	5	1	1	1
123745	1710	signal transmission pathway in T lymphocyte	[signal transmission pathways in T lymphocytes]	0.0	6	1	1	1
123746	1710	1 minute of stimulation	[1 min of stimulation]	0.0	4	1	1	1
123747	1710	activation of c-Jun	[activation of c-Jun]	0.0	3	1	1	1
123748	1710	iL1-induced activity	[IL1-induced activity]	0.0	2	1	1	1
123749	1710	control mouse (94.4%)	[control mice (94.4%)]	0.0	3	1	1	1
123750	1710	EVI1 gene,	[EVI1 gene,]	0.0	2	1	1	1
123751	1710	association of terminus ct	[association of terminus CT]	0.0	4	1	1	1
123752	1710	again suggest lack of (a) factor	[again suggesting lack of (a) factor]	0.0	6	1	1	1
123753	1710	effect on nuclear factor-kappaB regulation	[effects on nuclear factor-kappaB regulation]	0.0	5	1	1	1
123754	1710	acute myelogenous leukemia respectively,	[acute myelogenous leukemia respectively,]	0.0	4	1	1	1
123755	1710	blood healthy volunteer	[blood healthy volunteers]	0.0	3	1	1	1
123756	1710	exposure to sf	[Exposure to SFs]	0.0	3	1	1	1
123757	1710	unknown mineralocorticoid may,	[unknown mineralocorticoid may,]	0.0	3	1	1	1
123758	1710	effect through binding	[effects through binding]	0.0	3	1	1	1
123759	1710	chronic exposure	[chronic exposure]	0.0	2	1	1	1
123760	1710	metastatic tumor	[metastatic tumors]	0.0	2	1	1	1
123761	1710	control of host factor	[control of host factors]	0.0	4	1	1	1
123762	1710	activation 2 globin promoter role	[activation 2 globin promoter role]	0.0	5	1	1	1
123763	1710	expression of a pkb	[expression of an PKB]	0.0	4	1	1	1
123764	1710	activity (nf)-kappab	[activity (NF)-kappaB]	0.0	2	1	1	1
123765	1710	activity (colony formation	[activity (colony formation]	0.0	3	1	1	1
123766	1710	preassociation in signalling complex	[Preassociation in signalling complexes]	0.0	4	1	1	1
123767	1710	contain fetal bovine serum	[containing fetal bovine serum]	0.0	4	1	1	1
123768	1710	class molecule through the system	[class molecules through the system]	0.0	5	1	1	1
123769	1710	arm of chromosome (Chr)	[arm of Chromosome (Chr)]	0.0	4	1	1	1
123770	1710	use a consensus b oligonucleotide	[using a consensus B oligonucleotide]	0.0	5	1	1	1
123771	1710	uptake in pbmc of woman	[uptake in PBMC of women]	0.0	5	1	1	1
123772	1710	METHODS: case	[METHODS: cases]	0.0	2	1	1	1
123773	1710	z-vad-fmk	[Z-VAD-fmk]	0.0	1	1	1	1
123774	1710	negative regulatory effect	[negative regulatory effect]	0.0	3	1	1	1
123775	1710	ppargamma differentiation-dependent receptor gamma expression	[PPARgamma differentiation-dependent receptor gamma expression]	0.0	5	1	1	1
123776	1710	other member of the family,	[other members of the family,]	0.0	5	1	1	1
123777	1710	ebv b-cell line	[EBV B-cell lines]	0.0	3	1	1	1
123778	1710	ester-inducible element	[ester-inducible element]	0.0	2	1	1	1
123779	1710	t-derived cell	[T-derived cells]	0.0	2	1	1	1
123780	1710	concentration range from mmol/L.	[concentrations ranging from mmol/L.]	0.0	4	1	1	1
123781	1710	collagenase mmp-1	[collagenase MMP-1]	0.0	2	1	1	1
123782	1710	property of CsA in cell	[properties of CsA in cells]	0.0	5	1	1	1
123783	1710	control activity	[control activity]	0.0	2	1	1	1
123784	1710	independent interaction with p100	[independent interaction with p100]	0.0	4	1	1	1
123785	1710	vivo occupancy	[vivo occupancy]	0.0	2	1	1	1
123786	1710	GR element GRE	[GR element GRE]	0.0	3	1	1	1
123787	1710	steroid-sensitive patient	[steroid-sensitive patients]	0.0	2	1	1	1
123788	1710	kb of genomic DNA	[kb of genomic DNA]	0.0	4	1	1	1
123789	1710	correlation with the sba	[correlation with the SBA]	0.0	4	1	1	1
123790	1710	tad-a activity,	[TAD-A activity,]	0.0	2	1	1	1
123791	1710	1 microm RU	[1 microM RU]	0.0	3	1	1	1
123792	1710	gamma-ifn of action	[gamma-IFN of action]	0.0	3	1	1	1
123793	1710	pmn neutrophil granulocyte	[PMN neutrophil granulocytes]	0.0	3	1	1	1
123794	1710	parameter restoration of content lymphocyte	[parameters restoration of content lymphocytes]	0.0	5	1	1	1
123795	1710	lead to adhesion of monocytic cell	[leading to adhesion of monocytic cells]	0.0	6	1	1	1
123796	1710	analysis of the human ICAM-1 promoter	[analysis of the human ICAM-1 promoter]	0.0	6	1	1	1
123797	1710	nf-kappa benefit	[NF-kappa b]	0.0	2	1	1	1
123798	1710	97 young (18- volunteer	[97 young (18- volunteers]	0.0	4	1	1	1
123799	1710	activation-dependent expression of protein	[activation-dependent expression of proteins]	0.0	4	1	1	1
123800	1710	expression of only the exon	[expression of only the exon]	0.0	5	1	1	1
123801	1710	breast cancer reactive cellular cytotoxicity	[breast cancer reactive cellular cytotoxicity]	0.0	5	1	1	1
123802	1710	centroblast	[centroblasts]	0.0	1	1	1	1
123803	1710	CD28 and/or CD2	[CD28 and/or CD2]	0.0	3	1	1	1
123804	1710	harbor the C-terminal part	[harboring the C-terminal part]	0.0	4	1	1	1
123805	1710	pafr transcript tissue-type	[PAFR transcript tissue-type]	0.0	3	1	1	1
123806	1710	characterization of additional cis-acting element	[characterization of additional cis-acting elements]	0.0	5	1	1	1
123807	1710	short amino-	[short amino-]	0.0	2	1	1	1
123808	1710	nordihydroguaiaretic	[nordihydroguaiaretic]	0.0	1	1	1	1
123809	1710	hormone erythropoietin	[hormone erythropoietin]	0.0	2	1	1	1
123810	1710	progesterone receptor hpr cDNA probe	[progesterone receptor hPR cDNA probe]	0.0	5	1	1	1
123811	1710	heterodimerization with retinoid x receptor	[heterodimerization with Retinoid X Receptors]	0.0	5	1	1	1
123812	1710	dose mm) of ethanol treatment	[dose mM) of ethanol treatment]	0.0	5	1	1	1
123813	1710	novel, sequence variant	[novel, sequence variants]	0.0	3	1	1	1
123814	1710	RhoA mutant	[RhoA mutant]	0.0	2	1	1	1
123815	1710	bind affinity (Kd) in term	[binding affinity (Kd) in term]	0.0	5	1	1	1
123816	1710	intestinal epithelial cell response	[intestinal epithelial cell responses]	0.0	4	1	1	1
123817	1710	range of signal pathway	[range of signaling pathways]	0.0	4	1	1	1
123818	1710	anti-Class	[anti-Class]	0.0	1	1	1	1
123819	1710	level of hladq	[levels of HLADQ]	0.0	3	1	1	1
123820	1710	accumulation of IkappaB-alpha mrna transcript	[accumulation of IkappaB-alpha mRNA transcripts]	0.0	5	1	1	1
123821	1710	viral interference	[viral interference]	0.0	2	1	1	1
123822	1710	binding of isgf3 gene factor	[binding of ISGF3 gene factor]	0.0	5	1	1	1
123823	1710	vivo exposure to ifn-alpha	[vivo exposure to IFN-alpha]	0.0	4	1	1	1
123824	1710	mutation in the gas element	[mutations in the GAS element]	0.0	5	1	1	1
123825	1710	megakaryocytic gene expression	[megakaryocytic gene expression]	0.0	3	1	1	1
123826	1710	endothelial cell in hypoxia	[endothelial cells in hypoxia]	0.0	4	1	1	1
123827	1710	action between a element at -21/-1	[action between an element at -21/-12,]	0.0	6	1	1	1
123828	1710	activation of functionally distinct stat5 protein	[activation of functionally distinct STAT5 proteins]	0.0	6	1	1	1
123829	1710	mammalian response to ultra-violet irradiation	[mammalian responses to UV irradiation]	0.0	5	1	1	1
123830	1710	transactivator zebra	[transactivator ZEBRA]	0.0	2	1	1	1
123831	1710	multiple lytic reactivity at level	[multiple lytic reactivities at levels]	0.0	5	1	1	1
123832	1710	support property	[supporting properties]	0.0	2	1	1	1
123833	1710	nf-kappab -dependent in contrast	[NF-kappaB -dependent in contrast]	0.0	4	1	1	1
123834	1710	molecular mechanism of regulation	[molecular mechanism of regulation]	0.0	4	1	1	1
123835	1710	antioxidant n-acetyl-l-cysteine nac	[antioxidant N-acetyl-L-cysteine NAC]	0.0	3	1	1	1
123836	1710	symmetry element dse	[symmetry element DSE]	0.0	3	1	1	1
123837	1710	rest normal lymphocyte from blood	[resting normal lymphocytes from blood]	0.0	5	1	1	1
123838	1710	interaction with distinct protein	[interaction with distinct proteins]	0.0	4	1	1	1
123839	1710	terminal insert	[terminal insert]	0.0	2	1	1	1
123840	1710	antigen in vitro	[antigens in vitro]	0.0	3	1	1	1
123841	1710	opposite glucocorticoid receptor changes, oppose	[opposite glucocorticoid receptor changes, opposing]	0.0	5	1	1	1
123842	1710	reporter gene triangle uplngfr EGFP	[reporter genes triangle upLNGFR EGFP]	0.0	5	1	1	1
123843	1710	defect in x-linked hypophosphatemic ricket	[defect in X-linked hypophosphatemic rickets]	0.0	5	1	1	1
123844	1710	growth of human leukemia cell	[growth of human leukemia cells]	0.0	5	1	1	1
123845	1710	show a effect	[showing a effect]	0.0	3	1	1	1
123846	1710	2) fibrinogen	[2) fibrinogen]	0.0	2	1	1	1
123847	1710	physiologic role of 135(oh)2d3 receptor	[physiologic role of 1,25(OH)2D3 receptors]	0.0	5	1	1	1
123848	1710	other RAR ligand	[other RAR ligands]	0.0	3	1	1	1
123849	1710	sequence of the gene	[sequence of the gene]	0.0	4	1	1	1
123850	1710	Mac 6	[Mac 6]	0.0	2	1	1	1
123851	1710	family of molecule	[family of molecules]	0.0	3	1	1	1
123852	1710	neutrophil interleukin-8 production	[neutrophil interleukin-8 production]	0.0	3	1	1	1
123853	1710	5'-positive unit	[5'-positive unit]	0.0	2	1	1	1
123854	1710	kinetic in T	[kinetics in T]	0.0	3	1	1	1
123855	1710	MHC class ii mrna expression	[MHC class II mRNA expression]	0.0	5	1	1	1
123856	1710	antigen EBNAs	[antigen EBNAs]	0.0	2	2	2	1
123857	1710	synergistic action between a element CPRE	[synergistic action between an element CPRE]	0.0	6	1	1	1
123858	1710	hyperactivity of the stress system	[hyperactivity of the stress system]	0.0	5	1	1	1
123859	1710	DNA accessibility to restriction enzyme	[DNA accessibility to restriction enzymes]	0.0	5	1	1	1
123860	1710	101pp dnase site-forming element HSFE	[101bp, DNase site-forming element HSFE]	0.0	5	1	1	1
123861	1710	human ptf	[human PTF]	0.0	2	1	1	1
123862	1710	Duffy polymorphic antigen Fya	[Duffy polymorphic antigens Fya]	0.0	4	1	1	1
123863	1710	varicella vaccine	[varicella vaccine]	0.0	2	1	1	1
123864	1710	protein-tyrosine kinase	[protein-tyrosine kinase]	0.0	2	1	1	1
123865	1710	adhesion protein	[adhesion proteins]	0.0	2	1	1	1
123866	1710	proliferation of type of cell line	[proliferation of types of cell lines]	0.0	6	1	1	1
123867	1710	lymphocytic leukemia cell	[lymphocytic leukemia cells]	0.0	3	1	1	1
123868	1710	activation of stat1 protein start	[activation of STAT1 protein starting]	0.0	5	1	1	1
123869	1710	pseudohypoaldosteronism in eight different form	[Pseudohypoaldosteronism in eight different forms]	0.0	5	1	1	1
123870	1710	marker expression in blast	[markers expression in blasts]	0.0	4	1	1	1
123871	1710	pcl gamma	[PCL gamma]	0.0	2	1	1	1
123872	1710	splicing of a primary transcript	[splicing of a primary transcript]	0.0	5	1	1	1
123873	1710	transcriptional regulatory sequence	[transcriptional regulatory sequences]	0.0	3	1	1	1
123874	1710	local modulation by mechanism	[local modulation by mechanisms]	0.0	4	1	1	1
123875	1710	TRAF6 interaction domain	[TRAF6 interaction domain]	0.0	3	1	1	1
123876	1710	chain-breaking	[chain-breaking]	0.0	1	1	1	1
123877	1710	effect of androgen on cell	[effects of androgens on cells]	0.0	5	1	1	1
123878	1710	196 base pair region	[196 base pair region]	0.0	4	1	1	1
123879	1710	and/or modification	[and/or modification]	0.0	2	2	2	1
123880	1710	use a assay as the ligand.	[using a assay as the ligand.]	0.0	6	1	1	1
123881	1710	expression of reporter gata-1/lacz gene	[expression of reporter GATA-1/lacZ genes]	0.0	5	1	1	1
123882	1710	Glucocorticoid receptor on mononuclear leukocyte	[Glucocorticoid receptors on mononuclear leukocytes]	0.0	5	2	2	1
123883	1710	suggest great	[suggesting greater]	0.0	2	1	1	1
123884	1710	similar maximal increase in c-fo	[similar maximal increases in c-fos]	0.0	5	1	1	1
123885	1710	high translocation	[higher translocation]	0.0	2	1	1	1
123886	1710	gene transactivation	[gene transactivation]	0.0	2	1	1	1
123887	1710	aspect of v-Abl signal	[aspects of v-Abl signaling]	0.0	4	1	1	1
123888	1710	androgen receptor gene Humara	[androgen receptor gene Humara]	0.0	4	1	1	1
123889	1710	nuclear marker	[nuclear marker]	0.0	2	1	1	1
123890	1710	several site originate bp upstream	[several sites originating bp upstream]	0.0	5	1	1	1
123891	1710	analysis use a mutant stock	[analysis using a mutant stock]	0.0	5	1	1	1
123892	1710	viable alternative	[viable alternatives]	0.0	2	1	1	1
123893	1710	proximal CD19 promoter	[proximal CD19 promoter]	0.0	3	1	1	1
123894	1710	explore the molecular pathogenesis	[exploring the molecular pathogenesis]	0.0	4	1	1	1
123895	1710	DRE -binding protein, p37	[DRE -binding protein, p37]	0.0	4	1	1	1
123896	1710	putative regulatory sites.	[putative regulatory sites.]	0.0	3	1	1	1
123897	1710	T lymphocyte during aging.	[T lymphocytes during aging.]	0.0	4	1	1	1
123898	1710	synthesis of ig mrna	[synthesis of Ig mRNA]	0.0	4	1	1	1
123899	1710	regulator of numerous cellular gene	[regulators of numerous cellular genes]	0.0	5	1	1	1
123900	1710	stress on transcriptional activity	[stress on transcriptional activities]	0.0	4	1	1	1
123901	1710	minute pha stimulation,	[min PHA stimulation,]	0.0	3	1	1	1
123902	1710	development of erythrocytes.	[development of erythrocytes.]	0.0	3	1	1	1
123903	1710	h2o2 scavenger	[H2O2 scavenger]	0.0	2	1	1	1
123904	1710	cross-priming	[Cross-priming]	0.0	1	2	2	1
123905	1710	initial proliferation	[initial proliferation]	0.0	2	1	1	1
123906	1710	proximal cis-acting element	[proximal cis-acting elements]	0.0	3	1	1	1
123907	1710	90% suppression sla-dr	[90% suppression SLA-DR]	0.0	3	1	1	1
123908	1710	(start at 532, 710,	[(starting at 532, 710,]	0.0	4	1	1	1
123909	1710	follow such alteration	[following such alterations]	0.0	3	1	1	1
123910	1710	level of cell adhesion molecule vcam-1	[levels of cell adhesion molecule VCAM-1]	0.0	6	1	1	1
123911	1710	factor enf)-kappa b	[factor (NF)-kappa B]	0.0	3	1	1	1
123912	1710	serum level of cortisol	[serum levels of cortisol]	0.0	4	1	1	1
123913	1710	39 kilometer	[39 kd]	0.0	2	1	1	1
123914	1710	(range, 4-.11), (range, 5.86-6.74) nm,	[(range, 4-5.13), (range, 5.86-6.74) nM,]	0.0	5	1	1	1
123915	1710	future therapeutic strategy	[future therapeutic strategies]	0.0	3	1	1	1
123916	1710	cell)	[cell)]	0.0	1	1	1	1
123917	1710	domain of homologous member	[domains of homologous members]	0.0	4	1	1	1
123918	1710	micrograms/d)	[micrograms/d)]	0.0	1	1	1	1
123919	1710	recombinant human tnf receptor rhu tnfr:fc	[recombinant human TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
123920	1710	rheumatoid synovial	[rheumatoid synovial]	0.0	2	1	1	1
123921	1710	immunogenic protein	[immunogenic proteins]	0.0	2	1	1	1
123922	1710	deletion of sequence	[deletion of sequences]	0.0	3	1	1	1
123923	1710	cell;	[cell;]	0.0	1	1	1	1
123924	1710	dexamethasone a potent inhibitor	[dexamethasone a potent inhibitor]	0.0	4	1	1	1
123925	1710	origin of replication	[origin of replication]	0.0	3	1	1	1
123926	1710	competitive radioassay	[competitive radioassay]	0.0	2	1	1	1
123927	1710	level of hla-dra gene expression	[levels of HLA-DRA gene expression]	0.0	5	1	1	1
123928	1710	interleukin-5 a eosinophil-activating factor	[interleukin-5 a eosinophil-activating factor]	0.0	4	1	1	1
123929	1710	relationship in tonsil	[relationship in tonsils]	0.0	3	1	1	1
123930	1710	anti- zebra activity	[anti- ZEBRA activity]	0.0	3	1	1	1
123931	1710	also specific binding interaction	[also specific binding interactions]	0.0	4	1	1	1
123932	1710	5' two CCAAT sequence	[5' two CCAAT sequences]	0.0	4	1	1	1
123933	1710	general correlation	[general correlation]	0.0	2	1	1	1
123934	1710	transcriptional activation the initial gene promoter	[transcriptional activation the initial gene promoter]	0.0	6	1	1	1
123935	1710	transactivation by herpesvirus hhv-6 strain	[Transactivation by herpesvirus HHV-6 strains]	0.0	5	1	1	1
123936	1710	level of htr beta	[levels of hTR beta]	0.0	4	1	1	1
123937	1710	new dual cyclooxygenase/5-lipoxygenase anti-inflammatory compound	[new dual cyclooxygenase/5-lipoxygenase anti-inflammatory compound]	0.0	5	1	1	1
123938	1710	positive selection expansion) (by stimulation	[positive selection expansion) (by stimulation]	0.0	5	1	1	1
123939	1710	leukemia/B	[leukemia/B]	0.0	1	1	1	1
123940	1710	cell death specification protein	[cell death specification protein]	0.0	4	1	1	1
123941	1710	immunodeficiency virus type long repeat	[immunodeficiency virus type long repeats]	0.0	5	1	1	1
123942	1710	early gene in T cell	[early gene in T cells]	0.0	5	1	1	1
123943	1710	transcription-PCR analysis	[transcription-PCR analysis]	0.0	2	1	1	1
123944	1710	more monocytic phenotype	[more monocytic phenotype]	0.0	3	1	1	1
123945	1710	translocation of mitogen-activated protein kinase	[translocation of mitogen-activated protein kinase]	0.0	5	1	1	1
123946	1710	footprint in the region	[footprint in the region]	0.0	4	1	1	1
123947	1710	fibrosarcoma fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[fibrosarcoma fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
123948	1710	thymus lobule	[thymus lobules]	0.0	2	1	1	1
123949	1710	only (2%)	[only (2%)]	0.0	2	1	1	1
123950	1710	CD8+CD28null	[CD8+CD28null]	0.0	1	1	1	1
123951	1710	event downstream of ZAP-70	[events downstream of ZAP-70]	0.0	4	1	1	1
123952	1710	overexpression CN a protein phosphatase	[overexpression CN a protein phosphatase]	0.0	5	1	1	1
123953	1710	patient with ovary syndrome pco	[patients with ovary syndrome PCOS]	0.0	5	1	1	1
123954	1710	activator protein-1 ap-1 factor il-6 nf-il6	[activator protein-1 AP-1 factor IL-6 NF-IL6]	0.0	6	1	1	1
123955	1710	patient with myelopathy/tropical paraparesis	[patient with myelopathy/tropical paraparesis]	0.0	4	1	1	1
123956	1710	covariant analysis take age-related change	[covariant analysis taking age-related changes]	0.0	5	1	1	1
123957	1710	value of 0.91,	[value of 0.91,]	0.0	3	1	1	1
123958	1710	ciita activity	[CIITA activity]	0.0	2	2	2	1
123959	1710	Epstein-Barr virus oncoprotein	[Epstein-Barr virus oncoprotein]	0.0	3	1	1	1
123960	1710	several set	[several sets]	0.0	2	1	1	1
123961	1710	mainly lactone such as helenalin	[mainly lactones such as helenalin]	0.0	5	1	1	1
123962	1710	drug rapamycin	[drug rapamycin]	0.0	2	1	1	1
123963	1710	source of production	[source of production]	0.0	3	1	1	1
123964	1710	contrast, inhibition of IL-1	[contrast, inhibition of IL-1]	0.0	4	1	1	1
123965	1710	htlv-1 transactivator protein	[HTLV-1 transactivator protein]	0.0	3	1	1	1
123966	1710	reduction in gr number	[reduction in GR number]	0.0	4	1	1	1
123967	1710	S9a at 10 nm	[S9a at 10 nM]	0.0	4	1	1	1
123968	1710	also element CRE	[also elements CRE]	0.0	3	1	1	1
123969	1710	6 Yang deficient patient	[6 Yang deficient patients]	0.0	4	1	1	1
123970	1710	p21-activated protein kinase	[p21-activated protein kinase]	0.0	3	1	1	1
123971	1710	concert with PMA/ionomycin factor	[concert with PMA/ionomycin factors]	0.0	4	1	1	1
123972	1710	[age-related change in glucocorticoid receptor	[[Age-related changes in glucocorticoid receptors]	0.0	5	1	1	1
123973	1710	endogenous mechanism involve steroid hormone	[endogenous mechanisms involving steroid hormones]	0.0	5	1	1	1
123974	1710	cell along the Th1	[cells along the Th1]	0.0	4	1	1	1
123975	1710	interaction between nervous system	[interaction between nervous systems]	0.0	4	1	1	1
123976	1710	certain subclone	[certain subclones]	0.0	2	1	1	1
123977	1710	mononuclear leukocyte in obesity.	[mononuclear leukocyte in obesity.]	0.0	4	1	1	1
123978	1710	high level of immunoglobulin heavy-chain mrna	[high levels of immunoglobulin heavy-chain mRNA]	0.0	6	1	1	1
123979	1710	K+ channel blockade	[K+ channel blockade]	0.0	3	1	1	1
123980	1710	effect of arsenic trioxide	[effect of arsenic trioxide]	0.0	4	1	1	1
123981	1710	cord T lymphocyte	[cord T lymphocytes]	0.0	3	1	1	1
123982	1710	association of carboxyl terminus ct	[association of carboxyl terminus CT]	0.0	5	1	1	1
123983	1710	binding of interferon-gamma to receptor	[Binding of interferon-gamma to receptor]	0.0	5	1	1	1
123984	1710	135eoh)2d3 -vdr binding	[1,25(OH)2D3 -VDR binding]	0.0	3	1	1	1
123985	1710	hiv-1 isolate contain alteration	[HIV-1 isolate containing alterations]	0.0	4	1	1	1
123986	1710	regulation of interleukin gene through interference	[regulation of interleukin gene through interference]	0.0	6	1	1	1
123987	1710	major disorder: lack	[major disorder: lack]	0.0	3	1	1	1
123988	1710	Mac-6	[Mac-6]	0.0	1	1	1	1
123989	1710	regulate e2f	[regulating E2F]	0.0	2	1	1	1
123990	1710	two related lineage	[two related lineages]	0.0	3	1	1	1
123991	1710	regulation in blood mononuclear cell	[Regulation in blood mononuclear cells]	0.0	5	1	1	1
123992	1710	competition between two activator	[competition between two activators]	0.0	4	1	1	1
123993	1710	priming under that condition	[priming under those conditions]	0.0	4	1	1	1
123994	1710	viral particle	[viral particle]	0.0	2	1	1	1
123995	1710	catalytic activity of cyclin/cdk complex	[catalytic activity of cyclin/cdks complexes]	0.0	5	1	1	1
123996	1710	normal b-cell by mutant virus	[normal B-cells by mutant virus]	0.0	5	1	1	1
123997	1710	Effect of intranasal glucocorticoid on function	[Effects of intranasal glucocorticoids on function]	0.0	6	1	1	1
123998	1710	transfection use reporter construct	[transfections using reporter constructs]	0.0	4	1	1	1
123999	1710	leukemia (cll) sample	[leukemia (CLL) samples]	0.0	3	1	1	1
124000	1710	calcineurin a phosphatase	[calcineurin a phosphatase]	0.0	3	1	1	1
124001	1710	patient with leukemic spread	[patients with leukemic spread]	0.0	4	1	1	1
124002	1710	tar activation of the immunodeficiency virus	[TAR activation of the immunodeficiency virus]	0.0	6	1	1	1
124003	1710	statg in immature human myeloid cell	[StatG in immature human myeloid cells]	0.0	6	1	1	1
124004	1710	potential clinical significance.	[potential clinical significance.]	0.0	3	1	1	1
124005	1710	affinity class of site	[affinity class of sites]	0.0	4	1	1	1
124006	1710	100 ng/ml of il-10	[100 ng/ml of IL-10]	0.0	4	1	1	1
124007	1710	phorbol ester motif	[phorbol ester motifs]	0.0	3	1	1	1
124008	1710	cell-type induction by PMA treatment	[cell-type induction by PMA treatment]	0.0	5	1	1	1
124009	1710	understand the mechanism of affinity	[understanding the mechanism of affinity]	0.0	5	1	1	1
124010	1710	predominant factor	[predominant factor]	0.0	2	1	1	1
124011	1710	percutaneous coronary angioplasty	[percutaneous coronary angioplasty]	0.0	3	1	1	1
124012	1710	normal progenitor cell growth	[normal progenitor cell growth]	0.0	4	1	1	1
124013	1710	cmml	[CMML]	0.0	1	1	1	1
124014	1710	identify a mechanism	[identifying a mechanism]	0.0	3	1	1	1
124015	1710	vertebrate homolog	[vertebrate homolog]	0.0	2	1	1	1
124016	1710	nuclear magnetic resonance 3d-nmr spectroscopy	[nuclear magnetic resonance 3D-NMR spectroscopy]	0.0	5	1	1	1
124017	1710	TNF-alpha hiv-1 repeat transcription	[TNF-alpha HIV-1 repeat transcription]	0.0	4	1	1	1
124018	1710	signal-regulated kinase in monocyte	[signal-regulated kinase in monocytes]	0.0	4	1	1	1
124019	1710	U9-IIIB	[U9-IIIB]	0.0	1	1	1	1
124020	1710	neutralize csf-1r antibody	[neutralizing CSF-1R antibodies]	0.0	3	1	1	1
124021	1710	mucosa-associated lymphoid tissue malt	[mucosa-associated lymphoid tissue MALT]	0.0	4	1	1	1
124022	1710	Functional study in non-epithelial cell	[Functional studies in non-epithelial cells]	0.0	5	1	1	1
124023	1710	nucleosome	[nucleosome]	0.0	1	1	1	1
124024	1710	govern selection	[governing selection]	0.0	2	1	1	1
124025	1710	similar transfection analysis of the region	[Similar transfection analysis of the region]	0.0	6	1	1	1
124026	1710	rrna for gene	[mRNAs for genes]	0.0	3	1	1	1
124027	1710	effect on NFkappaB /inhibitor-kappaB system	[effects on NFkappaB /inhibitor-kappaB system]	0.0	5	1	1	1
124028	1710	protein, with a m.w.	[protein, with an m.w.]	0.0	4	1	1	1
124029	1710	clinical picture of pseudohypoaldosteronism	[clinical picture of pseudohypoaldosteronism]	0.0	4	1	1	1
124030	1710	specific,	[specific,]	0.0	1	1	1	1
124031	1710	different dose	[different doses]	0.0	2	1	1	1
124032	1710	t-cell-activating superantigen enterotoxin	[T-cell-activating superantigen enterotoxin]	0.0	3	1	1	1
124033	1710	selection against mutation	[Selection against mutations]	0.0	3	1	1	1
124034	1710	tpa -inducible factor protein	[TPA -inducible factor protein]	0.0	4	1	1	1
124035	1710	Rel/NF-kB	[Rel/NF-kB]	0.0	1	1	1	1
124036	1710	complex (mhc) class molecule	[complex (MHC) class molecules]	0.0	4	1	1	1
124037	1710	anti- immunoglobulin g-seropositive donor	[anti- immunoglobulin G-seropositive donors]	0.0	4	1	1	1
124038	1710	-C-C family	[-C-C family]	0.0	2	1	1	1
124039	1710	peripheral blood cell proliferation	[peripheral blood cell proliferation]	0.0	4	1	1	1
124040	1710	develop from blood precursor	[developing from blood precursors]	0.0	4	1	1	1
124041	1710	transactivation factor	[transactivation factor]	0.0	2	1	1	1
124042	1710	transcription of the repeat region	[transcription of the repeat region]	0.0	5	1	1	1
124043	1710	breast aspirate at high risk	[breast aspirates at high risk]	0.0	5	1	1	1
124044	1710	land globular, structure distinct	[LANDs globular, structures distinct]	0.0	4	1	1	1
124045	1710	forty-one hd sample	[Forty-one HD samples]	0.0	3	1	1	1
124046	1710	further 6 hours.	[further 6 hours.]	0.0	3	1	1	1
124047	1710	region of the domain common	[region of the domain common]	0.0	5	1	1	1
124048	1710	cross-talk mechanism	[cross-talk mechanism]	0.0	2	1	1	1
124049	1710	transgenic pig donor in xenotransplantation	[transgenic pig donors in xenotransplantation]	0.0	5	1	1	1
124050	1710	2-type	[2-type]	0.0	1	1	1	1
124051	1710	stimulation of CD40 on immunogenic melanoma	[Stimulation of CD40 on immunogenic melanomas]	0.0	6	1	1	1
124052	1710	gamma-ifn gene in scavenger receptor	[gamma-IFN genes in scavenger receptor]	0.0	5	1	1	1
124053	1710	differ defect	[differing defects]	0.0	2	1	1	1
124054	1710	responsiveness to the stimulation.	[responsiveness to the stimulation.]	0.0	4	1	1	1
124055	1710	effect on lymphocyte 1) inhibition depletion	[effects on lymphocytes 1) inhibition depletion]	0.0	6	1	1	1
124056	1710	gene activator	[gene activator]	0.0	2	1	1	1
124057	1710	widespread extinction of gene	[widespread extinction of genes]	0.0	4	1	1	1
124058	1710	cell (sites/cell) value	[cell (sites/cell) values]	0.0	3	1	1	1
124059	1710	express major (mhc) class ii gene	[expressing major (MHC) class II genes]	0.0	6	1	1	1
124060	1710	strain with mutation	[Strains with mutations]	0.0	3	1	1	1
124061	1710	blockade of progenitor proliferation	[blockade of progenitor proliferation]	0.0	4	1	1	1
124062	1710	allele ratio great	[allele ratio greater]	0.0	3	1	1	1
124063	1710	i(kappa)b(alpha)	[I(kappa)B(alpha)]	0.0	1	3	3	1
124064	1710	disease of the newborn	[disease of the newborn]	0.0	4	1	1	1
124065	1710	cytokine-stimulated human vein cell	[cytokine-stimulated human vein cells]	0.0	4	1	1	1
124066	1710	b cell neoplasia	[B cell neoplasia]	0.0	3	1	1	1
124067	1710	drug resistance	[drug resistance]	0.0	2	1	1	1
124068	1710	lineage commitment role of transcription factor	[lineage commitment role of transcription factors]	0.0	6	1	1	1
124069	1710	several erythroid cell line	[several erythroid cell lines]	0.0	4	1	1	1
124070	1710	externalization	[externalization]	0.0	1	1	1	1
124071	1710	determinant for b cell-specific activation	[determinant for B cell-specific activation]	0.0	5	1	1	1
124072	1710	antiatherosclerotic potential of antioxidant	[antiatherosclerotic potential of antioxidants]	0.0	4	1	1	1
124073	1710	negative regulator of transcription	[negative regulator of transcription]	0.0	4	1	1	1
124074	1710	cd15 Lewis X a monocyte counter-receptor	[CD15 Lewis X a monocyte counter-receptor]	0.0	6	1	1	1
124075	1710	impact on slp-76 augmentation	[impact on SLP-76 augmentation]	0.0	4	1	1	1
124076	1710	couple of the beta globin sequence	[Coupling of the beta globin sequence]	0.0	6	1	1	1
124077	1710	patient receive glucocorticoid therapy for disease	[patients receiving glucocorticoid therapy for diseases]	0.0	6	1	1	1
124078	1710	hemin increases,	[hemin increases,]	0.0	2	1	1	1
124079	1710	relationship between effect	[relationship between effect]	0.0	3	1	1	1
124080	1710	epitope on the aminoterminal region	[epitope on the aminoterminal region]	0.0	5	1	1	1
124081	1710	expression in center	[Expression in center]	0.0	3	1	1	1
124082	1710	use mpl concentration in plasma	[using MPL concentrations in plasma]	0.0	5	1	1	1
124083	1710	stat4 -contain complex	[STAT4 -containing complexes]	0.0	3	1	1	1
124084	1710	significantly favorable clinical course (p	[significantly favorable clinical course (P]	0.0	5	1	1	1
124085	1710	decrease in concentration	[decrease in concentration]	0.0	3	1	1	1
124086	1710	complex (mhc) class ii gene	[complex (MHC) class II genes]	0.0	5	3	3	1
124087	1710	80.2 (p p 0.01	[80.2 (P P 0.01]	0.0	4	1	1	1
124088	1710	multiple response	[multiple responses]	0.0	2	1	1	1
124089	1710	overexpression of protein- tyrosine phosphatase	[Overexpression of protein- tyrosine phosphatase]	0.0	5	1	1	1
124090	1710	cytolytic effect	[cytolytic effects]	0.0	2	1	1	1
124091	1710	mediate ifn-beta induction	[mediating IFN-beta induction]	0.0	3	1	1	1
124092	1710	result of the accompanying gssg deficiency	[results of the accompanying GSSG deficiency]	0.0	6	1	1	1
124093	1710	upregulation evidence	[upregulation evidence]	0.0	2	1	1	1
124094	1710	Tcf-1 transcription differential role	[Tcf-1 transcription differential role]	0.0	4	1	1	1
124095	1710	bimodal expression pattern suggest a property	[bimodal expression patterns suggesting a property]	0.0	6	1	1	1
124096	1710	hours' exposure to 135(oh)2d3	[hours' exposure to 1,25(OH)2D3]	0.0	4	1	1	1
124097	1710	unquestionably a form	[unquestionably a form]	0.0	3	1	1	1
124098	1710	use pd-98059 potent inhibitor	[using PD-98059 potent inhibitors]	0.0	4	1	1	1
124099	1710	stimulation on malignant melanoma	[Stimulation on malignant melanomas]	0.0	4	1	1	1
124100	1710	characteristic of this new pathway	[characteristics of this new pathway]	0.0	5	2	2	1
124101	1710	function of Spi-B	[function of Spi-B]	0.0	3	1	1	1
124102	1710	similar pattern	[similar pattern]	0.0	2	3	3	1
124103	1710	dependent adhesion human vein endothelial cell	[dependent adhesion human vein endothelial cells]	0.0	6	1	1	1
124104	1710	action of protease	[action of proteases]	0.0	3	1	1	1
124105	1710	development of specific pathology	[development of specific pathologies]	0.0	4	1	1	1
124106	1710	exception of b lymphocyte	[exception of B lymphocytes]	0.0	4	1	1	1
124107	1710	xenogeneic human serum	[xenogeneic human serum]	0.0	3	1	1	1
124108	1710	effect of CD40	[effects of CD40]	0.0	3	1	1	1
124109	1710	50-kDa hlp-1 protein	[50-kDa HLP-1 protein]	0.0	3	1	1	1
124110	1710	several generation of 12 family	[several generations of 12 families]	0.0	5	1	1	1
124111	1710	individual response	[individual responses]	0.0	2	1	1	1
124112	1710	biochemically distinct dna-binding protein	[biochemically distinct DNA-binding proteins]	0.0	4	1	1	1
124113	1710	correlation inflammation	[correlation inflammation]	0.0	2	1	1	1
124114	1710	alpha1 thp-1 cell	[alpha1 THP-1 cells]	0.0	3	1	1	1
124115	1710	BA overexpression	[BA overexpression]	0.0	2	1	1	1
124116	1710	Rac response	[Rac responses]	0.0	2	1	1	1
124117	1710	antagonism of the production	[antagonism of the production]	0.0	4	1	1	1
124118	1710	c-c chemokine gene	[C-C chemokine genes]	0.0	3	1	1	1
124119	1710	dna-binding domain of the receptor	[DNA-binding domain of the receptor]	0.0	5	1	1	1
124120	1710	estrogen receptor in human leucocyte	[estrogen receptors in human leucocytes]	0.0	5	1	1	1
124121	1710	healthy male with age distribution	[healthy males with age distribution]	0.0	5	1	1	1
124122	1710	stat1 protein start at day	[STAT1 protein starting at day]	0.0	5	1	1	1
124123	1710	accurate initiation	[accurate initiation]	0.0	2	1	1	1
124124	1710	whole-cell bind radioassay	[whole-cell binding radioassay]	0.0	3	1	1	1
124125	1710	thus prevent induction of several cytokine	[thus preventing induction of several cytokine]	0.0	6	1	1	1
124126	1710	woman with recurrent spontaneous abortion	[women with recurrent spontaneous abortion]	0.0	5	1	1	1
124127	1710	downregulation during differentiation of k562 cell	[downregulation during differentiation of K562 cells]	0.0	6	1	1	1
124128	1710	normal neutrophil	[normal neutrophils]	0.0	2	1	1	1
124129	1710	linear loop peptide	[linear loop peptides]	0.0	3	1	1	1
124130	1710	progressive decline in the capacity	[progressive decline in the capacities]	0.0	5	1	1	1
124131	1710	MNC homogenate	[MNC homogenates]	0.0	2	1	1	1
124132	1710	peptide contact	[peptide contact]	0.0	2	1	1	1
124133	1710	pg/ml pg/mL,	[pg/mL pg/mL,]	0.0	2	1	1	1
124134	1710	comparison with control cell	[comparison with control cells]	0.0	4	1	1	1
124135	1710	stably overexpress hIRAK a activation	[stably overexpressing hIRAK a activation]	0.0	5	1	1	1
124136	1710	decrease in lps	[decrease in LPS]	0.0	3	1	1	1
124137	1710	seen, migration of 48-hr antigen t-cell	[seen, migration of 48-hr antigen T-cells]	0.0	6	1	1	1
124138	1710	accumulation a finding consistent	[accumulation a finding consistent]	0.0	4	1	1	1
124139	1710	canonical elements,	[canonical elements,]	0.0	2	1	1	1
124140	1710	Recognition of NFATp/AP-1 element	[Recognition of NFATp/AP-1 elements]	0.0	4	1	1	1
124141	1710	normal blood monocyte	[normal blood monocytes]	0.0	3	1	1	1
124142	1710	evidence for intracellular signal pathway	[Evidence for intracellular signaling pathways]	0.0	5	1	1	1
124143	1710	1 allele allele ratio	[1 allele allele ratio]	0.0	4	1	1	1
124144	1710	binding of interleukin-2 to receptor	[binding of interleukin-2 to receptor]	0.0	5	1	1	1
124145	1710	machinery.	[machinery.]	0.0	1	1	1	1
124146	1710	cut edge: effect of Ile50Val variant	[Cutting edge: effect of Ile50Val variant]	0.0	6	1	1	1
124147	1710	preterm baby	[preterm babies]	0.0	2	1	1	1
124148	1710	fast kinetic in T	[fast kinetics in T]	0.0	4	1	1	1
124149	1710	response to NF-kappa b	[responses to NF-kappa B]	0.0	4	1	1	1
124150	1710	group of compound	[group of compounds]	0.0	3	1	1	1
124151	1710	leukemic cd4+ t-lymphocyte cell line	[leukemic CD4+ T-lymphocyte cell line]	0.0	5	1	1	1
124152	1710	appropriate alignment of this element	[appropriate alignment of these elements]	0.0	5	1	1	1
124153	1710	differential regulation specific	[differential regulation specific]	0.0	3	1	1	1
124154	1710	second element the N element	[second element the N element]	0.0	5	1	1	1
124155	1710	400-fold excess of testosterone	[400-fold excess of testosterone]	0.0	4	1	1	1
124156	1710	27 child aged year with nephropathy	[27 children aged years with nephropathies]	0.0	6	1	1	1
124157	1710	investigate the role	[investigating the role]	0.0	3	1	1	1
124158	1710	exposure of u-937 cell to 135-(oh)2d3	[exposure of U-937 cells to 1,25-(OH)2D3]	0.0	6	1	1	1
124159	1710	blastogenesis of blood lymphocyte	[blastogenesis of blood lymphocytes]	0.0	4	1	1	1
124160	1710	hematopoietic cell specific molecule	[hematopoietic cell specific molecules]	0.0	4	1	1	1
124161	1710	binding of a antibody	[Binding of a antibody]	0.0	4	1	1	1
124162	1710	(gabp)	[(GABP)]	0.0	1	1	1	1
124163	1710	human taf	[human TAF]	0.0	2	1	1	1
124164	1710	apparently identical signal pathways, lead	[apparently identical signaling pathways, leading]	0.0	5	1	1	1
124165	1710	constitutive phosphorylation of Jak3	[Constitutive phosphorylation of Jak3]	0.0	4	1	1	1
124166	1710	Ig chain	[Ig chain]	0.0	2	1	1	1
124167	1710	element alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[Elements alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	0.0	5	1	1	1
124168	1710	culminate in cell differentiation	[culminating in cell differentiation]	0.0	4	1	1	1
124169	1710	histiocytoma 6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma	[histiocytoma 6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma]	0.0	6	1	1	1
124170	1710	inducible cyclosporin -sensitive dnase site	[inducible cyclosporin -sensitive DNase site]	0.0	5	1	1	1
124171	1710	patient with inactive sle	[patients with inactive SLE]	0.0	4	1	1	1
124172	1710	marker of event in cells.	[marker of events in cells.]	0.0	5	1	1	1
124173	1710	disease with pathogenesis	[diseases with pathogenesis]	0.0	3	1	1	1
124174	1710	however, simultaneous incubation of RU 486	[However, simultaneous incubation of RU 486]	0.0	6	1	1	1
124175	1710	insensitivity of T lymphocyte	[insensitivity of T lymphocytes]	0.0	4	1	1	1
124176	1710	Kappa	[Kappa]	0.0	1	1	1	1
124177	1710	identity with a core	[identity with a core]	0.0	4	1	1	1
124178	1710	syphilis	[syphilis]	0.0	1	1	1	1
124179	1710	interestingly, early treatment with alpha-pml	[Interestingly, early treatment with alpha-PML]	0.0	5	1	1	1
124180	1710	cell with the property of macrophage	[cells with the properties of macrophages]	0.0	6	1	1	1
124181	1710	transcriptional activity of hlh protein	[transcriptional activities of HLH proteins]	0.0	5	1	1	1
124182	1710	occupancy of the viral enhancer heterodimer	[occupancy of the viral enhancer heterodimers]	0.0	6	1	1	1
124183	1710	blur the distinction	[blurring the distinction]	0.0	3	1	1	1
124184	1710	patient than in healthy person	[patients than in healthy persons]	0.0	5	1	1	1
124185	1710	u937 cell to lps cell	[U937 cells to LPS cells]	0.0	5	1	1	1
124186	1710	result cytosol	[resulting cytosol]	0.0	2	1	1	1
124187	1710	two promoter promoter	[two promoters promoter]	0.0	3	1	1	1
124188	1710	active factor	[active factor]	0.0	2	1	1	1
124189	1710	two disorders: xeroderma pigmentosum	[two disorders: xeroderma pigmentosum]	0.0	4	1	1	1
124190	1710	migrate isoform, Stat3alpha	[migrating isoform, Stat3alpha]	0.0	3	1	1	1
124191	1710	coiled-coil region of Stat5b	[coiled-coil region of Stat5b]	0.0	4	1	1	1
124192	1710	selection of sequence	[Selection of sequences]	0.0	3	1	1	1
124193	1710	alteration in nuclear factor-kappa b	[alterations in nuclear factor-kappa B]	0.0	5	1	1	1
124194	1710	GCR-alpha DNA binding	[GCR-alpha DNA binding]	0.0	3	1	1	1
124195	1710	operate at a step	[operating at a step]	0.0	4	1	1	1
124196	1710	evaluate respiratory epithelium	[evaluating respiratory epithelium]	0.0	3	1	1	1
124197	1710	Rapid tyrosine phosphorylation of key protein	[Rapid tyrosine phosphorylation of key proteins]	0.0	6	1	1	1
124198	1710	one problem	[One problem]	0.0	2	1	1	1
124199	1710	uas1	[UAS1]	0.0	1	1	1	1
124200	1710	particular, two interleukin	[particular, two interleukins]	0.0	3	1	1	1
124201	1710	selective modulation by adenoviral transfer	[selective modulation by adenoviral transfer]	0.0	5	1	1	1
124202	1710	induction of adhesion molecule-1	[induction of adhesion molecule-1]	0.0	4	1	1	1
124203	1710	subset representative	[subset representative]	0.0	2	1	1	1
124204	1710	all-tran retinoic acid washed,	[all-trans retinoic acid washed,]	0.0	4	1	1	1
124205	1710	correlation points), low body mass	[correlation points), low body mass]	0.0	5	1	1	1
124206	1710	acid treatment of hl60 leukemia cell	[acid treatment of HL60 leukemia cells]	0.0	6	1	1	1
124207	1710	human th2	[human Th2]	0.0	2	1	1	1
124208	1710	four b binding site at position	[four B binding sites at positions]	0.0	6	1	1	1
124209	1710	dominant-negative mutant TNFRI	[dominant-negative mutant TNFRI]	0.0	3	1	1	1
124210	1710	dominant version	[dominant version]	0.0	2	1	1	1
124211	1710	cell lack functional receptor.	[cells lacking functional receptor.]	0.0	4	1	1	1
124212	1710	novelty stress	[novelty stress]	0.0	2	1	1	1
124213	1710	sh2 motif	[SH2 motifs]	0.0	2	1	1	1
124214	1710	involvement of oncogene	[involvement of oncogenes]	0.0	3	1	1	1
124215	1710	1alpha,25-dihydroxyvitamin	[1alpha,25-dihydroxyvitamin]	0.0	1	1	1	1
124216	1710	encompass this site	[encompassing this site]	0.0	3	1	1	1
124217	1710	use this drug	[Using these drugs]	0.0	3	1	1	1
124218	1710	maturation effect	[maturation effect]	0.0	2	1	1	1
124219	1710	suggest a role of e220k	[suggesting a role of E220K]	0.0	5	1	1	1
124220	1710	activation follow viral binding	[activation following viral binding]	0.0	4	1	1	1
124221	1710	lef-1 among T transcription factor	[LEF-1 among T transcription factors]	0.0	5	1	1	1
124222	1710	effect 1) inhibition of growth depletion	[effects 1) inhibition of growth depletion]	0.0	6	1	1	1
124223	1710	NOTCH1 transmembrane receptor	[NOTCH1 transmembrane receptor]	0.0	3	1	1	1
124224	1710	huvec adhesion molecule	[HUVEC adhesion molecules]	0.0	3	1	1	1
124225	1710	strongly BCL-6	[strongly BCL-6]	0.0	2	1	1	1
124226	1710	b cell-specific enhancer element	[B cell-specific enhancer elements]	0.0	4	1	1	1
124227	1710	terminal of FK506 pathway	[terminals of FK506 pathway]	0.0	4	1	1	1
124228	1710	pcr analysis from three individual	[PCR analysis from three individuals]	0.0	5	1	1	1
124229	1710	cell as a model for differentiation	[cells as a model for differentiation]	0.0	6	1	1	1
124230	1710	activation by a mechanism	[activation by a mechanism]	0.0	4	1	1	1
124231	1710	apparent glucocorticoid resistance in disorder	[apparent glucocorticoid resistance in disorder]	0.0	5	1	1	1
124232	1710	Chr centromere	[Chr centromere]	0.0	2	1	1	1
124233	1710	protein-protein interaction with molecule	[protein-protein interactions with molecules]	0.0	4	1	1	1
124234	1710	regulate alpha2 gene expression	[regulating alpha2 gene expression]	0.0	4	1	1	1
124235	1710	favorable activity profile than UP	[favorable activity profile than UP]	0.0	5	1	1	1
124236	1710	selection of differential strategy	[selection of differential strategies]	0.0	4	1	1	1
124237	1710	t-cell lymphoma with gcs aitl/gc	[T-cell lymphoma with GCs AITL/GC]	0.0	5	1	1	1
124238	1710	rapamycin -resistant mutant	[rapamycin -resistant mutant]	0.0	3	1	1	1
124239	1710	3-kinase activation of epf	[3-kinase activation of E2Fs]	0.0	4	1	1	1
124240	1710	cluster of translocation	[cluster of translocations]	0.0	3	1	1	1
124241	1710	specimens,	[specimens,]	0.0	1	1	1	1
124242	1710	transcription of complex class ii gene	[transcription of complex class II genes]	0.0	6	1	1	1
124243	1710	part of the panoply	[part of the panoply]	0.0	4	1	1	1
124244	1710	much high concentration	[Much higher concentrations]	0.0	3	2	2	1
124245	1710	glycosaminoglycan gag	[glycosaminoglycan GAG]	0.0	2	1	1	1
124246	1710	recombinant soluble tnf receptor rhu tnfr:fc	[recombinant soluble TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
124247	1710	form the p50 subunit	[forming the p50 subunit]	0.0	4	1	1	1
124248	1710	function in common	[functions in common]	0.0	3	1	1	1
124249	1710	indistinguishable sequence specificity	[indistinguishable sequence specificity]	0.0	3	1	1	1
124250	1710	1 complex	[1 complexes]	0.0	2	1	1	1
124251	1710	pkc inhibitor ro 31-8425	[PKC inhibitor Ro 31-8425]	0.0	4	1	1	1
124252	1710	PU.1-	[PU.1-]	0.0	1	1	1	1
124253	1710	bp capable of coding	[bp capable of coding]	0.0	4	1	1	1
124254	1710	CPRE at -49/41	[CPRE at -49/-41,]	0.0	3	1	1	1
124255	1710	month after delivery	[months after delivery]	0.0	3	1	1	1
124256	1710	significance of nonepithelial mineralocorticoid receptor	[significance of nonepithelial mineralocorticoid receptors]	0.0	5	1	1	1
124257	1710	starting with a clone	[Starting with a clone]	0.0	4	1	1	1
124258	1710	endothelial cell in culture, lead	[endothelial cells in culture, leading]	0.0	5	1	1	1
124259	1710	range conditions.	[range conditions.]	0.0	2	1	1	1
124260	1710	site GAS	[site GAS]	0.0	2	1	1	1
124261	1710	abundance of jak3	[abundance of JAK3]	0.0	3	1	1	1
124262	1710	role for dr-nm23	[role for DR-nm23]	0.0	3	1	1	1
124263	1710	use pd-98059 potent inhibitor of MEK1	[using PD-98059 potent inhibitors of MEK1]	0.0	6	1	1	1
124264	1710	human alpha-like globin promoter	[human alpha-like globin promoters]	0.0	4	1	1	1
124265	1710	0.05, chi2 test).	[0.05, chi2 test).]	0.0	3	1	1	1
124266	1710	dna-binding activity complex in response	[DNA-binding activity complex in response]	0.0	5	1	1	1
124267	1710	Tat sfv intrabody	[Tat sFv intrabodies]	0.0	3	1	1	1
124268	1710	steroid hormone anti-sera estradiol	[steroid hormone anti-sera estradiol]	0.0	4	1	1	1
124269	1710	factor bind except for pu.1/spi-1	[factors binding except for PU.1/Spi-1]	0.0	5	1	1	1
124270	1710	th2 T	[Th2 T]	0.0	2	1	1	1
124271	1710	immunoglobulin chain class switch recombination	[immunoglobulin chain class switch recombination]	0.0	5	1	1	1
124272	1710	nuclear factor kappab kinase	[nuclear factor kappaB kinase]	0.0	4	1	1	1
124273	1710	phosphorylation of il-4 stat	[phosphorylation of IL-4 STAT]	0.0	4	1	1	1
124274	1710	transfection of creb protein	[transfection of CREB protein]	0.0	4	1	1	1
124275	1710	ppas)	[(PAS)]	0.0	1	1	1	1
124276	1710	involvement of the RXR-RXR pathway	[involvement of the RXR-RXR pathway]	0.0	5	1	1	1
124277	1710	functional tcr delta mrna	[functional TcR delta mRNA]	0.0	4	1	1	1
124278	1710	serum-contain mediuhd small colony	[serum-containing medium, small colonies]	0.0	4	1	1	1
124279	1710	fk506 a calcineurin inhibitor	[FK506 a calcineurin inhibitor]	0.0	4	1	1	1
124280	1710	cellular proliferation of human T cell	[cellular proliferation of human T cells]	0.0	6	1	1	1
124281	1710	intracellular glutathione disulfide level	[intracellular glutathione disulfide levels]	0.0	4	1	1	1
124282	1710	profoundly decreased, z-lll-h -insensitive activity	[profoundly decreased, Z-LLL-H -insensitive activity]	0.0	5	1	1	1
124283	1710	expression of the nf	[expression of the NF]	0.0	4	1	1	1
124284	1710	sodium dodecyl	[sodium dodecyl]	0.0	2	2	2	1
124285	1710	disruption of the SCL locus	[Disruption of the SCL locus]	0.0	5	1	1	1
124286	1710	bp upstream of the site	[bp upstream of the site]	0.0	5	1	1	1
124287	1710	cyclic protein kinase inhibitor ha-1004	[cyclic protein kinase inhibitor HA-1004]	0.0	5	1	1	1
124288	1710	produce a retrovirus	[producing a retrovirus]	0.0	3	1	1	1
124289	1710	especially in inflammatory-type condition	[especially in inflammatory-type conditions]	0.0	4	1	1	1
124290	1710	cDNA clone of differentiation	[cDNA clones of differentiation]	0.0	4	1	1	1
124291	1710	(hiv-1) therapy in this study.	[(HIV-1) therapy in this study.]	0.0	5	1	1	1
124292	1710	developmental stage- manner	[developmental stage- manner]	0.0	3	1	1	1
124293	1710	light of work	[light of work]	0.0	3	1	1	1
124294	1710	effect on malignant lymphocyte	[effects on malignant lymphocytes]	0.0	4	1	1	1
124295	1710	effect of a drug	[effects of a drug]	0.0	4	1	1	1
124296	1710	monocyte-binding receptor on cell	[monocyte-binding receptors on cells]	0.0	4	1	1	1
124297	1710	Microtubule	[Microtubule]	0.0	1	2	2	1
124298	1710	together with the finding of expression	[together with the findings of expression]	0.0	6	1	1	1
124299	1710	severity of sign of illness	[severity of signs of illness]	0.0	5	1	1	1
124300	1710	14 kb	[14 kb]	0.0	2	1	1	1
124301	1710	generation of surrogate receptor	[generation of surrogate receptors]	0.0	4	1	1	1
124302	1710	number without change	[number without changes]	0.0	3	1	1	1
124303	1710	suggest a common property	[suggesting a common property]	0.0	4	1	1	1
124304	1710	exposure dyn/cm2)	[exposure dyn/cm2)]	0.0	2	1	1	1
124305	1710	anti- CD30 antibody	[anti- CD30 antibodies]	0.0	3	1	1	1
124306	1710	initiation by RNA polymerase	[initiation by RNA polymerase]	0.0	4	1	1	1
124307	1710	ap-1 binding activity in monocyte	[AP-1 binding activity in monocytes]	0.0	5	1	1	1
124308	1710	kappa 3/cre site	[kappa 3/CRE site]	0.0	3	1	1	1
124309	1710	molecular mass between 94	[molecular mass between 94]	0.0	4	1	1	1
124310	1710	NF kappa b species	[NF kappa B species]	0.0	4	1	1	1
124311	1710	cell counting	[cell counting]	0.0	2	1	1	1
124312	1710	(monocytoid)	[(monocytoid)]	0.0	1	1	1	1
124313	1710	normal oncogene-expressing	[normal oncogene-expressing]	0.0	2	1	1	1
124314	1710	dramatic shift	[dramatic shift]	0.0	2	1	1	1
124315	1710	syndrome of pha	[syndrome of PHA]	0.0	3	1	1	1
124316	1710	binding of the complex	[Binding of the complexes]	0.0	4	1	1	1
124317	1710	high level of the activity	[High levels of the activity]	0.0	5	1	1	1
124318	1710	type of stress.	[types of stress.]	0.0	3	1	1	1
124319	1710	region of b gene	[regions of B genes]	0.0	4	1	1	1
124320	1710	JCam	[JCam]	0.0	1	1	1	1
124321	1710	pao phosphatase	[PAO phosphatase]	0.0	2	1	1	1
124322	1710	unknown locus interrupt locus	[unknown locus interrupting locus]	0.0	4	1	1	1
124323	1710	size heterogeneity	[size heterogeneity]	0.0	2	1	1	1
124324	1710	proline acidic amino acid-rich	[proline acidic amino acid-rich]	0.0	4	1	1	1
124325	1710	eosinophil infiltrate hamster wound	[Eosinophils infiltrating hamster wounds]	0.0	4	1	1	1
124326	1710	phenotype of nf-kappab suppression	[phenotype of NF-kappaB suppression]	0.0	4	1	1	1
124327	1710	selective activation of factor	[selective activation of factors]	0.0	4	1	1	1
124328	1710	jun family of proto-oncogent	[jun family of proto-oncogenes]	0.0	4	1	1	1
124329	1710	erythroid cell fate	[erythroid cell fate]	0.0	3	1	1	1
124330	1710	thyroid hormone receptor TRs	[thyroid hormone receptors TRs]	0.0	4	1	1	1
124331	1710	step in cell systems.	[step in cell systems.]	0.0	4	1	1	1
124332	1710	glutathione antioxidant	[glutathione antioxidant]	0.0	2	1	1	1
124333	1710	increase in thf the number	[increase in THF the number]	0.0	5	1	1	1
124334	1710	concentration of etoposide microM)	[concentrations of etoposide microM)]	0.0	4	1	1	1
124335	1710	protein responsive through the effect	[proteins responsive through the effect]	0.0	5	1	1	1
124336	1710	adenoviral gene expression	[adenoviral gene expression]	0.0	3	1	1	1
124337	1710	structure morphologically distinct from the structure	[structures morphologically distinct from the structures]	0.0	6	1	1	1
124338	1710	member of a class gene	[member of a class genes]	0.0	5	1	1	1
124339	1710	protein-DNA binding study	[protein-DNA binding studies]	0.0	3	1	1	1
124340	1710	development of myeloid cell	[development of myeloid cells]	0.0	4	1	1	1
124341	1710	pattern of nuclear factor binding	[pattern of nuclear factor binding]	0.0	5	1	1	1
124342	1710	consider the positive regulatory effect	[Considering the positive regulatory effect]	0.0	5	1	1	1
124343	1710	human 15-lipoxygenase	[Human 15-lipoxygenase]	0.0	2	1	1	1
124344	1710	IFN mrna	[IFN mRNA]	0.0	2	1	1	1
124345	1710	bhlh-pas	[bHLH-PAS]	0.0	1	1	1	1
124346	1710	transient transfection study a e(2) line,	[Transient transfection studies an E(2) line,]	0.0	6	1	1	1
124347	1710	receptor ppargamma	[receptor PPARgamma]	0.0	2	1	1	1
124348	1710	factor-dependent manner	[factor-dependent manner]	0.0	2	1	1	1
124349	1710	tissue fibrosis	[tissue fibrosis]	0.0	2	1	1	1
124350	1710	prognostic parameter	[prognostic parameter]	0.0	2	1	1	1
124351	1710	evidence in support	[evidence in support]	0.0	3	1	1	1
124352	1710	expression of a set	[expression of a set]	0.0	4	1	1	1
124353	1710	feature of variation	[features of variation]	0.0	3	1	1	1
124354	1710	select aberration	[select aberrations]	0.0	2	1	1	1
124355	1710	chemical modification arginine residue	[chemical modification arginine residues]	0.0	4	1	1	1
124356	1710	purine box site	[purine box sites]	0.0	3	1	1	1
124357	1710	region -119	[region -119]	0.0	2	1	1	1
124358	1710	form of protein kinase iv	[form of protein kinase IV]	0.0	5	2	2	1
124359	1710	Ca2+ redistribution	[Ca2+ redistribution]	0.0	2	1	1	1
124360	1710	high population	[higher population]	0.0	2	1	1	1
124361	1710	10000-fold selectivity	[10000-fold selectivity]	0.0	2	2	2	1
124362	1710	production of interleukin 3 factor	[production of interleukin 3 factor]	0.0	5	1	1	1
124363	1710	distinct transcription factor family	[distinct transcription factor families]	0.0	4	1	1	1
124364	1710	stimulate the release of cytokine	[stimulating the release of cytokines]	0.0	5	1	1	1
124365	1710	s element	[S element]	0.0	2	1	1	1
124366	1710	exogenous provision	[exogenous provision]	0.0	2	2	2	1
124367	1710	quantification of glucocorticoid receptor expression	[quantification of glucocorticoid receptor expression]	0.0	5	1	1	1
124368	1710	relevant implications.	[relevant implications.]	0.0	2	1	1	1
124369	1710	variety of actions,	[variety of actions,]	0.0	3	1	1	1
124370	1710	min) submaximal physical exercise	[min) submaximal physical exercise]	0.0	4	1	1	1
124371	1710	full activity,	[full activity,]	0.0	2	1	1	1
124372	1710	t-cell precursor	[T-cell precursors]	0.0	2	1	1	1
124373	1710	hour 1 of the enzyme	[hours 1 of the enzyme]	0.0	5	1	1	1
124374	1710	risk: cell reaction grade	[risk: cell reaction grade]	0.0	4	1	1	1
124375	1710	understanding of the event	[understanding of the events]	0.0	4	1	1	1
124376	1710	healthy pregnant woman (11 second	[healthy pregnant women (11 second]	0.0	5	1	1	1
124377	1710	TK inhibitor	[TK inhibitors]	0.0	2	1	1	1
124378	1710	study on population progenitor	[studies on populations progenitors]	0.0	4	1	1	1
124379	1710	antioxidant thioctic acid	[antioxidant thioctic acid]	0.0	3	1	1	1
124380	1710	exhibit Arre-2 binding activity	[exhibiting ARRE-2 binding activity]	0.0	4	1	1	1
124381	1710	60% decrease	[60% decrease]	0.0	2	1	1	1
124382	1710	set of receptor	[set of receptors]	0.0	3	1	1	1
124383	1710	long terminal repeat sequence diversity	[long terminal repeat sequence diversity]	0.0	5	1	1	1
124384	1710	interaction between positive transcriptional element	[interactions between positive transcriptional elements]	0.0	5	1	1	1
124385	1710	addition, this decrease in induction	[addition, this decrease in induction]	0.0	5	1	1	1
124386	1710	hl-60/vinc,	[HL-60/vinc,]	0.0	1	1	1	1
124387	1710	role for beta-hydroxysteroid dehydrogenase	[role for beta-hydroxysteroid dehydrogenase]	0.0	4	1	1	1
124388	1710	contain four repeat	[containing four repeats]	0.0	3	1	1	1
124389	1710	rest Raji cell	[resting Raji cells]	0.0	3	1	1	1
124390	1710	change in cell glutathione gsh	[changes in cell glutathione GSH]	0.0	5	1	1	1
124391	1710	protein bind protein	[protein binding protein]	0.0	3	1	1	1
124392	1710	many helix-loop-helix (bhlh) transcription factor	[many helix-loop-helix (bHLH) transcription factors]	0.0	5	1	1	1
124393	1710	family of transcriptional protein	[family of transcriptional proteins]	0.0	4	1	1	1
124394	1710	Lewis	[Lewis]	0.0	1	1	1	1
124395	1710	NF-kappa b /p50 homodimer	[NF-kappa B /p50 homodimer]	0.0	4	1	1	1
124396	1710	transcription factor include nf- il-6	[transcription factors including NF- IL-6]	0.0	5	1	1	1
124397	1710	peripheral blood pb DC	[peripheral blood PB DC]	0.0	4	1	1	1
124398	1710	immunomodulating activity	[immunomodulating activity]	0.0	2	1	1	1
124399	1710	human T cell clone	[human T cell clones]	0.0	4	1	1	1
124400	1710	b lymphocyte ig production	[B lymphocyte Ig production]	0.0	4	1	1	1
124401	1710	nonpeptidyl molecule sb 247464 capable	[nonpeptidyl molecule SB 247464 capable]	0.0	5	1	1	1
124402	1710	repeat DR of 21 bp	[repeats DR of 21 bp]	0.0	5	1	1	1
124403	1710	binding of YY1	[Binding of YY1]	0.0	3	1	1	1
124404	1710	contrast, prostaglandin I2	[contrast, prostaglandin I2]	0.0	3	1	1	1
124405	1710	value of D3 calcitriol determination	[value of D3 calcitriol determination]	0.0	5	1	1	1
124406	1710	constitutive phosphorylation STAT3	[Constitutive phosphorylation STAT3]	0.0	3	1	1	1
124407	1710	block the translocation	[blocking the translocation]	0.0	3	1	1	1
124408	1710	5'-Rapid amplification of cDNA end analysis	[5'-Rapid amplification of cDNA ends analysis]	0.0	6	1	1	1
124409	1710	structural characteristic	[structural characteristics]	0.0	2	1	1	1
124410	1710	nuclear translocation of nfat nuclear factor	[nuclear translocation of NFAT nuclear factor]	0.0	6	1	1	1
124411	1710	stat complex in human T	[STAT complexes in human T]	0.0	5	1	1	1
124412	1710	especially with marker	[especially with markers]	0.0	3	1	1	1
124413	1710	development of feature	[development of features]	0.0	3	1	1	1
124414	1710	response of lymphocyte	[responses of lymphocytes]	0.0	3	1	1	1
124415	1710	expression of membrane protein-1	[expression of membrane protein-1]	0.0	4	1	1	1
124416	1710	cognate interaction between tissue fibroblast	[cognate interactions between tissue fibroblasts]	0.0	5	1	1	1
124417	1710	regulatory network operate	[regulatory network operating]	0.0	3	1	1	1
124418	1710	anti-c/ebpbeta	[anti-C/EBPbeta]	0.0	1	1	1	1
124419	1710	instead of pp2a	[instead of PP2A]	0.0	3	1	1	1
124420	1710	long arm,	[long arm,]	0.0	2	1	1	1
124421	1710	appearance of a inducible nuclear factor	[appearance of an inducible nuclear factor]	0.0	6	1	1	1
124422	1710	cd95 expression	[CD95 expression]	0.0	2	1	1	1
124423	1710	hormone suppression of tumor cell cytostasis	[hormone suppression of tumor cell cytostasis]	0.0	6	1	1	1
124424	1710	acid response	[acid response]	0.0	2	1	1	1
124425	1710	site suitable	[sites suitable]	0.0	2	1	1	1
124426	1710	-NHOH	[-NHOH]	0.0	1	2	2	1
124427	1710	reduction in transcription	[reduction in transcription]	0.0	3	1	1	1
124428	1710	moreover, oligodeoxynucleotides	[Moreover, oligodeoxynucleotides]	0.0	2	1	1	1
124429	1710	proliferative activity,	[proliferative activity,]	0.0	2	1	1	1
124430	1710	clinical course chi2	[clinical course chi2]	0.0	3	1	1	1
124431	1710	agonist as lipopolysaccharide	[agonists as lipopolysaccharide]	0.0	3	1	1	1
124432	1710	interaction with membrane	[interaction with membrane]	0.0	3	1	1	1
124433	1710	phorbol myristake	[phorbol myristake]	0.0	2	1	1	1
124434	1710	allergen-specific population	[allergen-specific populations]	0.0	2	1	1	1
124435	1710	mutation/deletion -223 basis	[mutation/deletion -223 bases]	0.0	3	1	1	1
124436	1710	role in normal T cell	[Role in normal T cells]	0.0	5	1	1	1
124437	1710	small number mutant progenitor cell	[small number mutant progenitor cells]	0.0	5	1	1	1
124438	1710	mouse astrocyte	[mouse astrocytes]	0.0	2	1	1	1
124439	1710	expression of downstream, gene	[expression of downstream, genes]	0.0	4	1	1	1
124440	1710	ebv-negative Burkitt lymphoma	[EBV-negative Burkitt lymphoma]	0.0	3	1	1	1
124441	1710	platelet from untreated euthymic	[platelets from untreated euthymic]	0.0	4	1	1	1
124442	1710	preincubation of cell lipopolysaccharide	[Preincubation of cells lipopolysaccharide]	0.0	4	1	1	1
124443	1710	encode subunit of this factor	[encoding subunits of these factors]	0.0	5	1	1	1
124444	1710	explore signal pathway	[exploring signaling pathways]	0.0	3	1	1	1
124445	1710	localization of the 135eoh)2d3 receptor	[localization of the 1,25(OH)2D3 receptor]	0.0	5	1	1	1
124446	1710	result in a induction	[resulting in a induction]	0.0	4	1	1	1
124447	1710	insight into the biological function	[insight into the biological function]	0.0	5	1	1	1
124448	1710	T cell costimulation	[T cell costimulation]	0.0	3	1	1	1
124449	1710	4.5-kilobase pair mrna	[4.5-kilobase pair mRNA]	0.0	3	1	1	1
124450	1710	understand th1/th2 development	[understanding Th1/Th2 development]	0.0	3	1	1	1
124451	1710	image	[image]	0.0	1	1	1	1
124452	1710	gata-1 binding transcription	[GATA-1 binding transcription]	0.0	3	1	1	1
124453	1710	cd14 signal transduction	[CD14 signal transduction]	0.0	3	1	1	1
124454	1710	activation in a T-lymphocytic cell line	[Activation in a T-lymphocytic cell line]	0.0	6	1	1	1
124455	1710	five dermatitis patient	[five dermatitis patients]	0.0	3	1	1	1
124456	1710	many basic (bhlh) transcription factor	[many basic (bHLH) transcription factors]	0.0	5	1	1	1
124457	1710	gel shift analysis on extract	[gel shift analysis on extracts]	0.0	5	1	1	1
124458	1710	indirect, alteration of the sequence	[indirect, alteration of the sequence]	0.0	5	1	1	1
124459	1710	gene activation in blood-derived monocyte	[gene activation in blood-derived monocytes]	0.0	5	1	1	1
124460	1710	iron availability during erythropoiesis	[iron availability during erythropoiesis]	0.0	4	1	1	1
124461	1710	IL-4 receptor subunit alpha	[IL-4 receptor subunits alpha]	0.0	4	1	1	1
124462	1710	mediate low shear- ec-mn adhesion	[mediating low shear- EC-Mn adhesion]	0.0	5	1	1	1
124463	1710	immunodeficiency virus hiv persistence	[immunodeficiency virus HIV persistence]	0.0	4	2	2	1
124464	1710	mnda cell nuclear differentiation antigen	[MNDA cell nuclear differentiation antigen]	0.0	5	1	1	1
124465	1710	cycle antigen	[cycle antigens]	0.0	2	1	1	1
124466	1710	scant cytoplasm with fine granularity	[scant cytoplasm with fine granularity]	0.0	5	1	1	1
124467	1710	healthy female aged	[healthy females aged]	0.0	3	1	1	1
124468	1710	abnormal morphology indicative of dysplasia	[abnormal morphology indicative of dysplasia]	0.0	5	1	1	1
124469	1710	strains.	[strains.]	0.0	1	1	1	1
124470	1710	subtype of retinoic acid receptor	[subtypes of retinoic acid receptors]	0.0	5	1	1	1
124471	1710	human sle	[human SLE]	0.0	2	1	1	1
124472	1710	basis for induction of antibody	[basis for induction of antibodies]	0.0	5	1	1	1
124473	1710	platelet to thrombin	[platelets to thrombin]	0.0	3	1	1	1
124474	1710	two protein BZLF1	[two proteins BZLF1]	0.0	3	1	1	1
124475	1710	sequence downstream	[sequences downstream]	0.0	2	1	1	1
124476	1710	expressed; cell express receptor	[expressed; cells expressing receptors]	0.0	4	1	1	1
124477	1710	other T mouse	[other T mice]	0.0	3	1	1	1
124478	1710	noninvasive, blood pressure monitor	[noninvasive, blood pressure monitor]	0.0	4	1	1	1
124479	1710	TPA responsiveness	[TPA responsiveness]	0.0	2	1	1	1
124480	1710	decrease activation after pretreatment	[decrease activation after pretreatment]	0.0	4	1	1	1
124481	1710	any, basal activity	[any, basal activity]	0.0	3	1	1	1
124482	1710	1600 VDR	[1600 VDR]	0.0	2	1	1	1
124483	1710	mitogenic activation of b	[mitogenic activation of B]	0.0	4	1	1	1
124484	1710	il-2 receptor (il-2r)	[IL-2 receptor (IL-2R)]	0.0	3	1	1	1
124485	1710	differentiate effect	[differentiating effects]	0.0	2	1	1	1
124486	1710	Furthermore, acid receptor RAR	[Furthermore, acid receptor RAR]	0.0	4	1	1	1
124487	1710	evasion of response	[evasion of responses]	0.0	3	1	1	1
124488	1710	characterization of a new transcription factor	[Characterization of a new transcription factor]	0.0	6	1	1	1
124489	1710	region between -46	[region between -46]	0.0	3	1	1	1
124490	1710	constitutive, low-level expression	[constitutive, low-level expression]	0.0	3	1	1	1
124491	1710	six cell line	[six cell lines]	0.0	3	1	1	1
124492	1710	trans relationship	[trans relationship]	0.0	2	1	1	1
124493	1710	emergence of transcription factor	[emergence of transcription factors]	0.0	4	1	1	1
124494	1710	role for intracellular thiol	[role for intracellular thiols]	0.0	4	1	1	1
124495	1710	viral segment	[viral segment]	0.0	2	1	1	1
124496	1710	start at the stage	[starting at the stages]	0.0	4	1	1	1
124497	1710	GM-CSF blood polymorphonuclear leukocyte functional activation	[GM-CSF blood polymorphonuclear leukocytes functional activation]	0.0	6	1	1	1
124498	1710	hyper-sensitivity	[hyper-sensitivity]	0.0	1	1	1	1
124499	1710	calcitriol (final ethanol concentration 0.0001%	[calcitriol (final ethanol concentration 0.0001%]	0.0	5	1	1	1
124500	1710	platelet transfusion	[platelet transfusion]	0.0	2	1	1	1
124501	1710	human pebp2 alpha a	[human PEBP2 alpha A]	0.0	4	1	1	1
124502	1710	complex with Abs	[complexes with Abs]	0.0	3	1	1	1
124503	1710	herpesvirus capable	[herpesvirus capable]	0.0	2	1	1	1
124504	1710	expression of phenotype	[expression of phenotypes]	0.0	3	1	1	1
124505	1710	feature of monocyte/macrophage function	[features of monocyte/macrophage function]	0.0	4	1	1	1
124506	1710	oct-2a	[Oct-2A]	0.0	1	1	1	1
124507	1710	patient with lymphatic leukemia	[patients with lymphatic leukemia]	0.0	4	1	1	1
124508	1710	constituent in adult blood	[constituent in adult blood]	0.0	4	1	1	1
124509	1710	deletion of the enhancer upstream	[Deletion of the enhancer upstream]	0.0	5	1	1	1
124510	1710	butyric-acid yy-1	[butyric-acid YY-1]	0.0	2	1	1	1
124511	1710	addition to diffuse localization	[addition to diffuse localization]	0.0	4	1	1	1
124512	1710	pt of 172	[PT of 172]	0.0	3	1	1	1
124513	1710	alpha line	[alpha lines]	0.0	2	1	1	1
124514	1710	heterozygous status	[heterozygous status]	0.0	2	1	1	1
124515	1710	region of il-2r beta Ser386-Val525	[region of IL-2R beta Ser386-Val525]	0.0	5	1	1	1
124516	1710	recombinant il-2 rhil-2	[recombinant IL-2 rhIL-2]	0.0	3	1	1	1
124517	1710	one BL case	[one BL case]	0.0	3	1	1	1
124518	1710	RA subclone hl60r	[RA subclone HL60R]	0.0	3	1	1	1
124519	1710	distinct pathway during activation	[distinct pathways during activation]	0.0	4	1	1	1
124520	1710	clipping bandshift assay	[clipping bandshift assays]	0.0	3	1	1	1
124521	1710	b nuclear factor	[B nuclear factor]	0.0	3	1	1	1
124522	1710	AML1 runt	[AML1 runt]	0.0	2	1	1	1
124523	1710	hepatic nuclear factor hnf3 beta	[hepatic nuclear factor HNF3 beta]	0.0	5	1	1	1
124524	1710	ifn-gamma stat1 receptor activation	[IFN-gamma STAT1 receptor activation]	0.0	4	1	1	1
124525	1710	70z/3	[70Z/3]	0.0	1	1	1	1
124526	1710	TR:TRE	[TR:TRE]	0.0	1	1	1	1
124527	1710	exposure to fludarabine	[exposure to fludarabine]	0.0	3	1	1	1
124528	1710	CD28 effect	[CD28 effects]	0.0	2	1	1	1
124529	1710	Furthermore, retinoic acid receptor alpha	[Furthermore, retinoic acid receptor alpha]	0.0	5	1	1	1
124530	1710	ikbalpha	[IkBalpha]	0.0	1	1	1	1
124531	1710	domain common	[domain common]	0.0	2	1	1	1
124532	1710	overnight dexamethasone test	[overnight dexamethasone test]	0.0	3	1	1	1
124533	1710	expression during differentiation of myeloid cells.	[expression during differentiation of myeloid cells.]	0.0	6	1	1	1
124534	1710	human erythrocyte ndp kinase protein	[human erythrocyte NDP kinase protein]	0.0	5	1	1	1
124535	1710	c/ebp-epsilon amino acid	[C/EBP-epsilon amino acids]	0.0	3	1	1	1
124536	1710	Conversely, genistein	[Conversely, genistein]	0.0	2	1	1	1
124537	1710	glucocorticoid therapy for systemic disease	[glucocorticoid therapy for systemic diseases]	0.0	5	1	1	1
124538	1710	contain copy of the nf-at site	[containing copies of the NF-AT site]	0.0	6	1	1	1
124539	1710	il-9 activation	[IL-9 activation]	0.0	2	1	1	1
124540	1710	candidate gene hepatic factor 3 beta	[candidate genes hepatic factor 3 beta]	0.0	6	1	1	1
124541	1710	T cell-specific control region	[T cell-specific control regions]	0.0	4	1	1	1
124542	1710	coupling between sIg protein	[coupling between sIg proteins]	0.0	4	1	1	1
124543	1710	export in cell	[export in cells]	0.0	3	1	1	1
124544	1710	only the first exon	[only the first exon]	0.0	4	1	1	1
124545	1710	8, malignant histiocytoma 6, rhabdomyosarcoma	[8, malignant histiocytoma 6, rhabdomyosarcoma]	0.0	5	1	1	1
124546	1710	contain the IL-4 promoter	[containing the IL-4 promoter]	0.0	4	1	1	1
124547	1710	binding of pac-1 two antibody	[binding of PAC-1 two antibodies]	0.0	5	1	1	1
124548	1710	signalling cascade	[signalling cascade]	0.0	2	1	1	1
124549	1710	partial sequence of the region	[partial sequences of the region]	0.0	5	1	1	1
124550	1710	mature c epsilon transcription	[mature C epsilon transcription]	0.0	4	1	1	1
124551	1710	two product of monocyte	[two products of monocytes]	0.0	4	1	1	1
124552	1710	characterization binding to element	[characterization Binding to element]	0.0	4	1	1	1
124553	1710	affect the effector mechanism	[affecting the effector mechanism]	0.0	4	1	1	1
124554	1710	tax through enhancement	[Tax through enhancement]	0.0	3	1	1	1
124555	1710	nuclei of b cell	[nuclei of B cells]	0.0	4	1	1	1
124556	1710	NFATp/c-	[NFATp/c-]	0.0	1	1	1	1
124557	1710	maximal inhibition of 90%.	[maximal inhibition of 90%.]	0.0	4	1	1	1
124558	1710	granulocyte-macrophage colony	[Granulocyte-macrophage colony]	0.0	2	1	1	1
124559	1710	dose (more	[dose (more]	0.0	2	1	1	1
124560	1710	cell-specific expression	[cell-specific expression]	0.0	2	2	2	1
124561	1710	human peripheral blood cell response	[human peripheral blood cell responses]	0.0	5	1	1	1
124562	1710	jeg-3 cell	[JEG-3 cells]	0.0	2	1	1	1
124563	1710	understand the function of gata-1	[understanding the function of GATA-1]	0.0	5	1	1	1
124564	1710	Retinoic expression of CD38 antigen	[Retinoic expression of CD38 antigen]	0.0	5	1	1	1
124565	1710	factor-kappaB nf-kappab regulation	[factor-kappaB NF-kappaB regulation]	0.0	3	1	1	1
124566	1710	22 woman	[22 women]	0.0	2	1	1	1
124567	1710	potential of the vsmc-myc cell	[potential of the VSMC-myc cells]	0.0	5	1	1	1
124568	1710	mouse splenic b cell	[mouse splenic B cells]	0.0	4	1	1	1
124569	1710	immediate gene Ie of cytomegalovirus	[immediate genes IE of cytomegalovirus]	0.0	5	1	1	1
124570	1710	induction protein	[induction protein]	0.0	2	1	1	1
124571	1710	corresponding to a novel factor	[corresponding to a novel factor]	0.0	5	1	1	1
124572	1710	two IL-1alpha kappab-like site	[two IL-1alpha kappaB-like sites]	0.0	4	1	1	1
124573	1710	o,o'-bismyristoyl esterification	[o,o'-bismyristoyl esterification]	0.0	2	1	1	1
124574	1710	regulation of proto-oncogent	[regulation of proto-oncogenes]	0.0	3	1	1	1
124575	1710	alpha thf/thf (0.35; n: 0.92+/-0.42)	[alpha THF/THF (0.35; N: 0.92+/-0.42)]	0.0	5	1	1	1
124576	1710	occur upon activation	[occurring upon activation]	0.0	3	1	1	1
124577	1710	determinant regulate nuclear factor-kappa b activation	[determinants regulating nuclear factor-kappa B activation]	0.0	6	1	1	1
124578	1710	combination of 1, 25(oh)2d3	[combination of 1, 25(OH)2D3]	0.0	4	1	1	1
124579	1710	involve defective sexual differentiation	[involving defective sexual differentiation]	0.0	4	1	1	1
124580	1710	-contain plasmid	[-containing plasmids]	0.0	2	1	1	1
124581	1710	temporal analysis	[Temporal analysis]	0.0	2	1	1	1
124582	1710	nmol/l, incubation time h	[nmol/l, incubation time h]	0.0	4	1	1	1
124583	1710	physical interaction NF-kappaB/NFAT protein	[Physical interactions NF-kappaB/NFAT proteins]	0.0	4	1	1	1
124584	1710	generate granulocyte	[generating granulocytes]	0.0	2	1	1	1
124585	1710	activation in Jurkat T cell	[activation in Jurkat T cells]	0.0	5	1	1	1
124586	1710	proliferative ability in response	[proliferative ability in response]	0.0	4	1	1	1
124587	1710	liposomal	[Liposomal]	0.0	1	1	1	1
124588	1710	ionophore a23187	[ionophore A23187]	0.0	2	1	1	1
124589	1710	herbimycin A a inhibitor	[herbimycin A a inhibitor]	0.0	4	1	1	1
124590	1710	1) PMA	[1) PMA]	0.0	2	1	1	1
124591	1710	expression of function-related gene	[expression of function-related genes]	0.0	4	1	1	1
124592	1710	element active	[element active]	0.0	2	1	1	1
124593	1710	macrophage culture	[macrophage cultures]	0.0	2	1	1	1
124594	1710	ifn-gamma-induced class gene expression	[IFN-gamma-induced class gene expression]	0.0	4	1	1	1
124595	1710	24 woman	[24 women]	0.0	2	1	1	1
124596	1710	contain the protein p60	[containing the proteins p60]	0.0	4	1	1	1
124597	1710	serum element	[serum element]	0.0	2	1	1	1
124598	1710	hil-5 cell line	[hIL-5 cell lines]	0.0	3	1	1	1
124599	1710	trans-disulfide of thiamine disulfide	[trans-disulfide of thiamine disulfide]	0.0	4	1	1	1
124600	1710	multiple transcriptional element	[multiple transcriptional elements]	0.0	3	1	1	1
124601	1710	stimulation of eosinophil	[stimulation of eosinophils]	0.0	3	1	1	1
124602	1710	glucocorticoid receptor level in leukocyte	[glucocorticoid receptor levels in leukocytes]	0.0	5	1	1	1
124603	1710	promoter sequence responsive to AMP	[Promoter sequences responsive to AMP]	0.0	5	1	1	1
124604	1710	domain)	[domain)]	0.0	1	1	1	1
124605	1710	primary source of interferon gamma	[primary source of interferon gamma]	0.0	5	1	1	1
124606	1710	dna-binding molecule	[DNA-binding molecules]	0.0	2	1	1	1
124607	1710	3kb upstream	[3kb upstream]	0.0	2	1	1	1
124608	1710	interaction of pr	[interactions of PR]	0.0	3	1	1	1
124609	1710	ligand for acid receptor	[ligands for acid receptors]	0.0	4	1	1	1
124610	1710	e2f transcription	[E2F transcription]	0.0	2	1	1	1
124611	1710	follow factor treatment of neutrophils.	[following factor treatment of neutrophils.]	0.0	5	1	1	1
124612	1710	T cell line of two infant	[T cell lines of two infants]	0.0	6	1	1	1
124613	1710	implication in research	[implication in research]	0.0	3	1	1	1
124614	1710	constitutive binding of further factor protein	[Constitutive binding of further factor proteins]	0.0	6	1	1	1
124615	1710	103-amino-acid protein	[103-amino-acid protein]	0.0	2	1	1	1
124616	1710	blood volunteer (86 man	[blood volunteers (86 men]	0.0	4	1	1	1
124617	1710	signal-regulated kinase erk	[signal-regulated kinase Erk]	0.0	3	1	1	1
124618	1710	enhancer-like element	[enhancer-like element]	0.0	2	1	1	1
124619	1710	enzyme-linked immunosorbent assay procedure	[enzyme-linked immunosorbent assay procedure]	0.0	4	1	1	1
124620	1710	two nf-at complex with a oligonucleotide	[two NF-AT complexes with an oligonucleotide]	0.0	6	1	1	1
124621	1710	activation by phorbol 13-acetate	[activation by phorbol 13-acetate]	0.0	4	1	1	1
124622	1710	lyso-	[lyso-]	0.0	1	1	1	1
124623	1710	Novel therapy	[Novel therapies]	0.0	2	1	1	1
124624	1710	ru-38486	[RU-38486]	0.0	1	1	1	1
124625	1710	cell-cycle progression	[cell-cycle progression]	0.0	2	1	1	1
124626	1710	use mobility shift analysis	[Using mobility shift analysis]	0.0	4	1	1	1
124627	1710	monocytic cell type-specific induction	[Monocytic cell type-specific induction]	0.0	4	1	1	1
124628	1710	serum-inducible element hSIE dna-probe	[serum-inducible element hSIE DNA-probe]	0.0	4	1	1	1
124629	1710	important pathway lead from cell	[important pathway leading from cells]	0.0	5	1	1	1
124630	1710	two transactivator	[two transactivators]	0.0	2	1	1	1
124631	1710	ca2+ channel	[Ca2+ channels]	0.0	2	1	1	1
124632	1710	study of the Epstein-Barr virus antigen	[studies of the Epstein-Barr virus antigen]	0.0	6	1	1	1
124633	1710	GST- tax	[GST- Tax]	0.0	2	1	1	1
124634	1710	platelet to monocyte	[platelets to monocytes]	0.0	3	1	1	1
124635	1710	basis ifn-gamma tumor necrosis factor-alpha	[basis IFN-gamma tumor necrosis factor-alpha]	0.0	5	1	1	1
124636	1710	terminal repeat (ltr)	[terminal repeat (LTR)]	0.0	3	1	1	1
124637	1710	comparison with clinical factor	[comparison with clinical factors]	0.0	4	1	1	1
124638	1710	udg gene product	[UDG gene product]	0.0	3	1	1	1
124639	1710	leukemias.	[leukemias.]	0.0	1	1	1	1
124640	1710	mrna differential display reverse transcriptase pcr	[mRNA differential display reverse transcriptase PCR]	0.0	6	1	1	1
124641	1710	(gs) cDNA	[(GS) cDNA]	0.0	2	1	1	1
124642	1710	shock lung	[shock lungs]	0.0	2	1	1	1
124643	1710	notably product such as lipopolysaccharide lps	[notably products such as lipopolysaccharide LPS]	0.0	6	1	1	1
124644	1710	interleukin-10 production in monocyte	[interleukin-10 production in monocytes]	0.0	4	1	1	1
124645	1710	cold	[cold]	0.0	1	1	1	1
124646	1710	camp kinase c pathway	[cAMP kinase C pathways]	0.0	4	1	1	1
124647	1710	stromal tcell rescue	[stromal Tcell rescue]	0.0	3	1	1	1
124648	1710	exposure to weak stress	[exposure to weak stress]	0.0	4	1	1	1
124649	1710	finely granular Sudan b	[finely granular Sudan B]	0.0	4	1	1	1
124650	1710	alpha-like globin promoter	[alpha-like globin promoters]	0.0	3	1	1	1
124651	1710	contrast, stimulus such as shock	[contrast, stimuli such as shock]	0.0	5	1	1	1
124652	1710	raralpha exhibit dominant-negative activity	[RARalpha exhibiting dominant-negative activity]	0.0	4	1	1	1
124653	1710	NF-kappa b segment	[NF-kappa B segments]	0.0	3	1	1	1
124654	1710	viable mature cell	[viable mature cells]	0.0	3	1	1	1
124655	1710	(100b	[(100B]	0.0	1	1	1	1
124656	1710	regulation of fas-ligand expression	[Regulation of fas-ligand expression]	0.0	4	1	1	1
124657	1710	convert signal into event	[converting signals into events]	0.0	4	1	1	1
124658	1710	intervene region upstream	[intervening regions upstream]	0.0	3	1	1	1
124659	1710	mutation in the viral repeat	[mutations in the viral repeat]	0.0	5	1	1	1
124660	1710	presence of the site	[presence of the site]	0.0	4	1	1	1
124661	1710	cycle, phyto- hemagglutinin	[cycle, phyto- hemagglutinin]	0.0	3	1	1	1
124662	1710	transcription of il-2	[transcription of IL-2]	0.0	3	1	1	1
124663	1710	fundamental insight	[fundamental insights]	0.0	2	1	1	1
124664	1710	g1 transition	[G1 transition]	0.0	2	1	1	1
124665	1710	hiv-infected cell with antibody (mab)	[HIV-infected cells with antibody (MAb)]	0.0	5	1	1	1
124666	1710	several chemoattract at relevant concentrations.	[several chemoattractants at relevant concentrations.]	0.0	5	1	1	1
124667	1710	influenza infection	[influenza infection]	0.0	2	1	1	1
124668	1710	nonlymphoid tissue during murine embryogenesis	[nonlymphoid tissues during murine embryogenesis]	0.0	5	1	1	1
124669	1710	nuclear inhibition of activation	[nuclear inhibition of activation]	0.0	4	1	1	1
124670	1710	stimulation with chemoattract fmlp	[Stimulation with chemoattractants FMLP]	0.0	4	1	1	1
124671	1710	role of /threonine phosphatase	[role of /threonine phosphatases]	0.0	4	1	1	1
124672	1710	determination of receptor site	[determination of receptor sites]	0.0	4	1	1	1
124673	1710	cell surface adhesion molecule	[cell surface adhesion molecules]	0.0	4	1	1	1
124674	1710	two-dimensional gel electrophoresis system	[two-dimensional gel electrophoresis system]	0.0	4	1	1	1
124675	1710	cytopathic effects.	[cytopathic effects.]	0.0	2	1	1	1
124676	1710	two form stat3alpha	[two forms STAT3alpha]	0.0	3	1	1	1
124677	1710	site for NF-ATp	[site for NF-ATp]	0.0	3	1	1	1
124678	1710	density of receptor	[density of receptors]	0.0	3	1	1	1
124679	1710	factor-beta promoter polymorphism	[factor-beta promoter polymorphisms]	0.0	3	1	1	1
124680	1710	10, granulocyte-macrophage factor	[10, granulocyte-macrophage factor]	0.0	3	1	1	1
124681	1710	clone with sensitive technique	[clone with sensitive techniques]	0.0	4	1	1	1
124682	1710	transcription factor to element	[transcription factors to elements]	0.0	4	1	1	1
124683	1710	tnf-alpha receptor type	[TNF-alpha receptor type]	0.0	3	1	1	1
124684	1710	hybridoma pc60	[hybridoma PC60]	0.0	2	1	1	1
124685	1710	mrna expression of g0/g1 switch gene	[mRNA expression of G0/G1 switch gene]	0.0	6	1	1	1
124686	1710	in-situ labelling	[in-situ labelling]	0.0	2	1	1	1
124687	1710	activity of other transcription factor	[activity of other transcription factors]	0.0	5	1	1	1
124688	1710	hGR level in untreated ibd patient	[hGR levels in untreated IBD patients]	0.0	6	1	1	1
124689	1710	receptor in aged runner	[receptor in aged runner]	0.0	4	1	1	1
124690	1710	ebna gene promoter activity	[EBNA gene promoter activity]	0.0	4	1	1	1
124691	1710	study evidence	[studies evidence]	0.0	2	1	1	1
124692	1710	25 basal cell carcinoma use immunohistochemistry	[25 basal cell carcinomas using immunohistochemistry]	0.0	6	1	1	1
124693	1710	functional importance of the region	[functional importance of the region]	0.0	5	1	1	1
124694	1710	differentiation of naive cell	[differentiation of naive cells]	0.0	4	1	1	1
124695	1710	rbtn-2 binding region	[RBTN-2 binding regions]	0.0	3	1	1	1
124696	1710	therefore fold	[therefore folding]	0.0	2	1	1	1
124697	1710	encode interleukin-2 a cytokine	[encoding interleukin-2 a cytokine]	0.0	4	1	1	1
124698	1710	multiple X1 dna-binding activity	[multiple X1 DNA-binding activities]	0.0	4	1	1	1
124699	1710	hierarchy of control in development	[hierarchy of control in development]	0.0	5	1	1	1
124700	1710	suprachiasmatic nuclei	[suprachiasmatic nuclei]	0.0	2	1	1	1
124701	1710	expression of the expression	[expression of the expression]	0.0	4	1	1	1
124702	1710	roset	[rosetting]	0.0	1	1	1	1
124703	1710	cytokine in vitro	[cytokines in vitro]	0.0	3	1	1	1
124704	1710	human monoblast cell line	[human monoblast cell line]	0.0	4	2	2	1
124705	1710	factor-kappa b nf-kappa b	[factor-kappa B NF-kappa B]	0.0	4	3	3	1
124706	1710	response to IL-13 treatment	[response to IL-13 treatment]	0.0	4	1	1	1
124707	1710	involvement in tcf-mediated transcription	[involvement in Tcf-mediated transcription]	0.0	4	1	1	1
124708	1710	(gamma(c))-like molecule	[(gamma(c))-like molecule]	0.0	2	1	1	1
124709	1710	overexpression in Jurkat T cell	[overexpression in Jurkat T cells]	0.0	5	1	1	1
124710	1710	lysosomal serine protease such as elastase	[lysosomal serine proteases such as elastase]	0.0	6	1	1	1
124711	1710	near-perfect direct repeat	[near-perfect direct repeats]	0.0	3	1	1	1
124712	1710	encode a factor	[encoding a factor]	0.0	3	1	1	1
124713	1710	inhibition by a novel combination	[Inhibition by a novel combination]	0.0	5	1	1	1
124714	1710	relb protein in accessory cell	[RelB proteins in accessory cells]	0.0	5	1	1	1
124715	1710	cell level: association	[cell level: association]	0.0	3	1	1	1
124716	1710	subsequent rolling, adhesion,	[subsequent rolling, adhesion,]	0.0	3	1	1	1
124717	1710	negative molecule of pkc-zeta	[negative molecule of PKC-zeta]	0.0	4	1	1	1
124718	1710	event of inflammation	[events of inflammation]	0.0	3	1	1	1
124719	1710	anti-D antibody	[anti-D antibodies]	0.0	2	1	1	1
124720	1710	human t-cell acute leukemia	[human T-cell acute leukemia]	0.0	4	1	1	1
124721	1710	Peripheral lymphocyte	[Peripheral lymphocytes]	0.0	2	1	1	1
124722	1710	nf-kappab deprivation	[NF-kappaB deprivation]	0.0	2	1	1	1
124723	1710	stat binding factor	[STAT binding factors]	0.0	3	1	1	1
124724	1710	follow transient expression	[following transient expression]	0.0	3	1	1	1
124725	1710	progesterone antibody	[progesterone antibody]	0.0	2	1	1	1
124726	1710	HIV long repeat LTR	[HIV long repeat LTR]	0.0	4	1	1	1
124727	1710	estrogen receptor level	[estrogen receptor levels]	0.0	3	2	2	1
124728	1710	effect through direct binding	[effects through direct binding]	0.0	4	1	1	1
124729	1710	IL-6 response element	[IL-6 response elements]	0.0	3	1	1	1
124730	1710	level in monocytoid u937	[levels in monocytoid U937]	0.0	4	1	1	1
124731	1710	release of IkappaB	[release of IkappaB]	0.0	3	1	1	1
124732	1710	terminal tax deletion mutant	[terminal Tax deletion mutant]	0.0	4	1	1	1
124733	1710	nf-kappab activation by cytokine	[NF-kappaB activation by cytokines]	0.0	4	1	1	1
124734	1710	1-wk course	[1-wk course]	0.0	2	1	1	1
124735	1710	increase in glucocorticoid apoptosis	[increase in glucocorticoid apoptosis]	0.0	4	1	1	1
124736	1710	ebv-positive malignancy	[EBV-positive malignancies]	0.0	2	1	1	1
124737	1710	JAK stat signal pathway	[JAK STAT signaling pathway]	0.0	4	1	1	1
124738	1710	cell of a factor	[cells of a factor]	0.0	4	1	1	1
124739	1710	response of the mother	[response of the mother]	0.0	4	1	1	1
124740	1710	production ifn-gamma	[production IFN-gamma]	0.0	2	1	1	1
124741	1710	site originate 204 bp	[sites originating 204 bp]	0.0	4	1	1	1
124742	1710	om-10.1 cell	[OM-10.1 cells]	0.0	2	1	1	1
124743	1710	human myeloid differentiation antigen MNDA	[human myeloid differentiation antigen MNDA]	0.0	5	1	1	1
124744	1710	hepatocyte nuclear factor HNF-1alpha	[hepatocyte nuclear factors HNF-1alpha]	0.0	4	1	1	1
124745	1710	IL-13 gene locus	[IL-13 gene locus]	0.0	3	1	1	1
124746	1710	(map)	[(MAP)]	0.0	1	2	2	1
124747	1710	stimulate factor treatment of human neutrophils.	[stimulating factor treatment of human neutrophils.]	0.0	6	1	1	1
124748	1710	ces-2	[CES-2]	0.0	1	1	1	1
124749	1710	calcineurin cn	[calcineurin CN]	0.0	2	1	1	1
124750	1710	govern lineage switch from the eosinophil	[governing lineage switching from the eosinophil]	0.0	6	1	1	1
124751	1710	danazol on site	[danazol on sites]	0.0	3	1	1	1
124752	1710	globin element HS-40	[globin element HS-40]	0.0	3	1	1	1
124753	1710	weak complex resemble factor	[weak complex resembling factor]	0.0	4	1	1	1
124754	1710	tyrosine phosphorylation of transcriptional factor	[tyrosine phosphorylation of transcriptional factor]	0.0	5	1	1	1
124755	1710	coup	[COUP]	0.0	1	1	1	1
124756	1710	basal promoter for activity	[basal promoter for activity]	0.0	4	1	1	1
124757	1710	BZLF-1 mechanism	[BZLF-1 mechanism]	0.0	2	1	1	1
124758	1710	x receptor RXR	[X receptor RXR]	0.0	3	1	1	1
124759	1710	naive, DC -mediate response	[naive, DC -mediated responses]	0.0	4	1	1	1
124760	1710	activation of transcription by binding	[Activation of transcription by binding]	0.0	5	1	1	1
124761	1710	regulation of the level	[regulation of the levels]	0.0	4	1	1	1
124762	1710	acid on human embryonic/fetal hematopoiesis	[acid on human embryonic/fetal hematopoiesis]	0.0	5	1	1	1
124763	1710	vein segment	[vein segments]	0.0	2	1	1	1
124764	1710	METHODS: eight malignant cell line	[METHODS: Eight malignant cell lines]	0.0	5	1	1	1
124765	1710	use a anti CD20 antibody	[using an anti CD20 antibody]	0.0	5	1	1	1
124766	1710	e2-f1	[E2-F1]	0.0	1	1	1	1
124767	1710	specific uptake	[specific uptake]	0.0	2	2	2	1
124768	1710	interaction between RA	[interactions between RA]	0.0	3	1	1	1
124769	1710	tyrosine of SLP-76	[tyrosines of SLP-76]	0.0	3	1	1	1
124770	1710	pyrimidine -rich element 5'-pyctttg-3'	[pyrimidine -rich elements 5'-PyCTTTG-3']	0.0	4	1	1	1
124771	1710	present in infancy	[presenting in infancy]	0.0	3	1	1	1
124772	1710	such as tyrosine phosphorylation	[such as tyrosine phosphorylation]	0.0	4	1	1	1
124773	1710	extensive intraductal component	[extensive intraductal component]	0.0	3	1	1	1
124774	1710	p less than 0.005).	[p less than 0.005).]	0.0	4	1	1	1
124775	1710	functional phosphoserine residue	[functional phosphoserine residues]	0.0	3	1	1	1
124776	1710	co-localization with antigen	[co-localization with antigens]	0.0	3	1	1	1
124777	1710	such as vascular cell adhesion molecule-1	[such as vascular cell adhesion molecule-1]	0.0	6	1	1	1
124778	1710	congruence	[congruence]	0.0	1	1	1	1
124779	1710	renewal of progenitor	[renewal of progenitors]	0.0	3	1	1	1
124780	1710	role for PGE2	[role for PGE2]	0.0	3	1	1	1
124781	1710	enable efficient activation	[enabling efficient activation]	0.0	3	1	1	1
124782	1710	three mouse strain	[Three mouse strains]	0.0	3	1	1	1
124783	1710	20 mu/l testing concentration),	[20 mU/L testing concentration),]	0.0	4	1	1	1
124784	1710	simple binding of tnf-alpha	[simple binding of TNF-alpha]	0.0	4	1	1	1
124785	1710	17-bp serum response factor	[17-bp serum response factor]	0.0	4	1	1	1
124786	1710	part of sequence	[part of sequences]	0.0	3	1	1	1
124787	1710	tat affinity	[Tat affinity]	0.0	2	1	1	1
124788	1710	adenoviral transfer	[adenoviral transfer]	0.0	2	1	1	1
124789	1710	follicular hyperplasias	[follicular hyperplasias]	0.0	2	2	2	1
124790	1710	expression of two gene	[expression of two genes]	0.0	4	1	1	1
124791	1710	affinity of transcriptional regulatory element	[affinities of transcriptional regulatory elements]	0.0	5	1	1	1
124792	1710	protein 50 kda	[proteins 50 kDa]	0.0	3	1	1	1
124793	1710	induction (ifn)-inducible protein 10 differentiation	[induction (IFN)-inducible protein 10 differentiation]	0.0	5	1	1	1
124794	1710	glucocorticoid receptor changes, oppose	[glucocorticoid receptor changes, opposing]	0.0	4	1	1	1
124795	1710	mechanism of this inhibition.	[mechanism of this inhibition.]	0.0	4	1	1	1
124796	1710	list	[list]	0.0	1	2	2	1
124797	1710	target structure the protein	[Target structures the protein]	0.0	4	1	1	1
124798	1710	factor-90	[factor-90]	0.0	1	1	1	1
124799	1710	other aspect of the signalling network	[other aspects of the signalling network]	0.0	6	1	1	1
124800	1710	dissociation constant of 0.1 nm	[dissociation constant of 0.1 nM]	0.0	5	1	1	1
124801	1710	addition to initiation factor	[addition to initiation factors]	0.0	4	1	1	1
124802	1710	one molecular mechanism	[one molecular mechanism]	0.0	3	1	1	1
124803	1710	IcsA	[IcsA]	0.0	1	1	1	1
124804	1710	circulate human monocyte	[circulating human monocytes]	0.0	3	1	1	1
124805	1710	site within the element	[sites within the element]	0.0	4	1	1	1
124806	1710	1 mm)	[1 mM)]	0.0	2	1	1	1
124807	1710	transcript, PML/RARalpha	[transcript, PML/RARalpha]	0.0	2	1	1	1
124808	1710	regulation of the octamer motif enhancer	[regulation of the octamer motif enhancer]	0.0	6	1	1	1
124809	1710	(ars) protein	[(AES) protein]	0.0	2	1	1	1
124810	1710	antiproliferative effects,	[antiproliferative effects,]	0.0	2	1	1	1
124811	1710	decline in il-2 production	[decline in IL-2 production]	0.0	4	1	1	1
124812	1710	interference of RU 486	[interference of RU 486]	0.0	4	1	1	1
124813	1710	activity of the classic GCR	[activity of the classic GCR]	0.0	5	1	1	1
124814	1710	adenocarcinoma reactive monoclonal antibody	[adenocarcinoma reactive monoclonal antibody]	0.0	4	1	1	1
124815	1710	retinoid X receptor agonist-induced activation	[Retinoid X receptor agonist-induced activation]	0.0	5	1	1	1
124816	1710	overexpression of bcl-2	[overexpression of bcl-2]	0.0	3	1	1	1
124817	1710	DNA synthesis for up would	[DNA synthesis for up d]	0.0	5	1	1	1
124818	1710	intracellular level of nf-kappab subunit	[intracellular levels of NF-kappaB subunits]	0.0	5	1	1	1
124819	1710	region of the genome	[region of the genome]	0.0	4	1	1	1
124820	1710	seven gene	[seven genes]	0.0	2	1	1	1
124821	1710	Indeed, binding	[Indeed, binding]	0.0	2	1	1	1
124822	1710	24-hydroxylase mrna expression	[24-hydroxylase mRNA expression]	0.0	3	1	1	1
124823	1710	germinal center b	[germinal center B]	0.0	3	1	1	1
124824	1710	beta,19-epoxy-3-hydroxypregnan-20-one (6) beta,19-epoxy-4-hydroxypregnane-3,20-dione	[beta,19-epoxy-3-hydroxypregnan-20-one (6) beta,19-epoxy-4-hydroxypregnane-3,20-dione]	0.0	3	1	1	1
124825	1710	include immunodeficiency virus gene	[including immunodeficiency virus genes]	0.0	4	1	1	1
124826	1710	putative gene	[putative gene]	0.0	2	1	1	1
124827	1710	reactive oxygen -release of monocyte	[Reactive oxygen -release of monocytes]	0.0	5	1	1	1
124828	1710	hormonal status after surgery	[Hormonal status after surgery]	0.0	4	1	1	1
124829	1710	effect in patient with asthma	[effect in patients with asthma]	0.0	5	1	1	1
124830	1710	role for RanBP1	[role for RanBP1]	0.0	3	1	1	1
124831	1710	(30 minutes) to acid atra washed,	[(30 minutes) to acid ATRA washed,]	0.0	6	1	1	1
124832	1710	dicoumarol	[dicoumarol]	0.0	1	1	1	1
124833	1710	cell-specific difference in transactivation	[cell-specific differences in transactivation]	0.0	4	1	1	1
124834	1710	CD28 effect on NF-kappaB	[CD28 effects on NF-kappaB]	0.0	4	1	1	1
124835	1710	(p<.001)	[(P<.001)]	0.0	1	1	1	1
124836	1710	cooperation between signal pathway	[cooperation between signaling pathways]	0.0	4	1	1	1
124837	1710	overproduction by macrophage	[overproduction by macrophages]	0.0	3	1	1	1
124838	1710	linkage between marker on 5q31.1	[linkage between markers on 5q31.1]	0.0	5	1	1	1
124839	1710	5 min.	[5 min.]	0.0	2	1	1	1
124840	1710	GRbeta activity	[GRbeta activity]	0.0	2	1	1	1
124841	1710	also a receptor for chemokine	[also a receptor for chemokines]	0.0	5	1	1	1
124842	1710	involvement of FDC	[involvement of FDC]	0.0	3	1	1	1
124843	1710	hGR level in patient	[hGR levels in patients]	0.0	4	1	1	1
124844	1710	muscle actin	[muscle actin]	0.0	2	1	1	1
124845	1710	complex activator protein-1 ap-1	[complex activator protein-1 AP-1]	0.0	4	1	1	1
124846	1710	increase in virus expression	[increase in virus expression]	0.0	4	1	1	1
124847	1710	CLEO hcleo	[CLEO hCLEO]	0.0	2	1	1	1
124848	1710	microm OP	[microM OP]	0.0	2	1	1	1
124849	1710	single domain	[single domain]	0.0	2	1	1	1
124850	1710	exact etiology	[exact etiology]	0.0	2	1	1	1
124851	1710	thymic choice	[thymic choice]	0.0	2	1	1	1
124852	1710	one possible explanation for toxicity	[one possible explanation for toxicities]	0.0	5	1	1	1
124853	1710	gene in a erythropoietin -dependent manner	[genes in an erythropoietin -dependent manner]	0.0	6	1	1	1
124854	1710	role in malignancy	[role in malignancies]	0.0	3	1	1	1
124855	1710	pertain to LPS	[pertaining to LPS]	0.0	3	1	1	1
124856	1710	transgenic mouse with cd3epsilon gene	[Transgenic mice with CD3epsilon gene]	0.0	5	1	1	1
124857	1710	involvement in chromosomal translocation	[involvement in chromosomal translocations]	0.0	4	1	1	1
124858	1710	cross-reactive specificities,	[cross-reactive specificities,]	0.0	2	1	1	1
124859	1710	activate protein-1 ap-1 bind tpa element	[Activating protein-1 AP-1 binding TPA elements]	0.0	6	1	1	1
124860	1710	herpes simplex virus type 1	[herpes simplex virus type 1]	0.0	5	1	1	1
124861	1710	inclusion of microm RU 38486	[inclusion of microM RU 38486]	0.0	5	1	1	1
124862	1710	regeneration of tetrahydrobiopterin	[regeneration of tetrahydrobiopterin]	0.0	3	1	1	1
124863	1710	constitutive binding in nuclear extract	[constitutive binding in nuclear extracts]	0.0	5	1	1	1
124864	1710	member of the superfamily	[member of the superfamily]	0.0	4	1	1	1
124865	1710	(il)-10 blocking factor pibf	[(IL)-10 blocking factor PIBF]	0.0	4	1	1	1
124866	1710	factor-AT	[factor-AT]	0.0	1	1	1	1
124867	1710	first 900 bp	[first 900 bp]	0.0	3	1	1	1
124868	1710	adhesion with inhibition at 20 mM.	[adhesion with inhibition at 20 mM.]	0.0	6	1	1	1
124869	1710	differ only at residue 57	[differing only at residue 57]	0.0	5	1	1	1
124870	1710	weak site	[weak site]	0.0	2	1	1	1
124871	1710	(U937) cell	[(U937) cells]	0.0	2	1	1	1
124872	1710	Chronic disease mpd	[Chronic diseases MPDs]	0.0	3	1	1	1
124873	1710	autoreactive t-cell in iddm	[autoreactive T-cells in IDDM]	0.0	4	1	1	1
124874	1710	other domain	[other domains]	0.0	2	1	1	1
124875	1710	eight patient 3 years)	[Eight patients 3 years)]	0.0	4	1	1	1
124876	1710	return by 30 min.	[returning by 30 min.]	0.0	4	1	1	1
124877	1710	antibody to il-4r alpha	[antibody to IL-4R alpha]	0.0	4	1	1	1
124878	1710	granulopoiesis postnatally, die by 8 days.	[granulopoiesis postnatally, dying by 8 days.]	0.0	6	1	1	1
124879	1710	microm RU	[microM RU]	0.0	2	1	1	1
124880	1710	NF-kappaB intracellular signal pathway	[NF-kappaB intracellular signaling pathway]	0.0	4	1	1	1
124881	1710	primitive cell in transgenic mouse	[primitive cells in transgenic mice]	0.0	5	1	1	1
124882	1710	burst activity	[burst activity]	0.0	2	1	1	1
124883	1710	Octamer activation	[Octamer activation]	0.0	2	1	1	1
124884	1710	microm RA	[microM RA]	0.0	2	1	1	1
124885	1710	herpesvirus 6 hhv-6	[herpesvirus 6 HHV-6]	0.0	3	3	3	1
124886	1710	thus, deregulation of gene	[Thus, deregulation of genes]	0.0	4	1	1	1
124887	1710	region responsible for ctl-specific expression	[region responsible for CTL-specific expression]	0.0	5	1	1	1
124888	1710	unique morphologic feature membrane	[unique morphologic features membranes]	0.0	4	1	1	1
124889	1710	vascular property	[vascular properties]	0.0	2	1	1	1
124890	1710	tissue oligonucleotide	[tissue oligonucleotide]	0.0	2	1	1	1
124891	1710	differentiation of this cells,	[differentiation of these cells,]	0.0	4	1	1	1
124892	1710	(h292)	[(H292)]	0.0	1	1	1	1
124893	1710	nuclear factor T cell	[nuclear factor T cells]	0.0	4	1	1	1
124894	1710	thus, failure	[Thus, failure]	0.0	2	1	1	1
124895	1710	NF-kappaB/Rel pathway	[NF-kappaB/Rel pathway]	0.0	2	1	1	1
124896	1710	0.7 micromol/(mg	[0.7 micromol/(mg]	0.0	2	1	1	1
124897	1710	scant cytoplasm	[scant cytoplasm]	0.0	2	1	1	1
124898	1710	differentiation of this cells.	[differentiation of these cells.]	0.0	4	1	1	1
124899	1710	general marker	[general marker]	0.0	2	1	1	1
124900	1710	make use	[making use]	0.0	2	1	1	1
124901	1710	description of a class of structure	[description of a class of structures]	0.0	6	1	1	1
124902	1710	cell in culture, lead to adhesion	[cells in culture, leading to adhesion]	0.0	6	1	1	1
124903	1710	N-terminal fragment of bactericidal/permeability-increasing protein	[N-terminal fragment of bactericidal/permeability-increasing protein]	0.0	5	1	1	1
124904	1710	phorbol ester in T	[phorbol esters in T]	0.0	4	1	1	1
124905	1710	indicate molecular heterogeneity within muscle	[indicating molecular heterogeneity within muscle]	0.0	5	1	1	1
124906	1710	ISGF3 alpha	[ISGF3 alpha]	0.0	2	1	1	1
124907	1710	i antibody mab	[I antibody mAb]	0.0	3	1	1	1
124908	1710	tuning	[tuning]	0.0	1	1	1	1
124909	1710	receptor model of lps signal	[receptor model of LPS signaling]	0.0	5	1	1	1
124910	1710	therefore, exposure to nsaid	[therefore, exposure to NSAIDs]	0.0	4	1	1	1
124911	1710	transformation through carboxyl-terminal tail	[transformation through carboxyl-terminal tail]	0.0	4	1	1	1
124912	1710	domain of CD4 virus envelope	[domain of CD4 virus envelope]	0.0	5	1	1	1
124913	1710	other cell-specific gene	[other cell-specific genes]	0.0	3	1	1	1
124914	1710	new insight into role	[new insights into role]	0.0	4	1	1	1
124915	1710	factor bind to site	[Factors binding to site]	0.0	4	1	1	1
124916	1710	trimester pregnancy	[trimester pregnancies]	0.0	2	1	1	1
124917	1710	cell in mouse	[cells in mice]	0.0	3	1	1	1
124918	1710	minute of ifn-beta treatment	[min of IFN-beta treatment]	0.0	4	1	1	1
124919	1710	Ser551	[Ser551]	0.0	1	1	1	1
124920	1710	regulation of factor-kappa beta	[regulation of factor-kappa beta]	0.0	4	1	1	1
124921	1710	CD30 -specific antibody,	[CD30 -specific antibody,]	0.0	3	1	1	1
124922	1710	effect in bone morphogenetic protein-2-	[effects in bone morphogenetic protein-2-]	0.0	5	1	1	1
124923	1710	expression of mmp-9	[expression of MMP-9]	0.0	3	1	1	1
124924	1710	role of c-myb gene	[role of c-myb gene]	0.0	4	1	1	1
124925	1710	nf.kappa b protein from store	[NF.kappa B proteins from stores]	0.0	5	1	1	1
124926	1710	produce concurrent enhancement of lps uptake	[producing concurrent enhancement of LPS uptake]	0.0	6	1	1	1
124927	1710	also for maintenance	[also for maintenance]	0.0	3	1	1	1
124928	1710	sedimentation peak	[sedimentation peak]	0.0	2	1	1	1
124929	1710	critical role integrate the signal	[critical role integrating the signal]	0.0	5	1	1	1
124930	1710	anti-inflammatory mediator like IL	[anti-inflammatory mediators like IL]	0.0	4	1	1	1
124931	1710	IL-4 mrna accumulation of the cytokine	[IL-4 mRNA accumulation of the cytokines]	0.0	6	1	1	1
124932	1710	ras-related protein (rap) 1	[Ras-related protein (Rap) 1]	0.0	4	1	1	1
124933	1710	late effect	[later effects]	0.0	2	2	2	1
124934	1710	include human fibroblast	[including human fibroblasts]	0.0	3	1	1	1
124935	1710	nf-microb	[NF-microB]	0.0	1	1	1	1
124936	1710	activity of Bcl-2	[activity of Bcl-2]	0.0	3	1	1	1
124937	1710	IkappaB-alpha protein level	[IkappaB-alpha protein levels]	0.0	3	1	1	1
124938	1710	box in the putative gene	[boxes in the putative gene]	0.0	5	1	1	1
124939	1710	phosphorylation follow cell stimulation.	[phosphorylation following cell stimulation.]	0.0	4	1	1	1
124940	1710	rest pbmc	[resting PBMCs]	0.0	2	1	1	1
124941	1710	cDNA clone of a response gene,	[cDNA clone of a response gene,]	0.0	6	1	1	1
124942	1710	E2A-HLF mutant	[E2A-HLF mutants]	0.0	2	1	1	1
124943	1710	gata-1 expression in differentiate progenitor	[GATA-1 expression in differentiating progenitors]	0.0	5	1	1	1
124944	1710	thrombin generation by vsmc	[thrombin generation by VSMCs]	0.0	4	1	1	1
124945	1710	factor-KB	[factor-KB]	0.0	1	1	1	1
124946	1710	Growing	[Growing]	0.0	1	1	1	1
124947	1710	reduction in monocyte	[reduction in monocytes]	0.0	3	1	1	1
124948	1710	protein (map) kinase isoform erk2	[protein (MAP) kinase isoform ERK2]	0.0	5	1	1	1
124949	1710	binding at level	[binding at levels]	0.0	3	1	1	1
124950	1710	costimulation of phytohemagglutinin /anti-cd28 T lymphocyte	[Costimulation of phytohemagglutinin /anti-CD28 T lymphocytes]	0.0	6	1	1	1
124951	1710	promoter region of Bcl-x	[promoter region of Bcl-x]	0.0	4	1	1	1
124952	1710	mass of 35.2 kda.	[mass of 35.2 kDa.]	0.0	4	1	1	1
124953	1710	disease cirrhosis	[disease cirrhosis]	0.0	2	1	1	1
124954	1710	unilineage differentiation of progenitor cell	[unilineage differentiation of progenitor cells]	0.0	5	1	1	1
124955	1710	T cells-family protein	[T cells-family proteins]	0.0	3	1	1	1
124956	1710	cd8(+)-t-cell target than opinion	[CD8(+)-T-cell target than opinion]	0.0	4	1	1	1
124957	1710	bending by the hmg domain	[bending by the HMG domain]	0.0	5	1	1	1
124958	1710	number of mutant	[number of mutants]	0.0	3	1	1	1
124959	1710	binding of October protein	[binding of Oct proteins]	0.0	4	1	1	1
124960	1710	requirement in differentiation process	[requirement in differentiation process]	0.0	4	1	1	1
124961	1710	partial reversion	[partial reversion]	0.0	2	1	1	1
124962	1710	wilfordii Hook	[wilfordii Hook]	0.0	2	1	1	1
124963	1710	c1 protein	[C1 protein]	0.0	2	1	1	1
124964	1710	dysregulation by gene fusion	[dysregulation by gene fusion]	0.0	4	1	1	1
124965	1710	interaction functional antagonism	[interaction functional antagonism]	0.0	3	1	1	1
124966	1710	cell growth factor	[cells growth factors]	0.0	3	1	1	1
124967	1710	promoter response	[promoter response]	0.0	2	1	1	1
124968	1710	h at a receptor saturate concentration	[h at a receptor saturating concentration]	0.0	6	1	1	1
124969	1710	biphasic increase with peak	[biphasic increase with peaks]	0.0	4	1	1	1
124970	1710	glucose oxidase	[glucose oxidase]	0.0	2	1	1	1
124971	1710	signal to in vivo modulation	[signal to in vivo modulation]	0.0	5	1	1	1
124972	1710	decrease in the percentage	[decrease in the percentage]	0.0	4	1	1	1
124973	1710	STAT 5 protein in T cell	[STAT 5 proteins in T cells]	0.0	6	1	1	1
124974	1710	role of IL-1 beta	[role of IL-1 beta]	0.0	4	1	1	1
124975	1710	action of physiological concentration	[action of physiological concentration]	0.0	4	1	1	1
124976	1710	variety of human malignancy	[variety of human malignancies]	0.0	4	1	1	1
124977	1710	ERK stimulus	[ERK stimuli]	0.0	2	1	1	1
124978	1710	alternative stage of differentiation	[alternative stages of differentiation]	0.0	4	1	1	1
124979	1710	57.1 dpm	[57.1 dpm]	0.0	2	1	1	1
124980	1710	receptor in FMS patient	[receptors in FMS patients]	0.0	4	1	1	1
124981	1710	(also in arterial cell	[(also in arterial cells]	0.0	4	1	1	1
124982	1710	extensive granulopoiesis typically die days.	[extensive granulopoiesis typically dying days.]	0.0	5	1	1	1
124983	1710	lymphocyte syndrome-associated transactivator	[lymphocyte syndrome-associated transactivators]	0.0	3	1	1	1
124984	1710	major histocompatibility complex (mhc) haplotype	[major histocompatibility complex (MHC) haplotypes]	0.0	5	1	1	1
124985	1710	other region coding	[other regions coding]	0.0	3	1	1	1
124986	1710	proximal short arm	[proximal short arm]	0.0	3	1	1	1
124987	1710	relatively low level	[relatively low levels]	0.0	3	1	1	1
124988	1710	early, transient stimulation	[early, transient stimulation]	0.0	3	1	1	1
124989	1710	extent, ebv antigen	[extent, EBV antigen]	0.0	3	1	1	1
124990	1710	four novel, frequently occur sequence variant	[four novel, frequently occurring sequence variants]	0.0	6	1	1	1
124991	1710	(nmax)	[(Nmax)]	0.0	1	1	1	1
124992	1710	translocation to activation	[translocation to activation]	0.0	3	1	1	1
124993	1710	treatment with soluble, mab j393	[Treatment with soluble, mAb J393]	0.0	5	1	1	1
124994	1710	ht29 cell	[HT29 cells]	0.0	2	1	1	1
124995	1710	mutant tax retain ability	[mutant Tax retaining ability]	0.0	4	1	1	1
124996	1710	artifact	[artifact]	0.0	1	1	1	1
124997	1710	45-nucleotide sequence regulatory element DRE	[45-nucleotide sequence regulatory element DRE]	0.0	5	1	1	1
124998	1710	gamma-ifn gene monocyte	[gamma-IFN genes monocytes]	0.0	3	1	1	1
124999	1710	ICAM-1 mrna	[ICAM-1 mRNA]	0.0	2	1	1	1
125000	1710	leukocyte-platelet conjugate	[leukocyte-platelet conjugates]	0.0	2	1	1	1
125001	1710	phosphorylation-dependent signal	[phosphorylation-dependent signal]	0.0	2	1	1	1
125002	1710	magnetic separation	[magnetic separation]	0.0	2	1	1	1
125003	1710	vascular occlusion a major cause	[vascular occlusion a major cause]	0.0	5	1	1	1
125004	1710	apoptotic "targets" eosinophil	[apoptotic "targets" eosinophils]	0.0	3	1	1	1
125005	1710	basis for the interaction	[basis for the interaction]	0.0	4	1	1	1
125006	1710	phase of development.	[phases of development.]	0.0	3	1	1	1
125007	1710	(b) subunit binding domain.	[(B) subunit binding domain.]	0.0	4	1	1	1
125008	1710	produce the regulating protein fos	[producing the regulating proteins Fos]	0.0	5	1	1	1
125009	1710	alpha b isomer	[alpha B isomers]	0.0	3	1	1	1
125010	1710	Egr-1 Ramos cell	[Egr-1 Ramos cells]	0.0	3	1	1	1
125011	1710	interleukin-4-induced tyrosine phosphorylation	[interleukin-4-induced tyrosine phosphorylation]	0.0	3	1	1	1
125012	1710	metalloproteinase activity	[metalloproteinase activities]	0.0	2	1	1	1
125013	1710	XISTE-	[XISTE-]	0.0	1	1	1	1
125014	1710	cell in a ifn-gamma manner	[cells in an IFN-gamma manner]	0.0	5	1	1	1
125015	1710	transcription of a great variety	[transcription of a great variety]	0.0	5	1	1	1
125016	1710	e2re	[E2RE]	0.0	1	1	1	1
125017	1710	biochemically distinct protein	[biochemically distinct proteins]	0.0	3	1	1	1
125018	1710	mediate the release of the subunit	[mediating the release of the subunit]	0.0	6	1	1	1
125019	1710	inhibition kappa b binding	[inhibition kappa B binding]	0.0	4	1	1	1
125020	1710	T ag	[T ag]	0.0	2	1	1	1
125021	1710	include a gata-1	[including a GATA-1]	0.0	3	1	1	1
125022	1710	sources.	[sources.]	0.0	1	1	1	1
125023	1710	content of ebv DNA	[content of EBV DNA]	0.0	4	1	1	1
125024	1710	rest secretion of the cytokine interleukin-8	[resting secretion of the cytokine interleukin-8]	0.0	6	1	1	1
125025	1710	cp a region	[Cp a region]	0.0	3	1	1	1
125026	1710	recently circulate lymphocyte	[recently circulating lymphocytes]	0.0	3	2	2	1
125027	1710	(3/5 tuberculosis patient	[(3/5 tuberculosis patients]	0.0	3	1	1	1
125028	1710	relationship between DC	[relationships between DC]	0.0	3	1	1	1
125029	1710	use anti-c/ebpbeta NF-IL6 anti-c/ebpdelta	[Using anti-C/EBPbeta NF-IL6 anti-C/EBPdelta]	0.0	4	1	1	1
125030	1710	professional antigen	[professional antigen]	0.0	2	1	1	1
125031	1710	position of XIC/XIST	[position of XIC/XIST]	0.0	3	1	1	1
125032	1710	encode for hemopoietic growth factor	[encoding for hemopoietic growth factors]	0.0	5	1	1	1
125033	1710	regulate the growth	[regulating the growth]	0.0	3	1	1	1
125034	1710	model infection	[model infection]	0.0	2	1	1	1
125035	1710	slowly migrate complex pu-sf	[slowly migrating complex PU-SF]	0.0	4	1	1	1
125036	1710	chronic disease (12: four	[chronic diseases (12: four]	0.0	4	1	1	1
125037	1710	5' negative DNA sequence	[5' negative DNA sequences]	0.0	4	1	1	1
125038	1710	result of inhibition	[result of inhibition]	0.0	3	1	1	1
125039	1710	transcription factor atf-1	[transcription factors ATF-1]	0.0	3	1	1	1
125040	1710	cases, DNA	[cases, DNA]	0.0	2	1	1	1
125041	1710	CD5 antigen	[CD5 antigen]	0.0	2	1	1	1
125042	1710	deletion analysis of the region	[Deletion analysis of the region]	0.0	5	1	1	1
125043	1710	expression from a patient	[expression from a patient]	0.0	4	1	1	1
125044	1710	concern the regulation	[concerning the regulation]	0.0	3	1	1	1
125045	1710	determine the quality	[determining the quality]	0.0	3	1	1	1
125046	1710	accord to results, entities.	[According to results, entities.]	0.0	4	1	1	1
125047	1710	select group	[select group]	0.0	2	1	1	1
125048	1710	minority of the number	[minority of the number]	0.0	4	1	1	1
125049	1710	mumol/L),	[mumol/L),]	0.0	1	1	1	1
125050	1710	IL-3 murine pro-B cell	[IL-3 murine pro-B cells]	0.0	4	1	1	1
125051	1710	putative hormone binding domain	[putative hormone binding domain]	0.0	4	1	1	1
125052	1710	steroid state	[steroid state]	0.0	2	1	1	1
125053	1710	cell include monocyte	[cells including monocytes]	0.0	3	1	1	1
125054	1710	40 minimal promoter region	[40 minimal promoter regions]	0.0	4	1	1	1
125055	1710	last nucleotide	[last nucleotide]	0.0	2	1	1	1
125056	1710	il-1beta gene	[IL-1beta gene]	0.0	2	2	2	1
125057	1710	combination of acid RA	[combination of acid RA]	0.0	4	1	1	1
125058	1710	normal retinoic-acid receptor type alpha	[normal retinoic-acid receptors type alpha]	0.0	5	1	1	1
125059	1710	expression jun b proto-oncogent	[expression jun B proto-oncogenes]	0.0	4	1	1	1
125060	1710	cell-monocyte (ec-mn) adhesion	[cell-monocyte (EC-Mn) adhesion]	0.0	3	1	1	1
125061	1710	IL-10 up-regulation	[IL-10 up-regulation]	0.0	2	1	1	1
125062	1710	peptide bcr1/9	[peptides BCR1/9]	0.0	2	1	1	1
125063	1710	encode gamma c	[encoding gamma c]	0.0	3	1	1	1
125064	1710	Ca2+ isoform	[Ca2+ isoforms]	0.0	2	1	1	1
125065	1710	significant (p	[significant (P]	0.0	2	1	1	1
125066	1710	different event	[different events]	0.0	2	1	1	1
125067	1710	production of population	[production of populations]	0.0	3	1	1	1
125068	1710	/hypereosinophilic agent	[/hypereosinophilic agents]	0.0	2	1	1	1
125069	1710	development of secondary tissue	[Development of secondary tissues]	0.0	4	1	1	1
125070	1710	part by transcript stabilization	[part by transcript stabilization]	0.0	4	1	1	1
125071	1710	28 dayus- glucocorticoid therapy	[28 day, glucocorticoid therapy]	0.0	4	1	1	1
125072	1710	substantial evidence for a effect	[substantial evidence for an effect]	0.0	5	1	1	1
125073	1710	effective dose mol/L).	[effective dose mol/L).]	0.0	3	1	1	1
125074	1710	vaccination with peptide	[Vaccination with peptides]	0.0	3	1	1	1
125075	1710	major cellular component	[major cellular component]	0.0	3	1	1	1
125076	1710	primary astrocytomas /glioblastomas	[primary astrocytomas /glioblastomas]	0.0	3	1	1	1
125077	1710	sideroblast in colony	[sideroblasts in colonies]	0.0	3	1	1	1
125078	1710	3h-tdr	[3H-TdR]	0.0	1	1	1	1
125079	1710	encode other protein	[encoding other proteins]	0.0	3	2	2	1
125080	1710	ibr/f binding site	[IBR/F binding sites]	0.0	3	1	1	1
125081	1710	inhibit protein kinase c activity	[inhibiting protein kinase C activity]	0.0	5	1	1	1
125082	1710	response in allergic rhinitis	[Response in allergic rhinitis]	0.0	4	1	1	1
125083	1710	suppressor of the immune system	[suppressors of the immune system]	0.0	5	1	1	1
125084	1710	c-jun of ras signal	[c-jun of ras signaling]	0.0	4	1	1	1
125085	1710	novel T cell-specific element nre	[novel T cell-specific element NRE]	0.0	5	1	1	1
125086	1710	occur sequence variation	[occurring sequence variation]	0.0	3	1	1	1
125087	1710	gr expression in cell	[GR expression in cells]	0.0	4	1	1	1
125088	1710	complex interplay of protein	[complex interplay of proteins]	0.0	4	1	1	1
125089	1710	dose (>10 microm	[doses (>10 microM]	0.0	3	1	1	1
125090	1710	major complex class ii gene	[major complex class II genes]	0.0	5	1	1	1
125091	1710	CD30 domain	[CD30 domain]	0.0	2	1	1	1
125092	1710	0.5 microgram/day	[0.5 microgram/day]	0.0	2	1	1	1
125093	1710	content of leucocytic er	[contents of leucocytic ER]	0.0	4	1	1	1
125094	1710	initiate tyrosine phosphorylation of intracellular substrate	[initiating tyrosine phosphorylation of intracellular substrates]	0.0	6	1	1	1
125095	1710	little detectable activation	[little detectable activation]	0.0	3	1	1	1
125096	1710	two interleukin	[two interleukins]	0.0	2	1	1	1
125097	1710	Affinity-driven peptide selection selective	[Affinity-driven peptide selection selective]	0.0	4	1	1	1
125098	1710	Minimal residual disease in acute leukemia	[Minimal residual disease in acute leukemia]	0.0	6	1	1	1
125099	1710	c-myc transcript	[c-myc transcripts]	0.0	2	1	1	1
125100	1710	phenotypic study of leukocyte	[Phenotypic studies of leukocytes]	0.0	4	1	1	1
125101	1710	means use deoxyribonuclease	[means using deoxyribonuclease]	0.0	3	1	1	1
125102	1710	also BCL-6	[also BCL-6]	0.0	2	1	1	1
125103	1710	t-cell fk506	[T-cell FK506]	0.0	2	1	1	1
125104	1710	expression of construct	[expression of constructs]	0.0	3	1	1	1
125105	1710	binding of 3h-dexamethasone by lymphocyte receptor	[Binding of 3H-dexamethasone by lymphocyte receptors]	0.0	6	1	1	1
125106	1710	immune stimulation	[immune stimulation]	0.0	2	1	1	1
125107	1710	major histocompatibility class gene expression	[major histocompatibility class gene expression]	0.0	5	1	1	1
125108	1710	disruption of a proline-rich sequence motif	[disruption of a proline-rich sequence motif]	0.0	6	1	1	1
125109	1710	new informative probe	[new informative probes]	0.0	3	1	1	1
125110	1710	induce NF-kappaB	[inducing NF-kappaB]	0.0	2	1	1	1
125111	1710	diethylstilbestrol DES tamoxifen	[diethylstilbestrol DES tamoxifen]	0.0	3	1	1	1
125112	1710	normal cell population	[normal cell population]	0.0	3	1	1	1
125113	1710	prostatic cancer lncap cell	[prostatic cancer LNCaP cells]	0.0	4	1	1	1
125114	1710	lps activation of JNK	[LPS activation of JNK]	0.0	4	1	1	1
125115	1710	1 alphav5 dihydroxyvitamin	[1 alpha,25 dihydroxyvitamin]	0.0	3	1	1	1
125116	1710	lie at the level	[lying at the level]	0.0	4	1	1	1
125117	1710	2-5 fold increase	[2-5 fold increase]	0.0	3	1	1	1
125118	1710	human interferon beta IFN-beta	[human interferon beta IFN-beta]	0.0	4	1	1	1
125119	1710	purine-box/antigen	[purine-box/antigen]	0.0	1	1	1	1
125120	1710	none of pbmc specimen from adult	[None of PBMC specimens from adults]	0.0	6	2	2	1
125121	1710	MRD -positive relapsed.	[MRD -positive relapsed.]	0.0	3	1	1	1
125122	1710	presence of surface	[presence of surfaces]	0.0	3	1	1	1
125123	1710	95.5% amino acid homology	[95.5% amino acid homology]	0.0	4	1	1	1
125124	1710	CD3 signal	[CD3 signals]	0.0	2	1	1	1
125125	1710	mature definitive erythroid cell	[mature definitive erythroid cells]	0.0	4	1	1	1
125126	1710	energy substrate hormone response	[Energy substrates, hormone responses]	0.0	4	1	1	1
125127	1710	3' cytosin	[3' cytosins]	0.0	2	1	1	1
125128	1710	equal amount of a size variant	[equal amounts of a size variant]	0.0	6	1	1	1
125129	1710	mechanism of il-5 synthesis in disease	[mechanisms of IL-5 synthesis in diseases]	0.0	6	1	1	1
125130	1710	regulation effect of glucocorticoid treatment	[Regulation effects of glucocorticoid treatment]	0.0	5	1	1	1
125131	1710	TCL1 oncogene expression in lymphoma	[TCL1 oncogene expression in lymphomas]	0.0	5	1	1	1
125132	1710	phenotype of infected cell	[phenotypes of infected cells]	0.0	4	1	1	1
125133	1710	mutant myc protein capable	[mutant Myc protein capable]	0.0	4	1	1	1
125134	1710	potential role of physical interaction	[potential role of physical interactions]	0.0	5	1	1	1
125135	1710	gene pax-5	[gene Pax-5]	0.0	2	1	1	1
125136	1710	RNA-dependent protein kinase	[RNA-dependent protein kinase]	0.0	3	2	2	1
125137	1710	ac unit	[AC unit]	0.0	2	1	1	1
125138	1710	functional capability pre-treatment	[functional capabilities pre-treatment]	0.0	3	1	1	1
125139	1710	erythroid factor eklf	[erythroid factor EKLF]	0.0	3	1	1	1
125140	1710	proliferative ability	[proliferative ability]	0.0	2	1	1	1
125141	1710	nbt activity	[NBT activity]	0.0	2	1	1	1
125142	1710	Th1 immune response	[Th1 immune responses]	0.0	3	1	1	1
125143	1710	(1) htlv-i infection	[(1) HTLV-I infection]	0.0	3	1	1	1
125144	1710	lymphocyte-specific factor	[lymphocyte-specific factors]	0.0	2	1	1	1
125145	1710	use weak binding peptide	[using weaker binding peptides]	0.0	4	1	1	1
125146	1710	largely through inhibition	[largely through inhibition]	0.0	3	1	1	1
125147	1710	irf-1 5'-flanking	[IRF-1 5'-flanking]	0.0	2	1	1	1
125148	1710	region of the promoter UAS1	[regions of the promoter UAS1]	0.0	5	1	1	1
125149	1710	role in T	[role in T]	0.0	3	1	1	1
125150	1710	encode the tax protein	[encoding the Tax protein]	0.0	4	1	1	1
125151	1710	jurkat mouse el-4 cell	[Jurkat mouse EL-4 cells]	0.0	4	1	1	1
125152	1710	line u937	[lines U937]	0.0	2	1	1	1
125153	1710	harbor a yeast artificial chromosome transgene	[harboring a yeast artificial chromosome transgene]	0.0	6	1	1	1
125154	1710	critical regulator of human apoptosis	[critical regulator of human apoptosis]	0.0	5	1	1	1
125155	1710	il-10 in activity	[IL-10 in activity]	0.0	3	1	1	1
125156	1710	peroxisome-proliferator receptor gamma PPARgamma	[peroxisome-proliferator receptor gamma PPARgamma]	0.0	4	1	1	1
125157	1710	(paf)- receptor antagonist cv3988	[(PAF)- receptor antagonist CV3988]	0.0	4	1	1	1
125158	1710	three regulatory sequence	[three regulatory sequences]	0.0	3	1	1	1
125159	1710	suggest a rapid mode	[suggesting a rapid mode]	0.0	4	1	1	1
125160	1710	nfkb2 induction	[NFKB2 induction]	0.0	2	1	1	1
125161	1710	currently under investigation	[currently under investigation]	0.0	3	1	1	1
125162	1710	mechanism responsible for this phenomenon	[mechanism responsible for this phenomenon]	0.0	5	1	1	1
125163	1710	B-cell extract	[B-cell extracts]	0.0	2	1	1	1
125164	1710	induction of response gene	[Induction of response genes]	0.0	4	1	1	1
125165	1710	amino acid 154	[amino acids 154]	0.0	3	1	1	1
125166	1710	further study signal	[further studies signaling]	0.0	3	1	1	1
125167	1710	blast from 18 patient	[blasts from 18 patients]	0.0	4	1	1	1
125168	1710	human adult erythroid cell	[human adult erythroid cell]	0.0	4	1	1	1
125169	1710	neu-related lipocalin	[neu-related lipocalin]	0.0	2	1	1	1
125170	1710	protein kinase iv camkiv	[protein kinase IV CaMKIV]	0.0	4	1	1	1
125171	1710	distribution evidence for gene topography	[distribution evidence for gene topography]	0.0	5	1	1	1
125172	1710	interleukin IL-2	[interleukin IL-2]	0.0	2	1	1	1
125173	1710	uptake and/or	[uptake and/or]	0.0	2	1	1	1
125174	1710	pattern of cytokine lymphokine secretion.	[patterns of cytokine lymphokine secretion.]	0.0	5	1	1	1
125175	1710	differentiated)	[differentiated)]	0.0	1	1	1	1
125176	1710	RAR -selective antagonist er27191	[RAR -selective antagonist ER27191]	0.0	4	1	1	1
125177	1710	regulation signal transduction pathway	[Regulation signal transduction pathways]	0.0	4	1	1	1
125178	1710	transfection of nf-atp	[transfection of NF-ATp]	0.0	3	1	1	1
125179	1710	bind selectivity	[binding selectivity]	0.0	2	1	1	1
125180	1710	regulation c-jun	[regulation c-jun]	0.0	2	1	1	1
125181	1710	development in response	[development in response]	0.0	3	1	1	1
125182	1710	interaction of thymocyte	[interaction of thymocytes]	0.0	3	1	1	1
125183	1710	Locus Control Region	[Locus Control Region]	0.0	3	1	1	1
125184	1710	expression of another protein	[expression of another protein]	0.0	4	1	1	1
125185	1710	convergence of signal	[Convergence of signals]	0.0	3	1	1	1
125186	1710	lyonization	[lyonization]	0.0	1	1	1	1
125187	1710	inducible expression:	[inducible expression:]	0.0	2	1	1	1
125188	1710	receptor domain sequence	[receptor domain sequences]	0.0	3	1	1	1
125189	1710	IL-12 -dependent up-regulation	[IL-12 -dependent up-regulation]	0.0	3	1	1	1
125190	1710	molecular basis of a lymphokine deficiency	[Molecular basis of a lymphokine deficiency]	0.0	6	1	1	1
125191	1710	inducible expression.	[inducible expression.]	0.0	2	1	1	1
125192	1710	leukemic spread of lymphoma	[leukemic spread of lymphomas]	0.0	4	1	1	1
125193	1710	NFAT composite element in promoter	[NFAT composite elements in promoters]	0.0	5	1	1	1
125194	1710	negative feedback	[negative feedback]	0.0	2	2	2	1
125195	1710	receptor domain sequence contain phosphotyrosine	[receptor domain sequences containing phosphotyrosine]	0.0	5	1	1	1
125196	1710	glucocorticoid-resistant cell lack functional receptor.	[glucocorticoid-resistant cells lacking functional receptor.]	0.0	5	1	1	1
125197	1710	more proximal site	[more proximal site]	0.0	3	1	1	1
125198	1710	CD28 mab	[CD28 mAb]	0.0	2	1	1	1
125199	1710	HSV-2 gene	[HSV-2 genes]	0.0	2	1	1	1
125200	1710	amino acid 199	[amino acids 199]	0.0	3	1	1	1
125201	1710	runoff experiments,	[runoff experiments,]	0.0	2	1	1	1
125202	1710	phase of allergic reaction	[phase of allergic reaction]	0.0	4	1	1	1
125203	1710	concept a distinct, subtype	[concept an distinct, subtype]	0.0	4	1	1	1
125204	1710	raji cell	[Raji cells]	0.0	2	1	1	1
125205	1710	mosaic 45,X/46,X,X)	[mosaic 45,X/46,X,r(X)]	0.0	2	1	1	1
125206	1710	vp16 fusion protein	[VP16 fusion proteins]	0.0	3	1	1	1
125207	1710	secretion of protein-1 mcp-1	[secretion of protein-1 MCP-1]	0.0	4	1	1	1
125208	1710	undifferentiated non-PRL-secreting cell	[undifferentiated non-PRL-secreting cells]	0.0	3	1	1	1
125209	1710	rapidly tyrosine-phosphorylated granulocyte-colony stimulate factor treatment	[rapidly tyrosine-phosphorylated granulocyte-colony stimulating factor treatment]	0.0	6	1	1	1
125210	1710	maltose binding protein	[Maltose Binding Protein]	0.0	3	2	2	1
125211	1710	link bcr signal	[linking BCR signals]	0.0	3	1	1	1
125212	1710	human bone marrow	[human bone marrow]	0.0	3	1	1	1
125213	1710	context-dependent coactivator	[context-dependent coactivator]	0.0	2	1	1	1
125214	1710	almost all case	[almost all cases]	0.0	3	1	1	1
125215	1710	CD14 positive cell line	[CD14 positive cell line]	0.0	4	1	1	1
125216	1710	lymphocyte clonotypes:	[lymphocyte clonotypes:]	0.0	2	1	1	1
125217	1710	Translational initiation of encephalomyocarditis virus	[Translational initiation of encephalomyocarditis virus]	0.0	5	1	1	1
125218	1710	transcriptional induction of p40	[transcriptional induction of p40]	0.0	4	1	1	1
125219	1710	triglyceride accumulation in 3t3-l1 adipocyte	[triglyceride accumulation in 3T3-L1 adipocytes]	0.0	5	1	1	1
125220	1710	particular, one class of protein	[particular, one class of proteins]	0.0	5	1	1	1
125221	1710	expression of inhibitor b alpha evidence	[expression of inhibitor B alpha evidence]	0.0	6	1	1	1
125222	1710	positive role for camp	[positive role for cAMP]	0.0	4	1	1	1
125223	1710	granulocyte antibody of significance.	[granulocyte antibodies of significance.]	0.0	4	1	1	1
125224	1710	surface with taci antibody	[surface with TACI antibodies]	0.0	4	1	1	1
125225	1710	histocompatibility class immunodeficiency	[histocompatibility class immunodeficiency]	0.0	3	1	1	1
125226	1710	steroid receptor complex	[steroid receptor complexes]	0.0	3	1	1	1
125227	1710	protein- tyrosine phosphatase heptp	[protein- tyrosine phosphatase HePTP]	0.0	4	1	1	1
125228	1710	mrna isoform of kb	[mRNA isoforms of kb]	0.0	4	1	1	1
125229	1710	factor-mu	[factor-mu]	0.0	1	1	1	1
125230	1710	forty-one hd sample nlphd	[Forty-one HD samples NLPHD]	0.0	4	1	1	1
125231	1710	rodent system	[rodent system]	0.0	2	1	1	1
125232	1710	amount of the inhibitory	[amounts of the inhibitory]	0.0	4	1	1	1
125233	1710	phorbol-13-acetate for h	[phorbol-13-acetate for h]	0.0	3	1	1	1
125234	1710	potentiation in the induction	[potentiation in the induction]	0.0	4	1	1	1
125235	1710	transcription element tar	[transcription element TAR]	0.0	3	1	1	1
125236	1710	vivo testing	[vivo testing]	0.0	2	1	1	1
125237	1710	leukemogenetic role	[leukemogenetic role]	0.0	2	1	1	1
125238	1710	nomenclature	[nomenclature]	0.0	1	1	1	1
125239	1710	progenitor cell hpc	[progenitor cells HPCs]	0.0	3	2	2	1
125240	1710	role in, il-2 3-kinase activation	[role in, IL-2 3-kinase activation]	0.0	5	1	1	1
125241	1710	ALY a coactivator	[ALY a coactivator]	0.0	3	1	1	1
125242	1710	susceptibility to functional inhibition	[susceptibility to functional inhibition]	0.0	4	1	1	1
125243	1710	extract from scm-1-producer T cell line	[extracts from SCM-1-producer T cell lines]	0.0	6	1	1	1
125244	1710	alpha-tocopherol a free scavenger	[alpha-tocopherol a free scavenger]	0.0	4	1	1	1
125245	1710	plasma sialyltransferase level as a indicator	[Plasma sialyltransferase levels as a indicator]	0.0	6	1	1	1
125246	1710	BZLF1 Z	[BZLF1 Z]	0.0	2	1	1	1
125247	1710	only the addition of tfiid	[only the addition of TFIID]	0.0	5	1	1	1
125248	1710	immunodeficiency virus variant sivsmmpbj14	[immunodeficiency virus variant SIVsmmPBj14]	0.0	4	1	1	1
125249	1710	B-cell marker	[B-cell markers]	0.0	2	1	1	1
125250	1710	factor enf)-kappa b binding activity	[factor (NF)-kappa B binding activities]	0.0	5	1	1	1
125251	1710	maximal increase in c-fo	[maximal increases in c-fos]	0.0	4	1	1	1
125252	1710	lysp100 cDNA	[LYSP100 cDNA]	0.0	2	1	1	1
125253	1710	colony-stimulating factor receptor g-csfr	[colony-stimulating factor receptor G-CSFR]	0.0	4	1	1	1
125254	1710	Nuclear transcription factor kB	[Nuclear transcription factor kB]	0.0	4	1	1	1
125255	1710	stimulus notably product	[stimuli notably products]	0.0	3	1	1	1
125256	1710	novel cooperation of factor	[novel cooperation of factors]	0.0	4	1	1	1
125257	1710	presence of estrogen type	[presence of estrogen type]	0.0	4	1	1	1
125258	1710	control of this promoter	[control of this promoter]	0.0	4	1	1	1
125259	1710	interleukin-beta gene transcription, protein synthesis	[interleukin-beta gene transcription, protein synthesis]	0.0	5	1	1	1
125260	1710	B-alpha(	[B-alpha(]	0.0	1	1	1	1
125261	1710	SPD in patient before month	[SPD in patients before months]	0.0	5	1	1	1
125262	1710	Retinoic expression	[Retinoic expression]	0.0	2	1	1	1
125263	1710	granulocyte/macrophage colony stimulate	[granulocyte/macrophage colony stimulating]	0.0	3	1	1	1
125264	1710	study the link	[studying the link]	0.0	3	1	1	1
125265	1710	percentage of the cell population	[percentage of the cell populations]	0.0	5	1	1	1
125266	1710	addition, inhibition	[addition, inhibition]	0.0	2	1	1	1
125267	1710	treatment with 10(-7) m all-tran acid	[treatment with 10(-7) M all-trans acid]	0.0	6	1	1	1
125268	1710	child with ricket	[children with rickets]	0.0	3	2	2	1
125269	1710	senescent T lymphocyte	[senescent T lymphocytes]	0.0	3	1	1	1
125270	1710	MHC hla-dra class ii	[MHC HLA-DRA class II]	0.0	4	1	1	1
125271	1710	individual cell	[individual cells]	0.0	2	1	1	1
125272	1710	alpha,25-dihydroxyvitamin D3 (vitd3)-induced differentiation	[alpha,25-dihydroxyvitamin D3 (VitD3)-induced differentiation]	0.0	4	1	1	1
125273	1710	perihepatic lymph node	[perihepatic lymph nodes]	0.0	3	1	1	1
125274	1710	colony formation by erythroid progenitor	[colony formation by erythroid progenitors]	0.0	5	1	1	1
125275	1710	signal transduction pathway in control	[signal transduction pathways in control]	0.0	5	1	1	1
125276	1710	dna-protein complex	[DNA-protein complex]	0.0	2	1	1	1
125277	1710	member of gene	[members of genes]	0.0	3	1	1	1
125278	1710	nongenomic response	[nongenomic response]	0.0	2	1	1	1
125279	1710	type of acute myeloid leukemia	[type of acute myeloid leukemia]	0.0	5	1	1	1
125280	1710	3 aml	[3 AML]	0.0	2	1	1	1
125281	1710	inverse correlation inflammation	[inverse correlation inflammation]	0.0	3	1	1	1
125282	1710	analysis of lymphocyte subset	[analysis of lymphocyte subsets]	0.0	4	1	1	1
125283	1710	two child with adenoviral infection	[two children with adenoviral infection]	0.0	5	2	2	1
125284	1710	response to ultra-violet	[responses to UV]	0.0	3	1	1	1
125285	1710	2B protein phosphatase	[2B protein phosphatase]	0.0	3	1	1	1
125286	1710	several set of protein	[several sets of proteins]	0.0	4	1	1	1
125287	1710	IL-8 a potent chemotactic factor	[IL-8 a potent chemotactic factor]	0.0	5	1	1	1
125288	1710	long repeat (ltr) region	[long repeat (LTR) region]	0.0	4	1	1	1
125289	1710	1 P; binding	[1 h; binding]	0.0	3	1	1	1
125290	1710	modulate adhesion	[modulating adhesion]	0.0	2	1	1	1
125291	1710	constitutive basal phosphorylation of Jak3	[Constitutive basal phosphorylation of Jak3]	0.0	5	1	1	1
125292	1710	control of immunodeficiency virus	[control of immunodeficiency virus]	0.0	4	1	1	1
125293	1710	size of dalton	[size of daltons]	0.0	3	1	1	1
125294	1710	induction by ifn-beta	[Induction by IFN-beta]	0.0	3	1	1	1
125295	1710	nuclear translocation factor lymphocyte	[nuclear translocation factor lymphocytes]	0.0	4	1	1	1
125296	1710	rel/stat complex	[Rel/STAT complexes]	0.0	2	1	1	1
125297	1710	Furthermore, LMP1	[Furthermore, LMP1]	0.0	2	1	1	1
125298	1710	result in the isolation	[resulting in the isolation]	0.0	4	1	1	1
125299	1710	direct binding of ebna-2 type	[direct binding of EBNA-2 type]	0.0	5	1	1	1
125300	1710	specific binding.	[specific binding.]	0.0	2	1	1	1
125301	1710	differentiation of leukemia cell line	[differentiation of leukemia cell lines]	0.0	5	1	1	1
125302	1710	direct substrate for shp1	[direct substrates for SHP1]	0.0	4	1	1	1
125303	1710	2 gene expression	[2 gene expression]	0.0	3	1	1	1
125304	1710	lipoxygenase activity	[lipoxygenase activity]	0.0	2	1	1	1
125305	1710	receptor mr count in leukocyte	[receptor MR count in leukocytes]	0.0	5	1	1	1
125306	1710	case of leukaemia CML	[cases of leukaemia CML]	0.0	4	1	1	1
125307	1710	self-reactive T cell	[self-reactive T cells]	0.0	3	1	1	1
125308	1710	tnf-alpha rna	[TNF-alpha RNA]	0.0	2	1	1	1
125309	1710	sf-2 strain	[SF-2 strain]	0.0	2	1	1	1
125310	1710	inhibition of IL-1 of magnitude	[inhibition of IL-1 of magnitude]	0.0	5	1	1	1
125311	1710	BZLF1 mRNA a gene	[BZLF1 mRNA an gene]	0.0	4	1	1	1
125312	1710	carcinoma cell line ht29	[carcinoma cell line HT29]	0.0	4	2	2	1
125313	1710	specificity phosphatase	[specificity phosphatase]	0.0	2	1	1	1
125314	1710	41 patient with ovarian carcinoma	[41 patients with ovarian carcinoma]	0.0	5	1	1	1
125315	1710	respectively, in independent fusions.	[respectively, in independent fusions.]	0.0	4	1	1	1
125316	1710	tyrosine-containing stat docking site	[tyrosine-containing STAT docking sites]	0.0	4	1	1	1
125317	1710	active dimer b subunit	[active dimer B subunits]	0.0	4	1	1	1
125318	1710	RESULTS: mobility shift assay	[RESULTS: mobility shift assays]	0.0	4	1	1	1
125319	1710	breakpoint on chromosome range to q23	[breakpoints on chromosome ranging to q23]	0.0	6	1	1	1
125320	1710	GIRE sequence	[GIRE sequence]	0.0	2	1	1	1
125321	1710	low level in b	[low levels in B]	0.0	4	1	1	1
125322	1710	protein kinase C isoenzyme	[protein kinase C isoenzymes]	0.0	4	1	1	1
125323	1710	antisense egr-1 rna	[antisense Egr-1 RNA]	0.0	3	1	1	1
125324	1710	target for a response	[target for a response]	0.0	4	1	1	1
125325	1710	P.S.Sarin,	[P.S.Sarin,]	0.0	1	1	1	1
125326	1710	T cell during development	[T cells during development]	0.0	4	1	1	1
125327	1710	comparison group	[comparison group]	0.0	2	1	1	1
125328	1710	function for pi 3-kinase	[function for PI 3-kinase]	0.0	4	1	1	1
125329	1710	cell with ionomycin	[cells with ionomycin]	0.0	3	1	1	1
125330	1710	arise in case of ataxia-telangiectasia	[arising in cases of ataxia-telangiectasia]	0.0	5	1	1	1
125331	1710	infection of tat- human immunodeficiency virus	[Infection of Tat- human immunodeficiency viruses]	0.0	6	1	1	1
125332	1710	amplification of erythroid cell	[amplification of erythroid cells]	0.0	4	1	1	1
125333	1710	peripheral granurocyte	[peripheral granurocytes]	0.0	2	1	1	1
125334	1710	SLP-76 hematopoietic cell specific molecule	[SLP-76 hematopoietic cell specific molecules]	0.0	5	1	1	1
125335	1710	b104 growth	[B104 growth]	0.0	2	1	1	1
125336	1710	bhrf1 a Epstein-Barr virus protein	[BHRF1 an Epstein-Barr virus protein]	0.0	5	1	1	1
125337	1710	two stimuli, tcr	[two stimuli, TCR]	0.0	3	1	1	1
125338	1710	protein capable to three sequence	[proteins capable to three sequences]	0.0	5	1	1	1
125339	1710	1 nm,	[1 nM,]	0.0	2	1	1	1
125340	1710	cell with chemoattract	[cells with chemoattractants]	0.0	3	1	1	1
125341	1710	patient with myelodysplastic syndrome MDS	[patients with myelodysplastic syndromes MDS]	0.0	5	1	1	1
125342	1710	ebv-positive carcinoma	[EBV-positive carcinoma]	0.0	2	1	1	1
125343	1710	dominant allele of c-Raf-1	[dominant allele of c-Raf-1]	0.0	4	1	1	1
125344	1710	human trx	[human Trx]	0.0	2	1	1	1
125345	1710	complex formation between the type ii	[complex formation between the type II]	0.0	6	1	1	1
125346	1710	activation of replication by phorbol ester	[activation of replication by phorbol ester]	0.0	6	1	1	1
125347	1710	five copy	[five copies]	0.0	2	1	1	1
125348	1710	thus implicate CAML	[thus implicating CAML]	0.0	3	1	1	1
125349	1710	colony-stimulating factor receptor g-csf-r	[colony-stimulating factor receptor G-CSF-R]	0.0	4	1	1	1
125350	1710	human tsp	[human TSP]	0.0	2	3	3	1
125351	1710	reduction in dose	[reduction in dose]	0.0	3	1	1	1
125352	1710	receptor GCR in peripheral leukocyte	[receptors GCR in peripheral leukocytes]	0.0	5	1	1	1
125353	1710	function of bhrf1	[function of BHRF1]	0.0	3	1	1	1
125354	1710	three molecular clone	[Three molecular clones]	0.0	3	1	1	1
125355	1710	other hormone receptor	[other hormone receptors]	0.0	3	1	1	1
125356	1710	gene in the human locus	[genes in the human locus]	0.0	5	1	1	1
125357	1710	substantial importance for counseling.	[substantial importance for counseling.]	0.0	4	1	1	1
125358	1710	transactivator of promoter	[transactivators of promoters]	0.0	3	1	1	1
125359	1710	over-representation	[over-representation]	0.0	1	1	1	1
125360	1710	residue beyond TES1	[residues beyond TES1]	0.0	3	1	1	1
125361	1710	furthermore, CD28 elevation	[Furthermore, CD28 elevation]	0.0	3	1	1	1
125362	1710	early pseudoautosomal segment	[early pseudoautosomal segment]	0.0	3	1	1	1
125363	1710	red cell during anemia	[red cells during anemia]	0.0	4	1	1	1
125364	1710	activation upon human interleukin-5 stimulation	[activation upon human interleukin-5 stimulation]	0.0	5	1	1	1
125365	1710	profoundly for protein substrate	[profoundly for protein substrate]	0.0	4	1	1	1
125366	1710	result in expression of gene	[resulting in expression of genes]	0.0	5	1	1	1
125367	1710	such that Th2 effect	[such that Th2 effects]	0.0	4	1	1	1
125368	1710	form by CD28	[form by CD28]	0.0	3	1	1	1
125369	1710	21 base-pair sequence	[21 base-pair sequence]	0.0	3	1	1	1
125370	1710	proliferative signal in b cell	[proliferative signaling in B cells]	0.0	5	1	1	1
125371	1710	human tr2	[human TR2]	0.0	2	1	1	1
125372	1710	normal human lung fibroblast	[normal human lung fibroblasts]	0.0	4	1	1	1
125373	1710	heavy chain gene enhancer by proteins.	[heavy chain gene enhancer by proteins.]	0.0	6	1	1	1
125374	1710	innate immune response in drosophila	[innate immune response in Drosophila]	0.0	5	1	1	1
125375	1710	CD4 antigen	[CD4 antigen]	0.0	2	1	1	1
125376	1710	different activation in EL4 cell	[different activation in EL4 cells]	0.0	5	1	1	1
125377	1710	human T lymphocyte culture	[human T lymphocyte cultures]	0.0	4	1	1	1
125378	1710	primary astrocyte	[primary astrocytes]	0.0	2	1	1	1
125379	1710	histocompatibility complex class immunodeficiency	[histocompatibility complex class immunodeficiency]	0.0	4	1	1	1
125380	1710	binding of glucocorticoid	[Binding of glucocorticoids]	0.0	3	1	1	1
125381	1710	CD28 monoclonal antibody	[CD28 monoclonal antibody]	0.0	3	1	1	1
125382	1710	adhesion human vein cell	[adhesion human vein cells]	0.0	4	1	1	1
125383	1710	additional transcription factor nf-microb	[additional transcription factor NF-microB]	0.0	4	1	1	1
125384	1710	gr binding by FKBP51	[GR binding by FKBP51]	0.0	4	1	1	1
125385	1710	glucocorticoid receptor GRs	[glucocorticoid receptors GRs]	0.0	3	1	1	1
125386	1710	nucleosome-assembled DNA	[nucleosome-assembled DNA]	0.0	2	1	1	1
125387	1710	putative target	[putative targets]	0.0	2	1	1	1
125388	1710	progenitor/precursor cell	[progenitor/precursor cells]	0.0	2	1	1	1
125389	1710	signal transmission	[signal transmission]	0.0	2	1	1	1
125390	1710	NF-AT/AP-1-binding site	[NF-AT/AP-1-binding site]	0.0	2	1	1	1
125391	1710	intrinsic activation domain	[intrinsic activation domain]	0.0	3	1	1	1
125392	1710	erythroblast from bone marrow	[erythroblasts from bone marrow]	0.0	4	1	1	1
125393	1710	hypermethylation-associated silencing	[hypermethylation-associated silencing]	0.0	2	1	1	1
125394	1710	sequence (start	[sequences (starting]	0.0	2	1	1	1
125395	1710	form complex	[forming complexes]	0.0	2	1	1	1
125396	1710	incubation with a combination	[incubation with a combination]	0.0	4	1	1	1
125397	1710	following: significantly increased;	[following: significantly increased;]	0.0	3	1	1	1
125398	1710	optimal cell differentiation	[optimal cell differentiation]	0.0	3	1	1	1
125399	1710	U2 nuclear rna(snrna)-encoding gene	[U2 nuclear RNA(snRNA)-encoding gene]	0.0	4	1	1	1
125400	1710	member of the Ig superfamily	[member of the Ig superfamily]	0.0	5	1	1	1
125401	1710	cd44 mrna	[CD44 mRNA]	0.0	2	1	1	1
125402	1710	rel family	[rel family]	0.0	2	1	1	1
125403	1710	pathway operate	[pathways operating]	0.0	2	1	1	1
125404	1710	response to t-cell activator	[response to T-cell activators]	0.0	4	1	1	1
125405	1710	transcriptase -polymerase	[transcriptase -polymerase]	0.0	2	2	2	1
125406	1710	ionizing radiation gy	[ionizing radiation Gy]	0.0	3	1	1	1
125407	1710	abundant,	[abundant,]	0.0	1	1	1	1
125408	1710	round	[round]	0.0	1	1	1	1
125409	1710	large number in late phase	[large numbers in late phase]	0.0	5	1	1	1
125410	1710	one end of the cleft	[one end of the cleft]	0.0	5	1	1	1
125411	1710	Ser616	[Ser616]	0.0	1	1	1	1
125412	1710	nontoxic concentration	[nontoxic concentrations]	0.0	2	1	1	1
125413	1710	sensitivity to dexamethasone: regulation	[sensitivity to dexamethasone: regulation]	0.0	4	1	1	1
125414	1710	such as acid	[such as acid]	0.0	3	1	1	1
125415	1710	adhesion to endothelial cell	[adhesion to endothelial cells]	0.0	4	1	1	1
125416	1710	311% increase	[311% increase]	0.0	2	1	1	1
125417	1710	outcome of the reaction	[outcome of the reactions]	0.0	4	1	1	1
125418	1710	pretreatment of monocyte	[Pretreatment of monocytes]	0.0	3	2	2	1
125419	1710	b lymphoma cell line	[B lymphoma cell line]	0.0	4	3	3	1
125420	1710	clinically aggressive histologic type	[clinically aggressive histologic types]	0.0	4	1	1	1
125421	1710	expression in early stage	[expression in early stages]	0.0	4	1	1	1
125422	1710	view of the nuclear factor-kappaB	[view of the nuclear factor-kappaB]	0.0	5	1	1	1
125423	1710	min) submaximal physical exercise ppe	[min) submaximal physical exercise PPE]	0.0	5	1	1	1
125424	1710	modest reduction	[modest reduction]	0.0	2	1	1	1
125425	1710	class antigen processing	[class antigen processing]	0.0	3	1	1	1
125426	1710	autopresentation	[autopresentation]	0.0	1	1	1	1
125427	1710	1 infection of myelomonoblastic cell	[1 infection of myelomonoblastic cells]	0.0	5	1	1	1
125428	1710	adherent colony	[adherent colonies]	0.0	2	1	1	1
125429	1710	patient remission	[patients remission]	0.0	2	1	1	1
125430	1710	G1/S phase	[G1/S phase]	0.0	2	1	1	1
125431	1710	approximately eightfold amount	[approximately eightfold amounts]	0.0	3	1	1	1
125432	1710	GCR in 6 Yang deficient patient	[GCR in 6 Yang deficient patients]	0.0	6	1	1	1
125433	1710	tight binding	[tighter binding]	0.0	2	1	1	1
125434	1710	consensus,	[consensus,]	0.0	1	1	1	1
125435	1710	phosphorylation of a single serine residue	[phosphorylation of a single serine residue]	0.0	6	1	1	1
125436	1710	competitive progesterone antagonist	[competitive progesterone antagonist]	0.0	3	1	1	1
125437	1710	stress-induced susceptibility to infections.	[stress-induced susceptibility to infections.]	0.0	4	1	1	1
125438	1710	adnexal mass	[adnexal mass]	0.0	2	1	1	1
125439	1710	amount of receptor	[amount of receptors]	0.0	3	1	1	1
125440	1710	agent on hiv repeat activation	[agents on HIV repeat activation]	0.0	5	1	1	1
125441	1710	rapid change in phosphorylation	[rapid changes in phosphorylation]	0.0	4	1	1	1
125442	1710	transduction of il-6 signal	[transduction of IL-6 signals]	0.0	4	1	1	1
125443	1710	immature positive cell	[immature positive cells]	0.0	3	1	1	1
125444	1710	development of inflammatory pathology	[development of inflammatory pathologies]	0.0	4	1	1	1
125445	1710	effect in process	[effects in processes]	0.0	3	1	1	1
125446	1710	activation by inflammatory stimulus in neutrophil	[Activation by inflammatory stimuli in neutrophils]	0.0	6	1	1	1
125447	1710	oral salt supplementation	[oral salt supplementation]	0.0	3	1	1	1
125448	1710	thus, constitutive activation	[Thus, constitutive activation]	0.0	3	1	1	1
125449	1710	v-j recombination	[V-J recombination]	0.0	2	1	1	1
125450	1710	large extent than jak1	[larger extent than JAK1]	0.0	4	1	1	1
125451	1710	NF-kappa b recognition site	[NF-kappa B recognition sites]	0.0	4	1	1	1
125452	1710	traf association.	[TRAF association.]	0.0	2	1	1	1
125453	1710	immunodominant target	[immunodominant targets]	0.0	2	1	1	1
125454	1710	peak value from hour	[peak values from hr]	0.0	4	1	1	1
125455	1710	treatment in preeclampsia	[treatment in preeclampsia]	0.0	3	1	1	1
125456	1710	transcriptional regulator nuclear factor-kappaB	[transcriptional regulator nuclear factor-kappaB]	0.0	4	1	1	1
125457	1710	anemia with ring sideroblast	[anemia with ring sideroblasts]	0.0	4	1	1	1
125458	1710	proliferation, stat-5	[proliferation, STAT-5]	0.0	2	1	1	1
125459	1710	FCS- clonogenic culture	[FCS- clonogenic culture]	0.0	3	1	1	1
125460	1710	appear soon	[appearing soon]	0.0	2	1	1	1
125461	1710	light regime, peak value	[light regime, peak values]	0.0	4	1	1	1
125462	1710	T helper (th) clone	[T helper (Th) clones]	0.0	4	1	1	1
125463	1710	element in the tsp 1	[elements in the TSP 1]	0.0	5	1	1	1
125464	1710	erythroid cell in liquid culture	[erythroid cells in liquid cultures]	0.0	5	1	1	1
125465	1710	include adherence	[including adherence]	0.0	2	1	1	1
125466	1710	transactivation by factor	[transactivation by factor]	0.0	3	1	1	1
125467	1710	zinc finger protein mzf-2	[zinc finger protein MZF-2]	0.0	4	1	1	1
125468	1710	means use deoxyribonuclease dnase	[means using deoxyribonuclease DNase]	0.0	4	1	1	1
125469	1710	high malignancy melanoma	[high malignancy melanomas]	0.0	3	1	1	1
125470	1710	samples, activity	[samples, activity]	0.0	2	1	1	1
125471	1710	viral transcription basal transcription	[viral transcription basal transcription]	0.0	4	1	1	1
125472	1710	genetic marker of leukemia	[genetic markers of leukemias]	0.0	4	1	1	1
125473	1710	serological technique	[serological techniques]	0.0	2	1	1	1
125474	1710	expression of a gene ORF	[expression of a gene ORF]	0.0	5	1	1	1
125475	1710	capability of the gcr	[capability of the GCR]	0.0	4	1	1	1
125476	1710	exposure to SE	[exposure to SE]	0.0	3	1	1	1
125477	1710	symbiotic, persistent relationship in tonsil	[symbiotic, persistent relationship in tonsils]	0.0	5	1	1	1
125478	1710	contain deletion mutant	[containing deletion mutants]	0.0	3	1	1	1
125479	1710	61 pmol/L; in normal woman	[61 pmol/L; in normal women]	0.0	5	1	1	1
125480	1710	encode a component of the NB	[encoding a component of the NB]	0.0	6	1	1	1
125481	1710	I receptor 267	[I receptors 267]	0.0	3	1	1	1
125482	1710	growth of a variant line	[growth of a variant line]	0.0	5	1	1	1
125483	1710	bacterial lysate	[bacterial lysates]	0.0	2	1	1	1
125484	1710	pseudoautosomal segment	[pseudoautosomal segment]	0.0	2	1	1	1
125485	1710	nm alpha,25-dihydroxyvitamin D3 D3	[nM alpha,25-dihydroxyvitamin D3 D3]	0.0	4	1	1	1
125486	1710	association proviral latency in monocytic cell	[Association proviral latency in monocytic cells]	0.0	6	1	1	1
125487	1710	factor-kappaB NFkappaB	[factor-kappaB NFkappaB]	0.0	2	2	2	1
125488	1710	potential importance	[potential importance]	0.0	2	1	1	1
125489	1710	study: lymphocyte	[STUDY: lymphocytes]	0.0	2	1	1	1
125490	1710	Korsmeyer	[Korsmeyer]	0.0	1	1	1	1
125491	1710	lymphoma (25 of 59	[lymphoma (25 of 59]	0.0	4	1	1	1
125492	1710	leukemia-associated fusion	[leukemia-associated fusion]	0.0	2	1	1	1
125493	1710	zinc-inducible vector.	[zinc-inducible vector.]	0.0	2	1	1	1
125494	1710	nonactivate domain from GAL4 activator	[nonactivating domain from GAL4 activators]	0.0	5	1	1	1
125495	1710	important role in immune dysregulation	[important role in immune dysregulation]	0.0	5	1	1	1
125496	1710	two distinct family	[two distinct families]	0.0	3	2	2	1
125497	1710	plasma sialyltransferase level in disorder	[Plasma sialyltransferase levels in disorders]	0.0	5	1	1	1
125498	1710	de novo translocation between the Xi	[de novo translocations between the Xi]	0.0	6	1	1	1
125499	1710	Pit-1 gene	[Pit-1 gene]	0.0	2	2	2	1
125500	1710	anti-early antigen anti-viral antigen	[anti-early antigen anti-viral antigen]	0.0	4	1	1	1
125501	1710	episode simulate insufficiency	[episode simulating insufficiency]	0.0	3	1	1	1
125502	1710	t-cell prolymphocytic leukemia T-PLL	[T-cell prolymphocytic leukemia T-PLL]	0.0	4	1	1	1
125503	1710	gata-binding protein in eosinophil	[GATA-binding proteins in eosinophils]	0.0	4	1	1	1
125504	1710	target for anti- hiv-1 therapy	[targets for anti- HIV-1 therapy]	0.0	5	1	1	1
125505	1710	important regulator of atherogenesis	[important regulator of atherogenesis]	0.0	4	1	1	1
125506	1710	pmn chemotaxis in a manner	[PMNs chemotaxis in a manner]	0.0	5	1	1	1
125507	1710	reduction in affinity	[reduction in affinity]	0.0	3	1	1	1
125508	1710	mononuclear cell with interleukin-4	[mononuclear cells with interleukin-4]	0.0	4	1	1	1
125509	1710	role in dysregulation accompany aging	[role in dysregulation accompanying aging]	0.0	5	1	1	1
125510	1710	potential NFAT element	[potential NFAT elements]	0.0	3	1	1	1
125511	1710	significant proportion	[significant proportion]	0.0	2	2	2	1
125512	1710	0.05, chi2	[0.05, chi2]	0.0	2	1	1	1
125513	1710	cell resistant to apoptosis	[cells resistant to apoptosis]	0.0	4	1	1	1
125514	1710	several t-cell-expressed cytokine gene	[several T-cell-expressed cytokine genes]	0.0	4	1	1	1
125515	1710	antioxidant glutathione	[antioxidant glutathione]	0.0	2	1	1	1
125516	1710	cytotoxicity of phosphorothioate oligodeoxynucleotides complementary	[cytotoxicity of phosphorothioate oligodeoxynucleotides complementary]	0.0	5	1	1	1
125517	1710	p50.c-rel	[p50.c-rel]	0.0	1	1	1	1
125518	1710	integrin -dependent cell adhesion to fibronectin	[integrin -dependent cell adhesion to fibronectin]	0.0	6	1	1	1
125519	1710	cell line with heat shock	[cell line with heat shock]	0.0	5	1	1	1
125520	1710	T cell during aging.	[T cells during aging.]	0.0	4	1	1	1
125521	1710	histocompatibility class molecule on cell	[histocompatibility class molecules on cells]	0.0	5	1	1	1
125522	1710	factor-1 irf-1 gene expression	[factor-1 IRF-1 gene expression]	0.0	4	1	1	1
125523	1710	polyclonal activator phorbol	[polyclonal activator phorbol]	0.0	3	1	1	1
125524	1710	23 amino acid rich residue	[23 amino acids rich residues]	0.0	5	1	1	1
125525	1710	blastogenesis of human blood lymphocyte generation	[blastogenesis of human blood lymphocytes Generation]	0.0	6	1	1	1
125526	1710	pbmo cell	[PBMo cells]	0.0	2	1	1	1
125527	1710	blastic transformation in chronic leukemia	[blastic transformation in chronic leukemia]	0.0	5	1	1	1
125528	1710	even in thymus environment	[even in thymus environment]	0.0	4	1	1	1
125529	1710	responsiveness of NFAT	[responsiveness of NFAT]	0.0	3	1	1	1
125530	1710	(p p less than 0.01	[(P P less than 0.01]	0.0	5	1	1	1
125531	1710	detectable involvement	[detectable involvement]	0.0	2	1	1	1
125532	1710	hamster ovary cell express alphaiibbeta3	[hamster ovary cells expressing alphaIIbbeta3]	0.0	5	1	1	1
125533	1710	thyroid hormone action	[thyroid hormone action]	0.0	3	1	1	1
125534	1710	order nf-atp complex	[order NF-ATp complex]	0.0	3	1	1	1
125535	1710	immunodeficiency virus type factor	[immunodeficiency virus type factor]	0.0	4	1	1	1
125536	1710	contributor to il-12 signal	[contributor to IL-12 signaling]	0.0	4	1	1	1
125537	1710	peptide-loaded cell	[peptide-loaded cells]	0.0	2	1	1	1
125538	1710	renal failure A-CRF	[renal failure A-CRF]	0.0	3	1	1	1
125539	1710	cyclic AMP inhibition	[cyclic AMP inhibition]	0.0	3	1	1	1
125540	1710	glycosphingolipid beta-(1,3)-glucan receptor	[glycosphingolipid beta-(1,3)-glucan receptor]	0.0	3	1	1	1
125541	1710	CREB binding protein	[CREB binding protein]	0.0	3	1	1	1
125542	1710	human immunodeficiency virus type a protein	[Human immunodeficiency virus type an protein]	0.0	6	1	1	1
125543	1710	use blood mononuclear cell pbmc	[Using blood mononuclear cells PBMC]	0.0	5	1	1	1
125544	1710	expression of CTCF a c-myc regulator,	[expression of CTCF a c-myc regulator,]	0.0	6	1	1	1
125545	1710	rar(alpha) gene expression	[RAR(alpha) gene expression]	0.0	3	1	1	1
125546	1710	accumulation the hydrolysis	[accumulation the hydrolysis]	0.0	3	1	1	1
125547	1710	alpha- herpesvirus system	[alpha- herpesvirus systems]	0.0	3	1	1	1
125548	1710	normal blood mononuclear cell	[normal blood mononuclear cells]	0.0	4	2	2	1
125549	1710	1-wk course mg	[1-wk course mg]	0.0	3	1	1	1
125550	1710	IL-4-binding IL-4Ralpha chain	[IL-4-binding IL-4Ralpha chain]	0.0	3	1	1	1
125551	1710	biologic role	[biologic role]	0.0	2	1	1	1
125552	1710	4-acetoxy derivative 16	[4-acetoxy derivative 16]	0.0	3	1	1	1
125553	1710	IL-5 promoter region	[IL-5 promoter region]	0.0	3	1	1	1
125554	1710	critical domain	[Critical domains]	0.0	2	1	1	1
125555	1710	production tumor necrosis factor	[production tumor necrosis factor]	0.0	4	1	1	1
125556	1710	therefore a critical element	[therefore a critical element]	0.0	4	1	1	1
125557	1710	various haematopoietic line	[various haematopoietic lines]	0.0	3	1	1	1
125558	1710	such adaptive change	[such adaptive changes]	0.0	3	1	1	1
125559	1710	leukemic cell line CEM	[leukemic cell line CEM]	0.0	4	1	1	1
125560	1710	leukemogenesis of atl	[leukemogenesis of ATL]	0.0	3	1	1	1
125561	1710	high frequency of brca2 mutation	[High frequency of BRCA2 mutations]	0.0	5	1	1	1
125562	1710	TNF-alpha localization of NFkappaB	[TNF-alpha localization of NFkappaB]	0.0	4	1	1	1
125563	1710	peripheral leukocyte of patient	[peripheral leukocytes of patients]	0.0	4	2	2	1
125564	1710	two region of the promoter	[two regions of the promoter]	0.0	5	1	1	1
125565	1710	feature of signal transduction	[features of signal transduction]	0.0	4	1	1	1
125566	1710	two factor-IL6 motif	[two factor-IL6 motifs]	0.0	3	1	1	1
125567	1710	histone deacetylase (hdac) inhibitor	[histone deacetylase (HDAC) inhibitor]	0.0	4	1	1	1
125568	1710	male combat Vietnam veteran	[male combat Vietnam veterans]	0.0	4	1	1	1
125569	1710	gene expression in Epstein-Barr virus	[gene expression in Epstein-Barr virus]	0.0	5	1	1	1
125570	1710	T cell il-5 synthesis	[T cell IL-5 synthesis]	0.0	4	1	1	1
125571	1710	amino acid 207	[amino acids 207]	0.0	3	2	2	1
125572	1710	correlation, indicate a effect.	[correlation, indicating a effect.]	0.0	4	1	1	1
125573	1710	anti-Class ii monoclonal antibody	[anti-Class II monoclonal antibodies]	0.0	4	1	1	1
125574	1710	activation of intracellular event lead	[activation of intracellular events leading]	0.0	5	1	1	1
125575	1710	24,25-dihydroxy-vitamin D3 a response	[24,25-dihydroxy-vitamin D3 a response]	0.0	4	1	1	1
125576	1710	micromol/L)	[micromol/L)]	0.0	1	1	1	1
125577	1710	mouse line	[mouse lines]	0.0	2	1	1	1
125578	1710	ebf sequence on human chromosome	[EBF sequences on human Chromosome]	0.0	5	1	1	1
125579	1710	Stat binding	[Stat binding]	0.0	2	1	1	1
125580	1710	protein suggest Oct-1	[proteins suggesting Oct-1]	0.0	3	1	1	1
125581	1710	RB antisense	[RB antisense]	0.0	2	1	1	1
125582	1710	(hela)	[(HeLa)]	0.0	1	1	1	1
125583	1710	-200 bp relative	[-200 bp relative]	0.0	3	1	1	1
125584	1710	phenolic, chain-breaking antioxidant hydroxyanisole	[phenolic, chain-breaking antioxidants hydroxyanisole]	0.0	4	1	1	1
125585	1710	failure A-CRF with renal insufficiency	[failure A-CRF with renal insufficiency]	0.0	5	1	1	1
125586	1710	reach a maximum after 3 h	[reaching a maximum after 3 h]	0.0	6	1	1	1
125587	1710	phosphatidylinositol-3,4,5-trisphosphate pi-3,4,5-p3	[phosphatidylinositol-3,4,5-trisphosphate PI-3,4,5-P3]	0.0	2	1	1	1
125588	1710	coding for a protein	[coding for a protein]	0.0	4	1	1	1
125589	1710	add (10(-6)	[adding (10(-6)]	0.0	2	1	1	1
125590	1710	invasive disease	[invasive disease]	0.0	2	2	2	1
125591	1710	wild-type protein of the family	[wild-type proteins of the family]	0.0	5	1	1	1
125592	1710	receptor from patient	[receptors from patients]	0.0	3	1	1	1
125593	1710	crp1	[CRP1]	0.0	1	1	1	1
125594	1710	overexpression of constitutive activation	[overexpression of constitutive activation]	0.0	4	1	1	1
125595	1710	primitive cell cd34(2+)/cd38-	[primitive cells CD34(2+)/CD38-]	0.0	3	1	1	1
125596	1710	two related hematopoietic lineage	[two related hematopoietic lineages]	0.0	4	1	1	1
125597	1710	clinical remission in patient with leukemia	[clinical remission in patients with leukemia]	0.0	6	1	1	1
125598	1710	human interleukin-4 IL-4	[human interleukin-4 IL-4]	0.0	3	1	1	1
125599	1710	t-cell receptor (tcr)-zeta in 4	[T-cell receptor (TCR)-zeta in 4]	0.0	5	1	1	1
125600	1710	naturally-occurg compound	[naturally-occurring compounds]	0.0	2	1	1	1
125601	1710	response immunity	[responses immunity]	0.0	2	1	1	1
125602	1710	inhibit generation of molecule	[inhibiting generation of molecule]	0.0	4	1	1	1
125603	1710	interleukin-1alpha promoter	[interleukin-1alpha promoter]	0.0	2	1	1	1
125604	1710	element tre1 necessary	[element TRE1 necessary]	0.0	3	1	1	1
125605	1710	protein bind protein hxbp-1	[protein binding protein hXBP-1]	0.0	4	1	1	1
125606	1710	10 patient with pco	[10 patients with PCOS]	0.0	4	1	1	1
125607	1710	Pills LDP	[Pills LDP]	0.0	2	1	1	1
125608	1710	cytolytic phenotype of cell	[cytolytic phenotypes of cells]	0.0	4	1	1	1
125609	1710	gene important to leukocyte biology,	[genes important to leukocyte biology,]	0.0	5	1	1	1
125610	1710	expression of monocytic gene	[expression of monocytic genes]	0.0	4	1	1	1
125611	1710	interleukin (il)-2-receptor expression on the surface	[interleukin (IL)-2-receptor expression on the surface]	0.0	6	1	1	1
125612	1710	STAT 5 isoform	[STAT 5 isoforms]	0.0	3	1	1	1
125613	1710	P56lck pathway	[p56lck pathway]	0.0	2	1	1	1
125614	1710	differentiation in normal epidermal cell	[differentiation in normal epidermal cells]	0.0	5	1	1	1
125615	1710	stem structure	[stem structure]	0.0	2	2	2	1
125616	1710	c-Jun NH2-terminal kinase	[c-Jun NH2-terminal kinase]	0.0	3	2	2	1
125617	1710	vasculature	[vasculature]	0.0	1	1	1	1
125618	1710	span kb of DNA	[spanning kb of DNA]	0.0	4	1	1	1
125619	1710	case of a old woman	[case of a old woman]	0.0	5	1	1	1
125620	1710	terminally cell	[terminally cells]	0.0	2	1	1	1
125621	1710	binding site similar	[binding sites similar]	0.0	3	1	1	1
125622	1710	distinct pathway of interleukin-5 synthesis	[distinct pathways of interleukin-5 synthesis]	0.0	5	1	1	1
125623	1710	mn-dependent superoxide dismutase	[Mn-dependent superoxide dismutase]	0.0	3	1	1	1
125624	1710	distal region of mouse	[distal region of mouse]	0.0	4	1	1	1
125625	1710	contain tr alpha 1	[containing TR alpha 1]	0.0	4	1	1	1
125626	1710	factor-kappaB translocation in lipopolysaccharide human monocyte	[factor-kappaB translocation in lipopolysaccharide human monocytes]	0.0	6	1	1	1
125627	1710	presence of 135eoh)2d3	[presence of 1,25(OH)2D3]	0.0	3	1	1	1
125628	1710	cysteine t-cell determinant in a number	[cysteine T-cell determinants in a number]	0.0	6	1	1	1
125629	1710	low micromolar	[low micromolar]	0.0	2	1	1	1
125630	1710	T lymphoid Jurkat cell line	[T lymphoid Jurkat cell lines]	0.0	5	1	1	1
125631	1710	degree, 11alpha,13-dihydrohelenalin	[degree, 11alpha,13-dihydrohelenalin]	0.0	2	1	1	1
125632	1710	study variation as a means	[studying variation as a means]	0.0	5	1	1	1
125633	1710	individual with lymphatic pathology	[individuals with lymphatic pathology]	0.0	4	1	1	1
125634	1710	low molecular protein	[low molecular proteins]	0.0	3	1	1	1
125635	1710	metabolite polar than 135(oh)2d3	[metabolites polar than 1,25(OH)2D3]	0.0	4	1	1	1
125636	1710	h incubation with PMA	[h incubation with PMA]	0.0	4	1	1	1
125637	1710	amino acid 210	[amino acid 210]	0.0	3	1	1	1
125638	1710	ability of 135eoh)2d3	[ability of 1,25(OH)2D3]	0.0	3	1	1	1
125639	1710	-immunoreactive cell than gc-sensitive asthmatics	[-immunoreactive cells than GC-sensitive asthmatics]	0.0	5	1	1	1
125640	1710	discourse	[discourse]	0.0	1	1	1	1
125641	1710	evidence at bind element	[Evidence at binding element]	0.0	4	1	1	1
125642	1710	(monocytoid) b cell lymphoma	[(monocytoid) B cell lymphoma]	0.0	4	1	1	1
125643	1710	two crossreact protein in human lymphocyte	[two crossreacting proteins in human lymphocytes]	0.0	6	1	1	1
125644	1710	cyclic AMP -responsive element-like sequence	[cyclic AMP -responsive element-like sequence]	0.0	5	1	1	1
125645	1710	land electron-dense structure morphologically distinct	[LANDs electron-dense structures morphologically distinct]	0.0	5	1	1	1
125646	1710	dephosphorylation of extract	[dephosphorylation of extracts]	0.0	3	1	1	1
125647	1710	effect on msr expression	[effects on MSR expression]	0.0	4	1	1	1
125648	1710	oct-binding factor 1 obf-1 a protein	[Oct-binding factor 1 OBF-1 a protein]	0.0	6	1	1	1
125649	1710	protective property	[protective properties]	0.0	2	1	1	1
125650	1710	two consensus site	[two consensus sites]	0.0	3	1	1	1
125651	1710	evidence for a antioxidant activate pathway	[evidence for an antioxidant activating pathway]	0.0	6	1	1	1
125652	1710	modeling	[modeling]	0.0	1	1	1	1
125653	1710	interaction between element	[interactions between elements]	0.0	3	1	1	1
125654	1710	phagocytosis of cell	[phagocytosis of cells]	0.0	3	1	1	1
125655	1710	isoform of the cyclic element modulator	[isoforms of the cyclic element modulator]	0.0	6	1	1	1
125656	1710	radical gene transcription in t-cell	[radical gene transcription in T-cells]	0.0	5	1	1	1
125657	1710	diagnosis of pel	[diagnosis of PEL]	0.0	3	1	1	1
125658	1710	adenylyl cyclase	[adenylyl cyclase]	0.0	2	1	1	1
125659	1710	displacement of a repressor implication	[Displacement of an repressor implications]	0.0	5	1	1	1
125660	1710	relevance for human disease	[relevance for human disease]	0.0	4	1	1	1
125661	1710	toler	[toler]	0.0	1	1	1	1
125662	1710	bp of upstream sequence	[bp of upstream sequence]	0.0	4	1	1	1
125663	1710	non-cytotoxic lmp-1 signal	[non-cytotoxic LMP-1 signaling]	0.0	3	1	1	1
125664	1710	glutamine synthetase induction	[glutamine synthetase induction]	0.0	3	1	1	1
125665	1710	feature of the disease	[features of the disease]	0.0	4	1	1	1
125666	1710	assay analysis	[assay analysis]	0.0	2	1	1	1
125667	1710	involvement in activation at two subregion	[Involvement in activation at two subregions]	0.0	6	1	1	1
125668	1710	protein extract from chronic leukemia cell	[protein extracts from chronic leukemia cells]	0.0	6	1	1	1
125669	1710	individual to autoimmune disease	[individual to autoimmune diseases]	0.0	4	1	1	1
125670	1710	cellular transcriptional factor-KB NF-kappa b	[cellular transcriptional factor-KB NF-kappa B]	0.0	5	1	1	1
125671	1710	binding of distinct multi-protein complex	[binding of distinct multi-protein complexes]	0.0	5	1	1	1
125672	1710	first protein of hiv-1	[first protein of HIV-1]	0.0	4	1	1	1
125673	1710	interaction of thymocyte with cell TEC	[interaction of thymocytes with cells TEC]	0.0	6	1	1	1
125674	1710	secretion of antigen	[secretion of antigen]	0.0	3	1	1	1
125675	1710	immunological parameter	[immunological parameters]	0.0	2	1	1	1
125676	1710	lack of response in leukocyte	[lack of response in leukocytes]	0.0	5	1	1	1
125677	1710	lipoprotein in amounts,	[lipoprotein in amounts,]	0.0	3	1	1	1
125678	1710	myeloid leukemia AML	[myeloid leukemia AML]	0.0	3	3	3	1
125679	1710	different sequence requirement within a element	[Different sequence requirements within a element]	0.0	6	1	1	1
125680	1710	structural characterization identification	[Structural characterization identification]	0.0	3	1	1	1
125681	1710	also for region	[also for regions]	0.0	3	1	1	1
125682	1710	human immunodeficiency virus type hiv	[human immunodeficiency virus type HIV]	0.0	5	1	1	1
125683	1710	culture condition from normal pbmc	[culture conditions from normal PBMC]	0.0	5	1	1	1
125684	1710	activator protein-1 ap-1 binding activity;	[activator protein-1 AP-1 binding activity;]	0.0	5	1	1	1
125685	1710	nonpeptidyl small molecule sb 247464	[nonpeptidyl small molecule SB 247464]	0.0	5	1	1	1
125686	1710	regulatory pair	[regulatory pair]	0.0	2	1	1	1
125687	1710	complex, factor	[complex, factor]	0.0	2	1	1	1
125688	1710	treatment of the b-cell line bal-17	[Treatment of the B-cell line BAL-17]	0.0	6	1	1	1
125689	1710	factor on b lymphocyte	[factor on B lymphocytes]	0.0	4	1	1	1
125690	1710	interference from cp	[interference from Cp]	0.0	3	1	1	1
125691	1710	AIDS Res Hum	[AIDS Res Hum]	0.0	3	1	1	1
125692	1710	index subject'	[index subject's]	0.0	2	1	1	1
125693	1710	crux	[crux]	0.0	1	1	1	1
125694	1710	contrast, antisense inhibition	[contrast, antisense inhibition]	0.0	3	1	1	1
125695	1710	cd45ro+ (memory) T	[CD45RO+ (memory) T]	0.0	3	1	1	1
125696	1710	expression of hsp60 hour	[expression of Hsp60 hr]	0.0	4	1	1	1
125697	1710	gata sequence	[GATA sequence]	0.0	2	1	1	1
125698	1710	inhibitor of protein kinase	[inhibitor of protein kinase]	0.0	4	1	1	1
125699	1710	clinical course (p	[clinical course (P]	0.0	3	1	1	1
125700	1710	salivary gland biopsy from patient	[salivary gland biopsies from patients]	0.0	5	1	1	1
125701	1710	part, induce expression	[part, inducing expression]	0.0	3	1	1	1
125702	1710	number include phorbol 12-myristate	[number including phorbol 12-myristate]	0.0	4	1	1	1
125703	1710	mechanism in cell line	[mechanism in cell lines]	0.0	4	1	1	1
125704	1710	inhibitory action of flavonoid	[inhibitory action of flavonoids]	0.0	4	1	1	1
125705	1710	immunocytochemical evaluation of tissue	[immunocytochemical evaluation of tissues]	0.0	4	1	1	1
125706	1710	gal4 -hsf3 protein	[GAL4 -HSF3 protein]	0.0	3	1	1	1
125707	1710	encode a protein protein hxbp-1	[encoding a protein protein hXBP-1]	0.0	5	1	1	1
125708	1710	two distinct domain the domain	[two distinct domains the domain]	0.0	5	1	1	1
125709	1710	liver disease	[liver disease]	0.0	2	1	1	1
125710	1710	transcription of the gene at stage	[transcription of the gene at stages]	0.0	6	1	1	1
125711	1710	essential core region	[essential core regions]	0.0	3	1	1	1
125712	1710	negative regulator of cell death.	[negative regulator of cell death.]	0.0	5	1	1	1
125713	1710	expression immuno-cytochemistry	[expression immuno-cytochemistry]	0.0	2	1	1	1
125714	1710	repeat nf-kappa b	[repeat NF-kappa B]	0.0	3	1	1	1
125715	1710	distinct stimuli, lipopolysaccharide	[distinct stimuli, lipopolysaccharide]	0.0	3	1	1	1
125716	1710	influence on gr function	[influence on GR function]	0.0	4	1	1	1
125717	1710	identify high malignancy melanoma	[identifying high malignancy melanomas]	0.0	4	1	1	1
125718	1710	molecular mechanism increase il-2 transcription	[molecular mechanism increasing IL-2 transcription]	0.0	5	1	1	1
125719	1710	significant proliferation iddm subject 8	[significant proliferation IDDM subjects 8]	0.0	5	1	1	1
125720	1710	5 blood cell hrbc	[5 blood cells HRBC]	0.0	4	1	1	1
125721	1710	er (less	[ER (less]	0.0	2	1	1	1
125722	1710	mechanism regulate granulocyte apoptosis	[mechanisms regulating granulocyte apoptosis]	0.0	4	1	1	1
125723	1710	Furthermore, analysis	[Furthermore, analysis]	0.0	2	1	1	1
125724	1710	hla-dr11	[HLA-DR11]	0.0	1	1	1	1
125725	1710	enhancer-dependent effect	[enhancer-dependent effect]	0.0	2	1	1	1
125726	1710	concentration compatible	[concentrations compatible]	0.0	2	1	1	1
125727	1710	specific depletion of the population	[specific depletion of the population]	0.0	5	1	1	1
125728	1710	polymorphonuclear leukocyte adhesion to cell	[polymorphonuclear leukocyte adhesion to cells]	0.0	5	1	1	1
125729	1710	binding of calmodulin	[binding of calmodulin]	0.0	3	1	1	1
125730	1710	cellular immune pathway	[Cellular immune pathways]	0.0	3	1	1	1
125731	1710	vitro, of a distinct deletion	[vitro, of a distinct deletion]	0.0	5	1	1	1
125732	1710	other control transcription factor	[other control transcription factors]	0.0	4	1	1	1
125733	1710	elucidate the function	[elucidating the function]	0.0	3	1	1	1
125734	1710	adolescent depressive disorder	[adolescent depressive disorder]	0.0	3	1	1	1
125735	1710	level for macrophage protein-1 another member	[levels for macrophage protein-1 another member]	0.0	6	1	1	1
125736	1710	32-kDa phosphoprotein	[32-kDa phosphoprotein]	0.0	2	1	1	1
125737	1710	10-fold less il-10	[10-fold less IL-10]	0.0	3	1	1	1
125738	1710	30 minute pha stimulation,	[30 min PHA stimulation,]	0.0	4	1	1	1
125739	1710	mrna in peripheral cell	[mRNA in peripheral cells]	0.0	4	1	1	1
125740	1710	include the sequence thr729-lys984	[including the sequence Thr729-Lys984]	0.0	4	1	1	1
125741	1710	alpha A1 antibody	[alpha A1 antibodies]	0.0	3	1	1	1
125742	1710	Physiol.	[Physiol.]	0.0	1	1	1	1
125743	1710	impaired activation of transcriptional factor	[impaired activation of transcriptional factors]	0.0	5	1	1	1
125744	1710	other synthetic nonselective RAR ligand	[other synthetic nonselective RAR ligands]	0.0	5	1	1	1
125745	1710	expression in fresh cell	[expression in fresh cells]	0.0	4	1	1	1
125746	1710	mononulear leukocyte from control subject	[mononulear leukocytes from control subjects]	0.0	5	1	1	1
125747	1710	differentiation a model for lineage restriction	[differentiation a model for lineage restriction]	0.0	6	1	1	1
125748	1710	role for intracellular oxidant generation	[role for intracellular oxidant generation]	0.0	5	1	1	1
125749	1710	potential tool for evaluation	[potential tool for evaluation]	0.0	4	1	1	1
125750	1710	myb-transformed cell as a model	[Myb-transformed cells as a model]	0.0	5	1	1	1
125751	1710	individual of particular complex (mhc) haplotype	[individuals of particular complex (MHC) haplotypes]	0.0	6	1	1	1
125752	1710	molecular weight of Dalton	[molecular weight of Dalton]	0.0	4	1	1	1
125753	1710	balance of c-jun protein	[balance of c-Jun protein]	0.0	4	1	1	1
125754	1710	allele specificity	[allele specificity]	0.0	2	1	1	1
125755	1710	early regulation	[early regulation]	0.0	2	1	1	1
125756	1710	cooperation of cellular transcription factor	[cooperation of cellular transcription factors]	0.0	5	1	1	1
125757	1710	rBPI21 a N-terminal fragment lps expression	[rBPI21 a N-terminal fragment LPS expression]	0.0	6	1	1	1
125758	1710	deficient cell line	[deficient cell lines]	0.0	3	1	1	1
125759	1710	intact human leukocyte	[intact human leukocytes]	0.0	3	1	1	1
125760	1710	state of latency	[state of latency]	0.0	3	1	1	1
125761	1710	distinct, b-cell-derived subtype	[distinct, B-cell-derived subtype]	0.0	3	1	1	1
125762	1710	point mutation in the SRE	[point mutation in the SRE]	0.0	5	1	1	1
125763	1710	inhibition by VCAM-1 monoclonal antibody 1g11	[Inhibition by VCAM-1 monoclonal antibody 1G11]	0.0	6	1	1	1
125764	1710	colony-stimumulatelany-stg factor in human monocyte	[colony-stimulating factor in human monocytes]	0.0	5	1	1	1
125765	1710	(also in human umbilical endothelial cell	[(also in human umbilical endothelial cells]	0.0	6	1	1	1
125766	1710	IL-2R alpha-chain	[IL-2R alpha-chain]	0.0	2	1	1	1
125767	1710	six isomorph by two-dimensional gel analysis	[six isomorphs by two-dimensional gel analysis]	0.0	6	1	1	1
125768	1710	important determinant of expression	[important determinant of expression]	0.0	4	1	1	1
125769	1710	giant cell from monocyte	[giant cells from monocytes]	0.0	4	1	1	1
125770	1710	role of BSAP Pax-5	[role of BSAP Pax-5]	0.0	4	1	1	1
125771	1710	742 bp region	[742 bp region]	0.0	3	1	1	1
125772	1710	cytoplasmic transcription factor	[cytoplasmic transcription factors]	0.0	3	1	1	1
125773	1710	new transcription factor family	[new transcription factor family]	0.0	4	1	1	1
125774	1710	burst during phorbol ester-induced differentiation	[burst during phorbol ester-induced differentiation]	0.0	5	1	1	1
125775	1710	evidence at element	[Evidence at element]	0.0	3	1	1	1
125776	1710	several method for down-regulation	[Several methods for down-regulation]	0.0	4	1	1	1
125777	1710	six isomorph of p56	[six isomorphs of p56]	0.0	4	1	1	1
125778	1710	CD4 thymocyte	[CD4 thymocytes]	0.0	2	1	1	1
125779	1710	property with hsf1	[properties with HSF1]	0.0	3	1	1	1
125780	1710	single mutation	[single mutations]	0.0	2	1	1	1
125781	1710	differentiation by T3	[differentiation by T3]	0.0	3	1	1	1
125782	1710	include immunodeficiency virus tat	[including immunodeficiency virus Tat]	0.0	4	1	1	1
125783	1710	active extract from Jurkat	[active extracts from Jurkat]	0.0	4	1	1	1
125784	1710	control of vcam-1 gene expression	[control of VCAM-1 gene expression]	0.0	5	1	1	1
125785	1710	course of infections.	[course of infections.]	0.0	3	1	1	1
125786	1710	H-RS cell	[H-RS cells]	0.0	2	1	1	1
125787	1710	HLA-DR3 positive with no association	[HLA-DR3 positive with no association]	0.0	5	1	1	1
125788	1710	drug for inflammatory disease	[drugs for inflammatory diseases]	0.0	4	1	1	1
125789	1710	promoter-binding protein in EBNA-2 cell line	[promoter-binding proteins in EBNA-2 cell lines]	0.0	6	1	1	1
125790	1710	lt promoter activity	[LT promoter activity]	0.0	3	1	1	1
125791	1710	trans-activation activity	[trans-activation activities]	0.0	2	1	1	1
125792	1710	encode a protein bind protein	[encoding a protein binding protein]	0.0	5	1	1	1
125793	1710	nf-at rdna	[NF-AT cDNAs]	0.0	2	1	1	1
125794	1710	cell gelatinase	[cell gelatinase]	0.0	2	1	1	1
125795	1710	drug in APL patient refractory	[drug in APL patients refractory]	0.0	5	1	1	1
125796	1710	mediator generate mechanism	[mediator generating mechanisms]	0.0	3	1	1	1
125797	1710	beta activation of stat6	[beta activation of STAT6]	0.0	4	1	1	1
125798	1710	small cytokine	[small cytokines]	0.0	2	1	1	1
125799	1710	major positive role for GATA-1	[major positive role for GATA-1]	0.0	5	1	1	1
125800	1710	steady state kappa	[steady state kappa]	0.0	3	1	1	1
125801	1710	binding between JAK1	[binding between JAK1]	0.0	3	1	1	1
125802	1710	primary sensitization	[primary sensitization]	0.0	2	1	1	1
125803	1710	interaction with epithelial cell TEC	[interaction with epithelial cells TEC]	0.0	5	1	1	1
125804	1710	sensitive polymerase chain reaction assay	[sensitive polymerase chain reaction assay]	0.0	5	1	1	1
125805	1710	antitumor immune response	[antitumor immune responses]	0.0	3	1	1	1
125806	1710	initiate the pathway	[initiating the pathway]	0.0	3	1	1	1
125807	1710	contribution to the unique phenotype	[contribution to the unique phenotype]	0.0	5	1	1	1
125808	1710	41 small exon	[41 small exons]	0.0	3	1	1	1
125809	1710	reciprocal elevation of gamma-globin expression	[reciprocal elevation of gamma-globin expression]	0.0	5	1	1	1
125810	1710	gas exchange	[gas exchange]	0.0	2	1	1	1
125811	1710	101pp dnase site-forming element	[101bp, DNase site-forming element]	0.0	4	1	1	1
125812	1710	hemin-treated k562 cell	[hemin-treated K562 cells]	0.0	3	1	1	1
125813	1710	complex by antibody	[complexes by antibodies]	0.0	3	1	1	1
125814	1710	class histocompatibility complex promoter	[class histocompatibility complex promoters]	0.0	4	2	2	1
125815	1710	regulation gene expression in myeloid cell	[Regulation gene expression in myeloid cells]	0.0	6	1	1	1
125816	1710	expression of human cd14	[expression of human CD14]	0.0	4	1	1	1
125817	1710	normal component	[normal components]	0.0	2	1	1	1
125818	1710	numerous abnormality in immune regulation	[Numerous abnormalities in immune regulation]	0.0	5	1	1	1
125819	1710	immunoglobulin switch	[immunoglobulin switch]	0.0	2	1	1	1
125820	1710	lead to B-cell apoptosis	[leading to B-cell apoptosis]	0.0	4	1	1	1
125821	1710	none of the putative regulatory site	[None of the putative regulatory sites]	0.0	6	1	1	1
125822	1710	(ccrf-cem)	[(CCRF-CEM)]	0.0	1	1	1	1
125823	1710	previous investigation	[previous investigations]	0.0	2	1	1	1
125824	1710	(<2 gene expression	[(<2 gene expression]	0.0	3	1	1	1
125825	1710	15 patient remission	[15 patients remission]	0.0	3	1	1	1
125826	1710	therapeutic value for vascular disease	[therapeutic value for vascular disease]	0.0	5	1	1	1
125827	1710	hiv-1 long repeat promoter region	[HIV-1 long repeat promoter region]	0.0	5	1	1	1
125828	1710	class of helix-loop-helix protein	[class of helix-loop-helix proteins]	0.0	4	1	1	1
125829	1710	increase in the glutathione level	[increase in the glutathione levels]	0.0	5	1	1	1
125830	1710	signal transduction to the IL-2 gene	[signal transduction to the IL-2 gene]	0.0	6	1	1	1
125831	1710	one abnormal biomarker	[one abnormal biomarkers]	0.0	3	1	1	1
125832	1710	undergo elective ptca	[undergoing elective PTCA]	0.0	3	1	1	1
125833	1710	discovery factor kappa b	[discovery factor kappa B]	0.0	4	1	1	1
125834	1710	include pathway of monocyte activation	[including pathways of monocyte activation]	0.0	5	1	1	1
125835	1710	NFkappaB translocation follow lps activation	[NFkappaB translocation following LPS activation]	0.0	5	1	1	1
125836	1710	interferon beta IFN-beta regulatory element	[interferon beta IFN-beta regulatory element]	0.0	5	1	1	1
125837	1710	crossreactive cytotoxicity pattern	[crossreactive cytotoxicity patterns]	0.0	3	1	1	1
125838	1710	nf kappab -dependent enzyme	[NF kappaB -dependent enzyme]	0.0	4	1	1	1
125839	1710	conversion of 25(oh)d3	[conversion of 25(OH)D3]	0.0	3	1	1	1
125840	1710	NF-kappa b -dependent	[NF-kappa B -dependent]	0.0	3	1	1	1
125841	1710	accord to a work Formulation	[according to an Working Formulation]	0.0	5	1	1	1
125842	1710	selective factor	[selective factor]	0.0	2	1	1	1
125843	1710	piec line	[PIEC line]	0.0	2	1	1	1
125844	1710	anionic surface	[anionic surface]	0.0	2	1	1	1
125845	1710	expression of Rev M10	[expression of Rev M10]	0.0	4	1	1	1
125846	1710	latter complex	[latter complexes]	0.0	2	1	1	1
125847	1710	chloramphenicol acetyl-transferase expression	[chloramphenicol acetyl-transferase expression]	0.0	3	1	1	1
125848	1710	regulation of normal differentiation	[regulation of normal differentiation]	0.0	4	1	1	1
125849	1710	cepsilon	[Cepsilon]	0.0	1	2	2	1
125850	1710	human yeast chromosome transgene	[human yeast chromosome transgene]	0.0	4	1	1	1
125851	1710	activation of macrophage by ventilation	[Activation of macrophages by ventilation]	0.0	5	1	1	1
125852	1710	endothelial-leukocyte adhesion molecule elam-1	[endothelial-leukocyte adhesion molecule ELAM-1]	0.0	4	1	1	1
125853	1710	differ from dq3.2 only at residue	[differing from DQ3.2 only at residue]	0.0	6	1	1	1
125854	1710	kda ca(2+)-atpase	[kDa Ca(2+)-ATPase]	0.0	2	1	1	1
125855	1710	human leucocyte in 13 man	[human leucocytes in 13 men]	0.0	5	1	1	1
125856	1710	carry Val at 50	[carrying Val at 50]	0.0	4	1	1	1
125857	1710	sperm type protocol	[sperm typing protocol]	0.0	3	1	1	1
125858	1710	glucocorticoid receptor on mononuclear leukocyte	[glucocorticoid receptors on mononuclear leukocytes]	0.0	5	1	1	1
125859	1710	interferon-alpha treatment	[interferon-alpha treatment]	0.0	2	1	1	1
125860	1710	gp91phox promoter construct	[gp91phox promoter constructs]	0.0	3	1	1	1
125861	1710	dihydro derivative 5,	[dihydro derivatives 5,]	0.0	3	1	1	1
125862	1710	ebv transactivate	[EBV transactivating]	0.0	2	1	1	1
125863	1710	catalyze the exchange of chain-derived peptide	[catalyzing the exchange of chain-derived peptides]	0.0	6	1	1	1
125864	1710	form of the IL-6 promoter	[forms of the IL-6 promoter]	0.0	5	1	1	1
125865	1710	number i of type receptor	[numbers I of Type receptors]	0.0	5	1	1	1
125866	1710	follow discontinuation of glucocorticoid drug	[Following discontinuation of glucocorticoid drugs]	0.0	5	1	1	1
125867	1710	eight cell line	[eight cell lines]	0.0	3	1	1	1
125868	1710	experiment with cytokine IL-2	[experiments with cytokines IL-2]	0.0	4	1	1	1
125869	1710	productive hiv-1 infection of T cell	[productive HIV-1 infection of T cells]	0.0	6	1	1	1
125870	1710	healthy individual for the purpose	[healthy individuals for the purpose]	0.0	5	1	1	1
125871	1710	measure decay of the message	[measuring decay of the message]	0.0	5	1	1	1
125872	1710	functional protein binding sequence	[functional protein binding sequences]	0.0	4	1	1	1
125873	1710	guanine residue	[guanine residues]	0.0	2	1	1	1
125874	1710	transcriptional regulating protein	[transcriptional regulating proteins]	0.0	3	1	1	1
125875	1710	four direct repeat of 21 bp	[four direct repeats of 21 bp]	0.0	6	1	1	1
125876	1710	rolling, adhesion,	[rolling, adhesion,]	0.0	2	1	1	1
125877	1710	one pattern	[one pattern]	0.0	2	1	1	1
125878	1710	second A/R insult	[second A/R insult]	0.0	3	1	1	1
125879	1710	environmental factors, in particular, cytokine	[environmental factors, in particular, cytokines]	0.0	5	1	1	1
125880	1710	bp downstream of the nre	[bp downstream of the NRE]	0.0	5	1	1	1
125881	1710	block fragmentation	[blocking fragmentation]	0.0	2	1	1	1
125882	1710	block a potential therapeutic target	[blocking a potential therapeutic target]	0.0	5	1	1	1
125883	1710	tetrahydrocortisone mg/24h; n: 2.7+/-2.0) excretion,	[tetrahydrocortisone mg/24h; N: 2.7+/-2.0) excretion,]	0.0	5	1	1	1
125884	1710	affinity for the 12-bp insert	[affinity for the 12-bp insert]	0.0	5	1	1	1
125885	1710	transcription pcr	[transcription PCR]	0.0	2	1	1	1
125886	1710	immunoglobulin chain IgH	[immunoglobulin chain IgH]	0.0	3	1	1	1
125887	1710	coordinate activation of hsf of NFkappaB	[coordinate activation of HSF of NFkappaB]	0.0	6	1	1	1
125888	1710	cf11/cd18 adhesion receptor	[CD11/CD18 adhesion receptors]	0.0	3	1	1	1
125889	1710	likely identical proteins,	[likely identical proteins,]	0.0	3	1	1	1
125890	1710	JCam/	[JCam/]	0.0	1	1	1	1
125891	1710	CD40 ligand fibroblast activation	[CD40 ligand fibroblast activation]	0.0	4	1	1	1
125892	1710	l-selectin gene	[L-selectin gene]	0.0	2	1	1	1
125893	1710	pge2 bind	[PGE2 bind]	0.0	2	1	1	1
125894	1710	prevent transcriptional induction of several cytokine	[preventing transcriptional induction of several cytokine]	0.0	6	1	1	1
125895	1710	series: at normal (17 subject	[series: at normal (17 subjects]	0.0	5	1	1	1
125896	1710	LAL -mRNA	[LAL -mRNA]	0.0	2	1	1	1
125897	1710	CsA -sensitive T cell factor	[CsA -sensitive T cell factors]	0.0	5	1	1	1
125898	1710	effect on il-2 production	[effect on IL-2 production]	0.0	4	1	1	1
125899	1710	germline deletion of tsc2	[germline deletions of TSC2]	0.0	4	1	1	1
125900	1710	normal gene expression in cell	[normal gene expression in cells]	0.0	5	1	1	1
125901	1710	novel elastase inhibitor synthetic peptide	[novel elastase inhibitor synthetic peptide]	0.0	5	1	1	1
125902	1710	Instead,	[Instead,]	0.0	1	1	1	1
125903	1710	presence of a positive element	[presence of a positive element]	0.0	5	1	1	1
125904	1710	megakaryoblastic leukemia	[megakaryoblastic leukemia]	0.0	2	1	1	1
125905	1710	hugata-3 by sds-page	[huGATA-3 by SDS-PAGE]	0.0	3	1	1	1
125906	1710	determination of GH in child	[determination of GH in children]	0.0	5	1	1	1
125907	1710	t-cell virus type tax	[T-cell virus type Tax]	0.0	4	1	1	1
125908	1710	HLA-DRA gene expression	[HLA-DRA gene expression]	0.0	3	1	1	1
125909	1710	sf during priming	[SFs during priming]	0.0	3	1	1	1
125910	1710	bmt drug	[BMT drug]	0.0	2	1	1	1
125911	1710	20 mM.	[20 mM.]	0.0	2	1	1	1
125912	1710	gcr of control	[GCR of controls]	0.0	3	1	1	1
125913	1710	high level in mature monocyte	[highest levels in mature monocytes]	0.0	5	1	1	1
125914	1710	Additionally, preincubation	[Additionally, preincubation]	0.0	2	1	1	1
125915	1710	estrogen receptor in leucocyte	[estrogen receptors in leucocytes]	0.0	4	1	1	1
125916	1710	function of human macrophage	[functions of human macrophages]	0.0	4	1	1	1
125917	1710	absence in Hodgkin' Reed-Sternberg cell	[Absence in Hodgkin's Reed-Sternberg cells]	0.0	5	1	1	1
125918	1710	regulate stage of B cell development	[regulating stages of B cell development]	0.0	6	1	1	1
125919	1710	lytic antigen-specific reactivity as high	[lytic antigen-specific reactivities as high]	0.0	5	1	1	1
125920	1710	sole cause	[sole cause]	0.0	2	1	1	1
125921	1710	mediate transcription from position	[mediating transcription from positions]	0.0	4	1	1	1
125922	1710	carcinogen	[carcinogens]	0.0	1	1	1	1
125923	1710	CD3 delta	[CD3 delta]	0.0	2	1	1	1
125924	1710	mutation in codon 10	[mutation in codon 10]	0.0	4	1	1	1
125925	1710	nuclear factor-kappaB a activator	[nuclear factor-kappaB a activator]	0.0	4	1	1	1
125926	1710	dephosphorylation of prb of form 3	[dephosphorylation of pRb of Form 3]	0.0	6	1	1	1
125927	1710	5'-positive unit consist	[5'-positive unit consisting]	0.0	3	1	1	1
125928	1710	role of nuclear I(kappa)B(alpha)	[role of nuclear I(kappa)B(alpha)]	0.0	4	1	1	1
125929	1710	upstream factor USF	[upstream factor USF]	0.0	3	1	1	1
125930	1710	signal pathway of T cell activation.	[signaling pathways of T cell activation.]	0.0	6	1	1	1
125931	1710	age of the attack	[age of the attack]	0.0	4	1	1	1
125932	1710	affinity class	[affinity class]	0.0	2	1	1	1
125933	1710	myelogenous leukemia 1- evi1 fusion	[myelogenous leukemia 1- EVI1 fusions]	0.0	5	1	1	1
125934	1710	five species	[five species]	0.0	2	1	1	1
125935	1710	multiple nf-atc isoform with transcriptional property	[Multiple NF-ATc isoforms with transcriptional properties]	0.0	6	1	1	1
125936	1710	nonlymphoid tumor	[nonlymphoid tumors]	0.0	2	1	1	1
125937	1710	more than one bind site	[more than one binding site]	0.0	5	1	1	1
125938	1710	T cell receptor element	[T cell receptor elements]	0.0	4	1	1	1
125939	1710	grade, DNA aneuploidy	[grade, DNA aneuploidy]	0.0	3	2	2	1
125940	1710	role in immune senescence	[role in immune senescence]	0.0	4	1	1	1
125941	1710	regulation of the gm-csf gene	[regulation of the GM-CSF gene]	0.0	5	1	1	1
125942	1710	effect on the ability	[effects on the ability]	0.0	4	1	1	1
125943	1710	pre-B leukemia	[pre-B leukemia]	0.0	2	1	1	1
125944	1710	methyl ether	[methyl ether]	0.0	2	1	1	1
125945	1710	degenerative tropical spastic paraparesis	[degenerative tropical spastic paraparesis]	0.0	4	1	1	1
125946	1710	heterogeneous population of progenitor /precursor	[heterogeneous populations of progenitors /precursors]	0.0	5	1	1	1
125947	1710	h with mAb l243	[h with mAb L243]	0.0	4	1	1	1
125948	1710	mobility-shift assay of huvec nuclear protein	[mobility-shift assays of HUVEC nuclear proteins]	0.0	6	1	1	1
125949	1710	Glucocorticoid receptor concentration in leukocyte	[Glucocorticoid receptor concentrations in leukocytes]	0.0	5	1	1	1
125950	1710	kb telomeric	[kb telomeric]	0.0	2	1	1	1
125951	1710	distal nuclear factor NF-AT AP-1/Octamer UPS	[distal nuclear factor NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
125952	1710	era in research	[era in research]	0.0	3	1	1	1
125953	1710	patient with low affinity to glucocorticoid	[patients with low affinity to glucocorticoids]	0.0	6	1	1	1
125954	1710	alpha-helice class MHC molecule	[alpha-helices class MHC molecules]	0.0	4	1	1	1
125955	1710	eosinophil effect	[eosinophil effects]	0.0	2	1	1	1
125956	1710	production of type cytokine il-4	[production of type cytokines IL-4]	0.0	5	1	1	1
125957	1710	sequence of biochemical event	[sequence of biochemical events]	0.0	4	1	1	1
125958	1710	six zinc-finger motif	[six zinc-finger motifs]	0.0	3	1	1	1
125959	1710	integrin adhesive function	[integrin adhesive function]	0.0	3	1	1	1
125960	1710	transcriptional activator function af-1	[transcriptional activator functions AF-1]	0.0	4	1	1	1
125961	1710	evidence for biochemical change	[evidence for biochemical changes]	0.0	4	1	1	1
125962	1710	role in effect	[role in effects]	0.0	3	1	1	1
125963	1710	85 to 45 kda	[85 to 45 kDa]	0.0	4	1	1	1
125964	1710	only in u-937	[only in U-937]	0.0	3	1	1	1
125965	1710	murine interleukin	[murine interleukin]	0.0	2	1	1	1
125966	1710	function of this positive element	[function of this positive element]	0.0	5	1	1	1
125967	1710	change in gene nuclear topography	[changes in gene nuclear topography]	0.0	5	1	1	1
125968	1710	steroid hormone estrogen e2	[steroid hormones estrogen E2]	0.0	4	1	1	1
125969	1710	retinoic acid -responsive element-containing promoter	[retinoic acid -responsive element-containing promoters]	0.0	5	1	1	1
125970	1710	stat1alpha gene	[STAT1alpha gene]	0.0	2	1	1	1
125971	1710	thus any cellular defect	[thus any cellular defect]	0.0	4	1	1	1
125972	1710	increase extracellular concentration	[increasing extracellular concentrations]	0.0	3	1	1	1
125973	1710	marker include vpreb1	[markers including VpreB1]	0.0	3	1	1	1
125974	1710	series of immune response	[series of immune responses]	0.0	4	1	1	1
125975	1710	relation to classical features: implications.	[relations to classical features: implications.]	0.0	5	1	1	1
125976	1710	mononuclear leukocyte from subject	[mononuclear leukocytes from subjects]	0.0	4	1	1	1
125977	1710	understanding of the cascade	[understanding of the cascade]	0.0	4	1	1	1
125978	1710	result in production	[resulting in production]	0.0	3	1	1	1
125979	1710	directly, provide evidence	[directly, providing evidence]	0.0	3	1	1	1
125980	1710	LPS binding of factor-kappaB/Rel	[LPS binding of factor-kappaB/Rel]	0.0	4	1	1	1
125981	1710	236 ng/ml) in plasma	[236 ng/mL) in plasma]	0.0	4	1	1	1
125982	1710	nf-kappa b for transcription,	[NF-kappa B for transcription,]	0.0	4	1	1	1
125983	1710	membrane protein LMP1 of ebv	[membrane protein LMP1 of EBV]	0.0	5	1	1	1
125984	1710	release into the bloodstream	[release into the bloodstream]	0.0	4	1	1	1
125985	1710	healthy woman (11 first, second	[healthy women (11 first, second]	0.0	5	1	1	1
125986	1710	vertebrate gene	[vertebrate gene]	0.0	2	1	1	1
125987	1710	reverse-transcription	[reverse-transcription]	0.0	1	1	1	1
125988	1710	cause of arthritis	[cause of arthritis]	0.0	3	2	2	1
125989	1710	essential role in lymphoid development	[essential role in lymphoid development]	0.0	5	1	1	1
125990	1710	anti-dnp antibody	[anti-DNP antibodies]	0.0	2	1	1	1
125991	1710	increase in suppressor activity	[increase in suppressor activity]	0.0	4	1	1	1
125992	1710	amino acid 346	[amino acids 346]	0.0	3	1	1	1
125993	1710	EB1 a EBV product	[EB1 an EBV product]	0.0	4	1	1	1
125994	1710	more intense staining	[more intense staining]	0.0	3	1	1	1
125995	1710	transcription of ap-1 pathway	[transcription of AP-1 pathways]	0.0	4	1	1	1
125996	1710	ability of glucocorticoid receptor	[ability of glucocorticoid receptors]	0.0	4	1	1	1
125997	1710	mutation ap-1(iii)/ ap3-l	[mutation AP-1(III)/ AP3-L]	0.0	3	1	1	1
125998	1710	IL-10 inhibition	[IL-10 inhibition]	0.0	2	2	2	1
125999	1710	h peak at 24 h.	[h peaks at 24 h,]	0.0	5	1	1	1
126000	1710	recombinant human il-2	[recombinant human IL-2]	0.0	3	1	1	1
126001	1710	gp41 envelope	[gp41 envelope]	0.0	2	1	1	1
126002	1710	increase in the expression of transcription	[increase in the expression of transcription]	0.0	6	1	1	1
126003	1710	most kb	[most kb]	0.0	2	1	1	1
126004	1710	transcript of the wild type er	[transcripts of the wild type ER]	0.0	6	1	1	1
126005	1710	role of DNA binding	[role of DNA binding]	0.0	4	1	1	1
126006	1710	gamma interferon activation site	[gamma interferon activation site]	0.0	4	1	1	1
126007	1710	developmental stage.	[developmental stage.]	0.0	2	1	1	1
126008	1710	suggest a requirement for pc4 component	[suggesting a requirement for PC4 component]	0.0	6	1	1	1
126009	1710	patient with tuberculosis,	[patients with tuberculosis,]	0.0	3	1	1	1
126010	1710	rel homology domain	[Rel homology domain]	0.0	3	1	1	1
126011	1710	tissue inhibitor metalloproteinase	[tissue inhibitor metalloproteinases]	0.0	3	1	1	1
126012	1710	stimulation by CBF alpha	[stimulation by CBF alpha]	0.0	4	1	1	1
126013	1710	thus, stable expression	[Thus, stable expression]	0.0	3	1	1	1
126014	1710	stress agent like ionize radiation exposure	[stress agents like ionizing radiation exposure]	0.0	6	1	1	1
126015	1710	kappa b-alpha proteolysis by phosphorylation	[kappa B-alpha proteolysis by phosphorylation]	0.0	5	1	1	1
126016	1710	Furthermore, addition	[Furthermore, addition]	0.0	2	1	1	1
126017	1710	therapy for inflammatory bowel disease	[therapies for inflammatory bowel disease]	0.0	5	1	1	1
126018	1710	[effect of the regimen	[[Effect of the regimen]	0.0	4	1	1	1
126019	1710	negative regulator in differentiation	[negative regulators in differentiation]	0.0	4	1	1	1
126020	1710	concentration of corticosteroid	[concentration of corticosteroid]	0.0	3	1	1	1
126021	1710	germinal centers.	[germinal centers.]	0.0	2	1	1	1
126022	1710	salt loss lead despite level	[salt loss leading despite levels]	0.0	5	1	1	1
126023	1710	D not 4816	[D nt 4816]	0.0	3	1	1	1
126024	1710	agreement a accumulation	[agreement an accumulation]	0.0	3	1	1	1
126025	1710	mechanisms: protein stabilization	[mechanisms: protein stabilization]	0.0	3	1	1	1
126026	1710	stimulator cause secretion	[stimulator causing secretion]	0.0	3	1	1	1
126027	1710	signal mediator in dermal endothelial cell	[signaling mediators in dermal endothelial cells]	0.0	6	1	1	1
126028	1710	18-hydroxy-corticosterone 18-oh-b level with pih	[18-hydroxy-corticosterone 18-OH-B levels with PIH]	0.0	5	1	1	1
126029	1710	potentiation of trancriptional activity	[potentiation of trancriptional activity]	0.0	4	1	1	1
126030	1710	addition of gm-csf hgm-csf	[addition of GM-CSF hGM-CSF]	0.0	4	1	1	1
126031	1710	lymphocyte proliferation ic50	[lymphocyte proliferation IC50s]	0.0	3	2	2	1
126032	1710	thus, competition between transcriptional activator RelA	[Thus, competition between transcriptional activators RelA]	0.0	6	1	1	1
126033	1710	Jun-Fos heterodimer	[Jun-Fos heterodimers]	0.0	2	1	1	1
126034	1710	production of androgen	[production of androgens]	0.0	3	1	1	1
126035	1710	related disorder	[related disorders]	0.0	2	1	1	1
126036	1710	ifna2 gene	[IFNA2 gene]	0.0	2	1	1	1
126037	1710	maximum binding capacity	[maximum binding capacity]	0.0	3	1	1	1
126038	1710	cloning of a gene lysp100	[cloning of a gene LYSP100]	0.0	5	1	1	1
126039	1710	binding of protein (s) from lam-	[binding of protein (s) from LAM-]	0.0	6	1	1	1
126040	1710	role of a downstream intronic sequence	[role of a downstream intronic sequence]	0.0	6	1	1	1
126041	1710	characterization of the GPIX promoter	[characterization of the GPIX promoter]	0.0	5	1	1	1
126042	1710	second complex resemble factor	[second complex resembling factor]	0.0	4	1	1	1
126043	1710	(sapk)/jun	[(SAPK)/Jun]	0.0	1	1	1	1
126044	1710	ball1	[BALL1]	0.0	1	1	1	1
126045	1710	other family member in development	[other family members in development]	0.0	5	1	1	1
126046	1710	professional apc fibroblast	[professional APCs fibroblasts]	0.0	3	1	1	1
126047	1710	human herpesvirus hhv-6 strain	[human herpesvirus HHV-6 strains]	0.0	4	1	1	1
126048	1710	liuwei	[liuwei]	0.0	1	1	1	1
126049	1710	likely target	[likely targets]	0.0	2	1	1	1
126050	1710	action of different hormone compound	[action of different hormone compounds]	0.0	5	1	1	1
126051	1710	Arre-2	[ARRE-2]	0.0	1	1	1	1
126052	1710	gene regulate the machinery	[genes regulating the machinery]	0.0	4	1	1	1
126053	1710	1-long repeat	[1-long repeat]	0.0	2	1	1	1
126054	1710	value on day	[values on day]	0.0	3	1	1	1
126055	1710	level in rest platelet	[levels in resting platelets]	0.0	4	1	1	1
126056	1710	other "octamer" complex	[other "octamer" complex]	0.0	3	1	1	1
126057	1710	eiconsanoid thromboxane	[eiconsanoids thromboxane]	0.0	2	1	1	1
126058	1710	supernatant from macrophage	[supernatants from macrophages]	0.0	3	1	1	1
126059	1710	use concentration of peptide ligand	[using concentrations of peptide ligand]	0.0	5	1	1	1
126060	1710	potassium concentration	[potassium concentrations]	0.0	2	1	1	1
126061	1710	at-Xq28	[at-Xq28]	0.0	1	1	1	1
126062	1710	Fas/APO-1	[Fas/APO-1]	0.0	1	1	1	1
126063	1710	fmol/10(7) cell in control	[fmol/10(7) cells in controls]	0.0	4	3	3	1
126064	1710	ATL sample	[ATL samples]	0.0	2	1	1	1
126065	1710	absence of migrating form	[absence of migrating forms]	0.0	4	1	1	1
126066	1710	such as gata-1	[such as GATA-1]	0.0	3	1	1	1
126067	1710	patient aml (10	[patients AML (10]	0.0	3	1	1	1
126068	1710	analysis for diagnosis, genetic counseling,	[analysis for diagnosis, genetic counseling,]	0.0	5	1	1	1
126069	1710	incubation MCM	[Incubation MCM]	0.0	2	1	1	1
126070	1710	prevent the degradation	[preventing the degradation]	0.0	3	2	2	1
126071	1710	distinct factor	[distinct factors]	0.0	2	1	1	1
126072	1710	gene encode EBNA	[gene encoding EBNA]	0.0	3	1	1	1
126073	1710	induction, lytic superinfection with ebv	[induction, lytic superinfection with EBV]	0.0	5	1	1	1
126074	1710	respond to ifn-alpha therapy	[responding to IFN-alpha therapy]	0.0	4	1	1	1
126075	1710	nuclear localization of I(kappa)B(alpha)	[nuclear localization of I(kappa)B(alpha)]	0.0	4	1	1	1
126076	1710	transcription factor complex isgf3	[transcription factor complex ISGF3]	0.0	4	1	1	1
126077	1710	immunmodulatory effect	[immunmodulatory effects]	0.0	2	1	1	1
126078	1710	7 precursor	[7 precursors]	0.0	2	1	1	1
126079	1710	phosphorylation of dna-binding protein	[phosphorylation of DNA-binding proteins]	0.0	4	1	1	1
126080	1710	potent compound	[potent compound]	0.0	2	1	1	1
126081	1710	part in this process.	[part in this process.]	0.0	4	1	1	1
126082	1710	different molecular origin	[different molecular origin]	0.0	3	1	1	1
126083	1710	Differential contribution 1 gene product	[Differential contribution 1 gene products]	0.0	5	1	1	1
126084	1710	manipulate immune response	[manipulating immune responses]	0.0	3	1	1	1
126085	1710	transrepressor domain	[transrepressor domain]	0.0	2	1	1	1
126086	1710	lymphocyte of 24 woman second	[lymphocytes of 24 women second]	0.0	5	1	1	1
126087	1710	cell carcinoma of the head	[cell carcinomas of the head]	0.0	5	2	2	1
126088	1710	g1 specific response	[G1 specific response]	0.0	3	1	1	1
126089	1710	blood monocyte to macrophage	[blood monocytes to macrophages]	0.0	4	1	1	1
126090	1710	transcription start site (-7	[transcription start site (-7]	0.0	4	1	1	1
126091	1710	initial evidence link behavior	[initial evidence linking behavior]	0.0	4	1	1	1
126092	1710	major property of effect	[major properties of effects]	0.0	4	1	1	1
126093	1710	activate the t-cell-specific transcription factor	[activating the T-cell-specific transcription factors]	0.0	5	1	1	1
126094	1710	regulate the response by stimuli.	[regulating the response by stimuli.]	0.0	5	1	1	1
126095	1710	interferon-gamma ifn-gamma in human blood lymphocyte	[interferon-gamma IFN-gamma in human blood lymphocytes]	0.0	6	1	1	1
126096	1710	induction of NFAT	[induction of NFAT]	0.0	3	1	1	1
126097	1710	involve interaction between multiple positive element	[involving interactions between multiple positive elements]	0.0	6	1	1	1
126098	1710	persistent viral replication	[persistent viral replication]	0.0	3	1	1	1
126099	1710	lmp-1 allele	[LMP-1 allele]	0.0	2	1	1	1
126100	1710	hybrid express nf-kappa b	[hybrids expressing NF-kappa B]	0.0	4	1	1	1
126101	1710	AM580 a stable derivative of acid	[AM580 a stable derivative of acid]	0.0	6	1	1	1
126102	1710	time of h (viability great	[times of h (viability greater]	0.0	5	1	1	1
126103	1710	presence epo factor	[presence EPO factor]	0.0	3	1	1	1
126104	1710	additional reading frame	[additional reading frame]	0.0	3	1	1	1
126105	1710	lymphocyte proliferation by glucocorticoid	[lymphocyte proliferation by glucocorticoids]	0.0	4	1	1	1
126106	1710	pp repeat element	[pp repeat elements]	0.0	3	1	1	1
126107	1710	such as camp response element-binding protein	[such as cAMP response element-binding protein]	0.0	6	1	1	1
126108	1710	constitutively express a egr-1 transgene	[constitutively expressing an Egr-1 transgene]	0.0	5	1	1	1
126109	1710	nitric oxide a powerful pathway	[nitric oxide a powerful pathway]	0.0	5	1	1	1
126110	1710	synovial microenvironment	[synovial microenvironment]	0.0	2	1	1	1
126111	1710	adhesion of human monocyte	[Adhesion of human monocytes]	0.0	4	1	1	1
126112	1710	chimaeric	[chimaeric]	0.0	1	1	1	1
126113	1710	alpha-tocopherol a radical scavenger	[alpha-tocopherol a radical scavenger]	0.0	4	1	1	1
126114	1710	p65/p50 nf-kappab	[p65/p50 NF-kappaB]	0.0	2	1	1	1
126115	1710	opioid effect	[opioid effects]	0.0	2	1	1	1
126116	1710	respect to the promoter	[respect to the promoter]	0.0	4	1	1	1
126117	1710	also significantly (p 0.025)	[also significantly (P 0.025)]	0.0	4	1	1	1
126118	1710	after crosslinking of a conditional ngf-r	[after crosslinking of a conditional NGF-R]	0.0	6	1	1	1
126119	1710	multiple substitution in the human counterpart	[multiple substitutions in the human counterpart]	0.0	6	1	1	1
126120	1710	b regulation of the blk	[B regulation of the blk]	0.0	5	1	1	1
126121	1710	receptor/progesterone receptor binding	[receptor/progesterone receptor binding]	0.0	3	1	1	1
126122	1710	malfunction of the normal response	[malfunction of the normal response]	0.0	5	1	1	1
126123	1710	selection during infection.	[Selection during infection.]	0.0	3	1	1	1
126124	1710	cytokine lymphokine	[cytokine lymphokine]	0.0	2	1	1	1
126125	1710	only amino acid	[only amino acids]	0.0	3	1	1	1
126126	1710	RA alpha	[RA alpha]	0.0	2	1	1	1
126127	1710	DNA for the subunit	[DNA for the subunit]	0.0	4	1	1	1
126128	1710	molecular mechanism of control	[molecular mechanisms of control]	0.0	4	1	1	1
126129	1710	proline-rich sequence motif box1	[proline-rich sequence motif box1]	0.0	4	1	1	1
126130	1710	age-related impairment in the activation	[age-related impairments in the activation]	0.0	5	1	1	1
126131	1710	strong positivity for the bcl-6 protein	[Strong positivity for the BCL-6 protein]	0.0	6	1	1	1
126132	1710	hie asthma.	[HIE asthma.]	0.0	2	1	1	1
126133	1710	mouse ets-1 cDNA	[mouse ets-1 cDNA]	0.0	3	1	1	1
126134	1710	"late" T lymphocyte	["late" T lymphocyte]	0.0	3	1	1	1
126135	1710	dose of ionizing radiation 0.25-2.0 gy	[doses of ionizing radiation 0.25-2.0 Gy]	0.0	6	1	1	1
126136	1710	recruitment via sh2 domain	[recruitment via SH2 domains]	0.0	4	1	1	1
126137	1710	represent different stage of maturation,	[representing different stages of maturation,]	0.0	5	1	1	1
126138	1710	phosphocreatine pcr	[phosphocreatine PCr]	0.0	2	1	1	1
126139	1710	treatment of normal monocyte with phorbol-13-acetate	[Treatment of normal monocytes with phorbol-13-acetate]	0.0	6	1	1	1
126140	1710	Effect on transcription factor	[Effects on transcription factors]	0.0	4	1	1	1
126141	1710	binding protein for fk506	[binding protein for FK506]	0.0	4	1	1	1
126142	1710	belong to subgroup A	[belonging to subgroups A]	0.0	4	1	1	1
126143	1710	stable variant	[stable variants]	0.0	2	1	1	1
126144	1710	novel, proline carboxy terminus	[novel, proline carboxy terminus]	0.0	4	1	1	1
126145	1710	monocyte with influenza a virus	[monocytes with influenza A virus]	0.0	5	1	1	1
126146	1710	Jun NH2-terminal kinase	[Jun NH2-terminal kinase]	0.0	3	1	1	1
126147	1710	activation of the cdc42 effector	[Activation of the CDC42 effector]	0.0	5	1	1	1
126148	1710	EBNA2 transcriptional induction	[EBNA2 transcriptional induction]	0.0	3	1	1	1
126149	1710	least three multi-protein complex	[least three multi-protein complexes]	0.0	4	1	1	1
126150	1710	regulation of factor-kappa beta in monocyte	[regulation of factor-kappa beta in monocytes]	0.0	6	1	1	1
126151	1710	colony-stimumulatelany-stg factor-1 receptor csf-1r	[colony-stimulating factor-1 receptor CSF-1R]	0.0	4	1	1	1
126152	1710	immune system target for tcdd	[immune system targets for TCDD]	0.0	5	1	1	1
126153	1710	c-terminal serine region	[C-terminal serine region]	0.0	3	1	1	1
126154	1710	level capable of binding	[levels capable of binding]	0.0	4	1	1	1
126155	1710	exception, and/or in cell	[exception, and/or in cells]	0.0	4	1	1	1
126156	1710	treatment approach for recalcitrant asthma	[treatment approaches for recalcitrant asthma]	0.0	5	1	1	1
126157	1710	reflection for activation	[reflection for activation]	0.0	3	1	1	1
126158	1710	Helix-loop-helix	[Helix-loop-helix]	0.0	1	1	1	1
126159	1710	lipocalin ngal	[lipocalin NGAL]	0.0	2	1	1	1
126160	1710	cytoplasmic inhibitor b alpha	[cytoplasmic inhibitor B alpha]	0.0	4	1	1	1
126161	1710	uncouple hs1 phosphorylation from factor activation	[Uncoupling HS1 phosphorylation from factor activation]	0.0	6	1	1	1
126162	1710	cytoplasm of lymphocyte clusters.	[cytoplasm of lymphocytes clusters.]	0.0	4	1	1	1
126163	1710	distinct form of virus latency	[distinct forms of virus latency]	0.0	5	1	1	1
126164	1710	least dense granule	[least dense granules]	0.0	3	1	1	1
126165	1710	generation of antibody	[generation of antibodies]	0.0	3	1	1	1
126166	1710	value with measurement	[values with measurements]	0.0	3	1	1	1
126167	1710	activator protein-2	[activator protein-2]	0.0	2	1	1	1
126168	1710	epsilon- globin	[epsilon- globin]	0.0	2	1	1	1
126169	1710	combination of gm-csf	[combination of GM-CSF]	0.0	3	1	1	1
126170	1710	modulate release	[modulating release]	0.0	2	1	1	1
126171	1710	immediate region	[immediate region]	0.0	2	1	1	1
126172	1710	contain gene by the factor Oct-1	[containing genes by the factor Oct-1]	0.0	6	1	1	1
126173	1710	cutaneous carcinogenesis	[cutaneous carcinogenesis]	0.0	2	1	1	1
126174	1710	hie than control subject	[HIE than control subjects]	0.0	4	1	1	1
126175	1710	Crabtree	[Crabtree]	0.0	1	1	1	1
126176	1710	regard, level of c-fo	[regard, levels of c-fos]	0.0	4	1	1	1
126177	1710	rdna encode subunit of this factor	[cDNAs encoding subunits of these factors]	0.0	6	1	1	1
126178	1710	EBV-B cell clone	[EBV-B cell clones]	0.0	3	1	1	1
126179	1710	Hsp70 induction	[Hsp70 induction]	0.0	2	1	1	1
126180	1710	expiratory volume	[expiratory volume]	0.0	2	1	1	1
126181	1710	development of reaction	[development of reactions]	0.0	3	1	1	1
126182	1710	b-alpha level in pbmc	[B-alpha levels in PBMC]	0.0	4	1	1	1
126183	1710	endotoxin-stimulated c ytokine mrna level	[endotoxin-stimulated c ytokine mRNA levels]	0.0	5	1	1	1
126184	1710	insulin concentration	[insulin concentration]	0.0	2	1	1	1
126185	1710	768-bp upstream negative region	[768-bp upstream negative region]	0.0	4	1	1	1
126186	1710	encode EBNA 2	[encoding EBNA 2]	0.0	3	1	1	1
126187	1710	predominant b species	[predominant B species]	0.0	3	1	1	1
126188	1710	hiv-1 b-laip	[HIV-1 B-LAIp]	0.0	2	1	1	1
126189	1710	l-selectin expression	[L-selectin expression]	0.0	2	1	1	1
126190	1710	IL-1RI kinase	[IL-1RI kinase]	0.0	2	1	1	1
126191	1710	2 T cell	[2 T cells]	0.0	3	1	1	1
126192	1710	feature of senescence in vitro	[feature of senescence in vitro]	0.0	5	1	1	1
126193	1710	ap-2 nuclear factor	[AP-2 nuclear factor]	0.0	3	1	1	1
126194	1710	different hiv-1 LTR vector	[different HIV-1 LTR vectors]	0.0	4	1	1	1
126195	1710	interaction of b cell recognize DNA	[interaction of B cells recognizing DNA]	0.0	6	1	1	1
126196	1710	inducer of ap1	[inducer of AP1]	0.0	3	1	1	1
126197	1710	risk factor for human disease	[risk factor for human disease]	0.0	5	1	1	1
126198	1710	Promiscuous activity	[Promiscuous activity]	0.0	2	1	1	1
126199	1710	allele-specific mrna stability	[allele-specific mRNA stability]	0.0	3	1	1	1
126200	1710	important immune-modulating effect	[important immune-modulating effects]	0.0	3	1	1	1
126201	1710	tumor-suppressor gene expression through inhibition	[tumor-suppressor gene expression through inhibition]	0.0	5	1	1	1
126202	1710	rat vascular muscle cell	[rat vascular muscle cells]	0.0	4	1	1	1
126203	1710	human t-lymphotropic virus type model	[human T-lymphotropic virus type model]	0.0	5	1	1	1
126204	1710	sr 31747a-binding protein	[SR 31747A-binding protein]	0.0	3	1	1	1
126205	1710	human cell line,	[human cell line,]	0.0	3	1	1	1
126206	1710	relationship between the change in il-1	[relationship between the changes in IL-1]	0.0	6	1	1	1
126207	1710	injection of sea	[Injection of SEA]	0.0	3	1	1	1
126208	1710	Gene target experiment	[Gene targeting experiments]	0.0	3	1	1	1
126209	1710	-infected cell	[-infected cells]	0.0	2	1	1	1
126210	1710	lymphocyte CTL	[lymphocyte CTL]	0.0	2	1	1	1
126211	1710	ligation of cd16	[Ligation of CD16]	0.0	3	1	1	1
126212	1710	molar ratio	[molar ratio]	0.0	2	1	1	1
126213	1710	use protein extract	[using protein extracts]	0.0	3	1	1	1
126214	1710	multiple nf-atc isoform with property	[Multiple NF-ATc isoforms with properties]	0.0	5	1	1	1
126215	1710	involve the short arm	[involving the short arm]	0.0	4	1	1	1
126216	1710	erythroid progenitor in vitro.	[erythroid progenitors in vitro.]	0.0	4	1	1	1
126217	1710	Anetholdithiolthione	[Anetholdithiolthione]	0.0	1	1	1	1
126218	1710	activation in a pathway	[Activation in A pathway]	0.0	4	1	1	1
126219	1710	site ap1	[sites AP1]	0.0	2	1	1	1
126220	1710	assay in soft tissue tumor	[assay in soft tissue tumors]	0.0	5	1	1	1
126221	1710	analysis of aml1 /eto transcript	[analysis of AML1 /ETO transcripts]	0.0	5	2	2	1
126222	1710	transient rise	[transient rise]	0.0	2	1	1	1
126223	1710	Jak family	[Jak family]	0.0	2	1	1	1
126224	1710	mobility shift assay of protein extract	[mobility shift assay of protein extracts]	0.0	6	1	1	1
126225	1710	competitive assay ELISA	[competitive assay ELISA]	0.0	3	1	1	1
126226	1710	class trans-activator ciita	[class trans-activator CIITA]	0.0	3	1	1	1
126227	1710	T cell lymphotropic virus	[T cell lymphotropic virus]	0.0	4	1	1	1
126228	1710	patient with regular mense	[patients with regular menses]	0.0	4	1	1	1
126229	1710	t(15;17) leukemia	[t(15;17) leukemia]	0.0	2	1	1	1
126230	1710	elevation of calcium concentration	[elevation of calcium concentrations]	0.0	4	1	1	1
126231	1710	active creb protein p-creb	[active CREB protein P-CREB]	0.0	4	1	1	1
126232	1710	cyclase signal	[cyclase signal]	0.0	2	1	1	1
126233	1710	constitutive activation of Jak tyrosine kinase	[Constitutive activation of Jak tyrosine kinases]	0.0	6	1	1	1
126234	1710	and/or receptor	[and/or receptor]	0.0	2	1	1	1
126235	1710	blood organ	[blood organs]	0.0	2	1	1	1
126236	1710	lytic ebv replication	[lytic EBV replication]	0.0	3	1	1	1
126237	1710	inflammatory cytokine production by monocyte	[inflammatory cytokine production by monocytes]	0.0	5	1	1	1
126238	1710	act together	[acting together]	0.0	2	1	1	1
126239	1710	fourfold susceptibility	[fourfold susceptibility]	0.0	2	1	1	1
126240	1710	immunostaining of cytospin preparation	[immunostaining of cytospin preparations]	0.0	4	1	1	1
126241	1710	protein of the notch complex	[protein of the Notch complex]	0.0	5	1	1	1
126242	1710	role in cytokine gene transcription	[role in cytokine gene transcription]	0.0	5	1	1	1
126243	1710	sequence within the heavy-chain promoter	[sequences within the heavy-chain promoter]	0.0	5	1	1	1
126244	1710	number of motif	[number of motifs]	0.0	3	1	1	1
126245	1710	Class ii histocompatibility	[Class II histocompatibility]	0.0	3	1	1	1
126246	1710	occur at 30 minute (phase 1)	[occurring at 30 minutes (phase 1)]	0.0	6	1	1	1
126247	1710	set a series of immune response	[setting a series of immune responses]	0.0	6	1	1	1
126248	1710	Specific nuclear translocation	[Specific nuclear translocation]	0.0	3	2	2	1
126249	1710	statg	[StatG]	0.0	1	1	1	1
126250	1710	decrease of transcriptional activation	[decrease of transcriptional activation]	0.0	4	1	1	1
126251	1710	mature definitive cell a phenotype	[mature definitive cells a phenotype]	0.0	5	1	1	1
126252	1710	anti-inflammatory effect of lactone	[anti-inflammatory effect of lactones]	0.0	4	1	1	1
126253	1710	early development of hematopoietic lineage	[early development of hematopoietic lineages]	0.0	5	1	1	1
126254	1710	cooperation among b-	[cooperation among B-]	0.0	3	1	1	1
126255	1710	nonpermissive u-937 cell culture	[nonpermissive U-937 cell cultures]	0.0	4	1	1	1
126256	1710	two distinct, inhibitor of NFAT transcription	[two distinct, inhibitors of NFAT transcription]	0.0	6	1	1	1
126257	1710	affect the activity independent of age.	[affecting the activity independent of age.]	0.0	6	1	1	1
126258	1710	MDS progression	[MDS progression]	0.0	2	1	1	1
126259	1710	use pd-98059 potent inhibitor kinase upstream	[using PD-98059 potent inhibitors kinase upstream]	0.0	6	1	1	1
126260	1710	expansion of the number	[expansion of the number]	0.0	4	1	1	1
126261	1710	several SLE patient	[several SLE patients]	0.0	3	1	1	1
126262	1710	135eoh)2d3 repression	[1,25(OH)2D3 repression]	0.0	2	1	1	1
126263	1710	(range, 2594-3979)	[(range, 2594-3979)]	0.0	2	1	1	1
126264	1710	immediate-early transactivator zebra	[immediate-early transactivator ZEBRA]	0.0	3	1	1	1
126265	1710	short period	[shorter period]	0.0	2	1	1	1
126266	1710	zidovudine	[zidovudine]	0.0	1	1	1	1
126267	1710	stress this mouse with irradiation	[stressing these mice with irradiation]	0.0	5	1	1	1
126268	1710	C base pair	[C base pairs]	0.0	3	1	1	1
126269	1710	ap-2 DNA binding	[AP-2 DNA binding]	0.0	3	1	1	1
126270	1710	Thrombopoietin TPO the regulator	[Thrombopoietin TPO the regulator]	0.0	4	1	1	1
126271	1710	transcription-6	[transcription-6]	0.0	1	2	2	1
126272	1710	transcription-4	[transcription-4]	0.0	1	1	1	1
126273	1710	normal glucocorticoid response	[normal glucocorticoid response]	0.0	3	1	1	1
126274	1710	mechanism of hormone-receptor interaction	[mechanisms of hormone-receptor interactions]	0.0	4	1	1	1
126275	1710	cytosolic nf-kappa b accumulation	[cytosolic NF-kappa B accumulation]	0.0	4	1	1	1
126276	1710	control of certain process	[control of certain processes]	0.0	4	1	1	1
126277	1710	defensin np-1	[defensins NP-1]	0.0	2	1	1	1
126278	1710	(mel)	[(MEL)]	0.0	1	3	3	1
126279	1710	human il4	[human IL4]	0.0	2	1	1	1
126280	1710	inhibition of pp1	[inhibition of PP1]	0.0	3	1	1	1
126281	1710	region of mzf-1	[region of MZF-1]	0.0	3	1	1	1
126282	1710	whole-cell lysate	[whole-cell lysates]	0.0	2	1	1	1
126283	1710	immunomagnetic bead	[immunomagnetic beads]	0.0	2	1	1	1
126284	1710	alpha tcr	[alpha TCR]	0.0	2	1	1	1
126285	1710	promote the selective NK cell-mediated clearance	[promoting the selective NK cell-mediated clearance]	0.0	6	1	1	1
126286	1710	heat alkaline phosphatase	[heat alkaline phosphatase]	0.0	3	1	1	1
126287	1710	patient (58.3	[patients (58.3]	0.0	2	1	1	1
126288	1710	Class antigen	[Class antigen]	0.0	2	1	1	1
126289	1710	monocyte peptide-1 mcp-1 a chemokine	[monocyte peptide-1 MCP-1 a chemokine]	0.0	5	1	1	1
126290	1710	METHODS: atopic asthmatic subject	[METHODS: atopic asthmatic subjects]	0.0	4	1	1	1
126291	1710	presence of antihuman tnf-alpha	[presence of antihuman TNF-alpha]	0.0	4	1	1	1
126292	1710	activity of 8e51 cell	[activity of 8e51 cells]	0.0	4	1	1	1
126293	1710	latent, transcription factor	[latent, transcription factors]	0.0	3	1	1	1
126294	1710	regulation potential role	[Regulation potential role]	0.0	3	1	1	1
126295	1710	prolonged exposure of cell	[prolonged exposure of cells]	0.0	4	1	1	1
126296	1710	regulation of shear haec vcam-1 expression	[Regulation of shear HAEC VCAM-1 expression]	0.0	6	1	1	1
126297	1710	constitutively active mutant of Toll	[constitutively active mutant of Toll]	0.0	5	1	1	1
126298	1710	hyperadhesivity of huvec to human neutrophil	[hyperadhesivity of HUVECs to human neutrophils]	0.0	6	1	1	1
126299	1710	cooperation among b- binding sequence	[cooperation among B- binding sequences]	0.0	5	1	1	1
126300	1710	rodent central system	[rodent central system]	0.0	3	1	1	1
126301	1710	however, order potent than H	[however, orders potent than H]	0.0	5	1	1	1
126302	1710	lead despite level	[leading despite levels]	0.0	3	1	1	1
126303	1710	RNA transcript of the gene	[RNA transcript of the gene]	0.0	5	1	1	1
126304	1710	macrophage nuclear protein	[macrophage nuclear proteins]	0.0	3	1	1	1
126305	1710	transcriptional regulation of gene expression	[Transcriptional regulation of gene expression]	0.0	5	1	1	1
126306	1710	nonrandom	[nonrandom]	0.0	1	1	1	1
126307	1710	feature of transformation in leukemia	[feature of transformation in leukemia]	0.0	5	1	1	1
126308	1710	change in the form	[changes in the form]	0.0	4	1	1	1
126309	1710	only tool assess the risk	[only tool assessing the risk]	0.0	5	1	1	1
126310	1710	overexpression of the gene	[overexpression of the gene]	0.0	4	1	1	1
126311	1710	role in t-cell-specific transcriptional regulation	[role in T-cell-specific transcriptional regulation]	0.0	5	1	1	1
126312	1710	predominantly as a result	[predominantly as a result]	0.0	4	1	1	1
126313	1710	apoptosis inhibition in lymphocyte after treatment	[Apoptosis inhibition in lymphocytes after treatment]	0.0	6	1	1	1
126314	1710	response in vivo	[response in vivo]	0.0	3	1	1	1
126315	1710	transcriptionally active extract	[transcriptionally active extracts]	0.0	3	1	1	1
126316	1710	h to hormone	[h to hormone]	0.0	3	1	1	1
126317	1710	human igg	[human IgG]	0.0	2	1	1	1
126318	1710	transcription)5	[transcription)5]	0.0	1	1	1	1
126319	1710	monocytic cell induction	[Monocytic cell induction]	0.0	3	1	1	1
126320	1710	PBL generation	[PBL Generation]	0.0	2	1	1	1
126321	1710	proliferation control	[proliferation control]	0.0	2	1	1	1
126322	1710	DNA polymerase	[DNA polymerase]	0.0	2	1	1	1
126323	1710	involve interaction between positive element	[involving interactions between positive elements]	0.0	5	1	1	1
126324	1710	patient with corticosteroid -resistant asthma	[patients with corticosteroid -resistant asthma]	0.0	5	1	1	1
126325	1710	CD40 ig receptor	[CD40 Ig receptors]	0.0	3	1	1	1
126326	1710	measurable amount	[measurable amounts]	0.0	2	1	1	1
126327	1710	steroid receptor agonist	[steroid receptor agonist]	0.0	3	1	1	1
126328	1710	pathogenesis of rheumatoid	[pathogenesis of rheumatoid]	0.0	3	1	1	1
126329	1710	(positive)	[(positive)]	0.0	1	1	1	1
126330	1710	morphogen in development, a constituent	[morphogen in development, a constituent]	0.0	5	1	1	1
126331	1710	stress hsp70b promoter	[stress HSP70B promoter]	0.0	3	1	1	1
126332	1710	transfection of this "nonresponsive" clone	[transfection of these "nonresponsive" clones]	0.0	5	1	1	1
126333	1710	express level of hsf2-alpha	[expressing levels of HSF2-alpha]	0.0	4	1	1	1
126334	1710	response to the two immediate protein	[responses to the two immediate proteins]	0.0	6	1	1	1
126335	1710	T cell death	[T cell death]	0.0	3	1	1	1
126336	1710	oncogenicity of human adenoviruse	[oncogenicities of human adenoviruses]	0.0	4	1	1	1
126337	1710	gene transcription in leukocyte	[gene transcription in leukocytes]	0.0	4	1	1	1
126338	1710	monocyte monokine synthesis	[monocyte monokine synthesis]	0.0	3	1	1	1
126339	1710	mode of regulation	[modes of regulation]	0.0	3	1	1	1
126340	1710	generation of primary response	[generation of primary responses]	0.0	4	1	1	1
126341	1710	tnf interleukin-1	[TNF interleukin-1]	0.0	2	1	1	1
126342	1710	expression of hiv-1 Tat	[expression of HIV-1 Tat]	0.0	4	1	1	1
126343	1710	normal equivalent c-myb	[normal equivalent c-myb]	0.0	3	1	1	1
126344	1710	dependent adhesion of polymorphonuclear cell	[dependent adhesion of polymorphonuclear cells]	0.0	5	1	1	1
126345	1710	subset of chronic leukemia	[subset of chronic leukemias]	0.0	4	1	1	1
126346	1710	use high concentration	[using high concentrations]	0.0	3	1	1	1
126347	1710	use mpl concentration	[using MPL concentrations]	0.0	3	1	1	1
126348	1710	distinct complex with nuclear protein	[distinct complexes with nuclear proteins]	0.0	5	1	1	1
126349	1710	character under the influence	[character under the influence]	0.0	4	1	1	1
126350	1710	stimulation of peripheral T cell	[Stimulation of peripheral T cells]	0.0	5	1	1	1
126351	1710	primary bone marrow cell	[primary bone marrow cells]	0.0	4	1	1	1
126352	1710	efficient interaction than Grb2	[efficient interaction than Grb2]	0.0	4	1	1	1
126353	1710	notch1 oncogenesis	[NOTCH1 oncogenesis]	0.0	2	1	1	1
126354	1710	explore the pathogenesis of APL	[exploring the pathogenesis of APL]	0.0	5	1	1	1
126355	1710	use a clone	[using an clone]	0.0	3	1	1	1
126356	1710	activator protein-1 ap-1 factor nf-il6	[activator protein-1 AP-1 factor NF-IL6]	0.0	5	1	1	1
126357	1710	use hl60 cell	[using HL60 cells]	0.0	3	1	1	1
126358	1710	alteration in sequence	[alterations in sequences]	0.0	3	1	1	1
126359	1710	erythropoietin receptor mutant	[erythropoietin receptor mutant]	0.0	3	1	1	1
126360	1710	novel T negative regulatory element	[novel T negative regulatory element]	0.0	5	1	1	1
126361	1710	17beta-estradiol il-1beta promoter CAT activity	[17beta-estradiol IL-1beta promoter CAT activity]	0.0	5	1	1	1
126362	1710	alternative "targets"	[alternative "targets"]	0.0	2	1	1	1
126363	1710	case of AML m4	[case of AML M4]	0.0	4	1	1	1
126364	1710	definition of critical region with cofactor	[definition of critical regions with cofactors]	0.0	6	1	1	1
126365	1710	ubiquitous protein (s)	[ubiquitous protein (s)]	0.0	3	1	1	1
126366	1710	indicate responsible for class expression	[indicating responsible for class expression]	0.0	5	1	1	1
126367	1710	repression by the upstream region	[repression by the upstream region]	0.0	5	1	1	1
126368	1710	malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[malignant histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
126369	1710	potent compound in vitro.	[potent compound in vitro.]	0.0	4	1	1	1
126370	1710	activation of other hematopoietic gene	[activation of other hematopoietic genes]	0.0	5	1	1	1
126371	1710	contain the vp16 viral transactivation domain	[containing the VP16 viral transactivation domains]	0.0	6	1	1	1
126372	1710	wild type domain	[wild type domain]	0.0	3	1	1	1
126373	1710	acid CD40 signal determinant	[acid CD40 signaling determinant]	0.0	4	1	1	1
126374	1710	thin-layer chromatography tlc analysis	[thin-layer chromatography TLC analyses]	0.0	4	1	1	1
126375	1710	ifn-gamma response element	[IFN-gamma response element]	0.0	3	1	1	1
126376	1710	significant factor	[significant factor]	0.0	2	1	1	1
126377	1710	ca2+-binding	[Ca2+-binding]	0.0	1	1	1	1
126378	1710	autologous antigen-present cell	[autologous antigen-presenting cell]	0.0	3	1	1	1
126379	1710	high rakfkqllq CTL precursor frequency	[high RAKFKQLLQ CTL precursor frequency]	0.0	5	1	1	1
126380	1710	myelodysplastic syndrome MDS in stage	[myelodysplastic syndromes MDS in stage]	0.0	5	1	1	1
126381	1710	peripheral blood of 145 volunteer	[peripheral blood of 145 volunteers]	0.0	5	1	1	1
126382	1710	patient with Philadelphia myeloid leukemia	[patients with Philadelphia myeloid leukemia]	0.0	5	1	1	1
126383	1710	differentiate stimulus	[differentiating stimulus]	0.0	2	1	1	1
126384	1710	Class antigen express t-cell line	[Class antigen expressing T-cell lines]	0.0	5	1	1	1
126385	1710	absence of functional il-13r	[absence of functional IL-13R]	0.0	4	1	1	1
126386	1710	ca2+ co-stimulus	[Ca2+ co-stimulus]	0.0	2	2	2	1
126387	1710	protein kinase ii	[protein kinase II]	0.0	3	1	1	1
126388	1710	proximal regulatory element	[proximal regulatory element]	0.0	3	1	1	1
126389	1710	protein kinase iv	[protein kinase IV]	0.0	3	2	2	1
126390	1710	use a molecular clone	[using an molecular clone]	0.0	4	1	1	1
126391	1710	Rapid nongenomic	[Rapid nongenomic]	0.0	2	1	1	1
126392	1710	alpha-tcp decrease	[alpha-tcp decrease]	0.0	2	1	1	1
126393	1710	agonistic activity of a single-chain Fv	[Agonistic activity of a single-chain Fv]	0.0	6	1	1	1
126394	1710	rest cd4+ memory T cell	[resting CD4+ memory T cells]	0.0	5	1	1	1
126395	1710	synergism between element during activation	[Synergism between elements during activation]	0.0	5	1	1	1
126396	1710	point in the activation	[pointing in the activation]	0.0	4	1	1	1
126397	1710	approximately 1 P; binding	[approximately 1 h; binding]	0.0	4	1	1	1
126398	1710	cell in the system CNS	[cells in the system CNS]	0.0	5	1	1	1
126399	1710	couple from -500 bp	[Coupling from -500 bp]	0.0	4	1	1	1
126400	1710	interleukin-4 on cell	[interleukin-4 on cells]	0.0	3	1	1	1
126401	1710	h of cd19 cross-linking in cell	[h of CD19 cross-linking in cells]	0.0	6	1	1	1
126402	1710	concern the nature	[concerning the nature]	0.0	3	1	1	1
126403	1710	inflammatory cytokine expression	[inflammatory cytokine expression]	0.0	3	1	1	1
126404	1710	induction of immunodeficiency virus type expression	[Induction of immunodeficiency virus type expression]	0.0	6	1	1	1
126405	1710	GM-CSF gene transcription	[GM-CSF gene transcription]	0.0	3	1	1	1
126406	1710	inhibition of expression	[inhibition of expression]	0.0	3	1	1	1
126407	1710	transcription 1	[transcription 1]	0.0	2	1	1	1
126408	1710	similar circadian rhythm of gr	[similar circadian rhythm of GR]	0.0	5	1	1	1
126409	1710	induce certain characteristic	[inducing certain characteristics]	0.0	3	1	1	1
126410	1710	concentration of ng/ml	[concentration of ng/ml]	0.0	3	1	1	1
126411	1710	plasma factor vii/viia	[plasma Factor VII/VIIa]	0.0	3	1	1	1
126412	1710	increase infiltrate (p than 0.02).	[increasing infiltrate (P than 0.02).]	0.0	5	1	1	1
126413	1710	microvessel cell MVEC	[microvessel cells MVEC]	0.0	3	1	1	1
126414	1710	cell line U	[cell line U]	0.0	3	1	1	1
126415	1710	related DNA sequence	[related DNA sequences]	0.0	3	1	1	1
126416	1710	human thymocytes.	[human thymocytes.]	0.0	2	1	1	1
126417	1710	element inducible by lps	[element inducible by LPS]	0.0	4	1	1	1
126418	1710	positive cooperativity	[positive cooperativity]	0.0	2	1	1	1
126419	1710	apoptotic vsmc express c-myc	[apoptotic VSMCs expressing c-myc]	0.0	4	1	1	1
126420	1710	(apparent mass,	[(apparent mass,]	0.0	2	1	1	1
126421	1710	cell of salivary gland	[cells of salivary glands]	0.0	4	1	1	1
126422	1710	Stat5 gene expression	[Stat5 gene expression]	0.0	3	1	1	1
126423	1710	receptor sequence	[receptor sequences]	0.0	2	1	1	1
126424	1710	region of the collagenase-1 promoter	[regions of the collagenase-1 promoter]	0.0	5	1	1	1
126425	1710	immunoglobulin mu gene enhancer	[immunoglobulin mu gene enhancer]	0.0	4	1	1	1
126426	1710	peripheral blood lymphocyte bronchial asthma	[peripheral blood lymphocytes bronchial asthma]	0.0	5	1	1	1
126427	1710	western-blot analysis	[Western-blot analysis]	0.0	2	1	1	1
126428	1710	disappointing result	[disappointing results]	0.0	2	1	1	1
126429	1710	orf a major tegument protein	[ORF an major tegument protein]	0.0	5	1	1	1
126430	1710	interaction with two distinct protein	[interaction with two distinct proteins]	0.0	5	1	1	1
126431	1710	T lymphocyte against immunorecessive epitope	[T lymphocytes against immunorecessive epitopes]	0.0	5	1	1	1
126432	1710	mechanism govern the response	[mechanism governing the response]	0.0	4	1	1	1
126433	1710	distinct normalize effect on pattern increase	[distinct normalizing effect on patterns increase]	0.0	6	1	1	1
126434	1710	induction of interferon 10 differentiation	[induction of interferon 10 differentiation]	0.0	5	1	1	1
126435	1710	inhibition evidence for lck/fyn-	[inhibition evidence for Lck/Fyn-]	0.0	4	1	1	1
126436	1710	12.1 1.3, respectively), indicate a rate	[12.1 1.3, respectively), indicating an rate]	0.0	6	1	1	1
126437	1710	element in c motif-1/lymphotactin promoter	[element in C motif-1/lymphotactin promoter]	0.0	5	1	1	1
126438	1710	hormone bind	[hormone binding]	0.0	2	1	1	1
126439	1710	plasma cell-specific repressor function	[plasma cell-specific repressor function]	0.0	4	1	1	1
126440	1710	acid phosphatase osteoclast-like giant cell	[acid phosphatase osteoclast-like giant cells]	0.0	5	1	1	1
126441	1710	degree of inhibition dephosphorylation	[degree of inhibition dephosphorylation]	0.0	4	1	1	1
126442	1710	cd138/syndecan-1	[CD138/syndecan-1]	0.0	1	1	1	1
126443	1710	mutant adenovirus with DNA sequence	[Mutants adenovirus with DNA sequences]	0.0	5	1	1	1
126444	1710	element capable	[element capable]	0.0	2	1	1	1
126445	1710	pml promyelocytic leukemia	[PML promyelocytic leukemia]	0.0	3	1	1	1
126446	1710	interplay of element	[interplay of elements]	0.0	3	1	1	1
126447	1710	DNA-relaxing activity	[DNA-relaxing activity]	0.0	2	1	1	1
126448	1710	interaction between b transcriptional coactivator	[interactions between B transcriptional coactivators]	0.0	5	1	1	1
126449	1710	MODY and/or late-onset type	[MODY and/or late-onset type]	0.0	4	1	1	1
126450	1710	implicate gata-1 function	[implicating GATA-1 function]	0.0	3	1	1	1
126451	1710	"Plus"	["Plus"]	0.0	1	1	1	1
126452	1710	bind to a receptor belong	[binding to an receptor belonging]	0.0	5	1	1	1
126453	1710	hyperactivation	[hyperactivation]	0.0	1	1	1	1
126454	1710	benefit of salicylate	[benefits of salicylates]	0.0	3	1	1	1
126455	1710	pathogenesis of chronic leukemia	[pathogenesis of chronic leukemia]	0.0	4	1	1	1
126456	1710	monocyte by csf	[monocytes by CSFs]	0.0	3	1	1	1
126457	1710	culminate in the phosphorylation	[culminating in the phosphorylation]	0.0	4	1	1	1
126458	1710	mobility form	[mobility forms]	0.0	2	1	1	1
126459	1710	stimulate blood mononuclear cell hla b8+	[stimulating blood mononuclear cells HLA B8+]	0.0	6	1	1	1
126460	1710	activation of functional program	[activation of functional programs]	0.0	4	1	1	1
126461	1710	ecd45ra+) T cell subset	[(CD45RA+) T cell subsets]	0.0	4	1	1	1
126462	1710	affinity of regulatory element for factor	[affinities of regulatory elements for factor]	0.0	6	1	1	1
126463	1710	gata element in the promoter	[GATA element in the promoter]	0.0	5	1	1	1
126464	1710	distribution monocyte-binding receptor	[distribution monocyte-binding receptors]	0.0	3	1	1	1
126465	1710	bp -245 construct	[bp -245 construct]	0.0	3	1	1	1
126466	1710	clear-cut synergy	[clear-cut synergy]	0.0	2	1	1	1
126467	1710	alteration in receptor gr binding	[alterations in receptor GR binding]	0.0	5	1	1	1
126468	1710	child aged year with nephropathy	[children aged years with nephropathies]	0.0	5	1	1	1
126469	1710	allergen-specific helper T cell	[allergen-specific helper T cells]	0.0	4	1	1	1
126470	1710	unique subclone	[unique subclone]	0.0	2	1	1	1
126471	1710	anorexic patient (range	[anorexic patients (ranging]	0.0	3	1	1	1
126472	1710	5' guanine residue	[5' guanine residues]	0.0	3	1	1	1
126473	1710	independent cloning from olfactory cell	[independent cloning from olfactory cells]	0.0	5	1	1	1
126474	1710	deterioration immunodeficiency virus type	[deterioration immunodeficiency virus type]	0.0	4	1	1	1
126475	1710	time of 25 h for culture	[times of 25 h for cultures]	0.0	6	1	1	1
126476	1710	preformed, nfkb2 p49	[preformed, NFKB2 p49]	0.0	3	1	1	1
126477	1710	positive domain (prd) ii binding protein	[positive domain (PRD) II binding proteins]	0.0	6	1	1	1
126478	1710	T cell of subject	[T cells of subjects]	0.0	4	2	2	1
126479	1710	13 age-matched healthy subject	[13 age-matched healthy subjects]	0.0	4	1	1	1
126480	1710	gene expression in Th1/Th2	[gene expression in Th1/Th2]	0.0	4	1	1	1
126481	1710	development of alteration in T cell	[development of alterations in T cells]	0.0	6	1	1	1
126482	1710	lymphocyte DNA	[lymphocyte DNA]	0.0	2	1	1	1
126483	1710	autoimmune	[autoimmune]	0.0	1	1	1	1
126484	1710	glucocorticoid binding circadian rhythm	[glucocorticoid binding circadian rhythms]	0.0	4	1	1	1
126485	1710	cobalt chloride	[Cobalt chloride]	0.0	2	1	1	1
126486	1710	characterization binding to tax -responsive element	[characterization Binding to Tax -responsive element]	0.0	6	1	1	1
126487	1710	structure distinct	[structures distinct]	0.0	2	1	1	1
126488	1710	activity of various estrogen	[activities of various estrogens]	0.0	4	1	1	1
126489	1710	level in a population	[level in a population]	0.0	4	1	1	1
126490	1710	treatment 0 hpc	[treatment 0 HPCs]	0.0	3	1	1	1
126491	1710	m elevation in calcium level	[M elevation in calcium levels]	0.0	5	1	1	1
126492	1710	signal transducing pathway	[signal transducing pathways]	0.0	3	1	1	1
126493	1710	multiple functionally critical element	[multiple functionally critical elements]	0.0	4	1	1	1
126494	1710	properties unlike other nuclear oncoprotein	[properties, unlike other nuclear oncoproteins]	0.0	5	1	1	1
126495	1710	transcription in monocytic cell	[transcription in monocytic cells]	0.0	4	1	1	1
126496	1710	local metabolism	[local metabolism]	0.0	2	1	1	1
126497	1710	transient outgrowth of cell	[transient outgrowth of cells]	0.0	4	1	1	1
126498	1710	antibody monoclonal antibody	[antibodies monoclonal antibodies]	0.0	3	1	1	1
126499	1710	genital tract infection	[genital tract infection]	0.0	3	1	1	1
126500	1710	kb sequence	[kb sequence]	0.0	2	1	1	1
126501	1710	Biphasic control of factor-kappa b activation	[Biphasic control of factor-kappa B activation]	0.0	6	1	1	1
126502	1710	ppargamma with troglitazone	[PPARgamma with troglitazone]	0.0	3	1	1	1
126503	1710	B7 costimulatory molecule	[B7 costimulatory molecule]	0.0	3	1	1	1
126504	1710	framework signal in mononuclear phagocyte	[framework signaling in mononuclear phagocytes]	0.0	5	1	1	1
126505	1710	interaction of hematopoietic transcription factor	[interaction of hematopoietic transcription factors]	0.0	5	1	1	1
126506	1710	mechanism control the competence in response	[mechanisms controlling the competence in response]	0.0	6	1	1	1
126507	1710	role protect vascular injury	[role protecting vascular injury]	0.0	4	1	1	1
126508	1710	hla-dr- a form of acute leukemia	[HLA-DR- a form of acute leukemia]	0.0	6	1	1	1
126509	1710	apoptosis signal pathway with sensitivity	[apoptosis signaling pathways with sensitivity]	0.0	5	1	1	1
126510	1710	DNA accessibility within the copy	[DNA accessibility within the copy]	0.0	5	1	1	1
126511	1710	ino promoter to lps	[iNOS promoter to LPS]	0.0	4	1	1	1
126512	1710	factor kappa b NFkappaB	[factor kappa B NFkappaB]	0.0	4	1	1	1
126513	1710	regulate map kinase	[regulating MAP kinases]	0.0	3	1	1	1
126514	1710	activation, T cell	[activation, T cell]	0.0	3	1	1	1
126515	1710	role as a messenger	[role as an messenger]	0.0	4	1	1	1
126516	1710	WEHI-3B/D+	[WEHI-3B/D+]	0.0	1	1	1	1
126517	1710	proinflammatory cytokine in monocyte	[proinflammatory cytokines in monocytes]	0.0	4	1	1	1
126518	1710	type estrogen binding site type EBS	[type estrogen binding sites type EBS]	0.0	6	1	1	1
126519	1710	b-cell-specific transcription factor in h-rs cell	[B-cell-specific transcription factor in H-RS cells]	0.0	6	1	1	1
126520	1710	lead to t-cell activation	[leading to T-cell activation]	0.0	4	1	1	1
126521	1710	m) activation	[M) activation]	0.0	2	1	1	1
126522	1710	21 ms patient	[21 MS patients]	0.0	3	1	1	1
126523	1710	glucocorticoid expression	[glucocorticoid expression]	0.0	2	1	1	1
126524	1710	MHC class transcription	[MHC class transcription]	0.0	3	1	1	1
126525	1710	activation (pkc)	[activation (PKC)]	0.0	2	1	1	1
126526	1710	origin of neoplastic disorder	[origin of neoplastic disorders]	0.0	4	1	1	1
126527	1710	C gamma 3 gene	[C gamma 3 gene]	0.0	4	2	2	1
126528	1710	eosinophil infiltrate into process	[eosinophils infiltrating into processes]	0.0	4	1	1	1
126529	1710	feature characteristic of activator	[features characteristic of activators]	0.0	4	1	1	1
126530	1710	hallmark of CML	[hallmark of CML]	0.0	3	1	1	1
126531	1710	trigger of the human interleukin-6 gene	[Triggering of the human interleukin-6 gene]	0.0	6	1	1	1
126532	1710	homozygote for a polymorphism	[Homozygotes for a polymorphism]	0.0	4	1	1	1
126533	1710	E2A-HLF chimaeric transcription factor	[E2A-HLF chimaeric transcription factor]	0.0	4	1	1	1
126534	1710	4.3 pts; fluticasone:	[4.3 pts; fluticasone:]	0.0	3	1	1	1
126535	1710	pbmc from healthy individual	[PBMC from healthy individuals]	0.0	4	1	1	1
126536	1710	failure in effectiveness	[failures in effectiveness]	0.0	3	1	1	1
126537	1710	nuclear expression of nuclear factor kappab	[nuclear expression of nuclear factor kappaB]	0.0	6	1	1	1
126538	1710	proliferative control of cell	[proliferative control of cells]	0.0	4	1	1	1
126539	1710	pretreatment with 100-500 microm OP	[Pretreatment with 100-500 microM OP]	0.0	5	1	1	1
126540	1710	mutation in the receptor	[mutations in the receptor]	0.0	4	1	1	1
126541	1710	form of the human protein	[forms of the human protein]	0.0	5	1	1	1
126542	1710	element of the LCR	[elements of the LCR]	0.0	4	1	1	1
126543	1710	resonance 3d-nmr	[resonance 3D-NMR]	0.0	2	1	1	1
126544	1710	thymocyte undergo selection	[thymocytes undergoing selection]	0.0	3	1	1	1
126545	1710	glucocorticoid in mononuclear leukocyte	[glucocorticoids in mononuclear leukocytes]	0.0	4	1	1	1
126546	1710	5- to 7-fold increase	[5- to 7-fold increase]	0.0	4	1	1	1
126547	1710	DNA bind homo-	[DNA binding homo-]	0.0	3	1	1	1
126548	1710	P-4501A1 CYP1A1 activity by ultra-violet	[P-4501A1 CYP1A1 activity by UV]	0.0	5	1	1	1
126549	1710	(stimulatory effect on RA -dependent differentiation	[(stimulatory effects on RA -dependent differentiation]	0.0	6	1	1	1
126550	1710	map erk kinase kinase-1	[MAP ERK kinase kinase-1]	0.0	4	1	1	1
126551	1710	evolutionary event of some,	[evolutionary events of some,]	0.0	4	1	1	1
126552	1710	correlation with impairment	[correlation with impairment]	0.0	3	1	1	1
126553	1710	high dose of corticosteroid	[high doses of corticosteroid]	0.0	4	1	1	1
126554	1710	cell use a recombinant adenovirus	[cells using a recombinant adenovirus]	0.0	5	1	1	1
126555	1710	study the binding of SR	[studying the binding of SR]	0.0	5	1	1	1
126556	1710	inflammatory mediator in disease	[inflammatory mediators in diseases]	0.0	4	1	1	1
126557	1710	bcl-2 oncogene	[bcl-2 oncogene]	0.0	2	1	1	1
126558	1710	risk of local failure,	[risk of local failure,]	0.0	4	1	1	1
126559	1710	report of variant translocation	[reports of variant translocations]	0.0	4	1	1	1
126560	1710	span the nucleotide from position -502	[spanning the nucleotides from positions -502]	0.0	6	1	1	1
126561	1710	regulatory sequence within the AU-rich element	[regulatory sequences within the AU-rich elements]	0.0	6	1	1	1
126562	1710	domain variant in	[domain variants in]	0.0	3	1	1	1
126563	1710	hla-dr expression by phagocyte	[HLA-DR expression by phagocytes]	0.0	4	1	1	1
126564	1710	prevent activation of non-erythroid gene	[preventing activation of non-erythroid genes]	0.0	5	1	1	1
126565	1710	porcine aortic cell PAEC	[Porcine aortic cells PAEC]	0.0	4	1	1	1
126566	1710	stimulation signal pathway	[Stimulation signaling pathway]	0.0	3	1	1	1
126567	1710	various effect on macrophage	[various effects on macrophages]	0.0	4	1	1	1
126568	1710	such as histocompatibility (mhc) class ii	[such as histocompatibility (MHC) class II]	0.0	6	1	1	1
126569	1710	direct effect of hgata-3	[direct effect of hGATA-3]	0.0	4	1	1	1
126570	1710	human b29 gene expression	[human B29 gene expression]	0.0	4	1	1	1
126571	1710	human cell include monocyte	[human cells including monocytes]	0.0	4	1	1	1
126572	1710	expression of a subset include fcepsilonriib	[expression of a subset including FcepsilonRIIb]	0.0	6	1	1	1
126573	1710	hemopoiesis, overexpression	[hemopoiesis, overexpression]	0.0	2	1	1	1
126574	1710	annexin V (p .0001	[annexin V (P .0001]	0.0	4	1	1	1
126575	1710	fetal bovine serum-contain	[fetal bovine serum-containing]	0.0	3	1	1	1
126576	1710	inhibition for ifn-induced gene	[inhibition for IFN-induced genes]	0.0	4	1	1	1
126577	1710	ca2+-dependent	[Ca2+-dependent]	0.0	1	1	1	1
126578	1710	digestion in hepatocyte	[digestion in hepatocytes]	0.0	3	1	1	1
126579	1710	new option bcl-2 mutein	[new option bcl-2 muteins]	0.0	4	1	1	1
126580	1710	other leukemia-derived cell line	[other leukemia-derived cell lines]	0.0	4	1	1	1
126581	1710	deaminase pbgd	[deaminase PBGD]	0.0	2	1	1	1
126582	1710	macrophage factor in monocyte	[macrophage factor in monocytes]	0.0	4	1	1	1
126583	1710	membrane form of mu	[membrane forms of mu]	0.0	4	1	1	1
126584	1710	adherent igg	[adherent IgG]	0.0	2	1	1	1
126585	1710	stimulation of interleukin-2 promoter	[stimulation of interleukin-2 promoter]	0.0	4	1	1	1
126586	1710	level in b-cell line	[levels in B-cell lines]	0.0	4	1	1	1
126587	1710	immunofluorescence study carry transgene in combination	[Immunofluorescence studies carrying transgenes in combinations]	0.0	6	1	1	1
126588	1710	complete inhibition occur	[complete inhibition occurring]	0.0	3	1	1	1
126589	1710	influence immunodeficiency virus replication	[influencing immunodeficiency virus replication]	0.0	4	1	1	1
126590	1710	plasminogen activator	[plasminogen activator]	0.0	2	1	1	1
126591	1710	permanent cell line	[permanent cell lines]	0.0	3	1	1	1
126592	1710	release of platelet	[release of platelets]	0.0	3	1	1	1
126593	1710	interact with motif	[interacting with motifs]	0.0	3	1	1	1
126594	1710	use of retroviruse	[use of retroviruses]	0.0	3	1	1	1
126595	1710	activation of the glucocorticoid receptor	[activation of the glucocorticoid receptor]	0.0	5	1	1	1
126596	1710	case of chronic leukaemias	[cases of chronic leukaemias]	0.0	4	1	1	1
126597	1710	stat6 isoform	[STAT6 isoforms]	0.0	2	1	1	1
126598	1710	high glutathione level	[higher glutathione levels]	0.0	3	1	1	1
126599	1710	two leucine domain	[two leucine domains]	0.0	3	1	1	1
126600	1710	h2o2 release	[H2O2 release]	0.0	2	1	1	1
126601	1710	important contributor	[important contributor]	0.0	2	1	1	1
126602	1710	means of a immunophilin	[means of a immunophilin]	0.0	4	1	1	1
126603	1710	C57BL/10SnJ [h-2b]	[C57BL/10SnJ [H-2b]]	0.0	2	1	1	1
126604	1710	24 woman first, 10 second	[24 women first, 10 second]	0.0	5	1	1	1
126605	1710	leukemia evi1 fusion respectively,	[leukemia EVI1 fusions respectively,]	0.0	4	1	1	1
126606	1710	two negative regulatory pathway	[two negative regulatory pathways]	0.0	4	1	1	1
126607	1710	variety signal transducer	[variety signal transducers]	0.0	3	1	1	1
126608	1710	transcriptional co-activator for the expression	[transcriptional co-activator for the expression]	0.0	5	1	1	1
126609	1710	cellular receptor on b cell	[cellular receptor on B cells]	0.0	5	1	1	1
126610	1710	Furthermore, cross-linking	[Furthermore, cross-linking]	0.0	2	1	1	1
126611	1710	nac to MLR	[NAC to MLR]	0.0	3	1	1	1
126612	1710	dexamethasone binding site	[dexamethasone binding sites]	0.0	3	1	1	1
126613	1710	two crossreact protein	[two crossreacting proteins]	0.0	3	1	1	1
126614	1710	potent transcriptional activator of promoter	[potent transcriptional activator of promoters]	0.0	5	1	1	1
126615	1710	hbv mrna	[HBV mRNA]	0.0	2	1	1	1
126616	1710	hyperabsorption	[hyperabsorption]	0.0	1	1	1	1
126617	1710	high proportion of residue	[high proportion of residues]	0.0	4	1	1	1
126618	1710	transcript the coat protein of ebv	[Transcripts the coat protein of EBV]	0.0	6	1	1	1
126619	1710	infect baboon	[infecting baboons]	0.0	2	1	1	1
126620	1710	ablation of htlv-i tumor	[Ablation of HTLV-I tumors]	0.0	4	1	1	1
126621	1710	OM-10.1 model of infection,	[OM-10.1 model of infection,]	0.0	4	1	1	1
126622	1710	inducibility on a heterologous promoter	[inducibility on a heterologous promoter]	0.0	5	1	1	1
126623	1710	monocyte chemoattractant protein (mcp)-1	[monocyte chemoattractant protein (MCP)-1]	0.0	4	1	1	1
126624	1710	level of the hpa axis	[levels of the HPA axis]	0.0	5	1	1	1
126625	1710	occur GRE	[occurring GRE]	0.0	2	1	1	1
126626	1710	include the surface	[including the surface]	0.0	3	1	1	1
126627	1710	nuclear foci	[nuclear foci]	0.0	2	1	1	1
126628	1710	cell susceptibility to lysis	[cell susceptibility to lysis]	0.0	4	1	1	1
126629	1710	good definition	[better definition]	0.0	2	1	1	1
126630	1710	exogenous glutathione	[exogenous glutathione]	0.0	2	1	1	1
126631	1710	NK cell follow immortalization	[NK cells following immortalization]	0.0	4	1	1	1
126632	1710	inhibition through adenosine triphosphate depletion	[inhibition through adenosine triphosphate depletion]	0.0	5	1	1	1
126633	1710	Janus protein tyrosine kinase	[Janus protein tyrosine kinases]	0.0	4	1	1	1
126634	1710	inhibitor of light chain kinase	[inhibitors of light chain kinase]	0.0	5	1	1	1
126635	1710	effect, steady state level	[effect, steady state levels]	0.0	4	1	1	1
126636	1710	vitamin d deficiency	[vitamin D deficiency]	0.0	3	1	1	1
126637	1710	child with immunodeficiency	[child with immunodeficiency]	0.0	3	1	1	1
126638	1710	pebp2 alpha factor	[PEBP2 alpha factors]	0.0	3	1	1	1
126639	1710	-encoding	[-encoding]	0.0	1	1	1	1
126640	1710	cd45 -t	[CD45 -T]	0.0	2	1	1	1
126641	1710	combination with antiretroviral compound	[combination with antiretroviral compounds]	0.0	4	1	1	1
126642	1710	synthesis of rna	[synthesis of RNA]	0.0	3	1	1	1
126643	1710	tpo receptor	[TPO receptor]	0.0	2	1	1	1
126644	1710	hematopoietic pattern	[hematopoietic pattern]	0.0	2	1	1	1
126645	1710	65-kilodalton subunit	[65-kilodalton subunit]	0.0	2	1	1	1
126646	1710	alg-4 transcription of fasl	[ALG-4 transcription of FasL]	0.0	4	1	1	1
126647	1710	level of snrna	[levels of snRNA]	0.0	3	1	1	1
126648	1710	cell specific molecule	[cell specific molecules]	0.0	3	1	1	1
126649	1710	novel Ets family member	[novel Ets family member]	0.0	4	1	1	1
126650	1710	Functional study use cell	[Functional studies using cells]	0.0	4	1	1	1
126651	1710	such as camp production	[such as cAMP production]	0.0	4	1	1	1
126652	1710	CD28 stimulation by CHO cell	[CD28 stimulation by CHO cells]	0.0	5	1	1	1
126653	1710	patient with vitamin d-dependent ricket	[patients with vitamin D-dependent rickets]	0.0	5	1	1	1
126654	1710	trace element for immune function	[trace element for immune function]	0.0	5	1	1	1
126655	1710	induction during differentiation of blood monocyte	[Induction during differentiation of blood monocytes]	0.0	6	1	1	1
126656	1710	switch in gene expression	[switch in gene expression]	0.0	4	1	1	1
126657	1710	regulate expression of cell adhesion molecule	[regulating expression of cell adhesion molecules]	0.0	6	1	1	1
126658	1710	stress nf-kappab activation	[stress NF-kappaB activation]	0.0	3	1	1	1
126659	1710	human T lymphoid cell line	[human T lymphoid cell line]	0.0	5	1	1	1
126660	1710	monocyte-macrophage ag	[monocyte-macrophage Ag]	0.0	2	1	1	1
126661	1710	influence NFAT-1	[influencing NFAT-1]	0.0	2	1	1	1
126662	1710	evidence for a tissue-specific interindividual variation	[evidence for a tissue-specific interindividual variation]	0.0	6	1	1	1
126663	1710	Glucocorticoid receptor hormone-binding activity	[Glucocorticoid receptor hormone-binding activity]	0.0	4	1	1	1
126664	1710	patient with hypo hyper thyroidism	[Patients with hypo hyper thyroidism]	0.0	5	1	1	1
126665	1710	ec bone marrow ec	[EC bone marrow EC]	0.0	4	1	1	1
126666	1710	dexamethasone of glucocorticoid	[dexamethasone of glucocorticoids]	0.0	3	1	1	1
126667	1710	possible killer	[possible killer]	0.0	2	1	1	1
126668	1710	human pml expression by interferon	[human PML expression by interferons]	0.0	5	1	1	1
126669	1710	gcs patient	[GCS patients]	0.0	2	1	1	1
126670	1710	hexon ad protein	[hexon Ad proteins]	0.0	3	1	1	1
126671	1710	cd11b/cd18 on hl60 cell	[CD11b/CD18 on HL60 cells]	0.0	4	1	1	1
126672	1710	specific antibody induction	[specific antibody induction]	0.0	3	1	1	1
126673	1710	phosphatidylinositol-3,4,5-trisphosphate	[phosphatidylinositol-3,4,5-trisphosphate]	0.0	1	1	1	1
126674	1710	weight 49	[weight 49]	0.0	2	1	1	1
126675	1710	all-tran RA (94%	[all-trans RA (94%]	0.0	3	1	1	1
126676	1710	3- to 4-fold increase	[3- to 4-fold increase]	0.0	4	1	1	1
126677	1710	pma-) T	[PMA-) T]	0.0	2	1	1	1
126678	1710	treatment, at interval week	[treatment, at intervals week]	0.0	4	1	1	1
126679	1710	specific b heteromer	[specific B heteromers]	0.0	3	1	1	1
126680	1710	order less potent	[orders less potent]	0.0	3	1	1	1
126681	1710	impaired silencing of expression	[Impaired silencing of expression]	0.0	4	1	1	1
126682	1710	20 nmol/l,	[20 nmol/l,]	0.0	2	1	1	1
126683	1710	N-terminal domain with sh2 motif	[N-terminal domains with SH2 motifs]	0.0	5	1	1	1
126684	1710	particular that cytokine	[particular those cytokines]	0.0	3	1	1	1
126685	1710	deletion alone	[deletion alone]	0.0	2	1	1	1
126686	1710	assay for a transactivator activity	[assaying for a transactivator activity]	0.0	5	1	1	1
126687	1710	obf-1/bob1/oca-b	[OBF-1/Bob1/OCA-B]	0.0	1	1	1	1
126688	1710	distinct role for hsp90	[distinct roles for hsp90]	0.0	4	1	1	1
126689	1710	molar amount of tata-binding protein tbp	[molar amounts of TATA-binding protein TBP]	0.0	6	1	1	1
126690	1710	herpesvirus closely related	[herpesvirus closely related]	0.0	3	1	1	1
126691	1710	hla-dr- a form	[HLA-DR- a form]	0.0	3	1	1	1
126692	1710	normal human cell	[normal human cells]	0.0	3	1	1	1
126693	1710	ldl cell	[LDL cells]	0.0	2	1	1	1
126694	1710	/anti-cd28 T	[/anti-CD28 T]	0.0	2	1	1	1
126695	1710	cotransfection study	[Cotransfection studies]	0.0	2	1	1	1
126696	1710	rapamycin -sensitive pathway	[rapamycin -sensitive pathways]	0.0	3	1	1	1
126697	1710	adenovirus promoter	[adenovirus promoter]	0.0	2	2	2	1
126698	1710	transcriptional activity,	[transcriptional activity,]	0.0	2	1	1	1
126699	1710	comparative mapping in the ape	[Comparative mapping in the apes]	0.0	5	1	1	1
126700	1710	Interferon factor irf-2	[Interferon factor IRF-2]	0.0	3	1	1	1
126701	1710	hsp90 complex	[hsp90 complexes]	0.0	2	1	1	1
126702	1710	use serum-free hl60 cell	[using serum-free HL60 cells]	0.0	4	1	1	1
126703	1710	eosinophil biology	[eosinophil biology]	0.0	2	1	1	1
126704	1710	regulation of pafr gene expression	[regulation of PAFR gene expression]	0.0	5	1	1	1
126705	1710	erythrocyte-specific carbonic anhydrase caii	[erythrocyte-specific carbonic anhydrase CAII]	0.0	4	1	1	1
126706	1710	p50/p65 form	[p50/p65 form]	0.0	2	1	1	1
126707	1710	treatment approach for asthma	[treatment approaches for asthma]	0.0	4	1	1	1
126708	1710	paucity of substrate	[paucity of substrates]	0.0	3	1	1	1
126709	1710	hour 1 to 6)	[hours 1 to 6)]	0.0	4	1	1	1
126710	1710	various chronic rheumatic disease four	[various chronic rheumatic diseases four]	0.0	5	1	1	1
126711	1710	hematopoietic support property of cell	[hematopoietic supporting properties of cells]	0.0	5	1	1	1
126712	1710	272 97 receptor /cell	[272 97 receptors /cell]	0.0	4	1	1	1
126713	1710	HIV LTR deletion mutant	[HIV LTR deletion mutants]	0.0	4	1	1	1
126714	1710	nf-at nuclear factor	[NF-AT nuclear factor]	0.0	3	1	1	1
126715	1710	(also in umbilical cell	[(also in umbilical cells]	0.0	4	1	1	1
126716	1710	blood of leukemia patient	[blood of leukemia patients]	0.0	4	1	1	1
126717	1710	expression system	[expression system]	0.0	2	1	1	1
126718	1710	very inefficient inducer	[very inefficient inducer]	0.0	3	1	1	1
126719	1710	microgranular variant	[microgranular variant]	0.0	2	1	1	1
126720	1710	more indirect, role: alteration	[more indirect, role: alteration]	0.0	4	1	1	1
126721	1710	105-kDa protein precursor	[105-kDa protein precursor]	0.0	3	1	1	1
126722	1710	inhibitor of serine/threonine phosphatase -1	[inhibitors of serine/threonine phosphatases -1]	0.0	5	1	1	1
126723	1710	growth factor include IL-6	[growth factors including IL-6]	0.0	4	1	1	1
126724	1710	blood leukocyte of six patient	[blood leukocytes of six patients]	0.0	5	1	1	1
126725	1710	bimodal expression pattern during induction,	[bimodal expression patterns during induction,]	0.0	5	1	1	1
126726	1710	subline region,	[sublining region,]	0.0	2	1	1	1
126727	1710	translocation involve the CBFA2 locus	[Translocations involving the CBFA2 locus]	0.0	5	1	1	1
126728	1710	plasmon	[plasmon]	0.0	1	1	1	1
126729	1710	mutation in the ebf binding site	[mutations in the EBF binding sites]	0.0	6	1	1	1
126730	1710	leukocyte of ad patient	[leukocytes of AD patients]	0.0	4	1	1	1
126731	1710	1-mg dexamethasone test	[1-mg dexamethasone test]	0.0	3	1	1	1
126732	1710	analysis of NF-AT -deficient mouse	[analysis of NF-AT -deficient mice]	0.0	5	1	1	1
126733	1710	intervene (i) region	[intervening (I) regions]	0.0	3	1	1	1
126734	1710	dna-binding homeodomain	[DNA-binding homeodomain]	0.0	2	1	1	1
126735	1710	basophilia in promyelocytic leukaemia analysis	[basophilia in promyelocytic leukaemia analysis]	0.0	5	1	1	1
126736	1710	activity of various environmental estrogen	[activities of various environmental estrogens]	0.0	5	1	1	1
126737	1710	chain gene enhancer	[chain gene enhancer]	0.0	3	1	1	1
126738	1710	posttranscriptional trans-activator	[posttranscriptional trans-activator]	0.0	2	1	1	1
126739	1710	tumor suppressor gene brca1	[tumor suppressor gene BRCA1]	0.0	4	1	1	1
126740	1710	position- manner	[position- manner]	0.0	2	1	1	1
126741	1710	natural antibody	[natural antibodies]	0.0	2	1	1	1
126742	1710	effect on this two signal	[effects on these two signals]	0.0	5	1	1	1
126743	1710	cell activation with leukocyte adhesion	[cell activation with leukocyte adhesion]	0.0	5	1	1	1
126744	1710	CD40 trigger	[CD40 triggering]	0.0	2	1	1	1
126745	1710	rapidly tyrosine-phosphorylated factor treatment of neutrophils.	[rapidly tyrosine-phosphorylated factor treatment of neutrophils.]	0.0	6	1	1	1
126746	1710	single dna-binding hmg box	[single DNA-binding HMG box]	0.0	4	1	1	1
126747	1710	murine macrophage-like cell	[murine macrophage-like cells]	0.0	3	1	1	1
126748	1710	specific uptake with hyperparathyroidism	[specific uptake with hyperparathyroidism]	0.0	4	1	1	1
126749	1710	anoxia/reoxygenation-induced tolerance	[Anoxia/reoxygenation-induced tolerance]	0.0	2	1	1	1
126750	1710	intact e(gre) motif	[intact E(gre) motifs]	0.0	3	1	1	1
126751	1710	pattern at the single-cell level	[pattern at the single-cell level]	0.0	5	1	1	1
126752	1710	pattern of element	[pattern of elements]	0.0	3	1	1	1
126753	1710	interaction with rbp	[interaction with RBP]	0.0	3	1	1	1
126754	1710	encode the enzyme aldehyde dehydrogenase Aldh1	[encoding the enzyme aldehyde dehydrogenase Aldh1]	0.0	6	1	1	1
126755	1710	specific consequence	[specific consequence]	0.0	2	1	1	1
126756	1710	12.91 fmol/10(6)	[12.91 fmol/10(6)]	0.0	2	1	1	1
126757	1710	low cortisol excretion	[low cortisol excretion]	0.0	3	1	1	1
126758	1710	reduction in the number	[reduction in the number]	0.0	4	1	1	1
126759	1710	regulation of the receptor	[regulation of the receptor]	0.0	4	1	1	1
126760	1710	regulatory mechanism of il-5 synthesis	[regulatory mechanisms of IL-5 synthesis]	0.0	5	1	1	1
126761	1710	Differential regulation in primary NK cell	[Differential regulation in primary NK cells]	0.0	6	1	1	1
126762	1710	lymphocyte-specific defect	[lymphocyte-specific defect]	0.0	2	1	1	1
126763	1710	encode a zinc-binding transcription factor	[encoding a zinc-binding transcription factor]	0.0	5	1	1	1
126764	1710	(ie62) protein vzv	[(IE62) protein VZV]	0.0	3	1	1	1
126765	1710	stimulatory g protein	[stimulatory G protein]	0.0	3	1	1	1
126766	1710	truncated, 60-kda precursor	[truncated, 60-kDa precursor]	0.0	3	1	1	1
126767	1710	cell death of precurser	[cell death of precursers]	0.0	4	1	1	1
126768	1710	Kaposi's sarcoma herpesvirus	[Kaposi's sarcoma herpesvirus]	0.0	3	1	1	1
126769	1710	(from hour of the enzyme	[(from hours of the enzyme]	0.0	5	1	1	1
126770	1710	transcriptional activator property	[transcriptional activator properties]	0.0	3	1	1	1
126771	1710	collagenase a metalloproteinase	[collagenase a metalloproteinase]	0.0	3	1	1	1
126772	1710	human lymphotropic virus type tax	[human lymphotropic virus type Tax]	0.0	5	1	1	1
126773	1710	asparagine side	[asparagine side]	0.0	2	1	1	1
126774	1710	mediate activation	[mediating activation]	0.0	2	1	1	1
126775	1710	furthermore, point	[Furthermore, point]	0.0	2	1	1	1
126776	1710	analysis of the form	[Analysis of the forms]	0.0	4	1	1	1
126777	1710	Oct-2 -dependent cis-regulatory function element.	[Oct-2 -dependent cis-regulatory function element.]	0.0	5	1	1	1
126778	1710	stat induction pattern	[STAT induction patterns]	0.0	3	1	1	1
126779	1710	1 P;	[1 h;]	0.0	2	1	1	1
126780	1710	transcriptional repressive effect	[transcriptional repressive effect]	0.0	3	1	1	1
126781	1710	act independently of each control expression	[acting independently of each control expression]	0.0	6	1	1	1
126782	1710	nf-atc isoform with individual transcriptional property	[NF-ATc isoforms with individual transcriptional properties]	0.0	6	1	1	1
126783	1710	activation of the oxidative-stress transcription factor	[activation of the oxidative-stress transcription factor]	0.0	6	1	1	1
126784	1710	haemolytic disease	[haemolytic disease]	0.0	2	1	1	1
126785	1710	E1A oncogene induction	[E1A oncogene induction]	0.0	3	1	1	1
126786	1710	dysfunctional T cell	[dysfunctional T cells]	0.0	3	1	1	1
126787	1710	Dithiocarbamates DTC	[Dithiocarbamates DTC]	0.0	2	1	1	1
126788	1710	regulation in a circumstance	[regulation in a circumstance]	0.0	4	1	1	1
126789	1710	discordance in mnda cell	[discordance in MNDA cells]	0.0	4	1	1	1
126790	1710	EBNA-2 expression	[EBNA-2 expression]	0.0	2	1	1	1
126791	1710	expression in t-cell acute lymphoblastic leukemia	[expression in T-cell acute lymphoblastic leukemia]	0.0	6	1	1	1
126792	1710	responsive element il-4re	[responsive element IL-4RE]	0.0	3	1	1	1
126793	1710	primitive progenitor cell	[primitive progenitor cells]	0.0	3	1	1	1
126794	1710	novel activator tcf-1 t-cell factor-1	[novel activator TCF-1 T-Cell Factor-1]	0.0	5	1	1	1
126795	1710	encode primary granule protein	[encoding primary granule proteins]	0.0	4	1	1	1
126796	1710	phosphatase-positive osteoclast-like giant cell from monocyte	[phosphatase-positive osteoclast-like giant cells from monocytes]	0.0	6	1	1	1
126797	1710	p element site	[P element sites]	0.0	3	1	1	1
126798	1710	protein p107	[protein p107]	0.0	2	1	1	1
126799	1710	nuclear, acid (dna) protein	[nuclear, acid (DNA) proteins]	0.0	4	1	1	1
126800	1710	trifluoromethylketone inhibitor of cytosolic phospholipase a2	[trifluoromethylketone inhibitors of cytosolic phospholipase A2]	0.0	6	1	1	1
126801	1710	mixture, associate with p65	[mixture, associates with p65]	0.0	4	1	1	1
126802	1710	autoregulatory inhibitor of vascular inflammation	[autoregulatory inhibitor of vascular inflammation]	0.0	5	1	1	1
126803	1710	recombinant gp41	[recombinant gp41]	0.0	2	1	1	1
126804	1710	cis-acting dominant negative effect	[cis-acting dominant negative effect]	0.0	4	1	1	1
126805	1710	direct activation of PKC	[Direct activation of PKC]	0.0	4	1	1	1
126806	1710	distinct complex with other nuclear protein	[distinct complexes with other nuclear proteins]	0.0	6	1	1	1
126807	1710	counseling.	[counseling.]	0.0	1	1	1	1
126808	1710	manner in T cell	[manner in T cells]	0.0	4	1	1	1
126809	1710	express very high level of bcl-2	[expressing very high levels of Bcl-2]	0.0	6	1	1	1
126810	1710	bond of peptide substrate	[bond of peptide substrates]	0.0	4	1	1	1
126811	1710	binding affinity the high	[binding affinities the highest]	0.0	4	1	1	1
126812	1710	main circadian pacemaker	[main circadian pacemaker]	0.0	3	1	1	1
126813	1710	immunomodulatory molecule	[immunomodulatory molecule]	0.0	2	1	1	1
126814	1710	uncouple of tyrosine kinase cell.	[Uncoupling of tyrosine kinases cell.]	0.0	5	1	1	1
126815	1710	nuclear b activity	[nuclear B activity]	0.0	3	1	1	1
126816	1710	gene g0/g1 switch regulatory gene	[genes G0/G1 switch regulatory genes]	0.0	5	1	1	1
126817	1710	(10-fold expansion)	[(10-fold expansion)]	0.0	2	1	1	1
126818	1710	clonal expansion) (by stimulation	[clonal expansion) (by stimulation]	0.0	4	1	1	1
126819	1710	transcript monocyte chemoattractant protein	[transcripts monocyte chemoattractant protein]	0.0	4	1	1	1
126820	1710	group one with sensitivity	[groups one with sensitivity]	0.0	4	1	1	1
126821	1710	initiate proinflammatory event	[initiating proinflammatory events]	0.0	3	1	1	1
126822	1710	appearance with the kda protein	[appearance with the kDa protein]	0.0	5	1	1	1
126823	1710	require glucocorticoid for a degree	[requiring glucocorticoids for an degree]	0.0	5	1	1	1
126824	1710	degenerative tropical paraparesis	[degenerative tropical paraparesis]	0.0	3	1	1	1
126825	1710	early protein and/or DNA	[early proteins and/or DNA]	0.0	4	1	1	1
126826	1710	good understanding of the event	[better understanding of the events]	0.0	5	1	1	1
126827	1710	Interleukin-9	[Interleukin-9]	0.0	1	1	1	1
126828	1710	Interleukin-8	[Interleukin-8]	0.0	1	1	1	1
126829	1710	common mechanism of regulation	[common mechanism of regulation]	0.0	4	1	1	1
126830	1710	one point.	[one point.]	0.0	2	1	1	1
126831	1710	human disease xeroderma pigmentosum	[human disease xeroderma pigmentosum]	0.0	4	1	1	1
126832	1710	generate high level of cl	[generating high levels of CL]	0.0	5	1	1	1
126833	1710	total of severe,	[total of severe,]	0.0	3	1	1	1
126834	1710	prb of p130 form	[pRb of p130 Form]	0.0	4	1	1	1
126835	1710	breast cancer antibody-dependent cytotoxicity	[breast cancer antibody-dependent cytotoxicity]	0.0	4	1	1	1
126836	1710	induction through nf-kappab	[Induction through NF-kappaB]	0.0	3	1	1	1
126837	1710	antioxidant agent pyrrolidine dithiocarbamate	[antioxidant agents pyrrolidine dithiocarbamate]	0.0	4	1	1	1
126838	1710	various disease with rheumatoid arthritis	[various diseases with rheumatoid arthritis]	0.0	5	1	1	1
126839	1710	difference with difference in the spacing	[differences with differences in the spacing]	0.0	6	1	1	1
126840	1710	set at stage of b-lymphocyte	[sets at stages of B-lymphocyte]	0.0	5	1	1	1
126841	1710	such form of the protein	[such forms of the protein]	0.0	5	1	1	1
126842	1710	human t-cell line Wurzburg	[human T-cell lines Wurzburg]	0.0	4	1	1	1
126843	1710	significant depression of type	[significant depression of Type]	0.0	4	1	1	1
126844	1710	suggest a involvement in the control	[suggesting an involvement in the control]	0.0	6	1	1	1
126845	1710	resonance spectroscopy	[resonance spectroscopy]	0.0	2	1	1	1
126846	1710	panoply of change	[panoply of changes]	0.0	3	1	1	1
126847	1710	t-cell line IARC	[T-cell line IARC]	0.0	3	1	1	1
126848	1710	glucocorticoid receptor present	[glucocorticoid receptor present]	0.0	3	2	2	1
126849	1710	protein (and	[protein (and]	0.0	2	1	1	1
126850	1710	promoter central bp repeat	[promoter central bp repeat]	0.0	4	1	1	1
126851	1710	activation-inducible enhancer element responsible	[activation-inducible enhancer elements responsible]	0.0	4	1	1	1
126852	1710	effect of anti-inflammatory drug	[effects of anti-inflammatory drugs]	0.0	4	1	1	1
126853	1710	immediate lytic cycle protein	[Immediate lytic cycle proteins]	0.0	4	1	1	1
126854	1710	value from healthy volunteer	[values from healthy volunteers]	0.0	4	1	1	1
126855	1710	mrna display reverse transcriptase pcr	[mRNA display reverse transcriptase PCR]	0.0	5	1	1	1
126856	1710	ifn-gamma component	[IFN-gamma component]	0.0	2	1	1	1
126857	1710	gdsp a specific elastase inhibitor	[GDSP a specific elastase inhibitor]	0.0	5	1	1	1
126858	1710	center maturation	[center maturation]	0.0	2	1	1	1
126859	1710	virus type tax	[virus type Tax]	0.0	3	1	1	1
126860	1710	secretable cytokine	[secretable cytokines]	0.0	2	1	1	1
126861	1710	alternative splicing of a transcript	[alternative splicing of a transcript]	0.0	5	1	1	1
126862	1710	dependent adhesion of cell vein cell	[dependent adhesion of cells vein cells]	0.0	6	1	1	1
126863	1710	adherence to the endothelium,	[adherence to the endothelium,]	0.0	4	1	1	1
126864	1710	mobilize Ca2+ from stores.	[mobilizing Ca2+ from stores.]	0.0	4	1	1	1
126865	1710	several human leukemia cell line	[Several human leukemia cell lines]	0.0	5	1	1	1
126866	1710	p55/p75 late	[p55/p75 late]	0.0	2	1	1	1
126867	1710	lung injury include ARDS	[lung injury including ARDS]	0.0	4	1	1	1
126868	1710	gs in T lymphocyte	[GS in T lymphocytes]	0.0	4	1	1	1
126869	1710	transcriptional transrepressive activity	[transcriptional transrepressive activity]	0.0	3	1	1	1
126870	1710	state of cortex	[state of cortex]	0.0	3	1	1	1
126871	1710	form of severe immunodeficiency SCID	[forms of severe immunodeficiency SCID]	0.0	5	1	1	1
126872	1710	apoplexic patient	[apoplexic patients]	0.0	2	1	1	1
126873	1710	proteins; type a transcript code	[proteins; type A transcripts code]	0.0	5	1	1	1
126874	1710	therapeutic use as agent	[therapeutic use as agents]	0.0	4	1	1	1
126875	1710	significant aldosterone binding	[significant aldosterone binding]	0.0	3	1	1	1
126876	1710	cell inhibitory	[cell inhibitory]	0.0	2	1	1	1
126877	1710	putative role in igh gene expression	[putative role in IgH gene expression]	0.0	6	1	1	1
126878	1710	clinical course (p chi2 test).	[clinical course (P chi2 test).]	0.0	5	1	1	1
126879	1710	intermediate activity with a kd	[intermediate activity with an Kd]	0.0	5	1	1	1
126880	1710	22 kda form	[22 kDa form]	0.0	3	1	1	1
126881	1710	induction of the leukaemia gene	[Induction of the leukaemia gene]	0.0	5	1	1	1
126882	1710	characterize NF-kappa b activation	[characterizing NF-kappa B activation]	0.0	4	1	1	1
126883	1710	Jak kinase pathway	[Jak kinase pathway]	0.0	3	1	1	1
126884	1710	-negative	[-negative]	0.0	1	1	1	1
126885	1710	spectrum with potential	[spectrum with potential]	0.0	3	1	1	1
126886	1710	activation of cd4+ t-cell	[activation of CD4+ T-cells]	0.0	4	1	1	1
126887	1710	induction of CYP1A1 mrna	[induction of CYP1A1 mRNA]	0.0	4	1	1	1
126888	1710	evaluation of the prognostic importance	[evaluation of the prognostic importance]	0.0	5	1	1	1
126889	1710	culture system,	[culture system,]	0.0	2	1	1	1
126890	1710	independent cloning of a protein,	[independent cloning of a protein,]	0.0	5	1	1	1
126891	1710	encode gamma-globin deaminase a enzyme	[encoding gamma-globin deaminase an enzyme]	0.0	5	1	1	1
126892	1710	hsv-1-activated cellular factor	[HSV-1-activated cellular factor]	0.0	3	1	1	1
126893	1710	forms: the mutant p53	[forms: the mutant p53]	0.0	4	1	1	1
126894	1710	factor of chicken t-cell	[factors of chicken T-cells]	0.0	4	1	1	1
126895	1710	involvement of the lymphokine element	[involvement of the lymphokine element]	0.0	5	1	1	1
126896	1710	hsv-2 peptide	[HSV-2 peptide]	0.0	2	1	1	1
126897	1710	activate stat protein	[activating STAT proteins]	0.0	3	1	1	1
126898	1710	effect on virus gene expression	[effect on virus gene expression]	0.0	5	1	1	1
126899	1710	continuous replication	[continuous replication]	0.0	2	1	1	1
126900	1710	-EVI1	[-EVI1]	0.0	1	1	1	1
126901	1710	novel homeobox gene related	[novel homeobox gene related]	0.0	4	1	1	1
126902	1710	patient with Philadelphia leukemia	[patients with Philadelphia leukemia]	0.0	4	1	1	1
126903	1710	active type	[active type]	0.0	2	1	1	1
126904	1710	RA differentiation	[RA differentiation]	0.0	2	1	1	1
126905	1710	disorder,	[disorder,]	0.0	1	1	1	1
126906	1710	two separate pathway	[two separate pathways]	0.0	3	1	1	1
126907	1710	dependence for the response to erythropoietin	[Dependence for the response to erythropoietin]	0.0	6	1	1	1
126908	1710	major class I molecule	[major class I molecules]	0.0	4	1	1	1
126909	1710	heterodimeric nfkb2	[heterodimeric NFKB2]	0.0	2	1	1	1
126910	1710	somatic gene therapy	[somatic gene therapy]	0.0	3	1	1	1
126911	1710	rate of apoptosis in 80.5%	[rate of apoptosis in 80.5%]	0.0	5	1	1	1
126912	1710	phorbol ester production	[phorbol ester production]	0.0	3	1	1	1
126913	1710	ligand avidity	[ligand avidity]	0.0	2	1	1	1
126914	1710	antiinflammatory property of CsA	[antiinflammatory properties of CsA]	0.0	4	1	1	1
126915	1710	group of woman	[group of women]	0.0	3	1	1	1
126916	1710	cyclin kinase inhibitor	[cyclin kinase inhibitor]	0.0	3	1	1	1
126917	1710	classic GCR	[classic GCR]	0.0	2	1	1	1
126918	1710	immunocytochemistry; fmol/mg protein	[immunocytochemistry; fmol/mg protein]	0.0	3	1	1	1
126919	1710	CD80 ag	[CD80 Ag]	0.0	2	1	1	1
126920	1710	effectiveness of approaches.	[effectiveness of approaches.]	0.0	3	1	1	1
126921	1710	ifn-gamma element GIRE	[IFN-gamma element GIRE]	0.0	3	1	1	1
126922	1710	casein kinase site (37 to 67),	[casein kinase sites (37 to 67),]	0.0	6	1	1	1
126923	1710	activation of b activity	[activation of B activity]	0.0	4	1	1	1
126924	1710	specific pathology such as failure	[specific pathologies such as failure]	0.0	5	1	1	1
126925	1710	multiple, protein	[multiple, proteins]	0.0	2	1	1	1
126926	1710	include the product	[including the products]	0.0	3	1	1	1
126927	1710	prb modification during apoptosis	[pRB modification during apoptosis]	0.0	4	1	1	1
126928	1710	expression of immediate serum gene	[expression of immediate serum genes]	0.0	5	1	1	1
126929	1710	nuclear, deoxyribonucleic acid (dna) protein	[nuclear, deoxyribonucleic acid (DNA) proteins]	0.0	5	1	1	1
126930	1710	qualitatively similar response	[qualitatively similar responses]	0.0	3	1	1	1
126931	1710	major treatment modality	[major treatment modality]	0.0	3	1	1	1
126932	1710	peripheral blood cell pbmc response	[peripheral blood cell PBMC responses]	0.0	5	1	1	1
126933	1710	cytokine -specific mrna	[cytokine -specific mRNA]	0.0	3	1	1	1
126934	1710	constitutive induction of cell cycle regulator	[constitutive induction of cell cycle regulators]	0.0	6	1	1	1
126935	1710	kd nmol/L) nmol/L) for cortisol	[Kd nmol/L) nmol/L) for cortisol]	0.0	5	1	1	1
126936	1710	U3 region transcriptional domain	[U3 region transcriptional domain]	0.0	4	1	1	1
126937	1710	sequence upstream of cp	[sequences upstream of Cp]	0.0	4	1	1	1
126938	1710	two different schedule	[two different schedules]	0.0	3	1	1	1
126939	1710	CD4(+) T	[CD4(+) T]	0.0	2	1	1	1
126940	1710	respiratory epithelium of 19	[respiratory epithelium of 19]	0.0	4	1	1	1
126941	1710	role of e220k	[role of E220K]	0.0	3	1	1	1
126942	1710	human zinc finger protein	[human zinc finger proteins]	0.0	4	1	1	1
126943	1710	63% identity with a core	[63% identity with a core]	0.0	5	1	1	1
126944	1710	patient with transient pseudohypoaldosteronism	[patients with transient pseudohypoaldosteronism]	0.0	4	1	1	1
126945	1710	hiv-ltr activation	[HIV-LTR activation]	0.0	2	1	1	1
126946	1710	effect of deletion mutation	[effects of deletion mutations]	0.0	4	1	1	1
126947	1710	malignant clone with technique	[malignant clone with techniques]	0.0	4	1	1	1
126948	1710	incorporation into gr heterocomplex	[incorporation into GR heterocomplexes]	0.0	4	1	1	1
126949	1710	translocation of nfat	[translocation of NFAT]	0.0	3	2	2	1
126950	1710	variant translocation in acute leukaemia	[variant translocation in acute leukaemia]	0.0	5	1	1	1
126951	1710	encode the homolog	[encoding the homolog]	0.0	3	1	1	1
126952	1710	biological property of the compound	[biological properties of the compounds]	0.0	5	1	1	1
126953	1710	protein kinase SAPK	[protein kinases SAPK]	0.0	3	1	1	1
126954	1710	monocyte into macrophage	[monocytes into macrophages]	0.0	3	2	2	1
126955	1710	30% large b-cell lymphoma	[30% large B-cell lymphomas]	0.0	4	1	1	1
126956	1710	counteract negative DNA sequence	[counteracting negative DNA sequences]	0.0	4	1	1	1
126957	1710	patient to therapy	[patients to therapy]	0.0	3	1	1	1
126958	1710	p38 protein kinase mapk	[p38 protein kinase MAPk]	0.0	4	1	1	1
126959	1710	neoplastic progression of cell	[neoplastic progression of cells]	0.0	4	1	1	1
126960	1710	two signal transmission pathway	[Two signal transmission pathways]	0.0	4	1	1	1
126961	1710	ligand-induced activation event	[ligand-induced activation events]	0.0	3	1	1	1
126962	1710	Thrombopoietin TPO the primary physiological regulator	[Thrombopoietin TPO the primary physiological regulator]	0.0	6	1	1	1
126963	1710	colony-stimulating factor granulocyte-macrophage factor proliferation	[colony-stimulating factor granulocyte-macrophage factor proliferation]	0.0	5	1	1	1
126964	1710	tetanus toxoid T cell proliferation	[tetanus toxoid T cell proliferation]	0.0	5	1	1	1
126965	1710	culture of human T lymphocyte	[cultures of human T lymphocytes]	0.0	5	1	1	1
126966	1710	activity of element	[activity of elements]	0.0	3	1	1	1
126967	1710	extract of mouse astrocyte	[extracts of mouse astrocytes]	0.0	4	1	1	1
126968	1710	alpha (tnf-alpha) antibody	[alpha (TNF-alpha) antibody]	0.0	3	1	1	1
126969	1710	antiserum against kbf1 (identical	[antiserum against KBF1 (identical]	0.0	4	1	1	1
126970	1710	subset with translocation t(10;11)	[subsets with translocation t(10;11)]	0.0	4	1	1	1
126971	1710	role for NFAT-1 in activation	[role for NFAT-1 in activation]	0.0	5	1	1	1
126972	1710	neutrophil stimulation	[neutrophil stimulation]	0.0	2	1	1	1
126973	1710	cytoplasmic proteic inhibitor	[cytoplasmic proteic inhibitor]	0.0	3	1	1	1
126974	1710	granulocyte-colony factor	[granulocyte-colony factor]	0.0	2	1	1	1
126975	1710	intrinsic high potential	[intrinsic high potential]	0.0	3	1	1	1
126976	1710	mM edta	[mM EDTA]	0.0	2	1	1	1
126977	1710	oxidative stress with reactive oxygen formation	[Oxidative stress with reactive oxygen formation]	0.0	6	1	1	1
126978	1710	IFN activity equivalent to 0.3	[IFN activity equivalent to 0.3]	0.0	5	1	1	1
126979	1710	activation by beta-phorbol 12-myristate	[activation by beta-phorbol 12-myristate]	0.0	4	1	1	1
126980	1710	cell-type-specific transcriptional regulator	[cell-type-specific transcriptional regulators]	0.0	3	1	1	1
126981	1710	analysis of the immune function	[analysis of the immune functions]	0.0	5	1	1	1
126982	1710	several putative cis-acting element	[several putative cis-acting elements]	0.0	4	1	1	1
126983	1710	POU domain transcription factor	[POU domain transcription factor]	0.0	4	1	1	1
126984	1710	u/ml of erythropoietin	[U/mL of erythropoietin]	0.0	3	1	1	1
126985	1710	suppress transcription	[suppressing transcription]	0.0	2	1	1	1
126986	1710	monoallelic of 7 patient	[monoallelic of 7 patients]	0.0	4	1	1	1
126987	1710	expression:	[expression:]	0.0	1	1	1	1
126988	1710	fact, heat shock protein association	[fact, heat shock protein association]	0.0	5	1	1	1
126989	1710	sexual hormone	[Sexual hormones]	0.0	2	1	1	1
126990	1710	CD3 molecule	[CD3 molecules]	0.0	2	1	1	1
126991	1710	JAK family	[JAK family]	0.0	2	1	1	1
126992	1710	non-mammalian cytokine gene	[non-mammalian cytokine gene]	0.0	3	1	1	1
126993	1710	inductive signal	[inductive signal]	0.0	2	1	1	1
126994	1710	rev activity	[Rev activity]	0.0	2	1	1	1
126995	1710	wave,	[wave,]	0.0	1	1	1	1
126996	1710	marginal amount	[marginal amounts]	0.0	2	1	1	1
126997	1710	membrane protein 1 of Epstein-Barr virus	[membrane protein 1 of Epstein-Barr virus]	0.0	6	1	1	1
126998	1710	vivo footprint on nf-e2	[vivo footprints on NF-E2]	0.0	4	1	1	1
126999	1710	concentration of alpha	[concentrations of alpha]	0.0	3	1	1	1
127000	1710	hypotetraploid DNA	[hypotetraploid DNA]	0.0	2	1	1	1
127001	1710	four direct repeat DR of bp	[four direct repeats DR of bp]	0.0	6	1	1	1
127002	1710	involvement receptor (tnfr)-associated factor	[involvement receptor (TNFR)-associated factors]	0.0	4	1	1	1
127003	1710	delicate balance between positive mechanism	[delicate balance between positive mechanisms]	0.0	5	1	1	1
127004	1710	erythroid tissue	[erythroid tissues]	0.0	2	1	1	1
127005	1710	Oligoclonal	[Oligoclonal]	0.0	1	1	1	1
127006	1710	antigen (include smooth muscle actin	[antigens (including smooth muscle actin]	0.0	5	1	1	1
127007	1710	overcome several block to provirus establishment	[overcoming several blocks to provirus establishment]	0.0	6	1	1	1
127008	1710	major tr	[major TR]	0.0	2	1	1	1
127009	1710	autoimmune serum	[autoimmune serum]	0.0	2	1	1	1
127010	1710	PEBP2/CBF factor	[PEBP2/CBF factors]	0.0	2	1	1	1
127011	1710	cellular nuclear factor-KB	[cellular nuclear factor-KB]	0.0	3	1	1	1
127012	1710	sporadic report of chromosome abnormality	[sporadic reports of chromosome abnormalities]	0.0	5	1	1	1
127013	1710	timp-1 bl line	[TIMP-1 BL lines]	0.0	3	1	1	1
127014	1710	activity of the transcriptional activator	[activities of the transcriptional activators]	0.0	5	1	1	1
127015	1710	lymphoma, diffuse, large cell" type	[lymphoma, diffuse, large cell" type]	0.0	5	1	1	1
127016	1710	presence of 3,4-dichloroisocoumarin	[presence of 3,4-dichloroisocoumarin]	0.0	3	1	1	1
127017	1710	same electrophoretic mobility (approximately kd)	[same electrophoretic mobility (approximately kD)]	0.0	5	1	1	1
127018	1710	hand, stimulation	[hand, stimulation]	0.0	2	2	2	1
127019	1710	hl60 cell with combination	[HL60 cells with combinations]	0.0	4	1	1	1
127020	1710	contain sequence from gene	[containing sequences from genes]	0.0	4	1	1	1
127021	1710	ALAS IRE	[ALAS IRE]	0.0	2	1	1	1
127022	1710	event upstream	[events upstream]	0.0	2	1	1	1
127023	1710	change in lymphocyte	[changes in lymphocytes]	0.0	3	1	1	1
127024	1710	property of heparin	[properties of heparin]	0.0	3	1	1	1
127025	1710	transcription factor bind site	[transcription factor binding sites]	0.0	4	1	1	1
127026	1710	imply a defect	[implying a defect]	0.0	3	1	1	1
127027	1710	ul55	[UL55]	0.0	1	1	1	1
127028	1710	human immunodeficiency virus type terminal repeat	[human immunodeficiency virus type terminal repeats]	0.0	6	1	1	1
127029	1710	however, expression of the beta-casein gene	[However, expression of the beta-casein gene]	0.0	6	1	1	1
127030	1710	use vary conditions, distinct complex	[Using varying conditions, distinct complexes]	0.0	5	1	1	1
127031	1710	chromosomal abnormality	[chromosomal abnormalities]	0.0	2	1	1	1
127032	1710	common site of damage	[common site of damage]	0.0	4	1	1	1
127033	1710	IL-8 a chemotactic factor	[IL-8 a chemotactic factor]	0.0	4	1	1	1
127034	1710	common use	[common use]	0.0	2	1	1	1
127035	1710	ca2+ load	[Ca2+ load]	0.0	2	1	1	1
127036	1710	expression of effector molecule granzyme b	[expression of effector molecules granzyme B]	0.0	6	1	1	1
127037	1710	Biophys Acta	[Biophys Acta]	0.0	2	1	1	1
127038	1710	7.03 (range, (range, (range, 5.86-6.74) nm,	[7.03 (range, (range, (range, 5.86-6.74) nM,]	0.0	6	1	1	1
127039	1710	centimorgan	[centimorgan]	0.0	1	1	1	1
127040	1710	3413 (range,	[3413 (range,]	0.0	2	1	1	1
127041	1710	protein fraction require the addition	[protein fraction requiring the addition]	0.0	5	1	1	1
127042	1710	hiv in peripheral blood lymphocyte	[HIV in peripheral blood lymphocytes]	0.0	5	1	1	1
127043	1710	function of nuclear protein	[functions of nuclear proteins]	0.0	4	1	1	1
127044	1710	adhesion human umbilical vein endothelial cell	[adhesion human umbilical vein endothelial cells]	0.0	6	1	1	1
127045	1710	cellular content of ebv DNA	[cellular content of EBV DNA]	0.0	5	1	1	1
127046	1710	IL-2 to receptor	[IL-2 to receptor]	0.0	3	1	1	1
127047	1710	m alphav5 dihydroxyvitamin D3	[M alpha,25 dihydroxyvitamin D3]	0.0	4	1	1	1
127048	1710	Effect lead to IL-2 expression	[Effects leading to IL-2 expression]	0.0	5	1	1	1
127049	1710	ul75	[UL75]	0.0	1	1	1	1
127050	1710	normal limit of er content	[normal limit of ER content]	0.0	5	1	1	1
127051	1710	two cell systems.	[two cell systems.]	0.0	3	1	1	1
127052	1710	many function	[many functions]	0.0	2	1	1	1
127053	1710	estrogen target	[estrogen target]	0.0	2	1	1	1
127054	1710	responsiveness of cd4+ t-cell line	[responsiveness of CD4+ T-cell lines]	0.0	5	1	1	1
127055	1710	include glucocorticoid receptor	[including glucocorticoid receptor]	0.0	3	1	1	1
127056	1710	ccaat binding factor	[CCAAT binding factor]	0.0	3	1	1	1
127057	1710	protein/dna interaction of the ifn-gamma promoter	[protein/DNA interactions of the IFN-gamma promoter]	0.0	6	1	1	1
127058	1710	receptor count in mononuclear leukocyte	[receptor count in mononuclear leukocytes]	0.0	5	1	1	1
127059	1710	mutant Stat3 incapable	[mutant Stat3 incapable]	0.0	3	1	1	1
127060	1710	il-2r beta Ser386-Val525	[IL-2R beta Ser386-Val525]	0.0	3	1	1	1
127061	1710	only that tcc	[Only those TCC]	0.0	3	1	1	1
127062	1710	apc during primary response	[APC during primary responses]	0.0	4	1	1	1
127063	1710	gene of interest	[gene of interest]	0.0	3	1	1	1
127064	1710	term therapy with atd	[term therapy with ATD]	0.0	4	1	1	1
127065	1710	transglycosylase	[transglycosylase]	0.0	1	1	1	1
127066	1710	NFATc.beta probe	[NFATc.beta probe]	0.0	2	1	1	1
127067	1710	factor in human monocyte	[factor in human monocytes]	0.0	4	1	1	1
127068	1710	level of p59fyn	[levels of p59fyn]	0.0	3	1	1	1
127069	1710	methylprednisolone mp	[methylprednisolone MP]	0.0	2	1	1	1
127070	1710	level of U2 snrna	[levels of U2 snRNA]	0.0	4	1	1	1
127071	1710	near-perfect repeat DR	[near-perfect repeats DR]	0.0	3	1	1	1
127072	1710	cyclin-dependent kinase cdk inhibitor	[cyclin-dependent kinase cdk inhibitor]	0.0	4	1	1	1
127073	1710	view of the use	[view of the use]	0.0	4	1	1	1
127074	1710	include 3 aml	[including 3 AML]	0.0	3	1	1	1
127075	1710	p65 Rel	[p65 Rel]	0.0	2	1	1	1
127076	1710	transcription the gene	[transcription the gene]	0.0	3	1	1	1
127077	1710	abundant expression p45 nf-e2 mrna	[Abundant expression P45 NF-E2 mRNA]	0.0	5	1	1	1
127078	1710	dexamethasone dxm	[dexamethasone DXM]	0.0	2	1	1	1
127079	1710	co-treatment with phenylarsine oxide	[co-treatment with phenylarsine oxide]	0.0	4	1	1	1
127080	1710	effect on shear-induced vcam-1 expression	[effect on shear-induced VCAM-1 expression]	0.0	5	1	1	1
127081	1710	variety include septic shock	[variety including septic shock]	0.0	4	1	1	1
127082	1710	region of ifn-stimulated gene	[region of IFN-stimulated gene]	0.0	4	1	1	1
127083	1710	microm cold aldosterone	[microM cold aldosterone]	0.0	3	1	1	1
127084	1710	intermediate thymocyte culture	[intermediate thymocyte cultures]	0.0	3	1	1	1
127085	1710	microscopy	[microscopy]	0.0	1	1	1	1
127086	1710	process rescue MHC thymocyte	[process rescuing MHC thymocytes]	0.0	4	1	1	1
127087	1710	transcriptional activation of the long repeat	[transcriptional activation of the long repeat]	0.0	6	1	1	1
127088	1710	hiv-1 gene regulation	[HIV-1 gene regulation]	0.0	3	1	1	1
127089	1710	similar action	[similar actions]	0.0	2	1	1	1
127090	1710	Northern (RNA) blot	[Northern (RNA) blots]	0.0	3	1	1	1
127091	1710	nfat IL-2 promoter-beta-galactosidase reporter gene construct	[NFAT IL-2 promoter-beta-galactosidase reporter gene constructs]	0.0	6	1	1	1
127092	1710	expression of two transcription factor	[expression of two transcription factors]	0.0	5	1	1	1
127093	1710	con thymocyte	[Con thymocytes]	0.0	2	1	1	1
127094	1710	degree in cn activity	[degree in CN activity]	0.0	4	1	1	1
127095	1710	emulsion of alpha-tocopherol	[emulsion of alpha-tocopherol]	0.0	3	1	1	1
127096	1710	gr mrna in cell	[GR mRNA in cells]	0.0	4	1	1	1
127097	1710	lymphoid tissue lymphoma (19	[lymphoid tissue lymphoma (19]	0.0	4	1	1	1
127098	1710	Negative transcriptional regulation	[Negative transcriptional regulation]	0.0	3	1	1	1
127099	1710	membrane-proximal determinant	[membrane-proximal determinants]	0.0	2	1	1	1
127100	1710	monocyte counter-receptor for selectin	[monocyte counter-receptor for selectins]	0.0	4	1	1	1
127101	1710	blood lymphocyte PBL from human	[blood lymphocytes PBL from humans]	0.0	5	1	1	1
127102	1710	histocompatibility complex class ii transactivator	[histocompatibility complex class II transactivator]	0.0	5	1	1	1
127103	1710	triglyceride accumulation	[triglyceride accumulation]	0.0	2	1	1	1
127104	1710	expression a homeobox gene	[expression a homeobox gene]	0.0	4	1	1	1
127105	1710	3 hr.	[3 hr.]	0.0	2	1	1	1
127106	1710	diverse syndrome	[diverse syndromes]	0.0	2	1	1	1
127107	1710	infection of Reed-Sternberg (rs) cell	[infection of Reed-Sternberg (RS) cells]	0.0	5	1	1	1
127108	1710	reliable tool	[reliable tool]	0.0	2	1	1	1
127109	1710	activator phytohemagglutinin	[activator phytohemagglutinin]	0.0	2	1	1	1
127110	1710	fibrosarcoma malignant histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma malignant histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
127111	1710	Ib-IX-V	[Ib-IX-V]	0.0	1	1	1	1
127112	1710	induction of differentiation cell	[induction of differentiation cells]	0.0	4	1	1	1
127113	1710	anti-p65 antibody	[anti-p65 antibody]	0.0	2	1	1	1
127114	1710	Ca2+ pathway	[Ca2+ pathway]	0.0	2	1	1	1
127115	1710	lymphocyte-specific protein 1	[lymphocyte-specific protein 1]	0.0	3	1	1	1
127116	1710	seven ankyrin repeat	[seven ankyrin repeats]	0.0	3	1	1	1
127117	1710	ppar activator 15-deoxy-delta(12,14)-prostaglandin	[PPAR activators 15-deoxy-Delta(12,14)-prostaglandin]	0.0	3	1	1	1
127118	1710	traf-binding member	[TRAF-binding members]	0.0	2	1	1	1
127119	1710	treatment with TNF-alpha localization of NFkappaB	[treatment with TNF-alpha localization of NFkappaB]	0.0	6	1	1	1
127120	1710	VDR by 24 P.	[VDR by 24 h.]	0.0	4	1	1	1
127121	1710	lambda L chain	[lambda L chain]	0.0	3	1	1	1
127122	1710	splicing of the tsg101 gene	[splicing of the TSG101 genes]	0.0	5	1	1	1
127123	1710	live-hiv-1 by gain	[live-HIV-1 by gain]	0.0	3	1	1	1
127124	1710	stimulate the expression of genes.	[stimulating the expression of genes.]	0.0	5	1	1	1
127125	1710	effect of csf-1	[effects of CSF-1]	0.0	3	1	1	1
127126	1710	avian sarcoma/leukemia	[avian sarcoma/leukemia]	0.0	2	1	1	1
127127	1710	bind competition	[binding competition]	0.0	2	1	1	1
127128	1710	thus, ebv binding	[Thus, EBV binding]	0.0	3	1	1	1
127129	1710	region of the promoter between basis	[regions of the promoter between bases]	0.0	6	1	1	1
127130	1710	similar change in nf-il6beta expression	[similar changes in NF-IL6beta expression]	0.0	5	1	1	1
127131	1710	prl -responsive element	[PRL -responsive elements]	0.0	3	1	1	1
127132	1710	cell carcinoma (scc) cell line	[cell carcinoma (SCC) cell lines]	0.0	5	1	1	1
127133	1710	important tissue-specific DNA element present	[important tissue-specific DNA element present]	0.0	5	1	1	1
127134	1710	type interleukin-1	[type interleukin-1]	0.0	2	1	1	1
127135	1710	M-CSF expression of the gene fra-1	[M-CSF expression of the gene fra-1]	0.0	6	1	1	1
127136	1710	MNP family	[MNP family]	0.0	2	1	1	1
127137	1710	distinct regulator of the cycle	[distinct regulators of the cycle]	0.0	5	1	1	1
127138	1710	12 reactive hyperplasia fh	[12 reactive hyperplasia FH]	0.0	4	1	1	1
127139	1710	activation in the extract	[activation in the extracts]	0.0	4	1	1	1
127140	1710	important marker for tcr gene	[important markers for TCR genes]	0.0	5	1	1	1
127141	1710	regulator of the production	[regulator of the production]	0.0	4	1	1	1
127142	1710	helix-loop-helix protein in the regulation	[helix-loop-helix proteins in the regulation]	0.0	5	1	1	1
127143	1710	lps e-selectin	[LPS E-selectin]	0.0	2	1	1	1
127144	1710	suggest a carboxy-terminal negative domain	[suggesting a carboxy-terminal negative domain]	0.0	5	1	1	1
127145	1710	other e1a activities, cellular sensitization	[other E1A activities, cellular sensitization]	0.0	5	1	1	1
127146	1710	cyclin a-cdk2- dependent phosphorylation	[cyclin A-Cdk2- dependent phosphorylation]	0.0	4	1	1	1
127147	1710	cell in blood than asthmatics	[cells in blood than asthmatics]	0.0	5	1	1	1
127148	1710	determine the outcome	[determining the outcome]	0.0	3	1	1	1
127149	1710	role of stat5	[roles of STAT5]	0.0	3	1	1	1
127150	1710	lung vascular icam-1	[lung vascular ICAM-1]	0.0	3	2	2	1
127151	1710	regulation in several lymphoid cell line	[regulation in several lymphoid cell lines]	0.0	6	1	1	1
127152	1710	expression antigen	[expression antigens]	0.0	2	1	1	1
127153	1710	glucocorticoid receptor in long-distance runner	[glucocorticoid receptor in long-distance runner]	0.0	5	1	1	1
127154	1710	time of pretreatment	[time of pretreatment]	0.0	3	1	1	1
127155	1710	exact defect(s)	[exact defect(s)]	0.0	2	1	1	1
127156	1710	10% homologous porcine serum	[10% homologous porcine serum]	0.0	4	1	1	1
127157	1710	human umbilical endothelial cell	[human umbilical endothelial cells]	0.0	4	1	1	1
127158	1710	3-o-methyl-d-glucose transport	[3-O-methyl-D-glucose transport]	0.0	2	1	1	1
127159	1710	fragment of OCA-B	[fragment of OCA-B]	0.0	3	1	1	1
127160	1710	alcohol-induced regulation	[Alcohol-induced regulation]	0.0	2	1	1	1
127161	1710	Class ii cell	[Class II cell]	0.0	3	1	1	1
127162	1710	apoptosis m.tremblay,	[apoptosis M.Tremblay,]	0.0	2	1	1	1
127163	1710	embryonic zeta 2 globin promoter	[embryonic zeta 2 globin promoter]	0.0	5	1	1	1
127164	1710	as2o3 (1-2 microM)	[As2O3 (1-2 microM)]	0.0	3	1	1	1
127165	1710	Epstein-Barr virus EBV gene expression	[Epstein-Barr virus EBV gene expression]	0.0	5	1	1	1
127166	1710	leukemia-associated fusion protein	[leukemia-associated fusion protein]	0.0	3	1	1	1
127167	1710	other previously unrecognized NFATp -binding site	[other previously unrecognized NFATp -binding sites]	0.0	6	1	1	1
127168	1710	level of proto-oncogent c-jun	[levels of proto-oncogenes c-jun]	0.0	4	1	1	1
127169	1710	unknown locus	[unknown locus]	0.0	2	1	1	1
127170	1710	different LTR -based vector	[different LTR -based vectors]	0.0	4	1	1	1
127171	1710	tissue undergo termination	[Tissues undergoing termination]	0.0	3	1	1	1
127172	1710	Jurkat cell T lymphocyte	[Jurkat cells T lymphocytes]	0.0	4	1	1	1
127173	1710	ciita cell line rj2.2.5	[CIITA cell line RJ2.2.5]	0.0	4	1	1	1
127174	1710	inflammatory disorder a clinical problem	[inflammatory disorders a clinical problem]	0.0	5	1	1	1
127175	1710	6 micrometer	[6 micrometer]	0.0	2	1	1	1
127176	1710	study the the essential gene	[studying the the essential genes]	0.0	5	1	1	1
127177	1710	attractive target	[attractive target]	0.0	2	1	1	1
127178	1710	grow myeloid leukemic cell line	[growing myeloid leukemic cell line]	0.0	5	1	1	1
127179	1710	untreated depressed patient	[untreated depressed patients]	0.0	3	1	1	1
127180	1710	augment promoter activity in the presence	[augmenting promoter activity in the presence]	0.0	6	1	1	1
127181	1710	spermine binding protein mrna	[spermine binding protein mRNA]	0.0	4	1	1	1
127182	1710	tax -independent binding of multiple factor	[Tax -independent binding of multiple factors]	0.0	6	1	1	1
127183	1710	human t-cell leukemia human T cell	[human T-cell leukemia human T cells]	0.0	6	1	1	1
127184	1710	activation of DNA present	[activation of DNA present]	0.0	4	1	1	1
127185	1710	pentoxifylline inhibition	[pentoxifylline inhibition]	0.0	2	1	1	1
127186	1710	unique target	[unique targets]	0.0	2	1	1	1
127187	1710	rearrangement in the ape	[rearrangements in the apes]	0.0	4	1	1	1
127188	1710	function of this regulatory site	[function of these regulatory sites]	0.0	5	1	1	1
127189	1710	myeloid leukemia cell line grow	[myeloid leukemia cell lines growing]	0.0	5	1	1	1
127190	1710	regulatory pathway for the activity	[regulatory pathway for the activity]	0.0	5	1	1	1
127191	1710	period of latent infection	[periods of latent infection]	0.0	4	1	1	1
127192	1710	gamma-Interferon resistance to 1,25-(oh)2 D3	[gamma-Interferon resistance to 1,25-(OH)2 D3]	0.0	5	1	1	1
127193	1710	contain nf-kappa b DNA binding site	[containing NF-kappa B DNA binding sites]	0.0	6	1	1	1
127194	1710	production of interleukin-12	[production of interleukin-12]	0.0	3	1	1	1
127195	1710	tcf-1 antibody	[TCF-1 antibodies]	0.0	2	1	1	1
127196	1710	hdac-containing repressor complex	[HDAC-containing repressor complexes]	0.0	3	1	1	1
127197	1710	inhibition of tax	[inhibition of Tax]	0.0	3	1	1	1
127198	1710	hang transfer into 2-deoxyguanosine-treated thymus lobe	[Hanging transfer into 2-deoxyguanosine-treated thymus lobes]	0.0	6	1	1	1
127199	1710	retinoid with different binding specificity	[retinoids with different binding specificity]	0.0	5	1	1	1
127200	1710	TNF activation	[TNF activation]	0.0	2	1	1	1
127201	1710	patient from family	[patients from families]	0.0	3	1	1	1
127202	1710	onset of the phase	[onset of the phase]	0.0	4	1	1	1
127203	1710	aml with myelomonocytic differentiation aml-m2	[AML with myelomonocytic differentiation AML-M2]	0.0	5	1	1	1
127204	1710	activation and/or differentiation	[activation and/or differentiation]	0.0	3	1	1	1
127205	1710	5 human blood cell hrbc	[5 human blood cells HRBC]	0.0	5	1	1	1
127206	1710	design a vector	[designing a vector]	0.0	3	1	1	1
127207	1710	subunit of the ifn-alpha receptor	[subunit of the IFN-alpha receptor]	0.0	5	1	1	1
127208	1710	directly use cell line	[directly using cell lines]	0.0	4	1	1	1
127209	1710	determinant of cell	[determinants of cell]	0.0	3	1	1	1
127210	1710	respect little	[respect little]	0.0	2	1	1	1
127211	1710	two form of transcription factor	[Two forms of transcription factor]	0.0	5	1	1	1
127212	1710	i transcription	[I transcription]	0.0	2	1	1	1
127213	1710	conserved, ubiquitous protein	[conserved, ubiquitous protein]	0.0	3	1	1	1
127214	1710	cross-link of FcR	[Cross-linking of FcR]	0.0	3	1	1	1
127215	1710	international-toxicity equivalency	[International-Toxicity Equivalencies]	0.0	2	1	1	1
127216	1710	non-pregnant endometrium	[non-pregnant endometrium]	0.0	2	2	2	1
127217	1710	pulse glucocorticoid therapy	[pulse glucocorticoid therapy]	0.0	3	1	1	1
127218	1710	most common detectable abnormality	[most common detectable abnormalities]	0.0	4	1	1	1
127219	1710	rest blood monocyte	[resting blood monocytes]	0.0	3	1	1	1
127220	1710	promoter ISG15 LTR upstream	[promoter ISG15 LTR upstream]	0.0	4	1	1	1
127221	1710	immune reactivity	[immune reactivity]	0.0	2	1	1	1
127222	1710	-2 molecule	[-2 molecules]	0.0	2	1	1	1
127223	1710	retention of rela	[retention of RelA]	0.0	3	1	1	1
127224	1710	cellular haptenation	[Cellular haptenation]	0.0	2	1	1	1
127225	1710	interaction with prb	[interaction with pRb]	0.0	3	1	1	1
127226	1710	only abundant dna-binding activity	[only abundant DNA-binding activity]	0.0	4	1	1	1
127227	1710	protein/dna interaction erratum	[protein/DNA interactions erratum]	0.0	3	1	1	1
127228	1710	gammadelta-type	[gammadelta-type]	0.0	1	1	1	1
127229	1710	Vitamin d receptor	[Vitamin D receptor]	0.0	3	1	1	1
127230	1710	several antioxidant	[several antioxidants]	0.0	2	1	1	1
127231	1710	effect in term	[effects in terms]	0.0	3	1	1	1
127232	1710	major dnase site	[major DNase site]	0.0	3	1	1	1
127233	1710	protein (MNP)	[protein (MNP)]	0.0	2	1	1	1
127234	1710	analysis by blotting of hematopoietic population	[analysis by blotting of hematopoietic populations]	0.0	6	1	1	1
127235	1710	Epstein-Barr virus membrane protein	[Epstein-Barr virus membrane protein]	0.0	4	1	1	1
127236	1710	n-acetylcysteine inhibition	[N-acetylcysteine inhibition]	0.0	2	1	1	1
127237	1710	interferon (ifn)	[interferon (IFN)]	0.0	2	1	1	1
127238	1710	diverse clinical syndrome include disease	[diverse clinical syndromes including diseases]	0.0	5	1	1	1
127239	1710	suggest a early divergence	[suggesting an early divergence]	0.0	4	1	1	1
127240	1710	contain a island	[containing a island]	0.0	3	1	1	1
127241	1710	e(gre) motif mediate activation	[E(gre) motifs mediating activation]	0.0	4	1	1	1
127242	1710	expression of proto-oncogene c-fo	[expression of proto-oncogene c-fos]	0.0	4	1	1	1
127243	1710	year: versus 14.1	[year: versus 14.1]	0.0	3	1	1	1
127244	1710	low content of t3, dysfunction hypophyseal	[low content of T3, dysfunction hypophyseal]	0.0	6	1	1	1
127245	1710	RA -resistant	[RA -resistant]	0.0	2	1	1	1
127246	1710	response to the two early protein	[responses to the two early proteins]	0.0	6	1	1	1
127247	1710	human cell inflammatory response to infection	[Human cell inflammatory responses to infection]	0.0	6	1	1	1
127248	1710	good clinical predictor	[good clinical predictor]	0.0	3	1	1	1
127249	1710	consequent decrease	[consequent decrease]	0.0	2	1	1	1
127250	1710	receptor gamma PPARgamma a transcription factor	[receptor gamma PPARgamma a transcription factor]	0.0	6	1	1	1
127251	1710	Pellicciari,	[Pellicciari,]	0.0	1	1	1	1
127252	1710	pharmacological kinetic (high turnover) property	[pharmacological kinetic (high turnover) properties]	0.0	5	1	1	1
127253	1710	various disease four	[various diseases four]	0.0	3	1	1	1
127254	1710	blood lymphocyte leukemia	[blood lymphocytes leukemia]	0.0	3	1	1	1
127255	1710	factor(s), protease treatment	[factor(s), protease treatment]	0.0	3	1	1	1
127256	1710	structural class	[structural classes]	0.0	2	1	1	1
127257	1710	multiple receptor signal pathway	[multiple receptor signaling pathways]	0.0	4	1	1	1
127258	1710	decrease of e2f	[decrease of E2F]	0.0	3	1	1	1
127259	1710	nomenclature for IFN gene	[nomenclature for IFN genes]	0.0	4	1	1	1
127260	1710	rel/nuclear factor kappab nf-kappab	[Rel/nuclear factor kappaB NF-kappaB]	0.0	4	1	1	1
127261	1710	tyrosine stat1 protein 91	[tyrosine stat1 proteins 91]	0.0	4	1	1	1
127262	1710	minimal effect in hela cell	[minimal effects in HeLa cells]	0.0	5	1	1	1
127263	1710	glucocorticoid clearance	[glucocorticoid clearance]	0.0	2	1	1	1
127264	1710	ppar-alpha	[PPAR-alpha]	0.0	1	1	1	1
127265	1710	20- to 50-fold great affinity	[20- to 50-fold greater affinity]	0.0	5	1	1	1
127266	1710	interaction between cell in growth	[interaction between cells in growth]	0.0	5	1	1	1
127267	1710	level in supernatant	[levels in supernatants]	0.0	3	1	1	1
127268	1710	TRAIL a dil	[TRAIL a DIL]	0.0	3	1	1	1
127269	1710	m/l calcitriol	[M/l calcitriol]	0.0	2	1	1	1
127270	1710	two pathways: Lyn	[two pathways: Lyn]	0.0	3	1	1	1
127271	1710	tamoxifen a antagonist	[tamoxifen an antagonist]	0.0	3	1	1	1
127272	1710	important regulator of transcription	[important regulators of transcription]	0.0	4	1	1	1
127273	1710	flavonoid on IkappaB kinase	[flavonoids on IkappaB kinase]	0.0	4	1	1	1
127274	1710	9.36 nm, bmax	[9.36 nM, Bmax]	0.0	3	1	1	1
127275	1710	index absorptive hypercalciuric patient	[index absorptive hypercalciuric patients]	0.0	4	1	1	1
127276	1710	induction requirement in human T cell	[Induction requirements in human T cells]	0.0	6	1	1	1
127277	1710	T gene	[T genes]	0.0	2	1	1	1
127278	1710	specific DNA motif	[specific DNA motifs]	0.0	3	1	1	1
127279	1710	common step	[common step]	0.0	2	1	1	1
127280	1710	temperature-induced down-regulation of the receptor	[Temperature-induced down-regulation of the receptor]	0.0	5	1	1	1
127281	1710	ten normal adult blood lymphocyte sample	[ten normal adult blood lymphocyte samples]	0.0	6	1	1	1
127282	1710	antiinflammatory property	[antiinflammatory properties]	0.0	2	1	1	1
127283	1710	key role in vcam-1 expression	[key role in VCAM-1 expression]	0.0	5	1	1	1
127284	1710	favorable clinical course 0.05, chi2	[favorable clinical course 0.05, chi2]	0.0	5	1	1	1
127285	1710	tax1 antigen molecule	[tax1 antigen molecules]	0.0	3	1	1	1
127286	1710	A-CRF with insufficiency M-CRF	[A-CRF with insufficiency M-CRF]	0.0	4	1	1	1
127287	1710	minor salivary gland	[minor salivary glands]	0.0	3	1	1	1
127288	1710	about 90 degree	[about 90 degrees]	0.0	3	1	1	1
127289	1710	regulatory function for the lineage	[regulatory function for the lineages]	0.0	5	1	1	1
127290	1710	consider the effect	[Considering the effect]	0.0	3	1	1	1
127291	1710	substantial number	[substantial number]	0.0	2	1	1	1
127292	1710	most important IL-2 element	[most important IL-2 elements]	0.0	4	1	1	1
127293	1710	untreated ibd patient	[untreated IBD patients]	0.0	3	1	1	1
127294	1710	class of abundant cytosolic receptor	[classes of abundant cytosolic receptors]	0.0	5	1	1	1
127295	1710	sp3 expression	[Sp3 expression]	0.0	2	1	1	1
127296	1710	tnf-alpha independent in the time	[TNF-alpha independent in the time]	0.0	5	1	1	1
127297	1710	acidic amino acid-rich par	[acidic amino acid-rich PAR]	0.0	4	1	1	1
127298	1710	charybdotoxin a inhibitor	[charybdotoxin a inhibitor]	0.0	3	1	1	1
127299	1710	cell line keep erythroid-specific property	[cell lines keeping erythroid-specific properties]	0.0	5	1	1	1
127300	1710	e(2) receptor-negative line,	[E(2) receptor-negative line,]	0.0	3	1	1	1
127301	1710	limited side effect	[limited side effects]	0.0	3	1	1	1
127302	1710	49 healthy subject	[49 healthy subjects]	0.0	3	1	1	1
127303	1710	135(oh)2d3 overproduction	[1,25(OH)2D3 overproduction]	0.0	2	1	1	1
127304	1710	(p leukocyte adhesion in respect	[(P leukocyte adhesion in respect]	0.0	5	1	1	1
127305	1710	nuclear factor NF-AT AP-1/Octamer	[nuclear factor NF-AT AP-1/Octamer]	0.0	4	1	1	1
127306	1710	Furthermore, epithelial level	[Furthermore, epithelial levels]	0.0	3	1	1	1
127307	1710	defect in production of 3 factor	[defects in production of 3 factor]	0.0	6	1	1	1
127308	1710	modulation of factor	[modulation of factors]	0.0	3	1	1	1
127309	1710	Differanisole A a antitumor antibiotic	[Differanisole A a antitumor antibiotic]	0.0	5	1	1	1
127310	1710	inhibition during infection	[inhibition during infection]	0.0	3	1	1	1
127311	1710	almost all case of leukemia	[almost all cases of leukemia]	0.0	5	1	1	1
127312	1710	CsA translocation of a component	[CsA translocation of a component]	0.0	5	1	1	1
127313	1710	transgenic pig donor	[transgenic pig donors]	0.0	3	1	1	1
127314	1710	29% decrease in adhesion	[29% decrease in adhesion]	0.0	4	1	1	1
127315	1710	only mature myelomonocytic cell	[only maturing myelomonocytic cells]	0.0	4	1	1	1
127316	1710	methov with factor paf	[METHODS with factor PAF]	0.0	4	1	1	1
127317	1710	kidney tissue	[kidney tissue]	0.0	2	1	1	1
127318	1710	high level of beta-globin expression	[high levels of beta-globin expression]	0.0	5	1	1	1
127319	1710	vitamin d binding protein present	[vitamin D binding protein present]	0.0	5	1	1	1
127320	1710	results: factor	[RESULTS: factor]	0.0	2	1	1	1
127321	1710	other adhesion molecule	[other adhesion molecules]	0.0	3	1	1	1
127322	1710	acidification	[acidification]	0.0	1	1	1	1
127323	1710	binding of protein to the silencer	[Binding of proteins to the silencer]	0.0	6	1	1	1
127324	1710	express VDR mrna	[expressing VDR mRNA]	0.0	3	1	1	1
127325	1710	er positive cell by immunocytochemistry;	[ER positive cells by immunocytochemistry;]	0.0	5	1	1	1
127326	1710	occur in promyelocyte	[occurring in promyelocyte]	0.0	3	1	1	1
127327	1710	include T lymphocyte	[including T lymphocytes]	0.0	3	1	1	1
127328	1710	maximally effective dose of t3	[maximally effective dose of T3]	0.0	5	1	1	1
127329	1710	strong trans-activation domain	[strong trans-activation domain]	0.0	3	1	1	1
127330	1710	W696-bp coding region	[3696-bp coding region]	0.0	3	1	1	1
127331	1710	important target cell	[important target cells]	0.0	3	1	1	1
127332	1710	reversible dose-dependent inhibition	[reversible dose-dependent inhibition]	0.0	3	1	1	1
127333	1710	multimerized region	[multimerized region]	0.0	2	1	1	1
127334	1710	consequently, one function	[Consequently, one function]	0.0	3	1	1	1
127335	1710	large protein ligand.	[large protein ligand.]	0.0	3	1	1	1
127336	1710	increase in gr mrna	[increase in GR mRNA]	0.0	4	1	1	1
127337	1710	blood cell pbmc response	[blood cell PBMC responses]	0.0	4	1	1	1
127338	1710	ensure the differentiation of thymocyte	[ensuring the differentiation of thymocytes]	0.0	5	1	1	1
127339	1710	domain homologous	[domain homologous]	0.0	2	1	1	1
127340	1710	enhancement HL 60 cell	[enhancement HL 60 cells]	0.0	4	1	1	1
127341	1710	early wk to mo)	[early wk to mo)]	0.0	4	1	1	1
127342	1710	htlv-1 transcription	[HTLV-1 transcription]	0.0	2	1	1	1
127343	1710	localization by different techniques: blot	[localization by different techniques: blot]	0.0	5	1	1	1
127344	1710	basis of localization	[basis of localization]	0.0	3	1	1	1
127345	1710	production by this cell	[production by these cells]	0.0	4	1	1	1
127346	1710	manipulate pathological response	[manipulating pathological responses]	0.0	3	1	1	1
127347	1710	receptor model	[receptor model]	0.0	2	1	1	1
127348	1710	epithelial cell of salivary gland	[epithelial cells of salivary glands]	0.0	5	1	1	1
127349	1710	specific type	[specific type]	0.0	2	1	1	1
127350	1710	downstream of notch,	[downstream of Notch,]	0.0	3	1	1	1
127351	1710	characterization of FKHRL1	[characterization of FKHRL1]	0.0	3	1	1	1
127352	1710	cell-specific factor-DNA complex	[cell-specific factor-DNA complexes]	0.0	3	1	1	1
127353	1710	expression of a viral protein bzlf1	[expression of a viral protein BZLF1]	0.0	6	1	1	1
127354	1710	molecular analysis use blot hybridisation	[Molecular analysis using blot hybridisation]	0.0	5	1	1	1
127355	1710	change in endothelial cell glutathione	[changes in endothelial cell glutathione]	0.0	5	1	1	1
127356	1710	phytohemagglutinin blood lymphocyte	[phytohemagglutinin blood lymphocytes]	0.0	3	1	1	1
127357	1710	immediate gene in cell	[immediate genes in cells]	0.0	4	1	1	1
127358	1710	deoxyribonucleic acid (dna) bind protein	[deoxyribonucleic acid (DNA) binding proteins]	0.0	5	1	1	1
127359	1710	thrombospondin gene	[thrombospondin gene]	0.0	2	1	1	1
127360	1710	cloning sr-bp	[Cloning SR-BP]	0.0	2	1	1	1
127361	1710	immune disorder	[immune disorders]	0.0	2	1	1	1
127362	1710	inhibitory concentration of mp	[inhibitory concentrations of MP]	0.0	4	1	1	1
127363	1710	immune senescence	[immune senescence]	0.0	2	1	1	1
127364	1710	electron microscopy on cell	[electron microscopy on cells]	0.0	4	1	1	1
127365	1710	tnf-alpha -dependent induction	[TNF-alpha -dependent induction]	0.0	3	1	1	1
127366	1710	suggest new strategy	[suggesting new strategies]	0.0	3	1	1	1
127367	1710	activation in human killer cell	[Activation in human killer cells]	0.0	5	1	1	1
127368	1710	pig donor	[pig donors]	0.0	2	1	1	1
127369	1710	property similar for t cell	[properties similar for t cell]	0.0	5	1	1	1
127370	1710	nfil3/e4bp4 in a growth signal pathway	[NFIL3/E4BP4 in a growth signaling pathway]	0.0	6	1	1	1
127371	1710	negative DNA sequence	[negative DNA sequences]	0.0	3	1	1	1
127372	1710	herpesvirus 6 hhv-6 strain gs	[herpesvirus 6 HHV-6 strains GS]	0.0	5	1	1	1
127373	1710	lysoPE	[lysoPE]	0.0	1	1	1	1
127374	1710	-contain molecule	[-containing molecules]	0.0	2	1	1	1
127375	1710	consequence of the mutation.	[consequences of the mutation.]	0.0	4	1	1	1
127376	1710	activator 1 htlv-1 transcription	[activator 1 HTLV-1 transcription]	0.0	4	1	1	1
127377	1710	mutation of the aml1-	[Mutations of the AML1-]	0.0	4	1	1	1
127378	1710	bamhi-q promoter activity	[BamHI-Q promoter activity]	0.0	3	1	1	1
127379	1710	transactivation factor nf-kb	[transactivation factor NF-KB]	0.0	3	1	1	1
127380	1710	cell include cell	[cells including cells]	0.0	3	1	1	1
127381	1710	specificity mutant of EKLF	[specificity mutants of EKLF]	0.0	4	1	1	1
127382	1710	asthmatic patient with reversible airway obstruction	[asthmatic patients with reversible airways obstruction]	0.0	6	1	1	1
127383	1710	appropriate receptors.	[appropriate receptors.]	0.0	2	1	1	1
127384	1710	factor bind C 4681	[Factors binding C 4681]	0.0	4	1	1	1
127385	1710	leukocyte from 11 subject	[leukocytes from 11 subjects]	0.0	4	1	1	1
127386	1710	single-stranded polymorphism	[single-stranded polymorphism]	0.0	2	1	1	1
127387	1710	immunoglobulin gene promoter activity	[immunoglobulin gene promoter activity]	0.0	4	1	1	1
127388	1710	sarcoma/leukemia	[sarcoma/leukemia]	0.0	1	1	1	1
127389	1710	activity of ring x chromosome	[activity of ring X chromosomes]	0.0	5	1	1	1
127390	1710	independent interaction of tax	[independent interaction of Tax]	0.0	4	1	1	1
127391	1710	normalize effect	[normalizing effect]	0.0	2	1	1	1
127392	1710	high level in cell	[high levels in cells]	0.0	4	1	1	1
127393	1710	bob1/obf-1/oca-b	[Bob1/OBF-1/OCA-B]	0.0	1	1	1	1
127394	1710	several thymocyte	[several thymocytes]	0.0	2	1	1	1
127395	1710	hereditary disorder present	[hereditary disorder presenting]	0.0	3	1	1	1
127396	1710	reflect difference in glucocorticoid sensitivity	[reflecting differences in glucocorticoid sensitivity]	0.0	5	1	1	1
127397	1710	unusually high activity	[unusually high activity]	0.0	3	1	1	1
127398	1710	kd, result	[kD, resulting]	0.0	2	1	1	1
127399	1710	lesion of c-myc	[lesions of c-MYC]	0.0	3	1	1	1
127400	1710	/signal	[/signal]	0.0	1	1	1	1
127401	1710	infiltrate leukemic cell	[infiltrating leukemic cells]	0.0	3	1	1	1
127402	1710	hmg box closely related	[HMG box closely related]	0.0	4	1	1	1
127403	1710	labeling of membrane	[labeling of membranes]	0.0	3	1	1	1
127404	1710	E220K polyubiquitinylation	[E220K polyubiquitinylation]	0.0	2	1	1	1
127405	1710	repeat hiv-1-ltr CAT construct	[repeat HIV-1-LTR CAT constructs]	0.0	4	1	1	1
127406	1710	cd5+ b cell	[CD5+ B cells]	0.0	3	1	1	1
127407	1710	lps synthesis	[LPS synthesis]	0.0	2	1	1	1
127408	1710	x1 interaction	[X1 interactions]	0.0	2	1	1	1
127409	1710	6, rhabdomyosarcoma leiomyosarcoma	[6, rhabdomyosarcoma leiomyosarcoma]	0.0	3	1	1	1
127410	1710	strong transcription	[strong transcription]	0.0	2	1	1	1
127411	1710	binding 31747a	[binding 31747A]	0.0	2	1	1	1
127412	1710	prolactin target gene	[prolactin target genes]	0.0	3	1	1	1
127413	1710	gene encode interleukin-2	[gene encoding interleukin-2]	0.0	3	1	1	1
127414	1710	activation of zeta globin promoter role	[activation of zeta globin promoter role]	0.0	6	1	1	1
127415	1710	apoptosis ligand	[apoptosis ligand]	0.0	2	1	1	1
127416	1710	acid receptor type	[acid receptor type]	0.0	3	1	1	1
127417	1710	peptide fragment	[peptide fragments]	0.0	2	1	1	1
127418	1710	level of IFN synthesis	[levels of IFN synthesis]	0.0	4	1	1	1
127419	1710	electron-dense structure distinct from the structure	[electron-dense structures distinct from the structures]	0.0	6	1	1	1
127420	1710	indicate a role as a immunomodulator	[indicating a role as a immunomodulator]	0.0	6	1	1	1
127421	1710	glucocorticoid on glucocorticoid function	[glucocorticoids on glucocorticoid function]	0.0	4	1	1	1
127422	1710	simian immunodeficiency virus in vitro.	[simian immunodeficiency virus in vitro.]	0.0	5	1	1	1
127423	1710	t-cell-mediated recognition	[T-cell-mediated recognition]	0.0	2	1	1	1
127424	1710	time of 25 h (viability	[times of 25 h (viability]	0.0	5	1	1	1
127425	1710	runting, skin defect	[runting, skin defects]	0.0	3	1	1	1
127426	1710	lymphocyte in 14 active sle	[lymphocytes in 14 active SLE]	0.0	5	1	1	1
127427	1710	spread of lymphoma	[spread of lymphomas]	0.0	3	1	1	1
127428	1710	clinical importance of apoptosis	[clinical importance of apoptosis]	0.0	4	1	1	1
127429	1710	nontoxic concentration of metabolite	[nontoxic concentrations of metabolites]	0.0	4	1	1	1
127430	1710	97 (18- female volunteer	[97 (18- female volunteers]	0.0	4	1	1	1
127431	1710	evidence different	[evidence different]	0.0	2	1	1	1
127432	1710	60 bp upstream	[60 bp upstream]	0.0	3	1	1	1
127433	1710	immediate gene after kind	[immediate genes after kinds]	0.0	4	1	1	1
127434	1710	modulation of the response	[Modulation of the response]	0.0	4	2	2	1
127435	1710	stimulation with all-tran acid	[stimulation with all-trans acid]	0.0	4	1	1	1
127436	1710	further emphasize the potential	[further emphasizing the potential]	0.0	4	1	1	1
127437	1710	mode after administration of megadosis	[mode after administration of megadoses]	0.0	5	1	1	1
127438	1710	use a clone of HTLV-II	[using an clone of HTLV-II]	0.0	5	1	1	1
127439	1710	bear tumor for a week (>26	[bearing tumor for a weeks (>26]	0.0	6	1	1	1
127440	1710	two dhs in intron	[two DHS in intron]	0.0	4	1	1	1
127441	1710	lack the activator function	[lacking the activator functions]	0.0	4	1	1	1
127442	1710	programme of gene expression	[programme of gene expression]	0.0	4	1	1	1
127443	1710	concern the role of nm23 gene	[concerning the role of nm23 gene]	0.0	6	1	1	1
127444	1710	great proportion	[greater proportion]	0.0	2	1	1	1
127445	1710	mechanism of lymphocyte dysfunction	[mechanisms of lymphocyte dysfunction]	0.0	4	1	1	1
127446	1710	interleukin-2 receptor gamma chain	[interleukin-2 receptor gamma chain]	0.0	4	1	1	1
127447	1710	minimal b29 promoter	[minimal B29 promoter]	0.0	3	1	1	1
127448	1710	ltr- chloramphenicol acetyltransferase	[LTR- chloramphenicol acetyltransferase]	0.0	3	1	1	1
127449	1710	minutes)	[minutes)]	0.0	1	1	1	1
127450	1710	suggest a cooperative interaction	[suggesting a cooperative interaction]	0.0	4	1	1	1
127451	1710	contain complex capable	[containing complexes capable]	0.0	3	1	1	1
127452	1710	region of potential	[Regions of potential]	0.0	3	1	1	1
127453	1710	add nf-kappa b protein	[Adding NF-kappa B protein]	0.0	4	1	1	1
127454	1710	early serum responsive gene	[early serum responsive genes]	0.0	4	1	1	1
127455	1710	shear-induced activation of nf-kappab	[shear-induced activation of NF-kappaB]	0.0	4	2	2	1
127456	1710	acute leukemia (apl): ii	[acute leukemia (APL): II]	0.0	4	1	1	1
127457	1710	interleukin-12 expression in b cell	[Interleukin-12 expression in B cells]	0.0	5	1	1	1
127458	1710	statg in normal myeloid cell	[StatG in normal myeloid cells]	0.0	5	1	1	1
127459	1710	major tr TREp complex	[major TR TREp complex]	0.0	4	1	1	1
127460	1710	process of virus activation	[process of virus activation]	0.0	4	1	1	1
127461	1710	control of expression in T cell	[control of expression in T cells]	0.0	6	1	1	1
127462	1710	human receptor hGR	[human receptor hGR]	0.0	3	1	1	1
127463	1710	include wbJun	[including wbJun]	0.0	2	1	1	1
127464	1710	adult erythroid cell system	[adult erythroid cell system]	0.0	4	1	1	1
127465	1710	sequence requirement within a regulatory element	[sequence requirements within a regulatory element]	0.0	6	1	1	1
127466	1710	E.Ramazzotti, M.C.Re, G.Visani,	[E.Ramazzotti, M.C.Re, G.Visani,]	0.0	3	1	1	1
127467	1710	immediate-early viral gene	[immediate-early viral genes]	0.0	3	1	1	1
127468	1710	day of the disease,	[day of the disease,]	0.0	4	1	1	1
127469	1710	proband ii-2	[proband II-2]	0.0	2	1	1	1
127470	1710	lymphocyte of woman (11 second	[lymphocytes of women (11 second]	0.0	5	1	1	1
127471	1710	mechanism for gene transcription	[mechanisms for gene transcription]	0.0	4	1	1	1
127472	1710	cis-acting element responsible	[cis-acting elements responsible]	0.0	3	1	1	1
127473	1710	regulation of receptor	[Regulation of receptors]	0.0	3	1	1	1
127474	1710	relative binding affinity RBA	[relative binding affinities RBA]	0.0	4	1	1	1
127475	1710	RANTES expression	[RANTES expression]	0.0	2	1	1	1
127476	1710	early adult hematopoiesis	[early adult hematopoiesis]	0.0	3	1	1	1
127477	1710	regulator factor-kappaB nf-kappab	[regulator factor-kappaB NF-kappaB]	0.0	3	1	1	1
127478	1710	g1 cell cycle function	[G1 cell cycle function]	0.0	4	1	1	1
127479	1710	thereby contribute	[thereby contributing]	0.0	2	2	2	1
127480	1710	ten patient with normal receptor affinity	[Ten patients with normal receptor affinity]	0.0	6	1	1	1
127481	1710	kappa b-binding,	[kappa B-binding,]	0.0	2	1	1	1
127482	1710	immunodeficiency virus type 1 hiv-1 factor	[immunodeficiency virus type 1 HIV-1 factor]	0.0	6	1	1	1
127483	1710	response to glycoprotein b gb	[responses to glycoprotein B gB]	0.0	5	1	1	1
127484	1710	human oxide synthase gene	[human oxide synthase gene]	0.0	4	1	1	1
127485	1710	total cell gelatinase	[total cell gelatinase]	0.0	3	1	1	1
127486	1710	multipotent/erythroid/monocytic	[multipotent/erythroid/monocytic]	0.0	1	1	1	1
127487	1710	negative circuit	[negative circuits]	0.0	2	1	1	1
127488	1710	such as the PyG box	[such as the PyG boxes]	0.0	5	1	1	1
127489	1710	time of about 25 h (viability	[times of about 25 h (viability]	0.0	6	1	1	1
127490	1710	patient f.r., m.m., P. g.)	[patients F.R., M.M., P. G.)]	0.0	5	1	1	1
127491	1710	chromosomal translocation in a leukemia	[chromosomal translocation in a leukemia]	0.0	5	1	1	1
127492	1710	effect on IL-2 promoter	[effect on IL-2 promoter]	0.0	4	1	1	1
127493	1710	consider group	[considering groups]	0.0	2	1	1	1
127494	1710	locus sil	[locus SIL]	0.0	2	1	1	1
127495	1710	number include phorbol	[number including phorbol]	0.0	3	1	1	1
127496	1710	physical interaction between gata-1	[physical interaction between GATA-1]	0.0	4	1	1	1
127497	1710	substantial importance	[substantial importance]	0.0	2	1	1	1
127498	1710	six mutation	[six mutations]	0.0	2	1	1	1
127499	1710	repressor.	[repressor.]	0.0	1	1	1	1
127500	1710	paradigm for the study	[paradigm for the study]	0.0	4	1	1	1
127501	1710	add m).	[adding M).]	0.0	2	1	1	1
127502	1710	DNasel site	[DNasel sites]	0.0	2	1	1	1
127503	1710	patient with spread	[patients with spread]	0.0	3	1	1	1
127504	1710	inhibition of il-1ra protein secretion	[inhibition of IL-1ra protein secretion]	0.0	5	1	1	1
127505	1710	interaction in the proximal promoter	[Interaction in the proximal promoter]	0.0	5	1	1	1
127506	1710	infection of human immunodeficiency virus analysis	[Infection of human immunodeficiency viruses analyses]	0.0	6	1	1	1
127507	1710	trans-activator protein BZLF1	[trans-activator protein BZLF1]	0.0	3	1	1	1
127508	1710	concentration to &mgr;m)	[concentrations to &mgr;M)]	0.0	3	1	1	1
127509	1710	cell layer of epithelium	[cell layer of epithelium]	0.0	4	1	1	1
127510	1710	circuit	[circuits]	0.0	1	1	1	1
127511	1710	pseudohypoaldosteronism in eight form of inheritance	[Pseudohypoaldosteronism in eight forms of inheritance]	0.0	6	1	1	1
127512	1710	3,5,3'-triiodothyronine receptor circulate human lymphocyte thyroidism	[3,5,3'-triiodothyronine receptors circulating human lymphocytes thyroidism]	0.0	6	1	1	1
127513	1710	produce the regulating protein	[producing the regulating proteins]	0.0	4	1	1	1
127514	1710	platelet (auc 15 nmol	[platelets (AUC 15 nmol]	0.0	4	1	1	1
127515	1710	induction infection of cell	[Induction infection of cells]	0.0	4	1	1	1
127516	1710	nuclear t3 maximal binding capacity	[nuclear T3 maximal binding capacity]	0.0	5	1	1	1
127517	1710	common scatchard analysis	[common Scatchard analysis]	0.0	3	1	1	1
127518	1710	leucine-zipper structure	[leucine-zipper structure]	0.0	2	1	1	1
127519	1710	1 out consecutive control	[1 out consecutive controls]	0.0	4	1	1	1
127520	1710	stat5 rrna	[STAT5 mRNAs]	0.0	2	1	1	1
127521	1710	standard d oligonucleotide	[standard ds oligonucleotides]	0.0	3	1	1	1
127522	1710	previous localization	[previous localization]	0.0	2	1	1	1
127523	1710	units/ml human recombinant m-csf	[units/ml human recombinant M-CSF]	0.0	4	1	1	1
127524	1710	alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3	[alpha,25-dihydroxyvitamin D3 1 alpha,25(OH)2D3]	0.0	4	1	1	1
127525	1710	NF-kappa b specific oligonucleotide	[NF-kappa B specific oligonucleotide]	0.0	4	1	1	1
127526	1710	t) cell from 11	[T) cells from 11]	0.0	4	1	1	1
127527	1710	simultaneous exposure	[simultaneous exposure]	0.0	2	1	1	1
127528	1710	study of clonality	[study of clonality]	0.0	3	1	1	1
127529	1710	immunoglobulin histocompatibility (mhc) gene	[immunoglobulin histocompatibility (MHC) genes]	0.0	4	1	1	1
127530	1710	set of negative pi3-k construct	[set of negative PI3-K constructs]	0.0	5	1	1	1
127531	1710	incubation of human cell	[Incubation of human cells]	0.0	4	1	1	1
127532	1710	cd34+ hematopoietic progenitor cell	[CD34+ hematopoietic progenitor cells]	0.0	4	2	2	1
127533	1710	potential of drug	[potential of drugs]	0.0	3	1	1	1
127534	1710	use as a photoactivatable crosslinker	[use as a photoactivatable crosslinker]	0.0	5	1	1	1
127535	1710	microsome in short term culture	[microsomes in short term culture]	0.0	5	1	1	1
127536	1710	tartrate acid phosphatase (trap+) cell	[tartrate acid phosphatase (TRAP+) cells]	0.0	5	1	1	1
127537	1710	glucocorticoid inhibition of the uptake	[glucocorticoid inhibition of the uptake]	0.0	5	1	1	1
127538	1710	normal exon genomic sequence	[normal exon genomic sequence]	0.0	4	1	1	1
127539	1710	cell production	[cell production]	0.0	2	1	1	1
127540	1710	agent endotoxin	[agents endotoxin]	0.0	2	1	1	1
127541	1710	combination of promoter	[combinations of promoters]	0.0	3	1	1	1
127542	1710	fy*b gata	[FY*B GATA]	0.0	2	1	1	1
127543	1710	second feature of T cell	[second feature of T cells]	0.0	5	1	1	1
127544	1710	anti-tumor CTL	[anti-tumor CTL]	0.0	2	1	1	1
127545	1710	imprint a th2 phenotype	[imprinting a Th2 phenotype]	0.0	4	1	1	1
127546	1710	also significantly (p less than 0.025)	[also significantly (P less than 0.025)]	0.0	6	1	1	1
127547	1710	apoptosis in thymoma cell	[apoptosis in thymoma cells]	0.0	4	1	1	1
127548	1710	lead to efficient hiv replication	[leading to efficient HIV replication]	0.0	5	1	1	1
127549	1710	action of retinoic acid	[action of retinoic acid]	0.0	4	1	1	1
127550	1710	good correlation,	[good correlation,]	0.0	2	1	1	1
127551	1710	human aortic cell harc	[human aortic cells HAECs]	0.0	4	1	1	1
127552	1710	nonreceptor protein tyrosine kinase	[nonreceptor protein tyrosine kinases]	0.0	4	1	1	1
127553	1710	transcript encode gp350/220 the coat protein	[Transcripts encoding gp350/220 the coat protein]	0.0	6	1	1	1
127554	1710	transcription factor as molecular target	[transcription factors as molecular targets]	0.0	5	1	1	1
127555	1710	nf-kappa b probe	[NF-kappa B probe]	0.0	3	1	1	1
127556	1710	species capable	[species capable]	0.0	2	1	1	1
127557	1710	pax-5 transcript	[Pax-5 transcripts]	0.0	2	1	1	1
127558	1710	glucocorticoid on glucocorticoid peripheral function	[glucocorticoids on glucocorticoid peripheral function]	0.0	5	1	1	1
127559	1710	elam-1 (ic50	[ELAM-1 (IC50]	0.0	2	1	1	1
127560	1710	Effect of glucocorticoid on function	[Effects of glucocorticoids on function]	0.0	5	1	1	1
127561	1710	four proteins--a major protein	[four proteins--a major protein]	0.0	4	1	1	1
127562	1710	mononuclear leukocyte of donor of sexes.	[mononuclear leukocytes of donors of sexes.]	0.0	6	1	1	1
127563	1710	two signal for induction,	[two signals for induction,]	0.0	4	1	1	1
127564	1710	S9a at nm	[S9a at nM]	0.0	3	1	1	1
127565	1710	kd versus 19.2+/-2.4 nmol/L)	[Kd versus 19.2+/-2.4 nmol/L)]	0.0	4	1	1	1
127566	1710	putative silencer	[putative silencer]	0.0	2	1	1	1
127567	1710	NFAT-1 gene expression in transgenic mouse	[NFAT-1 gene expression in transgenic mice]	0.0	6	1	1	1
127568	1710	firm structural basis	[firm structural basis]	0.0	3	1	1	1
127569	1710	granulocyte- factor gm-csf	[granulocyte- factor GM-CSF]	0.0	3	1	1	1
127570	1710	Recognition of herpes simplex virus type	[Recognition of herpes simplex virus type]	0.0	6	1	1	1
127571	1710	immunodeficiency virus type enhancer	[immunodeficiency virus type enhancer]	0.0	4	1	1	1
127572	1710	n-Acetyl-L-cysteine NAC a antioxidant,	[n-Acetyl-L-cysteine NAC a antioxidant,]	0.0	4	1	1	1
127573	1710	uptake of [3h]1,25(oh)2d3 with failure	[uptake of [3H]1,25(OH)2D3 with failure]	0.0	5	1	1	1
127574	1710	translocation of factor kappab	[translocation of factor kappaB]	0.0	4	1	1	1
127575	1710	abnormality in immune regulation	[abnormalities in immune regulation]	0.0	4	1	1	1
127576	1710	regulator of several cytokine receptor genes,	[regulators of several cytokine receptor genes,]	0.0	6	1	1	1
127577	1710	rifn-alpha 2c	[rIFN-alpha 2c]	0.0	2	1	1	1
127578	1710	pcr approach with oligonucleotide	[PCR approach with oligonucleotides]	0.0	4	1	1	1
127579	1710	moreover, a marker	[moreover, a marker]	0.0	3	1	1	1
127580	1710	effect inhibition through adenosine triphosphate atp	[effects inhibition through adenosine triphosphate ATP]	0.0	6	1	1	1
127581	1710	study the molecular mechanism	[studying the molecular mechanisms]	0.0	4	1	1	1
127582	1710	interference of receptor binding	[interference of receptor binding]	0.0	4	1	1	1
127583	1710	regulation during differentiation of leukemic cell	[regulation during differentiation of leukemic cells]	0.0	6	1	1	1
127584	1710	10(2.9) pfu/animal,	[10(2.9) pfu/animal,]	0.0	2	1	1	1
127585	1710	act in insertional actin polymerization	[acting in insertional actin polymerization]	0.0	5	1	1	1
127586	1710	lim-hox gene	[LIM-Hox gene]	0.0	2	1	1	1
127587	1710	important hormone	[important hormone]	0.0	2	1	1	1
127588	1710	proteolysis profile of this protein	[proteolysis profile of this protein]	0.0	5	1	1	1
127589	1710	fitc-	[FITC-]	0.0	1	1	1	1
127590	1710	colony-stimulating factor factor proliferation	[colony-stimulating factor factor proliferation]	0.0	4	1	1	1
127591	1710	acute patient	[acute patients]	0.0	2	1	1	1
127592	1710	nuclear expression of factor kappab	[nuclear expression of factor kappaB]	0.0	5	1	1	1
127593	1710	range from kda	[ranging from kDa]	0.0	3	1	1	1
127594	1710	hour at neutral pH	[hr at neutral pH]	0.0	4	1	1	1
127595	1710	t1/2 accumulation	[t1/2, accumulation]	0.0	2	1	1	1
127596	1710	histocompatibility complex (mhc) class gene	[histocompatibility complex (MHC) class genes]	0.0	5	3	3	1
127597	1710	abrogate bhlh homo-	[abrogating bHLH homo-]	0.0	3	1	1	1
127598	1710	cleavage of transcription factor during apoptosis	[Cleavage of transcription factor during apoptosis]	0.0	6	1	1	1
127599	1710	gene inhibition	[gene inhibition]	0.0	2	1	1	1
127600	1710	HLA DQ2 heterodimer	[HLA DQ2 heterodimers]	0.0	3	1	1	1
127601	1710	cytokine-stimulated human saphenous vein cell	[cytokine-stimulated human saphenous vein cells]	0.0	5	1	1	1
127602	1710	several cis-acting site	[Several cis-acting sites]	0.0	3	1	1	1
127603	1710	extract from PMA cell	[extracts from PMA cells]	0.0	4	1	1	1
127604	1710	treatment (day hpc with alpha-pml	[treatment (day HPCs with alpha-PML]	0.0	5	1	1	1
127605	1710	regulation by a signal pathway	[regulation by a signaling pathway]	0.0	5	1	1	1
127606	1710	glucocorticoid-resistant cell	[glucocorticoid-resistant cells]	0.0	2	1	1	1
127607	1710	bear dqa1*0201	[bearing DQA1*0201]	0.0	2	1	1	1
127608	1710	female patient with MPD	[female patients with MPD]	0.0	4	1	1	1
127609	1710	b/rel/nfat	[B/Rel/NFAT]	0.0	1	1	1	1
127610	1710	trend for some	[trends for some]	0.0	3	1	1	1
127611	1710	presence of STAT-1	[presence of STAT-1]	0.0	3	1	1	1
127612	1710	three candidate gene hepatic factor	[three candidate genes hepatic factor]	0.0	5	1	1	1
127613	1710	lipoprotein through toll-like receptor-2	[lipoproteins through toll-like receptor-2]	0.0	4	1	1	1
127614	1710	evidence for a site	[evidence for an site]	0.0	4	1	1	1
127615	1710	mechanism of synergy	[mechanisms of synergy]	0.0	3	1	1	1
127616	1710	sequence analysis of HS between show	[sequence analysis of HS between shows]	0.0	6	1	1	1
127617	1710	difference between each mean group	[differences between each mean group]	0.0	5	1	1	1
127618	1710	however, restimulation	[However, restimulation]	0.0	2	1	1	1
127619	1710	immunoglobulin (mhc) gene	[immunoglobulin (MHC) genes]	0.0	3	1	1	1
127620	1710	guanylhydrazone	[guanylhydrazone]	0.0	1	1	1	1
127621	1710	acid phosphatase giant cell mgc	[acid phosphatase giant cells MGC]	0.0	5	1	1	1
127622	1710	des-arg form	[des-Arg form]	0.0	2	1	1	1
127623	1710	approach against aids by application	[approach against AIDS by application]	0.0	5	1	1	1
127624	1710	p21ras gtp binding protein	[p21ras GTP binding proteins]	0.0	4	1	1	1
127625	1710	osteoclastogenic cytokine tnf-alpha	[osteoclastogenic cytokine TNF-alpha]	0.0	3	1	1	1
127626	1710	chemotactic factor for neutrophil granulocyte	[chemotactic factor for neutrophil granulocytes]	0.0	5	1	1	1
127627	1710	/ap-1-dna	[/AP-1-DNA]	0.0	1	1	1	1
127628	1710	chloramphenicol acetyltransferase CAT plasmid	[chloramphenicol acetyltransferase CAT plasmids]	0.0	4	1	1	1
127629	1710	12-o-tetradecanoylphorbol induction of factor-kappaB activity	[12-O-tetradecanoylphorbol induction of factor-kappaB activity]	0.0	5	1	1	1
127630	1710	g0/g1 prolongation	[G0/G1 prolongation]	0.0	2	1	1	1
127631	1710	include the tyrosine phosphorylation CD28	[including the tyrosine phosphorylation CD28]	0.0	5	1	1	1
127632	1710	Stat3EE a mutant incapable	[Stat3EE a mutant incapable]	0.0	4	1	1	1
127633	1710	interleukin-3 promoter	[interleukin-3 promoter]	0.0	2	1	1	1
127634	1710	affinity for motif	[affinity for motifs]	0.0	3	1	1	1
127635	1710	response identical	[response identical]	0.0	2	1	1	1
127636	1710	activity in reproductive tissue	[activity in reproductive tissue]	0.0	4	1	1	1
127637	1710	myeloid cell lineage	[myeloid cell lineages]	0.0	3	1	1	1
127638	1710	HIV-2 tat gene	[HIV-2 tat genes]	0.0	3	1	1	1
127639	1710	class ii complex cell line	[class II complex cell lines]	0.0	5	1	1	1
127640	1710	subclassification	[subclassification]	0.0	1	1	1	1
127641	1710	motility assay	[motility assays]	0.0	2	1	1	1
127642	1710	activation of factor with mobilities,	[activation of factors with mobilities,]	0.0	5	1	1	1
127643	1710	other immediate-early factor	[other immediate-early factor]	0.0	3	1	1	1
127644	1710	rat neutrophil	[rat neutrophils]	0.0	2	1	1	1
127645	1710	clonogenic capacity of cd34+thy-1+ cell	[clonogenic capacity of CD34+Thy-1+ cells]	0.0	5	1	1	1
127646	1710	haematopoietic line u937 in fibroblast	[haematopoietic lines U937 in fibroblasts]	0.0	5	1	1	1
127647	1710	functional t1/2 of hour	[functional t1/2 of hr]	0.0	4	1	1	1
127648	1710	region of STP-C488	[region of STP-C488]	0.0	3	1	1	1
127649	1710	promoter element of nf-at gene	[promoter elements of NF-AT genes]	0.0	5	1	1	1
127650	1710	second inhibitory pathway	[second inhibitory pathway]	0.0	3	1	1	1
127651	1710	Stat3 recruitment by ligand-induced, docking site	[Stat3 recruitment by ligand-induced, docking sites]	0.0	6	1	1	1
127652	1710	distinct constraint	[distinct constraints]	0.0	2	1	1	1
127653	1710	number of stimuli,	[number of stimuli,]	0.0	3	1	1	1
127654	1710	occur between day	[occurring between day]	0.0	3	1	1	1
127655	1710	aldosterone receptor specificity-conferring mechanism	[aldosterone receptors specificity-conferring mechanism]	0.0	4	1	1	1
127656	1710	sensitivity of monocyte /macrophage	[sensitivity of monocytes /macrophages]	0.0	4	1	1	1
127657	1710	response in leukocyte	[response in leukocytes]	0.0	3	1	1	1
127658	1710	regulation of MHC class ii expression	[regulation of MHC class II expression]	0.0	6	1	1	1
127659	1710	different line	[different lines]	0.0	2	1	1	1
127660	1710	nmol/L to 100 mumol/L)	[nmol/L to 100 mumol/L)]	0.0	4	1	1	1
127661	1710	eems)	[(EMS)]	0.0	1	1	1	1
127662	1710	megakaryocytic gene in Epo-dependent cell line	[megakaryocytic genes in Epo-dependent cell lines]	0.0	6	1	1	1
127663	1710	overexpression of full-length SCL protein	[Overexpression of full-length SCL protein]	0.0	5	1	1	1
127664	1710	14 sle	[14 SLE]	0.0	2	1	1	1
127665	1710	globin gene program	[globin gene program]	0.0	3	1	1	1
127666	1710	activator sequence	[activator sequence]	0.0	2	1	1	1
127667	1710	protein kinase MAPK pathway	[protein kinase MAPK pathway]	0.0	4	1	1	1
127668	1710	end of the cleft	[end of the cleft]	0.0	4	1	1	1
127669	1710	60 base pair	[60 base pairs]	0.0	3	1	1	1
127670	1710	oligodeoxyribonucleotide contain a sp1-box	[oligodeoxyribonucleotide containing an SP1-box]	0.0	4	1	1	1
127671	1710	sp1 phosphorylation	[Sp1 phosphorylation]	0.0	2	1	1	1
127672	1710	hiv-1 repeat transcription in human monocyte	[HIV-1 repeat transcription in human monocytes]	0.0	6	1	1	1
127673	1710	role of alveolar macrophage in activation	[role of alveolar macrophages in activation]	0.0	6	1	1	1
127674	1710	phorbol 12-myristate 13-acetate differentiation	[phorbol 12-myristate 13-acetate differentiation]	0.0	4	1	1	1
127675	1710	CD40 response during stimulation	[CD40 responses during stimulation]	0.0	4	1	1	1
127676	1710	Staurosporine a inhibitor	[Staurosporine a inhibitor]	0.0	3	1	1	1
127677	1710	human arterial endothelial cell	[human arterial endothelial cells]	0.0	4	1	1	1
127678	1710	normalize effect on pattern	[normalizing effect on patterns]	0.0	4	1	1	1
127679	1710	IL-6 abs	[IL-6 Abs]	0.0	2	1	1	1
127680	1710	contain various length	[containing various lengths]	0.0	3	1	1	1
127681	1710	lineage commitment role	[lineage commitment role]	0.0	3	1	1	1
127682	1710	adenocarcinoma chimeric monoclonal antibody ing-1	[adenocarcinoma chimeric monoclonal antibody ING-1]	0.0	5	1	1	1
127683	1710	regulator of apoptosis in vitro.	[regulator of apoptosis in vitro.]	0.0	5	1	1	1
127684	1710	prevent target cell uptake through mcd14	[preventing target cell uptake through mCD14]	0.0	6	1	1	1
127685	1710	dexamethasone (3.4+/-0.3	[dexamethasone (3.4+/-0.3]	0.0	2	1	1	1
127686	1710	253 nucleotide retain promoter activity	[253 nucleotides retaining promoter activity]	0.0	5	1	1	1
127687	1710	important common event	[important common event]	0.0	3	1	1	1
127688	1710	acid (dna) bind protein	[acid (DNA) binding proteins]	0.0	4	1	1	1
127689	1710	clonal cytogenetic change	[clonal cytogenetic change]	0.0	3	1	1	1
127690	1710	sex steroid hormone	[sex steroid hormones]	0.0	3	1	1	1
127691	1710	anti-Z	[anti-Z]	0.0	1	1	1	1
127692	1710	monocyte-derived protein	[monocyte-derived protein]	0.0	2	1	1	1
127693	1710	isoform of wt1	[isoforms of WT1]	0.0	3	1	1	1
127694	1710	protein include the surface	[proteins including the surface]	0.0	4	1	1	1
127695	1710	migrate isoform,	[migrating isoform,]	0.0	2	1	1	1
127696	1710	acute pancreatitis	[acute pancreatitis]	0.0	2	1	1	1
127697	1710	agent phorbol myristate acetate	[agent phorbol myristate acetate]	0.0	4	1	1	1
127698	1710	oct-binding factor 1 a novel protein	[Oct-binding factor 1 a novel protein]	0.0	6	1	1	1
127699	1710	dexamethasone (apparent kd,	[dexamethasone (apparent Kd,]	0.0	3	1	1	1
127700	1710	anti-porcine t-cell immune response	[anti-porcine T-cell immune responses]	0.0	4	1	1	1
127701	1710	molecular weight species of 24	[molecular weight species of 24]	0.0	5	1	1	1
127702	1710	place nucleus	[placed, nucleus]	0.0	2	1	1	1
127703	1710	immunodeficiency virus type hiv-1 progeny	[immunodeficiency virus type HIV-1 progeny]	0.0	5	1	1	1
127704	1710	nuclease S1 protection	[nuclease S1 protection]	0.0	3	1	1	1
127705	1710	crucial MHC class gene factor	[crucial MHC class gene factor]	0.0	5	1	1	1
127706	1710	MTCP1 oncogene	[MTCP1 oncogenes]	0.0	2	1	1	1
127707	1710	two events: the CsA -sensitive translocation	[two events: the CsA -sensitive translocation]	0.0	6	1	1	1
127708	1710	express bcl2	[expressing BCL2]	0.0	2	1	1	1
127709	1710	shift assay EMSA	[shift assay EMSA]	0.0	3	1	1	1
127710	1710	concomitant overexpression	[concomitant overexpression]	0.0	2	1	1	1
127711	1710	unknown cDNA sequence Nov1	[unknown cDNA sequences Nov1]	0.0	4	1	1	1
127712	1710	DNA sequence homology	[DNA sequence homology]	0.0	3	1	1	1
127713	1710	electro mobility shift assay	[electro mobility shift assay]	0.0	4	1	1	1
127714	1710	pattern of cytokine secretion.	[patterns of cytokine secretion.]	0.0	4	1	1	1
127715	1710	Mn sod in monocyte	[Mn SOD in monocytes]	0.0	4	1	1	1
127716	1710	part by import	[part by import]	0.0	3	1	1	1
127717	1710	several transcription factor include nf- il-6	[Several transcription factors including NF- IL-6]	0.0	6	1	1	1
127718	1710	cytotoxicity to monocyte	[cytotoxicity to monocytes]	0.0	3	1	1	1
127719	1710	most pathway	[most pathways]	0.0	2	1	1	1
127720	1710	carboxylesterase gene transcription	[carboxylesterase gene transcription]	0.0	3	1	1	1
127721	1710	occasional aggregate formation	[occasional aggregate formation]	0.0	3	1	1	1
127722	1710	3.8 kb)	[3.8 kb)]	0.0	2	1	1	1
127723	1710	about 25 h	[about 25 h]	0.0	3	1	1	1
127724	1710	xist expression	[XIST expression]	0.0	2	1	1	1
127725	1710	common step, involve a modulation	[common step, involving a modulation]	0.0	5	1	1	1
127726	1710	Rando, O.J., Goldberg, a.l.,	[Rando, O.J., Goldberg, A.L.,]	0.0	4	1	1	1
127727	1710	NK hla-dr alpha mrna expression	[NK HLA-DR alpha mRNA expression]	0.0	5	1	1	1
127728	1710	analysis unique latency	[analysis unique latency]	0.0	3	1	1	1
127729	1710	transactivation of this promoter	[transactivation of these promoters]	0.0	4	1	1	1
127730	1710	two such form lack a portion	[two such forms lacking a portion]	0.0	6	1	1	1
127731	1710	human cell line bf24	[human cell line BF24]	0.0	4	1	1	1
127732	1710	peripheral blood of healthy woman	[peripheral blood of healthy women]	0.0	5	1	1	1
127733	1710	cytokine repertoire	[cytokine repertoire]	0.0	2	1	1	1
127734	1710	transformation of several cell type	[transformation of several cell types]	0.0	5	1	1	1
127735	1710	cd8(-) CD3 thymocyte a role	[CD8(-) CD3 thymocytes a role]	0.0	5	1	1	1
127736	1710	factor pybf	[factor PYBF]	0.0	2	1	1	1
127737	1710	one group	[one group]	0.0	2	2	2	1
127738	1710	LFA-I alpha chain	[LFA-I alpha chain]	0.0	3	1	1	1
127739	1710	independent form	[independent forms]	0.0	2	1	1	1
127740	1710	flexi-12 delivery to acute leukemic blast	[Flexi-12 delivery to acute leukemic blasts]	0.0	6	1	1	1
127741	1710	allele of gata-1	[alleles of GATA-1]	0.0	3	1	1	1
127742	1710	role for transrepression	[role for transrepression]	0.0	3	1	1	1
127743	1710	encode a regulator of myeloid differentiation	[encoding a regulator of myeloid differentiation]	0.0	6	1	1	1
127744	1710	amino acid 425 to 444	[amino acids 425 to 444]	0.0	5	1	1	1
127745	1710	two cleavage product of 68 kda	[two cleavage products of 68 kDa]	0.0	6	1	1	1
127746	1710	cross-linking CD2	[cross-linking CD2]	0.0	2	1	1	1
127747	1710	signal to pbl	[signals to PBL]	0.0	3	1	1	1
127748	1710	augment viral replication	[augmenting viral replication]	0.0	3	1	1	1
127749	1710	portion of the cytoplasmic domain	[portion of the cytoplasmic domain]	0.0	5	1	1	1
127750	1710	p27rex	[p27rex]	0.0	1	1	1	1
127751	1710	h2o2 lipid peroxidation	[H2O2 lipid peroxidation]	0.0	3	1	1	1
127752	1710	peroxisome-proliferator receptor gamma	[peroxisome-proliferator receptor gamma]	0.0	3	1	1	1
127753	1710	expression with kinetic	[expression with kinetics]	0.0	3	1	1	1
127754	1710	cDNA end 5'-race	[cDNA ends 5'-RACE]	0.0	3	1	1	1
127755	1710	therefore, chromosome band 11p15	[Therefore, chromosome bands 11p15]	0.0	4	1	1	1
127756	1710	oncogenic human herpesvirus	[oncogenic human herpesvirus]	0.0	3	1	1	1
127757	1710	concentration in this cells,	[concentration in these cells,]	0.0	4	1	1	1
127758	1710	strike insensitivity of arterial endothelium	[striking insensitivity of arterial endothelium]	0.0	5	1	1	1
127759	1710	mouse Chr	[mouse Chr]	0.0	2	1	1	1
127760	1710	receptor functionality	[receptor functionality]	0.0	2	1	1	1
127761	1710	express a form	[expressing a form]	0.0	3	1	1	1
127762	1710	keratoacanthomas kas	[keratoacanthomas KAs]	0.0	2	1	1	1
127763	1710	majority of lymphoblastic leukemia	[majority of lymphoblastic leukemias]	0.0	4	1	1	1
127764	1710	tetrahydrocortisone	[tetrahydrocortisone]	0.0	1	1	1	1
127765	1710	number of subject	[number of subjects]	0.0	3	1	1	1
127766	1710	survival of month (24-58	[survival of months (24-58]	0.0	4	1	1	1
127767	1710	active component	[active component]	0.0	2	1	1	1
127768	1710	important common event in signalling	[important common event in signalling]	0.0	5	1	1	1
127769	1710	inhibition by a Tat-activated, interferon gene	[Inhibition by a Tat-activated, interferon gene]	0.0	6	1	1	1
127770	1710	receptor alpha-chain il-2r alpha	[receptor alpha-chain IL-2R alpha]	0.0	4	1	1	1
127771	1710	role of PML in hematopoiesis	[role of PML in hematopoiesis]	0.0	5	1	1	1
127772	1710	mature definitive erythroid cell a phenotype	[mature definitive erythroid cells a phenotype]	0.0	6	1	1	1
127773	1710	Drosophila segment	[Drosophila segment]	0.0	2	1	1	1
127774	1710	repress Th1 development distinct	[repressing Th1 development distinct]	0.0	4	1	1	1
127775	1710	nuclear staining for c/ebp beta	[nuclear staining for C/EBP beta]	0.0	5	1	1	1
127776	1710	lymphocyte into tumor tissue	[lymphocytes into tumor tissues]	0.0	4	1	1	1
127777	1710	step,	[step,]	0.0	1	1	1	1
127778	1710	transactivation by Tat	[transactivation by Tat]	0.0	3	1	1	1
127779	1710	two schedule of oral calcitriol	[two schedules of oral calcitriol]	0.0	5	1	1	1
127780	1710	Scholl	[Scholl]	0.0	1	1	1	1
127781	1710	mechanism of a nutritional component	[mechanism of a nutritional component]	0.0	5	1	1	1
127782	1710	cDNA hybridization	[cDNA hybridization]	0.0	2	1	1	1
127783	1710	calcium -dependent gene induction in lymphocyte	[Calcium -dependent gene induction in lymphocytes]	0.0	6	1	1	1
127784	1710	-ribose	[-ribose)]	0.0	1	1	1	1
127785	1710	factor kappab kinase NIK	[factor kappaB kinase NIK]	0.0	4	1	1	1
127786	1710	presence of the box	[presence of the box]	0.0	4	1	1	1
127787	1710	diurnal decline	[diurnal decline]	0.0	2	1	1	1
127788	1710	translocation of VDR	[translocation of VDR]	0.0	3	1	1	1
127789	1710	more infiltrate primary melanoma	[more infiltrating primary melanomas]	0.0	4	1	1	1
127790	1710	monocyte binding to endothelial cell	[monocyte binding to endothelial cells]	0.0	5	1	1	1
127791	1710	METHODS: T cell clone	[METHODS: T cell clones]	0.0	4	1	1	1
127792	1710	virtual abrogation	[virtual abrogation]	0.0	2	1	1	1
127793	1710	rest lymphocyte from blood	[resting lymphocytes from blood]	0.0	4	1	1	1
127794	1710	anti-p-selectin antibody monoclonal antibody mab	[anti-P-selectin antibodies monoclonal antibodies mAbs]	0.0	5	1	1	1
127795	1710	cell from effusion	[cells from effusions]	0.0	3	1	1	1
127796	1710	alpha-helice of class I	[alpha-helices of class I]	0.0	4	1	1	1
127797	1710	treatment of hl-60 subline with interleukin-5	[Treatment of HL-60 sublines with interleukin-5]	0.0	6	1	1	1
127798	1710	local metabolism by normal	[local metabolism by normal]	0.0	4	1	1	1
127799	1710	concentration of the compound	[concentrations of the compound]	0.0	4	1	1	1
127800	1710	preclude the lysis of hpv cell	[precluding the lysis of HPV cells]	0.0	6	1	1	1
127801	1710	camp protein kinase inhibitor	[cAMP protein kinase inhibitor]	0.0	4	1	1	1
127802	1710	evidence of ig gene hypermutation	[evidence of Ig gene hypermutation]	0.0	5	1	1	1
127803	1710	deletion of the -70 region	[Deletion of the -70 regions]	0.0	5	1	1	1
127804	1710	sequence corresponding	[sequences corresponding]	0.0	2	1	1	1
127805	1710	intense exercise in human	[intense exercise in humans]	0.0	4	1	1	1
127806	1710	pathogenesis of neoplasia	[pathogenesis of neoplasia]	0.0	3	1	1	1
127807	1710	similar comparison	[similar comparison]	0.0	2	1	1	1
127808	1710	specific pkc inhibition	[specific PKC inhibition]	0.0	3	1	1	1
127809	1710	kinase upstream	[kinase upstream]	0.0	2	1	1	1
127810	1710	lineage-dependent maintenance	[lineage-dependent maintenance]	0.0	2	1	1	1
127811	1710	family with a proband	[families with an proband]	0.0	4	1	1	1
127812	1710	population of hematopoietic progenitor /precursor	[populations of hematopoietic progenitors /precursors]	0.0	5	1	1	1
127813	1710	untransformed T	[untransformed T]	0.0	2	1	1	1
127814	1710	comparison to activator	[comparison to activators]	0.0	3	1	1	1
127815	1710	form in b cell	[form in B cells]	0.0	4	1	1	1
127816	1710	characterization of expression	[Characterization of expression]	0.0	3	1	1	1
127817	1710	contain the negative element	[containing the negative elements]	0.0	4	1	1	1
127818	1710	significant amount of e2	[significant amounts of E2]	0.0	4	1	1	1
127819	1710	binding sequence for transcription factor	[binding sequences for transcription factors]	0.0	5	1	1	1
127820	1710	immunodeficiency virus hiv individual	[immunodeficiency virus HIV individuals]	0.0	4	1	1	1
127821	1710	tax protein a potent transactivator	[Tax protein a potent transactivator]	0.0	5	1	1	1
127822	1710	ap1 complex in monocyte	[AP1 complex in monocytes]	0.0	4	1	1	1
127823	1710	Complementary DNA cDNA	[Complementary DNA cDNA]	0.0	3	1	1	1
127824	1710	two synthetic nonselective RAR ligand	[two synthetic nonselective RAR ligands]	0.0	5	1	1	1
127825	1710	intron/exon junctions, the region	[intron/exon junctions, the region]	0.0	4	1	1	1
127826	1710	stat1 gene transcription	[STAT1 gene transcription]	0.0	3	1	1	1
127827	1710	modular structure of Oct-2a	[modular structure of Oct-2a]	0.0	4	1	1	1
127828	1710	stimulation by agents,	[stimulation by agents,]	0.0	3	1	1	1
127829	1710	novel protein elf-1	[novel protein Elf-1]	0.0	3	1	1	1
127830	1710	even after 12 hour	[even after 12 hr]	0.0	4	1	1	1
127831	1710	pre-B cell-specific gene	[pre-B cell-specific genes]	0.0	3	1	1	1
127832	1710	nucleolar protein	[nucleolar protein]	0.0	2	1	1	1
127833	1710	important morphogen	[important morphogen]	0.0	2	1	1	1
127834	1710	candidate gene factor	[candidate genes factor]	0.0	3	1	1	1
127835	1710	expression of t-cell-specific transcription factor	[expression of T-cell-specific transcription factors]	0.0	5	1	1	1
127836	1710	response to IL-12	[response to IL-12]	0.0	3	1	1	1
127837	1710	c/ebp beta abs	[C/EBP beta Abs]	0.0	3	1	1	1
127838	1710	cell -specific transcription factor	[cell -specific transcription factors]	0.0	4	1	1	1
127839	1710	potential in hiv-1 patient	[potential in HIV-1 patients]	0.0	4	1	1	1
127840	1710	transfer to in vitro culture	[transfer to in vitro culture]	0.0	5	1	1	1
127841	1710	evidence for signal pathway	[Evidence for signaling pathways]	0.0	4	1	1	1
127842	1710	apoptosis in t-cell-line-expressing wild-type CD4 receptor	[apoptosis in T-cell-line-expressing wild-type CD4 receptors]	0.0	6	1	1	1
127843	1710	CIITA overexpression	[CIITA overexpression]	0.0	2	1	1	1
127844	1710	-independent transactivation in cell	[-independent transactivation in cells]	0.0	4	1	1	1
127845	1710	Holley-Guthrie,	[Holley-Guthrie,]	0.0	1	1	1	1
127846	1710	group of 60 subject	[group of 60 subjects]	0.0	4	1	1	1
127847	1710	respect little to no binding	[respect little to no binding]	0.0	5	1	1	1
127848	1710	two cell-surface isoform of cd43	[two cell-surface isoforms of CD43]	0.0	5	1	1	1
127849	1710	assay use ligand	[assays using ligands]	0.0	3	1	1	1
127850	1710	variance with the transfection	[variance with the transfection]	0.0	4	1	1	1
127851	1710	route of exposure, animal species	[route of exposure, animal species]	0.0	5	1	1	1
127852	1710	10 healthy individual as control	[10 healthy individuals as control]	0.0	5	1	1	1
127853	1710	CD3 ab	[CD3 Ab]	0.0	2	1	1	1
127854	1710	action of D3 (1325(oh)2d3)	[actions of D3 (1,25(OH)2D3)]	0.0	4	1	1	1
127855	1710	gene in human T lymphocyte	[genes in human T lymphocytes]	0.0	5	1	1	1
127856	1710	strategy manipulate pathological immune response	[strategies manipulating pathological immune responses]	0.0	5	1	1	1
127857	1710	complex with tlr2	[complexes with TLR2]	0.0	3	1	1	1
127858	1710	factor kappa B	[Factor kappa B]	0.0	3	1	1	1
127859	1710	activate function	[activating function]	0.0	2	1	1	1
127860	1710	continue for 24 hours.	[continuing for 24 hours.]	0.0	4	1	1	1
127861	1710	show cross-reactivity	[showing cross-reactivity]	0.0	2	1	1	1
127862	1710	monocytic differentiation of human cell	[monocytic differentiation of human cells]	0.0	5	1	1	1
127863	1710	chemotactic adhesive ICAM-1 property	[chemotactic adhesive ICAM-1 properties]	0.0	4	1	1	1
127864	1710	BZLF1 component	[BZLF1 component]	0.0	2	1	1	1
127865	1710	dr-nm23 in hematopoiesis	[DR-nm23 in hematopoiesis]	0.0	3	1	1	1
127866	1710	antigenic peptide in the endoplasmic reticulum	[antigenic peptides in the endoplasmic reticulum]	0.0	6	1	1	1
127867	1710	evidence of a role	[evidence of a role]	0.0	4	1	1	1
127868	1710	[Noteborn J.	[[Noteborn J.]	0.0	2	1	1	1
127869	1710	protein interaction with CREB	[protein interactions with CREB]	0.0	4	1	1	1
127870	1710	sialylated tetra-	[sialylated tetra-]	0.0	2	1	1	1
127871	1710	circulate leukocyte of donor	[circulating leukocytes of donors]	0.0	4	1	1	1
127872	1710	reactivity at least as high	[reactivities at least as high]	0.0	5	1	1	1
127873	1710	one cause	[one cause]	0.0	2	2	2	1
127874	1710	cell carcinoma use immunohistochemistry	[cell carcinomas using immunohistochemistry]	0.0	4	1	1	1
127875	1710	close homologue,	[close homologue,]	0.0	2	1	1	1
127876	1710	anti- hrbc antibody production	[anti- HRBC antibody production]	0.0	4	1	1	1
127877	1710	environmental factors, in proinflammatory cytokine	[environmental factors, in proinflammatory cytokines]	0.0	5	1	1	1
127878	1710	immunodeficiency due to binding	[immunodeficiency due to binding]	0.0	4	1	1	1
127879	1710	relation to class	[relation to classes]	0.0	3	1	1	1
127880	1710	significant inactivation	[significant inactivation]	0.0	2	1	1	1
127881	1710	specific human inflammatory pathology	[specific human inflammatory pathologies]	0.0	4	1	1	1
127882	1710	use a supernatant	[using a supernatant]	0.0	3	1	1	1
127883	1710	il-2 secretion by cell	[IL-2 secretion by cells]	0.0	4	1	1	1
127884	1710	twenty-two patient with restrictive anorexia nervosa	[Twenty-two patients with restrictive anorexia nervosa]	0.0	6	1	1	1
127885	1710	activity transactivation	[activities transactivation]	0.0	2	1	1	1
127886	1710	nf-kappab transcriptional activity	[NF-kappaB transcriptional activity]	0.0	3	1	1	1
127887	1710	Mutated human ciita construct	[Mutated human CIITA constructs]	0.0	4	1	1	1
127888	1710	subject (p	[subjects (P]	0.0	2	2	2	1
127889	1710	membrane protein 1 promoter	[membrane protein 1 promoter]	0.0	4	1	1	1
127890	1710	5' deletion derivative	[5' deletion derivatives]	0.0	3	1	1	1
127891	1710	dual effect inhibition	[dual effects inhibition]	0.0	3	1	1	1
127892	1710	1 growth	[1 growth]	0.0	2	2	2	1
127893	1710	ss rbc adhesion	[SS RBC adhesion]	0.0	3	1	1	1
127894	1710	transformation of a precursor cell	[transformation of a precursor cell]	0.0	5	1	1	1
127895	1710	elevation of intracellular calcium concentration	[elevation of intracellular calcium concentrations]	0.0	5	1	1	1
127896	1710	small tissue sample	[small tissue samples]	0.0	3	1	1	1
127897	1710	cell wall of bacterium	[cell wall of bacteria]	0.0	4	1	1	1
127898	1710	event of ZAP-70	[events of ZAP-70]	0.0	3	1	1	1
127899	1710	signal function similar to il-6r	[signaling functions similar to IL-6R]	0.0	5	1	1	1
127900	1710	embryonic kidney	[embryonic kidney]	0.0	2	1	1	1
127901	1710	corresponding mrna	[corresponding mRNA]	0.0	2	1	1	1
127902	1710	than b cell	[than B cells]	0.0	3	1	1	1
127903	1710	adult hematopoietic cell factor pybf	[adult hematopoietic cells factor PYBF]	0.0	5	1	1	1
127904	1710	prednisolone therapy	[prednisolone therapy]	0.0	2	1	1	1
127905	1710	induction through nf-kappab in t-cell transfectant	[Induction through NF-kappaB in T-cell transfectants]	0.0	6	1	1	1
127906	1710	migration rate of leukocyte	[migration rate of leukocytes]	0.0	4	1	1	1
127907	1710	great than 10(-6) mol/L	[greater than 10(-6) mol/L]	0.0	4	1	1	1
127908	1710	bioactivation of sulphamethoxazole to chemically-reactive metabolite	[Bioactivation of sulphamethoxazole to chemically-reactive metabolites]	0.0	6	1	1	1
127909	1710	Differential induction of interferon	[Differential induction of interferon]	0.0	4	1	1	1
127910	1710	subunit of this complex, gpiiia	[subunit of this complex, GPIIIa]	0.0	5	1	1	1
127911	1710	affinity (dissociation constant	[affinity (dissociation constant]	0.0	3	1	1	1
127912	1710	potential role of hsf1	[potential role of HSF1]	0.0	4	1	1	1
127913	1710	prescription Liuwei Dihuang Pills LDP	[prescription Liuwei Dihuang Pills LDP]	0.0	5	1	1	1
127914	1710	polyadenylylation	[polyadenylylation]	0.0	1	1	1	1
127915	1710	3-deazaadenosine a inhibitor for s-adenosylhomocysteine hydrolase	[3-deazaadenosine a inhibitor for S-adenosylhomocysteine hydrolase]	0.0	6	1	1	1
127916	1710	include the tyrosine phosphorylation	[including the tyrosine phosphorylation]	0.0	4	1	1	1
127917	1710	tuberous sclerosis complex	[tuberous sclerosis complex]	0.0	3	1	1	1
127918	1710	level of response	[levels of response]	0.0	3	1	1	1
127919	1710	optimal activity of ifn-gamma	[optimal activity of IFN-gamma]	0.0	4	1	1	1
127920	1710	residue 122 to 293	[residues 122 to 293]	0.0	4	1	1	1
127921	1710	translocation mechanism	[translocation mechanism]	0.0	2	1	1	1
127922	1710	evidence for a preferential coupling	[evidence for a preferential coupling]	0.0	5	1	1	1
127923	1710	salicylic acid inhibition	[salicylic acid inhibition]	0.0	3	1	1	1
127924	1710	other cDNA cloning strategy	[other cDNA cloning strategies]	0.0	4	1	1	1
127925	1710	number of granulocyte	[numbers of granulocytes]	0.0	3	1	1	1
127926	1710	regulator of the proliferation	[regulators of the proliferation]	0.0	4	1	1	1
127927	1710	only the x1- box	[only the X1- boxes]	0.0	4	1	1	1
127928	1710	alpha globin element HS-40	[alpha globin element HS-40]	0.0	4	2	2	1
127929	1710	protein dimerization domain of HLF	[protein dimerization domain of HLF]	0.0	5	1	1	1
127930	1710	subsequent transformation	[subsequent transformation]	0.0	2	1	1	1
127931	1710	independence despite a number	[independence despite a number]	0.0	4	1	1	1
127932	1710	loss of potential in response	[loss of potential in response]	0.0	5	1	1	1
127933	1710	characterization binding of tax to element	[characterization Binding of Tax to element]	0.0	6	1	1	1
127934	1710	sensitivity against enzyme inhibitor	[Sensitivity against enzyme inhibitors]	0.0	4	1	1	1
127935	1710	signal originate	[signals originating]	0.0	2	1	1	1
127936	1710	hormone-activated binding to regulatory region	[hormone-activated binding to regulatory regions]	0.0	5	1	1	1
127937	1710	PBMC from child with infection	[PBMC from children with infection]	0.0	5	2	2	1
127938	1710	sensitive pathway distinct	[sensitive pathway distinct]	0.0	3	1	1	1
127939	1710	tar independent activation	[TAR independent activation]	0.0	3	1	1	1
127940	1710	IL-8 a factor for neutrophil granulocyte	[IL-8 a factor for neutrophil granulocytes]	0.0	6	1	1	1
127941	1710	incubation ultra-violet irradiation.	[incubation UV irradiation.]	0.0	3	1	1	1
127942	1710	include cell from individual	[including cells from individuals]	0.0	4	1	1	1
127943	1710	lack of activation of nf-at	[Lack of activation of NF-AT]	0.0	5	1	1	1
127944	1710	significant finding	[significant finding]	0.0	2	1	1	1
127945	1710	role of reactive oxygen intermediate	[role of reactive oxygen intermediates]	0.0	5	1	1	1
127946	1710	il-5, tnf-alpha	[IL-5, TNF-alpha]	0.0	2	1	1	1
127947	1710	tumor-draining lymph node	[tumor-draining lymph node]	0.0	3	1	1	1
127948	1710	(+/-	[(+/-]	0.0	1	1	1	1
127949	1710	isomorph by two-dimensional gel analysis	[isomorphs by two-dimensional gel analysis]	0.0	5	1	1	1
127950	1710	increase awareness	[increasing awareness]	0.0	2	1	1	1
127951	1710	expression of hb24	[expression of HB24]	0.0	3	1	1	1
127952	1710	word oligopeptide	[words oligopeptides]	0.0	2	1	1	1
127953	1710	distinct region important, respectively, for recruitment	[distinct regions important, respectively, for recruitment]	0.0	6	1	1	1
127954	1710	profile, reduce the response	[profile, reducing the response]	0.0	4	1	1	1
127955	1710	binding profile for steroid hormone	[binding profile for steroid hormones]	0.0	5	1	1	1
127956	1710	maximum value at hour	[maximum value at hour]	0.0	4	1	1	1
127957	1710	1,25-dihydroxyvitamin D3 calcitriol determination	[1,25-dihydroxyvitamin D3 calcitriol determination]	0.0	4	1	1	1
127958	1710	erythroid stage-specific factor-DNA complex	[erythroid stage-specific factor-DNA complexes]	0.0	4	1	1	1
127959	1710	low apparent dissociation constant	[low apparent dissociation constant]	0.0	4	1	1	1
127960	1710	role of oxygen intermediate	[role of oxygen intermediates]	0.0	4	1	1	1
127961	1710	immunoprecipitation of the gp extract	[Immunoprecipitation of the gp extracts]	0.0	5	1	1	1
127962	1710	decrease nf-at accumulation	[decreasing NF-AT accumulation]	0.0	3	1	1	1
127963	1710	outgrowth of ad5e1a tumor	[outgrowth of Ad5E1A tumors]	0.0	4	1	1	1
127964	1710	disease of patient with myeloid leukemia	[disease of patients with myeloid leukemia]	0.0	6	1	1	1
127965	1710	exposure to CD40L together with il-4	[exposure to CD40L together with IL-4]	0.0	6	1	1	1
127966	1710	inhibitory activity in HeLa cell	[inhibitory activity in HeLa cells]	0.0	5	1	1	1
127967	1710	expression (maximal	[expression (maximal]	0.0	2	1	1	1
127968	1710	agent, alpha,25-dihydroxycholecalciferol dhcc	[agent, alpha,25-dihydroxycholecalciferol DHCC]	0.0	3	1	1	1
127969	1710	blood of volunteer	[blood of volunteers]	0.0	3	1	1	1
127970	1710	motif of the TNF promoter	[motif of the TNF promoter]	0.0	5	1	1	1
127971	1710	role of regulation	[Role of regulation]	0.0	3	1	1	1
127972	1710	egr-1 promoter fragment	[EGR-1 promoter fragments]	0.0	3	1	1	1
127973	1710	express high level of bcl-2	[expressing high levels of Bcl-2]	0.0	5	1	1	1
127974	1710	t-cell immune response	[T-cell immune responses]	0.0	3	1	1	1
127975	1710	inhibition of cyclooxygenase-2 expression	[Inhibition of cyclooxygenase-2 expression]	0.0	4	1	1	1
127976	1710	dominant mutant of traf2	[dominant mutant of TRAF2]	0.0	4	1	1	1
127977	1710	2 subject in patient	[2 subjects in patients]	0.0	4	1	1	1
127978	1710	calcemic effect in	[calcemic effects in]	0.0	3	1	1	1
127979	1710	negative expression vector	[negative expression vectors]	0.0	3	1	1	1
127980	1710	useful system	[useful system]	0.0	2	1	1	1
127981	1710	glutaminyl-ttg substrate	[glutaminyl-tTG substrates]	0.0	2	1	1	1
127982	1710	complex with AMP response protein CREB	[complexes with AMP response protein CREB]	0.0	6	1	1	1
127983	1710	preincubation of endothelial cell	[Preincubation of endothelial cells]	0.0	4	1	1	1
127984	1710	adenovirus type e1a-region Ad5E1A234-243	[adenovirus type E1A-region Ad5E1A234-243]	0.0	4	1	1	1
127985	1710	role of the transcriptional ap-1	[role of the transcriptional AP-1]	0.0	5	1	1	1
127986	1710	regulation of coproporphyrinogen oxidase gene	[regulation of coproporphyrinogen oxidase gene]	0.0	5	1	1	1
127987	1710	extracellular ca2+	[extracellular Ca2+]	0.0	2	1	1	1
127988	1710	Iepsilon promoter	[Iepsilon promoter]	0.0	2	1	1	1
127989	1710	element from bp -267	[element from bp -267]	0.0	4	1	1	1
127990	1710	two proteins; type a transcript code	[two proteins; type A transcripts code]	0.0	6	1	1	1
127991	1710	contain wild-type kappab site	[containing wild-type kappaB sites]	0.0	4	1	1	1
127992	1710	12 reactive follicular hyperplasia fh	[12 reactive follicular hyperplasia FH]	0.0	5	1	1	1
127993	1710	level of progeny virion	[level of progeny virions]	0.0	4	1	1	1
127994	1710	segregation of autosome 11	[segregation of autosome 11]	0.0	4	1	1	1
127995	1710	pregnant woman (11 first, second	[pregnant women (11 first, second]	0.0	5	1	1	1
127996	1710	10 pair of grade astrocytomas	[10 pairs of grade astrocytomas]	0.0	5	1	1	1
127997	1710	redundancy in coactivator	[redundancy in coactivators]	0.0	3	1	1	1
127998	1710	tissue lymphoma	[tissue lymphoma]	0.0	2	1	1	1
127999	1710	marker of other, nearby polymorphism	[marker(s) of other, nearby polymorphisms]	0.0	5	1	1	1
128000	1710	testing of a set	[testing of a set]	0.0	4	1	1	1
128001	1710	1.16 units, p 0.01, young	[1.16 units, P 0.01, young]	0.0	5	1	1	1
128002	1710	effect on the growth	[effect on the growth]	0.0	4	1	1	1
128003	1710	fresh cell whatever stage of differentiation,	[fresh cells whatever stage of differentiation,]	0.0	6	1	1	1
128004	1710	RESULTS: inhibition	[RESULTS: inhibition]	0.0	2	1	1	1
128005	1710	glucocorticoid receptor content	[glucocorticoid receptor content]	0.0	3	1	1	1
128006	1710	treatment of lymphoproliferative disorder	[treatment of lymphoproliferative disorders]	0.0	4	1	1	1
128007	1710	rapid expansion suitable	[rapid expansion suitable]	0.0	3	1	1	1
128008	1710	cd4(+) T lymphocyte	[CD4(+) T lymphocytes]	0.0	3	1	1	1
128009	1710	leukocyte endothelial-leukocyte adhesion molecule	[leukocytes endothelial-leukocyte adhesion molecule]	0.0	4	1	1	1
128010	1710	kappa b alpha /mad-3 mrna	[kappa B alpha /MAD-3 mRNA]	0.0	5	1	1	1
128011	1710	oleic	[Oleic]	0.0	1	2	2	1
128012	1710	expression activator protein-1 factor nf-il6	[expression activator protein-1 factor NF-IL6]	0.0	5	1	1	1
128013	1710	overexpression of dominant form	[Overexpression of dominant forms]	0.0	4	1	1	1
128014	1710	extinction of gene expression	[Extinction of gene expression]	0.0	4	1	1	1
128015	1710	bzlf1 transactivator protein	[BZLF1 transactivator protein]	0.0	3	1	1	1
128016	1710	hypercalciuric patient	[hypercalciuric patients]	0.0	2	1	1	1
128017	1710	binding of low-density lipoprotein	[binding of low-density lipoprotein]	0.0	4	1	1	1
128018	1710	t-cell-specific transcriptional regulation	[T-cell-specific transcriptional regulation]	0.0	3	1	1	1
128019	1710	beta-promoter activity	[beta-promoter activity]	0.0	2	1	1	1
128020	1710	two nuclear factor nf-il6 (position -153	[Two nuclear factor NF-IL6 (positions -153]	0.0	6	1	1	1
128021	1710	peptidyl cis-tran isomerase activity	[peptidyl cis-trans isomerase activities]	0.0	4	1	1	1
128022	1710	1beta,25-dihydroxyvitamin D3	[1beta,25-dihydroxyvitamin D3]	0.0	2	1	1	1
128023	1710	exposure to low shear	[exposure to low shear]	0.0	4	1	1	1
128024	1710	virus contain the cytomegalovirus immediate-early enhancer	[Viruses containing the cytomegalovirus immediate-early enhancer]	0.0	6	1	1	1
128025	1710	CD30 monoclonal antibody,	[CD30 monoclonal antibody,]	0.0	3	1	1	1
128026	1710	tumour suppressor gene fhit	[tumour suppressor gene FHIT]	0.0	4	1	1	1
128027	1710	subject type ii receptor	[subjects Type II receptors]	0.0	4	1	1	1
128028	1710	contain the c-fo promoter fc3	[containing the c-fos promoter FC3]	0.0	5	1	1	1
128029	1710	use ng/ml of il-10	[using ng/ml of IL-10]	0.0	4	1	1	1
128030	1710	cell in the pathogenesis	[cells in the pathogenesis]	0.0	4	1	1	1
128031	1710	lymphoid-restricted gene in differentiation	[lymphoid-restricted gene in differentiation]	0.0	4	1	1	1
128032	1710	activation-dependent expression	[activation-dependent expression]	0.0	2	1	1	1
128033	1710	analog of OspA	[analogs of OspA]	0.0	3	1	1	1
128034	1710	ceramide analog	[ceramide analog]	0.0	2	1	1	1
128035	1710	mol/microgram rna corresponding	[mol/microgram RNA corresponding]	0.0	3	1	1	1
128036	1710	number of integration sites,	[number of integration sites,]	0.0	4	1	1	1
128037	1710	expression of the element	[expression of the elements]	0.0	4	1	1	1
128038	1710	Sjogren' antigen la(ssb)	[Sjogren's antigen La(SSB)]	0.0	3	1	1	1
128039	1710	pituitary adrenocorticotropic hormone acth release	[pituitary adrenocorticotropic hormone ACTH release]	0.0	5	1	1	1
128040	1710	GR domain	[GR domain]	0.0	2	1	1	1
128041	1710	genomic alteration	[genomic alteration]	0.0	2	1	1	1
128042	1710	role of distal promoter sequence	[role of distal promoter sequences]	0.0	5	1	1	1
128043	1710	agent, alpha,25-dihydroxycholecalciferol	[agent, alpha,25-dihydroxycholecalciferol]	0.0	2	1	1	1
128044	1710	suggest a negative domain	[suggesting a negative domain]	0.0	4	1	1	1
128045	1710	activation by beta-phorbol	[activation by beta-phorbol]	0.0	3	1	1	1
128046	1710	significant change of binding	[significant changes of binding]	0.0	4	1	1	1
128047	1710	dna-binding activity NFkappaB	[DNA-binding activities NFkappaB]	0.0	3	1	1	1
128048	1710	array of cellular response	[array of cellular responses]	0.0	4	1	1	1
128049	1710	assay with wild-type form of EBF	[assays with wild-type forms of EBF]	0.0	6	1	1	1
128050	1710	class ii transcriptional mutant cell line	[class II transcriptional mutant cell lines]	0.0	6	1	1	1
128051	1710	cd34+ progenitor cell HPC	[CD34+ progenitor cells HPC]	0.0	4	1	1	1
128052	1710	status of knowledge concern	[status of knowledge concerning]	0.0	4	1	1	1
128053	1710	(1) part of the anti-atherogenic effect	[(1) part of the anti-atherogenic effect]	0.0	6	1	1	1
128054	1710	truncation mutant of LEF-1	[truncation mutant of LEF-1]	0.0	4	1	1	1
128055	1710	arterial cell ec	[arterial cells EC]	0.0	3	1	1	1
128056	1710	element for the regulation	[element for the regulation]	0.0	4	1	1	1
128057	1710	obvious sequence homology	[obvious sequence homology]	0.0	3	1	1	1
128058	1710	decrease in il-2r alpha	[decrease in IL-2R alpha]	0.0	4	1	1	1
128059	1710	base pair (bp))	[base pairs (bp))]	0.0	3	1	1	1
128060	1710	many messenger	[many messengers]	0.0	2	1	1	1
128061	1710	replicative phenotype.	[replicative phenotype.]	0.0	2	1	1	1
128062	1710	CEM-ICR	[CEM-ICR]	0.0	1	1	1	1
128063	1710	ap-1 activity of nuclear protein	[AP-1 activity of nuclear proteins]	0.0	5	1	1	1
128064	1710	abnormal expression in Hox11 null mouse	[abnormal expression in Hox11 null mice]	0.0	6	1	1	1
128065	1710	nuclear abundance of a VDR	[nuclear abundance of a VDR]	0.0	5	1	1	1
128066	1710	internal standard	[internal standard]	0.0	2	1	1	1
128067	1710	wide spectrum of level	[wide spectrum of levels]	0.0	4	1	1	1
128068	1710	show variable degree	[showing variable degrees]	0.0	3	1	1	1
128069	1710	diverse clinical syndrome	[diverse clinical syndromes]	0.0	3	1	1	1
128070	1710	signal capability	[signaling capabilities]	0.0	2	1	1	1
128071	1710	EBV immediate-early gene transcript	[EBV immediate-early gene transcripts]	0.0	4	1	1	1
128072	1710	adaptor function of subunit	[adaptor function of subunit]	0.0	4	1	1	1
128073	1710	single protein	[single protein]	0.0	2	1	1	1
128074	1710	study the the gene	[studying the the genes]	0.0	4	1	1	1
128075	1710	b1/ p105	[B1/ p105]	0.0	2	1	1	1
128076	1710	molecule kappa b	[molecule kappa B]	0.0	3	1	1	1
128077	1710	b activity in sle patient	[B activity in SLE patients]	0.0	5	1	1	1
128078	1710	assay use FUra	[assay using FUra]	0.0	3	1	1	1
128079	1710	expression of a single viral protein	[expression of a single viral protein]	0.0	6	1	1	1
128080	1710	progression to event	[progression to events]	0.0	3	1	1	1
128081	1710	of lap much	[of LAP much]	0.0	3	1	1	1
128082	1710	regulate signal pathway	[regulating signaling pathways]	0.0	3	1	1	1
128083	1710	contain regulatory sequence from gene	[containing regulatory sequences from genes]	0.0	5	1	1	1
128084	1710	very potent agonist	[very potent agonists]	0.0	3	1	1	1
128085	1710	protein kinase family	[protein kinase family]	0.0	3	2	2	1
128086	1710	similar mrna levels,	[similar mRNA levels,]	0.0	3	1	1	1
128087	1710	hormone on tumor cell cytostasis	[hormones on tumor cell cytostasis]	0.0	5	1	1	1
128088	1710	human tsh receptor cDNA probe	[human TSH receptor cDNA probe]	0.0	5	1	1	1
128089	1710	rar-rxr response element	[RAR-RXR response elements]	0.0	3	1	1	1
128090	1710	high dose p50 on tissue oligonucleotide	[High doses p50 on tissue oligonucleotide]	0.0	6	1	1	1
128091	1710	cytomegalovirus early gene	[Cytomegalovirus early genes]	0.0	3	1	1	1
128092	1710	increase in gr protein	[increase in GR protein]	0.0	4	1	1	1
128093	1710	3 different factor	[3 different factors]	0.0	3	1	1	1
128094	1710	N-terminal domain with sh2 domain-binding motif	[N-terminal domains with SH2 domain-binding motifs]	0.0	6	1	1	1
128095	1710	gata1 induction	[GATA1 induction]	0.0	2	1	1	1
128096	1710	protein lead to t-cell activation	[proteins leading to T-cell activation]	0.0	5	1	1	1
128097	1710	many disorder a problem	[many disorders a problem]	0.0	4	1	1	1
128098	1710	block in granulocyte maturation	[block in granulocyte maturation]	0.0	4	1	1	1
128099	1710	rapid phosphorylation the three	[rapid phosphorylation the three]	0.0	4	1	1	1
128100	1710	glucocorticoid hormone inhibition	[glucocorticoid hormone inhibition]	0.0	3	1	1	1
128101	1710	thymic lymphoma-derived hybridoma	[thymic lymphoma-derived hybridoma]	0.0	3	1	1	1
128102	1710	4 subject	[4 subjects]	0.0	2	1	1	1
128103	1710	pathological response	[pathological responses]	0.0	2	1	1	1
128104	1710	macrophage gene regulation	[macrophage gene regulation]	0.0	3	1	1	1
128105	1710	kda labile repressor protein	[kDA labile repressor protein]	0.0	4	1	1	1
128106	1710	2 h in this cell	[2 h in these cells]	0.0	5	1	1	1
128107	1710	Nuclear association of a transcription factor	[Nuclear association of a transcription factor]	0.0	6	1	1	1
128108	1710	modality	[modality]	0.0	1	1	1	1
128109	1710	Interleukin-12 a heterodimeric cytokine	[Interleukin-12 a heterodimeric cytokine]	0.0	4	1	1	1
128110	1710	Differential induction 10 differentiation	[Differential induction 10 differentiation]	0.0	4	1	1	1
128111	1710	several KV channel	[several KV channels]	0.0	3	1	1	1
128112	1710	human zeta globin promoter	[human zeta globin promoter]	0.0	4	1	1	1
128113	1710	C/EBPbeta Jurkat t-cell line	[C/EBPbeta Jurkat T-cell line]	0.0	4	1	1	1
128114	1710	VDR message	[VDR message]	0.0	2	1	1	1
128115	1710	promoter of CIITA	[promoter of CIITA]	0.0	3	1	1	1
128116	1710	acid during neutrophil maturation	[acid during neutrophil maturation]	0.0	4	1	1	1
128117	1710	human pbl	[human PBL]	0.0	2	1	1	1
128118	1710	level of virus,	[level of virus,]	0.0	3	1	1	1
128119	1710	are: (memory) T cell	[are: (memory) T cells]	0.0	4	1	1	1
128120	1710	favorable course (p chi2	[favorable course (P chi2]	0.0	4	1	1	1
128121	1710	receptors/cell,	[receptors/cell,]	0.0	1	1	1	1
128122	1710	pseudo-hypoaldosteronism level of aldosterone receptor	[pseudo-hypoaldosteronism level of aldosterone receptors]	0.0	5	1	1	1
128123	1710	protein expression by IFN-alpha	[protein expression by IFN-alpha]	0.0	4	1	1	1
128124	1710	burst-form units-erythroid	[burst-forming units-erythroid]	0.0	2	1	1	1
128125	1710	Burkitt' lymphoma cell lines,	[Burkitt's lymphoma cell lines,]	0.0	4	1	1	1
128126	1710	receptors/cell;	[receptors/cell;]	0.0	1	1	1	1
128127	1710	anti-cd3 antibody t-cell proliferation	[anti-CD3 antibody T-cell proliferation]	0.0	4	1	1	1
128128	1710	gdsp on weight	[GDSP on weight]	0.0	3	1	1	1
128129	1710	class ii histocompatibility promoter	[class II histocompatibility promoters]	0.0	4	2	2	1
128130	1710	simulate insufficiency	[simulating insufficiency]	0.0	2	1	1	1
128131	1710	differentiation in cell line tested;	[differentiation in cell lines tested;]	0.0	5	1	1	1
128132	1710	potency of analogue	[potency of analogues]	0.0	3	1	1	1
128133	1710	320-kda species	[320-kDa species]	0.0	2	1	1	1
128134	1710	Furthermore, concentration	[Furthermore, concentrations]	0.0	2	1	1	1
128135	1710	10 patient with receptor affinity	[10 patients with receptor affinity]	0.0	5	1	1	1
128136	1710	volunteer (86 man	[volunteers (86 men]	0.0	3	1	1	1
128137	1710	proviral clone	[proviral clones]	0.0	2	1	1	1
128138	1710	normal cellular c-myb	[normal cellular c-myb]	0.0	3	1	1	1
128139	1710	individual as normal control	[individuals as normal control]	0.0	4	1	1	1
128140	1710	cytomegalovirus ul44	[cytomegalovirus UL44]	0.0	2	1	1	1
128141	1710	NF-IL6 mrna	[NF-IL6 mRNA]	0.0	2	1	1	1
128142	1710	rationale	[rationale]	0.0	1	1	1	1
128143	1710	putative novel loci relevant to pel	[putative novel loci relevant to PEL]	0.0	6	1	1	1
128144	1710	understanding with emphasis	[understanding with emphasis]	0.0	3	1	1	1
128145	1710	(a) of -resistant variant	[(A) of -resistant variants]	0.0	4	1	1	1
128146	1710	role for change	[role for changes]	0.0	3	1	1	1
128147	1710	well-known consequence	[well-known consequences]	0.0	2	1	1	1
128148	1710	GCR-beta cell in peripheral blood	[GCR-beta cells in peripheral blood]	0.0	5	1	1	1
128149	1710	second allele	[second allele]	0.0	2	1	1	1
128150	1710	addition to a effect	[addition to a effect]	0.0	4	1	1	1
128151	1710	translocation with one	[translocations with one]	0.0	3	1	1	1
128152	1710	activity of NF-kappa b complex	[activity of NF-kappa B complex]	0.0	5	1	1	1
128153	1710	abnormality, the majority related	[abnormality, the majority related]	0.0	4	1	1	1
128154	1710	activity of member	[activity of members]	0.0	3	1	1	1
128155	1710	subpopulation express the CD4 receptor	[subpopulation expressing the CD4 receptor]	0.0	5	1	1	1
128156	1710	oligonucleotide type	[oligonucleotide typing]	0.0	2	1	1	1
128157	1710	cotransfection of a form	[Cotransfection of a form]	0.0	4	1	1	1
128158	1710	viability and/or	[viability and/or]	0.0	2	1	1	1
128159	1710	secretion of macrophage	[secretion of macrophage]	0.0	3	1	1	1
128160	1710	affinity for the groove	[affinity for the groove]	0.0	4	1	1	1
128161	1710	mature monocytic cell	[mature monocytic cells]	0.0	3	1	1	1
128162	1710	recent investigations, use hl60 cell	[recent investigations, using HL60 cells]	0.0	5	1	1	1
128163	1710	(0-125 microM)	[(0-125 microM)]	0.0	2	1	1	1
128164	1710	suppression of transcription factor function	[suppression of transcription factor functions]	0.0	5	1	1	1
128165	1710	contain two domain	[containing two domains]	0.0	3	1	1	1
128166	1710	person with back pain	[persons with back pain]	0.0	4	1	1	1
128167	1710	absence transcription factor tcf-1	[Absence transcription factors TCF-1]	0.0	4	1	1	1
128168	1710	IL-4 receptor in b cell	[IL-4 receptor in B cells]	0.0	5	1	1	1
128169	1710	immunodeficiency virus type tat	[immunodeficiency virus type Tat]	0.0	4	1	1	1
128170	1710	drastic effect	[drastic effect]	0.0	2	1	1	1
128171	1710	hormone receptor protein	[hormone receptor proteins]	0.0	3	1	1	1
128172	1710	40 promoter region	[40 promoter regions]	0.0	3	1	1	1
128173	1710	angioplasty PTCA	[angioplasty PTCA]	0.0	2	1	1	1
128174	1710	thus, aberration in the apoptotic pathway	[Thus, aberrations in the apoptotic pathway]	0.0	6	1	1	1
128175	1710	small deletion model	[small deletion model]	0.0	3	1	1	1
128176	1710	characteristic result	[characteristic result]	0.0	2	1	1	1
128177	1710	serine proteinase	[serine proteinases]	0.0	2	1	1	1
128178	1710	interferon-inducible regulatory element	[interferon-inducible regulatory element]	0.0	3	1	1	1
128179	1710	Functional study in nonepithelial cell	[Functional studies in nonepithelial cells]	0.0	5	1	1	1
128180	1710	group of b cell tumor	[group of B cell tumors]	0.0	5	1	1	1
128181	1710	ARRE-1 site	[ARRE-1 site]	0.0	2	1	1	1
128182	1710	role for colony formation	[role for colony formation]	0.0	4	1	1	1
128183	1710	at (on average by 6.8%)	[AT (on average by 6.8%)]	0.0	5	1	1	1
128184	1710	72 h in culture.	[72 h in culture.]	0.0	4	1	1	1
128185	1710	cell growth in acute leukemia	[cell growth in acute leukemia]	0.0	5	1	1	1
128186	1710	erythrocyte-specific anhydrase caii	[erythrocyte-specific anhydrase CAII]	0.0	3	1	1	1
128187	1710	metabolic status after conservative surgery	[metabolic status after conservative surgery]	0.0	5	1	1	1
128188	1710	self ligand by class	[self, ligands by class]	0.0	4	1	1	1
128189	1710	various condition	[various conditions]	0.0	2	1	1	1
128190	1710	interaction of tax with p100	[interaction of Tax with p100]	0.0	5	1	1	1
128191	1710	two- increase in the amount	[two- increase in the amount]	0.0	5	1	1	1
128192	1710	selective removal of pc4	[selective removal of PC4]	0.0	4	1	1	1
128193	1710	lack a portion	[lacking a portion]	0.0	3	1	1	1
128194	1710	CBF beta-myh11 fusion	[CBF beta-MYH11 fusion]	0.0	3	1	1	1
128195	1710	cotreatment	[cotreatment]	0.0	1	2	2	1
128196	1710	mediate repression	[mediating repression]	0.0	2	1	1	1
128197	1710	express c-myc vsmc-myc	[expressing c-myc VSMC-myc]	0.0	3	1	1	1
128198	1710	female (18 year of age),	[female (18 years of age),]	0.0	5	1	1	1
128199	1710	nf-kappa b-related moiety	[NF-kappa B-related moieties]	0.0	3	1	1	1
128200	1710	nuclear extract of th1 clone	[nuclear extracts of Th1 clones]	0.0	5	1	1	1
128201	1710	insertional actin polymerization	[insertional actin polymerization]	0.0	3	1	1	1
128202	1710	cyclooxygenase-2 expression	[cyclooxygenase-2 expression]	0.0	2	1	1	1
128203	1710	approximately 40-fold activity	[approximately 40-fold activity]	0.0	3	1	1	1
128204	1710	mimick cell growth	[mimicking cell growth]	0.0	3	1	1	1
128205	1710	differentiation into macrophage	[differentiation into macrophages]	0.0	3	1	1	1
128206	1710	various human haematopoietic line u937	[various human haematopoietic lines U937]	0.0	5	1	1	1
128207	1710	modification in flanking sequence	[modifications in flanking sequences]	0.0	4	1	1	1
128208	1710	interferon-gamma-induced factor role in transient up-regulation	[Interferon-gamma-induced factor role in transient up-regulation]	0.0	6	1	1	1
128209	1710	dnase site-forming element	[DNase site-forming element]	0.0	3	1	1	1
128210	1710	term of activity	[terms of activity]	0.0	3	1	1	1
128211	1710	consequence of tyrosine phosphorylation	[consequences of tyrosine phosphorylation]	0.0	4	1	1	1
128212	1710	gata-1 in proliferation	[GATA-1 in proliferation]	0.0	3	1	1	1
128213	1710	abnormality in mineralocorticoid effector mechanism	[abnormalities in mineralocorticoid effector mechanisms]	0.0	5	1	1	1
128214	1710	nm, bmax 158 +/- 16	[nM, Bmax 158 +/- 16]	0.0	5	1	1	1
128215	1710	e1a expression in cell	[E1A expression in cells]	0.0	4	1	1	1
128216	1710	immediate-early activation gene family	[immediate-early activation genes family]	0.0	4	1	1	1
128217	1710	leukocyte gene expression	[leukocytes gene expression]	0.0	3	1	1	1
128218	1710	protein of native weight	[proteins of native weights]	0.0	4	1	1	1
128219	1710	range).	[range).]	0.0	1	1	1	1
128220	1710	Tat -mediated activation	[Tat -mediated activation]	0.0	3	1	1	1
128221	1710	circulate cell	[Circulating cells]	0.0	2	1	1	1
128222	1710	treatment of human leukemia cell	[treatment of human leukemia cells]	0.0	5	1	1	1
128223	1710	sp-1 element	[Sp-1 elements]	0.0	2	1	1	1
128224	1710	two potential open reading frame a	[two potential open reading frames A]	0.0	6	1	1	1
128225	1710	high (66 millileter at 10:00 P;	[high (66 ml at 10:00 h;]	0.0	6	1	1	1
128226	1710	two form lack a major portion	[two forms lacking a major portion]	0.0	6	1	1	1
128227	1710	many pathogen	[many pathogens]	0.0	2	1	1	1
128228	1710	development of diabetic complication	[development of diabetic complications]	0.0	4	1	1	1
128229	1710	1.5-1.6 time of the control	[1.5-1.6 times of the controls]	0.0	5	1	1	1
128230	1710	cysteine deficiency	[cysteine deficiency]	0.0	2	1	1	1
128231	1710	weak reactivation	[weak reactivation]	0.0	2	1	1	1
128232	1710	shuttling of NF-AT in discrimination	[shuttling of NF-AT in discrimination]	0.0	5	1	1	1
128233	1710	cellular catalyst thioredoxin	[cellular catalyst thioredoxin]	0.0	3	1	1	1
128234	1710	plasma membrane fraction	[plasma membrane fractions]	0.0	3	1	1	1
128235	1710	influence on the selection of lymphocyte	[influence on the selection of lymphocytes]	0.0	6	1	1	1
128236	1710	include a function	[including a function]	0.0	3	1	1	1
128237	1710	responder oligopeptide in all proteins.	[responder oligopeptides in all proteins.]	0.0	5	1	1	1
128238	1710	increase the normal number	[increase the normal number]	0.0	4	1	1	1
128239	1710	aids pathogenesis in vivo	[AIDS pathogenesis in vivo]	0.0	4	1	1	1
128240	1710	index of infiltration	[index of infiltration]	0.0	3	1	1	1
128241	1710	m-tat/gm-csf cell	[M-TAT/GM-CSF cells]	0.0	2	2	2	1
128242	1710	ltr-	[LTR-]	0.0	1	1	1	1
128243	1710	response-1 gene expression by pokeweed mitogen	[response-1 gene expression by pokeweed mitogen]	0.0	6	1	1	1
128244	1710	presence of a second pathway	[presence of a second pathway]	0.0	5	1	1	1
128245	1710	dermatitis patient	[dermatitis patients]	0.0	2	1	1	1
128246	1710	90% decrease in promoter activity	[90% decrease in promoter activity]	0.0	5	1	1	1
128247	1710	main anti-inflammatory mediator	[main anti-inflammatory mediators]	0.0	3	1	1	1
128248	1710	estrogen metabolism	[estrogen metabolism]	0.0	2	1	1	1
128249	1710	signal agent during cell cycle entry	[signalling agents during cell cycle entry]	0.0	6	1	1	1
128250	1710	proximal octamer -75	[proximal octamer -75]	0.0	3	1	1	1
128251	1710	expression of active raf-1	[Expression of active Raf-1]	0.0	4	1	1	1
128252	1710	myeloid leukemic blast	[myeloid leukemic blasts]	0.0	3	1	1	1
128253	1710	U2 snrna	[U2 snRNA]	0.0	2	1	1	1
128254	1710	activity of the CD30 ligand	[activities of the CD30 ligand]	0.0	5	1	1	1
128255	1710	regulatory region 5'	[regulatory region 5']	0.0	3	1	1	1
128256	1710	th2 proliferation	[Th2 proliferation]	0.0	2	1	1	1
128257	1710	TCR/CD3	[TCR/CD3]	0.0	1	1	1	1
128258	1710	fide th2 cell	[fide Th2 cells]	0.0	3	1	1	1
128259	1710	two major site within the element	[Two major sites within the element]	0.0	6	1	1	1
128260	1710	component current	[components current]	0.0	2	1	1	1
128261	1710	step in the activation	[step in the activation]	0.0	4	1	1	1
128262	1710	recognize other tumor ag	[recognizing other tumor Ag]	0.0	4	1	1	1
128263	1710	dna-binding protein protein hxbp-1	[DNA-binding protein protein hXBP-1]	0.0	4	1	1	1
128264	1710	differentiation-dependent peroxisomal receptor gamma ppargamma	[differentiation-dependent peroxisomal receptor gamma PPARgamma]	0.0	5	1	1	1
128265	1710	hpr cDNA probe	[hPR cDNA probes]	0.0	3	1	1	1
128266	1710	[regulation of cholesterol synthesis	[[Regulation of cholesterol synthesis]	0.0	4	1	1	1
128267	1710	description of a negative region	[description of a negative region]	0.0	5	1	1	1
128268	1710	tcr delta transcript	[TcR delta transcript]	0.0	3	1	1	1
128269	1710	75 kilometer tnf receptor expression	[75 kd TNF receptor expression]	0.0	5	1	1	1
128270	1710	optimal tyrosine phosphorylation	[optimal tyrosine phosphorylation]	0.0	3	1	1	1
128271	1710	factor in the signal mechanism	[factors in the signaling mechanisms]	0.0	5	1	1	1
128272	1710	effect with dose	[effects with doses]	0.0	3	1	1	1
128273	1710	rare form	[rare form]	0.0	2	1	1	1
128274	1710	b activation with other inducer	[B activation with other inducers]	0.0	5	1	1	1
128275	1710	peptide show weak cross-reactivity	[peptide showing weak cross-reactivity]	0.0	4	1	1	1
128276	1710	mouse tissue in the adult	[mouse tissues in the adult]	0.0	5	1	1	1
128277	1710	characterization of transactivation	[characterization of transactivation]	0.0	3	1	1	1
128278	1710	three cases.	[three cases.]	0.0	2	1	1	1
128279	1710	gene regulate the growth	[genes regulating the growth]	0.0	4	1	1	1
128280	1710	central system cell	[central system cells]	0.0	3	1	1	1
128281	1710	system in alzheimer' disease	[system in Alzheimer's disease]	0.0	4	1	1	1
128282	1710	expression of latent gene	[expression of latent genes]	0.0	4	1	1	1
128283	1710	breast carcinoma cell	[breast carcinoma cells]	0.0	3	1	1	1
128284	1710	target structure the major protein	[Target structures the major protein]	0.0	5	1	1	1
128285	1710	distinct element act	[distinct elements acting]	0.0	3	1	1	1
128286	1710	FN induction	[FN induction]	0.0	2	1	1	1
128287	1710	several rearrangement in the great ape	[several rearrangements in the great apes]	0.0	6	1	1	1
128288	1710	progenitor in vitro.	[progenitors in vitro.]	0.0	3	1	1	1
128289	1710	deletion il-9 cell growth	[Deletion IL-9 cell growth]	0.0	4	1	1	1
128290	1710	immunoglobulin promoter by transcription factor	[immunoglobulin promoters by transcription factors]	0.0	5	1	1	1
128291	1710	pak activation	[PAK activation]	0.0	2	1	1	1
128292	1710	change in haemoglobin production	[changes in haemoglobin production]	0.0	4	1	1	1
128293	1710	removal of the effect	[removal of the effect]	0.0	4	1	1	1
128294	1710	MARCKS protein	[MARCKS protein]	0.0	2	1	1	1
128295	1710	lipopolysaccharide induction of 1beta	[lipopolysaccharide induction of 1beta]	0.0	4	1	1	1
128296	1710	latent membrane protein promoter	[latent membrane protein promoter]	0.0	4	1	1	1
128297	1710	cytotoxicity of growth	[cytotoxicity of growth]	0.0	3	1	1	1
128298	1710	electrophoretic shift assay	[electrophoretic shift assay]	0.0	3	1	1	1
128299	1710	purpose other	[purposes other]	0.0	2	1	1	1
128300	1710	m all-tran RA	[M all-trans RA]	0.0	3	1	1	1
128301	1710	g betagamma subunit	[G betagamma subunits]	0.0	3	1	1	1
128302	1710	signal through the il-5 receptor	[signaling through the IL-5 receptor]	0.0	5	1	1	1
128303	1710	stimulation of dnd39 cell	[Stimulation of DND39 cells]	0.0	4	1	1	1
128304	1710	balance between regulatory mechanism	[balance between regulatory mechanisms]	0.0	4	1	1	1
128305	1710	element of many t-cell gene	[elements of many T-cell genes]	0.0	5	1	1	1
128306	1710	Epstein-Barr virus (ebv)-associated tumor	[Epstein-Barr virus (EBV)-associated tumors]	0.0	4	1	1	1
128307	1710	interleukin-1beta gene a model	[interleukin-1beta gene a model]	0.0	4	1	1	1
128308	1710	large number in secretory phase	[large numbers in secretory phase]	0.0	5	1	1	1
128309	1710	16-bp see	[16-bp SEE]	0.0	2	1	1	1
128310	1710	human hormone gene promoter	[human hormone gene promoter]	0.0	4	1	1	1
128311	1710	transcription of the beta-globin gene cluster	[Transcription of the beta-globin gene cluster]	0.0	6	1	1	1
128312	1710	peptidyl substrate	[peptidyl substrates]	0.0	2	1	1	1
128313	1710	vectors.	[vectors.]	0.0	1	1	1	1
128314	1710	vectors,	[vectors,]	0.0	1	1	1	1
128315	1710	NF-muNR repressor	[NF-muNR repressor]	0.0	2	1	1	1
128316	1710	blot analysis of SR-BP gene expression	[blot analysis of SR-BP gene expression]	0.0	6	1	1	1
128317	1710	two potent immunosuppressive agent	[two potent immunosuppressive agents]	0.0	4	1	1	1
128318	1710	two nuclear binding protein	[two nuclear binding proteins]	0.0	4	1	1	1
128319	1710	complement in animal model	[complement in animal models]	0.0	4	1	1	1
128320	1710	hiv-1 terminal repeat LTR transcription	[HIV-1 terminal repeat LTR transcription]	0.0	5	1	1	1
128321	1710	(also in umbilical endothelial cell	[(also in umbilical endothelial cells]	0.0	5	1	1	1
128322	1710	interaction between b cell-specific coactivator	[interactions between B cell-specific coactivators]	0.0	5	1	1	1
128323	1710	sodium handling	[sodium handling]	0.0	2	1	1	1
128324	1710	likely cause	[likely cause]	0.0	2	1	1	1
128325	1710	concentration range from 10(-9)	[concentrations ranging from 10(-9)]	0.0	4	1	1	1
128326	1710	adenovirus type 2	[adenovirus type 2]	0.0	3	1	1	1
128327	1710	inactive, form of the protein.	[inactive, form of the protein.]	0.0	5	1	1	1
128328	1710	superantigen enterotoxin a sea	[superantigen enterotoxin A SEA]	0.0	4	1	1	1
128329	1710	biliary cirrhosis	[biliary cirrhosis]	0.0	2	2	2	1
128330	1710	prevalence of abnormal biomarker	[prevalence of abnormal biomarkers]	0.0	4	1	1	1
128331	1710	direct percutaneous angioplasty	[direct percutaneous angioplasty]	0.0	3	1	1	1
128332	1710	pseudo-tumor necrosis factor receptor	[pseudo-tumor necrosis factor receptor]	0.0	4	1	1	1
128333	1710	use blot analysis with a antibody	[Using blot analysis with a antibody]	0.0	6	1	1	1
128334	1710	cellular differentiation program	[cellular differentiation program]	0.0	3	1	1	1
128335	1710	induction upon stimulation rest T lymphocyte	[induction upon stimulation resting T lymphocytes]	0.0	6	1	1	1
128336	1710	binding of erythroid protein	[Binding of erythroid proteins]	0.0	4	1	1	1
128337	1710	example intracellular glucocorticoid receptor	[example intracellular glucocorticoid receptors]	0.0	4	1	1	1
128338	1710	distinct type	[distinct types]	0.0	2	1	1	1
128339	1710	diffuse localization	[diffuse localization]	0.0	2	1	1	1
128340	1710	distinct dna-binding complex	[distinct DNA-binding complexes]	0.0	3	1	1	1
128341	1710	normal monocyte with phorbol-13-acetate	[normal monocytes with phorbol-13-acetate]	0.0	4	1	1	1
128342	1710	female with onset menarche year	[female with onset menarche years]	0.0	5	1	1	1
128343	1710	induction via activation of nuclear factor-kappaB	[Induction via activation of nuclear factor-kappaB]	0.0	6	1	1	1
128344	1710	PMA inducibility on a promoter	[PMA inducibility on a promoter]	0.0	5	1	1	1
128345	1710	hormone receptor retinoid	[hormone receptor retinoid]	0.0	3	1	1	1
128346	1710	correlation 3-o-mg transport	[correlation 3-O-MG transport]	0.0	3	1	1	1
128347	1710	degradation of IkB alpha	[degradation of IkB alpha]	0.0	4	1	1	1
128348	1710	Stat3 recruitment by docking site	[Stat3 recruitment by docking sites]	0.0	5	1	1	1
128349	1710	cooperation between p50b	[cooperation between p50B]	0.0	3	1	1	1
128350	1710	2 tegument protein	[2 tegument proteins]	0.0	3	1	1	1
128351	1710	mouse MHC class gene	[mouse MHC class genes]	0.0	4	1	1	1
128352	1710	one family	[One family]	0.0	2	1	1	1
128353	1710	effect on the chemotactic migration	[effect on the chemotactic migration]	0.0	5	1	1	1
128354	1710	Effect erythroid differentiation of k562 cell	[Effects erythroid differentiation of K562 cells]	0.0	6	1	1	1
128355	1710	mechanism of resistance	[mechanism of resistance]	0.0	3	1	1	1
128356	1710	several low molecular weight adaptor protein	[several low molecular weight adaptor proteins]	0.0	6	1	1	1
128357	1710	group c adenoviral infection	[group C adenoviral infection]	0.0	4	2	2	1
128358	1710	minute of monocyte adhesion	[min of monocyte adhesion]	0.0	4	1	1	1
128359	1710	gene putative g0/g1 switch gene	[genes putative G0/G1 switch genes]	0.0	5	1	1	1
128360	1710	erythroid-specific transcription factor	[erythroid-specific transcription factor]	0.0	3	1	1	1
128361	1710	cytoplasm clusters.	[cytoplasm clusters.]	0.0	2	1	1	1
128362	1710	persistent transcription	[persistent transcription]	0.0	2	1	1	1
128363	1710	relatedness with the human reticulocyte-type 15-lipoxygenase	[relatedness with the human reticulocyte-type 15-lipoxygenase]	0.0	6	1	1	1
128364	1710	potential cross point between signal pathway	[potential cross points between signaling pathways]	0.0	6	1	1	1
128365	1710	expression of e2a-pbx1	[expression of E2a-Pbx1]	0.0	3	1	1	1
128366	1710	fcs(-)-culture	[FCS(-)-culture]	0.0	1	1	1	1
128367	1710	amount e1b	[amounts E1B]	0.0	2	1	1	1
128368	1710	most likely dpii,	[most likely DP-I,]	0.0	3	1	1	1
128369	1710	E15 embryonic liver	[E15 embryonic liver]	0.0	3	1	1	1
128370	1710	species specific,	[species specific,]	0.0	2	1	1	1
128371	1710	murine transcription factor	[murine transcription factor]	0.0	3	1	1	1
128372	1710	mediator in dermal endothelial cell	[mediators in dermal endothelial cells]	0.0	5	1	1	1
128373	1710	adhesiveness of cell	[adhesiveness of cells]	0.0	3	1	1	1
128374	1710	(dra)	[(DRA)]	0.0	1	1	1	1
128375	1710	transcription factor one through interaction	[transcription factor one through interactions]	0.0	5	1	1	1
128376	1710	control of igh gene expression	[control of IgH gene expression]	0.0	5	1	1	1
128377	1710	Glucocorticoid receptor concentration in mononuclear leukocyte	[Glucocorticoid receptor concentrations in mononuclear leukocytes]	0.0	6	1	1	1
128378	1710	biological activity,	[biological activity,]	0.0	2	1	1	1
128379	1710	14-kd	[14-kD]	0.0	1	1	1	1
128380	1710	granulopoiesis typically die	[granulopoiesis typically dying]	0.0	3	1	1	1
128381	1710	response to HIV-1 Tat	[response to HIV-1 Tat]	0.0	4	1	1	1
128382	1710	role for the transcription factor Ikaros	[roles for the transcription factors Ikaros]	0.0	6	1	1	1
128383	1710	reduction transcripts.	[reduction transcripts.]	0.0	2	1	1	1
128384	1710	17 case by immunohistology	[17 cases by immunohistology]	0.0	4	1	1	1
128385	1710	surface of jurkat cell	[surface of Jurkat cells]	0.0	4	1	1	1
128386	1710	elevation of free calcium	[elevation of free calcium]	0.0	4	1	1	1
128387	1710	existence of difference	[existence of differences]	0.0	3	1	1	1
128388	1710	prb weight	[pRB weight]	0.0	2	1	1	1
128389	1710	therapy specific	[therapy specific]	0.0	2	1	1	1
128390	1710	proliferative samples, cytotoxic activity	[proliferative samples, cytotoxic activity]	0.0	4	1	1	1
128391	1710	IL-3 pro-B cell	[IL-3 pro-B cells]	0.0	3	1	1	1
128392	1710	leukemia t-all	[leukemia T-ALL]	0.0	2	1	1	1
128393	1710	variant receptor transcript lack exon	[Variant receptor transcripts lacking exon]	0.0	5	1	1	1
128394	1710	natural negative HLH factor Id3	[natural negative HLH factor Id3]	0.0	5	1	1	1
128395	1710	gene reporter	[gene reporters]	0.0	2	1	1	1
128396	1710	determine the rank order	[determining the rank order]	0.0	4	1	1	1
128397	1710	b lymphocyte responsive	[B lymphocytes responsive]	0.0	3	1	1	1
128398	1710	vaginosis bv	[vaginosis BV]	0.0	2	1	1	1
128399	1710	distinct form of e2f	[distinct forms of E2F]	0.0	4	1	1	1
128400	1710	preference for any promoter combination	[preference for any promoter combination]	0.0	5	1	1	1
128401	1710	elderly (mean 78	[elderly (mean 78]	0.0	3	1	1	1
128402	1710	role of tumor necrosis factor	[Role of tumor necrosis factor]	0.0	5	1	1	1
128403	1710	significant proliferation (71%) iddm subject	[significant proliferation (71%) IDDM subjects]	0.0	5	1	1	1
128404	1710	furthermore, the protein complex	[Furthermore, the protein complexes]	0.0	4	1	1	1
128405	1710	multiple antigen-specific reactivity at level high	[multiple antigen-specific reactivities at levels high]	0.0	6	1	1	1
128406	1710	major cytokine in human monocyte	[major cytokines in human monocytes]	0.0	5	1	1	1
128407	1710	reduce status for fasl induction	[reducing status for FasL induction]	0.0	5	1	1	1
128408	1710	abnormality in kappa b-binding activity	[abnormality in kappa B-binding activity]	0.0	5	1	1	1
128409	1710	inducible transcriptional activity	[inducible transcriptional activity]	0.0	3	1	1	1
128410	1710	single viral protein bzlf1	[single viral protein BZLF1]	0.0	4	1	1	1
128411	1710	receptor-ligand interaction	[receptor-ligand interactions]	0.0	2	1	1	1
128412	1710	transcriptional activation of the beta-globin promoter	[transcriptional activation of the beta-globin promoter]	0.0	6	1	1	1
128413	1710	healthy volunteers.	[healthy volunteers.]	0.0	2	1	1	1
128414	1710	strike concordance	[striking concordance]	0.0	2	1	1	1
128415	1710	modulate agent, 1 alpha,25-dihydroxycholecalciferol	[modulating agent, 1 alpha,25-dihydroxycholecalciferol]	0.0	4	1	1	1
128416	1710	salt-losing episode simulate insufficiency	[salt-losing episode simulating insufficiency]	0.0	4	1	1	1
128417	1710	endotoxin-stimulated thp-1 a cell line	[endotoxin-stimulated THP-1 a cell line]	0.0	5	1	1	1
128418	1710	factor-kappa beta in monocyte	[factor-kappa beta in monocytes]	0.0	4	1	1	1
128419	1710	hugata-3 transcription	[huGATA-3 transcription]	0.0	2	1	1	1
128420	1710	mechanism in human T lymphocyte	[mechanism in human T lymphocytes]	0.0	5	1	1	1
128421	1710	t(17;19) chromosomal translocation	[t(17;19) chromosomal translocation]	0.0	3	1	1	1
128422	1710	capacity of tumor	[capacity of tumors]	0.0	3	1	1	1
128423	1710	especially density lipoprotein	[especially density lipoprotein]	0.0	3	1	1	1
128424	1710	generate positive mechanism control the competence	[generating positive mechanisms controlling the competence]	0.0	6	1	1	1
128425	1710	protein'	[protein's]	0.0	1	1	1	1
128426	1710	atrophy a form	[atrophy an form]	0.0	3	1	1	1
128427	1710	regulation by dimethyl sulfoxide	[regulation by dimethyl sulfoxide]	0.0	4	1	1	1
128428	1710	malignant lymphoma,	[malignant lymphoma,]	0.0	2	1	1	1
128429	1710	sufficient number of receptor	[sufficient numbers of receptors]	0.0	4	1	1	1
128430	1710	reduction of er mrna	[reduction of ER mRNA]	0.0	4	1	1	1
128431	1710	three order the concentration	[three orders the concentration]	0.0	4	1	1	1
128432	1710	presence in t-cell-expressed cytokine gene	[presence in T-cell-expressed cytokine genes]	0.0	5	1	1	1
128433	1710	group at risk	[group at risk]	0.0	3	1	1	1
128434	1710	aberrant intracellular signal	[aberrant intracellular signaling]	0.0	3	1	1	1
128435	1710	level of ap-1 activity	[levels of AP-1 activities]	0.0	4	1	1	1
128436	1710	cd86 b7-2 principal ligand	[CD86 B7-2 principal ligands]	0.0	4	1	1	1
128437	1710	distinct nfkb2 rela(p65)	[distinct NFKB2 RelA(p65)]	0.0	3	1	1	1
128438	1710	such as leukocyte migration	[such as leukocyte migration]	0.0	4	1	1	1
128439	1710	fos/g0s7	[FOS/G0S7]	0.0	1	1	1	1
128440	1710	key regulator of inflammatory response	[key regulator of inflammatory responses]	0.0	5	1	1	1
128441	1710	synthesis of isoform	[synthesis of isoforms]	0.0	3	1	1	1
128442	1710	fibrosarcoma fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrosarcoma fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
128443	1710	m-tat/scf	[M-TAT/SCF]	0.0	1	1	1	1
128444	1710	mechanism of adherence to endothelial cell	[mechanisms of adherence to endothelial cells]	0.0	6	1	1	1
128445	1710	frequent expression	[frequent expression]	0.0	2	1	1	1
128446	1710	interleukin (il)-10 blocking factor pibf	[interleukin (IL)-10 blocking factor PIBF]	0.0	5	1	1	1
128447	1710	level by okadaic acid	[level by okadaic acid]	0.0	4	1	1	1
128448	1710	Nonradioactive quantification of receptor expression	[Nonradioactive quantification of receptor expression]	0.0	5	1	1	1
128449	1710	Philadelphia chromosome-positive myeloid leukemia	[Philadelphia chromosome-positive myeloid leukemia]	0.0	4	2	2	1
128450	1710	priming of human monocyte	[Priming of human monocytes]	0.0	4	1	1	1
128451	1710	10(3) units/ml recombinant m-csf	[10(3) units/ml recombinant M-CSF]	0.0	4	1	1	1
128452	1710	n-terminal (1-60) peptide	[N-terminal (1-60) peptide]	0.0	3	1	1	1
128453	1710	synthetic oligonucleotide probe	[synthetic oligonucleotide probes]	0.0	3	1	1	1
128454	1710	homologous porcine serum	[homologous porcine serum]	0.0	3	1	1	1
128455	1710	include stat6 phosphorylation	[including STAT6 phosphorylation]	0.0	3	1	1	1
128456	1710	processing to the nfkb2 induction	[processing to the NFKB2 induction]	0.0	5	1	1	1
128457	1710	metabolism of steroid	[metabolism of steroids]	0.0	3	1	1	1
128458	1710	translocation after hormone binding	[translocation after hormone binding]	0.0	4	1	1	1
128459	1710	activity a new potential	[activity a new potential]	0.0	4	1	1	1
128460	1710	detectable ad 2/5 e1a sequence	[detectable Ad 2/5 E1a sequences]	0.0	5	1	1	1
128461	1710	various defect	[various defects]	0.0	2	1	1	1
128462	1710	arthritis pathogenesis	[arthritis pathogenesis]	0.0	2	1	1	1
128463	1710	Effect differentiation	[Effects differentiation]	0.0	2	1	1	1
128464	1710	B nuclear factor	[B nuclear factor]	0.0	3	1	1	1
128465	1710	cd8(-) CD3 thymocyte a critical role	[CD8(-) CD3 thymocytes a critical role]	0.0	6	1	1	1
128466	1710	thereby preclude the lysis	[thereby precluding the lysis]	0.0	4	1	1	1
128467	1710	chaperone hsp90	[chaperone hsp90]	0.0	2	1	1	1
128468	1710	gene encode LBR a protein	[gene encoding LBR an protein]	0.0	5	1	1	1
128469	1710	tal-1 rearrangement	[tal-1 rearrangements]	0.0	2	1	1	1
128470	1710	human mononulear leukocyte hMNL	[human mononulear leukocytes hMNL]	0.0	4	1	1	1
128471	1710	phospholipase C gamma plc gamma	[phospholipase C gamma PLC gamma]	0.0	5	1	1	1
128472	1710	inducible transcriptional regulator of gene	[inducible transcriptional regulators of genes]	0.0	5	1	1	1
128473	1710	mature haematopoietic population	[mature haematopoietic populations]	0.0	3	1	1	1
128474	1710	major cytokine in monocyte	[major cytokines in monocytes]	0.0	4	1	1	1
128475	1710	morphologic feature nuclear membrane	[morphologic features nuclear membranes]	0.0	4	1	1	1
128476	1710	adhesion in cell	[adhesion in cells]	0.0	3	1	1	1
128477	1710	32-34 kda protein	[32-34 kDa protein]	0.0	3	1	1	1
128478	1710	activation follow binding	[activation following binding]	0.0	3	1	1	1
128479	1710	zeta isoform	[zeta isoform]	0.0	2	1	1	1
128480	1710	activation of a factor T cell	[activation of a factor T cells]	0.0	6	1	1	1
128481	1710	t-cell cycle entry,	[T-cell cycle entry,]	0.0	3	1	1	1
128482	1710	result in activation include NF-kappa b	[resulting in activation including NF-kappa B]	0.0	6	1	1	1
128483	1710	differentiation of precursor cell line u937	[differentiation of precursor cell lines U937]	0.0	6	1	1	1
128484	1710	Ad12 13S mrna product	[Ad12 13S mRNA product]	0.0	4	1	1	1
128485	1710	fibrosarcoma histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma histiocytoma 6, rhabdomyosarcoma]	0.0	4	1	1	1
128486	1710	thioredoxin T cell factor	[thioredoxin T cell factor]	0.0	4	1	1	1
128487	1710	DNA clone contain hhv-6(gs) fragment	[DNA clones containing HHV-6(GS) fragments]	0.0	5	1	1	1
128488	1710	expression of the first exon	[expression of the first exon]	0.0	5	1	1	1
128489	1710	sequence than the liver pcd/dcoh	[sequence than the liver PCD/DCoH]	0.0	5	1	1	1
128490	1710	more than one mechanism	[more than one mechanism]	0.0	4	1	1	1
128491	1710	important trigger for the expression	[important trigger for the expression]	0.0	5	1	1	1
128492	1710	new, relevant compound	[new, relevant compounds]	0.0	3	1	1	1
128493	1710	growth response gene-1 egr-1	[growth response gene-1 EGR-1]	0.0	4	1	1	1
128494	1710	SCC with metastasis	[SCC with metastasis]	0.0	3	1	1	1
128495	1710	mutant of lps induction	[mutant of LPS induction]	0.0	4	1	1	1
128496	1710	activation via release	[activation via release]	0.0	3	1	1	1
128497	1710	of induce lap much	[of inducing LAP much]	0.0	4	1	1	1
128498	1710	complex with the same mobility	[complex with the same mobility]	0.0	5	1	1	1
128499	1710	Philadelphia chromosome-positive chronic leukemia	[Philadelphia chromosome-positive chronic leukemia]	0.0	4	2	2	1
128500	1710	th2 phenotype on a population	[Th2 phenotype on a population]	0.0	5	1	1	1
128501	1710	wide spectrum	[wide spectrum]	0.0	2	1	1	1
128502	1710	murine leukemia virus	[murine leukemia virus]	0.0	3	1	1	1
128503	1710	camp-response element alpha motif	[cAMP-response element alpha motif]	0.0	4	1	1	1
128504	1710	serum 135eoh)2d3	[serum 1,25(OH)2D3]	0.0	2	1	1	1
128505	1710	distinct pathway of synthesis	[distinct pathways of synthesis]	0.0	4	1	1	1
128506	1710	dna- binding domain	[DNA- binding domains]	0.0	3	1	1	1
128507	1710	integral protein	[integral protein]	0.0	2	2	2	1
128508	1710	study pertain	[studies pertaining]	0.0	2	1	1	1
128509	1710	traffic together	[traffic together]	0.0	2	1	1	1
128510	1710	24 pregnant woman second	[24 pregnant women second]	0.0	4	1	1	1
128511	1710	E2F sequence in mcm6 promoter	[E2F sequence in MCM6 promoter]	0.0	5	1	1	1
128512	1710	cellular tip-associated protein tap	[cellular Tip-associated protein Tap]	0.0	4	1	1	1
128513	1710	role for NFAT-1	[role for NFAT-1]	0.0	3	1	1	1
128514	1710	early 62 (ie62) protein	[early 62 (IE62) protein]	0.0	4	1	1	1
128515	1710	hormonal metabolic status comparison	[Hormonal metabolic status comparison]	0.0	4	1	1	1
128516	1710	regulation of acid lipase in monocyte	[regulation of acid lipase in monocytes]	0.0	6	1	1	1
128517	1710	hybrid protein	[hybrid protein]	0.0	2	1	1	1
128518	1710	(hiv-1) tat	[(HIV-1) Tat]	0.0	2	1	1	1
128519	1710	wild-type promoter construct	[wild-type promoter construct]	0.0	3	1	1	1
128520	1710	tnf-alpha in u937 cell	[TNF-alpha in U937 cells]	0.0	4	1	1	1
128521	1710	activation of the ap-1 reporter plasmid	[activation of the AP-1 reporter plasmid]	0.0	6	1	1	1
128522	1710	myeloid patient aml (10 cases)	[myeloid patients AML (10 cases)]	0.0	5	1	1	1
128523	1710	human blood lymphocyte generation	[human blood lymphocytes Generation]	0.0	4	1	1	1
128524	1710	pair of jak kinase	[pairs of JAK kinases]	0.0	4	1	1	1
128525	1710	prognosis, with a survival	[prognosis, with a survival]	0.0	4	1	1	1
128526	1710	novel kappa b-binding activity	[novel kappa B-binding activity]	0.0	4	1	1	1
128527	1710	alternative potential nf-kappab element	[alternative potential NF-kappaB elements]	0.0	4	1	1	1
128528	1710	identity of 75.3%	[identity of 75.3%]	0.0	3	1	1	1
128529	1710	tumor necrosis factor protein	[tumor necrosis factor proteins]	0.0	4	1	1	1
128530	1710	mip-1alpha-r	[MIP-1alpha-R]	0.0	1	1	1	1
128531	1710	suspension on surface	[suspension on surfaces]	0.0	3	1	1	1
128532	1710	DNA binding protein of 85	[DNA binding proteins of 85]	0.0	5	1	1	1
128533	1710	culture, lead onto the surface	[culture, leading onto the surface]	0.0	5	1	1	1
128534	1710	binding to element 1	[Binding to element 1]	0.0	4	1	1	1
128535	1710	-express fibroblastic cell	[-expressing fibroblastic cells]	0.0	3	1	1	1
128536	1710	induction consistent	[induction consistent]	0.0	2	1	1	1
128537	1710	polymorphic nucleotide	[polymorphic nucleotides]	0.0	2	1	1	1
128538	1710	form 1,	[Form 1,]	0.0	2	1	1	1
128539	1710	97 relatively young (18- volunteer	[97 relatively young (18- volunteers]	0.0	5	1	1	1
128540	1710	nuclear factor (NF)-kappaB binding site	[nuclear factor (NF)-kappaB binding sites]	0.0	5	1	1	1
128541	1710	group of control subject	[group of control subjects]	0.0	4	1	1	1
128542	1710	hiv infection of u937 cell	[HIV infection of U937 cells]	0.0	5	1	1	1
128543	1710	overexpression the product of bzlf1	[Overexpression the product of BZLF1]	0.0	5	1	1	1
128544	1710	change in response to alpha-IFN	[change in response to alpha-IFN]	0.0	5	1	1	1
128545	1710	cosignaling via the lt-beta	[cosignaling via the LT-beta]	0.0	4	1	1	1
128546	1710	(partial) cortisol receptor resistance	[(partial) cortisol receptor resistance]	0.0	4	1	1	1
128547	1710	1) biochemical sign of primary hypothyroidism	[1) biochemical signs of primary hypothyroidism]	0.0	6	1	1	1
128548	1710	activity of wild-type protein kbf1/p50	[activity of wild-type proteins KBF1/p50]	0.0	5	1	1	1
128549	1710	activation of phospholipase c	[activation of phospholipase C]	0.0	4	1	1	1
128550	1710	fuse each	[fusing each]	0.0	2	1	1	1
128551	1710	il-2-alpha	[IL-2-alpha]	0.0	1	1	1	1
128552	1710	use as /hypereosinophilic agent	[use as /hypereosinophilic agents]	0.0	4	1	1	1
128553	1710	alphaIIb subunit chain alphaIIbH	[alphaIIb subunit chain alphaIIbH]	0.0	4	1	1	1
128554	1710	cis element S	[cis elements S]	0.0	3	1	1	1
128555	1710	luteal	[luteal]	0.0	1	1	1	1
128556	1710	(igh) gene	[(IgH) gene]	0.0	2	1	1	1
128557	1710	NF kappab activation lack nno	[NF kappaB activation lacking nNOS]	0.0	5	1	1	1
128558	1710	plasma membrane phospholipid	[plasma membrane phospholipids]	0.0	3	1	1	1
128559	1710	gp130 tail	[gp130 tail]	0.0	2	1	1	1
128560	1710	cell from a lncap cell line	[cells from an LNCaP cell line]	0.0	6	1	1	1
128561	1710	promoter 5' sequence	[promoter 5' sequences]	0.0	3	1	1	1
128562	1710	cho-dr enterotoxin a	[CHO-DR enterotoxin A]	0.0	3	1	1	1
128563	1710	latent membrane protein of ebv	[latent membrane protein of EBV]	0.0	5	1	1	1
128564	1710	differentiation inhibitory factor	[differentiation inhibitory factor]	0.0	3	1	1	1
128565	1710	splice site sequence	[splice site sequences]	0.0	3	1	1	1
128566	1710	opioid receptor	[opioid receptors]	0.0	2	1	1	1
128567	1710	dprl promoter construct	[dPRL promoter construct]	0.0	3	1	1	1
128568	1710	involve nuclear factor (nfat) protein	[involving nuclear factor (NFAT) proteins]	0.0	5	1	1	1
128569	1710	receptor for stimulation	[receptors for stimulation]	0.0	3	1	1	1
128570	1710	analysis of thp-1 cell	[analysis of THP-1 cells]	0.0	4	1	1	1
128571	1710	CAII -specific erba-binding site	[CAII -specific erbA-binding site]	0.0	4	1	1	1
128572	1710	interleukin-2-gene expression	[interleukin-2-gene expression]	0.0	2	1	1	1
128573	1710	lytic effect in cell	[lytic effect in cells]	0.0	4	1	1	1
128574	1710	transformation of b lymphocyte	[transformation of B lymphocytes]	0.0	4	1	1	1
128575	1710	total	[total]	0.0	1	6	6	1
128576	1710	establish NF-kappaB	[establishing NF-kappaB]	0.0	2	1	1	1
128577	1710	significant rapid twofold increase	[significant rapid twofold increase]	0.0	4	1	1	1
128578	1710	combination of recycling	[combination of recycling]	0.0	3	1	1	1
128579	1710	apparent glucocorticoid resistance	[apparent glucocorticoid resistance]	0.0	3	1	1	1
128580	1710	membrane form of csf-1	[membrane form of CSF-1]	0.0	4	1	1	1
128581	1710	onset of numerous feature	[onset of numerous features]	0.0	4	1	1	1
128582	1710	activation of phospholipase C	[activation of phospholipase C]	0.0	4	1	1	1
128583	1710	modulation of normal differentiation	[Modulation of normal differentiation]	0.0	4	1	1	1
128584	1710	level of p62c-fo	[levels of p62c-fos]	0.0	3	1	1	1
128585	1710	(2-6 h) pro-apoptotic effect	[(2-6 h) pro-apoptotic effects]	0.0	4	1	1	1
128586	1710	5-aminolevulinate synthetase transcript	[5-aminolevulinate synthetase transcripts]	0.0	3	1	1	1
128587	1710	cd13lo, cd15lo, cd34+/-, hla-dr cd16	[CD13lo, CD15lo, CD34+/-, HLA-DR CD16]	0.0	5	1	1	1
128588	1710	receptor status in mononuclear leukocyte	[receptor status in mononuclear leukocytes]	0.0	5	1	1	1
128589	1710	form of ras ras(g12v)	[form of Ras Ras(G12V)]	0.0	4	1	1	1
128590	1710	treatment of mt-i with 5-azacytidine re-expression	[treatment of MT-I with 5-azacytidine re-expression]	0.0	6	1	1	1
128591	1710	transformation of Philadelphia chronic leukemia	[transformation of Philadelphia chronic leukemia]	0.0	5	1	1	1
128592	1710	546-nucleotide reading frame	[546-nucleotide reading frame]	0.0	3	1	1	1
128593	1710	new aspect of down-regulation	[new aspect of down-regulation]	0.0	4	1	1	1
128594	1710	level for macrophage protein-1	[levels for macrophage protein-1]	0.0	4	1	1	1
128595	1710	anti- CD4 antibody	[anti- CD4 antibodies]	0.0	3	1	1	1
128596	1710	reduce kv1.3 component of KV	[reducing Kv1.3 components of KV]	0.0	5	1	1	1
128597	1710	structure of domain	[structures of domains]	0.0	3	1	1	1
128598	1710	redundancy in general coactivator	[redundancy in general coactivators]	0.0	4	1	1	1
128599	1710	c-Fos mutant protein	[c-Fos mutant proteins]	0.0	3	1	1	1
128600	1710	immunogenic murine melanoma D5	[immunogenic murine melanoma D5]	0.0	4	1	1	1
128601	1710	IL-2 region	[IL-2 region]	0.0	2	1	1	1
128602	1710	breast cancer reactive antibody-dependent cytotoxicity	[breast cancer reactive antibody-dependent cytotoxicity]	0.0	5	1	1	1
128603	1710	individual of major complex (mhc) haplotype	[individuals of major complex (MHC) haplotypes]	0.0	6	1	1	1
128604	1710	endogenous IL-6 gene	[endogenous IL-6 genes]	0.0	3	1	1	1
128605	1710	concentration of RA to &mgr;m)	[concentrations of RA to &mgr;M)]	0.0	5	1	1	1
128606	1710	distal nuclear factor NF-AT	[distal nuclear factor NF-AT]	0.0	4	1	1	1
128607	1710	enzymatic means	[enzymatic means]	0.0	2	1	1	1
128608	1710	DD product	[DD products]	0.0	2	1	1	1
128609	1710	bcr1/25 a pml/ rar-alpha	[BCR1/25 a pml/ RAR-alpha]	0.0	4	1	1	1
128610	1710	only significant effect	[only significant effects]	0.0	3	1	1	1
128611	1710	nucleoplasmic localization	[nucleoplasmic localization]	0.0	2	1	1	1
128612	1710	concomitant 40-50% decrease	[concomitant 40-50% decrease]	0.0	3	1	1	1
128613	1710	activity-alpha	[activity-alpha]	0.0	1	1	1	1
128614	1710	prevent induction of cytokine	[preventing induction of cytokine]	0.0	4	1	1	1
128615	1710	proximal gamma-globin promoter	[proximal gamma-globin promoter]	0.0	3	1	1	1
128616	1710	e2f1 gene	[E2F1 gene]	0.0	2	1	1	1
128617	1710	addition, vitamin	[addition, vitamin]	0.0	2	1	1	1
128618	1710	nuclear factor of T	[nuclear factor of T]	0.0	4	1	1	1
128619	1710	moderate form	[moderate form]	0.0	2	1	1	1
128620	1710	vascular-cell adhesion	[vascular-cell adhesion]	0.0	2	1	1	1
128621	1710	two rdna the catalytic sub-unit	[two cDNAs the catalytic sub-unit]	0.0	5	1	1	1
128622	1710	normal -resistant cell	[normal -resistant cells]	0.0	3	1	1	1
128623	1710	extrathymic t-cell precursor	[extrathymic T-cell precursors]	0.0	3	1	1	1
128624	1710	group of healthy female aged	[group of healthy females aged]	0.0	5	1	1	1
128625	1710	activation of macrophage by lipopolysaccharide	[Activation of macrophages by lipopolysaccharide]	0.0	5	1	1	1
128626	1710	activate pathway	[activating pathway]	0.0	2	1	1	1
128627	1710	up-regulation of il-1ra production	[up-regulation of IL-1ra production]	0.0	4	1	1	1
128628	1710	erythrocyte nuclear protein	[erythrocyte nuclear proteins]	0.0	3	1	1	1
128629	1710	BCL-6 mutation in center b cell	[BCL-6 mutations in center B cells]	0.0	6	1	1	1
128630	1710	content of vacuolar h+-atpase	[content of vacuolar H+-ATPase]	0.0	4	1	1	1
128631	1710	partially.	[partially.]	0.0	1	1	1	1
128632	1710	conclusion: Mutated ciita construct	[CONCLUSION: Mutated CIITA constructs]	0.0	4	1	1	1
128633	1710	two form diabete maturity-onset diabete	[two forms diabetes maturity-onset diabetes]	0.0	5	1	1	1
128634	1710	isolation of a b-cell-specific promoter	[Isolation of a B-cell-specific promoter]	0.0	5	1	1	1
128635	1710	agent cyclosporin A	[agent cyclosporin A]	0.0	3	1	1	1
128636	1710	interaction with the MOPC promoter	[interaction with the MOPC promoter]	0.0	5	1	1	1
128637	1710	specific glucocorticoid binding circadian rhythm	[specific glucocorticoid binding circadian rhythms]	0.0	5	1	1	1
128638	1710	extract consist of Mr	[extracts consisting of Mr]	0.0	4	1	1	1
128639	1710	transcription factor isgf3	[transcription factor ISGF3]	0.0	3	1	1	1
128640	1710	mm, respectively).	[mM, respectively).]	0.0	2	1	1	1
128641	1710	receptor capacity	[receptor capacity]	0.0	2	1	1	1
128642	1710	common pathway for activation	[common pathway for activation]	0.0	4	1	1	1
128643	1710	mpc11 cell	[MPC11 cells]	0.0	2	1	1	1
128644	1710	lymphocytic leukaemia	[lymphocytic leukaemia]	0.0	2	1	1	1
128645	1710	-dependent activation of 2 gene	[-dependent activation of 2 gene]	0.0	5	1	1	1
128646	1710	clinical remission in patient	[clinical remission in patients]	0.0	4	1	1	1
128647	1710	antiatherosclerotic potential of soluble antioxidant	[antiatherosclerotic potential of soluble antioxidants]	0.0	5	1	1	1
128648	1710	agent cyclosporin a	[agent cyclosporin A]	0.0	3	1	1	1
128649	1710	little detectable activation of ap-1	[little detectable activation of AP-1]	0.0	5	1	1	1
128650	1710	site around position -585	[sites around positions -585]	0.0	4	1	1	1
128651	1710	octamer transcription factor October	[octamer transcription factors Oct]	0.0	4	1	1	1
128652	1710	activation of the il-6 gene	[activation of the IL-6 gene]	0.0	5	1	1	1
128653	1710	activity of the proteasome independent	[activity of the proteasome independent]	0.0	5	1	1	1
128654	1710	only of the domain	[only of the domain]	0.0	4	1	1	1
128655	1710	mitogen activation of human T lymphocyte	[Mitogen activation of human T lymphocytes]	0.0	6	2	2	1
128656	1710	exposure of monocytic cell	[Exposure of monocytic cells]	0.0	4	1	1	1
128657	1710	b-cll cell death	[B-CLL cell death]	0.0	3	1	1	1
128658	1710	promoter construct in Jurkat cell	[promoter constructs in Jurkat cells]	0.0	5	1	1	1
128659	1710	contrast, oxidation	[contrast, oxidation]	0.0	2	1	1	1
128660	1710	acid sequence of NFATx1	[acid sequence of NFATx1]	0.0	4	1	1	1
128661	1710	two complex include Stat1 alpha	[two complexes including Stat1 alpha]	0.0	5	1	1	1
128662	1710	face of infection.	[face of infection.]	0.0	3	1	1	1
128663	1710	association of hla-dr3	[association of HLA-DR3]	0.0	3	1	1	1
128664	1710	genomic footprinting datum	[genomic footprinting data]	0.0	3	1	1	1
128665	1710	IL-12 developmental stage	[IL-12 developmental stage]	0.0	3	1	1	1
128666	1710	study of leukocyte in human endometrium	[studies of leukocytes in human endometrium]	0.0	6	1	1	1
128667	1710	B-cell immortalization by Epstein-Barr virus	[B-cell immortalization by Epstein-Barr virus]	0.0	5	1	1	1
128668	1710	characteristic domains,	[characteristic domains,]	0.0	2	1	1	1
128669	1710	phenotype of cell	[phenotypes of cells]	0.0	3	1	1	1
128670	1710	Stable transfection	[Stable transfection]	0.0	2	1	1	1
128671	1710	tissue in cd28+ T cell	[tissues in CD28+ T cells]	0.0	5	1	1	1
128672	1710	issue in herpesvirus biology	[issue in herpesvirus biology]	0.0	4	1	1	1
128673	1710	monocyte soluble interleukin-2 receptor	[monocytes soluble interleukin-2 receptor]	0.0	4	1	1	1
128674	1710	total ige (p	[total IgE (p]	0.0	3	1	1	1
128675	1710	expression of the il-2ralpha on phagocyte	[expression of the IL-2Ralpha on phagocytes]	0.0	6	1	1	1
128676	1710	replication of the template	[replication of the template]	0.0	4	1	1	1
128677	1710	independence despite a normal number	[independence despite a normal number]	0.0	5	1	1	1
128678	1710	creb /atf	[CREB /ATF]	0.0	2	1	1	1
128679	1710	active shp2-deltash2	[active SHP2-DeltaSH2]	0.0	2	1	1	1
128680	1710	status comparison	[status comparison]	0.0	2	1	1	1
128681	1710	dermal cell	[dermal cells]	0.0	2	1	1	1
128682	1710	long nuclear expression	[long-term nuclear expression]	0.0	3	1	1	1
128683	1710	phosphatase-positive giant cell from monocyte	[phosphatase-positive giant cells from monocytes]	0.0	5	1	1	1
128684	1710	transform growth factor-beta expression	[transforming growth factor-beta expression]	0.0	4	1	1	1
128685	1710	production macrophage precursors,	[production macrophage precursors,]	0.0	3	1	1	1
128686	1710	target for the agent	[target for the agents]	0.0	4	1	1	1
128687	1710	nuclear factor (NF)-AT AP-1/Octamer UPS	[nuclear factor (NF)-AT AP-1/Octamer UPS]	0.0	5	1	1	1
128688	1710	excessive sodium loss	[excessive sodium losses]	0.0	3	1	1	1
128689	1710	beta-globin expression during erythroid ontogeny	[beta-globin expression during erythroid ontogeny]	0.0	5	1	1	1
128690	1710	related retroviruse	[related retroviruses]	0.0	2	1	1	1
128691	1710	efficient viral DNA replication	[efficient viral DNA replication]	0.0	4	1	1	1
128692	1710	hotspot	[hotspot]	0.0	1	1	1	1
128693	1710	t-cell lymphoma with hyperplastic gcs	[T-cell lymphoma with hyperplastic GCs]	0.0	5	1	1	1
128694	1710	imbalanced expression of the receptor isoform	[Imbalanced expression of the receptor isoforms]	0.0	6	1	1	1
128695	1710	stimulation of hiv replication	[Stimulation of HIV replication]	0.0	4	1	1	1
128696	1710	tamoxifen a antagonist of E2	[tamoxifen an antagonist of E2]	0.0	5	1	1	1
128697	1710	cyp1a1 gene	[CYP1A1 gene]	0.0	2	1	1	1
128698	1710	interferon protein ip-10	[interferon protein IP-10]	0.0	3	1	1	1
128699	1710	subunits; genes, nfkb1 nfkb2	[subunits; genes, NFKB1 NFKB2]	0.0	4	1	1	1
128700	1710	nonresponsive hematopoietic progenitor	[nonresponsive hematopoietic progenitors]	0.0	3	1	1	1
128701	1710	yeast artificial chromosome transgene	[yeast artificial chromosome transgene]	0.0	4	1	1	1
128702	1710	tpa /ca2+	[TPA /Ca2+]	0.0	2	1	1	1
128703	1710	negative,	[Negative,]	0.0	1	1	1	1
128704	1710	carcinoma IDC	[carcinoma IDC]	0.0	2	1	1	1
128705	1710	apparent kd of nm	[apparent Kd of nM]	0.0	4	1	1	1
128706	1710	effect of selenium a component	[effects of selenium an component]	0.0	5	1	1	1
128707	1710	activity in gel shift assay	[activity in gel shift assays]	0.0	5	1	1	1
128708	1710	histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).	[histiocytoma rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).]	0.0	6	1	1	1
128709	1710	characterization binding to element 1	[characterization Binding to element 1]	0.0	5	1	1	1
128710	1710	healthy pregnant woman 10 second	[healthy pregnant women 10 second]	0.0	5	1	1	1
128711	1710	polymorphonuclear leukocyte adhesion to huvec	[polymorphonuclear leukocyte adhesion to HUVECs]	0.0	5	1	1	1
128712	1710	permanently a major challenge	[Permanently a major challenge]	0.0	4	1	1	1
128713	1710	g-csf 8% cell g-csf	[G-CSF 8% cells G-CSF]	0.0	4	1	1	1
128714	1710	activation of the provirus	[activation of the provirus]	0.0	4	1	1	1
128715	1710	extract of htlv-1-transformed cell	[extracts of HTLV-1-transformed cells]	0.0	4	1	1	1
128716	1710	decrease of sodium	[decrease of sodium]	0.0	3	1	1	1
128717	1710	period of activation,	[period of activation,]	0.0	3	1	1	1
128718	1710	negligible cytotoxic activity	[negligible cytotoxic activity]	0.0	3	1	1	1
128719	1710	multiple lineage	[multiple lineages]	0.0	2	1	1	1
128720	1710	current understanding of the mechanism	[current understanding of the mechanisms]	0.0	5	1	1	1
128721	1710	factor-mu negative regulator NF-muNR	[factor-mu negative regulator NF-muNR]	0.0	4	1	1	1
128722	1710	increase awareness of necrosis	[increasing awareness of necrosis]	0.0	4	1	1	1
128723	1710	hang transfer	[Hanging transfer]	0.0	2	1	1	1
128724	1710	effect of angiotensin (ang) ii	[effect of angiotensin (ANG) II]	0.0	5	1	1	1
128725	1710	hiv-infected cell with antibody	[HIV-infected cells with antibody]	0.0	4	1	1	1
128726	1710	disease MRD of patient	[disease MRD of patients]	0.0	4	1	1	1
128727	1710	primate lentiviruse	[primate lentiviruses]	0.0	2	1	1	1
128728	1710	two drugs, one	[two drugs, one]	0.0	3	1	1	1
128729	1710	mAECA to aortic ec	[mAECA to aortic EC]	0.0	4	1	1	1
128730	1710	mitogen for vascular muscle cell	[mitogen for vascular muscle cells]	0.0	5	1	1	1
128731	1710	b-cell by ebv	[B-cells by EBV]	0.0	3	1	1	1
128732	1710	switch by cytokine	[switching by cytokines]	0.0	3	1	1	1
128733	1710	include phytohemagglutinin pha	[including phytohemagglutinin PHA]	0.0	3	1	1	1
128734	1710	g-csf cell at day 6; g-csf	[G-CSF cells at day 6; G-CSF]	0.0	6	1	1	1
128735	1710	myeloid differentiation a model	[myeloid differentiation a model]	0.0	4	1	1	1
128736	1710	CIITA mutant construction	[CIITA mutant constructions]	0.0	3	1	1	1
128737	1710	ionomycin glycerol	[ionomycin glycerol]	0.0	2	1	1	1
128738	1710	CstF-64 to the polyA site	[CstF-64 to the polyA site]	0.0	5	1	1	1
128739	1710	protein extract from leukemia cell	[protein extracts from leukemia cells]	0.0	5	1	1	1
128740	1710	act on AP-1- binding site	[acting on AP-1- binding sites]	0.0	5	1	1	1
128741	1710	different mobility of extract-DNA complex	[different mobilities of extract-DNA complexes]	0.0	5	1	1	1
128742	1710	5 rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione	[5 rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione]	0.0	5	1	1	1
128743	1710	reticulum ser ca2+-atpase	[reticulum SER Ca2+-ATPase]	0.0	3	1	1	1
128744	1710	myelomonocytic expression	[myelomonocytic expression]	0.0	2	1	1	1
128745	1710	finally, potential target of regulation	[Finally, potential targets of regulation]	0.0	5	1	1	1
128746	1710	effect of sesquiterpene lactone	[effect of sesquiterpene lactones]	0.0	4	1	1	1
128747	1710	action of the thiazolidinedion	[actions of the thiazolidinediones]	0.0	4	1	1	1
128748	1710	hypothesis requirement for the formation	[hypothesis requirements for the formation]	0.0	5	1	1	1
128749	1710	ways.	[ways.]	0.0	1	2	2	1
128750	1710	neutrophil with factor	[neutrophils with factor]	0.0	3	1	1	1
128751	1710	gamma ECS responsiveness	[gamma ECS responsiveness]	0.0	3	1	1	1
128752	1710	regulation role of activator protein	[Regulation role of activator protein]	0.0	5	1	1	1
128753	1710	activation of the NF-kappaB	[activation of the NF-kappaB]	0.0	4	1	1	1
128754	1710	Ile50Val	[Ile50Val]	0.0	1	1	1	1
128755	1710	woman young	[women younger]	0.0	2	2	2	1
128756	1710	association of carboxyl terminus	[association of carboxyl terminus]	0.0	4	1	1	1
128757	1710	id3 protein	[Id3 protein]	0.0	2	1	1	1
128758	1710	problem for patient with leukemia	[problem for patients with leukemia]	0.0	5	1	1	1
128759	1710	cell by a silencer	[cells by a silencer]	0.0	4	1	1	1
128760	1710	acetylation of Kruppel-like factor activity	[Acetylation of Kruppel-like factor activity]	0.0	5	1	1	1
128761	1710	chronic disease with rheumatoid arthritis	[chronic diseases with rheumatoid arthritis]	0.0	5	1	1	1
128762	1710	use two experimental approach	[using two experimental approaches]	0.0	4	1	1	1
128763	1710	increase of ca2+	[increase of Ca2+]	0.0	3	1	1	1
128764	1710	positive role for otf-2	[positive role for OTF-2]	0.0	4	1	1	1
128765	1710	suboptimal concentration of a beta	[suboptimal concentrations of A beta]	0.0	5	1	1	1
128766	1710	two ligand-induced, docking site	[two ligand-induced, docking sites]	0.0	4	1	1	1
128767	1710	inhibitory IkappaB mutant	[inhibitory IkappaB mutant]	0.0	3	1	1	1
128768	1710	Raw cell	[Raw cells]	0.0	2	1	1	1
128769	1710	metabolic status after conservative surgery comparison	[metabolic status after conservative surgery comparison]	0.0	6	1	1	1
128770	1710	action to the monocyte	[action to the monocytes]	0.0	4	1	1	1
128771	1710	1-(5-chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride ml-9	[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride ML-9]	0.0	3	1	1	1
128772	1710	HaCaT cell line	[HaCaT cell line]	0.0	3	1	1	1
128773	1710	regulation 1 expression	[regulation 1 expression]	0.0	3	1	1	1
128774	1710	human immunodeficiency virus-type	[Human immunodeficiency virus-type]	0.0	3	1	1	1
128775	1710	interleukin receptor alpha-chain il-2r alpha	[interleukin receptor alpha-chain IL-2R alpha]	0.0	5	1	1	1
128776	1710	IL-4 response element	[IL-4 response element]	0.0	3	1	1	1
128777	1710	acute respiratory distress syndrome	[acute respiratory distress syndrome]	0.0	4	1	1	1
128778	1710	level for chemotactic protein-1	[levels for chemotactic protein-1]	0.0	4	1	1	1
128779	1710	consequence for the function	[consequences for the function]	0.0	4	1	1	1
128780	1710	receptor on t-lymphocyte	[receptor on T-lymphocytes]	0.0	3	1	1	1
128781	1710	epidermal basal cell	[epidermal basal cells]	0.0	3	1	1	1
128782	1710	individual colony	[individual colonies]	0.0	2	1	1	1
128783	1710	hyperplastic gcs	[hyperplastic GCs]	0.0	2	1	1	1
128784	1710	blood cell receptor in volunteer	[Blood cell receptors in volunteers]	0.0	5	1	1	1
128785	1710	135-(oh)2d3 receptors; 2)	[1,25-(OH)2D3 receptors; 2)]	0.0	3	1	1	1
128786	1710	X2 binds.	[X2 binds.]	0.0	2	1	1	1
128787	1710	surprisingly, however, removal of pc4	[Surprisingly, however, removal of PC4]	0.0	5	1	1	1
128788	1710	anti-ig inducibility	[anti-Ig inducibility]	0.0	2	1	1	1
128789	1710	icr27tk.3 T cell	[ICR27TK.3 T cells]	0.0	3	1	1	1
128790	1710	t-cell-specific activator	[T-cell-specific activator]	0.0	2	1	1	1
128791	1710	specific protein	[specific proteins]	0.0	2	1	1	1
128792	1710	increase-ratio (post/pre ratio)	[increase-ratios (post/pre ratio)]	0.0	3	1	1	1
128793	1710	cell nf-at	[cells NF-AT]	0.0	2	1	1	1
128794	1710	far the potent site	[far the potent site]	0.0	4	1	1	1
128795	1710	276 mumol cortisol	[276 mumol cortisol]	0.0	3	1	1	1
128796	1710	brief review	[brief review]	0.0	2	1	1	1
128797	1710	FH adenopathy	[FH adenopathy]	0.0	2	1	1	1
128798	1710	extent of proliferation	[extent of proliferation]	0.0	3	1	1	1
128799	1710	correlation between VDR concentration	[correlation between VDR concentration]	0.0	4	1	1	1
128800	1710	form partially substitute	[form partially substitutes]	0.0	3	1	1	1
128801	1710	NF-kappa b in	[NF-kappa B in]	0.0	3	1	1	1
128802	1710	immunodeficiency virus apoptosis	[immunodeficiency virus apoptosis]	0.0	3	1	1	1
128803	1710	protein Oct-1	[proteins Oct-1]	0.0	2	1	1	1
128804	1710	chromosome of L.	[chromosome of L.]	0.0	3	1	1	1
128805	1710	reactivity of monoclonal antibody	[reactivity of monoclonal antibodies]	0.0	4	1	1	1
128806	1710	direct suppression during infection	[Direct suppression during infection]	0.0	4	1	1	1
128807	1710	genetic makaume mtbe	[genetic makeup, MTBE]	0.0	3	1	1	1
128808	1710	number of regulatory sequence	[number of regulatory sequences]	0.0	4	1	1	1
128809	1710	replacement of homodimer with heterodimer	[replacement of homodimers with heterodimers]	0.0	5	1	1	1
128810	1710	3'-end	[3'-end]	0.0	1	1	1	1
128811	1710	nuclear factor-kappaB in memory	[nuclear factor-kappaB in memory]	0.0	4	1	1	1
128812	1710	percentage of the subset	[percentages of the subsets]	0.0	4	1	1	1
128813	1710	cotransfection with a negative mutant	[Cotransfection with a negative mutant]	0.0	5	1	1	1
128814	1710	joint requirement for pc4 component	[joint requirement for PC4 component]	0.0	5	1	1	1
128815	1710	demonstration of a interaction	[demonstration of a interaction]	0.0	4	1	1	1
128816	1710	none of the putative site	[None of the putative sites]	0.0	5	1	1	1
128817	1710	harbor a human yeast chromosome transgene	[harboring a human yeast chromosome transgene]	0.0	6	1	1	1
128818	1710	bifunctional regulator of growth of cell	[bifunctional regulators of growth of cells]	0.0	6	1	1	1
128819	1710	igg FcgammaRI	[IgG FcgammaRI]	0.0	2	1	1	1
128820	1710	genome homologue of four herpesviruse	[genome homologues of four herpesviruses]	0.0	5	1	1	1
128821	1710	synergistic complex formation	[synergistic complex formation]	0.0	3	1	1	1
128822	1710	class of growth gene	[class of growth genes]	0.0	4	1	1	1
128823	1710	form of vitamin D3	[form of vitamin D3]	0.0	4	1	1	1
128824	1710	H-8, a kinase inhibitor	[H-8, a kinase inhibitor]	0.0	4	1	1	1
128825	1710	previous experiment	[previous experiments]	0.0	2	1	1	1
128826	1710	incubation with oleate microg/mL lps	[incubation with oleate microg/mL LPS]	0.0	5	1	1	1
128827	1710	Chinese medicine chan'su	[Chinese medicine chan'su]	0.0	3	1	1	1
128828	1710	genomic response	[genomic response]	0.0	2	1	1	1
128829	1710	more genetic change in the form	[more genetic changes in the form]	0.0	6	1	1	1
128830	1710	mononuclear leukocyte glucocorticoid	[Mononuclear leukocyte glucocorticoid]	0.0	3	1	1	1
128831	1710	single injection	[single injection]	0.0	2	1	1	1
128832	1710	induction of factor-kappaB NFkappaB	[induction of factor-kappaB NFkappaB]	0.0	4	1	1	1
128833	1710	mechanism influence immunodeficiency virus replication	[mechanism influencing immunodeficiency virus replication]	0.0	5	1	1	1
128834	1710	However, examination of activity	[However, examination of activity]	0.0	4	1	1	1
128835	1710	intrinsic potential for mutation expansion	[intrinsic potential for mutation expansion]	0.0	5	1	1	1
128836	1710	parameter of the protein	[parameters of the proteins]	0.0	4	1	1	1
128837	1710	TNF regulation	[TNF regulation]	0.0	2	1	1	1
128838	1710	jun family include c-jun	[jun family including c-jun]	0.0	4	1	1	1
128839	1710	mutant of SIVmacMER derivative	[mutants of SIVmacMER derivative]	0.0	4	1	1	1
128840	1710	primitive hpc high-proliferative colony-forming cell	[primitive HPCs high-proliferative colony-forming cells]	0.0	5	1	1	1
128841	1710	Specific binding	[Specific binding]	0.0	2	1	1	1
128842	1710	cascade culminate in cell differentiation	[cascade culminating in cell differentiation]	0.0	5	1	1	1
128843	1710	regulation of the activator nf-kappa b	[regulation of the activator NF-kappa B]	0.0	6	1	1	1
128844	1710	T cell commitment	[T cell commitment]	0.0	3	1	1	1
128845	1710	reversible loss of phorbol differentiation	[reversible loss of phorbol differentiation]	0.0	5	1	1	1
128846	1710	molecule on Jurkat T cell	[molecules on Jurkat T cells]	0.0	5	1	1	1
128847	1710	well-defined gc border	[well-defined GC borders]	0.0	3	1	1	1
128848	1710	cem-c1 cell	[CEM-C1 cells]	0.0	2	1	1	1
128849	1710	several aspect of IBR/F	[several aspects of IBR/F]	0.0	4	1	1	1
128850	1710	isolation of the exon	[Isolation of the exon]	0.0	4	1	1	1
128851	1710	NF-kappaB /rel family	[NF-kappaB /Rel family]	0.0	3	1	1	1
128852	1710	distinct lipopolysaccharide	[distinct lipopolysaccharide]	0.0	2	1	1	1
128853	1710	major NFAT family member	[major NFAT family member]	0.0	4	1	1	1
128854	1710	hypothesis concern the role	[hypothesis concerning the role]	0.0	4	1	1	1
128855	1710	human tonsillar	[human tonsillar]	0.0	2	1	1	1
128856	1710	GATA-3 initiation site	[GATA-3 initiation site]	0.0	3	1	1	1
128857	1710	il-7 signal	[IL-7 signaling]	0.0	2	1	1	1
128858	1710	pha related to the importance	[PHA related to the importance]	0.0	5	1	1	1
128859	1710	cemxl74 cell nfkappab	[CEMxl74 cells NFKappaB]	0.0	3	1	1	1
128860	1710	tumorigenic transformation	[tumorigenic transformation]	0.0	2	1	1	1
128861	1710	leukocyte by stimulus	[leukocytes by stimuli]	0.0	3	1	1	1
128862	1710	blastic transformation	[blastic transformation]	0.0	2	1	1	1
128863	1710	hybrid clone,	[hybrid clone,]	0.0	2	1	1	1
128864	1710	tyrosine-phosphorylated granulocyte-colony factor treatment of neutrophils.	[tyrosine-phosphorylated granulocyte-colony factor treatment of neutrophils.]	0.0	6	1	1	1
128865	1710	TAP-deficient cell line lack er peptide	[TAP-deficient cell lines lacking ER peptides]	0.0	6	1	1	1
128866	1710	activation after CD40 trigger	[Activation after CD40 triggering]	0.0	4	1	1	1
128867	1710	moreover, anti- TNF-alpha hiv-1 repeat LTR	[Moreover, anti- TNF-alpha HIV-1 repeat LTR]	0.0	6	1	1	1
128868	1710	coproporphyrinogen oxidase gene	[coproporphyrinogen oxidase gene]	0.0	3	1	1	1
128869	1710	(irf) family of protein	[(IRF) family of proteins]	0.0	4	1	1	1
128870	1710	use ligand to acid receptor	[Using ligands to acid receptors]	0.0	5	1	1	1
128871	1710	colour fish	[colour FISH]	0.0	2	1	1	1
128872	1710	D3 analog	[D3 analogs]	0.0	2	1	1	1
128873	1710	such as downregulation of major molecule	[such as downregulation of major molecules]	0.0	6	1	1	1
128874	1710	low level of response element-binding activity	[low levels of response element-binding activity]	0.0	6	1	1	1
128875	1710	occur mutation t-c)	[occurring mutation T-C)]	0.0	3	1	1	1
128876	1710	mediate the release	[mediating the release]	0.0	3	1	1	1
128877	1710	antigen anti-viral antigen	[antigen anti-viral antigen]	0.0	3	1	1	1
128878	1710	only dna-binding activity	[only DNA-binding activity]	0.0	3	1	1	1
128879	1710	nonspecific reactive hyperplasia	[nonspecific reactive hyperplasia]	0.0	3	1	1	1
128880	1710	deleterious mechanism fundamentally related	[deleterious mechanism fundamentally related]	0.0	4	1	1	1
128881	1710	interference activity of Ikaros isoform	[interference activity of Ikaros isoforms]	0.0	5	1	1	1
128882	1710	however, suppression	[However, suppression]	0.0	2	1	1	1
128883	1710	halflife	[halflife]	0.0	1	1	1	1
128884	1710	(range from 11.1 to 174))	[(ranging from 11.1 to 17.4),]	0.0	5	1	1	1
128885	1710	proinflammatory event	[proinflammatory events]	0.0	2	1	1	1
128886	1710	human homologue activation of immunity	[human homologue activation of immunity]	0.0	5	1	1	1
128887	1710	molecular origin	[molecular origin]	0.0	2	1	1	1
128888	1710	specific p38 mapk inhibitor	[specific p38 MAPk inhibitor]	0.0	4	1	1	1
128889	1710	272 amino acid	[272 amino acids]	0.0	3	1	1	1
128890	1710	constitutive association with each stat5 isomer	[constitutive association with each STAT5 isomer]	0.0	6	1	1	1
128891	1710	biological form	[biological form]	0.0	2	1	1	1
128892	1710	disproportionate severity of sign	[disproportionate severity of signs]	0.0	4	1	1	1
128893	1710	macrophages/	[macrophages/]	0.0	1	1	1	1
128894	1710	grow in vitro	[growing in vitro]	0.0	3	1	1	1
128895	1710	weight of 50 kD	[weight of 50 kD]	0.0	4	1	1	1
128896	1710	24 h with methylprednisolone	[24 h with methylprednisolone]	0.0	4	1	1	1
128897	1710	detectable activation of caspase	[detectable activation of caspase]	0.0	4	1	1	1
128898	1710	recent finding of association	[recent findings of associations]	0.0	4	1	1	1
128899	1710	production of interleukin il-2	[production of interleukin IL-2]	0.0	4	1	1	1
128900	1710	mitogenic stimulation with phytohaemagglutinin	[mitogenic stimulation with phytohaemagglutinin]	0.0	4	1	1	1
128901	1710	link to responses.	[link to responses.]	0.0	3	1	1	1
128902	1710	primary granule protein	[primary granule proteins]	0.0	3	1	1	1
128903	1710	glucocorticoid-resistant cell lack receptor.	[glucocorticoid-resistant cells lacking receptor.]	0.0	4	1	1	1
128904	1710	two potential nuclear factor	[two potential nuclear factor]	0.0	4	1	1	1
128905	1710	two factor kB NF-kB element	[two factor kB NF-kB elements]	0.0	5	1	1	1
128906	1710	atf1 isoform	[ATF1 isoforms]	0.0	2	1	1	1
128907	1710	susceptibility to malaria	[susceptibility to malaria]	0.0	3	1	1	1
128908	1710	unphosphorylated 27-kda protein	[unphosphorylated 27-kDa protein]	0.0	3	1	1	1
128909	1710	child under long term treatment	[children under long term treatment]	0.0	5	1	1	1
128910	1710	potential domain	[potential domains]	0.0	2	1	1	1
128911	1710	interleukin mrna level	[interleukin mRNA levels]	0.0	3	1	1	1
128912	1710	toxic shock syndrome	[toxic shock syndrome]	0.0	3	1	1	1
128913	1710	Ciprofibrate a proliferator	[Ciprofibrate an proliferator]	0.0	3	1	1	1
128914	1710	difference in the immune system	[differences in the immune system]	0.0	5	1	1	1
128915	1710	hepatic nuclear factor beta	[hepatic nuclear factor beta]	0.0	4	1	1	1
128916	1710	gcrbeta -specific antibody	[GCRbeta -specific antibody]	0.0	3	1	1	1
128917	1710	Intratracheal instillation of IL-6 alone	[Intratracheal instillation of IL-6 alone]	0.0	5	1	1	1
128918	1710	access Epstein-Barr virus memory with cell	[Accessing Epstein-Barr virus memory with cells]	0.0	6	1	1	1
128919	1710	PGE2 modulation	[PGE2 modulation]	0.0	2	1	1	1
128920	1710	relation to features: clinical implications.	[relations to features: clinical implications.]	0.0	5	1	1	1
128921	1710	suggest a direct action	[suggesting a direct action]	0.0	4	1	1	1
128922	1710	risk factor for atherosclerosis	[risk factor for atherosclerosis]	0.0	4	1	1	1
128923	1710	histocompatibility complex class transactivator	[histocompatibility complex class transactivator]	0.0	4	1	1	1
128924	1710	sixteen anorexic patient (range	[Sixteen anorexic patients (ranging]	0.0	4	1	1	1
128925	1710	stage-specific factor-DNA complex	[stage-specific factor-DNA complexes]	0.0	3	1	1	1
128926	1710	rapid twofold increase	[rapid twofold increase]	0.0	3	1	1	1
128927	1710	express (mhc) class gene	[expressing (MHC) class genes]	0.0	4	1	1	1
128928	1710	lead to gene response	[leading to gene responses]	0.0	4	1	1	1
128929	1710	anti-cd3 antibody	[anti-CD3 antibodies]	0.0	2	1	1	1
128930	1710	syndrome patient	[syndrome patients]	0.0	2	1	1	1
128931	1710	repeat CAT construct	[repeat CAT constructs]	0.0	3	1	1	1
128932	1710	mobility shift analysis utilize oligonucleotide	[mobility shift analyses utilizing oligonucleotides]	0.0	5	1	1	1
128933	1710	polypeptide of kD	[polypeptides of kD]	0.0	3	1	1	1
128934	1710	low level of c-myb protein	[low levels of c-Myb protein]	0.0	5	1	1	1
128935	1710	acute leukemia-M3	[acute leukemia-M3]	0.0	2	1	1	1
128936	1710	expression in ec	[expression in EC]	0.0	3	1	1	1
128937	1710	phosphatase activity cn	[phosphatase activity CN]	0.0	3	1	1	1
128938	1710	genetic target for early factor	[genetic target for early factor]	0.0	5	1	1	1
128939	1710	low plasma cysteine level	[low plasma cysteine levels]	0.0	4	1	1	1
128940	1710	selection against the expression	[selection against the expression]	0.0	4	1	1	1
128941	1710	expression of most gene	[expression of most genes]	0.0	4	1	1	1
128942	1710	toxicity towards lymphocyte	[toxicity towards lymphocytes]	0.0	3	1	1	1
128943	1710	underlie the translocation of b	[underlying the translocation of B]	0.0	5	1	1	1
128944	1710	hypercortisolemic patient suffer	[hypercortisolemic patients suffering]	0.0	3	1	1	1
128945	1710	elevation in the level	[elevations in the levels]	0.0	4	1	1	1
128946	1710	down-modulation of /monocytic hpc growth	[down-modulation of /monocytic HPC growth]	0.0	5	1	1	1
128947	1710	low temperature degree c)	[low temperature degrees C)]	0.0	4	1	1	1
128948	1710	gc receptor affinity	[GC receptor affinity]	0.0	3	1	1	1
128949	1710	concentration of receptor of form	[Concentration of receptors of form]	0.0	5	1	1	1
128950	1710	adhesive property of cell	[adhesive properties of cells]	0.0	4	1	1	1
128951	1710	cloning of human gata-4	[cloning of human GATA-4]	0.0	4	1	1	1
128952	1710	range from q13	[ranging from q13]	0.0	3	1	1	1
128953	1710	CIITA construct	[CIITA constructs]	0.0	2	1	1	1
128954	1710	inhibition phorbol ester	[inhibition phorbol ester]	0.0	3	1	1	1
128955	1710	specific positive regulation	[specific positive regulation]	0.0	3	1	1	1
128956	1710	differential treatment with growth factor	[differential treatment with growth factors]	0.0	5	1	1	1
128957	1710	region (position -69 responsive	[region (positions -69 responsive]	0.0	4	1	1	1
128958	1710	formation of complex common	[formation of complexes common]	0.0	4	1	1	1
128959	1710	DNA-protein interaction involve nuclear factor	[DNA-protein interactions involving nuclear factor]	0.0	5	1	1	1
128960	1710	differ in degree of glycosylation	[differing in degree of glycosylation]	0.0	5	1	1	1
128961	1710	crucial molecule	[crucial molecules]	0.0	2	1	1	1
128962	1710	soccer player	[soccer players]	0.0	2	1	1	1
128963	1710	neoplastic disorder	[neoplastic disorders]	0.0	2	1	1	1
128964	1710	two substance	[two substances]	0.0	2	1	1	1
128965	1710	methyl prednisolone for 10 days.	[methyl prednisolone for 10 days.]	0.0	5	1	1	1
128966	1710	class II-positive glioblastoma cell line	[class II-positive glioblastoma cell line]	0.0	5	1	1	1
128967	1710	ricket -like disease	[rickets -like diseases]	0.0	3	2	2	1
128968	1710	analysis of protein kinase c--responsive element	[analysis of protein kinase C--responsive elements]	0.0	6	1	1	1
128969	1710	glucocorticoid in monocyte	[glucocorticoids in monocytes]	0.0	3	1	1	1
128970	1710	potent effector	[potent effector]	0.0	2	1	1	1
128971	1710	awareness of necrosis of bone	[awareness of necrosis of bone]	0.0	5	1	1	1
128972	1710	treatment of vein cell monolayer	[Treatment of vein cell monolayers]	0.0	5	1	1	1
128973	1710	inhibitory protein in lps monocyte	[inhibitory protein in LPS monocytes]	0.0	5	1	1	1
128974	1710	productive form of Epstein-Barr DNA	[productive form of Epstein-Barr DNA]	0.0	5	1	1	1
128975	1710	prolonged exposure of aortic cell HAEC	[prolonged exposure of aortic cells HAEC]	0.0	6	1	1	1
128976	1710	intrinsic stimulus	[intrinsic stimulus]	0.0	2	1	1	1
128977	1710	24-hydroxylated metabolite polar than 135(oh)2d3	[24-hydroxylated metabolites polar than 1,25(OH)2D3]	0.0	5	1	1	1
128978	1710	peripheral blood monocyte pbmo	[peripheral blood monocytes PBMo]	0.0	4	1	1	1
128979	1710	depletion from SCID-HU- int mouse	[depletion from SCID-HU- INT mice]	0.0	5	1	1	1
128980	1710	ibr sites.	[IBR sites.]	0.0	2	1	1	1
128981	1710	structural feature of the rna	[structural feature of the RNA]	0.0	5	1	1	1
128982	1710	5' base pair	[5' base pairs]	0.0	3	1	1	1
128983	1710	three isoform of NFATx	[three isoforms of NFATx]	0.0	4	1	1	1
128984	1710	activation of human thymocyte	[Activation of human thymocytes]	0.0	4	1	1	1
128985	1710	selection marker	[selection marker]	0.0	2	1	1	1
128986	1710	influence on the induction of expression	[influence on the induction of expression]	0.0	6	1	1	1
128987	1710	migrate complex	[migrating complex]	0.0	2	1	1	1
128988	1710	inflammatory stimulus notably product	[inflammatory stimuli notably products]	0.0	4	1	1	1
128989	1710	lysis.	[lysis.]	0.0	1	1	1	1
128990	1710	subunit in this cell line,	[subunits in this cell line,]	0.0	5	1	1	1
128991	1710	complex phenomenon	[complex phenomenon]	0.0	2	1	1	1
128992	1710	uncomplicated pregnancy by measurement	[uncomplicated pregnancies by measurement]	0.0	4	1	1	1
128993	1710	Oct-1 in nf-atp	[Oct-1 in NF-ATp]	0.0	3	1	1	1
128994	1710	correlation between inflammation receptor positivity	[correlation between inflammation receptor positivity]	0.0	5	1	1	1
128995	1710	distinct pattern	[distinct patterns]	0.0	2	5	5	1
128996	1710	p27kip1 gene from murine DNA	[p27Kip1 gene from murine DNA]	0.0	5	1	1	1
128997	1710	only in the structure	[only in the structures]	0.0	4	1	1	1
128998	1710	interaction between multiple element	[interactions between multiple elements]	0.0	4	1	1	1
128999	1710	possible linkage polymorphism	[possible linkage polymorphism]	0.0	3	1	1	1
129000	1710	persistent type	[persistent type]	0.0	2	1	1	1
129001	1710	high kinase activity	[high kinase activity]	0.0	3	1	1	1
129002	1710	decrease in the order.	[decrease in the order.]	0.0	4	1	1	1
129003	1710	potent IL-1/tumor necrosis element	[potent IL-1/tumor necrosis element]	0.0	4	1	1	1
129004	1710	nonphlogistic clearance	[nonphlogistic clearance]	0.0	2	1	1	1
129005	1710	describe the activation of gene	[describing the activation of genes]	0.0	5	1	1	1
129006	1710	potential sequence similar	[potential sequences similar]	0.0	3	1	1	1
129007	1710	phase.	[phase.]	0.0	1	1	1	1
129008	1710	phase,	[phase,]	0.0	1	1	1	1
129009	1710	inhibition of p105 processing	[Inhibition of p105 processing]	0.0	4	1	1	1
129010	1710	chromosome 5q23-31	[chromosome 5q23-31]	0.0	2	1	1	1
129011	1710	delivery of protein	[delivery of proteins]	0.0	3	1	1	1
129012	1710	intense T	[intense T]	0.0	2	1	1	1
129013	1710	anti-ERK kinase antibody	[anti-ERK kinase antibodies]	0.0	3	1	1	1
129014	1710	opposite effect on RA -dependent differentiation	[opposite effects on RA -dependent differentiation]	0.0	6	1	1	1
129015	1710	age-matched control subject	[age-matched control subjects]	0.0	3	1	1	1
129016	1710	signal pathway responsible	[signaling pathways responsible]	0.0	3	1	1	1
129017	1710	glucocorticoid receptor binding from ms patient	[glucocorticoid receptor binding from MS patients]	0.0	6	1	1	1
129018	1710	Addition of r-htbp-1 during the h	[Addition of r-hTBP-1 during the h]	0.0	6	1	1	1
129019	1710	Indeed, transient transfection	[Indeed, transient transfection]	0.0	3	1	1	1
129020	1710	three zinc finger of the c2h2-type	[three zinc fingers of the C2H2-type]	0.0	6	1	1	1
129021	1710	friend virus	[Friend virus]	0.0	2	1	1	1
129022	1710	sensitivity to retinoic acid differentiation	[sensitivity to retinoic acid differentiation]	0.0	5	1	1	1
129023	1710	nuclear nf-kb	[nuclear NF-kB]	0.0	2	1	1	1
129024	1710	glutathione -s-transferase assay	[glutathione -S-transferase assay]	0.0	3	1	1	1
129025	1710	kd (30.3+/-2.5 versus 19.2+/-2.4 nmol/L)	[Kd (30.3+/-2.5 versus 19.2+/-2.4 nmol/L)]	0.0	5	1	1	1
129026	1710	three 21-bp repeat	[three 21-bp repeats]	0.0	3	1	1	1
129027	1710	two enzyme participate	[two enzymes participating]	0.0	3	1	1	1
129028	1710	respect use a bind assay	[respect using a binding assay]	0.0	5	1	1	1
129029	1710	cd38(-) cell differentiate in erythroid culture	[CD38(-) cells differentiating in erythroid cultures]	0.0	6	1	1	1
129030	1710	blast from patient with acute leukaemia	[blasts from patients with acute leukaemia]	0.0	6	1	1	1
129031	1710	carbonic anhydrase	[carbonic anhydrase]	0.0	2	1	1	1
129032	1710	form of activation.	[form of activation.]	0.0	3	1	1	1
129033	1710	serum ige in subject heterozygotic	[serum IgE in subjects heterozygotic]	0.0	5	1	1	1
129034	1710	25 cell carcinoma use immunohistochemistry	[25 cell carcinomas using immunohistochemistry]	0.0	5	1	1	1
129035	1710	glucocorticoid receptor in steroid-resistant asthma	[glucocorticoid receptor in steroid-resistant asthma]	0.0	5	1	1	1
129036	1710	leukemic cell line model	[leukemic cell line model]	0.0	4	1	1	1
129037	1710	b-acute	[B-acute]	0.0	1	1	1	1
129038	1710	expression of Jagged1	[expression of Jagged1]	0.0	3	1	1	1
129039	1710	32pi-labeled stat5 binding site	[32Pi-labeled STAT5 binding site]	0.0	4	1	1	1
129040	1710	I interferon ifn-alpha/beta to receptor	[I interferon IFN-alpha/beta to receptors]	0.0	5	1	1	1
129041	1710	clinical therapeutic initiative	[clinical therapeutic initiative]	0.0	3	1	1	1
129042	1710	responsiveness to p40tax	[responsiveness to p40tax]	0.0	3	1	1	1
129043	1710	response to phorbol 13-acetate	[response to phorbol 13-acetate]	0.0	4	1	1	1
129044	1710	affinity column fraction,	[affinity column fraction,]	0.0	3	1	1	1
129045	1710	cell target	[cell targets]	0.0	2	1	1	1
129046	1710	almost value	[almost values]	0.0	2	1	1	1
129047	1710	growth factor-1	[growth factor-1]	0.0	2	1	1	1
129048	1710	5' utr	[5' UTR]	0.0	2	1	1	1
129049	1710	icam-1 molecules,	[ICAM-1 molecules,]	0.0	2	1	1	1
129050	1710	mainly sesquiterpene lactone	[mainly sesquiterpene lactones]	0.0	3	1	1	1
129051	1710	growth factor-B	[growth factor-B]	0.0	2	1	1	1
129052	1710	course 0.05, chi2	[course 0.05, chi2]	0.0	3	1	1	1
129053	1710	il-5 production	[IL-5 production]	0.0	2	1	1	1
129054	1710	control of CD4 transcription	[control of CD4 transcription]	0.0	4	1	1	1
129055	1710	40 late promoter erratum	[40 late promoter erratum]	0.0	4	1	1	1
129056	1710	bcr1 type-pml/RAR alpha fusion	[bcr1 type-pml/RAR alpha fusion]	0.0	4	1	1	1
129057	1710	depend on the rate	[depending on the rate]	0.0	4	1	1	1
129058	1710	induction of il-10 production	[induction of IL-10 production]	0.0	4	1	1	1
129059	1710	regulate immunodeficiency virus persistence	[regulating immunodeficiency virus persistence]	0.0	4	2	2	1
129060	1710	region of 0.7 kb	[region of 0.7 kb]	0.0	4	1	1	1
129061	1710	posttranslational modification of protein	[posttranslational modification of proteins]	0.0	4	1	1	1
129062	1710	organism avirulent	[organism avirulent]	0.0	2	1	1	1
129063	1710	displacement of fatty acid	[displacement of fatty acids]	0.0	4	1	1	1
129064	1710	form a response	[form a response]	0.0	3	1	1	1
129065	1710	granule population	[granule populations]	0.0	2	1	1	1
129066	1710	diversity generation	[diversity generation]	0.0	2	1	1	1
129067	1710	dominant function in the absence	[dominant functions in the absence]	0.0	5	1	1	1
129068	1710	(activated)	[(activated)]	0.0	1	1	1	1
129069	1710	(mnc)	[(MNC)]	0.0	1	1	1	1
129070	1710	htlv-i tumor	[HTLV-I tumors]	0.0	2	1	1	1
129071	1710	gr mrna turnover	[GR mRNA turnover]	0.0	3	1	1	1
129072	1710	exonic cryptic splice site	[exonic cryptic splice site]	0.0	4	1	1	1
129073	1710	nucleus, correlate	[nucleus, correlating]	0.0	2	1	1	1
129074	1710	70/z3-derived murine pre-B cell line	[70/Z3-derived murine pre-B cell line]	0.0	5	1	1	1
129075	1710	fibrosarcoma histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	5	1	1	1
129076	1710	novel loci relevant	[novel loci relevant]	0.0	3	1	1	1
129077	1710	methyl prednisolone 120 mg/day) for days.	[methyl prednisolone 120 mg/day) for days.]	0.0	6	1	1	1
129078	1710	only by a immunosorbent assay	[only by an immunosorbent assay]	0.0	5	1	1	1
129079	1710	control (HIV) repeat	[control (HIV) repeat]	0.0	3	1	1	1
129080	1710	61 stage	[61 Stage]	0.0	2	1	1	1
129081	1710	selective cck(b) receptor antagonist	[selective CCK(B) receptor antagonist]	0.0	4	1	1	1
129082	1710	sertraline responder	[sertraline responders]	0.0	2	1	1	1
129083	1710	function of related protein	[function of related proteins]	0.0	4	1	1	1
129084	1710	thymus-derived t-cell homeostasis	[thymus-derived T-cell homeostasis]	0.0	3	1	1	1
129085	1710	critical tool	[critical tools]	0.0	2	1	1	1
129086	1710	991.9 ng/mL,	[991.9 ng/mL,]	0.0	2	1	1	1
129087	1710	approach significance for patient	[approaching significance for patients]	0.0	4	1	1	1
129088	1710	receptor gcR in lymphocyte	[receptors gcR in lymphocytes]	0.0	4	1	1	1
129089	1710	anti-p-selectin antibody	[anti-P-selectin antibodies]	0.0	2	1	1	1
129090	1710	direct the synthesis	[directing the synthesis]	0.0	3	1	1	1
129091	1710	steroid hormone expression	[steroid hormone expression]	0.0	3	1	1	1
129092	1710	gas DNA binding pattern	[GAS DNA binding patterns]	0.0	4	1	1	1
129093	1710	two domain act together	[two domains acting together]	0.0	4	1	1	1
129094	1710	constitutive dnase site	[constitutive DNase site]	0.0	3	1	1	1
129095	1710	retinoic acid differentiation	[retinoic acid differentiation]	0.0	3	1	1	1
129096	1710	normalize effect on pattern increase	[normalizing effect on patterns increase]	0.0	5	1	1	1
129097	1710	drand_ reporter construct	[DRA/DQB reporter constructs]	0.0	3	1	1	1
129098	1710	partial sensitivity	[partial sensitivity]	0.0	2	1	1	1
129099	1710	bone marrow culture	[bone marrow cultures]	0.0	3	1	1	1
129100	1710	mrna I	[mRNA I]	0.0	2	1	1	1
129101	1710	ad group Ad12	[Ad groups Ad12]	0.0	3	1	1	1
129102	1710	hiv-2 like hiv-1	[HIV-2 like HIV-1]	0.0	3	1	1	1
129103	1710	27-amino acid motif	[27-amino acid motif]	0.0	3	1	1	1
129104	1710	distinguished: 1) sign of hypothyroidism	[distinguished: 1) signs of hypothyroidism]	0.0	5	1	1	1
129105	1710	activity as potent	[activity as potent]	0.0	3	1	1	1
129106	1710	response to a stimulus	[response to a stimuli]	0.0	4	1	1	1
129107	1710	vein ec	[vein EC]	0.0	2	1	1	1
129108	1710	transcription of the endogenous	[transcription of the endogenous]	0.0	4	1	1	1
129109	1710	shift from erythroid	[shift from erythroid]	0.0	3	1	1	1
129110	1710	(30 minutes) to all-tran acid	[(30 minutes) to all-trans acid]	0.0	5	1	1	1
129111	1710	tax transactivator	[tax transactivator]	0.0	2	1	1	1
129112	1710	induction of the Ie gene	[inductions of the IE genes]	0.0	5	1	1	1
129113	1710	deletion within the EBNA-2 gene	[deletions within the EBNA-2 gene]	0.0	5	1	1	1
129114	1710	carboxy-terminal negative domain	[carboxy-terminal negative domain]	0.0	3	1	1	1
129115	1710	block include inhibition	[block including inhibition]	0.0	3	1	1	1
129116	1710	product from RCC explant	[products from RCC explants]	0.0	4	1	1	1
129117	1710	role of interaction	[role of interactions]	0.0	3	1	1	1
129118	1710	hypoxic induction	[Hypoxic induction]	0.0	2	1	1	1
129119	1710	oxide guanine nucleotide exchange on p21ras	[oxide guanine nucleotide exchange on p21ras]	0.0	6	1	1	1
129120	1710	previous study in primate	[previous studies in primates]	0.0	4	1	1	1
129121	1710	hormone test	[hormone test]	0.0	2	2	2	1
129122	1710	lymphocyte of woman 10 second	[lymphocytes of women 10 second]	0.0	5	1	1	1
129123	1710	mutagenesis sp-1 element within the LTR	[Mutagenesis Sp-1 elements within the LTR]	0.0	6	1	1	1
129124	1710	oxide a powerful microbicidal pathway	[oxide a powerful microbicidal pathway]	0.0	5	1	1	1
129125	1710	other myelomonocytic cell gene	[other myelomonocytic cell genes]	0.0	4	1	1	1
129126	1710	TGF-beta 1 signal pathway	[TGF-beta 1 signaling pathway]	0.0	4	1	1	1
129127	1710	modulation of corticosensitivity u937 cell	[modulation of corticosensitivity U937 cells]	0.0	5	1	1	1
129128	1710	protect cell against death	[protecting cells against death]	0.0	4	1	1	1
129129	1710	involve class CTL in the pathogenesis	[involving class CTLs in the pathogenesis]	0.0	6	1	1	1
129130	1710	induction of wp activity consistent	[induction of Wp activity consistent]	0.0	5	1	1	1
129131	1710	limited expression of marker	[limited expression of markers]	0.0	4	1	1	1
129132	1710	small panel	[small panel]	0.0	2	1	1	1
129133	1710	cellular system a cell line	[cellular systems a cell line]	0.0	5	1	1	1
129134	1710	activity of complex	[activity of complexes]	0.0	3	1	1	1
129135	1710	study from group	[studies from group]	0.0	3	1	1	1
129136	1710	transactivation transrepression model	[transactivation transrepression models]	0.0	3	1	1	1
129137	1710	400 kb	[400 kb]	0.0	2	1	1	1
129138	1710	Differential regulation during myeloid cell differentiation	[Differential regulation during myeloid cell differentiation]	0.0	6	1	1	1
129139	1710	prdi element	[PRDI elements]	0.0	2	1	1	1
129140	1710	pre-treatment with IL-10	[pre-treatment with IL-10]	0.0	3	1	1	1
129141	1710	rna from brain	[RNAs from brain]	0.0	3	1	1	1
129142	1710	NF-kappaB nuclear transcription factor	[NF-kappaB nuclear transcription factor]	0.0	4	1	1	1
129143	1710	sodium acetate	[sodium acetate]	0.0	2	1	1	1
129144	1710	growth of T	[growth of T]	0.0	3	1	1	1
129145	1710	colony form unit-erythroid cell	[colony forming unit-erythroid cells]	0.0	4	1	1	1
129146	1710	mr form	[MR form]	0.0	2	1	1	1
129147	1710	nonactivate domain	[nonactivating domain]	0.0	2	1	1	1
129148	1710	significant number of granulocyte	[significant numbers of granulocytes]	0.0	4	1	1	1
129149	1710	silencing of gene expression	[silencing of gene expression]	0.0	4	1	1	1
129150	1710	accumulation of concentration of nf-atc	[accumulation of concentrations of NF-ATc]	0.0	5	1	1	1
129151	1710	induction of collagenase-1 in (U937) cell	[induction of collagenase-1 in (U937) cells]	0.0	6	1	1	1
129152	1710	include CD28 signaling.	[including CD28 signaling.]	0.0	3	1	1	1
129153	1710	cryptic promoter	[cryptic promoter]	0.0	2	1	1	1
129154	1710	acid receptor alpha raralpha locus	[acid receptor alpha RARalpha locus]	0.0	5	1	1	1
129155	1710	implication for dysregulation of c-myc	[implications for dysregulation of c-myc]	0.0	5	1	1	1
129156	1710	regulator of expression in monocytes/macrophages	[regulators of expression in monocytes/macrophages]	0.0	5	1	1	1
129157	1710	immediate early protein BZLF1	[immediate early proteins BZLF1]	0.0	4	1	1	1
129158	1710	differentiation, burst	[differentiation, burst]	0.0	2	1	1	1
129159	1710	cd3-epsilon.	[CD3-epsilon.]	0.0	1	1	1	1
129160	1710	mechanism of ap-1 induction	[mechanism of AP-1 induction]	0.0	4	1	1	1
129161	1710	mutant derivative	[mutants derivative]	0.0	2	1	1	1
129162	1710	negative IkappaBalpha construct	[negative IkappaBalpha construct]	0.0	3	1	1	1
129163	1710	activity of the hiv enhancer	[activity of the HIV enhancer]	0.0	5	1	1	1
129164	1710	factor-KB result in the suppression	[factor-KB resulting in the suppression]	0.0	5	1	1	1
129165	1710	such as lymphocyte function associated-antigen-1	[such as lymphocyte function associated-antigen-1]	0.0	5	1	1	1
129166	1710	concurrent addition of iron	[concurrent addition of iron]	0.0	4	1	1	1
129167	1710	NFAT regulatory element	[NFAT regulatory elements]	0.0	3	1	1	1
129168	1710	dominant negative ikappabalpha	[dominant negative IkappaBalpha]	0.0	3	1	1	1
129169	1710	use method	[using methods]	0.0	2	1	1	1
129170	1710	expression of interleukin-1beta	[expression of interleukin-1beta]	0.0	3	1	1	1
129171	1710	therapy with captopril	[therapy with captopril]	0.0	3	1	1	1
129172	1710	thymic dendritic cell	[Thymic dendritic cells]	0.0	3	1	1	1
129173	1710	induction in human blood monocyte	[Induction in human blood monocytes]	0.0	5	1	1	1
129174	1710	footprinting of the HS-40 enhancer region	[footprinting of the HS-40 enhancer region]	0.0	6	1	1	1
129175	1710	target of regulation	[targets of regulation]	0.0	3	1	1	1
129176	1710	initially, four novel, occur sequence variant	[Initially, four novel, occurring sequence variants]	0.0	6	1	1	1
129177	1710	cellular gene include IL-2	[cellular genes including IL-2]	0.0	4	1	1	1
129178	1710	preclude the lysis	[precluding the lysis]	0.0	3	1	1	1
129179	1710	different dose of dexamethasone	[different doses of dexamethasone]	0.0	4	1	1	1
129180	1710	relate ros activity	[relating ROS activity]	0.0	3	1	1	1
129181	1710	ALF1 transcription through the E(gre) motif	[ALF1 transcription through the E(gre) motifs]	0.0	6	1	1	1
129182	1710	pathological event	[pathological events]	0.0	2	1	1	1
129183	1710	3-deazaadenosine	[3-deazaadenosine]	0.0	1	2	2	1
129184	1710	formation between the type ii	[formation between the type II]	0.0	5	1	1	1
129185	1710	factor of kappab nf-kappab	[factor of kappaB NF-kappaB]	0.0	4	1	1	1
129186	1710	interleukin-2 receptor expression	[interleukin-2 receptor expression]	0.0	3	1	1	1
129187	1710	thus suggest a divergence	[thus suggesting an divergence]	0.0	4	1	1	1
129188	1710	nucleotide upstream of the TATA box	[nucleotides upstream of the TATA box]	0.0	6	1	1	1
129189	1710	switch region for recombination	[switch region for recombination]	0.0	4	1	1	1
129190	1710	stably express tax	[stably expressing tax]	0.0	3	1	1	1
129191	1710	two salicylate derivative	[two salicylate derivatives]	0.0	3	1	1	1
129192	1710	potent inducer in T cell	[potent inducers in T cells]	0.0	5	1	1	1
129193	1710	nuclear translocation independent	[nuclear translocation independent]	0.0	3	1	1	1
129194	1710	increase of c/ebp epsilon	[increase of C/EBP epsilon]	0.0	4	1	1	1
129195	1710	first case of female twin	[first case of female twins]	0.0	5	1	1	1
129196	1710	regulation in fibroblast	[regulation in fibroblasts]	0.0	3	1	1	1
129197	1710	early gene such as IL-8	[early genes such as IL-8]	0.0	5	1	1	1
129198	1710	role of radical-induced tissue damage	[role of radical-induced tissue damage]	0.0	5	1	1	1
129199	1710	effect on IL-2 expression	[effect on IL-2 expression]	0.0	4	1	1	1
129200	1710	prerequisite of enhancer activity	[prerequisite of enhancer activity]	0.0	4	1	1	1
129201	1710	extract NE	[extracts NE]	0.0	2	1	1	1
129202	1710	upregulation of 6 colony-stimulating factor receptor	[Upregulation of 6 colony-stimulating factor receptors]	0.0	6	1	1	1
129203	1710	binding pattern	[binding patterns]	0.0	2	1	1	1
129204	1710	human blood with PGG-Glucan	[human blood with PGG-Glucan]	0.0	4	1	1	1
129205	1710	confirmation of the significance	[Confirmation of the significance]	0.0	4	1	1	1
129206	1710	hormonal status comparison	[Hormonal status comparison]	0.0	3	1	1	1
129207	1710	time points.	[time points.]	0.0	2	1	1	1
129208	1710	CEM-ICR 27 lymphoblast	[CEM-ICR 27 lymphoblasts]	0.0	3	1	1	1
129209	1710	alteration in the p16	[alterations in the p16]	0.0	4	1	1	1
129210	1710	CBF1/RBP-Jkappa binding site	[CBF1/RBP-Jkappa binding site]	0.0	3	1	1	1
129211	1710	cDNA end	[cDNA ends]	0.0	2	1	1	1
129212	1710	lbf2 to lbf7	[LBF2 to LBF7]	0.0	3	1	1	1
129213	1710	inducible regulator of numerous cellular gene	[inducible regulators of numerous cellular genes]	0.0	6	1	1	1
129214	1710	retinoblastoma family	[retinoblastoma family]	0.0	2	1	1	1
129215	1710	band 3q26	[band 3q26]	0.0	2	1	1	1
129216	1710	potent activator of many gene	[potent activator of many genes]	0.0	5	1	1	1
129217	1710	T lymphocyte-specific	[T lymphocyte-specific]	0.0	2	1	1	1
129218	1710	costimulatory signal essential	[costimulatory signals essential]	0.0	3	1	1	1
129219	1710	noncanonical gata site	[noncanonical GATA site]	0.0	3	1	1	1
129220	1710	Germ line c	[Germ line C]	0.0	3	1	1	1
129221	1710	camp protein kinase	[cAMP protein kinase]	0.0	3	1	1	1
129222	1710	none to on cell	[none to on cells]	0.0	4	1	1	1
129223	1710	characterization of cis-acting element	[characterization of cis-acting elements]	0.0	4	1	1	1
129224	1710	report of chromosome 16 abnormality	[reports of chromosome 16 abnormalities]	0.0	5	1	1	1
129225	1710	two member of the family	[Two members of the family]	0.0	5	1	1	1
129226	1710	determinant of t-cell homeostasis	[determinant of T-cell homeostasis]	0.0	4	1	1	1
129227	1710	less than 4 hour	[less than 4 hr]	0.0	4	1	1	1
129228	1710	non-PRL-secreting endometrial stromal cell	[non-PRL-secreting endometrial stromal cells]	0.0	4	1	1	1
129229	1710	direct activity	[directing activity]	0.0	2	1	1	1
129230	1710	GATA-1(d)	[GATA-1(d)]	0.0	1	1	1	1
129231	1710	bHLH-	[bHLH-]	0.0	1	1	1	1
129232	1710	target for gssg action	[targets for GSSG action]	0.0	4	1	1	1
129233	1710	runt box	[runt box]	0.0	2	1	1	1
129234	1710	brother.	[brother.]	0.0	1	1	1	1
129235	1710	cytokine for hiv long repeat transactivation	[cytokines for HIV long repeat transactivation]	0.0	6	1	1	1
129236	1710	proliferation rate than adult lymphocyte	[proliferation rate than adult lymphocytes]	0.0	5	1	1	1
129237	1710	also to plasma testosterone	[also to plasma testosterone]	0.0	4	1	1	1
129238	1710	elucidate the mechanism govern lineage	[elucidating the mechanisms governing lineage]	0.0	5	1	1	1
129239	1710	transient pseudo-hypoaldosteronism normal level	[Transient pseudo-hypoaldosteronism normal level]	0.0	4	1	1	1
129240	1710	species specificity	[species specificity]	0.0	2	1	1	1
129241	1710	Epstein-Barr virus antigen diffuse component	[Epstein-Barr virus antigen diffuse component]	0.0	5	1	1	1
129242	1710	one test	[one test]	0.0	2	1	1	1
129243	1710	invertebrate transcription	[invertebrate transcription]	0.0	2	1	1	1
129244	1710	effect of this reagent	[effect of these reagents]	0.0	4	1	1	1
129245	1710	activity for NF-AT ap-1 site	[activities for NF-AT AP-1 sites]	0.0	5	1	1	1
129246	1710	acid in 12	[acids in 12]	0.0	3	1	1	1
129247	1710	receptor gr by glucocorticoid	[receptor GR by glucocorticoids]	0.0	4	1	1	1
129248	1710	high (66 microg/100 millileter	[high (66 microg/100 ml]	0.0	4	1	1	1
129249	1710	nitro tetrazolium reduction assay	[nitro tetrazolium reduction assay]	0.0	4	1	1	1
129250	1710	nuclear nf kappab	[nuclear NF kappaB]	0.0	3	1	1	1
129251	1710	discovery of the transcription factor	[discovery of the transcription factor]	0.0	5	1	1	1
129252	1710	SN50	[SN50]	0.0	1	1	1	1
129253	1710	IFN factor-1 irf-1	[IFN factor-1 IRF-1]	0.0	3	2	2	1
129254	1710	assembly of stat1 alpha	[assembly of STAT1 alpha]	0.0	4	1	1	1
129255	1710	control of gata-1 transcription	[control of GATA-1 transcription]	0.0	4	1	1	1
129256	1710	weak inhibition of the generation	[weak inhibition of the generation]	0.0	5	1	1	1
129257	1710	identification of a major positive element	[Identification of a major positive element]	0.0	6	1	1	1
129258	1710	okadaic acid exposure	[okadaic acid exposure]	0.0	3	1	1	1
129259	1710	involvement of Jak kinase	[involvement of Jak kinases]	0.0	4	1	1	1
129260	1710	contain as little as 72 bp	[containing as little as 72 bp]	0.0	6	1	1	1
129261	1710	anti-viral antigen	[anti-viral antigen]	0.0	2	1	1	1
129262	1710	NF-kappa B/Rel activity	[NF-kappa B/Rel activity]	0.0	3	1	1	1
129263	1710	diurnal decline in cortisol level	[diurnal decline in cortisol levels]	0.0	5	1	1	1
129264	1710	three additional region	[Three additional regions]	0.0	3	1	1	1
129265	1710	substitution on C-11	[substitutions on C-11]	0.0	3	1	1	1
129266	1710	powerful inducer of maturation	[powerful inducer of maturation]	0.0	4	1	1	1
129267	1710	interaction with endothelial cell	[interaction with endothelial cells]	0.0	4	1	1	1
129268	1710	interaction at concentration	[interaction at concentration]	0.0	3	1	1	1
129269	1710	Glucocorticoid receptor in mononuclear cell	[Glucocorticoid receptors in mononuclear cells]	0.0	5	1	1	1
129270	1710	effect of c-Rel	[effects of c-Rel]	0.0	3	1	1	1
129271	1710	two protein kinase pathway	[two protein kinase pathways]	0.0	4	1	1	1
129272	1710	lipid a myristoyl fatty acid	[lipid A myristoyl fatty acid]	0.0	5	1	1	1
129273	1710	killing by NK cell	[killing by NK cells]	0.0	4	1	1	1
129274	1710	transient transfectant	[Transient transfectants]	0.0	2	1	1	1
129275	1710	SLP-76 leukocyte protein of 76	[SLP-76 leukocyte protein of 76]	0.0	5	1	1	1
129276	1710	strong transactivator for rante	[strong transactivator for RANTES]	0.0	4	1	1	1
129277	1710	dmso solvent/media	[DMSO solvent/media]	0.0	2	1	1	1
129278	1710	HsN3 subunit	[HsN3 subunit]	0.0	2	1	1	1
129279	1710	signal in primary human precursor	[signaling in primary human precursors]	0.0	5	1	1	1
129280	1710	cooperativity between TNFalpha	[cooperativity between TNFalpha]	0.0	3	1	1	1
129281	1710	10% bovine serum	[10% bovine serum]	0.0	3	1	1	1
129282	1710	augment replication in monocyte	[augmenting replication in monocytes]	0.0	4	1	1	1
129283	1710	March	[Mar]	0.0	1	1	1	1
129284	1710	role in the coordinate induction	[role in the coordinate induction]	0.0	5	1	1	1
129285	1710	simultaneous exposure to CD40L with il-4	[simultaneous exposure to CD40L with IL-4]	0.0	6	1	1	1
129286	1710	homodimerization of chimeric surface receptor consist	[homodimerization of chimeric surface receptors consisting]	0.0	6	1	1	1
129287	1710	rheumatoid synovitis,	[rheumatoid synovitis,]	0.0	2	1	1	1
129288	1710	hematopoietic growth cell line	[hematopoietic growth cell lines]	0.0	4	1	1	1
129289	1710	accumulation of cyclic AMP	[accumulation of cyclic AMP]	0.0	4	1	1	1
129290	1710	also camp-responsive element	[also cAMP-responsive elements]	0.0	3	1	1	1
129291	1710	specific methylation	[specific methylation]	0.0	2	1	1	1
129292	1710	lineage choice	[lineage choice]	0.0	2	1	1	1
129293	1710	such as messenger assay	[such as messenger assays]	0.0	4	1	1	1
129294	1710	them, Platelet factor	[them, Platelet Factor]	0.0	3	1	1	1
129295	1710	grow in culture	[growing in culture]	0.0	3	1	1	1
129296	1710	serum responsive gene	[serum responsive genes]	0.0	3	1	1	1
129297	1710	rapid cell death	[rapid cell death]	0.0	3	1	1	1
129298	1710	classical ar present	[classical AR present]	0.0	3	1	1	1
129299	1710	thrombin -generation curve	[thrombin -generation curve]	0.0	3	1	1	1
129300	1710	translational component	[translational component]	0.0	2	1	1	1
129301	1710	difference in t-cell immortalization mechanism	[differences in T-cell immortalization mechanism]	0.0	5	1	1	1
129302	1710	potential cross point	[potential cross points]	0.0	3	1	1	1
129303	1710	inflammatory reaction of asthma	[inflammatory reaction of asthma]	0.0	4	1	1	1
129304	1710	form of p50 dimer	[form of p50 dimer]	0.0	4	1	1	1
129305	1710	immunofluorescence p	[immunofluorescence P]	0.0	2	1	1	1
129306	1710	fusion DNA	[fusion DNA]	0.0	2	1	1	1
129307	1710	essential role in development	[essential role in development]	0.0	4	1	1	1
129308	1710	acid receptor alpha rar-alpha	[acid receptor alpha RAR-alpha]	0.0	4	1	1	1
129309	1710	factor-kappa B/Rel activity	[factor-kappa B/Rel activity]	0.0	3	1	1	1
129310	1710	c-terminal amino acid residue	[C-terminal amino acid residues]	0.0	4	1	1	1
129311	1710	infection of immunodeficiency virus	[Infection of immunodeficiency viruses]	0.0	4	1	1	1
129312	1710	enhancement of human immunodeficiency virus	[Enhancement of human immunodeficiency virus]	0.0	5	1	1	1
129313	1710	effector function in response	[effector functions in responses]	0.0	4	1	1	1
129314	1710	degree c,	[degrees C,]	0.0	2	1	1	1
129315	1710	ubiquitin-protein	[ubiquitin-protein]	0.0	1	1	1	1
129316	1710	important DNA element present	[important DNA element present]	0.0	4	1	1	1
129317	1710	jun gene	[jun genes]	0.0	2	1	1	1
129318	1710	complex element-binding protein	[complexes element-binding protein]	0.0	3	1	1	1
129319	1710	regulation by messenger	[Regulation by messengers]	0.0	3	1	1	1
129320	1710	day after appearance	[days after appearance]	0.0	3	1	1	1
129321	1710	nf-e2 complex in the cells.	[NF-E2 complex in the cells.]	0.0	5	1	1	1
129322	1710	patient with scid	[patient with SCID]	0.0	3	1	1	1
129323	1710	intense positive staining	[intense positive staining]	0.0	3	1	1	1
129324	1710	component of T cell activation	[component of T cell activation]	0.0	5	1	1	1
129325	1710	p45 lineage cell	[p45 lineage cells]	0.0	3	1	1	1
129326	1710	currently under investigation as a therapy	[currently under investigation as a therapy]	0.0	6	1	1	1
129327	1710	analog of 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Analogs of 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	6	1	1	1
129328	1710	Glucocorticoid receptor on peripheral mononuclear change	[Glucocorticoid receptors on peripheral mononuclear changes]	0.0	6	1	1	1
129329	1710	autophosphorylation of the kinase	[autophosphorylation of the kinase]	0.0	4	1	1	1
129330	1710	potent immunosuppressive compound	[potent immunosuppressive compound]	0.0	3	1	1	1
129331	1710	unrestricted expression	[unrestricted expression]	0.0	2	1	1	1
129332	1710	cell lineages.	[cell lineages.]	0.0	2	1	1	1
129333	1710	disorder involve defective differentiation	[disorders involving defective differentiation]	0.0	4	1	1	1
129334	1710	therapeutic efficiency in ad	[therapeutic efficiency in AD]	0.0	4	1	1	1
129335	1710	anti-tnf-alpha antibody	[Anti-TNF-alpha antibody]	0.0	2	1	1	1
129336	1710	b cell 110-kda	[B cell 110-kDa]	0.0	3	1	1	1
129337	1710	dp2 -353 to -304 bp	[DP2 -353 to -304 bp]	0.0	5	1	1	1
129338	1710	recessive disease	[recessive disease]	0.0	2	1	1	1
129339	1710	respective role	[respective roles]	0.0	2	1	1	1
129340	1710	human epithelial cell inflammatory response	[Human epithelial cell inflammatory responses]	0.0	5	1	1	1
129341	1710	amino acid in the region	[amino acids in the region]	0.0	5	1	1	1
129342	1710	lps (endotoxin)	[LPS (endotoxin)]	0.0	2	1	1	1
129343	1710	Finally, addition of ref-1	[Finally, addition of REF-1]	0.0	4	1	1	1
129344	1710	cd34 expression	[CD34 expression]	0.0	2	1	1	1
129345	1710	rabbit anti-c/ebp-epsilon antibody	[rabbit anti-C/EBP-epsilon antibodies]	0.0	3	1	1	1
129346	1710	macrophage by lipopolysaccharide	[macrophages by lipopolysaccharide]	0.0	3	1	1	1
129347	1710	CAGGTG e-box	[CAGGTG E-boxes]	0.0	2	1	1	1
129348	1710	events: the CsA translocation	[events: the CsA translocation]	0.0	4	1	1	1
129349	1710	interaction via the CD40 /cd40l pathway	[interactions via the CD40 /CD40L pathway]	0.0	6	1	1	1
129350	1710	factor (NF)-AT NF-AT	[factor (NF)-AT NF-AT]	0.0	3	1	1	1
129351	1710	bcl-6 cell	[Bcl-6 cells]	0.0	2	1	1	1
129352	1710	physical property of the molecule	[physical properties of the molecule]	0.0	5	1	1	1
129353	1710	viable cell a phenotype	[viable cells a phenotype]	0.0	4	1	1	1
129354	1710	t-cell effect together with PGE2	[T-cell effects together with PGE2]	0.0	5	1	1	1
129355	1710	typically die days.	[typically dying days.]	0.0	3	1	1	1
129356	1710	candidate repressor/activator NF-E1	[candidate repressor/activator NF-E1]	0.0	3	1	1	1
129357	1710	1.5-1.6 time of the normal control	[1.5-1.6 times of the normal controls]	0.0	6	1	1	1
129358	1710	receptor in target tissue	[receptor in target tissues]	0.0	4	1	1	1
129359	1710	leukemia u937 cell by ML-9	[leukemia U937 cells by ML-9]	0.0	5	1	1	1
129360	1710	time of h (viability	[times of h (viability]	0.0	4	1	1	1
129361	1710	Minimal residual disease in myelogenous leukemia	[Minimal residual disease in myelogenous leukemia]	0.0	6	1	1	1
129362	1710	six octamer binding protein	[six octamer binding proteins]	0.0	4	1	1	1
129363	1710	different binding specificity cd336	[different binding specificity CD336]	0.0	4	1	1	1
129364	1710	oncogene in cell lysis	[oncogenes in cell lysis]	0.0	4	1	1	1
129365	1710	corresponding to sequence of the region	[corresponding to sequences of the region]	0.0	6	1	1	1
129366	1710	native envelope glycoprotein	[native envelope glycoproteins]	0.0	3	2	2	1
129367	1710	dominant negative allele of c-Raf-1	[dominant negative allele of c-Raf-1]	0.0	5	1	1	1
129368	1710	gastric cell	[gastric cells]	0.0	2	1	1	1
129369	1710	t-cell-expressed cytokine interleukin	[T-cell-expressed cytokines interleukin]	0.0	3	1	1	1
129370	1710	productive hiv-1 infection	[productive HIV-1 infection]	0.0	3	1	1	1
129371	1710	complete 491-amino-acid sequence	[complete 491-amino-acid sequence]	0.0	3	1	1	1
129372	1710	Isoflavones, activation	[Isoflavones, activation]	0.0	2	1	1	1
129373	1710	dexamethasone a inhibitor of apoptosis	[dexamethasone a inhibitor of apoptosis]	0.0	5	1	1	1
129374	1710	function in common with ebv LMP1	[functions in common with EBV LMP1]	0.0	6	1	1	1
129375	1710	induction role for acidosis	[induction role for acidosis]	0.0	4	1	1	1
129376	1710	analysis with hugata-3	[analysis with huGATA-3]	0.0	3	1	1	1
129377	1710	peripheral blood cell proliferation from patient	[peripheral blood cell proliferation from patients]	0.0	6	1	1	1
129378	1710	messenger ribonucleic acid	[messenger ribonucleic acid]	0.0	3	1	1	1
129379	1710	autocrine role	[autocrine role]	0.0	2	1	1	1
129380	1710	binding at pH	[binding at pH]	0.0	3	1	1	1
129381	1710	major physiological human glucocorticoid	[major physiological human glucocorticoid]	0.0	4	1	1	1
129382	1710	convert ligand-receptor interaction into modulation	[converting ligand-receptor interactions into modulation]	0.0	5	1	1	1
129383	1710	expression on T cell	[expression on T cells]	0.0	4	1	1	1
129384	1710	prolonged cyclic strain	[prolonged cyclic strain]	0.0	3	1	1	1
129385	1710	childhood acute leukemia	[childhood acute leukemia]	0.0	3	1	1	1
129386	1710	recombinant adeno-associated virus	[recombinant adeno-associated virus]	0.0	3	1	1	1
129387	1710	(il) 4 production	[(IL) 4 production]	0.0	3	1	1	1
129388	1710	pb cell population	[PB cell populations]	0.0	3	1	1	1
129389	1710	episode simulate adrenal insufficiency	[episode simulating adrenal insufficiency]	0.0	4	1	1	1
129390	1710	survival of lymphocyte	[survival of lymphocytes]	0.0	3	1	1	1
129391	1710	identification of a positive regulatory element	[Identification of a positive regulatory element]	0.0	6	1	1	1
129392	1710	triepoxide with potent property	[triepoxide with potent properties]	0.0	4	1	1	1
129393	1710	level of two elf-2 transcript	[levels of two elf-2 transcripts]	0.0	5	1	1	1
129394	1710	action on U-937 leukemia cell	[action on U-937 leukemia cells]	0.0	5	1	1	1
129395	1710	SPD in patient with preeclampsia	[SPD in patients with preeclampsia]	0.0	5	1	1	1
129396	1710	interaction of eed with partners,	[interaction of Eed with partners,]	0.0	5	1	1	1
129397	1710	catalyst thioredoxin trx	[catalyst thioredoxin Trx]	0.0	3	1	1	1
129398	1710	spinal muscular atrophy	[spinal muscular atrophy]	0.0	3	1	1	1
129399	1710	glycosaminoglycan	[glycosaminoglycan]	0.0	1	1	1	1
129400	1710	response to the early protein	[responses to the early proteins]	0.0	5	1	1	1
129401	1710	generation of epsilon transcript,	[generation of epsilon transcript,]	0.0	4	1	1	1
129402	1710	mu/l limit	[mU/L limit]	0.0	2	1	1	1
129403	1710	histamine receptor	[histamine receptor]	0.0	2	1	1	1
129404	1710	starting with a replication-incompetent clone	[Starting with a replication-incompetent clone]	0.0	5	1	1	1
129405	1710	labeling of microsomal membrane	[labeling of microsomal membranes]	0.0	4	1	1	1
129406	1710	2 element	[2 elements]	0.0	2	1	1	1
129407	1710	integrin-mediated tyrosine phosphorylation in cell	[Integrin-mediated tyrosine phosphorylation in cells]	0.0	5	1	1	1
129408	1710	complex formation by extract	[complex formation by extracts]	0.0	4	1	1	1
129409	1710	such as a effect	[such as an effect]	0.0	4	1	1	1
129410	1710	knowledge of the signal pathway	[knowledge of the signaling pathways]	0.0	5	1	1	1
129411	1710	donor' DNA	[donor's DNA]	0.0	2	1	1	1
129412	1710	include tumor necrosis factor pkc activation	[including tumor necrosis factor PKC activation]	0.0	6	1	1	1
129413	1710	multiple cellular transcription factor	[Multiple cellular transcription factors]	0.0	4	1	1	1
129414	1710	LPS nuclear binding	[LPS nuclear binding]	0.0	3	1	1	1
129415	1710	use T lymphocyte	[Using T lymphocytes]	0.0	3	1	1	1
129416	1710	level of specific chromosome translocation	[level of specific chromosome translocations]	0.0	5	1	1	1
129417	1710	induction in monocyte	[induction in monocytes]	0.0	3	1	1	1
129418	1710	immunological consequence	[immunological consequences]	0.0	2	1	1	1
129419	1710	overexpression of receptor kinase 1 peptide	[Overexpression of receptor kinase 1 peptide]	0.0	6	1	1	1
129420	1710	cdk2 inhibitor	[cdk2 inhibitor]	0.0	2	1	1	1
129421	1710	probably in the nuclei	[probably in the nuclei]	0.0	4	1	1	1
129422	1710	signal for transformation through cytoplasmic tail	[signals for transformation through cytoplasmic tail]	0.0	6	1	1	1
129423	1710	protein-protein interaction with the amino-terminal region	[protein-protein interactions with the amino-terminal region]	0.0	6	1	1	1
129424	1710	role for xanthine oxidase	[role for xanthine oxidase]	0.0	4	1	1	1
129425	1710	cr in leukocyte	[CR in leukocytes]	0.0	3	1	1	1
129426	1710	lymphocyte dysfunction	[lymphocyte dysfunction]	0.0	2	1	1	1
129427	1710	critical concentration	[critical concentration]	0.0	2	1	1	1
129428	1710	establish a inverse relation MHC	[establishing an inverse relation MHC]	0.0	5	1	1	1
129429	1710	TRAIL apoptosis ligand a dil	[TRAIL apoptosis ligand a DIL]	0.0	5	1	1	1
129430	1710	supershif the complex with Abs	[supershifting the complexes with Abs]	0.0	5	1	1	1
129431	1710	primarily by host immune mechanism	[primarily by host immune mechanisms]	0.0	5	1	1	1
129432	1710	primarily by means	[primarily by means]	0.0	3	1	1	1
129433	1710	target of tax activity	[target of Tax activity]	0.0	4	1	1	1
129434	1710	o-phenanthroline	[o-phenanthroline]	0.0	1	1	1	1
129435	1710	(dp) CD4	[(DP) CD4]	0.0	2	1	1	1
129436	1710	dqa1 polymorphism	[DQA1 polymorphism]	0.0	2	1	1	1
129437	1710	marker for b-1 cell	[marker for B-1 cells]	0.0	4	1	1	1
129438	1710	loss-of-function mutation in this gene	[loss-of-function mutation in these genes]	0.0	5	1	1	1
129439	1710	clonality analysis method	[clonality analysis methods]	0.0	3	1	1	1
129440	1710	transient pseudo-hypoaldosteronism follow resection	[Transient pseudo-hypoaldosteronism following resection]	0.0	4	1	1	1
129441	1710	hyponatremia suggest pha	[hyponatremia suggesting PHA]	0.0	3	1	1	1
129442	1710	domain protein pax-1	[domain protein Pax-1]	0.0	3	1	1	1
129443	1710	cd34+ cell g-csf	[CD34+ cells G-CSF]	0.0	3	1	1	1
129444	1710	leukopenia in transgenic	[leukopenia in transgenic]	0.0	3	1	1	1
129445	1710	H2 agonist	[H2 agonists]	0.0	2	1	1	1
129446	1710	function of ptk substrate	[function of PTK substrates]	0.0	4	1	1	1
129447	1710	1.5 time	[1.5 times]	0.0	2	1	1	1
129448	1710	study with other isomerase inhibitor	[studies with other isomerase inhibitors]	0.0	5	1	1	1
129449	1710	nf-kappab promoter	[NF-kappaB promoter]	0.0	2	1	1	1
129450	1710	hierarchy of permissivity	[hierarchy of permissivity]	0.0	3	1	1	1
129451	1710	nonfunctional mutant	[nonfunctional mutants]	0.0	2	1	1	1
129452	1710	p50-p65 nf-kappab heterodimer	[p50-p65 NF-kappaB heterodimers]	0.0	3	1	1	1
129453	1710	(camk)	[(CaMK)]	0.0	1	1	1	1
129454	1710	furthermore, 1,25-dihydroxyvitamin D3 a agent	[Furthermore, 1,25-dihydroxyvitamin D3 a agent]	0.0	5	1	1	1
129455	1710	chimeric surface receptor consist	[chimeric surface receptors consisting]	0.0	4	1	1	1
129456	1710	role in animal model	[role in animal models]	0.0	4	1	1	1
129457	1710	interaction lead	[interaction leading]	0.0	2	1	1	1
129458	1710	two previously unrecognized NFATp -binding site	[Two previously unrecognized NFATp -binding sites]	0.0	6	1	1	1
129459	1710	protein include c-myc	[proteins including c-myc]	0.0	3	1	1	1
129460	1710	IL-2 cell growth	[IL-2 cell growth]	0.0	3	1	1	1
129461	1710	complex tetra-	[complex tetra-]	0.0	2	1	1	1
129462	1710	Functional characterization of IL-2 transcriptional inhibitor	[Functional characterization of IL-2 transcriptional inhibitors]	0.0	6	1	1	1
129463	1710	response of pbmc	[Responses of PBMC]	0.0	3	1	1	1
129464	1710	understanding of the transcriptional event	[understanding of the transcriptional events]	0.0	5	1	1	1
129465	1710	nonpeptidyl molecule sb	[nonpeptidyl molecule SB]	0.0	3	1	1	1
129466	1710	mammalian virus	[mammalian viruses]	0.0	2	1	1	1
129467	1710	region of this gene	[region of this gene]	0.0	4	1	1	1
129468	1710	analysis of pituitary beta-cell	[analyses of pituitary beta-cells]	0.0	4	1	1	1
129469	1710	rapidak gradually accumulating, tyrosine	[rapid, gradually accumulating, tyrosine]	0.0	4	1	1	1
129470	1710	cyclin a-cdk2-	[cyclin A-Cdk2-]	0.0	2	1	1	1
129471	1710	rodent nervous system	[rodent nervous system]	0.0	3	1	1	1
129472	1710	hla dqa1*0501	[HLA DQA1*0501]	0.0	2	1	1	1
129473	1710	18-hydroxy-corticosterone 18-oh-b level in 25 woman	[18-hydroxy-corticosterone 18-OH-B levels in 25 women]	0.0	6	1	1	1
129474	1710	involvement of cyclase	[Involvement of cyclase]	0.0	3	1	1	1
129475	1710	cell type-specific enhancer	[cell type-specific enhancer]	0.0	3	1	1	1
129476	1710	significant thrombin -generate capacity	[significant thrombin -generating capacity]	0.0	4	1	1	1
129477	1710	nucleus of cd45 -t	[nucleus of CD45 -T]	0.0	4	1	1	1
129478	1710	human osteosarcoma Saos-2	[human osteosarcoma Saos-2]	0.0	3	1	1	1
129479	1710	significant age-related decline	[significant age-related decline]	0.0	3	1	1	1
129480	1710	2 pre-B acute lymphoblastic leukemia	[2 pre-B acute lymphoblastic leukemia]	0.0	5	1	1	1
129481	1710	tissue-specific control of activity	[tissue-specific control of activity]	0.0	4	1	1	1
129482	1710	Th2 development	[Th2 development]	0.0	2	1	1	1
129483	1710	analysis of CD40 domain truncation	[Analysis of CD40 domain truncation]	0.0	5	1	1	1
129484	1710	blockade of the nuclear translocation	[blockade of the nuclear translocation]	0.0	5	1	1	1
129485	1710	receptor vitamin D3 receptor	[receptors vitamin D3 receptors]	0.0	4	1	1	1
129486	1710	granule of the neutrophil	[granules of the neutrophil]	0.0	4	1	1	1
129487	1710	splicing of the gc receptor pre-mrna	[splicing of the GC receptor pre-mRNA]	0.0	6	1	1	1
129488	1710	cloning from neuronal cell	[cloning from neuronal cells]	0.0	4	1	1	1
129489	1710	induction of differentiation infection	[Induction of differentiation infection]	0.0	4	1	1	1
129490	1710	eosinophilic disease such as dermatitis	[eosinophilic diseases such as dermatitis]	0.0	5	1	1	1
129491	1710	two form of cellular collaboration	[two forms of cellular collaboration]	0.0	5	1	1	1
129492	1710	peer cell	[PEER cells]	0.0	2	1	1	1
129493	1710	participation in cytoplasmic/nuclear signal	[participation in cytoplasmic/nuclear signaling]	0.0	4	1	1	1
129494	1710	virus HeLa extract	[virus HeLa extracts]	0.0	3	1	1	1
129495	1710	receptor of leukocyte	[receptor of leukocytes]	0.0	3	1	1	1
129496	1710	consist of cyclophosphamide CMF	[consisting of cyclophosphamide CMF]	0.0	4	1	1	1
129497	1710	new cyclic AMP response	[new cyclic AMP response]	0.0	4	1	1	1
129498	1710	increase in response	[increase in response]	0.0	3	1	1	1
129499	1710	cotransfection analysis in Drosophila cell	[cotransfection analysis in Drosophila cells]	0.0	5	1	1	1
129500	1710	site on the hiv-1 promoter	[sites on the HIV-1 promoter]	0.0	5	1	1	1
129501	1710	sequential development of structural alteration	[Sequential development of structural alterations]	0.0	5	1	1	1
129502	1710	specificity for pkc,	[specificity for PKC,]	0.0	3	1	1	1
129503	1710	specify high affinity	[specifying high affinity]	0.0	3	1	1	1
129504	1710	human blood precursor	[human blood precursors]	0.0	3	1	1	1
129505	1710	EBV anti-Z Epstein-Barr replicative activator	[EBV anti-Z Epstein-Barr replicative activator]	0.0	5	1	1	1
129506	1710	12 hour of treatment.	[12 hr of treatment.]	0.0	4	1	1	1
129507	1710	differentiation of non-antigen-selected b cell	[differentiation of non-antigen-selected B cells]	0.0	5	1	1	1
129508	1710	fresh leukemic cell whatever stage	[fresh leukemic cells whatever stage]	0.0	5	1	1	1
129509	1710	study in monocyte	[studies in monocytes]	0.0	3	1	1	1
129510	1710	CD40 -positive MMs	[CD40 -positive MMs]	0.0	3	1	1	1
129511	1710	activity il-1 in aged runner	[activity IL-1 in aged runner]	0.0	5	1	1	1
129512	1710	fcr activation	[FcR activation]	0.0	2	1	1	1
129513	1710	employ deletion	[employing deletions]	0.0	2	1	1	1
129514	1710	RA -dependent enhancer	[RA -dependent enhancers]	0.0	3	1	1	1
129515	1710	144 T	[144 T]	0.0	2	1	1	1
129516	1710	4 fmol/mg	[4 fmol/mg]	0.0	2	1	1	1
129517	1710	expression of a human carboxylesterase	[expression of a human carboxylesterase]	0.0	5	1	1	1
129518	1710	interferon factor-1 gene expression	[interferon factor-1 gene expression]	0.0	4	1	1	1
129519	1710	potent activator of hiv-1 gene	[potent activator of HIV-1 gene]	0.0	5	1	1	1
129520	1710	element in b cell	[element in B cells]	0.0	4	1	1	1
129521	1710	lipopolysaccharide-stimulated mouse b cell	[lipopolysaccharide-stimulated mouse B cells]	0.0	4	1	1	1
129522	1710	multiple partners, include k protein	[multiple partners, including K protein]	0.0	5	1	1	1
129523	1710	new variant translocation molecular characterization	[new variant translocation molecular characterization]	0.0	5	1	1	1
129524	1710	Spi-C a novel	[Spi-C a novel]	0.0	3	1	1	1
129525	1710	risk breast cancer	[risk breast cancer]	0.0	3	1	1	1
129526	1710	activation of il-2	[activation of IL-2]	0.0	3	1	1	1
129527	1710	gene necessary	[genes necessary]	0.0	2	1	1	1
129528	1710	hamster ovary	[hamster ovary]	0.0	2	1	1	1
129529	1710	Activation-dependent transcriptional regulation	[Activation-dependent transcriptional regulation]	0.0	3	1	1	1
129530	1710	encode the enzyme aldehyde dehydrogenase	[encoding the enzyme aldehyde dehydrogenase]	0.0	5	1	1	1
129531	1710	role in the cell progression	[role in the cell progression]	0.0	5	1	1	1
129532	1710	monocyte tf	[monocyte TF]	0.0	2	1	1	1
129533	1710	interaction of 135(oh)2d3	[interaction of 1,25(OH)2D3]	0.0	3	1	1	1
129534	1710	adherence to plastic	[adherence to plastic]	0.0	3	1	1	1
129535	1710	[3h]dexamethasone binding	[[3H]dexamethasone binding]	0.0	2	2	2	1
129536	1710	cleavage product after induction	[cleavage products after induction]	0.0	4	1	1	1
129537	1710	binding affinity RBA	[binding affinities RBA]	0.0	3	1	1	1
129538	1710	CD4(+),	[CD4(+),]	0.0	1	1	1	1
129539	1710	stimulation of neoglucogenesis	[stimulation of neoglucogenesis]	0.0	3	1	1	1
129540	1710	endothelial cell in vessel	[endothelial cells in vessel]	0.0	4	1	1	1
129541	1710	blot with a antibody	[blot with an antibody]	0.0	4	1	1	1
129542	1710	skeletal muscle lineage	[skeletal muscle lineage]	0.0	3	1	1	1
129543	1710	celiac disease due to mimicry	[celiac disease due to mimicry]	0.0	5	1	1	1
129544	1710	molecular weight in the range	[molecular weights in the range]	0.0	5	1	1	1
129545	1710	form of t-cell leukemia	[form of T-cell leukemias]	0.0	4	1	1	1
129546	1710	colony formation by early progenitor	[colony formation by early progenitors]	0.0	5	1	1	1
129547	1710	interferon (ifn)-inducible protein CXC chemokine	[interferon (IFN)-inducible protein CXC chemokine]	0.0	5	1	1	1
129548	1710	program in cd4+ cd8+ lymphocyte	[program in CD4+ CD8+ lymphocytes]	0.0	5	1	1	1
129549	1710	prolonged exposure of cell HAEC	[prolonged exposure of cells HAEC]	0.0	5	1	1	1
129550	1710	development of culture of megakaryocyte	[development of cultures of megakaryocytes]	0.0	5	1	1	1
129551	1710	comparable effect	[comparable effects]	0.0	2	1	1	1
129552	1710	analysis of gr receptor	[Analysis of GR receptors]	0.0	4	1	1	1
129553	1710	show cross-reactivity at concentration	[showing cross-reactivity at concentrations]	0.0	4	1	1	1
129554	1710	weak correlation between body temperature	[weak correlation between body temperature]	0.0	5	1	1	1
129555	1710	response nf-kappab to alteration	[response NF-kappaB to alterations]	0.0	4	1	1	1
129556	1710	contain near-perfect repeat DR of bp	[containing near-perfect repeats DR of bp]	0.0	6	1	1	1
129557	1710	tumor cell in cases,	[tumor cells in cases,]	0.0	4	1	1	1
129558	1710	carry the human irf-1 gene	[carrying the human IRF-1 gene]	0.0	5	1	1	1
129559	1710	involvement in the transcription	[involvement in the transcription]	0.0	4	1	1	1
129560	1710	identify a genetic disorder	[identifying a genetic disorder]	0.0	4	1	1	1
129561	1710	separate sequence element	[separate sequence elements]	0.0	3	1	1	1
129562	1710	dexamethasone dxm on the production	[dexamethasone DXM on the production]	0.0	5	1	1	1
129563	1710	association through the a domain	[association through the aa domain]	0.0	5	1	1	1
129564	1710	-leucine	[-leucine]	0.0	1	1	1	1
129565	1710	cytokine factor stimulation	[cytokine factor stimulation]	0.0	3	1	1	1
129566	1710	different residue kinetic analysis	[different residues Kinetic analysis]	0.0	4	1	1	1
129567	1710	extracellular domain of hiv-1 glycoprotein	[extracellular domain of HIV-1 glycoprotein]	0.0	5	1	1	1
129568	1710	Lyn tyrosine	[Lyn tyrosine]	0.0	2	1	1	1
129569	1710	camp-activated th2 cell	[cAMP-activated Th2 cells]	0.0	3	1	1	1
129570	1710	palindromic binding site of factor	[palindromic binding sites of factors]	0.0	5	1	1	1
129571	1710	P56lck -independent pathway	[p56lck -independent pathway]	0.0	3	1	1	1
129572	1710	typically die by 8	[typically dying by 8]	0.0	4	1	1	1
129573	1710	expression of related gene	[expression of related genes]	0.0	4	1	1	1
129574	1710	monocyte hm	[monocytes HM]	0.0	2	1	1	1
129575	1710	pathogen such as lipopolysaccharide lps	[pathogens such as lipopolysaccharide LPS]	0.0	5	1	1	1
129576	1710	possible explanation for toxicity	[possible explanation for toxicities]	0.0	4	1	1	1
129577	1710	statg in normal immature myeloid cell	[StatG in normal immature myeloid cells]	0.0	6	1	1	1
129578	1710	Gal4- k	[Gal4- K]	0.0	2	1	1	1
129579	1710	contain five copy	[containing five copies]	0.0	3	1	1	1
129580	1710	mutant mrna	[mutant mRNA]	0.0	2	1	1	1
129581	1710	myeloid progenitor cell growth	[myeloid progenitor cell growth]	0.0	4	1	1	1
129582	1710	potent AS oligonucleotide	[potent AS oligonucleotides]	0.0	3	1	1	1
129583	1710	corresponding to the sequence	[corresponding to the sequence]	0.0	4	1	1	1
129584	1710	7.03 (range, 5.66-10) 4.27 (range,	[7.03 (range, 5.66-10), 4.27 (range,]	0.0	5	1	1	1
129585	1710	action of trans-acting factor	[actions of trans-acting factors]	0.0	4	1	1	1
129586	1710	only in a percentage	[only in a percentage]	0.0	4	1	1	1
129587	1710	Rapid tyrosine phosphorylation of cellular protein	[Rapid tyrosine phosphorylation of cellular proteins]	0.0	6	1	1	1
129588	1710	cell malignancy carcinoma	[cell malignancies carcinoma]	0.0	3	1	1	1
129589	1710	Tax1 a activator 1 htlv-1 transcription	[Tax1 a activator 1 HTLV-1 transcription]	0.0	6	1	1	1
129590	1710	factor pu.1	[factor PU.1]	0.0	2	1	1	1
129591	1710	divide positive cell	[dividing positive cells]	0.0	3	1	1	1
129592	1710	0.05, respectively) increase	[0.05, respectively) increase]	0.0	3	1	1	1
129593	1710	complete disappearance	[complete disappearance]	0.0	2	1	1	1
129594	1710	action on ChtM	[action on ChtM]	0.0	3	1	1	1
129595	1710	trough value	[trough values]	0.0	2	1	1	1
129596	1710	activate factor	[activating factors]	0.0	2	1	1	1
129597	1710	moreover, id1	[Moreover, Id1]	0.0	2	1	1	1
129598	1710	explain the differentiation status	[explaining the differentiation status]	0.0	4	1	1	1
129599	1710	chain IgH class switch recombination	[chain IgH class switch recombination]	0.0	5	1	1	1
129600	1710	component of the secondary tissue	[components of the secondary tissues]	0.0	5	1	1	1
129601	1710	other microbial agonist	[other microbial agonists]	0.0	3	1	1	1
129602	1710	two hexameric binding site	[two hexameric binding sites]	0.0	4	1	1	1
129603	1710	function in	[functions in]	0.0	2	1	1	1
129604	1710	granulocyte-monocyte colony activity by 135(oh)2d3	[granulocyte-monocyte colony activity by 1,25(OH)2D3]	0.0	5	1	1	1
129605	1710	ubiquitous nuclear component within minute	[ubiquitous nuclear component within min]	0.0	5	1	1	1
129606	1710	presence of potential binding site	[presence of potential binding sites]	0.0	5	1	1	1
129607	1710	alternative signal transduction pathway	[alternative signal transduction pathways]	0.0	4	1	1	1
129608	1710	cloning of the NFAT family	[cloning of the NFAT family]	0.0	5	1	1	1
129609	1710	tshr molecule.	[TSHR molecule.]	0.0	2	1	1	1
129610	1710	migration of oligomer representative	[migration of oligomers representative]	0.0	4	1	1	1
129611	1710	complex devoid of NFAT2	[complexes devoid of NFAT2]	0.0	4	1	1	1
129612	1710	species of heterodimer involve rxr-alpha	[species of heterodimers involving RXR-alpha]	0.0	5	1	1	1
129613	1710	cell adhesion molecule-1 expression in cells,	[cell adhesion molecule-1 expression in cells,]	0.0	6	1	1	1
129614	1710	epsilon transcript	[epsilon transcripts]	0.0	2	1	1	1
129615	1710	p65 induction of the gene	[p65 induction of the gene]	0.0	5	1	1	1
129616	1710	acute patient aml (10	[acute patients AML (10]	0.0	4	1	1	1
129617	1710	strategy for immunodeficiency syndrome therapy	[strategy for immunodeficiency syndrome therapy]	0.0	5	1	1	1
129618	1710	constitutive activation of a signal transducer	[Constitutive activation of an signal transducer]	0.0	6	1	1	1
129619	1710	9 nucleotide	[9 nucleotides]	0.0	2	1	1	1
129620	1710	IL-2 -dependent cell line	[IL-2 -dependent cell lines]	0.0	4	1	1	1
129621	1710	change in chemical nature Arg91	[change in chemical nature Arg91]	0.0	5	1	1	1
129622	1710	electrostatic interaction of retinoid	[electrostatic interactions of retinoids]	0.0	4	1	1	1
129623	1710	human beta-globin promoter	[human beta-globin promoter]	0.0	3	1	1	1
129624	1710	latency in monocytic cell	[latency in monocytic cells]	0.0	4	1	1	1
129625	1710	proximal promoter region -620	[proximal promoter region -620]	0.0	4	1	1	1
129626	1710	strain of hhv-6	[strains of HHV-6]	0.0	3	1	1	1
129627	1710	high microg/100 millileter at P;	[high microg/100 ml at h;]	0.0	5	1	1	1
129628	1710	x-linked immunodeficiency X-SCID	[X-linked immunodeficiency X-SCID]	0.0	3	1	1	1
129629	1710	cell in vitro.	[cells in vitro.]	0.0	3	1	1	1
129630	1710	two different regulatory pathway	[two different regulatory pathways]	0.0	4	1	1	1
129631	1710	dose of peptide	[doses of peptide]	0.0	3	1	1	1
129632	1710	cell line thp-1 after stimulation	[cell line THP-1 after stimulation]	0.0	5	1	1	1
129633	1710	synergy between IL-12	[synergy between IL-12]	0.0	3	2	2	1
129634	1710	regulator, slap-130	[regulator, SLAP-130]	0.0	2	1	1	1
129635	1710	level of nf-kappa b of gene	[levels of NF-kappa B of genes]	0.0	6	1	1	1
129636	1710	dna- complex formation	[DNA- complex formation]	0.0	3	1	1	1
129637	1710	act predominantly on megakaryocytopoiesis	[acting predominantly on megakaryocytopoiesis]	0.0	4	1	1	1
129638	1710	cytoplasmic segment	[cytoplasmic segment]	0.0	2	1	1	1
129639	1710	CD4(+), CD8(-)	[CD4(+), CD8(-)]	0.0	2	1	1	1
129640	1710	role for hmg-i(y) in repression	[role for HMG-I(Y) in repression]	0.0	5	1	1	1
129641	1710	potentially dominant pi3-k construct	[potentially dominant PI3-K constructs]	0.0	4	1	1	1
129642	1710	breast cancer case	[breast cancer cases]	0.0	3	1	1	1
129643	1710	Differentiation-dependent expression	[Differentiation-dependent expression]	0.0	2	1	1	1
129644	1710	significantly into phosphatidylethanolamine at concentration	[significantly into phosphatidylethanolamine at concentrations]	0.0	5	1	1	1
129645	1710	factor completely,	[factor completely,]	0.0	2	1	1	1
129646	1710	RA signalling pathway	[RA signalling pathway]	0.0	3	1	1	1
129647	1710	cell membrane constituent	[cell membrane constituents]	0.0	3	1	1	1
129648	1710	dexamethasone binding to glucocorticoid receptor	[dexamethasone binding to glucocorticoid receptor]	0.0	5	1	1	1
129649	1710	transfection into human b cell	[transfection into human B cells]	0.0	5	1	1	1
129650	1710	(nf-e2) transcription factor	[(NF-E2) transcription factors]	0.0	3	1	1	1
129651	1710	govern the response of T lymphocyte	[governing the response of T lymphocytes]	0.0	6	1	1	1
129652	1710	early samples, activity from endometrium	[early samples, activity from endometrium]	0.0	5	1	1	1
129653	1710	placental cDNA	[placental cDNA]	0.0	2	1	1	1
129654	1710	viral pattern	[viral pattern]	0.0	2	1	1	1
129655	1710	implicate CAML as a intermediate	[implicating CAML as a intermediate]	0.0	5	1	1	1
129656	1710	mnda myeloid cell differentiation antigen	[MNDA myeloid cell differentiation antigen]	0.0	5	1	1	1
129657	1710	il-2r expression lead	[IL-2R expression leading]	0.0	3	1	1	1
129658	1710	I site	[I sites]	0.0	2	1	1	1
129659	1710	prominent enzyme	[prominent enzymes]	0.0	2	1	1	1
129660	1710	IL-10 receptor	[IL-10 receptor]	0.0	2	1	1	1
129661	1710	10.5 nmol/L	[10.5 nmol/L]	0.0	2	1	1	1
129662	1710	human genomic sterol element	[human genomic sterol element]	0.0	4	1	1	1
129663	1710	diverse signal	[diverse signals]	0.0	2	1	1	1
129664	1710	transform membrane protein-1	[transforming membrane protein-1]	0.0	3	1	1	1
129665	1710	non-genomic action of mineralocorticoid	[non-genomic actions of mineralocorticoids]	0.0	4	1	1	1
129666	1710	upstream factor-kappa b site	[upstream factor-kappa B site]	0.0	4	1	1	1
129667	1710	cell; mean	[cell; mean]	0.0	2	1	1	1
129668	1710	(Palombella,	[(Palombella,]	0.0	1	1	1	1
129669	1710	two regions, dp1 -140	[Two regions, DP1 -140]	0.0	4	1	1	1
129670	1710	th2 cell differentiation to inflammation.	[Th2 cell differentiation to inflammation.]	0.0	5	1	1	1
129671	1710	role cause cellular transformation	[role causing cellular transformation]	0.0	4	1	1	1
129672	1710	related species,	[related species,]	0.0	2	1	1	1
129673	1710	intact domain of Oct-2	[intact domain of Oct-2]	0.0	4	1	1	1
129674	1710	mouse express e2a-hlf	[mice expressing E2A-HLF]	0.0	3	1	1	1
129675	1710	highlight cancer related loci relevant	[highlighting cancer related loci relevant]	0.0	5	1	1	1
129676	1710	retinoic acid ATRA	[retinoic acid ATRA]	0.0	3	2	2	1
129677	1710	GCR-beta gene result	[GCR-beta gene resulting]	0.0	3	1	1	1
129678	1710	few cell from elderly donor	[Fewer cells from elderly donors]	0.0	5	1	1	1
129679	1710	lead to production of c-Jun	[leading to production of c-Jun]	0.0	5	1	1	1
129680	1710	wild- type	[wild- type]	0.0	2	1	1	1
129681	1710	stimulus in human neutrophil	[stimuli in human neutrophils]	0.0	4	1	1	1
129682	1710	such condition	[such conditions]	0.0	2	1	1	1
129683	1710	encode the functionally related hepatocyte factor	[encoding the functionally related hepatocyte factors]	0.0	6	1	1	1
129684	1710	major gc-box binding activity	[major GC-box binding activity]	0.0	4	1	1	1
129685	1710	summary, receptor determination	[summary, receptor determination]	0.0	3	1	1	1
129686	1710	ets family protein ga-binding protein	[Ets family proteins GA-binding protein]	0.0	5	1	1	1
129687	1710	predominantly cd56+ cd16+ killer cell	[predominantly CD56+ CD16+ killer cells]	0.0	5	1	1	1
129688	1710	hotspot for ifngr1 small deletion	[hotspot for IFNGR1 small deletions]	0.0	5	1	1	1
129689	1710	transformation of cell express e2a-hlf	[transformation of cells expressing E2A-HLF]	0.0	5	1	1	1
129690	1710	evidence for repression	[Evidence for repression]	0.0	3	1	1	1
129691	1710	transcriptional activity after transfection	[transcriptional activity after transfection]	0.0	4	1	1	1
129692	1710	expression of other adherence-associated gene	[expression of other adherence-associated genes]	0.0	5	1	1	1
129693	1710	isolation for the human class transactivator	[Isolation for the human class transactivator]	0.0	6	1	1	1
129694	1710	acetylation of Kruppel-like factor eklf activity	[Acetylation of Kruppel-like factor EKLF activity]	0.0	6	1	1	1
129695	1710	control of production precursors,	[control of production precursors,]	0.0	4	1	1	1
129696	1710	Stat transcription	[Stat transcription]	0.0	2	1	1	1
129697	1710	eightfold amount	[eightfold amounts]	0.0	2	1	1	1
129698	1710	effect of rbtn-2	[effect of RBTN-2]	0.0	3	1	1	1
129699	1710	activation of biochemical event	[activation of biochemical events]	0.0	4	1	1	1
129700	1710	glucocorticoid receptor concentration before glucocorticoid therapy	[glucocorticoid receptor concentrations before glucocorticoid therapy]	0.0	6	1	1	1
129701	1710	alter the redox status of protein	[altering the redox status of proteins]	0.0	6	1	1	1
129702	1710	cotransfection of JAK3	[Cotransfection of JAK3]	0.0	3	1	1	1
129703	1710	dysregulation of factor-kappa b by lipoprotein	[Dysregulation of factor-kappa B by lipoprotein]	0.0	6	1	1	1
129704	1710	vascular mechanism	[vascular mechanism]	0.0	2	1	1	1
129705	1710	patient with a breast tumor	[patients with a breast tumor]	0.0	5	1	1	1
129706	1710	5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione	[5 rearrangement beta,19-epoxypregn-5-ene-4,20-dione]	0.0	3	1	1	1
129707	1710	probe cysteamine	[probe cysteamine]	0.0	2	1	1	1
129708	1710	Effect of glucocorticoid on glucocorticoid function	[Effects of glucocorticoids on glucocorticoid function]	0.0	6	1	1	1
129709	1710	return to level	[returning to levels]	0.0	3	1	1	1
129710	1710	unknown host intracellular event	[unknown host intracellular events]	0.0	4	1	1	1
129711	1710	background: inhibition	[BACKGROUND: Inhibition]	0.0	2	1	1	1
129712	1710	b alpha -deficient mouse	[B alpha -deficient mice]	0.0	4	1	1	1
129713	1710	combination with all-tran acid RA	[combination with all-trans acid RA]	0.0	5	1	1	1
129714	1710	antimicrovascular ec activity	[antimicrovascular EC activity]	0.0	3	1	1	1
129715	1710	single-cell reverse transcriptase -polymerase chain reaction	[Single-cell reverse transcriptase -polymerase chain reaction]	0.0	6	1	1	1
129716	1710	decrease in activation	[decrease in activation]	0.0	3	1	1	1
129717	1710	phenylarsine oxide pao a inhibitor	[phenylarsine oxide PAO a inhibitor]	0.0	5	1	1	1
129718	1710	peripheral blood cell hla b8+	[peripheral blood cells HLA B8+]	0.0	5	1	1	1
129719	1710	indicate the capacity of CD28 change	[indicating the capacity of CD28 changes]	0.0	6	1	1	1
129720	1710	T cell line C5MJ2	[T cell line C5MJ2]	0.0	4	1	1	1
129721	1710	pretreatment with compound	[pretreatment with compounds]	0.0	3	1	1	1
129722	1710	new gene	[new gene]	0.0	2	1	1	1
129723	1710	human microvessel cell hdmec	[human microvessel cells HDMEC]	0.0	4	1	1	1
129724	1710	papillomaviruse hpv	[papillomaviruses HPV]	0.0	2	1	1	1
129725	1710	clarify the sequence of event	[clarifying the sequence of events]	0.0	5	1	1	1
129726	1710	antisense inhibition of tax	[antisense inhibition of Tax]	0.0	4	1	1	1
129727	1710	transcriptional regulator nuclear factor	[transcriptional regulator nuclear factor]	0.0	4	1	1	1
129728	1710	six patient with eosinophilias	[six patients with eosinophilias]	0.0	4	1	1	1
129729	1710	hiv-1 long repeat site	[HIV-1 long repeat sites]	0.0	4	1	1	1
129730	1710	anti- ras immunoprecipitate	[anti- Ras immunoprecipitates]	0.0	3	1	1	1
129731	1710	differentiation of peripheral blood monocyte	[differentiation of peripheral blood monocytes]	0.0	5	1	1	1
129732	1710	chimeric properties unlike other nuclear oncoprotein	[chimeric properties, unlike other nuclear oncoproteins]	0.0	6	1	1	1
129733	1710	pseudohypoaldosteronism in family form	[Pseudohypoaldosteronism in families: forms]	0.0	4	1	1	1
129734	1710	potential stat-binding site	[potential STAT-binding sites]	0.0	3	1	1	1
129735	1710	migration protein	[migration protein]	0.0	2	1	1	1
129736	1710	effect of LMP1	[effects of LMP1]	0.0	3	1	1	1
129737	1710	leukocyte adhesion molecule-1	[leukocyte adhesion molecule-1]	0.0	3	1	1	1
129738	1710	injection of blood cell	[injection of blood cells]	0.0	4	1	1	1
129739	1710	novel metalloproteinase activity	[novel metalloproteinase activities]	0.0	3	1	1	1
129740	1710	-hcmv	[-HCMV]	0.0	1	1	1	1
129741	1710	analysis of the difference	[Analysis of the differences]	0.0	4	1	1	1
129742	1710	cell against death	[cells against death]	0.0	3	1	1	1
129743	1710	major DNase-I site HS	[major DNase-I sites HS]	0.0	4	1	1	1
129744	1710	complex (mhc) class ii-like molecule	[complex (MHC) class II-like molecule]	0.0	5	1	1	1
129745	1710	unique region contain repeat DR	[unique region containing repeats DR]	0.0	5	1	1	1
129746	1710	hormonal status comparison with criteria]	[Hormonal status comparison with criteria]]	0.0	5	1	1	1
129747	1710	contain nf-e2 gata binding site	[containing NF-E2 GATA binding sites]	0.0	5	1	1	1
129748	1710	ineffective dose	[ineffective dose]	0.0	2	1	1	1
129749	1710	use antibody with a peroxidase-antiperoxidase technique	[using antibodies with a peroxidase-antiperoxidase technique]	0.0	6	1	1	1
129750	1710	icam-1 surface protein in human cell	[ICAM-1 surface protein in human cells]	0.0	6	1	1	1
129751	1710	cancer related loci	[cancer related loci]	0.0	3	1	1	1
129752	1710	pafr transcript 1	[PAFR transcript 1]	0.0	3	1	1	1
129753	1710	pafr transcript 2	[PAFR transcript 2]	0.0	3	1	1	1
129754	1710	change with RU	[change with RU]	0.0	3	1	1	1
129755	1710	Eighteen patient with regular mense	[Eighteen patients with regular menses]	0.0	5	1	1	1
129756	1710	different aetiology	[different aetiologies]	0.0	2	1	1	1
129757	1710	pmlrar alpha cDNA	[PMLRAR alpha cDNA]	0.0	3	1	1	1
129758	1710	keratoconjunctivitis vkc a disease	[keratoconjunctivitis VKC an disease.]	0.0	4	1	1	1
129759	1710	basis for study	[basis for studies]	0.0	3	1	1	1
129760	1710	identification of two element	[Identification of two elements]	0.0	4	1	1	1
129761	1710	photoactivatable crosslinker	[photoactivatable crosslinker]	0.0	2	1	1	1
129762	1710	important costimulatory molecule	[important costimulatory molecule]	0.0	3	1	1	1
129763	1710	trans-disulfide disulfide	[trans-disulfide disulfide]	0.0	2	1	1	1
129764	1710	lymphocyte subset in leukocyte	[lymphocyte subsets in leukocytes]	0.0	4	1	1	1
129765	1710	gene encode a member	[gene encoding a member]	0.0	4	1	1	1
129766	1710	retarded mobility	[retarded mobility]	0.0	2	1	1	1
129767	1710	severe immunodeficiency X-SCID	[severe immunodeficiency X-SCID]	0.0	3	1	1	1
129768	1710	interleukin 10, granulocyte-macrophage factor	[interleukin 10, granulocyte-macrophage factor]	0.0	4	1	1	1
129769	1710	Proteasome-dependent inhibitory kappa b alpha	[Proteasome-dependent inhibitory kappa B alpha]	0.0	5	1	1	1
129770	1710	human cd34+ hemopoietic progenitor cell	[human CD34+ hemopoietic progenitor cells]	0.0	5	1	1	1
129771	1710	interaction with the activator	[interaction with the activators]	0.0	4	1	1	1
129772	1710	cd86 b7-2 two ligand for CD28	[CD86 B7-2 two ligands for CD28]	0.0	6	1	1	1
129773	1710	proportion of residue	[proportion of residues]	0.0	3	1	1	1
129774	1710	transcriptional nuclear factor-KB result	[transcriptional nuclear factor-KB resulting]	0.0	4	1	1	1
129775	1710	Albuminemia indicator	[Albuminemia indicator]	0.0	2	1	1	1
129776	1710	abundant dna-binding activity	[abundant DNA-binding activity]	0.0	3	1	1	1
129777	1710	usf1	[USF1]	0.0	1	1	1	1
129778	1710	hour of exposure to SE	[hr of exposure to SE]	0.0	5	1	1	1
129779	1710	mediate the attachment	[mediating the attachment]	0.0	3	1	1	1
129780	1710	express er	[express ER]	0.0	2	1	1	1
129781	1710	promoter-bound complex	[promoter-bound complexes]	0.0	2	1	1	1
129782	1710	J region	[J region]	0.0	2	1	1	1
129783	1710	fos gene expression in monocyte	[fos gene expression in monocytes]	0.0	5	1	1	1
129784	1710	Putative cis-acting control element	[Putative cis-acting control elements]	0.0	4	1	1	1
129785	1710	incubation of hiv-infected cell	[Incubation of HIV-infected cells]	0.0	4	1	1	1
129786	1710	use.	[use.]	0.0	1	1	1	1
129787	1710	light on the mechanism	[light on the mechanisms]	0.0	4	1	1	1
129788	1710	extent interleukin-1 il-1	[extent interleukin-1 IL-1]	0.0	3	1	1	1
129789	1710	GM-CSFRalpha domain	[GM-CSFRalpha domain]	0.0	2	2	2	1
129790	1710	two factor nf-il6 (position -153	[Two factor NF-IL6 (positions -153]	0.0	5	1	1	1
129791	1710	antiphosphotyrosine immunoblot of cell lysate	[Antiphosphotyrosine immunoblots of cell lysates]	0.0	5	1	1	1
129792	1710	tubulointerstitial disease	[tubulointerstitial disease]	0.0	2	1	1	1
129793	1710	transcription of rna gene	[transcription of RNA genes]	0.0	4	1	1	1
129794	1710	different specific NF-kappaB complex	[different specific NF-kappaB complexes]	0.0	4	1	1	1
129795	1710	67 amino acid	[67 amino acids]	0.0	3	1	1	1
129796	1710	Regulatory effect during lung inflammatory injury	[Regulatory effects during lung inflammatory injury]	0.0	6	1	1	1
129797	1710	protein OAP40	[protein OAP40]	0.0	2	1	1	1
129798	1710	E1A sarcoma cell	[E1A sarcoma cells]	0.0	3	1	1	1
129799	1710	dn construct of differentiation protein	[DN constructs of differentiation protein]	0.0	5	1	1	1
129800	1710	precede the exon	[preceding the exon]	0.0	3	1	1	1
129801	1710	ebv lmp1	[EBV LMP1s]	0.0	2	2	2	1
129802	1710	concomitant transendothelial migration	[concomitant transendothelial migration]	0.0	3	1	1	1
129803	1710	human cd34+ progenitor cell HPC	[human CD34+ progenitor cells HPC]	0.0	5	1	1	1
129804	1710	CEM T cell line	[CEM T cell line]	0.0	4	1	1	1
129805	1710	hpc potential colony-forming cell	[HPCs potential colony-forming cells]	0.0	4	1	1	1
129806	1710	subset of leukemia with translocation	[subsets of leukemia with translocation]	0.0	5	1	1	1
129807	1710	pathway by phorbol acetate	[pathway by phorbol acetate]	0.0	4	1	1	1
129808	1710	tool to the understanding	[tool to the understanding]	0.0	4	1	1	1
129809	1710	transcription study in vitro	[transcription studies in vitro]	0.0	4	1	1	1
129810	1710	PML/RAR alpha fusion gene	[PML/RAR alpha fusion gene]	0.0	4	1	1	1
129811	1710	protein-protein interaction with transcription factor	[protein-protein interactions with transcription factors]	0.0	5	1	1	1
129812	1710	inactive sle	[inactive SLE]	0.0	2	1	1	1
129813	1710	tyrosine phosphorylation of insulin receptor substrate	[tyrosine phosphorylation of insulin receptor substrate]	0.0	6	1	1	1
129814	1710	adjuvant chemotherapy consist of cyclophosphamide	[adjuvant chemotherapy consisting of cyclophosphamide]	0.0	5	1	1	1
129815	1710	characterization of a transcription factor bind	[Characterization of a transcription factor binding]	0.0	6	1	1	1
129816	1710	anti-Class antibody	[anti-Class antibodies]	0.0	2	1	1	1
129817	1710	number in human leucocyte	[number in human leucocytes]	0.0	4	2	2	1
129818	1710	two binding protein	[two binding proteins]	0.0	3	1	1	1
129819	1710	then the initially high expression	[then the initially high expression]	0.0	5	1	1	1
129820	1710	factor 3 beta	[factor 3 beta]	0.0	3	1	1	1
129821	1710	subunit vaccine	[subunit vaccines]	0.0	2	1	1	1
129822	1710	extract form	[extracts form]	0.0	2	1	1	1
129823	1710	addition, factor	[addition, factor]	0.0	2	1	1	1
129824	1710	expression level of c-myc	[expression level of c-myc]	0.0	4	1	1	1
129825	1710	definition of the role	[definition of the role]	0.0	4	1	1	1
129826	1710	localize genital hsv	[localizing genital HSV]	0.0	3	1	1	1
129827	1710	the/thf n:	[THE/THF N:]	0.0	2	1	1	1
129828	1710	new leukemia cell line	[new leukemia cell line]	0.0	4	1	1	1
129829	1710	active metabolite	[active metabolite]	0.0	2	3	3	1
129830	1710	part dependent on oxidative stress	[part dependent on oxidative stress]	0.0	5	1	1	1
129831	1710	human cell line thp-1	[human cell line THP-1]	0.0	4	5	5	1
129832	1710	interaction between a tyrosine motif	[interaction between a tyrosine motif]	0.0	5	1	1	1
129833	1710	estrogen element	[estrogen elements]	0.0	2	1	1	1
129834	1710	origin of h-rs cell	[origin of H-RS cells]	0.0	4	1	1	1
129835	1710	ab variable fragment	[Ab variable fragment]	0.0	3	1	1	1
129836	1710	20 mg	[20 mg]	0.0	2	1	1	1
129837	1710	region of the genes,	[regions of the genes,]	0.0	4	1	1	1
129838	1710	(1-2	[(1-2]	0.0	1	1	1	1
129839	1710	constitutive generation	[constitutive generation]	0.0	2	1	1	1
129840	1710	latent form	[latent form]	0.0	2	1	1	1
129841	1710	er antagonist	[ER antagonist]	0.0	2	1	1	1
129842	1710	granulocyte fraction of blood cell	[granulocyte fraction of blood cells]	0.0	5	1	1	1
129843	1710	calcium concentration ca2+ ]i	[calcium concentration Ca2+ ]i]	0.0	4	1	1	1
129844	1710	gel electrophoresis mobility	[Gel electrophoresis mobility]	0.0	3	1	1	1
129845	1710	rheumatic disease with rheumatoid arthritis	[rheumatic diseases with rheumatoid arthritis]	0.0	5	1	1	1
129846	1710	86 patient with a MPD	[86 patients with a MPD]	0.0	5	1	1	1
129847	1710	T cell activation event	[T cell activation events]	0.0	4	1	1	1
129848	1710	micrograms/ml)	[micrograms/ml)]	0.0	1	1	1	1
129849	1710	cell differentiation a role	[cell differentiation a role]	0.0	4	1	1	1
129850	1710	primer extension method	[primer extension method]	0.0	3	1	1	1
129851	1710	oligonucleotide from the 1st	[oligonucleotides from the 1st]	0.0	4	1	1	1
129852	1710	add nf-kappa b protein from cell	[Adding NF-kappa B protein from cells]	0.0	6	1	1	1
129853	1710	expression of complex surface protein	[expression of complex surface proteins]	0.0	5	1	1	1
129854	1710	promoter sequence regulate collagenase-1 transcription	[promoter sequences regulating collagenase-1 transcription]	0.0	5	1	1	1
129855	1710	process such as atherosclerosis	[processes such as atherosclerosis]	0.0	4	1	1	1
129856	1710	Appraisal of potential index of antioxidant	[Appraisal of potential index of antioxidants]	0.0	6	1	1	1
129857	1710	use the primer	[using the primers]	0.0	3	1	1	1
129858	1710	antigen stimulation,	[antigen stimulation,]	0.0	2	1	1	1
129859	1710	consequence at the level	[consequences at the level]	0.0	4	1	1	1
129860	1710	expression of a specific protein inhibitor	[Expression of a specific protein inhibitor]	0.0	6	1	1	1
129861	1710	lack of (a) factor necessary	[lack of (a) factor necessary]	0.0	5	1	1	1
129862	1710	murine cell line 264.7	[murine cell line 264.7]	0.0	4	1	1	1
129863	1710	transformation of Philadelphia leukemia	[transformation of Philadelphia leukemia]	0.0	4	1	1	1
129864	1710	binding to E2F site	[binding to E2F sites]	0.0	4	1	1	1
129865	1710	20 gy	[20 Gy]	0.0	2	1	1	1
129866	1710	Ile761	[Ile761]	0.0	1	1	1	1
129867	1710	major component of atheroma	[major component of atheroma]	0.0	4	1	1	1
129868	1710	DNase I hypersensitive site DHS	[DNase I hypersensitive site DHS]	0.0	5	1	1	1
129869	1710	immune response with pharmaceutical agent	[immune response with pharmaceutical agents]	0.0	5	1	1	1
129870	1710	immune response to a challenge	[immune response to an challenge]	0.0	5	1	1	1
129871	1710	1 peptide	[1 peptide]	0.0	2	1	1	1
129872	1710	ectopic expression in HeLa cell	[ectopic expression in HeLa cells]	0.0	5	1	1	1
129873	1710	stimulation of factor paf	[stimulation of factor PAF]	0.0	4	1	1	1
129874	1710	thiamine holo drug	[thiamine holo drug]	0.0	3	1	1	1
129875	1710	cleavage a key regulator	[cleavage a key regulator]	0.0	4	1	1	1
129876	1710	tyrosine-phosphorylated factor treatment	[tyrosine-phosphorylated factor treatment]	0.0	3	1	1	1
129877	1710	herpesvirus a T lymphotropic virus	[herpesvirus a T lymphotropic virus]	0.0	5	1	1	1
129878	1710	management	[management]	0.0	1	3	3	1
129879	1710	gene ORF	[gene ORF]	0.0	2	1	1	1
129880	1710	incidence with cytomegalovirus	[incidence with cytomegalovirus]	0.0	3	1	1	1
129881	1710	increase in ifn-beta promoter transcription	[increase in IFN-beta promoter transcription]	0.0	5	1	1	1
129882	1710	kappa pathway	[kappa pathway]	0.0	2	1	1	1
129883	1710	beta cd49d/cd29 integrin costimulation	[beta CD49d/CD29 integrin costimulation]	0.0	4	1	1	1
129884	1710	signal upon treatment	[signalling upon treatment]	0.0	3	1	1	1
129885	1710	cytokine up-regulation	[cytokine up-regulation]	0.0	2	1	1	1
129886	1710	evidence to dendritic cell differentiation	[Evidence to dendritic cell differentiation]	0.0	5	1	1	1
129887	1710	BZLF1 transcription	[BZLF1 transcription]	0.0	2	1	1	1
129888	1710	endothelial activation a vascular antiatherogenic mechanism	[endothelial activation A vascular antiatherogenic mechanism]	0.0	6	1	1	1
129889	1710	blood of donor	[blood of donors]	0.0	3	2	2	1
129890	1710	transcription follow engagement cell-to-cell contact).	[transcription following engagement cell-to-cell contact).]	0.0	5	1	1	1
129891	1710	vitro-differentiated stem cell	[vitro-differentiated stem cells]	0.0	3	1	1	1
129892	1710	herpesvirus 6 strain	[herpesvirus 6 strains]	0.0	3	1	1	1
129893	1710	il-5 promoter/enhancer-luciferase gene construct	[IL-5 promoter/enhancer-luciferase gene construct]	0.0	4	1	1	1
129894	1710	I interferon ifn-alpha/beta	[I interferon IFN-alpha/beta]	0.0	3	1	1	1
129895	1710	cell in several experimental model	[cells in several experimental models]	0.0	5	1	1	1
129896	1710	implication of signal	[implications of signals]	0.0	3	1	1	1
129897	1710	include pcr	[including PCR]	0.0	2	1	1	1
129898	1710	A-CRF with mild-moderate renal insufficiency	[A-CRF with mild-moderate renal insufficiency]	0.0	5	1	1	1
129899	1710	little activation of ap-1	[little activation of AP-1]	0.0	4	1	1	1
129900	1710	tnf-alpha promoter element kappa	[TNF-alpha promoter element kappa]	0.0	4	1	1	1
129901	1710	cc(a/t)6gg (carg) motif	[CC(A/T)6GG (CArG) motifs]	0.0	3	1	1	1
129902	1710	cloning of the region.	[cloning of the region.]	0.0	4	1	1	1
129903	1710	initial diagnosis, counseling, of patient	[initial diagnosis, counseling, of patients]	0.0	5	1	1	1
129904	1710	clinical investigation as a therapy	[clinical investigation as a therapy]	0.0	5	1	1	1
129905	1710	group of healthy female	[group of healthy females]	0.0	4	1	1	1
129906	1710	ETS-domain proteins.	[ETS-domain proteins.]	0.0	2	1	1	1
129907	1710	fos -cat construct	[fos -CAT constructs]	0.0	3	1	1	1
129908	1710	alpha,25-dihydroxycholecalciferol	[alpha,25-dihydroxycholecalciferol]	0.0	1	1	1	1
129909	1710	binding at level of motor activity	[binding at levels of motor activity]	0.0	6	1	1	1
129910	1710	significant rise	[significant rise]	0.0	2	1	1	1
129911	1710	level of gm-csf	[levels of GM-CSF]	0.0	3	1	1	1
129912	1710	Oct-1 member in nf-atp	[Oct-1 members in NF-ATp]	0.0	4	1	1	1
129913	1710	contrast, even at dose	[contrast, even at doses]	0.0	4	1	1	1
129914	1710	b -like	[B -like]	0.0	2	1	1	1
129915	1710	large number endometrium	[large numbers endometrium]	0.0	3	1	1	1
129916	1710	cotton top	[cotton top]	0.0	2	1	1	1
129917	1710	normal developmental pattern	[normal developmental patterns]	0.0	3	1	1	1
129918	1710	Epstein-Barr virus zebra promoter	[Epstein-Barr virus zebra promoter]	0.0	4	1	1	1
129919	1710	cytokine mrna level	[cytokine mRNA levels]	0.0	3	1	1	1
129920	1710	compensate	[compensating]	0.0	1	1	1	1
129921	1710	sarcophytol	[sarcophytol]	0.0	1	1	1	1
129922	1710	kappa B/Rel activity in blood T	[kappa B/Rel activity in blood T]	0.0	6	1	1	1
129923	1710	promote the resolution	[promoting the resolution]	0.0	3	1	1	1
129924	1710	tcrg enhancer	[TCRG enhancer]	0.0	2	1	1	1
129925	1710	activation of messenger	[activation of messengers]	0.0	3	1	1	1
129926	1710	mrna transcript of kb.	[mRNA transcript of kb.]	0.0	4	1	1	1
129927	1710	developmental control protein	[developmental control protein]	0.0	3	1	1	1
129928	1710	clue assess responsiveness	[clue assessing responsiveness]	0.0	3	1	1	1
129929	1710	down-regulation in patient suffer	[down-regulation in patients suffering]	0.0	4	1	1	1
129930	1710	early b-cell precursor	[early B-cell precursors]	0.0	3	1	1	1
129931	1710	tumor originate from cell	[tumors originating from cells]	0.0	4	1	1	1
129932	1710	mrna transcript of 2.2 kilobasis	[mRNA transcript of 2.2 kilobases]	0.0	5	1	1	1
129933	1710	identification as the element	[identification as the elements]	0.0	4	1	1	1
129934	1710	formation of major stat complex	[formation of major STAT complexes]	0.0	5	1	1	1
129935	1710	Finally, time course analysis	[Finally, time course analysis]	0.0	4	1	1	1
129936	1710	endothelial surface	[endothelial surface]	0.0	2	1	1	1
129937	1710	class histocompatibility cell line	[class histocompatibility cell lines]	0.0	4	1	1	1
129938	1710	obese patient	[obese patient]	0.0	2	1	1	1
129939	1710	(18-	[(18-]	0.0	1	1	1	1
129940	1710	GGACTACAG	[GGACTACAG]	0.0	1	1	1	1
129941	1710	gcr in leukocyte	[GCR in leukocytes]	0.0	3	1	1	1
129942	1710	cd86 principal ligand for CD28	[CD86 principal ligands for CD28]	0.0	5	1	1	1
129943	1710	event during replication	[events during replication]	0.0	3	1	1	1
129944	1710	thereby amplify event lead	[thereby amplifying events leading]	0.0	4	1	1	1
129945	1710	human monoclonal antibody specific	[human monoclonal antibody specific]	0.0	4	1	1	1
129946	1710	T cell line IARC	[T cell line IARC]	0.0	4	1	1	1
129947	1710	difference in this closely related lineage	[differences in these closely related lineages]	0.0	6	1	1	1
129948	1710	patient with normal affinity to glucocorticoid	[patients with normal affinity to glucocorticoids]	0.0	6	1	1	1
129949	1710	up-regulation of the promoter	[up-regulation of the promoter]	0.0	4	1	1	1
129950	1710	ras pathway	[Ras pathway]	0.0	2	1	1	1
129951	1710	blood lymphocyte asthma	[blood lymphocytes asthma]	0.0	3	1	1	1
129952	1710	human Chr 20 centromere	[human Chr 20 centromere]	0.0	4	1	1	1
129953	1710	part, at a level	[part, at a level]	0.0	4	1	1	1
129954	1710	indicate the signal capacity	[indicating the signaling capacity]	0.0	4	1	1	1
129955	1710	multiple nucleotide substitution in the counterpart	[multiple nucleotide substitutions in the counterpart]	0.0	6	1	1	1
129956	1710	long repeat promoter	[long repeat promoter]	0.0	3	1	1	1
129957	1710	different lymphoid cell include cell	[different lymphoid cells including cells]	0.0	5	1	1	1
129958	1710	site (HS 2)	[site (HS 2)]	0.0	3	1	1	1
129959	1710	use monocyte as apc in 69%	[using monocytes as APC in 69%]	0.0	6	1	1	1
129960	1710	synthesis of cytokine	[synthesis of cytokines]	0.0	3	1	1	1
129961	1710	production of amount e1b	[production of amounts E1B]	0.0	4	1	1	1
129962	1710	proteasome inhibitor z-lll-h	[proteasome inhibitor Z-LLL-H]	0.0	3	1	1	1
129963	1710	inhibition by thp-1-hgh-transfected cell	[Inhibition by THP-1-hGH-transfected cells]	0.0	4	1	1	1
129964	1710	and/or modification of a factor,	[and/or modification of a factor,]	0.0	5	1	1	1
129965	1710	binding I interferon to specific receptor	[Binding I interferon to specific receptors]	0.0	6	1	1	1
129966	1710	nucleoprotein extract	[nucleoprotein extracts]	0.0	2	1	1	1
129967	1710	molecular weight complex	[molecular weight complex]	0.0	3	1	1	1
129968	1710	suggest a domain	[suggesting a domain]	0.0	3	1	1	1
129969	1710	Interleukin-2 promoter activity	[Interleukin-2 promoter activity]	0.0	3	1	1	1
129970	1710	ro(ssa) precipitins, 84%	[Ro(SSA) precipitins, 84%]	0.0	3	1	1	1
129971	1710	direct substrate in intact cells.	[direct substrates in intact cells.]	0.0	5	1	1	1
129972	1710	potent transactivation domain	[potent transactivation domain]	0.0	3	1	1	1
129973	1710	cell line tested;	[cell lines tested;]	0.0	3	1	1	1
129974	1710	STAT3alpha on serine	[STAT3alpha on serine]	0.0	3	1	1	1
129975	1710	vernal keratoconjunctivitis vkc a disease	[vernal keratoconjunctivitis VKC an disease.]	0.0	5	1	1	1
129976	1710	frequency isolate dest	[frequency isolating DESTs]	0.0	3	1	1	1
129977	1710	growth factor bFGF	[growth factor bFGF]	0.0	3	1	1	1
129978	1710	small number progenitor cell	[small number progenitor cells]	0.0	4	1	1	1
129979	1710	direct repeat of bp	[direct repeats of bp]	0.0	4	1	1	1
129980	1710	look in approach	[Looking in approaches]	0.0	3	1	1	1
129981	1710	murine helix-loop-helix transcription factor gene	[murine helix-loop-helix transcription factor gene]	0.0	5	1	1	1
129982	1710	maturation of leukemia cell	[maturation of leukemia cells]	0.0	4	1	1	1
129983	1710	class of subnuclear structure	[class of subnuclear structures]	0.0	4	1	1	1
129984	1710	N17-mutated Ras construct	[N17-mutated Ras construct]	0.0	3	1	1	1
129985	1710	constant (Kd) of the fms	[constant (Kd) of the FMS]	0.0	5	1	1	1
129986	1710	include gm-csf	[including GM-CSF]	0.0	2	1	1	1
129987	1710	pkc substrate marck	[PKC substrates MARCKS]	0.0	3	1	1	1
129988	1710	counterpart to lymphocytic leukemia	[counterpart to lymphocytic leukemias]	0.0	4	1	1	1
129989	1710	transcript, a transcription factor	[transcript, a transcription factor]	0.0	4	1	1	1
129990	1710	cell adhesion, il-6 production	[cell adhesion, IL-6 production]	0.0	4	1	1	1
129991	1710	cytoplasmic domain receptor alpha subunit	[cytoplasmic domain receptor alpha subunit]	0.0	5	1	1	1
129992	1710	activation by this form	[activation by this form]	0.0	4	1	1	1
129993	1710	hydrocortisone (F) of concentration (10(-9)-10(-7)	[hydrocortisone (F) of concentration (10(-9)-10(-7)]	0.0	5	1	1	1
129994	1710	regulatory role of e220k	[regulatory role of E220K]	0.0	4	1	1	1
129995	1710	beta-globin gene in cell	[beta-globin gene in cells]	0.0	4	1	1	1
129996	1710	physiological role in mitogen activation	[physiological role in mitogen activation]	0.0	5	1	1	1
129997	1710	number of related receptor in leukocyte	[number of related receptors in leukocytes]	0.0	6	1	1	1
129998	1710	non- b-cell line	[non- B-cell lines]	0.0	3	1	1	1
129999	1710	setting.	[setting.]	0.0	1	1	1	1
130000	1710	dominant pi3-k construct	[dominant PI3-K constructs]	0.0	3	1	1	1
130001	1710	express a pattern of x inactivation	[expressing a pattern of X inactivation]	0.0	6	1	1	1
130002	1710	immunity to VZV	[immunity to VZV]	0.0	3	1	1	1
130003	1710	transactivator activity in cell	[transactivator activity in cells]	0.0	4	1	1	1
130004	1710	exchangeable ca2+ feca2+	[exchangeable Ca2+ FECa2+]	0.0	3	1	1	1
130005	1710	signal molecule include tradd	[signaling molecules including TRADD]	0.0	4	1	1	1
130006	1710	signal pathway responsible for cell suicide	[signaling pathways responsible for cell suicide]	0.0	6	1	1	1
130007	1710	suggest still effective	[suggesting still effective]	0.0	3	1	1	1
130008	1710	parameter regulate the IL-12 signal pathway	[parameters regulating the IL-12 signaling pathway]	0.0	6	1	1	1
130009	1710	signal CD40 stimulation of monocyte	[signaling CD40 stimulation of monocytes]	0.0	5	1	1	1
130010	1710	/gsh	[/GSH]	0.0	1	1	1	1
130011	1710	/gtp	[/GTP]	0.0	1	1	1	1
130012	1710	protein, most likely dpii,	[protein, most likely DP-I,]	0.0	4	1	1	1
130013	1710	cell-cycle control	[cell-cycle control]	0.0	2	1	1	1
130014	1710	Effect of interleukin-10	[Effects of interleukin-10]	0.0	3	1	1	1
130015	1710	group of male subject	[group of male subjects]	0.0	4	1	1	1
130016	1710	replication of some virus	[replication of some viruses]	0.0	4	1	1	1
130017	1710	possible linkage	[possible linkage]	0.0	2	1	1	1
130018	1710	gene encode initiation factor	[Genes encoding initiation factors]	0.0	4	1	1	1
130019	1710	main activity transactivation	[main activities transactivation]	0.0	3	1	1	1
130020	1710	positive mechanism control the competence	[positive mechanisms controlling the competence]	0.0	5	1	1	1
130021	1710	develop from human blood mononuclear precursor	[developing from human blood mononuclear precursors]	0.0	6	1	1	1
130022	1710	anti-mhc class	[anti-MHC class]	0.0	2	2	2	1
130023	1710	Recent development of culture of megakaryocyte	[Recent development of cultures of megakaryocytes]	0.0	6	1	1	1
130024	1710	uptake with chronic renal failure	[uptake with chronic renal failure]	0.0	5	1	1	1
130025	1710	none of pbmc specimen	[None of PBMC specimens]	0.0	4	2	2	1
130026	1710	b-cell response in hepatitis c	[B-cell response in hepatitis C]	0.0	5	1	1	1
130027	1710	potentiation of nonphlogistic clearance of leukocyte	[potentiation of nonphlogistic clearance of leukocytes]	0.0	6	1	1	1
130028	1710	information from receptor to factor	[information from receptors to factor]	0.0	5	1	1	1
130029	1710	insight into plaque formation	[insight into plaque formation]	0.0	4	1	1	1
130030	1710	two different class of receptor	[two different classes of receptors]	0.0	5	1	1	1
130031	1710	expression of the tcf-1 protein	[expression of the TCF-1 protein]	0.0	5	1	1	1
130032	1710	mechanisms; inhibition	[mechanisms; inhibition]	0.0	2	1	1	1
130033	1710	ATP-dependent s multicatalytic protease	[ATP-dependent S multicatalytic proteases]	0.0	4	1	1	1
130034	1710	drastic change in gene topography	[drastic changes in gene topography]	0.0	5	1	1	1
130035	1710	base pair change	[base pair change]	0.0	3	1	1	1
130036	1710	evidence regard the role	[evidence regarding the role]	0.0	4	1	1	1
130037	1710	normal transcription	[normal transcription]	0.0	2	1	1	1
130038	1710	retinoid response pathway	[retinoid response pathways]	0.0	3	1	1	1
130039	1710	establish pbmc culture (1.5 in colony	[establishing PBMC cultures (1.5 in colonies]	0.0	6	1	1	1
130040	1710	tpa ca(2+)	[TPA Ca(2+)]	0.0	2	1	1	1
130041	1710	class ii RB -defective line	[class II RB -defective lines]	0.0	5	1	1	1
130042	1710	blood leukocyte in long-distance runner	[blood leukocytes in long-distance runner]	0.0	5	1	1	1
130043	1710	autosomal recessive disease xeroderma pigmentosum	[autosomal recessive disease xeroderma pigmentosum]	0.0	5	1	1	1
130044	1710	clearly high nuclear translocation	[clearly higher nuclear translocation]	0.0	4	1	1	1
130045	1710	secretion by macrophage in response	[secretion by macrophages in response]	0.0	5	1	1	1
130046	1710	target NFAT-1 -dependent gene expression	[targeting NFAT-1 -dependent gene expression]	0.0	5	1	1	1
130047	1710	effect on the IL-2mRNA synthesis	[effect on the IL-2mRNA synthesis]	0.0	5	1	1	1
130048	1710	Oct2 b cell	[Oct2 B cells]	0.0	3	1	1	1
130049	1710	relationship between ikappabalpha expression	[Relationship between IkappaBalpha expression]	0.0	4	1	1	1
130050	1710	signal transduction abnormality relevance	[Signal transduction abnormalities relevance]	0.0	4	1	1	1
130051	1710	appearance of nf-kappa b	[appearance of NF-kappa B]	0.0	4	1	1	1
130052	1710	10(-10) mol/L RA	[10(-10) mol/L RA]	0.0	3	1	1	1
130053	1710	-dependent transcriptional activation of interleukin gene	[-dependent transcriptional activation of interleukin gene]	0.0	6	1	1	1
130054	1710	individual with genetic makaume mtbe	[individuals with genetic makeup, MTBE]	0.0	5	1	1	1
130055	1710	concomitant	[concomitant]	0.0	1	1	1	1
130056	1710	regulator of expression	[regulators of expression]	0.0	3	1	1	1
130057	1710	activity potent	[activity potent]	0.0	2	1	1	1
130058	1710	other early response gene	[other early response genes]	0.0	4	1	1	1
130059	1710	level of octamer -dependent transcription	[levels of octamer -dependent transcription]	0.0	5	1	1	1
130060	1710	contain nuclear nf-kappa b	[containing nuclear NF-kappa B]	0.0	4	1	1	1
130061	1710	recombinant human soluble tnf receptor	[recombinant human soluble TNF receptor]	0.0	5	1	1	1
130062	1710	deficiency syndrome in property (deficiency-cold),	[deficiency syndromes in property (deficiency-cold),]	0.0	5	1	1	1
130063	1710	specificity for kappa b motif	[specificities for kappa B motifs]	0.0	5	1	1	1
130064	1710	mature.	[mature.]	0.0	1	1	1	1
130065	1710	different class of cytosolic receptor	[different classes of cytosolic receptors]	0.0	5	1	1	1
130066	1710	ascorbate free AFR act	[ascorbate free AFR acts]	0.0	4	1	1	1
130067	1710	immunoglobulin mu heavy-chain gene enhancer	[immunoglobulin mu heavy-chain gene enhancer]	0.0	5	1	1	1
130068	1710	antigen t-cell from LP individual	[antigen T-cells from LP individuals]	0.0	5	1	1	1
130069	1710	32 bp deletion	[32 bp deletion]	0.0	3	1	1	1
130070	1710	clinically relevant dose (25 mm)	[clinically relevant dose (25 mM)]	0.0	5	1	1	1
130071	1710	mutation site	[mutation site]	0.0	2	1	1	1
130072	1710	other X1 activity	[other X1 activities]	0.0	3	1	1	1
130073	1710	new membrane receptor	[new membrane receptor]	0.0	3	1	1	1
130074	1710	class determinant	[class determinants]	0.0	2	1	1	1
130075	1710	activation of STAT1alpha	[activation of STAT1alpha]	0.0	3	1	1	1
130076	1710	10-amino acid CD40 signal determinant	[10-amino acid CD40 signaling determinant]	0.0	5	1	1	1
130077	1710	basic bhlh motif contiguous	[basic bHLH motif contiguous]	0.0	4	1	1	1
130078	1710	look at success	[Looking at successes]	0.0	3	1	1	1
130079	1710	transcriptional factor-KB result	[transcriptional factor-KB resulting]	0.0	3	1	1	1
130080	1710	expression of distinct set	[expression of distinct sets]	0.0	4	1	1	1
130081	1710	repression of the transcription factor	[repression of the transcription factor]	0.0	5	1	1	1
130082	1710	donor' somatic DNA	[donor's somatic DNA]	0.0	3	1	1	1
130083	1710	examine change in protein tyrosine phosphorylation	[examining changes in protein tyrosine phosphorylation]	0.0	6	1	1	1
130084	1710	(2%)	[(2%)]	0.0	1	1	1	1
130085	1710	b cell by herpesvirus hhv-6	[B cells by herpesvirus HHV-6]	0.0	5	1	1	1
130086	1710	236 ng/ml) with the symptom score	[236 ng/mL) with the symptom score]	0.0	6	1	1	1
130087	1710	human class isotype	[human class isotypes]	0.0	3	1	1	1
130088	1710	complex with AMP response protein	[complexes with AMP response protein]	0.0	5	1	1	1
130089	1710	nf-kappab regulation of renal fibrosis	[NF-kappaB regulation of renal fibrosis]	0.0	5	1	1	1
130090	1710	testosterone responsiveness	[testosterone responsiveness]	0.0	2	1	1	1
130091	1710	dalton	[daltons]	0.0	1	1	1	1
130092	1710	correlate to the structural classification	[correlates to the structural classification]	0.0	5	1	1	1
130093	1710	correlation represent tumor defense	[correlation representing tumor defense]	0.0	4	1	1	1
130094	1710	large 67-kDa precursor protein	[large 67-kDa precursor protein]	0.0	4	1	1	1
130095	1710	transcription of a cytokine tgf-beta	[transcription of a cytokine TGF-beta]	0.0	5	1	1	1
130096	1710	rapid tyrosine phosphorylation of multiple substrate	[rapid tyrosine phosphorylation of multiple substrates]	0.0	6	1	1	1
130097	1710	significantly favorable course (p	[significantly favorable course (P]	0.0	4	1	1	1
130098	1710	profound change in p21ras	[profound change in p21ras]	0.0	4	1	1	1
130099	1710	sole cause arrest.	[sole cause arrest.]	0.0	3	1	1	1
130100	1710	PMA induction,	[PMA induction,]	0.0	2	1	1	1
130101	1710	feature of this chromatin reorganization	[feature of this chromatin reorganization]	0.0	5	1	1	1
130102	1710	lack of (a) transcriptional factor	[lack of (a) transcriptional factor]	0.0	5	1	1	1
130103	1710	octamer-associated protein OAP40	[octamer-associated protein OAP40]	0.0	3	1	1	1
130104	1710	correspondence with allelic variant	[correspondence with allelic variants]	0.0	4	1	1	1
130105	1710	tax -dependent transcriptional control	[Tax -dependent transcriptional control]	0.0	4	1	1	1
130106	1710	oncogenic form	[Oncogenic forms]	0.0	2	1	1	1
130107	1710	I aldosterone receptor	[I aldosterone receptors]	0.0	3	1	1	1
130108	1710	role for GATA-3	[role for GATA-3]	0.0	3	1	1	1
130109	1710	feedback inhibitor of inflammation	[feedback inhibitor of inflammation]	0.0	4	1	1	1
130110	1710	role for GATA-1	[role for GATA-1]	0.0	3	1	1	1
130111	1710	new kappa B-specific complex	[new kappa B-specific complexes]	0.0	4	1	1	1
130112	1710	extinction of other cell-encoded gene	[extinction of other cell-encoded genes]	0.0	5	1	1	1
130113	1710	human class ii gene	[human class II genes]	0.0	4	1	1	1
130114	1710	adult animal	[adult animals]	0.0	2	1	1	1
130115	1710	-stat5a pathway	[-STAT5a pathway]	0.0	2	1	1	1
130116	1710	Albuminemia platelet factor iv indicator	[Albuminemia Platelet Factor IV indicator]	0.0	5	1	1	1
130117	1710	global mechanism	[global mechanism]	0.0	2	1	1	1
130118	1710	open reading frame a	[open reading frames A]	0.0	4	1	1	1
130119	1710	contrast, IL-12 induction	[contrast, IL-12 induction]	0.0	3	1	1	1
130120	1710	J.Leahy,	[J.Leahy,]	0.0	1	1	1	1
130121	1710	enzyme,	[enzyme,]	0.0	1	1	1	1
130122	1710	tnf-treated T cell	[TNF-treated T cells]	0.0	3	1	1	1
130123	1710	regulator factor	[regulator factor]	0.0	2	1	1	1
130124	1710	accumulation of mrna for elam-1	[accumulation of mRNA for ELAM-1]	0.0	5	1	1	1
130125	1710	protein include the product	[proteins including the products]	0.0	4	1	1	1
130126	1710	double-negative lpr	[double-negative lpr]	0.0	2	1	1	1
130127	1710	activator protein-1 nuclear factor	[activator protein-1 nuclear factor]	0.0	4	1	1	1
130128	1710	bacterial lps (endotoxin)	[bacterial LPS (endotoxin)]	0.0	3	1	1	1
130129	1710	ifn-gamma colony-stimulating factor gm-csf mrna	[IFN-gamma colony-stimulating factor GM-CSF mRNA]	0.0	5	1	1	1
130130	1710	basal transcriptional activity	[basal transcriptional activity]	0.0	3	1	1	1
130131	1710	24 month (24-58	[24 months (24-58]	0.0	3	1	1	1
130132	1710	activation event occur	[activation events occurring]	0.0	3	1	1	1
130133	1710	signal mediate tnf-alpha release	[signals mediating TNF-alpha release]	0.0	4	1	1	1
130134	1710	range ppt tcdd	[range ppt TCDD]	0.0	3	1	1	1
130135	1710	functional factor kB NF-kB regulatory element	[functional factor kB NF-kB regulatory elements]	0.0	6	1	1	1
130136	1710	fetal bovine serum	[fetal bovine serum]	0.0	3	2	2	1
130137	1710	methov of human vein endothelial cell	[METHODS of human vein endothelial cells]	0.0	6	1	1	1
130138	1710	cell line keep strictly erythroid-specific property	[cell lines keeping strictly erythroid-specific properties]	0.0	6	1	1	1
130139	1710	IL-2 prl	[IL-2 PRL]	0.0	2	1	1	1
130140	1710	different techniques: blot	[different techniques: blot]	0.0	3	1	1	1
130141	1710	transcriptional activity of the repeat	[transcriptional activity of the repeat]	0.0	5	1	1	1
130142	1710	lipopolysaccharide expression of mediator	[lipopolysaccharide expression of mediators]	0.0	4	1	1	1
130143	1710	transcription of certain gene	[transcription of certain genes]	0.0	4	1	1	1
130144	1710	However, examination	[However, examination]	0.0	2	1	1	1
130145	1710	Eed gene expression	[Eed gene expression]	0.0	3	1	1	1
130146	1710	nf-kappab activation long repeat	[NF-kappaB activation long repeat]	0.0	4	1	1	1
130147	1710	development of the islet b cell	[development of the islet B cell]	0.0	6	1	1	1
130148	1710	multiple protein eventually lead	[multiple proteins eventually leading]	0.0	4	1	1	1
130149	1710	t-cell inhibitory effect together	[T-cell inhibitory effects together]	0.0	4	1	1	1
130150	1710	immunoregulatory gene IL-1beta	[immunoregulatory genes IL-1beta]	0.0	3	1	1	1
130151	1710	member of the nsaid	[members of the NSAIDs]	0.0	4	1	1	1
130152	1710	cell with long neurite process	[cells with long neurite processes]	0.0	5	1	1	1
130153	1710	course of serious infection	[course of serious infections]	0.0	4	2	2	1
130154	1710	developmental event	[developmental events]	0.0	2	1	1	1
130155	1710	two ets binding site EBS	[two Ets binding sites EBS]	0.0	5	1	1	1
130156	1710	observation of cortisol excretion	[observations of cortisol excretion]	0.0	4	1	1	1
130157	1710	induce CAT activity /mn2+ for h.	[inducing CAT activity /Mn2+ for h,]	0.0	6	1	1	1
130158	1710	down-regulate the cellular immune response	[down-regulating the cellular immune response]	0.0	5	1	1	1
130159	1710	bp downstream	[bp downstream]	0.0	2	1	1	1
130160	1710	long activation	[long-term activation]	0.0	2	1	1	1
130161	1710	element of the interleukin-2 promoter	[element of the interleukin-2 promoter]	0.0	5	1	1	1
130162	1710	stat4 binding to the IRF-1 promoter	[STAT4 binding to the IRF-1 promoter]	0.0	6	1	1	1
130163	1710	fluid phase	[fluid phase]	0.0	2	1	1	1
130164	1710	3h-dex	[3H-Dex]	0.0	1	1	1	1
130165	1710	surprisingly, different combination	[Surprisingly, different combinations]	0.0	3	1	1	1
130166	1710	g76:gpltplpv aes1/2	[G76:GPLTPLPV AES1/2]	0.0	2	1	1	1
130167	1710	high level of nf-atp capable	[higher levels of NF-ATp capable]	0.0	5	1	1	1
130168	1710	comparative sequence analysis	[Comparative sequence analysis]	0.0	3	1	1	1
130169	1710	HBx antibody titer	[HBx antibody titers]	0.0	3	1	1	1
130170	1710	kappa B-specific dna-binding activity	[kappa B-specific DNA-binding activity]	0.0	4	1	1	1
130171	1710	regulation by 135-(oh)2d3	[regulation by 1,25-(OH)2D3]	0.0	3	1	1	1
130172	1710	role in the differentiation	[role in the differentiation]	0.0	4	1	1	1
130173	1710	regulation dependent signal transduction pathway	[Regulation dependent signal transduction pathways]	0.0	5	1	1	1
130174	1710	-dependent modulation of gene transcription	[-dependent modulation of gene transcription]	0.0	5	1	1	1
130175	1710	implication of this result	[implications of these results]	0.0	4	1	1	1
130176	1710	anti-tumour activity in tumour	[anti-tumour activity in tumours]	0.0	4	1	1	1
130177	1710	only relative binding affinity the high	[only relative binding affinities the highest]	0.0	6	1	1	1
130178	1710	gene regulatory element	[gene regulatory elements]	0.0	3	1	1	1
130179	1710	DNA from four patient	[DNA from four patients]	0.0	4	1	1	1
130180	1710	role determine the efficiency	[roles determining the efficiency]	0.0	4	1	1	1
130181	1710	separate transduction pathway	[separate transduction pathways]	0.0	3	1	1	1
130182	1710	event in human lymphoid tumor	[events in human lymphoid tumors]	0.0	5	1	1	1
130183	1710	approximately a increase	[approximately a increase]	0.0	3	1	1	1
130184	1710	region flank sequence	[region flanking sequence]	0.0	3	1	1	1
130185	1710	mediator of tip function	[mediator of Tip function]	0.0	4	1	1	1
130186	1710	homologue of Drosophila Toll	[homologue of Drosophila Toll]	0.0	4	1	1	1
130187	1710	(stat) family of proteins.	[(STAT) family of proteins.]	0.0	4	1	1	1
130188	1710	expression of the cd20/b1 antigen	[expression of the CD20/B1 antigen]	0.0	5	1	1	1
130189	1710	inhibitor in cell	[inhibitor in cells]	0.0	3	1	1	1
130190	1710	gene fall into that category	[genes falling into those categories]	0.0	5	1	1	1
130191	1710	mediate lysis	[mediating lysis]	0.0	2	1	1	1
130192	1710	use the t-cell line Jurkat	[using the T-cell lines Jurkat]	0.0	5	1	1	1
130193	1710	high bcl-xl	[high Bcl-XL]	0.0	2	1	1	1
130194	1710	activity of a single-chain Fv	[activity of a single-chain Fv]	0.0	5	1	1	1
130195	1710	1.2-kb cDNA encoding c/ebp-epsilon	[1.2-kb cDNA encoding C/EBP-epsilon]	0.0	4	1	1	1
130196	1710	-myh11	[-MYH11]	0.0	1	2	2	1
130197	1710	nf-kappa b binding to DNA	[NF-kappa B binding to DNA]	0.0	5	1	1	1
130198	1710	include hiv	[including HIV]	0.0	2	1	1	1
130199	1710	nf-atp mouse old than week	[NF-ATp mice older than weeks]	0.0	5	1	1	1
130200	1710	factor, distinct	[factor, distinct]	0.0	2	1	1	1
130201	1710	rapidly tyrosine-phosphorylated follow granulocyte-colony factor treatment	[rapidly tyrosine-phosphorylated following granulocyte-colony factor treatment]	0.0	6	1	1	1
130202	1710	member,	[member,]	0.0	1	1	1	1
130203	1710	addition of oligomer	[addition of oligomers]	0.0	3	1	1	1
130204	1710	g-csf dead cell	[G-CSF dead cells]	0.0	3	1	1	1
130205	1710	/heb	[/HEB]	0.0	1	1	1	1
130206	1710	fibrosarcoma 8, fibrous histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma 8, fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	6	1	1	1
130207	1710	moreover, TNF-alpha hiv-1 long repeat LTR	[Moreover, TNF-alpha HIV-1 long repeat LTR]	0.0	6	1	1	1
130208	1710	expression in monocytes: role	[expression in monocytes: role]	0.0	4	1	1	1
130209	1710	factor (nfat) family	[factor (NFAT) family]	0.0	3	1	1	1
130210	1710	atopic clone	[atopics clones]	0.0	2	1	1	1
130211	1710	125i-labeled c-c chemokine in cell	[125I-labeled C-C chemokines in cells]	0.0	5	1	1	1
130212	1710	facet	[facet]	0.0	1	1	1	1
130213	1710	active protein-tyrosine kinase pathway	[active protein-tyrosine kinase pathway]	0.0	4	1	1	1
130214	1710	p[(TRE)3-tk-Luc]	[p[(TRE)3-tk-Luc]]	0.0	1	1	1	1
130215	1710	element such as the PyG box	[elements such as the PyG boxes]	0.0	6	1	1	1
130216	1710	activation of immunodeficiency virus type	[Activation of immunodeficiency virus type]	0.0	5	1	1	1
130217	1710	b development	[B development]	0.0	2	1	1	1
130218	1710	translocalization	[translocalization]	0.0	1	1	1	1
130219	1710	cd11b antigen in myeloid cell	[CD11b antigen in myeloid cells]	0.0	5	1	1	1
130220	1710	effect on the level	[effect on the levels]	0.0	4	1	1	1
130221	1710	EBNA-1 gene	[EBNA-1 gene]	0.0	2	1	1	1
130222	1710	MHC class antigen expression	[MHC class antigens expression]	0.0	4	1	1	1
130223	1710	pathophysiological condition such as cancer	[pathophysiological conditions such as cancer]	0.0	5	1	1	1
130224	1710	(i) region	[(I) regions]	0.0	2	1	1	1
130225	1710	Glucocorticoid receptor in ovary syndrome	[Glucocorticoid receptors in ovary syndrome]	0.0	5	1	1	1
130226	1710	cytokine stimulate	[cytokine stimulating]	0.0	2	1	1	1
130227	1710	clinical relevance for gastroenterology	[clinical relevance for gastroenterology]	0.0	4	1	1	1
130228	1710	lung leak	[lung leak]	0.0	2	1	1	1
130229	1710	function in b cell development	[function in B cell development]	0.0	5	1	1	1
130230	1710	set of evidence	[sets of evidences]	0.0	3	1	1	1
130231	1710	only relative binding affinity RBA	[only relative binding affinities RBA]	0.0	5	1	1	1
130232	1710	chronic lymphocytic leukemia cell	[chronic lymphocytic leukemia cells]	0.0	4	1	1	1
130233	1710	isozyme activity	[isozyme activity]	0.0	2	1	1	1
130234	1710	soluble, bivalent mab j393	[soluble, bivalent mAb J393]	0.0	4	1	1	1
130235	1710	response from linearity	[response from linearity]	0.0	3	1	1	1
130236	1710	body giant cell	[body giant cells]	0.0	3	1	1	1
130237	1710	16-bp see motif	[16-bp SEE motif]	0.0	3	1	1	1
130238	1710	expression of other monocytic gene	[expression of other monocytic genes]	0.0	5	1	1	1
130239	1710	woman A-CRF	[women A-CRF]	0.0	2	1	1	1
130240	1710	induction of similar set	[induction of similar sets]	0.0	4	1	1	1
130241	1710	extent, adhesion molecule-1	[extent, adhesion molecule-1]	0.0	3	1	1	1
130242	1710	lung adhesion molecule	[lung adhesion molecule]	0.0	3	1	1	1
130243	1710	CEM-C7 cell	[CEM-C7 cells]	0.0	2	1	1	1
130244	1710	anti-hla antibody	[anti-HLA antibodies]	0.0	2	1	1	1
130245	1710	long treatment with oxldl	[long-term treatment with oxLDL]	0.0	4	1	1	1
130246	1710	ingredient mediate the pharmacological effect	[ingredients mediating the pharmacological effect]	0.0	5	1	1	1
130247	1710	two repeat of amino acid	[two repeats of amino acids]	0.0	5	1	1	1
130248	1710	nf-kappa b in this cell	[NF-kappa B in these cells]	0.0	5	1	1	1
130249	1710	whole-cell assay with (6,7-3h) estradiol	[whole-cell assay with (6,7-3H) estradiol]	0.0	5	1	1	1
130250	1710	LAL promoter	[LAL promoter]	0.0	2	1	1	1
130251	1710	expression during human differentiation	[Expression during human differentiation]	0.0	4	1	1	1
130252	1710	high potential 47.10 cell	[high potential 47.10 cells]	0.0	4	1	1	1
130253	1710	T cell receptor/CD3	[T cell receptor/CD3]	0.0	3	1	1	1
130254	1710	selective defect	[selective defects]	0.0	2	1	1	1
130255	1710	suggest gamma-ifn inhibition	[suggesting gamma-IFN inhibition]	0.0	3	1	1	1
130256	1710	term therapy	[term therapy]	0.0	2	1	1	1
130257	1710	successive stage	[successive stages]	0.0	2	1	1	1
130258	1710	rela in extract	[RelA in extracts]	0.0	3	1	1	1
130259	1710	pulmonary alveolar macrophage PAM	[pulmonary alveolar macrophages PAM]	0.0	4	1	1	1
130260	1710	factor.kappa b	[factor.kappa B]	0.0	2	1	1	1
130261	1710	nuclear factor (NF)-AT	[nuclear factor (NF)-AT]	0.0	3	1	1	1
130262	1710	ec50 of 1.5 microM.	[EC50 of 1.5 microM.]	0.0	4	1	1	1
130263	1710	potential transcription factor binding site	[potential transcription factor binding sites]	0.0	5	1	1	1
130264	1710	human prointerleukin 1	[human prointerleukin 1]	0.0	3	1	1	1
130265	1710	fas /apo-1	[Fas /Apo-1]	0.0	2	1	1	1
130266	1710	confirmation	[Confirmation]	0.0	1	2	2	1
130267	1710	blot study use rabbit antibody	[blot studies using rabbit antibodies]	0.0	5	1	1	1
130268	1710	receptor expression in u937 cell	[receptor expression in U937 cells]	0.0	5	1	1	1
130269	1710	link include a function	[link including a function]	0.0	4	1	1	1
130270	1710	LMP1 of lymphycryptoviruss	[LMP1 of lymphycryptoviruses]	0.0	3	1	1	1
130271	1710	up-regulation of Bcl-6 expression	[up-regulation of Bcl-6 expression]	0.0	4	1	1	1
130272	1710	level in this cells.	[levels in these cells.]	0.0	4	1	1	1
130273	1710	3) selective deletion	[3) selective deletion]	0.0	3	1	1	1
130274	1710	expression of protein during human hematopoiesis	[Expression of proteins during human hematopoiesis]	0.0	6	1	1	1
130275	1710	study cytokine regulation	[studying cytokine regulation]	0.0	3	1	1	1
130276	1710	kappa b alpha kappa b alpha	[kappa B alpha kappa B alpha]	0.0	6	1	1	1
130277	1710	murine microglia	[murine microglia]	0.0	2	1	1	1
130278	1710	several other agonist	[several other agonists]	0.0	3	1	1	1
130279	1710	binding of the factor,	[binding of the factor,]	0.0	4	1	1	1
130280	1710	thrombin (auc	[thrombin (AUC]	0.0	2	1	1	1
130281	1710	/hla	[/HLA]	0.0	1	1	1	1
130282	1710	MZF-1 regulation of this promoter	[MZF-1 regulation of this promoter]	0.0	5	1	1	1
130283	1710	IFN-alpha responsiveness leukemia	[IFN-alpha responsiveness leukemia]	0.0	3	1	1	1
130284	1710	Oct-2 -dependent cis-regulatory function	[Oct-2 -dependent cis-regulatory function]	0.0	4	1	1	1
130285	1710	half-site	[half-sites]	0.0	1	1	1	1
130286	1710	3h-thymidine	[3H-thymidine]	0.0	1	1	1	1
130287	1710	mediate the activity	[mediating the activity]	0.0	3	1	1	1
130288	1710	ifn-alpha in T cell	[IFN-alpha in T cells]	0.0	4	1	1	1
130289	1710	significant difference in acid sequence	[significant differences in acid sequence]	0.0	5	1	1	1
130290	1710	protein via interaction	[proteins via interaction]	0.0	3	1	1	1
130291	1710	-specific t-cell memory	[-specific T-cell memory]	0.0	3	1	1	1
130292	1710	signal 2 signal	[signal 2 signal]	0.0	3	1	1	1
130293	1710	domain the domain	[domains the domain]	0.0	3	1	1	1
130294	1710	3 years)	[3 years)]	0.0	2	1	1	1
130295	1710	follow granulocyte-colony factor treatment of neutrophils.	[following granulocyte-colony factor treatment of neutrophils.]	0.0	6	1	1	1
130296	1710	TNF-alpha promoter (kappa	[TNF-alpha promoter (kappa]	0.0	3	1	1	1
130297	1710	potent differentiation inducer	[potent differentiation inducers]	0.0	3	1	1	1
130298	1710	differentiation of precursors.	[differentiation of precursors.]	0.0	3	1	1	1
130299	1710	infection with the tat -virus	[infection with the Tat -virus]	0.0	5	1	1	1
130300	1710	group one with normal sensitivity	[groups one with normal sensitivity]	0.0	5	1	1	1
130301	1710	9-cis-retinoic acid	[9-cis-retinoic acid]	0.0	2	1	1	1
130302	1710	include zinc finger motif	[including zinc finger motifs]	0.0	4	1	1	1
130303	1710	comparing, in 8 cases, DNA	[comparing, in 8 cases, DNA]	0.0	5	1	1	1
130304	1710	chronic myelomonocytic leukemia with eosinophilia	[chronic myelomonocytic leukemia with eosinophilia]	0.0	5	1	1	1
130305	1710	possibly due to nf-kappab subunit activation	[possibly due to NF-kappaB subunit activation]	0.0	6	1	1	1
130306	1710	modulation of function of protein	[modulation of functions of proteins]	0.0	5	1	1	1
130307	1710	expression of the CXC chemokine	[expression of the CXC chemokine]	0.0	5	1	1	1
130308	1710	CMV 1 gene product	[CMV 1 gene product]	0.0	4	1	1	1
130309	1710	induce apoptosis of lymphoid cell	[inducing apoptosis of lymphoid cells]	0.0	5	1	1	1
130310	1710	stock	[stock]	0.0	1	2	2	1
130311	1710	sequence-specific dna-binding characteristic	[sequence-specific DNA-binding characteristics]	0.0	3	1	1	1
130312	1710	system of culture	[system of cultures]	0.0	3	1	1	1
130313	1710	interleukin synthesis	[interleukin synthesis]	0.0	2	1	1	1
130314	1710	hiv-1 particle	[HIV-1 particle]	0.0	2	1	1	1
130315	1710	diverse pathway	[diverse pathway]	0.0	2	1	1	1
130316	1710	actively divide single cell	[actively dividing single cells]	0.0	4	1	1	1
130317	1710	cell in model	[cells in models]	0.0	3	1	1	1
130318	1710	homolog of nrl	[homolog of NRL]	0.0	3	1	1	1
130319	1710	hypercholesterolemic (fh) subject	[hypercholesterolemic (FH) subjects]	0.0	3	1	1	1
130320	1710	follow CMV hcmv infection	[following CMV HCMV infection]	0.0	4	1	1	1
130321	1710	three marker	[three markers]	0.0	2	1	1	1
130322	1710	anti-ig response	[anti-Ig response]	0.0	2	1	1	1
130323	1710	case of lymphoid t-cell proliferation	[cases of lymphoid T-cell proliferations]	0.0	5	1	1	1
130324	1710	thus imply a role	[thus implying a role]	0.0	4	1	1	1
130325	1710	lps factor-kappaB nf-kappab translocation	[LPS factor-kappaB NF-kappaB translocation]	0.0	4	1	1	1
130326	1710	oligomer target PML mrna alpha-PML	[oligomers targeting PML mRNA alpha-PML]	0.0	5	1	1	1
130327	1710	transfection study of hiv LTR construct	[transfection studies of HIV LTR constructs]	0.0	6	1	1	1
130328	1710	control this choice	[controlling this choice]	0.0	3	1	1	1
130329	1710	study responsiveness to viral transactivator BZLF1	[studying responsiveness to viral transactivators BZLF1]	0.0	6	1	1	1
130330	1710	event in yeast	[events in yeast]	0.0	3	1	1	1
130331	1710	alteration of any one cis-element	[alteration of any one cis-element]	0.0	5	1	1	1
130332	1710	anti- c/ebp beta abs	[anti- C/EBP beta Abs]	0.0	4	1	1	1
130333	1710	lymphocyte in hyperthyroidism	[lymphocytes in hyperthyroidism]	0.0	3	1	1	1
130334	1710	new approach.	[new approach.]	0.0	2	1	1	1
130335	1710	most case of hodgkin' disease	[most cases of Hodgkin's disease]	0.0	5	1	1	1
130336	1710	kinase inhibitor active	[kinase inhibitor active]	0.0	3	1	1	1
130337	1710	one patient with paraparesis	[one patient with paraparesis]	0.0	4	1	1	1
130338	1710	two cytosolic protein	[two cytosolic protein]	0.0	3	1	1	1
130339	1710	transcription from reporter bear ZEBRA promoter	[transcription from reporters bearing ZEBRA promoters]	0.0	6	1	1	1
130340	1710	event occur	[events occurring]	0.0	2	1	1	1
130341	1710	Messenger RNA level receptor	[Messenger RNA levels receptor]	0.0	4	1	1	1
130342	1710	mechanism regulate this early response	[mechanisms regulating this early response]	0.0	5	1	1	1
130343	1710	gene in ctll-2	[genes in CTLL-2]	0.0	3	1	1	1
130344	1710	Differential autoregulation of receptor expression	[Differential autoregulation of receptor expression]	0.0	5	1	1	1
130345	1710	patient respond to ifn-alpha therapy	[patients responding to IFN-alpha therapy]	0.0	5	1	1	1
130346	1710	cell death of lymphocyte	[cell death of lymphocytes]	0.0	4	1	1	1
130347	1710	and/or nuclear receptor	[and/or nuclear receptor]	0.0	3	1	1	1
130348	1710	n17rac	[N17Rac]	0.0	1	1	1	1
130349	1710	e2 response,	[E2 response,]	0.0	2	1	1	1
130350	1710	promoter for marker include vpreb1	[promoters for markers including VpreB1]	0.0	5	1	1	1
130351	1710	32 male	[32 males]	0.0	2	1	1	1
130352	1710	multicomponent cytokine receptor	[multicomponent cytokine receptors]	0.0	3	1	1	1
130353	1710	e1a oncoprotein expression	[E1A oncoprotein expression]	0.0	3	1	1	1
130354	1710	10 healthy individual	[10 healthy individuals]	0.0	3	1	1	1
130355	1710	activation by 4 beta-phorbol 13-acetate	[activation by 4 beta-phorbol 13-acetate]	0.0	5	1	1	1
130356	1710	mu/l pharmacological concentration	[mU/L pharmacological concentration]	0.0	3	1	1	1
130357	1710	die days.	[dying days.]	0.0	2	1	1	1
130358	1710	pituitary transcription factor pit-1	[pituitary transcription factor Pit-1]	0.0	4	1	1	1
130359	1710	absorption	[absorption]	0.0	1	1	1	1
130360	1710	typical nuclear localization	[typical nuclear localization]	0.0	3	1	1	1
130361	1710	kind carry Val	[kinds carrying Val]	0.0	3	1	1	1
130362	1710	evidence for a antioxidant pathway	[evidence for an antioxidant pathway]	0.0	5	1	1	1
130363	1710	treatment of leucocyte	[treatment of leucocytes]	0.0	3	1	1	1
130364	1710	octanucleotide promoter element	[octanucleotide promoter element]	0.0	3	1	1	1
130365	1710	tr beta 1 mrna level	[TR beta 1 mRNA levels]	0.0	5	1	1	1
130366	1710	t-cell lymphoma cell line	[T-cell lymphoma cell line]	0.0	4	1	1	1
130367	1710	density lipoprotein HDL	[density lipoprotein HDL]	0.0	3	1	1	1
130368	1710	inflammation in RA	[inflammation in RA]	0.0	3	1	1	1
130369	1710	15 minute posttreatment)	[15 minutes posttreatment)]	0.0	3	1	1	1
130370	1710	cis-acting negative element	[cis-acting negative element]	0.0	3	1	1	1
130371	1710	rapidak PP1 tyrosine	[rapid, PP1 tyrosine]	0.0	3	1	1	1
130372	1710	occupation of MHC class promoter	[occupation of MHC class promoters]	0.0	5	1	1	1
130373	1710	morphogen in vertebrate development,	[morphogen in vertebrate development,]	0.0	4	1	1	1
130374	1710	u937 cell in chemiluminescence assay	[U937 cells in chemiluminescence assays]	0.0	5	1	1	1
130375	1710	il-2 rhil-2	[IL-2 rhIL-2]	0.0	2	1	1	1
130376	1710	switch to monocytic lineage	[switching to monocytic lineages]	0.0	4	1	1	1
130377	1710	dual cyclooxygenase/5-lipoxygenase compound	[dual cyclooxygenase/5-lipoxygenase compound]	0.0	3	1	1	1
130378	1710	peptide carry the NLS	[peptide carrying the NLS]	0.0	4	1	1	1
130379	1710	Effect on transcription factor ap-1	[Effects on transcription factors AP-1]	0.0	5	1	1	1
130380	1710	fetal hemoglobin production in adulthood	[fetal hemoglobin production in adulthood]	0.0	5	1	1	1
130381	1710	alter the redox status fos	[altering the redox status FOS]	0.0	5	1	1	1
130382	1710	amino acid homology	[amino acid homology]	0.0	3	1	1	1
130383	1710	melana/mart1+	[MelanA/MART1+]	0.0	1	1	1	1
130384	1710	occur at 30 minute after reoxygenation	[occurring at 30 minutes after reoxygenation]	0.0	6	1	1	1
130385	1710	corticosteroid methyl prednisolone	[corticosteroid methyl prednisolone]	0.0	3	1	1	1
130386	1710	such as formylpeptide lps	[such as formylpeptides LPS]	0.0	4	1	1	1
130387	1710	stat1, stat3	[STAT1, STAT3]	0.0	2	1	1	1
130388	1710	treatment with MCM	[treatment with MCM]	0.0	3	1	1	1
130389	1710	potential role in C3a enhancement	[potential role in C3a enhancement]	0.0	5	1	1	1
130390	1710	blood cell to endothelial cell	[blood cells to endothelial cells]	0.0	5	1	1	1
130391	1710	express v-abl kinase activity as deficient	[expressing v-abl kinase activity as deficient]	0.0	6	1	1	1
130392	1710	cytochrome p-450 vcam-1 induction	[cytochrome P-450 VCAM-1 induction]	0.0	4	1	1	1
130393	1710	systems, such as cell-free extract	[systems, such as cell-free extracts]	0.0	5	1	1	1
130394	1710	effective agent	[effective agents]	0.0	2	1	1	1
130395	1710	salt-losing episode	[salt-losing episode]	0.0	2	1	1	1
130396	1710	presence of egta	[presence of EGTA]	0.0	3	1	1	1
130397	1710	progression of immune responsiveness	[progression of immune responsiveness]	0.0	4	1	1	1
130398	1710	b cell type	[B cell type]	0.0	3	1	1	1
130399	1710	aspect of ebv disease pathogenesis	[aspects of EBV disease pathogenesis]	0.0	5	1	1	1
130400	1710	line of cell	[line of cells]	0.0	3	1	1	1
130401	1710	interaction between stem cell	[interactions between stem cells]	0.0	4	1	1	1
130402	1710	silencing of human globin expression	[Silencing of human globin expression]	0.0	5	1	1	1
130403	1710	distinct nuclear factor	[distinct nuclear factors]	0.0	3	1	1	1
130404	1710	protein with cysteine region	[protein with cysteine regions]	0.0	4	1	1	1
130405	1710	binding of a myeloid-specific factor	[binding of a myeloid-specific factor]	0.0	5	1	1	1
130406	1710	activation through stimulation of the tcr	[activation through stimulation of the TCR]	0.0	6	1	1	1
130407	1710	monocyte adherent on surface	[monocytes adherent on surfaces]	0.0	4	1	1	1
130408	1710	processing to the nfkb2 p52 induction	[processing to the NFKB2 p52 induction]	0.0	6	1	1	1
130409	1710	adenovirus e2	[adenovirus E2]	0.0	2	1	1	1
130410	1710	furthermore, NF-kappaB factor	[Furthermore, NF-kappaB factor]	0.0	3	1	1	1
130411	1710	Eighteen patient with mense	[Eighteen patients with menses]	0.0	4	1	1	1
130412	1710	ccaat box a ccaat box	[CCAAT boxes a CCAAT box]	0.0	5	1	1	1
130413	1710	granule mediate response	[granules mediating responses]	0.0	3	1	1	1
130414	1710	secretion include il-2	[secretion including IL-2]	0.0	3	1	1	1
130415	1710	transcription of the gene in cell	[transcription of the gene in cells]	0.0	6	1	1	1
130416	1710	7-day exposure	[7-day exposure]	0.0	2	1	1	1
130417	1710	differentiation in liquid culture	[differentiation in liquid culture]	0.0	4	1	1	1
130418	1710	dramatic increase in the level	[dramatic increase in the levels]	0.0	5	1	1	1
130419	1710	augment alpha-globin promoter activity	[augmenting alpha-globin promoter activity]	0.0	4	1	1	1
130420	1710	expression of ah receptor tcdd receptor	[Expression of Ah receptor TCDD receptor]	0.0	6	1	1	1
130421	1710	low level of trap alpha-naphthyl-acetate-esterase naf-r-nse	[low levels of TRAP alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	6	1	1	1
130422	1710	DNA strand competition	[DNA strand competition]	0.0	3	1	1	1
130423	1710	adenovirus ad	[adenovirus Ad]	0.0	2	1	1	1
130424	1710	(RNA) blot of mouse tissue	[(RNA) blots of mouse tissues]	0.0	5	1	1	1
130425	1710	t-lymphoblastoid cell	[T-lymphoblastoid cells]	0.0	2	1	1	1
130426	1710	tsp -chloramphenicol acetyltransferase construct	[TSP -chloramphenicol acetyltransferase constructs]	0.0	4	1	1	1
130427	1710	two open reading frame orf a	[two open reading frames ORFs A]	0.0	6	1	1	1
130428	1710	current state of the mechanism	[current state of the mechanism]	0.0	5	1	1	1
130429	1710	role control gene transcription	[role controlling gene transcription]	0.0	4	1	1	1
130430	1710	response to activation: purification	[responses to activation: purification]	0.0	4	1	1	1
130431	1710	preincubation of endothelial cell lipopolysaccharide	[Preincubation of endothelial cells lipopolysaccharide]	0.0	5	1	1	1
130432	1710	thyroid hormone response element TRE	[thyroid hormone response element TRE]	0.0	5	1	1	1
130433	1710	formation of cap consistent	[formation of caps consistent]	0.0	4	1	1	1
130434	1710	detailed analysis of the rdna	[Detailed analysis of the cDNAs]	0.0	5	1	1	1
130435	1710	repress cytokine production	[repressing cytokine production]	0.0	3	1	1	1
130436	1710	level of elf-2 transcript	[levels of elf-2 transcripts]	0.0	4	1	1	1
130437	1710	putative binding site for transcription factor	[putative binding sites for transcription factors]	0.0	6	1	1	1
130438	1710	perhaps increase the probability	[perhaps increasing the probability]	0.0	4	1	1	1
130439	1710	However, examination of proteasome activity	[However, examination of proteasome activity]	0.0	5	1	1	1
130440	1710	hypoxia, sickle red blood cell	[hypoxia, sickle red blood cells]	0.0	5	1	1	1
130441	1710	interaction in T cell	[interactions in T cells]	0.0	4	1	1	1
130442	1710	family different form of inheritance	[families: different forms of inheritance]	0.0	5	1	1	1
130443	1710	25-dihydroxyvitamin D3 135(oh)2d3 receptor VDR	[25-dihydroxyvitamin D3 1,25(OH)2D3 receptor VDR]	0.0	5	1	1	1
130444	1710	primary culture of epithelial cell	[primary cultures of epithelial cells]	0.0	5	1	1	1
130445	1710	infancy	[infancy]	0.0	1	1	1	1
130446	1710	development of both	[development of both]	0.0	3	1	1	1
130447	1710	Epstein-Barr antigen EBNA	[Epstein-Barr antigen EBNA]	0.0	3	1	1	1
130448	1710	action between a element CPRE GGACTACAG	[action between an element CPRE GGACTACAG]	0.0	6	1	1	1
130449	1710	human granulocyte-macrophage	[human granulocyte-macrophage]	0.0	2	1	1	1
130450	1710	agent upon action	[agents upon action]	0.0	3	1	1	1
130451	1710	activation of pp70s6k	[activation of pp70S6K]	0.0	3	1	1	1
130452	1710	apoptosis of cd34+ hematopoietic progenitor cell	[apoptosis of CD34+ hematopoietic progenitor cells]	0.0	6	1	1	1
130453	1710	usf-related transcription factor	[USF-related transcription factor]	0.0	3	1	1	1
130454	1710	cyclin/cdk activation	[cyclin/cdks activation]	0.0	2	1	1	1
130455	1710	mechanism for promoter occupancy	[mechanisms for promoter occupancy]	0.0	4	1	1	1
130456	1710	different route	[different routes]	0.0	2	1	1	1
130457	1710	more potent agonist	[more potent agonist]	0.0	3	1	1	1
130458	1710	sequela of therapy	[sequela of therapy]	0.0	3	1	1	1
130459	1710	diurnal rhythm the inhibition	[diurnal rhythms the inhibition]	0.0	4	1	1	1
130460	1710	thereby amplify cellular event	[thereby amplifying cellular events]	0.0	4	1	1	1
130461	1710	important DNA element	[important DNA element]	0.0	3	1	1	1
130462	1710	promonocytic u1 cell	[promonocytic U1 cells]	0.0	3	1	1	1
130463	1710	tyrosine-phosphorylated stimulate factor treatment	[tyrosine-phosphorylated stimulating factor treatment]	0.0	4	1	1	1
130464	1710	RA -resistant cells.	[RA -resistant cells.]	0.0	3	1	1	1
130465	1710	signal-transduce smad protein	[signal-transducing Smad proteins]	0.0	3	1	1	1
130466	1710	second protein, dpii,	[second protein, DP-I,]	0.0	3	1	1	1
130467	1710	hrxr alpha receptor	[hRXR alpha receptor]	0.0	3	1	1	1
130468	1710	prolymphocytic leukemia (pll)	[prolymphocytic leukemias (PLL)]	0.0	3	1	1	1
130469	1710	express ikappab-alphas32/36a	[expressing IkappaB-alphaS32/36A]	0.0	2	1	1	1
130470	1710	cytokine-induced e-selectin	[cytokine-induced E-selectin]	0.0	2	1	1	1
130471	1710	other DNA fragment	[other DNA fragments]	0.0	3	1	1	1
130472	1710	cell priming	[cell priming]	0.0	2	1	1	1
130473	1710	presence of 135-(oh)2d3 receptors;	[presence of 1,25-(OH)2D3 receptors;]	0.0	4	1	1	1
130474	1710	wild-type leukemic ecem) cell	[wild-type leukemic (CEM) cells]	0.0	4	1	1	1
130475	1710	deviation in this variable	[deviations in these variables]	0.0	4	1	1	1
130476	1710	extend from -250 to +50 bp	[extending from -250 to +50 bp]	0.0	6	1	1	1
130477	1710	develop th1 cell	[developing Th1 cells]	0.0	3	1	1	1
130478	1710	camp protein	[cAMP protein]	0.0	2	1	1	1
130479	1710	govern positive selection	[governing positive selection]	0.0	3	1	1	1
130480	1710	Leu-7+ natural killer cell less	[Leu-7+ natural killer cells less]	0.0	5	1	1	1
130481	1710	transformation of the endometrial stroma	[transformation of the endometrial stroma]	0.0	5	1	1	1
130482	1710	lung inflammation	[lung inflammation]	0.0	2	1	1	1
130483	1710	C C[AT]6GG	[C C[AT]6GG]	0.0	2	1	1	1
130484	1710	Biological marker after a great	[Biological markers after a great]	0.0	5	1	1	1
130485	1710	mouse resistant to lethal dosage	[mice resistant to lethal dosages]	0.0	5	1	1	1
130486	1710	human cell line U	[human cell line U]	0.0	4	1	1	1
130487	1710	separable gene regulatory response	[separable gene regulatory responses]	0.0	4	1	1	1
130488	1710	receptor affinity to glucocorticoid AIDS-GR	[receptor affinity to glucocorticoids AIDS-GR]	0.0	5	1	1	1
130489	1710	turnover kappa b alpha	[turnover kappa B alpha]	0.0	4	1	1	1
130490	1710	ion channel	[ion channels]	0.0	2	1	1	1
130491	1710	ccaat binding	[CCAAT binding]	0.0	2	1	1	1
130492	1710	effect of expression of spi-1	[effects of expression of spi-1]	0.0	5	1	1	1
130493	1710	chromosome band 11p15 rhombotin	[chromosome bands 11p15 rhombotin]	0.0	4	1	1	1
130494	1710	October protein footprinting	[Oct proteins footprinting]	0.0	3	1	1	1
130495	1710	few subject down-regulated Bmax	[fewer subjects down-regulated Bmax]	0.0	4	1	1	1
130496	1710	metabolic status	[metabolic status]	0.0	2	1	1	1
130497	1710	membrane protein 1 lmp1	[membrane protein 1 LMP1]	0.0	4	1	1	1
130498	1710	SH3 domain	[SH3 domains]	0.0	2	1	1	1
130499	1710	total percentage	[total percentage]	0.0	2	1	1	1
130500	1710	ic50 value for dexamethasone (3.4+/-0.3 nmol/L)	[IC50 values for dexamethasone (3.4+/-0.3 nmol/L)]	0.0	6	1	1	1
130501	1710	Jurkat mutant deficient	[Jurkat mutants deficient]	0.0	3	1	1	1
130502	1710	coactivation	[Coactivation]	0.0	1	1	1	1
130503	1710	cell a major component	[cells a major component]	0.0	4	1	1	1
130504	1710	rna probe	[RNA probes]	0.0	2	1	1	1
130505	1710	subclone to dexamethasone in medium	[subclones to dexamethasone in medium]	0.0	5	1	1	1
130506	1710	1, 25-dihydroxyvitamin D3 receptor	[1, 25-dihydroxyvitamin D3 receptor]	0.0	4	1	1	1
130507	1710	only molecular weight species of 24	[only molecular weight species of 24]	0.0	6	1	1	1
130508	1710	mutation of the site	[Mutations of the site]	0.0	4	1	1	1
130509	1710	positive selection marker	[positive selection marker]	0.0	3	1	1	1
130510	1710	difference in expression	[differences in expression]	0.0	3	3	3	1
130511	1710	vivo therapy	[vivo therapy]	0.0	2	1	1	1
130512	1710	biphasic increase	[biphasic increase]	0.0	2	3	3	1
130513	1710	distal factor (NF)-AT NF-AT AP-1/Octamer	[distal factor (NF)-AT NF-AT AP-1/Octamer]	0.0	5	1	1	1
130514	1710	full-length alg-4 transcription	[full-length ALG-4 transcription]	0.0	3	1	1	1
130515	1710	1 signal pathway	[1 signaling pathways]	0.0	3	1	1	1
130516	1710	stop codon	[stop codon]	0.0	2	1	1	1
130517	1710	chronic hyperactivity	[chronic hyperactivity]	0.0	2	1	1	1
130518	1710	follow cell stimulation	[following cell stimulation]	0.0	3	1	1	1
130519	1710	key inflammatory mediator	[key inflammatory mediators]	0.0	3	1	1	1
130520	1710	receptor characteristic of blood mononuclear cell	[Receptor characteristics of blood mononuclear cells]	0.0	6	1	1	1
130521	1710	contrast, expression of mutant	[contrast, expression of mutants]	0.0	4	1	1	1
130522	1710	cell in the breast tumor	[cells in the breast tumors]	0.0	5	1	1	1
130523	1710	Nuclear 3,5,3'-triiodothyronine receptor	[Nuclear 3,5,3'-triiodothyronine receptors]	0.0	3	1	1	1
130524	1710	high density lipoprotein	[high density lipoprotein]	0.0	3	1	1	1
130525	1710	broad range of cytokine	[broad range of cytokines]	0.0	4	1	1	1
130526	1710	Eicosanoids in breast cancer patient	[Eicosanoids in breast cancer patients]	0.0	5	1	1	1
130527	1710	lack functional receptor.	[lacking functional receptor.]	0.0	3	1	1	1
130528	1710	following: at the end	[following: at the end]	0.0	4	1	1	1
130529	1710	herpesvirus hhv-6 strain	[herpesvirus HHV-6 strains]	0.0	3	1	1	1
130530	1710	putative function	[putative function]	0.0	2	2	2	1
130531	1710	ly294002	[LY294002]	0.0	1	1	1	1
130532	1710	cotransfection in sense orientation tata together	[cotransfection in sense orientation tat/S together]	0.0	6	1	1	1
130533	1710	similar proteins, cyclophilin	[similar proteins, cyclophilin]	0.0	3	1	1	1
130534	1710	requirement for immunodeficiency virus hiv	[requirement for immunodeficiency virus HIV]	0.0	5	1	1	1
130535	1710	healthy carrier	[healthy carriers]	0.0	2	1	1	1
130536	1710	immunodeficiency virus persistence	[immunodeficiency virus persistence]	0.0	3	2	2	1
130537	1710	clinically sensitive leukemia patient	[clinically sensitive leukemia patients]	0.0	4	1	1	1
130538	1710	ability of dominant Ras	[ability of dominant Ras]	0.0	4	1	1	1
130539	1710	dose of microM.	[dose of microM.]	0.0	3	1	1	1
130540	1710	pattern of mnda expression	[pattern of MNDA expression]	0.0	4	1	1	1
130541	1710	one distinct "octamer" complex	[one distinct "octamer" complex]	0.0	4	1	1	1
130542	1710	stimulation on immunogenic human malignant melanoma	[Stimulation on immunogenic human malignant melanomas]	0.0	6	1	1	1
130543	1710	link between signalling	[link between signalling]	0.0	3	1	1	1
130544	1710	many function of alveolar macrophage	[many functions of alveolar macrophages]	0.0	5	1	1	1
130545	1710	possible new strategy for the detection	[possible new strategies for the detection]	0.0	6	1	1	1
130546	1710	cyclic strain	[cyclic strain]	0.0	2	1	1	1
130547	1710	human saphenous vein cell	[human saphenous vein cells]	0.0	4	1	1	1
130548	1710	kv1.3 component current	[Kv1.3 components current]	0.0	3	1	1	1
130549	1710	11 alpha-methyl, alpha-fluoromethyl	[11 alpha-methyl, alpha-fluoromethyl]	0.0	3	1	1	1
130550	1710	approaches; however, monocyte interaction	[approaches; however, monocyte interactions]	0.0	4	1	1	1
130551	1710	negative transcriptional effect on the promoter	[negative transcriptional effects on the promoters]	0.0	6	1	1	1
130552	1710	IL-12 production	[IL-12 production]	0.0	2	1	1	1
130553	1710	30% diffuse large b-cell lymphoma	[30% diffuse large B-cell lymphomas]	0.0	5	1	1	1
130554	1710	cytokine production in monocyte	[cytokine production in monocytes]	0.0	4	1	1	1
130555	1710	tpa addition	[TPA addition]	0.0	2	1	1	1
130556	1710	reactvation of KSHV	[reactvation of KSHV]	0.0	3	1	1	1
130557	1710	gm-csfr	[GM-CSFR]	0.0	1	1	1	1
130558	1710	activating agents.	[activating agents.]	0.0	2	1	1	1
130559	1710	antigen/chemokine receptor	[antigen/chemokine receptor]	0.0	2	1	1	1
130560	1710	sequence-specific breakage	[sequence-specific breakage]	0.0	2	1	1	1
130561	1710	retinoid marker expression	[retinoid markers expression]	0.0	3	1	1	1
130562	1710	two day with m dexamethasone	[two days with M dexamethasone]	0.0	5	1	1	1
130563	1710	nf-kappab p65 in vitro	[NF-kappaB p65 in vitro]	0.0	4	1	1	1
130564	1710	therefore correct fold	[therefore correct folding]	0.0	3	1	1	1
130565	1710	Intracellular adhesion molecule-1 induction	[Intracellular adhesion molecule-1 induction]	0.0	4	1	1	1
130566	1710	U1 clone	[U1 clone]	0.0	2	1	1	1
130567	1710	99% suppression of sla-dq antigen induction	[99% suppression of SLA-DQ antigen induction]	0.0	6	1	1	1
130568	1710	labeling by immunofluorescence from tonsil	[labeling by immunofluorescence from tonsils]	0.0	5	1	1	1
130569	1710	bacterial lps (endotoxin) through membrane cd14	[bacterial LPS (endotoxin) through membrane CD14]	0.0	6	1	1	1
130570	1710	previous analysis of V region promoter	[Previous analyses of V region promoters]	0.0	6	1	1	1
130571	1710	several potential pathway	[several potential pathways]	0.0	3	1	1	1
130572	1710	b -binding motif	[B -binding motifs]	0.0	3	1	1	1
130573	1710	large number of neoplasm	[large number of neoplasms]	0.0	4	1	1	1
130574	1710	development role	[development roles]	0.0	2	1	1	1
130575	1710	human virus type 1 htlv-1	[human virus type 1 HTLV-1]	0.0	5	1	1	1
130576	1710	3-methylcholanthrene a ligand	[3-methylcholanthrene a ligand]	0.0	3	1	1	1
130577	1710	(mhc) class gene expression	[(MHC) class gene expression]	0.0	4	1	1	1
130578	1710	model of a situation	[models of an situation]	0.0	4	1	1	1
130579	1710	localization of p50	[localization of p50]	0.0	3	1	1	1
130580	1710	inhibitor of protein kinase kinase	[inhibitor of protein kinase kinase]	0.0	5	1	1	1
130581	1710	nos activity	[NOS activity]	0.0	2	1	1	1
130582	1710	analyze the relationship	[analyzing the relationships]	0.0	3	1	1	1
130583	1710	down-regulation of protein ebna2-ebna6	[Down-regulation of proteins EBNA2-EBNA6]	0.0	4	1	1	1
130584	1710	drug in the treatment	[drug in the treatment]	0.0	4	1	1	1
130585	1710	mouse strain C57BL/10SnJ [h-2b]	[mouse strains C57BL/10SnJ [H-2b]]	0.0	4	1	1	1
130586	1710	recognizable increase	[recognizable increase]	0.0	2	1	1	1
130587	1710	(cr) asthmatic subject	[(CR) asthmatic subjects]	0.0	3	1	1	1
130588	1710	autosome 11	[autosome 11]	0.0	2	1	1	1
130589	1710	structural domain	[structural domains]	0.0	2	1	1	1
130590	1710	original igg (from	[original IgG (from]	0.0	3	1	1	1
130591	1710	patient with menopausal type diabete	[patients with menopausal type diabetes]	0.0	5	1	1	1
130592	1710	early arthritis	[early arthritis]	0.0	2	1	1	1
130593	1710	key regulator of gene	[key regulator of genes]	0.0	4	1	1	1
130594	1710	activation-dependent tyrosine phosphorylation of HS1	[activation-dependent tyrosine phosphorylation of HS1]	0.0	5	1	1	1
130595	1710	potentiation of tnf effect	[potentiation of TNF effects]	0.0	4	1	1	1
130596	1710	oncology group	[oncology group]	0.0	2	1	1	1
130597	1710	lineage (with retinoic acid	[lineage (with retinoic acid]	0.0	4	1	1	1
130598	1710	controversies, of the more troublesome	[controversies, of the more troublesome]	0.0	5	1	1	1
130599	1710	circulate hormone concentration	[circulating hormone concentrations]	0.0	3	1	1	1
130600	1710	tgf-alpha expression in eosinophil	[TGF-alpha expression in eosinophils]	0.0	4	1	1	1
130601	1710	promoter flanking sequence	[promoter flanking sequences]	0.0	3	1	1	1
130602	1710	low level of tcf-1 alpha mrna	[low levels of TCF-1 alpha mRNA]	0.0	6	1	1	1
130603	1710	significance in 20 patient	[significance in 20 patients]	0.0	4	1	1	1
130604	1710	treatment by NE	[Treatment by NE]	0.0	3	1	1	1
130605	1710	atra true APL	[ATRA true APL]	0.0	3	1	1	1
130606	1710	intracellular free ca2+ concentration	[intracellular free Ca2+ concentration]	0.0	4	1	1	1
130607	1710	likely identical proteins, differ	[likely identical proteins, differing]	0.0	4	1	1	1
130608	1710	regulatory function at the level,	[regulatory function at the level,]	0.0	5	1	1	1
130609	1710	direct effect of dexamethasone	[direct effects of dexamethasone]	0.0	4	1	1	1
130610	1710	assess responsiveness to therapy	[assessing responsiveness to therapy]	0.0	4	1	1	1
130611	1710	0.2 kb act	[0.2 kb act]	0.0	3	1	1	1
130612	1710	9 young adult before dst	[9 young adults before DST]	0.0	5	1	1	1
130613	1710	follow-up NK activity	[follow-up NK activity]	0.0	3	1	1	1
130614	1710	proteins: RXR	[proteins: RXR]	0.0	2	1	1	1
130615	1710	normal immature myeloid cell	[normal immature myeloid cells]	0.0	4	1	1	1
130616	1710	express ad5e1a	[expressing Ad5E1A]	0.0	2	1	1	1
130617	1710	two major protein	[two major proteins]	0.0	3	1	1	1
130618	1710	c/ebp epsilon protein	[C/EBP epsilon protein]	0.0	3	1	1	1
130619	1710	initial ebv transcriptional program	[initial EBV transcriptional program]	0.0	4	2	2	1
130620	1710	high throughput screen	[high throughput screening]	0.0	3	1	1	1
130621	1710	enhance binding activity	[enhancing binding activity]	0.0	3	1	1	1
130622	1710	down-regulation by anti-sense oligonucleotide	[down-regulation by anti-sense oligonucleotides]	0.0	4	1	1	1
130623	1710	low nuclear expression	[low nuclear expression]	0.0	3	1	1	1
130624	1710	activation of Epstein-Barr virus antigen	[activation of Epstein-Barr virus antigen]	0.0	5	1	1	1
130625	1710	octamer motif 2 enhancer	[octamer motif 2 enhancer]	0.0	4	1	1	1
130626	1710	shear-	[shear-]	0.0	1	1	1	1
130627	1710	quantitative thin-layer chromatography	[Quantitative thin-layer chromatography]	0.0	3	1	1	1
130628	1710	accumulation of metal gold	[accumulation of metal gold]	0.0	4	1	1	1
130629	1710	functional synergy between tal1	[functional synergy between TAL1]	0.0	4	1	1	1
130630	1710	treat IBD	[treating IBD]	0.0	2	1	1	1
130631	1710	method for quantification of mrna	[method for quantification of mRNA]	0.0	5	1	1	1
130632	1710	protect injury	[protecting injury]	0.0	2	1	1	1
130633	1710	effect on a variety of response	[effects on a variety of responses]	0.0	6	1	1	1
130634	1710	differentiation status	[differentiation status]	0.0	2	1	1	1
130635	1710	bind activity of the transcription factor	[binding activities of the transcription factors]	0.0	6	1	1	1
130636	1710	endocrine precursor cell	[endocrine precursor cells]	0.0	3	1	1	1
130637	1710	enzyme inhibitor of cyclooxygenase	[enzyme inhibitor of cyclooxygenase]	0.0	4	1	1	1
130638	1710	retinoic acid on hiv-1 expression	[retinoic acids on HIV-1 expression]	0.0	5	1	1	1
130639	1710	active renin pg/ml;	[active renin pg/ml;]	0.0	3	1	1	1
130640	1710	vitamin gene regulation	[vitamin gene regulation]	0.0	3	1	1	1
130641	1710	family history for cancer	[family history for cancer]	0.0	4	1	1	1
130642	1710	expression of the il-1ri gene	[expression of the IL-1RI genes]	0.0	5	1	1	1
130643	1710	transcriptional activation of a factor	[transcriptional activation of a factor]	0.0	5	1	1	1
130644	1710	phosphorylation to two serine	[phosphorylation to two serines]	0.0	4	1	1	1
130645	1710	pattern of x chromosome inactivation	[pattern of X chromosome inactivation]	0.0	5	1	1	1
130646	1710	class ii non-inducible, RB line	[class II non-inducible, RB lines]	0.0	5	1	1	1
130647	1710	factor kB NF-kB element	[factor kB NF-kB elements]	0.0	4	1	1	1
130648	1710	activation of Janus tyrosine kinase Jak	[Activation of Janus tyrosine kinases Jak]	0.0	6	1	1	1
130649	1710	il-2 action	[IL-2 action]	0.0	2	1	1	1
130650	1710	IL-3 colony-stimumulatelany-stg factor complex in eosinophil	[IL-3 colony-stimulating factor complexes in eosinophils]	0.0	6	1	1	1
130651	1710	phenotype of mouse line	[phenotype of mouse lines]	0.0	4	1	1	1
130652	1710	NF-kappaB family member	[NF-kappaB family members,]	0.0	3	2	2	1
130653	1710	part dependent on oxygen intermediate	[part dependent on oxygen intermediates]	0.0	5	1	1	1
130654	1710	suppression downregulate the activity	[Suppression downregulating the activity]	0.0	4	1	1	1
130655	1710	nine patient with nephropathy	[nine patients with nephropathy]	0.0	4	1	1	1
130656	1710	T cell to response element	[T cells to response elements]	0.0	5	2	2	1
130657	1710	part of the effect of cya	[part of the effect of CyA]	0.0	6	1	1	1
130658	1710	68 triple-labelling with mab	[68 triple-labellings with mAbs]	0.0	4	1	1	1
130659	1710	B-cell activation, differentiation,	[B-cell activation, differentiation,]	0.0	3	1	1	1
130660	1710	feature of this disease	[features of this disease.]	0.0	4	1	1	1
130661	1710	15.5 (p less than 0.05, p	[15.5 (P less than 0.05, P]	0.0	6	1	1	1
130662	1710	determine the fluorescence anisotropy	[determining the fluorescence anisotropy]	0.0	4	1	1	1
130663	1710	gtp-bound form	[GTP-bound form]	0.0	2	1	1	1
130664	1710	SCL protein synthesis	[SCL protein synthesis]	0.0	3	1	1	1
130665	1710	potent inhibitor of MEK1	[potent inhibitors of MEK1]	0.0	4	1	1	1
130666	1710	footprint than the globin express cell	[footprints than the globin expressing cells]	0.0	6	1	1	1
130667	1710	activity in nuclear extract	[activity in nuclear extracts]	0.0	4	1	1	1
130668	1710	strong production of interleukin 2	[strong production of interleukin 2]	0.0	5	1	1	1
130669	1710	overall therefore, exposure	[Overall therefore, exposure]	0.0	3	1	1	1
130670	1710	human progenitor cell	[human progenitor cells]	0.0	3	1	1	1
130671	1710	subunit of NF-kappa b p50	[subunit of NF-kappa B p50]	0.0	5	1	1	1
130672	1710	four- amount	[four- amounts]	0.0	2	1	1	1
130673	1710	thereby contribute to the myeloid-specific expression	[thereby contributing to the myeloid-specific expression]	0.0	6	1	1	1
130674	1710	infection [see	[infection [see]	0.0	2	1	1	1
130675	1710	modulation u937 cell	[modulation U937 cells]	0.0	3	1	1	1
130676	1710	child with infection	[children with infection]	0.0	3	2	2	1
130677	1710	hematopoietic population	[hematopoietic populations]	0.0	2	1	1	1
130678	1710	hiv-1 transcriptional induction	[HIV-1 transcriptional induction]	0.0	3	1	1	1
130679	1710	calmodulin antagonist	[Calmodulin antagonists]	0.0	2	1	1	1
130680	1710	basis for further study	[basis for further studies]	0.0	4	1	1	1
130681	1710	express CD40 in T	[expressing CD40 in T]	0.0	4	1	1	1
130682	1710	release of m-csf protein	[release of M-CSF protein]	0.0	4	1	1	1
130683	1710	t-cell from individual	[T-cells from individuals]	0.0	3	1	1	1
130684	1710	susceptibility killing	[susceptibility killing]	0.0	2	1	1	1
130685	1710	anti-cd28 ab	[anti-CD28 Ab]	0.0	2	1	1	1
130686	1710	N-terminal trans-activation domain	[N-terminal trans-activation domain]	0.0	3	1	1	1
130687	1710	contain gelatinase	[containing gelatinase]	0.0	2	1	1	1
130688	1710	il-4 transcription factor Stat6	[IL-4 transcription factor Stat6]	0.0	4	1	1	1
130689	1710	difference in this lineage	[differences in these lineages]	0.0	4	1	1	1
130690	1710	leukemia CLL to combination chemotherapy	[leukemia CLL to combination chemotherapy]	0.0	5	1	1	1
130691	1710	live-attenuated human immunodeficiency virus	[Live-attenuated human immunodeficiency viruses]	0.0	4	1	1	1
130692	1710	optimal response	[optimal response]	0.0	2	1	1	1
130693	1710	5'-most ets site	[5'-most Ets sites]	0.0	3	1	1	1
130694	1710	feature of antiandrogen action	[feature of antiandrogen action]	0.0	4	1	1	1
130695	1710	emanate from cytokine factor receptor	[emanating from cytokine factor receptors]	0.0	5	1	1	1
130696	1710	depend on the environment	[depending on the environment]	0.0	4	1	1	1
130697	1710	four distinct binding site	[four distinct binding sites]	0.0	4	1	1	1
130698	1710	extensive cross-talk	[extensive cross-talk]	0.0	2	1	1	1
130699	1710	relevant spectrum of g(s)alpha expression	[relevant spectrum of G(S)alpha expression]	0.0	5	1	1	1
130700	1710	reticulum immunize cell	[reticulum immunizing cells]	0.0	3	1	1	1
130701	1710	promelocytic leukemia	[promelocytic leukemia]	0.0	2	1	1	1
130702	1710	high replicative capacity	[high replicative capacity]	0.0	3	1	1	1
130703	1710	transactivation of the factor	[transactivation of the factor]	0.0	4	1	1	1
130704	1710	require log-fold glucocorticoid for a degree	[requiring log-fold glucocorticoids for an degree]	0.0	6	1	1	1
130705	1710	react with hydrogen peroxide	[reacting with hydrogen peroxide]	0.0	4	1	1	1
130706	1710	represent different stage from early precursor	[representing different stages from early precursors]	0.0	6	1	1	1
130707	1710	6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).	[6, rhabdomyosarcoma leiomyosarcoma 10, liposarcoma 5).]	0.0	6	1	1	1
130708	1710	three epitope	[Three epitopes]	0.0	2	1	1	1
130709	1710	approximately 4 kilobasis	[approximately 4 kilobases]	0.0	3	1	1	1
130710	1710	transcription through the AP-1	[transcriptions through the AP-1]	0.0	4	1	1	1
130711	1710	receptor mr count	[receptor MR count]	0.0	3	1	1	1
130712	1710	regulator of nf-kappab neutralize antibody	[regulator of NF-kappaB neutralizing antibodies]	0.0	5	1	1	1
130713	1710	low-level expression of type	[low-level expression of type]	0.0	4	1	1	1
130714	1710	cell from form	[cells from form]	0.0	3	1	1	1
130715	1710	cause of persistent inflammatory arthritis	[cause of persistent inflammatory arthritis]	0.0	5	2	2	1
130716	1710	accordance	[accordance]	0.0	1	3	3	1
130717	1710	inhibition of cyclooxygenase-2 expression acid	[Inhibition of cyclooxygenase-2 expression acid]	0.0	5	1	1	1
130718	1710	liver culture	[liver cultures]	0.0	2	1	1	1
130719	1710	potential pathway	[potential pathways]	0.0	2	1	1	1
130720	1710	use a immunostaining technique	[using a immunostaining technique]	0.0	4	1	1	1
130721	1710	activity of the heterodimer	[activity of the heterodimer]	0.0	4	1	1	1
130722	1710	follow time	[following time]	0.0	2	1	1	1
130723	1710	preservation of tolerance,	[preservation of tolerance,]	0.0	3	1	1	1
130724	1710	induction of nfkappab	[induction of NFkappaB]	0.0	3	1	1	1
130725	1710	effect on low vcam-1 expression	[effect on low VCAM-1 expression]	0.0	5	1	1	1
130726	1710	pre-exist mcp-1	[pre-existing MCP-1]	0.0	2	1	1	1
130727	1710	b activating signal	[B activating signals]	0.0	3	1	1	1
130728	1710	replacement of the gamma(c) cytoplasmic domain	[replacement of the gamma(c) cytoplasmic domain]	0.0	6	1	1	1
130729	1710	mutant hematopoietic progenitor cell	[mutant hematopoietic progenitor cells]	0.0	4	1	1	1
130730	1710	herpesvirus a predominantly T virus	[herpesvirus a predominantly T virus]	0.0	5	1	1	1
130731	1710	introduction of gata-1	[introduction of GATA-1]	0.0	3	1	1	1
130732	1710	erythroid cell culture	[erythroid cell cultures]	0.0	3	1	1	1
130733	1710	cytokine effect	[cytokine effects]	0.0	2	2	2	1
130734	1710	site for protein(s)	[site for protein(s)]	0.0	3	2	2	1
130735	1710	e2a- HLF protein	[E2A- HLF proteins]	0.0	3	1	1	1
130736	1710	quantity of eicosanoid	[quantities of eicosanoids]	0.0	3	1	1	1
130737	1710	rho on AP-1 activity	[Rho on AP-1 activity]	0.0	4	1	1	1
130738	1710	thioredoxin adult T cell factor	[thioredoxin adult T cell factor]	0.0	5	1	1	1
130739	1710	expression of many genes,	[expression of many genes,]	0.0	4	1	1	1
130740	1710	T lymphocyte differentiation	[T lymphocyte differentiation]	0.0	3	1	1	1
130741	1710	various csf	[various CSFs]	0.0	2	1	1	1
130742	1710	murine kappa	[murine kappa]	0.0	2	1	1	1
130743	1710	indicate a effect.	[indicating a effect.]	0.0	3	1	1	1
130744	1710	common element response element ISRE	[common element Response Element ISRE]	0.0	5	1	1	1
130745	1710	stigmata of Turner syndrome	[stigmata of Turner syndrome]	0.0	4	1	1	1
130746	1710	overexpression a version of c-Raf	[Overexpression a version of c-Raf]	0.0	5	1	1	1
130747	1710	same calcium -mobilize potency	[same calcium -mobilizing potency]	0.0	4	1	1	1
130748	1710	hypothalamic-pituitary-adrenocortical axis in rat	[hypothalamic-pituitary-adrenocortical axis in rats]	0.0	4	1	1	1
130749	1710	dose mol/L).	[dose mol/L).]	0.0	2	1	1	1
130750	1710	patient in a region	[patients in a region]	0.0	4	1	1	1
130751	1710	significant role in lineage development	[significant role in lineage development]	0.0	5	1	1	1
130752	1710	minute follow il-2 stimulation	[min following IL-2 stimulation]	0.0	4	1	1	1
130753	1710	cell HAEC	[cells HAEC]	0.0	2	1	1	1
130754	1710	B/Rel nuclear activity	[B/Rel nuclear activity]	0.0	3	1	1	1
130755	1710	nf-kappa b heterodimer	[NF-kappa B heterodimer]	0.0	3	1	1	1
130756	1710	use a infectious clone of HTLV-II	[using an infectious clone of HTLV-II]	0.0	6	1	1	1
130757	1710	endogenous tat protein	[endogenous Tat protein]	0.0	3	1	1	1
130758	1710	form in cell line	[form in cell lines]	0.0	4	1	1	1
130759	1710	inhibition of tf induction	[Inhibition of TF induction]	0.0	4	1	1	1
130760	1710	25 basal cell carcinoma	[25 basal cell carcinomas]	0.0	4	1	1	1
130761	1710	polar substitution alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[polar substitutions alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	4	1	1	1
130762	1710	tcf-1 t-cell factor-1	[TCF-1 T-Cell Factor-1]	0.0	3	1	1	1
130763	1710	state of the genome	[state of the genome]	0.0	4	1	1	1
130764	1710	role for RAR alpha	[role for RAR alpha]	0.0	4	1	1	1
130765	1710	8421 (pre)	[8421 (pre)]	0.0	2	1	1	1
130766	1710	other chronic disease	[other chronic diseases]	0.0	3	1	1	1
130767	1710	CD28 T	[CD28 T]	0.0	2	1	1	1
130768	1710	msr promoter activity	[MSR promoter activity]	0.0	3	1	1	1
130769	1710	(p 0.05, p less than 0.01	[(P 0.05, P less than 0.01]	0.0	6	1	1	1
130770	1710	monocyte-specific transcription	[monocyte-specific transcription]	0.0	2	2	2	1
130771	1710	cytokine differential induction	[cytokine differential induction]	0.0	3	1	1	1
130772	1710	positioning of (ig) gene	[positioning of (Ig) genes]	0.0	4	1	1	1
130773	1710	transactivation activity of gata-1	[transactivation activity of GATA-1]	0.0	4	1	1	1
130774	1710	pha blood lymphocyte	[PHA blood lymphocytes]	0.0	3	1	1	1
130775	1710	surface markers, content	[surface markers, content]	0.0	3	1	1	1
130776	1710	precursor 32dc13 cell line	[precursor 32Dc13 cell line]	0.0	4	1	1	1
130777	1710	cooperative transcription complex	[cooperative transcription complexes]	0.0	3	1	1	1
130778	1710	arise in case	[arising in cases]	0.0	3	1	1	1
130779	1710	two monoclonal antibody	[two monoclonal antibodies]	0.0	3	1	1	1
130780	1710	T cell reporter	[T cells reporter]	0.0	3	1	1	1
130781	1710	recurrent malignant astrocytomas	[recurrent malignant astrocytomas]	0.0	3	1	1	1
130782	1710	role signal pathway in transformation	[role signaling pathways in transformation]	0.0	5	1	1	1
130783	1710	hmg-i binding to most	[HMG-I binding to most]	0.0	4	1	1	1
130784	1710	regulation switch by cytokine	[regulation switching by cytokines]	0.0	4	1	1	1
130785	1710	unrecognized mechanism regulate glucocorticoid sensitivity	[unrecognized mechanism regulating glucocorticoid sensitivity]	0.0	5	1	1	1
130786	1710	region extend from approximately -250 bp	[regions extending from approximately -250 bp]	0.0	6	1	1	1
130787	1710	95-bp fragment	[95-bp fragment]	0.0	2	1	1	1
130788	1710	recurrences,	[recurrences,]	0.0	1	1	1	1
130789	1710	immature cd34+thy-1+ cb subset	[immature CD34+Thy-1+ CB subset]	0.0	4	1	1	1
130790	1710	murine embryogenesis	[murine embryogenesis]	0.0	2	1	1	1
130791	1710	Chronic myeloproliferative disease	[Chronic myeloproliferative diseases]	0.0	3	1	1	1
130792	1710	cell-specific pathway	[cell-specific pathways]	0.0	2	1	1	1
130793	1710	anti-p-selectin antibody antibody phase-1 neutrophil adhesion	[anti-P-selectin antibodies antibodies phase-1 neutrophil adhesion]	0.0	6	1	1	1
130794	1710	rapid time	[rapid time]	0.0	2	2	2	1
130795	1710	other neotropical primate with resistance	[other neotropical primates with resistance]	0.0	5	1	1	1
130796	1710	E1A mutant protein	[E1A mutant proteins]	0.0	3	1	1	1
130797	1710	(3) pbl	[(3) PBL]	0.0	2	1	1	1
130798	1710	keratinocyte HaCaT cell line	[keratinocytes HaCaT cell line]	0.0	4	1	1	1
130799	1710	autopsy- tissue	[autopsy- tissues]	0.0	2	1	1	1
130800	1710	disease include allergy	[diseases including allergy]	0.0	3	1	1	1
130801	1710	Oct-2 function of this ap-1	[Oct-2 function of this AP-1]	0.0	5	1	1	1
130802	1710	early progenitor cell HPC	[early progenitor cells HPC]	0.0	4	1	1	1
130803	1710	different hybrid promoter	[different hybrid promoters]	0.0	3	1	1	1
130804	1710	endogenous terminal repeat activity	[endogenous terminal repeat activity]	0.0	4	1	1	1
130805	1710	twice/d, min/exposure,	[twice/d, min/exposure,]	0.0	2	1	1	1
130806	1710	affinity fc gammaRI receptor	[affinity Fc gammaRI receptor]	0.0	4	1	1	1
130807	1710	integration of t-cell-leukemia virus type 1	[integration of T-cell-leukemia virus type 1]	0.0	6	1	1	1
130808	1710	three unrelated child	[three unrelated children]	0.0	3	1	1	1
130809	1710	1 out of 13 consecutive control	[1 out of 13 consecutive controls]	0.0	6	1	1	1
130810	1710	differentiation program of erythroid progenitor	[differentiation program of erythroid progenitors]	0.0	5	1	1	1
130811	1710	high level of replication	[higher levels of replication]	0.0	4	1	1	1
130812	1710	sickle blood cell to cell	[sickle blood cells to cells]	0.0	5	1	1	1
130813	1710	category of factor cell-specific factor	[categories of factors cell-specific factors]	0.0	5	1	1	1
130814	1710	one member of this family,	[one member of this family,]	0.0	5	1	1	1
130815	1710	renal transplant	[renal transplant]	0.0	2	1	1	1
130816	1710	encompass exon	[encompassing exons]	0.0	2	1	1	1
130817	1710	modulation of expression	[modulation of expression]	0.0	3	1	1	1
130818	1710	expression pattern a transcription factor	[expression pattern a transcription factor]	0.0	5	2	2	1
130819	1710	represent acid sequence	[representing acid sequences]	0.0	3	1	1	1
130820	1710	monocyte from CS individual	[monocytes from CS individuals]	0.0	4	1	1	1
130821	1710	chamber	[chamber]	0.0	1	1	1	1
130822	1710	activation of ap-1 by gp160	[activation of AP-1 by gp160]	0.0	5	1	1	1
130823	1710	exhibit intrinsic behavior	[exhibiting intrinsic behavior]	0.0	3	1	1	1
130824	1710	amount in cell	[amounts in cells]	0.0	3	1	1	1
130825	1710	extend from -392 to -177 bp	[extending from -392 to -177 bp]	0.0	6	1	1	1
130826	1710	type ii/type	[type II/type]	0.0	2	1	1	1
130827	1710	monocyte interleukin-2 receptor	[monocytes interleukin-2 receptor]	0.0	3	1	1	1
130828	1710	level of lymphocytic aldosterone receptor	[level of lymphocytic aldosterone receptors]	0.0	5	1	1	1
130829	1710	neu-related lipocalin a member	[neu-related lipocalin a member]	0.0	4	1	1	1
130830	1710	two overlapping cosmid encode ciita	[two overlapping cosmids encoding CIITA]	0.0	5	1	1	1
130831	1710	binding in vitro.	[binding in vitro.]	0.0	3	1	1	1
130832	1710	number of leukocyte	[number of leukocytes]	0.0	3	1	1	1
130833	1710	early factor	[early factor]	0.0	2	1	1	1
130834	1710	expression of ikappab alpha	[expression of IkappaB alpha]	0.0	4	1	1	1
130835	1710	precursor cell in cell	[precursor cells in cells]	0.0	4	1	1	1
130836	1710	activator of the hiv enhancer	[activator of the HIV enhancer]	0.0	5	1	1	1
130837	1710	5' region UTR	[5' region UTR]	0.0	3	1	1	1
130838	1710	analysis of immunoglobulin V region promoter	[analyses of immunoglobulin V region promoters]	0.0	6	1	1	1
130839	1710	platelet function such as aggregation	[platelet function such as aggregation]	0.0	5	1	1	1
130840	1710	protein traf1	[protein TRAF1]	0.0	2	1	1	1
130841	1710	NF-kappa b granulocyte-macrophage colony	[NF-kappa B granulocyte-macrophage colony]	0.0	4	1	1	1
130842	1710	octamer factor variant	[octamer factor variants]	0.0	3	1	1	1
130843	1710	T cell-specific regulation	[T cell-specific regulation]	0.0	3	1	1	1
130844	1710	relatively short amino-	[relatively short amino-]	0.0	3	1	1	1
130845	1710	human T cell receptor gamma	[human T cell receptor gamma]	0.0	5	1	1	1
130846	1710	expression of a form whereas expression	[expression of an form whereas expression]	0.0	6	1	1	1
130847	1710	lat -contain	[LAT -containing]	0.0	2	1	1	1
130848	1710	stimulation of CD40 on human melanoma	[Stimulation of CD40 on human melanomas]	0.0	6	1	1	1
130849	1710	member the human homolog	[members the human homolog]	0.0	4	1	1	1
130850	1710	CCAAT sequence for transcription factor	[CCAAT sequences for transcription factors]	0.0	5	1	1	1
130851	1710	10(-8) g/g of total rna	[10(-8) g/g of total RNA]	0.0	5	1	1	1
130852	1710	status after surgery comparison	[status after surgery comparison]	0.0	4	1	1	1
130853	1710	icam-1 -dependent adhesivity	[ICAM-1 -dependent adhesivity]	0.0	3	1	1	1
130854	1710	direct demonstration of nfatp dephosphorylation	[Direct demonstration of NFATp dephosphorylation]	0.0	5	1	1	1
130855	1710	regard the use	[regarding the use]	0.0	3	1	1	1
130856	1710	agonist of cell pivotal	[agonist of cells pivotal]	0.0	4	1	1	1
130857	1710	30% b-cell lymphoma	[30% B-cell lymphomas]	0.0	3	1	1	1
130858	1710	Maximal lps induction	[Maximal LPS induction]	0.0	3	1	1	1
130859	1710	immunoglobulin germline	[immunoglobulin germline]	0.0	2	1	1	1
130860	1710	(for enhancer factor	[(for enhancer factor]	0.0	3	1	1	1
130861	1710	Specific inhibitor	[Specific inhibitors]	0.0	2	2	2	1
130862	1710	mild-moderate insufficiency M-CRF	[mild-moderate insufficiency M-CRF]	0.0	3	1	1	1
130863	1710	blood lymphocyte from ss patient	[blood lymphocytes from SS patients]	0.0	5	1	1	1
130864	1710	minute of sp-a treatment	[min of SP-A treatment]	0.0	4	1	1	1
130865	1710	class of nuclear body	[class of nuclear bodies]	0.0	4	1	1	1
130866	1710	specific hla-dq allele	[specific HLA-DQ alleles]	0.0	3	1	1	1
130867	1710	treatment of tonsillar t- lymphocyte	[treatment of tonsillar T- lymphocytes]	0.0	5	1	1	1
130868	1710	380 bp	[380 bp]	0.0	2	1	1	1
130869	1710	mutation cluster a proto-oncogene encoding	[mutations clustering a proto-oncogene encoding]	0.0	5	1	1	1
130870	1710	E-selectin surface	[E-selectin surface]	0.0	2	1	1	1
130871	1710	necessary prerequisite	[necessary prerequisite]	0.0	2	1	1	1
130872	1710	consequence, adhesion	[consequence, adhesion]	0.0	2	1	1	1
130873	1710	incubation of endothelial cell for hour	[Incubation of endothelial cells for hours]	0.0	6	1	1	1
130874	1710	expression gene in transgenic mouse	[expression gene in transgenic mice]	0.0	5	1	1	1
130875	1710	ten-day exposure	[Ten-day exposure]	0.0	2	1	1	1
130876	1710	cell from blood	[cells from blood]	0.0	3	1	1	1
130877	1710	tpa mitogen tnf-alpha	[TPA mitogen TNF-alpha]	0.0	3	1	1	1
130878	1710	alpha-galactosidase in blood leucocyte	[alpha-galactosidase in blood leucocytes]	0.0	4	1	1	1
130879	1710	closely related acid receptor alpha	[closely related acid receptor alpha]	0.0	5	1	1	1
130880	1710	immunodeficiency virus hodgkin' disease hiv-hd	[immunodeficiency virus Hodgkin's disease HIV-HD]	0.0	5	1	1	1
130881	1710	cell hybrid segregate the Chr	[cell hybrid segregating the Chr]	0.0	5	1	1	1
130882	1710	stat enhancer	[STAT enhancers]	0.0	2	1	1	1
130883	1710	JunB -control	[JunB -control]	0.0	2	1	1	1
130884	1710	37.5% reduction	[37.5% reduction]	0.0	2	1	1	1
130885	1710	reading frame ORF	[reading frame ORF]	0.0	3	1	1	1
130886	1710	human IL-1alpha promoter	[human IL-1alpha promoter]	0.0	3	1	1	1
130887	1710	fate of this cell	[fate of these cells]	0.0	4	1	1	1
130888	1710	depression in the level	[depression in the levels]	0.0	4	1	1	1
130889	1710	systemic disorder at this level.	[systemic disorder at this level.]	0.0	5	1	1	1
130890	1710	sense, in pathological situation	[sense, in pathological situations]	0.0	4	1	1	1
130891	1710	multiple X1 activity	[multiple X1 activities]	0.0	3	1	1	1
130892	1710	ikappab kinase activation	[IkappaB kinase activation]	0.0	3	1	1	1
130893	1710	tyrosine phosphorylation of intracellular substrate in	[tyrosine phosphorylation of intracellular substrates in]	0.0	6	1	1	1
130894	1710	high basal expression	[high basal expression]	0.0	3	1	1	1
130895	1710	Retroviral transduction into this hl-60r subclone	[Retroviral transduction into this HL-60R subclone]	0.0	6	1	1	1
130896	1710	professional apc (e.g. fibroblast	[professional APCs (e.g. fibroblasts]	0.0	4	1	1	1
130897	1710	ongoing protein synthesis.	[ongoing protein synthesis.]	0.0	3	1	1	1
130898	1710	inhibition by VCAM-1 antibody 1g11	[Inhibition by VCAM-1 antibody 1G11]	0.0	5	1	1	1
130899	1710	TINUR gene	[TINUR gene]	0.0	2	1	1	1
130900	1710	replacement dose of t3	[replacement dose of T3]	0.0	4	1	1	1
130901	1710	inhibitor of protein kinase erk	[inhibitor of protein kinase ERK]	0.0	5	1	1	1
130902	1710	activation by CD40 ligand	[activation by CD40 ligand]	0.0	4	1	1	1
130903	1710	three candidate gene factor beta	[three candidate genes factor beta]	0.0	5	1	1	1
130904	1710	(46%	[(46%]	0.0	1	1	1	1
130905	1710	poor response to therapy	[poor response to therapy]	0.0	4	1	1	1
130906	1710	positive transcriptional regulatory element	[positive transcriptional regulatory elements]	0.0	4	1	1	1
130907	1710	lipopolysaccharide (lps)-stimulated production of cytokine	[lipopolysaccharide (LPS)-stimulated production of cytokines]	0.0	5	1	1	1
130908	1710	major target.	[major target.]	0.0	2	1	1	1
130909	1710	human autosomal disease	[human autosomal disease]	0.0	3	1	1	1
130910	1710	counteract the effect	[counteracting the effects]	0.0	3	1	1	1
130911	1710	phorbol myristate induction	[phorbol myristate induction]	0.0	3	1	1	1
130912	1710	secretion of the cytokine interleukin-8	[secretion of the cytokine interleukin-8]	0.0	5	1	1	1
130913	1710	stimulation of nuclear relb translocation	[stimulation of nuclear RelB translocation]	0.0	5	1	1	1
130914	1710	influence on cytokine gene transcription	[influences on cytokine gene transcription]	0.0	5	1	1	1
130915	1710	domain with eight putative transmembrane segment	[domain with eight putative transmembrane segments]	0.0	6	1	1	1
130916	1710	two isoform of the transcription factor	[two isoforms of the transcription factor]	0.0	6	1	1	1
130917	1710	c-rel involvement	[c-Rel involvement]	0.0	2	1	1	1
130918	1710	nucleotide retain full promoter activity	[nucleotides retaining full promoter activity]	0.0	5	1	1	1
130919	1710	knowledge of the IL-12R complex	[knowledge of the IL-12R complex]	0.0	5	1	1	1
130920	1710	proline amino acid-rich par	[proline amino acid-rich PAR]	0.0	4	1	1	1
130921	1710	dominant clone in disorder	[dominant clone in disorders]	0.0	4	1	1	1
130922	1710	erythroid cell in culture	[erythroid cells in cultures]	0.0	4	1	1	1
130923	1710	unrelated antioxidants, n-acetylcysteine	[unrelated antioxidants, N-acetylcysteine]	0.0	3	1	1	1
130924	1710	receptor to glucocorticoid therapy	[receptor to glucocorticoid therapy]	0.0	4	1	1	1
130925	1710	pmn chemotaxis to FMLP	[PMNs chemotaxis to FMLP]	0.0	4	1	1	1
130926	1710	PGG-Glucan a soluble glucose homopolymer	[PGG-Glucan a soluble glucose homopolymer]	0.0	5	1	1	1
130927	1710	content in leukocyte	[content in leukocytes]	0.0	3	1	1	1
130928	1710	-257 region	[-257 region]	0.0	2	1	1	1
130929	1710	factor for activity	[factors for activity]	0.0	3	1	1	1
130930	1710	leukocyte cell membrane	[leukocyte cell membranes]	0.0	3	1	1	1
130931	1710	poor separation of specific granule	[poor separation of specific granules]	0.0	5	1	1	1
130932	1710	needle aspiration	[needle aspirations]	0.0	2	1	1	1
130933	1710	protein REF-1	[protein REF-1]	0.0	2	1	1	1
130934	1710	pretreatment of the mouse	[pretreatment of the mice]	0.0	4	1	1	1
130935	1710	second, stat4 binding	[second, STAT4 binding]	0.0	3	1	1	1
130936	1710	DNA sequence canntg	[DNA sequence CANNTG]	0.0	3	1	1	1
130937	1710	ALY a novel lef-1 protein	[ALY a novel LEF-1 protein]	0.0	5	1	1	1
130938	1710	suggest lack of (a) factor necessary	[suggesting lack of (a) factor necessary]	0.0	6	1	1	1
130939	1710	thymocytes.	[thymocytes.]	0.0	1	1	1	1
130940	1710	factor-B	[factor-B]	0.0	1	1	1	1
130941	1710	same ifn-gamma activation sequence	[same IFN-gamma activation sequence]	0.0	4	1	1	1
130942	1710	selective modification arginine residue	[selective modification arginine residues]	0.0	4	1	1	1
130943	1710	other member of the family	[other members of the family]	0.0	5	1	1	1
130944	1710	enzyme 17beta-hydroxysteroid dehydrogenase type	[enzyme 17beta-hydroxysteroid dehydrogenase type]	0.0	4	1	1	1
130945	1710	antigen-specific tolerance	[antigen-specific tolerance]	0.0	2	1	1	1
130946	1710	t-lymphocyte transformation	[T-lymphocyte transformation]	0.0	2	1	1	1
130947	1710	clinically relevant dose	[clinically relevant dose]	0.0	3	1	1	1
130948	1710	class I molecule	[class I molecules]	0.0	3	1	1	1
130949	1710	tyrosine-phosphorylated granulocyte-colony stimulate factor treatment	[tyrosine-phosphorylated granulocyte-colony stimulating factor treatment]	0.0	5	1	1	1
130950	1710	two new kappa complex	[two new kappa complexes]	0.0	4	1	1	1
130951	1710	role of glucocorticoid receptor	[role of glucocorticoid receptors]	0.0	4	1	1	1
130952	1710	expression a stat1alpha -responsive gene	[Expression a STAT1alpha -responsive gene]	0.0	5	1	1	1
130953	1710	enterotoxin a sea	[enterotoxin A SEA]	0.0	3	1	1	1
130954	1710	two cleavage product after induction	[two cleavage products after induction]	0.0	5	1	1	1
130955	1710	rest neutrophil	[resting neutrophils]	0.0	2	1	1	1
130956	1710	t-lymphotropic virus type 1 htlv-1	[T-lymphotropic virus type 1 HTLV-1]	0.0	5	1	1	1
130957	1710	c-fos/c-jun family	[c-fos/c-jun family]	0.0	2	1	1	1
130958	1710	evidence of somatic hypermutation	[evidence of somatic hypermutation]	0.0	4	1	1	1
130959	1710	primary impairment of metabolism	[primary impairment of metabolism]	0.0	4	1	1	1
130960	1710	two docking site	[two docking sites]	0.0	3	1	1	1
130961	1710	200 microgram fluticasone propionate aqueous spray	[200 micrograms fluticasone propionate aqueous spray]	0.0	6	1	1	1
130962	1710	endogenous fasL mrna in HeLa cell	[endogenous fasL mRNA in HeLa cells]	0.0	6	1	1	1
130963	1710	transcription of the il-4 gene	[transcription of the IL-4 gene]	0.0	5	1	1	1
130964	1710	transmembrane receptor	[transmembrane receptor]	0.0	2	1	1	1
130965	1710	basis from the translation start site	[bases from the translation start site]	0.0	6	1	1	1
130966	1710	acute myelogenous leukemia aml	[acute myelogenous leukemia AML]	0.0	4	1	1	1
130967	1710	exposure dyn/cm2) for 6 h.	[exposure dyn/cm2) for 6 h,]	0.0	5	1	1	1
130968	1710	consist of heterodimeric p50/p65 complex	[consisting of heterodimeric p50/p65 complexes]	0.0	5	1	1	1
130969	1710	metabolite of benzene include benzoquinone	[metabolites of benzene including benzoquinone]	0.0	5	1	1	1
130970	1710	regard to clinical relevance	[regard to clinical relevance]	0.0	4	1	1	1
130971	1710	induction in a t-cell line	[Induction in a T-cell line]	0.0	5	1	1	1
130972	1710	agonist of cell	[agonist of cells]	0.0	3	1	1	1
130973	1710	demonstration of clonal cell growth	[Demonstration of clonal cell growth]	0.0	5	1	1	1
130974	1710	activation of protein kinase MAPK	[activation of protein kinase MAPK]	0.0	5	1	1	1
130975	1710	passage cell	[passage cells]	0.0	2	1	1	1
130976	1710	vivo effect relationship to receptor	[vivo effects relationship to receptors]	0.0	5	1	1	1
130977	1710	androgen binding site in peripheral leukocyte	[Androgen binding sites in peripheral leukocytes]	0.0	6	1	1	1
130978	1710	DNA transfection	[DNA transfections]	0.0	2	1	1	1
130979	1710	irf-2 gene	[IRF-2 gene]	0.0	2	2	2	1
130980	1710	aids-associated lesion	[AIDS-associated lesion]	0.0	2	1	1	1
130981	1710	regulation of the number	[regulation of the number]	0.0	4	1	1	1
130982	1710	expression T cell	[expression T cells]	0.0	3	1	1	1
130983	1710	progesterone receptor hpr	[progesterone receptor hPR]	0.0	3	1	1	1
130984	1710	kit/il-4r alpha	[kit/IL-4R alpha]	0.0	2	2	2	1
130985	1710	level of human motor activity	[levels of human motor activity]	0.0	5	1	1	1
130986	1710	Tat- hiv-1	[Tat- HIV-1]	0.0	2	1	1	1
130987	1710	platelet patient with disorder	[platelets patients with disorder]	0.0	4	1	1	1
130988	1710	effector for the ras oncogene	[effector for the Ras oncogene]	0.0	5	1	1	1
130989	1710	infectious virus stock	[infectious virus stocks]	0.0	3	1	1	1
130990	1710	human cell lines,	[human cell lines,]	0.0	3	1	1	1
130991	1710	allogen-specific cd4+ T cell line	[allogen-specific CD4+ T cell lines]	0.0	5	1	1	1
130992	1710	relevant species	[relevant species]	0.0	2	1	1	1
130993	1710	additional formation	[additional formation]	0.0	2	1	1	1
130994	1710	strict dependence of HS	[Strict dependence of HS]	0.0	4	1	1	1
130995	1710	histocompatibility (MHC) class promoter	[histocompatibility (MHC) class promoters]	0.0	4	1	1	1
130996	1710	ica-positive first-degree relative	[ICA-positive first-degree relatives]	0.0	3	1	1	1
130997	1710	potent stimulator of il-12 production	[potent stimulators of IL-12 production]	0.0	5	1	1	1
130998	1710	binding to Myb consensus site	[binding to Myb consensus sites]	0.0	5	1	1	1
130999	1710	dichotomy	[dichotomy]	0.0	1	1	1	1
131000	1710	(66 microg/100 millileter at P;	[(66 microg/100 ml at h;]	0.0	5	1	1	1
131001	1710	high mobility group protein	[high mobility group protein]	0.0	4	1	1	1
131002	1710	third protein,	[third protein,]	0.0	2	1	1	1
131003	1710	role of Rel /nf-kappa b	[role of Rel /NF-kappa B]	0.0	5	1	1	1
131004	1710	direct mechanism	[direct mechanism]	0.0	2	1	1	1
131005	1710	additional information	[additional information]	0.0	2	1	1	1
131006	1710	lipocalin NRL	[lipocalin NRL]	0.0	2	1	1	1
131007	1710	molar amount	[molar amounts]	0.0	2	1	1	1
131008	1710	/rel transcription	[/Rel transcription]	0.0	2	1	1	1
131009	1710	selection of a tcr repertoire	[Selection of a TCR repertoire]	0.0	5	1	1	1
131010	1710	DNA cells, fludarabine	[DNA cells, fludarabine]	0.0	3	1	1	1
131011	1710	thrombin -generation	[thrombin -generation]	0.0	2	1	1	1
131012	1710	NK cell on stimulation	[NK cells on stimulation]	0.0	4	1	1	1
131013	1710	(4C)	[(4C)]	0.0	1	1	1	1
131014	1710	IL-4 down-regulated mrna accumulation il-1 beta	[IL-4 down-regulated mRNA accumulation IL-1 beta]	0.0	6	1	1	1
131015	1710	CEM-ICR 27 lymphoblast a clone	[CEM-ICR 27 lymphoblasts a clone]	0.0	5	1	1	1
131016	1710	inhibition of phorbol differentiation	[Inhibition of phorbol differentiation]	0.0	4	1	1	1
131017	1710	tuning of gene expression	[tuning of gene expression]	0.0	4	1	1	1
131018	1710	dexamethasone repression	[dexamethasone repression]	0.0	2	1	1	1
131019	1710	tumour necrosis factor TNF	[tumour necrosis factor TNF]	0.0	4	1	1	1
131020	1710	analysis of this cells,	[analysis of these cells,]	0.0	4	1	1	1
131021	1710	deletion of potentially self-reactive T cell	[deletion of potentially self-reactive T cells]	0.0	6	1	1	1
131022	1710	i BL cell contain level	[I BL cells containing levels]	0.0	5	1	1	1
131023	1710	regulation by a pathway	[regulation by a pathway]	0.0	4	1	1	1
131024	1710	elf-2 transcript	[elf-2 transcripts]	0.0	2	1	1	1
131025	1710	bind by in gr	[binding by in GR]	0.0	4	1	1	1
131026	1710	immunoprecipitation assay	[immunoprecipitation assays]	0.0	2	1	1	1
131027	1710	RB status	[RB status]	0.0	2	1	1	1
131028	1710	o., through antagonism of the action	[or, through antagonism of the action]	0.0	6	1	1	1
131029	1710	require more glucocorticoid for a degree	[requiring more glucocorticoids for an degree]	0.0	6	1	1	1
131030	1710	alternatively mediate	[alternatively mediating]	0.0	2	1	1	1
131031	1710	serine protease such as elastase	[serine proteases such as elastase]	0.0	5	1	1	1
131032	1710	CD28 alone	[CD28 alone]	0.0	2	1	1	1
131033	1710	differentiation of cd34+ hemopoietic progenitor cell	[differentiation of CD34+ hemopoietic progenitor cells]	0.0	6	1	1	1
131034	1710	pro-/antiinflammatory cytokine secretion	[pro-/antiinflammatory cytokine secretion]	0.0	3	1	1	1
131035	1710	subsequent squelching	[subsequent squelching]	0.0	2	1	1	1
131036	1710	lymphocyte to il-2	[lymphocytes to IL-2]	0.0	3	1	1	1
131037	1710	essential transcription factor	[essential transcription factors]	0.0	3	1	1	1
131038	1710	identification of two novel regulatory element	[Identification of two novel regulatory elements]	0.0	6	1	1	1
131039	1710	first-degree relative	[first-degree relatives]	0.0	2	1	1	1
131040	1710	low, concentration with a onset	[low, concentrations with an onset]	0.0	5	2	2	1
131041	1710	receptor concentration in infarction	[receptor concentration in infarction]	0.0	4	1	1	1
131042	1710	suggest present	[suggesting present]	0.0	2	1	1	1
131043	1710	cut/cdp protein a repressor	[cut/CDP protein a repressor]	0.0	4	1	1	1
131044	1710	cell in culture	[cells in cultures]	0.0	3	1	1	1
131045	1710	long persistence of CTL clone	[long-term persistence of CTL clones]	0.0	5	1	1	1
131046	1710	person with no history	[persons with no history]	0.0	4	1	1	1
131047	1710	class gene in b lymphocyte	[class genes in B lymphocytes]	0.0	5	1	1	1
131048	1710	tissue-specific histone h2a-2 gene	[tissue-specific histone H2A-2 genes]	0.0	4	1	1	1
131049	1710	twentyfold increase	[twentyfold increase]	0.0	2	1	1	1
131050	1710	similar increase in c-fo	[similar increases in c-fos]	0.0	4	1	1	1
131051	1710	constitutive nuclear translocation of NF-ATp	[constitutive nuclear translocation of NF-ATp]	0.0	5	1	1	1
131052	1710	mutant form of component	[mutant forms of components]	0.0	4	1	1	1
131053	1710	partner,	[partner,]	0.0	1	1	1	1
131054	1710	activation motif	[activation motifs]	0.0	2	1	1	1
131055	1710	transcript initiation	[transcript initiation]	0.0	2	1	1	1
131056	1710	study, therefore, bioavailability	[study, therefore, bioavailability]	0.0	3	1	1	1
131057	1710	region amino acid 1-450	[region amino acids 1-450]	0.0	4	1	1	1
131058	1710	test a series	[testing a series]	0.0	3	1	1	1
131059	1710	abolish	[abolishing]	0.0	1	1	1	1
131060	1710	heparin-like gag	[heparin-like GAGs]	0.0	2	1	1	1
131061	1710	tyrosine phosphorylation of phosphatidylinositol 3-kinase	[tyrosine phosphorylation of phosphatidylinositol 3-kinase]	0.0	5	1	1	1
131062	1710	igg response	[IgG response]	0.0	2	1	1	1
131063	1710	relation between functional parameter	[relation between functional parameters]	0.0	4	1	1	1
131064	1710	rest level	[resting levels]	0.0	2	1	1	1
131065	1710	ability of transcription factor	[ability of transcription factors]	0.0	4	1	1	1
131066	1710	-rich carboxy terminus	[-rich carboxy terminus]	0.0	3	1	1	1
131067	1710	various mode of helix-loop-helix regulation	[Various modes of helix-loop-helix regulation]	0.0	5	1	1	1
131068	1710	ranq69l	[RanQ69L]	0.0	1	1	1	1
131069	1710	fibrosarcoma 8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma 8, fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
131070	1710	neuroblastoma differentiation	[neuroblastoma differentiation]	0.0	2	1	1	1
131071	1710	two cis-acting element gm-kappa	[Two cis-acting elements GM-kappa]	0.0	4	1	1	1
131072	1710	study protein-protein interaction	[studying protein-protein interactions]	0.0	3	1	1	1
131073	1710	DNase-I	[DNase-I]	0.0	1	1	1	1
131074	1710	product expression	[product expression]	0.0	2	1	1	1
131075	1710	nuclear vitamin d	[nuclear vitamin D]	0.0	3	1	1	1
131076	1710	relation to complex class	[relation to complex classes]	0.0	4	1	1	1
131077	1710	anti-cd14 antibody	[anti-CD14 antibodies]	0.0	2	1	1	1
131078	1710	EBV genome	[EBV genome]	0.0	2	1	1	1
131079	1710	include monocyte/macrophages	[including monocyte/macrophages]	0.0	2	1	1	1
131080	1710	growth of leukemia cell	[growth of leukemia cells]	0.0	4	1	1	1
131081	1710	polymorphic short tandem repeat	[polymorphic short tandem repeat]	0.0	4	1	1	1
131082	1710	suppressive effect on function	[suppressive effect on functions]	0.0	4	1	1	1
131083	1710	common event	[common event]	0.0	2	1	1	1
131084	1710	extensive deletion	[extensive deletion]	0.0	2	1	1	1
131085	1710	megakaryocytic gene in a -dependent manner	[megakaryocytic genes in an -dependent manner]	0.0	6	1	1	1
131086	1710	sensitivity to a proteasome inhibitor	[sensitivities to a proteasome inhibitor]	0.0	5	1	1	1
131087	1710	tpa factor octamer-associated protein OAP40	[TPA factor octamer-associated protein OAP40]	0.0	5	1	1	1
131088	1710	BCL2 gene	[BCL2 gene]	0.0	2	2	2	1
131089	1710	activation-dependent engagement	[activation-dependent engagement]	0.0	2	1	1	1
131090	1710	unexpected observation with the finding	[unexpected observations with the findings]	0.0	5	1	1	1
131091	1710	synthetic peptide Arg-Gly-Asp	[synthetic peptide Arg-Gly-Asp]	0.0	3	1	1	1
131092	1710	chromosome 14q32.1	[chromosome 14q32.1]	0.0	2	1	1	1
131093	1710	cell type in the lung	[cell types in the lung]	0.0	5	1	1	1
131094	1710	high weight dextran sulfate hmd	[high weight dextran sulfate HMDS]	0.0	5	1	1	1
131095	1710	globin express cell	[globin expressing cells]	0.0	3	1	1	1
131096	1710	tropical spastic paraparesis tsp	[tropical spastic paraparesis TSP]	0.0	4	1	1	1
131097	1710	inducer of ap-1	[inducer of AP-1]	0.0	3	1	1	1
131098	1710	measure the phosphatidylinositol-3,4,5-trisphosphate concentration in cell	[measuring the phosphatidylinositol-3,4,5-trisphosphate concentration in cells]	0.0	6	1	1	1
131099	1710	ng/ml tbp-1	[ng/ml TBP-1]	0.0	2	1	1	1
131100	1710	use mobility shift assay after activation	[using mobility shift assays after activation]	0.0	6	1	1	1
131101	1710	outgrowth of cell	[outgrowth of cells]	0.0	3	1	1	1
131102	1710	respond element	[responding elements]	0.0	2	1	1	1
131103	1710	include 1 aml	[including 1 AML]	0.0	3	1	1	1
131104	1710	(stage I),	[(stage I),]	0.0	2	1	1	1
131105	1710	IFN regulatory factor promoter	[IFN regulatory factor promoter]	0.0	4	1	1	1
131106	1710	TPA-dependent activation	[TPA-dependent activation]	0.0	2	1	1	1
131107	1710	factor (nfat) group	[factor (NFAT) group]	0.0	3	1	1	1
131108	1710	effect of hgata-3	[effect of hGATA-3]	0.0	3	1	1	1
131109	1710	ionomycin p/i mimic	[ionomycin P/I mimics]	0.0	3	1	1	1
131110	1710	bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane ym-268	[bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane YM-268]	0.0	2	1	1	1
131111	1710	kidney 293 cell	[kidney 293 cells]	0.0	3	1	1	1
131112	1710	generation of mediator	[generation of mediators]	0.0	3	1	1	1
131113	1710	contribution to chronic rheumatoid arthritis	[contribution to chronic rheumatoid arthritis]	0.0	5	1	1	1
131114	1710	only weak inhibition	[only weak inhibition]	0.0	3	1	1	1
131115	1710	subtype hhv-8 +/ebv- pel	[subtypes HHV-8 +/EBV- PEL]	0.0	4	1	1	1
131116	1710	myeloperoxidase promoter	[myeloperoxidase promoters]	0.0	2	1	1	1
131117	1710	addition, a subset	[addition, a subset]	0.0	3	1	1	1
131118	1710	however, order	[however, orders]	0.0	2	1	1	1
131119	1710	express tal1	[expressing TAL1]	0.0	2	1	1	1
131120	1710	model of latent adenovirus infection	[model of latent adenovirus infection]	0.0	5	1	1	1
131121	1710	les-induced transcription factor	[LPS-induced transcription factors]	0.0	3	1	1	1
131122	1710	differentiation of normal center b cell	[differentiation of normal center B cells]	0.0	6	1	1	1
131123	1710	augmentation of c-rel	[augmentation of c-Rel]	0.0	3	1	1	1
131124	1710	viral capsid antigen	[viral capsid antigen]	0.0	3	1	1	1
131125	1710	DNA binding sites.	[DNA binding sites.]	0.0	3	1	1	1
131126	1710	peptide in jy25 cell	[peptide in JY25 cells]	0.0	4	1	1	1
131127	1710	involve expression jun	[involving expression jun]	0.0	3	1	1	1
131128	1710	constitutive activation of NF-kB	[Constitutive activation of NF-kB]	0.0	4	1	1	1
131129	1710	growth of tumor	[growth of tumors]	0.0	3	1	1	1
131130	1710	treatment of u937	[Treatment of U937]	0.0	3	1	1	1
131131	1710	c-myb gene	[c-myb gene]	0.0	2	1	1	1
131132	1710	suggest control of gata-1 transcription	[suggesting control of GATA-1 transcription]	0.0	5	1	1	1
131133	1710	inhibitory effect of CaM-K ii	[inhibitory effect of CaM-K II]	0.0	5	1	1	1
131134	1710	manifestation of infection	[manifestations of infection]	0.0	3	1	1	1
131135	1710	proportion of low responder	[proportions of low responders]	0.0	4	1	1	1
131136	1710	-overexpress	[-overexpressing]	0.0	1	1	1	1
131137	1710	retinoid -dependent marker expression	[retinoid -dependent markers expression]	0.0	4	1	1	1
131138	1710	4 fmol/mg protein).	[4 fmol/mg protein).]	0.0	3	1	1	1
131139	1710	cd23 gene expression	[CD23 gene expression]	0.0	3	1	1	1
131140	1710	phenotypic study	[Phenotypic studies]	0.0	2	1	1	1
131141	1710	leukemia cell line grow	[leukemia cell lines growing]	0.0	4	1	1	1
131142	1710	two bind motif	[two binding motifs]	0.0	3	1	1	1
131143	1710	tool study the regulation	[tool studying the regulation]	0.0	4	1	1	1
131144	1710	repressive state	[repressive state]	0.0	2	1	1	1
131145	1710	add-back experiment with cytokine	[Add-back experiments with cytokines]	0.0	4	1	1	1
131146	1710	factor 1	[factor 1]	0.0	2	1	1	1
131147	1710	factor 5	[factor 5]	0.0	2	1	1	1
131148	1710	fmol/10(7) cell in controls, p	[fmol/10(7) cells in controls, p]	0.0	5	1	1	1
131149	1710	factor 6	[factor 6]	0.0	2	1	1	1
131150	1710	different stage of B-cell differentiation	[different stages of B-cell differentiation]	0.0	5	1	1	1
131151	1710	addition of phosphatidic acid pa	[addition of phosphatidic acid PA]	0.0	5	1	1	1
131152	1710	Recognition tegument protein	[Recognition tegument proteins]	0.0	3	1	1	1
131153	1710	chain-derived peptide clip	[chain-derived peptides CLIP]	0.0	3	1	1	1
131154	1710	SH2/SH3 adapter protein	[SH2/SH3 adapter protein]	0.0	3	1	1	1
131155	1710	tpa maturation	[TPA maturation]	0.0	2	1	1	1
131156	1710	suppression of TNFalpha nfkappab activity	[Suppression of TNFalpha NFkappaB activity]	0.0	5	1	1	1
131157	1710	then after every exposures.	[then after every exposures.]	0.0	4	1	1	1
131158	1710	Stable transfectant	[Stable transfectants]	0.0	2	1	1	1
131159	1710	distinct pathways:	[distinct pathways:]	0.0	2	1	1	1
131160	1710	down-regulation of many erythroid gene	[down-regulation of many erythroid genes]	0.0	5	1	1	1
131161	1710	stimulation of relb translocation	[stimulation of RelB translocation]	0.0	4	1	1	1
131162	1710	susceptibility to a infection	[susceptibility to a infection]	0.0	4	1	1	1
131163	1710	cocultivation of activator cell	[cocultivation of activator cells]	0.0	4	1	1	1
131164	1710	unique characteristic of this pathway	[unique characteristics of this pathway]	0.0	5	2	2	1
131165	1710	prevent the expression of proinflammatory gene	[preventing the expression of proinflammatory genes]	0.0	6	1	1	1
131166	1710	c-jun response,	[c-Jun response,]	0.0	2	1	1	1
131167	1710	thy-tax mouse	[Thy-tax mice]	0.0	2	1	1	1
131168	1710	phosphoinositide turnover	[phosphoinositide turnover]	0.0	2	1	1	1
131169	1710	amount of v-erbA	[amounts of v-erbA]	0.0	3	1	1	1
131170	1710	pkc protein expression	[PKC protein expression]	0.0	3	1	1	1
131171	1710	shigella icsa protein	[Shigella IcsA protein]	0.0	3	1	1	1
131172	1710	tissue development	[tissue development]	0.0	2	1	1	1
131173	1710	delta psi(m)	[delta psi(m)]	0.0	2	1	1	1
131174	1710	dimer b subunit	[dimer B subunits]	0.0	3	1	1	1
131175	1710	difference in receptor expression	[differences in receptor expression]	0.0	4	1	1	1
131176	1710	deal	[deal]	0.0	1	1	1	1
131177	1710	modification in monocyte	[modification in monocytes]	0.0	3	1	1	1
131178	1710	rheumatic disease four	[rheumatic diseases four]	0.0	3	1	1	1
131179	1710	ap-2 DNA	[AP-2 DNA]	0.0	2	1	1	1
131180	1710	cell by glucocorticoid	[cells by glucocorticoids]	0.0	3	1	1	1
131181	1710	typically die	[typically dying]	0.0	2	1	1	1
131182	1710	13 patient with hypertension	[13 patients with hypertension]	0.0	4	1	1	1
131183	1710	carbonic anhydrase caii	[carbonic anhydrase CAII]	0.0	3	1	1	1
131184	1710	set with different residue kinetic analysis	[sets with different residues Kinetic analysis]	0.0	6	1	1	1
131185	1710	domain of human il-9ralpha	[domain of human IL-9Ralpha]	0.0	4	1	1	1
131186	1710	structure during deamidation	[structure during deamidation]	0.0	3	1	1	1
131187	1710	(mut)	[(mut)]	0.0	1	1	1	1
131188	1710	DNA bind characteristic	[DNA binding characteristics]	0.0	3	1	1	1
131189	1710	role in the quantitative control	[role in the quantitative control]	0.0	5	1	1	1
131190	1710	ten male volunteer	[ten male volunteers]	0.0	3	1	1	1
131191	1710	target cell hla-dr	[target cell HLA-DR]	0.0	3	1	1	1
131192	1710	create a -rich carboxy terminus	[creating a -rich carboxy terminus]	0.0	5	1	1	1
131193	1710	investigations, use hl60 cell	[investigations, using HL60 cells]	0.0	4	1	1	1
131194	1710	suggest a dominant effect	[suggesting a dominant effect]	0.0	4	1	1	1
131195	1710	effect on IL-6 production	[effects on IL-6 production]	0.0	4	1	1	1
131196	1710	4.3 pts; fluticasone: pts)	[4.3 pts; fluticasone: pts)]	0.0	4	1	1	1
131197	1710	(3) hhv-6	[(3) HHV-6]	0.0	2	1	1	1
131198	1710	express taxi	[expressing TaxI]	0.0	2	1	1	1
131199	1710	normal splicing	[normal splicing]	0.0	2	1	1	1
131200	1710	decrease in promoter activity	[decrease in promoter activity]	0.0	4	1	1	1
131201	1710	transcriptional activation element	[transcriptional activation elements]	0.0	3	1	1	1
131202	1710	erp transcript	[ERP transcripts]	0.0	2	1	1	1
131203	1710	involve sexual differentiation	[involving sexual differentiation]	0.0	3	1	1	1
131204	1710	dna-binding regulatory property of leukemia factor	[DNA-binding regulatory properties of leukemia factor]	0.0	6	1	1	1
131205	1710	PPARalpha expression in ECs	[PPARalpha expression in ECs]	0.0	4	1	1	1
131206	1710	common cis-acting element	[common cis-acting element]	0.0	3	1	1	1
131207	1710	mediate signal transduction	[mediating signal transduction]	0.0	3	1	1	1
131208	1710	inhibition of phorbol ester-induced monocytic differentiation	[Inhibition of phorbol ester-induced monocytic differentiation]	0.0	6	1	1	1
131209	1710	gamma induction	[gamma induction]	0.0	2	1	1	1
131210	1710	vivo genomic DMS footprinting	[vivo genomic DMS footprinting]	0.0	4	1	1	1
131211	1710	Dithiocarbamates a group of industrial chemical	[Dithiocarbamates a group of industrial chemicals]	0.0	6	1	1	1
131212	1710	understanding of biology	[understanding of biology]	0.0	3	1	1	1
131213	1710	transcriptional regulation of hiv	[transcriptional regulation of HIV]	0.0	4	1	1	1
131214	1710	immunodeficiency virus type replication	[immunodeficiency virus type replication]	0.0	4	1	1	1
131215	1710	cellular component of human atheroma	[cellular component of human atheroma]	0.0	5	1	1	1
131216	1710	domain contain cell cycle	[domain containing cell cycle]	0.0	4	1	1	1
131217	1710	binding of E2F	[binding of E2F]	0.0	3	1	1	1
131218	1710	transcription from region	[transcription from regions]	0.0	3	1	1	1
131219	1710	subline,	[subline,]	0.0	1	1	1	1
131220	1710	expression of the gene.	[expression of the gene.]	0.0	4	1	1	1
131221	1710	respectively, of SCF	[respectively, of SCF]	0.0	3	1	1	1
131222	1710	cell process	[cell processes]	0.0	2	1	1	1
131223	1710	response to taxi induction	[response to TaxI induction]	0.0	4	1	1	1
131224	1710	blood of 145 healthy volunteer	[blood of 145 healthy volunteers]	0.0	5	1	1	1
131225	1710	adsorption to property	[adsorption to properties]	0.0	3	1	1	1
131226	1710	finally week	[finally weeks]	0.0	2	1	1	1
131227	1710	the/thf 1.87+/-0.36)	[THE/THF 1.87+/-0.36)]	0.0	2	1	1	1
131228	1710	line by expression of ICAM-1	[lines by expression of ICAM-1]	0.0	5	1	1	1
131229	1710	macrophage by mechanical ventilation	[macrophages by mechanical ventilation]	0.0	4	1	1	1
131230	1710	(1) the appearance of NF-kappaB	[(1) the appearance of NF-kappaB]	0.0	5	1	1	1
131231	1710	two distinct form	[Two distinct forms]	0.0	3	2	2	1
131232	1710	pml-rar -contain cell	[PML-RAR -containing cells]	0.0	3	1	1	1
131233	1710	burst by a PKC mechanism	[burst by a PKC mechanism]	0.0	5	1	1	1
131234	1710	cell profibrotic growth factor	[cells profibrotic growth factors]	0.0	4	1	1	1
131235	1710	tissue concentration	[tissue concentrations]	0.0	2	1	1	1
131236	1710	(1) part	[(1) part]	0.0	2	1	1	1
131237	1710	fibrosarcoma 8, malignant fibrous histiocytoma rhabdomyosarcoma	[fibrosarcoma 8, malignant fibrous histiocytoma rhabdomyosarcoma]	0.0	6	1	1	1
131238	1710	class histocompatibility complex gene transcription	[class histocompatibility complex gene transcription]	0.0	5	1	1	1
131239	1710	high concentration in the luman	[high concentration in the lumen]	0.0	5	1	1	1
131240	1710	pathway for induction	[pathways for induction]	0.0	3	1	1	1
131241	1710	binding by monocyte -macrophage	[binding by monocyte -macrophages]	0.0	4	1	1	1
131242	1710	b cell protein	[B cell proteins]	0.0	3	1	1	1
131243	1710	5 m dexamethasone	[5 M dexamethasone]	0.0	3	1	1	1
131244	1710	evidence for two lck/fyn-	[evidence for two Lck/Fyn-]	0.0	4	1	1	1
131245	1710	patient respond to therapy	[patients responding to therapy]	0.0	4	1	1	1
131246	1710	differentiation response gene	[differentiation response gene]	0.0	3	1	1	1
131247	1710	potentially in cell cycle	[potentially in cell cycle]	0.0	4	1	1	1
131248	1710	thiobarbituric substance tbar	[thiobarbituric substances TBARS]	0.0	3	1	1	1
131249	1710	kv1.3 component of KV	[Kv1.3 components of KV]	0.0	4	1	1	1
131250	1710	double time, low saturation density	[doubling time, lower saturation density]	0.0	5	1	1	1
131251	1710	BZLF1 gene promoter	[BZLF1 gene promoter]	0.0	3	1	1	1
131252	1710	free ca2+ concentration ca2+	[free Ca2+ concentration Ca2+]	0.0	4	1	1	1
131253	1710	moreover, TNF-alpha hiv-1 terminal repeat LTR	[Moreover, TNF-alpha HIV-1 terminal repeat LTR]	0.0	6	1	1	1
131254	1710	activation in response to p40tax	[activation in response to p40tax]	0.0	5	1	1	1
131255	1710	interferon beta IFN-beta	[interferon beta IFN-beta]	0.0	3	1	1	1
131256	1710	suggest a action of RA	[suggesting a action of RA]	0.0	5	1	1	1
131257	1710	blood cell of individual	[blood cells of individuals]	0.0	4	1	1	1
131258	1710	control in Germany.	[controls in Germany.]	0.0	3	1	1	1
131259	1710	peptide (10 micrograms),	[peptide (10 micrograms),]	0.0	3	1	1	1
131260	1710	execution of the signal	[execution of the signal]	0.0	4	1	1	1
131261	1710	multiple cytokine receptor	[multiple cytokine receptors]	0.0	3	1	1	1
131262	1710	therapeutic response to acid	[therapeutic response to acid]	0.0	4	1	1	1
131263	1710	AES peptide	[AES peptides]	0.0	2	1	1	1
131264	1710	ah receptor tcdd receptor mrna	[Ah receptor TCDD receptor mRNA]	0.0	5	1	1	1
131265	1710	RNA protein kinase PKR	[RNA protein kinase PKR]	0.0	4	1	1	1
131266	1710	role during hematopoiesis translocation	[role during hematopoiesis translocations]	0.0	4	1	1	1
131267	1710	antibody from patient	[antibodies from patients]	0.0	3	1	1	1
131268	1710	kilobasis of dna.	[kilobases of DNA.]	0.0	3	1	1	1
131269	1710	overexpression of the subunit of pka	[overexpression of the subunit of PKA]	0.0	6	1	1	1
131270	1710	incubation of this cell	[incubation of these cells]	0.0	4	1	1	1
131271	1710	macrophage/monocyte type	[macrophage/monocyte type]	0.0	2	1	1	1
131272	1710	c-c chemokine receptor ccr-4	[C-C chemokine receptor CCR-4]	0.0	4	1	1	1
131273	1710	factor nf-kappa b (position	[factor NF-kappa B (positions]	0.0	4	1	1	1
131274	1710	expression of a interleukin-12 receptor component	[expression of an interleukin-12 receptor component]	0.0	6	1	1	1
131275	1710	fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
131276	1710	cd3.tcr	[CD3.TcR]	0.0	1	1	1	1
131277	1710	b-lymphocyte growth transformation 187	[B-lymphocyte growth transformation 187]	0.0	4	1	1	1
131278	1710	eight male volunteer	[Eight male volunteers]	0.0	3	1	1	1
131279	1710	nur77 knock-out mouse	[nur77 knock-out mice]	0.0	3	1	1	1
131280	1710	monocyte use anti- tf antibody	[monocytes using anti- TF antibody]	0.0	5	1	1	1
131281	1710	10(-6) m in a manner	[10(-6) M in a manner]	0.0	5	1	1	1
131282	1710	treatment of pbmc with anti-cd2 mab	[Treatment of PBMC with anti-CD2 mAb]	0.0	6	1	1	1
131283	1710	possible explanation for mechanism-based toxicity	[possible explanation for mechanism-based toxicities]	0.0	5	1	1	1
131284	1710	mature t-cell line	[mature T-cell lines]	0.0	3	1	1	1
131285	1710	EA-D promoter regulation	[EA-D promoter regulation]	0.0	3	1	1	1
131286	1710	use a fragment	[Using a fragment]	0.0	3	1	1	1
131287	1710	three female	[three females]	0.0	2	1	1	1
131288	1710	transcription by binding	[transcription by binding]	0.0	3	1	1	1
131289	1710	treatment with PMA	[Treatment with PMA]	0.0	3	1	1	1
131290	1710	overexpression in mouse T cell blast	[overexpression in mouse T cell blasts]	0.0	6	1	1	1
131291	1710	human c-fe	[human c-fes]	0.0	2	1	1	1
131292	1710	follow inoculation in mice,	[Following inoculation in mice,]	0.0	4	1	1	1
131293	1710	also with other protein	[also with other proteins]	0.0	4	1	1	1
131294	1710	high probability of relapse	[higher probability of relapse]	0.0	4	1	1	1
131295	1710	immunostaining against at least 1	[immunostaining against at least 1]	0.0	5	1	1	1
131296	1710	stabilization of the interaction	[stabilization of the interaction]	0.0	4	1	1	1
131297	1710	i ifi IFN-alpha/beta in addition	[I IFNs IFN-alpha/beta in addition]	0.0	5	1	1	1
131298	1710	t-cell antigen receptor-CD3	[T-cell antigen receptor-CD3]	0.0	3	1	1	1
131299	1710	allele loss in polycythemia vera	[allele loss in polycythemia vera]	0.0	5	1	1	1
131300	1710	signal alone	[signal alone]	0.0	2	1	1	1
131301	1710	stat1alpha expression	[STAT1alpha expression]	0.0	2	1	1	1
131302	1710	rearrangement corresponding to transcript contain deletion	[rearrangements corresponding to transcripts containing deletions]	0.0	6	1	1	1
131303	1710	increase mrna level	[increasing mRNA levels]	0.0	3	1	1	1
131304	1710	differential effect in bone morphogenetic protein-2-	[differential effects in bone morphogenetic protein-2-]	0.0	6	1	1	1
131305	1710	sphingomyelinase of the membrane	[sphingomyelinase of the membrane]	0.0	4	1	1	1
131306	1710	tissue-specific gene	[tissue-specific genes]	0.0	2	1	1	1
131307	1710	150 kD	[150 kD]	0.0	2	1	1	1
131308	1710	constitutive hiv-enhancer activity	[constitutive HIV-enhancer activity]	0.0	3	1	1	1
131309	1710	ccaat-box binding	[CCAAT-box binding]	0.0	2	1	1	1
131310	1710	suppression with sn50 peptide	[suppression with SN50 peptide]	0.0	4	1	1	1
131311	1710	t-lymphocyte from individual	[T-lymphocytes from individuals]	0.0	3	1	1	1
131312	1710	distinct expression	[distinct expression]	0.0	2	1	1	1
131313	1710	putative downstream site for E2F	[putative downstream site for E2F]	0.0	5	1	1	1
131314	1710	kD tnf receptor tr55	[kD TNF receptor TR55]	0.0	4	1	1	1
131315	1710	lps factor-kappa b/ rel complex	[LPS factor-kappa B/ Rel complex]	0.0	5	1	1	1
131316	1710	carboxy-terminal dimerization region contain repeat	[carboxy-terminal dimerization region containing repeats]	0.0	5	1	1	1
131317	1710	subset include fcepsilonriib cd23	[subset including FcepsilonRIIb CD23]	0.0	4	1	1	1
131318	1710	deoxidizing activity, d-ribose	[deoxidizing activity, D-ribose]	0.0	3	1	1	1
131319	1710	six other factor lbf2	[six other factors LBF2]	0.0	4	1	1	1
131320	1710	transduction mutant	[transduction mutant]	0.0	2	1	1	1
131321	1710	defect in ricket	[defect in rickets]	0.0	3	1	1	1
131322	1710	approximately 80% treatment with MCM	[approximately 80% treatment with MCM]	0.0	5	1	1	1
131323	1710	ppargamma peroxisomal receptor gamma expression	[PPARgamma peroxisomal receptor gamma expression]	0.0	5	1	1	1
131324	1710	immature morphology	[immature morphology]	0.0	2	1	1	1
131325	1710	gradient-gel	[gradient-gel]	0.0	1	1	1	1
131326	1710	trans-gene expression	[trans-gene expression]	0.0	2	1	1	1
131327	1710	mononuclear leukocyte in patient	[mononuclear leukocytes in patients]	0.0	4	1	1	1
131328	1710	5' terminus	[5' terminus]	0.0	2	1	1	1
131329	1710	signal pathway in cell	[signaling pathway in cells]	0.0	4	1	1	1
131330	1710	screen assay	[screening assay]	0.0	2	1	1	1
131331	1710	monolayer of vein cell huvec	[monolayers of vein cells HUVECs]	0.0	5	1	1	1
131332	1710	(4c)	[(4c)]	0.0	1	1	1	1
131333	1710	cell-cell adhesion	[cell-cell adhesion]	0.0	2	1	1	1
131334	1710	interference with the antigen-processing pathway	[interference with the antigen-processing pathway]	0.0	5	1	1	1
131335	1710	few steroid-regulated gene	[few steroid-regulated genes]	0.0	3	1	1	1
131336	1710	24 degree	[24 degrees]	0.0	2	1	1	1
131337	1710	gamma-Interferon resistance to D3 a mechanism	[gamma-Interferon resistance to D3 a mechanism]	0.0	6	1	1	1
131338	1710	Ser23-Ala49	[Ser23-Ala49]	0.0	1	1	1	1
131339	1710	level of other factor	[Levels of other factors]	0.0	4	1	1	1
131340	1710	activity through element specific	[activity through elements specific]	0.0	4	1	1	1
131341	1710	downstream sequence element	[downstream sequence elements]	0.0	3	1	1	1
131342	1710	follow chromosomal rearrangement	[following chromosomal rearrangements]	0.0	3	1	1	1
131343	1710	fine needle aspiration	[fine needle aspirations]	0.0	3	1	1	1
131344	1710	t-cell lymphoma AITL with gcs	[T-cell lymphoma AITL with GCs]	0.0	5	1	1	1
131345	1710	extract of cd15 cell	[extracts of CD15 cells]	0.0	4	1	1	1
131346	1710	Eighteen patient	[Eighteen patients]	0.0	2	1	1	1
131347	1710	positioning NFAT	[positioning NFAT]	0.0	2	1	1	1
131348	1710	variety include chemotherapy drug	[variety including chemotherapy drugs]	0.0	4	1	1	1
131349	1710	Cooperation of Spi-1/ pu.1	[Cooperation of Spi-1/ PU.1]	0.0	4	1	1	1
131350	1710	migration alone, suggest proliferation.	[migration alone, suggesting proliferation.]	0.0	4	1	1	1
131351	1710	only NF-kappa b /p50	[only NF-kappa B /p50]	0.0	4	1	1	1
131352	1710	bronchial asthma child	[bronchial asthma children]	0.0	3	1	1	1
131353	1710	only upon exposure to the level	[only upon exposure to the level]	0.0	6	1	1	1
131354	1710	cell of the system CNS	[cells of the system CNS]	0.0	5	1	1	1
131355	1710	possible interaction	[possible interaction]	0.0	2	1	1	1
131356	1710	different form include acute leukemia	[different forms including acute leukemia]	0.0	5	1	1	1
131357	1710	increase infiltrate (p	[increasing infiltrate (P]	0.0	3	1	1	1
131358	1710	hiv-infected patient with normal receptor affinity	[HIV-infected patients with normal receptor affinity]	0.0	6	1	1	1
131359	1710	activation of irf-2	[activation of IRF-2]	0.0	3	1	1	1
131360	1710	nf-kappa b DNA	[NF-kappa B DNA]	0.0	3	1	1	1
131361	1710	migrating form	[migrating forms]	0.0	2	2	2	1
131362	1710	abrogation of gata-1 expression in progenitor	[abrogation of GATA-1 expression in progenitors]	0.0	6	1	1	1
131363	1710	pif DNA binding activity	[PIF DNA binding activity]	0.0	4	1	1	1
131364	1710	nf-kappab/ntat ets binding site	[NF-kappaB/NFAT Ets binding sites]	0.0	4	1	1	1
131365	1710	p75tnf-r production	[p75TNF-R production]	0.0	2	1	1	1
131366	1710	specific tissue	[specific tissues]	0.0	2	1	1	1
131367	1710	(26 degree	[(26 degrees]	0.0	2	1	1	1
131368	1710	critical component of U1	[critical components of U1]	0.0	4	1	1	1
131369	1710	granulocyte-monocyte colony stimulate activity	[granulocyte-monocyte colony stimulating activity]	0.0	4	1	1	1
131370	1710	lps -inducible factor	[LPS -inducible factor]	0.0	3	1	1	1
131371	1710	induce protein expression	[inducing protein expression]	0.0	3	1	1	1
131372	1710	characterization the nuclear factor	[Characterization the nuclear factor]	0.0	4	1	1	1
131373	1710	administration of danazol for month	[Administration of danazol for month]	0.0	5	1	1	1
131374	1710	insight into the slow rate	[insights into the slow rate]	0.0	5	1	1	1
131375	1710	peripheral blood of woman	[peripheral blood of women]	0.0	4	1	1	1
131376	1710	binding of ICSAT	[binding of ICSAT]	0.0	3	1	1	1
131377	1710	BCP-ALL cell	[BCP-ALL cells]	0.0	2	1	1	1
131378	1710	globular, structure	[globular, structures]	0.0	2	1	1	1
131379	1710	preexisting form	[preexisting forms]	0.0	2	1	1	1
131380	1710	role in immune state	[role in immune states]	0.0	4	1	1	1
131381	1710	synovial biopsy specimen	[synovial biopsy specimen]	0.0	3	1	1	1
131382	1710	also with protein	[also with proteins]	0.0	3	1	1	1
131383	1710	p75tnf-r in mouse	[p75TNF-R in mice]	0.0	3	1	1	1
131384	1710	rapid tyrosine phosphorylation of set	[rapid tyrosine phosphorylation of sets]	0.0	5	1	1	1
131385	1710	acid washed,	[acid washed,]	0.0	2	1	1	1
131386	1710	feto-maternal interface in tissue	[feto-maternal interface in tissue]	0.0	4	1	1	1
131387	1710	19-bp nuclear factor binding site	[19-bp nuclear factor binding site]	0.0	5	1	1	1
131388	1710	human myeloid nuclear differentiation antigen	[human myeloid nuclear differentiation antigen]	0.0	5	1	1	1
131389	1710	activation lymphocyte by ags	[Activation lymphocytes by Ags]	0.0	4	1	1	1
131390	1710	tumor cell from blood	[tumor cells from blood]	0.0	4	1	1	1
131391	1710	produce a 50-fold induction of mrna	[producing a 50-fold induction of mRNA]	0.0	6	1	1	1
131392	1710	il-6 in lps	[IL-6 in LPS]	0.0	3	1	1	1
131393	1710	importance of the atg	[importance of the ATGs]	0.0	4	2	2	1
131394	1710	represses,	[represses,]	0.0	1	1	1	1
131395	1710	DNA fragment position	[DNA fragment positions]	0.0	3	1	1	1
131396	1710	processing of NF-kappa b activator precursor	[processing of NF-kappa B activator precursor]	0.0	6	1	1	1
131397	1710	intracellular level of c-fo	[intracellular levels of c-fos]	0.0	4	1	1	1
131398	1710	termini of the mrna	[termini of the mRNA]	0.0	4	1	1	1
131399	1710	use high throughput screen of broth	[using high throughput screening of broths]	0.0	6	1	1	1
131400	1710	use a lymphoma-derived hybridoma pc60	[using a lymphoma-derived hybridoma PC60]	0.0	5	1	1	1
131401	1710	major constitutive dnase site	[major constitutive DNase site]	0.0	4	1	1	1
131402	1710	terminal complement	[terminal complement]	0.0	2	1	1	1
131403	1710	enhance(	[enhance(s)]	0.0	1	1	1	1
131404	1710	indicator for local control	[indicator for local control]	0.0	4	1	1	1
131405	1710	GHF-1/Pit-1 binding site	[GHF-1/Pit-1 binding site]	0.0	3	1	1	1
131406	1710	other populations, include some group	[other populations, including some groups]	0.0	5	1	1	1
131407	1710	include ap-1	[including AP-1]	0.0	2	1	1	1
131408	1710	human fluid specimen	[Human fluid specimens]	0.0	3	1	1	1
131409	1710	result from delta psi(m) collapse	[resulting from delta psi(m) collapse]	0.0	5	1	1	1
131410	1710	hiv-1 clone	[HIV-1 clone]	0.0	2	1	1	1
131411	1710	4c DNA content	[4C DNA content]	0.0	3	1	1	1
131412	1710	return after 24 P.	[returning after 24 h.]	0.0	4	1	1	1
131413	1710	basic protein in the regulation	[basic proteins in the regulation]	0.0	5	1	1	1
131414	1710	macrophage migration related protein	[Macrophage migration related protein]	0.0	4	1	1	1
131415	1710	protein ebna2-ebna6 in lymphoma	[proteins EBNA2-EBNA6 in lymphoma]	0.0	4	1	1	1
131416	1710	addition in dna-transfected u-937 cell	[addition in DNA-transfected U-937 cells]	0.0	5	1	1	1
131417	1710	b function	[B function]	0.0	2	1	1	1
131418	1710	13-acetate/phytohemagglutinin-stimulated jurkat T cell	[13-acetate/phytohemagglutinin-stimulated Jurkat T cells]	0.0	4	1	1	1
131419	1710	d variant cell	[D variant cells]	0.0	3	1	1	1
131420	1710	active promoter	[active promoter]	0.0	2	1	1	1
131421	1710	growth of monocyte-type colony	[growth of monocyte-type colonies]	0.0	4	1	1	1
131422	1710	population killer T/NK population	[populations killer T/NK populations]	0.0	4	1	1	1
131423	1710	absence in the TF complex	[absence in the TF complex]	0.0	5	1	1	1
131424	1710	direct repeat of 21 bp	[direct repeats of 21 bp]	0.0	5	1	1	1
131425	1710	express receptor mutant Ba/F3	[expressing receptor mutants Ba/F3]	0.0	4	1	1	1
131426	1710	25 h (viability great	[25 h (viability greater]	0.0	4	1	1	1
131427	1710	DNaseI	[DNaseI]	0.0	1	1	1	1
131428	1710	prominent level	[prominent levels]	0.0	2	1	1	1
131429	1710	instead a marker	[instead a marker(s)]	0.0	3	1	1	1
131430	1710	pentazocine a inhibitor	[pentazocine a inhibitor]	0.0	3	1	1	1
131431	1710	moreover, virus enhancer activity	[Moreover, virus enhancer activity]	0.0	4	1	1	1
131432	1710	receptor-ligand pair	[receptor-ligand pair]	0.0	2	1	1	1
131433	1710	MHC class peptide	[MHC class peptide]	0.0	3	1	1	1
131434	1710	recombinant alphaiibbeta3	[recombinant alphaIIbbeta3]	0.0	2	1	1	1
131435	1710	dna-binding phosphoprotein effect	[DNA-binding phosphoproteins effects]	0.0	3	1	1	1
131436	1710	concentration of antioxidant --including acid	[concentrations of antioxidants --including acid]	0.0	5	1	1	1
131437	1710	expression of a negative form	[expression of a negative form]	0.0	5	1	1	1
131438	1710	antigen ea capsid antigen	[antigen EA capsid antigen]	0.0	4	1	1	1
131439	1710	symbiotic, relationship in human tonsil	[symbiotic, relationship in human tonsils]	0.0	5	1	1	1
131440	1710	non-cytotoxic dose (>10 microm	[non-cytotoxic doses (>10 microM]	0.0	4	1	1	1
131441	1710	induction kappa B/Rel activity lymphocyte	[Induction kappa B/Rel activity lymphocytes]	0.0	5	1	1	1
131442	1710	few cd8(+)-t-cell epitope	[few CD8(+)-T-cell epitopes]	0.0	3	1	1	1
131443	1710	Bcl-2 a repressor	[Bcl-2 a repressor]	0.0	3	1	1	1
131444	1710	t-lymphoblastoid	[T-lymphoblastoid]	0.0	1	1	1	1
131445	1710	first generation compound	[first generation compound]	0.0	3	1	1	1
131446	1710	t-helper cell dysfunction	[T-helper cell dysfunctions]	0.0	3	1	1	1
131447	1710	15 minute of addition	[15 min of addition]	0.0	4	1	1	1
131448	1710	total population possible killer population	[total populations possible killer populations]	0.0	5	1	1	1
131449	1710	mediator lipopolysaccharide	[mediators lipopolysaccharide]	0.0	2	1	1	1
131450	1710	create responder	[creating responders]	0.0	2	1	1	1
131451	1710	regulate the intensity	[regulating the intensity]	0.0	3	1	1	1
131452	1710	a/r insult	[A/R insult]	0.0	2	1	1	1
131453	1710	osteoclast differentiation factor	[osteoclast differentiation factor]	0.0	3	1	1	1
131454	1710	camp-response element present	[cAMP-response element present]	0.0	3	1	1	1
131455	1710	cell from subject	[cells from subjects]	0.0	3	1	1	1
131456	1710	death-inducing protein	[death-inducing protein]	0.0	2	1	1	1
131457	1710	human t-cell leukemia virus-infected T cell	[human T-cell leukemia virus-infected T cells]	0.0	6	1	1	1
131458	1710	u-937 cell differentiation	[U-937 cell differentiation]	0.0	3	1	1	1
131459	1710	postanoxic huvec to neutrophil	[postanoxic HUVECs to neutrophils]	0.0	4	1	1	1
131460	1710	correlation of method	[correlation of methods]	0.0	3	1	1	1
131461	1710	t-cell-restricted marker	[T-cell-restricted markers]	0.0	2	1	1	1
131462	1710	human growth	[human growth]	0.0	2	1	1	1
131463	1710	Thr729-Leu765	[Thr729-Leu765]	0.0	1	1	1	1
131464	1710	expression in erythroid cell line	[expression in erythroid cell lines]	0.0	5	1	1	1
131465	1710	adhesin	[adhesins]	0.0	1	1	1	1
131466	1710	subunit CBF alpha 2-451	[subunit CBF alpha 2-451]	0.0	4	1	1	1
131467	1710	mutants, include strain	[mutants, including strain]	0.0	3	1	1	1
131468	1710	t-cell prolymphocytic leukemia T-PLL a form	[T-cell prolymphocytic leukemia T-PLL a form]	0.0	6	1	1	1
131469	1710	detectable tal1 rearrangement	[detectable TAL1 rearrangements]	0.0	3	1	1	1
131470	1710	understanding at this important stage	[understanding at this important stage]	0.0	5	1	1	1
131471	1710	conventional b-2 cell	[conventional B-2 cells]	0.0	3	1	1	1
131472	1710	possibly transcription factor	[possibly transcription factors]	0.0	3	1	1	1
131473	1710	5.54 micromol/L	[5.54 micromol/L]	0.0	2	1	1	1
131474	1710	3-methylcholanthrene rat liver microsome	[3-methylcholanthrene rat liver microsomes]	0.0	4	1	1	1
131475	1710	lead by TNF alpha	[leading by TNF alpha]	0.0	4	1	1	1
131476	1710	t-cell leukemia a rare form	[T-cell leukemia a rare form]	0.0	5	1	1	1
131477	1710	tafii105 mrna	[TAFII105 mRNA]	0.0	2	1	1	1
131478	1710	Furthermore, introduction of gata-1	[Furthermore, introduction of GATA-1]	0.0	4	1	1	1
131479	1710	region in the LMP1 c-terminus	[region in the LMP1 C-terminus]	0.0	5	1	1	1
131480	1710	site-directed mutagenesis of HSs	[site-directed mutagenesis of HSs]	0.0	4	1	1	1
131481	1710	precursor cell line u937	[precursor cell lines U937]	0.0	4	1	1	1
131482	1710	expression from different REV ltr	[expression from different REV LTRs]	0.0	5	1	1	1
131483	1710	early gene c-fo	[early gene c-fos]	0.0	3	2	2	1
131484	1710	profile of gene on chromosome	[profiles of genes on chromosome]	0.0	5	1	1	1
131485	1710	related (if	[related (if]	0.0	2	1	1	1
131486	1710	four stimulus in t-cell	[four stimuli in T-cells]	0.0	4	1	1	1
131487	1710	normal occupation	[normal occupation]	0.0	2	1	1	1
131488	1710	Bcl-6 expression in hyperplasia heterogeneity	[Bcl-6 expression in hyperplasia heterogeneity]	0.0	5	1	1	1
131489	1710	T/NK cell	[T/NK cells]	0.0	2	1	1	1
131490	1710	cyclosporin-sensitive, modification	[cyclosporin-sensitive, modification]	0.0	2	1	1	1
131491	1710	T helper (th) cell	[T helper (TH) cells]	0.0	4	1	1	1
131492	1710	class ii gene regulation	[class II gene regulation]	0.0	4	1	1	1
131493	1710	proteolysis during extraction	[proteolysis during extraction]	0.0	3	1	1	1
131494	1710	use a form of binding partner,	[using a form of binding partner,]	0.0	6	1	1	1
131495	1710	absence with CD+8 t-cell number	[absence with CD+8 T-cell numbers]	0.0	5	1	1	1
131496	1710	activation of Stat in erythroid progenitor	[Activation of Stat in erythroid progenitors]	0.0	6	1	1	1
131497	1710	light of previous work	[light of previous work]	0.0	4	1	1	1
131498	1710	Study of the action	[Studies of the actions]	0.0	4	1	1	1
131499	1710	DNase I site DHS mapping	[DNase I site DHS mapping]	0.0	5	1	1	1
131500	1710	TH effect	[TH effect]	0.0	2	1	1	1
131501	1710	age-related decrease by T cell	[Age-related decreases by T cells]	0.0	5	1	1	1
131502	1710	enhancer-binding protein lef-1	[enhancer-binding proteins LEF-1]	0.0	3	1	1	1
131503	1710	decrease protein level	[decrease protein levels]	0.0	3	1	1	1
131504	1710	activity of the raralpha	[activity of the RARalpha]	0.0	4	1	1	1
131505	1710	more interestingly, transfection experiment	[More interestingly, transfection experiments]	0.0	4	1	1	1
131506	1710	hypophosphatemic ricket	[hypophosphatemic rickets]	0.0	2	2	2	1
131507	1710	new regulatory region	[new regulatory regions]	0.0	3	1	1	1
131508	1710	cell a component	[cells a component]	0.0	3	1	1	1
131509	1710	response to stimuli, include phytohemagglutinin	[response to stimuli, including phytohemagglutinin]	0.0	5	1	1	1
131510	1710	expression of gene in lymphoid cell	[expression of genes in lymphoid cells]	0.0	6	1	1	1
131511	1710	ductal sample	[ductal samples]	0.0	2	1	1	1
131512	1710	treatment of hl-60 cell with pdbu	[treatment of HL-60 cells with PDBu]	0.0	6	1	1	1
131513	1710	new controversies, of the troublesome	[new controversies, of the troublesome]	0.0	5	1	1	1
131514	1710	basic potential phosphoprotein	[basic potential phosphoprotein]	0.0	3	1	1	1
131515	1710	trough value hr.	[trough values hr.]	0.0	3	1	1	1
131516	1710	monocyte lineage.	[monocyte lineage.]	0.0	2	1	1	1
131517	1710	major developments, include the identification	[Major developments, including the identification]	0.0	5	1	1	1
131518	1710	unprecedented fashion.	[unprecedented fashion.]	0.0	2	1	1	1
131519	1710	response to the signal	[response to the signal]	0.0	4	1	1	1
131520	1710	cell selectivity	[cell selectivity]	0.0	2	1	1	1
131521	1710	SKW 6.4 cell 0.011	[SKW 6.4 cells 0.001),]	0.0	4	1	1	1
131522	1710	expression level characteristic	[expression level characteristic]	0.0	3	1	1	1
131523	1710	two unique pml/ raralpha	[two unique PML/ RARalpha]	0.0	4	1	1	1
131524	1710	t3 receptor	[T3 receptor]	0.0	2	1	1	1
131525	1710	inactive x-chromosome material	[inactive X-chromosome material]	0.0	3	1	1	1
131526	1710	cleavage by cathepsin b	[cleavage by cathepsin B]	0.0	4	1	1	1
131527	1710	cyclosporin A atherosclerotic lesion formation	[cyclosporin A atherosclerotic lesion formation]	0.0	5	1	1	1
131528	1710	one cofactor	[One cofactor]	0.0	2	1	1	1
131529	1710	isolate KMT	[isolates KMT]	0.0	2	1	1	1
131530	1710	thus, select genetic aberration	[Thus, select genetic aberrations]	0.0	4	1	1	1
131531	1710	molecule-1 icam-1	[molecule-1 ICAM-1]	0.0	2	1	1	1
131532	1710	deterioration in immunodeficiency virus type infection	[deterioration in immunodeficiency virus type infection]	0.0	6	1	1	1
131533	1710	half of the expansion	[half of the expansions]	0.0	4	1	1	1
131534	1710	cell-type distribution	[cell-type distribution]	0.0	2	1	1	1
131535	1710	acute myelogenous leukemia evi1 fusion	[acute myelogenous leukemia EVI1 fusions]	0.0	5	1	1	1
131536	1710	NF-kappa b related polypeptide range	[NF-kappa B related polypeptides ranging]	0.0	5	1	1	1
131537	1710	nm for hydrocortisone	[nM for hydrocortisone]	0.0	3	1	1	1
131538	1710	tissue-specific regulatory DNA element	[tissue-specific regulatory DNA element]	0.0	4	1	1	1
131539	1710	kappa b gamma isoform	[kappa B gamma isoforms]	0.0	4	2	2	1
131540	1710	tnf-alpha T	[TNF-alpha T]	0.0	2	1	1	1
131541	1710	regulation of the activation	[regulation of the activation]	0.0	4	1	1	1
131542	1710	late G1-to- phase	[late G1-to-S phase]	0.0	3	1	1	1
131543	1710	T cell proliferation in g1	[T cell proliferation in G1]	0.0	5	1	1	1
131544	1710	major focus	[major focus]	0.0	2	1	1	1
131545	1710	stimulation a CD3 -dependent event	[stimulation a CD3 -dependent event]	0.0	5	1	1	1
131546	1710	complex (MHC) class ii promoter	[complex (MHC) class II promoters]	0.0	5	1	1	1
131547	1710	present study use antibody	[present study using antibodies]	0.0	4	1	1	1
131548	1710	nf-kappab promoter activity	[NF-kappaB promoter activity]	0.0	3	1	1	1
131549	1710	property of RU486	[properties of RU486]	0.0	3	1	1	1
131550	1710	weight in the range of 36-41	[weights in the range of 36-41]	0.0	6	1	1	1
131551	1710	beta 1 integrin	[beta 1 integrins]	0.0	3	1	1	1
131552	1710	EMBO j.16:332-342,	[EMBO J.16:332-342,]	0.0	2	1	1	1
131553	1710	relative molecular mass (50k)	[relative molecular mass (50K)]	0.0	4	1	1	1
131554	1710	facilitate entry of hiv cell	[facilitating entry of HIV cells]	0.0	5	1	1	1
131555	1710	reports,	[reports,]	0.0	1	1	1	1
131556	1710	activation of tnf-alpha gene	[activation of TNF-alpha gene]	0.0	4	1	1	1
131557	1710	YY1 transcription	[YY1 transcription]	0.0	2	1	1	1
131558	1710	sequence identity in the two-third	[sequence identity in the two-thirds]	0.0	5	1	1	1
131559	1710	alpha,25-dihydroxyvitamin D3 in human lymphocyte	[alpha,25-dihydroxyvitamin D3 in human lymphocytes]	0.0	5	1	1	1
131560	1710	Glucocorticosteroid receptor	[Glucocorticosteroid receptors]	0.0	2	1	1	1
131561	1710	rat embryonal ref52 cell	[rat embryonal REF52 cells]	0.0	4	1	1	1
131562	1710	cytokine of kda	[cytokine of kDa]	0.0	3	1	1	1
131563	1710	amino acid tramp	[amino acid TRAMP]	0.0	3	1	1	1
131564	1710	suggest a common property of gene	[suggesting a common property of genes]	0.0	6	1	1	1
131565	1710	biochemical study	[biochemical studies]	0.0	2	2	2	1
131566	1710	activator site act-1	[activator site Act-1]	0.0	3	1	1	1
131567	1710	presumably through opening	[presumably through opening]	0.0	3	1	1	1
131568	1710	region coding of the genes,	[regions coding of the genes,]	0.0	5	1	1	1
131569	1710	down-regulation in cell	[down-regulation in cells]	0.0	3	1	1	1
131570	1710	immunodeficiency virus in vitro.	[immunodeficiency virus in vitro.]	0.0	4	1	1	1
131571	1710	detailed analysis of a mutation	[detailed analysis of a mutation]	0.0	5	1	1	1
131572	1710	gc at therapeutic concentration	[GC at therapeutic concentrations]	0.0	4	1	1	1
131573	1710	expose vein cell huvec	[Exposing vein cells HUVECs]	0.0	4	1	1	1
131574	1710	kda p65 polypeptide	[kDa p65 polypeptides]	0.0	3	1	1	1
131575	1710	induction follow differentiation of a monocyte	[induction following differentiation of a monocyte]	0.0	6	1	1	1
131576	1710	mitogenic stimulation as a parameter	[mitogenic stimulation as a parameter]	0.0	5	1	1	1
131577	1710	demonstrate coupling	[demonstrating coupling]	0.0	2	1	1	1
131578	1710	ebv trans-activator	[EBV trans-activator]	0.0	2	1	1	1
131579	1710	cycle reactivity rarely undetectable	[cycle reactivities rarely undetectable]	0.0	4	1	1	1
131580	1710	region critical	[region critical]	0.0	2	1	1	1
131581	1710	cell c-Myb reporter construct	[cells c-Myb reporter constructs]	0.0	4	1	1	1
131582	1710	ten patient with affinity	[Ten patients with affinity]	0.0	4	1	1	1
131583	1710	type EBS during the cycle	[type EBS during the cycle]	0.0	5	1	1	1
131584	1710	removal of the tnf-alpha	[removal of the TNF-alpha]	0.0	4	1	1	1
131585	1710	Bacterial lipopolysaccharide immune response	[Bacterial lipopolysaccharide immune responses]	0.0	4	1	1	1
131586	1710	human lymphocytic leukemia	[human lymphocytic leukemias]	0.0	3	1	1	1
131587	1710	T lymphocyte subset from the blood	[T lymphocyte subsets from the blood]	0.0	6	1	1	1
131588	1710	135(oh)2d3 receptor on lymphocyte	[1,25(OH)2D3 receptors on lymphocytes]	0.0	4	1	1	1
131589	1710	identification as the positive element	[identification as the positive elements]	0.0	5	1	1	1
131590	1710	component of cell death	[component of cell death]	0.0	4	1	1	1
131591	1710	amino acid 425 of vp16	[amino acids 425 of VP16]	0.0	5	1	1	1
131592	1710	ligand, start after stimulation.	[ligand, starting after stimulation.]	0.0	4	1	1	1
131593	1710	involve inhibition of nf-kappab activation	[involving inhibition of NF-kappaB activation]	0.0	5	1	1	1
131594	1710	specific activation signal	[specific activation signals]	0.0	3	1	1	1
131595	1710	microm in om10.1 cell	[microM in OM10.1 cells]	0.0	4	1	1	1
131596	1710	dose of desferrioxamine	[doses of desferrioxamine]	0.0	3	1	1	1
131597	1710	represent the spectrum	[representing the spectrum]	0.0	3	1	1	1
131598	1710	SH2 domain of SHP1	[SH2 domains of SHP1]	0.0	4	1	1	1
131599	1710	about 60 bp	[about 60 bp]	0.0	3	1	1	1
131600	1710	four control subject	[four control subjects]	0.0	3	1	1	1
131601	1710	128 bp of upstream sequence	[128 bp of upstream sequence]	0.0	5	1	1	1
131602	1710	antiinflammatory, activity	[antiinflammatory, activities]	0.0	2	1	1	1
131603	1710	enhanced, follow	[enhanced, following]	0.0	2	1	1	1
131604	1710	identification of stat protein	[Identification of Stat proteins]	0.0	4	1	1	1
131605	1710	classical p50-p65 complex	[classical p50-p65 complex]	0.0	3	1	1	1
131606	1710	distinct cis-acting element	[distinct cis-acting elements]	0.0	3	1	1	1
131607	1710	uptake of 3h-labelled 135(oh)2d3	[uptake of 3H-labelled 1,25(OH)2D3]	0.0	4	1	1	1
131608	1710	two glucocorticoid binding site	[Two glucocorticoid binding sites]	0.0	4	2	2	1
131609	1710	distinct receptor on T lymphocyte	[distinct receptors on T lymphocytes]	0.0	5	1	1	1
131610	1710	acute leukemic (aml) blast	[acute leukemic (AML) blasts]	0.0	4	1	1	1
131611	1710	hypermutation mechanism active	[hypermutation mechanism active]	0.0	3	1	1	1
131612	1710	glucocorticoid such as budesonide	[glucocorticoids such as budesonide]	0.0	4	1	1	1
131613	1710	unrearranged ch gene	[unrearranged CH genes]	0.0	3	1	1	1
131614	1710	primary resistance	[primary resistance]	0.0	2	1	1	1
131615	1710	regulation role of multiple sites.	[regulation role of multiple sites.]	0.0	5	1	1	1
131616	1710	include 3 kb	[including 3 kb]	0.0	3	1	1	1
131617	1710	Oct-2 mrna induction	[Oct-2 mRNA induction]	0.0	3	1	1	1
131618	1710	immunosuppressive therapy	[immunosuppressive therapies]	0.0	2	1	1	1
131619	1710	involve the sphingomyelinase	[involving the sphingomyelinase]	0.0	3	1	1	1
131620	1710	common condition	[common condition]	0.0	2	1	1	1
131621	1710	12-o-tetradecanoylphorbol-13-acetate represses, erythroid-specific gene expression	[12-O-tetradecanoylphorbol-13-acetate represses, erythroid-specific gene expression]	0.0	5	1	1	1
131622	1710	vivo mechanism	[vivo mechanisms]	0.0	2	1	1	1
131623	1710	NFATp/AP-1 composite element	[NFATp/AP-1 composite elements]	0.0	3	1	1	1
131624	1710	creatininemia	[creatininemia]	0.0	1	1	1	1
131625	1710	class transcription	[class transcription]	0.0	2	1	1	1
131626	1710	trans-disulfide	[trans-disulfide]	0.0	1	1	1	1
131627	1710	member of the CREB/activating transcription factor	[members of the CREB/activating transcription factor]	0.0	6	1	1	1
131628	1710	include disease	[including diseases]	0.0	2	1	1	1
131629	1710	substantially tyrosine stat5b	[substantially tyrosine STAT5B]	0.0	3	1	1	1
131630	1710	loss of cell viability.	[loss of cell viability.]	0.0	4	1	1	1
131631	1710	5-Aminolevulinate synthase	[5-Aminolevulinate synthase]	0.0	2	1	1	1
131632	1710	clinical importance of glucocorticoid apoptosis	[clinical importance of glucocorticoid apoptosis]	0.0	5	1	1	1
131633	1710	patient with tissue diseases,	[patients with tissue diseases,]	0.0	4	1	1	1
131634	1710	poly(A)+ rna	[poly(A)+ RNAs]	0.0	2	1	1	1
131635	1710	activation in monocytic cell	[activation in monocytic cells]	0.0	4	1	1	1
131636	1710	activation, differentiation,	[activation, differentiation,]	0.0	2	1	1	1
131637	1710	CD80 cho-cd80	[CD80 CHO-CD80]	0.0	2	1	1	1
131638	1710	transcript in the absence	[transcripts in the absence]	0.0	4	1	1	1
131639	1710	interaction with sequence-specific protein	[interaction with sequence-specific proteins]	0.0	4	1	1	1
131640	1710	cell count 2-6	[cell count 2-6]	0.0	3	1	1	1
131641	1710	cell of ATL patient	[cells of ATL patients]	0.0	4	1	1	1
131642	1710	protection in the mucosa	[protection in the mucosa]	0.0	4	1	1	1
131643	1710	common element within the core	[common elements within the core]	0.0	5	1	1	1
131644	1710	hyperadhesivity of postanoxic huvec	[hyperadhesivity of postanoxic HUVECs]	0.0	4	1	1	1
131645	1710	enhancer element essential for expression	[enhancer element essential for expression]	0.0	5	1	1	1
131646	1710	treatment of nfatp	[Treatment of NFATp]	0.0	3	1	1	1
131647	1710	serine protease granzyme	[serine protease granzyme]	0.0	3	1	1	1
131648	1710	(range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564 (range,	[(range, 4484-5643), (range,]	0.0	3	1	1	1
131649	1710	inhibition of ige synthesis	[inhibition of IgE synthesis]	0.0	4	1	1	1
131650	1710	Burkitt lymphoma cell	[Burkitt lymphoma cell]	0.0	3	1	1	1
131651	1710	inhibition experiment with antagonist	[inhibition experiments with antagonists]	0.0	4	1	1	1
131652	1710	cd86 b7-2 ligand	[CD86 B7-2 ligands]	0.0	3	1	1	1
131653	1710	kinetic of virus replication	[kinetics of virus replication]	0.0	4	1	1	1
131654	1710	proximal tsp element	[proximal TSP element]	0.0	3	1	1	1
131655	1710	result in dna-binding complex	[resulting in DNA-binding complexes]	0.0	4	1	1	1
131656	1710	activate the VCAM-1 promoter	[activating the VCAM-1 promoter]	0.0	4	1	1	1
131657	1710	induction of il-8 secretion	[induction of IL-8 secretion]	0.0	4	1	1	1
131658	1710	high transcriptional activity	[high transcriptional activity]	0.0	3	1	1	1
131659	1710	transient reduction of aldosterone receptor	[transient reduction of aldosterone receptors]	0.0	5	1	1	1
131660	1710	different form of inheritance	[different forms of inheritance]	0.0	4	1	1	1
131661	1710	effect of antioxidant therapy	[effects of antioxidant therapies.]	0.0	4	1	1	1
131662	1710	BLS complementation group group b	[BLS complementation group group B]	0.0	5	1	1	1
131663	1710	purulent airway secretion	[purulent airway secretions]	0.0	3	1	1	1
131664	1710	site in the c-sis/pdgb promoter	[site in the c-sis/PDGF-B promoter]	0.0	5	1	1	1
131665	1710	gene for cytokine regulation	[genes for cytokine regulation]	0.0	4	1	1	1
131666	1710	J Immunol	[J Immunol]	0.0	2	1	1	1
131667	1710	include phorbol	[including phorbol]	0.0	2	1	1	1
131668	1710	response versus dose	[responses versus doses]	0.0	3	1	1	1
131669	1710	leukocyte protein of 76 kD	[leukocyte protein of 76 kD]	0.0	5	1	1	1
131670	1710	1, D3	[1, D3]	0.0	2	1	1	1
131671	1710	critical threshold level for gene induction	[critical threshold levels for gene induction]	0.0	6	1	1	1
131672	1710	subclone of thp-1	[subclones of THP-1]	0.0	3	1	1	1
131673	1710	regulate the distribution in cell	[regulating the distribution in cells]	0.0	5	1	1	1
131674	1710	hiv-1 pool	[HIV-1 pool]	0.0	2	1	1	1
131675	1710	element of t-cell gene	[elements of T-cell genes]	0.0	4	1	1	1
131676	1710	colony-forming unit in C/EBPalpha mouse	[colony-forming units in C/EBPalpha mice]	0.0	5	1	1	1
131677	1710	important alteration in the cells.	[important alterations in the cells.]	0.0	5	1	1	1
131678	1710	adherence of polymorphonuclear leukocyte	[adherence of polymorphonuclear leukocytes]	0.0	4	1	1	1
131679	1710	induction of cell surface expression	[induction of cell surface expression]	0.0	5	1	1	1
131680	1710	gata transcription	[GATA transcription]	0.0	2	1	1	1
131681	1710	new kappa complex	[new kappa complexes]	0.0	3	1	1	1
131682	1710	consensus sequence in the VCAM-1	[consensus sequences in the VCAM-1]	0.0	5	1	1	1
131683	1710	guamerin-derived peptide a elastase inhibitor	[guamerin-derived peptide a elastase inhibitor]	0.0	5	1	1	1
131684	1710	mutation in the coding sequence	[mutation in the coding sequence]	0.0	5	1	1	1
131685	1710	7.03 (range,	[7.03 (range,]	0.0	2	1	1	1
131686	1710	labile repressor	[labile repressor]	0.0	2	1	1	1
131687	1710	contain the il-2	[containing the IL-2]	0.0	3	1	1	1
131688	1710	h. treatment of cell	[h, treatment of cells]	0.0	4	1	1	1
131689	1710	positive transcriptional activator	[positive transcriptional activator]	0.0	3	1	1	1
131690	1710	use 15 micrograms/ml	[using 15 micrograms/ml]	0.0	3	1	1	1
131691	1710	two- to threefold increase	[two- to threefold increase]	0.0	4	1	1	1
131692	1710	undergo cell death	[undergoing cell death]	0.0	3	1	1	1
131693	1710	kappab DNA binding	[kappaB DNA binding]	0.0	3	1	1	1
131694	1710	ie, the expression	[ie, the expression]	0.0	3	1	1	1
131695	1710	g28-5	[G28-5]	0.0	1	1	1	1
131696	1710	RNAase	[RNAase]	0.0	1	1	1	1
131697	1710	IFP53 GAS	[IFP53 GAS]	0.0	2	1	1	1
131698	1710	coactivator oca-b Bob-1	[coactivator OCA-B Bob-1]	0.0	3	1	1	1
131699	1710	membrane protein (lmp) 2a mrna	[membrane protein (LMP) 2A mRNA]	0.0	5	1	1	1
131700	1710	ICAM-1 /beta -dependent fashion	[ICAM-1 /beta -dependent fashion]	0.0	4	1	1	1
131701	1710	weak phosphorylation	[weak phosphorylation]	0.0	2	1	1	1
131702	1710	activation response-1 gene expression	[Activation response-1 gene expression]	0.0	4	1	1	1
131703	1710	proteolysis of p65	[proteolysis of p65]	0.0	3	1	1	1
131704	1710	female aged between 8 years,	[females aged between 8 years,]	0.0	5	1	1	1
131705	1710	macrophage CSF m-csf gene	[macrophage CSF M-CSF gene]	0.0	4	1	1	1
131706	1710	subtype of acid receptor RAR	[subtypes of acid receptors RAR]	0.0	5	1	1	1
131707	1710	transcription of immunodeficiency virus	[transcription of immunodeficiency virus]	0.0	4	1	1	1
131708	1710	amplify expression of receptor	[amplifying expression of receptor]	0.0	4	1	1	1
131709	1710	morphology, immunophenotype,	[morphology, immunophenotype,]	0.0	2	1	1	1
131710	1710	eosinophil protein ecp	[eosinophil protein ECP]	0.0	3	1	1	1
131711	1710	nuclear extract of u937 cell	[nuclear extracts of U937 cells]	0.0	5	1	1	1
131712	1710	circulate filarial t-cell	[circulating filarial T-cells]	0.0	3	1	1	1
131713	1710	gene, two transcript	[gene, two transcripts]	0.0	3	1	1	1
131714	1710	study the regulation	[studying the regulation]	0.0	3	1	1	1
131715	1710	signal transmission pathway	[signal transmission pathways]	0.0	3	1	1	1
131716	1710	activate transcription from the long repeat	[activating transcription from the long repeat]	0.0	6	1	1	1
131717	1710	high millileter at P;	[high ml at h;]	0.0	4	1	1	1
131718	1710	effect of gamma-ifn signal	[effects of gamma-IFN signaling]	0.0	4	1	1	1
131719	1710	activation-induced change	[activation-induced changes]	0.0	2	1	1	1
131720	1710	bind transcriptional property	[binding transcriptional properties]	0.0	3	1	1	1
131721	1710	32p-labeled probe	[32P-labeled probe]	0.0	2	1	1	1
131722	1710	genomic organisation	[genomic organisation]	0.0	2	1	1	1
131723	1710	applicability, allow rapid testing	[applicability, allowing rapid testing]	0.0	4	1	1	1
131724	1710	Epstein-Barr virus EBV replicative gene expression	[Epstein-Barr virus EBV replicative gene expression]	0.0	6	1	1	1
131725	1710	classical features:	[classical features:]	0.0	2	1	1	1
131726	1710	link between the efficiency	[links between the efficiency]	0.0	4	1	1	1
131727	1710	Computer	[Computer]	0.0	1	1	1	1
131728	1710	identification of several transcription factor	[identification of several transcription factors]	0.0	5	1	1	1
131729	1710	hiv long repeat -cat construct	[HIV long repeat -CAT constructs]	0.0	5	1	1	1
131730	1710	human recessive disease	[human recessive disease]	0.0	3	1	1	1
131731	1710	enzyme participate	[enzymes participating]	0.0	2	1	1	1
131732	1710	(7/8	[(7/8]	0.0	1	1	1	1
131733	1710	augment il-2 promoter activity	[augmenting IL-2 promoter activity]	0.0	4	1	1	1
131734	1710	transcription of 25-hydroxyvitamin D3 24-hydroxylase	[transcription of 25-hydroxyvitamin D3 24-hydroxylase]	0.0	5	1	1	1
131735	1710	coat protein of ebv	[coat protein of EBV]	0.0	4	1	1	1
131736	1710	region of low potential	[Regions of low potential]	0.0	4	1	1	1
131737	1710	prolyl isomerase inhibitor	[prolyl isomerase inhibitors]	0.0	3	1	1	1
131738	1710	cluster of t-cell translocation	[cluster of T-cell translocations]	0.0	4	1	1	1
131739	1710	molecule per cell.	[molecules per cell.]	0.0	3	1	1	1
131740	1710	dexamethasone suppressibility of incorporation of [3h]thymidine	[dexamethasone suppressibility of incorporation of [3H]thymidine]	0.0	6	1	1	1
131741	1710	little effect on the inducibility	[little effect on the inducibility]	0.0	5	1	1	1
131742	1710	rhabdomyosarcoma cell	[rhabdomyosarcoma cells]	0.0	2	1	1	1
131743	1710	lymphocyte binding,	[lymphocyte binding,]	0.0	2	1	1	1
131744	1710	low content	[low content]	0.0	2	1	1	1
131745	1710	e(2) murine	[E(2) murine]	0.0	2	1	1	1
131746	1710	/mek	[/MEK]	0.0	1	1	1	1
131747	1710	glycerol density	[glycerol density]	0.0	2	1	1	1
131748	1710	ara-c on sphingomyelinase	[Ara-C on sphingomyelinase]	0.0	3	1	1	1
131749	1710	class protein	[class proteins]	0.0	2	1	1	1
131750	1710	emphasize the potential of soluble antioxidant	[emphasizing the potential of soluble antioxidants]	0.0	6	1	1	1
131751	1710	similar time course	[similar time course]	0.0	3	1	1	1
131752	1710	t-lymphocyte from VZV human donor	[T-lymphocytes from VZV human donors]	0.0	5	1	1	1
131753	1710	grbeta	[GRbeta]	0.0	1	1	1	1
131754	1710	subgroups, protein	[subgroups, proteins]	0.0	2	1	1	1
131755	1710	receptor on rest b cell	[receptor on resting B cells]	0.0	5	1	1	1
131756	1710	interleukin 3 IL3 gene expression	[interleukin 3 IL3 gene expression]	0.0	5	1	1	1
131757	1710	pbmc of woman	[PBMC of women]	0.0	3	1	1	1
131758	1710	latter.	[latter.]	0.0	1	1	1	1
131759	1710	therapeutic potential for pathology	[therapeutic potential for pathologies]	0.0	4	1	1	1
131760	1710	ligands, glucocorticosteroids	[ligands, glucocorticosteroids]	0.0	2	1	1	1
131761	1710	hyperparathyroidism secondary to chronic failure	[hyperparathyroidism secondary to chronic failure]	0.0	5	1	1	1
131762	1710	infect baboon cercopithicine herpesvirus herpesvirus papio	[infecting baboons cercopithicine herpesvirus herpesvirus papio]	0.0	6	1	1	1
131763	1710	hypersensitive site 4481	[hypersensitive site 4481]	0.0	3	1	1	1
131764	1710	32 aged person	[32 aged persons]	0.0	3	1	1	1
131765	1710	system study the mechanism	[system studying the mechanisms]	0.0	4	1	1	1
131766	1710	favorable course (p 0.05, chi2	[favorable course (P 0.05, chi2]	0.0	5	1	1	1
131767	1710	30 min/exposure,	[30 min/exposure,]	0.0	2	1	1	1
131768	1710	only 10(-12) g/g of mrna	[only 10(-12) g/g of mRNA]	0.0	5	1	1	1
131769	1710	nfat -dependent activation	[NFAT -dependent activation]	0.0	3	1	1	1
131770	1710	rcgcrygcgy	[RCGCRYGCGY]	0.0	1	1	1	1
131771	1710	intracellular activity of this enzyme	[intracellular activity of this enzyme]	0.0	5	1	1	1
131772	1710	untreated thp-1	[untreated THP-1]	0.0	2	1	1	1
131773	1710	haematological remission	[haematological remission]	0.0	2	2	2	1
131774	1710	receptor activator a member	[receptor activator a member]	0.0	4	1	1	1
131775	1710	follow glucocorticoid treatment of cell	[Following glucocorticoid treatment of cells]	0.0	5	1	1	1
131776	1710	plasma interleukin-1	[plasma interleukin-1]	0.0	2	2	2	1
131777	1710	follow engagement (e.g. cell-to-cell	[following engagement (e.g. cell-to-cell]	0.0	4	1	1	1
131778	1710	NF kappab family protein	[NF kappaB family proteins]	0.0	4	1	1	1
131779	1710	DSL family	[DSL family]	0.0	2	1	1	1
131780	1710	transplantation of stem cell	[transplantation of stem cells]	0.0	4	1	1	1
131781	1710	evidence a role for NF-kappaB	[evidencing a role for NF-kappaB]	0.0	5	1	1	1
131782	1710	level of nuclear	[levels of nuclear]	0.0	3	1	1	1
131783	1710	icam-1 gene expression	[ICAM-1 gene expression]	0.0	3	1	1	1
131784	1710	putative teratogenic effect	[putative teratogenic effects]	0.0	3	1	1	1
131785	1710	CD40 signal cascade	[CD40 signaling cascade]	0.0	3	1	1	1
131786	1710	protection against a apoptotic signal	[protection against an apoptotic signal]	0.0	5	1	1	1
131787	1710	leukotriene b4 generation by human neutrophil	[leukotriene B4 generation by human neutrophils]	0.0	6	1	1	1
131788	1710	nuclear morphology	[nuclear morphology]	0.0	2	1	1	1
131789	1710	host range	[host range,]	0.0	2	1	1	1
131790	1710	leukemia particularly the variant	[leukemia particularly the variant]	0.0	4	1	1	1
131791	1710	early-lytic-cycle protein	[early-lytic-cycle protein]	0.0	2	1	1	1
131792	1710	three yeast polypeptide	[three yeast polypeptides]	0.0	3	1	1	1
131793	1710	functionally distinct stat5 protein	[functionally distinct STAT5 proteins]	0.0	4	1	1	1
131794	1710	ratio (m/z) of 793	[ratio (m/z) of 793]	0.0	4	1	1	1
131795	1710	EBV antigen	[EBV antigen]	0.0	2	1	1	1
131796	1710	nuclear staining in the lining	[nuclear staining in the lining]	0.0	5	1	1	1
131797	1710	1 alpha,25-dihydroxyvitamin D3 differentiation	[1 alpha,25-dihydroxyvitamin D3 differentiation]	0.0	4	1	1	1
131798	1710	role for acidosis	[role for acidosis]	0.0	3	1	1	1
131799	1710	sensitive myelogenous leukemia patient	[sensitive myelogenous leukemia patients]	0.0	4	1	1	1
131800	1710	also constitutive hiv-enhancer activity	[also constitutive HIV-enhancer activity]	0.0	4	1	1	1
131801	1710	transcription of this gene	[transcription of this gene]	0.0	4	1	1	1
131802	1710	behaviour of aldosterone	[behaviours of aldosterone]	0.0	3	1	1	1
131803	1710	myeloid zinc finger protein	[myeloid zinc finger protein]	0.0	4	1	1	1
131804	1710	primary ovarian carcinoma patient	[primary ovarian carcinoma patients]	0.0	4	1	1	1
131805	1710	aberrant expression gene	[aberrant expression gene]	0.0	3	1	1	1
131806	1710	two other nonsteroidal anti-inflammatory drug	[two other nonsteroidal anti-inflammatory drugs]	0.0	5	1	1	1
131807	1710	cortisol plasma level	[cortisol plasma levels]	0.0	3	1	1	1
131808	1710	induction by C. neoforman	[Induction by C. neoformans]	0.0	4	1	1	1
131809	1710	tandem zinc-finger sequence	[tandem zinc-finger sequences]	0.0	3	1	1	1
131810	1710	overexpression of retinoic acid receptor alpha	[overexpression of retinoic acid receptor alpha]	0.0	6	1	1	1
131811	1710	human th2 line	[human Th2 lines]	0.0	3	1	1	1
131812	1710	burst response of blood leukocyte	[burst response of blood leukocytes]	0.0	5	1	1	1
131813	1710	signal event include the activation	[signaling events including the activation]	0.0	5	1	1	1
131814	1710	Simon	[Simon]	0.0	1	1	1	1
131815	1710	putative homolog	[putative homolog]	0.0	2	1	1	1
131816	1710	low the/thf n: 1.87+/-0.36)	[low THE/THF N: 1.87+/-0.36)]	0.0	4	1	1	1
131817	1710	e1a- adenovirus	[E1a- adenovirus]	0.0	2	1	1	1
131818	1710	deranged cholesterol homeostasis	[Deranged cholesterol homeostasis]	0.0	3	1	1	1
131819	1710	chicken erythrocyte factor (apparent mass,	[chicken erythrocyte factor (apparent mass,]	0.0	5	1	1	1
131820	1710	T cell-specific transacting factor	[T cell-specific transacting factors]	0.0	4	1	1	1
131821	1710	most lps	[most LPS]	0.0	2	1	1	1
131822	1710	change in p130 phosphorylation	[change in p130 phosphorylation]	0.0	4	1	1	1
131823	1710	ccaat enhancer	[CCAAT enhancer]	0.0	2	1	1	1
131824	1710	G1 phase of gene promoter	[G1 phases of gene promoters]	0.0	5	1	1	1
131825	1710	sequencing of pcr product	[sequencing of PCR products]	0.0	4	1	1	1
131826	1710	(except in patient	[(except in patient]	0.0	3	1	1	1
131827	1710	translocation in the tissue	[translocation in the tissue]	0.0	4	1	1	1
131828	1710	advanced failure	[advanced failure]	0.0	2	1	1	1
131829	1710	10 hiv-infected patient with affinity	[10 HIV-infected patients with affinity]	0.0	5	1	1	1
131830	1710	role regulate gene expression	[role regulating gene expression]	0.0	4	1	1	1
131831	1710	overexpression of alg-4 transcription of fasl	[Overexpression of ALG-4 transcription of FasL]	0.0	6	1	1	1
131832	1710	clinical stage I-II patient	[clinical Stage I-II patients]	0.0	4	1	1	1
131833	1710	other protein include the product	[other proteins including the products]	0.0	5	1	1	1
131834	1710	compound aurothioglucose	[compound aurothioglucose]	0.0	2	1	1	1
131835	1710	affect elongation more	[affecting elongation more]	0.0	3	1	1	1
131836	1710	use cos cell	[using COS cells]	0.0	3	1	1	1
131837	1710	29.9% cd3+ cell (2.2%	[29.9% CD3+ cells (2.2%]	0.0	4	1	1	1
131838	1710	presentation in comparison to HLA dqa1*0201/dqb1*0201	[presentation in comparison to HLA DQA1*0201/DQB1*0201]	0.0	6	1	1	1
131839	1710	contain bp of 5'-flanking sequence	[containing bp of 5'-flanking sequences]	0.0	5	1	1	1
131840	1710	domain POUs	[domain POUs]	0.0	2	1	1	1
131841	1710	Helenalin a anti-inflammatory sesquiterpene lactone	[Helenalin an anti-inflammatory sesquiterpene lactone]	0.0	5	1	1	1
131842	1710	anti- tat antibody	[anti- Tat antibody]	0.0	3	1	1	1
131843	1710	from T cell	[from T cells]	0.0	3	1	1	1
131844	1710	produce a stable divergence	[producing a stable divergence]	0.0	4	1	1	1
131845	1710	hemopoietic progenitor	[hemopoietic progenitors]	0.0	2	1	1	1
131846	1710	kd versus 8.9+/-1.2 nmol/L) for cortisol	[Kd versus 8.9+/-1.2 nmol/L) for cortisol]	0.0	6	1	1	1
131847	1710	contain a sp1-box 5'-gggcgg	[containing an SP1-box 5'-GGGCGG]	0.0	4	1	1	1
131848	1710	simian CMV scmv	[simian CMV SCMV]	0.0	3	1	1	1
131849	1710	3rd base	[3rd base]	0.0	2	1	1	1
131850	1710	include a regulatory function of gh	[including a regulatory function of GH]	0.0	6	1	1	1
131851	1710	receptor binding from ms patient	[receptor binding from MS patients]	0.0	5	1	1	1
131852	1710	binding assay with extract	[binding assays with extracts]	0.0	4	1	1	1
131853	1710	nine DNA fragment	[nine DNA fragments]	0.0	3	1	1	1
131854	1710	clinical therapy	[clinical therapies]	0.0	2	1	1	1
131855	1710	primary culture of megakaryocyte	[primary cultures of megakaryocytes]	0.0	4	1	1	1
131856	1710	EA-D BMRF1 promoter regulation	[EA-D BMRF1 promoter regulation]	0.0	4	1	1	1
131857	1710	21-66 year	[21-66 yr]	0.0	2	1	1	1
131858	1710	femaless	[females)]	0.0	1	1	1	1
131859	1710	woman with thrombocytosis	[women with thrombocytosis]	0.0	3	1	1	1
131860	1710	treatment of 10 with hcl	[Treatment of 10 with HCl]	0.0	5	1	1	1
131861	1710	two kind of receptor complexes:	[two kinds of receptor complexes:]	0.0	5	1	1	1
131862	1710	spectrum of b cell differentiation	[spectrum of B cell differentiation]	0.0	5	1	1	1
131863	1710	two dna	[Two DNAs]	0.0	2	1	1	1
131864	1710	lps-stimulated cell	[LPS-stimulated cells]	0.0	2	1	1	1
131865	1710	t- leukemia arise	[T- leukemias arising]	0.0	3	1	1	1
131866	1710	H9 t-cell line	[H9 T-cell line]	0.0	3	1	1	1
131867	1710	specific tyrosine residue	[specific tyrosine residues]	0.0	3	1	1	1
131868	1710	effect on il-6	[effects on IL-6]	0.0	3	1	1	1
131869	1710	weight of the membrane receptor	[weight of the membrane receptor]	0.0	5	1	1	1
131870	1710	then (il)-10 blocking factor expression immuno-cytochemistry	[then (IL)-10 blocking factor expression immuno-cytochemistry]	0.0	6	1	1	1
131871	1710	CD28 of T lymphocyte	[CD28 of T lymphocytes]	0.0	4	1	1	1
131872	1710	intense physical exercise in human	[intense physical exercise in humans]	0.0	5	1	1	1
131873	1710	synthesis of a protein(s)	[synthesis of a protein(s)]	0.0	4	1	1	1
131874	1710	express the molecule	[expressing the molecule]	0.0	3	1	1	1
131875	1710	cell type follow expression	[cell types following expression]	0.0	4	1	1	1
131876	1710	stimulatory effect on a variety	[stimulatory effects on a variety]	0.0	5	1	1	1
131877	1710	envelope glycoprotein of hiv-1	[envelope glycoproteins of HIV-1]	0.0	4	1	1	1
131878	1710	T tyrosine kinase	[T tyrosine kinase]	0.0	3	1	1	1
131879	1710	antioxidant sensitive pathway	[antioxidant sensitive pathway]	0.0	3	1	1	1
131880	1710	cis-acting sequence (affect expression	[cis-acting sequences (affecting expression]	0.0	4	1	1	1
131881	1710	mafK	[mafK]	0.0	1	1	1	1
131882	1710	sensitivity to differentiation	[sensitivity to differentiation]	0.0	3	1	1	1
131883	1710	day 7 to day	[day 7 to day]	0.0	4	2	2	1
131884	1710	two dhs	[two DHS]	0.0	2	1	1	1
131885	1710	cytolytic effector molecule	[cytolytic effector molecules]	0.0	3	1	1	1
131886	1710	prognostic importance of comedo	[prognostic importance of comedo]	0.0	4	1	1	1
131887	1710	mechanism for induction of NF-kappaB	[mechanism for induction of NF-kappaB]	0.0	5	1	1	1
131888	1710	nucleotide -170	[nucleotides -170]	0.0	2	1	1	1
131889	1710	only effects.	[only effects.]	0.0	2	1	1	1
131890	1710	basophilia in acute leukaemia analysis	[basophilia in acute leukaemia analysis]	0.0	5	1	1	1
131891	1710	anti-ig stimulation	[anti-Ig stimulation]	0.0	2	1	1	1
131892	1710	complex activator protein-1	[complex activator protein-1]	0.0	3	1	1	1
131893	1710	e1a expression in human cell	[E1A expression in human cells]	0.0	5	1	1	1
131894	1710	vitro, six antigen	[vitro, six antigens]	0.0	3	1	1	1
131895	1710	aminolaevulinic acid synthase activity	[aminolaevulinic acid synthase activity]	0.0	4	1	1	1
131896	1710	culture condition and/or cytokine	[cultures conditions and/or cytokine]	0.0	4	1	1	1
131897	1710	alpha-naphthyl acetate esterase	[alpha-naphthyl acetate esterase]	0.0	3	1	1	1
131898	1710	even after infection	[even after infection]	0.0	3	1	1	1
131899	1710	distal region Chr	[distal region Chr]	0.0	3	1	1	1
131900	1710	diffusion	[diffusion]	0.0	1	1	1	1
131901	1710	nucleotide -158	[nucleotides -158]	0.0	2	1	1	1
131902	1710	12-myristate 13	[12-myristate 13]	0.0	2	1	1	1
131903	1710	normal hematopoiesis of leukocyte	[normal hematopoiesis of leukocytes]	0.0	4	1	1	1
131904	1710	70% sequence	[70% sequence]	0.0	2	1	1	1
131905	1710	anti- tat antibody intrabody	[anti- Tat antibody intrabody]	0.0	4	1	1	1
131906	1710	length of the 5' upstream sequence	[lengths of the 5' upstream sequence]	0.0	6	1	1	1
131907	1710	active form of vitamin D3	[active form of vitamin D3]	0.0	5	1	1	1
131908	1710	negative response element ngre	[negative response element nGRE]	0.0	4	1	1	1
131909	1710	primary involvement	[primary involvement]	0.0	2	1	1	1
131910	1710	mobilization factor-kappa b	[mobilization factor-kappa B]	0.0	3	1	1	1
131911	1710	differentiation of the cell line k562	[differentiation of the cell line K562]	0.0	6	1	1	1
131912	1710	cell whatever stage of differentiation,	[cells whatever stage of differentiation,]	0.0	5	1	1	1
131913	1710	o-phenanthroline on the induction	[o-phenanthroline on the induction]	0.0	4	1	1	1
131914	1710	captopril on gluco-	[captopril on gluco-]	0.0	3	1	1	1
131915	1710	tpa expression	[TPA expression]	0.0	2	1	1	1
131916	1710	structural classification	[structural classification]	0.0	2	1	1	1
131917	1710	rare event	[rare event]	0.0	2	1	1	1
131918	1710	nucleotide -135	[nucleotides -135]	0.0	2	1	1	1
131919	1710	CsA associate	[CsA associate]	0.0	2	1	1	1
131920	1710	include effect	[including effects]	0.0	2	1	1	1
131921	1710	human x receptor alpha	[human X receptor alpha]	0.0	4	1	1	1
131922	1710	tyrosine phosphorylation of endogenous Itk	[tyrosine phosphorylation of endogenous Itk]	0.0	5	1	1	1
131923	1710	Ig loci	[Ig loci]	0.0	2	1	1	1
131924	1710	local immunosuppression	[local immunosuppression]	0.0	2	1	1	1
131925	1710	ability -express human human cell	[abilities -expressing human human cells]	0.0	5	1	1	1
131926	1710	candidate compound	[candidate compounds]	0.0	2	1	1	1
131927	1710	antiserum against kbf1	[antiserum against KBF1]	0.0	3	1	1	1
131928	1710	(tnfr)-associated factor in the signal mechanism	[(TNFR)-associated factors in the signaling mechanisms]	0.0	6	1	1	1
131929	1710	undergo termination	[undergoing termination]	0.0	2	1	1	1
131930	1710	receptor-effector system	[receptor-effector system]	0.0	2	1	1	1
131931	1710	donor age, memory	[donor age, memory]	0.0	3	1	1	1
131932	1710	protein with molecular weight	[proteins with molecular weights]	0.0	4	1	1	1
131933	1710	min) in acid cell	[min) in acid cells]	0.0	4	1	1	1
131934	1710	myeloid cell transcription factor	[myeloid cell transcription factor]	0.0	4	1	1	1
131935	1710	50-fold induction of mrna	[50-fold induction of mRNA]	0.0	4	1	1	1
131936	1710	b-cell line of differentiation	[B-cell lines of differentiation]	0.0	4	1	1	1
131937	1710	bhrf1 in a line BJAB	[BHRF1 in a line BJAB]	0.0	5	1	1	1
131938	1710	other autoimmune disease subject	[other autoimmune disease subjects]	0.0	4	1	1	1
131939	1710	result from different research groups.	[results from different research groups.]	0.0	5	1	1	1
131940	1710	study use a dominant form	[studies using a dominant form]	0.0	5	1	1	1
131941	1710	thus implicate the N-terminal domain	[thus implicating the N-terminal domain]	0.0	5	1	1	1
131942	1710	subunit.	[subunit.]	0.0	1	1	1	1
131943	1710	only the time	[only the time]	0.0	3	1	1	1
131944	1710	constitutive binding in extract	[constitutive binding in extracts]	0.0	4	1	1	1
131945	1710	novel mitogen-inducible gene product	[novel mitogen-inducible gene product]	0.0	4	1	1	1
131946	1710	mmol/L diamide	[mmol/L diamide]	0.0	2	1	1	1
131947	1710	nucleotide -124	[nucleotides -124]	0.0	2	1	1	1
131948	1710	nfatp a protein	[NFATp a protein]	0.0	3	1	1	1
131949	1710	Ig chain enhancer component	[Ig chain enhancer components]	0.0	4	1	1	1
131950	1710	interferon gamma function	[interferon gamma functions]	0.0	3	1	1	1
131951	1710	factor at the AP-1 site	[factors at the AP-1 sites]	0.0	5	1	1	1
131952	1710	antigen molecule	[antigen molecules]	0.0	2	1	1	1
131953	1710	most function in common	[most functions in common]	0.0	4	1	1	1
131954	1710	regulate collagenase-1 transcription	[regulating collagenase-1 transcription]	0.0	3	1	1	1
131955	1710	bead separation	[bead separations]	0.0	2	1	1	1
131956	1710	IFN-beta promoter	[IFN-beta promoter]	0.0	2	1	1	1
131957	1710	venous blood sample	[venous blood samples]	0.0	3	1	1	1
131958	1710	model for basophil cell distribution	[model for basophil cell distribution]	0.0	5	1	1	1
131959	1710	other oxygen species ROS	[other oxygen species ROS]	0.0	4	1	1	1
131960	1710	production of thick tenacious, protease	[production of thick, tenacious, protease]	0.0	5	1	1	1
131961	1710	mip-1 alpha	[MIP-1 alpha]	0.0	2	1	1	1
131962	1710	leukemia-specific retinoic acid receptor	[leukemia-specific retinoic acid receptor]	0.0	4	1	1	1
131963	1710	infection of human immunodeficiency virus	[Infection of human immunodeficiency viruses]	0.0	5	1	1	1
131964	1710	colony-stimumulatelany-stg factor promoter in T cell	[colony-stimulating factor promoters in T cells]	0.0	6	1	1	1
131965	1710	meaning	[meaning]	0.0	1	1	1	1
131966	1710	modulation of cd23 a b	[modulation of CD23 a B]	0.0	5	1	1	1
131967	1710	megakaryocyte accumulation	[megakaryocyte accumulation]	0.0	2	1	1	1
131968	1710	interleukin il-2 gene	[interleukin IL-2 gene]	0.0	3	1	1	1
131969	1710	ifn-induced gene	[IFN-induced genes]	0.0	2	1	1	1
131970	1710	transcription of the terminal repeat region	[transcription of the terminal repeat region]	0.0	6	1	1	1
131971	1710	factor cell	[factor cells]	0.0	2	1	1	1
131972	1710	comparable effect on b-cll cell	[comparable effects on B-CLL cells]	0.0	5	1	1	1
131973	1710	anemic severity	[anemic severity]	0.0	2	1	1	1
131974	1710	large extent	[larger extent]	0.0	2	1	1	1
131975	1710	+/- 0.92 fmol/10(7) pbmc versus 4.43	[+/- 0.92 fmol/10(7) PBMC vs 4.43]	0.0	6	1	1	1
131976	1710	contain a histone beta-galactosidase gene	[containing a histone beta-galactosidase gene]	0.0	5	1	1	1
131977	1710	phorbol acetate PMA	[phorbol acetate PMA]	0.0	3	1	1	1
131978	1710	prominent member	[prominent members]	0.0	2	1	1	1
131979	1710	(hiv-1) infection	[(HIV-1) infection]	0.0	2	1	1	1
131980	1710	central role,	[central role,]	0.0	2	1	1	1
131981	1710	eg, tumor	[eg, tumor]	0.0	2	1	1	1
131982	1710	provide functional evidence	[providing functional evidence]	0.0	3	1	1	1
131983	1710	mc38	[MC38]	0.0	1	1	1	1
131984	1710	role of pld lipid	[role of PLD lipids]	0.0	4	1	1	1
131985	1710	Subunit a component	[Subunit an component]	0.0	3	1	1	1
131986	1710	insertion of igh element	[insertion of IgH elements]	0.0	4	1	1	1
131987	1710	dep-pah-activated cell	[DEP-PAH-activated cells]	0.0	2	1	1	1
131988	1710	t(8;21) myelogenous leukemia aml	[t(8;21) myelogenous leukemia AML]	0.0	4	1	1	1
131989	1710	rearrangement of the control regions,	[rearrangements of the control regions,]	0.0	5	1	1	1
131990	1710	trimester),	[trimester),]	0.0	1	1	1	1
131991	1710	powerful skewer	[powerful skewer]	0.0	2	1	1	1
131992	1710	ifn-gamma secretion	[IFN-gamma secretion]	0.0	2	1	1	1
131993	1710	lavage cellularity	[lavage cellularity]	0.0	2	1	1	1
131994	1710	thymocyte culture	[thymocyte cultures]	0.0	2	1	1	1
131995	1710	modulation of the nt3r	[modulation of the NT3R]	0.0	4	1	1	1
131996	1710	intercellular adhesion molecule-1 gene transcription	[intercellular adhesion molecule-1 gene transcription]	0.0	5	1	1	1
131997	1710	module in cell type	[module in cell types]	0.0	4	1	1	1
131998	1710	independent site	[independent sites]	0.0	2	1	1	1
131999	1710	encode the 105-kDa protein precursor	[encoding the 105-kDa protein precursor]	0.0	5	1	1	1
132000	1710	80.2 15.5 (p p	[80.2 15.5 (P P]	0.0	4	1	1	1
132001	1710	program of gene expression	[program of gene expression]	0.0	4	1	1	1
132002	1710	lymphoid tissue malt	[lymphoid tissue MALT]	0.0	3	1	1	1
132003	1710	abortion	[abortion]	0.0	1	4	4	1
132004	1710	erythropoietin epo factor gm-csf	[Erythropoietin Epo factor GM-CSF]	0.0	4	1	1	1
132005	1710	two stat complex	[two STAT complexes]	0.0	3	1	1	1
132006	1710	deletion of C-terminal residue	[deletion of C-terminal residues]	0.0	4	1	1	1
132007	1710	autocrine mechanism for cytokine	[autocrine mechanism for cytokine]	0.0	4	1	1	1
132008	1710	event underlie lymphocyte action	[event underlying lymphocyte action]	0.0	4	1	1	1
132009	1710	7 residue	[7 residues]	0.0	2	1	1	1
132010	1710	(cd33, cd13,	[(CD33, CD13,]	0.0	2	1	1	1
132011	1710	cell line keep property	[cell lines keeping properties]	0.0	4	1	1	1
132012	1710	incubation of human cell in hypoxia	[Incubation of human cells in hypoxia]	0.0	6	1	1	1
132013	1710	therefore part	[therefore part]	0.0	2	1	1	1
132014	1710	pml pathway	[PML pathways]	0.0	2	1	1	1
132015	1710	about 25 h (viability	[about 25 h (viability]	0.0	4	1	1	1
132016	1710	colour fish analysis	[colour FISH analysis]	0.0	3	1	1	1
132017	1710	functional importance of gamma(c)	[functional importance of gamma(c)]	0.0	4	1	1	1
132018	1710	mouse development	[mouse development]	0.0	2	1	1	1
132019	1710	high-affinity binding site for BSAP	[high-affinity binding site for BSAP]	0.0	5	1	1	1
132020	1710	form of nf-at1	[form of NF-AT1]	0.0	3	1	1	1
132021	1710	Pan expression	[Pan expression]	0.0	2	1	1	1
132022	1710	Glucocorticoid receptor in leukocyte	[Glucocorticoid receptors in leukocytes]	0.0	4	1	1	1
132023	1710	follow a intravenous injection	[following an intravenous injection]	0.0	4	1	1	1
132024	1710	illustrate a major target.	[illustrating a major target.]	0.0	4	1	1	1
132025	1710	several marker include vpreb1	[several markers including VpreB1]	0.0	4	1	1	1
132026	1710	cell toxicity.	[cell toxicity.]	0.0	2	1	1	1
132027	1710	2 beta thalassemia patient	[2 beta thalassemia patients]	0.0	4	1	1	1
132028	1710	fate of b transcription factor	[fate of B transcription factors]	0.0	5	1	1	1
132029	1710	effect on one cellular event	[effect on one cellular event]	0.0	5	1	1	1
132030	1710	hd sample (19 nlphd	[HD samples (19 NLPHD]	0.0	4	1	1	1
132031	1710	effect of mutant of shp1	[effects of mutants of SHP1]	0.0	5	1	1	1
132032	1710	iron-sulfur center	[iron-sulfur centers]	0.0	2	1	1	1
132033	1710	constitutive apoptosis	[constitutive apoptosis]	0.0	2	1	1	1
132034	1710	express the normal the fusion protein	[expressing the normal the fusion protein]	0.0	6	1	1	1
132035	1710	tat antibody intrabody	[Tat antibody intrabody]	0.0	3	1	1	1
132036	1710	two form diabete diabete	[two forms diabetes diabetes]	0.0	4	1	1	1
132037	1710	phytohaemagglutinin pha	[phytohaemagglutinin PHA]	0.0	2	1	1	1
132038	1710	factor beta hnf3 beta	[factor beta HNF3 beta]	0.0	4	1	1	1
132039	1710	the/thf (0.24; n: 1.87+/-0.36)	[THE/THF (0.24; N: 1.87+/-0.36)]	0.0	4	1	1	1
132040	1710	normal monocyte with 12-0-tetradecanoyl phorbol-13-acetate	[normal monocytes with 12-0-tetradecanoyl phorbol-13-acetate]	0.0	5	1	1	1
132041	1710	cd34+ hematopoietic stem cell	[CD34+ hematopoietic stem cells]	0.0	4	2	2	1
132042	1710	event along the pathway operate	[events along the pathways operating]	0.0	5	1	1	1
132043	1710	vp16 transactivation domain in place	[VP16 transactivation domains in place]	0.0	5	1	1	1
132044	1710	4-acetoxy derivative	[4-acetoxy derivative]	0.0	2	1	1	1
132045	1710	degree of sensitivity	[degree of sensitivity]	0.0	3	1	1	1
132046	1710	domain of the regulatory p85 subunit	[domains of the regulatory p85 subunit]	0.0	6	1	1	1
132047	1710	detection in blood mononuclear cell	[Detection in blood mononuclear cells]	0.0	5	2	2	1
132048	1710	signal than memory (cd45ro+) cell	[signals than memory (CD45RO+) cells]	0.0	5	1	1	1
132049	1710	htlv-1-infected T lymphocyte	[HTLV-1-infected T lymphocytes]	0.0	3	1	1	1
132050	1710	microm sodium orthovanadate	[microM sodium orthovanadate]	0.0	3	1	1	1
132051	1710	shock pathway	[shock pathways]	0.0	2	1	1	1
132052	1710	thus, exposure	[Thus, exposure]	0.0	2	1	1	1
132053	1710	purine-rich stretch	[purine-rich stretches]	0.0	2	1	1	1
132054	1710	pattern of intracellular signal for chemoattract	[patterns of intracellular signaling for chemoattractants]	0.0	6	1	1	1
132055	1710	p50 nf-kappa b protein	[p50 NF-kappa B protein]	0.0	4	1	1	1
132056	1710	structural protein sequence	[structural protein sequences]	0.0	3	1	1	1
132057	1710	regulate gene transcription in tissue	[regulating gene transcription in tissues]	0.0	5	1	1	1
132058	1710	(maximal at min), c-jun,	[(maximal at min), c-jun,]	0.0	4	1	1	1
132059	1710	namely the heavy chain enhancer igh-enhancer	[namely the heavy chain enhancer IgH-enhancer]	0.0	6	1	1	1
132060	1710	target of nf-kappab	[targets of NF-kappaB]	0.0	3	1	1	1
132061	1710	human venous huvec	[human venous HUVECs]	0.0	3	1	1	1
132062	1710	anti-ig response element within Zp	[anti-Ig response elements within Zp]	0.0	5	1	1	1
132063	1710	C-terminal two-third	[C-terminal two-thirds]	0.0	2	1	1	1
132064	1710	use increase amount of nfatp	[using increasing amounts of NFATp]	0.0	5	1	1	1
132065	1710	blockade of this signalling event	[Blockade of this signalling event]	0.0	5	1	1	1
132066	1710	activator on kappa b site	[activator on kappa B sites]	0.0	5	1	1	1
132067	1710	great extent	[greater extent]	0.0	2	1	1	1
132068	1710	increase in the workload	[increase in the workload]	0.0	4	1	1	1
132069	1710	vein endothelial cell huvec monolayer	[vein endothelial cell HUVEC monolayers]	0.0	5	1	1	1
132070	1710	InterleUkin	[InterleUkin]	0.0	1	1	1	1
132071	1710	two distinct family of factor	[two distinct families of factors]	0.0	5	1	1	1
132072	1710	sv40 promoter protein-1	[SV40 promoter protein-1]	0.0	3	1	1	1
132073	1710	s49 murine thymoma cell	[S49 murine thymoma cells]	0.0	4	1	1	1
132074	1710	heterozygous DNA variation	[heterozygous DNA variations]	0.0	3	1	1	1
132075	1710	untranslated sequence	[untranslated sequence]	0.0	2	1	1	1
132076	1710	negative HLH factor Id3	[negative HLH factor Id3]	0.0	4	1	1	1
132077	1710	molecular pathogenesis of lymphoma	[molecular pathogenesis of lymphoma]	0.0	4	1	1	1
132078	1710	moreover, simian virus	[Moreover, simian virus]	0.0	3	1	1	1
132079	1710	Nonimmunoglobulin gene	[Nonimmunoglobulin gene]	0.0	2	1	1	1
132080	1710	individual transcriptional property	[individual transcriptional properties]	0.0	3	1	1	1
132081	1710	only the two single mutation	[only the two single mutations]	0.0	5	1	1	1
132082	1710	the/thf n: alpha thf/thf (0.35;	[THE/THF N: alpha THF/THF (0.35;]	0.0	5	1	1	1
132083	1710	24-hour cortisol excretion before treatment	[24-hour cortisol excretion before treatment]	0.0	5	1	1	1
132084	1710	expression of cell gene	[expression of cell genes]	0.0	4	1	1	1
132085	1710	patient with immunodeficiency syndrome	[patients with immunodeficiency syndrome]	0.0	4	1	1	1
132086	1710	stimulation of t-lymphocyte	[stimulation of T-lymphocytes]	0.0	3	1	1	1
132087	1710	molecular basis of the effect	[molecular basis of the effect]	0.0	5	1	1	1
132088	1710	persist lifelong,	[persisting lifelong,]	0.0	2	1	1	1
132089	1710	49 case of chronic leukemia CLL	[49 cases of chronic leukemia CLL]	0.0	6	1	1	1
132090	1710	mixture of latency	[mixture of latency]	0.0	3	1	1	1
132091	1710	b cell in donor	[B cells in donors]	0.0	4	1	1	1
132092	1710	monokine gene expression	[monokine gene expression]	0.0	3	1	1	1
132093	1710	th1 response	[Th1 responses]	0.0	2	1	1	1
132094	1710	role for G(Anh)MTetra	[role for G(Anh)MTetra]	0.0	3	1	1	1
132095	1710	additional agent endotoxin	[additional agents endotoxin]	0.0	3	1	1	1
132096	1710	biochemical events,	[biochemical events,]	0.0	2	1	1	1
132097	1710	granulosa cell	[Granulosa cell]	0.0	2	1	1	1
132098	1710	great than 15 stimulation	[greater than 15 stimulation]	0.0	4	1	1	1
132099	1710	symptom of PIH	[symptoms of PIH]	0.0	3	1	1	1
132100	1710	human pulmonary macrophage	[human pulmonary macrophages]	0.0	3	1	1	1
132101	1710	cooperation between interferon factor-1	[cooperation between interferon factor-1]	0.0	4	1	1	1
132102	1710	persistent eosinophilia	[persistent eosinophilia]	0.0	2	1	1	1
132103	1710	production from this cell line	[production from this cell line]	0.0	5	1	1	1
132104	1710	specific transcription factor tcf-1	[specific transcription factors TCF-1]	0.0	4	1	1	1
132105	1710	bovine pulmonary artery cell from injury	[bovine pulmonary artery cells from injury]	0.0	6	1	1	1
132106	1710	property of inducible gene	[property of inducible genes]	0.0	4	1	1	1
132107	1710	gene of RARalpha	[gene of RARalpha]	0.0	3	1	1	1
132108	1710	1 macrophage colony-stimulating factor	[1 macrophage colony-stimulating factor]	0.0	4	1	1	1
132109	1710	promoter of t-cell-expressed cytokine	[promoters of T-cell-expressed cytokines]	0.0	4	1	1	1
132110	1710	site of ebv replication	[site of EBV replication]	0.0	4	1	1	1
132111	1710	stimulation, new kappa complex	[stimulation, new kappa complexes]	0.0	4	1	1	1
132112	1710	involvement in the stage	[involvement in the stage]	0.0	4	1	1	1
132113	1710	b-2 cell	[B-2 cells]	0.0	2	1	1	1
132114	1710	induction in pre-B cell	[induction in pre-B cells]	0.0	4	1	1	1
132115	1710	proportion of fatty acid	[proportions of fatty acids]	0.0	4	1	1	1
132116	1710	adult globin gene delta	[adult globin genes delta]	0.0	4	1	1	1
132117	1710	aneusomy with 1p36 under-representation	[aneusomy with 1p36 under-representation]	0.0	4	1	1	1
132118	1710	similar box in the gene	[similar boxes in the gene]	0.0	5	1	1	1
132119	1710	soluble tnf-alpha receptor type	[soluble TNF-alpha receptor type]	0.0	4	1	1	1
132120	1710	genetic component	[genetic component]	0.0	2	1	1	1
132121	1710	defect in CD40	[defects in CD40]	0.0	3	1	1	1
132122	1710	involvement regulate gene transcription	[involvement regulating gene transcription]	0.0	4	1	1	1
132123	1710	initial infection	[initial infection]	0.0	2	1	1	1
132124	1710	immunoglobulin heavy chain igh	[immunoglobulin heavy chain IgH]	0.0	4	1	1	1
132125	1710	controversies, of the troublesome	[controversies, of the troublesome]	0.0	4	1	1	1
132126	1710	favorable clinical course chi2	[favorable clinical course chi2]	0.0	4	1	1	1
132127	1710	large number in phase endometrium	[large numbers in phase endometrium]	0.0	5	1	1	1
132128	1710	form of disease	[forms of disease.]	0.0	3	1	1	1
132129	1710	human dominant control region	[human dominant control region]	0.0	4	1	1	1
132130	1710	cell-to-cell contact between blood lymphocyte	[Cell-to-cell contact between blood lymphocytes]	0.0	5	1	1	1
132131	1710	affinity of peptide	[affinity of peptide]	0.0	3	1	1	1
132132	1710	IFN-beta mrna	[IFN-beta mRNA]	0.0	2	1	1	1
132133	1710	ability I ifi	[ability I IFNs]	0.0	3	1	1	1
132134	1710	lef-1 lef-1	[LEF-1 LEF-1]	0.0	2	1	1	1
132135	1710	b /rel protein	[B /Rel proteins]	0.0	3	2	2	1
132136	1710	compared,	[compared,]	0.0	1	1	1	1
132137	1710	widespread applicability, allow testing	[widespread applicability, allowing testing]	0.0	4	1	1	1
132138	1710	young (18- to 35-year-old)	[young (18- to 35-year-old)]	0.0	4	1	1	1
132139	1710	regulation -encoding gene	[regulation -encoding genes]	0.0	3	1	1	1
132140	1710	TCEd DNA	[TCEd DNA]	0.0	2	1	1	1
132141	1710	subsequent adhesion in human vein cell	[subsequent adhesion in human vein cells]	0.0	6	1	1	1
132142	1710	lps nuclear factor-kappaB	[LPS nuclear factor-kappaB]	0.0	3	1	1	1
132143	1710	distinct, inhibitor of NFAT transcription	[distinct, inhibitors of NFAT transcription]	0.0	5	1	1	1
132144	1710	retinoic acid at dose	[retinoic acid at doses]	0.0	4	1	1	1
132145	1710	proper regulation	[proper regulation]	0.0	2	1	1	1
132146	1710	representative form	[representative forms]	0.0	2	1	1	1
132147	1710	cell in response CSF	[cells in response CSF]	0.0	4	1	1	1
132148	1710	decrease in the insulin mrna	[decrease in the insulin mRNA]	0.0	5	1	1	1
132149	1710	terminal protein gene promoter	[terminal protein gene promoter]	0.0	4	1	1	1
132150	1710	sr-bp 50-fold high for sr	[SR-BP 50-fold higher for SR]	0.0	5	1	1	1
132151	1710	kD tnf receptor	[kD TNF receptor]	0.0	3	1	1	1
132152	1710	T lymphocyte of male sibling	[T lymphocytes of male siblings]	0.0	5	1	1	1
132153	1710	expression of the c-fo protooncogene	[expression of the c-fos protooncogene]	0.0	5	1	1	1
132154	1710	kilometer tax1 antigen molecule	[kd tax1 antigen molecules]	0.0	4	1	1	1
132155	1710	exception of b	[exception of B]	0.0	3	1	1	1
132156	1710	stimulation with acid RA	[stimulation with acid RA]	0.0	4	1	1	1
132157	1710	assay volume millileter	[assay volume ml]	0.0	3	1	1	1
132158	1710	brain development due to immune challenge	[brain development due to immune challenge]	0.0	6	1	1	1
132159	1710	h with 50 nm vd3	[h with 50 nM VD3]	0.0	5	1	1	1
132160	1710	four repeat DR of 21 bp	[four repeats DR of 21 bp]	0.0	6	1	1	1
132161	1710	1 microm cold aldosterone	[1 microM cold aldosterone]	0.0	4	1	1	1
132162	1710	type diabete in period	[type diabetes in period]	0.0	4	1	1	1
132163	1710	eight healthy untrained volunteer	[Eight healthy untrained volunteers]	0.0	4	1	1	1
132164	1710	resistant icr27tk.3 leukemic T cell	[resistant ICR27TK.3 leukemic T cells]	0.0	5	1	1	1
132165	1710	second line	[second line]	0.0	2	1	1	1
132166	1710	clinical usefulness	[clinical usefulness]	0.0	2	1	1	1
132167	1710	ap-1 enhancer element	[AP-1 enhancer element]	0.0	3	1	1	1
132168	1710	GR element GRE level	[GR element GRE level]	0.0	4	1	1	1
132169	1710	inhibitory effect on the migration	[inhibitory effect on the migration]	0.0	5	1	1	1
132170	1710	induction of icer	[induction of ICER]	0.0	3	1	1	1
132171	1710	fibronectin -vla-5	[fibronectin -VLA-5]	0.0	2	1	1	1
132172	1710	two group one with sensitivity	[two groups one with sensitivity]	0.0	5	1	1	1
132173	1710	regulation of this zinc-finger gene	[regulation of these zinc-finger genes]	0.0	5	1	1	1
132174	1710	transcription in cancer patients' lymphocyte	[transcription in cancer patients' lymphocytes]	0.0	5	1	1	1
132175	1710	cells-family	[cells-family]	0.0	1	1	1	1
132176	1710	express gata-binding protein	[expressing GATA-binding proteins]	0.0	3	1	1	1
132177	1710	production by atopic b cell	[production by atopic B cells]	0.0	5	1	1	1
132178	1710	expression in Hox11 null mouse	[expression in Hox11 null mice]	0.0	5	1	1	1
132179	1710	activity capable	[activity capable]	0.0	2	1	1	1
132180	1710	effect in cell	[effect in cells]	0.0	3	1	1	1
132181	1710	anf-e2 promoter	[aNF-E2 promoter]	0.0	2	2	2	1
132182	1710	cleavage a key negative regulator	[cleavage a key negative regulator]	0.0	5	1	1	1
132183	1710	certain monocytic cell	[certain monocytic cells]	0.0	3	1	1	1
132184	1710	(3) expression	[(3) expression]	0.0	2	2	2	1
132185	1710	include fcepsilonriib cd23	[including FcepsilonRIIb CD23]	0.0	3	1	1	1
132186	1710	approximate map region 0.30	[approximate map regions 0.30]	0.0	4	1	1	1
132187	1710	analyze the component of NF-AT	[analyzing the components of NF-AT]	0.0	5	1	1	1
132188	1710	tetrahydrocortisone mg/24h; n: 2.7+/-2.0)	[tetrahydrocortisone mg/24h; N: 2.7+/-2.0)]	0.0	4	1	1	1
132189	1710	nature of signal	[nature of signals]	0.0	3	1	1	1
132190	1710	enhancer in b cell	[enhancer in B cells]	0.0	4	1	1	1
132191	1710	subsequent release	[subsequent release]	0.0	2	1	1	1
132192	1710	analysis of the CD19 promoter	[analysis of the CD19 promoter]	0.0	5	1	1	1
132193	1710	cell line CEM c7	[cell lines CEM C7]	0.0	4	1	1	1
132194	1710	4 beta cd49d/cd29 costimulation	[4 beta CD49d/CD29 costimulation]	0.0	4	1	1	1
132195	1710	cytokine-induced function of a type	[cytokine-induced functions of a type]	0.0	5	1	1	1
132196	1710	variant present	[variants present]	0.0	2	1	1	1
132197	1710	leukemic ecem) cell	[leukemic (CEM) cells]	0.0	3	1	1	1
132198	1710	set of gene at stage	[sets of genes at stages]	0.0	5	1	1	1
132199	1710	component of C1-C3	[components of C1-C3]	0.0	3	1	1	1
132200	1710	binding I interferon to receptor	[Binding I interferon to receptors]	0.0	5	1	1	1
132201	1710	cell nuclei,	[cell nuclei,]	0.0	2	1	1	1
132202	1710	interleukin receptor expression	[interleukin receptor expression]	0.0	3	1	1	1
132203	1710	differentiation of b cell with il-6	[differentiation of B cells with IL-6]	0.0	6	1	1	1
132204	1710	activate protein-1 ap-1 tpa element	[Activating protein-1 AP-1 TPA elements]	0.0	5	1	1	1
132205	1710	b-lymphotropic herpesvirus related	[B-lymphotropic herpesvirus related]	0.0	3	1	1	1
132206	1710	p93fe activity	[p93fes activity]	0.0	2	1	1	1
132207	1710	controversy.	[controversy.]	0.0	1	1	1	1
132208	1710	most significant variable	[most significant variable]	0.0	3	1	1	1
132209	1710	peak in response to concanavalin-a cona	[peaking in response to Concanavalin-A ConA]	0.0	6	1	1	1
132210	1710	nfat-sensitive gene	[NFAT-sensitive gene]	0.0	2	1	1	1
132211	1710	loss of one	[loss of one]	0.0	3	1	1	1
132212	1710	control (abdominal obese: 31.90	[controls (abdominal obese: 31.90]	0.0	4	1	1	1
132213	1710	(range, 5.66-10) (range,	[(range, 5.66-10), (range,]	0.0	3	1	1	1
132214	1710	spontaneous production by b cell	[spontaneous production by B cells]	0.0	5	1	1	1
132215	1710	6.04 2.35 fmol/10(6) cell respectively,	[6.04 2.35 fmol/10(6) cells respectively,]	0.0	5	1	1	1
132216	1710	include acute leukemia	[including acute leukemia]	0.0	3	1	1	1
132217	1710	crucial g1 checkpoint	[crucial G1 checkpoint]	0.0	3	1	1	1
132218	1710	different specific band	[different specific bands]	0.0	3	1	1	1
132219	1710	link between production	[link between production]	0.0	3	1	1	1
132220	1710	1 aneusomy with under-representation	[1 aneusomy with under-representation]	0.0	4	1	1	1
132221	1710	Prostaglandin E2 PGE2	[Prostaglandin E2 PGE2]	0.0	3	1	1	1
132222	1710	level of vcam-1 mrna	[levels of VCAM-1 mRNA]	0.0	4	1	1	1
132223	1710	polymorphic DNA marker	[polymorphic DNA markers]	0.0	3	1	1	1
132224	1710	response to differentiation.	[response to differentiation.]	0.0	3	1	1	1
132225	1710	cell reaction high grade	[cell reaction high grade]	0.0	4	1	1	1
132226	1710	potent druilkience pyrrolidine dithiocarbamate	[potent drug, pyrrolidine dithiocarbamate]	0.0	4	1	1	1
132227	1710	thus prevent transcriptional induction	[thus preventing transcriptional induction]	0.0	4	1	1	1
132228	1710	potent lipid mediator	[potent lipid mediator]	0.0	3	1	1	1
132229	1710	sensitive measurement of CIF	[sensitive measurement of CIF]	0.0	4	1	1	1
132230	1710	antibody against protein	[antibodies against proteins]	0.0	3	1	1	1
132231	1710	(myd)	[(MyD)]	0.0	1	1	1	1
132232	1710	promoter-proximal region	[promoter-proximal region]	0.0	2	1	1	1
132233	1710	immunoreactivity	[immunoreactivity]	0.0	1	1	1	1
132234	1710	estrogen receptor in peripheral monocyte	[estrogen receptors in peripheral monocytes]	0.0	5	1	1	1
132235	1710	three, rare heterozygous DNA variation	[three, rare heterozygous DNA variations]	0.0	5	1	1	1
132236	1710	pseudo-hypoaldosteronism normal level	[pseudo-hypoaldosteronism normal level]	0.0	3	1	1	1
132237	1710	endogenous tg receptor	[endogenous TG receptors]	0.0	3	1	1	1
132238	1710	breast cancer population	[breast cancer populations]	0.0	3	1	1	1
132239	1710	immunization.	[immunization.]	0.0	1	1	1	1
132240	1710	difference in factors,	[differences in factors,]	0.0	3	1	1	1
132241	1710	elderly (61-80 years) subject	[elderly (61-80 years) subjects]	0.0	4	1	1	1
132242	1710	control apoptosis	[controlling apoptosis]	0.0	2	1	1	1
132243	1710	radixin	[radixin]	0.0	1	1	1	1
132244	1710	Effect of agent	[Effects of agents]	0.0	3	1	1	1
132245	1710	treatment of u-937 with okadaic acid	[Treatment of U-937 with okadaic acid]	0.0	6	1	1	1
132246	1710	activator protein (ap)-1	[activator protein (AP)-1]	0.0	3	1	1	1
132247	1710	mosaicism of cell line	[Mosaicism of cell lines]	0.0	4	1	1	1
132248	1710	nf-kappab activation of long terminal repeat	[NF-kappaB activation of long terminal repeat]	0.0	6	1	1	1
132249	1710	buffy coat	[buffy coat]	0.0	2	1	1	1
132250	1710	human member	[human member]	0.0	2	1	1	1
132251	1710	number of potential element	[number of potential elements]	0.0	4	1	1	1
132252	1710	(delta)	[(delta)]	0.0	1	1	1	1
132253	1710	dna-binding activity in mitogen-stimulated t-cell	[DNA-binding activity in mitogen-stimulated T-cells]	0.0	5	1	1	1
132254	1710	effect on adhesiveness	[effect on adhesiveness]	0.0	3	1	1	1
132255	1710	190 c-terminal amino acid	[190 C-terminal amino acids]	0.0	4	1	1	1
132256	1710	target to the erythroblastic progeny	[targeting to the erythroblastic progeny]	0.0	5	1	1	1
132257	1710	double-label immunogold electron microscopy	[double-labeling immunogold electron microscopy]	0.0	4	1	1	1
132258	1710	include interleukin-2 IL-2	[including interleukin-2 IL-2]	0.0	3	1	1	1
132259	1710	represent stage from early precursor	[representing stages from early precursors]	0.0	5	1	1	1
132260	1710	have the amount of monocytic precursor	[having the amounts of monocytic precursors]	0.0	6	1	1	1
132261	1710	vitro cell culture system	[vitro cell culture system]	0.0	4	1	1	1
132262	1710	site within the regulatory element	[sites within the regulatory element]	0.0	5	1	1	1
132263	1710	inhibitory protein repressor element	[inhibitory protein repressor element]	0.0	4	1	1	1
132264	1710	transactivation by NFAT1	[transactivation by NFAT1]	0.0	3	1	1	1
132265	1710	then (il)-10 blocking factor pibf	[then (IL)-10 blocking factor PIBF]	0.0	5	1	1	1
132266	1710	-sensitive induction of tnf-alpha	[-sensitive induction of TNF-alpha]	0.0	4	1	1	1
132267	1710	CD30 with a CD30 antibody,	[CD30 with an CD30 antibody,]	0.0	5	1	1	1
132268	1710	evidence of expression	[evidence of expression]	0.0	3	1	1	1
132269	1710	level in monocyte-derived macrophage	[level in monocyte-derived macrophages]	0.0	4	1	1	1
132270	1710	oct-binding factor 1 a protein	[Oct-binding factor 1 a protein]	0.0	5	1	1	1
132271	1710	distinct type of macrophage	[distinct types of macrophages]	0.0	4	1	1	1
132272	1710	potent mediator of the response	[potent mediator of the response]	0.0	5	1	1	1
132273	1710	fetus against antibody	[fetus against antibodies]	0.0	3	1	1	1
132274	1710	normal population,	[normal population,]	0.0	2	1	1	1
132275	1710	beta2 integrin cd11b	[beta2 integrin CD11b]	0.0	3	1	1	1
132276	1710	proliferation of progenitor in vitro.	[proliferation of progenitors in vitro.]	0.0	5	1	1	1
132277	1710	IL-6 kappa b binding factor	[IL-6 kappa B binding factor]	0.0	5	1	1	1
132278	1710	fetal-calf	[fetal-calf]	0.0	1	1	1	1
132279	1710	D3 135(oh)2d3 receptor	[D3 1,25(OH)2D3 receptor]	0.0	3	1	1	1
132280	1710	antiretroviral compound	[antiretroviral compounds]	0.0	2	1	1	1
132281	1710	CD28 mab BW	[CD28 mAb BW]	0.0	3	1	1	1
132282	1710	12 nonspecific reactive hyperplasia	[12 nonspecific reactive hyperplasia]	0.0	4	1	1	1
132283	1710	stat-binding oligonucleotide	[STAT-binding oligonucleotides]	0.0	2	1	1	1
132284	1710	aberrancy in the induction	[aberrancies in the induction]	0.0	4	1	1	1
132285	1710	adenovirus region ES	[adenovirus region ES]	0.0	3	1	1	1
132286	1710	defense against microorganism	[defense against microorganisms]	0.0	3	1	1	1
132287	1710	include other sp1 binding protein	[including other Sp1 binding proteins]	0.0	5	1	1	1
132288	1710	heat shock of Hyon cell	[heat shock of Hyon cells]	0.0	5	1	1	1
132289	1710	activity in runner	[activity in runner]	0.0	3	1	1	1
132290	1710	involvement of a e1a-binding protein	[involvement of an E1A-binding protein]	0.0	5	1	1	1
132291	1710	contain ap-2	[containing AP-2]	0.0	2	1	1	1
132292	1710	production of Egr-1	[production of Egr-1]	0.0	3	1	1	1
132293	1710	activation of macrophage by bacterial lipopolysaccharide	[Activation of macrophages by bacterial lipopolysaccharide]	0.0	6	1	1	1
132294	1710	two DNA binding form	[two DNA binding forms]	0.0	4	1	1	1
132295	1710	minor effects.	[minor effects.]	0.0	2	1	1	1
132296	1710	estrogen administration	[estrogen administration]	0.0	2	1	1	1
132297	1710	two E(gre) motif	[two E(gre) motifs]	0.0	3	1	1	1
132298	1710	target of sr 31747a	[target of SR 31747A]	0.0	4	1	1	1
132299	1710	messenger mediate the release	[messengers mediating the release]	0.0	4	1	1	1
132300	1710	induction cell differentiation	[Induction cell differentiation]	0.0	3	1	1	1
132301	1710	block nfat translocation	[blocking NFAT translocation]	0.0	3	1	1	1
132302	1710	recurrent spontaneous abortion	[recurrent spontaneous abortion]	0.0	3	1	1	1
132303	1710	conclusion a component	[conclusion an component]	0.0	3	1	1	1
132304	1710	SWI3	[SWI3]	0.0	1	1	1	1
132305	1710	french-american-british acute leukemia-M3	[French-American-British acute leukemia-M3]	0.0	3	1	1	1
132306	1710	malignant transformation of cell	[malignant transformation of cells]	0.0	4	1	1	1
132307	1710	expression of dominant negative mutant	[expression of dominant negative mutants]	0.0	5	1	1	1
132308	1710	modulation of immune responsiveness in cell	[modulation of immune responsiveness in cells]	0.0	6	1	1	1
132309	1710	simultaneous incubation of RU	[simultaneous incubation of RU]	0.0	4	1	1	1
132310	1710	none of the protein lef-1	[none of the proteins LEF-1]	0.0	5	1	1	1
132311	1710	Comparison of sensitization of T cell	[Comparison of sensitization of T cells]	0.0	6	1	1	1
132312	1710	heat shock (hs)/stress protein	[heat shock (HS)/stress proteins]	0.0	4	1	1	1
132313	1710	activity of the terminal repeat LTR	[activity of the terminal repeat LTR]	0.0	6	1	1	1
132314	1710	cell line with high potential	[cell lines with high potential]	0.0	5	1	1	1
132315	1710	inflammatory effect	[inflammatory effects]	0.0	2	1	1	1
132316	1710	extract from Jurkat cell	[extracts from Jurkat cells]	0.0	4	1	1	1
132317	1710	cancer related loci relevant	[cancer related loci relevant]	0.0	4	1	1	1
132318	1710	back pain	[back pain]	0.0	2	2	2	1
132319	1710	same phenotype	[same phenotype]	0.0	2	2	2	1
132320	1710	standard serological technique	[standard serological techniques]	0.0	3	1	1	1
132321	1710	gammopathy	[gammopathy]	0.0	1	1	1	1
132322	1710	ataxia-telangiectasia a immunodeficiency syndrome	[ataxia-telangiectasia an immunodeficiency syndrome]	0.0	4	1	1	1
132323	1710	importance in the treatment	[importance in the treatment]	0.0	4	1	1	1
132324	1710	pig donor in clinical xenotransplantation	[pig donors in clinical xenotransplantation]	0.0	5	1	1	1
132325	1710	modulate function	[modulating function]	0.0	2	1	1	1
132326	1710	drip coactivator complex binding	[DRIP coactivator complex binding]	0.0	4	1	1	1
132327	1710	ig gene hypermutation	[Ig gene hypermutation]	0.0	3	1	1	1
132328	1710	oxidant stress lead	[oxidant stress leading]	0.0	3	2	2	1
132329	1710	GGTAGTTCCC	[GGTAGTTCCC]	0.0	1	1	1	1
132330	1710	immature b	[immature B]	0.0	2	1	1	1
132331	1710	contain little ng	[containing little ng]	0.0	3	1	1	1
132332	1710	(TNF)	[(TNF)]	0.0	1	1	1	1
132333	1710	so-called PML body	[so-called PML bodies]	0.0	3	1	1	1
132334	1710	activation of the promoter in cell	[activation of the promoter in cells]	0.0	6	1	1	1
132335	1710	formation ifn-gamma-activated sequence-binding complex contain STAT3	[formation IFN-gamma-activated sequence-binding complexes containing STAT3]	0.0	6	1	1	1
132336	1710	prior to the stimulation	[prior to the stimulation]	0.0	4	1	1	1
132337	1710	cyclophilin b	[cyclophilin B]	0.0	2	1	1	1
132338	1710	cyclophilin a	[cyclophilin A]	0.0	2	1	1	1
132339	1710	Systemic hGR level in ibd patient	[Systemic hGR levels in IBD patients]	0.0	6	1	1	1
132340	1710	glucocorticoid to hGR	[glucocorticoids to hGR]	0.0	3	1	1	1
132341	1710	bzlf -contain cell lysate	[BZLF -containing cell lysates]	0.0	4	1	1	1
132342	1710	lt remission	[LT remission]	0.0	2	1	1	1
132343	1710	transcription function of MZF-1	[transcription function of MZF-1]	0.0	4	1	1	1
132344	1710	use of antiestrogen	[use of antiestrogens]	0.0	3	1	1	1
132345	1710	kappa binding factor present	[kappa binding factors present]	0.0	4	1	1	1
132346	1710	cytokine receptor expression by glucocorticoid	[cytokine receptor expression by glucocorticoids]	0.0	5	1	1	1
132347	1710	trigger substance cause secretion	[trigger substances causing secretion]	0.0	4	1	1	1
132348	1710	primary cd34+ hemopoietic progenitor cell	[primary CD34+ hemopoietic progenitor cells]	0.0	5	1	1	1
132349	1710	cases).	[cases).]	0.0	1	1	1	1
132350	1710	regulate the maintenance of nf-kappa b	[regulating the maintenance of NF-kappa B]	0.0	6	1	1	1
132351	1710	T cell-specific negative regulatory element	[T cell-specific negative regulatory element]	0.0	5	1	1	1
132352	1710	mtcp1/c6.1b	[MTCP1/c6.1B]	0.0	1	1	1	1
132353	1710	reduction of size,	[reduction of size,]	0.0	3	1	1	1
132354	1710	affect the guanine residue	[affecting the guanine residues]	0.0	4	1	1	1
132355	1710	use proteolytic digestion	[using proteolytic digestion]	0.0	3	1	1	1
132356	1710	indicate the result	[indicating the result]	0.0	3	1	1	1
132357	1710	human (gamma)	[human (gamma)]	0.0	2	1	1	1
132358	1710	glucocorticoid in acute lymphoblastic leukemia	[glucocorticoids in acute lymphoblastic leukemia]	0.0	5	1	1	1
132359	1710	integrin signal pathway	[integrin signaling pathway]	0.0	3	1	1	1
132360	1710	rrna for c-fo	[mRNAs for c-fos]	0.0	3	1	1	1
132361	1710	DR alpha x box	[DR alpha X box]	0.0	4	1	1	1
132362	1710	activation of non-erythroid gene	[activation of non-erythroid genes]	0.0	4	1	1	1
132363	1710	Tax1 a trans-activator	[Tax1 a trans-activator]	0.0	3	1	1	1
132364	1710	impaired thymocyte development	[Impaired thymocyte development]	0.0	3	1	1	1
132365	1710	window	[window]	0.0	1	1	1	1
132366	1710	lytic antigen-specific reactivity high	[lytic antigen-specific reactivities high]	0.0	4	1	1	1
132367	1710	closely mimick into extravascular tissue	[closely mimicking into extravascular tissues]	0.0	5	1	1	1
132368	1710	receptor and/or transduction pathway	[receptors and/or transduction pathways]	0.0	4	1	1	1
132369	1710	pfp5a contain bp	[PFP5a containing bp]	0.0	3	1	1	1
132370	1710	tight linkage	[tight linkage]	0.0	2	1	1	1
132371	1710	h in quiescent endothelial cell	[h in quiescent endothelial cells]	0.0	5	1	1	1
132372	1710	adherent cell with neurite process	[adherent cells with neurite processes]	0.0	5	1	1	1
132373	1710	application against a cellular	[application against a cellular]	0.0	4	1	1	1
132374	1710	regulatory gene expression	[regulatory gene expression]	0.0	3	1	1	1
132375	1710	pattern by humara analysis	[pattern by HUMARA analysis]	0.0	4	1	1	1
132376	1710	therapeutic value through down regulation	[therapeutic value through down regulation]	0.0	5	1	1	1
132377	1710	quiescent T cell	[quiescent T cells]	0.0	3	1	1	1
132378	1710	coagulation factor	[coagulation factors]	0.0	2	1	1	1
132379	1710	erythroid development; addition of RA	[erythroid development; addition of RA]	0.0	5	1	1	1
132380	1710	use a whole-cell binding assay	[Using a whole-cell binding assay]	0.0	5	1	1	1
132381	1710	synthesis of tissue factor	[synthesis of tissue factor]	0.0	4	1	1	1
132382	1710	endothelial cell harc	[endothelial cells HAECs]	0.0	3	1	1	1
132383	1710	cytokine assembly contain complex	[cytokines assembly containing complexes]	0.0	4	1	1	1
132384	1710	regulation of CD38	[regulation of CD38]	0.0	3	1	1	1
132385	1710	ikappab -alpha	[IkappaB -alpha]	0.0	2	1	1	1
132386	1710	application of this form	[Application of this form]	0.0	4	1	1	1
132387	1710	oxide a pathway	[oxide a pathway]	0.0	3	1	1	1
132388	1710	dependence for activation	[dependence for activation]	0.0	3	1	1	1
132389	1710	increase in sensitivity	[increase in sensitivity]	0.0	3	1	1	1
132390	1710	vd response	[VD response]	0.0	2	1	1	1
132391	1710	blot analysis of genomic DNA	[blot analysis of genomic DNA]	0.0	5	1	1	1
132392	1710	regard to potential clinical relevance	[regard to potential clinical relevance]	0.0	5	1	1	1
132393	1710	aberrant form	[aberrant form]	0.0	2	1	1	1
132394	1710	negative modulator of LMP1	[negative modulator of LMP1]	0.0	4	1	1	1
132395	1710	identification of cytogenetic abnormality	[identification of cytogenetic abnormalities]	0.0	4	1	1	1
132396	1710	monoblastic cell line	[monoblastic cell line]	0.0	3	1	1	1
132397	1710	developmental pattern	[developmental patterns]	0.0	2	1	1	1
132398	1710	role of ERK in proliferation	[roles of ERK in proliferation]	0.0	5	1	1	1
132399	1710	profound inhibition of response	[profound inhibition of responses]	0.0	4	1	1	1
132400	1710	region of the promoter (termed UAS1	[regions of the promoter (termed UAS1]	0.0	6	1	1	1
132401	1710	level of iron	[levels of iron]	0.0	3	1	1	1
132402	1710	ag amino acid sequence	[Ag amino acid sequence]	0.0	4	1	1	1
132403	1710	genetic target in b-cell development	[genetic target in B-cell development]	0.0	5	1	1	1
132404	1710	contain STAT3 alone	[containing STAT3 alone]	0.0	3	1	1	1
132405	1710	association latency in certain monocytic cell	[Association latency in certain monocytic cells]	0.0	6	1	1	1
132406	1710	Recognition of this leukemic entity	[Recognition of this leukemic entity]	0.0	5	1	1	1
132407	1710	U2 snrna gene activation	[U2 snRNA gene activation]	0.0	4	1	1	1
132408	1710	master gene	[master gene]	0.0	2	1	1	1
132409	1710	unrecognized mechanism	[unrecognized mechanism]	0.0	2	1	1	1
132410	1710	activation function	[activation functions]	0.0	2	1	1	1
132411	1710	inhibition of 62% in pbmc	[inhibition of 62% in PBMC]	0.0	5	1	1	1
132412	1710	microvessel endothelial cell MVEC	[microvessel endothelial cells MVEC]	0.0	4	1	1	1
132413	1710	binding of multiple cellular factor	[binding of multiple cellular factors]	0.0	5	1	1	1
132414	1710	participate in the gamma-globin to switch	[participating in the gamma-globin to switch]	0.0	6	1	1	1
132415	1710	Sp1urday related transcription factor	[Sp1- related transcription factors]	0.0	4	1	1	1
132416	1710	interaction in hypertension	[interactions in hypertension]	0.0	3	1	1	1
132417	1710	high il-2 level	[high IL-2 levels]	0.0	3	1	1	1
132418	1710	b cell activator protein	[B cell activator protein]	0.0	4	1	1	1
132419	1710	highly homologous member	[highly homologous members]	0.0	3	1	1	1
132420	1710	two T cell line CEM	[Two T cell lines CEM]	0.0	5	1	1	1
132421	1710	selective suppression	[selective suppression]	0.0	2	1	1	1
132422	1710	cepharanthine on hiv-1 terminal repeat	[cepharanthine on HIV-1 terminal repeat]	0.0	5	1	1	1
132423	1710	comparison no synthase gene in response	[comparison NO synthase genes in response]	0.0	6	1	1	1
132424	1710	progenitor cells,	[progenitor cells,]	0.0	2	1	1	1
132425	1710	negative regulatory pathway	[negative regulatory pathways]	0.0	3	1	1	1
132426	1710	stimulation monoclonal antibody mab phosphatidylinositol 3-kinase	[Stimulation monoclonal antibody mAb phosphatidylinositol 3-kinase]	0.0	6	1	1	1
132427	1710	three bp repeat	[three bp repeats]	0.0	3	2	2	1
132428	1710	proteolytic cleavage	[proteolytic cleavage]	0.0	2	1	1	1
132429	1710	high-level replication of the hiv-1	[high-level replication of the HIV-1]	0.0	5	1	1	1
132430	1710	expose huvec	[Exposing HUVECs]	0.0	2	1	1	1
132431	1710	two proteins, cyclophilin	[two proteins, cyclophilin]	0.0	3	1	1	1
132432	1710	provide a mechanism	[providing an mechanism]	0.0	3	1	1	1
132433	1710	encode a dna-binding protein protein hxbp-1	[encoding a DNA-binding protein protein hXBP-1]	0.0	6	1	1	1
132434	1710	analysis nuclear factor	[analysis nuclear factor]	0.0	3	1	1	1
132435	1710	relative mass of kda.	[relative mass of kDa.]	0.0	4	1	1	1
132436	1710	eight patient 3 to 15 years)	[Eight patients 3 to 15 years)]	0.0	6	1	1	1
132437	1710	surface receptor for igg FcgammaRI	[surface receptor for IgG FcgammaRI]	0.0	5	1	1	1
132438	1710	evidence for a allosteric effect	[evidence for an allosteric effect]	0.0	5	1	1	1
132439	1710	factor-kappaB induction in cd45ro+	[factor-kappaB induction in CD45RO+]	0.0	4	1	1	1
132440	1710	and/or growth	[and/or growth]	0.0	2	1	1	1
132441	1710	molecular mechanism a type	[Molecular mechanisms a type]	0.0	4	1	1	1
132442	1710	GRE oligonucleotide	[GRE oligonucleotides]	0.0	2	1	1	1
132443	1710	producer	[producers]	0.0	1	1	1	1
132444	1710	agent on cell activation	[agents on cell activation]	0.0	4	1	1	1
132445	1710	study responsiveness to immediate-early transactivator	[studying responsiveness to immediate-early transactivators]	0.0	5	1	1	1
132446	1710	lps- transcriptional induction	[LPS- transcriptional induction]	0.0	3	1	1	1
132447	1710	rest b lymphocyte	[resting B lymphocytes]	0.0	3	1	1	1
132448	1710	1 out of 13 healthy control	[1 out of 13 healthy controls]	0.0	6	1	1	1
132449	1710	expression of early serum gene	[expression of early serum genes]	0.0	5	1	1	1
132450	1710	oct-2 gene expression	[Oct-2 gene expression]	0.0	3	1	1	1
132451	1710	drastic change	[drastic changes]	0.0	2	1	1	1
132452	1710	leukocyte differentiation	[leukocyte differentiation]	0.0	2	1	1	1
132453	1710	competent vector	[competent vector]	0.0	2	1	1	1
132454	1710	clone nuclear extract	[clone nuclear extracts]	0.0	3	1	1	1
132455	1710	Rapid induction	[Rapid induction]	0.0	2	1	1	1
132456	1710	normal affinity to glucocorticoid	[normal affinity to glucocorticoids]	0.0	4	1	1	1
132457	1710	factor kappab binding	[factor kappaB binding]	0.0	3	1	1	1
132458	1710	minimal discrepancy	[minimal discrepancies]	0.0	2	1	1	1
132459	1710	expression of effector molecule	[expression of effector molecules]	0.0	4	1	1	1
132460	1710	five element	[five elements]	0.0	2	1	1	1
132461	1710	all-tran acid RA treatment	[all-trans acid RA treatment]	0.0	4	1	1	1
132462	1710	bear dqa1*0501/dqb1*0201 heterodimer	[bearing DQA1*0501/DQB1*0201 heterodimers]	0.0	3	1	1	1
132463	1710	blot analysis of DNA	[blot analysis of DNA]	0.0	4	1	1	1
132464	1710	estrogen receptor er in leucocyte	[estrogen receptors ER in leucocytes]	0.0	5	1	1	1
132465	1710	dramatic response	[dramatic response]	0.0	2	1	1	1
132466	1710	10000-fold selectivity for aldosterone	[10000-fold selectivity for aldosterone]	0.0	4	2	2	1
132467	1710	(colony	[(colony]	0.0	1	1	1	1
132468	1710	bhrf1 early-lytic-cycle protein with homology	[BHRF1 early-lytic-cycle protein with homology]	0.0	5	1	1	1
132469	1710	and/or modification of transcription factor	[and/or modifications of transcription factors]	0.0	5	1	1	1
132470	1710	DNA-protein binding assay with nuclear extract	[DNA-protein binding assays with nuclear extracts]	0.0	6	1	1	1
132471	1710	formation of ap1 transcriptional complex	[formation of AP1 transcriptional complex]	0.0	5	1	1	1
132472	1710	induction cell differentiation into monocyte /macrophage	[Induction cell differentiation into monocytes /macrophages]	0.0	6	1	1	1
132473	1710	Dithiocarbamates DTC a group	[Dithiocarbamates DTC a group]	0.0	4	1	1	1
132474	1710	mutagenesis of CIITA	[mutagenesis of CIITA]	0.0	3	1	1	1
132475	1710	function-related gene	[function-related genes]	0.0	2	1	1	1
132476	1710	binding site of member	[binding sites of members]	0.0	4	1	1	1
132477	1710	role of receptor in cell	[role of receptors in cells]	0.0	5	1	1	1
132478	1710	role in cell proliferation	[role in cell proliferation]	0.0	4	1	1	1
132479	1710	ctf/cbp	[CTF/CBP]	0.0	1	1	1	1
132480	1710	expression of nuclear factor kappab	[expression of nuclear factor kappaB]	0.0	5	1	1	1
132481	1710	bp EBNA2 responsive region	[bp EBNA2 responsive region]	0.0	4	1	1	1
132482	1710	gene in Epo-dependent cell line	[genes in Epo-dependent cell lines]	0.0	5	1	1	1
132483	1710	type i interferon	[type I interferons]	0.0	3	1	1	1
132484	1710	Glucocorticoid resistance in asthma	[Glucocorticoid resistance in asthma]	0.0	4	1	1	1
132485	1710	also dinucleotide trinucleotide repeat	[also dinucleotide trinucleotide repeats]	0.0	4	1	1	1
132486	1710	Smu/Sepsilon switch fragment	[Smu/Sepsilon switch fragments]	0.0	3	1	1	1
132487	1710	day 12 hematopoietic liver	[day 12 hematopoietic liver]	0.0	4	1	1	1
132488	1710	cepharanthine on hiv-1 long repeat	[cepharanthine on HIV-1 long repeat]	0.0	5	1	1	1
132489	1710	comprehensive screen of individual	[comprehensive screening of individuals]	0.0	4	1	1	1
132490	1710	expression of STAT1	[expression of STAT1]	0.0	3	1	1	1
132491	1710	stimulation of platelet-activate factor	[stimulation of platelet-activating factor]	0.0	4	1	1	1
132492	1710	three series: at subject	[three series: at subjects]	0.0	4	1	1	1
132493	1710	early gene c-jun	[early gene c-jun]	0.0	3	1	1	1
132494	1710	partial characterization	[partial characterization]	0.0	2	1	1	1
132495	1710	glucocorticoid replacement in vitro by incubation	[glucocorticoid replacement in vitro by incubation]	0.0	6	1	1	1
132496	1710	proliferator-activated receptor (pparalpha) transcription factor	[proliferator-activated receptor (PPARalpha) transcription factor]	0.0	5	1	1	1
132497	1710	Chinese hamster ovary	[Chinese hamster ovary]	0.0	3	1	1	1
132498	1710	peptide show cross-reactivity	[peptide showing cross-reactivity]	0.0	3	1	1	1
132499	1710	combination, at concentration	[combination, at concentrations]	0.0	3	1	1	1
132500	1710	late gene expression in Epstein-Barr virus	[late gene expression in Epstein-Barr virus]	0.0	6	1	1	1
132501	1710	101pp dnase 1 site-forming element	[101bp, DNase 1 site-forming element]	0.0	5	1	1	1
132502	1710	minor b-cell component	[minor B-cell component]	0.0	3	1	1	1
132503	1710	addition, activity of il-2	[addition, activity of IL-2]	0.0	4	1	1	1
132504	1710	nuclear positivity	[nuclear positivity]	0.0	2	1	1	1
132505	1710	expression of class histocompatibility gene	[expression of class histocompatibility genes]	0.0	5	1	1	1
132506	1710	cloning of are-containing gene	[Cloning of ARE-containing genes]	0.0	4	1	1	1
132507	1710	il-1ra protein secretion	[IL-1ra protein secretion]	0.0	3	1	1	1
132508	1710	ascorbate free radical AFR act	[ascorbate free radical AFR acts]	0.0	5	1	1	1
132509	1710	ankyrin protein include the product	[ankyrin proteins including the products]	0.0	5	1	1	1
132510	1710	loss to a region	[loss to a region]	0.0	4	1	1	1
132511	1710	immune-endocrine interplay	[immune-endocrine interplay]	0.0	2	1	1	1
132512	1710	genomic action of D3 (1325(oh)2d3)	[genomic actions of D3 (1,25(OH)2D3)]	0.0	5	1	1	1
132513	1710	contrast to induction	[contrast to induction]	0.0	3	1	1	1
132514	1710	implicate sequence	[implicating sequences]	0.0	2	1	1	1
132515	1710	virus +55 region	[virus +55 region]	0.0	3	1	1	1
132516	1710	modulation of activity	[modulation of activity]	0.0	3	1	1	1
132517	1710	main transcriptional co-activator	[main transcriptional co-activator]	0.0	3	1	1	1
132518	1710	gene mrp14	[gene MRP14]	0.0	2	1	1	1
132519	1710	inhibition by overexpression of a inhibitor	[Inhibition by overexpression of a inhibitor]	0.0	6	1	1	1
132520	1710	T lymphocyte of patient	[T lymphocytes of patients]	0.0	4	1	1	1
132521	1710	show interaction between October factor	[showing interactions between Oct factors]	0.0	5	1	1	1
132522	1710	prolymphocytic leukemia	[prolymphocytic leukemias]	0.0	2	1	1	1
132523	1710	histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma	[histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	5	1	1	1
132524	1710	regulator of growth	[regulators of growth]	0.0	3	1	1	1
132525	1710	cooperativity in the response	[cooperativity in the response]	0.0	4	1	1	1
132526	1710	only low binding affinity	[only low binding affinities]	0.0	4	1	1	1
132527	1710	characterization of this pel cell line	[characterization of these PEL cell lines]	0.0	6	1	1	1
132528	1710	mass between 94	[mass between 94]	0.0	3	1	1	1
132529	1710	staining in comedo	[staining in comedo]	0.0	3	1	1	1
132530	1710	/microg	[/microg]	0.0	1	1	1	1
132531	1710	differentiation implication of signal in cell	[differentiation implications of signals in cells]	0.0	6	1	1	1
132532	1710	NF-kappa b binding site kappa b-1	[NF-kappa B binding sites kappa B-1]	0.0	6	1	1	1
132533	1710	gamma(c)-positive, il-13r alpha1 daudi cell	[gamma(c)-positive, IL-13R alpha1 Daudi cells]	0.0	5	1	1	1
132534	1710	kappa b/rel dna-binding motif	[kappa B/Rel DNA-binding motifs]	0.0	4	1	1	1
132535	1710	immunodeficiency virus type-1 hiv	[immunodeficiency virus type-1 HIV]	0.0	4	1	1	1
132536	1710	mutation of dq2-anchor residue	[mutations of DQ2-anchor residues]	0.0	4	1	1	1
132537	1710	Beres Drops Plus	[Beres Drops Plus]	0.0	3	1	1	1
132538	1710	gene, suppressor signal 3	[gene, suppressor signaling 3]	0.0	4	1	1	1
132539	1710	herpesvirus related	[herpesvirus related]	0.0	2	1	1	1
132540	1710	difference in the incidence	[difference in the incidence]	0.0	4	1	1	1
132541	1710	two immediate protein	[two immediate proteins]	0.0	3	1	1	1
132542	1710	Steady-state level	[Steady-state levels]	0.0	2	1	1	1
132543	1710	AP-1 consensus tre motif	[AP-1 consensus TRE motif]	0.0	4	1	1	1
132544	1710	45,x cell line	[45,X cell line]	0.0	3	1	1	1
132545	1710	transactivation incubation	[transactivation incubation]	0.0	2	1	1	1
132546	1710	carrier of xcid	[carriers of XCID]	0.0	3	1	1	1
132547	1710	multiple allelic family	[multiple allelic families]	0.0	3	1	1	1
132548	1710	nucleotide sequence from the tsc2	[nucleotide sequence from the TSC2]	0.0	5	1	1	1
132549	1710	signal pathway in neutrophil	[signaling pathways in neutrophils]	0.0	4	1	1	1
132550	1710	selective displacement	[selective displacement]	0.0	2	1	1	1
132551	1710	limited requirement	[limited requirement]	0.0	2	1	1	1
132552	1710	reflection of a threshold	[reflection of a threshold]	0.0	4	1	1	1
132553	1710	growth factor-B proto-oncogene	[growth factor-B proto-oncogene]	0.0	3	1	1	1
132554	1710	patient with thyroidism	[Patients with thyroidism]	0.0	3	1	1	1
132555	1710	killer cell line nkl	[killer cell line NKL]	0.0	4	1	1	1
132556	1710	Conclusions: epithelial cell	[CONCLUSIONS: epithelial cells]	0.0	3	1	1	1
132557	1710	ATL patient (mean ng/ml)	[ATL patients (mean ng/mL)]	0.0	4	1	1	1
132558	1710	relation to possible approach	[relation to possible approaches]	0.0	4	1	1	1
132559	1710	bind protein/activating transcription factor	[binding protein/activating transcription factor]	0.0	4	1	1	1
132560	1710	chain- mab	[chain- mAbs]	0.0	2	1	1	1
132561	1710	variable proliferative response	[variable proliferative response]	0.0	3	1	1	1
132562	1710	developmental-specific expression	[developmental-specific expression]	0.0	2	1	1	1
132563	1710	pc4 from the extract	[PC4 from the extract]	0.0	4	1	1	1
132564	1710	experimental series: at (17 subject	[experimental series: at (17 subjects]	0.0	5	1	1	1
132565	1710	evidence for defect	[evidence for defects]	0.0	3	1	1	1
132566	1710	IL-10 antibody	[IL-10 antibody]	0.0	2	1	1	1
132567	1710	subunit association	[subunit associations]	0.0	2	1	1	1
132568	1710	expression a enzyme	[Expression an enzyme]	0.0	3	1	1	1
132569	1710	antituberculous response	[antituberculous response]	0.0	2	1	1	1
132570	1710	preactivation of T cell	[Preactivation of T cells]	0.0	4	1	1	1
132571	1710	deactivate cytokine interleukin	[deactivating cytokine interleukin]	0.0	3	1	1	1
132572	1710	version of STAT5b	[version of STAT5b]	0.0	3	1	1	1
132573	1710	h2-antagonist	[H2-antagonist]	0.0	1	1	1	1
132574	1710	dish	[dishes]	0.0	1	1	1	1
132575	1710	stimulation as a prognostic parameter	[stimulation as a prognostic parameter]	0.0	5	1	1	1
132576	1710	mrp14 migration related protein	[MRP14 migration related protein]	0.0	4	1	1	1
132577	1710	member of rel protein	[members of Rel proteins]	0.0	4	1	1	1
132578	1710	tumor-derived soluble product	[Tumor-derived soluble products]	0.0	3	1	1	1
132579	1710	presence of NGAL	[presence of NGAL]	0.0	3	1	1	1
132580	1710	powerful suppressor most notably	[powerful suppressors most notably]	0.0	4	1	1	1
132581	1710	14 h	[14 h]	0.0	2	1	1	1
132582	1710	only ligand-induced tyrosine phosphorylation	[only ligand-induced tyrosine phosphorylation]	0.0	4	1	1	1
132583	1710	opposite receptor changes, oppose	[opposite receptor changes, opposing]	0.0	4	1	1	1
132584	1710	(ie, aitl	[(ie, AITL]	0.0	2	1	1	1
132585	1710	saturate amount	[saturating amounts]	0.0	2	1	1	1
132586	1710	ifn-alpha stimulation	[IFN-alpha stimulation]	0.0	2	1	1	1
132587	1710	NF-kappa b p65 transcriptional activation	[NF-kappa B p65 transcriptional activation]	0.0	5	1	1	1
132588	1710	binding to the peri-kappa b site	[binding to the peri-kappa B site]	0.0	6	1	1	1
132589	1710	tal1 mutant	[TAL1 mutant]	0.0	2	1	1	1
132590	1710	myeloid leukemia-M3	[myeloid leukemia-M3]	0.0	2	1	1	1
132591	1710	activity of this molecule.	[activity of this molecule.]	0.0	4	1	1	1
132592	1710	sensitive structure	[sensitive structures]	0.0	2	1	1	1
132593	1710	alteration in glucocorticoid receptor	[alterations in glucocorticoid receptor]	0.0	4	1	1	1
132594	1710	normal parent molecule	[normal parent molecules]	0.0	3	1	1	1
132595	1710	pathway of synthesis in t-cell clone	[pathways of synthesis in T-cell clones]	0.0	6	1	1	1
132596	1710	mature definitive cell	[mature definitive cells]	0.0	3	1	1	1
132597	1710	healthy volunteer (86 man	[healthy volunteers (86 men]	0.0	4	1	1	1
132598	1710	complete activation of T cell	[complete activation of T cells]	0.0	5	1	1	1
132599	1710	blood, cd56+ cd16+ killer cell	[blood, CD56+ CD16+ killer cells]	0.0	5	1	1	1
132600	1710	subsequent nf-kappa b accumulation ready	[subsequent NF-kappa B accumulation ready]	0.0	5	1	1	1
132601	1710	cd44 transcription in b	[CD44 transcription in B]	0.0	4	1	1	1
132602	1710	target for protein responsive	[target for proteins responsive]	0.0	4	1	1	1
132603	1710	cell with mrna encoding	[cells with mRNA encoding]	0.0	4	1	1	1
132604	1710	sequence homology with the oncogene product	[sequence homology with the oncogene product]	0.0	6	1	1	1
132605	1710	CMV element	[CMV elements]	0.0	2	1	1	1
132606	1710	relatively specific binding site	[relatively specific binding sites]	0.0	4	1	1	1
132607	1710	clone overexpress hIRAK a activation	[clones overexpressing hIRAK a activation]	0.0	5	1	1	1
132608	1710	effect on the gene	[effects on the genes]	0.0	4	1	1	1
132609	1710	relative quantification	[relative quantification]	0.0	2	1	1	1
132610	1710	age-related lymphocyte dysfunction	[age-related lymphocyte dysfunction]	0.0	3	1	1	1
132611	1710	amounts,	[amounts,]	0.0	1	1	1	1
132612	1710	galectin-3 expression	[galectin-3 expression]	0.0	2	1	1	1
132613	1710	suspension	[suspension]	0.0	1	1	1	1
132614	1710	deletion of the amino-terminal region	[Deletion of the amino-terminal region]	0.0	5	1	1	1
132615	1710	factor control expression	[factors controlling expression]	0.0	3	1	1	1
132616	1710	include myeloid leukaemia CML	[including myeloid leukaemia CML]	0.0	4	2	2	1
132617	1710	element necessary for the steroid hormone	[Elements necessary for the steroid hormone]	0.0	6	1	1	1
132618	1710	effect of interleukin-4	[effect of interleukin-4]	0.0	3	1	1	1
132619	1710	Effect similar	[Effects similar]	0.0	2	1	1	1
132620	1710	feature include sensitivity to neuraminidase	[features including sensitivity to neuraminidase]	0.0	5	1	1	1
132621	1710	expression of pkc isoform	[expression of PKC isoforms]	0.0	4	1	1	1
132622	1710	second site (HS 2)	[second site (HS 2)]	0.0	4	1	1	1
132623	1710	METHODS: seventeen out of 22 case	[METHODS: Seventeen out of 22 cases]	0.0	6	1	1	1
132624	1710	central mechanism	[central mechanisms]	0.0	2	1	1	1
132625	1710	E2F sequence	[E2F sequence]	0.0	2	1	1	1
132626	1710	principally ga-binding protein	[principally GA-binding protein]	0.0	3	1	1	1
132627	1710	four- great amount	[four- greater amounts]	0.0	3	1	1	1
132628	1710	evidence important	[evidence important]	0.0	2	1	1	1
132629	1710	16.5 nmol/L) for the glucocorticoid receptor	[16.5 nmol/L) for the glucocorticoid receptors]	0.0	6	1	1	1
132630	1710	specificity to a reporter gene	[specificity to a reporter gene]	0.0	5	1	1	1
132631	1710	factor AP-1/Octamer UPS	[factor AP-1/Octamer UPS]	0.0	3	1	1	1
132632	1710	difference in stability.	[difference in stability.]	0.0	3	1	1	1
132633	1710	Rb rescue	[Rb rescue]	0.0	2	1	1	1
132634	1710	modification of GR	[modification of GR]	0.0	3	1	1	1
132635	1710	treatment with microm sodium orthovanadate NaOV	[Treatment with microM sodium orthovanadate NaOV]	0.0	6	1	1	1
132636	1710	"normal" lymphokine	["normal" lymphokines]	0.0	2	1	1	1
132637	1710	human macrophage PAM	[human macrophages PAM]	0.0	3	1	1	1
132638	1710	phage	[phage]	0.0	1	1	1	1
132639	1710	bipotent human myeloid progenitor cell	[bipotent human myeloid progenitor cells]	0.0	5	1	1	1
132640	1710	androgen binding site in leukocyte	[Androgen binding sites in leukocytes]	0.0	5	1	1	1
132641	1710	induce CAT activity /mn2+	[inducing CAT activity /Mn2+]	0.0	4	1	1	1
132642	1710	nontransformed mouse T cell	[nontransformed mouse T cells]	0.0	4	1	1	1
132643	1710	evidence of regulation by IFNs	[evidence of regulation by IFNs]	0.0	5	1	1	1
132644	1710	nucleic acid sequence	[nucleic acid sequence]	0.0	3	1	1	1
132645	1710	ikk protein stimulus-mediated transcription,	[IKK protein stimulus-mediated transcription,]	0.0	4	1	1	1
132646	1710	specific binding of [3H]dexamethasone (p	[specific binding of [3H]dexamethasone (P]	0.0	5	1	1	1
132647	1710	shuttling of the nfat	[shuttling of the NFAT]	0.0	4	1	1	1
132648	1710	alpha thf/thf (0.35; n:	[alpha THF/THF (0.35; N:]	0.0	4	1	1	1
132649	1710	cell particularly b cell	[cells particularly B cells]	0.0	4	1	1	1
132650	1710	glucocorticoid in thp cell	[glucocorticoids in THP cells]	0.0	4	1	1	1
132651	1710	p95vav involvement	[p95vav involvement]	0.0	2	1	1	1
132652	1710	amp-responsive member	[AMP-responsive members]	0.0	2	1	1	1
132653	1710	major envelope glycoprotein	[major envelope glycoprotein]	0.0	3	1	1	1
132654	1710	concomitant removal	[concomitant removal]	0.0	2	1	1	1
132655	1710	minimal disease of patient	[minimal disease of patients]	0.0	4	1	1	1
132656	1710	expression of the tat protein	[Expression of the Tat protein]	0.0	5	1	1	1
132657	1710	promyelocytic leukemia particularly the variant	[promyelocytic leukemia particularly the variant]	0.0	5	1	1	1
132658	1710	ic50 for the steroid-resistant group	[IC50s for the steroid-resistant group]	0.0	5	1	1	1
132659	1710	contribute to the myeloid-specific expression	[contributing to the myeloid-specific expression]	0.0	5	1	1	1
132660	1710	particularly in the stage	[particularly in the stages]	0.0	4	1	1	1
132661	1710	novel pathway for action	[novel pathway for action]	0.0	4	1	1	1
132662	1710	STAT1 nuclear import by noninvasive delivery	[STAT1 nuclear import by noninvasive delivery]	0.0	6	1	1	1
132663	1710	use a mutant stock	[using a mutant stock]	0.0	4	1	1	1
132664	1710	thyroid hormone- response element	[thyroid hormone- response elements]	0.0	4	1	1	1
132665	1710	bisdioxopiperazine	[bisdioxopiperazine]	0.0	1	1	1	1
132666	1710	level of several cytokine	[levels of several cytokines]	0.0	4	1	1	1
132667	1710	pathogenic infection	[pathogenic infections]	0.0	2	1	1	1
132668	1710	plasticity	[plasticity]	0.0	1	1	1	1
132669	1710	glucocorticoid-sensitive cell	[glucocorticoid-sensitive cells]	0.0	2	1	1	1
132670	1710	furthermore, persistent hiv infection	[Furthermore, persistent HIV infection]	0.0	4	1	1	1
132671	1710	gene expression of receptor	[gene expression of receptors]	0.0	4	1	1	1
132672	1710	two distinct family acid receptor	[two distinct families acid receptors]	0.0	5	1	1	1
132673	1710	mechanism distinct from kinase	[mechanisms distinct from kinase]	0.0	4	1	1	1
132674	1710	T lymphocyte clonotypes: implication for mimicry	[T lymphocyte clonotypes: implications for mimicry]	0.0	6	1	1	1
132675	1710	several tumor	[several tumors]	0.0	2	1	1	1
132676	1710	presence of endogenous IFN activity	[presence of endogenous IFN activity]	0.0	5	1	1	1
132677	1710	Further, deletion	[Further, deletion]	0.0	2	1	1	1
132678	1710	cytokine synthesis activity	[cytokine synthesis activity]	0.0	3	1	1	1
132679	1710	functional specificity of regulator	[functional specificity of regulators]	0.0	4	1	1	1
132680	1710	colony size expansion) occur	[colony size expansion) occurring]	0.0	4	1	1	1
132681	1710	evidence of transcriptional regulation	[evidence of transcriptional regulation]	0.0	4	1	1	1
132682	1710	B-specific binding factor present	[B-specific binding factors present]	0.0	4	1	1	1
132683	1710	chicken shc	[chicken Shc]	0.0	2	1	1	1
132684	1710	single class of binding site	[single class of binding sites]	0.0	5	1	1	1
132685	1710	Class histocompatibility (class ii) gene	[Class histocompatibility (class II) genes]	0.0	5	1	1	1
132686	1710	none to slightly on epidermal cell	[none to slightly on epidermal cells]	0.0	6	1	1	1
132687	1710	mab BW 828	[mAb BW 828]	0.0	3	1	1	1
132688	1710	antibody cross-linking in U1 promonocytic culture	[antibody cross-linking in U1 promonocytic cultures]	0.0	6	1	1	1
132689	1710	49 case of b leukemia	[49 cases of B leukemias]	0.0	5	1	1	1
132690	1710	characterization binding	[characterization Binding]	0.0	2	1	1	1
132691	1710	unfused ebna3c	[unfused EBNA3C]	0.0	2	1	1	1
132692	1710	interaction with specific factor	[interaction with specific factors]	0.0	4	1	1	1
132693	1710	bind to intracellular domain sequence	[binding to intracellular domain sequences]	0.0	5	1	1	1
132694	1710	similar form of immunodeficiency SCID	[similar forms of immunodeficiency SCID]	0.0	5	1	1	1
132695	1710	profoundly decreased, z-lll-h activity	[profoundly decreased, Z-LLL-H activity]	0.0	4	1	1	1
132696	1710	MIP-1alpha gene	[MIP-1alpha gene]	0.0	2	1	1	1
132697	1710	nuclear)	[nuclear)]	0.0	1	1	1	1
132698	1710	event in primate	[events in primates]	0.0	3	1	1	1
132699	1710	Negative regulation of interleukin IL-2 gene	[Negative regulation of interleukin IL-2 gene]	0.0	6	1	1	1
132700	1710	lymphoma-derived hybridoma	[lymphoma-derived hybridoma]	0.0	2	1	1	1
132701	1710	PRL- factor	[PRL- factors]	0.0	2	1	1	1
132702	1710	tumor cell type	[tumor cell types]	0.0	3	1	1	1
132703	1710	class major histocompatibility gene hla-dra	[class major histocompatibility gene HLA-DRA]	0.0	5	1	1	1
132704	1710	such vector	[such vectors]	0.0	2	1	1	1
132705	1710	acetyltransferase expression	[acetyltransferase expression]	0.0	2	1	1	1
132706	1710	pml/ raralpha	[PML/ RARalpha]	0.0	2	1	1	1
132707	1710	inactive complex	[inactive complex]	0.0	2	2	2	1
132708	1710	minutes) to all-tran retinoic acid washed,	[minutes) to all-trans retinoic acid washed,]	0.0	6	1	1	1
132709	1710	phosphorylation of the ikappab inhibitor	[Phosphorylation of the IkappaB inhibitors]	0.0	5	1	1	1
132710	1710	inhibitor kinase upstream of ERK1/2	[inhibitors kinase upstream of ERK1/2]	0.0	5	1	1	1
132711	1710	expression of gene in megakaryoblastic disorder	[Expression of genes in megakaryoblastic disorders]	0.0	6	1	1	1
132712	1710	indicate entry	[indicating entry]	0.0	2	1	1	1
132713	1710	chloramphenicol acetyltransferase CAT assay after cotransfection	[Chloramphenicol acetyltransferase CAT assay after cotransfection]	0.0	6	1	1	1
132714	1710	important element NF-AT-1	[important element NF-AT-1]	0.0	3	1	1	1
132715	1710	two pkc substrate marck	[two PKC substrates MARCKS]	0.0	4	1	1	1
132716	1710	specific protein substrate	[specific protein substrates]	0.0	3	1	1	1
132717	1710	Rel-A	[Rel-A]	0.0	1	1	1	1
132718	1710	potentially disable sequela	[potentially disabling sequela]	0.0	3	1	1	1
132719	1710	low, concentration of aldosterone	[low, concentrations of aldosterone]	0.0	4	2	2	1
132720	1710	single site for ebf homologous sequence	[single sites for EBF homologous sequences]	0.0	6	1	1	1
132721	1710	determine receptor function	[determining receptor function]	0.0	3	1	1	1
132722	1710	melanoma RCC	[melanoma RCC]	0.0	2	1	1	1
132723	1710	inactivate substitution	[inactivating substitutions]	0.0	2	1	1	1
132724	1710	endometrium in endometriosis	[endometrium in endometriosis]	0.0	3	1	1	1
132725	1710	primary approach create hiv-1/siv	[primary approach creating HIV-1/SIV]	0.0	4	1	1	1
132726	1710	human membrane system	[human membrane system]	0.0	3	1	1	1
132727	1710	strong activity in HeLa cell	[stronger activity in HeLa cells]	0.0	5	1	1	1
132728	1710	ablation of htlv-i tumor by inhibition	[Ablation of HTLV-I tumors by inhibition]	0.0	6	1	1	1
132729	1710	ICK-1 family	[ICK-1 family]	0.0	2	1	1	1
132730	1710	numerous cellular abnormality	[Numerous cellular abnormalities]	0.0	3	1	1	1
132731	1710	receptor alpha PPARalpha	[receptor alpha PPARalpha]	0.0	3	1	1	1
132732	1710	human mammary epithelial cell grow	[human mammary epithelial cells growing]	0.0	5	1	1	1
132733	1710	cell adhesive property	[cell adhesive properties]	0.0	3	1	1	1
132734	1710	camkiv on activation	[CaMKIV on activation]	0.0	3	1	1	1
132735	1710	region from -429	[region from -429]	0.0	3	1	1	1
132736	1710	presence in several cytokine gene	[presence in several cytokine genes]	0.0	5	1	1	1
132737	1710	use a incompetent g-csfr mutant	[Using a incompetent G-CSFR mutant]	0.0	5	1	1	1
132738	1710	T cell receptor CD3 stimulation	[T cell receptor CD3 stimulation]	0.0	5	1	1	1
132739	1710	blood healthy volunteer (86 man	[blood healthy volunteers (86 men]	0.0	5	1	1	1
132740	1710	500-fold excess of ligand	[500-fold excess of ligand]	0.0	4	1	1	1
132741	1710	approximately 1600 VDR	[approximately 1600 VDR]	0.0	3	1	1	1
132742	1710	cytochrome p-450 vcam-1 induction by TNF,	[cytochrome P-450 VCAM-1 induction by TNF,]	0.0	6	1	1	1
132743	1710	daudi	[Daudi]	0.0	1	1	1	1
132744	1710	marrow progenitor	[marrow progenitor]	0.0	2	1	1	1
132745	1710	Rapid nongenomic in vitro effect	[Rapid nongenomic in vitro effects]	0.0	5	1	1	1
132746	1710	abundance of vd receptor	[abundance of VD receptor]	0.0	4	1	1	1
132747	1710	type EBS level	[type EBS levels]	0.0	3	1	1	1
132748	1710	elevation in the peripheral level	[elevations in the peripheral levels]	0.0	5	1	1	1
132749	1710	normalize effect increase of total ca2+	[normalizing effect increase of total Ca2+]	0.0	6	1	1	1
132750	1710	in-situ labelling breaks.	[in-situ labelling breaks.]	0.0	3	1	1	1
132751	1710	near-perfect repeat of 21 bp	[near-perfect repeats of 21 bp]	0.0	5	1	1	1
132752	1710	reconstitution of T cell antigen	[Reconstitution of T cell antigen]	0.0	5	1	1	1
132753	1710	HSV CD4 T cell localize	[HSV CD4 T cells localizing]	0.0	5	1	1	1
132754	1710	latent membrane protein 1 LMP1	[latent membrane protein 1 LMP1]	0.0	5	1	1	1
132755	1710	young adult before overnight dst	[young adults before overnight DST]	0.0	5	1	1	1
132756	1710	precise definition	[precise definition]	0.0	2	1	1	1
132757	1710	factor-1 gene expression in NK cell	[factor-1 gene expression in NK cells]	0.0	6	1	1	1
132758	1710	sublects: Fifteen patient	[SUBJECTS: Fifteen patients]	0.0	3	1	1	1
132759	1710	overexpression of BXB a constitutive version	[Overexpression of BXB a constitutive version]	0.0	6	1	1	1
132760	1710	modulator nf-kappab activation	[modulator NF-kappaB activation]	0.0	3	1	1	1
132761	1710	mutant of traf2	[mutant of TRAF2]	0.0	3	1	1	1
132762	1710	full promoter activity	[full promoter activity]	0.0	3	1	1	1
132763	1710	adult leukemia	[adult leukemia]	0.0	2	1	1	1
132764	1710	other effects,	[other effects,]	0.0	2	1	1	1
132765	1710	contain bovine serum	[containing bovine serum]	0.0	3	1	1	1
132766	1710	role in lps signal	[role in LPS signaling]	0.0	4	1	1	1
132767	1710	CD4 virus envelope	[CD4 virus envelope]	0.0	3	1	1	1
132768	1710	result of htlv-i infection	[result of HTLV-I infection]	0.0	4	1	1	1
132769	1710	also a potent inducer in all	[also a potent inducer in all]	0.0	6	1	1	1
132770	1710	activation of ISGF3 alpha	[Activation of ISGF3 alpha]	0.0	4	1	1	1
132771	1710	effect of cortisol	[effect of cortisol]	0.0	3	1	1	1
132772	1710	receptor-effector-mechor-mechanisms the sequence	[receptor-effector-mechanisms the sequence]	0.0	3	1	1	1
132773	1710	eutopic trimester human pregnancy	[eutopic trimester human pregnancies]	0.0	4	1	1	1
132774	1710	(cho)-k1	[(CHO)-K1]	0.0	1	1	1	1
132775	1710	effective apc after immunization.	[effective APC after immunization.]	0.0	4	1	1	1
132776	1710	kappa b beta degradation	[kappa B beta degradation]	0.0	4	1	1	1
132777	1710	suppression of the immune response	[suppression of the immune response]	0.0	5	1	1	1
132778	1710	respect to maximal suppression	[respect to maximal suppression]	0.0	4	1	1	1
132779	1710	50-kDa species	[50-kDa species]	0.0	2	1	1	1
132780	1710	recombinant soluble tnf receptor	[recombinant soluble TNF receptor]	0.0	4	1	1	1
132781	1710	of lap much as am580	[of LAP much as AM580]	0.0	5	1	1	1
132782	1710	torr),	[Torr),]	0.0	1	1	1	1
132783	1710	anti-CD3 mab stimulation	[anti-CD3 mAb stimulation]	0.0	3	1	1	1
132784	1710	work, employ deletion	[work, employing deletions]	0.0	3	1	1	1
132785	1710	cytoplasm with granularity	[cytoplasm with granularity]	0.0	3	1	1	1
132786	1710	map kinase extracellular kinase	[MAP kinase extracellular kinase]	0.0	4	1	1	1
132787	1710	competitive assay	[competitive assay]	0.0	2	1	1	1
132788	1710	vivo protein-DNA	[vivo protein-DNA]	0.0	2	2	2	1
132789	1710	analysis of the regulation of IkappaBalpha	[Analyses of the regulation of IkappaBalpha]	0.0	6	1	1	1
132790	1710	active kinase	[active kinase]	0.0	2	1	1	1
132791	1710	pathway of apoptosis	[pathways of apoptosis]	0.0	3	1	1	1
132792	1710	Jun NH(2)-terminal kinase	[Jun NH(2)-terminal kinase]	0.0	3	1	1	1
132793	1710	vivo inhibition of nf-kappa b	[vivo inhibition of NF-kappa B]	0.0	5	1	1	1
132794	1710	vitamin d-dependent ricket	[vitamin D-dependent rickets]	0.0	3	1	1	1
132795	1710	protein Epstein Barr	[proteins Epstein Barr]	0.0	3	1	1	1
132796	1710	AU-rich element	[AU-rich elements]	0.0	2	1	1	1
132797	1710	erythroblast cell line	[erythroblast cell line]	0.0	3	2	2	1
132798	1710	signal pathway upstream	[signaling pathways upstream]	0.0	3	1	1	1
132799	1710	novel protein (around 35 kda	[novel proteins (around 35 kDa]	0.0	5	1	1	1
132800	1710	insight into a new role	[insight into a new role]	0.0	5	1	1	1
132801	1710	degradation in lipopolysaccharide	[degradation in lipopolysaccharide]	0.0	3	1	1	1
132802	1710	selection clonal expansion) (by stimulation	[selection clonal expansion) (by stimulation]	0.0	5	1	1	1
132803	1710	involvement of oxygen species ROS	[involvement of oxygen species ROS]	0.0	5	1	1	1
132804	1710	polymorphonuclear granulocyte pmn	[polymorphonuclear granulocytes PMN]	0.0	3	1	1	1
132805	1710	primary T lymphocyte with	[primary T lymphocytes with]	0.0	4	1	1	1
132806	1710	level of plc gamma	[level of PLC gamma]	0.0	4	1	1	1
132807	1710	mode of transmission	[mode of transmission]	0.0	3	2	2	1
132808	1710	combination of reagent	[combination of reagents]	0.0	3	1	1	1
132809	1710	silence a beta-promoter	[silencing a beta-promoter]	0.0	3	1	1	1
132810	1710	HIV repeat LTR	[HIV repeat LTR]	0.0	3	1	1	1
132811	1710	interferon-gamma gene expression	[interferon-gamma gene expression]	0.0	3	1	1	1
132812	1710	increase in calcium level,	[increase in calcium level,]	0.0	4	1	1	1
132813	1710	anti-human cd14 antibody	[anti-human CD14 antibody]	0.0	3	1	1	1
132814	1710	novel octamer binding protein	[novel octamer binding proteins]	0.0	4	1	1	1
132815	1710	prominent protein kinase c substrate	[prominent protein kinase C substrate]	0.0	5	1	1	1
132816	1710	effect on human NK	[effects on human NK]	0.0	4	1	1	1
132817	1710	novel IL-2 transcriptional inhibitor	[novel IL-2 transcriptional inhibitors]	0.0	4	1	1	1
132818	1710	oestrogen organ	[oestrogen organs]	0.0	2	1	1	1
132819	1710	use a form Max	[using a form Max]	0.0	4	1	1	1
132820	1710	spontaneous expression in human sle	[spontaneous expression in human SLE]	0.0	5	1	1	1
132821	1710	oestrogen er	[oestrogen ER]	0.0	2	1	1	1
132822	1710	Immunological study in immunodeficiency virus patient	[Immunological studies in immunodeficiency virus patients]	0.0	6	1	1	1
132823	1710	leukemia blast cell	[leukemia blast cells]	0.0	3	1	1	1
132824	1710	human cell along the Th1	[human cells along the Th1]	0.0	5	1	1	1
132825	1710	essential mediator generate positive mechanism	[essential mediator generating positive mechanisms]	0.0	5	1	1	1
132826	1710	gr site	[GR sites]	0.0	2	1	1	1
132827	1710	study the mechanism responsible	[studying the mechanisms responsible]	0.0	4	1	1	1
132828	1710	other t-helper cell cytokine	[other T-helper cell cytokines]	0.0	4	1	1	1
132829	1710	x box region factor, RFX	[X box region factor, RFX]	0.0	5	1	1	1
132830	1710	moreover, cd3+	[Moreover, CD3+]	0.0	2	1	1	1
132831	1710	potent factor for neutrophil granulocyte	[potent factor for neutrophil granulocytes]	0.0	5	1	1	1
132832	1710	S2' subsite	[S2' subsites]	0.0	2	1	1	1
132833	1710	dual effect 1) inhibition of growth	[dual effects 1) inhibition of growth]	0.0	6	1	1	1
132834	1710	b-lcl	[B-LCL]	0.0	1	1	1	1
132835	1710	transcription factor with dominant function	[transcription factor with dominant functions]	0.0	5	1	1	1
132836	1710	conformation polymorphism (sscp) technique	[conformation polymorphism (SSCP) technique]	0.0	4	1	1	1
132837	1710	gata factor in erythropoiesis	[GATA factors in erythropoiesis]	0.0	4	1	1	1
132838	1710	CAAT/enhancer binding protein	[CAAT/enhancer binding proteins]	0.0	3	1	1	1
132839	1710	depend on environment.	[depending on environment.]	0.0	3	1	1	1
132840	1710	preterm of the group	[preterms of the group]	0.0	4	1	1	1
132841	1710	human leukocyte antigen	[human leukocyte antigen]	0.0	3	1	1	1
132842	1710	dnase 1 hypersensitive site-forming element	[DNase 1 hypersensitive site-forming element]	0.0	5	1	1	1
132843	1710	induce the constitutive degradation	[inducing the constitutive degradation]	0.0	4	1	1	1
132844	1710	strain of mouse	[strain of mice]	0.0	3	1	1	1
132845	1710	SCL transcription factor	[SCL transcription factors]	0.0	3	1	1	1
132846	1710	(egr-1) gene expression	[(EGR-1) gene expression]	0.0	3	1	1	1
132847	1710	same set	[same set]	0.0	2	1	1	1
132848	1710	ig heavy chain sequence	[Ig heavy chain sequences]	0.0	4	1	1	1
132849	1710	additionally, costimulation	[additionally, costimulation]	0.0	2	1	1	1
132850	1710	transfection under control of virus 40	[transfection under control of virus 40]	0.0	6	1	1	1
132851	1710	expression of surface markers, content	[Expression of surface markers, content]	0.0	5	1	1	1
132852	1710	crucial IL-4 promoter	[crucial IL-4 promoter]	0.0	3	1	1	1
132853	1710	two-site interaction of factor	[Two-site interaction of factor]	0.0	4	1	1	1
132854	1710	initiation of encephalomyocarditis virus mrna	[initiation of encephalomyocarditis virus mRNA]	0.0	5	1	1	1
132855	1710	obvious merit	[obvious merit]	0.0	2	1	1	1
132856	1710	trancriptional activity	[trancriptional activity]	0.0	2	1	1	1
132857	1710	minute of monocyte adherence	[min of monocyte adherence]	0.0	4	1	1	1
132858	1710	formation of ap1 complex	[formation of AP1 complex]	0.0	4	1	1	1
132859	1710	basophilia in acute promyelocytic leukaemia	[basophilia in acute promyelocytic leukaemia]	0.0	5	1	1	1
132860	1710	decrease after pretreatment	[decrease after pretreatment]	0.0	3	1	1	1
132861	1710	tumour sample	[tumour samples]	0.0	2	1	1	1
132862	1710	expression of stat binding factor	[expression of STAT binding factors]	0.0	5	1	1	1
132863	1710	redox regulation.	[redox regulation.]	0.0	2	1	1	1
132864	1710	protein include the tumor necrosis factor	[proteins including the tumor necrosis factor]	0.0	6	1	1	1
132865	1710	host immune mechanism	[host immune mechanisms]	0.0	3	1	1	1
132866	1710	significantly high number	[significantly higher number]	0.0	3	2	2	1
132867	1710	region resemble a dbd adjacent	[region resembling a DBD adjacent]	0.0	5	1	1	1
132868	1710	inhibit nf-kappab translocation from the cytosol	[inhibiting NF-kappaB translocation from the cytosol]	0.0	6	1	1	1
132869	1710	ubiquitous element	[ubiquitous element]	0.0	2	1	1	1
132870	1710	transcription of BZLF-1 a gene	[transcription of BZLF-1 an gene]	0.0	5	1	1	1
132871	1710	marker of high rate	[markers of high rate]	0.0	4	1	1	1
132872	1710	block nuclear factor of T lymphocyte	[blocking nuclear factor of T lymphocytes]	0.0	6	1	1	1
132873	1710	site of infection by adenoviruse	[site of infection by adenoviruses]	0.0	5	1	1	1
132874	1710	anti-early antigen anti-viral capsid antigen vca	[anti-early antigen anti-viral capsid antigen VCA]	0.0	6	1	1	1
132875	1710	tandem array of zinc finger	[tandem arrays of zinc fingers]	0.0	5	1	1	1
132876	1710	anti-early antigen antigen vca	[anti-early antigen antigen VCA]	0.0	4	1	1	1
132877	1710	immunodeficiency virus in thymocyte	[immunodeficiency virus in thymocytes]	0.0	4	1	1	1
132878	1710	cell from ATLL patient	[cells from ATLL patients]	0.0	4	1	1	1
132879	1710	presence epo factor gm-csf	[presence EPO factor GM-CSF]	0.0	4	1	1	1
132880	1710	mutation by gene truncation result	[mutations by gene truncation resulting]	0.0	5	1	1	1
132881	1710	human interleukin-2 gene	[human interleukin-2 gene]	0.0	3	1	1	1
132882	1710	nuclear factor-kappa b tnf-alpha release	[nuclear factor-kappa B TNF-alpha release]	0.0	5	1	1	1
132883	1710	such as IL-1beta	[such as IL-1beta]	0.0	3	1	1	1
132884	1710	1-wk course 20 mg	[1-wk course 20 mg]	0.0	4	1	1	1
132885	1710	synthase (nos) isoform	[synthase (NOS) isoforms]	0.0	3	1	1	1
132886	1710	(atf) family CREB isoform	[(ATF) family CREB isoforms]	0.0	4	1	1	1
132887	1710	ten patient with affinity to glucocorticoid	[Ten patients with affinity to glucocorticoids]	0.0	6	1	1	1
132888	1710	inflammatory bowel disease colitis	[inflammatory bowel diseases colitis]	0.0	4	1	1	1
132889	1710	HLA dr11	[HLA DR11]	0.0	2	1	1	1
132890	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one a inhibitor activation	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one an inhibitor activation]	0.0	4	1	1	1
132891	1710	effect of Rb expression	[effect of Rb expression]	0.0	4	1	1	1
132892	1710	Glucocorticoid receptor change	[Glucocorticoid receptors changes]	0.0	3	1	1	1
132893	1710	antifungal effect	[antifungal effects]	0.0	2	1	1	1
132894	1710	transcriptional regulation of gene	[transcriptional regulation of genes]	0.0	4	1	1	1
132895	1710	thalassaemia patient	[thalassaemia patients]	0.0	2	1	1	1
132896	1710	feedback "talking"	[feedback "talking"]	0.0	2	1	1	1
132897	1710	pbr 322-relaxation-assay	[PBR 322-relaxation-assay]	0.0	2	1	1	1
132898	1710	formation of dna-binding complex	[formation of DNA-binding complexes]	0.0	4	1	1	1
132899	1710	-positive T	[-positive T]	0.0	2	1	1	1
132900	1710	block this two element	[blocking these two elements]	0.0	4	1	1	1
132901	1710	icam-1 cd54 expression in cell	[ICAM-1 CD54 expression in cells]	0.0	5	1	1	1
132902	1710	originate from tissue cell	[originating from tissue cells]	0.0	4	1	1	1
132903	1710	few cell body	[Fewer cell bodies]	0.0	3	1	1	1
132904	1710	result of splicing.	[result of splicing.]	0.0	3	1	1	1
132905	1710	exhibit differentiation	[exhibiting differentiation]	0.0	2	1	1	1
132906	1710	EBV Epstein-Barr region (EBER) RNA-positive	[EBV Epstein-Barr region (EBER) RNA-positive]	0.0	5	1	1	1
132907	1710	cleavage by caspase during anti-igm-induced apoptosis	[Cleavage by caspases during anti-IgM-induced apoptosis]	0.0	6	1	1	1
132908	1710	binding of nf-kappab heterodimer	[binding of NF-kappaB heterodimers]	0.0	4	1	1	1
132909	1710	androgen receptor (humara)	[androgen receptor (HUMARA)]	0.0	3	1	1	1
132910	1710	threefold	[threefold]	0.0	1	1	1	1
132911	1710	delineation of pathway	[delineation of pathways]	0.0	3	1	1	1
132912	1710	differential strategy	[differential strategies]	0.0	2	1	1	1
132913	1710	g-seropositive	[G-seropositive]	0.0	1	1	1	1
132914	1710	molecular mass proteins.	[molecular masses proteins.]	0.0	3	1	1	1
132915	1710	1,2-bis(o-aminophenoxy)-ethane-n,n,n',n'-tetraacetic acid	[1,2-bis(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid]	0.0	2	1	1	1
132916	1710	acid-sensitive serine /threonine phosphatase	[acid-sensitive serine /threonine phosphatases]	0.0	4	1	1	1
132917	1710	range from 25 kD	[ranging from 25 kD]	0.0	4	1	1	1
132918	1710	haematopoietic cell in experimental model	[haematopoietic cells in experimental models]	0.0	5	1	1	1
132919	1710	focus on own study	[focus on own studies]	0.0	4	1	1	1
132920	1710	element within this region,	[elements within this region,]	0.0	4	1	1	1
132921	1710	ap1 reporter construct	[AP1 reporter constructs]	0.0	3	1	1	1
132922	1710	transcriptional means	[transcriptional means]	0.0	2	1	1	1
132923	1710	point in the response	[point in the response]	0.0	4	1	1	1
132924	1710	presumably occur in response	[presumably occurring in response]	0.0	4	1	1	1
132925	1710	characteristic of ef1 at low abundance	[characteristics of EF1 at low abundance]	0.0	6	1	1	1
132926	1710	weight variant in monocyte	[weight variant in monocytes]	0.0	4	1	1	1
132927	1710	human class transplantation gene	[human class transplantation gene]	0.0	4	1	1	1
132928	1710	platelet endothelial cell adhesion molecule	[platelet endothelial cell adhesion molecules]	0.0	5	1	1	1
132929	1710	naturally infect baboon	[naturally infecting baboons]	0.0	3	1	1	1
132930	1710	importance of comedo versus noncomedo	[importance of comedo versus noncomedo]	0.0	5	1	1	1
132931	1710	T3 receptor site	[T3 receptor sites]	0.0	3	1	1	1
132932	1710	Ran GTP -dependent association of CRM1	[Ran GTP -dependent association of CRM1]	0.0	6	1	1	1
132933	1710	myeloid differentiation protein	[myeloid differentiation protein]	0.0	3	1	1	1
132934	1710	differentiation a novel model	[differentiation a novel model]	0.0	4	1	1	1
132935	1710	blood transfusion	[blood transfusion]	0.0	2	1	1	1
132936	1710	peptide chemoattractant	[peptide chemoattractant]	0.0	2	1	1	1
132937	1710	high level of protein	[high levels of proteins]	0.0	4	1	1	1
132938	1710	negative expression vector of ras	[negative expression vectors of ras]	0.0	5	1	1	1
132939	1710	tcl1 protein	[TCL1 protein]	0.0	2	1	1	1
132940	1710	product of this loci	[products of these loci]	0.0	4	1	1	1
132941	1710	expression of human c-rel	[expression of human c-Rel]	0.0	4	1	1	1
132942	1710	association with targets.	[association with targets.]	0.0	3	1	1	1
132943	1710	importance such as creb	[importance such as CREB]	0.0	4	1	1	1
132944	1710	pou family primer	[POU family primers]	0.0	3	1	1	1
132945	1710	However, transactivation	[However, transactivation]	0.0	2	1	1	1
132946	1710	discussion	[discussion]	0.0	1	2	2	1
132947	1710	pore complex NPC	[pore complex NPC]	0.0	3	1	1	1
132948	1710	moreover, in contrast to subject	[Moreover, in contrast to subjects]	0.0	5	1	1	1
132949	1710	position within the protein.	[position within the protein.]	0.0	4	1	1	1
132950	1710	regulator of the activity	[regulator of the activity]	0.0	4	1	1	1
132951	1710	region resemble a dbd	[region resembling a DBD]	0.0	4	1	1	1
132952	1710	therapy in mononuclear leukocyte	[therapy in mononuclear leukocytes]	0.0	4	1	1	1
132953	1710	leukocyte lineages,	[leukocyte lineages,]	0.0	2	1	1	1
132954	1710	useful technique	[useful technique]	0.0	2	1	1	1
132955	1710	ap-1 from PHA-activated cell	[AP-1 from PHA-activated cells]	0.0	4	1	1	1
132956	1710	overexpression a protein	[Overexpression a protein]	0.0	3	1	1	1
132957	1710	0.5 (0.2-1.6)	[0.5 (0.2-1.6)]	0.0	2	1	1	1
132958	1710	association with event	[association with events]	0.0	3	1	1	1
132959	1710	erythroid ocim1	[erythroid OCIM1]	0.0	2	1	1	1
132960	1710	promoter promoter	[promoters promoter]	0.0	2	1	1	1
132961	1710	adolescent adult patient	[adolescent adult patients]	0.0	3	1	1	1
132962	1710	3,605 binding site	[3,605 binding sites]	0.0	3	1	1	1
132963	1710	four functional region	[four functional regions]	0.0	3	1	1	1
132964	1710	Differential induction during restimulation	[Differential induction during restimulation]	0.0	4	1	1	1
132965	1710	generation of primary immune response	[generation of primary immune responses]	0.0	5	1	1	1
132966	1710	IL-4 promoter more than 10-fold	[IL-4 promoter more than 10-fold]	0.0	5	1	1	1
132967	1710	signal abnormality in airway disease	[signaling abnormalities in airway disease]	0.0	5	1	1	1
132968	1710	three time for 12	[three times for 12]	0.0	4	1	1	1
132969	1710	hypertension.	[hypertension.]	0.0	1	2	2	1
132970	1710	recruitment of progenitor	[recruitment of progenitors]	0.0	3	1	1	1
132971	1710	bind to receptor intracellular domain sequence	[binding to receptor intracellular domain sequences]	0.0	6	1	1	1
132972	1710	type estrogen binding site variation	[Type estrogen binding sites variations]	0.0	5	1	1	1
132973	1710	erythroid cell express the fetal	[erythroid cells expressing the fetal]	0.0	5	1	1	1
132974	1710	repeat promoter	[repeat promoter]	0.0	2	1	1	1
132975	1710	T cell of patient	[T cells of patients]	0.0	4	1	1	1
132976	1710	cosmid encode human ciita	[cosmids encoding human CIITA]	0.0	4	1	1	1
132977	1710	cell with staining	[cells with staining]	0.0	3	1	1	1
132978	1710	16HBE human epithelial cell	[16HBE human epithelial cells]	0.0	4	1	1	1
132979	1710	stringent activation requirement	[stringent activation requirements]	0.0	3	1	1	1
132980	1710	inducible transcriptional regulator of numerous gene	[inducible transcriptional regulators of numerous genes]	0.0	6	1	1	1
132981	1710	absence of differentiation	[absence of differentiation]	0.0	3	1	1	1
132982	1710	dp2 of the promoter	[DP2 of the promoter]	0.0	4	1	1	1
132983	1710	case of bl	[cases of BL]	0.0	3	1	1	1
132984	1710	incubation with dose of dexamethasone	[incubation with doses of dexamethasone]	0.0	5	1	1	1
132985	1710	SCID-HU-INT mouse	[SCID-HU-INT mice]	0.0	2	1	1	1
132986	1710	effect on hiv-1 expression	[effect on HIV-1 expression]	0.0	4	1	1	1
132987	1710	hck expression	[hck expression]	0.0	2	1	1	1
132988	1710	novel type	[novel type]	0.0	2	1	1	1
132989	1710	viral antigen staining with bz1 reactivity	[viral antigen staining with BZ1 reactivity]	0.0	6	1	1	1
132990	1710	sclerosis patient	[sclerosis patients]	0.0	2	1	1	1
132991	1710	comedo variants.	[comedo variants.]	0.0	2	1	1	1
132992	1710	thiol-reduce compounds,	[thiol-reducing compounds,]	0.0	2	1	1	1
132993	1710	corticosteroid receptor in lymphocyte a marker	[Corticosteroid receptors in lymphocytes a marker]	0.0	6	1	1	1
132994	1710	ligand-dependent activation	[ligand-dependent activation]	0.0	2	1	1	1
132995	1710	Missense mutation in exon	[Missense mutation in exon]	0.0	4	1	1	1
132996	1710	glucocorticoid receptor on peripheral leucocyte	[glucocorticoid receptors on peripheral leucocytes]	0.0	5	1	1	1
132997	1710	kinase /pkb	[kinase /PKB]	0.0	2	1	1	1
132998	1710	development of specific human inflammatory pathology	[development of specific human inflammatory pathologies]	0.0	6	1	1	1
132999	1710	responder cell line	[responder cell line]	0.0	3	1	1	1
133000	1710	anti- v3 loop monoclonal antibody	[anti- V3 loop monoclonal antibody]	0.0	5	1	1	1
133001	1710	leukemic (aml) blast	[leukemic (AML) blasts]	0.0	3	1	1	1
133002	1710	pathway bypass the requirement	[pathway bypassing the requirement]	0.0	4	1	1	1
133003	1710	contain four direct repeat	[containing four direct repeats]	0.0	4	1	1	1
133004	1710	difference in this cells.	[differences in these cells.]	0.0	4	1	1	1
133005	1710	high number of cell	[higher number of cells]	0.0	4	1	1	1
133006	1710	therapy in colitis	[therapy in colitis]	0.0	3	1	1	1
133007	1710	occur at nm.	[occurring at nM.]	0.0	3	1	1	1
133008	1710	MIP1 alpha protein MNP	[MIP1 alpha protein MNP]	0.0	4	1	1	1
133009	1710	hTR beta 1 mrna level	[hTR beta 1 mRNA levels]	0.0	5	1	1	1
133010	1710	Hydroxyurea	[Hydroxyurea]	0.0	1	1	1	1
133011	1710	involve inadequate response	[involving inadequate responses]	0.0	3	1	1	1
133012	1710	binding site for a factor	[binding sites for a factor]	0.0	5	1	1	1
133013	1710	myelogenous leukemia 1-	[myelogenous leukemia 1-]	0.0	3	1	1	1
133014	1710	inhibition by a peptide inhibitor	[inhibition by a peptide inhibitor]	0.0	5	1	1	1
133015	1710	RU43044	[RU43044]	0.0	1	1	1	1
133016	1710	inhibition of pkc activity	[inhibition of PKC activity]	0.0	4	1	1	1
133017	1710	fibrosarcoma histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
133018	1710	D3 determination	[D3 determination]	0.0	2	1	1	1
133019	1710	inhibitory mechanims.	[inhibitory mechanims.]	0.0	2	1	1	1
133020	1710	potential mechanism for induction	[potential mechanism for induction]	0.0	4	1	1	1
133021	1710	hematopoietic cell-specific transcription factor	[hematopoietic cell-specific transcription factor]	0.0	4	1	1	1
133022	1710	macrophage in tissue	[macrophages in tissues]	0.0	3	1	1	1
133023	1710	rhythm of receptor in leukocyte	[rhythm of receptors in leukocytes]	0.0	5	1	1	1
133024	1710	footprinting agent	[footprinting agent]	0.0	2	1	1	1
133025	1710	e2 from E1	[E2 from E1]	0.0	3	1	1	1
133026	1710	kinetics, p84	[kinetics, p84]	0.0	2	1	1	1
133027	1710	contain cysteine -rich region	[containing cysteine -rich regions]	0.0	4	1	1	1
133028	1710	ms2-hbx fusion protein	[MS2-HBx fusion proteins]	0.0	3	1	1	1
133029	1710	region e1a	[regions E1A]	0.0	2	1	1	1
133030	1710	pHU-14 hybridize close	[pHU-14 hybridizes close]	0.0	3	1	1	1
133031	1710	two positive region PRRI	[two positive regions PRRI]	0.0	4	1	1	1
133032	1710	colony-stimulating factor receptor promoter	[colony-stimulating factor receptor promoter]	0.0	4	1	1	1
133033	1710	specific instance	[specific instance]	0.0	2	1	1	1
133034	1710	regulate the response in T cell	[regulating the response in T cells]	0.0	6	1	1	1
133035	1710	early receptor-triggered events,	[early receptor-triggered events,]	0.0	3	1	1	1
133036	1710	244-bp deoxycytidine	[244-bp deoxycytidine]	0.0	2	1	1	1
133037	1710	moreover, TNF-alpha hiv-1 long terminal repeat	[Moreover, TNF-alpha HIV-1 long terminal repeat]	0.0	6	1	1	1
133038	1710	bind radioassay	[binding radioassay]	0.0	2	1	1	1
133039	1710	activity of this transcription factor	[activity of this transcription factor]	0.0	5	1	1	1
133040	1710	cytolytic action of other protein	[cytolytic action of other proteins]	0.0	5	1	1	1
133041	1710	leukotriene b4 generation	[leukotriene B4 generation]	0.0	3	1	1	1
133042	1710	potent site	[potent site]	0.0	2	1	1	1
133043	1710	binding to MHC class molecule	[Binding to MHC class molecules]	0.0	5	1	1	1
133044	1710	Adherence-dependent increase	[Adherence-dependent increase]	0.0	2	1	1	1
133045	1710	simple derivation	[Simple derivation]	0.0	2	1	1	1
133046	1710	potent activity 100-fold low	[potent activity 100-fold lower]	0.0	4	1	1	1
133047	1710	cfp extract devoid	[CFP extracts devoid]	0.0	3	1	1	1
133048	1710	differentiation in the mouse erythroleukemia	[differentiation in the mouse erythroleukemia]	0.0	5	1	1	1
133049	1710	inhibitory molecule kappa b	[inhibitory molecule kappa B]	0.0	4	1	1	1
133050	1710	human herpesvirus strain	[human herpesvirus strains]	0.0	3	1	1	1
133051	1710	subsequent coordinate reduction	[subsequent coordinate reductions]	0.0	3	1	1	1
133052	1710	BCL-6 mutation evidence of somatic hypermutation	[BCL-6 mutations evidence of somatic hypermutation]	0.0	6	1	1	1
133053	1710	protein kinase c pkc downstream	[protein kinase C PKC downstream]	0.0	5	1	1	1
133054	1710	complementary DNA probe	[complementary DNA probe]	0.0	3	1	1	1
133055	1710	negative bl cell	[negative BL cells]	0.0	3	1	1	1
133056	1710	cell follow g-csf stimulation	[cells following G-CSF stimulation]	0.0	4	1	1	1
133057	1710	uncomplicated pregnancy	[uncomplicated pregnancies]	0.0	2	1	1	1
133058	1710	ghost membrane by glucocorticoid	[ghost membrane by glucocorticoids]	0.0	4	1	1	1
133059	1710	responsiveness of leukocyte	[responsiveness of leukocytes]	0.0	3	1	1	1
133060	1710	establishment of antigen-induced airway hyperresponsiveness	[establishment of antigen-induced airway hyperresponsiveness]	0.0	5	1	1	1
133061	1710	effect on the replication in cell	[effects on the replication in cells]	0.0	6	1	1	1
133062	1710	6- to 10-fold stimulation	[6- to 10-fold stimulation]	0.0	4	1	1	1
133063	1710	immune response through effect	[immune responses through effects]	0.0	4	1	1	1
133064	1710	5.6 kb of DNA	[5.6 kb of DNA]	0.0	4	1	1	1
133065	1710	DHEA receptor	[DHEA receptor]	0.0	2	2	2	1
133066	1710	kappa B/rel	[kappa B/rel]	0.0	2	1	1	1
133067	1710	strength of T cell receptor signal	[Strength of T cell receptor signaling]	0.0	6	1	1	1
133068	1710	mechanism involve the synthesis	[mechanism involving the synthesis]	0.0	4	1	1	1
133069	1710	activation and/or differentiation stage	[activation and/or differentiation stages]	0.0	4	1	1	1
133070	1710	relation to histocompatibility class	[relation to histocompatibility classes]	0.0	4	1	1	1
133071	1710	cell (nf-at)	[cell (NF-AT)]	0.0	2	1	1	1
133072	1710	tissue-specific regulatory DNA element present	[tissue-specific regulatory DNA element present]	0.0	5	1	1	1
133073	1710	normal hemopoiesis, overexpression	[normal hemopoiesis, overexpression]	0.0	3	1	1	1
133074	1710	B nuclear factor OTF-2	[B nuclear factor OTF-2]	0.0	4	1	1	1
133075	1710	identification of a pebp2/cbf site	[identification of a PEBP2/CBF site]	0.0	5	1	1	1
133076	1710	class ii isotype	[class II isotypes]	0.0	3	1	1	1
133077	1710	amp-responsive protein	[AMP-responsive protein]	0.0	2	1	1	1
133078	1710	experimental series: at subject	[experimental series: at subjects]	0.0	4	1	1	1
133079	1710	fetal calf serum-supplemented efcs culture	[fetal calf serum-supplemented (FCS+) culture]	0.0	5	1	1	1
133080	1710	act on IkappaBalpha	[acting on IkappaBalpha]	0.0	3	1	1	1
133081	1710	10 case	[10 cases]	0.0	2	1	1	1
133082	1710	histidine residue	[histidine residue]	0.0	2	1	1	1
133083	1710	effective apc only after immunization.	[effective APC only after immunization.]	0.0	5	1	1	1
133084	1710	deletion within beta-catenin Delta19	[deletion within beta-catenin Delta19]	0.0	4	1	1	1
133085	1710	specific antibody recognition	[specific antibody recognition]	0.0	3	1	1	1
133086	1710	bi-directional discourse	[bi-directional discourse]	0.0	2	1	1	1
133087	1710	factor (NF)-kappaB sequence	[factor (NF)-kappaB sequence]	0.0	3	1	1	1
133088	1710	receptor constant in human lymphocyte	[receptors constant in human lymphocytes]	0.0	5	1	1	1
133089	1710	u937 promonocytic cell	[U937 promonocytic cells]	0.0	3	1	1	1
133090	1710	property of the transcription factor Oct-2a	[properties of the transcription factor Oct-2a]	0.0	6	1	1	1
133091	1710	expression of c-myb mrna	[expression of c-myb mRNA]	0.0	4	1	1	1
133092	1710	activation the initial latent gene promoter	[activation the initial latent gene promoter]	0.0	6	1	1	1
133093	1710	follow treatment with 135(oh)2d3	[following treatment with 1,25(OH)2D3]	0.0	4	1	1	1
133094	1710	related site	[related sites]	0.0	2	1	1	1
133095	1710	deletion into the proximal promoter	[deletions into the proximal promoter]	0.0	5	1	1	1
133096	1710	evidence in T cell	[Evidence in T cells]	0.0	4	1	1	1
133097	1710	Rb inactivation, lead	[Rb inactivation, leading]	0.0	3	1	1	1
133098	1710	nucleoprotein extract show dna-binding activity	[nucleoprotein extracts showing DNA-binding activity]	0.0	5	1	1	1
133099	1710	DeltaSpi-B	[DeltaSpi-B]	0.0	1	1	1	1
133100	1710	immunoglobulin chain igh intronic enhancer	[immunoglobulin chain IgH intronic enhancer]	0.0	5	1	1	1
133101	1710	occur between HHV-6	[occurring between HHV-6]	0.0	3	1	1	1
133102	1710	degradative action	[degradative action]	0.0	2	1	1	1
133103	1710	TNF factor-kappaB activation	[TNF factor-kappaB activation]	0.0	3	1	1	1
133104	1710	methods: t-cell clone	[METHODS: T-cell clones]	0.0	3	1	1	1
133105	1710	alpha beta 1	[alpha beta 1]	0.0	3	1	1	1
133106	1710	U1 cell line	[U1 cell line]	0.0	3	1	1	1
133107	1710	granulocyte colony-stimulating factor colony-stimumulatelany-stg factor proliferation	[granulocyte colony-stimulating factor colony-stimulating factor proliferation]	0.0	6	1	1	1
133108	1710	nuclear calcium/calmodulin-dependent	[nuclear calcium/calmodulin-dependent]	0.0	2	1	1	1
133109	1710	element P0	[elements P0]	0.0	2	1	1	1
133110	1710	-dependent transcriptional activation	[-dependent transcriptional activation]	0.0	3	1	1	1
133111	1710	encode the granulocyte- macrophage colony-stimumulatelany-stg factor	[encoding the granulocyte- macrophage colony-stimulating factor]	0.0	6	1	1	1
133112	1710	kinase responsible	[kinases responsible]	0.0	2	1	1	1
133113	1710	topical fluticasone propionate	[topical fluticasone propionate]	0.0	3	1	1	1
133114	1710	include muscle	[including muscle]	0.0	2	1	1	1
133115	1710	sh2-containing protein	[SH2-containing protein]	0.0	2	1	1	1
133116	1710	5' untranslated sequence	[5' untranslated sequence]	0.0	3	1	1	1
133117	1710	interactor (s)	[interactor (s)]	0.0	2	1	1	1
133118	1710	glucose homopolymer	[glucose homopolymer]	0.0	2	1	1	1
133119	1710	Ig chain class switch	[Ig chain class switching]	0.0	4	1	1	1
133120	1710	several t-cell-restricted marker	[several T-cell-restricted markers]	0.0	3	1	1	1
133121	1710	either on the b29 promoter	[either on the B29 promoter]	0.0	5	1	1	1
133122	1710	surface marker cd11b	[surface markers CD11b]	0.0	3	1	1	1
133123	1710	moreover, alteration of any one	[Moreover, alteration of any one]	0.0	5	1	1	1
133124	1710	promoter chromatin structure result	[promoter chromatin structure resulting]	0.0	4	1	1	1
133125	1710	responsiveness positive myelogenous leukemia	[responsiveness positive myelogenous leukemia]	0.0	4	1	1	1
133126	1710	regulation of human alpha-like globin promoter	[regulation of human alpha-like globin promoters]	0.0	6	1	1	1
133127	1710	underlie the translocation	[underlying the translocation]	0.0	3	1	1	1
133128	1710	medium MCM	[medium MCM]	0.0	2	1	1	1
133129	1710	such as raloxifene in cell	[such as Raloxifene in cells]	0.0	5	1	1	1
133130	1710	one serine kinase	[one serine kinases]	0.0	3	1	1	1
133131	1710	overexpression of cbl-b	[overexpression of Cbl-b]	0.0	3	1	1	1
133132	1710	member of the IFN factor	[member of the IFN factor]	0.0	5	1	1	1
133133	1710	Raf-1 kinase activity maximum 3.3-fold	[Raf-1 kinase activity maximum 3.3-fold]	0.0	5	1	1	1
133134	1710	primer corresponding	[primers corresponding]	0.0	2	1	1	1
133135	1710	involve the pancrea	[involving the pancreas]	0.0	3	1	1	1
133136	1710	biopsy of oral hairy leukoplakia	[Biopsies of oral hairy leukoplakia]	0.0	5	1	1	1
133137	1710	order transcriptional complex	[order transcriptional complex]	0.0	3	1	1	1
133138	1710	inhibition of NF-kappaB activity	[Inhibition of NF-kappaB activity]	0.0	4	1	1	1
133139	1710	[Cortisone-resistant asthma]	[[Cortisone-resistant asthma]]	0.0	2	1	1	1
133140	1710	nuclear protein hmg-i	[nuclear protein HMG-I]	0.0	3	1	1	1
133141	1710	gene regulatory response	[gene regulatory responses]	0.0	3	1	1	1
133142	1710	functional deficiency virus type hiv-1	[functional deficiency virus type HIV-1]	0.0	5	1	1	1
133143	1710	catabolism	[catabolism]	0.0	1	1	1	1
133144	1710	thus a target	[thus a target]	0.0	3	1	1	1
133145	1710	remove repression	[removing repression]	0.0	2	1	1	1
133146	1710	clinical glucocorticoid resistance	[clinical glucocorticoid resistance]	0.0	3	1	1	1
133147	1710	dansylcadaverine a enzyme inhibitor	[dansylcadaverine a enzyme inhibitor]	0.0	4	1	1	1
133148	1710	10(-12) g/g	[10(-12) g/g]	0.0	2	1	1	1
133149	1710	slight flow	[slight flow]	0.0	2	1	1	1
133150	1710	moderate grade of lymphocyte	[moderate grades of lymphocytes]	0.0	4	1	1	1
133151	1710	immunologically related protein	[immunologically related protein]	0.0	3	1	1	1
133152	1710	fascinating field in molecular immunology	[fascinating field in molecular immunology]	0.0	5	1	1	1
133153	1710	tuberculosis patient sarcoidosis patient	[tuberculosis patients sarcoidosis patients]	0.0	4	1	1	1
133154	1710	conserved, aromatic residue	[conserved, aromatic residues]	0.0	3	1	1	1
133155	1710	signal for transformation	[signals for transformation]	0.0	3	1	1	1
133156	1710	body axis	[body axis]	0.0	2	1	1	1
133157	1710	suppression with cell-permeable sn50 peptide	[suppression with cell-permeable SN50 peptide]	0.0	5	1	1	1
133158	1710	crucial element important for expression	[crucial element important for expression]	0.0	5	1	1	1
133159	1710	anti-CD3 abs	[anti-CD3 Abs]	0.0	2	1	1	1
133160	1710	human interferon factor 2	[Human interferon factor 2]	0.0	4	1	1	1
133161	1710	cd45 in T cell	[CD45 in T cells]	0.0	4	1	1	1
133162	1710	mmp9 activity, unique	[MMP9 activity, unique]	0.0	3	1	1	1
133163	1710	human interferon factor 1	[human interferon factor 1]	0.0	4	1	1	1
133164	1710	C5a a peptide chemoattractant	[C5a a peptide chemoattractant]	0.0	4	1	1	1
133165	1710	role for a novel	[Role for a novel]	0.0	4	1	1	1
133166	1710	covalent homodimer	[covalent homodimer]	0.0	2	1	1	1
133167	1710	only by a assay ELISA	[only by an assay ELISA]	0.0	5	1	1	1
133168	1710	occupancy of the viral enhancer	[occupancy of the viral enhancer]	0.0	5	1	1	1
133169	1710	mg-1	[mg-1]	0.0	1	3	3	1
133170	1710	STAT3 binding motif	[STAT3 binding motif]	0.0	3	1	1	1
133171	1710	nonsmok	[nonsmoking]	0.0	1	1	1	1
133172	1710	complex surface protein	[complex surface proteins]	0.0	3	1	1	1
133173	1710	creb protein p-creb	[CREB protein P-CREB]	0.0	3	1	1	1
133174	1710	1.2-kb cDNA encoding human c/ebp-epsilon	[1.2-kb cDNA encoding human C/EBP-epsilon]	0.0	5	1	1	1
133175	1710	potent activator of gene expression	[potent activator of gene expression]	0.0	5	1	1	1
133176	1710	cellular switch	[cellular switch]	0.0	2	1	1	1
133177	1710	full transcriptional activation	[full transcriptional activation]	0.0	3	1	1	1
133178	1710	mechanism other	[mechanisms other]	0.0	2	1	1	1
133179	1710	active version of c-Raf	[active version of c-Raf]	0.0	4	2	2	1
133180	1710	silencing of the beta-gene	[silencing of the beta-gene]	0.0	4	1	1	1
133181	1710	nf-kappa b translocation result p105	[NF-kappa B translocation results p105]	0.0	5	1	1	1
133182	1710	even after covariant analysis	[even after covariant analysis]	0.0	4	1	1	1
133183	1710	proline carboxy terminus	[proline carboxy terminus]	0.0	3	1	1	1
133184	1710	tyrosine amino transferase gene	[tyrosine amino transferase gene]	0.0	4	1	1	1
133185	1710	major (mhc) class gene expression	[major (MHC) class gene expression]	0.0	5	1	1	1
133186	1710	epithelial cell TEC	[epithelial cells TEC]	0.0	3	3	3	1
133187	1710	basal state	[basal state]	0.0	2	1	1	1
133188	1710	non-transformed murine Th1	[non-transformed murine Th1]	0.0	3	1	1	1
133189	1710	globulin	[globulin]	0.0	1	1	1	1
133190	1710	RFX b cell	[RFX B cells]	0.0	3	1	1	1
133191	1710	human immunodeficiency virus hiv replication	[human immunodeficiency virus HIV replication]	0.0	5	1	1	1
133192	1710	number of the cell	[number of the cells]	0.0	4	1	1	1
133193	1710	endemic goiter	[endemic goiter]	0.0	2	1	1	1
133194	1710	early proliferative samples, cytotoxic activity	[early proliferative samples, cytotoxic activity]	0.0	5	1	1	1
133195	1710	production of oxygen species serve	[production of oxygen species serving]	0.0	5	1	1	1
133196	1710	progression toward immunodeficiency syndrome	[progression toward immunodeficiency syndrome]	0.0	4	1	1	1
133197	1710	normal blood DC	[normal blood DC]	0.0	3	1	1	1
133198	1710	differential RNA display	[differential RNA display]	0.0	3	1	1	1
133199	1710	level of xenobiotic response element-binding activity	[levels of xenobiotic response element-binding activity]	0.0	6	1	1	1
133200	1710	mrna transcript of 2.3 kb.	[mRNA transcript of 2.3 kb.]	0.0	5	1	1	1
133201	1710	activity of the respective transcription factor	[activities of the respective transcription factors]	0.0	6	1	1	1
133202	1710	activity a potent transcriptional activator	[activity a potent transcriptional activator]	0.0	5	1	1	1
133203	1710	three day	[Three days]	0.0	2	1	1	1
133204	1710	(1/kd)	[(1/Kd)]	0.0	1	1	1	1
133205	1710	artificial light regime, peak value	[artificial light regime, peak values]	0.0	5	1	1	1
133206	1710	increase success	[Increasing success]	0.0	2	1	1	1
133207	1710	cord lymphocyte maximum c-fo	[cord lymphocyte maximum c-fos]	0.0	4	1	1	1
133208	1710	strike insensitivity	[striking insensitivity]	0.0	2	1	1	1
133209	1710	stimulation of interleukin-1 alpha	[Stimulation of interleukin-1 alpha]	0.0	4	1	1	1
133210	1710	72-kDa major protein	[72-kDa major protein]	0.0	3	1	1	1
133211	1710	112 patient with bipolar disorder	[112 patients with bipolar disorder]	0.0	5	1	1	1
133212	1710	interaction between the class transactivator	[Interactions between the class transactivator]	0.0	5	1	1	1
133213	1710	dual effect on malignant lymphocyte inhibition	[dual effects on malignant lymphocytes inhibition]	0.0	6	1	1	1
133214	1710	concentration of [3h]testosterone	[concentrations of [3H]testosterone]	0.0	3	1	1	1
133215	1710	BH10	[BH10]	0.0	1	1	1	1
133216	1710	H-gene	[H-gene]	0.0	1	1	1	1
133217	1710	activin a-	[activin A-]	0.0	2	1	1	1
133218	1710	potential inhibition by acetylsalicylate aspirin	[potential inhibition by acetylsalicylate aspirin]	0.0	5	1	1	1
133219	1710	molecular weight variant of stat5	[molecular weight variants of STAT5]	0.0	5	1	1	1
133220	1710	latent cycle reactivity to epitope	[latent cycle reactivities to epitopes]	0.0	5	1	1	1
133221	1710	bryostatin (10 nm),	[bryostatin (10 nM),]	0.0	3	1	1	1
133222	1710	cDNA clone encode nf-x2	[cDNA clone encoding NF-X2]	0.0	4	1	1	1
133223	1710	scatchard analysis	[Scatchard analysis]	0.0	2	1	1	1
133224	1710	i-binding	[I-binding]	0.0	1	2	2	1
133225	1710	latter factor	[latter factor]	0.0	2	1	1	1
133226	1710	cell populations,	[cell populations,]	0.0	2	1	1	1
133227	1710	difference in the clinical spectra	[differences in the clinical spectra]	0.0	5	1	1	1
133228	1710	activation of endogenous gene	[activation of endogenous genes]	0.0	4	1	1	1
133229	1710	other nf-kappab subunit	[other NF-kappaB subunits]	0.0	3	1	1	1
133230	1710	day 6	[day 6]	0.0	2	1	1	1
133231	1710	short-term expression of the tax protein	[short-term expression of the Tax protein]	0.0	6	1	1	1
133232	1710	ic50 of microM.	[IC50 of microM.]	0.0	3	1	1	1
133233	1710	BMLF1 of the early protein	[BMLF1 of the early proteins]	0.0	5	1	1	1
133234	1710	therefore, chromosome band rhombotin	[Therefore, chromosome bands rhombotin]	0.0	4	1	1	1
133235	1710	three consensus binding site	[three consensus binding sites]	0.0	4	1	1	1
133236	1710	one patient, reduction	[one patient, reduction]	0.0	3	1	1	1
133237	1710	product.	[product.]	0.0	1	1	1	1
133238	1710	transcription efficiency from template	[transcription efficiencies from templates]	0.0	4	1	1	1
133239	1710	clinical evidence	[clinical evidence]	0.0	2	1	1	1
133240	1710	amino-terminal	[amino-terminal]	0.0	1	1	1	1
133241	1710	other form of non-rheumatoid arthritis	[other forms of non-rheumatoid arthritis]	0.0	5	1	1	1
133242	1710	induce CAT activity for 2 h.	[inducing CAT activity for 2 h,]	0.0	6	1	1	1
133243	1710	change in receptor gr	[changes in receptor GR]	0.0	4	1	1	1
133244	1710	activation in adult t-cell leukemia cell	[activation in adult T-cell leukemia cells]	0.0	6	1	1	1
133245	1710	Ig kappa b	[Ig kappa B]	0.0	3	1	1	1
133246	1710	class major complex gene transcription	[class major complex gene transcription]	0.0	5	1	1	1
133247	1710	process of senescence	[process of senescence]	0.0	3	1	1	1
133248	1710	course in most patient	[course in most patients]	0.0	4	1	1	1
133249	1710	pathway.	[pathway.]	0.0	1	1	1	1
133250	1710	coactivation definition of critical region	[Coactivation definition of critical regions]	0.0	5	1	1	1
133251	1710	primary syndrome in stage	[primary syndromes in stage]	0.0	4	1	1	1
133252	1710	size heterogeneity of nfatc	[size heterogeneity of NFATc]	0.0	4	1	1	1
133253	1710	monocyte arrest in shear flow	[monocyte arrest in shear flow]	0.0	5	1	1	1
133254	1710	induction upon tcr stimulation	[Induction upon TCR stimulation]	0.0	4	1	1	1
133255	1710	region of the Akv	[regions of the Akv]	0.0	4	1	1	1
133256	1710	sequence of action	[sequence of actions]	0.0	3	1	1	1
133257	1710	2.3 fmol/10(7) cell 0.011	[2.3 fmol/10(7) cells 0.001),]	0.0	4	1	1	1
133258	1710	-chaperoned antigenic peptide	[-chaperoned antigenic peptides]	0.0	3	1	1	1
133259	1710	nucleotide within the IL-10	[nucleotides within the IL-10]	0.0	4	1	1	1
133260	1710	pan/e2a complex	[Pan/E2A complexes]	0.0	2	1	1	1
133261	1710	in-vitro-stimulated normal peripheral blood lymphocyte sample	[in-vitro-stimulated normal peripheral blood lymphocyte samples]	0.0	6	1	1	1
133262	1710	activation activation	[activation activation]	0.0	2	1	1	1
133263	1710	androgen level	[androgen levels]	0.0	2	1	1	1
133264	1710	value of cancer patient	[values of cancer patients]	0.0	4	1	1	1
133265	1710	avidity, CD8 variable contribution	[avidity, CD8 variable contribution]	0.0	4	1	1	1
133266	1710	low failure rate (2.6%	[low failure rate (2.6%]	0.0	4	1	1	1
133267	1710	relevant dose mm)	[relevant dose mM)]	0.0	3	1	1	1
133268	1710	interleukin-12 fusion protein	[interleukin-12 fusion protein]	0.0	3	1	1	1
133269	1710	raise the activity of receptor	[raising the activity of receptors]	0.0	5	1	1	1
133270	1710	maintain the level of expression	[maintaining the level of expression]	0.0	5	1	1	1
133271	1710	endothelial cell with lps	[endothelial cells with LPS]	0.0	4	1	1	1
133272	1710	low nuclear protein sp	[low nuclear proteins SP]	0.0	4	1	1	1
133273	1710	affinity of transcriptional element	[affinities of transcriptional elements]	0.0	4	1	1	1
133274	1710	expression a study	[Expression an study]	0.0	3	1	1	1
133275	1710	signal downstream	[signaling downstream]	0.0	2	1	1	1
133276	1710	human jurkat-t cell	[human Jurkat-T cells]	0.0	3	1	1	1
133277	1710	variety of common malignancy	[variety of common malignancies]	0.0	4	1	1	1
133278	1710	deletion of p16	[deletion of p16]	0.0	3	2	2	1
133279	1710	POU-dependent change	[POU-dependent change]	0.0	2	1	1	1
133280	1710	biallelic	[biallelic]	0.0	1	1	1	1
133281	1710	time HBxAg	[time HBxAg]	0.0	2	1	1	1
133282	1710	pkc-zeta mut	[PKC-zeta mut]	0.0	2	1	1	1
133283	1710	other antigen (include smooth muscle actin	[other antigens (including smooth muscle actin]	0.0	6	1	1	1
133284	1710	recruitment of leukocyte	[recruitment of leukocytes]	0.0	3	1	1	1
133285	1710	immunophenotypic correlate	[immunophenotypic correlates]	0.0	2	1	1	1
133286	1710	myeloid/NK leukemia	[myeloid/NK leukemia]	0.0	2	1	1	1
133287	1710	consequence of formation	[consequence of formation]	0.0	3	1	1	1
133288	1710	potentially toxic effect	[potentially toxic effects]	0.0	3	1	1	1
133289	1710	enhancer of gene	[enhancers of genes]	0.0	3	1	1	1
133290	1710	encode gamma-globin erythroid delta-aminolevulinate synthase	[encoding gamma-globin erythroid delta-aminolevulinate synthase]	0.0	5	1	1	1
133291	1710	interference with nuclear transcription factor	[interference with nuclear transcription factors]	0.0	5	1	1	1
133292	1710	b activity in this cell	[B activity in these cells]	0.0	5	1	1	1
133293	1710	Epstein-Barr antigen EBNA expression	[Epstein-Barr antigen EBNA expression]	0.0	4	1	1	1
133294	1710	mediate repression by the region	[mediating repression by the region]	0.0	5	1	1	1
133295	1710	expansion) (by stimulation lead to anergy	[expansion) (by stimulation leading to anergy]	0.0	6	1	1	1
133296	1710	105-kDa protein p105 precursor	[105-kDa protein p105 precursor]	0.0	4	1	1	1
133297	1710	/rex	[/rex]	0.0	1	1	1	1
133298	1710	detectable cytokine	[detectable cytokines]	0.0	2	1	1	1
133299	1710	different stage of development	[different stages of development]	0.0	4	1	1	1
133300	1710	evidence for a component	[evidence for a component]	0.0	4	1	1	1
133301	1710	prb posttranslational modification	[pRB posttranslational modification]	0.0	3	1	1	1
133302	1710	signal transduction abnormality clinical relevance	[Signal transduction abnormalities clinical relevance]	0.0	5	1	1	1
133303	1710	tumor necrosis factor binding protein-1	[tumor necrosis factor binding protein-1]	0.0	5	1	1	1
133304	1710	Differential activation of distinct stat5 protein	[Differential activation of distinct STAT5 proteins]	0.0	6	1	1	1
133305	1710	suggest stat6 isoform	[suggesting STAT6 isoforms]	0.0	3	1	1	1
133306	1710	alpha-helical protein segment	[alpha-helical protein segments]	0.0	3	1	1	1
133307	1710	Nuclear localization complex	[Nuclear localization complexes]	0.0	3	1	1	1
133308	1710	induce apoptosis in t-lymphoblastoid cell	[inducing apoptosis in T-lymphoblastoid cells]	0.0	5	1	1	1
133309	1710	beta-globin-expressing murine leukemia cell	[beta-globin-expressing murine leukemia cells]	0.0	4	1	1	1
133310	1710	long persistence	[long-term persistence]	0.0	2	1	1	1
133311	1710	transform infection	[transforming infection]	0.0	2	1	1	1
133312	1710	employ a e box	[employing a E box]	0.0	4	1	1	1
133313	1710	nuclear factor beta hnf3 beta	[nuclear factor beta HNF3 beta]	0.0	5	1	1	1
133314	1710	use anti-ERK antibody	[using anti-ERK antibodies]	0.0	3	1	1	1
133315	1710	excision repair (ner)	[excision repair (NER)]	0.0	3	1	1	1
133316	1710	anti-intercellular adhesion molecule-1	[Anti-intercellular adhesion molecule-1]	0.0	3	1	1	1
133317	1710	(range, 5.66-10) 4.27 (range, 4-.11),	[(range, 5.66-10), 4.27 (range, 4-5.13),]	0.0	5	1	1	1
133318	1710	hemoglobin production on the manifestation	[hemoglobin production on the manifestation]	0.0	5	1	1	1
133319	1710	delivery of the gene	[delivery of the gene]	0.0	4	1	1	1
133320	1710	histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).	[histiocytoma rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
133321	1710	conservation across species	[conservation across species]	0.0	3	1	1	1
133322	1710	position -24	[position -24]	0.0	2	1	1	1
133323	1710	lipopolysaccharide immune response include activation	[lipopolysaccharide immune responses including activation]	0.0	5	1	1	1
133324	1710	3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid	[3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid]	0.0	2	1	1	1
133325	1710	deficiency-heat syndrome	[deficiency-heat syndrome]	0.0	2	1	1	1
133326	1710	30%, overexpression of er 10%,	[30%, overexpression of ER 10%,]	0.0	5	1	1	1
133327	1710	dominant-negative version	[dominant-negative version]	0.0	2	2	2	1
133328	1710	RFX family	[RFX family]	0.0	2	1	1	1
133329	1710	weight gain (14 8421 (pre)	[weight gain (14 8421 (pre)]	0.0	5	1	1	1
133330	1710	type of cells.	[type of cells.]	0.0	3	1	1	1
133331	1710	amount in theileria-infected cell	[amounts in Theileria-infected cells]	0.0	4	1	1	1
133332	1710	event to endothelial cell ECs	[event to endothelial cells ECs]	0.0	5	1	1	1
133333	1710	virus-induced murine erythroleukemias	[virus-induced murine erythroleukemias]	0.0	3	1	1	1
133334	1710	only in the expression a gene	[only in the expression a gene]	0.0	6	1	1	1
133335	1710	thus, tax	[Thus, Tax]	0.0	2	1	1	1
133336	1710	analysis of lysate	[Analysis of lysates]	0.0	3	1	1	1
133337	1710	(range, 5.66-10) (range, 4-.11),	[(range, 5.66-10), (range, 4-5.13),]	0.0	4	1	1	1
133338	1710	pattern secretion.	[patterns secretion.]	0.0	2	1	1	1
133339	1710	expression of WT1 in human fibroblast	[expression of WT1 in human fibroblasts]	0.0	6	1	1	1
133340	1710	induction kappa B/Rel activity lymphocyte antibody	[Induction kappa B/Rel activity lymphocytes antibodies]	0.0	6	1	1	1
133341	1710	NF-kappaB a regulator of inflammatory response	[NF-kappaB a regulator of inflammatory responses]	0.0	6	1	1	1
133342	1710	interferon activation	[interferon activation]	0.0	2	1	1	1
133343	1710	specific pattern of latency	[specific pattern of latency]	0.0	4	1	1	1
133344	1710	CD4 transduction	[CD4 transduction]	0.0	2	1	1	1
133345	1710	operate at the Arrednf-at site	[operating at the ARRE/NF-AT site]	0.0	5	1	1	1
133346	1710	hsv/vzv	[HSV/VZV]	0.0	1	1	1	1
133347	1710	TNF-alpha hiv-1 long terminal repeat LTR	[TNF-alpha HIV-1 long terminal repeat LTR]	0.0	6	1	1	1
133348	1710	apoptosis in neutrophil	[apoptosis in neutrophils]	0.0	3	1	1	1
133349	1710	tcr region	[TCR region]	0.0	2	1	1	1
133350	1710	il-10 effect on the g1 protein	[IL-10 effects on the G1 proteins]	0.0	6	1	1	1
133351	1710	900 bp of DNA	[900 bp of DNA]	0.0	4	1	1	1
133352	1710	transcript mad-3	[transcripts MAD-3]	0.0	2	1	1	1
133353	1710	N-Tera2	[N-Tera2]	0.0	1	1	1	1
133354	1710	gene in lymphoid differentiation	[gene in lymphoid differentiation]	0.0	4	1	1	1
133355	1710	sequence of the IL-4 gene	[sequences of the IL-4 gene]	0.0	5	1	1	1
133356	1710	other lymphocyte-specific protein	[other lymphocyte-specific proteins]	0.0	3	1	1	1
133357	1710	response include pathway	[responses including pathways]	0.0	3	1	1	1
133358	1710	YY1 a transcription factor	[YY1 a transcription factor]	0.0	4	1	1	1
133359	1710	STAT1alpha transcription	[STAT1alpha transcription]	0.0	2	1	1	1
133360	1710	cell follow hydrocortisone injection	[cells following hydrocortisone injection]	0.0	4	1	1	1
133361	1710	mechanism in epithelial cell	[mechanisms in epithelial cells]	0.0	4	1	1	1
133362	1710	pit-1b	[Pit-1b]	0.0	1	1	1	1
133363	1710	six isomorph	[six isomorphs]	0.0	2	1	1	1
133364	1710	Gs(alpha)	[Gs(alpha)]	0.0	1	1	1	1
133365	1710	total of combination	[total of combinations]	0.0	3	1	1	1
133366	1710	lef-1 CBF alpha2	[LEF-1 CBF alpha2]	0.0	3	1	1	1
133367	1710	transient expression of the tax protein	[Transient expression of the Tax protein]	0.0	6	1	1	1
133368	1710	background of the virus.	[background of the virus.]	0.0	4	1	1	1
133369	1710	p40 gene	[p40 gene]	0.0	2	1	1	1
133370	1710	CpG dinucleotide	[CpG dinucleotide]	0.0	2	1	1	1
133371	1710	nuclear phenomenon	[nuclear phenomenon]	0.0	2	1	1	1
133372	1710	putative novel cancer related loci	[putative novel cancer related loci]	0.0	5	1	1	1
133373	1710	activation of the signal transducer	[Activation of the signal transducer]	0.0	5	1	1	1
133374	1710	effect of vd analogue	[effect of VD analogues]	0.0	4	1	1	1
133375	1710	smooth muscle actin	[smooth muscle actin]	0.0	3	1	1	1
133376	1710	human leukemia ml-1 cell	[human leukemia ML-1 cells]	0.0	4	1	1	1
133377	1710	Functional association with Stat5	[Functional association with Stat5]	0.0	4	1	1	1
133378	1710	monocyte adhesion in cell	[monocyte adhesion in cells]	0.0	4	1	1	1
133379	1710	dual effect on lymphocyte inhibition	[dual effects on lymphocytes inhibition]	0.0	5	1	1	1
133380	1710	intracellular ar	[intracellular AR]	0.0	2	1	1	1
133381	1710	response include the activation	[responses including the activation]	0.0	4	1	1	1
133382	1710	lymphoblastic leukemia all	[lymphoblastic leukemia ALL]	0.0	3	3	3	1
133383	1710	implication for the use in treatment	[implications for the use in treatment]	0.0	6	1	1	1
133384	1710	role in EPO erythroid differentiation	[roles in EPO erythroid differentiation]	0.0	5	1	1	1
133385	1710	potentiation of clearance of leukocyte	[potentiation of clearance of leukocytes]	0.0	5	1	1	1
133386	1710	peripheral blood precursor	[peripheral blood precursors]	0.0	3	1	1	1
133387	1710	TNF-alpha hiv-1 repeat transcription in response	[TNF-alpha HIV-1 repeat transcription in response]	0.0	6	1	1	1
133388	1710	cell line bear STLV-I	[cell lines bearing STLV-I]	0.0	4	1	1	1
133389	1710	cDNA clone corresponding	[cDNA clones corresponding]	0.0	3	1	1	1
133390	1710	evidence for the role	[evidence for the role]	0.0	4	1	1	1
133391	1710	element p0	[element P0]	0.0	2	1	1	1
133392	1710	divide immature positive cell	[dividing immature positive cells]	0.0	4	1	1	1
133393	1710	factor critical	[factors critical]	0.0	2	1	1	1
133394	1710	deficiency virus type	[deficiency virus type]	0.0	3	1	1	1
133395	1710	import in jurkat T cell	[import in Jurkat T cells]	0.0	5	1	1	1
133396	1710	However, transduction develop T cell	[However, transduction developing T cells]	0.0	5	1	1	1
133397	1710	differentiation promonocytic cell by etoposide	[Differentiation promonocytic cells by etoposide]	0.0	5	1	1	1
133398	1710	continue for P.	[continuing for h.]	0.0	3	1	1	1
133399	1710	incubation with concentration of insulin	[incubation with concentrations of insulin]	0.0	5	1	1	1
133400	1710	c-type lectin receptor	[C-type lectin receptors]	0.0	3	1	1	1
133401	1710	serum testosterone concentration	[serum testosterone concentrations]	0.0	3	1	1	1
133402	1710	antiphosphotyrosine immunoblot	[Antiphosphotyrosine immunoblots]	0.0	2	1	1	1
133403	1710	(10(-10) mol/L)	[(10(-10) mol/L)]	0.0	2	1	1	1
133404	1710	basic helix-loop-helix (bhlh) transcription factor	[basic helix-loop-helix (bHLH) transcription factors]	0.0	5	1	1	1
133405	1710	diverse signal transduction pathway	[diverse, signal transduction pathways]	0.0	4	1	1	1
133406	1710	effect on C5a calcium mobilization	[effect on C5a calcium mobilization]	0.0	5	1	1	1
133407	1710	15 fibroblast line	[15 fibroblast lines]	0.0	3	1	1	1
133408	1710	cellular context	[cellular context]	0.0	2	1	1	1
133409	1710	direct activation	[Direct activation]	0.0	2	1	1	1
133410	1710	level of transcriptional activation	[level of transcriptional activation]	0.0	4	1	1	1
133411	1710	VCAM-1 mrna	[VCAM-1 mRNA]	0.0	2	1	1	1
133412	1710	bovine serum-contain	[bovine serum-containing]	0.0	2	1	1	1
133413	1710	potent antioxidant	[potent antioxidant]	0.0	2	1	1	1
133414	1710	low number of prediction	[lower number of predictions]	0.0	4	1	1	1
133415	1710	ptdin mcd14	[PtdIns mCD14]	0.0	2	1	1	1
133416	1710	human cell PBMC	[human cells PBMC]	0.0	3	1	1	1
133417	1710	mar-binding protein mar-bp1	[MAR-binding protein MAR-BP1]	0.0	3	1	1	1
133418	1710	activity great	[activity greater]	0.0	2	1	1	1
133419	1710	chronic failure A-CRF	[chronic failure A-CRF]	0.0	3	1	1	1
133420	1710	half-life of h.	[half-life of h,]	0.0	3	1	1	1
133421	1710	receptor/progesterone receptor pr	[receptor/progesterone receptor PR]	0.0	3	1	1	1
133422	1710	ebv antigen EBNA	[EBV antigen EBNA]	0.0	3	1	1	1
133423	1710	tranfection of a promyelocyte cell line	[tranfection of a promyelocyte cell line]	0.0	6	1	1	1
133424	1710	dermal microvessel endothelial cell MVEC	[dermal microvessel endothelial cells MVEC]	0.0	5	1	1	1
133425	1710	one signal transducer	[one signal transducer]	0.0	3	1	1	1
133426	1710	sclerosis gene	[sclerosis gene]	0.0	2	1	1	1
133427	1710	supraoptimal concentration of peptide	[supraoptimal concentrations of peptide]	0.0	4	1	1	1
133428	1710	interaction with p300/cbp-type transcriptional coactivator	[interaction with p300/CBP-type transcriptional coactivators]	0.0	5	1	1	1
133429	1710	endogenous b subunit	[endogenous B subunit]	0.0	3	1	1	1
133430	1710	number of potential sequence similar	[number of potential sequences similar]	0.0	5	1	1	1
133431	1710	kd (30.3+/-2.5 versus 8.9+/-1.2 nmol/L)	[Kd (30.3+/-2.5 versus 8.9+/-1.2 nmol/L)]	0.0	5	1	1	1
133432	1710	1-long repeat hiv-1-ltr CAT construct	[1-long repeat HIV-1-LTR CAT constructs]	0.0	5	1	1	1
133433	1710	virologic feature	[virologic features]	0.0	2	1	1	1
133434	1710	difference among the group	[difference among the groups]	0.0	4	1	1	1
133435	1710	e(2) line,	[E(2) line,]	0.0	2	1	1	1
133436	1710	phosphorylation of intracellular substrate	[phosphorylation of intracellular substrates]	0.0	4	1	1	1
133437	1710	identification of a factor	[Identification of a factor]	0.0	4	1	1	1
133438	1710	"octamer" complex	["octamer" complex]	0.0	2	1	1	1
133439	1710	however, anergic T cell	[however, anergic T cells]	0.0	4	1	1	1
133440	1710	expression of musculin	[expression of musculin]	0.0	3	1	1	1
133441	1710	effect of cn inhibition	[effect of CN inhibition]	0.0	4	1	1	1
133442	1710	presence of multiple element	[presence of multiple elements]	0.0	4	1	1	1
133443	1710	signal mediator in human dermal cell	[signaling mediators in human dermal cells]	0.0	6	1	1	1
133444	1710	step, presumably involve a modulation	[step, presumably involving a modulation]	0.0	5	1	1	1
133445	1710	sound basis for therapy	[sound basis for therapies]	0.0	4	1	1	1
133446	1710	superantigen staphylococcal enterotoxin	[superantigen staphylococcal enterotoxin]	0.0	3	1	1	1
133447	1710	cd14 sp1-binding site	[CD14 Sp1-binding site]	0.0	3	1	1	1
133448	1710	determine the regulation in lineage	[determining the regulation in lineages]	0.0	5	1	1	1
133449	1710	sites/cell), kd value versus nmol/L),	[sites/cell), Kd values versus nmol/L),]	0.0	5	1	1	1
133450	1710	cytoplasmic domain in -9-mediate cell proliferation	[cytoplasmic domains in -9-mediated cell proliferation]	0.0	6	1	1	1
133451	1710	Effect of the myb expression differentiation	[Effects of the myb expression differentiation]	0.0	6	1	1	1
133452	1710	dominant creb	[dominant CREB]	0.0	2	1	1	1
133453	1710	case of angioimmunoblastic t-cell lymphoma AITL	[cases of angioimmunoblastic T-cell lymphoma AITL]	0.0	6	1	1	1
133454	1710	/ikappab	[/IkappaB]	0.0	1	1	1	1
133455	1710	pathology such as multi-organ failure	[pathologies such as multi-organ failure]	0.0	5	1	1	1
133456	1710	all, adenovirus type during many year	[all, adenovirus types during many years]	0.0	6	1	1	1
133457	1710	bind c-fos/c-jun promoter element	[binding c-fos/c-jun promoter elements]	0.0	4	1	1	1
133458	1710	promyeloid leukemia cell hl-60	[promyeloid leukemia cells HL-60]	0.0	4	1	1	1
133459	1710	portion of the promoter	[portions of the promoter]	0.0	4	1	1	1
133460	1710	paraffin	[paraffin]	0.0	1	1	1	1
133461	1710	basis for molecular mimicry	[basis for molecular mimicry]	0.0	4	1	1	1
133462	1710	proliferate fresh epstein-barr virus b lymphocyte	[proliferating fresh Epstein-Barr virus B lymphocytes]	0.0	6	1	1	1
133463	1710	spouse	[spouse]	0.0	1	1	1	1
133464	1710	cytokine-stimulated saphenous vein endothelial cell	[cytokine-stimulated saphenous vein endothelial cells]	0.0	5	1	1	1
133465	1710	effect on IL-2 ifn-gamma production	[effect on IL-2 IFN-gamma production]	0.0	5	1	1	1
133466	1710	membrane form to form	[membrane forms to forms]	0.0	4	1	1	1
133467	1710	c-jun/ ap-1	[c-jun/ AP-1]	0.0	2	1	1	1
133468	1710	response of LFA-3	[response of LFA-3]	0.0	3	1	1	1
133469	1710	specific increase	[specific increases]	0.0	2	1	1	1
133470	1710	deletion upstream	[Deletions upstream]	0.0	2	1	1	1
133471	1710	massive enhancement	[massive enhancement]	0.0	2	1	1	1
133472	1710	regulation of the ap-1 activation pathway	[regulation of the AP-1 activation pathway]	0.0	6	1	1	1
133473	1710	surface markers,	[surface markers,]	0.0	2	1	1	1
133474	1710	different requirement for binding,	[different requirements for binding,]	0.0	4	1	1	1
133475	1710	maximal oxygen uptake	[maximal oxygen uptake]	0.0	3	1	1	1
133476	1710	NF-kappa b suppression of hiv expression	[NF-kappa B suppression of HIV expression]	0.0	6	1	1	1
133477	1710	noninvasive delivery	[noninvasive delivery]	0.0	2	1	1	1
133478	1710	nuclear factor nf-kappa b (position	[nuclear factor NF-kappa B (positions]	0.0	5	1	1	1
133479	1710	two putative ets binding site	[two putative Ets binding sites]	0.0	5	1	1	1
133480	1710	glucocorticoid in blood leukocyte	[glucocorticoids in blood leukocytes]	0.0	4	1	1	1
133481	1710	rapid increase from patient	[rapid increase from patients]	0.0	4	1	1	1
133482	1710	plasma membrane of HML	[plasma membranes of HML]	0.0	4	1	1	1
133483	1710	aldosterone derivative	[aldosterone derivative]	0.0	2	1	1	1
133484	1710	phosphorylation event	[phosphorylation events]	0.0	2	1	1	1
133485	1710	one b-cell-specific transcription factor bsap	[one B-cell-specific transcription factor BSAP]	0.0	5	1	1	1
133486	1710	14 control subject ige	[14 control subjects IgE]	0.0	4	1	1	1
133487	1710	regulation of progenitor	[regulation of progenitors]	0.0	3	1	1	1
133488	1710	several hallmark of t-lymphocyte activation	[several hallmarks of T-lymphocyte activation]	0.0	5	1	1	1
133489	1710	present cell	[presenting cells]	0.0	2	1	1	1
133490	1710	binding site of glucocorticoid receptor	[binding sites of glucocorticoid receptors]	0.0	5	1	1	1
133491	1710	efas)	[(Fas)]	0.0	1	1	1	1
133492	1710	human lymphocyte from peripheral blood	[human lymphocytes from peripheral blood]	0.0	5	1	1	1
133493	1710	two type of E-box consensus motif	[two types of E-box consensus motifs]	0.0	6	1	1	1
133494	1710	Also, (10(-10) to 10(-7) mol/L)	[Also, (10(-10) to 10(-7) mol/L)]	0.0	5	1	1	1
133495	1710	ingredient mediate the effect	[ingredients mediating the effect]	0.0	4	1	1	1
133496	1710	activity in aged runner	[activity in aged runner]	0.0	4	1	1	1
133497	1710	(20 microM,	[(20 microM,]	0.0	2	1	1	1
133498	1710	several tumor cell line	[several tumor cell lines]	0.0	4	1	1	1
133499	1710	weight of about 32, 36 50	[weights of about 32, 36 50]	0.0	6	1	1	1
133500	1710	combination chemotherapy	[combination chemotherapy]	0.0	2	1	1	1
133501	1710	subunit of cAMP-dependent protein kinase	[subunit of cAMP-dependent protein kinase]	0.0	5	1	1	1
133502	1710	aml m2	[AML M2]	0.0	2	1	1	1
133503	1710	return to near-basal level by min.	[returning to near-basal levels by min.]	0.0	6	1	1	1
133504	1710	onset of the late phase	[onset of the late phase]	0.0	5	1	1	1
133505	1710	cis-element responsible	[cis-elements responsible]	0.0	2	1	1	1
133506	1710	target ebv-positive malignancy	[targeting EBV-positive malignancies]	0.0	3	1	1	1
133507	1710	aml m5	[AML M5]	0.0	2	1	1	1
133508	1710	pre-B leukemia cell	[pre-B leukemia cells]	0.0	3	1	1	1
133509	1710	csf-1 receptor	[CSF-1 receptor]	0.0	2	2	2	1
133510	1710	analysis of sensorgram	[analysis of sensorgrams]	0.0	3	1	1	1
133511	1710	high translocation of b	[higher translocation of B]	0.0	4	1	1	1
133512	1710	tissue diseases,	[tissue diseases,]	0.0	2	1	1	1
133513	1710	cyclosporin mutant	[cyclosporin mutants]	0.0	2	1	1	1
133514	1710	fatty acid inhibit activation	[fatty acids inhibiting activation]	0.0	4	1	1	1
133515	1710	component of the normal floram	[component of the normal flora,]	0.0	5	1	1	1
133516	1710	15 term	[15 term]	0.0	2	1	1	1
133517	1710	melanoma MMs	[melanomas MMs]	0.0	2	1	1	1
133518	1710	PTF beta in protein fraction	[PTF beta in protein fractions]	0.0	5	1	1	1
133519	1710	event along the two pathway	[events along the two pathways]	0.0	5	1	1	1
133520	1710	deltadna-binding domain RXR	[deltaDNA-binding domain RXR]	0.0	3	1	1	1
133521	1710	Jak -Stat pathway	[Jak -Stat pathway]	0.0	3	1	1	1
133522	1710	study a further series	[studying a further series]	0.0	4	1	1	1
133523	1710	garlic s-allyl cysteine sac	[garlic S-allyl cysteine SAC]	0.0	4	1	1	1
133524	1710	analogue of dihydroxyvitamin D3	[analogues of dihydroxyvitamin D3]	0.0	4	1	1	1
133525	1710	from rest T cell	[from resting T cells]	0.0	4	1	1	1
133526	1710	NB protein	[NB protein]	0.0	2	1	1	1
133527	1710	firm basis for mimicry	[firm basis for mimicry]	0.0	4	1	1	1
133528	1710	exposure to nm tpa	[exposure to nM TPA]	0.0	4	1	1	1
133529	1710	kappaB-dependent gene	[kappaB-dependent gene]	0.0	2	1	1	1
133530	1710	Fy(b-) individual	[Fy(b-) individuals]	0.0	2	1	1	1
133531	1710	cell in response	[cells in response]	0.0	3	1	1	1
133532	1710	modulation of gene transcription	[modulation of gene transcription]	0.0	4	1	1	1
133533	1710	surface receptor with body burden	[surface receptors with body burdens]	0.0	5	1	1	1
133534	1710	sle (0.2979	[SLE (0.2979]	0.0	2	1	1	1
133535	1710	available iron result	[available iron resulting]	0.0	3	1	1	1
133536	1710	effect on nf-kappa b activity	[effect on NF-kappa B activity]	0.0	5	1	1	1
133537	1710	activation in response to many signal	[activation in response to many signals]	0.0	6	1	1	1
133538	1710	activation in lymphoblastoid cell	[Activation in lymphoblastoid cells]	0.0	4	1	1	1
133539	1710	target for drug therapy	[target for drug therapy]	0.0	4	1	1	1
133540	1710	cd95 efas) ligand expression	[CD95 (Fas) ligand expression]	0.0	4	1	1	1
133541	1710	tyrosine phosphorylation of stat	[tyrosine phosphorylation of STATs]	0.0	4	1	1	1
133542	1710	contain a promoter-driven beta-galactosidase gene	[containing a promoter-driven beta-galactosidase gene]	0.0	5	1	1	1
133543	1710	ifn-gamma receptor alpha-chain expression	[IFN-gamma receptor alpha-chain expression]	0.0	4	1	1	1
133544	1710	lack all signal transducer	[lacking all signal transducers]	0.0	4	1	1	1
133545	1710	transcription, amplify expression of receptor	[transcription, amplifying expression of receptor]	0.0	5	1	1	1
133546	1710	MHC class density	[MHC class density]	0.0	3	1	1	1
133547	1710	pyramidal cell of the cortex	[pyramidal cells of the cortex]	0.0	5	1	1	1
133548	1710	level of octamer transcription	[levels of octamer transcription]	0.0	4	1	1	1
133549	1710	almost exclusive selectivity	[almost exclusive selectivity]	0.0	3	1	1	1
133550	1710	squirrel monkey fkbp51	[squirrel monkey FKBP51]	0.0	3	1	1	1
133551	1710	expression fibronectin receptor mrna	[expression fibronectin receptor mRNA]	0.0	4	1	1	1
133552	1710	pf treatment	[PF treatment]	0.0	2	1	1	1
133553	1710	difference in route	[differences in route]	0.0	3	1	1	1
133554	1710	TNF-alpha nuclear translocation	[TNF-alpha nuclear translocation]	0.0	3	1	1	1
133555	1710	nm vd3 for 72 h	[nM VD3 for 72 h]	0.0	5	1	1	1
133556	1710	trans-activating domain	[trans-activating domains]	0.0	2	1	1	1
133557	1710	cd23 class	[CD23 class]	0.0	2	1	1	1
133558	1710	approximately 50% reduction,	[approximately 50% reduction,]	0.0	3	1	1	1
133559	1710	latter protein	[latter proteins]	0.0	2	1	1	1
133560	1710	pathway of transcriptional regulation	[pathway of transcriptional regulation]	0.0	4	1	1	1
133561	1710	grow in culture, in the stage	[growing in culture, in the stages]	0.0	6	1	1	1
133562	1710	lead to gene inhibitory response	[leading to gene inhibitory responses]	0.0	5	1	1	1
133563	1710	specific nuclear RA receptor	[specific nuclear RA receptors]	0.0	4	1	1	1
133564	1710	two schedule (five patient	[two schedules (five patients]	0.0	4	1	1	1
133565	1710	HEL/S	[HEL/S]	0.0	1	1	1	1
133566	1710	significantly great activation	[significantly greater activation]	0.0	3	1	1	1
133567	1710	two experimental approach	[two experimental approaches]	0.0	3	1	1	1
133568	1710	expression of various early serum gene	[expression of various early serum genes]	0.0	6	1	1	1
133569	1710	expression of dominant mutant	[expression of dominant mutants]	0.0	4	1	1	1
133570	1710	hla-dq class ii	[HLA-DQ class II]	0.0	3	1	1	1
133571	1710	blood-derived Mo	[blood-derived Mo]	0.0	2	1	1	1
133572	1710	glucocorticoid resistance in asthma	[glucocorticoid resistance in asthma]	0.0	4	1	1	1
133573	1710	6, rhabdomyosarcoma	[6, rhabdomyosarcoma]	0.0	2	1	1	1
133574	1710	gene dorsal of Drosophila	[gene dorsal of Drosophila]	0.0	4	1	1	1
133575	1710	hsf2-alpha result	[HSF2-alpha results]	0.0	2	1	1	1
133576	1710	temporal order	[temporal order]	0.0	2	1	1	1
133577	1710	alpha2beta1 integrin	[alpha2beta1 integrin]	0.0	2	1	1	1
133578	1710	conserved, protein	[conserved, protein]	0.0	2	1	1	1
133579	1710	extract with anti-STAT Abs	[extracts with anti-STAT Abs]	0.0	4	1	1	1
133580	1710	4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)	[4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)]	0.0	1	1	1	1
133581	1710	study of diseases,	[study of diseases,]	0.0	3	1	1	1
133582	1710	glucocorticoid on human interleukin	[glucocorticoids on human interleukin]	0.0	4	1	1	1
133583	1710	mutant of type 5	[Mutants of type 5]	0.0	4	1	1	1
133584	1710	adjacent sequence	[adjacent sequences]	0.0	2	1	1	1
133585	1710	transactivator of element-containing promoter	[transactivator of element-containing promoters]	0.0	4	1	1	1
133586	1710	Cross talk	[Cross talk]	0.0	2	1	1	1
133587	1710	protein tyrosine phosphorylation.	[protein tyrosine phosphorylation.]	0.0	3	1	1	1
133588	1710	overproduction of NFKB2 lyt-10 a mechanism	[Overproduction of NFKB2 lyt-10 a mechanism]	0.0	6	1	1	1
133589	1710	protein tyrosine phosphorylation,	[protein tyrosine phosphorylation,]	0.0	3	1	1	1
133590	1710	position -90	[positions -90]	0.0	2	1	1	1
133591	1710	protein myeloperoxidase	[proteins myeloperoxidase]	0.0	2	1	1	1
133592	1710	group hmg	[group HMG]	0.0	2	1	1	1
133593	1710	A1-VDR cell	[A1-VDR cells]	0.0	2	1	1	1
133594	1710	such as fibrosis (cf)	[such as fibrosis (CF)]	0.0	4	1	1	1
133595	1710	box pxp motif	[box PXP motif]	0.0	3	1	1	1
133596	1710	position -98	[positions -98]	0.0	2	1	1	1
133597	1710	position -97	[positions -97]	0.0	2	1	1	1
133598	1710	thus, select aberration in the pathway	[Thus, select aberrations in the pathway]	0.0	6	1	1	1
133599	1710	b-cell lymphoma diffuse lymphoma	[B-cell lymphomas diffuse lymphomas]	0.0	4	1	1	1
133600	1710	categories: induction of "death genes"	[categories: induction of "death genes"]	0.0	5	1	1	1
133601	1710	13 sex-and subject	[13 sex-and subjects]	0.0	3	1	1	1
133602	1710	use stable transfection	[Using stable transfection]	0.0	3	1	1	1
133603	1710	gm-csf element	[GM-CSF element]	0.0	2	1	1	1
133604	1710	antigen processing by intestinal cell	[antigen processing by intestinal cells]	0.0	5	1	1	1
133605	1710	binding of transactivation factor nf-kb	[binding of transactivation factor NF-KB]	0.0	5	1	1	1
133606	1710	control the pattern	[controlling the pattern]	0.0	3	1	1	1
133607	1710	PKC/Ras pathway	[PKC/Ras pathway]	0.0	2	1	1	1
133608	1710	joint from cytokine	[joint from cytokines]	0.0	3	1	1	1
133609	1710	position -82	[positions -82]	0.0	2	1	1	1
133610	1710	similar analysis of poly(A) rna	[Similar analysis of poly(A) RNA]	0.0	5	1	1	1
133611	1710	positive/negative regulation	[positive/negative regulation]	0.0	2	1	1	1
133612	1710	class compounds, 20-epi	[class compounds, 20-epi]	0.0	3	1	1	1
133613	1710	substitution within the ligand-binding domain	[substitutions within the ligand-binding domain]	0.0	5	1	1	1
133614	1710	control subject versus nmol/l,	[control subjects versus nmol/L,]	0.0	4	1	1	1
133615	1710	-79 region	[-79 region]	0.0	2	1	1	1
133616	1710	CD14 translocation of factor-kappa b	[CD14 translocation of factor-kappa B]	0.0	5	1	1	1
133617	1710	anti- cd45 antibody	[anti- CD45 antibodies]	0.0	3	1	1	1
133618	1710	benign behavior	[benign behavior]	0.0	2	1	1	1
133619	1710	low level in erythrocyte	[lower levels in erythrocytes]	0.0	4	1	1	1
133620	1710	three distinct multi-protein complex	[three distinct multi-protein complexes]	0.0	4	1	1	1
133621	1710	HNF-1	[HNF-1]	0.0	1	1	1	1
133622	1710	Stuber	[Stuber]	0.0	1	1	1	1
133623	1710	b cell with epstein-barr virus	[B cells with Epstein-Barr virus]	0.0	5	1	1	1
133624	1710	consist of the intracellular domain icn	[consisting of the intracellular domain ICN]	0.0	6	1	1	1
133625	1710	model of germinal center maturation	[model of germinal center maturation]	0.0	5	1	1	1
133626	1710	overnight dst mg).	[overnight DST mg).]	0.0	3	1	1	1
133627	1710	receptor binding in mononuclear leucocyte	[receptor binding in mononuclear leucocytes]	0.0	5	1	1	1
133628	1710	defects.	[defects.]	0.0	1	1	1	1
133629	1710	smear with a weight	[smear with a weight]	0.0	4	1	1	1
133630	1710	-express cell	[-expressing cells]	0.0	2	1	1	1
133631	1710	46.6% (39.9%	[46.6% (39.9%]	0.0	2	1	1	1
133632	1710	transcription factor pit-1 pit-1b	[transcription factor Pit-1 Pit-1b]	0.0	4	1	1	1
133633	1710	DNA-protein complex by antibody	[DNA-protein complexes by antibodies]	0.0	4	1	1	1
133634	1710	localisation	[localisation]	0.0	1	1	1	1
133635	1710	preclinical study	[preclinical studies]	0.0	2	1	1	1
133636	1710	GATA-2 transcription	[GATA-2 transcription]	0.0	2	1	1	1
133637	1710	histocompatibility (mhc) class ii-like molecule	[histocompatibility (MHC) class II-like molecule]	0.0	5	1	1	1
133638	1710	binding of aldosterone	[Binding of aldosterone]	0.0	3	1	1	1
133639	1710	default pathway	[default pathway]	0.0	2	1	1	1
133640	1710	position -51	[positions -51]	0.0	2	1	1	1
133641	1710	position -50	[positions -50]	0.0	2	1	1	1
133642	1710	intergenic fusion transcript	[intergenic fusion transcripts]	0.0	3	1	1	1
133643	1710	cooperation in transactivation	[cooperation in transactivation]	0.0	3	1	1	1
133644	1710	support the physiologic relevance	[supporting the physiologic relevance]	0.0	4	1	1	1
133645	1710	trigger of hla class ii antigen	[Triggering of HLA class II antigens]	0.0	6	1	1	1
133646	1710	(1) the nuclear appearance	[(1) the nuclear appearance]	0.0	4	1	1	1
133647	1710	physical proximity at position 61	[physical proximity at position 61]	0.0	5	1	1	1
133648	1710	dominant component	[dominant components]	0.0	2	1	1	1
133649	1710	follow chromosomal rearrangement involve band	[following chromosomal rearrangements involving band]	0.0	5	1	1	1
133650	1710	unusual syncytia	[unusual syncytia]	0.0	2	1	1	1
133651	1710	reliable indicator	[reliable indicators]	0.0	2	1	1	1
133652	1710	region of Stat5b	[region of Stat5b]	0.0	3	1	1	1
133653	1710	IL-12 transactivation	[IL-12 transactivation]	0.0	2	1	1	1
133654	1710	open reading frame in frame	[open reading frame in frame]	0.0	5	1	1	1
133655	1710	nuclear staining in 14.6 +/-	[nuclear staining in 14.6 +/-]	0.0	5	1	1	1
133656	1710	il-10 receptor expression	[IL-10 receptor expression]	0.0	3	1	1	1
133657	1710	-sensitive transcription	[-sensitive transcription]	0.0	2	1	1	1
133658	1710	administration of danazol for one month	[Administration of danazol for one month]	0.0	6	1	1	1
133659	1710	T cell transmembrane signal	[T cell transmembrane signaling]	0.0	4	1	1	1
133660	1710	distinct agent	[distinct agent]	0.0	2	1	1	1
133661	1710	prpneo-sl3	[pRPneo-SL3]	0.0	1	1	1	1
133662	1710	characterization of IL-2 transcriptional inhibitor	[characterization of IL-2 transcriptional inhibitors]	0.0	5	1	1	1
133663	1710	increase evidence inflammatory mediator	[increasing evidence inflammatory mediators]	0.0	4	1	1	1
133664	1710	nuclear factor kappab binding	[nuclear factor kappaB binding]	0.0	4	1	1	1
133665	1710	min) submaximal exercise ppe at 70%	[min) submaximal exercise PPE at 70%]	0.0	6	1	1	1
133666	1710	human collagenase-1 promoter	[human collagenase-1 promoter]	0.0	3	1	1	1
133667	1710	glucocorticoid receptor to DNA	[glucocorticoid receptor to DNA]	0.0	4	2	2	1
133668	1710	four mrna isoform of kb	[four mRNA isoforms of kb]	0.0	5	1	1	1
133669	1710	LBP-1 sequence	[LBP-1 sequences]	0.0	2	1	1	1
133670	1710	sodium in patient	[sodium in patients]	0.0	3	1	1	1
133671	1710	establish cell line keep property	[establishing cell lines keeping properties]	0.0	5	1	1	1
133672	1710	Conversely, anti-cd28 ab	[Conversely, anti-CD28 Ab]	0.0	3	1	1	1
133673	1710	mouse interleukin-2	[Mouse interleukin-2]	0.0	2	1	1	1
133674	1710	mrp MARCKS protein	[MRP MARCKS protein]	0.0	3	1	1	1
133675	1710	function of the x2 box	[function of the X2 box]	0.0	5	1	1	1
133676	1710	calcium -signal cyclophilin ligand caml	[calcium -signal cyclophilin ligand CAML]	0.0	5	1	1	1
133677	1710	region of the human gene	[region of the human gene]	0.0	5	1	1	1
133678	1710	ki-67 proliferation index	[Ki-67 proliferation indices]	0.0	3	1	1	1
133679	1710	-500 to -250 bp	[-500 to -250 bp]	0.0	4	1	1	1
133680	1710	presence of functionally critical element	[presence of functionally critical elements]	0.0	5	1	1	1
133681	1710	also in term	[also in terms]	0.0	3	1	1	1
133682	1710	30 kb telomeric	[30 kb telomeric]	0.0	3	1	1	1
133683	1710	activator protein-1 AP-1	[activator protein-1 AP-1]	0.0	3	1	1	1
133684	1710	calcium homeostasis	[calcium homeostasis]	0.0	2	1	1	1
133685	1710	mnda cell between steady-state level	[MNDA cells between steady-state levels]	0.0	5	1	1	1
133686	1710	human coactivator	[human coactivator]	0.0	2	1	1	1
133687	1710	phase of reaction	[phase of reaction]	0.0	3	1	1	1
133688	1710	vaginalis	[vaginalis]	0.0	1	3	3	1
133689	1710	follow binding to human monocyte	[following binding to human monocytes]	0.0	5	1	1	1
133690	1710	frequency among the cd14(+) cell	[frequency among the CD14(+) cells]	0.0	5	1	1	1
133691	1710	additional work, employ deletion	[Additional work, employing deletions]	0.0	4	1	1	1
133692	1710	retinoid-induced u-937 cell differentiation	[retinoid-induced U-937 cell differentiation]	0.0	4	1	1	1
133693	1710	Effect of agent upon action	[Effects of agents upon action]	0.0	5	1	1	1
133694	1710	killer cell-induced lysis	[killer cell-induced lysis]	0.0	3	1	1	1
133695	1710	function of p95vav	[function of p95vav]	0.0	3	1	1	1
133696	1710	prevent tnf-alpha apoptosis	[preventing TNF-alpha apoptosis]	0.0	3	1	1	1
133697	1710	constitutive expression in primary human monocyte	[constitutive expression in primary human monocytes]	0.0	6	1	1	1
133698	1710	negative allele	[negative allele]	0.0	2	1	1	1
133699	1710	only in the cytoplasm	[only in the cytoplasm]	0.0	4	1	1	1
133700	1710	high-level replication T-tropic isolate	[high-level replication T-tropic isolate]	0.0	4	1	1	1
133701	1710	include chronic leukaemia	[including chronic leukaemia]	0.0	3	2	2	1
133702	1710	characteristic competitive binding profile	[characteristic competitive binding profile]	0.0	4	1	1	1
133703	1710	relationship to PML body	[relationship to PML bodies]	0.0	4	1	1	1
133704	1710	expression of type interferon IFN	[expression of type interferon IFN]	0.0	5	1	1	1
133705	1710	tax transactivator with transcription factor iia	[tax transactivator with transcription factor IIA]	0.0	6	1	1	1
133706	1710	previous characterization	[Previous characterization]	0.0	2	1	1	1
133707	1710	components:	[components:]	0.0	1	1	1	1
133708	1710	in-vitro experiment	[in-vitro experiments]	0.0	2	1	1	1
133709	1710	inhibition of b mobilization by aspirin	[inhibition of B mobilization by aspirin]	0.0	6	1	1	1
133710	1710	govern lineage switch to lineage	[governing lineage switching to lineages]	0.0	5	1	1	1
133711	1710	membrane-proximal portion	[membrane-proximal portion]	0.0	2	1	1	1
133712	1710	however, millileter	[However, ml]	0.0	2	1	1	1
133713	1710	tetrahydrocortisone 3.16 mg/24h; n: 2.7+/-2.0)	[tetrahydrocortisone 3.16 mg/24h; N: 2.7+/-2.0)]	0.0	5	1	1	1
133714	1710	result necessity of monitoring	[resulting necessity of monitoring]	0.0	4	1	1	1
133715	1710	immunodeficiency virus hiv transcription	[immunodeficiency virus HIV transcription]	0.0	4	1	1	1
133716	1710	agonist as lipopolysaccharide lps	[agonists as lipopolysaccharide LPS]	0.0	4	1	1	1
133717	1710	homeodomain protein	[homeodomain protein]	0.0	2	1	1	1
133718	1710	p53 protein	[p53 protein]	0.0	2	3	3	1
133719	1710	myeloma cell growth	[myeloma cell growth]	0.0	3	1	1	1
133720	1710	human show	[human shows]	0.0	2	1	1	1
133721	1710	vascular adhesion molecule-1 cd106	[vascular adhesion molecule-1 CD106]	0.0	4	1	1	1
133722	1710	protein fli-1	[protein Fli-1]	0.0	2	1	1	1
133723	1710	icam-1 cytokine	[ICAM-1 cytokines]	0.0	2	1	1	1
133724	1710	use amount of nfatp	[using amounts of NFATp]	0.0	4	1	1	1
133725	1710	follicular center	[follicular center]	0.0	2	1	1	1
133726	1710	element at -21/-1	[element at -21/-12,]	0.0	3	1	1	1
133727	1710	response to all-tran retinoic acid	[response to all-trans retinoic acid]	0.0	5	1	1	1
133728	1710	recurrent astrocytomas	[recurrent astrocytomas]	0.0	2	1	1	1
133729	1710	DNA precursor	[DNA precursor]	0.0	2	1	1	1
133730	1710	catalytic sub-unit of dna-protein kinase	[catalytic sub-unit of DNA-protein kinase]	0.0	5	1	1	1
133731	1710	BCL2 -responsive checkpoint	[BCL2 -responsive checkpoint]	0.0	3	1	1	1
133732	1710	TNF-alpha nuclear translocation of p50-p65	[TNF-alpha nuclear translocation of p50-p65]	0.0	5	1	1	1
133733	1710	nm, in monocyte from CS individual	[nM, in monocytes from CS individuals]	0.0	6	1	1	1
133734	1710	Study with umbilical vein segment	[Studies with umbilical vein segments]	0.0	5	1	1	1
133735	1710	(b) factor such as NF-kappa b	[(b) factors such as NF-kappa B]	0.0	6	1	1	1
133736	1710	nucleosomal DNA	[nucleosomal DNA]	0.0	2	1	1	1
133737	1710	effect of dep- pah	[effect of DEP- PAHs]	0.0	4	1	1	1
133738	1710	transcriptional activator in cell line	[transcriptional activator in cell lines]	0.0	5	1	1	1
133739	1710	lead to Egr-1 induction	[leading to Egr-1 induction]	0.0	4	1	1	1
133740	1710	Interleukin-6 production in shock	[Interleukin-6 production in shock]	0.0	4	1	1	1
133741	1710	Further,	[Further,]	0.0	1	1	1	1
133742	1710	cover the surface	[covering the surface]	0.0	3	1	1	1
133743	1710	c-rel proto-oncogene	[c-rel proto-oncogene]	0.0	2	1	1	1
133744	1710	cell hybrid between IARC	[cell hybrids between IARC]	0.0	4	1	1	1
133745	1710	protein binding property of element	[protein binding properties of elements]	0.0	5	1	1	1
133746	1710	distribution of human gene	[distribution of human genes]	0.0	4	1	1	1
133747	1710	human myeloid leukemia cell line grow	[human myeloid leukemia cell lines growing]	0.0	6	1	1	1
133748	1710	major pkc substrate marck	[major PKC substrates MARCKS]	0.0	4	1	1	1
133749	1710	18-fold-lower affinity	[18-fold-lower affinity]	0.0	2	1	1	1
133750	1710	n-acetyl-L-cysteine	[n-acetyl-L-cysteine]	0.0	1	1	1	1
133751	1710	translocation in human myeloproliferative disorder	[translocations in human myeloproliferative disorders]	0.0	5	1	1	1
133752	1710	Recognition 2 tegument protein	[Recognition 2 tegument proteins]	0.0	4	1	1	1
133753	1710	Precise regulation of MHC class expression	[Precise regulation of MHC class expression]	0.0	6	1	1	1
133754	1710	protein of 20 kda.	[protein of 20 kDa.]	0.0	4	1	1	1
133755	1710	extract of the leukemia cell	[extracts of the leukemia cells]	0.0	5	1	1	1
133756	1710	selective function for pkc isotype	[selective functions for PKC isotypes]	0.0	5	1	1	1
133757	1710	Functional b-cell response in hepatitis c	[Functional B-cell response in hepatitis C]	0.0	6	1	1	1
133758	1710	serum-contain small adherent colony	[serum-containing small adherent colonies]	0.0	4	1	1	1
133759	1710	crisis	[crisis]	0.0	1	1	1	1
133760	1710	blood lymphocyte from young human	[blood lymphocytes from young humans]	0.0	5	1	1	1
133761	1710	activation after ligation i MHC-I	[Activation after ligation I MHC-I]	0.0	5	1	1	1
133762	1710	analysis of gata-3 factor	[Analysis of GATA-3 factors]	0.0	4	1	1	1
133763	1710	il-5 cell line	[IL-5 cell line]	0.0	3	1	1	1
133764	1710	gene include interleukin-2	[genes including interleukin-2]	0.0	3	1	1	1
133765	1710	family retinoic acid receptor rar	[families retinoic acid receptors RARs]	0.0	5	1	1	1
133766	1710	change in the Sp1 binding site	[changes in the Sp1 binding sites]	0.0	6	1	1	1
133767	1710	suggest a role for RAR alpha	[suggesting a role for RAR alpha]	0.0	6	1	1	1
133768	1710	resistant segment	[resistant segments]	0.0	2	1	1	1
133769	1710	dermal activation	[dermal activation]	0.0	2	1	1	1
133770	1710	different mechanims:	[different mechanims:]	0.0	2	1	1	1
133771	1710	690 kb	[690 kb]	0.0	2	1	1	1
133772	1710	(2.2%	[(2.2%]	0.0	1	1	1	1
133773	1710	junb mrna peak	[junB mRNA peak]	0.0	3	1	1	1
133774	1710	other type	[other types]	0.0	2	1	1	1
133775	1710	complexity probably due to difference	[complexity probably due to differences]	0.0	5	1	1	1
133776	1710	second essential element	[second essential element]	0.0	3	1	1	1
133777	1710	condition of immune glomerulopathy glomerulonephritis	[conditions of immune glomerulopathy glomerulonephritis]	0.0	5	1	1	1
133778	1710	MTHC line	[MTHC lines]	0.0	2	1	1	1
133779	1710	adherence-associated gene such as IL-8	[adherence-associated genes such as IL-8]	0.0	5	1	1	1
133780	1710	[correlation of lymphocytic infiltration	[[Correlation of lymphocytic infiltration]	0.0	4	1	1	1
133781	1710	DNA encode a human tfiid protein	[DNA encoding a human TFIID protein]	0.0	6	1	1	1
133782	1710	62 base pair	[62 base pairs]	0.0	3	1	1	1
133783	1710	multiple substitution in the counterpart	[multiple substitutions in the counterpart]	0.0	5	1	1	1
133784	1710	codeletion of p16	[codeletion of p16]	0.0	3	1	1	1
133785	1710	region 1a reiteration mutant	[region 1A reiteration mutants]	0.0	4	1	1	1
133786	1710	DS one	[DS ones]	0.0	2	1	1	1
133787	1710	equivalent	[equivalent]	0.0	1	1	1	1
133788	1710	cytokine in monocytes/macrophages	[cytokines in monocytes/macrophages]	0.0	3	1	1	1
133789	1710	amount during lps activation	[amounts during LPS activation]	0.0	4	1	1	1
133790	1710	population of ut-7/gm cell	[population of UT-7/GM cells]	0.0	4	1	1	1
133791	1710	SMX -nhoh	[SMX -NHOH]	0.0	2	1	1	1
133792	1710	Addition of il-2	[Addition of IL-2]	0.0	3	1	1	1
133793	1710	target for genetic manipulation	[targets for genetic manipulation]	0.0	4	1	1	1
133794	1710	c/ebp binding site	[C/EBP binding sites]	0.0	3	1	1	1
133795	1710	cytokine cell line m-tat	[cytokine cell line M-TAT]	0.0	4	1	1	1
133796	1710	evaluation of stat	[evaluation of STATs]	0.0	3	1	1	1
133797	1710	cell extract from lymphoblastic leukemia	[cell extracts from lymphoblastic leukemia]	0.0	5	1	1	1
133798	1710	suggest a aberrant consequence	[suggesting an aberrant consequence]	0.0	4	1	1	1
133799	1710	patient with neither risk factor	[patients with neither risk factor]	0.0	5	1	1	1
133800	1710	peripheral blood NK cell genistein	[peripheral blood NK cells genistein]	0.0	5	1	1	1
133801	1710	low dose (20 ng/ml)	[low dose (20 ng/ml)]	0.0	4	1	1	1
133802	1710	5'-flanking sequence	[5'-flanking sequence]	0.0	2	3	3	1
133803	1710	igg fc	[IgG Fc]	0.0	2	1	1	1
133804	1710	plate-bound anti-CD3 monoclonal antibody	[plate-bound anti-CD3 monoclonal antibody]	0.0	4	1	1	1
133805	1710	primary cd4+ T lymphocyte	[primary CD4+ T lymphocytes]	0.0	4	3	3	1
133806	1710	beta-globin-expressing leukemia cell	[beta-globin-expressing leukemia cells]	0.0	3	1	1	1
133807	1710	little change	[little change]	0.0	2	1	1	1
133808	1710	-immunoreactive cell	[-immunoreactive cells]	0.0	2	1	1	1
133809	1710	involvement of this receptor	[involvement of this receptor]	0.0	4	1	1	1
133810	1710	lac+clone out of transformant	[Lac+clones out of transformants]	0.0	4	1	1	1
133811	1710	-resistant pathway	[-resistant pathway]	0.0	2	1	1	1
133812	1710	cytomegalovirus enhancer	[cytomegalovirus enhancer]	0.0	2	1	1	1
133813	1710	on rest b cell	[on resting B cells]	0.0	4	1	1	1
133814	1710	b-cell-specific fashion	[B-cell-specific fashion]	0.0	2	1	1	1
133815	1710	contain	[containing]	0.0	1	1	1	1
133816	1710	use pd-98059 inhibitor	[using PD-98059 inhibitors]	0.0	3	1	1	1
133817	1710	incubation increase extracellular concentration	[incubation increasing extracellular concentrations]	0.0	4	1	1	1
133818	1710	ca(2+) pathway include the phosphatase calcineurin	[Ca(2+) pathways including the phosphatase calcineurin]	0.0	6	1	1	1
133819	1710	remain allele	[remaining allele]	0.0	2	1	1	1
133820	1710	Glucocorticoid gc resistance in patient	[Glucocorticoid GC resistance in patients]	0.0	5	1	1	1
133821	1710	Israel	[Israel]	0.0	1	1	1	1
133822	1710	include tax	[including Tax]	0.0	2	1	1	1
133823	1710	estradiol (cb50)	[estradiol (CB50)]	0.0	2	1	1	1
133824	1710	acid treatment granulocyte recovery.	[acid treatment granulocyte recovery.]	0.0	4	1	1	1
133825	1710	16 CBF beta-myh11	[16 CBF beta-MYH11]	0.0	3	1	1	1
133826	1710	include GRE DNA binding	[including GRE DNA binding]	0.0	4	1	1	1
133827	1710	include 3 aml with morphology aml	[including 3 AML with morphology AML]	0.0	6	1	1	1
133828	1710	wk untreated RA	[wk untreated RA]	0.0	3	1	1	1
133829	1710	growth response-1 gene	[growth response-1 gene]	0.0	3	1	1	1
133830	1710	major class ii molecule	[major class II molecules]	0.0	4	1	1	1
133831	1710	receptor in asthma	[receptor in asthma]	0.0	3	1	1	1
133832	1710	b-cell factor a regulator	[B-cell factor a regulator]	0.0	4	1	1	1
133833	1710	shift dephosphorylated	[shift dephosphorylated]	0.0	2	1	1	1
133834	1710	gene silencing	[gene silencing]	0.0	2	1	1	1
133835	1710	great effect	[greater effect]	0.0	2	1	1	1
133836	1710	factor traz	[factors TRAFs]	0.0	2	1	1	1
133837	1710	murine fosb gene	[murine FOSB gene]	0.0	3	1	1	1
133838	1710	CMV early gene product	[CMV early gene product]	0.0	4	1	1	1
133839	1710	elam-1 of elam-1	[ELAM-1 of ELAM-1]	0.0	3	1	1	1
133840	1710	extract from T cell	[extract from T cells]	0.0	4	2	2	1
133841	1710	circulate androgen level	[Circulating androgen levels]	0.0	3	1	1	1
133842	1710	specific decrease in the activity	[specific decrease in the activity]	0.0	5	1	1	1
133843	1710	terminal repeat LTR of hiv-1	[terminal repeat LTR of HIV-1]	0.0	5	1	1	1
133844	1710	primary culture of cell TEC	[primary cultures of cells TEC]	0.0	5	1	1	1
133845	1710	regulation of genes.	[regulation of genes.]	0.0	3	1	1	1
133846	1710	addition to PMA T lymphocyte	[addition to PMA T lymphocytes]	0.0	5	1	1	1
133847	1710	differentiation-associated pattern	[differentiation-associated pattern]	0.0	2	1	1	1
133848	1710	homing receptor blr1	[homing receptor BLR1]	0.0	3	1	1	1
133849	1710	myb expression on hemin-	[myb expression on hemin-]	0.0	4	1	1	1
133850	1710	monocyte differentiation analogous	[monocyte differentiation analogous]	0.0	3	1	1	1
133851	1710	two transcription factor family	[two transcription factor families]	0.0	4	1	1	1
133852	1710	low potencies,	[lower potencies,]	0.0	2	1	1	1
133853	1710	human t-cell lineage	[human T-cell lineages]	0.0	3	1	1	1
133854	1710	active nf-kappa b for transcription,	[active NF-kappa B for transcription,]	0.0	5	1	1	1
133855	1710	balance between oxidation to metabolite	[balance between oxidation to metabolites]	0.0	5	1	1	1
133856	1710	receptor for c-c chemokine	[receptor for C-C chemokine]	0.0	4	1	1	1
133857	1710	environmental photic cycle	[environmental photic cycle]	0.0	3	1	1	1
133858	1710	monocyte protein	[monocyte protein]	0.0	2	1	1	1
133859	1710	Enzymatic assay	[Enzymatic assay]	0.0	2	1	1	1
133860	1710	correlate of dqa1 polymorphism	[correlate of DQA1 polymorphism]	0.0	4	1	1	1
133861	1710	T expression of cd95l	[T expression of CD95L]	0.0	4	1	1	1
133862	1710	lack obvious sequence similarity	[lacking obvious sequence similarity]	0.0	4	1	1	1
133863	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD]	0.0	2	1	1	1
133864	1710	messenger response	[messenger response]	0.0	2	1	1	1
133865	1710	Effect of stress	[Effects of stress]	0.0	3	1	1	1
133866	1710	effect a steroid hormone	[effect a steroid hormone]	0.0	4	1	1	1
133867	1710	member of the NF-kappaB family	[members of the NF-kappaB family]	0.0	5	1	1	1
133868	1710	monocyte binding to aortic cell	[monocyte binding to aortic cells]	0.0	5	1	1	1
133869	1710	transfection into T	[transfection into T]	0.0	3	1	1	1
133870	1710	encode a chemokine receptor	[encoding a chemokine receptor]	0.0	4	1	1	1
133871	1710	hiv-1 trans-activation	[HIV-1 trans-activation]	0.0	2	1	1	1
133872	1710	event in this disorder.	[event in this disorder.]	0.0	4	1	1	1
133873	1710	regulation in h9 T cell	[regulation in H9 T cells]	0.0	5	1	1	1
133874	1710	element in the polarization	[element in the polarization]	0.0	4	1	1	1
133875	1710	rapid depletion of transcription factor	[rapid depletion of transcription factors]	0.0	5	1	1	1
133876	1710	consensus binding sequence	[consensus binding sequences]	0.0	3	1	1	1
133877	1710	period before development	[period before development]	0.0	3	1	1	1
133878	1710	month (i.e. 12 month	[months (i.e. 12 months]	0.0	4	1	1	1
133879	1710	DNA from peripheral blood leukocyte	[DNA from peripheral blood leukocytes]	0.0	5	1	1	1
133880	1710	/tcr	[/TCR]	0.0	1	1	1	1
133881	1710	response to activators, include J2	[response to activators, including J2]	0.0	5	1	1	1
133882	1710	differentiation-dependent peroxisomal receptor gamma ppargamma expression	[differentiation-dependent peroxisomal receptor gamma PPARgamma expression]	0.0	6	1	1	1
133883	1710	Endocrine status change in child	[Endocrine status changes in children]	0.0	5	1	1	1
133884	1710	support property of cell	[supporting properties of cells]	0.0	4	1	1	1
133885	1710	use a minimal promoter.	[using a minimal promoter.]	0.0	4	1	1	1
133886	1710	analysis apoptosis in t-cell-line-expressing CD4 receptor	[analysis apoptosis in T-cell-line-expressing CD4 receptors]	0.0	6	1	1	1
133887	1710	dest GIG10	[DESTs GIG10]	0.0	2	1	1	1
133888	1710	involve the human CBFA2 locus	[involving the human CBFA2 locus]	0.0	5	1	1	1
133889	1710	cell type-specific transcriptional induction of collagenase	[cell type-specific transcriptional induction of collagenase]	0.0	6	1	1	1
133890	1710	immortalization of cd4(+) T lymphocyte	[Immortalization of CD4(+) T lymphocytes]	0.0	5	1	1	1
133891	1710	case of B-cell lymphocytic leukemia	[cases of B-cell lymphocytic leukemia]	0.0	5	1	1	1
133892	1710	T Lymphocytes-1	[T Lymphocytes-1]	0.0	2	1	1	1
133893	1710	leukemic cell clone	[leukemic cell clone]	0.0	3	1	1	1
133894	1710	subsequent action	[subsequent actions]	0.0	2	1	1	1
133895	1710	susceptibility to inhibition	[susceptibility to inhibition]	0.0	3	1	1	1
133896	1710	phosphoprotein effect of cyclosporin a	[phosphoproteins effects of cyclosporin A]	0.0	5	1	1	1
133897	1710	stimulation by high dose	[Stimulation by high doses]	0.0	4	1	1	1
133898	1710	nf-kappa b chemokine	[NF-kappa B chemokine]	0.0	3	1	1	1
133899	1710	CBF beta positive,	[CBF beta positive,]	0.0	3	1	1	1
133900	1710	CTLL-2/ tax	[CTLL-2/ Tax]	0.0	2	1	1	1
133901	1710	appearance of virus	[appearance of virus]	0.0	3	1	1	1
133902	1710	pretreatment (or up minute posttreatment)	[Pretreatment (or up minutes posttreatment)]	0.0	5	1	1	1
133903	1710	cell types:	[cell types:]	0.0	2	1	1	1
133904	1710	Intratracheal instillation into normal rat	[Intratracheal instillation into normal rats]	0.0	5	1	1	1
133905	1710	sensitive monitoring	[sensitive monitoring]	0.0	2	1	1	1
133906	1710	serum element SRE	[serum element SRE]	0.0	3	1	1	1
133907	1710	nuclear tal1 protein	[nuclear TAL1 protein]	0.0	3	1	1	1
133908	1710	key signal calcineurin	[key signalling calcineurin]	0.0	3	1	1	1
133909	1710	marker of gr function	[marker of GR function]	0.0	4	1	1	1
133910	1710	further mutagenesis analysis	[Further mutagenesis analyses]	0.0	3	1	1	1
133911	1710	therefore a element	[therefore a element]	0.0	3	1	1	1
133912	1710	lymphotoxin on natural killer cell	[lymphotoxin on natural killer cells]	0.0	5	1	1	1
133913	1710	patient with acute hepatitis	[patients with acute hepatitis]	0.0	4	1	1	1
133914	1710	reactive disulfide of bmt	[reactive disulfide of BMT]	0.0	4	1	1	1
133915	1710	morning-to-afternoon decline in receptor concentration	[morning-to-afternoon decline in receptor concentrations]	0.0	5	1	1	1
133916	1710	double time	[doubling times]	0.0	2	1	1	1
133917	1710	human microvessel cell MVEC	[human microvessel cells MVEC]	0.0	4	1	1	1
133918	1710	analysis unique viral latency	[analysis unique viral latency]	0.0	4	1	1	1
133919	1710	mechanism of senescence	[mechanisms of senescence]	0.0	3	1	1	1
133920	1710	lymphocyte from the latter two	[lymphocytes from the latter two]	0.0	5	1	1	1
133921	1710	signal pathway molecule	[signaling pathway molecules]	0.0	3	1	1	1
133922	1710	ifn-activated NK cell	[IFN-activated NK cells]	0.0	3	1	1	1
133923	1710	cascade within the first minute	[cascade within the first minutes]	0.0	5	1	1	1
133924	1710	inhibition of nf-kappab translocation	[inhibition of NF-kappaB translocation]	0.0	4	1	1	1
133925	1710	bcl-xL expression	[bcl-xL expression]	0.0	2	1	1	1
133926	1710	binding of specific nuclear factor	[binding of specific nuclear factors]	0.0	5	1	1	1
133927	1710	protein oct-2a	[protein Oct-2A]	0.0	2	1	1	1
133928	1710	cis-acting element b/gc-box of the factor	[cis-acting elements B/GC-box of the factor]	0.0	6	1	1	1
133929	1710	propionate	[propionate]	0.0	1	1	1	1
133930	1710	17beta-estradiol	[17beta-estradiol]	0.0	1	1	1	1
133931	1710	dna'	[DNA's]	0.0	1	1	1	1
133932	1710	virus-infected T cell line	[virus-infected T cell line]	0.0	4	1	1	1
133933	1710	minimal b enhancer	[minimal B enhancer]	0.0	3	1	1	1
133934	1710	B1 /alpha	[B1 /alpha]	0.0	2	1	1	1
133935	1710	C1-C3	[C1-C3]	0.0	1	1	1	1
133936	1710	alteration in factor-kappa b	[alterations in factor-kappa B]	0.0	4	1	1	1
133937	1710	involvement of p23	[involvement of p23]	0.0	3	1	1	1
133938	1710	interaction functional antagonism in cell	[interaction functional antagonism in cells]	0.0	5	1	1	1
133939	1710	contain c-fo	[containing c-Fos]	0.0	2	1	1	1
133940	1710	expression of diverse receptor	[expression of diverse receptors]	0.0	4	1	1	1
133941	1710	-signalling	[-signalling]	0.0	1	1	1	1
133942	1710	/thr	[/Thr]	0.0	1	1	1	1
133943	1710	include tnf	[including TNF]	0.0	2	1	1	1
133944	1710	developmental stage of differentiation	[developmental stage of differentiation]	0.0	4	1	1	1
133945	1710	individual with filarial disease	[individuals with filarial disease]	0.0	4	1	1	1
133946	1710	cause of persistent arthritis	[cause of persistent arthritis]	0.0	4	2	2	1
133947	1710	relative quantification of mrna	[relative quantification of mRNA]	0.0	4	1	1	1
133948	1710	signal pathways,	[signaling pathways,]	0.0	2	1	1	1
133949	1710	deficiency syndrome the 10 hot	[deficiency syndromes the 10 hot]	0.0	5	1	1	1
133950	1710	amplify event lead to monocyte activation	[amplifying events leading to monocyte activation]	0.0	6	1	1	1
133951	1710	l540 cell	[L540 cells]	0.0	2	1	1	1
133952	1710	factor enf)-kappa b activity	[factor (NF)-kappa B activity]	0.0	4	1	1	1
133953	1710	Functional activation of gene expression	[Functional activation of gene expression]	0.0	5	1	1	1
133954	1710	affect synthesis of the subunit	[affecting synthesis of the subunit]	0.0	5	1	1	1
133955	1710	most cell types:	[most cell types:]	0.0	3	1	1	1
133956	1710	role for bcl-xL	[role for bcl-xL]	0.0	3	1	1	1
133957	1710	megakaryocyte differentiation	[megakaryocyte differentiation]	0.0	2	1	1	1
133958	1710	cell from malignant lymphoma	[cells from malignant lymphomas]	0.0	4	1	1	1
133959	1710	activity of tepoxalin a potential antirheumatic	[activity of tepoxalin a potential antirheumatic]	0.0	6	1	1	1
133960	1710	135-(oh)2d3 induction of mrna level	[1,25-(OH)2D3 induction of mRNA levels]	0.0	5	1	1	1
133961	1710	interferon regulatory factor gene	[interferon regulatory factor gene]	0.0	4	1	1	1
133962	1710	postnatally, typically die by 8	[postnatally, typically dying by 8]	0.0	5	1	1	1
133963	1710	cell of transgenic mouse	[cells of transgenic mice]	0.0	4	1	1	1
133964	1710	molecular origin than contraction	[molecular origin than contractions]	0.0	4	1	1	1
133965	1710	Germinal center GC formation	[Germinal center GC formation]	0.0	4	1	1	1
133966	1710	regulator neutralize antibody	[regulator neutralizing antibodies]	0.0	3	1	1	1
133967	1710	optimal function in the system	[optimal function in the system]	0.0	5	1	1	1
133968	1710	mobility shift assay EMSAs	[mobility shift assays EMSAs]	0.0	4	1	1	1
133969	1710	E1A oncogene induction of cellular susceptibility	[E1A oncogene induction of cellular susceptibility]	0.0	6	1	1	1
133970	1710	result from activation	[resulting from activation]	0.0	3	1	1	1
133971	1710	estrogen on il-1beta promoter activity	[estrogens on IL-1beta promoter activity]	0.0	5	1	1	1
133972	1710	induction of marker	[induction of markers]	0.0	3	1	1	1
133973	1710	il-9 activation of stat3	[IL-9 activation of STAT3]	0.0	4	1	1	1
133974	1710	-interfer	[-interfering]	0.0	1	1	1	1
133975	1710	T lymphocyte-specific enhancer	[T lymphocyte-specific enhancer]	0.0	3	1	1	1
133976	1710	activity-stimulating growth	[activity-stimulating growth]	0.0	2	1	1	1
133977	1710	type-specific t-cell clone	[type-specific T-cell clone]	0.0	3	1	1	1
133978	1710	persistence despite paralysis	[persistence despite paralysis]	0.0	3	1	1	1
133979	1710	leukocyte adhesion to huvec	[leukocyte adhesion to HUVECs]	0.0	4	1	1	1
133980	1710	instillation of liposome	[instillation of liposomes]	0.0	3	1	1	1
133981	1710	poor prognosis, with a survival	[poor prognosis, with a survival]	0.0	5	1	1	1
133982	1710	basal activity a potent transcriptional activator	[basal activity a potent transcriptional activator]	0.0	6	1	1	1
133983	1710	indicate proliferated,	[indicating proliferated,]	0.0	2	1	1	1
133984	1710	(i) patient with CLL express er	[(i) patients with CLL express ER]	0.0	6	1	1	1
133985	1710	BFRF3	[BFRF3]	0.0	1	1	1	1
133986	1710	triiodothyronine t3 plasma clearance rate	[triiodothyronine T3 plasma clearance rates]	0.0	5	1	1	1
133987	1710	cell line CEM	[cell line CEM]	0.0	3	1	1	1
133988	1710	insight into the rate in cell	[insights into the rate in cells]	0.0	6	1	1	1
133989	1710	cd56+ cd16- egl	[CD56+ CD16- eGLs]	0.0	3	1	1	1
133990	1710	MHC avidity	[MHC avidity]	0.0	2	1	1	1
133991	1710	exposure to nm vd3	[Exposure to nM VD3]	0.0	4	1	1	1
133992	1710	vacuolar h+-atpase	[vacuolar H+-ATPase]	0.0	2	1	1	1
133993	1710	40mer oligonucleotide	[40mer oligonucleotides]	0.0	2	1	1	1
133994	1710	TRAIL tnf-related apoptosis ligand	[TRAIL TNF-related apoptosis ligand]	0.0	4	1	1	1
133995	1710	major role in response	[major role in responses]	0.0	4	1	1	1
133996	1710	action of e1a oncoprotein	[action of E1A oncoprotein]	0.0	4	1	1	1
133997	1710	woman in good health	[women in good health]	0.0	4	1	1	1
133998	1710	nuclear rna EBERs	[nuclear RNAs EBERs]	0.0	3	1	1	1
133999	1710	relative affinity of Oct-1	[relative affinity of Oct-1]	0.0	4	1	1	1
134000	1710	specific gene include interleukin-2 IL-2	[specific genes including interleukin-2 IL-2]	0.0	5	1	1	1
134001	1710	genesis of lymphocytic leukemia	[genesis of lymphocytic leukemia]	0.0	4	1	1	1
134002	1710	prb protein	[pRB protein]	0.0	2	1	1	1
134003	1710	34-fold	[34-fold]	0.0	1	1	1	1
134004	1710	Potent inhibition in cell	[Potent inhibition in cells]	0.0	4	1	1	1
134005	1710	HBx sequence	[HBx sequence]	0.0	2	1	1	1
134006	1710	high bind affinity	[highest binding affinity]	0.0	3	1	1	1
134007	1710	RXR effects.	[RXR effects.]	0.0	2	1	1	1
134008	1710	suppress two pathway	[suppressing two pathways]	0.0	3	1	1	1
134009	1710	minimal element inducible	[minimal element inducible]	0.0	3	1	1	1
134010	1710	binding capacity versus 4131+/-321	[Binding capacity versus 4131+/-321]	0.0	4	1	1	1
134011	1710	inducible, factor	[inducible, factor]	0.0	2	2	2	1
134012	1710	evaluation of anti-D reagent	[Evaluation of anti-D reagents]	0.0	4	1	1	1
134013	1710	expression of the viral protein	[expression of the viral protein]	0.0	5	1	1	1
134014	1710	three subtype	[Three subtypes]	0.0	2	1	1	1
134015	1710	high-affinity surface receptor	[high-affinity surface receptor]	0.0	3	1	1	1
134016	1710	p-selectin translocation	[P-selectin translocation]	0.0	2	1	1	1
134017	1710	clinical predictor	[clinical predictor]	0.0	2	1	1	1
134018	1710	normal range.	[normal range.]	0.0	2	1	1	1
134019	1710	other synthetic RAR ligand	[other synthetic RAR ligands]	0.0	4	1	1	1
134020	1710	high activity against ec	[high activity against EC]	0.0	4	1	1	1
134021	1710	p50 dimer	[p50 dimer]	0.0	2	1	1	1
134022	1710	presence of the type	[presence of the type]	0.0	4	1	1	1
134023	1710	biodisposal	[biodisposal]	0.0	1	1	1	1
134024	1710	metabolite dihydroxyvitamin d3,	[metabolite dihydroxyvitamin D3,]	0.0	3	1	1	1
134025	1710	novel form of mzf protein	[novel form of MZF protein]	0.0	5	1	1	1
134026	1710	(ec-mn)	[(EC-Mn)]	0.0	1	1	1	1
134027	1710	equal, unequal paternal expression	[equal, unequal paternal expression]	0.0	4	1	1	1
134028	1710	interleukin 3 gene expression	[interleukin 3 gene expression]	0.0	4	1	1	1
134029	1710	il-4 receptor il-4r	[IL-4 receptor IL-4R]	0.0	3	1	1	1
134030	1710	evidence rate-limiting for primary lymphocyte activation	[Evidence rate-limiting for primary lymphocyte activation]	0.0	6	1	1	1
134031	1710	pmn of the response.	[PMN of the response.]	0.0	4	1	1	1
134032	1710	receptor for B-cell stimulation	[receptors for B-cell stimulation]	0.0	4	1	1	1
134033	1710	-bound	[-bound]	0.0	1	1	1	1
134034	1710	secretion of amount	[secretion of amounts]	0.0	3	1	1	1
134035	1710	weak binding peptide	[weaker binding peptides]	0.0	3	1	1	1
134036	1710	expose umbilical vein cell	[Exposing umbilical vein cells]	0.0	4	1	1	1
134037	1710	alter normal signal transduction	[altering normal signal transduction]	0.0	4	1	1	1
134038	1710	min) exercise at 70%	[min) exercise at 70%]	0.0	4	1	1	1
134039	1710	histocompatibility class gene promoter	[histocompatibility class gene promoter]	0.0	4	1	1	1
134040	1710	myelofibrosis	[myelofibrosis]	0.0	1	1	1	1
134041	1710	c-myc regulation	[c-myc regulation]	0.0	2	1	1	1
134042	1710	ureteral obstruction	[ureteral obstruction]	0.0	2	1	1	1
134043	1710	reticulum ca2+-atpase	[reticulum Ca2+-ATPase]	0.0	2	1	1	1
134044	1710	phosphotyrosine labeling of proteins.	[phosphotyrosine labeling of proteins.]	0.0	4	1	1	1
134045	1710	regulatory sequence within the element AREs	[regulatory sequences within the elements AREs]	0.0	6	1	1	1
134046	1710	prior to hybridization	[prior to hybridization]	0.0	3	1	1	1
134047	1710	body in erythroblast	[bodies in erythroblasts]	0.0	3	1	1	1
134048	1710	lytic reactivity at least as high	[lytic reactivities at least as high]	0.0	6	1	1	1
134049	1710	intraperitoneal injection of ccl4	[intraperitoneal injection of CCl4]	0.0	4	1	1	1
134050	1710	related 16-bp see	[related 16-bp SEE]	0.0	3	1	1	1
134051	1710	factor for the inducible expression	[factor for the inducible expression]	0.0	5	1	1	1
134052	1710	mutation in primary lymphoid cell	[mutations in primary lymphoid cells]	0.0	5	1	1	1
134053	1710	mixture, p50 associate preferentially	[mixture, p50 associates preferentially]	0.0	4	1	1	1
134054	1710	predominantly c-rel	[predominantly c-Rel]	0.0	2	1	1	1
134055	1710	multiple transcription factor to element	[multiple transcription factors to elements]	0.0	5	1	1	1
134056	1710	cause arrest.	[cause arrest.]	0.0	2	1	1	1
134057	1710	loss of CD5 surface expression	[loss of CD5 surface expression]	0.0	5	1	1	1
134058	1710	contrast, two other drug	[contrast, two other drugs]	0.0	4	1	1	1
134059	1710	phospholipase c gamma overexpression	[Phospholipase C gamma overexpression]	0.0	4	1	1	1
134060	1710	normal blood pb	[normal blood PB]	0.0	3	1	1	1
134061	1710	receptor family,	[receptor family,]	0.0	2	1	1	1
134062	1710	level of viral transcription	[levels of viral transcription]	0.0	4	1	1	1
134063	1710	glial astrocyte	[glial astrocytes]	0.0	2	1	1	1
134064	1710	receptor/	[receptor/s]	0.0	1	1	1	1
134065	1710	t-cell line H9	[T-cell line H9]	0.0	3	1	1	1
134066	1710	i.e. transactivation	[i.e. transactivation]	0.0	2	1	1	1
134067	1710	basis.	[basis.]	0.0	1	1	1	1
134068	1710	represent stage of maturation,	[representing stages of maturation,]	0.0	4	1	1	1
134069	1710	include suppression	[including suppression]	0.0	2	1	1	1
134070	1710	involvement of a set	[involvement of a set]	0.0	4	1	1	1
134071	1710	number of -immunoreactive cell	[number of -immunoreactive cells]	0.0	4	1	1	1
134072	1710	il-12/10(6) cell	[IL-12/10(6) cells]	0.0	2	1	1	1
134073	1710	40 kb	[40 kb]	0.0	2	1	1	1
134074	1710	expression of a Itk mutant	[expression of an Itk mutant]	0.0	5	1	1	1
134075	1710	ras immunoprecipitate	[Ras immunoprecipitates]	0.0	2	1	1	1
134076	1710	ets-related transcription factor	[Ets-related transcription factor]	0.0	3	1	1	1
134077	1710	encode gp350/220	[encoding gp350/220]	0.0	2	1	1	1
134078	1710	signal pathway downstream	[signaling pathways downstream]	0.0	3	1	1	1
134079	1710	modification and/or translocation	[modification and/or translocation]	0.0	3	1	1	1
134080	1710	tuberous sclerosis gene tsc2	[tuberous sclerosis gene TSC2]	0.0	4	1	1	1
134081	1710	(mrna)	[(mRNA)]	0.0	1	1	1	1
134082	1710	adherence to endothelial cell	[adherence to endothelial cells]	0.0	4	1	1	1
134083	1710	th2-restricted il-4 expression	[Th2-restricted IL-4 expression]	0.0	3	1	1	1
134084	1710	action in t- lymphocyte	[action in T- lymphocytes]	0.0	4	1	1	1
134085	1710	anti- IL-6 abs	[anti- IL-6 Abs]	0.0	3	1	1	1
134086	1710	(p less than 0.025)	[(P less than 0.025)]	0.0	4	1	1	1
134087	1710	antigen-specific T cell line	[antigen-specific T cell lines]	0.0	4	1	1	1
134088	1710	pbmc resistance in CRF patient	[PBMC resistance in CRF patients]	0.0	5	1	1	1
134089	1710	chrysotile b	[Chrysotile B]	0.0	2	1	1	1
134090	1710	activation of NF-kappaB by lps	[activation of NF-kappaB by LPS]	0.0	5	1	1	1
134091	1710	elicit remission	[eliciting remissions]	0.0	2	1	1	1
134092	1710	category factor	[categories factors]	0.0	2	1	1	1
134093	1710	Differential regulation of il-6 gene transcription	[Differential regulation of IL-6 gene transcription]	0.0	6	1	1	1
134094	1710	physiologically relevant functional interaction	[physiologically relevant functional interaction]	0.0	4	1	1	1
134095	1710	transduce a raralpha exhibit dominant-negative activity	[transducing a RARalpha exhibiting dominant-negative activity]	0.0	6	1	1	1
134096	1710	unstimulated jurkat T cell	[unstimulated Jurkat T cells]	0.0	4	1	1	1
134097	1710	infiltrate hamster cutaneous wound	[infiltrating hamster cutaneous wounds]	0.0	4	1	1	1
134098	1710	-acting	[-acting]	0.0	1	1	1	1
134099	1710	jak kinase protein	[JAK kinases proteins]	0.0	3	1	1	1
134100	1710	id2 mrna in lymphocyte	[Id2 mRNA in lymphocytes]	0.0	4	1	1	1
134101	1710	expression of thrombospondin a member	[expression of thrombospondin a member]	0.0	5	1	1	1
134102	1710	36 control subject	[36 control subjects]	0.0	3	1	1	1
134103	1710	four proteins--a protein	[four proteins--a protein]	0.0	3	1	1	1
134104	1710	pluripotent activator	[pluripotent activator]	0.0	2	1	1	1
134105	1710	regulation of regulatory factor-kappa beta	[regulation of regulatory factor-kappa beta]	0.0	5	1	1	1
134106	1710	Stuart	[Stuart]	0.0	1	1	1	1
134107	1710	selective inhibition signal	[selective inhibition signaling]	0.0	3	1	1	1
134108	1710	specific dna-binding of Stat	[specific DNA-binding of Stat]	0.0	4	1	1	1
134109	1710	selective modulation of immune responsiveness	[Selective modulation of immune responsiveness]	0.0	5	1	1	1
134110	1710	culture of thymic cell	[cultures of thymic cells]	0.0	4	1	1	1
134111	1710	polypeptide of 106 kda	[polypeptides of 106 kDa]	0.0	4	1	1	1
134112	1710	factor for the monocytic expression	[factor for the monocytic expression]	0.0	5	1	1	1
134113	1710	hiv long repeat transactivation	[HIV long repeat transactivation]	0.0	4	1	1	1
134114	1710	western blot study	[Western blot studies]	0.0	3	1	1	1
134115	1710	Activation, T	[Activation, T]	0.0	2	1	1	1
134116	1710	anti- hcmv g-seropositive donor	[anti- HCMV G-seropositive donors]	0.0	4	1	1	1
134117	1710	however a strong association between amplification	[however a strong association between amplification]	0.0	6	1	1	1
134118	1710	about a 35% decrease	[about a 35% decrease]	0.0	4	1	1	1
134119	1710	hiv-1 entry	[HIV-1 entry]	0.0	2	1	1	1
134120	1710	potential activation element	[potential activation elements]	0.0	3	1	1	1
134121	1710	adhesion of human monocyte to p-selectin	[Adhesion of human monocytes to P-selectin]	0.0	6	1	1	1
134122	1710	12 woman of childbearing	[12 women of childbearing]	0.0	4	1	1	1
134123	1710	generation of immune response	[generation of immune responses]	0.0	4	1	1	1
134124	1710	cyclosporin a a undecapeptide	[cyclosporin A a undecapeptide]	0.0	4	1	1	1
134125	1710	IFN-alpha responsiveness	[IFN-alpha responsiveness]	0.0	2	1	1	1
134126	1710	CD40 b cell	[CD40 B cells]	0.0	3	1	1	1
134127	1710	use mobility shift assay,	[Using mobility shift assay,]	0.0	4	1	1	1
134128	1710	exchange of peptide	[exchange of peptides]	0.0	3	1	1	1
134129	1710	nuclear affinity	[nuclear affinity]	0.0	2	1	1	1
134130	1710	T cell-specific function	[T cell-specific function]	0.0	3	1	1	1
134131	1710	mechanism for the anti-inflammatory effect	[mechanism for the anti-inflammatory effect]	0.0	5	1	1	1
134132	1710	exon, result in protein	[exon, resulting in proteins]	0.0	4	1	1	1
134133	1710	alpha-naphthyl acetate esterase anae activity	[alpha-naphthyl acetate esterase ANAE activity]	0.0	5	1	1	1
134134	1710	encompass band p11.23	[encompassing bands p11.23]	0.0	3	1	1	1
134135	1710	tissue of the joint	[tissue of the joints]	0.0	4	1	1	1
134136	1710	sp-a increase	[SP-A increases]	0.0	2	1	1	1
134137	1710	effect on LTR activity	[effect on LTR activity]	0.0	4	1	1	1
134138	1710	transmit the signal	[transmitting the signal]	0.0	3	1	1	1
134139	1710	pcr analysis of lymphoblastoid cell line	[PCR analysis of lymphoblastoid cell lines]	0.0	6	1	1	1
134140	1710	a pha	[A PHA]	0.0	2	1	1	1
134141	1710	production of factor	[production of factor]	0.0	3	1	1	1
134142	1710	synthesis of ifn-gamma	[synthesis of IFN-gamma]	0.0	3	1	1	1
134143	1710	novel T cell-specific element	[novel T cell-specific element]	0.0	4	1	1	1
134144	1710	membrane receptor a 50 kda protein	[membrane receptors a 50 kDa protein]	0.0	6	1	1	1
134145	1710	period of 5	[period of 5]	0.0	3	1	1	1
134146	1710	feature in PML/RARalpha mouse	[features in PML/RARalpha mice]	0.0	4	1	1	1
134147	1710	MHC population	[MHC population]	0.0	2	1	1	1
134148	1710	dp65	[dp65]	0.0	1	1	1	1
134149	1710	addition to anti-cd3 T cell	[addition to anti-CD3 T cells]	0.0	5	1	1	1
134150	1710	differentiation of the progenitor cell	[differentiation of the progenitor cells]	0.0	5	1	1	1
134151	1710	samples, cytotoxic activity from endometrium	[samples, cytotoxic activity from endometrium]	0.0	5	1	1	1
134152	1710	same samples.	[same samples.]	0.0	2	1	1	1
134153	1710	migration of antigen t-cell	[migration of antigen T-cells]	0.0	4	1	1	1
134154	1710	nongenomic in vitro effect of aldosterone	[nongenomic in vitro effects of aldosterone]	0.0	6	1	1	1
134155	1710	affinity of NFKB2 p49	[affinity of NFKB2 p49]	0.0	4	1	1	1
134156	1710	also (p less than 0.025)	[also (P less than 0.025)]	0.0	5	1	1	1
134157	1710	contain repeat DR	[containing repeats DR]	0.0	3	1	1	1
134158	1710	coronary angioplasty	[coronary angioplasty]	0.0	2	1	1	1
134159	1710	role of cis-acting DNA element	[role of cis-acting DNA elements]	0.0	5	1	1	1
134160	1710	pro-coagulant protein tissue factor	[pro-coagulant protein tissue factor]	0.0	4	1	1	1
134161	1710	increase moderately during exposure	[increasing moderately during exposure]	0.0	4	1	1	1
134162	1710	slowly migrate isoform,	[slowly migrating isoform,]	0.0	3	1	1	1
134163	1710	glucocorticoid receptor GCR in leukocyte	[glucocorticoid receptors GCR in leukocytes]	0.0	5	1	1	1
134164	1710	cd86 b7-2 two principal ligand	[CD86 B7-2 two principal ligands]	0.0	5	1	1	1
134165	1710	DNase footprinting assay	[DNase footprinting assays]	0.0	3	1	1	1
134166	1710	RESULTS: in the OM-10.1 model	[RESULTS: In the OM-10.1 model]	0.0	5	1	1	1
134167	1710	stat5b in human precursor	[STAT5B in human precursors]	0.0	4	1	1	1
134168	1710	il-12 production by macrophage	[IL-12 production by macrophages]	0.0	4	1	1	1
134169	1710	tissue-specific constraint	[tissue-specific constraints]	0.0	2	1	1	1
134170	1710	early gene under the control	[early genes under the control]	0.0	5	1	1	1
134171	1710	evidence a modulator of gene expression	[evidence a modulator of gene expression]	0.0	6	1	1	1
134172	1710	thereby preclude the selective lysis	[thereby precluding the selective lysis]	0.0	5	1	1	1
134173	1710	human 1beta	[human 1beta]	0.0	2	1	1	1
134174	1710	cxcr4	[CXCR4]	0.0	1	1	1	1
134175	1710	independently of the pre-culture condition	[independently of the pre-culture conditions]	0.0	5	1	1	1
134176	1710	3,5,3'-triiodothyronine receptor circulate lymphocyte thyroidism	[3,5,3'-triiodothyronine receptors circulating lymphocytes thyroidism]	0.0	5	1	1	1
134177	1710	mutant of P. aeruginosa pak	[mutants of P. aeruginosa PAK]	0.0	5	1	1	1
134178	1710	substantial amount of nf-kappab	[substantial amount of NF-kappaB]	0.0	4	1	1	1
134179	1710	IkappaBalpha by DEX	[IkappaBalpha by DEX]	0.0	3	1	1	1
134180	1710	primary role of aml1/eto	[primary role of AML1/ETO]	0.0	4	1	1	1
134181	1710	nf-kappa-b	[NF-kappa-B]	0.0	1	1	1	1
134182	1710	histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	4	1	1	1
134183	1710	activation of zeta globin gene	[activation of zeta globin gene]	0.0	5	1	1	1
134184	1710	probably antagonize the IL-1 synthesis	[probably antagonizing the IL-1 synthesis]	0.0	5	1	1	1
134185	1710	nuclear hormone receptor coactivator activity	[nuclear hormone receptor coactivator activity]	0.0	5	1	1	1
134186	1710	myf3 gene	[myf3 gene]	0.0	2	1	1	1
134187	1710	expansion) occur	[expansion) occurring]	0.0	2	1	1	1
134188	1710	T-cell lineage	[T-cell lineage]	0.0	2	1	1	1
134189	1710	important role modulate function	[important role modulating function]	0.0	4	1	1	1
134190	1710	result in translocation from the cytoplasm	[resulting in translocation from the cytoplasm]	0.0	6	1	1	1
134191	1710	stem cell hsc	[stem cells HSCs]	0.0	3	1	1	1
134192	1710	contain bp of c-fe 5'-flanking sequence	[containing bp of c-fes 5'-flanking sequences]	0.0	6	1	1	1
134193	1710	CR2 complement receptor	[CR2 complement receptor]	0.0	3	1	1	1
134194	1710	relevant functional interaction	[relevant functional interaction]	0.0	3	1	1	1
134195	1710	aml1/mds1/evi1 block differentiation	[AML1/MDS1/EVI1 blocks differentiation]	0.0	3	1	1	1
134196	1710	prevention of degradation	[prevention of degradation]	0.0	3	1	1	1
134197	1710	express bcl-2	[expressing Bcl-2]	0.0	2	1	1	1
134198	1710	eight untrained volunteer	[Eight untrained volunteers]	0.0	3	1	1	1
134199	1710	comparative study with IL-4	[comparative study with IL-4]	0.0	4	1	1	1
134200	1710	value equal	[value equal]	0.0	2	1	1	1
134201	1710	require interaction of steroid -receptor complex	[requiring interaction of steroid -receptor complexes]	0.0	6	1	1	1
134202	1710	mono Mac cell	[Mono Mac cells]	0.0	3	1	1	1
134203	1710	human irf-1 gene	[human IRF-1 gene]	0.0	3	1	1	1
134204	1710	use the coiled-coil region of Stat5b	[Using the coiled-coil region of Stat5b]	0.0	6	1	1	1
134205	1710	[molecular mechanism of lymphocyte dysfunction	[[Molecular mechanisms of lymphocyte dysfunction]	0.0	5	1	1	1
134206	1710	transcriptional domain	[transcriptional domain]	0.0	2	1	1	1
134207	1710	diterpene triepoxide with property	[diterpene triepoxide with properties]	0.0	4	1	1	1
134208	1710	cellular disposition implication	[Cellular disposition implications]	0.0	3	1	1	1
134209	1710	identification of a major element	[Identification of a major element]	0.0	5	1	1	1
134210	1710	1.8 kilobase (kb)	[1.8 kilobase (kb)]	0.0	3	1	1	1
134211	1710	approximately 0.67 map unit	[approximately 0.67 map units]	0.0	4	1	1	1
134212	1710	especially the homolog of chicken nf-m	[especially the homolog of chicken NF-M]	0.0	6	1	1	1
134213	1710	alas isozyme	[ALAS isozyme]	0.0	2	1	1	1
134214	1710	various human haematopoietic line	[various human haematopoietic lines]	0.0	4	1	1	1
134215	1710	only tyrosine phosphorylation	[only tyrosine phosphorylation]	0.0	3	1	1	1
134216	1710	Rel/kappaB a family	[Rel/kappaB a family]	0.0	3	1	1	1
134217	1710	genomic sequence	[genomic sequence]	0.0	2	2	2	1
134218	1710	less CAT activity	[less CAT activity]	0.0	3	1	1	1
134219	1710	notion a transcription factor	[notion a transcription factor]	0.0	4	1	1	1
134220	1710	vary time	[varying times]	0.0	2	1	1	1
134221	1710	involvement in disease	[involvement in diseases]	0.0	3	1	1	1
134222	1710	mediate the effect of drug	[mediating the effects of drugs]	0.0	5	1	1	1
134223	1710	cleavage of ester	[cleavage of esters]	0.0	3	1	1	1
134224	1710	LPS member	[LPS member]	0.0	2	1	1	1
134225	1710	4 h in quiescent cell	[4 h in quiescent cells]	0.0	5	1	1	1
134226	1710	size, indicative	[size, indicative]	0.0	2	1	1	1
134227	1710	unrecognized NFATp -binding site	[unrecognized NFATp -binding sites]	0.0	4	1	1	1
134228	1710	oxidation to toxic metabolite	[oxidation to toxic metabolites]	0.0	4	1	1	1
134229	1710	p young vs. old)	[P young vs. old)]	0.0	4	1	1	1
134230	1710	phosphopeptide map of the ets-1 protein	[phosphopeptide maps of the Ets-1 protein]	0.0	6	1	1	1
134231	1710	salmonella typhimurium strain	[Salmonella typhimurium strains]	0.0	3	1	1	1
134232	1710	htlv-i tumor by inhibition	[HTLV-I tumors by inhibition]	0.0	4	1	1	1
134233	1710	particularly with cytomegalovirus	[particularly with cytomegalovirus]	0.0	3	1	1	1
134234	1710	receptor-negative s49 thymoma cell	[receptor-negative S49 thymoma cells]	0.0	4	1	1	1
134235	1710	ifn-gamma varies,	[IFN-gamma varies,]	0.0	2	1	1	1
134236	1710	human xenograft	[human xenografts]	0.0	2	1	1	1
134237	1710	association of the kinase	[association of the kinase]	0.0	4	1	1	1
134238	1710	th2 cytokine develop th1 cell	[Th2 cytokines developing Th1 cells]	0.0	5	1	1	1
134239	1710	contain a glucocorticosteroid response element	[containing a glucocorticosteroid response element]	0.0	5	1	1	1
134240	1710	intracellular store	[intracellular stores]	0.0	2	1	1	1
134241	1710	erythropoietic culture analysis of gene expression	[erythropoietic cultures analysis of gene expression]	0.0	6	1	1	1
134242	1710	mu/l physiological upper limit	[mU/L physiological upper limit]	0.0	4	1	1	1
134243	1710	treatment of skw cell	[Treatment of SKW cells]	0.0	4	1	1	1
134244	1710	excess of ligand	[excess of ligand]	0.0	3	1	1	1
134245	1710	domain dbd of GALA.	[domain DBD of GALA.]	0.0	4	1	1	1
134246	1710	more substitution	[more substitutions]	0.0	2	1	1	1
134247	1710	specific granule mediate response	[specific granules mediating responses]	0.0	4	1	1	1
134248	1710	il-10 receptor site per cell,	[IL-10 receptor sites per cell,]	0.0	5	1	1	1
134249	1710	pathogen such as lipopolysaccharide	[pathogens such as lipopolysaccharide]	0.0	4	1	1	1
134250	1710	bp upstream of the functional site	[bp upstream of the functional site]	0.0	6	1	1	1
134251	1710	Epstein-Barr virus EBV the agent	[Epstein-Barr virus EBV the agent]	0.0	5	1	1	1
134252	1710	direct contribution	[direct contribution]	0.0	2	1	1	1
134253	1710	mediate different aspect	[mediating different aspects]	0.0	3	1	1	1
134254	1710	activation of class gene	[activation of class genes]	0.0	4	1	1	1
134255	1710	human immunodeficiency virus type (hiv-1) infection	[human immunodeficiency virus type (HIV-1) infection]	0.0	6	1	1	1
134256	1710	aids-related primary effusion lymphoma	[AIDS-related primary effusion lymphoma]	0.0	4	1	1	1
134257	1710	action of BHRF1	[action of BHRF1]	0.0	3	1	1	1
134258	1710	undetectable consolidation with chemotherapy	[undetectable consolidation with chemotherapy]	0.0	4	1	1	1
134259	1710	glucocorticoid receptor in human leukocyte	[glucocorticoid receptor in human leukocytes]	0.0	5	2	2	1
134260	1710	TNF alpha one	[TNF alpha one]	0.0	3	1	1	1
134261	1710	recent information	[recent information]	0.0	2	1	1	1
134262	1710	rhythm in glucocorticoid receptor gr	[rhythm in glucocorticoid receptor GR]	0.0	5	1	1	1
134263	1710	All-trans-retinoic acid	[All-trans-retinoic acid]	0.0	2	1	1	1
134264	1710	induction of hl-60 cell differentiation	[Induction of HL-60 cell differentiation]	0.0	5	1	1	1
134265	1710	(a/t)gata(g/	[(A/T)GATA(G/]	0.0	1	1	1	1
134266	1710	vitro transendothelial migration	[vitro transendothelial migration]	0.0	3	1	1	1
134267	1710	classical prognostic features: implications.	[classical prognostic features: implications.]	0.0	4	1	1	1
134268	1710	level of il-6 protein	[levels of IL-6 protein]	0.0	4	1	1	1
134269	1710	ras in anti- ras immunoprecipitate	[Ras in anti- Ras immunoprecipitates]	0.0	5	1	1	1
134270	1710	3rd base substitution polymorphism	[3rd base substitution polymorphisms]	0.0	4	1	1	1
134271	1710	Genetic characterization binding	[Genetic characterization Binding]	0.0	3	1	1	1
134272	1710	antibody induction	[antibody induction]	0.0	2	1	1	1
134273	1710	PU.1 spi-1	[PU.1 spi-1]	0.0	2	1	1	1
134274	1710	release of bioactive m-csf protein	[release of bioactive M-CSF protein]	0.0	5	1	1	1
134275	1710	nfat group	[NFAT group]	0.0	2	1	1	1
134276	1710	activity of il-1alpha promoter -cat construct	[activity of IL-1alpha promoter -CAT constructs]	0.0	6	1	1	1
134277	1710	nuclear c/ebp beta	[nuclear C/EBP beta]	0.0	3	3	3	1
134278	1710	class promoter in b cell	[class promoters in B cells]	0.0	5	1	1	1
134279	1710	pre-B line	[pre-B lines]	0.0	2	1	1	1
134280	1710	role in neutrophil maturation	[role in neutrophil maturation]	0.0	4	1	1	1
134281	1710	alpha thf/thf n: 0.92+/-0.42)	[alpha THF/THF N: 0.92+/-0.42)]	0.0	4	1	1	1
134282	1710	processing of NF-kappa b1/	[processing of NF-kappa B1/]	0.0	4	1	1	1
134283	1710	discrete stage of development	[discrete stages of development]	0.0	4	1	1	1
134284	1710	propenoic	[propenoic]	0.0	1	1	1	1
134285	1710	mononuclear cell differentiation	[mononuclear cell differentiation]	0.0	3	1	1	1
134286	1710	augmentative cis element	[augmentative cis elements]	0.0	3	1	1	1
134287	1710	killer cell (nk) activation	[killer cell (NK) activation]	0.0	4	1	1	1
134288	1710	infectious construct	[infectious constructs]	0.0	2	1	1	1
134289	1710	decrease in nuclear nf-kappa b	[decrease in nuclear NF-kappa B]	0.0	5	1	1	1
134290	1710	responsive element ionophore	[responsive element ionophore]	0.0	3	1	1	1
134291	1710	nucleotide binding factor	[nucleotide binding factor]	0.0	3	1	1	1
134292	1710	endocrine culture of rat pancrea	[endocrine cultures of rat pancreas]	0.0	5	1	1	1
134293	1710	kb mrna	[kb mRNA]	0.0	2	1	1	1
134294	1710	molecule a cytosolic-anchoring protein	[molecule a cytosolic-anchoring protein]	0.0	4	1	1	1
134295	1710	strong cyto-differentiating potential	[strong cyto-differentiating potential]	0.0	3	1	1	1
134296	1710	however, special culture condition	[however, special cultures conditions]	0.0	4	1	1	1
134297	1710	peak of junb mrna	[peak of junB mRNA]	0.0	4	1	1	1
134298	1710	cd34+ bone marrow cell	[CD34+ bone marrow cells]	0.0	4	2	2	1
134299	1710	transcriptional nuclear factor-KB NF-kappa b	[transcriptional nuclear factor-KB NF-kappa B]	0.0	5	1	1	1
134300	1710	cytokine in epithelial cell	[cytokines in epithelial cells]	0.0	4	1	1	1
134301	1710	structural comparison no synthase ino gene	[structural comparison NO synthase iNOS genes]	0.0	6	1	1	1
134302	1710	cis-active relationship	[cis-active relationship]	0.0	2	1	1	1
134303	1710	mitogenic pair	[mitogenic pairs]	0.0	2	1	1	1
134304	1710	-9-mediate cell proliferation	[-9-mediated cell proliferation]	0.0	3	1	1	1
134305	1710	t translocation	[t translocation]	0.0	2	1	1	1
134306	1710	methylation of HpaII	[Methylation of HpaII]	0.0	3	1	1	1
134307	1710	CHO cell	[CHO cells]	0.0	2	1	1	1
134308	1710	sex distribution of receptor	[Sex distribution of receptors]	0.0	4	1	1	1
134309	1710	lymphocyte from subject	[lymphocytes from subjects]	0.0	3	2	2	1
134310	1710	induce expression in human lymphoblastoid cell	[inducing expression in human lymphoblastoid cells]	0.0	6	1	1	1
134311	1710	pkb/pi3-kinase	[PKB/PI3-kinase]	0.0	1	1	1	1
134312	1710	Ile for Val	[Ile for Val]	0.0	3	1	1	1
134313	1710	isolation of human dendritic cell	[Isolation of human dendritic cells]	0.0	5	1	1	1
134314	1710	signal from TCR- CD3	[signals from TCR- CD3]	0.0	4	1	1	1
134315	1710	independent criteria,	[independent criteria,]	0.0	2	1	1	1
134316	1710	transcription of major histocompatibility class gene	[transcription of major histocompatibility class genes]	0.0	6	1	1	1
134317	1710	sequela of glucocorticoid therapy	[sequela of glucocorticoid therapy]	0.0	4	1	1	1
134318	1710	use cd34+	[using CD34+]	0.0	2	1	1	1
134319	1710	use a dominant negative form Max	[using a dominant negative form Max]	0.0	6	1	1	1
134320	1710	presence of binding site	[presence of binding sites]	0.0	4	1	1	1
134321	1710	treatment of hl-60/vinc cell	[treatment of HL-60/vinc cells]	0.0	4	1	1	1
134322	1710	2.3 fmol/million cells; p less	[2.3 fmol/million cells; P less]	0.0	5	1	1	1
134323	1710	globular, electron-dense structure distinct	[globular, electron-dense structures distinct]	0.0	4	1	1	1
134324	1710	variety during the response	[variety during the response]	0.0	4	1	1	1
134325	1710	differentiated, plasma cell-like b cell	[differentiated, plasma cell-like B cells]	0.0	5	1	1	1
134326	1710	development of a organism.	[development of an organism.]	0.0	4	1	1	1
134327	1710	mechanism for therapeutic effect	[mechanism for therapeutic effects]	0.0	4	1	1	1
134328	1710	camp -dependent regulation	[cAMP -dependent regulation]	0.0	3	1	1	1
134329	1710	coordinate activation of hsf effect	[coordinate activation of HSF effects]	0.0	5	1	1	1
134330	1710	nf-kappab family protein	[NF-kappaB family proteins]	0.0	3	1	1	1
134331	1710	DNA sequence affinity profile	[DNA sequence affinity profile]	0.0	4	1	1	1
134332	1710	distinct stat protein	[distinct STAT proteins]	0.0	3	1	1	1
134333	1710	neutralize tnf-alpha antibody antigen release	[neutralizing TNF-alpha antibodies antigen release]	0.0	5	1	1	1
134334	1710	interaction with the region of E2A	[interactions with the region of E2A]	0.0	6	1	1	1
134335	1710	tfiid subunit	[TFIID subunit]	0.0	2	1	1	1
134336	1710	b level	[B levels]	0.0	2	1	1	1
134337	1710	strong positivity	[Strong positivity]	0.0	2	1	1	1
134338	1710	cytokine in cell	[cytokines in cells]	0.0	3	1	1	1
134339	1710	interferon beta regulatory element	[interferon beta regulatory element]	0.0	4	1	1	1
134340	1710	h with nm vd3	[h with nM VD3]	0.0	4	1	1	1
134341	1710	wide variety of response gene	[wide variety of response genes]	0.0	5	1	1	1
134342	1710	Lymphotoxin-alpha	[Lymphotoxin-alpha]	0.0	1	1	1	1
134343	1710	thereby amplify cellular event lead	[thereby amplifying cellular events leading]	0.0	5	1	1	1
134344	1710	encompass this site 4481 to 4982	[encompassing this site 4481 to 4982]	0.0	6	1	1	1
134345	1710	h in bovine serum-contain medium	[h in bovine serum-containing medium]	0.0	5	1	1	1
134346	1710	normal limit	[normal limit]	0.0	2	1	1	1
134347	1710	abundant expression	[Abundant expression]	0.0	2	2	2	1
134348	1710	recombinant ssb rssb	[recombinant SSB rSSB]	0.0	3	1	1	1
134349	1710	patient with various rheumatic disease	[patients with various rheumatic diseases]	0.0	5	1	1	1
134350	1710	Oct-2 protein	[Oct-2 protein]	0.0	2	1	1	1
134351	1710	fuse each to the hormone-binding domain	[fusing each to the hormone-binding domain]	0.0	6	1	1	1
134352	1710	association of terminus	[association of terminus]	0.0	3	1	1	1
134353	1710	interaction between gata-1	[interaction between GATA-1]	0.0	3	1	1	1
134354	1710	Furthermore, level of stat1	[Furthermore, levels of Stat1]	0.0	4	1	1	1
134355	1710	significant partial correlation	[significant partial correlations]	0.0	3	1	1	1
134356	1710	strong genetic component	[strong genetic component]	0.0	3	1	1	1
134357	1710	HLA-DQB1 codon	[HLA-DQB1 codon]	0.0	2	1	1	1
134358	1710	positive one	[positive one]	0.0	2	1	1	1
134359	1710	additional site	[additional site]	0.0	2	2	2	1
134360	1710	cytokine dysregulation immunodeficiency virus type hiv-1	[Cytokine dysregulation immunodeficiency virus type HIV-1]	0.0	6	1	1	1
134361	1710	profound depression in the level	[profound depression in the levels]	0.0	5	1	1	1
134362	1710	house dust mite	[house dust mite]	0.0	3	2	2	1
134363	1710	deletion of TSG101	[deletions of TSG101]	0.0	3	1	1	1
134364	1710	different activation	[different activation]	0.0	2	1	1	1
134365	1710	effect comparison to anti-CD3 antibody	[effect comparison to anti-CD3 antibodies]	0.0	5	1	1	1
134366	1710	combinatorial effect	[combinatorial effects]	0.0	2	1	1	1
134367	1710	strong binding	[strong binding]	0.0	2	1	1	1
134368	1710	late kinetic	[late kinetics]	0.0	2	1	1	1
134369	1710	cell of leukemia	[cells of leukemia]	0.0	3	1	1	1
134370	1710	ligand for retinoic acid receptor	[ligands for retinoic acid receptors]	0.0	5	1	1	1
134371	1710	inflammation of asthma	[inflammation of asthma]	0.0	3	2	2	1
134372	1710	trigger of hla class antigen	[Triggering of HLA class antigens]	0.0	5	1	1	1
134373	1710	nuclear c-rel expression	[nuclear c-Rel expression]	0.0	3	1	1	1
134374	1710	regulation during myeloid cell differentiation	[regulation during myeloid cell differentiation]	0.0	5	1	1	1
134375	1710	IFNgamma treatment	[IFNgamma treatment]	0.0	2	1	1	1
134376	1710	treatment of promyelocytic leukemia hl-60 cell	[Treatment of promyelocytic leukemia HL-60 cells]	0.0	6	1	1	1
134377	1710	functional activation by beta-phorbol	[functional activation by beta-phorbol]	0.0	4	1	1	1
134378	1710	ach functional clone	[ACH functional clone]	0.0	3	1	1	1
134379	1710	leukocyte-platelet adhesion in patient	[leukocyte-platelet adhesion in patients]	0.0	4	1	1	1
134380	1710	sublects: Fifteen patient (age 25-79)	[SUBJECTS: Fifteen patients (age 25-79)]	0.0	5	1	1	1
134381	1710	regard the effect	[regarding the effects]	0.0	3	1	1	1
134382	1710	time course analysis during the step	[time course analysis during the steps]	0.0	6	1	1	1
134383	1710	transcript isolation of a transcript	[transcripts isolation of an transcript]	0.0	5	1	1	1
134384	1710	h2o2 activation	[H2O2 activation]	0.0	2	1	1	1
134385	1710	cortisol excretion in FMS	[cortisol excretion in FMS]	0.0	4	1	1	1
134386	1710	enhancer sequence a transcription factor	[enhancer sequences a transcription factor]	0.0	5	1	1	1
134387	1710	complex with other nuclear protein	[complexes with other nuclear proteins]	0.0	5	1	1	1
134388	1710	Comparison of enhancement	[Comparison of enhancement]	0.0	3	1	1	1
134389	1710	KOX 25 on chromosome band	[KOX 25 on chromosome bands]	0.0	5	1	1	1
134390	1710	RANTES factor of T Lymphocytes-1 RFLAT-1	[RANTES Factor of T Lymphocytes-1 RFLAT-1]	0.0	6	1	1	1
134391	1710	interleukin-2 a T cell cytokine	[interleukin-2 a T cell cytokine]	0.0	5	1	1	1
134392	1710	polypeptide chain	[polypeptide chain]	0.0	2	1	1	1
134393	1710	common use as anti-inflammatory agent	[common use as anti-inflammatory agents]	0.0	5	1	1	1
134394	1710	activity consist	[activity consisting]	0.0	2	1	1	1
134395	1710	pybf activity	[PYBF activity]	0.0	2	1	1	1
134396	1710	sequestration of immature class heterodimer	[sequestration of immature class heterodimers]	0.0	5	1	1	1
134397	1710	induction role for metabolic acidosis	[induction role for metabolic acidosis]	0.0	5	1	1	1
134398	1710	expression of the coding	[expression of the coding]	0.0	4	1	1	1
134399	1710	inducer of differentiation of cell	[inducer of differentiation of cells]	0.0	5	1	1	1
134400	1710	decrease in LTR activity	[decreases in LTR activity]	0.0	4	1	1	1
134401	1710	tyrosine-phosphorylated stimulate factor treatment of neutrophils.	[tyrosine-phosphorylated stimulating factor treatment of neutrophils.]	0.0	6	1	1	1
134402	1710	16HBE human cell	[16HBE human cells]	0.0	3	1	1	1
134403	1710	ferritin gene	[ferritin gene]	0.0	2	1	1	1
134404	1710	281 61 pmol/L; in pregnant woman	[281 61 pmol/L; in pregnant women]	0.0	6	1	1	1
134405	1710	constitute two model of a situation	[constituting two models of an situation]	0.0	6	1	1	1
134406	1710	fos gene expression	[fos gene expression]	0.0	3	1	1	1
134407	1710	T cell -1	[T cells -1]	0.0	3	1	1	1
134408	1710	distinct region important, to immunoglobulin promoter	[distinct regions important, to immunoglobulin promoters]	0.0	6	1	1	1
134409	1710	presence of genistein	[presence of genistein]	0.0	3	1	1	1
134410	1710	hiv-1 gene expression in cell	[HIV-1 gene expression in cells]	0.0	5	1	1	1
134411	1710	molecular detail	[molecular details]	0.0	2	1	1	1
134412	1710	exon V in individual	[exon V in individuals]	0.0	4	1	1	1
134413	1710	switch affect cell fate	[switch affecting cell fate]	0.0	4	1	1	1
134414	1710	reversal to the control level	[reversal to the control level]	0.0	5	1	1	1
134415	1710	site for specific depletion	[site for specific depletion]	0.0	4	1	1	1
134416	1710	affinity receptor for 1,25-dihydroxycholecalciferol calcitriol	[affinity receptors for 1,25-dihydroxycholecalciferol calcitriol]	0.0	5	1	1	1
134417	1710	large population	[large population]	0.0	2	1	1	1
134418	1710	lipopolysaccharide in mononuclear leukocyte	[lipopolysaccharide in mononuclear leukocytes]	0.0	4	1	1	1
134419	1710	sucrose gradients,	[sucrose gradients,]	0.0	2	1	1	1
134420	1710	il-2 promoter activation requirement	[IL-2 promoter activation requirement]	0.0	4	1	1	1
134421	1710	Glucocorticoid receptor in cell of patient	[Glucocorticoid receptors in cells of patients]	0.0	6	1	1	1
134422	1710	restoration of content of t-	[restoration of content of T-]	0.0	5	1	1	1
134423	1710	BL-2	[BL-2]	0.0	1	1	1	1
134424	1710	acid maturation	[acid maturation]	0.0	2	1	1	1
134425	1710	vivo DMS footprinting upstream	[vivo DMS footprinting upstream]	0.0	4	1	1	1
134426	1710	(61-80 years) subject	[(61-80 years) subjects]	0.0	3	1	1	1
134427	1710	inhibit translocation	[inhibiting translocation]	0.0	2	1	1	1
134428	1710	molecule on human lung fibroblast	[molecule on human lung fibroblasts]	0.0	5	1	1	1
134429	1710	receptor to therapy	[receptor to therapy]	0.0	3	1	1	1
134430	1710	specifically with stat5	[specifically with STAT5]	0.0	3	1	1	1
134431	1710	activation by interferon-gamma in neutrophil	[activation by interferon-gamma in neutrophils]	0.0	5	1	1	1
134432	1710	two cell-surface isoform	[two cell-surface isoforms]	0.0	3	1	1	1
134433	1710	ino promoter region	[iNOS promoter regions]	0.0	3	1	1	1
134434	1710	distinct normalize effect increase of ca2+	[distinct normalizing effect increase of Ca2+]	0.0	6	1	1	1
134435	1710	human immunodeficiency virus persistence	[human immunodeficiency virus persistence]	0.0	4	2	2	1
134436	1710	action throughout the vasculature	[actions throughout the vasculature]	0.0	4	1	1	1
134437	1710	autologous epithelial cell TEC	[autologous epithelial cells TEC]	0.0	4	1	1	1
134438	1710	active, form of Rap1	[active, form of Rap1]	0.0	4	1	1	1
134439	1710	expression in t-cell leukemia	[expression in T-cell leukemia]	0.0	4	1	1	1
134440	1710	intracellular factor	[intracellular factors]	0.0	2	1	1	1
134441	1710	of b cell	[of B cells]	0.0	3	1	1	1
134442	1710	role in vivo	[roles in vivo]	0.0	3	1	1	1
134443	1710	human umbilical cell	[human umbilical cells]	0.0	3	1	1	1
134444	1710	type-specific clone reactive	[type-specific clone reactive]	0.0	3	1	1	1
134445	1710	high level of p59fyn	[high levels of p59fyn]	0.0	4	1	1	1
134446	1710	existence of fundamental difference	[existence of fundamental differences]	0.0	4	1	1	1
134447	1710	synthesis of type	[synthesis of type]	0.0	3	1	1	1
134448	1710	overcome cellular block to provirus establishment	[overcoming cellular blocks to provirus establishment]	0.0	6	1	1	1
134449	1710	recessive disease xeroderma pigmentosum XP	[recessive disease xeroderma pigmentosum XP]	0.0	5	1	1	1
134450	1710	receptor system	[receptor system]	0.0	2	1	1	1
134451	1710	only the sh2 domain	[only the SH2 domains]	0.0	4	1	1	1
134452	1710	lysis substrate	[lysis substrate]	0.0	2	1	1	1
134453	1710	differentiation of the DC	[differentiation of the DC]	0.0	4	1	1	1
134454	1710	two pathway operate downstream	[two pathways operating downstream]	0.0	4	1	1	1
134455	1710	protection employ extract	[protection employing extracts]	0.0	3	1	1	1
134456	1710	result from the t translocation	[resulting from the t translocation]	0.0	5	1	1	1
134457	1710	low risk	[low risk]	0.0	2	1	1	1
134458	1710	part of the subunit	[part of the subunit]	0.0	4	1	1	1
134459	1710	addition, mobility shift	[addition, mobility shift]	0.0	3	1	1	1
134460	1710	IL-4 effect	[IL-4 effect]	0.0	2	1	1	1
134461	1710	high expression of CD20	[high expression of CD20]	0.0	4	1	1	1
134462	1710	mechanism of Rb rescue	[mechanism of Rb rescue]	0.0	4	1	1	1
134463	1710	cd4+ cell to th1 cell	[CD4+ cells to Th1 cells]	0.0	5	1	1	1
134464	1710	amount of nf-kappab	[amount of NF-kappaB]	0.0	3	1	1	1
134465	1710	generation of cytotoxic T lymphocyte	[Generation of cytotoxic T lymphocytes]	0.0	5	1	1	1
134466	1710	especially aurothioglucose AuTG	[especially aurothioglucose AuTG]	0.0	3	1	1	1
134467	1710	lymphocyte of 24 woman (11	[lymphocytes of 24 women (11]	0.0	5	1	1	1
134468	1710	mil.	[mil.]	0.0	1	1	1	1
134469	1710	dexamethasone a inhibitor	[dexamethasone a inhibitor]	0.0	3	1	1	1
134470	1710	alveolar macrophage PAM	[alveolar macrophages PAM]	0.0	3	1	1	1
134471	1710	C-11	[C-11]	0.0	1	1	1	1
134472	1710	replacement of x box sequence	[replacement of X box sequences]	0.0	5	1	1	1
134473	1710	extent the 50 kD factor	[extent the 50 kD factor]	0.0	5	1	1	1
134474	1710	sustained reduction	[sustained reduction]	0.0	2	1	1	1
134475	1710	inducibility by PMA	[inducibility by PMA]	0.0	3	1	1	1
134476	1710	nuclear factor ap-1	[nuclear factors AP-1]	0.0	3	1	1	1
134477	1710	two man	[two men]	0.0	2	1	1	1
134478	1710	species range to mammal	[species ranging to mammals]	0.0	4	1	1	1
134479	1710	specific nfatp polyclonal antibody	[specific NFATp polyclonal antibody]	0.0	4	1	1	1
134480	1710	intrafollicular	[Intrafollicular]	0.0	1	1	1	1
134481	1710	formation consistent with suggestion	[formation consistent with suggestions]	0.0	4	1	1	1
134482	1710	factor-kappaB activation in monocyte	[factor-kappaB activation in monocytes]	0.0	4	1	1	1
134483	1710	i BL cell contain low level	[I BL cells containing low levels]	0.0	6	1	1	1
134484	1710	specific induction	[specific induction]	0.0	2	1	1	1
134485	1710	transcriptional up-regulation via nf-at	[transcriptional up-regulation via NF-AT]	0.0	4	1	1	1
134486	1710	tandem repeat of the cdc10/ankyrin motif	[tandem repeats of the cdc10/ankyrin motif]	0.0	6	1	1	1
134487	1710	interaction of transcription factor pu.1	[interaction of transcription factors PU.1]	0.0	5	1	1	1
134488	1710	inhibition of human immunodeficiency virus type	[Inhibition of human immunodeficiency virus type]	0.0	6	2	2	1
134489	1710	otf-1 factor	[OTF-1 factor]	0.0	2	1	1	1
134490	1710	understand the death signal	[understanding the death signals]	0.0	4	1	1	1
134491	1710	potential drug for inflammatory disease	[potential drugs for inflammatory diseases]	0.0	5	1	1	1
134492	1710	beta 1 cd49d/cd29 integrin costimulation	[beta 1 CD49d/CD29 integrin costimulation]	0.0	5	1	1	1
134493	1710	novel T cell-specific regulatory element	[novel T cell-specific regulatory element]	0.0	5	1	1	1
134494	1710	homologue, KIAA0144	[homologue, KIAA0144]	0.0	2	1	1	1
134495	1710	c-jun activation	[c-Jun activation]	0.0	2	1	1	1
134496	1710	patient with perennial rhinitis	[patients with perennial rhinitis]	0.0	4	1	1	1
134497	1710	exposure of cell HAEC	[exposure of cells HAEC]	0.0	4	1	1	1
134498	1710	trans-activate phenotype into blood lymphocyte	[trans-activating phenotypes into blood lymphocytes]	0.0	5	1	1	1
134499	1710	gene related	[genes related]	0.0	2	1	1	1
134500	1710	double labeling by immunofluorescence from tonsil	[double labeling by immunofluorescence from tonsils]	0.0	6	1	1	1
134501	1710	treatment of PIH	[treatment of PIH]	0.0	3	1	1	1
134502	1710	hsv-1 intertypic recombinant virus	[HSV-1 intertypic recombinant virus]	0.0	4	1	1	1
134503	1710	induction in myeloblastic leukemia cell	[Induction in myeloblastic leukemia cells]	0.0	5	1	1	1
134504	1710	tumor additional study	[tumor additional studies]	0.0	3	1	1	1
134505	1710	osteoclast vitronectin receptor VR	[osteoclasts vitronectin receptor VR]	0.0	4	1	1	1
134506	1710	follow exposure of platelet	[following exposure of platelets]	0.0	4	1	1	1
134507	1710	receptor of protein synthesis,	[receptors of protein synthesis,]	0.0	4	1	1	1
134508	1710	dnase hypersensitive site-forming element HSFE	[DNase hypersensitive site-forming element HSFE]	0.0	5	1	1	1
134509	1710	mink	[mink]	0.0	1	1	1	1
134510	1710	hiv-enhancer activity concomitant	[HIV-enhancer activity concomitant]	0.0	3	1	1	1
134511	1710	tax protein a transcriptional activator	[Tax protein a transcriptional activator]	0.0	5	1	1	1
134512	1710	rhesus monkey for a study	[rhesus monkeys for a study]	0.0	5	1	1	1
134513	1710	mature human m phi	[maturing human M phi]	0.0	4	1	1	1
134514	1710	suppression of serum cortisol concentration	[suppression of serum cortisol concentrations]	0.0	5	1	1	1
134515	1710	effective inhibitory concentration	[effective inhibitory concentrations]	0.0	3	1	1	1
134516	1710	years, study of insulin-gene regulation	[years, studies of insulin-gene regulation]	0.0	5	1	1	1
134517	1710	molecular weight of 35 kD	[molecular weights of 35 kD]	0.0	5	1	1	1
134518	1710	mechanism in the immune system	[mechanism in the immune system]	0.0	5	1	1	1
134519	1710	stat5 isomer	[STAT5 isomer]	0.0	2	1	1	1
134520	1710	cytolytic lymphocyte CL	[cytolytic lymphocytes CLs]	0.0	3	1	1	1
134521	1710	18c7	[18C7]	0.0	1	1	1	1
134522	1710	Comparison of sensitization	[Comparison of sensitization]	0.0	3	1	1	1
134523	1710	expression by cell	[expression by cells]	0.0	3	1	1	1
134524	1710	endocrine cell formation	[endocrine cell formation]	0.0	3	1	1	1
134525	1710	antibody (ic50 of ng/ml),	[antibody (IC50 of ng/ml),]	0.0	4	1	1	1
134526	1710	sixteen patient	[Sixteen patients]	0.0	2	1	1	1
134527	1710	phenotypic change resemble b cell activation	[phenotypic changes resembling B cell activation]	0.0	6	1	1	1
134528	1710	transmit the signal to a domain	[transmitting the signal to a domain]	0.0	6	1	1	1
134529	1710	frequent absence	[frequent absence]	0.0	2	1	1	1
134530	1710	signal by a variety include interferon	[Signaling by a variety including interferons]	0.0	6	1	1	1
134531	1710	B-lymphocyte cDNA library	[B-lymphocyte cDNA library]	0.0	3	1	1	1
134532	1710	basal cell carcinoma	[basal cell carcinomas]	0.0	3	1	1	1
134533	1710	control by a domain	[Control by a domain]	0.0	4	1	1	1
134534	1710	transcription complex isgf3	[transcription complex ISGF3]	0.0	3	1	1	1
134535	1710	y341 F mutant	[Y341 F mutant]	0.0	3	1	1	1
134536	1710	HLA-DQB1	[HLA-DQB1]	0.0	1	1	1	1
134537	1710	target cell during inflammation	[target cells during inflammation]	0.0	4	1	1	1
134538	1710	functional capability pre-treatment with gp160	[functional capabilities pre-treatment with gp160]	0.0	5	1	1	1
134539	1710	transcription-PCR assay	[transcription-PCR assay]	0.0	2	1	1	1
134540	1710	disease in patient with APL	[disease in patients with APL]	0.0	5	1	1	1
134541	1710	ox-ox40	[OX-OX40]	0.0	1	1	1	1
134542	1710	long expression of NF-kappa b	[long-term expression of NF-kappa B]	0.0	5	1	1	1
134543	1710	differentiation assay	[Differentiation assays]	0.0	2	1	1	1
134544	1710	oncogenic form lack the binding site	[Oncogenic forms lacking the binding site]	0.0	6	1	1	1
134545	1710	NK function	[NK functions]	0.0	2	1	1	1
134546	1710	development of late complication	[development of late complications]	0.0	4	1	1	1
134547	1710	runt product in hematopoiesis	[runt products in hematopoiesis]	0.0	4	1	1	1
134548	1710	erythroid-specific gene in leukaemia	[erythroid-specific genes in leukaemia]	0.0	4	1	1	1
134549	1710	transformation into cell line	[transformation into cell lines]	0.0	4	1	1	1
134550	1710	molecular weight of 32, 36 50	[molecular weights of 32, 36 50]	0.0	6	1	1	1
134551	1710	palindromic target sequence	[palindromic target sequence]	0.0	3	1	1	1
134552	1710	such as downregulation of molecule	[such as downregulation of molecules]	0.0	5	1	1	1
134553	1710	distinguishable gr bind abnormalities: 15	[distinguishable GR binding abnormalities: 15]	0.0	5	1	1	1
134554	1710	activation of gene expression by Pb	[activation of gene expression by Pb]	0.0	6	1	1	1
134555	1710	gp39-cd8 fusion protein	[gp39-CD8 fusion protein]	0.0	3	1	1	1
134556	1710	various breakpoint range to q23	[various breakpoints ranging to q23]	0.0	5	1	1	1
134557	1710	megakaryoblastic phenotype	[megakaryoblastic phenotype]	0.0	2	1	1	1
134558	1710	Bcl-6 gene product	[Bcl-6 gene product]	0.0	3	1	1	1
134559	1710	two type of macrophage	[two types of macrophages]	0.0	4	1	1	1
134560	1710	different model	[different models]	0.0	2	1	1	1
134561	1710	induce the constitutive degradation of inhibitor	[inducing the constitutive degradation of inhibitors]	0.0	6	1	1	1
134562	1710	Society of Hematology.	[Society of Hematology.]	0.0	3	1	1	1
134563	1710	catalytic activity of Syk	[catalytic activity of Syk]	0.0	4	1	1	1
134564	1710	therapeutic effect in the treatment	[therapeutic effect in the treatment]	0.0	5	1	1	1
134565	1710	dominant negative ras	[dominant negative Ras]	0.0	3	1	1	1
134566	1710	form of ras	[form of Ras]	0.0	3	1	1	1
134567	1710	encode tcf-1 alpha	[encoding TCF-1 alpha]	0.0	3	1	1	1
134568	1710	p65 (rel a)	[p65 (Rel A)]	0.0	3	1	1	1
134569	1710	significant systemic effect on adrenal function	[significant systemic effects on adrenal function]	0.0	6	1	1	1
134570	1710	dominant negative rac	[dominant negative Rac]	0.0	3	1	1	1
134571	1710	cytolytic action of protein	[cytolytic action of proteins]	0.0	4	1	1	1
134572	1710	easy means	[easy means]	0.0	2	1	1	1
134573	1710	distinct nucleoprotein complex	[distinct nucleoprotein complexes]	0.0	3	1	1	1
134574	1710	mediator in cytokine activation	[mediator in cytokine activation]	0.0	4	1	1	1
134575	1710	location of site	[location of site]	0.0	3	1	1	1
134576	1710	trigger molecule in the process	[triggering molecule in the process]	0.0	5	1	1	1
134577	1710	one aspect of gata factor expression	[One aspect of GATA factor expression]	0.0	6	1	1	1
134578	1710	immediate early gene of cytomegalovirus	[immediate early genes of cytomegalovirus]	0.0	5	1	1	1
134579	1710	decrease of er level	[decrease of ER level]	0.0	4	2	2	1
134580	1710	immediate cycle protein	[Immediate cycle proteins]	0.0	3	1	1	1
134581	1710	multipotential stem cell	[multipotential stem cells]	0.0	3	1	1	1
134582	1710	examined: serum calcitriol	[examined: serum calcitriol]	0.0	3	1	1	1
134583	1710	cytotoxicity of phosphorothioate oligodeoxynucleotides	[cytotoxicity of phosphorothioate oligodeoxynucleotides]	0.0	4	1	1	1
134584	1710	treatment of u-937	[Treatment of U-937]	0.0	3	1	1	1
134585	1710	tyrosyl	[tyrosyl]	0.0	1	1	1	1
134586	1710	1.16 units,	[1.16 units,]	0.0	2	1	1	1
134587	1710	mature human T	[mature human T]	0.0	3	1	1	1
134588	1710	AMP inhibition	[AMP inhibition]	0.0	2	1	1	1
134589	1710	cell-type-specific differential response	[cell-type-specific differential response]	0.0	3	1	1	1
134590	1710	ap-1 protein.	[AP-1 protein.]	0.0	2	1	1	1
134591	1710	respectively by RA	[respectively by RA]	0.0	3	1	1	1
134592	1710	B-cell lineage-specific transcription factor	[B-cell lineage-specific transcription factor]	0.0	4	1	1	1
134593	1710	level of nuclear i(kappa)b(alpha)	[levels of nuclear I(kappa)B(alpha)]	0.0	4	1	1	1
134594	1710	chain germline epsilon promotor sequence	[chain germline epsilon promotor sequence]	0.0	5	1	1	1
134595	1710	sequencing of the genome	[sequencing of the genomes]	0.0	4	1	1	1
134596	1710	studies, cell mono Mac	[studies, cells Mono Mac]	0.0	4	1	1	1
134597	1710	ssb rssb	[SSB rSSB]	0.0	2	1	1	1
134598	1710	ap-1 -binding	[AP-1 -binding]	0.0	2	1	1	1
134599	1710	regulatory mechanism during t-cell activation	[regulatory mechanisms during T-cell activation]	0.0	5	1	1	1
134600	1710	expression of Smad7	[expression of Smad7]	0.0	3	1	1	1
134601	1710	lymphoid enhancer-binding factor	[Lymphoid enhancer-binding factor]	0.0	3	1	1	1
134602	1710	expression of Smad6	[expressions of Smad6]	0.0	3	1	1	1
134603	1710	ongoing study	[ongoing study]	0.0	2	1	1	1
134604	1710	Activation-dependent regulation of the fas promoter	[Activation-dependent regulation of the Fas promoter]	0.0	6	1	1	1
134605	1710	majority of class molecule	[majority of class molecules]	0.0	4	1	1	1
134606	1710	regulation of the rabbit 15-lipoxygenase gene	[regulation of the rabbit 15-lipoxygenase gene]	0.0	6	1	1	1
134607	1710	promyelocytic (apl) cell line	[promyelocytic (APL) cell line]	0.0	4	1	1	1
134608	1710	anaerobic	[Anaerobic]	0.0	1	1	1	1
134609	1710	treatment of peripheral blood lymphocyte	[Treatment of peripheral blood lymphocytes]	0.0	5	1	1	1
134610	1710	latent membrane protein gene	[latent membrane protein gene]	0.0	4	1	1	1
134611	1710	influenza a virus infection	[influenza A virus infection]	0.0	4	1	1	1
134612	1710	recombinant human soluble dimeric tnf receptor	[recombinant human soluble dimeric TNF receptor]	0.0	6	1	1	1
134613	1710	mobility shift assay with a oligonucleotide	[mobility shift assays with a oligonucleotide]	0.0	6	1	1	1
134614	1710	immunofluorescence from tonsil	[immunofluorescence from tonsils]	0.0	3	1	1	1
134615	1710	alpha-pml	[alpha-PML]	0.0	1	2	2	1
134616	1710	NFATp/AP-1 element within gene	[NFATp/AP-1 elements within genes]	0.0	4	1	1	1
134617	1710	transcript-2/leukocyte	[transcript-2/leukocyte]	0.0	1	1	1	1
134618	1710	cDNA encoding murine (m) nfatc	[cDNA encoding murine (m) NFATc]	0.0	5	1	1	1
134619	1710	capacity of CD28 change	[capacity of CD28 changes]	0.0	4	1	1	1
134620	1710	great than inhibition of migration	[greater than inhibition of migration]	0.0	5	1	1	1
134621	1710	determinant distinct	[determinants distinct]	0.0	2	1	1	1
134622	1710	homologous recombination,	[homologous recombination,]	0.0	2	1	1	1
134623	1710	specific granule mediate early response	[specific granules mediating early responses]	0.0	5	1	1	1
134624	1710	novel transcription factor Elf-1	[novel transcription factor Elf-1]	0.0	4	2	2	1
134625	1710	three order potent than H	[three orders potent than H]	0.0	5	1	1	1
134626	1710	T-helper 0 th0 subset	[T-helper 0 Th0 subset]	0.0	4	1	1	1
134627	1710	interleukin 2 Il-2	[Interleukin 2 Il-2]	0.0	3	1	1	1
134628	1710	single inoculation	[single inoculation]	0.0	2	1	1	1
134629	1710	adhesion of Mo	[adhesion of Mo]	0.0	3	1	1	1
134630	1710	monocyte chemotactic peptide-1 mcp-1	[monocyte chemotactic peptide-1 MCP-1]	0.0	4	1	1	1
134631	1710	many function of macrophage	[many functions of macrophages]	0.0	4	1	1	1
134632	1710	two gr isoform	[two GR isoforms]	0.0	3	1	1	1
134633	1710	amount of b b mrna	[amount of B B mRNA]	0.0	5	1	1	1
134634	1710	type CEM	[type CEM]	0.0	2	1	1	1
134635	1710	196, p less	[196, p less]	0.0	3	1	1	1
134636	1710	de LCL	[DE LCL]	0.0	2	1	1	1
134637	1710	precursor into mature myelomonocytic cell	[precursors into mature myelomonocytic cells]	0.0	5	1	1	1
134638	1710	peripheral blood neutrophil	[peripheral blood neutrophils]	0.0	3	1	1	1
134639	1710	inhibitory effect on VCAM-1 gene transcription	[inhibitory effects on VCAM-1 gene transcription]	0.0	6	1	1	1
134640	1710	(n-cor)	[(N-CoR)]	0.0	1	1	1	1
134641	1710	two different b inducer	[two different B inducers]	0.0	4	1	1	1
134642	1710	growth, differentiation of osteoclast	[growth, differentiation of osteoclasts]	0.0	4	1	1	1
134643	1710	evidence the result of infection	[evidence the result of infection]	0.0	5	1	1	1
134644	1710	first report of a interaction	[first report of a interaction]	0.0	5	1	1	1
134645	1710	breast cancer antibody-dependent cytotoxicity facilitate antibody	[breast cancer antibody-dependent cytotoxicity facilitating antibody]	0.0	6	1	1	1
134646	1710	relationship between ebv DNA replication	[relationship between EBV DNA replication]	0.0	5	1	1	1
134647	1710	significance of receptor determination	[significance of receptor determination]	0.0	4	1	1	1
134648	1710	acid-Schiff ppas) staining	[acid-Schiff (PAS) staining]	0.0	3	1	1	1
134649	1710	induction of lysis gene	[induction of lysis genes]	0.0	4	1	1	1
134650	1710	primary lymphocyte activation	[primary lymphocyte activation]	0.0	3	1	1	1
134651	1710	erythropoietin protein kinase b	[erythropoietin protein kinase B]	0.0	4	1	1	1
134652	1710	triiodothyronine sulfate	[triiodothyronine sulfate]	0.0	2	1	1	1
134653	1710	analog methylthiogliotoxin	[analog methylthiogliotoxin]	0.0	2	1	1	1
134654	1710	flexible regulatory mechanism	[flexible regulatory mechanism]	0.0	3	1	1	1
134655	1710	two structurally distinct, inhibitor	[two structurally distinct, inhibitors]	0.0	4	1	1	1
134656	1710	transfection L23	[transfection L23]	0.0	2	1	1	1
134657	1710	expression of cd95 fas /apo-1	[expression of CD95 Fas /Apo-1]	0.0	5	1	1	1
134658	1710	single T substitution	[single T substitution]	0.0	3	1	1	1
134659	1710	signal calcineurin	[signalling calcineurin]	0.0	2	1	1	1
134660	1710	Th1 subset	[Th1 subsets]	0.0	2	1	1	1
134661	1710	dissociation constant of homodimeric p49	[dissociation constants of homodimeric p49]	0.0	5	1	1	1
134662	1710	(regulatory)	[(regulatory)]	0.0	1	1	1	1
134663	1710	-hsf3	[-HSF3]	0.0	1	1	1	1
134664	1710	b-cell-specific cofactor with the effector domain	[B-cell-specific cofactors with the effector domains]	0.0	6	1	1	1
134665	1710	gamma-ifn gene	[gamma-IFN genes]	0.0	2	1	1	1
134666	1710	TATA sequence	[TATA sequence]	0.0	2	1	1	1
134667	1710	death-promoting activity	[death-promoting activity]	0.0	2	1	1	1
134668	1710	jak kinase interferon receptor	[JAK kinases interferon receptors]	0.0	4	1	1	1
134669	1710	growth, terminal differentiation	[growth, terminal differentiation]	0.0	3	1	1	1
134670	1710	homolog of crp1	[homolog of CRP1]	0.0	3	1	1	1
134671	1710	single intraperitoneal injection	[single intraperitoneal injection]	0.0	3	1	1	1
134672	1710	homology with binding site	[homology with binding sites]	0.0	4	1	1	1
134673	1710	cd69 reporter gene construct	[CD69 reporter gene constructs]	0.0	4	1	1	1
134674	1710	cross-competition assay among the element	[Cross-competition assays among the elements]	0.0	5	1	1	1
134675	1710	expression p45 nf-e2 mrna	[expression P45 NF-E2 mRNA]	0.0	4	1	1	1
134676	1710	vitamin D3 repression	[vitamin D3 repression]	0.0	3	1	1	1
134677	1710	peptide contact site	[peptide contact site]	0.0	3	1	1	1
134678	1710	EBNA 2 enhancer	[EBNA 2 enhancer]	0.0	3	3	3	1
134679	1710	again suggest lack	[again suggesting lack]	0.0	3	1	1	1
134680	1710	promoter in monocytes/macrophages	[promoters in monocytes/macrophages]	0.0	3	1	1	1
134681	1710	significant level of proto-oncogent	[significant levels of proto-oncogenes]	0.0	4	1	1	1
134682	1710	further transcription factor	[further transcription factor]	0.0	3	1	1	1
134683	1710	triepoxide with immunosuppressive property	[triepoxide with immunosuppressive properties]	0.0	4	1	1	1
134684	1710	heavy chain gene	[heavy chain genes]	0.0	3	1	1	1
134685	1710	karyophilic protein	[karyophilic protein]	0.0	2	1	1	1
134686	1710	oxldl (50	[oxLDLs (50]	0.0	2	1	1	1
134687	1710	monitoring of the mother	[monitoring of the mother]	0.0	4	1	1	1
134688	1710	Tat1-72	[Tat1-72]	0.0	1	1	1	1
134689	1710	human gamma-herpesvirus	[human gamma-herpesvirus]	0.0	2	1	1	1
134690	1710	information about the presence	[information about the presence]	0.0	4	1	1	1
134691	1710	unrecognized function	[unrecognized function]	0.0	2	1	1	1
134692	1710	ca2+-mediated activation in platelet	[Ca2+-mediated activation in platelets]	0.0	4	1	1	1
134693	1710	oxide iNO	[oxide iNO]	0.0	2	1	1	1
134694	1710	tcr -CD8 condition	[TCR -CD8 conditions]	0.0	3	1	1	1
134695	1710	mechanism of IL-5 signal in eosinophil	[mechanisms of IL-5 signaling in eosinophils]	0.0	6	1	1	1
134696	1710	concentration of the epitope	[concentrations of the epitope]	0.0	4	1	1	1
134697	1710	wall cell	[wall cells]	0.0	2	1	1	1
134698	1710	c-jun by antisense oligonucleotide	[c-jun by antisense oligonucleotides]	0.0	4	1	1	1
134699	1710	labeling with [35s]methionine with anti-igm	[labeling with [35S]methionine with anti-IgM]	0.0	5	1	1	1
134700	1710	cDNA encode factor	[cDNA encoding factor]	0.0	3	1	1	1
134701	1710	treatment of normal human blood lymphocyte	[Treatment of normal human blood lymphocytes]	0.0	6	1	1	1
134702	1710	role in the cyclosporin	[role in the cyclosporin]	0.0	4	1	1	1
134703	1710	one c-rel	[one c-Rel]	0.0	2	1	1	1
134704	1710	Rapid shuttling in discrimination	[Rapid shuttling in discrimination]	0.0	4	1	1	1
134705	1710	leukemia virus type 1	[leukemia virus type 1]	0.0	4	1	1	1
134706	1710	structural element within the core	[structural elements within the core]	0.0	5	1	1	1
134707	1710	interrelation between the system hpa	[Interrelations between the system HPA]	0.0	5	1	1	1
134708	1710	suggest a involvement of stat5b	[suggesting an involvement of STAT5b]	0.0	5	1	1	1
134709	1710	p65 (rel	[p65 (Rel]	0.0	2	1	1	1
134710	1710	b activity in T lymphocyte	[B activity in T lymphocytes]	0.0	5	1	1	1
134711	1710	-contain molecule to the cell membrane	[-containing molecules to the cell membrane]	0.0	6	1	1	1
134712	1710	structural basis	[structural basis]	0.0	2	1	1	1
134713	1710	10(-7) g/g of total rna	[10(-7) g/g of total RNA]	0.0	5	1	1	1
134714	1710	reduce the yield of protein	[reducing the yields of proteins]	0.0	5	1	1	1
134715	1710	t-lymphocyte by t-cell receptor	[T-lymphocytes by T-cell receptor]	0.0	4	1	1	1
134716	1710	myeloid-specific factor pu.1	[myeloid-specific factor PU.1]	0.0	3	1	1	1
134717	1710	p210bcr-abl product	[p210bcr-abl product]	0.0	2	1	1	1
134718	1710	enhancerless promoter,	[enhancerless promoter,]	0.0	2	1	1	1
134719	1710	effect of overexpression	[effect of overexpression]	0.0	3	1	1	1
134720	1710	biochemical signal lead to activation	[biochemical signals leading to activation]	0.0	5	1	1	1
134721	1710	24 pregnant woman	[24 pregnant women]	0.0	3	1	1	1
134722	1710	Functional b-cell response in follicle	[Functional B-cell response in follicles]	0.0	5	1	1	1
134723	1710	method of lymphocyte from pregnant woman	[METHOD OF lymphocytes from pregnant women]	0.0	6	1	1	1
134724	1710	nf-kappab kinase	[NF-kappaB kinase]	0.0	2	1	1	1
134725	1710	triple-labelling	[triple-labellings]	0.0	1	1	1	1
134726	1710	il4 enhancer	[IL4 enhancer]	0.0	2	1	1	1
134727	1710	purine-rich stretch with site	[purine-rich stretches with sites]	0.0	4	1	1	1
134728	1710	t-lymphocyte cell	[T-lymphocyte cell]	0.0	2	1	1	1
134729	1710	recombinant dimeric tnf receptor rhu tnfr:fc	[recombinant dimeric TNF receptor rhu TNFR:Fc]	0.0	6	1	1	1
134730	1710	colony-stimumulatelany-stg factor-1 receptor	[colony-stimulating factor-1 receptor]	0.0	3	1	1	1
134731	1710	culture of T lymphocyte	[cultures of T lymphocytes]	0.0	4	1	1	1
134732	1710	transgenic mouse spleen	[transgenic mice spleen]	0.0	3	1	1	1
134733	1710	usefulness of mouse	[usefulness of mice]	0.0	3	1	1	1
134734	1710	increase in response element binding	[increase in response element binding]	0.0	5	1	1	1
134735	1710	mrp14 migration protein	[MRP14 migration protein]	0.0	3	1	1	1
134736	1710	self-renewal capacity of progenitor cell	[self-renewal capacity of progenitor cells]	0.0	5	1	1	1
134737	1710	basal cell carcinoma use immunohistochemistry	[basal cell carcinomas using immunohistochemistry]	0.0	5	1	1	1
134738	1710	signal pathway regulate alpha2 gene expression	[signaling pathway regulating alpha2 gene expression]	0.0	6	1	1	1
134739	1710	13-acetate/phytohemagglutinin-stimulated human jurkat T cell	[13-acetate/phytohemagglutinin-stimulated human Jurkat T cells]	0.0	5	1	1	1
134740	1710	limbic-hippocampal glucocorticoid type receptor gcii	[limbic-hippocampal glucocorticoid type receptor GCII]	0.0	5	1	1	1
134741	1710	DNA template contain two copy	[DNA templates containing two copies]	0.0	5	1	1	1
134742	1710	child aged 6 year	[children aged 6 years]	0.0	4	1	1	1
134743	1710	activate transcription from the viral repeat	[activating transcription from the viral repeat]	0.0	6	1	1	1
134744	1710	response, reach a maximum min,	[response, reaching a maximum min,]	0.0	5	1	1	1
134745	1710	extend bp relative	[extending bp relative]	0.0	3	1	1	1
134746	1710	leukemia virus type I	[leukemia virus type I]	0.0	4	1	1	1
134747	1710	low dose of flutamide	[low doses of flutamide]	0.0	4	1	1	1
134748	1710	level of hiv-1 production	[level of HIV-1 production]	0.0	4	1	1	1
134749	1710	contain STAT3 with complex	[containing STAT3 with complexes]	0.0	4	1	1	1
134750	1710	affect the chymotryptic activity	[affecting the chymotryptic activity]	0.0	4	1	1	1
134751	1710	chemical nature	[chemical nature]	0.0	2	1	1	1
134752	1710	eutopic trimester pregnancy	[eutopic trimester pregnancies]	0.0	3	1	1	1
134753	1710	3 Hashimoto patient	[3 Hashimoto patients]	0.0	3	1	1	1
134754	1710	11 phosphoprotein	[11 phosphoproteins]	0.0	2	1	1	1
134755	1710	72-hour incubation	[72-hour incubation]	0.0	2	1	1	1
134756	1710	person with low back pain	[persons with low back pain]	0.0	5	1	1	1
134757	1710	addition, anti-cd29	[addition, anti-CD29]	0.0	2	1	1	1
134758	1710	il-2ralpha expression	[IL-2Ralpha expression]	0.0	2	1	1	1
134759	1710	repeat-luciferase construct	[repeat-luciferase constructs]	0.0	2	1	1	1
134760	1710	cytokine by human monocyte	[cytokines by human monocytes]	0.0	4	1	1	1
134761	1710	effect on the capacity	[effect on the capacity]	0.0	4	1	1	1
134762	1710	relevant doses.	[relevant doses.]	0.0	2	1	1	1
134763	1710	peroxyl scavenging tnf- cell	[peroxyl scavenging TNF- cells]	0.0	4	1	1	1
134764	1710	respiratory pathogen	[respiratory pathogen]	0.0	2	1	1	1
134765	1710	sequence similarity to the suppressor gene	[sequence similarity to the suppressor genes]	0.0	6	1	1	1
134766	1710	D3 receptor in mononuclear cell	[D3 receptors in mononuclear cells]	0.0	5	1	1	1
134767	1710	synthesis of hiv transcript	[synthesis of HIV transcripts]	0.0	4	1	1	1
134768	1710	24 woman (11 10 second	[24 women (11 10 second]	0.0	5	1	1	1
134769	1710	administration of danazol	[Administration of danazol]	0.0	3	1	1	1
134770	1710	regulation of pml expression	[regulation of PML expression]	0.0	4	1	1	1
134771	1710	patient after adjuvant chemotherapy	[patients after adjuvant chemotherapy]	0.0	4	1	1	1
134772	1710	regulate the distribution of the e-selectin	[regulating the distribution of the E-selectin]	0.0	6	1	1	1
134773	1710	divalent gold ion	[divalent gold ion]	0.0	3	1	1	1
134774	1710	5'-deletion construct of a segment	[5'-deletion constructs of a segment]	0.0	5	1	1	1
134775	1710	protein/activation transcription factor	[protein/activation transcription factor]	0.0	3	1	1	1
134776	1710	regulatory response toward cytokine stimulation	[regulatory response toward cytokine stimulation]	0.0	5	1	1	1
134777	1710	contain a verprolin-homology region	[containing a verprolin-homology region]	0.0	4	1	1	1
134778	1710	identification of tcf-1	[Identification of TCF-1]	0.0	3	1	1	1
134779	1710	major downstream site	[major downstream site]	0.0	3	1	1	1
134780	1710	Organizational analysis	[Organizational analysis]	0.0	2	1	1	1
134781	1710	htlv-i basal transcription	[HTLV-I basal transcription]	0.0	3	1	1	1
134782	1710	cell type i	[cell Type I]	0.0	3	1	1	1
134783	1710	mmhg,	[mmHg,]	0.0	1	1	1	1
134784	1710	response of patient	[response of patients]	0.0	3	1	1	1
134785	1710	direct exposure to nm	[Direct exposure to nM]	0.0	4	1	1	1
134786	1710	year of relationship in tonsil	[years of relationship in tonsils]	0.0	5	1	1	1
134787	1710	sequence downstream element DRE	[sequence downstream element DRE]	0.0	4	1	1	1
134788	1710	Nuclear extract lps	[Nuclear extracts LPS]	0.0	3	1	1	1
134789	1710	nf-kappab -mediated transcription	[NF-kappaB -mediated transcription]	0.0	3	1	1	1
134790	1710	selection of sequence along the differentiation	[Selection of sequences along the differentiation]	0.0	6	1	1	1
134791	1710	role control cell release	[role controlling cell release]	0.0	4	1	1	1
134792	1710	cytolytic phenotype	[cytolytic phenotypes]	0.0	2	1	1	1
134793	1710	regulation of the beta-casein gene cross-talk	[regulation of the beta-casein gene cross-talk]	0.0	6	1	1	1
134794	1710	T cell p55/p75 late	[T cells p55/p75 late]	0.0	4	1	1	1
134795	1710	0.016 microg/ml	[0.016 microg/ml]	0.0	2	1	1	1
134796	1710	G60: Aes1/2	[G60: AES1/2]	0.0	2	1	1	1
134797	1710	expression of dominant mutant form	[expression of dominant mutant forms]	0.0	5	1	1	1
134798	1710	dse bind heterodimer	[DSE bind heterodimers]	0.0	3	1	1	1
134799	1710	PMA factors,	[PMA factors,]	0.0	2	1	1	1
134800	1710	form a complex system	[forming a complex system]	0.0	4	1	1	1
134801	1710	role mediate adhesion during inflammation	[role mediating adhesion during inflammation]	0.0	5	1	1	1
134802	1710	down-regulation by 1,25-dihydroxyvitamin D3 erratum	[Down-regulation by 1,25-dihydroxyvitamin D3 erratum]	0.0	5	1	1	1
134803	1710	evidence rate-limiting	[Evidence rate-limiting]	0.0	2	1	1	1
134804	1710	myeloblast cell	[myeloblast cells]	0.0	2	1	1	1
134805	1710	T lymphoid cell line PEER	[T lymphoid cell line PEER]	0.0	5	1	1	1
134806	1710	protein via interaction with rbp	[proteins via interaction with RBP]	0.0	5	1	1	1
134807	1710	specific human pathology	[specific human pathologies]	0.0	3	1	1	1
134808	1710	mutation in the long repeat	[mutations in the long repeat]	0.0	5	1	1	1
134809	1710	subsequent adhesion in vein cell	[subsequent adhesion in vein cells]	0.0	5	1	1	1
134810	1710	glucocorticoid in aged subject	[glucocorticoids in aged subjects]	0.0	4	1	1	1
134811	1710	phenolic compound	[phenolic compounds]	0.0	2	1	1	1
134812	1710	signal often converge in intracellular pathway	[signals often converging in intracellular pathways]	0.0	6	1	1	1
134813	1710	germinal center maturation	[germinal center maturation]	0.0	3	1	1	1
134814	1710	detection of intracellular signal protein	[Detection of intracellular signaling proteins]	0.0	5	1	1	1
134815	1710	transcription of sv40 t-antigen	[transcription of SV40 T-antigen]	0.0	4	1	1	1
134816	1710	activation of the gene promoter	[Activation of the gene promoter]	0.0	5	1	1	1
134817	1710	ileostomized patient	[ileostomized patients]	0.0	2	1	1	1
134818	1710	woman with abortion	[women with abortion]	0.0	3	1	1	1
134819	1710	blot analysis use antibody	[Blot analysis using antibodies]	0.0	4	1	1	1
134820	1710	determine the fluorescence anisotropy of diphenylhexatriene	[determining the fluorescence anisotropy of diphenylhexatriene]	0.0	6	1	1	1
134821	1710	characterization of two cis-acting element	[characterization of two cis-acting elements]	0.0	5	1	1	1
134822	1710	consequently lead to severity	[consequently leading to severity]	0.0	4	1	1	1
134823	1710	Representative estrogenic compound from plant source	[Representative estrogenic compounds from plant sources]	0.0	6	1	1	1
134824	1710	nuclear expression of a protein	[nuclear expression of an protein]	0.0	5	1	1	1
134825	1710	effect than the membrane-related response	[effects than the membrane-related responses]	0.0	5	1	1	1
134826	1710	binding of NFkappaB	[binding of NFkappaB]	0.0	3	1	1	1
134827	1710	tcf-1 expression	[TCF-1 expression]	0.0	2	1	1	1
134828	1710	immortal cell line	[immortal cell lines]	0.0	3	1	1	1
134829	1710	specific component	[specific components]	0.0	2	1	1	1
134830	1710	tumor cell from effusion	[tumor cells from effusions]	0.0	4	1	1	1
134831	1710	myeloid-associated gene	[myeloid-associated genes]	0.0	2	1	1	1
134832	1710	fresh primary cell	[fresh primary cells]	0.0	3	1	1	1
134833	1710	good correlation between the methods.	[good correlation between the methods.]	0.0	5	1	1	1
134834	1710	interleukin T cell growth erratum	[interleukin T cell growth erratum]	0.0	5	1	1	1
134835	1710	c-11 alpha,25-(OH)2D3	[C-11 alpha,25-(OH)2D3]	0.0	2	1	1	1
134836	1710	very low failure rate	[very low failure rate]	0.0	4	1	1	1
134837	1710	b transcriptional coactivator protein	[B transcriptional coactivator protein]	0.0	4	1	1	1
134838	1710	normal late gene expression in cell	[normal late gene expression in cells]	0.0	6	1	1	1
134839	1710	polyadenylation event	[polyadenylation events]	0.0	2	2	2	1
134840	1710	regulatory activity of analogue	[regulatory activities of analogues]	0.0	4	1	1	1
134841	1710	absence in lymphocyte	[absence in lymphocytes]	0.0	3	2	2	1
134842	1710	aberrant er form	[aberrant ER forms]	0.0	3	1	1	1
134843	1710	cc(a/t)6gg (carg)	[CC(A/T)6GG (CArG)]	0.0	2	1	1	1
134844	1710	regulation of adhesion molecule-1	[regulation of adhesion molecule-1]	0.0	4	1	1	1
134845	1710	center of lymphoid organ	[center of lymphoid organs]	0.0	4	1	1	1
134846	1710	order potent than H 1285	[orders potent than H 1285]	0.0	5	1	1	1
134847	1710	background: evidence	[BACKGROUND: evidence]	0.0	2	1	1	1
134848	1710	human monocyte thp-1	[human monocytes THP-1]	0.0	3	1	1	1
134849	1710	opposite (stimulatory effect on RA differentiation	[opposite (stimulatory effects on RA differentiation]	0.0	6	1	1	1
134850	1710	estradiol in plasma	[estradiol in plasma]	0.0	3	1	1	1
134851	1710	specific type of leukemia	[specific type of leukemia]	0.0	4	1	1	1
134852	1710	include annexin-V staining	[including annexin-V staining]	0.0	3	1	1	1
134853	1710	prominent isoform	[prominent isoforms]	0.0	2	1	1	1
134854	1710	role of Aiolos a gene	[role of Aiolos a gene]	0.0	5	1	1	1
134855	1710	virus reactivation in pbmc	[virus reactivation in PBMCs]	0.0	4	1	1	1
134856	1710	phase of pregnancy	[phase of pregnancy]	0.0	3	1	1	1
134857	1710	proliferator-activated receptor gamma PPARgamma	[proliferator-activated receptor gamma PPARgamma]	0.0	4	1	1	1
134858	1710	response to lymphocyte-activating cytokine	[response to lymphocyte-activating cytokines]	0.0	4	1	1	1
134859	1710	factor of T cells-family protein	[factor of T cells-family proteins]	0.0	5	1	1	1
134860	1710	E-selectin expression in endothelial cell	[E-selectin expression in endothelial cells]	0.0	5	1	1	1
134861	1710	copy of the vpr protein	[copies of the vpr protein]	0.0	5	1	1	1
134862	1710	analog of vp16	[analog of VP16]	0.0	3	1	1	1
134863	1710	level of all b	[levels of all B]	0.0	4	1	1	1
134864	1710	cover more than 10%	[covering more than 10%]	0.0	4	1	1	1
134865	1710	fetal thymocyte development after efficient inhibition	[fetal thymocyte development after efficient inhibition]	0.0	6	1	1	1
134866	1710	b104 cell growth	[B104 cell growth]	0.0	3	1	1	1
134867	1710	history of disorder	[history of disorders]	0.0	3	1	1	1
134868	1710	cDNA encoding full-length human c/ebp-epsilon	[cDNA encoding full-length human C/EBP-epsilon]	0.0	5	1	1	1
134869	1710	receptor density;	[receptor density;]	0.0	2	1	1	1
134870	1710	suppression of sla-dr sla-dq antigen induction	[suppression of SLA-DR SLA-DQ antigen induction]	0.0	6	1	1	1
134871	1710	stat1 from the cytosol	[STAT1 from the cytosol]	0.0	4	1	1	1
134872	1710	bovine artery cell from injury	[bovine artery cells from injury]	0.0	5	1	1	1
134873	1710	novel family	[novel family]	0.0	2	2	2	1
134874	1710	regulate the transcriptional response to activation	[regulating the transcriptional response to activation]	0.0	6	1	1	1
134875	1710	respect after transient transfection	[respect after transient transfection]	0.0	4	1	1	1
134876	1710	stimulation in conjunction	[Stimulation in conjunction]	0.0	3	1	1	1
134877	1710	effect of peptide vaccination	[effect of peptide vaccination]	0.0	4	1	1	1
134878	1710	six breast cancer sample	[six breast cancer samples]	0.0	4	1	1	1
134879	1710	part, by activation.	[part, by activation.]	0.0	3	1	1	1
134880	1710	apoptotic "targets"	[apoptotic "targets"]	0.0	2	1	1	1
134881	1710	new, transcription factor	[new, transcription factors]	0.0	3	1	1	1
134882	1710	acid serine-rich insertion present	[acid serine-rich insertion present]	0.0	4	1	1	1
134883	1710	terminal granulocytic differentiation	[terminal granulocytic differentiation]	0.0	3	2	2	1
134884	1710	understanding of this process	[understanding of this process]	0.0	4	1	1	1
134885	1710	different hormone	[Different hormones]	0.0	2	1	1	1
134886	1710	gal4 -p65(286-551)-mediated	[GAL4 -p65(286-551)-mediated]	0.0	2	1	1	1
134887	1710	creb- b- like factor	[CREB- B- like factors]	0.0	4	1	1	1
134888	1710	adherence of leukocyte	[adherence of leukocytes]	0.0	3	1	1	1
134889	1710	employ deletion of N-terminal activation domain	[employing deletions of N-terminal activation domain]	0.0	6	1	1	1
134890	1710	41 patient with primary carcinoma	[41 patients with primary carcinoma]	0.0	5	1	1	1
134891	1710	bcl-6 (+)/ syn-1	[BCL-6 (+)/ syn-1]	0.0	3	1	1	1
134892	1710	selection of down-regulated sequence	[Selection of down-regulated sequences]	0.0	4	1	1	1
134893	1710	domain RXR	[domain RXR]	0.0	2	1	1	1
134894	1710	potential immunogenicity of protein epitope	[potential immunogenicity of protein epitopes]	0.0	5	1	1	1
134895	1710	leukocyte protein of 76 kda)	[leukocyte protein of 76 kDa)]	0.0	5	1	1	1
134896	1710	surfactant protein	[surfactant protein]	0.0	2	1	1	1
134897	1710	Chinese hamster ovary (cho)-k1 cell	[Chinese hamster ovary (CHO)-K1 cells]	0.0	5	1	1	1
134898	1710	glucocorticoid-receptors in renal failure patient	[glucocorticoid-receptors in renal failure patients]	0.0	5	1	1	1
134899	1710	participate quantitatively in the gamma-globin	[participating quantitatively in the gamma-globin]	0.0	5	1	1	1
134900	1710	retinoid x receptor acid receptor	[retinoid X receptor acid receptor]	0.0	5	1	1	1
134901	1710	binding site for BSAP	[binding site for BSAP]	0.0	4	1	1	1
134902	1710	chromatin degradation in the process	[chromatin degradation in the process]	0.0	5	1	1	1
134903	1710	activity profile	[activity profile]	0.0	2	1	1	1
134904	1710	1 bp insertion	[1 bp insertion]	0.0	3	1	1	1
134905	1710	proliferation cessation	[proliferation cessation]	0.0	2	1	1	1
134906	1710	glucocorticoid receptor/ gr characteristic	[glucocorticoid receptor/s GR characteristics]	0.0	4	1	1	1
134907	1710	endotoxin lipopolysaccharide lps	[endotoxin lipopolysaccharide LPS]	0.0	3	1	1	1
134908	1710	level of trap fluoride-resistant- alpha-naphthyl-acetate-esterase	[levels of TRAP fluoride-resistant- alpha-naphthyl-acetate-esterase]	0.0	5	1	1	1
134909	1710	potent thiol antioxidant	[potent thiol antioxidant]	0.0	3	1	1	1
134910	1710	slow initial decline	[slower initial decline]	0.0	3	1	1	1
134911	1710	specificity for tyrosine kinase	[specificity for tyrosine kinases]	0.0	4	1	1	1
134912	1710	defect(s) lead to gc resistance	[defect(s) leading to GC resistance]	0.0	5	1	1	1
134913	1710	bipartite interleukin-4	[bipartite interleukin-4]	0.0	2	1	1	1
134914	1710	series of events.	[series of events.]	0.0	3	1	1	1
134915	1710	rp1 mrna	[RP1 mRNA]	0.0	2	1	1	1
134916	1710	cd4+ cell count (p	[CD4+ cell counts (P]	0.0	4	1	1	1
134917	1710	ing-1	[ING-1]	0.0	1	1	1	1
134918	1710	analysis of this cell act	[analysis of these cells acting]	0.0	5	1	1	1
134919	1710	anti-c/ebpdelta	[anti-C/EBPdelta]	0.0	1	1	1	1
134920	1710	use blood mononuclear cell	[Using blood mononuclear cells]	0.0	4	1	1	1
134921	1710	hemoglobin HbF production	[hemoglobin HbF production]	0.0	3	1	1	1
134922	1710	transfection experiments, overexpression ikk1	[transfection experiments, overexpression IKK1]	0.0	4	1	1	1
134923	1710	gene Ie	[genes IE]	0.0	2	1	1	1
134924	1710	importance for the activity	[importance for the activity]	0.0	4	1	1	1
134925	1710	Nuclear b activity a report.	[Nuclear B activity a report.]	0.0	5	1	1	1
134926	1710	membrane metabolism	[membrane metabolism]	0.0	2	1	1	1
134927	1710	absence of apparent alteration	[absence of apparent alteration]	0.0	4	1	1	1
134928	1710	therapy of hematopoietic tumor	[therapy of hematopoietic tumors]	0.0	4	1	1	1
134929	1710	deletion terminal region	[Deletions terminal region]	0.0	3	1	1	1
134930	1710	phenotypic DC characteristic of KG1 cell	[Phenotypic DC characteristics of KG1 cells]	0.0	6	1	1	1
134931	1710	nf-atp mouse old than 6 week	[NF-ATp mice older than 6 weeks]	0.0	6	1	1	1
134932	1710	absence specific transcription factor	[Absence specific transcription factors]	0.0	4	1	1	1
134933	1710	use a combination with Escherichia coli	[Using a combination with Escherichia coli]	0.0	6	1	1	1
134934	1710	expression of the E1A -conserved region	[expression of the E1A -conserved regions]	0.0	6	1	1	1
134935	1710	1 Hashimoto' goiter	[1 Hashimoto's goiter]	0.0	3	1	1	1
134936	1710	t(9;22)(q34;q11) translocation	[t(9;22)(q34;q11) translocation]	0.0	2	1	1	1
134937	1710	subject with malaria	[subjects with malaria]	0.0	3	1	1	1
134938	1710	elderly interferon-gamma	[elderly interferon-gamma]	0.0	2	1	1	1
134939	1710	cell reaction high histologic grade	[cell reaction high histologic grade]	0.0	5	1	1	1
134940	1710	Jurkat mutant	[Jurkat mutants]	0.0	2	1	1	1
134941	1710	threshold for T cell recognition	[threshold for T cell recognition]	0.0	5	1	1	1
134942	1710	12-o-tetradecanoylphorbol-13-acetate a activator	[12-O-tetradecanoylphorbol-13-acetate an activator]	0.0	3	1	1	1
134943	1710	Surprisingly, expression	[Surprisingly, expression]	0.0	2	1	1	1
134944	1710	soluble interleukin-2 receptor	[soluble interleukin-2 receptor]	0.0	3	1	1	1
134945	1710	three base substitution polymorphism	[Three base substitution polymorphisms]	0.0	4	1	1	1
134946	1710	14 control subject ige 112+/-28	[14 control subjects IgE 112+/-28]	0.0	5	1	1	1
134947	1710	ctl-mediated immunity	[CTL-mediated immunity]	0.0	2	1	1	1
134948	1710	factor production	[factor production]	0.0	2	1	1	1
134949	1710	BHA a lipid-soluble, antioxidant	[BHA a lipid-soluble, antioxidant]	0.0	4	1	1	1
134950	1710	leukocyte of donor	[leukocytes of donors]	0.0	3	1	1	1
134951	1710	gamma region	[gamma region]	0.0	2	1	1	1
134952	1710	dose-dependent increase	[dose-dependent increase]	0.0	2	1	1	1
134953	1710	cell redox	[cell redox]	0.0	2	1	1	1
134954	1710	subclone NF-kappa b segment	[Subcloning NF-kappa B segments]	0.0	4	1	1	1
134955	1710	approximately 500-bp il-5 gene segment	[approximately 500-bp IL-5 gene segment]	0.0	5	1	1	1
134956	1710	receptors/cell; controls, +/- 168)	[receptors/cell; controls, +/- 168)]	0.0	4	1	1	1
134957	1710	induction versus cytokine gene expression	[induction versus cytokine gene expression]	0.0	5	1	1	1
134958	1710	additional evidence	[additional evidence]	0.0	2	1	1	1
134959	1710	mnp-1 transcription	[MNP-1 transcription]	0.0	2	1	1	1
134960	1710	abnormality of receptor	[abnormalities of receptors]	0.0	3	1	1	1
134961	1710	effect hemin	[effects hemin]	0.0	2	1	1	1
134962	1710	rare DNA variation 2418delA in tumor	[rare DNA variations 2418delA in tumor]	0.0	6	1	1	1
134963	1710	activity of the interleukin-2 promoter	[activity of the interleukin-2 promoter]	0.0	5	1	1	1
134964	1710	promoter region (-508	[promoter region (-508]	0.0	3	1	1	1
134965	1710	individual with fibrosis	[individuals with fibrosis]	0.0	3	1	1	1
134966	1710	translocation a variant translocation	[Translocation a variant translocation]	0.0	4	1	1	1
134967	1710	cd36 cho cell	[CD36 CHO cells]	0.0	3	1	1	1
134968	1710	functional disomy of Xp.	[functional disomy of Xp.]	0.0	4	1	1	1
134969	1710	clinical feature of resistance	[clinical features of resistance]	0.0	4	1	1	1
134970	1710	analog of alpha,25-dihydroxyvitamin D3	[Analogs of alpha,25-dihydroxyvitamin D3]	0.0	4	1	1	1
134971	1710	malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	5	1	1	1
134972	1710	induction by immunodeficiency virus 1 infection	[Induction by immunodeficiency virus 1 infection]	0.0	6	1	1	1
134973	1710	several mammalian response to ultra-violet irradiation	[Several mammalian responses to UV irradiation]	0.0	6	1	1	1
134974	1710	cysteine-rich dna-binding domain	[cysteine-rich DNA-binding domain]	0.0	3	1	1	1
134975	1710	BCL-2 family	[BCL-2 family]	0.0	2	1	1	1
134976	1710	class ii alphabeta dimer	[class II alphabeta dimers]	0.0	4	1	1	1
134977	1710	requirement in induction	[requirements in induction]	0.0	3	1	1	1
134978	1710	version of C/EBP beta	[version of C/EBP beta]	0.0	4	1	1	1
134979	1710	(35 min) submaximal exercise	[(35 min) submaximal exercise]	0.0	4	1	1	1
134980	1710	IL-4 -dependent regulation	[IL-4 -dependent regulation]	0.0	3	1	1	1
134981	1710	regulator of human apoptosis	[regulator of human apoptosis]	0.0	4	1	1	1
134982	1710	absence of t-cell- specific transcription factor	[Absence of T-cell- specific transcription factors]	0.0	6	1	1	1
134983	1710	induction of AhR	[induction of AhR]	0.0	3	1	1	1
134984	1710	motif of NFAT family member	[motifs of NFAT family members]	0.0	5	1	1	1
134985	1710	stat1 -dependent immune-response	[Stat1 -dependent immune-response]	0.0	3	1	1	1
134986	1710	escape from HLA-DR cd4(+) t-cell response	[Escape from HLA-DR CD4(+) T-cell response]	0.0	6	1	1	1
134987	1710	time-dependent binding of pac-1 antibody	[time-dependent binding of PAC-1 antibodies]	0.0	5	1	1	1
134988	1710	number with alteration	[numbers with alteration]	0.0	3	1	1	1
134989	1710	regulatory sequence from -repressible gene	[regulatory sequences from -repressible genes]	0.0	5	1	1	1
134990	1710	employ nuclear extract	[employing nuclear extracts]	0.0	3	1	1	1
134991	1710	synchronization to permissive condition	[synchronization to permissive conditions]	0.0	4	1	1	1
134992	1710	mediator in the response	[mediators in the response]	0.0	4	1	1	1
134993	1710	basis of different pattern	[basis of different patterns]	0.0	4	1	1	1
134994	1710	synthesis of the protein	[synthesis of the protein]	0.0	4	1	1	1
134995	1710	ebv serology include zebra activity	[EBV serology including ZEBRA activity]	0.0	5	1	1	1
134996	1710	il-4 -dependent induction	[IL-4 -dependent induction]	0.0	3	1	1	1
134997	1710	minutes) to retinoic acid	[minutes) to retinoic acid]	0.0	4	1	1	1
134998	1710	nucleotide-dependent protein kinase inhibitor ha-1004	[nucleotide-dependent protein kinase inhibitor HA-1004]	0.0	5	1	1	1
134999	1710	target for cellular protein	[target for cellular proteins]	0.0	4	1	1	1
135000	1710	mannose	[mannose]	0.0	1	1	1	1
135001	1710	highlight putative loci relevant to pel	[highlighting putative loci relevant to PEL]	0.0	6	1	1	1
135002	1710	undergo apoptosis during activation	[undergoing apoptosis during activation]	0.0	4	1	1	1
135003	1710	overexpression of er	[overexpression of ER]	0.0	3	1	1	1
135004	1710	include nfat	[including NFAT]	0.0	2	1	1	1
135005	1710	yeast system,	[yeast system,]	0.0	2	1	1	1
135006	1710	cis-regulatory DNA element	[cis-regulatory DNA elements]	0.0	3	1	1	1
135007	1710	consist of the domain icn	[consisting of the domain ICN]	0.0	5	1	1	1
135008	1710	b27 antigen	[B27 antigen]	0.0	2	1	1	1
135009	1710	contain little ng of rna.	[containing little ng of RNA.]	0.0	5	1	1	1
135010	1710	use plasmid	[Using plasmids]	0.0	2	1	1	1
135011	1710	mediator of septic shock	[mediator of septic shock]	0.0	4	1	1	1
135012	1710	FKBP52	[FKBP52]	0.0	1	1	1	1
135013	1710	show dna-binding activity	[showing DNA-binding activity]	0.0	3	1	1	1
135014	1710	apparent variation	[apparent variation]	0.0	2	1	1	1
135015	1710	cross-talking among distinct adhesion molecule	[cross-talking among distinct adhesion molecules]	0.0	5	1	1	1
135016	1710	kb transcript than tissues.	[kb transcript than tissues.]	0.0	4	1	1	1
135017	1710	capacity in t-cell type	[capacities in T-cell types]	0.0	4	1	1	1
135018	1710	isolation of human cell from blood	[Isolation of human cells from blood]	0.0	6	1	1	1
135019	1710	several cis-acting element include a gata-1	[several cis-acting elements including a GATA-1]	0.0	6	1	1	1
135020	1710	basis for a assay	[basis for a assay]	0.0	4	1	1	1
135021	1710	tumor necrosis factor-alpha (25	[tumor necrosis factor-alpha (25]	0.0	4	1	1	1
135022	1710	antiserum against kbf1 to kda	[antiserum against KBF1 to kDa]	0.0	5	1	1	1
135023	1710	hour follow stimulation.	[hours following stimulation.]	0.0	3	1	1	1
135024	1710	downstream site for E2F	[downstream site for E2F]	0.0	4	1	1	1
135025	1710	even after 72 h	[even after 72 h]	0.0	4	1	1	1
135026	1710	event important	[events important]	0.0	2	1	1	1
135027	1710	neutrophil-mediated tissue damage	[neutrophil-mediated tissue damage]	0.0	3	1	1	1
135028	1710	broad sense, in situation	[broader sense, in situations]	0.0	4	1	1	1
135029	1710	(vzv)	[(VZV)]	0.0	1	1	1	1
135030	1710	copyright by the American Society	[Copyright by The American Society]	0.0	5	2	2	1
135031	1710	5869-bp region	[5869-bp region]	0.0	2	1	1	1
135032	1710	rare heterozygous DNA variation	[rare heterozygous DNA variations]	0.0	4	1	1	1
135033	1710	constitutive expression in human monocyte	[constitutive expression in human monocytes]	0.0	5	1	1	1
135034	1710	g0/g1 switch gene G0S2	[G0/G1 switch gene G0S2]	0.0	4	1	1	1
135035	1710	main activity of glucocorticoid	[main activities of glucocorticoids]	0.0	4	1	1	1
135036	1710	appearance of the phenotype	[appearance of the phenotype]	0.0	4	1	1	1
135037	1710	effect to the ap-1 site	[effect to the AP-1 site]	0.0	5	1	1	1
135038	1710	granulocyte colony-stimulating factor granulocyte-macrophage factor	[granulocyte colony-stimulating factor granulocyte-macrophage factor]	0.0	5	1	1	1
135039	1710	displacement of estradiol (cb50)	[displacement of estradiol (CB50)]	0.0	4	1	1	1
135040	1710	event to cell	[event to cells]	0.0	3	1	1	1
135041	1710	change of specific glucocorticoid binding	[changes of specific glucocorticoid binding]	0.0	5	1	1	1
135042	1710	block effect	[blocking effect]	0.0	2	1	1	1
135043	1710	tradd activation	[TRADD activation]	0.0	2	1	1	1
135044	1710	adult stage-specific interaction	[adult stage-specific interaction]	0.0	3	1	1	1
135045	1710	corresponding amino acid sequence	[corresponding amino acid sequences]	0.0	4	1	1	1
135046	1710	infection with virion	[infection with virions]	0.0	3	1	1	1
135047	1710	characterization of the component	[Characterization of the components]	0.0	4	1	1	1
135048	1710	dual action of acid	[Dual action of acid]	0.0	4	1	1	1
135049	1710	view of the factor-kappaB NFkappaB	[view of the factor-kappaB NFkappaB]	0.0	5	1	1	1
135050	1710	activation of leukocyte	[Activation of leukocytes]	0.0	3	1	1	1
135051	1710	Addition of GM-CSF	[Addition of GM-CSF]	0.0	3	1	1	1
135052	1710	880 comparison of DNA	[880 comparisons of DNA]	0.0	4	1	1	1
135053	1710	contain different region	[containing different regions]	0.0	3	1	1	1
135054	1710	assessment of stat-1 phosphorylation	[assessment of STAT-1 phosphorylation]	0.0	4	1	1	1
135055	1710	factor-kappa b site -85	[factor-kappa B site -85]	0.0	4	1	1	1
135056	1710	NF-AT assembly	[NF-AT assembly]	0.0	2	1	1	1
135057	1710	factor for the specific expression	[factor for the specific expression]	0.0	5	1	1	1
135058	1710	novel homeobox gene distantly related	[novel homeobox gene distantly related]	0.0	5	1	1	1
135059	1710	(xic)/xist	[(XIC)/XIST]	0.0	1	1	1	1
135060	1710	two distinct gene	[two distinct genes]	0.0	3	1	1	1
135061	1710	ascorbic	[Ascorbic]	0.0	1	1	1	1
135062	1710	gpix promoter /reporter construct	[GPIX promoter /reporter constructs]	0.0	4	1	1	1
135063	1710	acid-alpha receptor	[acid-alpha receptor]	0.0	2	1	1	1
135064	1710	ebv latency in epithelium	[EBV latency in epithelium]	0.0	4	1	1	1
135065	1710	hydrophobic domain with segment	[hydrophobic domain with segments]	0.0	4	1	1	1
135066	1710	11 index patient	[11 index patients]	0.0	3	1	1	1
135067	1710	include the ca2+ protein kinase ii	[including the Ca2+ protein kinase II]	0.0	6	1	1	1
135068	1710	TL-OmI	[TL-OmI]	0.0	1	1	1	1
135069	1710	patient with hyperparathyroidism to failure	[patients with hyperparathyroidism to failure]	0.0	5	1	1	1
135070	1710	overexpression of c-maf	[overexpression of c-Maf]	0.0	3	1	1	1
135071	1710	jak kinase signal transducer	[JAK kinases Signal transducers]	0.0	4	1	1	1
135072	1710	production of the cytokine tnf-alpha	[production of the cytokine TNF-alpha]	0.0	5	1	1	1
135073	1710	stress conditions,	[stress conditions,]	0.0	2	1	1	1
135074	1710	study use anti- ptf beta antibody	[studies using anti- PTF beta antibodies]	0.0	6	1	1	1
135075	1710	number include the Janus kinase	[number including the Janus kinases]	0.0	5	1	1	1
135076	1710	level fos/cun-contain nf-at complex	[levels Fos/Jun-containing NF-AT complexes]	0.0	4	1	1	1
135077	1710	adenovirus e1b-19 kda	[adenovirus E1B-19 kDa]	0.0	3	1	1	1
135078	1710	important insight into the molecular mechanism	[important insights into the molecular mechanisms]	0.0	6	1	1	1
135079	1710	form heterodimer with nuclear hormone receptor	[forming heterodimers with nuclear hormone receptors]	0.0	6	1	1	1
135080	1710	histocompatibility (mhc) class molecule	[histocompatibility (MHC) class molecules]	0.0	4	1	1	1
135081	1710	antitumor function	[antitumor function]	0.0	2	2	2	1
135082	1710	elastase inhibitor guamerin-derived synthetic peptide	[elastase inhibitor guamerin-derived synthetic peptide]	0.0	5	1	1	1
135083	1710	degradation by a signal on c-Jun	[degradation by a signal on c-Jun]	0.0	6	1	1	1
135084	1710	novel positive element	[novel positive element]	0.0	3	1	1	1
135085	1710	e2a basic protein	[E2A basic proteins]	0.0	3	1	1	1
135086	1710	absence of t-cell-	[Absence of T-cell-]	0.0	3	1	1	1
135087	1710	activation by hiv protease	[activation by HIV protease]	0.0	4	1	1	1
135088	1710	anti- ap-1 activity	[anti- AP-1 activity]	0.0	3	1	1	1
135089	1710	sarco(endo)plasmic reticulum	[sarco(endo)plasmic reticulum]	0.0	2	1	1	1
135090	1710	proinflammatory cytokine signal cascade	[proinflammatory cytokine signaling cascade]	0.0	4	1	1	1
135091	1710	nonpermissive monocyte-like u-937 cell culture	[nonpermissive monocyte-like U-937 cell cultures]	0.0	5	1	1	1
135092	1710	stimulation of neutrophil interleukin-8 production protein	[Stimulation of neutrophil interleukin-8 production protein]	0.0	6	1	1	1
135093	1710	cell from ligand.	[cells from ligand.]	0.0	3	1	1	1
135094	1710	mediate the neurologic dysfunction	[mediating the neurologic dysfunction]	0.0	4	1	1	1
135095	1710	dependence activity	[dependence activity]	0.0	2	1	1	1
135096	1710	activation the low weight variant	[activation the lower weight variant]	0.0	5	1	1	1
135097	1710	(high turnover) property identical	[(high turnover) properties identical]	0.0	4	1	1	1
135098	1710	nf-kappa b activating signal	[NF-kappa B activating signals]	0.0	4	1	1	1
135099	1710	localization of Delta19	[localization of Delta19]	0.0	3	1	1	1
135100	1710	affinity receptor for igg	[affinity receptor for IgG]	0.0	4	1	1	1
135101	1710	related interaction	[related interaction]	0.0	2	1	1	1
135102	1710	discrete structure	[discrete structures]	0.0	2	1	1	1
135103	1710	malignancy melanoma	[malignancy melanomas]	0.0	2	1	1	1
135104	1710	leukocyte of donor of sexes.	[leukocytes of donors of sexes.]	0.0	5	1	1	1
135105	1710	stimulation of human neutrophil	[Stimulation of human neutrophils]	0.0	4	1	1	1
135106	1710	overexpression peptide	[Overexpression peptide]	0.0	2	1	1	1
135107	1710	several other tissue	[several other tissues]	0.0	3	1	1	1
135108	1710	inhibitors, cyclosporin	[inhibitors, cyclosporin]	0.0	2	1	1	1
135109	1710	mnda cell	[MNDA cells]	0.0	2	1	1	1
135110	1710	proliferation of myeloid cell	[proliferation of myeloid cells]	0.0	4	1	1	1
135111	1710	tract infection with G. vaginalis	[tract infection with G. vaginalis]	0.0	5	1	1	1
135112	1710	bind activity (nf)-kappab	[binding activity (NF)-kappaB]	0.0	3	1	1	1
135113	1710	gap in understanding of this process	[gaps in understanding of this process]	0.0	6	1	1	1
135114	1710	immunodeficiency virus type 1 negative factor	[immunodeficiency virus type 1 negative factor]	0.0	6	1	1	1
135115	1710	related hepatocyte nuclear factor HNF-1alpha	[related hepatocyte nuclear factors HNF-1alpha]	0.0	5	1	1	1
135116	1710	follow induction	[following induction]	0.0	2	1	1	1
135117	1710	synthetic oligodeoxyribonucleotide	[synthetic oligodeoxyribonucleotide]	0.0	2	1	1	1
135118	1710	three lymphoblastoid cell line	[three lymphoblastoid cell lines]	0.0	4	1	1	1
135119	1710	antigen-activated T cell	[antigen-activated T cells]	0.0	3	1	1	1
135120	1710	acid in 12 of 17	[acids in 12 of 17]	0.0	5	1	1	1
135121	1710	vii/viia	[VII/VIIa]	0.0	1	1	1	1
135122	1710	Burkitt lymphoma line	[Burkitt lymphoma line]	0.0	3	1	1	1
135123	1710	aspect of the program	[aspects of the program]	0.0	4	1	1	1
135124	1710	-interact	[-interacting]	0.0	1	1	1	1
135125	1710	bl41-p3hr1	[BL41-P3HR1]	0.0	1	1	1	1
135126	1710	tetra-	[tetra-]	0.0	1	1	1	1
135127	1710	condition occur in patient	[condition occurring in patients]	0.0	4	1	1	1
135128	1710	include AML1/CBF beta	[including AML1/CBF beta]	0.0	3	1	1	1
135129	1710	involve two transcription factor family	[involving two transcription factor families]	0.0	5	1	1	1
135130	1710	interleukin-4 on cellular function	[interleukin-4 on cellular functions]	0.0	4	1	1	1
135131	1710	position 234	[position 234]	0.0	2	1	1	1
135132	1710	living cells,	[living cells,]	0.0	2	1	1	1
135133	1710	Janus family JAKs	[Janus family JAKs]	0.0	3	1	1	1
135134	1710	arthritis synovium express	[arthritis synovium express]	0.0	3	1	1	1
135135	1710	erk2 kinase activation	[Erk2 kinase activation]	0.0	3	1	1	1
135136	1710	rate of apoptosis in neutrophil	[rate of apoptosis in neutrophils]	0.0	5	1	1	1
135137	1710	similar comparison with extract	[similar comparison with extracts]	0.0	4	1	1	1
135138	1710	4 leukemia	[4 leukemias]	0.0	2	1	1	1
135139	1710	activation during eosinophil differentiation	[activation during eosinophil differentiation]	0.0	4	1	1	1
135140	1710	results: therapeutic concentration	[RESULTS: Therapeutic concentrations]	0.0	3	1	1	1
135141	1710	degree (or lack thereof)	[degree (or lack thereof)]	0.0	4	1	1	1
135142	1710	sequence requirement within a element upstream	[sequence requirements within a element upstream]	0.0	6	1	1	1
135143	1710	chimeric transcriptional properties	[chimeric transcriptional properties,]	0.0	3	1	1	1
135144	1710	part to dna-binding activity	[part to DNA-binding activity]	0.0	4	1	1	1
135145	1710	receptor receptor gamma ppargamma	[receptor receptor gamma PPARgamma]	0.0	4	1	1	1
135146	1710	human plaque	[human plaques]	0.0	2	1	1	1
135147	1710	such as e-selectin to a extent,	[such as E-selectin to a extent,]	0.0	6	1	1	1
135148	1710	human MHC hla-dra class gene	[human MHC HLA-DRA class gene]	0.0	5	1	1	1
135149	1710	indicate a determinant	[indicating an determinant]	0.0	3	1	1	1
135150	1710	TACI	[TACI]	0.0	1	1	1	1
135151	1710	inhibition of transcription factor stat1 activity	[Inhibition of transcription factor Stat1 activity]	0.0	6	1	1	1
135152	1710	affect change	[affecting changes]	0.0	2	1	1	1
135153	1710	trancriptional role in normal human monocyte	[trancriptional roles in normal human monocytes]	0.0	6	1	1	1
135154	1710	small cell lymphoma	[small cell lymphomas]	0.0	3	1	1	1
135155	1710	70% of oxygen uptake)	[70% of oxygen uptake)]	0.0	4	1	1	1
135156	1710	cycle,	[cycle,]	0.0	1	1	1	1
135157	1710	blood of patient with rheumatoid arthritis	[blood of patients with rheumatoid arthritis]	0.0	6	1	1	1
135158	1710	classical NF-kappa b heterodimer	[classical NF-kappa B heterodimer]	0.0	4	1	1	1
135159	1710	transcription pathway	[transcription pathway]	0.0	2	1	1	1
135160	1710	two representative form	[two representative forms]	0.0	3	1	1	1
135161	1710	negative correlation between ic5	[negative correlation between IC50S]	0.0	4	1	1	1
135162	1710	interestingly, the combination	[Interestingly, the combination]	0.0	3	1	1	1
135163	1710	particular, class	[particular, class]	0.0	2	1	1	1
135164	1710	Furthermore, S9a in combination,	[Furthermore, S9a in combination,]	0.0	4	1	1	1
135165	1710	gender-specific difference	[gender-specific differences]	0.0	2	1	1	1
135166	1710	PMA+ ionomycin	[PMA+ ionomycin]	0.0	2	1	1	1
135167	1710	t(8;21) leukemia aml	[t(8;21) leukemia AML]	0.0	3	1	1	1
135168	1710	circulate leukocyte into tissue	[circulating leukocytes into tissues]	0.0	4	1	1	1
135169	1710	mid-late g1	[mid-late G1]	0.0	2	1	1	1
135170	1710	recent advance in regulation	[recent advances in regulation]	0.0	4	1	1	1
135171	1710	potential role in hb-egf expression	[potential role in HB-EGF expression]	0.0	5	1	1	1
135172	1710	sequential development	[Sequential development]	0.0	2	1	1	1
135173	1710	free gene transcription	[free gene transcription]	0.0	3	1	1	1
135174	1710	hematopoietic property of cell	[hematopoietic properties of cells]	0.0	4	1	1	1
135175	1710	blood-derived human monocyte	[blood-derived human monocytes]	0.0	3	1	1	1
135176	1710	mouse development in central system	[mouse development in central system]	0.0	5	1	1	1
135177	1710	have weight in the range	[having weights in the range]	0.0	5	1	1	1
135178	1710	contrast to effect	[contrast to effects]	0.0	3	1	1	1
135179	1710	accordance with improvement	[accordance with improvement]	0.0	3	1	1	1
135180	1710	bcr1 type-pml/RAR alpha	[bcr1 type-pml/RAR alpha]	0.0	3	1	1	1
135181	1710	smad protein	[Smad proteins]	0.0	2	1	1	1
135182	1710	x receptor rxr	[X receptors RXRs]	0.0	3	1	1	1
135183	1710	inability of stimulation	[inability of stimulation]	0.0	3	1	1	1
135184	1710	differentiate to monocyte	[differentiating to monocytes]	0.0	3	1	1	1
135185	1710	transcriptional activation gene	[transcriptional activation genes]	0.0	3	1	1	1
135186	1710	responsiveness of human mononuclear leukocyte	[responsiveness of human mononuclear leukocytes]	0.0	5	1	1	1
135187	1710	protein motif	[protein motif]	0.0	2	1	1	1
135188	1710	8.20; control:	[8.20; control:]	0.0	2	1	1	1
135189	1710	cd95 ligand reporter activity	[CD95 ligand reporter activity]	0.0	4	1	1	1
135190	1710	salivary gland with disease duration	[salivary glands with disease duration]	0.0	5	1	1	1
135191	1710	DRA reporter plasmid	[DRA reporter plasmid]	0.0	3	1	1	1
135192	1710	subunit (type I	[subunits (type I]	0.0	3	1	1	1
135193	1710	also determine the quality	[also determining the quality]	0.0	4	1	1	1
135194	1710	inhibitor of NFAT -1-mediated transcription	[inhibitors of NFAT -1-mediated transcription]	0.0	5	1	1	1
135195	1710	obstacle design a vector	[obstacle designing a vector]	0.0	4	1	1	1
135196	1710	Tepoxalin a dual enzyme inhibitor	[Tepoxalin a dual enzyme inhibitor]	0.0	5	1	1	1
135197	1710	involvement of intracellular ca2+	[Involvement of intracellular Ca2+]	0.0	4	1	1	1
135198	1710	stimulation of nuclear factor kappa b	[stimulation of nuclear factor kappa B]	0.0	6	1	1	1
135199	1710	leukemic ml-1 cell	[leukemic ML-1 cell]	0.0	3	1	1	1
135200	1710	express SR-BP	[expressing SR-BP]	0.0	2	1	1	1
135201	1710	syncytium formation	[syncytium formation]	0.0	2	1	1	1
135202	1710	one consequence of the activation	[One consequence of the activation]	0.0	5	1	1	1
135203	1710	band range	[bands ranging]	0.0	2	1	1	1
135204	1710	mutual regulation	[Mutual regulation]	0.0	2	1	1	1
135205	1710	however a association between oncogene amplification	[however a association between oncogene amplification]	0.0	6	1	1	1
135206	1710	body burden of pcdd	[body burdens of PCDDs/PCDFs]	0.0	4	1	1	1
135207	1710	expression of cd69 by leukocyte	[expression of CD69 by leukocytes]	0.0	5	1	1	1
135208	1710	interaction in the promoter	[Interaction in the promoter]	0.0	4	1	1	1
135209	1710	such as bacterial endotoxin	[such as bacterial endotoxin]	0.0	4	1	1	1
135210	1710	caspase-3 -like	[caspase-3 -like]	0.0	2	1	1	1
135211	1710	neuronal ceroid-lypofuscinosis	[neuronal ceroid-lypofuscinosis]	0.0	2	1	1	1
135212	1710	control of hemoglobin-encoding gene	[control of hemoglobin-encoding genes]	0.0	4	1	1	1
135213	1710	culture lack cell	[cultures lacking cells]	0.0	3	1	1	1
135214	1710	emergence of binding protein	[emergence of binding proteins]	0.0	4	1	1	1
135215	1710	unactivated nuclear extract	[unactivated nuclear extracts]	0.0	3	1	1	1
135216	1710	the/thf n: alpha thf/thf ratios.	[THE/THF N: alpha THF/THF ratios.]	0.0	5	1	1	1
135217	1710	positive prediction	[positive predictions]	0.0	2	1	1	1
135218	1710	/rel binding	[/Rel binding]	0.0	2	1	1	1
135219	1710	rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma	[rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma]	0.0	5	1	1	1
135220	1710	E1 region	[E1 region]	0.0	2	1	1	1
135221	1710	formation in response consistent	[formation in response consistent]	0.0	4	1	1	1
135222	1710	state of the mechanism	[state of the mechanism]	0.0	4	1	1	1
135223	1710	oxidize	[Oxidizing]	0.0	1	1	1	1
135224	1710	response at the level	[response at the level]	0.0	4	1	1	1
135225	1710	respective transcription factor	[respective transcription factors]	0.0	3	1	1	1
135226	1710	pkb/akt activity	[PKB/Akt activity]	0.0	2	1	1	1
135227	1710	important regulator of gene	[important regulator of genes]	0.0	4	1	1	1
135228	1710	possible use in the treatment	[possible use in the treatment]	0.0	5	1	1	1
135229	1710	C CST3	[C CST3]	0.0	2	1	1	1
135230	1710	level in culture supernatant	[level in culture supernatants]	0.0	4	1	1	1
135231	1710	ig variable heavy chain sequence	[Ig variable heavy chain sequences]	0.0	5	1	1	1
135232	1710	tumor cell nuclei	[tumor cell nuclei]	0.0	3	1	1	1
135233	1710	ciita b-cell-specific promoter suppression cell hybrid	[CIITA B-cell-specific promoter suppression cell hybrids]	0.0	6	1	1	1
135234	1710	immunohistochemical procedure	[immunohistochemical procedure]	0.0	2	1	1	1
135235	1710	presence of intrinsic activation motif	[presence of intrinsic activation motifs]	0.0	5	1	1	1
135236	1710	localization of pkc isoenzyme	[localization of PKC isoenzymes]	0.0	4	1	1	1
135237	1710	domain 1 d1 of CD4	[domain 1 D1 of CD4]	0.0	5	1	1	1
135238	1710	contain repeat DR of bp	[containing repeats DR of bp]	0.0	5	1	1	1
135239	1710	expression 6 hour	[expression 6 hr]	0.0	3	1	1	1
135240	1710	stimulation by microbial superantigen	[stimulation by microbial superantigens]	0.0	4	1	1	1
135241	1710	differentiation protein	[differentiation protein]	0.0	2	1	1	1
135242	1710	isolation of dendritic cell from blood	[Isolation of dendritic cells from blood]	0.0	6	1	1	1
135243	1710	plasma cell-like b cell	[plasma cell-like B cells]	0.0	4	1	1	1
135244	1710	NF of T cell	[NF of T cells]	0.0	4	1	1	1
135245	1710	start at concentration	[starting at concentrations]	0.0	3	1	1	1
135246	1710	NF-AT concentration-dependent assembly	[NF-AT concentration-dependent assembly]	0.0	3	1	1	1
135247	1710	patient subsequently respond	[patients subsequently responding]	0.0	3	1	1	1
135248	1710	lps translocation	[LPS translocation]	0.0	2	1	1	1
135249	1710	control from RCC patient	[controls from RCC patients]	0.0	4	1	1	1
135250	1710	action of t-cell mitogen	[action of T-cell mitogens]	0.0	4	1	1	1
135251	1710	T cell biology	[T cell biology]	0.0	3	1	1	1
135252	1710	3) low content of t3, dysfunction	[3) low content of T3, dysfunction]	0.0	6	1	1	1
135253	1710	intrinsic activation motif	[intrinsic activation motifs]	0.0	3	1	1	1
135254	1710	substitution of Ile	[substitution of Ile]	0.0	3	1	1	1
135255	1710	duration of exposure	[duration of exposure]	0.0	3	1	1	1
135256	1710	Immunochemical staining of thymus section	[Immunochemical staining of thymus sections]	0.0	5	1	1	1
135257	1710	Native PTF beta	[Native PTF beta]	0.0	3	1	1	1
135258	1710	pre-treatment with gp160 for 4 h	[pre-treatment with gp160 for 4 h]	0.0	6	1	1	1
135259	1710	two pre-B-cell line	[two pre-B-cell lines]	0.0	3	1	1	1
135260	1710	Specific inhibitor of p70(S6)-kinase	[Specific inhibitors of p70(S6)-kinase]	0.0	4	1	1	1
135261	1710	leukemia with feature in PML/RARalpha mouse	[leukemia with features in PML/RARalpha mice]	0.0	6	1	1	1
135262	1710	epithelial cell BEAS-2B	[epithelial cells BEAS-2B]	0.0	3	1	1	1
135263	1710	differentiate in erythroid culture	[differentiating in erythroid cultures]	0.0	4	1	1	1
135264	1710	absorptive hypercalciuric patient	[absorptive hypercalciuric patients]	0.0	3	1	1	1
135265	1710	blood lymphocyte from individual	[blood lymphocytes from individuals]	0.0	4	1	1	1
135266	1710	nfat dna-binding activity	[NFAT DNA-binding activity]	0.0	3	1	1	1
135267	1710	event in t-cell transformation	[event in T-cell transformation]	0.0	4	1	1	1
135268	1710	epitope in vp22	[epitopes in VP22]	0.0	3	1	1	1
135269	1710	differentiation of monocytic cell	[differentiation of monocytic cells]	0.0	4	1	1	1
135270	1710	effect of dexamethasone on uptake	[effect of dexamethasone on uptake]	0.0	5	1	1	1
135271	1710	PMA T lymphocyte	[PMA T lymphocytes]	0.0	3	1	1	1
135272	1710	presence of progenitor	[presence of progenitors]	0.0	3	1	1	1
135273	1710	activity of peptide	[activities of peptides]	0.0	3	1	1	1
135274	1710	interleukin alpha-chain receptor	[interleukin alpha-chain receptor]	0.0	3	1	1	1
135275	1710	normal concentration	[normal concentration]	0.0	2	1	1	1
135276	1710	giant cell arteritis	[Giant cell arteritis]	0.0	3	1	1	1
135277	1710	AP-1/ATF/CREB family	[AP-1/ATF/CREB families]	0.0	2	1	1	1
135278	1710	gm-csf receptor alpha	[GM-CSF receptor alpha]	0.0	3	1	1	1
135279	1710	disorder (52 euthymic,	[disorder (52 euthymic,]	0.0	3	1	1	1
135280	1710	patient with chain deficiency	[patients with chain deficiency]	0.0	4	1	1	1
135281	1710	normal hematopoietic differentiation	[normal hematopoietic differentiation]	0.0	3	1	1	1
135282	1710	event of some,	[events of some,]	0.0	3	1	1	1
135283	1710	contain a additional reading frame	[containing an additional reading frame]	0.0	5	1	1	1
135284	1710	d-responsive	[D-responsive]	0.0	1	1	1	1
135285	1710	set of c-myb targets,	[set of c-Myb targets,]	0.0	4	1	1	1
135286	1710	inducible footprint	[inducible footprint]	0.0	2	1	1	1
135287	1710	sedimentation coefficient of s	[sedimentation coefficient of S]	0.0	4	1	1	1
135288	1710	mechanism of transcriptional control	[mechanisms of transcriptional control]	0.0	4	1	1	1
135289	1710	pld activation under experimental conditions.	[PLD activation under experimental conditions.]	0.0	5	1	1	1
135290	1710	tg presentation of T cell	[TG presentation of T cells]	0.0	5	1	1	1
135291	1710	length promoter construct	[length promoter construct]	0.0	3	1	1	1
135292	1710	include hydroxyanisole tetrahydropapaveroline	[including hydroxyanisole tetrahydropapaveroline]	0.0	3	1	1	1
135293	1710	CD4 CD8	[CD4 CD8]	0.0	2	1	1	1
135294	1710	patient in transformation	[patient in transformation]	0.0	3	1	1	1
135295	1710	role as a level	[role as a level]	0.0	4	1	1	1
135296	1710	cyclooxygenase/5-lipoxygenase compound under clinical investigation.	[cyclooxygenase/5-lipoxygenase compound under clinical investigation.]	0.0	5	1	1	1
135297	1710	quantification of receptor expression during differentiation	[quantification of receptor expression during differentiation]	0.0	6	1	1	1
135298	1710	leukemic blast use adeno-associated virus	[leukemic blasts using adeno-associated virus]	0.0	5	1	1	1
135299	1710	peptide encompass the fusion region	[peptide encompassing the fusion region]	0.0	5	1	1	1
135300	1710	dehydratase	[dehydratase]	0.0	1	1	1	1
135301	1710	tf activity in monocyte	[TF activity in monocytes]	0.0	4	1	1	1
135302	1710	proliferative potential hpp- 47.10 cell	[proliferative potential HPP- 47.10 cells]	0.0	5	1	1	1
135303	1710	pilot gene	[PILOT gene]	0.0	2	1	1	1
135304	1710	specific regulation in fibroblast	[specific regulation in fibroblasts]	0.0	4	1	1	1
135305	1710	e1a activities, sensitization to apoptosis	[E1A activities, sensitization to apoptosis]	0.0	5	1	1	1
135306	1710	organelle	[organelle]	0.0	1	2	2	1
135307	1710	annexinv	[AnnexinV]	0.0	1	1	1	1
135308	1710	chronic leukemia (b-cll) cell	[chronic leukemia (B-CLL) cells]	0.0	4	1	1	1
135309	1710	expression of helix-loop-helix transcription factor	[expression of helix-loop-helix transcription factors]	0.0	5	1	1	1
135310	1710	calcium -dependent immediate-early gene induction	[Calcium -dependent immediate-early gene induction]	0.0	5	1	1	1
135311	1710	state of the gene	[state of the gene]	0.0	4	1	1	1
135312	1710	histocompatibility (mhc) class	[histocompatibility (MHC) class]	0.0	3	1	1	1
135313	1710	only by a enzyme-linked assay ELISA	[only by an enzyme-linked assay ELISA]	0.0	6	1	1	1
135314	1710	STAT protein	[STAT proteins]	0.0	2	1	1	1
135315	1710	immune hyporesponsiveness	[immune hyporesponsiveness]	0.0	2	1	1	1
135316	1710	Glucocorticoid receptor in cell	[Glucocorticoid receptors in cells]	0.0	4	1	1	1
135317	1710	t-cell-specific response element	[T-cell-specific response element]	0.0	3	1	1	1
135318	1710	myelomonocytic differentiation aml-m2 include aml	[myelomonocytic differentiation AML-M2 including AML]	0.0	5	1	1	1
135319	1710	nuclear factor nf-at (ref.	[nuclear factor NF-AT (ref.]	0.0	4	1	1	1
135320	1710	subtype of hd	[subtype of HD]	0.0	3	1	1	1
135321	1710	sex distribution	[Sex distribution]	0.0	2	1	1	1
135322	1710	parameter for the course	[parameter for the course]	0.0	4	1	1	1
135323	1710	Tcf-1 mouse	[Tcf-1 mice]	0.0	2	1	1	1
135324	1710	explanation important.	[explanation important.]	0.0	2	1	1	1
135325	1710	distal nuclear factor (NF)-AT NF-AT AP-1/Octamer	[distal nuclear factor (NF)-AT NF-AT AP-1/Octamer]	0.0	6	1	1	1
135326	1710	negative allele of c-Raf-1	[negative allele of c-Raf-1]	0.0	4	1	1	1
135327	1710	difference from the human sequence	[differences from the human sequence]	0.0	5	1	1	1
135328	1710	population of effector cell eTh1	[populations of effector cells eTh1]	0.0	5	1	1	1
135329	1710	dominant T lymphocyte response	[Dominant T lymphocyte response]	0.0	4	1	1	1
135330	1710	kinase ERK in monocyte	[kinase ERK in monocytes]	0.0	4	1	1	1
135331	1710	severe immunodeficiency due to binding	[Severe immunodeficiency due to binding]	0.0	5	1	1	1
135332	1710	potential motifs:	[potential motifs:]	0.0	2	1	1	1
135333	1710	9 adult before dst	[9 adults before DST]	0.0	4	1	1	1
135334	1710	effect of nm dexamethasone	[effects of nM dexamethasone]	0.0	4	1	1	1
135335	1710	haptenation by SMX -NO	[haptenation by SMX -NO]	0.0	4	1	1	1
135336	1710	extract consist	[extracts consisting]	0.0	2	1	1	1
135337	1710	MHC class mrna expression	[MHC class mRNA expression]	0.0	4	1	1	1
135338	1710	kappaB- Sp1 concatamer	[kappaB- Sp1 concatamers]	0.0	3	1	1	1
135339	1710	efficacy in treatment	[efficacy in treatment]	0.0	3	1	1	1
135340	1710	vivo effect relationship	[vivo effects relationship]	0.0	3	1	1	1
135341	1710	polypeptide range from 85 kda	[polypeptides ranging from 85 kDa]	0.0	5	1	1	1
135342	1710	cytogenetics	[cytogenetics]	0.0	1	1	1	1
135343	1710	10 to 100 micromol/L	[10 to 100 micromol/L]	0.0	4	1	1	1
135344	1710	polymerase chain reaction (pcr) assay	[polymerase chain reaction (PCR) assay]	0.0	5	1	1	1
135345	1710	pentadecamer peptide cover the 491-amino-acid sequence	[pentadecamer peptides covering the 491-amino-acid sequence]	0.0	6	1	1	1
135346	1710	multiple creb isoform with specificity	[multiple CREB isoforms with specificities]	0.0	5	1	1	1
135347	1710	t-cell lysate	[T-cell lysates]	0.0	2	1	1	1
135348	1710	e2f-1 promoter	[E2F-1 promoter]	0.0	2	1	1	1
135349	1710	diterpene triepoxide with immunosuppressive property	[diterpene triepoxide with immunosuppressive properties]	0.0	5	1	1	1
135350	1710	repression by the regulatory region	[repression by the regulatory region]	0.0	5	1	1	1
135351	1710	1000 VDR by P.	[1000 VDR by h.]	0.0	4	1	1	1
135352	1710	expression of the nfil3/e4bp4 cDNA	[expression of the NFIL3/E4BP4 cDNA]	0.0	5	1	1	1
135353	1710	CD95-dependent shock pathway	[CD95-dependent shock pathways]	0.0	3	1	1	1
135354	1710	member of the same factor family	[members of the same factor family]	0.0	6	1	1	1
135355	1710	proline rich sequence	[proline rich sequence]	0.0	3	1	1	1
135356	1710	requirement for protein-protein interaction	[requirement for protein-protein interactions]	0.0	4	1	1	1
135357	1710	study in T cell line	[studies in T cell lines]	0.0	5	1	1	1
135358	1710	receptor-mediated agonist gm-csf	[receptor-mediated agonists GM-CSF]	0.0	3	1	1	1
135359	1710	chloramphenicol acetyltransferase CAT production	[chloramphenicol acetyltransferase CAT production]	0.0	4	1	1	1
135360	1710	inhibitor of ptpase include pervanadate	[inhibitors of PTPase including pervanadate]	0.0	5	1	1	1
135361	1710	contain regulatory sequence	[containing regulatory sequences]	0.0	3	1	1	1
135362	1710	lps ng/ml	[LPS ng/ml]	0.0	2	1	1	1
135363	1710	endothelial cell in hypoxia po2	[endothelial cells in hypoxia PO2]	0.0	5	1	1	1
135364	1710	Th2 lineage	[Th2 lineage]	0.0	2	1	1	1
135365	1710	gardnerella	[Gardnerella]	0.0	1	1	1	1
135366	1710	human immunodeficiency virus type replication	[human immunodeficiency virus type replication]	0.0	5	1	1	1
135367	1710	activity of nf-kb	[activity of NF-kB]	0.0	3	1	1	1
135368	1710	investigation on the formation	[investigations on the formation]	0.0	4	1	1	1
135369	1710	deletion/substitution mutant	[deletion/substitution mutant]	0.0	2	1	1	1
135370	1710	activation of a tata-less promoter	[activation of a TATA-less promoter]	0.0	5	1	1	1
135371	1710	bimodal expression pattern	[bimodal expression patterns]	0.0	3	1	1	1
135372	1710	number with little alteration in affinity	[numbers with little alteration in affinity]	0.0	6	1	1	1
135373	1710	cDNA genomic sequence	[cDNA genomic sequences]	0.0	3	1	1	1
135374	1710	dose result in suppression	[doses resulting in suppression]	0.0	4	1	1	1
135375	1710	level of translocation	[level of translocation]	0.0	3	1	1	1
135376	1710	b -dependent	[B -dependent]	0.0	2	1	1	1
135377	1710	effect of multidrug resistance	[effects of multidrug resistance]	0.0	4	1	1	1
135378	1710	constituent such as lps as stimuli.	[constituents such as LPS as stimuli.]	0.0	6	1	1	1
135379	1710	contrast, treatment with oxldl	[contrast, treatment with oxLDL]	0.0	4	1	1	1
135380	1710	target the protein to cp	[targeting the protein to Cp]	0.0	5	1	1	1
135381	1710	neutropenia	[neutropenia]	0.0	1	1	1	1
135382	1710	tfiid subunit related	[TFIID subunit related]	0.0	3	1	1	1
135383	1710	lymphoid enhancer	[lymphoid enhancer]	0.0	2	1	1	1
135384	1710	one DHS	[one DHS]	0.0	2	1	1	1
135385	1710	contribute to the induction	[contributing to the induction]	0.0	4	1	1	1
135386	1710	nearly 90% decrease	[nearly 90% decrease]	0.0	3	1	1	1
135387	1710	systemic anaphylaxis	[systemic anaphylaxis]	0.0	2	1	1	1
135388	1710	1 tax -responsive element tre-1	[1 Tax -responsive element TRE-1]	0.0	5	1	1	1
135389	1710	result from splicing	[resulting from splicing]	0.0	3	1	1	1
135390	1710	drop	[drop]	0.0	1	3	3	1
135391	1710	downregulate the activity	[downregulating the activity]	0.0	3	1	1	1
135392	1710	recessive form in familiess	[recessive form in families,]	0.0	4	1	1	1
135393	1710	biochemical lesion with age	[biochemical lesions with age]	0.0	4	1	1	1
135394	1710	incubation time.	[incubation time.]	0.0	2	1	1	1
135395	1710	blockade use a dominant ikappabalpha	[blockade using a dominant IkappaBalpha]	0.0	5	1	1	1
135396	1710	antitumour DNA topoisomerase ii	[antitumour DNA topoisomerase II]	0.0	4	1	1	1
135397	1710	contain cysteine region	[containing cysteine regions]	0.0	3	1	1	1
135398	1710	rule the zymogen plasma factor	[rules the zymogen plasma factors]	0.0	5	1	1	1
135399	1710	proliferate epstein-barr virus -negative b lymphocyte	[proliferating Epstein-Barr virus -negative B lymphocytes]	0.0	6	1	1	1
135400	1710	interleukin-12 receptor component	[interleukin-12 receptor component]	0.0	3	1	1	1
135401	1710	represent plasma cell-like b cell	[representing plasma cell-like B cells]	0.0	5	1	1	1
135402	1710	specific recovery	[specific recovery]	0.0	2	1	1	1
135403	1710	Epstein-Barr virus a oncogenic herpesvirus	[Epstein-Barr virus an oncogenic herpesvirus]	0.0	5	1	1	1
135404	1710	erythroid-specific gene in megakaryoblastic leukaemia	[erythroid-specific genes in megakaryoblastic leukaemia]	0.0	5	1	1	1
135405	1710	race- control subject	[race- control subjects]	0.0	3	1	1	1
135406	1710	clonal immune response	[clonal immune response]	0.0	3	1	1	1
135407	1710	different x-inactivation pattern	[different X-inactivation patterns]	0.0	3	1	1	1
135408	1710	suggest persistence	[suggesting persistence]	0.0	2	1	1	1
135409	1710	ebna-2 expression vector	[EBNA-2 expression vectors]	0.0	3	1	1	1
135410	1710	blood lymphocyte from at case	[blood lymphocytes from AT cases]	0.0	5	1	1	1
135411	1710	B-cell stimulation by superantigen	[B-cell stimulation by superantigens]	0.0	4	1	1	1
135412	1710	adhesion molecule-1 icam-1 cd11b/cd18	[adhesion molecule-1 ICAM-1 CD11b/CD18]	0.0	4	1	1	1
135413	1710	rest normal pbl	[resting normal PBL]	0.0	3	1	1	1
135414	1710	survival, growth, differentiation,	[survival, growth, differentiation,]	0.0	3	1	1	1
135415	1710	etiology of multiple sclerosis	[etiology of multiple sclerosis]	0.0	4	1	1	1
135416	1710	cell type cd4+ T cell	[cell types CD4+ T cells]	0.0	5	1	1	1
135417	1710	produce p40 by in vitro transformation	[producing p40 by in vitro transformation]	0.0	6	1	1	1
135418	1710	eight healthy volunteer	[Eight healthy volunteers]	0.0	3	1	1	1
135419	1710	apoptosis in t-cell-line-expressing CD4 receptor	[apoptosis in T-cell-line-expressing CD4 receptors]	0.0	5	1	1	1
135420	1710	IFN activity	[IFN activity]	0.0	2	1	1	1
135421	1710	accumulation of c-rel	[accumulation of c-Rel]	0.0	3	1	1	1
135422	1710	dna-binding of factor-kappaB	[DNA-binding of factor-kappaB]	0.0	3	1	1	1
135423	1710	camp -dependent regulation positive effect	[cAMP -dependent regulation positive effects]	0.0	5	1	1	1
135424	1710	family of small cytokine	[family of small cytokines]	0.0	4	1	1	1
135425	1710	inhibit nf-kappab translocation	[inhibiting NF-kappaB translocation]	0.0	3	1	1	1
135426	1710	proximal promoter region span position	[proximal promoter region spanning positions]	0.0	5	1	1	1
135427	1710	encompass the cd28re	[encompassing the CD28RE]	0.0	3	1	1	1
135428	1710	localization.	[localization.]	0.0	1	1	1	1
135429	1710	localization,	[localization,]	0.0	1	1	1	1
135430	1710	control of the expression	[control of the expression]	0.0	4	1	1	1
135431	1710	Ran GTP association with this nucleoporin	[Ran GTP association with these nucleoporins]	0.0	6	1	1	1
135432	1710	tamoxifen Tx	[tamoxifen Tx]	0.0	2	1	1	1
135433	1710	rat prostate tissue	[rat prostate tissue]	0.0	3	1	1	1
135434	1710	quiescent blood mononuclear cell	[quiescent blood mononuclear cells]	0.0	4	1	1	1
135435	1710	2.5-fold increase	[2.5-fold increase]	0.0	2	1	1	1
135436	1710	M2 blast cell	[M2 blast cells]	0.0	3	1	1	1
135437	1710	CD28 signal transduction	[CD28 signal transduction]	0.0	3	1	1	1
135438	1710	gene, two transcript isolation	[gene, two transcripts isolation]	0.0	4	1	1	1
135439	1710	MRD -positive	[MRD -positive]	0.0	2	1	1	1
135440	1710	expression of major surface protein	[expression of major surface proteins]	0.0	5	1	1	1
135441	1710	protein range	[proteins ranging]	0.0	2	1	1	1
135442	1710	activity of nf-at	[activity of NF-AT]	0.0	3	1	1	1
135443	1710	other family	[other families]	0.0	2	1	1	1
135444	1710	binding by lymphocyte receptor	[Binding by lymphocyte receptors]	0.0	4	1	1	1
135445	1710	use template	[Using templates,]	0.0	2	1	1	1
135446	1710	parallel series	[parallel series]	0.0	2	1	1	1
135447	1710	immunohistological staining for nf-kappabp65 than patient	[immunohistological staining for NF-kappaBp65 than patients]	0.0	6	1	1	1
135448	1710	cleavage product after induction of apoptosis	[cleavage products after induction of apoptosis]	0.0	6	1	1	1
135449	1710	reduce component of KV	[reducing components of KV]	0.0	4	1	1	1
135450	1710	murine thymus	[murine thymus]	0.0	2	1	1	1
135451	1710	example of target gene	[example of target genes]	0.0	4	1	1	1
135452	1710	urinary thf	[urinary THF]	0.0	2	1	1	1
135453	1710	potent pkc inhibitor 31-8425	[potent PKC inhibitor 31-8425]	0.0	4	1	1	1
135454	1710	activity of granulocyte-macrophage factor	[activity of granulocyte-macrophage factor]	0.0	4	1	1	1
135455	1710	immediate gene c-jun	[immediate gene c-jun]	0.0	3	1	1	1
135456	1710	calf serum on the binding	[calf serum on the binding]	0.0	5	1	1	1
135457	1710	presumably due to the high expression	[presumably due to the higher expression]	0.0	6	1	1	1
135458	1710	monocyte-derived m phi	[monocyte-derived M phi]	0.0	3	1	1	1
135459	1710	virus type htlv-1	[virus type HTLV-1]	0.0	3	1	1	1
135460	1710	Phenylarsine	[Phenylarsine]	0.0	1	2	2	1
135461	1710	activation of signal cascade	[activation of signaling cascades]	0.0	4	1	1	1
135462	1710	transcription factor stimulatory factor	[transcription factor stimulatory factor]	0.0	4	1	1	1
135463	1710	human prointerleukin beta gene	[human prointerleukin beta gene]	0.0	4	2	2	1
135464	1710	tyrosine residue in form	[tyrosine residues in form]	0.0	4	1	1	1
135465	1710	radiosensitivity of cell carcinoma	[radiosensitivity of cell carcinomas]	0.0	4	1	1	1
135466	1710	box in the gene	[boxes in the gene]	0.0	4	1	1	1
135467	1710	cell-type expression of genes.	[cell-type expression of genes.]	0.0	4	1	1	1
135468	1710	osteoclast cell	[osteoclast cells]	0.0	2	1	1	1
135469	1710	TNF-alpha hiv-1 repeat LTR	[TNF-alpha HIV-1 repeat LTR]	0.0	4	1	1	1
135470	1710	244b lymphoblastoid cell	[244B lymphoblastoid cells]	0.0	3	1	1	1
135471	1710	beta-globin dominant control region	[beta-globin dominant control region]	0.0	4	1	1	1
135472	1710	m all-tran RA 9-cis RA	[M all-trans RA 9-cis RA]	0.0	5	1	1	1
135473	1710	adolescent disorder MDD	[adolescent disorder MDD]	0.0	3	1	1	1
135474	1710	autophosphorylation site y518	[autophosphorylation site Y518]	0.0	3	1	1	1
135475	1710	long period of incubation	[longer periods of incubation]	0.0	4	1	1	1
135476	1710	novel 9-bp motif (-90/-82	[novel 9-bp motifs (-90/-82]	0.0	4	1	1	1
135477	1710	suggest a requirement for function	[suggesting a requirement for function]	0.0	5	1	1	1
135478	1710	low potential in a segment	[low potential in a segment]	0.0	5	1	1	1
135479	1710	increase awareness as a disable sequela	[increasing awareness as a disabling sequela]	0.0	6	1	1	1
135480	1710	Ran -binding domain	[Ran -binding domains]	0.0	3	1	1	1
135481	1710	use human endothelial cell	[using human endothelial cells]	0.0	4	1	1	1
135482	1710	polar substitution alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl	[polar substitutions alpha-hydroxymethyl, 11 alpha-(2-hydroxyethyl]	0.0	5	1	1	1
135483	1710	rise of a10 antigen incidence	[rise of A10 antigen incidence]	0.0	5	1	1	1
135484	1710	hormone/receptor	[hormone/receptor]	0.0	1	2	2	1
135485	1710	DNA basic domain of MyoD	[DNA basic domain of MyoD]	0.0	5	1	1	1
135486	1710	Flow cytometric cell sorting	[Flow cytometric cell sorting]	0.0	4	1	1	1
135487	1710	amplify cellular event	[amplifying cellular events]	0.0	3	1	1	1
135488	1710	activation of the hiv long repeat	[activation of the HIV long repeat]	0.0	6	1	1	1
135489	1710	potential nuclear factor	[potential nuclear factor]	0.0	3	1	1	1
135490	1710	contain cysteine -rich region LIM domain	[containing cysteine -rich regions LIM domains]	0.0	6	1	1	1
135491	1710	sequence-specific dna-binding molecule	[Sequence-specific DNA-binding molecules]	0.0	3	1	1	1
135492	1710	Specific depletion of the population	[Specific depletion of the population]	0.0	5	1	1	1
135493	1710	transactivation domain of E2A	[transactivation domains of E2A]	0.0	4	1	1	1
135494	1710	immunodeficiency virus entry into cell	[immunodeficiency virus entry into cells]	0.0	5	1	1	1
135495	1710	target site for positive factor	[target site for positive factors]	0.0	5	1	1	1
135496	1710	rich sequence	[rich sequence]	0.0	2	1	1	1
135497	1710	benign course	[benign course]	0.0	2	1	1	1
135498	1710	SS RBC	[SS RBC]	0.0	2	1	1	1
135499	1710	seven ebv -positive gastric carcinoma tissue	[seven EBV -positive gastric carcinoma tissues]	0.0	6	1	1	1
135500	1710	prepartal treatment	[prepartal treatment]	0.0	2	1	1	1
135501	1710	involve deletion analysis	[involving deletion analysis]	0.0	3	1	1	1
135502	1710	concentration high	[concentration high]	0.0	2	1	1	1
135503	1710	example of development	[examples of development]	0.0	3	1	1	1
135504	1710	standard technique	[standard techniques]	0.0	2	1	1	1
135505	1710	major pkc substrate	[major PKC substrates]	0.0	3	1	1	1
135506	1710	ligation of CD40 ag	[ligation of CD40 Ag]	0.0	4	1	1	1
135507	1710	isoform of the element modulator	[isoforms of the element modulator]	0.0	5	1	1	1
135508	1710	characterization of a essential element	[characterization of a essential element]	0.0	5	1	1	1
135509	1710	accumulation for elam-1	[accumulation for ELAM-1]	0.0	3	1	1	1
135510	1710	vivo: role	[vivo: role]	0.0	2	1	1	1
135511	1710	late expression pattern	[late expression patterns]	0.0	3	1	1	1
135512	1710	abrogation of gata-1 expression	[abrogation of GATA-1 expression]	0.0	4	1	1	1
135513	1710	homologue of Drosophila Toll hToll	[homologue of Drosophila Toll hToll]	0.0	5	1	1	1
135514	1710	other viral product	[other viral products]	0.0	3	1	1	1
135515	1710	blood healthy volunteer man	[blood healthy volunteers men]	0.0	4	1	1	1
135516	1710	single locus	[single locus]	0.0	2	1	1	1
135517	1710	observation of paternal expression of wt1	[observations of paternal expression of WT1]	0.0	6	1	1	1
135518	1710	two B-cell line	[two B-cell lines]	0.0	3	1	1	1
135519	1710	three gata element of the repeat	[three GATA elements of the repeat]	0.0	6	1	1	1
135520	1710	role of BHRF1	[role of BHRF1]	0.0	3	1	1	1
135521	1710	vitro to macrophage	[vitro to macrophages]	0.0	3	1	1	1
135522	1710	Cyclosporine	[Cyclosporine]	0.0	1	1	1	1
135523	1710	fas promoter induction	[fas promoter induction]	0.0	3	1	1	1
135524	1710	alpha-tocopheryl	[alpha-tocopheryl]	0.0	1	1	1	1
135525	1710	human virus type HTLV-I	[human virus type HTLV-I]	0.0	4	1	1	1
135526	1710	multicolor flow assay	[Multicolor flow assays]	0.0	3	1	1	1
135527	1710	b-cell-specific EB1 -responsive element	[B-cell-specific EB1 -responsive element]	0.0	4	1	1	1
135528	1710	negative cross-talk	[negative cross-talk]	0.0	2	1	1	1
135529	1710	stimulation major protein	[Stimulation major protein]	0.0	3	1	1	1
135530	1710	myb-transformed hematopoietic cell as a model	[Myb-transformed hematopoietic cells as a model]	0.0	6	1	1	1
135531	1710	Mol.Cell.	[Mol.Cell.]	0.0	1	1	1	1
135532	1710	biological active form	[biological active form]	0.0	3	1	1	1
135533	1710	endothelial cell with oleate	[endothelial cells with oleate]	0.0	4	1	1	1
135534	1710	10(-7) g/g	[10(-7) g/g]	0.0	2	1	1	1
135535	1710	ras manner	[Ras manner]	0.0	2	1	1	1
135536	1710	association of p47phox	[association of p47phox]	0.0	3	1	1	1
135537	1710	downstream 3' region	[downstream 3' regions]	0.0	3	1	1	1
135538	1710	parallel decline	[parallel decline]	0.0	2	1	1	1
135539	1710	chi b formation	[chi B formation]	0.0	3	1	1	1
135540	1710	11 alpha-methyl, 11 alpha-fluoromethyl	[11 alpha-methyl, 11 alpha-fluoromethyl]	0.0	4	1	1	1
135541	1710	(ndp)	[(NDP)]	0.0	1	1	1	1
135542	1710	number include change	[number including changes]	0.0	3	1	1	1
135543	1710	nf-kappab in contrast to the mediator	[NF-kappaB in contrast to the mediators]	0.0	6	1	1	1
135544	1710	hamster wound	[hamster wounds]	0.0	2	1	1	1
135545	1710	sequence of the subunit	[sequence of the subunit]	0.0	4	1	1	1
135546	1710	pretreatment of human ECs	[Pretreatment of human ECs]	0.0	4	1	1	1
135547	1710	element for PMA ionophore	[element for PMA ionophore]	0.0	4	1	1	1
135548	1710	initial evidence link abnormal behavior	[initial evidence linking abnormal behavior]	0.0	5	1	1	1
135549	1710	cis-acting element gm-kappa	[cis-acting elements GM-kappa]	0.0	3	1	1	1
135550	1710	cytotoxicity against cell line	[cytotoxicity against cell lines]	0.0	4	1	1	1
135551	1710	factor promoter activity	[factor promoter activity]	0.0	3	1	1	1
135552	1710	tpa b cell harbour type	[TPA B cells harbouring type]	0.0	5	1	1	1
135553	1710	include aml with morphology	[including AML with morphology]	0.0	4	1	1	1
135554	1710	cell type-specific reporter	[cell type-specific reporter]	0.0	3	1	1	1
135555	1710	Promiscuous activity reticuloendotheliosis virus	[Promiscuous activity reticuloendotheliosis virus]	0.0	4	1	1	1
135556	1710	mechanism of MDS progression	[mechanism of MDS progression]	0.0	4	1	1	1
135557	1710	acute myelogenous leukemia evi1 fusion respectively,	[acute myelogenous leukemia EVI1 fusions respectively,]	0.0	6	1	1	1
135558	1710	mM concentration	[mM concentration]	0.0	2	1	1	1
135559	1710	two cell molecule	[two cell molecules]	0.0	3	1	1	1
135560	1710	receive glucocorticoid therapy for disease	[receiving glucocorticoid therapy for diseases]	0.0	5	1	1	1
135561	1710	sharp contrast	[sharp contrast]	0.0	2	1	1	1
135562	1710	putative il-2re	[putative IL-2rE]	0.0	2	1	1	1
135563	1710	homology with c-type lectin receptor	[homology with C-type lectin receptors]	0.0	5	1	1	1
135564	1710	prevalence of lupus	[prevalence of lupus]	0.0	3	1	1	1
135565	1710	G point	[G point]	0.0	2	1	1	1
135566	1710	coexpression of dominant ras	[Coexpression of dominant Ras]	0.0	4	1	1	1
135567	1710	TCL1 expression	[TCL1 expression]	0.0	2	1	1	1
135568	1710	equivalent c-myb	[equivalent c-myb]	0.0	2	1	1	1
135569	1710	difference in c-fo promoter activity	[difference in c-fos promoter activity]	0.0	5	1	1	1
135570	1710	myelogenous leukemia respectively,	[myelogenous leukemia respectively,]	0.0	3	1	1	1
135571	1710	only in the unregulated expression	[only in the unregulated expression]	0.0	5	1	1	1
135572	1710	osteoclast-like giant cell from human monocyte	[osteoclast-like giant cells from human monocytes]	0.0	6	1	1	1
135573	1710	encode oct-binding factor 1	[encoding Oct-binding factor 1]	0.0	4	1	1	1
135574	1710	1alpha,25(oh)2-lumisterol3 nb4 leukemia cell	[1alpha,25(OH)2-lumisterol3 NB4 leukemia cells]	0.0	4	1	1	1
135575	1710	diurnal rhythm the fractional inhibition	[diurnal rhythms the fractional inhibition]	0.0	5	1	1	1
135576	1710	amino acid 1-450	[amino acids 1-450]	0.0	3	1	1	1
135577	1710	chronically hiv-infected pbmc	[chronically HIV-infected PBMC]	0.0	3	1	1	1
135578	1710	follow ligand engagement (e.g. cell-to-cell	[following ligand engagement (e.g. cell-to-cell]	0.0	5	1	1	1
135579	1710	dysregulation of the system	[dysregulation of the system]	0.0	4	1	1	1
135580	1710	uncouple of nonreceptor tyrosine kinase	[Uncoupling of nonreceptor tyrosine kinases]	0.0	5	1	1	1
135581	1710	approach for regulation	[approach for regulation]	0.0	3	1	1	1
135582	1710	woman of childbearing	[women of childbearing]	0.0	3	1	1	1
135583	1710	immune-modulating effect on T cell function	[immune-modulating effects on T cell function]	0.0	6	1	1	1
135584	1710	gr chimeric receptor	[GR chimeric receptors]	0.0	3	1	1	1
135585	1710	x transcriptional pathway	[X transcriptional pathway]	0.0	3	1	1	1
135586	1710	link this class of signal molecule	[linking these classes of signaling molecules]	0.0	6	1	1	1
135587	1710	contrast, long treatment	[contrast, long-term treatment]	0.0	3	1	1	1
135588	1710	receptor-positive lymphocyte sarcoidosis	[receptor-positive lymphocytes sarcoidosis]	0.0	3	1	1	1
135589	1710	corticoid receptor	[corticoid receptors]	0.0	2	1	1	1
135590	1710	overexpression a version	[Overexpression a version]	0.0	3	1	1	1
135591	1710	study: lymphocyte from healthy woman	[STUDY: lymphocytes from healthy women]	0.0	5	1	1	1
135592	1710	effective humoral immune response	[effective humoral immune response]	0.0	4	1	1	1
135593	1710	2nd exon	[2nd exon]	0.0	2	1	1	1
135594	1710	addition of the sequence	[addition of the sequence]	0.0	4	1	1	1
135595	1710	existence of binding factor present	[existence of binding factors present]	0.0	5	1	1	1
135596	1710	addition of acid the product	[addition of acid the product]	0.0	5	1	1	1
135597	1710	enhancer in assay	[enhancer in assays]	0.0	3	1	1	1
135598	1710	nuclear target for PI3K	[nuclear targets for PI3K]	0.0	4	1	1	1
135599	1710	physiologic product	[physiologic product]	0.0	2	1	1	1
135600	1710	human leucocyte in man	[human leucocytes in men]	0.0	4	1	1	1
135601	1710	[correlation of infiltration of tumor tissue	[[Correlation of infiltration of tumor tissue]	0.0	6	1	1	1
135602	1710	circadian rhythm of gr	[circadian rhythm of GR]	0.0	4	1	1	1
135603	1710	interleukin colony-stimulating factor receptor	[interleukin colony-stimulating factor receptors]	0.0	4	1	1	1
135604	1710	creb isoform with specificity	[CREB isoforms with specificities]	0.0	4	1	1	1
135605	1710	vitamin e derivative	[vitamin E derivative]	0.0	3	1	1	1
135606	1710	induction 1 expression	[Induction 1 expression]	0.0	3	1	1	1
135607	1710	tcf-1 gene	[TCF-1 gene]	0.0	2	1	1	1
135608	1710	involve activation	[involving activation]	0.0	2	1	1	1
135609	1710	induction of activation	[induction of activation]	0.0	3	1	1	1
135610	1710	trilineage	[trilineage]	0.0	1	1	1	1
135611	1710	Ca2+/calmodulin-regulated, serine/threonine-specific protein phosphatase	[Ca2+/calmodulin-regulated, serine/threonine-specific protein phosphatase]	0.0	4	1	1	1
135612	1710	follow a injection of phosphocreatine pcr	[following an injection of phosphocreatine PCr]	0.0	6	1	1	1
135613	1710	evidence of a positive role	[evidence of a positive role]	0.0	5	1	1	1
135614	1710	immunosuppressive activity low than cyclosporin a	[immunosuppressive activity lower than cyclosporin A]	0.0	6	1	1	1
135615	1710	TRE -DNA binding protein	[TRE -DNA binding proteins]	0.0	4	1	1	1
135616	1710	glucocorticoid responsiveness	[glucocorticoid responsiveness]	0.0	2	2	2	1
135617	1710	alpha 4 beta 1	[alpha 4 beta 1]	0.0	4	1	1	1
135618	1710	show weak cross-reactivity	[showing weak cross-reactivity]	0.0	3	1	1	1
135619	1710	(from hour 1 to 6)	[(from hours 1 to 6)]	0.0	5	1	1	1
135620	1710	transcriptional response in leishmania-infected cell	[transcriptional responses in leishmania-infected cells]	0.0	5	1	1	1
135621	1710	action of the two receptor	[action of the two receptors]	0.0	5	1	1	1
135622	1710	non- b	[non- B]	0.0	2	1	1	1
135623	1710	inhibition by a antiinflammatory alkaloid	[inhibition by an antiinflammatory alkaloid]	0.0	5	1	1	1
135624	1710	42- kda protein	[42- kDa proteins]	0.0	3	1	1	1
135625	1710	participation of cis-acting element	[participation of cis-acting elements]	0.0	4	1	1	1
135626	1710	ubiquitously express protein	[ubiquitously expressed, protein]	0.0	3	1	1	1
135627	1710	nonproliferateraterateratiferatiferatiferatiferati b cell	[nonproliferating B cells]	0.0	3	1	1	1
135628	1710	suppression of human t-cell immune response	[Suppression of human T-cell immune responses]	0.0	6	1	1	1
135629	1710	ikappab alpha in sensitive cell	[IkappaB alpha in sensitive cells]	0.0	5	1	1	1
135630	1710	tax -dependent control	[Tax -dependent control]	0.0	3	1	1	1
135631	1710	Dithiocarbamates a group	[Dithiocarbamates a group]	0.0	3	1	1	1
135632	1710	similar action of IL-10R	[similar actions of IL-10R]	0.0	4	1	1	1
135633	1710	differentiation-dependent receptor gamma ppargamma	[differentiation-dependent receptor gamma PPARgamma]	0.0	4	1	1	1
135634	1710	maturation suppression	[maturation suppression]	0.0	2	1	1	1
135635	1710	two major pkc substrate	[two major PKC substrates]	0.0	4	1	1	1
135636	1710	efficacy of immunosuppression	[efficacy of immunosuppression]	0.0	3	1	1	1
135637	1710	two kappa b-like motif	[Two kappa B-like motifs]	0.0	4	1	1	1
135638	1710	Promiscuous transcriptional activity	[Promiscuous transcriptional activity]	0.0	3	1	1	1
135639	1710	cell extract from acute leukemia	[cell extracts from acute leukemia]	0.0	5	1	1	1
135640	1710	human histocompatibility complex	[human histocompatibility complex]	0.0	3	1	1	1
135641	1710	dendritic cell in germinal center	[dendritic cells in germinal centers]	0.0	5	1	1	1
135642	1710	innate defense mechanism against pathogen	[innate defense mechanisms against pathogens]	0.0	5	1	1	1
135643	1710	long terminal repeat type	[long terminal repeat type]	0.0	4	1	1	1
135644	1710	propensity for transformation	[propensity for transformation]	0.0	3	1	1	1
135645	1710	exon 10 genomic sequence	[exon 10 genomic sequence]	0.0	4	1	1	1
135646	1710	disease primary biliary cirrhosis	[disease primary biliary cirrhosis]	0.0	4	1	1	1
135647	1710	conservation with consensus site	[conservation with consensus sites]	0.0	4	1	1	1
135648	1710	evolutionary event	[evolutionary events]	0.0	2	1	1	1
135649	1710	apparent molecular mass of kda	[apparent molecular mass of kDa]	0.0	5	1	1	1
135650	1710	major histocompatibility class promoter	[major histocompatibility class promoter]	0.0	4	1	1	1
135651	1710	inhibition of NF-AT signal transduction event	[Inhibition of NF-AT signal transduction events]	0.0	6	1	1	1
135652	1710	level only 2	[levels only 2]	0.0	3	1	1	1
135653	1710	expression of n17rac	[Expression of N17Rac]	0.0	3	1	1	1
135654	1710	low-potency agonist,	[low-potency agonist,]	0.0	2	1	1	1
135655	1710	activate transcription from the repeat LTR	[activating transcription from the repeat LTR]	0.0	6	1	1	1
135656	1710	agar)	[agar)]	0.0	1	1	1	1
135657	1710	activity of specific factor	[activity of specific factors]	0.0	4	1	1	1
135658	1710	eTh1	[eTh1]	0.0	1	1	1	1
135659	1710	element propagate the state,	[elements propagating the state,]	0.0	4	1	1	1
135660	1710	stress lead	[stress leading]	0.0	2	1	1	1
135661	1710	lymphoma/leukemia-2	[lymphoma/leukemia-2]	0.0	1	1	1	1
135662	1710	expression in fresh leukemic cell	[expression in fresh leukemic cells]	0.0	5	1	1	1
135663	1710	monocyte with pertussis toxin	[monocytes with pertussis toxin]	0.0	4	1	1	1
135664	1710	[correlation of infiltration with the state	[[Correlation of infiltration with the state]	0.0	6	1	1	1
135665	1710	fibrosarcoma malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
135666	1710	phosphoserine residue	[phosphoserine residues]	0.0	2	1	1	1
135667	1710	vitro, six viral antigen EBNAs	[vitro, six viral antigens EBNAs]	0.0	5	1	1	1
135668	1710	dramatic dose-dependent shift	[dramatic dose-dependent shift]	0.0	3	1	1	1
135669	1710	hGATA-3 expression plasmid	[hGATA-3 expression plasmid]	0.0	3	1	1	1
135670	1710	17-bp gas	[17-bp GAS]	0.0	2	1	1	1
135671	1710	NF-kappa b mechanism in cell	[NF-kappa B mechanisms in cells]	0.0	5	1	1	1
135672	1710	gene in recurrent astrocytomas	[genes in recurrent astrocytomas]	0.0	4	1	1	1
135673	1710	pkc protein kinase	[PKC protein kinase]	0.0	3	1	1	1
135674	1710	maintenance of transcription in cell	[maintenance of transcription in cells]	0.0	5	1	1	1
135675	1710	development of novel therapy	[development of novel therapies]	0.0	4	1	1	1
135676	1710	nuclear factor 3 beta hnf3 beta	[nuclear factor 3 beta HNF3 beta]	0.0	6	1	1	1
135677	1710	human element	[human element]	0.0	2	1	1	1
135678	1710	gt motif	[GT motifs]	0.0	2	1	1	1
135679	1710	myelogenous leukemia evi1 fusion respectively,	[myelogenous leukemia EVI1 fusions respectively,]	0.0	5	1	1	1
135680	1710	several human lymphoid cell line	[several human lymphoid cell lines]	0.0	5	1	1	1
135681	1710	betagamma	[betagamma]	0.0	1	1	1	1
135682	1710	mobilize Ca2+	[mobilizing Ca2+]	0.0	2	1	1	1
135683	1710	induction protein follow differentiation	[induction protein following differentiation]	0.0	4	1	1	1
135684	1710	T cell from blood	[T cells from blood]	0.0	4	1	1	1
135685	1710	contribution in the expression of promoter	[contribution in the expression of promoters]	0.0	6	1	1	1
135686	1710	receptor in -mediated apoptosis	[receptor in -mediated apoptosis]	0.0	4	1	1	1
135687	1710	use a sugar	[using a sugar]	0.0	3	1	1	1
135688	1710	minimum core region	[minimum core regions]	0.0	3	1	1	1
135689	1710	NF-E2/AP1 motif of HS-40	[NF-E2/AP1 motifs of HS-40]	0.0	4	1	1	1
135690	1710	site, meta(d-) adjacent	[site, META(D-) adjacent]	0.0	3	1	1	1
135691	1710	set of dominant pi3-k construct	[set of dominant PI3-K constructs]	0.0	5	1	1	1
135692	1710	drug development	[drug development]	0.0	2	1	1	1
135693	1710	p27(kip1) expression	[p27(KIP1) expression]	0.0	2	1	1	1
135694	1710	Genetic characterization	[Genetic characterization]	0.0	2	1	1	1
135695	1710	GALA.	[GALA.]	0.0	1	1	1	1
135696	1710	encompass this hypersensitive site	[encompassing this hypersensitive site]	0.0	4	1	1	1
135697	1710	pathological finding	[pathological finding]	0.0	2	1	1	1
135698	1710	kb act	[kb act]	0.0	2	1	1	1
135699	1710	adult before overnight dst mg).	[adults before overnight DST mg).]	0.0	5	1	1	1
135700	1710	nfat-binding site	[NFAT-binding sites]	0.0	2	1	1	1
135701	1710	lcr/gamma-globin gene	[LCR/gamma-globin gene]	0.0	2	1	1	1
135702	1710	relationship to receptor	[relationship to receptors]	0.0	3	1	1	1
135703	1710	expose umbilical vein endothelial cell huvec	[Exposing umbilical vein endothelial cells HUVECs]	0.0	6	1	1	1
135704	1710	examine in stem cell	[examining in stem cells]	0.0	4	1	1	1
135705	1710	suggest due,	[suggesting due,]	0.0	2	2	2	1
135706	1710	gt motif,	[GT motif,]	0.0	2	1	1	1
135707	1710	creb complex	[CREB complexes]	0.0	2	1	1	1
135708	1710	df, p=.01)	[df, P=.01)]	0.0	2	2	2	1
135709	1710	FUra chemotherapy	[FUra chemotherapy]	0.0	2	1	1	1
135710	1710	indistinguishable kappa b complex	[indistinguishable kappa B complexes]	0.0	4	1	1	1
135711	1710	growth inhibition of human leukemia cell	[growth inhibition of human leukemia cells]	0.0	6	1	1	1
135712	1710	region responsible for expression	[region responsible for expression]	0.0	4	1	1	1
135713	1710	lytic antigen-specific reactivity at level	[lytic antigen-specific reactivities at levels]	0.0	5	1	1	1
135714	1710	functional characterization of early b-cell factor	[functional characterization of early B-cell factor]	0.0	6	1	1	1
135715	1710	single reading frame of 1458	[single reading frame of 1,458]	0.0	5	1	1	1
135716	1710	non-heat shock gene	[non-heat shock genes]	0.0	3	1	1	1
135717	1710	significant DNA fragmentation	[significant DNA fragmentation]	0.0	3	1	1	1
135718	1710	inhibitory effect on response	[inhibitory effect on responses]	0.0	4	1	1	1
135719	1710	second protein, likely dpii,	[second protein, likely DP-I,]	0.0	4	1	1	1
135720	1710	multiple cis-acting site	[multiple cis-acting sites]	0.0	3	1	1	1
135721	1710	expression a enzyme catalyze the step	[Expression an enzyme catalyzing the step]	0.0	6	1	1	1
135722	1710	(b) of such variants,	[(B) of such variants,]	0.0	4	1	1	1
135723	1710	deficiency virus type hiv-1	[deficiency virus type HIV-1]	0.0	4	1	1	1
135724	1710	ZAP-70 such as activation	[ZAP-70 such as activation]	0.0	4	1	1	1
135725	1710	Society of Hematology	[Society of Hematology]	0.0	3	1	1	1
135726	1710	1alpha,25(OH)2-d5-previtamin D3	[1alpha,25(OH)2-d5-previtamin D3]	0.0	2	1	1	1
135727	1710	mild oxidation with glucose oxidase	[mild oxidation with glucose oxidase]	0.0	5	1	1	1
135728	1710	many genetic change	[many genetic changes]	0.0	3	1	1	1
135729	1710	octamer-dependent enhancer element in b cell	[octamer-dependent enhancer elements in B cells]	0.0	6	1	1	1
135730	1710	recovery of beta-galactosidase	[recovery of beta-galactosidase]	0.0	3	1	1	1
135731	1710	erythroblast express gata-2	[erythroblasts expressing GATA-2]	0.0	3	1	1	1
135732	1710	colony stimulate activity by 135(oh)2d3	[colony stimulating activity by 1,25(OH)2D3]	0.0	5	1	1	1
135733	1710	Karyotypic detection	[Karyotypic detection]	0.0	2	1	1	1
135734	1710	cytokine-encoding gene	[cytokine-encoding genes]	0.0	2	1	1	1
135735	1710	regulation of receptor effect of treatment	[Regulation of receptors effects of treatment]	0.0	6	1	1	1
135736	1710	use hematopoietic progenitor cell	[using hematopoietic progenitor cells]	0.0	4	1	1	1
135737	1710	years) remission	[years) remission]	0.0	2	1	1	1
135738	1710	imply a role in the activation	[implying a role in the activation]	0.0	6	1	1	1
135739	1710	prolonged exercise at 70%	[prolonged exercises at 70%]	0.0	4	1	1	1
135740	1710	nuclear extract from ml-1 cell	[nuclear extracts from ML-1 cells]	0.0	5	1	1	1
135741	1710	murine system	[murine system]	0.0	2	1	1	1
135742	1710	encode the related hepatocyte nuclear factor	[encoding the related hepatocyte nuclear factors]	0.0	6	1	1	1
135743	1710	function among herpesviral protein	[function among herpesviral proteins]	0.0	4	1	1	1
135744	1710	linker substitution mutation	[linker substitution mutations]	0.0	3	1	1	1
135745	1710	multipotential cytokine	[multipotential cytokine]	0.0	2	1	1	1
135746	1710	regulation role of regulatory sites.	[regulation role of regulatory sites.]	0.0	5	1	1	1
135747	1710	determine the fluorescence anisotropy dph	[determining the fluorescence anisotropy DPH]	0.0	5	1	1	1
135748	1710	recur by 5	[recurring by 5]	0.0	3	1	1	1
135749	1710	distinguishable gr abnormalities: 15	[distinguishable GR abnormalities: 15]	0.0	4	1	1	1
135750	1710	(3/5 tuberculosis patient sarcoidosis patient	[(3/5 tuberculosis patients sarcoidosis patients]	0.0	5	1	1	1
135751	1710	aspect of leukocyte function	[aspects of leukocyte function]	0.0	4	1	1	1
135752	1710	evidence for the suppression	[evidence for the suppression]	0.0	4	1	1	1
135753	1710	leukocyte from male	[leukocytes from males]	0.0	3	1	1	1
135754	1710	contrast, expression of negative mutant	[contrast, expression of negative mutants]	0.0	5	1	1	1
135755	1710	normal number of receptor	[normal number of receptors]	0.0	4	1	1	1
135756	1710	cellular c-myb	[cellular c-myb]	0.0	2	1	1	1
135757	1710	partners, include k protein	[partners, including K protein]	0.0	4	1	1	1
135758	1710	mediate diverse immune response	[mediating diverse immune responses]	0.0	4	1	1	1
135759	1710	50% concentration of mp	[50% concentrations of MP]	0.0	4	1	1	1
135760	1710	translocation of hiv-1 transactivator tat	[translocation of HIV-1 transactivator TAT]	0.0	5	1	1	1
135761	1710	action in cell	[action in cells]	0.0	3	1	1	1
135762	1710	response to cues,	[responses to cues,]	0.0	3	1	1	1
135763	1710	co-operativity between RA	[co-operativity between RA]	0.0	3	1	1	1
135764	1710	prevalence of one biomarker	[prevalence of one biomarkers]	0.0	4	1	1	1
135765	1710	er form in tumour	[ER forms in tumours]	0.0	4	1	1	1
135766	1710	three minor protein	[three minor proteins]	0.0	3	1	1	1
135767	1710	expression of cell cycle-related protein	[expression of cell cycle-related proteins]	0.0	5	1	1	1
135768	1710	2 intron	[2 introns]	0.0	2	1	1	1
135769	1710	TCR- CD3	[TCR- CD3]	0.0	2	1	1	1
135770	1710	important event in agonist-induced signalling	[important event in agonist-induced signalling]	0.0	5	1	1	1
135771	1710	utilize the transfection	[utilizing the transfection]	0.0	3	1	1	1
135772	1710	part of the effect of aspirin	[part of the effect of aspirin]	0.0	6	1	1	1
135773	1710	one (2%)	[one (2%)]	0.0	2	1	1	1
135774	1710	involve transcription factor family	[involving transcription factor families]	0.0	4	1	1	1
135775	1710	peripheral blood-derived human monocyte	[peripheral blood-derived human monocytes]	0.0	4	1	1	1
135776	1710	divide immature single cell	[dividing immature single cells]	0.0	4	1	1	1
135777	1710	gene result in reduction	[gene resulting in reduction]	0.0	4	1	1	1
135778	1710	host intracellular event	[host intracellular events]	0.0	3	1	1	1
135779	1710	T cell leukaemia	[T cell leukaemia]	0.0	3	1	1	1
135780	1710	nuclear factor transcriptional activation	[nuclear factor transcriptional activation]	0.0	4	1	1	1
135781	1710	myeloid zinc finger protein mzf-1	[myeloid zinc finger protein MZF-1]	0.0	5	1	1	1
135782	1710	October factor	[Oct factors]	0.0	2	1	1	1
135783	1710	apoptosis in cell induce apoptosis	[apoptosis in cells inducing apoptosis]	0.0	5	1	1	1
135784	1710	suppression result	[suppression resulting]	0.0	2	1	1	1
135785	1710	ifn-gamma-induced class ii	[IFN-gamma-induced class II]	0.0	3	1	1	1
135786	1710	normal level of aldosterone receptor	[normal level of aldosterone receptors]	0.0	5	1	1	1
135787	1710	E2F regulation	[E2F regulation]	0.0	2	1	1	1
135788	1710	distal factor AP-1/Octamer UPS	[distal factor AP-1/Octamer UPS]	0.0	4	1	1	1
135789	1710	target in that vitamin d receptor	[targets in that vitamin D receptors]	0.0	6	1	1	1
135790	1710	great than 70% reduction	[greater than 70% reduction]	0.0	4	1	1	1
135791	1710	increase in ea-d promoter activity	[increases in EA-D promoter activity]	0.0	5	1	1	1
135792	1710	dna-binding assay with wild-type form	[DNA-binding assays with wild-type forms]	0.0	5	1	1	1
135793	1710	regulation of factor-kappa b	[Regulation of factor-kappa B]	0.0	4	1	1	1
135794	1710	new group of dna-binding protein	[new group of DNA-binding proteins]	0.0	5	1	1	1
135795	1710	IFN tyrosine phosphorylation	[IFN tyrosine phosphorylation]	0.0	3	1	1	1
135796	1710	inhibitor of neutrophil apoptosis	[inhibitor of neutrophil apoptosis]	0.0	4	1	1	1
135797	1710	functional disomy of sequence on xp	[functional disomy of sequences on Xp]	0.0	6	1	1	1
135798	1710	IL2 promoter	[IL2 promoters]	0.0	2	1	1	1
135799	1710	assay in yeast	[assays in yeast]	0.0	3	1	1	1
135800	1710	mzf-1 transcriptional function	[MZF-1 transcriptional function]	0.0	3	1	1	1
135801	1710	support specific DNA binding than antagonist	[supporting specific DNA binding than antagonist]	0.0	6	1	1	1
135802	1710	emphasis on: regulation	[emphasis on: regulation]	0.0	3	1	1	1
135803	1710	peak expiratory flow pef after prednisolone	[peak expiratory flow PEF after prednisolone]	0.0	6	1	1	1
135804	1710	Challenge develop strategy	[Challenges developing strategies]	0.0	3	1	1	1
135805	1710	cell surface interaction	[cell surface interactions]	0.0	3	1	1	1
135806	1710	alteration in a 70-base-pair fragment	[alteration in a 70-base-pair fragment]	0.0	5	1	1	1
135807	1710	SH with transplant	[SH with transplant]	0.0	3	1	1	1
135808	1710	promoter-driven reporter gene activity	[promoter-driven reporter gene activity]	0.0	4	1	1	1
135809	1710	only effect	[only effects]	0.0	2	1	1	1
135810	1710	tat function	[Tat function]	0.0	2	1	1	1
135811	1710	effect of tamoxifen	[effects of tamoxifen]	0.0	3	1	1	1
135812	1710	role in tissue-specific expression	[role in tissue-specific expression]	0.0	4	1	1	1
135813	1710	favorable clinical course (p	[favorable clinical course (P]	0.0	4	1	1	1
135814	1710	ifn-alpha/b-stimulated response gene	[IFN-alpha/B-stimulated response genes]	0.0	3	1	1	1
135815	1710	b-lymphocyte transformation	[B-lymphocyte transformation]	0.0	2	1	1	1
135816	1710	pge2 activate effect	[PGE2 activating effect]	0.0	3	1	1	1
135817	1710	blood sample of female	[blood samples of females]	0.0	4	1	1	1
135818	1710	lipopolysaccharide stimulation	[lipopolysaccharide stimulation]	0.0	2	1	1	1
135819	1710	transcriptional activation of gata-1	[transcriptional activation of GATA-1]	0.0	4	1	1	1
135820	1710	hla-dq T cell recognition	[HLA-DQ T cell recognition]	0.0	4	1	1	1
135821	1710	Importantly, nucleoprotein extract show activity	[Importantly, nucleoprotein extracts showing activity]	0.0	5	1	1	1
135822	1710	protein, presumably Sp1	[protein, presumably Sp1]	0.0	3	1	1	1
135823	1710	emergence to combination	[emergence to combinations]	0.0	3	1	1	1
135824	1710	protein species of the rele family	[protein species of the rel family]	0.0	6	1	1	1
135825	1710	production of 3 factor	[production of 3 factor]	0.0	4	1	1	1
135826	1710	circulate neutrophil	[circulating neutrophils]	0.0	2	1	1	1
135827	1710	various ankyrin-rich protein	[various ankyrin-rich proteins]	0.0	3	1	1	1
135828	1710	receptor engagement	[receptor engagement]	0.0	2	1	1	1
135829	1710	6.18 (range, 5.86-6.74) nm,	[6.18 (range, 5.86-6.74) nM,]	0.0	4	1	1	1
135830	1710	epithelium of a percentage	[epithelium of a percentage]	0.0	4	1	1	1
135831	1710	hiv-infected myelomonocytic cell line	[HIV-infected myelomonocytic cell line]	0.0	4	1	1	1
135832	1710	Intratracheal instillation of IL-6 into rat	[Intratracheal instillation of IL-6 into rats]	0.0	6	1	1	1
135833	1710	muscle myosin chain	[muscle myosin chain]	0.0	3	1	1	1
135834	1710	specific responsive element	[specific responsive element]	0.0	3	1	1	1
135835	1710	analysis of the methylation	[Analysis of the methylation]	0.0	4	1	1	1
135836	1710	role in lineage development	[role in lineage development]	0.0	4	1	1	1
135837	1710	Hence,	[Hence,]	0.0	1	1	1	1
135838	1710	treatment for disease	[treatments for diseases]	0.0	3	1	1	1
135839	1710	prevent the degradation block the translocation	[preventing the degradation blocking the translocation]	0.0	6	1	1	1
135840	1710	contain DC	[containing DC]	0.0	2	1	1	1
135841	1710	SJO extract	[SJO extracts]	0.0	2	1	1	1
135842	1710	subclone Wurzburg cell oxidant challenge	[subclone Wurzburg cells oxidant challenge]	0.0	5	1	1	1
135843	1710	Nuclear translocation	[Nuclear translocation]	0.0	2	3	3	1
135844	1710	C196	[C196]	0.0	1	1	1	1
135845	1710	nuclei of the layer	[nuclei of the layer]	0.0	4	1	1	1
135846	1710	basal phosphorylation in the cell	[basal phosphorylation in the cells]	0.0	5	1	1	1
135847	1710	stimulator of the MLR	[stimulators of the MLR]	0.0	4	1	1	1
135848	1710	transactivation domain in cell	[transactivation domains in cells]	0.0	4	1	1	1
135849	1710	acid lipase expression	[acid lipase expression]	0.0	3	1	1	1
135850	1710	Nuclear extract from primary T lymphocyte	[Nuclear extracts from primary T lymphocytes]	0.0	6	1	1	1
135851	1710	as tracer, mnl	[as tracer, MNL]	0.0	3	1	1	1
135852	1710	recombinant chloramphenicol acetyltransferase CAT	[recombinant chloramphenicol acetyltransferase CAT]	0.0	4	1	1	1
135853	1710	such activity.	[such activity.]	0.0	2	1	1	1
135854	1710	value of receptor	[value of receptors]	0.0	3	1	1	1
135855	1710	however, exposure	[However, exposure]	0.0	2	1	1	1
135856	1710	mek1 in vitro	[MEK1 in vitro]	0.0	3	1	1	1
135857	1710	hgata-3 binding site	[hGATA-3 binding sites]	0.0	3	1	1	1
135858	1710	p65 activation of this transcription units.	[p65 activation of these transcription units.]	0.0	6	1	1	1
135859	1710	patient with severe vkc	[patients with severe VKC]	0.0	4	1	1	1
135860	1710	pattern of infiltration	[pattern of infiltration]	0.0	3	1	1	1
135861	1710	thymus-dependent immune response	[thymus-dependent immune responses]	0.0	3	1	1	1
135862	1710	classification of IDC	[classification of IDC]	0.0	3	1	1	1
135863	1710	ROI in this cell	[ROI in these cells]	0.0	4	1	1	1
135864	1710	role in a number	[role in a number]	0.0	4	1	1	1
135865	1710	Addition of a preparation	[Addition of a preparation]	0.0	4	1	1	1
135866	1710	involvement of hb9	[involvement of HB9]	0.0	3	1	1	1
135867	1710	autoimmune disease subject	[autoimmune disease subjects]	0.0	3	1	1	1
135868	1710	distribution (cytoplasmic	[distribution (cytoplasmic]	0.0	2	1	1	1
135869	1710	localization of RelB	[localization of RelB]	0.0	3	1	1	1
135870	1710	long-lasting suppression	[long-lasting suppression]	0.0	2	1	1	1
135871	1710	leader region 5'-utr	[leader region 5'-UTR]	0.0	3	1	1	1
135872	1710	transcriptional enhancer of hiv-1	[transcriptional enhancers of HIV-1]	0.0	4	1	1	1
135873	1710	transcriptional activation in fibroblast	[transcriptional activation in fibroblasts]	0.0	4	1	1	1
135874	1710	evidence for a coupling jak1 beta	[evidence for a coupling JAK1 beta]	0.0	6	1	1	1
135875	1710	mean hTR beta mrna level	[mean hTR beta mRNA levels]	0.0	5	1	1	1
135876	1710	control (40-48%	[control (40-48%]	0.0	2	1	1	1
135877	1710	similar transfection analysis	[Similar transfection analysis]	0.0	3	1	1	1
135878	1710	high-affinity dehydroepiandrosterone binding activity	[high-affinity dehydroepiandrosterone binding activity]	0.0	4	1	1	1
135879	1710	recognize tumor ag	[recognizing tumor Ag]	0.0	3	1	1	1
135880	1710	receptor clone icr-27 tk-3	[receptor clone ICR-27 TK-3]	0.0	4	1	1	1
135881	1710	bp truncation	[bp truncation]	0.0	2	2	2	1
135882	1710	express the region beta chain	[expressing the region beta chain]	0.0	5	1	1	1
135883	1710	colony activity	[colony activity]	0.0	2	1	1	1
135884	1710	tpa -inducible nuclear factor protein	[TPA -inducible nuclear factor protein]	0.0	5	1	1	1
135885	1710	CsA stage	[CsA stage]	0.0	2	1	1	1
135886	1710	degradation in the apoptotic process	[degradation in the apoptotic process]	0.0	5	1	1	1
135887	1710	biological phenomenon	[biological phenomenon]	0.0	2	1	1	1
135888	1710	micrograms/ml of the C. sub.	[micrograms/ml of the C. Sub.]	0.0	5	1	1	1
135889	1710	mediator leukotriene b4	[mediator leukotriene B4]	0.0	3	1	1	1
135890	1710	many patient	[Many patients]	0.0	2	1	1	1
135891	1710	cfu-m	[CFU-M]	0.0	1	1	1	1
135892	1710	resolution of infection	[resolution of infections]	0.0	3	1	1	1
135893	1710	percutaneous angioplasty PTCA	[percutaneous angioplasty PTCA]	0.0	3	1	1	1
135894	1710	increase from steroid-sensitive asthmatic patient	[increase from steroid-sensitive asthmatic patients]	0.0	5	1	1	1
135895	1710	induction during t-cell activation	[Induction during T-cell activation]	0.0	4	1	1	1
135896	1710	alternative stage	[alternative stages]	0.0	2	1	1	1
135897	1710	consistent site	[consistent sites]	0.0	2	1	1	1
135898	1710	nuclear nf-kb binding protein	[nuclear NF-kB binding proteins]	0.0	4	1	1	1
135899	1710	represent stage of maturation, from precursor	[representing stages of maturation, from precursors]	0.0	6	1	1	1
135900	1710	more slowly migrate complex	[more slowly migrating complex]	0.0	4	1	1	1
135901	1710	genetic determinant	[genetic determinants]	0.0	2	1	1	1
135902	1710	effect on cellular gene activation	[Effect on cellular gene activation]	0.0	5	1	1	1
135903	1710	erythroid-specific dnase hypersensitive site-forming element	[erythroid-specific DNase hypersensitive site-forming element]	0.0	5	1	1	1
135904	1710	less extent interleukin-1	[lesser extent interleukin-1]	0.0	3	1	1	1
135905	1710	NF-kappa B1 promoter	[NF-kappa B1 promoter]	0.0	3	1	1	1
135906	1710	slightly on cell	[slightly on cells]	0.0	3	1	1	1
135907	1710	important trace element	[important trace element]	0.0	3	1	1	1
135908	1710	uv-induced tyrosine phosphorylation	[UV-induced tyrosine phosphorylation]	0.0	3	1	1	1
135909	1710	activation of the IL-2 gene	[activation of the IL-2 gene]	0.0	5	1	1	1
135910	1710	platelet-induced activation	[Platelet-induced activation]	0.0	2	1	1	1
135911	1710	monocyte adhesion to monolayer	[monocyte adhesion to monolayers]	0.0	4	1	1	1
135912	1710	sickle erythrocyte with cell	[sickle erythrocytes with cells]	0.0	4	1	1	1
135913	1710	transient expression analysis in cell	[Transient expression analyses in cells]	0.0	5	1	1	1
135914	1710	jurkat carry the taxi gene	[Jurkat carrying the TaxI gene]	0.0	5	1	1	1
135915	1710	chemotactic adhesive property of cell	[chemotactic adhesive properties of cells]	0.0	5	1	1	1
135916	1710	inhibitor of caspase	[inhibitor of caspases]	0.0	3	1	1	1
135917	1710	expression of l-selectin mrna	[expression of L-selectin mRNA]	0.0	4	1	1	1
135918	1710	amino-terminal region amino acid	[amino-terminal region amino acids]	0.0	4	1	1	1
135919	1710	experience in the treatment	[experiences in the treatment]	0.0	4	1	1	1
135920	1710	leukaemia PML gene product	[leukaemia PML gene product]	0.0	4	1	1	1
135921	1710	level in promyelocytic hl60 cell	[levels in promyelocytic HL60 cells]	0.0	5	1	1	1
135922	1710	induce CAT activity costimulation with fibrinogen	[inducing CAT activity costimulation with fibrinogen]	0.0	6	1	1	1
135923	1710	condition include breast cancer	[conditions including breast cancer]	0.0	4	1	1	1
135924	1710	rate of grade of lymphocyte	[rate of grades of lymphocytes]	0.0	5	1	1	1
135925	1710	translocation into the nuclear compartment	[translocation into the nuclear compartment]	0.0	5	1	1	1
135926	1710	TCR-	[TCR-]	0.0	1	1	1	1
135927	1710	T cell subclone	[T cell subclones]	0.0	3	1	1	1
135928	1710	more than additive increase	[more than additive increase]	0.0	4	1	1	1
135929	1710	1-2 peak	[1-2 peaks]	0.0	2	1	1	1
135930	1710	use murine Th1 th2 clone	[using murine Th1 Th2 clones]	0.0	5	1	1	1
135931	1710	Saos	[Saos]	0.0	1	1	1	1
135932	1710	several gene in quiescent cell	[several genes in quiescent cells]	0.0	5	1	1	1
135933	1710	property in cell	[properties in cells]	0.0	3	1	1	1
135934	1710	atf/ creb recognition motif	[ATF/ CREB recognition motifs]	0.0	4	1	1	1
135935	1710	multiple polypeptide range from 85 kda	[multiple polypeptides ranging from 85 kDa]	0.0	6	1	1	1
135936	1710	transcription-polymerase chain reaction (rt-pcr) assay	[transcription-polymerase chain reaction (RT-PCR) assay]	0.0	5	1	1	1
135937	1710	diphosphate(ndp)	[diphosphate(NDP)]	0.0	1	1	1	1
135938	1710	-contain leukocyte protein of kD tightly	[-containing leukocyte protein of kD tightly]	0.0	6	1	1	1
135939	1710	macrophage growth	[macrophage growth]	0.0	2	1	1	1
135940	1710	truncation at amino acid 210	[Truncation at amino acid 210]	0.0	5	1	1	1
135941	1710	pha normal human blood lymphocyte pbl	[PHA normal human blood lymphocytes PBL]	0.0	6	1	1	1
135942	1710	transcription factor in the control	[transcription factor in the control]	0.0	5	1	1	1
135943	1710	change of the differentiate thymocyte	[changes of the differentiating thymocyte]	0.0	5	1	1	1
135944	1710	incubation of APL cell	[Incubation of APL cells]	0.0	4	1	1	1
135945	1710	the/thf alpha thf/thf n: 0.92+/-0.42)	[THE/THF alpha THF/THF N: 0.92+/-0.42)]	0.0	5	1	1	1
135946	1710	t-cell activation by antigen	[T-cell activation by antigen]	0.0	4	1	1	1
135947	1710	function of EBNA2	[function of EBNA2]	0.0	3	1	1	1
135948	1710	atopic disorder	[atopic disorders]	0.0	2	1	1	1
135949	1710	effect on cytokine expression	[effects on cytokine expression]	0.0	4	1	1	1
135950	1710	transcriptional properties unlike oncoprotein	[transcriptional properties, unlike oncoproteins]	0.0	4	1	1	1
135951	1710	involvement in the cell-specific regulation	[Involvement in the cell-specific regulation]	0.0	5	1	1	1
135952	1710	lack Oct-2	[lacking Oct-2]	0.0	2	1	1	1
135953	1710	IL-6 transcription	[IL-6 transcription]	0.0	2	1	1	1
135954	1710	AMP element -dependent activation	[AMP element -dependent activation]	0.0	4	1	1	1
135955	1710	candidate for a member family.	[candidate for a member family.]	0.0	5	1	1	1
135956	1710	cell supernatant	[cell supernatants]	0.0	2	1	1	1
135957	1710	small cis-acting element	[small cis-acting element]	0.0	3	1	1	1
135958	1710	pattern of b-related moiety	[pattern of B-related moieties]	0.0	4	1	1	1
135959	1710	decreased, z-lll-h activity	[decreased, Z-LLL-H activity]	0.0	3	1	1	1
135960	1710	sequence homology between	[sequence homology between]	0.0	3	1	1	1
135961	1710	180 amino acid (aa)	[180 amino acids (aa)]	0.0	4	1	1	1
135962	1710	suppression of nuclear factor kappa b	[Suppression of nuclear factor kappa B]	0.0	6	1	1	1
135963	1710	DNA binding protein such as NF-kB	[DNA binding protein such as NF-kB]	0.0	6	1	1	1
135964	1710	translational machinery during differentiation	[translational machinery during differentiation]	0.0	4	1	1	1
135965	1710	element between 0.2 kb act	[elements between 0.2 kb act]	0.0	5	1	1	1
135966	1710	several methods, include pcr	[several methods, including PCR]	0.0	4	1	1	1
135967	1710	immunophenotype of carcinoma	[Immunophenotype of carcinoma]	0.0	3	1	1	1
135968	1710	high-density pbmc culture (1.5	[high-density PBMC cultures (1.5]	0.0	4	1	1	1
135969	1710	replication in cell	[replication in cells]	0.0	3	1	1	1
135970	1710	three order of magnitude less potent	[three orders of magnitude less potent]	0.0	6	1	1	1
135971	1710	plasticity of receptor regulation	[plasticity of receptor regulation]	0.0	4	1	1	1
135972	1710	background: study	[BACKGROUND: studies]	0.0	2	1	1	1
135973	1710	activator (s) of p38 mapk	[activator (s) of p38 MAPk]	0.0	5	1	1	1
135974	1710	(nfat) family protein	[(NFAT) family proteins]	0.0	3	1	1	1
135975	1710	interaction between two b cell-specific coactivator	[interactions between two B cell-specific coactivators]	0.0	6	1	1	1
135976	1710	process via recognition of glycoconjugate	[processes via recognition of glycoconjugates]	0.0	5	1	1	1
135977	1710	HLA DQ2 heterodimer vary	[HLA DQ2 heterodimers varying]	0.0	4	1	1	1
135978	1710	again, treatment	[again, treatment]	0.0	2	1	1	1
135979	1710	implication for latency.	[implications for latency.]	0.0	3	1	1	1
135980	1710	technique for the rapidak measurement	[technique for the rapid, measurement]	0.0	5	1	1	1
135981	1710	Further, cotransfection analysis	[Further, cotransfection analysis]	0.0	3	1	1	1
135982	1710	receptor for stimulation by superantigen	[receptors for stimulation by superantigens]	0.0	5	1	1	1
135983	1710	lymphocytic aldosterone receptor	[lymphocytic aldosterone receptors]	0.0	3	2	2	1
135984	1710	express MHC class ii	[expressing MHC class II]	0.0	4	1	1	1
135985	1710	244-bp	[244-bp]	0.0	1	1	1	1
135986	1710	lps (endotoxin) through membrane cd14	[LPS (endotoxin) through membrane CD14]	0.0	5	1	1	1
135987	1710	concentration high as m	[concentration high as M]	0.0	4	1	1	1
135988	1710	monocyte infiltration in plaque	[monocyte infiltration in plaques]	0.0	4	1	1	1
135989	1710	class ii molecule for peptide	[class II molecules for peptides]	0.0	5	1	1	1
135990	1710	significance of analysis	[Significance of analysis]	0.0	3	1	1	1
135991	1710	cellular redox status in activity	[cellular redox status in activity]	0.0	5	1	1	1
135992	1710	lack in the patient	[lacking in the patients]	0.0	4	1	1	1
135993	1710	p27(kip1) protein	[p27(KIP1) protein]	0.0	2	1	1	1
135994	1710	erythroleukemic cell	[erythroleukemic cells]	0.0	2	1	1	1
135995	1710	tuberculosis infection	[tuberculosis infection]	0.0	2	1	1	1
135996	1710	major signal event	[major signaling events]	0.0	3	1	1	1
135997	1710	megakaryocytic enhancer	[megakaryocytic enhancers]	0.0	2	1	1	1
135998	1710	molecular mechanism of steroid action	[Molecular mechanisms of steroid action]	0.0	5	1	1	1
135999	1710	interferon gamma-	[interferon gamma-]	0.0	2	1	1	1
136000	1710	CD28 together with PMA	[CD28 together with PMA]	0.0	4	1	1	1
136001	1710	domain variant	[domain variants]	0.0	2	1	1	1
136002	1710	direct significant correlation	[direct significant correlation]	0.0	3	1	1	1
136003	1710	effusion lymphoma	[effusion lymphoma]	0.0	2	1	1	1
136004	1710	nf-kappab subunit include RelA	[NF-kappaB subunits including RelA]	0.0	4	1	1	1
136005	1710	beta-galactoside-binding lectin galectin-3	[beta-galactoside-binding lectin galectin-3]	0.0	3	1	1	1
136006	1710	G75:AES1/2	[G75:AES1/2]	0.0	1	1	1	1
136007	1710	several method for specific down-regulation	[Several methods for specific down-regulation]	0.0	5	1	1	1
136008	1710	protein epitope in	[protein epitopes in]	0.0	3	1	1	1
136009	1710	th cell subsets.	[Th cell subsets.]	0.0	3	1	1	1
136010	1710	CBFA2	[CBFA2]	0.0	1	1	1	1
136011	1710	However, reintroduction	[However, reintroduction]	0.0	2	1	1	1
136012	1710	pHU-14 hybridize	[pHU-14 hybridizes]	0.0	2	1	1	1
136013	1710	cloning of a protein, from cell	[cloning of a protein, from cells]	0.0	6	1	1	1
136014	1710	include the interleukin receptor alpha chain	[including the interleukin receptor alpha chain]	0.0	6	1	1	1
136015	1710	enhancer in cell	[enhancer in cells]	0.0	3	1	1	1
136016	1710	certain (tcr) variable region beta-chain family	[certain (TCR) variable region beta-chain families]	0.0	6	1	1	1
136017	1710	suggest a joint requirement	[suggesting a joint requirement]	0.0	4	1	1	1
136018	1710	nf-at complex to NF-ATp	[NF-AT complexes to NF-ATp]	0.0	4	1	1	1
136019	1710	cell type-specific transcriptional induction	[cell type-specific transcriptional induction]	0.0	4	1	1	1
136020	1710	mouse express PML/RARalpha	[mice expressing PML/RARalpha]	0.0	3	1	1	1
136021	1710	human cd3-cd16+ killer cell	[Human CD3-CD16+ killer cells]	0.0	4	1	1	1
136022	1710	role for tcf-1	[role for TCF-1]	0.0	3	1	1	1
136023	1710	b-laip	[B-LAIp]	0.0	1	1	1	1
136024	1710	two undifferentiated carcinoma	[two undifferentiated carcinomas]	0.0	3	1	1	1
136025	1710	mediator of tcell rescue	[mediator of Tcell rescue]	0.0	4	1	1	1
136026	1710	STAT5- factor	[STAT5- factors]	0.0	2	1	1	1
136027	1710	transcription factor nfat factor	[transcription factor NFAT factor]	0.0	4	1	1	1
136028	1710	patient nine of blood relative	[patient nine of blood relatives]	0.0	5	1	1	1
136029	1710	rag gene expression	[RAG gene expression]	0.0	3	1	1	1
136030	1710	maturation of myeloid leukemia cell	[maturation of myeloid leukemia cells]	0.0	5	1	1	1
136031	1710	assembly of element	[assemblies of elements]	0.0	3	1	1	1
136032	1710	EBNA2 cell extract	[EBNA2 cell extracts]	0.0	3	1	1	1
136033	1710	child aged year	[children aged years]	0.0	3	1	1	1
136034	1710	adult patient	[adult patients]	0.0	2	1	1	1
136035	1710	b lymphoma	[B lymphoma]	0.0	2	1	1	1
136036	1710	transactivator of gene expression.	[transactivators of gene expression.]	0.0	4	1	1	1
136037	1710	site META(D+)	[site META(D+)]	0.0	2	1	1	1
136038	1710	mouse il-2r	[mouse IL-2R]	0.0	2	1	1	1
136039	1710	whole venous blood from donor	[whole venous blood from donors]	0.0	5	1	1	1
136040	1710	adenoviruse in human	[adenoviruses in humans]	0.0	3	1	1	1
136041	1710	receptor on mononuclear leukocyte hml	[receptors on mononuclear leukocytes HML]	0.0	5	1	1	1
136042	1710	complex response involve activation	[complex response involving activation]	0.0	4	1	1	1
136043	1710	previous analysis	[Previous analyses]	0.0	2	1	1	1
136044	1710	mechanism underlie expression	[mechanisms underlying expression]	0.0	3	1	1	1
136045	1710	importance of NF-kappa b	[importance of NF-kappa B]	0.0	4	1	1	1
136046	1710	constitutive redox status	[constitutive redox status]	0.0	3	1	1	1
136047	1710	binding site for ms-2	[binding sites for MS-2]	0.0	4	1	1	1
136048	1710	lack of oxygen	[lacking of oxygen]	0.0	3	1	1	1
136049	1710	increase in thf	[increase in THF]	0.0	3	1	1	1
136050	1710	interaction with the amino-terminal region	[interactions with the amino-terminal region]	0.0	5	1	1	1
136051	1710	NK granule than cell	[NK granules than cells]	0.0	4	1	1	1
136052	1710	include stat5	[including Stat5]	0.0	2	1	1	1
136053	1710	also a potent inducer	[also a potent inducer]	0.0	4	1	1	1
136054	1710	remarkably poor prognosis,	[remarkably poor prognosis,]	0.0	3	1	1	1
136055	1710	decrease in nf-kappa b	[decrease in NF-kappa B]	0.0	4	1	1	1
136056	1710	Close examination	[Closer examination]	0.0	2	1	1	1
136057	1710	mediate this effect	[mediating this effect]	0.0	3	1	1	1
136058	1710	h1-histamine receptor in Jurkat cell	[H1-histamine receptors in Jurkat cells]	0.0	5	1	1	1
136059	1710	significantly high (p<.001) in untreated patient	[significantly higher (P<.001) in untreated patients]	0.0	6	1	1	1
136060	1710	IL-12 signal pathway	[IL-12 signaling pathway]	0.0	3	1	1	1
136061	1710	upstream sequence kb)	[upstream sequence kb)]	0.0	3	1	1	1
136062	1710	nonphlogistic degradation	[nonphlogistic degradation]	0.0	2	1	1	1
136063	1710	number of functional glucocorticoid receptor	[numbers of functional glucocorticoid receptors]	0.0	5	1	1	1
136064	1710	regulate cell-cycle progression	[regulating cell-cycle progression]	0.0	3	1	1	1
136065	1710	express receptor mutant	[expressing receptor mutants]	0.0	3	1	1	1
136066	1710	cyclin D3	[cyclin D3]	0.0	2	2	2	1
136067	1710	accord to results, distinct entities.	[According to results, distinct entities.]	0.0	5	1	1	1
136068	1710	major histocompatibility surface protein	[major histocompatibility surface proteins]	0.0	4	1	1	1
136069	1710	depletion of glutathione	[depletion of glutathione]	0.0	3	1	1	1
136070	1710	STAT1 activation during monocyte role	[STAT1 activation during monocyte role]	0.0	5	1	1	1
136071	1710	c-myc regulator,	[c-myc regulator,]	0.0	2	1	1	1
136072	1710	increase in state level	[increase in state levels]	0.0	4	1	1	1
136073	1710	participant mediate the dysfunction	[participants mediating the dysfunction]	0.0	4	1	1	1
136074	1710	peroxisome receptor-alpha PPARalpha	[Peroxisome receptor-alpha PPARalpha]	0.0	3	1	1	1
136075	1710	distinct groups.	[distinct groups.]	0.0	2	1	1	1
136076	1710	great sensitivity	[greater sensitivity]	0.0	2	1	1	1
136077	1710	p60 protein	[p60 protein]	0.0	2	1	1	1
136078	1710	p21 a VDR target gene	[p21 a VDR target gene]	0.0	5	1	1	1
136079	1710	CD28 surface receptor	[CD28 surface receptor]	0.0	3	1	1	1
136080	1710	ebv burkitt' lymphoma cell	[EBV Burkitt's lymphoma cells]	0.0	4	1	1	1
136081	1710	Differential expression of CTCF during differentiation	[Differential expression of CTCF during differentiation]	0.0	6	1	1	1
136082	1710	microg/mL	[microg/mL]	0.0	1	1	1	1
136083	1710	form a system	[forming a system]	0.0	3	1	1	1
136084	1710	dual action of acid blockade	[Dual action of acid blockade]	0.0	5	1	1	1
136085	1710	eosinophil by cytokine	[eosinophils by cytokines]	0.0	3	1	1	1
136086	1710	nondegradable mutant	[nondegradable mutant]	0.0	2	1	1	1
136087	1710	side of the NPC	[side of the NPC]	0.0	4	1	1	1
136088	1710	TPA translocation	[TPA translocation]	0.0	2	1	1	1
136089	1710	hacat cell after h	[HaCaT cells after h]	0.0	4	1	1	1
136090	1710	human vein endothelial cell CoCl2	[human vein endothelial cells CoCl2]	0.0	5	1	1	1
136091	1710	decoy oligodeoxynucleotide	[decoy oligodeoxynucleotide]	0.0	2	1	1	1
136092	1710	notably dendritic cell	[notably dendritic cells]	0.0	3	1	1	1
136093	1710	nf-kappab activation in level	[NF-kappaB activation in levels]	0.0	4	1	1	1
136094	1710	overexpression il-1 activation	[Overexpression IL-1 activation]	0.0	3	1	1	1
136095	1710	antioxidant pyrrolidine dithiocarbamate	[antioxidant pyrrolidine dithiocarbamate]	0.0	3	3	3	1
136096	1710	variable such as stage	[variables such as stage]	0.0	4	1	1	1
136097	1710	stochastic activation of hematopoietic gene	[stochastic activation of hematopoietic genes]	0.0	5	1	1	1
136098	1710	examination of this system	[examination of this system]	0.0	4	1	1	1
136099	1710	activation, with phytohemagglutinin	[activation, with phytohemagglutinin]	0.0	3	1	1	1
136100	1710	heterotrans-activation	[heterotrans-activation]	0.0	1	1	1	1
136101	1710	/anti-cd3+	[/anti-CD3+]	0.0	1	1	1	1
136102	1710	contain hsp70	[containing hsp70]	0.0	2	1	1	1
136103	1710	/anti-cd28	[/anti-CD28]	0.0	1	1	1	1
136104	1710	proto-oncogene encoding	[proto-oncogene encoding]	0.0	2	1	1	1
136105	1710	traf2 to CD40	[TRAF2 to CD40]	0.0	3	1	1	1
136106	1710	similar functional cooperation	[similar functional cooperation]	0.0	3	1	1	1
136107	1710	lam lipopolysaccharide	[LAM lipopolysaccharide]	0.0	2	1	1	1
136108	1710	interleukin-5 a selective factor	[interleukin-5 a selective factor]	0.0	4	1	1	1
136109	1710	dependence activity on a gata site	[dependence activity on a GATA site]	0.0	6	1	1	1
136110	1710	Chemical cross-linking with 125i-labeled	[Chemical cross-linking with 125I-labeled]	0.0	4	1	1	1
136111	1710	dendritic-like cell	[dendritic-like cells]	0.0	2	1	1	1
136112	1710	>25 F.M	[>25 F.M]	0.0	2	1	1	1
136113	1710	increase in susceptibility	[increase in susceptibility]	0.0	3	1	1	1
136114	1710	other TNF polymorphism	[other TNF polymorphisms]	0.0	3	1	1	1
136115	1710	establish cell line	[establishing cell lines]	0.0	3	1	1	1
136116	1710	cyto-differentiating potential of am580	[cyto-differentiating potential of AM580]	0.0	4	1	1	1
136117	1710	signal essential for lymphokine production	[signals essential for lymphokine production]	0.0	5	1	1	1
136118	1710	analysis for initial diagnosis, counseling,	[analysis for initial diagnosis, counseling,]	0.0	5	1	1	1
136119	1710	however, such difference	[however, such differences]	0.0	3	1	1	1
136120	1710	receptor for interleukin	[receptor for interleukin]	0.0	3	1	1	1
136121	1710	region two element	[region two elements]	0.0	3	1	1	1
136122	1710	binding complex of NF-kappaB subunit	[binding complex of NF-kappaB subunits]	0.0	5	1	1	1
136123	1710	thereby suggest a mechanism	[thereby suggesting a mechanism]	0.0	4	1	1	1
136124	1710	polymorphonuclear neutrophilic granulocyte pmn	[polymorphonuclear neutrophilic granulocytes PMN]	0.0	4	1	1	1
136125	1710	molecule such as endotoxin	[molecules such as endotoxin]	0.0	4	1	1	1
136126	1710	unstable patient	[unstable patients]	0.0	2	1	1	1
136127	1710	protein ligand.	[protein ligand.]	0.0	2	1	1	1
136128	1710	responsiveness of cd4+ t-cell clonal line	[responsiveness of CD4+ T-cell clonal lines]	0.0	6	1	1	1
136129	1710	angle of 90 degree	[angle of 90 degrees]	0.0	4	1	1	1
136130	1710	maximally effective dose	[maximally effective dose]	0.0	3	1	1	1
136131	1710	(+/- sem)	[(+/- SEM)]	0.0	2	1	1	1
136132	1710	pha pbl from adult	[PHA PBL from adults]	0.0	4	1	1	1
136133	1710	f774l	[F774L]	0.0	1	1	1	1
136134	1710	microg/ml	[microg/ml]	0.0	1	1	1	1
136135	1710	intact cooh-terminal domain	[intact COOH-terminal domain]	0.0	3	1	1	1
136136	1710	human interleukin-5 hil-5 stimulation	[human interleukin-5 hIL-5 stimulation]	0.0	4	1	1	1
136137	1710	biopsy from seven patient with vkc	[biopsies from seven patients with VKC]	0.0	6	1	1	1
136138	1710	vcam-1 nac	[VCAM-1 NAC]	0.0	2	1	1	1
136139	1710	bp of flank DNA	[bp of flanking DNA]	0.0	4	1	1	1
136140	1710	cell with nef gene express nef	[cells with nef genes expressing Nefs]	0.0	6	1	1	1
136141	1710	-resistant aids	[-resistant AIDS]	0.0	2	1	1	1
136142	1710	genetic locus	[genetic locus]	0.0	2	1	1	1
136143	1710	peak between h. in response	[peaking between h, in response]	0.0	5	1	1	1
136144	1710	difference in hGR level	[difference in hGR levels]	0.0	4	1	1	1
136145	1710	panel of antisera	[panel of antisera]	0.0	3	1	1	1
136146	1710	evidence in T lymphocyte	[Evidence in T lymphocytes]	0.0	4	1	1	1
136147	1710	key regulator of peripheral blood T	[key regulators of peripheral blood T]	0.0	6	1	1	1
136148	1710	phorbol-13-acetate tpa for 4-24 h	[phorbol-13-acetate TPA for 4-24 h]	0.0	5	1	1	1
136149	1710	majority of disease syndrome	[majority of disease syndromes]	0.0	4	1	1	1
136150	1710	cause of low level	[cause of lower levels]	0.0	4	1	1	1
136151	1710	ATP-dependent s protease	[ATP-dependent S proteases]	0.0	3	1	1	1
136152	1710	autosomal sex reversal map	[autosomal sex reversal map]	0.0	4	1	1	1
136153	1710	extensive immunocytochemical evaluation	[extensive immunocytochemical evaluation]	0.0	3	1	1	1
136154	1710	pkc activation of enf)-kappa b	[PKC activation of (NF)-kappa B]	0.0	5	1	1	1
136155	1710	rather marker for tcr gene	[rather markers for TCR genes]	0.0	5	1	1	1
136156	1710	acute leukemia with promyelocytic feature	[Acute leukemia with promyelocytic features]	0.0	5	1	1	1
136157	1710	express kinase activity as deficient	[expressing kinase activity as deficient]	0.0	5	1	1	1
136158	1710	only level of ifn-gamma	[only levels of IFN-gamma]	0.0	4	1	1	1
136159	1710	induction of cytokine promoter	[induction of cytokine promoters]	0.0	4	1	1	1
136160	1710	patient suffer from cushingd' disease	[patients suffering from Cushing's disease]	0.0	5	1	1	1
136161	1710	NF-kappa b -independent transcriptional activation	[NF-kappa B -independent transcriptional activation]	0.0	5	1	1	1
136162	1710	gata-1 mrna concomitant	[GATA-1 mRNA concomitant]	0.0	3	1	1	1
136163	1710	tnf-treated human vein cell HUVECs	[TNF-treated human vein cells HUVECs]	0.0	5	1	1	1
136164	1710	nmol/L) for the glucocorticoid receptor	[nmol/L) for the glucocorticoid receptors]	0.0	5	1	1	1
136165	1710	detection of stat-1	[Detection of STAT-1]	0.0	3	1	1	1
136166	1710	level of H2O2	[levels of H2O2]	0.0	3	1	1	1
136167	1710	vitamin d treatment	[vitamin D treatment]	0.0	3	1	1	1
136168	1710	dnase I footprinting	[DNase I footprinting]	0.0	3	1	1	1
136169	1710	dose of ionizing radiation gy	[doses of ionizing radiation Gy]	0.0	5	1	1	1
136170	1710	novel B-cell transcription factor	[novel B-cell transcription factor]	0.0	4	1	1	1
136171	1710	T cell-receptor	[T cell-receptor]	0.0	2	1	1	1
136172	1710	analysis of phosphotyrosine protein	[Analysis of phosphotyrosine proteins]	0.0	4	1	1	1
136173	1710	level of estradiol	[level of estradiol]	0.0	3	1	1	1
136174	1710	limbic-hippocampal glucocorticoid type ii receptor	[limbic-hippocampal glucocorticoid type II receptor]	0.0	5	1	1	1
136175	1710	mz twin pair	[MZ twin pair]	0.0	3	1	1	1
136176	1710	use specific probe	[using specific probes]	0.0	3	1	1	1
136177	1710	-cd30l	[-CD30L]	0.0	1	1	1	1
136178	1710	229-bp region	[229-bp region]	0.0	2	1	1	1
136179	1710	cell from control	[cells from controls]	0.0	3	1	1	1
136180	1710	activation in peripheral blood T cell	[Activation in peripheral blood T cells]	0.0	6	1	1	1
136181	1710	b-2 cell with anti-ig	[B-2 cells with anti-Ig]	0.0	4	1	1	1
136182	1710	treatment of leukemia hl-60 cell	[Treatment of leukemia HL-60 cells]	0.0	5	1	1	1
136183	1710	il-1 production	[IL-1 production]	0.0	2	1	1	1
136184	1710	use centromere specific probe	[using centromere specific probes]	0.0	4	1	1	1
136185	1710	growth response-1 gene egr-1	[growth response-1 gene EGR-1]	0.0	4	1	1	1
136186	1710	binding to element	[Binding to element]	0.0	3	1	1	1
136187	1710	difficulty in determination	[difficulty in determination]	0.0	3	1	1	1
136188	1710	empty expression vector	[empty expression vector]	0.0	3	1	1	1
136189	1710	target of reactive oxygen intermediate	[target of reactive oxygen intermediates]	0.0	5	1	1	1
136190	1710	vd gene	[VD genes]	0.0	2	1	1	1
136191	1710	specific stage of differentiation	[specific stage of differentiation]	0.0	4	1	1	1
136192	1710	erythrocyte ghost membrane by glucocorticoid	[erythrocyte ghost membrane by glucocorticoids]	0.0	5	1	1	1
136193	1710	protein binding region	[protein binding regions]	0.0	3	1	1	1
136194	1710	activity of b	[activity of B]	0.0	3	1	1	1
136195	1710	position 10182	[position 10182]	0.0	2	1	1	1
136196	1710	score	[score]	0.0	1	1	1	1
136197	1710	apparently novel, complex	[apparently novel, complex]	0.0	3	1	1	1
136198	1710	splice site	[splice site]	0.0	2	2	2	1
136199	1710	concentration of metabolite	[concentrations of metabolites]	0.0	3	1	1	1
136200	1710	have the amount of precursor	[having the amounts of precursors]	0.0	5	1	1	1
136201	1710	lysis of the normal cell	[lysis of the normal cells]	0.0	5	1	1	1
136202	1710	nfatp in activation	[NFATp in activation]	0.0	3	1	1	1
136203	1710	demonstration of physical interaction	[demonstration of physical interactions]	0.0	4	1	1	1
136204	1710	small messenger response	[smaller messenger response]	0.0	3	1	1	1
136205	1710	involvement of the Jak/Stat pathway	[involvement of the Jak/Stat pathway]	0.0	5	1	1	1
136206	1710	year) in the presence of erythropoietin	[year) in the presence of erythropoietin]	0.0	6	1	1	1
136207	1710	potential index of antioxidant	[potential index of antioxidants]	0.0	4	1	1	1
136208	1710	cooperativity in transfection study	[cooperativity in transfection studies]	0.0	4	1	1	1
136209	1710	stat-1 alpha	[STAT-1 alpha]	0.0	2	1	1	1
136210	1710	two regions, dp1	[Two regions, DP1]	0.0	3	1	1	1
136211	1710	alpha-helice Val10-Gln22	[alpha-helices Val10-Gln22]	0.0	2	1	1	1
136212	1710	sorting,	[sorting,]	0.0	1	1	1	1
136213	1710	four repeat	[four repeats]	0.0	2	1	1	1
136214	1710	downstream interactor (s) limit	[downstream interactor (s) limits]	0.0	4	1	1	1
136215	1710	pattern of nuclear induction	[pattern of nuclear induction]	0.0	4	1	1	1
136216	1710	region of mAb g28-5	[regions of mAb G28-5]	0.0	4	1	1	1
136217	1710	nuclear factor-mu negative regulator	[nuclear factor-mu negative regulator]	0.0	4	1	1	1
136218	1710	dephosphorylation of a member	[dephosphorylation of a member]	0.0	4	1	1	1
136219	1710	tetrahydrocortisone 3.16 mg/24h; n:	[tetrahydrocortisone 3.16 mg/24h; N:]	0.0	4	1	1	1
136220	1710	SCL hemopoietic transcription factor	[SCL hemopoietic transcription factors]	0.0	4	1	1	1
136221	1710	day intervention study	[day intervention study]	0.0	3	1	1	1
136222	1710	corresponding to amino acid	[corresponding to amino acids]	0.0	4	1	1	1
136223	1710	f(ab')2 fragment of CR1	[F(ab')2 fragments of CR1]	0.0	4	1	1	1
136224	1710	induction of rap1	[induction of Rap1]	0.0	3	1	1	1
136225	1710	monocyte signal	[monocyte signal]	0.0	2	1	1	1
136226	1710	expression in a macrophage cell line	[expression in a macrophage cell line]	0.0	6	1	1	1
136227	1710	illustrate a target.	[illustrating a target.]	0.0	3	1	1	1
136228	1710	activator through induction	[activator through induction]	0.0	3	1	1	1
136229	1710	contrast, proviruse carry mutation	[contrast, proviruses carrying mutations]	0.0	4	1	1	1
136230	1710	Duffy Antigen Receptor	[Duffy Antigen Receptor]	0.0	3	1	1	1
136231	1710	consist of the promoter	[consisting of the promoter]	0.0	4	1	1	1
136232	1710	stat-1 by flow cytometry	[STAT-1 by flow cytometry]	0.0	4	1	1	1
136233	1710	store of latent nf-kappa b	[stores of latent NF-kappa B]	0.0	5	1	1	1
136234	1710	transduce membrane-associated signal	[transducing membrane-associated signals]	0.0	3	1	1	1
136235	1710	essential cis-acting element responsible	[essential cis-acting elements responsible]	0.0	4	1	1	1
136236	1710	homologue of Cbl	[homologue of Cbl]	0.0	3	1	1	1
136237	1710	activator of cellular gene	[activator of cellular genes]	0.0	4	1	1	1
136238	1710	etv6- evi1	[ETV6- EVI1]	0.0	2	1	1	1
136239	1710	tumor necrosis factor-alpha tnf-alpha U/ml,	[tumor necrosis factor-alpha TNF-alpha U/ml,]	0.0	5	1	1	1
136240	1710	threshold level of nf-atc	[threshold levels of NF-ATc]	0.0	4	1	1	1
136241	1710	even distribution	[even distribution]	0.0	2	1	1	1
136242	1710	mediate aspect of the process.	[mediating aspects of the process.]	0.0	5	1	1	1
136243	1710	CD3 phosphorylation of HS1	[CD3 phosphorylation of HS1]	0.0	4	1	1	1
136244	1710	simultaneous translocation	[simultaneous translocation]	0.0	2	1	1	1
136245	1710	human leukemia virus type 1	[human leukemia virus type 1]	0.0	5	1	1	1
136246	1710	valine gtt substitution	[valine GTT substitution]	0.0	3	1	1	1
136247	1710	relb translocation	[RelB translocation]	0.0	2	1	1	1
136248	1710	case of angioimmunoblastic t-cell lymphoma	[cases of angioimmunoblastic T-cell lymphoma]	0.0	5	1	1	1
136249	1710	response of blood mononuclear cell	[responses of blood mononuclear cells]	0.0	5	1	1	1
136250	1710	ro(ssa) -positive patient	[Ro(SSA) -positive patients]	0.0	3	1	1	1
136251	1710	BK virus vector	[BK virus vector]	0.0	3	1	1	1
136252	1710	possibly through interference	[possibly through interference]	0.0	3	1	1	1
136253	1710	stress-inducing signal	[stress-inducing signals]	0.0	2	1	1	1
136254	1710	thyromimetic effect	[thyromimetic effect]	0.0	2	1	1	1
136255	1710	unilineage differentiation in culture	[unilineage differentiation in culture]	0.0	4	1	1	1
136256	1710	transcription of inducible oxide synthase	[transcription of inducible oxide synthase]	0.0	5	1	1	1
136257	1710	RNA partition of HTLV-I	[RNA partition of HTLV-I]	0.0	4	1	1	1
136258	1710	24 laboratory employees.	[24 laboratory employees.]	0.0	3	1	1	1
136259	1710	u1 cell with lps	[U1 cells with LPS]	0.0	4	1	1	1
136260	1710	minor transcription start site	[minor transcription start site]	0.0	4	1	1	1
136261	1710	turnover in non-B cell	[turnover in non-B cells]	0.0	4	1	1	1
136262	1710	activation by lps	[activation by LPS]	0.0	3	1	1	1
136263	1710	human leukemia virus type I	[Human leukemia virus type I]	0.0	5	1	1	1
136264	1710	transcription of pathway	[transcription of pathways]	0.0	3	1	1	1
136265	1710	follow alteration	[following alterations]	0.0	2	1	1	1
136266	1710	therapy for the treatment	[therapy for the treatment]	0.0	4	1	1	1
136267	1710	important role in tnf-alpha expression	[important role in TNF-alpha expression]	0.0	5	1	1	1
136268	1710	high salt concentration mM edta	[high salt concentrations mM EDTA]	0.0	5	1	1	1
136269	1710	ie2 transactivation of promoter	[IE2 transactivation of promoters]	0.0	4	1	1	1
136270	1710	characteristic localization	[characteristic localization]	0.0	2	1	1	1
136271	1710	critical regulator of apoptosis	[critical regulator of apoptosis]	0.0	4	1	1	1
136272	1710	size, indicative in NFATx1	[size, indicative in NFATx1]	0.0	4	1	1	1
136273	1710	USA fraction	[USA fraction]	0.0	2	1	1	1
136274	1710	monocytoid u937 cell to lps	[monocytoid U937 cells to LPS]	0.0	5	1	1	1
136275	1710	serum phosphate	[serum phosphate]	0.0	2	1	1	1
136276	1710	hyporesponsiveness accompany aging.	[hyporesponsiveness accompanying aging.]	0.0	3	1	1	1
136277	1710	peroxide sensitive Wurzburg t-cell	[peroxide sensitive Wurzburg T-cells]	0.0	4	1	1	1
136278	1710	ig chain sequence	[Ig chain sequences]	0.0	3	1	1	1
136279	1710	apoptosis T cell	[Apoptosis T cells]	0.0	3	1	1	1
136280	1710	presence of antibody in	[presence of antibodies in]	0.0	4	1	1	1
136281	1710	retinoid response	[retinoid response]	0.0	2	1	1	1
136282	1710	study use human cell	[studies using human cells]	0.0	4	1	1	1
136283	1710	deoxyribonuclease dnase	[deoxyribonuclease DNase]	0.0	2	1	1	1
136284	1710	distribution of fitc- lps	[distribution of FITC- LPS]	0.0	4	1	1	1
136285	1710	il-4 -signal	[IL-4 -signaling]	0.0	2	1	1	1
136286	1710	tendency	[tendency]	0.0	1	1	1	1
136287	1710	main transcription-activation element with characteristic	[main transcription-activation element with characteristics]	0.0	5	1	1	1
136288	1710	average number of GCR	[average number of GCR]	0.0	4	1	1	1
136289	1710	naive cd4+ cell	[naive CD4+ cells]	0.0	3	1	1	1
136290	1710	dominant negative version	[dominant negative version]	0.0	3	1	1	1
136291	1710	affinity, high capacity) binding site	[affinity, high capacity) binding sites]	0.0	5	1	1	1
136292	1710	progesterone antibody mPRI	[progesterone antibody mPRI]	0.0	3	1	1	1
136293	1710	discrepancy,	[discrepancy,]	0.0	1	1	1	1
136294	1710	inhibition of cell growth	[inhibition of cell growth]	0.0	4	1	1	1
136295	1710	sites/cell), kd value for dexamethasone (6.7+/-0.5	[sites/cell), Kd values for dexamethasone (6.7+/-0.5]	0.0	6	1	1	1
136296	1710	value for vascular disease	[value for vascular disease]	0.0	4	1	1	1
136297	1710	event mediate this effect	[events mediating this effect]	0.0	4	1	1	1
136298	1710	include interferon-gamma	[including interferon-gamma]	0.0	2	1	1	1
136299	1710	three day establish high-density pbmc culture	[Three days establishing high-density PBMC cultures]	0.0	6	1	1	1
136300	1710	result present	[result present]	0.0	2	1	1	1
136301	1710	sequence CCGAAACTGAAAAGG	[sequence CCGAAACTGAAAAGG]	0.0	2	1	1	1
136302	1710	(3) division	[(3) divisions]	0.0	2	1	1	1
136303	1710	three infectious disease	[three infectious diseases]	0.0	3	1	1	1
136304	1710	promyeloid leukemia cell line	[promyeloid leukemia cell line]	0.0	4	1	1	1
136305	1710	PML locus	[PML locus]	0.0	2	1	1	1
136306	1710	important source of production	[important source of production]	0.0	4	1	1	1
136307	1710	hematopoietic progenitor cell HPC	[hematopoietic progenitor cells HPC]	0.0	4	1	1	1
136308	1710	decrease of p65/	[decrease of p65/]	0.0	3	1	1	1
136309	1710	total pkc enzymatic activity	[Total PKC enzymatic activity]	0.0	4	1	1	1
136310	1710	transactivate function of the protein	[transactivating function of the proteins]	0.0	5	1	1	1
136311	1710	seven untreated asthmatic patient	[seven untreated asthmatic patients]	0.0	4	1	1	1
136312	1710	cd8+cd18bright T	[CD8+CD18bright T]	0.0	2	1	1	1
136313	1710	leukemia m2-type	[leukemia M2-type]	0.0	2	1	1	1
136314	1710	effect on the lipopolysaccharide induction	[effect on the lipopolysaccharide induction]	0.0	5	1	1	1
136315	1710	typical receptor characteristics.	[typical receptor characteristics.]	0.0	3	1	1	1
136316	1710	bacterial product such as lipopolysaccharide	[bacterial products such as lipopolysaccharide]	0.0	5	1	1	1
136317	1710	hamster ovary (cho)-k1 cell	[hamster ovary (CHO)-K1 cells]	0.0	4	1	1	1
136318	1710	change in host cell gene expression	[changes in host cell gene expression]	0.0	6	1	1	1
136319	1710	apoptosis role	[apoptosis role]	0.0	2	1	1	1
136320	1710	marker of response,	[markers of response,]	0.0	3	1	1	1
136321	1710	description of a regulatory region	[description of a regulatory region]	0.0	5	1	1	1
136322	1710	helix-loop-helix family	[helix-loop-helix family]	0.0	2	1	1	1
136323	1710	e lambda	[E lambda]	0.0	2	1	1	1
136324	1710	high level of protease	[high levels of proteases]	0.0	4	1	1	1
136325	1710	eosinophil in the syndrome	[eosinophils in the syndrome]	0.0	4	1	1	1
136326	1710	significant effect on the development	[significant effects on the development]	0.0	5	1	1	1
136327	1710	NF-kappaB function as a factor	[NF-kappaB functions as a factor]	0.0	5	1	1	1
136328	1710	site of injury	[sites of injury]	0.0	3	2	2	1
136329	1710	glucocorticoid receptor concentration in leukocyte	[glucocorticoid receptor concentration in leukocytes]	0.0	5	1	1	1
136330	1710	buffer	[buffer]	0.0	1	1	1	1
136331	1710	one variable	[one variable]	0.0	2	1	1	1
136332	1710	(mean of two independent assays),	[(mean of two independent assays),]	0.0	5	1	1	1
136333	1710	DNasel hypersensitive site	[DNasel hypersensitive sites]	0.0	3	1	1	1
136334	1710	0.75 yeast colonies,	[0.75 yeast colonies,]	0.0	3	1	1	1
136335	1710	core ets	[core ETS]	0.0	2	1	1	1
136336	1710	glucocorticoid membrane perturbation	[glucocorticoid membrane perturbation]	0.0	3	1	1	1
136337	1710	include J2	[including J2]	0.0	2	1	1	1
136338	1710	further 16-hour incubation	[further 16-hour incubation]	0.0	3	1	1	1
136339	1710	increase in binding	[increase in binding]	0.0	3	1	1	1
136340	1710	form of binding partner, Max	[form of binding partner, Max]	0.0	5	1	1	1
136341	1710	mutation of the binding site	[mutation of the binding sites]	0.0	5	1	1	1
136342	1710	domain of IL-4Ralpha	[domain of IL-4Ralpha]	0.0	3	1	1	1
136343	1710	ceramide release in fas-mediated apoptosis	[ceramide release in Fas-mediated apoptosis]	0.0	5	1	1	1
136344	1710	26 cell carcinoma	[26 cell carcinomas]	0.0	3	1	1	1
136345	1710	more mature population	[more mature populations]	0.0	3	1	1	1
136346	1710	family of activate proteins,	[family of activating proteins,]	0.0	4	1	1	1
136347	1710	addition, activation of c-raf	[addition, activation of c-raf]	0.0	4	1	1	1
136348	1710	measurement of CIF	[measurement of CIF]	0.0	3	1	1	1
136349	1710	replication-incompetent molecular clone	[replication-incompetent molecular clone]	0.0	3	1	1	1
136350	1710	immunity against many infectious pathogen	[immunity against many infectious pathogens]	0.0	5	1	1	1
136351	1710	(10-fold expansion) occur between day	[(10-fold expansion) occurring between day]	0.0	5	1	1	1
136352	1710	fragment lps E-selectin expression	[fragment LPS E-selectin expression]	0.0	4	1	1	1
136353	1710	also effect on electrolyte movement	[also effects on electrolyte movements]	0.0	5	2	2	1
136354	1710	nf-at/ element	[NF-AT/ element]	0.0	2	1	1	1
136355	1710	cd4+cd45r0+ cell	[CD4+CD45R0+ cells]	0.0	2	1	1	1
136356	1710	binding elf-1	[binding Elf-1]	0.0	2	1	1	1
136357	1710	sis-inducible	[sis-inducible]	0.0	1	1	1	1
136358	1710	low density lipoprotein response	[low density lipoprotein responses]	0.0	4	1	1	1
136359	1710	Indeed, transfection of HLA-DRA	[Indeed, transfection of HLA-DRA]	0.0	4	1	1	1
136360	1710	patient with eosinophilias	[patients with eosinophilias]	0.0	3	1	1	1
136361	1710	binding experiments,	[Binding experiments,]	0.0	2	1	1	1
136362	1710	principal mediator	[principal mediator]	0.0	2	1	1	1
136363	1710	pretreatment with 135-(oh)2d3	[pretreatment with 1,25-(OH)2D3]	0.0	3	1	1	1
136364	1710	factor such as c-Jun	[factors such as c-Jun]	0.0	4	1	1	1
136365	1710	specific antiserum	[specific antiserum]	0.0	2	1	1	1
136366	1710	unique biological function among protein	[unique biological function among proteins]	0.0	5	1	1	1
136367	1710	ATL patient (mean	[ATL patients (mean]	0.0	3	1	1	1
136368	1710	sixth month	[sixth month]	0.0	2	1	1	1
136369	1710	receptor gene activation	[receptor gene activation]	0.0	3	1	1	1
136370	1710	susceptibility to certain infections.	[susceptibility to certain infections.]	0.0	4	1	1	1
136371	1710	oxidant production	[oxidant production]	0.0	2	1	1	1
136372	1710	definition of critical region	[definition of critical regions]	0.0	4	1	1	1
136373	1710	very little activity	[very little activity]	0.0	3	1	1	1
136374	1710	substrate in intact cells.	[substrates in intact cells.]	0.0	4	1	1	1
136375	1710	cell functions.	[cell functions.]	0.0	2	1	1	1
136376	1710	htr beta mrna level	[hTR beta mRNA levels]	0.0	4	2	2	1
136377	1710	(nk) T cell subtractive library	[(NK) T cell subtractive library]	0.0	5	1	1	1
136378	1710	androgen-binding domain	[androgen-binding domains]	0.0	2	1	1	1
136379	1710	gene, mtcp1	[gene, MTCP1]	0.0	2	1	1	1
136380	1710	datum on regulation	[data on regulation]	0.0	3	1	1	1
136381	1710	convergence of signal from T cell	[Convergence of signals from T cells]	0.0	6	1	1	1
136382	1710	exhibit a ap-1 specificity	[exhibiting an AP-1 specificity]	0.0	4	1	1	1
136383	1710	tnf-alpha in undifferentiated u937 cell	[TNF-alpha in undifferentiated U937 cells]	0.0	5	1	1	1
136384	1710	wild-type kappab site	[wild-type kappaB sites]	0.0	3	1	1	1
136385	1710	regulation of other promoter	[regulation of other promoters]	0.0	4	1	1	1
136386	1710	TNFRp55-deficient mouse	[TNFRp55-deficient mice]	0.0	2	1	1	1
136387	1710	transactivation of this enhancer.	[transactivation of this enhancer.]	0.0	4	1	1	1
136388	1710	protein pml/rar	[protein pml/RAR]	0.0	2	1	1	1
136389	1710	inflammatory fluid	[inflammatory fluids]	0.0	2	1	1	1
136390	1710	mobility-shift assay EMSA	[mobility-shift assays EMSA]	0.0	3	1	1	1
136391	1710	apoptosis effector protein	[apoptosis effector proteins]	0.0	3	1	1	1
136392	1710	egr-1 transgene	[Egr-1 transgene]	0.0	2	1	1	1
136393	1710	rBPI21	[rBPI21]	0.0	1	1	1	1
136394	1710	two nuclear rna gene	[two nuclear RNA genes]	0.0	4	1	1	1
136395	1710	various chronic disease (12:	[various chronic diseases (12:]	0.0	4	1	1	1
136396	1710	other gene include interferon factor	[other genes including interferon factor]	0.0	5	1	1	1
136397	1710	domain lack obvious sequence similarity	[domain lacking obvious sequence similarity]	0.0	5	1	1	1
136398	1710	tnf-alpha activation of replication	[TNF-alpha activation of replication]	0.0	4	1	1	1
136399	1710	measure the contribution to the release	[measuring the contribution to the release]	0.0	6	1	1	1
136400	1710	mononuclear cell reaction histologic grade	[mononuclear cell reaction histologic grade]	0.0	5	1	1	1
136401	1710	vice	[vice]	0.0	1	1	1	1
136402	1710	healthy untrained male volunteer	[healthy untrained male volunteers]	0.0	4	1	1	1
136403	1710	control E2F activity during the transition	[controlling E2F activity during the transition]	0.0	6	1	1	1
136404	1710	dihydrolipoic	[dihydrolipoic]	0.0	1	1	1	1
136405	1710	high 12-lipoxygenase activity than cell	[higher 12-lipoxygenase activity than cells]	0.0	5	1	1	1
136406	1710	depressed patient with bipolar disorder	[depressed patients with bipolar disorder]	0.0	5	1	1	1
136407	1710	energy study	[energy studies]	0.0	2	1	1	1
136408	1710	ifn-gamma responsive element	[IFN-gamma responsive element]	0.0	3	1	1	1
136409	1710	consistent abnormality	[consistent abnormalities]	0.0	2	1	1	1
136410	1710	lipopolysaccharide effect	[lipopolysaccharide effects]	0.0	2	1	1	1
136411	1710	correlation between body temperature	[correlation between body temperature]	0.0	4	1	1	1
136412	1710	ultra-violet irradiation of keratinocyte	[UV irradiation of keratinocytes]	0.0	4	1	1	1
136413	1710	nonpeptidyl molecule 247464 capable	[nonpeptidyl molecule 247464 capable]	0.0	4	1	1	1
136414	1710	immune response specific	[immune response specific]	0.0	3	1	1	1
136415	1710	Half-maximal induction	[Half-maximal induction]	0.0	2	1	1	1
136416	1710	organisation	[organisation]	0.0	1	1	1	1
136417	1710	multiple consensus binding site	[multiple consensus binding sites]	0.0	4	1	1	1
136418	1710	inhibitory effect together	[inhibitory effects together]	0.0	3	1	1	1
136419	1710	dust	[dust]	0.0	1	2	2	1
136420	1710	adjuvant tamoxifen treatment	[adjuvant tamoxifen treatment]	0.0	3	1	1	1
136421	1710	regulator of several gene	[regulator of several genes]	0.0	4	1	1	1
136422	1710	immunoblastic lymphoma plasmacytoid	[immunoblastic lymphoma plasmacytoid]	0.0	3	1	1	1
136423	1710	analysis on b-cll cell	[analysis on B-CLL cells]	0.0	4	1	1	1
136424	1710	pair mrna	[pair mRNA]	0.0	2	1	1	1
136425	1710	growth inhibition of leukemia cell	[growth inhibition of leukemia cells]	0.0	5	1	1	1
136426	1710	-417 region	[-417 region]	0.0	2	1	1	1
136427	1710	indicator of gene regulation	[indicators of gene regulation]	0.0	4	1	1	1
136428	1710	mood	[mood]	0.0	1	1	1	1
136429	1710	virus-exposed cell from donor	[virus-exposed cells from donors]	0.0	4	1	1	1
136430	1710	T cell in	[T cells in]	0.0	3	1	1	1
136431	1710	endothelial cell-monocyte	[endothelial cell-monocyte]	0.0	2	1	1	1
136432	1710	bovine pulmonary artery	[bovine pulmonary artery]	0.0	3	1	1	1
136433	1710	patient with failure CRF	[patients with failure CRF]	0.0	4	1	1	1
136434	1710	stimulation of cell with interleukin-1beta il-1beta	[Stimulation of cells with interleukin-1beta IL-1beta]	0.0	6	1	1	1
136435	1710	receptor VDR	[receptor VDR]	0.0	2	1	1	1
136436	1710	transfection experiment with CRE -cat plasmide	[transfection experiments with CRE -CAT plasmide]	0.0	6	1	1	1
136437	1710	evidence for disomy of Xp.	[evidence for disomy of Xp.]	0.0	5	1	1	1
136438	1710	rapidak sensitive measurement	[rapid, sensitive measurement]	0.0	3	1	1	1
136439	1710	monoblastoid cell undergo apoptosis	[monoblastoid cells undergoing apoptosis]	0.0	4	1	1	1
136440	1710	cell line absent	[cell lines absent]	0.0	3	1	1	1
136441	1710	strike increase within h	[striking increase within h]	0.0	4	1	1	1
136442	1710	T transcription factor binding	[T transcription factor binding]	0.0	4	1	1	1
136443	1710	total population	[total populations]	0.0	2	1	1	1
136444	1710	undifferentiated DC	[undifferentiated DC]	0.0	2	1	1	1
136445	1710	impaired nf-kappab activation	[impaired NF-kappaB activation]	0.0	3	1	1	1
136446	1710	ligand RANKL	[ligand RANKL]	0.0	2	1	1	1
136447	1710	express the hpv type	[expressing the HPV type]	0.0	4	1	1	1
136448	1710	intracellular level of camp	[intracellular levels of cAMP]	0.0	4	1	1	1
136449	1710	physiological coculture assay system	[physiological coculture assay system]	0.0	4	1	1	1
136450	1710	human leukemic cell clone	[human leukemic cell clone]	0.0	4	1	1	1
136451	1710	patient individual	[patient individuals]	0.0	2	1	1	1
136452	1710	factor-activated T	[factor-activated T]	0.0	2	1	1	1
136453	1710	candidate gene nuclear factor beta	[candidate genes nuclear factor beta]	0.0	5	1	1	1
136454	1710	four genes, suggest	[four genes, suggesting]	0.0	3	1	1	1
136455	1710	factor bind to the PRE-I site	[factors binding to the PRE-I site]	0.0	6	1	1	1
136456	1710	plasma membrane from mononuclear leukocyte	[plasma membranes from mononuclear leukocytes]	0.0	5	1	1	1
136457	1710	drug resistance inhibition	[drug resistance inhibition]	0.0	3	1	1	1
136458	1710	moreover, follow IL-2 stimulation	[Moreover, following IL-2 stimulation]	0.0	4	1	1	1
136459	1710	two variant	[Two variants]	0.0	2	1	1	1
136460	1710	feature of hla-dq evolution occur	[feature of HLA-DQ evolution occurring]	0.0	5	1	1	1
136461	1710	diffuse lymphoma with a large-cell component	[diffuse lymphomas with a large-cell component]	0.0	6	1	1	1
136462	1710	1988 several family	[1988, several families]	0.0	3	1	1	1
136463	1710	-cd40l	[-CD40L]	0.0	1	1	1	1
136464	1710	erythroblastic cell line	[erythroblastic cell lines]	0.0	3	1	1	1
136465	1710	regulation during the immune response	[regulation during the immune response]	0.0	5	1	1	1
136466	1710	biochemical basis	[biochemical basis]	0.0	2	1	1	1
136467	1710	proteolysis-resistant factor-kappaB inhibitor	[proteolysis-resistant factor-kappaB inhibitor]	0.0	3	1	1	1
136468	1710	deletion between a locus	[deletion between a locus]	0.0	4	1	1	1
136469	1710	virus plasmid	[virus plasmid]	0.0	2	1	1	1
136470	1710	putative retrovirus	[putative retrovirus]	0.0	2	1	1	1
136471	1710	cell mass,	[cell mass,]	0.0	2	1	1	1
136472	1710	treatment of hiv-tf1	[treatment of HIV-TF1]	0.0	3	1	1	1
136473	1710	Stat3EE	[Stat3EE]	0.0	1	1	1	1
136474	1710	inactivate substitution in the counterpart	[inactivating substitutions in the counterpart]	0.0	5	1	1	1
136475	1710	distinct lymphoid-specific protein	[distinct lymphoid-specific protein]	0.0	3	1	1	1
136476	1710	NK granule than parental cell	[NK granules than parental cells]	0.0	5	1	1	1
136477	1710	blood T lymphoblast	[blood T lymphoblasts]	0.0	3	2	2	1
136478	1710	however, restimulation of th2 line	[However, restimulation of Th2 lines]	0.0	5	1	1	1
136479	1710	Potent inhibition	[Potent inhibition]	0.0	2	1	1	1
136480	1710	b-cell epitope x protein	[B-cell epitopes X protein]	0.0	4	1	1	1
136481	1710	result tissue damage in response	[resulting tissue damage in response]	0.0	5	1	1	1
136482	1710	MHC class immunodeficiency erratum	[MHC class immunodeficiency erratum]	0.0	4	1	1	1
136483	1710	ebv program	[EBV program]	0.0	2	1	1	1
136484	1710	define the characteristic	[defining the characteristics]	0.0	3	1	1	1
136485	1710	dissociation constant (kd)	[dissociation constant (KD)]	0.0	3	1	1	1
136486	1710	deleterious mechanism	[deleterious mechanism]	0.0	2	1	1	1
136487	1710	binding protein (85 kD	[binding proteins (85 kD]	0.0	4	1	1	1
136488	1710	major regulatory element	[major regulatory element]	0.0	3	1	1	1
136489	1710	gut response	[gut response]	0.0	2	1	1	1
136490	1710	increase expression along the pathway	[increasing expression along the pathway]	0.0	5	1	1	1
136491	1710	patient with low receptor affinity	[patients with low receptor affinity]	0.0	5	1	1	1
136492	1710	cis-acting elements,	[cis-acting elements,]	0.0	2	1	1	1
136493	1710	contain a gata-binding site	[containing a GATA-binding site]	0.0	4	1	1	1
136494	1710	production of interferon-gamma	[production of interferon-gamma]	0.0	3	1	1	1
136495	1710	anti-human ec activity	[anti-human EC activity]	0.0	3	1	1	1
136496	1710	1.54 nm	[1.54 nM]	0.0	2	1	1	1
136497	1710	encode a dna-binding protein bind protein	[encoding a DNA-binding protein binding protein]	0.0	6	1	1	1
136498	1710	two p35	[two p35]	0.0	2	1	1	1
136499	1710	Sci.	[Sci.]	0.0	1	1	1	1
136500	1710	clinical importance for genetic counseling.	[clinical importance for genetic counseling.]	0.0	5	1	1	1
136501	1710	suggest a link	[suggesting a link]	0.0	3	2	2	1
136502	1710	Oct-2 induction	[Oct-2 induction]	0.0	2	1	1	1
136503	1710	consensus element consistent	[consensus elements consistent]	0.0	3	1	1	1
136504	1710	bind reaction	[binding reaction]	0.0	2	1	1	1
136505	1710	atg of the rex gene	[ATG of the rex gene]	0.0	5	1	1	1
136506	1710	Fabry disease a disorder	[Fabry disease an disorder]	0.0	4	1	1	1
136507	1710	Comparison of group	[Comparison of group]	0.0	3	1	1	1
136508	1710	develop new therapeutic strategy	[developing new therapeutic strategies]	0.0	4	1	1	1
136509	1710	fc gamma endocytosis	[Fc gamma endocytosis]	0.0	3	1	1	1
136510	1710	bind after ltb4 stimulation	[binding after LTB4 stimulation]	0.0	4	1	1	1
136511	1710	variable serum calcitriol	[variables serum calcitriol]	0.0	3	1	1	1
136512	1710	contrast, at a stage.	[contrast, at a stage.]	0.0	4	1	1	1
136513	1710	activation in the extract of HUVEC	[activation in the extracts of HUVEC]	0.0	6	1	1	1
136514	1710	regulation of leukemia virus transcription	[regulation of leukemia virus transcription]	0.0	5	1	1	1
136515	1710	expression on malignant melanoma MMs	[expression on malignant melanomas MMs]	0.0	5	1	1	1
136516	1710	PEBP2 alpha a	[PEBP2 alpha A]	0.0	3	1	1	1
136517	1710	macrophage growth factor	[macrophage growth factor]	0.0	3	1	1	1
136518	1710	thirteen preterm of the group	[Thirteen preterms of the group]	0.0	5	1	1	1
136519	1710	active creb protein	[active CREB protein]	0.0	3	1	1	1
136520	1710	none of the three protein lef-1	[none of the three proteins LEF-1]	0.0	6	1	1	1
136521	1710	study responsiveness to two immediate-early transactivator	[studying responsiveness to two immediate-early transactivators]	0.0	6	1	1	1
136522	1710	profound state of latency	[profound state of latency]	0.0	4	1	1	1
136523	1710	Functional synergy	[Functional synergy]	0.0	2	1	1	1
136524	1710	express AML1/ETO	[expressing AML1/ETO]	0.0	2	1	1	1
136525	1710	A-CRF with mild-moderate insufficiency M-CRF	[A-CRF with mild-moderate insufficiency M-CRF]	0.0	5	1	1	1
136526	1710	action of IL-10R	[actions of IL-10R]	0.0	3	1	1	1
136527	1710	mouse t-lymphoma	[mouse T-lymphoma]	0.0	2	1	1	1
136528	1710	phenotypic conversion	[phenotypic conversion]	0.0	2	1	1	1
136529	1710	alpha,25-dihydroxyvitamin D3 gene regulation	[alpha,25-dihydroxyvitamin D3 gene regulation]	0.0	4	1	1	1
136530	1710	two crossreact protein in normal lymphocyte	[two crossreacting proteins in normal lymphocytes]	0.0	6	1	1	1
136531	1710	m 1 alphav5 dihydroxyvitamin D3	[M 1 alpha,25 dihydroxyvitamin D3]	0.0	5	1	1	1
136532	1710	hematopoietic growth factor requirement	[hematopoietic growth factor requirement]	0.0	4	1	1	1
136533	1710	requirement of thp-1 cell	[Requirement of THP-1 cells]	0.0	4	1	1	1
136534	1710	complex class chain promoter	[complex class chain promoter]	0.0	4	1	1	1
136535	1710	single-stranded polymorphism SSCP	[single-stranded polymorphism SSCP]	0.0	3	1	1	1
136536	1710	nuclear factor kB NF-kB element	[nuclear factor kB NF-kB elements]	0.0	5	1	1	1
136537	1710	homology between this gene	[homologies between these genes]	0.0	4	1	1	1
136538	1710	various disorder in woman	[various disorders in women]	0.0	4	1	1	1
136539	1710	major risk factor for disease	[major risk factor for disease]	0.0	5	1	1	1
136540	1710	b alpha mouse	[B alpha mice]	0.0	3	1	1	1
136541	1710	fas ligand induction	[Fas ligand induction]	0.0	3	1	1	1
136542	1710	most important IL-2 cis-regulatory element	[most important IL-2 cis-regulatory elements]	0.0	5	1	1	1
136543	1710	treatment, week	[treatment, week]	0.0	2	1	1	1
136544	1710	heat shock protein complex	[heat shock protein complexes]	0.0	4	1	1	1
136545	1710	only b heteromer	[only B heteromers]	0.0	3	1	1	1
136546	1710	other marker of poor prognosis,	[other markers of poor prognosis,]	0.0	5	1	1	1
136547	1710	cell-specific protein	[cell-specific protein]	0.0	2	1	1	1
136548	1710	function from proliferation to apoptosis,	[functions from proliferation to apoptosis,]	0.0	5	1	1	1
136549	1710	differential cDNA cloning strategy	[differential cDNA cloning strategies]	0.0	4	1	1	1
136550	1710	favor	[favor]	0.0	1	1	1	1
136551	1710	protein in human eosinophil	[proteins in human eosinophils]	0.0	4	1	1	1
136552	1710	total of chronic, severe, patient	[total of chronic, severe, patients]	0.0	5	1	1	1
136553	1710	ebna2 transactivation	[EBNA2 transactivation]	0.0	2	1	1	1
136554	1710	class HeLa cell	[class HeLa cells]	0.0	3	1	1	1
136555	1710	activation of ifn-alpha/b-stimulated response gene	[activation of IFN-alpha/B-stimulated response genes]	0.0	5	1	1	1
136556	1710	8% cell at day 6; g-csf	[8% cells at day 6; G-CSF]	0.0	6	1	1	1
136557	1710	non-T immune cell	[non-T immune cells]	0.0	3	1	1	1
136558	1710	parallel activation transactivate function	[parallel activation transactivating functions]	0.0	4	1	1	1
136559	1710	vein endothelial cell huvec	[vein endothelial cells HUVECs]	0.0	4	2	2	1
136560	1710	process of antigen-driven hypermutation	[process of antigen-driven hypermutation]	0.0	4	1	1	1
136561	1710	effect on hiv production	[effects on HIV production]	0.0	4	1	1	1
136562	1710	usually result	[usually resulting]	0.0	2	1	1	1
136563	1710	retinoidal activity (agonist	[retinoidal activity (agonist]	0.0	3	1	1	1
136564	1710	biopsy use a radioassay	[biopsies using a radioassay]	0.0	4	1	1	1
136565	1710	key regulator of transcription	[key regulator of transcription]	0.0	4	1	1	1
136566	1710	stat6-dna	[STAT6-DNA]	0.0	1	1	1	1
136567	1710	relatively high, pharmacological concentration of RA	[relatively high, pharmacological concentrations of RA]	0.0	6	1	1	1
136568	1710	hela extract	[HeLa extract]	0.0	2	1	1	1
136569	1710	transglutaminase type	[transglutaminase type]	0.0	2	1	1	1
136570	1710	SKW cell	[SKW cells]	0.0	2	1	1	1
136571	1710	therefore as a determinant of homeostasis	[therefore as a determinant of homeostasis]	0.0	6	1	1	1
136572	1710	similar box	[similar boxes]	0.0	2	1	1	1
136573	1710	activation of a signal transducer	[activation of an signal transducer]	0.0	5	1	1	1
136574	1710	establish the effectiveness of ciita	[establishing the effectiveness of CIITA]	0.0	5	1	1	1
136575	1710	gene expression in resting T cell	[gene expression in resting T cells]	0.0	6	1	1	1
136576	1710	granulocytic lineage retinoic acid	[granulocytic lineage retinoic acid]	0.0	4	1	1	1
136577	1710	other EBV-associated, hla-b8-restricted latent epitope	[other EBV-associated, HLA-B8-restricted latent epitopes]	0.0	5	1	1	1
136578	1710	reporter gene transcription in erythroblast	[reporter gene transcription in erythroblasts]	0.0	5	1	1	1
136579	1710	acute leukemia (apl):	[acute leukemia (APL):]	0.0	3	1	1	1
136580	1710	role in this effects.	[role in these effects.]	0.0	4	1	1	1
136581	1710	depend on the mutual repression	[depending on the mutual repression]	0.0	5	1	1	1
136582	1710	normal lymph node	[normal lymph nodes]	0.0	3	1	1	1
136583	1710	tcf/lef function	[TCF/LEF function]	0.0	2	1	1	1
136584	1710	coexpression a tnf transgene	[coexpression a TNF transgene]	0.0	4	1	1	1
136585	1710	high malignancy	[high malignancy]	0.0	2	1	1	1
136586	1710	avenue in acute leukemia	[avenue in acute leukemia]	0.0	4	1	1	1
136587	1710	lymphokine expression	[lymphokine expression]	0.0	2	1	1	1
136588	1710	osteosarcoma cell	[osteosarcoma cells]	0.0	2	1	1	1
136589	1710	cation such as mg2+	[cations such as Mg2+]	0.0	4	1	1	1
136590	1710	repeat-KB enhancer sequence	[repeat-KB enhancer sequence]	0.0	3	1	1	1
136591	1710	increase the probability of interaction	[increasing the probability of interaction]	0.0	5	1	1	1
136592	1710	five atopic dermatitis patient	[five atopic dermatitis patients]	0.0	4	1	1	1
136593	1710	comparison with criteria]	[comparison with criteria]]	0.0	3	1	1	1
136594	1710	close link	[close link]	0.0	2	1	1	1
136595	1710	mid-S phase	[mid-S phase]	0.0	2	1	1	1
136596	1710	series of uninfected hl-60 subclone	[series of uninfected HL-60 subclones]	0.0	5	1	1	1
136597	1710	il-5 gene promoter	[IL-5 gene promoter]	0.0	3	2	2	1
136598	1710	nf-kappa b binding sites)	[NF-kappa B binding sites)]	0.0	4	1	1	1
136599	1710	25 cell carcinoma bcc	[25 cell carcinomas BCCs]	0.0	4	1	1	1
136600	1710	activation of pp70s6k during tpa-	[activation of pp70S6K during TPA-]	0.0	5	1	1	1
136601	1710	naturally infect baboon cercopithicine herpesvirus	[naturally infecting baboons cercopithicine herpesvirus]	0.0	5	1	1	1
136602	1710	subsequent replacement in vitro by incubation	[subsequent replacement in vitro by incubation]	0.0	6	1	1	1
136603	1710	activity of the classic gcr	[activity of the classic GCR]	0.0	5	1	1	1
136604	1710	/threonine phosphatase in stat3 signal	[/threonine phosphatases in STAT3 signaling]	0.0	5	1	1	1
136605	1710	MIP1 alpha protein	[MIP1 alpha protein]	0.0	3	1	1	1
136606	1710	secretion by cord blood mononuclear cell	[secretion by cord blood mononuclear cells]	0.0	6	1	1	1
136607	1710	n-acetyl-l-cysteine nac	[N-acetyl-L-cysteine NAC]	0.0	2	1	1	1
136608	1710	major human glucocorticoid	[major human glucocorticoid]	0.0	3	1	1	1
136609	1710	biologic marker	[biologic markers]	0.0	2	1	1	1
136610	1710	expression of immunologically important protein	[expression of immunologically important proteins]	0.0	5	1	1	1
136611	1710	steady-state mrna	[steady-state mRNA]	0.0	2	1	1	1
136612	1710	multiple ets	[multiple Ets]	0.0	2	1	1	1
136613	1710	improvement of finding	[improvement of findings]	0.0	3	1	1	1
136614	1710	Interferon regulatory factor	[Interferon regulatory factor]	0.0	3	1	1	1
136615	1710	primary cell in liquid culture	[primary cells in liquid cultures]	0.0	5	1	1	1
136616	1710	erythroid Kruppel-like factor	[erythroid Kruppel-like factor]	0.0	3	1	1	1
136617	1710	sixfold increase	[sixfold increase]	0.0	2	1	1	1
136618	1710	distinct, inhibitor	[distinct, inhibitors]	0.0	2	1	1	1
136619	1710	retinoid with receptor binding specificity cd336	[retinoids with receptor binding specificity CD336]	0.0	6	1	1	1
136620	1710	differentiation of human k562 cell	[differentiation of human K562 cells]	0.0	5	1	1	1
136621	1710	1 microm dexamethasone	[1 microM dexamethasone]	0.0	3	1	1	1
136622	1710	surface immunoglobulin m	[surface immunoglobulin M]	0.0	3	1	1	1
136623	1710	amount of nfatp	[amounts of NFATp]	0.0	3	1	1	1
136624	1710	5' upstream sequence kb)	[5' upstream sequence kb)]	0.0	4	1	1	1
136625	1710	alternative approach	[alternative approaches]	0.0	2	1	1	1
136626	1710	crucial human IL-4 promoter	[crucial human IL-4 promoter]	0.0	4	1	1	1
136627	1710	[E(spl)] gene	[[E(spl)] genes]	0.0	2	1	1	1
136628	1710	elevation of AhR mrna level	[elevation of AhR mRNA level]	0.0	5	1	1	1
136629	1710	activation translocation	[activation translocation]	0.0	2	1	1	1
136630	1710	gene sox9	[gene SOX9]	0.0	2	1	1	1
136631	1710	action of glucocorticoid hormone compound	[action of glucocorticoid hormone compounds]	0.0	5	1	1	1
136632	1710	class -negative cell line	[class -negative cell lines]	0.0	4	1	1	1
136633	1710	many tyrosine	[many tyrosines]	0.0	2	1	1	1
136634	1710	15.5 (p p 0.01	[15.5 (P P 0.01]	0.0	4	1	1	1
136635	1710	step maintain the phenotype	[step maintaining the phenotype]	0.0	4	1	1	1
136636	1710	double time of h	[doubling times of h]	0.0	4	1	1	1
136637	1710	inhibit vdr-rxr heterodimer binding	[inhibiting VDR-RXR heterodimer binding]	0.0	4	1	1	1
136638	1710	lymphocyte-tropic strain	[lymphocyte-tropic strains]	0.0	2	1	1	1
136639	1710	natural gc	[natural gC]	0.0	2	1	1	1
136640	1710	CAT enzyme	[CAT enzyme]	0.0	2	1	1	1
136641	1710	nf-kappa b binding site at position	[NF-kappa B binding sites at positions]	0.0	6	1	1	1
136642	1710	rel/nf-kappab induction	[Rel/NF-kappaB induction]	0.0	2	1	1	1
136643	1710	mutant ikk1 k44m	[mutant IKK1 K44M]	0.0	3	1	1	1
136644	1710	signal to PHA-stimulated pbl	[signals to PHA-stimulated PBL]	0.0	4	1	1	1
136645	1710	gC2- cd4+ clone	[gC2- CD4+ clones]	0.0	3	1	1	1
136646	1710	facilitate the collaboration	[facilitating the collaboration]	0.0	3	1	1	1
136647	1710	base pair repeat	[base pair repeats]	0.0	3	1	1	1
136648	1710	RA sensitivity of cell	[RA sensitivity of cells]	0.0	4	1	1	1
136649	1710	massive overexpression	[massive overexpression]	0.0	2	1	1	1
136650	1710	transfection experiments, overexpression	[transfection experiments, overexpression]	0.0	3	1	1	1
136651	1710	150 bp promoter	[150 bp promoter]	0.0	3	1	1	1
136652	1710	uninduced expression	[uninduced expression]	0.0	2	1	1	1
136653	1710	potent inhibitor of neutrophil apoptosis	[potent inhibitor of neutrophil apoptosis]	0.0	5	1	1	1
136654	1710	inhibition of IL-4 -inducible gene expression	[Inhibition of IL-4 -inducible gene expression]	0.0	6	1	1	1
136655	1710	spinal atrophy a adult-onset form	[spinal atrophy an adult-onset form]	0.0	5	1	1	1
136656	1710	12 family	[12 families]	0.0	2	1	1	1
136657	1710	source of natural antibody	[source of natural antibodies]	0.0	4	1	1	1
136658	1710	monocyte adhesion in tnf-treated vein cell	[monocyte adhesion in TNF-treated vein cells]	0.0	6	1	1	1
136659	1710	show weak cross-reactivity at high concentration	[showing weak cross-reactivity at high concentrations]	0.0	6	1	1	1
136660	1710	BCL-2 T cell	[BCL-2 T cells]	0.0	3	1	1	1
136661	1710	chaperoning protein to various organelle	[chaperoning proteins to various organelles]	0.0	5	1	1	1
136662	1710	4,19-substituted steroid	[4,19-substituted steroids]	0.0	2	1	1	1
136663	1710	role of NFAT1	[role of NFAT1]	0.0	3	1	1	1
136664	1710	deletion of thymocyte	[deletion of thymocytes]	0.0	3	1	1	1
136665	1710	D3 receptor in cell	[D3 receptors in cells]	0.0	4	1	1	1
136666	1710	live-attenuated immunodeficiency virus	[Live-attenuated immunodeficiency viruses]	0.0	3	1	1	1
136667	1710	circulate level of steroid hormone	[circulating levels of steroid hormones]	0.0	5	1	1	1
136668	1710	apoptosis in vitro	[apoptosis in vitro]	0.0	3	1	1	1
136669	1710	estradiol receptor level	[estradiol receptor levels]	0.0	3	1	1	1
136670	1710	quantification of mrna	[quantification of mRNA]	0.0	3	1	1	1
136671	1710	IkappaBalpha by DZA	[IkappaBalpha by DZA]	0.0	3	1	1	1
136672	1710	cell adhesion molecule-1 by lipoprotein	[cell adhesion molecule-1 by lipoprotein]	0.0	5	1	1	1
136673	1710	entire pool of rela	[entire pool of RelA]	0.0	4	1	1	1
136674	1710	utilize oligonucleotide homologous	[utilizing oligonucleotides homologous]	0.0	3	1	1	1
136675	1710	Bcl-6 staining in hyperplasias	[Bcl-6 staining in hyperplasias]	0.0	4	1	1	1
136676	1710	reach the effect at nm	[reaching the effect at nM]	0.0	5	1	1	1
136677	1710	stable phase	[stable phase]	0.0	2	1	1	1
136678	1710	Ig-expressing (rare)	[Ig-expressing (rare)]	0.0	2	1	1	1
136679	1710	analog of alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3	[Analogs of alpha,25-dihydroxyvitamin D3 1 alpha,25-(OH)2D3]	0.0	6	1	1	1
136680	1710	major target for immunosuppression	[major target for immunosuppression]	0.0	4	1	1	1
136681	1710	course of estrogen	[course of estrogen]	0.0	3	1	1	1
136682	1710	SML cell	[SML cells]	0.0	2	1	1	1
136683	1710	essential role of Jak3	[essential role of Jak3]	0.0	4	1	1	1
136684	1710	lps antibody on uptake	[LPS antibodies on uptake]	0.0	4	1	1	1
136685	1710	factor include sp1 binding protein	[factors including Sp1 binding proteins]	0.0	5	1	1	1
136686	1710	possible t-cell killer T/NK population	[possible T-cell killer T/NK populations]	0.0	5	1	1	1
136687	1710	rapidak long-lasting tyrosine	[rapid, long-lasting tyrosine]	0.0	3	1	1	1
136688	1710	contrast, inhibition of tax	[contrast, inhibition of Tax]	0.0	4	1	1	1
136689	1710	10% serum	[10% serum]	0.0	2	1	1	1
136690	1710	giant cell from human monocyte	[giant cells from human monocytes]	0.0	5	1	1	1
136691	1710	DNase I hypersensitive site	[DNase I hypersensitive site]	0.0	4	1	1	1
136692	1710	pathway protect	[pathways protecting]	0.0	2	1	1	1
136693	1710	localize hsv	[localizing HSV]	0.0	2	1	1	1
136694	1710	critical involvement	[critical involvement]	0.0	2	1	1	1
136695	1710	expression of p50-p65 heterodimer	[expression of p50-p65 heterodimers]	0.0	4	1	1	1
136696	1710	pharmaceutical product	[pharmaceutical products]	0.0	2	1	1	1
136697	1710	histocompatibility class promoter	[histocompatibility class promoter]	0.0	3	1	1	1
136698	1710	thrombocytosis	[thrombocytosis]	0.0	1	2	2	1
136699	1710	switch of tgf expression	[switch of TGF expression]	0.0	4	1	1	1
136700	1710	element include binding site	[elements including binding sites]	0.0	4	1	1	1
136701	1710	nf-kb DNA	[NF-kB DNA]	0.0	2	1	1	1
136702	1710	c-terminal tail of CAML	[C-terminal tail of CAML]	0.0	4	1	1	1
136703	1710	gamma-globin chain	[gamma-globin chains]	0.0	2	1	1	1
136704	1710	activation of stat1 protein	[activation of STAT1 protein]	0.0	4	1	1	1
136705	1710	major site within the element	[major sites within the element]	0.0	5	1	1	1
136706	1710	epo (100%).	[Epo (100%).]	0.0	2	1	1	1
136707	1710	include kb	[including kb]	0.0	2	1	1	1
136708	1710	oestrogen on oestrogen organ	[oestrogens on oestrogen organs]	0.0	4	1	1	1
136709	1710	detectable phosphorylation of Jak3	[detectable phosphorylation of Jak3]	0.0	4	1	1	1
136710	1710	part of complex	[part of complexes]	0.0	3	1	1	1
136711	1710	ligand-induced tyrosine phosphorylation of Janus kinase	[ligand-induced tyrosine phosphorylation of Janus kinases]	0.0	6	1	1	1
136712	1710	malignant lymphoma, large cell" type	[malignant lymphoma, large cell" type]	0.0	5	1	1	1
136713	1710	phytohemagglutin	[phytohemagglutin]	0.0	1	1	1	1
136714	1710	lymphocyte syndrome-associated transactivator ciita	[lymphocyte syndrome-associated transactivators CIITA]	0.0	4	1	1	1
136715	1710	developmentally important gene dorsal	[developmentally important gene dorsal]	0.0	4	1	1	1
136716	1710	multi-protein transcription factor complex	[multi-protein transcription factor complex]	0.0	4	1	1	1
136717	1710	functional collaboration	[functional collaboration]	0.0	2	1	1	1
136718	1710	activation on transcription	[activation on transcription]	0.0	3	1	1	1
136719	1710	abnormal myelopoiesis	[abnormal myelopoiesis]	0.0	2	1	1	1
136720	1710	mcp-1 mcp-1	[MCP-1 MCP-1]	0.0	2	1	1	1
136721	1710	jun-B the transcription protein	[jun-B the transcription protein]	0.0	4	1	1	1
136722	1710	undergo erythroid differentiation	[undergoing erythroid differentiation]	0.0	3	1	1	1
136723	1710	MHC class transactivator	[MHC class transactivator]	0.0	3	2	2	1
136724	1710	presence lymphocyte sarcoidosis	[presence lymphocytes sarcoidosis]	0.0	3	1	1	1
136725	1710	pathogenesis include RA synovitis	[pathogenesis including RA synovitis]	0.0	4	1	1	1
136726	1710	positive-acting element	[positive-acting element]	0.0	2	1	1	1
136727	1710	non-ig	[non-Ig]	0.0	1	1	1	1
136728	1710	fivefold decrease	[fivefold decrease]	0.0	2	1	1	1
136729	1710	guideline related to the apl cell	[guidelines related to the APL cell]	0.0	6	1	1	1
136730	1710	one t-cell clone reactive	[one T-cell clone reactive]	0.0	4	1	1	1
136731	1710	1 expression by Gardnerella vaginalis	[1 expression by Gardnerella vaginalis]	0.0	5	1	1	1
136732	1710	slope factor	[slope factors]	0.0	2	1	1	1
136733	1710	primary effect	[primary effect]	0.0	2	3	3	1
136734	1710	study on pluripotent endocrine culture	[studies on pluripotent endocrine cultures]	0.0	5	1	1	1
136735	1710	acid treatment of pml/raralpha mouse	[acid treatment of PML/RARalpha mice]	0.0	5	1	1	1
136736	1710	correlation of the level	[correlations of the levels]	0.0	4	1	1	1
136737	1710	neutralize antiserum	[Neutralizing antiserum]	0.0	2	1	1	1
136738	1710	purification of ptf	[purification of PTF]	0.0	3	1	1	1
136739	1710	major complex MHC way	[major complex MHC way]	0.0	4	1	1	1
136740	1710	calcium ca2+	[calcium Ca2+]	0.0	2	1	1	1
136741	1710	hamster ovary (cho)-dr transfectant	[hamster ovary (CHO)-DR transfectants]	0.0	4	1	1	1
136742	1710	nuclear factor (NF)-AT proximal NF-AT	[nuclear factor (NF)-AT proximal NF-AT]	0.0	5	1	1	1
136743	1710	self-perpetuating loop	[self-perpetuating loop]	0.0	2	1	1	1
136744	1710	increase evidence mediator during syphilis disease	[increasing evidence mediators during syphilis disease]	0.0	6	1	1	1
136745	1710	mmp-1	[MMP-1]	0.0	1	1	1	1
136746	1710	TG myristate acetate	[TG myristate acetate]	0.0	3	1	1	1
136747	1710	eg, tumor necrosis	[eg, tumor necrosis]	0.0	3	1	1	1
136748	1710	transfection of u937 cell	[transfection of U937 cells]	0.0	4	1	1	1
136749	1710	core of the nonleukemogenic virus	[core of the nonleukemogenic virus]	0.0	5	1	1	1
136750	1710	hiv enhancer transcription in T cell	[HIV enhancer transcription in T cells]	0.0	6	1	1	1
136751	1710	nb4 cell for monocytic differentiation	[NB4 cells for monocytic differentiation]	0.0	5	1	1	1
136752	1710	kappa 3/CRE	[kappa 3/CRE]	0.0	2	1	1	1
136753	1710	initiate dna-unwinding a prerequisite	[initiating DNA-unwinding a prerequisite]	0.0	4	1	1	1
136754	1710	pkc isotype in T cell	[PKC isotypes in T cells]	0.0	5	1	1	1
136755	1710	activation inducer	[activation inducer]	0.0	2	1	1	1
136756	1710	addition of anti-ifn-alpha/beta antibody	[addition of anti-IFN-alpha/beta antibody]	0.0	4	1	1	1
136757	1710	composition of StatG	[composition of StatG]	0.0	3	1	1	1
136758	1710	thus, competition between two general activator	[Thus, competition between two general activators]	0.0	6	1	1	1
136759	1710	multiple ebf	[Multiple EBF]	0.0	2	1	1	1
136760	1710	pathway lead to tnf-alpha production	[pathways leading to TNF-alpha production]	0.0	5	1	1	1
136761	1710	expand population	[expanding populations]	0.0	2	1	1	1
136762	1710	EMSA displacement study	[EMSA displacement studies]	0.0	3	1	1	1
136763	1710	transient and/or expression of delta-	[transient and/or expression of delta-]	0.0	5	1	1	1
136764	1710	affinity of the gr	[affinity of the GR]	0.0	4	1	1	1
136765	1710	2126 (pre)	[2126 (pre)]	0.0	2	1	1	1
136766	1710	T regulation of transcription	[T regulation of transcription]	0.0	4	1	1	1
136767	1710	thus permit the release of nf-kappab	[thus permitting the release of NF-kappaB]	0.0	6	1	1	1
136768	1710	increase in phosphorylation	[increase in phosphorylation]	0.0	3	1	1	1
136769	1710	assay in malignant tissue tumor	[assay in malignant tissue tumors]	0.0	5	1	1	1
136770	1710	reading frame of 1458	[reading frame of 1,458]	0.0	4	1	1	1
136771	1710	very strong affinity	[very strong affinity]	0.0	3	1	1	1
136772	1710	one candidate	[one candidate]	0.0	2	1	1	1
136773	1710	sister of one patient	[sister of one patient]	0.0	4	1	1	1
136774	1710	delta globin	[delta globin]	0.0	2	1	1	1
136775	1710	antigen release	[antigen release]	0.0	2	1	1	1
136776	1710	pha stimulation c-fo	[PHA stimulation c-fos]	0.0	3	1	1	1
136777	1710	sensitive identification	[sensitive identification]	0.0	2	1	1	1
136778	1710	furthermore, NF-kappaB factor of cell	[Furthermore, NF-kappaB factor of cells]	0.0	5	1	1	1
136779	1710	vitro by incubation	[vitro by incubation]	0.0	3	1	1	1
136780	1710	two gata-binding site	[two GATA-binding sites]	0.0	3	1	1	1
136781	1710	nuclear expression of nf-kappa b	[nuclear expression of NF-kappa B]	0.0	5	1	1	1
136782	1710	fluorescent probe	[fluorescent probe]	0.0	2	1	1	1
136783	1710	preincubation with a peptide Arg-Gly-Asp RGD	[preincubation with a peptide Arg-Gly-Asp RGD]	0.0	6	1	1	1
136784	1710	identification of specific inhibitor	[Identification of specific inhibitors]	0.0	4	1	1	1
136785	1710	nuclear affinity Ka	[nuclear affinity Ka]	0.0	3	1	1	1
136786	1710	center region	[center region]	0.0	2	1	1	1
136787	1710	multinucleated giant cell from human monocyte	[multinucleated giant cells from human monocytes]	0.0	6	1	1	1
136788	1710	central system pyramidal cell	[central system pyramidal cells]	0.0	4	1	1	1
136789	1710	weight of 32, 36 50	[weights of 32, 36 50]	0.0	5	1	1	1
136790	1710	cell line by 12-o-tetradecanoylphorbol-13-acetate	[cell lines by 12-O-tetradecanoylphorbol-13-acetate]	0.0	4	1	1	1
136791	1710	pathway of P- lps	[pathway of P- LPS]	0.0	4	1	1	1
136792	1710	property similar to NF	[properties similar to NF]	0.0	4	1	1	1
136793	1710	activation of a receptor	[activation of a receptor]	0.0	4	1	1	1
136794	1710	particularly b cell	[particularly B cells]	0.0	3	1	1	1
136795	1710	two hla-b8-restricted epitope	[two HLA-B8-restricted epitopes]	0.0	3	1	1	1
136796	1710	relapse follow autologous pbsct	[relapse following autologous PBSCT]	0.0	4	2	2	1
136797	1710	chronic failure CRF	[chronic failure CRF]	0.0	3	1	1	1
136798	1710	activity of c-ErbB	[activity of c-ErbB]	0.0	3	1	1	1
136799	1710	regulate the transcriptional response	[regulating the transcriptional response]	0.0	4	1	1	1
136800	1710	cooperative interaction between b coactivator	[cooperative interactions between B coactivators]	0.0	5	1	1	1
136801	1710	site within the negative element	[sites within the negative element]	0.0	5	1	1	1
136802	1710	collectively, factor	[Collectively, factor]	0.0	2	1	1	1
136803	1710	affinity aldosterone binding site	[affinity aldosterone binding sites]	0.0	4	1	1	1
136804	1710	immunogenic protein ebna2-ebna6	[immunogenic proteins EBNA2-EBNA6]	0.0	3	1	1	1
136805	1710	adult before dst mg).	[adults before DST mg).]	0.0	4	1	1	1
136806	1710	exchange of chain-derived peptide clip	[exchange of chain-derived peptides CLIP]	0.0	5	1	1	1
136807	1710	single isolate	[single isolate]	0.0	2	1	1	1
136808	1710	two other nonsteroidal drug	[two other nonsteroidal drugs]	0.0	4	1	1	1
136809	1710	alteration of structural order	[Alteration of structural order]	0.0	4	1	1	1
136810	1710	inhibitor of nadph oxidase	[inhibitors of NADPH oxidase]	0.0	4	1	1	1
136811	1710	sensitivity to acid (ra)-induced differentiation	[sensitivity to acid (RA)-induced differentiation]	0.0	5	1	1	1
136812	1710	prolonged submaximal exercise	[prolonged submaximal exercises]	0.0	3	1	1	1
136813	1710	signal mediator in endothelial cell	[signaling mediators in endothelial cells]	0.0	5	1	1	1
136814	1710	factor ATF-2	[factors ATF-2]	0.0	2	1	1	1
136815	1710	active form of aml1	[active form of AML1]	0.0	4	1	1	1
136816	1710	Trx-expressing	[Trx-expressing]	0.0	1	1	1	1
136817	1710	HIV1 infection of monocyte	[HIV1 infection of monocytes]	0.0	4	1	1	1
136818	1710	functional study use ptf beta antibody	[functional studies using PTF beta antibodies]	0.0	6	1	1	1
136819	1710	streptoavidin -biotin peroxidase method	[streptoavidin -biotin peroxidase method]	0.0	4	1	1	1
136820	1710	single mrna transcript	[single mRNA transcript]	0.0	3	1	1	1
136821	1710	existence of a few copy	[existence of a few copies]	0.0	5	1	1	1
136822	1710	AMP element activation	[AMP element activation]	0.0	3	1	1	1
136823	1710	four kind carry Val	[four kinds carrying Val]	0.0	4	1	1	1
136824	1710	background: datum	[BACKGROUND: data]	0.0	2	1	1	1
136825	1710	nuclear protein- dependent complex	[nuclear protein- dependent complexes]	0.0	4	1	1	1
136826	1710	decrease in adhesion	[decrease in adhesion]	0.0	3	1	1	1
136827	1710	potent inhibitor of replication	[potent inhibitor of replication]	0.0	4	1	1	1
136828	1710	oxygen intermediate -release	[oxygen intermediate -release]	0.0	3	1	1	1
136829	1710	requirement for il-2 promoter repression	[requirements for IL-2 promoter repression]	0.0	5	1	1	1
136830	1710	morphology cell with neurite process	[morphology cells with neurite processes]	0.0	5	1	1	1
136831	1710	regulation of receptor (gr) expression	[Regulation of receptor (GR) expression]	0.0	5	1	1	1
136832	1710	terminal b differentiation	[terminal B differentiation]	0.0	3	1	1	1
136833	1710	interferon-induced transcription factor isgf3	[interferon-induced transcription factor ISGF3]	0.0	4	1	1	1
136834	1710	in-vitro-stimulated normal adult blood lymphocyte sample	[in-vitro-stimulated normal adult blood lymphocyte samples]	0.0	6	1	1	1
136835	1710	cause mobility	[causing mobility]	0.0	2	1	1	1
136836	1710	analysis MS	[analysis MS]	0.0	2	1	1	1
136837	1710	(G0)	[(G0)]	0.0	1	1	1	1
136838	1710	functional stimulation	[functional stimulation]	0.0	2	1	1	1
136839	1710	box pax1	[box PAX1]	0.0	2	1	1	1
136840	1710	leukotriene b4 adhesion	[leukotriene B4 adhesion]	0.0	3	1	1	1
136841	1710	dexamethasone: regulation of the receptor	[dexamethasone: regulation of the receptor]	0.0	5	1	1	1
136842	1710	maintain the phenotype	[maintaining the phenotype]	0.0	3	1	1	1
136843	1710	several casein kinase site	[several casein kinase sites]	0.0	4	1	1	1
136844	1710	interleukin 2 transcription	[interleukin 2 transcription]	0.0	3	1	1	1
136845	1710	transcriptional regulator of numerous cellular gene	[transcriptional regulators of numerous cellular genes]	0.0	6	1	1	1
136846	1710	t(17;19)-bearing leukemia	[t(17;19)-bearing leukemias]	0.0	2	1	1	1
136847	1710	level of fosb/g0s3	[levels of FOSB/G0S3]	0.0	3	1	1	1
136848	1710	cd4+ lymphocyte in culture	[CD4+ lymphocytes in culture]	0.0	4	1	1	1
136849	1710	hiv-1 gp160	[HIV-1 gp160]	0.0	2	1	1	1
136850	1710	tight complex with two class	[tight complexes with two classes]	0.0	5	1	1	1
136851	1710	Precise alignment	[Precise alignment]	0.0	2	1	1	1
136852	1710	colonic carcinoma cell line ht29	[colonic carcinoma cell line HT29]	0.0	5	2	2	1
136853	1710	potential drug	[potential drugs]	0.0	2	1	1	1
136854	1710	respect to leukocyte adhesion	[respect to leukocyte adhesion]	0.0	4	1	1	1
136855	1710	conventional ventilation	[conventional ventilation]	0.0	2	1	1	1
136856	1710	indicate a dominant role	[indicating a dominant role]	0.0	4	1	1	1
136857	1710	create hiv-1/siv	[creating HIV-1/SIV]	0.0	2	1	1	1
136858	1710	stage of erythropoietic development	[stages of erythropoietic development]	0.0	4	1	1	1
136859	1710	monocyte by 1,25-dihydroxycholecalciferol	[monocytes by 1,25-dihydroxycholecalciferol]	0.0	3	1	1	1
136860	1710	signal determinant regulate factor-kappa b activation	[signaling determinants regulating factor-kappa B activation]	0.0	6	1	1	1
136861	1710	incidence particularly with cytomegalovirus CMV	[incidence particularly with cytomegalovirus CMV]	0.0	5	1	1	1
136862	1710	cooperative interaction between cell-specific transcriptional coactivator	[cooperative interactions between cell-specific transcriptional coactivators]	0.0	6	1	1	1
136863	1710	breast tumor lymphocyte brtal of peptide	[breast tumor lymphocytes BRTAL of peptides]	0.0	6	1	1	1
136864	1710	gene expression through pharmacologic inhibition	[gene expression through pharmacologic inhibition]	0.0	5	1	1	1
136865	1710	down-regulation of protein in lymphoma	[Down-regulation of proteins in lymphoma]	0.0	5	1	1	1
136866	1710	27 combination of promoter	[27 combinations of promoters]	0.0	4	1	1	1
136867	1710	potent regulator of differentiation	[potent regulators of differentiation]	0.0	4	1	1	1
136868	1710	regulation of proenkephalin	[regulation of proenkephalin]	0.0	3	1	1	1
136869	1710	putative regulator of differentiation	[putative regulator of differentiation]	0.0	4	1	1	1
136870	1710	induction in Jurkat T cell	[induction in Jurkat T cells]	0.0	5	1	1	1
136871	1710	lps (endotoxin) through membrane cd14 mcd14	[LPS (endotoxin) through membrane CD14 mCD14]	0.0	6	1	1	1
136872	1710	presence in oestrogen target organ	[presence in oestrogen target organs]	0.0	5	1	1	1
136873	1710	rela(p65) mrna	[RelA(p65) mRNA]	0.0	2	1	1	1
136874	1710	exhibit property	[exhibiting properties]	0.0	2	1	1	1
136875	1710	difference (p	[difference (P]	0.0	2	1	1	1
136876	1710	calcineurin a Ca2+/calmodulin-regulated, protein phosphatase	[calcineurin a Ca2+/calmodulin-regulated, protein phosphatase]	0.0	5	1	1	1
136877	1710	tax-responsive element tre1 necessary for transactivation	[Tax-responsive element TRE1 necessary for transactivation]	0.0	6	1	1	1
136878	1710	50 kD protein	[50 kD protein]	0.0	3	1	1	1
136879	1710	cd4(-)cd8(-)cd3(-)	[CD4(-)CD8(-)CD3(-)]	0.0	1	1	1	1
136880	1710	presence of 1,25-dihydroxyvitamin D3	[presence of 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
136881	1710	age),	[age),]	0.0	1	1	1	1
136882	1710	T3 nuclear receptor site	[T3 nuclear receptor sites]	0.0	4	1	1	1
136883	1710	acute promyelocytic leukemia the variant	[acute promyelocytic leukemia the variant]	0.0	5	1	1	1
136884	1710	cell whatever	[cells whatever]	0.0	2	1	1	1
136885	1710	mechanism of inhibition of factor	[mechanisms of inhibition of factor]	0.0	5	1	1	1
136886	1710	Daidzein	[Daidzein]	0.0	1	2	2	1
136887	1710	class CTL	[class CTLs]	0.0	2	1	1	1
136888	1710	treatment of hiv-tf1 by phosphatase	[treatment of HIV-TF1 by phosphatase]	0.0	5	1	1	1
136889	1710	el4 overexpress human (h) irak	[EL4 overexpressing human (h) IRAK]	0.0	5	1	1	1
136890	1710	cell line 3t3	[cell lines 3T3]	0.0	3	1	1	1
136891	1710	mouse erythroleukemia cell	[mouse erythroleukemia cells]	0.0	3	1	1	1
136892	1710	cytokine receptor activation	[cytokine receptor activation]	0.0	3	1	1	1
136893	1710	complex with other protein	[complexes with other proteins]	0.0	4	1	1	1
136894	1710	copy of repeat	[copies of repeats]	0.0	3	1	1	1
136895	1710	selection of a diverse tcr repertoire	[Selection of a diverse TCR repertoire]	0.0	6	1	1	1
136896	1710	T lymphocyte by IFN-beta	[T lymphocytes by IFN-beta]	0.0	4	1	1	1
136897	1710	mature cytokine of kda	[mature cytokine of kDa]	0.0	4	1	1	1
136898	1710	use bacterial constituent	[using bacterial constituents]	0.0	3	1	1	1
136899	1710	low level of hiv production	[low levels of HIV production]	0.0	5	1	1	1
136900	1710	transfectant of mouse 70z/3 cell	[transfectants of mouse 70Z/3 cells]	0.0	5	1	1	1
136901	1710	transform protein lmp1	[transforming protein LMP1]	0.0	3	1	1	1
136902	1710	use the binding assay with 3h-r1881	[using the binding assay with 3H-R1881]	0.0	6	1	1	1
136903	1710	monocyte tissue factor	[monocyte tissue factor]	0.0	3	1	1	1
136904	1710	patient with spastic paraparesis	[patient with spastic paraparesis]	0.0	4	1	1	1
136905	1710	ligand in combination	[ligand in combination]	0.0	3	1	1	1
136906	1710	endothelial receptor for lipoprotein	[endothelial receptor for lipoprotein]	0.0	4	1	1	1
136907	1710	random breast aspirate at risk	[random breast aspirates at risk]	0.0	5	1	1	1
136908	1710	deficiency-cold syndrome dcs	[deficiency-cold syndrome DCS]	0.0	3	1	1	1
136909	1710	tyrosine phosphorylation of multiple substrate	[tyrosine phosphorylation of multiple substrates]	0.0	5	1	1	1
136910	1710	PGG-Glucan a beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer	[PGG-Glucan a beta-(1,6)-branched beta-(1,3)-linked glucose homopolymer]	0.0	6	1	1	1
136911	1710	five inhibitors, cyclosporin a CsA	[five inhibitors, cyclosporin A CsA]	0.0	5	1	1	1
136912	1710	lymphocyte proliferation in control	[lymphocyte proliferation in controls]	0.0	4	1	1	1
136913	1710	activate pathway distinct	[activating pathway distinct]	0.0	3	1	1	1
136914	1710	immunoregulatory signal transduction	[immunoregulatory signal transduction]	0.0	3	1	1	1
136915	1710	direct interaction of calcineurin	[direct interaction of calcineurin]	0.0	4	1	1	1
136916	1710	haptenation of the metabolite	[haptenation of the metabolites]	0.0	4	1	1	1
136917	1710	mild down-regulation in hypercortisolemic patient suffer	[mild down-regulation in hypercortisolemic patients suffering]	0.0	6	1	1	1
136918	1710	high-frequency rearrangement of kappa gene	[high-frequency rearrangement of kappa genes]	0.0	5	1	1	1
136919	1710	burst upon acid stimulation	[burst upon acid stimulation]	0.0	4	1	1	1
136920	1710	include the ca2+ protein kinase cam-k	[including the Ca2+ protein kinase CaM-K]	0.0	6	1	1	1
136921	1710	NF-kappaB /IkappaBalpha	[NF-kappaB /IkappaBalpha]	0.0	2	1	1	1
136922	1710	affect the enhancer activity	[affecting the enhancer activity]	0.0	4	1	1	1
136923	1710	cell factor	[cells factor]	0.0	2	1	1	1
136924	1710	increase transcription	[increasing transcription]	0.0	2	1	1	1
136925	1710	2 ng	[2 ng]	0.0	2	1	1	1
136926	1710	hla-dr+ cell	[HLA-DR+ cells]	0.0	2	1	1	1
136927	1710	marker of subpopulation	[marker of subpopulations]	0.0	3	1	1	1
136928	1710	footprinting procedure	[footprinting procedures]	0.0	2	1	1	1
136929	1710	mm cell growth	[MM cell growth]	0.0	3	1	1	1
136930	1710	gene within the control	[gene within the control]	0.0	4	1	1	1
136931	1710	vitro fibroblast	[vitro fibroblast]	0.0	2	1	1	1
136932	1710	factor include NFAT-1	[factors including NFAT-1]	0.0	3	1	1	1
136933	1710	stable e1a expression in cell	[stable E1A expression in cells]	0.0	5	1	1	1
136934	1710	k562 cell undergo erythroid differentiation	[K562 cells undergoing erythroid differentiation]	0.0	5	1	1	1
136935	1710	regulation in primary NK cell	[regulation in primary NK cells]	0.0	5	1	1	1
136936	1710	specific modification	[specific modification]	0.0	2	1	1	1
136937	1710	pre-term delivery,	[pre-term delivery,]	0.0	2	1	1	1
136938	1710	use RNA display	[using RNA display]	0.0	3	1	1	1
136939	1710	65-year-old woman with non-hodgkin' lymphoma	[65-year-old woman with non-Hodgkin's lymphoma]	0.0	5	1	1	1
136940	1710	yeast interaction system	[yeast interaction system]	0.0	3	1	1	1
136941	1710	comparison to anti-CD3 antibody	[comparison to anti-CD3 antibodies]	0.0	4	1	1	1
136942	1710	tyrosine phosphorylation of a group	[tyrosine phosphorylation of a group]	0.0	5	1	1	1
136943	1710	role of EGR1 lymphocytes.	[Role of EGR1 lymphocytes.]	0.0	4	1	1	1
136944	1710	CD28 expression	[CD28 expression]	0.0	2	1	1	1
136945	1710	study responsiveness to immediate-early transactivator BZLF1	[studying responsiveness to immediate-early transactivators BZLF1]	0.0	6	1	1	1
136946	1710	sequence within the 33 stretch	[sequence within the 33 stretch]	0.0	5	1	1	1
136947	1710	distinct nuclear protein complex a factor	[distinct nuclear protein complexes a factor]	0.0	6	1	1	1
136948	1710	enhance nf-kappa b activity	[enhancing NF-kappa B activity]	0.0	4	1	1	1
136949	1710	24 healthy pregnant woman	[24 healthy pregnant women]	0.0	4	1	1	1
136950	1710	corresponding to transcript contain deletion	[corresponding to transcripts containing deletions]	0.0	5	1	1	1
136951	1710	characterize NF-kappa b -independent activation	[characterizing NF-kappa B -independent activation]	0.0	5	1	1	1
136952	1710	double infection	[double infection]	0.0	2	1	1	1
136953	1710	primary culture of leukemia	[primary cultures of leukemia]	0.0	4	1	1	1
136954	1710	Escherichia coli lps	[Escherichia coli LPS]	0.0	3	1	1	1
136955	1710	mineralocorticoid receptor count in leukocyte	[mineralocorticoid receptor count in leukocytes]	0.0	5	1	1	1
136956	1710	most probably in the nuclei	[most probably in the nuclei]	0.0	5	1	1	1
136957	1710	host killer	[host killer]	0.0	2	1	1	1
136958	1710	cut expression of the nf	[Cutting expression of the NF]	0.0	5	1	1	1
136959	1710	activation of stat5 protein by il-5	[activation of STAT5 proteins by IL-5]	0.0	6	1	1	1
136960	1710	mutant of the TRAF2 adaptor	[mutants of the TRAF2 adaptors]	0.0	5	1	1	1
136961	1710	feature of resistance	[features of resistance]	0.0	3	1	1	1
136962	1710	consensus sequence oligonucleotide	[consensus sequence oligonucleotides]	0.0	3	1	1	1
136963	1710	effect directly related	[effects directly related]	0.0	3	1	1	1
136964	1710	regulate the expression of several gene	[regulating the expression of several genes]	0.0	6	1	1	1
136965	1710	class of gene	[classes of genes]	0.0	3	1	1	1
136966	1710	nf-at a sequence	[NF-AT a sequence]	0.0	3	1	1	1
136967	1710	domain icn	[domain ICN]	0.0	2	1	1	1
136968	1710	-dependent nf-kappab activation	[-dependent NF-kappaB activation]	0.0	3	1	1	1
136969	1710	increase of junb protein	[increase of JunB protein]	0.0	4	1	1	1
136970	1710	mobility shift eems) analysis	[mobility shift (EMS) analyses]	0.0	4	1	1	1
136971	1710	analog0 rapamycin	[analog, rapamycin]	0.0	2	1	1	1
136972	1710	preferential presentation dqa1*0501/dqb1*0201 in comparison	[Preferential presentation DQA1*0501/DQB1*0201 in comparison]	0.0	5	1	1	1
136973	1710	potent differentiation inducer 12-o-tetradecanoylphorbol 13-acetate	[potent differentiation inducers 12-O-tetradecanoylphorbol 13-acetate]	0.0	5	1	1	1
136974	1710	tax1 a protein	[tax1 a protein]	0.0	3	1	1	1
136975	1710	presence of critical element	[presence of critical elements]	0.0	4	1	1	1
136976	1710	autophosphorylation site	[autophosphorylation site]	0.0	2	1	1	1
136977	1710	protein kD	[proteins kD]	0.0	2	1	1	1
136978	1710	overexpression of receptor kinase peptide	[Overexpression of receptor kinase peptide]	0.0	5	1	1	1
136979	1710	divergent expression	[divergent expression]	0.0	2	1	1	1
136980	1710	th2-regulated response immunity	[TH2-regulated responses immunity]	0.0	3	1	1	1
136981	1710	il-6 DNA binding	[IL-6 DNA binding]	0.0	3	1	1	1
136982	1710	site for c-Myc	[site for c-Myc]	0.0	3	1	1	1
136983	1710	strain of immunodeficiency virus type	[strain of immunodeficiency virus type]	0.0	5	1	1	1
136984	1710	include secondary aml	[including secondary AML]	0.0	3	1	1	1
136985	1710	cd8(-) CD3 (+) thymocyte a role	[CD8(-) CD3 (+) thymocytes a role]	0.0	6	1	1	1
136986	1710	P; binding	[h; binding]	0.0	2	1	1	1
136987	1710	centromere specific probe	[centromere specific probes]	0.0	3	1	1	1
136988	1710	infiltration of lymphocyte	[infiltration of lymphocytes]	0.0	3	1	1	1
136989	1710	(igm)-,	[(IgM)-,]	0.0	1	1	1	1
136990	1710	significantly high (p<.001)	[significantly higher (P<.001)]	0.0	3	1	1	1
136991	1710	development of cell	[development of cells]	0.0	3	1	1	1
136992	1710	active TATA binding factor	[active TATA binding factor]	0.0	4	1	1	1
136993	1710	tetrahydrocortisone mg/24h; n:	[tetrahydrocortisone mg/24h; N:]	0.0	3	1	1	1
136994	1710	encode hepatocyte factor -3alpha	[encoding hepatocyte factor -3alpha]	0.0	4	1	1	1
136995	1710	transient transfection study in HeLa cell	[Transient transfection studies in HeLa cells]	0.0	6	1	1	1
136996	1710	patient with Philadelphia chromosome-positive leukemia	[patients with Philadelphia chromosome-positive leukemia]	0.0	5	1	1	1
136997	1710	action on DC	[action on DC]	0.0	3	1	1	1
136998	1710	cell-specific stage-specific factor-DNA complex	[cell-specific stage-specific factor-DNA complexes]	0.0	4	1	1	1
136999	1710	bind site-specific transcriptional property	[binding site-specific transcriptional properties]	0.0	4	1	1	1
137000	1710	relationship between the events.	[relationship between the events.]	0.0	4	1	1	1
137001	1710	inducible t-cell gene	[inducible T-cell genes]	0.0	3	2	2	1
137002	1710	role of adhesion molecule	[role of adhesion molecules]	0.0	4	1	1	1
137003	1710	amino acid sequence information	[amino acid sequence information]	0.0	4	1	1	1
137004	1710	mean ic50	[mean IC50s]	0.0	2	1	1	1
137005	1710	5-fluorouracil	[5-fluorouracil]	0.0	1	1	1	1
137006	1710	potent transcription activator	[potent transcription activator]	0.0	3	1	1	1
137007	1710	Glucocorticoid receptor in Alzheimer's disease	[Glucocorticoid receptors in Alzheimer's disease]	0.0	5	1	1	1
137008	1710	interaction of ags with tcr	[interaction of Ags with TCR]	0.0	5	1	1	1
137009	1710	drug for disease	[drugs for diseases]	0.0	3	1	1	1
137010	1710	encode a dna-binding protein	[encoding a DNA-binding protein]	0.0	4	1	1	1
137011	1710	several rearrangement in the ape	[several rearrangements in the apes]	0.0	5	1	1	1
137012	1710	exogenous gene in primary cell	[exogenous genes in primary cells]	0.0	5	1	1	1
137013	1710	inducible form of nf-kappab	[inducible form of NF-kappaB]	0.0	4	1	1	1
137014	1710	ebna2 activity	[EBNA2 activity]	0.0	2	1	1	1
137015	1710	specific inhibitor of serine/threonine phosphatase -1	[specific inhibitors of serine/threonine phosphatases -1]	0.0	6	1	1	1
137016	1710	10, leiomyosarcoma 10, liposarcoma	[10, leiomyosarcoma 10, liposarcoma]	0.0	4	1	1	1
137017	1710	cell adhesion molecule vcam-1	[cell adhesion molecule VCAM-1]	0.0	4	3	3	1
137018	1710	neutrophil adherence	[neutrophil adherence]	0.0	2	1	1	1
137019	1710	up-regulated endogenous fasL mrna	[up-regulated endogenous fasL mRNA]	0.0	4	1	1	1
137020	1710	NF-kappa b -dependent pathway	[NF-kappa B -dependent pathways]	0.0	4	1	1	1
137021	1710	ap3-like motif	[AP3-like motif]	0.0	2	1	1	1
137022	1710	(nk)-	[(NK)-]	0.0	1	1	1	1
137023	1710	unique involvement	[unique involvement]	0.0	2	1	1	1
137024	1710	rapid nuclear depletion	[rapid nuclear depletion]	0.0	3	1	1	1
137025	1710	4s receptor	[4S receptors]	0.0	2	1	1	1
137026	1710	two transcript isolation of a transcript	[two transcripts isolation of an transcript]	0.0	6	1	1	1
137027	1710	lead in a T cell line	[leading in a T cell line]	0.0	6	1	1	1
137028	1710	rank order for different corticosteroid	[rank order for different corticosteroids]	0.0	5	1	1	1
137029	1710	particularly with cytomegalovirus CMV	[particularly with cytomegalovirus CMV]	0.0	4	1	1	1
137030	1710	low concentration of ng/ml	[lower concentration of ng/ml]	0.0	4	1	1	1
137031	1710	interaction between this proteins.	[interactions between these proteins.]	0.0	4	1	1	1
137032	1710	myeloid u937 cell	[myeloid U937 cells]	0.0	3	1	1	1
137033	1710	competitive polymerase chain reaction	[competitive polymerase chain reaction]	0.0	4	1	1	1
137034	1710	time course of adhesion	[time course of adhesion]	0.0	4	1	1	1
137035	1710	cell cycle-dependent transcription factor	[cell cycle-dependent transcription factor]	0.0	4	1	1	1
137036	1710	individual with disease	[individuals with disease]	0.0	3	1	1	1
137037	1710	mobility shift assays,	[mobility shift assays,]	0.0	3	1	1	1
137038	1710	proinflammatory agonist as lipopolysaccharide	[proinflammatory agonists as lipopolysaccharide]	0.0	4	1	1	1
137039	1710	Northern analysis of mrna from ECs	[Northern analysis of mRNA from ECs]	0.0	6	1	1	1
137040	1710	transformation of cell	[transformation of cells]	0.0	3	1	1	1
137041	1710	inhibit apoptosis	[inhibiting apoptosis]	0.0	2	1	1	1
137042	1710	similar form of severe immunodeficiency	[similar forms of severe immunodeficiency]	0.0	5	1	1	1
137043	1710	use t-lymphocyte from VZV immune donor	[using T-lymphocytes from VZV immune donors]	0.0	6	1	1	1
137044	1710	concentration dependent	[concentration dependent]	0.0	2	1	1	1
137045	1710	type of progenitor cell	[type of progenitor cell]	0.0	4	1	1	1
137046	1710	possibly mononuclear cell	[possibly mononuclear cells]	0.0	3	1	1	1
137047	1710	range ppt	[range ppt]	0.0	2	1	1	1
137048	1710	molecular weight of 32, 36	[molecular weights of 32, 36]	0.0	5	1	1	1
137049	1710	b29 gene expression	[B29 gene expression]	0.0	3	1	1	1
137050	1710	human cd14-transfected hamster ovary fibroblast	[human CD14-transfected hamster ovary fibroblasts]	0.0	5	1	1	1
137051	1710	origin of various disorder	[origin of various disorders]	0.0	4	1	1	1
137052	1710	mue3 -binding protein tfe3	[muE3 -binding protein TFE3]	0.0	4	1	1	1
137053	1710	mitochondrial transmembrane potential	[Mitochondrial transmembrane potential]	0.0	3	1	1	1
137054	1710	size range	[size range]	0.0	2	1	1	1
137055	1710	dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	0.0	4	1	1	1
137056	1710	Stable expression a human homeobox gene	[Stable expression a human homeobox gene]	0.0	6	1	1	1
137057	1710	extract with sodium deoxycholate	[extracts with sodium deoxycholate]	0.0	4	1	1	1
137058	1710	modulation of the competence	[modulation of the competence]	0.0	4	1	1	1
137059	1710	transcription of class	[transcription of classes]	0.0	3	1	1	1
137060	1710	acute hepatitis b virus infection	[acute hepatitis B virus infection]	0.0	5	1	1	1
137061	1710	immunodeficiency virus hiv promoter	[immunodeficiency virus HIV promoter]	0.0	4	1	1	1
137062	1710	peripheral blood of donor	[peripheral blood of donors]	0.0	4	2	2	1
137063	1710	direct circulate leukocyte into tissue	[directing circulating leukocytes into tissues]	0.0	5	1	1	1
137064	1710	amino acid 425	[amino acids 425]	0.0	3	1	1	1
137065	1710	related lineage	[related lineages]	0.0	2	1	1	1
137066	1710	relative ease	[relative ease]	0.0	2	1	1	1
137067	1710	little evidence regard the role	[little evidence regarding the role]	0.0	5	1	1	1
137068	1710	Granzyme	[Granzyme]	0.0	1	1	1	1
137069	1710	search protein ag	[searching protein Ag]	0.0	3	1	1	1
137070	1710	concentration of parath hormone	[concentration of parath hormone]	0.0	4	1	1	1
137071	1710	approximately 2 log-fold more glucocorticoid	[approximately 2 log-fold more glucocorticoids]	0.0	5	1	1	1
137072	1710	defective survival	[Defective survival]	0.0	2	1	1	1
137073	1710	(2) search for loss of allele	[(2) search for losses of allele]	0.0	6	1	1	1
137074	1710	one hour pulse-treatment	[One hour pulse-treatment]	0.0	3	1	1	1
137075	1710	other marker	[other markers]	0.0	2	1	1	1
137076	1710	other ccgccc binding protein	[other CCGCCC binding proteins]	0.0	4	1	1	1
137077	1710	regulation of the promoter function	[regulation of the promoter function]	0.0	5	1	1	1
137078	1710	coordination between Sp1	[coordination between Sp1]	0.0	3	1	1	1
137079	1710	protein rip	[protein RIP]	0.0	2	2	2	1
137080	1710	treatment of endothelial cell	[treatment of endothelial cells]	0.0	4	2	2	1
137081	1710	early protein BZLF1	[early proteins BZLF1]	0.0	3	1	1	1
137082	1710	(p 0.025)	[(P 0.025)]	0.0	2	1	1	1
137083	1710	analysis of cyclosporin mutant	[analysis of cyclosporin mutants]	0.0	4	1	1	1
137084	1710	potential effect of antioxidant therapy	[potential effects of antioxidant therapies.]	0.0	5	1	1	1
137085	1710	DNA-protein interaction in T cell	[DNA-protein interactions in T cells]	0.0	5	1	1	1
137086	1710	upstream region UAS3 -1168	[upstream regions UAS3 -1168]	0.0	4	1	1	1
137087	1710	agent phorbol	[agent phorbol]	0.0	2	1	1	1
137088	1710	h with cd16 ligand	[h with CD16 ligands]	0.0	4	1	1	1
137089	1710	transcription factor in hematopoietic differentiation	[transcription factors in hematopoietic differentiation]	0.0	5	1	1	1
137090	1710	protein set a series	[proteins setting a series]	0.0	4	1	1	1
137091	1710	absence of cyclosporin	[absence of cyclosporin]	0.0	3	1	1	1
137092	1710	several generation of unrelated family	[several generations of unrelated families]	0.0	5	1	1	1
137093	1710	50% inhibitory concentration of mp	[50% inhibitory concentrations of MP]	0.0	5	1	1	1
137094	1710	expression of v-src	[Expression of v-src]	0.0	3	1	1	1
137095	1710	peak between 1-2 h. in response	[peaking between 1-2 h, in response]	0.0	6	1	1	1
137096	1710	paternal expression in three,	[paternal expression in three,]	0.0	4	1	1	1
137097	1710	serum-contain mediuhd adherent colony	[serum-containing medium, adherent colonies]	0.0	4	1	1	1
137098	1710	addition to the phosphorylation	[addition to the phosphorylation]	0.0	4	1	1	1
137099	1710	cell shape change	[cell shape changes]	0.0	3	1	1	1
137100	1710	form of Epstein-Barr virus	[form of Epstein-Barr virus]	0.0	4	1	1	1
137101	1710	reflection	[reflection]	0.0	1	1	1	1
137102	1710	differentiation of hemopoietic progenitor	[differentiation of hemopoietic progenitors]	0.0	4	1	1	1
137103	1710	negative IkappaBalpha construct resistant	[negative IkappaBalpha construct resistant]	0.0	4	1	1	1
137104	1710	notch,	[Notch,]	0.0	1	1	1	1
137105	1710	resistance of this domain	[resistance of this domain]	0.0	4	1	1	1
137106	1710	NF-IL6 anti-c/ebpdelta nf-il6beta	[NF-IL6 anti-C/EBPdelta NF-IL6beta]	0.0	3	1	1	1
137107	1710	detection rate	[detection rate]	0.0	2	1	1	1
137108	1710	1 out of 13 control	[1 out of 13 controls]	0.0	5	1	1	1
137109	1710	soluble glucose homopolymer	[soluble glucose homopolymer]	0.0	3	1	1	1
137110	1710	G61: Aes1/2	[G61: AES1/2]	0.0	2	1	1	1
137111	1710	cell hybridization approach	[cell hybridization approach]	0.0	3	1	1	1
137112	1710	subsequent increase in the ikappabalpha level	[subsequent increase in the IkappaBalpha levels]	0.0	6	1	1	1
137113	1710	even after analysis	[even after analysis]	0.0	3	1	1	1
137114	1710	"minus"	["minus"]	0.0	1	1	1	1
137115	1710	ebv replication,	[EBV replication,]	0.0	2	1	1	1
137116	1710	receptor beta-chain core promoter	[receptor beta-chain core promoter]	0.0	4	1	1	1
137117	1710	cell dysregulation	[cell dysregulation]	0.0	2	1	1	1
137118	1710	contrast to the autoregulation	[contrast to the autoregulation]	0.0	4	1	1	1
137119	1710	light of therapeutic use	[light of therapeutic use]	0.0	4	1	1	1
137120	1710	remodeling of tissue	[remodeling of tissues]	0.0	3	1	1	1
137121	1710	viral latent gene promoter	[viral latent gene promoter]	0.0	4	1	1	1
137122	1710	strong nuclear positivity	[Strong nuclear positivity]	0.0	3	1	1	1
137123	1710	pml/raralpha mouse	[PML/RARalpha mice]	0.0	2	1	1	1
137124	1710	pbl from donor	[PBL from donors]	0.0	3	1	1	1
137125	1710	kda variant	[kDa variant]	0.0	2	1	1	1
137126	1710	major (mhc) haplotype	[major (MHC) haplotypes]	0.0	3	1	1	1
137127	1710	IL2 mrna	[IL2 mRNA]	0.0	2	1	1	1
137128	1710	thymocyte with epithelial cell TEC	[thymocytes with epithelial cells TEC]	0.0	5	1	1	1
137129	1710	lead onto the endothelial surface	[leading onto the endothelial surface]	0.0	5	1	1	1
137130	1710	other steroid receptor drug	[Other steroid receptor drugs]	0.0	4	1	1	1
137131	1710	effect of monochloramine nh2cl	[effects of monochloramine NH2Cl]	0.0	4	1	1	1
137132	1710	ccaat/enhancer-binding	[CCAAT/enhancer-binding]	0.0	1	1	1	1
137133	1710	unicellular-unilineage culture analysis of gene expression	[Unicellular-unilineage cultures analysis of gene expression]	0.0	6	1	1	1
137134	1710	Finally, tpa addition	[Finally, TPA addition]	0.0	3	1	1	1
137135	1710	pkc depletion	[PKC depletion]	0.0	2	1	1	1
137136	1710	peripheral leucocyte in man	[peripheral leucocytes in men]	0.0	4	1	1	1
137137	1710	interindividual difference	[interindividual differences]	0.0	2	1	1	1
137138	1710	transfer of IkappaB-alpha	[transfer of IkappaB-alpha]	0.0	3	1	1	1
137139	1710	3) content of t3, dysfunction	[3) content of T3, dysfunction]	0.0	5	1	1	1
137140	1710	mechanism in infarction AMI	[mechanism in infarction AMI]	0.0	4	1	1	1
137141	1710	secretion of the cytokine interleukin-8 il-8	[secretion of the cytokine interleukin-8 IL-8]	0.0	6	1	1	1
137142	1710	CIITA mechanism	[CIITA mechanism]	0.0	2	1	1	1
137143	1710	epidermis	[epidermis]	0.0	1	1	1	1
137144	1710	protein rna	[protein RNA]	0.0	2	1	1	1
137145	1710	treatment of hpc	[treatment of HPCs]	0.0	3	1	1	1
137146	1710	-independent transactivation	[-independent transactivation]	0.0	2	1	1	1
137147	1710	early inhibition of g0s2 expression	[early inhibition of G0S2 expression]	0.0	5	1	1	1
137148	1710	(GP)	[(GP)]	0.0	1	1	1	1
137149	1710	SCM-1-producer T	[SCM-1-producer T]	0.0	2	1	1	1
137150	1710	several stimulus elicit oxidative stress	[several stimuli eliciting oxidative stress]	0.0	5	1	1	1
137151	1710	effect of growth hormone	[effect of growth hormone]	0.0	4	1	1	1
137152	1710	exposure of cell type to lipopolysaccharide	[Exposure of cell types to lipopolysaccharide]	0.0	6	1	1	1
137153	1710	cell use mrna display	[cells using mRNA display]	0.0	4	1	1	1
137154	1710	proinflammatory cytokine gene	[proinflammatory cytokine genes]	0.0	3	1	1	1
137155	1710	il-6 gene expression in monocyte	[IL-6 gene expression in monocytes]	0.0	5	1	1	1
137156	1710	pcr analysis from individual	[PCR analysis from individuals]	0.0	4	1	1	1
137157	1710	murine p40 gene	[murine p40 genes]	0.0	3	1	1	1
137158	1710	oxygen species in inflammatory disease	[oxygen species in inflammatory diseases]	0.0	5	1	1	1
137159	1710	120 minute	[120 min]	0.0	2	1	1	1
137160	1710	increase moderately	[increasing moderately]	0.0	2	1	1	1
137161	1710	type adenovirus in human t-lymphocyte	[type adenovirus in human T-lymphocytes]	0.0	5	1	1	1
137162	1710	47 cd4+ t-cell clone	[47 CD4+ T-cell clones]	0.0	4	1	1	1
137163	1710	action of pcdd	[action of PCDDs/PCDFs]	0.0	3	1	1	1
137164	1710	grow particularly in the stage	[growing particularly in the stages]	0.0	5	1	1	1
137165	1710	single cyclic element	[single cyclic element]	0.0	3	1	1	1
137166	1710	diffusible protein such as soluble e-selectin	[Diffusible proteins such as soluble E-selectin]	0.0	6	1	1	1
137167	1710	central role in vertebrate regulation	[central role in vertebrate regulation]	0.0	5	1	1	1
137168	1710	have eosinophilic granule	[having eosinophilic granules]	0.0	3	1	1	1
137169	1710	pxqxt/ sequence	[PXQXT/S sequence]	0.0	2	1	1	1
137170	1710	cis -regulatory element	[cis -regulatory elements]	0.0	3	1	1	1
137171	1710	malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[malignant fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	6	1	1	1
137172	1710	T cell nfat activator protein-1	[T cells NFAT activator protein-1]	0.0	5	1	1	1
137173	1710	essential gene	[essential genes]	0.0	2	1	1	1
137174	1710	immunodeficiency virus hiv-1 infection	[immunodeficiency virus HIV-1 infection]	0.0	4	1	1	1
137175	1710	patient risk	[patients risk]	0.0	2	1	1	1
137176	1710	stimulus mediate aspect	[stimuli mediating aspects]	0.0	3	1	1	1
137177	1710	normal human tonsil	[normal human tonsils]	0.0	3	1	1	1
137178	1710	monocyte to alveolar macrophage protein	[monocytes to alveolar macrophage proteins]	0.0	5	1	1	1
137179	1710	mobility group protein i/y	[mobility group protein I/Y]	0.0	4	1	1	1
137180	1710	specific radiometric assay	[specific radiometric assay]	0.0	3	1	1	1
137181	1710	evidence most likely identical proteins,	[evidence most likely identical proteins,]	0.0	5	1	1	1
137182	1710	vitamin d receptor -retinoid	[vitamin D receptor -retinoid]	0.0	4	1	1	1
137183	1710	mM aminoguanidine	[mM aminoguanidine]	0.0	2	1	1	1
137184	1710	course of prednisone mg	[course of prednisone mg]	0.0	4	1	1	1
137185	1710	factor from T lymphocyte	[factors from T lymphocytes]	0.0	4	1	1	1
137186	1710	multiple distinct allelic family	[multiple distinct allelic families]	0.0	4	1	1	1
137187	1710	transcriptional properties unlike other oncoprotein	[transcriptional properties, unlike other oncoproteins]	0.0	5	1	1	1
137188	1710	receptor superfamily,	[receptor superfamily,]	0.0	2	1	1	1
137189	1710	leukocyte lineages, include b lymphocyte	[leukocyte lineages, including B lymphocytes]	0.0	5	1	1	1
137190	1710	modulate release of factor	[modulating release of factors]	0.0	4	1	1	1
137191	1710	(th1) cell	[(TH1) cells]	0.0	2	1	1	1
137192	1710	only use constituent	[only using constituents]	0.0	3	1	1	1
137193	1710	undifferentiated u937 cell	[undifferentiated U937 cells]	0.0	3	1	1	1
137194	1710	stat5 with signal pathway	[STAT5 with signaling pathways]	0.0	4	1	1	1
137195	1710	appear soon after the induction	[appearing soon after the induction]	0.0	5	1	1	1
137196	1710	makaume mtbe	[makeup, MTBE]	0.0	2	1	1	1
137197	1710	PTK inhibition	[PTK inhibition]	0.0	2	1	1	1
137198	1710	dissociation constant (Kd)	[dissociation constant (Kd)]	0.0	3	1	1	1
137199	1710	contrast to ln cell	[contrast to LN cells]	0.0	4	1	1	1
137200	1710	analysis use a probe	[analysis using a probe]	0.0	4	1	1	1
137201	1710	inactivation of JAK3	[inactivation of JAK3]	0.0	3	1	1	1
137202	1710	blood lymphocyte B-cell leukemia	[blood lymphocytes B-cell leukemia]	0.0	4	1	1	1
137203	1710	transient pseudo-hypoaldosteronism level of aldosterone receptor	[Transient pseudo-hypoaldosteronism level of aldosterone receptors]	0.0	6	1	1	1
137204	1710	cytokine facilitate progression	[cytokine facilitating progression]	0.0	3	1	1	1
137205	1710	dissociation constant of receptor	[dissociation constant of receptor]	0.0	4	4	4	1
137206	1710	complex class transactivator	[complex class transactivator]	0.0	3	1	1	1
137207	1710	hsp70 peptide	[Hsp70 peptide]	0.0	2	1	1	1
137208	1710	monocyte in response	[monocytes in response]	0.0	3	1	1	1
137209	1710	terminal repeat quasispecy	[terminal repeat quasispecies]	0.0	3	1	1	1
137210	1710	level in mature human monocyte	[levels in mature human monocytes]	0.0	5	1	1	1
137211	1710	include breast cancer	[including breast cancer]	0.0	3	1	1	1
137212	1710	expression of a receptor	[expression of a receptor]	0.0	4	1	1	1
137213	1710	Ser5	[Ser5]	0.0	1	1	1	1
137214	1710	dominant component of latent memory	[dominant components of latent memory]	0.0	5	1	1	1
137215	1710	prominent binding between JAK1	[prominent binding between JAK1]	0.0	4	1	1	1
137216	1710	serum responsive element	[serum responsive element]	0.0	3	1	1	1
137217	1710	specific region	[specific regions]	0.0	2	1	1	1
137218	1710	kb id-3l transcript together	[kb Id-3L transcript together]	0.0	4	1	1	1
137219	1710	series (a) of variant	[series (A) of variants]	0.0	4	1	1	1
137220	1710	structural basis for mimicry	[structural basis for mimicry]	0.0	4	1	1	1
137221	1710	t-cell activation response	[T-cell activation response]	0.0	3	1	1	1
137222	1710	rephosphorylation	[rephosphorylation]	0.0	1	1	1	1
137223	1710	principal objective of the study	[principal objective of the study]	0.0	5	1	1	1
137224	1710	carcinoma HeLa cell	[carcinoma HeLa cells]	0.0	3	1	1	1
137225	1710	inducer of adhesion molecule	[inducers of adhesion molecules]	0.0	4	1	1	1
137226	1710	interleukin-1 beta production in monocyte	[interleukin-1 beta production in monocytes]	0.0	5	1	1	1
137227	1710	expression of a dominant form	[expression of a dominant form]	0.0	5	1	1	1
137228	1710	16-bp see srf/ ets element	[16-bp SEE SRF/ ETS element]	0.0	5	1	1	1
137229	1710	proliferator receptor	[proliferator receptor]	0.0	2	1	1	1
137230	1710	effect of ciprofloxacin at concentration	[effect of ciprofloxacin at concentrations]	0.0	5	1	1	1
137231	1710	contain repeat of 21 bp	[containing repeats of 21 bp]	0.0	5	1	1	1
137232	1710	abnormally low level	[abnormally low levels]	0.0	3	1	1	1
137233	1710	mainly block induction	[mainly blocking induction]	0.0	3	1	1	1
137234	1710	activity of several element	[activity of several elements]	0.0	4	1	1	1
137235	1710	various type include chronic leukaemia	[various types including chronic leukaemia]	0.0	5	2	2	1
137236	1710	activity of this cell population	[activities of these cell populations]	0.0	5	1	1	1
137237	1710	-dependent induction	[-dependent induction]	0.0	2	1	1	1
137238	1710	dominant mutant mek1s218/222a	[dominant mutant MEK1S218/222A]	0.0	3	1	1	1
137239	1710	bteb2	[BTEB2]	0.0	1	1	1	1
137240	1710	element in HeLa cell	[element in HeLa cells]	0.0	4	1	1	1
137241	1710	class molecule in cell	[class molecules in cells]	0.0	4	2	2	1
137242	1710	regulation of many cytokine gene	[regulation of many cytokine genes]	0.0	5	1	1	1
137243	1710	NF-AT1 transcription factor complex	[NF-AT1 transcription factor complexes]	0.0	4	1	1	1
137244	1710	disease-free survival idfs)	[disease-free survival (DFS)]	0.0	3	1	1	1
137245	1710	t) cell	[T) cells]	0.0	2	1	1	1
137246	1710	part of the atherosclerosis-promoting effect	[part of the atherosclerosis-promoting effect]	0.0	5	1	1	1
137247	1710	relationship in human tonsil	[relationship in human tonsils]	0.0	4	1	1	1
137248	1710	8, fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma	[8, fibrous histiocytoma 6, rhabdomyosarcoma leiomyosarcoma]	0.0	6	1	1	1
137249	1710	il-1 beta release	[IL-1 beta release]	0.0	3	1	1	1
137250	1710	cell of the adult lineage	[cells of the adult lineage]	0.0	5	1	1	1
137251	1710	548 bp il-2	[548 bp IL-2]	0.0	3	1	1	1
137252	1710	organ transplant	[organ transplants]	0.0	2	1	1	1
137253	1710	use nuclear extract from brain	[using nuclear extracts from brain]	0.0	5	1	1	1
137254	1710	less mature form	[less mature forms]	0.0	3	1	1	1
137255	1710	human U937 cell line	[human U937 cell line]	0.0	4	1	1	1
137256	1710	leukemia cell u937	[leukemia cells U937]	0.0	3	1	1	1
137257	1710	suggest a feedback loop	[suggesting a feedback loop]	0.0	4	1	1	1
137258	1710	Jeg-3 human immunosuppression downregulation	[Jeg-3 human immunosuppression downregulation]	0.0	4	1	1	1
137259	1710	pro-inflammatory mediator	[pro-inflammatory mediators]	0.0	2	1	1	1
137260	1710	HHV-6 (gs) cDNA clone	[HHV-6 (GS) cDNA clone]	0.0	4	1	1	1
137261	1710	process similar to the periodontal disease	[processes similar to the periodontal diseases]	0.0	6	1	1	1
137262	1710	prb form	[pRB forms]	0.0	2	1	1	1
137263	1710	expression of type 1 interferon	[expression of type 1 interferon]	0.0	5	1	1	1
137264	1710	several b transcription factor	[several B transcription factors]	0.0	4	1	1	1
137265	1710	uvb range	[UVB range]	0.0	2	1	1	1
137266	1710	large number eutopic endometrium	[large numbers eutopic endometrium]	0.0	4	1	1	1
137267	1710	effect of a p21ras	[effect of a p21ras]	0.0	4	1	1	1
137268	1710	active b	[active B]	0.0	2	1	1	1
137269	1710	transcriptional pattern	[transcriptional pattern]	0.0	2	1	1	1
137270	1710	receptor in runner	[receptor in runner]	0.0	3	1	1	1
137271	1710	fibrous histiocytoma	[fibrous histiocytoma]	0.0	2	1	1	1
137272	1710	tcc c5b-7	[TCC C5b-7]	0.0	2	1	1	1
137273	1710	stimulate peripheral blood cell hla b8+	[stimulating peripheral blood cells HLA B8+]	0.0	6	1	1	1
137274	1710	autosomal pattern of inheritance	[autosomal pattern of inheritance]	0.0	4	1	1	1
137275	1710	form of severe immunodeficiency	[forms of severe immunodeficiency]	0.0	4	1	1	1
137276	1710	binding to kappa b site	[binding to kappa B sites]	0.0	5	1	1	1
137277	1710	cd15lo, cd34+/-, hla-dr	[CD15lo, CD34+/-, HLA-DR]	0.0	3	1	1	1
137278	1710	interaction with recognition sequence	[interaction with recognition sequence]	0.0	4	1	1	1
137279	1710	unrecognized mutation in this gene	[unrecognized mutation in this gene]	0.0	5	1	1	1
137280	1710	a /csa	[A /CsA]	0.0	2	1	1	1
137281	1710	three distinct form	[three distinct forms]	0.0	3	2	2	1
137282	1710	individual member of rel protein	[individual members of Rel proteins]	0.0	5	1	1	1
137283	1710	dexamethasone-induced transcription	[dexamethasone-induced transcription]	0.0	2	1	1	1
137284	1710	over-expression by transfection into b cell	[over-expression by transfection into B cells]	0.0	6	1	1	1
137285	1710	stimulus in primary b-cell	[stimuli in primary B-cells]	0.0	4	1	1	1
137286	1710	heterodimerization with Max	[heterodimerization with Max]	0.0	3	1	1	1
137287	1710	breast aspirate of woman	[breast aspirates of women]	0.0	4	1	1	1
137288	1710	determinant of the promoter's activity	[determinant of the promoter's activity]	0.0	5	1	1	1
137289	1710	exposure to 5 nm vd3	[Exposure to 5 nM VD3]	0.0	5	1	1	1
137290	1710	phase of the menstrual cycle	[phases of the menstrual cycle]	0.0	5	1	1	1
137291	1710	OBF-1 a novel b coactivator	[OBF-1 a novel B coactivator]	0.0	5	1	1	1
137292	1710	10-fold 4 day	[10-fold 4 days]	0.0	3	1	1	1
137293	1710	indexing term	[indexing terms]	0.0	2	1	1	1
137294	1710	-bsa-fitc	[-BSA-FITC]	0.0	1	1	1	1
137295	1710	immunoglobulin g-seropositive donor	[immunoglobulin G-seropositive donors]	0.0	3	1	1	1
137296	1710	1 mcp-1	[1 MCP-1]	0.0	2	1	1	1
137297	1710	index patient	[index patients]	0.0	2	1	1	1
137298	1710	VDR RAR alpha	[VDR RAR alpha]	0.0	3	1	1	1
137299	1710	specificity of the formation	[specificity of the formation]	0.0	4	1	1	1
137300	1710	abnormally low gr number	[abnormally low GR number]	0.0	4	1	1	1
137301	1710	immunodeficiency virus type 1 expression	[immunodeficiency virus type 1 expression]	0.0	5	1	1	1
137302	1710	parent with receptor binding in leucocyte	[parent with receptor binding in leucocytes]	0.0	6	1	1	1
137303	1710	inhibition of the hiv-1 antigen expression	[inhibition of the HIV-1 antigen expression]	0.0	6	1	1	1
137304	1710	receptor to therapy in colitis	[receptor to therapy in colitis]	0.0	5	1	1	1
137305	1710	u937 in human fibroblast	[U937 in human fibroblasts]	0.0	4	1	1	1
137306	1710	heterogeneity within fetal muscle	[heterogeneity within fetal muscle]	0.0	4	1	1	1
137307	1710	contradiction, expression of a form	[contradiction, expression of a form]	0.0	5	1	1	1
137308	1710	amount in testis	[amounts in testis]	0.0	3	1	1	1
137309	1710	activation by phosphatase inhibitor	[Activation by phosphatase inhibitors]	0.0	4	1	1	1
137310	1710	preassociation of stat1 with stat2	[Preassociation of STAT1 with STAT2]	0.0	5	1	1	1
137311	1710	after activation,	[After activation,]	0.0	2	1	1	1
137312	1710	cyclic amp-responsive protein	[cyclic AMP-responsive protein]	0.0	3	1	1	1
137313	1710	role of MMTV	[role of MMTV]	0.0	3	1	1	1
137314	1710	exposure to multiple signals, include cytokine	[exposure to multiple signals, including cytokines]	0.0	6	1	1	1
137315	1710	egr1 regulation	[EGR1 regulation]	0.0	2	1	1	1
137316	1710	LMP transcriptional start site	[LMP transcriptional start site]	0.0	4	1	1	1
137317	1710	concentration of blood substrate	[concentrations of blood substrates]	0.0	4	1	1	1
137318	1710	cross-link of fcr	[Cross-linking of FcR]	0.0	3	1	1	1
137319	1710	generate mechanism	[generating mechanisms]	0.0	2	1	1	1
137320	1710	ap1 reporter construct (ic50	[AP1 reporter constructs (IC50]	0.0	4	1	1	1
137321	1710	tyrosine kinase inhibition by herbimycin	[Tyrosine kinase inhibition by herbimycin]	0.0	5	1	1	1
137322	1710	cis-tran isomerase activity	[cis-trans isomerase activities]	0.0	3	1	1	1
137323	1710	mononuclear leukocyte of MDD patient	[mononuclear leukocytes of MDD patients]	0.0	5	1	1	1
137324	1710	12-O-tetradecanoylphorbol-13-acetate	[12-O-tetradecanoylphorbol-13-acetate]	0.0	1	1	1	1
137325	1710	harbor mutation	[harboring mutations]	0.0	2	1	1	1
137326	1710	plaque assay	[plaque assay]	0.0	2	1	1	1
137327	1710	different expression pattern	[different expression patterns]	0.0	3	1	1	1
137328	1710	25-dihydroxyvitamin	[25-dihydroxyvitamin]	0.0	1	3	3	1
137329	1710	C 571 base pair	[C 571 base pairs]	0.0	4	1	1	1
137330	1710	peripheral lymph node of mouse	[peripheral lymph nodes of mice]	0.0	5	1	1	1
137331	1710	kappab transcriptional activity	[kappaB transcriptional activity]	0.0	3	1	1	1
137332	1710	activation of jak3	[activation of JAK3]	0.0	3	1	1	1
137333	1710	domain include domain for DNA	[domains including domains for DNA]	0.0	5	1	1	1
137334	1710	presence of several element	[presence of several elements]	0.0	4	1	1	1
137335	1710	however, high microg/100 millileter	[However, high microg/100 ml]	0.0	4	1	1	1
137336	1710	diffuse large cell lymphoma	[diffuse large cell lymphoma]	0.0	4	1	1	1
137337	1710	include pre-B lymphoblastic leukemia	[including pre-B lymphoblastic leukemia]	0.0	4	1	1	1
137338	1710	synergistic action CPRE	[synergistic action CPRE]	0.0	3	1	1	1
137339	1710	chimeric receptor kit/il-4r alpha	[chimeric receptor kit/IL-4R alpha]	0.0	4	1	1	1
137340	1710	C-terminal portion	[C-terminal portion]	0.0	2	1	1	1
137341	1710	add ttg to extract	[adding tTG to extracts]	0.0	4	1	1	1
137342	1710	patient with micrograms/day	[patients with micrograms/day]	0.0	3	1	1	1
137343	1710	specific assay	[specific assay]	0.0	2	1	1	1
137344	1710	apoptosis induce apoptosis in cell	[apoptosis inducing apoptosis in cells]	0.0	5	1	1	1
137345	1710	inflammatory stimulus product	[inflammatory stimuli products]	0.0	3	1	1	1
137346	1710	molecular probe	[molecular probes]	0.0	2	1	1	1
137347	1710	interleukin-2 state	[interleukin-2 state]	0.0	2	1	1	1
137348	1710	DNA present into T cell	[DNA present into T cells]	0.0	5	1	1	1
137349	1710	features:	[features:]	0.0	1	1	1	1
137350	1710	disease in Japan, cepharanthine	[diseases in Japan, cepharanthine]	0.0	4	1	1	1
137351	1710	normal control subject use technique	[normal control subjects using techniques]	0.0	5	1	1	1
137352	1710	most important target cell	[most important target cells]	0.0	4	1	1	1
137353	1710	three, heterozygous DNA variation	[three, heterozygous DNA variations]	0.0	4	1	1	1
137354	1710	absorbance maxima shift	[absorbance maxima shifts]	0.0	3	1	1	1
137355	1710	suggest dependent on constraint	[suggesting dependent on constraints]	0.0	4	1	1	1
137356	1710	adult mel cell	[adult MEL cells]	0.0	3	1	1	1
137357	1710	finding of eosinophilia	[finding of eosinophilia]	0.0	3	1	1	1
137358	1710	key event lymphocyte action	[key event lymphocyte action]	0.0	4	1	1	1
137359	1710	8 a.m.	[8 a.m.]	0.0	2	1	1	1
137360	1710	hormonal metabolic status after surgery comparison	[Hormonal metabolic status after surgery comparison]	0.0	6	1	1	1
137361	1710	loosely cell with long neurite process	[loosely cells with long neurite processes]	0.0	6	1	1	1
137362	1710	dex-resistant, receptor clone icr-27	[dex-resistant, receptor clone ICR-27]	0.0	4	1	1	1
137363	1710	case by immunohistology	[cases by immunohistology]	0.0	3	1	1	1
137364	1710	0.67 to 0.73 map unit	[0.67 to 0.73 map units]	0.0	5	1	1	1
137365	1710	proline -rich carboxy terminus	[proline -rich carboxy terminus]	0.0	4	1	1	1
137366	1710	characteristic among nuclear factor	[characteristic among nuclear factors]	0.0	4	1	1	1
137367	1710	cellular proliferation of T cell	[cellular proliferation of T cells]	0.0	5	1	1	1
137368	1710	human gene encode b-binding-proteins	[human genes encoding B-binding-proteins]	0.0	4	1	1	1
137369	1710	include phorbol 13-acetate	[including phorbol 13-acetate]	0.0	3	1	1	1
137370	1710	dramatic coordinate induction	[dramatic coordinate induction]	0.0	3	1	1	1
137371	1710	activation of signal-transduce smad protein	[activation of signal-transducing Smad proteins]	0.0	5	1	1	1
137372	1710	coinfected T cell	[coinfected T cells]	0.0	3	1	1	1
137373	1710	type of E-box consensus motif CAGATG	[types of E-box consensus motifs CAGATG]	0.0	6	1	1	1
137374	1710	ifn-beta induction	[IFN-beta induction]	0.0	2	1	1	1
137375	1710	interstitial collagenase	[Interstitial collagenase]	0.0	2	1	1	1
137376	1710	activity of erythrocyte protein	[activities of erythrocyte proteins]	0.0	4	1	1	1
137377	1710	woman young than year	[women younger than years]	0.0	4	1	1	1
137378	1710	interaction in anergic T cell	[interactions in anergic T cells]	0.0	5	1	1	1
137379	1710	h of culture	[h of culture]	0.0	3	1	1	1
137380	1710	contain the kda stat5 protein	[containing the kDa STAT5 proteins]	0.0	5	1	1	1
137381	1710	tar pathway	[TAR pathway]	0.0	2	1	1	1
137382	1710	truncation mutant of the e2f-1 promoter	[truncation mutants of the E2F-1 promoter]	0.0	6	1	1	1
137383	1710	effect on (il)-2 promoter activity	[effect on (IL)-2 promoter activity]	0.0	5	1	1	1
137384	1710	modulate calcium in vascular muscle cell	[modulating calcium in vascular muscle cells]	0.0	6	1	1	1
137385	1710	matrix preparation	[matrix preparations]	0.0	2	2	2	1
137386	1710	Abl sh3-interacting protein	[Abl SH3-interacting protein]	0.0	3	1	1	1
137387	1710	hsp70 production	[hsp70 production]	0.0	2	1	1	1
137388	1710	evidence for a sensitive activate pathway	[evidence for an sensitive activating pathway]	0.0	6	1	1	1
137389	1710	interleukin receptor	[interleukin receptor]	0.0	2	1	1	1
137390	1710	subunit of the il-4r	[subunit of the IL-4R]	0.0	4	1	1	1
137391	1710	unusual cd56+ cd16- egl	[unusual CD56+ CD16- eGLs]	0.0	4	1	1	1
137392	1710	weight.	[weight.]	0.0	1	1	1	1
137393	1710	principal objective	[principal objective]	0.0	2	1	1	1
137394	1710	aids Epstein-Barr virus EBV	[AIDS Epstein-Barr virus EBV]	0.0	4	1	1	1
137395	1710	complex biological process	[complex biological process]	0.0	3	1	1	1
137396	1710	nf-at nuclear factor a sequence	[NF-AT nuclear factor a sequence]	0.0	5	1	1	1
137397	1710	first lesion	[first lesion]	0.0	2	1	1	1
137398	1710	80.2 15.5 (p p 0.01	[80.2 15.5 (P P 0.01]	0.0	5	1	1	1
137399	1710	role protect cell	[role protecting cells]	0.0	3	1	1	1
137400	1710	vulvar leiomyosarcoma	[vulvar leiomyosarcoma]	0.0	2	1	1	1
137401	1710	Reciprocally, inhibition of nf-kappab activation	[Reciprocally, inhibition of NF-kappaB activation]	0.0	5	1	1	1
137402	1710	MHC class transcription factor	[MHC class transcription factor]	0.0	4	1	1	1
137403	1710	cellular incorporation	[cellular incorporation]	0.0	2	1	1	1
137404	1710	n-Acetyl-L-cysteine	[n-Acetyl-L-cysteine]	0.0	1	1	1	1
137405	1710	Comparison of group 1	[Comparison of group 1]	0.0	4	1	1	1
137406	1710	acid during maturation	[acid during maturation]	0.0	3	1	1	1
137407	1710	abolish acute hepatic injury	[abolishing acute hepatic injury]	0.0	4	1	1	1
137408	1710	down-modulation of /erythroid hpc growth	[down-modulation of /erythroid HPC growth]	0.0	5	1	1	1
137409	1710	only through the effect of acetate	[only through the effect of acetate]	0.0	6	1	1	1
137410	1710	monoallelic	[monoallelic]	0.0	1	1	1	1
137411	1710	nf-kappab p65 rela	[NF-kappaB p65 RelA]	0.0	3	1	1	1
137412	1710	epithelial cell malignancy carcinoma	[epithelial cell malignancies carcinoma]	0.0	4	1	1	1
137413	1710	endogenous receptor.	[endogenous receptor.]	0.0	2	1	1	1
137414	1710	airways,	[airways,]	0.0	1	1	1	1
137415	1710	target for early factor	[target for early factor]	0.0	4	1	1	1
137416	1710	loss of dnase	[loss of DNase]	0.0	3	1	1	1
137417	1710	lead to separable gene regulatory response	[leading to separable gene regulatory responses]	0.0	6	1	1	1
137418	1710	granulopoiesis postnatally, die by 8	[granulopoiesis postnatally, dying by 8]	0.0	5	1	1	1
137419	1710	bind to tre-1 in a manner	[binding to TRE-1 in a manner]	0.0	6	1	1	1
137420	1710	risk group	[risk groups]	0.0	2	1	1	1
137421	1710	member in chromosome translocation	[members in chromosome translocations]	0.0	4	1	1	1
137422	1710	target tissue as ovulation marker	[target tissues as ovulation markers]	0.0	5	1	1	1
137423	1710	express a specific pattern	[expressing a specific pattern]	0.0	4	1	1	1
137424	1710	differ from dq3.2 at residue 57	[differing from DQ3.2 at residue 57]	0.0	6	1	1	1
137425	1710	fetal stage.	[fetal stage.]	0.0	2	1	1	1
137426	1710	substrate necessary	[substrates necessary]	0.0	2	1	1	1
137427	1710	mouse development in nervous system	[mouse development in nervous system]	0.0	5	1	1	1
137428	1710	macrophage in human lesion	[macrophages in human lesions]	0.0	4	1	1	1
137429	1710	(gamma	[(gamma]	0.0	1	1	1	1
137430	1710	otf-1 protein fraction	[OTF-1 protein fractions]	0.0	3	1	1	1
137431	1710	multiple lytic reactivity high	[multiple lytic reactivities high]	0.0	4	1	1	1
137432	1710	produce a putative new retrovirus	[producing a putative new retrovirus]	0.0	5	1	1	1
137433	1710	molecular interaction of PML	[molecular interaction of PML]	0.0	4	1	1	1
137434	1710	promoter-dependent reporter construct	[promoter-dependent reporter constructs]	0.0	3	1	1	1
137435	1710	leucocyte in woman with syndrome	[leucocytes in women with syndrome]	0.0	5	1	1	1
137436	1710	membrane-proximal box pxp motif	[membrane-proximal box PXP motif]	0.0	4	1	1	1
137437	1710	important b cell-specific co-activator	[important B cell-specific co-activator]	0.0	4	1	1	1
137438	1710	induce degradation through enhancement	[inducing degradation through enhancement]	0.0	4	1	1	1
137439	1710	individual domain of the p85 subunit	[individual domains of the p85 subunit]	0.0	6	1	1	1
137440	1710	substrate for this kinase	[substrates for these kinases]	0.0	4	1	1	1
137441	1710	produce progeny	[producing progeny]	0.0	2	1	1	1
137442	1710	reach the half-maximal effect	[reaching the half-maximal effect]	0.0	4	1	1	1
137443	1710	comparison, a inefficient inducer	[comparison, a inefficient inducer]	0.0	4	1	1	1
137444	1710	NK k562 cancer cell killing	[NK K562 cancer cell killing]	0.0	5	1	1	1
137445	1710	transfection of a expression	[Transfection of an expression]	0.0	4	1	1	1
137446	1710	aspect include presentation, response with acid	[aspects including presentation, response with acid]	0.0	6	1	1	1
137447	1710	comparison, nuclei of lymphocyte	[comparison, nuclei of lymphocytes]	0.0	4	1	1	1
137448	1710	NF-kappa B1 homodimer	[NF-kappa B1 homodimers]	0.0	3	1	1	1
137449	1710	thymic T cell from the mouse	[thymic T cells from the mice]	0.0	6	1	1	1
137450	1710	t(3;14) (q27;q32)	[t(3;14) (q27;q32)]	0.0	2	1	1	1
137451	1710	cd8+ CTL line	[CD8+ CTL line]	0.0	3	1	1	1
137452	1710	25-Dihydroxyvitamin	[25-Dihydroxyvitamin]	0.0	1	1	1	1
137453	1710	effective humoral response	[effective humoral response]	0.0	3	1	1	1
137454	1710	erythroblastosis virus	[erythroblastosis virus]	0.0	2	1	1	1
137455	1710	medium ng/ml)	[medium ng/ml)]	0.0	2	1	1	1
137456	1710	contain media	[containing media]	0.0	2	1	1	1
137457	1710	des-arg	[des-Arg]	0.0	1	1	1	1
137458	1710	interaction on nkl cell	[Interaction on NKL cells]	0.0	4	1	1	1
137459	1710	prb molecular weight	[pRB molecular weight]	0.0	3	1	1	1
137460	1710	difference in the mechanism(s) of action	[differences in the mechanism(s) of action]	0.0	6	1	1	1
137461	1710	lt-beta	[LT-beta]	0.0	1	1	1	1
137462	1710	Differential induction of the NF-AT complex	[Differential induction of the NF-AT complex]	0.0	6	1	1	1
137463	1710	70% decrease	[70% decrease]	0.0	2	1	1	1
137464	1710	(creb/atf)	[(CREB/ATF)]	0.0	1	1	1	1
137465	1710	induction of transformation	[induction of transformation]	0.0	3	1	1	1
137466	1710	39 ms patient	[39 MS patients]	0.0	3	1	1	1
137467	1710	HbF production	[HbF production]	0.0	2	1	1	1
137468	1710	marker as Ki-67 staining	[markers as Ki-67 staining]	0.0	4	1	1	1
137469	1710	uninfected hl-60 subclone	[uninfected HL-60 subclones]	0.0	3	1	1	1
137470	1710	two specific inhibitor of serine/threonine phosphatase	[two specific inhibitors of serine/threonine phosphatases]	0.0	6	1	1	1
137471	1710	26 ovarian carcinoma patient	[26 ovarian carcinoma patients]	0.0	4	1	1	1
137472	1710	sequence within the stretch	[sequence within the stretch]	0.0	4	1	1	1
137473	1710	mark chromatin domain	[marking chromatin domains]	0.0	3	1	1	1
137474	1710	41-kDa nuclear protein	[41-kDa nuclear protein]	0.0	3	1	1	1
137475	1710	pro-B-cell acute leukemia	[pro-B-cell acute leukemia]	0.0	3	1	1	1
137476	1710	molecules, nfatp	[molecules, NFATp]	0.0	2	1	1	1
137477	1710	Th1-dominated (auto)immune inflammation	[Th1-dominated (auto)immune inflammation]	0.0	3	1	1	1
137478	1710	modulation by intracrine mechanism	[modulation by intracrine mechanisms]	0.0	4	1	1	1
137479	1710	cyclin e-cdk2-	[cyclin E-Cdk2-]	0.0	2	1	1	1
137480	1710	four signal transducer	[four signal transducers]	0.0	3	1	1	1
137481	1710	involve the BCL-6 gene	[involving the BCL-6 gene]	0.0	4	1	1	1
137482	1710	oligonucleotide sequence	[oligonucleotide sequence]	0.0	2	1	1	1
137483	1710	low level lps	[low levels LPS]	0.0	3	1	1	1
137484	1710	Ca(2+) -dependent phosphatase calcineurin	[Ca(2+) -dependent phosphatase calcineurin]	0.0	4	1	1	1
137485	1710	electrophoretic DNA mobility	[electrophoretic DNA mobility]	0.0	3	1	1	1
137486	1710	calcium-dependent, modification	[calcium-dependent, modification]	0.0	2	1	1	1
137487	1710	rapidak tyrosine	[rapid, tyrosine]	0.0	2	1	1	1
137488	1710	mobility group protein hmg	[mobility group protein HMG]	0.0	4	1	1	1
137489	1710	factor transcriptional activation	[factor transcriptional activation]	0.0	3	1	1	1
137490	1710	nonresponsive progenitor with no potential	[nonresponsive progenitors with no potential]	0.0	5	1	1	1
137491	1710	(54%) clone from the centre	[(54%) clones from the centre]	0.0	5	1	1	1
137492	1710	vitro administration	[vitro administration]	0.0	2	2	2	1
137493	1710	competition between ZEB	[competition between ZEB]	0.0	3	1	1	1
137494	1710	huvec adhesion	[HUVEC adhesion]	0.0	2	1	1	1
137495	1710	suggest important.	[suggesting important.]	0.0	2	1	1	1
137496	1710	control (21-50	[controls (21-50]	0.0	2	1	1	1
137497	1710	gtp -binding protein	[GTP -binding proteins]	0.0	3	1	1	1
137498	1710	specific binding power	[specific binding power]	0.0	3	1	1	1
137499	1710	cytopathic effect in human T cell	[cytopathic effects in human T cells]	0.0	6	1	1	1
137500	1710	moreover, in T helper (th) clone	[Moreover, in T helper (Th) clones]	0.0	6	1	1	1
137501	1710	intragenic mutation	[intragenic mutations]	0.0	2	1	1	1
137502	1710	/pebp2/cbf	[/PEBP2/CBF]	0.0	1	1	1	1
137503	1710	(HS)	[(HS)]	0.0	1	1	1	1
137504	1710	peptide in vitro	[peptides in vitro]	0.0	3	1	1	1
137505	1710	integrin tyrosine phosphorylation indicate a relationship	[integrin tyrosine phosphorylation indicating a relationship]	0.0	6	1	1	1
137506	1710	follow translocation in acute leukemia	[following translocations in acute leukemias]	0.0	5	1	1	1
137507	1710	slight effect.	[slight effect.]	0.0	2	2	2	1
137508	1710	(within min) nf-kappa b	[(within min) NF-kappa B]	0.0	4	1	1	1
137509	1710	exon-intron structure	[exon-intron structure]	0.0	2	1	1	1
137510	1710	inhibition process	[inhibition processes]	0.0	2	1	1	1
137511	1710	differentiation toward neutrophil	[differentiation toward neutrophils]	0.0	3	1	1	1
137512	1710	primary transcriptional response	[primary transcriptional response]	0.0	3	1	1	1
137513	1710	lead to activation of genes.	[leading to activation of genes.]	0.0	5	1	1	1
137514	1710	tnf factor traf3	[TNF factor TRAF3]	0.0	3	1	1	1
137515	1710	genes, include receptor	[genes, including receptor]	0.0	3	1	1	1
137516	1710	tnf factor traf2	[TNF factor TRAF2]	0.0	3	1	1	1
137517	1710	differentiation of cell in model	[differentiation of cells in models]	0.0	5	1	1	1
137518	1710	responsiveness of human mononuclear leukocyte HML	[responsiveness of human mononuclear leukocytes HML]	0.0	6	1	1	1
137519	1710	Rel-related, kappa b-binding protein	[Rel-related, kappa B-binding protein]	0.0	4	1	1	1
137520	1710	18-deoxyaldosterone	[18-deoxyaldosterone]	0.0	1	1	1	1
137521	1710	interaction of sickle erythrocyte	[Interaction of sickle erythrocytes]	0.0	4	1	1	1
137522	1710	set of B-lymphoid-specific gene	[set of B-lymphoid-specific genes]	0.0	4	1	1	1
137523	1710	interaction include the retinoblastoma protein Rb	[interactions including the retinoblastoma protein Rb]	0.0	6	1	1	1
137524	1710	direct the synthesis through the DNA	[directing the synthesis through the DNA]	0.0	6	1	1	1
137525	1710	phagocyte glomerular mesangial cell	[phagocytes glomerular mesangial cells]	0.0	4	1	1	1
137526	1710	initial stage of development.	[initial stages of development.]	0.0	4	1	1	1
137527	1710	suggest independent	[suggesting independent]	0.0	2	2	2	1
137528	1710	growth phase	[growth phase]	0.0	2	1	1	1
137529	1710	oxidant acid mm) in vitro,	[oxidant acid mM) in vitro,]	0.0	5	1	1	1
137530	1710	compound sarcophytol a	[compound sarcophytol A]	0.0	3	1	1	1
137531	1710	extract from mt-2 cell	[extract from MT-2 cells]	0.0	4	1	1	1
137532	1710	mutation/deletion	[mutation/deletion]	0.0	1	1	1	1
137533	1710	effect of signal	[effect of signaling]	0.0	3	1	1	1
137534	1710	putative lymphoid-specific transcription factor	[putative lymphoid-specific transcription factor]	0.0	4	1	1	1
137535	1710	specific receptor blocker	[specific receptor blocker]	0.0	3	1	1	1
137536	1710	domain of the factor	[domains of the factors]	0.0	4	1	1	1
137537	1710	provision	[provision]	0.0	1	2	2	1
137538	1710	contain two cysteine region	[containing two cysteine regions]	0.0	4	1	1	1
137539	1710	rise in the number	[rise in the number]	0.0	4	1	1	1
137540	1710	exposure to high level	[exposure to high levels]	0.0	4	1	1	1
137541	1710	Furthermore, introduction of exogenous gata-1	[Furthermore, introduction of exogenous GATA-1]	0.0	5	1	1	1
137542	1710	growth of diverse cell type	[growth of diverse cell types]	0.0	5	1	1	1
137543	1710	select outcomes,	[select outcomes,]	0.0	2	1	1	1
137544	1710	(tcr) gene rearrangement	[(TcR) gene rearrangement]	0.0	3	1	1	1
137545	1710	expression of receptor on lymphocyte	[Expression of receptors on lymphocytes]	0.0	5	1	1	1
137546	1710	growth of various cell type	[growth of various cell types]	0.0	5	1	1	1
137547	1710	hours, oleate	[hours, oleate]	0.0	2	1	1	1
137548	1710	specific uptake of [3h]1,25(oh)2d3	[specific uptake of [3H]1,25(OH)2D3]	0.0	4	1	1	1
137549	1710	eosinophil cell line YJ	[eosinophil cell line YJ]	0.0	4	1	1	1
137550	1710	effect on the release expression	[effect on the release expression]	0.0	5	1	1	1
137551	1710	inhibition of gene	[inhibition of genes]	0.0	3	1	1	1
137552	1710	Ca2+ -dependent induction	[Ca2+ -dependent induction]	0.0	3	1	1	1
137553	1710	nur77 beta cDNA	[nur77 beta cDNA]	0.0	3	1	1	1
137554	1710	expression of superoxide dismutase	[expression of superoxide dismutase]	0.0	4	1	1	1
137555	1710	receptor concentration before therapy	[receptor concentrations before therapy]	0.0	4	1	1	1
137556	1710	hypothalamic-pituitary-adrenocortical axis	[hypothalamic-pituitary-adrenocortical axis]	0.0	2	1	1	1
137557	1710	signal-transduction pathway	[signal-transduction pathway]	0.0	2	1	1	1
137558	1710	finally, study a further series	[Finally, studying a further series]	0.0	5	1	1	1
137559	1710	regulation of il-6 synthesis	[Regulation of IL-6 synthesis]	0.0	4	1	1	1
137560	1710	member especially the homolog	[members especially the homolog]	0.0	4	1	1	1
137561	1710	rapid tyrosine phosphorylation of protein	[rapid tyrosine phosphorylation of proteins]	0.0	5	1	1	1
137562	1710	protein sp	[proteins SP]	0.0	2	1	1	1
137563	1710	formation with nf-at	[formation with NF-AT]	0.0	3	1	1	1
137564	1710	mechanism of antiviral action	[mechanism of antiviral action]	0.0	4	1	1	1
137565	1710	t-cell growth factor	[T-cell growth factor]	0.0	3	1	1	1
137566	1710	1, 25-dihydroxyvitamin D3 135(oh)2d3 receptor	[1, 25-dihydroxyvitamin D3 1,25(OH)2D3 receptor]	0.0	5	1	1	1
137567	1710	antioxidant activity	[antioxidant activity]	0.0	2	1	1	1
137568	1710	(contain a base pair mutation	[(containing a base pair mutation]	0.0	5	1	1	1
137569	1710	dhs in intron	[DHS in intron]	0.0	3	1	1	1
137570	1710	DNA binding activity factor	[DNA binding activity factor]	0.0	4	1	1	1
137571	1710	stage of the lytic cycle	[stages of the lytic cycle]	0.0	5	1	1	1
137572	1710	IL-8 concentration	[IL-8 concentration]	0.0	2	1	1	1
137573	1710	novel t-cell-specific activator tcf-1	[novel T-cell-specific activator TCF-1]	0.0	4	1	1	1
137574	1710	colostrum inhibitory	[colostrum inhibitory]	0.0	2	1	1	1
137575	1710	heterodimer partner	[heterodimer partner]	0.0	2	1	1	1
137576	1710	ng/mL,	[ng/mL,]	0.0	1	1	1	1
137577	1710	T enhancer element	[T enhancer element]	0.0	3	1	1	1
137578	1710	hgmw-approved symbol	[HGMW-approved symbol]	0.0	2	1	1	1
137579	1710	alveolar macrophage in activation	[alveolar macrophages in activation]	0.0	4	1	1	1
137580	1710	low concentration of RA	[Low concentrations of RA]	0.0	4	1	1	1
137581	1710	nature of stat protein	[nature of STAT proteins]	0.0	4	1	1	1
137582	1710	direct interaction of transcription factor	[Direct interaction of transcription factors]	0.0	5	1	1	1
137583	1710	member of the receptor family,	[members of the receptor family,]	0.0	5	1	1	1
137584	1710	pha blood lymphocyte pbl	[PHA blood lymphocytes PBL]	0.0	4	1	1	1
137585	1710	granulocytic lineage (with acid	[granulocytic lineage (with acid]	0.0	4	1	1	1
137586	1710	ubiquitous component	[ubiquitous component]	0.0	2	1	1	1
137587	1710	151 bp	[151 bp]	0.0	2	1	1	1
137588	1710	motif ap3-l	[motif AP3-L]	0.0	2	1	1	1
137589	1710	stage of the maturation	[stages of the maturation]	0.0	4	1	1	1
137590	1710	express a egr-1 transgene	[expressing an Egr-1 transgene]	0.0	4	1	1	1
137591	1710	patient cases)	[patients cases)]	0.0	2	1	1	1
137592	1710	cell during anemia in mouse	[cells during anemia in mice]	0.0	5	1	1	1
137593	1710	histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[histiocytoma 6, rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
137594	1710	co-stimulatory molecule by cell	[co-stimulatory molecules by cells]	0.0	4	1	1	1
137595	1710	transcriptional factor include sp1	[transcriptional factors including Sp1]	0.0	4	1	1	1
137596	1710	pattern of beta-gal expression	[pattern of beta-gal expression]	0.0	4	1	1	1
137597	1710	bone marrow sample from patient	[Bone marrow samples from patients]	0.0	5	1	1	1
137598	1710	mua element	[muA elements]	0.0	2	1	1	1
137599	1710	receptor in human mononuclear cell	[receptors in human mononuclear cells]	0.0	5	1	1	1
137600	1710	low cortisol excretion in subject	[low cortisol excretion in subjects]	0.0	5	1	1	1
137601	1710	c-terminus of Oct-2a	[C-terminus of Oct-2a]	0.0	3	1	1	1
137602	1710	heterodimer consist of subunits, p50	[heterodimer consisting of subunits, p50]	0.0	5	1	1	1
137603	1710	cloning human sr-bp	[Cloning human SR-BP]	0.0	3	1	1	1
137604	1710	role for acid	[role for acid]	0.0	3	1	1	1
137605	1710	use rt- pcr	[Using RT- PCR]	0.0	3	1	1	1
137606	1710	60 bp	[60 bp]	0.0	2	1	1	1
137607	1710	study of roles.	[study of roles.]	0.0	3	1	1	1
137608	1710	promoter by Oct-2	[promoter by Oct-2]	0.0	3	1	1	1
137609	1710	human cell HAEC	[human cells HAEC]	0.0	3	1	1	1
137610	1710	chronic renal failure A-CRF	[chronic renal failure A-CRF]	0.0	4	1	1	1
137611	1710	primary sensitization of T cell	[primary sensitization of T cells]	0.0	5	1	1	1
137612	1710	biopsy a aids-associated lesion	[Biopsies an AIDS-associated lesion]	0.0	4	1	1	1
137613	1710	oxidant acid hocl	[oxidant acid HOCl]	0.0	3	1	1	1
137614	1710	ras upstream	[ras upstream]	0.0	2	1	1	1
137615	1710	increase in camp	[increase in cAMP]	0.0	3	1	1	1
137616	1710	agreement with decrease	[agreement with decrease]	0.0	3	1	1	1
137617	1710	nf-kappab /rel	[NF-kappaB /Rel]	0.0	2	1	1	1
137618	1710	CCAAT box	[CCAAT box]	0.0	2	1	1	1
137619	1710	concept of heterotrans-activation	[concept of heterotrans-activation]	0.0	3	1	1	1
137620	1710	nm RA cell for response	[nM RA cells for response]	0.0	5	1	1	1
137621	1710	receptor dimerization process	[receptor dimerization process]	0.0	3	1	1	1
137622	1710	study on population hematopoietic progenitor	[studies on populations hematopoietic progenitors]	0.0	5	1	1	1
137623	1710	radical stress	[radical stress]	0.0	2	1	1	1
137624	1710	33 stretch of c-terminus	[33 stretch of C-terminus]	0.0	4	1	1	1
137625	1710	m all-tran acid	[M all-trans acid]	0.0	3	1	1	1
137626	1710	role for the residue	[role for the residues]	0.0	4	1	1	1
137627	1710	Rh(D) positive cell	[Rh(D) positive cells]	0.0	3	1	1	1
137628	1710	proinflammatory agonist	[proinflammatory agonists]	0.0	2	1	1	1
137629	1710	factor AP-1/Octamer	[factor AP-1/Octamer]	0.0	2	1	1	1
137630	1710	interferon gamma induction	[interferon gamma induction]	0.0	3	1	1	1
137631	1710	use a gcrbeta antibody	[using a GCRbeta antibody]	0.0	4	1	1	1
137632	1710	transcription coactivator oca-b	[transcription coactivator OCA-B]	0.0	3	1	1	1
137633	1710	autocrine mechanism for persistent cytokine	[autocrine mechanism for persistent cytokine]	0.0	5	1	1	1
137634	1710	human adult erythroid cell system	[human adult erythroid cell system]	0.0	5	1	1	1
137635	1710	achievable concentrations.	[achievable concentrations.]	0.0	2	1	1	1
137636	1710	tr2re-sv40	[TR2RE-SV40]	0.0	1	1	1	1
137637	1710	occur at 30 minute (phase	[occurring at 30 minutes (phase]	0.0	5	1	1	1
137638	1710	three isoform of CBF beta	[Three isoforms of CBF beta]	0.0	5	1	1	1
137639	1710	growth factor gf	[growth factor GF]	0.0	3	1	1	1
137640	1710	lymphotrophic virus type-i tax gene	[lymphotrophic virus type-I tax gene]	0.0	5	1	1	1
137641	1710	analogous framework signal in phagocyte	[analogous framework signaling in phagocytes]	0.0	5	1	1	1
137642	1710	lymphoid precursor cell in cell	[lymphoid precursor cells in cells]	0.0	5	1	1	1
137643	1710	nf-kappa b (consist	[NF-kappa B (consisting]	0.0	3	1	1	1
137644	1710	multiple family	[multiple families]	0.0	2	1	1	1
137645	1710	nuclear factor-kappa b activation in ec	[nuclear factor-kappa B activation in EC]	0.0	6	1	1	1
137646	1710	interleukin-6 of the class	[interleukin-6 of the class]	0.0	4	1	1	1
137647	1710	patient with php	[patients with PHP]	0.0	3	1	1	1
137648	1710	reciprocal elevation of expression	[reciprocal elevation of expression]	0.0	4	1	1	1
137649	1710	transcription factor e2f1	[transcription factor E2F1]	0.0	3	1	1	1
137650	1710	setting of pathology	[settings of pathology]	0.0	3	1	1	1
137651	1710	calcium/calmodulin-dependent	[calcium/calmodulin-dependent]	0.0	1	1	1	1
137652	1710	nfatc protein in nuclear extract	[NFATc protein in nuclear extracts]	0.0	5	1	1	1
137653	1710	localize to lesion	[localizing to lesions]	0.0	3	1	1	1
137654	1710	accumulation of lesion with age	[accumulation of lesions with age]	0.0	5	1	1	1
137655	1710	adult expression	[adult expression]	0.0	2	1	1	1
137656	1710	low molecular protein sp	[low molecular proteins SP]	0.0	4	1	1	1
137657	1710	Specific foci	[Specific foci]	0.0	2	1	1	1
137658	1710	effect include antitumor activity	[effects including antitumor activities]	0.0	4	1	1	1
137659	1710	protein tax	[protein Tax]	0.0	2	3	3	1
137660	1710	vmax	[Vmax]	0.0	1	1	1	1
137661	1710	subunit of gtp-binding protein	[subunits of GTP-binding proteins]	0.0	4	1	1	1
137662	1710	vitro growth	[vitro growth]	0.0	2	1	1	1
137663	1710	disrupt nf-kappa b signal	[disrupting NF-kappa B signaling]	0.0	4	1	1	1
137664	1710	phorbol ester neutrophil burst activation	[phorbol ester neutrophil burst activation]	0.0	5	1	1	1
137665	1710	lineage in human leukemia hl-60 cell	[lineage in human leukemia HL-60 cells]	0.0	6	1	1	1
137666	1710	virus of primate	[virus of primates]	0.0	3	1	1	1
137667	1710	erk1 kinase	[ERK1 kinase]	0.0	2	1	1	1
137668	1710	analysis of the first rdna	[analysis of the first cDNAs]	0.0	5	1	1	1
137669	1710	converge	[converging]	0.0	1	1	1	1
137670	1710	class histocompatibility complex cell line	[class histocompatibility complex cell lines]	0.0	5	1	1	1
137671	1710	susceptibility of monocyte	[susceptibility of monocytes]	0.0	3	1	1	1
137672	1710	role of aml1/eto in leukemogenesis	[role of AML1/ETO in leukemogenesis]	0.0	5	1	1	1
137673	1710	20 h of stimulation	[20 h of stimulation]	0.0	4	1	1	1
137674	1710	G receptor	[G receptor]	0.0	2	1	1	1
137675	1710	further study of the immunity	[further studies of the immunity]	0.0	5	1	1	1
137676	1710	major positive regulatory role	[major positive regulatory role]	0.0	4	1	1	1
137677	1710	treatment with all-tran acid	[treatment with all-trans acid]	0.0	4	1	1	1
137678	1710	novel elastase inhibitor peptide gdsp	[novel elastase inhibitor peptide GDSP]	0.0	5	1	1	1
137679	1710	significant capacity secondary	[significant capacity secondary]	0.0	3	1	1	1
137680	1710	encode jun-B the transcription protein	[encoding jun-B the transcription protein]	0.0	5	1	1	1
137681	1710	synthesis in human t-cell clone	[synthesis in human T-cell clones]	0.0	5	1	1	1
137682	1710	molecule a1/bfl-1	[molecule A1/Bfl-1]	0.0	2	1	1	1
137683	1710	pathogenesis of promyelocytic leukemia	[pathogenesis of promyelocytic leukemia]	0.0	4	2	2	1
137684	1710	a-sensitive mechanism	[A-sensitive mechanism]	0.0	2	1	1	1
137685	1710	inducible ubiquitous component after activation	[inducible ubiquitous component after activation]	0.0	5	1	1	1
137686	1710	indicate a affinity of sr-bp high	[indicating an affinity of SR-BP higher]	0.0	6	1	1	1
137687	1710	ifn-gamma gene transcription	[IFN-gamma gene transcription]	0.0	3	1	1	1
137688	1710	IL-4 upregulation	[IL-4 upregulation]	0.0	2	1	1	1
137689	1710	most important mediator	[most important mediators]	0.0	3	1	1	1
137690	1710	gene of the pair	[gene of the pair]	0.0	4	1	1	1
137691	1710	exclusively in the cytoplasm clusters.	[exclusively in the cytoplasm clusters.]	0.0	5	1	1	1
137692	1710	first NH2-terminal residue	[first NH2-terminal residues]	0.0	3	1	1	1
137693	1710	PL/IM 430 antibody	[PL/IM 430 antibody]	0.0	3	1	1	1
137694	1710	stimulation by il-1 alpha	[stimulation by IL-1 alpha]	0.0	4	1	1	1
137695	1710	split protein	[split protein]	0.0	2	1	1	1
137696	1710	form diabete	[forms diabetes]	0.0	2	1	1	1
137697	1710	Glucocorticoid receptor characteristic in monocyte	[Glucocorticoid receptor characteristics in monocytes]	0.0	5	1	1	1
137698	1710	enhancer element essential	[enhancer element essential]	0.0	3	1	1	1
137699	1710	10 kilobasis	[10 kilobases]	0.0	2	1	1	1
137700	1710	-250 bp	[-250 bp]	0.0	2	1	1	1
137701	1710	0.21-0.33 nm.	[0.21-0.33 nM.]	0.0	2	1	1	1
137702	1710	1 terminal repeat in T cell	[1 terminal repeat in T cells]	0.0	6	1	1	1
137703	1710	c-fo mrna expression in cell line	[c-fos mRNA expression in cell lines]	0.0	6	1	1	1
137704	1710	chronic lymphocytic leukaemias	[chronic lymphocytic leukaemias]	0.0	3	1	1	1
137705	1710	c/ebp-epsilon mrna	[C/EBP-epsilon mRNA]	0.0	2	1	1	1
137706	1710	Jak3 expression	[Jak3 expression]	0.0	2	1	1	1
137707	1710	lineage acid	[lineage acid]	0.0	2	1	1	1
137708	1710	cell line myeloblast	[cell lines myeloblasts]	0.0	3	1	1	1
137709	1710	new therapeutic strategy	[new therapeutic strategies]	0.0	3	1	1	1
137710	1710	deletion of V beta	[deletion of V beta]	0.0	4	1	1	1
137711	1710	gsh glutathione gssg ratio	[GSH glutathione GSSG ratio]	0.0	4	1	1	1
137712	1710	lymphokine of cytokine	[lymphokines of cytokines]	0.0	3	1	1	1
137713	1710	hla-dq heterodimer	[HLA-DQ heterodimer]	0.0	2	1	1	1
137714	1710	establish pbmc culture in colony	[establishing PBMC cultures in colonies]	0.0	5	1	1	1
137715	1710	slowly migrate b1 complex	[slowly migrating B1 complex]	0.0	4	1	1	1
137716	1710	interleukin receptor alpha chain	[interleukin receptor alpha chain]	0.0	4	1	1	1
137717	1710	central nervous system cell	[central nervous system cells]	0.0	4	1	1	1
137718	1710	absence the area	[absence the area]	0.0	3	1	1	1
137719	1710	tissue insult	[tissue insult]	0.0	2	1	1	1
137720	1710	induction of proto-oncogene in blood monocyte	[Induction of proto-oncogene in blood monocytes]	0.0	6	1	1	1
137721	1710	helper-inducer (memory) T cell cd4+cd45r0+cd45ra-cd29highcd11a+	[helper-inducer (memory) T cells CD4+CD45R0+CD45RA-CD29highCD11a+]	0.0	5	1	1	1
137722	1710	leukemia APL particularly the variant	[leukemia APL particularly the variant]	0.0	5	1	1	1
137723	1710	T lymphocyte CTL response	[T lymphocyte CTL response]	0.0	4	1	1	1
137724	1710	adhesion molecule-1 icam-1 on cell	[adhesion molecule-1 ICAM-1 on cells]	0.0	5	1	1	1
137725	1710	activity of the upstream region	[activity of the upstream region]	0.0	5	1	1	1
137726	1710	majority of acute leukemia	[majority of acute leukemias]	0.0	4	1	1	1
137727	1710	use of inhibitors.	[use of inhibitors.]	0.0	3	1	1	1
137728	1710	possible relevance	[possible relevance]	0.0	2	1	1	1
137729	1710	virulence characteristic	[virulence characteristic]	0.0	2	1	1	1
137730	1710	immunoglobulin V region promoter	[immunoglobulin V region promoters]	0.0	4	1	1	1
137731	1710	nuclear translocation of NF-ATp	[nuclear translocation of NF-ATp]	0.0	4	1	1	1
137732	1710	T cell deficit	[T cell deficit]	0.0	3	1	1	1
137733	1710	proliferation of cells.	[proliferation of cells.]	0.0	3	1	1	1
137734	1710	interferon ifi	[interferons IFNs]	0.0	2	1	1	1
137735	1710	downstream camp response element	[downstream cAMP response elements]	0.0	4	1	1	1
137736	1710	level of mineralocorticoid receptor mr	[levels of mineralocorticoid receptor MR]	0.0	5	1	1	1
137737	1710	50 mcr young than 40.	[50, MCR younger than 40.]	0.0	5	1	1	1
137738	1710	cytokine-stimulated vein cell HUVEC	[cytokine-stimulated vein cells HUVEC]	0.0	4	1	1	1
137739	1710	corticosteroid inhibit the generation	[corticosteroids inhibiting the generation]	0.0	4	1	1	1
137740	1710	stretch of amino acid	[stretch of amino acids]	0.0	4	1	1	1
137741	1710	specifically in mature cell	[specifically in maturing cells]	0.0	4	1	1	1
137742	1710	genetic basis of the translocation	[genetic basis of the translocation]	0.0	5	1	1	1
137743	1710	autoregulatory feedback inhibitor	[autoregulatory feedback inhibitor]	0.0	3	1	1	1
137744	1710	recurrent abnormality highlight putative loci	[recurrent abnormalities highlighting putative loci]	0.0	5	1	1	1
137745	1710	kd, result from alternative splicing	[kD, resulting from alternative splicing]	0.0	5	1	1	1
137746	1710	means of shift assay EMSA	[means of shift assay EMSA]	0.0	5	1	1	1
137747	1710	pcr method	[PCR method]	0.0	2	1	1	1
137748	1710	monocytic activity factor	[monocytic activity factor]	0.0	3	1	1	1
137749	1710	x1- box	[X1- boxes]	0.0	2	1	1	1
137750	1710	high interindividual variation	[high interindividual variation]	0.0	3	1	1	1
137751	1710	overexpress pkc-zeta	[overexpressing PKC-zeta]	0.0	2	1	1	1
137752	1710	index of lmp1	[indices of LMP1]	0.0	3	1	1	1
137753	1710	granulocyte-macrophage colony-stimumulatelany-stg factor proliferation	[granulocyte-macrophage colony-stimulating factor proliferation]	0.0	4	1	1	1
137754	1710	transient cotransfection in sense orientation tata	[Transient cotransfection in sense orientation tat/S]	0.0	6	1	1	1
137755	1710	cytokine such as IL-1beta	[cytokines such as IL-1beta]	0.0	4	1	1	1
137756	1710	problem of therapy	[Problems of therapy]	0.0	3	1	1	1
137757	1710	cell resistance to glucocorticoid	[cell resistance to glucocorticoids]	0.0	4	1	1	1
137758	1710	concurrent addition	[concurrent addition]	0.0	2	1	1	1
137759	1710	infection with epstein-barr virus	[infection with Epstein-Barr virus]	0.0	4	1	1	1
137760	1710	expression of colony-stimumulatelany-stg factor-1 receptor	[expression of colony-stimulating factor-1 receptor]	0.0	5	1	1	1
137761	1710	several agonist	[several agonists]	0.0	2	1	1	1
137762	1710	accessible human cell model	[accessible human cell model]	0.0	4	1	1	1
137763	1710	mouse nm23	[mouse nm23]	0.0	2	1	1	1
137764	1710	importantly, testing of a corresponding set	[Importantly, testing of a corresponding set]	0.0	6	1	1	1
137765	1710	domain of VIIa	[domain of VIIa]	0.0	3	1	1	1
137766	1710	cd45 event such as tyrosine phosphorylation	[CD45 events such as tyrosine phosphorylation]	0.0	6	1	1	1
137767	1710	accordingly, blot	[Accordingly, blots]	0.0	2	1	1	1
137768	1710	action of other protein	[action of other proteins]	0.0	4	1	1	1
137769	1710	transfer into hepatocyte	[transfer into hepatocytes]	0.0	3	1	1	1
137770	1710	binding of low-mobility complex	[binding of low-mobility complexes]	0.0	4	1	1	1
137771	1710	double- transgenic mouse	[double- transgenic mice]	0.0	3	1	1	1
137772	1710	viral RNA partition	[viral RNA partition]	0.0	3	1	1	1
137773	1710	alternative potential element	[alternative potential elements]	0.0	3	1	1	1
137774	1710	form stat3alpha	[forms STAT3alpha]	0.0	2	1	1	1
137775	1710	stably erythroblast	[stably erythroblasts]	0.0	2	1	1	1
137776	1710	(p 0.001)	[(p 0.001)]	0.0	2	1	1	1
137777	1710	apparent dissociation constant for aldosterone	[apparent dissociation constant for aldosterone]	0.0	5	1	1	1
137778	1710	positive effect on the expression	[positive effect on the expression]	0.0	5	1	1	1
137779	1710	include tissue factor	[including tissue factor]	0.0	3	1	1	1
137780	1710	activation of il4 transcription	[activation of IL4 transcription]	0.0	4	1	1	1
137781	1710	absence of treatment	[absence of treatment]	0.0	3	1	1	1
137782	1710	unique inhibitory role	[unique inhibitory role]	0.0	3	1	1	1
137783	1710	cytokine-induced immunodeficiency virus type hiv-1	[cytokine-induced immunodeficiency virus type HIV-1]	0.0	5	1	1	1
137784	1710	two DNA fragment pzvb10	[two DNA fragments pZVB10]	0.0	4	1	1	1
137785	1710	use autoradiographic technique	[using autoradiographic techniques]	0.0	3	1	1	1
137786	1710	cloning of a homeobox gene	[Cloning of a homeobox gene]	0.0	5	1	1	1
137787	1710	presence of TNF-alpha	[presence of TNF-alpha]	0.0	3	1	1	1
137788	1710	IRF-1 pathway of DNA apoptosis	[IRF-1 pathway of DNA apoptosis]	0.0	5	1	1	1
137789	1710	erythroid differentiation program of progenitor	[erythroid differentiation program of progenitors]	0.0	5	1	1	1
137790	1710	transformation by htlv-i	[transformation by HTLV-I]	0.0	3	1	1	1
137791	1710	potent immunosuppressive activity at concentration	[potent immunosuppressive activity at concentrations]	0.0	5	1	1	1
137792	1710	predominantly by cell	[predominantly by cells]	0.0	3	1	1	1
137793	1710	latency latency iii	[latency latency III]	0.0	3	1	1	1
137794	1710	binding site of ets-like factor	[binding sites of Ets-like factors]	0.0	5	1	1	1
137795	1710	important signal pathway	[important signaling pathways]	0.0	3	1	1	1
137796	1710	normal blood lymphocyte sample	[normal blood lymphocyte samples]	0.0	4	1	1	1
137797	1710	L132	[L132]	0.0	1	1	1	1
137798	1710	incorporation of atp	[incorporation of ATP]	0.0	3	1	1	1
137799	1710	c-myb in myelomonocytic expression	[c-Myb in myelomonocytic expression]	0.0	4	1	1	1
137800	1710	stimulation of tpa microM)	[stimulation of TPA microM)]	0.0	4	1	1	1
137801	1710	blood NK cell	[blood NK cells]	0.0	3	1	1	1
137802	1710	result in infant	[Results in infants]	0.0	3	1	1	1
137803	1710	basis for the regulatory interaction	[basis for the regulatory interaction]	0.0	5	1	1	1
137804	1710	mineralocorticoid receptor hormone-binding domain	[mineralocorticoid receptor hormone-binding domain]	0.0	4	1	1	1
137805	1710	event convert ligand-receptor interaction	[event converting ligand-receptor interactions]	0.0	4	1	1	1
137806	1710	costimulation with ec	[costimulation with EC]	0.0	3	1	1	1
137807	1710	(p 0.05, p	[(P 0.05, P]	0.0	3	1	1	1
137808	1710	machinery underlie this process.	[machinery underlying this process.]	0.0	4	1	1	1
137809	1710	subpopulation of stably cd4+ cell	[subpopulation of stably CD4+ cells]	0.0	5	1	1	1
137810	1710	therapeutic drug	[therapeutic drugs]	0.0	2	1	1	1
137811	1710	glucocorticoid gc inhibition	[glucocorticoid GC inhibition]	0.0	3	1	1	1
137812	1710	length c-jun promoter	[length c-jun promoter]	0.0	3	1	1	1
137813	1710	transcriptional repression domain	[transcriptional repression domain]	0.0	3	1	1	1
137814	1710	promonocytic u-937 cell	[promonocytic U-937 cells]	0.0	3	1	1	1
137815	1710	flank the 196 base pair region	[flanking the 196 base pair region]	0.0	6	1	1	1
137816	1710	study of development	[study of development]	0.0	3	1	1	1
137817	1710	gr cDNA	[GR cDNA]	0.0	2	1	1	1
137818	1710	induce transcription of the nuclear proto-oncogent	[inducing transcription of the nuclear proto-oncogenes]	0.0	6	1	1	1
137819	1710	progenitor with no erythropoietic potential	[progenitors with no erythropoietic potential]	0.0	5	1	1	1
137820	1710	tg epsilon26 mice,	[tg epsilon26 mice,]	0.0	3	1	1	1
137821	1710	platelet from untreated patient	[platelets from untreated patients]	0.0	4	1	1	1
137822	1710	act in actin polymerization	[acting in actin polymerization]	0.0	4	1	1	1
137823	1710	activation of cd4+ T cell	[Activation of CD4+ T cells]	0.0	5	1	1	1
137824	1710	reach a peak at 30 min.	[reaching a peak at 30 min.]	0.0	6	1	1	1
137825	1710	glucocorticoid receptor changes, respectively oppose	[glucocorticoid receptor changes, respectively opposing]	0.0	5	1	1	1
137826	1710	sequence in the HTLV-1 promoter.	[sequence in the HTLV-1 promoter.]	0.0	5	1	1	1
137827	1710	radiosensitivity	[radiosensitivity]	0.0	1	1	1	1
137828	1710	level of motor activity	[levels of motor activity]	0.0	4	1	1	1
137829	1710	exposure to nm 2,3,377-tc	[exposure to nM 2,3,7,8-TCDD]	0.0	4	1	1	1
137830	1710	effect on a voltage-gated na+ channel	[effect on a voltage-gated Na+ channel]	0.0	6	1	1	1
137831	1710	express the htlv-i tax protein	[expressing the HTLV-I Tax protein]	0.0	5	1	1	1
137832	1710	mismatch cleavage analysis	[mismatch cleavage analysis]	0.0	3	1	1	1
137833	1710	MHC class ii antigen induction	[MHC class II antigen induction]	0.0	5	1	1	1
137834	1710	effect on T cell function	[effects on T cell function]	0.0	5	1	1	1
137835	1710	phosphatase-positive multinucleated cell from monocyte	[phosphatase-positive multinucleated cells from monocytes]	0.0	5	1	1	1
137836	1710	property of early stage cell	[properties of early stage cells]	0.0	5	1	1	1
137837	1710	Rb of cyclin D3	[Rb of cyclin D3]	0.0	4	1	1	1
137838	1710	addition of preformed, nfkb2	[addition of preformed, NFKB2]	0.0	4	1	1	1
137839	1710	such as gata-1 common	[such as GATA-1 common]	0.0	4	1	1	1
137840	1710	human epstein-barr virus -negative b lymphocyte	[human Epstein-Barr virus -negative B lymphocytes]	0.0	6	1	1	1
137841	1710	expression in leukemia/lymphoma line	[expression in leukemia/lymphoma lines]	0.0	4	1	1	1
137842	1710	precursor cell line in vitro.	[precursor cell lines in vitro.]	0.0	5	1	1	1
137843	1710	IkappaBalpha turnover	[IkappaBalpha turnover]	0.0	2	1	1	1
137844	1710	context of T lymphocyte	[context of T lymphocytes]	0.0	4	1	1	1
137845	1710	bryostatin 1 (10 nm),	[bryostatin 1 (10 nM),]	0.0	4	1	1	1
137846	1710	weakly in lymph node	[weakly in lymph nodes]	0.0	4	1	1	1
137847	1710	hdlm-1 cell	[HDLM-1 cells]	0.0	2	1	1	1
137848	1710	difference in receptor number	[difference in receptor number]	0.0	4	1	1	1
137849	1710	regulation by metallothionein promoter	[regulation by metallothionein promoters]	0.0	4	1	1	1
137850	1710	ultrastructure	[ultrastructure]	0.0	1	1	1	1
137851	1710	interfere with the activity	[interfering with the activity]	0.0	4	1	1	1
137852	1710	increase in g0s2 mrna	[increase in G0S2 mRNA]	0.0	4	1	1	1
137853	1710	characteristic of one phagocyte system	[characteristics of one phagocyte system]	0.0	5	1	1	1
137854	1710	ls mutation -201/-184 NXS	[LS mutations -201/-184 NXS]	0.0	4	1	1	1
137855	1710	induction of a phenotype	[induction of a phenotype]	0.0	4	1	1	1
137856	1710	amount of activity	[amounts of activity]	0.0	3	1	1	1
137857	1710	E2F heterodimer	[E2F heterodimers]	0.0	2	1	1	1
137858	1710	binding monoclonal antibody specific	[binding monoclonal antibodies specific]	0.0	4	1	1	1
137859	1710	protein dimerization domain leukemic factor	[protein dimerization domain leukemic factor]	0.0	5	1	1	1
137860	1710	tolerance for tcf-1	[tolerance for TCF-1]	0.0	3	1	1	1
137861	1710	site such as the uterus	[sites such as the uterus]	0.0	5	1	1	1
137862	1710	technique block nf-kappab	[technique blocking NF-kappaB]	0.0	3	1	1	1
137863	1710	interestingly, in ciita cell hybrid	[Interestingly, in CIITA cell hybrids]	0.0	5	1	1	1
137864	1710	number of blood leukocyte	[number of blood leukocytes]	0.0	4	1	1	1
137865	1710	binding heterodimers, at early times.	[binding heterodimers, at early times.]	0.0	5	1	1	1
137866	1710	most specific oligonucleotide sequence	[most specific oligonucleotide sequence]	0.0	4	1	1	1
137867	1710	disorder involve differentiation	[disorders involving differentiation]	0.0	3	1	1	1
137868	1710	relatively young (18- female volunteer	[relatively young (18- female volunteers]	0.0	5	1	1	1
137869	1710	late stage of the maturation	[late stages of the maturation]	0.0	5	1	1	1
137870	1710	level of il-8 secretion	[levels of IL-8 secretion]	0.0	4	1	1	1
137871	1710	general inhibitor of proliferation	[general inhibitor of proliferation]	0.0	4	1	1	1
137872	1710	antigen-processing	[antigen-processing]	0.0	1	1	1	1
137873	1710	autoregulatory loop in monocyte	[autoregulatory loop in monocytes]	0.0	4	1	1	1
137874	1710	ets bind	[Ets binding]	0.0	2	1	1	1
137875	1710	LNCaP prostate cancer cell	[LNCaP prostate cancer cells]	0.0	4	1	1	1
137876	1710	hepatic factor hnf3 beta	[hepatic factor HNF3 beta]	0.0	4	1	1	1
137877	1710	breakpoint on chromosome 11 range	[breakpoints on chromosome 11 ranging]	0.0	5	1	1	1
137878	1710	potential role in the effect	[potential role in the effects]	0.0	5	1	1	1
137879	1710	antigen present cell apc	[antigen presenting cells APCs]	0.0	4	1	1	1
137880	1710	20 nmol/l, incubation time h	[20 nmol/l, incubation time h]	0.0	5	1	1	1
137881	1710	produce concurrent enhancement	[producing concurrent enhancement]	0.0	3	1	1	1
137882	1710	defective transport of class molecule	[defective transport of class molecules]	0.0	5	1	1	1
137883	1710	level in b	[levels in B]	0.0	3	1	1	1
137884	1710	1 ng/ml tbp-1	[1 ng/ml TBP-1]	0.0	3	1	1	1
137885	1710	event result	[events resulting]	0.0	2	1	1	1
137886	1710	preincubation only in u-937	[Preincubation only in U-937]	0.0	4	1	1	1
137887	1710	negative feedback loop	[negative feedback loop]	0.0	3	1	1	1
137888	1710	/CD28RE	[/CD28RE]	0.0	1	1	1	1
137889	1710	deletion derivative	[deletion derivatives]	0.0	2	1	1	1
137890	1710	myelomonocytic leukemia cmmol	[myelomonocytic leukemia CMMoL]	0.0	3	1	1	1
137891	1710	uptake by phagocyte	[uptake by phagocytes]	0.0	3	1	1	1
137892	1710	c-Raf increase	[c-Raf increase]	0.0	2	1	1	1
137893	1710	lung vascular leak	[lung vascular leak]	0.0	3	1	1	1
137894	1710	1) inhibition depletion	[1) inhibition depletion]	0.0	3	1	1	1
137895	1710	modify agent like diamide	[modifying agents like diamide]	0.0	4	1	1	1
137896	1710	inducible ubiquitous component within minute	[inducible ubiquitous component within min]	0.0	5	1	1	1
137897	1710	JAK3 immunodeficiency lymphocyte JAK3 pathway	[JAK3 immunodeficiency lymphocytes JAK3 pathways]	0.0	5	1	1	1
137898	1710	corticosteroid receptor in human leukocyte	[corticosteroid receptors in human leukocytes]	0.0	5	1	1	1
137899	1710	proliferation-specific transcription factor	[proliferation-specific transcription factor]	0.0	3	1	1	1
137900	1710	distal box	[distal box]	0.0	2	1	1	1
137901	1710	effect on gr transcription	[effect on GR transcription]	0.0	4	1	1	1
137902	1710	thus lead to production of c-Jun	[thus leading to production of c-Jun]	0.0	6	1	1	1
137903	1710	initiation of encephalomyocarditis virus emcv	[initiation of encephalomyocarditis virus EMCV]	0.0	5	1	1	1
137904	1710	upstream signal molecule	[upstream signaling molecules]	0.0	3	1	1	1
137905	1710	macrophage through CD14	[macrophages through CD14]	0.0	3	1	1	1
137906	1710	kd (30.3+/-2.5 nmol/L) for cortisol	[Kd (30.3+/-2.5 nmol/L) for cortisol]	0.0	5	1	1	1
137907	1710	distinguish carrier in androgen resistance	[distinguishing carriers in androgen resistance]	0.0	5	1	1	1
137908	1710	detailed analysis of deletion	[detailed analysis of deletions]	0.0	4	1	1	1
137909	1710	10 time	[10 times]	0.0	2	2	2	1
137910	1710	regulator in early t-cell activation	[regulator in early T-cell activation]	0.0	5	1	1	1
137911	1710	two ligand-induced, tyrosine-phosphorylated docking site	[two ligand-induced, tyrosine-phosphorylated docking sites]	0.0	5	1	1	1
137912	1710	activity factor colony-stimulating factor	[activity factor colony-stimulating factor]	0.0	4	1	1	1
137913	1710	role in HTLV-1 transformation	[role in HTLV-1 transformation]	0.0	4	1	1	1
137914	1710	new cell line	[new cell lines]	0.0	3	1	1	1
137915	1710	upregulation adhesion molecule-1 icam-1	[upregulation adhesion molecule-1 ICAM-1]	0.0	4	1	1	1
137916	1710	accord to model	[According to models]	0.0	3	1	1	1
137917	1710	expression of gamma-interferon protein	[Expression of gamma-interferon protein]	0.0	4	1	1	1
137918	1710	SIVmac replication	[SIVmac replication]	0.0	2	1	1	1
137919	1710	activation nf-chi b	[activation NF-chi B]	0.0	3	1	1	1
137920	1710	muE3	[muE3]	0.0	1	1	1	1
137921	1710	apoptosis-mediating receptor with sequence homology	[apoptosis-mediating receptor with sequence homology]	0.0	5	1	1	1
137922	1710	tshr extracellular domain	[TSHR extracellular domain]	0.0	3	1	1	1
137923	1710	CD20 promoter-CAT	[CD20 promoter-CAT]	0.0	2	1	1	1
137924	1710	contain enhancer/promoters	[containing enhancer/promoters]	0.0	2	1	1	1
137925	1710	contrast to lps	[contrast to LPS]	0.0	3	1	1	1
137926	1710	10-fold day	[10-fold days]	0.0	2	1	1	1
137927	1710	insight into event coincide	[insights into events coinciding]	0.0	4	1	1	1
137928	1710	cell express mutant	[cells expressing mutants]	0.0	3	1	1	1
137929	1710	immunoglobulin class	[immunoglobulin class]	0.0	2	1	1	1
137930	1710	single-residue substitution in the peptide	[single-residue substitution in the peptide]	0.0	5	1	1	1
137931	1710	promising avenue in leukemia	[promising avenue in leukemia]	0.0	4	1	1	1
137932	1710	expression of b	[expression of B]	0.0	3	1	1	1
137933	1710	T cell from 1	[T cells from 1]	0.0	4	1	1	1
137934	1710	new, two-step model	[new, two-step model]	0.0	3	1	1	1
137935	1710	ldl-receptor gene	[LDL-receptor gene]	0.0	2	1	1	1
137936	1710	cell enhancement transactivate protein tax	[cells enhancement transactivating protein Tax]	0.0	5	1	1	1
137937	1710	htlv-i tumor by antisense inhibition	[HTLV-I tumors by antisense inhibition]	0.0	5	1	1	1
137938	1710	incompetent g-csfr mutant	[incompetent G-CSFR mutant]	0.0	3	1	1	1
137939	1710	major protein-DNA interaction	[major protein-DNA interactions]	0.0	3	1	1	1
137940	1710	two region PRRI	[two regions PRRI]	0.0	3	1	1	1
137941	1710	genetic blockade	[genetic blockade]	0.0	2	1	1	1
137942	1710	125 mg flutamide	[125 mg flutamide]	0.0	3	1	1	1
137943	1710	datum from fibroblast	[data from fibroblasts]	0.0	3	1	1	1
137944	1710	hour 12	[hour 12]	0.0	2	1	1	1
137945	1710	major histocompatibility (MHC) class gene	[major histocompatibility (MHC) class genes]	0.0	5	1	1	1
137946	1710	-dependent activation of gene	[-dependent activation of gene]	0.0	4	1	1	1
137947	1710	CD28 induction of c-jun expression	[CD28 induction of c-jun expression]	0.0	5	1	1	1
137948	1710	protein family member	[protein family members]	0.0	3	1	1	1
137949	1710	airway T	[airway T]	0.0	2	2	2	1
137950	1710	represent different stage of differentiation	[representing different stages of differentiation]	0.0	5	1	1	1
137951	1710	material in the study,	[MATERIAL In the study,]	0.0	4	1	1	1
137952	1710	reduction of vcam-1 mrna level	[reduction of VCAM-1 mRNA levels]	0.0	5	1	1	1
137953	1710	ng/ml.	[ng/ml.]	0.0	1	1	1	1
137954	1710	mechanism underlie expression of cytokine	[mechanisms underlying expression of cytokines]	0.0	5	1	1	1
137955	1710	csf-1r monoclonal antibody	[CSF-1R monoclonal antibodies]	0.0	3	1	1	1
137956	1710	strand conformation	[strand conformation]	0.0	2	3	3	1
137957	1710	expression of 2	[expression of 2]	0.0	3	1	1	1
137958	1710	binding of nfkb2	[binding of NFKB2]	0.0	3	1	1	1
137959	1710	stimulation il-2 gene	[stimulation IL-2 gene]	0.0	3	1	1	1
137960	1710	two DNA topoisomerase ii inhibitor	[two DNA topoisomerase II inhibitors]	0.0	5	1	1	1
137961	1710	tat antibody	[Tat antibody]	0.0	2	1	1	1
137962	1710	5'-most carg sequence	[5'-most CArG sequences]	0.0	3	1	1	1
137963	1710	il-2 mrna production	[IL-2 mRNA production]	0.0	3	1	1	1
137964	1710	complex element-binding protein CREB	[complexes element-binding protein CREB]	0.0	4	1	1	1
137965	1710	modulatory effect of glucocorticoid on interleukin	[Modulatory effects of glucocorticoids on interleukin]	0.0	6	1	1	1
137966	1710	pattern of GRbeta activity	[pattern of GRbeta activity]	0.0	4	1	1	1
137967	1710	cell include many	[cells including many]	0.0	3	1	1	1
137968	1710	n-formyl-methionyl-leucyl-phenylalanine cytokine	[N-formyl-methionyl-leucyl-phenylalanine cytokines]	0.0	2	1	1	1
137969	1710	b-cell-derived subtype of hd	[B-cell-derived subtype of HD]	0.0	4	1	1	1
137970	1710	6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	5	1	1	1
137971	1710	convert extracellular signal into event	[converting extracellular signals into events]	0.0	5	1	1	1
137972	1710	signal-transduce protein stat6	[signal-transducing protein Stat6]	0.0	3	1	1	1
137973	1710	combination of all-tran acid	[combination of all-trans acid]	0.0	4	2	2	1
137974	1710	nevertheless, relatively high, pharmacological concentration	[Nevertheless, relatively high, pharmacological concentrations]	0.0	5	1	1	1
137975	1710	human Chr 20	[human Chr 20]	0.0	3	1	1	1
137976	1710	nf-at transactivate	[NF-AT transactivating]	0.0	2	1	1	1
137977	1710	six factor	[six factors]	0.0	2	1	1	1
137978	1710	expression of hla-do	[Expression of HLA-DO]	0.0	3	1	1	1
137979	1710	transactivation of cis element	[transactivation of cis elements]	0.0	4	1	1	1
137980	1710	interleukin-1beta transcription	[interleukin-1beta transcription]	0.0	2	1	1	1
137981	1710	demonstration a number	[demonstration a number]	0.0	3	1	1	1
137982	1710	mv),	[mV),]	0.0	1	1	1	1
137983	1710	mammalian sex-determine gene	[mammalian sex-determining gene]	0.0	3	1	1	1
137984	1710	[change in estrogen receptor level	[[Changes in estrogen receptor levels]	0.0	5	2	2	1
137985	1710	x-linked muscular atrophy a form	[X-linked muscular atrophy an form]	0.0	5	1	1	1
137986	1710	selection during primary infection.	[Selection during primary infection.]	0.0	4	1	1	1
137987	1710	intact il-4 promoter construct	[intact IL-4 promoter constructs]	0.0	4	1	1	1
137988	1710	membrane localization	[membrane localization]	0.0	2	1	1	1
137989	1710	clonal alpha b5a	[clonal alpha B5A]	0.0	3	1	1	1
137990	1710	cluster in the region	[clustering in the region]	0.0	4	1	1	1
137991	1710	gr apparent affinity	[GR apparent affinity]	0.0	3	1	1	1
137992	1710	pathway involve kinase c	[pathways involving kinase C]	0.0	4	1	1	1
137993	1710	transactivation by herpesvirus hhv-6 strain gs	[Transactivation by herpesvirus HHV-6 strains GS]	0.0	6	1	1	1
137994	1710	bZIP family	[bZIP family]	0.0	2	1	1	1
137995	1710	mn-dependent superoxide dismutase a enzyme	[Mn-dependent superoxide dismutase a enzyme]	0.0	5	1	1	1
137996	1710	assay with form	[assays with forms]	0.0	3	1	1	1
137997	1710	formation with member	[formation with members]	0.0	3	1	1	1
137998	1710	formation of NF-kappa b heterodimer	[formation of NF-kappa B heterodimer]	0.0	5	1	1	1
137999	1710	subdominant cycle reactivity though undetectable	[subdominant cycle reactivities though undetectable]	0.0	5	1	1	1
138000	1710	other gene in the locus	[other genes in the locus]	0.0	5	1	1	1
138001	1710	drug of choice	[drug of choice]	0.0	3	1	1	1
138002	1710	dnase i-hypersensitive chromatin site	[DNase I-hypersensitive chromatin site]	0.0	4	1	1	1
138003	1710	ebv b cell line	[EBV B cell lines]	0.0	4	1	1	1
138004	1710	activation of 4e-bp1	[activation of 4E-BP1]	0.0	3	1	1	1
138005	1710	level of ROI in this cell	[levels of ROI in these cells]	0.0	6	1	1	1
138006	1710	gtp -binding	[GTP -binding]	0.0	2	1	1	1
138007	1710	complete correlation	[complete correlation]	0.0	2	1	1	1
138008	1710	common regulatory mechanism	[common regulatory mechanisms]	0.0	3	1	1	1
138009	1710	efficient precursor in culture.	[efficient precursors in culture.]	0.0	4	1	1	1
138010	1710	respectively, in monocyte	[respectively, in monocytes]	0.0	3	1	1	1
138011	1710	regulation of il-5 gene transcription	[regulation of IL-5 gene transcription]	0.0	5	1	1	1
138012	1710	GATA-1 -mutant stem cell	[GATA-1 -mutant stem cells]	0.0	4	1	1	1
138013	1710	have g3 tumor	[having G3 tumors]	0.0	3	1	1	1
138014	1710	consider the strong positive regulatory effect	[Considering the strong positive regulatory effect]	0.0	6	1	1	1
138015	1710	Epstein-Barr virus the agent of mononucleosis	[Epstein-Barr virus the agent of mononucleosis]	0.0	6	1	1	1
138016	1710	spacing of the mua element	[spacing of the muA elements]	0.0	5	1	1	1
138017	1710	molecular machinery	[molecular machinery]	0.0	2	1	1	1
138018	1710	implication for differentiation-inducing therapy of tumor	[implications for differentiation-inducing therapy of tumors]	0.0	6	1	1	1
138019	1710	Elsevier Science Ireland Ltd.	[Elsevier Science Ireland Ltd.]	0.0	4	1	1	1
138020	1710	regulation of the human eotaxin gene	[regulation of the human eotaxin gene]	0.0	6	1	1	1
138021	1710	target for hiv-1 therapy	[targets for HIV-1 therapy]	0.0	4	1	1	1
138022	1710	96 peptide	[96 peptides]	0.0	2	1	1	1
138023	1710	lymphocyte of subject	[lymphocytes of subjects]	0.0	3	1	1	1
138024	1710	phenotype of impaired nf-kappab activation	[phenotype of impaired NF-kappaB activation]	0.0	5	1	1	1
138025	1710	impact of platelet-activate factor binding	[impact of platelet-activating factor binding]	0.0	5	1	1	1
138026	1710	ovulatory situation	[ovulatory situation]	0.0	2	1	1	1
138027	1710	study of lymphocyte	[study of lymphocytes]	0.0	3	1	1	1
138028	1710	human cd37 b lymphocyte	[human CD37 B lymphocytes]	0.0	4	1	1	1
138029	1710	effect on the entry	[effects on the entry]	0.0	4	1	1	1
138030	1710	different mode	[different modes]	0.0	2	1	1	1
138031	1710	clinical importance in the treatment	[clinical importance in the treatment]	0.0	5	1	1	1
138032	1710	autoregulation by multiple cytoplasmic inhibitor	[Autoregulation by multiple cytoplasmic inhibitors]	0.0	5	1	1	1
138033	1710	role in t-cell signal	[role in T-cell signaling]	0.0	4	1	1	1
138034	1710	pre-treatment with gp160 for h	[pre-treatment with gp160 for h]	0.0	5	1	1	1
138035	1710	effector cell function	[effector cell function]	0.0	3	1	1	1
138036	1710	concept for drug discovery	[concept for drug discovery]	0.0	4	1	1	1
138037	1710	kinetic for virus	[kinetics for viruses]	0.0	3	1	1	1
138038	1710	membrane receptor for aldosterone a pathway	[Membrane receptors for aldosterone a pathway]	0.0	6	1	1	1
138039	1710	low prevalence	[low prevalence]	0.0	2	1	1	1
138040	1710	great than mol/L	[greater than mol/L]	0.0	3	1	1	1
138041	1710	activation in killer cell from patient	[activation in killer cells from patients]	0.0	6	1	1	1
138042	1710	hiv expression in cell	[HIV expression in cells]	0.0	4	2	2	1
138043	1710	phosphorylation the three	[phosphorylation the three]	0.0	3	1	1	1
138044	1710	granulocyte/macrophage-colony	[granulocyte/macrophage-colony]	0.0	1	1	1	1
138045	1710	human stat	[human Stat]	0.0	2	1	1	1
138046	1710	represent rrna	[representing mRNAs]	0.0	2	1	1	1
138047	1710	circadian rhythm of receptor	[circadian rhythm of receptor]	0.0	4	1	1	1
138048	1710	effect of the receptor	[effect of the receptor]	0.0	4	1	1	1
138049	1710	possible enhancement	[possible enhancement]	0.0	2	1	1	1
138050	1710	major PB1 protein-binding complex	[major PB1 protein-binding complex]	0.0	4	1	1	1
138051	1710	human band	[human bands]	0.0	2	1	1	1
138052	1710	result in activation of factor	[resulting in activation of factors]	0.0	5	1	1	1
138053	1710	EBNA promoter Qp	[EBNA promoters Qp]	0.0	3	1	1	1
138054	1710	vitamin d gene regulation	[vitamin D gene regulation]	0.0	4	1	1	1
138055	1710	factor e1-binding site	[factor E1-binding site]	0.0	3	1	1	1
138056	1710	use FUra	[using FUra]	0.0	2	1	1	1
138057	1710	mechanism of activation of interleukin-1beta	[mechanisms of activation of interleukin-1beta]	0.0	5	1	1	1
138058	1710	weakly by NFATx2	[weakly by NFATx2]	0.0	3	1	1	1
138059	1710	synthase ino gene	[synthase iNOS genes]	0.0	3	1	1	1
138060	1710	Interestingly, apoptosis	[Interestingly, apoptosis]	0.0	2	1	1	1
138061	1710	forms:	[forms:]	0.0	1	1	1	1
138062	1710	E1A induction	[E1A induction]	0.0	2	1	1	1
138063	1710	primary IL-13 receptor complex	[primary IL-13 receptor complex]	0.0	4	1	1	1
138064	1710	nonstructural trans-acting gene	[nonstructural trans-acting genes]	0.0	3	1	1	1
138065	1710	high dose of peptide	[high doses of peptide]	0.0	4	1	1	1
138066	1710	role of cellular tumor necrosis factor	[Role of cellular tumor necrosis factor]	0.0	6	1	1	1
138067	1710	ifngamma-driven, stat1 gene activation	[IFNgamma-driven, Stat1 gene activation]	0.0	4	1	1	1
138068	1710	factor-KB NF-kappa b	[factor-KB NF-kappa B]	0.0	3	1	1	1
138069	1710	different kox gene	[different KOX genes]	0.0	3	1	1	1
138070	1710	tsc2 gene expression in tissue	[TSC2 gene expression in tissues]	0.0	5	1	1	1
138071	1710	glucocorticoid in rheumatoid arthritis	[glucocorticoids in rheumatoid arthritis]	0.0	4	1	1	1
138072	1710	fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
138073	1710	clone of CVZ cell	[clones of CVZ cells]	0.0	4	1	1	1
138074	1710	only a portion	[only a portion]	0.0	3	1	1	1
138075	1710	corepressor (n-cor) histone deacetylase complex	[corepressor (N-CoR) histone deacetylase complex]	0.0	5	1	1	1
138076	1710	42 month	[42 months]	0.0	2	1	1	1
138077	1710	protein Ag	[protein Ag]	0.0	2	1	1	1
138078	1710	b29 gene b29	[B29 gene B29]	0.0	3	1	1	1
138079	1710	study, binding activity	[study, binding activity]	0.0	3	1	1	1
138080	1710	Comparison of cDNA sequence	[Comparison of cDNA sequences]	0.0	4	1	1	1
138081	1710	t-cell extract consist of Mr	[T-cell extracts consisting of Mr]	0.0	5	1	1	1
138082	1710	kD molecule	[kD molecule]	0.0	2	1	1	1
138083	1710	macrophage differentiation of monocyte /macrophage	[macrophage differentiation of monocytes /macrophages]	0.0	5	1	1	1
138084	1710	caccc-binding	[CACCC-binding]	0.0	1	2	2	1
138085	1710	two reading frame a	[two reading frames A]	0.0	4	1	1	1
138086	1710	transcriptional activity of SV40 promoter	[transcriptional activities of SV40 promoter]	0.0	5	1	1	1
138087	1710	level gene expression	[level gene expression]	0.0	3	2	2	1
138088	1710	outcome after therapy	[outcome after therapy]	0.0	3	1	1	1
138089	1710	Stat3EE a mutant Stat3	[Stat3EE a mutant Stat3]	0.0	4	1	1	1
138090	1710	antiglucocorticoid property	[antiglucocorticoid properties]	0.0	2	1	1	1
138091	1710	use in the treatment	[use in the treatment]	0.0	4	1	1	1
138092	1710	deletion in NFATx1	[deletion in NFATx1]	0.0	3	1	1	1
138093	1710	aml m4 with atypical eosinophil	[AML M4 with atypical eosinophils]	0.0	5	1	1	1
138094	1710	gas exchange in patient	[gas exchange in patients]	0.0	4	1	1	1
138095	1710	transcriptional regulation of the eotaxin gene	[transcriptional regulation of the eotaxin gene]	0.0	6	1	1	1
138096	1710	several kRAB-containing zinc finger gene	[several KRAB-containing zinc finger genes]	0.0	5	1	1	1
138097	1710	trancriptional role in monocyte	[trancriptional roles in monocytes]	0.0	4	1	1	1
138098	1710	contribution to the activation	[contribution to the activation]	0.0	4	1	1	1
138099	1710	nonresident wall cell	[nonresident wall cells]	0.0	3	1	1	1
138100	1710	inverse relation between density lipoprotein	[inverse relation between density lipoprotein]	0.0	5	1	1	1
138101	1710	optimal induction, PMA	[optimal induction, PMA]	0.0	3	1	1	1
138102	1710	combination of retinoid	[combinations of retinoids]	0.0	3	1	1	1
138103	1710	fusion reporter gene	[fusion reporter genes]	0.0	3	1	1	1
138104	1710	(20-50%) reduction	[(20-50%) reduction]	0.0	2	1	1	1
138105	1710	preformed, nfkb2	[preformed, NFKB2]	0.0	2	1	1	1
138106	1710	effect of notch-1	[effects of notch-1]	0.0	3	1	1	1
138107	1710	importance of the region	[importance of the region]	0.0	4	1	1	1
138108	1710	expression in hdlm-1 cell	[expression in HDLM-1 cells]	0.0	4	1	1	1
138109	1710	Interestingly, treatment of hiv-tf1	[Interestingly, treatment of HIV-TF1]	0.0	4	1	1	1
138110	1710	suffer from ataxia telangiectasia	[suffering from ataxia telangiectasia]	0.0	4	1	1	1
138111	1710	low dissociation constant of nm	[low dissociation constant of nM]	0.0	5	1	1	1
138112	1710	concentration of active tfiiib molecule	[concentration of active TFIIIB molecules]	0.0	5	1	1	1
138113	1710	role of growth response gene	[role of growth response gene]	0.0	5	1	1	1
138114	1710	Genetic inactivation	[Genetic inactivation]	0.0	2	1	1	1
138115	1710	macrophage-colony stimulate factor promoter	[macrophage-colony stimulating factor promoter]	0.0	4	1	1	1
138116	1710	host control of parasitism	[Host control of parasitism]	0.0	4	1	1	1
138117	1710	cell line HL60	[cell line HL60]	0.0	3	1	1	1
138118	1710	transcription factor pu.1/spi-1	[transcription factor PU.1/Spi-1]	0.0	3	1	1	1
138119	1710	bacterial lipopolysaccharide-activated blood	[bacterial lipopolysaccharide-activated blood]	0.0	3	1	1	1
138120	1710	protein-1 another member	[protein-1 another member]	0.0	3	1	1	1
138121	1710	dendritic-like cell in response CSF	[dendritic-like cells in response CSF]	0.0	5	1	1	1
138122	1710	obtain probe specific for the deletion	[obtaining probes specific for the deletion]	0.0	6	1	1	1
138123	1710	avidity of beta2 integrin	[avidity of beta2 integrin]	0.0	4	1	1	1
138124	1710	property of mcp-1	[properties of MCP-1]	0.0	3	1	1	1
138125	1710	necrosis factor-alpha in monocytic cell	[necrosis factor-alpha in monocytic cells]	0.0	5	1	1	1
138126	1710	pma-mediated induction	[PMA-mediated induction]	0.0	2	1	1	1
138127	1710	change.	[change.]	0.0	1	1	1	1
138128	1710	six healthy volunteer	[six healthy volunteers]	0.0	3	1	1	1
138129	1710	homolog of the pip/lsirf	[homolog of the Pip/LSIRF]	0.0	4	1	1	1
138130	1710	mode of action,	[modes of action,]	0.0	3	1	1	1
138131	1710	cervical carcinoma cell	[cervical carcinoma cells]	0.0	3	1	1	1
138132	1710	morphology cell	[morphology cells]	0.0	2	1	1	1
138133	1710	growth, differentiation	[growth, differentiation]	0.0	2	1	1	1
138134	1710	Ca(2+) pathway	[Ca(2+) pathways]	0.0	2	1	1	1
138135	1710	staphylococcal enterotoxin a	[staphylococcal enterotoxin A]	0.0	3	1	1	1
138136	1710	gene activation in T cell	[gene activation in T cells]	0.0	5	1	1	1
138137	1710	cell than gc-sensitive asthmatics	[cells than GC-sensitive asthmatics]	0.0	4	1	1	1
138138	1710	terminal repeat promoter region	[terminal repeat promoter region]	0.0	4	1	1	1
138139	1710	great amplification of allele	[greater amplification of allele]	0.0	4	1	1	1
138140	1710	similarly, a mutant of NIK	[Similarly, a mutant of NIK]	0.0	5	1	1	1
138141	1710	attenuate hiv-1	[attenuating HIV-1]	0.0	2	1	1	1
138142	1710	analysis take change	[analysis taking changes]	0.0	3	1	1	1
138143	1710	reach the half-maximal effect at nm	[reaching the half-maximal effect at nM]	0.0	6	1	1	1
138144	1710	receptor activator	[receptor activator]	0.0	2	2	2	1
138145	1710	multiple mutation	[multiple mutations]	0.0	2	1	1	1
138146	1710	nf-kappa b -binding activity	[NF-kappa B -binding activity]	0.0	4	1	1	1
138147	1710	blotting experiment use antibody	[blotting experiments using antibodies]	0.0	4	1	1	1
138148	1710	mrp14 macrophage migration related protein	[MRP14 Macrophage migration related protein]	0.0	5	1	1	1
138149	1710	depletion from extract	[depletion from extracts]	0.0	3	1	1	1
138150	1710	tonsil- b cell	[tonsil- B cells]	0.0	3	1	1	1
138151	1710	span position -78	[spanning positions -78]	0.0	3	1	1	1
138152	1710	role of variation	[role of variation]	0.0	3	1	1	1
138153	1710	27th week	[27th week]	0.0	2	1	1	1
138154	1710	leukemia (apl):	[leukemia (APL):]	0.0	2	1	1	1
138155	1710	inhibitory effect of beta- estradiol	[inhibitory effect of beta- estradiol]	0.0	5	1	1	1
138156	1710	enhancer by nf-kappab	[enhancer by NF-kappaB]	0.0	3	1	1	1
138157	1710	three individual	[three individuals]	0.0	2	1	1	1
138158	1710	m-csf expression	[M-CSF expression]	0.0	2	1	1	1
138159	1710	histocompatibility fashion	[histocompatibility fashion]	0.0	2	1	1	1
138160	1710	fresh cell stage of differentiation,	[fresh cells stage of differentiation,]	0.0	5	1	1	1
138161	1710	aldosterone antagonist canrenone nmol/l).	[aldosterone antagonist canrenone nmol/l).]	0.0	4	1	1	1
138162	1710	RP1 a member	[RP1 a member]	0.0	3	1	1	1
138163	1710	immunoadsorption of stat1	[immunoadsorption of STAT1]	0.0	3	1	1	1
138164	1710	t-cell nucleus	[T-cell nucleus]	0.0	2	1	1	1
138165	1710	CD4+ T	[CD4+ T]	0.0	2	1	1	1
138166	1710	bind sites,	[binding sites,]	0.0	2	1	1	1
138167	1710	50% of cell gelatinase	[50% of cell gelatinase]	0.0	4	1	1	1
138168	1710	binding nf-kappa b	[binding NF-kappa B]	0.0	3	1	1	1
138169	1710	variant fusion partner	[variant fusion partners]	0.0	3	1	1	1
138170	1710	(CMV)	[(CMV)]	0.0	1	1	1	1
138171	1710	cytoplasmic pool of rela	[cytoplasmic pool of RelA]	0.0	4	1	1	1
138172	1710	latter gene	[latter genes]	0.0	2	1	1	1
138173	1710	Concomitant downregulation in a plasmacytoma	[Concomitant downregulation in a plasmacytoma]	0.0	5	1	1	1
138174	1710	hpc high-proliferative colony-forming cell hppecfcs	[HPCs high-proliferative colony-forming cells HPP-CFCs]	0.0	5	1	1	1
138175	1710	hour 72	[hours 72]	0.0	2	1	1	1
138176	1710	indicate a cell type-specific pattern	[indicating a cell type-specific pattern]	0.0	5	1	1	1
138177	1710	young subject type	[young subjects Type]	0.0	3	1	1	1
138178	1710	(type ii) oxide synthase expression	[(type II) oxide synthase expression]	0.0	5	1	1	1
138179	1710	mass of kD.	[mass of kD.]	0.0	3	1	1	1
138180	1710	expression sh2 domain-contain leukocyte protein	[expression SH2 domain-containing leukocyte protein]	0.0	5	1	1	1
138181	1710	evidence for activity at proximal element	[Evidence for activity at proximal element]	0.0	6	1	1	1
138182	1710	b DNA binding	[B DNA binding]	0.0	3	1	1	1
138183	1710	cotransfection of tat cDNA	[cotransfection of tat cDNA]	0.0	4	1	1	1
138184	1710	disable sequela	[disabling sequela]	0.0	2	1	1	1
138185	1710	beta-casein expression	[beta-casein expression]	0.0	2	1	1	1
138186	1710	aml-m7	[AML-M7]	0.0	1	1	1	1
138187	1710	aml-m5	[AML-M5]	0.0	1	1	1	1
138188	1710	aml-m2	[AML-M2]	0.0	1	1	1	1
138189	1710	Granulocyte-macrophage colony-stimumulatelany-stg factor	[Granulocyte-macrophage colony-stimulating factor]	0.0	3	1	1	1
138190	1710	JAK Janus kinase family	[JAK Janus kinase family]	0.0	4	1	1	1
138191	1710	leukaemia cell	[leukaemia cells]	0.0	2	1	1	1
138192	1710	gene trans-activation	[gene trans-activation]	0.0	2	1	1	1
138193	1710	expression of the tcl1 oncogene	[Expression of the TCL1 oncogene]	0.0	5	1	1	1
138194	1710	protein such as e-selectin	[proteins such as E-selectin]	0.0	4	1	1	1
138195	1710	human immunodeficiency virus type infection	[human immunodeficiency virus type infection]	0.0	5	1	1	1
138196	1710	-lymphoid	[-lymphoid]	0.0	1	1	1	1
138197	1710	HTLV-I blood T cell	[HTLV-I blood T cells]	0.0	4	1	1	1
138198	1710	cd30+ cell	[CD30+ cells]	0.0	2	1	1	1
138199	1710	indicator of clinical progression	[indicator of clinical progression]	0.0	4	1	1	1
138200	1710	efficient precursor of DC	[efficient precursors of DC]	0.0	4	1	1	1
138201	1710	event coincide	[events coinciding]	0.0	2	1	1	1
138202	1710	acid (dna) protein exhibit rapid change	[acid (DNA) proteins exhibiting rapid changes]	0.0	6	1	1	1
138203	1710	initiate event	[initiating events]	0.0	2	1	1	1
138204	1710	dna-unwinding	[DNA-unwinding]	0.0	1	1	1	1
138205	1710	substrata	[substrata]	0.0	1	1	1	1
138206	1710	FAB aml -m3v	[FAB AML -M3v]	0.0	3	1	1	1
138207	1710	t-cell line a2.01	[T-cell line A2.01]	0.0	3	1	1	1
138208	1710	protein nf-kappab	[protein NF-kappaB]	0.0	2	1	1	1
138209	1710	melanosis	[melanosis]	0.0	1	1	1	1
138210	1710	mobility-shift assay of huvec protein	[mobility-shift assays of HUVEC proteins]	0.0	5	1	1	1
138211	1710	T cell leukemia virus-i htlv-i	[T cell leukemia virus-I HTLV-I]	0.0	5	1	1	1
138212	1710	role of the complex ap-1	[role of the complex AP-1]	0.0	5	1	1	1
138213	1710	free ca2+ concentration	[free Ca2+ concentration]	0.0	3	1	1	1
138214	1710	il-10-	[IL-10-]	0.0	1	1	1	1
138215	1710	condition of DNA replication	[conditions of DNA replication]	0.0	4	1	1	1
138216	1710	relevance of the variant er form	[relevance of the variant ER forms]	0.0	6	1	1	1
138217	1710	leukotriene B4 a mediator	[leukotriene B4 a mediator]	0.0	4	1	1	1
138218	1710	substantial hormone receptor coactivator activity	[substantial hormone receptor coactivator activity]	0.0	5	1	1	1
138219	1710	(gc-r)	[(GC-R)]	0.0	1	1	1	1
138220	1710	transient reduction	[transient reduction]	0.0	2	1	1	1
138221	1710	protein 76	[protein 76]	0.0	2	1	1	1
138222	1710	transcriptional activator of viral promoter	[transcriptional activator of viral promoters]	0.0	5	1	1	1
138223	1710	negative pathway	[negative pathways]	0.0	2	1	1	1
138224	1710	binding specificity	[binding specificity]	0.0	2	1	1	1
138225	1710	lead to hyponatremia despite high level	[leading to hyponatremia despite high levels]	0.0	6	1	1	1
138226	1710	role for retinoic acid	[role for retinoic acid]	0.0	4	1	1	1
138227	1710	cell of chronic leukemia patient	[cells of chronic leukemia patients]	0.0	5	1	1	1
138228	1710	such as ap-1 proto-oncogene product	[such as AP-1 proto-oncogene products]	0.0	5	1	1	1
138229	1710	combination)	[combination)]	0.0	1	1	1	1
138230	1710	25 normal woman	[25 normal women]	0.0	3	1	1	1
138231	1710	treatment regimen	[treatment regimens]	0.0	2	1	1	1
138232	1710	deletion of a amino- region	[Deletions of a amino- region]	0.0	5	1	1	1
138233	1710	cd28+ T cell	[CD28+ T cells]	0.0	3	1	1	1
138234	1710	proximal step in the initiation	[proximal step in the initiation]	0.0	5	1	1	1
138235	1710	Nuclear b activity a preliminary report.	[Nuclear B activity a preliminary report.]	0.0	6	1	1	1
138236	1710	relevance in septic shock	[relevance in septic shock]	0.0	4	1	1	1
138237	1710	addition of acid	[addition of acid]	0.0	3	1	1	1
138238	1710	follow binding to monocyte	[following binding to monocytes]	0.0	4	1	1	1
138239	1710	multiple immunization	[multiple immunizations]	0.0	2	1	1	1
138240	1710	homologue mtcp1/c6.1b	[homologue MTCP1/c6.1B]	0.0	2	1	1	1
138241	1710	binding to TF catalytic cofactor	[binding to TF catalytic cofactor]	0.0	5	1	1	1
138242	1710	family, aml-1b	[family, AML-1B]	0.0	2	1	1	1
138243	1710	tool for clinical evaluation	[tool for clinical evaluation]	0.0	4	1	1	1
138244	1710	lipoarabinomannan of mycobacterium tuberculosis M. tuberculosis	[lipoarabinomannan of Mycobacterium tuberculosis M. tuberculosis]	0.0	6	1	1	1
138245	1710	il-12.	[IL-12.]	0.0	1	1	1	1
138246	1710	amount b mrna	[amount B mRNA]	0.0	3	1	1	1
138247	1710	gene encode fas	[genes encoding Fas]	0.0	3	1	1	1
138248	1710	receptor gr functionality	[receptor GR functionality]	0.0	3	1	1	1
138249	1710	transcriptional activator of promoter	[transcriptional activator of promoters]	0.0	4	1	1	1
138250	1710	tyrosine phosphorylation of two set	[tyrosine phosphorylation of two sets]	0.0	5	1	1	1
138251	1710	positive regulatory region PRRI	[positive regulatory regions PRRI]	0.0	4	1	1	1
138252	1710	pulmonary disease tuberculosis	[pulmonary diseases tuberculosis]	0.0	3	1	1	1
138253	1710	cell-mediated tcell rescue from apoptosis	[cell-mediated Tcell rescue from apoptosis]	0.0	5	1	1	1
138254	1710	anti-inflammatory drug such as salicylate	[anti-inflammatory drugs such as salicylates]	0.0	5	1	1	1
138255	1710	hour 48	[hour 48]	0.0	2	1	1	1
138256	1710	isgf3 gene factor	[ISGF3 gene factor]	0.0	3	1	1	1
138257	1710	nontoxic concentration of reactive metabolite	[nontoxic concentrations of reactive metabolites]	0.0	5	1	1	1
138258	1710	Positive regulation role	[Positive regulation role]	0.0	3	1	1	1
138259	1710	use conditions, three complex	[Using conditions, three complexes]	0.0	4	1	1	1
138260	1710	concentration of ca2+	[concentrations of Ca2+]	0.0	3	1	1	1
138261	1710	granulocytic differentiation program	[granulocytic differentiation program]	0.0	3	1	1	1
138262	1710	form kinase C transcription	[forms kinase C transcription]	0.0	4	1	1	1
138263	1710	ap-1/tpa	[AP-1/TPA]	0.0	1	1	1	1
138264	1710	bovine corneal	[bovine corneal]	0.0	2	1	1	1
138265	1710	breast aspirate at risk	[breast aspirates at risk]	0.0	4	1	1	1
138266	1710	estrogen induction of survival	[Estrogen induction of survival]	0.0	4	2	2	1
138267	1710	PEBP2betaMYH11 mouse	[PEBP2betaMYH11 mice]	0.0	2	1	1	1
138268	1710	cell tumor	[cell tumor]	0.0	2	1	1	1
138269	1710	follicular hyperplasia fh	[follicular hyperplasia FH]	0.0	3	1	1	1
138270	1710	sphingomyelinase smase	[sphingomyelinase SMase]	0.0	2	1	1	1
138271	1710	include hl-60 leukemia cell	[including HL-60 leukemia cells]	0.0	4	1	1	1
138272	1710	site for ebf sequence	[sites for EBF sequences]	0.0	4	1	1	1
138273	1710	multiple leukocyte lineages,	[multiple leukocyte lineages,]	0.0	3	1	1	1
138274	1710	two factor (NF)-kappaB binding site	[two factor (NF)-kappaB binding sites]	0.0	5	1	1	1
138275	1710	additional isoform	[additional isoforms]	0.0	2	1	1	1
138276	1710	widespread extinction of b gene	[widespread extinction of B genes]	0.0	5	1	1	1
138277	1710	leucocyte recruitment across endothelium	[leucocyte recruitment across endothelium]	0.0	4	1	1	1
138278	1710	produce infectious progeny at the time.	[producing infectious progeny at the time.]	0.0	6	1	1	1
138279	1710	u937-derived clone	[U937-derived clones]	0.0	2	1	1	1
138280	1710	additional month month	[additional months months]	0.0	3	1	1	1
138281	1710	uptake of 135(oh)2d3 with hyperparathyroidism	[uptake of 1,25(OH)2D3 with hyperparathyroidism]	0.0	5	1	1	1
138282	1710	stimulation with interleukin-6 (il-6) a cytokine	[stimulation with interleukin-6 (IL-6) an cytokine]	0.0	6	1	1	1
138283	1710	HLA Class	[HLA Class]	0.0	2	1	1	1
138284	1710	initiation binding repressor [corrected]	[Initiation binding repressor [corrected]]	0.0	4	1	1	1
138285	1710	purine-rich part	[purine-rich part]	0.0	2	1	1	1
138286	1710	progressive narrowing	[progressive narrowing]	0.0	2	1	1	1
138287	1710	level of proto-oncogent	[levels of proto-oncogenes]	0.0	3	1	1	1
138288	1710	control translocation	[controlling translocation]	0.0	2	1	1	1
138289	1710	c-myc translocation	[c-myc translocation]	0.0	2	1	1	1
138290	1710	infection with immunodeficiency virus type	[infection with immunodeficiency virus type]	0.0	5	1	1	1
138291	1710	two inhibitor of NFAT transcription	[two inhibitors of NFAT transcription]	0.0	5	1	1	1
138292	1710	lineage-associated cytokine receptor	[lineage-associated cytokine receptors]	0.0	3	1	1	1
138293	1710	differentiation a inhibitor	[differentiation an inhibitor]	0.0	3	1	1	1
138294	1710	constant (Kd)	[constant (Kd)]	0.0	2	1	1	1
138295	1710	Electrophoretic mobility-shift assay of huvec protein	[Electrophoretic mobility-shift assays of HUVEC proteins]	0.0	6	1	1	1
138296	1710	similar region of several sequence	[similar regions of several sequences]	0.0	5	1	1	1
138297	1710	acid (dna)	[acid (DNA)]	0.0	2	1	1	1
138298	1710	example of b cell	[examples of B cells]	0.0	4	1	1	1
138299	1710	Coproporphyrinogen oxidase	[Coproporphyrinogen oxidase]	0.0	2	1	1	1
138300	1710	expression analysis,	[expression analysis,]	0.0	2	1	1	1
138301	1710	blood t-lymphocyte	[blood T-lymphocytes]	0.0	2	3	3	1
138302	1710	erythroid cell in mouse	[erythroid cells in mice]	0.0	4	1	1	1
138303	1710	protein kinase C isoform	[protein kinase C isoforms]	0.0	4	1	1	1
138304	1710	intracellular oxidant activity.	[intracellular oxidant activity.]	0.0	3	1	1	1
138305	1710	abnormality in effector mechanism	[abnormalities in effector mechanisms]	0.0	4	1	1	1
138306	1710	conformational polymorphism	[conformational polymorphism]	0.0	2	1	1	1
138307	1710	recur locally	[recurring locally]	0.0	2	1	1	1
138308	1710	FasL mrna	[FasL mRNA]	0.0	2	1	1	1
138309	1710	activity of a protein	[activity of an protein]	0.0	4	1	1	1
138310	1710	Prostaglandin e2 induction to CRE element	[Prostaglandin E2 induction to CRE elements]	0.0	6	1	1	1
138311	1710	glutathione -depleting agent	[glutathione -depleting agent]	0.0	3	1	1	1
138312	1710	rescue MHC -restricted thymocyte	[rescuing MHC -restricted thymocytes]	0.0	4	1	1	1
138313	1710	involvement of NF-kappaB p50/p65 heterodimer	[Involvement of NF-kappaB p50/p65 heterodimer]	0.0	5	1	1	1
138314	1710	dimer regulate T cell activation	[dimer regulating T cell activation]	0.0	5	1	1	1
138315	1710	fresh leukemic cell stage	[fresh leukemic cells stage]	0.0	4	1	1	1
138316	1710	16HBE bronchial cell	[16HBE bronchial cells]	0.0	3	1	1	1
138317	1710	relevance of this phenomenon	[relevance of this phenomenon]	0.0	4	1	1	1
138318	1710	growth inhibition of progenitor cell	[growth inhibition of progenitor cells]	0.0	5	1	1	1
138319	1710	h of steroid treatment	[h of steroid treatment]	0.0	4	1	1	1
138320	1710	sp1-box	[SP1-box]	0.0	1	1	1	1
138321	1710	nuclear pool	[nuclear pool]	0.0	2	1	1	1
138322	1710	low concentration (21.7	[lower concentration (21.7]	0.0	3	1	1	1
138323	1710	hiv terminal repeat -cat construct	[HIV terminal repeat -CAT constructs]	0.0	5	1	1	1
138324	1710	factor (NF)-AT	[factor (NF)-AT]	0.0	2	1	1	1
138325	1710	exhibit property of stage cell	[exhibiting properties of stage cells]	0.0	5	1	1	1
138326	1710	virus-replicative lesion in aspect	[virus-replicative lesions in aspects]	0.0	4	1	1	1
138327	1710	AML m4	[AML M4]	0.0	2	1	1	1
138328	1710	step for effect	[step for effects]	0.0	3	1	1	1
138329	1710	direct inhibition of NFATp/AP-1 formation	[direct inhibition of NFATp/AP-1 formation]	0.0	5	1	1	1
138330	1710	human receptor domain binding	[human receptor domain binding]	0.0	4	1	1	1
138331	1710	terminal repeat LTR proviruse	[terminal repeat LTR proviruses]	0.0	4	1	1	1
138332	1710	human immunodeficiency virus type long repeat	[human immunodeficiency virus type long repeats]	0.0	6	1	1	1
138333	1710	expression of the immediate gene	[expression of the immediate genes]	0.0	5	1	1	1
138334	1710	express CD80 cho-cd80	[expressing CD80 CHO-CD80]	0.0	3	1	1	1
138335	1710	rhesus monkey cercopithicine herpesvirus	[rhesus monkeys cercopithicine herpesvirus]	0.0	4	1	1	1
138336	1710	p sequence lymphokine element	[P sequence lymphokine element]	0.0	4	1	1	1
138337	1710	specificity of the immunoglobulin enhancer	[specificity of the immunoglobulin enhancer]	0.0	5	1	1	1
138338	1710	interaction with coactivator	[interactions with coactivators]	0.0	3	1	1	1
138339	1710	gcs aitl/gc	[GCs AITL/GC]	0.0	2	1	1	1
138340	1710	expression of human interferon factor	[expression of human interferon factor]	0.0	5	1	1	1
138341	1710	phenotype for marmoset t-lymphocyte transformation	[phenotype for marmoset T-lymphocyte transformation]	0.0	5	1	1	1
138342	1710	HLA-DQ molecule	[HLA-DQ molecules]	0.0	2	1	1	1
138343	1710	overexpression of irf-1	[overexpression of IRF-1]	0.0	3	1	1	1
138344	1710	migration of human leukocyte to serum	[migration of human leukocytes to serum]	0.0	6	1	1	1
138345	1710	add b protein to nuclear extract	[Adding B protein to nuclear extracts]	0.0	6	1	1	1
138346	1710	patient with early arthritis	[patients with early arthritis]	0.0	4	1	1	1
138347	1710	different proto-oncogene response	[different proto-oncogene responses]	0.0	3	1	1	1
138348	1710	samples, activity from endometrium	[samples, activity from endometrium]	0.0	4	1	1	1
138349	1710	myeloid-cell-specific c-mim	[myeloid-cell-specific c-mim]	0.0	2	1	1	1
138350	1710	activation of enzyme participate	[activation of enzymes participating]	0.0	4	1	1	1
138351	1710	alpha decreases,	[alpha decreases,]	0.0	2	1	1	1
138352	1710	guanylhydrazone cni-1493	[guanylhydrazone CNI-1493]	0.0	2	1	1	1
138353	1710	bind to site	[binding to site]	0.0	3	1	1	1
138354	1710	encode the retinoic enzyme aldehyde dehydrogenase	[encoding the retinoic enzyme aldehyde dehydrogenase]	0.0	6	1	1	1
138355	1710	use neutralize antibody	[using neutralizing antibodies]	0.0	3	1	1	1
138356	1710	explanation for hyporesponsiveness	[explanations for hyporesponsiveness]	0.0	3	1	1	1
138357	1710	gradual downmodulation	[gradual downmodulation]	0.0	2	1	1	1
138358	1710	canonical gata site	[canonical GATA site]	0.0	3	1	1	1
138359	1710	encode a muscle myosin chain Smmhc	[encoding a muscle myosin chain Smmhc]	0.0	6	1	1	1
138360	1710	5'-positive regulatory unit consist	[5'-positive regulatory unit consisting]	0.0	4	1	1	1
138361	1710	transcription of the epsilon-globin-encoding gene	[transcription of the epsilon-globin-encoding gene]	0.0	5	1	1	1
138362	1710	amino acid difference Ser551 to Throger	[amino acid differences Ser551 to Thr]	0.0	6	1	1	1
138363	1710	use a anti-p65 antibody	[using an anti-p65 antibody]	0.0	4	1	1	1
138364	1710	constitutive transcriptional activation	[constitutive transcriptional activation]	0.0	3	1	1	1
138365	1710	Drosophila control protein	[Drosophila control protein]	0.0	3	1	1	1
138366	1710	pathogenesis of chronic leukemia CLL	[pathogenesis of chronic leukemia CLL]	0.0	5	1	1	1
138367	1710	pre-term	[pre-term]	0.0	1	1	1	1
138368	1710	intralymphocytic sodium	[intralymphocytic sodium]	0.0	2	1	1	1
138369	1710	h follow lps stimulation	[h following LPS stimulation]	0.0	4	1	1	1
138370	1710	constitutive presence of nuclear factor	[constitutive presence of nuclear factors]	0.0	5	1	1	1
138371	1710	protein activity	[protein activity]	0.0	2	1	1	1
138372	1710	viral long repeat LTR	[viral long repeat LTR]	0.0	4	5	5	1
138373	1710	biochemical nature	[biochemical nature]	0.0	2	1	1	1
138374	1710	ambiguity intrinsic to study	[ambiguities intrinsic to studies]	0.0	4	1	1	1
138375	1710	NFeB p65	[NFeB p65]	0.0	2	1	1	1
138376	1710	cd56+ cd16- egl present	[CD56+ CD16- eGLs present]	0.0	4	1	1	1
138377	1710	subsequently inhibition	[subsequently inhibition]	0.0	2	1	1	1
138378	1710	moreover, in contrast	[Moreover, in contrast]	0.0	3	1	1	1
138379	1710	transactivation by herpesvirus strain gs	[Transactivation by herpesvirus strains GS]	0.0	5	1	1	1
138380	1710	Flutamide in the treatment	[Flutamide in the treatment]	0.0	4	1	1	1
138381	1710	B-cell lymphocytic leukaemias	[B-cell lymphocytic leukaemias]	0.0	3	1	1	1
138382	1710	NF(P) a factor	[NF(P) a factor]	0.0	3	2	2	1
138383	1710	erythropoietin protein kinase b pkb/akt	[erythropoietin protein kinase B PKB/Akt]	0.0	5	1	1	1
138384	1710	interaction of NFAT	[interaction of NFAT]	0.0	3	1	1	1
138385	1710	deal of attention	[deal of attention]	0.0	3	1	1	1
138386	1710	phop virulence	[phoP virulence]	0.0	2	1	1	1
138387	1710	Regulatory effect	[Regulatory effects]	0.0	2	1	1	1
138388	1710	gold compound aurothioglucose	[gold compounds aurothioglucose]	0.0	3	1	1	1
138389	1710	alkaloid	[alkaloid]	0.0	1	1	1	1
138390	1710	expose human vein endothelial cell huvec	[Exposing human vein endothelial cells HUVECs]	0.0	6	1	1	1
138391	1710	transcriptional activator function	[transcriptional activator functions]	0.0	3	1	1	1
138392	1710	first analysis of a mutation	[first analysis of a mutation]	0.0	5	1	1	1
138393	1710	estrogen response element	[estrogen response element]	0.0	3	1	1	1
138394	1710	-288ctttttgctt-tgc-300	[-288CTTTTTGCTT-TGC-300]	0.0	1	1	1	1
138395	1710	transient transfection L23	[transient transfection L23]	0.0	3	1	1	1
138396	1710	about 30% diffuse b-cell lymphoma	[about 30% diffuse B-cell lymphomas]	0.0	5	1	1	1
138397	1710	effect of LSF	[effects of LSF]	0.0	3	1	1	1
138398	1710	proximal promoter fragment	[proximal promoter fragment]	0.0	3	1	1	1
138399	1710	major sialoglycoprotein	[major sialoglycoprotein]	0.0	2	1	1	1
138400	1710	constitute model of a situation	[constituting models of an situation]	0.0	5	1	1	1
138401	1710	amino terminal insert exon 7a	[amino terminal insert exon 7a]	0.0	5	1	1	1
138402	1710	induction in a t-cell line jurkat	[Induction in a T-cell line Jurkat]	0.0	6	1	1	1
138403	1710	importance of the region promoter.	[importance of the region promoter.]	0.0	5	1	1	1
138404	1710	cell-type-specific regulator	[cell-type-specific regulators]	0.0	2	1	1	1
138405	1710	CD20 mrna	[CD20 mRNA]	0.0	2	1	1	1
138406	1710	affinity to the gata site	[affinity to the GATA site]	0.0	5	1	1	1
138407	1710	phenotype suggestive	[phenotype suggestive]	0.0	2	1	1	1
138408	1710	lps nf-kappa b/c-rel translocation	[LPS NF-kappa B/c-Rel translocation]	0.0	4	1	1	1
138409	1710	expression of the human rar-alpha	[Expression of the human RAR-alpha]	0.0	5	1	1	1
138410	1710	immunodeficiency virus apoptosis m.tremblay, j.exp.med.183:39-48,	[immunodeficiency virus apoptosis M.Tremblay, J.Exp.Med.183:39-48,]	0.0	5	1	1	1
138411	1710	o., through antagonism	[or, through antagonism]	0.0	3	1	1	1
138412	1710	implicate specific cis-active sequence	[implicating specific cis-active sequences]	0.0	4	1	1	1
138413	1710	particularly in the context	[particularly in the context]	0.0	4	1	1	1
138414	1710	furthermore, ectopic expression	[Furthermore, ectopic expression]	0.0	3	1	1	1
138415	1710	genomic footprinting	[genomic footprinting]	0.0	2	1	1	1
138416	1710	recessive pattern	[recessive pattern]	0.0	2	1	1	1
138417	1710	control from the same individuals,	[controls from the same individuals,]	0.0	5	1	1	1
138418	1710	IL-5 gene expression	[IL-5 gene expression]	0.0	3	1	1	1
138419	1710	oxidative stress-inducing signal	[oxidative stress-inducing signals]	0.0	3	1	1	1
138420	1710	human beta-globin control region	[human beta-globin control region]	0.0	4	1	1	1
138421	1710	p65-50 heterodimer	[p65-50 heterodimer]	0.0	2	1	1	1
138422	1710	murine b-cell transcriptional coactivator	[murine B-cell transcriptional coactivator]	0.0	4	1	1	1
138423	1710	additional mechanism for effect	[additional mechanism for effects]	0.0	4	1	1	1
138424	1710	study of aspect	[study of aspects]	0.0	3	1	1	1
138425	1710	new insight into development	[new insights into development]	0.0	4	1	1	1
138426	1710	Negative regulation of interleukin 2 gene	[Negative regulation of interleukin 2 gene]	0.0	6	1	1	1
138427	1710	nf-ya protein	[NF-YA protein]	0.0	2	1	1	1
138428	1710	receptor by plasma cortisol concentration	[receptors by plasma cortisol concentrations]	0.0	5	1	1	1
138429	1710	number in leucocyte	[number in leucocytes]	0.0	3	2	2	1
138430	1710	several nearby site	[several nearby sites]	0.0	3	1	1	1
138431	1710	mhc/peptide complex	[MHC/peptide complex]	0.0	2	1	1	1
138432	1710	promyelocytic leukemia line	[promyelocytic leukemia line]	0.0	3	1	1	1
138433	1710	lac+clone	[Lac+clones]	0.0	1	1	1	1
138434	1710	concomitant removal of the effect	[concomitant removal of the effect]	0.0	5	1	1	1
138435	1710	characterization of b-cell factor a regulator	[characterization of B-cell factor a regulator]	0.0	6	1	1	1
138436	1710	definition of ebv latency	[definition of EBV latencies]	0.0	4	1	1	1
138437	1710	mbob1 clone	[mBob1 clone]	0.0	2	1	1	1
138438	1710	translocation factor of T cell	[translocation factor of T cells]	0.0	5	1	1	1
138439	1710	HS2 enhancer function	[HS2 enhancer function]	0.0	3	1	1	1
138440	1710	input	[input]	0.0	1	1	1	1
138441	1710	level of receptor mr	[levels of receptor MR]	0.0	4	1	1	1
138442	1710	encode a protein human x box	[encoding a protein human X box]	0.0	6	1	1	1
138443	1710	control vh-to-dhjh recombination	[controlling VH-to-DHJH recombination]	0.0	3	1	1	1
138444	1710	3-o-methyl-d-glucose transport in mononuclear leukocyte	[3-O-methyl-D-glucose transport in mononuclear leukocyte]	0.0	5	1	1	1
138445	1710	impaired rel-a translocation	[impaired Rel-A translocation]	0.0	3	1	1	1
138446	1710	high probability	[higher probability]	0.0	2	1	1	1
138447	1710	VDR by P.	[VDR by h.]	0.0	3	1	1	1
138448	1710	different perspective to the interaction	[different perspective to the interactions]	0.0	5	1	1	1
138449	1710	il-4 enhancement	[IL-4 enhancement]	0.0	2	1	1	1
138450	1710	October 1	[Oct 1]	0.0	2	1	1	1
138451	1710	nucleotide binding protein	[nucleotide binding protein]	0.0	3	1	1	1
138452	1710	12-o-tetradecanoylphorbol-13-acetate tpa mitogen	[12-O-tetradecanoylphorbol-13-acetate TPA mitogen]	0.0	3	1	1	1
138453	1710	substitution in a HLA-DQ3.2 molecule	[substitution in an HLA-DQ3.2 molecule]	0.0	5	1	1	1
138454	1710	segregation of chromosome	[segregation of chromosomes]	0.0	3	1	1	1
138455	1710	efficiently by H-8,	[efficiently by H-8,]	0.0	3	1	1	1
138456	1710	overexpression of the L-selectin gene	[overexpression of the L-selectin gene]	0.0	5	1	1	1
138457	1710	inhibition through adenosine triphosphate atp depletion	[inhibition through adenosine triphosphate ATP depletion]	0.0	6	1	1	1
138458	1710	level of IFN a	[levels of IFN A]	0.0	4	1	1	1
138459	1710	significant proliferation in response iddm subject	[significant proliferation in response IDDM subjects]	0.0	6	1	1	1
138460	1710	electrolyte response in leukocyte	[electrolyte response in leukocytes]	0.0	4	1	1	1
138461	1710	state for hiv-1 replication	[state for HIV-1 replication]	0.0	4	1	1	1
138462	1710	two protein kinase signal pathway	[two protein kinase signaling pathways]	0.0	5	1	1	1
138463	1710	amount of active b	[amount of active B]	0.0	4	1	1	1
138464	1710	statistically significant proliferation capacity	[statistically significant proliferation capacity]	0.0	4	1	1	1
138465	1710	part of this protein complex	[part of these protein complexes]	0.0	5	1	1	1
138466	1710	exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin	[exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.0	3	1	1	1
138467	1710	combination with cytokine	[combination with cytokines]	0.0	3	1	1	1
138468	1710	woman (11 first, 10 second	[women (11 first, 10 second]	0.0	5	1	1	1
138469	1710	such as raloxifene	[such as Raloxifene]	0.0	3	1	1	1
138470	1710	step, involve a modulation	[step, involving a modulation]	0.0	4	1	1	1
138471	1710	dose of flutamide on parameter	[doses of flutamide on parameters]	0.0	5	1	1	1
138472	1710	24 RA patient	[24 RA patients]	0.0	3	1	1	1
138473	1710	number (mnl) of patient	[number (MNL) of patients]	0.0	4	1	1	1
138474	1710	patient with graves' disease	[patients with Graves' disease]	0.0	4	1	1	1
138475	1710	other condition such as cancer	[other conditions such as cancer]	0.0	5	1	1	1
138476	1710	micromol/L) dose-dependently	[micromol/L) dose-dependently]	0.0	2	1	1	1
138477	1710	mucocutaneous melanosis	[mucocutaneous melanosis]	0.0	2	1	1	1
138478	1710	promoter chromatin	[promoter chromatin]	0.0	2	1	1	1
138479	1710	two independent form	[two independent forms]	0.0	3	1	1	1
138480	1710	translocation of cytosolic nf-kappa b	[translocation of cytosolic NF-kappa B]	0.0	5	1	1	1
138481	1710	several molecular weight transmembrane adaptor protein	[several molecular weight transmembrane adaptor proteins]	0.0	6	1	1	1
138482	1710	NFAT reporter	[NFAT reporter]	0.0	2	1	1	1
138483	1710	such as pyrrolidine dithiocarbamate	[such as pyrrolidine dithiocarbamate]	0.0	4	1	1	1
138484	1710	mature m phi	[maturing M phi]	0.0	3	1	1	1
138485	1710	basis of pattern	[basis of patterns]	0.0	3	1	1	1
138486	1710	c-Myc in apoptosis	[c-Myc in apoptosis]	0.0	3	1	1	1
138487	1710	gene in ctll-2 beta-casein	[genes in CTLL-2 beta-casein]	0.0	4	1	1	1
138488	1710	sequence variant	[sequence variants]	0.0	2	1	1	1
138489	1710	vivo activation	[vivo activation]	0.0	2	1	1	1
138490	1710	other gene product	[other gene products]	0.0	3	1	1	1
138491	1710	eosinophilic inflammatory disease	[eosinophilic inflammatory diseases]	0.0	3	1	1	1
138492	1710	antisense myb expression	[antisense myb expression]	0.0	3	1	1	1
138493	1710	evidence for a interindividual variation	[evidence for a interindividual variation]	0.0	5	1	1	1
138494	1710	b2 complex	[B2 complex]	0.0	2	1	1	1
138495	1710	mass of 32 kda	[mass of 32 kDa]	0.0	4	1	1	1
138496	1710	semiquantitative rt-pcr analysis from reticulocyte	[semiquantitative RT-PCR analysis from reticulocytes]	0.0	5	1	1	1
138497	1710	presumably gata-1	[presumably GATA-1]	0.0	2	1	1	1
138498	1710	receptor messenger ribonucleic acid	[receptor messenger ribonucleic acid]	0.0	4	1	1	1
138499	1710	constitutively active raf-1	[constitutively active Raf-1]	0.0	3	1	1	1
138500	1710	oxygen species serve as messenger	[oxygen species serving as messengers]	0.0	5	1	1	1
138501	1710	Helenalin a sesquiterpene lactone	[Helenalin an sesquiterpene lactone]	0.0	4	1	1	1
138502	1710	transcription enhancement by site	[transcription enhancement by sites]	0.0	4	1	1	1
138503	1710	10(-8) g/g of rna in monocyte	[10(-8) g/g of RNA in monocytes]	0.0	6	1	1	1
138504	1710	p50 homodimer in monocyte	[p50 homodimer in monocytes]	0.0	4	1	1	1
138505	1710	various rheumatic disease (12: four	[various rheumatic diseases (12: four]	0.0	5	1	1	1
138506	1710	clonal eosinophilia in a patient	[clonal eosinophilia in a patient]	0.0	5	1	1	1
138507	1710	tcl1 mrna	[TCL1 mRNA]	0.0	2	1	1	1
138508	1710	Negative regulation of immunodeficiency virus type	[Negative regulation of immunodeficiency virus type]	0.0	6	1	1	1
138509	1710	DNA bind nfkb2	[DNA binding NFKB2]	0.0	3	1	1	1
138510	1710	induction of nf-kappab	[induction of NF-kappaB]	0.0	3	1	1	1
138511	1710	cytokine expression pattern	[cytokine expression patterns]	0.0	3	1	1	1
138512	1710	regulation by cyclic AMP	[regulation by cyclic AMP]	0.0	4	1	1	1
138513	1710	P; early),	[h; early),]	0.0	2	1	1	1
138514	1710	component of this element	[components of this element]	0.0	4	1	1	1
138515	1710	DNA relax enzyme	[DNA relaxing enzymes]	0.0	3	1	1	1
138516	1710	multiple blood sample	[multiple blood samples]	0.0	3	1	1	1
138517	1710	heparin gag with mcp-1	[heparin GAGs with MCP-1]	0.0	4	1	1	1
138518	1710	elevation of expression upon repression,	[elevation of expression upon repression,]	0.0	5	1	1	1
138519	1710	platelet morphogenesis	[platelet morphogenesis]	0.0	2	1	1	1
138520	1710	response to hypoglycemia	[response to hypoglycemia]	0.0	3	1	1	1
138521	1710	patient with CLL rarely express er	[patients with CLL rarely express ER]	0.0	6	1	1	1
138522	1710	induction of interferon protein	[induction of interferon protein]	0.0	4	1	1	1
138523	1710	total nonsmok patient	[total nonsmoking patients]	0.0	3	1	1	1
138524	1710	component of the network operate	[components of the network operating]	0.0	5	1	1	1
138525	1710	use synovial cell	[Using synovial cells]	0.0	3	1	1	1
138526	1710	critical serine residue	[critical serine residues]	0.0	3	1	1	1
138527	1710	dehydratase/dimerization	[dehydratase/dimerization]	0.0	1	2	2	1
138528	1710	analysis of pp90rsk activity	[analysis of pp90rsk activity]	0.0	4	1	1	1
138529	1710	transcription in HeLa cell	[transcription in HeLa cells]	0.0	4	1	1	1
138530	1710	functional motifs:	[functional motifs:]	0.0	2	1	1	1
138531	1710	incubation of blood with PGG-Glucan	[Incubation of blood with PGG-Glucan]	0.0	5	1	1	1
138532	1710	1 to 10 mmol/L.	[1 to 10 mmol/L.]	0.0	4	1	1	1
138533	1710	selection expansion) (by abortive stimulation	[selection expansion) (by abortive stimulation]	0.0	5	1	1	1
138534	1710	c-terminus in b cell	[C-terminus in B cells]	0.0	4	1	1	1
138535	1710	exposure of human aortic cell	[exposure of human aortic cells]	0.0	5	1	1	1
138536	1710	basAl, adhesion at 20 mM.	[basal, adhesion at 20 mM.]	0.0	5	1	1	1
138537	1710	longer-ter potentiation	[longer-term potentiation]	0.0	2	1	1	1
138538	1710	thus, competition	[Thus, competition]	0.0	2	1	1	1
138539	1710	3-fold great effect	[3-fold greater effect]	0.0	3	1	1	1
138540	1710	confirm the importance	[confirming the importance]	0.0	3	1	1	1
138541	1710	one sp 1-binding site	[one Sp 1-binding site]	0.0	4	1	1	1
138542	1710	DNA variation in tumor	[DNA variations in tumor]	0.0	4	1	1	1
138543	1710	vitro expression	[vitro expression]	0.0	2	1	1	1
138544	1710	micrograms/mL phytohemagglutinin	[micrograms/mL phytohemagglutinin]	0.0	2	1	1	1
138545	1710	integer number of turn	[integer numbers of turns]	0.0	4	1	1	1
138546	1710	MHC class ii ligand	[MHC class II ligands]	0.0	4	1	1	1
138547	1710	Ie gene induction	[IE gene induction]	0.0	3	1	1	1
138548	1710	alpha beta 1 in T cell	[alpha beta 1 in T cells]	0.0	6	1	1	1
138549	1710	characterization of a positive element	[characterization of a positive element]	0.0	5	1	1	1
138550	1710	human element hSIE dna-probe	[human element hSIE DNA-probe]	0.0	4	1	1	1
138551	1710	indicator of ca2+ load	[indicators of Ca2+ load]	0.0	4	1	1	1
138552	1710	transcription activator of cellular gene	[transcription activator of cellular genes]	0.0	5	1	1	1
138553	1710	self-distructed response	[self-distructed response]	0.0	2	1	1	1
138554	1710	individual cytokine receptor	[individual cytokine receptors]	0.0	3	1	1	1
138555	1710	also improve the definition	[also improving the definitions]	0.0	4	1	1	1
138556	1710	high mobility group (hmg) protein	[high mobility group (HMG) protein]	0.0	5	1	1	1
138557	1710	megadosis	[megadoses]	0.0	1	1	1	1
138558	1710	high wt1 expression	[high WT1 expression]	0.0	3	1	1	1
138559	1710	only useful tool	[only useful tool]	0.0	3	1	1	1
138560	1710	protein of hiv-1	[protein of HIV-1]	0.0	3	1	1	1
138561	1710	member family.	[member family.]	0.0	2	1	1	1
138562	1710	then (il)-10 blocking factor expression	[then (IL)-10 blocking factor expression]	0.0	5	1	1	1
138563	1710	contrast, two other anti-inflammatory drug	[contrast, two other anti-inflammatory drugs]	0.0	5	1	1	1
138564	1710	such related protein	[such related proteins]	0.0	3	1	1	1
138565	1710	cellular factor responsible	[cellular factors responsible]	0.0	3	1	1	1
138566	1710	transcription of cellular gene include IL-2	[transcription of cellular genes including IL-2]	0.0	6	1	1	1
138567	1710	basal factor	[basal factors]	0.0	2	1	1	1
138568	1710	cell with receptor	[cells with receptors]	0.0	3	1	1	1
138569	1710	gender difference	[Gender difference]	0.0	2	1	1	1
138570	1710	3D-NMR	[3D-NMR]	0.0	1	1	1	1
138571	1710	event.	[event.]	0.0	1	1	1	1
138572	1710	cyclooxygenase/5-lipoxygenase	[cyclooxygenase/5-lipoxygenase]	0.0	1	1	1	1
138573	1710	series of cell line	[series of cell lines]	0.0	4	1	1	1
138574	1710	Raji b lymphoblastoid cell	[Raji B lymphoblastoid cells]	0.0	4	1	1	1
138575	1710	5-lox system	[5-LOX system]	0.0	2	1	1	1
138576	1710	three A1 protein	[three A1 proteins]	0.0	3	1	1	1
138577	1710	depletion of glucocorticoid	[depletion of glucocorticoids]	0.0	3	1	1	1
138578	1710	vivo regulation	[vivo regulation]	0.0	2	1	1	1
138579	1710	relevant form	[relevant form]	0.0	2	1	1	1
138580	1710	patient with invasive breast cancer	[patients with invasive breast cancer]	0.0	5	1	1	1
138581	1710	following: at the end increased;	[following: at the end increased;]	0.0	5	1	1	1
138582	1710	fluid monocyte /macrophage	[fluid monocytes /macrophages]	0.0	3	1	1	1
138583	1710	physiologically, high level of nuclear	[physiologically, high levels of nuclear]	0.0	5	1	1	1
138584	1710	chemotactic mcp-1 adhesive ICAM-1 property	[chemotactic MCP-1 adhesive ICAM-1 properties]	0.0	5	1	1	1
138585	1710	antigen anti-viral antigen vca	[antigen anti-viral antigen VCA]	0.0	4	1	1	1
138586	1710	domain 1 of CD4	[domain 1 of CD4]	0.0	4	1	1	1
138587	1710	intron downstream	[intron downstream]	0.0	2	1	1	1
138588	1710	mutant macrophage-competent derivative	[mutants macrophage-competent derivative]	0.0	3	1	1	1
138589	1710	binding at this region	[binding at this region]	0.0	4	1	1	1
138590	1710	activation of S6 kinase	[activation of S6 kinase]	0.0	4	1	1	1
138591	1710	nuclear factor-kappaB/Rel	[nuclear factor-kappaB/Rel]	0.0	2	1	1	1
138592	1710	copy repeat	[copy repeat]	0.0	2	1	1	1
138593	1710	continued, bcl-6 expression	[continued, BCL-6 expression]	0.0	3	1	1	1
138594	1710	chronic myelomonocytic leukemia	[chronic myelomonocytic leukemia]	0.0	3	1	1	1
138595	1710	immediate-early viral transactivator	[immediate-early viral transactivators]	0.0	3	1	1	1
138596	1710	N-acetyl-L-cysteine NAC a well-characterized, antioxidant	[N-acetyl-L-cysteine NAC a well-characterized, antioxidant]	0.0	5	1	1	1
138597	1710	receptor-associated factor traz	[receptor-associated factors TRAFs]	0.0	3	1	1	1
138598	1710	expression of the beta-casein gene	[expression of the beta-casein gene]	0.0	5	1	1	1
138599	1710	Cotransfection	[Cotransfection]	0.0	1	1	1	1
138600	1710	methods: protein production	[METHODS: Protein production]	0.0	3	1	1	1
138601	1710	role of E2F	[role of E2F]	0.0	3	1	1	1
138602	1710	additional staining	[additional staining]	0.0	2	1	1	1
138603	1710	lymphocyte of child	[lymphocytes of children]	0.0	3	2	2	1
138604	1710	iil)-1alpha	[(IL)-1alpha]	0.0	1	1	1	1
138605	1710	patient 1.5-1.6 time	[patients 1.5-1.6 times]	0.0	3	1	1	1
138606	1710	patient risk of breast recurrence	[patients risk of breast recurrence]	0.0	5	1	1	1
138607	1710	DRE protein, p37	[DRE protein, p37]	0.0	3	1	1	1
138608	1710	G28-5 IgG	[G28-5 IgG]	0.0	2	1	1	1
138609	1710	16 (50%) ica-positive first-degree relative	[16 (50%) ICA-positive first-degree relatives]	0.0	5	1	1	1
138610	1710	autoreactive T	[autoreactive T]	0.0	2	1	1	1
138611	1710	percutaneous coronary angioplasty PTCA	[percutaneous coronary angioplasty PTCA]	0.0	4	1	1	1
138612	1710	consequence in the clinical use	[consequences in the clinical use]	0.0	5	1	1	1
138613	1710	use the acid receptor alpha	[Using the acid receptor alpha]	0.0	5	1	1	1
138614	1710	protein vital	[protein vital]	0.0	2	1	1	1
138615	1710	synergistic activation by NF-kappaB	[synergistic activation by NF-kappaB]	0.0	4	1	1	1
138616	1710	NF-muNR binding	[NF-muNR binding]	0.0	2	1	1	1
138617	1710	CD40 induction of gene expression	[CD40 induction of gene expression]	0.0	5	1	1	1
138618	1710	oxidative-stress transcription factor	[oxidative-stress transcription factor]	0.0	3	1	1	1
138619	1710	costimulation requirement	[Costimulation requirement]	0.0	2	1	1	1
138620	1710	result via C-terminal activating region	[resulting via C-terminal activating regions]	0.0	5	1	1	1
138621	1710	human bcl2	[human BCL2]	0.0	2	1	1	1
138622	1710	role of the transcription factor Oct-2A	[roles of the transcription factor Oct-2A]	0.0	6	1	1	1
138623	1710	protection from apoptosis	[protection from apoptosis]	0.0	3	1	1	1
138624	1710	recognition cytotoxic T lymphocyte clonotypes: implication	[recognition cytotoxic T lymphocyte clonotypes: implications]	0.0	6	1	1	1
138625	1710	acth concentration	[ACTH concentrations]	0.0	2	1	1	1
138626	1710	activity of three transcription factor NFkappaB	[activities of three transcription factors NFkappaB]	0.0	6	1	1	1
138627	1710	4.3 pts; fluticasone: 1.55 pts)	[4.3 pts; fluticasone: 1.55 pts)]	0.0	5	1	1	1
138628	1710	familial disorder	[familial disorders]	0.0	2	1	1	1
138629	1710	barrier function	[barrier function]	0.0	2	1	1	1
138630	1710	effect on monocytic differentiation	[effects on monocytic differentiation]	0.0	4	1	1	1
138631	1710	binding site for a factor present	[binding sites for a factor present]	0.0	6	1	1	1
138632	1710	classic hd CHD	[classic HD CHD]	0.0	3	1	1	1
138633	1710	interleukin-5 hil-5 stimulation	[interleukin-5 hIL-5 stimulation]	0.0	3	1	1	1
138634	1710	tax mouse model	[tax mouse model]	0.0	3	1	1	1
138635	1710	count	[counts]	0.0	1	2	2	1
138636	1710	human vein ec	[human vein EC]	0.0	3	1	1	1
138637	1710	include pervanadate	[including pervanadate]	0.0	2	1	1	1
138638	1710	adhesion after h	[adhesion after h]	0.0	3	1	1	1
138639	1710	phosphorylation of IkappaB alpha a inhibitor	[phosphorylation of IkappaB alpha a inhibitor]	0.0	6	1	1	1
138640	1710	catalytic activity a autophosphorylation site	[catalytic activity an autophosphorylation site]	0.0	5	1	1	1
138641	1710	approximately substnfkappab	[approximately substNFkappaB]	0.0	2	1	1	1
138642	1710	fas ligand element	[Fas ligand element]	0.0	3	1	1	1
138643	1710	h in culture media.	[h in culture media.]	0.0	4	1	1	1
138644	1710	gata-1 motif,	[GATA-1 motif,]	0.0	2	1	1	1
138645	1710	T and,	[T and,]	0.0	2	1	1	1
138646	1710	molecular analysis of deletion	[molecular analysis of deletions]	0.0	4	1	1	1
138647	1710	exact etiology of multiple sclerosis	[exact etiology of multiple sclerosis]	0.0	5	1	1	1
138648	1710	constitutive nuclear translocation	[constitutive nuclear translocation]	0.0	3	2	2	1
138649	1710	effect of histamine	[effects of histamine]	0.0	3	1	1	1
138650	1710	TK inhibitor herbimycin	[TK inhibitors herbimycin]	0.0	3	1	1	1
138651	1710	potential phosphoprotein of function.	[potential phosphoprotein of function.]	0.0	4	1	1	1
138652	1710	constitutive association of traz domain	[constitutive association of TRAFs domain]	0.0	5	1	1	1
138653	1710	inducible cyclosporin dnase site	[inducible cyclosporin DNase site]	0.0	4	1	1	1
138654	1710	effect of term therapy	[effect of term therapy]	0.0	4	1	1	1
138655	1710	swi2 protein	[SWI2 protein]	0.0	2	1	1	1
138656	1710	high wt1 expression in cell	[high WT1 expression in cells]	0.0	5	1	1	1
138657	1710	possible role of Ras	[possible role of Ras]	0.0	4	1	1	1
138658	1710	protein of 65-75 kda	[proteins of 65-75 kDa]	0.0	4	1	1	1
138659	1710	poor separation on percoll gradient	[poor separation on Percoll gradients]	0.0	5	1	1	1
138660	1710	staining for nf-kappabp65	[staining for NF-kappaBp65]	0.0	3	1	1	1
138661	1710	regulation during differentiation of cell	[regulation during differentiation of cells]	0.0	5	1	1	1
138662	1710	intact carboxyl-terminal cytoplasmic segment	[intact carboxyl-terminal cytoplasmic segment]	0.0	4	1	1	1
138663	1710	SH2 domain-contain protein	[SH2 domain-containing protein]	0.0	3	1	1	1
138664	1710	IL-12 activation	[IL-12 activation]	0.0	2	2	2	1
138665	1710	contrast to the signal	[contrast to the signaling]	0.0	4	1	1	1
138666	1710	level of trap alpha-naphthyl-acetate-esterase	[levels of TRAP alpha-naphthyl-acetate-esterase]	0.0	4	1	1	1
138667	1710	3 mrna level	[3 mRNA levels]	0.0	3	1	1	1
138668	1710	class promoter occupancy alteration	[class promoter occupancy alterations]	0.0	4	1	1	1
138669	1710	cell (apc)	[cell (APC)]	0.0	2	1	1	1
138670	1710	320-kda species of ubiquitin -protein ligase	[320-kDa species of ubiquitin -protein ligase]	0.0	6	1	1	1
138671	1710	inhibition of the original igg (from	[inhibition of the original IgG (from]	0.0	6	1	1	1
138672	1710	medium e-cm	[medium E-CM]	0.0	2	1	1	1
138673	1710	down-regulation of immune response	[down-regulation of immune responses]	0.0	4	1	1	1
138674	1710	EMBO 1997).	[EMBO 1997).]	0.0	2	1	1	1
138675	1710	transcriptional activator RelA	[transcriptional activators RelA]	0.0	3	1	1	1
138676	1710	HIV terminal repeat LTR	[HIV terminal repeat LTR]	0.0	4	1	1	1
138677	1710	low tcrzeta level	[lower TCRzeta levels]	0.0	3	1	1	1
138678	1710	expose vein endothelial cell to anoxia/reoxygenation	[Exposing vein endothelial cells to anoxia/reoxygenation]	0.0	6	1	1	1
138679	1710	transactivate property	[transactivating properties]	0.0	2	1	1	1
138680	1710	Epstein-Barr virus a gammaherpesvirus	[Epstein-Barr virus a gammaherpesvirus]	0.0	4	1	1	1
138681	1710	MZF-1 transcriptional regulation of this promoter	[MZF-1 transcriptional regulation of this promoter]	0.0	6	1	1	1
138682	1710	murine splenocyte	[murine splenocytes]	0.0	2	1	1	1
138683	1710	IL-2 cis-regulatory element	[IL-2 cis-regulatory elements]	0.0	3	1	1	1
138684	1710	six repeat	[six repeats]	0.0	2	1	1	1
138685	1710	raji cell ebv b-cell	[Raji cells EBV B-cell]	0.0	4	1	1	1
138686	1710	cd45 -dependent event	[CD45 -dependent events]	0.0	3	1	1	1
138687	1710	fos protein	[FOS proteins]	0.0	2	1	1	1
138688	1710	serine /threonine phosphatase calcineurin	[serine /threonine phosphatase calcineurin]	0.0	4	1	1	1
138689	1710	inhibition by a alkaloid	[inhibition by an alkaloid]	0.0	4	1	1	1
138690	1710	male with x-linked immunodeficiency xscid	[Males with X-linked immunodeficiency XSCID]	0.0	5	1	1	1
138691	1710	(i) patient rarely express er	[(i) patients rarely express ER]	0.0	5	1	1	1
138692	1710	apoptosis inhibition in lymphocyte	[Apoptosis inhibition in lymphocytes]	0.0	4	1	1	1
138693	1710	potential role for IL-7	[potential role for IL-7]	0.0	4	1	1	1
138694	1710	approach create hiv-1/siv	[approach creating HIV-1/SIV]	0.0	3	1	1	1
138695	1710	transcription STAT3	[transcription STAT3]	0.0	2	1	1	1
138696	1710	harbour type	[harbouring type]	0.0	2	1	1	1
138697	1710	survival through upregulation	[survival through upregulation]	0.0	3	1	1	1
138698	1710	S. typhimurium	[S. typhimurium]	0.0	2	1	1	1
138699	1710	woman first, 10 second	[women first, 10 second]	0.0	4	1	1	1
138700	1710	epsilon-globin-encoding gene in cell	[epsilon-globin-encoding gene in cells]	0.0	4	1	1	1
138701	1710	Promiscuous transcriptional activity reticuloendotheliosis virus	[Promiscuous transcriptional activity reticuloendotheliosis virus]	0.0	5	1	1	1
138702	1710	il-1 beta mrna level	[IL-1 beta mRNA levels]	0.0	4	1	1	1
138703	1710	blood leukocyte to activator	[blood leukocytes to activators]	0.0	4	1	1	1
138704	1710	growth of hemopoietic cell	[growth of hemopoietic cells]	0.0	4	1	1	1
138705	1710	suggest a relevant interaction	[suggesting a relevant interaction]	0.0	4	1	1	1
138706	1710	gr transcriptional activation	[GR transcriptional activation]	0.0	3	1	1	1
138707	1710	histopathological entity	[histopathological entity]	0.0	2	1	1	1
138708	1710	epithelium of normal with cf	[epithelium of normals with CF]	0.0	5	1	1	1
138709	1710	effect comparison	[effect comparison]	0.0	2	1	1	1
138710	1710	line u937 in diploid fibroblast	[lines U937 in diploid fibroblasts]	0.0	5	1	1	1
138711	1710	member of the cascade	[members of the cascade]	0.0	4	1	1	1
138712	1710	contrast to the wild-type endotoxin,	[contrast to the wild-type endotoxin,]	0.0	5	1	1	1
138713	1710	role of cysteine	[role of cysteine]	0.0	3	1	1	1
138714	1710	bp of 5' DNA	[bp of 5' DNA]	0.0	4	1	1	1
138715	1710	(stimulatory effect	[(stimulatory effects]	0.0	2	1	1	1
138716	1710	calcium CD28 pathway	[calcium CD28 pathway]	0.0	3	1	1	1
138717	1710	mobility of the e2f component	[mobility of the E2F components]	0.0	5	1	1	1
138718	1710	join gene segment for VDJ recombination	[joining gene segments for VDJ recombination]	0.0	6	1	1	1
138719	1710	49 aged subject (62-97 yr)	[49 aged subjects (62-97 yr)]	0.0	5	1	1	1
138720	1710	Class cell MHC class	[Class cell MHC class]	0.0	4	1	1	1
138721	1710	Sp1 protein	[Sp1 proteins]	0.0	2	1	1	1
138722	1710	chronic leukemia B-CLL	[chronic leukemia B-CLL]	0.0	3	1	1	1
138723	1710	response of b lymphocyte	[responses of B lymphocytes]	0.0	4	1	1	1
138724	1710	posttransplant disorder	[posttransplant disorders]	0.0	2	1	1	1
138725	1710	c-terminal half of mzf-2	[C-terminal half of MZF-2]	0.0	4	1	1	1
138726	1710	gene regulatory mechanism	[gene regulatory mechanisms]	0.0	3	1	1	1
138727	1710	[3H]1 alpha,25-dihydroxyvitamin D3	[[3H]1 alpha,25-dihydroxyvitamin D3]	0.0	3	1	1	1
138728	1710	calcineurin process	[calcineurin process]	0.0	2	1	1	1
138729	1710	p 0.005	[P 0.005,]	0.0	2	1	1	1
138730	1710	years).	[years).]	0.0	1	1	1	1
138731	1710	years),	[years),]	0.0	1	1	1	1
138732	1710	C.botulinum	[C.botulinum]	0.0	1	1	1	1
138733	1710	progenitor-specific surface marker	[progenitor-specific surface markers]	0.0	3	1	1	1
138734	1710	distinct role in the control	[distinct roles in the control]	0.0	5	1	1	1
138735	1710	However, presentation	[However, presentation]	0.0	2	1	1	1
138736	1710	htlv-1 gene regulation	[HTLV-1 gene regulation]	0.0	3	1	1	1
138737	1710	response to C. albican	[response to C. albicans]	0.0	4	1	1	1
138738	1710	protein of kda.	[protein of kDa.]	0.0	3	1	1	1
138739	1710	syndrome after resection respond	[syndrome after resection responding]	0.0	4	1	1	1
138740	1710	multiple promoter	[multiple promoters]	0.0	2	1	1	1
138741	1710	chain deficiency	[chain deficiency]	0.0	2	1	1	1
138742	1710	three prototype stress hormone dexamethasone	[three prototype stress hormones dexamethasone]	0.0	5	1	1	1
138743	1710	IL-1RI complex	[IL-1RI complex]	0.0	2	1	1	1
138744	1710	upstream sequence (-7.0 kb)	[upstream sequence (-7.0 kb)]	0.0	4	1	1	1
138745	1710	receptor/ characteristic in the develop	[receptor/s characteristics in the developing]	0.0	5	1	1	1
138746	1710	none of the enhancer-binding protein	[none of the enhancer-binding proteins]	0.0	5	1	1	1
138747	1710	activation of lymphokine gene	[Activation of lymphokine genes]	0.0	4	1	1	1
138748	1710	luteinize	[luteinizing]	0.0	1	1	1	1
138749	1710	interferon-gamma-induced factor binding role in up-regulation	[Interferon-gamma-induced factor binding role in up-regulation]	0.0	6	1	1	1
138750	1710	dendritic cell from blood	[dendritic cells from blood]	0.0	4	1	1	1
138751	1710	synthetic peptide substrate	[synthetic peptide substrate]	0.0	3	1	1	1
138752	1710	activity in IL-4 T cell	[activities in IL-4 T cells]	0.0	5	1	1	1
138753	1710	Dr. Dezube (Boston)	[Dr. Dezube (Boston)]	0.0	3	1	1	1
138754	1710	positive physiological role	[positive physiological role]	0.0	3	1	1	1
138755	1710	sequence in the membrane-proximal region	[sequence in the membrane-proximal region]	0.0	5	1	1	1
138756	1710	class MHC antigen expression	[class MHC antigen expression]	0.0	4	1	1	1
138757	1710	icr27tk.3 human leukemic T cell	[ICR27TK.3 human leukemic T cells]	0.0	5	1	1	1
138758	1710	follow iv dosing	[following IV dosing]	0.0	3	1	1	1
138759	1710	granulocyte colony-stimulating factor factor	[granulocyte colony-stimulating factor factor]	0.0	4	1	1	1
138760	1710	distinctly different requirement	[distinctly different requirements]	0.0	3	1	1	1
138761	1710	independent mutation event	[independent mutation events]	0.0	3	1	1	1
138762	1710	suggest a role for hmg-i(y)	[suggesting a role for HMG-I(Y)]	0.0	5	1	1	1
138763	1710	Nuclear factor-kappaB induction evidence	[Nuclear factor-kappaB induction evidence]	0.0	4	1	1	1
138764	1710	activity of breast cancer	[activity of breast cancers]	0.0	4	1	1	1
138765	1710	specific induction during differentiation	[specific induction during differentiation]	0.0	4	1	1	1
138766	1710	additional h	[additional h]	0.0	2	1	1	1
138767	1710	variable anemic severity	[variable anemic severity]	0.0	3	1	1	1
138768	1710	hour of microm cadmium chloride	[hours of microM cadmium chloride]	0.0	5	1	1	1
138769	1710	immortalization 1 tax mutant	[Immortalization 1 Tax mutants]	0.0	4	1	1	1
138770	1710	cell type-specific difference	[cell type-specific differences]	0.0	3	1	1	1
138771	1710	removal of a part	[removal of a part]	0.0	4	1	1	1
138772	1710	(LS)	[(LS)]	0.0	1	1	1	1
138773	1710	-contact site	[-contact site]	0.0	2	1	1	1
138774	1710	development of antibody	[development of antibodies]	0.0	3	1	1	1
138775	1710	isolated housekeeping alas precursor	[isolated housekeeping ALAS precursor]	0.0	4	1	1	1
138776	1710	eosinophil from patient	[eosinophils from patients]	0.0	3	1	1	1
138777	1710	result in the generation	[resulting in the generation]	0.0	4	2	2	1
138778	1710	immortalization mechanism	[immortalization mechanism]	0.0	2	1	1	1
138779	1710	Differential autoregulation	[Differential autoregulation]	0.0	2	1	1	1
138780	1710	regulation gene expression in cell	[Regulation gene expression in cells]	0.0	5	1	1	1
138781	1710	(i) patient with CLL er	[(i) patients with CLL ER]	0.0	5	1	1	1
138782	1710	encode immediate-early transcriptional transactivator	[encoding immediate-early transcriptional transactivators]	0.0	4	1	1	1
138783	1710	new approach treat IBD	[newer approaches treating IBD]	0.0	4	1	1	1
138784	1710	subunits; five independent genes, nfkb1 p105	[subunits; five independent genes, NFKB1 p105]	0.0	6	1	1	1
138785	1710	two t-cell clone	[two T-cell clones]	0.0	3	1	1	1
138786	1710	concentration of the ligand,	[concentrations of the ligand,]	0.0	4	1	1	1
138787	1710	synovial fluid sf	[synovial fluids SFs]	0.0	3	1	1	1
138788	1710	factor 1 colony-stimulating factor	[factor 1 colony-stimulating factor]	0.0	4	1	1	1
138789	1710	lymphocyte from pregnant woman	[lymphocytes from pregnant women]	0.0	4	1	1	1
138790	1710	structure morphologically distinct	[structures morphologically distinct]	0.0	3	1	1	1
138791	1710	affinity fc receptor for ige	[affinity Fc receptor for IgE]	0.0	5	1	1	1
138792	1710	s-lb1 T lymphocyte	[S-LB1 T lymphocytes]	0.0	3	1	1	1
138793	1710	growth-factor-dependent cell line	[growth-factor-dependent cell line]	0.0	3	1	1	1
138794	1710	most potent site	[most potent site]	0.0	3	1	1	1
138795	1710	inhibition use a excess	[Inhibition using an excess]	0.0	4	1	1	1
138796	1710	exact role	[exact role]	0.0	2	1	1	1
138797	1710	role of Cbl	[role of Cbl]	0.0	3	1	1	1
138798	1710	dna-binding property of leukemia factor HLF	[DNA-binding properties of leukemia factor HLF]	0.0	6	1	1	1
138799	1710	carry copy of the p sequence	[carrying copies of the P sequence]	0.0	6	1	1	1
138800	1710	Activation,	[Activation,]	0.0	1	1	1	1
138801	1710	mammary cell in vitro	[mammary cells in vitro]	0.0	4	1	1	1
138802	1710	responsiveness of the il-5 gene	[responsiveness of the IL-5 genes]	0.0	5	1	1	1
138803	1710	sequence from the tcr locus	[sequences from the TCR locus]	0.0	5	1	1	1
138804	1710	osteoclast-like multinucleated giant cell from monocyte	[osteoclast-like multinucleated giant cells from monocytes]	0.0	6	1	1	1
138805	1710	micrometer	[micrometer]	0.0	1	1	1	1
138806	1710	b regulatory element	[B regulatory elements]	0.0	3	1	1	1
138807	1710	gene encode scm-1alpha	[genes encoding SCM-1alpha]	0.0	3	1	1	1
138808	1710	absolute block	[absolute block]	0.0	2	1	1	1
138809	1710	infection of a cell	[infection of a cell]	0.0	4	1	1	1
138810	1710	triiodothyronine receptor	[triiodothyronine receptors]	0.0	2	1	1	1
138811	1710	histocompatibility complex -restricted fashion	[histocompatibility complex -restricted fashion]	0.0	4	1	1	1
138812	1710	germline epsilon	[germline epsilon]	0.0	2	1	1	1
138813	1710	receptor domain binding	[receptor domain binding]	0.0	3	1	1	1
138814	1710	ebv reactivation	[EBV reactivation]	0.0	2	1	1	1
138815	1710	mouse epor	[mouse EpoR]	0.0	2	1	1	1
138816	1710	uptake in mononuclear leukocyte	[uptake in mononuclear leukocytes]	0.0	4	1	1	1
138817	1710	study with the ebv	[study with the EBV]	0.0	4	1	1	1
138818	1710	pulse exposure	[Pulse exposure]	0.0	2	1	1	1
138819	1710	severe skewing	[Severe skewing]	0.0	2	1	1	1
138820	1710	inhibition of complement in animal model	[Inhibition of complement in animal models]	0.0	6	1	1	1
138821	1710	membrane cd14 a lps receptor	[membrane CD14 a LPS receptor]	0.0	5	1	1	1
138822	1710	predictor of sertraline response	[predictor of sertraline response]	0.0	4	1	1	1
138823	1710	presence of phorbol	[presence of phorbol]	0.0	3	1	1	1
138824	1710	intrapulmonary accumulation	[intrapulmonary accumulation]	0.0	2	1	1	1
138825	1710	downregulation of igh 3' enhancer activity	[downregulation of IgH 3' enhancer activity]	0.0	6	1	1	1
138826	1710	evaluation of the epithelium	[Evaluation of the epithelium]	0.0	4	1	1	1
138827	1710	interaction at the x box	[interactions at the X boxes]	0.0	5	1	1	1
138828	1710	comprise a b-cell component	[comprising a B-cell component]	0.0	4	1	1	1
138829	1710	normal pulmonary alveolar macrophage PAM	[Normal pulmonary alveolar macrophages PAM]	0.0	5	1	1	1
138830	1710	NF kappa b cis-acting sequence	[NF kappa B cis-acting sequences]	0.0	5	1	1	1
138831	1710	expression of transcription factor TCF-1	[expression of transcription factors TCF-1]	0.0	5	1	1	1
138832	1710	range from plant	[ranging from plants]	0.0	3	1	1	1
138833	1710	content in syndrome patient	[contents in syndrome patients]	0.0	4	1	1	1
138834	1710	effect as gdsp	[effects as GDSP]	0.0	3	1	1	1
138835	1710	dramatic response in cases.	[dramatic response in cases.]	0.0	4	1	1	1
138836	1710	expression of Fli-1	[expression of Fli-1]	0.0	3	1	1	1
138837	1710	response to 5 u/ml interleukin-2	[response to 5 U/ml interleukin-2]	0.0	5	1	1	1
138838	1710	activation of jak kinase protein	[activation of JAK kinases proteins]	0.0	5	1	1	1
138839	1710	change of the protein	[changes of the proteins]	0.0	4	1	1	1
138840	1710	4.55 nm,	[4.55 nM,]	0.0	2	1	1	1
138841	1710	gene in transgenic mouse	[gene in transgenic mice]	0.0	4	1	1	1
138842	1710	IL-2 activation in human T cell	[IL-2 activation in human T cells]	0.0	6	1	1	1
138843	1710	administration of megadosis	[administration of megadoses]	0.0	3	1	1	1
138844	1710	IE2 gene product	[IE2 gene product]	0.0	3	1	1	1
138845	1710	Ter cell population	[Ter cell population]	0.0	3	1	1	1
138846	1710	1 element 1	[1 element 1]	0.0	3	1	1	1
138847	1710	individual nfat element	[individual NFAT elements]	0.0	3	1	1	1
138848	1710	low level of virus expression	[low levels of virus expression]	0.0	5	1	1	1
138849	1710	involvement at two subregion	[Involvement at two subregions]	0.0	4	1	1	1
138850	1710	cross-react with a antibody	[cross-reacting with a antibody]	0.0	4	1	1	1
138851	1710	study of steroid hormone	[study of steroid hormones]	0.0	4	1	1	1
138852	1710	t-cell lymphoma/leukemia ATLL	[T-cell lymphoma/leukemia ATLL]	0.0	3	1	1	1
138853	1710	aldosterone to receptor on leukocyte	[aldosterone to receptors on leukocytes]	0.0	5	1	1	1
138854	1710	Octamer activation of transcription	[Octamer activation of transcription]	0.0	4	1	1	1
138855	1710	vitro responsiveness	[vitro responsiveness]	0.0	2	1	1	1
138856	1710	androgen receptor in peripheral leukocyte	[androgen receptors in peripheral leukocytes]	0.0	5	2	2	1
138857	1710	lymphocyte with the progesterone antibody mPRI	[lymphocytes with the progesterone antibody mPRI]	0.0	6	1	1	1
138858	1710	transcription control	[transcription control]	0.0	2	1	1	1
138859	1710	include interferon	[including interferons]	0.0	2	1	1	1
138860	1710	CD8 interaction	[CD8 interaction]	0.0	2	1	1	1
138861	1710	presence of progenitor cell	[presence of progenitor cells]	0.0	4	1	1	1
138862	1710	target NFAT-1 gene expression in mouse	[targeting NFAT-1 gene expression in mice]	0.0	6	1	1	1
138863	1710	DQA1 locus	[DQA1 locus]	0.0	2	1	1	1
138864	1710	APL blast available only from patient	[APL blasts available only from patients]	0.0	6	1	1	1
138865	1710	peptide a elastase inhibitor	[peptide a elastase inhibitor]	0.0	4	1	1	1
138866	1710	production type	[production type]	0.0	2	1	1	1
138867	1710	permanently a challenge	[Permanently a challenge]	0.0	3	1	1	1
138868	1710	domain dbd	[domain DBD]	0.0	2	1	1	1
138869	1710	evidence for a possible relationship	[evidence for a possible relationship]	0.0	5	1	1	1
138870	1710	myeloid leukemic (aml) blast	[myeloid leukemic (AML) blasts]	0.0	4	1	1	1
138871	1710	kidney cell	[kidney cells]	0.0	2	1	1	1
138872	1710	pathway as wild-type zap-70	[pathways as wild-type ZAP-70]	0.0	4	1	1	1
138873	1710	statistical significance for patient	[statistical significance for patients]	0.0	4	1	1	1
138874	1710	16 (50%) relative	[16 (50%) relatives]	0.0	3	1	1	1
138875	1710	TNF-alpha hiv-1 long terminal repeat	[TNF-alpha HIV-1 long terminal repeat]	0.0	5	1	1	1
138876	1710	epithelial inflammation	[Epithelial inflammation]	0.0	2	1	1	1
138877	1710	rather surface icam-1 expression	[rather surface ICAM-1 expression]	0.0	4	1	1	1
138878	1710	action of hormone compound	[action of hormone compounds]	0.0	4	1	1	1
138879	1710	fundamental implication	[fundamental implications]	0.0	2	1	1	1
138880	1710	50 kda p65 polypeptide	[50 kDa p65 polypeptides]	0.0	4	1	1	1
138881	1710	endogenous il-1 beta	[endogenous IL-1 beta]	0.0	3	1	1	1
138882	1710	occur at 30 minute	[occurring at 30 minutes]	0.0	4	1	1	1
138883	1710	methov of human umbilical vein cell	[METHODS of human umbilical vein cells]	0.0	6	1	1	1
138884	1710	modulation of hiv expression	[modulation of HIV expression]	0.0	4	1	1	1
138885	1710	access Epstein-Barr virus -specific memory	[Accessing Epstein-Barr virus -specific memory]	0.0	5	1	1	1
138886	1710	attendant	[attendant]	0.0	1	1	1	1
138887	1710	2.3-kb cDNA clone	[2.3-kb cDNA clones]	0.0	3	1	1	1
138888	1710	ion flux	[ion fluxes]	0.0	2	1	1	1
138889	1710	coordinate downregulation	[coordinate downregulation]	0.0	2	1	1	1
138890	1710	phorbol protein kinase c	[phorbol protein kinase C]	0.0	4	1	1	1
138891	1710	strong N-terminal trans-activation domain	[strong N-terminal trans-activation domain]	0.0	4	1	1	1
138892	1710	cyclosporin dnase site	[cyclosporin DNase site]	0.0	3	1	1	1
138893	1710	one explanation for mechanism-based toxicity	[one explanation for mechanism-based toxicities]	0.0	5	1	1	1
138894	1710	simultaneously; pbl	[simultaneously; PBL]	0.0	2	1	1	1
138895	1710	tyrosine-phosphorylated granulocyte-colony factor treatment	[tyrosine-phosphorylated granulocyte-colony factor treatment]	0.0	4	1	1	1
138896	1710	3 autoantigen pbc.m2	[3 autoantigens PBC.M2]	0.0	3	1	1	1
138897	1710	incubation with microm mbp	[Incubation with microM MBP]	0.0	4	1	1	1
138898	1710	use extract from eosinophil	[using extracts from eosinophils]	0.0	4	1	1	1
138899	1710	Irish/German population	[Irish/German population]	0.0	2	1	1	1
138900	1710	lymphoblastoid T	[lymphoblastoid T]	0.0	2	1	1	1
138901	1710	mouse Chr in a region	[mouse Chr in an region]	0.0	5	1	1	1
138902	1710	the/thf n: 1.87+/-0.36)	[THE/THF N: 1.87+/-0.36)]	0.0	3	1	1	1
138903	1710	subtle alteration in cis-acting sequence	[subtle alterations in cis-acting sequences]	0.0	5	1	1	1
138904	1710	antiinflammatory property in cell	[antiinflammatory properties in cells]	0.0	4	1	1	1
138905	1710	positive correlation with the percentage	[positive correlation with the percentage]	0.0	5	1	1	1
138906	1710	effect of agent on cell activation	[effects of agents on cell activation]	0.0	6	1	1	1
138907	1710	three stati DNA binding element	[three STATI DNA binding elements]	0.0	5	1	1	1
138908	1710	transient myeloproliferative disorder	[transient myeloproliferative disorder]	0.0	3	3	3	1
138909	1710	dominant cytotoxic T lymphocyte response	[Dominant cytotoxic T lymphocyte response]	0.0	5	1	1	1
138910	1710	distal carg sequence	[distal CArG sequences]	0.0	3	1	1	1
138911	1710	role of ERK	[roles of ERK]	0.0	3	1	1	1
138912	1710	rna elongation	[RNA elongation]	0.0	2	1	1	1
138913	1710	hiv virus	[HIV virus]	0.0	2	1	1	1
138914	1710	transcription activator of gene	[transcription activator of genes]	0.0	4	1	1	1
138915	1710	ihiv-1	[iHIV-1]	0.0	1	1	1	1
138916	1710	four NFkappaB site	[four NFkappaB sites]	0.0	3	1	1	1
138917	1710	several tat mutant	[several tat mutants]	0.0	3	1	1	1
138918	1710	dhea (dissociation constant	[DHEA (dissociation constant]	0.0	3	1	1	1
138919	1710	correlate to the classification of IDC	[correlates to the classification of IDC]	0.0	6	1	1	1
138920	1710	means staining	[means staining]	0.0	2	1	1	1
138921	1710	homodimer with active heterodimer	[homodimers with active heterodimers]	0.0	4	1	1	1
138922	1710	tandem repeat of the p element	[tandem repeats of the P element]	0.0	6	1	1	1
138923	1710	potential of soluble antioxidant	[potential of soluble antioxidants]	0.0	4	1	1	1
138924	1710	marker of CML	[marker of CML]	0.0	3	1	1	1
138925	1710	(p 0.05).	[(P 0.05).]	0.0	2	1	1	1
138926	1710	IFN -dependent increase	[IFN -dependent increase]	0.0	3	1	1	1
138927	1710	mononuclear leukocyte MNL from subject	[mononuclear leukocytes MNL from subjects]	0.0	5	1	1	1
138928	1710	presence base pair	[presence base pairs]	0.0	3	1	1	1
138929	1710	enhanced, follow h	[enhanced, following h]	0.0	3	1	1	1
138930	1710	phenotypic analysis	[phenotypic analysis]	0.0	2	3	3	1
138931	1710	region in the cd14 promoter	[regions in the CD14 promoter]	0.0	5	1	1	1
138932	1710	translocation of transcription factor	[translocation of transcription factors]	0.0	4	1	1	1
138933	1710	dual enzyme inhibitor	[dual enzyme inhibitor]	0.0	3	1	1	1
138934	1710	composition in mature myeloid cell	[composition in mature myeloid cells]	0.0	5	1	1	1
138935	1710	novel T negative element nre	[novel T negative element NRE]	0.0	5	1	1	1
138936	1710	72 h),	[72 h),]	0.0	2	1	1	1
138937	1710	hour pulse-treatment with microm etoposide	[hour pulse-treatment with microM etoposide]	0.0	5	1	1	1
138938	1710	proliferation iddm subject 8	[proliferation IDDM subjects 8]	0.0	4	1	1	1
138939	1710	phase of apoptosis	[phases of apoptosis]	0.0	3	1	1	1
138940	1710	two allele in early progenitor	[two alleles in early progenitors]	0.0	5	1	1	1
138941	1710	histiocytoma	[histiocytoma]	0.0	1	1	1	1
138942	1710	use co-transfection assay	[using co-transfection assays]	0.0	3	1	1	1
138943	1710	C-terminal region of Tat	[C-terminal region of Tat]	0.0	4	1	1	1
138944	1710	present with immunodeficiency	[presenting with immunodeficiency]	0.0	3	1	1	1
138945	1710	approximately eightfold low amount a member	[approximately eightfold lower amounts a member]	0.0	6	1	1	1
138946	1710	m all-tran acid all-tran RA	[M all-trans acid all-trans RA]	0.0	5	1	1	1
138947	1710	factor kappa b NF-kappa b heterodimer	[factor kappa B NF-kappa B heterodimer]	0.0	6	1	1	1
138948	1710	subsequent activation	[subsequent activation]	0.0	2	3	3	1
138949	1710	transcriptional cooperativity	[transcriptional cooperativity]	0.0	2	1	1	1
138950	1710	sampling of blood	[sampling of blood]	0.0	3	1	1	1
138951	1710	event in erythroid maturation	[events in erythroid maturation]	0.0	4	1	1	1
138952	1710	patient with primary sjogren' syndrome (ss)	[patients with primary Sjogren's syndrome (SS)]	0.0	6	1	1	1
138953	1710	response to type interferon	[response to type interferons]	0.0	4	1	1	1
138954	1710	novel loci	[novel loci]	0.0	2	1	1	1
138955	1710	temperature-induced down-regulation	[Temperature-induced down-regulation]	0.0	2	1	1	1
138956	1710	immunoglobulin kappa	[immunoglobulin kappa]	0.0	2	1	1	1
138957	1710	number in phase	[numbers in phase]	0.0	3	1	1	1
138958	1710	notion direct substrate	[notion direct substrates]	0.0	3	1	1	1
138959	1710	ciita (for class transactivator	[CIITA (for class transactivator]	0.0	4	1	1	1
138960	1710	twenty-two patient with anorexia nervosa	[Twenty-two patients with anorexia nervosa]	0.0	5	1	1	1
138961	1710	5 of cases,	[5 of cases,]	0.0	3	1	1	1
138962	1710	B/Rel activity	[B/Rel activity]	0.0	2	1	1	1
138963	1710	concentration with a acute onset	[concentrations with an acute onset]	0.0	5	2	2	1
138964	1710	stat6 protein	[Stat6 protein]	0.0	2	1	1	1
138965	1710	potential alpha-helical domain	[potential alpha-helical domains]	0.0	3	1	1	1
138966	1710	correlation between c-jun expression	[correlation between c-jun expression]	0.0	4	1	1	1
138967	1710	molecule for hypoxia	[molecule for hypoxia]	0.0	3	1	1	1
138968	1710	eightfold amount a member	[eightfold amounts a member]	0.0	4	1	1	1
138969	1710	lymphocyte from healthy pregnant woman	[lymphocytes from healthy pregnant women]	0.0	5	1	1	1
138970	1710	Immunological study	[Immunological studies]	0.0	2	1	1	1
138971	1710	contain asparagine	[containing asparagine]	0.0	2	1	1	1
138972	1710	inhibition by combination	[Inhibition by combination]	0.0	3	1	1	1
138973	1710	critical role in the cyclosporin	[critical role in the cyclosporin]	0.0	5	1	1	1
138974	1710	functional promoter region (-36	[functional promoter region (-36]	0.0	4	1	1	1
138975	1710	regulation of nfatp	[regulation of NFATp]	0.0	3	1	1	1
138976	1710	normal function of the c-erbA	[normal function of the c-erbA]	0.0	5	1	1	1
138977	1710	such difference	[such differences]	0.0	2	1	1	1
138978	1710	tubules:	[tubules:]	0.0	1	1	1	1
138979	1710	frequent infection	[frequent infection]	0.0	2	1	1	1
138980	1710	early increase	[early increase]	0.0	2	1	1	1
138981	1710	two element in the tsp 1	[Two elements in the TSP 1]	0.0	6	1	1	1
138982	1710	HpaII site	[HpaII site]	0.0	2	1	1	1
138983	1710	paternal expression of WT1	[paternal expression of WT1]	0.0	4	1	1	1
138984	1710	TFIIIB	[TFIIIB]	0.0	1	1	1	1
138985	1710	two DNA fragment	[two DNA fragments]	0.0	3	1	1	1
138986	1710	incubation of RU 486 with dexamethasone	[incubation of RU 486 with dexamethasone]	0.0	6	1	1	1
138987	1710	level of BCL-2	[levels of BCL-2]	0.0	3	1	1	1
138988	1710	beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation	[beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation]	0.0	4	1	1	1
138989	1710	hiv reverse	[HIV reverse]	0.0	2	1	1	1
138990	1710	presence antibody	[presence antibodies]	0.0	2	1	1	1
138991	1710	catalytic cofactor	[catalytic cofactor]	0.0	2	1	1	1
138992	1710	mp treatment with suppression	[MP treatments with suppression]	0.0	4	1	1	1
138993	1710	variable monosomy	[variable monosomy]	0.0	2	1	1	1
138994	1710	other possibilities,	[other possibilities,]	0.0	2	1	1	1
138995	1710	transdominant negative mutant	[transdominant negative mutant]	0.0	3	2	2	1
138996	1710	however, two potent agent	[However, two potent agents]	0.0	4	1	1	1
138997	1710	stage of t-cell development	[stages of T-cell development]	0.0	4	1	1	1
138998	1710	element of repeat	[elements of repeats]	0.0	3	1	1	1
138999	1710	such cross-talking among adhesion molecule	[such cross-talking among adhesion molecules]	0.0	5	1	1	1
139000	1710	state of the beta-globin gene	[state of the beta-globin gene]	0.0	5	1	1	1
139001	1710	expression (maximal hours)	[expression (maximal hours)]	0.0	3	1	1	1
139002	1710	closely mimick	[closely mimicking]	0.0	2	1	1	1
139003	1710	most World primate	[Most World primate]	0.0	3	1	1	1
139004	1710	interleukin-1beta protein	[interleukin-1beta protein]	0.0	2	1	1	1
139005	1710	level in monocytic	[levels in monocytic]	0.0	3	1	1	1
139006	1710	regulation during activation-induced cell death	[Regulation during activation-induced cell death]	0.0	5	1	1	1
139007	1710	sh2 -dependent association with CD28	[SH2 -dependent association with CD28]	0.0	5	1	1	1
139008	1710	cd3/cd4+	[CD3/CD4+]	0.0	1	1	1	1
139009	1710	target structure the immediate-early protein	[Target structures the immediate-early protein]	0.0	5	1	1	1
139010	1710	release of ng/ml il-8	[release of ng/ml IL-8]	0.0	4	1	1	1
139011	1710	killer T/NK population	[killer T/NK populations]	0.0	3	1	1	1
139012	1710	use a hybridoma pc60	[using a hybridoma PC60]	0.0	4	1	1	1
139013	1710	block factor of T lymphocyte	[blocking factor of T lymphocytes]	0.0	5	1	1	1
139014	1710	Differential regulation during cell differentiation	[Differential regulation during cell differentiation]	0.0	5	1	1	1
139015	1710	vascular-specific expression of PECAM-1	[vascular-specific expression of PECAM-1]	0.0	4	1	1	1
139016	1710	inactive x chromosome xi	[inactive X chromosome Xi]	0.0	4	1	1	1
139017	1710	(b) ubiquitous factor	[(b) ubiquitous factors]	0.0	3	1	1	1
139018	1710	Cushing' syndrome	[Cushing's syndrome]	0.0	2	1	1	1
139019	1710	hla-cw*0702	[HLA-Cw*0702]	0.0	1	1	1	1
139020	1710	myeloid/NK acute leukemia	[myeloid/NK acute leukemia]	0.0	3	1	1	1
139021	1710	activation level	[activation levels]	0.0	2	1	1	1
139022	1710	8, malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[8, malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
139023	1710	catalytic activity	[catalytic activity]	0.0	2	2	2	1
139024	1710	median time	[median time]	0.0	2	1	1	1
139025	1710	plasma cysteine level	[plasma cysteine levels]	0.0	3	1	1	1
139026	1710	total of 37 severe, patient	[total of 37 severe, patients]	0.0	5	1	1	1
139027	1710	cytokine rescue from apoptosis	[Cytokine rescue from apoptosis]	0.0	4	1	1	1
139028	1710	large 14-day colony mm)	[large 14-day colonies mm)]	0.0	4	1	1	1
139029	1710	express high kinase activity	[expressing high kinase activity]	0.0	4	1	1	1
139030	1710	differentiation of myeloid precursors.	[differentiation of myeloid precursors.]	0.0	4	1	1	1
139031	1710	affinity receptor VDR	[affinity receptors VDR]	0.0	3	1	1	1
139032	1710	(wild	[(wild]	0.0	1	1	1	1
139033	1710	female mz twin pair	[female MZ twin pair]	0.0	4	1	1	1
139034	1710	fivefold formation	[fivefold formation]	0.0	2	1	1	1
139035	1710	activity of triiodothyronine sulfate	[activity of triiodothyronine sulfate]	0.0	4	1	1	1
139036	1710	autocrine tnf-alpha secretion	[autocrine TNF-alpha secretion]	0.0	3	1	1	1
139037	1710	receptor beta chain	[receptor beta chain]	0.0	3	1	1	1
139038	1710	role in hematopoiesis of leukocyte	[role in hematopoiesis of leukocytes]	0.0	5	1	1	1
139039	1710	human saphenous vein	[human saphenous vein]	0.0	3	1	1	1
139040	1710	major site of gc production	[major site of GC production]	0.0	5	1	1	1
139041	1710	molt T cell	[Molt T cells]	0.0	3	1	1	1
139042	1710	present with salt loss lead	[presenting with salt loss leading]	0.0	5	1	1	1
139043	1710	stat5b in primary precursor	[STAT5B in primary precursors]	0.0	4	1	1	1
139044	1710	(nos)	[(NOS)]	0.0	1	1	1	1
139045	1710	interaction of b cell	[interaction of B cells]	0.0	4	1	1	1
139046	1710	differentiation of human myeloid cell	[differentiation of human myeloid cells]	0.0	5	1	1	1
139047	1710	diabete maturity-onset diabete	[diabetes maturity-onset diabetes]	0.0	3	1	1	1
139048	1710	populations, include some group	[populations, including some groups]	0.0	4	1	1	1
139049	1710	nuclear translocation of nfat	[nuclear translocation of NFAT]	0.0	4	2	2	1
139050	1710	cytotoxicity at concentration	[cytotoxicity at concentrations]	0.0	3	1	1	1
139051	1710	cell contamination in pbsc harvest	[cell contamination in PBSC harvests]	0.0	5	1	1	1
139052	1710	circulate mononuclear leukocyte of healthy donor	[circulating mononuclear leukocytes of healthy donors]	0.0	6	1	1	1
139053	1710	serum-inducible element hsie	[serum-inducible element hSIE]	0.0	3	1	1	1
139054	1710	(ie, aitl without gc	[(ie, AITL without GC]	0.0	4	1	1	1
139055	1710	activation the expression of gene product	[activation the expression of gene products]	0.0	6	1	1	1
139056	1710	six truncate mutation	[six truncating mutations]	0.0	3	1	1	1
139057	1710	segregate this pathway	[segregating these pathways]	0.0	3	1	1	1
139058	1710	induction follow differentiation	[induction following differentiation]	0.0	3	1	1	1
139059	1710	mediate tnf-alpha induction	[mediating TNF-alpha induction]	0.0	3	1	1	1
139060	1710	in vitro substrate	[in vitro substrate]	0.0	3	1	1	1
139061	1710	link between microbial product	[link between microbial products]	0.0	4	1	1	1
139062	1710	clinical xenotransplantation	[clinical xenotransplantation]	0.0	2	1	1	1
139063	1710	TRAF2 adaptor	[TRAF2 adaptors]	0.0	2	1	1	1
139064	1710	cell infiltration with epithelial necrosis	[cell infiltration with epithelial necrosis]	0.0	5	1	1	1
139065	1710	alpha, 25-Dihydroxyvitamin D3 vd	[alpha, 25-Dihydroxyvitamin D3 VD]	0.0	4	1	1	1
139066	1710	hpc high-proliferative colony-forming cell	[HPCs high-proliferative colony-forming cells]	0.0	4	1	1	1
139067	1710	apoptotic event in steroid-treated cells.	[apoptotic events in steroid-treated cells.]	0.0	5	1	1	1
139068	1710	natural cytotoxicity program	[natural cytotoxicity programs]	0.0	3	1	1	1
139069	1710	provide the transactivator bzlf1	[providing the transactivator BZLF1]	0.0	4	1	1	1
139070	1710	I interleukin-1 receptor	[I interleukin-1 receptor]	0.0	3	1	1	1
139071	1710	schedule of calcitriol	[schedules of calcitriol]	0.0	3	1	1	1
139072	1710	receptors, leukocyte	[receptors, leukocytes]	0.0	2	1	1	1
139073	1710	clonal alpha g2s	[clonal alpha G2S]	0.0	3	1	1	1
139074	1710	analysis of the ICAM-1 promoter	[analysis of the ICAM-1 promoter]	0.0	5	1	1	1
139075	1710	sarco(endo)plasmic reticulum ca2+-atpase SERCA	[sarco(endo)plasmic reticulum Ca2+-ATPase SERCA]	0.0	4	1	1	1
139076	1710	activator of the terminal repeat	[activator of the terminal repeat]	0.0	5	1	1	1
139077	1710	association with different disorder	[association with different disorders]	0.0	4	1	1	1
139078	1710	e1a cell	[E1A cells]	0.0	2	1	1	1
139079	1710	actively seek support	[actively seeking support]	0.0	3	1	1	1
139080	1710	factor eklf activity by interaction	[factor EKLF activity by interaction]	0.0	5	1	1	1
139081	1710	large amount e1b	[large amounts E1B]	0.0	3	1	1	1
139082	1710	delta-globin-encoding gene hbd	[delta-globin-encoding gene HBD]	0.0	3	1	1	1
139083	1710	colitis (56.1	[colitis (56.1]	0.0	2	1	1	1
139084	1710	substantially great number	[substantially greater number]	0.0	3	1	1	1
139085	1710	type ii diabete in period	[type II diabetes in period]	0.0	5	1	1	1
139086	1710	intracellular generation of oxygen species	[intracellular generation of oxygen species]	0.0	5	1	1	1
139087	1710	increase of total ca2+	[increase of total Ca2+]	0.0	4	1	1	1
139088	1710	pou-specific homeodomain pouhd	[POU-specific homeodomain POUHD]	0.0	3	1	1	1
139089	1710	Study over the past year	[Studies over the past years]	0.0	5	1	1	1
139090	1710	activation of ap-1 transcription	[activation of AP-1 transcription]	0.0	4	1	1	1
139091	1710	other oxygen species	[other oxygen species]	0.0	3	1	1	1
139092	1710	disappointing result of trial	[disappointing results of trials]	0.0	4	1	1	1
139093	1710	use immunofluorescence method	[using immunofluorescence method]	0.0	3	1	1	1
139094	1710	IL-5 a growth factor	[IL-5 a growth factor]	0.0	4	1	1	1
139095	1710	[125i]-labeled aldosterone derivative	[[125I]-labeled aldosterone derivative]	0.0	3	1	1	1
139096	1710	hl-60 subline	[HL-60 sublines]	0.0	2	1	1	1
139097	1710	seven receptor	[seven receptor]	0.0	2	1	1	1
139098	1710	two dna-binding complex include Stat1 alpha	[two DNA-binding complexes including Stat1 alpha]	0.0	6	1	1	1
139099	1710	activator of many promoter	[activator of many promoters]	0.0	4	1	1	1
139100	1710	Ets family member Elf-1	[Ets family member Elf-1]	0.0	4	1	1	1
139101	1710	unit-erythroid cell	[unit-erythroid cells]	0.0	2	1	1	1
139102	1710	DQ2 homo hetero zygous bulcl	[DQ2 homo hetero zygous B-LCLs]	0.0	5	1	1	1
139103	1710	use the protein truncation test	[using the protein truncation test]	0.0	5	2	2	1
139104	1710	basis of a multiple lymphokine deficiency	[basis of a multiple lymphokine deficiency]	0.0	6	1	1	1
139105	1710	factor with sequence specificity	[factor with sequence specificity]	0.0	4	1	1	1
139106	1710	formulation of methylprednisolone MPL	[formulation of methylprednisolone MPL]	0.0	4	1	1	1
139107	1710	role in rhythm	[role in rhythms]	0.0	3	1	1	1
139108	1710	modulate calcium in muscle cell	[modulating calcium in muscle cells]	0.0	5	1	1	1
139109	1710	additional factor for activity	[additional factors for activity]	0.0	4	1	1	1
139110	1710	molecular nuclear protein	[molecular nuclear proteins]	0.0	3	1	1	1
139111	1710	access Epstein-Barr virus -specific t-cell memory	[Accessing Epstein-Barr virus -specific T-cell memory]	0.0	6	1	1	1
139112	1710	exon 10 sequence	[exon 10 sequence]	0.0	3	1	1	1
139113	1710	pml expression by interferon IFNs	[PML expression by interferons IFNs]	0.0	5	1	1	1
139114	1710	(38.9 +/-	[(38.9 +/-]	0.0	2	1	1	1
139115	1710	cell-free hGR	[cell-free hGR]	0.0	2	1	1	1
139116	1710	/NF-kappa	[/NF-kappa]	0.0	1	1	1	1
139117	1710	CD3 T cell activation	[CD3 T cell activation]	0.0	4	1	1	1
139118	1710	change in the dna-binding domain	[change in the DNA-binding domain]	0.0	5	1	1	1
139119	1710	drive proliferation	[driving proliferation]	0.0	2	1	1	1
139120	1710	receptor of interleukin-2	[receptors of interleukin-2]	0.0	3	1	1	1
139121	1710	less than 0.13 ng angiotensin i/l	[less than 0.13 ng angiotensin I/L]	0.0	6	1	1	1
139122	1710	sp1/ap-2 site	[Sp1/AP-2 site]	0.0	2	1	1	1
139123	1710	distinguished: biochemical sign of primary hypothyroidism	[distinguished: biochemical signs of primary hypothyroidism]	0.0	6	1	1	1
139124	1710	treatment of rest T cell	[Treatment of resting T cells]	0.0	5	1	1	1
139125	1710	virus enhancer activity	[virus enhancer activity]	0.0	3	1	1	1
139126	1710	adult cell factor	[adult cells factor]	0.0	3	1	1	1
139127	1710	apolar substitution 11 alpha-methyl, alpha-fluoromethyl	[apolar substitutions 11 alpha-methyl, alpha-fluoromethyl]	0.0	5	1	1	1
139128	1710	entry of the virus	[entry of the virus]	0.0	4	1	1	1
139129	1710	healthy woman first, second	[healthy women first, second]	0.0	4	1	1	1
139130	1710	sodium phenylacetate treatment	[sodium phenylacetate treatment]	0.0	3	1	1	1
139131	1710	activity of NRE gamma	[activity of NRE gamma]	0.0	4	1	1	1
139132	1710	fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	5	1	1	1
139133	1710	low relative binding affinity RBA	[low relative binding affinities RBA]	0.0	5	1	1	1
139134	1710	activator of T lymphocyte	[activator of T lymphocytes]	0.0	4	1	1	1
139135	1710	inducer of monocyte differentiation	[inducers of monocyte differentiation]	0.0	4	1	1	1
139136	1710	major regulator	[major regulator]	0.0	2	3	3	1
139137	1710	human cell response to infection	[Human cell responses to infection]	0.0	5	1	1	1
139138	1710	cd4+cd45r0+cd45ra-cd29highcd11a+	[CD4+CD45R0+CD45RA-CD29highCD11a+]	0.0	1	1	1	1
139139	1710	cytoplasmic signal step	[cytoplasmic signaling steps]	0.0	3	1	1	1
139140	1710	fat/lean	[fat/lean]	0.0	1	1	1	1
139141	1710	dose-dependent inhibition of cell proliferation	[dose-dependent inhibition of cell proliferation]	0.0	5	1	1	1
139142	1710	requirement in normal development	[requirement in normal development]	0.0	4	1	1	1
139143	1710	production of important mediator	[production of important mediators]	0.0	4	1	1	1
139144	1710	tax protein in 19d	[Tax protein in 19D]	0.0	4	1	1	1
139145	1710	aqueous phenol extraction	[aqueous phenol extraction]	0.0	3	1	1	1
139146	1710	kappa dna-binding activity	[kappa DNA-binding activity]	0.0	3	1	1	1
139147	1710	thp-1 monocytoid cell	[THP-1 monocytoid cells]	0.0	3	1	1	1
139148	1710	development of cell macrophage	[development of cells macrophages]	0.0	4	1	1	1
139149	1710	create a novel, proline carboxy terminus	[creating a novel, proline carboxy terminus]	0.0	6	1	1	1
139150	1710	expression of ciita rdna	[expression of CIITA cDNAs]	0.0	4	1	1	1
139151	1710	transcription of small rna gene	[transcription of small RNA genes]	0.0	5	1	1	1
139152	1710	general transcriptional activator RelA	[general transcriptional activators RelA]	0.0	4	1	1	1
139153	1710	role element-binding protein	[Role element-binding protein]	0.0	3	1	1	1
139154	1710	DHEA effect	[DHEA effects]	0.0	2	1	1	1
139155	1710	concentration of Ca2+ ca2+	[concentration of Ca2+ Ca2+]	0.0	4	1	1	1
139156	1710	class major histocompatibility gene DPA	[class major histocompatibility gene DPA]	0.0	5	1	1	1
139157	1710	immunoglobulin mu gene intronic enhancer	[immunoglobulin mu gene intronic enhancer]	0.0	5	1	1	1
139158	1710	4% cells;	[4% cells;]	0.0	2	1	1	1
139159	1710	two major glial cell	[two major glial cells]	0.0	4	1	1	1
139160	1710	level of two protein	[levels of two proteins]	0.0	4	1	1	1
139161	1710	many more change in the form	[many more changes in the form]	0.0	6	1	1	1
139162	1710	survival rate of tal-1 animal	[survival rate of tal-1 animals]	0.0	5	1	1	1
139163	1710	cell line with high metastatic potential	[cell lines with high metastatic potential]	0.0	6	1	1	1
139164	1710	form 3	[Form 3]	0.0	2	2	2	1
139165	1710	adhesion in vein cell HUVECs	[adhesion in vein cells HUVECs]	0.0	5	1	1	1
139166	1710	normal profile	[normal profile]	0.0	2	1	1	1
139167	1710	jcam1 cell	[JCaM1 cells]	0.0	2	1	1	1
139168	1710	glucocorticoid receptor/ characteristic	[glucocorticoid receptor/s characteristics]	0.0	3	1	1	1
139169	1710	697 pmol/L (p than 0.025).	[697 pmol/L (P than 0.025).]	0.0	5	1	1	1
139170	1710	act as response element	[acting as response elements]	0.0	4	1	1	1
139171	1710	absence of Spi-B	[absence of Spi-B]	0.0	3	1	1	1
139172	1710	transform protein from the pathogenic retrovirus	[transforming protein from the pathogenic retrovirus]	0.0	6	1	1	1
139173	1710	exposure of human cell	[exposure of human cells]	0.0	4	1	1	1
139174	1710	bms2.4	[BMS2.4]	0.0	1	1	1	1
139175	1710	viral episome	[viral episome]	0.0	2	1	1	1
139176	1710	replication in monocyte by 1,25-dihydroxycholecalciferol	[replication in monocytes by 1,25-dihydroxycholecalciferol]	0.0	5	1	1	1
139177	1710	analogue of the NF-AT-binding site	[analogue of the NF-AT-binding site]	0.0	5	1	1	1
139178	1710	androgen receptor assay humara	[androgen receptor assay HUMARA]	0.0	4	1	1	1
139179	1710	10(-7) m,	[10(-7) M,]	0.0	2	1	1	1
139180	1710	determination of dissociation constant	[determination of dissociation constants]	0.0	4	1	1	1
139181	1710	transient pseudohypoaldosteronism with transient reduction	[Transient pseudohypoaldosteronism with transient reduction]	0.0	5	1	1	1
139182	1710	two biological model	[two biological models]	0.0	3	1	1	1
139183	1710	EBNA-2 fusion protein	[EBNA-2 fusion protein]	0.0	3	1	1	1
139184	1710	NF-kappaB translocation of virus production	[NF-kappaB translocation of virus production]	0.0	5	1	1	1
139185	1710	membrane related responses.	[membrane related responses.]	0.0	3	1	1	1
139186	1710	transcription of the hiv-1 terminal repeat	[transcription of the HIV-1 terminal repeat]	0.0	6	1	1	1
139187	1710	element in the mrna	[element in the mRNA]	0.0	4	1	1	1
139188	1710	non-erythroid gene	[non-erythroid genes]	0.0	2	1	1	1
139189	1710	activate the ebv genome	[activating the EBV genome]	0.0	4	1	1	1
139190	1710	lead pb	[lead Pb]	0.0	2	1	1	1
139191	1710	catalyze the exchange of peptide clip	[catalyzing the exchange of peptides CLIP]	0.0	6	1	1	1
139192	1710	suggest a role negatively regulate e2f	[suggesting a role negatively regulating E2F]	0.0	6	1	1	1
139193	1710	expression of ets member	[expression of Ets members]	0.0	4	1	1	1
139194	1710	trend towards a down-regulation	[trend towards a down-regulation]	0.0	4	1	1	1
139195	1710	concentration of other antioxidant --including acid	[concentrations of other antioxidants --including acid]	0.0	6	1	1	1
139196	1710	octamer binding protein	[octamer binding proteins]	0.0	3	1	1	1
139197	1710	wilfordii	[wilfordii]	0.0	1	1	1	1
139198	1710	weight gain 2126 (pre)	[weight gain 2126 (pre)]	0.0	4	1	1	1
139199	1710	encode granule protein ecp	[encoding granule proteins ECP]	0.0	4	1	1	1
139200	1710	monocyte adhesion tnf-alpha endothelial cell	[monocyte adhesion TNF-alpha endothelial cells]	0.0	5	1	1	1
139201	1710	range nm.	[ranging nM.]	0.0	2	1	1	1
139202	1710	human breast cancer cell	[human breast cancer cell]	0.0	4	1	1	1
139203	1710	necessity of chemotherapy	[necessity of chemotherapy]	0.0	3	1	1	1
139204	1710	blood of pregnant woman	[blood of pregnant women]	0.0	4	1	1	1
139205	1710	histocompatibility complex immune deficiency	[histocompatibility complex immune deficiency]	0.0	4	1	1	1
139206	1710	evidence for a possible mechanism	[evidence for a possible mechanism]	0.0	5	1	1	1
139207	1710	factor-kappa b activity a preliminary report.	[factor-kappa B activity a preliminary report.]	0.0	6	1	1	1
139208	1710	E1A gene product	[E1A gene products]	0.0	3	2	2	1
139209	1710	kappa b fibroblast	[kappa B fibroblasts]	0.0	3	1	1	1
139210	1710	novel, occur sequence variant	[novel, occurring sequence variants]	0.0	4	1	1	1
139211	1710	Oct-2a effector region	[Oct-2a effector regions]	0.0	3	1	1	1
139212	1710	maintenance of persistence	[maintenance of persistence]	0.0	3	1	1	1
139213	1710	subunit of NF-kappaB	[subunits of NF-kappaB]	0.0	3	1	1	1
139214	1710	lead to the secretion	[leading to the secretion]	0.0	4	1	1	1
139215	1710	separate function	[separate functions]	0.0	2	1	1	1
139216	1710	promoter repeat	[promoter repeat]	0.0	2	1	1	1
139217	1710	maximum binding capacity mbc	[maximum binding capacity MBC]	0.0	4	1	1	1
139218	1710	class cell line	[class cell lines]	0.0	3	1	1	1
139219	1710	thrombin generation by apoptotic vsmc	[thrombin generation by apoptotic VSMCs]	0.0	5	1	1	1
139220	1710	NF-kappa b il-6 expression	[NF-kappa B IL-6 expression]	0.0	4	1	1	1
139221	1710	drug cyclosporin a CsA	[drug cyclosporin A CsA]	0.0	4	1	1	1
139222	1710	additional enhancement	[additional enhancement]	0.0	2	1	1	1
139223	1710	interaction with sequence-specific transcription factor	[interactions with sequence-specific transcription factors]	0.0	5	1	1	1
139224	1710	il-5 -produce	[IL-5 -producing]	0.0	2	1	1	1
139225	1710	related family	[related family]	0.0	2	1	1	1
139226	1710	12 woman of childbearing age.	[12 women of childbearing age.]	0.0	5	1	1	1
139227	1710	il-4 mrna	[IL-4 mRNA]	0.0	2	1	1	1
139228	1710	cell type as a complex	[cell types as an complex]	0.0	5	1	1	1
139229	1710	conferr the responsiveness	[conferring the responsiveness]	0.0	3	1	1	1
139230	1710	control of several gene	[control of several genes]	0.0	4	1	1	1
139231	1710	promoter for several t-cell-restricted marker	[promoters for several T-cell-restricted markers]	0.0	5	1	1	1
139232	1710	use blotting	[Using blotting]	0.0	2	1	1	1
139233	1710	lysopc content	[lysoPC content]	0.0	2	1	1	1
139234	1710	enhanced, h of cd19 cross-linking	[enhanced, h of CD19 cross-linking]	0.0	5	1	1	1
139235	1710	cd45 ptpase	[CD45 PTPase]	0.0	2	1	1	1
139236	1710	33 nucleotide change	[33 nucleotide changes]	0.0	3	1	1	1
139237	1710	set at stage	[sets at stages]	0.0	3	1	1	1
139238	1710	lymphocyte of male sibling	[lymphocytes of male siblings]	0.0	4	1	1	1
139239	1710	area include Sp1	[areas including Sp1]	0.0	3	1	1	1
139240	1710	receptor number in the monocyte	[receptor numbers in the monocytes]	0.0	5	1	1	1
139241	1710	tsc2 gene	[TSC2 gene]	0.0	2	4	4	1
139242	1710	binding two antibody specific	[binding two antibodies specific]	0.0	4	1	1	1
139243	1710	control mechanism in response to signal	[control mechanisms in response to signals]	0.0	6	1	1	1
139244	1710	factor act predominantly on megakaryocytopoiesis	[factor acting predominantly on megakaryocytopoiesis]	0.0	5	1	1	1
139245	1710	endogenous ig chain enhancer	[endogenous Ig chain enhancer]	0.0	4	3	3	1
139246	1710	h in medium	[h in medium]	0.0	3	1	1	1
139247	1710	combination of anti CD2	[combination of anti CD2]	0.0	4	1	1	1
139248	1710	transcript for osteoprotegerin ligand	[Transcripts for osteoprotegerin ligand]	0.0	4	1	1	1
139249	1710	pre-existing, component	[pre-existing, component]	0.0	2	1	1	1
139250	1710	thymic T lymphocyte	[thymic T lymphocytes]	0.0	3	1	1	1
139251	1710	low range [1-3	[lower range [1-3]	0.0	3	1	1	1
139252	1710	genetic marker apl	[genetic markers APLs]	0.0	3	1	1	1
139253	1710	analogous phosphorylation	[analogous phosphorylation]	0.0	2	1	1	1
139254	1710	LT promoter CAT construct	[LT promoter CAT construct]	0.0	4	1	1	1
139255	1710	50% reduction	[50% reduction]	0.0	2	1	1	1
139256	1710	activity of p70(s6k)	[activity of p70(s6k)]	0.0	3	1	1	1
139257	1710	three adhesion protein	[three adhesion proteins]	0.0	3	1	1	1
139258	1710	core Sp1 consensus	[core Sp1 consensus]	0.0	3	1	1	1
139259	1710	receive therapy for disease	[receiving therapy for diseases]	0.0	4	1	1	1
139260	1710	CD28 mab BW 828	[CD28 mAb BW 828]	0.0	4	1	1	1
139261	1710	however, inhibition	[however, inhibition]	0.0	2	2	2	1
139262	1710	b cell ag receptor	[B cell Ag receptor]	0.0	4	1	1	1
139263	1710	programming	[programming]	0.0	1	2	2	1
139264	1710	9-mer peptide	[9-mer peptides]	0.0	2	1	1	1
139265	1710	aml1 /eto transcript	[AML1 /ETO transcripts]	0.0	3	3	3	1
139266	1710	human IL-4 gene of kilobasis	[human IL-4 gene of kilobases]	0.0	5	1	1	1
139267	1710	tnf-alpha in pma-differentiated u937 cell	[TNF-alpha in PMA-differentiated U937 cells]	0.0	5	1	1	1
139268	1710	expression a marker for cell	[expression a marker for cells]	0.0	5	1	1	1
139269	1710	histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	5	1	1	1
139270	1710	level 1 mrna level	[levels 1 mRNA levels]	0.0	4	1	1	1
139271	1710	T lymphocyte present in the spleen	[T lymphocytes present in the spleen]	0.0	6	1	1	1
139272	1710	dna-binding activity in human t-cell	[DNA-binding activity in human T-cells]	0.0	5	1	1	1
139273	1710	glucose transport	[glucose transport]	0.0	2	1	1	1
139274	1710	interleukin-1 production	[interleukin-1 production]	0.0	2	1	1	1
139275	1710	epsilon transcript,	[epsilon transcript,]	0.0	2	1	1	1
139276	1710	primary translocation	[primary translocation]	0.0	2	1	1	1
139277	1710	stimulation, two new kappa complex	[stimulation, two new kappa complexes]	0.0	5	1	1	1
139278	1710	three main pathway	[three main pathways]	0.0	3	1	1	1
139279	1710	consequent modulation	[consequent modulation]	0.0	2	1	1	1
139280	1710	tricyclic antidepressant	[tricyclic antidepressants]	0.0	2	1	1	1
139281	1710	buthionine sulfoximine bso	[buthionine sulfoximine BSO]	0.0	3	1	1	1
139282	1710	indicator of ca2+ load in platelet	[indicators of Ca2+ load in platelets]	0.0	6	1	1	1
139283	1710	Ca(2+)- pathway	[Ca(2+)- pathways]	0.0	2	1	1	1
139284	1710	aspect of the genetic program	[aspects of the genetic program]	0.0	5	1	1	1
139285	1710	polypeptide product of c-jun	[polypeptide product of c-jun]	0.0	4	1	1	1
139286	1710	distinct phase	[distinct phases]	0.0	2	1	1	1
139287	1710	specific increase in phosphotyrosine labeling	[specific increases in phosphotyrosine labeling]	0.0	5	1	1	1
139288	1710	family with atrophy	[families with atrophy]	0.0	3	1	1	1
139289	1710	90.8 dpm mg-1	[90.8 dpm mg-1]	0.0	3	1	1	1
139290	1710	action human leukemia cell	[action human leukemia cells]	0.0	4	1	1	1
139291	1710	clue for genetic predisposition	[clue for genetic predisposition]	0.0	4	1	1	1
139292	1710	gad-creb fusion protein	[GAD-CREB fusion protein]	0.0	3	1	1	1
139293	1710	-150 ap-1 site	[-150 AP-1 site]	0.0	3	1	1	1
139294	1710	strong decrease	[strong decrease]	0.0	2	1	1	1
139295	1710	rationale for in vivo testing	[rationale for in vivo testing]	0.0	5	1	1	1
139296	1710	interleukin-2 (il-2)	[interleukin-2 (IL-2)]	0.0	2	1	1	1
139297	1710	individual mutation ap3-l site	[Individual mutation AP3-L site]	0.0	4	1	1	1
139298	1710	respectively) increase in the percentage	[respectively) increase in the percentage]	0.0	5	1	1	1
139299	1710	three subtype of retinoic acid receptor	[Three subtypes of retinoic acid receptors]	0.0	6	1	1	1
139300	1710	functional activation by 4 beta-phorbol	[functional activation by 4 beta-phorbol]	0.0	5	1	1	1
139301	1710	minus U937 clone	[minus U937 clones]	0.0	3	1	1	1
139302	1710	U-937 cell line	[U-937 cell line]	0.0	3	1	1	1
139303	1710	bha treatment	[BHA treatment]	0.0	2	1	1	1
139304	1710	glucocorticoid receptor (gr) expression	[glucocorticoid receptor (GR) expression]	0.0	4	1	1	1
139305	1710	clear evidence	[clear evidence]	0.0	2	1	1	1
139306	1710	crude estimate	[crude estimate]	0.0	2	1	1	1
139307	1710	weak interaction	[weak interaction]	0.0	2	1	1	1
139308	1710	alveolar macrophage AMs	[alveolar macrophages AMs]	0.0	3	1	1	1
139309	1710	DNA protein complex formation	[DNA protein complex formation]	0.0	4	1	1	1
139310	1710	tumor in Group A	[tumors in Group A]	0.0	4	1	1	1
139311	1710	human primary b-cell	[human primary B-cells]	0.0	3	1	1	1
139312	1710	GATA-1(d) motif	[GATA-1(d) motif]	0.0	2	1	1	1
139313	1710	tumor in Group C	[tumors in Group C]	0.0	4	1	1	1
139314	1710	effusion lymphoma cell line	[effusion lymphoma cell lines]	0.0	4	1	1	1
139315	1710	colony-stimumulatelany-stg factor promoter	[colony-stimulating factor promoters]	0.0	3	1	1	1
139316	1710	isoleucine lmp1	[isoleucine LMP1]	0.0	2	1	1	1
139317	1710	functional 135-(oh)2d3 receptors;	[functional 1,25-(OH)2D3 receptors;]	0.0	3	1	1	1
139318	1710	Kmone value	[Km value]	0.0	2	1	1	1
139319	1710	early event in the process	[early event in the process]	0.0	5	1	1	1
139320	1710	change in redox	[changes in redox]	0.0	3	1	1	1
139321	1710	ebna2 gene	[EBNA2 gene]	0.0	2	1	1	1
139322	1710	only a dna-binding domain	[only a DNA-binding domain]	0.0	4	1	1	1
139323	1710	closely related lineage	[closely related lineages]	0.0	3	1	1	1
139324	1710	disruption of motifs:	[disruptions of motifs:]	0.0	3	1	1	1
139325	1710	active form of ras	[active form of Ras]	0.0	4	1	1	1
139326	1710	event in signalling	[event in signalling]	0.0	3	1	1	1
139327	1710	expression of the lipocalin ngal	[expression of the lipocalin NGAL]	0.0	5	1	1	1
139328	1710	activity with a apparent kd	[activity with an apparent Kd]	0.0	5	1	1	1
139329	1710	patient with syndrome in stage	[patients with syndromes in stage]	0.0	5	1	1	1
139330	1710	proliferative response of T cell	[proliferative response of T cells]	0.0	5	1	1	1
139331	1710	involve activation of form 90-kda stat3alpha	[involving activation of forms 90-kDa STAT3alpha]	0.0	6	1	1	1
139332	1710	cut edge: expression	[Cutting edge: expression]	0.0	3	1	1	1
139333	1710	clinical investigation	[clinical investigation]	0.0	2	1	1	1
139334	1710	T cell (nfat) complex	[T cells (NFAT) complex]	0.0	4	1	1	1
139335	1710	differentiation antigen MNDA	[differentiation antigen MNDA]	0.0	3	1	1	1
139336	1710	peptide match	[peptide matches]	0.0	2	1	1	1
139337	1710	C-terminal peptide	[C-terminal peptide]	0.0	2	1	1	1
139338	1710	use peptide in subunit vaccine	[using peptides in subunit vaccines]	0.0	5	1	1	1
139339	1710	ikappab -epsilon	[IkappaB -epsilon]	0.0	2	1	1	1
139340	1710	quantitative difference	[quantitative differences]	0.0	2	1	1	1
139341	1710	limits.	[limits.]	0.0	1	2	2	1
139342	1710	sequence in T cell	[sequence in T cells]	0.0	4	1	1	1
139343	1710	NF-kB in thymocyte	[NF-kB in thymocytes]	0.0	3	1	1	1
139344	1710	differential RNA display DD	[differential RNA display DD]	0.0	4	1	1	1
139345	1710	core of HS-40	[core of HS-40]	0.0	3	1	1	1
139346	1710	replacement suggest a structural role	[Replacement suggesting an structural role]	0.0	5	1	1	1
139347	1710	(b) factor	[(b) factors]	0.0	2	1	1	1
139348	1710	colony-forming cell hppecfcs	[colony-forming cells HPP-CFCs]	0.0	3	1	1	1
139349	1710	glucocorticoid receptor concentration before therapy	[glucocorticoid receptor concentrations before therapy]	0.0	5	1	1	1
139350	1710	dominant allele of c-Raf-1 Raf	[dominant allele of c-Raf-1 Raf]	0.0	5	1	1	1
139351	1710	promyelocyte-late lambda gt11 library	[promyelocyte-late lambda gt11 library]	0.0	4	1	1	1
139352	1710	anti-inflammatory agent on cell activation	[anti-inflammatory agents on cell activation]	0.0	5	1	1	1
139353	1710	woman with pregnancy	[women with pregnancy]	0.0	3	1	1	1
139354	1710	oriP the origin for maintenance	[oriP the origin for maintenance]	0.0	5	1	1	1
139355	1710	ISG15 LTR	[ISG15 LTR]	0.0	2	1	1	1
139356	1710	aspect of the process.	[aspects of the process.]	0.0	4	1	1	1
139357	1710	8, histiocytoma 6, rhabdomyosarcoma	[8, histiocytoma 6, rhabdomyosarcoma]	0.0	4	1	1	1
139358	1710	Differential regulation during human cell differentiation	[Differential regulation during human cell differentiation]	0.0	6	1	1	1
139359	1710	predominantly in form	[predominantly in Form]	0.0	3	1	1	1
139360	1710	recently, human leukocyte	[recently, human leukocytes]	0.0	3	1	1	1
139361	1710	cell pivotal	[cells pivotal]	0.0	2	1	1	1
139362	1710	effect on the development, maturation,	[effects on the development, maturation,]	0.0	5	1	1	1
139363	1710	activation of distinct transcription factor	[Activation of distinct transcription factors]	0.0	5	1	1	1
139364	1710	effect of pokeweed mitogen	[effects of pokeweed mitogen]	0.0	4	1	1	1
139365	1710	Tax1 a potent activator htlv-1 transcription	[Tax1 a potent activator HTLV-1 transcription]	0.0	6	1	1	1
139366	1710	various neoplastic disorder	[various neoplastic disorders]	0.0	3	1	1	1
139367	1710	significant protection	[significant protection]	0.0	2	1	1	1
139368	1710	affinity of sr-bp 50-fold	[affinity of SR-BP 50-fold]	0.0	4	1	1	1
139369	1710	cell wall derivative	[cell wall derivatives]	0.0	3	1	1	1
139370	1710	diffusible activity	[diffusible activity]	0.0	2	1	1	1
139371	1710	stem cell factor-dependent progenitor	[stem cell factor-dependent progenitors]	0.0	4	1	1	1
139372	1710	bryostatin 1 nm),	[bryostatin 1 nM),]	0.0	3	1	1	1
139373	1710	part of the gene	[part of the genes]	0.0	4	1	1	1
139374	1710	transcription of the csf-1 receptor	[transcription of the CSF-1 receptor]	0.0	5	1	1	1
139375	1710	free thiol	[free thiols]	0.0	2	1	1	1
139376	1710	use synthetic ligand	[Using synthetic ligands]	0.0	3	1	1	1
139377	1710	murine macrophage inflammatory protein	[Murine macrophage inflammatory protein]	0.0	4	1	1	1
139378	1710	granulocyte-colony factor treatment	[granulocyte-colony factor treatment]	0.0	3	1	1	1
139379	1710	deletion basis from translation start site	[deletion bases from translation start site]	0.0	6	1	1	1
139380	1710	base pair of 5'-flanking DNA	[base pairs of 5'-flanking DNA]	0.0	5	1	1	1
139381	1710	test the effect	[testing the effects]	0.0	3	1	1	1
139382	1710	12-o-tetradecanoylphorbol induction	[12-O-tetradecanoylphorbol induction]	0.0	2	1	1	1
139383	1710	depression I receptor 267	[depression I receptors 267]	0.0	4	1	1	1
139384	1710	gm-kappa	[GM-kappa]	0.0	1	1	1	1
139385	1710	only certain individual of (mhc) haplotype	[only certain individuals of (MHC) haplotypes]	0.0	6	1	1	1
139386	1710	unresponsiveness to gamma interferon for activation	[Unresponsiveness to gamma interferon for activation]	0.0	6	1	1	1
139387	1710	initiative	[initiative]	0.0	1	1	1	1
139388	1710	type of human neoplasm	[types of human neoplasms]	0.0	4	1	1	1
139389	1710	strong induction	[strong induction]	0.0	2	3	3	1
139390	1710	different requirement	[different requirements]	0.0	2	1	1	1
139391	1710	resemble a basic dbd	[resembling a basic DBD]	0.0	4	1	1	1
139392	1710	monolayer of human vein cell	[monolayers of human vein cells]	0.0	5	1	1	1
139393	1710	Effect of il-10 on transcription factor	[Effects of IL-10 on transcription factors]	0.0	6	1	1	1
139394	1710	effect on c-jun transcription	[effect on c-jun transcription]	0.0	4	1	1	1
139395	1710	lymphoma with a large-cell component	[lymphomas with a large-cell component]	0.0	5	1	1	1
139396	1710	genesis of leukemia	[genesis of leukemia]	0.0	3	1	1	1
139397	1710	interleukin-1 stimulation	[interleukin-1 stimulation]	0.0	2	1	1	1
139398	1710	receptor per cell ro	[receptors per cell Ro]	0.0	4	1	1	1
139399	1710	IkappaBalpha gene	[IkappaBalpha gene]	0.0	2	2	2	1
139400	1710	escape of cytomegalovirus	[Escape of cytomegalovirus]	0.0	3	1	1	1
139401	1710	(threshold	[(threshold]	0.0	1	1	1	1
139402	1710	bare promoter	[bare promoter]	0.0	2	1	1	1
139403	1710	latent precursor	[latent precursors]	0.0	2	1	1	1
139404	1710	exposure to CD40L with il-4	[exposure to CD40L with IL-4]	0.0	5	1	1	1
139405	1710	activity on human T cell	[activities on human T cells]	0.0	5	1	1	1
139406	1710	important determinant of gene expression	[important determinants of gene expression]	0.0	5	1	1	1
139407	1710	differentiation-dependent transcription	[differentiation-dependent transcription]	0.0	2	1	1	1
139408	1710	early, stage	[early, stages]	0.0	2	1	1	1
139409	1710	epsilon-globin-encoding gene [Cao	[epsilon-globin-encoding gene [Cao]	0.0	3	1	1	1
139410	1710	isolate AL1	[isolate AL1]	0.0	2	1	1	1
139411	1710	large colony (>1 mm)	[large colonies (>1 mm)]	0.0	4	1	1	1
139412	1710	function in the tuning	[function in the tuning]	0.0	4	1	1	1
139413	1710	cytomegalovirus binding to human monocyte	[cytomegalovirus binding to human monocytes]	0.0	5	1	1	1
139414	1710	cytoplasmic complex in cell	[cytoplasmic complex in cells]	0.0	4	1	1	1
139415	1710	i.e. neutrophilic granulocyte	[i.e. neutrophilic granulocytes]	0.0	3	1	1	1
139416	1710	quantification of specific mrna	[quantification of specific mRNA]	0.0	4	1	1	1
139417	1710	adrenal axis	[adrenal axis]	0.0	2	1	1	1
139418	1710	high value in untreated patient	[higher values in untreated patients]	0.0	5	1	1	1
139419	1710	monocytic cell adhesion to endothelial cell	[monocytic cell adhesion to endothelial cells]	0.0	6	1	1	1
139420	1710	cDNA encode	[cDNA encoding]	0.0	2	1	1	1
139421	1710	MHC class gene transcription one	[MHC class gene transcription one]	0.0	5	1	1	1
139422	1710	gamma/delta tcr+ pregnancy lymphocyte	[gamma/delta TCR+ pregnancy lymphocytes]	0.0	4	1	1	1
139423	1710	mrna expression of acid-binding protein	[mRNA expression of acid-binding protein]	0.0	5	1	1	1
139424	1710	erythropoietin epo factor	[Erythropoietin Epo factor]	0.0	3	1	1	1
139425	1710	Ca2+ signal-dependent element	[Ca2+ signal-dependent element]	0.0	3	1	1	1
139426	1710	number of hybrid	[number of hybrids]	0.0	3	1	1	1
139427	1710	emergence to combination of drug	[emergence to combinations of drugs]	0.0	5	1	1	1
139428	1710	loss of the activity.	[loss of the activity.]	0.0	4	1	1	1
139429	1710	increase time of monocyte	[increasing time of monocytes]	0.0	4	1	1	1
139430	1710	none of the three enhancer-binding protein	[none of the three enhancer-binding proteins]	0.0	6	1	1	1
139431	1710	dexamethasone binding to receptor	[dexamethasone binding to receptor]	0.0	4	1	1	1
139432	1710	cellular signal pathway result	[cellular signaling pathways resulting]	0.0	4	1	1	1
139433	1710	mnda positive cell	[MNDA positive cells]	0.0	3	1	1	1
139434	1710	leukemia cell line grow in vitro	[leukemia cell lines growing in vitro]	0.0	6	1	1	1
139435	1710	gene cluster	[gene cluster]	0.0	2	1	1	1
139436	1710	induction of early response gene	[Induction of early response genes]	0.0	5	1	1	1
139437	1710	incompetent human g-csfr mutant	[incompetent human G-CSFR mutant]	0.0	4	1	1	1
139438	1710	action on cytokine	[actions on cytokines]	0.0	3	1	1	1
139439	1710	CaMKIV/	[CaMKIV/]	0.0	1	1	1	1
139440	1710	implication of a mutation	[implications of a mutation]	0.0	4	1	1	1
139441	1710	phosphatidylinositol-3,4,5-trisphosphate concentration	[phosphatidylinositol-3,4,5-trisphosphate concentration]	0.0	2	1	1	1
139442	1710	electrolyte response to aldosterone	[electrolyte response to aldosterone]	0.0	4	1	1	1
139443	1710	type.	[type.]	0.0	1	1	1	1
139444	1710	igg (from	[IgG (from]	0.0	2	1	1	1
139445	1710	millileter per 48 hr.	[ml per 48 hr.]	0.0	4	1	1	1
139446	1710	CD4 tcr-induced il-2 production	[CD4 TCR-induced IL-2 production]	0.0	4	1	1	1
139447	1710	human NK cell membrane-bound lt signal	[Human NK cell membrane-bound LT signals]	0.0	6	1	1	1
139448	1710	respond to factor	[responding to factor]	0.0	3	1	1	1
139449	1710	acid-reactive substance	[acid-reactive substances]	0.0	2	1	1	1
139450	1710	treatment with ifn-alpha	[Treatment with IFN-alpha]	0.0	3	1	1	1
139451	1710	treatment for weeks.	[treatment for weeks.]	0.0	3	1	1	1
139452	1710	very specific role	[very specific role]	0.0	3	1	1	1
139453	1710	day 14 of culture,	[day 14 of culture,]	0.0	4	1	1	1
139454	1710	treatment lymphocyte with ifn-alpha	[Treatment lymphocytes with IFN-alpha]	0.0	4	1	1	1
139455	1710	component within minute after activation	[component within min after activation]	0.0	5	1	1	1
139456	1710	c-fo and/or c-jun mrna	[c-fos and/or c-jun mRNA]	0.0	4	1	1	1
139457	1710	end target of fk506-sensitive pathway	[end targets of FK506-sensitive pathway]	0.0	5	1	1	1
139458	1710	induction of the transcription factor	[induction of the transcription factors]	0.0	5	1	1	1
139459	1710	kd of nm	[Kd of nM]	0.0	3	1	1	1
139460	1710	synergist hx630	[synergist HX630]	0.0	2	1	1	1
139461	1710	various line u937	[various lines U937]	0.0	3	1	1	1
139462	1710	major determinant for b activation	[major determinant for B activation]	0.0	5	1	1	1
139463	1710	activation by stimulus in neutrophils.	[Activation by stimuli in neutrophils.]	0.0	5	1	1	1
139464	1710	independent, b-cell line im-9	[independent, B-cell line IM-9]	0.0	4	1	1	1
139465	1710	PKC mechanism	[PKC mechanism]	0.0	2	1	1	1
139466	1710	IL-2 phosphorylation	[IL-2 phosphorylation]	0.0	2	1	1	1
139467	1710	lysis gene by the receptor	[lysis genes by the receptor]	0.0	5	1	1	1
139468	1710	substSpl234	[substSpl234]	0.0	1	1	1	1
139469	1710	CD28 cosignaling	[CD28 cosignaling]	0.0	2	1	1	1
139470	1710	docking site within cytokine receptor	[docking sites within cytokine receptors]	0.0	5	1	1	1
139471	1710	Yang deficient patient	[Yang deficient patients]	0.0	3	1	1	1
139472	1710	severe leukopenia	[severe leukopenia]	0.0	2	1	1	1
139473	1710	different subvolumes:	[different subvolumes:]	0.0	2	1	1	1
139474	1710	dysmenorrhoea	[dysmenorrhoea]	0.0	1	1	1	1
139475	1710	MHC class mrna	[MHC class mRNA]	0.0	3	1	1	1
139476	1710	four different NF-kappaB complex	[four different NF-kappaB complexes]	0.0	4	1	1	1
139477	1710	so-called AU-rich element	[so-called AU-rich elements]	0.0	3	1	1	1
139478	1710	contain titre antibody	[containing titre antibodies]	0.0	3	1	1	1
139479	1710	constitutive overexpression	[Constitutive overexpression]	0.0	2	1	1	1
139480	1710	inhibition in vitro.	[inhibition in vitro.]	0.0	3	1	1	1
139481	1710	necessity of monitoring	[necessity of monitoring]	0.0	3	1	1	1
139482	1710	protein kinase camp response element	[protein kinase cAMP response elements]	0.0	5	1	1	1
139483	1710	nf-kappab protein bind	[NF-kappaB proteins binding]	0.0	3	1	1	1
139484	1710	subclone cem-4r4	[subclones, CEM-4R4]	0.0	2	1	1	1
139485	1710	T helper 2	[T helper 2]	0.0	3	1	1	1
139486	1710	adult erythroid cell haec	[adult erythroid cell hAEC]	0.0	4	1	1	1
139487	1710	Peripheral lymphocyte from woman	[Peripheral lymphocytes from women]	0.0	4	1	1	1
139488	1710	portion of E2A	[portion of E2A]	0.0	3	1	1	1
139489	1710	tax -independent binding of factor	[Tax -independent binding of factors]	0.0	5	1	1	1
139490	1710	bcl-2 mutein	[bcl-2 muteins]	0.0	2	1	1	1
139491	1710	determine the outcome of exposure	[determining the outcome of exposure]	0.0	5	1	1	1
139492	1710	intestinal cell inflammatory response to infection	[intestinal cell inflammatory responses to infection]	0.0	6	1	1	1
139493	1710	candidate for this factor	[candidates for this factor]	0.0	4	1	1	1
139494	1710	importance consider study	[importance considering studies]	0.0	3	1	1	1
139495	1710	cytokine lps	[cytokines LPS]	0.0	2	1	1	1
139496	1710	worker [25-140 ppt tcdd	[workers [25-140 ppt TCDD]	0.0	4	1	1	1
139497	1710	chain-breaking antioxidant hydroxyanisole bha	[chain-breaking antioxidants hydroxyanisole BHA]	0.0	4	1	1	1
139498	1710	therapy in ulcerative colitis	[therapy in ulcerative colitis]	0.0	4	1	1	1
139499	1710	subunit of nf-kappab	[subunit of NF-kappaB]	0.0	3	1	1	1
139500	1710	antibody phosphatidylinositol 3-kinase	[antibody phosphatidylinositol 3-kinase]	0.0	3	1	1	1
139501	1710	distinct foci	[distinct foci]	0.0	2	1	1	1
139502	1710	suggest a role regulate e2f	[suggesting a role regulating E2F]	0.0	5	1	1	1
139503	1710	tfiid polypeptide	[TFIID polypeptide]	0.0	2	1	1	1
139504	1710	gold compound contain monovalent gold ion	[gold compounds containing monovalent gold ion]	0.0	6	1	1	1
139505	1710	overlapping activity	[overlapping activities]	0.0	2	1	1	1
139506	1710	related hematopoietic lineage	[related hematopoietic lineages]	0.0	3	1	1	1
139507	1710	various inhibitory protein	[various inhibitory proteins]	0.0	3	1	1	1
139508	1710	phorbol ester -inducible neutrophil	[phorbol ester -inducible neutrophil]	0.0	4	1	1	1
139509	1710	human fibroblastic human cell	[human fibroblastic human cells]	0.0	4	1	1	1
139510	1710	support specific DNA binding	[supporting specific DNA binding]	0.0	4	1	1	1
139511	1710	0.025, chi2 test),	[0.025, chi2 test),]	0.0	3	1	1	1
139512	1710	study in human	[studies in humans]	0.0	3	1	1	1
139513	1710	understand the role	[understanding the role]	0.0	3	1	1	1
139514	1710	NFAT -1 element	[NFAT -1 elements]	0.0	3	1	1	1
139515	1710	pleiotropic molecule	[pleiotropic molecule]	0.0	2	1	1	1
139516	1710	monocyte protein-1 monocyte colony-stimulating factor	[monocyte protein-1 monocyte colony-stimulating factor]	0.0	5	1	1	1
139517	1710	hiv-1 mrna level	[HIV-1 mRNA levels]	0.0	3	1	1	1
139518	1710	T cell site	[T cell sites]	0.0	3	1	1	1
139519	1710	regulatory region of the IL-1alpha promoter	[regulatory regions of the IL-1alpha promoter]	0.0	6	1	1	1
139520	1710	cellular defect	[cellular defect]	0.0	2	1	1	1
139521	1710	case-oriented evidence	[case-oriented evidence]	0.0	2	1	1	1
139522	1710	precise role signal	[precise roles signaling]	0.0	3	1	1	1
139523	1710	adhesion in vein endothelial cell	[adhesion in vein endothelial cells]	0.0	5	1	1	1
139524	1710	involve defective differentiation in male	[involving defective differentiation in males]	0.0	5	1	1	1
139525	1710	expansion suitable	[expansion suitable]	0.0	2	1	1	1
139526	1710	function such as downregulation	[functions such as downregulation]	0.0	4	1	1	1
139527	1710	C/EBP activator	[C/EBP activators]	0.0	2	1	1	1
139528	1710	camp -dependent regulation of proenkephalin	[cAMP -dependent regulation of proenkephalin]	0.0	5	1	1	1
139529	1710	hiv-1 T cell	[HIV-1 T cells]	0.0	3	1	1	1
139530	1710	generate level of lucigenin-enhanced cl	[generating levels of lucigenin-enhanced CL]	0.0	5	1	1	1
139531	1710	pattern of kappa activity	[pattern of kappa activity]	0.0	4	1	1	1
139532	1710	transduction of biochemical signal	[transduction of biochemical signals]	0.0	4	1	1	1
139533	1710	migrate b2 complex	[migrating B2 complex]	0.0	3	1	1	1
139534	1710	histone deacetylase catalytic subunit	[histone deacetylase catalytic subunit]	0.0	4	1	1	1
139535	1710	however, order potent	[however, orders potent]	0.0	3	1	1	1
139536	1710	further evidence for the suppression	[Further evidence for the suppression]	0.0	5	1	1	1
139537	1710	transfection overexpression of wild type	[transfection overexpression of wild type]	0.0	5	1	1	1
139538	1710	nef of lentiviruse	[Nef of lentiviruses]	0.0	3	1	1	1
139539	1710	activity in RAW 264.7 cell	[activity in RAW 264.7 cells]	0.0	5	1	1	1
139540	1710	underlie this effect	[underlying these effects]	0.0	3	1	1	1
139541	1710	human CD4 T lymphocyte	[human CD4 T lymphocytes]	0.0	4	1	1	1
139542	1710	use of peptide	[use of peptides]	0.0	3	1	1	1
139543	1710	globular, electron-dense structure morphologically distinct	[globular, electron-dense structures morphologically distinct]	0.0	5	1	1	1
139544	1710	HIV reporter	[HIV reporter]	0.0	2	1	1	1
139545	1710	presence of propranolol	[presence of propranolol]	0.0	3	1	1	1
139546	1710	t-cell region of the IL-3 promoter	[T-cell regions of the IL-3 promoter]	0.0	6	1	1	1
139547	1710	packaging of DNA into chromatin	[packaging of DNA into chromatin]	0.0	5	1	1	1
139548	1710	myc protein capable	[Myc protein capable]	0.0	3	1	1	1
139549	1710	element nre	[element NRE]	0.0	2	1	1	1
139550	1710	somatic mutation a encoding	[somatic mutations a encoding]	0.0	4	1	1	1
139551	1710	effect of MCM	[effects of MCM]	0.0	3	1	1	1
139552	1710	E3 enhancer motif	[E3 enhancer motif]	0.0	3	1	1	1
139553	1710	divide immature cell	[dividing immature cells]	0.0	3	1	1	1
139554	1710	(npc)	[(NPC)]	0.0	1	1	1	1
139555	1710	intergenic splicing	[intergenic splicing]	0.0	2	1	1	1
139556	1710	monocyte through complement receptor-1	[monocytes through complement receptor-1]	0.0	4	1	1	1
139557	1710	hiv-1 plasmid	[HIV-1 plasmids]	0.0	2	1	1	1
139558	1710	transcription of the proto-oncogent	[transcription of the proto-oncogenes]	0.0	4	1	1	1
139559	1710	T cell p55/p75 early	[T cells p55/p75 early]	0.0	4	1	1	1
139560	1710	(il-2r) receptor on the line	[(IL-2R) receptors on the line]	0.0	5	1	1	1
139561	1710	stat serine	[STAT serine]	0.0	2	1	1	1
139562	1710	blot analysis on multiple tissue	[blot analysis on multiple tissues]	0.0	5	1	1	1
139563	1710	infection interleukin-8	[infection interleukin-8]	0.0	2	1	1	1
139564	1710	cell population exhibit behavior	[cell population exhibiting behavior]	0.0	4	1	1	1
139565	1710	lipopolysaccharide lps enhancer element	[lipopolysaccharide LPS enhancer element]	0.0	4	1	1	1
139566	1710	globin gene kilobasis	[globin genes kilobases]	0.0	3	1	1	1
139567	1710	provide a firm structural basis	[providing a firm structural basis]	0.0	5	1	1	1
139568	1710	pregnancy by measurement	[pregnancies by measurement]	0.0	3	1	1	1
139569	1710	sertraline response in major disorder	[sertraline response in major disorder]	0.0	5	1	1	1
139570	1710	regulate transcription of collagenase-1 in cell	[regulating transcription of collagenase-1 in cells]	0.0	6	1	1	1
139571	1710	cryptic epitope	[cryptic epitopes]	0.0	2	1	1	1
139572	1710	binding of protein,	[binding of protein,]	0.0	3	1	1	1
139573	1710	mycoplasma material	[Mycoplasma material]	0.0	2	1	1	1
139574	1710	JAK3 -deficient immunodeficiency lymphocyte	[JAK3 -deficient immunodeficiency lymphocytes]	0.0	4	1	1	1
139575	1710	small rna	[small RNAs]	0.0	2	1	1	1
139576	1710	incubation of T cell with concentration	[incubation of T cells with concentrations]	0.0	6	1	1	1
139577	1710	type b	[type B]	0.0	2	1	1	1
139578	1710	lysosomal acid lipase expression	[lysosomal acid lipase expression]	0.0	4	1	1	1
139579	1710	(i) acute transfection under control	[(i) Acute transfection under control]	0.0	5	1	1	1
139580	1710	namely the immunoglobulin heavy chain enhancer	[namely the immunoglobulin heavy chain enhancer]	0.0	6	1	1	1
139581	1710	latent cycle reactivity undetectable	[latent cycle reactivities undetectable]	0.0	4	1	1	1
139582	1710	two genes, alpha a	[two genes, alpha A]	0.0	4	1	1	1
139583	1710	incubation with concentration	[incubation with concentrations]	0.0	3	1	1	1
139584	1710	same pathway	[same pathways]	0.0	2	1	1	1
139585	1710	primary binding site	[primary binding site]	0.0	3	1	1	1
139586	1710	units, p young vs. old)	[units, P young vs. old)]	0.0	5	1	1	1
139587	1710	gata-1 DNA	[GATA-1 DNA]	0.0	2	1	1	1
139588	1710	lymphocyte proliferation in healthy control	[lymphocyte proliferation in healthy controls]	0.0	5	1	1	1
139589	1710	lymphocyte of healthy woman (11	[lymphocytes of healthy women (11]	0.0	5	1	1	1
139590	1710	CD+8 t-cell number	[CD+8 T-cell numbers]	0.0	3	1	1	1
139591	1710	distinct protein tcf-2 alpha	[distinct protein TCF-2 alpha]	0.0	4	1	1	1
139592	1710	overexpress	[overexpressing]	0.0	1	1	1	1
139593	1710	immediate-early factor	[immediate-early factor]	0.0	2	1	1	1
139594	1710	BamHI-A	[BamHI-A]	0.0	1	1	1	1
139595	1710	over 17 kb	[over 17 kb]	0.0	3	1	1	1
139596	1710	RNAzol	[RNAzol]	0.0	1	1	1	1
139597	1710	trigger of the expression	[triggering of the expression]	0.0	4	1	1	1
139598	1710	immediate-early t-cell specific gene	[immediate-early T-cell specific genes]	0.0	4	1	1	1
139599	1710	infection interleukin-8 gene transcription lead	[infection interleukin-8 gene transcription leading]	0.0	5	1	1	1
139600	1710	copy DNA	[copy DNA]	0.0	2	1	1	1
139601	1710	unmodified asparagine	[unmodified asparagine]	0.0	2	1	1	1
139602	1710	participant mediate the neurologic dysfunction	[participants mediating the neurologic dysfunction]	0.0	5	1	1	1
139603	1710	blood monocyte from donor	[blood monocytes from donors]	0.0	4	1	1	1
139604	1710	multiple signal pathway	[multiple signaling pathways]	0.0	3	1	1	1
139605	1710	transcriptional activity of CREB	[transcriptional activity of CREB]	0.0	4	1	1	1
139606	1710	analysis of sucrose gradient fraction	[analysis of sucrose gradient fractions]	0.0	5	1	1	1
139607	1710	mw antigen	[MW antigen]	0.0	2	1	1	1
139608	1710	enhanson domain	[enhanson domains]	0.0	2	1	1	1
139609	1710	5 e1a-region	[5 E1A-region]	0.0	2	1	1	1
139610	1710	cd40l fusion	[CD40L fusion]	0.0	2	1	1	1
139611	1710	infection of human mononuclear phagocyte	[infection of human mononuclear phagocytes]	0.0	5	1	1	1
139612	1710	14-day colony (>1 mm)	[14-day colonies (>1 mm)]	0.0	4	1	1	1
139613	1710	key regulator of cell death.	[key regulator of cell death.]	0.0	5	1	1	1
139614	1710	glut1 expression	[GLUT1 expression]	0.0	2	1	1	1
139615	1710	Effect on expression of proto-oncogene c-fo	[Effects on expression of proto-oncogene c-fos]	0.0	6	1	1	1
139616	1710	high cytotoxicity	[high cytotoxicity]	0.0	2	1	1	1
139617	1710	subunit in platelet patient	[subunits in platelets patients]	0.0	4	1	1	1
139618	1710	nf-kappab heterodimer p50/p65	[NF-kappaB heterodimer p50/p65]	0.0	3	1	1	1
139619	1710	potential target for Oct2	[potential targets for Oct2]	0.0	4	1	1	1
139620	1710	pathogenicity of the respective virus	[pathogenicity of the respective viruses]	0.0	5	1	1	1
139621	1710	generate mechanism control the competence	[generating mechanisms controlling the competence]	0.0	5	1	1	1
139622	1710	D3 receptor VDR	[D3 receptor VDR]	0.0	3	1	1	1
139623	1710	clear-cut defect	[clear-cut defects]	0.0	2	1	1	1
139624	1710	stimuli, alpha	[stimuli, alpha]	0.0	2	1	1	1
139625	1710	infection [see comments]	[infection [see comments]]	0.0	3	1	1	1
139626	1710	upstream gene segment	[upstream gene segments]	0.0	3	1	1	1
139627	1710	anti-ig antibody	[anti-Ig antibody]	0.0	2	1	1	1
139628	1710	tyrosine-phosphorylated follow factor treatment of neutrophils.	[tyrosine-phosphorylated following factor treatment of neutrophils.]	0.0	6	1	1	1
139629	1710	long term therapy	[long term therapy]	0.0	3	1	1	1
139630	1710	protein id3	[protein Id3]	0.0	2	1	1	1
139631	1710	study on blood lymphocyte culture	[studies on blood lymphocyte cultures]	0.0	5	1	1	1
139632	1710	immunocytochemistry use a anti-p65 antibody	[immunocytochemistry using an anti-p65 antibody]	0.0	5	1	1	1
139633	1710	role of h2o2	[role of H2O2]	0.0	3	1	1	1
139634	1710	activity of hsf3	[activity of HSF3]	0.0	3	1	1	1
139635	1710	acid epitope	[acid epitope]	0.0	2	1	1	1
139636	1710	cell transfection	[cell transfection]	0.0	2	1	1	1
139637	1710	proliferation in response iddm subject	[proliferation in response IDDM subjects]	0.0	5	1	1	1
139638	1710	692 binding site	[692 binding sites]	0.0	3	1	1	1
139639	1710	casein kinase site	[casein kinase sites]	0.0	3	1	1	1
139640	1710	type of latency	[type of latency]	0.0	3	1	1	1
139641	1710	induce CAT activity 2) fibrinogen	[inducing CAT activity 2) fibrinogen]	0.0	5	1	1	1
139642	1710	(average gr concentration	[(average GR concentration]	0.0	3	1	1	1
139643	1710	long repeat (ltr)	[long repeat (LTR)]	0.0	3	1	1	1
139644	1710	protein ie1	[protein IE1]	0.0	2	1	1	1
139645	1710	CBF alpha twofold	[CBF alpha twofold]	0.0	3	1	1	1
139646	1710	bone marrow-derived cell	[bone marrow-derived cells]	0.0	3	1	1	1
139647	1710	population type	[population type]	0.0	2	1	1	1
139648	1710	primary human precursor	[primary human precursors]	0.0	3	2	2	1
139649	1710	transactivation by human herpesvirus hhv-6 strain	[Transactivation by human herpesvirus HHV-6 strains]	0.0	6	1	1	1
139650	1710	interaction with element	[interaction with elements]	0.0	3	1	1	1
139651	1710	presumably MCM member	[presumably MCM members,]	0.0	3	1	1	1
139652	1710	type),	[type),]	0.0	1	1	1	1
139653	1710	differentiation-dependent peroxisomal receptor gamma expression	[differentiation-dependent peroxisomal receptor gamma expression]	0.0	5	1	1	1
139654	1710	use a specific proteasome inhibitor	[using a specific proteasome inhibitor]	0.0	5	1	1	1
139655	1710	consequent leukocyte adhesion	[consequent leukocyte adhesion]	0.0	3	1	1	1
139656	1710	viral cascade	[viral cascade]	0.0	2	1	1	1
139657	1710	human type interleukin-1	[human type interleukin-1]	0.0	3	1	1	1
139658	1710	viral protein and/or DNA	[viral proteins and/or DNA]	0.0	4	1	1	1
139659	1710	two mechanims:	[two mechanims:]	0.0	2	1	1	1
139660	1710	switch from human (gamma)	[switch from human (gamma)]	0.0	4	1	1	1
139661	1710	such as formylpeptide	[such as formylpeptides]	0.0	3	1	1	1
139662	1710	avascular necrosis of bone	[avascular necrosis of bone]	0.0	4	1	1	1
139663	1710	cell of x-ray cell	[cells of X-ray cells]	0.0	4	1	1	1
139664	1710	transcription protein,	[transcription protein,]	0.0	2	1	1	1
139665	1710	SKW cell less than 0.011	[SKW cells less than 0.001),]	0.0	5	1	1	1
139666	1710	fibrosarcoma histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma	[fibrosarcoma histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
139667	1710	sequence of many gene	[sequences of many genes]	0.0	4	1	1	1
139668	1710	mutation of the pu box	[mutation of the PU box]	0.0	5	1	1	1
139669	1710	chemokine important	[chemokine important]	0.0	2	1	1	1
139670	1710	contain Oct2	[containing Oct2]	0.0	2	1	1	1
139671	1710	role of gata factor	[roles of GATA factors]	0.0	4	1	1	1
139672	1710	inhibition of ciita expression	[inhibition of CIITA expression]	0.0	4	1	1	1
139673	1710	ggaaagtccc	[GGAAAGTCCC]	0.0	1	1	1	1
139674	1710	MCM gene promoter	[MCM gene promoters]	0.0	3	1	1	1
139675	1710	selection antigen-driven expansion) (by stimulation	[selection antigen-driven expansion) (by stimulation]	0.0	5	1	1	1
139676	1710	killer cell in bone marrow	[killer cells in bone marrow]	0.0	5	1	1	1
139677	1710	CD40 cell	[CD40 cells]	0.0	2	1	1	1
139678	1710	individual mutation	[Individual mutation]	0.0	2	1	1	1
139679	1710	matrix metalloproteinase mmp9	[matrix metalloproteinase MMP9]	0.0	3	1	1	1
139680	1710	importance in tissue	[importance in tissues]	0.0	3	1	1	1
139681	1710	other domains,	[other domains,]	0.0	2	1	1	1
139682	1710	dnase site-forming element HSFE	[DNase site-forming element HSFE]	0.0	4	1	1	1
139683	1710	certain cell types,	[certain cell types,]	0.0	3	1	1	1
139684	1710	106 kda	[106 kDa]	0.0	2	1	1	1
139685	1710	level of inactive p50 homodimer	[levels of inactive p50 homodimer]	0.0	5	1	1	1
139686	1710	autosomal disease xeroderma pigmentosum	[autosomal disease xeroderma pigmentosum]	0.0	4	1	1	1
139687	1710	major regulator of the promoter activity	[major regulators of the promoter activity]	0.0	6	1	1	1
139688	1710	characterization of nf(p) the nuclear factor	[Characterization of NF(P) the nuclear factor]	0.0	6	1	1	1
139689	1710	feature of apoptosis	[features of apoptosis]	0.0	3	1	1	1
139690	1710	NF-kappaB function as a regulatory factor	[NF-kappaB functions as a regulatory factor]	0.0	6	1	1	1
139691	1710	97 kda ca(2+)-atpase target	[97 kDa Ca(2+)-ATPase target]	0.0	4	1	1	1
139692	1710	mature T lymphocyte erratum	[mature T lymphocytes erratum]	0.0	4	1	1	1
139693	1710	role cell-dependent b cell maturation	[role cell-dependent B cell maturation]	0.0	5	1	1	1
139694	1710	nuclear factor (NF)-AT NF-AT AP-1/Octamer UPS	[nuclear factor (NF)-AT NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
139695	1710	binding site for inhibitor	[binding site for inhibitor]	0.0	4	1	1	1
139696	1710	implication in aids pathogenesis in vivo	[implications in AIDS pathogenesis in vivo]	0.0	6	1	1	1
139697	1710	molecular analysis apoptosis	[Molecular analysis apoptosis]	0.0	3	1	1	1
139698	1710	ALY a context-dependent coactivator	[ALY a context-dependent coactivator]	0.0	4	1	1	1
139699	1710	bcl-6 cd40l	[BCL-6 CD40L]	0.0	2	1	1	1
139700	1710	copy of the genome	[copies of the genome]	0.0	4	1	1	1
139701	1710	s.c. lymph nodes;	[s.c. lymph nodes;]	0.0	3	1	1	1
139702	1710	receptor or positivity	[receptor OR positivity]	0.0	3	1	1	1
139703	1710	sulfhydryl group with diamide (reversible)	[sulfhydryl groups with diamide (reversible)]	0.0	5	1	1	1
139704	1710	proximal lck promoter	[proximal lck promoter]	0.0	3	1	1	1
139705	1710	hyperadhesivity	[hyperadhesivity]	0.0	1	1	1	1
139706	1710	normal T cell population	[normal T cell populations]	0.0	4	1	1	1
139707	1710	tyrosyl phosphorylation of cellular protein	[tyrosyl phosphorylation of cellular proteins]	0.0	5	1	1	1
139708	1710	human proenkephalin gene	[human proenkephalin gene]	0.0	3	1	1	1
139709	1710	I -182 bp	[I -182 bp]	0.0	3	1	1	1
139710	1710	two mechanims.	[two mechanims.]	0.0	2	1	1	1
139711	1710	engagement by ligands,	[engagement by ligands,]	0.0	3	1	1	1
139712	1710	eig)-secreting cell	[(Ig)-secreting cells]	0.0	2	1	1	1
139713	1710	major histocompatibility (mhc) haplotype	[major histocompatibility (MHC) haplotypes]	0.0	4	1	1	1
139714	1710	overexpress icsat in lymphocyte	[overexpressing ICSAT in lymphocytes]	0.0	4	1	1	1
139715	1710	force in diversity generation	[force in diversity generation]	0.0	4	1	1	1
139716	1710	Japanese child	[Japanese children]	0.0	2	1	1	1
139717	1710	antigen peptide analog	[antigen peptide analogs]	0.0	3	1	1	1
139718	1710	proportion of responder	[proportions of responders]	0.0	3	1	1	1
139719	1710	activity tag capable	[activity TAG capable]	0.0	3	1	1	1
139720	1710	stable benzoic derivative	[stable benzoic derivative]	0.0	3	1	1	1
139721	1710	include the region	[including the region]	0.0	3	1	1	1
139722	1710	HAuCl3	[HAuCl3]	0.0	1	1	1	1
139723	1710	protein/dna interaction of the interferon-gamma promoter	[protein/DNA interactions of the interferon-gamma promoter]	0.0	6	1	1	1
139724	1710	interspecy cell hybrid	[Interspecies cell hybrids]	0.0	3	1	1	1
139725	1710	mutation in the region coding	[mutation in the region coding]	0.0	5	1	1	1
139726	1710	mzf1 transcription	[MZF1 transcription]	0.0	2	1	1	1
139727	1710	analyze the normal component	[analyzing the normal components]	0.0	4	1	1	1
139728	1710	dominant IkappaB molecule	[dominant IkappaB molecule]	0.0	3	1	1	1
139729	1710	part, due to ability	[part, due to ability]	0.0	4	1	1	1
139730	1710	mostly at the level	[mostly at the level]	0.0	4	1	1	1
139731	1710	number of gata-1.05 progenitor cell	[number of GATA-1.05 progenitor cells]	0.0	5	1	1	1
139732	1710	involvement of tfiiib90	[involvement of TFIIIB90]	0.0	3	1	1	1
139733	1710	(delta99)	[(delta99)]	0.0	1	1	1	1
139734	1710	tumor necrosis factor-responsive gene	[tumor necrosis factor-responsive genes]	0.0	4	1	1	1
139735	1710	different system	[different systems]	0.0	2	1	1	1
139736	1710	temporal analysis of the IL-4 effect	[Temporal analysis of the IL-4 effect]	0.0	6	1	1	1
139737	1710	symptom in xp-b	[symptoms in XP-B]	0.0	3	1	1	1
139738	1710	assays),	[assays),]	0.0	1	1	1	1
139739	1710	interferon protein ip-10 CXC chemokine	[interferon protein IP-10 CXC chemokine]	0.0	5	1	1	1
139740	1710	chemoattract fmlp	[chemoattractants FMLP]	0.0	2	1	1	1
139741	1710	capacity upon k562 cell	[capacity upon K562 cells]	0.0	4	1	1	1
139742	1710	1, 25-dihydroxyvitamin D3 135(oh)2d3	[1, 25-dihydroxyvitamin D3 1,25(OH)2D3]	0.0	4	1	1	1
139743	1710	efficient ebv activation	[efficient EBV activation]	0.0	3	1	1	1
139744	1710	existence of a promoter	[existence of an promoter]	0.0	4	1	1	1
139745	1710	GM-CSF blood polymorphonuclear leukocyte activation	[GM-CSF blood polymorphonuclear leukocytes activation]	0.0	5	1	1	1
139746	1710	percent of gc b cell	[percent of GC B cells]	0.0	5	1	1	1
139747	1710	continuous nf-kappa b	[continuous NF-kappa B]	0.0	3	1	1	1
139748	1710	E2A- hepatic leukemia factor protein	[E2A- hepatic leukemia factor proteins]	0.0	5	1	1	1
139749	1710	Mn sod mrna	[Mn SOD mRNA]	0.0	3	1	1	1
139750	1710	coping strategy	[coping strategy]	0.0	2	2	2	1
139751	1710	type-i	[type-I]	0.0	1	1	1	1
139752	1710	reactivation of Kaposi's sarcoma herpesvirus infection	[Reactivation of Kaposi's sarcoma herpesvirus infection]	0.0	6	1	1	1
139753	1710	primary b-cell by mutant virus	[primary B-cells by mutant virus]	0.0	5	1	1	1
139754	1710	untransformed glucocorticoid receptor complex	[untransformed glucocorticoid receptor complexes]	0.0	4	1	1	1
139755	1710	position -67 bp	[position -67 bp]	0.0	3	1	1	1
139756	1710	low degree	[low degree]	0.0	2	1	1	1
139757	1710	vein cell at mM concentration	[vein cells at mM concentration]	0.0	5	1	1	1
139758	1710	transfer of the cell	[transfer of the cells]	0.0	4	1	1	1
139759	1710	hitherto unrecognized property	[hitherto unrecognized property]	0.0	3	1	1	1
139760	1710	stimulation of nonopsonic phagocytosis	[stimulation of nonopsonic phagocytosis]	0.0	4	1	1	1
139761	1710	binding protein kD	[binding proteins kD]	0.0	3	1	1	1
139762	1710	conformation in cell	[conformation in cells]	0.0	3	1	1	1
139763	1710	titre antibody with specificity	[titre antibodies with specificities]	0.0	4	1	1	1
139764	1710	secreted-type alkaline phosphatase reporter gene	[secreted-type alkaline phosphatase reporter gene]	0.0	5	1	1	1
139765	1710	drosophila elegan	[Drosophila elegans]	0.0	2	1	1	1
139766	1710	acid treatment in acute leukemia	[acid treatment in acute leukemia]	0.0	5	1	1	1
139767	1710	uncoupling from the expression	[Uncoupling from the expression]	0.0	4	1	1	1
139768	1710	surface MHC class ii expression	[surface MHC class II expression]	0.0	5	1	1	1
139769	1710	use Southern blot hybridisation	[using Southern blot hybridisation]	0.0	4	1	1	1
139770	1710	kappaB-dependent gene expression	[kappaB-dependent gene expression]	0.0	3	1	1	1
139771	1710	characteristics.	[characteristics.]	0.0	1	1	1	1
139772	1710	characteristics,	[characteristics,]	0.0	1	1	1	1
139773	1710	favorable course chi2	[favorable course chi2]	0.0	3	1	1	1
139774	1710	type-2	[type-2]	0.0	1	1	1	1
139775	1710	3 sequence	[3 sequence]	0.0	2	1	1	1
139776	1710	type-1	[type-1]	0.0	1	1	1	1
139777	1710	repressive effect on the gene	[repressive effects on the genes]	0.0	5	1	1	1
139778	1710	stimulator of il-12 production by macrophage	[stimulators of IL-12 production by macrophages]	0.0	6	1	1	1
139779	1710	approximately eightfold amount of nf-at	[approximately eightfold amounts of NF-AT]	0.0	5	1	1	1
139780	1710	similar activation of the NF-kappaB	[similar activation of the NF-kappaB]	0.0	5	1	1	1
139781	1710	ttg substrate	[tTG substrate]	0.0	2	1	1	1
139782	1710	binding to the LBP-1 sequence	[binding to the LBP-1 sequences]	0.0	5	1	1	1
139783	1710	hiv DNA	[HIV DNA]	0.0	2	1	1	1
139784	1710	1-(5-chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride	[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride]	0.0	2	1	1	1
139785	1710	adhesion of monocytic cell	[adhesion of monocytic cells]	0.0	4	1	1	1
139786	1710	cc(a/t)6gg	[CC(A/T)6GG]	0.0	1	1	1	1
139787	1710	(xiste-),	[(XISTE-),]	0.0	1	1	1	1
139788	1710	IEF-1 a beta-cell type-specific complex	[IEF-1 a beta-cell type-specific complex]	0.0	5	1	1	1
139789	1710	gh in one obese patient	[GH in one obese patient]	0.0	5	1	1	1
139790	1710	mzf1	[MZF1]	0.0	1	1	1	1
139791	1710	such as HeLa	[such as HeLa]	0.0	3	1	1	1
139792	1710	activity after transient transfection	[activity after transient transfection]	0.0	4	1	1	1
139793	1710	mutant adenovirus	[Mutants adenovirus]	0.0	2	1	1	1
139794	1710	IM-9 extract	[IM-9 extracts]	0.0	2	1	1	1
139795	1710	litaf	[LITAF]	0.0	1	1	1	1
139796	1710	inhibitor in intact cell	[inhibitor in intact cells]	0.0	4	1	1	1
139797	1710	CMV by treatment	[CMV by treatment]	0.0	3	1	1	1
139798	1710	minute in Jurkat cell	[minutes in Jurkat cells]	0.0	4	1	1	1
139799	1710	Native erythrocyte ndp kinase protein	[Native erythrocyte NDP kinase protein]	0.0	5	1	1	1
139800	1710	domain act	[domains acting]	0.0	2	1	1	1
139801	1710	albumin	[albumin]	0.0	1	1	1	1
139802	1710	action on expression	[actions on expression]	0.0	3	1	1	1
139803	1710	expression to the class of gene	[expression to the classes of genes]	0.0	6	1	1	1
139804	1710	critical role in beta-cell function	[critical role in beta-cell function]	0.0	5	1	1	1
139805	1710	cell with oleate	[cells with oleate]	0.0	3	1	1	1
139806	1710	rela(p65) for this site	[RelA(p65) for this site]	0.0	4	1	1	1
139807	1710	up-regulation of GcR	[up-regulation of GcR]	0.0	3	1	1	1
139808	1710	15 stimulation	[15 stimulation]	0.0	2	1	1	1
139809	1710	D3 dioxyvit on can metabolism	[D3 dioxyvit on Ca metabolism]	0.0	5	1	1	1
139810	1710	pre-B cell by lipopolysaccharide	[pre-B cells by lipopolysaccharide]	0.0	4	1	1	1
139811	1710	human gene promoter	[human gene promoter]	0.0	3	1	1	1
139812	1710	presence in the plaque	[presence in the plaques]	0.0	4	1	1	1
139813	1710	competitive immunosorbent assay	[competitive immunosorbent assay]	0.0	3	1	1	1
139814	1710	contrast, expression within limits.	[contrast, expression within limits.]	0.0	4	1	1	1
139815	1710	promoter-binding protein Sp1	[promoter-binding protein Sp1]	0.0	3	1	1	1
139816	1710	suggest responsible for the inhibitory activity	[suggesting responsible for the inhibitory activities]	0.0	6	1	1	1
139817	1710	existence of a non-syntenic locus	[existence of a non-syntenic locus]	0.0	5	1	1	1
139818	1710	mean percent	[mean percent]	0.0	2	1	1	1
139819	1710	alteration in receptor binding	[alterations in receptor binding]	0.0	4	1	1	1
139820	1710	intermediate-dependent nf-kappab activation	[intermediate-dependent NF-kappaB activation]	0.0	3	1	1	1
139821	1710	8, fibrous histiocytoma	[8, fibrous histiocytoma]	0.0	3	1	1	1
139822	1710	experimental system study the mechanism	[experimental system studying the mechanisms]	0.0	5	1	1	1
139823	1710	profibrotic growth	[profibrotic growth]	0.0	2	1	1	1
139824	1710	proline sequence within the stretch	[proline sequence within the stretch]	0.0	5	1	1	1
139825	1710	interaction of CD2 with ligand	[interaction of CD2 with ligand]	0.0	5	1	1	1
139826	1710	mutant cell resistant	[mutant cells resistant]	0.0	3	1	1	1
139827	1710	human GM-CSF tata box	[human GM-CSF TATA box]	0.0	4	1	1	1
139828	1710	fusion/entry	[fusion/entry]	0.0	1	1	1	1
139829	1710	modulation during G0 phase transition	[Modulation during G0 phase transition]	0.0	5	1	1	1
139830	1710	c-Jun -contain complex	[c-Jun -containing complexes]	0.0	3	1	1	1
139831	1710	translocation oligonucleotide	[translocation oligonucleotides]	0.0	2	1	1	1
139832	1710	(39.9%	[(39.9%]	0.0	1	1	1	1
139833	1710	attack of bowel disease IBD	[attacks of bowel disease IBD]	0.0	5	1	1	1
139834	1710	acute myeloid blast	[acute myeloid blasts]	0.0	3	1	1	1
139835	1710	DNA binding activity consist	[DNA binding activity consisting]	0.0	4	1	1	1
139836	1710	novel 9-bp motif (-90/-82 with homology	[novel 9-bp motifs (-90/-82 with homology]	0.0	6	1	1	1
139837	1710	htoll activation of protein kinase/c-Jun	[hToll activation of protein kinase/c-Jun]	0.0	5	1	1	1
139838	1710	respectively, in three fusions.	[respectively, in three fusions.]	0.0	4	1	1	1
139839	1710	Staurosporine PKC inhibitor	[Staurosporine PKC inhibitor]	0.0	3	1	1	1
139840	1710	form 90-kda stat3alpha	[forms 90-kDa STAT3alpha]	0.0	3	1	1	1
139841	1710	distinct form of (free) e2f	[distinct forms of (free) E2F]	0.0	5	1	1	1
139842	1710	toll signal pathway	[toll signaling pathway]	0.0	3	1	1	1
139843	1710	production of amount early	[production of amounts early]	0.0	4	1	1	1
139844	1710	immunodeficiency virus type-1 hiv-1	[immunodeficiency virus type-1 HIV-1]	0.0	4	4	4	1
139845	1710	removal of the first amino acid	[removal of the first amino acids]	0.0	6	1	1	1
139846	1710	hormone-activated binding to region	[hormone-activated binding to regions]	0.0	4	1	1	1
139847	1710	cycle reactivity to epitope	[cycle reactivities to epitopes]	0.0	4	1	1	1
139848	1710	oral administration	[Oral administration]	0.0	2	2	2	1
139849	1710	role as a secondary messenger	[role as an secondary messenger]	0.0	5	1	1	1
139850	1710	transcription factor expression vector	[transcription factor expression vectors]	0.0	4	1	1	1
139851	1710	role in germline Cepsilon transcription	[role in germline Cepsilon transcription]	0.0	5	1	1	1
139852	1710	nuclear ribonucleoprotein k protein	[nuclear ribonucleoprotein K protein]	0.0	4	1	1	1
139853	1710	steroid hormone receptor	[steroid hormone receptors]	0.0	3	1	1	1
139854	1710	receptor of hormonal form	[receptors of hormonal form]	0.0	4	1	1	1
139855	1710	increase (on average	[increase (on average]	0.0	3	1	1	1
139856	1710	T cell element	[T cell element]	0.0	3	1	1	1
139857	1710	intense study.	[intense study.]	0.0	2	1	1	1
139858	1710	apparent genomic alteration	[apparent genomic alteration]	0.0	3	1	1	1
139859	1710	induction, lytic superinfection	[induction, lytic superinfection]	0.0	3	1	1	1
139860	1710	cell line absent in Hela	[cell lines absent in Hela]	0.0	5	1	1	1
139861	1710	primary cell in culture	[primary cells in cultures]	0.0	4	1	1	1
139862	1710	11 phosphoprotein with dna-binding activity	[11 phosphoproteins with DNA-binding activity]	0.0	5	1	1	1
139863	1710	activity through element	[activity through elements]	0.0	3	1	1	1
139864	1710	1 element 1 tre-1	[1 element 1 TRE-1]	0.0	4	1	1	1
139865	1710	protein flap	[protein FLAP]	0.0	2	1	1	1
139866	1710	interaction with partners,	[interaction with partners,]	0.0	3	1	1	1
139867	1710	thus positioning NFAT for dephosphorylation	[thus positioning NFAT for dephosphorylation]	0.0	5	1	1	1
139868	1710	immediate 62 (ie62) protein	[immediate 62 (IE62) protein]	0.0	4	1	1	1
139869	1710	bp for optimal binding.	[bp for optimal binding.]	0.0	4	1	1	1
139870	1710	Thus, p21ras regulation in T cell	[Thus, p21ras regulation in T cells]	0.0	6	1	1	1
139871	1710	context of abortion	[context of abortion]	0.0	3	1	1	1
139872	1710	number in peripheral blood lymphocyte	[numbers in peripheral blood lymphocytes]	0.0	5	1	1	1
139873	1710	RJ cell	[RJ cells]	0.0	2	1	1	1
139874	1710	level in plasmacytoma	[levels in plasmacytoma]	0.0	3	1	1	1
139875	1710	glucocorticoid type receptor gcii	[glucocorticoid type receptor GCII]	0.0	4	1	1	1
139876	1710	phosphorylation of Id3	[phosphorylation of Id3]	0.0	3	1	1	1
139877	1710	crucial role in tissue damage	[crucial role in tissue damage]	0.0	5	1	1	1
139878	1710	role for a novel 5'	[Role for a novel 5']	0.0	5	1	1	1
139879	1710	ease	[ease]	0.0	1	1	1	1
139880	1710	cyclosporin dnase i-hypersensitive site	[cyclosporin DNase I-hypersensitive site]	0.0	4	1	1	1
139881	1710	cell precursor	[cell precursors]	0.0	2	1	1	1
139882	1710	growth of abnormal blast cell	[growth of abnormal blast cells]	0.0	5	2	2	1
139883	1710	result of a promoter switch	[result of a promoter switching]	0.0	5	1	1	1
139884	1710	cases, include aml with morphology	[cases, including AML with morphology]	0.0	5	1	1	1
139885	1710	high-level replication	[high-level replication]	0.0	2	3	3	1
139886	1710	substoichiometric taf of 105 kda	[substoichiometric TAF of 105 kDa]	0.0	5	1	1	1
139887	1710	region of several sequence	[regions of several sequences]	0.0	4	1	1	1
139888	1710	1.7 nm	[1.7 nM]	0.0	2	1	1	1
139889	1710	silencing of the promoter	[silencing of the promoter]	0.0	4	1	1	1
139890	1710	malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[malignant histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
139891	1710	early thymus	[early thymus]	0.0	2	1	1	1
139892	1710	dysregulation of nuclear factor-kappa b	[Dysregulation of nuclear factor-kappa B]	0.0	5	1	1	1
139893	1710	implications,	[implications,]	0.0	1	1	1	1
139894	1710	IL-4 region for enhancer activity	[IL-4 regions for enhancer activity]	0.0	5	1	1	1
139895	1710	induce antiviral protection	[inducing antiviral protection]	0.0	3	1	1	1
139896	1710	only for the patient	[only for the patients]	0.0	4	1	1	1
139897	1710	decline in site alpha-	[decline in site alpha-]	0.0	4	1	1	1
139898	1710	5' CCAAT sequence for transcription factor	[5' CCAAT sequences for transcription factors]	0.0	6	1	1	1
139899	1710	administration of 276 mumol cortisol	[administration of 276 mumol cortisol]	0.0	5	1	1	1
139900	1710	block element alpha/delta 1	[blocking element alpha/delta 1]	0.0	4	1	1	1
139901	1710	contain the extracellular domain	[containing the extracellular domain]	0.0	4	1	1	1
139902	1710	contrast, in b cell	[contrast, in B cells]	0.0	4	1	1	1
139903	1710	monocytes/macrophages in atherosclerotic lesion	[monocytes/macrophages in atherosclerotic lesions]	0.0	4	1	1	1
139904	1710	several signalling molecule brid the generation	[several signalling molecules bridging the generation]	0.0	6	1	1	1
139905	1710	p65 activation	[p65 activation]	0.0	2	1	1	1
139906	1710	line of monoblastic cell	[line of monoblastic cells]	0.0	4	1	1	1
139907	1710	t-lymphocyte culture in condition	[T-lymphocytes culture in conditions]	0.0	4	1	1	1
139908	1710	treatment with RA	[treatment with RA]	0.0	3	1	1	1
139909	1710	6 month 12 month	[6 months 12 months]	0.0	4	1	1	1
139910	1710	basic domain of the factor	[basic domains of the factors]	0.0	5	1	1	1
139911	1710	human intestinal epithelial cell inflammatory response	[Human intestinal epithelial cell inflammatory responses]	0.0	6	1	1	1
139912	1710	NF-AT ap-1 site	[NF-AT AP-1 sites]	0.0	3	1	1	1
139913	1710	vitro, six viral antigen	[vitro, six viral antigens]	0.0	4	1	1	1
139914	1710	s.m.schnittman,	[S.M.Schnittman,]	0.0	1	1	1	1
139915	1710	8e51 t-cell	[8e51 T-cells]	0.0	2	1	1	1
139916	1710	pathway upstream	[pathways upstream]	0.0	2	1	1	1
139917	1710	three different region	[three different regions]	0.0	3	1	1	1
139918	1710	different stimulus mediate aspect	[different stimuli mediating aspects]	0.0	4	1	1	1
139919	1710	nonlymphoid cell reporter plasmid	[nonlymphoid cells reporter plasmids]	0.0	4	1	1	1
139920	1710	cooperative interaction between transcriptional coactivator	[cooperative interactions between transcriptional coactivators]	0.0	5	1	1	1
139921	1710	de novo	[de novo]	0.0	2	1	1	1
139922	1710	cpp32/yama/apopain	[CPP32/Yama/apopain]	0.0	1	1	1	1
139923	1710	heat shock protein association hsp	[heat shock protein association hsp]	0.0	5	1	1	1
139924	1710	subunit of NF-AT	[subunit of NF-AT]	0.0	3	1	1	1
139925	1710	Fos kinase activity	[Fos kinase activity]	0.0	3	1	1	1
139926	1710	treatment of the (apl) cell line	[Treatment of the (APL) cell line]	0.0	6	1	1	1
139927	1710	time-dependent binding monoclonal antibody	[time-dependent binding monoclonal antibodies]	0.0	4	1	1	1
139928	1710	receptor GRs	[receptors GRs]	0.0	2	1	1	1
139929	1710	contrast, injection	[contrast, injections]	0.0	2	1	1	1
139930	1710	childhood leukemia	[childhood leukemia]	0.0	2	1	1	1
139931	1710	class ii MHC molecule	[class II MHC molecules]	0.0	4	1	1	1
139932	1710	nf-kappa b target	[NF-kappa B target]	0.0	3	1	1	1
139933	1710	early lymphoid precursor	[early lymphoid precursors]	0.0	3	1	1	1
139934	1710	incubation of human blood with PGG-Glucan	[Incubation of human blood with PGG-Glucan]	0.0	6	1	1	1
139935	1710	expression of differentiation antigen	[expression of differentiation antigens]	0.0	4	1	1	1
139936	1710	DNA factor	[DNA factors]	0.0	2	1	1	1
139937	1710	inhibition of g0s2 expression by CsA	[inhibition of G0S2 expression by CsA]	0.0	6	1	1	1
139938	1710	eosinophilic phenotype	[eosinophilic phenotype]	0.0	2	1	1	1
139939	1710	extract from primary human T lymphocyte	[extracts from primary human T lymphocytes]	0.0	6	1	1	1
139940	1710	regulation of the ecto-5'-nucleotidase promoter	[regulation of the ecto-5'-nucleotidase promoter]	0.0	5	1	1	1
139941	1710	transendothelial migration of filarial antigen t-cell	[transendothelial migration of filarial antigen T-cells]	0.0	6	1	1	1
139942	1710	regulator of lymphocyte proliferation	[regulator of lymphocyte proliferation]	0.0	4	1	1	1
139943	1710	molecular protein	[molecular proteins]	0.0	2	1	1	1
139944	1710	mouse thymoma line	[Mouse thymoma line]	0.0	3	1	1	1
139945	1710	inhibitory molecule a protein	[inhibitory molecule a protein]	0.0	4	1	1	1
139946	1710	cell cycle-related protein	[cell cycle-related proteins]	0.0	3	1	1	1
139947	1710	subsequent cross-linking	[Subsequent cross-linking]	0.0	2	1	1	1
139948	1710	stimulus in neutrophils.	[stimuli in neutrophils.]	0.0	3	1	1	1
139949	1710	factor-IL-6beta -ig/ebp-1 heterodimer	[factor-IL-6beta -Ig/EBP-1 heterodimer]	0.0	3	1	1	1
139950	1710	calcium-dependent phosphatase	[calcium-dependent phosphatase]	0.0	2	1	1	1
139951	1710	double labeling by immunofluorescence	[double labeling by immunofluorescence]	0.0	4	1	1	1
139952	1710	traz in transformation of lymphocyte	[TRAFs in transformation of lymphocytes]	0.0	5	1	1	1
139953	1710	crucial determinant process	[crucial determinant processes]	0.0	3	1	1	1
139954	1710	evidence for various defect	[evidence for various defects]	0.0	4	1	1	1
139955	1710	consistent involvement in translocation	[consistent involvement in translocations]	0.0	4	1	1	1
139956	1710	postvaccine response	[postvaccine responses]	0.0	2	1	1	1
139957	1710	level of c-jun transcript	[levels of c-jun transcripts]	0.0	4	2	2	1
139958	1710	number in late phase endometrium	[numbers in late phase endometrium]	0.0	5	1	1	1
139959	1710	basis for cytokine expression	[basis for cytokine expression]	0.0	4	1	1	1
139960	1710	myelogenous leukemia 1- evi1 fusion respectively,	[myelogenous leukemia 1- EVI1 fusions respectively,]	0.0	6	1	1	1
139961	1710	multiple antigen-specific reactivity as high	[multiple antigen-specific reactivities as high]	0.0	5	1	1	1
139962	1710	concentration of mp value	[concentrations of MP values]	0.0	4	1	1	1
139963	1710	increase in 9-cis differentiation	[increase in 9-cis differentiation]	0.0	4	1	1	1
139964	1710	c-c chemokine in mammalian cell	[C-C chemokines in mammalian cells]	0.0	5	1	1	1
139965	1710	bzlf1 transactivator protein in leukoplakia	[BZLF1 transactivator protein in leukoplakia]	0.0	5	1	1	1
139966	1710	reduction of ikappab-alpha	[reduction of IkappaB-alpha]	0.0	3	1	1	1
139967	1710	element within promoter	[element within promoters]	0.0	3	1	1	1
139968	1710	component of the regulatory network	[components of the regulatory network]	0.0	5	1	1	1
139969	1710	blood monocyte PBM	[blood monocytes PBM]	0.0	3	1	1	1
139970	1710	mimicry involve class I-restricted CTL	[mimicry involving class I-restricted CTLs]	0.0	5	1	1	1
139971	1710	heterodimerization partner	[heterodimerization partner]	0.0	2	1	1	1
139972	1710	subpopulation the (dp) CD4	[subpopulation the (DP) CD4]	0.0	4	1	1	1
139973	1710	effect of tgf-beta	[effects of TGF-beta]	0.0	3	1	1	1
139974	1710	phop locus	[phoP locus]	0.0	2	1	1	1
139975	1710	domain, interference	[domain, interference]	0.0	2	1	1	1
139976	1710	progression of type include chronic leukaemia	[progression of types including chronic leukaemia]	0.0	6	2	2	1
139977	1710	virus of nonhuman primate	[virus of nonhuman primates]	0.0	4	1	1	1
139978	1710	sequence in a region (bp	[sequences in a region (bp]	0.0	5	1	1	1
139979	1710	mrna level in anthracycline cell	[mRNA level in anthracycline cells]	0.0	5	1	1	1
139980	1710	formation of the catalytically active dimer	[formation of the catalytically active dimer]	0.0	6	1	1	1
139981	1710	term of modulation	[terms of modulation]	0.0	3	1	1	1
139982	1710	result of distinct activation	[result of distinct activation]	0.0	4	1	1	1
139983	1710	target.	[target.]	0.0	1	1	1	1
139984	1710	great negative feedback sensitivity	[greater negative feedback sensitivity]	0.0	4	1	1	1
139985	1710	target,	[target,]	0.0	1	1	1	1
139986	1710	pathologic sign	[pathologic signs]	0.0	2	1	1	1
139987	1710	increase in e3 mrna level	[increase in E3 mRNA levels]	0.0	5	1	1	1
139988	1710	attack of bowel disease	[attacks of bowel disease]	0.0	4	1	1	1
139989	1710	two antibody	[two antibodies]	0.0	2	1	1	1
139990	1710	mechanism of transcriptional activation	[mechanisms of transcriptional activation]	0.0	4	1	1	1
139991	1710	exclusion cell counting	[exclusion cell counting]	0.0	3	1	1	1
139992	1710	sensitive leukemia patient	[sensitive leukemia patients]	0.0	3	1	1	1
139993	1710	0.8 microm for dutp	[0.8 microM for dUTP]	0.0	4	1	1	1
139994	1710	two other RAR ligand	[two other RAR ligands]	0.0	4	1	1	1
139995	1710	reach a maximum of binding sites/nucleus	[reaching a maximum of binding sites/nucleus]	0.0	6	1	1	1
139996	1710	failure rate for patient	[failure rate for patients]	0.0	4	1	1	1
139997	1710	ebv infection ebv reactivation	[EBV infection EBV reactivation]	0.0	4	1	1	1
139998	1710	membrane protein LMP1 homolog	[membrane protein LMP1 homologs]	0.0	4	1	1	1
139999	1710	il-2 production in murine lymphocyte	[IL-2 production in murine lymphocytes]	0.0	5	1	1	1
140000	1710	blood stem	[blood stem]	0.0	2	3	3	1
140001	1710	multimer of kappa 1-kappa 3	[multimers of kappa 1-kappa 3]	0.0	5	1	1	1
140002	1710	myoblast	[myoblasts]	0.0	1	1	1	1
140003	1710	reverse effect on macrophage	[reverse effects on macrophages]	0.0	4	1	1	1
140004	1710	only this gene	[only these genes]	0.0	3	1	1	1
140005	1710	human t-lymphoblastoid cell	[human T-lymphoblastoid cells]	0.0	3	1	1	1
140006	1710	colony stimulate factor	[colony stimulating factor]	0.0	3	1	1	1
140007	1710	significant upregulation	[significant upregulation]	0.0	2	1	1	1
140008	1710	therapeutic potential.	[therapeutic potential.]	0.0	2	1	1	1
140009	1710	further, mutation	[further, mutations]	0.0	2	1	1	1
140010	1710	transcription factor Elf-1	[transcription factor Elf-1]	0.0	3	1	1	1
140011	1710	formation of a	[Formation of a]	0.0	3	1	1	1
140012	1710	gag p24	[gag p24]	0.0	2	1	1	1
140013	1710	salivary gland biopsy	[salivary gland biopsies]	0.0	3	1	1	1
140014	1710	IL-4 gene of kilobasis	[IL-4 gene of kilobases]	0.0	4	1	1	1
140015	1710	72-kDa major protein ie-1	[72-kDa major protein IE-1]	0.0	4	1	1	1
140016	1710	2-4 fold increase	[2-4 fold increase]	0.0	3	1	1	1
140017	1710	apoptosis in human monocyte potential role	[apoptosis in human monocytes potential role]	0.0	6	1	1	1
140018	1710	capacity 3.3	[capacity 3.3]	0.0	2	1	1	1
140019	1710	use in transplant medicine	[use in transplant medicine]	0.0	4	1	1	1
140020	1710	16-hour incubation microg/mL lps	[16-hour incubation microg/mL LPS]	0.0	4	1	1	1
140021	1710	sites/cell), kd value for dexamethasone	[sites/cell), Kd values for dexamethasone]	0.0	5	1	1	1
140022	1710	distinct mechanism	[distinct mechanism]	0.0	2	2	2	1
140023	1710	motifs, a	[motifs, A]	0.0	2	1	1	1
140024	1710	messenger cascade	[messenger cascade]	0.0	2	2	2	1
140025	1710	evidence for induction in T lymphocyte	[Evidence for induction in T lymphocytes]	0.0	6	1	1	1
140026	1710	major protein of 52	[major proteins of 52]	0.0	4	1	1	1
140027	1710	(p65)	[(p65)]	0.0	1	1	1	1
140028	1710	48-hr filarial antigen t-cell	[48-hr filarial antigen T-cells]	0.0	4	1	1	1
140029	1710	mixture with ifn-gamma up-regulation	[mixture with IFN-gamma up-regulation]	0.0	4	1	1	1
140030	1710	S-adenosylhomocysteine hydrolase inhibitor	[S-adenosylhomocysteine hydrolase inhibitor]	0.0	3	1	1	1
140031	1710	Bp65 Rel A	[Bp65 Rel A]	0.0	3	1	1	1
140032	1710	antibody (ic50	[antibody (IC50]	0.0	2	1	1	1
140033	1710	amount at the cell surface	[amount at the cell surface]	0.0	5	1	1	1
140034	1710	nuclear factor NF-AT AP-1/Octamer UPS	[nuclear factor NF-AT AP-1/Octamer UPS]	0.0	5	1	1	1
140035	1710	major subunit of NF-kappaB	[major subunits of NF-kappaB]	0.0	4	1	1	1
140036	1710	Sp1,	[Sp1,]	0.0	1	1	1	1
140037	1710	5-day human monocyte-derived macrophage	[5-day human monocyte-derived macrophages]	0.0	4	1	1	1
140038	1710	extent as lps	[extent as LPS]	0.0	3	1	1	1
140039	1710	mechanism for disease expression	[mechanism for disease expression]	0.0	4	1	1	1
140040	1710	factor IkappaBalpha	[factor IkappaBalpha]	0.0	2	1	1	1
140041	1710	Positive regulation of il-2 gene expression	[Positive regulation of IL-2 gene expression]	0.0	6	1	1	1
140042	1710	diffusible endothelial protein	[Diffusible endothelial proteins]	0.0	3	1	1	1
140043	1710	subsequent adhesion in cell	[subsequent adhesion in cells]	0.0	4	1	1	1
140044	1710	acidic region	[acidic region]	0.0	2	1	1	1
140045	1710	unrelated pathway	[unrelated pathways]	0.0	2	1	1	1
140046	1710	three-dimensional positioning	[three-dimensional positioning]	0.0	2	1	1	1
140047	1710	pathways: Lyn	[pathways: Lyn]	0.0	2	1	1	1
140048	1710	NF-kappa b enhancer	[NF-kappa B enhancer]	0.0	3	2	2	1
140049	1710	linkage to XIC/XIST	[linkage to XIC/XIST]	0.0	3	1	1	1
140050	1710	molecular-biologic aspect of interaction	[Molecular-biologic aspects of interaction]	0.0	4	1	1	1
140051	1710	hla-dq immune response	[HLA-DQ immune response]	0.0	3	1	1	1
140052	1710	phosphorylation of inhibitory subunit	[phosphorylation of inhibitory subunit]	0.0	4	1	1	1
140053	1710	er 10%,	[ER 10%,]	0.0	2	1	1	1
140054	1710	post-dose	[post-dosing]	0.0	1	1	1	1
140055	1710	cytokine by T cell	[cytokines by T cells]	0.0	4	1	1	1
140056	1710	cd8+ CTL response	[CD8+ CTL response]	0.0	3	1	1	1
140057	1710	setting of vascular pathology	[settings of vascular pathology]	0.0	4	1	1	1
140058	1710	control less	[controls less]	0.0	2	1	1	1
140059	1710	blue exclusion cell counting	[blue exclusion cell counting]	0.0	4	1	1	1
140060	1710	suggest the presence of regulatory element	[suggesting the presence of regulatory elements]	0.0	6	1	1	1
140061	1710	recessive pattern of inheritance	[recessive pattern of inheritance]	0.0	4	1	1	1
140062	1710	binding of October protein footprinting	[binding of Oct proteins footprinting]	0.0	5	1	1	1
140063	1710	correlation of lining layer depth	[correlation of lining layer depth]	0.0	5	1	1	1
140064	1710	decrease in the number	[decrease in the number]	0.0	4	1	1	1
140065	1710	probucol	[probucol]	0.0	1	1	1	1
140066	1710	spatial distribution of gene	[spatial distribution of genes]	0.0	4	1	1	1
140067	1710	cell have granule	[cells having granules]	0.0	3	1	1	1
140068	1710	mutation to Arg	[mutation to Arg]	0.0	3	1	1	1
140069	1710	responsive cis-acting element	[responsive cis-acting elements]	0.0	3	1	1	1
140070	1710	leukemia breakpoint	[leukemia breakpoint]	0.0	2	1	1	1
140071	1710	regulator of growth of cell	[regulators of growth of cells]	0.0	5	1	1	1
140072	1710	aggressive malignancy	[aggressive malignancy]	0.0	2	1	1	1
140073	1710	myeloid (aml) blast	[myeloid (AML) blasts]	0.0	3	1	1	1
140074	1710	retention of factor-kappaB	[retention of factor-kappaB]	0.0	3	1	1	1
140075	1710	form of selection antigen-driven expansion)	[forms of selection antigen-driven expansion)]	0.0	5	1	1	1
140076	1710	binding of a hsv-2 peptide	[binding of an HSV-2 peptide]	0.0	5	1	1	1
140077	1710	three, rare DNA variation 2418delA	[three, rare DNA variations 2418delA]	0.0	5	1	1	1
140078	1710	induction of transcriptional activity	[induction of transcriptional activity]	0.0	4	1	1	1
140079	1710	exon encode a protein	[exons encoding a protein]	0.0	4	1	1	1
140080	1710	high-level responsiveness	[high-level responsiveness]	0.0	2	1	1	1
140081	1710	STAT3 translocation	[STAT3 translocation]	0.0	2	1	1	1
140082	1710	adenocarcinoma human-mouse monoclonal antibody ing-1	[adenocarcinoma human-mouse monoclonal antibody ING-1]	0.0	5	1	1	1
140083	1710	loss of form 3	[loss of Form 3]	0.0	4	1	1	1
140084	1710	3 promoter	[3 promoter]	0.0	2	1	1	1
140085	1710	degradation of ikb alpha	[degradation of IkB alpha]	0.0	4	1	1	1
140086	1710	population of large, cell	[population of large, cells]	0.0	4	1	1	1
140087	1710	patient with ovarian carcinoma	[patients with ovarian carcinoma]	0.0	4	1	1	1
140088	1710	increase in CAT activity during expression	[Increases in CAT activity during expression]	0.0	6	1	1	1
140089	1710	regard the effect on expression	[regarding the effects on expression]	0.0	5	1	1	1
140090	1710	NH(2)-termini	[NH(2)-termini]	0.0	1	1	1	1
140091	1710	induction by factor	[Induction by factor]	0.0	3	1	1	1
140092	1710	presence of i(kappa)b(alpha)	[presence of I(kappa)B(alpha)]	0.0	3	1	1	1
140093	1710	activation structure	[activation structure]	0.0	2	1	1	1
140094	1710	activate protein-1 tpa element	[Activating protein-1 TPA elements]	0.0	4	1	1	1
140095	1710	exclusive expression	[exclusive expression]	0.0	2	1	1	1
140096	1710	contain the beta-casein stat5 element	[containing the beta-casein STAT5 element]	0.0	5	1	1	1
140097	1710	response to level	[response to levels]	0.0	3	1	1	1
140098	1710	cyclosporin a pathway	[cyclosporin A pathway]	0.0	3	1	1	1
140099	1710	describe the stochastic activation of gene	[describing the stochastic activation of genes]	0.0	6	1	1	1
140100	1710	1G5 cell line	[1G5 cell line]	0.0	3	1	1	1
140101	1710	binding to the result	[Binding to the results]	0.0	4	1	1	1
140102	1710	wide array of response	[wide array of responses]	0.0	4	1	1	1
140103	1710	response to concanavalin-a	[response to Concanavalin-A]	0.0	3	1	1	1
140104	1710	cotransfection (p50/p65)- expression vector	[Cotransfection (p50/p65)- expression vectors]	0.0	4	1	1	1
140105	1710	cell reaction mcr high grade	[cell reaction MCR high grade]	0.0	5	1	1	1
140106	1710	appropriate reporter gene triangle uplngfr	[appropriate reporter genes triangle upLNGFR]	0.0	5	1	1	1
140107	1710	t cell	[t cell]	0.0	2	1	1	1
140108	1710	sequence of the aminoenhancer	[sequence of the Aminoenhancer]	0.0	4	1	1	1
140109	1710	translocation partner	[translocation partner]	0.0	2	1	1	1
140110	1710	response in human	[responses in humans]	0.0	3	1	1	1
140111	1710	CD28 trigger	[CD28 trigger]	0.0	2	1	1	1
140112	1710	responsiveness of leukocyte HML	[responsiveness of leukocytes HML]	0.0	4	1	1	1
140113	1710	treatment with fp	[treatment with FP]	0.0	3	1	1	1
140114	1710	gamma activation site gas	[gamma activation site GAS]	0.0	4	1	1	1
140115	1710	xpb helicase defect	[XPB helicase defect]	0.0	3	1	1	1
140116	1710	105-kDa precursor polypeptide	[105-kDa precursor polypeptide]	0.0	3	1	1	1
140117	1710	most lytic cycle gene	[most lytic cycle genes]	0.0	4	1	1	1
140118	1710	flexi-12 delivery to leukemic blast	[Flexi-12 delivery to leukemic blasts]	0.0	5	1	1	1
140119	1710	agent with hepatoprotective activity	[agent with hepatoprotective activity]	0.0	4	1	1	1
140120	1710	kappa B NFkappaB	[kappa B NFkappaB]	0.0	3	1	1	1
140121	1710	little sequence similarity	[little sequence similarity]	0.0	3	1	1	1
140122	1710	activation in human blood monocyte	[Activation in human blood monocytes]	0.0	5	1	1	1
140123	1710	135(oh)2d3 binding	[1,25(OH)2D3 binding]	0.0	2	1	1	1
140124	1710	preassociation of stat1	[Preassociation of STAT1]	0.0	3	1	1	1
140125	1710	receptor binding in peripheral blood lymphocyte	[receptor binding in peripheral blood lymphocytes]	0.0	6	1	1	1
140126	1710	other ion of masses;	[other ions of masses;]	0.0	4	1	1	1
140127	1710	mutation cluster a encoding	[mutations clustering a encoding]	0.0	4	1	1	1
140128	1710	activity in fibroblast	[activity in fibroblasts]	0.0	3	1	1	1
140129	1710	nerve growth	[nerve growth]	0.0	2	1	1	1
140130	1710	three b-cell line	[three B-cell lines]	0.0	3	1	1	1
140131	1710	fraction of nwp cell	[fractions of NWP cells]	0.0	4	1	1	1
140132	1710	HLH factor Id3	[HLH factor Id3]	0.0	3	1	1	1
140133	1710	150 nucleotide	[150 nucleotides]	0.0	2	1	1	1
140134	1710	specificity of regulator in lymphocyte	[specificity of regulators in lymphocytes]	0.0	5	1	1	1
140135	1710	other effects, such as the activation	[other effects, such as the activation]	0.0	6	1	1	1
140136	1710	site specific mutation	[site specific mutation]	0.0	3	1	1	1
140137	1710	Control	[Control]	0.0	1	1	1	1
140138	1710	molecular regulation during the immune response	[Molecular regulation during the immune response]	0.0	6	1	1	1
140139	1710	effect on factor activation	[effect on factor activation]	0.0	4	1	1	1
140140	1710	two anti-onco-genic transcription factor	[two anti-onco-genic transcription factors]	0.0	4	1	1	1
140141	1710	suppression into the nucleus	[suppression into the nucleus]	0.0	4	1	1	1
140142	1710	subunit of mass	[subunits of mass]	0.0	3	1	1	1
140143	1710	il-2 DNA enhancer element	[IL-2 DNA enhancer elements]	0.0	4	1	1	1
140144	1710	activation of stat5a	[activation of STAT5A]	0.0	3	1	1	1
140145	1710	1% staining;	[1% staining;]	0.0	2	1	1	1
140146	1710	region (position responsive to eb1	[region (positions responsive to EB1]	0.0	5	1	1	1
140147	1710	prolonged exposure of aortic endothelial cell	[prolonged exposure of aortic endothelial cells]	0.0	6	1	1	1
140148	1710	release of nf-kappab	[release of NF-kappaB]	0.0	3	1	1	1
140149	1710	protein kinase signal cascade	[protein kinase signaling cascade]	0.0	4	1	1	1
140150	1710	sequence similar to the S-X-Y region	[sequences similar to the S-X-Y region]	0.0	6	1	1	1
140151	1710	bone density in many populations,	[bone density in many populations,]	0.0	5	1	1	1
140152	1710	independent role	[independent role]	0.0	2	1	1	1
140153	1710	often comprise a b-cell component	[often comprising a B-cell component]	0.0	5	1	1	1
140154	1710	uterine pregnancy for cd56.	[uterine pregnancy for CD56.]	0.0	4	1	1	1
140155	1710	rdna encode protein	[cDNAs encoding proteins]	0.0	3	1	1	1
140156	1710	specificity for MHC class gene	[specificity for MHC class genes]	0.0	5	1	1	1
140157	1710	synthesis by 135(oh)2d3	[synthesis by 1,25(OH)2D3]	0.0	3	1	1	1
140158	1710	activator, transcription	[activator, transcription]	0.0	2	1	1	1
140159	1710	tyrosine stat5b	[tyrosine STAT5B]	0.0	2	1	1	1
140160	1710	lack xist expression (xiste-),	[lacking XIST expression (XISTE-),]	0.0	4	1	1	1
140161	1710	conclusions: in patient	[CONCLUSIONS: In patients]	0.0	3	1	1	1
140162	1710	interaction with multiple molecular partners,	[interaction with multiple molecular partners,]	0.0	5	1	1	1
140163	1710	histogenetically distinct, subtype of hd	[histogenetically distinct, subtype of HD]	0.0	5	1	1	1
140164	1710	characteristic of blood mononuclear cell	[characteristics of blood mononuclear cells]	0.0	5	1	1	1
140165	1710	absence of lymphoid marker	[absence of lymphoid markers]	0.0	4	1	1	1
140166	1710	two inhibitor of MEK1 kinase upstream	[two inhibitors of MEK1 kinase upstream]	0.0	6	1	1	1
140167	1710	function of this site	[function of these sites]	0.0	4	1	1	1
140168	1710	rare heterozygous DNA variation in tumor	[rare heterozygous DNA variations in tumor]	0.0	6	1	1	1
140169	1710	G76 128-135	[G76 128-135]	0.0	2	1	1	1
140170	1710	subsequent isolation	[subsequent isolation]	0.0	2	1	1	1
140171	1710	binding to site	[binding to site]	0.0	3	1	1	1
140172	1710	lymphoid tissues,	[lymphoid tissues,]	0.0	2	1	1	1
140173	1710	affect the 5' guanine residue	[affecting the 5' guanine residues]	0.0	5	1	1	1
140174	1710	assembly of integrin-containing adhesion	[assembly of integrin-containing adhesions]	0.0	4	1	1	1
140175	1710	tissue breast	[tissues breast]	0.0	2	1	1	1
140176	1710	undergo termination of uterine pregnancy	[undergoing termination of uterine pregnancy]	0.0	5	1	1	1
140177	1710	acute leukemia of childhood.	[acute leukemia of childhood.]	0.0	4	1	1	1
140178	1710	modulation of corticosensitivity	[modulation of corticosensitivity]	0.0	3	1	1	1
140179	1710	suggest cross-talk between the partner	[suggesting cross-talk between the partners]	0.0	5	1	1	1
140180	1710	control E2F activity	[controlling E2F activity]	0.0	3	1	1	1
140181	1710	biology study on eosinophil	[biology study on eosinophils]	0.0	4	1	1	1
140182	1710	abnormality highlight cancer related loci	[abnormalities highlighting cancer related loci]	0.0	5	1	1	1
140183	1710	certain NF-kappaB/Rel member	[certain NF-kappaB/Rel members]	0.0	3	1	1	1
140184	1710	CAM vcam-1	[CAMs VCAM-1]	0.0	2	1	1	1
140185	1710	potential role of PGE2	[potential role of PGE2]	0.0	4	1	1	1
140186	1710	NF-kappaB function	[NF-kappaB functions]	0.0	2	1	1	1
140187	1710	lack la(ssb) precipitin	[lacking La(SSB) precipitins]	0.0	3	1	1	1
140188	1710	previous study in monocyte	[previous studies in monocytes]	0.0	4	1	1	1
140189	1710	sle of polyomavirus t-antigen	[SLE of polyomavirus T-antigen]	0.0	4	1	1	1
140190	1710	corresponding to protein of molecular weight	[corresponding to proteins of molecular weights]	0.0	6	1	1	1
140191	1710	Additionally, preincubation of HUVEC	[Additionally, preincubation of HUVEC]	0.0	4	1	1	1
140192	1710	schedule of oral calcitriol	[schedules of oral calcitriol]	0.0	4	1	1	1
140193	1710	use the pkc inhibitor ro 31-8425	[using the PKC inhibitor Ro 31-8425]	0.0	6	1	1	1
140194	1710	c-Jun expression	[c-Jun expression]	0.0	2	1	1	1
140195	1710	ige (p 0.01).	[IgE (p 0.01).]	0.0	3	1	1	1
140196	1710	probably due in part to difference	[probably due in part to differences]	0.0	6	1	1	1
140197	1710	male infant	[male infants]	0.0	2	1	1	1
140198	1710	leukemia APL the variant	[leukemia APL the variant]	0.0	4	1	1	1
140199	1710	first outpatient visit, within week	[first outpatient visit, within weeks]	0.0	5	1	1	1
140200	1710	erythroblast from adult bone marrow	[erythroblasts from adult bone marrow]	0.0	5	1	1	1
140201	1710	case of Burkitt' lymphoma	[cases of Burkitt's lymphoma]	0.0	4	1	1	1
140202	1710	atra chemotherapy	[ATRA chemotherapy]	0.0	2	1	1	1
140203	1710	thymus lobe	[thymus lobes]	0.0	2	1	1	1
140204	1710	employ extract from B	[employing extracts from B]	0.0	4	1	1	1
140205	1710	regulation of inflammatory cytokine gene	[regulation of inflammatory cytokine genes]	0.0	5	1	1	1
140206	1710	binding of natural ligand	[binding of natural ligands]	0.0	4	1	1	1
140207	1710	subunit of NF-E2	[subunit of NF-E2]	0.0	3	1	1	1
140208	1710	only affinity	[only affinity]	0.0	2	1	1	1
140209	1710	activation of event	[activation of events]	0.0	3	1	1	1
140210	1710	mouse homologue of baf170	[mouse homologue of BAF170]	0.0	4	1	1	1
140211	1710	little effect on the b29 promoter	[little effect on the B29 promoter]	0.0	6	1	1	1
140212	1710	ebv-	[EBV-]	0.0	1	1	1	1
140213	1710	'default'	['default']	0.0	1	1	1	1
140214	1710	cover 10% of the tbp7 sequence	[covering 10% of the TBP7 sequence]	0.0	6	1	1	1
140215	1710	Ciprofibrate	[Ciprofibrate]	0.0	1	1	1	1
140216	1710	apoptosis in T cell hybridoma	[apoptosis in T cell hybridomas]	0.0	5	1	1	1
140217	1710	action of cytokine	[actions of cytokines]	0.0	3	1	1	1
140218	1710	(for class	[(for class]	0.0	2	1	1	1
140219	1710	particular pathway,	[particular pathway,]	0.0	2	1	1	1
140220	1710	serine/threonine phosphatase necessary	[serine/threonine phosphatase necessary]	0.0	3	1	1	1
140221	1710	transformation through tail	[transformation through tail]	0.0	3	1	1	1
140222	1710	express endogeneous tal1	[expressing endogeneous TAL1]	0.0	3	1	1	1
140223	1710	structurally distinct immunophilin-drug complex	[structurally distinct immunophilin-drug complexes]	0.0	4	1	1	1
140224	1710	membrane-proximal sequence motif	[membrane-proximal sequence motif]	0.0	3	1	1	1
140225	1710	differentiation of pluripotent progenitor to cell	[differentiation of pluripotent progenitors to cells]	0.0	6	1	1	1
140226	1710	acid on hiv-1 expression	[acids on HIV-1 expression]	0.0	4	1	1	1
140227	1710	stat to GRR	[STATs to GRR]	0.0	3	1	1	1
140228	1710	10 epitope	[10 epitopes]	0.0	2	1	1	1
140229	1710	related oligonucleotide	[related oligonucleotides]	0.0	2	1	1	1
140230	1710	inhibition of activation of NF-kappaB	[inhibition of activation of NF-kappaB]	0.0	5	1	1	1
140231	1710	bind the interferon-inducible element	[binding the interferon-inducible element]	0.0	4	1	1	1
140232	1710	Representative estrogenic compound	[Representative estrogenic compounds]	0.0	3	1	1	1
140233	1710	mcp-1 expression by aspirin	[MCP-1 expression by aspirin]	0.0	4	1	1	1
140234	1710	mrna encoding c-fo	[mRNA encoding c-Fos]	0.0	3	1	1	1
140235	1710	immune response to antigens.	[immune responses to antigens.]	0.0	4	1	1	1
140236	1710	cloning of the receptor	[Cloning of the receptor]	0.0	4	1	1	1
140237	1710	aldosterone antagonist nmol/l).	[aldosterone antagonist nmol/l).]	0.0	3	1	1	1
140238	1710	Glucocorticoid receptor change in patient	[Glucocorticoid receptors changes in patients]	0.0	5	1	1	1
140239	1710	normal cell mimick cell growth	[normal cells mimicking cell growth]	0.0	5	1	1	1
140240	1710	receptor of blood leukocyte	[receptors of blood leukocytes]	0.0	4	1	1	1
140241	1710	most important trans-acting factor	[most important trans-acting factors]	0.0	4	1	1	1
140242	1710	converge in pathway	[converging in pathways]	0.0	3	1	1	1
140243	1710	GATA3 transcription unit	[GATA3 transcription unit]	0.0	3	2	2	1
140244	1710	b inducer	[B inducer]	0.0	2	2	2	1
140245	1710	human progesterone receptor cDNA probe	[human progesterone receptor cDNA probe]	0.0	5	1	1	1
140246	1710	Erythroid kruppel-like factor	[Erythroid Kruppel-like factor]	0.0	3	2	2	1
140247	1710	clone 13 nuclear extract	[clone 13 nuclear extracts]	0.0	4	1	1	1
140248	1710	role of aml1/eto	[role of AML1/ETO]	0.0	3	1	1	1
140249	1710	persistence of tgf-beta1-transcribing macrophage	[persistence of TGF-beta1-transcribing macrophages]	0.0	4	1	1	1
140250	1710	pattern of tyrosine phosphorylation	[pattern of tyrosine phosphorylation]	0.0	4	1	1	1
140251	1710	IL-4 binding site	[IL-4 binding sites]	0.0	3	1	1	1
140252	1710	human sterol regulatory element SRE	[human sterol regulatory element SRE]	0.0	5	1	1	1
140253	1710	apoptosis by curcumin	[apoptosis by curcumin]	0.0	3	1	1	1
140254	1710	Immunochemical staining	[Immunochemical staining]	0.0	2	1	1	1
140255	1710	one type-specific clone	[one type-specific clone]	0.0	3	1	1	1
140256	1710	(mhc) class ii molecule	[(MHC) class II molecules]	0.0	4	1	1	1
140257	1710	lipopolysaccharide activation system	[lipopolysaccharide activation system]	0.0	3	1	1	1
140258	1710	behavior of stat pathway	[behavior of STAT pathways]	0.0	4	1	1	1
140259	1710	role of regulatory element	[role of regulatory elements]	0.0	4	1	1	1
140260	1710	effector gene product similar	[effector gene products similar]	0.0	4	1	1	1
140261	1710	CTCF a c-myc regulator,	[CTCF a c-myc regulator,]	0.0	4	1	1	1
140262	1710	[h-2b]	[[H-2b]]	0.0	1	1	1	1
140263	1710	possibility of inactivation of material	[possibility of inactivation of material]	0.0	5	1	1	1
140264	1710	protein kda	[proteins kDa]	0.0	2	1	1	1
140265	1710	interact basic protein	[interacting basic proteins]	0.0	3	1	1	1
140266	1710	response toward immunity	[response toward immunity]	0.0	3	1	1	1
140267	1710	two mechanisms.	[two mechanisms.]	0.0	2	1	1	1
140268	1710	tandem cysteine -rich LIM domain	[tandem cysteine -rich LIM domains]	0.0	5	1	1	1
140269	1710	active metabolite 1,25 dihydroxyvitamin d3,	[active metabolite 1,25 dihydroxyvitamin D3,]	0.0	5	1	1	1
140270	1710	early region e1a	[early regions E1A]	0.0	3	1	1	1
140271	1710	abnormal glucocorticoid receptor	[abnormal glucocorticoid receptors]	0.0	3	1	1	1
140272	1710	amino-terminal region of CBP	[amino-terminal region of CBP]	0.0	4	1	1	1
140273	1710	alpha1 germ-line	[alpha1 germ-line]	0.0	2	1	1	1
140274	1710	major role for GATA-1	[major role for GATA-1]	0.0	4	1	1	1
140275	1710	include tumorigenesis.	[including tumorigenesis.]	0.0	2	1	1	1
140276	1710	Rh(D)	[Rh(D)]	0.0	1	1	1	1
140277	1710	augment promoter activity	[augmenting promoter activity]	0.0	3	1	1	1
140278	1710	certain mnda cell between level	[certain MNDA cells between levels]	0.0	5	1	1	1
140279	1710	hydrocortisone (F) of physiological concentration	[hydrocortisone (F) of physiological concentration]	0.0	5	1	1	1
140280	1710	cell a major cellular component	[cells a major cellular component]	0.0	5	1	1	1
140281	1710	135eoh)2d3 receptor similar	[1,25(OH)2D3 receptor similar]	0.0	3	1	1	1
140282	1710	lack xist expression with severe phenotypes.	[lacking XIST expression with severe phenotypes.]	0.0	6	1	1	1
140283	1710	cell line lack antigenic er peptide	[cell lines lacking antigenic ER peptides]	0.0	6	1	1	1
140284	1710	function of tax in cell	[function of Tax in cells]	0.0	5	1	1	1
140285	1710	kd versus 19.2+/-2.4 nmol/L) nmol/L)	[Kd versus 19.2+/-2.4 nmol/L) nmol/L)]	0.0	5	1	1	1
140286	1710	cell-type specific expression of genes.	[cell-type specific expression of genes.]	0.0	5	1	1	1
140287	1710	monocyte/macrophage-specific stimulator	[monocyte/macrophage-specific stimulator]	0.0	2	1	1	1
140288	1710	form of resistance to glucocorticoid	[form of resistance to glucocorticoids]	0.0	5	1	1	1
140289	1710	monocyte in each case correlate	[monocytes in each case correlating]	0.0	5	1	1	1
140290	1710	opioid receptor by T lymphocyte	[opioid receptors by T lymphocytes]	0.0	5	1	1	1
140291	1710	use the subunit	[using the subunit]	0.0	3	1	1	1
140292	1710	corticosteroid fp	[corticosteroid FP]	0.0	2	1	1	1
140293	1710	disposition of sulphamethoxazole	[disposition of sulphamethoxazole]	0.0	3	1	1	1
140294	1710	resistance to tumor necrosis factor apoptosis	[Resistance to tumor necrosis factor apoptosis]	0.0	6	1	1	1
140295	1710	phorbol ester-inducible transcription factor ap1	[phorbol ester-inducible transcription factor AP1]	0.0	5	1	1	1
140296	1710	crucial element important	[crucial element important]	0.0	3	1	1	1
140297	1710	dysregulation of c-myc	[dysregulation of c-myc]	0.0	3	1	1	1
140298	1710	variable response	[variable response]	0.0	2	1	1	1
140299	1710	(Ca2+)i requirement	[(Ca2+)i requirement]	0.0	2	1	1	1
140300	1710	correlation with the percentage	[correlation with the percentage]	0.0	4	1	1	1
140301	1710	glucocorticoid hormone gch	[glucocorticoid hormones GCH]	0.0	3	1	1	1
140302	1710	contain the hmg box	[containing the HMG box]	0.0	4	1	1	1
140303	1710	cell molecule	[cell molecules]	0.0	2	1	1	1
140304	1710	+/- nM; mean	[+/- nM; mean]	0.0	3	1	1	1
140305	1710	two other member	[Two other members]	0.0	3	1	1	1
140306	1710	process similar	[processes similar]	0.0	2	1	1	1
140307	1710	Chemical cross-linking tgf-beta	[Chemical cross-linking TGF-beta]	0.0	3	1	1	1
140308	1710	B-cell growth factor	[B-cell growth factor]	0.0	3	1	1	1
140309	1710	IL-2 regulator c-fo	[IL-2 regulators c-fos]	0.0	3	1	1	1
140310	1710	general agreement a accumulation	[general agreement an accumulation]	0.0	4	1	1	1
140311	1710	encode the granulocyte- factor	[encoding the granulocyte- factor]	0.0	4	1	1	1
140312	1710	increase within h	[increase within h]	0.0	3	1	1	1
140313	1710	activation of ifn-alpha-stimulated gene	[activation of IFN-alpha-stimulated genes]	0.0	4	1	1	1
140314	1710	differanisole a in combination	[Differanisole A in combination]	0.0	4	1	1	1
140315	1710	progenitor cell,	[progenitor cell,]	0.0	2	1	1	1
140316	1710	sex-and age-matched healthy subject	[sex-and age-matched healthy subjects]	0.0	4	1	1	1
140317	1710	activator of htlv-i gene expression	[activator of HTLV-I gene expression]	0.0	5	1	1	1
140318	1710	represent amino acid sequence	[representing amino acid sequences]	0.0	4	1	1	1
140319	1710	completely promoter	[completely promoter]	0.0	2	1	1	1
140320	1710	requirement for activation by BSAP	[requirements for activation by BSAP]	0.0	5	1	1	1
140321	1710	activator of the factor gene	[activator of the factor gene]	0.0	5	1	1	1
140322	1710	fasL reporter construct	[fasL reporter constructs]	0.0	3	1	1	1
140323	1710	case of hiv-1	[case of HIV-1]	0.0	3	1	1	1
140324	1710	peroxisomal receptor gamma expression	[peroxisomal receptor gamma expression]	0.0	4	1	1	1
140325	1710	antigen processing by cell	[antigen processing by cells]	0.0	4	1	1	1
140326	1710	modest nuclear translocation	[modest nuclear translocation]	0.0	3	1	1	1
140327	1710	interrelationship between the messenger	[interrelationship between the messengers]	0.0	4	1	1	1
140328	1710	deficit	[deficit]	0.0	1	1	1	1
140329	1710	A20 b	[A20 B]	0.0	2	1	1	1
140330	1710	effect on transmembrane electrolyte movement	[effects on transmembrane electrolyte movements]	0.0	5	2	2	1
140331	1710	alteration responsible for the deficient response	[alterations responsible for the deficient response]	0.0	6	1	1	1
140332	1710	certain early response gene	[certain early response genes]	0.0	4	1	1	1
140333	1710	vitro migration	[vitro migration]	0.0	2	1	1	1
140334	1710	modulation of nf-kappab by adenoviral transfer	[modulation of NF-kappaB by adenoviral transfer]	0.0	6	1	1	1
140335	1710	proinflammatory regulator	[proinflammatory regulators]	0.0	2	1	1	1
140336	1710	tcrzeta level (p 0.001)	[TCRzeta levels (P 0.001)]	0.0	4	1	1	1
140337	1710	level of il-5	[levels of IL-5]	0.0	3	1	1	1
140338	1710	y731eam	[Y731EAM]	0.0	1	1	1	1
140339	1710	B-alpha( mad-3	[B-alpha( MAD-3]	0.0	2	1	1	1
140340	1710	nonpeptidyl molecule sb capable	[nonpeptidyl molecule SB capable]	0.0	4	1	1	1
140341	1710	xy sex reversal sra1	[XY sex reversal SRA1]	0.0	4	1	1	1
140342	1710	vcam-1 promoter construct	[VCAM-1 promoter constructs]	0.0	3	1	1	1
140343	1710	octamer family	[octamer families]	0.0	2	1	1	1
140344	1710	regulatory domain (prd) binding protein	[regulatory domain (PRD) binding proteins]	0.0	5	1	1	1
140345	1710	moreover, antisense oligodeoxynucleotides	[Moreover, antisense oligodeoxynucleotides]	0.0	3	1	1	1
140346	1710	acute distress syndrome	[acute distress syndrome]	0.0	3	1	1	1
140347	1710	number in the asthmatics	[number in the asthmatics]	0.0	4	1	1	1
140348	1710	peripheral mononuclear cell of patient	[peripheral mononuclear cells of patients]	0.0	5	1	1	1
140349	1710	y731eac	[Y731EAC]	0.0	1	1	1	1
140350	1710	extract of U937 cell	[extracts of U937 cells]	0.0	4	1	1	1
140351	1710	immune response gene	[immune response genes]	0.0	3	1	1	1
140352	1710	limiting-component	[limiting-component]	0.0	1	1	1	1
140353	1710	inhibitor of NF-kappaB	[inhibitor of NF-kappaB]	0.0	3	1	1	1
140354	1710	G1-to- phase	[G1-to-S phase]	0.0	2	1	1	1
140355	1710	immune effect of RA	[immune effects of RA]	0.0	4	1	1	1
140356	1710	only in response	[only in response]	0.0	3	1	1	1
140357	1710	consecutive cardiac transplant recipient	[consecutive cardiac transplant recipients]	0.0	4	1	1	1
140358	1710	selection in response during primary infection.	[Selection in response during primary infection.]	0.0	6	1	1	1
140359	1710	sv40 t-antigen in mouse	[SV40 T-antigen in mice]	0.0	4	1	1	1
140360	1710	nfat -1 element	[NFAT -1 element]	0.0	3	1	1	1
140361	1710	myristake acetate-A23187 stimulation	[myristake acetate-A23187 stimulation]	0.0	3	1	1	1
140362	1710	tax -protein	[Tax -protein]	0.0	2	1	1	1
140363	1710	STAT3 antibody	[STAT3 antibodies]	0.0	2	1	1	1
140364	1710	reduction of up to 65%	[reduction of up to 65%]	0.0	5	1	1	1
140365	1710	shear-induced activation	[shear-induced activation]	0.0	2	2	2	1
140366	1710	prickle cell	[prickle cells]	0.0	2	1	1	1
140367	1710	define	[defining]	0.0	1	1	1	1
140368	1710	superfamily of cytokine	[superfamily of cytokines]	0.0	3	1	1	1
140369	1710	potent cellular activator	[potent cellular activator]	0.0	3	1	1	1
140370	1710	requirement in erythroid development	[requirement in erythroid development]	0.0	4	1	1	1
140371	1710	bhlh transcription	[bHLH transcription]	0.0	2	1	1	1
140372	1710	combination of a inhibitor	[combination of a inhibitor]	0.0	4	1	1	1
140373	1710	use specific probe for chromosome	[using specific probes for chromosomes]	0.0	5	1	1	1
140374	1710	murine basic transcription factor gene	[murine basic transcription factor gene]	0.0	5	1	1	1
140375	1710	nucleotide sequence responsible	[nucleotide sequences responsible]	0.0	3	1	1	1
140376	1710	utilize CD40	[utilizing CD40]	0.0	2	1	1	1
140377	1710	cell-based assay	[cell-based assay]	0.0	2	1	1	1
140378	1710	primary immune response	[primary immune responses]	0.0	3	1	1	1
140379	1710	IL-1 synthesis	[IL-1 synthesis]	0.0	2	1	1	1
140380	1710	nfatc protein in extract	[NFATc protein in extracts]	0.0	4	1	1	1
140381	1710	specific aldosterone binding	[specific aldosterone binding]	0.0	3	1	1	1
140382	1710	factor-kappaB translocation in lipopolysaccharide monocyte	[factor-kappaB translocation in lipopolysaccharide monocytes]	0.0	5	1	1	1
140383	1710	tnf-alpha in alveolar rat	[TNF-alpha in alveolar rats]	0.0	4	1	1	1
140384	1710	interleukin-5 stimulation	[interleukin-5 stimulation]	0.0	2	1	1	1
140385	1710	b-cell-specific transcription factor BSAP	[B-cell-specific transcription factor BSAP]	0.0	4	1	1	1
140386	1710	residue 122	[residues 122]	0.0	2	1	1	1
140387	1710	vitamin d receptor content	[vitamin D receptor content]	0.0	4	1	1	1
140388	1710	binding to receptors.	[binding to receptors.]	0.0	3	1	1	1
140389	1710	mechanism in infarction	[mechanism in infarction]	0.0	3	1	1	1
140390	1710	assembly transcription factor complex	[assembly transcription factor complex]	0.0	4	1	1	1
140391	1710	control element of the virus,	[control elements of the virus,]	0.0	5	1	1	1
140392	1710	diabete of the young	[diabetes of the young]	0.0	4	1	1	1
140393	1710	distinct early regulator	[distinct early regulators]	0.0	3	1	1	1
140394	1710	long repeat of immunodeficiency virus	[long repeat of immunodeficiency virus]	0.0	5	1	1	1
140395	1710	aneusomy	[aneusomy]	0.0	1	1	1	1
140396	1710	functional NK cytotoxicity	[functional NK cytotoxicity]	0.0	3	1	1	1
140397	1710	complex with cyclic AMP response	[complexes with cyclic AMP response]	0.0	5	1	1	1
140398	1710	analysis with cd8+ T cell	[analysis with CD8+ T cells]	0.0	5	1	1	1
140399	1710	b-cell response in follicle	[B-cell response in follicles]	0.0	4	1	1	1
140400	1710	important molecule in the activation	[important molecule in the activation]	0.0	5	1	1	1
140401	1710	resemble factor of T cell	[resembling factor of T cells]	0.0	5	1	1	1
140402	1710	Essential role	[Essential role]	0.0	2	1	1	1
140403	1710	magnetic bead	[magnetic beads]	0.0	2	1	1	1
140404	1710	far-Western blot assay	[far-Western blot assays]	0.0	3	1	1	1
140405	1710	High concentration	[Higher concentrations]	0.0	2	1	1	1
140406	1710	CD3 expression	[CD3 expression]	0.0	2	1	1	1
140407	1710	t-cell immortalization mechanism	[T-cell immortalization mechanism]	0.0	3	1	1	1
140408	1710	little effect on the property	[little effect on the property]	0.0	5	1	1	1
140409	1710	4 cases, include 3 aml	[4 cases, including 3 AML]	0.0	5	1	1	1
140410	1710	expression of the class ii isotype	[expression of the class II isotypes]	0.0	6	1	1	1
140411	1710	density lipoprotein inflammatory response	[density lipoprotein inflammatory responses]	0.0	4	1	1	1
140412	1710	use a ikappabalpha	[using a IkappaBalpha]	0.0	3	1	1	1
140413	1710	gel electrophoresis (pfge) analysis	[gel electrophoresis (PFGE) analysis]	0.0	4	1	1	1
140414	1710	ovulation marker	[ovulation markers]	0.0	2	1	1	1
140415	1710	glucocorticoid receptor in blood monocyte	[glucocorticoid receptor in blood monocytes]	0.0	5	1	1	1
140416	1710	polyclonal activation of b cell	[polyclonal activation of B cells]	0.0	5	1	1	1
140417	1710	follow ligand engagement cell-to-cell	[following ligand engagement cell-to-cell]	0.0	4	1	1	1
140418	1710	interphase nuclei of cell types.	[interphase nuclei of cell types.]	0.0	5	1	1	1
140419	1710	even level expression	[even level expression]	0.0	3	1	1	1
140420	1710	allele-specific system of WT1	[allele-specific system of WT1]	0.0	4	1	1	1
140421	1710	simian virus 40 enhancer activity	[simian virus 40 enhancer activity]	0.0	5	1	1	1
140422	1710	difference in the regulation	[differences in the regulation]	0.0	4	1	1	1
140423	1710	type of La mrna	[type of La mRNA]	0.0	4	1	1	1
140424	1710	pif DNA	[PIF DNA]	0.0	2	1	1	1
140425	1710	arginine mutation	[arginine mutations]	0.0	2	1	1	1
140426	1710	dp2 bp of the promoter	[DP2 bp of the promoter]	0.0	5	1	1	1
140427	1710	loci for rearrangement	[loci for rearrangement]	0.0	3	1	1	1
140428	1710	failure A-CRF with insufficiency M-CRF	[failure A-CRF with insufficiency M-CRF]	0.0	5	1	1	1
140429	1710	little alteration in affinity	[little alteration in affinity]	0.0	4	1	1	1
140430	1710	link abnormal behavior	[linking abnormal behavior]	0.0	3	1	1	1
140431	1710	member of the same family,	[members of the same family,]	0.0	5	1	1	1
140432	1710	suppressive effect in comparison	[suppressive effect in comparison]	0.0	4	1	1	1
140433	1710	regulation gene	[regulation genes]	0.0	2	1	1	1
140434	1710	effusion from patient with breast cancer	[effusions from patients with breast cancer]	0.0	6	1	1	1
140435	1710	samples, cytotoxic activity	[samples, cytotoxic activity]	0.0	3	1	1	1
140436	1710	translocation nuclear factor of T cell	[translocation nuclear factor of T cells]	0.0	6	1	1	1
140437	1710	(q27;q32)	[(q27;q32)]	0.0	1	1	1	1
140438	1710	nf-y expression	[NF-Y expression]	0.0	2	1	1	1
140439	1710	nuclear signal	[nuclear signal]	0.0	2	1	1	1
140440	1710	signal for optimal induction,	[signals for optimal induction,]	0.0	4	1	1	1
140441	1710	several marker of prognosis,	[several markers of prognosis,]	0.0	4	1	1	1
140442	1710	patient with t-cell lymphoma/leukemia	[patients with T-cell lymphoma/leukemia]	0.0	4	1	1	1
140443	1710	putative gtp motif	[putative GTP motif]	0.0	3	1	1	1
140444	1710	il-4- factor	[IL-4- factors]	0.0	2	1	1	1
140445	1710	nuclear factor proximal NF-AT	[nuclear factor proximal NF-AT]	0.0	4	1	1	1
140446	1710	[correlation with the state in patient	[[Correlation with the state in patients]	0.0	6	1	1	1
140447	1710	osteoclast-like cell	[osteoclast-like cells]	0.0	2	1	1	1
140448	1710	four binding site	[four binding sites]	0.0	3	1	1	1
140449	1710	role in culture of T lymphocyte	[role in cultures of T lymphocytes]	0.0	6	1	1	1
140450	1710	CLEO -54	[CLEO -54]	0.0	2	1	1	1
140451	1710	patient with hie	[patients with HIE]	0.0	3	1	1	1
140452	1710	patient with renal carcinoma	[patients with renal carcinoma]	0.0	4	1	1	1
140453	1710	basis of specific activity	[basis of specific activity]	0.0	4	1	1	1
140454	1710	2 to 4 h	[2 to 4 h]	0.0	4	1	1	1
140455	1710	acute leukemia with feature	[Acute leukemia with features]	0.0	4	1	1	1
140456	1710	collagenase mmp-1 a metalloproteinase	[collagenase MMP-1 a metalloproteinase]	0.0	4	1	1	1
140457	1710	numerous abnormality	[Numerous abnormalities]	0.0	2	1	1	1
140458	1710	include cyclophilin	[including cyclophilin]	0.0	2	1	1	1
140459	1710	competitive immunosorbent assay ELISA	[competitive immunosorbent assay ELISA]	0.0	4	1	1	1
140460	1710	peripheral blood leukocyte from human	[peripheral blood leukocytes from humans]	0.0	5	1	1	1
140461	1710	T cell-specific inducibility	[T cell-specific inducibility]	0.0	3	1	1	1
140462	1710	microm pdtc	[microM PDTC]	0.0	2	1	1	1
140463	1710	adhesive molecule	[adhesive molecules]	0.0	2	1	1	1
140464	1710	pbmc response	[PBMC responses]	0.0	2	1	1	1
140465	1710	72-kilodalton protein	[72-kilodalton protein]	0.0	2	1	1	1
140466	1710	peripheral blood healthy volunteer	[peripheral blood healthy volunteers]	0.0	4	1	1	1
140467	1710	phosphorylate	[phosphorylates]	0.0	1	1	1	1
140468	1710	presence of a inhibitory pathway	[presence of a inhibitory pathway]	0.0	5	1	1	1
140469	1710	optimal induction,	[optimal induction,]	0.0	2	1	1	1
140470	1710	cyclooxygenase/5-lipoxygenase anti-inflammatory compound under investigation.	[cyclooxygenase/5-lipoxygenase anti-inflammatory compound under investigation.]	0.0	5	1	1	1
140471	1710	(37.8 patient	[(37.8 patients]	0.0	2	1	1	1
140472	1710	region in the domain of il-9ralpha	[regions in the domain of IL-9Ralpha]	0.0	6	1	1	1
140473	1710	50% inhibition of transendothelial migration	[50% inhibition of transendothelial migration]	0.0	5	1	1	1
140474	1710	activation by deletion of CIITA	[activation by deletions of CIITA]	0.0	5	1	1	1
140475	1710	interleukin-3 gene	[interleukin-3 gene]	0.0	2	1	1	1
140476	1710	breakpoint in CMPD1 translocation case	[breakpoints in CMPD1 translocation cases]	0.0	5	1	1	1
140477	1710	factor in rest PBL	[factors in resting PBL]	0.0	4	1	1	1
140478	1710	function of PPARalpha	[function of PPARalpha]	0.0	3	1	1	1
140479	1710	c-sis/pdgb promoter element	[c-sis/PDGF-B promoter element]	0.0	3	1	1	1
140480	1710	(mnl) of 10 patient	[(MNL) of 10 patients]	0.0	4	1	1	1
140481	1710	pfu/animal,	[pfu/animal,]	0.0	1	1	1	1
140482	1710	genomic action of D3	[genomic actions of D3]	0.0	4	1	1	1
140483	1710	tonically suppress system	[tonically suppressing system]	0.0	3	1	1	1
140484	1710	CD3 complex	[CD3 complex]	0.0	2	1	1	1
140485	1710	class of dex clone	[classes of dex clones]	0.0	4	1	1	1
140486	1710	affect erk1	[affecting ERK1]	0.0	2	1	1	1
140487	1710	mobility shift assay and/or	[mobility shift assays and/or]	0.0	4	1	1	1
140488	1710	replicative form DNA	[replicative form DNA]	0.0	3	1	1	1
140489	1710	hGR cDNA	[hGR cDNA]	0.0	2	1	1	1
140490	1710	biological function among herpesviral protein	[biological function among herpesviral proteins]	0.0	5	1	1	1
140491	1710	isoform of STAT5	[isoforms of STAT5]	0.0	3	1	1	1
140492	1710	abrogation of the activation	[abrogation of the activation]	0.0	4	1	1	1
140493	1710	three exon	[three exons]	0.0	2	1	1	1
140494	1710	interaction(s)	[interaction(s)]	0.0	1	1	1	1
140495	1710	ldl lipid	[LDL lipids]	0.0	2	1	1	1
140496	1710	specific protein myeloperoxidase mpo	[specific proteins myeloperoxidase MPO]	0.0	4	1	1	1
140497	1710	binding power with [3H] dex	[binding power with [3H] Dex]	0.0	5	1	1	1
140498	1710	induction antibody	[Induction antibodies]	0.0	2	1	1	1
140499	1710	blood mononuclear cell of adult upon	[blood mononuclear cells of adults upon]	0.0	6	1	1	1
140500	1710	sensitivity for induction	[Sensitivity for induction]	0.0	3	1	1	1
140501	1710	inactive allele	[inactive alleles]	0.0	2	1	1	1
140502	1710	distal nuclear factor	[distal nuclear factor]	0.0	3	1	1	1
140503	1710	ets in vitro	[Ets in vitro]	0.0	3	1	1	1
140504	1710	regulatory mechanism for persistent cytokine	[regulatory mechanism for persistent cytokine]	0.0	5	1	1	1
140505	1710	phosphorylation of a serine residue Ser5	[phosphorylation of a serine residue Ser5]	0.0	6	1	1	1
140506	1710	provide further evidence	[providing further evidence]	0.0	3	1	1	1
140507	1710	potent mitogen for muscle cell	[potent mitogen for muscle cells]	0.0	5	1	1	1
140508	1710	permissivity to virus replication	[permissivity to virus replication]	0.0	4	1	1	1
140509	1710	16HBE human bronchial cell	[16HBE human bronchial cells]	0.0	4	1	1	1
140510	1710	a protein a region	[A protein a region]	0.0	4	1	1	1
140511	1710	child with fatal adenoviral infection	[children with fatal adenoviral infection]	0.0	5	2	2	1
140512	1710	BL cell contain level	[BL cells containing levels]	0.0	4	1	1	1
140513	1710	TRE1	[TRE1]	0.0	1	1	1	1
140514	1710	addition of iron	[addition of iron]	0.0	3	1	1	1
140515	1710	45-nucleotide sequence DRE	[45-nucleotide sequence DRE]	0.0	3	1	1	1
140516	1710	knowledge of the radiation-induced signal cascade	[knowledge of the radiation-induced signaling cascade]	0.0	6	1	1	1
140517	1710	pathogenesis of leukemia CLL	[pathogenesis of leukemia CLL]	0.0	4	1	1	1
140518	1710	Kruppel-like factor eklf activity	[Kruppel-like factor EKLF activity]	0.0	4	1	1	1
140519	1710	contrast, stimulation of calcium influx	[contrast, stimulation of calcium influx]	0.0	5	1	1	1
140520	1710	source of xenoreactive antibody	[source of xenoreactive antibodies]	0.0	4	1	1	1
140521	1710	clinical progression	[clinical progression]	0.0	2	1	1	1
140522	1710	t-helper-cell epitope	[T-helper-cell epitopes]	0.0	2	1	1	1
140523	1710	substitution in the human counterpart	[substitutions in the human counterpart]	0.0	5	1	1	1
140524	1710	HLA class ii fashion	[HLA class II fashion]	0.0	4	1	1	1
140525	1710	analysis of human immunodeficiency virus	[analysis of human immunodeficiency virus]	0.0	5	1	1	1
140526	1710	important mediator in disease	[important mediators in diseases]	0.0	4	1	1	1
140527	1710	lymphocyte-specific dna-binding protein	[lymphocyte-specific DNA-binding proteins]	0.0	3	1	1	1
140528	1710	receptor without change	[receptors without changes]	0.0	3	1	1	1
140529	1710	cell in continuous culture.	[cells in continuous culture.]	0.0	4	1	1	1
140530	1710	leukocyte of patient with dermatitis	[leukocytes of patients with dermatitis]	0.0	5	2	2	1
140531	1710	lack the x element	[lacking the X element]	0.0	4	1	1	1
140532	1710	lymph node involvement	[lymph node involvement]	0.0	3	1	1	1
140533	1710	electrolyte response in mononuclear leukocyte	[electrolyte response in mononuclear leukocytes]	0.0	5	1	1	1
140534	1710	oct-binding factor	[Oct-binding factor]	0.0	2	1	1	1
140535	1710	gene locus	[gene locus]	0.0	2	1	1	1
140536	1710	acute myeloid patient aml (10	[acute myeloid patients AML (10]	0.0	5	1	1	1
140537	1710	bioactivation of sulphamethoxazole SMX	[Bioactivation of sulphamethoxazole SMX]	0.0	4	1	1	1
140538	1710	change of serine 186	[change of serine 186]	0.0	4	1	1	1
140539	1710	protein in lymphocyte	[proteins in lymphocytes]	0.0	3	1	1	1
140540	1710	divide single positive cell	[dividing single positive cells]	0.0	4	1	1	1
140541	1710	nuclear translocation of hiv-1 transactivator	[nuclear translocation of HIV-1 transactivator]	0.0	5	1	1	1
140542	1710	level rag gene expression	[level RAG gene expression]	0.0	4	1	1	1
140543	1710	(also in arterial endothelial cell	[(also in arterial endothelial cells]	0.0	5	1	1	1
140544	1710	novel lymphoma cell line CRO-AP/3	[novel lymphoma cell lines CRO-AP/3]	0.0	5	1	1	1
140545	1710	Conclusions: hormone	[CONCLUSIONS: hormones]	0.0	2	1	1	1
140546	1710	expression of the SCM-1 gene	[expression of the SCM-1 genes]	0.0	5	1	1	1
140547	1710	preovulatory period	[preovulatory period]	0.0	2	1	1	1
140548	1710	2 EBNA-2	[2 EBNA-2]	0.0	2	1	1	1
140549	1710	high-dose RA	[high-dose RA]	0.0	2	1	1	1
140550	1710	leukocyte in this patient	[leukocytes in these patients]	0.0	4	1	1	1
140551	1710	three order less potent than H	[three orders less potent than H]	0.0	6	1	1	1
140552	1710	mild down-regulation	[mild down-regulation]	0.0	2	1	1	1
140553	1710	lytic reactivity at level high	[lytic reactivities at levels high]	0.0	5	1	1	1
140554	1710	pretreatment with the pparalpha activator fenofibrate	[Pretreatment with the PPARalpha activators fenofibrate]	0.0	6	1	1	1
140555	1710	simian T cell	[simian T cell]	0.0	3	1	1	1
140556	1710	three gata regulatory element	[three GATA regulatory elements]	0.0	4	1	1	1
140557	1710	disordered memory T	[disordered memory T]	0.0	3	1	1	1
140558	1710	activation of embryonic zeta globin gene	[activation of embryonic zeta globin gene]	0.0	6	1	1	1
140559	1710	interaction with receptor, cd21	[interaction with receptor, CD21]	0.0	4	1	1	1
140560	1710	Furthermore, acid receptor alpha	[Furthermore, acid receptor alpha]	0.0	4	1	1	1
140561	1710	ectopic expression of ebf	[ectopic expression of EBF]	0.0	4	1	1	1
140562	1710	translation and/or	[translation and/or]	0.0	2	1	1	1
140563	1710	acidic domain with sh2 phosphotyrosine-based motif	[acidic domains with SH2 phosphotyrosine-based motifs]	0.0	6	1	1	1
140564	1710	hhv-6 (gs) gene fragment	[HHV-6 (GS) gene fragments]	0.0	4	1	1	1
140565	1710	hypothesis common requirement	[hypothesis common requirements]	0.0	3	1	1	1
140566	1710	vitro, b lymphocyte	[vitro, B lymphocytes]	0.0	3	1	1	1
140567	1710	quantitation by transcription polymerase chain reaction	[Quantitation by transcription polymerase chain reaction]	0.0	6	1	1	1
140568	1710	biological activity of Tat	[biological activity of Tat]	0.0	4	1	1	1
140569	1710	involvement of g betagamma subunit	[involvement of G betagamma subunits]	0.0	5	1	1	1
140570	1710	influence of lymphocyte activation	[influence of lymphocyte activation]	0.0	4	1	1	1
140571	1710	mutant mouse lack T cell	[mutant mice lacking T cells]	0.0	5	1	1	1
140572	1710	response to a fragment	[response to a fragment]	0.0	4	1	1	1
140573	1710	substitution mutation	[Substitution mutations]	0.0	2	1	1	1
140574	1710	18 patient with leukaemia AML	[18 patients with leukaemia AML]	0.0	5	1	1	1
140575	1710	activate proteins,	[activating proteins,]	0.0	2	1	1	1
140576	1710	suffer from distress syndrome	[suffering from distress syndrome]	0.0	4	1	1	1
140577	1710	nuclear accumulation of RelB	[nuclear accumulation of RelB]	0.0	4	2	2	1
140578	1710	transcription initiation by RNA polymerase	[transcription initiation by RNA polymerase]	0.0	5	1	1	1
140579	1710	asp at position	[Asp at position]	0.0	3	1	1	1
140580	1710	presence of as gene product	[presence of as gene products]	0.0	5	1	1	1
140581	1710	two site within the element	[Two sites within the element]	0.0	5	1	1	1
140582	1710	activation of human zeta globin promoter	[activation of human zeta globin promoter]	0.0	6	1	1	1
140583	1710	estrogen receptor content in patient	[Estrogen receptor content in patients]	0.0	5	1	1	1
140584	1710	centipoise).	[centipoise).]	0.0	1	1	1	1
140585	1710	short-term,	[short-term,]	0.0	1	1	1	1
140586	1710	treatment with cd14 antibody	[treatment with CD14 antibody]	0.0	4	1	1	1
140587	1710	one domain contain tandem repeat	[one domain containing tandem repeats]	0.0	5	1	1	1
140588	1710	leukemia-M3	[leukemia-M3]	0.0	1	1	1	1
140589	1710	molecular weight variant in monocyte	[molecular weight variant in monocytes]	0.0	5	1	1	1
140590	1710	adenovirus ad5	[adenovirus Ad5]	0.0	2	1	1	1
140591	1710	mutation of the ap-1 -binding site	[mutations of the AP-1 -binding site]	0.0	6	1	1	1
140592	1710	region of the human IL-1alpha promoter	[regions of the human IL-1alpha promoter]	0.0	6	1	1	1
140593	1710	endothelial cell with MM-LDL	[endothelial cells with MM-LDL]	0.0	4	1	1	1
140594	1710	October protein to dna,	[Oct proteins to DNA,]	0.0	4	1	1	1
140595	1710	chronic disease four	[chronic diseases four]	0.0	3	1	1	1
140596	1710	NF-kappaB regulatory effect	[NF-kappaB regulatory effect]	0.0	3	1	1	1
140597	1710	oncogene,	[oncogene,]	0.0	1	1	1	1
140598	1710	selective modification	[selective modification]	0.0	2	1	1	1
140599	1710	potential clinical significance	[potential clinical significance]	0.0	3	1	1	1
140600	1710	inhibition of tcr signal	[inhibition of TCR signals]	0.0	4	1	1	1
140601	1710	expression a immunohistochemical study	[Expression an immunohistochemical study]	0.0	4	1	1	1
140602	1710	abnormality of gene	[abnormalities of genes]	0.0	3	1	1	1
140603	1710	-dependent reporter construct	[-dependent reporter constructs]	0.0	3	1	1	1
140604	1710	multiple NF-kappa b related polypeptide range	[multiple NF-kappa B related polypeptides ranging]	0.0	6	1	1	1
140605	1710	particularly in relationship	[particularly in relationship]	0.0	3	1	1	1
140606	1710	molecular mechanism lead	[Molecular mechanisms leading]	0.0	3	1	1	1
140607	1710	suppressor most notably of T cell	[suppressors most notably of T cells]	0.0	6	1	1	1
140608	1710	treatment nb4 with interferon alpha ifn(alpha)	[Treatment NB4 with interferon alpha IFN(alpha)]	0.0	6	1	1	1
140609	1710	stimulation antibody phosphatidylinositol 3-kinase	[Stimulation antibody phosphatidylinositol 3-kinase]	0.0	4	1	1	1
140610	1710	Gene for a transcriptional activator	[Gene for a transcriptional activator]	0.0	5	1	1	1
140611	1710	200 microgram fluticasone propionate nasal spray	[200 micrograms fluticasone propionate nasal spray]	0.0	6	1	1	1
140612	1710	dependent activation	[dependent activation]	0.0	2	1	1	1
140613	1710	component of glutathione peroxidase	[component of glutathione peroxidase]	0.0	4	1	1	1
140614	1710	selection use a CD20 antibody	[selection using an CD20 antibody]	0.0	5	1	1	1
140615	1710	2 log-fold more glucocorticoid	[2 log-fold more glucocorticoids]	0.0	4	1	1	1
140616	1710	b lymphocyte-specific gene	[B lymphocyte-specific genes]	0.0	3	1	1	1
140617	1710	other response gene	[other response genes]	0.0	3	1	1	1
140618	1710	closely related immunodeficiency virus	[closely related immunodeficiency virus]	0.0	4	1	1	1
140619	1710	relative bind affinity	[relative binding affinity]	0.0	3	2	2	1
140620	1710	primarily by lps	[primarily by LPS]	0.0	3	1	1	1
140621	1710	major inhibitor in pbmc	[major inhibitor in PBMC]	0.0	4	1	1	1
140622	1710	regulation of chain expression	[regulation of chain expression]	0.0	4	1	1	1
140623	1710	tax -response	[Tax -response]	0.0	2	1	1	1
140624	1710	NH2-terminal truncation mutant	[NH2-terminal truncation mutant]	0.0	3	1	1	1
140625	1710	limit in remodeling	[limiting in remodeling]	0.0	3	1	1	1
140626	1710	blood cell from leukemia patient	[blood cells from leukemia patients]	0.0	5	1	1	1
140627	1710	initial decline	[initial decline]	0.0	2	1	1	1
140628	1710	specific feature	[specific features]	0.0	2	1	1	1
140629	1710	role of EGR1 in regulation	[Role of EGR1 in regulation]	0.0	5	1	1	1
140630	1710	D3 135(oh)2d3	[D3 1,25(OH)2D3]	0.0	2	1	1	1
140631	1710	pathological model	[pathological model]	0.0	2	1	1	1
140632	1710	(ebna2)-oestrogen	[(EBNA2)-oestrogen]	0.0	1	1	1	1
140633	1710	tax -responsive element tre-1	[Tax -responsive element TRE-1]	0.0	4	1	1	1
140634	1710	IFN-gamma promoter of CIITA	[IFN-gamma promoter of CIITA]	0.0	4	1	1	1
140635	1710	Specific foci of gata-1 fluorescence	[Specific foci of GATA-1 fluorescence]	0.0	5	1	1	1
140636	1710	expression of gata-1 mrna	[expression of GATA-1 mRNA]	0.0	4	1	1	1
140637	1710	expression of mn-dependent superoxide dismutase	[expression of Mn-dependent superoxide dismutase]	0.0	5	1	1	1
140638	1710	induction of key cell cycle regulator	[induction of key cell cycle regulators]	0.0	6	1	1	1
140639	1710	include repression	[including repression]	0.0	2	1	1	1
140640	1710	defect in production of colony-stimulating factor	[defects in production of colony-stimulating factor]	0.0	6	1	1	1
140641	1710	active ne	[active NE]	0.0	2	1	1	1
140642	1710	infection genetic analysis of LTR mutation	[Infection genetic analyses of LTR mutations]	0.0	6	1	1	1
140643	1710	gene pml	[gene PML]	0.0	2	1	1	1
140644	1710	risk: cell reaction histologic grade	[risk: cell reaction histologic grade]	0.0	5	1	1	1
140645	1710	cellular mechanism a study	[Cellular mechanisms a study]	0.0	4	1	1	1
140646	1710	DNA clone contain the region	[DNA clones containing the region]	0.0	5	1	1	1
140647	1710	Ig chain sequence	[Ig chain sequences]	0.0	3	1	1	1
140648	1710	effect in comparison	[effect in comparison]	0.0	3	1	1	1
140649	1710	Study over the year	[Studies over the years]	0.0	4	1	1	1
140650	1710	other patient	[other patients]	0.0	2	1	1	1
140651	1710	ethanol exposure	[ethanol exposure]	0.0	2	1	1	1
140652	1710	evidence indicate a function	[evidence indicating a function]	0.0	4	1	1	1
140653	1710	csf by IL-2	[CSFs by IL-2]	0.0	3	1	1	1
140654	1710	young (mean years)	[young (mean years)]	0.0	3	1	1	1
140655	1710	control hiv replication	[controlling HIV replication]	0.0	3	1	1	1
140656	1710	constitutive interaction	[constitutive interactions]	0.0	2	1	1	1
140657	1710	eosinophil abnormality	[eosinophil abnormalities]	0.0	2	1	1	1
140658	1710	double time, saturation density	[doubling time, saturation density]	0.0	4	1	1	1
140659	1710	EBNA promoter	[EBNA promoters]	0.0	2	1	1	1
140660	1710	burst during phorbol differentiation	[burst during phorbol differentiation]	0.0	4	1	1	1
140661	1710	antigen receptor function	[antigen receptor function]	0.0	3	1	1	1
140662	1710	probably a target site	[probably a target site]	0.0	4	1	1	1
140663	1710	efficiency of glucocorticoid	[efficiency of glucocorticoids]	0.0	3	1	1	1
140664	1710	reactivities.	[reactivities.]	0.0	1	1	1	1
140665	1710	element act	[elements acting]	0.0	2	1	1	1
140666	1710	second, in contrast	[Second, in contrast]	0.0	3	1	1	1
140667	1710	permissivity factor	[permissivity factors]	0.0	2	1	1	1
140668	1710	stress activation	[stress activation]	0.0	2	1	1	1
140669	1710	contain VDR-RXR	[containing VDR-RXR]	0.0	2	1	1	1
140670	1710	element for factor	[elements for factor]	0.0	3	1	1	1
140671	1710	anti- CD2 mab	[anti- CD2 mAbs]	0.0	3	1	1	1
140672	1710	different feature of monocyte/macrophage function	[different features of monocyte/macrophage function]	0.0	5	1	1	1
140673	1710	central Rel similarity region	[central Rel similarity region]	0.0	4	1	1	1
140674	1710	erythrocyte-specific anhydrase ii	[erythrocyte-specific anhydrase II]	0.0	3	1	1	1
140675	1710	role in lipopolysaccharide	[Role in lipopolysaccharide]	0.0	3	1	1	1
140676	1710	sds-stable class	[SDS-stable class]	0.0	2	1	1	1
140677	1710	especially density lipoprotein ldl	[especially density lipoprotein LDL]	0.0	4	1	1	1
140678	1710	glucocorticoid receptor in the lymphocyte	[glucocorticoid receptor in the lymphocytes]	0.0	5	1	1	1
140679	1710	chicken c/ebp beta	[chicken C/EBP beta]	0.0	3	1	1	1
140680	1710	cases, include 1 case	[cases, including 1 case]	0.0	4	1	1	1
140681	1710	NFkappaB /inhibitor-kappaB ikappab system	[NFkappaB /inhibitor-kappaB IkappaB system]	0.0	4	1	1	1
140682	1710	oncogenic herpesviruse	[oncogenic herpesviruses]	0.0	2	1	1	1
140683	1710	analysis of the protein phosphorylation pattern	[analysis of the protein phosphorylation pattern]	0.0	6	1	1	1
140684	1710	kda protein factor	[kDa protein factor]	0.0	3	3	3	1
140685	1710	study, cysteamine	[study, cysteamine]	0.0	2	1	1	1
140686	1710	id3 cell cycle function	[Id3 cell cycle function]	0.0	4	1	1	1
140687	1710	reproduce the function of USA	[reproducing the function of USA]	0.0	5	1	1	1
140688	1710	EBV mrna	[EBV mRNA]	0.0	2	1	1	1
140689	1710	DPA promoter	[DPA promoter]	0.0	2	1	1	1
140690	1710	phosphatidyl inositol level	[phosphatidyl inositol levels]	0.0	3	1	1	1
140691	1710	crucial determinant	[crucial determinant]	0.0	2	1	1	1
140692	1710	CS group	[CS group]	0.0	2	1	1	1
140693	1710	regulatory circuit	[regulatory circuits]	0.0	2	1	1	1
140694	1710	prognostic features:	[prognostic features:]	0.0	2	1	1	1
140695	1710	1,25-dihydroxyvitamin D3 a distinct agent	[1,25-dihydroxyvitamin D3 a distinct agent]	0.0	5	1	1	1
140696	1710	signal via CD28	[Signalling via CD28]	0.0	3	1	1	1
140697	1710	n-acetyl-cysteine	[N-acetyl-cysteine]	0.0	1	1	1	1
140698	1710	only in ebv b-lymphoblastoid cell line	[only in EBV B-lymphoblastoid cell lines]	0.0	6	1	1	1
140699	1710	rest vein cell HUVEC	[resting vein cells HUVEC]	0.0	4	1	1	1
140700	1710	T/NK cell of aml	[T/NK cells of AML]	0.0	4	1	1	1
140701	1710	event related to DNA damage	[events related to DNA damage]	0.0	5	1	1	1
140702	1710	rhabdomyosarcoma 10, leiomyosarcoma liposarcoma	[rhabdomyosarcoma 10, leiomyosarcoma liposarcoma]	0.0	4	1	1	1
140703	1710	94 kda stat5 protein	[94 kDa STAT5 proteins]	0.0	4	1	1	1
140704	1710	death of T cell hybridoma	[death of T cell hybridomas]	0.0	5	1	1	1
140705	1710	localization analysis	[localization analysis]	0.0	2	1	1	1
140706	1710	extracellular signal converge in pathway	[extracellular signals converging in pathways]	0.0	5	1	1	1
140707	1710	initiate tyrosine phosphorylation	[initiating tyrosine phosphorylation]	0.0	3	1	1	1
140708	1710	alteration of this cytokine pathway	[alteration of this cytokine pathway]	0.0	5	1	1	1
140709	1710	myocyte-enhancer factor	[myocyte-enhancer factor]	0.0	2	1	1	1
140710	1710	change in c-jun mrna expression	[changes in c-jun mRNA expression]	0.0	5	1	1	1
140711	1710	transient-cotransfection	[transient-cotransfection]	0.0	1	1	1	1
140712	1710	weight stat5 isoform	[weight STAT5 isoforms]	0.0	3	1	1	1
140713	1710	presumably involve a modulation	[presumably involving a modulation]	0.0	4	1	1	1
140714	1710	adult peripheral blood lymphocyte sample	[adult peripheral blood lymphocyte samples]	0.0	5	1	1	1
140715	1710	IL-3 factor	[IL-3 factor]	0.0	2	1	1	1
140716	1710	2.0 nm than 0.01).	[2.0 nM than 0.01).]	0.0	4	1	1	1
140717	1710	individual for the purpose	[individuals for the purpose]	0.0	4	1	1	1
140718	1710	use vary conditions, complex	[Using varying conditions, complexes]	0.0	4	1	1	1
140719	1710	er phenotype	[ER phenotype]	0.0	2	1	1	1
140720	1710	h for serum-supplemented culture	[h for serum-supplemented cultures]	0.0	4	1	1	1
140721	1710	effect on type i	[effects on type I]	0.0	4	1	1	1
140722	1710	panel of tissue	[panel of tissues]	0.0	3	1	1	1
140723	1710	promyelocytic leukemia APL the variant	[promyelocytic leukemia APL the variant]	0.0	5	1	1	1
140724	1710	progression of various type	[progression of various types]	0.0	4	2	2	1
140725	1710	surface receptor on lymphocyte subpopulation	[surface receptors on lymphocyte subpopulations]	0.0	5	1	1	1
140726	1710	inhibitor Gen	[inhibitor Gen]	0.0	2	1	1	1
140727	1710	role protein	[Role protein]	0.0	2	1	1	1
140728	1710	beta,19-epoxy-3-hydroxypregnan-20-one (6)	[beta,19-epoxy-3-hydroxypregnan-20-one (6)]	0.0	2	1	1	1
140729	1710	anti- il-6 antibody	[anti- IL-6 antibody]	0.0	3	1	1	1
140730	1710	analysis of mnda	[analysis of MNDA]	0.0	3	1	1	1
140731	1710	b cell hyperreactivity	[B cell hyperreactivity]	0.0	3	1	1	1
140732	1710	feto-maternal interface	[feto-maternal interface]	0.0	2	1	1	1
140733	1710	introduce mutation	[introducing mutations]	0.0	2	1	1	1
140734	1710	infection of human peripheral blood lymphocyte	[Infection of human peripheral blood lymphocytes]	0.0	6	1	1	1
140735	1710	protein BRLF1	[protein BRLF1]	0.0	2	1	1	1
140736	1710	ets-1 proto-oncogene	[ets-1 proto-oncogene]	0.0	2	1	1	1
140737	1710	express mutant form	[expressing mutant forms]	0.0	3	1	1	1
140738	1710	phenotypically similar MHC class cell	[phenotypically similar MHC class cells]	0.0	5	1	1	1
140739	1710	glucocorticoid in acute leukemia	[glucocorticoids in acute leukemia]	0.0	4	1	1	1
140740	1710	lupus erythematosus sle	[lupus erythematosus SLE]	0.0	3	3	3	1
140741	1710	NF-kappaB inhibition	[NF-kappaB inhibition]	0.0	2	1	1	1
140742	1710	-priming stage	[-priming stage]	0.0	2	1	1	1
140743	1710	pcd41 trans-activation	[pCD41 trans-activation]	0.0	2	1	1	1
140744	1710	provision of NFkB	[provision of NFkB]	0.0	3	1	1	1
140745	1710	growth inhibition without evidence	[growth inhibition without evidence]	0.0	4	1	1	1
140746	1710	lipocalin NRL a member	[lipocalin NRL a member]	0.0	4	1	1	1
140747	1710	Drosophila Schneider cell	[Drosophila Schneider cells]	0.0	3	1	1	1
140748	1710	nf-kappab in contrast	[NF-kappaB in contrast]	0.0	3	1	1	1
140749	1710	PPARalpha a potentially important regulator	[PPARalpha a potentially important regulator]	0.0	5	1	1	1
140750	1710	human gamma 3	[human gamma 3]	0.0	3	1	1	1
140751	1710	form of e2f	[forms of E2F]	0.0	3	1	1	1
140752	1710	differentiation of hematopoietic progenitor cell	[differentiation of hematopoietic progenitor cells]	0.0	5	1	1	1
140753	1710	aberrancy in the induction of c-fos/c-jun	[aberrancies in the induction of c-fos/c-jun]	0.0	6	1	1	1
140754	1710	receptor in leucocyte	[receptor in leucocytes]	0.0	3	1	1	1
140755	1710	mismatch cleavage analysis of copy DNA	[mismatch cleavage analysis of copy DNA]	0.0	6	1	1	1
140756	1710	depression of type	[depression of Type]	0.0	3	1	1	1
140757	1710	unusual feature	[unusual feature]	0.0	2	1	1	1
140758	1710	m.a. Martin,	[M.A. Martin,]	0.0	2	1	1	1
140759	1710	early lesion	[earliest lesion]	0.0	2	1	1	1
140760	1710	HLA class dr11-restricted fashion	[HLA class DR11-restricted fashion]	0.0	4	1	1	1
140761	1710	quantitative reverse transcriptase -polymerase chain reaction	[Quantitative reverse transcriptase -polymerase chain reaction]	0.0	6	1	1	1
140762	1710	amino acid 286-551	[amino acids 286-551]	0.0	3	1	1	1
140763	1710	mature erythroid cell a phenotype	[mature erythroid cells a phenotype]	0.0	5	1	1	1
140764	1710	Functional analysis of cis-linked sequence	[Functional analysis of cis-linked sequences]	0.0	5	1	1	1
140765	1710	peptide selection selective	[peptide selection selective]	0.0	3	1	1	1
140766	1710	element within the IL-2 promoter	[element within the IL-2 promoter]	0.0	5	1	1	1
140767	1710	Hox11 mouse embryo	[Hox11 mouse embryos]	0.0	3	1	1	1
140768	1710	metal response	[metal response]	0.0	2	1	1	1
140769	1710	adhesion in umbilical vein cell HUVECs	[adhesion in umbilical vein cells HUVECs]	0.0	6	1	1	1
140770	1710	simultaneous exposure together	[simultaneous exposure together]	0.0	3	1	1	1
140771	1710	virtual amino acid sequence identity	[virtual amino acid sequence identity]	0.0	5	1	1	1
140772	1710	tight complex with two different class	[tight complexes with two different classes]	0.0	6	1	1	1
140773	1710	form of stat3 90-kda stat3alpha	[forms of STAT3 90-kDa STAT3alpha]	0.0	5	1	1	1
140774	1710	characterization determinant regulate factor-kappa b activation	[Characterization determinants regulating factor-kappa B activation]	0.0	6	1	1	1
140775	1710	number progenitor cell	[number progenitor cells]	0.0	3	1	1	1
140776	1710	activator of hiv-1 gene expression	[activator of HIV-1 gene expression]	0.0	5	1	1	1
140777	1710	subsequent mutagenesis	[subsequent mutagenesis]	0.0	2	1	1	1
140778	1710	major dnase i-hypersensitive site	[major DNase I-hypersensitive site]	0.0	4	1	1	1
140779	1710	platelet-activate factor to 10(-6) m elevation	[platelet-activating factor to 10(-6) M elevation]	0.0	6	1	1	1
140780	1710	double time of h (viability great	[doubling times of h (viability greater]	0.0	6	1	1	1
140781	1710	limited stimulation of il-2	[limited stimulation of IL-2]	0.0	4	1	1	1
140782	1710	difference in the architecture	[differences in the architecture]	0.0	4	1	1	1
140783	1710	counterpart to chronic leukemia	[counterpart to chronic leukemias]	0.0	4	1	1	1
140784	1710	relation to classical features: clinical implications.	[relations to classical features: clinical implications.]	0.0	6	1	1	1
140785	1710	formation of the active dimer	[formation of the active dimer]	0.0	5	1	1	1
140786	1710	informative probe specific	[informative probes specific]	0.0	3	1	1	1
140787	1710	efficient control	[efficient control]	0.0	2	1	1	1
140788	1710	synergistic function	[synergistic function]	0.0	2	1	1	1
140789	1710	IL-12 stage	[IL-12 stage]	0.0	2	1	1	1
140790	1710	35% decrease in translation	[35% decrease in translation]	0.0	4	1	1	1
140791	1710	thus, failure of T cell	[Thus, failure of T cells]	0.0	5	1	1	1
140792	1710	5.5-kilobase clone	[5.5-kilobase clone]	0.0	2	1	1	1
140793	1710	treatment 0 hpc with alpha-pml	[treatment 0 HPCs with alpha-PML]	0.0	5	1	1	1
140794	1710	agonistic antibody against CD40	[agonistic antibody against CD40]	0.0	4	1	1	1
140795	1710	cpo gene	[CPO gene]	0.0	2	1	1	1
140796	1710	E1B- CTL	[E1B- CTLs]	0.0	2	1	1	1
140797	1710	subject of study.	[subject of study.]	0.0	3	1	1	1
140798	1710	METHODS: eight lymphocytic cell line	[METHODS: Eight lymphocytic cell lines]	0.0	5	1	1	1
140799	1710	microg/100 millileter	[microg/100 ml]	0.0	2	1	1	1
140800	1710	nonimmune hela cell	[nonimmune HeLa cells]	0.0	3	1	1	1
140801	1710	2.5-kilobase sequence upstream	[2.5-kilobase sequence upstream]	0.0	3	1	1	1
140802	1710	-ii; t-cell	[-II; T-cells]	0.0	2	1	1	1
140803	1710	70Z/3 induction	[70Z/3 induction]	0.0	2	1	1	1
140804	1710	NB4 cells,	[NB4 cells,]	0.0	2	1	1	1
140805	1710	h at dose	[h at doses]	0.0	3	1	1	1
140806	1710	contain the human cytomegalovirus enhancer	[containing the human cytomegalovirus enhancer]	0.0	5	1	1	1
140807	1710	source for inflammatory mediator	[source for inflammatory mediators]	0.0	4	1	1	1
140808	1710	receptor c	[receptor C]	0.0	2	1	1	1
140809	1710	inhibition signal through Janus kinase	[inhibition signaling through Janus kinases]	0.0	5	1	1	1
140810	1710	three candidate	[three candidate]	0.0	2	1	1	1
140811	1710	-107 bp	[-107 bp]	0.0	2	1	1	1
140812	1710	region in the domain	[regions in the domain]	0.0	4	1	1	1
140813	1710	perspective to the interaction	[perspective to the interactions]	0.0	4	1	1	1
140814	1710	erythroid factor activity	[erythroid factor activity]	0.0	3	1	1	1
140815	1710	ra-mediated type	[RA-mediated type]	0.0	2	1	1	1
140816	1710	reflect the level of hepor expression	[reflecting the levels of hEpoR expression]	0.0	6	1	1	1
140817	1710	early event in steroid-treated cells.	[early events in steroid-treated cells.]	0.0	5	1	1	1
140818	1710	receptor per cell).	[receptors per cell).]	0.0	3	1	1	1
140819	1710	receptor per cell),	[receptors per cell),]	0.0	3	1	1	1
140820	1710	weakly active region	[weakly active region]	0.0	3	1	1	1
140821	1710	level of this substance	[levels of these substances]	0.0	4	1	1	1
140822	1710	signal-mediated induction	[signal-mediated induction]	0.0	2	1	1	1
140823	1710	alone in combination with colony-stimulating factor	[alone in combination with colony-stimulating factor]	0.0	6	1	1	1
140824	1710	incubation with dose DEX	[incubation with doses DEX]	0.0	4	1	1	1
140825	1710	hypoxia (0.02% o2)	[hypoxia (0.02% O2)]	0.0	3	1	1	1
140826	1710	include anti-CD3 PMA	[including anti-CD3 PMA]	0.0	3	1	1	1
140827	1710	catalytic sub-unit	[catalytic sub-unit]	0.0	2	1	1	1
140828	1710	functional expression on human melanoma	[functional expression on human melanomas]	0.0	5	1	1	1
140829	1710	g1 checkpoint in T lymphocyte	[G1 checkpoint in T lymphocytes]	0.0	5	1	1	1
140830	1710	human growth hormone	[human growth hormone]	0.0	3	1	1	1
140831	1710	adherence/contact to endothelial cell	[adherence/contact to endothelial cells]	0.0	4	1	1	1
140832	1710	woman young than year (2/73)	[women younger than years (2/73)]	0.0	5	1	1	1
140833	1710	cell hybrid between IARC 301.5	[cell hybrids between IARC 301.5]	0.0	5	1	1	1
140834	1710	stimulus towards neutrophil gene expression	[stimuli towards neutrophil gene expression]	0.0	5	1	1	1
140835	1710	atf1 protein	[ATF1 proteins]	0.0	2	1	1	1
140836	1710	TCRhigh population	[TCRhigh population]	0.0	2	1	1	1
140837	1710	close proximity	[close proximity]	0.0	2	2	2	1
140838	1710	use the BZ1 antibody	[using the BZ1 antibody]	0.0	4	1	1	1
140839	1710	acute leukemia t-all	[acute leukemia T-ALL]	0.0	3	1	1	1
140840	1710	treatment hpc with alpha-pml	[treatment HPCs with alpha-PML]	0.0	4	1	1	1
140841	1710	certain response through effect	[certain responses through effects]	0.0	4	1	1	1
140842	1710	primary involvement I receptor	[primary involvement I receptors]	0.0	4	1	1	1
140843	1710	range from 10(-9)	[ranging from 10(-9)]	0.0	3	1	1	1
140844	1710	stimulation of mature T cell	[Stimulation of mature T cells]	0.0	5	1	1	1
140845	1710	fraction of human blood cell	[fraction of human blood cells]	0.0	5	1	1	1
140846	1710	eklf binding	[EKLF binding]	0.0	2	1	1	1
140847	1710	store of nf-kappa b	[stores of NF-kappa B]	0.0	4	1	1	1
140848	1710	role convert extracellular signal	[role converting extracellular signals]	0.0	4	1	1	1
140849	1710	studies, interferon-gamma	[studies, interferon-gamma]	0.0	2	1	1	1
140850	1710	tal1/scl gene	[TAL1/SCL gene]	0.0	2	1	1	1
140851	1710	RALDH2 transcript	[RALDH2 transcripts]	0.0	2	1	1	1
140852	1710	upstream splice site	[upstream splice site]	0.0	3	1	1	1
140853	1710	site on DNA.	[site on DNA.]	0.0	3	1	1	1
140854	1710	two assays),	[two assays),]	0.0	2	1	1	1
140855	1710	only in that cell line	[only in that cell line]	0.0	5	1	1	1
140856	1710	hiv repeat activation	[HIV repeat activation]	0.0	3	1	1	1
140857	1710	effect in inflammatory disease	[effects in inflammatory diseases]	0.0	4	1	1	1
140858	1710	characterization of Grb2-binding protein in platelet	[Characterization of Grb2-binding proteins in platelets]	0.0	6	1	1	1
140859	1710	disulfide of bmt drug	[disulfide of BMT drug]	0.0	4	1	1	1
140860	1710	mouse el-4	[mouse EL-4]	0.0	2	1	1	1
140861	1710	express histocompatibility (mhc) class gene	[expressing histocompatibility (MHC) class genes]	0.0	5	1	1	1
140862	1710	normal mense	[normal menses]	0.0	2	1	1	1
140863	1710	Jak kinase antibody	[Jak kinase antibodies]	0.0	3	1	1	1
140864	1710	inflammatory disorder	[inflammatory disorders]	0.0	2	1	1	1
140865	1710	western blotting of fetal population	[Western blotting of fetal populations]	0.0	5	1	1	1
140866	1710	kappab dna-binding activity	[kappaB DNA-binding activity]	0.0	3	1	1	1
140867	1710	program mediate t-cell activation	[program mediating T-cell activation]	0.0	4	1	1	1
140868	1710	protein mbp	[protein MBP]	0.0	2	1	1	1
140869	1710	migration of media-stimulated t-cell	[migration of media-stimulated T-cells]	0.0	4	1	1	1
140870	1710	other peroxisome proliferator receptor	[Other peroxisome proliferator receptor]	0.0	4	1	1	1
140871	1710	evidence for cytokine production	[evidence for cytokine production]	0.0	4	1	1	1
140872	1710	useful tool assess the risk	[useful tool assessing the risk]	0.0	5	1	1	1
140873	1710	two cis-acting element gm-kappa b/gc-box	[Two cis-acting elements GM-kappa B/GC-box]	0.0	5	1	1	1
140874	1710	distinguish heterozygous carrier	[distinguishing heterozygous carriers]	0.0	3	1	1	1
140875	1710	promoter for activity	[promoter for activity]	0.0	3	1	1	1
140876	1710	acid-reactive substance tbar	[acid-reactive substances TBARS]	0.0	3	1	1	1
140877	1710	reactivity of human neonate	[reactivity of human neonates]	0.0	4	1	1	1
140878	1710	potent transactivator of gene expression.	[potent transactivators of gene expression.]	0.0	5	1	1	1
140879	1710	value in patient	[values in patients]	0.0	3	1	1	1
140880	1710	transcription factor oct-1	[transcription factors OCT-1]	0.0	3	1	1	1
140881	1710	lack mature T cell	[lacking mature T cells]	0.0	4	1	1	1
140882	1710	U/ml, il-10	[U/ml, IL-10]	0.0	2	1	1	1
140883	1710	probe for chromosome	[probes for chromosomes]	0.0	3	1	1	1
140884	1710	3-o-mg transport	[3-O-MG transport]	0.0	2	1	1	1
140885	1710	possibly one member	[possibly one members]	0.0	3	1	1	1
140886	1710	apply the mobility shift assay	[applying the mobility shift assay]	0.0	5	1	1	1
140887	1710	nuclear factor-kappaB in memory (cd45ro+)	[nuclear factor-kappaB in memory (CD45RO+)]	0.0	5	1	1	1
140888	1710	involve expression of stat4 protein	[involving expression of Stat4 proteins]	0.0	5	1	1	1
140889	1710	b sequence-specific DNA binding activity	[B sequence-specific DNA binding activity]	0.0	5	1	1	1
140890	1710	action of cysteamine	[action of cysteamine]	0.0	3	1	1	1
140891	1710	local failure	[local failure]	0.0	2	1	1	1
140892	1710	cell body	[cell bodies]	0.0	2	1	1	1
140893	1710	include phytohemagglutinin	[including phytohemagglutinin]	0.0	2	1	1	1
140894	1710	IL-2 growth of ctll-2 cell	[IL-2 growth of CTLL-2 cells]	0.0	5	1	1	1
140895	1710	show only weak cross-reactivity at concentration	[showing only weak cross-reactivity at concentrations]	0.0	6	1	1	1
140896	1710	unusually high proportion	[unusually high proportion]	0.0	3	1	1	1
140897	1710	expression of the early gene	[expression of the early genes]	0.0	5	1	1	1
140898	1710	follicular cell in germinal center	[follicular cells in germinal centers]	0.0	5	1	1	1
140899	1710	receptor in lupus erythematosus	[receptors in lupus erythematosus]	0.0	4	1	1	1
140900	1710	identical signal pathways,	[identical signaling pathways,]	0.0	3	1	1	1
140901	1710	course of month	[course of months]	0.0	3	1	1	1
140902	1710	oxygen intermediate production	[oxygen intermediate production]	0.0	3	1	1	1
140903	1710	lymphocyte of 24 pregnant woman	[lymphocytes of 24 pregnant women]	0.0	5	1	1	1
140904	1710	regulation of endothelial cell adhesion molecule	[regulation of endothelial cell adhesion molecules]	0.0	6	1	1	1
140905	1710	blood (PB) granulocyte	[blood (PB) granulocytes]	0.0	3	1	1	1
140906	1710	90% identity	[90% identity]	0.0	2	1	1	1
140907	1710	phosphorylation the three out of four	[phosphorylation the three out of four]	0.0	6	1	1	1
140908	1710	protein with weight	[proteins with weights]	0.0	3	1	1	1
140909	1710	case of lymphocytic leukemia	[cases of lymphocytic leukemia]	0.0	4	1	1	1
140910	1710	seven patient with vkc	[seven patients with VKC]	0.0	4	1	1	1
140911	1710	vzv glycoprotein e	[VZV glycoprotein E]	0.0	3	1	1	1
140912	1710	requirement for pkc stimulation	[requirement for PKC stimulation]	0.0	4	1	1	1
140913	1710	diesel extract	[diesel extracts]	0.0	2	1	1	1
140914	1710	corresponding to the domain	[corresponding to the domain]	0.0	4	1	1	1
140915	1710	protein as p97	[protein as p97]	0.0	3	1	1	1
140916	1710	new murine member	[new murine member]	0.0	3	1	1	1
140917	1710	vector-mediated transduction of RA receptor	[vector-mediated transduction of RA receptor]	0.0	5	1	1	1
140918	1710	negative effect on the trans-activation	[negative effect on the trans-activation]	0.0	5	1	1	1
140919	1710	Class ii cell MHC class	[Class II cell MHC class]	0.0	5	1	1	1
140920	1710	29 salivary gland biopsy	[29 salivary gland biopsies]	0.0	4	1	1	1
140921	1710	expression of Oct2 cDNA	[expression of Oct2 cDNA]	0.0	4	1	1	1
140922	1710	fold increase in receptor number	[fold increase in receptor number]	0.0	5	1	1	1
140923	1710	intense staining for estrogen receptor	[intense staining for estrogen receptors]	0.0	5	1	1	1
140924	1710	primary monocyte thp-1	[primary monocytes THP-1]	0.0	3	1	1	1
140925	1710	temperature-induced down-regulation in patient	[Temperature-induced down-regulation in patients]	0.0	4	1	1	1
140926	1710	hormone-binding	[hormone-binding]	0.0	1	1	1	1
140927	1710	effect of n-acetyl-l-cysteine nac	[effects of N-acetyl-L-cysteine NAC]	0.0	4	1	1	1
140928	1710	hiv-1 DNA	[HIV-1 DNA]	0.0	2	1	1	1
140929	1710	approximately substnfkappab approximately substSpl2	[approximately substNFkappaB approximately substSpl2]	0.0	4	1	1	1
140930	1710	childbearing	[childbearing]	0.0	1	1	1	1
140931	1710	genome of T	[genome of T]	0.0	3	1	1	1
140932	1710	at (on average	[AT (on average]	0.0	3	1	1	1
140933	1710	survivalepromot activity	[survival-promoting activity]	0.0	2	1	1	1
140934	1710	calcium influx signal	[calcium influx signaling]	0.0	3	1	1	1
140935	1710	tpa maturation response	[TPA maturation response]	0.0	3	1	1	1
140936	1710	(57.3 +/-	[(57.3 +/-]	0.0	2	1	1	1
140937	1710	CsA sensitivity	[CsA sensitivity]	0.0	2	1	1	1
140938	1710	different system a cell line	[different systems a cell line]	0.0	5	1	1	1
140939	1710	hl60r	[HL60R]	0.0	1	1	1	1
140940	1710	alpha gene	[alpha gene]	0.0	2	1	1	1
140941	1710	(cd70)	[(CD70)]	0.0	1	1	1	1
140942	1710	hydrocarbons	[hydrocarbons]	0.0	1	1	1	1
140943	1710	activity of a kinase	[activity of a kinase]	0.0	4	1	1	1
140944	1710	tissue include cell	[tissues including cells]	0.0	3	1	1	1
140945	1710	NFAT complex formation	[NFAT complex formation]	0.0	3	1	1	1
140946	1710	conclusion: human ciita construct	[CONCLUSION: human CIITA constructs]	0.0	4	1	1	1
140947	1710	retinoid -dependent differentiation	[retinoid -dependent differentiation]	0.0	3	1	1	1
140948	1710	sertraline response	[sertraline response]	0.0	2	1	1	1
140949	1710	T cell (nf-at) factor	[T cell (NF-AT) factors]	0.0	4	1	1	1
140950	1710	region of HBxAg	[region of HBxAg]	0.0	3	1	1	1
140951	1710	specific feature of variation	[specific features of variation]	0.0	4	1	1	1
140952	1710	molecular mechanism signal in human eosinophil	[molecular mechanisms signaling in human eosinophils]	0.0	6	1	1	1
140953	1710	patient with failure	[patients with failure]	0.0	3	2	2	1
140954	1710	treatment of monocyte with 12-0-tetradecanoyl phorbol-13-acetate	[Treatment of monocytes with 12-0-tetradecanoyl phorbol-13-acetate]	0.0	6	1	1	1
140955	1710	distal element upstream	[distal element upstream]	0.0	3	1	1	1
140956	1710	expression of irf-1	[expression of IRF-1]	0.0	3	1	1	1
140957	1710	Paternal expression in fibroblast	[Paternal expression in fibroblasts]	0.0	4	1	1	1
140958	1710	47-kd glycoprotein	[47-kD glycoprotein]	0.0	2	1	1	1
140959	1710	thymocyte with autologous thymic cell	[thymocytes with autologous thymic cells]	0.0	5	1	1	1
140960	1710	signalsome	[signalsome]	0.0	1	1	1	1
140961	1710	little activation in response	[little activation in response]	0.0	4	1	1	1
140962	1710	regulation during T cell activation	[regulation during T cell activation]	0.0	5	1	1	1
140963	1710	receptor component	[receptor component]	0.0	2	1	1	1
140964	1710	dual action blockade	[Dual action blockade]	0.0	3	1	1	1
140965	1710	significance of this modification	[significance of this modification]	0.0	4	1	1	1
140966	1710	virus 40 enhancer activity	[virus 40 enhancer activity]	0.0	4	1	1	1
140967	1710	Isoflavones,	[Isoflavones,]	0.0	1	1	1	1
140968	1710	moreover, the only factor	[Moreover, the only factor]	0.0	4	1	1	1
140969	1710	socs-3 expression	[SOCS-3 expression]	0.0	2	1	1	1
140970	1710	T lymphocyte the producer	[T lymphocytes the producers]	0.0	4	1	1	1
140971	1710	ifi in addition to IL-12	[IFNs in addition to IL-12]	0.0	5	1	1	1
140972	1710	assembly via the clustering	[assembly via the clustering]	0.0	4	1	1	1
140973	1710	degree relative	[degree relative]	0.0	2	1	1	1
140974	1710	same series	[same series]	0.0	2	1	1	1
140975	1710	2) sign of hypothyroidism	[2) signs of hypothyroidism]	0.0	4	1	1	1
140976	1710	laboratory mutant	[laboratory mutants]	0.0	2	1	1	1
140977	1710	-reactive fluorochrome	[-reactive fluorochrome]	0.0	2	1	1	1
140978	1710	transfectant of HB24	[transfectants of HB24]	0.0	3	1	1	1
140979	1710	use c-jun -specific (as) phosphorothioate oligonucleotide	[using c-jun -specific (AS) phosphorothioate oligonucleotides]	0.0	6	1	1	1
140980	1710	METHODS: malignant lymphocytic cell line	[METHODS: malignant lymphocytic cell lines]	0.0	5	1	1	1
140981	1710	regulate il-4 transcription	[regulating IL-4 transcription]	0.0	3	1	1	1
140982	1710	divergent expression of gene	[divergent expression of genes]	0.0	4	1	1	1
140983	1710	several signalling molecule	[several signalling molecules]	0.0	3	1	1	1
140984	1710	leukemic (aml)	[leukemic (AML)]	0.0	2	1	1	1
140985	1710	LTR function	[LTR function]	0.0	2	1	1	1
140986	1710	general transcriptional activator	[general transcriptional activators]	0.0	3	1	1	1
140987	1710	anti-early antigen ea capsid antigen	[anti-early antigen EA capsid antigen]	0.0	5	1	1	1
140988	1710	egl from early samples, activity	[eGLs from early samples, activity]	0.0	5	1	1	1
140989	1710	beta-casein stat5 element	[beta-casein STAT5 element]	0.0	3	1	1	1
140990	1710	cytotoxic T lymphocyte against epitope	[cytotoxic T lymphocytes against epitopes]	0.0	5	1	1	1
140991	1710	potential inhibition of this pathway	[potential inhibition of this pathway]	0.0	5	1	1	1
140992	1710	respond to macrophage colony-stimumulatelany-stg factor	[responding to macrophage colony-stimulating factor]	0.0	5	1	1	1
140993	1710	marker of cortisol receptor	[marker of cortisol receptor]	0.0	4	1	1	1
140994	1710	exon of 132,	[exons of 132,]	0.0	3	1	1	1
140995	1710	alternative apoptotic "targets"	[alternative apoptotic "targets"]	0.0	3	1	1	1
140996	1710	very low activity,	[very low activity,]	0.0	3	1	1	1
140997	1710	growth of normal cell type	[growth of normal cell types]	0.0	5	1	1	1
140998	1710	potent activator of gene	[potent activator of genes]	0.0	4	1	1	1
140999	1710	effect of DES	[effect of DES]	0.0	3	1	1	1
141000	1710	panel of specific antisera	[panel of specific antisera]	0.0	4	1	1	1
141001	1710	B-cell specific transcription factor	[B-cell specific transcription factor]	0.0	4	1	1	1
141002	1710	result of lack	[result of lacking]	0.0	3	1	1	1
141003	1710	bryostatin nm),	[bryostatin nM),]	0.0	2	1	1	1
141004	1710	specific activity.	[specific activity.]	0.0	2	1	1	1
141005	1710	src homology (sh)2 domain	[src homology (SH)2 domain]	0.0	4	1	1	1
141006	1710	nuclear nf-kappa b in cell	[nuclear NF-kappa B in cells]	0.0	5	1	1	1
141007	1710	one mechanism of DNA repair	[one mechanism of DNA repair]	0.0	5	1	1	1
141008	1710	"death genes"	["death genes"]	0.0	2	1	1	1
141009	1710	Messenger RNA	[Messenger RNA]	0.0	2	1	1	1
141010	1710	Dithiothreitol	[Dithiothreitol]	0.0	1	1	1	1
141011	1710	interpretation of this datum	[interpretation of these data]	0.0	4	1	1	1
141012	1710	mM d-ribose respectively.	[mM D-ribose respectively.]	0.0	3	1	1	1
141013	1710	leukaemia factor)	[leukaemia factor)]	0.0	2	1	1	1
141014	1710	nine binding site	[nine binding sites]	0.0	3	1	1	1
141015	1710	capacity of human receptor hGR	[capacity of human receptor hGR]	0.0	5	1	1	1
141016	1710	PBMC from two child with infection	[PBMC from two children with infection]	0.0	6	2	2	1
141017	1710	activation of human thymocyte after infection	[Activation of human thymocytes after infection]	0.0	6	1	1	1
141018	1710	lymphocyte transformation	[lymphocyte transformation]	0.0	2	1	1	1
141019	1710	gene nuclear topography	[gene nuclear topography]	0.0	3	1	1	1
141020	1710	cell sensitive to cell death	[cells sensitive to cell death]	0.0	5	1	1	1
141021	1710	clarify the sequence	[clarifying the sequence]	0.0	3	1	1	1
141022	1710	er antagonist ICI	[ER antagonist ICI]	0.0	3	1	1	1
141023	1710	increase factor of T cell	[increasing factor of T cells]	0.0	5	1	1	1
141024	1710	two EBV-associated, epitope	[two EBV-associated, epitopes]	0.0	3	1	1	1
141025	1710	IL-13 by monocyte	[IL-13 by monocytes]	0.0	3	1	1	1
141026	1710	nm 2,3,377-tc	[nM 2,3,7,8-TCDD]	0.0	2	1	1	1
141027	1710	simultaneous incubation with dexamethasone	[simultaneous incubation with dexamethasone]	0.0	4	1	1	1
141028	1710	induction by macrophage-CSF	[induction by macrophage-CSF]	0.0	3	1	1	1
141029	1710	factor in macrophage	[factors in macrophages]	0.0	3	1	1	1
141030	1710	expression in human leukemia/lymphoma line	[expression in human leukemia/lymphoma lines]	0.0	5	1	1	1
141031	1710	specific binding of nuclear protein (s)	[specific binding of nuclear protein (s)]	0.0	6	1	1	1
141032	1710	repeat DR	[repeats DR]	0.0	2	1	1	1
141033	1710	erythropoietin stem cell factor	[erythropoietin stem cell factor]	0.0	4	1	1	1
141034	1710	Dithiocarbamates a diverse group	[Dithiocarbamates a diverse group]	0.0	4	1	1	1
141035	1710	otherwise ineffective dose	[otherwise ineffective dose]	0.0	3	1	1	1
141036	1710	intracellular store of nf-kappa b	[intracellular stores of NF-kappa B]	0.0	5	1	1	1
141037	1710	incubation of lymphocyte	[incubation of lymphocytes]	0.0	3	1	1	1
141038	1710	role in vivo in the pathogenesis	[roles in vivo in the pathogenesis]	0.0	6	1	1	1
141039	1710	cell receptor tcr	[cell receptor TcR]	0.0	3	1	1	1
141040	1710	Bacterial lipopolysaccharide immune response include activation	[Bacterial lipopolysaccharide immune responses including activation]	0.0	6	1	1	1
141041	1710	major complex class gene	[major complex class genes]	0.0	4	1	1	1
141042	1710	effect of il-13 on primary NK	[effects of IL-13 on primary NK]	0.0	6	1	1	1
141043	1710	Epstein-Barr virus ebv a herpesvirus	[Epstein-Barr virus EBV an herpesvirus]	0.0	5	1	1	1
141044	1710	u/ml interleukin-2 time	[U/ml interleukin-2 time]	0.0	3	1	1	1
141045	1710	response to u/ml interleukin-2	[response to U/ml interleukin-2]	0.0	4	1	1	1
141046	1710	rapamycin inhibition	[rapamycin inhibition]	0.0	2	2	2	1
141047	1710	set of b agent	[set of B agents]	0.0	4	1	1	1
141048	1710	cross-link camp	[cross-linking cAMP]	0.0	2	1	1	1
141049	1710	segregation of human autosome	[segregation of human autosome]	0.0	4	1	1	1
141050	1710	crucial role for the transcription factor	[crucial roles for the transcription factors]	0.0	6	1	1	1
141051	1710	differentiation of human b cell	[differentiation of human B cells]	0.0	5	1	1	1
141052	1710	leukocyte MNL from subject	[leukocytes MNL from subjects]	0.0	4	1	1	1
141053	1710	intrabody	[intrabody]	0.0	1	1	1	1
141054	1710	contrast, expression of the interfere	[contrast, expression of the interfering]	0.0	5	1	1	1
141055	1710	peripheral blood mononuclear	[peripheral blood mononuclear]	0.0	3	1	1	1
141056	1710	autoimmune patient	[autoimmune patient]	0.0	2	1	1	1
141057	1710	extensive inflammatory cell infiltration	[extensive inflammatory cell infiltration]	0.0	4	1	1	1
141058	1710	Calcitriol	[Calcitriol]	0.0	1	1	1	1
141059	1710	MNC extract	[MNC extracts]	0.0	2	1	1	1
141060	1710	feature for c-fo induction	[feature for c-fos induction]	0.0	4	1	1	1
141061	1710	protein of the lineage	[protein of the lineage]	0.0	4	1	1	1
141062	1710	62 subject	[62 subjects]	0.0	2	1	1	1
141063	1710	FL progenitor	[FL progenitors]	0.0	2	1	1	1
141064	1710	distribution from G1 phase	[distribution from G1 phase]	0.0	4	1	1	1
141065	1710	protein related	[protein related]	0.0	2	1	1	1
141066	1710	transmission of activation signal	[transmission of activation signals]	0.0	4	1	1	1
141067	1710	constitutive activity concomitant	[constitutive activity concomitant]	0.0	3	1	1	1
141068	1710	corticosteroid receptor characteristic	[corticosteroid receptor characteristics]	0.0	3	1	1	1
141069	1710	induction of response gene by factor	[Induction of response genes by factor]	0.0	6	1	1	1
141070	1710	peripheral blood of subject	[peripheral blood of subjects]	0.0	4	1	1	1
141071	1710	erythroid environment	[erythroid environment]	0.0	2	1	1	1
141072	1710	use a radioassay	[using a radioassay]	0.0	3	1	1	1
141073	1710	treatment with phorbol ester	[Treatment with phorbol esters]	0.0	4	1	1	1
141074	1710	3' xpb helicase defect	[3' XPB helicase defect]	0.0	4	1	1	1
141075	1710	other unidentified factor lbf2	[other unidentified factors LBF2]	0.0	4	1	1	1
141076	1710	macrophage by endotoxin	[macrophages by endotoxin]	0.0	3	1	1	1
141077	1710	T lymphocyte in female	[T lymphocytes in females]	0.0	4	1	1	1
141078	1710	resting nuclear extract	[Resting nuclear extracts]	0.0	3	1	1	1
141079	1710	stress disorder ptsd	[stress disorder PTSD]	0.0	3	1	1	1
141080	1710	modulate release of endothelium-derived factor	[modulating release of endothelium-derived factors]	0.0	5	1	1	1
141081	1710	18 aml sample	[18 AML samples]	0.0	3	1	1	1
141082	1710	keratoconjunctivitis a eosinophilic disease	[keratoconjunctivitis an eosinophilic disease.]	0.0	4	1	1	1
141083	1710	one line	[One line]	0.0	2	1	1	1
141084	1710	PAF up-regulation	[PAF up-regulation]	0.0	2	1	1	1
141085	1710	mitogen-activated protein kinase kinase	[mitogen-activated protein kinase kinase]	0.0	4	1	1	1
141086	1710	relationship with the change in receptor	[relationship with the changes in receptor]	0.0	6	2	2	1
141087	1710	nitrogen intermediate release	[nitrogen intermediate release]	0.0	3	1	1	1
141088	1710	TTCC	[TTCC]	0.0	1	1	1	1
141089	1710	encode the tax protein a transactivator	[encoding the Tax protein a transactivator]	0.0	6	1	1	1
141090	1710	progeny virion	[progeny virions]	0.0	2	2	2	1
141091	1710	blockade use a ikappabalpha	[blockade using a IkappaBalpha]	0.0	4	1	1	1
141092	1710	selective activation at the IFN-gamma receptor	[Selective activation at the IFN-gamma receptor]	0.0	6	1	1	1
141093	1710	monocyte binding to aortic cell harc	[monocyte binding to aortic cells HAECs]	0.0	6	1	1	1
141094	1710	domain of gal4	[domain of GAL4]	0.0	3	1	1	1
141095	1710	remain wild-type allele	[remaining wild-type allele]	0.0	3	1	1	1
141096	1710	capacity of single cd34+thy-1+ cell	[capacity of single CD34+Thy-1+ cells]	0.0	5	1	1	1
141097	1710	goal of study	[goal of study]	0.0	3	1	1	1
141098	1710	carbonic anhydrase a gene	[carbonic anhydrase a gene]	0.0	4	1	1	1
141099	1710	u937 with ifn-gamma	[U937 with IFN-gamma]	0.0	3	1	1	1
141100	1710	produce progeny at the time.	[producing progeny at the time.]	0.0	5	1	1	1
141101	1710	assess responsiveness	[assessing responsiveness]	0.0	2	1	1	1
141102	1710	bipotential myelomonoblastic cell population	[bipotential myelomonoblastic cell population]	0.0	4	1	1	1
141103	1710	endogenous no production	[endogenous NO production]	0.0	3	1	1	1
141104	1710	early progenitor cell hpc	[early progenitor cells HPCs]	0.0	4	1	1	1
141105	1710	PPARgamma a partner of RXR	[PPARgamma a partner of RXR]	0.0	5	1	1	1
141106	1710	immediate-early gene expression	[immediate-early gene expression]	0.0	3	1	1	1
141107	1710	general consequence of DNA damage	[general consequence of DNA damage]	0.0	5	1	1	1
141108	1710	use a b oligonucleotide	[using a B oligonucleotide]	0.0	4	1	1	1
141109	1710	breakpoint kb from sox9	[breakpoints kb from SOX9]	0.0	4	1	1	1
141110	1710	macrophage protein	[macrophage proteins]	0.0	2	1	1	1
141111	1710	gene expression in the tumour	[gene expression in the tumour]	0.0	5	1	1	1
141112	1710	il-1 signal transduction	[IL-1 signal transduction]	0.0	3	1	1	1
141113	1710	system a leukemic cell line	[systems a leukemic cell line]	0.0	5	1	1	1
141114	1710	exposure of monocytic cell to lipopolysaccharide	[Exposure of monocytic cells to lipopolysaccharide]	0.0	6	1	1	1
141115	1710	exposure of aortic endothelial cell HAEC	[exposure of aortic endothelial cells HAEC]	0.0	6	1	1	1
141116	1710	evaluation of cohort	[Evaluation of cohorts]	0.0	3	1	1	1
141117	1710	nf-kappa b probe homologous	[NF-kappa B probe homologous]	0.0	4	1	1	1
141118	1710	hormone-inducible trans-activate protein in transfection	[hormone-inducible trans-activating proteins in transfection]	0.0	5	1	1	1
141119	1710	pml/raralpha expression in cell	[PML/RARalpha expression in cells]	0.0	4	1	1	1
141120	1710	breast aspirate	[breast aspirates]	0.0	2	1	1	1
141121	1710	utilization of signal transduction pathway	[utilization of signal transduction pathways]	0.0	5	1	1	1
141122	1710	b chemokine	[B chemokine]	0.0	2	1	1	1
141123	1710	th0-type T cell clone	[Th0-type T cell clones]	0.0	4	1	1	1
141124	1710	theme	[theme]	0.0	1	1	1	1
141125	1710	mediator of the cellular response	[mediator of the cellular response]	0.0	5	1	1	1
141126	1710	presence in vaginal fluid	[presence in vaginal fluid]	0.0	4	1	1	1
141127	1710	trancriptional role	[trancriptional roles]	0.0	2	1	1	1
141128	1710	DM+, DO-	[DM+, DO-]	0.0	2	1	1	1
141129	1710	complete VDR coding region	[complete VDR coding region]	0.0	4	1	1	1
141130	1710	phenotype, t-cell receptor	[phenotype, T-cell receptor]	0.0	3	1	1	1
141131	1710	fate decision of hematopoietic progenitor	[fate decisions of hematopoietic progenitors]	0.0	5	1	1	1
141132	1710	cell-type induction	[cell-type induction]	0.0	2	1	1	1
141133	1710	specific translocation mechanism	[specific translocation mechanism]	0.0	3	1	1	1
141134	1710	demonstration of cell growth by analysis	[Demonstration of cell growth by analysis]	0.0	6	1	1	1
141135	1710	major proinflammatory cytokine in monocyte	[major proinflammatory cytokines in monocytes]	0.0	5	1	1	1
141136	1710	bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane	[bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane]	0.0	1	1	1	1
141137	1710	calf serum-supplemented efcs clonogenic culture	[calf serum-supplemented (FCS+) clonogenic culture]	0.0	5	1	1	1
141138	1710	affinity for dna-binding	[affinity for DNA-binding]	0.0	3	1	1	1
141139	1710	expression of ah receptor during differentiation	[Expression of Ah receptor during differentiation]	0.0	6	1	1	1
141140	1710	estrogenic	[estrogenic]	0.0	1	1	1	1
141141	1710	apparently accurate model	[apparently accurate model]	0.0	3	1	1	1
141142	1710	signal-mediating kinase	[signal-mediating kinases]	0.0	2	1	1	1
141143	1710	human monocytic differentiation	[human monocytic differentiation]	0.0	3	1	1	1
141144	1710	evidence identical proteins, differ in degree	[evidence identical proteins, differing in degree]	0.0	6	1	1	1
141145	1710	expression of ciita surface protein	[expression of CIITA surface proteins]	0.0	5	1	1	1
141146	1710	undifferentiated spindle-shaped carcinoma	[undifferentiated spindle-shaped carcinomas]	0.0	3	1	1	1
141147	1710	cd37 b lymphocyte from blood	[CD37 B lymphocytes from blood]	0.0	5	1	1	1
141148	1710	distal factor	[distal factor]	0.0	2	1	1	1
141149	1710	other amino acid	[other amino acids]	0.0	3	1	1	1
141150	1710	putative downstream site	[putative downstream site]	0.0	3	1	1	1
141151	1710	competition between two transcriptional activator RelA	[competition between two transcriptional activators RelA]	0.0	6	1	1	1
141152	1710	regulate il-4 gene expression	[regulating IL-4 gene expression]	0.0	4	1	1	1
141153	1710	therapy in leukocyte of patient	[therapy in leukocytes of patients]	0.0	5	1	1	1
141154	1710	effect of oxygen intermediate	[effects of oxygen intermediates]	0.0	4	1	1	1
141155	1710	C5a il-8 production	[C5a IL-8 production]	0.0	3	1	1	1
141156	1710	anonymous probe	[anonymous probes]	0.0	2	1	1	1
141157	1710	PL/IM 430 monoclonal antibody	[PL/IM 430 monoclonal antibody]	0.0	4	1	1	1
141158	1710	contrast, induction	[contrast, induction]	0.0	2	1	1	1
141159	1710	mechanism for immunosuppression: inhibition	[mechanism for immunosuppression: inhibition]	0.0	4	1	1	1
141160	1710	dp2 -353 bp of the promoter	[DP2 -353 bp of the promoter]	0.0	6	1	1	1
141161	1710	upstream region (position responsive	[upstream region (positions responsive]	0.0	4	1	1	1
141162	1710	many factors, in particular, proinflammatory cytokine	[Many factors, in particular, proinflammatory cytokines]	0.0	6	1	1	1
141163	1710	tyrosine phosphorylation of protein include Cbl	[tyrosine phosphorylation of proteins including Cbl]	0.0	6	1	1	1
141164	1710	reactivation of tumor-suppressor gene expression	[reactivation of tumor-suppressor gene expression]	0.0	5	1	1	1
141165	1710	major disease tuberculosis	[major diseases tuberculosis]	0.0	3	1	1	1
141166	1710	function in development	[function in development]	0.0	3	1	1	1
141167	1710	several feature characteristic	[several features characteristic]	0.0	3	1	1	1
141168	1710	ifngr1 deletion	[IFNGR1 deletions]	0.0	2	1	1	1
141169	1710	level of viral transcription basal transcription	[levels of viral transcription basal transcription]	0.0	6	1	1	1
141170	1710	interaction with two protein	[interaction with two proteins]	0.0	4	1	1	1
141171	1710	activation c-Jun n-terminal kinase JNK	[activation c-Jun N-terminal kinase JNK]	0.0	5	1	1	1
141172	1710	function of a type	[functions of a type]	0.0	4	1	1	1
141173	1710	mad3 protein	[MAD3 protein]	0.0	2	1	1	1
141174	1710	patient with polycythemia vera	[patients with polycythemia vera]	0.0	4	1	1	1
141175	1710	Goldberg, a.l.,	[Goldberg, A.L.,]	0.0	2	1	1	1
141176	1710	LTR vector	[LTR vectors]	0.0	2	1	1	1
141177	1710	contain nfat-family protein	[containing NFAT-family proteins]	0.0	3	1	1	1
141178	1710	c-jun tre-like promoter element	[c-jun TRE-like promoter element]	0.0	4	1	1	1
141179	1710	pretreatment with microm OP	[Pretreatment with microM OP]	0.0	4	1	1	1
141180	1710	substoichiometric taf of kda	[substoichiometric TAF of kDa]	0.0	4	1	1	1
141181	1710	combination of the antagonist	[combination of the antagonist]	0.0	4	1	1	1
141182	1710	interference with dexamethasone	[interference with dexamethasone]	0.0	3	1	1	1
141183	1710	aberrant consequence of memory	[aberrant consequence of memory]	0.0	4	1	1	1
141184	1710	induction of other gene	[induction of other genes]	0.0	4	1	1	1
141185	1710	ceroid-lypofuscinosis	[ceroid-lypofuscinosis]	0.0	1	1	1	1
141186	1710	tfiid-dependent rna polymerase transcription system	[TFIID-dependent RNA polymerase transcription systems]	0.0	5	1	1	1
141187	1710	correlation between receptor or positivity	[correlation between receptor OR positivity]	0.0	5	1	1	1
141188	1710	t-cell (nfat) site	[T-cell (NFAT) sites]	0.0	3	1	1	1
141189	1710	human nuclear differentiation antigen MNDA	[human nuclear differentiation antigen MNDA]	0.0	5	1	1	1
141190	1710	early expression	[early expression]	0.0	2	1	1	1
141191	1710	Functional study in extrarenal, cell	[Functional studies in extrarenal, cells]	0.0	5	1	1	1
141192	1710	beta-globin reporter gene expression	[beta-globin reporter gene expression]	0.0	4	1	1	1
141193	1710	presence in the extract	[presence in the extract]	0.0	4	1	1	1
141194	1710	P. g.)	[P. G.)]	0.0	2	1	1	1
141195	1710	canrenone (140	[canrenone (140]	0.0	2	1	1	1
141196	1710	twenty two man	[Twenty two men]	0.0	3	1	1	1
141197	1710	morphogen a normal constituent	[morphogen a normal constituent]	0.0	4	1	1	1
141198	1710	novel gene product	[novel gene product]	0.0	3	1	1	1
141199	1710	treatment tyrosine phosphorylation	[Treatment tyrosine phosphorylation]	0.0	3	1	1	1
141200	1710	tnf alpha/beta	[TNF alpha/beta]	0.0	2	1	1	1
141201	1710	expression above level	[expression above levels]	0.0	3	1	1	1
141202	1710	contain STAT3 alpha	[containing STAT3 alpha]	0.0	3	1	1	1
141203	1710	antigen-specific T helper clone	[antigen-specific T helper clones]	0.0	4	1	1	1
141204	1710	moreover, replacement	[Moreover, replacement]	0.0	2	1	1	1
141205	1710	inhibitory protein of nf-kappa b	[inhibitory protein of NF-kappa B]	0.0	5	1	1	1
141206	1710	event detectable	[events detectable]	0.0	2	1	1	1
141207	1710	such as the activation	[such as the activation]	0.0	4	1	1	1
141208	1710	nf-kappab generation	[NF-kappaB generation]	0.0	2	1	1	1
141209	1710	new, complex	[new, complex]	0.0	2	1	1	1
141210	1710	defect in different aspect	[defects in different aspects]	0.0	4	1	1	1
141211	1710	suppression to the endothelium	[Suppression to the endothelium]	0.0	4	1	1	1
141212	1710	peroxisome receptor ppar member	[Peroxisome receptors PPARs members]	0.0	4	1	1	1
141213	1710	such as the tyrosine phosphorylation	[such as the tyrosine phosphorylation]	0.0	5	1	1	1
141214	1710	protein p52	[proteins p52]	0.0	2	1	1	1
141215	1710	mutation/deletion of NF-kappa b site	[mutation/deletion of NF-kappa B site]	0.0	5	1	1	1
141216	1710	subunit to distinct region	[subunits to distinct regions]	0.0	4	1	1	1
141217	1710	determine the rank order of potency	[determining the rank order of potency]	0.0	6	1	1	1
141218	1710	dual pattern	[dual pattern]	0.0	2	1	1	1
141219	1710	serum-contain mediuhd colony	[serum-containing medium, colonies]	0.0	3	1	1	1
141220	1710	provide a initial point	[providing an initial point]	0.0	4	1	1	1
141221	1710	patient with primary carcinoma	[patients with primary carcinoma]	0.0	4	1	1	1
141222	1710	year Gail risk probability)	[year Gail risk probability)]	0.0	4	1	1	1
141223	1710	steroid binding activity	[steroid binding activity]	0.0	3	1	1	1
141224	1710	several factors,	[several factors,]	0.0	2	1	1	1
141225	1710	genomic DNA clone	[genomic DNA clones]	0.0	3	1	1	1
141226	1710	NFkappaB site	[NFkappaB sites]	0.0	2	1	1	1
141227	1710	set in motion a series	[setting in motion a series]	0.0	5	1	1	1
141228	1710	therapeutic potential in the treatment	[therapeutic potential in the treatment]	0.0	5	1	1	1
141229	1710	deleterious mechanism related	[deleterious mechanism related]	0.0	3	1	1	1
141230	1710	change in runner	[changes in runner]	0.0	3	1	1	1
141231	1710	leukopenia	[leukopenia]	0.0	1	1	1	1
141232	1710	uptake by PBMC with failure	[uptake by PBMC with failure]	0.0	5	1	1	1
141233	1710	element in the tsp promoter,	[elements in the TSP promoter,]	0.0	5	1	1	1
141234	1710	inflammatory cell infiltration	[inflammatory cell infiltration]	0.0	3	1	1	1
141235	1710	protein-1 binding	[protein-1 binding]	0.0	2	1	1	1
141236	1710	influence of estrogen metabolism	[influence of estrogen metabolism]	0.0	4	1	1	1
141237	1710	lymphocyte CL	[lymphocytes CLs]	0.0	2	1	1	1
141238	1710	catalytic cleft	[catalytic cleft]	0.0	2	1	1	1
141239	1710	reactivity to the ligand	[reactivity to the ligand]	0.0	4	1	1	1
141240	1710	extend from the transcriptional start site	[extending from the transcriptional start site]	0.0	6	1	1	1
141241	1710	endothelial cell glutathione gsh	[endothelial cell glutathione GSH]	0.0	4	1	1	1
141242	1710	X inactivation analysis evidence for disomy	[X inactivation analysis evidence for disomy]	0.0	6	1	1	1
141243	1710	function in human T lymphocyte	[functions in human T lymphocytes]	0.0	5	1	1	1
141244	1710	actual proliferative activity	[actual proliferative activity]	0.0	3	1	1	1
141245	1710	defective production type 1	[defective production type 1]	0.0	4	1	1	1
141246	1710	involvement distinguish T cell activation	[Involvement distinguishing T cell activation]	0.0	5	1	1	1
141247	1710	major 29-kda protein	[major 29-kDa proteins]	0.0	3	1	1	1
141248	1710	intensity,	[intensity,]	0.0	1	1	1	1
141249	1710	consent, biopsy	[consent, biopsies]	0.0	2	1	1	1
141250	1710	localization by techniques: western blot	[localization by techniques: Western blot]	0.0	5	1	1	1
141251	1710	region -1168 to -440	[regions -1168 to -440]	0.0	4	1	1	1
141252	1710	pair of oligonucleotide	[pairs of oligonucleotides]	0.0	3	1	1	1
141253	1710	Epstein-Barr virus gene transcription	[Epstein-Barr virus gene transcription]	0.0	4	1	1	1
141254	1710	variant line	[variant line]	0.0	2	1	1	1
141255	1710	adenoviral group A-F	[adenoviral groups A-F]	0.0	3	1	1	1
141256	1710	impaired transcriptional response	[impaired transcriptional responses]	0.0	3	1	1	1
141257	1710	pigmentosum	[pigmentosum]	0.0	1	2	2	1
141258	1710	suggest action	[suggesting action]	0.0	2	1	1	1
141259	1710	production of antigen	[production of antigens]	0.0	3	1	1	1
141260	1710	contain alteration	[containing alterations]	0.0	2	1	1	1
141261	1710	activate protein-1	[activating protein-1]	0.0	2	2	2	1
141262	1710	fibrinogen nf-kappa b activation	[fibrinogen NF-kappa B activation]	0.0	4	1	1	1
141263	1710	capability pre-treatment	[capabilities pre-treatment]	0.0	2	1	1	1
141264	1710	b-dependent	[B-dependent]	0.0	1	1	1	1
141265	1710	establish new cell line keep property	[establishing new cell lines keeping properties]	0.0	6	1	1	1
141266	1710	272 receptor /cell for type	[272 receptors /cell for type]	0.0	5	1	1	1
141267	1710	vivo inhibition in t-lineage cell	[vivo inhibition in T-lineage cells]	0.0	5	1	1	1
141268	1710	effective treatment	[effective treatment]	0.0	2	1	1	1
141269	1710	protein by a receptor	[protein by a receptor]	0.0	4	1	1	1
141270	1710	year) in the presence epo factor	[year) in the presence EPO factor]	0.0	6	1	1	1
141271	1710	slight transient increase	[slight transient increase]	0.0	3	1	1	1
141272	1710	intracellular messenger	[intracellular messengers]	0.0	2	1	1	1
141273	1710	cancerous cell line	[cancerous cell lines]	0.0	3	1	1	1
141274	1710	pbmc receptor	[PBMC receptors]	0.0	2	1	1	1
141275	1710	transcription factor factor-kappaB nf-kappab	[transcription factor factor-kappaB NF-kappaB]	0.0	4	2	2	1
141276	1710	Pancreatic development	[Pancreatic development]	0.0	2	1	1	1
141277	1710	transformation of Philadelphia chromosome-positive leukemia	[transformation of Philadelphia chromosome-positive leukemia]	0.0	5	1	1	1
141278	1710	oxidant acid	[oxidant acid]	0.0	2	1	1	1
141279	1710	autosomal mode	[autosomal mode]	0.0	2	2	2	1
141280	1710	distinct protein complex a ubiquitous factor	[distinct protein complexes a ubiquitous factor]	0.0	6	1	1	1
141281	1710	urinary cortisol the number	[urinary cortisol the number]	0.0	4	1	1	1
141282	1710	relevant creb kinase	[relevant CREB kinase]	0.0	3	1	1	1
141283	1710	STAT binding sequence	[STAT binding sequences]	0.0	3	1	1	1
141284	1710	selection in the cortex	[selection in the cortex]	0.0	4	1	1	1
141285	1710	steroid -receptor complex	[steroid -receptor complexes]	0.0	3	1	1	1
141286	1710	Pax-gene family	[Pax-gene family]	0.0	2	1	1	1
141287	1710	aspect of senescence.	[aspects of senescence.]	0.0	3	1	1	1
141288	1710	approximately the same transactivation ability	[approximately the same transactivation ability]	0.0	5	1	1	1
141289	1710	also terminal of FK506 pathway	[also terminals of FK506 pathway]	0.0	5	1	1	1
141290	1710	signal mediator in dermal cell	[signaling mediators in dermal cells]	0.0	5	1	1	1
141291	1710	multiple form	[multiple forms]	0.0	2	1	1	1
141292	1710	chick intestinal 135eoh)2d3 receptor	[chick intestinal 1,25(OH)2D3 receptor]	0.0	4	1	1	1
141293	1710	effect of CD4	[effect of CD4]	0.0	3	1	1	1
141294	1710	sometimes at variance results.	[sometimes at variance results.]	0.0	4	1	1	1
141295	1710	model of human cd34+ hpc	[model of human CD34+ HPC]	0.0	5	1	1	1
141296	1710	short c-terminal peptide	[shorter C-terminal peptide]	0.0	3	1	1	1
141297	1710	T cytoplasmic factor	[T cytoplasmic factor]	0.0	3	1	1	1
141298	1710	(cdiia)	[(CDIIa)]	0.0	1	1	1	1
141299	1710	ly294002 a specific inhibitor	[LY294002 a specific inhibitor]	0.0	4	1	1	1
141300	1710	protein slp-76	[protein SLP-76]	0.0	2	1	1	1
141301	1710	interleukin-2 IL2 a cytokine facilitate progression	[interleukin-2 IL2 a cytokine facilitating progression]	0.0	6	1	1	1
141302	1710	x-linked severe immunodeficiency xscid	[X-linked severe immunodeficiency XSCID]	0.0	4	1	1	1
141303	1710	antiapoptotic property	[antiapoptotic property]	0.0	2	1	1	1
141304	1710	hypermutation act outside Ig loci	[hypermutation acting outside Ig loci]	0.0	5	1	1	1
141305	1710	regulating protein	[regulating proteins]	0.0	2	1	1	1
141306	1710	extent after cho-cd86 stimulation.	[extent after CHO-CD86 stimulation.]	0.0	4	1	1	1
141307	1710	induction of RALDH2	[induction of RALDH2]	0.0	3	1	1	1
141308	1710	quantitative dnase footprinting use amount	[quantitative DNase footprinting using amounts]	0.0	5	1	1	1
141309	1710	patient with sle (0.2979	[patients with SLE (0.2979]	0.0	4	1	1	1
141310	1710	immunoglobulin mu chain gene	[immunoglobulin mu chain gene]	0.0	4	1	1	1
141311	1710	lack of electrolyte response	[lack of electrolyte response]	0.0	4	1	1	1
141312	1710	fatty protein	[fatty protein]	0.0	2	1	1	1
141313	1710	action of gata-2/er	[action of GATA-2/ER]	0.0	3	1	1	1
141314	1710	potential stati DNA binding element	[potential STATI DNA binding elements]	0.0	5	1	1	1
141315	1710	characterization of transactivation binding	[characterization of transactivation Binding]	0.0	4	1	1	1
141316	1710	mrna -contain	[mRNA -containing]	0.0	2	1	1	1
141317	1710	follow stimulation in normal control	[following stimulation in normal controls]	0.0	5	1	1	1
141318	1710	localization by techniques: blot	[localization by techniques: blot]	0.0	4	1	1	1
141319	1710	modality for hiv-1 infection	[modality for HIV-1 infection]	0.0	4	1	1	1
141320	1710	hiv in human blood lymphocyte	[HIV in human blood lymphocytes]	0.0	5	1	1	1
141321	1710	case of aitl/gc	[cases of AITL/GC]	0.0	3	1	1	1
141322	1710	apparently accurate model for apl	[apparently accurate model for APL]	0.0	5	1	1	1
141323	1710	dose within 72 P;	[dose within 72 h;]	0.0	4	1	1	1
141324	1710	second protein related	[second protein related]	0.0	3	1	1	1
141325	1710	cell per millileter	[cells per ml]	0.0	3	1	1	1
141326	1710	down-regulation of protein in nasal lymphoma	[Down-regulation of proteins in nasal lymphoma]	0.0	6	1	1	1
141327	1710	cooperative transcription complex contain protein	[cooperative transcription complexes containing proteins]	0.0	5	1	1	1
141328	1710	couple from -500 to -250 bp	[Coupling from -500 to -250 bp]	0.0	6	1	1	1
141329	1710	human T cell progenitor	[human T cell progenitors]	0.0	4	1	1	1
141330	1710	kruppel-like factor eklf	[Kruppel-like factor EKLF]	0.0	3	1	1	1
141331	1710	cytokine of neutrophil	[cytokines of neutrophils]	0.0	3	1	1	1
141332	1710	IL-3 factor complex in eosinophil	[IL-3 factor complexes in eosinophils]	0.0	5	1	1	1
141333	1710	requirement of element	[requirement of elements]	0.0	3	1	1	1
141334	1710	cytokine assembly of stat5a	[cytokines assembly of STAT5A]	0.0	4	1	1	1
141335	1710	(cck(b))	[(CCK(B))]	0.0	1	1	1	1
141336	1710	respectively)	[respectively)]	0.0	1	1	1	1
141337	1710	rare hereditary disorder	[rare hereditary disorder]	0.0	3	1	1	1
141338	1710	death-inducing ligand	[Death-inducing ligands]	0.0	2	1	1	1
141339	1710	4 hour of exposure	[4 hr of exposure]	0.0	4	1	1	1
141340	1710	inhibition a macrophage scavenger receptor	[inhibition A macrophage scavenger receptor]	0.0	5	1	1	1
141341	1710	cDNA sequence Nov1	[cDNA sequences Nov1]	0.0	3	1	1	1
141342	1710	oligonucleotide competition experiments,	[oligonucleotide competition experiments,]	0.0	3	1	1	1
141343	1710	syndrome MDS in stage	[syndromes MDS in stage]	0.0	4	1	1	1
141344	1710	x-linked immunodeficiency xscid	[X-linked immunodeficiency XSCID]	0.0	3	1	1	1
141345	1710	t(15;17) chromosomal translocation	[t(15;17) chromosomal translocation]	0.0	3	1	1	1
141346	1710	regulate the distribution receptor	[regulating the distribution receptors]	0.0	4	1	1	1
141347	1710	patient with tumor of the cavity	[patients with tumors of the cavity]	0.0	6	1	1	1
141348	1710	IL-2 tyrosine phosphorylation	[IL-2 tyrosine phosphorylation]	0.0	3	2	2	1
141349	1710	response through form of collaboration	[response through forms of collaboration]	0.0	5	1	1	1
141350	1710	phorbol differentiation of U937 cell	[phorbol differentiation of U937 cells]	0.0	5	1	1	1
141351	1710	proinflammatory cytokine gene expression	[proinflammatory cytokine gene expression]	0.0	4	1	1	1
141352	1710	only by a assay	[only by an assay]	0.0	4	1	1	1
141353	1710	correlation between level in vitro.	[correlation between level in vitro.]	0.0	5	1	1	1
141354	1710	indicate negative regulation of the promoter	[indicating negative regulation of the promoter]	0.0	6	1	1	1
141355	1710	human bactericidal/permeability-increasing protein	[human bactericidal/permeability-increasing protein]	0.0	3	1	1	1
141356	1710	activator of host defense gene	[activator of host defense genes]	0.0	5	1	1	1
141357	1710	costimulatory role	[costimulatory role]	0.0	2	1	1	1
141358	1710	engagement of the P0 element	[engagement of the P0 elements]	0.0	5	1	1	1
141359	1710	tumor material	[tumor material]	0.0	2	1	1	1
141360	1710	regulator i HTLV-I	[regulator I HTLV-I]	0.0	3	1	1	1
141361	1710	oxide a feedback inhibitor	[oxide an feedback inhibitor]	0.0	4	1	1	1
141362	1710	Ets family member Ets-1	[Ets family members Ets-1]	0.0	4	1	1	1
141363	1710	majority of gene	[majority of genes]	0.0	3	1	1	1
141364	1710	signal CD40 stimulation	[signaling CD40 stimulation]	0.0	3	1	1	1
141365	1710	express T antigen	[expressing T antigen]	0.0	3	1	1	1
141366	1710	female aged between 8	[females aged between 8]	0.0	4	1	1	1
141367	1710	two distinguishable gr bind abnormalities:	[two distinguishable GR binding abnormalities:]	0.0	5	1	1	1
141368	1710	mediate t-cell activation	[mediating T-cell activation]	0.0	3	1	1	1
141369	1710	interleukin-2 promoter activity b lymphocyte	[Interleukin-2 promoter activity B lymphocytes]	0.0	5	1	1	1
141370	1710	t-cell lymphoma with hyperplastic center	[T-cell lymphoma with hyperplastic centers]	0.0	5	1	1	1
141371	1710	cell differentiation antigen	[cell differentiation antigen]	0.0	3	1	1	1
141372	1710	incidence particularly with cytomegalovirus	[incidence particularly with cytomegalovirus]	0.0	4	1	1	1
141373	1710	include the induction of cyclin D2	[including the induction of cyclin D2]	0.0	6	1	1	1
141374	1710	expression of another immediate-early protein BRLF1	[expression of another immediate-early protein BRLF1]	0.0	6	1	1	1
141375	1710	expression of p13mtcp1 lymphoid tissue	[expression of p13MTCP1 lymphoid tissues]	0.0	5	1	1	1
141376	1710	replication of strain of hiv	[replication of strains of HIV]	0.0	5	1	1	1
141377	1710	homodimeric rel-related protein	[homodimeric Rel-related proteins]	0.0	3	1	1	1
141378	1710	bronchoscopy with endobronchial biopsy	[bronchoscopy with endobronchial biopsy]	0.0	4	1	1	1
141379	1710	estrogen replacement	[estrogen replacement]	0.0	2	1	1	1
141380	1710	aml-1b	[AML-1B]	0.0	1	1	1	1
141381	1710	gc -receptor	[GC -receptor]	0.0	2	1	1	1
141382	1710	epo hcd57-srei cell	[EPO HCD57-SREI cells]	0.0	3	1	1	1
141383	1710	stimulation of b-cell	[stimulation of B-cells]	0.0	3	1	1	1
141384	1710	pretreatment of "semimature" human monocyte-derived macrophage	[Pretreatment of "semimature" human monocyte-derived macrophages]	0.0	6	1	1	1
141385	1710	thymocyte undergo negative selection	[thymocytes undergoing negative selection]	0.0	4	1	1	1
141386	1710	other cell specific gene	[other cell specific genes]	0.0	4	1	1	1
141387	1710	transcription factor z	[transcription factor Z]	0.0	3	1	1	1
141388	1710	ebv-induced growth	[EBV-induced growth]	0.0	2	1	1	1
141389	1710	proline amino acid-rich	[proline amino acid-rich]	0.0	3	1	1	1
141390	1710	receptor gr in human lymphocyte	[receptors GR in human lymphocytes]	0.0	5	1	1	1
141391	1710	chronic back pain a pain	[chronic back pain a pain]	0.0	5	1	1	1
141392	1710	activity of monocyte	[activity of monocytes]	0.0	3	1	1	1
141393	1710	t-pll tumour	[T-PLL tumours]	0.0	2	1	1	1
141394	1710	tissue from woman	[Tissues from women]	0.0	3	1	1	1
141395	1710	Latent infection	[Latent infection]	0.0	2	1	1	1
141396	1710	cross-link cd19	[Cross-linking CD19]	0.0	2	1	1	1
141397	1710	tyrosine phosphorylation of phospholipase c-gamma1	[tyrosine phosphorylation of phospholipase C-gamma1]	0.0	5	1	1	1
141398	1710	binding motif by mutagenesis	[binding motifs by mutagenesis]	0.0	4	1	1	1
141399	1710	include blood monocyte	[including blood monocytes]	0.0	3	1	1	1
141400	1710	A6H antibody (mAb)	[A6H antibody (mAb)]	0.0	3	1	1	1
141401	1710	suggest crucial	[suggesting crucial]	0.0	2	1	1	1
141402	1710	drug such as 1-beta-d-arabino-furanosylcytosine	[drug such as 1-beta-D-arabino-furanosylcytosine]	0.0	4	1	1	1
141403	1710	nf-at transcription by NF-kappa b	[NF-AT transcription by NF-kappa B]	0.0	5	1	1	1
141404	1710	soluble matrix preparation	[soluble matrix preparations]	0.0	3	1	1	1
141405	1710	eosinophil stimulation	[eosinophil stimulation]	0.0	2	1	1	1
141406	1710	T cell-specific negative regulation	[T cell-specific negative regulation]	0.0	4	1	1	1
141407	1710	mechanism underlie this capacity	[mechanisms underlying this capacity]	0.0	4	1	1	1
141408	1710	activator RelA	[activators RelA]	0.0	2	1	1	1
141409	1710	gene for ebv replication,	[gene for EBV replication,]	0.0	4	1	1	1
141410	1710	parameter of cerulein-induced pancreatitis	[parameters of cerulein-induced pancreatitis]	0.0	4	1	1	1
141411	1710	profound implication in research	[profound implication in research]	0.0	4	1	1	1
141412	1710	onset of feature	[onset of features]	0.0	3	1	1	1
141413	1710	encode oct-binding factor 1 a protein	[encoding Oct-binding factor 1 a protein]	0.0	6	1	1	1
141414	1710	highly hydrophobic, polypeptide	[highly hydrophobic, polypeptide]	0.0	3	1	1	1
141415	1710	contribution of CD28 signal	[contribution of CD28 signals]	0.0	4	1	1	1
141416	1710	inhibitory dominant-negative Ras construct	[inhibitory dominant-negative Ras construct]	0.0	4	1	1	1
141417	1710	cellular transcription factor creb/atf	[cellular transcription factors CREB/ATF]	0.0	4	1	1	1
141418	1710	serine residue of IkappaB	[serine residues of IkappaB]	0.0	4	1	1	1
141419	1710	rapid decrease in nf-kappa b	[rapid decrease in NF-kappa B]	0.0	5	1	1	1
141420	1710	f(ab')2 fragment of anti- CR1	[F(ab')2 fragments of anti- CR1]	0.0	5	1	1	1
141421	1710	adenovirus cell	[adenovirus cells]	0.0	2	1	1	1
141422	1710	expression of the other factor	[expression of the other factor]	0.0	5	1	1	1
141423	1710	specify the unique 5' terminus	[specifying the unique 5' terminus]	0.0	5	1	1	1
141424	1710	differential display rt-pcr	[differential display RT-PCR]	0.0	3	1	1	1
141425	1710	combination with lps	[combination with LPS]	0.0	3	1	1	1
141426	1710	such as IL-2	[such as IL-2]	0.0	3	1	1	1
141427	1710	association of NF-kappaB activation	[association of NF-kappaB activation]	0.0	4	1	1	1
141428	1710	psi(m)	[psi(m)]	0.0	1	2	2	1
141429	1710	content of t3, dysfunction hypophyseal	[content of T3, dysfunction hypophyseal]	0.0	5	1	1	1
141430	1710	acetylation of factor eklf activity	[Acetylation of factor EKLF activity]	0.0	5	1	1	1
141431	1710	viable definitive erythroid cell a phenotype	[viable definitive erythroid cells a phenotype]	0.0	6	1	1	1
141432	1710	significantly favorable course chi2 test).	[significantly favorable course chi2 test).]	0.0	5	1	1	1
141433	1710	mutation in the NF-kappa b	[Mutations in the NF-kappa B]	0.0	5	1	1	1
141434	1710	interestingly, a transcriptional activator	[Interestingly, a transcriptional activator]	0.0	4	1	1	1
141435	1710	-immunoreactive cell in blood	[-immunoreactive cells in blood]	0.0	4	1	1	1
141436	1710	receptor GCR on leucocyte	[receptors GCR on leucocytes]	0.0	4	1	1	1
141437	1710	emergence follow administration	[emergence following administrations]	0.0	3	1	1	1
141438	1710	g-csf 8% dead cell	[G-CSF 8% dead cells]	0.0	4	1	1	1
141439	1710	appearance of specific transcription factor	[appearance of specific transcription factors]	0.0	5	1	1	1
141440	1710	ng of rna.	[ng of RNA.]	0.0	3	1	1	1
141441	1710	other functional region coding	[other functional regions coding]	0.0	4	1	1	1
141442	1710	role in the response	[role in the response]	0.0	4	1	1	1
141443	1710	NFAT gene family	[NFAT gene family]	0.0	3	1	1	1
141444	1710	exact cellular defect(s)	[exact cellular defect(s)]	0.0	3	1	1	1
141445	1710	evidence important in transformation	[evidence important in transformation]	0.0	4	1	1	1
141446	1710	ifn-gamma tumor necrosis factor-alpha	[IFN-gamma tumor necrosis factor-alpha]	0.0	4	1	1	1
141447	1710	matrix attachment (Scheuermann, R. h.,	[matrix attachment (Scheuermann, R. H.,]	0.0	5	1	1	1
141448	1710	tat single-chain intracellular antibody	[Tat single-chain intracellular antibody]	0.0	4	1	1	1
141449	1710	co-stimulation of microglia with suboptimal concentration	[Co-stimulation of microglia with suboptimal concentrations]	0.0	6	1	1	1
141450	1710	GM-CSF element	[GM-CSF element]	0.0	2	1	1	1
141451	1710	41 exon span kb of DNA	[41 exons spanning kb of DNA]	0.0	6	1	1	1
141452	1710	apoptosisprone cell	[apoptosisprone cells]	0.0	2	1	1	1
141453	1710	methods: thp-1 cell	[METHODS: THP-1 cells]	0.0	3	1	1	1
141454	1710	growth growth factor a mitogen	[growth growth factor a mitogen]	0.0	5	1	1	1
141455	1710	examination of phosphorylation	[Examination of phosphorylation]	0.0	3	1	1	1
141456	1710	fibrinogen-binding integrin	[fibrinogen-binding integrins]	0.0	2	1	1	1
141457	1710	rearrangement of bcl-6	[rearrangements of BCL-6]	0.0	3	1	1	1
141458	1710	tarsal biopsy	[tarsal biopsies]	0.0	2	1	1	1
141459	1710	common pathway bypass the requirement	[common pathway bypassing the requirement]	0.0	5	1	1	1
141460	1710	receptor for chemokine	[receptor for chemokines]	0.0	3	1	1	1
141461	1710	effect during lung injury	[effects during lung injury]	0.0	4	1	1	1
141462	1710	two activation-dependent events:	[two activation-dependent events:]	0.0	3	1	1	1
141463	1710	cell of lupus patient	[cells of lupus patients]	0.0	4	1	1	1
141464	1710	relate ros activity to disease	[relating ROS activity to diseases]	0.0	5	1	1	1
141465	1710	understand the event of some,	[understanding the events of some,]	0.0	5	1	1	1
141466	1710	promotion of differentiation	[promotion of differentiation]	0.0	3	1	1	1
141467	1710	cofactor for protein	[cofactor for proteins]	0.0	3	1	1	1
141468	1710	action on dendritic cell (dc)	[action on dendritic cells (DC)]	0.0	5	1	1	1
141469	1710	cell with function	[cells with functions]	0.0	3	1	1	1
141470	1710	adhesion in tnf-treated vein cell HUVECs	[adhesion in TNF-treated vein cells HUVECs]	0.0	6	1	1	1
141471	1710	u-937 cell with tpa	[U-937 cells with TPA]	0.0	4	1	1	1
141472	1710	activation of ig synthesis	[activation of Ig synthesis]	0.0	4	1	1	1
141473	1710	several mammalian response	[Several mammalian responses]	0.0	3	1	1	1
141474	1710	AES peptide G75	[AES peptides G75]	0.0	3	1	1	1
141475	1710	glucocorticoid for a degree of inhibition.	[glucocorticoids for an degree of inhibition.]	0.0	6	1	1	1
141476	1710	thus establish a relation	[thus establishing an relation]	0.0	4	1	1	1
141477	1710	secretion of prostate-specific antigen	[secretion of prostate-specific antigen]	0.0	4	1	1	1
141478	1710	Germany.	[Germany.]	0.0	1	1	1	1
141479	1710	initial fate of transcription factor	[initial fate of transcription factors]	0.0	5	1	1	1
141480	1710	regulation of epsilon germline transcription role	[Regulation of epsilon germline transcription role]	0.0	6	1	1	1
141481	1710	transcription factor with a domain	[transcription factor with a domain]	0.0	5	1	1	1
141482	1710	link between the induction	[link between the induction]	0.0	4	1	1	1
141483	1710	preincubation with lef-1 lef-1	[preincubation with LEF-1 LEF-1]	0.0	4	1	1	1
141484	1710	mutant tax protein	[mutant Tax protein]	0.0	3	1	1	1
141485	1710	NF-kappa B/Rel activation	[NF-kappa B/Rel activation]	0.0	3	1	1	1
141486	1710	cell-type-specific trans-acting factor	[cell-type-specific trans-acting factors]	0.0	3	1	1	1
141487	1710	isolation for Kruppel-related zinc finger protein	[Isolation for Kruppel-related zinc finger proteins]	0.0	6	1	1	1
141488	1710	ebv tumour tissue	[EBV tumour tissues]	0.0	3	1	1	1
141489	1710	concentration of native peptide	[concentrations of native peptide]	0.0	4	1	1	1
141490	1710	bind the kappa b sequence	[binding the kappa B sequence]	0.0	5	1	1	1
141491	1710	combination of retinoic acid RA	[combination of retinoic acid RA]	0.0	5	1	1	1
141492	1710	even after prolonged infection	[even after prolonged infection]	0.0	4	1	1	1
141493	1710	furthermore, 68 triple-labelling	[Furthermore, 68 triple-labellings]	0.0	3	1	1	1
141494	1710	potentially more common syndrome	[potentially more common syndrome]	0.0	4	1	1	1
141495	1710	cell THP-1	[cells THP-1]	0.0	2	1	1	1
141496	1710	induction via activation	[Induction via activation]	0.0	3	1	1	1
141497	1710	study role	[studying role]	0.0	2	1	1	1
141498	1710	mediator lipopolysaccharide lps	[mediators lipopolysaccharide LPS]	0.0	3	1	1	1
141499	1710	role of hlh-2	[role of hLH-2]	0.0	3	1	1	1
141500	1710	different mobility.	[different mobility.]	0.0	2	1	1	1
141501	1710	intervention.	[intervention.]	0.0	1	1	1	1
141502	1710	increase in avp	[increase in AVP]	0.0	3	1	1	1
141503	1710	effect of FCM	[effect of FCM]	0.0	3	1	1	1
141504	1710	umbilical arterial cell	[umbilical arterial cells]	0.0	3	1	1	1
141505	1710	pathogenesis of syndrome	[pathogenesis of syndrome]	0.0	3	1	1	1
141506	1710	colony-stimulating factor granulocyte-macrophage factor	[colony-stimulating factor granulocyte-macrophage factor]	0.0	4	1	1	1
141507	1710	reaction at various stages.	[reactions at various stages.]	0.0	4	1	1	1
141508	1710	alter pathway lead	[altering pathways leading]	0.0	3	1	1	1
141509	1710	primary cell from ATL patient	[primary cells from ATL patients]	0.0	5	1	1	1
141510	1710	related retinoic acid receptor alpha	[related retinoic acid receptor alpha]	0.0	5	1	1	1
141511	1710	marker for acute promyelocytic leukemia	[marker for acute promyelocytic leukemia]	0.0	5	1	1	1
141512	1710	maximal reaction velocity	[maximal reaction velocity]	0.0	3	1	1	1
141513	1710	molecule inflammation	[molecules inflammation]	0.0	2	1	1	1
141514	1710	potential in response to challenge	[potential in response to challenge]	0.0	5	1	1	1
141515	1710	expression to the class	[expression to the classes]	0.0	4	1	1	1
141516	1710	21 emcv ires fragment	[21 EMCV IRES fragments]	0.0	4	1	1	1
141517	1710	protein 1 lsp1	[protein 1 LSP1]	0.0	3	1	1	1
141518	1710	nmol/L to mumol/L)	[nmol/L to mumol/L)]	0.0	3	1	1	1
141519	1710	oncogenic effect of rbtn-2	[oncogenic effect of RBTN-2]	0.0	4	1	1	1
141520	1710	inhibitor of signal-regulated protein kinase	[inhibitor of signal-regulated protein kinase]	0.0	5	1	1	1
141521	1710	low concentration inhibit ige synthesis	[Low concentrations inhibiting IgE synthesis]	0.0	5	1	1	1
141522	1710	erythroid Kruppel-like factor eklf activity	[erythroid Kruppel-like factor EKLF activity]	0.0	5	1	1	1
141523	1710	T lymphocyte by curcumin	[T lymphocytes by curcumin]	0.0	4	1	1	1
141524	1710	gp extract with antibody	[gp extracts with antibodies]	0.0	4	1	1	1
141525	1710	b alpha protein level	[B alpha protein levels]	0.0	4	1	1	1
141526	1710	21 CRF patient	[21 CRF patients]	0.0	3	1	1	1
141527	1710	20 amino acid	[20 amino acids]	0.0	3	1	1	1
141528	1710	bzlf1 memory T cell	[BZLF1 memory T cells]	0.0	4	1	1	1
141529	1710	e1a -negative cell	[E1A -negative cells]	0.0	3	1	1	1
141530	1710	involve the acid receptor alpha	[involving the acid receptor alpha]	0.0	5	1	1	1
141531	1710	leukocyte antigen status.	[leukocyte antigen status.]	0.0	3	1	1	1
141532	1710	individual component	[individual components]	0.0	2	1	1	1
141533	1710	primary adult erythroid cell system	[primary adult erythroid cell system]	0.0	5	1	1	1
141534	1710	also (p low	[also (P lower]	0.0	3	1	1	1
141535	1710	NK granule	[NK granules]	0.0	2	1	1	1
141536	1710	pathogenic mechanism	[pathogenic mechanisms]	0.0	2	1	1	1
141537	1710	thyroxine	[thyroxine]	0.0	1	1	1	1
141538	1710	level of response element-binding activity	[levels of response element-binding activity]	0.0	5	1	1	1
141539	1710	acid CD40	[acid CD40]	0.0	2	1	1	1
141540	1710	b cell line contain level	[B cell lines containing levels]	0.0	5	1	1	1
141541	1710	gata3 zinc finger	[GATA3 zinc fingers]	0.0	3	1	1	1
141542	1710	EPO erythroid differentiation	[EPO erythroid differentiation]	0.0	3	1	1	1
141543	1710	5'-positive regulatory unit	[5'-positive regulatory unit]	0.0	3	1	1	1
141544	1710	inhibition of transcriptional activation of NF-kappaB	[inhibition of transcriptional activation of NF-kappaB]	0.0	6	1	1	1
141545	1710	(il) 4	[(IL) 4]	0.0	2	1	1	1
141546	1710	NFAT factor element	[NFAT factor element]	0.0	3	1	1	1
141547	1710	type 430-444	[type 430-444]	0.0	2	1	1	1
141548	1710	expression of Aldh1 in Hox11 mouse	[expression of Aldh1 in Hox11 mice]	0.0	6	1	1	1
141549	1710	sp1 activity	[SP1 activity]	0.0	2	1	1	1
141550	1710	one important factor determine gene activation	[one important factor determining gene activation]	0.0	6	1	1	1
141551	1710	corresponding sequence	[corresponding sequence]	0.0	2	2	2	1
141552	1710	l-pk isozyme	[L-PK isozymes]	0.0	2	1	1	1
141553	1710	interleukin (il-2) enhancer	[interleukin (IL-2) enhancer]	0.0	3	1	1	1
141554	1710	lineage requirement	[lineage requirements]	0.0	2	1	1	1
141555	1710	cocktail of the ligand	[cocktails of the ligands]	0.0	4	1	1	1
141556	1710	approach create enfeebled, hiv-1/siv	[approach creating enfeebled, HIV-1/SIV]	0.0	4	1	1	1
141557	1710	short sequence motif	[short sequence motifs]	0.0	3	1	1	1
141558	1710	characteristic of peripheral blood mononuclear cell	[characteristics of peripheral blood mononuclear cells]	0.0	6	1	1	1
141559	1710	/pkb/akt	[/PKB/Akt]	0.0	1	1	1	1
141560	1710	protein critical in species range	[proteins critical in species ranging]	0.0	5	1	1	1
141561	1710	myeloid cell i.e. polymorphonuclear granulocyte	[myeloid cells i.e. polymorphonuclear granulocytes]	0.0	5	1	1	1
141562	1710	antigen ea antigen	[antigen EA antigen]	0.0	3	1	1	1
141563	1710	xanthine oxidase	[xanthine oxidase]	0.0	2	1	1	1
141564	1710	myeloid stage	[myeloid stages]	0.0	2	1	1	1
141565	1710	shock syndrome toxin-I	[shock syndrome toxin-I]	0.0	3	1	1	1
141566	1710	replicative function	[replicative functions]	0.0	2	1	1	1
141567	1710	contain the sh2 domain nfat activity	[containing the SH2 domains NFAT activity]	0.0	6	1	1	1
141568	1710	agent retinoic acid RA	[agent retinoic acid RA]	0.0	4	1	1	1
141569	1710	molecule in solution	[molecule in solution]	0.0	3	1	1	1
141570	1710	transcriptional regulation of human interleukin gene	[transcriptional regulation of human interleukin gene]	0.0	6	1	1	1
141571	1710	significant ec activity	[significant EC activity]	0.0	3	1	1	1
141572	1710	N-terminal fragment lps E-selectin expression	[N-terminal fragment LPS E-selectin expression]	0.0	5	1	1	1
141573	1710	cd11b+ population	[CD11b+ populations]	0.0	2	1	1	1
141574	1710	suggest responsible for the transcriptional activity	[suggesting responsible for the transcriptional activities]	0.0	6	1	1	1
141575	1710	network of cytokine	[network of cytokines]	0.0	3	1	1	1
141576	1710	main aim	[main aims]	0.0	2	1	1	1
141577	1710	colony-stimumulatelany-stg factor mrna level	[colony-stimulating factor mRNA levels]	0.0	4	1	1	1
141578	1710	lps fashion	[LPS fashion]	0.0	2	1	1	1
141579	1710	interestingly, early treatment (day 0 hpc	[Interestingly, early treatment (day 0 HPCs]	0.0	6	1	1	1
141580	1710	role for IK	[role for IK]	0.0	3	1	1	1
141581	1710	behavior of stat pathway for cytokine	[behavior of STAT pathways for cytokine]	0.0	6	1	1	1
141582	1710	neutralize abs to growth factor bFGF	[neutralizing Abs to growth factor bFGF]	0.0	6	1	1	1
141583	1710	human c-c chemokine receptor	[human C-C chemokine receptor]	0.0	4	1	1	1
141584	1710	non-cytotoxic dose of autg microm	[non-cytotoxic doses of AuTG microM]	0.0	5	1	1	1
141585	1710	cell hybridization	[cell hybridization]	0.0	2	1	1	1
141586	1710	chancre	[chancre]	0.0	1	1	1	1
141587	1710	transactivation transrepression model in cell	[transactivation transrepression models in cells]	0.0	5	1	1	1
141588	1710	(6,7-3h) estradiol	[(6,7-3H) estradiol]	0.0	2	1	1	1
141589	1710	shock syndrome toxin-1	[shock syndrome toxin-1]	0.0	3	1	1	1
141590	1710	member of a protein family,	[Members of a protein family,]	0.0	5	1	1	1
141591	1710	formation of dimer	[formation of dimers]	0.0	3	1	1	1
141592	1710	particular (mhc) haplotype	[particular (MHC) haplotypes]	0.0	3	1	1	1
141593	1710	fms patient	[FMS patients]	0.0	2	1	1	1
141594	1710	complexess	[complexes,]	0.0	1	1	1	1
141595	1710	36 normal control subject	[36 normal control subjects]	0.0	4	1	1	1
141596	1710	succinimide-containing peptide show only cross-reactivity	[succinimide-containing peptide showing only cross-reactivity]	0.0	5	1	1	1
141597	1710	potential relevance for gastroenterology	[potential relevance for gastroenterology]	0.0	4	1	1	1
141598	1710	high cortisol	[high cortisol]	0.0	2	1	1	1
141599	1710	comprise a anti-hapten ab variable fragment	[comprising an anti-hapten Ab variable fragment]	0.0	6	1	1	1
141600	1710	Oct-2 -dependent function element.	[Oct-2 -dependent function element.]	0.0	4	1	1	1
141601	1710	alpha fusion	[alpha fusion]	0.0	2	1	1	1
141602	1710	stably cd4+ cell	[stably CD4+ cells]	0.0	3	1	1	1
141603	1710	specific property	[specific property]	0.0	2	1	1	1
141604	1710	cytokine-induced modulation	[Cytokine-induced modulation]	0.0	2	1	1	1
141605	1710	effect of 17 beta-estradiol	[effect of 17 beta-estradiol]	0.0	4	1	1	1
141606	1710	significant proliferation (71%) recent-onset iddm subject	[significant proliferation (71%) recent-onset IDDM subjects]	0.0	6	1	1	1
141607	1710	magnitude in MDMac	[magnitude in MDMac]	0.0	3	1	1	1
141608	1710	factor beta	[factor beta]	0.0	2	1	1	1
141609	1710	difference in repressor complex	[differences in repressor complexes]	0.0	4	1	1	1
141610	1710	hematopoietic property of stromal cell	[hematopoietic properties of stromal cells]	0.0	5	1	1	1
141611	1710	co-stimulation with suboptimal concentration	[Co-stimulation with suboptimal concentrations]	0.0	4	1	1	1
141612	1710	Chronic rejection	[Chronic rejection]	0.0	2	1	1	1
141613	1710	successful use in transplant medicine	[successful use in transplant medicine]	0.0	5	1	1	1
141614	1710	novel system	[novel system]	0.0	2	1	1	1
141615	1710	h of prl stimulation	[h of PRL stimulation]	0.0	4	1	1	1
141616	1710	favor expansion	[favoring expansion]	0.0	2	1	1	1
141617	1710	350 case of leukemia	[350 cases of leukemia]	0.0	4	1	1	1
141618	1710	use normal monocyte	[using normal monocytes]	0.0	3	1	1	1
141619	1710	tpa ionophore	[TPA ionophore]	0.0	2	1	1	1
141620	1710	fragment contain sequence from -repressible gene	[fragments containing sequences from -repressible genes]	0.0	6	1	1	1
141621	1710	activation of enzyme	[activation of enzymes]	0.0	3	1	1	1
141622	1710	type bare lymphocyte syndrome-associated factor	[type bare lymphocyte syndrome-associated factor]	0.0	5	1	1	1
141623	1710	qualitative, difference	[qualitative, differences]	0.0	2	1	1	1
141624	1710	antiinflammatory potential of glucocorticoid	[antiinflammatory potential of glucocorticoids]	0.0	4	1	1	1
141625	1710	immediate-early specific gene include interleukin-2	[immediate-early specific genes including interleukin-2]	0.0	5	1	1	1
141626	1710	patient young	[patients younger]	0.0	2	1	1	1
141627	1710	(25%) disease subject	[(25%) disease subjects]	0.0	3	1	1	1
141628	1710	receptor heterodimerization	[receptor heterodimerization]	0.0	2	1	1	1
141629	1710	follow a intravenous injection of phosphocreatine	[following an intravenous injection of phosphocreatine]	0.0	6	1	1	1
141630	1710	dose-dependent stimulation of c-jun	[dose-dependent stimulation of c-jun]	0.0	4	1	1	1
141631	1710	heteromeric complex with nuclear protein	[heteromeric complexes with nuclear proteins]	0.0	5	1	1	1
141632	1710	induction of interferon protein differentiation	[induction of interferon protein differentiation]	0.0	5	1	1	1
141633	1710	subset 25%	[subset 25%]	0.0	2	1	1	1
141634	1710	common haplotype bat	[common haplotypes BAt]	0.0	3	1	1	1
141635	1710	inhibitor of transcription	[inhibitor of transcription]	0.0	3	1	1	1
141636	1710	cell in peripheral blood	[cells in peripheral blood]	0.0	4	1	1	1
141637	1710	HIV promoter	[HIV promoter]	0.0	2	1	1	1
141638	1710	contact between peripheral blood lymphocyte	[contact between peripheral blood lymphocytes]	0.0	5	1	1	1
141639	1710	activation in JY25 b cell line.	[activation in JY25 B cell line.]	0.0	6	1	1	1
141640	1710	contain C-terminal zinc-finger motif	[containing C-terminal zinc-finger motifs]	0.0	4	1	1	1
141641	1710	receptor-containing cell	[receptor-containing cells]	0.0	2	1	1	1
141642	1710	number of hematologic neoplasm	[number of hematologic neoplasms]	0.0	4	1	1	1
141643	1710	multiple intracellular substrate in cell	[multiple intracellular substrates in cells]	0.0	5	1	1	1
141644	1710	impaired cortisol binding	[Impaired cortisol binding]	0.0	3	1	1	1
141645	1710	series of GM-CSFRalpha mutant	[series of GM-CSFRalpha mutants]	0.0	4	1	1	1
141646	1710	th effector	[Th effectors]	0.0	2	1	1	1
141647	1710	power of glucocorticoid receptor	[power of glucocorticoid receptor]	0.0	4	1	1	1
141648	1710	expression of multiple promoter	[expression of multiple promoters]	0.0	4	1	1	1
141649	1710	study in platelet	[study in platelets]	0.0	3	1	1	1
141650	1710	cells; factor	[cells; factors]	0.0	2	1	1	1
141651	1710	ap-1 inhibition	[AP-1 inhibition]	0.0	2	1	1	1
141652	1710	individual with cell carcinoma	[individuals with cell carcinoma]	0.0	4	1	1	1
141653	1710	synergistic formation	[synergistic formation]	0.0	2	1	1	1
141654	1710	include activation	[including activation]	0.0	2	1	1	1
141655	1710	fragment contain sequence from glucocorticoid gene	[fragments containing sequences from glucocorticoid genes]	0.0	6	1	1	1
141656	1710	15 minute (phase	[15 minutes (phase]	0.0	3	1	1	1
141657	1710	Fos peptide c-fo	[Fos peptide c-Fos]	0.0	3	1	1	1
141658	1710	IL-4 mrna accumulation il-1 beta	[IL-4 mRNA accumulation IL-1 beta]	0.0	5	1	1	1
141659	1710	differentiation in culture,	[differentiation in culture,]	0.0	3	1	1	1
141660	1710	nih-3t3 fibroblast	[NIH-3T3 fibroblasts]	0.0	2	1	1	1
141661	1710	12 nonspecific follicular hyperplasia	[12 nonspecific follicular hyperplasia]	0.0	4	1	1	1
141662	1710	inhibition of b	[inhibition of B]	0.0	3	1	1	1
141663	1710	lymphocyte from the preparation.	[lymphocytes from the preparation.]	0.0	4	1	1	1
141664	1710	dual pattern of transmission	[dual pattern of transmission]	0.0	4	1	1	1
141665	1710	1 alpha,25-(OH)2D3 -responsive cell	[1 alpha,25-(OH)2D3 -responsive cells]	0.0	4	1	1	1
141666	1710	reduce mrna stability,	[reducing mRNA stability,]	0.0	3	1	1	1
141667	1710	reactivity at level high	[reactivities at levels high]	0.0	4	1	1	1
141668	1710	kappa ggaaagtccc	[kappa GGAAAGTCCC]	0.0	2	1	1	1
141669	1710	endpoint	[endpoints]	0.0	1	1	1	1
141670	1710	origin of sideroblast	[origin of sideroblasts]	0.0	3	1	1	1
141671	1710	criteria, include vigorous tyrosine phosphorylation	[criteria, including vigorous tyrosine phosphorylation]	0.0	5	1	1	1
141672	1710	fibroblastic cell	[fibroblastic cells]	0.0	2	1	1	1
141673	1710	injury with alpha-tocopherol a scavenger	[injury with alpha-tocopherol a scavenger]	0.0	5	1	1	1
141674	1710	determinant of b-cell-specific expression	[determinant of B-cell-specific expression]	0.0	4	1	1	1
141675	1710	treatment with D3	[treatment with D3]	0.0	3	1	1	1
141676	1710	mrna expression at 100 mumol/L pdtc	[mRNA expression at 100 mumol/L PDTC]	0.0	6	1	1	1
141677	1710	10(-7) g/g of rna	[10(-7) g/g of RNA]	0.0	4	1	1	1
141678	1710	transition inactive	[transition inactive]	0.0	2	1	1	1
141679	1710	interaction antagonism	[interaction antagonism]	0.0	2	1	1	1
141680	1710	various Jurkat mutant	[various Jurkat mutants]	0.0	3	1	1	1
141681	1710	promoter- plap plasmid	[promoter- PLAP plasmids]	0.0	3	1	1	1
141682	1710	average by 6.8%)	[average by 6.8%)]	0.0	3	1	1	1
141683	1710	cis-acting element b/gc-box	[cis-acting elements B/GC-box]	0.0	3	1	1	1
141684	1710	activity of primary breast cancer	[activity of primary breast cancers]	0.0	5	1	1	1
141685	1710	inhibition 2 expression	[inhibition 2 expression]	0.0	3	1	1	1
141686	1710	fk506 consistent	[FK506 consistent]	0.0	2	1	1	1
141687	1710	cloning of ptf gamma	[cloning of PTF gamma]	0.0	4	1	1	1
141688	1710	also role	[also role]	0.0	2	1	1	1
141689	1710	nm in controls; p	[nM in controls; P]	0.0	4	1	1	1
141690	1710	first case of twin discordant	[first case of twins discordant]	0.0	5	1	1	1
141691	1710	calcitropic effect of dioxyvit with correction	[calcitropic effect of dioxyvit with correction]	0.0	6	1	1	1
141692	1710	oligonucleotide competition	[oligonucleotide competition]	0.0	2	1	1	1
141693	1710	role of cis-act regulatory element	[role of cis-acting regulatory elements]	0.0	5	1	1	1
141694	1710	igkappa	[Igkappa]	0.0	1	1	1	1
141695	1710	t-cell-expressed cytokine human interleukin	[T-cell-expressed cytokines human interleukin]	0.0	4	1	1	1
141696	1710	eed gene	[eed gene]	0.0	2	1	1	1
141697	1710	rhythm of acth	[rhythm of ACTH]	0.0	3	1	1	1
141698	1710	surfactant lipid	[surfactant lipids]	0.0	2	1	1	1
141699	1710	1 P; immediate) binding	[1 h; immediate) binding]	0.0	4	1	1	1
141700	1710	Barr	[Barr]	0.0	1	1	1	1
141701	1710	SEB induction	[SEB induction]	0.0	2	1	1	1
141702	1710	lymphoma NL	[lymphoma NL]	0.0	2	1	1	1
141703	1710	twenty healthy man aged	[Twenty healthy men aged]	0.0	4	1	1	1
141704	1710	androgen -bound	[androgen -bound]	0.0	2	1	1	1
141705	1710	two haplotype bat	[two haplotypes BAt]	0.0	3	1	1	1
141706	1710	disomy of Xp.	[disomy of Xp.]	0.0	3	1	1	1
141707	1710	least one nfat-sensitive gene	[least one NFAT-sensitive gene]	0.0	4	1	1	1
141708	1710	regulation gene expression	[Regulation gene expression]	0.0	3	1	1	1
141709	1710	receptor cell population	[receptor cell population]	0.0	3	1	1	1
141710	1710	woman with recurrent abortion	[women with recurrent abortion]	0.0	4	1	1	1
141711	1710	P. g.) with bcr1/25	[P. G.) with BCR1/25]	0.0	4	1	1	1
141712	1710	delivery and/or	[delivery and/or]	0.0	2	1	1	1
141713	1710	(p 0.025) low	[(P 0.025) lower]	0.0	3	1	1	1
141714	1710	cyclophilin b-binding-proteins	[cyclophilin B-binding-proteins]	0.0	2	1	1	1
141715	1710	c/ebpbeta protein	[C/EBPbeta protein]	0.0	2	1	1	1
141716	1710	human blood neutrophil	[human blood neutrophils]	0.0	3	1	1	1
141717	1710	effect on pbmc response	[effects on PBMC responses]	0.0	4	1	1	1
141718	1710	CLEO hcleo element	[CLEO hCLEO element]	0.0	3	1	1	1
141719	1710	region just upstream	[region just upstream]	0.0	3	1	1	1
141720	1710	effect of replacement	[effects of replacement]	0.0	3	1	1	1
141721	1710	cercopithicine herpesvirus 15	[cercopithicine herpesvirus 15]	0.0	3	1	1	1
141722	1710	other polychlorinated dibenzo-p-dioxin	[other polychlorinated dibenzo-p-dioxins]	0.0	3	1	1	1
141723	1710	cellular assay	[cellular assays]	0.0	2	1	1	1
141724	1710	NF(P) a nuclear factor	[NF(P) a nuclear factor]	0.0	4	2	2	1
141725	1710	rational strategy	[rational strategies]	0.0	2	1	1	1
141726	1710	site NF kappa b1	[site NF kappa B1]	0.0	4	1	1	1
141727	1710	background: Retinoic acid	[BACKGROUND: Retinoic acid]	0.0	3	1	1	1
141728	1710	range from q13 to q23	[ranging from q13 to q23]	0.0	5	1	1	1
141729	1710	serial sectioning	[Serial sectioning]	0.0	2	1	1	1
141730	1710	site NF kappa b2	[site NF kappa B2]	0.0	4	1	1	1
141731	1710	Pterin carbinolamine dehydratase/dimerization cofactor	[Pterin carbinolamine dehydratase/dimerization cofactor]	0.0	4	1	1	1
141732	1710	regulator of the growth	[regulator of the growth]	0.0	4	1	1	1
141733	1710	immediate-early viral transactivator BZLF1	[immediate-early viral transactivators BZLF1]	0.0	4	1	1	1
141734	1710	1 alpha,25-dihydroxycholecalciferol	[1 alpha,25-dihydroxycholecalciferol]	0.0	2	1	1	1
141735	1710	/receptor	[/receptor]	0.0	1	1	1	1
141736	1710	even 10(-10) mol/L RA	[even 10(-10) mol/L RA]	0.0	4	1	1	1
141737	1710	activity a potential antirheumatic	[activity a potential antirheumatic]	0.0	4	1	1	1
141738	1710	band migration	[band migration]	0.0	2	1	1	1
141739	1710	elastase inhibitor guamerin-derived peptide gdsp	[elastase inhibitor guamerin-derived peptide GDSP]	0.0	5	1	1	1
141740	1710	putative suppressor gene	[putative suppressor genes]	0.0	3	1	1	1
141741	1710	immediate biochemical response	[immediate biochemical response]	0.0	3	1	1	1
141742	1710	h (viability great to 90%).	[h (viability greater to 90%).]	0.0	5	1	1	1
141743	1710	role in cell proliferation,	[role in cell proliferation,]	0.0	4	1	1	1
141744	1710	divergent protein kinase	[divergent protein kinases]	0.0	3	1	1	1
141745	1710	effect on the minimal promoter	[effect on the minimal promoter]	0.0	5	1	1	1
141746	1710	protein secretion of il-6	[protein secretion of IL-6]	0.0	4	1	1	1
141747	1710	characterization of a transcription factor	[Characterization of a transcription factor]	0.0	5	1	1	1
141748	1710	u937 monoblastic cell	[U937 monoblastic cells]	0.0	3	1	1	1
141749	1710	retention of VDR by h	[retention of VDR by h]	0.0	5	1	1	1
141750	1710	Slight difference together with difference	[Slight differences together with differences]	0.0	5	1	1	1
141751	1710	four tandem repeat	[four tandem repeats]	0.0	3	1	1	1
141752	1710	most New World primate	[Most New World primate]	0.0	4	1	1	1
141753	1710	evidence proteins, differ in degree	[evidence proteins, differing in degree]	0.0	5	1	1	1
141754	1710	MHC class by ifn-gamma	[MHC class by IFN-gamma]	0.0	4	1	1	1
141755	1710	Janus kinase/STAT	[Janus kinase/STAT]	0.0	2	1	1	1
141756	1710	use activator phorbol ester	[using activator phorbol ester]	0.0	4	1	1	1
141757	1710	development of multiple lineage	[development of multiple lineages]	0.0	4	1	1	1
141758	1710	plasma sialyltransferase level in psychiatric disorder	[Plasma sialyltransferase levels in psychiatric disorders]	0.0	6	1	1	1
141759	1710	host cell gene expression	[host cell gene expression]	0.0	4	1	1	1
141760	1710	receptor changes, respectively oppose	[receptor changes, respectively opposing]	0.0	4	1	1	1
141761	1710	direct sequencing	[direct sequencing]	0.0	2	3	3	1
141762	1710	cell culture of monocyte	[cell cultures of monocytes]	0.0	4	1	1	1
141763	1710	factor HEB-1	[factors HEB-1]	0.0	2	1	1	1
141764	1710	matrix glycoprotein	[matrix glycoprotein]	0.0	2	1	1	1
141765	1710	inactivate nucleotide substitution	[inactivating nucleotide substitutions]	0.0	3	1	1	1
141766	1710	normal lymphocyte from blood	[normal lymphocytes from blood]	0.0	4	1	1	1
141767	1710	noticeable exception of patient	[noticeable exception of patient]	0.0	4	1	1	1
141768	1710	proto-oncogent in myeloid leukemia	[proto-oncogenes in myeloid leukemia]	0.0	4	1	1	1
141769	1710	total patient with airway obstruction	[total patients with airways obstruction]	0.0	5	1	1	1
141770	1710	competitors,	[competitors,]	0.0	1	1	1	1
141771	1710	(cd56)	[(CD56)]	0.0	1	1	1	1
141772	1710	human T cell proliferation in g1	[human T cell proliferation in G1]	0.0	6	1	1	1
141773	1710	naive ecd45ra+) T cell subset	[naive (CD45RA+) T cell subsets]	0.0	5	1	1	1
141774	1710	ige-binding protein	[IgE-binding protein]	0.0	2	1	1	1
141775	1710	1.5-1.6 time	[1.5-1.6 times]	0.0	2	1	1	1
141776	1710	application of this system	[application of this system]	0.0	4	1	1	1
141777	1710	(2) search for constitutional loss	[(2) search for constitutional losses]	0.0	5	1	1	1
141778	1710	use primary lymphocyte model	[using primary lymphocyte models]	0.0	4	1	1	1
141779	1710	rapid time course	[rapid time course]	0.0	3	1	1	1
141780	1710	flow of information	[flow of information]	0.0	3	1	1	1
141781	1710	deletion variant lack c-terminal a fail	[deletion variants lacking C-terminal aa fail]	0.0	6	1	1	1
141782	1710	Positive regulator	[Positive regulators]	0.0	2	1	1	1
141783	1710	GC in monocyte	[GC in monocytes]	0.0	3	2	2	1
141784	1710	affinity of regulatory element	[affinities of regulatory elements]	0.0	4	1	1	1
141785	1710	candidate gene for ags factor	[candidate genes for AGS factor]	0.0	5	1	1	1
141786	1710	rather a process unique	[rather a process unique]	0.0	4	1	1	1
141787	1710	transcriptional enhancer element	[transcriptional enhancer element]	0.0	3	1	1	1
141788	1710	target than opinion	[target than opinion]	0.0	3	1	1	1
141789	1710	cellular activation event	[cellular activation events]	0.0	3	1	1	1
141790	1710	link between estrogenic pathway	[link between estrogenic pathways]	0.0	4	1	1	1
141791	1710	spectrum of transcript deletion	[spectrum of transcript deletions]	0.0	4	1	1	1
141792	1710	cell-specific protein bsap/pax5	[cell-specific protein BSAP/PAX5]	0.0	3	1	1	1
141793	1710	alpha-helice each	[alpha-helices each]	0.0	2	1	1	1
141794	1710	platelet from white	[Platelets from white]	0.0	3	1	1	1
141795	1710	contrast, addition	[contrast, addition]	0.0	2	1	1	1
141796	1710	PGG-Glucan a soluble beta-(1,3)-linked glucose homopolymer	[PGG-Glucan a soluble beta-(1,3)-linked glucose homopolymer]	0.0	6	1	1	1
141797	1710	such form	[such forms]	0.0	2	1	1	1
141798	1710	muscle lineage	[muscle lineage]	0.0	2	1	1	1
141799	1710	induction of promoter	[induction of promoters]	0.0	3	1	1	1
141800	1710	trans-dominant expression vector	[trans-dominant expression vectors]	0.0	3	1	1	1
141801	1710	certain type	[certain types]	0.0	2	1	1	1
141802	1710	2 u/ml	[2 U/mL]	0.0	2	1	1	1
141803	1710	functional criteria.	[functional criteria.]	0.0	2	1	1	1
141804	1710	complex in response	[complex in response]	0.0	3	1	1	1
141805	1710	other T cell activity present	[other T cell activities present]	0.0	5	1	1	1
141806	1710	Biol.	[Biol.]	0.0	1	1	1	1
141807	1710	IL-2 -secret cell	[IL-2 -secreting cells]	0.0	3	1	1	1
141808	1710	transient-cotransfection assay	[transient-cotransfection assay]	0.0	2	1	1	1
141809	1710	however, cell line with metastatic potential	[However, cell lines with metastatic potential]	0.0	6	1	1	1
141810	1710	oligomerization to a trimer	[oligomerization to a trimer]	0.0	4	1	1	1
141811	1710	normal adult blood	[normal adult blood]	0.0	3	1	1	1
141812	1710	tissue transglutaminase-dependent modification	[Tissue transglutaminase-dependent modification]	0.0	3	1	1	1
141813	1710	major cycle progeny virus expression	[major cycle progeny virus expression]	0.0	5	1	1	1
141814	1710	PLB-IIIB	[PLB-IIIB]	0.0	1	1	1	1
141815	1710	probability of survival idfs)	[probability of survival (DFS)]	0.0	4	1	1	1
141816	1710	phospholipase c result	[phospholipase C resulting]	0.0	3	1	1	1
141817	1710	HEK cell	[HEK cells]	0.0	2	1	1	1
141818	1710	chemotherapeutic drug	[chemotherapeutic drugs]	0.0	2	1	1	1
141819	1710	individual homodimeric protein	[individual homodimeric proteins]	0.0	3	1	1	1
141820	1710	beta,19-epoxypregn-5-ene-4,20-dione (8)	[beta,19-epoxypregn-5-ene-4,20-dione (8)]	0.0	2	1	1	1
141821	1710	ikk-gamma nf-kappab modulator),	[IKK-gamma NF-kappaB modulator),]	0.0	3	1	1	1
141822	1710	chemical	[chemicals]	0.0	1	1	1	1
141823	1710	promising new avenue in leukemia	[promising new avenue in leukemia]	0.0	5	1	1	1
141824	1710	other, polymorphism	[other, polymorphisms]	0.0	2	1	1	1
141825	1710	organ inflammation independent	[organ inflammation independent]	0.0	3	1	1	1
141826	1710	cell-free assay	[cell-free assays]	0.0	2	1	1	1
141827	1710	SR 31747a -binding protein	[SR 31747A -binding protein]	0.0	4	1	1	1
141828	1710	cd3+ intrafollicular T cell	[CD3+ intrafollicular T cells]	0.0	4	1	1	1
141829	1710	gamma-ray	[gamma-rays]	0.0	1	1	1	1
141830	1710	low level of response activity	[low levels of response activity]	0.0	5	1	1	1
141831	1710	leukemic k562 cell	[leukemic K562 cells]	0.0	3	1	1	1
141832	1710	part at the transcriptional level	[part at the transcriptional level]	0.0	5	1	1	1
141833	1710	CTL recognize other tumor ag	[CTL recognizing other tumor Ag]	0.0	5	1	1	1
141834	1710	mrna from ECs	[mRNA from ECs]	0.0	3	1	1	1
141835	1710	0.05, respectively) increase in the percentage	[0.05, respectively) increase in the percentage]	0.0	6	1	1	1
141836	1710	atl-derived cell line	[ATL-derived cell lines]	0.0	3	1	1	1
141837	1710	rhom-2 gene	[Rhom-2 gene]	0.0	2	1	1	1
141838	1710	activation of c-fo expression	[activation of c-fos expression]	0.0	4	1	1	1
141839	1710	signal event like Erk2 activation	[signaling events like Erk2 activation]	0.0	5	1	1	1
141840	1710	synergy between slp-76	[synergy between SLP-76]	0.0	3	1	1	1
141841	1710	Prostaglandin e2 induction of binding activity	[Prostaglandin E2 induction of binding activity]	0.0	6	1	1	1
141842	1710	unique target of 1 alpha,25-dihydroxyvitamin D3	[unique targets of 1 alpha,25-dihydroxyvitamin D3]	0.0	6	1	1	1
141843	1710	suggest primarily dependent	[suggesting primarily dependent]	0.0	3	1	1	1
141844	1710	expression of the isoform	[expression of the isoforms]	0.0	4	1	1	1
141845	1710	phenotypic drift from latency	[phenotypic drift from latency]	0.0	4	1	1	1
141846	1710	disease of patient	[disease of patients]	0.0	3	1	1	1
141847	1710	9 rat	[9 rats]	0.0	2	1	1	1
141848	1710	prevent translocation of NF-kappaB complex	[preventing translocation of NF-kappaB complexes]	0.0	5	1	1	1
141849	1710	sites/cell), kd value versus 5.7+/-0.3 nmol/L),	[sites/cell), Kd values versus 5.7+/-0.3 nmol/L),]	0.0	6	1	1	1
141850	1710	T. cell	[T. cells]	0.0	2	1	1	1
141851	1710	patient with reactive eosinophilias	[patients with reactive eosinophilias]	0.0	4	1	1	1
141852	1710	clomiphene	[clomiphene]	0.0	1	1	1	1
141853	1710	human b-cell transcription	[human B-cell transcription]	0.0	3	1	1	1
141854	1710	regulate glucocorticoid sensitivity	[regulating glucocorticoid sensitivity]	0.0	3	1	1	1
141855	1710	anti- tat intracellular antibody intrabody	[anti- Tat intracellular antibody intrabody]	0.0	5	1	1	1
141856	1710	factor-kappaB NFkappaB in memory (cd45ro+)	[factor-kappaB NFkappaB in memory (CD45RO+)]	0.0	5	1	1	1
141857	1710	pattern of globin gene expression	[patterns of globin gene expression]	0.0	5	1	1	1
141858	1710	region at COOH terminus	[region at COOH terminus]	0.0	4	1	1	1
141859	1710	and/or modification of pre-bound transcription factor	[and/or modifications of pre-bound transcription factors]	0.0	6	1	1	1
141860	1710	number of feature	[number of features]	0.0	3	1	1	1
141861	1710	susceptibility kill	[susceptibility killing]	0.0	2	1	1	1
141862	1710	tyrosyl phosphorylation of several protein	[tyrosyl phosphorylation of several proteins]	0.0	5	1	1	1
141863	1710	repeat of hiv-1	[repeat of HIV-1]	0.0	3	3	3	1
141864	1710	ap-1 reporter plasmid	[AP-1 reporter plasmid]	0.0	3	1	1	1
141865	1710	consensus sequence E-selectin gene exhibit	[consensus sequences E-selectin gene exhibits]	0.0	5	1	1	1
141866	1710	immunoglobulin chain intronic enhancer	[immunoglobulin chain intronic enhancer]	0.0	4	1	1	1
141867	1710	comparative analysis of nfat factor	[Comparative analysis of NFAT factor]	0.0	5	1	1	1
141868	1710	resistance against anti-fa antibody	[resistance against anti-Fas antibody]	0.0	4	1	1	1
141869	1710	RU a -receptor antagonist	[RU a -receptor antagonist]	0.0	4	1	1	1
141870	1710	crucial factor	[crucial factor]	0.0	2	1	1	1
141871	1710	protein family,	[protein family,]	0.0	2	1	1	1
141872	1710	additional T protein	[additional T protein]	0.0	3	1	1	1
141873	1710	hiv macrophage	[HIV macrophages]	0.0	2	1	1	1
141874	1710	transmembrane domain of il-7r alpha	[transmembrane domains of IL-7R alpha]	0.0	5	1	1	1
141875	1710	Consequently, T lymphocyte	[Consequently, T lymphocytes]	0.0	3	1	1	1
141876	1710	other IL-4 substrate	[other IL-4 substrates]	0.0	3	1	1	1
141877	1710	property of leukemia factor	[properties of leukemia factor]	0.0	4	1	1	1
141878	1710	fibrosis (cf) patient	[fibrosis (CF) patients]	0.0	3	1	1	1
141879	1710	peripheral blood mononuclear cell proliferation	[peripheral blood mononuclear cell proliferation]	0.0	5	1	1	1
141880	1710	several class	[several class]	0.0	2	1	1	1
141881	1710	basis interfere with this process	[basis interfering with these processes]	0.0	5	1	1	1
141882	1710	recent result	[recent results]	0.0	2	1	1	1
141883	1710	virus, implicate specific sequence	[virus, implicating specific sequences]	0.0	4	1	1	1
141884	1710	epithelium of 19	[epithelium of 19]	0.0	3	1	1	1
141885	1710	thus, a target site for factor	[Thus, a target site for factors]	0.0	6	1	1	1
141886	1710	erythrocyte ndp kinase protein	[erythrocyte NDP kinase protein]	0.0	4	1	1	1
141887	1710	excess of corticosteroid	[excess of corticosteroids]	0.0	3	1	1	1
141888	1710	breakpoint on chromosome range	[breakpoints on chromosome ranging]	0.0	4	1	1	1
141889	1710	4.27 (range, (range, 5.86-6.74) nm,	[4.27 (range, (range, 5.86-6.74) nM,]	0.0	5	1	1	1
141890	1710	tolerization of ad5e1a CTL activity	[tolerization of Ad5E1A CTL activity]	0.0	5	1	1	1
141891	1710	machinery during myeloid differentiation	[machinery during myeloid differentiation]	0.0	4	1	1	1
141892	1710	ebv replication within the host	[EBV replication within the host]	0.0	5	1	1	1
141893	1710	activation a mechanism	[activation A mechanism]	0.0	3	1	1	1
141894	1710	cytoplasmic mrna	[cytoplasmic mRNA]	0.0	2	1	1	1
141895	1710	adult (beta)-globin expression	[adult (beta)-globin expression]	0.0	3	1	1	1
141896	1710	mixture of heparin with ifn-gamma up-regulation	[mixture of heparin with IFN-gamma up-regulation]	0.0	6	1	1	1
141897	1710	functional evidence for the presence	[functional evidence for the presence]	0.0	5	1	1	1
141898	1710	3.16 mg/24h;	[3.16 mg/24h;]	0.0	2	1	1	1
141899	1710	aml sample by EMSA	[AML samples by EMSA]	0.0	4	1	1	1
141900	1710	small exon span kb of DNA	[small exons spanning kb of DNA]	0.0	6	1	1	1
141901	1710	metabolite include benzoquinone	[metabolites including benzoquinone]	0.0	3	1	1	1
141902	1710	three distinct cellular transcription factor	[three distinct cellular transcription factors]	0.0	5	1	1	1
141903	1710	mcr in woman	[MCR in women]	0.0	3	1	1	1
141904	1710	receptor (gr) level	[receptor (GR) levels]	0.0	3	1	1	1
141905	1710	other mcd14 ligand	[other mCD14 ligands]	0.0	3	1	1	1
141906	1710	competitive bind radioassay	[competitive binding radioassay]	0.0	3	1	1	1
141907	1710	cd14 a antigen	[CD14 a antigen]	0.0	3	1	1	1
141908	1710	effect on the bind avidity	[effects on the binding avidity]	0.0	5	1	1	1
141909	1710	two ring x chromosome	[two ring X chromosomes]	0.0	4	1	1	1
141910	1710	binding to TF	[binding to TF]	0.0	3	1	1	1
141911	1710	lmp signal	[LMP signaling]	0.0	2	1	1	1
141912	1710	mechanism in bronchial epithelial cell	[mechanisms in bronchial epithelial cells]	0.0	5	1	1	1
141913	1710	understand the regulation	[understanding the regulation]	0.0	3	1	1	1
141914	1710	include hemodynamic instability	[including hemodynamic instability]	0.0	3	1	1	1
141915	1710	approximately 40-fold okadaic acid exposure	[approximately 40-fold okadaic acid exposure]	0.0	5	1	1	1
141916	1710	b-cell epitope	[B-cell epitopes]	0.0	2	1	1	1
141917	1710	8, fibrous histiocytoma rhabdomyosarcoma	[8, fibrous histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
141918	1710	specificities, the reactivity toward antisera	[specificities, the reactivities toward antisera]	0.0	5	1	1	1
141919	1710	normalize effect increase	[normalizing effect increase]	0.0	3	1	1	1
141920	1710	t-cell-activating superantigen staphylococcal enterotoxin	[T-cell-activating superantigen staphylococcal enterotoxin]	0.0	4	1	1	1
141921	1710	core Sp1	[core Sp1]	0.0	2	1	1	1
141922	1710	sera (0/3) carrier	[sera (0/3) carriers]	0.0	3	1	1	1
141923	1710	approximately 42 gene	[approximately 42 genes]	0.0	3	1	1	1
141924	1710	three-dimensional magnetic resonance 3d-nmr spectroscopy	[three-dimensional magnetic resonance 3D-NMR spectroscopy]	0.0	5	1	1	1
141925	1710	same signal molecule	[same signaling molecules]	0.0	3	1	1	1
141926	1710	antiinflammatory, activity in	[antiinflammatory, activities in]	0.0	3	1	1	1
141927	1710	prevalence of biomarker	[prevalence of biomarkers]	0.0	3	1	1	1
141928	1710	human arterial cell	[human arterial cells]	0.0	3	1	1	1
141929	1710	underlying degree of inflammation	[underlying degree of inflammation]	0.0	4	1	1	1
141930	1710	virus-uninfected T cell line	[virus-uninfected T cell lines]	0.0	4	1	1	1
141931	1710	upstream activator (s)	[upstream activator (s)]	0.0	3	1	1	1
141932	1710	regulator of eukaryotic transcription	[regulator of eukaryotic transcription]	0.0	4	1	1	1
141933	1710	tropical paraparesis/ htlv-i myelopathy	[tropical paraparesis/ HTLV-I myelopathy]	0.0	4	1	1	1
141934	1710	also rapidak effect on electrolyte movement	[also rapid, effects on electrolyte movements]	0.0	6	1	1	1
141935	1710	signal transduction pathway distinct	[signal transduction pathways distinct]	0.0	4	1	1	1
141936	1710	mutation in the ap-1(iii)	[mutations in the AP-1(III)]	0.0	4	1	1	1
141937	1710	quantitative analysis of mononuclear	[Quantitative analysis of mononuclear]	0.0	4	1	1	1
141938	1710	deletion of a short amino-	[Deletions of a short amino-]	0.0	5	1	1	1
141939	1710	monocyte with ifn-gamma	[monocytes with IFN-gamma]	0.0	3	1	1	1
141940	1710	PMA differentiation	[PMA differentiation]	0.0	2	1	1	1
141941	1710	stimulation with gc at therapeutic concentration	[Stimulation with GC at therapeutic concentrations]	0.0	6	1	1	1
141942	1710	pulmonary tuberculosis	[pulmonary tuberculosis]	0.0	2	2	2	1
141943	1710	37 severe,	[37 severe,]	0.0	2	1	1	1
141944	1710	patient with sarcoidosis	[patients with sarcoidosis]	0.0	3	1	1	1
141945	1710	clone in the presence	[clones in the presence]	0.0	4	1	1	1
141946	1710	progressive increase in susceptibility	[progressive increase in susceptibility]	0.0	4	1	1	1
141947	1710	preactivation	[Preactivation]	0.0	1	1	1	1
141948	1710	type of inflammatory process	[types of inflammatory processes]	0.0	4	1	1	1
141949	1710	homolog of chicken nf-m	[homolog of chicken NF-M]	0.0	4	1	1	1
141950	1710	pituitary beta-cell	[pituitary beta-cells]	0.0	2	1	1	1
141951	1710	shuttling in discrimination of ca2+ signal	[shuttling in discrimination of Ca2+ signals]	0.0	6	1	1	1
141952	1710	microgranular variant FAB aml -m3v	[microgranular variant FAB AML -M3v]	0.0	5	1	1	1
141953	1710	antibody to CD3 (ic50	[antibody to CD3 (IC50]	0.0	4	1	1	1
141954	1710	nordihydroguiauretic	[nordihydroguiauretic]	0.0	1	1	1	1
141955	1710	potent proinflammatory mediator	[potent proinflammatory mediator]	0.0	3	1	1	1
141956	1710	quantitative thin-layer chromatography analysis	[Quantitative thin-layer chromatography analyses]	0.0	4	1	1	1
141957	1710	24,25-dihydroxy-vitamin D3	[24,25-dihydroxy-vitamin D3]	0.0	2	1	1	1
141958	1710	effect on adrenal function	[effects on adrenal function]	0.0	4	1	1	1
141959	1710	dissection of the transcription coactivator oca-b	[dissection of the transcription coactivator OCA-B]	0.0	6	1	1	1
141960	1710	CD43/leukosialin the sialoglycoprotein of leukocyte	[CD43/leukosialin the sialoglycoprotein of leukocytes]	0.0	5	1	1	1
141961	1710	adipocyte differentiation through receptor gamma ppargamma	[adipocyte differentiation through receptor gamma PPARgamma]	0.0	6	1	1	1
141962	1710	phorbol ester in human T	[phorbol esters in human T]	0.0	5	1	1	1
141963	1710	necessary, optimal induction	[necessary, optimal induction]	0.0	3	1	1	1
141964	1710	loss of both	[loss of both]	0.0	3	1	1	1
141965	1710	cell-specific activity of Jun	[cell-specific activity of Jun]	0.0	4	1	1	1
141966	1710	promyelocytic cell line	[promyelocytic cell line]	0.0	3	1	1	1
141967	1710	possible use of combination	[possible use of combinations]	0.0	4	1	1	1
141968	1710	follow lps activation	[following LPS activation]	0.0	3	1	1	1
141969	1710	ad5e1a -specific CTL activity	[Ad5E1A -specific CTL activity]	0.0	4	1	1	1
141970	1710	major regulatory role for GATA-1	[major regulatory role for GATA-1]	0.0	5	1	1	1
141971	1710	(b) conjugation of ubiquitin	[(b) conjugation of ubiquitin]	0.0	4	1	1	1
141972	1710	prolonged exposure of human cell HAEC	[prolonged exposure of human cells HAEC]	0.0	6	1	1	1
141973	1710	kappab-binding protein	[kappaB-binding proteins]	0.0	2	1	1	1
141974	1710	myelogenous leukemia cell	[myelogenous leukemia cells]	0.0	3	1	1	1
141975	1710	induction h.	[induction h,]	0.0	2	1	1	1
141976	1710	cell adhesion molecule-1 expression in cell	[cell adhesion molecule-1 expression in cells]	0.0	6	1	1	1
141977	1710	similar number	[similar numbers]	0.0	2	1	1	1
141978	1710	two ets site	[two Ets sites]	0.0	3	1	1	1
141979	1710	bz1 reactivity	[BZ1 reactivity]	0.0	2	1	1	1
141980	1710	role in leukemia	[role in leukemias]	0.0	3	1	1	1
141981	1710	minute of heat shock	[min of heat shock]	0.0	4	1	1	1
141982	1710	Differential induction follow differentiation	[Differential induction following differentiation]	0.0	4	1	1	1
141983	1710	nf-at complex with a oligonucleotide corresponding	[NF-AT complexes with an oligonucleotide corresponding]	0.0	6	1	1	1
141984	1710	ICAM-1 transcription	[ICAM-1 transcription]	0.0	2	1	1	1
141985	1710	tfiid from all organism	[TFIIDs from all organisms]	0.0	4	1	1	1
141986	1710	lymphoblastic leukemia of childhood.	[lymphoblastic leukemia of childhood.]	0.0	4	1	1	1
141987	1710	three month	[Three months]	0.0	2	1	1	1
141988	1710	second transformation effector site	[second transformation effector site]	0.0	4	1	1	1
141989	1710	analysis of the preexisting form	[Analysis of the preexisting forms]	0.0	5	1	1	1
141990	1710	relatively high, concentration of RA	[relatively high, concentrations of RA]	0.0	5	1	1	1
141991	1710	mutation of R-276	[mutations of R-276]	0.0	3	1	1	1
141992	1710	pAT gene	[pAT gene]	0.0	2	2	2	1
141993	1710	potent suppressive property	[potent suppressive properties]	0.0	3	1	1	1
141994	1710	tcp (200 h),	[TCP (200 h),]	0.0	3	1	1	1
141995	1710	extend to -300bp	[extending to -300bp]	0.0	3	1	1	1
141996	1710	monomeric form of the protein.	[monomeric form of the protein.]	0.0	5	1	1	1
141997	1710	treatment prior to treatment	[Treatment prior to treatment]	0.0	4	1	1	1
141998	1710	sequence immediately upstream	[sequence immediately upstream]	0.0	3	1	1	1
141999	1710	gtpase ran	[GTPase Ran]	0.0	2	1	1	1
142000	1710	human hla-dq class subset	[human HLA-DQ class subset]	0.0	4	1	1	1
142001	1710	single ubiquitous cyclic element	[single ubiquitous cyclic element]	0.0	4	1	1	1
142002	1710	nf(kappa)b expression	[NF(kappa)B expression]	0.0	2	1	1	1
142003	1710	active proliferation	[active proliferation]	0.0	2	1	1	1
142004	1710	azeptin	[Azeptin]	0.0	1	1	1	1
142005	1710	(il)-6	[(IL)-6]	0.0	1	2	2	1
142006	1710	persistence of clonotype	[persistence of clonotypes]	0.0	3	1	1	1
142007	1710	mineralocorticoid receptor outside the episode	[mineralocorticoid receptors outside the episode]	0.0	5	1	1	1
142008	1710	site originate approximately 204 bp	[sites originating approximately 204 bp]	0.0	5	1	1	1
142009	1710	human kidney cell	[human kidney cells]	0.0	3	1	1	1
142010	1710	high potential hpp- cell	[high potential HPP- cells]	0.0	4	1	1	1
142011	1710	cut edge: effect	[Cutting edge: effect]	0.0	3	1	1	1
142012	1710	autologous thymic cell TEC	[autologous thymic cells TEC]	0.0	4	1	1	1
142013	1710	6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).	[6, rhabdomyosarcoma 10, leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
142014	1710	vivo study in mouse	[vivo studies in mice]	0.0	4	1	1	1
142015	1710	immunologic nos	[immunologic NOS]	0.0	2	1	1	1
142016	1710	very mild down-regulation in patient suffer	[very mild down-regulation in patients suffering]	0.0	6	1	1	1
142017	1710	(il),1	[(IL),1]	0.0	1	1	1	1
142018	1710	prolonged submaximal exercise at 70%	[prolonged submaximal exercises at 70%]	0.0	5	1	1	1
142019	1710	self renewal in progenitor	[self renewal in progenitors]	0.0	4	1	1	1
142020	1710	great increase in m phi uptake	[greater increases in M phi uptake]	0.0	6	1	1	1
142021	1710	ach clone	[ACH clone]	0.0	2	1	1	1
142022	1710	pseudohypoaldosteronism in eight form	[Pseudohypoaldosteronism in eight forms]	0.0	4	1	1	1
142023	1710	nf-kappa b regulatory element	[NF-kappa B regulatory elements]	0.0	4	1	1	1
142024	1710	truncation of tr alpha	[Truncation of TR alpha]	0.0	4	1	1	1
142025	1710	contain a basic region (4c)	[containing a basic region (4c)]	0.0	5	1	1	1
142026	1710	two lymphoma cell line CRO-AP/3	[two lymphoma cell lines CRO-AP/3]	0.0	5	1	1	1
142027	1710	Kruppel-like factor activity	[Kruppel-like factor activity]	0.0	3	1	1	1
142028	1710	predict response	[predicting response]	0.0	2	1	1	1
142029	1710	hl-60 granulocyte	[HL-60 granulocytes]	0.0	2	1	1	1
142030	1710	-dependent up-regulating	[-dependent up-regulating]	0.0	2	1	1	1
142031	1710	epithelial cell inflammatory response	[epithelial cell inflammatory responses]	0.0	4	1	1	1
142032	1710	phagocyte by leukemia inhibitory factor	[phagocytes by leukemia inhibitory factor]	0.0	5	1	1	1
142033	1710	Erythropoietin Epo the regulator	[Erythropoietin Epo the regulator]	0.0	4	1	1	1
142034	1710	proteolysis.	[proteolysis.]	0.0	1	1	1	1
142035	1710	one level	[one levels]	0.0	2	1	1	1
142036	1710	gene encode relevant protein	[genes encoding relevant proteins]	0.0	4	1	1	1
142037	1710	-DNA binding protein	[-DNA binding proteins]	0.0	3	1	1	1
142038	1710	coordination with other cell-specific factor	[coordination with other cell-specific factors]	0.0	5	1	1	1
142039	1710	group one	[groups one]	0.0	2	1	1	1
142040	1710	patient with class immunodeficiency	[patients with class immunodeficiency]	0.0	4	1	1	1
142041	1710	indicate cell-specific difference	[indicating cell-specific differences]	0.0	3	1	1	1
142042	1710	domain of stat6	[domains of STAT6]	0.0	3	1	1	1
142043	1710	dose of nm	[dose of nM]	0.0	3	1	1	1
142044	1710	high level in this patient	[high levels in these patients]	0.0	5	1	1	1
142045	1710	nuclei of pbl from donor	[Nuclei of PBL from donors]	0.0	5	1	1	1
142046	1710	conformational polymorphism SSCP	[conformational polymorphism SSCP]	0.0	3	1	1	1
142047	1710	proximal domain of the tail	[proximal domains of the tail]	0.0	5	1	1	1
142048	1710	splenocyte response	[splenocyte responses]	0.0	2	1	1	1
142049	1710	M.LaPlaca,	[M.LaPlaca,]	0.0	1	1	1	1
142050	1710	>24 hours, oleate	[>24 hours, oleate]	0.0	3	1	1	1
142051	1710	class immunoblastic lymphoma plasmacytoid	[class immunoblastic lymphoma plasmacytoid]	0.0	4	1	1	1
142052	1710	proteolysist	[proteolysis-resisting]	0.0	1	1	1	1
142053	1710	corresponding mutation	[corresponding mutations]	0.0	2	1	1	1
142054	1710	cell with monoclonal antibody	[cells with monoclonal antibody]	0.0	4	1	1	1
142055	1710	relationship between the ca2+	[relationship between the Ca2+]	0.0	4	1	1	1
142056	1710	1 terminal repeat LTR	[1 terminal repeat LTR]	0.0	4	1	1	1
142057	1710	induction of cell cycle regulator	[induction of cell cycle regulators]	0.0	5	1	1	1
142058	1710	specific b /rel subunit	[specific B /Rel subunits]	0.0	4	1	1	1
142059	1710	cell level	[cell level]	0.0	2	1	1	1
142060	1710	nuclear differentiation antigen MNDA	[nuclear differentiation antigen MNDA]	0.0	4	1	1	1
142061	1710	response gene inducibility	[response gene inducibility]	0.0	3	1	1	1
142062	1710	dominant mapkk-1	[dominant MAPKK-1]	0.0	2	1	1	1
142063	1710	trypan exclusion	[trypan exclusion]	0.0	2	1	1	1
142064	1710	m all-tran retinoic acid	[M all-trans retinoic acid]	0.0	4	1	1	1
142065	1710	distinct nuclear protein complex	[distinct nuclear protein complexes]	0.0	4	1	1	1
142066	1710	host defense:	[host defense:]	0.0	2	1	1	1
142067	1710	glucocorticoid on interleukin	[glucocorticoids on interleukin]	0.0	3	1	1	1
142068	1710	u/ml interleukin-2 over 48-h time	[U/ml interleukin-2 over 48-h time]	0.0	5	1	1	1
142069	1710	increase in anh	[increase in ANH]	0.0	3	1	1	1
142070	1710	glucocorticoid in healthy subject	[glucocorticoids in healthy subjects]	0.0	4	1	1	1
142071	1710	other activity downstream	[other activities downstream]	0.0	3	1	1	1
142072	1710	element (igh) enhancer	[elements (IgH) enhancer]	0.0	3	1	1	1
142073	1710	new group	[new group]	0.0	2	1	1	1
142074	1710	pkc -specific inhibitor	[PKC -specific inhibitor]	0.0	3	1	1	1
142075	1710	rapidak dose-related increase	[rapid, dose-related increase]	0.0	3	1	1	1
142076	1710	role of multiple regulatory sites.	[role of multiple regulatory sites.]	0.0	5	1	1	1
142077	1710	expression of immediate-early gene	[expression of immediate-early genes]	0.0	4	1	1	1
142078	1710	shp2-interacting transmembrane adaptor protein SIT	[SHP2-interacting transmembrane adaptor protein SIT]	0.0	5	1	1	1
142079	1710	pituitary adrenocorticotropic hormone acth	[pituitary adrenocorticotropic hormone ACTH]	0.0	4	1	1	1
142080	1710	detection of DNA	[detection of DNA]	0.0	3	1	1	1
142081	1710	strong increase in thf	[strong increase in THF]	0.0	4	1	1	1
142082	1710	dose of t3	[dose of T3]	0.0	3	1	1	1
142083	1710	ap-1 concentration	[AP-1 concentrations]	0.0	2	1	1	1
142084	1710	participate in the gamma-globin	[participating in the gamma-globin]	0.0	4	1	1	1
142085	1710	patient with promyelocytic leukemia APL	[patients with promyelocytic leukemia APL]	0.0	5	1	1	1
142086	1710	functional il-6 protein	[functional IL-6 protein]	0.0	3	1	1	1
142087	1710	element consistent with myeloid-specific gene expression	[elements consistent with myeloid-specific gene expression]	0.0	6	1	1	1
142088	1710	density lipoprotein ldl	[density lipoprotein LDL]	0.0	3	3	3	1
142089	1710	PU.1 consensus	[PU.1 consensus]	0.0	2	1	1	1
142090	1710	h in this tonsillar cell	[h in these tonsillar cells]	0.0	5	1	1	1
142091	1710	sevenfold) of site 3.	[sevenfold) of site 3.]	0.0	4	1	1	1
142092	1710	follow chromosomal translocation in leukemia	[following chromosomal translocations in leukemias]	0.0	5	1	1	1
142093	1710	stimulation of transcription	[stimulation of transcription]	0.0	3	1	1	1
142094	1710	monocytic cell a major component	[monocytic cells a major component]	0.0	5	1	1	1
142095	1710	factor proliferation	[factor proliferation]	0.0	2	1	1	1
142096	1710	causal role	[causal role]	0.0	2	2	2	1
142097	1710	phenylpyrazolo glucocorticoid	[phenylpyrazolo glucocorticoid]	0.0	2	1	1	1
142098	1710	IFN regulation	[IFN regulation]	0.0	2	1	1	1
142099	1710	immune response in drosophila	[immune response in Drosophila]	0.0	4	1	1	1
142100	1710	signal determinant	[signaling determinants]	0.0	2	1	1	1
142101	1710	cd86 ligand	[CD86 ligands]	0.0	2	1	1	1
142102	1710	role for TN	[role for TN]	0.0	3	1	1	1
142103	1710	camp -dependent protein kinase activity	[cAMP -dependent protein kinase activities]	0.0	5	1	1	1
142104	1710	cis-acting region GM-kappa B/GC-box	[cis-acting region GM-kappa B/GC-box]	0.0	4	1	1	1
142105	1710	complex response	[complex response]	0.0	2	1	1	1
142106	1710	upstream nuclear factor-kappa b	[upstream nuclear factor-kappa B]	0.0	4	1	1	1
142107	1710	identification of target	[identification of targets]	0.0	3	1	1	1
142108	1710	expression regulation of gene	[expression regulation of genes]	0.0	4	1	1	1
142109	1710	follow stimulation tumor necrosis factor-alpha	[Following stimulation tumor necrosis factor-alpha]	0.0	5	1	1	1
142110	1710	effect of DEX together	[effects of DEX together]	0.0	4	1	1	1
142111	1710	interaction between factor	[interactions between factors]	0.0	3	1	1	1
142112	1710	point mutation change ylpq	[point mutation changing YLPQ]	0.0	4	1	1	1
142113	1710	defect in this cell	[defect in these cells]	0.0	4	1	1	1
142114	1710	component of U1 u1a/u1b	[components of U1 U1A/U1B]	0.0	4	1	1	1
142115	1710	correlation between receptor level	[correlation between receptor level]	0.0	4	1	1	1
142116	1710	increase in the period	[increase in the period]	0.0	4	1	1	1
142117	1710	nrf-1/alpha-pal factor	[NRF-1/alpha-Pal factor]	0.0	2	1	1	1
142118	1710	transactivation of the interleukin-1alpha promoter	[Transactivation of the interleukin-1alpha promoter]	0.0	5	1	1	1
142119	1710	photoproduct	[photoproducts]	0.0	1	1	1	1
142120	1710	ns-meg	[NS-Meg]	0.0	1	1	1	1
142121	1710	six different band	[six different bands]	0.0	3	1	1	1
142122	1710	oxidative-stress sensor for vcam regulation	[oxidative-stress sensor for VCAM regulation]	0.0	5	1	1	1
142123	1710	promote the nuclear translocation	[promoting the nuclear translocation]	0.0	4	1	1	1
142124	1710	regulatory protein of hiv-1	[regulatory protein of HIV-1]	0.0	4	1	1	1
142125	1710	activity of tyrosine phosphatase	[activity of tyrosine phosphatase]	0.0	4	1	1	1
142126	1710	Intriguingly, surface expression	[Intriguingly, surface expression]	0.0	3	1	1	1
142127	1710	fivefold increase over subject	[fivefold increase over subjects]	0.0	4	1	1	1
142128	1710	detectable phosphorylation in the cell	[detectable phosphorylation in the cells]	0.0	5	1	1	1
142129	1710	role for rxr-alpha	[role for RXR-alpha]	0.0	3	1	1	1
142130	1710	sp-a dose low	[SP-A doses low]	0.0	3	1	1	1
142131	1710	contain a sp1-box	[containing an SP1-box]	0.0	3	1	1	1
142132	1710	ICAM-1 pire	[ICAM-1 pIRE]	0.0	2	1	1	1
142133	1710	need for il-12 signaling,	[need for IL-12 signaling,]	0.0	4	1	1	1
142134	1710	hematopoietic precursor cell	[hematopoietic precursor cells]	0.0	3	1	1	1
142135	1710	nuclear retention of 1600 VDR	[nuclear retention of 1600 VDR]	0.0	5	1	1	1
142136	1710	activity of okadaic serine /threonine phosphatase	[activity of okadaic serine /threonine phosphatases]	0.0	6	1	1	1
142137	1710	myeloblastic leukemia ml-1 cell	[myeloblastic leukemia ML-1 cells]	0.0	4	1	1	1
142138	1710	cellularity of this mouse	[cellularity of these mice]	0.0	4	1	1	1
142139	1710	presence of duplication	[presence of duplications]	0.0	3	1	1	1
142140	1710	ds-oligonucleotides	[ds-oligonucleotides]	0.0	1	2	2	1
142141	1710	intermediate structure during deamidation	[intermediate structure during deamidation]	0.0	4	1	1	1
142142	1710	induction consistent with suppression	[induction consistent with suppression]	0.0	4	1	1	1
142143	1710	substnfkappab substSpl2	[substNFkappaB substSpl2]	0.0	2	1	1	1
142144	1710	presence of several regulatory element	[presence of several regulatory elements]	0.0	5	1	1	1
142145	1710	m elevation	[M elevation]	0.0	2	1	1	1
142146	1710	such as respiratory distress syndrome ards	[such as respiratory distress syndrome ARDS]	0.0	6	1	1	1
142147	1710	presence of inducers,	[presence of inducers,]	0.0	3	1	1	1
142148	1710	potential of am580	[potential of AM580]	0.0	3	1	1	1
142149	1710	great than microm	[greater than microM]	0.0	3	1	1	1
142150	1710	ligand bind affinity	[ligand binding affinity]	0.0	3	1	1	1
142151	1710	(bfu-e)	[(BFU-E)]	0.0	1	1	1	1
142152	1710	ap1 complex in human monocyte	[AP1 complex in human monocytes]	0.0	5	1	1	1
142153	1710	r24 stimulation	[R24 stimulation]	0.0	2	1	1	1
142154	1710	infection with a recombinant retrovirus	[infection with a recombinant retrovirus]	0.0	5	1	1	1
142155	1710	amino acid rich in serine	[amino acids rich in serine]	0.0	5	1	1	1
142156	1710	shp-1 phosphatase	[SHP-1 phosphatase]	0.0	2	1	1	1
142157	1710	human atherosclerotic plaque	[human atherosclerotic plaques]	0.0	3	1	1	1
142158	1710	regulation of epsilon germline transcription	[Regulation of epsilon germline transcription]	0.0	5	1	1	1
142159	1710	apparent mass of 84 kda	[apparent mass of 84 kDa]	0.0	5	1	1	1
142160	1710	expression of virus	[expression of virus]	0.0	3	1	1	1
142161	1710	acid RA similar	[acid RA similar]	0.0	3	1	1	1
142162	1710	regulate immunodeficiency virus hiv persistence	[regulating immunodeficiency virus HIV persistence]	0.0	5	2	2	1
142163	1710	amp-responsive element modulator	[AMP-responsive element modulator]	0.0	3	1	1	1
142164	1710	kappa b activity	[kappa B activity]	0.0	3	1	1	1
142165	1710	retinoid -dependent marker	[retinoid -dependent markers]	0.0	3	1	1	1
142166	1710	adhesion of cell vein cell	[adhesion of cells vein cells]	0.0	5	1	1	1
142167	1710	cyclic member	[cyclic members]	0.0	2	1	1	1
142168	1710	circulate antigen-specific t-cell	[circulating antigen-specific T-cells]	0.0	3	1	1	1
142169	1710	translocation of factor-kappaB	[translocation of factor-kappaB]	0.0	3	1	1	1
142170	1710	transient stimulation of b lymphocyte	[Transient stimulation of B lymphocytes]	0.0	5	1	1	1
142171	1710	tyrosine phosphorylation of factor	[tyrosine phosphorylation of factor]	0.0	4	1	1	1
142172	1710	cognate factor	[cognate factors]	0.0	2	1	1	1
142173	1710	12 mutation event	[12 mutation events]	0.0	3	1	1	1
142174	1710	progenitor to cell	[progenitors to cells]	0.0	3	1	1	1
142175	1710	future strategy	[future strategies]	0.0	2	1	1	1
142176	1710	cd34+/-,	[CD34+/-,]	0.0	1	1	1	1
142177	1710	occupancy enhancer by nf-kappa b	[occupancy enhancer by NF-kappa B]	0.0	5	1	1	1
142178	1710	free production/oxidative stress	[free production/oxidative stress]	0.0	3	1	1	1
142179	1710	ikappabalpha degradation in this cells.	[IkappaBalpha degradation in these cells.]	0.0	5	1	1	1
142180	1710	pkc -dependent pathway	[PKC -dependent pathways]	0.0	3	1	1	1
142181	1710	role of PKC	[role of PKC]	0.0	3	1	1	1
142182	1710	phenolic, chain-break antioxidant	[phenolic, chain-breaking antioxidant]	0.0	3	1	1	1
142183	1710	more than 90% identity	[more than 90% identity]	0.0	4	1	1	1
142184	1710	consist mainly	[consisting mainly]	0.0	2	1	1	1
142185	1710	great effect on IKK	[greater effect on IKK]	0.0	4	1	1	1
142186	1710	rna splice	[RNA splice]	0.0	2	1	1	1
142187	1710	primitive cell in mouse	[primitive cells in mice]	0.0	4	1	1	1
142188	1710	stage of t-cell maturation	[stage of T-cell maturation]	0.0	4	1	1	1
142189	1710	putative cis-acting element include a gata-1	[putative cis-acting elements including a GATA-1]	0.0	6	1	1	1
142190	1710	level element-binding activity	[levels element-binding activity]	0.0	3	1	1	1
142191	1710	signal through the CD4 receptor	[signaling through the CD4 receptor]	0.0	5	1	1	1
142192	1710	autosomal neurocutaneous disorder	[autosomal neurocutaneous disorder]	0.0	3	1	1	1
142193	1710	sex-and healthy subject	[sex-and healthy subjects]	0.0	3	1	1	1
142194	1710	apoptotic cells;	[apoptotic cells;]	0.0	2	1	1	1
142195	1710	mature myeloid cell i.e. granulocyte	[mature myeloid cells i.e. granulocytes]	0.0	5	1	1	1
142196	1710	even with the small messenger response	[even with the smaller messenger response]	0.0	6	1	1	1
142197	1710	structural protein expression gag	[structural protein expression Gag]	0.0	4	1	1	1
142198	1710	cycle epitope	[cycle epitopes]	0.0	2	1	1	1
142199	1710	nonexpression	[nonexpression]	0.0	1	1	1	1
142200	1710	multiple lytic reactivity as high	[multiple lytic reactivities as high]	0.0	5	1	1	1
142201	1710	gene IL-2	[genes IL-2]	0.0	2	1	1	1
142202	1710	yeast chromosome transgene	[yeast chromosome transgene]	0.0	3	1	1	1
142203	1710	deterioration in infection	[deterioration in infection]	0.0	3	1	1	1
142204	1710	increase in phosphotyrosine labeling	[increases in phosphotyrosine labeling]	0.0	4	1	1	1
142205	1710	messenger in T cell	[messengers in T cells]	0.0	4	1	1	1
142206	1710	response to costimulation	[response to costimulation]	0.0	3	1	1	1
142207	1710	patient with corticosteroid bronchial asthma	[patients with corticosteroid bronchial asthma]	0.0	5	1	1	1
142208	1710	sequence DRE to +240	[sequence DRE to +240]	0.0	4	1	1	1
142209	1710	cell gssg /gsh	[cell GSSG /GSH]	0.0	3	1	1	1
142210	1710	production of no	[production of NO]	0.0	3	1	1	1
142211	1710	normal lymphoid tissue	[normal lymphoid tissues]	0.0	3	1	1	1
142212	1710	lps induction of gene expression	[LPS induction of gene expression]	0.0	5	1	1	1
142213	1710	EBNAI	[EBNAI]	0.0	1	1	1	1
142214	1710	indirect observations,	[indirect observations,]	0.0	2	1	1	1
142215	1710	sequence-binding complex contain STAT3 alone	[sequence-binding complexes containing STAT3 alone]	0.0	5	1	1	1
142216	1710	distinct signalling pathway	[distinct signalling pathways]	0.0	3	1	1	1
142217	1710	complex with the mobility	[complex with the mobility]	0.0	4	1	1	1
142218	1710	include 1 case	[including 1 case]	0.0	3	1	1	1
142219	1710	Nuclear t3r	[Nuclear T3R]	0.0	2	1	1	1
142220	1710	use the t-cell line JPX-9	[using the T-cell line JPX-9]	0.0	5	1	1	1
142221	1710	il-2 mrna stability.	[IL-2 mRNA stability.]	0.0	3	1	1	1
142222	1710	domain with segment	[domain with segments]	0.0	3	1	1	1
142223	1710	implicate cis-active sequence	[implicating cis-active sequences]	0.0	3	1	1	1
142224	1710	anti- CD30 antibody mab	[anti- CD30 antibodies mAb]	0.0	4	1	1	1
142225	1710	negative n17rac	[negative N17Rac]	0.0	2	1	1	1
142226	1710	mutated).	[mutated).]	0.0	1	1	1	1
142227	1710	RXR mutant	[RXR mutants]	0.0	2	1	1	1
142228	1710	ten patient	[Ten patients]	0.0	2	1	1	1
142229	1710	regulation of interleukin gene by glucocorticoid	[regulation of interleukin gene by glucocorticoids]	0.0	6	1	1	1
142230	1710	distribution of Aiolos	[distribution of Aiolos]	0.0	3	1	1	1
142231	1710	vzv ie62 protein coding sequence	[VZV IE62 protein coding sequences]	0.0	5	1	1	1
142232	1710	cytokine -inducible neutrophil chemoattractant	[cytokine -inducible neutrophil chemoattractant]	0.0	4	1	1	1
142233	1710	activate gst-pi promoter	[activating GST-pi promoter]	0.0	3	1	1	1
142234	1710	mande b lymphocyte	[mande B lymphocytes]	0.0	3	1	1	1
142235	1710	many growth factor-dependent cell line	[many growth factor-dependent cell lines]	0.0	5	1	1	1
142236	1710	M7 case	[M7 cases]	0.0	2	2	2	1
142237	1710	additional small region	[additional smaller regions]	0.0	3	1	1	1
142238	1710	HL-60/vinc revertant	[HL-60/vinc revertant]	0.0	2	1	1	1
142239	1710	chimeric promoter	[chimeric promoter]	0.0	2	1	1	1
142240	1710	culture analysis of regulatory gene expression	[cultures analysis of regulatory gene expression]	0.0	6	1	1	1
142241	1710	independent manner	[independent manner]	0.0	2	1	1	1
142242	1710	basis of several observations,	[basis of several observations,]	0.0	4	1	1	1
142243	1710	IL-4 gamma	[IL-4 gamma]	0.0	2	1	1	1
142244	1710	clones, pzvh14	[clones, pZVH14]	0.0	2	1	1	1
142245	1710	challenge, cytokine gene expression	[challenge, cytokine gene expression]	0.0	4	1	1	1
142246	1710	malignant human b-cell line	[malignant human B-cell lines]	0.0	4	1	1	1
142247	1710	sp ii promoter	[SP II promoter]	0.0	3	1	1	1
142248	1710	48% binding activity	[48% binding activity]	0.0	3	1	1	1
142249	1710	reduction in cell proliferation	[reduction in cell proliferation]	0.0	4	1	1	1
142250	1710	stat protein in extract	[STAT proteins in extracts]	0.0	4	1	1	1
142251	1710	disease x-linked agammaglobulinemia XLA	[disease X-linked agammaglobulinemia XLA]	0.0	4	1	1	1
142252	1710	recombinant tumor	[recombinant tumor]	0.0	2	1	1	1
142253	1710	(i) transfection	[(i) transfection]	0.0	2	1	1	1
142254	1710	dna-binding property of hepatic leukemia factor	[DNA-binding properties of hepatic leukemia factor]	0.0	6	1	1	1
142255	1710	distinct impaired deletion	[distinct impaired deletion]	0.0	3	1	1	1
142256	1710	nf-kappab heterodimer binding to DNA,	[NF-kappaB heterodimer binding to DNA,]	0.0	5	1	1	1
142257	1710	EBNA-2A	[EBNA-2A]	0.0	1	1	1	1
142258	1710	primary sequence	[primary sequence]	0.0	2	1	1	1
142259	1710	identification of a interaction	[Identification of a interaction]	0.0	4	1	1	1
142260	1710	history of clinical disease	[history of clinical disease.]	0.0	4	1	1	1
142261	1710	part, in the expression	[part, in the expression]	0.0	4	1	1	1
142262	1710	neonatal cord blood	[neonatal cord bloods]	0.0	3	1	1	1
142263	1710	iii-dependent	[III-dependent]	0.0	1	1	1	1
142264	1710	cytotoxic chemotherapy in a patient	[cytotoxic chemotherapy in a patient]	0.0	5	1	1	1
142265	1710	dna-protein binding formation	[DNA-protein binding formation]	0.0	3	1	1	1
142266	1710	role of PML	[role of PML]	0.0	3	1	1	1
142267	1710	such oct2 target gene	[such Oct2 target genes]	0.0	4	1	1	1
142268	1710	magnitude.	[magnitude.]	0.0	1	1	1	1
142269	1710	cancer.	[cancer.]	0.0	1	1	1	1
142270	1710	fourfold susceptibility to cerebral malaria	[fourfold susceptibility to cerebral malaria]	0.0	5	1	1	1
142271	1710	maintain a load	[maintaining a load]	0.0	3	1	1	1
142272	1710	erythropoietin -dependent induction	[Erythropoietin -dependent induction]	0.0	3	1	1	1
142273	1710	classical paradigm	[classical paradigm]	0.0	2	1	1	1
142274	1710	mu/l concentration insulin	[mU/L concentration insulin]	0.0	3	1	1	1
142275	1710	hiv-1 tat gene	[HIV-1 tat gene]	0.0	3	1	1	1
142276	1710	ts on NFkappaB	[TS on NFkappaB]	0.0	3	1	1	1
142277	1710	p27(kip1	[p27(Kip1]	0.0	1	1	1	1
142278	1710	calcitriol (final ethanol concentration	[calcitriol (final ethanol concentration]	0.0	4	1	1	1
142279	1710	constitutive binding in unactivated nuclear extract	[constitutive binding in unactivated nuclear extracts]	0.0	6	1	1	1
142280	1710	a2 b4 ltb4	[A2 B4 LTB4]	0.0	3	1	1	1
142281	1710	nuclear protein sp	[nuclear proteins SP]	0.0	3	1	1	1
142282	1710	govern process	[governing processes]	0.0	2	1	1	1
142283	1710	cytomegalovirus binding	[cytomegalovirus binding]	0.0	2	1	1	1
142284	1710	subset of signalling pathway	[subset of signalling pathways]	0.0	4	1	1	1
142285	1710	overexpression of c-Rel	[overexpression of c-Rel]	0.0	3	1	1	1
142286	1710	enhancer/promoters	[enhancer/promoters]	0.0	1	3	3	1
142287	1710	response to many signal	[response to many signals]	0.0	4	1	1	1
142288	1710	b-directed	[B-directed]	0.0	1	1	1	1
142289	1710	granule enzyme	[granule enzymes]	0.0	2	1	1	1
142290	1710	T lymphoid jurkat cell	[T lymphoid Jurkat cells]	0.0	4	1	1	1
142291	1710	cell carcinoma bcc use immunohistochemistry	[cell carcinomas BCCs using immunohistochemistry]	0.0	5	1	1	1
142292	1710	addition of the inhibitor	[addition of the inhibitor]	0.0	4	1	1	1
142293	1710	catalyze the exchange of invariant peptide	[catalyzing the exchange of invariant peptides]	0.0	6	1	1	1
142294	1710	transcription of protooncogene	[transcription of protooncogenes]	0.0	3	1	1	1
142295	1710	significant depression I receptor 267	[significant depression I receptors 267]	0.0	5	1	1	1
142296	1710	loss-of-function mutation in allele	[loss-of-function mutation in allele]	0.0	4	1	1	1
142297	1710	immediate gene Ie	[immediate genes IE]	0.0	3	1	1	1
142298	1710	lymphocyte of person	[lymphocytes of persons]	0.0	3	1	1	1
142299	1710	related polypeptide	[related polypeptides]	0.0	2	1	1	1
142300	1710	kd (30.3+/-2.5 nmol/L) versus 8.9+/-1.2 nmol/L)	[Kd (30.3+/-2.5 nmol/L) versus 8.9+/-1.2 nmol/L)]	0.0	6	1	1	1
142301	1710	roles.	[roles.]	0.0	1	1	1	1
142302	1710	consequence of DNA damage	[consequence of DNA damage]	0.0	4	1	1	1
142303	1710	number of gata-1.05	[number of GATA-1.05]	0.0	3	1	1	1
142304	1710	kappa b-alpha proteolysis by signal-induced phosphorylation	[kappa B-alpha proteolysis by signal-induced phosphorylation]	0.0	6	1	1	1
142305	1710	same domain for receptor coupling	[same domain for receptor coupling]	0.0	5	1	1	1
142306	1710	binding two monoclonal antibody	[binding two monoclonal antibodies]	0.0	4	1	1	1
142307	1710	complex class ii gene	[complex class II genes]	0.0	4	1	1	1
142308	1710	t-cell maturation rante	[T-cell maturation RANTES]	0.0	3	1	1	1
142309	1710	type diabete in menopausal period	[type diabetes in menopausal period]	0.0	5	1	1	1
142310	1710	spleen formation	[spleen formation]	0.0	2	1	1	1
142311	1710	Hodgkin' Reed-Sternberg cell	[Hodgkin's Reed-Sternberg cells]	0.0	3	1	1	1
142312	1710	level of lipopolysaccharide	[levels of lipopolysaccharide]	0.0	3	1	1	1
142313	1710	evidence show interaction	[evidence showing interactions]	0.0	3	1	1	1
142314	1710	production of oxide	[production of oxide]	0.0	3	1	1	1
142315	1710	product by polymerase chain reaction	[product by polymerase chain reaction]	0.0	5	1	1	1
142316	1710	role of PRL	[role of PRL]	0.0	3	1	1	1
142317	1710	il-2 cd28re	[IL-2 CD28RE]	0.0	2	1	1	1
142318	1710	infection of peripheral blood lymphocyte	[Infection of peripheral blood lymphocytes]	0.0	5	1	1	1
142319	1710	second activation signal	[second activation signal]	0.0	3	1	1	1
142320	1710	assembly of terminal complement complex c5b-7	[Assembly of terminal complement complexes C5b-7]	0.0	6	1	1	1
142321	1710	detailed molecular analysis	[detailed molecular analysis]	0.0	3	1	1	1
142322	1710	target cell of ebv	[target cells of EBV]	0.0	4	1	1	1
142323	1710	such as adult respiratory distress syndrome	[such as adult respiratory distress syndrome]	0.0	6	1	1	1
142324	1710	survival in breast cancer population	[survival in breast cancer populations]	0.0	5	1	1	1
142325	1710	vitellogenin gene	[vitellogenin gene]	0.0	2	1	1	1
142326	1710	new entity	[new entity]	0.0	2	1	1	1
142327	1710	gamma-ifn gene over-express monocyte	[gamma-IFN genes over-expressing monocytes]	0.0	4	1	1	1
142328	1710	use the puc probe	[using the pUC probes]	0.0	4	1	1	1
142329	1710	specific function in the tuning	[specific function in the tuning]	0.0	5	1	1	1
142330	1710	th2-associated cytokine	[Th2-associated cytokines]	0.0	2	1	1	1
142331	1710	effect on signal event	[effect on signaling events]	0.0	4	1	1	1
142332	1710	kb of the sequence kb)	[kb of the sequence kb)]	0.0	5	1	1	1
142333	1710	extract with dmdtc	[extracts with DMDTC]	0.0	3	1	1	1
142334	1710	T lymphocyte (ctl) epitope	[T lymphocyte (CTL) epitopes]	0.0	4	1	1	1
142335	1710	specify the unique terminus	[specifying the unique terminus]	0.0	4	1	1	1
142336	1710	mutation in the 5' region	[mutations in the 5' region]	0.0	5	1	1	1
142337	1710	patient from family with degree	[patients from families with degrees]	0.0	5	1	1	1
142338	1710	il-7 effect	[IL-7 effect]	0.0	2	1	1	1
142339	1710	additional characteristic of htlv-i infection	[additional characteristic of HTLV-I infection]	0.0	5	1	1	1
142340	1710	basis of several assay	[basis of several assays]	0.0	4	1	1	1
142341	1710	apparent requirement	[apparent requirement]	0.0	2	1	1	1
142342	1710	cd peptide	[CD peptides]	0.0	2	1	1	1
142343	1710	necessary component for production	[necessary components for production]	0.0	4	1	1	1
142344	1710	-mediate	[-mediated]	0.0	1	1	1	1
142345	1710	pharmacodynamic response versus dose of methylprednisolone	[pharmacodynamic responses versus doses of methylprednisolone]	0.0	6	1	1	1
142346	1710	coli rpo	[coli rpoS]	0.0	2	1	1	1
142347	1710	lack xist expression (xiste-), with phenotypes.	[lacking XIST expression (XISTE-), with phenotypes.]	0.0	6	1	1	1
142348	1710	general model	[general model]	0.0	2	1	1	1
142349	1710	various gene coding	[various genes coding]	0.0	3	1	1	1
142350	1710	lymphotrophic	[lymphotrophic]	0.0	1	1	1	1
142351	1710	expression in MHC class -cell	[expression in MHC class -cells]	0.0	5	1	1	1
142352	1710	cell-specific binding of protein, Sp1	[cell-specific binding of protein, Sp1]	0.0	5	1	1	1
142353	1710	interferon (ifn) factor IRF-1	[interferon (IFN) factors IRF-1]	0.0	4	1	1	1
142354	1710	approach with saccharomy cerevisiae	[approach with Saccharomyces cerevisiae]	0.0	4	1	1	1
142355	1710	granulocyte colony-stimulating factor receptor g-csf-r	[granulocyte colony-stimulating factor receptor G-CSF-R]	0.0	5	1	1	1
142356	1710	sixteen patient aged years, (range	[Sixteen patients aged years, (ranging]	0.0	5	1	1	1
142357	1710	Deoxycholate treatment of the extract	[Deoxycholate treatment of the extract]	0.0	5	1	1	1
142358	1710	study: Peripheral lymphocyte from woman	[STUDY: Peripheral lymphocytes from women]	0.0	5	1	1	1
142359	1710	inverse correlation between infiltration	[inverse correlation between infiltration]	0.0	4	1	1	1
142360	1710	coordinate the activity of regulatory element	[coordinating the activity of regulatory elements]	0.0	6	1	1	1
142361	1710	target for antiviral therapy	[target for antiviral therapy]	0.0	4	1	1	1
142362	1710	EBNA-2 -positive cell line	[EBNA-2 -positive cell lines]	0.0	4	1	1	1
142363	1710	predictive value of a response	[predictive value of a response]	0.0	5	1	1	1
142364	1710	content lymphocyte	[content lymphocytes]	0.0	2	1	1	1
142365	1710	90% decrease	[90% decrease]	0.0	2	1	1	1
142366	1710	corticosteroid receptor a marker	[Corticosteroid receptors a marker]	0.0	4	1	1	1
142367	1710	N-terminal deletion	[N-terminal deletions]	0.0	2	1	1	1
142368	1710	functional analogue	[functional analogue]	0.0	2	1	1	1
142369	1710	lack a portion of the domain	[lacking a portion of the domain]	0.0	6	1	1	1
142370	1710	human t-cell virus type htlv-1	[human T-cell virus type HTLV-1]	0.0	5	1	1	1
142371	1710	24 healthy woman (11 second	[24 healthy women (11 second]	0.0	5	1	1	1
142372	1710	il-12 response	[IL-12 responses]	0.0	2	1	1	1
142373	1710	distinct histone deacetylase complex	[distinct histone deacetylase complexes]	0.0	4	1	1	1
142374	1710	productive human immunodeficiency virus type	[Productive human immunodeficiency virus type]	0.0	5	1	1	1
142375	1710	cyclic-AMP element bind	[cyclic-AMP element binding]	0.0	3	1	1	1
142376	1710	staining with a small panel	[staining with a small panel]	0.0	5	1	1	1
142377	1710	complex contain nf-atp	[complex containing NF-ATp]	0.0	3	1	1	1
142378	1710	reduction of lymphocytic aldosterone receptor	[reduction of lymphocytic aldosterone receptors]	0.0	5	1	1	1
142379	1710	thigh	[thigh]	0.0	1	1	1	1
142380	1710	however, culture condition and/or cytokine	[however, cultures conditions and/or cytokine]	0.0	5	1	1	1
142381	1710	peptide-affinity manner	[peptide-affinity manner]	0.0	2	1	1	1
142382	1710	most cell clone	[most cell clones]	0.0	3	1	1	1
142383	1710	novel activator tcf-1	[novel activator TCF-1]	0.0	3	1	1	1
142384	1710	anti- STAT3 antibody	[anti- STAT3 antibodies]	0.0	3	1	1	1
142385	1710	receptor belong	[receptor belonging]	0.0	2	1	1	1
142386	1710	identify malignancy human melanoma	[identifying malignancy human melanomas]	0.0	4	1	1	1
142387	1710	role as a effector	[role as an effector]	0.0	4	1	1	1
142388	1710	role in anti-inflammatory effect	[role in anti-inflammatory effects]	0.0	4	1	1	1
142389	1710	kind of stresses,	[kinds of stresses,]	0.0	3	1	1	1
142390	1710	naf-r-nse	[NaF-R-NSE]	0.0	1	1	1	1
142391	1710	activation requirement in the neonate	[activation requirements in the neonate]	0.0	5	1	1	1
142392	1710	cross-linked anti-cd3epsilon mab	[cross-linked anti-CD3epsilon mAb]	0.0	3	1	1	1
142393	1710	id inhibitor	[Id inhibitor]	0.0	2	1	1	1
142394	1710	high dose result	[High doses resulting]	0.0	3	1	1	1
142395	1710	function of e2a-hlf	[function of E2A-HLF]	0.0	3	1	1	1
142396	1710	content of t3, 4) dysfunction	[content of T3, 4) dysfunction]	0.0	5	1	1	1
142397	1710	administration for over one month	[Administration for over one month]	0.0	5	1	1	1
142398	1710	orf 62	[ORF 62]	0.0	2	1	1	1
142399	1710	long terminal repeat proviruse	[long terminal repeat proviruses]	0.0	4	1	1	1
142400	1710	level of galectin-3	[levels of galectin-3]	0.0	3	1	1	1
142401	1710	expression of the cytokine	[expression of the cytokines]	0.0	4	1	1	1
142402	1710	dna-binding subunit of mass (50k)	[DNA-binding subunits of mass (50K)]	0.0	5	1	1	1
142403	1710	contain hhv-6(gs) fragment	[containing HHV-6(GS) fragments]	0.0	3	1	1	1
142404	1710	osteoclast with nuclearity,	[osteoclasts with nuclearity,]	0.0	3	1	1	1
142405	1710	active form of nf-kb	[active form of NF-kB]	0.0	4	1	1	1
142406	1710	human monocyte nuclear extract	[human monocyte nuclear extracts]	0.0	4	1	1	1
142407	1710	protein act	[proteins acting]	0.0	2	1	1	1
142408	1710	nuclear factor-kappa B/Rel activity	[nuclear factor-kappa B/Rel activity]	0.0	4	1	1	1
142409	1710	anti-onco-genic transcription factor	[anti-onco-genic transcription factors]	0.0	3	1	1	1
142410	1710	continuous expression	[continuous expression]	0.0	2	1	1	1
142411	1710	indicate essential	[indicating essential]	0.0	2	1	1	1
142412	1710	magnetic resonance 3d-nmr	[magnetic resonance 3D-NMR]	0.0	3	1	1	1
142413	1710	significant level in cell	[significant levels in cells]	0.0	4	1	1	1
142414	1710	average angle of 90 degree	[average angle of 90 degrees]	0.0	5	1	1	1
142415	1710	Epstein-Barr virus ebv with carcinoma	[Epstein-Barr virus EBV with carcinoma]	0.0	5	1	1	1
142416	1710	repeat motif	[repeat motifs]	0.0	2	1	1	1
142417	1710	basal cell carcinoma bcc use immunohistochemistry	[basal cell carcinomas BCCs using immunohistochemistry]	0.0	6	1	1	1
142418	1710	Jun kinase JNK a mediator	[Jun kinase JNK a mediator]	0.0	5	1	1	1
142419	1710	marker of leukemia apl	[markers of leukemias APLs]	0.0	4	1	1	1
142420	1710	CCGAAACTGAAAAGG E6	[CCGAAACTGAAAAGG E6]	0.0	2	1	1	1
142421	1710	contain the negative respond element	[containing the negative responding elements]	0.0	5	1	1	1
142422	1710	generation of condition	[generation of conditions]	0.0	3	1	1	1
142423	1710	reactive nitrogen release	[reactive nitrogen release]	0.0	3	1	1	1
142424	1710	p50 homodimer,	[p50 homodimer,]	0.0	2	1	1	1
142425	1710	group A-F	[groups A-F]	0.0	2	1	1	1
142426	1710	correlation between her-2/neu expression	[correlation between HER-2/neu expression]	0.0	4	1	1	1
142427	1710	breast cancer reactive cytotoxicity facilitate antibody	[breast cancer reactive cytotoxicity facilitating antibody]	0.0	6	1	1	1
142428	1710	rapid effect of aldosterone	[rapid effects of aldosterone]	0.0	4	1	1	1
142429	1710	leukemic cell whatever stage	[leukemic cells whatever stage]	0.0	4	1	1	1
142430	1710	t-helper (th) cell	[T-helper (Th) cells]	0.0	3	1	1	1
142431	1710	cord lymphocyte proliferation	[cord lymphocyte proliferation]	0.0	3	1	1	1
142432	1710	Specific bright foci	[Specific bright foci]	0.0	3	1	1	1
142433	1710	implications, in relation	[implications, in relation]	0.0	3	1	1	1
142434	1710	high level of SRF binding	[high level of SRF binding]	0.0	5	1	1	1
142435	1710	good option	[better options]	0.0	2	1	1	1
142436	1710	new era	[new era]	0.0	2	1	1	1
142437	1710	two independent form of collaboration	[two independent forms of collaboration]	0.0	5	1	1	1
142438	1710	rBPI21 a fragment of bactericidal/permeability-increasing protein	[rBPI21 a fragment of bactericidal/permeability-increasing protein]	0.0	6	1	1	1
142439	1710	cell cycle activity	[cell cycle activity]	0.0	3	1	1	1
142440	1710	immediate-early cytokine gene	[immediate-early cytokine genes]	0.0	3	1	1	1
142441	1710	patient with apl	[patient with APL]	0.0	3	1	1	1
142442	1710	tool in the delineation	[tools in the delineation]	0.0	4	1	1	1
142443	1710	insensitivity of endothelium to the effect	[insensitivity of endothelium to the effects]	0.0	6	1	1	1
142444	1710	feedback regulation of synthesis	[feedback regulation of synthesis]	0.0	4	1	1	1
142445	1710	Granulocyte-macrophage factor	[Granulocyte-macrophage factor]	0.0	2	1	1	1
142446	1710	unidentified position	[unidentified position]	0.0	2	1	1	1
142447	1710	major site of ebv replication	[major site of EBV replication]	0.0	5	1	1	1
142448	1710	furthermore, CD28 elevation of c-jun mrna	[Furthermore, CD28 elevation of c-jun mRNA]	0.0	6	1	1	1
142449	1710	lymphoid nuclear extract	[lymphoid nuclear extracts]	0.0	3	1	1	1
142450	1710	affect change in ca2+	[affecting changes in Ca2+]	0.0	4	1	1	1
142451	1710	plasmalemmal localization of tf antigen	[plasmalemmal localization of TF antigen]	0.0	5	1	1	1
142452	1710	Caspase-3 activation	[Caspase-3 activation]	0.0	2	1	1	1
142453	1710	mouse peritoneal	[mouse peritoneal]	0.0	2	1	1	1
142454	1710	two hil-5 -responsive cell line	[two hIL-5 -responsive cell lines]	0.0	5	1	1	1
142455	1710	cd8+cd18bright T cell	[CD8+CD18bright T cells]	0.0	3	1	1	1
142456	1710	basal serum cortisol	[basal serum cortisol]	0.0	3	1	1	1
142457	1710	postvaccine response use monocyte	[postvaccine responses using monocytes]	0.0	4	1	1	1
142458	1710	additional effect	[additional effect]	0.0	2	1	1	1
142459	1710	rap1 protein expression	[Rap1 protein expression]	0.0	3	1	1	1
142460	1710	level of exogenous bcl-2	[levels of exogenous Bcl-2]	0.0	4	1	1	1
142461	1710	importance of this support variable	[importance of this support variable]	0.0	5	1	1	1
142462	1710	follow amplification	[following amplification]	0.0	2	1	1	1
142463	1710	time-dependent expression	[time-dependent expression]	0.0	2	1	1	1
142464	1710	1 receptor in mononuclear leukocyte	[1 receptors in mononuclear leukocytes]	0.0	5	1	1	1
142465	1710	nuclear egr1 protein	[nuclear EGR1 protein]	0.0	3	1	1	1
142466	1710	two pathway of signal transduction	[two pathways of signal transduction]	0.0	5	1	1	1
142467	1710	deletion -70 to -65	[Deletion -70 to -65]	0.0	4	1	1	1
142468	1710	IL-2 promoter nuclear factor	[IL-2 promoter nuclear factor]	0.0	4	1	1	1
142469	1710	oligomerization of a inert monomer	[oligomerization of an inert monomer]	0.0	5	1	1	1
142470	1710	govern the control	[governing the control]	0.0	3	1	1	1
142471	1710	myeloid developmental stage	[myeloid developmental stages]	0.0	3	1	1	1
142472	1710	urinary protein excretion	[urinary protein excretion]	0.0	3	1	1	1
142473	1710	dexamethasone binding to human receptor	[dexamethasone binding to human receptor]	0.0	5	1	1	1
142474	1710	63-kda isoform	[63-kDa isoform]	0.0	2	1	1	1
142475	1710	level of protein capable	[level of proteins capable]	0.0	4	1	1	1
142476	1710	most distal site	[most distal site]	0.0	3	1	1	1
142477	1710	matrix gene	[matrix genes]	0.0	2	1	1	1
142478	1710	pattern of chromosome abnormality	[patterns of chromosome abnormalities]	0.0	4	1	1	1
142479	1710	addition to nucleoplasmic localization	[addition to nucleoplasmic localization]	0.0	4	1	1	1
142480	1710	form DNA	[form DNA]	0.0	2	1	1	1
142481	1710	decreased, z-lll-h -insensitive transcriptional activity	[decreased, Z-LLL-H -insensitive transcriptional activity]	0.0	5	1	1	1
142482	1710	component of atheroma	[component of atheroma]	0.0	3	1	1	1
142483	1710	result in response	[resulting in response]	0.0	3	1	1	1
142484	1710	272 97 receptor /cell for type	[272 97 receptors /cell for type]	0.0	6	1	1	1
142485	1710	critical domain in -9-mediate cell proliferation	[Critical domains in -9-mediated cell proliferation]	0.0	6	1	1	1
142486	1710	this,	[this,]	0.0	1	1	1	1
142487	1710	DHEA modulation	[DHEA modulation]	0.0	2	1	1	1
142488	1710	expression of matrix metalloproteinase 9 factor	[expression of matrix metalloproteinase 9 factor]	0.0	6	1	1	1
142489	1710	effect on one event	[effect on one event]	0.0	4	1	1	1
142490	1710	four near-perfect repeat	[four near-perfect repeats]	0.0	3	1	1	1
142491	1710	activation by T cell stimulus	[activation by T cell stimuli]	0.0	5	1	1	1
142492	1710	two enhancer motif	[Two enhancer motifs]	0.0	3	1	1	1
142493	1710	many important protein	[many important proteins]	0.0	3	1	1	1
142494	1710	nuclear stat6 activity	[nuclear STAT6 activity]	0.0	3	1	1	1
142495	1710	deterioration human immunodeficiency virus type	[deterioration human immunodeficiency virus type]	0.0	5	1	1	1
142496	1710	NK clearance of cell	[NK clearance of cells]	0.0	4	1	1	1
142497	1710	interaction between multiple positive element	[interactions between multiple positive elements]	0.0	5	1	1	1
142498	1710	inducible regulator of numerous gene	[inducible regulators of numerous genes]	0.0	5	1	1	1
142499	1710	that: induction of c-jun	[that: induction of c-jun]	0.0	4	1	1	1
142500	1710	kinase JAK3	[kinase JAK3]	0.0	2	1	1	1
142501	1710	inhibition on bone protein-	[inhibition on bone protein-]	0.0	4	1	1	1
142502	1710	fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
142503	1710	pathophysiology of PIH	[pathophysiology of PIH]	0.0	3	1	1	1
142504	1710	correlation between high lymphocytic infiltration	[correlation between high lymphocytic infiltration]	0.0	5	1	1	1
142505	1710	significantly (p leukocyte adhesion	[significantly (P leukocyte adhesion]	0.0	4	1	1	1
142506	1710	same protein suggest Oct-1	[same proteins suggesting Oct-1]	0.0	4	1	1	1
142507	1710	multiple mutation a proto-oncogene encoding	[multiple mutations a proto-oncogene encoding]	0.0	5	1	1	1
142508	1710	variability to the agent	[variability to the agents]	0.0	4	1	1	1
142509	1710	only specific b heteromer	[only specific B heteromers]	0.0	4	1	1	1
142510	1710	helix-loop-helix transcription factor	[helix-loop-helix transcription factors]	0.0	3	1	1	1
142511	1710	utility of agent	[utility of agents]	0.0	3	1	1	1
142512	1710	cell count mil.	[cell count mil.]	0.0	3	1	1	1
142513	1710	low level fluoride-resistant- alpha-naphthyl-acetate-esterase naf-r-nse	[low levels fluoride-resistant- alpha-naphthyl-acetate-esterase NaF-R-NSE]	0.0	5	1	1	1
142514	1710	encompass nucleotide -135	[encompassing nucleotides -135]	0.0	3	1	1	1
142515	1710	suppression in normal T cell	[Suppression in normal T cells]	0.0	5	1	1	1
142516	1710	factor irf-1 interferon factor	[factor IRF-1 interferon factor]	0.0	4	1	1	1
142517	1710	case of immature t-cell proliferation	[cases of immature T-cell proliferations]	0.0	5	1	1	1
142518	1710	group c adenoviruse	[group C adenoviruses]	0.0	3	1	1	1
142519	1710	critical cytokine for terminal repeat transactivation	[critical cytokines for terminal repeat transactivation]	0.0	6	1	1	1
142520	1710	mcm5 promoter	[MCM5 promoters]	0.0	2	1	1	1
142521	1710	upstream of activation	[upstream of activation]	0.0	3	1	1	1
142522	1710	tumor-bearing mouse	[tumor-bearing mice]	0.0	2	1	1	1
142523	1710	modulate the fusion/entry process	[modulating the fusion/entry process]	0.0	4	1	1	1
142524	1710	vernal keratoconjunctivitis a allergic disease	[vernal keratoconjunctivitis an allergic disease.]	0.0	5	1	1	1
142525	1710	acid transactivation	[acid transactivation]	0.0	2	1	1	1
142526	1710	cells, DNA	[cells, DNA]	0.0	2	1	1	1
142527	1710	E1A induction of susceptibility	[E1A induction of susceptibility]	0.0	4	1	1	1
142528	1710	activation of factor c-fos/c-jun ap-1	[activation of factor c-Fos/c-Jun AP-1]	0.0	5	1	1	1
142529	1710	dn construct	[DN constructs]	0.0	2	1	1	1
142530	1710	regulation role of interaction	[Regulation role of interactions]	0.0	4	1	1	1
142531	1710	mechanism control reactvation	[mechanisms controlling reactvation]	0.0	3	1	1	1
142532	1710	mnp-1 expression,	[MNP-1 expression,]	0.0	2	1	1	1
142533	1710	several novel zinc finger gene	[several novel zinc finger genes]	0.0	5	1	1	1
142534	1710	importance of comedo variants.	[importance of comedo variants.]	0.0	4	1	1	1
142535	1710	level of the activity	[levels of the activity]	0.0	4	1	1	1
142536	1710	2 bp deletion	[2 bp deletion]	0.0	3	1	1	1
142537	1710	factor bind specifically	[factors binding specifically]	0.0	3	1	1	1
142538	1710	effect of ap-1 protein	[effects of AP-1 proteins]	0.0	4	1	1	1
142539	1710	virus envelope	[virus envelope]	0.0	2	1	1	1
142540	1710	pterin carbinolamine dehydratase/dimerization cofactor	[pterin carbinolamine dehydratase/dimerization cofactor]	0.0	4	1	1	1
142541	1710	low level fluoride-resistant- alpha-naphthyl-acetate-esterase	[low levels fluoride-resistant- alpha-naphthyl-acetate-esterase]	0.0	4	1	1	1
142542	1710	inhibition by a soluble peptide inhibitor	[inhibition by a soluble peptide inhibitor]	0.0	6	1	1	1
142543	1710	(also in human cell	[(also in human cells]	0.0	4	1	1	1
142544	1710	one possible explanation	[one possible explanation]	0.0	3	1	1	1
142545	1710	presence of oligonucleotide	[presence of oligonucleotides]	0.0	3	1	1	1
142546	1710	phenotypic marker	[phenotypic marker]	0.0	2	2	2	1
142547	1710	TGF-beta -mediated modulation	[TGF-beta -mediated modulation]	0.0	3	1	1	1
142548	1710	similar, affinity binding	[similar, affinity binding]	0.0	3	1	1	1
142549	1710	active stage	[active stage]	0.0	2	1	1	1
142550	1710	unoccupied receptor site	[unoccupied receptor sites]	0.0	3	1	1	1
142551	1710	distal purine box -291	[distal purine box -291]	0.0	4	1	1	1
142552	1710	long period of clinical latency	[long period of clinical latency]	0.0	5	1	1	1
142553	1710	trigger role,	[triggering role,]	0.0	2	1	1	1
142554	1710	cytokine gene mapped.	[cytokine gene mapped.]	0.0	3	1	1	1
142555	1710	complex (mhc) class gene	[complex (MHC) class genes]	0.0	4	4	4	1
142556	1710	two analogue	[two analogues]	0.0	2	1	1	1
142557	1710	HEK 293 cell	[HEK 293 cells]	0.0	3	1	1	1
142558	1710	datum from human fibroblast	[data from human fibroblasts]	0.0	4	1	1	1
142559	1710	semi-purified ap1 protein	[semi-purified AP1 proteins]	0.0	3	1	1	1
142560	1710	finally, immunoblot analysis	[Finally, immunoblot analysis]	0.0	3	1	1	1
142561	1710	new 4,19-substituted steroid	[new 4,19-substituted steroids]	0.0	3	1	1	1
142562	1710	evidence likely identical proteins,	[evidence likely identical proteins,]	0.0	4	1	1	1
142563	1710	Ab-associated change	[Ab-associated changes]	0.0	2	1	1	1
142564	1710	region of human sequence	[regions of human sequences]	0.0	4	1	1	1
142565	1710	effect of dexamethasone on adhesiveness	[effect of dexamethasone on adhesiveness]	0.0	5	1	1	1
142566	1710	(v) a case	[(v) a case]	0.0	3	1	1	1
142567	1710	ability of b subunit	[abilities of B subunits]	0.0	4	1	1	1
142568	1710	such condition of immune glomerulopathy	[such conditions of immune glomerulopathy]	0.0	5	1	1	1
142569	1710	definition of region with cofactor	[definition of regions with cofactors]	0.0	5	1	1	1
142570	1710	presence of IFN activity equivalent	[presence of IFN activity equivalent]	0.0	5	1	1	1
142571	1710	glutathione s-transferase	[glutathione S-transferase]	0.0	2	1	1	1
142572	1710	Chr centromere as probes.	[Chr centromere as probes.]	0.0	4	1	1	1
142573	1710	basophil cell distribution	[basophil cell distribution]	0.0	3	1	1	1
142574	1710	treatment with mab j393	[Treatment with mAb J393]	0.0	4	1	1	1
142575	1710	induce the degradation of cytoplasmic inhibitor	[inducing the degradation of cytoplasmic inhibitors]	0.0	6	1	1	1
142576	1710	intact cytoplasmic segment	[intact cytoplasmic segment]	0.0	3	1	1	1
142577	1710	link behavior	[linking behavior]	0.0	2	1	1	1
142578	1710	CD2 antibody	[CD2 antibodies]	0.0	2	1	1	1
142579	1710	range of cytokine attract chemokine	[range of cytokines attracting chemokines]	0.0	5	1	1	1
142580	1710	direct evidence for the time	[direct evidence for the time]	0.0	5	1	1	1
142581	1710	b-cell neoplasia	[B-cell neoplasias]	0.0	2	1	1	1
142582	1710	component of the picture	[component of the picture]	0.0	4	1	1	1
142583	1710	mcm5 promoter with mutation	[MCM5 promoters with mutation]	0.0	4	1	1	1
142584	1710	quantification of glucocorticoid expression	[quantification of glucocorticoid expression]	0.0	4	1	1	1
142585	1710	two DNA motif	[two DNA motifs]	0.0	3	1	1	1
142586	1710	regulator of lymphocyte differentiation	[regulator of lymphocyte differentiation]	0.0	4	1	1	1
142587	1710	activity by GM-CSF	[activity by GM-CSF]	0.0	3	1	1	1
142588	1710	half-maximal effect at nm	[half-maximal effect at nM]	0.0	4	1	1	1
142589	1710	glucocorticoid-sensitive t-cell line	[glucocorticoid-sensitive T-cell line]	0.0	3	1	1	1
142590	1710	eosinophilia in a patient present	[eosinophilia in a patient presenting]	0.0	5	1	1	1
142591	1710	recombinant fragment acid 1-180)	[recombinant fragment acids 1-180)]	0.0	4	1	1	1
142592	1710	oncogene with cysteine LIM domain	[oncogenes with cysteine LIM domains]	0.0	5	1	1	1
142593	1710	Rho on AP-1	[Rho on AP-1]	0.0	3	1	1	1
142594	1710	level of mineralocorticoid	[level of mineralocorticoids]	0.0	3	2	2	1
142595	1710	ad group group A Ad12	[Ad groups group A Ad12]	0.0	5	1	1	1
142596	1710	control from Ireland,	[controls from Ireland,]	0.0	3	1	1	1
142597	1710	alpha/beta interferon gene	[alpha/beta interferon gene]	0.0	3	1	1	1
142598	1710	ng of il-12/10(6) cell	[ng of IL-12/10(6) cells]	0.0	4	1	1	1
142599	1710	physical separation	[physical separation]	0.0	2	1	1	1
142600	1710	plasmalemmal localization	[plasmalemmal localization]	0.0	2	1	1	1
142601	1710	bhlh homo hetero dimer formation m.hall,	[bHLH homo hetero dimer formation M.Hall,]	0.0	6	1	1	1
142602	1710	rat astrocyte	[rat astrocytes]	0.0	2	1	1	1
142603	1710	phagocytic stimulus in neutrophils.	[phagocytic stimuli in neutrophils.]	0.0	4	1	1	1
142604	1710	follow okadaic acid exposure	[following okadaic acid exposure]	0.0	4	1	1	1
142605	1710	vitamin ricket type ii	[vitamin rickets type II]	0.0	4	1	1	1
142606	1710	Bcl-6 expression heterogeneity of intrafollicular t-cell	[Bcl-6 expression heterogeneity of intrafollicular T-cells]	0.0	6	1	1	1
142607	1710	production of more mature population	[production of more mature populations]	0.0	5	1	1	1
142608	1710	C/EBPbeta expression vector	[C/EBPbeta expression vectors]	0.0	3	1	1	1
142609	1710	distinct regulatory pathway	[distinct regulatory pathways]	0.0	3	1	1	1
142610	1710	blood lymphocyte in multiple sclerosis	[blood lymphocytes in multiple sclerosis]	0.0	5	1	1	1
142611	1710	promotion of neutrophil transendothelial migration	[promotion of neutrophil transendothelial migration]	0.0	5	1	1	1
142612	1710	abnormality highlight novel loci	[abnormalities highlighting novel loci]	0.0	4	1	1	1
142613	1710	sites/cell with the low gcr	[sites/cell with the lowest GCR]	0.0	5	1	1	1
142614	1710	glucocorticoid prednisolone	[glucocorticoid prednisolone]	0.0	2	1	1	1
142615	1710	transcription element	[transcription element]	0.0	2	1	1	1
142616	1710	syncytia-forming activity of cell	[syncytia-forming activity of cells]	0.0	4	1	1	1
142617	1710	part, to a delay	[part, to a delay]	0.0	4	1	1	1
142618	1710	L gene promoter	[L gene promoter]	0.0	3	1	1	1
142619	1710	camp-response element	[cAMP-response element]	0.0	2	2	2	1
142620	1710	hla class antigen processing	[HLA class antigen processing]	0.0	4	1	1	1
142621	1710	limbic-hippocampal glucocorticoid type receptor	[limbic-hippocampal glucocorticoid type receptor]	0.0	4	1	1	1
142622	1710	tax1 with NF-YB	[Tax1 with NF-YB]	0.0	3	1	1	1
142623	1710	recombinant soluble dimeric tnf receptor	[recombinant soluble dimeric TNF receptor]	0.0	5	1	1	1
142624	1710	particular, class of helix-loop-helix protein	[particular, class of helix-loop-helix proteins]	0.0	5	1	1	1
142625	1710	various pathway	[various pathways]	0.0	2	1	1	1
142626	1710	tetraproline repeat	[tetraproline repeats]	0.0	2	1	1	1
142627	1710	nf-m	[NF-M]	0.0	1	1	1	1
142628	1710	one patient with spastic paraparesis	[one patient with spastic paraparesis]	0.0	5	1	1	1
142629	1710	cytosolic ca2+	[cytosolic Ca2+]	0.0	2	1	1	1
142630	1710	require the addition for the initiation	[requiring the addition for the initiation]	0.0	6	1	1	1
142631	1710	new model	[new model]	0.0	2	1	1	1
142632	1710	monocyte activation in patient	[monocyte activation in patients]	0.0	4	1	1	1
142633	1710	ESb-L	[ESb-L]	0.0	1	1	1	1
142634	1710	basal phosphorylation of Jak3 usually, STAT3	[basal phosphorylation of Jak3 usually, STAT3]	0.0	6	1	1	1
142635	1710	chicken erythrocyte factor	[chicken erythrocyte factor]	0.0	3	1	1	1
142636	1710	1 alpha,25-dihydroxycholecalciferol dhcc	[1 alpha,25-dihydroxycholecalciferol DHCC]	0.0	3	1	1	1
142637	1710	EB1 -responsive b-cell-specific element	[EB1 -responsive B-cell-specific element]	0.0	4	1	1	1
142638	1710	activity between the two promoter	[activity between the two promoters]	0.0	5	1	1	1
142639	1710	effect on the avidity	[effects on the avidity]	0.0	4	1	1	1
142640	1710	free radical gene transcription	[free radical gene transcription]	0.0	4	1	1	1
142641	1710	course chi2 test).	[course chi2 test).]	0.0	3	1	1	1
142642	1710	I kappa b-alpha	[I kappa B-alpha]	0.0	3	1	1	1
142643	1710	locus in erythroid cell	[locus in erythroid cells]	0.0	4	1	1	1
142644	1710	genes, in particular	[genes, in particular]	0.0	3	1	1	1
142645	1710	already activated, addition	[already activated, addition]	0.0	3	1	1	1
142646	1710	25 h	[25 h]	0.0	2	1	1	1
142647	1710	at1 receptor antagonist	[AT1 receptor antagonist]	0.0	3	1	1	1
142648	1710	positioning NFAT for immediate dephosphorylation	[positioning NFAT for immediate dephosphorylation]	0.0	5	1	1	1
142649	1710	cell contamination	[cell contamination]	0.0	2	2	2	1
142650	1710	base exchange by single-stranded polymorphism	[base exchanges by single-stranded polymorphism]	0.0	5	1	1	1
142651	1710	response to corticosteroid treatment	[response to corticosteroid treatment]	0.0	4	1	1	1
142652	1710	enhanced, follow 2 h	[enhanced, following 2 h]	0.0	4	1	1	1
142653	1710	(p great than p	[(P greater than P]	0.0	4	1	1	1
142654	1710	potent activity at concentration	[potent activity at concentrations]	0.0	4	1	1	1
142655	1710	human nrf-1/alpha-pal factor	[human NRF-1/alpha-Pal factor]	0.0	3	1	1	1
142656	1710	two synthetic RAR ligand	[two synthetic RAR ligands]	0.0	4	1	1	1
142657	1710	stimulation, mrna T	[stimulation, mRNA T]	0.0	3	1	1	1
142658	1710	gcr gcrbeta	[GCR GCRbeta]	0.0	2	1	1	1
142659	1710	IL-2 proliferative growth in T cell	[IL-2 proliferative growth in T cells]	0.0	6	1	1	1
142660	1710	extensive granulopoiesis postnatally, die	[extensive granulopoiesis postnatally, dying]	0.0	4	1	1	1
142661	1710	common mechanisms,	[common mechanisms,]	0.0	2	1	1	1
142662	1710	efficacy of the gold compound	[efficacy of the gold compound]	0.0	5	1	1	1
142663	1710	homogeneous manner	[homogeneous manner]	0.0	2	1	1	1
142664	1710	leukocyte adhesion under flow conditions.	[leukocyte adhesion under flow conditions.]	0.0	5	1	1	1
142665	1710	response of lymphocyte to il-2	[responses of lymphocytes to IL-2]	0.0	5	1	1	1
142666	1710	distinct mitogen-inducible dna-binding complex	[distinct mitogen-inducible DNA-binding complexes]	0.0	4	1	1	1
142667	1710	HTLV-1 transcription	[HTLV-1 transcription]	0.0	2	1	1	1
142668	1710	pathway for steroid action	[pathway for steroid action]	0.0	4	2	2	1
142669	1710	activation of interleukin 9 gene	[activation of interleukin 9 gene]	0.0	5	1	1	1
142670	1710	cytokine factor receptor	[cytokine factor receptors]	0.0	3	1	1	1
142671	1710	Differential induction protein 10 differentiation	[Differential induction protein 10 differentiation]	0.0	5	1	1	1
142672	1710	particle by transmission electron microscopy	[particles by transmission electron microscopy]	0.0	5	1	1	1
142673	1710	-beta-catenin	[-beta-catenin]	0.0	1	1	1	1
142674	1710	gcr bind	[GCR binding]	0.0	2	1	1	1
142675	1710	activation of a protein	[Activation of a protein]	0.0	4	1	1	1
142676	1710	key regulator of response	[key regulator of responses]	0.0	4	1	1	1
142677	1710	stimulation of interleukin-8 production	[Stimulation of interleukin-8 production]	0.0	4	1	1	1
142678	1710	signal transduction abnormality	[Signal transduction abnormalities]	0.0	3	1	1	1
142679	1710	increase from asthmatic patient	[increase from asthmatic patients]	0.0	4	1	1	1
142680	1710	cell microg/ml)/mn2+ (50 microM) for h	[Cells microg/ml)/Mn2+ (50 microM) for h]	0.0	6	1	1	1
142681	1710	binding to a factor	[binding to an factor]	0.0	4	1	1	1
142682	1710	Grb2-associated tyrosine -phosphorylated protein	[Grb2-associated tyrosine -phosphorylated protein]	0.0	4	1	1	1
142683	1710	pentoxifylline NF-kappa b inhibitor	[pentoxifylline NF-kappa B inhibitor]	0.0	4	1	1	1
142684	1710	protein hmg-i	[protein HMG-I]	0.0	2	1	1	1
142685	1710	healthy pregnant woman second	[healthy pregnant women second]	0.0	4	1	1	1
142686	1710	dominant-negative mutant	[dominant-negative mutant]	0.0	2	1	1	1
142687	1710	overexpression of grf40	[Overexpression of Grf40]	0.0	3	1	1	1
142688	1710	activity of this agent	[activities of these agents]	0.0	4	1	1	1
142689	1710	downregulation implication for dysregulation of c-myc	[downregulation implications for dysregulation of c-myc]	0.0	6	1	1	1
142690	1710	tnf-alpha inhibition of cell proliferation	[TNF-alpha inhibition of cell proliferation]	0.0	5	1	1	1
142691	1710	U/ml, h)	[U/ml, h)]	0.0	2	1	1	1
142692	1710	ca2+ flux	[Ca2+ flux]	0.0	2	1	1	1
142693	1710	consider a common element	[Considering a common element]	0.0	4	1	1	1
142694	1710	cellular factor-KB NF-kappa b result	[cellular factor-KB NF-kappa B resulting]	0.0	5	1	1	1
142695	1710	concentration of RA to 10 &mgr;m)	[concentrations of RA to 10 &mgr;M)]	0.0	6	1	1	1
142696	1710	differentiation arrest of cell	[differentiation arrest of cells]	0.0	4	1	1	1
142697	1710	association latency	[Association latency]	0.0	2	1	1	1
142698	1710	Differential induction follow cd19 cross-linking	[Differential induction following CD19 cross-linking]	0.0	5	1	1	1
142699	1710	euthyroid subjects,	[euthyroid subjects,]	0.0	2	1	1	1
142700	1710	overlapping activity on T cell	[overlapping activities on T cells]	0.0	5	1	1	1
142701	1710	have a biopsy as surgical treatment	[having an biopsy as surgical treatment]	0.0	6	1	1	1
142702	1710	analysis nuclear factor of T cell	[analysis nuclear factor of T cells]	0.0	6	1	1	1
142703	1710	survival il-3 pro-B cell	[survival IL-3 pro-B cells]	0.0	4	1	1	1
142704	1710	mutation affect the guanine residue	[Mutations affecting the guanine residues]	0.0	5	1	1	1
142705	1710	tbp -contain complex related	[TBP -containing complex related]	0.0	4	1	1	1
142706	1710	assembly c5b-7 on target cell	[Assembly C5b-7 on target cells]	0.0	5	1	1	1
142707	1710	lps nuclear factor-kappaB translocation	[LPS nuclear factor-kappaB translocation]	0.0	4	1	1	1
142708	1710	cell with specific receptor	[cells with specific receptors]	0.0	4	1	1	1
142709	1710	immunosuppressive factor	[immunosuppressive factor]	0.0	2	1	1	1
142710	1710	acidic domain with sh2 motif	[acidic domains with SH2 motifs]	0.0	5	1	1	1
142711	1710	potent activator of viral gene	[potent activator of viral genes]	0.0	5	1	1	1
142712	1710	subtle gene movement	[subtle gene movements]	0.0	3	1	1	1
142713	1710	Europe,	[Europe,]	0.0	1	1	1	1
142714	1710	control in development	[control in development]	0.0	3	1	1	1
142715	1710	two complex in human eosinophil	[two complexes in human eosinophils]	0.0	5	1	1	1
142716	1710	lectin switch	[lectin switch]	0.0	2	1	1	1
142717	1710	infection of hl-60 promyelocyte	[infection of HL-60 promyelocytes]	0.0	4	1	1	1
142718	1710	level kappa b alpha /mad-3 mrna	[levels kappa B alpha /MAD-3 mRNA]	0.0	6	1	1	1
142719	1710	macrophage in activation	[macrophages in activation]	0.0	3	1	1	1
142720	1710	potential nf-kappab element	[potential NF-kappaB elements]	0.0	3	1	1	1
142721	1710	activity gene regulatory element	[activity gene regulatory elements]	0.0	4	1	1	1
142722	1710	ala asp amino acid substitution	[Ala Asp amino acid substitution]	0.0	5	1	1	1
142723	1710	transluminal angioplasty PTCA	[transluminal angioplasty PTCA]	0.0	3	1	1	1
142724	1710	effect of redox change	[effect of redox changes]	0.0	4	1	1	1
142725	1710	histogenesis.	[histogenesis.]	0.0	1	1	1	1
142726	1710	assay with peptide	[assay with peptides]	0.0	3	1	1	1
142727	1710	block fragmentation as inhibition	[blocking fragmentation as inhibition]	0.0	4	1	1	1
142728	1710	CK-1 /cd28re	[CK-1 /CD28RE]	0.0	2	1	1	1
142729	1710	two regulatory factor	[two regulatory factors]	0.0	3	1	1	1
142730	1710	pleiotropic regulator	[pleiotropic regulator]	0.0	2	3	3	1
142731	1710	regulatory region PRRI	[regulatory regions PRRI]	0.0	3	1	1	1
142732	1710	b fibroblast	[B fibroblasts]	0.0	2	1	1	1
142733	1710	Suppressive effect of agent	[Suppressive effects of agents]	0.0	4	1	1	1
142734	1710	rela c-rel	[RelA c-Rel]	0.0	2	1	1	1
142735	1710	protein hmg-1	[protein HMG-1]	0.0	2	1	1	1
142736	1710	absence of genomic alteration	[absence of genomic alteration]	0.0	4	1	1	1
142737	1710	Biochemical analysis by blotting	[Biochemical analysis by blotting]	0.0	4	1	1	1
142738	1710	only extremely low level of expression	[only extremely low levels of expression]	0.0	6	1	1	1
142739	1710	hydrophobicity	[hydrophobicity]	0.0	1	1	1	1
142740	1710	link the expression	[linking the expression]	0.0	3	1	1	1
142741	1710	protein critical	[proteins critical]	0.0	2	1	1	1
142742	1710	cytoplasm with fine granularity	[cytoplasm with fine granularity]	0.0	4	1	1	1
142743	1710	T cell prolymphocytic leukaemia	[T cell prolymphocytic leukaemia]	0.0	4	1	1	1
142744	1710	exception, and/or	[exception, and/or]	0.0	2	1	1	1
142745	1710	rrna for Fra-1	[mRNAs for Fra-1]	0.0	3	1	1	1
142746	1710	Glucocorticoid receptor in lupus erythematosus	[Glucocorticoid receptors in lupus erythematosus]	0.0	5	1	1	1
142747	1710	enhancer/ promoter interaction	[enhancer/ promoter interaction]	0.0	3	1	1	1
142748	1710	potential regulation of the receptor	[potential regulation of the receptor]	0.0	5	1	1	1
142749	1710	relate the nuclear nf-at complex	[relating the nuclear NF-AT complexes]	0.0	5	1	1	1
142750	1710	inflammatory mechanism	[inflammatory mechanisms]	0.0	2	2	2	1
142751	1710	short pulse	[short pulse]	0.0	2	1	1	1
142752	1710	study of the enhancer element	[studies of the enhancer elements]	0.0	5	1	1	1
142753	1710	mrna in cell pbmc	[mRNA in cells PBMC]	0.0	4	1	1	1
142754	1710	105k precursor p105	[105K precursor p105]	0.0	3	1	1	1
142755	1710	10(2) normal cell	[10(2) normal cells]	0.0	3	1	1	1
142756	1710	malignant astrocytomas	[malignant astrocytomas]	0.0	2	1	1	1
142757	1710	tissue structure	[tissue structure]	0.0	2	1	1	1
142758	1710	b activity, p65 complex	[B activity, p65 complexes]	0.0	4	1	1	1
142759	1710	possible relationship with the change	[possible relationship with the changes]	0.0	5	2	2	1
142760	1710	hiv-1 glycoprotein	[HIV-1 glycoprotein]	0.0	2	1	1	1
142761	1710	cd4+ cell capable	[CD4+ cells capable]	0.0	3	1	1	1
142762	1710	basal [3H]thymidine incorporation	[Basal [3H]thymidine incorporation]	0.0	3	1	1	1
142763	1710	principle a regulator	[principle a regulator]	0.0	3	1	1	1
142764	1710	growth-promoting effect	[growth-promoting effects]	0.0	2	1	1	1
142765	1710	secret	[secreting]	0.0	1	1	1	1
142766	1710	c/ebpbeta activity	[C/EBPbeta activity]	0.0	2	1	1	1
142767	1710	regulator nuclear factor-kappaB nf-kappab	[regulator nuclear factor-kappaB NF-kappaB]	0.0	4	1	1	1
142768	1710	suppress system	[suppressing system]	0.0	2	1	1	1
142769	1710	3,5,3'-triiodothyronine receptor circulate human lymphocyte	[3,5,3'-triiodothyronine receptors circulating human lymphocytes]	0.0	5	1	1	1
142770	1710	synthetic oligonucleotide corresponding to sequence	[synthetic oligonucleotides corresponding to sequences]	0.0	5	1	1	1
142771	1710	epse)-binding	[(PSE)-binding]	0.0	1	1	1	1
142772	1710	(mean of assays),	[(mean of assays),]	0.0	3	1	1	1
142773	1710	mutagenesis study	[mutagenesis studies]	0.0	2	1	1	1
142774	1710	up-regulation of nf-kappab level	[up-regulation of NF-kappaB levels]	0.0	4	1	1	1
142775	1710	upstream positive element	[upstream positive elements]	0.0	3	1	1	1
142776	1710	critical factor modulate the transcription	[critical factors modulating the transcription]	0.0	5	1	1	1
142777	1710	severe immunodeficiency disease	[severe immunodeficiency disease]	0.0	3	1	1	1
142778	1710	examination of the factor interact	[Examination of the factors interacting]	0.0	5	1	1	1
142779	1710	sjogrens' syndrome	[Sjogrens' syndrome]	0.0	2	2	2	1
142780	1710	(25%) autoimmune disease subject	[(25%) autoimmune disease subjects]	0.0	4	1	1	1
142781	1710	Concomitant stimulation	[Concomitant stimulation]	0.0	2	1	1	1
142782	1710	active form of Raf-1	[active forms of Raf-1]	0.0	4	1	1	1
142783	1710	thus, genetic aberration in the pathway	[Thus, genetic aberrations in the pathway]	0.0	6	1	1	1
142784	1710	essentially complete inhibition occur	[essentially complete inhibition occurring]	0.0	4	1	1	1
142785	1710	human blood cell response	[human blood cell responses]	0.0	4	1	1	1
142786	1710	induction 10 differentiation of a monocyte	[induction 10 differentiation of a monocyte]	0.0	6	1	1	1
142787	1710	(also in umbilical arterial cell	[(also in umbilical arterial cells]	0.0	5	1	1	1
142788	1710	significantly change the relative proportion	[significantly changing the relative proportions]	0.0	5	1	1	1
142789	1710	primer specific	[primers specific]	0.0	2	1	1	1
142790	1710	several effects,	[several effects,]	0.0	2	1	1	1
142791	1710	domain with sh2 motif	[domains with SH2 motifs]	0.0	4	1	1	1
142792	1710	two polypeptide of kda	[two polypeptides of kDa]	0.0	4	1	1	1
142793	1710	coexpression of active calcineurin	[coexpression of active calcineurin]	0.0	4	1	1	1
142794	1710	putative b DNA probe	[putative B DNA probes]	0.0	4	1	1	1
142795	1710	Tyrosine phosphorylation	[Tyrosine phosphorylation]	0.0	2	1	1	1
142796	1710	(i) stimulation	[(i) stimulation]	0.0	2	1	1	1
142797	1710	metalloproteinase inhibitor bb-94	[metalloproteinase inhibitor BB-94]	0.0	3	1	1	1
142798	1710	discrete cell-surface isoform of cd43	[discrete cell-surface isoforms of CD43]	0.0	5	1	1	1
142799	1710	Yang patient	[Yang patients]	0.0	2	1	1	1
142800	1710	gtp -binding motif	[GTP -binding motif]	0.0	3	1	1	1
142801	1710	subunits; five genes, nfkb1 p105	[subunits; five genes, NFKB1 p105]	0.0	5	1	1	1
142802	1710	th2 cells, expression of gata-3	[Th2 cells, expression of GATA-3]	0.0	5	1	1	1
142803	1710	distinct multi-protein complex	[distinct multi-protein complexes]	0.0	3	1	1	1
142804	1710	spindle-shaped carcinoma	[spindle-shaped carcinomas]	0.0	2	1	1	1
142805	1710	negative regulator of platelet function	[negative regulator of platelet function]	0.0	5	1	1	1
142806	1710	immunophenotypic correlate to the structural classification	[immunophenotypic correlates to the structural classification]	0.0	6	1	1	1
142807	1710	element within promoter response element	[element within promoters Response Element]	0.0	5	1	1	1
142808	1710	intranasal glucocorticoid on glucocorticoid function	[intranasal glucocorticoids on glucocorticoid function]	0.0	5	1	1	1
142809	1710	tre1 probe	[TRE1 probe]	0.0	2	1	1	1
142810	1710	human myelodysplastic syndrome	[human myelodysplastic syndrome]	0.0	3	1	1	1
142811	1710	increase in activity	[increase in activity]	0.0	3	1	1	1
142812	1710	heat-shock for 2 hour	[Heat-shock for 2 hours]	0.0	4	1	1	1
142813	1710	ng/ml) with the symptom score	[ng/mL) with the symptom score]	0.0	5	1	1	1
142814	1710	inhibition in cell	[inhibition in cells]	0.0	3	1	1	1
142815	1710	b promoter	[B promoter]	0.0	2	1	1	1
142816	1710	-mediated apoptosis	[-mediated apoptosis]	0.0	2	2	2	1
142817	1710	steady state level ifn-gamma	[steady state levels IFN-gamma]	0.0	4	1	1	1
142818	1710	wide array	[wide array]	0.0	2	1	1	1
142819	1710	DNA apoptosis in this T lymphocyte	[DNA apoptosis in these T lymphocytes]	0.0	6	1	1	1
142820	1710	dependence in a cell line	[Dependence in a cell line]	0.0	5	1	1	1
142821	1710	diagnostic purpose	[diagnostic purposes]	0.0	2	1	1	1
142822	1710	45 residue of the cytoplasmic tail,	[45 residues of the cytoplasmic tail,]	0.0	6	1	1	1
142823	1710	death domain death receptor 3	[death domain death receptor 3]	0.0	5	1	1	1
142824	1710	two nf-kappa b inducer	[two NF-kappa B inducers]	0.0	4	1	1	1
142825	1710	Potent inhibition by a antiinflammatory alkaloid	[Potent inhibition by an antiinflammatory alkaloid]	0.0	6	1	1	1
142826	1710	amount of information	[amount of information]	0.0	3	1	1	1
142827	1710	range to q23	[ranging to q23]	0.0	3	1	1	1
142828	1710	factor proliferation of cd34+ cell	[factor proliferation of CD34+ cells]	0.0	5	1	1	1
142829	1710	size in the cell line	[size in the cell lines]	0.0	5	1	1	1
142830	1710	b complex	[B complex]	0.0	2	1	1	1
142831	1710	use immunohistochemistry with antibody	[using immunohistochemistry with antibodies]	0.0	4	1	1	1
142832	1710	form coding for a protein	[form coding for a protein]	0.0	5	1	1	1
142833	1710	preliminary evidence for negative cross-talk	[preliminary evidence for negative cross-talk]	0.0	5	1	1	1
142834	1710	increase in GRE binding	[increase in GRE binding]	0.0	4	1	1	1
142835	1710	treatment with micrograms/mL etoposide	[Treatment with micrograms/mL etoposide]	0.0	4	1	1	1
142836	1710	negative mouse	[negative mice]	0.0	2	1	1	1
142837	1710	ad5-induced inhibition	[Ad5-induced inhibition]	0.0	2	1	1	1
142838	1710	concomitant elevation in the level	[concomitant elevations in the levels]	0.0	5	1	1	1
142839	1710	further characterization	[Further characterization]	0.0	2	4	4	1
142840	1710	pattern of b activation	[patterns of B activation]	0.0	4	1	1	1
142841	1710	receptor superfamily responsible	[receptor superfamily responsible]	0.0	3	1	1	1
142842	1710	h in endothelial cell	[h in endothelial cells]	0.0	4	1	1	1
142843	1710	activate protein flap	[activating protein FLAP]	0.0	3	1	1	1
142844	1710	slightly on epidermal cell	[slightly on epidermal cells]	0.0	4	1	1	1
142845	1710	t-cell prolymphocytic leukemia a rare form	[T-cell prolymphocytic leukemia a rare form]	0.0	6	1	1	1
142846	1710	method for assessment of IL production	[METHOD For assessment of IL production]	0.0	6	1	1	1
142847	1710	abolish acute hepatic injury with alpha-tocopherol	[abolishing acute hepatic injury with alpha-tocopherol]	0.0	6	1	1	1
142848	1710	acidic activator protein	[acidic activator proteins]	0.0	3	1	1	1
142849	1710	downstream globin gene kilobasis	[downstream globin genes kilobases]	0.0	4	1	1	1
142850	1710	major DNase-I hypersensitive site	[major DNase-I hypersensitive sites]	0.0	4	1	1	1
142851	1710	hirsute patient	[hirsute patients]	0.0	2	1	1	1
142852	1710	replacement of the gamma(c) domain	[replacement of the gamma(c) domain]	0.0	5	1	1	1
142853	1710	receptor or	[receptor OR]	0.0	2	1	1	1
142854	1710	postcapillary venule pcv	[postcapillary venules PCVs]	0.0	3	1	1	1
142855	1710	amount of precursor	[amounts of precursors]	0.0	3	1	1	1
142856	1710	biochemical marker of cortisol receptor	[biochemical marker of cortisol receptor]	0.0	5	1	1	1
142857	1710	simultaneous expression	[simultaneous expression]	0.0	2	1	1	1
142858	1710	nuclear protein nf-kappa b (consist	[nuclear proteins NF-kappa B (consisting]	0.0	5	1	1	1
142859	1710	synchronous recognition	[Synchronous recognition]	0.0	2	1	1	1
142860	1710	relative affinity of element	[Relative affinities of elements]	0.0	4	1	1	1
142861	1710	attenuation of hla-dr expression	[Attenuation of HLA-DR expression]	0.0	4	1	1	1
142862	1710	receptor rna	[receptor RNA]	0.0	2	3	3	1
142863	1710	specify the 5' terminus	[specifying the 5' terminus]	0.0	4	1	1	1
142864	1710	expression of the early response gene	[expression of the early response genes]	0.0	6	1	1	1
142865	1710	mumol cortisol	[mumol cortisol]	0.0	2	1	1	1
142866	1710	gata sequence at position	[GATA sequence at position]	0.0	4	1	1	1
142867	1710	chromosome 11 at band	[chromosome 11 at band]	0.0	4	1	1	1
142868	1710	cell type-specific tfiid subunit	[cell type-specific TFIID subunit]	0.0	4	1	1	1
142869	1710	AP-1/ATF/CREB	[AP-1/ATF/CREB]	0.0	1	1	1	1
142870	1710	second domain	[second domain]	0.0	2	1	1	1
142871	1710	creb camp element	[CREB cAMP element]	0.0	3	1	1	1
142872	1710	residue of the immediate protein	[residues of the immediate protein]	0.0	5	1	1	1
142873	1710	72-kDa immediate-early protein ie-1	[72-kDa immediate-early protein IE-1]	0.0	4	1	1	1
142874	1710	general octamer site	[general octamer site]	0.0	3	1	1	1
142875	1710	inasmuch through opening of Ca(2+)-stimulated K+	[Inasmuch through opening of Ca(2+)-stimulated K+]	0.0	6	1	1	1
142876	1710	e1a activities, sensitization	[E1A activities, sensitization]	0.0	3	1	1	1
142877	1710	guideline	[guidelines]	0.0	1	1	1	1
142878	1710	receptor ro	[receptors Ro]	0.0	2	1	1	1
142879	1710	interfer	[Interfering]	0.0	1	1	1	1
142880	1710	c-cerba/thyroid	[c-cerbA/thyroid]	0.0	1	1	1	1
142881	1710	somatic mutation rna sample	[somatic mutations RNA samples]	0.0	4	1	1	1
142882	1710	mature human cell	[mature human cells]	0.0	3	1	1	1
142883	1710	interaction between multiple ets	[interaction between multiple Ets]	0.0	4	1	1	1
142884	1710	probability recur locally	[probability recurring locally]	0.0	3	1	1	1
142885	1710	predominant producer	[predominant producers]	0.0	2	1	1	1
142886	1710	amino acid hydroxylase	[amino acid hydroxylases]	0.0	3	1	1	1
142887	1710	biopsy of hairy leukoplakia a lesion	[Biopsies of hairy leukoplakia an lesion]	0.0	6	1	1	1
142888	1710	change in membrane structural order	[change in membrane structural order]	0.0	5	1	1	1
142889	1710	768-bp negative regulatory region	[768-bp negative regulatory region]	0.0	4	1	1	1
142890	1710	acinar cell	[acinar cells]	0.0	2	1	1	1
142891	1710	concentration of estradiol	[concentration of estradiol]	0.0	3	2	2	1
142892	1710	signal transducing component	[signal transducing components]	0.0	3	1	1	1
142893	1710	employ extract	[employing extracts]	0.0	2	1	1	1
142894	1710	different protein tyrosine kinase module	[different protein tyrosine kinase modules]	0.0	5	1	1	1
142895	1710	activation of zeta functional role	[activation of zeta functional role]	0.0	5	1	1	1
142896	1710	regular borders.	[regular borders.]	0.0	2	1	1	1
142897	1710	incubation of b-chronic leukemia (b-cll) cell	[Incubation of B-chronic leukemia (B-CLL) cells]	0.0	6	1	1	1
142898	1710	hormone metabolic status	[hormone metabolic status]	0.0	3	1	1	1
142899	1710	T lymphocyte from individual	[T lymphocytes from individuals]	0.0	4	1	1	1
142900	1710	Maximal induction	[Maximal induction]	0.0	2	2	2	1
142901	1710	event in inflammation	[event in inflammation]	0.0	3	1	1	1
142902	1710	cell from inactive form	[cells from inactive form]	0.0	4	1	1	1
142903	1710	interaction of rank receptor-associated factor	[interaction of RANK receptor-associated factors]	0.0	5	1	1	1
142904	1710	substnfkappab substSp23	[substNFkappaB substSp23]	0.0	2	1	1	1
142905	1710	degradation of the NF-kappaB molecule IkappaBalpha	[degradation of the NF-kappaB molecule IkappaBalpha]	0.0	6	1	1	1
142906	1710	present with immunodeficiency SCID	[presenting with immunodeficiency SCID]	0.0	4	1	1	1
142907	1710	promote the generation through up-regulation	[promoting the generation through up-regulation]	0.0	5	1	1	1
142908	1710	Bal deletion mapping datum	[Bal deletion mapping data]	0.0	4	1	1	1
142909	1710	10 individual	[10 individuals]	0.0	2	1	1	1
142910	1710	unaffected, inhibitor	[unaffected, inhibitors]	0.0	2	1	1	1
142911	1710	protein aml1/mds1/evi1	[protein AML1/MDS1/EVI1]	0.0	2	2	2	1
142912	1710	competent transcription initiation by RNA polymerase	[Competent transcription initiation by RNA polymerase]	0.0	6	1	1	1
142913	1710	dyad sequence	[dyad sequence]	0.0	2	1	1	1
142914	1710	hb24 expression in lymphoid	[HB24 expression in lymphoid]	0.0	4	1	1	1
142915	1710	heterologous cell type	[heterologous cell types]	0.0	3	1	1	1
142916	1710	function during hiv replication	[functions during HIV replication]	0.0	4	1	1	1
142917	1710	interact helix-loop-helix protein	[interacting helix-loop-helix proteins]	0.0	3	1	1	1
142918	1710	hereditary hypercholesteremia	[hereditary hypercholesteremia]	0.0	2	1	1	1
142919	1710	activation in human neuroblastoma cell line	[Activation in human neuroblastoma cell lines]	0.0	6	1	1	1
142920	1710	different domain of il-9ralpha	[different domains of IL-9Ralpha]	0.0	4	1	1	1
142921	1710	interaction of transcription factor functional antagonism	[interaction of transcription factors functional antagonism]	0.0	6	1	1	1
142922	1710	content of tfiih	[content of TFIIH]	0.0	3	1	1	1
142923	1710	suggest also important	[suggesting also important]	0.0	3	1	1	1
142924	1710	nf-kappab -dependent transcription	[NF-kappaB -dependent transcription]	0.0	3	1	1	1
142925	1710	-13- acetate PMA	[-13- acetate PMA]	0.0	3	1	1	1
142926	1710	significant proliferation (71%) iddm subject 8	[significant proliferation (71%) IDDM subjects 8]	0.0	6	1	1	1
142927	1710	nls peptide	[NLS peptide]	0.0	2	1	1	1
142928	1710	units, p	[units, P]	0.0	2	1	1	1
142929	1710	IL-2 promoter drive the expression	[IL-2 promoter driving the expression]	0.0	5	1	1	1
142930	1710	case of preincubation	[case of preincubation]	0.0	3	1	1	1
142931	1710	fra-1 engagement of CD40	[fra-1 engagement of CD40]	0.0	4	1	1	1
142932	1710	phosphorylation of IkappaBalpha protein,	[phosphorylation of IkappaBalpha protein,]	0.0	4	1	1	1
142933	1710	transport along the pathway	[transport along the pathway]	0.0	4	1	1	1
142934	1710	Glucocorticoid receptor binding	[Glucocorticoid receptor binding]	0.0	3	1	1	1
142935	1710	expression transcript	[expression transcripts]	0.0	2	1	1	1
142936	1710	malignant cell of leukemia APL	[malignant cells of leukemia APL]	0.0	5	1	1	1
142937	1710	important transcriptional regulator	[important transcriptional regulator]	0.0	3	1	1	1
142938	1710	vein endothelial cell HUVECs	[vein endothelial cells HUVECs]	0.0	4	2	2	1
142939	1710	sv40 T antigen	[SV40 T antigen]	0.0	3	2	2	1
142940	1710	analysis of translocation	[Analyses of translocation]	0.0	3	1	1	1
142941	1710	rare DNA variation 2418delA	[rare DNA variations 2418delA]	0.0	4	1	1	1
142942	1710	naturally-occurg phenolic compound	[naturally-occurring phenolic compounds]	0.0	3	1	1	1
142943	1710	mechanism of synergy between tal1	[mechanisms of synergy between TAL1]	0.0	5	1	1	1
142944	1710	include skeletal muscle	[including skeletal muscle]	0.0	3	1	1	1
142945	1710	necessity for appropriate alignment	[necessity for appropriate alignment]	0.0	4	1	1	1
142946	1710	human naive T lymphocyte	[human naive T lymphocytes]	0.0	4	1	1	1
142947	1710	other subpopulation	[other subpopulation]	0.0	2	1	1	1
142948	1710	14-amino acid insertion present	[14-amino acid insertion present]	0.0	4	1	1	1
142949	1710	interaction of fibronectin	[Interaction of fibronectin]	0.0	3	1	1	1
142950	1710	x-chromosome inactivation pattern	[X-chromosome inactivation patterns]	0.0	3	1	1	1
142951	1710	direct t-cell recognition	[direct T-cell recognition]	0.0	3	1	1	1
142952	1710	animal with malignancy	[animals with malignancy]	0.0	3	1	1	1
142953	1710	transcription protein stat3	[transcription proteins Stat3]	0.0	3	1	1	1
142954	1710	(18 year	[(18 years]	0.0	2	1	1	1
142955	1710	sequence analysis of ltr	[Sequence analysis of LTRs]	0.0	4	1	1	1
142956	1710	event lead by TNF alpha	[events leading by TNF alpha]	0.0	5	1	1	1
142957	1710	regulation of proto-oncogent c-jun	[regulation of proto-oncogenes c-jun]	0.0	4	1	1	1
142958	1710	negative transcriptional effect	[negative transcriptional effects]	0.0	3	1	1	1
142959	1710	multiple lytic antigen-specific reactivity at level	[multiple lytic antigen-specific reactivities at levels]	0.0	6	1	1	1
142960	1710	role of RXR	[role of RXR]	0.0	3	1	1	1
142961	1710	new cyclooxygenase/5-lipoxygenase anti-inflammatory compound	[new cyclooxygenase/5-lipoxygenase anti-inflammatory compound]	0.0	4	1	1	1
142962	1710	more transfection experiment	[More transfection experiments]	0.0	3	1	1	1
142963	1710	female with late onset menarche	[female with late onset menarche]	0.0	5	1	1	1
142964	1710	advance in understanding of mechanism	[advances in understanding of mechanisms]	0.0	5	1	1	1
142965	1710	inhibitor of serine/threonine phosphatase okadaic acid	[inhibitors of serine/threonine phosphatases okadaic acid]	0.0	6	1	1	1
142966	1710	demonstrate a population	[demonstrating a population]	0.0	3	1	1	1
142967	1710	modification in sequence	[modifications in sequences]	0.0	3	1	1	1
142968	1710	target PML mrna	[targeting PML mRNA]	0.0	3	1	1	1
142969	1710	numerous clinical feature	[numerous clinical features]	0.0	3	1	1	1
142970	1710	lymphotoxin-alpha	[lymphotoxin-alpha]	0.0	1	1	1	1
142971	1710	region of thymus lobule	[regions of thymus lobules]	0.0	4	1	1	1
142972	1710	lineage specificity	[lineage specificity]	0.0	2	1	1	1
142973	1710	redox sensitivity, allow	[redox sensitivity, allowing]	0.0	3	1	1	1
142974	1710	cell surface marker in response	[cell surface markers in response]	0.0	5	1	1	1
142975	1710	pmol/L; control	[pmol/L; controls]	0.0	2	1	1	1
142976	1710	reconstitution in lck-negative jcam1 cell	[Reconstitution in Lck-negative JCaM1 cells]	0.0	5	1	1	1
142977	1710	immunotoxicity of member	[immunotoxicity of member]	0.0	3	1	1	1
142978	1710	recombinant adhesion molecule-1	[recombinant adhesion molecule-1]	0.0	3	1	1	1
142979	1710	(also in human endothelial cell	[(also in human endothelial cells]	0.0	5	1	1	1
142980	1710	potentiation of clearance of apoptotic leukocyte	[potentiation of clearance of apoptotic leukocytes]	0.0	6	1	1	1
142981	1710	lipopolysaccharide (lps)-induced increase	[lipopolysaccharide (LPS)-induced increases]	0.0	3	1	1	1
142982	1710	regulation of gr binding	[Regulation of GR binding]	0.0	4	1	1	1
142983	1710	activator (stat) protein	[activator (Stat) protein]	0.0	3	1	1	1
142984	1710	variation in gr	[variation in GR]	0.0	3	1	1	1
142985	1710	Glycation-dependent oxygen	[Glycation-dependent oxygen]	0.0	2	1	1	1
142986	1710	intragenic deletion of TSG101	[Intragenic deletions of TSG101]	0.0	4	1	1	1
142987	1710	bhrf1 in a line	[BHRF1 in a line]	0.0	4	1	1	1
142988	1710	blood cell response	[blood cell responses]	0.0	3	1	1	1
142989	1710	acid receptor alpha fusion transcript	[acid receptor alpha fusion transcript]	0.0	5	1	1	1
142990	1710	interleukin-12 a signal	[interleukin-12 a signal]	0.0	3	1	1	1
142991	1710	C epsilon gas DNA-protein binding complex	[C epsilon GAS DNA-protein binding complexes]	0.0	6	1	1	1
142992	1710	also in airway cell	[also in airway cells]	0.0	4	1	1	1
142993	1710	20- affinity consistent with effect	[20- affinity consistent with effects]	0.0	5	1	1	1
142994	1710	tam quercetin	[TAM quercetin]	0.0	2	1	1	1
142995	1710	Jun 17;269(24):16983]	[Jun 17;269(24):16983]]	0.0	2	1	1	1
142996	1710	expression of a transgene	[expression of a transgene]	0.0	4	1	1	1
142997	1710	agreement on the pathogenesis a accumulation	[agreement on the pathogenesis an accumulation]	0.0	6	1	1	1
142998	1710	receptor for fk506	[receptors for FK506]	0.0	3	1	1	1
142999	1710	normal exon 10 sequence	[normal exon 10 sequence]	0.0	4	1	1	1
143000	1710	tissue tumor fibrosarcoma histiocytoma	[tissue tumors fibrosarcoma histiocytoma]	0.0	4	1	1	1
143001	1710	inflammatory mediator lipopolysaccharide	[inflammatory mediators lipopolysaccharide]	0.0	3	1	1	1
143002	1710	decisive role	[decisive role]	0.0	2	1	1	1
143003	1710	only in the vast majority	[only in the vast majority]	0.0	5	1	1	1
143004	1710	change in patient	[changes in patients]	0.0	3	1	1	1
143005	1710	ebv-positive bl	[EBV-positive BL]	0.0	2	1	1	1
143006	1710	additional characteristic	[additional characteristic]	0.0	2	1	1	1
143007	1710	importance of glucocorticoid apoptosis	[importance of glucocorticoid apoptosis]	0.0	4	1	1	1
143008	1710	divalent cation	[divalent cations]	0.0	2	1	1	1
143009	1710	recombinant hugata-3	[recombinant huGATA-3]	0.0	2	1	1	1
143010	1710	receptor characteristic in monocyte of patient	[receptor characteristics in monocytes of patients]	0.0	6	1	1	1
143011	1710	frequent emergence to combination	[frequent emergence to combinations]	0.0	4	1	1	1
143012	1710	I ATL-1k	[I ATL-1k]	0.0	2	1	1	1
143013	1710	reactivity of pregnancy lymphocyte	[reactivity of pregnancy lymphocytes]	0.0	4	1	1	1
143014	1710	four gene	[four genes]	0.0	2	1	1	1
143015	1710	osteocalcin promoter	[osteocalcin promoter]	0.0	2	1	1	1
143016	1710	two oligonucleotide from the 1st	[Two oligonucleotides from the 1st]	0.0	5	1	1	1
143017	1710	viral peptide residue	[viral peptide residues]	0.0	3	1	1	1
143018	1710	monoclonal antibody-mediated cross-linking tyrosine phosphorylation	[monoclonal antibody-mediated cross-linking tyrosine phosphorylation]	0.0	5	1	1	1
143019	1710	lymphoma with a component	[lymphomas with a component]	0.0	4	1	1	1
143020	1710	production of matrix metalloproteinase	[production of matrix metalloproteinases]	0.0	4	1	1	1
143021	1710	several non-T immune cell	[several non-T immune cells]	0.0	4	1	1	1
143022	1710	APC culture	[APC culture]	0.0	2	1	1	1
143023	1710	two cell specific molecule	[two cell specific molecules]	0.0	4	1	1	1
143024	1710	phosphorylation of c-Jun at NH(2)-termini	[phosphorylation of c-Jun at NH(2)-termini]	0.0	5	1	1	1
143025	1710	contain the ciita gene	[containing the CIITA gene]	0.0	4	1	1	1
143026	1710	quality support	[quality support]	0.0	2	1	1	1
143027	1710	pituitary (gh3) cell	[pituitary (GH3) cells]	0.0	3	1	1	1
143028	1710	malignant b-cell line	[malignant B-cell lines]	0.0	3	1	1	1
143029	1710	CAAT consensus	[CAAT consensus]	0.0	2	1	1	1
143030	1710	physical stress-induced signal pathway	[physical stress-induced signaling pathways]	0.0	4	1	1	1
143031	1710	stage selector element	[stage selector element]	0.0	3	1	1	1
143032	1710	human b cell extract	[human B cell extract]	0.0	4	1	1	1
143033	1710	DNA intercalate agent	[DNA intercalating agents]	0.0	3	1	1	1
143034	1710	essential rise in the number	[essential rise in the number]	0.0	5	1	1	1
143035	1710	autopsy tissue from patient	[autopsy tissues from patients]	0.0	4	1	1	1
143036	1710	peripheral tissue	[peripheral tissues]	0.0	2	1	1	1
143037	1710	extract of Jurkat cell	[extracts of Jurkat cells]	0.0	4	1	1	1
143038	1710	comparable sensitivity	[comparable sensitivity]	0.0	2	1	1	1
143039	1710	protein such as transcription factor	[proteins such as transcription factors]	0.0	5	1	1	1
143040	1710	loss of potential	[loss of potential]	0.0	3	1	1	1
143041	1710	infiltrate into process	[infiltrating into processes]	0.0	3	1	1	1
143042	1710	peripheral blood b lymphocyte	[peripheral blood B lymphocytes]	0.0	4	1	1	1
143043	1710	manifestation of fibrosis	[manifestations of fibrosis]	0.0	3	1	1	1
143044	1710	neutralize anti- tnf-alpha antibody antigen release	[neutralizing anti- TNF-alpha antibodies antigen release]	0.0	6	1	1	1
143045	1710	strict dependence	[Strict dependence]	0.0	2	1	1	1
143046	1710	change affect the LTR	[changes affecting the LTR]	0.0	4	1	1	1
143047	1710	interferon gamma a activator	[interferon gamma a activator]	0.0	4	1	1	1
143048	1710	further study of the defect(s)	[further study of the defect(s)]	0.0	5	1	1	1
143049	1710	phosphorylation reaction	[phosphorylation reaction]	0.0	2	1	1	1
143050	1710	effect on G-CSF colony formation	[effect on G-CSF colony formation]	0.0	5	1	1	1
143051	1710	untreated asthmatic patient	[untreated asthmatic patients]	0.0	3	1	1	1
143052	1710	transfection of kinase-deficient mutant	[Transfection of kinase-deficient mutants]	0.0	4	1	1	1
143053	1710	other mechanism for promoter occupancy	[other mechanisms for promoter occupancy]	0.0	5	1	1	1
143054	1710	importance in vitro	[importance in vitro]	0.0	3	1	1	1
143055	1710	cell proliferation rate	[cell proliferation rates]	0.0	3	1	1	1
143056	1710	cloning by display	[Cloning by display]	0.0	3	1	1	1
143057	1710	different contribution	[different contribution]	0.0	2	1	1	1
143058	1710	GPIIb gene	[GPIIb gene]	0.0	2	1	1	1
143059	1710	human neuroblastoma	[human neuroblastoma]	0.0	2	1	1	1
143060	1710	mutagenesis,	[mutagenesis,]	0.0	1	1	1	1
143061	1710	C-terminal pou-specific homeodomain	[C-terminal POU-specific homeodomain]	0.0	3	1	1	1
143062	1710	abnormality for probe	[Abnormalities for probes]	0.0	3	1	1	1
143063	1710	human immunodeficiency virus type repeat	[human immunodeficiency virus type repeats]	0.0	5	1	1	1
143064	1710	mouse globin gene	[mouse globin genes]	0.0	3	1	1	1
143065	1710	role in dermal activation	[role in dermal activation]	0.0	4	1	1	1
143066	1710	cytotoxicity against cancerous cell line	[cytotoxicity against cancerous cell lines]	0.0	5	1	1	1
143067	1710	alpha1 -negative daudi cell	[alpha1 -negative Daudi cells]	0.0	4	1	1	1
143068	1710	HHV-6 variant b	[HHV-6 variant B]	0.0	3	1	1	1
143069	1710	histocompatibility complex class promoter	[histocompatibility complex class promoter]	0.0	4	1	1	1
143070	1710	abnormality highlight putative loci	[abnormalities highlighting putative loci]	0.0	4	1	1	1
143071	1710	hour with the antibody,	[hr with the antibody,]	0.0	4	1	1	1
143072	1710	namely, the (dp) CD4 thymocyte	[namely, the (DP) CD4 thymocytes]	0.0	5	1	1	1
143073	1710	E2F -binding site	[E2F -binding sites]	0.0	3	1	1	1
143074	1710	hbx immune response	[HBx immune response]	0.0	3	1	1	1
143075	1710	major tegument protein	[major tegument protein]	0.0	3	1	1	1
143076	1710	chimaeric transcription	[chimaeric transcription]	0.0	2	1	1	1
143077	1710	interleukin-6 apoptosis	[interleukin-6 apoptosis]	0.0	2	1	1	1
143078	1710	lps 1.0	[LPS 1.0]	0.0	2	1	1	1
143079	1710	pathway by virtue	[pathway by virtue]	0.0	3	1	1	1
143080	1710	include interferon factor	[including interferon factor]	0.0	3	1	1	1
143081	1710	pretreatment macrophage	[Pretreatment macrophages]	0.0	2	1	1	1
143082	1710	separation of the granule	[separation of the granules]	0.0	4	1	1	1
143083	1710	"targets"	["targets"]	0.0	1	1	1	1
143084	1710	pax-5 isoform	[Pax-5 isoforms]	0.0	2	1	1	1
143085	1710	pathway for action	[pathway for action]	0.0	3	1	1	1
143086	1710	normal developmental regulation	[normal developmental regulation]	0.0	3	1	1	1
143087	1710	regulate this activation	[regulating this activation]	0.0	3	1	1	1
143088	1710	variant translocation in APL	[variant translocations in APL]	0.0	4	1	1	1
143089	1710	splicing of a transcript	[splicing of a transcript]	0.0	4	1	1	1
143090	1710	replication of immunodeficiency virus type-1 hiv-1	[Replication of immunodeficiency virus type-1 HIV-1]	0.0	6	1	1	1
143091	1710	subsequently, increase expression along the pathway	[Subsequently, increasing expression along the pathway]	0.0	6	1	1	1
143092	1710	mediate il-6 gene expression in monocyte	[mediating IL-6 gene expression in monocytes]	0.0	6	1	1	1
143093	1710	activity a potent activator	[activity a potent activator]	0.0	4	1	1	1
143094	1710	metabolism of methylprednisolone	[metabolism of methylprednisolone]	0.0	3	1	1	1
143095	1710	component in the extract	[component in the extract]	0.0	4	1	1	1
143096	1710	Hypothetically, on/off switch	[Hypothetically, on/off switches]	0.0	3	1	1	1
143097	1710	kappa transcription	[kappa transcription]	0.0	2	1	1	1
143098	1710	membrane by salt concentration	[membranes by salt concentrations]	0.0	4	1	1	1
143099	1710	tyrosine-phosphorylated factor treatment of neutrophils.	[tyrosine-phosphorylated factor treatment of neutrophils.]	0.0	5	1	1	1
143100	1710	putative transcription factor nf-microb	[putative transcription factor NF-microB]	0.0	4	1	1	1
143101	1710	two new kappa B-specific complex	[two new kappa B-specific complexes]	0.0	5	1	1	1
143102	1710	process affect several transcription factor	[process affecting several transcription factors]	0.0	5	1	1	1
143103	1710	regulation elf-1 by binding	[Regulation Elf-1 by binding]	0.0	4	1	1	1
143104	1710	DNA of lymphocyte	[DNA of lymphocytes]	0.0	3	1	1	1
143105	1710	genetic screen	[genetic screen]	0.0	2	1	1	1
143106	1710	udg expression	[UDG expression]	0.0	2	1	1	1
143107	1710	approach attenuate hiv-1	[approach attenuating HIV-1]	0.0	3	1	1	1
143108	1710	flexi-12 delivery to myeloid blast	[Flexi-12 delivery to myeloid blasts]	0.0	5	1	1	1
143109	1710	IL-4 transcription,	[IL-4 transcription,]	0.0	2	1	1	1
143110	1710	inhibition of U1 proliferation	[inhibition of U1 proliferation]	0.0	4	1	1	1
143111	1710	carotid artery ECs	[carotid artery ECs]	0.0	3	1	1	1
143112	1710	growth similar to cultures.	[growth similar to cultures.]	0.0	4	1	1	1
143113	1710	Ca2+ -dependent pkc isoform	[Ca2+ -dependent PKC isoforms]	0.0	4	1	1	1
143114	1710	many disorder a clinical problem	[many disorders a clinical problem]	0.0	5	1	1	1
143115	1710	transcription pcr assay	[transcription PCR assay]	0.0	3	1	1	1
143116	1710	alter the physiologic status in response	[altering the physiologic status in response]	0.0	6	1	1	1
143117	1710	endotoxin-stimulated thp-1	[endotoxin-stimulated THP-1]	0.0	2	1	1	1
143118	1710	30 minute 1)	[30 minutes 1)]	0.0	3	1	1	1
143119	1710	hla-dr- a unrecognized form	[HLA-DR- a unrecognized form]	0.0	4	1	1	1
143120	1710	Bernard, R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,	[Bernard, R.Leonard, R.Cheynier, M.Feldman, P.S.Sarin,]	0.0	5	1	1	1
143121	1710	symbiotic, relationship	[symbiotic, relationship]	0.0	2	1	1	1
143122	1710	protein indistinguishable	[protein indistinguishable]	0.0	2	1	1	1
143123	1710	monozygotic twin pair	[monozygotic twin pair]	0.0	3	1	1	1
143124	1710	esterase anae	[esterase ANAE]	0.0	2	1	1	1
143125	1710	receptor for thrombopoietin	[receptor for thrombopoietin]	0.0	3	1	1	1
143126	1710	360-d bed rest)	[360-d bed rest)]	0.0	3	1	1	1
143127	1710	lower,	[lower,]	0.0	1	1	1	1
143128	1710	leukoplakia	[leukoplakia]	0.0	1	1	1	1
143129	1710	thymocyte in vitro.	[thymocytes in vitro.]	0.0	3	1	1	1
143130	1710	negative effector	[negative effector]	0.0	2	1	1	1
143131	1710	long terminal repeat quasispecy	[long terminal repeat quasispecies]	0.0	4	1	1	1
143132	1710	protein e2a	[proteins E2A]	0.0	2	1	1	1
143133	1710	series (a) of 125d3 variant	[series (A) of 1,25D3 variants]	0.0	5	1	1	1
143134	1710	tlr-dependent transcription	[TLR-dependent transcription]	0.0	2	1	1	1
143135	1710	modification of I kappa b molecule	[modifications of I kappa B molecules]	0.0	6	1	1	1
143136	1710	virtually all line	[Virtually all lines]	0.0	3	1	1	1
143137	1710	sensitivity to 135eoh)2d3	[sensitivity to 1,25(OH)2D3]	0.0	3	1	1	1
143138	1710	high-level zeta	[high-level zeta]	0.0	2	1	1	1
143139	1710	site in the promoter	[sites in the promoter]	0.0	4	1	1	1
143140	1710	chain (igh) promoter	[chain (IgH) promoter]	0.0	3	1	1	1
143141	1710	cell line (Singh	[cell line (Singh]	0.0	3	1	1	1
143142	1710	induction of CAT enzyme activity	[induction of CAT enzyme activity]	0.0	5	1	1	1
143143	1710	kda protein on sds-page	[kDa protein on SDS-PAGE]	0.0	4	1	1	1
143144	1710	overexpression of activation of factor	[overexpression of activation of factor]	0.0	5	1	1	1
143145	1710	affinity on peripheral blood cell	[affinity on peripheral blood cells]	0.0	5	1	1	1
143146	1710	increase to huvec	[increase to HUVECs]	0.0	3	1	1	1
143147	1710	contrast to the gene	[contrast to the gene]	0.0	4	1	1	1
143148	1710	predict the location	[predicting the location]	0.0	3	1	1	1
143149	1710	map kinase kinase	[MAP kinase kinase]	0.0	3	1	1	1
143150	1710	Janus kinase jak3	[Janus kinase JAK3]	0.0	3	1	1	1
143151	1710	widespread extinction of several gene	[widespread extinction of several genes]	0.0	5	1	1	1
143152	1710	hypo eu hyper	[hypo eu hyper]	0.0	3	1	1	1
143153	1710	mechanism via the polymorphonuclear leukocyte	[mechanisms via the polymorphonuclear leukocytes]	0.0	5	1	1	1
143154	1710	add (10(-6) m).	[adding (10(-6) M).]	0.0	3	1	1	1
143155	1710	minute of activation,	[min of activation,]	0.0	3	1	1	1
143156	1710	interrelationship	[interrelationship]	0.0	1	2	2	1
143157	1710	(u937vhl-1) cell line	[(U937,THP-1) cell lines]	0.0	3	1	1	1
143158	1710	emphasize the antiatherosclerotic potential	[emphasizing the antiatherosclerotic potential]	0.0	4	1	1	1
143159	1710	significant thrombin -generate capacity secondary	[significant thrombin -generating capacity secondary]	0.0	5	1	1	1
143160	1710	specific receptor domain sequence	[specific receptor domain sequences]	0.0	4	1	1	1
143161	1710	ctf/nf-1	[CTF/NF-1]	0.0	1	1	1	1
143162	1710	gene include the enhancer	[genes including the enhancer]	0.0	4	1	1	1
143163	1710	primary haemopoietic cell of lineages.	[primary haemopoietic cells of lineages.]	0.0	5	1	1	1
143164	1710	quantitation of receptor	[Quantitation of receptors]	0.0	3	1	1	1
143165	1710	thus, competition between two transcriptional activator	[Thus, competition between two transcriptional activators]	0.0	6	1	1	1
143166	1710	interferon-gamma receptor on eosinophil	[interferon-gamma receptor on eosinophils]	0.0	4	1	1	1
143167	1710	5 m D3 induce differentiation	[5 M D3 inducing differentiation]	0.0	5	1	1	1
143168	1710	two hematopoietic cell specific molecule	[two hematopoietic cell specific molecules]	0.0	5	1	1	1
143169	1710	increase the spacing	[increasing the spacing]	0.0	3	1	1	1
143170	1710	retinaldehyde dehydrogenase 2	[retinaldehyde dehydrogenase 2]	0.0	3	1	1	1
143171	1710	inhibitory molecule kappa bs	[inhibitory molecules kappa Bs]	0.0	4	1	1	1
143172	1710	TNF-alpha translocation of p50-p65	[TNF-alpha translocation of p50-p65]	0.0	4	1	1	1
143173	1710	treatment with schedule of calcitriol	[Treatment with schedules of calcitriol]	0.0	5	1	1	1
143174	1710	position relative to the atg	[positions relative to the ATG]	0.0	5	1	1	1
143175	1710	virus contain the human cytomegalovirus enhancer	[Viruses containing the human cytomegalovirus enhancer]	0.0	6	1	1	1
143176	1710	effect of danazol	[effects of danazol]	0.0	3	2	2	1
143177	1710	actin cytoskeleton	[actin cytoskeleton]	0.0	2	1	1	1
143178	1710	BSAP recognition sequence	[BSAP recognition sequences]	0.0	3	1	1	1
143179	1710	vascular-specific expression	[vascular-specific expression]	0.0	2	1	1	1
143180	1710	level of 135eoh)2d3 receptor rna analysis	[levels of 1,25(OH)2D3 receptor RNA analysis]	0.0	6	1	1	1
143181	1710	polymorphonuclear leukocyte pmn adhesion	[polymorphonuclear leukocyte PMN adhesion]	0.0	4	1	1	1
143182	1710	49 subject	[49 subjects]	0.0	2	1	1	1
143183	1710	beta-(1,6)-branched glucose homopolymer	[beta-(1,6)-branched glucose homopolymer]	0.0	3	1	1	1
143184	1710	electrophoretic mobility 120 kd)	[electrophoretic mobility 120 kD)]	0.0	4	1	1	1
143185	1710	express 135eoh)2d3 receptor	[expressing 1,25(OH)2D3 receptors]	0.0	3	1	1	1
143186	1710	heat-activated receptor	[heat-activated receptors]	0.0	2	1	1	1
143187	1710	5' regulatory DNA sequence	[5' regulatory DNA sequences]	0.0	4	1	1	1
143188	1710	convert signal into intracellular event	[converting signals into intracellular events]	0.0	5	1	1	1
143189	1710	superfamily of proinflammatory cytokine	[superfamily of proinflammatory cytokines]	0.0	4	1	1	1
143190	1710	expression of protein during hematopoiesis	[Expression of proteins during hematopoiesis]	0.0	5	1	1	1
143191	1710	cell-specific transcriptional coactivator	[cell-specific transcriptional coactivators]	0.0	3	2	2	1
143192	1710	NF-kappa b activator precursor p105	[NF-kappa B activator precursor p105]	0.0	5	1	1	1
143193	1710	rapid pma-mediated induction	[rapid PMA-mediated induction]	0.0	3	1	1	1
143194	1710	Fas ligand interaction	[Fas ligand interaction]	0.0	3	1	1	1
143195	1710	estrogen type I	[estrogen type I]	0.0	3	1	1	1
143196	1710	difference in acid sequence	[differences in acid sequence]	0.0	4	1	1	1
143197	1710	oestrogen receptor er analysis	[Oestrogen receptor ER analysis]	0.0	4	1	1	1
143198	1710	80 kda repressor protein	[80 kDA repressor protein]	0.0	4	1	1	1
143199	1710	cis-acting control element present	[cis-acting control elements present]	0.0	4	1	1	1
143200	1710	goal of study of mouse	[goal of study of mice]	0.0	5	1	1	1
143201	1710	mitomycin	[mitomycin]	0.0	1	1	1	1
143202	1710	event in the thyrocyte	[events in the thyrocyte]	0.0	4	1	1	1
143203	1710	motif include Src homology	[motifs including Src homology]	0.0	4	1	1	1
143204	1710	requirement for activity, provide explanation	[requirement for activity, providing explanation]	0.0	5	1	1	1
143205	1710	normal cell StatG	[normal cells StatG]	0.0	3	1	1	1
143206	1710	mouse th1	[mouse Th1]	0.0	2	1	1	1
143207	1710	age-related T	[age-related T]	0.0	2	1	1	1
143208	1710	follow inoculation	[Following inoculation]	0.0	2	1	1	1
143209	1710	myeloid cell development	[myeloid cell development]	0.0	3	1	1	1
143210	1710	role of ascorbate dha	[role of ascorbate DHA]	0.0	4	1	1	1
143211	1710	margin (31%	[margins (31%]	0.0	2	1	1	1
143212	1710	piece	[pieces]	0.0	1	1	1	1
143213	1710	mediator by bronchial cell	[mediators by bronchial cells]	0.0	4	1	1	1
143214	1710	contain four near-perfect repeat	[containing four near-perfect repeats]	0.0	4	1	1	1
143215	1710	maximum (3h)-thymidine incorporation with nrd	[maximum (3H)-thymidine incorporation with NRDS]	0.0	5	1	1	1
143216	1710	Fe2+ /cu2+ ion	[Fe2+ /Cu2+ ions]	0.0	3	1	1	1
143217	1710	generate b cell	[generating B cells]	0.0	3	1	1	1
143218	1710	(Boston)	[(Boston)]	0.0	1	1	1	1
143219	1710	differentiation of megakaryocytic lineage	[differentiation of megakaryocytic lineages]	0.0	4	1	1	1
143220	1710	function in vitro	[functions in vitro]	0.0	3	1	1	1
143221	1710	tnf-alpha nuclear factor-kappa b	[TNF-alpha nuclear factor-kappa B]	0.0	4	1	1	1
143222	1710	span position	[spanning positions]	0.0	2	1	1	1
143223	1710	pretreatment with CD4	[pretreatment with CD4]	0.0	3	1	1	1
143224	1710	type tax protein	[type Tax proteins]	0.0	3	1	1	1
143225	1710	protein-protein interaction with the region	[protein-protein interactions with the region]	0.0	5	1	1	1
143226	1710	modification of the ddpcr protocol	[Modifications of the DDPCR protocol]	0.0	5	1	1	1
143227	1710	role of e2f-1	[role of E2F-1]	0.0	3	1	1	1
143228	1710	freely exchangeable ca2+ in the tubules:	[freely exchangeable Ca2+ in the tubules:]	0.0	6	1	1	1
143229	1710	isolation of the CD11b promoter	[isolation of the CD11b promoter]	0.0	5	1	1	1
143230	1710	mechanism responsible for downmodulation	[mechanisms responsible for downmodulation]	0.0	4	1	1	1
143231	1710	high-resolution mapping of this site	[high-resolution mapping of this site]	0.0	5	1	1	1
143232	1710	flanking sequence of the gene	[flanking sequence of the gene]	0.0	5	1	1	1
143233	1710	tat -virus	[Tat -virus]	0.0	2	1	1	1
143234	1710	use throughput screen of broth	[using throughput screening of broths]	0.0	5	1	1	1
143235	1710	tested, (ii) mrna level	[tested, (ii) mRNA levels]	0.0	4	1	1	1
143236	1710	polymorphonuclear neutrophil transendothelial migration	[polymorphonuclear neutrophil transendothelial migration]	0.0	4	1	1	1
143237	1710	trigger of signal pathway	[triggering of signaling pathways]	0.0	4	1	1	1
143238	1710	reduce the inflammatory response	[reducing the inflammatory response]	0.0	4	1	1	1
143239	1710	active metabolite of vitamin d,	[active metabolite of vitamin D,]	0.0	5	1	1	1
143240	1710	cis-acting regulatory elements,	[cis-acting regulatory elements,]	0.0	3	1	1	1
143241	1710	other transcription factor binding site	[other transcription factor binding sites]	0.0	5	1	1	1
143242	1710	mechanism in T lymphocyte	[mechanism in T lymphocytes]	0.0	4	1	1	1
143243	1710	reveal a unexpected redundancy	[revealing an unexpected redundancy.]	0.0	4	1	1	1
143244	1710	encode the domain of the receptor	[encoding the domain of the receptor]	0.0	6	1	1	1
143245	1710	tissue specific regulation	[Tissue specific regulation]	0.0	3	1	1	1
143246	1710	suppress the tyrosine phosphorylation	[suppressing the tyrosine phosphorylation]	0.0	4	1	1	1
143247	1710	other lineage	[other lineages]	0.0	2	1	1	1
143248	1710	helix-loop-helix protein e2a	[helix-loop-helix proteins E2A]	0.0	3	1	1	1
143249	1710	early gene of cytomegalovirus CMV	[early genes of cytomegalovirus CMV]	0.0	5	1	1	1
143250	1710	chemotactic migration ChtM of leukocyte	[chemotactic migration ChtM of leukocytes]	0.0	5	1	1	1
143251	1710	minority of LYSP100 dot	[minority of LYSP100 dots]	0.0	4	1	1	1
143252	1710	problem in vectors,	[problems in vectors,]	0.0	3	1	1	1
143253	1710	down-regulation of caii transcription	[down-regulation of CAII transcription]	0.0	4	1	1	1
143254	1710	okadaic ser /thr phosphatase	[okadaic Ser /Thr phosphatases]	0.0	4	1	1	1
143255	1710	promoter-beta-galactosidase	[promoter-beta-galactosidase]	0.0	1	1	1	1
143256	1710	eosinophil in patient	[eosinophils in patients]	0.0	3	1	1	1
143257	1710	mutation of Leu122	[mutation of Leu122]	0.0	3	1	1	1
143258	1710	evaluation of clinical evidence	[evaluation of clinical evidence]	0.0	4	1	1	1
143259	1710	decrease in steady state kappa	[decrease in steady state kappa]	0.0	5	1	1	1
143260	1710	human mm cell line	[human MM cell lines]	0.0	4	1	1	1
143261	1710	bipolar disorder euthymic,	[bipolar disorder euthymic,]	0.0	3	1	1	1
143262	1710	target for e2f-1/dp1	[target for E2F-1/DP1]	0.0	3	1	1	1
143263	1710	advanced renal failure	[advanced renal failure]	0.0	3	1	1	1
143264	1710	measure decay	[measuring decay]	0.0	2	1	1	1
143265	1710	binding of multiple factor	[binding of multiple factors]	0.0	4	1	1	1
143266	1710	ebv gastric carcinoma tissue	[EBV gastric carcinoma tissues]	0.0	4	1	1	1
143267	1710	hygromycin resistance	[hygromycin resistance]	0.0	2	1	1	1
143268	1710	molecular effect	[molecular effects]	0.0	2	1	1	1
143269	1710	microg/ml)/mn2+ microM)	[microg/ml)/Mn2+ microM)]	0.0	2	1	1	1
143270	1710	development of treatment for disease	[development of treatments for diseases]	0.0	5	1	1	1
143271	1710	herpes simplex virus lesion	[herpes simplex virus lesion]	0.0	4	1	1	1
143272	1710	efficient rescue	[Efficient rescue]	0.0	2	1	1	1
143273	1710	glucocorticoid receptor on leukocyte MNL	[glucocorticoid receptors on leukocytes MNL]	0.0	5	1	1	1
143274	1710	suggest responsible for the activity	[suggesting responsible for the activities]	0.0	5	1	1	1
143275	1710	use centromere probe for chromosome	[using centromere probes for chromosomes]	0.0	5	1	1	1
143276	1710	expression of vcam-1 in huvec	[expression of VCAM-1 in HUVEC]	0.0	5	1	1	1
143277	1710	haematopoietic cell in model	[haematopoietic cells in models]	0.0	4	1	1	1
143278	1710	immune factor	[immune factors]	0.0	2	1	1	1
143279	1710	interstitial collagenase mmp-1	[Interstitial collagenase MMP-1]	0.0	3	1	1	1
143280	1710	2 transcription in murine lymphocyte	[2 transcription in murine lymphocytes]	0.0	5	1	1	1
143281	1710	early protein and/or	[early proteins and/or]	0.0	3	1	1	1
143282	1710	gamma-ifn responsive gene monocyte	[gamma-IFN responsive genes monocytes]	0.0	4	1	1	1
143283	1710	LTR construct	[LTR constructs]	0.0	2	1	1	1
143284	1710	class RB tumor line	[class RB tumor lines]	0.0	4	1	1	1
143285	1710	upstream of a promoter	[upstream of a promoter]	0.0	4	1	1	1
143286	1710	exposure to Epo	[exposure to Epo]	0.0	3	1	1	1
143287	1710	HIV glycoprotein	[HIV glycoprotein]	0.0	2	1	1	1
143288	1710	activation of human monocytic cell	[Activation of human monocytic cells]	0.0	5	1	1	1
143289	1710	differential activation of member	[differential activation of members]	0.0	4	1	1	1
143290	1710	express the il-10r	[expressing the IL-10R]	0.0	3	1	1	1
143291	1710	biomarker between the risk	[biomarkers between the risk]	0.0	4	1	1	1
143292	1710	RAR x receptor receptor	[RAR X receptor receptors]	0.0	4	1	1	1
143293	1710	immunodeficiency virus type negative factor Nef	[immunodeficiency virus type negative factor Nef]	0.0	6	1	1	1
143294	1710	dna- formation	[DNA- formation]	0.0	2	1	1	1
143295	1710	annexin V .0001 for auc	[annexin V .0001 for AUC]	0.0	5	1	1	1
143296	1710	(12d:12l;	[(12D:12L;]	0.0	1	1	1	1
143297	1710	change in the affinity	[change in the affinity]	0.0	4	1	1	1
143298	1710	class complex gene	[class complex genes]	0.0	3	1	1	1
143299	1710	characterization of element	[characterization of elements]	0.0	3	1	1	1
143300	1710	chronic hepatitis b patient	[chronic hepatitis B patients]	0.0	4	1	1	1
143301	1710	interaction with two dna-binding protein	[interaction with two DNA-binding proteins]	0.0	5	1	1	1
143302	1710	language.	[language.]	0.0	1	1	1	1
143303	1710	on/off switch of transactivator	[on/off switches of transactivators]	0.0	4	1	1	1
143304	1710	binding-protein pebp2	[binding-protein PEBP2]	0.0	2	1	1	1
143305	1710	switch -to adult (beta)-globin expression	[switch -to adult (beta)-globin expression]	0.0	5	1	1	1
143306	1710	blood pressure monitor Finapres	[blood pressure monitor Finapres]	0.0	4	1	1	1
143307	1710	viability blue exclusion	[viability blue exclusion]	0.0	3	1	1	1
143308	1710	expression of factor kappab nf-kappab	[expression of factor kappaB NF-kappaB]	0.0	5	1	1	1
143309	1710	free calcium level	[free calcium levels]	0.0	3	1	1	1
143310	1710	type 1 interferon	[type 1 interferon]	0.0	3	1	1	1
143311	1710	18 patient with myeloid leukaemia	[18 patients with myeloid leukaemia]	0.0	5	1	1	1
143312	1710	establish the cross-specy effectiveness of ciita	[establishing the cross-species effectiveness of CIITA]	0.0	6	1	1	1
143313	1710	untransformed receptor complex in cytosol	[untransformed receptor complexes in cytosol]	0.0	5	1	1	1
143314	1710	Monoallelic expression of Pax5	[Monoallelic expression of Pax5]	0.0	4	1	1	1
143315	1710	cysteine supply	[cysteine supply]	0.0	2	2	2	1
143316	1710	t-cell lymphotrophic virus type-i tax gene	[T-cell lymphotrophic virus type-I tax gene]	0.0	6	1	1	1
143317	1710	tyrosine phosphorylation a component	[tyrosine phosphorylation a component]	0.0	4	1	1	1
143318	1710	three erp -related transcript	[three ERP -related transcripts]	0.0	4	1	1	1
143319	1710	utility for a good definition	[utility for a better definition]	0.0	5	1	1	1
143320	1710	lymphoblastic leukemia chimera	[lymphoblastic leukemia chimera]	0.0	3	1	1	1
143321	1710	roi- pathway in cell	[ROI- pathway in cells]	0.0	4	1	1	1
143322	1710	girl with feature indistinguishable	[girl with features indistinguishable]	0.0	4	1	1	1
143323	1710	normal wound healing,	[normal wound healing,]	0.0	3	1	1	1
143324	1710	induction during restimulation	[induction during restimulation]	0.0	3	1	1	1
143325	1710	lipid-soluble, chain-breaking antioxidant hydroxyanisole	[lipid-soluble, chain-breaking antioxidants hydroxyanisole]	0.0	4	1	1	1
143326	1710	Negative regulation expression in monocytes: role	[Negative regulation expression in monocytes: role]	0.0	6	1	1	1
143327	1710	importantly, constitutive expression	[Importantly, constitutive expression]	0.0	3	1	1	1
143328	1710	variation in GR	[variations in GR]	0.0	3	1	1	1
143329	1710	express human alphaiibbeta3	[expressing human alphaIIbbeta3]	0.0	3	1	1	1
143330	1710	define the tyrosine kinase	[defining the tyrosine kinases]	0.0	4	1	1	1
143331	1710	cDNA encoding full-length c/ebp-epsilon	[cDNA encoding full-length C/EBP-epsilon]	0.0	4	1	1	1
143332	1710	responsiveness of il-10 binding	[responsiveness of IL-10 binding]	0.0	4	1	1	1
143333	1710	MHC class antigen	[MHC class antigens]	0.0	3	1	1	1
143334	1710	difference in transcription factor recruitment	[differences in transcription factor recruitment]	0.0	5	1	1	1
143335	1710	key regulator of human blood T	[key regulators of human blood T]	0.0	6	1	1	1
143336	1710	inhibitor of cyclin-dependent-kinase-	[inhibitor of cyclin-dependent-kinase-]	0.0	3	1	1	1
143337	1710	patient with disorder (52 euthymic,	[patients with disorder (52 euthymic,]	0.0	5	1	1	1
143338	1710	response in human leukocyte	[response in human leukocytes]	0.0	4	1	1	1
143339	1710	control obese: 31.90	[controls obese: 31.90]	0.0	3	1	1	1
143340	1710	1311-base pair tumor necrosis factor	[1311-base pair tumor necrosis factor]	0.0	5	1	1	1
143341	1710	135(oh)2d3 -dependent modulation	[1,25(OH)2D3 -dependent modulation]	0.0	3	1	1	1
143342	1710	recent information about the mechanism	[recent information about the mechanisms]	0.0	5	1	1	1
143343	1710	lymphocyte-specific member of the factor	[lymphocyte-specific member of the factor]	0.0	5	1	1	1
143344	1710	prl induction time course,	[PRL induction time course,]	0.0	4	1	1	1
143345	1710	only in a small percentage	[only in a small percentage]	0.0	5	1	1	1
143346	1710	human t-lymphocyte transformation	[human T-lymphocyte transformation]	0.0	3	1	1	1
143347	1710	nfat component	[NFAT component]	0.0	2	1	1	1
143348	1710	underlying difference	[underlying difference]	0.0	2	1	1	1
143349	1710	day in 5% human serum	[days in 5% human serum]	0.0	5	1	1	1
143350	1710	treatment of cytokine-mediated disease	[treatment of cytokine-mediated diseases]	0.0	4	1	1	1
143351	1710	caprine arthritis-encephalitis virus long repeat	[caprine arthritis-encephalitis virus long repeat]	0.0	5	1	1	1
143352	1710	flavonoid on IkappaB kinase IKK	[flavonoids on IkappaB kinase IKK]	0.0	5	1	1	1
143353	1710	germline TaqI restriction	[germline TaqI restriction]	0.0	3	1	1	1
143354	1710	p27kip1 gene from DNA	[p27Kip1 gene from DNA]	0.0	4	1	1	1
143355	1710	level expression of the IL3	[level expression of the IL3]	0.0	5	1	1	1
143356	1710	protein kinase calpha	[protein kinase Calpha]	0.0	3	1	1	1
143357	1710	prostatic epithelial cell	[prostatic epithelial cells]	0.0	3	1	1	1
143358	1710	IL-2 growth in T cell	[IL-2 growth in T cells]	0.0	5	1	1	1
143359	1710	include that encode	[including those encoding]	0.0	3	1	1	1
143360	1710	leukocyte of patient with pseudohypoaldosteronism	[leukocytes of patients with pseudohypoaldosteronism]	0.0	5	1	1	1
143361	1710	IkappaB alpha a cytoplasmic inhibitor	[IkappaB alpha a cytoplasmic inhibitor]	0.0	5	1	1	1
143362	1710	overexpression in the 206 risk woman	[overexpression in the 206 risk women]	0.0	6	1	1	1
143363	1710	NFATx NFATx1	[NFATx NFATx1]	0.0	2	1	1	1
143364	1710	(Jurkat) t-cell line	[(Jurkat) T-cell lines]	0.0	3	1	1	1
143365	1710	mobility shift analysis utilize oligonucleotide homologous	[mobility shift analyses utilizing oligonucleotides homologous]	0.0	6	1	1	1
143366	1710	nearby polymorphism	[nearby polymorphisms]	0.0	2	1	1	1
143367	1710	h. induce CAT activity fibrinogen	[h, inducing CAT activity fibrinogen]	0.0	5	1	1	1
143368	1710	rapid tyrosine phosphorylation of cellular protein	[rapid tyrosine phosphorylation of cellular proteins]	0.0	6	1	1	1
143369	1710	adhesion of cell vein endothelial cell	[adhesion of cells vein endothelial cells]	0.0	6	1	1	1
143370	1710	pathogenesis of chronic disease	[pathogenesis of chronic diseases]	0.0	4	1	1	1
143371	1710	effect on b cell membrane protein	[effects on B cell membrane proteins]	0.0	6	1	1	1
143372	1710	Tax1 transcriptional pathway	[Tax1 transcriptional pathway]	0.0	3	1	1	1
143373	1710	start at concentration of mol/L	[starting at concentrations of mol/L]	0.0	5	1	1	1
143374	1710	candidate gene for ags factor beta	[candidate genes for AGS factor beta]	0.0	6	1	1	1
143375	1710	EBNA-LP	[EBNA-LP]	0.0	1	1	1	1
143376	1710	receptor complex in cytosol	[receptor complexes in cytosol]	0.0	4	1	1	1
143377	1710	encode several member	[encoding several members]	0.0	3	1	1	1
143378	1710	closely mimick in vivo migration	[closely mimicking in vivo migration]	0.0	5	1	1	1
143379	1710	(i) patient with CLL	[(i) patients with CLL]	0.0	4	1	1	1
143380	1710	compound zk161422	[compounds ZK161422]	0.0	2	1	1	1
143381	1710	ambiguity	[ambiguities]	0.0	1	1	1	1
143382	1710	express nf-kappa b	[expressing NF-kappa B]	0.0	3	1	1	1
143383	1710	cytosolic inhibitor IkappaBalpha	[cytosolic inhibitor IkappaBalpha]	0.0	3	1	1	1
143384	1710	senescence in vitro	[senescence in vitro]	0.0	3	1	1	1
143385	1710	nf-kappa b p65 mrna accumulation	[NF-kappa B p65 mRNA accumulation]	0.0	5	1	1	1
143386	1710	regulation by gene	[Regulation by gene]	0.0	3	1	1	1
143387	1710	genes, loss	[genes, loss]	0.0	2	1	1	1
143388	1710	key role in T	[key role in T]	0.0	4	1	1	1
143389	1710	receptor tcr	[receptor TCR]	0.0	2	1	1	1
143390	1710	evidence for theory	[evidence for theories]	0.0	3	1	1	1
143391	1710	more indirect, alteration	[more indirect, alteration]	0.0	3	1	1	1
143392	1710	unknown factor for maximal activity	[unknown factors for maximal activity]	0.0	5	1	1	1
143393	1710	approximate location	[approximate locations]	0.0	2	1	1	1
143394	1710	promoter largely dependent	[promoter largely dependent]	0.0	3	1	1	1
143395	1710	active mutant of shp1	[active mutants of SHP1]	0.0	4	1	1	1
143396	1710	defect in t-cell signal	[defects in T-cell signaling]	0.0	4	1	1	1
143397	1710	finding a characteristic of breast cancer	[findings a characteristic of breast cancer]	0.0	6	1	1	1
143398	1710	decrease in level	[decrease in levels]	0.0	3	1	1	1
143399	1710	interleukin-12 IL-12 a signal	[interleukin-12 IL-12 a signal]	0.0	4	1	1	1
143400	1710	5-day m phi ingestion	[5-day M phi ingestion]	0.0	4	1	1	1
143401	1710	beta-estradiol on NK cell activity	[beta-estradiol on NK cell activity]	0.0	5	1	1	1
143402	1710	inhibitory effect on the expression	[inhibitory effects on the expression]	0.0	5	1	1	1
143403	1710	organizational pattern of element	[organizational pattern of elements]	0.0	4	1	1	1
143404	1710	Ter 119 cell from mouse	[Ter 119 cells from mice]	0.0	5	1	1	1
143405	1710	role for gata-2	[role for GATA-2]	0.0	3	1	1	1
143406	1710	7.03 (range, 5.66-10)	[7.03 (range, 5.66-10),]	0.0	3	1	1	1
143407	1710	Retroviral transduction	[Retroviral transduction]	0.0	2	1	1	1
143408	1710	2) sign	[2) signs]	0.0	2	1	1	1
143409	1710	leukocyte protein of 76 kilodaltons),	[leukocyte protein of 76 kilodaltons),]	0.0	5	1	1	1
143410	1710	only the kda form	[only the kDa form]	0.0	4	1	1	1
143411	1710	output of lmp signal	[output of LMP signaling]	0.0	4	1	1	1
143412	1710	analysis of NF-AT mouse	[analysis of NF-AT mice]	0.0	4	1	1	1
143413	1710	structure of BSAP	[structure of BSAP]	0.0	3	1	1	1
143414	1710	cytoplasmic precursor isgf3 alpha	[cytoplasmic precursors ISGF3 alpha]	0.0	4	1	1	1
143415	1710	fc gamma RIC	[Fc gamma RIC]	0.0	3	1	1	1
143416	1710	transcription factor usf1	[Transcription factors USF1]	0.0	3	1	1	1
143417	1710	interaction between b coactivator	[interactions between B coactivators]	0.0	4	1	1	1
143418	1710	ap2 binding site	[AP2 binding sites]	0.0	3	1	1	1
143419	1710	morning glucocorticoid receptor	[morning glucocorticoid receptors]	0.0	3	1	1	1
143420	1710	Recent development of primary culture	[Recent development of primary cultures]	0.0	5	1	1	1
143421	1710	cortisol excretion before treatment	[cortisol excretion before treatment]	0.0	4	1	1	1
143422	1710	monocyte phenotype	[monocyte phenotype]	0.0	2	1	1	1
143423	1710	implication of signal in leukemic cell	[implications of signals in leukemic cells]	0.0	6	1	1	1
143424	1710	two deletion	[Two deletions]	0.0	2	1	1	1
143425	1710	spleen focus	[spleen focus]	0.0	2	1	1	1
143426	1710	increase in apoptosis	[increase in apoptosis]	0.0	3	1	1	1
143427	1710	analysis LTR	[analyses LTR]	0.0	2	1	1	1
143428	1710	frequency of brca2 mutation	[frequency of BRCA2 mutations]	0.0	4	1	1	1
143429	1710	order of magnitude less potent	[orders of magnitude less potent]	0.0	5	1	1	1
143430	1710	proximal signal event	[proximal signaling events]	0.0	3	1	1	1
143431	1710	beta-Catenin	[beta-Catenin]	0.0	1	1	1	1
143432	1710	decrease in potency	[decrease in potency]	0.0	3	1	1	1
143433	1710	electrolyte from aldosterone	[electrolytes from aldosterone]	0.0	3	1	1	1
143434	1710	localize	[localizing]	0.0	1	1	1	1
143435	1710	loci on the proximal arm	[loci on the proximal arm]	0.0	5	1	1	1
143436	1710	Jurkat a t-cell line	[Jurkat a T-cell line]	0.0	4	1	1	1
143437	1710	much the protein.	[much the protein.]	0.0	3	1	1	1
143438	1710	translocation independent	[translocation independent]	0.0	2	1	1	1
143439	1710	increase in nf-y binding activity	[increase in NF-Y binding activity]	0.0	5	1	1	1
143440	1710	spectrum include stem cell	[spectrum including stem cells]	0.0	4	1	1	1
143441	1710	operate in t-cell	[operating in T-cells]	0.0	3	1	1	1
143442	1710	blot analysis of human genomic DNA	[blot analysis of human genomic DNA]	0.0	6	1	1	1
143443	1710	outcome in ovarian carcinoma	[outcome in ovarian carcinoma]	0.0	4	1	1	1
143444	1710	role of SCL	[role of SCL]	0.0	3	1	1	1
143445	1710	transglutaminase	[transglutaminase]	0.0	1	1	1	1
143446	1710	role of Ras	[role of Ras]	0.0	3	1	1	1
143447	1710	report of change	[reports of changes]	0.0	3	1	1	1
143448	1710	SCM-1-producer	[SCM-1-producer]	0.0	1	1	1	1
143449	1710	receptor for 1,25 Dihydroxyvitamin D3	[receptors for 1,25 Dihydroxyvitamin D3]	0.0	5	1	1	1
143450	1710	role of EGR1	[Role of EGR1]	0.0	3	1	1	1
143451	1710	anoxia/reoxygenation-induced adherence to cell	[anoxia/reoxygenation-induced adherence to cells]	0.0	4	1	1	1
143452	1710	domain analysis	[domain analysis]	0.0	2	1	1	1
143453	1710	comprise a single-chain ab fragment	[comprising an single-chain Ab fragment]	0.0	5	1	1	1
143454	1710	subsequent synthesis	[subsequent synthesis]	0.0	2	1	1	1
143455	1710	lymphoma, diffuse, cell" type	[lymphoma, diffuse, cell" type]	0.0	4	1	1	1
143456	1710	POZ/Zinc finger	[POZ/Zinc finger]	0.0	2	1	1	1
143457	1710	nuclear factor-kappaB inhibitor IkappaB-alphaS32/36A	[nuclear factor-kappaB inhibitor IkappaB-alphaS32/36A]	0.0	4	1	1	1
143458	1710	A-CRF with mild-moderate insufficiency	[A-CRF with mild-moderate insufficiency]	0.0	4	1	1	1
143459	1710	Interleukin-3 expression	[Interleukin-3 expression]	0.0	2	1	1	1
143460	1710	significant decline	[significant decline]	0.0	2	1	1	1
143461	1710	cd45r0 cd4+ T	[CD45R0 CD4+ T]	0.0	3	1	1	1
143462	1710	cyclase signal transduction cascade	[cyclase signal transduction cascade]	0.0	4	1	1	1
143463	1710	toll signal	[toll signaling]	0.0	2	1	1	1
143464	1710	factor STAT-1 p91	[factor STAT-1 p91]	0.0	3	1	1	1
143465	1710	pkc linkage	[PKC linkage]	0.0	2	1	1	1
143466	1710	factor-chi b	[factor-chi B]	0.0	2	1	1	1
143467	1710	125d3 variant of hl60 cell	[1,25D3 variants of HL60 cells]	0.0	5	1	1	1
143468	1710	parallel the normal diurnal decline	[paralleling the normal diurnal decline]	0.0	5	1	1	1
143469	1710	blood volunteer man	[blood volunteers men]	0.0	3	1	1	1
143470	1710	correlation between serum testosterone concentration	[correlation between serum testosterone concentrations]	0.0	5	1	1	1
143471	1710	27 SLE patient	[27 SLE patients]	0.0	3	1	1	1
143472	1710	inhibitor of hiv-1 iiib replication	[inhibitors of HIV-1 IIIB replication]	0.0	5	1	1	1
143473	1710	induction of c-fo	[induction of c-fos]	0.0	3	1	1	1
143474	1710	presence factor	[presence factor]	0.0	2	1	1	1
143475	1710	appear after the induction of differentiation	[appearing after the induction of differentiation]	0.0	6	1	1	1
143476	1710	high-level replication isolate	[high-level replication isolate]	0.0	3	1	1	1
143477	1710	right mass	[right mass]	0.0	2	1	1	1
143478	1710	cd56 neural cell adhesion molecule	[CD56 neural cell adhesion molecule]	0.0	5	1	1	1
143479	1710	interaction with vein endothelial cell	[interaction with vein endothelial cells]	0.0	5	1	1	1
143480	1710	down-regulation of erythroid gene	[down-regulation of erythroid genes]	0.0	4	1	1	1
143481	1710	cell from other neotropical primate	[cells from other neotropical primates]	0.0	5	1	1	1
143482	1710	regulator of human monocyte/macrophage function	[regulator of human monocyte/macrophage function]	0.0	5	1	1	1
143483	1710	"nonresponsive" clone	["nonresponsive" clones]	0.0	2	1	1	1
143484	1710	continuous nf-kappa b p50/p65	[continuous NF-kappa B p50/p65]	0.0	4	1	1	1
143485	1710	effect in term of inhibition	[effects in terms of inhibition]	0.0	5	1	1	1
143486	1710	contrast, phosphatidic acid accumulation	[contrast, phosphatidic acid accumulation]	0.0	4	1	1	1
143487	1710	gene include interferon regulatory factor	[genes including interferon regulatory factor]	0.0	5	1	1	1
143488	1710	nfat activator protein-1	[NFAT activator protein-1]	0.0	3	1	1	1
143489	1710	binding site for the glucocorticoid	[binding sites for the glucocorticoids]	0.0	5	1	1	1
143490	1710	involvement of transduction pathway	[Involvement of transduction pathways]	0.0	4	1	1	1
143491	1710	various signal converge in common pathway	[Various signals converging in common pathways]	0.0	6	1	1	1
143492	1710	increase in DNA	[increase in DNA]	0.0	3	1	1	1
143493	1710	mechanism than ligand	[mechanisms than ligand]	0.0	3	1	1	1
143494	1710	0.82 unit	[0.82 units]	0.0	2	1	1	1
143495	1710	differential b gene expression	[differential B gene expression]	0.0	4	1	1	1
143496	1710	expression leukocyte protein	[expression leukocyte protein]	0.0	3	1	1	1
143497	1710	pbmc respond	[PBMC responding]	0.0	2	1	1	1
143498	1710	CD4 promoter mutant	[CD4 promoter mutants]	0.0	3	1	1	1
143499	1710	emit	[emitting]	0.0	1	1	1	1
143500	1710	cellular factors,	[cellular factors,]	0.0	2	1	1	1
143501	1710	[an overexpression	[[An overexpression]	0.0	2	1	1	1
143502	1710	murine fdcp-mix a4 cell	[murine FDCP-mix A4 cells]	0.0	4	1	1	1
143503	1710	gamma-ifn responsive gene	[gamma-IFN responsive genes]	0.0	3	1	1	1
143504	1710	anti-VLA-5 fibronectin receptor	[anti-VLA-5 fibronectin receptor]	0.0	3	1	1	1
143505	1710	two isoform of the element modulator	[two isoforms of the element modulator]	0.0	6	1	1	1
143506	1710	effect on some differentiation marker	[effect on some differentiation markers]	0.0	5	1	1	1
143507	1710	JCam cell with lck	[JCam cells with Lck]	0.0	4	1	1	1
143508	1710	man with gynecomastia	[men with gynecomastia]	0.0	3	1	1	1
143509	1710	cell of hemopoietic system	[cells of hemopoietic systems]	0.0	4	1	1	1
143510	1710	mediator of interaction	[mediators of interactions]	0.0	3	1	1	1
143511	1710	expression of CD38 antigen	[expression of CD38 antigen]	0.0	4	1	1	1
143512	1710	type of myeloid leukemia blast cell	[types of myeloid leukemia blast cells]	0.0	6	1	1	1
143513	1710	protein inhibitor	[protein inhibitor]	0.0	2	1	1	1
143514	1710	predominant expression of heterodimer	[predominant expression of heterodimers]	0.0	4	1	1	1
143515	1710	presence in the preparation,	[presence in the preparation,]	0.0	4	1	1	1
143516	1710	gp160 with soluble cd4-igg	[gp160 with soluble CD4-IgG]	0.0	4	1	1	1
143517	1710	role of Sp1	[role of Sp1]	0.0	3	1	1	1
143518	1710	single site for ebf sequence	[single sites for EBF sequences]	0.0	5	1	1	1
143519	1710	replication immunodeficiency virus	[Replication immunodeficiency viruses]	0.0	3	1	1	1
143520	1710	blood cell receptor	[Blood cell receptors]	0.0	3	1	1	1
143521	1710	airway cell of glucocorticoid asthma	[airway cells of glucocorticoid asthma]	0.0	5	1	1	1
143522	1710	interaction with the element	[interaction with the element]	0.0	4	1	1	1
143523	1710	efficient transcription of immunodeficiency virus	[Efficient transcription of immunodeficiency virus]	0.0	5	1	1	1
143524	1710	high (66 millileter at P;	[high (66 ml at h;]	0.0	5	1	1	1
143525	1710	underlie such phenomena.	[underlying such phenomena.]	0.0	3	1	1	1
143526	1710	dominant mouse	[dominant mice]	0.0	2	1	1	1
143527	1710	salt concentration 1 mM edta	[salt concentrations 1 mM EDTA]	0.0	5	1	1	1
143528	1710	retention of 1600 VDR	[retention of 1600 VDR]	0.0	4	1	1	1
143529	1710	response include adhesion-dependent pathway	[responses including adhesion-dependent pathways]	0.0	4	1	1	1
143530	1710	hyperresponsiveness	[hyperresponsiveness]	0.0	1	1	1	1
143531	1710	also rapid effect on electrolyte movement	[also rapid effects on electrolyte movements]	0.0	6	1	1	1
143532	1710	covariant analysis take change	[covariant analysis taking changes]	0.0	4	1	1	1
143533	1710	enhanced,	[enhanced,]	0.0	1	1	1	1
143534	1710	mol/L for budesonide	[mol/L for budesonide]	0.0	3	2	2	1
143535	1710	TNFR factor TRAF1	[TNFR factors TRAF1]	0.0	3	1	1	1
143536	1710	three category of factor factor	[three categories of factors factors]	0.0	5	1	1	1
143537	1710	RA concentration	[RA concentrations]	0.0	2	1	1	1
143538	1710	mammary cell grow in culture	[mammary cells growing in culture]	0.0	5	1	1	1
143539	1710	49 healthy subject (62-97 yr)	[49 healthy subjects (62-97 yr)]	0.0	5	1	1	1
143540	1710	distribution evidence	[distribution evidence]	0.0	2	1	1	1
143541	1710	network operate	[network operating]	0.0	2	1	1	1
143542	1710	META(D+) transcription	[META(D+) transcription]	0.0	2	1	1	1
143543	1710	activation upon interleukin-5 stimulation	[activation upon interleukin-5 stimulation]	0.0	4	1	1	1
143544	1710	dose (25 mm)	[dose (25 mM)]	0.0	3	1	1	1
143545	1710	blood monocyte bm	[blood monocytes BM]	0.0	3	1	1	1
143546	1710	-induced, cell-T-cell syncytia	[-induced, cell-T-cell syncytia]	0.0	3	1	1	1
143547	1710	contrast IL-12 IFN -alpha-inducible gene	[contrasting IL-12 IFN -alpha-inducible genes]	0.0	5	1	1	1
143548	1710	21-bp repeat	[21-bp repeats]	0.0	2	1	1	1
143549	1710	cell of multinuclearity	[cells of multinuclearity]	0.0	3	1	1	1
143550	1710	baby rat	[baby rat]	0.0	2	1	1	1
143551	1710	cell with antibody (mab)	[cells with antibody (MAb)]	0.0	4	1	1	1
143552	1710	ZEBRA -responsive promoter	[ZEBRA -responsive promoters]	0.0	3	1	1	1
143553	1710	fasL mrna in HeLa cell	[fasL mRNA in HeLa cells]	0.0	5	1	1	1
143554	1710	potential inhibition by acetylsalicylate	[potential inhibition by acetylsalicylate]	0.0	4	1	1	1
143555	1710	express a lacz reporter gene	[expressing a lacZ reporter gene]	0.0	5	1	1	1
143556	1710	determinant of the strength	[determinant of the strength]	0.0	4	1	1	1
143557	1710	colony development	[colony development]	0.0	2	1	1	1
143558	1710	several compound	[Several compounds]	0.0	2	1	1	1
143559	1710	capacity of receptor	[capacity of receptor]	0.0	3	1	1	1
143560	1710	segregate the Chr	[segregating the Chr]	0.0	3	1	1	1
143561	1710	receptor messenger	[receptor messenger]	0.0	2	1	1	1
143562	1710	palmitate conjugate	[palmitate conjugate]	0.0	2	1	1	1
143563	1710	expression with lipopolysaccharide production	[expression with lipopolysaccharide production]	0.0	4	1	1	1
143564	1710	level of viral transcription transcription	[levels of viral transcription transcription]	0.0	5	1	1	1
143565	1710	classical hd case	[classical HD cases]	0.0	3	1	1	1
143566	1710	moderate grade before radiotherapy	[moderate grades before radiotherapy]	0.0	4	1	1	1
143567	1710	kinase in monocyte	[kinase in monocytes]	0.0	3	1	1	1
143568	1710	enhancer-blocking element block element alpha/delta	[enhancer-blocking element blocking element alpha/delta]	0.0	5	1	1	1
143569	1710	t-cell activation response element	[T-cell activation response element]	0.0	4	1	1	1
143570	1710	only a effect.	[only a effect.]	0.0	3	2	2	1
143571	1710	carboxyterminal region	[carboxyterminal region]	0.0	2	1	1	1
143572	1710	platelet-activating factor receptor pafr gene	[platelet-activating factor receptor PAFR gene]	0.0	5	1	1	1
143573	1710	dexamethasone DEX a glucocorticoid	[dexamethasone DEX a glucocorticoid]	0.0	4	1	1	1
143574	1710	Palombella (Palombella,	[Palombella (Palombella,]	0.0	2	1	1	1
143575	1710	repetitive stretch of c-terminus	[repetitive stretch of C-terminus]	0.0	4	1	1	1
143576	1710	role of receptor/ gr characteristic	[role of receptor/s GR characteristics]	0.0	5	1	1	1
143577	1710	several microbial agonist	[several microbial agonists]	0.0	3	1	1	1
143578	1710	hormone datum	[hormone data]	0.0	2	1	1	1
143579	1710	b target gene	[B target genes]	0.0	3	1	1	1
143580	1710	much less extent	[much lesser extent]	0.0	3	1	1	1
143581	1710	strand conformation polymorphism analysis application	[strand conformation polymorphism analysis application]	0.0	5	1	1	1
143582	1710	culture of leukemia cell	[culture of leukemia cells]	0.0	4	1	1	1
143583	1710	limitation to effect	[limitation to effects]	0.0	3	1	1	1
143584	1710	cd4+ cell count (p 0.05)	[CD4+ cell counts (P 0.05)]	0.0	5	1	1	1
143585	1710	such as the gene	[such as the genes]	0.0	4	1	1	1
143586	1710	expression of gene encode protein	[expression of genes encoding proteins]	0.0	5	1	1	1
143587	1710	Jeg-3 human immunosuppression	[Jeg-3 human immunosuppression]	0.0	3	1	1	1
143588	1710	analysis of viral replication	[analysis of viral replication]	0.0	4	1	1	1
143589	1710	understanding of differentiation	[understanding of differentiation]	0.0	3	1	1	1
143590	1710	role for IL-7	[role for IL-7]	0.0	3	1	1	1
143591	1710	role for IL-6	[role for IL-6]	0.0	3	1	1	1
143592	1710	transcription factor in disease	[Transcription factors in disease]	0.0	4	1	1	1
143593	1710	regulator of the cycle	[regulators of the cycle]	0.0	4	1	1	1
143594	1710	number of other neoplasm	[number of other neoplasms]	0.0	4	1	1	1
143595	1710	MHC class gene transcription	[MHC class gene transcription]	0.0	4	1	1	1
143596	1710	stat4 in lymphocyte	[STAT4 in lymphocytes]	0.0	3	1	1	1
143597	1710	exclude other targets,	[excluding other targets,]	0.0	3	1	1	1
143598	1710	several steroid	[Several steroids]	0.0	2	1	1	1
143599	1710	withdrawal drug.	[withdrawal drug.]	0.0	2	1	1	1
143600	1710	deficiency in precursor cell	[deficiencies in precursor cells]	0.0	4	1	1	1
143601	1710	property of natural killer	[properties of natural killer]	0.0	4	1	1	1
143602	1710	present with renal salt loss	[presenting with renal salt loss]	0.0	5	1	1	1
143603	1710	spleen, of the animals.	[spleen, of the animals.]	0.0	4	1	1	1
143604	1710	Cooperation with a erythropoietin receptor	[Cooperation with an erythropoietin receptor]	0.0	5	1	1	1
143605	1710	G1/S phase control and/or	[G1/S phase control and/or]	0.0	4	1	1	1
143606	1710	region of low base stem-loop potential	[Regions of low base stem-loop potential]	0.0	6	1	1	1
143607	1710	mechanism for this effect	[mechanisms for these effects]	0.0	4	1	1	1
143608	1710	il-12/10(6) cell per millileter	[IL-12/10(6) cells per ml]	0.0	4	1	1	1
143609	1710	cell-specific nuclear factor in vivo	[cell-specific nuclear factor in vivo]	0.0	5	1	1	1
143610	1710	down-regulation of receptor	[down-regulation of receptors]	0.0	3	1	1	1
143611	1710	10(-10) mol/L 9-cis RA	[10(-10) mol/L 9-cis RA]	0.0	4	1	1	1
143612	1710	activation by LEF-1	[activation by LEF-1]	0.0	3	1	1	1
143613	1710	differentiate in culture	[differentiating in cultures]	0.0	3	1	1	1
143614	1710	adult murine	[adult murine]	0.0	2	1	1	1
143615	1710	association of glucocorticoid insensitivity	[Association of glucocorticoid insensitivity]	0.0	4	1	1	1
143616	1710	agonist-induced signalling	[agonist-induced signalling]	0.0	2	1	1	1
143617	1710	method of study: Peripheral lymphocyte	[METHOD OF STUDY: Peripheral lymphocytes]	0.0	5	1	1	1
143618	1710	potentially useful drug	[potentially useful drug]	0.0	3	1	1	1
143619	1710	genesis of leukemia CLL	[genesis of leukemia CLL]	0.0	4	1	1	1
143620	1710	p50 subunit nuclear factor	[p50 subunits nuclear factor]	0.0	4	1	1	1
143621	1710	functionally active state	[functionally active state]	0.0	3	1	1	1
143622	1710	use anti-Class antibody	[using anti-Class antibodies]	0.0	3	1	1	1
143623	1710	sign of immune remission	[sign of immune remission]	0.0	4	1	1	1
143624	1710	even after h in culture.	[even after h in culture.]	0.0	5	1	1	1
143625	1710	response in leukocyte of patient	[response in leukocytes of patients]	0.0	5	1	1	1
143626	1710	complementary substitution	[complementary substitution]	0.0	2	1	1	1
143627	1710	addition of antisense oligonucleotide	[addition of antisense oligonucleotides]	0.0	4	1	1	1
143628	1710	unspliced mrna I	[unspliced mRNA I]	0.0	3	1	1	1
143629	1710	primary human erythroid precursor	[primary human erythroid precursors]	0.0	4	2	2	1
143630	1710	treatment of APL patient	[treatment of APL patients]	0.0	4	1	1	1
143631	1710	activity of ligand	[activity of ligands]	0.0	3	1	1	1
143632	1710	ngre	[nGRE]	0.0	1	2	2	1
143633	1710	region/leucine zipper domain	[region/leucine zipper domain]	0.0	3	1	1	1
143634	1710	related hepatocyte nuclear factor	[related hepatocyte nuclear factors]	0.0	4	1	1	1
143635	1710	responder in t-cell response oligopeptide	[responder in T-cell responses oligopeptides]	0.0	5	1	1	1
143636	1710	functional t1/2	[functional t1/2]	0.0	2	1	1	1
143637	1710	potent agonist than G28-5 IgG	[potent agonist than G28-5 IgG]	0.0	5	1	1	1
143638	1710	antibody mib-1	[antibody MIB-1]	0.0	2	1	1	1
143639	1710	Ki-67 antigen	[Ki-67 antigens]	0.0	2	1	1	1
143640	1710	include that encode p105	[including those encoding p105]	0.0	4	1	1	1
143641	1710	rescue by cytokine	[Rescue by cytokines]	0.0	3	1	1	1
143642	1710	regular interval	[regular intervals]	0.0	2	1	1	1
143643	1710	extinction of several b gene	[extinction of several B genes]	0.0	5	1	1	1
143644	1710	down-regulation of cell-specific gene	[down-regulation of cell-specific genes]	0.0	4	1	1	1
143645	1710	first transcription factor	[first transcription factor]	0.0	3	1	1	1
143646	1710	understanding of the activity	[understanding of the activity]	0.0	4	1	1	1
143647	1710	active regulatory event	[active regulatory events]	0.0	3	1	1	1
143648	1710	process essential to a effective response	[processes essential to an effective response]	0.0	6	1	1	1
143649	1710	incorporation of dideoxy atp	[incorporation of dideoxy ATP]	0.0	4	1	1	1
143650	1710	human IL-5	[human IL-5]	0.0	2	1	1	1
143651	1710	include the T cell line	[including the T cell line]	0.0	5	1	1	1
143652	1710	profile, reduce the inflammatory response	[profile, reducing the inflammatory response]	0.0	5	1	1	1
143653	1710	two separate cis-acting element	[two separate cis-acting elements]	0.0	4	1	1	1
143654	1710	gal4-substituted hiv-1 enhancer	[GAL4-substituted HIV-1 enhancer]	0.0	3	1	1	1
143655	1710	chronic state of hyperactivation	[chronic state of hyperactivation]	0.0	4	1	1	1
143656	1710	human class MHC Ag	[Human class MHC Ag]	0.0	4	1	1	1
143657	1710	transcription of lymphokine gene	[transcription of lymphokine genes]	0.0	4	1	1	1
143658	1710	understand the variability	[understanding the variability]	0.0	3	1	1	1
143659	1710	anti-early antigen	[anti-early antigen]	0.0	2	1	1	1
143660	1710	transcriptional activator of the repeat	[transcriptional activator of the repeat]	0.0	5	1	1	1
143661	1710	distinct interference of RU	[distinct interference of RU]	0.0	4	1	1	1
143662	1710	expression a paradigm for the haploinsufficiency	[expression a paradigm for the haploinsufficiency]	0.0	6	1	1	1
143663	1710	kappa b/mad3	[kappa B/MAD3]	0.0	2	1	1	1
143664	1710	transcription coactivator	[transcription coactivator]	0.0	2	1	1	1
143665	1710	wall	[wall]	0.0	1	1	1	1
143666	1710	suggest a regulatory domain	[suggesting a regulatory domain]	0.0	4	1	1	1
143667	1710	(mf) individual	[(MF) individuals]	0.0	2	1	1	1
143668	1710	transcriptase polymerase chain reaction rt-pcr	[transcriptase polymerase chain reaction RT-PCR]	0.0	5	1	1	1
143669	1710	relatively high, concentration to &mgr;m)	[relatively high, concentrations to &mgr;M)]	0.0	5	1	1	1
143670	1710	follow hiv infection of lymphocyte	[following HIV infection of lymphocytes]	0.0	5	1	1	1
143671	1710	new protein factor	[new protein factors]	0.0	3	1	1	1
143672	1710	nephrotoxicity	[nephrotoxicity]	0.0	1	1	1	1
143673	1710	study on pluripotent culture	[studies on pluripotent cultures]	0.0	4	1	1	1
143674	1710	additional screen	[additional screening]	0.0	2	1	1	1
143675	1710	resistance in the squirrel monkey	[resistance in the squirrel monkey]	0.0	5	1	1	1
143676	1710	monocyte-macrophage surface antigen cd14	[monocyte-macrophage surface antigen CD14]	0.0	4	1	1	1
143677	1710	expression, DNA	[expression, DNA]	0.0	2	1	1	1
143678	1710	only one case	[only one case]	0.0	3	1	1	1
143679	1710	deletion of NF-kappa b site	[deletion of NF-kappa B site]	0.0	5	1	1	1
143680	1710	involvement transcription factor	[involvement transcription factor]	0.0	3	1	1	1
143681	1710	significant relatedness	[significant relatedness]	0.0	2	1	1	1
143682	1710	follow irradiation PML/RARalpha mouse	[Following irradiation PML/RARalpha mice]	0.0	4	1	1	1
143683	1710	consecutive sample of blood	[consecutive samples of blood]	0.0	4	1	1	1
143684	1710	contain the vp16 transactivation domain	[containing the VP16 transactivation domains]	0.0	5	1	1	1
143685	1710	IkappaB mutant	[IkappaB mutant]	0.0	2	1	1	1
143686	1710	i-kappabalpha	[I-kappaBalpha]	0.0	1	1	1	1
143687	1710	dna-binding ligand	[DNA-binding ligands]	0.0	2	1	1	1
143688	1710	airway cell after challenge	[airway cells after challenge]	0.0	4	1	1	1
143689	1710	protein-tyrosine kinase regulatory pathway	[protein-tyrosine kinase regulatory pathway]	0.0	4	1	1	1
143690	1710	lymphoid-specific element	[lymphoid-specific element]	0.0	2	1	1	1
143691	1710	harbor the part of the region	[harboring the part of the region]	0.0	6	1	1	1
143692	1710	analogue of 1,25 dihydroxyvitamin D3	[analogues of 1,25 dihydroxyvitamin D3]	0.0	5	1	1	1
143693	1710	one means understand the role	[One means understanding the role]	0.0	5	1	1	1
143694	1710	three other ATL cell line	[Three other ATL cell lines]	0.0	5	1	1	1
143695	1710	sequential use	[sequential use]	0.0	2	1	1	1
143696	1710	loci of the tf.viia complex	[loci of the TF.VIIa complex]	0.0	5	1	1	1
143697	1710	ebv- b cell	[EBV- B cells]	0.0	3	1	1	1
143698	1710	artificial light regime,	[artificial light regime,]	0.0	3	1	1	1
143699	1710	ptk genistein	[PTK genistein]	0.0	2	1	1	1
143700	1710	use a thymic hybridoma	[using a thymic hybridoma]	0.0	4	1	1	1
143701	1710	also (p	[also (P]	0.0	2	1	1	1
143702	1710	bcl-6 function	[BCL-6 function]	0.0	2	1	1	1
143703	1710	active vitamin D3 metabolite 1,25-dihydroxycholecalciferol	[active vitamin D3 metabolite 1,25-dihydroxycholecalciferol]	0.0	5	1	1	1
143704	1710	low to undetectable level	[low to undetectable levels]	0.0	4	1	1	1
143705	1710	cd patient	[CD patients]	0.0	2	1	1	1
143706	1710	dna-binding of e2f	[DNA-binding of E2F]	0.0	3	1	1	1
143707	1710	CD25 promoter	[CD25 promoter]	0.0	2	1	1	1
143708	1710	study with IL-6 promoter	[studies with IL-6 promoter]	0.0	4	1	1	1
143709	1710	transcription factor in cell	[transcription factor in cells]	0.0	4	1	1	1
143710	1710	relb translocation by CD40	[RelB translocation by CD40]	0.0	4	1	1	1
143711	1710	g igg	[G IgG]	0.0	2	1	1	1
143712	1710	nuclear localization contain factor kappab complex	[nuclear localization containing factor kappaB complexes]	0.0	6	1	1	1
143713	1710	activity of NFAT-1	[activity of NFAT-1]	0.0	3	1	1	1
143714	1710	response to all-tran acid atra	[response to all-trans acid ATRA]	0.0	5	1	1	1
143715	1710	migrate b1 complex	[migrating B1 complex]	0.0	3	1	1	1
143716	1710	cyclase (ac) cascade	[cyclase (AC) cascade]	0.0	3	1	1	1
143717	1710	amino acid 1	[amino acids 1]	0.0	3	1	1	1
143718	1710	interaction of nuclear protein	[interactions of nuclear proteins]	0.0	4	1	1	1
143719	1710	manner in	[manner in]	0.0	2	1	1	1
143720	1710	involve the gene	[involving the genes]	0.0	3	1	1	1
143721	1710	endothelial receptor	[endothelial receptor]	0.0	2	1	1	1
143722	1710	immediate regulator of the cycle	[immediate regulators of the cycle]	0.0	5	1	1	1
143723	1710	arbitrary units, p young	[arbitrary units, P young]	0.0	4	1	1	1
143724	1710	mobilization of the transcription factor	[mobilization of the transcription factor]	0.0	5	1	1	1
143725	1710	b transcriptional coactivator	[B transcriptional coactivators]	0.0	3	2	2	1
143726	1710	clinical implication of t3r alteration	[clinical implications of T3R alterations]	0.0	5	1	1	1
143727	1710	Caspase-3	[Caspase-3]	0.0	1	1	1	1
143728	1710	interestingly, early treatment	[Interestingly, early treatment]	0.0	3	1	1	1
143729	1710	beta-cell function	[beta-cell function]	0.0	2	1	1	1
143730	1710	positive myelogenous leukemia	[positive myelogenous leukemia]	0.0	3	1	1	1
143731	1710	presence of antibody	[presence of antibodies]	0.0	3	1	1	1
143732	1710	units/ml	[units/ml]	0.0	1	1	1	1
143733	1710	antibody (mab) 13b8-2	[antibody (MAb) 13B8-2]	0.0	3	1	1	1
143734	1710	include that cytokine	[including those cytokines]	0.0	3	1	1	1
143735	1710	woman young than 30 year	[women younger than 30 years]	0.0	5	1	1	1
143736	1710	response together	[response together]	0.0	2	1	1	1
143737	1710	suggest control of Bcl-2 expression	[suggesting control of Bcl-2 expression]	0.0	5	1	1	1
143738	1710	concentration range between 200-500	[concentrations ranging between 200-500]	0.0	4	1	1	1
143739	1710	inhibitory N17-mutated Ras construct	[inhibitory N17-mutated Ras construct]	0.0	4	1	1	1
143740	1710	t-cell leukemia virus-infected T cell	[T-cell leukemia virus-infected T cells]	0.0	5	1	1	1
143741	1710	novel 9-bp motif	[novel 9-bp motifs]	0.0	3	1	1	1
143742	1710	kinase type	[kinase type]	0.0	2	1	1	1
143743	1710	uptake of lps	[uptake of LPS]	0.0	3	1	1	1
143744	1710	species of heterodimer	[species of heterodimers]	0.0	3	1	1	1
143745	1710	potentiate il-3 commitment	[potentiating IL-3 commitment]	0.0	3	1	1	1
143746	1710	contrast, caspase	[contrast, caspase]	0.0	2	1	1	1
143747	1710	reaction with the tumor cell	[reaction with the tumor cells]	0.0	5	1	1	1
143748	1710	formation of the dimer	[formation of the dimer]	0.0	4	1	1	1
143749	1710	intact human leukocyte HML	[intact human leukocytes HML]	0.0	4	1	1	1
143750	1710	examine in vitro-differentiated stem cell	[examining in vitro-differentiated stem cells]	0.0	5	1	1	1
143751	1710	wave	[wave]	0.0	1	1	1	1
143752	1710	density lipoprotein inflammatory response in cell	[density lipoprotein inflammatory responses in cells]	0.0	6	1	1	1
143753	1710	level by ar	[levels by AR]	0.0	3	1	1	1
143754	1710	tetrahydrocortisone mg/24h; n: excretion,	[tetrahydrocortisone mg/24h; N: excretion,]	0.0	4	1	1	1
143755	1710	regulator of pi 3-kinase	[regulator of PI 3-kinase]	0.0	4	1	1	1
143756	1710	expression assay in erythroid cell culture	[expression assay in erythroid cell cultures]	0.0	6	1	1	1
143757	1710	have a proline region	[having a proline region]	0.0	4	1	1	1
143758	1710	elevation of intracellular AMP	[elevation of intracellular AMP]	0.0	4	1	1	1
143759	1710	successful use	[successful use]	0.0	2	1	1	1
143760	1710	influence disease	[influencing disease]	0.0	2	1	1	1
143761	1710	use mutagenesis,	[Using mutagenesis,]	0.0	2	1	1	1
143762	1710	however, only expression	[However, only expression]	0.0	3	1	1	1
143763	1710	partial correlation of the level	[partial correlations of the levels]	0.0	5	1	1	1
143764	1710	nonspecific hyperplasia fh	[nonspecific hyperplasia FH]	0.0	3	1	1	1
143765	1710	one event to endothelial cell	[one event to endothelial cells]	0.0	5	1	1	1
143766	1710	production of tenacious, protease	[production of tenacious, protease]	0.0	4	1	1	1
143767	1710	other region of the genes,	[other regions of the genes,]	0.0	5	1	1	1
143768	1710	transcription units.	[transcription units.]	0.0	2	1	1	1
143769	1710	ubiquitous oligopeptide	[ubiquitous oligopeptides]	0.0	2	1	1	1
143770	1710	activation of NF-kB in thymocyte	[activation of NF-kB in thymocytes]	0.0	5	1	1	1
143771	1710	addition of ligand in combination	[addition of ligand in combination]	0.0	5	1	1	1
143772	1710	4 beta-phorbol 12-myristate 13-acetate PMA addition	[4 beta-phorbol 12-myristate 13-acetate PMA addition]	0.0	6	1	1	1
143773	1710	IL-2 element in T cell	[IL-2 elements in T cells]	0.0	5	1	1	1
143774	1710	plasma cortisol in the group	[plasma cortisol in the group]	0.0	5	1	1	1
143775	1710	monocyte infiltration critical	[monocyte infiltration critical]	0.0	3	1	1	1
143776	1710	Spi-1 family member	[Spi-1 family members]	0.0	3	1	1	1
143777	1710	tumor necrosis factor-alpha U/ml,	[tumor necrosis factor-alpha U/ml,]	0.0	4	1	1	1
143778	1710	confocal laser scanning microscopy	[confocal laser scanning microscopy]	0.0	4	1	1	1
143779	1710	correlation of activity	[Correlation of activity]	0.0	3	1	1	1
143780	1710	vd treatment	[VD treatment]	0.0	2	1	1	1
143781	1710	mzf-1 function	[MZF-1 function]	0.0	2	1	1	1
143782	1710	ig variable chain sequence	[Ig variable chain sequences]	0.0	4	1	1	1
143783	1710	affinity of NFKB2	[affinity of NFKB2]	0.0	3	1	1	1
143784	1710	glycolipid	[glycolipid]	0.0	1	1	1	1
143785	1710	overexpression 1 carboxyl-terminal peptide	[Overexpression 1 carboxyl-terminal peptide]	0.0	4	1	1	1
143786	1710	erythropoietic differentiation in liquid culture	[erythropoietic differentiation in liquid culture]	0.0	5	1	1	1
143787	1710	way.	[way.]	0.0	1	1	1	1
143788	1710	property of the glucocorticoid receptor	[properties of the glucocorticoid receptors]	0.0	5	1	1	1
143789	1710	produce 50% inhibition ic50	[producing 50% inhibition IC50]	0.0	4	1	1	1
143790	1710	gene [Cao	[gene [Cao]	0.0	2	1	1	1
143791	1710	three protein-DNA complex	[three protein-DNA complexes]	0.0	3	1	1	1
143792	1710	nuclear envelope membrane	[nuclear envelope membrane]	0.0	3	2	2	1
143793	1710	autoregulation by inhibitor	[Autoregulation by inhibitors]	0.0	3	1	1	1
143794	1710	active ocim1 cell	[active OCIM1 cells]	0.0	3	1	1	1
143795	1710	specificity of ANG nf-kappab activation	[Specificity of ANG NF-kappaB activation]	0.0	5	1	1	1
143796	1710	osteoclast-like multinucleated cell from human monocyte	[osteoclast-like multinucleated cells from human monocytes]	0.0	6	1	1	1
143797	1710	presence of critical cis element	[presence of critical cis elements]	0.0	5	1	1	1
143798	1710	t(15;17) promyelocytic leukemia APL	[t(15;17) promyelocytic leukemia APL]	0.0	4	1	1	1
143799	1710	NK cell inhibitory receptor	[NK cell inhibitory receptors]	0.0	4	1	1	1
143800	1710	important mediator of inflammation	[important mediators of inflammation]	0.0	4	1	1	1
143801	1710	cell surface activation	[cell surface activation]	0.0	3	2	2	1
143802	1710	time of pretreatment with 135-(oh)2d3	[time of pretreatment with 1,25-(OH)2D3]	0.0	5	1	1	1
143803	1710	pou-specific domain a linker	[POU-specific domain a linker]	0.0	4	1	1	1
143804	1710	nonsteroidal drug such as salicylate	[Nonsteroidal drugs such as salicylates]	0.0	5	1	1	1
143805	1710	binding protein-1	[binding protein-1]	0.0	2	1	1	1
143806	1710	distinct complex with other protein	[distinct complexes with other proteins]	0.0	5	1	1	1
143807	1710	t-cell-specific enhancer in	[T-cell-specific enhancer in]	0.0	3	1	1	1
143808	1710	Ca2+ transient	[Ca2+ transient]	0.0	2	1	1	1
143809	1710	regulation of platelet ca(2+)-atpase	[regulation of platelet Ca(2+)-ATPases]	0.0	4	1	1	1
143810	1710	binding of receptor in asthma	[binding of receptor in asthma]	0.0	5	1	1	1
143811	1710	phenotypic female	[phenotypic female]	0.0	2	1	1	1
143812	1710	Stat3 recruitment by tyrosine-phosphorylated docking site	[Stat3 recruitment by tyrosine-phosphorylated docking sites]	0.0	6	1	1	1
143813	1710	e2f binding site	[E2F binding site]	0.0	3	1	1	1
143814	1710	have molecular weight	[having molecular weights]	0.0	3	1	1	1
143815	1710	activation event occur in T lymphocyte	[activation events occurring in T lymphocytes]	0.0	6	1	1	1
143816	1710	identification of a regulator	[Identification of an regulator]	0.0	4	1	1	1
143817	1710	24 healthy volunteer without disorder	[24 healthy volunteers without disorders]	0.0	5	1	1	1
143818	1710	low concentration inhibit ige synthesis mol/L)	[Low concentrations inhibiting IgE synthesis mol/L)]	0.0	6	1	1	1
143819	1710	rolling, adhesion, of leukocyte monocyte	[rolling, adhesion, of leukocytes monocytes]	0.0	5	1	1	1
143820	1710	primary cell in G0	[primary cells in G0]	0.0	4	1	1	1
143821	1710	LAL expression	[LAL expression]	0.0	2	1	1	1
143822	1710	regulatory response	[regulatory response]	0.0	2	1	1	1
143823	1710	regulation of class	[regulation of class]	0.0	3	1	1	1
143824	1710	24,25-dihydroxy-vitamin D3 2422(oh)2d3	[24,25-dihydroxy-vitamin D3 24,25(OH)2D3]	0.0	3	1	1	1
143825	1710	binding of tnf-alpha	[binding of TNF-alpha]	0.0	3	1	1	1
143826	1710	intracellular signal for chemoattract	[intracellular signaling for chemoattractants]	0.0	4	1	1	1
143827	1710	role of Jak3 in lymphoid development	[role of Jak3 in lymphoid development]	0.0	6	1	1	1
143828	1710	chicken erythrocyte factor molecular mass,	[chicken erythrocyte factor molecular mass,]	0.0	5	1	1	1
143829	1710	t-cell prolymphocytic leukemia	[T-cell prolymphocytic leukemia]	0.0	3	1	1	1
143830	1710	1, D3 135(oh)2d3 receptor VDR	[1, D3 1,25(OH)2D3 receptor VDR]	0.0	5	1	1	1
143831	1710	kinase upstream of ERK1/2	[kinase upstream of ERK1/2]	0.0	4	1	1	1
143832	1710	additionally, virus reactivation in pbmc	[Additionally, virus reactivation in PBMCs]	0.0	5	1	1	1
143833	1710	region downstream	[region downstream]	0.0	2	1	1	1
143834	1710	receptor/stat	[Receptor/Stat]	0.0	1	1	1	1
143835	1710	responsiveness chronic leukemia	[responsiveness chronic leukemia]	0.0	3	1	1	1
143836	1710	IRF family transcription	[IRF family transcription]	0.0	3	1	1	1
143837	1710	direct evidence regard the role	[direct evidence regarding the role]	0.0	5	1	1	1
143838	1710	expression of gamma-interferon inducible protein	[Expression of gamma-interferon inducible protein]	0.0	5	1	1	1
143839	1710	preferential induction of c-jun	[preferential induction of c-jun]	0.0	4	1	1	1
143840	1710	important difference	[important difference]	0.0	2	1	1	1
143841	1710	drop in glutathione	[drop in glutathione]	0.0	3	1	1	1
143842	1710	overexpression of SRF	[Overexpression of SRF]	0.0	3	1	1	1
143843	1710	glucocorticosteroids gcs	[glucocorticosteroids GCS]	0.0	2	1	1	1
143844	1710	distinct pathway in T lymphocyte	[distinct pathways in T lymphocytes]	0.0	5	1	1	1
143845	1710	exogenous gene	[exogenous genes]	0.0	2	1	1	1
143846	1710	use extract from human brain	[using extracts from human brain]	0.0	5	1	1	1
143847	1710	bright foci of gata-1 fluorescence	[bright foci of GATA-1 fluorescence]	0.0	5	1	1	1
143848	1710	pcr product cover the coding sequence	[PCR products covering the coding sequence]	0.0	6	1	1	1
143849	1710	fdcp-mix	[FDCP-mix]	0.0	1	1	1	1
143850	1710	gcr gcr-beta	[GCR GCR-beta]	0.0	2	1	1	1
143851	1710	anti-estrogenic action	[anti-estrogenic action]	0.0	2	1	1	1
143852	1710	regulation of heavy chain expression	[regulation of heavy chain expression]	0.0	5	1	1	1
143853	1710	evidence presented.	[evidence presented.]	0.0	2	1	1	1
143854	1710	bending/flexure	[bending/flexure]	0.0	1	1	1	1
143855	1710	cell from lymphoma	[cells from lymphomas]	0.0	3	1	1	1
143856	1710	characteristic localization of tf antigen	[characteristic localization of TF antigen]	0.0	5	1	1	1
143857	1710	dyn/cm2) haec	[dyn/cm2) HAEC]	0.0	2	1	1	1
143858	1710	specific factor( binding	[specific factor(s) binding]	0.0	3	1	1	1
143859	1710	downstream signalling,	[downstream signalling,]	0.0	2	1	1	1
143860	1710	evidence at element p0	[Evidence at element P0]	0.0	4	1	1	1
143861	1710	remission of the state	[remissions of the state]	0.0	4	1	1	1
143862	1710	continuous treatment with concentration	[continuous treatments with concentrations]	0.0	4	1	1	1
143863	1710	sp1 factor	[Sp1 factor]	0.0	2	1	1	1
143864	1710	permissive temperature	[permissive temperature]	0.0	2	1	1	1
143865	1710	binding of androgen	[binding of androgen]	0.0	3	1	1	1
143866	1710	set of protein of kda	[sets of proteins of kDa]	0.0	5	1	1	1
143867	1710	tgf beta 1	[TGF beta 1]	0.0	3	1	1	1
143868	1710	consist of male with age distribution	[consisting of males with age distribution]	0.0	6	1	1	1
143869	1710	aids deletion	[AIDS deletion]	0.0	2	1	1	1
143870	1710	component of basal promoter activity	[component of basal promoter activity]	0.0	5	1	1	1
143871	1710	trans-activation domain in peptide	[trans-activation domain in peptide]	0.0	4	1	1	1
143872	1710	P0 nfat activity	[P0 NFAT activity]	0.0	3	1	1	1
143873	1710	underlie the isotype switch	[underlying the isotype switch]	0.0	4	1	1	1
143874	1710	dominant allele Raf	[dominant allele Raf]	0.0	3	1	1	1
143875	1710	progression of type include myeloid leukaemia	[progression of types including myeloid leukaemia]	0.0	6	2	2	1
143876	1710	significant rapid increase from patient	[significant rapid increase from patients]	0.0	5	1	1	1
143877	1710	osteoclast-like giant cell	[osteoclast-like giant cells]	0.0	3	1	1	1
143878	1710	expression of NF-kappaB/Rel family	[expression of NF-kappaB/Rel family]	0.0	4	1	1	1
143879	1710	group of female aged	[group of females aged]	0.0	4	1	1	1
143880	1710	weight gain (14	[weight gain (14]	0.0	3	1	1	1
143881	1710	acid receptor RAR alpha	[acid receptor RAR alpha]	0.0	4	1	1	1
143882	1710	preexisting, T cell-specific component	[preexisting, T cell-specific component]	0.0	4	1	1	1
143883	1710	sequestration of the tax protein	[sequestration of the Tax protein]	0.0	5	1	1	1
143884	1710	emission of a fluorescent probe	[emission of a fluorescent probe]	0.0	5	1	1	1
143885	1710	lineage absent in cell	[lineages absent in cells]	0.0	4	1	1	1
143886	1710	interior	[interior]	0.0	1	1	1	1
143887	1710	day result in the production	[days, resulting in the production]	0.0	5	1	1	1
143888	1710	nf-at response element	[NF-AT response element]	0.0	3	1	1	1
143889	1710	kappa b alpha mouse	[kappa B alpha mice]	0.0	4	1	1	1
143890	1710	transcriptional machinery.	[transcriptional machinery.]	0.0	2	1	1	1
143891	1710	cause a influx	[causing an influx]	0.0	3	1	1	1
143892	1710	use DNA transfer	[using DNA transfer]	0.0	3	1	1	1
143893	1710	histocompatibility class ii promoter	[histocompatibility class II promoter]	0.0	4	1	1	1
143894	1710	beta-globin gene transcription	[beta-globin gene transcription]	0.0	3	1	1	1
143895	1710	human vein cell CoCl2	[human vein cells CoCl2]	0.0	4	1	1	1
143896	1710	exon span kb of DNA	[exons spanning kb of DNA]	0.0	5	1	1	1
143897	1710	regulation during human cell differentiation	[regulation during human cell differentiation]	0.0	5	1	1	1
143898	1710	site in the hiv-1 enhancer	[sites in the HIV-1 enhancer]	0.0	5	1	1	1
143899	1710	growth similar	[growth similar]	0.0	2	1	1	1
143900	1710	sequence responsible	[sequences responsible]	0.0	2	1	1	1
143901	1710	possibly reflect difference in sensitivity	[possibly reflecting differences in sensitivity]	0.0	5	1	1	1
143902	1710	68-amino-acid domain	[68-amino-acid domain]	0.0	2	1	1	1
143903	1710	vernal keratoconjunctivitis a disease	[vernal keratoconjunctivitis an disease.]	0.0	4	1	1	1
143904	1710	peripheral blood leukocyte of patient	[peripheral blood leukocytes of patients]	0.0	5	1	1	1
143905	1710	express CAT under control	[expressing CAT under control]	0.0	4	1	1	1
143906	1710	growth factor in pathways.	[growth factor in pathways.]	0.0	4	1	1	1
143907	1710	other unidentified ets-like factor present	[Other unidentified ETS-like factors present]	0.0	5	1	1	1
143908	1710	consequent formation of active binding heterodimers,	[consequent formation of active binding heterodimers,]	0.0	6	1	1	1
143909	1710	patient with spread of lymphoma	[patients with spread of lymphomas]	0.0	5	1	1	1
143910	1710	effect of adenovirus ad2 infection	[effect of adenovirus Ad2 infection]	0.0	5	1	1	1
143911	1710	particularly cd40l T cell	[particularly CD40L T cells]	0.0	4	1	1	1
143912	1710	sequence requirement for expression in cell	[sequence requirements for expression in cells]	0.0	6	1	1	1
143913	1710	potential c/ebP-binding site bp	[potential C/EBP-binding site bp]	0.0	4	1	1	1
143914	1710	phosphatidylserine exposure	[phosphatidylserine exposure]	0.0	2	1	1	1
143915	1710	phenotype reversal	[phenotype reversal]	0.0	2	1	1	1
143916	1710	CONCLUSION: cytomegalovirus immediate early gene product	[CONCLUSION: Cytomegalovirus immediate early gene products]	0.0	6	1	1	1
143917	1710	other ankyrin motif-rich protein	[other ankyrin motif-rich proteins]	0.0	4	1	1	1
143918	1710	t3so4	[T3SO4]	0.0	1	1	1	1
143919	1710	tumor characteristic	[tumor characteristics]	0.0	2	1	1	1
143920	1710	aspect of the intracellular signalling network	[aspects of the intracellular signalling network]	0.0	6	1	1	1
143921	1710	diverse immune response	[diverse immune responses]	0.0	3	1	1	1
143922	1710	target cell uptake	[target cell uptake]	0.0	3	1	1	1
143923	1710	construct express CAT	[constructs expressing CAT]	0.0	3	1	1	1
143924	1710	injection of sea cause	[injections of SEA cause]	0.0	4	1	1	1
143925	1710	receptor cluster	[receptor clusters]	0.0	2	1	1	1
143926	1710	more change in the form	[more changes in the form]	0.0	5	1	1	1
143927	1710	so, medullary thymocyte	[so, medullary thymocytes]	0.0	3	1	1	1
143928	1710	continuum of capacity	[continuum of capacities]	0.0	3	1	1	1
143929	1710	stimulation with ifn-gamma	[stimulation with IFN-gamma]	0.0	3	1	1	1
143930	1710	intrinsic abnormality	[intrinsic abnormality]	0.0	2	1	1	1
143931	1710	human cd36 antibody okm5	[human CD36 antibody OKM5]	0.0	4	1	1	1
143932	1710	transcription factor Ikaros	[transcription factors Ikaros]	0.0	3	1	1	1
143933	1710	pretreatment with tcp succinate	[pretreatment with TCP succinate]	0.0	4	1	1	1
143934	1710	regulate the distribution in human cell	[regulating the distribution in human cells]	0.0	6	1	1	1
143935	1710	use anti-c/ebpbeta anti-c/ebpdelta nf-il6beta	[Using anti-C/EBPbeta anti-C/EBPdelta NF-IL6beta]	0.0	4	1	1	1
143936	1710	GR number in the patient'	[GR number in the patient's]	0.0	5	1	1	1
143937	1710	only the inhibition	[only the inhibition]	0.0	3	1	1	1
143938	1710	potential transcription factor	[potential transcription factor]	0.0	3	1	1	1
143939	1710	lymphocyte syndrome ebls)	[Lymphocyte Syndrome (BLS)]	0.0	3	1	1	1
143940	1710	tracking mechanism	[tracking mechanism]	0.0	2	1	1	1
143941	1710	(3h)-thymidine incorporation with nrd	[(3H)-thymidine incorporation with NRDS]	0.0	4	1	1	1
143942	1710	contain medium	[containing medium]	0.0	2	1	1	1
143943	1710	induce protection	[inducing protection]	0.0	2	1	1	1
143944	1710	BSAP a regulator of b-cell development	[BSAP a regulator of B-cell development]	0.0	6	1	1	1
143945	1710	5' sequence (-7.0 kb)	[5' sequence (-7.0 kb)]	0.0	4	1	1	1
143946	1710	anion-exchange chromatography	[anion-exchange chromatography]	0.0	2	1	1	1
143947	1710	transcription of nitric oxide synthase	[transcription of nitric oxide synthase]	0.0	5	1	1	1
143948	1710	pml-rar alpha fusion oncoprotein	[PML-RAR alpha fusion oncoprotein]	0.0	4	1	1	1
143949	1710	trimester human pregnancy	[trimester human pregnancies]	0.0	3	1	1	1
143950	1710	two homologous gene encode scm-1alpha	[two homologous genes encoding SCM-1alpha]	0.0	5	1	1	1
143951	1710	transcript the coat protein	[Transcripts the coat protein]	0.0	4	1	1	1
143952	1710	many year of persistent relationship	[many years of persistent relationship]	0.0	5	1	1	1
143953	1710	tumor necrosis factor-alpha by the leukocyte	[tumor necrosis factor-alpha by the leukocytes]	0.0	6	1	1	1
143954	1710	response gene,	[response gene,]	0.0	2	1	1	1
143955	1710	add b protein to extract	[Adding B protein to extracts]	0.0	5	1	1	1
143956	1710	blood monocyte Mo	[blood monocytes Mo]	0.0	3	1	1	1
143957	1710	essential enhancer motif	[essential enhancer motif]	0.0	3	1	1	1
143958	1710	BZLF1 transcript	[BZLF1 transcripts]	0.0	2	1	1	1
143959	1710	extent, cd11c/cd18	[extent, CD11c/CD18]	0.0	2	1	1	1
143960	1710	blockage	[blockage]	0.0	1	1	1	1
143961	1710	correct fold	[correct folding]	0.0	2	1	1	1
143962	1710	(3) normal pbl	[(3) normal PBL]	0.0	3	1	1	1
143963	1710	human cd3epsilon mouse	[human CD3epsilon mice]	0.0	3	1	1	1
143964	1710	571 base pair upstream	[571 base pairs upstream]	0.0	4	1	1	1
143965	1710	failure CRF	[failure CRF]	0.0	2	1	1	1
143966	1710	20 microM,	[20 microM,]	0.0	2	1	1	1
143967	1710	Conclusions: growth inhibition without evidence	[CONCLUSIONS: growth inhibition without evidence]	0.0	5	1	1	1
143968	1710	regulation of glucocorticoid receptor	[Regulation of glucocorticoid receptors]	0.0	4	1	1	1
143969	1710	IL-2 DNA binding activity	[IL-2 DNA binding activities]	0.0	4	1	1	1
143970	1710	pattern of early signal event	[pattern of early signaling events]	0.0	5	1	1	1
143971	1710	various lesion	[various lesions]	0.0	2	1	1	1
143972	1710	expression in airway T cell	[expression in airway T cells]	0.0	5	1	1	1
143973	1710	novel transcriptional activator	[novel transcriptional activator]	0.0	3	1	1	1
143974	1710	gene include alpha- globin band	[genes including alpha- globin band]	0.0	5	1	1	1
143975	1710	DNA bind specificities, the reactivity	[DNA binding specificities, the reactivities]	0.0	5	1	1	1
143976	1710	association of the component	[association of the component]	0.0	4	1	1	1
143977	1710	unit consist	[unit consisting]	0.0	2	1	1	1
143978	1710	activation of the MMTV LTR	[activation of the MMTV LTR]	0.0	5	1	1	1
143979	1710	impact of factor	[impact of factor]	0.0	3	1	1	1
143980	1710	form of DeltaE	[form of DeltaE]	0.0	3	1	1	1
143981	1710	90-kda stat3alpha	[90-kDa STAT3alpha]	0.0	2	1	1	1
143982	1710	further study signal in precursor	[further studies signaling in precursors]	0.0	5	1	1	1
143983	1710	evidence for mrna stability	[evidence for mRNA stability]	0.0	4	1	1	1
143984	1710	member of the interferon factor	[member of the interferon factor]	0.0	5	1	1	1
143985	1710	cystatin C	[cystatin C]	0.0	2	1	1	1
143986	1710	transcription kappa B-like site	[transcriptions kappa B-like sites]	0.0	4	1	1	1
143987	1710	homology with the murine fosb gene	[homology with the murine FOSB gene]	0.0	6	1	1	1
143988	1710	great than inhibition	[greater than inhibition]	0.0	3	1	1	1
143989	1710	conditional allele	[conditional alleles]	0.0	2	1	1	1
143990	1710	C3/5, CD3(+), CD4(+), CD8(-)	[C3/5, CD3(+), CD4(+), CD8(-)]	0.0	4	1	1	1
143991	1710	increase during transient expression	[Increases during transient expression]	0.0	4	1	1	1
143992	1710	native weight of kD	[native weights of kD]	0.0	4	1	1	1
143993	1710	IFN-alpha responsiveness positive leukemia	[IFN-alpha responsiveness positive leukemia]	0.0	4	1	1	1
143994	1710	pathological finding the infiltration	[pathological finding the infiltration]	0.0	4	1	1	1
143995	1710	mapping in the great ape	[mapping in the great apes]	0.0	5	1	1	1
143996	1710	biologic concentration	[biologic concentrations]	0.0	2	1	1	1
143997	1710	protein nf-kappa b	[proteins NF-kappa B]	0.0	3	1	1	1
143998	1710	six week after subtotal thyroidectomy	[Six weeks after subtotal thyroidectomy]	0.0	5	1	1	1
143999	1710	possibility also the mechanism	[possibility also the mechanism]	0.0	4	1	1	1
144000	1710	two CCAAT sequence	[two CCAAT sequences]	0.0	3	1	1	1
144001	1710	52-kDa form	[52-kDa form]	0.0	2	1	1	1
144002	1710	unique amino acid carboxy-terminus	[unique amino acid carboxy-terminus]	0.0	4	1	1	1
144003	1710	recognition motif	[recognition motif]	0.0	2	1	1	1
144004	1710	least two domain the domain	[least two domains the domain]	0.0	5	1	1	1
144005	1710	protein bind the kappa b sequence	[proteins binding the kappa B sequence]	0.0	6	1	1	1
144006	1710	previously, a enhancer between nucleotide	[Previously, an enhancer between nucleotides]	0.0	5	1	1	1
144007	1710	kinase pathway in T cell	[kinase pathways in T cells]	0.0	5	1	1	1
144008	1710	include a NF-kappa b element	[including a NF-kappa B element]	0.0	5	1	1	1
144009	1710	stat complex in T	[STAT complexes in T]	0.0	4	1	1	1
144010	1710	receptor characteristic on mononuclear leukocyte	[receptor characteristics on mononuclear leukocytes]	0.0	5	1	1	1
144011	1710	cyclin e kinase activity	[cyclin E kinase activity]	0.0	4	1	1	1
144012	1710	tf activation	[TF activation]	0.0	2	1	1	1
144013	1710	class restriction element	[class restriction element]	0.0	3	1	1	1
144014	1710	key nuclear factor	[key nuclear factors]	0.0	3	1	1	1
144015	1710	rapid accumulation	[rapid accumulation]	0.0	2	1	1	1
144016	1710	overexpression carboxyl-terminal peptide in jy25 cell	[Overexpression carboxyl-terminal peptide in JY25 cells]	0.0	6	1	1	1
144017	1710	vivo to a 40-bp region	[vivo to a 40-bp region]	0.0	5	1	1	1
144018	1710	role in the defense	[role in the defense]	0.0	4	1	1	1
144019	1710	complex specific	[complexes specific]	0.0	2	1	1	1
144020	1710	inhibit the phosphatase activity cn	[inhibiting the phosphatase activity CN]	0.0	5	1	1	1
144021	1710	regulate nuclear matrix attachment	[regulating nuclear matrix attachment]	0.0	4	1	1	1
144022	1710	resemble a RBP-Jkappa binding site	[resembling a RBP-Jkappa binding site]	0.0	5	1	1	1
144023	1710	/ionomycin	[/ionomycin]	0.0	1	1	1	1
144024	1710	involvement of this messenger	[involvement of these messengers]	0.0	4	1	1	1
144025	1710	usefulness of knock-out mouse	[usefulness of knock-out mice]	0.0	4	1	1	1
144026	1710	hour in the presence	[hr in the presence]	0.0	4	1	1	1
144027	1710	STAT-1 Ab	[STAT-1 Ab]	0.0	2	1	1	1
144028	1710	growth growth factor HB-EGF	[growth growth factor HB-EGF]	0.0	4	1	1	1
144029	1710	association latency in cell	[Association latency in cells]	0.0	4	1	1	1
144030	1710	ten in-vitro-stimulated blood lymphocyte sample	[ten in-vitro-stimulated blood lymphocyte samples]	0.0	5	1	1	1
144031	1710	well-known and/or cytokine	[well-known and/or cytokine]	0.0	3	1	1	1
144032	1710	protein kinase tyrosine phosphatase	[protein kinase tyrosine phosphatase]	0.0	4	1	1	1
144033	1710	divergent region of STP-C488	[divergent region of STP-C488]	0.0	4	1	1	1
144034	1710	pathogenesis of hypercalcemia	[pathogenesis of hypercalcemia]	0.0	3	1	1	1
144035	1710	enhancer-	[enhancer-]	0.0	1	1	1	1
144036	1710	nfkb2 form, induction	[NFKB2 form, induction]	0.0	3	1	1	1
144037	1710	superoxide dismutase a mitochondrial enzyme	[superoxide dismutase a mitochondrial enzyme]	0.0	5	1	1	1
144038	1710	certain ebv-positive malignancy	[certain EBV-positive malignancies]	0.0	3	1	1	1
144039	1710	72-kDa protein ie-1	[72-kDa protein IE-1]	0.0	3	1	1	1
144040	1710	development of strategy	[development of strategies]	0.0	3	1	1	1
144041	1710	LAM il-6 promoter activity	[LAM IL-6 promoter activity]	0.0	4	1	1	1
144042	1710	myeloid zinc finger gene	[myeloid zinc finger gene]	0.0	4	1	1	1
144043	1710	Epstein-Barr virus EBV antigen 2 ebna-2	[Epstein-Barr virus EBV antigen 2 EBNA-2]	0.0	6	1	1	1
144044	1710	embryonic-fetal liver	[embryonic-fetal liver]	0.0	2	1	1	1
144045	1710	However, retroviral transduction	[However, retroviral transduction]	0.0	3	1	1	1
144046	1710	gamma interferon tyrosine phosphorylation	[gamma interferon tyrosine phosphorylation]	0.0	4	1	1	1
144047	1710	viral evasion	[viral evasion]	0.0	2	1	1	1
144048	1710	lack the catalytic domain	[lacking the catalytic domain]	0.0	4	1	1	1
144049	1710	drug nsaid	[drugs NSAIDs]	0.0	2	2	2	1
144050	1710	inactive methylation	[inactive methylation]	0.0	2	1	1	1
144051	1710	erythroid cell line k562	[erythroid cell line K562]	0.0	4	1	1	1
144052	1710	response to stimulation with phytohaemagglutinin	[response to stimulation with phytohaemagglutinin]	0.0	5	1	1	1
144053	1710	release of endothelium-derived vasoactive factor	[release of endothelium-derived vasoactive factors]	0.0	5	1	1	1
144054	1710	ligand testosterone	[ligand testosterone]	0.0	2	1	1	1
144055	1710	signal event dependent	[signaling events dependent]	0.0	3	1	1	1
144056	1710	induce expression from lytic cycle promoter	[inducing expression from lytic cycle promoters]	0.0	6	1	1	1
144057	1710	development of tissue	[Development of tissues]	0.0	3	1	1	1
144058	1710	pseudohypoaldosteronism in renal disease	[pseudohypoaldosteronism in renal disease]	0.0	4	1	1	1
144059	1710	(1) multiple nucleotide substitution	[(1) multiple nucleotide substitutions]	0.0	4	1	1	1
144060	1710	second trans-activation domain tad-b	[second trans-activation domain TAD-B]	0.0	4	1	1	1
144061	1710	functional analog	[functional analog]	0.0	2	1	1	1
144062	1710	part of the program	[parts of the program]	0.0	4	1	1	1
144063	1710	tolerance with respect to leukocyte adhesion	[tolerance with respect to leukocyte adhesion]	0.0	6	1	1	1
144064	1710	evidence for the involvement of stat6	[evidence for the involvement of STAT6]	0.0	6	1	1	1
144065	1710	blotting of population	[blotting of populations]	0.0	3	1	1	1
144066	1710	several T cell receptor element	[several T cell receptor elements]	0.0	5	1	1	1
144067	1710	tyrosyl phosphorylation of protein	[tyrosyl phosphorylation of proteins]	0.0	4	1	1	1
144068	1710	activity of receptor	[activity of receptors]	0.0	3	1	1	1
144069	1710	Lymphocytes-1	[Lymphocytes-1]	0.0	1	1	1	1
144070	1710	probably lead	[probably leading]	0.0	2	1	1	1
144071	1710	breast cancer control	[breast cancer control]	0.0	3	1	1	1
144072	1710	ten control	[ten controls]	0.0	2	1	1	1
144073	1710	acute blast use adeno-associated virus	[acute blasts using adeno-associated virus]	0.0	5	1	1	1
144074	1710	partial loss	[partial loss]	0.0	2	1	1	1
144075	1710	binding to proline region	[binding to proline regions]	0.0	4	1	1	1
144076	1710	cover the complete coding sequence	[covering the complete coding sequence]	0.0	5	1	1	1
144077	1710	proteins, the gata factor	[proteins, the GATA factors]	0.0	4	1	1	1
144078	1710	pharmacological modification	[Pharmacological modification]	0.0	2	1	1	1
144079	1710	aim of the study	[aim of the study]	0.0	4	3	3	1
144080	1710	picture,	[picture,]	0.0	1	1	1	1
144081	1710	trigger substance for monocyte	[trigger substances for monocytes]	0.0	4	1	1	1
144082	1710	sideroblast in patient with anemia	[sideroblasts in patients with anemia]	0.0	5	1	1	1
144083	1710	leucocytic estrogen receptor level	[leucocytic estrogen receptor levels]	0.0	4	2	2	1
144084	1710	receptor gr binding in blood lymphocyte	[receptor GR binding in blood lymphocytes]	0.0	6	1	1	1
144085	1710	interaction with the 5' region	[interactions with the 5' regions]	0.0	5	1	1	1
144086	1710	patient with paraparesis	[patient with paraparesis]	0.0	3	1	1	1
144087	1710	factor by PGG-Glucan	[factor by PGG-Glucan]	0.0	3	1	1	1
144088	1710	subject with asthma	[subjects with asthma]	0.0	3	2	2	1
144089	1710	natural killer NK	[natural killer NK]	0.0	3	1	1	1
144090	1710	inducible form of NF-AT	[inducible form of NF-AT]	0.0	4	1	1	1
144091	1710	amino acid alteration within dna-binding domain	[amino acid alterations within DNA-binding domain]	0.0	6	1	1	1
144092	1710	two child with fatal infection	[two children with fatal infection]	0.0	5	2	2	1
144093	1710	low 24-hour cortisol excretion	[low 24-hour cortisol excretion]	0.0	4	1	1	1
144094	1710	calcium CD28 -specific pathway	[calcium CD28 -specific pathway]	0.0	4	1	1	1
144095	1710	cholesterol feedback	[cholesterol feedback]	0.0	2	1	1	1
144096	1710	breast cancer a study	[breast cancer a study]	0.0	4	1	1	1
144097	1710	receptors/cell; controls, 306 +/-	[receptors/cell; controls, 306 +/-]	0.0	4	1	1	1
144098	1710	that: (1) induction	[that: (1) induction]	0.0	3	1	1	1
144099	1710	origin of disorder	[origin of disorders]	0.0	3	1	1	1
144100	1710	sequence similarity to transcription factor	[sequence similarity to transcription factors]	0.0	5	1	1	1
144101	1710	potentiate interleukin-3 il-3 commitment	[potentiating interleukin-3 IL-3 commitment]	0.0	4	1	1	1
144102	1710	(HIV) repeat in T cell	[(HIV) repeat in T cells]	0.0	5	1	1	1
144103	1710	transient cotransfection together	[Transient cotransfection together]	0.0	3	1	1	1
144104	1710	human leukocyte in obesity.	[human leukocyte in obesity.]	0.0	4	1	1	1
144105	1710	membrane-proximal determinant distinct	[membrane-proximal determinants distinct]	0.0	3	1	1	1
144106	1710	hiv gene therapy	[HIV gene therapy]	0.0	3	1	1	1
144107	1710	activation of human interleukin gene	[activation of human interleukin gene]	0.0	5	1	1	1
144108	1710	ppt i-te in blood fat	[ppt I-TE in blood fat]	0.0	5	1	1	1
144109	1710	interferon-gamma-activated site	[interferon-gamma-activated site]	0.0	2	1	1	1
144110	1710	alcohol-induced regulation of regulatory factor-kappa beta	[Alcohol-induced regulation of regulatory factor-kappa beta]	0.0	6	1	1	1
144111	1710	mg/d.	[mg/d.]	0.0	1	1	1	1
144112	1710	ras ras(g12v)	[Ras Ras(G12V)]	0.0	2	1	1	1
144113	1710	baboon cercopithicine herpesvirus	[baboons cercopithicine herpesvirus]	0.0	3	1	1	1
144114	1710	antibody (ic50 of 10 ng/ml),	[antibody (IC50 of 10 ng/ml),]	0.0	5	1	1	1
144115	1710	mediator generate positive mechanism	[mediator generating positive mechanisms]	0.0	4	1	1	1
144116	1710	collection of datum	[collection of data.]	0.0	3	1	1	1
144117	1710	pre-leukemic phase	[pre-leukemic phase]	0.0	2	1	1	1
144118	1710	low-grade disorder	[low-grade disorder]	0.0	2	1	1	1
144119	1710	time-dependent binding two antibody specific	[time-dependent binding two antibodies specific]	0.0	5	1	1	1
144120	1710	adolescent major disorder	[adolescent major disorder]	0.0	3	1	1	1
144121	1710	clone with sensitive pcr-based technique	[clone with sensitive PCR-based techniques]	0.0	5	1	1	1
144122	1710	number with type ii diabete	[number with type II diabetes]	0.0	5	1	1	1
144123	1710	group in blood mononuclear cell	[group in blood mononuclear cells]	0.0	5	1	1	1
144124	1710	activation domain at the N	[activation domains at the N]	0.0	5	1	1	1
144125	1710	nf-kappa b activation within hour	[NF-kappa B activation within hr]	0.0	5	1	1	1
144126	1710	major class ii	[major class II]	0.0	3	1	1	1
144127	1710	low-level expression of type interferon	[low-level expression of type interferon]	0.0	5	1	1	1
144128	1710	binding to a response element	[Binding to an response element]	0.0	5	1	1	1
144129	1710	igh gene rearrangement	[IgH gene rearrangement]	0.0	3	1	1	1
144130	1710	complex with cyclic AMP response protein	[complexes with cyclic AMP response protein]	0.0	6	1	1	1
144131	1710	relationship between gene expression	[relationship between gene expression]	0.0	4	1	1	1
144132	1710	interact transmembrane adaptor protein	[interacting transmembrane adaptor protein]	0.0	4	1	1	1
144133	1710	association between i(kappa)b(alpha)	[association between I(kappa)B(alpha)]	0.0	3	1	1	1
144134	1710	14-amino-acid peptide	[14-amino-acid peptide]	0.0	2	1	1	1
144135	1710	rdna encode mouse oct2	[cDNAs encoding mouse Oct2]	0.0	4	1	1	1
144136	1710	level of the aml1 gene	[level of the AML1 gene]	0.0	5	1	1	1
144137	1710	Society	[Society]	0.0	1	2	2	1
144138	1710	cos cell express protein	[COS cells expressing proteins]	0.0	4	1	1	1
144139	1710	other mechanism such as a effect	[other mechanisms such as an effect]	0.0	6	1	1	1
144140	1710	renal sodium handling	[renal sodium handling]	0.0	3	1	1	1
144141	1710	regulation of interleukin 2 gene	[regulation of interleukin 2 gene]	0.0	5	1	1	1
144142	1710	regulation of IkB alpha phosphorylation	[Regulation of IkB alpha phosphorylation]	0.0	5	1	1	1
144143	1710	gene regulation of the vacuolar h(+)-atpase	[gene regulation of the vacuolar H(+)-ATPase]	0.0	6	1	1	1
144144	1710	sequence downstream regulatory element DRE	[sequence downstream regulatory element DRE]	0.0	5	1	1	1
144145	1710	IL-1 manner	[IL-1 manner]	0.0	2	1	1	1
144146	1710	venule pcv	[venules PCVs]	0.0	2	1	1	1
144147	1710	b cell immunopoiesis occur	[B cell immunopoiesis occurring]	0.0	4	1	1	1
144148	1710	homolog baf155	[homolog BAF155]	0.0	2	1	1	1
144149	1710	leukocyte protein of kilodaltons),	[leukocyte protein of kilodaltons),]	0.0	4	1	1	1
144150	1710	several mammalian response include the activation	[Several mammalian responses including the activation]	0.0	6	1	1	1
144151	1710	such as uterus	[such as uterus]	0.0	3	1	1	1
144152	1710	interaction of thymocyte with cell	[interaction of thymocytes with cells]	0.0	5	1	1	1
144153	1710	amount of NK activity variance	[amount of NK activity variance]	0.0	5	1	1	1
144154	1710	octamerlike sequence with base substitution	[octamerlike sequence with base substitution]	0.0	5	1	1	1
144155	1710	healthy, control person	[healthy, control persons]	0.0	3	1	1	1
144156	1710	ccgccc binding protein from erythroid cell	[CCGCCC binding proteins from erythroid cells]	0.0	6	1	1	1
144157	1710	prolonged, 28 dayus- glucocorticoid therapy	[prolonged, 28 day, glucocorticoid therapy]	0.0	5	1	1	1
144158	1710	inhibition of endogenous no production	[Inhibition of endogenous NO production]	0.0	5	1	1	1
144159	1710	human t-cell lymphoblastic leukemia	[human T-cell lymphoblastic leukemia]	0.0	4	1	1	1
144160	1710	allergic inflammatory disease	[allergic inflammatory diseases]	0.0	3	1	1	1
144161	1710	ROI -reactive fluorochrome dcfh	[ROI -reactive fluorochrome DCFH-DA]	0.0	4	1	1	1
144162	1710	production 2	[production 2]	0.0	2	1	1	1
144163	1710	include the identification of family	[including the identification of families]	0.0	5	1	1	1
144164	1710	transcription factor iia	[transcription factor IIA]	0.0	3	1	1	1
144165	1710	expression of il-2ralpha gene	[expression of IL-2Ralpha genes]	0.0	4	1	1	1
144166	1710	intracellular receptor gr	[intracellular receptor GR]	0.0	3	1	1	1
144167	1710	factor in addition	[factors in addition]	0.0	3	1	1	1
144168	1710	immunodeficiency virus-1 hiv-1 enhancer	[immunodeficiency virus-1 HIV-1 enhancer]	0.0	4	1	1	1
144169	1710	b1 complex	[B1 complex]	0.0	2	1	1	1
144170	1710	implication in regulation	[implications in regulation]	0.0	3	1	1	1
144171	1710	twenty man aged	[Twenty men aged]	0.0	3	1	1	1
144172	1710	7 aml case	[7 AML cases]	0.0	3	1	1	1
144173	1710	production of large amount	[production of large amounts]	0.0	4	1	1	1
144174	1710	Proteasome-dependent kappa b alpha	[Proteasome-dependent kappa B alpha]	0.0	4	1	1	1
144175	1710	subset 25% of cases).	[subset 25% of cases).]	0.0	4	1	1	1
144176	1710	vivo effect of glucocorticoid relationship	[vivo effects of glucocorticoids relationship]	0.0	5	1	1	1
144177	1710	oxidative stress on activity	[oxidative stress on activities]	0.0	4	1	1	1
144178	1710	candidate gene for ags	[candidate genes for AGS]	0.0	4	1	1	1
144179	1710	element-containing promoter than the retinoid	[element-containing promoters than the retinoid]	0.0	5	1	1	1
144180	1710	factor-kappaB regulation	[factor-kappaB regulation]	0.0	2	1	1	1
144181	1710	regulate nuclear factor-kappa b activation	[regulating nuclear factor-kappa B activation]	0.0	5	1	1	1
144182	1710	maintenance of NFAT	[maintenance of NFAT]	0.0	3	1	1	1
144183	1710	human DR alpha	[human DR alpha]	0.0	3	1	1	1
144184	1710	many situations,	[many situations,]	0.0	2	1	1	1
144185	1710	igh element	[IgH elements]	0.0	2	1	1	1
144186	1710	important fundamental insight into the mechanism	[important fundamental insights into the mechanisms]	0.0	6	1	1	1
144187	1710	mechanism regulate glucocorticoid sensitivity	[mechanism regulating glucocorticoid sensitivity]	0.0	4	1	1	1
144188	1710	stimulation with phytohaemagglutinin	[stimulation with phytohaemagglutinin]	0.0	3	1	1	1
144189	1710	myeloid/natural killer	[myeloid/natural killer]	0.0	2	1	1	1
144190	1710	risk of infarction	[risk of infarction]	0.0	3	1	1	1
144191	1710	flexible mechanism control gene expression	[flexible mechanism controlling gene expression]	0.0	5	1	1	1
144192	1710	gene in acute megakaryoblastic leukaemia	[genes in acute megakaryoblastic leukaemia]	0.0	5	1	1	1
144193	1710	human ptf a complex	[human PTF a complex]	0.0	4	1	1	1
144194	1710	significantly favorable course chi2	[significantly favorable course chi2]	0.0	4	1	1	1
144195	1710	inhibitory pathway	[inhibitory pathway]	0.0	2	1	1	1
144196	1710	transcriptional activity of ap-1/tpa element	[transcriptional activity of AP-1/TPA elements]	0.0	5	1	1	1
144197	1710	most effective agent	[most effective agents]	0.0	3	1	1	1
144198	1710	few cell from donor	[Fewer cells from donors]	0.0	4	1	1	1
144199	1710	inhibitor of tumor cell growth.	[inhibitors of tumor cell growth.]	0.0	5	1	1	1
144200	1710	Southern blot analysis of genomic DNA	[Southern blot analysis of genomic DNA]	0.0	6	1	1	1
144201	1710	gata-1 to consensus site	[GATA-1 to consensus sites]	0.0	4	1	1	1
144202	1710	nm growth factor	[nM growth factor]	0.0	3	1	1	1
144203	1710	gradient gel electrophoresis	[gradient gel electrophoresis]	0.0	3	1	1	1
144204	1710	activation-inducible enhancer element	[activation-inducible enhancer elements]	0.0	3	1	1	1
144205	1710	activation of HSF2	[activation of HSF2]	0.0	3	1	1	1
144206	1710	spite of this similar signalling,	[spite of this similar signalling,]	0.0	5	1	1	1
144207	1710	transcription factor iid	[Transcription factor IID]	0.0	3	1	1	1
144208	1710	standard treatment	[standard treatment]	0.0	2	1	1	1
144209	1710	regulation in primary T lymphocyte	[regulation in primary T lymphocytes]	0.0	5	1	1	1
144210	1710	alpha-hydroxylase	[alpha-hydroxylase]	0.0	1	1	1	1
144211	1710	the/thf alpha thf/thf (0.35; ratios.	[THE/THF alpha THF/THF (0.35; ratios.]	0.0	5	1	1	1
144212	1710	p .001	[p .001]	0.0	2	1	1	1
144213	1710	primary b-cell by ebv	[primary B-cells by EBV]	0.0	4	1	1	1
144214	1710	two different experimental approach	[two different experimental approaches]	0.0	4	1	1	1
144215	1710	inducible protein ip-10	[inducible protein IP-10]	0.0	3	1	1	1
144216	1710	pituitary axis	[pituitary axis]	0.0	2	1	1	1
144217	1710	differ from dq3.2	[differing from DQ3.2]	0.0	3	1	1	1
144218	1710	G75 128-135	[G75 128-135]	0.0	2	1	1	1
144219	1710	induction of vcam-1 surface expression	[Induction of VCAM-1 surface expression]	0.0	5	1	1	1
144220	1710	cell express high kinase activity	[cells expressing high kinase activity]	0.0	5	1	1	1
144221	1710	key role for the residue	[key role for the residues]	0.0	5	1	1	1
144222	1710	putative loci relevant	[putative loci relevant]	0.0	3	1	1	1
144223	1710	human herpesvirus-6	[human herpesvirus-6]	0.0	2	1	1	1
144224	1710	responsiveness to activation	[responsiveness to activation]	0.0	3	1	1	1
144225	1710	receptor gcr in the lymphocyte	[receptor GCR in the lymphocytes]	0.0	5	1	1	1
144226	1710	aberrancy in the regulation	[aberrancies in the regulation]	0.0	4	1	1	1
144227	1710	nuclear factor-kappaB inhibitor	[nuclear factor-kappaB inhibitor]	0.0	3	1	1	1
144228	1710	such as CBL	[such as CBL]	0.0	3	1	1	1
144229	1710	analysis of nfat	[analysis of NFAT]	0.0	3	1	1	1
144230	1710	difference with difference	[differences with differences]	0.0	3	1	1	1
144231	1710	enhancement of non- lps uptake	[enhancement of non- LPS uptake]	0.0	5	1	1	1
144232	1710	il-10r unlike member	[IL-10R unlike members]	0.0	3	1	1	1
144233	1710	macrophage CSF gene	[macrophage CSF gene]	0.0	3	1	1	1
144234	1710	groove between the subdomain	[groove between the subdomains]	0.0	4	1	1	1
144235	1710	increment in promoter activity	[increment in promoter activity]	0.0	4	1	1	1
144236	1710	enhancer-dependent transcription	[enhancer-dependent transcription]	0.0	2	1	1	1
144237	1710	cyclic kinases.	[cyclic kinases.]	0.0	2	1	1	1
144238	1710	similarity to a initiator	[similarity to an initiator]	0.0	4	1	1	1
144239	1710	proteins, differ	[proteins, differing]	0.0	2	1	1	1
144240	1710	band range from kD	[bands ranging from kD]	0.0	4	1	1	1
144241	1710	alpha A1	[alpha A1]	0.0	2	1	1	1
144242	1710	synergistic formation between protein	[synergistic formation between proteins]	0.0	4	1	1	1
144243	1710	extensive analysis	[extensive analyses]	0.0	2	1	1	1
144244	1710	mouse,	[mouse,]	0.0	1	1	1	1
144245	1710	-inductive	[-inductive]	0.0	1	1	1	1
144246	1710	mechanism of the capacity	[mechanisms of the capacities]	0.0	4	1	1	1
144247	1710	range to kd,	[ranging to kD,]	0.0	3	1	1	1
144248	1710	subtraction potential	[subtraction potential]	0.0	2	1	1	1
144249	1710	gc enhancement of sialoadhesin expression	[GC enhancement of sialoadhesin expression]	0.0	5	1	1	1
144250	1710	bcl-6 +/cd3+ cell	[Bcl-6 +/CD3+ cells]	0.0	3	1	1	1
144251	1710	roi- -independent pathway	[ROI- -independent pathway]	0.0	3	1	1	1
144252	1710	Furthermore, concentration of HU	[Furthermore, concentrations of HU]	0.0	4	1	1	1
144253	1710	inflammatory pathology such as failure	[inflammatory pathologies such as failure]	0.0	5	1	1	1
144254	1710	mechanism for n-acetylcysteine inhibition e-selectin	[mechanisms for N-acetylcysteine inhibition E-selectin]	0.0	5	1	1	1
144255	1710	samples, cytotoxic activity of egl	[samples, cytotoxic activity of eGLs]	0.0	5	1	1	1
144256	1710	transcription include gamma-globin	[transcription including gamma-globin]	0.0	3	1	1	1
144257	1710	low renin	[low renin]	0.0	2	1	1	1
144258	1710	other condition of importance.	[other conditions of importance.]	0.0	4	1	1	1
144259	1710	9.36 nm, bmax 158 +/- 16	[9.36 nM, Bmax 158 +/- 16]	0.0	6	1	1	1
144260	1710	blood monocyte pbm	[blood monocytes PBM]	0.0	3	1	1	1
144261	1710	peak at 4-6 h.	[peaks at 4-6 h,]	0.0	4	1	1	1
144262	1710	human immunoglobulin gene	[human immunoglobulin genes]	0.0	3	1	1	1
144263	1710	type 5 adenovirus in t-lymphocyte	[type 5 adenovirus in T-lymphocytes]	0.0	5	1	1	1
144264	1710	event to cell ECs	[event to cells ECs]	0.0	4	1	1	1
144265	1710	infection analysis of LTR mutation	[Infection analyses of LTR mutations]	0.0	5	1	1	1
144266	1710	human member of a class	[human member of a class]	0.0	5	1	1	1
144267	1710	A6H monoclonal antibody	[A6H monoclonal antibody]	0.0	3	1	1	1
144268	1710	monocyte from familial (fh) subject	[monocytes from familial (FH) subjects]	0.0	5	1	1	1
144269	1710	mixture, associate preferentially	[mixture, associates preferentially]	0.0	3	1	1	1
144270	1710	generation of chronic condition	[generation of chronic conditions]	0.0	4	1	1	1
144271	1710	site of nfat-1 activity	[sites of NFAT-1 activity]	0.0	4	1	1	1
144272	1710	contrast, inhibition of less magnitude	[contrast, inhibition of lesser magnitude]	0.0	5	1	1	1
144273	1710	receptor (pparalpha) transcription factor	[receptor (PPARalpha) transcription factor]	0.0	4	1	1	1
144274	1710	ap1 complex	[AP1 complex]	0.0	2	1	1	1
144275	1710	negative regulatory domain	[negative regulatory domain]	0.0	3	1	1	1
144276	1710	role of protein kinase c	[role of protein kinase C]	0.0	5	1	1	1
144277	1710	bind to a intracellular receptor	[binding to an intracellular receptor]	0.0	5	1	1	1
144278	1710	cd34+ cell g-csf cell g-csf	[CD34+ cells G-CSF cells G-CSF]	0.0	5	1	1	1
144279	1710	induction of rela(p65)	[Induction of relA(p65)]	0.0	3	1	1	1
144280	1710	glucocorticoid sensitivity between tissues.	[glucocorticoid sensitivity between tissues.]	0.0	4	1	1	1
144281	1710	interaction of within the compartment	[interaction of within the compartment]	0.0	5	1	1	1
144282	1710	use a screen	[Using a screen]	0.0	3	1	1	1
144283	1710	rna splicing pattern	[RNA splicing patterns]	0.0	3	1	1	1
144284	1710	human-peripheral-blood T cell	[human-peripheral-blood T cells]	0.0	3	1	1	1
144285	1710	consist only of the intracellular domain	[consisting only of the intracellular domain]	0.0	6	1	1	1
144286	1710	corticosteroid receptor human glucocorticoid receptor	[corticosteroid receptors human glucocorticoid receptors]	0.0	5	1	1	1
144287	1710	various disorder	[various disorders]	0.0	2	1	1	1
144288	1710	porcine serum (control)	[porcine serum (control)]	0.0	3	1	1	1
144289	1710	sequencing 20 amino acid	[sequencing 20 amino acids]	0.0	4	1	1	1
144290	1710	activation of the factor FcRFgamma	[activation of the factor FcRFgamma]	0.0	5	1	1	1
144291	1710	contain the gamma 3 ECS	[containing the gamma 3 ECS]	0.0	5	1	1	1
144292	1710	difference between the patient	[difference between the patients]	0.0	4	1	1	1
144293	1710	immunodeficiency virus enhancer	[immunodeficiency virus enhancer]	0.0	3	2	2	1
144294	1710	presence of clinical responsiveness	[presence of clinical responsiveness]	0.0	4	1	1	1
144295	1710	125(oh)2d2 production	[1,25(OH)2D2 production]	0.0	2	1	1	1
144296	1710	induction kappa B/Rel activity monoclonal antibody	[Induction kappa B/Rel activity monoclonal antibodies]	0.0	6	1	1	1
144297	1710	activity of the viral repeat	[activity of the viral repeat]	0.0	5	1	1	1
144298	1710	vitamin cell line	[vitamin cell line]	0.0	3	1	1	1
144299	1710	yb-1 expression	[YB-1 expression]	0.0	2	1	1	1
144300	1710	specific target for a screen	[specific targets for a screening]	0.0	5	1	1	1
144301	1710	form of selection	[forms of selection]	0.0	3	1	1	1
144302	1710	portion of this region,	[portion of this region,]	0.0	4	1	1	1
144303	1710	important role protect injury	[important role protecting injury]	0.0	4	1	1	1
144304	1710	major product of monocyte	[major products of monocytes]	0.0	4	1	1	1
144305	1710	tateas	[tat/AS]	0.0	1	1	1	1
144306	1710	les-induced transcription factor ap-1	[LPS-induced transcription factors AP-1]	0.0	4	1	1	1
144307	1710	region of human il-2r beta	[region of human IL-2R beta]	0.0	5	1	1	1
144308	1710	gene activity plasmid	[gene activity plasmids]	0.0	3	1	1	1
144309	1710	t-cell protein hox11	[T-cell protein HOX11]	0.0	3	1	1	1
144310	1710	seen, migration of antigen t-cell	[seen, migration of antigen T-cells]	0.0	5	1	1	1
144311	1710	peptide library	[peptide libraries]	0.0	2	1	1	1
144312	1710	-raralpha403	[-RARalpha403]	0.0	1	1	1	1
144313	1710	component of bacterium	[component of bacteria]	0.0	3	1	1	1
144314	1710	inhibitor of protease	[inhibitor of proteases]	0.0	3	1	1	1
144315	1710	role of Egr-2 in up-regulation	[Role of Egr-2 in up-regulation]	0.0	5	1	1	1
144316	1710	pkc -alpha	[PKC -alpha]	0.0	2	1	1	1
144317	1710	t(12;15)	[t(12;15)]	0.0	1	1	1	1
144318	1710	(bear nf-kappa b site	[(bearing NF-kappa B sites]	0.0	4	1	1	1
144319	1710	reading frame encode a protein	[reading frame encoding a protein]	0.0	5	1	1	1
144320	1710	stage of myeloid development	[stages of myeloid development]	0.0	4	1	1	1
144321	1710	HC11 mammary cell	[HC11 mammary cells]	0.0	3	1	1	1
144322	1710	response-specific pattern	[response-specific patterns]	0.0	2	1	1	1
144323	1710	phase of interleukin-2	[phase of interleukin-2]	0.0	3	1	1	1
144324	1710	scant cytoplasm with azurophilic granularity	[scant cytoplasm with azurophilic granularity]	0.0	5	1	1	1
144325	1710	similar rearrangement	[Similar rearrangements]	0.0	2	1	1	1
144326	1710	promoter region in the u-937	[promoter regions in the U-937]	0.0	5	1	1	1
144327	1710	12 rdna	[12 cDNAs]	0.0	2	1	1	1
144328	1710	fast feedback	[fast feedback]	0.0	2	1	1	1
144329	1710	A.Rickinson, cell	[A.Rickinson, Cell]	0.0	2	1	1	1
144330	1710	H-RS cell line	[H-RS cell lines]	0.0	3	1	1	1
144331	1710	maintenance of proviral transcription	[maintenance of proviral transcription]	0.0	4	1	1	1
144332	1710	rna, p	[RNA, P]	0.0	2	1	1	1
144333	1710	low effect in	[lower effects in]	0.0	3	1	1	1
144334	1710	maturing granulocyte	[maturing granulocytes]	0.0	2	1	1	1
144335	1710	contain the cytomegalovirus enhancer	[containing the cytomegalovirus enhancer]	0.0	4	1	1	1
144336	1710	cis-tran isomerase distinct from cyclophilin	[cis-trans isomerase distinct from cyclophilin]	0.0	5	1	1	1
144337	1710	long acting	[longer acting]	0.0	2	1	1	1
144338	1710	uptake by PBMC	[uptake by PBMC]	0.0	3	1	1	1
144339	1710	costimulation of cd4+ T cell	[Costimulation of CD4+ T cells]	0.0	5	1	1	1
144340	1710	contain base pair substitution	[containing base pair substitutions]	0.0	4	1	1	1
144341	1710	transcription factor include factor	[transcription factors including factor]	0.0	4	1	1	1
144342	1710	neutralize il-1beta antibody	[neutralizing IL-1beta antibody]	0.0	3	1	1	1
144343	1710	substitution of the pro-x-pro	[substitution of the Pro-X-Pro]	0.0	4	1	1	1
144344	1710	stretch of 23 amino acid	[stretch of 23 amino acids]	0.0	5	1	1	1
144345	1710	receptor on ut-7/gmt cell	[receptor on UT-7/GMT cells]	0.0	4	1	1	1
144346	1710	monocyte with 12-0-tetradecanoyl phorbol-13-acetate tpa	[monocytes with 12-0-tetradecanoyl phorbol-13-acetate TPA]	0.0	5	1	1	1
144347	1710	expressed; however, cell	[expressed; however, cells]	0.0	3	1	1	1
144348	1710	cd8+ CTL response to ebv	[CD8+ CTL response to EBV]	0.0	5	1	1	1
144349	1710	carry ig heavy chain sequence	[carrying Ig heavy chain sequences]	0.0	5	1	1	1
144350	1710	pathophysiologic events,	[pathophysiologic events,]	0.0	2	1	1	1
144351	1710	steroid include DHEA sulfate	[steroids including DHEA sulfate]	0.0	4	1	1	1
144352	1710	il-2 receptivity	[IL-2 receptivity]	0.0	2	1	1	1
144353	1710	hematopoietic origin	[hematopoietic origin]	0.0	2	3	3	1
144354	1710	level by dexamethasone	[level by dexamethasone]	0.0	3	1	1	1
144355	1710	repeat-cat	[repeat-CAT]	0.0	1	1	1	1
144356	1710	require approximately 2 log-fold glucocorticoid	[requiring approximately 2 log-fold glucocorticoids]	0.0	5	1	1	1
144357	1710	VZV human donor	[VZV human donors]	0.0	3	1	1	1
144358	1710	osteoclast phenotypic property	[osteoclast phenotypic properties]	0.0	3	1	1	1
144359	1710	two other hla-b8-restricted epitope	[two other HLA-B8-restricted epitopes]	0.0	4	1	1	1
144360	1710	4.27 (range,	[4.27 (range,]	0.0	2	1	1	1
144361	1710	sixteen anorexic patient aged years,	[Sixteen anorexic patients aged years,]	0.0	5	1	1	1
144362	1710	first limitation to potential effect	[first limitation to potential effects]	0.0	5	1	1	1
144363	1710	patient aml cases)	[patients AML cases)]	0.0	3	1	1	1
144364	1710	M0/M1	[M0/M1]	0.0	1	1	1	1
144365	1710	activation the initial gene promoter	[activation the initial gene promoter]	0.0	5	1	1	1
144366	1710	calcium -independent CD28 pathway	[calcium -independent CD28 pathway]	0.0	4	1	1	1
144367	1710	transactivation by nuclear factor	[transactivation by nuclear factor]	0.0	4	1	1	1
144368	1710	various breakpoint 11 range from q13	[various breakpoints 11 ranging from q13]	0.0	6	1	1	1
144369	1710	Dexamethasone a synthetic hormone	[Dexamethasone a synthetic hormone]	0.0	4	1	1	1
144370	1710	four distinct protein complex	[four distinct protein complexes]	0.0	4	1	1	1
144371	1710	infection with a retrovirus	[infection with a retrovirus]	0.0	4	1	1	1
144372	1710	effect of lipopolysaccharide lps	[effects of lipopolysaccharide LPS]	0.0	4	1	1	1
144373	1710	runt domain	[Runt domain]	0.0	2	1	1	1
144374	1710	similarly in human macrophage	[similarly in human macrophages]	0.0	4	1	1	1
144375	1710	Slight difference	[Slight differences]	0.0	2	1	1	1
144376	1710	h1-histamine receptor	[H1-histamine receptors]	0.0	2	1	1	1
144377	1710	99% suppression sla-dr	[99% suppression SLA-DR]	0.0	3	1	1	1
144378	1710	(oas)	[(OAS)]	0.0	1	1	1	1
144379	1710	function of the c-erbA	[function of the c-erbA]	0.0	4	1	1	1
144380	1710	frequent hypermutation	[frequent hypermutation]	0.0	2	1	1	1
144381	1710	such as gamma-globin erythroid delta-aminolevulinate synthase	[such as gamma-globin erythroid delta-aminolevulinate synthase]	0.0	6	1	1	1
144382	1710	1.7 kilobasis (kb)	[1.7 kilobases (kb)]	0.0	3	1	1	1
144383	1710	sex difference	[sex difference]	0.0	2	1	1	1
144384	1710	nfat activation with ic50	[NFAT activation with IC50s]	0.0	4	1	1	1
144385	1710	interleukin (il)-4 stimulation	[interleukin (IL)-4 stimulation]	0.0	3	1	1	1
144386	1710	Sublethal level of stress	[Sublethal levels of stress]	0.0	4	2	2	1
144387	1710	modulation by mechanism	[modulation by mechanisms]	0.0	3	1	1	1
144388	1710	leukocyte function such as chemotaxis	[leukocyte functions such as chemotaxis]	0.0	5	1	1	1
144389	1710	follow IL-2 stimulation of T cell	[following IL-2 stimulation of T cells]	0.0	6	1	1	1
144390	1710	beta-catenin Delta19	[beta-catenin Delta19]	0.0	2	1	1	1
144391	1710	significance of nf-kappab activation	[significance of NF-kappaB activation]	0.0	4	1	1	1
144392	1710	mobility shift assay with mutant probe	[Mobility shift assays with mutant probes]	0.0	6	1	1	1
144393	1710	Jak1 activation	[Jak1 activation]	0.0	2	1	1	1
144394	1710	high translocation of nf-kappa b	[higher translocation of NF-kappa B]	0.0	5	1	1	1
144395	1710	number of different kinases,	[number of different kinases,]	0.0	4	1	1	1
144396	1710	novel octamer sequence pos	[novel octamer sequence POS]	0.0	4	1	1	1
144397	1710	gos19	[GOS19]	0.0	1	1	1	1
144398	1710	novel step	[novel step]	0.0	2	1	1	1
144399	1710	DNA divide	[DNA dividing]	0.0	2	1	1	1
144400	1710	micromolar amount	[micromolar amounts]	0.0	2	1	1	1
144401	1710	lead to proteolysis of substrate	[leading to proteolysis of substrates]	0.0	5	1	1	1
144402	1710	study use cytosol	[studies using cytosol]	0.0	3	1	1	1
144403	1710	interleukin il-10r	[interleukin IL-10R]	0.0	2	1	1	1
144404	1710	several adhesion molecule	[several adhesion molecules]	0.0	3	1	1	1
144405	1710	element act somewhat independently	[elements acting somewhat independently]	0.0	4	1	1	1
144406	1710	Jeg-3 human immunosuppression downregulation of interleukin-2	[Jeg-3 human immunosuppression downregulation of interleukin-2]	0.0	6	1	1	1
144407	1710	vivo, elicit remission	[vivo, eliciting remissions]	0.0	3	1	1	1
144408	1710	mineralocorticoid may,	[mineralocorticoid may,]	0.0	2	1	1	1
144409	1710	one factor determine gene activation	[one factor determining gene activation]	0.0	5	1	1	1
144410	1710	membrane from mononuclear leukocyte	[membranes from mononuclear leukocytes]	0.0	4	1	1	1
144411	1710	addition, detergent treatment	[addition, detergent treatment]	0.0	3	1	1	1
144412	1710	tumorigenic T	[tumorigenic T]	0.0	2	1	1	1
144413	1710	calcitriol ethanol concentration	[calcitriol ethanol concentration]	0.0	3	1	1	1
144414	1710	mechanism mediate cell death	[mechanisms mediating cell death]	0.0	4	1	1	1
144415	1710	mechanism of t-lymphocyte anergy	[mechanisms of T-lymphocyte anergy]	0.0	4	1	1	1
144416	1710	transcriptional activation of Wp,	[transcriptional activation of Wp,]	0.0	4	1	1	1
144417	1710	biochemical event lead	[biochemical events leading]	0.0	3	1	1	1
144418	1710	proportion of tumor cell	[proportions of tumor cells]	0.0	4	1	1	1
144419	1710	cytosine at position	[cytosine at position]	0.0	3	1	1	1
144420	1710	and/or stage-specific expression	[and/or stage-specific expression]	0.0	3	1	1	1
144421	1710	antigen ea	[antigen EA]	0.0	2	1	1	1
144422	1710	lack the consensus binding site	[lacking the consensus binding sites]	0.0	5	1	1	1
144423	1710	sodium supplementation	[sodium supplementation]	0.0	2	1	1	1
144424	1710	glutathione-s-transferase pi gst-pi	[glutathione-S-transferase pi GST-pi]	0.0	3	1	1	1
144425	1710	23 amino acid rich	[23 amino acids rich]	0.0	4	1	1	1
144426	1710	183 +/- 29.8	[183 +/- 29.8]	0.0	3	1	1	1
144427	1710	rapidak effect on transmembrane electrolyte movement	[rapid, effects on transmembrane electrolyte movements]	0.0	6	1	1	1
144428	1710	cytosolic c-rel/ p65 heterodimer	[cytosolic c-Rel/ p65 heterodimers]	0.0	4	1	1	1
144429	1710	mutation (-175 t-c)	[mutation (-175 T-C)]	0.0	3	1	1	1
144430	1710	suggest cooperativity in the response	[suggesting cooperativity in the response]	0.0	5	1	1	1
144431	1710	renaturation experiment with the use	[renaturation experiments with the use]	0.0	5	1	1	1
144432	1710	stimulus elicit stress such as cytokine	[stimuli eliciting stress such as cytokines]	0.0	6	1	1	1
144433	1710	ineffectiveness of spironolactone	[ineffectiveness of spironolactones]	0.0	3	2	2	1
144434	1710	methionine codon-initiated reading frame	[methionine codon-initiated reading frame]	0.0	4	1	1	1
144435	1710	total pkc activity	[Total PKC activity]	0.0	3	1	1	1
144436	1710	class major histocompatibility gene transcription	[class major histocompatibility gene transcription]	0.0	5	1	1	1
144437	1710	Hela extract	[Hela extracts]	0.0	2	1	1	1
144438	1710	inhibit the cox-2 activity	[inhibiting the COX-2 activity]	0.0	4	1	1	1
144439	1710	t-cell-specific factor tcf-1 alpha	[T-cell-specific factor TCF-1 alpha]	0.0	4	1	1	1
144440	1710	first 18 h	[first 18 h]	0.0	3	1	1	1
144441	1710	mitogenic effect on organ	[mitogenic effects on organs]	0.0	4	1	1	1
144442	1710	nf-kappab -dependent promoter	[NF-kappaB -dependent promoter]	0.0	3	1	1	1
144443	1710	increase phospholipase c	[increase phospholipase C]	0.0	3	1	1	1
144444	1710	anti-Tat intrabody	[anti-Tat intrabodies]	0.0	2	1	1	1
144445	1710	chromatin-integrated yeast cell	[chromatin-integrated yeast cells]	0.0	3	1	1	1
144446	1710	prevalence in random breast aspirate	[Prevalence in random breast aspirates]	0.0	5	1	1	1
144447	1710	powerful suppressor notably of T cell	[powerful suppressors notably of T cells]	0.0	6	1	1	1
144448	1710	granulopoiesis typically die by 8	[granulopoiesis typically dying by 8]	0.0	5	1	1	1
144449	1710	differentiation of leukemic hl-60 cell	[differentiation of leukemic HL-60 cells]	0.0	5	1	1	1
144450	1710	protection against hiv infection	[protection against HIV infection]	0.0	4	1	1	1
144451	1710	dinucleotide repeat in the sequence	[dinucleotide repeat in the sequences]	0.0	5	1	1	1
144452	1710	ATP-dependent 26 s protease	[ATP-dependent 26 S proteases]	0.0	4	1	1	1
144453	1710	DNA transfection of various gene	[DNA transfections of various gene]	0.0	5	1	1	1
144454	1710	b alpha /mad-3 mrna level	[B alpha /MAD-3 mRNA levels]	0.0	5	1	1	1
144455	1710	stains,	[stains,]	0.0	1	1	1	1
144456	1710	OCA-B -dependent transcription	[OCA-B -dependent transcription]	0.0	3	1	1	1
144457	1710	intense T lymphocyte	[intense T lymphocyte]	0.0	3	1	1	1
144458	1710	pc4 component	[PC4 component]	0.0	2	1	1	1
144459	1710	Nuclear 3,5,3'-triiodothyronine receptor circulate lymphocyte thyroidism	[Nuclear 3,5,3'-triiodothyronine receptors circulating lymphocytes thyroidism]	0.0	6	1	1	1
144460	1710	response of pml-rar alpha	[responses of PML-RAR alpha]	0.0	4	1	1	1
144461	1710	radiation dose	[radiation dose]	0.0	2	2	2	1
144462	1710	number of affinity il-2r	[number of affinity IL-2Rs]	0.0	4	1	1	1
144463	1710	hypothesis factor	[hypothesis factors]	0.0	2	1	1	1
144464	1710	6 month month	[6 months months]	0.0	3	1	1	1
144465	1710	critical mechanism.	[critical mechanism.]	0.0	2	1	1	1
144466	1710	C/EBPalpha -deficient mouse	[C/EBPalpha -deficient mice]	0.0	3	1	1	1
144467	1710	growth transformation of b-cell	[Growth transformation of B-cells]	0.0	4	1	1	1
144468	1710	megakaryocyte-specific protein	[megakaryocyte-specific proteins]	0.0	2	1	1	1
144469	1710	expression of gene in disorder	[Expression of genes in disorders]	0.0	5	1	1	1
144470	1710	role of this motif	[role of these motifs]	0.0	4	1	1	1
144471	1710	induction of Jurkat T cell	[Induction of Jurkat T cells]	0.0	5	1	1	1
144472	1710	androgen-modulated rat prostate tissue	[androgen-modulated rat prostate tissue]	0.0	4	1	1	1
144473	1710	character in spontaneous abortion	[character in spontaneous abortion]	0.0	4	1	1	1
144474	1710	synergistic interaction between binding site	[Synergistic interactions between binding sites]	0.0	5	1	1	1
144475	1710	hla-dr synthesis	[HLA-DR synthesis]	0.0	2	1	1	1
144476	1710	human blood monocyte pbmo	[human blood monocytes PBMo]	0.0	4	1	1	1
144477	1710	genes, include adhesive molecule	[genes, including adhesive molecules]	0.0	4	1	1	1
144478	1710	er-:	[ER-:]	0.0	1	1	1	1
144479	1710	PRDII domain	[PRDII domain]	0.0	2	1	1	1
144480	1710	nuclear protein (s)	[nuclear protein (s)]	0.0	3	1	1	1
144481	1710	ability of type domain	[ability of type domain]	0.0	4	1	1	1
144482	1710	acute process	[acute processes]	0.0	2	1	1	1
144483	1710	MHC class w-x-y	[MHC class W-X-Y]	0.0	3	1	1	1
144484	1710	hsp60 expression	[Hsp60 expression]	0.0	2	1	1	1
144485	1710	bind affinity (Kd)	[binding affinity (Kd)]	0.0	3	1	1	1
144486	1710	vehicle	[vehicle]	0.0	1	1	1	1
144487	1710	FL progenitor colony-form unit monocyte cfu-m	[FL progenitors colony-forming unit monocyte CFU-M]	0.0	6	1	1	1
144488	1710	pattern of activity	[pattern of activity]	0.0	3	1	1	1
144489	1710	protein bind the element	[proteins binding the element]	0.0	4	1	1	1
144490	1710	receptor such as tnfr1	[receptors such as TNFR1]	0.0	4	1	1	1
144491	1710	th2-specific activity	[Th2-specific activity]	0.0	2	1	1	1
144492	1710	contain receptor l753f	[containing receptors L753F]	0.0	3	1	1	1
144493	1710	absence of a signal	[absence of an signal]	0.0	4	1	1	1
144494	1710	effect in the remain patient	[effect in the remaining patients]	0.0	5	1	1	1
144495	1710	multiple transcriptional regulatory element	[multiple transcriptional regulatory elements]	0.0	4	1	1	1
144496	1710	two regulatory pathway	[two regulatory pathways]	0.0	3	1	1	1
144497	1710	anti-immunoglobulin m	[anti-immunoglobulin M]	0.0	2	1	1	1
144498	1710	adolescent Callithrix jacchus	[adolescent Callithrix jacchus]	0.0	3	1	1	1
144499	1710	effect of this hormone	[effects of this hormone]	0.0	4	1	1	1
144500	1710	IL-3 granulocyte-macrophage colony-stimumulatelany-stg factor complex	[IL-3 granulocyte-macrophage colony-stimulating factor complexes]	0.0	5	1	1	1
144501	1710	cell within plaque	[cells within plaques]	0.0	3	1	1	1
144502	1710	expression in primary monocyte	[expression in primary monocytes]	0.0	4	1	1	1
144503	1710	CD2 mab	[CD2 mAbs]	0.0	2	1	1	1
144504	1710	retinoid X receptor activation	[Retinoid X receptor activation]	0.0	4	1	1	1
144505	1710	unexpected observation of expression	[unexpected observations of expression]	0.0	4	1	1	1
144506	1710	express adhesive molecule	[expressing adhesive molecules]	0.0	3	1	1	1
144507	1710	nf-kappab modulator),	[NF-kappaB modulator),]	0.0	2	1	1	1
144508	1710	Sp1urday transcription factor	[Sp1- transcription factors]	0.0	3	1	1	1
144509	1710	acid phosphatase multinucleated giant cell	[acid phosphatase multinucleated giant cells]	0.0	5	1	1	1
144510	1710	member of NFAT gene family	[members of NFAT gene family]	0.0	5	1	1	1
144511	1710	AM580 a benzoic derivative	[AM580 a benzoic derivative]	0.0	4	1	1	1
144512	1710	recombinant thyroid	[recombinant thyroid]	0.0	2	1	1	1
144513	1710	much high concentration of antioxidant	[Much higher concentrations of antioxidants]	0.0	5	1	1	1
144514	1710	Jurkat expression	[Jurkat expression]	0.0	2	1	1	1
144515	1710	direct interaction antagonism in cell	[Direct interaction antagonism in cells]	0.0	5	1	1	1
144516	1710	cd4(-) cell	[CD4(-) cells]	0.0	2	1	1	1
144517	1710	aldosterone to receptor	[aldosterone to receptors]	0.0	3	1	1	1
144518	1710	lymphocyte-specific gene	[lymphocyte-specific genes]	0.0	2	1	1	1
144519	1710	environmental factors,	[environmental factors,]	0.0	2	1	1	1
144520	1710	directly to hiv-1 replication	[directly to HIV-1 replication]	0.0	4	1	1	1
144521	1710	enhancer of hiv-1	[enhancers of HIV-1]	0.0	3	1	1	1
144522	1710	T lymphocyte present	[T lymphocytes present]	0.0	3	1	1	1
144523	1710	plant source	[plant sources]	0.0	2	1	1	1
144524	1710	human blood lymphocyte with cysteamine	[human blood lymphocytes with cysteamine]	0.0	5	1	1	1
144525	1710	moderate abundance	[moderate abundance]	0.0	2	1	1	1
144526	1710	difference in sensitivity between tissues.	[differences in sensitivity between tissues.]	0.0	5	1	1	1
144527	1710	recombinant nucleolin	[recombinant nucleolin]	0.0	2	1	1	1
144528	1710	p50/nf-kappa b	[p50/NF-kappa B]	0.0	2	1	1	1
144529	1710	domain of member	[domains of members]	0.0	3	1	1	1
144530	1710	disease biliary cirrhosis	[disease biliary cirrhosis]	0.0	3	1	1	1
144531	1710	entire IL2 region	[entire IL2 region]	0.0	3	1	1	1
144532	1710	cell type-specificity	[cell type-specificity]	0.0	2	1	1	1
144533	1710	icam-1 surface protein in endothelial cell	[ICAM-1 surface protein in endothelial cells]	0.0	6	1	1	1
144534	1710	expression activation of the il-2 receptor	[expression activation of the IL-2 receptor]	0.0	6	1	1	1
144535	1710	71 months)	[71 months)]	0.0	2	1	1	1
144536	1710	factor interact	[factors interacting]	0.0	2	1	1	1
144537	1710	immunoglobulin switch region	[immunoglobulin switch region]	0.0	3	1	1	1
144538	1710	MHC class cell	[MHC class cells]	0.0	3	1	1	1
144539	1710	other adherence-associated early gene	[other adherence-associated early genes]	0.0	4	1	1	1
144540	1710	action of the regulatory element	[actions of the regulatory elements]	0.0	5	1	1	1
144541	1710	Epstein-Barr virus EBV nuclear antigen 2	[Epstein-Barr virus EBV nuclear antigen 2]	0.0	6	1	1	1
144542	1710	arm of Chr	[arm of Chr]	0.0	3	1	1	1
144543	1710	16-96 h	[16-96 h]	0.0	2	1	1	1
144544	1710	inhibitor of pi3-kinase	[inhibitor of PI3-kinase]	0.0	3	1	1	1
144545	1710	GH4C1 cell	[GH4C1 cells]	0.0	2	1	1	1
144546	1710	human glucocorticoid cortisol	[human glucocorticoid cortisol]	0.0	3	1	1	1
144547	1710	response involve activation	[response involving activation]	0.0	3	1	1	1
144548	1710	concomitant inhibitory effect	[concomitant inhibitory effects]	0.0	3	1	1	1
144549	1710	cover 10%	[covering 10%]	0.0	2	1	1	1
144550	1710	survival il-3 murine pro-B cell	[survival IL-3 murine pro-B cells]	0.0	5	1	1	1
144551	1710	domain heterogeneity of igg fc receptor	[domain heterogeneity of IgG Fc receptors]	0.0	6	1	1	1
144552	1710	signal of BW	[signaling of BW]	0.0	3	1	1	1
144553	1710	multiple nucleotide substitution	[multiple nucleotide substitutions]	0.0	3	1	1	1
144554	1710	Comparison of the combination of olp	[Comparison of the combinations of /LPS]	0.0	6	1	1	1
144555	1710	strong increase the number	[strong increase the number]	0.0	4	1	1	1
144556	1710	tsc2 gene expression	[TSC2 gene expression]	0.0	3	1	1	1
144557	1710	viral insertion site in leukemia	[viral insertion site in leukemia]	0.0	5	1	1	1
144558	1710	tpa -inducible factor protein OAP40	[TPA -inducible factor protein OAP40]	0.0	5	1	1	1
144559	1710	contrast, two anti-inflammatory drug	[contrast, two anti-inflammatory drugs]	0.0	4	1	1	1
144560	1710	solution structure 3D-NMR study	[Solution structure 3D-NMR studies]	0.0	4	1	1	1
144561	1710	discordance in certain mnda cell	[discordance in certain MNDA cells]	0.0	5	1	1	1
144562	1710	p45 nf-e2 mrna in peripheral granurocyte	[P45 NF-E2 mRNA in peripheral granurocytes]	0.0	6	1	1	1
144563	1710	region of the IL-3	[region of the IL-3]	0.0	4	1	1	1
144564	1710	23 clearly cells, respectively),	[23 clearly cells, respectively),]	0.0	4	1	1	1
144565	1710	expression of superoxide dismutase Mn-SOD	[expression of superoxide dismutase Mn-SOD]	0.0	5	1	1	1
144566	1710	factor in cell	[factor in cells]	0.0	3	1	1	1
144567	1710	histocompatibility complex way	[histocompatibility complex way]	0.0	3	1	1	1
144568	1710	full length promoter	[full length promoter]	0.0	3	1	1	1
144569	1710	anti-inflammatory cytokine	[anti-inflammatory cytokines]	0.0	2	1	1	1
144570	1710	representative form of proteins, aml1a	[representative forms of proteins, AML1a]	0.0	5	1	1	1
144571	1710	motif present a similarity	[motif presenting a similarity]	0.0	4	1	1	1
144572	1710	great diversity	[great diversity]	0.0	2	1	1	1
144573	1710	use T cell hybridoma model a1.1	[Using T cell hybridoma model A1.1]	0.0	6	1	1	1
144574	1710	e(2) receptor-positive murine line, e(2)	[E(2) receptor-positive murine line, E(2)]	0.0	5	1	1	1
144575	1710	only through evaluation of evidence	[Only through evaluation of evidence]	0.0	5	1	1	1
144576	1710	principle of medicine	[principle of medicine]	0.0	3	1	1	1
144577	1710	signal from the TCR/CD3 complex	[signals from the TCR/CD3 complex]	0.0	5	1	1	1
144578	1710	common finding	[common finding]	0.0	2	1	1	1
144579	1710	phenolic, chain-breaking antioxidant hydroxyanisole bha	[phenolic, chain-breaking antioxidants hydroxyanisole BHA]	0.0	5	1	1	1
144580	1710	vitro study use pure p21ras	[vitro studies using pure p21ras]	0.0	5	1	1	1
144581	1710	other gene on chromosome 11	[other genes on chromosome 11]	0.0	5	1	1	1
144582	1710	suppression of specific transcription factor function	[suppression of specific transcription factor functions]	0.0	6	1	1	1
144583	1710	treatment with schedule of oral calcitriol	[Treatment with schedules of oral calcitriol]	0.0	6	1	1	1
144584	1710	nfat activity in a ras manner	[NFAT activity in a Ras manner]	0.0	6	1	1	1
144585	1710	c -alpha	[C -alpha]	0.0	2	1	1	1
144586	1710	long-lasting effect on the transcription	[long-lasting effect on the transcription]	0.0	5	1	1	1
144587	1710	vitro, in culture	[vitro, in culture]	0.0	3	1	1	1
144588	1710	protein function	[protein function]	0.0	2	1	1	1
144589	1710	trigger into phenotypic changes, include repression	[triggering into phenotypic changes, including repression]	0.0	6	1	1	1
144590	1710	135(oh)2d3 receptor on alveolar lymphocyte	[1,25(OH)2D3 receptors on alveolar lymphocytes]	0.0	5	1	1	1
144591	1710	endoglycosidase h consistent	[endoglycosidase H consistent]	0.0	3	1	1	1
144592	1710	myc-max heterodimer	[Myc-Max heterodimer]	0.0	2	1	1	1
144593	1710	diffusion of ones.	[diffusion of ones.]	0.0	3	1	1	1
144594	1710	sample of fresh blood	[samples of fresh blood]	0.0	4	1	1	1
144595	1710	understand the involvement	[understanding the involvement]	0.0	3	1	1	1
144596	1710	proliferation of T	[proliferation of T]	0.0	3	1	1	1
144597	1710	(inhibitory) effect	[(inhibitory) effects]	0.0	2	1	1	1
144598	1710	negative mutant of the IL-1 pathway	[negative mutants of the IL-1 pathway]	0.0	6	1	1	1
144599	1710	variant analysis of promoter	[variants analysis of promoters]	0.0	4	1	1	1
144600	1710	analysis of the expression I	[Analysis of the expression I]	0.0	5	1	1	1
144601	1710	difference in sensitivity	[differences in sensitivity]	0.0	3	1	1	1
144602	1710	Growing evidence	[Growing evidence]	0.0	2	1	1	1
144603	1710	weak correlation	[weak correlation]	0.0	2	1	1	1
144604	1710	accumulation of biochemical lesion	[accumulation of biochemical lesions]	0.0	4	1	1	1
144605	1710	overexpression of SIT	[Overexpression of SIT]	0.0	3	1	1	1
144606	1710	element of the blr1 core promoter	[elements of the blr1 core promoter]	0.0	6	1	1	1
144607	1710	vitro tyrosine kinase	[vitro tyrosine kinase]	0.0	3	1	1	1
144608	1710	HTLV-I terminal repeat	[HTLV-I terminal repeat]	0.0	3	1	1	1
144609	1710	proliferation of b	[proliferation of B]	0.0	3	1	1	1
144610	1710	intact IL-4 promoter	[intact IL-4 promoter]	0.0	3	1	1	1
144611	1710	other ets-like factor	[Other ETS-like factors]	0.0	3	1	1	1
144612	1710	de novo translocation	[de novo translocations]	0.0	3	1	1	1
144613	1710	cell type in disorder: lack	[cell types in disorder: lack]	0.0	5	1	1	1
144614	1710	cd95 ligand gene expression	[CD95 ligand gene expression]	0.0	4	1	1	1
144615	1710	cytotoxic protein	[cytotoxic proteins]	0.0	2	1	1	1
144616	1710	level induction of il-2r	[level induction of IL-2R]	0.0	4	1	1	1
144617	1710	normal upper limit	[normal upper limit]	0.0	3	1	1	1
144618	1710	certain immediate response gene	[certain immediate response genes]	0.0	4	1	1	1
144619	1710	chronic ebv infection	[chronic EBV infection]	0.0	3	1	1	1
144620	1710	involvement of this messenger induction	[involvement of these messengers induction]	0.0	5	1	1	1
144621	1710	mutation in allele	[mutation in allele]	0.0	3	1	1	1
144622	1710	different AUG codon	[different AUG codons]	0.0	3	1	1	1
144623	1710	uncouple hs1 phosphorylation	[Uncoupling HS1 phosphorylation]	0.0	3	1	1	1
144624	1710	trancriptional activity by GM-CSF	[trancriptional activity by GM-CSF]	0.0	4	1	1	1
144625	1710	consecutive control	[consecutive controls]	0.0	2	1	1	1
144626	1710	modulate t-cell function	[modulating T-cell function]	0.0	3	1	1	1
144627	1710	two signalling pathway	[Two signalling pathways]	0.0	3	1	1	1
144628	1710	monocytic cell by treponema pallidum	[monocytic cells by Treponema pallidum]	0.0	5	1	1	1
144629	1710	stimulation, mrna from lymphocyte	[stimulation, mRNA from lymphocytes]	0.0	4	1	1	1
144630	1710	regulation in human blood T cell	[regulation in human blood T cells]	0.0	6	1	1	1
144631	1710	relative contribution	[relative contribution]	0.0	2	3	3	1
144632	1710	difference in the number sites/cell	[differences in the number sites/cell]	0.0	5	1	1	1
144633	1710	multiple important ebf	[Multiple important EBF]	0.0	3	1	1	1
144634	1710	define signal for the biogenesis	[defining signals for the biogenesis]	0.0	5	1	1	1
144635	1710	different concentration of alpha	[different concentrations of alpha]	0.0	4	1	1	1
144636	1710	adhesion molecule expression in umbilical venous	[adhesion molecule expression in umbilical venous]	0.0	6	1	1	1
144637	1710	nfat IL-2	[NFAT IL-2]	0.0	2	1	1	1
144638	1710	representative serotype	[representative serotypes]	0.0	2	2	2	1
144639	1710	anti-tr55 antibody cross-linking in U1 culture	[Anti-TR55 antibody cross-linking in U1 cultures]	0.0	6	1	1	1
144640	1710	element hSIE dna-probe	[element hSIE DNA-probe]	0.0	3	1	1	1
144641	1710	procedure avidin-biotin complex	[procedure avidin-biotin complex]	0.0	3	1	1	1
144642	1710	signals, one	[signals, one]	0.0	2	2	2	1
144643	1710	acute myeloid patient cases)	[acute myeloid patients cases)]	0.0	4	1	1	1
144644	1710	thus exclude skewedness	[thus excluding skewedness]	0.0	3	1	1	1
144645	1710	accumulation of various biochemical lesion	[accumulation of various biochemical lesions]	0.0	5	1	1	1
144646	1710	b -dependent gene	[B -dependent genes]	0.0	3	1	1	1
144647	1710	b-cell activation from apoptosis.	[B-cell activation from apoptosis.]	0.0	4	1	1	1
144648	1710	direct demonstration	[Direct demonstration]	0.0	2	1	1	1
144649	1710	initiation binding repressor	[Initiation binding repressor]	0.0	3	1	1	1
144650	1710	critical regulator in vitro.	[critical regulator in vitro.]	0.0	4	1	1	1
144651	1710	level of heat placental alkaline phosphatase	[levels of heat placental alkaline phosphatase]	0.0	6	1	1	1
144652	1710	various processes, include cell growth	[various processes, including cell growth]	0.0	5	1	1	1
144653	1710	m dexamethasone (207.9+/-31.5	[M dexamethasone (207.9+/-31.5]	0.0	3	1	1	1
144654	1710	contain the response element	[containing the response element]	0.0	4	1	1	1
144655	1710	blastogenesis of human blood lymphocyte	[blastogenesis of human blood lymphocytes]	0.0	5	1	1	1
144656	1710	physiotherapy	[physiotherapy]	0.0	1	1	1	1
144657	1710	lymphoid-enhancer binding factor	[lymphoid-enhancer binding factor]	0.0	3	1	1	1
144658	1710	relatively low number	[relatively low number]	0.0	3	1	1	1
144659	1710	transcriptional stimulation by CBF alpha	[transcriptional stimulation by CBF alpha]	0.0	5	1	1	1
144660	1710	nongenomic mechanism	[nongenomic mechanism]	0.0	2	1	1	1
144661	1710	few copy	[few copies]	0.0	2	1	1	1
144662	1710	use zebra protein	[using ZEBRA protein]	0.0	3	1	1	1
144663	1710	crossreactivity	[crossreactivity]	0.0	1	1	1	1
144664	1710	65 +/-	[65 +/-]	0.0	2	1	1	1
144665	1710	role regulate the inflammatory response	[role regulating the inflammatory response]	0.0	5	1	1	1
144666	1710	aspect of this regulation	[aspects of this regulation]	0.0	4	1	1	1
144667	1710	regulator of DNA binding,	[regulators of DNA binding,]	0.0	4	1	1	1
144668	1710	aspect of gata factor expression	[aspect of GATA factor expression]	0.0	5	1	1	1
144669	1710	protein crisp-3	[protein CRISP-3]	0.0	2	1	1	1
144670	1710	cell suicide	[cell suicide]	0.0	2	1	1	1
144671	1710	colony-forming capacity	[colony-forming capacity]	0.0	2	1	1	1
144672	1710	design of approach	[design of approaches]	0.0	3	1	1	1
144673	1710	pcd41 orf-a	[pCD41 ORF-A]	0.0	2	1	1	1
144674	1710	probe of this region,	[probes of this region,]	0.0	4	1	1	1
144675	1710	oncogene transcript	[oncogene transcripts]	0.0	2	1	1	1
144676	1710	there,	[there,]	0.0	1	1	1	1
144677	1710	regulator of inflammatory response	[regulator of inflammatory responses]	0.0	4	1	1	1
144678	1710	obtain quiescent monocyte	[obtaining quiescent monocytes]	0.0	3	1	1	1
144679	1710	role of macrophage in intrapulmonary activation	[role of macrophages in intrapulmonary activation]	0.0	6	1	1	1
144680	1710	evidence the CsA component	[evidence the CsA component]	0.0	4	1	1	1
144681	1710	tal-1 protein during hematopoiesis	[tal-1 proteins during hematopoiesis]	0.0	4	1	1	1
144682	1710	common structure	[common structure]	0.0	2	1	1	1
144683	1710	cysteine LIM domain	[cysteine LIM domains]	0.0	3	1	1	1
144684	1710	case of female twin discordant	[case of female twins discordant]	0.0	5	1	1	1
144685	1710	stage of b-lymphocyte development	[stages of B-lymphocyte development]	0.0	4	1	1	1
144686	1710	major (mhc) class ii molecule	[major (MHC) class II molecules]	0.0	5	1	1	1
144687	1710	well-characterized role	[well-characterized role]	0.0	2	1	1	1
144688	1710	cell activation,	[cell activation,]	0.0	2	1	1	1
144689	1710	105 kda precursor	[105 kDa precursor]	0.0	3	1	1	1
144690	1710	high, establish a relation MHC	[high, establishing an relation MHC]	0.0	5	1	1	1
144691	1710	interferon-gamma receptor ifn-gammar	[interferon-gamma receptor IFN-gammaR]	0.0	3	1	1	1
144692	1710	tyrosine within the region	[tyrosine within the region]	0.0	4	1	1	1
144693	1710	interleukin-2 (il-2) receptor gamma chain	[interleukin-2 (IL-2) receptor gamma chain]	0.0	5	1	1	1
144694	1710	gel-mobility shift	[gel-mobility shift]	0.0	2	1	1	1
144695	1710	physiology of selection	[physiology of selection]	0.0	3	1	1	1
144696	1710	certain processes, for example,	[certain processes, for example,]	0.0	4	1	1	1
144697	1710	novel continuous cell line	[novel continuous cell line]	0.0	4	1	1	1
144698	1710	mechanism whereby HTLV-I	[mechanisms whereby HTLV-I]	0.0	3	1	1	1
144699	1710	parasite survival	[parasite survival]	0.0	2	1	1	1
144700	1710	parenteral corticosteroid methyl prednisolone mg/day)	[parenteral corticosteroid methyl prednisolone mg/day)]	0.0	5	1	1	1
144701	1710	differentiation of m2-type leukemic blast cell	[differentiation of M2-type leukemic blast cells]	0.0	6	1	1	1
144702	1710	stat1 alpha consistent	[STAT1 alpha consistent]	0.0	3	1	1	1
144703	1710	leukemia with feature	[leukemia with features]	0.0	3	1	1	1
144704	1710	nuclear oncoprotein	[nuclear oncoproteins]	0.0	2	1	1	1
144705	1710	b DNA probe	[B DNA probes]	0.0	3	1	1	1
144706	1710	cd14 -dependent activation of transcription factor	[CD14 -dependent activation of transcription factors]	0.0	6	1	1	1
144707	1710	endothelial activation a mechanism	[endothelial activation A mechanism]	0.0	4	1	1	1
144708	1710	sodium diclofenac at microm	[sodium diclofenac at microM]	0.0	4	1	1	1
144709	1710	expression of mutant of Ras	[expression of mutants of Ras]	0.0	5	1	1	1
144710	1710	/rank	[/RANK]	0.0	1	1	1	1
144711	1710	points), low body mass	[points), low body mass]	0.0	4	1	1	1
144712	1710	firm basis	[firm basis]	0.0	2	1	1	1
144713	1710	human immunodeficiency virus type hiv-2	[Human immunodeficiency virus type HIV-2]	0.0	5	1	1	1
144714	1710	combination on ap-1 transcription	[combinations on AP-1 transcription]	0.0	4	1	1	1
144715	1710	promoter in primary cell	[promoter in primary cells]	0.0	4	1	1	1
144716	1710	nm 1	[nM 1]	0.0	2	1	1	1
144717	1710	NK cell killing	[NK cell killing]	0.0	3	1	1	1
144718	1710	six other factor	[six other factors]	0.0	3	1	1	1
144719	1710	constitutive expression of Rev M10	[constitutive expression of Rev M10]	0.0	5	1	1	1
144720	1710	state of growth,	[state of growth,]	0.0	3	1	1	1
144721	1710	sixteen anorexic patient (range from 11.1	[Sixteen anorexic patients (ranging from 11.1]	0.0	6	1	1	1
144722	1710	use mutagenesis of human HSs	[Using mutagenesis of human HSs]	0.0	5	1	1	1
144723	1710	trna gene transcription	[tRNA gene transcription]	0.0	3	1	1	1
144724	1710	use a combination of motility assay	[Using a combination of motility assays]	0.0	6	1	1	1
144725	1710	many inflammatory disorder a problem	[many inflammatory disorders a problem]	0.0	5	1	1	1
144726	1710	differential nf-kappab subunit activation	[differential NF-kappaB subunit activation]	0.0	4	1	1	1
144727	1710	endogenous nfat	[endogenous NFAT]	0.0	2	1	1	1
144728	1710	treatment 1alpha,25-dihydroxyvitamin D3	[treatment 1alpha,25-dihydroxyvitamin D3]	0.0	3	1	1	1
144729	1710	day embryo	[day embryos]	0.0	2	1	1	1
144730	1710	eig)-secreting plasmacytoma	[(Ig)-secreting plasmacytomas]	0.0	2	1	1	1
144731	1710	candidate gene nuclear factor 3 beta	[candidate genes nuclear factor 3 beta]	0.0	6	1	1	1
144732	1710	only after internalization	[only after internalization]	0.0	3	1	1	1
144733	1710	regulation cross-talk	[regulation cross-talk]	0.0	2	1	1	1
144734	1710	constitutively high level	[constitutively high levels]	0.0	3	1	1	1
144735	1710	increase in transcription.	[increases in transcription.]	0.0	3	1	1	1
144736	1710	n-Acetyl-L-cysteine a potent antioxidant,	[n-Acetyl-L-cysteine a potent antioxidant,]	0.0	4	1	1	1
144737	1710	prl induction time	[PRL induction time]	0.0	3	1	1	1
144738	1710	trans-acting factor nf-kb	[trans-acting factors NF-kB]	0.0	3	1	1	1
144739	1710	phenotypic change of the thymocyte	[phenotypic changes of the thymocyte]	0.0	5	1	1	1
144740	1710	reticuloendotheliosis virus repeat element	[Reticuloendotheliosis virus repeat elements]	0.0	4	1	1	1
144741	1710	promyelocytic feature in PML/RARalpha mouse	[promyelocytic features in PML/RARalpha mice]	0.0	5	1	1	1
144742	1710	rna(snrna)-encoding	[RNA(snRNA)-encoding]	0.0	1	1	1	1
144743	1710	binding site on the receptor	[binding sites on the receptor]	0.0	5	1	1	1
144744	1710	subsequent nf-kappa b accumulation	[subsequent NF-kappa B accumulation]	0.0	4	1	1	1
144745	1710	vivo through a infection	[vivo through a infection]	0.0	4	1	1	1
144746	1710	active mutant of human Toll	[active mutant of human Toll]	0.0	5	1	1	1
144747	1710	transduce a raralpha exhibit activity RARalpha403	[transducing a RARalpha exhibiting activity RARalpha403]	0.0	6	1	1	1
144748	1710	transcriptional regulation of interleukin 2 gene	[transcriptional regulation of interleukin 2 gene]	0.0	6	1	1	1
144749	1710	induction of factor-kappaB	[induction of factor-kappaB]	0.0	3	1	1	1
144750	1710	expression activator protein-1 ap-1 factor	[expression activator protein-1 AP-1 factor]	0.0	5	1	1	1
144751	1710	primary T cell responsive	[primary T cells responsive]	0.0	4	1	1	1
144752	1710	factor kappa b heterodimer	[factor kappa B heterodimer]	0.0	4	1	1	1
144753	1710	antagonism between vitamin D3	[antagonism between vitamin D3]	0.0	4	1	1	1
144754	1710	twin discordant	[twins discordant]	0.0	2	1	1	1
144755	1710	cytokine chemokine	[cytokine chemokine]	0.0	2	1	1	1
144756	1710	mouse promoter	[mouse promoter]	0.0	2	1	1	1
144757	1710	phoq gene product	[phoQ gene product]	0.0	3	1	1	1
144758	1710	-reporter	[-reporter]	0.0	1	1	1	1
144759	1710	tyrosine-phosphorylated peptide contain Tyr374	[tyrosine-phosphorylated peptides containing Tyr374]	0.0	4	1	1	1
144760	1710	Tyrosine	[Tyrosine]	0.0	1	1	1	1
144761	1710	49 aged subject yr)	[49 aged subjects yr)]	0.0	4	1	1	1
144762	1710	day with 5 m dexamethasone	[days with 5 M dexamethasone]	0.0	5	1	1	1
144763	1710	activity of tumor	[activity of tumors]	0.0	3	1	1	1
144764	1710	series of patient	[series of patients]	0.0	3	1	1	1
144765	1710	induction of mcp-1	[induction of MCP-1]	0.0	3	1	1	1
144766	1710	8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).	[8, histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma 5).]	0.0	6	1	1	1
144767	1710	important functional region	[important functional regions]	0.0	3	1	1	1
144768	1710	differentiation of erythroleukemic cell	[differentiation of erythroleukemic cells]	0.0	4	1	1	1
144769	1710	comparative sequence analysis between human show	[Comparative sequence analysis between human shows]	0.0	6	1	1	1
144770	1710	transactivation by the b-cell-specific ciita	[transactivation by the B-cell-specific CIITA]	0.0	5	1	1	1
144771	1710	hypercholesteremia of homozygous type	[hypercholesteremia of homozygous type]	0.0	4	1	1	1
144772	1710	actin stress	[actin stress]	0.0	2	1	1	1
144773	1710	IL-2 receptor beta chain	[IL-2 receptor beta chain]	0.0	4	1	1	1
144774	1710	IL-6 dephosphorylated prb	[IL-6 dephosphorylated pRB]	0.0	3	1	1	1
144775	1710	cell with antibody	[cells with antibody]	0.0	3	1	1	1
144776	1710	prolonged load	[prolonged load]	0.0	2	1	1	1
144777	1710	-533 basis	[-533 bases]	0.0	2	1	1	1
144778	1710	manner than T lymphocyte	[manner than T lymphocytes]	0.0	4	1	1	1
144779	1710	stimulate expression of cycle gene	[stimulating expression of cycle genes]	0.0	5	1	1	1
144780	1710	human erythroleukemia cell line	[human erythroleukemia cell line]	0.0	4	1	1	1
144781	1710	acute patient aml	[acute patients AML]	0.0	3	1	1	1
144782	1710	die by 8 days.	[dying by 8 days.]	0.0	4	1	1	1
144783	1710	low level of IFN a IFNA	[low levels of IFN A IFNA]	0.0	6	1	1	1
144784	1710	cytosolic transcription factor	[cytosolic transcription factor]	0.0	3	1	1	1
144785	1710	peroxisome receptor-alpha a member	[Peroxisome receptor-alpha a member]	0.0	4	1	1	1
144786	1710	microarray	[microarray]	0.0	1	1	1	1
144787	1710	60% (46% identical)	[60% (46% identical)]	0.0	3	1	1	1
144788	1710	effect with regard	[effect with regard]	0.0	3	1	1	1
144789	1710	overexpression of egfr	[overexpression of EGFR]	0.0	3	1	1	1
144790	1710	commitment by polymerase chain reaction	[commitment by polymerase chain reaction]	0.0	5	1	1	1
144791	1710	peripheral resistance	[peripheral resistance]	0.0	2	2	2	1
144792	1710	b-cell neoplasia bl	[B-cell neoplasias BL]	0.0	3	1	1	1
144793	1710	TCL1 expression in lymphoma	[TCL1 expression in lymphomas]	0.0	4	1	1	1
144794	1710	(abdominal obese:	[(abdominal obese:]	0.0	2	1	1	1
144795	1710	(starting day	[(starting day]	0.0	2	1	1	1
144796	1710	PMA subline kg1a	[PMA subline KG1a]	0.0	3	1	1	1
144797	1710	hat activity	[HAT activity]	0.0	2	1	1	1
144798	1710	third member of the family	[third member of the family]	0.0	5	1	1	1
144799	1710	ioct)	[(Oct)]	0.0	1	1	1	1
144800	1710	locus a,	[locus A,]	0.0	2	1	1	1
144801	1710	sequela plaque	[sequela plaque]	0.0	2	1	1	1
144802	1710	transcriptional activation of the repeat	[transcriptional activation of the repeat]	0.0	5	1	1	1
144803	1710	(R) pre-messenger rna	[(R) pre-messenger RNA]	0.0	3	1	1	1
144804	1710	heterogeneity of the t-cell population	[heterogeneity of the T-cell population]	0.0	5	1	1	1
144805	1710	lymphocyte against peptide	[lymphocytes against peptides]	0.0	3	1	1	1
144806	1710	extrapituitary site	[extrapituitary sites]	0.0	2	1	1	1
144807	1710	macrophage-colony stimulate factor gm-csf	[macrophage-colony stimulating factor GM-CSF]	0.0	4	1	1	1
144808	1710	DNA-protein binding assay	[DNA-protein binding assays]	0.0	3	1	1	1
144809	1710	flank region of the gene	[flanking region of the gene]	0.0	5	1	1	1
144810	1710	site for Sp1	[site for Sp1]	0.0	3	1	1	1
144811	1710	effect of tpa induction	[effects of TPA induction]	0.0	4	1	1	1
144812	1710	site -187 to -181	[site -187 to -181]	0.0	4	1	1	1
144813	1710	CD40 cross-link link to responses.	[CD40 cross-linking link to responses.]	0.0	5	1	1	1
144814	1710	counteract negative regulatory DNA sequence	[counteracting negative regulatory DNA sequences]	0.0	5	1	1	1
144815	1710	induction of differentiation infection of cell	[Induction of differentiation infection of cells]	0.0	6	1	1	1
144816	1710	(average gr concentration 7131	[(average GR concentration 7131]	0.0	4	1	1	1
144817	1710	activation by BSAP	[activation by BSAP]	0.0	3	1	1	1
144818	1710	inflammatory protein-2	[inflammatory protein-2]	0.0	2	1	1	1
144819	1710	weight gain +/-	[weight gain +/-]	0.0	3	1	1	1
144820	1710	patient with type	[Patients with type]	0.0	3	1	1	1
144821	1710	pcr assay	[PCR assay]	0.0	2	2	2	1
144822	1710	fusion partner at 11q14	[fusion partner at 11q14]	0.0	4	1	1	1
144823	1710	tertiary-butyl ether	[tertiary-butyl ether]	0.0	2	1	1	1
144824	1710	child under term glucocorticoid treatment	[children under term glucocorticoid treatment]	0.0	5	1	1	1
144825	1710	even medullary thymocyte	[Even medullary thymocytes]	0.0	3	1	1	1
144826	1710	additional month 12 month	[additional months 12 months]	0.0	4	1	1	1
144827	1710	hpv type hpv-16	[HPV type HPV-16]	0.0	3	1	1	1
144828	1710	concentration of type peptide	[concentrations of type peptides]	0.0	4	1	1	1
144829	1710	encompass a proline sequence	[encompassing a proline sequence]	0.0	4	1	1	1
144830	1710	pathway of the two cell systems.	[pathways of the two cell systems.]	0.0	6	1	1	1
144831	1710	early-induced peak	[early-induced peak]	0.0	2	1	1	1
144832	1710	requirement for pc4	[requirement for PC4]	0.0	3	1	1	1
144833	1710	77 +/- 16	[77 +/- 16]	0.0	3	1	1	1
144834	1710	quantitative immunohistochemical analysis	[Quantitative immunohistochemical analysis]	0.0	3	1	1	1
144835	1710	carboxyl-terminal cytoplasmic segment	[carboxyl-terminal cytoplasmic segment]	0.0	3	1	1	1
144836	1710	equal level	[equal levels]	0.0	2	1	1	1
144837	1710	80 percent	[80 percent]	0.0	2	1	1	1
144838	1710	colony by iron staining	[colonies by iron staining]	0.0	4	1	1	1
144839	1710	class immunodeficiency	[class immunodeficiency]	0.0	2	1	1	1
144840	1710	1beta protein production	[1beta protein production]	0.0	3	1	1	1
144841	1710	lack exon 5	[lacking exon 5]	0.0	3	1	1	1
144842	1710	suggest a role in the release	[suggesting a role in the release]	0.0	6	1	1	1
144843	1710	-201 to -130 region	[-201 to -130 region]	0.0	4	1	1	1
144844	1710	mutant delta sp	[mutant delta SP]	0.0	3	1	1	1
144845	1710	g-csf-r /il-7r alpha	[G-CSF-R /IL-7R alpha]	0.0	3	1	1	1
144846	1710	molecule of blood T lymphocyte	[molecules of blood T lymphocytes]	0.0	5	1	1	1
144847	1710	8% cell g-csf	[8% cells G-CSF]	0.0	3	1	1	1
144848	1710	only the NF-kappa b /p50 homodimer	[only the NF-kappa B /p50 homodimer]	0.0	6	1	1	1
144849	1710	min) submaximal exercise at 70%	[min) submaximal exercise at 70%]	0.0	5	1	1	1
144850	1710	ISG15-LTR-IFN	[ISG15-LTR-IFN]	0.0	1	1	1	1
144851	1710	fgf-1 T cell	[FGF-1 T cells]	0.0	3	1	1	1
144852	1710	family with various degree	[families with various degrees]	0.0	4	1	1	1
144853	1710	peripheral level	[peripheral levels]	0.0	2	1	1	1
144854	1710	apoptosis of monoblastoid cell	[apoptosis of monoblastoid cells]	0.0	4	1	1	1
144855	1710	ifn-gamma transcription in cd45r0 T cell	[IFN-gamma transcription in CD45R0 T cells]	0.0	6	1	1	1
144856	1710	major responses, nf-kappab activation	[major responses, NF-kappaB activation]	0.0	4	1	1	1
144857	1710	masses;	[masses;]	0.0	1	1	1	1
144858	1710	distal nf-at site	[distal NF-AT site]	0.0	3	1	1	1
144859	1710	lack thereof)	[lack thereof)]	0.0	2	1	1	1
144860	1710	unrestricted expression of viral gene	[unrestricted expression of viral genes]	0.0	5	1	1	1
144861	1710	contain length in a region	[containing lengths in a region]	0.0	5	1	1	1
144862	1710	tyrosine phosphorylation the stat-1alpha signal transducer	[tyrosine phosphorylation the STAT-1alpha signal transducer]	0.0	6	1	1	1
144863	1710	Interleukin-5 signal in eosinophil	[Interleukin-5 signaling in eosinophils]	0.0	4	1	1	1
144864	1710	cytokine interleukin-8 in monocyte	[cytokine interleukin-8 in monocytes]	0.0	4	1	1	1
144865	1710	basal redox equilibrium	[basal redox equilibrium]	0.0	3	1	1	1
144866	1710	moderate level in hl60 cell	[moderate levels in HL60 cells]	0.0	5	1	1	1
144867	1710	monocytic lineage follow exposure	[monocytic lineage following exposures]	0.0	4	1	1	1
144868	1710	venous blood lactate concentration	[venous blood lactate concentrations]	0.0	4	1	1	1
144869	1710	primary cell in g0	[primary cells in G0]	0.0	4	1	1	1
144870	1710	express cell in the regulatory sequence	[expressing cells in the regulatory sequences]	0.0	6	1	1	1
144871	1710	Erythroid kruppel-like	[Erythroid Kruppel-like]	0.0	2	1	1	1
144872	1710	antigen proceed	[antigen proceeds]	0.0	2	1	1	1
144873	1710	ah receptor gene	[Ah receptor gene]	0.0	3	1	1	1
144874	1710	normal gene expression	[normal gene expression]	0.0	3	1	1	1
144875	1710	colon carcinoma cell line HT-29	[colon carcinoma cell lines HT-29]	0.0	5	1	1	1
144876	1710	gamma-globin (5-fold)	[gamma-globin (5-fold)]	0.0	2	1	1	1
144877	1710	incidence of infection, with cytomegalovirus	[incidence of infection, with cytomegalovirus]	0.0	5	1	1	1
144878	1710	level of nf-kappab transcriptional activity	[level of NF-kappaB transcriptional activity]	0.0	5	1	1	1
144879	1710	namely the chain enhancer igh-enhancer	[namely the chain enhancer IgH-enhancer]	0.0	5	1	1	1
144880	1710	new, cellular transcription factor	[new, cellular transcription factors]	0.0	4	1	1	1
144881	1710	role of alveolar macrophage	[role of alveolar macrophages]	0.0	4	1	1	1
144882	1710	transcriptional regulator of cellular gene	[transcriptional regulators of cellular genes]	0.0	5	1	1	1
144883	1710	cell line WEHI-3B/D+	[cell line WEHI-3B/D+]	0.0	3	1	1	1
144884	1710	excretion	[excretion]	0.0	1	1	1	1
144885	1710	requirement for CD28 up-regulation	[requirement for CD28 up-regulation]	0.0	4	1	1	1
144886	1710	binding site for NF-E1 ref	[binding sites for NF-E1 refs]	0.0	5	1	1	1
144887	1710	different schedule	[different schedules]	0.0	2	1	1	1
144888	1710	promoter-enhancer.	[promoter-enhancer.]	0.0	1	1	1	1
144889	1710	involvement of phospholipase d	[Involvement of phospholipase D]	0.0	4	1	1	1
144890	1710	risk: cell reaction high grade	[risk: cell reaction high grade]	0.0	5	1	1	1
144891	1710	platelet-activating factor receptor	[platelet-activating factor receptor]	0.0	3	1	1	1
144892	1710	myeloid-specific promoter activity	[myeloid-specific promoter activity]	0.0	3	1	1	1
144893	1710	trancriptional role of stat5 in monocyte	[trancriptional roles of STAT5 in monocytes]	0.0	6	1	1	1
144894	1710	use of a antagonist	[use of a antagonist]	0.0	4	1	1	1
144895	1710	action of Ro	[action of Ro]	0.0	3	1	1	1
144896	1710	agonist WY	[agonist WY]	0.0	2	1	1	1
144897	1710	g1 cell cycle arrest	[G1 cell cycle arrest]	0.0	4	1	1	1
144898	1710	full-length c/ebp-epsilon	[full-length C/EBP-epsilon]	0.0	2	1	1	1
144899	1710	impdh type ii gene	[IMPDH type II gene]	0.0	4	1	1	1
144900	1710	ii-negative T cell	[II-negative T cells]	0.0	3	1	1	1
144901	1710	Jeg-3 human choriocarcinoma-induced immunosuppression	[Jeg-3 human choriocarcinoma-induced immunosuppression]	0.0	4	1	1	1
144902	1710	inflammatory cytokine in monocytes/macrophages	[inflammatory cytokines in monocytes/macrophages]	0.0	4	1	1	1
144903	1710	mmhg, dehydration	[mmHg, dehydration]	0.0	2	1	1	1
144904	1710	cloning of are-containing gene by display	[Cloning of ARE-containing genes by display]	0.0	6	1	1	1
144905	1710	wehi	[WEHI]	0.0	1	1	1	1
144906	1710	C. activation	[C. activation]	0.0	2	1	1	1
144907	1710	different cellular system	[different cellular systems]	0.0	3	1	1	1
144908	1710	plap activity	[PLAP activity]	0.0	2	1	1	1
144909	1710	basis of NK ec activation	[basis of NK EC activation]	0.0	5	1	1	1
144910	1710	pre-incubation of extract with dmdtc	[pre-incubation of extracts with DMDTC]	0.0	5	1	1	1
144911	1710	factor irf-1 interferon regulatory factor	[factor IRF-1 interferon regulatory factor]	0.0	5	1	1	1
144912	1710	non-lymphoid cell line	[non-lymphoid cell line]	0.0	3	1	1	1
144913	1710	contain sense rxr-alpha sequence	[containing sense RXR-alpha sequences]	0.0	4	1	1	1
144914	1710	RESULTS: administration of the oligonucleotide	[RESULTS: Administration of the oligonucleotide]	0.0	5	1	1	1
144915	1710	ratio of glutathione	[ratio of glutathione]	0.0	3	1	1	1
144916	1710	infiltrate joint	[infiltrating joints]	0.0	2	1	1	1
144917	1710	female (mz) twin	[female (MZ) twins]	0.0	3	1	1	1
144918	1710	most potent trigger substance	[most potent trigger substances]	0.0	4	1	1	1
144919	1710	more mrna	[more mRNA]	0.0	2	1	1	1
144920	1710	(18- volunteer	[(18- volunteers]	0.0	2	1	1	1
144921	1710	modest translocation of kappab-binding protein	[modest translocation of kappaB-binding proteins]	0.0	5	1	1	1
144922	1710	regulation of il-2 gene expression role	[regulation of IL-2 gene expression role]	0.0	6	1	1	1
144923	1710	contain a hmg box	[containing a HMG box]	0.0	4	1	1	1
144924	1710	cd34+ cell g-csf dead cell	[CD34+ cells G-CSF dead cells]	0.0	5	1	1	1
144925	1710	factor-kappaB in memory (cd45ro+)	[factor-kappaB in memory (CD45RO+)]	0.0	4	1	1	1
144926	1710	harbour type 1	[harbouring type 1]	0.0	3	1	1	1
144927	1710	major disorder patient	[major disorder patients]	0.0	3	1	1	1
144928	1710	overcome the differentiation arrest	[overcoming the differentiation arrest]	0.0	4	1	1	1
144929	1710	clone by transfection.	[clones by transfection.]	0.0	3	1	1	1
144930	1710	use the dose for T cell	[using the dose for T cells]	0.0	6	1	1	1
144931	1710	Th1-dominated chronic inflammation	[Th1-dominated chronic inflammation]	0.0	3	1	1	1
144932	1710	risk of coagulopathy	[risks of coagulopathy]	0.0	3	1	1	1
144933	1710	(five	[(five]	0.0	1	1	1	1
144934	1710	5'-flanking region of gene	[5'-flanking region of gene]	0.0	4	1	1	1
144935	1710	(dp) CD4 cd8(+) CD3 thymocyte	[(DP) CD4 CD8(+) CD3 thymocytes]	0.0	5	1	1	1
144936	1710	Oct-2 by RAR	[Oct-2 by RAR]	0.0	3	1	1	1
144937	1710	hiv-1 repeat LTR reporter gene activity	[HIV-1 repeat LTR reporter gene activity]	0.0	6	1	1	1
144938	1710	neutrophil transendothelial migration during inflammation	[neutrophil transendothelial migration during inflammation]	0.0	5	1	1	1
144939	1710	recombinase	[recombinase]	0.0	1	2	2	1
144940	1710	cooperative binding	[cooperative binding]	0.0	2	2	2	1
144941	1710	branchpoint	[branchpoints]	0.0	1	1	1	1
144942	1710	use the ifn-gamma-activated sequence oligonucleotide	[using the IFN-gamma-activated sequence oligonucleotides]	0.0	5	1	1	1
144943	1710	ablation of htlv-i tumor in mouse	[Ablation of HTLV-I tumors in mice]	0.0	6	1	1	1
144944	1710	panel of antibody	[panel of antibodies]	0.0	3	1	1	1
144945	1710	extensive granulopoiesis postnatally, die days.	[extensive granulopoiesis postnatally, dying days.]	0.0	5	1	1	1
144946	1710	concentrate	[concentrating]	0.0	1	1	1	1
144947	1710	acid on human hematopoiesis	[acid on human hematopoiesis]	0.0	4	1	1	1
144948	1710	phosphorylation and/or	[phosphorylation and/or]	0.0	2	1	1	1
144949	1710	handling	[handling]	0.0	1	1	1	1
144950	1710	precisely similarity	[precisely similarities]	0.0	2	1	1	1
144951	1710	signal alone without signal 1	[signal alone without signal 1]	0.0	5	1	1	1
144952	1710	monocyte pbm	[monocytes PBM]	0.0	2	1	1	1
144953	1710	infection of Epstein-Barr virus	[infection of Epstein-Barr virus]	0.0	4	1	1	1
144954	1710	several signal protein such as CBL	[Several signaling proteins such as CBL]	0.0	6	1	1	1
144955	1710	also a inducer	[also a inducer]	0.0	3	1	1	1
144956	1710	regulate signal	[regulating signaling]	0.0	2	1	1	1
144957	1710	results: concentration of as2o3 (1-2 microM)	[RESULTS: concentrations of As2O3 (1-2 microM)]	0.0	6	1	1	1
144958	1710	binding of type I interferon ifn-alpha/beta	[Binding of type I interferon IFN-alpha/beta]	0.0	6	1	1	1
144959	1710	protein(s).	[protein(s).]	0.0	1	1	1	1
144960	1710	subunit of protein	[subunits of proteins]	0.0	3	1	1	1
144961	1710	October -DNA interaction	[Oct -DNA interaction]	0.0	3	1	1	1
144962	1710	cross-linking with 125i-labeled tgf-beta	[cross-linking with 125I-labeled TGF-beta]	0.0	4	1	1	1
144963	1710	influence by influenza T cell	[Influence by influenza T cells]	0.0	5	1	1	1
144964	1710	ebv -positive b-cell	[EBV -positive B-cell]	0.0	3	1	1	1
144965	1710	requirement of ne	[requirement of NE]	0.0	3	1	1	1
144966	1710	extract from Jurkat	[extracts from Jurkat]	0.0	3	1	1	1
144967	1710	monocyte cultivation	[monocyte cultivation]	0.0	2	1	1	1
144968	1710	subunit of nf kappa b	[subunits of NF kappa B]	0.0	5	1	1	1
144969	1710	gel shift complex Mono A	[gel shift complexes Mono A]	0.0	5	1	1	1
144970	1710	3-like	[3-like]	0.0	1	2	2	1
144971	1710	activation-dependent tyrosine phosphorylation	[activation-dependent tyrosine phosphorylation]	0.0	3	1	1	1
144972	1710	1 terminal repeat in macrophages/ monocyte	[1 terminal repeat in macrophages/ monocytes]	0.0	6	1	1	1
144973	1710	case of a Japanese woman	[case of a Japanese woman]	0.0	5	1	1	1
144974	1710	maintenance of homeostasis by apoptosis	[maintenance of homeostasis by apoptosis]	0.0	5	1	1	1
144975	1710	rdna for cn	[cDNAs for CN]	0.0	3	1	1	1
144976	1710	activation pathway for NF-kappa b induction	[activation pathways for NF-kappa B induction]	0.0	6	1	1	1
144977	1710	interaction in the proximal gamma-globin promoter	[Interaction in the proximal gamma-globin promoter]	0.0	6	1	1	1
144978	1710	50% displacement	[50% displacement]	0.0	2	1	1	1
144979	1710	relative;	[relative;]	0.0	1	1	1	1
144980	1710	great affinity	[greater affinity]	0.0	2	1	1	1
144981	1710	human herpesvirus hhv-6 strain gs	[human herpesvirus HHV-6 strains GS]	0.0	5	1	1	1
144982	1710	clinic population	[clinic population]	0.0	2	1	1	1
144983	1710	fibrosarcoma fibrous histiocytoma	[fibrosarcoma fibrous histiocytoma]	0.0	3	1	1	1
144984	1710	drug treatment	[drug treatment]	0.0	2	1	1	1
144985	1710	cell with pd98059	[cells with PD98059]	0.0	3	1	1	1
144986	1710	RA-resistant cell	[RA-resistant cells]	0.0	2	1	1	1
144987	1710	regulate the transcriptional response by stimuli.	[regulating the transcriptional response by stimuli.]	0.0	6	1	1	1
144988	1710	activity in b cell	[activity in B cells]	0.0	4	1	1	1
144989	1710	tissue-specific protein	[tissue-specific protein]	0.0	2	1	1	1
144990	1710	order.	[order.]	0.0	1	1	1	1
144991	1710	activation of protein kinase pkc	[activation of protein kinase PKC]	0.0	5	1	1	1
144992	1710	alpha-PML	[alpha-PML]	0.0	1	1	1	1
144993	1710	(66 millileter	[(66 ml]	0.0	2	1	1	1
144994	1710	kinase of the mapk pathway	[kinase of the MAPK pathway]	0.0	5	1	1	1
144995	1710	pair META region	[pair META region]	0.0	3	1	1	1
144996	1710	pyramidal cell	[pyramidal cells]	0.0	2	1	1	1
144997	1710	ng/ml sodium selenite	[ng/ml sodium selenite]	0.0	3	1	1	1
144998	1710	contain 72 bp of -flanking sequence	[containing 72 bp of -flanking sequence]	0.0	6	1	1	1
144999	1710	oxidative stress nf-kappab activation	[oxidative stress NF-kappaB activation]	0.0	4	1	1	1
145000	1710	seventeen patient with myelodysplastic syndrome	[seventeen patients with myelodysplastic syndromes]	0.0	5	1	1	1
145001	1710	analysis of the IL-8 gene	[analysis of the IL-8 gene]	0.0	5	1	1	1
145002	1710	alpha/gabp	[alpha/GABP]	0.0	1	1	1	1
145003	1710	region of human mzf-1	[region of human MZF-1]	0.0	4	1	1	1
145004	1710	prognostic value	[prognostic value]	0.0	2	1	1	1
145005	1710	mobility gel shift	[mobility gel shift]	0.0	3	1	1	1
145006	1710	-carrier	[-carrier]	0.0	1	1	1	1
145007	1710	cd8+),	[CD8+),]	0.0	1	1	1	1
145008	1710	expression of cytokine by monocyte	[expression of cytokines by monocytes]	0.0	5	1	1	1
145009	1710	t-lymphoid CEM	[T-lymphoid CEM]	0.0	2	1	1	1
145010	1710	name tnf-alpha factor	[name TNF-alpha factor]	0.0	3	1	1	1
145011	1710	potent inhibitor of protein phosphatase type	[potent inhibitors of protein phosphatase type]	0.0	6	1	1	1
145012	1710	cooperation between the transcription factor	[cooperation between the transcription factors]	0.0	5	1	1	1
145013	1710	stat1s1	[STAT1s1]	0.0	1	1	1	1
145014	1710	kd of 100 nm.	[Kd of 100 nM.]	0.0	4	1	1	1
145015	1710	leukocyte cell interaction	[leukocyte cell interaction]	0.0	3	1	1	1
145016	1710	function of cbp/p300	[functions of CBP/p300]	0.0	3	1	1	1
145017	1710	get some insight	[getting some insights]	0.0	3	1	1	1
145018	1710	tcr/cd3 complex	[TCR/CD3 complex]	0.0	2	1	1	1
145019	1710	endothelial recruitment	[endothelial recruitment]	0.0	2	1	1	1
145020	1710	regulate cytokine T cell response	[regulating cytokine T cell responses]	0.0	5	1	1	1
145021	1710	identity).	[identity).]	0.0	1	1	1	1
145022	1710	many other cytokine	[many other cytokines]	0.0	3	1	1	1
145023	1710	genetic, biologic,	[genetic, biologic,]	0.0	2	1	1	1
145024	1710	colony-forming unit cfu-il6	[colony-forming units CFU-IL6]	0.0	3	1	1	1
145025	1710	subsequent increase	[subsequent increase]	0.0	2	1	1	1
145026	1710	gr number with bind affinity	[GR number with binding affinity]	0.0	5	1	1	1
145027	1710	level ap-1	[levels AP-1]	0.0	2	1	1	1
145028	1710	week of gestation	[week of gestation]	0.0	3	1	1	1
145029	1710	(paf)- receptor antagonist	[(PAF)- receptor antagonist]	0.0	3	1	1	1
145030	1710	genital hsv	[genital HSV]	0.0	2	1	1	1
145031	1710	activation by N-terminal deletion of CIITA	[activation by N-terminal deletions of CIITA]	0.0	6	1	1	1
145032	1710	Effect of glucocorticoid on lymphocyte activation	[Effects of glucocorticoids on lymphocyte activation]	0.0	6	1	1	1
145033	1710	include bone marrow cell	[including bone marrow cells]	0.0	4	1	1	1
145034	1710	phosphoprotein with activity	[phosphoproteins with activity]	0.0	3	1	1	1
145035	1710	binding in extract	[binding in extracts]	0.0	3	1	1	1
145036	1710	Functional b-cell response in intrahepatic follicle	[Functional B-cell response in intrahepatic follicles]	0.0	6	1	1	1
145037	1710	hybrid cell	[hybrid cells]	0.0	2	1	1	1
145038	1710	protein co-migrating	[protein co-migrating]	0.0	2	1	1	1
145039	1710	genetic target for B-cell factor	[genetic target for B-cell factor]	0.0	5	1	1	1
145040	1710	5-azacytidine re-expression of icam-i	[5-azacytidine re-expression of ICAM-I]	0.0	4	1	1	1
145041	1710	gold ion HAuCl3	[gold ion HAuCl3]	0.0	3	1	1	1
145042	1710	Comparison of sensitization to virus peptide	[Comparison of sensitization to virus peptides]	0.0	6	1	1	1
145043	1710	two regulatory region	[two regulatory regions]	0.0	3	1	1	1
145044	1710	MRD patient in lt remission	[MRD patients in LT remission]	0.0	5	1	1	1
145045	1710	hormonal metabolic status after surgery	[Hormonal metabolic status after surgery]	0.0	5	1	1	1
145046	1710	defect lead to a lack	[defect leading to a lack]	0.0	5	1	1	1
145047	1710	factor binding role	[factor binding role]	0.0	3	1	1	1
145048	1710	effective drug in APL patient	[effective drug in APL patients]	0.0	5	1	1	1
145049	1710	block the accumulation	[blocking the accumulation]	0.0	3	1	1	1
145050	1710	inhibitory effect together with PGE2	[inhibitory effects together with PGE2]	0.0	5	1	1	1
145051	1710	so-called lysis gene	[so-called lysis genes]	0.0	3	1	1	1
145052	1710	many systems,	[many systems,]	0.0	2	1	1	1
145053	1710	T cell line of male infant	[T cell lines of male infants]	0.0	6	1	1	1
145054	1710	radiation-induced signal cascade	[radiation-induced signaling cascade]	0.0	3	1	1	1
145055	1710	lysate by antiphosphotyrosine immunoblotting	[lysates by antiphosphotyrosine immunoblotting]	0.0	4	1	1	1
145056	1710	transcript stabilization	[transcript stabilization]	0.0	2	1	1	1
145057	1710	underlie ig gene extinction	[underlying Ig gene extinction]	0.0	4	1	1	1
145058	1710	human dendritic assay	[human dendritic assay]	0.0	3	1	1	1
145059	1710	long protection	[long-term protection]	0.0	2	1	1	1
145060	1710	pmol/L (p less than 0.025).	[pmol/L (P less than 0.025).]	0.0	5	1	1	1
145061	1710	control of trans-gene expression	[control of trans-gene expression]	0.0	4	1	1	1
145062	1710	/calcineurin	[/calcineurin]	0.0	1	2	2	1
145063	1710	specific promoter motif	[specific promoter motifs]	0.0	3	1	1	1
145064	1710	evidence for a etiology	[Evidence for a etiology]	0.0	4	1	1	1
145065	1710	value for disease	[value for disease]	0.0	3	1	1	1
145066	1710	deletion the human homolog	[deletions the human homolog]	0.0	4	1	1	1
145067	1710	regulation of erythroid differentiation	[regulation of erythroid differentiation]	0.0	4	1	1	1
145068	1710	use of the residual gr	[use of the residual GR]	0.0	5	1	1	1
145069	1710	c-fo sre	[c-fos SRE]	0.0	2	1	1	1
145070	1710	two brother	[two brothers]	0.0	2	1	1	1
145071	1710	curry spice	[curry spice]	0.0	2	1	1	1
145072	1710	(0.02%	[(0.02%]	0.0	1	1	1	1
145073	1710	contrast to ar	[contrast to AR]	0.0	3	1	1	1
145074	1710	induction of the immune response	[Induction of the immune response]	0.0	5	1	1	1
145075	1710	merit of ddpcr	[merits of DDPCR]	0.0	3	1	1	1
145076	1710	suppression of MHC class expression	[Suppression of MHC class expression]	0.0	5	1	1	1
145077	1710	killer cell with il-12	[killer cells with IL-12]	0.0	4	1	1	1
145078	1710	distal marker	[distal markers]	0.0	2	1	1	1
145079	1710	probes, chemist	[probes, chemists]	0.0	2	1	1	1
145080	1710	cytokine in normal monocyte	[cytokines in normal monocytes]	0.0	4	1	1	1
145081	1710	Differential induction of dna-binding activity	[Differential induction of DNA-binding activities]	0.0	5	1	1	1
145082	1710	15- to 20-fold reduction	[15- to 20-fold reduction]	0.0	4	1	1	1
145083	1710	hcmv g-seropositive donor	[HCMV G-seropositive donors]	0.0	3	1	1	1
145084	1710	pathway of the cell systems.	[pathways of the cell systems.]	0.0	5	1	1	1
145085	1710	protein in normal lymphocyte	[proteins in normal lymphocytes]	0.0	4	1	1	1
145086	1710	monocyte with ltb4	[monocytes with LTB4]	0.0	3	1	1	1
145087	1710	mineralocorticoid receptor mrna	[mineralocorticoid receptor mRNA]	0.0	3	1	1	1
145088	1710	great reduction	[greater reduction]	0.0	2	1	1	1
145089	1710	hematologic neoplasm	[hematologic neoplasms]	0.0	2	1	1	1
145090	1710	J kappa -binding site	[J kappa -binding site]	0.0	4	1	1	1
145091	1710	phytohemagglutinin pha blast	[phytohemagglutinin PHA blasts]	0.0	3	1	1	1
145092	1710	other cells; a component	[other cells; a component]	0.0	4	1	1	1
145093	1710	cocktail of anti-CD40	[cocktail of anti-CD40]	0.0	3	1	1	1
145094	1710	hyperparathyroidism in uremia	[hyperparathyroidism in uremia]	0.0	3	1	1	1
145095	1710	negative Ras	[negative Ras]	0.0	2	1	1	1
145096	1710	extensive granulopoiesis die by 8 days.	[extensive granulopoiesis dying by 8 days.]	0.0	6	1	1	1
145097	1710	role in the apoptotic process	[role in the apoptotic process]	0.0	5	1	1	1
145098	1710	minimal promoter region in the u-937	[minimal promoter regions in the U-937]	0.0	6	1	1	1
145099	1710	interaction involve factor	[interactions involving factor]	0.0	3	1	1	1
145100	1710	moreover, TNF-alpha hiv-1 repeat transcription	[Moreover, TNF-alpha HIV-1 repeat transcription]	0.0	5	1	1	1
145101	1710	acceleration of the effects.	[acceleration of the effects.]	0.0	4	1	1	1
145102	1710	activation of a novel gene	[Activation of a novel gene]	0.0	5	1	1	1
145103	1710	recombinant virus contain vp16	[recombinant virus containing VP16]	0.0	4	1	1	1
145104	1710	intracellular stores.	[intracellular stores.]	0.0	2	1	1	1
145105	1710	incubation with 40%	[Incubation with 40%]	0.0	3	1	1	1
145106	1710	transcript degradation	[transcript degradation]	0.0	2	1	1	1
145107	1710	result in tissue fibrosis	[resulting in tissue fibrosis]	0.0	4	1	1	1
145108	1710	variety include skeletal muscle	[variety including skeletal muscle]	0.0	4	1	1	1
145109	1710	potential site for phosphorylation	[potential sites for phosphorylation]	0.0	4	1	1	1
145110	1710	investigate the nature	[investigating the nature]	0.0	3	1	1	1
145111	1710	U2 rna(snrna)-encoding gene	[U2 RNA(snRNA)-encoding gene]	0.0	3	1	1	1
145112	1710	gamma interferon hla-dr expression	[gamma interferon HLA-DR expression]	0.0	4	1	1	1
145113	1710	histocompatibility class gene	[histocompatibility class genes]	0.0	3	1	1	1
145114	1710	rna transcription activity	[RNA transcription activity]	0.0	3	1	1	1
145115	1710	also to the transcription factor	[also to the transcription factors]	0.0	5	1	1	1
145116	1710	datum along with report	[data, along with reports]	0.0	4	1	1	1
145117	1710	m; control	[M; controls]	0.0	2	1	1	1
145118	1710	susceptibility during infection	[susceptibility during infection]	0.0	3	1	1	1
145119	1710	p.k.	[P.K.]	0.0	1	1	1	1
145120	1710	Functional antagonism	[Functional antagonism]	0.0	2	1	1	1
145121	1710	differentiation in cell	[differentiation in cells]	0.0	3	1	1	1
145122	1710	DNA clone pzvb70	[DNA clone pZVB70]	0.0	3	1	1	1
145123	1710	G.Visani,	[G.Visani,]	0.0	1	1	1	1
145124	1710	strain of hiv	[strains of HIV]	0.0	3	2	2	1
145125	1710	active tfiiib molecule	[active TFIIIB molecules]	0.0	3	1	1	1
145126	1710	various cell type include cd8+	[various cell types including CD8+]	0.0	5	1	1	1
145127	1710	49 case of leukemia	[49 cases of leukemia]	0.0	4	1	1	1
145128	1710	dna-binding phosphoprotein	[DNA-binding phosphoproteins]	0.0	2	1	1	1
145129	1710	leukemia 1-	[leukemia 1-]	0.0	2	1	1	1
145130	1710	transcriptional response in cell	[transcriptional responses in cells]	0.0	4	1	1	1
145131	1710	100% of patient	[100% of patients]	0.0	3	1	1	1
145132	1710	Rapid ca2+-mediated activation in human platelet	[Rapid Ca2+-mediated activation in human platelets]	0.0	6	1	1	1
145133	1710	moreover, simian virus enhancer activity	[Moreover, simian virus enhancer activity]	0.0	5	1	1	1
145134	1710	Xenogeneic serum	[Xenogeneic serum]	0.0	2	2	2	1
145135	1710	pattern in brain	[pattern in brain]	0.0	3	1	1	1
145136	1710	fibroblast growth factor	[fibroblast growth factor]	0.0	3	1	1	1
145137	1710	Indeed, IL-10	[Indeed, IL-10]	0.0	2	1	1	1
145138	1710	enhancement of il-2 production	[enhancement of IL-2 production]	0.0	4	1	1	1
145139	1710	form by immunoprecipitation study	[forms by immunoprecipitation studies]	0.0	4	1	1	1
145140	1710	role for tnf-alpha secretion	[role for TNF-alpha secretion]	0.0	4	1	1	1
145141	1710	one mechanism of cellular transformation	[one mechanism of cellular transformation]	0.0	5	1	1	1
145142	1710	effect of the combination	[effect of the combinations]	0.0	4	1	1	1
145143	1710	cell include cell from individual	[cells including cells from individuals]	0.0	5	1	1	1
145144	1710	activation tax protein	[activation tax protein]	0.0	3	1	1	1
145145	1710	few viruses,	[few viruses,]	0.0	2	1	1	1
145146	1710	oxygen intermediate after stress	[oxygen intermediates after stress]	0.0	4	1	1	1
145147	1710	cotransfection with the IL-2 promoter construct	[Cotransfection with the IL-2 promoter construct]	0.0	6	1	1	1
145148	1710	(45-50 min)	[(45-50 min)]	0.0	2	1	1	1
145149	1710	response to phorbol 12-myristate 13-acetate	[response to phorbol 12-myristate 13-acetate]	0.0	5	1	1	1
145150	1710	N-acetyl-L-cysteine a thiol-containing antioxidant	[N-acetyl-L-cysteine a thiol-containing antioxidant]	0.0	4	1	1	1
145151	1710	half-live	[half-lives]	0.0	1	1	1	1
145152	1710	identification of a inducible regulator	[Identification of an inducible regulator]	0.0	5	1	1	1
145153	1710	infection by herpesviruse	[infections by herpesviruses]	0.0	3	1	1	1
145154	1710	genetic manipulation	[genetic manipulation]	0.0	2	1	1	1
145155	1710	intron of TNF-alpha	[intron of TNF-alpha]	0.0	3	1	1	1
145156	1710	2.9 nmol/l, p	[2.9 nmol/L, p]	0.0	3	1	1	1
145157	1710	Ki-67 antigen in tumor cell	[Ki-67 antigens in tumor cells]	0.0	5	1	1	1
145158	1710	Peroxisomal receptor gamma a transcription factor	[Peroxisomal receptor gamma a transcription factor]	0.0	6	1	1	1
145159	1710	>10(-10) mol/L	[>10(-10) mol/L]	0.0	2	1	1	1
145160	1710	suggest particularly deleterious	[suggesting particularly deleterious]	0.0	3	1	1	1
145161	1710	strain contain a deletion	[strain containing a deletion]	0.0	4	1	1	1
145162	1710	p65 rel-a	[p65 Rel-A]	0.0	2	1	1	1
145163	1710	transcriptional level in macrophage	[transcriptional level in macrophages]	0.0	4	1	1	1
145164	1710	ligand of ahr	[ligand of AhR]	0.0	3	1	1	1
145165	1710	generation of isoform	[generation of isoforms]	0.0	3	1	1	1
145166	1710	efficient transcription of simian immunodeficiency virus	[Efficient transcription of simian immunodeficiency virus]	0.0	6	1	1	1
145167	1710	-137 to -64 element	[-137 to -64 element]	0.0	4	1	1	1
145168	1710	significance with respect	[significance with respect]	0.0	3	1	1	1
145169	1710	proenkephalin by JunD	[proenkephalin by JunD]	0.0	3	1	1	1
145170	1710	binding of c-rel	[Binding of c-Rel]	0.0	3	1	1	1
145171	1710	specific expression of a form	[specific expression of a form]	0.0	5	1	1	1
145172	1710	reporter construct contain copy	[reporter construct containing copies]	0.0	4	1	1	1
145173	1710	nf-kappab in human mononuclear cell	[NF-kappaB in human mononuclear cells]	0.0	5	1	1	1
145174	1710	macrophage-restricted member	[macrophage-restricted member]	0.0	2	1	1	1
145175	1710	distinguish carrier	[distinguishing carriers]	0.0	2	1	1	1
145176	1710	region of the hbd fragment	[region of the HBD fragment]	0.0	5	1	1	1
145177	1710	region of Oct-2a	[regions of Oct-2a]	0.0	3	1	1	1
145178	1710	major downstream site for E2F	[major downstream site for E2F]	0.0	5	1	1	1
145179	1710	Lung instillation	[Lung instillation]	0.0	2	1	1	1
145180	1710	mechanism of down-regulation of ICAM-I	[mechanism of down-regulation of ICAM-I]	0.0	5	1	1	1
145181	1710	microsatellite marker	[microsatellite markers]	0.0	2	1	1	1
145182	1710	fas ligand cd95	[Fas ligand CD95]	0.0	3	1	1	1
145183	1710	-176 sequence	[-176 sequence]	0.0	2	1	1	1
145184	1710	production of metabolite	[production of metabolites]	0.0	3	1	1	1
145185	1710	complex in IM-9 extract	[complex in IM-9 extracts]	0.0	4	1	1	1
145186	1710	control resting	[control resting]	0.0	2	1	1	1
145187	1710	integrin -dependent cell adhesion	[integrin -dependent cell adhesion]	0.0	4	1	1	1
145188	1710	variant of the t(15;17)	[variant of the t(15;17)]	0.0	4	1	1	1
145189	1710	induction of the proinflammatory cytokine	[induction of the proinflammatory cytokines]	0.0	5	1	1	1
145190	1710	mobility complex	[mobility complex]	0.0	2	1	1	1
145191	1710	inducible phosphorylation to serine	[inducible phosphorylation to serines]	0.0	4	1	1	1
145192	1710	ige hyperimmunoglobulin e	[IgE hyperimmunoglobulin E]	0.0	3	1	1	1
145193	1710	two family of factor	[two families of factors]	0.0	4	1	1	1
145194	1710	x-linked atrophy a adult-onset form	[X-linked atrophy an adult-onset form]	0.0	5	1	1	1
145195	1710	promoter in b cell	[promoters in B cells]	0.0	4	1	1	1
145196	1710	measure venule	[measuring venules]	0.0	2	1	1	1
145197	1710	inhibition of rante expression	[inhibition of RANTES expression]	0.0	4	1	1	1
145198	1710	level of transcript for IP-10	[levels of transcripts for IP-10]	0.0	5	1	1	1
145199	1710	trigger include repression	[triggering including repression]	0.0	3	1	1	1
145200	1710	dimerization region	[dimerization region]	0.0	2	1	1	1
145201	1710	Ca(2+) phosphatase calcineurin a target	[Ca(2+) phosphatase calcineurin a target]	0.0	5	1	1	1
145202	1710	level of ndp kinase expression	[levels of NDP kinase expression]	0.0	5	1	1	1
145203	1710	cd11b antigen in leukemic cell	[CD11b antigen in leukemic cells]	0.0	5	1	1	1
145204	1710	specific regulatory protein	[specific regulatory proteins]	0.0	3	1	1	1
145205	1710	subclone to dexamethasone	[subclones to dexamethasone]	0.0	3	1	1	1
145206	1710	inhibition of gtp-cyclohydrolase	[inhibition of GTP-cyclohydrolase]	0.0	3	1	1	1
145207	1710	agent of mononucleosis	[agent of mononucleosis]	0.0	3	1	1	1
145208	1710	passage cell in function	[passage cells in function]	0.0	4	1	1	1
145209	1710	26 primary carcinoma patient	[26 primary carcinoma patients]	0.0	4	1	1	1
145210	1710	step of export	[step of export]	0.0	3	1	1	1
145211	1710	act as cofactor	[acting as cofactors]	0.0	3	1	1	1
145212	1710	/il-2	[/IL-2]	0.0	1	1	1	1
145213	1710	tyrosine kinase Syk	[tyrosine kinase Syk]	0.0	3	1	1	1
145214	1710	mimicry in disease	[mimicry in disease]	0.0	3	1	1	1
145215	1710	enzyme aldehyde dehydrogenase Aldh1	[enzyme aldehyde dehydrogenase Aldh1]	0.0	4	1	1	1
145216	1710	regulatory sequence from gene	[regulatory sequences from genes]	0.0	4	1	1	1
145217	1710	regulation specific	[regulation specific]	0.0	2	1	1	1
145218	1710	major phorbol ester motif	[major phorbol ester motifs]	0.0	4	1	1	1
145219	1710	experimental model for lineage restriction	[experimental model for lineage restriction]	0.0	5	1	1	1
145220	1710	EA-D promoter	[EA-D promoter]	0.0	2	1	1	1
145221	1710	(high turnover)	[(high turnover)]	0.0	2	1	1	1
145222	1710	overexpression of a inhibitor	[overexpression of a inhibitor]	0.0	4	1	1	1
145223	1710	cell of endothelial-leukocyte adhesion molecule	[cells of endothelial-leukocyte adhesion molecule]	0.0	5	1	1	1
145224	1710	difference in the turnover	[difference in the turnover]	0.0	4	1	1	1
145225	1710	nasal lymphoma NL	[nasal lymphoma NL]	0.0	3	1	1	1
145226	1710	ets family transcription factor	[Ets family transcription factor]	0.0	4	1	1	1
145227	1710	+/- 16 versus 35 +/-	[+/- 16 versus 35 +/-]	0.0	5	1	1	1
145228	1710	two class of receptor	[two classes of receptors]	0.0	4	1	1	1
145229	1710	concentration of 10(-5) m	[concentrations of 10(-5) M]	0.0	4	1	1	1
145230	1710	feature of hla-dq evolution	[feature of HLA-DQ evolution]	0.0	4	1	1	1
145231	1710	introduction in mel cell	[introduction in MEL cells]	0.0	4	1	1	1
145232	1710	complex with AMP response	[complexes with AMP response]	0.0	4	1	1	1
145233	1710	erk-2 pathway	[ERK-2 pathway]	0.0	2	1	1	1
145234	1710	development of therapy	[development of therapies]	0.0	3	1	1	1
145235	1710	gata-1 function	[GATA-1 function]	0.0	2	1	1	1
145236	1710	sequence analysis of HS	[sequence analysis of HS]	0.0	4	1	1	1
145237	1710	ebf homologous sequence on chromosome	[EBF homologous sequences on Chromosome]	0.0	5	1	1	1
145238	1710	mean level in Cushing' disease	[mean level in Cushing's disease]	0.0	5	1	1	1
145239	1710	c-Myc fibroblast	[c-Myc fibroblasts]	0.0	2	1	1	1
145240	1710	overexpression in the lymphocyte	[overexpression in the lymphocytes]	0.0	4	1	1	1
145241	1710	genomic rearrangement corresponding	[genomic rearrangements corresponding]	0.0	3	1	1	1
145242	1710	N-terminal antibody	[N-terminal antibody]	0.0	2	1	1	1
145243	1710	insertion into 5' region	[insertion into 5' region]	0.0	4	1	1	1
145244	1710	T cell leukaemia t-pll	[T cell leukaemia T-PLL]	0.0	4	1	1	1
145245	1710	NF-kappaB modulator	[NF-kappaB modulator]	0.0	2	1	1	1
145246	1710	overexpression 1 peptide in jy25 cell	[Overexpression 1 peptide in JY25 cells]	0.0	6	1	1	1
145247	1710	correlation between expression	[correlation between expression]	0.0	3	1	1	1
145248	1710	incubation of endothelial cell in hypoxia	[Incubation of endothelial cells in hypoxia]	0.0	6	1	1	1
145249	1710	direct interaction functional antagonism in cell	[Direct interaction functional antagonism in cells]	0.0	6	1	1	1
145250	1710	elucidate the molecular mechanism	[elucidating the molecular mechanisms]	0.0	4	1	1	1
145251	1710	correlation to clinical response.	[correlation to clinical response.]	0.0	4	1	1	1
145252	1710	cortical region of thymus lobule	[cortical regions of thymus lobules]	0.0	5	1	1	1
145253	1710	interplay of regulatory element	[interplay of regulatory elements]	0.0	4	1	1	1
145254	1710	glucocorticoid in patient with asthma	[glucocorticoids in patients with asthma]	0.0	5	1	1	1
145255	1710	prevent the phase	[preventing the phase]	0.0	3	1	1	1
145256	1710	sequence tag dest	[sequence tags DESTs]	0.0	3	1	1	1
145257	1710	blood of 145 volunteer man	[blood of 145 volunteers men]	0.0	5	1	1	1
145258	1710	tissue during murine embryogenesis	[tissues during murine embryogenesis]	0.0	4	1	1	1
145259	1710	degree for 2 h	[degrees for 2 h]	0.0	4	1	1	1
145260	1710	repeats;	[repeats;]	0.0	1	1	1	1
145261	1710	(range, 5.66-10) (range, (range, 5.86-6.74) nm,	[(range, 5.66-10), (range, (range, 5.86-6.74) nM,]	0.0	6	1	1	1
145262	1710	repeats.	[repeats.]	0.0	1	1	1	1
145263	1710	hiv-1 repeat reporter gene activity	[HIV-1 repeat reporter gene activity]	0.0	5	1	1	1
145264	1710	tryptophan photoproduct 6-formylindolo[3,2-b]carbazole	[tryptophan photoproduct 6-formylindolo[3,2-b]carbazole]	0.0	3	1	1	1
145265	1710	egr family binding element	[Egr family binding element]	0.0	4	1	1	1
145266	1710	implication for the control	[implications for the control]	0.0	4	1	1	1
145267	1710	tuberculosis 1 df,	[tuberculosis 1 df,]	0.0	3	1	1	1
145268	1710	negative glucocorticoid response element	[negative glucocorticoid response element]	0.0	4	1	1	1
145269	1710	b cell-associated gene	[B cell-associated genes]	0.0	3	1	1	1
145270	1710	derivation of rna polymerase transcription system	[derivation of RNA polymerase transcription systems]	0.0	6	1	1	1
145271	1710	include phorbol 12-myristate 13-acetate	[including phorbol 12-myristate 13-acetate]	0.0	4	1	1	1
145272	1710	repeat expansion	[repeat expansions]	0.0	2	1	1	1
145273	1710	balance between progenitor proliferation	[balance between progenitor proliferation]	0.0	4	1	1	1
145274	1710	biosynthesis	[biosynthesis]	0.0	1	2	2	1
145275	1710	significance of the study	[significance of the study]	0.0	4	1	1	1
145276	1710	rational strategy manipulate immune response	[rational strategies manipulating immune responses]	0.0	5	1	1	1
145277	1710	administration of As2O3	[administration of As2O3]	0.0	3	1	1	1
145278	1710	inositoltrisphosphate generation	[inositoltrisphosphate generation]	0.0	2	1	1	1
145279	1710	immunodeficiency virus type 1 long repeat	[immunodeficiency virus type 1 long repeats]	0.0	6	1	1	1
145280	1710	different perspective	[different perspective]	0.0	2	1	1	1
145281	1710	key role in the expression	[key role in the expression]	0.0	5	1	1	1
145282	1710	thus, probably a target site	[Thus, probably a target site]	0.0	5	1	1	1
145283	1710	colony mm)	[colonies mm)]	0.0	2	1	1	1
145284	1710	potentiation of activity by GM-CSF	[potentiation of activity by GM-CSF]	0.0	5	1	1	1
145285	1710	nuclear factor-kappaB in the cytosol	[nuclear factor-kappaB in the cytosol]	0.0	5	1	1	1
145286	1710	12-o-tetradecanoylphorbol induction of nuclear factor-kappaB activity	[12-O-tetradecanoylphorbol induction of nuclear factor-kappaB activity]	0.0	6	1	1	1
145287	1710	element-1	[element-1]	0.0	1	1	1	1
145288	1710	linear ebv DNA	[linear EBV DNA]	0.0	3	1	1	1
145289	1710	related acid receptor alpha rar-alpha	[related acid receptor alpha RAR-alpha]	0.0	5	1	1	1
145290	1710	expression during B-lymphocyte development	[expression during B-lymphocyte development]	0.0	4	1	1	1
145291	1710	typical pattern of transcription factor	[typical pattern of transcription factors]	0.0	5	1	1	1
145292	1710	monoclonal reagent	[monoclonal reagents]	0.0	2	1	1	1
145293	1710	resumption of pge2 synthesis	[resumption of PGE2 synthesis]	0.0	4	1	1	1
145294	1710	progression of disease	[progression of diseases]	0.0	3	1	1	1
145295	1710	resection in patient	[resection in patients]	0.0	3	1	1	1
145296	1710	bind affinity in World primate	[binding affinity in World primates]	0.0	5	1	1	1
145297	1710	involvement of factor-kappa b activation	[Involvement of factor-kappa B activation]	0.0	5	1	1	1
145298	1710	Ig chain promoter,	[Ig chain promoter,]	0.0	3	1	1	1
145299	1710	receptor gene in s194 cell	[receptor genes in S194 cells]	0.0	5	1	1	1
145300	1710	human rest T cell	[human resting T cells]	0.0	4	1	1	1
145301	1710	toll signal pathway divergence	[toll signaling pathway divergence]	0.0	4	1	1	1
145302	1710	cDNA encode a component	[cDNA encoding a component]	0.0	4	1	1	1
145303	1710	cd14 5' sequence	[CD14 5' sequence]	0.0	3	1	1	1
145304	1710	migration RM	[migration RM]	0.0	2	1	1	1
145305	1710	mobility of osteoblast extract-DNA complex	[mobilities of osteoblast extract-DNA complexes]	0.0	5	1	1	1
145306	1710	two site CACCC	[two sites CACCC]	0.0	3	1	1	1
145307	1710	effect (in comparison	[effect (in comparison]	0.0	3	1	1	1
145308	1710	activation of mitogen-activated protein kinase	[activation of mitogen-activated protein kinase]	0.0	5	1	1	1
145309	1710	human herpesvirus strain gs	[human herpesvirus strains GS]	0.0	4	1	1	1
145310	1710	lack T cell	[lacking T cells]	0.0	3	1	1	1
145311	1710	blood mononuclear cell glucocorticoid receptor	[blood mononuclear cell glucocorticoid receptors]	0.0	5	1	1	1
145312	1710	CD4 scd4	[CD4 sCD4]	0.0	2	1	1	1
145313	1710	5-lox activate protein	[5-LOX activating protein]	0.0	3	1	1	1
145314	1710	mutagenesis in the portion	[mutagenesis in the portion]	0.0	4	1	1	1
145315	1710	important regulatory element	[important regulatory element]	0.0	3	1	1	1
145316	1710	lbp patient (25:3)	[LBP patients (25:3)]	0.0	3	1	1	1
145317	1710	putative localization sequence	[putative localization sequences]	0.0	3	1	1	1
145318	1710	two protein-binding site within the element	[Two protein-binding sites within the element]	0.0	6	1	1	1
145319	1710	human t-cell leukemia t-all	[human T-cell leukemia T-ALL]	0.0	4	1	1	1
145320	1710	adhesion of polymorphonuclear cell vein cell	[adhesion of polymorphonuclear cells vein cells]	0.0	6	1	1	1
145321	1710	cell line HL	[cell line HL]	0.0	3	1	1	1
145322	1710	HL-60 leukemia cell	[HL-60 leukemia cells]	0.0	3	1	1	1
145323	1710	apparent resistance	[apparent resistance]	0.0	2	1	1	1
145324	1710	ica-positive relative of IDDM subject	[ICA-positive relatives of IDDM subjects]	0.0	5	1	1	1
145325	1710	contain near-perfect direct repeat of bp	[containing near-perfect direct repeats of bp]	0.0	6	1	1	1
145326	1710	finding of maternal expression	[findings of maternal expression]	0.0	4	1	1	1
145327	1710	response to many cytokine	[response to many cytokines]	0.0	4	1	1	1
145328	1710	E2A-HLF leukaemia factor) fusion gene	[E2A-HLF leukaemia factor) fusion gene]	0.0	5	1	1	1
145329	1710	pretreatment with m dexamethasone (207.9+/-31.5	[pretreatment with M dexamethasone (207.9+/-31.5]	0.0	5	1	1	1
145330	1710	addition, assay by the adenovirus	[addition, assay by the adenovirus]	0.0	5	2	2	1
145331	1710	formation between the type	[formation between the type]	0.0	4	1	1	1
145332	1710	contain the mua	[containing the muA]	0.0	3	1	1	1
145333	1710	dysregulation immunodeficiency virus type 1	[dysregulation immunodeficiency virus type 1]	0.0	5	1	1	1
145334	1710	haematopoietic population	[haematopoietic populations]	0.0	2	1	1	1
145335	1710	cause a 29 bp truncation	[causing a 29 bp truncation]	0.0	5	1	1	1
145336	1710	promoter sequence responsive	[Promoter sequences responsive]	0.0	3	1	1	1
145337	1710	replacement of homodimer	[replacement of homodimers]	0.0	3	1	1	1
145338	1710	control p27kip1 gene expression,	[controlling p27Kip1 gene expression,]	0.0	4	1	1	1
145339	1710	lymphocyte of blood	[lymphocytes of blood]	0.0	3	1	1	1
145340	1710	beta,19-epoxypregn-5-ene-4,20-dione (8) pd-c hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione	[beta,19-epoxypregn-5-ene-4,20-dione (8) Pd-C hydrogenation beta,19-cyclopregna-2,9(11)-diene-4,20-dione]	0.0	5	1	1	1
145341	1710	Cp the major promoter	[Cp the major promoter]	0.0	4	1	1	1
145342	1710	noncomedo carcinoma	[noncomedo carcinomas]	0.0	2	1	1	1
145343	1710	synchronization to condition	[synchronization to conditions]	0.0	3	1	1	1
145344	1710	Alternate immune system target stem cell	[Alternate immune system targets stem cells]	0.0	6	1	1	1
145345	1710	JAK3 severe immunodeficiency lymphocyte	[JAK3 severe immunodeficiency lymphocytes]	0.0	4	1	1	1
145346	1710	prevent the late phase	[preventing the late phase]	0.0	4	1	1	1
145347	1710	rapidly tyrosine-phosphorylated granulocyte-colony factor treatment	[rapidly tyrosine-phosphorylated granulocyte-colony factor treatment]	0.0	5	1	1	1
145348	1710	release expression	[release expression]	0.0	2	1	1	1
145349	1710	interaction between Ets NF-kappaB/NFAT protein	[interactions between Ets NF-kappaB/NFAT proteins]	0.0	5	1	1	1
145350	1710	promoter sequence responsive to cyclic AMP	[Promoter sequences responsive to cyclic AMP]	0.0	6	1	1	1
145351	1710	co-activation of ca(2+) pathway	[co-activation of Ca(2+) pathways]	0.0	4	1	1	1
145352	1710	Hsp60 -specific T cell	[Hsp60 -specific T cells]	0.0	4	1	1	1
145353	1710	complex with AMP response element-binding protein	[complexes with AMP response element-binding protein]	0.0	6	1	1	1
145354	1710	nearby site originate 204 bp	[nearby sites originating 204 bp]	0.0	5	1	1	1
145355	1710	nmax	[Nmax]	0.0	1	1	1	1
145356	1710	marker of brain involution	[marker of brain involution]	0.0	4	2	2	1
145357	1710	antibody cross-linking of tr55	[Antibody cross-linking of TR55]	0.0	4	1	1	1
145358	1710	step in the transmission	[step in the transmission]	0.0	4	1	1	1
145359	1710	month (p	[months (P]	0.0	2	1	1	1
145360	1710	IL-2 nuclear translocation	[IL-2 nuclear translocation]	0.0	3	1	1	1
145361	1710	protein capable of binding	[proteins capable of binding]	0.0	4	1	1	1
145362	1710	tnf binding protein-1	[TNF binding protein-1]	0.0	3	1	1	1
145363	1710	inhibitor of Jun phosphorylation	[inhibitor of Jun phosphorylation]	0.0	4	1	1	1
145364	1710	originate from case	[originating from cases]	0.0	3	1	1	1
145365	1710	however, continuous treatment with concentration	[However, continuous treatments with concentrations]	0.0	5	1	1	1
145366	1710	[differential value	[[Differential value]	0.0	2	1	1	1
145367	1710	lymphocyte from the control group	[lymphocytes from the control group,]	0.0	5	1	1	1
145368	1710	nf kappab enzyme	[NF kappaB enzyme]	0.0	3	1	1	1
145369	1710	amplify expression of own high-affinity receptor	[amplifying expression of own high-affinity receptor]	0.0	6	1	1	1
145370	1710	nf-kappab regulation during obstruction	[NF-kappaB regulation during obstruction]	0.0	4	1	1	1
145371	1710	/octamer	[/octamer]	0.0	1	1	1	1
145372	1710	cell of various species	[cells of various species]	0.0	4	1	1	1
145373	1710	CD2:lymphocyte ag-3 pathway	[CD2:lymphocyte Ag-3 pathway]	0.0	3	1	1	1
145374	1710	activity of estrogen	[activities of estrogens]	0.0	3	1	1	1
145375	1710	pretreatment of pbmc	[Pretreatment of PBMCs]	0.0	3	1	1	1
145376	1710	0.016 microg/ml respectively.	[0.016 microg/ml respectively.]	0.0	3	1	1	1
145377	1710	b cell surface	[B cell surface]	0.0	3	1	1	1
145378	1710	critical threshold level of nf-atc	[critical threshold levels of NF-ATc]	0.0	5	1	1	1
145379	1710	october sequence	[october sequence]	0.0	2	1	1	1
145380	1710	breast duct	[breast ducts]	0.0	2	1	1	1
145381	1710	inducer of IL-6 gene expression	[inducers of IL-6 gene expression]	0.0	5	1	1	1
145382	1710	diagnosis, genetic counseling, of patient	[diagnosis, genetic counseling, of patients]	0.0	5	1	1	1
145383	1710	factor-1 receptor	[factor-1 receptor]	0.0	2	1	1	1
145384	1710	interleukin a potent activator	[interleukin a potent activator]	0.0	4	1	1	1
145385	1710	structurally distinct, inhibitor	[structurally distinct, inhibitors]	0.0	3	1	1	1
145386	1710	contain gene pax-5	[containing gene Pax-5]	0.0	3	1	1	1
145387	1710	range include interferon-gamma	[range including interferon-gamma]	0.0	3	1	1	1
145388	1710	f.r., m.m., P. g.)	[F.R., M.M., P. G.)]	0.0	4	1	1	1
145389	1710	gland,y	[gland,]	0.0	1	1	1	1
145390	1710	actions, include effect	[actions, including effects]	0.0	3	1	1	1
145391	1710	locus enhancer	[locus enhancers]	0.0	2	1	1	1
145392	1710	factor (nfat) protein	[factor (NFAT) proteins]	0.0	3	1	1	1
145393	1710	co-cultured bronchial cell BEAS-2B	[co-cultured bronchial cells BEAS-2B]	0.0	4	1	1	1
145394	1710	contrast to DC	[contrast to DC]	0.0	3	1	1	1
145395	1710	wk to 12 mo)	[wk to 12 mo)]	0.0	4	1	1	1
145396	1710	hepor transcription	[hEpoR transcription]	0.0	2	1	1	1
145397	1710	line BJAB	[line BJAB]	0.0	2	1	1	1
145398	1710	regulate localization through a protein module	[regulating localization through a protein module]	0.0	6	1	1	1
145399	1710	test).	[test).]	0.0	1	1	1	1
145400	1710	difference in transcription assay	[difference in transcription assays]	0.0	4	1	1	1
145401	1710	different gc	[different GC]	0.0	2	1	1	1
145402	1710	value of the test	[value of the test]	0.0	4	1	1	1
145403	1710	provide the transactivator bzlf1 in trans	[providing the transactivator BZLF1 in trans]	0.0	6	1	1	1
145404	1710	modulate sensitivity of cells.	[modulating sensitivity of cells.]	0.0	4	1	1	1
145405	1710	receptor-effector-mechor-mechanisms the sequence of effect	[receptor-effector-mechanisms the sequence of effects]	0.0	5	1	1	1
145406	1710	one case with a reaction	[one case with a reaction]	0.0	5	1	1	1
145407	1710	presence of positive element	[presence of positive elements]	0.0	4	1	1	1
145408	1710	superfamily	[superfamily]	0.0	1	1	1	1
145409	1710	40 residue	[40 residues]	0.0	2	1	1	1
145410	1710	DNA accessibility	[DNA accessibility]	0.0	2	1	1	1
145411	1710	activity of tcf-1 alpha	[activity of TCF-1 alpha]	0.0	4	1	1	1
145412	1710	dna-protein binding complex by il-2	[DNA-protein binding complexes by IL-2]	0.0	5	1	1	1
145413	1710	Missense mutation in exon 7	[Missense mutation in exon 7]	0.0	5	1	1	1
145414	1710	downregulation of hiv transcription	[downregulation of HIV transcription]	0.0	4	1	1	1
145415	1710	increase in nuclear factor kappab	[increase in nuclear factor kappaB]	0.0	5	1	1	1
145416	1710	ikappab kinase alpha	[IkappaB kinase alpha]	0.0	3	1	1	1
145417	1710	include hl-60	[including HL-60]	0.0	2	1	1	1
145418	1710	presentation by autologous antigen-present cell	[presentation by autologous antigen-presenting cell]	0.0	5	1	1	1
145419	1710	activation functional role of factor-DNA complex	[activation functional role of factor-DNA complexes]	0.0	6	1	1	1
145420	1710	three form of virus latency	[three forms of virus latency]	0.0	5	1	1	1
145421	1710	downmodulation of cd34 mrna	[downmodulation of CD34 mRNA]	0.0	4	1	1	1
145422	1710	regulation of cytokine cytokine receptor expression	[Regulation of cytokine cytokine receptor expression]	0.0	6	1	1	1
145423	1710	kinase in u-937	[kinase in U-937]	0.0	3	1	1	1
145424	1710	8% dead cell at day 6;	[8% dead cells at day 6;]	0.0	6	1	1	1
145425	1710	high relative level in monocytic	[higher relative levels in monocytic]	0.0	5	1	1	1
145426	1710	other oncoprotein	[other oncoproteins]	0.0	2	1	1	1
145427	1710	obligatory heterodimerization	[obligatory heterodimerization]	0.0	2	1	1	1
145428	1710	1,25-(oh)2 D3	[1,25-(OH)2 D3]	0.0	2	1	1	1
145429	1710	expression in precursor	[expression in precursors]	0.0	3	1	1	1
145430	1710	coordination with other factor	[coordination with other factors]	0.0	4	1	1	1
145431	1710	marker of leukemia	[markers of leukemias]	0.0	3	1	1	1
145432	1710	U-373 MG cell	[U-373 MG cells]	0.0	3	1	1	1
145433	1710	Affinity-driven peptide selection	[Affinity-driven peptide selection]	0.0	3	1	1	1
145434	1710	defect downstream	[defect downstream]	0.0	2	1	1	1
145435	1710	herpesvirus saimiry associate with Lck	[herpesvirus saimiri associates with Lck]	0.0	5	1	1	1
145436	1710	c-jun expression good	[c-jun expression best]	0.0	3	1	1	1
145437	1710	deoxynucleotidyl transferase labeling	[deoxynucleotidyl transferase labeling]	0.0	3	1	1	1
145438	1710	(aa)	[(aa)]	0.0	1	1	1	1
145439	1710	lower-affinity site	[lower-affinity site]	0.0	2	1	1	1
145440	1710	thymocyte with thymic epithelial cell	[thymocytes with thymic epithelial cells]	0.0	5	1	1	1
145441	1710	three site kappa	[three sites kappa]	0.0	3	1	1	1
145442	1710	two AS oligonucleotide	[two AS oligonucleotides]	0.0	3	1	1	1
145443	1710	(ac)	[(AC)]	0.0	1	1	1	1
145444	1710	suggest activation	[suggesting activation]	0.0	2	1	1	1
145445	1710	first experience with Urapidil	[first experiences with Urapidil]	0.0	4	1	1	1
145446	1710	maximal induction between 1	[maximal induction between 1]	0.0	4	1	1	1
145447	1710	receptor constant in lymphocyte	[receptors constant in lymphocytes]	0.0	4	1	1	1
145448	1710	5' truncation mutant	[5' truncation mutants]	0.0	3	1	1	1
145449	1710	decrease in the nuclear level	[decrease in the nuclear levels]	0.0	5	1	1	1
145450	1710	cytokine release from lps-responsive cell	[cytokine release from LPS-responsive cells]	0.0	5	1	1	1
145451	1710	hiv-1 repeat promoter region	[HIV-1 repeat promoter region]	0.0	4	1	1	1
145452	1710	number of individual	[number of individuals]	0.0	3	1	1	1
145453	1710	segregation of autosome	[segregation of autosome]	0.0	3	1	1	1
145454	1710	protein of 52 kD	[protein of 52 kD]	0.0	4	1	1	1
145455	1710	G0 phase transition in b-lymphocyte	[G0 phase transition in B-lymphocytes]	0.0	5	1	1	1
145456	1710	base substitution polymorphism	[base substitution polymorphisms]	0.0	3	1	1	1
145457	1710	mitochondrial potential	[Mitochondrial potential]	0.0	2	1	1	1
145458	1710	two unrecognized NFATp -binding site	[Two unrecognized NFATp -binding sites]	0.0	5	1	1	1
145459	1710	factor NF-AT AP-1/Octamer	[factor NF-AT AP-1/Octamer]	0.0	3	1	1	1
145460	1710	twenty-two patient with severe anorexia nervosa	[Twenty-two patients with severe anorexia nervosa]	0.0	6	1	1	1
145461	1710	BZLF-1 a early gene	[BZLF-1 an early gene]	0.0	4	1	1	1
145462	1710	expression of the E1A region	[expression of the E1A regions]	0.0	5	1	1	1
145463	1710	human mediator	[human mediator]	0.0	2	1	1	1
145464	1710	megakaryocytic-specific gene	[megakaryocytic-specific genes]	0.0	2	1	1	1
145465	1710	suppressor-inducer T cell	[suppressor-inducer T cells]	0.0	3	1	1	1
145466	1710	hour 1	[hours 1]	0.0	2	1	1	1
145467	1710	apparent association	[apparent association]	0.0	2	1	1	1
145468	1710	t-cell leukemia T-PLL a form	[T-cell leukemia T-PLL a form]	0.0	5	1	1	1
145469	1710	site of vascular inflammation	[sites of vascular inflammation]	0.0	4	1	1	1
145470	1710	heterodimerization with c-fo	[heterodimerization with c-Fos]	0.0	3	1	1	1
145471	1710	transduction of g-csf receptor	[transduction of G-CSF receptors]	0.0	4	1	1	1
145472	1710	simple culture condition from pbmc	[simple culture conditions from PBMC]	0.0	5	1	1	1
145473	1710	flexibility	[flexibility]	0.0	1	1	1	1
145474	1710	[3H]thymidine incorporation in MNL	[[3H]thymidine incorporation in MNL]	0.0	4	1	1	1
145475	1710	chromosome abnormality in aml m4	[chromosome abnormalities in AML M4]	0.0	5	1	1	1
145476	1710	lymphotoxin on killer cell	[lymphotoxin on killer cells]	0.0	4	1	1	1
145477	1710	treatment of fibrosis	[treatment of fibrosis]	0.0	3	1	1	1
145478	1710	transcription, amplify expression of high-affinity receptor	[transcription, amplifying expression of high-affinity receptor]	0.0	6	1	1	1
145479	1710	mapping of b-cell epitope	[Mapping of B-cell epitopes]	0.0	4	1	1	1
145480	1710	estrogen receptor transcript	[estrogen receptor transcripts]	0.0	3	1	1	1
145481	1710	anti-apoptotic effect on cd34+ cell g-csf	[anti-apoptotic effects on CD34+ cells G-CSF]	0.0	6	1	1	1
145482	1710	contain a single site	[containing a single site]	0.0	4	1	1	1
145483	1710	abolish hepatic injury	[abolishing hepatic injury]	0.0	3	1	1	1
145484	1710	cyclic-AMP element	[cyclic-AMP element]	0.0	2	1	1	1
145485	1710	fibrosarcoma fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma fibrous histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
145486	1710	involvement in virus type	[Involvement in virus type]	0.0	4	1	1	1
145487	1710	downregulation implication for dysregulation	[downregulation implications for dysregulation]	0.0	4	1	1	1
145488	1710	class of self-antigen	[class of self-antigens]	0.0	3	1	1	1
145489	1710	appropriate group	[appropriate group]	0.0	2	1	1	1
145490	1710	tat cDNA in orientation	[tat cDNA in orientation]	0.0	4	1	1	1
145491	1710	gm-csf promoter	[GM-CSF promoter]	0.0	2	1	1	1
145492	1710	significant 2-4 fold increase	[significant 2-4 fold increase]	0.0	4	1	1	1
145493	1710	action of dm	[action of DM]	0.0	3	1	1	1
145494	1710	HIV-LTR-kappaB	[HIV-LTR-kappaB]	0.0	1	1	1	1
145495	1710	nuclear translocation mechanism	[nuclear translocation mechanism]	0.0	3	1	1	1
145496	1710	adenovirus ad2 infection on monocyte	[adenovirus Ad2 infection on monocytes]	0.0	5	1	1	1
145497	1710	constituent in human adult blood	[constituent in human adult blood]	0.0	5	1	1	1
145498	1710	adhesiveness	[adhesiveness]	0.0	1	1	1	1
145499	1710	gene class transactivator	[gene class transactivator]	0.0	3	1	1	1
145500	1710	first case of twin	[first case of twins]	0.0	4	1	1	1
145501	1710	hla class gene	[HLA class genes]	0.0	3	1	1	1
145502	1710	intact platelet to thrombin	[intact platelets to thrombin]	0.0	4	1	1	1
145503	1710	margin (31% at 5 years).	[margins (31% at 5 years).]	0.0	5	1	1	1
145504	1710	nonexpress erythroleukemia cell line	[nonexpressing erythroleukemia cell lines]	0.0	4	1	1	1
145505	1710	involvement of a protein other	[involvement of an protein other]	0.0	5	1	1	1
145506	1710	(outer limits, 127 one	[(outer limits, 127 one]	0.0	4	1	1	1
145507	1710	immune costimulatory molecule	[immune costimulatory molecule]	0.0	3	1	1	1
145508	1710	resistance of T cell	[resistance of T cells]	0.0	4	1	1	1
145509	1710	contain 5' deletion mutant	[containing 5' deletion mutants]	0.0	4	1	1	1
145510	1710	activator htlv-1 transcription	[activator HTLV-1 transcription]	0.0	3	1	1	1
145511	1710	maturation of a retinoid-resistant cell line	[maturation of a retinoid-resistant cell line]	0.0	6	1	1	1
145512	1710	expression the histone h5 gene	[expression the histone H5 gene]	0.0	5	1	1	1
145513	1710	c-fe 5'-flanking sequence	[c-fes 5'-flanking sequences]	0.0	3	1	1	1
145514	1710	phorbol 12-myristate (pma)-mediated differentiation	[phorbol 12-myristate (PMA)-mediated differentiation]	0.0	4	1	1	1
145515	1710	logarithmic mean	[logarithmic mean]	0.0	2	1	1	1
145516	1710	such as the interleukin-2 gene	[such as the interleukin-2 gene]	0.0	5	1	1	1
145517	1710	motility assay in platelet extract	[motility assays in platelet extracts]	0.0	5	1	1	1
145518	1710	regulate signal by virtue	[regulating signaling by virtue]	0.0	4	1	1	1
145519	1710	signal in b lymphocyte	[signaling in B lymphocytes]	0.0	4	1	1	1
145520	1710	clone with response to glycoprotein b	[Clones with responses to glycoprotein B]	0.0	6	1	1	1
145521	1710	5'-atgcaaag-3'	[5'-ATGCAAAG-3']	0.0	1	1	1	1
145522	1710	bind protein in b cell	[binding proteins in B cells]	0.0	5	1	1	1
145523	1710	T regulation	[T regulation]	0.0	2	1	1	1
145524	1710	alternative receptor complex	[alternative receptor complex]	0.0	3	1	1	1
145525	1710	human interleukin 9 gene	[human interleukin 9 gene]	0.0	4	1	1	1
145526	1710	concentration of all three	[concentrations of all three]	0.0	4	1	1	1
145527	1710	distinct differentiation pathway	[distinct differentiation pathways]	0.0	3	1	1	1
145528	1710	leukocyte antigen-B8	[leukocyte antigen-B8]	0.0	2	1	1	1
145529	1710	Comparison of transcriptional enhancement	[Comparison of transcriptional enhancement]	0.0	4	1	1	1
145530	1710	CONCLUSIONS: gcs	[CONCLUSIONS: GCs]	0.0	2	1	1	1
145531	1710	mouse gene 24p3	[mouse gene 24p3]	0.0	3	1	1	1
145532	1710	treatment by NE of platelet	[Treatment by NE of platelets]	0.0	5	1	1	1
145533	1710	coordinate activation	[coordinate activation]	0.0	2	2	2	1
145534	1710	encode primary granule protein ecp	[encoding primary granule proteins ECP]	0.0	5	1	1	1
145535	1710	soundness	[soundness]	0.0	1	1	1	1
145536	1710	peripheral blood lymphocyte PBL from human	[peripheral blood lymphocytes PBL from humans]	0.0	6	1	1	1
145537	1710	tumor-derived cell line	[tumor-derived cell lines]	0.0	3	1	1	1
145538	1710	regulate the response to cellular activation	[regulating the response to cellular activation]	0.0	6	1	1	1
145539	1710	mesangial	[mesangial]	0.0	1	1	1	1
145540	1710	agent, 1 alpha,25-dihydroxycholecalciferol	[agent, 1 alpha,25-dihydroxycholecalciferol]	0.0	3	1	1	1
145541	1710	Baf-3	[Baf-3]	0.0	1	1	1	1
145542	1710	permanently produce hiv tat protein	[permanently producing HIV Tat protein]	0.0	5	1	1	1
145543	1710	improve the definition of endpoint	[improving the definitions of endpoints]	0.0	5	1	1	1
145544	1710	yb-1 expression plasmid	[YB-1 expression plasmid]	0.0	3	1	1	1
145545	1710	contrast to healthy subject	[contrast to healthy subjects]	0.0	4	1	1	1
145546	1710	prevent translocation of c-Rel/p65 heterodimer	[preventing translocation of c-Rel/p65 heterodimers]	0.0	5	1	1	1
145547	1710	region Chr	[region Chr]	0.0	2	1	1	1
145548	1710	monocyte to a cell	[monocytes to a cell]	0.0	4	1	1	1
145549	1710	GR number	[GR number]	0.0	2	1	1	1
145550	1710	include pathway	[including pathways]	0.0	2	1	1	1
145551	1710	study evidence for formation	[studies evidence for formation]	0.0	4	1	1	1
145552	1710	additional difference	[additional differences]	0.0	2	1	1	1
145553	1710	synovial lymphocyte	[synovial lymphocytes]	0.0	2	1	1	1
145554	1710	even subdivide the subject	[even subdividing the subjects]	0.0	4	1	1	1
145555	1710	replication of the transcriptional template	[replication of the transcriptional template]	0.0	5	1	1	1
145556	1710	(q22;p13)	[(q22;p13)]	0.0	1	1	1	1
145557	1710	lymphocyte g0/g1	[lymphocyte G0/G1]	0.0	2	2	2	1
145558	1710	differentiation of skw 6.4 cell	[differentiation of SKW 6.4 cells]	0.0	5	1	1	1
145559	1710	ROI -form mechanism	[ROI -forming mechanisms]	0.0	3	1	1	1
145560	1710	(in comparison	[(in comparison]	0.0	2	1	1	1
145561	1710	increase phospholipase c gamma 1	[increase phospholipase C gamma 1]	0.0	5	1	1	1
145562	1710	subpopulation the (dp) CD4 thymocyte	[subpopulation the (DP) CD4 thymocytes]	0.0	5	1	1	1
145563	1710	mixture up-regulation	[mixture up-regulation]	0.0	2	1	1	1
145564	1710	ap-2 expression	[AP-2 expression]	0.0	2	1	1	1
145565	1710	specific expression of cd14	[specific expression of CD14]	0.0	4	1	1	1
145566	1710	c(h) gene	[C(H) genes]	0.0	2	1	1	1
145567	1710	interestingly, phase	[Interestingly, phase]	0.0	2	1	1	1
145568	1710	CsA -insensitive stage	[CsA -insensitive stage]	0.0	3	1	1	1
145569	1710	three other transcription factor	[three other transcription factors]	0.0	4	1	1	1
145570	1710	dimerization cofactor	[dimerization cofactor]	0.0	2	2	2	1
145571	1710	activation from patient	[activation from patients]	0.0	3	1	1	1
145572	1710	many lymphoid cell type	[many lymphoid cell types]	0.0	4	1	1	1
145573	1710	increase in the migration	[increase in the migration]	0.0	4	1	1	1
145574	1710	oxide a feedback inhibitor of inflammation	[oxide an feedback inhibitor of inflammation]	0.0	6	1	1	1
145575	1710	1) sign of hypothyroidism	[1) signs of hypothyroidism]	0.0	4	1	1	1
145576	1710	idea of a association	[idea of a association]	0.0	4	1	1	1
145577	1710	transactivation potential pax-2	[transactivation potential Pax-2]	0.0	3	1	1	1
145578	1710	unstimulated huvec monolayer	[unstimulated HUVEC monolayers]	0.0	3	1	1	1
145579	1710	nuclear factor for T cell	[nuclear factor for T cells]	0.0	5	1	1	1
145580	1710	expression occur	[expression occurring]	0.0	2	1	1	1
145581	1710	saturable binding	[saturable binding]	0.0	2	1	1	1
145582	1710	(ao)	[(AO)]	0.0	1	1	1	1
145583	1710	down-regulation of inflammation	[down-regulation of inflammation]	0.0	3	1	1	1
145584	1710	DNA fragment pzvb10	[DNA fragments pZVB10]	0.0	3	1	1	1
145585	1710	(aml	[(AML]	0.0	1	1	1	1
145586	1710	role on GM-CSF transcription	[role on GM-CSF transcription]	0.0	4	1	1	1
145587	1710	x inactivation in a twin pair	[X inactivation in a twin pair]	0.0	6	1	1	1
145588	1710	possibly cytokine receptors,	[possibly cytokine receptors,]	0.0	3	1	1	1
145589	1710	weight gain (14 (pre)	[weight gain (14 (pre)]	0.0	4	1	1	1
145590	1710	impaired transcriptional response in cell	[impaired transcriptional responses in cells]	0.0	5	1	1	1
145591	1710	such as cell	[such as cells]	0.0	3	1	1	1
145592	1710	two novel 9-bp motif with homology	[two novel 9-bp motifs with homology]	0.0	6	1	1	1
145593	1710	eklf-/- erythrocyte	[EKLF-/- erythrocytes]	0.0	2	1	1	1
145594	1710	occupancy of the enhancer by nf-kappab	[occupancy of the enhancer by NF-kappaB]	0.0	6	1	1	1
145595	1710	correlation between the number	[correlation between the number]	0.0	4	2	2	1
145596	1710	immunodeficiency SCID	[immunodeficiency SCID]	0.0	2	2	2	1
145597	1710	activation in blood T cell	[Activation in blood T cells]	0.0	5	1	1	1
145598	1710	t-lymphotropic virus type model transcription	[T-lymphotropic virus type model transcription]	0.0	5	1	1	1
145599	1710	mouse stem (es) cell	[mouse stem (ES) cells]	0.0	4	1	1	1
145600	1710	(ic50 of ng/ml),	[(IC50 of ng/ml),]	0.0	3	1	1	1
145601	1710	malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[malignant histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	5	1	1	1
145602	1710	h of cd19 cross-linking	[h of CD19 cross-linking]	0.0	4	1	1	1
145603	1710	regulator in erythroid differentiation	[regulators in erythroid differentiation]	0.0	4	1	1	1
145604	1710	individual factor	[individual factor]	0.0	2	1	1	1
145605	1710	ebv -receptor interaction	[EBV -receptor interactions]	0.0	3	1	1	1
145606	1710	release into the nucleus.	[release into the nucleus.]	0.0	4	1	1	1
145607	1710	peroxyl radical scavenging tnf- cell	[peroxyl radical scavenging TNF- cells]	0.0	5	1	1	1
145608	1710	ubiquitous, component	[ubiquitous, component]	0.0	2	1	1	1
145609	1710	potent immunosuppressive activity 100-fold low	[potent immunosuppressive activity 100-fold lower]	0.0	5	1	1	1
145610	1710	PEBP2 factor	[PEBP2 factor]	0.0	2	1	1	1
145611	1710	degree of T cell	[degree of T cells]	0.0	4	1	1	1
145612	1710	least two epitope	[least two epitopes]	0.0	3	1	1	1
145613	1710	direct result of activation	[direct result of activation]	0.0	4	1	1	1
145614	1710	use the wild-type acid receptor alpha	[Using the wild-type acid receptor alpha]	0.0	6	1	1	1
145615	1710	cn inhibition in primary leukocyte	[CN inhibition in primary leukocytes]	0.0	5	1	1	1
145616	1710	MHC /peptide density requirement	[MHC /peptide density requirements]	0.0	4	1	1	1
145617	1710	(ar)	[(AR)]	0.0	1	2	2	1
145618	1710	functional diversification of a limited number	[functional diversification of a limited number]	0.0	6	1	1	1
145619	1710	megakaryocytic gene in cell line	[megakaryocytic genes in cell lines]	0.0	5	1	1	1
145620	1710	protein kinase family member	[protein kinase family members]	0.0	4	1	1	1
145621	1710	cell from non-tumorous cavity fluid	[cells from non-tumorous cavity fluids]	0.0	5	1	1	1
145622	1710	provide evidence to the notion	[providing evidence to the notion]	0.0	5	1	1	1
145623	1710	crucial link	[crucial link]	0.0	2	1	1	1
145624	1710	interaction with lymphocyte	[interaction with lymphocytes]	0.0	3	1	1	1
145625	1710	subsequent accumulation	[subsequent accumulation]	0.0	2	1	1	1
145626	1710	moreover, a marker of event	[moreover, a marker of events]	0.0	5	1	1	1
145627	1710	2-fold affinity	[2-fold affinity]	0.0	2	1	1	1
145628	1710	encode the dna-binding domain	[encoding the DNA-binding domain]	0.0	4	1	1	1
145629	1710	posttranslational activation in response	[posttranslational activation in response]	0.0	4	1	1	1
145630	1710	consist of chain	[consisting of chains]	0.0	3	1	1	1
145631	1710	malignant lymphoma, cell" type	[malignant lymphoma, cell" type]	0.0	4	1	1	1
145632	1710	pHU-14 a probe hybridize	[pHU-14 a probe hybridizes]	0.0	4	1	1	1
145633	1710	(as)	[(AS)]	0.0	1	1	1	1
145634	1710	apoptosis in cell	[apoptosis in cells]	0.0	3	1	1	1
145635	1710	western blot with antibody specific	[Western blots with antibodies specific]	0.0	5	1	1	1
145636	1710	protein human x box protein	[protein human X box protein]	0.0	5	1	1	1
145637	1710	umbilical endothelial cell	[umbilical endothelial cells]	0.0	3	1	1	1
145638	1710	b cell bob1/obf-1/oca-b	[B cells Bob1/OBF-1/OCA-B]	0.0	3	1	1	1
145639	1710	LYSP100 cDNA isoform	[LYSP100 cDNA isoform]	0.0	3	1	1	1
145640	1710	activation of stat transcription factor	[activation of STAT transcription factors]	0.0	5	1	1	1
145641	1710	mechanism a novel type of cross-talk	[mechanisms a novel type of cross-talk]	0.0	6	1	1	1
145642	1710	T cell-specific component nf-atp	[T cell-specific component NF-ATp]	0.0	4	1	1	1
145643	1710	ifn-gamma manner	[IFN-gamma manner]	0.0	2	1	1	1
145644	1710	cd86 ligand for CD28	[CD86 ligands for CD28]	0.0	4	1	1	1
145645	1710	variability in the expression	[variability in the expression]	0.0	4	1	1	1
145646	1710	globin regulatory element HS-40	[globin regulatory element HS-40]	0.0	4	1	1	1
145647	1710	follow discontinuation gcr count	[Following discontinuation GCR count]	0.0	4	1	1	1
145648	1710	screen of individual	[screening of individuals]	0.0	3	1	1	1
145649	1710	u937 cell with sense	[U937 cells with sense]	0.0	4	1	1	1
145650	1710	well-differentiated th1 cell	[well-differentiated Th1 cells]	0.0	3	1	1	1
145651	1710	nf-kappab -dependent activation 1 terminal repeat	[NF-kappaB -dependent activation 1 terminal repeat]	0.0	6	1	1	1
145652	1710	mass between 94 kda	[mass between 94 kDa]	0.0	4	1	1	1
145653	1710	key factor	[key factors]	0.0	2	1	1	1
145654	1710	mutant of SIVmacMER macrophage-competent derivative	[mutants of SIVmacMER macrophage-competent derivative]	0.0	5	1	1	1
145655	1710	numerous process	[numerous processes]	0.0	2	1	1	1
145656	1710	amplification of 1 allele	[amplification of 1 allele]	0.0	4	1	1	1
145657	1710	inhibition by IL-10	[inhibition by IL-10]	0.0	3	1	1	1
145658	1710	minimal residual disease in patient	[minimal residual disease in patients]	0.0	5	1	1	1
145659	1710	previous finding a characteristic	[previous findings a characteristic]	0.0	4	1	1	1
145660	1710	(auto)immune inflammation in RA	[(auto)immune inflammation in RA]	0.0	4	1	1	1
145661	1710	oxidation of SMX	[oxidation of SMX]	0.0	3	1	1	1
145662	1710	intracellular calcium increase	[intracellular calcium increase]	0.0	3	1	1	1
145663	1710	significantly favorable course 0.05, chi2	[significantly favorable course 0.05, chi2]	0.0	5	1	1	1
145664	1710	osteoclast-like multinucleated cell from monocyte	[osteoclast-like multinucleated cells from monocytes]	0.0	5	1	1	1
145665	1710	interaction between ets protein	[interaction between Ets proteins]	0.0	4	2	2	1
145666	1710	regulation during differentiation of human cell	[regulation during differentiation of human cells]	0.0	6	1	1	1
145667	1710	ifn-gamma-activated sequence gas	[IFN-gamma-activated sequence GAS]	0.0	3	1	1	1
145668	1710	porcine MHC class antigen	[Porcine MHC class antigens]	0.0	4	1	1	1
145669	1710	four near-perfect repeat of bp	[four near-perfect repeats of bp]	0.0	5	1	1	1
145670	1710	role for camp	[role for cAMP]	0.0	3	2	2	1
145671	1710	nfs-60	[NFS-60]	0.0	1	1	1	1
145672	1710	production of such mediator	[production of such mediators]	0.0	4	1	1	1
145673	1710	t(10;11)	[t(10;11)]	0.0	1	1	1	1
145674	1710	Tat-	[Tat-]	0.0	1	1	1	1
145675	1710	mechanism govern selection	[mechanisms governing selection]	0.0	3	1	1	1
145676	1710	major gene	[major gene]	0.0	2	1	1	1
145677	1710	individual member after CD40 induction	[individual members after CD40 induction]	0.0	5	1	1	1
145678	1710	stimulation by a combination of antibody	[Stimulation by a combination of antibodies]	0.0	6	1	1	1
145679	1710	g-csfr in neutrophil	[G-CSFR in neutrophils]	0.0	3	1	1	1
145680	1710	Jeg-3 choriocarcinoma cell line supernatant	[Jeg-3 choriocarcinoma cell line supernatants]	0.0	5	1	1	1
145681	1710	backbone vector	[backbone vector]	0.0	2	1	1	1
145682	1710	protein kinase c PKC isoform	[protein kinase C PKC isoforms]	0.0	5	1	1	1
145683	1710	Electrophoretic mobility gel	[Electrophoretic mobility gel]	0.0	3	1	1	1
145684	1710	means 123 staining	[means 123 staining]	0.0	3	1	1	1
145685	1710	major complex surface protein	[major complex surface proteins]	0.0	4	1	1	1
145686	1710	increase in c-fo (99+/-15	[increases in c-fos (99+/-15]	0.0	4	1	1	1
145687	1710	IL-10 concentration of 20	[IL-10 concentration of 20]	0.0	4	1	1	1
145688	1710	free e2f	[free E2F]	0.0	2	2	2	1
145689	1710	require phosphorylation	[requiring phosphorylation]	0.0	2	1	1	1
145690	1710	level of rxr-alpha	[levels of RXR-alpha]	0.0	3	1	1	1
145691	1710	dimerization region contain repeat	[dimerization region containing repeats]	0.0	4	1	1	1
145692	1710	relevant dose (25 mm)	[relevant dose (25 mM)]	0.0	4	1	1	1
145693	1710	range of effect	[range of effects]	0.0	3	1	1	1
145694	1710	evidence for a relationship	[evidence for a relationship]	0.0	4	1	1	1
145695	1710	low affinity for gata-1	[low affinity for GATA-1]	0.0	4	1	1	1
145696	1710	recombinant length tf	[recombinant length TF]	0.0	3	1	1	1
145697	1710	analysis of the alpha-galactosidase a gene	[analysis of the alpha-galactosidase A gene]	0.0	6	1	1	1
145698	1710	tarsal conjunctival biopsy from seven patient	[tarsal conjunctival biopsies from seven patients]	0.0	6	1	1	1
145699	1710	expression of factor-1 receptor	[expression of factor-1 receptor]	0.0	4	1	1	1
145700	1710	different C epsilon gas binding complex	[different C epsilon GAS binding complexes]	0.0	6	1	1	1
145701	1710	defensin resistance phenotype	[defensin resistance phenotypes]	0.0	3	1	1	1
145702	1710	multifactor regulation of IL-2 gene expression	[Multifactor regulation of IL-2 gene expression]	0.0	6	1	1	1
145703	1710	stimulation of c-jun synthesis.	[stimulation of c-jun synthesis.]	0.0	4	1	1	1
145704	1710	CD4 epitope	[CD4 epitopes]	0.0	2	2	2	1
145705	1710	AP-1 transactivation	[AP-1 transactivation]	0.0	2	1	1	1
145706	1710	anti-hla	[anti-HLA]	0.0	1	1	1	1
145707	1710	very high level	[very high levels]	0.0	3	1	1	1
145708	1710	basis for the commitment	[basis for the commitment]	0.0	4	1	1	1
145709	1710	contrast, at dose as high	[contrast, at doses as high]	0.0	5	1	1	1
145710	1710	natural gata element	[natural GATA elements]	0.0	3	1	1	1
145711	1710	expression of HB24	[expression of HB24]	0.0	3	1	1	1
145712	1710	role modulate the balance	[role modulating the balance]	0.0	4	1	1	1
145713	1710	selective effect on nf-kappab transcription	[selective effects on NF-kappaB transcription]	0.0	5	1	1	1
145714	1710	cell surface CD4	[cell surface CD4]	0.0	3	1	1	1
145715	1710	treatment of human myeloid leukemia cell	[treatment of human myeloid leukemia cells]	0.0	6	1	1	1
145716	1710	cell surface CD3	[cell surface CD3]	0.0	3	1	1	1
145717	1710	different gene HZF	[different genes HZF]	0.0	3	1	1	1
145718	1710	nuclear protein suggest Oct-1	[nuclear proteins suggesting Oct-1]	0.0	4	1	1	1
145719	1710	mature cytokine	[mature cytokine]	0.0	2	1	1	1
145720	1710	TGF-beta signal pathway	[TGF-beta signaling pathway]	0.0	3	1	1	1
145721	1710	binding site of receptor	[binding sites of receptors]	0.0	4	1	1	1
145722	1710	nf-kappab to DNA	[NF-kappaB to DNA]	0.0	3	1	1	1
145723	1710	mcp-1 binding	[MCP-1 binding]	0.0	2	1	1	1
145724	1710	sequence analysis of the region	[Sequence analysis of the region]	0.0	5	1	1	1
145725	1710	B-LCL	[B-LCL]	0.0	1	1	1	1
145726	1710	month month	[months months]	0.0	2	1	1	1
145727	1710	testing of a corresponding set	[testing of a corresponding set]	0.0	5	1	1	1
145728	1710	deletion CD20 promoter-CAT construct	[deletion CD20 promoter-CAT constructs]	0.0	4	1	1	1
145729	1710	tandem zinc-finger	[tandem zinc-finger]	0.0	2	1	1	1
145730	1710	synergistic transactivation in Drosophila Schneider cell	[Synergistic transactivation in Drosophila Schneider cells]	0.0	6	1	1	1
145731	1710	response to pathogenic signal	[response to pathogenic signals]	0.0	4	1	1	1
145732	1710	suggest a molecule	[suggesting a molecule]	0.0	3	1	1	1
145733	1710	one nf-kappa b element	[one NF-kappa B elements]	0.0	4	1	1	1
145734	1710	2.2 kilobasis	[2.2 kilobases]	0.0	2	1	1	1
145735	1710	patient undergo elective ptca	[patients undergoing elective PTCA]	0.0	4	1	1	1
145736	1710	Burkitt lymphoma cell Raji	[Burkitt lymphoma cell Raji]	0.0	4	1	1	1
145737	1710	distinct domains, a	[distinct domains, A]	0.0	3	1	1	1
145738	1710	mnda positive cell between level	[MNDA positive cells between levels]	0.0	5	1	1	1
145739	1710	analysis of the 12 rdna HZF	[analysis of the 12 cDNAs HZF]	0.0	6	1	1	1
145740	1710	nonpeptidyl small molecule sb	[nonpeptidyl small molecule SB]	0.0	4	1	1	1
145741	1710	electrolyte transport in lymphocyte	[electrolyte transport in lymphocytes]	0.0	4	1	1	1
145742	1710	array of gene	[array of genes]	0.0	3	2	2	1
145743	1710	quantitation of receptor GCR	[Quantitation of receptors GCR]	0.0	4	1	1	1
145744	1710	number mutant hematopoietic progenitor cell	[number mutant hematopoietic progenitor cells]	0.0	5	1	1	1
145745	1710	binding of factor protein to dna,	[binding of factor proteins to DNA,]	0.0	6	1	1	1
145746	1710	subsequent interaction lead	[subsequent interaction leading]	0.0	3	1	1	1
145747	1710	third patient suggest great	[third patient suggesting greater]	0.0	4	1	1	1
145748	1710	yeast two-hybrid blot assay	[yeast two-hybrid blot assays]	0.0	4	1	1	1
145749	1710	adenocarcinoma human-mouse chimeric monoclonal antibody	[adenocarcinoma human-mouse chimeric monoclonal antibody]	0.0	5	1	1	1
145750	1710	other autoantigen	[other autoantigens]	0.0	2	1	1	1
145751	1710	class determinant on the surface	[class determinants on the surface]	0.0	5	1	1	1
145752	1710	order less potent than H 1285	[orders less potent than H 1285]	0.0	6	1	1	1
145753	1710	expression of pecam-1	[expression of PECAM-1]	0.0	3	1	1	1
145754	1710	small exon span 45 kb	[small exons spanning 45 kb]	0.0	5	1	1	1
145755	1710	NF-kappaB activation a pathway	[NF-kappaB activation a pathway]	0.0	4	1	1	1
145756	1710	leukocyte in subject	[leukocytes in subjects]	0.0	3	1	1	1
145757	1710	pattern in parent	[pattern in parents]	0.0	3	1	1	1
145758	1710	differentiation of cell line u937	[differentiation of cell lines U937]	0.0	5	1	1	1
145759	1710	metabolic status comparison with criteria]	[metabolic status comparison with criteria]]	0.0	5	1	1	1
145760	1710	evaluation of the datum	[evaluation of the data]	0.0	4	1	1	1
145761	1710	tax -dependent manner	[Tax -dependent manner]	0.0	3	1	1	1
145762	1710	(9.36 3.44 nm	[(9.36 3.44 nM]	0.0	3	1	1	1
145763	1710	loss of phorbol differentiation	[loss of phorbol differentiation]	0.0	4	1	1	1
145764	1710	mrna steady-state level	[mRNA steady-state level]	0.0	3	1	1	1
145765	1710	culture with il-2	[culture with IL-2]	0.0	3	1	1	1
145766	1710	regulation of immunoglobulin chain expression	[regulation of immunoglobulin chain expression]	0.0	5	1	1	1
145767	1710	cloning of the cDNA encoding sr-bp	[Cloning of the cDNA encoding SR-BP]	0.0	6	1	1	1
145768	1710	signal pathway involve expression	[signaling pathways involving expression]	0.0	4	1	1	1
145769	1710	involvement of stat6	[involvement of STAT6]	0.0	3	1	1	1
145770	1710	identical signal requirement	[identical signal requirement]	0.0	3	1	1	1
145771	1710	trend approach statistical significance	[trend approaching statistical significance]	0.0	4	1	1	1
145772	1710	variability of presentation	[variability of presentation]	0.0	3	1	1	1
145773	1710	75 kD	[75 kD]	0.0	2	1	1	1
145774	1710	nf-kappa b activation in monocyte	[NF-kappa B activation in monocytes]	0.0	5	1	1	1
145775	1710	several gene in neutrophil	[several genes in neutrophils]	0.0	4	1	1	1
145776	1710	human dermal microvessel cell hdmec	[human dermal microvessel cells HDMEC]	0.0	5	1	1	1
145777	1710	effect on monocytic cell adhesion	[effects on monocytic cell adhesion]	0.0	5	1	1	1
145778	1710	biological rhythm	[biological rhythms]	0.0	2	1	1	1
145779	1710	modes,	[modes,]	0.0	1	1	1	1
145780	1710	evidence for a genetic component	[evidence for a genetic component]	0.0	5	1	1	1
145781	1710	abortive stimulation lead	[abortive stimulation leading]	0.0	3	1	1	1
145782	1710	none of the protein	[none of the proteins]	0.0	4	1	1	1
145783	1710	yeast,	[yeast,]	0.0	1	1	1	1
145784	1710	activation of cell by treponema pallidum	[Activation of cells by Treponema pallidum]	0.0	6	1	1	1
145785	1710	limit amount	[limiting amounts]	0.0	2	2	2	1
145786	1710	effect of infection	[effect of infection]	0.0	3	1	1	1
145787	1710	program underlie monocytic differentiation	[program underlying monocytic differentiation]	0.0	4	1	1	1
145788	1710	finally week after termination of treatment,	[finally weeks after termination of treatment,]	0.0	6	1	1	1
145789	1710	2 h with cd16 ligand	[2 h with CD16 ligands]	0.0	5	1	1	1
145790	1710	np-1	[NP-1]	0.0	1	1	1	1
145791	1710	encode a regulator	[encoding a regulator]	0.0	3	1	1	1
145792	1710	dissociation constant of p49	[dissociation constants of p49]	0.0	4	1	1	1
145793	1710	Epstein-Barr virus antigen gene	[Epstein-Barr virus antigen gene]	0.0	4	1	1	1
145794	1710	low level of hiv-1	[low levels of HIV-1]	0.0	4	1	1	1
145795	1710	somatic mutation cluster a proto-oncogene encoding	[somatic mutations clustering a proto-oncogene encoding]	0.0	6	1	1	1
145796	1710	further information on the event occur	[further information on the events occurring]	0.0	6	1	1	1
145797	1710	ten adult blood lymphocyte sample	[ten adult blood lymphocyte samples]	0.0	5	1	1	1
145798	1710	lipopolysaccharide immune response	[lipopolysaccharide immune responses]	0.0	3	1	1	1
145799	1710	classification of intraductal carcinoma	[classification of intraductal carcinoma]	0.0	4	1	1	1
145800	1710	requirement for transcriptional activity,	[requirement for transcriptional activity,]	0.0	4	1	1	1
145801	1710	inositoltrisphosphate generation corresponding binding at kd-value	[inositoltrisphosphate generation corresponding binding at Kd-values]	0.0	6	1	1	1
145802	1710	action leukemia cell	[action leukemia cells]	0.0	3	1	1	1
145803	1710	fmol/mg protein (mean of assays),	[fmol/mg protein (mean of assays),]	0.0	5	1	1	1
145804	1710	simian virus +55 region	[simian virus +55 region]	0.0	4	1	1	1
145805	1710	apoptosis progression in human	[apoptosis progression in humans]	0.0	4	1	1	1
145806	1710	base pair bp of 5'-flanking DNA	[base pairs bp of 5'-flanking DNA]	0.0	6	1	1	1
145807	1710	largely due to transcriptional inhibition	[largely due to transcriptional inhibition]	0.0	5	1	1	1
145808	1710	dual effect inhibition depletion	[dual effects inhibition depletion]	0.0	4	1	1	1
145809	1710	expression of exogenous c-erba/tr-alpha	[expression of exogenous c-erbA/TR-alpha]	0.0	4	1	1	1
145810	1710	immunodeficiency virus type hiv-1 factor	[immunodeficiency virus type HIV-1 factor]	0.0	5	1	1	1
145811	1710	role in differentiation event	[role in differentiation events]	0.0	4	1	1	1
145812	1710	four b DNA probe	[four B DNA probes]	0.0	4	1	1	1
145813	1710	induction of the NF-AT complex	[induction of the NF-AT complex]	0.0	5	1	1	1
145814	1710	assay with (6,7-3h) estradiol 3h-e2	[assay with (6,7-3H) estradiol 3H-E2]	0.0	5	1	1	1
145815	1710	characteristic for dexamethasone	[characteristics for dexamethasone]	0.0	3	1	1	1
145816	1710	light of common use	[light of common use]	0.0	4	1	1	1
145817	1710	years) subject after captopril treatment	[years) subjects after captopril treatment]	0.0	5	1	1	1
145818	1710	kd of 0.1 nm	[Kd of 0.1 nM]	0.0	4	1	1	1
145819	1710	heart, spleen,	[heart, spleen,]	0.0	2	1	1	1
145820	1710	multiple E2F site	[multiple E2F sites]	0.0	3	1	1	1
145821	1710	colour fish analysis use centromere probe	[colour FISH analysis using centromere probes]	0.0	6	1	1	1
145822	1710	expression in t-cell acute leukemia	[expression in T-cell acute leukemia]	0.0	5	1	1	1
145823	1710	over 6 kilobasis	[over 6 kilobases]	0.0	3	1	1	1
145824	1710	alter the status of the cell	[altering the status of the cells]	0.0	6	1	1	1
145825	1710	binding to the STAT5 site	[binding to the STAT5 site]	0.0	5	1	1	1
145826	1710	pro-myelocytic leukaemia gene	[pro-myelocytic leukaemia gene]	0.0	3	1	1	1
145827	1710	peripheral blood burst-forming unit-erythroid bfu-e	[peripheral blood burst-forming unit-erythroid BFU-E]	0.0	5	1	1	1
145828	1710	possible t-cell killer	[possible T-cell killer]	0.0	3	1	1	1
145829	1710	namely the lymphocyte proliferation	[namely the lymphocyte proliferation]	0.0	4	1	1	1
145830	1710	pathway of cell type	[pathway of cell types]	0.0	4	1	1	1
145831	1710	circulation of mouse	[circulation of mice]	0.0	3	1	1	1
145832	1710	tax through enhancement of the activity	[Tax through enhancement of the activity]	0.0	6	1	1	1
145833	1710	molecular weight transmembrane adaptor protein	[molecular weight transmembrane adaptor proteins]	0.0	5	1	1	1
145834	1710	target site for factor	[target site for factors]	0.0	4	1	1	1
145835	1710	receptor in peripheral human lymphocyte	[receptors in peripheral human lymphocytes]	0.0	5	1	1	1
145836	1710	gene molecule	[gene molecules]	0.0	2	1	1	1
145837	1710	role of all-tran retinoic acid	[role of all-trans retinoic acid]	0.0	5	1	1	1
145838	1710	vitro model system	[vitro model systems]	0.0	3	1	1	1
145839	1710	alpha tcr gene	[alpha TCR gene]	0.0	3	1	1	1
145840	1710	il-4 costimulation	[IL-4 costimulation]	0.0	2	1	1	1
145841	1710	domain heterogeneity	[domain heterogeneity]	0.0	2	1	1	1
145842	1710	restimulation cell	[Restimulation cell]	0.0	2	1	1	1
145843	1710	marker of event	[marker of events]	0.0	3	1	1	1
145844	1710	CPRE	[CPRE]	0.0	1	1	1	1
145845	1710	search Ag for alpha-helical protein segment	[searching Ag for alpha-helical protein segments]	0.0	6	1	1	1
145846	1710	weight of Dalton	[weight of Dalton]	0.0	3	1	1	1
145847	1710	unknown pathway	[unknown pathway]	0.0	2	1	1	1
145848	1710	sequence from -417 5'	[sequences from -417 5']	0.0	4	1	1	1
145849	1710	long-distance effect through tnf-alpha release	[long-distance effect through TNF-alpha release]	0.0	5	1	1	1
145850	1710	endothelial medium	[endothelial medium]	0.0	2	1	1	1
145851	1710	lead to variable severity	[leading to variable severity]	0.0	4	1	1	1
145852	1710	nonproductive interaction	[nonproductive interactions]	0.0	2	1	1	1
145853	1710	LTR transcriptional activity	[LTR transcriptional activity]	0.0	3	1	1	1
145854	1710	inflammatory c	[inflammatory c]	0.0	2	1	1	1
145855	1710	Bp65	[Bp65]	0.0	1	1	1	1
145856	1710	MHC class ii transcription activator	[MHC class II transcription activator]	0.0	5	1	1	1
145857	1710	notably product such as lipopolysaccharide	[notably products such as lipopolysaccharide]	0.0	5	1	1	1
145858	1710	datum support a two-step model	[data supporting a two-step model]	0.0	5	1	1	1
145859	1710	important site of steroid action.	[important site of steroid action.]	0.0	5	1	1	1
145860	1710	great than 50% inhibition	[greater than 50% inhibition]	0.0	4	1	1	1
145861	1710	component in the signal cascade	[component in the signaling cascade]	0.0	5	1	1	1
145862	1710	25(oh)d3 uptake	[25(OH)D3 uptake]	0.0	2	1	1	1
145863	1710	cysteine -rich oncogene	[cysteine -rich oncogenes]	0.0	3	1	1	1
145864	1710	component of the il-12r	[component of the IL-12R]	0.0	4	1	1	1
145865	1710	molecular-biologic aspect of interaction between system	[Molecular-biologic aspects of interaction between systems]	0.0	6	1	1	1
145866	1710	costimulatory factor	[costimulatory factor]	0.0	2	1	1	1
145867	1710	induction of factor monoclonal antibody	[Induction of factor monoclonal antibodies]	0.0	5	1	1	1
145868	1710	copy of the 21-bp element	[copy of the 21-bp element]	0.0	5	1	1	1
145869	1710	cell leukemia/lymphoma	[cell leukemia/lymphoma]	0.0	2	1	1	1
145870	1710	belong to a family	[belonging to a family]	0.0	4	1	1	1
145871	1710	NF-kappa B1 subunit	[NF-kappa B1 subunit]	0.0	3	1	1	1
145872	1710	superoxide dismutase Mn-SOD a enzyme	[superoxide dismutase Mn-SOD a enzyme]	0.0	5	1	1	1
145873	1710	similar action on the induction	[similar actions on the induction]	0.0	5	1	1	1
145874	1710	cd34(+) bone marrow cell	[CD34(+) bone marrow cells]	0.0	4	2	2	1
145875	1710	peripheral blood cell compartment	[peripheral blood cell compartment]	0.0	4	1	1	1
145876	1710	subsequent glucocorticoid replacement in vitro	[subsequent glucocorticoid replacement in vitro]	0.0	5	1	1	1
145877	1710	nontuberculous condition	[nontuberculous conditions]	0.0	2	1	1	1
145878	1710	fluorescence microscopy	[fluorescence microscopy]	0.0	2	1	1	1
145879	1710	disorder involve sexual differentiation	[disorders involving sexual differentiation]	0.0	4	1	1	1
145880	1710	cellular activation agent	[cellular activation agents]	0.0	3	1	1	1
145881	1710	11.5+/-7.1 pg/mL,	[11.5+/-7.1 pg/mL,]	0.0	2	1	1	1
145882	1710	evidence for a etiology of fibromatosis	[Evidence for a etiology of fibromatosis]	0.0	6	1	1	1
145883	1710	activation of the interleukin gene	[Activation of the interleukin gene]	0.0	5	1	1	1
145884	1710	response in t-cell line	[response in T-cell lines]	0.0	4	1	1	1
145885	1710	abolish acute injury with alpha-tocopherol	[abolishing acute injury with alpha-tocopherol]	0.0	5	1	1	1
145886	1710	study of therapeutic regimen	[studies of therapeutic regimens]	0.0	4	1	1	1
145887	1710	monocyte to MVEC	[monocytes to MVEC]	0.0	3	1	1	1
145888	1710	displacement of 17beta-(3H) estradiol	[displacement of 17beta-(3H) estradiol]	0.0	4	1	1	1
145889	1710	novel enhancer-like element	[novel enhancer-like element]	0.0	3	1	1	1
145890	1710	immunodeficiency virus entry into immune cell	[immunodeficiency virus entry into immune cells]	0.0	6	1	1	1
145891	1710	also to a increase	[also to an increase]	0.0	4	1	1	1
145892	1710	maintenance of microarchitecture	[maintenance of microarchitecture]	0.0	3	1	1	1
145893	1710	il-1 induction	[IL-1 induction]	0.0	2	1	1	1
145894	1710	furthermore, region ii	[Furthermore, region II]	0.0	3	1	1	1
145895	1710	lineage (with acid	[lineage (with acid]	0.0	3	1	1	1
145896	1710	patient with chronic disease four	[patients with chronic diseases four]	0.0	5	1	1	1
145897	1710	leukemia the microgranular variant	[leukemia the microgranular variant]	0.0	4	1	1	1
145898	1710	virus 40 SV40 region	[virus 40 SV40 region]	0.0	4	1	1	1
145899	1710	hormone crh gene	[hormone CRH gene]	0.0	3	1	1	1
145900	1710	germinal centre	[germinal centre]	0.0	2	1	1	1
145901	1710	IL-2 -secret cell consist	[IL-2 -secreting cells consisting]	0.0	4	1	1	1
145902	1710	professional apc	[professional APCs]	0.0	2	1	1	1
145903	1710	diffuse large cell subtype	[diffuse large cell subtype]	0.0	4	1	1	1
145904	1710	distinct cofactor	[distinct cofactors]	0.0	2	1	1	1
145905	1710	relevant dose	[relevant dose]	0.0	2	1	1	1
145906	1710	protein-DNA complex with electrophoretic mobility	[protein-DNA complexes with electrophoretic mobilities]	0.0	5	1	1	1
145907	1710	acute distress syndrome ARDS	[acute distress syndrome ARDS]	0.0	4	1	1	1
145908	1710	factor kappab nf-kappab kinase NIK	[factor kappaB NF-kappaB kinase NIK]	0.0	5	1	1	1
145909	1710	novel role for nno	[novel role for nNOS]	0.0	4	1	1	1
145910	1710	regulation of proenkephalin positive effect	[regulation of proenkephalin positive effects]	0.0	5	1	1	1
145911	1710	toxic/septic shock	[toxic/septic shock]	0.0	2	1	1	1
145912	1710	quantification during differentiation	[quantification during differentiation]	0.0	3	1	1	1
145913	1710	low cd4+ cell count (p	[low CD4+ cell counts (P]	0.0	5	1	1	1
145914	1710	ebv binding to receptor	[EBV binding to receptor]	0.0	4	1	1	1
145915	1710	bipartite localization signal (89	[bipartite localization signal (89]	0.0	4	1	1	1
145916	1710	amino acids.	[amino acids.]	0.0	2	1	1	1
145917	1710	healthy woman aged	[healthy women aged]	0.0	3	1	1	1
145918	1710	superaddition under condition of immune glomerulopathy	[superaddition under conditions of immune glomerulopathy]	0.0	6	1	1	1
145919	1710	multiple reactivity at level	[multiple reactivities at levels]	0.0	4	1	1	1
145920	1710	implication for the regulation	[implications for the regulation]	0.0	4	1	1	1
145921	1710	limited activation	[limited activation]	0.0	2	1	1	1
145922	1710	IL-4 gene expression in monocyte	[IL-4 gene expression in monocytes]	0.0	5	1	1	1
145923	1710	combination of mutation	[combinations of mutations]	0.0	3	1	1	1
145924	1710	cell cycle checkpoint	[cell cycle checkpoint]	0.0	3	1	1	1
145925	1710	nfat activation by a receptor	[NFAT activation by a receptor]	0.0	5	1	1	1
145926	1710	weight in the range kd.	[weights in the range kd.]	0.0	5	1	1	1
145927	1710	Recognition of this new entity	[Recognition of this new entity]	0.0	5	1	1	1
145928	1710	high cell turnover	[high cell turnover]	0.0	3	1	1	1
145929	1710	phagocyte by leukemia factor	[phagocytes by leukemia factor]	0.0	4	1	1	1
145930	1710	immunogenic stimulus	[immunogenic stimulus]	0.0	2	1	1	1
145931	1710	signal pathway regulate integrin gene expression	[signaling pathway regulating integrin gene expression]	0.0	6	1	1	1
145932	1710	packaging of DNA	[packaging of DNA]	0.0	3	1	1	1
145933	1710	addition, il-2 nuclear factor	[addition, IL-2 nuclear factors]	0.0	4	1	1	1
145934	1710	encode the granulocyte- factor gm-csf	[encoding the granulocyte- factor GM-CSF]	0.0	5	1	1	1
145935	1710	overexpression of WT1	[Overexpression of WT1]	0.0	3	1	1	1
145936	1710	parameter restoration of content	[parameters restoration of content]	0.0	4	1	1	1
145937	1710	thyroid state	[thyroid states]	0.0	2	1	1	1
145938	1710	n-acetyl-L-cysteine NAC a thiol antioxidant	[n-acetyl-L-cysteine NAC a thiol antioxidant]	0.0	5	1	1	1
145939	1710	control group consist	[control group consisting]	0.0	3	1	1	1
145940	1710	[age-related change in receptor	[[Age-related changes in receptors]	0.0	4	1	1	1
145941	1710	synthesis,	[synthesis,]	0.0	1	1	1	1
145942	1710	native peptide ligand	[native peptide ligand]	0.0	3	1	1	1
145943	1710	precaution	[precautions]	0.0	1	1	1	1
145944	1710	displacement of a ZEB repressor	[displacement of a ZEB repressor]	0.0	5	1	1	1
145945	1710	suffer from depression	[suffering from depression]	0.0	3	1	1	1
145946	1710	woman young than 50 mcr	[women younger than 50, MCR]	0.0	5	1	1	1
145947	1710	signal as il-1	[signaling as IL-1]	0.0	3	1	1	1
145948	1710	extracellular kinase n-terminal kinase	[extracellular kinase N-terminal kinase]	0.0	4	1	1	1
145949	1710	HUMARA allele	[HUMARA alleles]	0.0	2	1	1	1
145950	1710	finally, soluble CD4	[Finally, soluble CD4]	0.0	3	1	1	1
145951	1710	two rdna the sub-unit	[two cDNAs the sub-unit]	0.0	4	1	1	1
145952	1710	breast tumor lymphocyte brtal corresponding	[breast tumor lymphocytes BRTAL corresponding]	0.0	5	1	1	1
145953	1710	C-terminal region hiv-1	[C-terminal region HIV-1]	0.0	3	1	1	1
145954	1710	antibody antibody	[antibodies antibodies]	0.0	2	1	1	1
145955	1710	myeloid differentiation response gene	[myeloid differentiation response gene]	0.0	4	1	1	1
145956	1710	step in the transition	[step in the transition]	0.0	4	1	1	1
145957	1710	h2o2 N-acetyl-L-cysteine	[H2O2 N-acetyl-L-cysteine]	0.0	2	1	1	1
145958	1710	selection antigen-driven clonal expansion)	[selection antigen-driven clonal expansion)]	0.0	4	1	1	1
145959	1710	camp-response-element-binding protein	[cAMP-response-element-binding protein]	0.0	2	1	1	1
145960	1710	constitutive expression of p50 homodimer	[Constitutive expression of p50 homodimer]	0.0	5	1	1	1
145961	1710	group b type	[group B type]	0.0	3	2	2	1
145962	1710	site (-213)	[site (-213)]	0.0	2	1	1	1
145963	1710	recombinant lef-1	[recombinant LEF-1]	0.0	2	1	1	1
145964	1710	up- of nf kappab	[up- of NF kappaB]	0.0	4	1	1	1
145965	1710	novel class of body	[novel class of bodies]	0.0	4	1	1	1
145966	1710	hours)	[hours)]	0.0	1	1	1	1
145967	1710	component of NFAT	[component of NFAT]	0.0	3	1	1	1
145968	1710	hypothesis a factor	[hypothesis a factor]	0.0	3	1	1	1
145969	1710	form of Ras	[form of Ras]	0.0	3	1	1	1
145970	1710	expression gene transcription	[Expression gene transcription]	0.0	3	1	1	1
145971	1710	class trans- activator CIITA	[class trans- activator CIITA]	0.0	4	1	1	1
145972	1710	icam-1 cd54 expression	[ICAM-1 CD54 expression]	0.0	3	1	1	1
145973	1710	range of tcr affinity	[range of TCR affinities]	0.0	4	1	1	1
145974	1710	programme drive proliferation	[programme driving proliferation]	0.0	3	1	1	1
145975	1710	balance between a inducer	[balance between an inducer]	0.0	4	1	1	1
145976	1710	fraction of resting cell	[fractions of resting cells]	0.0	4	1	1	1
145977	1710	similar cellular response	[similar cellular responses]	0.0	3	1	1	1
145978	1710	transformation by v-Abl	[transformation by v-Abl]	0.0	3	1	1	1
145979	1710	Separate epitope	[Separate epitopes]	0.0	2	1	1	1
145980	1710	e1a activities, cellular sensitization	[E1A activities, cellular sensitization]	0.0	4	1	1	1
145981	1710	difference between the patient 2.7)	[difference between the patients 2.7)]	0.0	5	1	1	1
145982	1710	slight decreases.	[slight decreases.]	0.0	2	1	1	1
145983	1710	recombinant N-terminal fragment	[recombinant N-terminal fragment]	0.0	3	1	1	1
145984	1710	high affinity for interleukin-6	[high affinity for interleukin-6]	0.0	4	1	1	1
145985	1710	c/ebp-epsilon protein	[C/EBP-epsilon protein]	0.0	2	1	1	1
145986	1710	regulate this response	[regulating this response]	0.0	3	1	1	1
145987	1710	induction by tax1	[Induction by Tax1]	0.0	3	1	1	1
145988	1710	internalization of lps	[internalization of LPS]	0.0	3	1	1	1
145989	1710	lymphoma cell line CRO-AP/3	[lymphoma cell lines CRO-AP/3]	0.0	4	1	1	1
145990	1710	chronic rheumatic disease	[chronic rheumatic diseases]	0.0	3	1	1	1
145991	1710	domain of the gata-binding protein	[domains of the GATA-binding proteins]	0.0	5	1	1	1
145992	1710	dyn/cm2) for 6 h.	[dyn/cm2) for 6 h,]	0.0	4	1	1	1
145993	1710	different species involve rxr-alpha	[different species involving RXR-alpha]	0.0	4	1	1	1
145994	1710	104-522 ppt i-te	[104-522 ppt I-TE]	0.0	3	1	1	1
145995	1710	locus in cell	[locus in cells]	0.0	3	1	1	1
145996	1710	patient with 2 micrograms/day for day	[patients with 2 micrograms/day for days)]	0.0	6	1	1	1
145997	1710	cellular production of important mediator	[cellular production of important mediators]	0.0	5	1	1	1
145998	1710	promyelomonocytic hl-60 cell	[promyelomonocytic HL-60 cells]	0.0	3	1	1	1
145999	1710	regulation of B-cell commitment	[Regulation of B-cell commitment]	0.0	4	1	1	1
146000	1710	control of virus 40	[control of virus 40]	0.0	4	1	1	1
146001	1710	lead to migration of monocyte	[leading to migration of monocytes]	0.0	5	1	1	1
146002	1710	uncouple of nonreceptor tyrosine kinase cell.	[Uncoupling of nonreceptor tyrosine kinases cell.]	0.0	6	1	1	1
146003	1710	Clinical deterioration immunodeficiency virus type 1	[Clinical deterioration immunodeficiency virus type 1]	0.0	6	1	1	1
146004	1710	special leukocyte function	[special leukocyte functions]	0.0	3	1	1	1
146005	1710	identical.	[identical.]	0.0	1	1	1	1
146006	1710	inhibition of nf-at activation	[inhibition of NF-AT activation]	0.0	4	1	1	1
146007	1710	histone beta-galactosidase gene	[histone beta-galactosidase gene]	0.0	3	1	1	1
146008	1710	bsap/pax5	[BSAP/PAX5]	0.0	1	1	1	1
146009	1710	granulocyte colony-stimulating factor factor proliferation	[granulocyte colony-stimulating factor factor proliferation]	0.0	5	1	1	1
146010	1710	TCR complex	[TCR complex]	0.0	2	1	1	1
146011	1710	available iron	[available iron]	0.0	2	1	1	1
146012	1710	abolish injury	[abolishing injury]	0.0	2	1	1	1
146013	1710	encode the domain	[encoding the domain]	0.0	3	1	1	1
146014	1710	p94 share homology	[p94 share homology]	0.0	3	1	1	1
146015	1710	hiv regulation	[HIV regulation]	0.0	2	1	1	1
146016	1710	runt isoform	[runt isoforms]	0.0	2	1	1	1
146017	1710	RA on hl60 cell differentiation	[RA on HL60 cell differentiation]	0.0	5	1	1	1
146018	1710	form of Rho	[form of Rho]	0.0	3	1	1	1
146019	1710	initial diameter,	[initial diameter,]	0.0	2	1	1	1
146020	1710	include leukaemia	[including leukaemia]	0.0	2	2	2	1
146021	1710	induction kappa B/Rel activity	[Induction kappa B/Rel activity]	0.0	4	1	1	1
146022	1710	form of factor	[forms of factor]	0.0	3	1	1	1
146023	1710	probe corresponding	[probe corresponding]	0.0	2	1	1	1
146024	1710	contrary, 32Dcl3 cell	[contrary, 32Dcl3 cells]	0.0	3	1	1	1
146025	1710	activation of the hiv-ltr	[activation of the HIV-LTR]	0.0	4	1	1	1
146026	1710	expression of important protein	[expression of important proteins]	0.0	4	1	1	1
146027	1710	(i) suppression of transcription factor function	[(i) suppression of transcription factor functions]	0.0	6	1	1	1
146028	1710	transcription from functional promoter	[transcription from functional promoters]	0.0	4	1	1	1
146029	1710	recurrent abnormality highlight loci relevant	[recurrent abnormalities highlighting loci relevant]	0.0	5	1	1	1
146030	1710	low bind affinity	[low binding affinity]	0.0	3	1	1	1
146031	1710	member of family	[members of family]	0.0	3	1	1	1
146032	1710	subunits; genes, nfkb1 p105 nfkb2	[subunits; genes, NFKB1 p105 NFKB2]	0.0	5	1	1	1
146033	1710	spectrum of cell line	[spectrum of cell lines]	0.0	4	1	1	1
146034	1710	alteration of any one	[alteration of any one]	0.0	4	1	1	1
146035	1710	form in familiess	[form in families,]	0.0	3	1	1	1
146036	1710	ebv individual	[EBV individuals]	0.0	2	1	1	1
146037	1710	severe restrictive anorexia nervosa	[severe restrictive anorexia nervosa]	0.0	4	1	1	1
146038	1710	mechanism different	[mechanisms different]	0.0	2	1	1	1
146039	1710	heterodimer in cd4+ T cell	[heterodimers in CD4+ T cells]	0.0	5	1	1	1
146040	1710	thereof)	[thereof)]	0.0	1	1	1	1
146041	1710	aspect of T cell immunity	[aspects of T cell immunity]	0.0	5	1	1	1
146042	1710	interaction of thymocyte with autologous cell	[interaction of thymocytes with autologous cells]	0.0	6	1	1	1
146043	1710	production, indicate the presence	[production, indicating the presence]	0.0	4	1	1	1
146044	1710	cellular susceptibility kill by lymphocyte	[cellular susceptibility killing by lymphocytes]	0.0	5	1	1	1
146045	1710	ubiquitous component after activation	[ubiquitous component after activation]	0.0	4	1	1	1
146046	1710	4922 (range, (range,	[4922 (range, (range,]	0.0	3	1	1	1
146047	1710	vitro globin	[vitro globin]	0.0	2	1	1	1
146048	1710	region of A-MYB	[region of A-MYB]	0.0	3	1	1	1
146049	1710	death receptor	[death receptor]	0.0	2	1	1	1
146050	1710	different il-6-responsive gene element	[different IL-6-responsive gene elements]	0.0	4	1	1	1
146051	1710	expression of the cd95 APO-1/Fas ligand	[Expression of the CD95 APO-1/Fas ligand]	0.0	6	1	1	1
146052	1710	basis of pattern secretion.	[basis of patterns secretion.]	0.0	4	1	1	1
146053	1710	system include autoimmunity	[system including autoimmunity]	0.0	3	1	1	1
146054	1710	strike concordance of c-myb expression	[striking concordance of c-myb expression]	0.0	5	1	1	1
146055	1710	suggest a role for FGF receptor	[suggesting a role for FGF receptors]	0.0	6	1	1	1
146056	1710	lps antibody	[LPS antibodies]	0.0	2	1	1	1
146057	1710	related hepatocyte factor	[related hepatocyte factors]	0.0	3	1	1	1
146058	1710	selective modulation in cell	[Selective modulation in cells]	0.0	4	1	1	1
146059	1710	active oxygen species	[active oxygen species]	0.0	3	1	1	1
146060	1710	ap-1, nf-kappab	[AP-1, NF-kappaB]	0.0	2	1	1	1
146061	1710	14 healthy subject	[14 healthy subjects]	0.0	3	1	1	1
146062	1710	number of calcitriol	[number of calcitriol]	0.0	3	1	1	1
146063	1710	presentation by autologous cell apc	[presentation by autologous cell APC]	0.0	5	1	1	1
146064	1710	include blood mononuclear cell from individual	[including blood mononuclear cells from individuals]	0.0	6	1	1	1
146065	1710	tyrosine-phosphorylated follow stimulate factor treatment	[tyrosine-phosphorylated following stimulating factor treatment]	0.0	5	1	1	1
146066	1710	analogue of 1,25-dihydroxyvitamin D3	[analogues of 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
146067	1710	signal in phagocyte	[signaling in phagocytes]	0.0	3	1	1	1
146068	1710	role lymphocytes.	[Role lymphocytes.]	0.0	2	1	1	1
146069	1710	provide a point in the response	[providing an point in the response]	0.0	6	1	1	1
146070	1710	octamer motif October	[octamer motif Oct]	0.0	3	1	1	1
146071	1710	Spl binding element	[Spl binding elements]	0.0	3	1	1	1
146072	1710	beta-globin switch	[beta-globin switch]	0.0	2	1	1	1
146073	1710	median dissociation constant	[median dissociation constant]	0.0	3	1	1	1
146074	1710	rat Nb2 T lymphocyte	[rat Nb2 T lymphocytes]	0.0	4	1	1	1
146075	1710	blood lymphocyte with cysteamine	[blood lymphocytes with cysteamine]	0.0	4	1	1	1
146076	1710	hydroxyl radical	[hydroxyl radicals]	0.0	2	1	1	1
146077	1710	cell glucocorticoid	[cell glucocorticoid]	0.0	2	1	1	1
146078	1710	21-base-pair (bp)	[21-base-pair (bp)]	0.0	2	1	1	1
146079	1710	lipopolysaccharide (lps)-mediated immune response include activation	[lipopolysaccharide (LPS)-mediated immune responses including activation]	0.0	6	1	1	1
146080	1710	grb2-related protein	[Grb2-related protein]	0.0	2	1	1	1
146081	1710	elements.	[elements.]	0.0	1	1	1	1
146082	1710	intervene (i) region upstream	[intervening (I) regions upstream]	0.0	4	1	1	1
146083	1710	role mediate fasl expression	[role mediating FasL expression]	0.0	4	1	1	1
146084	1710	leukocyte adhesion to corneal cell	[leukocyte adhesion to corneal cells]	0.0	5	1	1	1
146085	1710	z binding	[Z binding]	0.0	2	1	1	1
146086	1710	region of class molecule	[regions of class molecules]	0.0	4	1	1	1
146087	1710	deletion of the BOX1 motif	[deletion of the BOX1 motif]	0.0	5	1	1	1
146088	1710	prototypic class	[prototypic class]	0.0	2	1	1	1
146089	1710	contrast, p85 allele	[contrast, p85 alleles]	0.0	3	1	1	1
146090	1710	th2 cells, expression	[Th2 cells, expression]	0.0	3	1	1	1
146091	1710	Peripheral blood mononuclear cell from patient	[Peripheral blood mononuclear cells from patients]	0.0	6	1	1	1
146092	1710	insight into t-cell development	[insights into T-cell development]	0.0	4	1	1	1
146093	1710	various lesion with age	[various lesions with age]	0.0	4	1	1	1
146094	1710	il-6-responsive colony-forming unit cfu-il6	[IL-6-responsive colony-forming units CFU-IL6]	0.0	4	1	1	1
146095	1710	several human sequence	[several human sequences]	0.0	3	1	1	1
146096	1710	only increase	[only increases]	0.0	2	1	1	1
146097	1710	blr2/ebi1	[BLR2/EBI1]	0.0	1	1	1	1
146098	1710	chromatin structure reorganization	[chromatin structure reorganization]	0.0	3	2	2	1
146099	1710	distribution of pkc-zeta	[distribution of PKC-zeta]	0.0	3	1	1	1
146100	1710	stimulatory factor USF	[stimulatory factor USF]	0.0	3	1	1	1
146101	1710	collectively, factor necessary for expression	[Collectively, factor necessary for expression]	0.0	5	1	1	1
146102	1710	various VCAM-1 promoter construct	[various VCAM-1 promoter constructs]	0.0	4	1	1	1
146103	1710	activation signal lead	[activation signals leading]	0.0	3	1	1	1
146104	1710	treatment with TNF-alpha localization in memory	[treatment with TNF-alpha localization in memory]	0.0	6	1	1	1
146105	1710	chronic disorder a problem	[chronic disorders a problem]	0.0	4	1	1	1
146106	1710	recruitment of hpc	[recruitment of HPCs]	0.0	3	1	1	1
146107	1710	separate gene	[separate genes]	0.0	2	1	1	1
146108	1710	histocompatibility class ii immunodeficiency	[histocompatibility class II immunodeficiency]	0.0	4	1	1	1
146109	1710	level of hiv production	[levels of HIV production]	0.0	4	1	1	1
146110	1710	formation of reactive oxygen intermediate ROI	[Formation of reactive oxygen intermediates ROI]	0.0	6	1	1	1
146111	1710	tumorigenesis of cancer	[tumorigenesis of cancers]	0.0	3	1	1	1
146112	1710	(b) conjugation	[(b) conjugation]	0.0	2	1	1	1
146113	1710	rna target	[RNA target]	0.0	2	1	1	1
146114	1710	increase).	[increase).]	0.0	1	1	1	1
146115	1710	receptor (tcr) region beta-chain family	[receptor (TCR) region beta-chain families]	0.0	5	1	1	1
146116	1710	zap-70 jurkat cell	[ZAP-70 Jurkat cells]	0.0	3	1	1	1
146117	1710	cpp32	[CPP32]	0.0	1	1	1	1
146118	1710	ifn-gamma for h.	[IFN-gamma for h,]	0.0	3	1	1	1
146119	1710	(cf)	[(CF)]	0.0	1	1	1	1
146120	1710	gene in b-lymphocyte	[genes in B-lymphocytes]	0.0	3	1	1	1
146121	1710	retain promoter activity	[retaining promoter activity]	0.0	3	1	1	1
146122	1710	induction by macrophage-CSF in monocyte	[induction by macrophage-CSF in monocytes]	0.0	5	1	1	1
146123	1710	atf1 isoform consistent with the role	[ATF1 isoforms consistent with the role]	0.0	6	1	1	1
146124	1710	marker of retinoid-induced u-937 cell differentiation	[markers of retinoid-induced U-937 cell differentiation]	0.0	6	1	1	1
146125	1710	relevant concentration of ethanol	[relevant concentrations of ethanol]	0.0	4	1	1	1
146126	1710	transfer T cell	[transfer T cells]	0.0	3	1	1	1
146127	1710	predominantly to T cell	[predominantly to T cells]	0.0	4	1	1	1
146128	1710	colony-stimumulatelany-stg factor promoter activity	[colony-stimulating factor promoter activity]	0.0	4	1	1	1
146129	1710	subordinate gene	[subordinate genes]	0.0	2	1	1	1
146130	1710	association in reduction	[association in reduction]	0.0	3	1	1	1
146131	1710	potential role in induction	[potential role in induction]	0.0	4	1	1	1
146132	1710	colonize hosts.	[colonizing hosts.]	0.0	2	1	1	1
146133	1710	target for e2f-1/dp1 binding	[target for E2F-1/DP1 binding]	0.0	4	1	1	1
146134	1710	bryostatin 1 nm), another activator	[bryostatin 1 nM), another activator]	0.0	5	1	1	1
146135	1710	seen, transendothelial migration of antigen t-cell	[seen, transendothelial migration of antigen T-cells]	0.0	6	1	1	1
146136	1710	control of 15-lo expression	[control of 15-LO expression]	0.0	4	1	1	1
146137	1710	transcript in cd4+ T lymphocyte	[transcripts in CD4+ T lymphocytes]	0.0	5	1	1	1
146138	1710	hla stabilization	[HLA stabilization]	0.0	2	1	1	1
146139	1710	distinct cell surface receptor	[distinct cell surface receptors]	0.0	4	1	1	1
146140	1710	signal pathway involve expression jun	[signaling pathways involving expression jun]	0.0	5	1	1	1
146141	1710	retinoid x receptor alpha	[Retinoid X Receptor alpha]	0.0	4	1	1	1
146142	1710	disruption the activation domain	[disruptions the activation domain]	0.0	4	1	1	1
146143	1710	target of 1 alpha,25-dihydroxyvitamin D3	[targets of 1 alpha,25-dihydroxyvitamin D3]	0.0	5	1	1	1
146144	1710	formation in response	[formation in response]	0.0	3	1	1	1
146145	1710	dnase 1 site-forming element	[DNase 1 site-forming element]	0.0	4	1	1	1
146146	1710	derivative of acid	[derivative of acid]	0.0	3	1	1	1
146147	1710	inhibition of alloreactive response	[inhibition of alloreactive responses]	0.0	4	1	1	1
146148	1710	novel combination	[novel combination]	0.0	2	1	1	1
146149	1710	stimulation of lymphoid cell with interleukin-1beta	[Stimulation of lymphoid cells with interleukin-1beta]	0.0	6	1	1	1
146150	1710	similar CD30 -mediated effect	[similar CD30 -mediated effects]	0.0	4	1	1	1
146151	1710	t-cell lymphotropic	[T-cell lymphotropic]	0.0	2	7	7	1
146152	1710	throughput screen of broth	[throughput screening of broths]	0.0	4	1	1	1
146153	1710	transformation activity	[transformation activity]	0.0	2	1	1	1
146154	1710	marker apl	[markers APLs]	0.0	2	1	1	1
146155	1710	ifna2	[IFNA2]	0.0	1	1	1	1
146156	1710	expression in b cell by transformation	[expression in B cells by transformation]	0.0	6	1	1	1
146157	1710	antisense oligodeoxynucleotides target gata-1 nf-e2 protein	[antisense oligodeoxynucleotides targeting GATA-1 NF-E2 proteins]	0.0	6	1	1	1
146158	1710	chain-	[chain-]	0.0	1	1	1	1
146159	1710	post-transcriptional regulator i HTLV-I	[post-transcriptional regulator I HTLV-I]	0.0	4	1	1	1
146160	1710	two child with infection	[two children with infection]	0.0	4	2	2	1
146161	1710	cooperative interaction between two b coactivator	[cooperative interactions between two B coactivators]	0.0	6	1	1	1
146162	1710	nf-kappab -dependent activation long repeat	[NF-kappaB -dependent activation long repeat]	0.0	5	1	1	1
146163	1710	example, in experiment	[example, in experiments]	0.0	3	1	1	1
146164	1710	kd versus 8.9+/-1.2 nmol/L)	[Kd versus 8.9+/-1.2 nmol/L)]	0.0	4	1	1	1
146165	1710	-secret	[-secreting]	0.0	1	1	1	1
146166	1710	Biphasic control	[Biphasic control]	0.0	2	2	2	1
146167	1710	cd45 event	[CD45 events]	0.0	2	1	1	1
146168	1710	minimum	[minimum]	0.0	1	1	1	1
146169	1710	Kim,	[Kim,]	0.0	1	1	1	1
146170	1710	inactive factor-kappaB	[inactive factor-kappaB]	0.0	2	1	1	1
146171	1710	constitute model of a opposite situation	[constituting models of an opposite situation]	0.0	6	1	1	1
146172	1710	tnf-alpha bioavailability from cell	[TNF-alpha bioavailability from cells]	0.0	4	1	1	1
146173	1710	range kd.	[range kd.]	0.0	2	1	1	1
146174	1710	transient overexpression	[Transient overexpression]	0.0	2	5	5	1
146175	1710	expression in erythroblast	[Expression in erythroblasts]	0.0	3	1	1	1
146176	1710	mitogenically incompetent g-csfr mutant	[mitogenically incompetent G-CSFR mutant]	0.0	4	1	1	1
146177	1710	mechanism underlie effect	[mechanisms underlying effects]	0.0	3	1	1	1
146178	1710	tissue specific expression	[Tissue specific expression]	0.0	3	1	1	1
146179	1710	probe, nuclear extract from T	[probe, nuclear extracts from T]	0.0	5	1	1	1
146180	1710	form of type diabete	[forms of type diabetes]	0.0	4	1	1	1
146181	1710	proto-enhancer activity	[proto-enhancer activity]	0.0	2	1	1	1
146182	1710	two subunit of mass (50k)	[two subunits of mass (50K)]	0.0	5	1	1	1
146183	1710	purine box -291 to -277	[purine box -291 to -277]	0.0	5	1	1	1
146184	1710	transcription factor as a wild-type	[transcription factor as a wild-type]	0.0	5	1	1	1
146185	1710	lymphoid tissue lymphoma	[lymphoid tissue lymphoma]	0.0	3	1	1	1
146186	1710	leucine zipper (bzip) dna-binding	[leucine zipper (bZIP) DNA-binding]	0.0	4	1	1	1
146187	1710	h of ifn-alpha treatment	[h of IFN-alpha treatment]	0.0	4	1	1	1
146188	1710	(cl)	[(CL)]	0.0	1	1	1	1
146189	1710	evidence for complex formation	[evidence for complex formation]	0.0	4	1	1	1
146190	1710	vitality of cell	[vitality of cells]	0.0	3	1	1	1
146191	1710	fmol/10(6) cells).	[fmol/10(6) cells).]	0.0	2	1	1	1
146192	1710	-protein kinase -specific inhibitor	[-protein kinase -specific inhibitor]	0.0	4	1	1	1
146193	1710	disulfide-linked dimer	[disulfide-linked dimer]	0.0	2	1	1	1
146194	1710	nf-kappa b in extract	[NF-kappa B in extracts]	0.0	4	1	1	1
146195	1710	patient, reduction	[patient, reduction]	0.0	2	1	1	1
146196	1710	htlv-1 tax	[HTLV-1 tax]	0.0	2	2	2	1
146197	1710	low concentration (21.7 5.1	[lower concentration (21.7 5.1]	0.0	4	1	1	1
146198	1710	attenuation of live-hiv-1 by gain	[attenuation of live-HIV-1 by gain]	0.0	5	1	1	1
146199	1710	tax in cell	[Tax in cells]	0.0	3	1	1	1
146200	1710	incubation of human cell ECs	[Incubation of human cells ECs]	0.0	5	1	1	1
146201	1710	UF-1	[UF-1]	0.0	1	1	1	1
146202	1710	acid ATRA	[acid ATRA]	0.0	2	2	2	1
146203	1710	include phorbol 12-myristate	[including phorbol 12-myristate]	0.0	3	1	1	1
146204	1710	(0.2-1.6)	[(0.2-1.6)]	0.0	1	1	1	1
146205	1710	primary requirement	[primary requirement]	0.0	2	1	1	1
146206	1710	response to four stimulus	[response to four stimuli]	0.0	4	1	1	1
146207	1710	role of Itk	[role of Itk]	0.0	3	1	1	1
146208	1710	pathogenesis of several disease	[pathogenesis of several diseases]	0.0	4	1	1	1
146209	1710	Currently, adenovirus	[Currently, adenovirus]	0.0	2	1	1	1
146210	1710	ribosome salt wash	[ribosome salt wash]	0.0	3	1	1	1
146211	1710	distinct proteins; type a transcript code	[distinct proteins; type A transcripts code]	0.0	6	1	1	1
146212	1710	vein endothelial cell HUVEC CoCl2	[vein endothelial cells HUVEC CoCl2]	0.0	5	1	1	1
146213	1710	TCR beta chain sequence	[TCR beta chain sequences]	0.0	4	1	1	1
146214	1710	effect on two factor	[effects on two factors]	0.0	4	1	1	1
146215	1710	gene on human chromosome 11	[genes on human chromosome 11]	0.0	5	1	1	1
146216	1710	requirement of another element	[requirement of another element]	0.0	4	1	1	1
146217	1710	expansion per se,	[expansion per se,]	0.0	3	1	1	1
146218	1710	regulator of cell death.	[regulator of cell death.]	0.0	4	1	1	1
146219	1710	reactive nitrogen	[reactive nitrogen]	0.0	2	1	1	1
146220	1710	cytokine in eosinophil	[cytokines in eosinophils]	0.0	3	1	1	1
146221	1710	activation of ifn-gamma gene	[Activation of IFN-gamma genes]	0.0	4	1	1	1
146222	1710	establishment of allergic airway hyperresponsiveness	[establishment of allergic airway hyperresponsiveness]	0.0	5	1	1	1
146223	1710	cytokine secretion in response	[cytokine secretion in response]	0.0	4	1	1	1
146224	1710	recombinant il-12	[recombinant IL-12]	0.0	2	1	1	1
146225	1710	eosinophil-specific gene encode primary granule protein	[eosinophil-specific genes encoding primary granule proteins]	0.0	6	1	1	1
146226	1710	expression on melanoma MMs	[expression on melanomas MMs]	0.0	4	1	1	1
146227	1710	mmol/L buthionine sulfoximine bso	[mmol/L buthionine sulfoximine BSO]	0.0	4	1	1	1
146228	1710	p388	[P388]	0.0	1	1	1	1
146229	1710	lower, at doses.	[lower, at doses.]	0.0	3	1	1	1
146230	1710	prognostic importance of comedo variants.	[prognostic importance of comedo variants.]	0.0	5	1	1	1
146231	1710	administration of mumol cortisol	[administration of mumol cortisol]	0.0	4	1	1	1
146232	1710	rejection of organ	[rejection of organs]	0.0	3	1	1	1
146233	1710	wing	[wing]	0.0	1	1	1	1
146234	1710	factor-kappa b factor	[factor-kappa B factors]	0.0	3	1	1	1
146235	1710	receptor tlr	[receptors TLRs]	0.0	2	1	1	1
146236	1710	id3 cell	[Id3 cell]	0.0	2	1	1	1
146237	1710	regulate fas death	[regulating Fas death]	0.0	3	1	1	1
146238	1710	translocation breakpoint in patient	[Translocation breakpoints in patients]	0.0	4	1	1	1
146239	1710	expression in cell by cyclosporin A	[expression in cells by cyclosporin A]	0.0	6	1	1	1
146240	1710	anti-CD3 interleukin-2 secretion	[anti-CD3 interleukin-2 secretion]	0.0	3	1	1	1
146241	1710	nuclear factor (NF)-AT proximal NF-AT AP-1/Octamer	[nuclear factor (NF)-AT proximal NF-AT AP-1/Octamer]	0.0	6	1	1	1
146242	1710	gtp -binding protein rho	[GTP -binding protein Rho]	0.0	4	1	1	1
146243	1710	E3 a transcript	[E3 a transcript]	0.0	3	1	1	1
146244	1710	elk-1 gene expression	[elk-1 gene expression]	0.0	3	1	1	1
146245	1710	related effector mechanism	[related effector mechanism]	0.0	3	1	1	1
146246	1710	(cr)	[(CR)]	0.0	1	1	1	1
146247	1710	protein kinase pkc	[protein kinase PKC]	0.0	3	1	1	1
146248	1710	expression of early serum responsive gene	[expression of early serum responsive genes]	0.0	6	1	1	1
146249	1710	inhibit nf-kappab transcription	[inhibiting NF-kappaB transcription]	0.0	3	1	1	1
146250	1710	follow granulocyte-colony stimulate factor treatment	[following granulocyte-colony stimulating factor treatment]	0.0	5	1	1	1
146251	1710	selective mobilization	[selective mobilization]	0.0	2	1	1	1
146252	1710	class non-inducible, RB line	[class non-inducible, RB lines]	0.0	4	1	1	1
146253	1710	1 aml m4 with abnormal eosinophil	[1 AML M4 with abnormal eosinophils]	0.0	6	1	1	1
146254	1710	protein kinase pkr	[protein kinase PKR]	0.0	3	2	2	1
146255	1710	varicella-zoster virus peptide by cell	[varicella-zoster virus peptides by cells]	0.0	5	1	1	1
146256	1710	(cs)	[(CS)]	0.0	1	1	1	1
146257	1710	factor kappab system	[factor kappaB system]	0.0	3	1	1	1
146258	1710	advantage of autologous pbsct	[advantages of autologous PBSCT]	0.0	4	1	1	1
146259	1710	labile factor	[labile factor]	0.0	2	1	1	1
146260	1710	antibody recognize DNA	[Antibodies recognizing DNA]	0.0	3	1	1	1
146261	1710	signal by a variety	[Signaling by a variety]	0.0	4	1	1	1
146262	1710	carry mutation in the purine-rich part	[carrying mutations in the purine-rich part]	0.0	6	1	1	1
146263	1710	(+) tumor cell	[(+) tumor cells]	0.0	3	1	1	1
146264	1710	typical sedimentation coefficient of s	[typical sedimentation coefficient of S]	0.0	5	1	1	1
146265	1710	extract of nuclei	[extracts of nuclei]	0.0	3	1	1	1
146266	1710	gain a understanding of the regulation	[gaining a understanding of the regulation]	0.0	6	1	1	1
146267	1710	pancreatic beta-cell complex	[pancreatic beta-cell complex]	0.0	3	1	1	1
146268	1710	transfection of CAT reporter gene construct	[transfections of CAT reporter gene constructs]	0.0	6	1	1	1
146269	1710	anti-early antigen ea anti-viral capsid antigen	[anti-early antigen EA anti-viral capsid antigen]	0.0	6	1	1	1
146270	1710	initiation in this type	[initiation in these types]	0.0	4	1	1	1
146271	1710	suppressor notably of T cell	[suppressors notably of T cells]	0.0	5	1	1	1
146272	1710	unique domain	[unique domains]	0.0	2	1	1	1
146273	1710	also in the activation	[also in the activation]	0.0	4	1	1	1
146274	1710	H/C link	[H/C link]	0.0	2	1	1	1
146275	1710	syndrome include infectious disease	[syndromes including infectious diseases]	0.0	4	1	1	1
146276	1710	two cellular system	[two cellular systems]	0.0	3	1	1	1
146277	1710	sensitive chronic myelogenous leukemia patient	[sensitive chronic myelogenous leukemia patients]	0.0	5	1	1	1
146278	1710	analog 433-442a	[analog 433-442A]	0.0	2	1	1	1
146279	1710	dna-binding subunit of mass	[DNA-binding subunits of mass]	0.0	4	1	1	1
146280	1710	unresponsiveness to gamma interferon	[Unresponsiveness to gamma interferon]	0.0	4	1	1	1
146281	1710	site for cellular factor	[sites for cellular factors]	0.0	4	1	1	1
146282	1710	reverse transcription-pcr-based approach	[reverse transcription-PCR-based approach]	0.0	3	1	1	1
146283	1710	oncoprotein spi-1/pu.1	[oncoprotein Spi-1/PU.1]	0.0	2	1	1	1
146284	1710	oxide a microbicidal pathway	[oxide a microbicidal pathway]	0.0	4	1	1	1
146285	1710	time course,	[time course,]	0.0	2	1	1	1
146286	1710	antisense rxr-alpha	[antisense RXR-alpha]	0.0	2	1	1	1
146287	1710	mouse osteocalcin	[mouse osteocalcin]	0.0	2	1	1	1
146288	1710	wild-type allele	[wild-type allele]	0.0	2	1	1	1
146289	1710	design: cell	[DESIGN: cells]	0.0	2	1	1	1
146290	1710	Karyotypic	[Karyotypic]	0.0	1	1	1	1
146291	1710	construct contain deletion	[constructs containing deletions]	0.0	3	1	1	1
146292	1710	major histocompatibility (mhc) class antigen	[major histocompatibility (MHC) class antigens]	0.0	5	2	2	1
146293	1710	only minimal effect	[only minimal effects]	0.0	3	1	1	1
146294	1710	osteoclast-like multinucleated cell	[osteoclast-like multinucleated cells]	0.0	3	1	1	1
146295	1710	well-known immunosuppressive and/or cytokine	[well-known immunosuppressive and/or cytokine]	0.0	4	1	1	1
146296	1710	autocrine action	[autocrine action]	0.0	2	1	1	1
146297	1710	interleukin transcription in murine lymphocyte	[interleukin transcription in murine lymphocytes]	0.0	5	1	1	1
146298	1710	tyrosine phosphorylation, translocation	[tyrosine phosphorylation, translocation]	0.0	3	1	1	1
146299	1710	means of electrophoretic shift assay	[means of electrophoretic shift assay]	0.0	5	1	1	1
146300	1710	curry pigment	[curry pigment]	0.0	2	1	1	1
146301	1710	mutant Jurkat cell	[mutant Jurkat cells]	0.0	3	1	1	1
146302	1710	type T lymphocyte th2	[type T lymphocytes Th2]	0.0	4	1	1	1
146303	1710	il-1beta specific mrna level	[IL-1beta specific mRNA levels]	0.0	4	1	1	1
146304	1710	blood of normal individual	[blood of normal individuals]	0.0	4	1	1	1
146305	1710	approximately 1 ng/ml	[approximately 1 ng/ml]	0.0	3	1	1	1
146306	1710	thymocyte maturation	[thymocyte maturation]	0.0	2	1	1	1
146307	1710	cys gsh	[CYS GSH]	0.0	2	1	1	1
146308	1710	activity of this factor	[activities of these factors]	0.0	4	1	1	1
146309	1710	map unit 0.67	[map units 0.67]	0.0	3	1	1	1
146310	1710	lead to the entry	[leading to the entry]	0.0	4	1	1	1
146311	1710	key gene coding	[key genes coding]	0.0	3	1	1	1
146312	1710	g 5' flank region	[G 5' flanking region]	0.0	4	1	1	1
146313	1710	use a steroid binding assay	[using a steroid binding assay]	0.0	5	1	1	1
146314	1710	transactivator e2f-i	[transactivator E2F-I]	0.0	2	1	1	1
146315	1710	expression activator protein-1 nuclear factor	[expression activator protein-1 nuclear factor]	0.0	5	1	1	1
146316	1710	E2F family	[E2F family]	0.0	2	1	1	1
146317	1710	presence by a anti-mbp antibody	[presence by a anti-MBP antibody]	0.0	5	1	1	1
146318	1710	repeat site	[repeat sites]	0.0	2	1	1	1
146319	1710	dexamethasone glucocorticoid	[dexamethasone glucocorticoid]	0.0	2	1	1	1
146320	1710	hiv-1 molecular clone	[HIV-1 molecular clone]	0.0	3	1	1	1
146321	1710	proliferate g1	[proliferating G1]	0.0	2	1	1	1
146322	1710	interleukin-7 receptor complex	[interleukin-7 receptor complex]	0.0	3	1	1	1
146323	1710	induction by IL-4	[induction by IL-4]	0.0	3	1	1	1
146324	1710	minor importance	[minor importance]	0.0	2	1	1	1
146325	1710	nf-kappabp65	[NF-kappaBp65]	0.0	1	1	1	1
146326	1710	anti-Class ii antibody	[anti-Class II antibodies]	0.0	3	1	1	1
146327	1710	change in set	[changes in set]	0.0	3	1	1	1
146328	1710	mnda in bone marrow	[MNDA in bone marrow]	0.0	4	1	1	1
146329	1710	also (p less than 0.025) low	[also (P less than 0.025) lower]	0.0	6	1	1	1
146330	1710	limited portion	[limited portion]	0.0	2	1	1	1
146331	1710	induction of isg	[induction of ISGs]	0.0	3	1	1	1
146332	1710	normal human blood mononuclear cell	[normal human blood mononuclear cells]	0.0	5	1	1	1
146333	1710	developmental- regulation	[developmental- regulation]	0.0	2	1	1	1
146334	1710	one intron	[one intron]	0.0	2	1	1	1
146335	1710	tnf-treated huvec	[TNF-treated HUVECs]	0.0	2	1	1	1
146336	1710	use micrograms/ml of the C. sub.	[using micrograms/ml of the C. Sub.]	0.0	6	1	1	1
146337	1710	3,605 binding site per nucleus	[3,605 binding sites per nucleus]	0.0	5	1	1	1
146338	1710	great feedback sensitivity	[greater feedback sensitivity]	0.0	3	1	1	1
146339	1710	nf-e2 factor	[NF-E2 factor]	0.0	2	1	1	1
146340	1710	patient with class congenital immunodeficiency	[patients with class congenital immunodeficiency]	0.0	5	1	1	1
146341	1710	activation role of cis-acting DNA element	[Activation role of cis-acting DNA elements]	0.0	6	1	1	1
146342	1710	infection b cell by human herpesvirus	[infection B cells by human herpesvirus]	0.0	6	1	1	1
146343	1710	transcription factor creb	[transcription factor CREB]	0.0	3	1	1	1
146344	1710	substance such as formylpeptide	[substances such as formylpeptides]	0.0	4	1	1	1
146345	1710	dimorphism of autoimmunity	[dimorphism of autoimmunity]	0.0	3	1	1	1
146346	1710	chronic rheumatic disease (12:	[chronic rheumatic diseases (12:]	0.0	4	1	1	1
146347	1710	nf-kappa b activity after stimulation.	[NF-kappa B activity after stimulation.]	0.0	5	1	1	1
146348	1710	low urinary cortisol excretion	[low urinary cortisol excretion]	0.0	4	1	1	1
146349	1710	regulatory region in vitro	[regulatory region in vitro]	0.0	4	1	1	1
146350	1710	collective name	[collective name]	0.0	2	1	1	1
146351	1710	dose result	[doses resulting]	0.0	2	1	1	1
146352	1710	different negative pathway	[different negative pathways]	0.0	3	1	1	1
146353	1710	strong predisposition	[strong predisposition]	0.0	2	1	1	1
146354	1710	low density lipoprotein response in cell	[low density lipoprotein responses in cells]	0.0	6	1	1	1
146355	1710	intron of RARA	[intron of RARA]	0.0	3	1	1	1
146356	1710	such as muscle cell	[such as muscle cells]	0.0	4	2	2	1
146357	1710	characterization of IL-2 inhibitor	[characterization of IL-2 inhibitors]	0.0	4	1	1	1
146358	1710	set of repressor	[set of repressors]	0.0	3	1	1	1
146359	1710	9011 (post) sites/cell,	[9011 (post) sites/cell,]	0.0	3	1	1	1
146360	1710	latent membrane protein activation	[latent membrane protein activation]	0.0	4	1	1	1
146361	1710	discrete cell-surface isoform	[discrete cell-surface isoforms]	0.0	3	1	1	1
146362	1710	core promoter structure	[core promoter structure]	0.0	3	1	1	1
146363	1710	activation of human immunodeficiency virus type	[Activation of human immunodeficiency virus type]	0.0	6	1	1	1
146364	1710	current understanding of the regulation	[current understanding of the regulation]	0.0	5	1	1	1
146365	1710	role signal in lymphocyte	[roles signaling in lymphocytes]	0.0	4	1	1	1
146366	1710	condition such as autoimmune disease	[conditions such as autoimmune diseases]	0.0	5	1	1	1
146367	1710	only a small amount	[only a small amount]	0.0	4	2	2	1
146368	1710	related cation	[related cations]	0.0	2	1	1	1
146369	1710	exon of E1A	[exon of E1A]	0.0	3	2	2	1
146370	1710	activating region	[activating regions]	0.0	2	1	1	1
146371	1710	expression of mutant	[expression of mutants]	0.0	3	1	1	1
146372	1710	b-cell proliferation of G1-regulating protein	[B-cell proliferation of G1-regulating proteins]	0.0	5	1	1	1
146373	1710	Th1 development distinct	[Th1 development distinct]	0.0	3	1	1	1
146374	1710	apoptosis of factor kappab	[apoptosis of factor kappaB]	0.0	4	1	1	1
146375	1710	treatment of mt-i	[treatment of MT-I]	0.0	3	1	1	1
146376	1710	origin than contraction	[origin than contractions]	0.0	3	1	1	1
146377	1710	ligand gp39-cd8 fusion protein	[ligand gp39-CD8 fusion protein]	0.0	4	1	1	1
146378	1710	transcriptional activator ebf	[transcriptional activator EBF]	0.0	3	1	1	1
146379	1710	competent transcription initiation in cell-free extract	[Competent transcription initiation in cell-free extracts]	0.0	6	1	1	1
146380	1710	transcription factor of the nfat factor	[Transcription factors of the NFAT factor]	0.0	6	1	1	1
146381	1710	evil	[Evil]	0.0	1	1	1	1
146382	1710	lie at the level of control	[lying at the level of control]	0.0	6	1	1	1
146383	1710	other tumor ag	[other tumor Ag]	0.0	3	1	1	1
146384	1710	encode the 40-kd tax protein	[encoding the 40-kd Tax protein]	0.0	5	1	1	1
146385	1710	example of a transcription factor	[example of a transcription factor]	0.0	5	1	1	1
146386	1710	negative correlation, indicate a effect.	[negative correlation, indicating a effect.]	0.0	5	1	1	1
146387	1710	land structure morphologically distinct	[LANDs structures morphologically distinct]	0.0	4	1	1	1
146388	1710	expression a marker	[expression a marker]	0.0	3	1	1	1
146389	1710	response to retinoic acid atra	[response to retinoic acid ATRA]	0.0	5	1	1	1
146390	1710	influence on the production	[Influence on the production]	0.0	4	1	1	1
146391	1710	normal breast duct	[normal breast ducts]	0.0	3	1	1	1
146392	1710	different stat6 isoform	[different STAT6 isoforms]	0.0	3	1	1	1
146393	1710	activation programme.	[activation programme.]	0.0	2	1	1	1
146394	1710	degradation human monocytic cell	[degradation human monocytic cells]	0.0	4	1	1	1
146395	1710	molecular analysis of the cDNA clone	[Molecular analysis of the cDNA clones]	0.0	6	1	1	1
146396	1710	permanent th2 phenotype	[permanent Th2 phenotype]	0.0	3	1	1	1
146397	1710	percentage of normal	[percentage of normals]	0.0	3	1	1	1
146398	1710	agent cyclosporin	[agent cyclosporin]	0.0	2	1	1	1
146399	1710	region of BCL-6	[region of BCL-6]	0.0	3	1	1	1
146400	1710	impaired b cell function	[impaired B cell functions]	0.0	4	1	1	1
146401	1710	employ a novel lysis substrate	[employing a novel lysis substrate]	0.0	5	1	1	1
146402	1710	18 patient with acute leukaemia	[18 patients with acute leukaemia]	0.0	5	1	1	1
146403	1710	labeling of membrane from leukocyte	[labeling of membranes from leukocytes]	0.0	5	1	1	1
146404	1710	similar mode	[similar mode]	0.0	2	1	1	1
146405	1710	peak expiratory flow	[peak expiratory flow]	0.0	3	1	1	1
146406	1710	two major nonoverlapping epitope	[two major nonoverlapping epitopes]	0.0	4	1	1	1
146407	1710	-inducible interferon factor-1 gene	[-inducible interferon factor-1 gene]	0.0	4	1	1	1
146408	1710	Smu-->S	[Smu-->S]	0.0	1	1	1	1
146409	1710	antioxidant,	[antioxidant,]	0.0	1	2	2	1
146410	1710	(64 8 mv),	[(64 8 mV),]	0.0	3	1	1	1
146411	1710	progression from infection to aids	[progression from infection to AIDS]	0.0	5	1	1	1
146412	1710	signal 2 signal alone without signal	[signal 2 signal alone without signal]	0.0	6	1	1	1
146413	1710	ligation of class	[ligation of class]	0.0	3	1	1	1
146414	1710	Novel therapy for bowel disease	[Novel therapies for bowel disease]	0.0	5	1	1	1
146415	1710	interesting potential.	[interesting potential.]	0.0	2	1	1	1
146416	1710	sh2 domain-binding motif	[SH2 domain-binding motifs]	0.0	3	1	1	1
146417	1710	recently circulate human lymphocyte	[recently circulating human lymphocytes]	0.0	4	2	2	1
146418	1710	s-x-y region	[S-X-Y region]	0.0	2	1	1	1
146419	1710	monoclonal antibody (mab)	[monoclonal antibody (MAb)]	0.0	3	1	1	1
146420	1710	autologous epithelial cell	[autologous epithelial cells]	0.0	3	1	1	1
146421	1710	transcription regulatory function	[transcription regulatory function]	0.0	3	1	1	1
146422	1710	CsA cell	[CsA cells]	0.0	2	1	1	1
146423	1710	transcriptional activation by N-terminal deletion	[transcriptional activation by N-terminal deletions]	0.0	5	1	1	1
146424	1710	understand the function during erythroid ontogeny	[understanding the function during erythroid ontogeny]	0.0	6	1	1	1
146425	1710	Duffy antigen/chemokine receptor gene	[Duffy antigen/chemokine receptor gene]	0.0	4	1	1	1
146426	1710	unique kda protein factor	[unique kDa protein factor]	0.0	4	2	2	1
146427	1710	synergistic manner.	[synergistic manner.]	0.0	2	1	1	1
146428	1710	b-cell-mediated immune response	[B-cell-mediated immune responses]	0.0	3	1	1	1
146429	1710	10 child	[10 children]	0.0	2	1	1	1
146430	1710	tsg101 transcript deletion	[TSG101 transcript deletions]	0.0	3	1	1	1
146431	1710	total of 37 chronic, severe,	[total of 37 chronic, severe,]	0.0	5	1	1	1
146432	1710	factor in function	[factors in functions]	0.0	3	1	1	1
146433	1710	two-site interaction	[Two-site interaction]	0.0	2	1	1	1
146434	1710	sarco(endo)plasmic reticulum ca2+-atpase	[sarco(endo)plasmic reticulum Ca2+-ATPase]	0.0	3	1	1	1
146435	1710	USF/c-Myc up-regulation	[USF/c-Myc up-regulation]	0.0	2	1	1	1
146436	1710	MHC class ii gene factor	[MHC class II gene factor]	0.0	5	1	1	1
146437	1710	peptide rakfkqll	[peptide RAKFKQLL]	0.0	2	1	1	1
146438	1710	kappa 3	[kappa 3]	0.0	2	1	1	1
146439	1710	Jurkat T cell express tax	[Jurkat T cells expressing tax]	0.0	5	1	1	1
146440	1710	acetylsalicylate aspirin	[acetylsalicylate aspirin]	0.0	2	1	1	1
146441	1710	transient expression analysis	[Transient expression analyses]	0.0	3	1	1	1
146442	1710	overexpress IkappaB-alpha	[overexpressing IkappaB-alpha]	0.0	2	1	1	1
146443	1710	eosinophil infiltrate into pathologic process	[eosinophils infiltrating into pathologic processes]	0.0	5	1	1	1
146444	1710	RA start	[RA starting]	0.0	2	1	1	1
146445	1710	mobility of nuclear extract-DNA complex	[mobilities of nuclear extract-DNA complexes]	0.0	5	1	1	1
146446	1710	helix-loop-helix domain	[helix-loop-helix domain]	0.0	2	2	2	1
146447	1710	signal pathway in transformation	[signaling pathways in transformation]	0.0	4	1	1	1
146448	1710	gp120-anti-gp120	[gp120-anti-gp120]	0.0	1	1	1	1
146449	1710	distinct set of factor	[distinct set of factor]	0.0	4	1	1	1
146450	1710	repressor by basic protein	[repressor by basic proteins]	0.0	4	1	1	1
146451	1710	g76:gpltplpv (128-135)	[G76:GPLTPLPV (128-135)]	0.0	2	1	1	1
146452	1710	latent memory	[latent memory]	0.0	2	1	1	1
146453	1710	effect of adenovirus	[Effect of adenovirus]	0.0	3	1	1	1
146454	1710	normal expansion	[normal expansion]	0.0	2	1	1	1
146455	1710	alteration in kappa b motif activity	[alterations in kappa B motif activity]	0.0	6	1	1	1
146456	1710	level gr expression	[level GR expression]	0.0	3	2	2	1
146457	1710	chimeric properties unlike other oncoprotein	[chimeric properties, unlike other oncoproteins]	0.0	5	1	1	1
146458	1710	repression inhibition	[repression inhibition]	0.0	2	1	1	1
146459	1710	area of the IL-6 promoter	[area of the IL-6 promoter]	0.0	5	1	1	1
146460	1710	growth factor-beta expression	[growth factor-beta expression]	0.0	3	1	1	1
146461	1710	concentration inhibit ige synthesis	[concentrations inhibiting IgE synthesis]	0.0	4	1	1	1
146462	1710	line with RB expression vector	[lines with RB expression vectors]	0.0	5	1	1	1
146463	1710	mutation in breast tumor	[mutation in breast tumors]	0.0	4	1	1	1
146464	1710	basal nfat activity	[basal NFAT activity]	0.0	3	1	1	1
146465	1710	candidate for a member	[candidate for a member]	0.0	4	1	1	1
146466	1710	namely activator protein-1 ap-1 factor il-6	[namely activator protein-1 AP-1 factor IL-6]	0.0	6	1	1	1
146467	1710	crucial proximal IL-4 promoter	[crucial proximal IL-4 promoter]	0.0	4	1	1	1
146468	1710	stimulate blood mononuclear cell	[stimulating blood mononuclear cells]	0.0	4	1	1	1
146469	1710	mutant of NF-kappaB p50	[mutant of NF-kappaB p50]	0.0	4	1	1	1
146470	1710	five- to eightfold increase	[five- to eightfold increase]	0.0	4	1	1	1
146471	1710	intracellular event lead to activation	[intracellular events leading to activation]	0.0	5	1	1	1
146472	1710	t-cell memory	[T-cell memory]	0.0	2	1	1	1
146473	1710	rat t-cell line	[rat T-cell line]	0.0	3	1	1	1
146474	1710	receptor gr binding	[receptor GR binding]	0.0	3	1	1	1
146475	1710	identical signal pathways, lead	[identical signaling pathways, leading]	0.0	4	1	1	1
146476	1710	activity 100-fold low than cyclosporin a	[activity 100-fold lower than cyclosporin A]	0.0	6	1	1	1
146477	1710	slight trend for some	[slight trends for some]	0.0	4	1	1	1
146478	1710	three candidate gene for ags	[three candidate genes for AGS]	0.0	5	1	1	1
146479	1710	puzzle of the drug	[puzzles of the drugs]	0.0	4	1	1	1
146480	1710	fragment extend	[fragment extending]	0.0	2	1	1	1
146481	1710	comparison, RBA in this system	[comparison, RBA in this system]	0.0	5	1	1	1
146482	1710	macrophage protein-1 another member	[macrophage protein-1 another member]	0.0	4	1	1	1
146483	1710	atrophy a adult-onset form	[atrophy an adult-onset form]	0.0	4	1	1	1
146484	1710	small molecules,	[small molecules,]	0.0	2	1	1	1
146485	1710	cd15 a monocyte counter-receptor	[CD15 a monocyte counter-receptor]	0.0	4	1	1	1
146486	1710	1311-base pair	[1311-base pair]	0.0	2	1	1	1
146487	1710	bp upstream from the enhancer	[bp upstream from the enhancer]	0.0	5	1	1	1
146488	1710	trapoxin affinity	[trapoxin affinity]	0.0	2	1	1	1
146489	1710	previous finding of expression	[previous findings of expression]	0.0	4	1	1	1
146490	1710	accordingly, blot with antibody	[Accordingly, blots with antibodies]	0.0	4	1	1	1
146491	1710	clinical feature of peripheral resistance	[clinical features of peripheral resistance]	0.0	5	1	1	1
146492	1710	p50 subunit of kappa b	[p50 subunits of kappa B]	0.0	5	1	1	1
146493	1710	blood resting	[blood resting]	0.0	2	1	1	1
146494	1710	enhancer between nucleotide -299	[enhancer between nucleotides -299]	0.0	4	1	1	1
146495	1710	receptor content	[receptor content]	0.0	2	1	1	1
146496	1710	sharp bend	[sharp bend]	0.0	2	1	1	1
146497	1710	amount additionally, costimulation with anti-CD3	[amounts additionally, costimulation with anti-CD3]	0.0	5	1	1	1
146498	1710	probe, extract from T	[probe, extracts from T]	0.0	4	1	1	1
146499	1710	hormone-dependent activation	[hormone-dependent activation]	0.0	2	1	1	1
146500	1710	aldosterone on the sodium-proton-antiport	[aldosterone on the sodium-proton-antiport]	0.0	4	1	1	1
146501	1710	complex of proteins,	[complex of proteins,]	0.0	3	1	1	1
146502	1710	unrelated n-acetylcysteine nac	[unrelated N-acetylcysteine NAC]	0.0	3	1	1	1
146503	1710	(trap+)	[(TRAP+)]	0.0	1	1	1	1
146504	1710	relationship between the ca2+ feca2+	[relationship between the Ca2+ FECa2+]	0.0	5	1	1	1
146505	1710	erbA target	[erbA target]	0.0	2	1	1	1
146506	1710	breast cancer reactive antibody-dependent cellular cytotoxicity	[breast cancer reactive antibody-dependent cellular cytotoxicity]	0.0	6	1	1	1
146507	1710	evidence for activity at element p0	[Evidence for activity at element P0]	0.0	6	1	1	1
146508	1710	activation of the inflammatory cytokine	[activation of the inflammatory cytokines]	0.0	5	1	1	1
146509	1710	search for loss of one allele	[search for losses of one allele]	0.0	6	1	1	1
146510	1710	pathology,	[pathology,]	0.0	1	1	1	1
146511	1710	leukemia APL the microgranular variant	[leukemia APL the microgranular variant]	0.0	5	1	1	1
146512	1710	play a costimulatory role	[playing an costimulatory role]	0.0	4	1	1	1
146513	1710	ecto-5'-nucleotidase promoter	[ecto-5'-nucleotidase promoter]	0.0	2	1	1	1
146514	1710	expression of the interleukin-5 gene	[expression of the interleukin-5 gene]	0.0	5	1	1	1
146515	1710	viral gene expression.	[viral gene expression.]	0.0	3	1	1	1
146516	1710	etoposide dexamethasone-induced apoptosis in thymocyte	[etoposide dexamethasone-induced apoptosis in thymocytes]	0.0	5	1	1	1
146517	1710	role of this adhesion molecule	[role of this adhesion molecule]	0.0	5	1	1	1
146518	1710	Chemical cross-linking tgf-beta 1	[Chemical cross-linking TGF-beta 1]	0.0	4	1	1	1
146519	1710	human interferon beta element	[human interferon beta element]	0.0	4	1	1	1
146520	1710	use a nf-kappa b probe	[using a NF-kappa B probe]	0.0	5	1	1	1
146521	1710	position gggaactacc	[positions GGGAACTACC]	0.0	2	1	1	1
146522	1710	renal tubular phosphate transport	[renal tubular phosphate transport]	0.0	4	1	1	1
146523	1710	primary initiator	[primary initiator]	0.0	2	1	1	1
146524	1710	mutant form of lps	[mutant forms of LPS]	0.0	4	1	1	1
146525	1710	FK506 pathway involve ca2+ mobilization	[FK506 pathway involving Ca2+ mobilization]	0.0	5	1	1	1
146526	1710	chemical modification	[chemical modification]	0.0	2	1	1	1
146527	1710	copy of the viral genome	[copies of the viral genome]	0.0	5	1	1	1
146528	1710	use a t-lymphocyte cell line s-lb1	[using a T-lymphocyte cell line S-LB1]	0.0	6	1	1	1
146529	1710	variable weak phosphorylation	[variable weak phosphorylation]	0.0	3	1	1	1
146530	1710	great number of lymphocyte receptor	[greater number of lymphocyte receptors]	0.0	5	1	1	1
146531	1710	four near-perfect direct repeat	[four near-perfect direct repeats]	0.0	4	1	1	1
146532	1710	5 rearrangement to 21-acetoxy-11	[5 rearrangement to 21-acetoxy-11]	0.0	4	1	1	1
146533	1710	expansion of cd4+ t-cell	[expansion of CD4+ T-cells]	0.0	4	1	1	1
146534	1710	molecule of mrna	[molecule of mRNA]	0.0	3	1	1	1
146535	1710	hyperreactive adrenocorticotropic hormone release	[hyperreactive adrenocorticotropic hormone release]	0.0	4	1	1	1
146536	1710	effect on gr -dependent transcription	[effect on GR -dependent transcription]	0.0	5	1	1	1
146537	1710	e2f-dna binding complex	[E2F-DNA binding complex]	0.0	3	1	1	1
146538	1710	bone mineral density in populations,	[bone mineral density in populations,]	0.0	5	1	1	1
146539	1710	pre-bound transcription	[pre-bound transcription]	0.0	2	1	1	1
146540	1710	new factor tcf-1 alpha	[new factor TCF-1 alpha]	0.0	4	1	1	1
146541	1710	increase notably phospholipase c 1	[increase notably phospholipase C 1]	0.0	5	1	1	1
146542	1710	important determinant of the ability	[important determinants of the ability]	0.0	5	1	1	1
146543	1710	ppar activator j(2) 15d-PGJ(2)	[PPAR activators J(2) 15d-PGJ(2)]	0.0	4	1	1	1
146544	1710	hormone-inducible protein	[hormone-inducible proteins]	0.0	2	1	1	1
146545	1710	weight variant of stat5	[weight variants of STAT5]	0.0	4	1	1	1
146546	1710	recent developments,	[recent developments,]	0.0	2	1	1	1
146547	1710	presence of positive regulatory element	[presence of positive regulatory elements]	0.0	5	1	1	1
146548	1710	low dissociation constant kd	[low dissociation constant Kd]	0.0	4	1	1	1
146549	1710	least one t-cell clone	[least one T-cell clone]	0.0	4	1	1	1
146550	1710	activator of IL-8 gene expression	[activator of IL-8 gene expression]	0.0	5	1	1	1
146551	1710	Clinical feature	[Clinical features]	0.0	2	1	1	1
146552	1710	lymphocyte follow stimulation, lymphocyte activation	[lymphocytes following stimulation, lymphocyte activation]	0.0	5	1	1	1
146553	1710	particular cell line	[particular cell line]	0.0	3	1	1	1
146554	1710	immediate (ie62) protein	[immediate (IE62) protein]	0.0	3	1	1	1
146555	1710	sensitivity to agent	[sensitivity to agents]	0.0	3	1	1	1
146556	1710	cellular signal to	[cellular signal to]	0.0	3	1	1	1
146557	1710	concentration consistent with specificity	[concentrations consistent with specificity]	0.0	4	1	1	1
146558	1710	element binding protein with DNA receptor	[element binding protein with DNA receptors]	0.0	6	1	1	1
146559	1710	difference between Th1 clone	[differences between Th1 clones]	0.0	4	1	1	1
146560	1710	1,25-dihydroxyvitamin D3 receptor	[1,25-dihydroxyvitamin D3 receptors]	0.0	3	1	1	1
146561	1710	constitutional loss	[constitutional losses]	0.0	2	1	1	1
146562	1710	portion of Stat3alpha	[portion of Stat3alpha]	0.0	3	1	1	1
146563	1710	32Dcl3 cell	[32Dcl3 cells]	0.0	2	1	1	1
146564	1710	aids-gr	[AIDS-GR]	0.0	1	1	1	1
146565	1710	multi-point scatchard analysis	[multi-point Scatchard analysis]	0.0	3	1	1	1
146566	1710	(dp)	[(DP)]	0.0	1	1	1	1
146567	1710	vitro, antigen EBNAs	[vitro, antigens EBNAs]	0.0	3	1	1	1
146568	1710	human homeobox gene HB9	[human homeobox gene HB9]	0.0	4	1	1	1
146569	1710	differential expression of coreceptor	[differential expression of coreceptors]	0.0	4	1	1	1
146570	1710	various signal converge	[Various signals converging]	0.0	3	1	1	1
146571	1710	surprisingly, different combination of mutation	[Surprisingly, different combinations of mutations]	0.0	5	1	1	1
146572	1710	interferon-gamma-induced factor binding role	[Interferon-gamma-induced factor binding role]	0.0	4	1	1	1
146573	1710	relapsed.	[relapsed.]	0.0	1	1	1	1
146574	1710	endogeneous tal1	[endogeneous TAL1]	0.0	2	1	1	1
146575	1710	abnormal biomarker	[abnormal biomarkers]	0.0	2	1	1	1
146576	1710	assay procedure	[assay procedure]	0.0	2	1	1	1
146577	1710	subject in two patient	[subjects in two patients]	0.0	4	1	1	1
146578	1710	examination of the patient' brother,	[examination of the patient's brother,]	0.0	5	1	1	1
146579	1710	mutation of mds1/evi1 by gene truncation	[mutations of MDS1/EVI1 by gene truncation]	0.0	6	1	1	1
146580	1710	involvement factor	[involvement factors]	0.0	2	1	1	1
146581	1710	important role control gene transcription	[important role controlling gene transcription]	0.0	5	1	1	1
146582	1710	interaction between multiple regulatory element	[interactions between multiple regulatory elements]	0.0	5	1	1	1
146583	1710	extracellular protein kinase erk	[extracellular protein kinase ERK]	0.0	4	1	1	1
146584	1710	avenue in leukemia	[avenue in leukemia]	0.0	3	1	1	1
146585	1710	position -306 to -260 relative	[positions -306 to -260 relative]	0.0	5	1	1	1
146586	1710	healthy woman 10 second	[healthy women 10 second]	0.0	4	1	1	1
146587	1710	thyroid hormone responsive element	[thyroid hormone responsive element]	0.0	4	1	1	1
146588	1710	presence of 25(oh)d3	[presence of 25(OH)D3]	0.0	3	1	1	1
146589	1710	level of id2	[levels of Id2]	0.0	3	1	1	1
146590	1710	igg (from the patient	[IgG (from the patient]	0.0	4	1	1	1
146591	1710	case microM),	[case microM),]	0.0	2	1	1	1
146592	1710	PMLRAR alpha mouse	[PMLRAR alpha mice]	0.0	3	1	1	1
146593	1710	seven asthmatic patient	[seven asthmatic patients]	0.0	3	1	1	1
146594	1710	yeast colonies,	[yeast colonies,]	0.0	2	1	1	1
146595	1710	transcriptional induction of gene	[transcriptional induction of genes]	0.0	4	1	1	1
146596	1710	promoter element kappa 3	[promoter element kappa 3]	0.0	4	1	1	1
146597	1710	human cytomegalovirus binding to monocyte	[Human cytomegalovirus binding to monocytes]	0.0	5	1	1	1
146598	1710	70% level	[70% levels]	0.0	2	1	1	1
146599	1710	amino terminal insert	[amino terminal insert]	0.0	3	1	1	1
146600	1710	criteria, inactivation	[criteria, inactivation]	0.0	2	1	1	1
146601	1710	AP-1 components,	[AP-1 components,]	0.0	2	1	1	1
146602	1710	mechanism of anoxia/reoxygenation-induced adherence to cell	[mechanisms of anoxia/reoxygenation-induced adherence to cells]	0.0	6	1	1	1
146603	1710	decrease activation	[decrease activation]	0.0	2	1	1	1
146604	1710	deletion of N-terminal activation domain	[deletions of N-terminal activation domain]	0.0	5	1	1	1
146605	1710	immature normal cell StatG	[immature normal cells StatG]	0.0	4	1	1	1
146606	1710	DNA polymerase inhibitor	[DNA polymerase inhibitor]	0.0	3	1	1	1
146607	1710	grade astrocytomas	[grade astrocytomas]	0.0	2	1	1	1
146608	1710	gene such as fibroblast	[genes such as fibroblasts]	0.0	4	1	1	1
146609	1710	four different stimulus	[four different stimuli]	0.0	3	1	1	1
146610	1710	P; in protein	[h; in protein]	0.0	3	1	1	1
146611	1710	apparent resistance in disorder	[apparent resistance in disorder]	0.0	4	1	1	1
146612	1710	tetrazolium cell	[tetrazolium cells]	0.0	2	1	1	1
146613	1710	level of ap-2 activation	[levels of AP-2 activation]	0.0	4	1	1	1
146614	1710	breast cancer a longitudinal study	[breast cancer a longitudinal study]	0.0	5	1	1	1
146615	1710	class MHC x1 box	[class MHC X1 box]	0.0	4	1	1	1
146616	1710	thus relieve effect.	[thus relieving effect.]	0.0	3	1	1	1
146617	1710	HBxAg -specific stimulation in patient	[HBxAg -specific stimulation in patients]	0.0	5	1	1	1
146618	1710	calphostin	[calphostin]	0.0	1	1	1	1
146619	1710	term of inhibition	[terms of inhibition]	0.0	3	1	1	1
146620	1710	inhibitor pp pp1	[inhibitor PPs PP1/PP2A]	0.0	3	1	1	1
146621	1710	intracellular sequestration	[intracellular sequestration]	0.0	2	1	1	1
146622	1710	day (p	[day (p]	0.0	2	1	1	1
146623	1710	t- cell line of importance	[T- cell lines of importance]	0.0	5	1	1	1
146624	1710	leukotriene b4 generation by neutrophil	[leukotriene B4 generation by neutrophils]	0.0	5	1	1	1
146625	1710	ifngr1 allele	[IFNGR1 allele]	0.0	2	1	1	1
146626	1710	interleukin IL2 promoter	[interleukin IL2 promoter]	0.0	3	1	1	1
146627	1710	role of Lck	[role of Lck]	0.0	3	1	1	1
146628	1710	prion	[Prion]	0.0	1	1	1	1
146629	1710	eosinophil cell line	[eosinophil cell line]	0.0	3	1	1	1
146630	1710	cell adhesion molecule vcam surface expression	[cell adhesion molecule VCAM surface expression]	0.0	6	1	1	1
146631	1710	1 allele	[1 allele]	0.0	2	1	1	1
146632	1710	such as correction	[such as correction]	0.0	3	1	1	1
146633	1710	inducible expression of cytokine gene	[inducible expression of cytokine genes]	0.0	5	1	1	1
146634	1710	fas ligand on lymphocyte	[Fas ligand on lymphocytes]	0.0	4	1	1	1
146635	1710	evaluate epithelium of normal	[evaluating epithelium of normals]	0.0	4	1	1	1
146636	1710	respond to therapy	[responding to therapy]	0.0	3	1	1	1
146637	1710	effectively by other steroid	[effectively by other steroids]	0.0	4	1	1	1
146638	1710	downregulation of WT1	[downregulation of WT1]	0.0	3	1	1	1
146639	1710	17-bp sequence between position	[17-bp sequence between positions]	0.0	4	1	1	1
146640	1710	NF-kappa b in vivo	[NF-kappa B in vivo]	0.0	4	1	1	1
146641	1710	increase amount	[increasing amounts]	0.0	2	1	1	1
146642	1710	relieve effect.	[relieving effect.]	0.0	2	1	1	1
146643	1710	great activation	[greater activation]	0.0	2	1	1	1
146644	1710	extracellular kinase pathway	[extracellular kinase pathway]	0.0	3	1	1	1
146645	1710	sequence element within this region.	[sequence elements within this region.]	0.0	5	1	1	1
146646	1710	encode from a cDNA library	[encoding from a cDNA library]	0.0	5	1	1	1
146647	1710	of lap	[of LAP]	0.0	2	1	1	1
146648	1710	luciferase gene system	[luciferase gene system]	0.0	3	1	1	1
146649	1710	p3a2	[P3A2]	0.0	1	1	1	1
146650	1710	presence progesterone receptor by immunohistochemistry	[presence progesterone receptors by immunohistochemistry]	0.0	5	1	1	1
146651	1710	inducible T enhancer kb upstream	[inducible T enhancer kb upstream]	0.0	5	1	1	1
146652	1710	export signal	[export signal]	0.0	2	2	2	1
146653	1710	interaction between two transcriptional coactivator	[interactions between two transcriptional coactivators]	0.0	5	1	1	1
146654	1710	drosophila sex comb gene	[Drosophila sex combs gene]	0.0	4	1	1	1
146655	1710	variation in this gene	[variation in these genes]	0.0	4	1	1	1
146656	1710	expression in human T lymphocyte	[expression in human T lymphocytes]	0.0	5	1	1	1
146657	1710	defective phenotype.	[defective phenotype.]	0.0	2	1	1	1
146658	1710	IL-2 transcriptional regulator	[IL-2 transcriptional regulators]	0.0	3	1	1	1
146659	1710	regimen on change	[regimen on changes]	0.0	3	1	1	1
146660	1710	late time (12-24	[later times (12-24]	0.0	3	1	1	1
146661	1710	single viral protein	[single viral protein]	0.0	3	1	1	1
146662	1710	transwell system	[transwell system]	0.0	2	1	1	1
146663	1710	prevent the degradation of b inhibitor	[preventing the degradation of B inhibitor]	0.0	6	1	1	1
146664	1710	basophilia in acute leukaemia molecular analysis	[basophilia in acute leukaemia molecular analysis]	0.0	6	1	1	1
146665	1710	I aldosterone receptor in peripheral leucocyte	[I aldosterone receptors in peripheral leucocytes]	0.0	6	1	1	1
146666	1710	upregulation by interleukin-4	[upregulation by interleukin-4]	0.0	3	1	1	1
146667	1710	binding of specific factor	[binding of specific factors]	0.0	4	1	1	1
146668	1710	12.1 respectively),	[12.1 respectively),]	0.0	2	1	1	1
146669	1710	immunomodulatory stress response	[immunomodulatory stress response]	0.0	3	1	1	1
146670	1710	convert signal into intracellular biochemical event	[converting signals into intracellular biochemical events]	0.0	6	1	1	1
146671	1710	regulation in normal cells,	[regulation in normal cells,]	0.0	4	1	1	1
146672	1710	production of mediator	[production of mediators]	0.0	3	1	1	1
146673	1710	induction of interferon	[induction of interferon]	0.0	3	1	1	1
146674	1710	adhesion molecule expression in venous huvec	[adhesion molecule expression in venous HUVECs]	0.0	6	1	1	1
146675	1710	normal T cell response	[normal T cell responses]	0.0	4	1	1	1
146676	1710	novel continuous myeloid cell line	[novel continuous myeloid cell line]	0.0	5	1	1	1
146677	1710	-resistance in peripheral-blood lymphocyte	[-resistance in peripheral-blood lymphocytes]	0.0	4	1	1	1
146678	1710	first outpatient visit,	[first outpatient visit,]	0.0	3	1	1	1
146679	1710	gene c-jun	[gene c-jun]	0.0	2	1	1	1
146680	1710	other cell-encoded gene	[other cell-encoded genes]	0.0	3	1	1	1
146681	1710	two 9-bp motif with high homology	[two 9-bp motifs with high homology]	0.0	6	1	1	1
146682	1710	early model	[earliest models]	0.0	2	1	1	1
146683	1710	useful tool for the investigation	[useful tool for the investigation]	0.0	5	1	1	1
146684	1710	protein sequence against database	[protein sequences against databases]	0.0	4	1	1	1
146685	1710	nf-kappa b DNA binding site	[NF-kappa B DNA binding sites]	0.0	5	1	1	1
146686	1710	LN T	[LN T]	0.0	2	1	1	1
146687	1710	cascade lead	[cascade leading]	0.0	2	1	1	1
146688	1710	day 15	[day 15]	0.0	2	1	1	1
146689	1710	low the/thf 1.87+/-0.36) alpha thf/thf	[low THE/THF 1.87+/-0.36) alpha THF/THF]	0.0	5	1	1	1
146690	1710	interaction between transcriptional regulatory element	[interactions between transcriptional regulatory elements]	0.0	5	1	1	1
146691	1710	nf-kappa b cytokine gene expression	[NF-kappa B cytokine gene expression]	0.0	5	1	1	1
146692	1710	incubation for several day	[incubation for several days,]	0.0	4	1	1	1
146693	1710	Chronic disease	[Chronic diseases]	0.0	2	1	1	1
146694	1710	stimulate il-6 release from cell	[stimulating IL-6 release from cells]	0.0	5	1	1	1
146695	1710	leukemia/lymphoma	[leukemia/lymphoma]	0.0	1	1	1	1
146696	1710	group of patient one	[groups of patients one]	0.0	4	1	1	1
146697	1710	indicate a determinant of expression	[indicating an determinant of expression]	0.0	5	1	1	1
146698	1710	hla-dq allele	[HLA-DQ alleles]	0.0	2	1	1	1
146699	1710	sre- binding site	[SRE- binding sites]	0.0	3	1	1	1
146700	1710	stimuli, stimulus-	[stimuli, stimulus-]	0.0	2	1	1	1
146701	1710	effect of aldosterone on the sodium-proton-antiport	[effects of aldosterone on the sodium-proton-antiport]	0.0	6	1	1	1
146702	1710	translocation of receptor protein	[translocation of receptor proteins]	0.0	4	1	1	1
146703	1710	CAT gene expression	[CAT gene expression]	0.0	3	1	1	1
146704	1710	19-bp factor binding site	[19-bp factor binding site]	0.0	4	1	1	1
146705	1710	substance tbar	[substances TBARS]	0.0	2	1	1	1
146706	1710	level of p-nitrophenyl sulfatase activity	[level of p-nitrophenyl sulfatase activity]	0.0	5	1	1	1
146707	1710	population in atopic patient	[populations in atopic patients]	0.0	4	1	1	1
146708	1710	steroidogram	[steroidogram]	0.0	1	1	1	1
146709	1710	factor nf-gm2 the other	[factor NF-GM2 the other]	0.0	4	1	1	1
146710	1710	il-2 cytokine	[IL-2 cytokines]	0.0	2	1	1	1
146711	1710	rapid effect on transmembrane electrolyte movement	[rapid effects on transmembrane electrolyte movements]	0.0	6	1	1	1
146712	1710	expression of p16 in normal lymphocyte	[expression of p16 in normal lymphocytes]	0.0	6	1	1	1
146713	1710	deficiency syndrome the other hot	[deficiency syndromes the other hot]	0.0	5	1	1	1
146714	1710	hyperactivity	[hyperactivity]	0.0	1	1	1	1
146715	1710	total protein content	[total protein content]	0.0	3	1	1	1
146716	1710	2.3-kb LCR	[2.3-kb LCR]	0.0	2	1	1	1
146717	1710	deflazacort	[deflazacort]	0.0	1	1	1	1
146718	1710	mediator of specific gene expression	[mediator of specific gene expression]	0.0	5	1	1	1
146719	1710	role in class gene regulation	[role in class gene regulation]	0.0	5	1	1	1
146720	1710	(p<.001) in patient than in person	[(P<.001) in patients than in persons]	0.0	6	1	1	1
146721	1710	Circadian rhythm of receptor in leukocyte	[Circadian rhythm of receptors in leukocytes]	0.0	6	1	1	1
146722	1710	major histocompatibility (MHC) class promoter	[major histocompatibility (MHC) class promoters]	0.0	5	1	1	1
146723	1710	function thyroid gland	[functioning thyroid gland]	0.0	3	1	1	1
146724	1710	low the/thf alpha thf/thf (0.35;	[low THE/THF alpha THF/THF (0.35;]	0.0	5	1	1	1
146725	1710	OM-10.1 model	[OM-10.1 model]	0.0	2	1	1	1
146726	1710	88% sequence identity	[88% sequence identity]	0.0	3	1	1	1
146727	1710	interleukin-2 nonresponsive state	[interleukin-2 nonresponsive state]	0.0	3	1	1	1
146728	1710	E2F -mediate	[E2F -mediated]	0.0	2	1	1	1
146729	1710	adolescent	[adolescents]	0.0	1	1	1	1
146730	1710	level of ige	[levels of IgE]	0.0	3	1	1	1
146731	1710	fetal-calf serum	[fetal-calf serum]	0.0	2	1	1	1
146732	1710	decrease by T cell	[decreases by T cells]	0.0	4	1	1	1
146733	1710	transcription from globin	[transcription from globin]	0.0	3	1	1	1
146734	1710	mucosa-associated lymphoid tissue lymphoma (19	[mucosa-associated lymphoid tissue lymphoma (19]	0.0	5	1	1	1
146735	1710	Fli-1 protein	[Fli-1 protein]	0.0	2	1	1	1
146736	1710	activation the expression	[activation the expression]	0.0	3	1	1	1
146737	1710	relation to leukemogenesis	[relation to leukemogenesis]	0.0	3	1	1	1
146738	1710	dual effect inhibition of growth	[dual effects inhibition of growth]	0.0	5	1	1	1
146739	1710	terminal repeat transcriptional activity	[terminal repeat transcriptional activity]	0.0	4	1	1	1
146740	1710	essential IL-2 response element	[essential IL-2 response element]	0.0	4	1	1	1
146741	1710	establish high-density pbmc culture in colony	[establishing high-density PBMC cultures in colonies]	0.0	6	1	1	1
146742	1710	work from several laboratory	[work from several laboratories]	0.0	4	1	1	1
146743	1710	competition between two transcriptional activator	[competition between two transcriptional activators]	0.0	5	1	1	1
146744	1710	vpr protein	[vpr protein]	0.0	2	1	1	1
146745	1710	inhibition evidence	[inhibition evidence]	0.0	2	1	1	1
146746	1710	quiescent state	[quiescent state]	0.0	2	1	1	1
146747	1710	lineage- expression of runt box polypeptide	[Lineage- expression of runt box polypeptides]	0.0	6	1	1	1
146748	1710	15 to 30 minute	[15 to 30 min]	0.0	4	1	1	1
146749	1710	Calcineurin a ca2+ protein phosphatase	[Calcineurin a Ca2+ protein phosphatase]	0.0	5	1	1	1
146750	1710	ebna-2 cell extract	[EBNA-2 cell extracts]	0.0	3	1	1	1
146751	1710	rt-pcr analysis,	[RT-PCR analysis,]	0.0	2	1	1	1
146752	1710	binding of nf-kb	[binding of NF-kB]	0.0	3	1	1	1
146753	1710	involve kinase c	[involving kinase C]	0.0	3	1	1	1
146754	1710	wild-type element	[wild-type elements]	0.0	2	1	1	1
146755	1710	tcr cross-linking	[TCR cross-linking]	0.0	2	1	1	1
146756	1710	phenotypic DC characteristic	[Phenotypic DC characteristics]	0.0	3	1	1	1
146757	1710	cd86 b7-2	[CD86 B7-2]	0.0	2	1	1	1
146758	1710	genomic IL-4 region for enhancer activity	[genomic IL-4 regions for enhancer activity]	0.0	6	1	1	1
146759	1710	predominantly T virus	[predominantly T virus]	0.0	3	1	1	1
146760	1710	increase-ratio (post/pre	[increase-ratios (post/pre]	0.0	2	1	1	1
146761	1710	impaired translocation	[impaired translocation]	0.0	2	1	1	1
146762	1710	mitogen-stimulated incorporation	[mitogen-stimulated incorporation]	0.0	2	1	1	1
146763	1710	low to level of c-jun	[low to levels of c-jun]	0.0	5	1	1	1
146764	1710	immunodeficiency virus-type 1 hiv-1	[immunodeficiency virus-type 1 HIV-1]	0.0	4	1	1	1
146765	1710	features: clinical implications.	[features: clinical implications.]	0.0	3	1	1	1
146766	1710	high affinity receptor for 1,25-dihydroxycholecalciferol calcitriol	[High affinity receptors for 1,25-dihydroxycholecalciferol calcitriol]	0.0	6	1	1	1
146767	1710	transcription at stage	[transcription at stages]	0.0	3	1	1	1
146768	1710	increase understanding of the pathway	[increasing understanding of the pathways]	0.0	5	1	1	1
146769	1710	mcd14 uptake of lps produce enhancement	[mCD14 uptake of LPS producing enhancement]	0.0	6	1	1	1
146770	1710	tumor necrosis factor-alpha ng/ml)	[tumor necrosis factor-alpha ng/ml)]	0.0	4	1	1	1
146771	1710	inducible complex resemble factor	[inducible complex resembling factor]	0.0	4	1	1	1
146772	1710	human dimeric tnf receptor	[human dimeric TNF receptor]	0.0	4	1	1	1
146773	1710	fibrosarcoma malignant fibrous histiocytoma 6, rhabdomyosarcoma	[fibrosarcoma malignant fibrous histiocytoma 6, rhabdomyosarcoma]	0.0	6	1	1	1
146774	1710	endometrium from woman with endometriosis	[endometrium from women with endometriosis]	0.0	5	1	1	1
146775	1710	lymphoid line	[lymphoid lines]	0.0	2	1	1	1
146776	1710	expression of monkey glucocorticoid receptor	[Expressions of monkey glucocorticoid receptors]	0.0	5	1	1	1
146777	1710	glucocorticoid responsiveness of mononuclear leukocyte	[glucocorticoid responsiveness of mononuclear leukocytes]	0.0	5	1	1	1
146778	1710	glutathione peroxidase	[glutathione peroxidase]	0.0	2	1	1	1
146779	1710	regard the process	[regarding the processes]	0.0	3	1	1	1
146780	1710	syndrome with severe hyperkalemia	[syndrome with severe hyperkalemia]	0.0	4	1	1	1
146781	1710	wild-type retinoic acid receptor alpha	[wild-type retinoic acid receptor alpha]	0.0	5	1	1	1
146782	1710	active extract	[active extracts]	0.0	2	1	1	1
146783	1710	helix loop helix zipper transcription factor	[helix loop helix zipper transcription factors]	0.0	6	1	1	1
146784	1710	gene therapy strategy	[gene therapy strategies]	0.0	3	1	1	1
146785	1710	new creb complex	[new CREB complexes]	0.0	3	1	1	1
146786	1710	phyto- hemagglutinin pha blood lymphocyte	[phyto- hemagglutinin PHA blood lymphocytes]	0.0	5	1	1	1
146787	1710	protein with homology	[protein with homology]	0.0	3	1	1	1
146788	1710	suggest effective in the hemodynamic phase	[suggesting effective in the hemodynamic phase]	0.0	6	1	1	1
146789	1710	terminal repeat CAT construct	[terminal repeat CAT constructs]	0.0	4	1	1	1
146790	1710	functionally different activation domain	[functionally different activation domains]	0.0	4	1	1	1
146791	1710	cause the haploinsufficiency	[causing the haploinsufficiency]	0.0	3	1	1	1
146792	1710	look back in approach treat IBD	[Looking back in approaches treating IBD]	0.0	6	1	1	1
146793	1710	four direct repeat DR	[four direct repeats DR]	0.0	4	1	1	1
146794	1710	evidence to observation	[evidence to observations]	0.0	3	1	1	1
146795	1710	nuclear factor in vivo	[nuclear factor in vivo]	0.0	4	1	1	1
146796	1710	a and/or protein kinase	[A and/or protein kinase]	0.0	4	1	1	1
146797	1710	effect of C3a on induction	[effects of C3a on induction]	0.0	5	1	1	1
146798	1710	P. with bcr1/25	[P. with BCR1/25]	0.0	3	1	1	1
146799	1710	stimulation by dose of peptide	[Stimulation by doses of peptide]	0.0	5	1	1	1
146800	1710	(h292) cell-line	[(H292) cell-line]	0.0	2	1	1	1
146801	1710	time of h for serum-supplemented culture	[times of h for serum-supplemented cultures]	0.0	6	1	1	1
146802	1710	cleft of VIIa	[cleft of VIIa]	0.0	3	1	1	1
146803	1710	ca2+ chelator	[Ca2+ chelator]	0.0	2	1	1	1
146804	1710	possibly through binding	[possibly through binding]	0.0	3	1	1	1
146805	1710	secretion of the lymphokine interleukin-1beta	[secretion of the lymphokine interleukin-1beta]	0.0	5	1	1	1
146806	1710	1-2 h	[1-2 h]	0.0	2	1	1	1
146807	1710	protein 1/octamer-binding	[protein 1/octamer-binding]	0.0	2	1	1	1
146808	1710	large variety of inducers,	[large variety of inducers,]	0.0	4	1	1	1
146809	1710	nf-kappab -dependent activation terminal repeat	[NF-kappaB -dependent activation terminal repeat]	0.0	5	1	1	1
146810	1710	consensus element	[consensus elements]	0.0	2	1	1	1
146811	1710	use a luciferase encoding vector	[using a luciferase encoding vector]	0.0	5	1	1	1
146812	1710	critical tool for sensitive monitoring	[critical tools for sensitive monitoring]	0.0	5	1	1	1
146813	1710	thus a therapeutic target in state	[thus a therapeutic target in states]	0.0	6	1	1	1
146814	1710	function of such protein	[function of such proteins]	0.0	4	1	1	1
146815	1710	likely components.	[likely components.]	0.0	2	1	1	1
146816	1710	il-2 promoter transcription	[IL-2 promoter transcription]	0.0	3	2	2	1
146817	1710	c-fos/c-jun gene	[c-fos/c-jun genes]	0.0	2	1	1	1
146818	1710	inhibition of stat3	[inhibition of STAT3]	0.0	3	1	1	1
146819	1710	sensitivity to dexamethasone: potential regulation	[sensitivity to dexamethasone: potential regulation]	0.0	5	1	1	1
146820	1710	p50/	[p50/]	0.0	1	1	1	1
146821	1710	activator tcf-1 t-cell factor-1	[activator TCF-1 T-Cell Factor-1]	0.0	4	1	1	1
146822	1710	tissue-specific splicing in nfatx isoform	[tissue-specific splicing in NFATx isoforms]	0.0	5	1	1	1
146823	1710	female patient with acne	[female patients with acne]	0.0	4	1	1	1
146824	1710	regulation of glucocorticoid receptor in cell	[Regulation of glucocorticoid receptors in cells]	0.0	6	1	1	1
146825	1710	specific antibody from healthy carrier	[specific antibodies from healthy carriers]	0.0	5	1	1	1
146826	1710	alloreactive T cell line	[alloreactive T cell lines]	0.0	4	1	1	1
146827	1710	new avenue in acute leukemia	[new avenue in acute leukemia]	0.0	5	1	1	1
146828	1710	CST3	[CST3]	0.0	1	1	1	1
146829	1710	transcription of the long repeat	[transcription of the long repeats]	0.0	5	1	1	1
146830	1710	least one other gene	[least one other gene]	0.0	4	1	1	1
146831	1710	histocompatibility complex (mhc) class antigen	[histocompatibility complex (MHC) class antigens]	0.0	5	3	3	1
146832	1710	growth response gene-1	[growth response gene-1]	0.0	3	1	1	1
146833	1710	linkage 10 polymorphism to condition	[linkage 10 polymorphism to conditions]	0.0	5	1	1	1
146834	1710	constitutive activation of Egr-1 gene	[constitutive activation of Egr-1 gene]	0.0	5	1	1	1
146835	1710	type ii EBS level	[type II EBS levels]	0.0	4	1	1	1
146836	1710	c/ebp-beta site	[C/EBP-beta site]	0.0	2	1	1	1
146837	1710	unknown, effector molecule	[unknown, effector molecule]	0.0	3	1	1	1
146838	1710	unconventional cell surface receptor	[unconventional cell surface receptors]	0.0	4	1	1	1
146839	1710	three, DNA variation in tumor	[three, DNA variations in tumor]	0.0	5	1	1	1
146840	1710	target in early b-cell development	[target in early B-cell development]	0.0	5	1	1	1
146841	1710	stage-specificity	[stage-specificity]	0.0	1	1	1	1
146842	1710	such as intercellular adhesion molecule-1	[such as intercellular adhesion molecule-1]	0.0	5	1	1	1
146843	1710	sequence within the AU-rich element	[sequences within the AU-rich elements]	0.0	5	1	1	1
146844	1710	islet encode jun-B	[islet encoding jun-B]	0.0	3	1	1	1
146845	1710	FCS- culture	[FCS- culture]	0.0	2	1	1	1
146846	1710	risk factor for disease	[risk factor for disease]	0.0	4	1	1	1
146847	1710	maturation defect	[maturation defects]	0.0	2	1	1	1
146848	1710	c-fo /c-Jun heterodimer in cell	[c-Fos /c-Jun heterodimers in cells]	0.0	5	1	1	1
146849	1710	dual function of this protein	[dual function of this protein]	0.0	5	1	1	1
146850	1710	cell common	[cell common]	0.0	2	1	1	1
146851	1710	downstream nf-kappab activation of repeat LTR	[downstream NF-kappaB activation of repeat LTR]	0.0	6	1	1	1
146852	1710	p55/	[p55/]	0.0	1	1	1	1
146853	1710	agonist WY of cell	[agonist WY of cells]	0.0	4	1	1	1
146854	1710	endotoxin lps signal transduction	[Endotoxin LPS signal transduction]	0.0	4	1	1	1
146855	1710	tetrahydrocortisone 3.16 mg/24h; n: excretion,	[tetrahydrocortisone 3.16 mg/24h; N: excretion,]	0.0	5	1	1	1
146856	1710	cell response to amebic infection	[cell responses to amebic infection]	0.0	5	1	1	1
146857	1710	follow consolidation	[following consolidation]	0.0	2	1	1	1
146858	1710	768-bp negative region	[768-bp negative region]	0.0	3	1	1	1
146859	1710	least some aspect	[least some aspects]	0.0	3	1	1	1
146860	1710	immunodeficiency virus type hiv-1 tat protein	[immunodeficiency virus type HIV-1 Tat protein]	0.0	6	1	1	1
146861	1710	phosphorylation in	[phosphorylation in]	0.0	2	1	1	1
146862	1710	u937 cell to ec	[U937 cells to EC]	0.0	4	1	1	1
146863	1710	immunofluorescence study on population of mouse	[Immunofluorescence studies on populations of mice]	0.0	6	1	1	1
146864	1710	multifactor cis-dominant negative regulation	[Multifactor cis-dominant negative regulation]	0.0	4	1	1	1
146865	1710	sensitivity of monocyte	[sensitivity of monocytes]	0.0	3	1	1	1
146866	1710	thin-layer	[thin-layer]	0.0	1	1	1	1
146867	1710	human cell from peripheral blood	[human cells from peripheral blood]	0.0	5	1	1	1
146868	1710	Interferon factor 2	[Interferon factor 2]	0.0	3	1	1	1
146869	1710	repeat of this retrovirus	[repeat of this retrovirus]	0.0	4	1	1	1
146870	1710	produce a human retrovirus	[producing a human retrovirus]	0.0	4	1	1	1
146871	1710	differentiation stage of granulocyte	[differentiation stages of granulocytes]	0.0	4	1	1	1
146872	1710	peptide represent amino acid sequence	[peptides representing amino acid sequences]	0.0	5	1	1	1
146873	1710	1 tax -responsive element	[1 Tax -responsive element]	0.0	4	1	1	1
146874	1710	gene with expression pattern	[genes with expression patterns]	0.0	4	1	1	1
146875	1710	Sp family	[Sp family]	0.0	2	1	1	1
146876	1710	bear STLV-I	[bearing STLV-I]	0.0	2	1	1	1
146877	1710	b gamma-2	[B gamma-2]	0.0	2	1	1	1
146878	1710	b gamma-1	[B gamma-1]	0.0	2	1	1	1
146879	1710	binding of interferon-gamma to heterodimeric receptor	[Binding of interferon-gamma to heterodimeric receptor]	0.0	6	1	1	1
146880	1710	pi3-k construct	[PI3-K constructs]	0.0	2	1	1	1
146881	1710	include estrogen receptor	[including estrogen receptor]	0.0	3	1	1	1
146882	1710	analysis of whole-cell lysate	[Analysis of whole-cell lysates]	0.0	4	1	1	1
146883	1710	part of a set	[part of a set]	0.0	4	1	1	1
146884	1710	tissue factor the initiator	[tissue factor the initiator]	0.0	4	1	1	1
146885	1710	only by a assay with peptide	[only by an assay with peptides]	0.0	6	1	1	1
146886	1710	alternative transcript encode	[alternative transcript encoding]	0.0	3	1	1	1
146887	1710	Cbl-b activation	[Cbl-b activation]	0.0	2	1	1	1
146888	1710	merge point	[merging point]	0.0	2	1	1	1
146889	1710	lead to severity	[leading to severity]	0.0	3	1	1	1
146890	1710	D3 calcitriol determination	[D3 calcitriol determination]	0.0	3	1	1	1
146891	1710	adenovirus e1a gene	[adenovirus E1A genes]	0.0	3	2	2	1
146892	1710	glucocorticoid receptor present in extract	[glucocorticoid receptor present in extracts]	0.0	5	1	1	1
146893	1710	follow PHA stimulation	[Following PHA stimulation]	0.0	3	1	1	1
146894	1710	long repeat nf-kappa b	[long repeat NF-kappa B]	0.0	4	1	1	1
146895	1710	increase peak	[increase peaking]	0.0	2	1	1	1
146896	1710	mature platelet function	[mature platelet function]	0.0	3	1	1	1
146897	1710	-ligand	[-ligand]	0.0	1	1	1	1
146898	1710	protein kinase c isoform result	[protein kinase C isoforms resulting]	0.0	5	1	1	1
146899	1710	signal transduce component	[signal transducing component]	0.0	3	1	1	1
146900	1710	weight gain +/- 2 (pre)	[weight gain +/- 2 (pre)]	0.0	5	1	1	1
146901	1710	genetic entity	[genetic entity]	0.0	2	1	1	1
146902	1710	picture of pseudohypoaldosteronism	[picture of pseudohypoaldosteronism]	0.0	3	1	1	1
146903	1710	role of the expression	[role of the expression]	0.0	4	1	1	1
146904	1710	peptide Arg-Gly-Asp RGD	[peptide Arg-Gly-Asp RGD]	0.0	3	1	1	1
146905	1710	encode for growth factor	[encoding for growth factors]	0.0	4	1	1	1
146906	1710	basis for specificity	[basis for specificity]	0.0	3	1	1	1
146907	1710	complete amino acid sequence identity	[complete amino acid sequence identity]	0.0	5	1	1	1
146908	1710	-150 bp	[-150 bp]	0.0	2	2	2	1
146909	1710	two active nfat-like element	[two active NFAT-like elements]	0.0	4	1	1	1
146910	1710	decrease in mineralocorticoid (mr)	[decreases in mineralocorticoid (MR)]	0.0	4	1	1	1
146911	1710	surface il-4r	[surface IL-4R]	0.0	2	1	1	1
146912	1710	low number false (positive)	[low number false (positive)]	0.0	4	1	1	1
146913	1710	finger transcription	[finger transcription]	0.0	2	1	1	1
146914	1710	sequence in the promoter region	[sequences in the promoter region]	0.0	5	1	1	1
146915	1710	incubation increase concentration	[incubation increasing concentrations]	0.0	3	1	1	1
146916	1710	increase-ratio (post/pre ratio) of Bmax	[increase-ratios (post/pre ratio) of Bmax]	0.0	5	1	1	1
146917	1710	(39.9% of cd3+	[(39.9% of CD3+]	0.0	3	1	1	1
146918	1710	stochastic activation	[stochastic activation]	0.0	2	1	1	1
146919	1710	level of beta-catenin	[levels of beta-catenin]	0.0	3	1	1	1
146920	1710	condition such as disease	[conditions such as diseases]	0.0	4	1	1	1
146921	1710	disease of patient with leukemia AML	[disease of patients with leukemia AML]	0.0	6	1	1	1
146922	1710	two structurally distinct, novel inhibitor	[two structurally distinct, novel inhibitors]	0.0	5	1	1	1
146923	1710	extracellular signal often converge	[extracellular signals often converging]	0.0	4	1	1	1
146924	1710	transendothelial migration of 48-hr antigen t-cell	[transendothelial migration of 48-hr antigen T-cells]	0.0	6	1	1	1
146925	1710	subpopulation of cd4+ cell capable	[subpopulation of CD4+ cells capable]	0.0	5	1	1	1
146926	1710	ppar activator 15-deoxy-delta(12,14)-prostaglandin j(2) 15d-PGJ(2)	[PPAR activators 15-deoxy-Delta(12,14)-prostaglandin J(2) 15d-PGJ(2)]	0.0	5	1	1	1
146927	1710	cytoplasmic retention of p65	[cytoplasmic retention of p65]	0.0	4	1	1	1
146928	1710	peak at 24 h	[peak at 24 h]	0.0	4	1	1	1
146929	1710	moreover, STAT3 antibody	[Moreover, STAT3 antibodies]	0.0	3	1	1	1
146930	1710	role mediate adhesion	[role mediating adhesion]	0.0	3	1	1	1
146931	1710	small lipophilic substance	[small lipophilic substances]	0.0	3	1	1	1
146932	1710	activation a vascular antiatherogenic mechanism	[activation A vascular antiatherogenic mechanism]	0.0	5	1	1	1
146933	1710	effect in vitro.	[effects in vitro.]	0.0	3	1	1	1
146934	1710	interaction occur between HHV-6	[interactions occurring between HHV-6]	0.0	4	1	1	1
146935	1710	compare the effect	[comparing the effects]	0.0	3	1	1	1
146936	1710	degree in cellular immunity	[degree in cellular immunity]	0.0	4	1	1	1
146937	1710	linkage polymorphism to physiological condition	[linkage polymorphism to physiological conditions]	0.0	5	1	1	1
146938	1710	ca2+ ]i	[Ca2+ ]i]	0.0	2	1	1	1
146939	1710	inhibitor in blood lymphocyte culture	[inhibitors in blood lymphocyte cultures]	0.0	5	1	1	1
146940	1710	lack of level of Spi-B	[lack of levels of Spi-B]	0.0	5	1	1	1
146941	1710	isgf3 activity	[ISGF3 activity]	0.0	2	1	1	1
146942	1710	clone-13	[clone-13]	0.0	1	1	1	1
146943	1710	subunit in particular, the b2 isoform	[subunit in particular, the B2 isoform]	0.0	6	1	1	1
146944	1710	displacement of estradiol	[displacement of estradiol]	0.0	3	1	1	1
146945	1710	temperature degree c)	[temperature degrees C)]	0.0	3	1	1	1
146946	1710	nuclear appearance of transcription factor	[nuclear appearance of transcription factors]	0.0	5	1	1	1
146947	1710	progenitor to cell DC	[progenitors to cells DC]	0.0	4	1	1	1
146948	1710	overexpression of this protein.	[overexpression of this protein.]	0.0	4	1	1	1
146949	1710	deletion construct in k562 cell	[deletion constructs in K562 cells]	0.0	5	1	1	1
146950	1710	reflect difference in sensitivity	[reflecting differences in sensitivity]	0.0	4	1	1	1
146951	1710	heterogeneous population progenitor	[heterogeneous populations progenitors]	0.0	3	1	1	1
146952	1710	mechanism for transduction	[Mechanisms for transduction]	0.0	3	1	1	1
146953	1710	treatment prior to treatment with PAO	[Treatment prior to treatment with PAO]	0.0	6	1	1	1
146954	1710	2 line	[2 lines]	0.0	2	1	1	1
146955	1710	multiple cytoplasmic inhibitor	[multiple cytoplasmic inhibitors]	0.0	3	1	1	1
146956	1710	rat smooth muscle cell	[rat smooth muscle cells]	0.0	4	1	1	1
146957	1710	amino acid difference	[amino acid differences]	0.0	3	1	1	1
146958	1710	transcription factor with tre-1	[transcription factors with TRE-1]	0.0	4	1	1	1
146959	1710	twenty two healthy man	[Twenty two healthy men]	0.0	4	1	1	1
146960	1710	N-terminus	[N-terminus]	0.0	1	1	1	1
146961	1710	cytokine signal in patient	[cytokine signaling in patients]	0.0	4	1	1	1
146962	1710	interaction of calcineurin with nfatp	[interaction of calcineurin with NFATp]	0.0	5	1	1	1
146963	1710	c-jun by H2O2	[c-jun by H2O2]	0.0	3	1	1	1
146964	1710	also a effector of lmp-1 signal	[also an effector of LMP-1 signaling]	0.0	6	1	1	1
146965	1710	induction during a response,	[induction during an response,]	0.0	4	1	1	1
146966	1710	14-day colony	[14-day colonies]	0.0	2	1	1	1
146967	1710	other immunosuppressive drug	[other immunosuppressive drugs]	0.0	3	1	1	1
146968	1710	0.5 microgram/day for month	[0.5 microgram/day for month]	0.0	4	1	1	1
146969	1710	inducible, T enhancer	[inducible, T enhancers]	0.0	3	1	1	1
146970	1710	seventeen patient	[seventeen patients]	0.0	2	1	1	1
146971	1710	serum-contain adherent colony	[serum-containing adherent colonies]	0.0	3	1	1	1
146972	1710	much high concentration of type peptide	[Much higher concentrations of type peptides]	0.0	6	1	1	1
146973	1710	active dimer	[active dimer]	0.0	2	1	1	1
146974	1710	/macrophage	[/macrophage]	0.0	1	1	1	1
146975	1710	decrease in membrane order	[decrease in membrane order]	0.0	4	1	1	1
146976	1710	nuclear factor of kappab	[nuclear factor of kappaB]	0.0	4	1	1	1
146977	1710	result in the lack	[resulting in the lack]	0.0	4	1	1	1
146978	1710	contribute to response to therapy	[contributing to response to therapy]	0.0	5	1	1	1
146979	1710	effectiveness of ciita	[effectiveness of CIITA]	0.0	3	1	1	1
146980	1710	transcription factor generation	[transcription factor generation]	0.0	3	1	1	1
146981	1710	tf expression datum	[TF expression data]	0.0	3	1	1	1
146982	1710	number of false positive prediction	[number of false positive predictions]	0.0	5	1	1	1
146983	1710	class of signal molecule	[classes of signaling molecules]	0.0	4	1	1	1
146984	1710	Differential interaction	[Differential interaction]	0.0	2	2	2	1
146985	1710	resemble a dbd	[resembling a DBD]	0.0	3	1	1	1
146986	1710	concomitant migration	[concomitant migration]	0.0	2	1	1	1
146987	1710	human activator	[human activators]	0.0	2	1	1	1
146988	1710	role for metabolic acidosis	[role for metabolic acidosis]	0.0	4	1	1	1
146989	1710	eosinophil infiltrate	[eosinophils infiltrating]	0.0	2	1	1	1
146990	1710	allosteric effect	[allosteric effect]	0.0	2	1	1	1
146991	1710	covalently p35	[covalently p35]	0.0	2	1	1	1
146992	1710	pHU-14 a probe	[pHU-14 a probe]	0.0	3	1	1	1
146993	1710	protein of 150 kD	[protein of 150 kD]	0.0	4	1	1	1
146994	1710	status after conservative surgery comparison	[status after conservative surgery comparison]	0.0	5	1	1	1
146995	1710	12-O-tetradecanoylphorbol-13-acetate differentiation, with c-jun expression	[12-O-tetradecanoylphorbol-13-acetate differentiation, with c-jun expression]	0.0	5	1	1	1
146996	1710	ubiquitous factor such as NF-kappa b	[ubiquitous factors such as NF-kappa B]	0.0	6	1	1	1
146997	1710	diabete mellitus patient	[diabetes mellitus patients]	0.0	3	1	1	1
146998	1710	detergent lysate	[detergent lysates]	0.0	2	1	1	1
146999	1710	Peripheral T lymphocyte	[Peripheral T lymphocytes]	0.0	3	1	1	1
147000	1710	binding motif by site-directed mutagenesis	[binding motifs by site-directed mutagenesis]	0.0	5	1	1	1
147001	1710	human genomic sterol regulatory element	[human genomic sterol regulatory element]	0.0	5	1	1	1
147002	1710	pafr transcript leukocyte-type	[PAFR transcript leukocyte-type]	0.0	3	1	1	1
147003	1710	include human immunodeficiency virus gene	[including human immunodeficiency virus genes]	0.0	5	1	1	1
147004	1710	substitution on c-11 of 1 alpha,25-(OH)2D3	[substitutions on C-11 of 1 alpha,25-(OH)2D3]	0.0	6	1	1	1
147005	1710	cytokine tnf	[cytokines TNF]	0.0	2	1	1	1
147006	1710	selective agonist	[selective agonist]	0.0	2	1	1	1
147007	1710	presence of polyclonal granulocyte	[presence of polyclonal granulocytes]	0.0	4	1	1	1
147008	1710	however, (66 millileter at P;	[However, (66 ml at h;]	0.0	5	1	1	1
147009	1710	specific protein kinase c	[specific protein kinase C]	0.0	4	1	1	1
147010	1710	epithelial cell inflammatory response to infection	[epithelial cell inflammatory responses to infection]	0.0	6	1	1	1
147011	1710	antibody lt-4	[antibody Lt-4]	0.0	2	1	1	1
147012	1710	regulation kappa b alpha	[Regulation kappa B alpha]	0.0	4	1	1	1
147013	1710	induction of b/rel activity	[induction of B/Rel activity]	0.0	4	1	1	1
147014	1710	comparing, in cases, DNA	[comparing, in cases, DNA]	0.0	4	1	1	1
147015	1710	ebna-lp	[EBNA-LP]	0.0	1	1	1	1
147016	1710	two open reading frame a	[two open reading frames A]	0.0	5	1	1	1
147017	1710	alter the physiologic status	[altering the physiologic status]	0.0	4	1	1	1
147018	1710	crossreactive recognition	[Crossreactive recognition]	0.0	2	1	1	1
147019	1710	expression of ig ligand	[expression of Ig ligand]	0.0	4	1	1	1
147020	1710	proximal signal event dependent	[proximal signaling events dependent]	0.0	4	1	1	1
147021	1710	closely cell	[closely cells]	0.0	2	1	1	1
147022	1710	effect of tgf-beta1	[effect of TGF-beta1]	0.0	3	2	2	1
147023	1710	sr-bp high for sr 31747a	[SR-BP higher for SR 31747A]	0.0	5	1	1	1
147024	1710	reduction in bind affinity	[reduction in binding affinity]	0.0	4	1	1	1
147025	1710	dominant effect on the trans-activation	[dominant effect on the trans-activation]	0.0	5	1	1	1
147026	1710	leukocyte from abdominal subject	[leukocytes from abdominal subjects]	0.0	4	1	1	1
147027	1710	heterodimer nf-kappa b	[heterodimer NF-kappa B]	0.0	3	1	1	1
147028	1710	lack the binding site for RBP-Jkappa	[lacking the binding site for RBP-Jkappa]	0.0	6	1	1	1
147029	1710	murine macrophage protein alpha mip-1 alpha	[Murine macrophage protein alpha MIP-1 alpha]	0.0	6	1	1	1
147030	1710	tissue-specific transcriptional control	[tissue-specific transcriptional control]	0.0	3	1	1	1
147031	1710	crucial regulatory event	[crucial regulatory events]	0.0	3	1	1	1
147032	1710	intraspecy hybrid	[intraspecies hybrids]	0.0	2	1	1	1
147033	1710	role for BCL-6	[role for BCL-6]	0.0	3	1	1	1
147034	1710	Gene for a activator	[Gene for a activator]	0.0	4	1	1	1
147035	1710	tax protein a activator	[Tax protein a activator]	0.0	4	1	1	1
147036	1710	constitutively active form of cn	[constitutively active forms of CN]	0.0	5	1	1	1
147037	1710	induction of M-CSF	[induction of M-CSF]	0.0	3	1	1	1
147038	1710	cell in hypoxia	[cells in hypoxia]	0.0	3	1	1	1
147039	1710	induction of differentiation 1 infection	[Induction of differentiation 1 infection]	0.0	5	1	1	1
147040	1710	possibly other organ	[possibly other organs]	0.0	3	1	1	1
147041	1710	source of il-4	[source of IL-4]	0.0	3	1	1	1
147042	1710	-express r59z activator cell	[-expressing R59Z activator cells]	0.0	4	1	1	1
147043	1710	loss of susceptibility to apoptosis	[Loss of susceptibility to apoptosis]	0.0	5	1	1	1
147044	1710	contain low level	[containing low levels]	0.0	3	1	1	1
147045	1710	four different specific NF-kappaB complex	[four different specific NF-kappaB complexes]	0.0	5	1	1	1
147046	1710	repeat of the Kruppel-like zinc-finger motif	[repeats of the Kruppel-like zinc-finger motif]	0.0	6	1	1	1
147047	1710	viable definitive cell	[viable definitive cells]	0.0	3	1	1	1
147048	1710	appearance of NF-kappaB	[appearance of NF-kappaB]	0.0	3	1	1	1
147049	1710	granule contain gelatinase	[granules containing gelatinase]	0.0	3	1	1	1
147050	1710	proliferation of hemopoietic cells.	[proliferation of hemopoietic cells.]	0.0	4	1	1	1
147051	1710	immunity against infectious pathogen	[immunity against infectious pathogens]	0.0	4	1	1	1
147052	1710	e(2) receptor-positive murine line,	[E(2) receptor-positive murine line,]	0.0	4	1	1	1
147053	1710	cell line nb4 leukemia	[cell lines NB4 leukemia]	0.0	4	1	1	1
147054	1710	reciprocal elevation	[reciprocal elevation]	0.0	2	1	1	1
147055	1710	myelomonocytic cell lines.	[myelomonocytic cell lines.]	0.0	3	1	1	1
147056	1710	utilize this transcription factor	[utilizing these transcription factors]	0.0	4	1	1	1
147057	1710	important cellular	[important cellular]	0.0	2	1	1	1
147058	1710	aldosterone antagonist canrenone	[aldosterone antagonist canrenone]	0.0	3	1	1	1
147059	1710	bipotential cell population	[bipotential cell population]	0.0	3	1	1	1
147060	1710	nf-kappa b -dependent	[NF-kappa B -dependent]	0.0	3	1	1	1
147061	1710	biology study	[biology study]	0.0	2	1	1	1
147062	1710	positive selection antigen-driven clonal expansion)	[positive selection antigen-driven clonal expansion)]	0.0	5	1	1	1
147063	1710	involve interaction between positive regulatory element	[involving interactions between positive regulatory elements]	0.0	6	1	1	1
147064	1710	hla-dq allele with autoimmunity	[HLA-DQ alleles with autoimmunity]	0.0	4	1	1	1
147065	1710	secretion of human macrophage protein-1alpha	[secretion of human macrophage protein-1alpha]	0.0	5	1	1	1
147066	1710	mutant Jak1 HeLa cell line	[mutant Jak1 HeLa cell line]	0.0	5	1	1	1
147067	1710	il-1beta promoter CAT activity	[IL-1beta promoter CAT activity]	0.0	4	1	1	1
147068	1710	interrelation between the system	[Interrelations between the system]	0.0	4	1	1	1
147069	1710	surprisingly high replicative capacity	[surprisingly high replicative capacity]	0.0	4	1	1	1
147070	1710	synthetic oligonucleotide corresponding	[synthetic oligonucleotides corresponding]	0.0	3	1	1	1
147071	1710	(gC)	[(gC)]	0.0	1	1	1	1
147072	1710	trypsin -resistant fragment	[trypsin -resistant fragments]	0.0	3	1	1	1
147073	1710	gc abnormality	[GC abnormality]	0.0	2	1	1	1
147074	1710	antioxidant druilkience pyrrolidine dithiocarbamate	[antioxidant drug, pyrrolidine dithiocarbamate]	0.0	4	1	1	1
147075	1710	initial diameter, corresponding	[initial diameter, corresponding]	0.0	3	1	1	1
147076	1710	neutralize csf-1r monoclonal antibody	[neutralizing CSF-1R monoclonal antibodies]	0.0	4	1	1	1
147077	1710	lps nuclear factor-kappaB nf-kappab	[LPS nuclear factor-kappaB NF-kappaB]	0.0	4	1	1	1
147078	1710	promising avenue of therapy	[promising avenue of therapy]	0.0	4	1	1	1
147079	1710	isoforms, GRalpha	[isoforms, GRalpha]	0.0	2	1	1	1
147080	1710	level of b1 encoding transcript	[levels of B1 encoding transcripts]	0.0	5	1	1	1
147081	1710	estrogen -binding site type-II EBS	[estrogen -binding sites type-II EBS]	0.0	5	1	1	1
147082	1710	CBF alpha2	[CBF alpha2]	0.0	2	1	1	1
147083	1710	stimulate peripheral blood cell	[stimulating peripheral blood cells]	0.0	4	1	1	1
147084	1710	(fc)	[(FC)]	0.0	1	1	1	1
147085	1710	RB lines.	[RB lines.]	0.0	2	1	1	1
147086	1710	activation domain,	[activation domain,]	0.0	2	1	1	1
147087	1710	NFAT -1 complex	[NFAT -1 complex]	0.0	3	1	1	1
147088	1710	Effect of prostaglandin e2 modulation	[Effects of prostaglandin E2 modulation]	0.0	5	1	1	1
147089	1710	use different experimental approach	[using different experimental approaches]	0.0	4	1	1	1
147090	1710	GCR-beta -immunoreactive cell in blood	[GCR-beta -immunoreactive cells in blood]	0.0	5	1	1	1
147091	1710	extract of lymphoid cell	[extracts of lymphoid cells]	0.0	4	1	1	1
147092	1710	response to different signal	[response to different signals]	0.0	4	1	1	1
147093	1710	enhancement of dna-binding	[enhancement of DNA-binding]	0.0	3	1	1	1
147094	1710	Epstein-Barr region (EBER)	[Epstein-Barr region (EBER)]	0.0	3	1	1	1
147095	1710	indicate a pattern	[indicating a pattern]	0.0	3	1	1	1
147096	1710	individual reactivity	[individual reactivity]	0.0	2	1	1	1
147097	1710	b species in cell	[B species in cells]	0.0	4	1	1	1
147098	1710	3-fold less CAT activity	[3-fold less CAT activity]	0.0	4	1	1	1
147099	1710	pit-1	[Pit-1]	0.0	1	1	1	1
147100	1710	select genetic aberration	[select genetic aberrations]	0.0	3	1	1	1
147101	1710	m D3 induce monocyte differentiation	[M D3 inducing monocyte differentiation]	0.0	5	1	1	1
147102	1710	prothrombinase	[prothrombinase]	0.0	1	1	1	1
147103	1710	accumulation result	[accumulation resulting]	0.0	2	1	1	1
147104	1710	outcome of antigen processing	[outcome of antigen processing]	0.0	4	1	1	1
147105	1710	glucocorticoid receptor gr in lymphocyte	[glucocorticoid receptors GR in lymphocytes]	0.0	5	1	1	1
147106	1710	regulation of two repressor	[regulation of two repressors]	0.0	4	1	1	1
147107	1710	interestingly, a potent activator	[Interestingly, a potent activator]	0.0	4	1	1	1
147108	1710	extracellular matrice	[extracellular matrices]	0.0	2	1	1	1
147109	1710	line with the long-standing notion	[line with the long-standing notion]	0.0	5	1	1	1
147110	1710	regulate multiple stage B	[regulating multiple stages B]	0.0	4	1	1	1
147111	1710	artery specimen	[artery specimens]	0.0	2	1	1	1
147112	1710	membrane from human mononuclear leukocyte	[membranes from human mononuclear leukocytes]	0.0	5	1	1	1
147113	1710	mediator of stress activation	[mediator of stress activation]	0.0	4	1	1	1
147114	1710	interaction with two region	[interaction with two regions]	0.0	4	1	1	1
147115	1710	embryonic development abnormality	[embryonic development abnormalities]	0.0	3	1	1	1
147116	1710	expression of gene in ctll-2	[expression of genes in CTLL-2]	0.0	5	1	1	1
147117	1710	awareness of avascular necrosis	[awareness of avascular necrosis]	0.0	4	1	1	1
147118	1710	NH2-terminal 126 amino acid	[NH2-terminal 126 amino acids]	0.0	4	1	1	1
147119	1710	consequence of a gssg deficiency	[consequence of a GSSG deficiency]	0.0	5	1	1	1
147120	1710	pure recombinant p21ras	[pure recombinant p21ras]	0.0	3	1	1	1
147121	1710	hemopoietic system	[hemopoietic systems]	0.0	2	1	1	1
147122	1710	kappa 3/cre	[kappa 3/CRE]	0.0	2	1	1	1
147123	1710	activator of NF-kappaB a member	[activator of NF-kappaB a member]	0.0	5	1	1	1
147124	1710	chronic leukaemia CLL	[chronic leukaemia CLL]	0.0	3	1	1	1
147125	1710	induce CAT activity by 2.6-fold, fibrinogen	[inducing CAT activity by 2.6-fold, fibrinogen]	0.0	6	1	1	1
147126	1710	recurrence of tumor	[recurrence of tumors]	0.0	3	1	1	1
147127	1710	IL-10 activity	[IL-10 activity]	0.0	2	1	1	1
147128	1710	two elf-2 transcript	[two elf-2 transcripts]	0.0	3	1	1	1
147129	1710	control of factor-kappa b activation role	[control of factor-kappa B activation role]	0.0	6	1	1	1
147130	1710	oestrogen receptor er analysis in leukemia	[Oestrogen receptor ER analysis in leukemia]	0.0	6	1	1	1
147131	1710	demonstration of nfatp dephosphorylation	[demonstration of NFATp dephosphorylation]	0.0	4	1	1	1
147132	1710	early event in inflammation	[early event in inflammation]	0.0	4	1	1	1
147133	1710	Epstein-Barr virus antigen a protein	[Epstein-Barr virus antigen a protein]	0.0	5	1	1	1
147134	1710	cell-specific role	[Cell-specific role]	0.0	2	1	1	1
147135	1710	member of the factor family	[members of the factor family]	0.0	5	1	1	1
147136	1710	manner between 2	[manner between 2]	0.0	3	1	1	1
147137	1710	chronic leukaemia CML	[chronic leukaemia CML]	0.0	3	1	1	1
147138	1710	factor of cell nf-at	[factor of cells NF-AT]	0.0	4	1	1	1
147139	1710	history of familial disorder	[history of familial disorders]	0.0	4	1	1	1
147140	1710	Jurkat a line	[Jurkat a line]	0.0	3	1	1	1
147141	1710	instability	[instability]	0.0	1	1	1	1
147142	1710	Grb2-binding protein in platelet	[Grb2-binding proteins in platelets]	0.0	4	1	1	1
147143	1710	emphasis on the result	[emphasis on the results]	0.0	4	1	1	1
147144	1710	tight binding of nf-kb	[tighter binding of NF-kB]	0.0	4	1	1	1
147145	1710	translocation nuclear factor of T	[translocation nuclear factor of T]	0.0	5	1	1	1
147146	1710	ubiquitous, nuclear component	[ubiquitous, nuclear component]	0.0	3	1	1	1
147147	1710	T inducibility	[T inducibility]	0.0	2	1	1	1
147148	1710	component of this process.	[component of this process.]	0.0	4	1	1	1
147149	1710	area of dnase hypersensitivity	[area of DNase hypersensitivity]	0.0	4	1	1	1
147150	1710	arm encompass band p11.23	[arm encompassing bands p11.23]	0.0	4	1	1	1
147151	1710	base exchange by polymorphism	[base exchanges by polymorphism]	0.0	4	1	1	1
147152	1710	potent activator of viral promoter	[potent activator of viral promoters]	0.0	5	1	1	1
147153	1710	profilin-like fashion.	[profilin-like fashion.]	0.0	2	1	1	1
147154	1710	disable sequela of therapy	[disabling sequela of therapy]	0.0	4	1	1	1
147155	1710	p65/	[p65/]	0.0	1	1	1	1
147156	1710	several other transcription factor	[Several other transcription factors]	0.0	4	1	1	1
147157	1710	METHODS: atopic subject	[METHODS: atopic subjects]	0.0	3	1	1	1
147158	1710	cortivazol than the cell for lysis	[cortivazol than the cells for lysis]	0.0	6	1	1	1
147159	1710	cd3epsilon mouse line	[CD3epsilon mouse lines]	0.0	3	1	1	1
147160	1710	distinct, inhibitor of NFAT -1-mediated transcription	[distinct, inhibitors of NFAT -1-mediated transcription]	0.0	6	1	1	1
147161	1710	Addition during the last 4 h	[Addition during the last 4 h]	0.0	6	1	1	1
147162	1710	proil-1beta gene	[proIL-1beta gene]	0.0	2	1	1	1
147163	1710	association with signal molecule	[association with signaling molecules]	0.0	4	1	1	1
147164	1710	Dithiocarbamates a diverse group of chemical	[Dithiocarbamates a diverse group of chemicals]	0.0	6	1	1	1
147165	1710	antibody to CD3 (ic50 of ng/ml),	[antibody to CD3 (IC50 of ng/ml),]	0.0	6	1	1	1
147166	1710	plasma avp pmol/l;	[plasma AVP pmol/l;]	0.0	3	1	1	1
147167	1710	profound inhibition	[profound inhibition]	0.0	2	1	1	1
147168	1710	symbol olr1	[symbol OLR1]	0.0	2	1	1	1
147169	1710	g-csf cell at day 6;	[G-CSF cells at day 6;]	0.0	5	1	1	1
147170	1710	Rel/ NF-kappa b family member	[Rel/ NF-kappa B family members]	0.0	5	1	1	1
147171	1710	switch,	[switch,]	0.0	1	1	1	1
147172	1710	clinic.	[clinic.]	0.0	1	1	1	1
147173	1710	interaction with region	[interaction with regions]	0.0	3	1	1	1
147174	1710	feedback of cortisol	[feedback of cortisol]	0.0	3	1	1	1
147175	1710	RB a e2f-1 binding protein	[RB a E2F-1 binding protein]	0.0	5	1	1	1
147176	1710	express the membrane form	[expressing the membrane form]	0.0	4	1	1	1
147177	1710	DNA binding by in receptor	[DNA binding by in receptor]	0.0	5	1	1	1
147178	1710	decrease in neutrophil adhesion	[decrease in neutrophil adhesion]	0.0	4	1	1	1
147179	1710	microm sodium orthovanadate a inhibitor	[microM sodium orthovanadate an inhibitor]	0.0	5	1	1	1
147180	1710	effective barrier	[effective barrier]	0.0	2	1	1	1
147181	1710	functional antagonism in erythroid cell	[functional antagonism in erythroid cells]	0.0	5	1	1	1
147182	1710	SEB induction of interleukin-2	[SEB induction of interleukin-2]	0.0	4	1	1	1
147183	1710	medicine chan'su	[medicine chan'su]	0.0	2	1	1	1
147184	1710	runt box polypeptide	[runt box polypeptides]	0.0	3	1	1	1
147185	1710	infiltration of lymphocyte into tumor tissue	[infiltration of lymphocytes into tumor tissues]	0.0	6	1	1	1
147186	1710	determinant regulate factor-kappa b activation	[determinants regulating factor-kappa B activation]	0.0	5	1	1	1
147187	1710	mechanism of cellular transformation	[mechanism of cellular transformation]	0.0	4	1	1	1
147188	1710	defect(s) lead	[defect(s) leading]	0.0	2	1	1	1
147189	1710	interleukin-4 IL-4 gene	[interleukin-4 IL-4 gene]	0.0	3	1	1	1
147190	1710	control LTR	[control LTR]	0.0	2	1	1	1
147191	1710	900 x-chromosomes	[900 X-chromosomes]	0.0	2	1	1	1
147192	1710	other process essential	[other processes essential]	0.0	3	1	1	1
147193	1710	induction during T cell activation	[induction during T cell activation]	0.0	5	1	1	1
147194	1710	binding of SR 31747a	[binding of SR 31747A]	0.0	4	1	1	1
147195	1710	(xci)	[(XCI)]	0.0	1	1	1	1
147196	1710	adequate approximation	[adequate approximation]	0.0	2	1	1	1
147197	1710	Comparison to virus peptide	[Comparison to virus peptides]	0.0	4	1	1	1
147198	1710	include mmp-9	[including MMP-9]	0.0	2	1	1	1
147199	1710	bzip transcription	[bZIP transcription]	0.0	2	1	1	1
147200	1710	datum relate ros activity	[data relating ROS activity]	0.0	4	1	1	1
147201	1710	domain of hiv-1 glycoprotein	[domain of HIV-1 glycoprotein]	0.0	4	1	1	1
147202	1710	activity on a gata site	[activity on a GATA site]	0.0	5	1	1	1
147203	1710	cell-to-cell activation	[cell-to-cell activation]	0.0	2	1	1	1
147204	1710	differentiation, survival,	[differentiation, survival,]	0.0	2	1	1	1
147205	1710	class gene in mutant line	[class gene in mutant line]	0.0	5	1	1	1
147206	1710	Regulatory effect of interleukin-11	[Regulatory effects of interleukin-11]	0.0	4	1	1	1
147207	1710	nuclear inhibition	[nuclear inhibition]	0.0	2	1	1	1
147208	1710	protein (sap) kinase	[protein (SAP) kinases]	0.0	3	1	1	1
147209	1710	nordihydroquairetic	[nordihydroquairetic]	0.0	1	1	1	1
147210	1710	outcome of a response	[outcome of an response]	0.0	4	1	1	1
147211	1710	follow cell stimulation with a beta	[following cell stimulation with A beta]	0.0	6	1	1	1
147212	1710	number of hpp-cfc colony	[number of HPP-CFC colonies]	0.0	4	1	1	1
147213	1710	effect through subsequent tnf-alpha release	[effect through subsequent TNF-alpha release]	0.0	5	1	1	1
147214	1710	various alteration responsible	[various alterations responsible]	0.0	3	1	1	1
147215	1710	class major complex gene	[class major complex genes]	0.0	4	1	1	1
147216	1710	inheritance of combination	[inheritance of combinations]	0.0	3	1	1	1
147217	1710	stress on stimulation-dependent signal transduction	[stress on stimulation-dependent signal transduction]	0.0	5	1	1	1
147218	1710	cell express very high level	[cells expressing very high levels]	0.0	5	1	1	1
147219	1710	two distinct pathway of interleukin-5 synthesis	[Two distinct pathways of interleukin-5 synthesis]	0.0	6	1	1	1
147220	1710	surface marker expression	[surface marker expression]	0.0	3	1	1	1
147221	1710	also in healthy individual as control	[also in healthy individuals as control]	0.0	6	1	1	1
147222	1710	mutant myc protein	[mutant Myc protein]	0.0	3	1	1	1
147223	1710	similar sensitivity	[similar sensitivities]	0.0	2	1	1	1
147224	1710	aids vaccine	[AIDS vaccine]	0.0	2	1	1	1
147225	1710	odd with the prediction	[odds with the prediction]	0.0	4	1	1	1
147226	1710	World Web	[World Web]	0.0	2	1	1	1
147227	1710	model for regulation	[model for regulation]	0.0	3	1	1	1
147228	1710	cover the complete sequence individual	[covering the complete sequence individuals]	0.0	5	1	1	1
147229	1710	rate in 80.5% of individual	[rate in 80.5% of individuals]	0.0	5	1	1	1
147230	1710	composition ap-1	[composition AP-1]	0.0	2	1	1	1
147231	1710	tbp mutant	[TBP mutant]	0.0	2	1	1	1
147232	1710	process involve successive stage	[process involving successive stages]	0.0	4	1	1	1
147233	1710	interaction of protein	[interactions of proteins]	0.0	3	1	1	1
147234	1710	platelet from patient with disorder	[platelets from patients with disorder]	0.0	5	1	1	1
147235	1710	CIS tyrosine	[CIS tyrosine]	0.0	2	1	1	1
147236	1710	degree of suppression	[degree of suppression]	0.0	3	1	1	1
147237	1710	assignment	[assignment]	0.0	1	1	1	1
147238	1710	two findings.	[two findings.]	0.0	2	1	1	1
147239	1710	complex with class of abundant receptor	[complexes with classes of abundant receptors]	0.0	6	1	1	1
147240	1710	171.3 dpm mg-1	[171.3 dpm mg-1]	0.0	3	1	1	1
147241	1710	selective reduction of nfat1 activity	[selective reduction of NFAT1 activity]	0.0	5	1	1	1
147242	1710	17 out t-cell determinant	[17 out T-cell determinants]	0.0	4	1	1	1
147243	1710	rdna represent rrna	[cDNAs representing mRNAs]	0.0	3	1	1	1
147244	1710	t-cell effect	[T-cell effects]	0.0	2	1	1	1
147245	1710	various early serum gene	[various early serum genes]	0.0	4	1	1	1
147246	1710	pre-existing, component of the factor	[pre-existing, component of the factor]	0.0	5	1	1	1
147247	1710	selective chemical modification arginine residue	[selective chemical modification arginine residues]	0.0	5	1	1	1
147248	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione pd-c hydrogenation of 3,21-diacetoxy-5	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione Pd-C hydrogenation of 3,21-diacetoxy-5]	0.0	6	1	1	1
147249	1710	m.tremblay,	[M.Tremblay,]	0.0	1	1	1	1
147250	1710	termination of treatment,	[termination of treatment,]	0.0	3	1	1	1
147251	1710	2) induction	[2) induction]	0.0	2	1	1	1
147252	1710	murine g-csfr	[murine G-CSFR]	0.0	2	1	1	1
147253	1710	therefore convert the transactivation	[therefore converting the transactivation]	0.0	4	1	1	1
147254	1710	cell include macrophage	[cells including macrophages]	0.0	3	1	1	1
147255	1710	transcription factor pat	[transcription factors pAT]	0.0	3	1	1	1
147256	1710	different intact il-4 promoter construct	[different intact IL-4 promoter constructs]	0.0	5	1	1	1
147257	1710	generate a immune response	[generating an immune response]	0.0	4	1	1	1
147258	1710	regulator of peripheral blood T	[regulators of peripheral blood T]	0.0	5	1	1	1
147259	1710	tumour cell of aids-related lymphoma	[tumour cells of AIDS-related lymphoma]	0.0	5	1	1	1
147260	1710	major histocompatibility class I molecule	[major histocompatibility class I molecules]	0.0	5	1	1	1
147261	1710	SWI6/ankyrin	[SWI6/ankyrin]	0.0	1	1	1	1
147262	1710	rap1 protein phosphorylation	[Rap1 protein phosphorylation]	0.0	3	1	1	1
147263	1710	promoter combination	[promoter combination]	0.0	2	1	1	1
147264	1710	time of hypoxic exposure	[times of hypoxic exposure]	0.0	4	1	1	1
147265	1710	mitochondrial form	[mitochondrial forms]	0.0	2	1	1	1
147266	1710	subunits; independent genes, nfkb1 nfkb2	[subunits; independent genes, NFKB1 NFKB2]	0.0	5	1	1	1
147267	1710	subject type ii	[subjects Type II]	0.0	3	1	1	1
147268	1710	JAK-1 -deficient hela cell	[JAK-1 -deficient HeLa cells]	0.0	4	1	1	1
147269	1710	histocompatibility molecule	[histocompatibility molecules]	0.0	2	1	1	1
147270	1710	important initial step	[important initial step]	0.0	3	1	1	1
147271	1710	molecular basis in a patient	[Molecular basis in a patient]	0.0	5	1	1	1
147272	1710	month (range,	[months (range,]	0.0	2	1	1	1
147273	1710	t-cell from individual with filaria-induced pathology	[T-cells from individuals with filaria-induced pathology]	0.0	6	1	1	1
147274	1710	tpa -inducible factor	[TPA -inducible factor]	0.0	3	1	1	1
147275	1710	20- to 50-fold affinity consistent	[20- to 50-fold affinity consistent]	0.0	5	1	1	1
147276	1710	promoter region of the gene	[promoter regions of the genes]	0.0	5	1	1	1
147277	1710	two X1-specific factor	[two X1-specific factors]	0.0	3	1	1	1
147278	1710	class of viral gene	[classes of viral genes]	0.0	4	1	1	1
147279	1710	dominant-negative Ras construct	[dominant-negative Ras construct]	0.0	3	1	1	1
147280	1710	high affinity receptor	[High affinity receptors]	0.0	3	1	1	1
147281	1710	C)CTGTG	[C)CTGTG]	0.0	1	1	1	1
147282	1710	receptor of differentiation	[receptors of differentiation]	0.0	3	1	1	1
147283	1710	rodent mutant cell	[rodent mutant cells]	0.0	3	1	1	1
147284	1710	immunofluorescence from human tonsil	[immunofluorescence from human tonsils]	0.0	4	1	1	1
147285	1710	two C-terminal activating region	[two C-terminal activating regions]	0.0	4	1	1	1
147286	1710	syncytium-forming capacity	[syncytium-forming capacity]	0.0	2	1	1	1
147287	1710	NFkappaB in monocyte	[NFkappaB in monocytes]	0.0	3	1	1	1
147288	1710	common signal pathway	[Common signaling pathways]	0.0	3	1	1	1
147289	1710	pha related	[PHA related]	0.0	2	1	1	1
147290	1710	important role in biology	[important role in biology]	0.0	4	2	2	1
147291	1710	bp il-2 promoter	[bp IL-2 promoter]	0.0	3	1	1	1
147292	1710	gata element of the hiv-1 repeat	[GATA elements of the HIV-1 repeat]	0.0	6	1	1	1
147293	1710	localization analysis in cells,	[localization analysis in cells,]	0.0	4	1	1	1
147294	1710	cytokine-induced human immunodeficiency virus type hiv-1	[cytokine-induced human immunodeficiency virus type HIV-1]	0.0	6	1	1	1
147295	1710	start after stimulation.	[starting after stimulation.]	0.0	3	1	1	1
147296	1710	response to antigens.	[responses to antigens.]	0.0	3	1	1	1
147297	1710	LP T	[LP T]	0.0	2	2	2	1
147298	1710	interferon-gamma-induced factor role in up-regulation	[Interferon-gamma-induced factor role in up-regulation]	0.0	5	1	1	1
147299	1710	patient with severe immunodeficiency X-SCID	[patients with severe immunodeficiency X-SCID]	0.0	5	1	1	1
147300	1710	wild type er	[wild type ER]	0.0	3	1	1	1
147301	1710	il-12 namely,	[IL-12 namely,]	0.0	2	1	1	1
147302	1710	suppression of sla-dq antigen induction	[suppression of SLA-DQ antigen induction]	0.0	5	1	1	1
147303	1710	development pathway	[development pathways]	0.0	2	1	1	1
147304	1710	myeloid-associated gene in progenitor cell	[myeloid-associated genes in progenitor cells]	0.0	5	1	1	1
147305	1710	Drops	[Drops]	0.0	1	1	1	1
147306	1710	KOX on chromosome band 7q21q22	[KOX on chromosome bands 7q21q22]	0.0	5	1	1	1
147307	1710	p53-null cell resistant to apoptosis	[p53-null cells resistant to apoptosis]	0.0	5	1	1	1
147308	1710	co-expression with a negative c-fo	[co-expression with a negative c-Fos]	0.0	5	1	1	1
147309	1710	human toll signal pathway	[human toll signaling pathway]	0.0	4	1	1	1
147310	1710	new function of Ras	[new functions of Ras]	0.0	4	1	1	1
147311	1710	mechanism underlie il-2 blockade	[mechanism underlying IL-2 blockade]	0.0	4	1	1	1
147312	1710	collagen receptor	[collagen receptor]	0.0	2	1	1	1
147313	1710	Messenger RNA mrna level	[Messenger RNA mRNA levels]	0.0	4	1	1	1
147314	1710	physiological human glucocorticoid cortisol	[physiological human glucocorticoid cortisol]	0.0	4	1	1	1
147315	1710	presence receptor-positive lymphocyte sarcoidosis	[presence receptor-positive lymphocytes sarcoidosis]	0.0	4	1	1	1
147316	1710	vitro cleavage by elastase	[vitro cleavage by elastase]	0.0	4	1	1	1
147317	1710	precursor, lyso-platelet-activating factor	[precursor, lyso-platelet-activating factor]	0.0	3	1	1	1
147318	1710	vitamin d-dependent	[vitamin D-dependent]	0.0	2	1	1	1
147319	1710	oncogenicity of adenoviruse	[oncogenicities of adenoviruses]	0.0	3	1	1	1
147320	1710	specific ags	[specific Ags]	0.0	2	1	1	1
147321	1710	corticotropin release	[corticotropin releasing]	0.0	2	1	1	1
147322	1710	assembly in T cell	[assembly in T cells]	0.0	4	1	1	1
147323	1710	other factor.	[other factor.]	0.0	2	1	1	1
147324	1710	thrombospondin 1 gene	[thrombospondin 1 gene]	0.0	3	1	1	1
147325	1710	55 kd,	[55 kD,]	0.0	2	1	1	1
147326	1710	susceptibility to lysis	[susceptibility to lysis]	0.0	3	1	1	1
147327	1710	fasL promoter-dependent reporter construct	[fasL promoter-dependent reporter constructs]	0.0	4	1	1	1
147328	1710	cytokine by il-2	[cytokines by IL-2]	0.0	3	1	1	1
147329	1710	viable definitive cell a phenotype	[viable definitive cells a phenotype]	0.0	5	1	1	1
147330	1710	foreign antigens.	[foreign antigens.]	0.0	2	1	1	1
147331	1710	two early protein BZLF1	[two early proteins BZLF1]	0.0	4	1	1	1
147332	1710	virus SV40 region	[virus SV40 region]	0.0	3	1	1	1
147333	1710	blot analysis of L132 cell	[blot analysis of L132 cells]	0.0	5	1	1	1
147334	1710	peak in response to concanavalin-a	[peaking in response to Concanavalin-A]	0.0	5	1	1	1
147335	1710	thus indicate due to a factor	[thus indicating due to a factor]	0.0	6	1	1	1
147336	1710	Epstein-Barr virus gene expression in relation	[Epstein-Barr virus gene expression in relation]	0.0	6	1	1	1
147337	1710	[effect of therapy with captopril	[[Effect of therapy with captopril]	0.0	5	1	1	1
147338	1710	exact cellular defect(s) lead	[exact cellular defect(s) leading]	0.0	4	1	1	1
147339	1710	mol/L) in combination	[mol/L) in combination]	0.0	3	1	1	1
147340	1710	activity of sv40 early promoter	[activities of SV40 early promoters]	0.0	5	1	1	1
147341	1710	relationship a new approach.	[Relationship a new approach.]	0.0	4	1	1	1
147342	1710	information on pancrea development	[information on pancreas development]	0.0	4	1	1	1
147343	1710	-ligand+	[-ligand+]	0.0	1	1	1	1
147344	1710	neighbour	[Neighbouring]	0.0	1	1	1	1
147345	1710	index absorptive patient	[index absorptive patients]	0.0	3	1	1	1
147346	1710	mimick	[mimicking]	0.0	1	1	1	1
147347	1710	displacement of a repressor by protein	[Displacement of an repressor by proteins]	0.0	6	1	1	1
147348	1710	level of receptor rna	[levels of receptor RNA]	0.0	4	1	1	1
147349	1710	tyrosine phosphorylation of jak2	[tyrosine phosphorylation of JAK2]	0.0	4	1	1	1
147350	1710	tumor necrosis factor TNF cytokine	[tumor necrosis factor TNF cytokines]	0.0	5	1	1	1
147351	1710	TCRhigh thymocyte	[TCRhigh thymocytes]	0.0	2	1	1	1
147352	1710	non-epithelial cell	[non-epithelial cells]	0.0	2	1	1	1
147353	1710	stimulation, b lymphocyte	[stimulation, B lymphocytes]	0.0	3	1	1	1
147354	1710	factor-AT response	[factor-AT response]	0.0	2	1	1	1
147355	1710	regulatory DNA sequence	[regulatory DNA sequences]	0.0	3	1	1	1
147356	1710	+/- 13.9)	[+/- 13.9)]	0.0	2	1	1	1
147357	1710	establish the effectiveness of human ciita	[establishing the effectiveness of human CIITA]	0.0	6	1	1	1
147358	1710	EBV vector pmep4	[EBV vector pMEP4]	0.0	3	1	1	1
147359	1710	activity in myelopoiesis	[activity in myelopoiesis]	0.0	3	1	1	1
147360	1710	po2 14-18 Torr,	[PO2 14-18 Torr,]	0.0	3	1	1	1
147361	1710	cd34+ bone	[CD34+ bone]	0.0	2	2	2	1
147362	1710	level of gcr	[level of GcR]	0.0	3	1	1	1
147363	1710	inhibitor of p70(S6)-kinase	[inhibitors of p70(S6)-kinase]	0.0	3	1	1	1
147364	1710	patient with persistent arthritis	[patients with persistent arthritis]	0.0	4	1	1	1
147365	1710	activator cell	[activator cells]	0.0	2	1	1	1
147366	1710	key role in normal hematopoiesis	[key role in normal hematopoiesis]	0.0	5	1	1	1
147367	1710	9-cis differentiation	[9-cis differentiation]	0.0	2	1	1	1
147368	1710	small dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin	[small doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin]	0.0	4	1	1	1
147369	1710	only the two mutation	[only the two mutations]	0.0	4	1	1	1
147370	1710	select genetic aberration in the pathway	[select genetic aberrations in the pathway]	0.0	6	1	1	1
147371	1710	kruppel-type zinc finger protein	[Kruppel-type zinc finger protein]	0.0	4	1	1	1
147372	1710	alpha-Dihydroxicholecalciferol vitd3	[alpha-Dihydroxicholecalciferol VitD3]	0.0	2	1	1	1
147373	1710	platelet cell adhesion molecule PECAM-1	[platelet cell adhesion molecules PECAM-1]	0.0	5	1	1	1
147374	1710	ifn-induced gene such as ip-10	[IFN-induced genes such as IP-10]	0.0	5	1	1	1
147375	1710	effect on factor	[effects on factors]	0.0	3	1	1	1
147376	1710	lack nno	[lacking nNOS]	0.0	2	1	1	1
147377	1710	inhibitor platelet-activating factor (paf)- receptor antagonist	[Inhibitors platelet-activating factor (PAF)- receptor antagonist]	0.0	6	1	1	1
147378	1710	CD40 survival	[CD40 survival]	0.0	2	1	1	1
147379	1710	treatment of skw cell with IL	[Treatment of SKW cells with IL]	0.0	6	1	1	1
147380	1710	childhood lymphoblastic leukemia	[childhood lymphoblastic leukemia]	0.0	3	1	1	1
147381	1710	homologous region in the promoter	[homologous regions in the promoter]	0.0	5	1	1	1
147382	1710	Systemic hGR level	[Systemic hGR levels]	0.0	3	2	2	1
147383	1710	anti-rabbit hsp90 antibody	[anti-rabbit hsp90 antibody]	0.0	3	1	1	1
147384	1710	understand the mechanism of regulation	[Understanding the mechanism of regulation]	0.0	5	1	1	1
147385	1710	localization of 15-lo	[localization of 15-LO]	0.0	3	1	1	1
147386	1710	terminal repeat LTR sequence diversity	[terminal repeat LTR sequence diversity]	0.0	5	1	1	1
147387	1710	very low activity	[very low activity]	0.0	3	1	1	1
147388	1710	negative mutant ikk1	[negative mutant IKK1]	0.0	3	1	1	1
147389	1710	nmol/l).	[nmol/l).]	0.0	1	1	1	1
147390	1710	(globins)	[(globins)]	0.0	1	1	1	1
147391	1710	acute leukemia gene	[acute leukemia gene]	0.0	3	1	1	1
147392	1710	mutant receptor l753f	[mutant receptors L753F]	0.0	3	1	1	1
147393	1710	pu.1 function	[PU.1 function]	0.0	2	1	1	1
147394	1710	Dexamethasone a glucocorticoid hormone	[Dexamethasone a glucocorticoid hormone]	0.0	4	1	1	1
147395	1710	thymic hybridoma	[thymic hybridoma]	0.0	2	1	1	1
147396	1710	similar region of sequence	[similar regions of sequences]	0.0	4	1	1	1
147397	1710	localize to hsv -2 lesion	[localizing to HSV -2 lesions]	0.0	5	1	1	1
147398	1710	skewing of x inactivation	[skewing of X inactivation]	0.0	4	1	1	1
147399	1710	specific T lymphocyte	[specific T lymphocytes]	0.0	3	1	1	1
147400	1710	huvec monolayer	[HUVEC monolayers]	0.0	2	1	1	1
147401	1710	suggest positive cooperativity	[suggesting positive cooperativity]	0.0	3	1	1	1
147402	1710	mitogen-activated protein kinase MAPK pathway	[mitogen-activated protein kinase MAPK pathway]	0.0	5	1	1	1
147403	1710	suppression of il-1r gene expression	[suppression of IL-1R gene expression]	0.0	5	1	1	1
147404	1710	phosphorylation of a serine residue	[phosphorylation of a serine residue]	0.0	5	1	1	1
147405	1710	three main regulatory pathway	[three main regulatory pathways]	0.0	4	1	1	1
147406	1710	association with toxicity	[association with toxicity]	0.0	3	1	1	1
147407	1710	incubation increase concentration of cysteine	[incubation increasing concentrations of cysteine]	0.0	5	1	1	1
147408	1710	aminolaevulinic acid synthase	[aminolaevulinic acid synthase]	0.0	3	1	1	1
147409	1710	signal in JAK3 severe immunodeficiency lymphocyte	[Signaling in JAK3 severe immunodeficiency lymphocytes]	0.0	6	1	1	1
147410	1710	signal transducer of transcription stat1	[signal transducer of transcription STAT1]	0.0	5	1	1	1
147411	1710	IL-1beta stimulation	[IL-1beta stimulation]	0.0	2	1	1	1
147412	1710	(25 mm) of ethanol treatment	[(25 mM) of ethanol treatment]	0.0	5	1	1	1
147413	1710	eutopic endometrium from woman	[eutopic endometrium from women]	0.0	4	1	1	1
147414	1710	evidence for a autoregulatory pathway	[evidence for an autoregulatory pathway]	0.0	5	1	1	1
147415	1710	nuclear factor-KB	[nuclear factor-KB]	0.0	2	1	1	1
147416	1710	ppargamma differentiation-dependent proliferator-activated receptor gamma expression	[PPARgamma differentiation-dependent proliferator-activated receptor gamma expression]	0.0	6	1	1	1
147417	1710	extract of monocytes.	[extracts of monocytes.]	0.0	3	1	1	1
147418	1710	role in the effect	[role in the effects]	0.0	4	1	1	1
147419	1710	two cell surface receptor	[two cell surface receptors]	0.0	4	1	1	1
147420	1710	control of NFATx1 nuclear translocation	[Control of NFATx1 nuclear translocation]	0.0	5	1	1	1
147421	1710	activate proteins, the gata factor	[activating proteins, the GATA factors]	0.0	5	1	1	1
147422	1710	constitutive association of STAT3	[constitutive association of STAT3]	0.0	4	1	1	1
147423	1710	glucocorticoid receptor of leukocyte	[glucocorticoid receptor of leukocytes]	0.0	4	1	1	1
147424	1710	expression human T cell	[expression human T cells]	0.0	4	1	1	1
147425	1710	differentiation-dependent proliferator-activated receptor gamma	[differentiation-dependent proliferator-activated receptor gamma]	0.0	4	1	1	1
147426	1710	intrafollicular T cell	[intrafollicular T cells]	0.0	3	1	1	1
147427	1710	E220K ubiquitinylation	[E220K ubiquitinylation]	0.0	2	1	1	1
147428	1710	high level of p50 homodimer	[high levels of p50 homodimer]	0.0	5	1	1	1
147429	1710	avian erythroblastosis virus	[avian erythroblastosis virus]	0.0	3	1	1	1
147430	1710	EKLF binding site	[EKLF binding site]	0.0	3	1	1	1
147431	1710	one b-cell-specific transcription factor	[one B-cell-specific transcription factor]	0.0	4	1	1	1
147432	1710	(bhlh) protein e2a	[(bHLH) protein E2A]	0.0	3	1	1	1
147433	1710	genetic location	[genetic location]	0.0	2	1	1	1
147434	1710	proliferative response of T lymphocyte	[proliferative response of T lymphocytes]	0.0	5	1	1	1
147435	1710	l753f	[L753F]	0.0	1	1	1	1
147436	1710	target gata-1 p45 nf-e2 protein	[targeting GATA-1 p45 NF-E2 proteins]	0.0	5	1	1	1
147437	1710	Th1 cell-mediated response	[Th1 cell-mediated responses]	0.0	3	1	1	1
147438	1710	expression of eukaryotic gene	[expression of eukaryotic genes]	0.0	4	1	1	1
147439	1710	extend from approximately -500	[extending from approximately -500]	0.0	4	1	1	1
147440	1710	signalling agent	[signalling agents]	0.0	2	1	1	1
147441	1710	laboratory employees.	[laboratory employees.]	0.0	2	1	1	1
147442	1710	process involve interaction between element	[process involving interactions between elements]	0.0	5	1	1	1
147443	1710	long maintenance of transcription	[long-term maintenance of transcription]	0.0	4	1	1	1
147444	1710	vector suitable	[vectors suitable]	0.0	2	1	1	1
147445	1710	autosomal inheritance	[autosomal inheritance]	0.0	2	1	1	1
147446	1710	formation sequence-binding complex contain STAT3 alone	[formation sequence-binding complexes containing STAT3 alone]	0.0	6	1	1	1
147447	1710	effective site for depletion	[effective site for depletion]	0.0	4	1	1	1
147448	1710	1600 VDR by 8 h	[1600 VDR by 8 h]	0.0	5	1	1	1
147449	1710	anti-ERK extracellular signal-regulated kinase	[anti-ERK extracellular signal-regulated kinase]	0.0	4	1	1	1
147450	1710	binding of three distinct multi-protein complex	[binding of three distinct multi-protein complexes]	0.0	6	1	1	1
147451	1710	expression in normal skin	[Expression in normal skin]	0.0	4	1	1	1
147452	1710	hair follicle	[hair follicles]	0.0	2	1	1	1
147453	1710	human tissue sample	[human tissue samples]	0.0	3	1	1	1
147454	1710	genes, include cytokine	[genes, including cytokines]	0.0	3	1	1	1
147455	1710	replication of type immunodeficiency virus	[Replication of type immunodeficiency viruses]	0.0	5	1	1	1
147456	1710	certain erythrocyte gene	[certain erythrocyte genes]	0.0	3	1	1	1
147457	1710	reversible inhibition of cell proliferation	[reversible inhibition of cell proliferation]	0.0	5	1	1	1
147458	1710	0/3 sarcoidosis patient	[0/3 sarcoidosis patients]	0.0	3	1	1	1
147459	1710	disorder MDD in adolescent	[disorder MDD in adolescents]	0.0	4	1	1	1
147460	1710	sequestration of class ii heterodimer	[sequestration of class II heterodimers]	0.0	5	1	1	1
147461	1710	six primary breast cancer sample	[six primary breast cancer samples]	0.0	5	1	1	1
147462	1710	E-selectin expression in ec	[E-selectin expression in EC]	0.0	4	1	1	1
147463	1710	phase of adhesion	[phases of adhesion]	0.0	3	1	1	1
147464	1710	cellular/molecular event	[cellular/molecular events]	0.0	2	1	1	1
147465	1710	peptide/glycoprotein complex	[peptide/glycoprotein complexes]	0.0	2	1	1	1
147466	1710	response to signal transduction	[response to signal transduction]	0.0	4	1	1	1
147467	1710	production by T lymphocyte	[production by T lymphocytes]	0.0	4	1	1	1
147468	1710	change in ros	[changes in ROS]	0.0	3	1	1	1
147469	1710	follow t(1;19) chromosomal translocation in leukemia	[following t(1;19) chromosomal translocations in leukemias]	0.0	6	1	1	1
147470	1710	0.06 nm	[0.06 nM]	0.0	2	1	1	1
147471	1710	class ii MHC Ag	[class II MHC Ag]	0.0	4	1	1	1
147472	1710	alternative type	[alternative type]	0.0	2	1	1	1
147473	1710	cd4(+) t-cell	[CD4(+) T-cell]	0.0	2	1	1	1
147474	1710	immunoblot analysis of extract	[immunoblot analysis of extracts]	0.0	4	1	1	1
147475	1710	y113	[Y113]	0.0	1	1	1	1
147476	1710	expression of IL-2 regulator c-fo	[expression of IL-2 regulators c-fos]	0.0	5	1	1	1
147477	1710	transcription factor one	[transcription factor one]	0.0	3	1	1	1
147478	1710	range of human pathology	[range of human pathologies]	0.0	4	1	1	1
147479	1710	transcriptional template	[transcriptional template]	0.0	2	1	1	1
147480	1710	protect naive b cell	[protecting naive B cells]	0.0	4	1	1	1
147481	1710	experiment with a antibody	[Experiments with a antibody]	0.0	4	1	1	1
147482	1710	encode the hepatocyte nuclear factor	[encoding the hepatocyte nuclear factors]	0.0	5	1	1	1
147483	1710	cell leukemia virus type	[cell leukemia virus type]	0.0	4	1	1	1
147484	1710	alternative treatment approach	[alternative treatment approaches]	0.0	3	1	1	1
147485	1710	mass 50000 (50k)	[mass 50,000 (50K)]	0.0	3	1	1	1
147486	1710	high affinity receptor VDR for 1,25-dihydroxycholecalciferol	[High affinity receptors VDR for 1,25-dihydroxycholecalciferol]	0.0	6	1	1	1
147487	1710	applicability,	[applicability,]	0.0	1	1	1	1
147488	1710	physiological relationship	[physiological relationship]	0.0	2	1	1	1
147489	1710	just upstream	[just upstream]	0.0	2	1	1	1
147490	1710	gcr binding affinity	[GCR binding affinities]	0.0	3	1	1	1
147491	1710	Bcl-6 staining in follicular hyperplasias	[Bcl-6 staining in follicular hyperplasias]	0.0	5	1	1	1
147492	1710	cathepsin k	[cathepsin K]	0.0	2	1	1	1
147493	1710	D3 determination in lymphocyte	[D3 determination in lymphocytes]	0.0	4	1	1	1
147494	1710	enterotoxin SE	[enterotoxins SE]	0.0	2	1	1	1
147495	1710	current classification	[current classification]	0.0	2	1	1	1
147496	1710	role in pathophysiology	[role in pathophysiology]	0.0	3	1	1	1
147497	1710	rapid growth of blast cell	[rapid growth of blast cells]	0.0	5	2	2	1
147498	1710	subunit of rna polymerase	[subunit of RNA polymerase]	0.0	4	1	1	1
147499	1710	tax protein a positive activator	[Tax protein a positive activator]	0.0	5	1	1	1
147500	1710	cell per millileter per hr.	[cells per ml per hr.]	0.0	5	1	1	1
147501	1710	anti- CD28 with PMA	[anti- CD28 with PMA]	0.0	4	1	1	1
147502	1710	mechanism of gc	[mechanisms of GC]	0.0	3	1	1	1
147503	1710	receptor il-1r	[receptor IL-1R]	0.0	2	1	1	1
147504	1710	repression through the cooperation of factor	[Repression through the cooperation of factors]	0.0	6	1	1	1
147505	1710	abolish hepatic injury with alpha-tocopherol	[abolishing hepatic injury with alpha-tocopherol]	0.0	5	1	1	1
147506	1710	nfil3/e4bp4 cDNA	[NFIL3/E4BP4 cDNA]	0.0	2	1	1	1
147507	1710	occur at a dose	[occurring at a dose]	0.0	4	1	1	1
147508	1710	encompass all of the domain	[encompassing all of the domain]	0.0	5	1	1	1
147509	1710	characteristic decline	[characteristic decline]	0.0	2	1	1	1
147510	1710	glucocorticoid receptor clone icr-27	[glucocorticoid receptor clone ICR-27]	0.0	4	1	1	1
147511	1710	target for B-cell factor	[target for B-cell factor]	0.0	4	1	1	1
147512	1710	[3H]Thymidine	[[3H]Thymidine]	0.0	1	1	1	1
147513	1710	biopsy as surgical treatment	[biopsy as surgical treatment]	0.0	4	1	1	1
147514	1710	identify therapeutic target	[identifying therapeutic targets]	0.0	3	1	1	1
147515	1710	binding to e box	[binding to E box]	0.0	4	1	1	1
147516	1710	translocation adjacent to rhombotin	[translocation adjacent to rhombotin]	0.0	4	1	1	1
147517	1710	264.7 cell	[264.7 cells]	0.0	2	1	1	1
147518	1710	influenza virus antigen	[influenza virus antigen]	0.0	3	1	1	1
147519	1710	sequence with homology	[sequence with homology]	0.0	3	1	1	1
147520	1710	human DNA clone	[human DNA clones]	0.0	3	1	1	1
147521	1710	nuclear factor-AT	[nuclear factor-AT]	0.0	2	1	1	1
147522	1710	tnf myristate acetate	[TNF myristate acetate]	0.0	3	1	1	1
147523	1710	level of expression in mouse	[levels of expression in mice]	0.0	5	1	1	1
147524	1710	Functional association in IL-2 IFNgamma signal	[Functional association in IL-2 IFNgamma signaling]	0.0	6	1	1	1
147525	1710	glucocorticoid hormone compound	[glucocorticoid hormone compounds]	0.0	3	1	1	1
147526	1710	fresh blood mononuclear cell pbmc	[fresh blood mononuclear cells PBMC]	0.0	5	1	1	1
147527	1710	PMA phosphorylation	[PMA phosphorylation]	0.0	2	1	1	1
147528	1710	difference from passage cell	[difference from passage cells]	0.0	4	1	1	1
147529	1710	physiological processes,	[physiological processes,]	0.0	2	1	1	1
147530	1710	immunodeficiency X-SCID	[immunodeficiency X-SCID]	0.0	2	1	1	1
147531	1710	decrease of activation	[decrease of activation]	0.0	3	1	1	1
147532	1710	incorporation into phosphatidylcholine	[incorporation into phosphatidylcholine]	0.0	3	1	1	1
147533	1710	significance for patient	[significance for patients]	0.0	3	1	1	1
147534	1710	virus type htlv-1 tax	[virus type HTLV-1 Tax]	0.0	4	1	1	1
147535	1710	prescription	[prescription]	0.0	1	1	1	1
147536	1710	substnfkappab substSpl2 approximately substSp23	[substNFkappaB substSpl2 approximately substSp23]	0.0	4	1	1	1
147537	1710	prolactin -inducible interferon factor-1 gene	[prolactin -inducible interferon factor-1 gene]	0.0	5	1	1	1
147538	1710	human t-cell virus type tax	[human T-cell virus type Tax]	0.0	5	1	1	1
147539	1710	antigen-processing pathway	[antigen-processing pathway]	0.0	2	1	1	1
147540	1710	difference between each group	[differences between each group]	0.0	4	1	1	1
147541	1710	p50-p56 heterodimer	[p50-p56 heterodimer]	0.0	2	1	1	1
147542	1710	inadequate response to stress	[inadequate responses to stress]	0.0	4	1	1	1
147543	1710	versatile molecules:	[versatile molecules:]	0.0	2	1	1	1
147544	1710	correlate to the current structural classification	[correlates to the current structural classification]	0.0	6	1	1	1
147545	1710	gene important for the proliferation	[genes important for the proliferation]	0.0	5	1	1	1
147546	1710	late promoter	[late promoter]	0.0	2	1	1	1
147547	1710	counterpart.	[counterpart.]	0.0	1	1	1	1
147548	1710	Negative regulation 1 expression	[Negative regulation 1 expression]	0.0	4	1	1	1
147549	1710	counterpart,	[counterpart,]	0.0	1	1	1	1
147550	1710	impaired activation of NFkappaB	[impaired activation of NFkappaB]	0.0	4	1	1	1
147551	1710	loci on chromosome 17p	[loci on chromosome 17p]	0.0	4	1	1	1
147552	1710	Bacterial vaginosis	[Bacterial vaginosis]	0.0	2	1	1	1
147553	1710	protein gene promoter	[protein gene promoters]	0.0	3	1	1	1
147554	1710	glutathione level in EC	[glutathione levels in EC]	0.0	4	1	1	1
147555	1710	evidence the only CsA -sensitive component	[evidence the only CsA -sensitive component]	0.0	6	1	1	1
147556	1710	adhesion molecule-1 gene	[adhesion molecule-1 gene]	0.0	3	1	1	1
147557	1710	nonmobilized blood mononuclear cell	[nonmobilized blood mononuclear cells]	0.0	4	1	1	1
147558	1710	cell per well,	[cell per well,]	0.0	3	1	1	1
147559	1710	exposure to shear stress flow pattern	[exposure to shear stress flow patterns]	0.0	6	1	1	1
147560	1710	enigmatic aspect of gata factor expression	[enigmatic aspect of GATA factor expression]	0.0	6	1	1	1
147561	1710	nfat kinase	[NFAT kinase]	0.0	2	1	1	1
147562	1710	use ATL-16T nuclear extract	[using ATL-16T nuclear extract]	0.0	4	1	1	1
147563	1710	binding of bob.1/obf.1	[binding of BOB.1/OBF.1]	0.0	3	1	1	1
147564	1710	kda factor have affinity	[kDa factor having affinity]	0.0	4	1	1	1
147565	1710	stretch with multiple site	[stretches with multiple sites]	0.0	4	1	1	1
147566	1710	long repeat LTR sequence diversity	[long repeat LTR sequence diversity]	0.0	5	1	1	1
147567	1710	characteristic of monocytic differentiation	[characteristics of monocytic differentiation]	0.0	4	1	1	1
147568	1710	two nf-kappab site	[two NF-kappaB sites]	0.0	3	1	1	1
147569	1710	pharmacologic blockade of nfat activity	[Pharmacologic blockade of NFAT activity]	0.0	5	1	1	1
147570	1710	breast cancer reactive cytotoxicity	[breast cancer reactive cytotoxicity]	0.0	4	1	1	1
147571	1710	interfer with nf-kappab activation	[Interfering with NF-kappaB activation]	0.0	4	1	1	1
147572	1710	peroxidase-antiperoxidase technique	[peroxidase-antiperoxidase technique]	0.0	2	1	1	1
147573	1710	adjacent residue	[adjacent residues]	0.0	2	1	1	1
147574	1710	(2) synergism	[(2) synergism]	0.0	2	1	1	1
147575	1710	number of alveolar macrophage	[number of alveolar macrophages]	0.0	4	1	1	1
147576	1710	very early stage.	[very early stage.]	0.0	3	1	1	1
147577	1710	t-cell lymphoma with hyperplastic germinal center	[T-cell lymphoma with hyperplastic germinal centers]	0.0	6	1	1	1
147578	1710	induction 10 differentiation	[induction 10 differentiation]	0.0	3	1	1	1
147579	1710	5 rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione (8)	[5 rearrangement to 21-acetoxy-11 beta,19-epoxypregn-5-ene-4,20-dione (8)]	0.0	6	1	1	1
147580	1710	group of normal control subject	[group of normal control subjects]	0.0	5	1	1	1
147581	1710	neuroendocrine-immune regulatory interaction	[neuroendocrine-immune regulatory interactions]	0.0	3	1	1	1
147582	1710	few cell (3-5%)	[few cells (3-5%)]	0.0	3	1	1	1
147583	1710	cell cycle analysis of e2f	[Cell cycle analysis of E2F]	0.0	5	1	1	1
147584	1710	CsA transcription factor	[CsA transcription factors]	0.0	3	1	1	1
147585	1710	transcription factor factor family	[Transcription factors factor family]	0.0	4	1	1	1
147586	1710	oct-1 DNA	[Oct-1 DNA]	0.0	2	2	2	1
147587	1710	inhibitory effect on regulation	[inhibitory effect on regulation]	0.0	4	1	1	1
147588	1710	potential mechanism for constitutive induction	[potential mechanism for constitutive induction]	0.0	5	1	1	1
147589	1710	characteristic feature in patient	[characteristic features in patients]	0.0	4	1	1	1
147590	1710	moreover, -ligand interaction	[Moreover, -ligand interactions]	0.0	3	1	1	1
147591	1710	extinction of b cell-encoded gene	[extinction of B cell-encoded genes]	0.0	5	1	1	1
147592	1710	vitamin receptor	[vitamin receptor]	0.0	2	1	1	1
147593	1710	have granule	[having granules]	0.0	2	1	1	1
147594	1710	frequently the target	[frequently the targets]	0.0	3	1	1	1
147595	1710	contrast to activation in PBMC	[contrast to activation in PBMC]	0.0	5	1	1	1
147596	1710	feature of xenograft rejection	[feature of xenograft rejection]	0.0	4	1	1	1
147597	1710	result, growth	[result, growth]	0.0	2	1	1	1
147598	1710	Thapsigargin TG a inhibitor	[Thapsigargin TG an inhibitor]	0.0	4	1	1	1
147599	1710	helper activity	[helper activity]	0.0	2	1	1	1
147600	1710	transcriptionally active complex	[transcriptionally active complexes]	0.0	3	1	1	1
147601	1710	XCI pattern with amplification	[XCI pattern with amplification]	0.0	4	1	1	1
147602	1710	activity primarily consist	[activity primarily consisting]	0.0	3	1	1	1
147603	1710	function of immunocyte	[function of immunocytes]	0.0	3	1	1	1
147604	1710	intracellular thiol decrease,	[intracellular thiol decrease,]	0.0	3	1	1	1
147605	1710	anti-cd2 antibody in the presence	[anti-CD2 antibodies in the presence]	0.0	5	1	1	1
147606	1710	heterogeneity within muscle	[heterogeneity within muscle]	0.0	3	1	1	1
147607	1710	human gene therapy protocol for cf	[human gene therapy protocols for CF]	0.0	6	1	1	1
147608	1710	beta-globin/alpha-globin	[beta-globin/alpha-globin]	0.0	1	1	1	1
147609	1710	patient with micrograms/day for day	[patients with micrograms/day for days)]	0.0	5	1	1	1
147610	1710	underline the role	[underlining the role]	0.0	3	1	1	1
147611	1710	trigger the proliferation	[triggering the proliferation]	0.0	3	1	1	1
147612	1710	e1 element	[E1 element]	0.0	2	1	1	1
147613	1710	prothrombinase complex	[prothrombinase complex]	0.0	2	1	1	1
147614	1710	staining in the nuclei	[staining in the nuclei]	0.0	4	1	1	1
147615	1710	METHODS: seventeen case	[METHODS: Seventeen cases]	0.0	3	1	1	1
147616	1710	abnormality in neoplasia	[abnormalities in neoplasia]	0.0	3	1	1	1
147617	1710	hbob1	[hBob1]	0.0	1	1	1	1
147618	1710	I htlv-i tax	[I HTLV-I tax]	0.0	3	1	1	1
147619	1710	expression in endothelial cell	[expression in endothelial cells]	0.0	4	1	1	1
147620	1710	Negative transcriptional regulation of interleukin gene	[Negative transcriptional regulation of interleukin gene]	0.0	6	1	1	1
147621	1710	include NF-AT	[including NF-AT]	0.0	2	1	1	1
147622	1710	trancriptional role of stat5	[trancriptional roles of STAT5]	0.0	4	1	1	1
147623	1710	potentially regulate	[potentially regulating]	0.0	2	1	1	1
147624	1710	RA enhancer	[RA enhancers]	0.0	2	1	1	1
147625	1710	efficient mar-bp1 binding	[efficient MAR-BP1 binding]	0.0	3	1	1	1
147626	1710	accumulation of AMP camp	[accumulation of AMP cAMP]	0.0	4	1	1	1
147627	1710	preincubation with lef-1	[preincubation with LEF-1]	0.0	3	1	1	1
147628	1710	ubiquitous nuclear component after activation	[ubiquitous nuclear component after activation]	0.0	5	1	1	1
147629	1710	role binding motif	[roles binding motifs]	0.0	3	1	1	1
147630	1710	DNA homology	[DNA homology]	0.0	2	1	1	1
147631	1710	messenger in b cell	[messengers in B cells]	0.0	4	1	1	1
147632	1710	heterogeneous manifestation	[heterogeneous manifestations]	0.0	2	1	1	1
147633	1710	potentially influence expression	[potentially influencing expression]	0.0	3	1	1	1
147634	1710	weak competitor in cell	[weak competitor in cells]	0.0	4	1	1	1
147635	1710	fractional inhibition	[fractional inhibition]	0.0	2	1	1	1
147636	1710	human thp 1 cell	[human THP 1 cells]	0.0	4	1	1	1
147637	1710	bcl6 molecule	[BCL6 molecule]	0.0	2	1	1	1
147638	1710	hamster ovary cell	[hamster ovary cells]	0.0	3	1	1	1
147639	1710	uv-induced cyp1a1 gene expression in cell	[UV-induced CYP1A1 gene expression in cells]	0.0	6	1	1	1
147640	1710	CaM kinase family	[CaM kinase family]	0.0	3	1	1	1
147641	1710	unilineage culture	[unilineage cultures]	0.0	2	1	1	1
147642	1710	Calcitriol [editorial]	[Calcitriol [editorial]]	0.0	2	1	1	1
147643	1710	ng/mL, respectively).	[ng/mL, respectively).]	0.0	2	1	1	1
147644	1710	group dissociation constant	[groups dissociation constant]	0.0	3	1	1	1
147645	1710	dual effect inhibition through adenosine triphosphate	[dual effects inhibition through adenosine triphosphate]	0.0	6	1	1	1
147646	1710	contain length	[containing lengths]	0.0	2	1	1	1
147647	1710	different forms:	[different forms:]	0.0	2	1	1	1
147648	1710	active mutant with PMA	[active mutant with PMA]	0.0	4	1	1	1
147649	1710	effect of polymorphonuclear leukocyte	[effects of polymorphonuclear leukocytes]	0.0	4	1	1	1
147650	1710	75-kDa hematopoietic intracellular signal protein	[75-kDa hematopoietic intracellular signaling protein]	0.0	5	1	1	1
147651	1710	syncytia-forming activity	[syncytia-forming activity]	0.0	2	1	1	1
147652	1710	radical gene transcription	[radical gene transcription]	0.0	3	1	1	1
147653	1710	five leukocyte antigen-B8	[Five leukocyte antigen-B8]	0.0	3	1	1	1
147654	1710	one immunological variable	[one immunological variable]	0.0	3	1	1	1
147655	1710	terminal repeat transcription	[terminal repeat transcription]	0.0	3	1	1	1
147656	1710	number with little alteration	[numbers with little alteration]	0.0	4	1	1	1
147657	1710	histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma	[histiocytoma rhabdomyosarcoma leiomyosarcoma liposarcoma]	0.0	4	1	1	1
147658	1710	unfractionated blood cell	[unfractionated blood cells]	0.0	3	1	1	1
147659	1710	result of the study	[results of the study]	0.0	4	1	1	1
147660	1710	expression of a dominant mutant	[expression of a dominant mutant]	0.0	5	1	1	1
147661	1710	hiv p24	[HIV p24]	0.0	2	1	1	1
147662	1710	pattern of deactivation	[patterns of deactivation]	0.0	3	1	1	1
147663	1710	domain HBD	[domain HBD]	0.0	2	1	1	1
147664	1710	distribution of gata transcription factor	[distribution of GATA transcription factors]	0.0	5	1	1	1
147665	1710	down-regulation of gene	[down-regulation of genes]	0.0	3	1	1	1
147666	1710	role 3-kinase activation	[role 3-kinase activation]	0.0	3	1	1	1
147667	1710	extent, factor-kappa B/Rel induction	[extent, factor-kappa B/Rel induction]	0.0	4	1	1	1
147668	1710	stat-binding site	[STAT-binding sites]	0.0	2	1	1	1
147669	1710	report of a interaction	[report of a interaction]	0.0	4	1	1	1
147670	1710	protein responsive	[proteins responsive]	0.0	2	1	1	1
147671	1710	C. pneumoniae cell	[C. pneumoniae cells]	0.0	3	1	1	1
147672	1710	embryonal carcinoma cell	[embryonal carcinoma cells]	0.0	3	1	1	1
147673	1710	corresponding to the acidic domain	[corresponding to the acidic domain]	0.0	5	1	1	1
147674	1710	informative probe	[informative probes]	0.0	2	1	1	1
147675	1710	transcription enhancement	[transcription enhancement]	0.0	2	1	1	1
147676	1710	human herpesvirus a T lymphotropic virus	[Human herpesvirus a T lymphotropic virus]	0.0	6	1	1	1
147677	1710	hSIE-oligonucleotide probe	[hSIE-oligonucleotide probe]	0.0	2	1	1	1
147678	1710	patient with chronic lymphatic leukemia	[patients with chronic lymphatic leukemia]	0.0	5	1	1	1
147679	1710	cells; a component	[cells; a component]	0.0	3	1	1	1
147680	1710	cox-2 activity	[COX-2 activity]	0.0	2	1	1	1
147681	1710	activator property	[activator properties]	0.0	2	1	1	1
147682	1710	two isoform in T cell	[two isoforms in T cells]	0.0	5	1	1	1
147683	1710	activation of granulocyte by beta-phorbol	[activation of granulocytes by beta-phorbol]	0.0	5	1	1	1
147684	1710	two cis-acting element b/gc-box	[Two cis-acting elements B/GC-box]	0.0	4	1	1	1
147685	1710	recombinant human tnf receptor	[recombinant human TNF receptor]	0.0	4	1	1	1
147686	1710	kinase inhibitor genistein	[kinase inhibitors genistein]	0.0	3	1	1	1
147687	1710	possible killer T/NK	[possible killer T/NK]	0.0	3	1	1	1
147688	1710	Leiomyosarcoma	[Leiomyosarcoma]	0.0	1	1	1	1
147689	1710	patient with Philadelphia chronic leukemia	[patients with Philadelphia chronic leukemia]	0.0	5	1	1	1
147690	1710	erythrocyte-specific carbonic anhydrase	[erythrocyte-specific carbonic anhydrase]	0.0	3	1	1	1
147691	1710	two mitogen-inducible dna-binding complex	[two mitogen-inducible DNA-binding complexes]	0.0	4	1	1	1
147692	1710	IFN factor promoter	[IFN factor promoter]	0.0	3	1	1	1
147693	1710	allow activation	[allowing activation]	0.0	2	1	1	1
147694	1710	features: implications.	[features: implications.]	0.0	2	1	1	1
147695	1710	list of important molecule	[list of important molecules]	0.0	4	1	1	1
147696	1710	type 2 T lymphocyte	[type 2 T lymphocytes]	0.0	4	1	1	1
147697	1710	synchronization to temporary, condition	[synchronization to temporary, conditions]	0.0	4	1	1	1
147698	1710	x-linked spinal atrophy a adult-onset form	[X-linked spinal atrophy an adult-onset form]	0.0	6	1	1	1
147699	1710	2 mg/kg iv bolus dose	[2 mg/kg IV bolus doses]	0.0	5	1	1	1
147700	1710	lymphocyte from the site	[Lymphocytes from the site]	0.0	4	1	1	1
147701	1710	regulation of cd14 expression during differentiation	[Regulation of CD14 expression during differentiation]	0.0	6	1	1	1
147702	1710	disease mpd	[diseases MPDs]	0.0	2	1	1	1
147703	1710	erythropoietin stem cell factor SCF	[erythropoietin stem cell factor SCF]	0.0	5	1	1	1
147704	1710	ap1 reporter construct nm),	[AP1 reporter constructs nM),]	0.0	4	1	1	1
147705	1710	27 child aged 6 year	[27 children aged 6 years]	0.0	5	1	1	1
147706	1710	defensin NP-1	[defensins NP-1]	0.0	2	1	1	1
147707	1710	nuclear factor-kappa b by lipoprotein	[nuclear factor-kappa B by lipoprotein]	0.0	5	1	1	1
147708	1710	1 year) in the presence	[1 year) in the presence]	0.0	5	1	1	1
147709	1710	monocyte in vitro interleukin-2 receptor	[monocytes in vitro interleukin-2 receptor]	0.0	5	1	1	1
147710	1710	experience severe toxicity secondary	[experiencing severe toxicity secondary]	0.0	4	1	1	1
147711	1710	major histocompatibility complex class molecule	[major histocompatibility complex class molecules]	0.0	5	1	1	1
147712	1710	decrease in growth	[decrease in growth]	0.0	3	1	1	1
147713	1710	distinguishing characteristic of htlv-i infection	[distinguishing characteristic of HTLV-I infection]	0.0	5	1	1	1
147714	1710	cytokine expression in leukocyte	[cytokine expression in leukocytes]	0.0	4	1	1	1
147715	1710	interleukin-1beta il-1beta gene	[interleukin-1beta IL-1beta gene]	0.0	3	1	1	1
147716	1710	possibly other cells;	[possibly other cells;]	0.0	3	1	1	1
147717	1710	link to cellular responses.	[link to cellular responses.]	0.0	4	1	1	1
147718	1710	P-4501A1	[P-4501A1]	0.0	1	1	1	1
147719	1710	different nfat-family protein	[different NFAT-family proteins]	0.0	3	1	1	1
147720	1710	objective: activation of the axis	[OBJECTIVE: Activation of the axis]	0.0	5	1	1	1
147721	1710	cell surface event	[cell surface events]	0.0	3	1	1	1
147722	1710	single gata-binding site	[single GATA-binding site]	0.0	3	1	1	1
147723	1710	inflammatory pathogenesis of asthma	[inflammatory pathogenesis of asthma]	0.0	4	1	1	1
147724	1710	only the mutation of R-276	[only the mutations of R-276]	0.0	5	1	1	1
147725	1710	1 gene transcription	[1 gene transcription]	0.0	3	1	1	1
147726	1710	new variant translocation characterization	[new variant translocation characterization]	0.0	4	1	1	1
147727	1710	effect on cellular event	[effect on cellular event]	0.0	4	1	1	1
147728	1710	t-lymphotrophic virus type	[T-lymphotrophic virus type]	0.0	3	1	1	1
147729	1710	(m-csf) receptor	[(M-CSF) receptor]	0.0	2	2	2	1
147730	1710	(Kd) of the fms	[(Kd) of the FMS]	0.0	4	1	1	1
147731	1710	possible new strategy	[possible new strategies]	0.0	3	1	1	1
147732	1710	estrogen negativity	[estrogen negativity]	0.0	2	1	1	1
147733	1710	10(-8) mol/L	[10(-8) mol/L]	0.0	2	1	1	1
147734	1710	5' CCAAT sequence	[5' CCAAT sequences]	0.0	3	1	1	1
147735	1710	prime by cytokine from cellular signal	[priming by cytokines from cellular signal]	0.0	6	1	1	1
147736	1710	consider a regulatory element	[Considering a regulatory element]	0.0	4	1	1	1
147737	1710	CsA fk506 nuclear factor	[CsA FK506 nuclear factor]	0.0	4	1	1	1
147738	1710	(kb) upstream	[(kb) upstream]	0.0	2	1	1	1
147739	1710	growth factor of T lymphocyte	[growth factor of T lymphocytes]	0.0	5	1	1	1
147740	1710	response to acid atra	[response to acid ATRA]	0.0	4	1	1	1
147741	1710	Thrombopoietin the primary regulator	[Thrombopoietin the primary regulator]	0.0	4	1	1	1
147742	1710	child with different variant	[children with different variants]	0.0	4	1	1	1
147743	1710	anti-ERK extracellular kinase	[anti-ERK extracellular kinase]	0.0	3	1	1	1
147744	1710	element block element alpha/delta 1	[element blocking element alpha/delta 1]	0.0	5	1	1	1
147745	1710	mild oxidation	[mild oxidation]	0.0	2	1	1	1
147746	1710	other steroid	[other steroids]	0.0	2	1	1	1
147747	1710	PMA for h.	[PMA for h,]	0.0	3	1	1	1
147748	1710	expression of the map kinase-specific phosphatase	[Expression of the MAP kinase-specific phosphatase]	0.0	6	1	1	1
147749	1710	b-cell-specific activator site	[B-cell-specific activator site]	0.0	3	1	1	1
147750	1710	element of the GM-CSF promoter	[elements of the GM-CSF promoter]	0.0	5	1	1	1
147751	1710	gene g0/g1 switch gene	[genes G0/G1 switch genes]	0.0	4	1	1	1
147752	1710	mg/24h; 1.4+/-0.8)	[mg/24h; 1.4+/-0.8)]	0.0	2	1	1	1
147753	1710	Neutral sphingomyelinase	[Neutral sphingomyelinase]	0.0	2	1	1	1
147754	1710	isoform to the fraction	[isoforms to the fraction]	0.0	4	1	1	1
147755	1710	compounds' potency in vivo,	[compounds' potency in vivo,]	0.0	4	1	1	1
147756	1710	ZII domain upstream	[ZII domain upstream]	0.0	3	1	1	1
147757	1710	myb-transformed hemopoi-etic cell	[myb-transformed hemopoi-etic cells]	0.0	3	1	1	1
147758	1710	evidence a potent modulator	[evidence a potent modulator]	0.0	4	1	1	1
147759	1710	hit-t15 cell	[HIT-T15 cells]	0.0	2	1	1	1
147760	1710	(band pk)	[(band pk)]	0.0	2	1	1	1
147761	1710	component after activation	[component after activation]	0.0	3	1	1	1
147762	1710	two complex contain tr alpha	[two complexes containing TR alpha]	0.0	5	1	1	1
147763	1710	phosphatidylinositol 3-kinase wortmannin	[phosphatidylinositol 3-kinase wortmannin]	0.0	3	1	1	1
147764	1710	direct analysis of this cell	[Direct analysis of these cells]	0.0	5	1	1	1
147765	1710	nf-kappab activation 1 repeat	[NF-kappaB activation 1 repeat]	0.0	4	1	1	1
147766	1710	article, transcriptional regulation	[article, transcriptional regulation]	0.0	3	1	1	1
147767	1710	However, transduction of gata-3	[However, transduction of GATA-3]	0.0	4	1	1	1
147768	1710	functional modulation	[functional modulation]	0.0	2	1	1	1
147769	1710	3,5,3'-triiodothyronine receptor	[3,5,3'-triiodothyronine receptors]	0.0	2	1	1	1
147770	1710	novel model for lineage restriction	[novel model for lineage restriction]	0.0	5	1	1	1
147771	1710	trigger significantly (p	[Triggering significantly (P]	0.0	3	1	1	1
147772	1710	cytoplasmic terminus	[cytoplasmic terminus]	0.0	2	1	1	1
147773	1710	suppression of stat1 function during infection	[suppression of Stat1 function during infection]	0.0	6	1	1	1
147774	1710	cooperative interaction between two coactivator	[cooperative interactions between two coactivators]	0.0	5	1	1	1
147775	1710	corresponding mobility form	[corresponding mobility forms]	0.0	3	1	1	1
147776	1710	opposite effect in the HLA-Cw*0702 system	[opposite effects in the HLA-Cw*0702 system]	0.0	6	1	1	1
147777	1710	basis characteristics,	[basis characteristics,]	0.0	2	1	1	1
147778	1710	several complex	[Several complexes]	0.0	2	1	1	1
147779	1710	type I interferon	[type I interferon]	0.0	3	1	1	1
147780	1710	kinetic follow phorbol ester activation	[kinetics following phorbol ester activation]	0.0	5	1	1	1
147781	1710	antiretroviral	[antiretroviral]	0.0	1	1	1	1
147782	1710	CD28 antibody	[CD28 antibody]	0.0	2	1	1	1
147783	1710	consider group of patient	[considering groups of patients]	0.0	4	1	1	1
147784	1710	erythroid 5-aminolevulinate synthase promoter analysis	[erythroid 5-aminolevulinate synthase promoter analysis]	0.0	5	1	1	1
147785	1710	target in inflammatory state	[target in inflammatory states]	0.0	4	1	1	1
147786	1710	rapidly tyrosine-phosphorylated follow factor treatment	[rapidly tyrosine-phosphorylated following factor treatment]	0.0	5	1	1	1
147787	1710	cotransfection into cos-7 cell	[Cotransfection into COS-7 cells]	0.0	4	1	1	1
147788	1710	regard the use like fibric acid	[regarding the use like fibric acids]	0.0	6	1	1	1
147789	1710	require ROI production by NADPH oxidase	[requiring ROI production by NADPH oxidase]	0.0	6	1	1	1
147790	1710	response to fluticasone propionate	[Response to fluticasone propionate]	0.0	4	1	1	1
147791	1710	GM-kappa B/GC-box	[GM-kappa B/GC-box]	0.0	2	1	1	1
147792	1710	start at day 0/1	[starting at day 0/1]	0.0	4	1	1	1
147793	1710	expression of interferon regulatory factor	[expression of interferon regulatory factor]	0.0	5	1	1	1
147794	1710	thereby provide a basis	[thereby providing a basis]	0.0	4	1	1	1
147795	1710	first intron of bcl-6	[first intron of BCL-6]	0.0	4	1	1	1
147796	1710	only NF-kappa b	[only NF-kappa B]	0.0	3	1	1	1
147797	1710	lymphocyte infiltration in breast cancer	[lymphocyte infiltration in breast cancers]	0.0	5	1	1	1
147798	1710	high number	[higher number]	0.0	2	2	2	1
147799	1710	various haematopoietic line u937	[various haematopoietic lines U937]	0.0	4	1	1	1
147800	1710	other risk factor	[other risk factors]	0.0	3	1	1	1
147801	1710	element-binding activity	[element-binding activity]	0.0	2	1	1	1
147802	1710	tpa responsive element	[TPA responsive elements]	0.0	3	1	1	1
147803	1710	enhancement of factor kappa b	[enhancement of factor kappa B]	0.0	5	1	1	1
147804	1710	local modulation	[local modulation]	0.0	2	1	1	1
147805	1710	two major product	[two major products]	0.0	3	1	1	1
147806	1710	effect of replication	[effect of replication]	0.0	3	1	1	1
147807	1710	mutant of IkappaBalpha	[mutant of IkappaBalpha]	0.0	3	1	1	1
147808	1710	about 60 bp upstream	[about 60 bp upstream]	0.0	4	1	1	1
147809	1710	protein act as transcription factor	[proteins acting as transcription factors]	0.0	5	1	1	1
147810	1710	ligation of ag receptor	[Ligation of Ag receptors]	0.0	4	1	1	1
147811	1710	blood mononuclear cell proliferation	[blood mononuclear cell proliferation]	0.0	4	1	1	1
147812	1710	synergistic activation via cooperative nf-kappa b	[synergistic activation via cooperative NF-kappa B]	0.0	6	1	1	1
147813	1710	cell of acute leukemia	[cells of acute leukemia]	0.0	4	1	1	1
147814	1710	target k562	[target K562]	0.0	2	1	1	1
147815	1710	peripheral monocyte nuclear extract	[peripheral monocyte nuclear extracts]	0.0	4	1	1	1
147816	1710	other EBV-associated, epitope	[other EBV-associated, epitopes]	0.0	3	1	1	1
147817	1710	possibility toward this goal	[possibility toward this goal]	0.0	4	1	1	1
147818	1710	ap-1 -dependent activity	[AP-1 -dependent activity]	0.0	3	1	1	1
147819	1710	hiv type 1 protease activation	[HIV type 1 protease activation]	0.0	5	1	1	1
147820	1710	precursor into myelomonocytic cell	[precursors into myelomonocytic cells]	0.0	4	1	1	1
147821	1710	several rearrangement in the different ape	[several rearrangements in the different apes]	0.0	6	1	1	1
147822	1710	interdigitate DC	[interdigitating DC]	0.0	2	1	1	1
147823	1710	expression through cyclic AMP production	[expression through cyclic AMP production]	0.0	5	1	1	1
147824	1710	follow lps addition	[following LPS addition]	0.0	3	1	1	1
147825	1710	induce NF-kappaB through a transduction mechanism	[inducing NF-kappaB through a transduction mechanism]	0.0	6	1	1	1
147826	1710	element important for expression	[element important for expression]	0.0	4	1	1	1
147827	1710	sp promoter	[SP promoter]	0.0	2	1	1	1
147828	1710	similar differentiation-inducing capacity	[similar differentiation-inducing capacity]	0.0	3	1	1	1
147829	1710	activation of set	[activation of sets]	0.0	3	1	1	1
147830	1710	ifn-gamma -dependent up-regulation	[IFN-gamma -dependent up-regulation]	0.0	3	1	1	1
147831	1710	physiologically relevant creb kinase	[physiologically relevant CREB kinase]	0.0	4	1	1	1
147832	1710	least four specific NF-kappaB complex	[least four specific NF-kappaB complexes]	0.0	5	1	1	1
147833	1710	cytokine for the proliferation	[cytokines for the proliferation]	0.0	4	1	1	1
147834	1710	blot study	[blot studies]	0.0	2	1	1	1
147835	1710	jurkat cell with antisense,	[Jurkat cells with antisense,]	0.0	4	1	1	1
147836	1710	map kinase cascade	[MAP kinase cascade]	0.0	3	1	1	1
147837	1710	level of free cortisol	[levels of free cortisol]	0.0	4	1	1	1
147838	1710	converge in intracellular pathway	[converging in intracellular pathways]	0.0	4	1	1	1
147839	1710	inhibition by a inhibitor	[inhibition by an inhibitor]	0.0	4	1	1	1
147840	1710	result in b translocation	[resulting in B translocation]	0.0	4	1	1	1
147841	1710	il4 transcription	[IL4 transcription]	0.0	2	1	1	1
147842	1710	heat-shock for 2 hour at degree	[Heat-shock for 2 hours at degrees]	0.0	6	1	1	1
147843	1710	kinase target	[kinase target]	0.0	2	1	1	1
147844	1710	factor T cell nfat	[factor T cells NFAT]	0.0	4	1	1	1
147845	1710	ability -express human fibroblastic cell	[abilities -expressing human fibroblastic cells]	0.0	5	1	1	1
147846	1710	additional 6 month	[additional 6 months]	0.0	3	1	1	1
147847	1710	furthermore, NFkappaB translocation	[Furthermore, NFkappaB translocation]	0.0	3	1	1	1
147848	1710	similar inhibition	[Similar inhibition]	0.0	2	1	1	1
147849	1710	clonal deletion of T cell	[clonal deletion of T cells]	0.0	5	1	1	1
147850	1710	latent cycle reactivity	[latent cycle reactivities]	0.0	3	1	1	1
147851	1710	domain in the rank tail	[domains in the RANK tail]	0.0	5	1	1	1
147852	1710	Precise deletion	[Precise deletion]	0.0	2	1	1	1
147853	1710	element necessary for transactivation	[element necessary for transactivation]	0.0	4	1	1	1
147854	1710	expression datum	[expression data]	0.0	2	1	1	1
147855	1710	competition between activator RelA	[competition between activators RelA]	0.0	4	1	1	1
147856	1710	express (tcr) variable region beta-chain family	[expressing (TCR) variable region beta-chain families]	0.0	6	1	1	1
147857	1710	strong regulator of platelet function	[strong regulator of platelet function]	0.0	5	1	1	1
147858	1710	regulate T cell activation	[regulating T cell activation]	0.0	4	1	1	1
147859	1710	protein 76 slp-76	[protein 76 SLP-76]	0.0	3	1	1	1
147860	1710	cut expression	[Cutting expression]	0.0	2	1	1	1
147861	1710	gene chimera	[gene chimeras]	0.0	2	1	1	1
147862	1710	expression to human immunodeficiency virus type	[expression to human immunodeficiency virus type]	0.0	6	1	1	1
147863	1710	y292	[Y292]	0.0	1	1	1	1
147864	1710	encode a putative regulator of differentiation	[encoding a putative regulator of differentiation]	0.0	6	1	1	1
147865	1710	CD28 up-regulation	[CD28 up-regulation]	0.0	2	1	1	1
147866	1710	co-cultured epithelial cell BEAS-2B	[co-cultured epithelial cells BEAS-2B]	0.0	4	1	1	1
147867	1710	nf-kappa b activity from patient	[NF-kappa B activity from patients]	0.0	5	1	1	1
147868	1710	involvement in transcriptional regulation	[involvement in transcriptional regulation]	0.0	4	1	1	1
147869	1710	icam-1 surface protein in arterial cell	[ICAM-1 surface protein in arterial cells]	0.0	6	1	1	1
147870	1710	cd4+ t-lymphocyte cell line	[CD4+ T-lymphocyte cell line]	0.0	4	1	1	1
147871	1710	627-bp promoter fragment	[627-bp promoter fragment]	0.0	3	1	1	1
147872	1710	form include acute lymphoblastic leukemia	[forms including acute lymphoblastic leukemia]	0.0	5	1	1	1
147873	1710	accurate evaluation	[accurate evaluation]	0.0	2	1	1	1
147874	1710	novel motif	[novel motif]	0.0	2	1	1	1
147875	1710	translocation of c-Rel/p65 heterodimer	[translocation of c-Rel/p65 heterodimers]	0.0	4	2	2	1
147876	1710	five DNase-I hypersensitive site HS	[Five DNase-I hypersensitive sites HS]	0.0	5	1	1	1
147877	1710	PXQXT/S in STP-A11	[PXQXT/S in STP-A11]	0.0	3	1	1	1
147878	1710	change of the receptor.	[changes of the receptor.]	0.0	4	1	1	1
147879	1710	t-cell leukemia ATL patient	[T-cell leukemia ATL patients]	0.0	4	1	1	1
147880	1710	IL-2 promoter distal factor	[IL-2 promoter distal factor]	0.0	4	1	1	1
147881	1710	alpha-globin g 5' region	[alpha-globin G 5' region]	0.0	4	1	1	1
147882	1710	affinity binding of GATA-3	[affinity binding of GATA-3]	0.0	4	1	1	1
147883	1710	differ only at amino termini	[differing only at amino termini]	0.0	5	1	1	1
147884	1710	transcription include that encode	[transcription including those encoding]	0.0	4	1	1	1
147885	1710	T cell from (mean 78	[T cells from (mean 78]	0.0	5	1	1	1
147886	1710	-dependent	[-dependent]	0.0	1	1	1	1
147887	1710	hypermutation mechanism	[hypermutation mechanism]	0.0	2	1	1	1
147888	1710	relationship between receptor	[Relationship between receptor]	0.0	3	1	1	1
147889	1710	respiratory manifestation of fibrosis	[respiratory manifestations of fibrosis]	0.0	4	1	1	1
147890	1710	number of receptor constant	[number of receptors constant]	0.0	4	1	1	1
147891	1710	provide mechanism restrict hiv-1 gene expression	[providing mechanism restricting HIV-1 gene expression]	0.0	6	1	1	1
147892	1710	part of the il-1beta promoter	[parts of the IL-1beta promoter]	0.0	5	1	1	1
147893	1710	expression of surface markers, intracytoplasmic content	[Expression of surface markers, intracytoplasmic content]	0.0	6	1	1	1
147894	1710	promotion of neutrophil migration	[promotion of neutrophil migration]	0.0	4	1	1	1
147895	1710	one other,	[one other,]	0.0	2	1	1	1
147896	1710	corticosteroid receptor glucocorticoid receptor	[corticosteroid receptors glucocorticoid receptors]	0.0	4	1	1	1
147897	1710	dephosphorylation of nuclear factor	[dephosphorylation of nuclear factor]	0.0	4	1	1	1
147898	1710	nuclear stimulation	[nuclear stimulation]	0.0	2	1	1	1
147899	1710	tumour cell of non-hodgkin's lymphoma	[tumour cells of non-Hodgkin's lymphoma]	0.0	5	1	1	1
147900	1710	feature of T cell	[feature of T cells]	0.0	4	1	1	1
147901	1710	two principal ligand for CD28	[two principal ligands for CD28]	0.0	5	1	1	1
147902	1710	t-cell (tcr) region beta-chain family	[T-cell (TCR) region beta-chain families]	0.0	5	1	1	1
147903	1710	localization of tf antigen	[localization of TF antigen]	0.0	4	1	1	1
147904	1710	tonsils.	[tonsils.]	0.0	1	1	1	1
147905	1710	unrelated case of tsc	[unrelated cases of TSC]	0.0	4	1	1	1
147906	1710	zero- thalassemia patient with HbF production	[zero- thalassemia patient with HbF production]	0.0	6	1	1	1
147907	1710	significant twofold increase from patient	[significant twofold increase from patients]	0.0	5	1	1	1
147908	1710	significant class	[significant class]	0.0	2	1	1	1
147909	1710	cobalt, nickel,	[cobalt, nickel,]	0.0	2	1	1	1
147910	1710	pseudohypoaldosteronism with transient reduction	[pseudohypoaldosteronism with transient reduction]	0.0	4	1	1	1
147911	1710	host protein	[host proteins]	0.0	2	1	1	1
147912	1710	4 month	[4 months]	0.0	2	1	1	1
147913	1710	peripheral blood T lymphocyte PBL	[peripheral blood T lymphocytes PBL]	0.0	5	1	1	1
147914	1710	5 bovine serum	[5 bovine serum]	0.0	3	1	1	1
147915	1710	normal counterpart to leukemia	[normal counterpart to leukemias]	0.0	4	1	1	1
147916	1710	substitution in the counterpart	[substitutions in the counterpart]	0.0	4	1	1	1
147917	1710	occupancy 1 enhancer by nf-kappa b	[occupancy 1 enhancer by NF-kappa B]	0.0	6	1	1	1
147918	1710	tnf-alpha receptor type ii	[TNF-alpha receptor type II]	0.0	4	1	1	1
147919	1710	control of cell	[control of cells]	0.0	3	1	1	1
147920	1710	increase through activation	[increase through activation]	0.0	3	1	1	1
147921	1710	splicing,	[splicing,]	0.0	1	1	1	1
147922	1710	loss of phorbol ester-induced differentiation	[loss of phorbol ester-induced differentiation]	0.0	5	1	1	1
147923	1710	tissue with cell turnover	[tissues with cell turnover]	0.0	4	1	1	1
147924	1710	splicing.	[splicing.]	0.0	1	1	1	1
147925	1710	expression of level in the absence	[expression of levels in the absence]	0.0	6	1	1	1
147926	1710	stat family member Stat1	[STAT family member Stat1]	0.0	4	1	1	1
147927	1710	patient with primary resistance	[patients with primary resistance]	0.0	4	1	1	1
147928	1710	residual disease in myelogenous leukemia	[residual disease in myelogenous leukemia]	0.0	5	1	1	1
147929	1710	two 15-mer AS oligonucleotide	[two 15-mer AS oligonucleotides]	0.0	4	1	1	1
147930	1710	however a necessary cofactor	[However a necessary cofactor]	0.0	4	1	1	1
147931	1710	icam-1 molecules, blot analysis	[ICAM-1 molecules, blot analysis]	0.0	4	1	1	1
147932	1710	different promoter in cell	[different promoters in cells]	0.0	4	1	1	1
147933	1710	signal transduction on eosinophil	[signal transduction on eosinophils]	0.0	4	1	1	1
147934	1710	lack a major portion	[lacking a major portion]	0.0	4	1	1	1
147935	1710	humara method	[HUMARA method]	0.0	2	1	1	1
147936	1710	activate protein bsap/pax5	[activating protein BSAP/PAX5]	0.0	3	1	1	1
147937	1710	dependent adhesion umbilical vein endothelial cell	[dependent adhesion umbilical vein endothelial cells]	0.0	6	1	1	1
147938	1710	significance of p38alpha protein kinase	[significance of p38alpha protein kinase]	0.0	5	1	1	1
147939	1710	several condition such as disease	[several conditions such as diseases]	0.0	5	1	1	1
147940	1710	contrast, a dominant mutant	[contrast, a dominant mutant]	0.0	4	1	1	1
147941	1710	glutathione disulfide gssg	[glutathione disulfide GSSG]	0.0	3	1	1	1
147942	1710	cell adhesion assay	[cell adhesion assays]	0.0	3	1	1	1
147943	1710	effect in vivo	[effects in vivo]	0.0	3	1	1	1
147944	1710	dissociation of hGR	[dissociation of hGR]	0.0	3	1	1	1
147945	1710	leiomyosarcoma 10, liposarcoma	[leiomyosarcoma 10, liposarcoma]	0.0	3	1	1	1
147946	1710	peripheral blood monocyte from donor	[peripheral blood monocytes from donors]	0.0	5	1	1	1
147947	1710	metal-ion chelator	[metal-ion chelator]	0.0	2	1	1	1
147948	1710	parameter of the nuclear protein	[parameters of the nuclear proteins]	0.0	5	1	1	1
147949	1710	bq cell	[BQ cells]	0.0	2	1	1	1
147950	1710	ankyrin-rich protein	[ankyrin-rich proteins]	0.0	2	1	1	1
147951	1710	25 uncomplicated pregnancy	[25 uncomplicated pregnancies]	0.0	3	1	1	1
147952	1710	pattern recognition receptor	[pattern recognition receptor]	0.0	3	1	1	1
147953	1710	complementary substitution in the peptide	[complementary substitution in the peptide]	0.0	5	1	1	1
147954	1710	interleukin gene expression follow CD3	[interleukin gene expression following CD3]	0.0	5	1	1	1
147955	1710	differentiation of blood monocyte	[differentiation of blood monocytes]	0.0	4	1	1	1
147956	1710	most likely identical proteins,	[most likely identical proteins,]	0.0	4	1	1	1
147957	1710	activation of rxr	[activation of RXRs]	0.0	3	1	1	1
147958	1710	skewer induce ifn-gamma production	[skewer inducing IFN-gamma production]	0.0	4	1	1	1
147959	1710	rela function	[RelA function]	0.0	2	1	1	1
147960	1710	overexpression of a phosphorylation-defective form	[Overexpression of a phosphorylation-defective form]	0.0	5	1	1	1
147961	1710	signal distinct	[signal distinct]	0.0	2	1	1	1
147962	1710	ligation of CD80	[Ligation of CD80]	0.0	3	1	1	1
147963	1710	-148 to +60 region	[-148 to +60 region]	0.0	4	1	1	1
147964	1710	donor (d.e.	[donors (D.E.]	0.0	2	1	1	1
147965	1710	interleukin-1 induction	[interleukin-1 induction]	0.0	2	1	1	1
147966	1710	level of interleukin-1alpha	[levels of interleukin-1alpha]	0.0	3	1	1	1
147967	1710	immunodeficiency virus-1 terminal repeat	[immunodeficiency virus-1 terminal repeat]	0.0	4	1	1	1
147968	1710	expression of tissue inhibitor	[expression of tissue inhibitor]	0.0	4	1	1	1
147969	1710	memory (cd45ro+) cell	[memory (CD45RO+) cells]	0.0	3	1	1	1
147970	1710	well-characterized role in adipocytes.	[well-characterized role in adipocytes.]	0.0	4	1	1	1
147971	1710	inflammatory response result tissue damage	[inflammatory response resulting tissue damage]	0.0	5	1	1	1
147972	1710	DNA binding specificity of 3	[DNA binding specificity of 3]	0.0	5	1	1	1
147973	1710	second messenger response	[second messenger response]	0.0	3	1	1	1
147974	1710	relatively high, concentration to 10 &mgr;m)	[relatively high, concentrations to 10 &mgr;M)]	0.0	6	1	1	1
147975	1710	Interdomain B	[Interdomain B]	0.0	2	1	1	1
147976	1710	growth condition	[growth conditions]	0.0	2	1	1	1
147977	1710	myeloid-cell-specific promoter	[myeloid-cell-specific promoter]	0.0	2	1	1	1
147978	1710	activity a potential	[activity a potential]	0.0	3	1	1	1
147979	1710	IDDM subject	[IDDM subjects]	0.0	2	1	1	1
147980	1710	expression gene family member	[expression gene family members]	0.0	4	1	1	1
147981	1710	occasion	[occasions]	0.0	1	1	1	1
147982	1710	domain of amino acid	[domain of amino acids]	0.0	4	1	1	1
147983	1710	effect on transcriptional regulatory factor	[effects on transcriptional regulatory factors]	0.0	5	1	1	1
147984	1710	double infection of a cell	[double infection of a cell]	0.0	5	1	1	1
147985	1710	expression on human melanoma MMs	[expression on human melanomas MMs]	0.0	5	1	1	1
147986	1710	bind transcriptional property for E2A- HLF	[binding transcriptional properties for E2A- HLF]	0.0	6	1	1	1
147987	1710	spleen T	[spleen T]	0.0	2	1	1	1
147988	1710	cell line with the potential	[cell line with the potential]	0.0	5	1	1	1
147989	1710	important role in growth	[important role in growth]	0.0	4	1	1	1
147990	1710	isolation of human lh-2	[isolation of human LH-2]	0.0	4	1	1	1
147991	1710	housekeeping alas precursor kd.	[housekeeping ALAS precursor kd.]	0.0	4	1	1	1
147992	1710	select a patient	[selecting a patient]	0.0	3	1	1	1
147993	1710	maximal inhibition of 62%	[maximal inhibition of 62%]	0.0	4	1	1	1
147994	1710	plasmid carry copy	[plasmids carrying copies]	0.0	3	1	1	1
147995	1710	action CPRE GGACTACAG at -49/41	[action CPRE GGACTACAG at -49/-41,]	0.0	5	1	1	1
147996	1710	ribosome salt	[ribosome salt]	0.0	2	1	1	1
147997	1710	perhaps act	[perhaps acting]	0.0	2	1	1	1
147998	1710	development of symptom	[development of symptoms]	0.0	3	1	1	1
147999	1710	gold compound contain gold ion HAuCl3	[gold compound containing gold ion HAuCl3]	0.0	6	1	1	1
148000	1710	hla-dr- a unrecognized form of leukemia	[HLA-DR- a unrecognized form of leukemia]	0.0	6	1	1	1
148001	1710	anti-ERK kinase	[anti-ERK kinase]	0.0	2	1	1	1
148002	1710	paternal expression of wt1	[paternal expression of WT1]	0.0	4	1	1	1
148003	1710	amino acid of bob.1/obf.1	[amino acids of BOB.1/OBF.1]	0.0	4	1	1	1
148004	1710	TAL1 expression by cell in vivo	[TAL1 expression by cells in vivo]	0.0	6	1	1	1
148005	1710	htlv-i tax protein	[HTLV-I Tax protein]	0.0	3	1	1	1
148006	1710	stress agent like radiation exposure	[stress agents like radiation exposure]	0.0	5	1	1	1
148007	1710	well-characterized Ets family member	[well-characterized Ets family members]	0.0	4	1	1	1
148008	1710	epitope on the region	[epitope on the region]	0.0	4	1	1	1
148009	1710	ankyrin motif-rich protein	[ankyrin motif-rich proteins]	0.0	3	1	1	1
148010	1710	GHF-1/Pit-1 binding site footprint	[GHF-1/Pit-1 binding site footprint]	0.0	4	1	1	1
148011	1710	kinase in human monocyte	[kinase in human monocytes]	0.0	4	1	1	1
148012	1710	model during the initial stage	[model during the initial stages]	0.0	5	1	1	1
148013	1710	encode CD11a	[encoding CD11a]	0.0	2	1	1	1
148014	1710	analysis of translocation of member	[Analyses of translocation of members]	0.0	5	1	1	1
148015	1710	study of the -236 sequence	[studies of the -236 sequence]	0.0	5	1	1	1
148016	1710	response to granulocyte-macrophage	[response to granulocyte-macrophage]	0.0	3	1	1	1
148017	1710	polymorphonucleate	[polymorphonucleate]	0.0	1	1	1	1
148018	1710	immunoglobulin gene enhancer	[immunoglobulin gene enhancer]	0.0	3	1	1	1
148019	1710	binding of nuclear factor in	[binding of nuclear factors in]	0.0	5	1	1	1
148020	1710	evidence of switch recombination	[evidence of switch recombination]	0.0	4	1	1	1
148021	1710	promoter contain cis element	[promoter containing cis elements]	0.0	4	1	1	1
148022	1710	several b cell-encoded gene	[several B cell-encoded genes]	0.0	4	1	1	1
148023	1710	X-inactivation pattern	[X-inactivation patterns]	0.0	2	1	1	1
148024	1710	acute transfection	[Acute transfection]	0.0	2	1	1	1
148025	1710	control of other protein	[control of other proteins]	0.0	4	1	1	1
148026	1710	bryostatin nm), another activator	[bryostatin nM), another activator]	0.0	4	1	1	1
148027	1710	548 bp	[548 bp]	0.0	2	1	1	1
148028	1710	strategy manipulate pathological response	[strategies manipulating pathological responses]	0.0	4	1	1	1
148029	1710	Cdc42 machinery	[Cdc42 machinery]	0.0	2	1	1	1
148030	1710	activity after transfection	[activity after transfection]	0.0	3	1	1	1
148031	1710	28 kda	[28 kDa]	0.0	2	1	1	1
148032	1710	interaction than Grb2	[interaction than Grb2]	0.0	3	1	1	1
148033	1710	cd4+ T cell with sea	[CD4+ T cells with SEA]	0.0	5	1	1	1
148034	1710	involvement of cyclic protein kinase	[Involvement of cyclic protein kinases]	0.0	5	1	1	1
148035	1710	sequence similarity to the site	[sequence similarity to the site]	0.0	5	1	1	1
148036	1710	subsequent occurrence	[subsequent occurrence]	0.0	2	1	1	1
148037	1710	chromosome rearrangement	[chromosome rearrangements]	0.0	2	1	1	1
148038	1710	infection b cell by herpesvirus	[infection B cells by herpesvirus]	0.0	5	1	1	1
148039	1710	core NFAT complex	[core NFAT complex]	0.0	3	1	1	1
148040	1710	healthy thyroid gland	[healthy thyroid gland]	0.0	3	1	1	1
148041	1710	effect of tumor necrosis factor-alpha	[effects of tumor necrosis factor-alpha]	0.0	5	1	1	1
148042	1710	2422-erh)2d3 synthesis by 135(oh)2d3	[24,25-(OH)2D3 synthesis by 1,25(OH)2D3]	0.0	4	1	1	1
148043	1710	recombinant virus aav	[recombinant virus AAV]	0.0	3	1	1	1
148044	1710	NF-kappa b moiety	[NF-kappa B moieties]	0.0	3	1	1	1
148045	1710	directly modulate calcium in muscle cell	[directly modulating calcium in muscle cells]	0.0	6	1	1	1
148046	1710	reactive process	[reactive process]	0.0	2	1	1	1
148047	1710	use a quantitative polymerase chain method	[using a quantitative polymerase chain method]	0.0	6	1	1	1
148048	1710	epsilon-globin-encoding gene [Cao Proc.Natl.Acad.Sci.USA	[epsilon-globin-encoding gene [Cao Proc.Natl.Acad.Sci.USA]	0.0	4	1	1	1
148049	1710	content of h+-atpase	[content of H+-ATPase]	0.0	3	1	1	1
148050	1710	correlation with clinical variable	[correlation with clinical variables]	0.0	4	1	1	1
148051	1710	microtitre assay system concentration	[microtitre assay system concentration]	0.0	4	1	1	1
148052	1710	determinant for MLV activity	[determinants for MLV activity]	0.0	4	1	1	1
148053	1710	W-X-Y	[W-X-Y]	0.0	1	1	1	1
148054	1710	identify genetic target	[identifying genetic targets]	0.0	3	1	1	1
148055	1710	stimulation of the monocytic cell line	[Stimulation of the monocytic cell line]	0.0	6	1	1	1
148056	1710	gene lysp100	[gene LYSP100]	0.0	2	1	1	1
148057	1710	signal step in ald T cell	[signaling steps in ALD T cells]	0.0	6	1	1	1
148058	1710	(ie,	[(ie,]	0.0	1	1	1	1
148059	1710	absence of a costimulatory signal	[absence of an costimulatory signal]	0.0	5	1	1	1
148060	1710	deletion of the localization signal present	[deletion of the localization signal present]	0.0	6	1	1	1
148061	1710	vitro effect on the na+/h(+)-exchanger	[vitro effects on the Na+/H(+)-exchanger]	0.0	5	1	1	1
148062	1710	mediate lysis in T lymphoblast	[mediating lysis in T lymphoblasts]	0.0	5	1	1	1
148063	1710	metastatic suppressor gene nm23-h1	[metastatic suppressor genes nm23-H1]	0.0	4	1	1	1
148064	1710	receptor characteristics.	[receptor characteristics.]	0.0	2	1	1	1
148065	1710	regulation of the alpha-like globin gene	[regulation of the alpha-like globin genes]	0.0	6	1	1	1
148066	1710	receptor characteristics,	[receptor characteristics,]	0.0	2	1	1	1
148067	1710	high level of nf-kappab	[high levels of NF-kappaB]	0.0	4	1	1	1
148068	1710	export complex from the NPC	[export complexes from the NPC]	0.0	5	1	1	1
148069	1710	several cell type follow expression	[several cell types following expression]	0.0	5	1	1	1
148070	1710	activity of Stat1alpha	[activity of Stat1alpha]	0.0	3	1	1	1
148071	1710	multiple inactivate substitution in the counterpart	[multiple inactivating substitutions in the counterpart]	0.0	6	1	1	1
148072	1710	murine b-cell coactivator Bob1	[murine B-cell coactivator Bob1]	0.0	4	1	1	1
148073	1710	include presentation, response	[including presentation, response]	0.0	3	1	1	1
148074	1710	Effect on expression	[Effects on expression]	0.0	3	1	1	1
148075	1710	immune reaction at stages.	[immune reactions at stages.]	0.0	4	1	1	1
148076	1710	transactivation of the lps response element	[transactivation of the LPS response element]	0.0	6	1	1	1
148077	1710	two element promoter,	[Two elements promoter,]	0.0	3	1	1	1
148078	1710	lack precipitin	[lacking precipitins]	0.0	2	1	1	1
148079	1710	rat splenocyte proliferation	[rat splenocyte proliferation]	0.0	3	1	1	1
148080	1710	potent stimulator of t-cell recognition	[potent stimulators of T-cell recognition]	0.0	5	1	1	1
148081	1710	oxygen species such as hydrogen peroxide	[oxygen species such as hydrogen peroxide]	0.0	6	1	1	1
148082	1710	regulation 1 expression in monocytes: role	[regulation 1 expression in monocytes: role]	0.0	6	1	1	1
148083	1710	day in 5% serum	[days in 5% serum]	0.0	4	1	1	1
148084	1710	first protein	[first protein]	0.0	2	1	1	1
148085	1710	null	[null]	0.0	1	1	1	1
148086	1710	affect the viral LTR	[affecting the viral LTR]	0.0	4	1	1	1
148087	1710	3) low content	[3) low content]	0.0	3	1	1	1
148088	1710	cell of t-cell leukemia patient	[cells of T-cell leukemia patients]	0.0	5	1	1	1
148089	1710	regulate interferon (ifn)-gamma production	[regulating interferon (IFN)-gamma production]	0.0	4	1	1	1
148090	1710	presence within breast carcinoma cell	[presence within breast carcinoma cells]	0.0	5	1	1	1
148091	1710	sp1 /DNA	[SP1 /DNA]	0.0	2	1	1	1
148092	1710	mrna level alpha1	[mRNA levels alpha1]	0.0	3	1	1	1
148093	1710	extend from -250 bp	[extending from -250 bp]	0.0	4	1	1	1
148094	1710	(p50/p65)-	[(p50/p65)-]	0.0	1	1	1	1
148095	1710	recognize epithelial tumor ag	[recognizing epithelial tumor Ag]	0.0	4	1	1	1
148096	1710	eosinophil granule protein promoter	[eosinophil granule protein promoter]	0.0	4	1	1	1
148097	1710	vzv -susceptible donor	[VZV -susceptible donors]	0.0	3	1	1	1
148098	1710	STAT 5 protein	[STAT 5 proteins]	0.0	3	1	1	1
148099	1710	one function of tax in cell	[one function of Tax in cells]	0.0	6	1	1	1
148100	1710	therefore, initiation	[Therefore, initiation]	0.0	2	1	1	1
148101	1710	leukemia-specific acid receptor pml-rar	[leukemia-specific acid receptor PML-RAR]	0.0	4	1	1	1
148102	1710	il-12r beta expression	[IL-12R beta expression]	0.0	3	1	1	1
148103	1710	human monocyte-derived m phi	[human monocyte-derived M phi]	0.0	4	1	1	1
148104	1710	cell act	[cells acting]	0.0	2	1	1	1
148105	1710	role of the gene c-jun	[role of the gene c-jun]	0.0	5	1	1	1
148106	1710	3 survival of pro-B lymphocyte	[3 survival of pro-B lymphocytes]	0.0	5	1	1	1
148107	1710	PPARgamma mrna expression	[PPARgamma mRNA expression]	0.0	3	1	1	1
148108	1710	65-75 kda	[65-75 kDa]	0.0	2	1	1	1
148109	1710	C a exchange	[C A exchange]	0.0	3	1	1	1
148110	1710	differentiation via nongenomic signal pathway	[differentiation via nongenomic signaling pathways]	0.0	5	1	1	1
148111	1710	nip repression	[NIP repression]	0.0	2	1	1	1
148112	1710	fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	4	1	1	1
148113	1710	gene type	[genes type]	0.0	2	1	1	1
148114	1710	cells/tube in the assay volume	[cells/tube in the assay volume]	0.0	5	1	1	1
148115	1710	camp -dependent gene	[cAMP -dependent genes]	0.0	3	1	1	1
148116	1710	inhibition of relevant gene	[inhibition of relevant genes]	0.0	4	1	1	1
148117	1710	2 IL-2	[2 IL-2]	0.0	2	1	1	1
148118	1710	glucocorticoid in human thp cell	[glucocorticoids in human THP cells]	0.0	5	1	1	1
148119	1710	nonhistone protein	[nonhistone proteins]	0.0	2	1	1	1
148120	1710	sixteen anorexic patient aged 16-27 years,	[Sixteen anorexic patients aged 16-27 years,]	0.0	6	1	1	1
148121	1710	pronounced,	[pronounced,]	0.0	1	1	1	1
148122	1710	neutrophil -to-tumor	[neutrophil -to-tumor]	0.0	2	1	1	1
148123	1710	nf-kappa b binding in T cell	[NF-kappa B binding in T cells]	0.0	6	1	1	1
148124	1710	development of human inflammatory pathology	[development of human inflammatory pathologies]	0.0	5	1	1	1
148125	1710	cell with il-4	[cells with IL-4]	0.0	3	1	1	1
148126	1710	thp-1 cell with gamma-interferon	[THP-1 cells with gamma-interferon]	0.0	4	1	1	1
148127	1710	antigen ea anti-viral antigen	[antigen EA anti-viral antigen]	0.0	4	1	1	1
148128	1710	cryostat,	[cryostat,]	0.0	1	1	1	1
148129	1710	lipopolysaccharide cell-free activation system	[lipopolysaccharide cell-free activation system]	0.0	4	1	1	1
148130	1710	inhibit dissociation	[inhibiting dissociation]	0.0	2	1	1	1
148131	1710	Rb in extract	[Rb in extracts]	0.0	3	1	1	1
148132	1710	hampster	[hampster]	0.0	1	1	1	1
148133	1710	effect of mechanical stress	[effects of mechanical stress]	0.0	4	1	1	1
148134	1710	membrane protein activation	[membrane protein activation]	0.0	3	1	1	1
148135	1710	level of leukotriene	[levels of leukotriene]	0.0	3	1	1	1
148136	1710	occur mutation (-175 t-c)	[occurring mutation (-175 T-C)]	0.0	4	1	1	1
148137	1710	proliferation recent-onset iddm subject 8	[proliferation recent-onset IDDM subjects 8]	0.0	5	1	1	1
148138	1710	concentration of antigen	[concentration of antigen]	0.0	3	1	1	1
148139	1710	6 kilobasis of dna.	[6 kilobases of DNA.]	0.0	4	1	1	1
148140	1710	sox9 coding sequence	[SOX9 coding sequence]	0.0	3	1	1	1
148141	1710	involve defective sexual differentiation in male	[involving defective sexual differentiation in males]	0.0	6	1	1	1
148142	1710	immunodeficiency virus type expression	[immunodeficiency virus type expression]	0.0	4	1	1	1
148143	1710	5 rearrangement	[5 rearrangement]	0.0	2	1	1	1
148144	1710	pseudo-hypoaldosteronism level of lymphocytic aldosterone receptor	[pseudo-hypoaldosteronism level of lymphocytic aldosterone receptors]	0.0	6	1	1	1
148145	1710	clarify the chronological sequence	[clarifying the chronological sequence]	0.0	4	1	1	1
148146	1710	isomerase inhibitor	[isomerase inhibitors]	0.0	2	1	1	1
148147	1710	spectrum in binding	[spectrum in binding]	0.0	3	1	1	1
148148	1710	extracellular matrix component	[extracellular matrix components]	0.0	3	1	1	1
148149	1710	signal event such as generation	[signaling events such as generation]	0.0	5	1	1	1
148150	1710	genetic lesion of c-myc	[genetic lesions of c-MYC]	0.0	4	1	1	1
148151	1710	clonal cell	[clonal cells]	0.0	2	1	1	1
148152	1710	cofactor in concert	[cofactors in concert]	0.0	3	1	1	1
148153	1710	series of response	[series of responses]	0.0	3	1	1	1
148154	1710	antigen stimulation signal	[antigen stimulation signals]	0.0	3	1	1	1
148155	1710	development of novel treatment	[development of novel treatments]	0.0	4	1	1	1
148156	1710	active form kinase C transcription	[active forms kinase C transcription]	0.0	5	1	1	1
148157	1710	negative HLH factor	[negative HLH factor]	0.0	3	1	1	1
148158	1710	genetic end target	[genetic end targets]	0.0	3	1	1	1
148159	1710	ros generation	[ROS generation]	0.0	2	1	1	1
148160	1710	CD40 domain	[CD40 domain]	0.0	2	3	3	1
148161	1710	chimeric properties unlike nuclear oncoprotein	[chimeric properties, unlike nuclear oncoproteins]	0.0	5	1	1	1
148162	1710	transcript in 'aged' lymphocyte	[transcript in 'aged' lymphocytes]	0.0	4	1	1	1
148163	1710	sequence on 10	[sequence on 10]	0.0	3	1	1	1
148164	1710	peptide bond	[peptide bond]	0.0	2	1	1	1
148165	1710	study histogenesis.	[study histogenesis.]	0.0	2	1	1	1
148166	1710	p50/p65 contain b dimer	[p50/p65 containing B dimers]	0.0	4	1	1	1
148167	1710	overlap core recognition	[overlapping core recognition]	0.0	3	1	1	1
148168	1710	fascinating field in immunology	[fascinating field in immunology]	0.0	4	1	1	1
148169	1710	show interaction	[showing interactions]	0.0	2	1	1	1
148170	1710	gene in T lymphocyte	[genes in T lymphocytes]	0.0	4	1	1	1
148171	1710	development of culture	[development of cultures]	0.0	3	1	1	1
148172	1710	binding of multi-protein complex	[binding of multi-protein complexes]	0.0	4	1	1	1
148173	1710	stages: a chronic	[stages: a chronic]	0.0	3	1	1	1
148174	1710	regard ebv latency	[regarding EBV latency]	0.0	3	1	1	1
148175	1710	cross-linking of cd44	[Cross-linking of CD44]	0.0	3	1	1	1
148176	1710	remain cell	[remaining cells]	0.0	2	1	1	1
148177	1710	pcdd in adult	[PCDDs/PCDFs in adults]	0.0	3	1	1	1
148178	1710	adenovirus e1a sequence	[adenovirus E1a sequences]	0.0	3	1	1	1
148179	1710	dmso solvent/media control for 0,	[DMSO solvent/media control for 0,]	0.0	5	1	1	1
148180	1710	BZLF 1	[BZLF 1]	0.0	2	1	1	1
148181	1710	heterodimer with hormone receptor	[heterodimers with hormone receptors]	0.0	4	1	1	1
148182	1710	vasoactive peptide ANG	[vasoactive peptide ANG]	0.0	3	1	1	1
148183	1710	extend nucleotide	[extending nucleotides]	0.0	2	1	1	1
148184	1710	synthesis in material from cancer patient	[synthesis in material from cancer patients]	0.0	6	1	1	1
148185	1710	box1 motif	[BOX1 motif]	0.0	2	1	1	1
148186	1710	treatment with TNF-alpha localization	[treatment with TNF-alpha localization]	0.0	4	1	1	1
148187	1710	indicate a affinity	[indicating an affinity]	0.0	3	1	1	1
148188	1710	NF-Y DQbeta promoter	[NF-Y DQbeta promoter]	0.0	3	1	1	1
148189	1710	degree C	[degrees C]	0.0	2	1	1	1
148190	1710	Rel/NF-kB family	[Rel/NF-kB family]	0.0	2	1	1	1
148191	1710	human cd86	[human CD86]	0.0	2	1	1	1
148192	1710	participate quantitatively to switch	[participating quantitatively to switch]	0.0	4	1	1	1
148193	1710	indicate independent	[indicating independent]	0.0	2	1	1	1
148194	1710	microgram/ml) transcription	[microgram/ml) transcription]	0.0	2	1	1	1
148195	1710	only low binding affinity RBA	[only low binding affinities RBA]	0.0	5	1	1	1
148196	1710	phenotype of nf-kappab activation	[phenotype of NF-kappaB activation]	0.0	4	1	1	1
148197	1710	possibly member capable	[possibly members capable]	0.0	3	1	1	1
148198	1710	analysis of the cDNA clone	[analysis of the cDNA clones]	0.0	5	1	1	1
148199	1710	parent ut-7/gm cell	[parent UT-7/GM cells]	0.0	3	1	1	1
148200	1710	critical il-2 DNA enhancer element	[critical IL-2 DNA enhancer elements]	0.0	5	1	1	1
148201	1710	anti-hgh mab	[anti-hGH mAb]	0.0	2	1	1	1
148202	1710	end-labelled reverse primer	[end-labelled reverse primer]	0.0	3	1	1	1
148203	1710	total of exposures.	[total of exposures.]	0.0	3	1	1	1
148204	1710	1 thyroid gland	[1 thyroid gland]	0.0	3	1	1	1
148205	1710	postvaccine response use monocyte as apc	[postvaccine responses using monocytes as APC]	0.0	6	1	1	1
148206	1710	t-cell specific gene	[T-cell specific genes]	0.0	3	1	1	1
148207	1710	double time of h for culture	[doubling times of h for cultures]	0.0	6	1	1	1
148208	1710	possible difference	[Possible differences]	0.0	2	1	1	1
148209	1710	(lps)-induced monocyte tnf-alpha production	[(LPS)-induced monocyte TNF-alpha production]	0.0	4	1	1	1
148210	1710	latency in the tumour cell	[latency in the tumour cells]	0.0	5	1	1	1
148211	1710	degradation of c-fo by a signal	[degradation of c-Fos by a signal]	0.0	6	1	1	1
148212	1710	low the/thf (0.24; n: 1.87+/-0.36)	[low THE/THF (0.24; N: 1.87+/-0.36)]	0.0	5	1	1	1
148213	1710	equivalent phosphorylation	[equivalent phosphorylation]	0.0	2	1	1	1
148214	1710	word	[words]	0.0	1	1	1	1
148215	1710	coculture with tec	[coculture with TEC]	0.0	3	1	1	1
148216	1710	protein ebna2-ebna6	[proteins EBNA2-EBNA6]	0.0	2	1	1	1
148217	1710	use a dominant ikappabalpha	[using a dominant IkappaBalpha]	0.0	4	1	1	1
148218	1710	genetic background	[genetic background]	0.0	2	1	1	1
148219	1710	onset of response	[onset of responses]	0.0	3	1	1	1
148220	1710	appearance of protein co-migrating	[appearance of protein co-migrating]	0.0	4	1	1	1
148221	1710	human monocyte/macrophage function	[human monocyte/macrophage function]	0.0	3	1	1	1
148222	1710	tam to lysis	[TAM to lysis]	0.0	3	1	1	1
148223	1710	inhibition of hiv type in cell	[inhibition of HIV type in cells]	0.0	6	1	1	1
148224	1710	pattern of nf-kappa b activation	[patterns of NF-kappa B activation]	0.0	5	1	1	1
148225	1710	Val at 50	[Val at 50]	0.0	3	1	1	1
148226	1710	VDR secondary	[VDR secondary]	0.0	2	1	1	1
148227	1710	stabilizer like beta 2-m	[stabilizers like beta 2-m]	0.0	4	1	1	1
148228	1710	membrane receptor a pathway for action	[Membrane receptors a pathway for action]	0.0	6	1	1	1
148229	1710	lipopolysaccharide (lps)-stimulated production	[lipopolysaccharide (LPS)-stimulated production]	0.0	3	1	1	1
148230	1710	member capable	[members capable]	0.0	2	1	1	1
148231	1710	strand nick	[strand nicks]	0.0	2	1	1	1
148232	1710	Differential effect	[Differential effects]	0.0	2	2	2	1
148233	1710	cross-linking of cd15	[cross-linking of CD15]	0.0	3	1	1	1
148234	1710	activation element	[activation elements]	0.0	2	1	1	1
148235	1710	receptor-cDNA	[receptor-cDNA]	0.0	1	1	1	1
148236	1710	lps E-selectin expression	[LPS E-selectin expression]	0.0	3	1	1	1
148237	1710	substitution within the domain	[substitutions within the domain]	0.0	4	1	1	1
148238	1710	distress syndrome ARDS	[distress syndrome ARDS]	0.0	3	1	1	1
148239	1710	hepatic factor beta	[hepatic factor beta]	0.0	3	1	1	1
148240	1710	two distinct type of macrophage	[two distinct types of macrophages]	0.0	5	1	1	1
148241	1710	multiple partners,	[multiple partners,]	0.0	2	1	1	1
148242	1710	analysis of cytokine signal	[Analysis of cytokine signaling]	0.0	4	1	1	1
148243	1710	also, the same size	[also, the same size]	0.0	4	1	1	1
148244	1710	gata-1 expression in hematopoietic progenitor	[GATA-1 expression in hematopoietic progenitors]	0.0	5	1	1	1
148245	1710	signal capacity	[signaling capacity]	0.0	2	1	1	1
148246	1710	demonstrable effect	[demonstrable effect]	0.0	2	1	1	1
148247	1710	Platelet/endothelial cell adhesion molecule-1	[Platelet/endothelial cell adhesion molecule-1]	0.0	4	1	1	1
148248	1710	bronchoalveolar lavage cellularity	[bronchoalveolar lavage cellularity]	0.0	3	1	1	1
148249	1710	receptor binding from 39 ms patient	[receptor binding from 39 MS patients]	0.0	6	1	1	1
148250	1710	transient expression of p16 in lymphocyte	[Transient expression of p16 in lymphocytes]	0.0	6	1	1	1
148251	1710	interleukin 6	[interleukin 6]	0.0	2	1	1	1
148252	1710	interleukin 3	[interleukin 3]	0.0	2	1	1	1
148253	1710	cytolytic susceptibility to apoptosis	[cytolytic susceptibility to apoptosis]	0.0	4	1	1	1
148254	1710	apoptosis-linked gene 4	[apoptosis-linked gene 4]	0.0	3	1	1	1
148255	1710	human t-cell line JPX-9	[human T-cell line JPX-9]	0.0	4	1	1	1
148256	1710	formation of cyclic AMP response	[formation of cyclic AMP response]	0.0	5	1	1	1
148257	1710	Glucocorticoid repression	[Glucocorticoid repression]	0.0	2	1	1	1
148258	1710	low back pain a pain	[low back pain a pain]	0.0	5	1	1	1
148259	1710	tcr delta mrna (2.3	[TcR delta mRNA (2.3]	0.0	4	1	1	1
148260	1710	seven untreated patient	[seven untreated patients]	0.0	3	1	1	1
148261	1710	rise of ca2+	[rise of Ca2+]	0.0	3	1	1	1
148262	1710	class major complex cell line	[class major complex cell lines]	0.0	5	1	1	1
148263	1710	indicate a aspect to this disease	[indicating an aspect to this disease.]	0.0	6	1	1	1
148264	1710	quantitative analysis with C-terminal antibody	[quantitative analysis with C-terminal antibodies]	0.0	5	1	1	1
148265	1710	signal for the biogenesis	[signals for the biogenesis]	0.0	4	1	1	1
148266	1710	effect on OCA-B transcription	[effect on OCA-B transcription]	0.0	4	1	1	1
148267	1710	specific binding site,	[specific binding site,]	0.0	3	1	1	1
148268	1710	repeat of the nfat element	[repeats of the NFAT element]	0.0	5	1	1	1
148269	1710	histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma	[histiocytoma 6, rhabdomyosarcoma 10, leiomyosarcoma]	0.0	5	1	1	1
148270	1710	5' nf-kappab site	[5' NF-kappaB sites]	0.0	3	1	1	1
148271	1710	-dependent transactivation	[-dependent transactivation]	0.0	2	1	1	1
148272	1710	predominant subunit	[predominant subunits]	0.0	2	1	1	1
148273	1710	9-bp motif (-90/-82	[9-bp motifs (-90/-82]	0.0	3	1	1	1
148274	1710	er antagonist 182780	[ER antagonist 182,780]	0.0	3	1	1	1
148275	1710	translocation event	[translocation event]	0.0	2	1	1	1
148276	1710	act in synergy	[acting in synergy]	0.0	3	1	1	1
148277	1710	include that cytokine such as interleukin-2	[including those cytokines such as interleukin-2]	0.0	6	1	1	1
148278	1710	th cell with th2 cytokine profile	[Th cells with Th2 cytokine profiles]	0.0	6	1	1	1
148279	1710	minute of receptor stimulation	[min of receptor stimulation]	0.0	4	1	1	1
148280	1710	differential sensitivity to Bcl-2	[differential sensitivity to Bcl-2]	0.0	4	1	1	1
148281	1710	substnfkappab approximately substSpl2 approximately substSp23	[substNFkappaB approximately substSpl2 approximately substSp23]	0.0	5	1	1	1
148282	1710	IL-7 a factor	[IL-7 a factor]	0.0	3	1	1	1
148283	1710	sh2 -dependent association	[SH2 -dependent association]	0.0	3	1	1	1
148284	1710	any, basal activity a potent activator	[any, basal activity a potent activator]	0.0	6	1	1	1
148285	1710	migration of oligomer	[migration of oligomers]	0.0	3	1	1	1
148286	1710	certain cytokines,	[certain cytokines,]	0.0	2	1	1	1
148287	1710	interleukin T	[interleukin T]	0.0	2	1	1	1
148288	1710	respond efficiently to stimulation	[responding efficiently to stimulation]	0.0	4	1	1	1
148289	1710	human monoblastic cell	[human monoblastic cells]	0.0	3	1	1	1
148290	1710	polypeptide range	[polypeptides ranging]	0.0	2	1	1	1
148291	1710	various agonist	[various agonists]	0.0	2	1	1	1
148292	1710	protein RNA	[protein RNA]	0.0	2	1	1	1
148293	1710	site-directed mutagenesis,	[site-directed mutagenesis,]	0.0	2	1	1	1
148294	1710	aging: evidence	[aging: evidence]	0.0	2	1	1	1
148295	1710	basal il-2 production	[basal IL-2 production]	0.0	3	1	1	1
148296	1710	over-express	[over-expressing]	0.0	1	1	1	1
148297	1710	complex class I molecule	[complex class I molecules]	0.0	4	1	1	1
148298	1710	possibly member	[possibly members]	0.0	2	1	1	1
148299	1710	express the hpv type hpv-16	[expressing the HPV type HPV-16]	0.0	5	1	1	1
148300	1710	addition, high level	[addition, high level]	0.0	3	1	1	1
148301	1710	accurately, equal amount	[accurately, equal amounts]	0.0	3	1	1	1
148302	1710	potential Sp1 binding site	[potential Sp1 binding sites]	0.0	4	1	1	1
148303	1710	receptor ahr	[receptor AhR]	0.0	2	1	1	1
148304	1710	binding to a estrogen response element	[Binding to an estrogen response element]	0.0	6	1	1	1
148305	1710	2000-3000 sites/cell,	[2000-3000 sites/cell,]	0.0	2	1	1	1
148306	1710	expression of the component	[expression of the components]	0.0	4	1	1	1
148307	1710	transcription of collagenase-1	[transcription of collagenase-1]	0.0	3	1	1	1
148308	1710	major complex (mhc) class ii gene	[major complex (MHC) class II genes]	0.0	6	1	1	1
148309	1710	gene regulatory (E box) sequence	[gene regulatory (E box) sequences]	0.0	5	1	1	1
148310	1710	stimulation of gene transcription	[Stimulation of gene transcription]	0.0	4	1	1	1
148311	1710	intermediate activity	[intermediate activity]	0.0	2	1	1	1
148312	1710	two overlap rna probe	[two overlapping RNA probes]	0.0	4	1	1	1
148313	1710	same picture	[same picture]	0.0	2	1	1	1
148314	1710	critical role in cell proliferation	[critical role in cell proliferation]	0.0	5	1	1	1
148315	1710	bhlf1/noti oligoprobe	[BHLF1/NotI oligoprobes]	0.0	2	1	1	1
148316	1710	leukocyte adhesion molecule (elam)-1	[leukocyte adhesion molecule (ELAM)-1]	0.0	4	1	1	1
148317	1710	transcript, PML/RARalpha a transcription factor	[transcript, PML/RARalpha a transcription factor]	0.0	5	1	1	1
148318	1710	l-pk isozyme by the use	[L-PK isozymes by the use]	0.0	5	1	1	1
148319	1710	show cross-reactivity at high concentration	[showing cross-reactivity at high concentrations]	0.0	5	1	1	1
148320	1710	spite of the fact	[spite of the fact]	0.0	4	1	1	1
148321	1710	protein tyrosine kinase module	[protein tyrosine kinase modules]	0.0	4	1	1	1
148322	1710	myeloid cell polymorphonuclear granulocyte	[myeloid cells polymorphonuclear granulocytes]	0.0	4	1	1	1
148323	1710	pathological alteration	[pathological alteration]	0.0	2	1	1	1
148324	1710	fetal hemoglobin HbF production	[fetal hemoglobin HbF production]	0.0	4	1	1	1
148325	1710	participation in the regulation	[participation in the regulation]	0.0	4	1	1	1
148326	1710	b activity in T cell	[B activity in T cells]	0.0	5	1	1	1
148327	1710	characteristic at abundance	[characteristics at abundance]	0.0	3	1	1	1
148328	1710	expression of gh	[expression of GH]	0.0	3	1	1	1
148329	1710	relevance of this mechanism	[relevance of this mechanism]	0.0	4	1	1	1
148330	1710	Tripterygium wilfordii Hook	[Tripterygium wilfordii Hook]	0.0	3	1	1	1
148331	1710	half-maximal effect	[half-maximal effect]	0.0	2	1	1	1
148332	1710	rel oncogene	[rel oncogene]	0.0	2	1	1	1
148333	1710	formation in the presence	[formation in the presence]	0.0	4	1	1	1
148334	1710	b cell-specific promoter activity	[B cell-specific promoter activity]	0.0	4	1	1	1
148335	1710	G0 to S phase transition	[G0 to S phase transition]	0.0	5	1	1	1
148336	1710	overexpression of beta-adrenergic receptor kinase	[Overexpression of beta-adrenergic receptor kinase]	0.0	5	1	1	1
148337	1710	repressor protein with effect	[repressor proteins with effects]	0.0	4	1	1	1
148338	1710	such as downregulation of histocompatibility molecule	[such as downregulation of histocompatibility molecules]	0.0	6	1	1	1
148339	1710	failure of p65 translocation	[failure of p65 translocation]	0.0	4	1	1	1
148340	1710	significant modification	[significant modification]	0.0	2	1	1	1
148341	1710	4 femaless	[4 females)]	0.0	2	1	1	1
148342	1710	immunoprecipitation of the gp nuclear extract	[Immunoprecipitation of the gp nuclear extracts]	0.0	6	1	1	1
148343	1710	trigger substance	[trigger substances]	0.0	2	1	1	1
148344	1710	case of CLL	[case of CLL]	0.0	3	1	1	1
148345	1710	regulate the level	[regulating the levels]	0.0	3	1	1	1
148346	1710	adhesion of u937 cell to lps	[Adhesion of U937 cells to LPS]	0.0	6	1	1	1
148347	1710	use a ab	[using an Ab]	0.0	3	1	1	1
148348	1710	cell carcinomas.	[cell carcinomas.]	0.0	2	1	1	1
148349	1710	use the sequence oligonucleotide	[using the sequence oligonucleotides]	0.0	4	1	1	1
148350	1710	vdre -binding protein (s),	[VDRE -binding protein (s),]	0.0	4	1	1	1
148351	1710	three DNA-protein complex	[three DNA-protein complexes]	0.0	3	1	1	1
148352	1710	interaction of calcineurin	[interaction of calcineurin]	0.0	3	1	1	1
148353	1710	embryonic development in Hox11 mouse	[embryonic development in Hox11 mice]	0.0	5	1	1	1
148354	1710	extract from lps zymosan cell	[extracts from LPS zymosan cells]	0.0	5	1	1	1
148355	1710	transcriptional element for respective factor	[transcriptional elements for respective factor]	0.0	5	1	1	1
148356	1710	region include the poz motif	[regions including the POZ motif]	0.0	5	1	1	1
148357	1710	member, ICK-1A	[member, ICK-1A]	0.0	2	1	1	1
148358	1710	include SP-1	[including SP-1]	0.0	2	1	1	1
148359	1710	patient in long years)	[patients in long-term years)]	0.0	4	1	1	1
148360	1710	transiently express LMP1	[transiently expressing LMP1]	0.0	3	1	1	1
148361	1710	CD43/leukosialin the sialoglycoprotein	[CD43/leukosialin the sialoglycoprotein]	0.0	3	1	1	1
148362	1710	VDR secondary to hypophosphatemia	[VDR secondary to hypophosphatemia]	0.0	4	1	1	1
148363	1710	mineralocorticoid receptor domain	[mineralocorticoid receptor domain]	0.0	3	1	1	1
148364	1710	various extracellular signal converge	[Various extracellular signals converging]	0.0	4	1	1	1
148365	1710	asthmatic patient with airway obstruction	[asthmatic patients with airways obstruction]	0.0	5	1	1	1
148366	1710	inhibitor in peripheral blood lymphocyte culture	[inhibitors in peripheral blood lymphocyte cultures]	0.0	6	1	1	1
148367	1710	T cell family	[T cells family]	0.0	3	1	1	1
148368	1710	specific element il-4re	[specific element IL-4RE]	0.0	3	1	1	1
148369	1710	feature of cell rescue	[features of cell rescue]	0.0	4	1	1	1
148370	1710	further incubation with oleate	[further incubation with oleate]	0.0	4	1	1	1
148371	1710	cd34+/-, hla-dr	[CD34+/-, HLA-DR]	0.0	2	1	1	1
148372	1710	b alpha degradation	[B alpha degradation]	0.0	3	1	1	1
148373	1710	induction of the interleukin promoter	[induction of the interleukin promoter]	0.0	5	1	1	1
148374	1710	lps nuclear factor-kappaB nf-kappab translocation	[LPS nuclear factor-kappaB NF-kappaB translocation]	0.0	5	1	1	1
148375	1710	8, fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma	[8, fibrous histiocytoma rhabdomyosarcoma 10, leiomyosarcoma]	0.0	6	1	1	1
148376	1710	concept a b-cell-derived subtype	[concept an B-cell-derived subtype]	0.0	4	1	1	1
148377	1710	leukemia the variant	[leukemia the variant]	0.0	3	1	1	1
148378	1710	mutant p85 allele	[mutant p85 alleles]	0.0	3	1	1	1
148379	1710	step understand the mechanism	[step understanding the mechanism]	0.0	4	1	1	1
148380	1710	sh3-sh2-sh3 motif	[SH3-SH2-SH3 motif]	0.0	2	1	1	1
148381	1710	ki-67,	[Ki-67,]	0.0	1	1	1	1
148382	1710	hs-40 enhancer motif	[HS-40 enhancer motifs]	0.0	3	1	1	1
148383	1710	peripheral human cell	[peripheral human cells]	0.0	3	1	1	1
148384	1710	occupancy of the enhancer	[occupancy of the enhancer]	0.0	4	1	1	1
148385	1710	CS individual	[CS individuals]	0.0	2	1	1	1
148386	1710	antibody in from normal, carrier	[antibodies in from normal, carriers]	0.0	5	1	1	1
148387	1710	micromol/L for hours, oleate	[micromol/L for hours, oleate]	0.0	4	1	1	1
148388	1710	hypothesis of receptor number	[hypothesis of receptor numbers]	0.0	4	1	1	1
148389	1710	human m phi	[human M phi]	0.0	3	1	1	1
148390	1710	activation gamma 1	[activation gamma 1]	0.0	3	1	1	1
148391	1710	expression of another viral protein BRLF1	[expression of another viral protein BRLF1]	0.0	6	1	1	1
148392	1710	blot study use rabbit anti-c/ebp-epsilon antibody	[blot studies using rabbit anti-C/EBP-epsilon antibodies]	0.0	6	1	1	1
148393	1710	process essential to a immune response	[processes essential to an immune response]	0.0	6	1	1	1
148394	1710	il-2 ifn-gamma	[IL-2 IFN-gamma]	0.0	2	1	1	1
148395	1710	center formation	[center formation]	0.0	2	1	1	1
148396	1710	classical pkc-alpha	[classical PKC-alpha]	0.0	2	1	1	1
148397	1710	trigger in the presence	[triggering in the presence]	0.0	4	1	1	1
148398	1710	(1) inactivate nucleotide substitution	[(1) inactivating nucleotide substitutions]	0.0	4	1	1	1
148399	1710	limited skewing potential	[limited skewing potential]	0.0	3	1	1	1
148400	1710	feature occur in allelic family	[feature occurring in allelic families]	0.0	5	1	1	1
148401	1710	develop prostate cancer	[developing prostate cancer]	0.0	3	2	2	1
148402	1710	patient with disease four	[patients with diseases four]	0.0	4	1	1	1
148403	1710	FcepsilonRIIb receptor	[FcepsilonRIIb receptor]	0.0	2	1	1	1
148404	1710	2 log-fold glucocorticoid for a degree	[2 log-fold glucocorticoids for an degree]	0.0	6	1	1	1
148405	1710	t-cell leukemia virus-infected human T cell	[T-cell leukemia virus-infected human T cells]	0.0	6	1	1	1
148406	1710	NF-kappa b /p50	[NF-kappa B /p50]	0.0	3	1	1	1
148407	1710	protein kinase C PKC dependent	[protein kinase C PKC dependent]	0.0	5	1	1	1
148408	1710	cortisol suppression	[cortisol suppression]	0.0	2	1	1	1
148409	1710	U1 cells,	[U1 cells,]	0.0	2	1	1	1
148410	1710	Conversely, rhythmicity	[Conversely, rhythmicity]	0.0	2	1	1	1
148411	1710	well in line	[well in line]	0.0	3	1	1	1
148412	1710	x chromosome-containing	[X chromosome-containing]	0.0	2	1	1	1
148413	1710	murine fra-1	[murine fra-1]	0.0	2	1	1	1
148414	1710	dysregulation of hypothalamic-pituitary-adrenal (hpa) axis	[dysregulation of hypothalamic-pituitary-adrenal (HPA) axis]	0.0	5	1	1	1
148415	1710	expression of the lymphocyte-specific transcription factor	[expression of the lymphocyte-specific transcription factor]	0.0	6	1	1	1
148416	1710	allele t1	[alleles T1]	0.0	2	1	1	1
148417	1710	human paf receptor transcript 1	[human PAF receptor transcript 1]	0.0	5	1	1	1
148418	1710	abundance of vd receptor VDR	[abundance of VD receptor VDR]	0.0	5	1	1	1
148419	1710	von Willebrand receptor	[von Willebrand receptor]	0.0	3	1	1	1
148420	1710	cascade culminate	[cascade culminating]	0.0	2	1	1	1
148421	1710	transcriptional target gene	[transcriptional target genes]	0.0	3	1	1	1
148422	1710	two-third	[two-thirds]	0.0	1	1	1	1
148423	1710	aberrant fasL up-regulation	[aberrant fasL up-regulation]	0.0	3	1	1	1
148424	1710	response to pathogenic infection	[response to pathogenic infections]	0.0	4	1	1	1
148425	1710	have weight	[having weights]	0.0	2	1	1	1
148426	1710	alternative splicing (R) pre-messenger rna	[Alternative splicing (R) pre-messenger RNA]	0.0	5	1	1	1
148427	1710	NF-kappa b/rel complex	[NF-kappa B/Rel complexes]	0.0	3	1	1	1
148428	1710	CD4 cd8(-) CD3 subset	[CD4 CD8(-) CD3 subset]	0.0	4	1	1	1
148429	1710	include hematological malignancy	[including hematological malignancies]	0.0	3	1	1	1
148430	1710	10 microm at pH	[10 microM at pH]	0.0	4	1	1	1
148431	1710	identification a T transcription factor	[Identification a T transcription factor]	0.0	5	1	1	1
148432	1710	myeloma mm	[myeloma MM]	0.0	2	1	1	1
148433	1710	abnormal protein expression of signal molecule	[abnormal protein expression of signaling molecules]	0.0	6	1	1	1
148434	1710	Differential induction of interferon follow differentiation	[Differential induction of interferon following differentiation]	0.0	6	1	1	1
148435	1710	different phenotype into blood lymphocyte	[different phenotypes into blood lymphocytes]	0.0	5	1	1	1
148436	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one]	0.0	1	1	1	1
148437	1710	peptide in the reticulum	[peptides in the reticulum]	0.0	4	1	1	1
148438	1710	competitive bind radioassay use [3H]-dexamethasone	[competitive binding radioassay using [3H]-dexamethasone]	0.0	5	1	1	1
148439	1710	il-1beta message	[IL-1beta message]	0.0	2	1	1	1
148440	1710	level with response	[levels with response]	0.0	3	1	1	1
148441	1710	glucocorticoid on peripheral function	[glucocorticoids on peripheral function]	0.0	4	1	1	1
148442	1710	interferon alpha-	[interferon alpha-]	0.0	2	1	1	1
148443	1710	-90/-79 sequence	[-90/-79 sequence]	0.0	2	1	1	1
148444	1710	low molecular weight adaptor protein	[low molecular weight adaptor proteins]	0.0	5	1	1	1
148445	1710	subsequent binding	[subsequent binding]	0.0	2	1	1	1
148446	1710	receptor-mediated agonist	[receptor-mediated agonists]	0.0	2	1	1	1
148447	1710	monolayer in nonstatic assay	[monolayers in nonstatic assays]	0.0	4	1	1	1
148448	1710	Appraisal of index	[Appraisal of index]	0.0	3	1	1	1
148449	1710	kilometer tnf receptor tr75	[kd TNF receptor TR75]	0.0	4	1	1	1
148450	1710	specific cooperation between Spi-1	[specific cooperation between Spi-1]	0.0	4	1	1	1
148451	1710	critical regulator of granulocyte apoptosis	[critical regulator of granulocyte apoptosis]	0.0	5	1	1	1
148452	1710	role in T cell leukemia	[role in T cell leukemia]	0.0	5	1	1	1
148453	1710	however a association	[however a association]	0.0	3	1	1	1
148454	1710	period of immunosuppression	[period of immunosuppression]	0.0	3	1	1	1
148455	1710	segment on cd36	[segment on CD36]	0.0	3	1	1	1
148456	1710	progressive increase	[progressive increase]	0.0	2	2	2	1
148457	1710	macrophage-CSF in human monocyte	[macrophage-CSF in human monocytes]	0.0	4	1	1	1
148458	1710	ap1 -dependent reporter construct nm),	[AP1 -dependent reporter constructs nM),]	0.0	5	1	1	1
148459	1710	24 month (6-15	[24 months (6-15]	0.0	3	1	1	1
148460	1710	dhs in intron 2	[DHS in intron 2]	0.0	4	1	1	1
148461	1710	dominant mutant ikk1	[dominant mutant IKK1]	0.0	3	1	1	1
148462	1710	also without loss	[also without loss]	0.0	3	1	1	1
148463	1710	synthesis of enhancer transcript	[synthesis of enhancer transcripts]	0.0	4	1	1	1
148464	1710	chromosome band 7q21q22	[chromosome bands 7q21q22]	0.0	3	1	1	1
148465	1710	tyrosine pathway	[tyrosine pathways]	0.0	2	1	1	1
148466	1710	ebv-transformed human lymphoblastoid cell	[EBV-transformed human lymphoblastoid cells]	0.0	4	1	1	1
148467	1710	expression a transcription factor	[Expression a transcription factor]	0.0	4	1	1	1
148468	1710	Natural variant analysis	[Natural variants analysis]	0.0	3	1	1	1
148469	1710	patient with disease tuberculosis	[patients with diseases tuberculosis]	0.0	4	1	1	1
148470	1710	factor receptor	[factor receptor]	0.0	2	1	1	1
148471	1710	three candidate gene	[three candidate genes]	0.0	3	1	1	1
148472	1710	mediator of gene expression	[mediator of gene expression]	0.0	4	1	1	1
148473	1710	postmenopausal patient risk	[postmenopausal patients risk]	0.0	3	1	1	1
148474	1710	LTR -cat assay	[LTR -CAT assays]	0.0	3	1	1	1
148475	1710	unique function among protein	[unique function among proteins]	0.0	4	1	1	1
148476	1710	major histocompatibility -restricted fashion	[major histocompatibility -restricted fashion]	0.0	4	1	1	1
148477	1710	protein/activating transcription factor (creb/atf) family	[protein/activating transcription factor (CREB/ATF) family]	0.0	5	1	1	1
148478	1710	small number of gata-1.05	[small number of GATA-1.05]	0.0	4	1	1	1
148479	1710	NFAT-1 gene expression in mouse	[NFAT-1 gene expression in mice]	0.0	5	1	1	1
148480	1710	response through independent form	[response through independent forms]	0.0	4	1	1	1
148481	1710	pools.	[pools.]	0.0	1	1	1	1
148482	1710	pools,	[pools,]	0.0	1	1	1	1
148483	1710	blood apparently healthy volunteer man	[blood apparently healthy volunteers men]	0.0	5	1	1	1
148484	1710	contrast, blood lymphocyte	[contrast, blood lymphocytes]	0.0	3	1	1	1
148485	1710	HLA antigen	[HLA antigens]	0.0	2	1	1	1
148486	1710	putative ap-2	[putative AP-2]	0.0	2	1	1	1
148487	1710	antibody against markers, include p53	[antibodies against markers, including p53]	0.0	5	1	1	1
148488	1710	member MYC	[members MYC]	0.0	2	1	1	1
148489	1710	two main piece	[Two main pieces]	0.0	3	1	1	1
148490	1710	immunodeficiency virus (hiv)-positive patient	[immunodeficiency virus (HIV)-positive patients]	0.0	4	1	1	1
148491	1710	expression of Pax5	[expression of Pax5]	0.0	3	1	1	1
148492	1710	terminal differentiation of the mpro promyelocyte	[terminal differentiation of the MPRO promyelocytes]	0.0	6	1	1	1
148493	1710	four direct repeat	[four direct repeats]	0.0	3	1	1	1
148494	1710	33 case of immature t-cell proliferation	[33 cases of immature T-cell proliferations]	0.0	6	1	1	1
148495	1710	immediate-early transactivator BZLF1 Z	[immediate-early transactivators BZLF1 Z]	0.0	4	1	1	1
148496	1710	15B-7 cDNA	[15B-7 cDNA]	0.0	2	1	1	1
148497	1710	additional cis-acting element	[additional cis-acting elements]	0.0	3	1	1	1
148498	1710	culture molecular analysis	[cultures molecular analysis]	0.0	3	1	1	1
148499	1710	important role in animal model	[important role in animal models]	0.0	5	1	1	1
148500	1710	hormone receptors,	[hormone receptors,]	0.0	2	1	1	1
148501	1710	variant of syndrome	[variants of syndrome]	0.0	3	1	1	1
148502	1710	machinery of NK cell	[machinery of NK cells]	0.0	4	1	1	1
148503	1710	group of eukaryotic dna-binding protein	[group of eukaryotic DNA-binding proteins]	0.0	5	1	1	1
148504	1710	important consequence in the use	[important consequences in the use]	0.0	5	1	1	1
148505	1710	90% identity with the I gamma	[90% identity with the I gamma]	0.0	6	1	1	1
148506	1710	Pax-5 pro-B cell	[Pax-5 pro-B cells]	0.0	3	1	1	1
148507	1710	cytotoxic markers,	[cytotoxic markers,]	0.0	2	1	1	1
148508	1710	underlying aberrancy	[underlying aberrancies]	0.0	2	1	1	1
148509	1710	moderate level only 2	[moderate levels only 2]	0.0	4	1	1	1
148510	1710	represent pro-B	[representing pro-B]	0.0	2	1	1	1
148511	1710	mutation frequency datum	[mutation frequency data]	0.0	3	1	1	1
148512	1710	immature morphology aml	[immature morphology AML]	0.0	3	1	1	1
148513	1710	potential in a genomic segment	[potential in a genomic segment]	0.0	5	1	1	1
148514	1710	oxidant hypochlorous acid mm)	[oxidant hypochlorous acid mM)]	0.0	4	1	1	1
148515	1710	effect of lactone	[effect of lactones]	0.0	3	1	1	1
148516	1710	infection genetic analysis	[Infection genetic analyses]	0.0	3	1	1	1
148517	1710	use assay	[using assays]	0.0	2	1	1	1
148518	1710	lymphoblast cell line	[lymphoblast cell line]	0.0	3	1	1	1
148519	1710	induction type interferon	[Induction type interferons]	0.0	3	1	1	1
148520	1710	element-binding	[element-binding]	0.0	1	1	1	1
148521	1710	family, cGATA-3	[family, cGATA-3]	0.0	2	1	1	1
148522	1710	regulation during the response	[regulation during the response]	0.0	4	1	1	1
148523	1710	modification of protein	[modification of proteins]	0.0	3	1	1	1
148524	1710	CD36 hampster ovary (cho) cell	[CD36 hampster ovary (CHO) cells]	0.0	5	1	1	1
148525	1710	expression of shp-1 phosphatase	[expression of SHP-1 phosphatase]	0.0	4	1	1	1
148526	1710	seven ebv carcinoma tissue	[seven EBV carcinoma tissues]	0.0	4	1	1	1
148527	1710	dnase-i site	[DNase-I sites]	0.0	2	1	1	1
148528	1710	nonstimulated platelet for hours,	[nonstimulated platelets for hours,]	0.0	4	1	1	1
148529	1710	nf-kappa b DNA probe	[NF-kappa B DNA probes]	0.0	4	1	1	1
148530	1710	subject type receptor	[subjects Type receptors]	0.0	3	1	1	1
148531	1710	inducible Rel A	[inducible Rel A]	0.0	3	1	1	1
148532	1710	diverse tcr repertoire	[diverse TCR repertoire]	0.0	3	1	1	1
148533	1710	proviral latency	[proviral latency]	0.0	2	1	1	1
148534	1710	co-expression in nonlymphoid cell reporter plasmid	[Co-expression in nonlymphoid cells reporter plasmids]	0.0	6	1	1	1
148535	1710	degradation of ikappab-alpha of nf-kappab	[degradation of IkappaB-alpha of NF-kappaB]	0.0	5	1	1	1
148536	1710	subunit, CBF beta	[subunit, CBF beta]	0.0	3	1	1	1
148537	1710	differ at residue 57	[differing at residue 57]	0.0	4	1	1	1
148538	1710	moreover, transfection	[Moreover, transfection]	0.0	2	1	1	1
148539	1710	similar capacity upon k562 cell	[similar capacity upon K562 cells]	0.0	5	1	1	1
148540	1710	double	[doubling]	0.0	1	1	1	1
148541	1710	functional expression on malignant melanoma	[functional expression on malignant melanomas]	0.0	5	1	1	1
148542	1710	antigen in the form	[antigens in the form]	0.0	4	1	1	1
148543	1710	atf/ creb	[ATF/ CREB]	0.0	2	1	1	1
148544	1710	cleavage stimulation	[cleavage stimulation]	0.0	2	1	1	1
148545	1710	aged subject (62-97 yr)	[aged subjects (62-97 yr)]	0.0	4	1	1	1
148546	1710	control of hematopoiesis	[control of hematopoiesis]	0.0	3	1	1	1
148547	1710	hematopoietic progenitor with no potential	[hematopoietic progenitors with no potential]	0.0	5	1	1	1
148548	1710	wild-type shp1	[wild-type SHP1]	0.0	2	1	1	1
148549	1710	cellular iron availability	[cellular iron availability]	0.0	3	1	1	1
148550	1710	treatment with TNF-alpha nuclear localization	[treatment with TNF-alpha nuclear localization]	0.0	5	1	1	1
148551	1710	differentiation of muscle	[differentiation of muscle]	0.0	3	1	1	1
148552	1710	expression in different tissue	[expression in different tissues]	0.0	4	1	1	1
148553	1710	control of cd95l expression	[control of CD95L expression]	0.0	4	1	1	1
148554	1710	explanation for the repression	[explanation for the repression]	0.0	4	1	1	1
148555	1710	definitive cell a phenotype	[definitive cells a phenotype]	0.0	4	1	1	1
148556	1710	level of nf-kb activity	[levels of NF-kB activity]	0.0	4	1	1	1
148557	1710	possible involvement of hcmv	[possible involvement of HCMV]	0.0	4	1	1	1
148558	1710	second-site LTR revertant	[second-site LTR revertants]	0.0	3	1	1	1
148559	1710	IFN-beta mrna at level	[IFN-beta mRNA at levels]	0.0	4	1	1	1
148560	1710	namely activator protein-1 ap-1 factor nf-il6	[namely activator protein-1 AP-1 factor NF-IL6]	0.0	6	1	1	1
148561	1710	gr activation of GRE	[GR activation of GRE]	0.0	4	1	1	1
148562	1710	(mean of independent assays), a value	[(mean of independent assays), a value]	0.0	6	1	1	1
148563	1710	mechanism underlie selective expression	[mechanisms underlying selective expression]	0.0	4	1	1	1
148564	1710	molecule in the atherosclerotic process	[molecule in the atherosclerotic process]	0.0	5	1	1	1
148565	1710	induce the lytic cycle	[inducing the lytic cycle]	0.0	4	1	1	1
148566	1710	major site.	[major site.]	0.0	2	1	1	1
148567	1710	dose rate of 1.17	[dose rate of 1.17]	0.0	4	1	1	1
148568	1710	phosphorylation state	[phosphorylation state]	0.0	2	1	1	1
148569	1710	activation of tgf-beta transcription	[Activation of TGF-beta transcription]	0.0	4	1	1	1
148570	1710	purine box pb1	[purine box PB1]	0.0	3	1	1	1
148571	1710	macrophage bind activity	[macrophages binding activity]	0.0	3	1	1	1
148572	1710	inflammatory airway disease	[inflammatory airway disease]	0.0	3	1	1	1
148573	1710	(both with DNA element	[(both with DNA elements]	0.0	4	1	1	1
148574	1710	core tfiid	[core TFIID]	0.0	2	1	1	1
148575	1710	Group B.	[Group B.]	0.0	2	1	1	1
148576	1710	z protein	[Z protein]	0.0	2	1	1	1
148577	1710	eosinophil effect of hemopoietin	[eosinophil effects of hemopoietins]	0.0	4	1	1	1
148578	1710	approximately 300 bp	[approximately 300 bp]	0.0	3	1	1	1
148579	1710	adoptive transfer T cell	[adoptive transfer T cells]	0.0	4	1	1	1
148580	1710	R.C. Gallo, Science 1986).	[R.C. Gallo, Science 1986).]	0.0	4	1	1	1
148581	1710	antibody specific to the lactosylceramide	[antibody specific to the lactosylceramide]	0.0	5	1	1	1
148582	1710	consist of subunits, p50	[consisting of subunits, p50]	0.0	4	1	1	1
148583	1710	incubation of hiv-infected cell with antibody	[Incubation of HIV-infected cells with antibody]	0.0	6	1	1	1
148584	1710	HLA-DR3 positive with no apparent association	[HLA-DR3 positive with no apparent association]	0.0	6	1	1	1
148585	1710	Epstein-Barr antigen	[Epstein-Barr antigen]	0.0	2	1	1	1
148586	1710	contrast, semiquantitative rt-pcr analysis	[contrast, semiquantitative RT-PCR analysis]	0.0	4	1	1	1
148587	1710	mouse il-2 enhancer	[mouse IL-2 enhancer]	0.0	3	1	1	1
148588	1710	bear tumor for a week	[bearing tumor for a weeks]	0.0	5	1	1	1
148589	1710	bp apart,	[bp apart,]	0.0	2	1	1	1
148590	1710	retinoic acid receptor RAR alpha	[retinoic acid receptor RAR alpha]	0.0	5	1	1	1
148591	1710	most critical mechanism	[most critical mechanism]	0.0	3	1	1	1
148592	1710	switch from human fetal (gamma)	[switch from human fetal (gamma)]	0.0	5	1	1	1
148593	1710	collapse in the area	[collapse in the areas]	0.0	4	1	1	1
148594	1710	C/EBPepsilon	[C/EBPepsilon]	0.0	1	1	1	1
148595	1710	expression of a carboxylesterase	[expression of a carboxylesterase]	0.0	4	1	1	1
148596	1710	inactivation of the x	[inactivation of the X]	0.0	4	1	1	1
148597	1710	linear correlation	[linear correlation]	0.0	2	2	2	1
148598	1710	alternative splicing of the tsc2 gene	[Alternative splicing of the TSC2 gene]	0.0	6	1	1	1
148599	1710	asymptomatic family member	[asymptomatic family members]	0.0	3	1	1	1
148600	1710	NF-kappa b molecules.	[NF-kappa B molecules.]	0.0	3	1	1	1
148601	1710	constitutive interaction involve factor	[constitutive interactions involving factor]	0.0	4	1	1	1
148602	1710	three complex specific	[three complexes specific]	0.0	3	1	1	1
148603	1710	independent fusions.	[independent fusions.]	0.0	2	1	1	1
148604	1710	extensive footprint over the elements,	[extensive footprints over the elements,]	0.0	5	1	1	1
148605	1710	radiation exposure	[radiation exposure]	0.0	2	1	1	1
148606	1710	mapk kinase	[MAPK kinase]	0.0	2	1	1	1
148607	1710	include a function on monocyte activation.	[including a function on monocyte activation.]	0.0	6	1	1	1
148608	1710	prevalence of promoter methylation	[prevalence of promoter methylation]	0.0	4	1	1	1
148609	1710	IFN-alpha responsiveness positive myelogenous leukemia	[IFN-alpha responsiveness positive myelogenous leukemia]	0.0	5	1	1	1
148610	1710	human erythropoietin receptor	[human erythropoietin receptor]	0.0	3	1	1	1
148611	1710	transcription factor nf-kappab regulation of fibrosis	[Transcription factor NF-kappaB regulation of fibrosis]	0.0	6	1	1	1
148612	1710	polymerase chain reaction method	[polymerase chain reaction method]	0.0	4	1	1	1
148613	1710	approach against aids	[approach against AIDS]	0.0	3	1	1	1
148614	1710	bp fragment encompass nucleotide	[bp fragment encompassing nucleotides]	0.0	4	1	1	1
148615	1710	cytoplasmic precursor p105	[cytoplasmic precursor p105]	0.0	3	1	1	1
148616	1710	Functional analysis of deletion construct	[Functional analysis of deletion constructs]	0.0	5	1	1	1
148617	1710	specificity in binding	[specificity in binding]	0.0	3	1	1	1
148618	1710	production of nitric oxide	[production of nitric oxide]	0.0	4	1	1	1
148619	1710	estrogenic pathway	[estrogenic pathways]	0.0	2	1	1	1
148620	1710	human colony	[human colony]	0.0	2	1	1	1
148621	1710	Fas/APO-1 receptor	[Fas/APO-1 receptor]	0.0	2	1	1	1
148622	1710	aspect procedure.	[aspect procedure.]	0.0	2	1	1	1
148623	1710	characterization of CD40 determinant	[Characterization of CD40 determinants]	0.0	4	1	1	1
148624	1710	cyclophilin gene	[cyclophilin gene]	0.0	2	1	1	1
148625	1710	receptor gr binding characteristic	[receptor GR binding characteristics]	0.0	4	1	1	1
148626	1710	insufficient action	[insufficient action]	0.0	2	1	1	1
148627	1710	follow consolidation with chemotherapy	[following consolidation with chemotherapy]	0.0	4	1	1	1
148628	1710	contain different protein	[containing different proteins]	0.0	3	1	1	1
148629	1710	activator protein-1 ap-1 nuclear factor nf-il6	[activator protein-1 AP-1 nuclear factor NF-IL6]	0.0	6	1	1	1
148630	1710	egr-2	[egr-2]	0.0	1	1	1	1
148631	1710	Fc gamma RIC	[Fc gamma RIC]	0.0	3	1	1	1
148632	1710	cooperative interaction between two cell-specific coactivator	[cooperative interactions between two cell-specific coactivators]	0.0	6	1	1	1
148633	1710	instance of the general principle	[instance of the general principle]	0.0	5	1	1	1
148634	1710	absence of cytokine	[absence of cytokines]	0.0	3	1	1	1
148635	1710	lymphoid cell line HL	[lymphoid cell line HL]	0.0	4	1	1	1
148636	1710	bind specifically to the AP-1 element	[binding specifically to the AP-1 element]	0.0	6	1	1	1
148637	1710	EBNA2 element	[EBNA2 element]	0.0	2	1	1	1
148638	1710	taqi restriction fragment length polymorphism	[TaqI restriction fragment length polymorphism]	0.0	5	1	1	1
148639	1710	on-going lps signal	[on-going LPS signal]	0.0	3	1	1	1
148640	1710	role for phosphoinositide 3-kinase	[role for phosphoinositide 3-kinase]	0.0	4	1	1	1
148641	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one a inhibitor	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one an inhibitor]	0.0	3	1	1	1
148642	1710	sh2-containing protein CIS	[SH2-containing protein CIS]	0.0	3	1	1	1
148643	1710	occlusion	[occlusion]	0.0	1	1	1	1
148644	1710	novel inhibitor of NFAT -1-mediated transcription	[novel inhibitors of NFAT -1-mediated transcription]	0.0	6	1	1	1
148645	1710	cotransfection of a form of calcineurin	[Cotransfection of a form of calcineurin]	0.0	6	1	1	1
148646	1710	two tyrosine phosphoprotein	[Two tyrosine phosphoproteins]	0.0	3	1	1	1
148647	1710	transform growth factor-beta particularly in relationship	[transforming growth factor-beta particularly in relationship]	0.0	6	1	1	1
148648	1710	directly modulate intracellular calcium	[directly modulating intracellular calcium]	0.0	4	1	1	1
148649	1710	binding essential	[binding essential]	0.0	2	1	1	1
148650	1710	feature membrane	[features membranes]	0.0	2	1	1	1
148651	1710	antigenic determinant	[antigenic determinants]	0.0	2	1	1	1
148652	1710	cytokine deficiency	[cytokine deficiency]	0.0	2	1	1	1
148653	1710	switch in human	[switching in humans]	0.0	3	1	1	1
148654	1710	specific binding to plasma membrane	[specific binding to plasma membranes]	0.0	5	1	1	1
148655	1710	cd40l fusion protein	[CD40L fusion protein]	0.0	3	1	1	1
148656	1710	class major promoter	[class major promoters]	0.0	3	1	1	1
148657	1710	insight to the mechanism	[insight to the mechanisms]	0.0	4	1	1	1
148658	1710	mode of glucocorticoid action	[mode of glucocorticoid action]	0.0	4	1	1	1
148659	1710	just a instances.	[just a instances.]	0.0	3	1	1	1
148660	1710	include peripheral cell from individual	[including peripheral cells from individuals]	0.0	5	1	1	1
148661	1710	follow exposure of intact platelet	[following exposure of intact platelets]	0.0	5	1	1	1
148662	1710	effective apc	[effective APC]	0.0	2	1	1	1
148663	1710	72-kDa isoform	[72-kDa isoform]	0.0	2	1	1	1
148664	1710	immunosuppressive activity at concentration 100-fold low	[immunosuppressive activity at concentrations 100-fold lower]	0.0	6	1	1	1
148665	1710	cobalt chloride signal	[Cobalt chloride signaling]	0.0	3	1	1	1
148666	1710	gene like cd23	[genes like CD23]	0.0	3	1	1	1
148667	1710	env gene	[env gene]	0.0	2	1	1	1
148668	1710	expression namely c-fo	[expression namely c-fos]	0.0	3	1	1	1
148669	1710	four histone h2a-2 gene	[four histone H2A-2 genes]	0.0	4	1	1	1
148670	1710	10-fold increase in sensitivity	[10-fold increase in sensitivity]	0.0	4	1	1	1
148671	1710	22% probability recur locally	[22% probability recurring locally]	0.0	4	1	1	1
148672	1710	(median	[(median]	0.0	1	1	1	1
148673	1710	BCL-6 expression during B-cell	[BCL-6 expression during B-cell]	0.0	4	1	1	1
148674	1710	nuclear trans-acting factor	[nuclear trans-acting factors]	0.0	3	1	1	1
148675	1710	transcription stat-1 alpha	[transcription STAT-1 alpha]	0.0	3	1	1	1
148676	1710	RFX species	[RFX species]	0.0	2	1	1	1
148677	1710	variety in vivo	[variety in vivo]	0.0	3	1	1	1
148678	1710	classification of carcinoma	[classification of carcinoma]	0.0	3	1	1	1
148679	1710	element in the tsp 1 promoter,	[elements in the TSP 1 promoter,]	0.0	6	1	1	1
148680	1710	precursor of human	[precursors of humans]	0.0	3	1	1	1
148681	1710	downstream nf-kappab activation of terminal repeat	[downstream NF-kappaB activation of terminal repeat]	0.0	6	1	1	1
148682	1710	granular Sudan black b	[granular Sudan black B]	0.0	4	1	1	1
148683	1710	linkage dendritic cell development	[linkage dendritic cell development]	0.0	4	1	1	1
148684	1710	upstream region -1168	[upstream regions -1168]	0.0	3	1	1	1
148685	1710	induction of expression by binding	[Induction of expression by binding]	0.0	5	1	1	1
148686	1710	nuclear localization of rela	[nuclear localization of RelA]	0.0	4	1	1	1
148687	1710	(also in human arterial cell	[(also in human arterial cells]	0.0	5	1	1	1
148688	1710	stimuli, disparate stimulus-	[stimuli, disparate stimulus-]	0.0	3	1	1	1
148689	1710	rel/nuclear factor kappab factor	[Rel/nuclear factor kappaB factors]	0.0	4	1	1	1
148690	1710	strong immunohistological staining for nf-kappabp65	[stronger immunohistological staining for NF-kappaBp65]	0.0	5	1	1	1
148691	1710	uterine thromboxane receptor cDNA	[uterine thromboxane receptor cDNA]	0.0	4	1	1	1
148692	1710	icr27tk.3 human T cell	[ICR27TK.3 human T cells]	0.0	4	1	1	1
148693	1710	stochastic activation of gene	[stochastic activation of genes]	0.0	4	1	1	1
148694	1710	camp inducibility	[cAMP inducibility]	0.0	2	1	1	1
148695	1710	receptor 3'-untranslated region polymorphism lack	[receptor 3'-untranslated region polymorphisms lack]	0.0	5	1	1	1
148696	1710	tumor necrosis factor-alpha il-1 beta	[tumor necrosis factor-alpha IL-1 beta]	0.0	5	1	1	1
148697	1710	putative sites.	[putative sites.]	0.0	2	1	1	1
148698	1710	two model of a situation	[two models of an situation]	0.0	5	1	1	1
148699	1710	infection b cell by herpesvirus hhv-6	[infection B cells by herpesvirus HHV-6]	0.0	6	1	1	1
148700	1710	factor-kappa b subunit p65	[factor-kappa B subunit p65]	0.0	4	1	1	1
148701	1710	major difference between the mechanism	[major differences between the mechanism]	0.0	5	1	1	1
148702	1710	enhancer CD28 responsive element	[enhancer CD28 responsive element]	0.0	4	1	1	1
148703	1710	hl-60 myeloid leukemia cell	[HL-60 myeloid leukemia cells]	0.0	4	1	1	1
148704	1710	CD30 degradation of traf2	[CD30 degradation of TRAF2]	0.0	4	1	1	1
148705	1710	basal activity of the LTR	[basal activity of the LTR]	0.0	5	1	1	1
148706	1710	new, member	[new, member]	0.0	2	1	1	1
148707	1710	monocyte chemoattractant protein mcp-1	[monocyte chemoattractant protein MCP-1]	0.0	4	1	1	1
148708	1710	dna-binding lac repressor	[DNA-binding lac repressor]	0.0	3	1	1	1
148709	1710	small deletion model of event	[small deletion model of events]	0.0	5	1	1	1
148710	1710	hla-dra mrna synthesis	[HLA-DRA mRNA synthesis]	0.0	3	1	1	1
148711	1710	detectable effect	[detectable effect]	0.0	2	1	1	1
148712	1710	SIE gas	[SIE GAS]	0.0	2	1	1	1
148713	1710	element-containing promoter	[element-containing promoters]	0.0	2	1	1	1
148714	1710	receptor consist of chain	[receptor consisting of chains]	0.0	4	1	1	1
148715	1710	pathway of Ras	[pathway of Ras]	0.0	3	1	1	1
148716	1710	protein kinase pathway by monocyte	[protein kinase pathways by monocytes]	0.0	5	1	1	1
148717	1710	nonresponsive progenitor with no erythropoietic potential	[nonresponsive progenitors with no erythropoietic potential]	0.0	6	1	1	1
148718	1710	group patient	[group patients]	0.0	2	1	1	1
148719	1710	g0/g1 configuration	[G0/G1 configuration]	0.0	2	1	1	1
148720	1710	rate of staining	[rate of staining]	0.0	3	1	1	1
148721	1710	late histone h2a-2 gene	[late histone H2A-2 genes]	0.0	4	1	1	1
148722	1710	series of pathway	[series of pathways]	0.0	3	1	1	1
148723	1710	Chronic hiv-1 infection of cell	[Chronic HIV-1 infection of cells]	0.0	5	1	1	1
148724	1710	cd4(+) t-cell activation	[CD4(+) T-cell activation]	0.0	3	1	1	1
148725	1710	activation of event lead	[activation of events leading]	0.0	4	1	1	1
148726	1710	little information available	[little information available]	0.0	3	1	1	1
148727	1710	constitutive translocation of NF-ATp	[constitutive translocation of NF-ATp]	0.0	4	1	1	1
148728	1710	(hiv-1) therapy	[(HIV-1) therapy]	0.0	2	1	1	1
148729	1710	posttraumatic stress disorder	[posttraumatic stress disorder]	0.0	3	1	1	1
148730	1710	expression of vimentin	[expression of vimentin]	0.0	3	1	1	1
148731	1710	protein 3bp2	[protein 3BP2]	0.0	2	1	1	1
148732	1710	monocytic activity colony-stimumulatelany-stg factor	[monocytic activity colony-stimulating factor]	0.0	4	1	1	1
148733	1710	western blot analysis of extract	[Western blot analysis of extracts]	0.0	5	1	1	1
148734	1710	cytosolic tyrosine motif	[cytosolic tyrosine motif]	0.0	3	1	1	1
148735	1710	TNF-alpha- mechanism	[TNF-alpha- mechanism]	0.0	2	1	1	1
148736	1710	Octamer independent activation	[Octamer independent activation]	0.0	3	1	1	1
148737	1710	competitive enzyme-linked immunosorbent assay	[competitive enzyme-linked immunosorbent assay]	0.0	4	1	1	1
148738	1710	labeling with anti-igm	[labeling with anti-IgM]	0.0	3	1	1	1
148739	1710	EBNA-2 extract	[EBNA-2 extracts]	0.0	2	1	1	1
148740	1710	common growth factor	[common growth factor]	0.0	3	1	1	1
148741	1710	fetal cord blood	[fetal cord bloods]	0.0	3	1	1	1
148742	1710	(0.1 nmol/L	[(0.1 nmol/L]	0.0	2	1	1	1
148743	1710	key oxidative-stress sensor	[key oxidative-stress sensor]	0.0	3	1	1	1
148744	1710	(46% identical)	[(46% identical)]	0.0	2	1	1	1
148745	1710	genetic determinant of the ability	[genetic determinants of the ability]	0.0	5	1	1	1
148746	1710	maintain survival in stem	[maintaining survival in stem]	0.0	4	1	1	1
148747	1710	antidepressant of hypercortisolemia	[antidepressants of hypercortisolemia]	0.0	3	1	1	1
148748	1710	Erythropoietin the regulator of the production	[Erythropoietin the regulator of the production]	0.0	6	1	1	1
148749	1710	proliferative response to level	[proliferative response to levels]	0.0	4	1	1	1
148750	1710	appropriate regulation of response	[appropriate regulation of responses]	0.0	4	1	1	1
148751	1710	granulocyte factor factor proliferation	[granulocyte factor factor proliferation]	0.0	4	1	1	1
148752	1710	granulopoiesis typically die by 8 days.	[granulopoiesis typically dying by 8 days.]	0.0	6	1	1	1
148753	1710	runt polypeptide	[runt polypeptides]	0.0	2	1	1	1
148754	1710	pan-1 respectively), by the mechanism	[Pan-1 respectively), by the mechanism]	0.0	5	1	1	1
148755	1710	induction of a gene	[induction of an gene]	0.0	4	1	1	1
148756	1710	great than stimulation	[greater than stimulation]	0.0	3	1	1	1
148757	1710	nuclear grade (p 0.0001)	[nuclear grade (P 0.0001),]	0.0	4	1	1	1
148758	1710	infection genetic analysis of mutation	[Infection genetic analyses of mutations]	0.0	5	1	1	1
148759	1710	dihydropyrimidine dehydrogenase	[dihydropyrimidine dehydrogenase]	0.0	2	1	1	1
148760	1710	deletion of the domain	[deletion of the domain]	0.0	4	1	1	1
148761	1710	gene defective	[genes defective]	0.0	2	1	1	1
148762	1710	two other unrecognized NFATp -binding site	[Two other unrecognized NFATp -binding sites]	0.0	6	1	1	1
148763	1710	role of cya	[role of CyA]	0.0	3	1	1	1
148764	1710	chronic lymphocytic leukemia (b-cll) cell	[chronic lymphocytic leukemia (B-CLL) cells]	0.0	5	1	1	1
148765	1710	immunophenotype:	[immunophenotype:]	0.0	1	1	1	1
148766	1710	amount of viral rna	[amounts of viral RNA]	0.0	4	1	1	1
148767	1710	distinct binding site for protein	[distinct binding sites for proteins]	0.0	5	1	1	1
148768	1710	phorbol ester treatment,	[phorbol ester treatment,]	0.0	3	1	1	1
148769	1710	insight into development	[insights into development]	0.0	3	1	1	1
148770	1710	(18- to 35-year-old) healthy volunteer	[(18- to 35-year-old) healthy volunteers]	0.0	5	1	1	1
148771	1710	presence of activation motif	[presence of activation motifs]	0.0	4	1	1	1
148772	1710	BCL-6 expression activation.	[BCL-6 expression activation.]	0.0	3	1	1	1
148773	1710	expression il-1-induced gene transcription	[Expression IL-1-induced gene transcription]	0.0	4	1	1	1
148774	1710	regulation by a inflammatory microenvironment	[regulation by an inflammatory microenvironment]	0.0	5	1	1	1
148775	1710	DHEA effect on lps	[DHEA effects on LPS]	0.0	4	1	1	1
148776	1710	cell with neurite process	[cells with neurite processes]	0.0	4	1	1	1
148777	1710	defect during interaction	[defect during interaction]	0.0	3	1	1	1
148778	1710	activation from a position	[activation from a position]	0.0	4	1	1	1
148779	1710	specifically accumulation	[specifically accumulation]	0.0	2	1	1	1
148780	1710	effect on IRF-1 a effect	[effect on IRF-1 an effect]	0.0	5	1	1	1
148781	1710	receptor, fas	[receptor, Fas]	0.0	2	1	1	1
148782	1710	similar region	[similar regions]	0.0	2	1	1	1
148783	1710	expression of activity	[expression of activity]	0.0	3	1	1	1
148784	1710	fast mobility form	[faster mobility forms]	0.0	3	1	1	1
148785	1710	E1A sarcoma cell for tumorigenicity	[E1A sarcoma cells for tumorigenicity]	0.0	5	1	1	1
148786	1710	use with a mass of kilodalton	[using with a mass of kilodaltons]	0.0	6	1	1	1
148787	1710	65 woman with neutrophilia	[65 women with neutrophilia]	0.0	4	1	1	1
148788	1710	IL-2 -independent activation	[IL-2 -independent activation]	0.0	3	1	1	1
148789	1710	8 patient with asthma	[8 patients with asthma]	0.0	4	1	1	1
148790	1710	functional cp	[functional Cp]	0.0	2	1	1	1
148791	1710	expression of a carboxylesterase in cell	[expression of a carboxylesterase in cells]	0.0	6	1	1	1
148792	1710	effect on cell growth.	[effect on cell growth.]	0.0	4	1	1	1
148793	1710	examine change	[examining changes]	0.0	2	1	1	1
148794	1710	effect on cell growth,	[effect on cell growth,]	0.0	4	1	1	1
148795	1710	t-cell gene activation	[T-cell gene activation]	0.0	3	1	1	1
148796	1710	SCL transcription	[SCL transcription]	0.0	2	1	1	1
148797	1710	inhibitory sequence	[inhibitory sequence]	0.0	2	1	1	1
148798	1710	level of plasma aldosterone	[levels of plasma aldosterone]	0.0	4	1	1	1
148799	1710	5' deletion mutant	[5' deletion mutants]	0.0	3	1	1	1
148800	1710	KG1 dendritic-like cell	[KG1 dendritic-like cells]	0.0	3	1	1	1
148801	1710	difference in this hematopoietic lineage	[differences in these hematopoietic lineages]	0.0	5	1	1	1
148802	1710	experiment with intact	[experiments with intact]	0.0	3	1	1	1
148803	1710	actin tail	[actin tail]	0.0	2	1	1	1
148804	1710	factor ap-1	[factors AP-1]	0.0	2	1	1	1
148805	1710	effective suppressor	[effective suppressor]	0.0	2	1	1	1
148806	1710	activation by covalent modification	[activation by covalent modification]	0.0	4	1	1	1
148807	1710	four agents.	[four agents.]	0.0	2	1	1	1
148808	1710	interaction between system	[interaction between systems]	0.0	3	1	1	1
148809	1710	indicator of oxidant stress	[indicators of oxidant stress]	0.0	4	1	1	1
148810	1710	1 receptor in leukocyte	[1 receptors in leukocytes]	0.0	4	1	1	1
148811	1710	dominant-negative approach	[dominant-negative approach]	0.0	2	1	1	1
148812	1710	subsequent loss	[subsequent loss]	0.0	2	1	1	1
148813	1710	preexisting nf-il6	[preexisting NF-IL6]	0.0	2	1	1	1
148814	1710	peripheral blood lymphocyte in sclerosis	[peripheral blood lymphocytes in sclerosis]	0.0	5	1	1	1
148815	1710	-contain leukocyte protein via sh3 domain	[-containing leukocyte protein via SH3 domain]	0.0	6	1	1	1
148816	1710	eosinophil from female patient	[eosinophils from female patients]	0.0	4	1	1	1
148817	1710	even the cell express level	[even the cells expressing levels]	0.0	5	1	1	1
148818	1710	signal transducing protein	[signal transducing proteins]	0.0	3	1	1	1
148819	1710	NAD(P)H:quinone reductase mechanism	[NAD(P)H:quinone reductase mechanism]	0.0	3	1	1	1
148820	1710	4 hours)	[4 hours)]	0.0	2	1	1	1
148821	1710	replication of episome	[replication of episomes]	0.0	3	1	1	1
148822	1710	signal costimulatory signal alone	[signal costimulatory signal alone]	0.0	4	1	1	1
148823	1710	serve as messenger	[serving as messengers]	0.0	3	1	1	1
148824	1710	homodimerization of surface receptor	[homodimerization of surface receptors]	0.0	4	1	1	1
148825	1710	factor-kappaB induction evidence for a pathway	[factor-kappaB induction evidence for an pathway]	0.0	6	1	1	1
148826	1710	cis- rotamer	[cis- rotamers]	0.0	2	1	1	1
148827	1710	hhv-6(gs) fragment	[HHV-6(GS) fragments]	0.0	2	1	1	1
148828	1710	action in the immune system	[actions in the immune system]	0.0	5	1	1	1
148829	1710	survival of thymocyte in mouse	[survival of thymocytes in mice]	0.0	5	1	1	1
148830	1710	characterization of a tissue-specific transcription factor	[Characterization of a tissue-specific transcription factor]	0.0	6	1	1	1
148831	1710	regulatory region in Jurkat	[regulatory region in Jurkat]	0.0	4	1	1	1
148832	1710	detail of hormone action	[details of hormone action]	0.0	4	1	1	1
148833	1710	pseudomonas aeruginosa by macrophage	[Pseudomonas aeruginosa by macrophages]	0.0	4	1	1	1
148834	1710	many kind of stresses,	[many kinds of stresses,]	0.0	4	1	1	1
148835	1710	outside-in signal for activation	[outside-in signals for activation]	0.0	4	1	1	1
148836	1710	partial functional disomy of sequence	[partial functional disomy of sequences]	0.0	5	1	1	1
148837	1710	dimethyl sulfoxide dmso	[dimethyl sulfoxide DMSO]	0.0	3	1	1	1
148838	1710	cell lineage commitment,	[cell lineage commitment,]	0.0	3	1	1	1
148839	1710	NLS disruption	[NLS disruption]	0.0	2	1	1	1
148840	1710	Furthermore, expression of obf-1	[Furthermore, expression of OBF-1]	0.0	4	1	1	1
148841	1710	kinase IRAK	[kinase IRAK]	0.0	2	1	1	1
148842	1710	abnormality of Y chromosome sequence	[abnormalities of Y chromosome sequences]	0.0	5	1	1	1
148843	1710	different signal transducing pathway	[different signal transducing pathways]	0.0	4	1	1	1
148844	1710	human acute leukemia	[human acute leukemia]	0.0	3	1	1	1
148845	1710	(Scheuermann, R. h.,	[(Scheuermann, R. H.,]	0.0	3	1	1	1
148846	1710	formation of DNase 1 site	[formation of DNase 1 sites]	0.0	5	1	1	1
148847	1710	specific nuclear marker	[specific nuclear marker]	0.0	3	1	1	1
148848	1710	fast kinetic upon il-2	[fast kinetics upon IL-2]	0.0	4	1	1	1
148849	1710	hiv-1 envelope	[HIV-1 envelope]	0.0	2	1	1	1
148850	1710	interleukin-2 il-2 signal	[interleukin-2 IL-2 signaling]	0.0	3	1	1	1
148851	1710	however, cell express receptor	[however, cells expressing receptors]	0.0	4	1	1	1
148852	1710	Clevers	[Clevers]	0.0	1	1	1	1
148853	1710	functional NK	[functional NK]	0.0	2	1	1	1
148854	1710	blockage of dna- formation	[blockage of DNA- formation]	0.0	4	1	1	1
148855	1710	Epstein-Barr virus EBV nuclear antigen ebna-2	[Epstein-Barr virus EBV nuclear antigen EBNA-2]	0.0	6	1	1	1
148856	1710	trna gene	[tRNA gene]	0.0	2	1	1	1
148857	1710	immediate-early t-cell gene include interleukin-2	[immediate-early T-cell genes including interleukin-2]	0.0	5	1	1	1
148858	1710	activation of tlr	[Activation of TLRs]	0.0	3	1	1	1
148859	1710	mechanism underlie this role	[mechanism underlying this role]	0.0	4	1	1	1
148860	1710	stimulation interleukin-6	[stimulation interleukin-6]	0.0	2	1	1	1
148861	1710	NF-kappa b-inducible	[NF-kappa B-inducible]	0.0	2	1	1	1
148862	1710	only increases.	[only increases.]	0.0	2	1	1	1
148863	1710	min) submaximal exercise	[min) submaximal exercise]	0.0	3	1	1	1
148864	1710	GPIIb promoter	[GPIIb promoter]	0.0	2	1	1	1
148865	1710	delivery of functional nf-kappab	[delivery of functional NF-kappaB]	0.0	4	1	1	1
148866	1710	immunoblot analysis of nuclear extract	[immunoblot analysis of nuclear extracts]	0.0	5	1	1	1
148867	1710	child aged 6 to 15 year	[children aged 6 to 15 years]	0.0	6	1	1	1
148868	1710	NF-kappa b /p65	[NF-kappa B /p65]	0.0	3	1	1	1
148869	1710	potential signal pathway	[potential signaling pathways]	0.0	3	1	1	1
148870	1710	specificity to the gas-motif sequence	[specificity to the GAS-motif sequences]	0.0	5	1	1	1
148871	1710	site specificity	[site specificity]	0.0	2	1	1	1
148872	1710	NF-kappa B complex	[NF-kappa B complex]	0.0	3	3	3	1
148873	1710	dnase footprinting use amount of nfatp	[DNase footprinting using amounts of NFATp]	0.0	6	1	1	1
148874	1710	activity lef1/bcf1	[activity LEF1/BCF1]	0.0	2	1	1	1
148875	1710	divergence of the pathways.	[divergence of the pathways.]	0.0	4	1	1	1
148876	1710	deletion of accessory gene	[deletion of accessory genes]	0.0	4	1	1	1
148877	1710	and/or compound tested.	[and/or compound tested.]	0.0	3	1	1	1
148878	1710	number of factor	[number of factors]	0.0	3	1	1	1
148879	1710	stimulation with the stimulus	[stimulation with the stimuli]	0.0	4	1	1	1
148880	1710	expression of androgen receptor	[expression of androgen receptor]	0.0	4	1	1	1
148881	1710	heterologous transcription-activateactivateactivateactivating domain	[heterologous transcription-activating domain]	0.0	3	1	1	1
148882	1710	KOX on chromosome band	[KOX on chromosome bands]	0.0	4	1	1	1
148883	1710	linkage polymorphism	[linkage polymorphism]	0.0	2	1	1	1
148884	1710	proper balance	[proper balance]	0.0	2	1	1	1
148885	1710	efficient inhibition	[efficient inhibition]	0.0	2	1	1	1
148886	1710	concentration a inhibitor	[concentration an inhibitor]	0.0	3	1	1	1
148887	1710	genome-positive b cell	[genome-positive B cells]	0.0	3	1	1	1
148888	1710	er overexpression	[ER overexpression]	0.0	2	1	1	1
148889	1710	shp2-deltash2	[SHP2-DeltaSH2]	0.0	1	1	1	1
148890	1710	abnormality of glucocorticoid receptor	[abnormalities of glucocorticoid receptors]	0.0	4	1	1	1
148891	1710	350 case of leukemia aml	[350 cases of leukemia AML]	0.0	5	1	1	1
148892	1710	difference together with difference	[differences together with differences]	0.0	4	1	1	1
148893	1710	molecule on lung fibroblast	[molecule on lung fibroblasts]	0.0	4	1	1	1
148894	1710	multiple gene in monocyte	[multiple genes in monocytes]	0.0	4	1	1	1
148895	1710	receptor gamma PPARgamma	[receptor gamma PPARgamma]	0.0	3	1	1	1
148896	1710	ataxia telangiectasia proliferation	[ataxia telangiectasia proliferation]	0.0	3	1	1	1
148897	1710	prior to infection	[prior to infection]	0.0	3	1	1	1
148898	1710	-positive b cell	[-positive B cells]	0.0	3	1	1	1
148899	1710	synergism modulate gene expression	[synergism modulating gene expression]	0.0	4	1	1	1
148900	1710	amount of cytoplasmic nf-kappab	[amount of cytoplasmic NF-kappaB]	0.0	4	1	1	1
148901	1710	two human t-cell line	[two human T-cell lines]	0.0	4	1	1	1
148902	1710	stage cell cell specification	[stage cell cell specification]	0.0	4	1	1	1
148903	1710	many factors, in particular, cytokine	[Many factors, in particular, cytokines]	0.0	5	1	1	1
148904	1710	membrane protein LMP	[membrane proteins LMP]	0.0	3	1	1	1
148905	1710	Culture supernatant from U937 cell	[Culture supernatants from U937 cells]	0.0	5	1	1	1
148906	1710	four amino acid difference	[four amino acid differences]	0.0	4	1	1	1
148907	1710	reading frame orf of hhv-6	[reading frames ORFs of HHV-6]	0.0	5	1	1	1
148908	1710	first 0.2 kb	[first 0.2 kb]	0.0	3	1	1	1
148909	1710	GCR of the person	[GCR of the persons]	0.0	4	1	1	1
148910	1710	chromosomal band	[chromosomal bands]	0.0	2	1	1	1
148911	1710	such as adhesion molecule-1	[such as adhesion molecule-1]	0.0	4	1	1	1
148912	1710	profound change	[profound change]	0.0	2	1	1	1
148913	1710	rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma 5).	[rhabdomyosarcoma 10, leiomyosarcoma 10, liposarcoma 5).]	0.0	6	1	1	1
148914	1710	suggest a pivotal role	[suggesting a pivotal role]	0.0	4	1	1	1
148915	1710	OCT-1 (oct-1p)-binding site	[OCT-1 (OCT-1p)-binding site]	0.0	3	1	1	1
148916	1710	evidence the result	[evidence the result]	0.0	3	1	1	1
148917	1710	co-expression with the FasL promoter	[Co-expression with the FasL promoter]	0.0	5	1	1	1
148918	1710	repression inhibition of NFATp/AP-1 formation	[repression inhibition of NFATp/AP-1 formation]	0.0	5	1	1	1
148919	1710	U937 human cell	[U937 human cells]	0.0	3	1	1	1
148920	1710	human I gamma	[human I gamma]	0.0	3	1	1	1
148921	1710	C 571 base pair upstream	[C 571 base pairs upstream]	0.0	5	1	1	1
148922	1710	gamma/delta tcr+ cell	[gamma/delta TCR+ cells]	0.0	3	1	1	1
148923	1710	translocation in T cell	[translocation in T cells]	0.0	4	1	1	1
148924	1710	variety of organisms.	[variety of organisms.]	0.0	3	1	1	1
148925	1710	certain receptor (tcr) region beta-chain family	[certain receptor (TCR) region beta-chain families]	0.0	6	1	1	1
148926	1710	source for critical mediator	[source for critical mediators]	0.0	4	1	1	1
148927	1710	octamer-	[octamer-]	0.0	1	1	1	1
148928	1710	control subject use autoradiographic technique	[control subjects using autoradiographic techniques]	0.0	5	1	1	1
148929	1710	plasma testosterone	[plasma testosterone]	0.0	2	1	1	1
148930	1710	two immediate gene	[two immediate genes]	0.0	3	1	1	1
148931	1710	form of collaboration	[forms of collaboration]	0.0	3	1	1	1
148932	1710	signal 2 alone without signal 1	[signal 2 alone without signal 1]	0.0	6	1	1	1
148933	1710	factor-kappa b activity a report.	[factor-kappa B activity a report.]	0.0	5	1	1	1
148934	1710	favorable course 0.05, chi2	[favorable course 0.05, chi2]	0.0	4	1	1	1
148935	1710	strike similarity for protein	[striking similarity for proteins]	0.0	4	1	1	1
148936	1710	serum thyroxine tt4	[serum thyroxine TT4]	0.0	3	1	1	1
148937	1710	transcription factor in addition	[transcription factors in addition]	0.0	4	1	1	1
148938	1710	utilize CD4 T cell line	[Utilizing CD4 T cell lines]	0.0	5	1	1	1
148939	1710	contrast, injection of sea cause	[contrast, injections of SEA cause]	0.0	5	1	1	1
148940	1710	cd14 activation	[CD14 activation]	0.0	2	1	1	1
148941	1710	use the mab	[using the mAb]	0.0	3	1	1	1
148942	1710	prevent transcriptional induction	[preventing transcriptional induction]	0.0	3	1	1	1
148943	1710	MHC concentration	[MHC concentration]	0.0	2	1	1	1
148944	1710	many environmental factors, in cytokine	[Many environmental factors, in cytokines]	0.0	5	1	1	1
148945	1710	functional site between position -53	[functional site between positions -53]	0.0	5	1	1	1
148946	1710	protein Sp1	[protein Sp1]	0.0	2	1	1	1
148947	1710	Porphyromonas gingivalis lps	[Porphyromonas gingivalis LPS]	0.0	3	1	1	1
148948	1710	regulation of macrophage tissue factor expression	[regulation of macrophage tissue factor expression]	0.0	6	1	1	1
148949	1710	activation of tlr by lipoprotein	[Activation of TLRs by lipoproteins]	0.0	5	1	1	1
148950	1710	concentration (0-125 microM)	[concentrations (0-125 microM)]	0.0	3	1	1	1
148951	1710	peripheral-blood mononuclear cell	[peripheral-blood mononuclear cells]	0.0	3	1	1	1
148952	1710	works? with a therapy specific	[works? with a therapy specific]	0.0	5	1	1	1
148953	1710	corticosteroid -resistant asthma	[corticosteroid -resistant asthma]	0.0	3	1	1	1
148954	1710	incidence of disease	[incidence of diseases]	0.0	3	1	1	1
148955	1710	critical component of outgrowth	[critical component of outgrowth]	0.0	4	1	1	1
148956	1710	fetal program	[fetal program]	0.0	2	1	1	1
148957	1710	fnf-e2	[fNF-E2]	0.0	1	1	1	1
148958	1710	proportion of CD40 cell	[proportion of CD40 cells]	0.0	4	1	1	1
148959	1710	ef1 -like activity	[EF1 -like activity]	0.0	3	1	1	1
148960	1710	beta subunit binding	[beta subunit binding]	0.0	3	1	1	1
148961	1710	activation of tax	[activation of Tax]	0.0	3	1	1	1
148962	1710	sequence on xp	[sequences on Xp]	0.0	3	1	1	1
148963	1710	prevent target cell uptake of lps	[preventing target cell uptake of LPS]	0.0	6	1	1	1
148964	1710	phenotypic female (18 year	[phenotypic female (18 years]	0.0	4	1	1	1
148965	1710	EBNA2 -dependent synthesis	[EBNA2 -dependent synthesis]	0.0	3	1	1	1
148966	1710	affinity (at sevenfold) of site	[affinity (at sevenfold) of site]	0.0	5	1	1	1
148967	1710	old Japanese woman	[old Japanese woman]	0.0	3	1	1	1
148968	1710	riiia	[RIIIA]	0.0	1	1	1	1
148969	1710	regulatory mechanism for gene transcription	[regulatory mechanisms for gene transcription]	0.0	5	1	1	1
148970	1710	therapy of promyelocytic leukemia patient	[therapy of promyelocytic leukemia patients]	0.0	5	1	1	1
148971	1710	induction of IgE	[induction of IgE]	0.0	3	1	1	1
148972	1710	induce nf-kb expression	[inducing NF-KB expression]	0.0	3	1	1	1
148973	1710	results: neutrophil adhesion to cell	[RESULTS: Neutrophil adhesion to cells]	0.0	5	1	1	1
148974	1710	potential of the gene bzlf	[potential of the gene BZLF]	0.0	5	1	1	1
148975	1710	udg gene	[UDG gene]	0.0	2	1	1	1
148976	1710	functional Rb	[functional Rb]	0.0	2	1	1	1
148977	1710	FDC clusters,	[FDC clusters,]	0.0	2	1	1	1
148978	1710	LEF-1 -binding site	[LEF-1 -binding site]	0.0	3	1	1	1
148979	1710	kb telomeric to GR6	[kb telomeric to GR6]	0.0	4	1	1	1
148980	1710	cell of rat	[cells of rats]	0.0	3	1	1	1
148981	1710	ig mrna	[Ig mRNA]	0.0	2	2	2	1
148982	1710	DNA bind nfkb2 induction	[DNA binding NFKB2 induction]	0.0	4	1	1	1
148983	1710	activator protein-1 transcription complex	[activator protein-1 transcription complex]	0.0	4	1	1	1
148984	1710	method for quantification	[method for quantification]	0.0	3	1	1	1
148985	1710	glucocorticoid-sensitive human t-cell line	[glucocorticoid-sensitive human T-cell line]	0.0	4	1	1	1
148986	1710	signal for e2f regulation	[signals for E2F regulation]	0.0	4	1	1	1
148987	1710	loss of p130 form	[loss of p130 Form]	0.0	4	1	1	1
148988	1710	dna-binding protein x box	[DNA-binding protein X box]	0.0	4	1	1	1
148989	1710	dimer consist of nfkappab1	[dimers consisting of NFkappaB1]	0.0	4	1	1	1
148990	1710	stress-induced signal	[stress-induced signals]	0.0	2	1	1	1
148991	1710	critical role in gene expression	[critical role in gene expression]	0.0	5	1	1	1
148992	1710	phenylpyrazolo glucocorticoid of potency	[phenylpyrazolo glucocorticoid of potency]	0.0	4	1	1	1
148993	1710	represent pAT 591/EGR2	[representing pAT 591/EGR2]	0.0	3	1	1	1
148994	1710	injection of 5 blood cell	[injection of 5 blood cells]	0.0	5	1	1	1
148995	1710	10 ng/ml),	[10 ng/ml),]	0.0	2	1	1	1
148996	1710	transform membrane protein-1 lmp-1	[transforming membrane protein-1 LMP-1]	0.0	4	1	1	1
148997	1710	cell line present a structure	[cell line presenting a structure]	0.0	5	1	1	1
148998	1710	interaction with type-ii EBS	[interaction with type-II EBS]	0.0	4	1	1	1
148999	1710	tyrosine phosphorylation in monocytic cell	[tyrosine phosphorylation in monocytic cells]	0.0	5	1	1	1
149000	1710	intercellular adhesion molecule-1 gene	[intercellular adhesion molecule-1 gene]	0.0	4	1	1	1
149001	1710	ah-receptor agonist	[Ah-receptor agonists]	0.0	2	1	1	1
149002	1710	protein sox-4	[protein Sox-4]	0.0	2	1	1	1
149003	1710	cell line express the ikappab	[cell lines expressing the IkappaB]	0.0	5	1	1	1
149004	1710	nuclear hormone	[nuclear hormone]	0.0	2	1	1	1
149005	1710	activity follow T cell activation	[activity following T cell activation]	0.0	5	1	1	1
149006	1710	Dexamethasone Dex a synthetic hormone	[Dexamethasone Dex a synthetic hormone]	0.0	5	1	1	1
149007	1710	element of various gene	[elements of various genes]	0.0	4	1	1	1
149008	1710	small difference	[small differences]	0.0	2	1	1	1
149009	1710	NF-kappa b as activator	[NF-kappa B as activator]	0.0	4	1	1	1
149010	1710	alpha-zearalenol	[alpha-zearalenol]	0.0	1	1	1	1
149011	1710	tissue-specific activator ebf	[tissue-specific activator EBF]	0.0	3	1	1	1
149012	1710	1) inhibition through adenosine triphosphate	[1) inhibition through adenosine triphosphate]	0.0	5	1	1	1
149013	1710	Interleukin-12 a cytokine	[Interleukin-12 a cytokine]	0.0	3	1	1	1
149014	1710	expression of IFNgamma ip-10 mrna	[expression of IFNgamma IP-10 mRNA]	0.0	5	1	1	1
149015	1710	cotransfection together with a plasmid	[cotransfection together with a plasmid]	0.0	5	1	1	1
149016	1710	loss consistent	[loss consistent]	0.0	2	1	1	1
149017	1710	traf6 in activation event	[TRAF6 in activation events]	0.0	4	1	1	1
149018	1710	major cytoplasmic inhibitor in pbmc	[major cytoplasmic inhibitor in PBMC]	0.0	5	1	1	1
149019	1710	immunity against tumor	[immunity against tumors]	0.0	3	1	1	1
149020	1710	increase inflammatory infiltrate (p	[increasing inflammatory infiltrate (P]	0.0	4	1	1	1
149021	1710	gr transcription in T cell	[GR transcription in T cells]	0.0	5	1	1	1
149022	1710	slight enhancement	[slight enhancement]	0.0	2	1	1	1
149023	1710	potent trigger substance	[potent trigger substances]	0.0	3	1	1	1
149024	1710	contrast, activation	[contrast, activation]	0.0	2	1	1	1
149025	1710	local proliferation.	[local proliferation.]	0.0	2	1	1	1
149026	1710	moreover, supernatant from cell	[Moreover, supernatants from cells]	0.0	4	1	1	1
149027	1710	development of structural alteration	[development of structural alterations]	0.0	4	1	1	1
149028	1710	runt product in normal hematopoiesis	[runt products in normal hematopoiesis]	0.0	5	1	1	1
149029	1710	complex e2f-4	[complexes E2F-4]	0.0	2	1	1	1
149030	1710	again, treatment with RA	[again, treatment with RA]	0.0	4	1	1	1
149031	1710	quiescent blood T lymphocyte	[quiescent blood T lymphocytes]	0.0	4	1	1	1
149032	1710	ability of negative Ras	[ability of negative Ras]	0.0	4	1	1	1
149033	1710	cytokine such as interleukin	[cytokines such as interleukin]	0.0	4	1	1	1
149034	1710	little effect of tpa	[little effect of TPA]	0.0	4	1	1	1
149035	1710	(high affinity, capacity)	[(high affinity, capacity)]	0.0	3	1	1	1
149036	1710	NTF interaction	[NTF interactions]	0.0	2	1	1	1
149037	1710	understanding of the reason	[understanding of the reasons]	0.0	4	1	1	1
149038	1710	feature with ebv include tumorigenesis.	[features with EBV including tumorigenesis.]	0.0	5	1	1	1
149039	1710	enhancer b	[enhancer B]	0.0	2	1	1	1
149040	1710	Jak3 /Stat activation	[Jak3 /Stat activation]	0.0	3	1	1	1
149041	1710	cyto-differentiating effect on promyelocytic leukemia cell	[cyto-differentiating effects on promyelocytic leukemia cells]	0.0	6	1	1	1
149042	1710	cooperation of general transcription factor	[cooperation of general transcription factors]	0.0	5	1	1	1
149043	1710	use hbd subfragment	[using HBD subfragments]	0.0	3	1	1	1
149044	1710	formation of the complex, factor	[formation of the complex, factor]	0.0	5	1	1	1
149045	1710	dramatic reduction in hsp70 production	[dramatic reduction in hsp70 production]	0.0	5	1	1	1
149046	1710	permit translocation into the nucleus	[permitting translocation into the nucleus]	0.0	5	1	1	1
149047	1710	lipopolysaccharide production of inflammatory cytokine	[lipopolysaccharide production of inflammatory cytokines]	0.0	5	1	1	1
149048	1710	binding of interferon-gamma ifn-gamma	[Binding of interferon-gamma IFN-gamma]	0.0	4	1	1	1
149049	1710	domain of the type IL-1R	[domain of the type IL-1R]	0.0	5	1	1	1
149050	1710	phosphatase-positive osteoclast-like multinucleated cell	[phosphatase-positive osteoclast-like multinucleated cells]	0.0	4	1	1	1
149051	1710	cell divisions, corresponding to a amplification	[cell divisions, corresponding to a amplification]	0.0	6	1	1	1
149052	1710	nf-kappab in mononuclear cell	[NF-kappaB in mononuclear cells]	0.0	4	1	1	1
149053	1710	positive element in b-cell line	[positive element in B-cell lines]	0.0	5	1	1	1
149054	1710	4-month interval	[4-month intervals]	0.0	2	1	1	1
149055	1710	mzf-1 modification	[MZF-1 modifications]	0.0	2	1	1	1
149056	1710	T cell leukemia virus	[T cell leukemia virus]	0.0	4	1	1	1
149057	1710	basic growth factor bFGF	[basic growth factor bFGF]	0.0	4	1	1	1
149058	1710	enhancement replication	[Enhancement replication]	0.0	2	1	1	1
149059	1710	CsA stage involve the addition	[CsA stage involving the addition]	0.0	5	1	1	1
149060	1710	leiomyosarcoma 10, liposarcoma 5).	[leiomyosarcoma 10, liposarcoma 5).]	0.0	4	1	1	1
149061	1710	nuclear induction during a response,	[nuclear induction during an response,]	0.0	5	1	1	1
149062	1710	Active metabolite	[Active metabolite]	0.0	2	1	1	1
149063	1710	CsA -sensitive regulation	[CsA -sensitive regulation]	0.0	3	1	1	1
149064	1710	mouse genome	[mouse genome]	0.0	2	1	1	1
149065	1710	occur at minute	[occurring at minutes]	0.0	3	1	1	1
149066	1710	cell of nonhematopoietic lineage	[cells of nonhematopoietic lineage]	0.0	4	1	1	1
149067	1710	involvement signal by the g-csfr	[involvement signaling by the G-CSFR]	0.0	5	1	1	1
149068	1710	E1a- vector	[E1a- vector]	0.0	2	1	1	1
149069	1710	originate from cell	[originating from cells]	0.0	3	1	1	1
149070	1710	immunodeficiency virus type long terminal repeat	[immunodeficiency virus type long terminal repeats]	0.0	6	1	1	1
149071	1710	p85 subunit	[p85 subunit]	0.0	2	1	1	1
149072	1710	survival rate of transgenic animal	[survival rate of transgenic animals]	0.0	5	1	1	1
149073	1710	305 +/- nmol	[305 +/- nmol]	0.0	3	1	1	1
149074	1710	regulatory function of PPARalpha	[regulatory function of PPARalpha]	0.0	4	1	1	1
149075	1710	significantly great migration	[significantly greater migration]	0.0	3	1	1	1
149076	1710	bp insertion between muE3	[bp insertion between muE3]	0.0	4	1	1	1
149077	1710	membrane potential change	[membrane potential changes]	0.0	3	1	1	1
149078	1710	attack of inflammatory bowel disease	[attacks of inflammatory bowel disease]	0.0	5	1	1	1
149079	1710	asthma child aged	[asthma children aged]	0.0	3	1	1	1
149080	1710	different ad group Ad12	[different Ad groups Ad12]	0.0	4	1	1	1
149081	1710	case of t-cell lymphoma AITL	[cases of T-cell lymphoma AITL]	0.0	5	1	1	1
149082	1710	self ligand	[self, ligands]	0.0	2	1	1	1
149083	1710	cytokine for terminal repeat transactivation	[cytokines for terminal repeat transactivation]	0.0	5	1	1	1
149084	1710	heat shock factor 2	[heat shock factor 2]	0.0	4	1	1	1
149085	1710	transcript degradation use cycloheximide	[transcript degradation using cycloheximide]	0.0	4	1	1	1
149086	1710	other cells; factor	[other cells; factors]	0.0	3	1	1	1
149087	1710	group of transient response	[group of transient responses]	0.0	4	1	1	1
149088	1710	novel membrane receptor	[novel membrane receptor]	0.0	3	1	1	1
149089	1710	beta-globin expression during ontogeny	[beta-globin expression during ontogeny]	0.0	4	1	1	1
149090	1710	reduction in nf-at complex	[reductions in NF-AT complexes]	0.0	4	1	1	1
149091	1710	p21ras activity	[p21ras activity]	0.0	2	1	1	1
149092	1710	CD27-	[CD27-]	0.0	1	1	1	1
149093	1710	hypercalciuria stone-forming condition	[hypercalciuria stone-forming condition]	0.0	3	1	1	1
149094	1710	expression of 1beta	[Expression of 1beta]	0.0	3	1	1	1
149095	1710	distribution of cytokine receptor	[distribution of cytokine receptors]	0.0	4	1	1	1
149096	1710	direct angioplasty	[direct angioplasty]	0.0	2	1	1	1
149097	1710	stat5 target sequence	[STAT5 target sequences]	0.0	3	1	1	1
149098	1710	cell cycle-	[cell cycle-]	0.0	2	1	1	1
149099	1710	DNA for irf-2 gene	[DNA for IRF-2 gene]	0.0	4	1	1	1
149100	1710	lead to modulation of hiv expression	[leading to modulation of HIV expression]	0.0	6	1	1	1
149101	1710	structure of the receptors.	[structures of the receptors.]	0.0	4	1	1	1
149102	1710	association latency in certain cell	[Association latency in certain cells]	0.0	5	1	1	1
149103	1710	anti-m-csf antibody	[anti-M-CSF antibody]	0.0	2	1	1	1
149104	1710	complex on the site	[complex on the site]	0.0	4	1	1	1
149105	1710	class histocompatibility	[class histocompatibility]	0.0	2	1	1	1
149106	1710	single ap-2-	[single AP-2-]	0.0	2	1	1	1
149107	1710	alloreactive T cell line of infant	[alloreactive T cell lines of infants]	0.0	6	1	1	1
149108	1710	suggest deleterious in lung	[suggesting deleterious in lungs]	0.0	4	1	1	1
149109	1710	N-terminal phosphorylation of IkappaB alpha	[N-terminal phosphorylation of IkappaB alpha]	0.0	5	1	1	1
149110	1710	overrepresentation	[overrepresentation]	0.0	1	1	1	1
149111	1710	32 person	[32 persons]	0.0	2	1	1	1
149112	1710	activation with phorbol ester	[activation with phorbol esters]	0.0	4	1	1	1
149113	1710	transcriptional complex ap-1	[transcriptional complex AP-1]	0.0	3	1	1	1
149114	1710	prime nb4 cell for differentiation	[prime NB4 cells for differentiation]	0.0	5	1	1	1
149115	1710	presence alpha,25(OH)2D3	[presence alpha,25(OH)2D3]	0.0	2	1	1	1
149116	1710	immunologic (type ii) oxide synthase expression	[immunologic (type II) oxide synthase expression]	0.0	6	1	1	1
149117	1710	30%, overexpression of er	[30%, overexpression of ER]	0.0	4	1	1	1
149118	1710	isolated membrane system	[isolated membrane system]	0.0	3	1	1	1
149119	1710	loop of b production	[loop of B production]	0.0	4	1	1	1
149120	1710	17-bp serum response factor SRF	[17-bp serum response factor SRF]	0.0	5	1	1	1
149121	1710	pattern of viral growth	[patterns of viral growth]	0.0	4	1	1	1
149122	1710	culture of hiv-infected T lymphocyte	[cultures of HIV-infected T lymphocytes]	0.0	5	1	1	1
149123	1710	binding site for activator protein	[binding sites for activator protein]	0.0	5	1	1	1
149124	1710	size of the region	[size of the region]	0.0	4	1	1	1
149125	1710	60 mM d-ribose	[60 mM D-ribose]	0.0	3	1	1	1
149126	1710	edge: expression of the nf	[edge: expression of the NF]	0.0	5	1	1	1
149127	1710	dual action blockade of progenitor proliferation	[Dual action blockade of progenitor proliferation]	0.0	6	1	1	1
149128	1710	vitro: role	[vitro: role]	0.0	2	1	1	1
149129	1710	common stat protein	[common Stat proteins]	0.0	3	1	1	1
149130	1710	blood of healthy pregnant woman	[blood of healthy pregnant women]	0.0	5	1	1	1
149131	1710	position -502	[positions -502]	0.0	2	1	1	1
149132	1710	Hox11 null mouse	[Hox11 null mice]	0.0	3	2	2	1
149133	1710	detection in extract of cell	[detection in extracts of cells]	0.0	5	1	1	1
149134	1710	functional human deficiency virus type hiv-1	[functional human deficiency virus type HIV-1]	0.0	6	1	1	1
149135	1710	examined, inhibition	[examined, inhibition]	0.0	2	1	1	1
149136	1710	obf-1 in HeLa cell	[OBF-1 in HeLa cells]	0.0	4	1	1	1
149137	1710	isre binding	[ISRE binding]	0.0	2	1	1	1
149138	1710	transactivation of the immunodeficiency virus promoter	[Transactivation of the immunodeficiency virus promoter]	0.0	6	1	1	1
149139	1710	fibroadenomas	[fibroadenomas]	0.0	1	1	1	1
149140	1710	new t-cell-specific factor	[new T-cell-specific factor]	0.0	3	1	1	1
149141	1710	multiple signals,	[multiple signals,]	0.0	2	1	1	1
149142	1710	part, by this mechanism.	[part, by this mechanism.]	0.0	4	1	1	1
149143	1710	structure of the secondary tissue	[structure of the secondary tissues]	0.0	5	1	1	1
149144	1710	independent, b-cell line	[independent, B-cell line]	0.0	3	1	1	1
149145	1710	expression a gene	[expression a gene]	0.0	3	1	1	1
149146	1710	combination with overproduction	[combination with overproduction]	0.0	3	1	1	1
149147	1710	Essential role of macrophage in activation	[Essential role of macrophages in activation]	0.0	6	1	1	1
149148	1710	frequency (30%)	[frequency (30%)]	0.0	2	1	1	1
149149	1710	nf kappa b induction	[NF kappa B induction]	0.0	4	1	1	1
149150	1710	tal1 mutant bind	[TAL1 mutant binding]	0.0	3	1	1	1
149151	1710	Arnica Montana	[Arnica montana]	0.0	2	1	1	1
149152	1710	expression of classical pkc-alpha	[expression of classical PKC-alpha]	0.0	4	1	1	1
149153	1710	distal factor proximal NF-AT AP-1/Octamer UPS	[distal factor proximal NF-AT AP-1/Octamer UPS]	0.0	6	1	1	1
149154	1710	component by mobility shift assay	[component by mobility shift assay]	0.0	5	1	1	1
149155	1710	(lp)	[(LP)]	0.0	1	1	1	1
149156	1710	wt19	[WT19]	0.0	1	1	1	1
149157	1710	age of year	[age of yr]	0.0	3	1	1	1
149158	1710	change in the uptake	[changes in the uptake]	0.0	4	1	1	1
149159	1710	pool of I(kappa)B(alpha)	[pool of I(kappa)B(alpha)]	0.0	3	1	1	1
149160	1710	culture, lead	[culture, leading]	0.0	2	1	1	1
149161	1710	rflp TaqI	[RFLPs TaqI]	0.0	2	1	1	1
149162	1710	induction 1 infection of myelomonoblastic cell	[Induction 1 infection of myelomonoblastic cells]	0.0	6	1	1	1
149163	1710	variety of pathogens,	[variety of pathogens,]	0.0	3	1	1	1
149164	1710	binding defect	[binding defect]	0.0	2	1	1	1
149165	1710	one consequence	[One consequence]	0.0	2	2	2	1
149166	1710	Functional association of Nmi with Stat5	[Functional association of Nmi with Stat5]	0.0	6	1	1	1
149167	1710	-modulate	[-modulating]	0.0	1	1	1	1
149168	1710	m-csf receptor promoter	[M-CSF receptor promoter]	0.0	3	1	1	1
149169	1710	interleukin-11 IL-11	[interleukin-11 IL-11]	0.0	2	1	1	1
149170	1710	NF kappa b enhancer	[NF kappa B enhancer]	0.0	4	1	1	1
149171	1710	activation of Epstein-Barr virus zebra promoter	[activation of Epstein-Barr virus zebra promoter]	0.0	6	1	1	1
149172	1710	use a proteasome inhibitor z-lll-h	[using a proteasome inhibitor Z-LLL-H]	0.0	5	1	1	1
149173	1710	human cytomegalovirus enhancer	[human cytomegalovirus enhancer]	0.0	3	1	1	1
149174	1710	expression of a single protein	[expression of a single protein]	0.0	5	1	1	1
149175	1710	mediuhd colony	[medium, colonies]	0.0	2	1	1	1
149176	1710	limited activation by hiv protease	[limited activation by HIV protease]	0.0	5	1	1	1
149177	1710	line represent stage from precursor	[lines representing stages from precursors]	0.0	5	1	1	1
149178	1710	contain b element	[containing B elements]	0.0	3	1	1	1
149179	1710	Hodgkin cell	[Hodgkin cells]	0.0	2	1	1	1
149180	1710	study signal in human precursor	[studies signaling in human precursors]	0.0	5	1	1	1
149181	1710	syk protein tyrosine kinase	[syk protein tyrosine kinases]	0.0	4	1	1	1
149182	1710	general agreement on the inflammatory pathogenesis	[general agreement on the inflammatory pathogenesis]	0.0	6	1	1	1
149183	1710	t-cell lymphotropic virus	[T-cell lymphotropic virus]	0.0	3	1	1	1
149184	1710	overexpress c/ebp activator nf-il-6	[overexpressing C/EBP activator NF-IL-6]	0.0	4	1	1	1
149185	1710	IL-4R alpha domain	[IL-4R alpha domain]	0.0	3	1	1	1
149186	1710	phosphatidic acid accumulation	[phosphatidic acid accumulation]	0.0	3	1	1	1
149187	1710	study of hd	[study of HD]	0.0	3	1	1	1
149188	1710	regulator by myelomonocytic cell	[regulator by myelomonocytic cells]	0.0	4	1	1	1
149189	1710	antigens, particularly u1rnp	[antigens, particularly U1RNP]	0.0	3	1	1	1
149190	1710	dissociation from ig kappa b	[Dissociation from Ig kappa B]	0.0	5	1	1	1
149191	1710	involvement of a lymphoid-specific enhancer element	[Involvement of a lymphoid-specific enhancer element]	0.0	6	1	1	1
149192	1710	initiation factor for rna polymerase transcription	[initiation factors for RNA polymerase transcription]	0.0	6	1	1	1
149193	1710	parents,	[parents,]	0.0	1	1	1	1
149194	1710	24 healthy woman 10 second	[24 healthy women 10 second]	0.0	5	1	1	1
149195	1710	study of gr	[studies of GR]	0.0	3	1	1	1
149196	1710	understanding with emphasis on the result	[understanding with emphasis on the results]	0.0	6	1	1	1
149197	1710	healthy woman (11 second	[healthy women (11 second]	0.0	4	1	1	1
149198	1710	adhesion molecule-1 gene transcription in monocyte	[adhesion molecule-1 gene transcription in monocytes]	0.0	6	1	1	1
149199	1710	effect against the cancer cell	[effect against the cancer cells]	0.0	5	1	1	1
149200	1710	allogeneic	[allogeneic]	0.0	1	1	1	1
149201	1710	involvement of a distinct set	[involvement of a distinct set]	0.0	5	1	1	1
149202	1710	genotoxic stimulus	[genotoxic stimuli]	0.0	2	1	1	1
149203	1710	rxr-alpha respectively.	[RXR-alpha respectively.]	0.0	2	1	1	1
149204	1710	action of dopamine	[action of dopamine]	0.0	3	1	1	1
149205	1710	phospholipase Cgamma	[phospholipase Cgamma]	0.0	2	1	1	1
149206	1710	BZLF trans-activator Zta	[BZLF trans-activator Zta]	0.0	3	1	1	1
149207	1710	increase in the fragment	[increase in the fragment]	0.0	4	1	1	1
149208	1710	identification of a deoxyribonuclease	[identification of a deoxyribonuclease]	0.0	4	1	1	1
149209	1710	chotsh1-1	[CHOtsH1-1]	0.0	1	1	1	1
149210	1710	pretreatment of huvec	[pretreatment of HUVEC]	0.0	3	1	1	1
149211	1710	inhibit the phosphorylation	[inhibiting the phosphorylation]	0.0	3	1	1	1
149212	1710	downstream element	[downstream element]	0.0	2	1	1	1
149213	1710	protein content	[protein content]	0.0	2	1	1	1
149214	1710	signal requirement as c-rel induction	[signaling requirements as c-Rel induction]	0.0	5	1	1	1
149215	1710	response to type	[response to type]	0.0	3	1	1	1
149216	1710	influence on the selection in response	[influence on the selection in response]	0.0	6	1	1	1
149217	1710	mixture of heparin up-regulation	[mixture of heparin up-regulation]	0.0	4	1	1	1
149218	1710	use blot hybridisation	[using blot hybridisation]	0.0	3	1	1	1
149219	1710	PML gene in adult hematopoiesis	[PML gene in adult hematopoiesis]	0.0	5	1	1	1
149220	1710	effect of (delta383)	[effect of (delta383)]	0.0	3	1	1	1
149221	1710	initial activation	[initial activation]	0.0	2	1	1	1
149222	1710	synthetic GRE oligonucleotide	[synthetic GRE oligonucleotides]	0.0	3	1	1	1
149223	1710	zebra domain	[ZEBRA domain]	0.0	2	1	1	1
149224	1710	include the multifunctional ca2+ protein kinase	[including the multifunctional Ca2+ protein kinase]	0.0	6	1	1	1
149225	1710	activation of the cascade	[activation of the cascade]	0.0	4	1	1	1
149226	1710	good understanding at this stage	[better understanding at this stage]	0.0	5	1	1	1
149227	1710	on/off	[on/off]	0.0	1	1	1	1
149228	1710	expression of PECAM-1	[expression of PECAM-1]	0.0	3	1	1	1
149229	1710	other cell characteristic	[other cell characteristics]	0.0	3	1	1	1
149230	1710	gene interleukin-2 IL2	[gene interleukin-2 IL2]	0.0	3	1	1	1
149231	1710	cooperation between p50b in transactivation	[cooperation between p50B in transactivation]	0.0	5	1	1	1
149232	1710	permissiveness to replication	[Permissiveness to replication]	0.0	3	1	1	1
149233	1710	thp-1 cell at relevant doses.	[THP-1 cells at relevant doses.]	0.0	5	1	1	1
149234	1710	ligand-induced plasticity	[ligand-induced plasticity]	0.0	2	1	1	1
149235	1710	insight into a role	[insight into a role]	0.0	4	1	1	1
149236	1710	detectable nfatc protein	[detectable NFATc protein]	0.0	3	1	1	1
149237	1710	malignant clone with sensitive technique	[malignant clone with sensitive techniques]	0.0	5	1	1	1
149238	1710	overexpression of BXB	[Overexpression of BXB]	0.0	3	1	1	1
149239	1710	defect lead	[defect leading]	0.0	2	1	1	1
149240	1710	membrane from leukocyte	[membranes from leukocytes]	0.0	3	1	1	1
149241	1710	ulcerative colitis (56.1	[ulcerative colitis (56.1]	0.0	3	1	1	1
149242	1710	factor in normal monocyte	[factor in normal monocytes]	0.0	4	1	1	1
149243	1710	h peak	[h peaks]	0.0	2	1	1	1
149244	1710	kappa b-binding complex	[kappa B-binding complexes]	0.0	3	1	1	1
149245	1710	frequency of clone	[frequency of clones]	0.0	3	1	1	1
149246	1710	follicle-center b cell	[follicle-center B cells]	0.0	3	1	1	1
149247	1710	general agreement a accumulation of eosinophil	[general agreement an accumulation of eosinophils]	0.0	6	1	1	1
149248	1710	healthy person with back pain	[healthy persons with back pain]	0.0	5	1	1	1
149249	1710	receptor in mononuclear cell	[receptors in mononuclear cells]	0.0	4	1	1	1
149250	1710	region responsive	[region responsive]	0.0	2	1	1	1
149251	1710	test the effect of ventilatory strategy	[testing the effects of ventilatory strategies]	0.0	6	1	1	1
149252	1710	study responsiveness to transactivator	[studying responsiveness to transactivators]	0.0	4	1	1	1
149253	1710	1-long terminal repeat	[1-long terminal repeat]	0.0	3	1	1	1
149254	1710	only in EBNA2 cell extract	[only in EBNA2 cell extracts]	0.0	5	1	1	1
149255	1710	interaction between ets in vitro	[interaction between Ets in vitro]	0.0	5	1	1	1
149256	1710	HBxAg -specific synthetic polypeptide	[HBxAg -specific synthetic polypeptides]	0.0	4	1	1	1
149257	1710	similarly in normal human macrophage	[similarly in normal human macrophages]	0.0	5	1	1	1
149258	1710	8% dead cell g-csf	[8% dead cells G-CSF]	0.0	4	1	1	1
149259	1710	significant difference in the number	[significant differences in the number]	0.0	5	1	1	1
149260	1710	passage strains.	[passage strains.]	0.0	2	1	1	1
149261	1710	hla DQ individual	[HLA DQ individual]	0.0	3	1	1	1
149262	1710	expression of the jun response gene	[expression of the jun response genes]	0.0	6	1	1	1
149263	1710	effect of 24,25-dihydroxyvitamin D3	[effect of 24,25-dihydroxyvitamin D3]	0.0	4	1	1	1
149264	1710	myeloid patient aml cases)	[myeloid patients AML cases)]	0.0	4	1	1	1
149265	1710	pre-B lymphoblastic leukemia	[pre-B lymphoblastic leukemia]	0.0	3	1	1	1
149266	1710	regulate stage of cell development	[regulating stages of cell development]	0.0	5	1	1	1
149267	1710	current protocol	[current protocols]	0.0	2	1	1	1
149268	1710	hla b8+ LCL target	[HLA B8+ LCL targets]	0.0	4	1	1	1
149269	1710	wild-type, ebna3c	[wild-type, EBNA3C]	0.0	2	1	1	1
149270	1710	underlie il-2 transcriptional blockade	[underlying IL-2 transcriptional blockade]	0.0	4	1	1	1
149271	1710	ligation i MHC-I	[ligation I MHC-I]	0.0	3	1	1	1
149272	1710	cell with endotoxin	[cells with endotoxin]	0.0	3	1	1	1
149273	1710	reporter gene transcription of Stat 5b	[reporter gene transcription of Stat 5b]	0.0	6	1	1	1
149274	1710	15-deoxy-delta(12,14)-prostaglandin	[15-deoxy-Delta(12,14)-prostaglandin]	0.0	1	1	1	1
149275	1710	mutant of type adenovirus	[Mutants of type adenovirus]	0.0	4	1	1	1
149276	1710	entirety	[entirety]	0.0	1	1	1	1
149277	1710	virus SV40 +55 region	[virus SV40 +55 region]	0.0	4	1	1	1
149278	1710	disruption of functional motifs:	[disruptions of functional motifs:]	0.0	4	1	1	1
149279	1710	state of hyperactivation	[state of hyperactivation]	0.0	3	1	1	1
149280	1710	redox status in cytotoxic activity	[redox status in cytotoxic activity]	0.0	5	1	1	1
149281	1710	phagocytosis of leukocyte	[phagocytosis of leukocytes]	0.0	3	1	1	1
149282	1710	heme pathway	[heme pathway]	0.0	2	2	2	1
149283	1710	tissue-specific DNA element	[tissue-specific DNA element]	0.0	3	1	1	1
149284	1710	domain relative	[domain relative]	0.0	2	1	1	1
149285	1710	include kb of DNA	[including kb of DNA]	0.0	4	1	1	1
149286	1710	mediate adhesion	[mediating adhesion]	0.0	2	1	1	1
149287	1710	domain act together in actin polymerization	[domains acting together in actin polymerization]	0.0	6	1	1	1
149288	1710	-convert enzyme family protease inhibitor	[-converting enzyme family protease inhibitors]	0.0	5	1	1	1
149289	1710	prevention of monocyte adherence	[prevention of monocyte adherence]	0.0	4	1	1	1
149290	1710	evidence to the notion	[evidence to the notion]	0.0	4	1	1	1
149291	1710	inhibition of calcineurin	[Inhibition of calcineurin]	0.0	3	1	1	1
149292	1710	small-bowel resection	[Small-bowel resection]	0.0	2	1	1	1
149293	1710	proto-oncogene response	[proto-oncogene responses]	0.0	2	1	1	1
149294	1710	basophilia in promyelocytic leukaemia molecular analysis	[basophilia in promyelocytic leukaemia molecular analysis]	0.0	6	1	1	1
149295	1710	role of egr-1	[role of egr-1]	0.0	3	1	1	1
149296	1710	TCF-1 mouse	[TCF-1 mice]	0.0	2	1	1	1
149297	1710	two element P0	[two elements P0]	0.0	3	1	1	1
149298	1710	surface antigen expression,	[surface antigen expression,]	0.0	3	1	1	1
149299	1710	heat shock factor-1	[heat shock factor-1]	0.0	3	1	1	1
149300	1710	treatment with interferon alpha ifn(alpha)	[Treatment with interferon alpha IFN(alpha)]	0.0	5	1	1	1
149301	1710	ig/tcr	[Ig/TcR]	0.0	1	1	1	1
149302	1710	contain 10% bovine serum	[containing 10% bovine serum]	0.0	4	1	1	1
149303	1710	ATF binding site	[ATF binding site]	0.0	3	1	1	1
149304	1710	phagocytosis of yeast	[phagocytosis of yeasts]	0.0	3	1	1	1
149305	1710	factor as a ganglioside	[factor as a gangliosides]	0.0	4	1	1	1
149306	1710	autoradiographic technique	[autoradiographic techniques]	0.0	2	1	1	1
149307	1710	eccentrically place nucleus	[eccentrically placed, nucleus]	0.0	3	1	1	1
149308	1710	lymphoid precursor	[lymphoid precursors]	0.0	2	1	1	1
149309	1710	min) submaximal physical exercise at 70%	[min) submaximal physical exercise at 70%]	0.0	6	1	1	1
149310	1710	comparison with extract	[comparison with extracts]	0.0	3	1	1	1
149311	1710	subset of t-cell leukemia	[subset of T-cell leukemias]	0.0	4	1	1	1
149312	1710	induction, PMA	[induction, PMA]	0.0	2	1	1	1
149313	1710	competent transcription initiation	[Competent transcription initiation]	0.0	3	1	1	1
149314	1710	requirement for the formation	[requirements for the formation]	0.0	4	1	1	1
149315	1710	cell line keep property in vitro	[cell lines keeping properties in vitro]	0.0	6	1	1	1
149316	1710	specific binding interaction between CIITA	[specific binding interactions between CIITA]	0.0	5	1	1	1
149317	1710	mechanism of immune regulation	[mechanisms of immune regulation]	0.0	4	1	1	1
149318	1710	clonality analysis of refractory anemia study	[Clonality analysis of refractory anemia study]	0.0	6	1	1	1
149319	1710	only a weak effect	[only a weak effect]	0.0	4	1	1	1
149320	1710	U/ml, 6	[U/ml, 6]	0.0	2	1	1	1
149321	1710	action of protein	[action of proteins]	0.0	3	1	1	1
149322	1710	weak T cell response	[weaker T cell response]	0.0	4	1	1	1
149323	1710	positive effect of this element	[positive effect of this element]	0.0	5	1	1	1
149324	1710	individual with pathology LP	[individuals with pathology LP]	0.0	4	1	1	1
149325	1710	immunodeficiency virus type a protein	[immunodeficiency virus type an protein]	0.0	5	1	1	1
149326	1710	Class molecule	[Class molecules]	0.0	2	1	1	1
149327	1710	overexpress hIRAK a activation of NFkappaB	[overexpressing hIRAK a activation of NFkappaB]	0.0	6	1	1	1
149328	1710	control of the cellular process	[control of the cellular processes]	0.0	5	1	1	1
149329	1710	cytomegalovirus hcmv a betaherpesvirus	[cytomegalovirus HCMV a betaherpesvirus]	0.0	4	1	1	1
149330	1710	immunogenic human melanoma	[immunogenic human melanomas]	0.0	3	1	1	1
149331	1710	microg/ml)/mn2+ microM) for h	[microg/ml)/Mn2+ microM) for h]	0.0	4	1	1	1
149332	1710	average number	[average number]	0.0	2	3	3	1
149333	1710	hb -synthesizing cell	[Hb -synthesizing cells]	0.0	3	1	1	1
149334	1710	anti-cd8	[anti-CD8]	0.0	1	1	1	1
149335	1710	However, replication of ebv	[However, replication of EBV]	0.0	4	1	1	1
149336	1710	drive chloramphenicol acetyl-transferase expression	[driving chloramphenicol acetyl-transferase expression]	0.0	4	1	1	1
149337	1710	molecular mechanism underlie differentiation	[molecular mechanisms underlying differentiation]	0.0	4	1	1	1
149338	1710	infiltration into organs,	[infiltration into organs,]	0.0	3	1	1	1
149339	1710	active event	[active events]	0.0	2	1	1	1
149340	1710	domain of factor gm-csf	[domain of factor GM-CSF]	0.0	4	1	1	1
149341	1710	difference in activation of b element	[differences in activation of B elements]	0.0	6	1	1	1
149342	1710	thrombin -generate capacity	[thrombin -generating capacity]	0.0	3	1	1	1
149343	1710	difference in the amount	[difference in the amounts]	0.0	4	1	1	1
149344	1710	vitro with activity in vivo	[vitro with activity in vivo]	0.0	5	1	1	1
149345	1710	anorexic patient aged years, (range	[anorexic patients aged years, (ranging]	0.0	5	1	1	1
149346	1710	binding to bind site	[binding to binding site]	0.0	4	1	1	1
149347	1710	IL-3 colony-stimumulatelany-stg factor two dna-binding complex	[IL-3 colony-stimulating factor two DNA-binding complexes]	0.0	6	1	1	1
149348	1710	oestrogen receptor analysis in leukemia	[Oestrogen receptor analysis in leukemia]	0.0	5	1	1	1
149349	1710	bone marrow sample	[Bone marrow samples]	0.0	3	1	1	1
149350	1710	mitogenic pair of CD2 mab	[mitogenic pairs of CD2 mAbs]	0.0	5	1	1	1
149351	1710	clone with promoter	[clones with promoter]	0.0	3	1	1	1
149352	1710	transcription factor pit-1b	[transcription factor Pit-1b]	0.0	3	1	1	1
149353	1710	molecular partners,	[molecular partners,]	0.0	2	1	1	1
149354	1710	obstruction	[obstruction]	0.0	1	1	1	1
149355	1710	factor for T cell	[factor for T cells]	0.0	4	1	1	1
149356	1710	novel transcriptional activator tcf-1	[novel transcriptional activator TCF-1]	0.0	4	1	1	1
149357	1710	low level element-binding activity	[low levels element-binding activity]	0.0	4	1	1	1
149358	1710	diagnosis, counseling, of patient	[diagnosis, counseling, of patients]	0.0	4	1	1	1
149359	1710	expression of NFATc.beta	[expression of NFATc.beta]	0.0	3	1	1	1
149360	1710	corticosteroid suppression	[corticosteroid suppression]	0.0	2	1	1	1
149361	1710	neotropical primate with glucocorticoid resistance	[neotropical primates with glucocorticoid resistance]	0.0	5	1	1	1
149362	1710	anti-apoptotic effect of g-csf	[anti-apoptotic effects of G-CSF]	0.0	4	1	1	1
149363	1710	three EBNA promoter	[three EBNA promoters]	0.0	3	1	1	1
149364	1710	ptk to downstream signal pathway	[PTKs to downstream signaling pathways]	0.0	5	1	1	1
149365	1710	(mean ige	[(mean IgE]	0.0	2	1	1	1
149366	1710	impairment of metabolism	[impairment of metabolism]	0.0	3	1	1	1
149367	1710	localize the time-frame	[localizing the time-frame]	0.0	3	1	1	1
149368	1710	stat-1 activation	[STAT-1 activation]	0.0	2	1	1	1
149369	1710	stress on nfat activation	[stresses on NFAT activation]	0.0	4	1	1	1
149370	1710	truncation at amino acid	[Truncation at amino acid]	0.0	4	1	1	1
149371	1710	core of the virus Akv	[core of the virus Akv]	0.0	5	1	1	1
149372	1710	expose vein cell	[Exposing vein cells]	0.0	3	1	1	1
149373	1710	adaptor protein functioning	[adaptor protein functioning]	0.0	3	1	1	1
149374	1710	however, two agent	[However, two agents]	0.0	3	1	1	1
149375	1710	reflect the gc	[reflecting the GC]	0.0	3	1	1	1
149376	1710	premature onset	[premature onset]	0.0	2	1	1	1
149377	1710	nevertheless, high, concentration	[Nevertheless, high, concentrations]	0.0	3	1	1	1
149378	1710	receive therapy	[receiving therapy]	0.0	2	1	1	1
149379	1710	spectrum of level of expression	[spectrum of levels of expression]	0.0	5	1	1	1
149380	1710	phosphorylation 38-kd murine map kinase	[phosphorylation 38-kD murine MAP kinase]	0.0	5	1	1	1
149381	1710	regulate stage B	[regulating stages B]	0.0	3	1	1	1
149382	1710	(rare) hybrid	[(rare) hybrids]	0.0	2	1	1	1
149383	1710	u/ml interleukin-2 over 48-h	[U/ml interleukin-2 over 48-h]	0.0	4	1	1	1
149384	1710	Specific docking site	[Specific docking sites]	0.0	3	1	1	1
149385	1710	leukemia hl60 cell	[leukemia HL60 cells]	0.0	3	1	1	1
149386	1710	transient and/or stage-specific expression	[transient and/or stage-specific expression]	0.0	4	1	1	1
149387	1710	various protease	[various proteases]	0.0	2	1	1	1
149388	1710	red transcriptional activator	[red transcriptional activator]	0.0	3	1	1	1
149389	1710	calf serum-supplemented efcs culture	[calf serum-supplemented (FCS+) culture]	0.0	4	1	1	1
149390	1710	sodium without incubation	[sodium without incubation]	0.0	3	1	1	1
149391	1710	depletion of essential transcription factor	[depletion of essential transcription factors]	0.0	5	1	1	1
149392	1710	hybridization assay	[hybridization assay]	0.0	2	1	1	1
149393	1710	receptor from the six nonresponder	[receptors from the six nonresponders]	0.0	5	1	1	1
149394	1710	>10(-14) mol/L	[>10(-14) mol/L]	0.0	2	1	1	1
149395	1710	monoclonal anti-D reagent	[monoclonal anti-D reagents]	0.0	3	1	1	1
149396	1710	factor M-CSF	[factor M-CSF]	0.0	2	1	1	1
149397	1710	EBNA2 induction of the IFN-beta promoter	[EBNA2 induction of the IFN-beta promoter]	0.0	6	1	1	1
149398	1710	p53-null cell resistant	[p53-null cells resistant]	0.0	3	1	1	1
149399	1710	contrast, formation	[contrast, formation]	0.0	2	1	1	1
149400	1710	receptor for low-density lipoprotein	[receptor for low-density lipoprotein]	0.0	4	1	1	1
149401	1710	PMA p/i	[PMA P/I]	0.0	2	1	1	1
149402	1710	weight complex on the enhancer	[weight complex on the enhancer]	0.0	5	1	1	1
149403	1710	protein of weight of kD	[proteins of weights of kD]	0.0	5	1	1	1
149404	1710	block of gene Oct-2	[block of genes Oct-2]	0.0	4	1	1	1
149405	1710	GATA-3 specifically bind	[GATA-3 specifically binding]	0.0	3	1	1	1
149406	1710	strong regulatory effect	[strong regulatory effect]	0.0	3	1	1	1
149407	1710	contrast, deletion	[contrast, deletion]	0.0	2	1	1	1
149408	1710	high increase in the expression	[highest increase in the expression]	0.0	5	1	1	1
149409	1710	dose high	[doses high]	0.0	2	1	1	1
149410	1710	blood mononuclear cell by 38%.	[blood mononuclear cells by 38%.]	0.0	5	1	1	1
149411	1710	analogous cell-cycle-regulated phosphorylation	[analogous cell-cycle-regulated phosphorylation]	0.0	3	1	1	1
149412	1710	region/leucine zipper dna-binding domain	[region/leucine zipper DNA-binding domain]	0.0	4	1	1	1
149413	1710	delivery by kda heat shock protein	[delivery by kDa heat shock protein]	0.0	6	1	1	1
149414	1710	relatively low affinity	[relatively low affinity]	0.0	3	1	1	1
149415	1710	encompass a rich sequence	[encompassing a rich sequence]	0.0	4	1	1	1
149416	1710	activation of form of stat3	[activation of forms of STAT3]	0.0	5	1	1	1
149417	1710	indicate sensitive to action.	[indicating sensitive to action.]	0.0	4	1	1	1
149418	1710	splicing of mds1- evi1	[splicing of MDS1- EVI1]	0.0	4	1	1	1
149419	1710	patient with fibroadenomas	[patients with fibroadenomas]	0.0	3	1	1	1
149420	1710	physiologically, level	[physiologically, levels]	0.0	2	1	1	1
149421	1710	largely due to inhibition	[largely due to inhibition]	0.0	4	1	1	1
149422	1710	shear-induced vcam-1 expression	[shear-induced VCAM-1 expression]	0.0	3	2	2	1
149423	1710	b cell line skw6.4	[B cell line SKW6.4]	0.0	4	1	1	1
149424	1710	use a blot assay	[using a blot assay]	0.0	4	1	1	1
149425	1710	alter nonproductive interaction to strong interactions.	[altering nonproductive interactions to strong interactions.]	0.0	6	1	1	1
149426	1710	b subunit in Jurkat cell	[B subunit in Jurkat cells]	0.0	5	1	1	1
149427	1710	adherence to plastic.	[adherence to plastic.]	0.0	3	1	1	1
149428	1710	cord lymphocyte c-fo expression	[cord lymphocyte c-fos expression]	0.0	4	1	1	1
149429	1710	marginally in undifferentiated cell	[marginally in undifferentiated cells]	0.0	4	1	1	1
149430	1710	(il)-10 blocking factor expression	[(IL)-10 blocking factor expression]	0.0	4	1	1	1
149431	1710	tnfalpha level	[TNFalpha levels]	0.0	2	1	1	1
149432	1710	level of AP-1 nf-at complex	[levels of AP-1 NF-AT complexes]	0.0	5	1	1	1
149433	1710	colony-stimulating factor granulocyte-macrophage colony-stimumulatelany-stg factor proliferation	[colony-stimulating factor granulocyte-macrophage colony-stimulating factor proliferation]	0.0	6	1	1	1
149434	1710	nodular lymphocyte predominance hd	[nodular lymphocyte predominance HD]	0.0	4	1	1	1
149435	1710	gamma/PTF	[gamma/PTF]	0.0	1	1	1	1
149436	1710	mediate induction of hiv transcription	[mediating induction of HIV transcription]	0.0	5	1	1	1
149437	1710	stimulation of human monocyte	[stimulation of human monocytes]	0.0	4	1	1	1
149438	1710	suppression of MHC class antigen induction	[suppression of MHC class antigen induction]	0.0	6	1	1	1
149439	1710	production/oxidative stress	[production/oxidative stress]	0.0	2	1	1	1
149440	1710	unrecognized form of leukemia	[unrecognized form of leukemia]	0.0	4	2	2	1
149441	1710	overexpress human (h) irak	[overexpressing human (h) IRAK]	0.0	4	1	1	1
149442	1710	subsequent adhesion	[subsequent adhesion]	0.0	2	2	2	1
149443	1710	recognition structure	[recognition structure]	0.0	2	1	1	1
149444	1710	effective inhibition	[effective inhibition]	0.0	2	1	1	1
149445	1710	other phorbol ester production	[other phorbol ester production]	0.0	4	1	1	1
149446	1710	influence on physiology	[influence on physiology]	0.0	3	1	1	1
149447	1710	amino- (729-766)	[amino- (729-766)]	0.0	2	1	1	1
149448	1710	intravenous administration	[Intravenous administration]	0.0	2	1	1	1
149449	1710	derivation from gc b cell	[derivation from GC B cells]	0.0	5	1	1	1
149450	1710	approximately substnfkappab substSpl2 substSp23	[approximately substNFkappaB substSpl2 substSp23]	0.0	4	1	1	1
149451	1710	immunodeficiency virus apoptosis m.tremblay,	[immunodeficiency virus apoptosis M.Tremblay,]	0.0	4	1	1	1
149452	1710	lack c-terminal a fail	[lacking C-terminal aa fail]	0.0	4	1	1	1
149453	1710	ap-1 binding protein	[AP-1 binding proteins]	0.0	3	1	1	1
149454	1710	T lymphocyte from woman	[T lymphocytes from women]	0.0	4	1	1	1
149455	1710	unusual expression	[unusual expression]	0.0	2	1	1	1
149456	1710	y701	[Y701]	0.0	1	1	1	1
149457	1710	footprinting datum	[footprinting data]	0.0	2	1	1	1
149458	1710	type-ii estrogen -binding site	[Type-II estrogen -binding sites]	0.0	4	1	1	1
149459	1710	monitoring of disease	[monitoring of disease]	0.0	3	1	1	1
149460	1710	ifn-induced tyrosine phosphorylation a component	[IFN-induced tyrosine phosphorylation a component]	0.0	5	1	1	1
149461	1710	NF-kappaB site in t-cell	[NF-kappaB site in T-cells]	0.0	4	1	1	1
149462	1710	peptide g76	[peptide G76]	0.0	2	1	1	1
149463	1710	mononulear leukocyte hMNL	[mononulear leukocytes hMNL]	0.0	3	1	1	1
149464	1710	inhibition of production	[inhibition of production]	0.0	3	1	1	1
149465	1710	partial characterization of HZF	[partial characterization of HZF]	0.0	4	1	1	1
149466	1710	1 replication in vitro	[1 replication in vitro]	0.0	4	1	1	1
149467	1710	state include the phenomenon	[state including the phenomenon]	0.0	4	1	1	1
149468	1710	number of lymphocyte receptor	[number of lymphocyte receptors]	0.0	4	1	1	1
149469	1710	post- alphacd3 stimulation	[post- alphaCD3 stimulation]	0.0	3	1	1	1
149470	1710	immunodeficiency virus isolate	[immunodeficiency virus isolates]	0.0	3	1	1	1
149471	1710	affinity and/or specificity	[affinity and/or specificity]	0.0	3	1	1	1
149472	1710	tnf-alpha reporter gene activity	[TNF-alpha reporter gene activity]	0.0	4	1	1	1
149473	1710	contain the GATA3 transcription unit	[containing the GATA3 transcription unit]	0.0	5	1	1	1
149474	1710	study use endothelial cell	[studies using endothelial cells]	0.0	4	1	1	1
149475	1710	K562 cell line	[K562 cell line]	0.0	3	1	1	1
149476	1710	characteristic of phagocyte system	[characteristics of phagocyte system]	0.0	4	1	1	1
149477	1710	element necessary 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3	[Elements necessary 1 alpha,25-dihydroxyvitamin D3 alpha,25-(OH)2D3]	0.0	6	1	1	1
149478	1710	Functional characterization of IL-2 inhibitor	[Functional characterization of IL-2 inhibitors]	0.0	5	1	1	1
149479	1710	factor of T cell (nf-at) factor	[factor of T cell (NF-AT) factors]	0.0	6	1	1	1
149480	1710	action CPRE	[action CPRE]	0.0	2	1	1	1
149481	1710	coupling of a signal response domain	[Coupling of a signal response domain]	0.0	6	1	1	1
149482	1710	axis function	[axis function]	0.0	2	1	1	1
149483	1710	normal promyelocytic cell	[normal promyelocytic cells]	0.0	3	1	1	1
149484	1710	(mr)	[(MR)]	0.0	1	1	1	1
149485	1710	single transcript	[single transcript]	0.0	2	1	1	1
149486	1710	differentiation into th1 cell	[differentiation into Th1 cells]	0.0	4	1	1	1
149487	1710	overlapping pcr product	[overlapping PCR products]	0.0	3	1	1	1
149488	1710	inosine-5'-monophosphate dehydrogenase type gene expression	[inosine-5'-monophosphate dehydrogenase type gene expression]	0.0	5	1	1	1
149489	1710	lineage 21	[lineages 21]	0.0	2	1	1	1
149490	1710	evidence a direct result	[evidence a direct result]	0.0	4	1	1	1
149491	1710	induction of timp-1	[induction of TIMP-1]	0.0	3	1	1	1
149492	1710	several other cell	[several other cells]	0.0	3	1	1	1
149493	1710	cytoplasmic carboxyl terminus	[cytoplasmic carboxyl terminus]	0.0	3	1	1	1
149494	1710	action of nuclear nf-kappa b	[action of nuclear NF-kappa B]	0.0	5	1	1	1
149495	1710	T3 receptor site in lymphocyte	[T3 receptor sites in lymphocytes]	0.0	5	1	1	1
149496	1710	five motif	[five motif]	0.0	2	1	1	1
149497	1710	Recent development of culture	[Recent development of cultures]	0.0	4	1	1	1
149498	1710	one major transcription start site	[One major transcription start site]	0.0	5	1	1	1
149499	1710	redundant role	[redundant roles]	0.0	2	1	1	1
149500	1710	immunodeficiency virus (HIV) promoter	[immunodeficiency virus (HIV) promoter]	0.0	4	1	1	1
149501	1710	potent ah-receptor agonist	[potent Ah-receptor agonists]	0.0	3	1	1	1
149502	1710	repression of the p40 gene	[repression of the p40 gene]	0.0	5	1	1	1
149503	1710	IFN gene	[IFN genes]	0.0	2	1	1	1
149504	1710	induction of cytokine expression by binding	[Induction of cytokine expression by binding]	0.0	6	1	1	1
149505	1710	mature, TCRhigh thymocyte	[mature, TCRhigh thymocytes]	0.0	3	1	1	1
149506	1710	pha cell	[PHA cells]	0.0	2	1	1	1
149507	1710	activity of a individual nuclear factor	[activity of an individual nuclear factor]	0.0	6	1	1	1
149508	1710	contrast to the globin gene	[contrast to the globin gene]	0.0	5	1	1	1
149509	1710	PHA proliferation	[PHA proliferation]	0.0	2	1	1	1
149510	1710	SCF ligation	[SCF ligation]	0.0	2	1	1	1
149511	1710	presence in the nuclear extract	[presence in the nuclear extract]	0.0	5	1	1	1
149512	1710	-sensitive induction	[-sensitive induction]	0.0	2	1	1	1
149513	1710	ebv-transformed lymphoblastoid cell	[EBV-transformed lymphoblastoid cells]	0.0	3	1	1	1
149514	1710	distinct, b-cell-derived subtype of hd	[distinct, B-cell-derived subtype of HD]	0.0	5	1	1	1
149515	1710	explanation for a observation	[explanation for a observation]	0.0	4	1	1	1
149516	1710	abundance in brain	[abundance in brain]	0.0	3	1	1	1
149517	1710	outpatient visit, within two week	[outpatient visit, within two weeks]	0.0	5	1	1	1
149518	1710	platelet lysate	[platelet lysates]	0.0	2	1	1	1
149519	1710	differentiation dependent increase	[differentiation dependent increase]	0.0	3	1	1	1
149520	1710	(tcr) variable region beta-chain family	[(TCR) variable region beta-chain families]	0.0	5	1	1	1
149521	1710	histocompatibility complex (MHC) class promoter	[histocompatibility complex (MHC) class promoters]	0.0	5	1	1	1
149522	1710	GM-kappa b/gc-box	[GM-kappa B/GC-box]	0.0	2	1	1	1
149523	1710	present a structure similar	[presenting a structure similar]	0.0	4	1	1	1
149524	1710	face	[face]	0.0	1	1	1	1
149525	1710	blast Tcells	[blast Tcells]	0.0	2	1	1	1
149526	1710	constitutive association of traz	[constitutive association of TRAFs]	0.0	4	1	1	1
149527	1710	characterization relationship	[Characterization relationship]	0.0	2	1	1	1
149528	1710	five member of this family	[Five members of this family]	0.0	5	1	1	1
149529	1710	corticosteroid derivative	[corticosteroid derivatives]	0.0	2	1	1	1
149530	1710	enzyme-linked assay procedure	[enzyme-linked assay procedure]	0.0	3	1	1	1
149531	1710	direct activator	[direct activator]	0.0	2	1	1	1
149532	1710	submaximal exercise at 70%	[submaximal exercises at 70%]	0.0	4	1	1	1
149533	1710	mechanism fundamentally related	[mechanism fundamentally related]	0.0	3	1	1	1
149534	1710	hTR beta mrna level	[hTR beta mRNA levels]	0.0	4	1	1	1
149535	1710	contain four repeat of bp	[containing four repeats of bp]	0.0	5	1	1	1
149536	1710	role for this chemokine	[role for this chemokine]	0.0	4	1	1	1
149537	1710	induction of intercellular adhesion molecule-1	[induction of intercellular adhesion molecule-1]	0.0	5	1	1	1
149538	1710	role as a integratory messenger	[role as an integratory messenger]	0.0	5	1	1	1
149539	1710	role in aberrant fasL up-regulation	[role in aberrant fasL up-regulation]	0.0	5	1	1	1
149540	1710	binding of interleukin-2	[binding of interleukin-2]	0.0	3	1	1	1
149541	1710	developmental manner	[developmental manner]	0.0	2	1	1	1
149542	1710	dbd adjacent	[DBD adjacent]	0.0	2	1	1	1
149543	1710	er enzyme immunoassay	[ER enzyme immunoassay]	0.0	3	1	1	1
149544	1710	E2F-1 expression	[E2F-1 expression]	0.0	2	1	1	1
149545	1710	Lymphocytic level of receptor	[Lymphocytic levels of receptors]	0.0	4	1	1	1
149546	1710	CD3/T	[CD3/T]	0.0	1	1	1	1
149547	1710	subset of DLCL	[subsets of DLCL]	0.0	3	1	1	1
149548	1710	vzv gE protein coding sequence	[VZV gE protein coding sequences]	0.0	5	1	1	1
149549	1710	instance of the biological principle	[instance of the biological principle]	0.0	5	1	1	1
149550	1710	close correlation	[close correlation]	0.0	2	1	1	1
149551	1710	p65 the subunit	[p65 the subunits]	0.0	3	1	1	1
149552	1710	patient receive therapy for systemic disease	[patients receiving therapy for systemic diseases]	0.0	6	1	1	1
149553	1710	more durable inhibition	[more durable inhibition]	0.0	3	1	1	1
149554	1710	extend to -300bp of the promoter	[extending to -300bp of the promoter]	0.0	6	1	1	1
149555	1710	thus, ligation of CD28	[Thus, ligation of CD28]	0.0	4	1	1	1
149556	1710	radioligand-binding assay in asthmatics	[radioligand-binding assay in asthmatics]	0.0	4	1	1	1
149557	1710	use progenitor cell	[using progenitor cells]	0.0	3	1	1	1
149558	1710	MHC hla-dra class	[MHC HLA-DRA class]	0.0	3	1	1	1
149559	1710	furthermore, multimerized region ii	[Furthermore, multimerized region II]	0.0	4	1	1	1
149560	1710	function of Oct-2a	[function of Oct-2a]	0.0	3	1	1	1
149561	1710	distinguish T cell activation	[distinguishing T cell activation]	0.0	4	1	1	1
149562	1710	Partial proteolysis	[Partial proteolysis]	0.0	2	1	1	1
149563	1710	(mz)	[(MZ)]	0.0	1	1	1	1
149564	1710	amino acid rich residue	[amino acids rich residues]	0.0	4	1	1	1
149565	1710	hiv long repeat LTR	[HIV long repeat LTR]	0.0	4	1	1	1
149566	1710	gene Ie of cytomegalovirus CMV	[genes IE of cytomegalovirus CMV]	0.0	5	1	1	1
149567	1710	membrane expression	[membrane expression]	0.0	2	1	1	1
149568	1710	variation in the expression	[variation in the expression]	0.0	4	1	1	1
149569	1710	the/thf alpha thf/thf ratios.	[THE/THF alpha THF/THF ratios.]	0.0	4	1	1	1
149570	1710	coincident with selection.	[coincident with selection.]	0.0	3	1	1	1
149571	1710	protein extract from myelogenous leukemia cell	[protein extracts from myelogenous leukemia cells]	0.0	6	1	1	1
149572	1710	stat5 binding site	[STAT5 binding site]	0.0	3	1	1	1
149573	1710	agent acid	[agent acid]	0.0	2	1	1	1
149574	1710	use a gcrbeta -specific antibody	[using a GCRbeta -specific antibody]	0.0	5	1	1	1
149575	1710	DNA methylation change in malignancy	[DNA methylation changes in malignancies]	0.0	5	1	1	1
149576	1710	cross-reactive specificities, suggest a role	[cross-reactive specificities, suggesting a role]	0.0	5	1	1	1
149577	1710	co-stimulation of t-lymphocyte by t-cell receptor	[Co-stimulation of T-lymphocytes by T-cell receptor]	0.0	6	1	1	1
149578	1710	neoplastic progression	[neoplastic progression]	0.0	2	1	1	1
149579	1710	expression of the g protein	[Expression of the G protein]	0.0	5	1	1	1
149580	1710	cell population capable of differentiation	[cell population capable of differentiation]	0.0	5	1	1	1
149581	1710	genetic predisposition	[genetic predisposition]	0.0	2	1	1	1
149582	1710	result of double infection	[result of double infection]	0.0	4	1	1	1
149583	1710	cystic fibrosis sputum	[cystic fibrosis sputum]	0.0	3	1	1	1
149584	1710	il-2 growth factor	[IL-2 growth factor]	0.0	3	1	1	1
149585	1710	synthase (nos) isoform nos	[synthase (NOS) isoforms NOS]	0.0	4	1	1	1
149586	1710	induction of NF-KB during monocyte differentiation	[Induction of NF-KB during monocyte differentiation]	0.0	6	1	1	1
149587	1710	cell fusion partner	[cell fusion partner]	0.0	3	1	1	1
149588	1710	subunit of a general transcription factor	[subunits of a general transcription factor]	0.0	6	1	1	1
149589	1710	extracellular signal converge	[extracellular signals converging]	0.0	3	1	1	1
149590	1710	tax1 protein	[Tax1 protein]	0.0	2	1	1	1
149591	1710	tnf promoter activity	[TNF promoter activity]	0.0	3	1	1	1
149592	1710	pharmacodynamic response to single versus dose	[pharmacodynamic responses to single versus doses]	0.0	6	1	1	1
149593	1710	Prostaglandin E2 PGE2 a pleiotropic molecule	[Prostaglandin E2 PGE2 a pleiotropic molecule]	0.0	6	1	1	1
149594	1710	multiple lytic reactivity	[multiple lytic reactivities]	0.0	3	1	1	1
149595	1710	interestingly, transfection experiment	[interestingly, transfection experiments]	0.0	3	1	1	1
149596	1710	human intestinal cell response to infection	[Human intestinal cell responses to infection]	0.0	6	1	1	1
149597	1710	T delta	[T delta]	0.0	2	1	1	1
149598	1710	anti-tax1 antibody lt-4	[anti-tax1 antibody Lt-4]	0.0	3	1	1	1
149599	1710	lysis of adenovirus-transformed cell	[lysis of adenovirus-transformed cells]	0.0	4	1	1	1
149600	1710	cell within the lineage	[cells within the lineage]	0.0	4	1	1	1
149601	1710	pathway of T cell activation	[pathways of T cell activation]	0.0	5	1	1	1
149602	1710	inhibition of hiv-1 LTR gene expression	[inhibition of HIV-1 LTR gene expression]	0.0	6	1	1	1
149603	1710	ebv oncogenicity	[EBV oncogenicity]	0.0	2	1	1	1
149604	1710	GM-CSF to this cocktail	[GM-CSF to this cocktail]	0.0	4	1	1	1
149605	1710	fall	[falling]	0.0	1	1	1	1
149606	1710	up-regulation of p50	[up-regulation of p50]	0.0	3	1	1	1
149607	1710	h of cryptococcal stimulation	[h of cryptococcal stimulation]	0.0	4	1	1	1
149608	1710	sh2 association	[SH2 association]	0.0	2	1	1	1
149609	1710	tool for evaluation	[tool for evaluation]	0.0	3	1	1	1
149610	1710	15 depressed patient	[15 depressed patients]	0.0	3	1	1	1
149611	1710	promoter region (-36	[promoter region (-36]	0.0	3	1	1	1
149612	1710	activator protein-1 ap-1 factor il-6	[activator protein-1 AP-1 factor IL-6]	0.0	5	1	1	1
149613	1710	murine macrophage	[murine macrophages]	0.0	2	1	1	1
149614	1710	Promiscuous activity reticuloendotheliosis virus REV	[Promiscuous activity reticuloendotheliosis virus REV]	0.0	5	1	1	1
149615	1710	inhibition (an enzyme	[inhibition (an enzyme]	0.0	3	1	1	1
149616	1710	activation: purification	[activation: purification]	0.0	2	1	1	1
149617	1710	activation of transduction pathway	[activation of transduction pathways]	0.0	4	1	1	1
149618	1710	bryostatin 1	[bryostatin 1]	0.0	2	1	1	1
149619	1710	largely through binding	[largely through binding]	0.0	3	1	1	1
149620	1710	modest increase	[modest increase]	0.0	2	1	1	1
149621	1710	picornavirus rrna	[picornavirus mRNAs]	0.0	2	1	1	1
149622	1710	lectin galectin-3	[lectin galectin-3]	0.0	2	1	1	1
149623	1710	(p p	[(P P]	0.0	2	1	1	1
149624	1710	evidence to cell differentiation	[Evidence to cell differentiation]	0.0	4	1	1	1
149625	1710	such form lack a major portion	[such forms lacking a major portion]	0.0	6	1	1	1
149626	1710	pkc linkage between CD40	[PKC linkage between CD40]	0.0	4	1	1	1
149627	1710	acute hiv-1 infection	[acute HIV-1 infection]	0.0	3	1	1	1
149628	1710	administer mp	[administering MP]	0.0	2	1	1	1
149629	1710	marrow-derived macrophage activity	[marrow-derived macrophages activity]	0.0	3	1	1	1
149630	1710	works? with a therapy	[works? with a therapy]	0.0	4	1	1	1
149631	1710	mutation of a pair sequence	[Mutation of a pair sequence]	0.0	5	1	1	1
149632	1710	activity in erythroid ocim1	[activity in erythroid OCIM1]	0.0	4	1	1	1
149633	1710	pbmc specimen	[PBMC specimens]	0.0	2	2	2	1
149634	1710	induction of adhesion molecule-1 ICAM-1	[induction of adhesion molecule-1 ICAM-1]	0.0	5	1	1	1
149635	1710	factor mrna level	[factor mRNA levels]	0.0	3	1	1	1
149636	1710	hydroxyanisole bha	[hydroxyanisole BHA]	0.0	2	1	1	1
149637	1710	surfactant cytokine production	[surfactant cytokine production]	0.0	3	1	1	1
149638	1710	stat-related protein	[Stat-related proteins]	0.0	2	1	1	1
149639	1710	lymphocyte glucocorticoid	[Lymphocyte glucocorticoid]	0.0	2	3	3	1
149640	1710	numerous cytokine promoter	[numerous cytokine promoters]	0.0	3	1	1	1
149641	1710	level 1 beta	[levels 1 beta]	0.0	3	1	1	1
149642	1710	ri-gamma	[RI-gamma]	0.0	1	1	1	1
149643	1710	CMV 1 gene product expression	[CMV 1 gene product expression]	0.0	5	1	1	1
149644	1710	presence lymphocyte	[presence lymphocytes]	0.0	2	1	1	1
149645	1710	induce apoptosis in uninfected cell	[inducing apoptosis in uninfected cells]	0.0	5	1	1	1
149646	1710	T transcription factor with specificity	[T transcription factor with specificity]	0.0	5	1	1	1
149647	1710	same mobility (approximately kd)	[same mobility (approximately kD)]	0.0	4	1	1	1
149648	1710	dehydroepiandrosterone modulation of lipopolysaccharide	[Dehydroepiandrosterone modulation of lipopolysaccharide]	0.0	4	1	1	1
149649	1710	mutant of type with DNA sequence	[Mutants of type with DNA sequences]	0.0	6	1	1	1
149650	1710	hamster cutaneous wound	[hamster cutaneous wounds]	0.0	3	1	1	1
149651	1710	isoforms, hsf2-alpha	[isoforms, HSF2-alpha]	0.0	2	1	1	1
149652	1710	glucocorticoid receptor n-terminal domain	[glucocorticoid receptor N-terminal domain]	0.0	4	1	1	1
149653	1710	interferon consensus sequence binding protein	[Interferon Consensus Sequence binding protein]	0.0	5	1	1	1
149654	1710	nuclear factor (nfat) protein	[nuclear factor (NFAT) proteins]	0.0	4	1	1	1
149655	1710	ultimately, the transform property	[ultimately, the transforming properties]	0.0	4	1	1	1
149656	1710	overt homology	[overt homology]	0.0	2	1	1	1
149657	1710	restore tat responsiveness	[restoring Tat responsiveness]	0.0	3	1	1	1
149658	1710	factor-kappaB activation on mobility shift assay	[factor-kappaB activation on mobility shift assays]	0.0	6	1	1	1
149659	1710	CMV early cell	[CMV early cells]	0.0	3	1	1	1
149660	1710	muscle myosin heavy chain	[muscle myosin heavy chain]	0.0	4	1	1	1
149661	1710	bicycle	[bicycle]	0.0	1	1	1	1
149662	1710	heparin-binding protein	[heparin-binding proteins]	0.0	2	1	1	1
149663	1710	individual ptk substrate	[individual PTK substrates]	0.0	3	1	1	1
149664	1710	cell to m/l calcitriol	[cells to M/l calcitriol]	0.0	4	1	1	1
149665	1710	induction of dna-protein binding complex	[induction of DNA-protein binding complexes]	0.0	5	1	1	1
149666	1710	element (ire) motif	[element (IRE) motif]	0.0	3	1	1	1
149667	1710	presence of receptor	[presence of receptors]	0.0	3	1	1	1
149668	1710	occur in multiple allelic family	[occurring in multiple allelic families]	0.0	5	1	1	1
149669	1710	Finally, CD40 ligation growth inhibition	[Finally, CD40 ligation growth inhibition]	0.0	5	1	1	1
149670	1710	recurrent feature occur in family	[recurrent feature occurring in families]	0.0	5	1	1	1
149671	1710	large cell subtype	[large cell subtype]	0.0	3	1	1	1
149672	1710	two Duffy antigen	[two Duffy antigens]	0.0	3	1	1	1
149673	1710	dna-binding assay with form of EBF	[DNA-binding assays with forms of EBF]	0.0	6	1	1	1
149674	1710	nf-kappa b1	[NF-kappa B1]	0.0	2	1	1	1
149675	1710	inhibition of nf-at transcription	[Inhibition of NF-AT transcription]	0.0	4	1	1	1
149676	1710	content in climacteric syndrome patient	[contents in climacteric syndrome patients]	0.0	5	1	1	1
149677	1710	nf-kappa b-	[NF-kappa B-]	0.0	2	1	1	1
149678	1710	various tax mutant	[various Tax mutants]	0.0	3	1	1	1
149679	1710	lining positive	[lining positive]	0.0	2	1	1	1
149680	1710	regulatory role for nno	[regulatory role for nNOS]	0.0	4	1	1	1
149681	1710	lymphocyte activator	[lymphocyte activator]	0.0	2	1	1	1
149682	1710	occurrence in t(3;3)	[occurrence in t(3;3)]	0.0	3	1	1	1
149683	1710	implications, in relation to prognosis	[implications, in relation to prognosis]	0.0	5	1	1	1
149684	1710	polypeptide of about 50 kD	[polypeptides of about 50 kD]	0.0	5	1	1	1
149685	1710	NFkappaB /inhibitor-kappaB ikappab	[NFkappaB /inhibitor-kappaB IkappaB]	0.0	3	1	1	1
149686	1710	antioxidant include hydroxyanisole tetrahydropapaveroline	[antioxidants including hydroxyanisole tetrahydropapaveroline]	0.0	4	1	1	1
149687	1710	interaction with natural ligand LFA-3	[interaction with natural ligand LFA-3]	0.0	5	1	1	1
149688	1710	abnormality highlight putative novel loci	[abnormalities highlighting putative novel loci]	0.0	5	1	1	1
149689	1710	regulation of repressor	[regulation of repressors]	0.0	3	1	1	1
149690	1710	patient with SLE	[patients with SLE]	0.0	3	1	1	1
149691	1710	capacity of progenitor cell	[capacity of progenitor cells]	0.0	4	1	1	1
149692	1710	TNF-alpha hiv-1 terminal repeat transcription	[TNF-alpha HIV-1 terminal repeat transcription]	0.0	5	1	1	1
149693	1710	ebna2 protein	[EBNA2 protein]	0.0	2	2	2	1
149694	1710	similarly to the result	[similarly to the results]	0.0	4	1	1	1
149695	1710	homologous porcine serum (control)	[homologous porcine serum (control)]	0.0	4	1	1	1
149696	1710	detectable basal phosphorylation	[detectable basal phosphorylation]	0.0	3	1	1	1
149697	1710	100% inhibition of the igg (from	[100% inhibition of the IgG (from]	0.0	6	1	1	1
149698	1710	receptor in aged long-distance runner	[receptor in aged long-distance runner]	0.0	5	1	1	1
149699	1710	synthesis of transcription	[synthesis of transcription]	0.0	3	1	1	1
149700	1710	symmetry region	[symmetry region]	0.0	2	1	1	1
149701	1710	provide a structural basis for mimicry	[providing a structural basis for mimicry]	0.0	6	1	1	1
149702	1710	obtain new informative probe specific	[obtaining new informative probes specific]	0.0	5	1	1	1
149703	1710	cells/ml) with a thiol antioxidant	[cells/ml) with a thiol antioxidant]	0.0	5	1	1	1
149704	1710	bp promoter	[bp promoter]	0.0	2	1	1	1
149705	1710	effect of tpa on egr-1 transcription	[effect of TPA on EGR-1 transcription]	0.0	6	1	1	1
149706	1710	cis-cloned oligodeoxyribonudleotides	[cis-cloned oligodeoxyribonucleotides]	0.0	2	1	1	1
149707	1710	five-fold decrease	[five-fold decrease]	0.0	2	1	1	1
149708	1710	reduction in stimulus-dependent nf-at complex	[reductions in stimulus-dependent NF-AT complexes]	0.0	5	1	1	1
149709	1710	occurrence of such proliferations.	[occurrence of such proliferations.]	0.0	4	1	1	1
149710	1710	point ylpq into YLPA	[point YLPQ into YLPA]	0.0	4	1	1	1
149711	1710	umbilical venous huvec	[umbilical venous HUVECs]	0.0	3	1	1	1
149712	1710	only one signal	[only one signal]	0.0	3	1	1	1
149713	1710	b cell population	[B cell population]	0.0	3	1	1	1
149714	1710	pull-down	[pull-down]	0.0	1	1	1	1
149715	1710	ovarian carcinoma patient	[ovarian carcinoma patients]	0.0	3	1	1	1
149716	1710	first example	[first example]	0.0	2	3	3	1
149717	1710	therapeutic initiative	[therapeutic initiative]	0.0	2	1	1	1
149718	1710	progesterone receptor by immunohistochemistry	[progesterone receptors by immunohistochemistry]	0.0	4	1	1	1
149719	1710	overexpression of calcineurin a protein phosphatase	[overexpression of calcineurin a protein phosphatase]	0.0	6	1	1	1
149720	1710	incubation of lymphocytic leukemia (b-cll) cell	[Incubation of lymphocytic leukemia (B-CLL) cells]	0.0	6	1	1	1
149721	1710	tyrosine phosphorylation result	[tyrosine phosphorylation resulting]	0.0	3	1	1	1
149722	1710	factor bind after ltb4 stimulation	[factors binding after LTB4 stimulation]	0.0	5	1	1	1
149723	1710	requirement for c-myb for activity,	[requirement for c-Myb for activity,]	0.0	5	1	1	1
149724	1710	precondition	[precondition]	0.0	1	1	1	1
149725	1710	identification of protein	[identification of proteins]	0.0	3	1	1	1
149726	1710	defense mechanism against infectious pathogen	[defense mechanisms against infectious pathogens]	0.0	5	1	1	1
149727	1710	approximately 10-fold day	[approximately 10-fold days]	0.0	3	1	1	1
149728	1710	site in the TNF-alpha promoter kappa	[sites in the TNF-alpha promoter kappa]	0.0	6	1	1	1
149729	1710	soluble interleukin-2 receptor -alpha	[Soluble interleukin-2 receptor -alpha]	0.0	4	1	1	1
149730	1710	staining with a panel of antibody	[staining with a panel of antibodies]	0.0	6	1	1	1
149731	1710	involve the region	[involving the regions]	0.0	3	1	1	1
149732	1710	variable monosomy of loci	[variable monosomy of loci]	0.0	4	1	1	1
149733	1710	il-1 beta protein	[IL-1 beta protein]	0.0	3	1	1	1
149734	1710	receptor binding in leukocyte	[receptor binding in leukocytes]	0.0	4	1	1	1
149735	1710	inoculation intraperitoneally (i.p.)	[inoculation intraperitoneally (i.p.)]	0.0	3	1	1	1
149736	1710	1alpha,25(oh)2-lumisterol3 prime nb4 leukemia cell	[1alpha,25(OH)2-lumisterol3 prime NB4 leukemia cells]	0.0	5	1	1	1
149737	1710	short-term expression	[short-term expression]	0.0	2	1	1	1
149738	1710	Yin-Yang YY1	[Yin-Yang YY1]	0.0	2	1	1	1
149739	1710	expression to the immediate-early class	[expression to the immediate-early classes]	0.0	5	1	1	1
149740	1710	effect attributable to cn inhibition	[effects attributable to CN inhibition]	0.0	5	1	1	1
149741	1710	M-CSF by M-CSF	[M-CSF by M-CSF]	0.0	3	1	1	1
149742	1710	antigen processing by epithelial cell	[antigen processing by epithelial cells]	0.0	5	1	1	1
149743	1710	histocompatibility complex class ii molecule	[histocompatibility complex class II molecules]	0.0	5	1	1	1
149744	1710	different anti-onco-genic transcription factor	[different anti-onco-genic transcription factors]	0.0	4	1	1	1
149745	1710	position -306	[positions -306]	0.0	2	1	1	1
149746	1710	innate response in adult drosophila	[innate response in adult Drosophila]	0.0	5	1	1	1
149747	1710	use [3H]-dexamethasone	[using [3H]-dexamethasone]	0.0	2	1	1	1
149748	1710	common pathway as the way	[common pathway as the way]	0.0	5	1	1	1
149749	1710	fas ligand regulatory element	[Fas ligand regulatory element]	0.0	4	1	1	1
149750	1710	Agonist	[Agonist]	0.0	1	1	1	1
149751	1710	BZLF-1 a gene	[BZLF-1 an gene]	0.0	3	1	1	1
149752	1710	factor proximal NF-AT	[factor proximal NF-AT]	0.0	3	1	1	1
149753	1710	anti- TNF-alpha hiv-1 terminal repeat transcription	[anti- TNF-alpha HIV-1 terminal repeat transcription]	0.0	6	1	1	1
149754	1710	Stat family	[Stat family]	0.0	2	2	2	1
149755	1710	8% dead cell at day	[8% dead cells at day]	0.0	5	1	1	1
149756	1710	selection in response during infection.	[Selection in response during infection.]	0.0	5	1	1	1
149757	1710	expression of only the first exon	[expression of only the first exon]	0.0	6	1	1	1
149758	1710	major portion	[major portion]	0.0	2	1	1	1
149759	1710	exotoxin	[exotoxin]	0.0	1	1	1	1
149760	1710	differential function	[differential function]	0.0	2	1	1	1
149761	1710	antibody cross-linking in the absence	[Antibody cross-linking in the absence]	0.0	5	1	1	1
149762	1710	suppression of T cell mitogenesis	[suppression of T cell mitogenesis]	0.0	5	1	1	1
149763	1710	potential open reading frame orf	[potential open reading frames ORFs]	0.0	5	1	1	1
149764	1710	MYH11 rearrangement	[MYH11 rearrangement]	0.0	2	1	1	1
149765	1710	clonal expansion) (by abortive stimulation lead	[clonal expansion) (by abortive stimulation leading]	0.0	6	1	1	1
149766	1710	pa6-neo	[PA6-neo]	0.0	1	1	1	1
149767	1710	IL-12 IFN	[IL-12 IFN]	0.0	2	1	1	1
149768	1710	E3 promoter	[E3 promoter]	0.0	2	2	2	1
149769	1710	cytokine-inducible sh2-containing protein	[cytokine-inducible SH2-containing protein]	0.0	3	1	1	1
149770	1710	1 tax induction	[1 Tax induction]	0.0	3	1	1	1
149771	1710	element cd28re	[element CD28RE]	0.0	2	1	1	1
149772	1710	insulin on the specific power	[insulin on the specific power]	0.0	5	1	1	1
149773	1710	contrast, LPS nuclear binding	[contrast, LPS nuclear binding]	0.0	4	1	1	1
149774	1710	contain a region (4c)	[containing a region (4c)]	0.0	4	1	1	1
149775	1710	terminal repeat sequence diversity	[terminal repeat sequence diversity]	0.0	4	1	1	1
149776	1710	evidence a relevant role	[evidencing a relevant role]	0.0	4	1	1	1
149777	1710	(tcr)/cd3	[(TCR)/CD3]	0.0	1	1	1	1
149778	1710	blot analysis in mouse cell line	[blot analysis in mouse cell lines]	0.0	6	1	1	1
149779	1710	stat1alpha -responsive gene	[STAT1alpha -responsive gene]	0.0	3	1	1	1
149780	1710	report of NFAT in cell	[report of NFAT in cells]	0.0	5	1	1	1
149781	1710	hiv-1 antigen	[HIV-1 antigen]	0.0	2	1	1	1
149782	1710	adenovirus-mediated gene transfer	[adenovirus-mediated gene transfer]	0.0	3	1	1	1
149783	1710	process extend from cytoplasm	[processes extending from cytoplasm]	0.0	4	1	1	1
149784	1710	Burkitt' cell line	[Burkitt's cell line]	0.0	3	1	1	1
149785	1710	CD28 tyrosyl	[CD28 tyrosyl]	0.0	2	1	1	1
149786	1710	instillation of IL-6 into rat	[instillation of IL-6 into rats]	0.0	5	1	1	1
149787	1710	analysis of cyclosporin -resistant mutant	[analysis of cyclosporin -resistant mutants]	0.0	5	1	1	1
149788	1710	h of incubation	[h of incubation]	0.0	3	1	1	1
149789	1710	synergize with pkc pathway	[synergize with PKC pathways]	0.0	4	1	1	1
149790	1710	own study on endocrine culture	[own studies on endocrine cultures]	0.0	5	1	1	1
149791	1710	venous blood from donor	[venous blood from donors]	0.0	4	1	1	1
149792	1710	cellular immunity result	[cellular immunity resulting]	0.0	3	1	1	1
149793	1710	trans-activation domain tad-b	[trans-activation domain TAD-B]	0.0	3	1	1	1
149794	1710	trans-activation domain tad-a	[trans-activation domain TAD-A]	0.0	3	1	1	1
149795	1710	HHV-6 variant	[HHV-6 variant]	0.0	2	1	1	1
149796	1710	epo receptor for gata-1	[Epo receptor for GATA-1]	0.0	4	1	1	1
149797	1710	glucocorticoid induction	[glucocorticoid induction]	0.0	2	1	1	1
149798	1710	dna-binding factor specific	[DNA-binding factor specific]	0.0	3	1	1	1
149799	1710	status comparison with prognostic criteria]	[status comparison with prognostic criteria]]	0.0	5	1	1	1
149800	1710	failure A-CRF	[failure A-CRF]	0.0	2	1	1	1
149801	1710	Maximal accumulation	[Maximal accumulation]	0.0	2	1	1	1
149802	1710	molecular mechanism of synergy	[molecular mechanisms of synergy]	0.0	4	1	1	1
149803	1710	dependence for the proliferative response	[Dependence for the proliferative response]	0.0	5	1	1	1
149804	1710	common signal event	[common signaling events]	0.0	3	1	1	1
149805	1710	large IL-4 region	[large IL-4 regions]	0.0	3	1	1	1
149806	1710	intrinsic DNA affinity	[intrinsic DNA affinity]	0.0	3	1	1	1
149807	1710	most mutants.	[most mutants.]	0.0	2	1	1	1
149808	1710	aspect to knowledge	[aspect to knowledge]	0.0	3	1	1	1
149809	1710	analogous framework signal	[analogous framework signaling]	0.0	3	1	1	1
149810	1710	evidence for a antioxidant pathway distinct	[evidence for an antioxidant pathway distinct]	0.0	6	1	1	1
149811	1710	affect th cell	[affecting Th cells]	0.0	3	1	1	1
149812	1710	notion a control point	[notion a control point]	0.0	4	1	1	1
149813	1710	significant increase in GRE binding	[significant increase in GRE binding]	0.0	5	1	1	1
149814	1710	human aortic cell HAEC	[human aortic cells HAEC]	0.0	4	1	1	1
149815	1710	immunogenic protein in nasal lymphoma	[immunogenic proteins in nasal lymphoma]	0.0	5	1	1	1
149816	1710	distinct region important, for recruitment	[distinct regions important, for recruitment]	0.0	5	1	1	1
149817	1710	CAAT/enhancer	[CAAT/enhancer]	0.0	1	1	1	1
149818	1710	several T gene	[several T genes]	0.0	3	1	1	1
149819	1710	suggest lack	[suggesting lack]	0.0	2	1	1	1
149820	1710	(position -153	[(positions -153]	0.0	2	1	1	1
149821	1710	emerge family	[emerging family]	0.0	2	1	1	1
149822	1710	transcription factor up-regulate gene expression	[Transcription factors up-regulate gene expression]	0.0	5	1	1	1
149823	1710	densitometry	[densitometry]	0.0	1	2	2	1
149824	1710	il-7 receptor (il-7r)	[IL-7 receptor (IL-7R)]	0.0	3	1	1	1
149825	1710	eutopic first trimester pregnancy	[eutopic first trimester pregnancies]	0.0	4	1	1	1
149826	1710	study in extra-renal, cell	[studies in extra-renal, cells]	0.0	4	1	1	1
149827	1710	g0/g1 switch gene 2	[G0/G1 switch gene 2]	0.0	4	1	1	1
149828	1710	provide a firm basis	[providing a firm basis]	0.0	4	1	1	1
149829	1710	thapsigargin dependent	[thapsigargin dependent]	0.0	2	1	1	1
149830	1710	strong interactions.	[strong interactions.]	0.0	2	1	1	1
149831	1710	mediator of stromal tcell rescue	[mediator of stromal Tcell rescue]	0.0	5	1	1	1
149832	1710	three regulatory pathway	[three regulatory pathways]	0.0	3	1	1	1
149833	1710	viral protein bzlf1	[viral protein BZLF1]	0.0	3	1	1	1
149834	1710	role for myristylation	[role for myristylation]	0.0	3	1	1	1
149835	1710	part, by damage	[part, by damage]	0.0	3	1	1	1
149836	1710	response during pregnancy	[response during pregnancy]	0.0	3	1	1	1
149837	1710	mutation in DNA	[mutations in DNA]	0.0	3	1	1	1
149838	1710	two basal enhancer motif	[Two basal enhancer motifs]	0.0	4	1	1	1
149839	1710	lmp-1 mutant	[LMP-1 mutant]	0.0	2	1	1	1
149840	1710	resistance gene	[resistance gene]	0.0	2	1	1	1
149841	1710	b-cell lymphoma especially diffuse lymphoma	[B-cell lymphomas especially diffuse lymphomas]	0.0	5	1	1	1
149842	1710	tgf-beta1 mrna	[TGF-beta1 mRNA]	0.0	2	1	1	1
149843	1710	11 p.m.) type	[11 p.m.) Type]	0.0	3	1	1	1
149844	1710	BZLF trans-activator	[BZLF trans-activator]	0.0	2	1	1	1
149845	1710	protein-binding activity	[protein-binding activities]	0.0	2	1	1	1
149846	1710	reading frame of 1206 nucleotide	[reading frame of 1206 nucleotides]	0.0	5	1	1	1
149847	1710	lymph node with follicular hyperplasia	[lymph nodes with follicular hyperplasia]	0.0	5	1	1	1
149848	1710	T lymphocyte with major function	[T lymphocytes with major functions]	0.0	5	1	1	1
149849	1710	observation of expression of wt1	[observations of expression of WT1]	0.0	5	1	1	1
149850	1710	other organ	[other organs]	0.0	2	1	1	1
149851	1710	periodontal research	[periodontal research]	0.0	2	1	1	1
149852	1710	fragment of human bactericidal/permeability-increasing protein	[fragment of human bactericidal/permeability-increasing protein]	0.0	5	1	1	1
149853	1710	Comparing the regulation -encoding gene	[Comparing the regulation -encoding genes]	0.0	5	1	1	1
149854	1710	patient with hereditary hypercholesteremia	[patients with hereditary hypercholesteremia]	0.0	4	1	1	1
149855	1710	involve alteration	[involving alterations]	0.0	2	1	1	1
149856	1710	couple from bp	[Coupling from bp]	0.0	3	1	1	1
149857	1710	NK cytolysis	[NK cytolysis]	0.0	2	1	1	1
149858	1710	two group of U937 cell	[Two groups of U937 cells]	0.0	5	1	1	1
149859	1710	fate of transcription factor	[fate of transcription factors]	0.0	4	1	1	1
149860	1710	Nuclear transcription study	[Nuclear transcription studies]	0.0	3	1	1	1
149861	1710	contain -795 bp	[containing -795 bp]	0.0	3	1	1	1
149862	1710	neutrophil adherence to cell	[neutrophil adherence to cells]	0.0	4	1	1	1
149863	1710	involve NF-ATp	[involving NF-ATp]	0.0	2	1	1	1
149864	1710	extensive cross-talk between the partner	[extensive cross-talk between the partners]	0.0	5	1	1	1
149865	1710	human center	[human centers]	0.0	2	1	1	1
149866	1710	homologous member especially the homolog	[homologous members especially the homolog]	0.0	5	1	1	1
149867	1710	anhydrase ii	[anhydrase II]	0.0	2	1	1	1
149868	1710	shp2-interacting adaptor protein SIT a dimer	[SHP2-interacting adaptor protein SIT a dimer]	0.0	6	1	1	1
149869	1710	distinct protein complex	[distinct protein complexes]	0.0	3	1	1	1
149870	1710	form of NHL	[form of NHL]	0.0	3	1	1	1
149871	1710	other subunit	[other subunit]	0.0	2	1	1	1
149872	1710	impairment of glucocorticoid metabolism	[impairment of glucocorticoid metabolism]	0.0	4	1	1	1
149873	1710	most example	[most examples]	0.0	2	1	1	1
149874	1710	previously, a enhancer	[Previously, an enhancer]	0.0	3	1	1	1
149875	1710	bind assay analysis	[binding assay analysis]	0.0	3	1	1	1
149876	1710	early hematopoietic stage	[early hematopoietic stages]	0.0	3	1	1	1
149877	1710	observation together with the finding	[observations together with the findings]	0.0	5	1	1	1
149878	1710	immunodeficiency virus-type 1	[immunodeficiency virus-type 1]	0.0	3	1	1	1
149879	1710	cytokine in bronchial epithelial cell	[cytokines in bronchial epithelial cells]	0.0	5	1	1	1
149880	1710	also in maintenance of proviral transcription	[also in maintenance of proviral transcription]	0.0	6	1	1	1
149881	1710	domain of the myogenic factor	[domains of the myogenic factors]	0.0	5	1	1	1
149882	1710	general activator RelA	[general activators RelA]	0.0	3	1	1	1
149883	1710	differential expression of specific set	[differential expression of specific sets]	0.0	5	1	1	1
149884	1710	thus, development	[Thus, development]	0.0	2	1	1	1
149885	1710	signal for mcp-1 induction	[signal for MCP-1 induction]	0.0	4	1	1	1
149886	1710	analyze the component	[analyzing the components]	0.0	3	1	1	1
149887	1710	region resemble a basic dbd	[region resembling a basic DBD]	0.0	5	1	1	1
149888	1710	gene segment for VDJ recombination	[gene segments for VDJ recombination]	0.0	5	1	1	1
149889	1710	suffer from cushingd' disease	[suffering from Cushing's disease]	0.0	4	1	1	1
149890	1710	mediator leukotriene b4 degradation	[mediator leukotriene B4 degradation]	0.0	4	1	1	1
149891	1710	RESULTS: BZLF1	[RESULTS: BZLF1]	0.0	2	1	1	1
149892	1710	thus prevent induction	[thus preventing induction]	0.0	3	1	1	1
149893	1710	DOR1 ligation	[DOR1 ligation]	0.0	2	1	1	1
149894	1710	Glucocorticoid receptor in polycystic ovary syndrome	[Glucocorticoid receptors in polycystic ovary syndrome]	0.0	6	1	1	1
149895	1710	system study the mechanism responsible	[system studying the mechanisms responsible]	0.0	5	1	1	1
149896	1710	mucosa-associated tissue malt lymphoma (19	[mucosa-associated tissue MALT lymphoma (19]	0.0	5	1	1	1
149897	1710	transient pseudo-hypoaldosteronism	[Transient pseudo-hypoaldosteronism]	0.0	2	1	1	1
149898	1710	direct activate effect	[direct activating effect]	0.0	3	1	1	1
149899	1710	glucocorticoid therapy in peripheral leukocyte	[glucocorticoid therapy in peripheral leukocytes]	0.0	5	1	1	1
149900	1710	antisense oligo	[antisense oligos]	0.0	2	1	1	1
149901	1710	nf-kb activation	[NF-kB activation]	0.0	2	1	1	1
149902	1710	target experiment	[targeting experiments]	0.0	2	1	1	1
149903	1710	nucleotide exchange factor for gtpase	[nucleotide exchange factor for GTPases]	0.0	5	1	1	1
149904	1710	region of residue	[region of residues]	0.0	3	1	1	1
149905	1710	Antigenic specificity of cd4+ t-cell clone	[Antigenic specificities of CD4+ T-cell clones]	0.0	6	1	1	1
149906	1710	leukemic cell contamination	[leukemic cell contamination]	0.0	3	2	2	1
149907	1710	immunodeficiency virus type progeny	[immunodeficiency virus type progeny]	0.0	4	1	1	1
149908	1710	blockade of the translocation of NFkappaB	[blockade of the translocation of NFkappaB]	0.0	6	1	1	1
149909	1710	(stimulatory effect on RA differentiation	[(stimulatory effects on RA differentiation]	0.0	5	1	1	1
149910	1710	treat event	[treating events]	0.0	2	1	1	1
149911	1710	effect on signal pathway	[effects on signaling pathways]	0.0	4	1	1	1
149912	1710	contrast, a dominant negative mutant	[contrast, a dominant negative mutant]	0.0	5	1	1	1
149913	1710	two lymphoblastoid cell line	[two lymphoblastoid cell lines]	0.0	4	1	1	1
149914	1710	cellular disposition of sulphamethoxazole	[Cellular disposition of sulphamethoxazole]	0.0	4	1	1	1
149915	1710	biphasic stimulation	[biphasic stimulation]	0.0	2	1	1	1
149916	1710	element-binding complex	[element-binding complexes]	0.0	2	1	1	1
149917	1710	degradation of alpha	[degradation of alpha]	0.0	3	1	1	1
149918	1710	induction of cytochrome	[Induction of cytochrome]	0.0	3	1	1	1
149919	1710	selenium inhibition nf-kappa b	[Selenium inhibition NF-kappa B]	0.0	4	1	1	1
149920	1710	significant change follow treatment	[significant change following treatment]	0.0	4	1	1	1
149921	1710	differentiation effect	[differentiation effect]	0.0	2	1	1	1
149922	1710	cdc42 effector	[CDC42 effector]	0.0	2	1	1	1
149923	1710	fmol/mg protein (mean	[fmol/mg protein (mean]	0.0	3	1	1	1
149924	1710	leukocyte population in eutopic trimester pregnancy	[Leukocyte populations in eutopic trimester pregnancies]	0.0	6	1	1	1
149925	1710	theme in the regulation	[theme in the regulation]	0.0	4	1	1	1
149926	1710	oestrogen receptor analysis in chronic leukemia	[Oestrogen receptor analysis in chronic leukemia]	0.0	6	1	1	1
149927	1710	80.2 (p 0.05, p	[80.2 (P 0.05, P]	0.0	4	1	1	1
149928	1710	DNA cDNA encode a tfiid protein	[DNA cDNA encoding a TFIID protein]	0.0	6	1	1	1
149929	1710	arrangement of sequence	[arrangement of sequences]	0.0	3	1	1	1
149930	1710	property within the vessel wall	[properties within the vessel wall]	0.0	5	1	1	1
149931	1710	overexpression of GRbeta	[overexpression of GRbeta]	0.0	3	1	1	1
149932	1710	peptide with affinity	[peptide with affinity]	0.0	3	1	1	1
149933	1710	RAR antagonist er27191	[RAR antagonist ER27191]	0.0	3	1	1	1
149934	1710	high level of pu.1	[high levels of PU.1]	0.0	4	1	1	1
149935	1710	atherosclerosis-promoting effect	[atherosclerosis-promoting effect]	0.0	2	1	1	1
149936	1710	lead to IL-2 expression	[leading to IL-2 expression]	0.0	4	1	1	1
149937	1710	modest (20-50%) reduction	[modest (20-50%) reduction]	0.0	3	1	1	1
149938	1710	only (il)-2-receptor expression on the surface	[only (IL)-2-receptor expression on the surface]	0.0	6	1	1	1
149939	1710	nuclear factor NFs	[nuclear factors NFs]	0.0	3	1	1	1
149940	1710	mediuhd small colony	[medium, small colonies]	0.0	3	1	1	1
149941	1710	risk factor for failure	[Risk factors for failure]	0.0	4	1	1	1
149942	1710	adhesion of u937 monocytic cell	[adhesion of U937 monocytic cells]	0.0	5	1	1	1
149943	1710	sequence requirement for expression	[sequence requirements for expression]	0.0	4	1	1	1
149944	1710	action of host transcription factor	[action of host transcription factors]	0.0	5	1	1	1
149945	1710	expression in jurkat-t cell	[expression in Jurkat-T cells]	0.0	4	1	1	1
149946	1710	action in immune cell	[action in immune cells]	0.0	4	1	1	1
149947	1710	residue of the tail,	[residues of the tail,]	0.0	4	1	1	1
149948	1710	ng cell per millileter	[ng cells per ml]	0.0	4	1	1	1
149949	1710	anti-early antigen antigen	[anti-early antigen antigen]	0.0	3	1	1	1
149950	1710	different pebp2 isoform	[different PEBP2 isoforms]	0.0	3	1	1	1
149951	1710	nuclear antigens,	[nuclear antigens,]	0.0	2	1	1	1
149952	1710	activity of the long terminal repeat	[activity of the long terminal repeat]	0.0	6	1	1	1
149953	1710	unique complex	[unique complex]	0.0	2	1	1	1
149954	1710	10 cardiac transplant recipient	[10 cardiac transplant recipients]	0.0	4	1	1	1
149955	1710	dominant negative mutant form	[dominant negative mutant forms]	0.0	4	1	1	1
149956	1710	essential step in the processing,	[essential step in the processing,]	0.0	5	1	1	1
149957	1710	regulatory subunit in platelet	[regulatory subunits in platelets]	0.0	4	1	1	1
149958	1710	asthma child	[asthma children]	0.0	2	1	1	1
149959	1710	induce b activation	[inducing B activation]	0.0	3	1	1	1
149960	1710	exogenous virus	[exogenous virus]	0.0	2	1	1	1
149961	1710	covalent homodimer of e47	[covalent homodimer of E47]	0.0	4	1	1	1
149962	1710	interaction of HTLV-I tax	[Interaction of HTLV-I Tax]	0.0	4	1	1	1
149963	1710	marker for acute leukemia	[marker for acute leukemia]	0.0	4	1	1	1
149964	1710	two potential reading frame orf a	[two potential reading frames ORFs A]	0.0	6	1	1	1
149965	1710	histocompatibility complex class gene expression	[histocompatibility complex class gene expression]	0.0	5	1	1	1
149966	1710	change in the domain	[change in the domain]	0.0	4	1	1	1
149967	1710	simultaneous analysis of close gene	[Simultaneous analysis of close genes]	0.0	5	1	1	1
149968	1710	position -295	[positions -295]	0.0	2	1	1	1
149969	1710	t-cell-receptor-mediated activation	[T-cell-receptor-mediated activation]	0.0	2	1	1	1
149970	1710	binding partner,	[binding partner,]	0.0	2	1	1	1
149971	1710	allele of HLA-DR4	[alleles of HLA-DR4]	0.0	3	1	1	1
149972	1710	cause mobility on gel	[causing mobility on gels]	0.0	4	1	1	1
149973	1710	previous demonstration	[previous demonstration]	0.0	2	1	1	1
149974	1710	costimulation of phytohemagglutinin	[Costimulation of phytohemagglutinin]	0.0	3	1	1	1
149975	1710	166 female aged years,	[166 females aged years,]	0.0	4	1	1	1
149976	1710	patient with myelofibrosis	[patients with myelofibrosis]	0.0	3	1	1	1
149977	1710	functional role in early hematopoiesis	[functional role in early hematopoiesis]	0.0	5	1	1	1
149978	1710	interleukin 9 gene	[interleukin 9 gene]	0.0	3	1	1	1
149979	1710	large fraction	[large fraction]	0.0	2	1	1	1
149980	1710	component of human atheroma	[component of human atheroma]	0.0	4	1	1	1
149981	1710	free radical stress	[free radical stress]	0.0	3	1	1	1
149982	1710	role in commitment	[role in commitment]	0.0	3	1	1	1
149983	1710	decline in induction	[decline in induction]	0.0	3	1	1	1
149984	1710	different stimulus in t-cell	[different stimuli in T-cells]	0.0	4	1	1	1
149985	1710	Jun-Fos	[Jun-Fos]	0.0	1	1	1	1
149986	1710	P; immediate) binding of p50.p65 heterodimer	[h; immediate) binding of p50.p65 heterodimers]	0.0	6	1	1	1
149987	1710	intron (overall frequency:	[intron (overall frequency:]	0.0	3	1	1	1
149988	1710	40 promoter erratum	[40 promoter erratum]	0.0	3	1	1	1
149989	1710	csf-1 proliferation	[CSF-1 proliferation]	0.0	2	1	1	1
149990	1710	concentration of HU microm	[concentrations of HU microM]	0.0	4	1	1	1
149991	1710	presence of a cytosine	[presence of a cytosine]	0.0	4	1	1	1
149992	1710	cytokine differential	[cytokine differential]	0.0	2	1	1	1
149993	1710	les-induced ap-1	[LPS-induced AP-1]	0.0	2	1	1	1
149994	1710	transcript isolation	[transcripts isolation]	0.0	2	1	1	1
149995	1710	as tracer, mnl of abdominal subject	[as tracer, MNL of abdominal subjects]	0.0	6	1	1	1
149996	1710	factor kappab activation	[factor kappaB activation]	0.0	3	2	2	1
149997	1710	dynamic change	[dynamic changes]	0.0	2	1	1	1
149998	1710	molecular framework signal	[molecular framework signaling]	0.0	3	1	1	1
149999	1710	heat shock protein glycoprotein	[heat shock protein glycoprotein]	0.0	4	1	1	1
150000	1710	DNA from blood leukocyte	[DNA from blood leukocytes]	0.0	4	1	1	1
150001	1710	activity a autophosphorylation site	[activity an autophosphorylation site]	0.0	4	1	1	1
150002	1710	qualitative difference in the capacity	[qualitative differences in the capacity]	0.0	5	1	1	1
150003	1710	result study 1,25-dihydroxyvitamin D3	[results studying 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
150004	1710	most Burkitt' lymphoma cell lines,	[most Burkitt's lymphoma cell lines,]	0.0	5	1	1	1
150005	1710	structure of the 5' portion	[structure of the 5' portion]	0.0	5	1	1	1
150006	1710	dissociation constant of the receptor	[dissociation constant of the receptors]	0.0	5	1	1	1
150007	1710	especially lymphoma	[especially lymphomas]	0.0	2	1	1	1
150008	1710	astrocyte manner	[astrocyte manner]	0.0	2	1	1	1
150009	1710	element consistent	[elements consistent]	0.0	2	1	1	1
150010	1710	mutant tnfri	[mutant TNFRI]	0.0	2	1	1	1
150011	1710	old) in pbl	[old) in PBL]	0.0	3	1	1	1
150012	1710	mutation in the region	[mutations in the region]	0.0	4	1	1	1
150013	1710	12 amino acid	[12 amino acids]	0.0	3	1	1	1
150014	1710	use a western blot assay	[using a Western blot assay]	0.0	5	1	1	1
150015	1710	alteration of the locus.	[alteration of the locus.]	0.0	4	1	1	1
150016	1710	role of macrophage in activation	[role of macrophages in activation]	0.0	5	1	1	1
150017	1710	membrane-associated pkc activity	[membrane-associated PKC activity]	0.0	3	1	1	1
150018	1710	nf-kappab transcription in monocyte	[NF-kappaB transcription in monocytes]	0.0	4	1	1	1
150019	1710	H-8, a kinase inhibitor active	[H-8, a kinase inhibitor active]	0.0	5	1	1	1
150020	1710	beta-globin yeast artificial chromosome transgene	[beta-globin yeast artificial chromosome transgene]	0.0	5	1	1	1
150021	1710	cyclosporin-sensitive, posttranslational modification	[cyclosporin-sensitive, posttranslational modification]	0.0	3	1	1	1
150022	1710	methods: Eleven patient with colitis	[METHODS: Eleven patients with colitis]	0.0	5	1	1	1
150023	1710	cell number, from day 7	[cell number, from day 7]	0.0	5	1	1	1
150024	1710	(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD a inhibitor	[(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one PD an inhibitor]	0.0	4	1	1	1
150025	1710	interleukin-4 on function	[interleukin-4 on functions]	0.0	3	1	1	1
150026	1710	downregulation in a plasmacytoma implication	[downregulation in a plasmacytoma implications]	0.0	5	1	1	1
150027	1710	(35 min) submaximal exercise at 70%	[(35 min) submaximal exercise at 70%]	0.0	6	1	1	1
150028	1710	incorporation of [3H]thymidine	[incorporation of [3H]thymidine]	0.0	3	1	1	1
150029	1710	ab treatment	[Ab treatment]	0.0	2	1	1	1
150030	1710	type MHC cid	[type MHC CID]	0.0	3	1	1	1
150031	1710	lps a constituent	[LPS a constituent]	0.0	3	1	1	1
150032	1710	most malignant cell	[most malignant cells]	0.0	3	1	1	1
150033	1710	unrearranged tcr delta transcript	[unrearranged TcR delta transcript]	0.0	4	1	1	1
150034	1710	potent antiinflammatory agent	[potent antiinflammatory agents]	0.0	3	2	2	1
150035	1710	monocyte nuclear extract	[monocyte nuclear extracts]	0.0	3	1	1	1
150036	1710	CArG element	[CArG element]	0.0	2	1	1	1
150037	1710	dysregulation human immunodeficiency virus type	[dysregulation human immunodeficiency virus type]	0.0	5	1	1	1
150038	1710	aberrant signal include hyperresponsiveness	[aberrant signaling including hyperresponsiveness]	0.0	4	1	1	1
150039	1710	pathogenesis of lymphoma	[pathogenesis of lymphoma]	0.0	3	1	1	1
150040	1710	deletion (delta)	[deletions (delta)]	0.0	2	1	1	1
150041	1710	week of discharge.	[weeks of discharge.]	0.0	3	1	1	1
150042	1710	effect a novel quinone derivative	[effect a novel quinone derivative]	0.0	5	1	1	1
150043	1710	mechanism of insensitivity	[mechanism of insensitivity]	0.0	3	1	1	1
150044	1710	response to a pressure-stretch load	[response to a pressure-stretching load]	0.0	5	1	1	1
150045	1710	expression of slp-76	[expression of SLP-76]	0.0	3	1	1	1
150046	1710	thapsigargin ca2+ dependent	[thapsigargin Ca2+ dependent]	0.0	3	1	1	1
150047	1710	incubation of this cell with p50/p65	[incubation of these cells with p50/p65]	0.0	6	1	1	1
150048	1710	pivotal role for cell development	[pivotal role for cell development]	0.0	5	1	1	1
150049	1710	functional threshold	[functional threshold]	0.0	2	2	2	1
150050	1710	antigen-driven clonal expansion) (by stimulation	[antigen-driven clonal expansion) (by stimulation]	0.0	5	1	1	1
150051	1710	separation of the different granule	[separation of the different granules]	0.0	5	1	1	1
150052	1710	PML mrna alpha-PML	[PML mRNA alpha-PML]	0.0	3	1	1	1
150053	1710	p16 in normal lymphocyte	[p16 in normal lymphocytes]	0.0	4	1	1	1
150054	1710	response to stress	[responses to stress]	0.0	3	1	1	1
150055	1710	micrograms/day for day	[micrograms/day for days)]	0.0	3	1	1	1
150056	1710	CD95L proximal promoter sequence	[CD95L proximal promoter sequence]	0.0	4	1	1	1
150057	1710	retinoic acid RA treatment	[retinoic acid RA treatment]	0.0	4	1	1	1
150058	1710	bipartite interleukin-4 IL-4 receptor	[bipartite interleukin-4 IL-4 receptor]	0.0	4	1	1	1
150059	1710	follow atra therapy	[following ATRA therapy]	0.0	3	2	2	1
150060	1710	accumulation of eosinophil	[accumulation of eosinophils]	0.0	3	1	1	1
150061	1710	elk-1 point toward age-related defect	[Elk-1 pointing toward age-related defects]	0.0	5	1	1	1
150062	1710	mutation expansion	[mutation expansion]	0.0	2	1	1	1
150063	1710	antioxidant for hydroxyl radical	[antioxidant for hydroxyl radicals]	0.0	4	1	1	1
150064	1710	develop system CNS	[developing system CNS]	0.0	3	1	1	1
150065	1710	(nfat) group	[(NFAT) group]	0.0	2	1	1	1
150066	1710	binding of b transcription factor	[binding of B transcription factors]	0.0	5	1	1	1
150067	1710	pathway responsible	[pathway responsible]	0.0	2	1	1	1
150068	1710	ptpase inhibitor pervanadate	[PTPase inhibitor pervanadate]	0.0	3	1	1	1
150069	1710	down-regulation of immunogenic protein ebna2-ebna6	[Down-regulation of immunogenic proteins EBNA2-EBNA6]	0.0	5	1	1	1
150070	1710	polymorphonuclear neutrophil migration	[polymorphonuclear neutrophil migration]	0.0	3	1	1	1
150071	1710	syngeneic mouse	[syngeneic mice]	0.0	2	1	1	1
150072	1710	cytokine-induced immunodeficiency virus type 1 hiv-1	[cytokine-induced immunodeficiency virus type 1 HIV-1]	0.0	6	1	1	1
150073	1710	target of protein kinase c	[target of protein kinase C]	0.0	5	1	1	1
150074	1710	th1 cytokine gene	[Th1 cytokine genes]	0.0	3	1	1	1
150075	1710	use the lck promoter	[using the lck promoter]	0.0	4	1	1	1
150076	1710	role of Stat4	[role of Stat4]	0.0	3	1	1	1
150077	1710	suggest constitutively present	[suggesting constitutively present]	0.0	3	1	1	1
150078	1710	western blot study use rabbit antibody	[Western blot studies using rabbit antibodies]	0.0	6	1	1	1
150079	1710	quantitative polymerase chain method	[quantitative polymerase chain method]	0.0	4	1	1	1
150080	1710	ap-1 activity in cell	[AP-1 activity in cells]	0.0	4	1	1	1
150081	1710	neutralize il-6 monoclonal antibody	[neutralizing IL-6 monoclonal antibody]	0.0	4	1	1	1
150082	1710	serum-inducible element hSIE	[serum-inducible element hSIE]	0.0	3	1	1	1
150083	1710	zone cell	[zone cells]	0.0	2	1	1	1
150084	1710	various cis-act element	[various cis-acting elements]	0.0	3	1	1	1
150085	1710	variant allele	[variant allele]	0.0	2	1	1	1
150086	1710	hypoxic induction of interleukin-8 gene expression	[Hypoxic induction of interleukin-8 gene expression]	0.0	6	1	1	1
150087	1710	translocation factor of T lymphocyte	[translocation factor of T lymphocytes]	0.0	5	1	1	1
150088	1710	9 volunteer	[9 volunteers]	0.0	2	1	1	1
150089	1710	protein tissue factor	[protein tissue factor]	0.0	3	1	1	1
150090	1710	spleen with mpl	[spleen with MPL]	0.0	3	1	1	1
150091	1710	clinically relevant doses.	[clinically relevant doses.]	0.0	3	1	1	1
150092	1710	contrast, other product	[contrast, other products]	0.0	3	1	1	1
150093	1710	low the/thf n: alpha thf/thf	[low THE/THF N: alpha THF/THF]	0.0	5	1	1	1
150094	1710	copyright by the Society of Hematology	[Copyright by The Society of Hematology]	0.0	6	1	1	1
150095	1710	76 ppb	[76 PPB]	0.0	2	1	1	1
150096	1710	similar MHC class cell	[similar MHC class cells]	0.0	4	1	1	1
150097	1710	GATA-1 body	[GATA-1 bodies]	0.0	2	1	1	1
150098	1710	low expression of interleukin-2	[low expression of interleukin-2]	0.0	4	1	1	1
150099	1710	interleukin-2 promoter activity in Epstein-Barr virus	[Interleukin-2 promoter activity in Epstein-Barr virus]	0.0	6	1	1	1
150100	1710	gssg action	[GSSG action]	0.0	2	1	1	1
150101	1710	Retroviral vector-mediated transduction	[Retroviral vector-mediated transduction]	0.0	3	1	1	1
150102	1710	JY25 b cell line.	[JY25 B cell line.]	0.0	4	1	1	1
150103	1710	receptor for a inhibitor	[receptor for a inhibitor]	0.0	4	1	1	1
150104	1710	bulbar conjunctiva	[bulbar conjunctiva]	0.0	2	1	1	1
150105	1710	control with respect	[controls with respect]	0.0	3	1	1	1
150106	1710	binding of protein, Sp1	[binding of protein, Sp1]	0.0	4	1	1	1
150107	1710	positive antidsdna antibody	[positive antidsDNA antibody]	0.0	3	1	1	1
150108	1710	Ad5E1A immunity	[Ad5E1A immunity]	0.0	2	1	1	1
150109	1710	arrest.	[arrest.]	0.0	1	1	1	1
150110	1710	interferon gene transfer	[interferon gene transfer]	0.0	3	1	1	1
150111	1710	trophoblast, antigen	[trophoblast, antigens]	0.0	2	1	1	1
150112	1710	NH2-terminal residue	[NH2-terminal residues]	0.0	2	1	1	1
150113	1710	approximately 1.8 kilobasis	[approximately 1.8 kilobases]	0.0	3	1	1	1
150114	1710	(85 kD	[(85 kD]	0.0	2	1	1	1
150115	1710	purification of this b-cell factor ebf	[Purification of this B-cell factor EBF]	0.0	6	1	1	1
150116	1710	arrest,	[arrest,]	0.0	1	1	1	1
150117	1710	gamma-chain gamma(c)	[gamma-chain gamma(c)]	0.0	2	1	1	1
150118	1710	as, h	[as, h]	0.0	2	1	1	1
150119	1710	nucleotide substitution in the human counterpart	[nucleotide substitutions in the human counterpart]	0.0	6	1	1	1
150120	1710	only a role,	[only a role,]	0.0	3	1	1	1
150121	1710	binding domain	[binding domains]	0.0	2	1	1	1
150122	1710	repeat transactivation through nf-kappab activation	[repeat transactivation through NF-kappaB activation]	0.0	5	1	1	1
150123	1710	least in cell types,	[least in cell types,]	0.0	4	1	1	1
150124	1710	ldl endothelial cell	[LDL endothelial cells]	0.0	3	1	1	1
150125	1710	gal4 -p65(286-551)-mediated transcription	[GAL4 -p65(286-551)-mediated transcription]	0.0	3	1	1	1
150126	1710	lysosomal acid lipase lal expression	[lysosomal acid lipase LAL expression]	0.0	5	1	1	1
150127	1710	capacity in human t-cell type	[capacities in human T-cell types]	0.0	5	1	1	1
150128	1710	CMV scmv by treatment	[CMV SCMV by treatment]	0.0	4	1	1	1
150129	1710	extend 2738 nucleotide 5'	[extending 2,738 nucleotides 5']	0.0	4	1	1	1
150130	1710	predictive value	[predictive value]	0.0	2	2	2	1
150131	1710	gene include alpha- globin	[genes including alpha- globin]	0.0	4	1	1	1
150132	1710	establish a inverse relation	[establishing an inverse relation]	0.0	4	1	1	1
150133	1710	peripheral leukocyte in subject	[peripheral leukocytes in subjects]	0.0	4	1	1	1
150134	1710	results: incubation of human blood	[RESULTS: Incubation of human blood]	0.0	5	1	1	1
150135	1710	adaptive immune response	[adaptive immune response]	0.0	3	1	1	1
150136	1710	effect of beta-estradiol	[effect of beta-estradiol]	0.0	3	1	1	1
150137	1710	necessary component of cell death	[necessary component of cell death]	0.0	5	1	1	1
150138	1710	hla-dq class subset	[HLA-DQ class subset]	0.0	3	1	1	1
150139	1710	organogenesis of lymphoid tissue	[organogenesis of lymphoid tissues]	0.0	4	1	1	1
150140	1710	demonstration of a 1,25-dihydroxyvitamin D3 protein	[Demonstration of a 1,25-dihydroxyvitamin D3 protein]	0.0	6	1	1	1
150141	1710	intracellular state	[intracellular state]	0.0	2	1	1	1
150142	1710	47 il-10 receptor site	[47 IL-10 receptor sites]	0.0	4	1	1	1
150143	1710	extinction of cell-encoded gene	[extinction of cell-encoded genes]	0.0	4	1	1	1
150144	1710	92 base pair of DNA	[92 base pairs of DNA]	0.0	5	1	1	1
150145	1710	h2o2 exhibit	[H2O2 exhibit]	0.0	2	1	1	1
150146	1710	Comparison of a cDNA sequence	[Comparison of a cDNA sequence]	0.0	5	2	2	1
150147	1710	association proviral latency in cell	[Association proviral latency in cells]	0.0	5	1	1	1
150148	1710	cluster in the region of BCL-6	[clustering in the region of BCL-6]	0.0	6	1	1	1
150149	1710	role for stat	[role for STATs]	0.0	3	1	1	1
150150	1710	surprisingly high capacity	[surprisingly high capacity]	0.0	3	1	1	1
150151	1710	interleukin transcription	[interleukin transcription]	0.0	2	1	1	1
150152	1710	10(-8) mol/L for RA	[10(-8) mol/L for RA]	0.0	4	1	1	1
150153	1710	minor protein	[minor proteins]	0.0	2	1	1	1
150154	1710	t-cell virus type htlv-1	[T-cell virus type HTLV-1]	0.0	4	1	1	1
150155	1710	RA inflammation	[RA inflammation]	0.0	2	1	1	1
150156	1710	significant level of transcription	[significant levels of transcription]	0.0	4	1	1	1
150157	1710	regulator of viral gene	[regulator of viral genes]	0.0	4	1	1	1
150158	1710	six band	[six bands]	0.0	2	1	1	1
150159	1710	numerous genes,	[numerous genes,]	0.0	2	1	1	1
150160	1710	activation of phosphatidylinositol 3-kinase translocation	[activation of phosphatidylinositol 3-kinase translocation]	0.0	5	1	1	1
150161	1710	p56(lck) activation	[p56(lck) activation]	0.0	2	1	1	1
150162	1710	generate a humoral response	[generating an humoral response]	0.0	4	1	1	1
150163	1710	other latent epitope	[other latent epitopes]	0.0	3	1	1	1
150164	1710	nf-kappa b -like	[NF-kappa B -like]	0.0	3	2	2	1
150165	1710	patient use DNA transfer	[patient using DNA transfer]	0.0	4	1	1	1
150166	1710	human immunodeficiency virus contain enhancer/promoters	[Human immunodeficiency viruses containing enhancer/promoters]	0.0	5	1	1	1
150167	1710	differential activity between the promoter	[differential activity between the promoters]	0.0	5	1	1	1
150168	1710	model of IFNgamma enhanceosome formation	[model of IFNgamma enhanceosome formation]	0.0	5	1	1	1
150169	1710	distinct family acid receptor rar	[distinct families acid receptors RARs]	0.0	5	1	1	1
150170	1710	noninvasive delivery of peptide	[noninvasive delivery of peptide]	0.0	4	1	1	1
150171	1710	two- increase in the rate	[two- increase in the rate]	0.0	5	1	1	1
150172	1710	h1-agonist	[H1-agonists]	0.0	1	1	1	1
150173	1710	potential role of interaction between elf-1	[potential role of interactions between Elf-1]	0.0	6	1	1	1
150174	1710	component of the tissue	[components of the tissues]	0.0	4	1	1	1
150175	1710	cell in experimental model	[cells in experimental models]	0.0	4	1	1	1
150176	1710	molecular regulation during the response	[Molecular regulation during the response]	0.0	5	1	1	1
150177	1710	interferon-gamma in neutrophil	[interferon-gamma in neutrophils]	0.0	3	1	1	1
150178	1710	proliferative behavior	[proliferative behavior]	0.0	2	1	1	1
150179	1710	stat5 elements.	[STAT5 elements.]	0.0	2	1	1	1
150180	1710	basal induction	[basal induction]	0.0	2	1	1	1
150181	1710	signal converge in common pathway	[signals converging in common pathways]	0.0	5	1	1	1
150182	1710	two distinct pathway	[Two distinct pathways]	0.0	3	1	1	1
150183	1710	cotransfection with a plasmid	[cotransfection with a plasmid]	0.0	4	1	1	1
150184	1710	activation of latency.	[activation of latency.]	0.0	3	1	1	1
150185	1710	response element present	[response elements present]	0.0	3	1	1	1
150186	1710	9 keratoacanthomas	[9 keratoacanthomas]	0.0	2	1	1	1
150187	1710	detailed structural analysis	[Detailed structural analysis]	0.0	3	1	1	1
150188	1710	time point (40 P;	[time points (40 h;]	0.0	4	1	1	1
150189	1710	dimer complex	[dimer complexes]	0.0	2	1	1	1
150190	1710	microm mbp	[microM MBP]	0.0	2	1	1	1
150191	1710	micromol/(mg protein.	[micromol/(mg protein.]	0.0	2	1	1	1
150192	1710	vivo expression study	[vivo expression studies]	0.0	3	1	1	1
150193	1710	affinity for a genomic sterol sequence	[affinity for a genomic sterol sequence]	0.0	6	1	1	1
150194	1710	mastopathy	[mastopathy]	0.0	1	1	1	1
150195	1710	target the CD28 pathway	[targeting the CD28 pathway]	0.0	4	1	1	1
150196	1710	(dp) CD4 thymocyte	[(DP) CD4 thymocytes]	0.0	3	1	1	1
150197	1710	provide one mechanism	[providing one mechanism]	0.0	3	1	1	1
150198	1710	shift of the dose-response	[shift of the dose-response]	0.0	4	1	1	1
150199	1710	purine-box regulator	[purine-box regulator]	0.0	2	1	1	1
150200	1710	transcription of simian immunodeficiency virus	[transcription of simian immunodeficiency virus]	0.0	5	1	1	1
150201	1710	regulation in human blood mononuclear cell	[Regulation in human blood mononuclear cells]	0.0	6	1	1	1
150202	1710	q23-31 region	[q23-31 region]	0.0	2	1	1	1
150203	1710	antibody of clinical significance.	[antibodies of clinical significance.]	0.0	4	1	1	1
150204	1710	p-selectin nuclear translocation	[P-selectin nuclear translocation]	0.0	3	1	1	1
150205	1710	option bcl-2 mutein	[option bcl-2 muteins]	0.0	3	1	1	1
150206	1710	retinoid receptor	[retinoid receptor]	0.0	2	1	1	1
150207	1710	cause cellular transformation	[causing cellular transformation]	0.0	3	1	1	1
150208	1710	contain the domain	[containing the domain]	0.0	3	1	1	1
150209	1710	binding of this transcription factor	[binding of these transcription factors]	0.0	5	1	1	1
150210	1710	accounting for approximately 1%	[accounting for approximately 1%]	0.0	4	1	1	1
150211	1710	contain stat4 with stat1 alpha	[containing STAT4 with STAT1 alpha]	0.0	5	1	1	1
150212	1710	functional inhibition in vitro.	[functional inhibition in vitro.]	0.0	4	1	1	1
150213	1710	detectable level of antibodies patient	[detectable levels of antibodies, patients]	0.0	5	1	1	1
150214	1710	anorexic patient (range from 11.1	[anorexic patients (ranging from 11.1]	0.0	5	1	1	1
150215	1710	HeLaS3 cells, transfection	[HeLaS3 cells, transfection]	0.0	3	1	1	1
150216	1710	sometimes contain DC	[sometimes containing DC]	0.0	3	1	1	1
150217	1710	stimulation of U1 cell	[Stimulation of U1 cells]	0.0	4	1	1	1
150218	1710	PAX-5 gene	[PAX-5 gene]	0.0	2	1	1	1
150219	1710	constitutive expression of hiv-1 tat protein	[Constitutive expression of HIV-1 tat protein]	0.0	6	1	1	1
150220	1710	60% (46%	[60% (46%]	0.0	2	1	1	1
150221	1710	independent form of cellular collaboration	[independent forms of cellular collaboration]	0.0	5	1	1	1
150222	1710	antibody supershift assay complex	[antibody supershift assays complexes]	0.0	4	1	1	1
150223	1710	adenovirus ad2 infection	[adenovirus Ad2 infection]	0.0	3	1	1	1
150224	1710	h2-antagonist on the h3-antagonist	[H2-antagonist on the H3-antagonist]	0.0	4	1	1	1
150225	1710	ability of NK cell	[ability of NK cells]	0.0	4	1	1	1
150226	1710	tissue malt lymphoma (19	[tissue MALT lymphoma (19]	0.0	4	1	1	1
150227	1710	therapy the number	[therapy the number]	0.0	3	1	1	1
150228	1710	permanent occupancy	[Permanent occupancy]	0.0	2	1	1	1
150229	1710	antibody pmi-1	[antibody PMI-1]	0.0	2	1	1	1
150230	1710	4 beta-phorbol 13-acetate PMA	[4 beta-phorbol 13-acetate PMA]	0.0	4	1	1	1
150231	1710	nf-atc isoform with individual property	[NF-ATc isoforms with individual properties]	0.0	5	1	1	1
150232	1710	further 16-hour incubation with oleate	[further 16-hour incubation with oleate]	0.0	5	1	1	1
150233	1710	effect on monocyte cytotoxicity	[effect on monocyte cytotoxicity]	0.0	4	1	1	1
150234	1710	indicate due to a secondary factor	[indicating due to a secondary factor]	0.0	6	1	1	1
150235	1710	extracellular domain of c-kit	[extracellular domain of c-kit]	0.0	4	1	1	1
150236	1710	cellular defect(s) lead	[cellular defect(s) leading]	0.0	3	1	1	1
150237	1710	cis-acting element gm-kappa of the factor	[cis-acting elements GM-kappa of the factor]	0.0	6	1	1	1
150238	1710	region in this DNA fragment	[regions in this DNA fragment]	0.0	5	1	1	1
150239	1710	virus 40 (sv40) promoter	[virus 40 (SV40) promoters]	0.0	4	1	1	1
150240	1710	same activity	[same activity]	0.0	2	1	1	1
150241	1710	thus, erythroid precursor	[Thus, erythroid precursors]	0.0	3	1	1	1
150242	1710	nf-e2 expression	[NF-E2 expression]	0.0	2	1	1	1
150243	1710	Alternate immune system target for tcdd	[Alternate immune system targets for TCDD]	0.0	6	1	1	1
150244	1710	specific mrna use a assay	[specific mRNA using a assay]	0.0	5	1	1	1
150245	1710	characteristic of differentiation	[characteristics of differentiation]	0.0	3	1	1	1
150246	1710	atra APL	[ATRA APL]	0.0	2	1	1	1
150247	1710	activation of distinct nuclear factor	[activation of distinct nuclear factors]	0.0	5	1	1	1
150248	1710	transcription include that encode p105	[transcription including those encoding p105]	0.0	5	1	1	1
150249	1710	ZLF-1	[ZLF-1]	0.0	1	1	1	1
150250	1710	open reading frame orf a	[open reading frames ORFs A]	0.0	5	1	1	1
150251	1710	female aged with no history	[females aged with no history]	0.0	5	1	1	1
150252	1710	EBNA-2 gene	[EBNA-2 gene]	0.0	2	1	1	1
150253	1710	grade before radiotherapy	[grades before radiotherapy]	0.0	3	1	1	1
150254	1710	control level in T cell	[controlling levels in T cells]	0.0	5	1	1	1
150255	1710	hypothesis of effect	[hypothesis of effects]	0.0	3	1	1	1
150256	1710	50-kda form	[50-kDa forms]	0.0	2	1	1	1
150257	1710	epo -dependent cell line	[EPO -dependent cell lines]	0.0	4	1	1	1
150258	1710	leukemic T lymphoblast	[leukemic T lymphoblasts]	0.0	3	1	1	1
150259	1710	tal1 rearrangement	[TAL1 rearrangements]	0.0	2	1	1	1
150260	1710	fluorescence in-situ hybridization	[fluorescence in-situ hybridization]	0.0	3	1	1	1
150261	1710	heavy chain gene cluster	[heavy chain gene cluster]	0.0	4	1	1	1
150262	1710	presentation dqa1*0501/dqb1*0201 in comparison	[presentation DQA1*0501/DQB1*0201 in comparison]	0.0	4	1	1	1
150263	1710	addition of nfkb2 p49	[addition of NFKB2 p49]	0.0	4	1	1	1
150264	1710	murine b-cell coactivator mbob1	[murine B-cell coactivator mBob1]	0.0	4	1	1	1
150265	1710	region of the lymphomagenic Akv	[regions of the lymphomagenic Akv]	0.0	5	1	1	1
150266	1710	T cell from the mouse	[T cells from the mice]	0.0	5	1	1	1
150267	1710	virus (sv40) promoter	[virus (SV40) promoters]	0.0	3	1	1	1
150268	1710	property of the molecule	[properties of the molecule]	0.0	4	1	1	1
150269	1710	role of this site	[role of this site]	0.0	4	1	1	1
150270	1710	phenotype of human cell	[phenotypes of human cells]	0.0	4	1	1	1
150271	1710	specific enhancer	[specific enhancer]	0.0	2	1	1	1
150272	1710	mass of 84 kda	[mass of 84 kDa]	0.0	4	1	1	1
150273	1710	1 min)	[1 min)]	0.0	2	1	1	1
150274	1710	aCT-1-activating region promoter.	[ACT-1-activating region promoter.]	0.0	3	1	1	1
150275	1710	effect of lipopolysaccharide on gene expression	[effects of lipopolysaccharide on gene expression]	0.0	6	1	1	1
150276	1710	marker MHC	[markers MHC]	0.0	2	1	1	1
150277	1710	significant gap	[significant gaps]	0.0	2	1	1	1
150278	1710	purine-rich stretch for the factor	[purine-rich stretches for the factors]	0.0	5	1	1	1
150279	1710	occur splice variant	[occurring splice variant,]	0.0	3	1	1	1
150280	1710	possible role in proliferation	[Possible roles in proliferation]	0.0	4	1	1	1
150281	1710	bind to the tced	[binding to the TCEd]	0.0	4	1	1	1
150282	1710	contain a element	[containing a element]	0.0	3	1	1	1
150283	1710	multicopy enhancer motif	[multicopy enhancer motifs]	0.0	3	1	1	1
150284	1710	costimulation for cytokine secretion	[costimulation for cytokine secretion]	0.0	4	1	1	1
150285	1710	YY1 inhibition	[YY1 inhibition]	0.0	2	1	1	1
150286	1710	patient with colitis (56.1	[patients with colitis (56.1]	0.0	4	1	1	1
150287	1710	kinase-kinase	[kinase-kinase]	0.0	1	1	1	1
150288	1710	more migrate	[more migrating]	0.0	2	1	1	1
150289	1710	transform activity	[transforming activity]	0.0	2	1	1	1
150290	1710	4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl) 1h-imidazole	[4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl) 1H-imidazole]	0.0	2	1	1	1
150291	1710	role in inflammatory reaction	[role in inflammatory reactions]	0.0	4	1	1	1
150292	1710	signal network	[signal networks]	0.0	2	1	1	1
150293	1710	phenomenon of glucocorticoid resistance	[phenomenon of glucocorticoid resistance]	0.0	4	1	1	1
150294	1710	inactive specific methylation	[inactive specific methylation]	0.0	3	1	1	1
150295	1710	co-express the human il-10r	[co-expressing the human IL-10R]	0.0	4	1	1	1
150296	1710	spontaneous production of IgE	[spontaneous production of IgE]	0.0	4	1	1	1
150297	1710	1,25-dihydroxyvitamin D3 receptor in cell	[1,25-dihydroxyvitamin D3 receptors in cells]	0.0	5	1	1	1
150298	1710	relative binding affinity RBA the high	[relative binding affinities RBA the highest]	0.0	6	1	1	1
150299	1710	human h(+)-atpase v-atpase	[human H(+)-ATPase V-ATPase]	0.0	3	1	1	1
150300	1710	vitamin D-dependent ricket type	[vitamin D-dependent rickets type]	0.0	4	1	1	1
150301	1710	ultrastructural analysis	[Ultrastructural analysis]	0.0	2	1	1	1
150302	1710	effect of FCM by means	[effect of FCM by means]	0.0	5	1	1	1
150303	1710	neural cell adhesion molecule	[neural cell adhesion molecule]	0.0	4	1	1	1
150304	1710	dexamethasone in medium	[dexamethasone in medium]	0.0	3	1	1	1
150305	1710	important component lead	[important component leading]	0.0	3	1	1	1
150306	1710	several mutant p85 allele	[several mutant p85 alleles]	0.0	4	1	1	1
150307	1710	study on the function	[studies on the function]	0.0	4	1	1	1
150308	1710	production of 2 factor kappab binding	[production of 2 factor kappaB binding]	0.0	6	1	1	1
150309	1710	class gene transcription factor TFIIIB	[class gene transcription factor TFIIIB]	0.0	5	1	1	1
150310	1710	form include lymphoblastic leukemia	[forms including lymphoblastic leukemia]	0.0	4	1	1	1
150311	1710	(ii) a case	[(ii) a case]	0.0	3	1	1	1
150312	1710	reversible loss	[reversible loss]	0.0	2	1	1	1
150313	1710	EBS motif	[EBS motif]	0.0	2	1	1	1
150314	1710	CD5+)	[CD5+)]	0.0	1	1	1	1
150315	1710	g-csf receptor	[G-CSF receptors]	0.0	2	1	1	1
150316	1710	reading frame of 342	[reading frame of 342]	0.0	4	1	1	1
150317	1710	potential Sp1 binding site gc box	[potential Sp1 binding sites GC box]	0.0	6	1	1	1
150318	1710	relative contribution of hhv-8	[relative contribution of HHV-8]	0.0	4	1	1	1
150319	1710	thus, activation of Egr-1 gene	[Thus, activation of Egr-1 gene]	0.0	5	1	1	1
150320	1710	six specific band	[six specific bands]	0.0	3	1	1	1
150321	1710	il-4 production in th2 cell	[IL-4 production in Th2 cells]	0.0	5	1	1	1
150322	1710	posttranslational modification of NF-ATp	[posttranslational modification of NF-ATp]	0.0	4	1	1	1
150323	1710	involvement in activation at subregion	[Involvement in activation at subregions]	0.0	5	1	1	1
150324	1710	p16(ink4a)-negative t-cell line	[p16(INK4A)-negative T-cell line]	0.0	3	1	1	1
150325	1710	cell assay patient	[cell assay patients]	0.0	3	1	1	1
150326	1710	p49(100) DNA binding subunit	[p49(100) DNA binding subunit]	0.0	4	1	1	1
150327	1710	cut/cdp protein	[cut/CDP protein]	0.0	2	1	1	1
150328	1710	blot with antibody	[blots with antibodies]	0.0	3	1	1	1
150329	1710	distinct level of control	[distinct level of control]	0.0	4	1	1	1
150330	1710	p50 homodimer with active heterodimer	[p50 homodimers with active heterodimers]	0.0	5	1	1	1
150331	1710	histone promoter-driven beta-galactosidase gene	[histone promoter-driven beta-galactosidase gene]	0.0	4	1	1	1
150332	1710	mixture of heparin	[mixture of heparin]	0.0	3	1	1	1
150333	1710	activation of caspase	[activation of caspase]	0.0	3	1	1	1
150334	1710	mechanism for action	[mechanism for action]	0.0	3	1	1	1
150335	1710	form Max	[form Max]	0.0	2	1	1	1
150336	1710	natural surfactant	[natural surfactant]	0.0	2	1	1	1
150337	1710	mimick in vivo migration	[mimicking in vivo migration]	0.0	4	1	1	1
150338	1710	prenatal	[Prenatal]	0.0	1	1	1	1
150339	1710	B factor OTF-2	[B factor OTF-2]	0.0	3	1	1	1
150340	1710	modulation in cell	[modulation in cells]	0.0	3	1	1	1
150341	1710	select the oligonucleotide sequence	[selecting the oligonucleotide sequence]	0.0	4	1	1	1
150342	1710	first description of a region	[first description of a region]	0.0	5	1	1	1
150343	1710	differentiation of myeloid cell line	[differentiation of myeloid cell lines]	0.0	5	1	1	1
150344	1710	(per	[(per]	0.0	1	1	1	1
150345	1710	alpha/delta	[alpha/delta]	0.0	1	1	1	1
150346	1710	receptor gamma ppargamma expression	[receptor gamma PPARgamma expression]	0.0	4	1	1	1
150347	1710	new isoforms, pax-5b	[new isoforms, Pax-5b]	0.0	3	1	1	1
150348	1710	3.1+/-0.2 nmol/L) nmol/L)	[3.1+/-0.2 nmol/L) nmol/L)]	0.0	3	1	1	1
150349	1710	receptor binding defect	[receptor binding defect]	0.0	3	1	1	1
150350	1710	IL-10 promoter	[IL-10 promoter]	0.0	2	1	1	1
150351	1710	induction of NF-kappa b translocation	[induction of NF-kappa B translocation]	0.0	5	1	1	1
150352	1710	mitogenic stimulation as a prognostic parameter	[mitogenic stimulation as a prognostic parameter]	0.0	6	1	1	1
150353	1710	site selection	[site selection]	0.0	2	1	1	1
150354	1710	activity specific	[activity specific]	0.0	2	1	1	1
150355	1710	diffusible protein	[Diffusible proteins]	0.0	2	1	1	1
150356	1710	reporter mrna level	[reporter mRNA levels]	0.0	3	1	1	1
150357	1710	crossreact protein	[crossreacting proteins]	0.0	2	1	1	1
150358	1710	egr family binding	[Egr family binding]	0.0	3	1	1	1
150359	1710	biological property	[biological properties]	0.0	2	1	1	1
150360	1710	expression of A subunit	[expression of A subunit]	0.0	4	1	1	1
150361	1710	peroxisomal proliferator-activated receptor gamma	[peroxisomal proliferator-activated receptor gamma]	0.0	4	1	1	1
150362	1710	Furthermore, treatment of extract	[Furthermore, treatment of extracts]	0.0	4	1	1	1
150363	1710	biodisposal of retinoic acid	[biodisposal of retinoic acid]	0.0	4	1	1	1
150364	1710	position -158	[positions -158]	0.0	2	1	1	1
150365	1710	dual effect on lymphocyte inhibition depletion	[dual effects on lymphocytes inhibition depletion]	0.0	6	1	1	1
150366	1710	Retinoic acid-induced expression of CD38 antigen	[Retinoic acid-induced expression of CD38 antigen]	0.0	6	1	1	1
150367	1710	protease treatment of extract	[Protease treatment of extracts]	0.0	4	1	1	1
150368	1710	form of peptide	[form of peptides]	0.0	3	1	1	1
150369	1710	interaction with receptor on t-lymphocyte	[interaction with receptor on T-lymphocytes]	0.0	5	1	1	1
150370	1710	cell from neotropical primate	[cells from neotropical primates]	0.0	4	1	1	1
150371	1710	unknown factor for activity	[unknown factors for activity]	0.0	4	1	1	1
150372	1710	proliferation rate with pha	[proliferation rate with PHA]	0.0	4	1	1	1
150373	1710	two nuclear factor nf-il6	[Two nuclear factor NF-IL6]	0.0	4	1	1	1
150374	1710	addition IL igm production	[addition IL IgM production]	0.0	4	1	1	1
150375	1710	two viral transactivator BZLF1	[two viral transactivators BZLF1]	0.0	4	1	1	1
150376	1710	receptor il-2	[receptors IL-2]	0.0	2	1	1	1
150377	1710	interleukin-7 signal	[Interleukin-7 signaling]	0.0	2	1	1	1
150378	1710	dlcl cases,	[DLCL cases,]	0.0	2	1	1	1
150379	1710	p4501a1	[P4501A1]	0.0	1	1	1	1
150380	1710	protein (rap)	[protein (Rap)]	0.0	2	1	1	1
150381	1710	unexpectedly, in plasma cell line,	[unexpectedly, in plasma cell line,]	0.0	5	1	1	1
150382	1710	regulatory sequence of gene	[regulatory sequences of genes]	0.0	4	1	1	1
150383	1710	expression of gamma-interferon a stat1alpha gene	[Expression of gamma-interferon a STAT1alpha gene]	0.0	6	1	1	1
150384	1710	"receptors"	["receptors"]	0.0	1	1	1	1
150385	1710	alteration in cis-acting sequence	[alterations in cis-acting sequences]	0.0	4	1	1	1
150386	1710	suggest gamma-ifn inhibition transactivate function.	[suggesting gamma-IFN inhibition transactivating function.]	0.0	5	1	1	1
150387	1710	fibrosarcoma 8, fibrous histiocytoma	[fibrosarcoma 8, fibrous histiocytoma]	0.0	4	1	1	1
150388	1710	mmol/L buthionine sulfoximine	[mmol/L buthionine sulfoximine]	0.0	3	1	1	1
150389	1710	kappab-binding	[kappaB-binding]	0.0	1	1	1	1
150390	1710	xist expression (xiste-),	[XIST expression (XISTE-),]	0.0	3	1	1	1
150391	1710	T cell lymphoma line	[T cell lymphoma lines]	0.0	4	1	1	1
150392	1710	allow nf-kb expression	[allowing NF-KB expression]	0.0	3	1	1	1
150393	1710	basis for cytokine redundancy	[bases for cytokine redundancy]	0.0	4	1	1	1
150394	1710	exon span kb of genomic DNA	[exons spanning kb of genomic DNA]	0.0	6	1	1	1
150395	1710	independence of electrolyte from aldosterone	[independence of electrolytes from aldosterone]	0.0	5	1	1	1
150396	1710	role in the activation of NF-kappaB	[Role in the activation of NF-kappaB]	0.0	6	1	1	1
150397	1710	interleukin-10 il-10 production	[interleukin-10 IL-10 production]	0.0	3	1	1	1
150398	1710	E1A oncogene induction of susceptibility	[E1A oncogene induction of susceptibility]	0.0	5	1	1	1
150399	1710	three signal	[three signals]	0.0	2	1	1	1
150400	1710	nuclei of hiv1 macrophage	[nuclei of HIV1 macrophages]	0.0	4	1	1	1
150401	1710	third NF-kappa b inhibitor	[third NF-kappa B inhibitor]	0.0	4	1	1	1
150402	1710	anti-human lt	[anti-human LT]	0.0	2	1	1	1
150403	1710	essential cis-acting element	[essential cis-acting elements]	0.0	3	1	1	1
150404	1710	pancreatitis in the rat	[pancreatitis in the rat]	0.0	4	1	1	1
150405	1710	blood lymphoid organ	[blood lymphoid organs]	0.0	3	1	1	1
150406	1710	active cushingd' disease	[active Cushing's disease]	0.0	3	2	2	1
150407	1710	species involve rxr-alpha	[species involving RXR-alpha]	0.0	3	1	1	1
150408	1710	oligonucleotide probe from lymph node	[oligonucleotide probes from lymph nodes]	0.0	5	1	1	1
150409	1710	role for the NFIL3/E4BP4 transcription factor	[role for the NFIL3/E4BP4 transcription factor]	0.0	6	1	1	1
150410	1710	efficacy in child	[efficacy in children]	0.0	3	1	1	1
150411	1710	metabolic status comparison	[metabolic status comparison]	0.0	3	1	1	1
150412	1710	radical-induced tissue damage	[radical-induced tissue damage]	0.0	3	1	1	1
150413	1710	bind to tre-1	[binding to TRE-1]	0.0	3	1	1	1
150414	1710	factor for neutrophil granulocyte	[factor for neutrophil granulocytes]	0.0	4	1	1	1
150415	1710	contrast, mouse	[contrast, mice]	0.0	2	1	1	1
150416	1710	position -102	[positions -102]	0.0	2	1	1	1
150417	1710	human nk-like cell line	[human NK-like cell line]	0.0	4	1	1	1
150418	1710	case of FOSB	[case of FOSB]	0.0	3	1	1	1
150419	1710	correlation of differentiation-inducing activity	[Correlation of differentiation-inducing activity]	0.0	4	1	1	1
150420	1710	consequence of the content	[consequences of the content]	0.0	4	1	1	1
150421	1710	tail gp130	[tail gp130]	0.0	2	1	1	1
150422	1710	HBxAg stimulation in patient	[HBxAg stimulation in patients]	0.0	4	1	1	1
150423	1710	wild-type human CD40	[wild-type human CD40]	0.0	3	1	1	1
150424	1710	epo receptor epor	[Epo receptor EpoR]	0.0	3	1	1	1
150425	1710	potential reading frame a	[potential reading frames A]	0.0	4	1	1	1
150426	1710	more than 24 month	[more than 24 months]	0.0	4	1	1	1
150427	1710	pathophysiology of pregnancy-induced hypertension	[pathophysiology of pregnancy-induced hypertension]	0.0	4	1	1	1
150428	1710	cell-specific activate protein	[cell-specific activating protein]	0.0	3	1	1	1
150429	1710	kappa B2	[kappa B2]	0.0	2	1	1	1
150430	1710	intact cytoplasmic segment on cd36	[intact cytoplasmic segment on CD36]	0.0	5	1	1	1
150431	1710	FISH result	[FISH results]	0.0	2	1	1	1
150432	1710	30 min) nf-kappa b	[30 min) NF-kappa B]	0.0	4	1	1	1
150433	1710	difference within the U3 region	[differences within the U3 region]	0.0	5	1	1	1
150434	1710	hematopoietic transcription factor pu.1	[hematopoietic transcription factors PU.1]	0.0	4	1	1	1
150435	1710	immunoglobulin chain region	[immunoglobulin chain region]	0.0	3	1	1	1
150436	1710	prb of form	[pRb of Form]	0.0	3	1	1	1
150437	1710	inflammatory effector	[inflammatory effector]	0.0	2	1	1	1
150438	1710	hematopoietic support property	[hematopoietic supporting properties]	0.0	3	1	1	1
150439	1710	receptor gr of leukocyte	[receptor GR of leukocytes]	0.0	4	1	1	1
150440	1710	conjunctiva of patient	[conjunctiva of patients]	0.0	3	1	1	1
150441	1710	proximal 5' region	[proximal 5' region]	0.0	3	1	1	1
150442	1710	activity in ocim1	[activity in OCIM1]	0.0	3	1	1	1
150443	1710	lung leak of albumin	[lung leak of albumin]	0.0	4	1	1	1
150444	1710	(pp)	[(pp)]	0.0	1	1	1	1
150445	1710	IFN responsiveness	[IFN responsiveness]	0.0	2	1	1	1
150446	1710	correlation between expression of nfkb2	[correlation between expression of NFKB2]	0.0	5	1	1	1
150447	1710	tyrosine phosphatase shp2	[tyrosine phosphatase SHP2]	0.0	3	1	1	1
150448	1710	vd receptor	[VD receptor]	0.0	2	1	1	1
150449	1710	antigen segment	[antigen segments]	0.0	2	1	1	1
150450	1710	tarsal conjunctival biopsy	[tarsal conjunctival biopsies]	0.0	3	1	1	1
150451	1710	normal human pulmonary macrophage	[Normal human pulmonary macrophages]	0.0	4	1	1	1
150452	1710	blood resting cell	[blood resting cells]	0.0	3	1	1	1
150453	1710	joint requirement for function	[joint requirement for function]	0.0	4	1	1	1
150454	1710	intranasal glucocorticoid on endogenous function	[intranasal glucocorticoids on endogenous function]	0.0	5	1	1	1
150455	1710	22 case	[22 cases]	0.0	2	1	1	1
150456	1710	(pr)	[(PR)]	0.0	1	1	1	1
150457	1710	related acid receptor alpha	[related acid receptor alpha]	0.0	4	1	1	1
150458	1710	(35 min) exercise ppe at 70%	[(35 min) exercise PPE at 70%]	0.0	6	1	1	1
150459	1710	Phosphatidyl	[Phosphatidyl]	0.0	1	1	1	1
150460	1710	several human cell	[several human cells]	0.0	3	1	1	1
150461	1710	generation of plasma cell	[generation of plasma cells]	0.0	4	1	1	1
150462	1710	follow 3-day exposure to 12-o-tetradecanoylphorbol-13-acetate	[following 3-day exposures to 12-O-tetradecanoylphorbol-13-acetate]	0.0	5	1	1	1
150463	1710	binding of the cDNA fusion protein	[Binding of the cDNA fusion protein]	0.0	6	1	1	1
150464	1710	interleukin-1 gene transcription	[interleukin-1 gene transcription]	0.0	3	1	1	1
150465	1710	alter interaction	[altering interactions]	0.0	2	1	1	1
150466	1710	experiment involve clone with ltr	[experiments involving clones with LTRs]	0.0	5	1	1	1
150467	1710	monocyte colony-stimulating	[monocyte colony-stimulating]	0.0	2	1	1	1
150468	1710	Jeg-3 choriocarcinoma-induced immunosuppression downregulation	[Jeg-3 choriocarcinoma-induced immunosuppression downregulation]	0.0	4	1	1	1
150469	1710	relationship between the receptor	[relationship between the receptor]	0.0	4	1	1	1
150470	1710	/IL-7R	[/IL-7R]	0.0	1	1	1	1
150471	1710	phorbol ester cell	[phorbol ester cells]	0.0	3	1	1	1
150472	1710	11 MDD patient	[11 MDD patients]	0.0	3	1	1	1
150473	1710	factor-kappaB binding site	[factor-kappaB binding site]	0.0	3	1	1	1
150474	1710	intragenic tsg101 deletion	[Intragenic TSG101 deletions]	0.0	3	1	1	1
150475	1710	prointerleukin beta gene	[prointerleukin beta gene]	0.0	3	2	2	1
150476	1710	persistence of macrophage	[persistence of macrophages]	0.0	3	1	1	1
150477	1710	low gcr	[lowest GCR]	0.0	2	1	1	1
150478	1710	(pt)	[(PT)]	0.0	1	1	1	1
150479	1710	mutant leukemic cell resistant	[mutant leukemic cells resistant]	0.0	4	1	1	1
150480	1710	number of affinity	[number of affinity]	0.0	3	1	1	1
150481	1710	domain contain six cell cycle	[domain containing six cell cycle]	0.0	5	1	1	1
150482	1710	follow trigger	[following triggering]	0.0	2	1	1	1
150483	1710	induction in promyelocytic myeloblastic leukemia cell	[Induction in promyelocytic myeloblastic leukemia cells]	0.0	6	1	1	1
150484	1710	model, polymorphism within IL-4 element	[model, polymorphisms within IL-4 elements]	0.0	5	1	1	1
150485	1710	nh2- domain of bob.1/obf.1	[NH2- domains of BOB.1/OBF.1]	0.0	4	1	1	1
150486	1710	(G0) T cell	[(G0) T cells]	0.0	3	1	1	1
150487	1710	result in the production	[resulting in the production]	0.0	4	1	1	1
150488	1710	IL-2 transformation step	[IL-2 transformation steps]	0.0	3	1	1	1
150489	1710	c-sis/pdgb promoter element tre1	[c-sis/PDGF-B promoter element TRE1]	0.0	4	1	1	1
150490	1710	1 microm aldosterone	[1 microM aldosterone]	0.0	3	1	1	1
150491	1710	patient aged years,	[patients aged years,]	0.0	3	1	1	1
150492	1710	element RRLPIF	[element RRLPIF]	0.0	2	1	1	1
150493	1710	indicate a requirement for interaction	[indicating a requirement for interactions]	0.0	5	1	1	1
150494	1710	DNA replication in U937 cell	[DNA replication in U937 cells]	0.0	5	1	1	1
150495	1710	oxidative activation	[oxidative activation]	0.0	2	1	1	1
150496	1710	recombinant il-2	[recombinant IL-2]	0.0	2	1	1	1
150497	1710	pebp2/cbf site	[PEBP2/CBF site]	0.0	2	1	1	1
150498	1710	multiple sclerosis ms	[multiple sclerosis MS]	0.0	3	1	1	1
150499	1710	gene corresponding to a factor	[genes corresponding to a factor]	0.0	5	1	1	1
150500	1710	basal 12-myristate 13-acetate transcription	[basal 12-myristate 13-acetate transcription]	0.0	4	1	1	1
150501	1710	immunoperoxidase staining	[immunoperoxidase staining]	0.0	2	1	1	1
150502	1710	expression of the globin gene	[expression of the globin genes]	0.0	5	1	1	1
150503	1710	pkcalpha	[PKCalpha]	0.0	1	1	1	1
150504	1710	sites/cell;	[sites/cell;]	0.0	1	1	1	1
150505	1710	mobility of the complex	[mobility of the complex]	0.0	4	1	1	1
150506	1710	breast cancer a prospective study	[breast cancer a prospective study]	0.0	5	1	1	1
150507	1710	stat1 activity.	[Stat1 activity.]	0.0	2	1	1	1
150508	1710	datum from a CMPD1 /sra1 patient	[data from a CMPD1 /SRA1 patient]	0.0	6	1	1	1
150509	1710	mitogenic combination	[mitogenic combination]	0.0	2	3	3	1
150510	1710	STAT1 activation role	[STAT1 activation role]	0.0	3	1	1	1
150511	1710	method of study: lymphocyte from woman	[METHOD OF STUDY: lymphocytes from women]	0.0	6	1	1	1
150512	1710	histocompatibility complex in resting	[histocompatibility complex in resting]	0.0	4	1	1	1
150513	1710	nonsteroidal anti-inflammatory drug nsaid	[nonsteroidal anti-inflammatory drugs NSAIDs]	0.0	4	1	1	1
150514	1710	MEK inhibitor	[MEK inhibitor]	0.0	2	1	1	1
150515	1710	ultimately, the property of the virus	[ultimately, the properties of the virus]	0.0	6	1	1	1
150516	1710	potential cell	[potential cells]	0.0	2	1	1	1
150517	1710	course of il-2 therapy,	[course of IL-2 therapy,]	0.0	4	1	1	1
150518	1710	enhancement HL cell (granulocytic differentiated)	[enhancement HL cells (granulocytic differentiated)]	0.0	5	1	1	1
150519	1710	increase of junb mrna	[increase of junB mRNA]	0.0	4	1	1	1
150520	1710	slot blot	[slot blot]	0.0	2	1	1	1
150521	1710	colon cancer	[colon cancer]	0.0	2	1	1	1
150522	1710	particularly in the function of cell	[particularly in the function of cells]	0.0	6	1	1	1
150523	1710	humans, splicing	[humans, splicing]	0.0	2	1	1	1
150524	1710	copy of TRE-1	[copies of TRE-1]	0.0	3	1	1	1
150525	1710	considerable sequence identity in the two-third	[considerable sequence identity in the two-thirds]	0.0	6	1	1	1
150526	1710	balance between proliferation	[balance between proliferation]	0.0	3	1	1	1
150527	1710	critical role maintain a load	[critical role maintaining a load]	0.0	5	1	1	1
150528	1710	different stimuli, alpha	[different stimuli, alpha]	0.0	3	1	1	1
150529	1710	42 bp fragment	[42 bp fragment]	0.0	3	1	1	1
150530	1710	ICP36 family	[ICP36 family]	0.0	2	1	1	1
150531	1710	disease primary cirrhosis	[disease primary cirrhosis]	0.0	3	1	1	1
150532	1710	low the/thf (0.24; 1.87+/-0.36)	[low THE/THF (0.24; 1.87+/-0.36)]	0.0	4	1	1	1
150533	1710	structurally related family	[structurally related family]	0.0	3	1	1	1
150534	1710	inverse relation to major class	[inverse relation to major classes]	0.0	5	1	1	1
150535	1710	presence in fluid of agent(s)	[presence in fluid of agent(s)]	0.0	5	1	1	1
150536	1710	recombinant kappa	[Recombinant kappa]	0.0	2	1	1	1
150537	1710	AMP element	[AMP element]	0.0	2	1	1	1
150538	1710	correlation with her-2/neu expression	[correlation with HER-2/neu expression]	0.0	4	1	1	1
150539	1710	immature b cell line	[immature B cell line]	0.0	4	1	1	1
150540	1710	mnda in tissue section	[MNDA in tissue sections]	0.0	4	1	1	1
150541	1710	D3 (1325(oh)2d3)	[D3 (1,25(OH)2D3)]	0.0	2	1	1	1
150542	1710	MIBP1 gene	[MIBP1 gene]	0.0	2	1	1	1
150543	1710	level of cell adhesion molecule	[levels of cell adhesion molecule]	0.0	5	1	1	1
150544	1710	expression by blot analysis	[expression by blot analysis]	0.0	4	1	1	1
150545	1710	level in brain	[levels in brain]	0.0	3	1	1	1
150546	1710	STAT1 import	[STAT1 import]	0.0	2	1	1	1
150547	1710	40 60 mM d-ribose	[40 60 mM D-ribose]	0.0	4	1	1	1
150548	1710	adenovirus antigen	[adenovirus antigen]	0.0	2	1	1	1
150549	1710	calcium -signal modulate cyclophilin ligand	[calcium -signal modulating cyclophilin ligand]	0.0	5	1	1	1
150550	1710	act somewhat independently	[acting somewhat independently]	0.0	3	1	1	1
150551	1710	class ii antibody Ab	[class II antibodies Ab]	0.0	4	1	1	1
150552	1710	il-13 expression	[IL-13 expression]	0.0	2	1	1	1
150553	1710	apoptosis cell line	[apoptosis cell lines]	0.0	3	1	1	1
150554	1710	responder oligopeptide	[responder oligopeptides]	0.0	2	1	1	1
150555	1710	induce expression in ebv-transformed lymphoblastoid cell	[inducing expression in EBV-transformed lymphoblastoid cells]	0.0	6	1	1	1
150556	1710	x-ray-treated carcinoma cell line ht29	[X-ray-treated carcinoma cell line HT29]	0.0	5	1	1	1
150557	1710	protein binding sequence	[protein binding sequences]	0.0	3	1	1	1
150558	1710	transcription within the tissue.	[transcription within the tissue.]	0.0	4	1	1	1
150559	1710	gc-r bmax	[GC-R Bmax]	0.0	2	1	1	1
150560	1710	microsomal membrane from human leukocyte	[microsomal membranes from human leukocytes]	0.0	5	1	1	1
150561	1710	treatment of erythrocyte	[Treatment of erythrocytes]	0.0	3	1	1	1
150562	1710	level of serum ast/alt	[levels of serum AST/ALT]	0.0	4	1	1	1
150563	1710	lipopolysaccharide signal transduction	[lipopolysaccharide signal transduction]	0.0	3	1	1	1
150564	1710	Additionally, activation of signal transduction pathway	[Additionally, activation of signal transduction pathways]	0.0	6	1	1	1
150565	1710	subline cell of synovial tissue	[sublining cells of synovial tissue]	0.0	5	1	1	1
150566	1710	potent inducer here	[potent inducers here]	0.0	3	1	1	1
150567	1710	intracellular signalling molecule brid the generation	[intracellular signalling molecules bridging the generation]	0.0	6	1	1	1
150568	1710	other rheumatoid arthritis patient	[other rheumatoid arthritis patients]	0.0	4	1	1	1
150569	1710	[age-related change	[[Age-related changes]	0.0	2	1	1	1
150570	1710	highlight loci	[highlighting loci]	0.0	2	1	1	1
150571	1710	quantitation triiodothyronine receptor mrna	[Quantitation triiodothyronine receptor mRNA]	0.0	4	1	1	1
150572	1710	latent membrane protein gene protein	[latent membrane protein gene proteins]	0.0	5	1	1	1
150573	1710	sh2 association of phosphoinositide 3-kinase	[SH2 association of phosphoinositide 3-kinase]	0.0	5	1	1	1
150574	1710	high-level promoter activity	[high-level promoter activity]	0.0	3	1	1	1
150575	1710	IFN induction	[IFN induction]	0.0	2	1	1	1
150576	1710	EBV Epstein-Barr early region (EBER)	[EBV Epstein-Barr early region (EBER)]	0.0	5	1	1	1
150577	1710	process unique to genotoxic stimulus	[process unique to genotoxic stimuli]	0.0	5	1	1	1
150578	1710	gggactttcc	[GGGACTTTCC]	0.0	1	1	1	1
150579	1710	effect than the responses.	[effects than the responses.]	0.0	4	1	1	1
150580	1710	11.8 fmol/mg protein	[11.8 fmol/mg protein]	0.0	3	1	1	1
150581	1710	heterozygosity in pb granulocyte	[heterozygosity in PB granulocytes]	0.0	4	1	1	1
150582	1710	alkaloid cepharanthine	[alkaloid cepharanthine]	0.0	2	1	1	1
150583	1710	(range, 44845643),4-54856484<SOS>3)84-548564856484<SOS>3)84-548564 3413 (range,	[(range, 4484-5643), 3413 (range,]	0.0	4	1	1	1
150584	1710	cavity fluid	[cavity fluids]	0.0	2	1	1	1
150585	1710	herpesvirus papio	[herpesvirus papio]	0.0	2	1	1	1
150586	1710	distinct biological role	[distinct biological roles]	0.0	3	1	1	1
150587	1710	culture supernatant at level	[culture supernatants at levels]	0.0	4	1	1	1
150588	1710	interleukin-2 receptor alpha-chain gene expression	[interleukin-2 receptor alpha-chain gene expression]	0.0	5	1	1	1
150589	1710	megakaryopoiesis/ thrombopoiesis	[megakaryopoiesis/ thrombopoiesis]	0.0	2	1	1	1
150590	1710	lps-stimulated Raw cell	[LPS-stimulated Raw cells]	0.0	3	1	1	1
150591	1710	residue of PXQXT/S	[residues of PXQXT/S]	0.0	3	1	1	1
150592	1710	Tat loop	[Tat loop]	0.0	2	1	1	1
150593	1710	element in cos-7 cell	[element in COS-7 cells]	0.0	4	1	1	1
150594	1710	facilitate entry into the cns	[facilitating entry into the CNS]	0.0	5	1	1	1
150595	1710	role in the cascade	[role in the cascade]	0.0	4	1	1	1
150596	1710	replication T-tropic primary isolate	[replication T-tropic primary isolate]	0.0	4	1	1	1
150597	1710	selection procedure	[selection procedure]	0.0	2	1	1	1
150598	1710	different schedule of oral calcitriol	[different schedules of oral calcitriol]	0.0	5	1	1	1
150599	1710	review of property	[review of properties]	0.0	3	1	1	1
150600	1710	medication,	[medication,]	0.0	1	1	1	1
150601	1710	environment capable	[environment capable]	0.0	2	1	1	1
150602	1710	expression of a protein bzlf1	[expression of a protein BZLF1]	0.0	5	1	1	1
150603	1710	signal adaptor molecule	[signal adaptor molecule]	0.0	3	1	1	1
150604	1710	nuclear factor to this element	[nuclear factors to these elements]	0.0	5	1	1	1
150605	1710	weight of 64.6 k.0	[weight of 64.6 kd,]	0.0	4	1	1	1
150606	1710	cortisol ratio in the group	[cortisol ratio in the group]	0.0	5	1	1	1
150607	1710	gata-1 allele, lead to severity	[GATA-1 allele, leading to severity]	0.0	5	1	1	1
150608	1710	Lipopolysaccharide LPS stimulation of neutrophil	[Lipopolysaccharide LPS stimulation of neutrophils]	0.0	5	1	1	1
150609	1710	8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma	[8, malignant histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
150610	1710	immunologically important gene	[immunologically important genes]	0.0	3	1	1	1
150611	1710	regression model	[regression model]	0.0	2	1	1	1
150612	1710	degenerative spastic paraparesis	[degenerative spastic paraparesis]	0.0	3	1	1	1
150613	1710	pacemaker of GR	[pacemaker of GR]	0.0	3	1	1	1
150614	1710	5' regulatory region	[5' regulatory region]	0.0	3	1	1	1
150615	1710	nonreceptor tyrosine kinase	[nonreceptor tyrosine kinases]	0.0	3	1	1	1
150616	1710	proximal human IL-4 promoter	[proximal human IL-4 promoter]	0.0	4	1	1	1
150617	1710	synthase gene	[synthase genes]	0.0	2	1	1	1
150618	1710	-estrogen	[-estrogen]	0.0	1	1	1	1
150619	1710	suggest a regulator	[suggesting a regulator]	0.0	3	1	1	1
150620	1710	self-perpetuated viral transcription	[self-perpetuated viral transcription]	0.0	3	1	1	1
150621	1710	monocytic specific expression	[monocytic specific expression]	0.0	3	1	1	1
150622	1710	fluctuation of type EBS	[fluctuations of type EBS]	0.0	4	1	1	1
150623	1710	ino promoter	[iNOS promoter]	0.0	2	1	1	1
150624	1710	expression of multiple gene product	[expression of multiple gene products]	0.0	5	1	1	1
150625	1710	camp second-messenger pathway	[cAMP second-messenger pathway]	0.0	3	1	1	1
150626	1710	number hematopoietic progenitor cell	[number hematopoietic progenitor cells]	0.0	4	1	1	1
150627	1710	network operate in t-cell	[network operating in T-cells]	0.0	4	1	1	1
150628	1710	Specific inhibitor rapamycin	[Specific inhibitors rapamycin]	0.0	3	1	1	1
150629	1710	express a number	[expressing a number]	0.0	3	1	1	1
150630	1710	immunofluorescence study carry transgene	[Immunofluorescence studies carrying transgenes]	0.0	4	1	1	1
150631	1710	cytokine dysregulation in infection	[Cytokine dysregulation in infection]	0.0	4	1	1	1
150632	1710	moderate level 2 17	[moderate levels 2 17]	0.0	4	1	1	1
150633	1710	active oxygen species serve	[active oxygen species serving]	0.0	4	1	1	1
150634	1710	effect on two marker	[effects on two markers]	0.0	4	1	1	1
150635	1710	constitutive dnase i-hypersensitive site	[constitutive DNase I-hypersensitive site]	0.0	4	1	1	1
150636	1710	moreover, M-CSF expression	[Moreover, M-CSF expression]	0.0	3	1	1	1
150637	1710	factor-kappaB in the cytosol	[factor-kappaB in the cytosol]	0.0	4	1	1	1
150638	1710	interaction between multiple positive transcriptional element	[interactions between multiple positive transcriptional elements]	0.0	6	1	1	1
150639	1710	circulate human mononuclear leukocyte of donor	[circulating human mononuclear leukocytes of donors]	0.0	6	1	1	1
150640	1710	new therapy	[new therapy]	0.0	2	1	1	1
150641	1710	latent membrane protein 1 activation	[latent membrane protein 1 activation]	0.0	5	1	1	1
150642	1710	suboptimal concentration	[suboptimal concentrations]	0.0	2	1	1	1
150643	1710	active regulatory process	[active regulatory process]	0.0	3	1	1	1
150644	1710	calcineurin signal	[calcineurin signaling]	0.0	2	1	1	1
150645	1710	bind activity of factor	[binding activity of factor]	0.0	4	1	1	1
150646	1710	nuclear target sequence	[nuclear targeting sequence]	0.0	3	1	1	1
150647	1710	use oligonucleotide	[using oligonucleotides]	0.0	2	1	1	1
150648	1710	cell with drug resistant marker	[cells with drug resistant marker]	0.0	5	1	1	1
150649	1710	expression of SOCS-1	[expression of SOCS-1]	0.0	3	1	1	1
150650	1710	category cell-specific factor	[categories cell-specific factors]	0.0	3	1	1	1
150651	1710	protein-DNA complex with mobility	[protein-DNA complexes with mobilities]	0.0	4	1	1	1
150652	1710	activity of phosphotyrosine-containing peptide	[activities of phosphotyrosine-containing peptides]	0.0	4	1	1	1
150653	1710	kilometer TNFRp75	[kd TNFRp75]	0.0	2	1	1	1
150654	1710	provide the immediate transactivator bzlf1	[providing the immediate transactivator BZLF1]	0.0	5	1	1	1
150655	1710	tandem ap1	[tandem AP1]	0.0	2	1	1	1
150656	1710	displacement of a E-box-binding repressor	[Displacement of an E-box-binding repressor]	0.0	5	1	1	1
150657	1710	alpha beta in T cell	[alpha beta in T cells]	0.0	5	1	1	1
150658	1710	association of the HsN3 proteasome subunit	[association of the HsN3 proteasome subunit]	0.0	6	1	1	1
150659	1710	depend on the context	[depending on the context]	0.0	4	1	1	1
150660	1710	means of shift assay	[means of shift assay]	0.0	4	1	1	1
150661	1710	reactivation of hiv-1	[reactivation of HIV-1]	0.0	3	1	1	1
150662	1710	cd86 two principal ligand for CD28	[CD86 two principal ligands for CD28]	0.0	6	1	1	1
150663	1710	hydrophobic moiety of molecules.	[hydrophobic moiety of molecules.]	0.0	4	1	1	1
150664	1710	physiological concentration of aldosterone	[physiological concentrations of aldosterone]	0.0	4	2	2	1
150665	1710	tnf-alpha protein to level comparable	[TNF-alpha protein to levels comparable]	0.0	5	1	1	1
150666	1710	control of virus	[control of virus]	0.0	3	1	1	1
150667	1710	considerable protection	[considerable protection]	0.0	2	1	1	1
150668	1710	fetal calf serum on the binding	[fetal calf serum on the binding]	0.0	6	1	1	1
150669	1710	kilometer TNFRp55	[kd TNFRp55]	0.0	2	1	1	1
150670	1710	kd-value	[Kd-values]	0.0	1	1	1	1
150671	1710	factor granulocyte-macrophage colony-stimumulatelany-stg factor	[factor granulocyte-macrophage colony-stimulating factor]	0.0	4	1	1	1
150672	1710	week of treatment.	[week of treatment.]	0.0	3	1	1	1
150673	1710	transcription factor responsible	[transcription factors responsible]	0.0	3	1	1	1
150674	1710	intracellular domain sequence contain phosphotyrosine	[intracellular domain sequences containing phosphotyrosine]	0.0	5	1	1	1
150675	1710	affinity for this sre sequence	[affinity for this SRE sequence]	0.0	5	2	2	1
150676	1710	mature myeloid cell granulocyte	[mature myeloid cells granulocytes]	0.0	4	1	1	1
150677	1710	presence of RAR alpha	[presence of RAR alpha]	0.0	4	1	1	1
150678	1710	antigen antigen	[antigen antigen]	0.0	2	1	1	1
150679	1710	immune deficiency virus type	[immune deficiency virus type]	0.0	4	1	1	1
150680	1710	functional activation of cell	[functional activation of cells]	0.0	4	1	1	1
150681	1710	time-dependent binding antibody specific	[time-dependent binding antibodies specific]	0.0	4	1	1	1
150682	1710	intrinsic behavior	[intrinsic behavior]	0.0	2	1	1	1
150683	1710	efficient transcription,	[efficient transcription,]	0.0	2	1	1	1
150684	1710	nf-kappab -like factor	[NF-kappaB -like factor]	0.0	3	1	1	1
150685	1710	replication of type human immunodeficiency virus	[Replication of type human immunodeficiency viruses]	0.0	6	1	1	1
150686	1710	interaction of octamer transcription factor	[interaction of octamer transcription factors]	0.0	5	1	1	1
150687	1710	protein kinase erk1	[protein kinases erk1]	0.0	3	1	1	1
150688	1710	nonpeptidyl molecule sb 247464	[nonpeptidyl molecule SB 247464]	0.0	4	1	1	1
150689	1710	receptor-positive lymphocyte	[receptor-positive lymphocytes]	0.0	2	1	1	1
150690	1710	activity in non-erythroid cell	[activity in non-erythroid cells]	0.0	4	1	1	1
150691	1710	property of this hsf	[properties of these HSFs]	0.0	4	1	1	1
150692	1710	signal through Janus kinase	[signaling through Janus kinases]	0.0	4	1	1	1
150693	1710	also a scavenger	[also a scavenger]	0.0	3	1	1	1
150694	1710	establish due to constitutive expression	[establishing due to constitutive expression]	0.0	5	1	1	1
150695	1710	h with thp-1 cell	[h with THP-1 cells]	0.0	4	1	1	1
150696	1710	interaction with natural ligand	[interaction with natural ligand]	0.0	4	1	1	1
150697	1710	intimal plaque formation.	[intimal plaque formation.]	0.0	3	1	1	1
150698	1710	nonspecific reactive follicular hyperplasia fh	[nonspecific reactive follicular hyperplasia FH]	0.0	5	1	1	1
150699	1710	single gene ORF 50	[single gene ORF 50]	0.0	4	1	1	1
150700	1710	low transcription enhancement by site	[lower transcription enhancement by sites]	0.0	5	1	1	1
150701	1710	histogenetic characterization	[histogenetic characterization]	0.0	2	1	1	1
150702	1710	activation gene family	[activation genes family]	0.0	3	1	1	1
150703	1710	inhibition of calcineurin activity	[inhibition of calcineurin activity]	0.0	4	1	1	1
150704	1710	isolate of individual	[isolates of individuals]	0.0	3	1	1	1
150705	1710	outcomes,	[outcomes,]	0.0	1	1	1	1
150706	1710	as many as child	[As many as children]	0.0	4	1	1	1
150707	1710	ciita cell line	[CIITA cell line]	0.0	3	1	1	1
150708	1710	regard the use of agent	[regarding the use of agents]	0.0	5	1	1	1
150709	1710	TNF huvec	[TNF HUVECs]	0.0	2	1	1	1
150710	1710	helix-loop-helix bhlh motif	[helix-loop-helix bHLH motif]	0.0	3	1	1	1
150711	1710	great than 75% amplification	[greater than 75% amplification]	0.0	4	1	1	1
150712	1710	affinity in World primate	[affinity in World primates]	0.0	4	1	1	1
150713	1710	protein present	[proteins present]	0.0	2	1	1	1
150714	1710	hemin-mediated differentiation of k562 cell	[hemin-mediated differentiation of K562 cells]	0.0	5	1	1	1
150715	1710	means of rhodamine	[means of rhodamine]	0.0	3	1	1	1
150716	1710	new steroid	[new steroids]	0.0	2	1	1	1
150717	1710	immediate-early protein BRLF1	[immediate-early protein BRLF1]	0.0	3	1	1	1
150718	1710	VCAM-1 monoclonal antibody 1g11	[VCAM-1 monoclonal antibody 1G11]	0.0	4	1	1	1
150719	1710	2 healthy subject	[2 healthy subjects]	0.0	3	1	1	1
150720	1710	constitutive association of JAK1	[Constitutive association of JAK1]	0.0	4	1	1	1
150721	1710	level a extinction	[level a extinction]	0.0	3	1	1	1
150722	1710	stimulation lead to anergy	[stimulation leading to anergy]	0.0	4	1	1	1
150723	1710	manipulation of growth	[manipulation of growth]	0.0	3	1	1	1
150724	1710	sequence within the element nre	[sequences within the element NRE]	0.0	5	1	1	1
150725	1710	essential role of Jak3 in development	[essential role of Jak3 in development]	0.0	6	1	1	1
150726	1710	beneficial profile, reduce the response	[beneficial profile, reducing the response]	0.0	5	1	1	1
150727	1710	cord blood mononuclear cell	[cord blood mononuclear cells]	0.0	4	1	1	1
150728	1710	Mol cell	[Mol Cell]	0.0	2	1	1	1
150729	1710	sequential phosphorylation	[sequential phosphorylation]	0.0	2	1	1	1
150730	1710	action of GM-CSF	[actions of GM-CSF]	0.0	3	1	1	1
150731	1710	cd11b+ population in transgenic mouse	[CD11b+ populations in transgenic mice]	0.0	5	1	1	1
150732	1710	downstream nf-kappab activation of hiv-1 repeat	[downstream NF-kappaB activation of HIV-1 repeat]	0.0	6	1	1	1
150733	1710	constitute model	[constituting models]	0.0	2	1	1	1
150734	1710	response to testosterone	[response to testosterone]	0.0	3	1	1	1
150735	1710	blood mononuclear cell pbmc response	[blood mononuclear cell PBMC responses]	0.0	5	1	1	1
150736	1710	IkappaBalpha a inhibitor of nf-kappab	[IkappaBalpha a inhibitor of NF-kappaB]	0.0	5	1	1	1
150737	1710	synergistic action CPRE GGACTACAG	[synergistic action CPRE GGACTACAG]	0.0	4	1	1	1
150738	1710	human granulocyte-macrophage CSF gm-csf	[human granulocyte-macrophage CSF GM-CSF]	0.0	4	1	1	1
150739	1710	extravascular tissue	[extravascular tissues]	0.0	2	2	2	1
150740	1710	lymphocyte-specific gene expression	[lymphocyte-specific gene expression]	0.0	3	1	1	1
150741	1710	processing of NF-kappa	[processing of NF-kappa]	0.0	3	1	1	1
150742	1710	complex involve GrpL	[complexes involving GrpL]	0.0	3	1	1	1
150743	1710	parallel the diurnal decline	[paralleling the diurnal decline]	0.0	4	1	1	1
150744	1710	level of mrna for macrophage protein-1	[levels of mRNA for macrophage protein-1]	0.0	6	1	1	1
150745	1710	mg at p.m.) type	[mg at p.m.) Type]	0.0	4	1	1	1
150746	1710	octamer-like factor	[octamer-like factors]	0.0	2	1	1	1
150747	1710	background level	[background levels]	0.0	2	1	1	1
150748	1710	sequence within the regulatory element	[sequences within the regulatory element]	0.0	5	1	1	1
150749	1710	five cellular protein	[Five cellular proteins]	0.0	3	1	1	1
150750	1710	time of 25 h	[times of 25 h]	0.0	4	1	1	1
150751	1710	insight into the protein-protein interaction	[insights into the protein-protein interactions]	0.0	5	1	1	1
150752	1710	abnormality of p16 gene in astrocytomas	[Abnormalities of p16 genes in astrocytomas]	0.0	6	1	1	1
150753	1710	6tg1.1 resistant icr27tk.3 T cell	[6TG1.1 resistant ICR27TK.3 T cells]	0.0	5	1	1	1
150754	1710	addition to the exist isoform	[addition to the existing isoform]	0.0	5	1	1	1
150755	1710	cleavage of bcl-2 a regulator	[cleavage of bcl-2 a regulator]	0.0	5	1	1	1
150756	1710	native promoter construct	[native promoter constructs]	0.0	3	1	1	1
150757	1710	other heavy- chain gene	[other heavy- chain genes]	0.0	4	1	1	1
150758	1710	activity of acid-sensitive serine /threonine phosphatase	[activity of acid-sensitive serine /threonine phosphatases]	0.0	6	1	1	1
150759	1710	nfat complex	[NFAT complexes]	0.0	2	1	1	1
150760	1710	50 mcr in woman	[50, MCR in women]	0.0	4	1	1	1
150761	1710	acute respiratory distress syndrome ARDS	[acute respiratory distress syndrome ARDS]	0.0	5	1	1	1
150762	1710	B cell-specific factor	[B cell-specific factor]	0.0	3	1	1	1
150763	1710	functional nuclear factor kB regulatory element	[functional nuclear factor kB regulatory elements]	0.0	6	1	1	1
150764	1710	DNA clone contain the flank region	[DNA clones containing the flanking region]	0.0	6	1	1	1
150765	1710	4 others,	[4 others,]	0.0	2	1	1	1
150766	1710	such cluster	[such clusters]	0.0	2	1	1	1
150767	1710	day of culture	[days of culture]	0.0	3	1	1	1
150768	1710	kappa bs	[kappa Bs]	0.0	2	1	1	1
150769	1710	maintenance such as bcl-2+	[maintenance such as BCL-2+]	0.0	4	1	1	1
150770	1710	response to intranasal fluticasone propionate	[Response to intranasal fluticasone propionate]	0.0	5	1	1	1
150771	1710	encode member	[encoding members]	0.0	2	1	1	1
150772	1710	important gene dorsal	[important gene dorsal]	0.0	3	1	1	1
150773	1710	inhibition for several gene	[inhibition for several genes]	0.0	4	1	1	1
150774	1710	correlation between chromosome	[correlation between chromosome]	0.0	3	1	1	1
150775	1710	time interval	[time intervals]	0.0	2	1	1	1
150776	1710	extensive footprint than the globin	[extensive footprints than the globin]	0.0	5	1	1	1
150777	1710	selective ligand for acid receptor rar	[selective ligands for acid receptors RARs]	0.0	6	1	1	1
150778	1710	transcription activation by LEF-1	[transcription activation by LEF-1]	0.0	4	1	1	1
150779	1710	pro-B-cell lymphoblastic leukemia	[pro-B-cell lymphoblastic leukemia]	0.0	3	1	1	1
150780	1710	transcriptional activity reticuloendotheliosis virus REV	[transcriptional activity reticuloendotheliosis virus REV]	0.0	5	1	1	1
150781	1710	6 colony-stimulating factor receptor	[6 colony-stimulating factor receptors]	0.0	4	1	1	1
150782	1710	mineralocorticoid receptor hmr	[mineralocorticoid receptor hMR]	0.0	3	2	2	1
150783	1710	gene superfamily	[gene superfamily]	0.0	2	1	1	1
150784	1710	limitation to potential effect	[limitation to potential effects]	0.0	4	1	1	1
150785	1710	very low affinity	[very low affinity]	0.0	3	1	1	1
150786	1710	second trans-activation domain in peptide	[second trans-activation domain in peptide]	0.0	5	1	1	1
150787	1710	block a therapeutic target in culture	[blocking a therapeutic target in cultures]	0.0	6	1	1	1
150788	1710	more polar substitution 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl	[more polar substitutions 11 alpha-hydroxymethyl, alpha-(2-hydroxyethyl]	0.0	6	1	1	1
150789	1710	functional human deficiency virus type	[functional human deficiency virus type]	0.0	5	1	1	1
150790	1710	target for this transcription factor	[target for these transcription factors]	0.0	5	2	2	1
150791	1710	two-site interaction of nuclear factor	[Two-site interaction of nuclear factor]	0.0	5	1	1	1
150792	1710	rank order	[rank order]	0.0	2	1	1	1
150793	1710	fresh pbmc	[fresh PBMC]	0.0	2	1	1	1
150794	1710	phosphatase inhibitor for protein phosphatase pp1	[phosphatase inhibitors for protein phosphatase PP1]	0.0	6	1	1	1
150795	1710	critical involvement in the stage	[critical involvement in the stage]	0.0	5	1	1	1
150796	1710	novel negative element	[novel negative element]	0.0	3	1	1	1
150797	1710	patient with severe restrictive anorexia nervosa	[patients with severe restrictive anorexia nervosa]	0.0	6	1	1	1
150798	1710	cell-type-specific transcription	[cell-type-specific transcription]	0.0	2	1	1	1
150799	1710	transactivate complex, nuclear factor	[transactivating complex, nuclear factor]	0.0	4	1	1	1
150800	1710	stimulation gene expression	[Stimulation gene expression]	0.0	3	1	1	1
150801	1710	comparison with factor	[comparison with factors]	0.0	3	1	1	1
150802	1710	obvious exception, and/or	[obvious exception, and/or]	0.0	3	1	1	1
150803	1710	tetrahydrocortisol mg/24h; 1.4+/-0.8)	[tetrahydrocortisol mg/24h; 1.4+/-0.8)]	0.0	3	1	1	1
150804	1710	persistent phosphorylation	[persistent phosphorylation]	0.0	2	1	1	1
150805	1710	suitable position	[suitable position]	0.0	2	1	1	1
150806	1710	differentiation of u-937 leukemia cell	[differentiation of U-937 leukemia cells]	0.0	5	1	1	1
150807	1710	low relative binding affinity the high	[low relative binding affinities the highest]	0.0	6	1	1	1
150808	1710	primary granule protein ecp	[primary granule proteins ECP]	0.0	4	1	1	1
150809	1710	cases, include 3 aml	[cases, including 3 AML]	0.0	4	1	1	1
150810	1710	low weight species of 24	[lower weight species of 24]	0.0	5	1	1	1
150811	1710	rapid modulation of the nt3r	[rapid modulation of the NT3R]	0.0	5	1	1	1
150812	1710	pathway for NF-kappa b activation	[pathways for NF-kappa B activation]	0.0	5	1	1	1
150813	1710	(overall	[(overall]	0.0	1	1	1	1
150814	1710	analysis of myeloid-associated gene	[Analysis of myeloid-associated genes]	0.0	4	1	1	1
150815	1710	direct transluminal angioplasty PTCA	[direct transluminal angioplasty PTCA]	0.0	4	1	1	1
150816	1710	phosphorylation of the epor	[phosphorylation of the EPOR]	0.0	4	1	1	1
150817	1710	role of activator protein	[role of activator protein]	0.0	4	1	1	1
150818	1710	one fresh BL case	[one fresh BL case]	0.0	4	1	1	1
150819	1710	Jak/Stat signal	[Jak/Stat signal]	0.0	2	1	1	1
150820	1710	event in acute inflammation	[event in acute inflammation]	0.0	4	1	1	1
150821	1710	virus isolate	[virus isolates]	0.0	2	1	1	1
150822	1710	gch molecule	[GCH molecules]	0.0	2	1	1	1
150823	1710	indicator of progression	[indicator of progression]	0.0	3	1	1	1
150824	1710	component of lmp1 signal transduction	[component of LMP1 signal transduction]	0.0	5	1	1	1
150825	1710	tnf factor 2	[TNF factor 2]	0.0	3	1	1	1
150826	1710	16-hour incubation	[16-hour incubation]	0.0	2	1	1	1
150827	1710	requirement for c-myb provide explanation	[requirement for c-Myb providing explanation]	0.0	5	1	1	1
150828	1710	least two pan-1 respectively),	[least two Pan-1 respectively),]	0.0	4	1	1	1
150829	1710	immunofluorescence from five human tonsil	[immunofluorescence from five human tonsils]	0.0	5	1	1	1
150830	1710	serotype belong	[serotypes belonging]	0.0	2	1	1	1
150831	1710	follow phorbol ester activation	[following phorbol ester activation]	0.0	4	1	1	1
150832	1710	-endothelial cell interaction	[-endothelial cell interaction]	0.0	3	1	1	1
150833	1710	5-azacytidine	[5-azacytidine]	0.0	1	1	1	1
150834	1710	subsequent transfection	[subsequent transfection]	0.0	2	1	1	1
150835	1710	pharmacological (high turnover) property identical	[pharmacological (high turnover) properties identical]	0.0	5	1	1	1
150836	1710	region of clone	[region of clone]	0.0	3	1	1	1
150837	1710	only by a enzyme-linked assay	[only by an enzyme-linked assay]	0.0	5	1	1	1
150838	1710	tsh receptor tsh-r	[TSH receptor TSH-R]	0.0	3	1	1	1
150839	1710	immune receptor	[immune receptors]	0.0	2	1	1	1
150840	1710	species (of 110	[species (of 110]	0.0	3	1	1	1
150841	1710	high expression level	[high expression level]	0.0	3	1	1	1
150842	1710	TNF resistance	[TNF resistance]	0.0	2	1	1	1
150843	1710	arm of chromosome 5	[arm of chromosome 5]	0.0	4	1	1	1
150844	1710	create a proline -rich carboxy terminus	[creating a proline -rich carboxy terminus]	0.0	6	1	1	1
150845	1710	rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8)	[rearrangement beta,19-epoxypregn-5-ene-4,20-dione (8)]	0.0	3	1	1	1
150846	1710	two antibody specific for the conformer	[two antibodies specific for the conformers]	0.0	6	1	1	1
150847	1710	dose (20 ng/ml)	[dose (20 ng/ml)]	0.0	3	1	1	1
150848	1710	very little activation of ap-1	[very little activation of AP-1]	0.0	5	1	1	1
150849	1710	Furthermore, introduction in mel cell	[Furthermore, introduction in MEL cells]	0.0	5	1	1	1
150850	1710	arm of chromosome 1	[arm of chromosome 1]	0.0	4	1	1	1
150851	1710	the/thf (0.24; alpha thf/thf n:	[THE/THF (0.24; alpha THF/THF N:]	0.0	5	1	1	1
150852	1710	70 residue	[70 residues]	0.0	2	1	1	1
150853	1710	minimal transactivation	[minimal transactivation]	0.0	2	1	1	1
150854	1710	treatment with m all-tran acid RA	[treatment with M all-trans acid RA]	0.0	6	1	1	1
150855	1710	IgE germline	[IgE germline]	0.0	2	1	1	1
150856	1710	Ca2+ signal	[Ca2+ signals]	0.0	2	1	1	1
150857	1710	presence of transcriptional activation motif	[presence of transcriptional activation motifs]	0.0	5	1	1	1
150858	1710	high potency glucocorticoid	[high potency glucocorticoid]	0.0	3	1	1	1
150859	1710	importance of the aCT-1-activating region promoter.	[importance of the ACT-1-activating region promoter.]	0.0	6	1	1	1
150860	1710	moreover, tar -independent transactivation	[Moreover, TAR -independent transactivation]	0.0	4	1	1	1
150861	1710	spleen formation in mouse	[spleen formation in mice]	0.0	4	1	1	1
150862	1710	distinguish carrier in familial androgen resistance	[distinguishing carriers in familial androgen resistance]	0.0	6	1	1	1
150863	1710	formation of cap	[formation of caps]	0.0	3	1	1	1
150864	1710	erythroid line	[erythroid lines]	0.0	2	1	1	1
150865	1710	Thrombopoietin the regulator of platelet production	[Thrombopoietin the regulator of platelet production]	0.0	6	1	1	1
150866	1710	normal eosinophil	[normal eosinophils]	0.0	2	1	1	1
150867	1710	consensus c/ebp site	[consensus C/EBP sites]	0.0	3	1	1	1
150868	1710	bzip transcription factor as candidate	[bZIP transcription factors as candidates]	0.0	5	1	1	1
150869	1710	presence of complex	[presence of complexes]	0.0	3	1	1	1
150870	1710	il-2 induction cytoplasmic mrna	[IL-2 induction cytoplasmic mRNA]	0.0	4	1	1	1
150871	1710	tafii105	[TAFII105]	0.0	1	1	1	1
150872	1710	myeloid patient cases)	[myeloid patients cases)]	0.0	3	1	1	1
150873	1710	15 woman	[15 women]	0.0	2	1	1	1
150874	1710	existence of er variant	[existence of ER variants]	0.0	4	1	1	1
150875	1710	primary reservoir	[primary reservoir]	0.0	2	1	1	1
150876	1710	human leukemia cell with 12-o-tetradecanoylphorbol-13-acetate	[human leukemia cells with 12-O-tetradecanoylphorbol-13-acetate]	0.0	5	1	1	1
150877	1710	specific antibody in from carrier	[specific antibodies in from carriers]	0.0	5	1	1	1
150878	1710	form heterodimer with hormone receptor	[forming heterodimers with hormone receptors]	0.0	5	1	1	1
150879	1710	condition of inflammatory response	[conditions of inflammatory response]	0.0	4	1	1	1
150880	1710	CD8 T	[CD8 T]	0.0	2	1	1	1
150881	1710	gc cell	[GC cells]	0.0	2	1	1	1
150882	1710	synthesis of cytokine mrna	[synthesis of cytokine mRNA]	0.0	4	1	1	1
150883	1710	domain for activation	[domains for activation]	0.0	3	1	1	1
150884	1710	expression in normal human T cell	[Expression in normal human T cells]	0.0	6	1	1	1
150885	1710	ng to 50	[ng to 50]	0.0	3	1	1	1
150886	1710	kinases, ikk1	[kinases, IKK1]	0.0	2	1	1	1
150887	1710	Epstein-Barr virus a human gamma-herpesvirus	[Epstein-Barr virus a human gamma-herpesvirus]	0.0	5	1	1	1
150888	1710	factor tafii250	[factor TAFII250]	0.0	2	1	1	1
150889	1710	family of transcriptional proteins,	[family of transcriptional proteins,]	0.0	4	1	1	1
150890	1710	activity of the region	[activity of the region]	0.0	4	1	1	1
150891	1710	endogenous ifn-beta	[endogenous IFN-beta]	0.0	2	1	1	1
150892	1710	IL-2 IFNgamma signal	[IL-2 IFNgamma signaling]	0.0	3	1	1	1
150893	1710	mouse delta	[mouse delta]	0.0	2	1	1	1
150894	1710	change consistent	[changes consistent]	0.0	2	1	1	1
150895	1710	hiv-1 viral burden	[HIV-1 viral burden]	0.0	3	1	1	1
150896	1710	role of interleukin-11	[role of interleukin-11]	0.0	3	1	1	1
150897	1710	leucine zipper-like	[leucine zipper-like]	0.0	2	1	1	1
150898	1710	sex comb	[sex combs]	0.0	2	1	1	1
150899	1710	normal leukocyte	[normal leukocytes]	0.0	2	1	1	1
150900	1710	mechanism underlie the il-7 effect	[mechanisms underlying the IL-7 effect]	0.0	5	1	1	1
150901	1710	transformation of rodent cell	[transformation of rodent cells]	0.0	4	1	1	1
150902	1710	tranfection	[tranfection]	0.0	1	1	1	1
150903	1710	sequence of the ion	[sequence of the ion]	0.0	4	1	1	1
150904	1710	activation of the mitogen-activated kinase	[activation of the mitogen-activated kinase]	0.0	5	1	1	1
150905	1710	essential positive element	[essential positive element]	0.0	3	1	1	1
150906	1710	disparate effect	[disparate effects]	0.0	2	1	1	1
150907	1710	convert the transactivation	[converting the transactivation]	0.0	3	1	1	1
150908	1710	cd45ra+ T cell subset	[CD45RA+ T cell subsets]	0.0	4	1	1	1
150909	1710	expression of c-fo in blood lymphocyte	[Expression of c-fos in blood lymphocytes]	0.0	6	1	1	1
150910	1710	direct, receptor-mediated effect	[direct, receptor-mediated effects]	0.0	3	1	1	1
150911	1710	use a stock	[using a stock]	0.0	3	1	1	1
150912	1710	b cell lineage-specific activator protein	[B cell lineage-specific activator protein]	0.0	5	1	1	1
150913	1710	development of a immune system	[development of an immune system]	0.0	5	1	1	1
150914	1710	adhesion,	[adhesion,]	0.0	1	1	1	1
150915	1710	enhancement of immunodeficiency virus replication	[Enhancement of immunodeficiency virus replication]	0.0	5	1	1	1
150916	1710	same mobility (approximately 120 kd)	[same mobility (approximately 120 kD)]	0.0	5	1	1	1
150917	1710	transcriptional activity reticuloendotheliosis virus	[transcriptional activity reticuloendotheliosis virus]	0.0	4	1	1	1
150918	1710	binding of the homodimeric protein	[binding of the homodimeric proteins]	0.0	5	1	1	1
150919	1710	block of gene	[block of genes]	0.0	3	1	1	1
150920	1710	icam-1 on endothelium	[ICAM-1 on endothelium]	0.0	3	1	1	1
150921	1710	regulatory element act	[regulatory elements acting]	0.0	3	1	1	1
150922	1710	form diabete maturity-onset diabete	[forms diabetes maturity-onset diabetes]	0.0	4	1	1	1
150923	1710	variance with the transfection results.	[variance with the transfection results.]	0.0	5	1	1	1
150924	1710	coregulation	[coregulation]	0.0	1	1	1	1
150925	1710	carcinoma HeLa	[carcinoma HeLa]	0.0	2	1	1	1
150926	1710	human Burkitt' lymphoma b cell line	[human Burkitt's lymphoma B cell lines]	0.0	6	1	1	1
150927	1710	approximately 31 kda	[approximately 31 kDa]	0.0	3	1	1	1
150928	1710	downregulate the activity in ecv304 cell	[downregulating the activity in ECV304 cells]	0.0	6	1	1	1
150929	1710	action on il-2r alpha transcription	[action on IL-2R alpha transcription]	0.0	5	1	1	1
150930	1710	immunoglobulin-like transcript-2/leukocyte ig-like receptor	[immunoglobulin-like transcript-2/leukocyte Ig-like receptor]	0.0	4	1	1	1
150931	1710	weight gain +/- 2	[weight gain +/- 2]	0.0	4	1	1	1
150932	1710	ebf binding site	[EBF binding sites]	0.0	3	1	1	1
150933	1710	phosphatase-positive cell from monocyte	[phosphatase-positive cells from monocytes]	0.0	4	1	1	1
150934	1710	il-2r alpha gene transcription	[IL-2R alpha gene transcription]	0.0	4	1	1	1
150935	1710	CMPD1 /sra1 patient	[CMPD1 /SRA1 patient]	0.0	3	1	1	1
150936	1710	steroid effect	[steroid effects]	0.0	2	1	1	1
150937	1710	interferon alpha ifn(alpha)	[interferon alpha IFN(alpha)]	0.0	3	1	1	1
150938	1710	differentiation of the neuroblastoma cell line	[differentiation of the neuroblastoma cell lines]	0.0	6	1	1	1
150939	1710	monoclonal model	[monoclonal model]	0.0	2	2	2	1
150940	1710	apoptotic cell body	[apoptotic cell bodies]	0.0	3	1	1	1
150941	1710	transactivator whereas, in the presence	[transactivator whereas, in the presence]	0.0	5	1	1	1
150942	1710	Epstein-Barr virus EBV protein	[Epstein-Barr virus EBV proteins]	0.0	4	1	1	1
150943	1710	glucocorticoid receptor changes,	[glucocorticoid receptor changes,]	0.0	3	1	1	1
150944	1710	bloodstream	[bloodstream]	0.0	1	1	1	1
150945	1710	oligonucleotide corresponding to the binding site	[oligonucleotides corresponding to the binding sites]	0.0	6	1	1	1
150946	1710	JAK -stat	[JAK -STAT]	0.0	2	1	1	1
150947	1710	regard, intracellular level	[regard, intracellular levels]	0.0	3	1	1	1
150948	1710	concentration dependent between ng/ml	[concentration dependent between ng/ml]	0.0	4	1	1	1
150949	1710	region of this promoter	[region of this promoter]	0.0	4	1	1	1
150950	1710	use conditions, complex	[Using conditions, complexes]	0.0	3	1	1	1
150951	1710	-Aiolos	[-Aiolos]	0.0	1	1	1	1
150952	1710	ganglioside in supernatant	[gangliosides in supernatants]	0.0	3	1	1	1
150953	1710	receptor gr number	[receptor GR number]	0.0	3	1	1	1
150954	1710	presence of tnf-alpha antibody	[presence of TNF-alpha antibodies]	0.0	4	1	1	1
150955	1710	x-linked muscular atrophy	[X-linked muscular atrophy]	0.0	3	1	1	1
150956	1710	potential utility	[potential utility]	0.0	2	1	1	1
150957	1710	category Va	[Categories Va]	0.0	2	1	1	1
150958	1710	multiple intracellular protein eventually lead	[multiple intracellular proteins eventually leading]	0.0	5	1	1	1
150959	1710	accumulation a finding	[accumulation a finding]	0.0	3	1	1	1
150960	1710	form of mzf protein	[form of MZF protein]	0.0	4	1	1	1
150961	1710	two site at position	[two sites at positions]	0.0	4	1	1	1
150962	1710	eicosanoid synthesis in material	[eicosanoid synthesis in material]	0.0	4	1	1	1
150963	1710	five major DNase-I hypersensitive site	[Five major DNase-I hypersensitive sites]	0.0	5	1	1	1
150964	1710	(gpi-1)	[(GPI-1)]	0.0	1	1	1	1
150965	1710	gene product related	[gene product related]	0.0	3	1	1	1
150966	1710	(ra)	[(RA)]	0.0	1	1	1	1
150967	1710	expression of CTCF during differentiation	[expression of CTCF during differentiation]	0.0	5	1	1	1
150968	1710	mutation in the repeat	[mutations in the repeat]	0.0	4	1	1	1
150969	1710	5-60 mg	[5-60 mg]	0.0	2	1	1	1
150970	1710	CREB isoform of the element modulator	[CREB isoforms of the element modulator]	0.0	6	1	1	1
150971	1710	x-linked spinal muscular atrophy a form	[X-linked spinal muscular atrophy an form]	0.0	6	1	1	1
150972	1710	overexpress (h) irak	[overexpressing (h) IRAK]	0.0	3	1	1	1
150973	1710	interferon (ifn) regulatory factor	[interferon (IFN) regulatory factors]	0.0	4	1	1	1
150974	1710	study cytokine regulation in monocyte	[studying cytokine regulation in monocytes]	0.0	5	1	1	1
150975	1710	screening of a library	[Screening of a library]	0.0	4	1	1	1
150976	1710	annealing	[annealing]	0.0	1	1	1	1
150977	1710	requirement for CD28	[requirement for CD28]	0.0	3	1	1	1
150978	1710	trigger for a sequence	[trigger for a sequence]	0.0	4	1	1	1
150979	1710	mineralocorticoid receptor on human leukocyte	[mineralocorticoid receptors on human leukocytes]	0.0	5	1	1	1
150980	1710	activator 5a	[activator 5a]	0.0	2	1	1	1
150981	1710	murine Th1 th2 clone	[murine Th1 Th2 clones]	0.0	4	1	1	1
150982	1710	il-1beta receptor type	[IL-1beta receptor type]	0.0	3	1	1	1
150983	1710	pattern of BZLF1 expression	[pattern of BZLF1 expression]	0.0	4	1	1	1
150984	1710	different structural domain	[different structural domains]	0.0	3	1	1	1
150985	1710	non-genomic action	[non-genomic actions]	0.0	2	1	1	1
150986	1710	(rt)-pcr	[(RT)-PCR]	0.0	1	1	1	1
150987	1710	isolation of a transcript	[isolation of an transcript]	0.0	4	1	1	1
150988	1710	novel concept	[novel concept]	0.0	2	1	1	1
150989	1710	gene topography independent	[gene topography independent]	0.0	3	1	1	1
150990	1710	processing rate	[processing rate]	0.0	2	1	1	1
150991	1710	level of the factor ap-1	[levels of the factor AP-1]	0.0	5	1	1	1
150992	1710	complex with nuclear protein	[complexes with nuclear proteins]	0.0	4	1	1	1
150993	1710	melanoma study	[melanoma study]	0.0	2	1	1	1
150994	1710	cd27+ b	[CD27+ B]	0.0	2	1	1	1
150995	1710	in-vitro transcription/translation	[In-vitro transcription/translation]	0.0	2	1	1	1
150996	1710	role for VitD3	[role for VitD3]	0.0	3	1	1	1
150997	1710	development of drug	[development of drugs]	0.0	3	1	1	1
150998	1710	comparable event related	[comparable events related]	0.0	3	1	1	1
150999	1710	high radiosensitivity of cell carcinoma	[high radiosensitivity of cell carcinomas]	0.0	5	1	1	1
151000	1710	importance of the colon	[importance of the colon]	0.0	4	1	1	1
151001	1710	various length of the 5' sequence	[various lengths of the 5' sequence]	0.0	6	1	1	1
151002	1710	putative hematopoietic stem cell	[putative hematopoietic stem cells]	0.0	4	1	1	1
151003	1710	case of syndrome	[cases of syndrome]	0.0	3	1	1	1
151004	1710	treatment tur cell	[Treatment TUR cells]	0.0	3	1	1	1
151005	1710	multiple t-cell gene	[multiple T-cell genes]	0.0	3	1	1	1
151006	1710	mobility group protein	[mobility group protein]	0.0	3	1	1	1
151007	1710	distinct isoform of stat5	[distinct isoforms of STAT5]	0.0	4	1	1	1
151008	1710	B) enhancer binding protein	[B) enhancer binding proteins]	0.0	4	1	1	1
151009	1710	adhesion molecule-1 ICAM-1 gene	[adhesion molecule-1 ICAM-1 gene]	0.0	4	1	1	1
151010	1710	injury in rat lung	[injury in rat lung]	0.0	4	1	1	1
151011	1710	two male sibling	[two male siblings]	0.0	3	1	1	1
151012	1710	express the Notch1/TAN-1 receptor	[expressing the Notch1/TAN-1 receptor]	0.0	4	1	1	1
151013	1710	blood from donor	[blood from donors]	0.0	3	1	1	1
151014	1710	model in the guinea pig	[model in the guinea pig]	0.0	5	1	1	1
151015	1710	epo-r mrna	[Epo-R mRNA]	0.0	2	1	1	1
151016	1710	binding of NF-kappa Bp65 Rel A	[binding of NF-kappa Bp65 Rel A]	0.0	6	1	1	1
151017	1710	pebp2 protein (s)	[PEBP2 protein (s)]	0.0	3	1	1	1
151018	1710	(also in human arterial endothelial cell	[(also in human arterial endothelial cells]	0.0	6	1	1	1
151019	1710	however a strong association	[however a strong association]	0.0	4	1	1	1
151020	1710	three major class gene	[three major class genes]	0.0	4	1	1	1
151021	1710	eiconsanoid thromboxane a2 b4	[eiconsanoids thromboxane A2 B4]	0.0	4	1	1	1
151022	1710	bipartite nuclear localization signal (89	[bipartite nuclear localization signal (89]	0.0	5	1	1	1
151023	1710	uterus tumour	[uterus tumour]	0.0	2	2	2	1
151024	1710	provide a basis for a assay	[providing a basis for a assay]	0.0	6	1	1	1
151025	1710	female aged years,	[females aged years,]	0.0	3	1	1	1
151026	1710	15 minute 1)	[15 minutes 1)]	0.0	3	1	1	1
151027	1710	mediator(s)	[mediator(s)]	0.0	1	1	1	1
151028	1710	ehrlichiosis response	[ehrlichiosis responses]	0.0	2	1	1	1
151029	1710	contact activation	[contact activation]	0.0	2	1	1	1
151030	1710	iron result in activation	[iron resulting in activation]	0.0	4	1	1	1
151031	1710	finding related	[finding related]	0.0	2	1	1	1
151032	1710	part of the R- enhancer	[part of the R- enhancer]	0.0	5	1	1	1
151033	1710	activation of nfatp	[activation of NFATp]	0.0	3	1	1	1
151034	1710	bone mineral density	[bone mineral density]	0.0	3	1	1	1
151035	1710	replication of E1a- ad vector	[replication of E1a- Ad vectors]	0.0	5	1	1	1
151036	1710	use a nf-kappa b probe homologous	[using a NF-kappa B probe homologous]	0.0	6	1	1	1
151037	1710	activation of 2 gene	[activation of 2 gene]	0.0	4	1	1	1
151038	1710	site 2	[site 2]	0.0	2	1	1	1
151039	1710	1, D3 receptor	[1, D3 receptor]	0.0	3	1	1	1
151040	1710	two distinct dna-binding complex	[two distinct DNA-binding complexes]	0.0	4	1	1	1
151041	1710	acid 9-cis-ra	[acid 9-cis-RA]	0.0	2	1	1	1
151042	1710	prevent the expression of gene	[preventing the expression of genes]	0.0	5	1	1	1
151043	1710	81 bp EBNA2 region	[81 bp EBNA2 region]	0.0	4	1	1	1
151044	1710	near level	[near levels]	0.0	2	1	1	1
151045	1710	use progenitor cell HPC	[using progenitor cells HPC]	0.0	4	1	1	1
151046	1710	IL-13 a cytokine	[IL-13 a cytokine]	0.0	3	1	1	1
151047	1710	macrophage factor in human monocyte	[macrophage factor in human monocytes]	0.0	5	1	1	1
151048	1710	cleavage a negative regulator	[cleavage a negative regulator]	0.0	4	1	1	1
151049	1710	mechanism of generation	[mechanism of generation]	0.0	3	1	1	1
151050	1710	DLCL the relevant form	[DLCL the relevant form]	0.0	4	1	1	1
151051	1710	lymphoma plasmacytoid AIDS iblp	[lymphoma plasmacytoid AIDS IBLP]	0.0	4	1	1	1
151052	1710	acute myeloid patient aml	[acute myeloid patients AML]	0.0	4	1	1	1
151053	1710	demonstrate a vitro substrate	[demonstrating an vitro substrate]	0.0	4	1	1	1
151054	1710	benefit activation	[b activation]	0.0	2	1	1	1
151055	1710	calcium-dependent, modification of NF-ATp	[calcium-dependent, modification of NF-ATp]	0.0	4	1	1	1
151056	1710	action of acid on human hematopoiesis	[action of acid on human hematopoiesis]	0.0	6	1	1	1
151057	1710	dehydroepiandrosterone modulation	[Dehydroepiandrosterone modulation]	0.0	2	1	1	1
151058	1710	granulocyte-colony-stimulating factor receptor mrna	[granulocyte-colony-stimulating factor receptor mRNA]	0.0	4	1	1	1
151059	1710	m(r).	[M(r).]	0.0	1	1	1	1
151060	1710	tissue malt lymphoma (19 of 45	[tissue MALT lymphoma (19 of 45]	0.0	6	1	1	1
151061	1710	NGFI-A	[NGFI-A]	0.0	1	1	1	1
151062	1710	fourth, extensive purification	[Fourth, extensive purification]	0.0	3	1	1	1
151063	1710	oxygen intermediate in living cells,	[oxygen intermediates in living cells,]	0.0	5	1	1	1
151064	1710	effect on the LTR	[effects on the LTR]	0.0	4	1	1	1
151065	1710	variant translocation characterization	[variant translocation characterization]	0.0	3	1	1	1
151066	1710	CD4 monoclonal antibody	[CD4 monoclonal antibodies]	0.0	3	1	1	1
151067	1710	sequence of biotin-	[sequences of biotin-]	0.0	3	1	1	1
151068	1710	nuclear translocation of NF-kB	[nuclear translocation of NF-kB]	0.0	4	1	1	1
151069	1710	purification by cycle	[purification by cycles]	0.0	3	1	1	1
151070	1710	75-kDa signal protein of function.	[75-kDa signaling protein of function.]	0.0	5	1	1	1
151071	1710	maintenance of constitutive nf-kappa b	[maintenance of constitutive NF-kappa B]	0.0	5	1	1	1
151072	1710	control day	[control day]	0.0	2	1	1	1
151073	1710	patient with chronic leukaemia CLL	[patients with chronic leukaemia CLL]	0.0	5	1	1	1
151074	1710	cyclosporin a-treated b	[cyclosporin A-treated B]	0.0	3	1	1	1
151075	1710	binding to four icss	[binding to four ICSs]	0.0	4	1	1	1
151076	1710	erythroid precursor cell	[erythroid precursor cells]	0.0	3	1	1	1
151077	1710	polyclonal tf antibody	[polyclonal TF antibody]	0.0	3	1	1	1
151078	1710	protein x box protein	[protein X box protein]	0.0	4	1	1	1
151079	1710	human immunodeficiency virus (HIV) type	[human immunodeficiency virus (HIV) type]	0.0	5	1	1	1
151080	1710	768-bp upstream region	[768-bp upstream region]	0.0	3	1	1	1
151081	1710	proportion of immature cell	[proportion of immature cells]	0.0	4	1	1	1
151082	1710	three, DNA variation	[three, DNA variations]	0.0	3	1	1	1
151083	1710	cyclophosphamide	[cyclophosphamide]	0.0	1	1	1	1
151084	1710	(ic50 of 10 ng/ml),	[(IC50 of 10 ng/ml),]	0.0	4	1	1	1
151085	1710	tsg101 deletion	[TSG101 deletions]	0.0	2	1	1	1
151086	1710	adenovirus type genome	[adenovirus type genome]	0.0	3	2	2	1
151087	1710	binding in response	[binding in response]	0.0	3	1	1	1
151088	1710	component(s)	[component(s)]	0.0	1	1	1	1
151089	1710	broad range of proinflammatory cytokine	[broad range of proinflammatory cytokines]	0.0	5	1	1	1
151090	1710	second positive regulatory element	[second positive regulatory element]	0.0	4	1	1	1
151091	1710	transient pattern	[transient pattern]	0.0	2	1	1	1
151092	1710	mcr in woman young	[MCR in women younger]	0.0	4	1	1	1
151093	1710	immunodeficiency virus type hiv- replication	[immunodeficiency virus type HIV- replication]	0.0	5	1	1	1
151094	1710	human interleukin-3 gene	[human interleukin-3 gene]	0.0	3	1	1	1
151095	1710	induction infection of myelomonoblastic cell	[Induction infection of myelomonoblastic cells]	0.0	5	1	1	1
151096	1710	matrix metalloproteinase factor ap-1	[matrix metalloproteinase factor AP-1]	0.0	4	1	1	1
151097	1710	subset in the PB	[subsets in the PB]	0.0	4	1	1	1
151098	1710	increase of tad-a activity,	[increase of TAD-A activity,]	0.0	4	1	1	1
151099	1710	promoters, anf-e2 promoter	[promoters, aNF-E2 promoter]	0.0	3	1	1	1
151100	1710	exclusively cytoplasmic 105k precursor	[exclusively cytoplasmic 105K precursor]	0.0	4	1	1	1
151101	1710	activation of different signal transduction pathway	[activation of different signal transduction pathways]	0.0	6	1	1	1
151102	1710	maintain homeostasis	[maintaining homeostasis]	0.0	2	1	1	1
151103	1710	cell of acute leukemia APL	[cells of acute leukemia APL]	0.0	5	1	1	1
151104	1710	ras in anti- c5b-9 immunoprecipitate	[Ras in anti- C5b-9 immunoprecipitates]	0.0	5	1	1	1
151105	1710	4-trifluoromethyl salicylate derivative	[4-trifluoromethyl salicylate derivatives]	0.0	3	1	1	1
151106	1710	mass of this factor	[mass of these factors]	0.0	4	1	1	1
151107	1710	association with plasma renin activity	[associations with plasma renin activity]	0.0	5	1	1	1
151108	1710	hepatitis b infection	[hepatitis B infection]	0.0	3	1	1	1
151109	1710	association with ssb reactivity	[association with SSB reactivity]	0.0	4	1	1	1
151110	1710	act as positive transcription factor	[acting as positive transcription factors]	0.0	5	1	1	1
151111	1710	TFIIIA zinc-finger consensus	[TFIIIA zinc-finger consensus]	0.0	3	1	1	1
151112	1710	contain 1.3	[containing 1.3]	0.0	2	1	1	1
151113	1710	micromol/L; gg	[micromol/L; GG]	0.0	2	1	1	1
151114	1710	NF-AT(Rel) family member	[NF-AT(Rel) family members]	0.0	3	1	1	1
151115	1710	-contain leukocyte protein of 76 kD	[-containing leukocyte protein of 76 kD]	0.0	6	1	1	1
151116	1710	evidence for a beta-(1,3)-glucan receptor	[evidence for a beta-(1,3)-glucan receptor]	0.0	5	1	1	1
151117	1710	stably overexpress hIRAK a weak activation	[stably overexpressing hIRAK a weak activation]	0.0	6	1	1	1
151118	1710	30% diffuse b-cell lymphoma	[30% diffuse B-cell lymphomas]	0.0	4	1	1	1
151119	1710	serum-contain small colony	[serum-containing small colonies]	0.0	3	1	1	1
151120	1710	wide range of biological effect	[wide range of biological effects]	0.0	5	1	1	1
151121	1710	role in pathogenesis.	[role in pathogenesis.]	0.0	3	1	1	1
151122	1710	trans- gene expression	[trans- gene expression]	0.0	3	1	1	1
151123	1710	ig/tcr gene	[Ig/TcR gene]	0.0	2	1	1	1
151124	1710	role for cell development	[role for cell development]	0.0	4	1	1	1
151125	1710	stimulus lam	[stimuli LAM]	0.0	2	1	1	1
151126	1710	time-dependent binding monoclonal antibody specific	[time-dependent binding monoclonal antibodies specific]	0.0	5	1	1	1
151127	1710	icam-1 antibody	[ICAM-1 antibodies]	0.0	2	1	1	1
151128	1710	blood mononuclear cell of adult	[blood mononuclear cells of adults]	0.0	5	1	1	1
151129	1710	gain insight	[gaining insight]	0.0	2	1	1	1
151130	1710	nf-at factor a sequence	[NF-AT factor a sequence]	0.0	4	1	1	1
151131	1710	feature with this functional datum	[features with these functional data.]	0.0	5	1	1	1
151132	1710	main source for mediator	[main source for mediators]	0.0	4	1	1	1
151133	1710	oxidant stress lead to migration	[oxidant stress leading to migration]	0.0	5	1	1	1
151134	1710	increase in RXR alpha	[increase in RXR alpha]	0.0	4	1	1	1
151135	1710	mature blood cell	[mature blood cells]	0.0	3	1	1	1
151136	1710	exhibit rapid change	[exhibiting rapid changes]	0.0	3	1	1	1
151137	1710	efficacy in the treatment	[efficacy in the treatment]	0.0	4	1	1	1
151138	1710	evidence for a pathway distinct	[evidence for an pathway distinct]	0.0	5	1	1	1
151139	1710	cytosolic-anchoring protein	[cytosolic-anchoring protein]	0.0	2	1	1	1
151140	1710	rest ml-1 cell	[resting ML-1 cells]	0.0	3	1	1	1
151141	1710	42 different gene	[42 different genes]	0.0	3	1	1	1
151142	1710	additional mechanism for therapeutic effect	[additional mechanism for therapeutic effects]	0.0	5	1	1	1
151143	1710	micromol/L; dg	[micromol/L; DG]	0.0	2	1	1	1
151144	1710	three latent membrane protein	[three latent membrane proteins]	0.0	4	1	1	1
151145	1710	blast from patient with leukaemia	[blasts from patients with leukaemia]	0.0	5	1	1	1
151146	1710	contribution of major product	[contribution of major products]	0.0	4	1	1	1
151147	1710	patient of age]	[patients of age]]	0.0	3	1	1	1
151148	1710	flank element	[flanking elements]	0.0	2	1	1	1
151149	1710	control (60.7	[controls (60.7]	0.0	2	1	1	1
151150	1710	semiquantitative competitive hybridization assay	[semiquantitative competitive hybridization assay]	0.0	4	1	1	1
151151	1710	(t4)	[(T4)]	0.0	1	1	1	1
151152	1710	monocyte peptide-1 a chemokine	[monocyte peptide-1 a chemokine]	0.0	4	1	1	1
151153	1710	myc protein	[Myc protein]	0.0	2	1	1	1
151154	1710	proliferation index	[Proliferation index]	0.0	2	1	1	1
151155	1710	include the fatty acid binding protein	[including the fatty acid binding protein]	0.0	6	1	1	1
151156	1710	sequencing of the viral genome	[sequencing of the viral genomes]	0.0	5	1	1	1
151157	1710	especially in adult patient	[especially in adult patients]	0.0	4	1	1	1
151158	1710	fura-2-loaded T cell	[Fura-2-loaded T cells]	0.0	3	1	1	1
151159	1710	gi/go	[Gi/Go]	0.0	1	1	1	1
151160	1710	cell from peripheral blood	[cells from peripheral blood]	0.0	4	1	1	1
151161	1710	protein kinase c lead	[protein kinase C leading]	0.0	4	1	1	1
151162	1710	(rs)	[(RS)]	0.0	1	1	1	1
151163	1710	level of virus expression	[levels of virus expression]	0.0	4	1	1	1
151164	1710	tissue undergo termination of uterine pregnancy	[Tissues undergoing termination of uterine pregnancy]	0.0	6	1	1	1
151165	1710	selective activation include NF-kappa b	[selective activation including NF-kappa B]	0.0	5	1	1	1
151166	1710	value of plasma cortisol	[values of plasma cortisol]	0.0	4	1	1	1
151167	1710	candidate gene for ags hepatic factor	[candidate genes for AGS hepatic factor]	0.0	6	1	1	1
151168	1710	biological effect related	[biological effects related]	0.0	3	1	1	1
151169	1710	modulate calcium in smooth muscle cell	[modulating calcium in smooth muscle cells]	0.0	6	1	1	1
151170	1710	interaction with distinct cell-specific coactivator	[interactions with distinct cell-specific coactivators]	0.0	5	1	1	1
151171	1710	e-box motif	[E-box motif]	0.0	2	1	1	1
151172	1710	factor to 10(-6) m elevation	[factor to 10(-6) M elevation]	0.0	5	1	1	1
151173	1710	acid similar	[acid similar]	0.0	2	1	1	1
151174	1710	caspase-3 substrate	[caspase-3 substrates]	0.0	2	1	1	1
151175	1710	contact with parental	[contact with parental]	0.0	3	1	1	1
151176	1710	mutagenesis analysis with traf binding sequence	[mutagenesis analyses with TRAF binding sequences]	0.0	6	1	1	1
151177	1710	change follow treatment	[change following treatment]	0.0	3	1	1	1
151178	1710	results, together	[results, together]	0.0	2	1	1	1
151179	1710	dissociation rate	[dissociation rate]	0.0	2	1	1	1
151180	1710	beta-phorbol 13-acetate PMA	[beta-phorbol 13-acetate PMA]	0.0	3	1	1	1
151181	1710	5-day monocyte-derived macrophage	[5-day monocyte-derived macrophages]	0.0	3	1	1	1
151182	1710	level of type EBS	[levels of type EBS]	0.0	4	1	1	1
151183	1710	cross-specy effectiveness	[cross-species effectiveness]	0.0	2	1	1	1
151184	1710	significant change of glucocorticoid binding	[significant changes of glucocorticoid binding]	0.0	5	1	1	1
151185	1710	important mediator of immunotoxicity	[important mediator of immunotoxicity]	0.0	4	1	1	1
151186	1710	transcription factor otf-2	[transcription factor OTF-2]	0.0	3	1	1	1
151187	1710	regulate adhesion, nf-kappab activation	[regulating adhesion, NF-kappaB activation]	0.0	4	1	1	1
151188	1710	incubation for 72 hour	[Incubation for 72 hours]	0.0	4	1	1	1
151189	1710	the/thf alpha thf/thf (0.35; n:	[THE/THF alpha THF/THF (0.35; N:]	0.0	5	1	1	1
151190	1710	h (viability	[h (viability]	0.0	2	1	1	1
151191	1710	two factor nf-il6 (position	[Two factor NF-IL6 (positions]	0.0	4	1	1	1
151192	1710	immunofluorescence from five tonsil	[immunofluorescence from five tonsils]	0.0	4	1	1	1
151193	1710	multifactorial, involve genetic alteration	[multifactorial, involving genetic alterations]	0.0	4	1	1	1
151194	1710	source of MHC transcript	[source of MHC transcripts]	0.0	4	1	1	1
151195	1710	domain DeltaE	[domain DeltaE]	0.0	2	1	1	1
151196	1710	day with m dexamethasone	[days with M dexamethasone]	0.0	4	1	1	1
151197	1710	permissive state for hiv-1 replication	[permissive state for HIV-1 replication]	0.0	5	1	1	1
151198	1710	carry the NLS	[carrying the NLS]	0.0	3	1	1	1
151199	1710	1) lipid	[1) lipid]	0.0	2	1	1	1
151200	1710	model for ebv entry	[model for EBV entry]	0.0	4	1	1	1
151201	1710	matrix-associated Site IV	[matrix-associated Site IV]	0.0	3	1	1	1
151202	1710	hiv-1 gp41	[HIV-1 gp41]	0.0	2	1	1	1
151203	1710	activation-induced lymphocyte proliferation	[activation-induced lymphocyte proliferation]	0.0	3	1	1	1
151204	1710	agonist binding.	[agonist binding.]	0.0	2	1	1	1
151205	1710	protein in human lymphocyte	[proteins in human lymphocytes]	0.0	4	1	1	1
151206	1710	phenolic, lipid-soluble, chain-breaking antioxidant	[phenolic, lipid-soluble, chain-breaking antioxidants]	0.0	4	1	1	1
151207	1710	bone marrow ec	[bone marrow EC]	0.0	3	1	1	1
151208	1710	domain of GALA.	[domain of GALA.]	0.0	3	1	1	1
151209	1710	magnitude of activation	[magnitude of activation]	0.0	3	1	1	1
151210	1710	addition the physiologic product	[addition the physiologic product]	0.0	4	1	1	1
151211	1710	related protein c/ebp alpha	[related protein C/EBP alpha]	0.0	4	1	1	1
151212	1710	female twin discordant	[female twins discordant]	0.0	3	1	1	1
151213	1710	cell in G0	[cells in G0]	0.0	3	1	1	1
151214	1710	tissue-specific dna-binding protein	[tissue-specific DNA-binding protein]	0.0	3	1	1	1
151215	1710	cd40l b cell	[CD40L B cells]	0.0	3	1	1	1
151216	1710	DNase I hypersensitive site mapping	[DNase I hypersensitive site mapping]	0.0	5	1	1	1
151217	1710	stage of the cycle	[stages of the cycle]	0.0	4	1	1	1
151218	1710	involvement of protein kinase pathway	[Involvement of protein kinase pathways]	0.0	5	1	1	1
151219	1710	induction of proto-oncogene	[Induction of proto-oncogene]	0.0	3	1	1	1
151220	1710	moderate level 2	[moderate levels 2]	0.0	3	1	1	1
151221	1710	Antigenic specificity	[Antigenic specificities]	0.0	2	1	1	1
151222	1710	D.V.Ablashi,	[D.V.Ablashi,]	0.0	1	1	1	1
151223	1710	viral, self ligand by class	[viral, self, ligands by class]	0.0	5	1	1	1
151224	1710	gradient-gel electrophoresis	[gradient-gel electrophoresis]	0.0	2	1	1	1
151225	1710	universal finding in CLL	[universal finding in CLL]	0.0	4	1	1	1
151226	1710	signal to a cytoplasmic domain	[signal to a cytoplasmic domain]	0.0	5	1	1	1
151227	1710	cytokine-stimulated human vein endothelial cell	[cytokine-stimulated human vein endothelial cells]	0.0	5	1	1	1
151228	1710	mediate erythroid cell survival	[mediating erythroid cell survival]	0.0	4	1	1	1
151229	1710	redistribution,	[redistribution,]	0.0	1	1	1	1
151230	1710	membrane signaling,	[membrane signaling,]	0.0	2	1	1	1
151231	1710	TGF-beta 1 modulation	[TGF-beta 1 modulation]	0.0	3	1	1	1
151232	1710	selective modification of lysine	[selective modification of lysine]	0.0	4	1	1	1
151233	1710	glucocorticoid effector mechanism	[glucocorticoid effector mechanism]	0.0	3	1	1	1
151234	1710	protein dimerization domain factor	[protein dimerization domain factor]	0.0	4	1	1	1
151235	1710	subsequently respond	[subsequently responding]	0.0	2	1	1	1
151236	1710	mineralocorticoid antagonist	[mineralocorticoid antagonists]	0.0	2	2	2	1
151237	1710	Ig chain mu e1 site	[Ig chain mu E1 site]	0.0	5	1	1	1
151238	1710	generate a effective immune response	[generating an effective immune response]	0.0	5	1	1	1
151239	1710	backbone vector prpneo-sl3	[backbone vector pRPneo-SL3]	0.0	3	1	1	1
151240	1710	12-o-tetradecanoylphorbol-13-acetate mitogen	[12-O-tetradecanoylphorbol-13-acetate mitogen]	0.0	2	1	1	1
151241	1710	ic50 in the micromolar range).	[IC50s in the micromolar range).]	0.0	5	1	1	1
151242	1710	b cell clone	[B cell clones]	0.0	3	1	1	1
151243	1710	key role in early hematopoiesis	[key role in early hematopoiesis]	0.0	5	1	1	1
151244	1710	304g	[304G]	0.0	1	1	1	1
151245	1710	mutation in murine calcineurin	[mutations in murine calcineurin]	0.0	4	1	1	1
151246	1710	receptor in mononuclear leucocyte	[receptor in mononuclear leucocytes]	0.0	4	1	1	1
151247	1710	myeloid-specific gene encode	[myeloid-specific genes encoding]	0.0	3	1	1	1
151248	1710	transcriptional response include adhesion-dependent pathway	[transcriptional responses including adhesion-dependent pathways]	0.0	5	1	1	1
151249	1710	etoposide cell	[etoposide cells]	0.0	2	1	1	1
151250	1710	family of inhibitory protein	[family of inhibitory proteins]	0.0	4	1	1	1
151251	1710	HLA dqa1*0201/dqb1*0201	[HLA DQA1*0201/DQB1*0201]	0.0	2	1	1	1
151252	1710	acid receptor rar	[acid receptors RARs]	0.0	3	4	4	1
151253	1710	sequence-specific molecule	[Sequence-specific molecules]	0.0	2	1	1	1
151254	1710	characterization of CD40	[Characterization of CD40]	0.0	3	1	1	1
151255	1710	phosphoprotein along with 4 others,	[phosphoproteins along with 4 others,]	0.0	5	1	1	1
151256	1710	transfection study a e(2) line,	[transfection studies an E(2) line,]	0.0	5	1	1	1
151257	1710	anti-CD3 /il-2 activation, level	[anti-CD3 /IL-2 activation, levels]	0.0	4	1	1	1
151258	1710	multiple critical cis element	[multiple critical cis elements]	0.0	4	1	1	1
151259	1710	pattern of genetic transmission	[pattern of genetic transmission]	0.0	4	1	1	1
151260	1710	extract from T lymphocyte	[extracts from T lymphocytes]	0.0	4	1	1	1
151261	1710	novel e2f-1 binding protein	[novel E2F-1 binding protein]	0.0	4	1	1	1
151262	1710	x allele	[X allele]	0.0	2	1	1	1
151263	1710	exhibit dominant-negative activity	[exhibiting dominant-negative activity]	0.0	3	1	1	1
151264	1710	up-regulate gene expression hiv-1 repeat	[up-regulate gene expression HIV-1 repeats]	0.0	5	1	1	1
151265	1710	other cell systems.	[other cell systems.]	0.0	3	1	1	1
151266	1710	binding of isgf3	[binding of ISGF3]	0.0	3	1	1	1
151267	1710	potent immunosuppressive activity low	[potent immunosuppressive activity lower]	0.0	4	1	1	1
151268	1710	endogenous gm-csf mrna	[endogenous GM-CSF mRNA]	0.0	3	1	1	1
151269	1710	H-8, a related kinase inhibitor	[H-8, a related kinase inhibitor]	0.0	5	1	1	1
151270	1710	member of the jun	[members of the jun]	0.0	4	1	1	1
151271	1710	acute exposure to radiation	[acute exposure to radiation]	0.0	4	1	1	1
151272	1710	regulation of expression during cell death	[Regulation of expression during cell death]	0.0	6	1	1	1
151273	1710	Study over the few year	[Studies over the few years]	0.0	5	1	1	1
151274	1710	decisive role in the defense	[decisive role in the defense]	0.0	5	1	1	1
151275	1710	primary carcinoma patient	[primary carcinoma patients]	0.0	3	1	1	1
151276	1710	immune system cell	[immune system cells]	0.0	3	1	1	1
151277	1710	binding of a -specific protein	[binding of a -specific protein]	0.0	5	1	1	1
151278	1710	JCam/ Lck JCam cell	[JCam/ Lck JCam cells]	0.0	4	1	1	1
151279	1710	IBR/F	[IBR/F]	0.0	1	2	2	1
151280	1710	IV-VII	[IV-VII]	0.0	1	1	1	1
151281	1710	Clinical deterioration human immunodeficiency virus type	[Clinical deterioration human immunodeficiency virus type]	0.0	6	1	1	1
151282	1710	leukaemia gene by type	[leukaemia gene by type]	0.0	4	1	1	1
151283	1710	patient with colitis (56.1 51.6	[patients with colitis (56.1 51.6]	0.0	5	1	1	1
151284	1710	two AUG codon	[two AUG codons]	0.0	3	1	1	1
151285	1710	even in the absence of viral	[even in the absence of viral]	0.0	6	1	1	1
151286	1710	radiation in the dose range	[radiation in the dose range]	0.0	5	1	1	1
151287	1710	protein products, p27rex /p21rex	[protein products, p27rex /p21rex]	0.0	4	1	1	1
151288	1710	immediate transactivator	[immediate transactivator]	0.0	2	1	1	1
151289	1710	step for endotoxic effect	[step for endotoxic effects]	0.0	4	1	1	1
151290	1710	potential alpha-helical protein segment	[potential alpha-helical protein segments]	0.0	4	1	1	1
151291	1710	presence of IFN-alpha	[presence of IFN-alpha]	0.0	3	1	1	1
151292	1710	anti-VLA-5	[anti-VLA-5]	0.0	1	1	1	1
151293	1710	+/- 16	[+/- 16]	0.0	2	1	1	1
151294	1710	frequency of nfkappab activation	[frequency of NFkappaB activation]	0.0	4	1	1	1
151295	1710	signal transduction abnormality in T lymphocyte	[Signal transduction abnormalities in T lymphocytes]	0.0	6	1	1	1
151296	1710	survival of the allograft	[survival of the allograft]	0.0	4	1	1	1
151297	1710	hypo eu	[hypo eu]	0.0	2	1	1	1
151298	1710	phagocyte in vitro	[phagocytes in vitro]	0.0	3	1	1	1
151299	1710	activation in blood monocyte	[Activation in blood monocytes]	0.0	4	1	1	1
151300	1710	mechanism contribute to response to therapy	[mechanisms contributing to response to therapy]	0.0	6	1	1	1
151301	1710	effect of ls mutation	[effects of LS mutations]	0.0	4	1	1	1
151302	1710	less than 0.05, p 0.01	[less than 0.05, P 0.01]	0.0	5	1	1	1
151303	1710	unique region contain direct repeat	[unique region containing direct repeats]	0.0	5	1	1	1
151304	1710	cell gcr	[cell GCR]	0.0	2	1	1	1
151305	1710	hiv-1 transmembrane glycoprotein	[HIV-1 transmembrane glycoprotein]	0.0	3	1	1	1
151306	1710	transcriptional activation of interleukin-1beta	[transcriptional activation of interleukin-1beta]	0.0	4	1	1	1
151307	1710	only in cell of the lineage	[only in cells of the lineage]	0.0	6	1	1	1
151308	1710	moreover, the factor present	[Moreover, the factor present]	0.0	4	1	1	1
151309	1710	b lymphocyte in the circulation	[B lymphocytes in the circulation]	0.0	5	1	1	1
151310	1710	signal function similar	[signaling functions similar]	0.0	3	1	1	1
151311	1710	orf a tegument protein ie62	[ORF an tegument protein IE62]	0.0	5	1	1	1
151312	1710	corresponding to the nf-at site	[corresponding to the NF-AT site]	0.0	5	1	1	1
151313	1710	undifferentiated endometrial cell	[undifferentiated endometrial cells]	0.0	3	1	1	1
151314	1710	difference in platelet monoamine oxidase	[differences in platelet monoamine oxidase]	0.0	5	1	1	1
151315	1710	affinity of element for factor	[affinities of elements for factor]	0.0	5	1	1	1
151316	1710	cd8+ t-pll cell	[CD8+ T-PLL cells]	0.0	3	1	1	1
151317	1710	differentiation in response	[Differentiation in response]	0.0	3	1	1	1
151318	1710	three mode	[three modes]	0.0	2	2	2	1
151319	1710	protein with similarity	[protein with similarities]	0.0	3	1	1	1
151320	1710	lipopolysaccharide expression of 1beta	[lipopolysaccharide expression of 1beta]	0.0	4	1	1	1
151321	1710	cross-linking tyrosine phosphorylation	[cross-linking tyrosine phosphorylation]	0.0	3	1	1	1
151322	1710	prescription Liuwei Dihuang Pills	[prescription Liuwei Dihuang Pills]	0.0	4	1	1	1
151323	1710	granulocyte-colony stimulate factor treatment	[granulocyte-colony stimulating factor treatment]	0.0	4	1	1	1
151324	1710	subgroup within the CREB/ATF family	[subgroup within the CREB/ATF family]	0.0	5	1	1	1
151325	1710	implication for differentiation-inducing therapy	[implications for differentiation-inducing therapy]	0.0	4	1	1	1
151326	1710	binding sequence for inducible transcription factor	[binding sequences for inducible transcription factors]	0.0	6	1	1	1
151327	1710	Epstein-Barr virus latent protein	[Epstein-Barr virus latent proteins]	0.0	4	1	1	1
151328	1710	gata-1 fluorescence	[GATA-1 fluorescence]	0.0	2	1	1	1
151329	1710	group low dissociation constant	[groups lower dissociation constant]	0.0	4	1	1	1
151330	1710	potential of glucocorticoid	[potential of glucocorticoids]	0.0	3	1	1	1
151331	1710	induction of activity follow cd19 cross-linking	[induction of activities following CD19 cross-linking]	0.0	6	1	1	1
151332	1710	(Pit-Oct-Unc)	[(Pit-Oct-Unc)]	0.0	1	1	1	1
151333	1710	antiallergic, activity in	[antiallergic, activities in]	0.0	3	1	1	1
151334	1710	compound 8	[compounds 8]	0.0	2	1	1	1
151335	1710	compound 7	[compounds 7]	0.0	2	1	1	1
151336	1710	14 control subject	[14 control subjects]	0.0	3	1	1	1
151337	1710	level of pkc activity	[levels of PKC activity]	0.0	4	1	1	1
151338	1710	traz with LMP1	[TRAFs with LMP1]	0.0	3	1	1	1
151339	1710	family of gene	[family of genes]	0.0	3	1	1	1
151340	1710	1 terminal repeat hiv-1-ltr	[1 terminal repeat HIV-1-LTR]	0.0	4	1	1	1
151341	1710	monosomy	[monosomy]	0.0	1	1	1	1
151342	1710	NF-kappaB p50/p65 heterodimer	[NF-kappaB p50/p65 heterodimer]	0.0	3	1	1	1
151343	1710	class b cell	[class B cells]	0.0	3	1	1	1
151344	1710	response in mononuclear leukocyte	[response in mononuclear leukocytes]	0.0	4	1	1	1
151345	1710	interleukin-1 cell	[interleukin-1 cells]	0.0	2	1	1	1
151346	1710	include RelA	[including RelA]	0.0	2	1	1	1
151347	1710	differentiation of cell progenitor	[differentiation of cell progenitors]	0.0	4	1	1	1
151348	1710	rel-a protein	[Rel-A protein]	0.0	2	1	1	1
151349	1710	epithelial (h292) cell-line	[epithelial (H292) cell-line]	0.0	3	1	1	1
151350	1710	regard the role of macrophage	[regarding the role of macrophages]	0.0	5	1	1	1
151351	1710	follow t(1;19) translocation	[following t(1;19) translocations]	0.0	3	1	1	1
151352	1710	various physiologic concentration	[Various physiologic concentrations]	0.0	3	1	1	1
151353	1710	favorable clinical course chi2 test).	[favorable clinical course chi2 test).]	0.0	5	1	1	1
151354	1710	level of steroid hormone	[levels of steroid hormones]	0.0	4	1	1	1
151355	1710	difference in binding of receptor	[Differences in binding of receptor]	0.0	5	1	1	1
151356	1710	ym-268 a thiazolidinedione derivative	[YM-268 a thiazolidinedione derivative]	0.0	4	1	1	1
151357	1710	drug such as cyclosporin a	[drugs such as cyclosporin A]	0.0	5	2	2	1
151358	1710	monocyte adhesion in human vein cell	[monocyte adhesion in human vein cells]	0.0	6	1	1	1
151359	1710	dissociation of b translocation	[dissociation of B translocation]	0.0	4	1	1	1
151360	1710	unstimulated 13-acetate/phytohemagglutinin-stimulated jurkat T cell	[unstimulated 13-acetate/phytohemagglutinin-stimulated Jurkat T cells]	0.0	5	1	1	1
151361	1710	steroid action.	[steroid action.]	0.0	2	1	1	1
151362	1710	nuclear factor kB	[nuclear factor kB]	0.0	3	1	1	1
151363	1710	rapid expansion	[rapid expansion]	0.0	2	1	1	1
151364	1710	cell with anti-igm	[cells with anti-IgM]	0.0	3	1	1	1
151365	1710	level of ROI	[levels of ROI]	0.0	3	1	1	1
151366	1710	kind of human cell	[kinds of human cells]	0.0	4	1	1	1
151367	1710	vivo footprint analysis interaction	[vivo footprint analysis interaction]	0.0	4	1	1	1
151368	1710	in-vitro-stimulated adult blood lymphocyte sample	[in-vitro-stimulated adult blood lymphocyte samples]	0.0	5	1	1	1
151369	1710	viral product	[viral products]	0.0	2	1	1	1
151370	1710	nuclear factor in	[nuclear factors in]	0.0	3	1	1	1
151371	1710	evidence for gene topography	[evidence for gene topography]	0.0	4	1	1	1
151372	1710	tissue-specific DNA element present	[tissue-specific DNA element present]	0.0	4	1	1	1
151373	1710	clone with pcr-based technique	[clone with PCR-based techniques]	0.0	4	1	1	1
151374	1710	activation of this cell with VDR	[activation of these cells with VDR]	0.0	6	1	1	1
151375	1710	(30 minutes)	[(30 minutes)]	0.0	2	1	1	1
151376	1710	thymic cell DC	[Thymic cells DC]	0.0	3	1	1	1
151377	1710	implicate CAML as a signal intermediate	[implicating CAML as a signaling intermediate]	0.0	6	1	1	1
151378	1710	human il-5 synthesis	[human IL-5 synthesis]	0.0	3	1	1	1
151379	1710	two tyrosine residue stat3	[two tyrosine residues Stat3]	0.0	4	1	1	1
151380	1710	heat shock protein association	[heat shock protein association]	0.0	4	1	1	1
151381	1710	activity of Jun-Fos heterodimer	[activities of Jun-Fos heterodimers]	0.0	4	1	1	1
151382	1710	portion of sp140	[portion of Sp140]	0.0	3	1	1	1
151383	1710	treatment with 5-azacytidine re-expression	[treatment with 5-azacytidine re-expression]	0.0	4	1	1	1
151384	1710	sequence downstream regulatory element	[sequence downstream regulatory element]	0.0	4	1	1	1
151385	1710	rapid transcriptional activation in response	[rapid transcriptional activation in response]	0.0	5	1	1	1
151386	1710	intracellular signal pathway in human neutrophil	[intracellular signaling pathways in human neutrophils]	0.0	6	1	1	1
151387	1710	sequence analysis between human show	[sequence analysis between human shows]	0.0	5	1	1	1
151388	1710	reproduce the function	[reproducing the function]	0.0	3	1	1	1
151389	1710	extracellular kinase ERK in monocyte	[extracellular kinase ERK in monocytes]	0.0	5	1	1	1
151390	1710	-resistant transactivation	[-resistant transactivation]	0.0	2	1	1	1
151391	1710	erythrocyte compartment	[erythrocyte compartment]	0.0	2	1	1	1
151392	1710	presence of nuclear factor	[presence of nuclear factors]	0.0	4	1	1	1
151393	1710	normal thymic cell	[normal thymic cells]	0.0	3	1	1	1
151394	1710	symbiotic, persistent relationship	[symbiotic, persistent relationship]	0.0	3	1	1	1
151395	1710	CD28 cell surface	[CD28 cell surface]	0.0	3	1	1	1
151396	1710	include hydroxyanisole tetrahydropapaveroline thp	[including hydroxyanisole tetrahydropapaveroline THP]	0.0	4	1	1	1
151397	1710	NH2-terminal 29 residue	[NH2-terminal 29 residues]	0.0	3	1	1	1
151398	1710	bind to one	[binding to one]	0.0	3	1	1	1
151399	1710	Comparison of the different combination gc	[Comparison of the different combinations GC]	0.0	6	1	1	1
151400	1710	heterologous promoter construct	[heterologous promoter construct]	0.0	3	1	1	1
151401	1710	alveolar macrophage in intrapulmonary activation	[alveolar macrophages in intrapulmonary activation]	0.0	5	1	1	1
151402	1710	glucocorticoid in disease	[glucocorticoids in diseases]	0.0	3	1	1	1
151403	1710	inducible factor bind	[inducible factor binding]	0.0	3	1	1	1
151404	1710	such as tumor matrice	[such as tumor matrices]	0.0	4	1	1	1
151405	1710	substoichiometric taf	[substoichiometric TAF]	0.0	2	1	1	1
151406	1710	survival of 9.6	[survival of 9.6]	0.0	3	1	1	1
151407	1710	harbor the part	[harboring the part]	0.0	3	1	1	1
151408	1710	contrast to the inhibition	[contrast to the inhibition]	0.0	4	1	1	1
151409	1710	hmg box most closely related	[HMG box most closely related]	0.0	5	1	1	1
151410	1710	influence of serum thyroxine	[influence of serum thyroxine]	0.0	4	1	1	1
151411	1710	extract of human th1 clone	[extracts of human Th1 clones]	0.0	5	1	1	1
151412	1710	interleukin-2 enhancer function	[interleukin-2 enhancer function]	0.0	3	2	2	1
151413	1710	tnfrii associate	[TNFRII associating]	0.0	2	1	1	1
151414	1710	molecular target for signalling	[molecular targets for signalling]	0.0	4	1	1	1
151415	1710	level of il-8 production	[levels of IL-8 production]	0.0	4	1	1	1
151416	1710	IL-5-	[IL-5-]	0.0	1	1	1	1
151417	1710	condition of biomedical importance.	[conditions of biomedical importance.]	0.0	4	1	1	1
151418	1710	response gene for inducibility.	[response genes for inducibility.]	0.0	4	1	1	1
151419	1710	particular importance	[particular importance]	0.0	2	1	1	1
151420	1710	enzyme pyrimidine (and fura	[enzyme pyrimidine (and FUra]	0.0	4	1	1	1
151421	1710	NF-kappa b1 gene expression	[NF-kappa B1 gene expression]	0.0	4	1	1	1
151422	1710	irf-1 interferon factor 1	[IRF-1 interferon factor 1]	0.0	4	1	1	1
151423	1710	type ii tgase up-regulation	[type II TGase up-regulation]	0.0	4	1	1	1
151424	1710	deletion within beta-catenin	[deletion within beta-catenin]	0.0	3	1	1	1
151425	1710	human t-lymphotrophic virus type	[human T-lymphotrophic virus type]	0.0	4	1	1	1
151426	1710	GM-CSF proliferation	[GM-CSF proliferation]	0.0	2	1	1	1
151427	1710	813-bp reading frame	[813-bp reading frame]	0.0	3	1	1	1
151428	1710	normal human macrophage PAM	[Normal human macrophages PAM]	0.0	4	1	1	1
151429	1710	require ROI production in cell	[requiring ROI production in cells]	0.0	5	1	1	1
151430	1710	h after lps	[h after, LPS]	0.0	3	1	1	1
151431	1710	human immunodeficiency virus type factor	[Human immunodeficiency virus type factor]	0.0	5	1	1	1
151432	1710	factor recruitment	[factor recruitment]	0.0	2	1	1	1
151433	1710	c-fo p62c-fo c-jun gene	[c-fos p62c-fos c-jun genes]	0.0	4	1	1	1
151434	1710	worker ppt tcdd	[workers ppt TCDD]	0.0	3	1	1	1
151435	1710	BH1 domain	[BH1 domains]	0.0	2	1	1	1
151436	1710	mouse il-2 enhancer construct	[mouse IL-2 enhancer construct]	0.0	4	1	1	1
151437	1710	CD28 ligand	[CD28 ligands]	0.0	2	1	1	1
151438	1710	Olomoucine	[Olomoucine]	0.0	1	1	1	1
151439	1710	tgf-beta transcription	[TGF-beta transcription]	0.0	2	1	1	1
151440	1710	effects, such as the early activation	[effects, such as the early activation]	0.0	6	1	1	1
151441	1710	vivo transfection study	[vivo transfection studies]	0.0	3	1	1	1
151442	1710	regulator of blood cell development	[regulators of blood cell development]	0.0	5	1	1	1
151443	1710	involve another heat-labile serum factor	[involving another heat-labile serum factor]	0.0	5	1	1	1
151444	1710	follow cortisol depletion	[following cortisol depletion]	0.0	3	1	1	1
151445	1710	co-treatment induced,	[Co-treatment induced,]	0.0	2	1	1	1
151446	1710	asymmetric division	[asymmetric divisions]	0.0	2	1	1	1
151447	1710	Kennedy' disease	[Kennedy's disease]	0.0	2	1	1	1
151448	1710	decrease in apparent potency	[decrease in apparent potency]	0.0	4	1	1	1
151449	1710	activator property in cell	[activator properties in cells]	0.0	4	1	1	1
151450	1710	adolescent major disorder MDD	[adolescent major disorder MDD]	0.0	4	1	1	1
151451	1710	12.1% cells)	[12.1% cells)]	0.0	2	1	1	1
151452	1710	factor other	[factors other]	0.0	2	1	1	1
151453	1710	isomer 9-cis RA	[isomer 9-cis RA]	0.0	3	1	1	1
151454	1710	leukemia gene PML	[leukemia gene PML]	0.0	3	1	1	1
151455	1710	three repeat tax-responsive element-1	[three repeats Tax-responsive element-1]	0.0	4	1	1	1
151456	1710	immunodeficiency virus type 1 terminal repeat	[immunodeficiency virus type 1 terminal repeats]	0.0	6	1	1	1
151457	1710	activation of T	[Activation of T]	0.0	3	1	1	1
151458	1710	65-kDa heterodimer	[65-kDa heterodimer]	0.0	2	1	1	1
151459	1710	combination with retinoic acid	[combination with retinoic acid]	0.0	4	1	1	1
151460	1710	two regions, dp1 -140 bp	[Two regions, DP1 -140 bp]	0.0	5	1	1	1
151461	1710	nonstructural trans-acting	[nonstructural trans-acting]	0.0	2	1	1	1
151462	1710	effect of all-tran RA	[effect of all-trans RA]	0.0	4	1	1	1
151463	1710	m phi ingestion	[M phi ingestion]	0.0	3	1	1	1
151464	1710	part of a mechanism	[part of a mechanism]	0.0	4	1	1	1
151465	1710	integrin-mediated tyrosine phosphorylation	[Integrin-mediated tyrosine phosphorylation]	0.0	3	1	1	1
151466	1710	1 tax mutant	[1 Tax mutants]	0.0	3	1	1	1
151467	1710	promoter by trans-acting factor	[promoters by trans-acting factors]	0.0	4	1	1	1
151468	1710	requirement of the e-box	[requirements of the E-boxes]	0.0	4	1	1	1
151469	1710	seven unstable patient	[seven unstable patients]	0.0	3	1	1	1
151470	1710	germ-line epsilon transcript	[germ-line epsilon transcripts]	0.0	3	1	1	1
151471	1710	phorbol myristic acetate	[phorbol myristic acetate]	0.0	3	1	1	1
151472	1710	bovine colostrum	[bovine colostrum]	0.0	2	2	2	1
151473	1710	elastase inhibitor synthetic peptide	[elastase inhibitor synthetic peptide]	0.0	4	1	1	1
151474	1710	(sp)	[(SP)]	0.0	1	1	1	1
151475	1710	treatment of hl-60 eosinophilic subline	[Treatment of HL-60 eosinophilic sublines]	0.0	5	1	1	1
151476	1710	cardiac cell	[cardiac cells]	0.0	2	1	1	1
151477	1710	study responsiveness to two transactivator	[studying responsiveness to two transactivators]	0.0	5	1	1	1
151478	1710	type in contrast	[types in contrast]	0.0	3	1	1	1
151479	1710	particular set	[particular set]	0.0	2	1	1	1
151480	1710	develop from peripheral blood precursor	[developing from peripheral blood precursors]	0.0	5	1	1	1
151481	1710	idiopathic myelofibrosis	[idiopathic myelofibrosis]	0.0	2	1	1	1
151482	1710	neutralize abs to growth factor	[neutralizing Abs to growth factor]	0.0	5	1	1	1
151483	1710	Conclusions: substantial growth inhibition without evidence	[CONCLUSIONS: Substantial growth inhibition without evidence]	0.0	6	1	1	1
151484	1710	analog with substitution on C-11	[Analogs with substitutions on C-11]	0.0	5	1	1	1
151485	1710	hydroxytoluene	[hydroxytoluene]	0.0	1	1	1	1
151486	1710	identification as lymphocyte-specific protein	[Identification as lymphocyte-specific protein]	0.0	4	1	1	1
151487	1710	previous observation on the distinct regulation	[previous observations on the distinct regulation]	0.0	6	1	1	1
151488	1710	mutation in Cbl-b	[mutation in Cbl-b]	0.0	3	1	1	1
151489	1710	removal of pc4 from the extract	[removal of PC4 from the extract]	0.0	6	1	1	1
151490	1710	adult control (21-50	[adult controls (21-50]	0.0	3	1	1	1
151491	1710	dominant negative form of aml1	[dominant negative form of AML1]	0.0	5	1	1	1
151492	1710	induction of the IL-6 gene	[induction of the IL-6 gene]	0.0	5	1	1	1
151493	1710	clonal line	[clonal lines]	0.0	2	1	1	1
151494	1710	transcriptional regulation in differentiation	[Transcriptional regulation in differentiation]	0.0	4	1	1	1
151495	1710	sequence in cell lineage	[sequences in cell lineages]	0.0	4	1	1	1
151496	1710	translocation from the cytoplasm	[translocation from the cytoplasm]	0.0	4	1	1	1
151497	1710	T cell proliferative response	[T cell proliferative response]	0.0	4	1	1	1
151498	1710	reduce tnf production	[reducing TNF production]	0.0	3	1	1	1
151499	1710	fibrosarcoma 8, histiocytoma rhabdomyosarcoma leiomyosarcoma	[fibrosarcoma 8, histiocytoma rhabdomyosarcoma leiomyosarcoma]	0.0	5	1	1	1
151500	1710	regulator of TNF alpha	[regulator of TNF alpha]	0.0	4	1	1	1
151501	1710	generation of T lymphocyte	[Generation of T lymphocytes]	0.0	4	1	1	1
151502	1710	inhibitor of phospholipase a2	[inhibitors of phospholipase A2]	0.0	4	1	1	1
151503	1710	fc gamma RI gas binding pattern	[Fc gamma RI GAS binding patterns]	0.0	6	1	1	1
151504	1710	least two distinct domain	[least two distinct domains]	0.0	4	1	1	1
151505	1710	splenocyte proliferation	[splenocyte proliferation]	0.0	2	1	1	1
151506	1710	maintenance of lymphocyte homeostasis	[maintenance of lymphocyte homeostasis]	0.0	4	1	1	1
151507	1710	difference between patient	[difference between patients]	0.0	3	1	1	1
151508	1710	pathogenicity of the virus in	[pathogenicity of the viruses in]	0.0	5	1	1	1
151509	1710	four putative NF-kappa b binding site	[four putative NF-kappa B binding sites]	0.0	6	1	1	1
151510	1710	(st;	[(ST;]	0.0	1	1	1	1
151511	1710	effect of prostaglandin e2	[effects of prostaglandin E2]	0.0	4	1	1	1
151512	1710	Deoxycholate treatment of extract	[Deoxycholate treatment of extracts]	0.0	4	1	1	1
151513	1710	use early progenitor cell	[using early progenitor cells]	0.0	4	1	1	1
151514	1710	pml/rar alpha fusion gene	[pml/RAR alpha fusion gene]	0.0	4	1	1	1
151515	1710	add nf-kappa b protein to extract	[Adding NF-kappa B protein to extracts]	0.0	6	1	1	1
151516	1710	4-year probability	[4-year probability]	0.0	2	1	1	1
151517	1710	significant improvement	[significant improvements]	0.0	2	1	1	1
151518	1710	resection in ileostomized patient	[resection in ileostomized patients]	0.0	4	1	1	1
151519	1710	17-amino acid epitope	[17-amino acid epitope]	0.0	3	1	1	1
151520	1710	response nf-kappab	[response NF-kappaB]	0.0	2	1	1	1
151521	1710	growth-stimulatet	[growth-stimulating]	0.0	1	1	1	1
151522	1710	hla molecule of the first	[HLA molecule of the first]	0.0	5	1	1	1
151523	1710	initially, four novel, sequence variant	[Initially, four novel, sequence variants]	0.0	5	1	1	1
151524	1710	tnfr1 death domain protein tradd	[TNFR1 death domain protein TRADD]	0.0	5	1	1	1
151525	1710	level of expression from REV ltr	[levels of expression from REV LTRs]	0.0	6	1	1	1
151526	1710	injection of a rat t-cell line	[injection of a rat T-cell line]	0.0	6	1	1	1
151527	1710	activity independent	[activity independent]	0.0	2	1	1	1
151528	1710	tumor necrosis factor -alphaproduction	[tumor necrosis factor -alphaproduction]	0.0	4	1	1	1
151529	1710	dexamethasone suppression test	[dexamethasone suppression test]	0.0	3	1	1	1
151530	1710	include presentation, response to treatment	[including presentation, response to treatment]	0.0	5	1	1	1
151531	1710	trans-acting gene	[trans-acting genes]	0.0	2	1	1	1
151532	1710	granulocytic differentiation of the mpro promyelocyte	[granulocytic differentiation of the MPRO promyelocytes]	0.0	6	1	1	1
151533	1710	deterioration human immunodeficiency virus type hiv-1	[deterioration human immunodeficiency virus type HIV-1]	0.0	6	1	1	1
151534	1710	localization of the ets protein elf-1	[localization of the ETS protein Elf-1]	0.0	6	1	1	1
151535	1710	relatedness to a prolactin-induced transcription factor	[relatedness to a prolactin-induced transcription factor]	0.0	6	1	1	1
151536	1710	cross-linking with 125i-labeled tgf-beta 1	[cross-linking with 125I-labeled TGF-beta 1]	0.0	5	1	1	1
151537	1710	high level of nf-atp	[higher levels of NF-ATp]	0.0	4	1	1	1
151538	1710	blood cell to cell	[blood cells to cells]	0.0	4	1	1	1
151539	1710	class of binding site	[class of binding sites]	0.0	4	1	1	1
151540	1710	immunohistochemical evidence of low activity	[Immunohistochemical evidence of low activity]	0.0	5	1	1	1
151541	1710	pge2 effect	[PGE2 effect]	0.0	2	1	1	1
151542	1710	functional role of nuclear factor-DNA complex	[functional role of nuclear factor-DNA complexes]	0.0	6	1	1	1
151543	1710	value alter immune response	[value altering immune responses]	0.0	4	1	1	1
151544	1710	combination of stat protein	[combinations of Stat proteins]	0.0	4	1	1	1
151545	1710	hiv-infected patient with normal affinity	[HIV-infected patients with normal affinity]	0.0	5	1	1	1
151546	1710	about half	[about half]	0.0	2	1	1	1
151547	1710	hour of exposure to sea	[hr of exposure to SEA]	0.0	5	1	1	1
151548	1710	monocytic differentiation of m2-type blast cell	[monocytic differentiation of M2-type blast cells]	0.0	6	1	1	1
151549	1710	hiv-1 antigen expression	[HIV-1 antigen expression]	0.0	3	1	1	1
151550	1710	IL-2 ifn-gamma production	[IL-2 IFN-gamma production]	0.0	3	1	1	1
151551	1710	single cell layer	[single cell layer]	0.0	3	1	1	1
151552	1710	ebv transformation	[EBV transformation]	0.0	2	1	1	1
151553	1710	primitive erythroid cell	[primitive erythroid cells]	0.0	3	1	1	1
151554	1710	extrarenal, non-epithelial cell	[extrarenal, non-epithelial cells]	0.0	3	1	1	1
151555	1710	leukaemic	[leukaemic]	0.0	1	1	1	1
151556	1710	various physiological processes,	[various physiological processes,]	0.0	3	1	1	1
151557	1710	form of positive selection antigen-driven expansion)	[forms of positive selection antigen-driven expansion)]	0.0	6	1	1	1
151558	1710	HS-40 enhancer	[HS-40 enhancer]	0.0	2	1	1	1
151559	1710	low shear-induced activation	[low shear-induced activation]	0.0	3	2	2	1
151560	1710	comparison with the group	[comparison with the group]	0.0	4	1	1	1
151561	1710	translocation factor	[translocation factor]	0.0	2	2	2	1
151562	1710	reductase	[reductase]	0.0	1	1	1	1
151563	1710	cluster of binding site	[cluster of binding sites]	0.0	4	1	1	1
151564	1710	kd (30.3+/-2.5 nmol/L) nmol/L)	[Kd (30.3+/-2.5 nmol/L) nmol/L)]	0.0	4	1	1	1
151565	1710	element response element ISRE	[element Response Element ISRE]	0.0	4	1	1	1
151566	1710	number of sequence similar	[number of sequences similar]	0.0	4	1	1	1
151567	1710	cell in g0	[cells in G0]	0.0	3	1	1	1
151568	1710	breast cancer cellular cytotoxicity	[breast cancer cellular cytotoxicity]	0.0	4	1	1	1
151569	1710	feature with ebv include virus-induced tumorigenesis.	[features with EBV including virus-induced tumorigenesis.]	0.0	6	1	1	1
151570	1710	IL-3 factor complex	[IL-3 factor complexes]	0.0	3	1	1	1
151571	1710	encompass a positive regulatory element	[encompassing an positive regulatory element]	0.0	5	1	1	1
151572	1710	low affinity (Kd)	[low affinity (Kd)]	0.0	3	1	1	1
151573	1710	range in tissue	[range in tissues]	0.0	3	1	1	1
151574	1710	transcriptionally active creb protein	[transcriptionally active CREB protein]	0.0	4	1	1	1
151575	1710	induction in acute promyelocytic leukemia cell	[Induction in acute promyelocytic leukemia cells]	0.0	6	1	1	1
151576	1710	expression of ap1 -dependent reporter construct	[expression of AP1 -dependent reporter constructs]	0.0	6	1	1	1
151577	1710	affinity sites; 3)	[affinity sites; 3)]	0.0	3	1	1	1
151578	1710	human deficiency virus type 1 hiv-1	[human deficiency virus type 1 HIV-1]	0.0	6	1	1	1
151579	1710	hyperparathyroidism php	[hyperparathyroidism PHP]	0.0	2	1	1	1
151580	1710	culture of thymic epithelial cell	[cultures of thymic epithelial cells]	0.0	5	1	1	1
151581	1710	TATA promoter	[TATA promoters]	0.0	2	1	1	1
151582	1710	gene expression of a gene	[gene expression of an gene]	0.0	5	1	1	1
151583	1710	target of SR	[target of SR]	0.0	3	1	1	1
151584	1710	presence of il-4 mab	[presence of IL-4 mAb]	0.0	4	1	1	1
151585	1710	differentiation of ut-7/gm cell	[differentiation of UT-7/GM cells]	0.0	4	1	1	1
151586	1710	receptor receptor gamma	[receptor receptor gamma]	0.0	3	1	1	1
151587	1710	eicosanoid synthesis from cancer patient	[eicosanoid synthesis from cancer patients]	0.0	5	1	1	1
151588	1710	receptor for interferon-alpha	[receptors for interferon-alpha]	0.0	3	1	1	1
151589	1710	clearance of apoptotic leukocyte	[clearance of apoptotic leukocytes]	0.0	4	1	1	1
151590	1710	cell extract from acute leukemia all	[cell extracts from acute leukemia ALL]	0.0	6	1	1	1
151591	1710	stage homogeneity of progenitor/precursor cell	[stage homogeneity of progenitor/precursor cells]	0.0	5	1	1	1
151592	1710	wild-type phenotype in replication	[wild-type phenotype in replication]	0.0	4	1	1	1
151593	1710	sequence (bp	[sequences (bp]	0.0	2	1	1	1
151594	1710	role upstream	[role upstream]	0.0	2	1	1	1
151595	1710	erythroid-specific site HS2 enhancer	[erythroid-specific site HS2 enhancer]	0.0	4	1	1	1
151596	1710	Sudan b	[Sudan B]	0.0	2	1	1	1
151597	1710	intracellular substrate in cell	[intracellular substrates in cells]	0.0	4	1	1	1
151598	1710	ethanol a inhibitor	[ethanol an inhibitor]	0.0	3	1	1	1
151599	1710	b cell lymphoid	[B cell lymphoid]	0.0	3	1	1	1
151600	1710	loss of 32p consistent	[loss of 32P consistent]	0.0	4	1	1	1
151601	1710	viral activity downstream	[viral activities downstream]	0.0	3	1	1	1
151602	1710	primary mechanism of androgen insensitivity	[primary mechanism of androgen insensitivity]	0.0	5	1	1	1
151603	1710	transcription factor in lymphocyte	[transcription factors in lymphocytes]	0.0	4	1	1	1
151604	1710	precipitate Stat-3 with hsie probe	[precipitating Stat-3 with hSIE probe]	0.0	5	1	1	1
151605	1710	t-cell leukemia T-PLL	[T-cell leukemia T-PLL]	0.0	3	1	1	1
151606	1710	hpc with alpha-pml	[HPCs with alpha-PML]	0.0	3	1	1	1
151607	1710	human T helper	[human T helper]	0.0	3	1	1	1
151608	1710	different aspect of the process.	[different aspects of the process.]	0.0	5	1	1	1
151609	1710	gata-binding protein family member	[GATA-binding protein family members]	0.0	4	1	1	1
151610	1710	component of breast cancer	[component of breast cancer]	0.0	4	1	1	1
151611	1710	lineage in response	[lineages in response]	0.0	3	1	1	1
151612	1710	important role for NF-AT	[important role for NF-AT]	0.0	4	1	1	1
151613	1710	also in healthy individual	[also in healthy individuals]	0.0	4	1	1	1
151614	1710	triiodothyronine receptor mrna in tissue	[triiodothyronine receptor mRNA in tissues]	0.0	5	1	1	1
151615	1710	B29 immunoglobulin beta-chain	[B29 immunoglobulin beta-chain]	0.0	3	1	1	1
151616	1710	encode the transcription factor	[encoding the transcription factor]	0.0	4	1	1	1
151617	1710	transcription factor GATA-1	[transcription factors GATA-1]	0.0	3	1	1	1
151618	1710	monocyte il-1	[monocyte IL-1]	0.0	2	1	1	1
151619	1710	variety of regulatory protein	[variety of regulatory proteins]	0.0	4	1	1	1
151620	1710	MARCKS	[MARCKS]	0.0	1	1	1	1
151621	1710	deletion basis	[deletion bases]	0.0	2	1	1	1
151622	1710	non-cultured lymphocyte	[non-cultured lymphocytes]	0.0	2	1	1	1
151623	1710	expression in ebv-immortalized b lymphoblast	[expression in EBV-immortalized B lymphoblasts]	0.0	5	1	1	1
151624	1710	even low dose of ionizing radiation	[even lower doses of ionizing radiation]	0.0	6	1	1	1
151625	1710	imply a physiological role for camp	[implying a physiological role for cAMP]	0.0	6	1	1	1
151626	1710	such as t-prolymphocytic	[such as T-prolymphocytic]	0.0	3	1	1	1
151627	1710	cases, induction	[cases, induction]	0.0	2	1	1	1
151628	1710	box sry	[boxes SRY]	0.0	2	1	1	1
151629	1710	various parameter	[various parameters]	0.0	2	1	1	1
151630	1710	fmol/10(6) cell, min,	[fmol/10(6) cell, min,]	0.0	3	1	1	1
151631	1710	activation of nf-kappa b gene	[activation of NF-kappa B genes]	0.0	5	1	1	1
151632	1710	non-cultured lymphocyte from the two	[non-cultured lymphocytes from the two]	0.0	5	1	1	1
151633	1710	peroxisomal proliferator-activated receptor gamma ppargamma	[peroxisomal proliferator-activated receptor gamma PPARgamma]	0.0	5	1	1	1
151634	1710	activation of the IL-4 promoter	[activation of the IL-4 promoter]	0.0	5	1	1	1
151635	1710	box 1 pxp motif	[box 1 PXP motif]	0.0	4	1	1	1
151636	1710	adjacent sp 1-binding site	[adjacent Sp 1-binding site]	0.0	4	1	1	1
151637	1710	status after surgery comparison with criteria]	[status after surgery comparison with criteria]]	0.0	6	1	1	1
151638	1710	terminal repeat LTR region	[terminal repeat LTR region]	0.0	4	1	1	1
151639	1710	identification as the major element	[identification as the major elements]	0.0	5	1	1	1
151640	1710	treatment of hl-60 subline	[Treatment of HL-60 sublines]	0.0	4	1	1	1
151641	1710	C[AT]6GG	[C[AT]6GG]	0.0	1	1	1	1
151642	1710	aberrant signal	[aberrant signaling]	0.0	2	1	1	1
151643	1710	weak inhibition	[weak inhibition]	0.0	2	1	1	1
151644	1710	peroxisomal receptor gamma ppargamma expression	[peroxisomal receptor gamma PPARgamma expression]	0.0	5	1	1	1
151645	1710	number of gcrbeta cell	[number of GCRbeta cells]	0.0	4	1	1	1
151646	1710	+/- fmol/10(7) pbmc	[+/- fmol/10(7) PBMC]	0.0	3	1	1	1
151647	1710	activator protein-1 ap-1 site	[activator protein-1 AP-1 site]	0.0	4	1	1	1
151648	1710	peripheral white blood cell	[peripheral white blood cell]	0.0	4	1	1	1
151649	1710	human interleukin gene through interference	[human interleukin gene through interference]	0.0	5	1	1	1
151650	1710	Differential contribution to the activation	[Differential contribution to the activation]	0.0	5	1	1	1
151651	1710	combination with 9cisra	[combination with 9cisRA]	0.0	3	1	1	1
151652	1710	rapid mode	[rapid mode]	0.0	2	1	1	1
151653	1710	maturation effect on nb4 cell	[maturation effect on NB4 cells]	0.0	5	1	1	1
151654	1710	activation of Rel/kappaB	[activation of Rel/kappaB]	0.0	3	1	1	1
151655	1710	form of BLS	[form of BLS]	0.0	3	1	1	1
151656	1710	site site b	[site site B]	0.0	3	1	1	1
151657	1710	activation of signal transduction pathway	[activation of signal transduction pathways]	0.0	5	1	1	1
151658	1710	potential therapeutic value alter immune response	[potential therapeutic value altering immune responses]	0.0	6	1	1	1
151659	1710	microm pdtc with this agent	[microM PDTC with these agents]	0.0	5	1	1	1
151660	1710	combination of molecule	[combinations of molecules]	0.0	3	1	1	1
151661	1710	form of early-onset type 2	[forms of early-onset type 2]	0.0	5	1	1	1
151662	1710	transcription at stage of B-cell differentiation	[transcription at stages of B-cell differentiation]	0.0	6	1	1	1
151663	1710	binding site for RBP-Jkappa	[binding site for RBP-Jkappa]	0.0	4	1	1	1
151664	1710	preleukemic cell	[preleukemic cells]	0.0	2	1	1	1
151665	1710	expression such as the gene	[expression such as the genes]	0.0	5	1	1	1
151666	1710	product (band pk)	[products (band pk)]	0.0	3	1	1	1
151667	1710	tandem pair	[tandem pairs]	0.0	2	1	1	1
151668	1710	influx.	[influx.]	0.0	1	1	1	1
151669	1710	[g.nabel	[[G.Nabel]	0.0	1	1	1	1
151670	1710	kappa b motif dna-binding activity	[kappa B motif DNA-binding activity]	0.0	5	1	1	1
151671	1710	bowel disease IBD	[bowel disease IBD]	0.0	3	1	1	1
151672	1710	transcriptional activation by deletion	[transcriptional activation by deletions]	0.0	4	1	1	1
151673	1710	AMP -responsive element-like sequence	[AMP -responsive element-like sequence]	0.0	4	1	1	1
151674	1710	b cofactor	[B cofactors]	0.0	2	1	1	1
151675	1710	T cell activity present	[T cell activities present]	0.0	4	1	1	1
151676	1710	contain the c-fo promoter	[containing the c-fos promoter]	0.0	4	1	1	1
151677	1710	htlv-1 provirus	[HTLV-1 provirus]	0.0	2	1	1	1
151678	1710	th2 cytokine profile	[Th2 cytokine profiles]	0.0	3	1	1	1
151679	1710	leukocyte of 11 MDD patient	[leukocytes of 11 MDD patients]	0.0	5	1	1	1
151680	1710	differentiation into eth1	[differentiation into eTh1]	0.0	3	1	1	1
151681	1710	mutant of SIVmacMER derivative of SIVmac239	[mutants of SIVmacMER derivative of SIVmac239]	0.0	6	1	1	1
151682	1710	intact autophosphorylation site	[intact autophosphorylation site]	0.0	3	1	1	1
151683	1710	possible killer population	[possible killer populations]	0.0	3	1	1	1
151684	1710	umbilical vein endothelial cell CoCl2	[umbilical vein endothelial cells CoCl2]	0.0	5	1	1	1
151685	1710	induction in t-cell transfectant with tax	[Induction in T-cell transfectants with Tax]	0.0	6	1	1	1
151686	1710	novel, proteasome stimulus	[novel, proteasome stimulus]	0.0	3	1	1	1
151687	1710	only that tcc with ifn-gamma level	[Only those TCC with IFN-gamma levels]	0.0	6	1	1	1
151688	1710	treatment, at interval 1 week	[treatment, at intervals 1 week]	0.0	5	1	1	1
151689	1710	FasL reporter	[FasL reporter]	0.0	2	1	1	1
151690	1710	site of immune-mediated inflammation	[sites of immune-mediated inflammation]	0.0	4	1	1	1
151691	1710	k562 target	[K562 targets]	0.0	2	1	1	1
151692	1710	nuclear factor KB	[nuclear factor KB]	0.0	3	1	1	1
151693	1710	phorbol ester ionomycin	[phorbol ester ionomycin]	0.0	3	1	1	1
151694	1710	expression during human monocytic differentiation	[Expression during human monocytic differentiation]	0.0	5	1	1	1
151695	1710	barely positive cell	[barely positive cells]	0.0	3	1	1	1
151696	1710	double-stranded protein kinase pkr	[double-stranded protein kinase PKR]	0.0	4	2	2	1
151697	1710	cellular mechanism underlie this capacity	[cellular mechanisms underlying this capacity]	0.0	5	1	1	1
151698	1710	VDR abnormality	[VDR abnormalities]	0.0	2	1	1	1
151699	1710	additional effect on the capacity	[additional effect on the capacity]	0.0	5	1	1	1
151700	1710	spectrum of level	[spectrum of levels]	0.0	3	1	1	1
151701	1710	actively divide cell	[actively dividing cells]	0.0	3	1	1	1
151702	1710	receptor number Ro	[receptor numbers Ro]	0.0	3	1	1	1
151703	1710	primary cd34+ progenitor cell	[primary CD34+ progenitor cells]	0.0	4	1	1	1
151704	1710	minute of lps stimulation	[min of LPS stimulation]	0.0	4	1	1	1
151705	1710	fluorescein-labeled amplicon	[fluorescein-labeled amplicon]	0.0	2	1	1	1
151706	1710	iron storage,	[iron storage,]	0.0	2	1	1	1
151707	1710	female monozygotic (mz) twin	[female monozygotic (MZ) twins]	0.0	4	1	1	1
151708	1710	hl-60 cell with pdbu	[HL-60 cells with PDBu]	0.0	4	1	1	1
151709	1710	understand the pathogenesis	[understanding the pathogenesis]	0.0	3	1	1	1
151710	1710	nm23.h1 gene expression	[NM23.H1 gene expression]	0.0	3	1	1	1
151711	1710	myeloid cell neutrophilic granulocyte	[myeloid cells neutrophilic granulocytes]	0.0	4	1	1	1
151712	1710	substitution on replication	[substitutions on replication]	0.0	3	1	1	1
151713	1710	relieve repressive effect.	[relieving repressive effect.]	0.0	3	1	1	1
151714	1710	translation efficiency	[translation efficiency]	0.0	2	1	1	1
151715	1710	induction without cytokine production	[Induction without cytokine production]	0.0	4	1	1	1
151716	1710	preferential presentation	[Preferential presentation]	0.0	2	1	1	1
151717	1710	isolation of human cell	[Isolation of human cells]	0.0	4	1	1	1
151718	1710	important autoregulatory inhibitor of inflammation	[important autoregulatory inhibitor of inflammation]	0.0	5	1	1	1
151719	1710	pu.1 in xenopus embryo	[PU.1 in Xenopus embryos]	0.0	4	1	1	1
151720	1710	transcriptional element in the tsp 1	[transcriptional elements in the TSP 1]	0.0	6	1	1	1
151721	1710	three cell-specific pathway	[three cell-specific pathways]	0.0	3	1	1	1
151722	1710	regulator of transcription.	[regulator of transcription.]	0.0	3	1	1	1
151723	1710	addition, blot analysis	[addition, blot analysis]	0.0	3	1	1	1
151724	1710	regulator of transcription,	[regulator of transcription,]	0.0	3	1	1	1
151725	1710	consensus ap1 motif	[consensus AP1 motif]	0.0	3	1	1	1
151726	1710	create enfeebled, hiv-1/siv	[creating enfeebled, HIV-1/SIV]	0.0	3	1	1	1
151727	1710	structure of cytoplasmic domain	[structures of cytoplasmic domains]	0.0	4	1	1	1
151728	1710	mild down-regulation in patient suffer	[mild down-regulation in patients suffering]	0.0	5	1	1	1
151729	1710	aspect of secondary tissue development	[aspects of secondary tissue development]	0.0	5	1	1	1
151730	1710	carry the translocation t(17;19)	[carrying the translocation t(17;19)]	0.0	4	1	1	1
151731	1710	release of the subunit	[release of the subunit]	0.0	4	1	1	1
151732	1710	even after analysis take change	[even after analysis taking changes]	0.0	5	1	1	1
151733	1710	member (irf) family of protein	[member (IRF) family of proteins]	0.0	5	1	1	1
151734	1710	ltr-driven transcription unit	[LTR-driven transcription unit]	0.0	3	1	1	1
151735	1710	mcd14 uptake produce concurrent enhancement	[mCD14 uptake producing concurrent enhancement]	0.0	5	1	1	1
151736	1710	receptor (gr) in ad	[receptor (GR) in AD]	0.0	4	1	1	1
151737	1710	-immunoreactive cell than asthmatics	[-immunoreactive cells than asthmatics]	0.0	4	1	1	1
151738	1710	level of hsf2-alpha	[levels of HSF2-alpha]	0.0	3	1	1	1
151739	1710	activation via nf-kappa b	[activation via NF-kappa B]	0.0	4	1	1	1
151740	1710	activator region	[activator region]	0.0	2	1	1	1
151741	1710	basis for study signal	[basis for studies signaling]	0.0	4	1	1	1
151742	1710	GM-CSF reporter plasmid	[GM-CSF reporter plasmid]	0.0	3	1	1	1
151743	1710	transcription of the repeat LTR	[transcription of the repeats LTR]	0.0	5	1	1	1
151744	1710	pretreatment of thp-1 cell	[pretreatment of THP-1 cells]	0.0	4	1	1	1
151745	1710	nuclear factor kB NF-kB	[nuclear factor kB NF-kB]	0.0	4	1	1	1
151746	1710	thereby amplify event	[thereby amplifying events]	0.0	3	1	1	1
151747	1710	Biochemical analysis by western blotting	[Biochemical analysis by Western blotting]	0.0	5	1	1	1
151748	1710	chemical mismatch cleavage	[chemical mismatch cleavage]	0.0	3	1	1	1
151749	1710	B-cell chronic leukemia cell	[B-cell chronic leukemia cells]	0.0	4	1	1	1
151750	1710	activation of a epithelial signal transducer	[activation of an epithelial signal transducer]	0.0	6	1	1	1
151751	1710	GCR in Yang patient	[GCR in Yang patients]	0.0	4	1	1	1
151752	1710	cd27- b	[CD27- B]	0.0	2	1	1	1
151753	1710	high proportion of cell	[high proportion of cells]	0.0	4	1	1	1
151754	1710	phenotype of x-scid patient	[phenotype of X-SCID patients]	0.0	4	1	1	1
151755	1710	stimulation as a parameter	[stimulation as a parameter]	0.0	4	1	1	1
151756	1710	peroxisome receptor alpha PPARalpha	[peroxisome receptor alpha PPARalpha]	0.0	4	1	1	1
151757	1710	vein endothelial cell monolayer	[vein endothelial cell monolayers]	0.0	4	1	1	1
151758	1710	response of transcription factor nf-kappab	[response of transcription factor NF-kappaB]	0.0	5	1	1	1
151759	1710	additional region of residue	[additional region of residues]	0.0	4	1	1	1
151760	1710	use antibody against brdu	[using antibodies against BrdU]	0.0	4	1	1	1
151761	1710	previously unknown locus	[previously unknown locus]	0.0	3	1	1	1
151762	1710	LP mononuclear cell	[LP mononuclear cells]	0.0	3	1	1	1
151763	1710	CAT protein	[CAT protein]	0.0	2	1	1	1
151764	1710	inhibit the function	[inhibiting the function]	0.0	3	1	1	1
151765	1710	ad group Ad12 group C	[Ad groups Ad12 group C]	0.0	5	1	1	1
151766	1710	principle a hormone-dependent regulator	[principle a hormone-dependent regulator]	0.0	4	1	1	1
151767	1710	time-frame	[time-frame]	0.0	1	1	1	1
151768	1710	hormone receptor of activator	[hormone receptor of activators]	0.0	4	1	1	1
151769	1710	arbitrary units,	[arbitrary units,]	0.0	2	1	1	1
151770	1710	control the competence of T cell	[controlling the competence of T cells]	0.0	6	1	1	1
151771	1710	mrna stability in cell	[mRNA stability in cells]	0.0	4	1	1	1
151772	1710	select synergistic activity	[selecting synergistic activity]	0.0	3	1	1	1
151773	1710	single point estimation of receptor	[Single point estimation of receptors]	0.0	5	1	1	1
151774	1710	I gamma sequence ECS	[I gamma sequence ECS]	0.0	4	1	1	1
151775	1710	disomy of sequence in cell lineage	[disomy of sequences in cell lineages]	0.0	6	1	1	1
151776	1710	TNF-alpha nuclear localization	[TNF-alpha nuclear localization]	0.0	3	1	1	1
151777	1710	mutate	[mutating]	0.0	1	1	1	1
151778	1710	immature tissue	[immature tissues]	0.0	2	1	1	1
151779	1710	perspective for gastroenterology	[perspectives for gastroenterology]	0.0	3	1	1	1
151780	1710	dexamethasone on uptake	[dexamethasone on uptake]	0.0	3	1	1	1
151781	1710	one site.	[one site.]	0.0	2	1	1	1
151782	1710	two immediate-early gene	[two immediate-early genes]	0.0	3	1	1	1
151783	1710	express cell in the sequence	[expressing cells in the sequences]	0.0	5	1	1	1
151784	1710	common event in early signalling	[common event in early signalling]	0.0	5	1	1	1
151785	1710	include the interferon	[including the interferons]	0.0	3	1	1	1
151786	1710	linkage of er codon	[linkage of ER codon]	0.0	4	1	1	1
151787	1710	include two sp1	[including two Sp1]	0.0	3	1	1	1
151788	1710	hla-dr expression	[HLA-DR expression]	0.0	2	1	1	1
151789	1710	nuclear nf-at complex	[nuclear NF-AT complexes]	0.0	3	1	1	1
151790	1710	mimicry between one gliadin peptide	[mimicry between one gliadin peptides]	0.0	5	1	1	1
151791	1710	interest, ikappabalpha overexpression	[interest, IkappaBalpha overexpression]	0.0	3	1	1	1
151792	1710	promoter construction	[promoter constructions]	0.0	2	1	1	1
151793	1710	interpretation a tissue-specific response	[interpretation a tissue-specific response]	0.0	4	1	1	1
151794	1710	gene regulatory inhibitory response	[gene regulatory inhibitory responses]	0.0	4	1	1	1
151795	1710	target for a comprehensive screen	[targets for a comprehensive screening]	0.0	5	1	1	1
151796	1710	assessment of lymphocyte reactivity	[assessment of lymphocyte reactivity]	0.0	4	1	1	1
151797	1710	dnase footprinting use amount	[DNase footprinting using amounts]	0.0	4	1	1	1
151798	1710	alpha gene regulation	[alpha gene regulation]	0.0	3	1	1	1
151799	1710	hydrophobic, polypeptide	[hydrophobic, polypeptide]	0.0	2	1	1	1
151800	1710	gpix ets site	[GPIX Ets site]	0.0	3	1	1	1
151801	1710	activation independent of gene	[activation independent of genes]	0.0	4	1	1	1
151802	1710	multiple reactivity at level as high	[multiple reactivities at levels as high]	0.0	6	1	1	1
151803	1710	inhibit nuclear translocation	[inhibiting nuclear translocation]	0.0	3	1	1	1
151804	1710	injury/activation	[injury/activation]	0.0	1	1	1	1
151805	1710	chloramphenicol acetyl	[chloramphenicol acetyl]	0.0	2	1	1	1
151806	1710	pbmc in male	[PBMC in males]	0.0	3	1	1	1
151807	1710	p50 subunit factor	[p50 subunits factor]	0.0	3	1	1	1
151808	1710	signal with CD40 ligand fibroblast activation	[Signaling with CD40 ligand fibroblast activation]	0.0	6	1	1	1
151809	1710	milligram	[milligram]	0.0	1	1	1	1
151810	1710	structurally distinct agent	[structurally distinct agent]	0.0	3	1	1	1
151811	1710	vaginal fluid specimen	[vaginal fluid specimens]	0.0	3	1	1	1
151812	1710	B-cell lymphocytic leukemia B-CLL	[B-cell lymphocytic leukemia B-CLL]	0.0	4	1	1	1
151813	1710	cell by immunodeficiency virus-1 tat protein	[cells by immunodeficiency virus-1 Tat protein]	0.0	6	1	1	1
151814	1710	13 age-matched subject	[13 age-matched subjects]	0.0	3	1	1	1
151815	1710	constitutively shp2-deltash2	[constitutively SHP2-DeltaSH2]	0.0	2	1	1	1
151816	1710	case of deficiency-cold syndrome	[cases of deficiency-cold syndrome]	0.0	4	1	1	1
151817	1710	tissue structural cell	[tissue structural cells]	0.0	3	1	1	1
151818	1710	erythroblastic progeny of progenitor	[erythroblastic progeny of progenitors]	0.0	4	1	1	1
151819	1710	specific set	[specific sets]	0.0	2	1	1	1
151820	1710	protein neg-2 binding to NRE-I	[protein Neg-2 binding to NRE-I]	0.0	5	1	1	1
151821	1710	cd27 /cd70 interaction	[CD27 /CD70 interaction]	0.0	3	1	1	1
151822	1710	demonstrate novel coupling	[demonstrating novel coupling]	0.0	3	1	1	1
151823	1710	segment in Ag may,	[segments in Ag may,]	0.0	4	1	1	1
151824	1710	local failure,	[local failure,]	0.0	2	1	1	1
151825	1710	nf-kappa b p50/p65 translocation result p105	[NF-kappa B p50/p65 translocation results p105]	0.0	6	1	1	1
151826	1710	nuclear factor nf-at	[nuclear factor NF-AT]	0.0	3	1	1	1
151827	1710	(nfat) family	[(NFAT) family]	0.0	2	1	1	1
151828	1710	491-amino-acid sequence of ie-1	[491-amino-acid sequence of IE-1]	0.0	4	1	1	1
151829	1710	reproductive target tissue	[reproductive target tissues]	0.0	3	1	1	1
151830	1710	increase levels.	[increase levels.]	0.0	2	1	1	1
151831	1710	6tg1.1 icr27tk.3 leukemic T cell	[6TG1.1 ICR27TK.3 leukemic T cells]	0.0	5	1	1	1
151832	1710	interaction between multiple transcriptional element	[interactions between multiple transcriptional elements]	0.0	5	1	1	1
151833	1710	human platelet/endothelial	[human platelet/endothelial]	0.0	2	1	1	1
151834	1710	-bsa-fitc by laser scanning microscopy clsm	[-BSA-FITC by laser scanning microscopy CLSM]	0.0	6	1	1	1
151835	1710	five potential target	[five potential targets]	0.0	3	1	1	1
151836	1710	aurothioglucose	[aurothioglucose]	0.0	1	1	1	1
151837	1710	transcriptional state	[transcriptional state]	0.0	2	1	1	1
151838	1710	regulation during human myeloid cell differentiation	[regulation during human myeloid cell differentiation]	0.0	6	1	1	1
151839	1710	lymphocyte reactivity	[lymphocyte reactivity]	0.0	2	1	1	1
151840	1710	therapy for bowel disease	[therapies for bowel disease]	0.0	4	1	1	1
151841	1710	select activity depend on the microenvironment.	[selecting activity depending on the microenvironment.]	0.0	6	1	1	1
151842	1710	differentiation increase	[differentiation increase]	0.0	2	1	1	1
151843	1710	result in accumulation	[resulting in accumulation]	0.0	3	1	1	1
151844	1710	human prostatic carcinoma cell line	[human prostatic carcinoma cell lines]	0.0	5	1	1	1
151845	1710	subpopulation namely, the (dp) CD4	[subpopulation namely, the (DP) CD4]	0.0	5	1	1	1
151846	1710	il-5 -nonproduce	[IL-5 -nonproducing]	0.0	2	1	1	1
151847	1710	promoter sequence responsive to AMP camp	[Promoter sequences responsive to AMP cAMP]	0.0	6	1	1	1
151848	1710	use recombinant zebra protein	[using recombinant ZEBRA protein]	0.0	4	1	1	1
151849	1710	part, at a pretranslational level	[part, at a pretranslational level]	0.0	5	1	1	1
151850	1710	specific protein interaction necessary	[specific protein interactions necessary]	0.0	4	1	1	1
151851	1710	detailed analysis of the function	[detailed analysis of the functions]	0.0	5	1	1	1
151852	1710	form of CBP	[form of CBP]	0.0	3	1	1	1
151853	1710	stable binding of factor	[stable binding of factors]	0.0	4	1	1	1
151854	1710	lipid proinflammatory mediator	[lipid proinflammatory mediator]	0.0	3	1	1	1
151855	1710	transcription of BZLF-1	[transcription of BZLF-1]	0.0	3	1	1	1
151856	1710	simultaneous analysis	[Simultaneous analysis]	0.0	2	1	1	1
151857	1710	lox promoter fragment	[lox promoter fragment]	0.0	3	1	1	1
151858	1710	transcription of irf-2	[transcription of IRF-2]	0.0	3	1	1	1
151859	1710	increase the level	[Increasing the levels]	0.0	3	1	1	1
151860	1710	importance of comedo	[importance of comedo]	0.0	3	1	1	1
151861	1710	characterization of the inhibitory activity	[characterization of the inhibitory activity]	0.0	5	1	1	1
151862	1710	main target of regulatory signal	[main target of regulatory signals]	0.0	5	1	1	1
151863	1710	thyroglobulin receptor	[thyroglobulin receptors]	0.0	2	1	1	1
151864	1710	EBNA-2 transactivation	[EBNA-2 transactivation]	0.0	2	1	1	1
151865	1710	class for dhea (dissociation constant	[class for DHEA (dissociation constant]	0.0	5	1	1	1
151866	1710	expression in human gingival fibroblast	[expression in human gingival fibroblasts]	0.0	5	1	1	1
151867	1710	wild-type CD4 receptor	[wild-type CD4 receptors]	0.0	3	1	1	1
151868	1710	measurement of the transcriptional activity	[Measurement of the transcriptional activity]	0.0	5	1	1	1
151869	1710	receptor c-mpl	[receptor c-Mpl]	0.0	2	1	1	1
151870	1710	regulation in human T lymphocyte	[regulation in human T lymphocytes]	0.0	5	1	1	1
151871	1710	existence of binding factor	[existence of binding factors]	0.0	4	1	1	1
151872	1710	expression of negative mutant form	[expression of negative mutant forms]	0.0	5	1	1	1
151873	1710	low-dose drug	[low-dose drugs]	0.0	2	1	1	1
151874	1710	Rosen,	[Rosen,]	0.0	1	1	1	1
151875	1710	enhancement replication in monocyte	[Enhancement replication in monocytes]	0.0	4	1	1	1
151876	1710	respectively, corresponding to a 0.5 molecule	[respectively, corresponding to an 0.5 molecules]	0.0	6	1	1	1
151877	1710	complex in eosinophil include Stat1 alpha	[complexes in eosinophils including Stat1 alpha]	0.0	6	1	1	1
151878	1710	level of tnf-alpha rna	[level of TNF-alpha RNA]	0.0	4	1	1	1
151879	1710	2-deoxyguanosine-treated thymus lobe	[2-deoxyguanosine-treated thymus lobes]	0.0	3	1	1	1
151880	1710	NF-kappaB a transcriptional regulator	[NF-kappaB a transcriptional regulator]	0.0	4	1	1	1
151881	1710	activity, phosphorylation event	[activity, phosphorylation events]	0.0	3	1	1	1
151882	1710	increase in lt activity	[increase in LT activity]	0.0	4	1	1	1
151883	1710	gain a detailed understanding	[gaining a detailed understanding]	0.0	4	1	1	1
151884	1710	il-1beta antibody	[IL-1beta antibody]	0.0	2	1	1	1
151885	1710	association of traz domain	[association of TRAFs domain]	0.0	4	1	1	1
151886	1710	min) physical exercise at 70%	[min) physical exercise at 70%]	0.0	5	1	1	1
151887	1710	locus control region 5'HS3	[locus control region 5'HS3]	0.0	4	1	1	1
151888	1710	expression of sigm	[expression of sIgM]	0.0	3	1	1	1
151889	1710	interleukin-6 IL-6	[interleukin-6 IL-6]	0.0	2	1	1	1
151890	1710	mutation in exon	[mutation in exon]	0.0	3	1	1	1
151891	1710	isoform of the transcription factor	[isoforms of the transcription factor]	0.0	5	1	1	1
151892	1710	mouse oct2	[mouse Oct2]	0.0	2	1	1	1
151893	1710	evaluation of the importance	[evaluation of the importance]	0.0	4	1	1	1
151894	1710	round nucleus	[round nucleus]	0.0	2	1	1	1
151895	1710	translocation result in expression	[translocation resulting in expression]	0.0	4	1	1	1
151896	1710	antiinflammatory alkaloid	[antiinflammatory alkaloid]	0.0	2	1	1	1
151897	1710	decrease in state kappa	[decrease in state kappa]	0.0	4	1	1	1
151898	1710	dna-binding heterodimer nf-kappa b	[DNA-binding heterodimer NF-kappa B]	0.0	4	1	1	1
151899	1710	transcription in cell extract	[transcription in cell extracts]	0.0	4	1	1	1
151900	1710	similar (46%	[similar (46%]	0.0	2	1	1	1
151901	1710	involve NK-chi b	[involving NK-chi B]	0.0	3	1	1	1
151902	1710	cell cytokine production	[cell cytokine production]	0.0	3	1	1	1
151903	1710	Differential contribution gene product	[Differential contribution gene products]	0.0	4	1	1	1
151904	1710	epo -binding site	[Epo -binding sites]	0.0	3	1	1	1
151905	1710	constitutive expression in Jurkat T cell	[Constitutive expression in Jurkat T cells]	0.0	6	1	1	1
151906	1710	cross-talk between the partner	[cross-talk between the partners]	0.0	4	1	1	1
151907	1710	12 nonspecific hyperplasia	[12 nonspecific hyperplasia]	0.0	3	1	1	1
151908	1710	tlr-dependent transcription of inducible oxide synthase	[TLR-dependent transcription of inducible oxide synthase]	0.0	6	1	1	1
151909	1710	addition, reach the half-maximal effect	[addition, reaching the half-maximal effect]	0.0	5	1	1	1
151910	1710	genomic library	[genomic library]	0.0	2	1	1	1
151911	1710	lps factor-kappaB translocation	[LPS factor-kappaB translocation]	0.0	3	1	1	1
151912	1710	subsequent adhesion in endothelial cell	[subsequent adhesion in endothelial cells]	0.0	5	1	1	1
151913	1710	patient autoimmune serum	[patients autoimmune serum]	0.0	3	1	1	1
151914	1710	contain stat1	[containing STAT1]	0.0	2	1	1	1
151915	1710	contain stat4	[containing STAT4]	0.0	2	1	1	1
151916	1710	cloning of tcf-1	[Cloning of TCF-1]	0.0	3	1	1	1
151917	1710	blood hormone concentration	[blood hormone concentrations]	0.0	3	1	1	1
151918	1710	Vitamin d analog	[Vitamin D analogs]	0.0	3	1	1	1
151919	1710	hbd subfragment	[HBD subfragments]	0.0	2	1	1	1
151920	1710	gr abnormalities: 15	[GR abnormalities: 15]	0.0	3	1	1	1
151921	1710	exact site	[exact site]	0.0	2	1	1	1
151922	1710	trinucleotide repeat	[trinucleotide repeat]	0.0	2	1	1	1
151923	1710	degree c) twice/d,	[degrees C) twice/d,]	0.0	3	1	1	1
151924	1710	direct repeat DR of bp	[direct repeats DR of bp]	0.0	5	1	1	1
151925	1710	135-(oh)2d3 suppression	[1,25-(OH)2D3 suppression]	0.0	2	1	1	1
151926	1710	patient receive glucocorticoid therapy	[patients receiving glucocorticoid therapy]	0.0	4	1	1	1
151927	1710	microbial agonist	[microbial agonists]	0.0	2	1	1	1
151928	1710	effect on host cell activation	[effects on host cell activation]	0.0	5	1	1	1
151929	1710	47-bp sequence position -306	[47-bp sequence positions -306]	0.0	4	1	1	1
151930	1710	determinant of homeostasis	[determinant of homeostasis]	0.0	3	1	1	1
151931	1710	Specific effect of dioxyvit with correction	[Specific effect of dioxyvit with correction]	0.0	6	1	1	1
151932	1710	specific instance of the principle	[specific instance of the principle]	0.0	5	1	1	1
151933	1710	depend on the intensity	[depending on the intensity]	0.0	4	1	1	1
151934	1710	hydrophobic domain with putative segment	[hydrophobic domain with putative segments]	0.0	5	1	1	1
151935	1710	wk to mo)	[wk to mo)]	0.0	3	1	1	1
151936	1710	event in the degradation	[event in the degradation]	0.0	4	1	1	1
151937	1710	level in platelet	[levels in platelets]	0.0	3	1	1	1
151938	1710	use hpr cDNA probe	[Using hPR cDNA probes]	0.0	4	1	1	1
151939	1710	analogue of up	[analogue of UP]	0.0	3	1	1	1
151940	1710	13-myristate acetate	[13-myristate acetate]	0.0	2	1	1	1
151941	1710	bind in a manner	[binding in a manner]	0.0	4	1	1	1
151942	1710	replication of the isolate hiv-1	[replication of the isolate HIV-1]	0.0	5	1	1	1
151943	1710	kda id-3 protein	[kDa Id-3 protein]	0.0	3	1	1	1
151944	1710	shift from to prb	[shift from to pRB]	0.0	4	1	1	1
151945	1710	corresponding to a molecule	[corresponding to an molecules]	0.0	4	1	1	1
151946	1710	TNF factor-kappaB activation between huvec	[TNF factor-kappaB activation between HUVECs]	0.0	5	1	1	1
151947	1710	protein LR1	[protein LR1]	0.0	2	1	1	1
151948	1710	loss of zeta-chain	[loss of zeta-chain]	0.0	3	1	1	1
151949	1710	less il-10	[less IL-10]	0.0	2	1	1	1
151950	1710	contain mutant receptor	[containing mutant receptors]	0.0	3	1	1	1
151951	1710	defect carry mutation	[defects carrying mutations]	0.0	3	1	1	1
151952	1710	+/- 168)	[+/- 168)]	0.0	2	1	1	1
151953	1710	splenic cell	[splenic cells]	0.0	2	1	1	1
151954	1710	acute (aml) blast	[acute (AML) blasts]	0.0	3	1	1	1
151955	1710	respiratory manifestation	[respiratory manifestations]	0.0	2	1	1	1
151956	1710	genomic rearrangement	[genomic rearrangements]	0.0	2	1	1	1
151957	1710	tax -independent binding	[Tax -independent binding]	0.0	3	1	1	1
151958	1710	3-week course in patient	[3-week course in patients]	0.0	4	1	1	1
151959	1710	nuclear nf-kappa b protein	[nuclear NF-kappa B proteins]	0.0	4	1	1	1
151960	1710	particle transduce tat	[particles transducing tat]	0.0	3	1	1	1
151961	1710	follow stimulation tumor necrosis factor-alpha TNF-alpha	[Following stimulation tumor necrosis factor-alpha TNF-alpha]	0.0	6	1	1	1
151962	1710	significant inactivation of the x	[significant inactivation of the X]	0.0	5	1	1	1
151963	1710	cell mnc	[cells MNC]	0.0	2	1	1	1
151964	1710	change in immune-endocrine function	[change in immune-endocrine function]	0.0	4	1	1	1
151965	1710	b blk gene promoter	[B BLK gene promoter]	0.0	4	1	1	1
151966	1710	XLH patient	[XLH patients]	0.0	2	1	1	1
151967	1710	dysregulation of (hpa) axis	[dysregulation of (HPA) axis]	0.0	4	1	1	1
151968	1710	creb mutant	[CREB mutants]	0.0	2	1	1	1
151969	1710	min/exposure,	[min/exposure,]	0.0	1	1	1	1
151970	1710	lupus erythematosus SLE	[lupus erythematosus SLE]	0.0	3	3	3	1
151971	1710	rescue b cell	[rescuing B cells]	0.0	3	1	1	1
151972	1710	target under condition	[target under conditions]	0.0	3	1	1	1
151973	1710	adenovirus type during year	[adenovirus types during years]	0.0	4	1	1	1
151974	1710	dnase chromatin site HS	[DNase chromatin site HS]	0.0	4	1	1	1
151975	1710	suppress activation by IL-4	[suppressing activation by IL-4]	0.0	4	1	1	1
151976	1710	functional immune deficiency virus type	[functional immune deficiency virus type]	0.0	5	1	1	1
151977	1710	up-regulation of c-fo	[up-regulation of c-fos]	0.0	3	1	1	1
151978	1710	study indicate a determinant of expression	[studies indicating an determinant of expression]	0.0	6	1	1	1
151979	1710	extensive purification by cycle	[extensive purification by cycles]	0.0	4	1	1	1
151980	1710	regulator in lymphocyte	[regulators in lymphocytes]	0.0	3	1	1	1
151981	1710	direct action of RA	[direct action of RA]	0.0	4	1	1	1
151982	1710	increase in the cysteine supply	[increase in the cysteine supply]	0.0	5	1	1	1
151983	1710	human immunodeficiency virus type-2 gene expression	[Human immunodeficiency virus type-2 gene expression]	0.0	6	1	1	1
151984	1710	control of response	[control of responses]	0.0	3	1	1	1
151985	1710	binding to regulatory region	[binding to regulatory regions]	0.0	4	1	1	1
151986	1710	stimulation by a combination	[Stimulation by a combination]	0.0	4	1	1	1
151987	1710	icam-1 level	[ICAM-1 levels]	0.0	2	1	1	1
151988	1710	gc action	[GC actions]	0.0	2	1	1	1
151989	1710	heavy- chain gene	[heavy- chain genes]	0.0	3	1	1	1
151990	1710	moreover, transient transfection L23	[Moreover, transient transfection L23]	0.0	4	1	1	1
151991	1710	that: induction	[that: induction]	0.0	2	1	1	1
151992	1710	interleukin-4 element	[interleukin-4 element]	0.0	2	1	1	1
151993	1710	oct2-isoform expression	[Oct2-isoform expression]	0.0	2	1	1	1
151994	1710	complex formation in the presence	[complex formation in the presence]	0.0	5	1	1	1
151995	1710	novel molecule of SIT	[novel molecule of SIT]	0.0	4	1	1	1
151996	1710	also by the displacement	[also by the displacement]	0.0	4	1	1	1
151997	1710	p sequence 5'-cgaaaatttcc-3'	[P sequence 5'-CGAAAATTTCC-3']	0.0	3	1	1	1
151998	1710	chicken erythrocyte	[chicken erythrocyte]	0.0	2	1	1	1
151999	1710	constitutive nf-kappa b -binding activity	[constitutive NF-kappa B -binding activity]	0.0	5	1	1	1
152000	1710	partial variable monosomy	[partial variable monosomy]	0.0	3	1	1	1
152001	1710	binding of interferon	[binding of interferon]	0.0	3	1	1	1
152002	1710	exception lymphocyte	[exception lymphocytes]	0.0	2	1	1	1
152003	1710	similarly in macrophage	[similarly in macrophages]	0.0	3	1	1	1
152004	1710	express the murine g-csfr	[expressing the murine G-CSFR]	0.0	4	1	1	1
152005	1710	degradation of mad3/	[degradation of MAD3/]	0.0	3	1	1	1
152006	1710	high concentration of type peptide	[higher concentrations of type peptides]	0.0	5	1	1	1
152007	1710	expression of a active calcineurin cn	[Expression of a active calcineurin CN]	0.0	6	1	1	1
152008	1710	degradation monocytic cell	[degradation monocytic cells]	0.0	3	1	1	1
152009	1710	role of factor-kappa b	[role of factor-kappa B]	0.0	4	1	1	1
152010	1710	constitutive hiv production	[constitutive HIV production]	0.0	3	1	1	1
152011	1710	activation of the 2 gene enhancer	[activation of the 2 gene enhancer]	0.0	6	1	1	1
152012	1710	negative effect on the activity	[negative effect on the activity]	0.0	5	1	1	1
152013	1710	mutant approach	[mutant approach]	0.0	2	1	1	1
152014	1710	monocyte cell model system	[monocyte cell model systems]	0.0	4	1	1	1
152015	1710	only extremely low level	[only extremely low levels]	0.0	4	1	1	1
152016	1710	regulation of this response	[regulation of this response]	0.0	4	1	1	1
152017	1710	lectin-activated T	[lectin-activated T]	0.0	2	1	1	1
152018	1710	expression of runt polypeptide	[expression of runt polypeptides]	0.0	4	1	1	1
152019	1710	class of site similar	[class of sites similar]	0.0	4	1	1	1
152020	1710	overexpression of dominant negative form	[Overexpression of dominant negative forms]	0.0	5	1	1	1
152021	1710	patient with various chronic disease	[patients with various chronic diseases]	0.0	5	1	1	1
152022	1710	role in reaction	[role in reactions]	0.0	3	1	1	1
152023	1710	Vitamin d receptor expression	[Vitamin D receptor expression]	0.0	4	1	1	1
152024	1710	basis for expression	[basis for expression]	0.0	3	1	1	1
152025	1710	(type ii) nitric oxide synthase expression	[(type II) nitric oxide synthase expression]	0.0	6	1	1	1
152026	1710	only in a specific context	[only in a specific context]	0.0	5	1	1	1
152027	1710	radiosensitivity of squamous cell carcinoma	[radiosensitivity of squamous cell carcinomas]	0.0	5	1	1	1
152028	1710	slow decline in blood histamine	[slower decline in blood histamine]	0.0	5	1	1	1
152029	1710	msv LTR promoter	[MSV LTR promoter]	0.0	3	1	1	1
152030	1710	upper spinous layer	[upper spinous layer]	0.0	3	1	1	1
152031	1710	EBV early product	[EBV early product]	0.0	3	1	1	1
152032	1710	two family RA receptor rar	[two families RA receptors RARs]	0.0	5	1	1	1
152033	1710	effect on regulatory factor	[effects on regulatory factors]	0.0	4	1	1	1
152034	1710	tumor estrogen/progesterone	[tumor estrogen/progesterone]	0.0	2	1	1	1
152035	1710	switch recombination to epsilon	[switch recombination to epsilon]	0.0	4	1	1	1
152036	1710	induction of ikk activity	[induction of IKK activity]	0.0	4	1	1	1
152037	1710	monoclonal antibody lt-4	[monoclonal antibody Lt-4]	0.0	3	1	1	1
152038	1710	extraction	[extraction]	0.0	1	1	1	1
152039	1710	distinct apoptosis signal pathway	[distinct apoptosis signaling pathways]	0.0	4	1	1	1
152040	1710	level of bcl-6 mrna	[levels of BCL-6 mRNA]	0.0	4	1	1	1
152041	1710	PMA element	[PMA element]	0.0	2	3	3	1
152042	1710	express mutant form of the protein	[expressing mutant forms of the protein]	0.0	6	1	1	1
152043	1710	event of the female	[events of the female]	0.0	4	1	1	1
152044	1710	hiv-1 mutation within two C/EBP site	[HIV-1 mutations within two C/EBP sites]	0.0	6	1	1	1
152045	1710	activation of macrophage by lipopolysaccharide lps	[Activation of macrophages by lipopolysaccharide LPS]	0.0	6	1	1	1
152046	1710	indicate common	[indicating common]	0.0	2	1	1	1
152047	1710	increase to amount	[increases to amounts]	0.0	3	1	1	1
152048	1710	responsiveness positive chronic myelogenous leukemia	[responsiveness positive chronic myelogenous leukemia]	0.0	5	1	1	1
152049	1710	low, concentration	[low, concentrations]	0.0	2	2	2	1
152050	1710	pbmc culture (1.5	[PBMC cultures (1.5]	0.0	3	1	1	1
152051	1710	adjacent cis-acting elements,	[adjacent cis-acting elements,]	0.0	3	1	1	1
152052	1710	total DNA	[total DNA]	0.0	2	1	1	1
152053	1710	number of element	[number of elements]	0.0	3	1	1	1
152054	1710	mutagenesis of NF kappa b	[Mutagenesis of NF kappa B]	0.0	5	1	1	1
152055	1710	tnf-alpha promoter enhancer element	[TNF-alpha promoter enhancer elements]	0.0	4	1	1	1
152056	1710	high (p<.001) in patient	[higher (P<.001) in patients]	0.0	4	1	1	1
152057	1710	untrained volunteer	[untrained volunteers]	0.0	2	1	1	1
152058	1710	c/ebp protein LIP	[C/EBP protein LIP]	0.0	3	1	1	1
152059	1710	specific factor-DNA complex	[specific factor-DNA complexes]	0.0	3	1	1	1
152060	1710	induce CAT activity by 3.2-fold,	[inducing CAT activity by 3.2-fold,]	0.0	5	1	1	1
152061	1710	camp elevation	[cAMP elevation]	0.0	2	1	1	1
152062	1710	effect relative to transcription start site	[effects relative to transcription start sites]	0.0	6	1	1	1
152063	1710	expression of il-2ralpha	[expression of IL-2Ralpha]	0.0	3	1	1	1
152064	1710	B29 beta-chain gene	[B29 beta-chain gene]	0.0	3	1	1	1
152065	1710	level il-2 production	[level IL-2 production]	0.0	3	1	1	1
152066	1710	amount of the kb transcript	[amounts of the kb transcript]	0.0	5	1	1	1
152067	1710	Rb function	[Rb function]	0.0	2	1	1	1
152068	1710	response to 1,25-dihydroxyvitamin D3	[response to 1,25-dihydroxyvitamin D3]	0.0	4	1	1	1
152069	1710	disturbance of the hypothalamic-pituitary-adrenal system	[disturbances of the hypothalamic-pituitary-adrenal system]	0.0	5	1	1	1
152070	1710	semiquantitative hybridization assay	[semiquantitative hybridization assay]	0.0	3	1	1	1
152071	1710	human k562 cell differentiation	[human K562 cells differentiation]	0.0	4	1	1	1
152072	1710	definition of endpoint	[definitions of endpoints]	0.0	3	1	1	1
152073	1710	erythropoietic differentiation in culture	[erythropoietic differentiation in culture]	0.0	4	1	1	1
152074	1710	degenerative paraparesis tsp	[degenerative paraparesis TSP]	0.0	3	1	1	1
152075	1710	activity of analogue	[activities of analogues]	0.0	3	1	1	1
152076	1710	adult T cell factor	[adult T cell factor]	0.0	4	1	1	1
152077	1710	fibrosarcoma fibrous histiocytoma rhabdomyosarcoma	[fibrosarcoma fibrous histiocytoma rhabdomyosarcoma]	0.0	4	1	1	1
152078	1710	nonhistone	[nonhistone]	0.0	1	1	1	1
152079	1710	and/or post-translational modification of transcription factor	[and/or post-translational modifications of transcription factors]	0.0	6	1	1	1
152080	1710	83 control	[83 controls]	0.0	2	1	1	1
152081	1710	trans-activator such as tax	[trans-activators such as Tax]	0.0	4	1	1	1
152082	1710	er cell	[ER cells]	0.0	2	1	1	1
152083	1710	-2 molecule per cell.	[-2 molecules per cell.]	0.0	4	1	1	1
152084	1710	serum a gene	[serum A gene]	0.0	3	1	1	1
152085	1710	activation of map kinase	[activation of MAP kinase]	0.0	4	1	1	1
152086	1710	ras mutation	[ras mutations]	0.0	2	1	1	1
152087	1710	case-control study of disease tuberculosis	[case-control studies of diseases tuberculosis]	0.0	5	1	1	1
152088	1710	NF-kappa b oligonucleotide	[NF-kappa B oligonucleotide]	0.0	3	1	1	1
152089	1710	other factor present in Jurkat cell	[Other factors present in Jurkat cells]	0.0	6	1	1	1
152090	1710	affinity ligand-binding of the mr	[affinity ligand-binding of the MR]	0.0	5	1	1	1
152091	1710	damage to t-cell precursor	[damage to T-cell precursors]	0.0	4	1	1	1
152092	1710	signal of T cell	[signaling of T cells]	0.0	4	1	1	1
152093	1710	well-defined change of the thymocyte	[well-defined changes of the thymocyte]	0.0	5	1	1	1
152094	1710	29 asthma patient 70%	[29 asthma patients 70%]	0.0	4	1	1	1
152095	1710	1 mmol/L buthionine sulfoximine	[1 mmol/L buthionine sulfoximine]	0.0	4	1	1	1
152096	1710	great amplification of 1 allele	[greater amplification of 1 allele]	0.0	5	1	1	1
152097	1710	obscure, several line	[obscure, several lines]	0.0	3	1	1	1
152098	1710	cross-talk between glucocorticoid	[cross-talk between glucocorticoids]	0.0	3	1	1	1
152099	1710	lymphoid specific gene expression promoter	[Lymphoid specific gene expression promoter]	0.0	5	1	1	1
152100	1710	step signal cascade	[steps signaling cascade]	0.0	3	1	1	1
152101	1710	amplify event	[amplifying events]	0.0	2	1	1	1
152102	1710	year gail risk	[year Gail risk]	0.0	3	1	1	1
152103	1710	basal cell	[basal cells]	0.0	2	1	1	1
152104	1710	thyroid autoantigen	[thyroid autoantigens]	0.0	2	1	1	1
152105	1710	control expression in reporter gene assay	[controlling expression in reporter gene assays]	0.0	6	1	1	1
152106	1710	ap-1 -binding activity of nuclear protein	[AP-1 -binding activity of nuclear proteins]	0.0	6	1	1	1
152107	1710	deaminase a enzyme of heme synthesis	[deaminase an enzyme of heme synthesis]	0.0	6	1	1	1
152108	1710	different origin than contraction	[different origin than contractions]	0.0	4	1	1	1
152109	1710	constitutive binding of factor protein	[Constitutive binding of factor proteins]	0.0	5	1	1	1
152110	1710	expression of shp1	[Expression of SHP1]	0.0	3	1	1	1
152111	1710	Differential induction protein differentiation	[Differential induction protein differentiation]	0.0	4	1	1	1
152112	1710	powerful suppressor of the immune system	[powerful suppressors of the immune system]	0.0	6	1	1	1
152113	1710	role of all-tran acid	[role of all-trans acid]	0.0	4	1	1	1
152114	1710	il-5 synthesis in disease	[IL-5 synthesis in diseases]	0.0	4	1	1	1
152115	1710	leukocyte of MDD patient	[leukocytes of MDD patients]	0.0	4	1	1	1
152116	1710	suggest selective	[suggesting selective]	0.0	2	1	1	1
152117	1710	multimerized region ii	[multimerized region II]	0.0	3	1	1	1
152118	1710	cell population capable after induction	[cell population capable after induction]	0.0	5	1	1	1
152119	1710	(interquartile	[(interquartile]	0.0	1	1	1	1
152120	1710	biological characteristic	[biological characteristics]	0.0	2	2	2	1
152121	1710	tcr gene as a model	[TCR gene as a model]	0.0	5	1	1	1
152122	1710	reflect the high level	[reflecting the high levels]	0.0	4	1	1	1
152123	1710	stroma cell line	[stroma cell line]	0.0	3	1	1	1
152124	1710	contain a gata-factor	[containing a GATA-factor]	0.0	3	1	1	1
152125	1710	various neoplastic disorder in woman	[various neoplastic disorders in women]	0.0	5	1	1	1
152126	1710	role: alteration of the sequence	[role: alteration of the sequence]	0.0	5	1	1	1
152127	1710	responsiveness positive chronic leukemia	[responsiveness positive chronic leukemia]	0.0	4	1	1	1
152128	1710	decline in receptor concentration	[decline in receptor concentrations]	0.0	4	1	1	1
152129	1710	gs in human T lymphocyte	[GS in human T lymphocytes]	0.0	5	1	1	1
152130	1710	low degree of transcription,	[low degree of transcription,]	0.0	4	1	1	1
152131	1710	40-kd tax protein a transactivator	[40-kd Tax protein a transactivator]	0.0	5	1	1	1
152132	1710	main pathway	[main pathways]	0.0	2	1	1	1
152133	1710	impaired activation of nuclear factor	[impaired activation of nuclear factors]	0.0	5	1	1	1
152134	1710	14-day colony mm)	[14-day colonies mm)]	0.0	3	1	1	1
152135	1710	leucin-zipper region	[leucin-zipper region]	0.0	2	1	1	1
152136	1710	autoimmune disease cirrhosis	[autoimmune disease cirrhosis]	0.0	3	1	1	1
152137	1710	Effect of agent upon glucocorticoid action	[Effects of agents upon glucocorticoid action]	0.0	6	1	1	1
152138	1710	safety phenotype	[safety phenotype]	0.0	2	1	1	1
152139	1710	lead to export	[leading to export]	0.0	3	1	1	1
152140	1710	dissociation of the molecule	[dissociation of the molecule]	0.0	4	1	1	1
152141	1710	second messenger generation	[second messenger generation]	0.0	3	1	1	1
152142	1710	Stat6 activity	[Stat6 activity]	0.0	2	1	1	1
152143	1710	rapidity	[rapidity]	0.0	1	1	1	1
152144	1710	imply a positive role for camp	[implying a positive role for cAMP]	0.0	6	1	1	1
152145	1710	(mean of assays), a value	[(mean of assays), a value]	0.0	5	1	1	1
152146	1710	key mediator of regulatory interaction	[key mediators of regulatory interactions]	0.0	5	1	1	1
152147	1710	viral transcription transcription	[viral transcription transcription]	0.0	3	1	1	1
152148	1710	cellular transcription factor factor	[cellular transcription factor factor]	0.0	4	1	1	1
152149	1710	small intron	[small intron]	0.0	2	1	1	1
152150	1710	concentrations, triflusal	[concentrations, triflusal]	0.0	2	1	1	1
152151	1710	parent compound	[parent compound]	0.0	2	1	1	1
152152	1710	number false (positive)	[number false (positive)]	0.0	3	1	1	1
152153	1710	arrangement of positively sequence	[arrangement of positively sequences]	0.0	4	1	1	1
152154	1710	egfr 35%,	[EGFR 35%,]	0.0	2	1	1	1
152155	1710	lymphoid-related DC	[lymphoid-related DC]	0.0	2	1	1	1
152156	1710	four methods, include annexin-V staining	[four methods, including annexin-V staining]	0.0	5	1	1	1
152157	1710	lymphoid follicle formation	[lymphoid follicle formation]	0.0	3	1	1	1
152158	1710	nfkappab1	[NFkappaB1]	0.0	1	1	1	1
152159	1710	use a competitive binding assay	[Using a competitive binding assay]	0.0	5	1	1	1
152160	1710	100 nm dexamethasone	[100 nM dexamethasone]	0.0	3	1	1	1
152161	1710	METHODS: IBD	[METHODS: IBD]	0.0	2	1	1	1
152162	1710	look back in approach	[Looking back in approaches]	0.0	4	1	1	1
152163	1710	U1 proliferation	[U1 proliferation]	0.0	2	1	1	1
152164	1710	and/or paracrine factor	[and/or paracrine factor]	0.0	3	1	1	1
152165	1710	establish due to expression in monocyte	[establishing due to expression in monocytes]	0.0	6	1	1	1
152166	1710	unequal paternal expression	[unequal paternal expression]	0.0	3	1	1	1
152167	1710	t-cell receptor (tcr)-zeta	[T-cell receptor (TCR)-zeta]	0.0	3	1	1	1
152168	1710	protein kinase inhibition	[protein kinase inhibition]	0.0	3	1	1	1
152169	1710	human gene therapy protocol	[human gene therapy protocols]	0.0	4	1	1	1
152170	1710	contrast to the strong inhibition	[contrast to the strong inhibition]	0.0	5	1	1	1
152171	1710	study responsiveness to two viral transactivator	[studying responsiveness to two viral transactivators]	0.0	6	1	1	1
152172	1710	transfection analysis of the region	[transfection analysis of the region]	0.0	5	1	1	1
152173	1710	mechanism of il-2 activation	[mechanisms of IL-2 activation]	0.0	4	1	1	1
152174	1710	demonstrate a vitro substrate for calcineurin	[demonstrating an vitro substrate for calcineurin]	0.0	6	1	1	1
152175	1710	DEG5	[DEG5]	0.0	1	1	1	1
152176	1710	hiv-1/siv	[HIV-1/SIV]	0.0	1	1	1	1
152177	1710	similarly, covalent modification	[Similarly, covalent modification]	0.0	3	1	1	1
152178	1710	possibly other cell	[possibly other cells]	0.0	3	1	1	1
152179	1710	nonepithelial cell	[nonepithelial cells]	0.0	2	1	1	1
152180	1710	hemoglobin HbF	[hemoglobin HbF]	0.0	2	1	1	1
152181	1710	molecular size of kilodalton	[molecular size of kilodaltons]	0.0	4	1	1	1
152182	1710	induction in a human line	[Induction in a human line]	0.0	5	1	1	1
152183	1710	protein of 14 kda	[protein of 14 kDa]	0.0	4	1	1	1
152184	1710	human venous	[human venous]	0.0	2	1	1	1
152185	1710	transcription factor with negative function	[transcription factor with negative functions]	0.0	5	1	1	1
152186	1710	factor nf-il6 (position	[factor NF-IL6 (positions]	0.0	3	1	1	1
152187	1710	link between the magnitude	[link between the magnitude]	0.0	4	1	1	1
152188	1710	mammalian cell susceptibility to lysis	[mammalian cell susceptibility to lysis]	0.0	5	1	1	1
152189	1710	PD98059 a inhibitor of erk	[PD98059 a inhibitor of ERK]	0.0	5	1	1	1
152190	1710	b activity a report.	[B activity a report.]	0.0	4	1	1	1
152191	1710	phenotypic marker of osteoclast vitronectin receptor	[phenotypic markers of osteoclasts vitronectin receptor]	0.0	6	1	1	1
152192	1710	four important region	[four important regions]	0.0	3	1	1	1
152193	1710	proliferation (71%) iddm subject	[proliferation (71%) IDDM subjects]	0.0	4	1	1	1
152194	1710	glucose phosphate	[glucose phosphate]	0.0	2	1	1	1
152195	1710	metabolite gliotoxin	[metabolite gliotoxin]	0.0	2	1	1	1
152196	1710	TNF-alpha translocation	[TNF-alpha translocation]	0.0	2	1	1	1
152197	1710	carrier of XCID	[carriers of XCID]	0.0	3	1	1	1
152198	1710	gene control	[gene control]	0.0	2	1	1	1
152199	1710	action of retinoic acid blockade	[action of retinoic acid blockade]	0.0	5	1	1	1
152200	1710	binding of traf2 to the domain	[binding of TRAF2 to the domain]	0.0	6	1	1	1
152201	1710	use c/ebp beta abs	[using C/EBP beta Abs]	0.0	4	1	1	1
152202	1710	follow treatment with all-tran acid	[following treatment with all-trans acid]	0.0	5	1	1	1
152203	1710	mitogen in vitro.	[mitogens in vitro.]	0.0	3	1	1	1
152204	1710	human th1 clone	[human Th1 clones]	0.0	3	1	1	1
152205	1710	mediator by cell	[mediators by cells]	0.0	3	1	1	1
152206	1710	unknown mineralocorticoid	[unknown mineralocorticoid]	0.0	2	1	1	1
152207	1710	apoptosis of T. parva-transformed T cell	[apoptosis of T. parva-transformed T cells]	0.0	6	1	1	1
152208	1710	protein glycation in beta cell	[protein glycation in beta cells]	0.0	5	1	1	1
152209	1710	event in tumor	[events in tumors]	0.0	3	1	1	1
152210	1710	abnormality by metaphase analysis	[abnormalities by metaphase analysis]	0.0	4	1	1	1
152211	1710	control hematopoietic gene transcription	[controlling hematopoietic gene transcription]	0.0	4	1	1	1
152212	1710	(include smooth muscle actin	[(including smooth muscle actin]	0.0	4	1	1	1
152213	1710	use the pkc inhibitor ro	[using the PKC inhibitor Ro]	0.0	5	1	1	1
152214	1710	affinity of Oct-1	[affinity of Oct-1]	0.0	3	1	1	1
152215	1710	(average	[(average]	0.0	1	1	1	1
152216	1710	hypergammaglobulinemia or,	[hypergammaglobulinemia or,]	0.0	2	1	1	1
152217	1710	combination protocol	[combination protocols]	0.0	2	1	1	1
152218	1710	initiation at site of inflammation	[initiation at sites of inflammation]	0.0	5	1	1	1
152219	1710	include ARDS	[including ARDS]	0.0	2	1	1	1
152220	1710	mycoplasma fermentans-derived high-molecular-weight material	[Mycoplasma fermentans-derived high-molecular-weight material]	0.0	4	1	1	1
152221	1710	CBFalpha2	[CBFalpha2]	0.0	1	1	1	1
152222	1710	role in repression of globin	[role in repression of globin]	0.0	5	1	1	1
152223	1710	extracellular generation	[Extracellular generation]	0.0	2	1	1	1
152224	1710	human red blood cell	[human red blood cells]	0.0	4	1	1	1
152225	1710	wide variety include septic shock	[wide variety including septic shock]	0.0	5	1	1	1
152226	1710	consist only of the domain	[consisting only of the domain]	0.0	5	1	1	1
152227	1710	susceptibility kill by lymphocyte	[susceptibility killing by lymphocytes]	0.0	4	1	1	1
152228	1710	shigella	[Shigella]	0.0	1	1	1	1
152229	1710	induction by stimulation	[induction by stimulation]	0.0	3	1	1	1
152230	1710	abnormal T lymphocyte	[Abnormal T lymphocyte]	0.0	3	1	1	1
152231	1710	protein tyrosine kinase ptk module	[protein tyrosine kinase PTK modules]	0.0	5	1	1	1
152232	1710	transcriptionally active heterodimer follow time	[transcriptionally active heterodimers following time]	0.0	5	1	1	1
152233	1710	repeat region of hiv-1	[repeat region of HIV-1]	0.0	4	1	1	1
152234	1710	site originate 204 bp upstream	[sites originating 204 bp upstream]	0.0	5	1	1	1
152235	1710	CsA fk506 -sensitive factor	[CsA FK506 -sensitive factor]	0.0	4	1	1	1
152236	1710	induction of antibody	[induction of antibodies]	0.0	3	1	1	1
152237	1710	increase in intracellular camp	[increase in intracellular cAMP]	0.0	4	1	1	1
152238	1710	level beta	[levels beta]	0.0	2	1	1	1
152239	1710	multiple start site	[multiple start sites]	0.0	3	1	1	1
152240	1710	expression leukocyte protein of 76 kilodaltons),	[expression leukocyte protein of 76 kilodaltons),]	0.0	6	1	1	1
152241	1710	result in reduction	[resulting in reduction]	0.0	3	1	1	1
152242	1710	tgf-beta 2 transcription	[TGF-beta 2 transcription]	0.0	3	1	1	1
152243	1710	cooperation between the hsv-1-activated factor	[cooperation between the HSV-1-activated factor]	0.0	5	1	1	1
152244	1710	synovitis	[synovitis]	0.0	1	1	1	1
152245	1710	actively seek social support	[actively seeking social support]	0.0	4	1	1	1
152246	1710	human leukemia cell line grow	[human leukemia cell lines growing]	0.0	5	1	1	1
152247	1710	1,25-dihydroxyvitamin D3 determination	[1,25-dihydroxyvitamin D3 determination]	0.0	3	1	1	1
152248	1710	induction of icam-1 role for acidosis	[induction of ICAM-1 role for acidosis]	0.0	6	1	1	1
152249	1710	respect to the hiv-1 promoter	[respect to the HIV-1 promoter]	0.0	5	1	1	1
152250	1710	4 beta 1 cd49d/cd29 integrin costimulation	[4 beta 1 CD49d/CD29 integrin costimulation]	0.0	6	1	1	1
152251	1710	number of il-2r	[number of IL-2Rs]	0.0	3	1	1	1
152252	1710	immunodeficiency virus type negative factor	[immunodeficiency virus type negative factor]	0.0	5	1	1	1
152253	1710	Aldh1 gene expression	[Aldh1 gene expression]	0.0	3	1	1	1
152254	1710	firm	[firm]	0.0	1	1	1	1
152255	1710	cd86 b7-2 two ligand	[CD86 B7-2 two ligands]	0.0	4	1	1	1
152256	1710	(tgf)-beta1 responsiveness	[(TGF)-beta1 responsiveness]	0.0	2	1	1	1
152257	1710	constellation	[constellation]	0.0	1	1	1	1
152258	1710	form coding	[form coding]	0.0	2	1	1	1
152259	1710	family of regulator	[family of regulators]	0.0	3	1	1	1
152260	1710	TaqI restriction	[TaqI restriction]	0.0	2	1	1	1
152261	1710	myb-transformed hematopoietic cell	[Myb-transformed hematopoietic cells]	0.0	3	1	1	1
152262	1710	G(or C)CTGTG	[G(or C)CTGTG]	0.0	2	1	1	1
152263	1710	region ii sequence element	[region II sequence elements]	0.0	4	1	1	1
152264	1710	somatic mutation cluster in the region	[somatic mutations clustering in the region]	0.0	6	1	1	1
152265	1710	allow testing	[allowing testing]	0.0	2	1	1	1
152266	1710	follow neutrophil stimulation with proinflammatory agonist	[Following neutrophil stimulation with proinflammatory agonists]	0.0	6	1	1	1
152267	1710	evaluable cases, include case	[evaluable cases, including case]	0.0	4	1	1	1
152268	1710	heterodimer with nuclear hormone receptor	[heterodimers with nuclear hormone receptors]	0.0	5	1	1	1
152269	1710	CSF m-csf	[CSF M-CSF]	0.0	2	1	1	1
152270	1710	transcript-2/leukocyte ig-like receptor	[transcript-2/leukocyte Ig-like receptor]	0.0	3	1	1	1
152271	1710	megakaryocytic gene in a manner	[megakaryocytic genes in an manner]	0.0	5	1	1	1
152272	1710	somatic cell fusion between clone	[somatic cell fusion between clone]	0.0	5	1	1	1
152273	1710	monocytic cell type-specific transcriptional induction	[Monocytic cell type-specific transcriptional induction]	0.0	5	1	1	1
152274	1710	migration of monocyte-like hl-60 cell	[migration of monocyte-like HL-60 cells]	0.0	5	2	2	1
152275	1710	protein with a apparent mass	[protein with an apparent mass]	0.0	5	1	1	1
152276	1710	regulator during b-cell maturation	[regulators during B-cell maturation]	0.0	4	1	1	1
152277	1710	moreover, a marker of apoptotic event	[moreover, a marker of apoptotic events]	0.0	6	1	1	1
152278	1710	subset of lymphocytic leukemia	[subset of lymphocytic leukemias]	0.0	4	1	1	1
152279	1710	functional site between position	[functional site between positions]	0.0	4	1	1	1
152280	1710	induction by immunodeficiency virus infection	[Induction by immunodeficiency virus infection]	0.0	5	1	1	1
152281	1710	include the phenomenon of rebound,	[including the phenomenon of rebound,]	0.0	5	1	1	1
152282	1710	produce 50% inhibition	[producing 50% inhibition]	0.0	3	1	1	1
152283	1710	advanced chronic failure	[advanced chronic failure]	0.0	3	1	1	1
152284	1710	different negative regulatory pathway	[different negative regulatory pathways]	0.0	4	1	1	1
152285	1710	activation of a reporter plasmid	[activation of a reporter plasmid]	0.0	5	1	1	1
152286	1710	terminal of FK506 -sensitive pathway	[terminals of FK506 -sensitive pathway]	0.0	5	1	1	1
152287	1710	activation after infection	[Activation after infection]	0.0	3	1	1	1
152288	1710	weight gain +/- 8421 (pre)	[weight gain +/- 8421 (pre)]	0.0	5	1	1	1
152289	1710	extrinsic survival factor	[extrinsic survival factors]	0.0	3	1	1	1
152290	1710	sign of cachexia	[signs of cachexia]	0.0	3	1	1	1
152291	1710	binding in response together	[binding in response together]	0.0	4	1	1	1
152292	1710	-72 motif	[-72 motifs]	0.0	2	1	1	1
152293	1710	I gamma 3 sequence	[I gamma 3 sequence]	0.0	4	1	1	1
152294	1710	novel mar-binding protein mar-bp1	[novel MAR-binding protein MAR-BP1]	0.0	4	1	1	1
152295	1710	membrane binding	[membrane binding]	0.0	2	1	1	1
152296	1710	analysis of uas1 sequence	[analysis of UAS1 sequences]	0.0	4	1	1	1
152297	1710	transmembrane mechanism	[transmembrane mechanism]	0.0	2	1	1	1
152298	1710	down-regulation of response	[down-regulation of responses]	0.0	3	1	1	1
152299	1710	TNF-alpha hiv-1 repeat LTR transcription	[TNF-alpha HIV-1 repeat LTR transcription]	0.0	5	1	1	1
152300	1710	receptor mr status	[receptor MR status]	0.0	3	1	1	1
152301	1710	positive element NF-AT-1	[positive element NF-AT-1]	0.0	3	1	1	1
152302	1710	measure incorporation of 3h-thymidine	[measuring incorporation of 3H-thymidine]	0.0	4	1	1	1
152303	1710	bcl6 (hbcl6) cDNA	[BCL6 (hBCL6) cDNA]	0.0	3	1	1	1
152304	1710	engagement TCR complex	[Engagement TCR complex]	0.0	3	1	1	1
152305	1710	gamma-gene region	[gamma-gene region]	0.0	2	1	1	1
152306	1710	protein p38 kinase	[protein p38 kinase]	0.0	3	1	1	1
152307	1710	regulate the immune response	[regulating the immune response]	0.0	4	1	1	1
152308	1710	h-89	[H-89]	0.0	1	1	1	1
152309	1710	addition to c-kit	[addition to c-kit]	0.0	3	1	1	1
152310	1710	apoptotic features.	[apoptotic features.]	0.0	2	1	1	1
152311	1710	expression of cycle gene	[expression of cycle genes]	0.0	4	1	1	1
152312	1710	uracil-DNA glycosylase	[uracil-DNA glycosylase]	0.0	2	1	1	1
152313	1710	noncontiguous region	[noncontiguous regions]	0.0	2	1	1	1
152314	1710	signal molecule include Syk	[signaling molecules including Syk]	0.0	4	1	1	1
152315	1710	transactivation I htlv-i tax	[transactivation I HTLV-I tax]	0.0	4	1	1	1
152316	1710	property for E2A- HLF	[properties for E2A- HLF]	0.0	4	1	1	1
152317	1710	Duffy antigen Fya	[Duffy antigens Fya]	0.0	3	1	1	1
152318	1710	key factor in function	[key factors in functions]	0.0	4	1	1	1
152319	1710	hGR level between steroid-treated patient	[hGR levels between steroid-treated patients]	0.0	5	1	1	1
152320	1710	mouse t-lymphoma cell line	[mouse T-lymphoma cell line]	0.0	4	1	1	1
152321	1710	N terminus amino acid	[N terminus amino acids]	0.0	4	1	1	1
152322	1710	monocytic cell to bacterial lipopolysaccharide	[monocytic cells to bacterial lipopolysaccharide]	0.0	5	1	1	1
152323	1710	molecular weight form	[molecular weight forms]	0.0	3	1	1	1
152324	1710	Dehydroepiandrosterone the androgen	[Dehydroepiandrosterone the androgen]	0.0	3	1	1	1
152325	1710	myeloid blast use virus	[myeloid blasts using virus]	0.0	4	1	1	1
152326	1710	control resting cell	[control resting cells]	0.0	3	1	1	1
152327	1710	factor of kappab	[factor of kappaB]	0.0	3	1	1	1
152328	1710	(via	[(via]	0.0	1	1	1	1
152329	1710	only binding affinity the high	[only binding affinities the highest]	0.0	5	1	1	1
152330	1710	nucleus in mnc	[nucleus in MNC]	0.0	3	1	1	1
152331	1710	induction of hiv-1 gene transcription	[induction of HIV-1 gene transcription]	0.0	5	1	1	1
152332	1710	rxr-alpha cDNA	[RXR-alpha cDNA]	0.0	2	1	1	1
152333	1710	role alternatively mediate	[role alternatively mediating]	0.0	3	1	1	1
152334	1710	wild-type form of EBF	[wild-type forms of EBF]	0.0	4	1	1	1
152335	1710	resistant icr27tk.3 T cell	[resistant ICR27TK.3 T cells]	0.0	4	1	1	1
152336	1710	carboxyl-terminal 180 amino acid	[carboxyl-terminal 180 amino acids]	0.0	4	1	1	1
152337	1710	degree of inhibition.	[degree of inhibition.]	0.0	3	1	1	1
152338	1710	effect from a NFAT factor element	[effect from an NFAT factor element]	0.0	6	1	1	1
152339	1710	two distinct immunophilin-drug complex	[two distinct immunophilin-drug complexes]	0.0	4	1	1	1
152340	1710	bhrf1 in a B-cell line	[BHRF1 in a B-cell line]	0.0	5	1	1	1
152341	1710	cancer of the colon,	[cancer of the colon,]	0.0	4	1	1	1
152342	1710	murine calcineurin	[murine calcineurin]	0.0	2	1	1	1
152343	1710	3' element	[3' elements]	0.0	2	1	1	1
152344	1710	tyrosine phosphorylation of protein lead	[tyrosine phosphorylation of proteins leading]	0.0	5	1	1	1
152345	1710	heterogeneous hiv-1 pool	[heterogeneous HIV-1 pool]	0.0	3	1	1	1
152346	1710	t-cell prolymphocytic leukemia a form	[T-cell prolymphocytic leukemia a form]	0.0	5	1	1	1
152347	1710	composite octamer motif	[composite octamer motif]	0.0	3	1	1	1
152348	1710	ligand, il-2	[ligand, IL-2]	0.0	2	1	1	1
152349	1710	breast parenchyma	[breast parenchyma]	0.0	2	1	1	1
152350	1710	exon of Tat	[exon of Tat]	0.0	3	1	1	1
152351	1710	2 patient	[2 patients]	0.0	2	1	1	1
152352	1710	past years,	[past years,]	0.0	2	1	1	1
152353	1710	two major epitope	[two major epitopes]	0.0	3	1	1	1
152354	1710	Epstein-Barr latency	[Epstein-Barr latency]	0.0	2	1	1	1
152355	1710	standard immunofluorescence method	[standard immunofluorescence method]	0.0	3	1	1	1
152356	1710	b-cell,	[B-cell,]	0.0	1	1	1	1
152357	1710	t-cell fk506 -binding protein	[T-cell FK506 -binding protein]	0.0	4	1	1	1
152358	1710	cellular initiator	[cellular initiator]	0.0	2	1	1	1
152359	1710	nuclear expression of c-rel	[nuclear expression of c-Rel]	0.0	4	1	1	1
152360	1710	translocation t(10;11)	[translocation t(10;11)]	0.0	2	1	1	1
152361	1710	determine the pattern	[determining the patterns]	0.0	3	1	1	1
152362	1710	extract from cell line	[extracts from cell lines]	0.0	4	1	1	1
152363	1710	Ran GTP association	[Ran GTP association]	0.0	3	1	1	1
152364	1710	Bcd a novel proto-oncogene	[Bcd a novel proto-oncogene]	0.0	4	1	1	1
152365	1710	total of 27 combination	[total of 27 combinations]	0.0	4	1	1	1
152366	1710	Jeg-3 immunosuppression downregulation of interleukin-2	[Jeg-3 immunosuppression downregulation of interleukin-2]	0.0	5	1	1	1
152367	1710	ability of receptor	[ability of receptors]	0.0	3	1	1	1
152368	1710	sequence from exon 1-8	[sequences from exons 1-8]	0.0	4	1	1	1
152369	1710	-a23187	[-A23187]	0.0	1	1	1	1
152370	1710	rapidly tyrosine	[rapidly tyrosine]	0.0	2	1	1	1
152371	1710	several independent criteria,	[several independent criteria,]	0.0	3	1	1	1
152372	1710	differentiation from stem cell	[differentiation from stem cells]	0.0	4	1	1	1
152373	1710	interaction of HTLV-I tax implication	[Interaction of HTLV-I Tax implications]	0.0	5	1	1	1
152374	1710	thymocyte with epithelial cell	[thymocytes with epithelial cells]	0.0	4	1	1	1
152375	1710	p27kip1 gene	[p27Kip1 gene]	0.0	2	1	1	1
152376	1710	rapid activator produce a induction	[rapid activator producing a induction]	0.0	5	1	1	1
152377	1710	gcs with gc border	[GCs with GC borders]	0.0	4	1	1	1
152378	1710	stages, capacitance	[stages, capacitance]	0.0	2	1	1	1
152379	1710	human macrophage by mechanical ventilation	[human macrophages by mechanical ventilation]	0.0	5	1	1	1
152380	1710	contain sequence from -repressible gene	[containing sequences from -repressible genes]	0.0	5	1	1	1
152381	1710	consensus motif WGATAR	[consensus motif WGATAR]	0.0	3	1	1	1
152382	1710	promising avenue	[promising avenue]	0.0	2	1	1	1
152383	1710	cellular disposition	[Cellular disposition]	0.0	2	1	1	1
152384	1710	T cell recognition of peptide	[T cell recognition of peptides]	0.0	5	1	1	1
152385	1710	effect on the cell.	[effects on the cell.]	0.0	4	1	1	1
152386	1710	deaminase pbgd a enzyme	[deaminase PBGD an enzyme]	0.0	4	1	1	1
152387	1710	elderly, patient	[elderly, patients]	0.0	2	1	1	1
152388	1710	least one mechanism	[least one mechanism]	0.0	3	1	1	1
152389	1710	Recognition of this entity	[Recognition of this entity]	0.0	4	1	1	1
152390	1710	qr gene	[QR gene]	0.0	2	1	1	1
152391	1710	history of varicella	[history of varicella]	0.0	3	1	1	1
152392	1710	tyrosine-phosphorylated follow granulocyte-colony factor treatment	[tyrosine-phosphorylated following granulocyte-colony factor treatment]	0.0	5	1	1	1
152393	1710	accumulation of level	[accumulation of levels]	0.0	3	1	1	1
152394	1710	CD40 trigger of monocyte	[CD40 triggering of monocytes]	0.0	4	1	1	1
152395	1710	correlation of level with response	[Correlations of levels with response]	0.0	5	1	1	1
152396	1710	DNA sequence adjacent to binding site	[DNA sequences adjacent to binding sites]	0.0	6	1	1	1
152397	1710	NK- kappa b	[NK- kappa B]	0.0	3	1	1	1
152398	1710	thus of significance.	[thus of significance.]	0.0	3	1	1	1
152399	1710	cell in several model	[cells in several models]	0.0	4	1	1	1
152400	1710	1 year: versus 14.1	[1 year: versus 14.1]	0.0	4	1	1	1
152401	1710	novel t-cell-specific activator	[novel T-cell-specific activator]	0.0	3	1	1	1
152402	1710	infection of blood lymphocyte with hiv-1	[Infection of blood lymphocytes with HIV-1]	0.0	6	1	1	1
152403	1710	T cell nf-at1	[T cells NF-AT1]	0.0	3	1	1	1
152404	1710	high affinity sites;	[higher affinity sites;]	0.0	3	1	1	1
152405	1710	insight into the suppression phenomenon	[insight into the suppression phenomenon]	0.0	5	1	1	1
152406	1710	purification of ptf a complex	[purification of PTF a complex]	0.0	5	1	1	1
152407	1710	potential colony-forming cell	[potential colony-forming cells]	0.0	3	1	1	1
152408	1710	tartrate acid phosphatase	[tartrate acid phosphatase]	0.0	3	1	1	1
152409	1710	definition of region with general cofactor	[definition of regions with general cofactors]	0.0	6	1	1	1
152410	1710	dominant atra receptor (rar) gene	[dominant ATRA receptor (RAR) gene]	0.0	5	1	1	1
152411	1710	direct transluminal coronary angioplasty PTCA	[direct transluminal coronary angioplasty PTCA]	0.0	5	1	1	1
152412	1710	antigen-stimulated immune response	[antigen-stimulated immune responses]	0.0	3	1	1	1
152413	1710	pluripotent progenitor to cell DC	[pluripotent progenitors to cells DC]	0.0	5	1	1	1
152414	1710	dermal microvessel endothelial cell hdmec	[dermal microvessel endothelial cells HDMEC]	0.0	5	1	1	1
152415	1710	1 out consecutive healthy control	[1 out consecutive healthy controls]	0.0	5	1	1	1
152416	1710	statistically significant change	[statistically significant change]	0.0	3	1	1	1
152417	1710	mouse display erythroid-specific expression	[mice displaying erythroid-specific expression]	0.0	4	1	1	1
152418	1710	stimulation with different cytokine	[stimulation with different cytokines]	0.0	4	1	1	1
152419	1710	55- kda protein	[55- kDa proteins]	0.0	3	1	1	1
152420	1710	cascade lead to proteolysis	[cascade leading to proteolysis]	0.0	4	1	1	1
152421	1710	excessive expression of "normal" lymphokine	[excessive expression of "normal" lymphokines]	0.0	5	1	1	1
152422	1710	resultant decrease	[resultant decrease]	0.0	2	1	1	1
152423	1710	gene in 3q21	[gene in 3q21]	0.0	3	1	1	1
152424	1710	il-6 during 24 h	[IL-6 during 24 h]	0.0	4	1	1	1
152425	1710	two forms: the mutant p53	[two forms: the mutant p53]	0.0	5	1	1	1
152426	1710	localization complex	[localization complexes]	0.0	2	1	1	1
152427	1710	exchange of invariant peptide	[exchange of invariant peptides]	0.0	4	1	1	1
152428	1710	guanine nucleotide exchange domain	[guanine nucleotide exchange domain]	0.0	4	1	1	1
152429	1710	t-cell activity	[T-cell activity]	0.0	2	2	2	1
152430	1710	simultaneous exposure with il-4	[simultaneous exposure with IL-4]	0.0	4	1	1	1
152431	1710	secretion of interleukin	[secretion of interleukin]	0.0	3	1	1	1
152432	1710	amino acid side chain	[amino acid side chains]	0.0	4	1	1	1
152433	1710	phorbol transcription factor ap1 Jun/Fos	[phorbol transcription factor AP1 Jun/Fos]	0.0	5	1	1	1
152434	1710	littermate	[littermates]	0.0	1	1	1	1
152435	1710	murine il-2 mrna	[murine IL-2 mRNA]	0.0	3	1	1	1
152436	1710	alpha integrin gene promoter	[alpha integrin gene promoter]	0.0	4	1	1	1
152437	1710	expression of a receptor component	[expression of an receptor component]	0.0	5	1	1	1
152438	1710	function of the proto-oncogene c-erbA	[function of the proto-oncogene c-erbA]	0.0	5	1	1	1
152439	1710	induction by binding of thrombin-stimulated platelet	[Induction by binding of thrombin-stimulated platelets]	0.0	6	1	1	1
152440	1710	co-treatment of RBC	[Co-treatment of RBCs]	0.0	3	1	1	1
152441	1710	trigger event	[triggering event]	0.0	2	1	1	1
152442	1710	gene isg15	[gene ISG15]	0.0	2	1	1	1
152443	1710	increase of steroid	[increase of steroids]	0.0	3	1	1	1
152444	1710	receptor in the patient group.	[receptors in the patient group.]	0.0	5	1	1	1
152445	1710	adhesive property of endothelial cell	[adhesive properties of endothelial cells]	0.0	5	1	1	1
152446	1710	isoform, Stat3alpha	[isoform, Stat3alpha]	0.0	2	1	1	1
152447	1710	include a response to acid	[including a response to acid]	0.0	5	1	1	1
152448	1710	12 independent mutation event	[12 independent mutation events]	0.0	4	1	1	1
152449	1710	CD30 -mediated effect	[CD30 -mediated effects]	0.0	3	1	1	1
152450	1710	isogenic mutant	[isogenic mutants]	0.0	2	1	1	1
152451	1710	two alternative promoter	[two alternative promoters]	0.0	3	1	1	1
152452	1710	maxima	[maxima]	0.0	1	1	1	1
152453	1710	pkc activation factor	[PKC activation factor]	0.0	3	1	1	1
152454	1710	three- enhancement	[three- enhancement]	0.0	2	1	1	1
152455	1710	distinct effect on marker	[distinct effects on markers]	0.0	4	1	1	1
152456	1710	main NF-kappaB -binding site	[main NF-kappaB -binding site]	0.0	4	1	1	1
152457	1710	4 integrin	[4 integrins]	0.0	2	1	1	1
152458	1710	negative allele of c-Raf-1 Raf	[negative allele of c-Raf-1 Raf]	0.0	5	1	1	1
152459	1710	treatment of attack	[treatment of attacks]	0.0	3	1	1	1
152460	1710	gcrbeta antibody	[GCRbeta antibody]	0.0	2	1	1	1
152461	1710	substantial quantity	[substantial quantities]	0.0	2	1	1	1
152462	1710	urinary free cortisol excretion	[Urinary free cortisol excretion]	0.0	4	1	1	1
152463	1710	other inhibitor	[other inhibitors]	0.0	2	1	1	1
152464	1710	embryonic zeta globin gene	[embryonic zeta globin gene]	0.0	4	1	1	1
152465	1710	potential interaction with cytokine	[potential interactions with cytokines]	0.0	4	1	1	1
152466	1710	general transcription tfiid	[general transcription TFIID]	0.0	3	1	1	1
152467	1710	form of EBF	[forms of EBF]	0.0	3	1	1	1
152468	1710	part of the interaction	[part of the interaction]	0.0	4	1	1	1
152469	1710	specificity of tal1 transcription	[specificity of TAL1 transcription]	0.0	4	1	1	1
152470	1710	second week	[second week]	0.0	2	2	2	1
152471	1710	proportion of subject	[proportion of subjects]	0.0	3	1	1	1
152472	1710	recurrent abortion	[recurrent abortion]	0.0	2	1	1	1
152473	1710	transcription of complex class gene	[transcription of complex class genes]	0.0	5	1	1	1
152474	1710	event along the pathway	[events along the pathways]	0.0	4	1	1	1
152475	1710	mixture with ifn-gamma	[mixture with IFN-gamma]	0.0	3	1	1	1
152476	1710	diagnosis, genetic counseling,	[diagnosis, genetic counseling,]	0.0	3	1	1	1
152477	1710	existence of gelatinase granule	[existence of gelatinase granules]	0.0	4	1	1	1
152478	1710	brid the generation	[bridging the generation]	0.0	3	1	1	1
152479	1710	important site between position -53	[important site between positions -53]	0.0	5	1	1	1
152480	1710	peptide/glycoprotein	[peptide/glycoprotein]	0.0	1	1	1	1
152481	1710	CCK(B)	[CCK(B)]	0.0	1	1	1	1
152482	1710	mrna transcript of kilobasis	[mRNA transcript of kilobases]	0.0	4	1	1	1
152483	1710	h in culture.	[h in culture.]	0.0	3	1	1	1
152484	1710	subsequent proliferation of the T cell	[subsequent proliferation of the T cells]	0.0	6	1	1	1
152485	1710	multiple biologic activity	[multiple biologic activities]	0.0	3	1	1	1
152486	1710	negative phenotype	[negative phenotype]	0.0	2	1	1	1
152487	1710	murine monocyte	[murine monocytes]	0.0	2	1	1	1
152488	1710	stat-1alpha signal transducer	[STAT-1alpha signal transducer]	0.0	3	1	1	1
152489	1710	acid from membrane	[acid from membranes]	0.0	3	1	1	1
152490	1710	two distinct form creb	[Two distinct forms CREB]	0.0	4	1	1	1
152491	1710	span the AF10 breakpoint.	[spanning the AF10 breakpoint.]	0.0	4	1	1	1
152492	1710	indicate difference	[indicating differences]	0.0	2	1	1	1
152493	1710	oxygen uptake)	[oxygen uptake)]	0.0	2	1	1	1
152494	1710	agent upon glucocorticoid action	[agents upon glucocorticoid action]	0.0	4	1	1	1
152495	1710	presence in fluid	[presence in fluid]	0.0	3	1	1	1
152496	1710	b-cell line bal-17	[B-cell line BAL-17]	0.0	3	1	1	1
152497	1710	express p85 mutant	[expressing p85 mutants]	0.0	3	1	1	1
152498	1710	il-1alpha promoter -cat construct	[IL-1alpha promoter -CAT constructs]	0.0	4	1	1	1
152499	1710	adenosine monophosphate signal in platelet	[adenosine monophosphate signaling in platelets]	0.0	5	1	1	1
152500	1710	activator of transcription-3	[activator of transcription-3]	0.0	3	1	1	1
152501	1710	use a reverse approach	[using a reverse approach]	0.0	4	1	1	1
152502	1710	binding site, result	[binding site, resulting]	0.0	3	1	1	1
152503	1710	positive selection in response	[positive selection in response]	0.0	4	1	1	1
152504	1710	percutaneous transluminal angioplasty	[percutaneous transluminal angioplasty]	0.0	3	1	1	1
152505	1710	expression of a protein inhibitor	[Expression of a protein inhibitor]	0.0	5	1	1	1
152506	1710	cytokine tnf-alpha TNF	[cytokine TNF-alpha TNF]	0.0	3	1	1	1
152507	1710	NK cell on direct stimulation	[NK cells on direct stimulation]	0.0	5	1	1	1
152508	1710	T cell-specific element	[T cell-specific element]	0.0	3	1	1	1
152509	1710	bind property for E2A- HLF	[binding properties for E2A- HLF]	0.0	5	1	1	1
152510	1710	retinoid with different binding specificity cd336	[retinoids with different binding specificity CD336]	0.0	6	1	1	1
152511	1710	regulation of receptor in cell	[Regulation of receptors in cells]	0.0	5	1	1	1
152512	1710	component in the signal transduction event	[components in the signal transduction events]	0.0	6	1	1	1
152513	1710	PPARalpha expression	[PPARalpha expression]	0.0	2	1	1	1
152514	1710	large 14-day colony	[large 14-day colonies]	0.0	3	1	1	1
152515	1710	T component	[T component]	0.0	2	1	1	1
152516	1710	transcription at stage of differentiation	[transcription at stages of differentiation]	0.0	5	1	1	1
152517	1710	three no synthase (nos) isoform	[three NO synthase (NOS) isoforms]	0.0	5	1	1	1
152518	1710	genes, suggest	[genes, suggesting]	0.0	2	1	1	1
152519	1710	phase neutrophil adhesion	[phase neutrophil adhesion]	0.0	3	1	1	1
152520	1710	80% follow treatment with MCM	[80% following treatment with MCM]	0.0	5	1	1	1
152521	1710	protein and/or	[proteins and/or]	0.0	2	1	1	1
152522	1710	mutant with PMA	[mutant with PMA]	0.0	3	1	1	1
152523	1710	form of type 2	[forms of type 2]	0.0	4	1	1	1
152524	1710	third member	[third member]	0.0	2	1	1	1
152525	1710	protein set a series of response	[proteins setting a series of responses]	0.0	6	1	1	1
152526	1710	sequence-specific dna-binding characteristic of ef1	[sequence-specific DNA-binding characteristics of EF1]	0.0	5	1	1	1
152527	1710	tax-express T cell	[Tax-expressing T cells]	0.0	3	1	1	1
152528	1710	regulatory enhancer region	[regulatory enhancer region]	0.0	3	2	2	1
152529	1710	distinguished: sign of primary hypothyroidism	[distinguished: signs of primary hypothyroidism]	0.0	5	1	1	1
152530	1710	SDS-polyacrylamide gel electrophoresis	[SDS-polyacrylamide gel electrophoresis]	0.0	3	1	1	1
152531	1710	pluripotent culture of rat pancrea	[pluripotent cultures of rat pancreas]	0.0	5	1	1	1
152532	1710	IkappaB kinase IKK	[IkappaB kinase IKK]	0.0	3	1	1	1
152533	1710	molecule in T cell	[molecules in T cells]	0.0	4	1	1	1
152534	1710	response to activator	[response to activators]	0.0	3	1	1	1
152535	1710	different combination of mutation	[different combinations of mutations]	0.0	4	1	1	1
152536	1710	identity of cd56	[identity of CD56]	0.0	3	1	1	1
152537	1710	two adjacent site at position	[two adjacent sites at positions]	0.0	5	1	1	1
152538	1710	class ii major promoter	[class II major promoters]	0.0	4	1	1	1
152539	1710	pharmacological profile	[pharmacological profile]	0.0	2	1	1	1
152540	1710	element in the 5'-flanking region	[elements in the 5'-flanking region]	0.0	5	1	1	1
152541	1710	role in T lymphocyte activation	[role in T lymphocyte activation]	0.0	5	1	1	1
152542	1710	anti-endothelial cell antibody maeca	[anti-endothelial cell antibodies mAECA]	0.0	4	1	1	1
152543	1710	glucocorticoid inhibition	[glucocorticoid inhibition]	0.0	2	1	1	1
152544	1710	dictate pattern of expression	[dictating patterns of expression]	0.0	4	1	1	1
152545	1710	CsA -sensitive component	[CsA -sensitive component]	0.0	3	1	1	1
152546	1710	expression of a form of ras	[Expression of an form of Ras]	0.0	6	1	1	1
152547	1710	discovery of ebv	[discovery of EBV]	0.0	3	1	1	1
152548	1710	variation in Lyonization	[variation in Lyonization]	0.0	3	1	1	1
152549	1710	patient with fura toxicity secondary	[patient with FUra toxicity secondary]	0.0	5	1	1	1
152550	1710	circulate lymphocyte in hyper-	[circulating lymphocytes in hyper-]	0.0	4	1	1	1
152551	1710	form chloride	[form chloride]	0.0	2	1	1	1
152552	1710	signal pathway in human neutrophil	[signaling pathways in human neutrophils]	0.0	5	1	1	1
152553	1710	thf with the/thf	[THF with THE/THF]	0.0	3	1	1	1
152554	1710	identification of a splice variant	[identification of a splice variant]	0.0	5	1	1	1
152555	1710	require 2 log-fold glucocorticoid	[requiring 2 log-fold glucocorticoids]	0.0	4	1	1	1
152556	1710	Cdk2	[Cdk2]	0.0	1	1	1	1
152557	1710	expression of histocompatibility surface protein	[expression of histocompatibility surface proteins]	0.0	5	1	1	1
152558	1710	long-terminal repeat	[long-terminal repeat]	0.0	2	1	1	1
152559	1710	wild-type hamster ovary (cho)-k1 cell	[Wild-type hamster ovary (CHO)-K1 cells]	0.0	5	1	1	1
152560	1710	factor kB NF-kB	[factor kB NF-kB]	0.0	3	1	1	1
152561	1710	c-fo promoter activity in Jurkat	[c-fos promoter activity in Jurkat]	0.0	5	1	1	1
152562	1710	distinct coactivator	[distinct coactivators]	0.0	2	1	1	1
152563	1710	vulvar mass	[vulvar mass]	0.0	2	1	1	1
152564	1710	phenotypically distinct type	[phenotypically distinct types]	0.0	3	1	1	1
152565	1710	hiv repeat activation in vitro.	[HIV repeat activation in vitro.]	0.0	5	1	1	1
152566	1710	follow engagement cell-to-cell contact).	[following engagement cell-to-cell contact).]	0.0	4	1	1	1
152567	1710	AMP protein kinase	[AMP protein kinase]	0.0	3	1	1	1
152568	1710	P; immediate) binding of heterodimer	[h; immediate) binding of heterodimers]	0.0	5	1	1	1
152569	1710	normal increase in response	[normal increase in response]	0.0	4	1	1	1
152570	1710	similar effect on the expression	[similar effects on the expression]	0.0	5	1	1	1
152571	1710	antisense VDR mrna	[antisense VDR mRNA]	0.0	3	1	1	1
152572	1710	new class of structure	[new class of structures]	0.0	4	1	1	1
152573	1710	adsorption	[adsorption]	0.0	1	1	1	1
152574	1710	factor present in t-cell extract	[factor present in T-cell extracts]	0.0	5	1	1	1
152575	1710	class DRA promoter occupancy	[class DRA promoter occupancy]	0.0	4	1	1	1
152576	1710	anti- VCAM-1 antibody 1g11	[anti- VCAM-1 antibody 1G11]	0.0	4	1	1	1
152577	1710	T helper (th1) cell	[T helper (Th1) cells]	0.0	4	1	1	1
152578	1710	elicit stress such as cytokine	[eliciting stress such as cytokines]	0.0	5	1	1	1
152579	1710	composite binding site	[composite binding site]	0.0	3	1	1	1
152580	1710	incubation with different dose DEX	[incubation with different doses DEX]	0.0	5	1	1	1
152581	1710	DHEA effect monocyte	[DHEA effects monocytes]	0.0	3	1	1	1
152582	1710	dual specificity	[dual specificity]	0.0	2	1	1	1
152583	1710	dominant phenotype	[dominant phenotype]	0.0	2	1	1	1
152584	1710	use tumour necrosis factor induction	[Using tumour necrosis factor induction]	0.0	5	1	1	1
152585	1710	similar elevation	[similar elevation]	0.0	2	1	1	1
152586	1710	level such	[levels such]	0.0	2	1	1	1
152587	1710	Nmi a protein	[Nmi a protein]	0.0	3	1	1	1
152588	1710	micrograms/mL etoposide	[micrograms/mL etoposide]	0.0	2	1	1	1
152589	1710	hence, for replication	[hence, for replication]	0.0	3	1	1	1
152590	1710	other agonist	[other agonists]	0.0	2	1	1	1
152591	1710	terminal repeat-luciferase construct	[terminal repeat-luciferase constructs]	0.0	3	1	1	1
152592	1710	factor of T cell nf-at-1	[factor of T cells NF-AT-1]	0.0	5	1	1	1
152593	1710	normal development; addition	[normal development; addition]	0.0	3	1	1	1
152594	1710	deletion of a short amino- region	[Deletions of a short amino- region]	0.0	6	1	1	1
152595	1710	about 25 h (viability great	[about 25 h (viability greater]	0.0	5	1	1	1
152596	1710	have g3 tumor with margin (31%	[having G3 tumors with margins (31%]	0.0	6	1	1	1
152597	1710	AP-1 consensus	[AP-1 consensus]	0.0	2	1	1	1
152598	1710	shared, essential component	[shared, essential component]	0.0	3	1	1	1
152599	1710	export nfat factor	[export NFAT factor]	0.0	3	1	1	1
152600	1710	sequence analysis of 2.3-kb cDNA clone	[Sequence analysis of 2.3-kb cDNA clones]	0.0	6	1	1	1
152601	1710	nh2 terminus	[NH2 terminus]	0.0	2	1	1	1
152602	1710	10 micrograms/mL	[10 micrograms/mL]	0.0	2	1	1	1
152603	1710	stable clone of line	[stable clones of lines]	0.0	4	1	1	1
152604	1710	zinc finger protein maz	[zinc finger protein MAZ]	0.0	4	1	1	1
152605	1710	investigation of antagonism	[investigation of antagonism]	0.0	3	1	1	1
152606	1710	DNA bind domain dbd	[DNA binding domain DBD]	0.0	4	1	1	1
152607	1710	acid treatment of pml/raralpha mouse recovery.	[acid treatment of PML/RARalpha mice recovery.]	0.0	6	1	1	1
152608	1710	regulation of nuclear factor kappa b	[regulation of nuclear factor kappa B]	0.0	6	1	1	1
152609	1710	nfkappab site	[NFkappaB sites]	0.0	2	1	1	1
152610	1710	collapse	[collapse]	0.0	1	1	1	1
152611	1710	affinity ige receptor	[affinity IgE receptor]	0.0	3	1	1	1
152612	1710	cell from monocyte	[cells from monocytes]	0.0	3	1	1	1
152613	1710	three unrelated Japanese child	[three unrelated Japanese children]	0.0	4	1	1	1
152614	1710	different type of cell line	[different types of cell lines]	0.0	5	1	1	1
152615	1710	hsie probe	[hSIE probe]	0.0	2	1	1	1
152616	1710	role of the leader region	[role of the leader region]	0.0	5	1	1	1
152617	1710	enhance gene expression	[enhancing gene expression]	0.0	3	1	1	1
152618	1710	cytokine release a step	[cytokine release a step]	0.0	4	1	1	1
152619	1710	heterogeneity of development in myeloproliferative disorder	[Heterogeneity of development in myeloproliferative disorders]	0.0	6	1	1	1
152620	1710	rapidak increase in tal1 mrna	[rapid, increase in TAL1 mRNA]	0.0	5	1	1	1
152621	1710	subclone Wurzburg cell	[subclone Wurzburg cells]	0.0	3	1	1	1
152622	1710	E-box-dependent bhlh homo hetero dimer formation	[E-box-dependent bHLH homo hetero dimer formation]	0.0	6	1	1	1
152623	1710	ebv b cell transformation	[EBV B cell transformation]	0.0	4	1	1	1
152624	1710	primary transcription factor bind	[primary transcription factors binding]	0.0	4	1	1	1
152625	1710	subunit of molecular mass (50k)	[subunits of molecular mass (50K)]	0.0	5	1	1	1
152626	1710	transcription, amplify expression	[transcription, amplifying expression]	0.0	3	1	1	1
152627	1710	distinct region important, through interaction	[distinct regions important, through interaction]	0.0	5	1	1	1
152628	1710	target genome,	[target genome,]	0.0	2	1	1	1
152629	1710	dysregulation in immunodeficiency virus type infection	[dysregulation in immunodeficiency virus type infection]	0.0	6	1	1	1
152630	1710	exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin tcdd	[exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin TCDD]	0.0	4	1	1	1
152631	1710	developments,	[developments,]	0.0	1	1	1	1
152632	1710	co-cultured cell	[co-cultured cells]	0.0	2	1	1	1
152633	1710	evidence for a form in familiess	[evidence for an form in families,]	0.0	6	1	1	1
152634	1710	regard the clinical use of agent	[regarding the clinical use of agents]	0.0	6	1	1	1
152635	1710	lbf4-	[LBF4-]	0.0	1	1	1	1
152636	1710	reversible inhibition	[reversible inhibition]	0.0	2	1	1	1
152637	1710	analogous phosphorylation of Id3	[analogous phosphorylation of Id3]	0.0	4	1	1	1
152638	1710	Ala-X-Ala	[Ala-X-Ala]	0.0	1	1	1	1
152639	1710	signal cascade in T lymphocyte	[signal cascades in T lymphocytes]	0.0	5	1	1	1
152640	1710	pathogenesis of x-linked immunodeficiency	[pathogenesis of X-linked immunodeficiency]	0.0	4	1	1	1
152641	1710	prevalence of breast tissue abnormality	[prevalence of breast tissue abnormalities]	0.0	5	1	1	1
152642	1710	accumulation of AMP the hydrolysis	[accumulation of AMP the hydrolysis]	0.0	5	1	1	1
152643	1710	polyamine in breast cancer	[Polyamines in breast cancer]	0.0	4	1	1	1
152644	1710	glyocophorin a	[glyocophorin A]	0.0	2	1	1	1
152645	1710	ACH-2 T cell	[ACH-2 T cells]	0.0	3	1	1	1
152646	1710	characteristic at low abundance	[characteristics at low abundance]	0.0	4	1	1	1
152647	1710	continuous treatment of monocyte	[Continuous treatment of monocytes]	0.0	4	1	1	1
152648	1710	protein eib19k	[protein EIB19K]	0.0	2	1	1	1
152649	1710	series (b)	[series (B)]	0.0	2	1	1	1
152650	1710	one tumor.	[one tumor.]	0.0	2	1	1	1
152651	1710	cell cycle phase	[cell cycle phases]	0.0	3	1	1	1
152652	1710	active nf-kappab dna-binding complex	[active NF-kappaB DNA-binding complex]	0.0	4	1	1	1
152653	1710	enzyme 17beta-hydroxysteroid dehydrogenase type iv	[enzyme 17beta-hydroxysteroid dehydrogenase type IV]	0.0	5	1	1	1
152654	1710	transient pseudohypoaldosteronism in obstructive renal disease	[Transient pseudohypoaldosteronism in obstructive renal disease]	0.0	6	1	1	1
152655	1710	11.8 fmol/mg protein (mean	[11.8 fmol/mg protein (mean]	0.0	4	1	1	1
152656	1710	ets family transcription	[Ets family transcription]	0.0	3	1	1	1
152657	1710	basis of activity	[basis of activity]	0.0	3	1	1	1
152658	1710	two stimuli, lipopolysaccharide	[two stimuli, lipopolysaccharide]	0.0	3	1	1	1
152659	1710	subject (from 2849	[subjects (from 2849]	0.0	3	1	1	1
152660	1710	activation C with phorbol ester	[activation C with phorbol esters]	0.0	5	1	1	1
152661	1710	very beneficial profile,	[very beneficial profile,]	0.0	3	1	1	1
152662	1710	cd34+cd71+	[CD34+CD71+]	0.0	1	1	1	1
152663	1710	PMA/anti-CD28 mab	[PMA/anti-CD28 mAb]	0.0	2	1	1	1
152664	1710	pattern of growth	[patterns of growth]	0.0	3	1	1	1
152665	1710	pharmacodynamic response to single	[pharmacodynamic responses to single]	0.0	4	1	1	1
152666	1710	critical concentration at the surface	[critical concentration at the surface]	0.0	5	1	1	1
152667	1710	synthetic nonselective RAR ligand	[synthetic nonselective RAR ligands]	0.0	4	1	1	1
152668	1710	patient with affinity	[patients with affinity]	0.0	3	2	2	1
152669	1710	heavy chain (igh) promoter	[heavy chain (IgH) promoter]	0.0	4	1	1	1
152670	1710	inhibitor of factor kappa b activation	[inhibitors of factor kappa B activation]	0.0	6	1	1	1
152671	1710	blood monocyte during sepsis	[blood monocytes during sepsis]	0.0	4	1	1	1
152672	1710	ZEBRA promoter	[ZEBRA promoters]	0.0	2	1	1	1
152673	1710	close proximity to homologue	[close proximity to homologues]	0.0	4	1	1	1
152674	1710	interaction with b cell-specific coactivator	[interactions with B cell-specific coactivators]	0.0	5	1	1	1
152675	1710	cd40l T cell	[CD40L T cells]	0.0	3	1	1	1
152676	1710	nf-at response element present	[NF-AT response element present]	0.0	4	1	1	1
152677	1710	prevent the tyrosine phosphorylation	[preventing the tyrosine phosphorylation]	0.0	4	1	1	1
152678	1710	VDR by h	[VDR by h]	0.0	3	1	1	1
152679	1710	t-cell receptor delta	[T-cell receptor delta]	0.0	3	2	2	1
152680	1710	myristake	[myristake]	0.0	1	1	1	1
152681	1710	tcc signal	[TCC signaling]	0.0	2	1	1	1
152682	1710	nuclear factor lymphocyte	[nuclear factor lymphocytes]	0.0	3	1	1	1
152683	1710	Autosome/	[Autosome/]	0.0	1	1	1	1
152684	1710	human immunoglobulin enhancer	[human immunoglobulin enhancer]	0.0	3	1	1	1
152685	1710	dose of corticosteroid methyl prednisolone	[doses of corticosteroid methyl prednisolone]	0.0	5	1	1	1
152686	1710	addition to localization	[addition to localization]	0.0	3	1	1	1
152687	1710	ubiquitin protein ligase e3	[ubiquitin protein ligase E3]	0.0	4	1	1	1
152688	1710	affinity for the receptor	[affinity for the receptor]	0.0	4	1	1	1
152689	1710	physico-chemical parameter of the protein	[physico-chemical parameters of the proteins]	0.0	5	1	1	1
152690	1710	experience with Urapidil	[experiences with Urapidil]	0.0	3	1	1	1
152691	1710	Glucocorticoid responsiveness	[Glucocorticoid responsiveness]	0.0	2	1	1	1
152692	1710	extract of mammalian cell	[extracts of mammalian cells]	0.0	4	1	1	1
152693	1710	(overall frequency:	[(overall frequency:]	0.0	2	1	1	1
152694	1710	mixture up-regulation of the signal transducer	[mixture up-regulation of the signal transducer]	0.0	6	1	1	1
152695	1710	haematopoietic cell in several model	[haematopoietic cells in several models]	0.0	5	1	1	1
152696	1710	activation of a gene	[Activation of a gene]	0.0	4	1	1	1
152697	1710	cleavage during apoptosis	[Cleavage during apoptosis]	0.0	3	1	1	1
152698	1710	maximum value at hour 12	[maximum value at hour 12]	0.0	5	1	1	1
152699	1710	hexamethylene bisacetamide	[hexamethylene bisacetamide]	0.0	2	2	2	1
152700	1710	CD40 ligation growth inhibition	[CD40 ligation growth inhibition]	0.0	4	1	1	1
152701	1710	overexpression of BXB a version	[Overexpression of BXB a version]	0.0	5	1	1	1
152702	1710	activity of acid	[activities of acid]	0.0	3	1	1	1
152703	1710	non b cell	[non B cells]	0.0	3	1	1	1
152704	1710	element in the 5'-untranslated region	[element in the 5'-untranslated region]	0.0	5	1	1	1
152705	1710	potential role of paf	[potential role of PAF]	0.0	4	1	1	1
152706	1710	treatment of normal monocyte	[Treatment of normal monocytes]	0.0	4	1	1	1
152707	1710	lymphoblastic t-cell	[lymphoblastic T-cell]	0.0	2	1	1	1
152708	1710	rdna with identity the sub-unit	[cDNAs with identity the sub-unit]	0.0	5	1	1	1
152709	1710	Kruppel-like factor	[Kruppel-like factor]	0.0	2	1	1	1
152710	1710	Fifteen patient	[Fifteen patients]	0.0	2	1	1	1
152711	1710	map kinase phosphatase	[MAP kinase phosphatases]	0.0	3	1	1	1
152712	1710	direct demonstration in ht-2 cell	[Direct demonstration in HT-2 cells]	0.0	5	1	1	1
152713	1710	cell activation with consequent leukocyte adhesion	[cell activation with consequent leukocyte adhesion]	0.0	6	1	1	1
152714	1710	termination of antigen response	[termination of antigen responses]	0.0	4	1	1	1
152715	1710	Rapid ca2+-mediated activation	[Rapid Ca2+-mediated activation]	0.0	3	1	1	1
152716	1710	gr transcription in HeLa cell	[GR transcription in HeLa cells]	0.0	5	1	1	1
152717	1710	primate model	[primate model]	0.0	2	1	1	1
152718	1710	autoregulatory mechanism	[autoregulatory mechanism]	0.0	2	1	1	1
152719	1710	mechanism more fundamentally related	[mechanism more fundamentally related]	0.0	4	1	1	1
152720	1710	generation of lymphocyte	[generation of lymphocytes]	0.0	3	1	1	1
152721	1710	tandem cysteine LIM domain	[tandem cysteine LIM domains]	0.0	4	1	1	1
152722	1710	subsequent release of m-csf protein	[subsequent release of M-CSF protein]	0.0	5	1	1	1
152723	1710	transcription factor nf-microb	[transcription factor NF-microB]	0.0	3	1	1	1
152724	1710	stat protein by cytokine receptor	[STAT proteins by cytokine receptors]	0.0	5	1	1	1
152725	1710	involve interaction between regulatory element	[involving interactions between regulatory elements]	0.0	5	1	1	1
152726	1710	endocrine function	[endocrine functions]	0.0	2	1	1	1
152727	1710	bioactivation to chemically-reactive metabolite	[Bioactivation to chemically-reactive metabolites]	0.0	4	1	1	1
152728	1710	binding to Oct1	[binding to Oct1]	0.0	3	1	1	1
152729	1710	retinoic-acid receptor type alpha potentiation	[retinoic-acid receptors type alpha potentiation]	0.0	5	1	1	1
152730	1710	one patient, transient reduction	[one patient, transient reduction]	0.0	4	1	1	1
152731	1710	part of palindromic sequence	[part of palindromic sequences]	0.0	4	1	1	1
152732	1710	direct the action	[directing the action]	0.0	3	1	1	1
152733	1710	(wp)	[(Wp)]	0.0	1	1	1	1
152734	1710	coactivation definition of region with cofactor	[Coactivation definition of regions with cofactors]	0.0	6	1	1	1
152735	1710	activity of the repeat	[activity of the repeat]	0.0	4	1	1	1
152736	1710	salt concentration m nacl	[salt concentrations M NaCl]	0.0	4	1	1	1
152737	1710	ic50 in the low micromolar	[IC50s in the low micromolar]	0.0	5	1	1	1
152738	1710	glucocorticoid receptor isoform	[glucocorticoid receptor isoforms]	0.0	3	1	1	1
152739	1710	mody3	[MODY3]	0.0	1	1	1	1
152740	1710	negative feedback sensitivity	[negative feedback sensitivity]	0.0	3	1	1	1
152741	1710	transfection overexpression ikk1	[transfection overexpression IKK1]	0.0	3	1	1	1
152742	1710	follow granulocyte-colony factor treatment	[following granulocyte-colony factor treatment]	0.0	4	1	1	1
152743	1710	effect on the tyrosine phosphorylation	[effect on the tyrosine phosphorylation]	0.0	5	1	1	1
152744	1710	therefore, exposure	[therefore, exposure]	0.0	2	1	1	1
152745	1710	ddpcr protocol	[DDPCR protocol]	0.0	2	1	1	1
152746	1710	5 nm vd3	[5 nM VD3]	0.0	3	1	1	1
152747	1710	two cis-acting regulatory element	[two cis-acting regulatory elements]	0.0	4	1	1	1
152748	1710	series (a)	[series (A)]	0.0	2	1	1	1
152749	1710	murine IL-2 element qil-2re	[murine IL-2 element mIL-2rE]	0.0	4	1	1	1
152750	1710	il-8 production	[IL-8 production]	0.0	2	1	1	1
152751	1710	m-1 m-1)	[M-1 M-1)]	0.0	2	1	1	1
152752	1710	increase in mrna suggestive	[increase in mRNA suggestive]	0.0	4	1	1	1
152753	1710	pattern of GRbeta antiglucocorticoid activity	[pattern of GRbeta antiglucocorticoid activity]	0.0	5	1	1	1
152754	1710	protein kinase homologue	[protein kinase homologue]	0.0	3	1	1	1
152755	1710	inherent resistance	[inherent resistance]	0.0	2	1	1	1
152756	1710	ebv-induced growth transformation	[EBV-induced growth transformation]	0.0	3	1	1	1
152757	1710	result in the lysis	[resulting in the lysis]	0.0	4	1	1	1
152758	1710	(u937vhl-1)	[(U937,THP-1)]	0.0	1	1	1	1
152759	1710	finding only in CLL	[finding only in CLL]	0.0	4	1	1	1
152760	1710	cloning from olfactory neuronal cell	[cloning from olfactory neuronal cells]	0.0	5	1	1	1
152761	1710	transactivation in apoptosis	[transactivation in apoptosis]	0.0	3	1	1	1
152762	1710	characteristic of il-12	[characteristics of IL-12]	0.0	3	1	1	1
152763	1710	early cell line	[early cell lines]	0.0	3	1	1	1
152764	1710	metabolism by normal	[metabolism by normal]	0.0	3	1	1	1
152765	1710	accumulation of cholesterol	[accumulation of cholesterol]	0.0	3	1	1	1
152766	1710	patient with chronic renal failure	[patients with chronic renal failure]	0.0	5	1	1	1
152767	1710	level in 9 keratoacanthomas kas	[levels in 9 keratoacanthomas KAs]	0.0	5	1	1	1
152768	1710	sometimes at variance	[sometimes at variance]	0.0	3	1	1	1
152769	1710	idiopathic hypereosinophilic syndrome	[idiopathic hypereosinophilic syndrome]	0.0	3	1	1	1
152770	1710	antibody induction of supershift	[antibody induction of supershifts]	0.0	4	1	1	1
152771	1710	PMA manner	[PMA manner]	0.0	2	1	1	1
152772	1710	R.C. Gallo,	[R.C. Gallo,]	0.0	2	1	1	1
152773	1710	cem-c7 cell	[CEM-C7 cells]	0.0	2	1	1	1
152774	1710	importance for Akv MLV activity	[importance for Akv MLV activity]	0.0	5	1	1	1
152775	1710	aids -c	[AIDS -C]	0.0	2	1	1	1
152776	1710	distinct immediate early regulator	[distinct immediate early regulators]	0.0	4	1	1	1
152777	1710	base-pay substitution	[Base-pair substitutions]	0.0	2	1	1	1
152778	1710	consequence for cell activation	[consequences for cell activation]	0.0	4	1	1	1
152779	1710	effective concentration of tfiiib molecule	[effective concentration of TFIIIB molecules]	0.0	5	1	1	1
152780	1710	cytoplasmic protein extract from leukemia cell	[Cytoplasmic protein extracts from leukemia cells]	0.0	6	1	1	1
152781	1710	bzlf1 transactivator protein in hairy leukoplakia	[BZLF1 transactivator protein in hairy leukoplakia]	0.0	6	1	1	1
152782	1710	(wt)	[(wt)]	0.0	1	1	1	1
152783	1710	anti-ig induction	[anti-Ig induction]	0.0	2	2	2	1
152784	1710	dexamethasone: regulation	[dexamethasone: regulation]	0.0	2	1	1	1
152785	1710	NF-kappa b /rel	[NF-kappa B /Rel]	0.0	3	1	1	1
152786	1710	skw cell into igm-secreting cell	[SKW cells into IgM-secreting cells]	0.0	5	1	1	1
152787	1710	E2A- leukemia factor chimeric protein	[E2A- leukemia factor chimeric proteins]	0.0	5	1	1	1
152788	1710	direct percutaneous angioplasty PTCA	[direct percutaneous angioplasty PTCA]	0.0	4	1	1	1
152789	1710	il-6-responsive gene element	[IL-6-responsive gene elements]	0.0	3	1	1	1
152790	1710	include AP-1	[including AP-1]	0.0	2	1	1	1
152791	1710	tumor study	[tumor studies]	0.0	2	1	1	1
152792	1710	10-fold increase	[10-fold increase]	0.0	2	2	2	1
152793	1710	mechanism of ifn-gamma production	[mechanisms of IFN-gamma production]	0.0	4	1	1	1
152794	1710	effusion from patient	[effusions from patients]	0.0	3	1	1	1
152795	1710	energy study of bmt structure	[energy studies of BMT structure]	0.0	5	1	1	1
152796	1710	normal b lymphocytes.	[normal B lymphocytes.]	0.0	3	1	1	1
152797	1710	1206 nucleotide	[1206 nucleotides]	0.0	2	1	1	1
152798	1710	region of class ii molecule	[regions of class II molecules]	0.0	5	1	1	1
152799	1710	initiate il-4-induced tyrosine phosphorylation of substrate	[initiating IL-4-induced tyrosine phosphorylation of substrates]	0.0	6	1	1	1
152800	1710	resistance to protein	[resistance to proteins]	0.0	3	1	1	1
152801	1710	5' 62 base pair	[5' 62 base pairs]	0.0	4	1	1	1
152802	1710	four IL-2 cell line	[four IL-2 cell lines]	0.0	4	1	1	1
152803	1710	specificity in il-4 expression	[specificity in IL-4 expression]	0.0	4	1	1	1
152804	1710	p16 the inhibitor	[p16 the inhibitor]	0.0	3	1	1	1
152805	1710	program of monocyte differentiation	[program of monocyte differentiation]	0.0	4	1	1	1
152806	1710	vcam-1 mrna level	[VCAM-1 mRNA levels]	0.0	3	1	1	1
152807	1710	SOCS/CIS/SSI	[SOCS/CIS/SSI]	0.0	1	1	1	1
152808	1710	treatment of u-937 tur cell	[Treatment of U-937 TUR cells]	0.0	5	1	1	1
152809	1710	pretreatment 5-day monocyte-derived macrophage	[Pretreatment 5-day monocyte-derived macrophages]	0.0	4	1	1	1
152810	1710	lyn gene expression	[lyn gene expression]	0.0	3	1	1	1
152811	1710	signal pathways, lead to stat-1 activation	[signaling pathways, leading to STAT-1 activation]	0.0	6	1	1	1
152812	1710	stimulation in normal control	[stimulation in normal controls]	0.0	4	1	1	1
152813	1710	only in the context of sequence	[only in the context of sequences]	0.0	6	1	1	1
152814	1710	map phosphatase	[MAP phosphatase]	0.0	2	1	1	1
152815	1710	normal immunoregulatory signal transduction	[normal immunoregulatory signal transduction]	0.0	4	1	1	1
152816	1710	leukocyte signal	[leukocyte signal]	0.0	2	1	1	1
152817	1710	three, heterozygous DNA variation 2418delA	[three, heterozygous DNA variations 2418delA]	0.0	5	1	1	1
152818	1710	variant 5	[Variants 5]	0.0	2	1	1	1
152819	1710	c-jun induction by TPA	[c-jun induction by TPA]	0.0	4	1	1	1
152820	1710	overexpression of er 10%,	[overexpression of ER 10%,]	0.0	4	1	1	1
152821	1710	affect	[affect]	0.0	1	1	1	1
152822	1710	defect(s) in the receptor	[defect(s) in the receptor]	0.0	4	1	1	1
152823	1710	only affect th cell	[only affecting Th cells]	0.0	4	1	1	1
152824	1710	family, dimethyldithiocarbamate	[family, dimethyldithiocarbamate]	0.0	2	1	1	1
152825	1710	u937 in fibroblast	[U937 in fibroblasts]	0.0	3	1	1	1
152826	1710	overexpression of l-selectin	[overexpression of L-selectin]	0.0	3	1	1	1
152827	1710	5' flank clone	[5' flanking clone]	0.0	3	1	1	1
152828	1710	element of the promoter region	[element of the promoter region]	0.0	5	1	1	1
152829	1710	consensus sequence icss	[consensus sequences ICSs]	0.0	3	1	1	1
152830	1710	link between the dopamine system	[link between the dopamine system]	0.0	5	1	1	1
152831	1710	high (p<.001) in euthymic patient	[higher (P<.001) in euthymic patients]	0.0	5	1	1	1
152832	1710	stimulation by eosinophil granule major protein	[Stimulation by eosinophil granule major protein]	0.0	6	1	1	1
152833	1710	determinant process	[determinant processes]	0.0	2	1	1	1
152834	1710	concentration (21.7 5.1	[concentration (21.7 5.1]	0.0	3	1	1	1
152835	1710	functional activation of granulocyte	[functional activation of granulocytes]	0.0	4	1	1	1
152836	1710	phenotype into blood lymphocyte PBL	[phenotypes into blood lymphocytes PBL]	0.0	5	1	1	1
152837	1710	stat1 alpha in NK cell	[STAT1 alpha in NK cells]	0.0	5	1	1	1
152838	1710	monocytoid leukemia cell line	[monocytoid leukemia cell lines]	0.0	4	1	1	1
152839	1710	total number of clone	[total number of clones]	0.0	4	1	1	1
152840	1710	method of study:	[METHOD OF STUDY:]	0.0	3	1	1	1
152841	1710	mrna stability,	[mRNA stability,]	0.0	2	1	1	1
152842	1710	signal intermediate calcineurin	[signalling intermediate calcineurin]	0.0	3	1	1	1
152843	1710	protein similar	[protein similar]	0.0	2	1	1	1
152844	1710	myelomonocytic leukemia with eosinophilia	[myelomonocytic leukemia with eosinophilia]	0.0	4	1	1	1
152845	1710	cotransfection B*CaM-K	[Cotransfection B*CaM-K]	0.0	2	1	1	1
152846	1710	class of factor	[class of factors]	0.0	3	1	1	1
152847	1710	basophilia in leukaemia	[basophilia in leukaemia]	0.0	3	1	1	1
152848	1710	BZ1 antibody	[BZ1 antibody]	0.0	2	1	1	1
152849	1710	signal-regulated protein kinase (erk)-dependent	[signal-regulated protein kinase (ERK)-dependent]	0.0	4	1	1	1
152850	1710	anthropometric, parameter	[anthropometric, parameters]	0.0	2	1	1	1
152851	1710	CTL recognize epithelial tumor ag	[CTL recognizing epithelial tumor Ag]	0.0	5	1	1	1
152852	1710	purification by several cycle	[purification by several cycles]	0.0	4	1	1	1
152853	1710	leukocyte from person	[leukocytes from persons]	0.0	3	1	1	1
152854	1710	[induction between physiology	[[Induction between physiology]	0.0	3	1	1	1
152855	1710	genomic DNA clone contain the region	[genomic DNA clones containing the region]	0.0	6	1	1	1
152856	1710	stimulation of b lymphocyte by ligation	[Stimulation of B lymphocytes by ligation]	0.0	6	1	1	1
152857	1710	increase in differentiation	[increase in differentiation]	0.0	3	1	1	1
152858	1710	high titre antibody	[high titre antibodies]	0.0	3	1	1	1
152859	1710	135 kda	[135 kDa]	0.0	2	1	1	1
152860	1710	uptake with hyperparathyroidism php	[uptake with hyperparathyroidism PHP]	0.0	4	1	1	1
152861	1710	domain sequence	[domain sequences]	0.0	2	1	1	1
152862	1710	htlv-1-transfected T lymphocyte	[HTLV-1-transfected T lymphocytes]	0.0	3	1	1	1
152863	1710	weight gain 8421 2126 (pre)	[weight gain 8421 2126 (pre)]	0.0	5	1	1	1
152864	1710	stress lead to migration of monocyte	[stress leading to migration of monocytes]	0.0	6	1	1	1
152865	1710	cytokine-stimulated vein cell	[cytokine-stimulated vein cells]	0.0	3	1	1	1
152866	1710	express mnda	[expressing MNDA]	0.0	2	1	1	1
152867	1710	translocation breakpoint in patient with dysplasia	[Translocation breakpoints in patients with dysplasia]	0.0	6	1	1	1
152868	1710	activation of the long repeat	[activation of the long repeat]	0.0	5	1	1	1
152869	1710	domain a linker	[domain a linker]	0.0	3	1	1	1
152870	1710	sex-matched control in vitro.	[sex-matched controls in vitro.]	0.0	4	1	1	1
152871	1710	substnfkappab	[substNFkappaB]	0.0	1	1	1	1
152872	1710	total white blood cell	[total white blood cell]	0.0	4	1	1	1
152873	1710	predominant E2F heterodimer	[predominant E2F heterodimers]	0.0	3	1	1	1
152874	1710	malignant cell of promyelocytic leukemia	[malignant cells of promyelocytic leukemia]	0.0	5	1	1	1
152875	1710	interleukin -9-mediate	[interleukin -9-mediated]	0.0	2	1	1	1
152876	1710	several low weight transmembrane adaptor protein	[several low weight transmembrane adaptor proteins]	0.0	6	1	1	1
152877	1710	fos gene family member	[fos gene family members]	0.0	4	1	1	1
152878	1710	select	[selecting]	0.0	1	1	1	1
152879	1710	large number in phase	[large numbers in phase]	0.0	4	1	1	1
152880	1710	CD3 signal transduction	[CD3 signal transduction]	0.0	3	1	1	1
152881	1710	th2-regulated response	[TH2-regulated responses]	0.0	2	1	1	1
152882	1710	occur at minute (phase 1)	[occurring at minutes (phase 1)]	0.0	5	1	1	1
152883	1710	order of magnitude potent than H	[orders of magnitude potent than H]	0.0	6	1	1	1
152884	1710	mechanism of DNA repair	[mechanism of DNA repair]	0.0	4	1	1	1
152885	1710	three order less potent	[three orders less potent]	0.0	4	1	1	1
152886	1710	drift from latency	[drift from latency]	0.0	3	1	1	1
152887	1710	monocyte counter-receptor	[monocyte counter-receptor]	0.0	2	1	1	1
152888	1710	c-terminal residue amino acid	[C-terminal residues amino acids]	0.0	4	1	1	1
152889	1710	modulate agent, alpha,25-dihydroxycholecalciferol	[modulating agent, alpha,25-dihydroxycholecalciferol]	0.0	3	1	1	1
152890	1710	novel cooperation	[novel cooperation]	0.0	2	1	1	1
152891	1710	cd8+ t-pll	[CD8+ T-PLL]	0.0	2	1	1	1
152892	1710	ablation/supershift	[ablation/supershift]	0.0	1	1	1	1
152893	1710	neutrophilic granulocyte pmn	[neutrophilic granulocytes PMN]	0.0	3	1	1	1
152894	1710	strategy persist lifelong,	[strategy persisting lifelong,]	0.0	3	1	1	1
152895	1710	average, high level	[average, high levels]	0.0	3	1	1	1
152896	1710	loss consistent with nfatp dephosphorylation	[loss consistent with NFATp dephosphorylation]	0.0	5	1	1	1
152897	1710	susceptibility with respect	[susceptibility with respect]	0.0	3	1	1	1
152898	1710	fresh peripheral blood cell	[fresh peripheral blood cells]	0.0	4	1	1	1
152899	1710	sequence in GenBank database	[sequences in GenBank database]	0.0	4	1	1	1
152900	1710	transplant medicine	[transplant medicine]	0.0	2	1	1	1
152901	1710	pilot study	[pilot study]	0.0	2	1	1	1
152902	1710	method of Peripheral lymphocyte from woman	[METHOD OF Peripheral lymphocytes from women]	0.0	6	1	1	1
152903	1710	blood cell from patient aml	[blood cells from patients AML]	0.0	5	1	1	1
152904	1710	retinoic acid (ra)	[retinoic acid (RA)]	0.0	3	1	1	1
152905	1710	regulation of vascular cell adhesion molecule-1	[regulation of vascular cell adhesion molecule-1]	0.0	6	1	1	1
152906	1710	functional evidence	[functional evidence]	0.0	2	1	1	1
152907	1710	human c/ebp-epsilon transcription factor	[human C/EBP-epsilon transcription factor]	0.0	4	1	1	1
152908	1710	induction of monocytic differentiation cell	[induction of monocytic differentiation cells]	0.0	5	1	1	1
152909	1710	two chains,	[two chains,]	0.0	2	1	1	1
152910	1710	only in extract	[only in extracts]	0.0	3	1	1	1
152911	1710	expression of factor kappab activation	[expression of factor kappaB activation]	0.0	5	1	1	1
152912	1710	(median follow-up, months)	[(median follow-up, months)]	0.0	3	1	1	1
152913	1710	risk independent	[risk independent]	0.0	2	1	1	1
152914	1710	stat1 transcriptional activity	[Stat1 transcriptional activity]	0.0	3	1	1	1
152915	1710	membrane protein lmp2	[membrane protein LMP2]	0.0	3	1	1	1
152916	1710	sclerosis complex	[sclerosis complex]	0.0	2	1	1	1
152917	1710	human AML1	[human AML1]	0.0	2	1	1	1
152918	1710	set of phosphoprotein	[set of phosphoproteins]	0.0	3	1	1	1
152919	1710	enhancer region upstream	[enhancer region upstream]	0.0	3	1	1	1
152920	1710	end of the peptide-binding cleft	[end of the peptide-binding cleft]	0.0	5	1	1	1
152921	1710	fundamental implication in aids pathogenesis	[fundamental implications in AIDS pathogenesis]	0.0	5	1	1	1
152922	1710	efficacy of gc	[efficacy of GC]	0.0	3	1	1	1
152923	1710	predictions.	[predictions.]	0.0	1	1	1	1
152924	1710	T/NK cell in remission	[T/NK cells in remission]	0.0	4	1	1	1
152925	1710	malignant cell of leukemia	[malignant cells of leukemia]	0.0	4	1	1	1
152926	1710	thioredoxin T cell leukemia-derived factor	[thioredoxin T cell leukemia-derived factor]	0.0	5	1	1	1
152927	1710	induce CAT activity fibrinogen /mn2+	[inducing CAT activity fibrinogen /Mn2+]	0.0	5	1	1	1
152928	1710	activation by various stimulus	[Activation by various stimuli]	0.0	4	1	1	1
152929	1710	b-lineage commitment	[B-lineage commitment]	0.0	2	1	1	1
152930	1710	control the expression in transfection experiment	[controlling the expression in transfection experiments]	0.0	6	1	1	1
152931	1710	functional role binding motif	[functional roles binding motifs]	0.0	4	1	1	1
152932	1710	coordinate suppression	[coordinate suppression]	0.0	2	1	1	1
152933	1710	follow irradiation	[Following irradiation]	0.0	2	1	1	1
152934	1710	f.r.,	[F.R.,]	0.0	1	1	1	1
152935	1710	beta (p75) gene	[beta (p75) genes]	0.0	3	1	1	1
152936	1710	thrombin -generate potential	[thrombin -generating potential]	0.0	3	1	1	1
152937	1710	oestrogen receptor analysis in B-cell leukemia	[Oestrogen receptor analysis in B-cell leukemia]	0.0	6	1	1	1
152938	1710	b cell by herpesvirus	[B cells by herpesvirus]	0.0	4	1	1	1
152939	1710	1053 base pair	[1053 base pairs]	0.0	3	1	1	1
152940	1710	tsg101 intragenic transcript deletion	[TSG101 intragenic transcript deletions]	0.0	4	1	1	1
152941	1710	protein from u937 cell	[proteins from U937 cells]	0.0	4	1	1	1
152942	1710	Bfl-1 gene	[Bfl-1 genes]	0.0	2	1	1	1
152943	1710	important functional alteration	[important functional alterations]	0.0	3	1	1	1
152944	1710	surface expression of adhesion molecule	[surface expression of adhesion molecules]	0.0	5	1	1	1
152945	1710	signal from patient upon treatment	[signalling from patients upon treatment]	0.0	5	1	1	1
152946	1710	activation by inflammatory stimulus	[Activation by inflammatory stimuli]	0.0	4	1	1	1
152947	1710	low level of the signal molecule	[low levels of the signaling molecules]	0.0	6	1	1	1
152948	1710	binding of further factor protein	[binding of further factor proteins]	0.0	5	1	1	1
152949	1710	NFAT3	[NFAT3]	0.0	1	1	1	1
152950	1710	identify potential target	[identifying potential targets]	0.0	3	1	1	1
152951	1710	important role in immune state	[important role in immune states]	0.0	5	1	1	1
152952	1710	initiate that response.	[initiating that response.]	0.0	3	1	1	1
152953	1710	capsid	[capsid]	0.0	1	1	1	1
152954	1710	infectious provirus	[infectious provirus]	0.0	2	1	1	1
152955	1710	NFAT-	[NFAT-]	0.0	1	1	1	1
152956	1710	Recent evidence jak1 beta	[Recent evidence JAK1 beta]	0.0	4	1	1	1
152957	1710	affect the metabolism of methylprednisolone	[affecting the metabolism of methylprednisolone]	0.0	5	1	1	1
152958	1710	transcription of major class ii gene	[transcription of major class II genes]	0.0	6	1	1	1
152959	1710	normal skin	[normal skin]	0.0	2	2	2	1
152960	1710	HLA-DQ sequence	[HLA-DQ sequence]	0.0	2	1	1	1
152961	1710	desensitization	[desensitization]	0.0	1	1	1	1
152962	1710	ic50 range).	[IC50s range).]	0.0	2	1	1	1
152963	1710	36 h	[36 h]	0.0	2	1	1	1
152964	1710	regulation of immunoglobulin mu	[Regulation of immunoglobulin mu]	0.0	4	1	1	1
152965	1710	I aldosterone receptor in leucocyte	[I aldosterone receptors in leucocytes]	0.0	5	1	1	1
152966	1710	x-linked immunodeficiency disease	[X-linked immunodeficiency disease]	0.0	3	1	1	1
152967	1710	X chromosome	[X chromosome]	0.0	2	1	1	1
152968	1710	creb/atf-1 to TRE-1	[CREB/ATF-1 to TRE-1]	0.0	3	1	1	1
152969	1710	pathophysiology of leukaemia	[pathophysiology of leukaemia]	0.0	3	1	1	1
152970	1710	nkl cytotoxicity	[NKL cytotoxicity]	0.0	2	1	1	1
152971	1710	element modulator	[element modulator]	0.0	2	1	1	1
152972	1710	main goals:	[main goals:]	0.0	2	1	1	1
152973	1710	proportion than of cd8+ t-lymphocyte	[proportion than of CD8+ T-lymphocytes]	0.0	5	1	1	1
152974	1710	DH42	[DH42]	0.0	1	1	1	1
152975	1710	even dose	[even doses]	0.0	2	1	1	1
152976	1710	functional pafr transcript	[functional PAFR transcript]	0.0	3	1	1	1
152977	1710	pathway mediate shear- cytokine-induced ec-mn adhesion	[pathways mediating shear- cytokine-induced EC-Mn adhesion]	0.0	6	1	1	1
152978	1710	immediate-early class of gene	[immediate-early classes of genes]	0.0	4	1	1	1
152979	1710	establish cell line keep erythroid-specific property	[establishing cell lines keeping erythroid-specific properties]	0.0	6	1	1	1
152980	1710	receptor hGR	[receptor hGR]	0.0	2	2	2	1
152981	1710	include adhesion	[including adhesion]	0.0	2	1	1	1
152982	1710	receptor gcR	[receptors gcR]	0.0	2	1	1	1
152983	1710	increase awareness as a sequela	[increasing awareness as a sequela]	0.0	5	1	1	1
152984	1710	mcf13 murine leukemia virus terminal	[MCF13 murine leukemia virus terminal]	0.0	5	1	1	1
152985	1710	herpes kinase (tk) promoter	[herpes kinase (TK) promoter]	0.0	4	1	1	1
152986	1710	function of stat5	[function of STAT5]	0.0	3	1	1	1
152987	1710	long utr	[longer UTR]	0.0	2	1	1	1
152988	1710	responses, nf-kappab activation	[responses, NF-kappaB activation]	0.0	3	1	1	1
152989	1710	hiv long repeat activity in T	[HIV long repeat activity in T]	0.0	6	1	1	1
152990	1710	abundance, distribution,	[abundance, distribution,]	0.0	2	1	1	1
152991	1710	character of expression	[character of expression]	0.0	3	1	1	1
152992	1710	consequence of memory	[consequence of memory]	0.0	3	1	1	1
152993	1710	medium FCM	[medium FCM]	0.0	2	1	1	1
152994	1710	mg/24h; n: 2.7+/-2.0) excretion,	[mg/24h; N: 2.7+/-2.0) excretion,]	0.0	4	1	1	1
152995	1710	serine/threonine protein phosphatase	[serine/threonine protein phosphatases]	0.0	3	1	1	1
152996	1710	activator of transcription 6	[activator of transcription 6]	0.0	4	1	1	1
152997	1710	basic bhlh motif	[basic bHLH motif]	0.0	3	1	1	1
152998	1710	pha human peripheral blood lymphocyte pbl	[PHA human peripheral blood lymphocytes PBL]	0.0	6	1	1	1
152999	1710	DNA relax	[DNA relaxing]	0.0	2	1	1	1
153000	1710	erythroblast transformation	[erythroblast transformation]	0.0	2	1	1	1
153001	1710	ethyl-methanesulfonate-derived subclone	[ethyl-methanesulfonate-derived subclones]	0.0	2	1	1	1
153002	1710	(3) non-dividing, pbl	[(3) non-dividing, PBL]	0.0	3	1	1	1
153003	1710	human cell response	[Human cell responses]	0.0	3	1	1	1
153004	1710	two inhibitor of serine/threonine phosphatase	[two inhibitors of serine/threonine phosphatases]	0.0	5	1	1	1
153005	1710	potential in NIH 3t3 cell	[potential in NIH 3T3 cells]	0.0	5	1	1	1
153006	1710	positive regulation of gene	[positive regulation of genes]	0.0	4	1	1	1
153007	1710	monocyte binding to human cell harc	[monocyte binding to human cells HAECs]	0.0	6	1	1	1
153008	1710	pretreatment of "semimature" monocyte-derived macrophage	[Pretreatment of "semimature" monocyte-derived macrophages]	0.0	5	1	1	1
153009	1710	second trans-activation domain	[second trans-activation domain]	0.0	3	1	1	1
153010	1710	immunosuppressant pg490	[Immunosuppressant PG490]	0.0	2	1	1	1
153011	1710	(h292) cell-line dexamethasone basal	[(H292) cell-line dexamethasone basal]	0.0	4	1	1	1
153012	1710	severe development abnormality	[severe development abnormalities]	0.0	3	1	1	1
153013	1710	EPO cell	[EPO cells]	0.0	2	1	1	1
153014	1710	other condition of biomedical importance.	[other conditions of biomedical importance.]	0.0	5	1	1	1
153015	1710	kd-value of 0.1 nm	[Kd-values of 0.1 nM]	0.0	4	1	1	1
153016	1710	effective inhibition phorbol ester	[effective inhibition phorbol ester]	0.0	4	1	1	1
153017	1710	pou domain transcription	[POU domain transcription]	0.0	3	1	1	1
153018	1710	result in activator protein-1 transcription	[resulting in activator protein-1 transcription]	0.0	5	1	1	1
153019	1710	ciita in the pig	[CIITA in the pig]	0.0	4	1	1	1
153020	1710	other cellular parameters,	[Other cellular parameters,]	0.0	3	1	1	1
153021	1710	demonstration of a viral inhibition	[demonstration of a viral inhibition]	0.0	5	1	1	1
153022	1710	amino-terminal fragment	[amino-terminal fragment]	0.0	2	1	1	1
153023	1710	granulocyte-macrophage factor promoter	[granulocyte-macrophage factor promoters]	0.0	3	1	1	1
153024	1710	transcription factor change	[transcription factor changes]	0.0	3	1	1	1
153025	1710	transformation in chronic leukemia	[transformation in chronic leukemia]	0.0	4	1	1	1
153026	1710	patient with type diabete	[patients with type diabetes]	0.0	4	1	1	1
153027	1710	role in development.	[role in development.]	0.0	3	1	1	1
153028	1710	transgenic mouse carry the irf-1 gene	[transgenic mice carrying the IRF-1 gene]	0.0	6	1	1	1
153029	1710	il-1 beta promoter/enhancer sequence	[IL-1 beta promoter/enhancer sequences]	0.0	4	1	1	1
153030	1710	g3 tumor	[G3 tumors]	0.0	2	1	1	1
153031	1710	relative affinity (at least sevenfold)	[relative affinity (at least sevenfold)]	0.0	5	1	1	1
153032	1710	stimulation with a cocktail	[stimulation with a cocktail]	0.0	4	1	1	1
153033	1710	glutathione -s-transferase	[glutathione -S-transferase]	0.0	2	1	1	1
153034	1710	two explanation	[Two explanations]	0.0	2	1	1	1
153035	1710	block uptake through mcd14	[blocking uptake through mCD14]	0.0	4	1	1	1
153036	1710	fact, cell	[fact, cells]	0.0	2	1	1	1
153037	1710	however, order less potent	[however, orders less potent]	0.0	4	1	1	1
153038	1710	tpa nuclear factor	[TPA nuclear factor]	0.0	3	1	1	1
153039	1710	epo granulocyte/macrophage colony stimulate factor	[Epo granulocyte/macrophage colony stimulating factor]	0.0	5	1	1	1
153040	1710	cd14 promoter	[CD14 promoter]	0.0	2	1	1	1
153041	1710	use human cd34+	[using human CD34+]	0.0	3	1	1	1
153042	1710	il-2ralpha on phagocyte	[IL-2Ralpha on phagocytes]	0.0	3	1	1	1
153043	1710	govern process of differentiation	[governing processes of differentiation]	0.0	4	1	1	1
153044	1710	inhibition of nf-kappab nuclear translocation	[inhibition of NF-kappaB nuclear translocation]	0.0	5	1	1	1
153045	1710	early passage cell in function	[early passage cells in function]	0.0	5	1	1	1
153046	1710	pattern at the level consist	[pattern at the level consisting]	0.0	5	1	1	1
153047	1710	27-kda heat shock protein	[27-kDa heat shock protein]	0.0	4	1	1	1
153048	1710	cytochrome b558	[cytochrome b558]	0.0	2	1	1	1
153049	1710	m2 cell context	[M2 cell context]	0.0	3	1	1	1
153050	1710	immunodeficiency virus type 1 replication	[immunodeficiency virus type 1 replication]	0.0	5	1	1	1
153051	1710	killer T/NK	[killer T/NK]	0.0	2	1	1	1
153052	1710	protein ikk-alpha	[proteins IKK-alpha]	0.0	2	1	1	1
153053	1710	biochemical method	[biochemical methods]	0.0	2	1	1	1
153054	1710	further enhancement of potency	[further enhancement of potency]	0.0	4	1	1	1
153055	1710	T control region	[T control regions]	0.0	3	1	1	1
153056	1710	(delta99) sequence	[(delta99) sequences]	0.0	2	1	1	1
153057	1710	transcription) protein	[transcription) proteins]	0.0	2	1	1	1
153058	1710	hiv genomic rna	[HIV genomic RNA]	0.0	3	1	1	1
153059	1710	mutation of tyrosine 492/493	[Mutation of tyrosines 492/493]	0.0	4	1	1	1
153060	1710	obese: 31.90	[obese: 31.90]	0.0	2	1	1	1
153061	1710	vector expression	[vector expression]	0.0	2	1	1	1
153062	1710	activity in RAW cell	[activity in RAW cells]	0.0	4	1	1	1
153063	1710	far, transcriptional analysis	[far, transcriptional analyses]	0.0	3	1	1	1
153064	1710	laz3/bcl6 gene	[LAZ3/BCL6 gene]	0.0	2	1	1	1
153065	1710	PU-box	[PU-box]	0.0	1	1	1	1
153066	1710	murine IL-2 -responsive element	[murine IL-2 -responsive element]	0.0	4	1	1	1
153067	1710	factor treatment	[factor treatment]	0.0	2	1	1	1
153068	1710	IL-4 nuclear-activating factor	[IL-4 nuclear-activating factors]	0.0	3	1	1	1
153069	1710	least three erp transcript	[least three ERP transcripts]	0.0	4	1	1	1
153070	1710	target gene as a activator,	[target genes as a activator,]	0.0	5	1	1	1
153071	1710	+/- 7	[+/- 7]	0.0	2	1	1	1
153072	1710	cell surface mu chain	[cell surface mu chain]	0.0	4	1	1	1
153073	1710	thyroid tissue	[thyroid tissue]	0.0	2	1	1	1
153074	1710	familial androgen resistance	[familial androgen resistance]	0.0	3	1	1	1
153075	1710	result in activation of transcriptional factor	[resulting in activation of transcriptional factors]	0.0	6	1	1	1
153076	1710	rhesus monkey alveolar macrophage	[rhesus monkey alveolar macrophages]	0.0	4	1	1	1
153077	1710	(vmax)	[(Vmax)]	0.0	1	1	1	1
153078	1710	kinase in the signal pathway	[kinase in the signaling pathways]	0.0	5	1	1	1
153079	1710	span the DQB X-box	[spanning the DQB X-box]	0.0	4	1	1	1
153080	1710	anhydrase ii caii	[anhydrase II CAII]	0.0	3	1	1	1
153081	1710	Ad5E1A CTL activity	[Ad5E1A CTL activity]	0.0	3	1	1	1
153082	1710	heterodimer dna-binding complex	[heterodimer DNA-binding complexes]	0.0	3	1	1	1
153083	1710	thereby provide a firm basis	[thereby providing a firm basis]	0.0	5	1	1	1
153084	1710	formation of substance	[formation of substances]	0.0	3	1	1	1
153085	1710	immunostaining against 1	[immunostaining against 1]	0.0	3	1	1	1
153086	1710	HBxAg polypeptide	[HBxAg polypeptides]	0.0	2	1	1	1
153087	1710	role for transactivation	[role for transactivation]	0.0	3	1	1	1
153088	1710	factor-kappa b NF-kappa b site	[factor-kappa B NF-kappa B site]	0.0	5	1	1	1
153089	1710	argument	[arguments]	0.0	1	1	1	1
153090	1710	nuclear factor binding motif	[nuclear factor binding motifs]	0.0	4	1	1	1
153091	1710	induction of creb complex	[Induction of CREB complexes]	0.0	4	1	1	1
153092	1710	blood mononuclear cell gcr binding affinity	[blood mononuclear cell GCR binding affinities]	0.0	6	1	1	1
153093	1710	evaluate respiratory epithelium for the presence	[evaluating respiratory epithelium for the presence]	0.0	6	1	1	1
153094	1710	5.5 kb mrna	[5.5 kb mRNA]	0.0	3	1	1	1
153095	1710	inability of (mut)	[inability of (mut)]	0.0	3	1	1	1
153096	1710	19-bp factor binding site -570	[19-bp factor binding site -570]	0.0	5	1	1	1
153097	1710	erythroid-specific genomic footprint	[erythroid-specific genomic footprint]	0.0	3	1	1	1
153098	1710	distinct transcriptional activity	[distinct transcriptional activities]	0.0	3	1	1	1
153099	1710	suggest a association of the kinase	[suggesting a association of the kinase]	0.0	6	1	1	1
153100	1710	regulation of the eotaxin gene	[regulation of the eotaxin gene]	0.0	5	1	1	1
153101	1710	micrograms/day for 7 day	[micrograms/day for 7 days)]	0.0	4	1	1	1
153102	1710	chromosomal protein hmg-1	[chromosomal protein HMG-1]	0.0	3	1	1	1
153103	1710	nonpregnant value	[nonpregnant values]	0.0	2	1	1	1
153104	1710	association between ngal expression	[association between NGAL expression]	0.0	4	2	2	1
153105	1710	analysis of the function	[analysis of the functions]	0.0	4	1	1	1
153106	1710	maximum (3h)-thymidine incorporation into DNA	[maximum (3H)-thymidine incorporation into DNA]	0.0	5	1	1	1
153107	1710	cluster analysis of nfat composite element	[cluster analysis of NFAT composite elements]	0.0	6	1	1	1
153108	1710	12 nonspecific reactive hyperplasia fh	[12 nonspecific reactive hyperplasia FH]	0.0	5	1	1	1
153109	1710	constitutive dephosphorylation	[Constitutive dephosphorylation]	0.0	2	1	1	1
153110	1710	high-affinity serum-inducible element	[high-affinity serum-inducible element]	0.0	3	1	1	1
153111	1710	engagement by class MHC/superantigen	[engagement by class MHC/superantigen]	0.0	4	1	1	1
153112	1710	octamer site -dependent transcription	[octamer site -dependent transcription]	0.0	4	1	1	1
153113	1710	interferon-gamma receptor ifn-gammar expression	[interferon-gamma receptor IFN-gammaR expression]	0.0	4	1	1	1
153114	1710	anti- csf-1r antibody	[anti- CSF-1R antibodies]	0.0	3	1	1	1
153115	1710	complex of subunit	[complex of subunits]	0.0	3	1	1	1
153116	1710	inflammatory stimulus notably bacterial product	[inflammatory stimuli notably bacterial products]	0.0	5	1	1	1
153117	1710	MHC human population	[MHC human population]	0.0	3	1	1	1
153118	1710	early (6 wk to mo)	[early (6 wk to mo)]	0.0	5	1	1	1
153119	1710	possible influence on physiology	[possible influence on physiology]	0.0	4	1	1	1
153120	1710	1.8 kb	[1.8 kb]	0.0	2	1	1	1
153121	1710	sophisticated strategy	[sophisticated strategy]	0.0	2	1	1	1
153122	1710	property of stromal cell	[properties of stromal cells]	0.0	4	1	1	1
153123	1710	consecutive transplant recipient	[consecutive transplant recipients]	0.0	3	1	1	1
